DrugMAP Full Data Download File
Title - DrugMAP drug information in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
College of Pharmaceutical Sciences
Zhejiang University
https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)
ID: Drug ID
DN: Drug Name
HS: Highest Status
SN: Synonymous
CP: Company
TC: Therapeutic Class
DT: Drug Type
SQ: Sequence
PC: PubChem CID
MW: Molecular Weight
FM: Formula
IC: InChI
CS: Canonical SMILES
IK: InChIKey
IU: IUPAC Name
CA: CAS Number
CB: ChEBI ID
DE: Disease Entry
DMMHNU2 ID DMMHNU2
DMMHNU2 DN (S)-(+)-Dimethindene maleate
DMMHNU2 HS Approved
DMMHNU2 SN UNII-J43ZL3WTLN; J43ZL3WTLN; 136152-65-3; DSSTox_RID_83231; DSSTox_CID_28966; DSSTox_GSID_49040; Dimethindene maleate, (+)-; CAS-1217457-81-2; NCGC00025158-01; 121367-05-3; Dimethindene maleate, (S)-(+)-; DTXSID8049040; CHEMBL2356801; MolPort-023-276-095; HMS3267J12; Tox21_113582; AKOS024456589; Tox21_113582_1; NCGC00025158-02; 1H-Indene-2-ethanamine, N,N-dimethyl-3-((1S)-1-(2-pyridinyl)ethyl)-, (2Z)-2-butenedioate (1:1); B6734; (S)-(+)-Dimethindene maleate, > UNII-6LL60J9E0O component
DMMHNU2 TC Antiinflammatory Agents
DMMHNU2 DT Small molecular drug
DMMHNU2 PC 56972160
DMMHNU2 MW 408.5
DMMHNU2 FM C24H28N2O4
DMMHNU2 IC InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;5-3(6)1-2-4(7)8/h4-10,12,15H,11,13-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m1./s1
DMMHNU2 CS C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMMHNU2 IK SWECWXGUJQLXJF-HFNHQGOYSA-N
DMMHNU2 IU (Z)-but-2-enedioic acid;N,N-dimethyl-2-[3-[(1S)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine
DMMHNU2 CA CAS 136152-65-3
DMMHNU2 DE Pruritus
DMIAHVU ID DMIAHVU
DMIAHVU DN 2-deoxyglucose
DMIAHVU HS Approved
DMIAHVU SN 154-17-6; Deoxyglucose; 2-Deoxy-D-mannose; 2-Deoxy-D-arabinohexose; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; arabino-Hexose, 2-deoxy-; D-Glucose, 2-deoxy-; 9G2MP84A8W; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; AK-44445; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; d-2-glucodesose; D-2dGlc; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; 2-INNo-D-AEIIC; SCHEMBL7670; AC1L33KH; KSC175S5P; 4-01-00-04282 (Beilstein Handbook Reference); Jsp003004; CHEMBL2074932; CTK0H5957; MolPort-002-317-302; 2-deoxy-D-glucose
DMIAHVU CP Threshold Pharmaceuticals
DMIAHVU DT Small molecular drug
DMIAHVU PC 108223
DMIAHVU MW 164.16
DMIAHVU FM C6H12O5
DMIAHVU IC InChI=1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
DMIAHVU CS C(C=O)[C@H]([C@@H]([C@@H](CO)O)O)O
DMIAHVU IK VRYALKFFQXWPIH-PBXRRBTRSA-N
DMIAHVU IU (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal
DMIAHVU CA CAS 154-17-6
DMIAHVU DE Solid tumour/cancer
DMYFBMS ID DMYFBMS
DMYFBMS DN 99mTc-fanolesomab
DMYFBMS HS Approved
DMYFBMS SN LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody
DMYFBMS CP Palatin Technologies
DMYFBMS DT Antibody
DMYFBMS DE Appendicitis
DMVZO01 ID DMVZO01
DMVZO01 DN 99mTc-sestamibi
DMVZO01 HS Approved
DMVZO01 SN Sestamibi; RP-30; Tc-MIBI; Technetium-99m sestamibi
DMVZO01 CP Bristol-Myers Squibb Pharma Co
DMVZO01 DT Small molecular drug
DMVZO01 PC 9832136
DMVZO01 MW 777.9
DMVZO01 FM C36H66N6O6Tc+7
DMVZO01 IC InChI=1S/6C6H11NO.Tc/c6*1-6(2,8-4)5-7-3;/h6*5H2,1-2,4H3;/q;;;;;;+7/i;;;;;;1+1
DMVZO01 CS CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.[99Tc+7]
DMVZO01 IK ZGDBEIODOXIKGQ-KTTJZPQESA-N
DMVZO01 IU 1-isocyano-2-methoxy-2-methylpropane;technetium-99(7+)
DMVZO01 DE Breast cancer
DMMN36E ID DMMN36E
DMMN36E DN Abacavir
DMMN36E HS Approved
DMMN36E SN Trizivir; Ziagen; Abacavir [INN]; Abacavir (INN); Ziagen (TN); Ziagen (TM)(*Succinate salt*); [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol; {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; (+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; (+/-)-Abacavir; (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ABC
DMMN36E CP GlaxoSmithKline
DMMN36E TC Anti-HIV Agents
DMMN36E DT Small molecular drug
DMMN36E PC 441300
DMMN36E MW 286.33
DMMN36E FM C14H18N6O
DMMN36E IC InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1
DMMN36E CS C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@@H]4C[C@@H](C=C4)CO
DMMN36E IK MCGSCOLBFJQGHM-SCZZXKLOSA-N
DMMN36E IU [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
DMMN36E CA CAS 136470-78-5
DMMN36E CB CHEBI:421707
DMMN36E DE Human immunodeficiency virus infection
DMOERGM ID DMOERGM
DMOERGM DN Abaloparatide
DMOERGM HS Approved
DMOERGM SN Tymlos
DMOERGM CP Radius Health
DMOERGM DT Recombinant protein
DMOERGM SQ Abaloparatide N-terminal peptide sequence: AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA
DMOERGM PC 76943386
DMOERGM MW 3961
DMOERGM FM C174H300N56O49
DMOERGM IC InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
DMOERGM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMOERGM IK BVISQZFBLRSESR-XSCWXTNMSA-N
DMOERGM IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMOERGM CA CAS 247062-33-5
DMOERGM DE Postmenopausal osteoporosis
DM2RX0I ID DM2RX0I
DM2RX0I DN Abametapir
DM2RX0I HS Approved
DM2RX0I SN 5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl
DM2RX0I DT Small molecular drug
DM2RX0I PC 15664
DM2RX0I MW 184.24
DM2RX0I FM C12H12N2
DM2RX0I IC InChI=1S/C12H12N2/c1-9-3-5-11(13-7-9)12-6-4-10(2)8-14-12/h3-8H,1-2H3
DM2RX0I CS CC1=CN=C(C=C1)C2=NC=C(C=C2)C
DM2RX0I IK PTRATZCAGVBFIQ-UHFFFAOYSA-N
DM2RX0I IU 5-methyl-2-(5-methylpyridin-2-yl)pyridine
DM2RX0I CA CAS 1762-34-1
DM2RX0I DE Head and body lice
DM5WFNP ID DM5WFNP
DM5WFNP DN Abarelix
DM5WFNP HS Approved
DM5WFNP SN Plenaxis; Abarelix [USAN]; Plenaxis depot; PPI 149; R 3827; PPI-149; Plenaxis (TN); R-3827; Abarelix (USAN/INN); Abarelix-Depot-M; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(sup 6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparginyl-L-leucyl-N(6)-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-10
DM5WFNP CP Speciality European Pharma
DM5WFNP TC Anticancer Agents
DM5WFNP DT Small molecular drug
DM5WFNP PC 16131215
DM5WFNP MW 1416.1
DM5WFNP FM C72H95ClN14O14
DM5WFNP IC InChI=1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
DM5WFNP CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM5WFNP IK AIWRTTMUVOZGPW-HSPKUQOVSA-N
DM5WFNP IU (2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DM5WFNP CA CAS 183552-38-7
DM5WFNP CB CHEBI:337298
DM5WFNP DE Prostate cancer
DMSA8RU ID DMSA8RU
DMSA8RU DN Abatacept
DMSA8RU HS Approved
DMSA8RU SN Orencia (TN)
DMSA8RU CP Bristol-Myers Squibb
DMSA8RU TC Antirheumatic Agents
DMSA8RU SQ Abatacept monomer sequence: MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSA8RU DE Rheumatoid arthritis
DMJO6GV ID DMJO6GV
DMJO6GV DN Abciximab
DMJO6GV HS Approved
DMJO6GV SN ReoPro (TN)
DMJO6GV CP Eli Lilly
DMJO6GV TC Anticoagulants
DMJO6GV DT Monoclonal antibody
DMJO6GV SQ 1TXV:H ReoPro-like antibody Heavy Chain 1: EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 1DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >1TXV:H ReoPro-like antibody Heavy Chain 2EVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1TXV:L ReoPro-like antibody Light Chain 2DILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPSRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
DMJO6GV DE Angina pectoris
DM8V75C ID DM8V75C
DM8V75C DN ABIRATERONE
DM8V75C HS Approved
DM8V75C SN Abiraterone (AR inhibitor)
DM8V75C DT Small molecular drug
DM8V75C PC 132971
DM8V75C MW 349.5
DM8V75C FM C24H31NO
DM8V75C IC InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
DM8V75C CS C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
DM8V75C IK GZOSMCIZMLWJML-VJLLXTKPSA-N
DM8V75C IU (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DM8V75C CA CAS 154229-19-3
DM8V75C CB CHEBI:68642
DM8V75C DE Prostate cancer
DMANBZI ID DMANBZI
DMANBZI DN Abiraterone acetate
DMANBZI HS Approved
DMANBZI SN CB-7630; JNJ-212082; Zytiga
DMANBZI TC Anticancer Agents
DMANBZI DT Small molecular drug
DMANBZI PC 9821849
DMANBZI MW 391.5
DMANBZI FM C26H33NO2
DMANBZI IC InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
DMANBZI CS CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C
DMANBZI IK UVIQSJCZCSLXRZ-UBUQANBQSA-N
DMANBZI IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMANBZI CA CAS 154229-18-2
DMANBZI CB CHEBI:68639
DMANBZI DE Prostate cancer
DMZT2P0 ID DMZT2P0
DMZT2P0 DN Abobotulinum toxin A
DMZT2P0 HS Approved
DMZT2P0 SN AbobotulinumtoxinA; Azzalure; Dysport; Reloxin; Abobotulinum toxin A for injection; CNT-52120
DMZT2P0 CP Ipsen
DMZT2P0 DE Cervical cancer
DM7GCVW ID DM7GCVW
DM7GCVW DN Acalabrutinib
DM7GCVW HS Approved
DM7GCVW SN Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
DM7GCVW CP AstraZeneca/Acerta Pharma
DM7GCVW PC 71226662
DM7GCVW MW 465.5
DM7GCVW FM C26H23N7O2
DM7GCVW IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM7GCVW CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM7GCVW IK WDENQIQQYWYTPO-IBGZPJMESA-N
DM7GCVW IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM7GCVW CA CAS 1420477-60-6
DM7GCVW DE Chronic lymphocytic leukaemia; Mantle cell lymphoma
DMO381I ID DMO381I
DMO381I DN Acamprosate
DMO381I HS Approved
DMO381I SN AOTA; Acamprosato; Acamprosatum; Acamprostate; Aotal; Campral; Calcium acetyl homotaurinate; Calcium acetylhomotaurinate; Calcium acetylhomotaurine; Sodium acetylhomotaurine; Acamprosate 6473; Acamprosate (Campral); Acamprosate (INN); Acamprosate [INN:BAN]; Acamprosato [INN-Spanish]; Acamprosatum [INN-Latin]; Aotal (TN); Campral (TN); N-Acetylhomotaurine; 3-(Acetylamino)propanesulphonic acid; 3-Acetamido-1-propanesulfonic acid; 3-acetamidopropane-1-sulfonic acid
DMO381I TC Alcohol Deterrents
DMO381I DT Small molecular drug
DMO381I PC 71158
DMO381I MW 181.21
DMO381I FM C5H11NO4S
DMO381I IC InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)
DMO381I CS CC(=O)NCCCS(=O)(=O)O
DMO381I IK AFCGFAGUEYAMAO-UHFFFAOYSA-N
DMO381I IU 3-acetamidopropane-1-sulfonic acid
DMO381I CA CAS 77337-76-9
DMO381I CB CHEBI:51041
DMO381I DE Alcohol dependence
DMRM3AW ID DMRM3AW
DMRM3AW DN Acarbose
DMRM3AW HS Approved
DMRM3AW SN acarbose; 56180-94-0; Glucobay; Precose; Prandase; C25H43NO18; CHEBI:2376; CHEMBL3734896; BAY-g 5421; 4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose; SMR000466376; SR-01000759407; Acarbose/; Acarbose [USAN:BAN:INN:JAN]; Acarbose,(S); Precose (TN); AC1L26GM; Acarbose (JAN/USAN/INN); MLS006011898; MLS000759506; MLS001424056; SPECTRUM1505172; SCHEMBL5316305; CHEMBL404271; BDBM23406; MolPort-002-507-369
DMRM3AW CP Bayer
DMRM3AW TC Hypoglycemic Agents
DMRM3AW DT Small molecular drug
DMRM3AW PC 41774
DMRM3AW MW 645.6
DMRM3AW FM C25H43NO18
DMRM3AW IC InChI=1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23?,24-,25-/m1/s1
DMRM3AW CS C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO
DMRM3AW IK XUFXOAAUWZOOIT-UGEKTDRHSA-N
DMRM3AW IU (3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
DMRM3AW CA CAS 56180-94-0
DMRM3AW CB CHEBI:2376
DMRM3AW DE Diabetic complication; Cardiovascular disease
DM0TI4U ID DM0TI4U
DM0TI4U DN Acebutolol
DM0TI4U HS Approved
DM0TI4U SN Acebrutololum; Acebutololo; Acebutololum; Acetobutolol; Neptal; Prent; Sectral; Acebutolol HCL; RP 21823; Acebrutololum [INN-Latin]; Acebutololum [INN-Latin]; Acetobutolol [INN-Spanish]; Dl-Acebutolol; M & B 17803A; Prent (TN); Sectral (TN); Acebutolol (USAN/INN); Acebutolol [USAN:INN:BAN]; M&B-17803 A; N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide; N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide; N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide; N-{3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}butanamide; (+-)-3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; (+-)-Acebutolol; (+-)-N-(3-Acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)butanamide; 1-(2-Acetyl-4-n-butyramidophenoxy)-2-hydroxy-3-isopropylaminopropane; 3'-(Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide; 3'-Acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)butyranilid; 5'-Butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
DM0TI4U CP Promius Pharma Llc
DM0TI4U TC Antihypertensive Agents
DM0TI4U DT Small molecular drug
DM0TI4U PC 1978
DM0TI4U MW 336.4
DM0TI4U FM C18H28N2O4
DM0TI4U IC InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
DM0TI4U CS CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
DM0TI4U IK GOEMGAFJFRBGGG-UHFFFAOYSA-N
DM0TI4U IU N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide
DM0TI4U CA CAS 37517-30-9
DM0TI4U CB CHEBI:2379
DM0TI4U DE Hypertension
DMOLNCZ ID DMOLNCZ
DMOLNCZ DN ACECLIDINE
DMOLNCZ HS Approved
DMOLNCZ SN (-)-aceclidine; R-(-)-aceclidine; GTPL288; ZB016005; [(8R)-1-azoniabicyclo[2.2.2]octan-8-yl] acetate
DMOLNCZ DT Small molecular drug
DMOLNCZ PC 1979
DMOLNCZ MW 169.22
DMOLNCZ FM C9H15NO2
DMOLNCZ IC InChI=1S/C9H15NO2/c1-7(11)12-9-6-10-4-2-8(9)3-5-10/h8-9H,2-6H2,1H3
DMOLNCZ CS CC(=O)OC1CN2CCC1CC2
DMOLNCZ IK WRJPSSPFHGNBMG-UHFFFAOYSA-N
DMOLNCZ IU 1-azabicyclo[2.2.2]octan-3-yl acetate
DMOLNCZ CA CAS 827-61-2
DMOLNCZ CB CHEBI:93847
DMOLNCZ DE Glaucoma/ocular hypertension
DMZDF0B ID DMZDF0B
DMZDF0B DN Aceclofenac
DMZDF0B HS Approved
DMZDF0B SN Airtal; Barracan; Biofenac; Bristaflam; Falcol; Gerbin; Preservex; YT-919
DMZDF0B CP Almirall Prodesfarma SA
DMZDF0B DT Small molecular drug
DMZDF0B PC 71771
DMZDF0B MW 354.2
DMZDF0B FM C16H13Cl2NO4
DMZDF0B IC InChI=1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
DMZDF0B CS C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMZDF0B IK MNIPYSSQXLZQLJ-UHFFFAOYSA-N
DMZDF0B IU 2-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxyacetic acid
DMZDF0B CA CAS 89796-99-6
DMZDF0B CB CHEBI:31159
DMZDF0B DE Inflammation
DMH75KV ID DMH75KV
DMH75KV DN Acenocoumarol
DMH75KV HS Approved
DMH75KV SN Acenocoumarin; Acenocoumarolum; Acenocumarol; Acenocumarolo; Acenocumarolum; Acenokumarin; Ascumar; Minisintrom; Neositron;Nicoumalone; Nicumalon; Nitrovarfarian; Nitrowarfarin; Sincoumar; Sinkumar; Sinthrom; Sinthrome; Sintrom; Sintroma; Syncoumar; Syncumar; Synthrom; Syntrom; Zotil; Acenocoumarol Alliance Brand; Acenocoumarol Novartis Brand; Acenocoumarol [INN]; Acenocumarolo [DCIT]; Acenokumarin [Czech]; Alliance Brand of Acenocoumarol; Ciba Geigy Brand of Acenocoumarol; Mini Sintrom; Novartis Brand of Acenocoumarol; G 23350; Acenocoumarol (INN); Acenocoumarol Ciba-Geigy Brand; Acenocoumarolum [INN-Latin]; Ciba-Geigy Brand of Acenocoumarol; G-23350; Mini-sintrom; Sinthrome (TN); Sintrom (TN); AB-014/25000129; G-23,350; Mini-sintrom (TN); Nitrophenylacetylethyl-4-hydroxycoumarine; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-4h-chromen-4-one; 2-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-4-one; 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin; 3-(alpha-Acetonyl-para-nitrobenzyl)-4-hydroxy-coumarin; 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one;4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
DMH75KV TC Anticoagulants
DMH75KV DT Small molecular drug
DMH75KV PC 54676537
DMH75KV MW 353.3
DMH75KV FM C19H15NO6
DMH75KV IC InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
DMH75KV CS CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O
DMH75KV IK VABCILAOYCMVPS-UHFFFAOYSA-N
DMH75KV IU 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]chromen-2-one
DMH75KV CA CAS 152-72-7
DMH75KV CB CHEBI:53766
DMH75KV DE Thrombosis
DM1SRQT ID DM1SRQT
DM1SRQT DN Aceprometazine
DM1SRQT HS Approved
DM1SRQT SN Aceprometazina; Aceprometazinum; Acepromethazine; Aceprometazina [INN-Spanish]; Aceprometazine [INN:DCF]; Aceprometazinum [INN-Latin]; Mepronizine (TN); KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-(9CI); 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; 1664 CB
DM1SRQT TC Antihistamines
DM1SRQT DT Small molecular drug
DM1SRQT PC 26035
DM1SRQT MW 326.5
DM1SRQT FM C19H22N2OS
DM1SRQT IC InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
DM1SRQT CS CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)C)N(C)C
DM1SRQT IK XLOQNFNTQIRSOX-UHFFFAOYSA-N
DM1SRQT IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone
DM1SRQT CA CAS 13461-01-3
DM1SRQT CB CHEBI:53770
DM1SRQT DE Sleep-wake disorder
DMUIE76 ID DMUIE76
DMUIE76 DN Acetaminophen
DMUIE76 HS Approved
DMUIE76 SN acetaminophen; 4-Acetamidophenol; Paracetamol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Acetaminofen; Panadol; Datril; p-Hydroxyacetanilide; N-Acetyl-p-aminophenol; p-Acetamidophenol; Algotropyl; Naprinol; Lonarid; 4'-Hydroxyacetanilide; Multin; Acenol; Acamol; Anelix; p-Acetaminophenol; Liquagesic; Acetagesic; Gelocatil; Servigesic; Acetalgin; Abensanil; Pyrinazine; Injectapap; Clixodyne; Valgesic; Tussapap; Finimal; Paracet; Homoolan; Febrolin; Febrilix; Febridol; Dymadon; Anaflon; Apamide; Valadol; Tralgon; Tabalgin; Lestemp; Alvedon; Abenol; Abrol; Abrolet; Acephen; Acertol; Acetaco; Acetamol; Acetavance; Acetofen; Actamin; Actimol; Afebrin; Afebryl; Aferadol; Algesidal; Algina; Algomol; Alpiny; Alpinyl; Amadil; Aminofen; Analter; Anapap; Andox; Anhiba; Antidol; Anuphen; Apacet; Apadon; Apitrelal; Arfen; Arthralgen; Asetam; Asomal; Aspac; Asplin; Atasol; Atralidon; Babikan; Bacetamol; Banesin; Benmyo; Biocetamol; Cadafen; Calapol; Calmanticold; Calonal; Calpol; Capital; Captin; Causalon; Cefalex; Cetadol; Codabrol; Codalgin; Codapane; Codicet; Codisal; Codoliprane; Cofamol; Conacetol; Cosutone; Cuponol; Curadon; Curpol; Custodial; Dafalgan; Darocet; Darvocet; Daygrip; Deminofen; Democyl; Demogripal; Desfebre; Dhamol; Dimindol; Dirox; Disprol; Dolcor; Dolefin; Dolegrippin; Dolgesic; Doliprane; Dolko; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dolotec; Dolprone; Dorocoff; Dresan; Dristancito; Duaneo; Dularin; Duorol; Duracetamol; Durapan; Dypap; Ecosetol; Elixodyne; Empracet; Enelfa; Eneril; Excipain; Exdol; Fanalgic; Farmadol; Febranine; Febrectal; Febrectol; Febrex; Febricet; Febrin; Febrinol; Fendon; Fensum; Fepanil; Fevor; Finiweh; Fluparmol; Geluprane; Genapap; Genebs; Grippostad; Gynospasmine; Hedex; Ildamol; Inalgex; Infadrops; Janupap; Kataprin; Korum; Labamol; Lekadol; Lemgrip; Lemsip; Liqiprine; Lupocet; Lyteca; Magnidol; Malgis; Malidens; Maxadol; Medocodene; Mexalen; Minafen; Minoset; Miralgin; Momentum; NEBS; Napafen; Nealgyl; NeoCitran; Neodol; Neodolito; Neopap; Neotrend; Neuridon; NilnOcen; Nina; Nobedon; Nodolex; Noral; Ofirmev; Oltyl; Oralgan; Ortensan; Oxycocet; Paceco; Pacemo; Pacemol; Pacet; Pacimol; Paedialgon; Paedol; Painex; Paldesic; Pamol; Panacete; Panadeine; Panadiene; Panaleve; Panamax; Panasorb; Panasorbe; Panets; Panex; Panodil; Panofen; Pantalgin; Paracemol; Paracenol; Paracetamole; Paracetamolo; Paracetanol; Paracetol; Paracin; Paracod; Paracodol; Parador; Paradrops; Parakapton; Parake; Paralen; Paralief; Paralink; Paralyoc; Paramol; Paramolan; Paranox; Parapan; Parasedol; Parasin; Paraspen; Parcetol; Parelan; Parmol; Parogal; Paroma; Pasolind; Pediapirin; Pediatrix; Pedric; Perfalgan; Phendon; Phenipirin; Phogoglandin; Pinex; Piramin; Pirinasol; Plicet; Polmofen; Predimol; Predualito; Prodol; Prompt; Prontina; Puernol; Pulmofen; Pyrigesic; Pyromed; Redutemp; Reliv; Remedol; Rivalgyl; Robigesic; Rounox; RubieMol; Rubophen; Rupemol; Salzone; Sanicet; Sanicopyrine; Scanol; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Setakop; Setamol; Setol; Sifenol; Sinaspril; Sinedol; Sinmol; Stanback; Stopain; Sunetheton; Supofen; Suppap; TYL; Tachiprina; Tapanol; Tapar; Tazamol; Temlo; Tempanal; Tempra; Termacet; Termalgin; Termalgine; Termofren; Tiffy; Titralgan; Treuphadol; Tricoton; Tylex; Tylol; Tymol; Upsanol; Utragin; Valorin; Veralgina; Vermidon; Verpol; Vips; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Aceta Elixir; Actifed Plus; Aspirin free anacin; Bayer Select; D oliprane; Dymadon Co; Fortalidon P; Gattaphen T; Gripin Bebe; Helon N; Influbene N; Jin Gang; Lonarid Mono; Lyteca Syrup; Malex N; Panadeine Co; Panale ve; Pasolind N; Spalt N; Supadol mono; Toximer P; Treupel N; Treupel mon; Ty lenol; Tylex CD; Anacin 3; A-Per; Accu-Tap; Ultracet
DMUIE76 CP Beximco Pharma
DMUIE76 TC Analgesics
DMUIE76 DT Small molecular drug
DMUIE76 PC 1983
DMUIE76 MW 151.16
DMUIE76 FM C8H9NO2
DMUIE76 IC InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
DMUIE76 CS CC(=O)NC1=CC=C(C=C1)O
DMUIE76 IK RZVAJINKPMORJF-UHFFFAOYSA-N
DMUIE76 IU N-(4-hydroxyphenyl)acetamide
DMUIE76 CA CAS 103-90-2
DMUIE76 CB CHEBI:46195
DMUIE76 DE Pain
DM1AF5U ID DM1AF5U
DM1AF5U DN Acetazolamide
DM1AF5U HS Approved
DM1AF5U SN Acetadiazol; Acetamidothiadiazolesulfonamide; Acetamox; Acetazolam; Acetazolamid; Acetazolamida; Acetazolamidum; Acetazolamine; Acetazoleamide; Acetozalamide; AkZol; ApoAcetazolamide; Atenezol; Cidamex; Dazamide; Defiltran; Dehydratin; Diacarb; Diakarb; Diamox; Didoc; Diluran; Diuramid; Diuramide; Diuriwas; Diutazol; Donmox; Duiramid; Edemox; Eumicton; Fonurit; Glauconox; Glaumox; Glaupax; Glupax; HumaZolamide; Natrionex; Nephramid; Nephramide; Phonurit; Storzolamide; Vetamox; Acetazolamide Apotex Brand; Acetazolamide Chiesi Brand; Acetazolamide Dioptic Brand; Acetazolamide Grin Brand; Acetazolamide ICN Brand; Acetazolamide Jumer Brand; Acetazolamide Llorens Brand; Acetazolamide Medphano Brand; Acetazolamide Novopharm Brand; Acetazolamide Orion Brand; Acetazolamide Wassermann Brand; Ak Zol; Apo Acetazolamide; Apotex Brand of Acetazolamide; Chiesi Brand of Acetazolamide; Ciba Vision Brand of Acetazolamide; DiamoxSequels; Dioptic Brand of Acetazolamide; Grin Brand of Acetazolamide; Huma Zolamide; ICN Brand of Acetazolamide; Jumer Brand of Acetazolamide; Llorens Brand of Acetazolamide; Medphano Brand of Acetazolamide; Monosodium Salt Acetazolamide; Novopharm Brand of Acetazolamide; Orion Brand of Acetazolamide; Storz Brand of Acetazolamide Preparation; Wassermann Brand of Acetazolamide; Wyeth Brand of Acetazolamide Preparation; A 6011; Carbonic anhydrase inhibitor 6063; Acetazolamida [INN-Spanish]; Acetazolamide (AAZ); Acetazolamide, Monosodium Salt; Acetazolamidum [INN-Latin]; Ak-Zol; Apo-Acetazolamide; Carbonic Anhydrase Inhibitor No. 6063; Diamox (TN); Diureticum-holzinger; Huma-Zolamide; SK-acetazolamide; Acetazolamide Sodium, (Sterile); Acetazolamide [INN:BAN:JAN]; Acetazolamide (JP15/USP/INN); 4-Diamox
DM1AF5U TC Anticonvulsants
DM1AF5U DT Small molecular drug
DM1AF5U PC 1986
DM1AF5U MW 222.3
DM1AF5U FM C4H6N4O3S2
DM1AF5U IC InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
DM1AF5U CS CC(=O)NC1=NN=C(S1)S(=O)(=O)N
DM1AF5U IK BZKPWHYZMXOIDC-UHFFFAOYSA-N
DM1AF5U IU N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
DM1AF5U CA CAS 59-66-5
DM1AF5U CB CHEBI:27690
DM1AF5U DE Glaucoma/ocular hypertension
DM4SJ5Y ID DM4SJ5Y
DM4SJ5Y DN Acetic Acid, Glacial
DM4SJ5Y HS Approved
DM4SJ5Y SN ethanoic acid; 64-19-7; Ethylic acid; Acetic acid glacial; Acetic acid, glacial; Methanecarboxylic acid; Glacial acetic acid; Vinegar acid; Acetasol; Acide acetique; Essigsaeure; Aci-jel; Azijnzuur; Vinegar; Kyselina octova; Acido acetico; Octowy kwas; Pyroligneous acid; HOAc; Azijnzuur [Dutch]; Ethanoic acid monomer; acetyl alcohol; Aceticum acidum; Essigsaeure [German]; ethoic acid; Caswell No 003; Otic Tridesilon; Octowy kwas [Polish]; Otic Domeboro; Acetic acid (natural); Kyselina octova [Czech]; Acide acetique [French]; Orlex; Vosol; Acetic Acid 025% In Plastic Container
DM4SJ5Y CP Actavis Mid Atlantic Llc
DM4SJ5Y TC Antiinfective Agents
DM4SJ5Y DT Small molecular drug
DM4SJ5Y PC 176
DM4SJ5Y MW 60.05
DM4SJ5Y FM C2H4O2
DM4SJ5Y IC InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
DM4SJ5Y CS CC(=O)O
DM4SJ5Y IK QTBSBXVTEAMEQO-UHFFFAOYSA-N
DM4SJ5Y IU acetic acid
DM4SJ5Y CA CAS 64-19-7
DM4SJ5Y CB CHEBI:15366
DM4SJ5Y DE infection in the ear canal
DMR6N7H ID DMR6N7H
DMR6N7H DN Acetohexamide
DMR6N7H HS Approved
DMR6N7H SN Acetohexamid; Acetohexamida; Acetohexamidum; Dimelin; Dimelor; Dymelor; Gamadiabet; Hypoglicil; Metaglucina; Minoral; Ordimel; Tsiklamid; Acetohexamide Lilly Brand; Acetohexamide Salvat Brand; Lilly Brand of Acetohexamide; Ord imel; Salvat Brand of Acetohexamide; U 14812; A-178; Acetohexamida [INN-Spanish]; Acetohexamidum [INN-Latin]; Dimelin (antidiabetic); Dymelor (TN); U-14812; Acetohexamide (JP15/USP/INN); Acetohexamide [USAN:INN:BAN:JAN]; N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea; N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea; 1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea; 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea; 1-(p-Acetylbenzenesulfonyl)-3-cyclohexylurea; 3-cyclohexyl-1-(p-acetylphenylsulfonyl)urea; 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)-carbonyl]benzenesulfonamide; 4-Acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide; 4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulf onamide
DMR6N7H TC Hypoglycemic Agents
DMR6N7H DT Small molecular drug
DMR6N7H PC 1989
DMR6N7H MW 324.4
DMR6N7H FM C15H20N2O4S
DMR6N7H IC InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)
DMR6N7H CS CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
DMR6N7H IK VGZSUPCWNCWDAN-UHFFFAOYSA-N
DMR6N7H IU 1-(4-acetylphenyl)sulfonyl-3-cyclohexylurea
DMR6N7H CA CAS 968-81-0
DMR6N7H CB CHEBI:28052
DMR6N7H DE Diabetic complication
DMYX7NI ID DMYX7NI
DMYX7NI DN Acetohydroxamic Acid
DMYX7NI HS Approved
DMYX7NI SN AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI)
DMYX7NI TC Antiinfective Agents
DMYX7NI DT Small molecular drug
DMYX7NI PC 1990
DMYX7NI MW 75.07
DMYX7NI FM C2H5NO2
DMYX7NI IC InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
DMYX7NI CS CC(=O)NO
DMYX7NI IK RRUDCFGSUDOHDG-UHFFFAOYSA-N
DMYX7NI IU N-hydroxyacetamide
DMYX7NI CA CAS 546-88-3
DMYX7NI CB CHEBI:27777
DMYX7NI DE Urinary tract infection
DMZV2PJ ID DMZV2PJ
DMZV2PJ DN Acetophenazine
DMZV2PJ HS Approved
DMZV2PJ SN Acephenazinum; Acetophenazina; Acetophenazinum; Tindal; Acetophenazine [INN]; Acetophenazina [INN-Spanish]; Acetophenazinum [INN-Latin]; Ketone, 10-(3-(4-(2-hydroxyethyl-1-piperazinyl)propyl)phenothiazin-2-yl methyl; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone; 10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl methyl ketone; 2-acetyl-10-[3-[4-(b-hydroxyethyl)piperazinyl]propyl]phenothiazine
DMZV2PJ TC Antipsychotic Agents
DMZV2PJ DT Small molecular drug
DMZV2PJ PC 17676
DMZV2PJ MW 411.6
DMZV2PJ FM C23H29N3O2S
DMZV2PJ IC InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3
DMZV2PJ CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMZV2PJ IK WNTYBHLDCKXEOT-UHFFFAOYSA-N
DMZV2PJ IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMZV2PJ CA CAS 2751-68-0
DMZV2PJ CB CHEBI:2401
DMZV2PJ DE Bipolar disorder
DMDF79Z ID DMDF79Z
DMDF79Z DN Acetylcholine
DMDF79Z HS Approved
DMDF79Z SN acetylcholine; Choline acetate; O-Acetylcholine; Acetyl choline ion; Acetylcholinum; 51-84-3; (2-Acetoxyethyl)trimethylammonium; Acetyl choline cation; Choline acetate (ester); 2-(Acetyloxy)-N,N,N-trimethylethanaminium; Ach; Azetylcholin; ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; UNII-N9YNS0M02X; BRN 1764436; CHEBI:15355; Bromoacetylcholine; EINECS 200-128-9; CHEMBL667; N9YNS0M02X; [2-(acetyloxy)ethyl]trimethylazanium; Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- (9CI); 2-acetyloxyethyl-trimethylazanium; [3H]acetylcholine; Miochol; Miochol-e
DMDF79Z CP Novartis Pharmaceuticals Corp
DMDF79Z TC Cardiovascular Agents
DMDF79Z DT Small molecular drug
DMDF79Z PC 187
DMDF79Z MW 146.21
DMDF79Z FM C7H16NO2+
DMDF79Z IC InChI=1S/C7H16NO2/c1-7(9)10-6-5-8(2,3)4/h5-6H2,1-4H3/q+1
DMDF79Z CS CC(=O)OCC[N+](C)(C)C
DMDF79Z IK OIPILFWXSMYKGL-UHFFFAOYSA-N
DMDF79Z IU 2-acetyloxyethyl(trimethyl)azanium
DMDF79Z CA CAS 51-84-3
DMDF79Z CB CHEBI:15355
DMDF79Z DE Cataract
DMHAUO0 ID DMHAUO0
DMHAUO0 DN Acetyldigitoxin
DMHAUO0 HS Approved
DMHAUO0 SN Acedigal; Acetildigitoxina; Acetyldiginatin; Acetyldigitoxinum; Acigoxin; Acylanid; Acylanide; Adicin; Acetyldigitoxin [INN]; Desglucolanatoside A; Acetildigitoxina [INN-Spanish]; Acetyldigitoxin (INN); Acetyldigitoxinum [INN-Latin]; Acylanid (TN); Alpha-Acetyldigitoxin; Alpha-Acetyldigitoxins; Alpha-Monoacetyldigitoxin; Acetyl-digitoxin-alpha; Digitoxin 3'''-acetate; Digitoxin, 3'''-acetate; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-((O-3-O-Acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxycard-20(22)-enolide; (3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide; 3beta-[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide; [3-hydroxy-6-[4-hydroxy-6-[4-hydroxy-6-[[14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0 CP Norvatis Phamaceuticals Corporation
DMHAUO0 TC Cardiotonic Agents
DMHAUO0 DT Small molecular drug
DMHAUO0 PC 5284512
DMHAUO0 MW 807
DMHAUO0 FM C43H66O14
DMHAUO0 IC InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1
DMHAUO0 CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O
DMHAUO0 IK HPMZBILYSWLILX-UMDUKNJSSA-N
DMHAUO0 IU [(2R,3R,4S,6S)-3-hydroxy-6-[(2R,3S,4S,6S)-4-hydroxy-6-[(2R,3S,4S,6R)-4-hydroxy-6-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-yl]oxy-2-methyloxan-4-yl] acetate
DMHAUO0 CA CAS 1111-39-3
DMHAUO0 CB CHEBI:53773
DMHAUO0 DE Congestive heart failure
DMYLOVR ID DMYLOVR
DMYLOVR DN Aciclovir
DMYLOVR HS Approved
DMYLOVR SN acyclovir; Acycloguanosine; 59277-89-3; Zovirax; Vipral; Virorax; Wellcome-248U; 9-[(2-Hydroxyethoxy)methyl]guanine; Aciclovirum; Zovir; Aciclovirum [Latin]; Sitavig; Aciclovier; Zyclir; 9-HYROXYETHOXYMETHYLGUANINE; Aciclovirum [INN-Latin]; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; W-248-U; 9-(2-Hydroxyethoxy)methylguanine; Acyclovir-side chain-2-3H; ACYCLOVIR SODIUM; 9-((2-Hydroxyethoxy)methyl)guanine; Acicloftal; Cargosil; BW-248U; UNII-X4HES1O11F; DRG-0008; NSC 645011; CHEBI:2453; CCRIS 1953; Iontophoretic acyclovir
DMYLOVR CP GlaxoSmithKline
DMYLOVR TC Antiviral Agents
DMYLOVR DT Small molecular drug
DMYLOVR PC 135398513
DMYLOVR MW 225.2
DMYLOVR FM C8H11N5O3
DMYLOVR IC InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)
DMYLOVR CS C1=NC2=C(N1COCCO)N=C(NC2=O)N
DMYLOVR IK MKUXAQIIEYXACX-UHFFFAOYSA-N
DMYLOVR IU 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one
DMYLOVR CA CAS 59277-89-3
DMYLOVR CB CHEBI:2453
DMYLOVR DE Virus infection; Herpes simplex virus infection
DM8BKU9 ID DM8BKU9
DM8BKU9 DN Acitretin
DM8BKU9 HS Approved
DM8BKU9 SN Acitretina; Acitretine; Acitretinum; Etretin; Isoacitretin; Isoetretin; Neotigason; Soriatane; TMMP; Acitretina [Spanish]; Acitretine [French]; Acitretinum [Latin]; Retinoid etretin; U0279; Ro 10-1670; Ro 13-7652; Soriatane (TN); Soriatane, Acitretin; Acitretin (USAN/INN); Acitretin [USAN:INN:BAN]; All-trans-Acitretin; Ro 10-1670/000; Ro-10-1670; Ro-13-7652; Ro-10-1670/000; All-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid; (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid; (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid; (all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 13-cis-Acitretin; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid; 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9 TC Keratolytic Agents
DM8BKU9 DT Small molecular drug
DM8BKU9 PC 5284513
DM8BKU9 MW 326.4
DM8BKU9 FM C21H26O3
DM8BKU9 IC InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+
DM8BKU9 CS CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC
DM8BKU9 IK IHUNBGSDBOWDMA-AQFIFDHZSA-N
DM8BKU9 IU (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DM8BKU9 CA CAS 55079-83-9
DM8BKU9 CB CHEBI:50173
DM8BKU9 DE Psoriasis vulgaris
DMLFZHD ID DMLFZHD
DMLFZHD DN Aclarubicin
DMLFZHD HS Approved
DMLFZHD SN Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A
DMLFZHD TC Anticancer Agents
DMLFZHD DT Small molecular drug
DMLFZHD PC 451415
DMLFZHD MW 811.9
DMLFZHD FM C42H53NO15
DMLFZHD IC InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
DMLFZHD CS CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
DMLFZHD IK USZYSDMBJDPRIF-SVEJIMAYSA-N
DMLFZHD IU methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate
DMLFZHD CA CAS 57576-44-0
DMLFZHD CB CHEBI:77980
DMLFZHD DE Acute myeloid leukaemia
DM7JT24 ID DM7JT24
DM7JT24 DN Acocantherin
DM7JT24 HS Approved
DM7JT24 SN Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
DM7JT24 TC Cardiotonic Agents
DM7JT24 DT Small molecular drug
DM7JT24 PC 439501
DM7JT24 MW 584.7
DM7JT24 FM C29H44O12
DM7JT24 IC InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
DM7JT24 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
DM7JT24 IK LPMXVESGRSUGHW-HBYQJFLCSA-N
DM7JT24 IU 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DM7JT24 CA CAS 630-60-4
DM7JT24 CB CHEBI:472805
DM7JT24 DE Heart failure; Atrial fibrillation
DMTIGA0 ID DMTIGA0
DMTIGA0 DN Acrivastine
DMTIGA0 HS Approved
DMTIGA0 SN Acrivastin; Acrivastina; Acrivastinum; Semprex; Acrivastina [Spanish]; Acrivastinum [Latin]; Benadryl allergy relief; BW 0270C; BW 825C; BW A825C; BW-825C; Acrivastine (USAN/INN); Acrivastine [USAN:INN:BAN]; E-(9CI); (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (E)-6-((E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)-2-pyridineacrylic acid; (E)-6-((E)-3-(1-Pyrrolidinyl-1-p-tolylpropenyl)-2-pyridinacrylsaeure; (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoic acid; 3-{6-[1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
DMTIGA0 CP Pfizer Pharmaceuticals
DMTIGA0 TC Antiinflammatory Agents
DMTIGA0 DT Small molecular drug
DMTIGA0 PC 5284514
DMTIGA0 MW 348.4
DMTIGA0 FM C22H24N2O2
DMTIGA0 IC InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
DMTIGA0 CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC(=N3)/C=C/C(=O)O
DMTIGA0 IK PWACSDKDOHSSQD-IUTFFREVSA-N
DMTIGA0 IU (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
DMTIGA0 CA CAS 87848-99-5
DMTIGA0 CB CHEBI:83168
DMTIGA0 DE Allergic rhinitis
DMQMV1B ID DMQMV1B
DMQMV1B DN Adalimumab
DMQMV1B HS Approved
DMQMV1B SN Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)
DMQMV1B CP Abbott Laboratories
DMQMV1B TC Antirheumatic Agents
DMQMV1B DT Antibody
DMQMV1B SQ Light chain:: DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC > Heavy chain:EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
DMQMV1B DE Rheumatoid arthritis
DMX2358 ID DMX2358
DMX2358 DN Adapalene
DMX2358 HS Approved
DMX2358 SN Adaferin; Adapaleno; Adapalenum; Differin; Differine; CD 271; CD271; Adaferin (TN); Adapaleno [INN-Spanish]; Adapalenum [INN-Latin]; CD-271; Differin (TN); Differin, Adapalene; KS-1196; Adapalene [USAN:BAN:INN]; Adapalene (JAN/USAN/INN); 6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid; 6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid; 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid; 6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
DMX2358 CP Galderma Laboratories
DMX2358 TC Dermatologic Agents
DMX2358 DT Small molecular drug
DMX2358 PC 60164
DMX2358 MW 412.5
DMX2358 FM C28H28O3
DMX2358 IC InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
DMX2358 CS COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DMX2358 IK LZCDAPDGXCYOEH-UHFFFAOYSA-N
DMX2358 IU 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
DMX2358 CA CAS 106685-40-9
DMX2358 CB CHEBI:31174
DMX2358 DE Acne vulgaris
DMM278X ID DMM278X
DMM278X DN Adefovir
DMM278X HS Approved
DMM278X SN ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid
DMM278X DT Small molecular drug
DMM278X PC 60172
DMM278X MW 273.189
DMM278X FM C12H14Cl2N2
DMM278X IC InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
DMM278X CS C1=NC2=C(C(=N1)N)N=CN2CCOCP(=O)(O)O
DMM278X IK FIKAKWIAUPDISJ-UHFFFAOYSA-L
DMM278X IU 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid
DMM278X CA CAS 106941-25-7
DMM278X CB CHEBI:2469
DMM278X DE Hepatitis B virus infection; Herpes simplex virus infection
DMMAWY1 ID DMMAWY1
DMMAWY1 DN Adefovir dipivoxil
DMMAWY1 HS Approved
DMMAWY1 SN Adefovirdipivoxl; Hepsera; Preveon; YouHeDing; Adefovir depivoxil; Adefovir pivoxil; GS 0840; GS 840;Piv2PMEA; Adefovir dipivoxil (USAN); Adefovir pivoxil (JAN); Bis(pom)PMEA; Bis-POM PMEA; GS-0840; GS-840; Hepsera (TM); Hepsera (TN); Preveon (TN); Bis(POM)-PMEA; Bis-POM PMEA, Adefovir Dipivoxil; Bis-POM PMEA, Preveon, Hepsera, Adefovir Dipivoxil; Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine; [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; Propanoic acid,2,2-dimethyl-(((2-(6-amino-9H-purin-9-yl)ehtoxy)mehtyl)phosphinyldiene)bis(oxymehtylene)ester; Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester; (((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate; ((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid, diester with hydroxymethyl pivalate; 9-(2-((-Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; 9-(2-((Bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine; ADV
DMMAWY1 CP Gilead Sciences
DMMAWY1 TC Antiviral Agents
DMMAWY1 DT Small molecular drug
DMMAWY1 PC 60871
DMMAWY1 MW 501.5
DMMAWY1 FM C20H32N5O8P
DMMAWY1 IC InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)
DMMAWY1 CS CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N=CN=C21)N)OCOC(=O)C(C)(C)C
DMMAWY1 IK WOZSCQDILHKSGG-UHFFFAOYSA-N
DMMAWY1 IU [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMMAWY1 CA CAS 142340-99-6
DMMAWY1 CB CHEBI:31175
DMMAWY1 DE Hepatitis B virus infection
DMYQDBO ID DMYQDBO
DMYQDBO DN Ademetionine
DMYQDBO HS Approved
DMYQDBO SN Ceritan; Samyr; Transmetil; Ademetionine butandisulphonate; Ademetionine disulfate tosylate; Ademetionine sulfate tosilate; FD-1561; FO-1561
DMYQDBO CP Bioresearch SpA
DMYQDBO DT Small molecular drug
DMYQDBO PC 34755
DMYQDBO MW 398.4
DMYQDBO FM C15H22N6O5S
DMYQDBO IC InChI=1S/C15H22N6O5S/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/t7-,8+,10+,11+,14+,27?/m0/s1
DMYQDBO CS C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMYQDBO IK MEFKEPWMEQBLKI-AIRLBKTGSA-N
DMYQDBO IU (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-methylsulfonio]butanoate
DMYQDBO CA CAS 29908-03-0
DMYQDBO CB CHEBI:67040
DMYQDBO DE Cerebrovascular ischaemia; Hepatic fibrosis
DMZLHKJ ID DMZLHKJ
DMZLHKJ DN Adenine
DMZLHKJ HS Approved
DMZLHKJ SN ADE; ANE; Adenin; Adeninimine; Adenine [JAN]; Pedatisectine B; AD2; Vitamin B 4; Vitamin B4; ALBB-005925; Adenine (8CI); Adenine-ring; B 4, Vitamin; Leuco-4; Leucon (TN); Purine, 6; USAF CB-18; Vitamin-B4; Adenine (JAN/USP); Adenine-8-14C; 1,6-Dihydro-6-Imnopurine; 1,6-Dihydro-6-iminopurine; 1H-Purin-6-amine; 1H-Purin-6-amine (9CI); 1H-Purine, 6-amino; 2'-DEOXY-ADENOSINE-3'-5'-DIPHOSPHATE; 3,6-Dihydro-6-iminopurine; 4, Vitamin B; 6-Amino-1H-purine; 6-Amino-3H-purine; 6-Amino-7H-purine; 6-Amino-9H-purine; 6-Aminopurine; 7H-Purin-6-amine; 9H-Purin-6-amine
DMZLHKJ TC Dietary supplement
DMZLHKJ DT Small molecular drug
DMZLHKJ PC 190
DMZLHKJ MW 135.13
DMZLHKJ FM C5H5N5
DMZLHKJ IC InChI=1S/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)
DMZLHKJ CS C1=NC2=NC=NC(=C2N1)N
DMZLHKJ IK GFFGJBXGBJISGV-UHFFFAOYSA-N
DMZLHKJ IU 7H-purin-6-amine
DMZLHKJ CA CAS 73-24-5
DMZLHKJ CB CHEBI:16708
DMZLHKJ DE Malnutrition
DMM2NSK ID DMM2NSK
DMM2NSK DN Adenosine
DMM2NSK HS Approved
DMM2NSK SN Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine
DMM2NSK TC Antiarrhythmic Agents
DMM2NSK DT Small molecular drug
DMM2NSK PC 60961
DMM2NSK MW 267.24
DMM2NSK FM C10H13N5O4
DMM2NSK IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
DMM2NSK CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMM2NSK IK OIRDTQYFTABQOQ-KQYNXXCUSA-N
DMM2NSK IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMM2NSK CA CAS 5536-17-4
DMM2NSK CB CHEBI:16335
DMM2NSK DE Paroxysmal supraventricular tachycardia
DMNIJT0 ID DMNIJT0
DMNIJT0 DN Adenosine monophosphate
DMNIJT0 HS Approved
DMNIJT0 SN ASMP; Adenovite; Adenyl; Adenylate; Cardiomone; Lycedan; Monophosphadenine; Muskeladenylsaeure; Myoston; PAdo; Phosaden; Phosphaden; Phosphentaside; AMP dianion; Adenine polynucleotides; Adenosine phosphate; Adenosini phosphas; Adenylic acid; Ergadenylic acid; Fosfato de adenosina; Muscle adenylic acid; POLY A; Polyadenylic acids; Vitamin B8; A-5mp; AMP (VAN); AMP (nucleotide); Adenosine Monophosphate (Amp); Adenosine-monophosphate; Adenosine-phosphate; Adenosini phosphas [INN-Latin]; Adenyl (TN); Adenylic acid (VAN); Ado5'P; Fosfato de adenosina [INN-Spanish]; Muskeladenosin-phosphorsaeure; Phosphate d'adenosine; Adenosine 5'-monophosphate; Adenosine 5'-monophosphoric acid; Adenosine 5'-phosphate; Adenosine 5'-phosphoric acid; Adenosine phosphate (USAN/INN); Adenosine phosphate [USAN:BAN:INN]; Adenosine phosphate [USAN:INN:BAN]; Adenosine-5'P; Adenosine-5-monophosphate dianion; Adenosine-5-monophosphoric acid; Adenosine-5-phosphate; Formycin 5'-monophosphate hydrate; Formycin 5'-phosphate; Formycin 5'-phosphate hydrate; Formycin A 5'-monophosphate hydrate; My-B-Den; Phosphate d'adenosine [INN-French]; ADENOSINE-5'-PHOSPHATE; Adenosine 5'-(dihydrogen phosphate); Adenosine, mono(dihydrogen phosphate) (ester); Adenosine-5'-monophosphate; Adenosine-5'-monophosphoric acid; Adenosine-5-monophosphate(2-); GAMMA-ARSONO-BETA, GAMMA-METHYLENEADENOSINE-5'-DIPHOSPHATE; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(dihydrogen phosphate); 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-, 5'-(dihydrogen phosphate)-, hydrate; 5'-Adenylic acid, homopolymer; 5'-Deoxy-5'-thioadenosine 5'-monophosphate; 5'-O-phosphonatoadenosine; 5'-O-phosphonoadenosine; 5'-Thio-5'-adenylic acid; 5'-adenosine monophosphate; 5'-adenylic acid; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine 5'-(dihydrogen phosphate) hydrate; 7A8E6D15-9136-44C1-88C9-E1A224638E56; 7gpb; 8-Aminoadenosine 5'-monophosphate; 8gpb
DMNIJT0 TC Dietary supplement
DMNIJT0 DT Small molecular drug
DMNIJT0 PC 6083
DMNIJT0 MW 347.22
DMNIJT0 FM C10H14N5O7P
DMNIJT0 IC InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMNIJT0 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DMNIJT0 IK UDMBCSSLTHHNCD-KQYNXXCUSA-N
DMNIJT0 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMNIJT0 CA CAS 61-19-8
DMNIJT0 CB CHEBI:16027
DMNIJT0 DE Malnutrition
DM79F6G ID DM79F6G
DM79F6G DN Adenosine triphosphate
DM79F6G HS Approved
DM79F6G SN Adenylpyrophosphate; Triphosadenine; Triphosadenine (DCF); Adenosine 5'-triphosphate(4-); [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; 3b2q; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]
DM79F6G TC Dietary supplement
DM79F6G DT Small molecular drug
DM79F6G PC 5957
DM79F6G MW 507.18
DM79F6G FM C10H16N5O13P3
DM79F6G IC InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DM79F6G CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DM79F6G IK ZKHQWZAMYRWXGA-KQYNXXCUSA-N
DM79F6G IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM79F6G CA CAS 56-65-5
DM79F6G CB CHEBI:15422
DM79F6G DE Bradycardia; Heart disease; Malnutrition
DMBHO9Y ID DMBHO9Y
DMBHO9Y DN Adinazolam
DMBHO9Y HS Approved
DMBHO9Y SN Adinazolamum; Deracyn; Adinazolam [USAN]; U 41123; Adinazolamum [INN-Latin]; Deracyn (TN); U 41,123;U-41123; Adinazolam (USAN/INN); Adinazolam [USAN:BAN:INN]; 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine; 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine
DMBHO9Y TC Antidepressants
DMBHO9Y DT Small molecular drug
DMBHO9Y PC 37632
DMBHO9Y MW 351.8
DMBHO9Y FM C19H18ClN5
DMBHO9Y IC InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3
DMBHO9Y CS CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMBHO9Y IK GJSLOMWRLALDCT-UHFFFAOYSA-N
DMBHO9Y IU 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
DMBHO9Y CA CAS 37115-32-5
DMBHO9Y CB CHEBI:251412
DMBHO9Y DE Anxiety disorder
DMVWHTG ID DMVWHTG
DMVWHTG DN Afamelanotide
DMVWHTG HS Approved
DMVWHTG SN [Nle4,dPhe7]alpha-MSH; alpha-NDP-MSH; NDP-MSH
DMVWHTG DT Small molecular drug
DMVWHTG PC 16197727
DMVWHTG MW 1646.8
DMVWHTG FM C78H111N21O19
DMVWHTG IC InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMVWHTG CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMVWHTG IK UAHFGYDRQSXQEB-LEBBXHLNSA-N
DMVWHTG IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMVWHTG CA CAS 75921-69-6
DMVWHTG DE Vitiligo; Erythropoietic porphyrias
DMT3D5I ID DMT3D5I
DMT3D5I DN Aflibercept
DMT3D5I HS Approved
DMT3D5I SN Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
DMT3D5I CP Sanofi
DMT3D5I SQ Protein sequence for aflibercept: SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMT3D5I DE Metastatic colorectal cancer
DMPOD47 ID DMPOD47
DMPOD47 DN Ajmalicine
DMPOD47 HS Approved
DMPOD47 SN MLS000111555; methyl 19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate; NSC72115; SMR000107477; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (19.alpha.)-; 6474-90-4; WLN: T F6 D5 C666 EM ON SO TU& TTTJ R1 UVO1; Isoarteril; Oxayohimban-16-carboxylic acid,17-didehydro-19-methyl-, methyl ester, (19
DMPOD47 DT Small molecular drug
DMPOD47 PC 441975
DMPOD47 MW 352.4
DMPOD47 FM C21H24N2O3
DMPOD47 IC InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1
DMPOD47 CS C[C@H]1[C@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45
DMPOD47 IK GRTOGORTSDXSFK-XJTZBENFSA-N
DMPOD47 IU methyl (1S,15R,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
DMPOD47 CA CAS 483-04-5
DMPOD47 CB CHEBI:2524
DMPOD47 DE Circulatory disorder
DMDJW5K ID DMDJW5K
DMDJW5K DN Ajmaline
DMDJW5K HS Approved
DMDJW5K SN (17R,21
DMDJW5K DT Small molecular drug
DMDJW5K PC 6100671
DMDJW5K MW 326.4
DMDJW5K FM C20H26N2O2
DMDJW5K IC InChI=1S/C20H26N2O2/c1-3-10-11-8-14-17-20(12-6-4-5-7-13(12)21(17)2)9-15(16(11)18(20)23)22(14)19(10)24/h4-7,10-11,14-19,23-24H,3,8-9H2,1-2H3/t10-,11-,14-,15-,16-,17-,18+,19+,20+/m0/s1
DMDJW5K CS CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H]([C@H]2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C
DMDJW5K IK CJDRUOGAGYHKKD-RQBLFBSQSA-N
DMDJW5K IU (1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMDJW5K CA CAS 4360-12-7
DMDJW5K DE Atrial fibrillation
DML6SRO ID DML6SRO
DML6SRO DN Alacepril
DML6SRO HS Approved
DML6SRO SN Cetapril (TN)
DML6SRO CP Dainippon
DML6SRO DT Small molecular drug
DML6SRO PC 71992
DML6SRO MW 406.5
DML6SRO FM C20H26N2O5S
DML6SRO IC InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1
DML6SRO CS C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O
DML6SRO IK FHHHOYXPRDYHEZ-COXVUDFISA-N
DML6SRO IU (2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DML6SRO CA CAS 74258-86-9
DML6SRO CB CHEBI:31182
DML6SRO DE Cardiovascular disease
DMYZ57N ID DMYZ57N
DMYZ57N DN Albendazole
DMYZ57N HS Approved
DMYZ57N SN Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole
DMYZ57N CP GlaxoSmithKline
DMYZ57N TC Antiprotozoal Agents
DMYZ57N DT Small molecular drug
DMYZ57N PC 2082
DMYZ57N MW 265.33
DMYZ57N FM C12H15N3O2S
DMYZ57N IC InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
DMYZ57N CS CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
DMYZ57N IK HXHWSAZORRCQMX-UHFFFAOYSA-N
DMYZ57N IU methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
DMYZ57N CA CAS 54965-21-8
DMYZ57N CB CHEBI:16664
DMYZ57N DE Worm infection
DM1JEGF ID DM1JEGF
DM1JEGF DN Albiglutide
DM1JEGF HS Approved
DM1JEGF CP GSK
DM1JEGF SQ Albiglutide sequence: HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
DM1JEGF PC 122173812
DM1JEGF MW 3284.6
DM1JEGF FM C148H223N39O46
DM1JEGF IC InChI=1S/C148H223N39O46/c1-16-76(10)119(144(229)165-79(13)124(209)173-103(59-85-62-157-90-35-24-23-34-88(85)90)134(219)175-99(55-73(4)5)135(220)184-117(74(6)7)142(227)172-91(36-25-27-51-149)126(211)159-66-111(197)168-97(147(232)233)38-29-53-156-148(153)154)186-136(221)101(56-82-30-19-17-20-31-82)176-131(216)96(46-50-115(203)204)171-130(215)92(37-26-28-52-150)169-123(208)78(12)163-122(207)77(11)164-129(214)95(43-47-108(152)194)167-110(196)65-160-128(213)94(45-49-114(201)202)170-132(217)98(54-72(2)3)174-133(218)100(58-84-39-41-87(193)42-40-84)177-139(224)105(68-188)180-141(226)107(70-190)181-143(228)118(75(8)9)185-138(223)104(61-116(205)206)178-140(225)106(69-189)182-146(231)121(81(15)192)187-137(222)102(57-83-32-21-18-22-33-83)179-145(230)120(80(14)191)183-112(198)67-161-127(212)93(44-48-113(199)200)166-109(195)64-158-125(210)89(151)60-86-63-155-71-162-86/h17-24,30-35,39-42,62-63,71-81,89,91-107,117-121,157,188-193H,16,25-29,36-38,43-61,64-70,149-151H2,1-15H3,(H2,152,194)(H,155,162)(H,158,210)(H,159,211)(H,160,213)(H,161,212)(H,163,207)(H,164,214)(H,165,229)(H,166,195)(H,167,196)(H,168,197)(H,169,208)(H,170,217)(H,171,215)(H,172,227)(H,173,209)(H,174,218)(H,175,219)(H,176,216)(H,177,224)(H,178,225)(H,179,230)(H,180,226)(H,181,228)(H,182,231)(H,183,198)(H,184,220)(H,185,223)(H,186,221)(H,187,222)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,232,233)(H4,153,154,156)/t76-,77-,78-,79-,80+,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-/m0/s1
DM1JEGF CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CNC=N6)N
DM1JEGF IK OGWAVGNOAMXIIM-VTAHJYCESA-N
DM1JEGF IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM1JEGF CB CHEBI:78425
DM1JEGF DE Type-2 diabetes
DM5JTPU ID DM5JTPU
DM5JTPU DN Albumin Human
DM5JTPU HS Approved
DM5JTPU SN Albumin (Human); Kedbumin
DM5JTPU CP Ge Healthcare
DM5JTPU DE Hypoalbuminemia
DM5J1NH ID DM5J1NH
DM5J1NH DN Alcaftadine
DM5J1NH HS Approved
DM5J1NH SN Lastacaft (TN)
DM5J1NH CP Vistakon Pharmaceuticals
DM5J1NH DT Small molecular drug
DM5J1NH PC 19371515
DM5J1NH MW 307.4
DM5J1NH FM C19H21N3O
DM5J1NH IC InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3
DM5J1NH CS CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1
DM5J1NH IK MWTBKTRZPHJQLH-UHFFFAOYSA-N
DM5J1NH IU 11-(1-methylpiperidin-4-ylidene)-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carbaldehyde
DM5J1NH CA CAS 147084-10-4
DM5J1NH CB CHEBI:71023
DM5J1NH DE Allergic conjunctivitis
DMAE84F ID DMAE84F
DMAE84F DN Alclometasone
DMAE84F HS Approved
DMAE84F SN Aclometasone; Aclovate (TN); Alclometasone (INN); Alclometasone [INN:BAN]; (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 7alpha-Chloro-16alpha-methylprednisolone
DMAE84F CP GlaxoSmithKline
DMAE84F TC Antiinflammatory Agents
DMAE84F DT Small molecular drug
DMAE84F PC 5311000
DMAE84F MW 408.9
DMAE84F FM C22H29ClO5
DMAE84F IC InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
DMAE84F CS C[C@@H]1C[C@H]2[C@@H]3[C@@H](CC4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)Cl
DMAE84F IK FJXOGVLKCZQRDN-PHCHRAKRSA-N
DMAE84F IU (7R,8S,9S,10R,11S,13S,14S,16R,17R)-7-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMAE84F CA CAS 67452-97-5
DMAE84F CB CHEBI:53776
DMAE84F DE Inflammation
DM2U4XQ ID DM2U4XQ
DM2U4XQ DN ALCURONIUM
DM2U4XQ HS Approved
DM2U4XQ SN Alcuronium
DM2U4XQ DT Small molecular drug
DM2U4XQ PC 21158560
DM2U4XQ MW 666.9
DM2U4XQ FM C44H50N4O2+2
DM2U4XQ IC InChI=1S/C44H50N4O2/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2/q+2/b29-13-,30-14-,33-25-,34-26-/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-/m0/s1
DM2U4XQ CS C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\\CO)/C1)CC2
DM2U4XQ IK MUQUYTSLDVKIOF-CHJKCJHBSA-N
DM2U4XQ IU (2E)-2-[(1S,9Z,11S,13S,14R,17S,25Z,27S,30R,33S,35S,36S,38E)-38-(2-hydroxyethylidene)-14,30-bis(prop-2-enyl)-8,24-diaza-14,30-diazoniaundecacyclo[25.5.2.211,14.11,26.110,17.02,7.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,9,18,20,22,25-octaen-28-ylidene]ethanol
DM2U4XQ CA CAS 23214-96-2
DM2U4XQ CB CHEBI:55313
DM2U4XQ DE Anaesthesia
DM4YMIS ID DM4YMIS
DM4YMIS DN Aldesleukin
DM4YMIS HS Approved
DM4YMIS SN Proleukin (TN)
DM4YMIS CP Chiron
DM4YMIS TC Anticancer Agents
DM4YMIS SQ Aldesleukin sequence: MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DM4YMIS DE Renal cell carcinoma; Non-hodgkin lymphoma
DM9S2JW ID DM9S2JW
DM9S2JW DN Aldosterone
DM9S2JW HS Approved
DM9S2JW SN ALDOSTERONE; 52-39-1; Electrocortin; Aldocortin; Aldocortene; Aldocorten; (+)-Aldosterone; Elektrocortin; d-Aldosterone; Reichstein X; 18-Oxocorticosterone; Aldosteronum; Aldosterona; Aldosteronum [INN-Latin]; Aldosterona [INN-Spanish]; [3H]aldosterone; 18-Aldocorticosterone; Aldosterone [INN:BAN:DCF]; 11beta,21-Dihydroxypregn-4-ene-3,18,20-trione; 11beta,21-Dihydroxy-3,20-diketo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-diketopregn-4-ene-18-al; NSC 73856; 18-Formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione; UNII-4964P6T9RB; Aldocorten; D-Aldosterone; Aldosterone, (11 beta,17 alpha)-Isomer; Aldosterone, (+-)-Isomer; (11BETA)-11,21-DIHYDROXY-3,20-DIOXOPREGN-4-EN-18-AL; (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al; 11beta,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al, 18,11-halbacetal; 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al; 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
DM9S2JW TC Antihypertensive Agents
DM9S2JW DT Small molecular drug
DM9S2JW PC 5839
DM9S2JW MW 360.4
DM9S2JW FM C21H28O5
DM9S2JW IC InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1
DM9S2JW CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C=O)O
DM9S2JW IK PQSUYGKTWSAVDQ-ZVIOFETBSA-N
DM9S2JW IU (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-13-carbaldehyde
DM9S2JW CA CAS 52-39-1
DM9S2JW CB CHEBI:27584
DM9S2JW DE Hypertension
DMP1I6Y ID DMP1I6Y
DMP1I6Y DN Alectinib
DMP1I6Y HS Approved
DMP1I6Y SN 1256580-46-7; CH5424802; CH 5424802; AF-802; Alecensa; UNII-LIJ4CT1Z3Y; AF 802; LIJ4CT1Z3Y; Alectinib (CH5424802); 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile; CHEMBL1738797; AF802; 9-Ethyl-6,6-Dimethyl-8-[4-(Morpholin-4-Yl)piperidin-1-Yl]-11-Oxo-6,11-Dihydro-5h-Benzo[b]carbazole-3-Carbonitrile; 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile; AK170451; C30H34N4O2; Alectinib; 9-ethyl-6,6-dimethyl-
DMP1I6Y DT Small molecular drug
DMP1I6Y PC 49806720
DMP1I6Y MW 482.6
DMP1I6Y FM C30H34N4O2
DMP1I6Y IC InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
DMP1I6Y CS CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C
DMP1I6Y IK KDGFLJKFZUIJMX-UHFFFAOYSA-N
DMP1I6Y IU 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
DMP1I6Y CA CAS 1256580-46-7
DMP1I6Y CB CHEBI:90936
DMP1I6Y DE Lung cancer; Non-small-cell lung cancer
DMMYPWO ID DMMYPWO
DMMYPWO DN Alefacept
DMMYPWO HS Approved
DMMYPWO SN Amevive (TN)
DMMYPWO TC Analgesics
DMMYPWO SQ Alefacept heavy chain : CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Alefacept light chainMVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN
DMMYPWO DE Pain
DMZL3IV ID DMZL3IV
DMZL3IV DN Alemtuzumab
DMZL3IV HS Approved
DMZL3IV SN Campath (TN); MabCampath (TN); Campath-1H (TN)
DMZL3IV CP Bayer Schering Pharma
DMZL3IV TC Anticancer Agents
DMZL3IV DT Antibody
DMZL3IV SQ 1CE1:H CAMPATH-1H:Heavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 1DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1CE1:H CAMPATH-1H:Heavy Chain 2QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >1CE1:L CAMPATH-1H:Light Chain 2DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV >1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE >1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMZL3IV DE Chronic lymphocytic leukaemia; Multiple sclerosis
DMY2KX9 ID DMY2KX9
DMY2KX9 DN Alendronate
DMY2KX9 HS Approved
DMY2KX9 SN Arendal; Fosamax; ALENDRONATE SODIUM; ALENDRONIC ACID; Acide alendronique; Acido alendronico; Acidum alendronicum; MK 217; Acide alendronique [INN-French]; Acido alendronico [INN-Spanish]; Acidum alendronicum [INN-Latin]; Alendronic acid (INN); Alendronic acid [INN:BAN]; Bisphosphonate, 65; Fosamax (TN); MK-217; Phosphonic acid, (4-amino-1-hydroxybutylidene)bis; (4-Amino-1-hydroxybutylidene)bisphosphonic acid; (4-Amino-1-hydroxybutylidene)diphosphonic acid; (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid; (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); 4-Amino-1-hydroxybutane-1,1-diphosphonate; 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid; 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid); 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
DMY2KX9 CP Teva Pharmaceuticals
DMY2KX9 TC Bone Density Conservation Agents
DMY2KX9 DT Small molecular drug
DMY2KX9 PC 2088
DMY2KX9 MW 249.1
DMY2KX9 FM C4H13NO7P2
DMY2KX9 IC InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
DMY2KX9 CS C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
DMY2KX9 IK OGSPWJRAVKPPFI-UHFFFAOYSA-N
DMY2KX9 IU (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
DMY2KX9 CA CAS 66376-36-1
DMY2KX9 CB CHEBI:2567
DMY2KX9 DE Paget's disease; Osteoporosis
DMCKPUR ID DMCKPUR
DMCKPUR DN Alfaferone
DMCKPUR HS Approved
DMCKPUR SN Alfaferon; Cilferon-A; Alpha-IFN, ASW; Interferon, ASW (alpha)
DMCKPUR CP Alfa Wassermann SpA
DMCKPUR DE Hairy cell leukaemia
DMVO0UB ID DMVO0UB
DMVO0UB DN Alfentanil
DMVO0UB HS Approved
DMVO0UB SN Alfenta; Alfentanilum; Alfentanyl; Alfenta (TN); Alfentanil (INN); Alfentanil [INN:BAN]; Alfentanilum [INN-Latin]; Rapifen (TN); N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide; N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid; N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide; N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide; N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide
DMVO0UB CP Janssen Pharmaceutica
DMVO0UB TC Anesthetics
DMVO0UB DT Small molecular drug
DMVO0UB PC 51263
DMVO0UB MW 416.5
DMVO0UB FM C21H32N6O3
DMVO0UB IC InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3
DMVO0UB CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC
DMVO0UB IK IDBPHNDTYPBSNI-UHFFFAOYSA-N
DMVO0UB IU N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
DMVO0UB CA CAS 71195-58-9
DMVO0UB CB CHEBI:2569
DMVO0UB DE Anaesthesia
DMZVMKF ID DMZVMKF
DMZVMKF DN Alfuzosin
DMZVMKF HS Approved
DMZVMKF SN Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
DMZVMKF CP Sanofi-Aventis
DMZVMKF TC Antihypertensive Agents
DMZVMKF DT Small molecular drug
DMZVMKF PC 2092
DMZVMKF MW 389.4
DMZVMKF FM C19H27N5O4
DMZVMKF IC InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
DMZVMKF CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DMZVMKF IK WNMJYKCGWZFFKR-UHFFFAOYSA-N
DMZVMKF IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
DMZVMKF CA CAS 81403-80-7
DMZVMKF CB CHEBI:51141
DMZVMKF DE Benign prostatic hyperplasia
DM4LOD0 ID DM4LOD0
DM4LOD0 DN Alglucosidase alfa
DM4LOD0 HS Approved
DM4LOD0 SN Lumizyme (TN); Myozyme (TN)
DM4LOD0 CP Genzyme Corporation
DM4LOD0 TC Enzyme Replacement Agents
DM4LOD0 SQ Alglucosidase alfa: AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
DM4LOD0 DE Pompe disease
DM1BV7W ID DM1BV7W
DM1BV7W DN Aliskiren
DM1BV7W HS Approved
DM1BV7W SN Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]
DM1BV7W CP Norvatis Phamaceuticals Corporation
DM1BV7W TC Antihypertensive Agents
DM1BV7W DT Small molecular drug
DM1BV7W PC 5493444
DM1BV7W MW 551.8
DM1BV7W FM C30H53N3O6
DM1BV7W IC InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
DM1BV7W CS CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
DM1BV7W IK UXOWGYHJODZGMF-QORCZRPOSA-N
DM1BV7W IU (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide
DM1BV7W CA CAS 173334-57-1
DM1BV7W CB CHEBI:601027
DM1BV7W DE Hypertension
DMME8LH ID DMME8LH
DMME8LH DN Alitretinoin
DMME8LH HS Approved
DMME8LH CP Ligand Pharmaceuticals
DMME8LH TC Anticancer Agents
DMME8LH DT Small molecular drug
DMME8LH PC 449171
DMME8LH MW 300.4
DMME8LH FM C20H28O2
DMME8LH IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+
DMME8LH CS CC1=C(C(CCC1)(C)C)/C=C/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C
DMME8LH IK SHGAZHPCJJPHSC-ZVCIMWCZSA-N
DMME8LH IU (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMME8LH CA CAS 5300-03-8
DMME8LH CB CHEBI:50648
DMME8LH DE Kaposi sarcoma
DMB4HFI ID DMB4HFI
DMB4HFI DN Alkavervir
DMB4HFI HS Approved
DMB4HFI CP 3m Pharmaceuticals Inc
DMB4HFI TC Cardiovascular Agents
DMB4HFI DE High blood pressure
DMNLHAC ID DMNLHAC
DMNLHAC DN Allopregnanolone
DMNLHAC HS Approved
DMNLHAC SN 516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102
DMNLHAC DT Small molecular drug
DMNLHAC PC 92786
DMNLHAC MW 318.5
DMNLHAC FM C21H34O2
DMNLHAC IC InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
DMNLHAC CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
DMNLHAC IK AURFZBICLPNKBZ-SYBPFIFISA-N
DMNLHAC IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMNLHAC CA CAS 516-54-1
DMNLHAC CB CHEBI:50169
DMNLHAC DE Postpartum depression; Essential tremor or related tremors; Status epilepticus seizure; Depression
DMLPAOB ID DMLPAOB
DMLPAOB DN Allopurinol
DMLPAOB HS Approved
DMLPAOB SN Adenock; Ailural; Ailurial; Allohexal; Allohexan; Alloprin; Allopur; Allopurin; Allopurinolum; Allorin; Allozym; Allpargin; Allural; Aloprim; Alopurinol; Aloral; Alositol; Aluline; Anoprolin; Anzief; Apulonga; Apurin; Apurol; Atisuril; Bleminol; Bloxanth; Caplenal; Capurate; Cellidrin; Cosuric; Dabrosin; Dabroson; Embarin; Epidropal; Epuric; Foligan; Geapur; Gichtex; Gotax; Hamarin; Hexanuret; Jenapurinol; Ketanrift; Ledopur; Lopurin; Lysuron; Milurit; Milurite; Miniplanor; Monarch; Nektrohan; Novopurol; Progout; Pureduct; Purinol; Remid; Riball; Rimapurinol; Roucol; Sigapurol; Suspendol; Takanarumin; Tipuric; Urbol; Uribenz; Uricemil; Uridocid; Uriprim; Uripurinol; Uritas; Urobenyl; Urolit; Urosin; Urtias; Xanthomax; Xanturat; Xanturic; Zygout; Zyloprim; Zyloric; Dura Al; Pan Quimica; A 8003; BW 56158; Urtias 100; AL-100; Allo-Puren; Allohexal (TN); Allopurinol(I); Allosig (TN); Apo-Allopurinol; BW 56-158; Ketobun-A; Progout (TN); Puricos (TN); Quimica, Pan; Zyloprim (TN); Zyloric (TN); BW-56-158; B. W. 56-158; 4-HPP
DMLPAOB CP GlaxoSmithKline
DMLPAOB TC Antimetabolites
DMLPAOB DT Small molecular drug
DMLPAOB PC 135401907
DMLPAOB MW 136.11
DMLPAOB FM C5H4N4O
DMLPAOB IC InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
DMLPAOB CS C1=NNC2=C1C(=O)NC=N2
DMLPAOB IK OFCNXPDARWKPPY-UHFFFAOYSA-N
DMLPAOB IU 1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one
DMLPAOB CA CAS 315-30-0
DMLPAOB CB CHEBI:40279
DMLPAOB DE Hyperuricaemia
DM0SYAN ID DM0SYAN
DM0SYAN DN Almitrine
DM0SYAN HS Approved
DM0SYAN SN Almitrin; Almitrina; Almitrinum; Vectarion; Almitrine bismesylate; Almitrine dimesylate; S 2620; Almitrina [INN-Spanish]; Almitrine (INN); Almitrine Bis(methanesulfonate); Almitrine [BAN:INN]; Almitrine [INN:BAN]; Almitrinum [INN-Latin]; N,N'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine; 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine; 2,4-bis[allylamino]-6-[4-[bis(p-fluorophenyl)methyl]-1-piperazinyl]-s-triazine; 6-(4-(Bis(4-fluorphenyl)methyl)-1-piperazinyl)-N,N'-di-2-propenyl-1,3,5-triazin-2,4-diamin; 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN TC Antiinflammatory Agents
DM0SYAN DT Small molecular drug
DM0SYAN PC 33887
DM0SYAN MW 477.6
DM0SYAN FM C26H29F2N7
DM0SYAN IC InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)
DM0SYAN CS C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
DM0SYAN IK OBDOVFRMEYHSQB-UHFFFAOYSA-N
DM0SYAN IU 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DM0SYAN CA CAS 27469-53-0
DM0SYAN CB CHEBI:53778
DM0SYAN DE Chronic obstructive pulmonary disease
DM7I64Z ID DM7I64Z
DM7I64Z DN Almogran
DM7I64Z HS Approved
DM7I64Z SN Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
DM7I64Z CP Almirall Prodesfarma
DM7I64Z TC Antimigraine Agents
DM7I64Z DT Small molecular drug
DM7I64Z PC 123606
DM7I64Z MW 335.5
DM7I64Z FM C17H25N3O2S
DM7I64Z IC InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
DM7I64Z CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
DM7I64Z IK WKEMJKQOLOHJLZ-UHFFFAOYSA-N
DM7I64Z IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
DM7I64Z CA CAS 154323-57-6
DM7I64Z CB CHEBI:520985
DM7I64Z DE Migraine
DMFG5ST ID DMFG5ST
DMFG5ST DN Almotriptan malate
DMFG5ST HS Approved
DMFG5ST SN Almotriptan; Almotriptan (malate); Almotriptan malate; Almotriptan malate (USAN); Almotriptan malate [USAN]; Almotriptan maleate; CHEBI:53781; LAS 31416; LAS 31416 D,L-malate acid; PNU 180638E; PNU-180638E; Almogran; Almotriptan [USAN:INN:BAN]; Axert; CHEBI:520985; DSSTox_CID_24289; DSSTox_GSID_44289; DSSTox_RID_80142; LAS-31416; N,N-dimethyl-2-(5-((pyrrolidin-1-ylsulfonyl)methyl)-1H-indol-3-yl)ethanamine; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; NCGC00095135-01; UNII-1O4XL5SN61; WKEMJKQOLOHJLZ-UHFFFAOYSA-N; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine; 154323-57-6; 1O4XL5SN61; 1-(((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)pyrrolidine, hydroxybutanedionate (1:1); 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine malate (1:1); 1-[[[2-(Dimethyl-amino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine Malate; 181183-52-8; AK110510
DMFG5ST PC 123607
DMFG5ST MW 469.6
DMFG5ST FM C21H31N3O7S
DMFG5ST IC QHATUKWEVNMHRY-UHFFFAOYSA-N
DMFG5ST CS CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O
DMFG5ST IK 1S/C17H25N3O2S.C4H6O5/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20;5-2(4(8)9)1-3(6)7/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3;2,5H,1H2,(H,6,7)(H,8,9)
DMFG5ST IU N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine;2-hydroxybutanedioic acid
DMFG5ST CA CAS 181183-52-8
DMFG5ST CB CHEBI:53781
DMFG5ST DE Migraine
DM8WI3R ID DM8WI3R
DM8WI3R DN Alogliptin
DM8WI3R HS Approved
DM8WI3R SN 850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203; UNII-JHC049LO86
DM8WI3R CP Takeda
DM8WI3R DT Small molecular drug
DM8WI3R PC 11450633
DM8WI3R MW 339.4
DM8WI3R FM C18H21N5O2
DM8WI3R IC InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
DM8WI3R CS CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N
DM8WI3R IK ZSBOMTDTBDDKMP-OAHLLOKOSA-N
DM8WI3R IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile
DM8WI3R CA CAS 850649-61-5
DM8WI3R CB CHEBI:72323
DM8WI3R DE Type-2 diabetes
DML2A03 ID DML2A03
DML2A03 DN Alosetron
DML2A03 HS Approved
DML2A03 SN Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride
DML2A03 CP Prometheus Laboratories Inc
DML2A03 TC Gastrointestinal Agents
DML2A03 DT Small molecular drug
DML2A03 PC 2099
DML2A03 MW 294.35
DML2A03 FM C17H18N4O
DML2A03 IC InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
DML2A03 CS CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
DML2A03 IK JSWZEAMFRNKZNL-UHFFFAOYSA-N
DML2A03 IU 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
DML2A03 CA CAS 122852-42-0
DML2A03 CB CHEBI:253342
DML2A03 DE Irritable bowel syndrome
DMEXMYK ID DMEXMYK
DMEXMYK DN Alpelisib
DMEXMYK HS Approved
DMEXMYK SN alpelisib; 1217486-61-7; BYL-719; BYL719; UNII-08W5N2C97Q; BYL 719; Alpelisib (BYL719); (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide; NVP-BYL719; (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; CHEMBL2396661; 08W5N2C97Q; AK146107; C19H22F3N5O2S; (S)-N1-(4-Methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)-pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide
DMEXMYK CP Novartis
DMEXMYK DT Small molecular drug
DMEXMYK PC 56649450
DMEXMYK MW 441.5
DMEXMYK FM C19H22F3N5O2S
DMEXMYK IC InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
DMEXMYK CS CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
DMEXMYK IK STUWGJZDJHPWGZ-LBPRGKRZSA-N
DMEXMYK IU (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
DMEXMYK CA CAS 1217486-61-7
DMEXMYK CB CHEBI:93752
DMEXMYK DE Solid tumour/cancer; Breast cancer
DMXC1K9 ID DMXC1K9
DMXC1K9 DN Alpha 1-PI
DMXC1K9 HS Approved
DMXC1K9 SN Ifenprodil; 23210-56-2; Vadilex; ifenprodil tartrate; Dilvax; Creocral; 4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol; Ifenprodil [INN:DCF]; RC 61-91; Ifenprodilum [INN-Latin]; UNII-R8OE3P6O5S; EINECS 245-491-4; R8OE3P6O5S; CHEMBL305187; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol; 2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)propanol; 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol; NCGC00024643-03; IFENPRODIL HEMITARTRATE; alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine
DMXC1K9 DT Small molecular drug
DMXC1K9 PC 3689
DMXC1K9 MW 325.4
DMXC1K9 FM C21H27NO2
DMXC1K9 IC InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
DMXC1K9 CS CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
DMXC1K9 IK UYNVMODNBIQBMV-UHFFFAOYSA-N
DMXC1K9 IU 4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
DMXC1K9 CA CAS 23210-56-2
DMXC1K9 CB CHEBI:93829
DMXC1K9 DE Alpha-1 antitrypsin deficiency; Cancer related pain
DMAS02L ID DMAS02L
DMAS02L DN Alpha-acetyldigoxin
DMAS02L HS Approved
DMAS02L SN Dioxanin (TN); Lanatilin (TN); Sandolanid (TN)
DMAS02L DT Small molecular drug
DMAS02L PC 11765960
DMAS02L MW 823
DMAS02L FM C43H66O15
DMAS02L IC InChI=1S/C43H66O15/c1-20-38(49)32(55-23(4)44)18-37(52-20)58-40-22(3)54-36(17-31(40)46)57-39-21(2)53-35(16-30(39)45)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(47)42(6)27(10-12-43(28,42)50)24-13-34(48)51-19-24/h13,20-22,25-33,35-40,45-47,49-50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMAS02L CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)OC(=O)C)O
DMAS02L IK HWKJSYYYURVNQU-DXJNJSHLSA-N
DMAS02L IU [(2R,3R,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-3-hydroxy-2-methyloxan-4-yl] acetate
DMAS02L CA CAS 5511-98-8
DMAS02L DE Cardiovascular disease
DMN7Y9K ID DMN7Y9K
DMN7Y9K DN Alpidem
DMN7Y9K HS Approved
DMN7Y9K SN ALPIDEM; 82626-01-5; Ananxyl; Alpidemum [Latin]; UNII-I93SC245QZ; SL 80.0342-00; 2-(6-Chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-dipropylacetamide; 6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-acetamide; CHEMBL54349; I93SC245QZ; S-800342; NCGC00182850-01; 6-Chlor-2-(4-chlorphenyl)-N,N-dipropylimidazol(1,2-a)pyridin-3-acetamid; DSSTox_RID_83237; DSSTox_CID_28972; DSSTox_GSID_49046; Alpidemum; 6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide
DMN7Y9K DT Small molecular drug
DMN7Y9K PC 54897
DMN7Y9K MW 404.3
DMN7Y9K FM C21H23Cl2N3O
DMN7Y9K IC InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3
DMN7Y9K CS CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMN7Y9K IK JRTIDHTUMYMPRU-UHFFFAOYSA-N
DMN7Y9K IU 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
DMN7Y9K CA CAS 82626-01-5
DMN7Y9K CB CHEBI:135649
DMN7Y9K DE Anxiety disorder
DMC7XDN ID DMC7XDN
DMC7XDN DN Alprazolam
DMC7XDN HS Approved
DMC7XDN SN Alcelam; Algad; Alpaz; Alplax; Alpram; Alprax; Alprazolamum; Alprazolan; Alpronax; Alprox; Alviz; Alzam; Alzolam; Alzon;Anpress; ApoAlpraz; Azor; Bestrol; Cassadan; Constan; Esparon; Frontal; Helex; Intensol; Ksalol; Mialin; Neurol; Niravam; NovoAlprazol; NuAlpraz; Panistat; Panix; Pharnax; Prazam; Prazolan; Prinox; Ralozam; Relaxol; Restyl; Solanax; Tafil; Tensivan; Tranax; Trankimazin; Tranquinal; Tricalma; Unilan; Valeans; Xanagis; Xanax; Xanolam; Xanor; Zacetin; Zanapam; Zaxan; Zenax; Zolam; Zolan; Zolarem; Zoldac; Zoldax; Zopax; Zopic; Zotran; Alphapharm Brand of Alprazolam; Alprazolam Alphapharm Brand; Alprazolam Apotex Brand; Alprazolam Kenral Brand; Alprazolam Novopharm Brand; Alprazolam Orion Brand; Alprazolam Pfizer Brand; Alprazolam Temmler Brand; Alprazolam extended release tablets; Alprazolam intensol; Alprazolam solution; Apo Alpraz; Apotex Brand of Alprazolam; Arzneimittelwerk Dresden Brand of Alprazolam; Kenral Brand of Alprazolam; Novo Alprazol; Novopharm Brand of Alprazolam; Nu Alpraz; Nu Pharm Brand of Alprazolam; Orion Brand of Alprazolam; Pfizer Brand of Alprazolam; Tafil D; Temmler Brand of Alprazolam; Xanax TS; Xanax XR; D 65MT; D65MT; TGAR01P; Tus 1; U 31889; AP-1002; AZ-002; Alprazolam Nu-Pharm Brand; Alprazolam-d5; Alprazolamum [INN-Latin]; Apo-Alpraz; D-65MT; Gen-Alprazolan; Niravam (TN); Novo-Alprazol; Nu-Alpraz; Nu-Pharm Brand of Alprazolam; Staccato-alprazolam; TUS-1; U-31889; U31,889; Xanax (TN); Xanor (TN); U-31,889; Alprazolam (JP15/USP/INN); Alprazolam [USAN:INN:BAN:JAN]; 8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine; 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN CP Pfizer Pharmaceuticals
DMC7XDN TC Hypnotics and Sedatives
DMC7XDN DT Small molecular drug
DMC7XDN PC 2118
DMC7XDN MW 308.8
DMC7XDN FM C17H13ClN4
DMC7XDN IC InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
DMC7XDN CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
DMC7XDN IK VREFGVBLTWBCJP-UHFFFAOYSA-N
DMC7XDN IU 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMC7XDN CA CAS 28981-97-7
DMC7XDN CB CHEBI:2611
DMC7XDN DE Anxiety disorder; Epilepsy
DMWH7NQ ID DMWH7NQ
DMWH7NQ DN Alprostadil
DMWH7NQ HS Approved
DMWH7NQ SN Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil
DMWH7NQ CP Pfizer Pharmaceuticals
DMWH7NQ TC Vasodilator Agents
DMWH7NQ DT Small molecular drug
DMWH7NQ PC 5280723
DMWH7NQ MW 354.5
DMWH7NQ FM C20H34O5
DMWH7NQ IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
DMWH7NQ CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
DMWH7NQ IK GMVPRGQOIOIIMI-DWKJAMRDSA-N
DMWH7NQ IU 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
DMWH7NQ CA CAS 745-65-3
DMWH7NQ CB CHEBI:15544
DMWH7NQ DE Erectile dysfunction; Diabetic foot ulcer
DMB47TQ ID DMB47TQ
DMB47TQ DN Alseroxylon
DMB47TQ HS Approved
DMB47TQ TC Antihypertensive Agents
DMB47TQ DE Hypertension
DMRJ3YX ID DMRJ3YX
DMRJ3YX DN Alteplase
DMRJ3YX HS Approved
DMRJ3YX SN Activase (TN)
DMRJ3YX CP Boehringer Ingelheim Ltd
DMRJ3YX TC Thrombolytic Agents
DMRJ3YX SQ Alteplase sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMRJ3YX DE Pulmonary embolism
DMKLAYG ID DMKLAYG
DMKLAYG DN Altretamine
DMKLAYG HS Approved
DMKLAYG SN Altretamina; Altretaminum; HEXAMETHYLMELAMINE; HMM; HTM; HXM; Hemel; Hexalen; Hexastat; Hexinawas; Altretamine Bellon Brand; Altretamine Chiesi Brand; Altretamine Wassermann Brand; Bellon Brand of Altretamine; Chiesi Brand of Altretamine; MGI Pharma Brand of Altretamine; Rhone Poulenc Rorer Brand of Altretamine; Wassermann Brand of Altretamine; A 8723; ENT 50852; NC 195; Altretamina [INN-Spanish]; Altretaminum [INN-Latin]; Hexalen (TN); Hexalen, Altretamine; KB-913; Rhone-Poulenc Rorer Brand of Altretamine; Altretamine (USP/INN); Altretamine [USAN:INN:BAN]; No-s-triazine; N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine; N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine; 2,4, 6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylami; 2,4,6-Tris(dimethylamino)-1,3,5-triazine; 2,4,6-Tris(dimethylamino-s-triazine; 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG TC Anticancer Agents
DMKLAYG DT Small molecular drug
DMKLAYG PC 2123
DMKLAYG MW 210.28
DMKLAYG FM C9H18N6
DMKLAYG IC InChI=1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
DMKLAYG CS CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
DMKLAYG IK UUVWYPNAQBNQJQ-UHFFFAOYSA-N
DMKLAYG IU 2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
DMKLAYG CA CAS 645-05-6
DMKLAYG CB CHEBI:24564
DMKLAYG DE Ovarian cancer
DMO9WDS ID DMO9WDS
DMO9WDS DN Altropane
DMO9WDS HS Approved
DMO9WDS SN Carbon-11-Altropane; Iodine-123-Altropane; 11C-Altropane; 123I-Altropane
DMO9WDS CP Harvard University
DMO9WDS DT Small molecular drug
DMO9WDS PC 6440180
DMO9WDS MW 429.3
DMO9WDS FM C18H21FINO2
DMO9WDS IC InChI=1S/C18H21FINO2/c1-23-18(22)17-15(12-3-5-13(19)6-4-12)11-14-7-8-16(17)21(14)10-2-9-20/h2-6,9,14-17H,7-8,10-11H2,1H3/b9-2+/t14-,15+,16+,17-/m0/s1
DMO9WDS CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2C/C=C/I)C[C@@H]1C3=CC=C(C=C3)F
DMO9WDS IK GTQLIPQFXVKRKJ-UNSMHXHVSA-N
DMO9WDS IU methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[(E)-3-iodoprop-2-enyl]-8-azabicyclo[3.2.1]octane-2-carboxylate
DMO9WDS CA CAS 180468-34-2
DMO9WDS CB CHEBI:135696
DMO9WDS DE Attention deficit hyperactivity disorder
DM6ECN9 ID DM6ECN9
DM6ECN9 DN Aluminium
DM6ECN9 HS Approved
DM6ECN9 SN ALUMINUM; Adom; Aluminio; Metana; AO Al; Al alloy; Alaun [German]; Allbri aluminum paste and powder; Alumina fibre; Aluminium bronze; Aluminium flake; Aluminum alloy; Aluminum dehydrated; Aluminum dust; Aluminum metal; Aluminum powder; Aluminum production; Aluminum pyro powders; Aluminum soluble salts; Aluminum welding fumes; Emanay atomized aluminum powder; Metana aluminum paste; Noral Extra Fine Lining Grade; Noral Ink Grade Aluminum; Noral aluminium; Noral aluminum; Noral ink grade aluminium; A 00; A 95; A 99; A 995; A 999; AA 1099; AA1199; AD 1; AD1M; AO A1; AV00; AV000; Aa1193; Aluminum 27; Aluminum A00; Aluminum hydride [UN2463] [Dangerous when wet]; JISC 3108; JISC 3110; L16; NA9260; Pigment metal 1; ALUMINUM, ATOMIZED; Al(0); Aluminium(0); Aluminium, elementar; Aluminum (dust or fume); Aluminum (fume or dust); Aluminum (metal); Aluminum metal, alkyls; Aluminum metal, pyro powders; Aluminum metal, respirable fraction; Aluminum metal, soluble salts; Aluminum metal, total dust; Aluminum metal, welding fumes; Aluminum powder, coated [UN1309] [Flammable solid]; Aluminum powder, uncoated [UN1396] [Dangerous when wet]; Aluminum, elemental; Aluminum, molten [NA9260] [Class 9]; Aluminum, pyro powders; Aluminum, soluble salts; Aluminum, welding fumes; C-Pigment 1; C-Pigment 1 [German]; Noral non-leafing grade; Aluminum, pyro powders/welding fumes; C.I. 77000; ALUMINUM (SEE ALSO ALUMINUM OXIDE 1344-28-1); ALUMINUM, 99.999%; AQUANAL-plus aluminum (Al) 0.02-0.2 mg/L; AQUANAL(R)-plus aluminum (Al) 0.02-0.2 mg/L; 11008_ALDRICH; 11008_RIEDEL; 11009_ALDRICH; 11009_RIEDEL; 11010_ALDRICH; 11010_RIEDEL; 13Al
DM6ECN9 TC Antiinflammatory Agents
DM6ECN9 DT Small molecular drug
DM6ECN9 PC 5359268
DM6ECN9 MW 26.981
DM6ECN9 FM Al
DM6ECN9 IC InChI=1S/Al
DM6ECN9 CS [Al]
DM6ECN9 IK XAGFODPZIPBFFR-UHFFFAOYSA-N
DM6ECN9 IU aluminum
DM6ECN9 CA CAS 7429-90-5
DM6ECN9 CB CHEBI:28984
DM6ECN9 DE Hyperhidrosis
DMHR8KW ID DMHR8KW
DMHR8KW DN Alvimopan
DMHR8KW HS Approved
DMHR8KW SN Alvimopan anhydrous; LY 246736; LY246736; Adl 8-2698; Entereg (TN); Trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl; 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW CP GSK
DMHR8KW TC Analgesics
DMHR8KW DT Small molecular drug
DMHR8KW PC 5488548
DMHR8KW MW 424.5
DMHR8KW FM C25H32N2O4
DMHR8KW IC InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
DMHR8KW CS C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O
DMHR8KW IK UPNUIXSCZBYVBB-JVFUWBCBSA-N
DMHR8KW IU 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid
DMHR8KW CA CAS 156053-89-3
DMHR8KW CB CHEBI:135686
DMHR8KW DE Gastrointestinal disease
DMS3YE9 ID DMS3YE9
DMS3YE9 DN Amantadine
DMS3YE9 HS Approved
DMS3YE9 SN Adamantamine; Adamantanamine; Adamantylamine; Amant; Amantadina; Amantadinum; Amantidine; Aminoadamantane; Endantadine; Mantadine; Symadine; Wiregyt; Amantadine Base; BIA4304; OR14310; Amantadina [INN-Spanish]; Amantadine (INN); Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Gen-Amantadine; Pk-merz; Symmetrel (TN); TCMDC-125869; ADAMANTANE,1-AMINO; Adamantan-1-amine; Adamantan-1-ylamine; Tricyclo[3.3.1.1^3,7]decan-1-amine; Tricyclo(3.3.1.13,7)decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-ylamine; Tricyclo[3.3.1.1(3,7)]decane-1-amine; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; Tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo(3.3.1.1(3,7))-decan-1-amine; 1-Adamantamine; 1-Adamantanamine; 1-Adamantanamine (8CI); 1-Adamantylamine; 1-Aminoadamantane; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane
DMS3YE9 TC Antiviral Agents
DMS3YE9 DT Small molecular drug
DMS3YE9 PC 2130
DMS3YE9 MW 151.25
DMS3YE9 FM C10H17N
DMS3YE9 IC InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
DMS3YE9 CS C1C2CC3CC1CC(C2)(C3)N
DMS3YE9 IK DKNWSYNQZKUICI-UHFFFAOYSA-N
DMS3YE9 IU adamantan-1-amine
DMS3YE9 CA CAS 768-94-5
DMS3YE9 CB CHEBI:2618
DMS3YE9 DE Influenza A virus infection
DMOP0BL ID DMOP0BL
DMOP0BL DN Ambenonium
DMOP0BL HS Approved
DMOP0BL SN Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]
DMOP0BL CP Sanofi Aventis Us Llc
DMOP0BL TC Antiarrhythmic Agents
DMOP0BL DT Small molecular drug
DMOP0BL PC 2131
DMOP0BL MW 537.6
DMOP0BL FM C28H42Cl2N4O2+2
DMOP0BL IC InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
DMOP0BL CS CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl
DMOP0BL IK OMHBPUNFVFNHJK-UHFFFAOYSA-P
DMOP0BL IU (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium
DMOP0BL CA CAS 7648-98-8
DMOP0BL CB CHEBI:2627
DMOP0BL DE Myasthenia gravis
DMD1QXW ID DMD1QXW
DMD1QXW DN Ambrisentan
DMD1QXW HS Approved
DMD1QXW SN Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW CP GSK
DMD1QXW DT Small molecular drug
DMD1QXW PC 6918493
DMD1QXW MW 378.4
DMD1QXW FM C22H22N2O4
DMD1QXW IC InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMD1QXW CS CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
DMD1QXW IK OUJTZYPIHDYQMC-LJQANCHMSA-N
DMD1QXW IU (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMD1QXW CA CAS 177036-94-1
DMD1QXW CB CHEBI:135949
DMD1QXW DE Pulmonary arterial hypertension
DMWJE9D ID DMWJE9D
DMWJE9D DN Ambroxol
DMWJE9D HS Approved
DMWJE9D SN Ambroxol hydrochloride; 23828-92-4; Ambroxol HCl; Mucosolvan; Mucoangin; Ambroxolhydrochloride; cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; UNII-CC995ZMV90; Ambroxol hydrochloride; trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride; Ambroxol Hydrochloride [JAN]; CC995ZMV90; 15942-05-9; Ambroxol hydrochloride (JAN); 2-Amino-3,5-dibromo-N-[trans-4-hydroxycyclohexyl]benzylamine; 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol hydrochloride
DMWJE9D CP Exsar
DMWJE9D DT Small molecular drug
DMWJE9D PC 2132
DMWJE9D MW 378.1
DMWJE9D FM C13H18Br2N2O
DMWJE9D IC InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2
DMWJE9D CS C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O
DMWJE9D IK JBDGDEWWOUBZPM-UHFFFAOYSA-N
DMWJE9D IU 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
DMWJE9D CA CAS 18683-91-5
DMWJE9D CB CHEBI:92994
DMWJE9D DE Bronchitis
DMM1JL9 ID DMM1JL9
DMM1JL9 DN Amcinonide
DMM1JL9 HS Approved
DMM1JL9 SN Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate
DMM1JL9 TC Antiinflammatory Agents
DMM1JL9 DT Small molecular drug
DMM1JL9 PC 443958
DMM1JL9 MW 502.6
DMM1JL9 FM C28H35FO7
DMM1JL9 IC InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1
DMM1JL9 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6
DMM1JL9 IK ILKJAFIWWBXGDU-MOGDOJJUSA-N
DMM1JL9 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] acetate
DMM1JL9 CA CAS 51022-69-6
DMM1JL9 CB CHEBI:31199
DMM1JL9 DE Inflammation
DMIG6FY ID DMIG6FY
DMIG6FY DN Amdinocillin
DMIG6FY HS Approved
DMIG6FY SN Coactin; Hexacillin; Mecilinamo; Mecillinam; Mecillinamum; Selexidin; Amdinocillin Mecillinam; Amdinocillin [USAN]; Penicillin HX; FL 1060; Ro 109070; Amdinocillin (USAN); Coactin (TN); FL-1060; Mecilinamo [INN-Spanish]; Mecillinam (INN); Mecillinamum [INN-Latin]; Ro 10-9070; Ro-10-9070; Rel-(2R,6S)-6-{[(1E)-azepan-1-ylmethylene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(((Hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((Hexahydro-1H-azepin-1-yl)methyleneamino)penicillanic acid; 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylic acid
DMIG6FY CP Leo Pharmaceutical
DMIG6FY TC Antibiotics
DMIG6FY DT Small molecular drug
DMIG6FY PC 36273
DMIG6FY MW 325.4
DMIG6FY FM C15H23N3O3S
DMIG6FY IC InChI=1S/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1
DMIG6FY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C
DMIG6FY IK BWWVAEOLVKTZFQ-NTZNESFSSA-N
DMIG6FY IU (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIG6FY CA CAS 32887-01-7
DMIG6FY DE Bacterial infection
DM6I2WQ ID DM6I2WQ
DM6I2WQ DN Amezinium
DM6I2WQ HS Approved
DM6I2WQ SN Amezinium methyl sulfate
DM6I2WQ DT Small molecular drug
DM6I2WQ PC 71927
DM6I2WQ MW 202.23
DM6I2WQ FM C11H12N3O+
DM6I2WQ IC InChI=1S/C11H11N3O/c1-15-11-7-9(12)8-13-14(11)10-5-3-2-4-6-10/h2-8,12H,1H3/p+1
DM6I2WQ CS COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2
DM6I2WQ IK VXROHTDSRBRJLN-UHFFFAOYSA-O
DM6I2WQ IU 6-methoxy-1-phenylpyridazin-1-ium-4-amine
DM6I2WQ CA CAS 41658-78-0
DM6I2WQ CB CHEBI:145698
DM6I2WQ DE Hypotension
DM9YSNQ ID DM9YSNQ
DM9YSNQ DN Amfepramone
DM9YSNQ HS Approved
DM9YSNQ SN Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone; Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone
DM9YSNQ DT Small molecular drug
DM9YSNQ PC 7029
DM9YSNQ MW 205.3
DM9YSNQ FM C13H19NO
DM9YSNQ IC InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
DM9YSNQ CS CCN(CC)C(C)C(=O)C1=CC=CC=C1
DM9YSNQ IK XXEPPPIWZFICOJ-UHFFFAOYSA-N
DM9YSNQ IU 2-(diethylamino)-1-phenylpropan-1-one
DM9YSNQ CA CAS 90-84-6
DM9YSNQ CB CHEBI:4530
DM9YSNQ DE Obesity; Migraine
DMK08L3 ID DMK08L3
DMK08L3 DN Amifampridine
DMK08L3 HS Approved
DMK08L3 SN 3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 3,4-Pyridinediamine; Firdapse; Diamino-3,4 pyridine; 4,5-Diaminopyridine; 3,4-DAP; SC10; amifampridin; Zenas; UNII-RU4S6E2G0J; EINECS 200-220-9; NSC 521760; BRN 0110232; RU4S6E2G0J; OYTKINVCDFNREN-UHFFFAOYSA-N; WT559; NCGC00167560-01; SMR000752913
DMK08L3 CP Catalyst Pharmaceuticals
DMK08L3 PC 5918
DMK08L3 MW 109.13
DMK08L3 FM C5H7N3
DMK08L3 IC InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
DMK08L3 CS C1=CN=CC(=C1N)N
DMK08L3 IK OYTKINVCDFNREN-UHFFFAOYSA-N
DMK08L3 IU pyridine-3,4-diamine
DMK08L3 CA CAS 54-96-6
DMK08L3 CB CHEBI:135948
DMK08L3 DE LambertEaton myasthenic syndrome
DM5FL14 ID DM5FL14
DM5FL14 DN Amifostine
DM5FL14 HS Approved
DM5FL14 SN Ethiofos; Ethyol; Gammaphos; WR-1064; WR-2721; WR-2721C; YM-08310
DM5FL14 CP Medimmune Oncology Inc
DM5FL14 DT Small molecular drug
DM5FL14 PC 2141
DM5FL14 MW 214.23
DM5FL14 FM C5H15N2O3PS
DM5FL14 IC InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
DM5FL14 CS C(CN)CNCCSP(=O)(O)O
DM5FL14 IK JKOQGQFVAUAYPM-UHFFFAOYSA-N
DM5FL14 IU 2-(3-aminopropylamino)ethylsulfanylphosphonic acid
DM5FL14 CA CAS 20537-88-6
DM5FL14 CB CHEBI:2636
DM5FL14 DE Mucositis
DM5PDRB ID DM5PDRB
DM5PDRB DN Amikacin
DM5PDRB HS Approved
DM5PDRB SN Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
DM5PDRB CP Abbott Laboratories
DM5PDRB TC Antibiotics
DM5PDRB DT Small molecular drug
DM5PDRB PC 37768
DM5PDRB MW 585.6
DM5PDRB FM C22H43N5O13
DM5PDRB IC InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
DM5PDRB CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
DM5PDRB IK LKCWBDHBTVXHDL-RMDFUYIESA-N
DM5PDRB IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DM5PDRB CA CAS 37517-28-5
DM5PDRB CB CHEBI:2637
DM5PDRB DE Bacterial infection; Tuberculosis
DMRTSGP ID DMRTSGP
DMRTSGP DN Amiloride
DMRTSGP HS Approved
DMRTSGP SN Amiclaran; Amilorida; Amiloridum; Amipramidin; Amipramizid; Amipramizide; Amiprazidine; Amyloride; Guanamprazin; Guanamprazine; Midamor; Amiloride HCL; Amiloride hydrochloride hydrate; Amiclaran (TN); Amikal (Hydrochloride dihydrate); Amilorida [INN-Spanish]; Amiloride (INN); Amiloride [INN:BAN]; Amiloridum [INN-Latin]; Biduret (TN); Midamor (Hydrochloride dihydrate); MK-870 (Hydrochloride dihydrate); AMILORIDE (SEE ALSO: AMILORIDE HCL (2016-88-8)); N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide; N-Amidino-3,5-diamino-6-chlorpyrazincarboxamid; Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, monohydrochloride; 3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide; 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide; 3,5-diamino-N-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide; 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide; Amiloride (Na-Ca chanel blocker)
DMRTSGP CP Tornett pharmaceutical
DMRTSGP TC Diuretics
DMRTSGP DT Small molecular drug
DMRTSGP PC 16231
DMRTSGP MW 229.63
DMRTSGP FM C6H8ClN7O
DMRTSGP IC InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)
DMRTSGP CS C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
DMRTSGP IK XSDQTOBWRPYKKA-UHFFFAOYSA-N
DMRTSGP IU 3,5-diamino-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMRTSGP CA CAS 2609-46-3
DMRTSGP CB CHEBI:2639
DMRTSGP DE Congestive heart failure
DMFGND4 ID DMFGND4
DMFGND4 DN Aminocaproic acid
DMFGND4 HS Approved
DMFGND4 SN 6-Aminohexanoic acid; 6-aminohexanoic acid; 6-Aminocaproic acid; aminocaproic acid; 60-32-2; amicar; Epsikapron; Caprocid; Capramol; Epsamon; EACA; Caprolisin; Acepramin; Hemocaprol; Epsicapron; Respramin; Amikar; EPSILON-AMINOCAPROIC ACID; Hexanoic acid, 6-amino-; Epsilcapramin; Aminokapron; Caplamin; Acepramine; Capracid; Hemopar; Ipsilon; Afibrin; Atsemin; Hepin; Epsilon S; Aminocaproic; Capralense; epsilon-Leucine; EACS; epsilon-Norleucine; epsilcapramine; 6-Amino-n-hexanoic acid; omega-Aminocaproic acid; epsilon-Aminohexanoic acid; 6-amino-hexanoic acid; ACS; Amicar; Aminocaproate; Capranol; Caproamin; Epsicaprom; Epsilcapramine; Hemopar;Hepin; Acide aminocaproique; Acide aminocaproique [French]; Acide aminocaproque; Acido aminocaproico; Acidum aminocaproicum; Acidum aminocaproicum [Latin]; Aminocaproic Acid In Plastic Container; Aminocaproic Acids; Aminohexanoic acid; Eaca kabi; Epsilon Aminocaproic Acid; A 7824; CL 10304; CY 116; CY116; JD 177; Acide aminocaproique [INN-French]; Acido aminocaproico [DCIT,Spanish]; Acido aminocaproico [INN-Spanish]; Acidum aminocaproicum [INN-Latin]; Amicar (TN); Aminocaproic acid (USP); CL-10304; CY-116; Epsilon-Ahx; Epsilon-Aminocaproic acid; Epsilon-Aminocapronsaeure; Epsilon-Aminohexanoic acid; Epsilon-Leucine; Epsilon-Norleucine; Epsilon-aminocaproate; Epsilon-aminocapronzuur; Fullevir (TN); Kyselina omega-aminokapronova; Kyselina omega-aminokapronova [Czech]; Omega-Aminocaproic acid; Omega-Aminohexanoic acid; S04-0132; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; Aminocaproic acid (USP/INN); Aminocaproic acid [USAN:BAN:INN]; Aminocaproic acid [USAN:INN:BAN]; Epsilon-Aminocaproic acid (JAN); HEXANOIC ACID,6-AMINO; Epsilon-Amino-n-caproic acid; Epsilon-Amino-n-hexanoic acid; Amicar, A-amino caproic acid, A-Ahx, 6-aminohexanoic acid, Aminocaproic acid; 6 Aminocaproic Acid; 6 Aminohexanoic Acid; 6-amino-n-caproate; 6-amino-n-caproic acid; 6-aminohexanoate; 6-Amino Hexanoic Acid
DMFGND4 CP Intelfarm Co.
DMFGND4 TC Antifibrinolytic Agents
DMFGND4 DT Small molecular drug
DMFGND4 PC 564
DMFGND4 MW 131.17
DMFGND4 FM C6H13NO2
DMFGND4 IC InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
DMFGND4 CS C(CCC(=O)O)CCN
DMFGND4 IK SLXKOJJOQWFEFD-UHFFFAOYSA-N
DMFGND4 IU 6-aminohexanoic acid
DMFGND4 CA CAS 60-32-2
DMFGND4 CB CHEBI:16586
DMFGND4 DE Bleeding disorder; Postoperative hemorrhage
DMWFHMZ ID DMWFHMZ
DMWFHMZ DN Aminoglutethimide
DMWFHMZ HS Approved
DMWFHMZ SN Aminoglutethimidum; Aminoglutetimida; Cytadren; Elipten; Orimeten; Ciba Vision Brand of Aminoglutethimide; Novartis Brand of Aminoglutethimide; A 9657; Ba 16038; AG-1; Aminoglutethimide (AG); Aminoglutethimide [INN:BAN]; Aminoglutethimidum [INN-Latin]; Aminoglutetimida [INN-Spanish]; Ba-16038; C 16038-BA; Cytadren (TN); Dl-Aminoglutethimide; P-Aminoglutethimide; Aminoglutethimide (USP/INN); Glutethimide, para-amino; Alpha-(p-Aminophenyl)-alpha-ethylglutarimide; (+-)-3-(p-Aminophenyl)-3-ethyl-2,6-piperidinedione; (+/-)-p-AMINOGLUTETHIMIDE; (inverted question mark)-p-Aminoglutethimide; 2-(p-Aminophenyl)-2-ethylglutarimide; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidindion; 3-(4-Aminophenyl)-3-ethyl-2,6-piperidinedione; 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione; 3-(p-Aminophenyl)-3-ethylpiperidine-2,6-dione; 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine
DMWFHMZ CP Norvatis Phamaceuticals Corporation
DMWFHMZ TC Anticancer Agents
DMWFHMZ DT Small molecular drug
DMWFHMZ PC 2145
DMWFHMZ MW 232.28
DMWFHMZ FM C13H16N2O2
DMWFHMZ IC InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)
DMWFHMZ CS CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMWFHMZ IK ROBVIMPUHSLWNV-UHFFFAOYSA-N
DMWFHMZ IU 3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione
DMWFHMZ CA CAS 125-84-8
DMWFHMZ CB CHEBI:2654
DMWFHMZ DE Cushing disease
DMS4BLQ ID DMS4BLQ
DMS4BLQ DN Aminolevulinic acid hci
DMS4BLQ HS Approved
DMS4BLQ SN Aminolevulinic acid; 5-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid; 106-60-5; 5-Aminolevulinate; delta-aminolevulinic acid; Pentanoic acid, 5-amino-4-oxo-; Aladerm; 5-Amino-4-oxovaleric acid; Kerastick; Ameluz; Aminolevulinate; 5-ALA; delta-ALA; 5-Amino-4-oxopentanoate; 5-amino-levulinate; 5-amino-levulinic acid; 5-amino-4-oxo-pentanoic acid; CCRIS 8958; UNII-88755TAZ87; EINECS 203-414-1; Levulinic acid, 5-amino-; CHEMBL601; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; ZGXJTSGNIOSYLO-UHFFFAOYSA-N; 88755TAZ87; Levulan (TN)
DMS4BLQ DT Small molecular drug
DMS4BLQ PC 137
DMS4BLQ MW 131.13
DMS4BLQ FM C5H9NO3
DMS4BLQ IC InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
DMS4BLQ CS C(CC(=O)O)C(=O)CN
DMS4BLQ IK ZGXJTSGNIOSYLO-UHFFFAOYSA-N
DMS4BLQ IU 5-amino-4-oxopentanoic acid
DMS4BLQ CA CAS 106-60-5
DMS4BLQ CB CHEBI:17549
DMS4BLQ DE Acne vulgaris; Actinic keratosis
DMWNHPC ID DMWNHPC
DMWNHPC DN Aminolevulinic Acid Hydrochloride
DMWNHPC HS Approved
DMWNHPC SN Levulan; Levulan Kerastick
DMWNHPC CP Dusa Pharmaceuticals Inc
DMWNHPC DT Small molecular drug
DMWNHPC PC 123608
DMWNHPC MW 167.59
DMWNHPC FM C5H10ClNO3
DMWNHPC IC InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H
DMWNHPC CS C(CC(=O)O)C(=O)CN.Cl
DMWNHPC IK ZLHFONARZHCSET-UHFFFAOYSA-N
DMWNHPC IU 5-amino-4-oxopentanoic acid;hydrochloride
DMWNHPC CA CAS 5451-09-2
DMWNHPC CB CHEBI:132969
DMWNHPC DE Actinic keratosis
DML2NIB ID DML2NIB
DML2NIB DN Aminophylline
DML2NIB HS Approved
DML2NIB SN Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)
DML2NIB TC Bronchodilator Agents
DML2NIB DT Small molecular drug
DML2NIB PC 9433
DML2NIB MW 420.43
DML2NIB FM C16H24N10O4
DML2NIB IC InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
DML2NIB CS CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
DML2NIB IK FQPFAHBPWDRTLU-UHFFFAOYSA-N
DML2NIB IU 1,3-dimethyl-7H-purine-2,6-dione;ethane-1,2-diamine
DML2NIB CA CAS 317-34-0
DML2NIB CB CHEBI:2659
DML2NIB DE Bronchial asthma; Asthma
DMENSL5 ID DMENSL5
DMENSL5 DN Aminosalicylic acid
DMENSL5 HS Approved
DMENSL5 SN 4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium
DMENSL5 CP Panray Corp Sub Ormont Drug And Chemical Co Inc
DMENSL5 DT Small molecular drug
DMENSL5 PC 4649
DMENSL5 MW 153.14
DMENSL5 FM C7H7NO3
DMENSL5 IC InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
DMENSL5 CS C1=CC(=C(C=C1N)O)C(=O)O
DMENSL5 IK WUBBRNOQWQTFEX-UHFFFAOYSA-N
DMENSL5 IU 4-amino-2-hydroxybenzoic acid
DMENSL5 CA CAS 65-49-6
DMENSL5 CB CHEBI:27565
DMENSL5 DE Pulmonary and extrapulmonary tuberculosis; Inflammatory bowel disease
DMUTEX3 ID DMUTEX3
DMUTEX3 DN Amiodarone
DMUTEX3 HS Approved
DMUTEX3 SN Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
DMUTEX3 CP Wyeth-Ayerst Laboratories
DMUTEX3 TC Antiarrhythmic Agents
DMUTEX3 DT Small molecular drug
DMUTEX3 PC 2157
DMUTEX3 MW 645.3
DMUTEX3 FM C25H29I2NO3
DMUTEX3 IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMUTEX3 CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMUTEX3 IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMUTEX3 IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMUTEX3 CA CAS 1951-25-3
DMUTEX3 CB CHEBI:2663
DMUTEX3 DE Tachyarrhythmias
DMSJVAM ID DMSJVAM
DMSJVAM DN Amisulpride
DMSJVAM HS Approved
DMSJVAM SN Aminosultopride; Amisulpiride; Amisulprida; Amisulpridum; Deniban; Socian; Solian; Amisulpride [INN]; DAN 2163; Amisulprida [INN-Spanish]; Amisulpride (INN); Amisulpridum [INN-Latin]; DAN-2163; Deniban (TN); Solian (TN); Solian, Amisulpride; SL-91.1077; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM CP Sanofi-Aventis
DMSJVAM TC Antipsychotic Agents
DMSJVAM DT Small molecular drug
DMSJVAM PC 2159
DMSJVAM MW 369.5
DMSJVAM FM C17H27N3O4S
DMSJVAM IC InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
DMSJVAM CS CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
DMSJVAM IK NTJOBXMMWNYJFB-UHFFFAOYSA-N
DMSJVAM IU 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMSJVAM CA CAS 71675-85-9
DMSJVAM CB CHEBI:64045
DMSJVAM DE Schizophrenia
DMK7F9S ID DMK7F9S
DMK7F9S DN Amitriptyline
DMK7F9S HS Approved
DMK7F9S SN Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
DMK7F9S CP Hoffmann La Roche Inc
DMK7F9S TC Analgesics
DMK7F9S DT Small molecular drug
DMK7F9S PC 2160
DMK7F9S MW 277.4
DMK7F9S FM C20H23N
DMK7F9S IC InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
DMK7F9S CS CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DMK7F9S IK KRMDCWKBEZIMAB-UHFFFAOYSA-N
DMK7F9S IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DMK7F9S CA CAS 50-48-6
DMK7F9S CB CHEBI:2666
DMK7F9S DE Depression
DM0DQM5 ID DM0DQM5
DM0DQM5 DN Amlexanox
DM0DQM5 HS Approved
DM0DQM5 SN ANW; Amlenanox; Amlexanoxo; Amlexanoxum; Amoxanox; Aphthasol; Aptheal; Apthera; Elics; OraDisc; OraRinse; Solfa; Amlexanoxo [Spanish]; Amlexanoxum [Latin]; GlaxoSmithKline brand of amlexanox; OraDisc A; AA 673; CHX 3673; AA-673; Aphthasol (TN); CHX-3673; Solfa (TN); Amlexanox [USAN:INN:JAN]; Amlexanox (JAN/USAN/INN); 2-Amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid; 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid; 2-amino-7-isopropyl-5-oxo-5H-(1)benzopyrano(2,3b)pyridine-3-carboxylic acid
DM0DQM5 CP Access Pharmaceuticals
DM0DQM5 TC Antiulcer Agents
DM0DQM5 DT Small molecular drug
DM0DQM5 PC 2161
DM0DQM5 MW 298.29
DM0DQM5 FM C16H14N2O4
DM0DQM5 IC InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
DM0DQM5 CS CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N
DM0DQM5 IK SGRYPYWGNKJSDL-UHFFFAOYSA-N
DM0DQM5 IU 2-amino-5-oxo-7-propan-2-ylchromeno[2,3-b]pyridine-3-carboxylic acid
DM0DQM5 CA CAS 68302-57-8
DM0DQM5 CB CHEBI:31205
DM0DQM5 DE Respiratory tract inflammation
DMBDAZV ID DMBDAZV
DMBDAZV DN Amlodipine
DMBDAZV HS Approved
DMBDAZV SN Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV CP Dainippon Sumitomo
DMBDAZV TC Antihypertensive Agents
DMBDAZV DT Small molecular drug
DMBDAZV PC 2162
DMBDAZV MW 408.9
DMBDAZV FM C20H25ClN2O5
DMBDAZV IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
DMBDAZV CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DMBDAZV IK HTIQEAQVCYTUBX-UHFFFAOYSA-N
DMBDAZV IU 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMBDAZV CA CAS 88150-42-9
DMBDAZV CB CHEBI:2668
DMBDAZV DE Hypertension
DMOEVK6 ID DMOEVK6
DMOEVK6 DN Ammonia
DMOEVK6 HS Approved
DMOEVK6 SN Ammonia N13
DMOEVK6 CP Feinstein
DMOEVK6 DT Small molecular drug
DMOEVK6 PC 222
DMOEVK6 MW 17.031
DMOEVK6 FM H3N
DMOEVK6 IC InChI=1S/H3N/h1H3
DMOEVK6 CS N
DMOEVK6 IK QGZKDVFQNNGYKY-UHFFFAOYSA-N
DMOEVK6 IU azane
DMOEVK6 CA CAS 7664-41-7
DMOEVK6 CB CHEBI:16134
DMOEVK6 DE Coronary artery disease
DM0GQ8N ID DM0GQ8N
DM0GQ8N DN Amobarbital
DM0GQ8N HS Approved
DM0GQ8N SN AMAL; Amasust; Amital; Amobarbitale; Amobarbitalum; Amobarbitone; Amospan; Amybal; Amylbarbitone; Amylobarbital; Amylobarbitone; Amytal; Barbamil; Barbamyl; Binoctal; Dorlotyn; Dormytal; Eunoctal; Isomyl; Isomytal; Mylodorm; Pentymal; Pentymalum; Robarb; Schiwanox; Sednotic; Somnal; Stadadorm; Sumital; Talamo; Amobarbital suppository dosage form; Amobarbitale [DCIT]; Barbamyl acid; Component of Dexamyl; Ethylisopentylbarbituric acid; Isoamylethylbarbituric acid; Amobarbital [INN:JAN]; Amobarbitalum [INN-Latin]; Component of 15-90; Component of Amo-Dextrosule; Component of Q-Caps; Isomytal (TN); Amobarbital (JP15/INN); 5-Ethyl-5-(3-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(3-methylbutyl)barbituric acid;5-Ethyl-5-isoamylbarbituric acid; 5-Ethyl-5-isoamylmalonyl urea; 5-Ethyl-5-isopentylbarbituric acid; 5-Ethyl-5-isopentylbarbitursaeure; 5-Isoamyl-5-ethylbarbituric acid; 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(3-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
DM0GQ8N TC Hypnotics and Sedatives
DM0GQ8N DT Small molecular drug
DM0GQ8N PC 2164
DM0GQ8N MW 226.27
DM0GQ8N FM C11H18N2O3
DM0GQ8N IC InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DM0GQ8N CS CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
DM0GQ8N IK VIROVYVQCGLCII-UHFFFAOYSA-N
DM0GQ8N IU 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione
DM0GQ8N CA CAS 57-43-2
DM0GQ8N CB CHEBI:2673
DM0GQ8N DE Insomnia
DME4RA8 ID DME4RA8
DME4RA8 DN Amodiaquine
DME4RA8 HS Approved
DME4RA8 SN Amodiachin; Amodiachinum; Amodiaquin; Amodiaquina; Amodiaquinum; Basoquin; CQA; Camochin; Camoquin; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin; Sunoquine; Amodiaquine hydrochloride; Amodiaquine USP24; SN 10751; AMODIAQUINE, FLAVOQUINE; Amodiaquina [INN-Spanish]; Amodiaquinum [INN-Latin]; CAM-AQ 1; CAM-AQI; Cam-AQ1; Camoquin (TN); Flavoquine (TN); SN 10,751; WR-002977; Amodiaquine (USAN/INN); Amodiaquine [USAN:INN:BAN]; Amodiaquine, ring-closed; S. N. 10751
DME4RA8 TC Antimalarials
DME4RA8 DT Small molecular drug
DME4RA8 PC 2165
DME4RA8 MW 355.9
DME4RA8 FM C20H22ClN3O
DME4RA8 IC InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
DME4RA8 CS CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DME4RA8 IK OVCDSSHSILBFBN-UHFFFAOYSA-N
DME4RA8 IU 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DME4RA8 CA CAS 86-42-0
DME4RA8 CB CHEBI:2674
DME4RA8 DE Malaria
DML8QSZ ID DML8QSZ
DML8QSZ DN Amosulalol
DML8QSZ HS Approved
DML8QSZ SN Lowgan; LY-137224; YM-09538
DML8QSZ CP Yamanouchi Pharmaceutical Co Ltd
DML8QSZ DT Small molecular drug
DML8QSZ PC 2169
DML8QSZ MW 380.5
DML8QSZ FM C18H24N2O5S
DML8QSZ IC InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
DML8QSZ CS CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
DML8QSZ IK LVEXHFZHOIWIIP-UHFFFAOYSA-N
DML8QSZ IU 5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide
DML8QSZ CA CAS 85320-68-9
DML8QSZ CB CHEBI:135592
DML8QSZ DE Hypertension
DMKITQE ID DMKITQE
DMKITQE DN Amoxapine
DMKITQE HS Approved
DMKITQE SN Amoxan; Amoxapina; Amoxapinum; Amoxepine; Ascendin; Asendin; Asendis; Defanyl; Demolox; Desmethylloxapin; Desmethylloxapine; Moxadil; CL 67772; A-129; Amoxapina [INN-Spanish]; Amoxapinum [INN-Latin]; Asendin (TN); Asendis (TN); CL-67772; Defanyl (TN); Demolox (TN); KS-1197; Moxadil (TN); CL-67,772; Amoxapine (JP15/USP/INN); Amoxapine [USAN:BAN:INN:JAN]; 2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin; 2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine; 2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine; 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE TC Antidepressants
DMKITQE DT Small molecular drug
DMKITQE PC 2170
DMKITQE MW 313.8
DMKITQE FM C17H16ClN3O
DMKITQE IC InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
DMKITQE CS C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DMKITQE IK QWGDMFLQWFTERH-UHFFFAOYSA-N
DMKITQE IU 8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
DMKITQE CA CAS 14028-44-5
DMKITQE CB CHEBI:2675
DMKITQE DE Major depressive disorder
DMUYNEI ID DMUYNEI
DMUYNEI DN Amoxicillin
DMUYNEI HS Approved
DMUYNEI SN AMPC; Actimoxi; Amoclen; Amolin; Amopen; Amopenixin; Amoxi; Amoxibiotic; Amoxicaps; Amoxicilina; Amoxicillanyl; Amoxicilline; Amoxicillinum; Amoxiden; Amoxil; Amoxivet; Amoxycillin; Anemolin; Aspenil; Biomox; Bristamox; Cemoxin; Clamoxyl; Delacillin; DisperMox; Efpenix; Flemoxin; Hiconcil; Histocillin; Hydroxyampicillin; Ibiamox; Imacillin; Lamoxy; Larotid; Moxacin; Moxal; Moxatag; Ospamox; Pamoxicillin; Piramox; Polymox; Robamox; Sumox; Tolodina; Trimox; Unicillin; Utimox; Vetramox; Wymox; AMOXICILLIN CRYSTALLINE; AMOXICILLIN PEDIATRIC; Amoxicillin anhydrous; Amoxicilline [INN]; Amoxycillin Trihydrate; Metafarma capsules; Metifarma capsules; Sawamox PM; BLP 1410; AMK (TN); Actimoxi (TN); Alphamox (TN); Amoksibos (TN); Amoksiklav (TN); Amoxi-Mast; Amoxibiotic (TN); Amoxicilina (TN); Amoxicilina [INN-Spanish]; Amoxicillin (INN); Amoxicillin (TN); Amoxicillin (anhydrous); Amoxicilline [INN-French]; Amoxicillinum [INN-Latin]; Amoxiclav (TN); Amoxidal (TN); Amoxil (TN); Amoxin (TN); Apo-Amoxi; Augmentin (TN); BL-P 1410; BRL-2333; Bactox (TN); Betalaktam (TN); Cilamox (TN); Clamoxyl (TN); Curam (TN); D-Amoxicillin; Dedoxil (TN); Dispermox (TN); Duomox (TN); Enhancin (TN); Geramox (TN); Gimalxina (TN); Hiconcil (TN); Isimoxin (TN); Klavox (TN); Lamoxy (TN); Moxatag (TN); Moxilen (TN); Moxypen (TN); Moxyvit (TN); Nobactam (TN); Novamoxin (TN); Ospamox (TN); P-Hydroxyampicillin; Pamoxicillin (TN); Panamox (TN); Panklav (TN); Polymox (TN); Ro 10-8756; Samthongcillin (TN); Sandoz (TN); Senox (TN); Sinacilin (TN); Tolodina (TN); Trimox (TN); Wymox (TN); Yucla (TN); Zerrsox (TN); Zimox (TN); Apo-Amoxi (TN); Alpha-Amino-p-hydroxybenzylpenicillin; D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid; D-(-)-alpha-Amino-p-hydroxybenzylpenicillin; (-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D-(8CI); 6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid; 6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin; 6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMUYNEI CP AstraZeneca
DMUYNEI TC Antibiotics
DMUYNEI DT Small molecular drug
DMUYNEI PC 33613
DMUYNEI MW 365.4
DMUYNEI FM C16H19N3O5S
DMUYNEI IC InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
DMUYNEI CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
DMUYNEI IK LSQZJLSUYDQPKJ-NJBDSQKTSA-N
DMUYNEI IU (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUYNEI CA CAS 26787-78-0
DMUYNEI CB CHEBI:2676
DMUYNEI DE Bacterial infection
DMSZQAK ID DMSZQAK
DMSZQAK DN Amphetamine
DMSZQAK HS Approved
DMSZQAK SN Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
DMSZQAK CP PharmacoFore Inc
DMSZQAK DT Small molecular drug
DMSZQAK PC 3007
DMSZQAK MW 135.21
DMSZQAK FM C9H13N
DMSZQAK IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
DMSZQAK CS CC(CC1=CC=CC=C1)N
DMSZQAK IK KWTSXDURSIMDCE-UHFFFAOYSA-N
DMSZQAK IU 1-phenylpropan-2-amine
DMSZQAK CA CAS 300-62-9
DMSZQAK CB CHEBI:2679
DMSZQAK DE Attention deficit hyperactivity disorder
DMTAJQE ID DMTAJQE
DMTAJQE DN Amphotericin B
DMTAJQE HS Approved
DMTAJQE SN ABLC; Abelcet; Abelecet; Ambisome; Amphocin; Amphomoronal; Amphotec; Amphotericin; Amphotericinum; Amphotherizin; Amphozone; Fungilin; Fungisome; Fungisone; Fungizone; Halizon; SinuNase; Amfotericina B; Amophotericin B; Amphortericin B; Amphotericin B Cholesterol Dispersion; Amphotericin B Colloidal Dispersion; Amphotericin B liposomal; Amphotericin BETA; Amphotericine B; Amphotericinum B; Amphotherizin [German]; Liposomal Amphotericin B; NCI527017; NS 718; AMPH-B; Abelcet (TN); AmBisome (TN); Amfotericina B [INN-Spanish]; Ampho-Moronal; Amphocil (TN); Amphotec (TN); Amphotericin-B; Amphotericine B [INN-French]; Amphotericinum B [INN-Latin]; Fungilin (TN); Fungisome (TN); Fungizone (TN); LNS-AmB; Mysteclin-F; NKTR-024; Amphotericin B [USAN:INN:JAN]; Amphotericin B, Lipid-based; Amphotericin B, Streptomyces sp.; Amphotericin B (JP15/USP/INN)
DMTAJQE TC Antifungal Agents
DMTAJQE DT Small molecular drug
DMTAJQE PC 5280965
DMTAJQE MW 924.1
DMTAJQE FM C47H73NO17
DMTAJQE IC InChI=1S/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
DMTAJQE CS C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DMTAJQE IK APKFDSVGJQXUKY-INPOYWNPSA-N
DMTAJQE IU (1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid
DMTAJQE CA CAS 1397-89-3
DMTAJQE DE Fungal infection; Mycoses
DMHWE7P ID DMHWE7P
DMHWE7P DN Ampicillin
DMHWE7P HS Approved
DMHWE7P SN ABPC; Acillin; Adobacillin; Alpen; Amblosin; Amcill; Amfipen; Aminobenzylpenicillin; Ampen; Ampichel; Ampicil; Ampicilina; Ampicillanyl; Ampicillina; Ampicilline; Ampicillinum; Ampicin; Ampifarm; Ampikel; Ampimed; Ampipenin; Ampiscel; Ampisyn; Ampivax; Ampivet; Amplacilina; Amplin; Amplipenyl; Amplisom; Amplital; Austrapen; Binotal; Bonapicillin; Britacil; Campicillin; Cimex; Copharcilin; Delcillin; Deripen; Divercillin; Doktacillin; Duphacillin; Grampenil; Guicitrina; Guicitrine; Lifeampil; Morepen; Norobrittin; Nuvapen; Omnipen; Orbicilina; Penbristol; Penbritin; Penbrock; Penicline; Penimic; Pensyn; Pentrex; Pentrexl; Pentrexyl; Polycillin; Ponecil; Princillin; Principen; QIDamp; Racenacillin; Rosampline;Roscillin; Semicillin; Servicillin; Sumipanto; Supen; Synpenin; Texcillin; Tokiocillin; Tolomol; Totacillin; Totalciclina; Totapen; Trifacilina; Ukapen; Ultrabion; Ultrabron; Vampen; Viccillin; Wypicil; Amfipen V; Amipenix S; Ampicillin A; Ampicillin Anhydrous; Ampicillin Base; Ampicillin acid; Ampicillin anhydrate; Ampicillina [DCIT]; Anhydrous ampicillin; Olin Kid; Pen A; Pen A Oral; Pen Ampil;Penbritin paediatric; Penbritin syrup; Pfizerpen A; Semicillin R; Viccillin S; AY 6108; BA 7305; BRL 1341; Bayer 5427; HI 63; P 50; Principen 125; Principen 250; Principen 500; SQ 17382; AB-PC; AB-PCSol; AY-6108; Ambidrin (TN); Ampi-Co; Ampi-Tab; Ampi-bol; Ampicilina [INN-Spanish]; Ampicilline [INN-French]; Ampicillinum [INN-Latin]; Ampipenin, nt3; Ampy-Penyl; Anhydrous ampicillin (JP15); BRL-1341; D-Ampicillin; D-Cillin; KS-R1; Novo-ampicillin; OMNIPEN (AMPICILLIN); Omnipen (TN); Omnipen-N; P-50; Penbritin-S; Penicillin, Aminobenzyl; Pfizerpen-A; Polycillin-N; Polyflex (Veterinary); Ro-Ampen; SK-Ampicillin; Totacillin (sodium); Totacillin-N; WY-5103; Ampicillin (USP/INN); AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2); Ampicillin [USAN:BAN:INN:JAN]; Ampicillin [USAN:INN:BAN:JAN];D-(-)-Ampicillin; D-(-)-alpha-Aminobenzylpenicillin; D-(-)-alpha-Aminopenicillin; D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid; 6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl; 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMHWE7P CP Stadapharm GmbH
DMHWE7P TC Antibiotics
DMHWE7P DT Small molecular drug
DMHWE7P PC 6249
DMHWE7P MW 349.4
DMHWE7P FM C16H19N3O4S
DMHWE7P IC InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1
DMHWE7P CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
DMHWE7P IK AVKUERGKIZMTKX-NJBDSQKTSA-N
DMHWE7P IU (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHWE7P CA CAS 69-53-4
DMHWE7P CB CHEBI:28971
DMHWE7P DE Bacterial infection
DM5BS98 ID DM5BS98
DM5BS98 DN Ampiroxicam
DM5BS98 HS Approved
DM5BS98 SN Flucam; Nacyl; Nasil; CP-65703
DM5BS98 CP Pfizer Inc
DM5BS98 DT Small molecular drug
DM5BS98 PC 2176
DM5BS98 MW 447.5
DM5BS98 FM C20H21N3O7S
DM5BS98 IC InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)
DM5BS98 CS CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
DM5BS98 IK LSNWBKACGXCGAJ-UHFFFAOYSA-N
DM5BS98 IU ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl]oxy]ethyl carbonate
DM5BS98 CA CAS 99464-64-9
DM5BS98 CB CHEBI:31210
DM5BS98 DE Inflammation
DMLMXE0 ID DMLMXE0
DMLMXE0 DN Amprenavir
DMLMXE0 HS Approved
DMLMXE0 SN AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
DMLMXE0 CP GlaxoSmithKline
DMLMXE0 TC Anti-HIV Agents
DMLMXE0 DT Small molecular drug
DMLMXE0 PC 65016
DMLMXE0 MW 505.6
DMLMXE0 FM C25H35N3O6S
DMLMXE0 IC InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
DMLMXE0 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
DMLMXE0 IK YMARZQAQMVYCKC-OEMFJLHTSA-N
DMLMXE0 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMLMXE0 CA CAS 161814-49-9
DMLMXE0 CB CHEBI:40050
DMLMXE0 DE Human immunodeficiency virus infection
DMZKYIV ID DMZKYIV
DMZKYIV DN Amsacrine
DMZKYIV HS Approved
DMZKYIV SN Acridinylanisidide; Amecrin; Amekrin; Amsacrina; Amsacrinum; Amsidine; Amsidyl; Amsine; Lamasine; MAMSA; NAMSA; Acridinyl Anisidide; SN 21429; SN11841; AMSA P-D; Acridinyl anisidide (TN); Amsacrina [INN-Spanish]; Amsacrinum [INN-Latin]; Amsidyl (TN); Cain's Acridine; M-AMSA; Meta-AMSA; Meta-Amsacrine; SN-11841; Amsacrine (USAN/INN); Amsacrine [USAN:BAN:INN]; M-AMSA (TN); N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide; N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(9-Acridinylamino)-3-methoxy-phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide; N-[4-(acridin-9-ylmethyl)-3-methoxyphenyl]methanesulfonamide; N-(4-(Acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide; N-[4-(Acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide; 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 4'-(9-Acridinylamino)methanesulfon-m-anisidide; 4'-(9-Acridinylamino)methanesulfon-meta-anisidide; 4'-(9-Acridinylamino)methanesulphon-m-anisidide
DMZKYIV CP Travenol Laboratories Inc
DMZKYIV TC Anticancer Agents
DMZKYIV DT Small molecular drug
DMZKYIV PC 2179
DMZKYIV MW 393.5
DMZKYIV FM C21H19N3O3S
DMZKYIV IC InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)
DMZKYIV CS COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42
DMZKYIV IK XCPGHVQEEXUHNC-UHFFFAOYSA-N
DMZKYIV IU N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
DMZKYIV CA CAS 51264-14-3
DMZKYIV CB CHEBI:2687
DMZKYIV DE Acute lymphoblastic leukaemia
DMAWU35 ID DMAWU35
DMAWU35 DN Amtolmetin guacil
DMAWU35 HS Approved
DMAWU35 SN Artromed; Atromed; Eufans; Amtolmetin guacyl; MED-15; ST-679
DMAWU35 CP Sigma-Tau Ind Farm Riunite SpA
DMAWU35 DT Small molecular drug
DMAWU35 PC 65655
DMAWU35 MW 420.5
DMAWU35 FM C24H24N2O5
DMAWU35 IC InChI=1S/C24H24N2O5/c1-16-8-10-17(11-9-16)24(29)19-13-12-18(26(19)2)14-22(27)25-15-23(28)31-21-7-5-4-6-20(21)30-3/h4-13H,14-15H2,1-3H3,(H,25,27)
DMAWU35 CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC
DMAWU35 IK CWJNMKKMGIAGDK-UHFFFAOYSA-N
DMAWU35 IU (2-methoxyphenyl) 2-[[2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetate
DMAWU35 CA CAS 87344-06-7
DMAWU35 CB CHEBI:135678
DMAWU35 DE Inflammation
DMJKO05 ID DMJKO05
DMJKO05 DN Amyl nitrite
DMJKO05 HS Approved
DMJKO05 SN Amyl nitrite; Pentyl nitrite; n-Amyl nitrite; 463-04-7; Nitramyl; n-Pentyl nitrite; Nitrous acid, pentyl ester; Pentyl alcohol, nitrite; UNII-H2HUX79FYK; CCRIS 763; EINECS 207-332-7; H2HUX79FYK; BRN 1701241; AI3-25184; CHEBI:55344; CSDTZUBPSYWZDX-UHFFFAOYSA-N; Pentylnitrite; n-pentylnitrite; amyl 1 nitrite; N-Phenyl nitrile; ACMC-1ACPW; nitrous acid pentyl ester; Nitrousacid, pentyl ester; DSSTox_CID_4522; UN 1113 (Related); Pentyl nitrite, AldrichCPR; AC1L1UC5; DSSTox_RID_77442; SCHEMBL34065; DSSTox_GSID_24522; KSC492M8F; 4-01-00-01644
DMJKO05 DT Small molecular drug
DMJKO05 PC 10026
DMJKO05 MW 117.15
DMJKO05 FM C5H11NO2
DMJKO05 IC InChI=1S/C5H11NO2/c1-2-3-4-5-8-6-7/h2-5H2,1H3
DMJKO05 CS CCCCCON=O
DMJKO05 IK CSDTZUBPSYWZDX-UHFFFAOYSA-N
DMJKO05 IU pentyl nitrite
DMJKO05 CA CAS 463-04-7
DMJKO05 CB CHEBI:55344
DMJKO05 DE Angina pectoris
DMJXIC9 ID DMJXIC9
DMJXIC9 DN Anagliptin
DMJXIC9 HS Approved
DMJXIC9 SN Anagliptin; 739366-20-2; UNII-K726J96838; suiny; CHEMBL1929396; (S)-N-(2-((2-(2-Cyanopyrrolidin-1-yl)-2-oxoethyl)amino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; K726J96838; CHEMBL1929387; N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide; Anagliptin [INN]; N-[2-({2-[(2s)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl}amino)-2-Methylpropyl]-2-Methylpyrazolo[1,5-A]pyrimidine-6-Carboxamide; Anagliptin (JAN/INN); SCHEMBL905393; sk-0403
DMJXIC9 CP Kowa Research Institute
DMJXIC9 DT Small molecular drug
DMJXIC9 PC 44513473
DMJXIC9 MW 383.4
DMJXIC9 FM C19H25N7O2
DMJXIC9 IC InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
DMJXIC9 CS CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N
DMJXIC9 IK LDXYBEHACFJIEL-HNNXBMFYSA-N
DMJXIC9 IU N-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
DMJXIC9 CA CAS 739366-20-2
DMJXIC9 CB CHEBI:136043
DMJXIC9 DE Type-2 diabetes
DMSQ8MD ID DMSQ8MD
DMSQ8MD DN Anagrelide
DMSQ8MD HS Approved
DMSQ8MD SN Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD CP Shire Phamaceuticals
DMSQ8MD TC Antithrombotic Agents
DMSQ8MD DT Small molecular drug
DMSQ8MD PC 135409400
DMSQ8MD MW 256.079
DMSQ8MD FM C10H7Cl2N3O
DMSQ8MD IC InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
DMSQ8MD CS C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
DMSQ8MD IK OTBXOEAOVRKTNQ-UHFFFAOYSA-N
DMSQ8MD IU 6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
DMSQ8MD CA CAS 68475-42-3
DMSQ8MD CB CHEBI:142290
DMSQ8MD DE Thrombocythemia; Essential thrombocythemia
DMU8KOD ID DMU8KOD
DMU8KOD DN Anakinra
DMU8KOD HS Approved
DMU8KOD SN Kineret; Kineret (TN); Anakinra (USAN/INN)
DMU8KOD CP Amgen Inc
DMU8KOD TC Antiinflammatory Agents
DMU8KOD SQ DB00026 sequence: MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLGIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGWFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE
DMU8KOD DE Rheumatoid arthritis
DMV96ZH ID DMV96ZH
DMV96ZH DN Anapsos
DMV96ZH HS Approved
DMV96ZH SN Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC
DMV96ZH CP ASAC Pharmaceutical International AIE
DMV96ZH DE Atopic dermatitis
DMNP60F ID DMNP60F
DMNP60F DN Anastrozole
DMNP60F HS Approved
DMNP60F SN Anastrazole; Anastrole; Anastrozol; Arimidex; Asiolex; Astra brand of anastrozole; AstraZeneca brand of anastrozole; Zeneca brand of anastrozole; ZD 1033; ZD1033; Zeneca ZD 1033; Arimidex (TN); Arimidex (Zeneca); Arimidex, Anastrozole; ZD-1033; Anastrozole [USAN:INN:BAN]; Anastrozole (JAN/USAN/INN); Alpha,alpha,alpha',alpha'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; Alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile; 1,3-benzenediacetonitrile, a, a,a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl); 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile); 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile); 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F CP AstraZeneca
DMNP60F TC Anticancer Agents
DMNP60F DT Small molecular drug
DMNP60F PC 2187
DMNP60F MW 293.4
DMNP60F FM C17H19N5
DMNP60F IC InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
DMNP60F CS CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
DMNP60F IK YBBLVLTVTVSKRW-UHFFFAOYSA-N
DMNP60F IU 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
DMNP60F CA CAS 120511-73-1
DMNP60F CB CHEBI:2704
DMNP60F DE Breast cancer
DMLWQ27 ID DMLWQ27
DMLWQ27 DN Angiotensin Ii
DMLWQ27 HS Approved
DMLWQ27 SN Human angiotensin II; Angiotensin II human; 4474-91-3; Angiotensin II (mouse); Angiotensin II (human); Giapreza; Ang II; 5-Isoleucine-angiotensin II; 5-L-Isoleucineangiotensin II; Ile(5)-angiotensin II; 1-8-Angiotensin I; isoleucine(5)-angiotensin II;Angiotensin II, human; Isoleucine5-angiotensin II; Angiotensin II, ile(5)-; Angiotensin ii [INN:JAN]
DMLWQ27 CP La Jolla Pharmaceutical Company
DMLWQ27 DT Small molecular drug
DMLWQ27 PC 172198
DMLWQ27 MW 1046.2
DMLWQ27 FM C50H71N13O12
DMLWQ27 IC InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMLWQ27 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMLWQ27 IK CZGUSIXMZVURDU-JZXHSEFVSA-N
DMLWQ27 IU (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMLWQ27 CA CAS 4474-91-3
DMLWQ27 CB CHEBI:2719
DMLWQ27 DE Increase blood pressure
DM8QM5U ID DM8QM5U
DM8QM5U DN Anidulafungin
DM8QM5U HS Approved
DM8QM5U SN Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
DM8QM5U CP Pfizer Pharmaceuticals
DM8QM5U TC Antifungal Agents
DM8QM5U DT Small molecular drug
DM8QM5U PC 166548
DM8QM5U MW 1140.2
DM8QM5U FM C58H73N7O17
DM8QM5U IC InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
DM8QM5U CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O
DM8QM5U IK JHVAMHSQVVQIOT-MFAJLEFUSA-N
DM8QM5U IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
DM8QM5U CA CAS 166663-25-8
DM8QM5U CB CHEBI:55346
DM8QM5U DE Convulsion
DMBAUED ID DMBAUED
DMBAUED DN Anileridine
DMBAUED HS Approved
DMBAUED SN Adopol; Alidine; Anileridina; Anileridinum; Apidol; Apodol; Leritin; Nipecotan; Anileridina [INN-Spanish]; Anileridine [INN:BAN]; Anileridinum [INN-Latin]; Leritine (TN); Anileridine (USP/INN); N-beta-(p-Aminophenyl)ethylnormeperidine; Ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate; Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate; Isonipecotic acid, 1-(p-aminophenethyl)-4-phenyl-, ethyl ester; Ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate; N-(beta-(p-Aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine; 1-(2-(4-Aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylisonipecotic acid ethyl ester; 1-(p-Aminophenethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; 1-[2-(4-Aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester; 4-Piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-[2-(4-aminophenyl)ethyl]-4-phenyl-, ethyl ester
DMBAUED TC Analgesics
DMBAUED DT Small molecular drug
DMBAUED PC 8944
DMBAUED MW 352.5
DMBAUED FM C22H28N2O2
DMBAUED IC InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3
DMBAUED CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3
DMBAUED IK LKYQLAWMNBFNJT-UHFFFAOYSA-N
DMBAUED IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
DMBAUED CA CAS 144-14-9
DMBAUED CB CHEBI:61203
DMBAUED DE Pain
DMC128O ID DMC128O
DMC128O DN Anileridine Hydrochloride
DMC128O HS Approved
DMC128O SN Anileridine Phosphate; Leritine
DMC128O CP Merck And Co Inc
DMC128O TC Neurology Agents
DMC128O DT Small molecular drug
DMC128O PC 31338
DMC128O MW 425.4
DMC128O FM C22H30Cl2N2O2
DMC128O IC InChI=1S/C22H28N2O2.2ClH/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18;;/h3-11H,2,12-17,23H2,1H3;2*1H
DMC128O CS CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3.Cl.Cl
DMC128O IK ZYTHLJLPPSSDIP-UHFFFAOYSA-N
DMC128O IU ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate;dihydrochloride
DMC128O CA CAS 126-12-5
DMC128O CB CHEBI:61208
DMC128O DE Pain
DMOIFW0 ID DMOIFW0
DMOIFW0 DN Aniracetam
DMOIFW0 HS Approved
DMOIFW0 SN aniracetam; 72432-10-1; Draganon; Sarpul; 1-(4-Methoxybenzoyl)-2-pyrrolidinone; Ampamet; 1-(4-methoxybenzoyl)pyrrolidin-2-one; 1-p-Anisoyl-2-pyrrolidinone; Ro 13-5057; Aniracetamun [INN-Latin]; Aniracetam [USAN:INN:JAN]; UNII-5L16LKN964; Ro 135057; BRN 4807205; Ro-13-5057; 1-p-anisoylpyrrolidin-2-one; 2-Pyrrolidinone, 1-(4-methoxybenzoyl)-; CHEMBL36994; MLS000079240; CHEBI:47943; 1-(p-Methoxybenzoyl)-2-pyrrolidinon [German]; ZXNRTKGTQJPIJK-UHFFFAOYSA-N; 5L16LKN964; NCGC00015116-10; SMR000038438
DMOIFW0 DT Small molecular drug
DMOIFW0 PC 2196
DMOIFW0 MW 219.24
DMOIFW0 FM C12H13NO3
DMOIFW0 IC InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
DMOIFW0 CS COC1=CC=C(C=C1)C(=O)N2CCCC2=O
DMOIFW0 IK ZXNRTKGTQJPIJK-UHFFFAOYSA-N
DMOIFW0 IU 1-(4-methoxybenzoyl)pyrrolidin-2-one
DMOIFW0 CA CAS 72432-10-1
DMOIFW0 CB CHEBI:47943
DMOIFW0 DE Cerebrovascular ischaemia
DM2C48U ID DM2C48U
DM2C48U DN Anisindione
DM2C48U HS Approved
DM2C48U SN Anisindiona; Anisindionum; Miradon; Unidone; Anisin indandione; SPE 2792; Anisindiona [INN-Spanish]; Anisindione (INN); Anisindione [INN:BAN]; Anisindionum [INN-Latin]; Miradon (TN); 2-(4-Methoxy-phenyl)-indan-1,3-dione; 2-(4-Methoxyphenyl)-1H-indene-1,3(2H)-dione; 2-(4-Methoxyphenyl)indan-1,3-dione; 2-(4-methoxyphenyl)indene-1,3-dione; 2-(p-Methoxyphenyl)-1,3-indandione; 2-(p-Methoxyphenyl)indane-1,3-dione; 2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione; 2-p-Anisyl-1,3-indandione; 2-para-Anisyl-1,3-indandione
DM2C48U TC Anticoagulants
DM2C48U DT Small molecular drug
DM2C48U PC 2197
DM2C48U MW 252.26
DM2C48U FM C16H12O3
DM2C48U IC InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
DM2C48U CS COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2C48U IK XRCFXMGQEVUZFC-UHFFFAOYSA-N
DM2C48U IU 2-(4-methoxyphenyl)indene-1,3-dione
DM2C48U CA CAS 117-37-3
DM2C48U CB CHEBI:133809
DM2C48U DE Coagulation defect
DMW51AX ID DMW51AX
DMW51AX DN Anisodamine
DMW51AX HS Approved
DMW51AX SN anisodamine; racanisodamine; 55869-99-3; (6S)-6-Hydroxyhyoscyamine; (-)-Anisodamine; AC1O6SQS; AC1L4C7W; SCHEMBL620576; ZINC2112569; 8053AH; API0000388; 869A993; Q-100648; [(1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; (S)-((1S,3S,5S,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; [(1R,3S,5R,6R)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate
DMW51AX DT Small molecular drug
DMW51AX PC 6918612
DMW51AX MW 305.4
DMW51AX FM C17H23NO4
DMW51AX IC InChI=1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1
DMW51AX CS CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3
DMW51AX IK WTQYWNWRJNXDEG-RBZJEDDUSA-N
DMW51AX IU [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMW51AX CA CAS 55869-99-3
DMW51AX DE Central and peripheral nervous disease
DMNOSWU ID DMNOSWU
DMNOSWU DN Anisodine
DMNOSWU HS Approved
DMNOSWU SN anisodine; 52646-92-1; SCHEMBL474045; AC1N31M8; 2,3-Dihydroxy-2-phenylpropanoic acid 9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane-7alpha-yl ester
DMNOSWU DT Small molecular drug
DMNOSWU PC 11616712
DMNOSWU MW 319.4
DMNOSWU FM C17H21NO5
DMNOSWU IC InChI=1S/C17H21NO5/c1-18-12-7-11(8-13(18)15-14(12)23-15)22-16(20)17(21,9-19)10-5-3-2-4-6-10/h2-6,11-15,19,21H,7-9H2,1H3/t11?,12-,13+,14-,15+,17-/m1/s1
DMNOSWU CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@@](CO)(C4=CC=CC=C4)O
DMNOSWU IK JEJREKXHLFEVHN-QDXGGTILSA-N
DMNOSWU IU [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-2,3-dihydroxy-2-phenylpropanoate
DMNOSWU CA CAS 52646-92-1
DMNOSWU DE Central and peripheral nervous disease
DMIJRF0 ID DMIJRF0
DMIJRF0 DN Anisotropine Methylbromide
DMIJRF0 HS Approved
DMIJRF0 SN Anisotropine; Endovalpin; Lytispasm; Valpin; Anisotropine methobromide; Anisotropine methyl bromide;Methyloctatropine bromide; Metilbromuro de octatropina; Octatropine methylbromide; Octatropini methylbromidum; Octatropone Bromide; Valpin 50; Anisotropine methylbromide (USAN); Anisotropine methylbromide [USAN:JAN]; Endovalpin (TN); Lytispasm (TN); Methylbromure d'octatropine; Methyloctatropine bromide (JAN); Metilbromuro de octatropina [INN-Spanish]; Octatropine methylbromide (INN); Octatropinimethylbromidum [INN-Latin]; Valpin (TN); Valpin 50 (TN); Methylbromure d'octatropine [INN-French]; Anisotropine methylbromide, (endo)-isomer; [(1R,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate bromide; Endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide; (1r,5r)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; (3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 1-alpha-H,5-alpha-H-Tropanium,3-alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 1alphaH,5alphaH-Tropanium, 3alpha-hydroxy-8-methyl-, bromide, 2-propylvalerate; 2-Propylpentanoyltropinium methylbromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide 2-propylvalerate; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide 2-propylvalerate; 8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide; 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide; 8-Methyltropinium bromide 2-propylpentanoate; 8-Methyltropinium bromide 2-propylvalerate
DMIJRF0 TC Anticholinergic Agents
DMIJRF0 DT Small molecular drug
DMIJRF0 PC 657201
DMIJRF0 MW 362.3
DMIJRF0 FM C17H32BrNO2
DMIJRF0 IC InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1/t14-,15+,16?;
DMIJRF0 CS CCCC(CCC)C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-]
DMIJRF0 IK QSFKGMJOKUZAJM-JXMYBXCISA-M
DMIJRF0 IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate;bromide
DMIJRF0 CA CAS 80-50-2
DMIJRF0 DE Peptic ulcer
DM6Q4B0 ID DM6Q4B0
DM6Q4B0 DN Anistreplase
DM6Q4B0 HS Approved
DM6Q4B0 TC Thrombolytic Agents
DM6Q4B0 SQ DB00029 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DM6Q4B0 DE Acute coronary syndrome
DMUMOEV ID DMUMOEV
DMUMOEV DN Ansuvimab
DMUMOEV HS Approved
DMUMOEV DT Antibody
DMUMOEV DE Ebola virus infection
DMA04JS ID DMA04JS
DMA04JS DN Antazoline
DMA04JS HS Approved
DMA04JS SN Analergine; Antastan; Antasten; Antazolin; Antazolina; Antazolinum; Antihistal; Antistin; Antistine; Azalone; Histostab;Imidamin; Imidamine; Phenazolin; Phenazoline; Antazolina [Spanish]; Antazolinum [Latin]; Antazolina [INN-Spanish]; Antazoline (INN); Antazoline [INN:BAN]; Antazolinum [INN-Latin]; Ben-A-hist; N-Benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline; N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline; 2-(N-Benzylanilinomethyl)-2-imidazoline; 2-(N-Phenyl-N-benzylaminomethyl)imidazoline; 2-Phenyl-benzyl-amino-methylimidazolin; 2-Phenyl-benzyl-amino-methylimidazolin [German]; 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine; 5512-M
DMA04JS DT Small molecular drug
DMA04JS PC 2200
DMA04JS MW 265.35
DMA04JS FM C17H19N3
DMA04JS IC InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
DMA04JS CS C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3
DMA04JS IK REYFJDPCWQRWAA-UHFFFAOYSA-N
DMA04JS IU N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline
DMA04JS CA CAS 91-75-8
DMA04JS CB CHEBI:84115
DMA04JS DE Nasal congestion
DMNC64R ID DMNC64R
DMNC64R DN Antegren
DMNC64R HS Approved
DMNC64R DT Antibody
DMNC64R DE Multiple sclerosis
DMH4CFE ID DMH4CFE
DMH4CFE DN Antithymocyte globulin
DMH4CFE HS Approved
DMH4CFE SN Atgam (TN); Thymoglobulin (TN)
DMH4CFE CP Pfizer Pharmaceuticals
DMH4CFE TC Immunomodulatory Agents
DMH4CFE DE Aplastic anemia
DM89JLN ID DM89JLN
DM89JLN DN Apixaban
DM89JLN HS Approved
DM89JLN SN GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
DM89JLN CP Pfizer
DM89JLN DT Small molecular drug
DM89JLN PC 10182969
DM89JLN MW 459.5
DM89JLN FM C25H25N5O4
DM89JLN IC InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
DM89JLN CS COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
DM89JLN IK QNZCBYKSOIHPEH-UHFFFAOYSA-N
DM89JLN IU 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
DM89JLN CA CAS 503612-47-3
DM89JLN CB CHEBI:72296
DM89JLN DE Thrombosis
DMX38HQ ID DMX38HQ
DMX38HQ DN Apomorphine
DMX38HQ HS Approved
DMX38HQ SN Apomorphine (intranasal, Parkinson's disease)
DMX38HQ CP Archimedes Pharma Ltd
DMX38HQ DT Small molecular drug
DMX38HQ PC 6005
DMX38HQ MW 267.32
DMX38HQ FM C17H17NO2
DMX38HQ IC InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
DMX38HQ CS CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMX38HQ IK VMWNQDUVQKEIOC-CYBMUJFWSA-N
DMX38HQ IU (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMX38HQ CA CAS 58-00-4
DMX38HQ CB CHEBI:48538
DMX38HQ DE Parkinson disease; Sexual dysfunction; Idiopathic parkinson disease
DMO4PVE ID DMO4PVE
DMO4PVE DN Apraclonidine
DMO4PVE HS Approved
DMO4PVE SN Aplonidine; Apraclonidina; Apraclonidinum; Iopidine; Iopidine Eye; ALO 2145; Apraclonidina [INN-Spanish]; Apraclonidine (INN); Apraclonidine [INN:BAN]; Apraclonidinum [INN-Latin]; Iopidine (TN); P-aminoclonidine; Para-aminoclonidine; 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2,6-dichloro-N(1)-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine; 2-(4-Amino-2,6-dichloroanilino)-2-imidazoline hydrochloride; 2-(4-amino-2,6-dichloro)phenyliminoimidazolidine; 4-Aminoclonidine
DMO4PVE CP Alcon Canada Inc
DMO4PVE TC Antiglaucomic Agents
DMO4PVE DT Small molecular drug
DMO4PVE PC 2216
DMO4PVE MW 245.11
DMO4PVE FM C9H10Cl2N4
DMO4PVE IC InChI=1S/C9H10Cl2N4/c10-6-3-5(12)4-7(11)8(6)15-9-13-1-2-14-9/h3-4H,1-2,12H2,(H2,13,14,15)
DMO4PVE CS C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl
DMO4PVE IK IEJXVRYNEISIKR-UHFFFAOYSA-N
DMO4PVE IU 2,6-dichloro-1-N-(4,5-dihydro-1H-imidazol-2-yl)benzene-1,4-diamine
DMO4PVE CA CAS 66711-21-5
DMO4PVE CB CHEBI:2788
DMO4PVE DE Intra ocular pressure reduction
DMTWS9E ID DMTWS9E
DMTWS9E DN Apremilast
DMTWS9E HS Approved
DMTWS9E SN Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
DMTWS9E CP Celgene
DMTWS9E DT Small molecular drug
DMTWS9E PC 11561674
DMTWS9E MW 460.5
DMTWS9E FM C22H24N2O7S
DMTWS9E IC InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
DMTWS9E CS CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
DMTWS9E IK IMOZEMNVLZVGJZ-QGZVFWFLSA-N
DMTWS9E IU N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
DMTWS9E CA CAS 608141-41-9
DMTWS9E CB CHEBI:78540
DMTWS9E DE Psoriasis vulgaris
DM053KT ID DM053KT
DM053KT DN Aprepitant
DM053KT HS Approved
DM053KT SN Aprepitant [USAN]; L 754030; MK 0869; Emend (TN); L-754030; MK-0869; ONO-7436; Aprepitant (JAN/USAN/INN); MK-869, L-754030, Emend, Aprepitant; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one; 3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one; 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one; 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
DM053KT CP Merck & Co
DM053KT TC Antiemetics
DM053KT DT Small molecular drug
DM053KT PC 135413536
DM053KT MW 534.4
DM053KT FM C23H21F7N4O3
DM053KT IC InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1
DM053KT CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F
DM053KT IK ATALOFNDEOCMKK-OITMNORJSA-N
DM053KT IU 3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
DM053KT CA CAS 170729-80-3
DM053KT CB CHEBI:499361
DM053KT DE Depression; Nausea; Solid tumour/cancer
DMBXWU8 ID DMBXWU8
DMBXWU8 DN Aprindine
DMBXWU8 HS Approved
DMBXWU8 SN Aprindin; Aprindina; Aprindinum; Aprinidine; Fibocil; AC 1802; Aprindina [INN-Spanish]; Aprindinum [INN-Latin]; Aprindine (USAN/INN); Aprindine [USAN:BAN:INN]; N-(3-(Diethylamino)propyl)-N-phenyl-2-indanamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine; N,N-Diethyl-N'-2-indanyl-N'-phenyl-1,3-propanediaminemonohydrochloride; N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine; N-(2,3-Dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-1,3-propanediamine; N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine
DMBXWU8 TC Antiarrhythmic Agents
DMBXWU8 DT Small molecular drug
DMBXWU8 PC 2218
DMBXWU8 MW 322.5
DMBXWU8 FM C22H30N2
DMBXWU8 IC InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
DMBXWU8 CS CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3
DMBXWU8 IK NZLBHDRPUJLHCE-UHFFFAOYSA-N
DMBXWU8 IU N'-(2,3-dihydro-1H-inden-2-yl)-N,N-diethyl-N'-phenylpropane-1,3-diamine
DMBXWU8 CA CAS 37640-71-4
DMBXWU8 CB CHEBI:135370
DMBXWU8 DE Cardiac arrhythmias
DMOWK6B ID DMOWK6B
DMOWK6B DN Aprobarbital
DMOWK6B HS Approved
DMOWK6B SN Allional; Allonal; Allylisopropylmalonylurea; Allylpropymal; Allypropymal; Allypropymalum; Alurate; Aprobarbita; Aprobarbitale; Aprobarbitalum; Aprobarbitone; Aprozal; Numal; Allylisopropylbarbituric acid; Alurate elixir verdum; Aprobarbitale [DCIT]; Isopropylallylbarbituric acid; Alurate (TN); Aprobarbital (INN); Aprobarbital [INN:DCF]; Aprobarbitalum [INN-Latin]; Isonal (swedish); 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylethyl)-5-(2-propenyl)-(9CI); 5-(1-Methylethyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(propan-2-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-isopropylbarbiturate; 5-Allyl-5-isopropylbarbituricacid; 5-Isopropyl-5-allylbarbituric acid; 5-allyl-5-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B TC Anticonvulsants
DMOWK6B DT Small molecular drug
DMOWK6B PC 6464
DMOWK6B MW 210.23
DMOWK6B FM C10H14N2O3
DMOWK6B IC InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)
DMOWK6B CS CC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DMOWK6B IK UORJNBVJVRLXMQ-UHFFFAOYSA-N
DMOWK6B IU 5-propan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DMOWK6B CA CAS 77-02-1
DMOWK6B CB CHEBI:2791
DMOWK6B DE Anaesthesia; Insomnia
DM0QD4W ID DM0QD4W
DM0QD4W DN Aprotinin
DM0QD4W HS Approved
DM0QD4W SN Trasylol; Zymofren; Trazinin; Iniprol; Riker 52G; Bayer A 128; UNII-04XPW8C0FL; 04XPW8C0FL; APROTININ; RP-9921; Aprotininum; Aprotinina; Aprotinine; Antilysine; Repulson; Antagosan; Pantinol; Onquinin; Trascolan; Protimbin; Inhibin; Contrykal; Antilysin; Antikrein; Fosten; Tzalol; Gordox; Kir richter; Trypsin inhibitor; Aprotinin solution; 9087-70-1; BPTI; APROTININ BOVINE; Basic protease inhibitor; Aprotininum [INN-Latin]; Aprotinine [INN-French]; Aprotinina [INN-Spanish]; Pancreatic trypsin inhibitor; Kunitz and Northrop inhibitor
DM0QD4W CP Novo Nordisk A/S
DM0QD4W DT Small molecular drug
DM0QD4W SQ Aprotinin (bovine pancreatic trypsin inhibitor): RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
DM0QD4W PC 146027575
DM0QD4W MW 6511
DM0QD4W FM C284H432N84O79S7
DM0QD4W IC InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311)/t144-,145-,146-,147+,148-,149-,150+,151-,152-,153+,154+,167+,168-,169+,170+,171+,172+,173+,174-,175-,176+,177-,178+,179-,180+,181-,182+,183-,184+,185+,186+,187+,188+,189+,190-,191+,192+,193+,194+,195-,196+,197+,198+,199-,200+,201+,202-,203-,204+,205+,206+,221-,222+,223+,224-,225-,226-/m1/s1
DM0QD4W CS CC[C@@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N6CCC[C@@H]6C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)CCC(=O)N)[C@H](C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCNC(=N)N)C)CCCCN)[C@@H](C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(=O)O)[C@H](C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)[C@H](C)CC
DM0QD4W IK ZPNFWUPYTFPOJU-VKTQZXOTSA-N
DM0QD4W IU (3R)-4-[[(2S)-1-[[(1S,2aR,4R,5aR,8aR,11aR,13R,14aR,16S,17aS,19S,20aR,25S,26aR,29aR,31S,32aR,34S,35aS,37R,38aS,41aS,42R,44aS,45R,47aR,48S,50aS,51R,53aS,54R,56aR,57S,59aR,60S,62aS,63S,66S,69S,72S,75S,78S,81S,84S,87S,90S,93R)-29a,62a,69,84-tetrakis(4-aminobutyl)-35a,75,78-tris(2-amino-2-oxoethyl)-14a-(3-amino-3-oxopropyl)-8a,41a,72-tribenzyl-50a,53a-bis[(2R)-butan-2-yl]-47a,48,56a,81,90-pentakis(3-carbamimidamidopropyl)-31,60-bis(2-carboxyethyl)-42-[[2-[[2-[[(1R)-1-carboxyethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]carbamoyl]-57-(carboxymethyl)-11a,45-bis[(1S)-1-hydroxyethyl]-13-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-2a,16,38a,44a-tetrakis[(4-hydroxyphenyl)methyl]-26a,32a,59a,63,87-pentamethyl-20a,34-bis(2-methylpropyl)-51-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,22a,24,25a,28a,30,31a,33,34a,36,37a,40a,43a,44,46a,47,49a,50,52a,53,55a,56,58a,59,61a,62,64a,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-5a-propan-2-yl-39,40,66a,67a,70a,71a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,21a,23,24a,27a,29,30a,32,33a,35,36a,39a,42a,43,45a,46,48a,49,51a,52,54a,55,57a,58,60a,61,63a,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazahexacyclo[91.71.4.454,117.04,8.019,23.025,29]doheptacontahectan-37-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoic acid
DM0QD4W CA CAS 9087-70-1
DM0QD4W DE Bleeding disorder
DMHTXSL ID DMHTXSL
DMHTXSL DN Arbekacin
DMHTXSL HS Approved
DMHTXSL SN Habekacin (TN)
DMHTXSL CP Meiji Seika
DMHTXSL DT Small molecular drug
DMHTXSL PC 68682
DMHTXSL MW 552.6
DMHTXSL FM C22H44N6O10
DMHTXSL IC InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1
DMHTXSL CS C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N
DMHTXSL IK MKKYBZZTJQGVCD-XTCKQBCOSA-N
DMHTXSL IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMHTXSL CA CAS 51025-85-5
DMHTXSL CB CHEBI:37922
DMHTXSL DE Bacterial infection
DMOQK8Z ID DMOQK8Z
DMOQK8Z DN Arbidol
DMOQK8Z HS Approved
DMOQK8Z SN Umifenovir; Arbidole; MC-101
DMOQK8Z CP Good Earth Medicine
DMOQK8Z DT Small molecular drug
DMOQK8Z PC 131411
DMOQK8Z MW 477.4
DMOQK8Z FM C22H25BrN2O3S
DMOQK8Z IC InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
DMOQK8Z CS CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3
DMOQK8Z IK KCFYEAOKVJSACF-UHFFFAOYSA-N
DMOQK8Z IU ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
DMOQK8Z CA CAS 131707-25-0
DMOQK8Z CB CHEBI:134730
DMOQK8Z DE Virus infection
DMCY8AF ID DMCY8AF
DMCY8AF DN Arbutamine
DMCY8AF HS Approved
DMCY8AF SN Arbutamina; Arbutaminum; Genesa; Arbutamina [INN-Spanish]; Arbutamine [INN:BAN]; Arbutaminum [INN-Latin]; 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol; 4-[(1R)-1-hydroxy-2-{[4-(4-hydroxyphenyl)butyl]amino}ethyl]benzene-1,2-diol; 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF TC Cardiotonic Agents
DMCY8AF DT Small molecular drug
DMCY8AF PC 60789
DMCY8AF MW 317.4
DMCY8AF FM C18H23NO4
DMCY8AF IC InChI=1S/C18H23NO4/c20-15-7-4-13(5-8-15)3-1-2-10-19-12-18(23)14-6-9-16(21)17(22)11-14/h4-9,11,18-23H,1-3,10,12H2/t18-/m0/s1
DMCY8AF CS C1=CC(=CC=C1CCCCNC[C@@H](C2=CC(=C(C=C2)O)O)O)O
DMCY8AF IK IIRWWTKISYTTBL-SFHVURJKSA-N
DMCY8AF IU 4-[(1R)-1-hydroxy-2-[4-(4-hydroxyphenyl)butylamino]ethyl]benzene-1,2-diol
DMCY8AF CA CAS 128470-16-6
DMCY8AF CB CHEBI:50580
DMCY8AF DE Coronary artery disease
DM9GH25 ID DM9GH25
DM9GH25 DN Arcitumomab
DM9GH25 HS Approved
DM9GH25 SN CEA-Scan; Arcitumomab (USAN/INN); Cea-Scan (TN)
DM9GH25 TC Diagnostic Agents
DM9GH25 DT Antibody
DM9GH25 DE Breast cancer
DMYRX8B ID DMYRX8B
DMYRX8B DN Ardeparin
DMYRX8B HS Approved
DMYRX8B SN Arteven; Bemiparin; Certoparin; Clivarine; Dalteparin; Eparina; Fluxum; Fraxiparin; Heparina; Heparinate; Heparine; Heparinum; Hepathrom; Innohep; Liquaemin; Liquemin; Logiparin; Multiparin; Nadroparin; Nadroparine; Novoheparin; Pabyrin; Parnaparin; Parvoparin; Pularin; Sandoparin; Subeparin; Sublingula; Thromboliquine; Tinzaparin; Triofiban; Vetren; Allocinnamic acid; Ardeparin sodium; Bemiparin sodium; Enoxaparin sodium; Eparina [DCIT]; Fragmin A; Fragmin B; Fragmin IV; Hep Flush Kit in plastic container; Heparin Lock Flush in plastic container; Heparin Lock Flush preservative free; Heparin Lock Flush preservative free in plastic container; Heparin natrium; Heparin sulfate; Heparinic acid; Heparinum natricum; Isocinnamic acid; Minolteparin sodium; Parnaparin sodium; Reviparin sodium; Sodium acid heparin; Sodium heparinate; Tinzaparin sodium; Vitrum AB; CY 216; Cy 222; FR 860; H 2149; Heparin CY 216; KB 101; Kabi 2165; LHN 1; Lioton 1000; OP 386; OP 622; Ro 11; WY 90493RD; ALFA 87-120; ALFA 87-163; ALFA 87-198; ALFA 87-81; ALFA 88-247; Alpha-Heparin; Cis-Cinnamic acid; Depo-Heparin; Hed-heparin; Hep-Lock; Heparin, sodium salt; Heparina [INN-Spanish]; Heparine [INN-French]; Heparinum [INN-Latin]; Hepflush-10; Inno-Hep; Normiflo (TN); Hep-Lock U/P; Cis-.beta.-Carboxystyrene
DMYRX8B CP Celcius Laboratories
DMYRX8B TC Anticoagulants
DMYRX8B DT Small molecular drug
DMYRX8B PC 772
DMYRX8B MW 1134.9
DMYRX8B FM C26H42N2O37S5
DMYRX8B IC InChI=1S/C26H42N2O37S5/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)
DMYRX8B CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O
DMYRX8B IK HTTJABKRGRZYRN-UHFFFAOYSA-N
DMYRX8B IU 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DMYRX8B CA CAS 9005-49-6
DMYRX8B DE Venous thrombosis; Thrombosis; Deep vein thrombosis; Venous thromboembolism
DMVMY7K ID DMVMY7K
DMVMY7K DN Arepanrix
DMVMY7K HS Approved
DMVMY7K SN H1N1 pandemic influenza vaccine (AS03 adjuvanted) 2, GlaxoSmithKline; H1N1 pandemic influenza vaccine2 (AS03 adjuvanted), GSK
DMVMY7K CP GlaxoSmithKline plc
DMVMY7K DT Vaccine
DMVMY7K DE Influenza virus infection
DMYM974 ID DMYM974
DMYM974 DN Arformoterol
DMYM974 HS Approved
DMYM974 SN 67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate
DMYM974 CP Sepracor phamaceuticals
DMYM974 TC Bronchodilator Agents
DMYM974 DT Small molecular drug
DMYM974 PC 3083544
DMYM974 MW 344.4
DMYM974 FM C19H24N2O4
DMYM974 IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
DMYM974 CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O
DMYM974 IK BPZSYCZIITTYBL-YJYMSZOUSA-N
DMYM974 IU N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
DMYM974 CA CAS 67346-49-0
DMYM974 CB CHEBI:408174
DMYM974 DE Chronic obstructive pulmonary disease; Asthma
DMFI46A ID DMFI46A
DMFI46A DN Argatroban
DMFI46A HS Approved
DMFI46A SN Acova; Argatrobanum; MMTQAP; MPQA; Novastan; Argatrobanum [Latin]; MITSUBISHI INHIBITOR; MCI 9038; MD 805; MD805; Argatroban (anhydrous); Argatroban [INN:JAN]; GN-1600; MCI-9038; MD-805; MQI-ARG-MCP; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-1-[5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid; (2R,4R)-4-Methyl-1-((S)-N(sup 2)-(((RS)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl)sulfonyl)arginyl)pipecolic acid; (2R,4R)-4-Methyl-1[Nalpha-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2-piperadinecarboxylic acid; (2r,4r)-4-methyl-1-[n2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-l-arginyl]-2-piperidinecarboxylic acid; 21R-Argatroban; 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid
DMFI46A TC Anticoagulants
DMFI46A DT Small molecular drug
DMFI46A PC 92722
DMFI46A MW 508.6
DMFI46A FM C23H36N6O5S
DMFI46A IC InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1
DMFI46A CS C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
DMFI46A IK KXNPVXPOPUZYGB-IOVMHBDKSA-N
DMFI46A IU (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid
DMFI46A CA CAS 74863-84-6
DMFI46A CB CHEBI:94385
DMFI46A DE Thrombosis
DMRE4FC ID DMRE4FC
DMRE4FC DN Arginine
DMRE4FC HS Approved
DMRE4FC SN DL-Arginine hydrochloride; 32042-43-6; 2-Amino-5-guanidinopentanoic acid hydrochloride; argininhydrochlorid; DL-Arginine HCl; 220144-84-3; H-DL-Arg-OH.xHCl; DL-(+/-)-Arginine Hydrochloride; 1-Hydrochloride arginine; NSC7914; Arginine monochloride; 2-Amino-5-guanidinovaleric acid monohydrochloride; WLN: MUYZM3YZVQ & DL-Arginine hydrochloride, 98%, anhydrous; Arginine monohydrochloride, L-(+)-; ARGININE, (L); L(+)-Arginine hydrochloride; D-Arginine, hydrochloride (1:1); EINECS 250-903-0; EINECS 239-674-8
DMRE4FC DT Small molecular drug
DMRE4FC PC 6322
DMRE4FC MW 174.2
DMRE4FC FM C6H14N4O2
DMRE4FC IC InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
DMRE4FC CS C(C[C@@H](C(=O)O)N)CN=C(N)N
DMRE4FC IK ODKSFYDXXFIFQN-BYPYZUCNSA-N
DMRE4FC IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
DMRE4FC CA CAS 74-79-3
DMRE4FC CB CHEBI:16467
DMRE4FC DE Growth hormone deficiency
DM3NUMH ID DM3NUMH
DM3NUMH DN Aripiprazole
DM3NUMH HS Approved
DM3NUMH SN 129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-14597; Discmelt; Opc 14597; OPC 31; OPC-31; 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril; UNII-82VFR53I78; C23H27Cl2N3O2; HSDB 7320; 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL1112; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone; CHEBI:31236; Abilify; Aripiprazol; Aripiprazolum; Aripirazole; Arpizol; Asprito; Pripiprazole; Aripiprazole [USAN]; Otsuka brand of aripiprazole; OPC 14597; ALKS-9070; Abilify (TN); BMS-337039; Bristol-Myers Squibb brand of aripiprazole; Discmelt (TN); KS-1030; S06-0010; Aripiprazole (JAN/USAN/INN); 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril; 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one; 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one; ALKS9070/ALKS9072; Aripiprazole/escitalopram fixed-dose combination
DM3NUMH CP Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd
DM3NUMH TC Antipsychotic Agents
DM3NUMH DT Small molecular drug
DM3NUMH PC 60795
DM3NUMH MW 448.4
DM3NUMH FM C23H27Cl2N3O2
DM3NUMH IC InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
DM3NUMH CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
DM3NUMH IK CEUORZQYGODEFX-UHFFFAOYSA-N
DM3NUMH IU 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DM3NUMH CA CAS 129722-12-9
DM3NUMH CB CHEBI:31236
DM3NUMH DE Major depressive disorder; Schizophrenia; Bipolar disorder; Erythropoietic porphyrias
DMGB035 ID DMGB035
DMGB035 DN Armodafinil
DMGB035 HS Approved
DMGB035 SN Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035 CP Cephalon
DMGB035 DT Small molecular drug
DMGB035 PC 9690109
DMGB035 MW 273.4
DMGB035 FM C15H15NO2S
DMGB035 IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
DMGB035 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)[S@](=O)CC(=O)N
DMGB035 IK YFGHCGITMMYXAQ-LJQANCHMSA-N
DMGB035 IU 2-[(R)-benzhydrylsulfinyl]acetamide
DMGB035 CA CAS 112111-43-0
DMGB035 CB CHEBI:77590
DMGB035 DE Pediatric cancer
DMT81LZ ID DMT81LZ
DMT81LZ DN Arn-509
DMT81LZ HS Approved
DMT81LZ SN Arn-509 (AR inhibitor)
DMT81LZ CP Johnson & Johnson
DMT81LZ DT Small molecular drug
DMT81LZ PC 24872560
DMT81LZ MW 477.4
DMT81LZ FM C21H15F4N5O2S
DMT81LZ IC InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
DMT81LZ CS CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F
DMT81LZ IK HJBWBFZLDZWPHF-UHFFFAOYSA-N
DMT81LZ IU 4-[7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide
DMT81LZ CA CAS 956104-40-8
DMT81LZ DE Acute myeloid leukaemia; Prostate cancer
DM1P6FR ID DM1P6FR
DM1P6FR DN Arry-162
DM1P6FR HS Approved
DM1P6FR SN 606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME
DM1P6FR CP Array BioPharma
DM1P6FR DT Small molecular drug
DM1P6FR PC 10288191
DM1P6FR MW 441.2
DM1P6FR FM C17H15BrF2N4O3
DM1P6FR IC InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DM1P6FR CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
DM1P6FR IK ACWZRVQXLIRSDF-UHFFFAOYSA-N
DM1P6FR IU 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DM1P6FR CA CAS 606143-89-9
DM1P6FR CB CHEBI:145371
DM1P6FR DE Melanoma
DMTL2Y1 ID DMTL2Y1
DMTL2Y1 DN Arsenic
DMTL2Y1 HS Approved
DMTL2Y1 SN Agent SA; Arsen [German,Polish]; Arsenic; Arsenic Black; Arsenic Lump (Metals Basis); Arsenic and arsenic compounds; Arsenic compounds; Arsenic hydride (AsH3); Arsenic, elemental; Arsenic, inorganic; Arsenic, organic compounds; Arsenic-75; Arsenicals; Arsenowodor [Polish]; Arsenwasserstoff [German]; Colloidal arsenic; Gray arsenic; Grey arsenic; Metallic arsenic; UN 2188; UN1558; UN2188; V1I29R0RJQ; 7440-38-2; Arsen; As; CCRIS 55; EINECS 231-148-6; EINECS 232-066-3; HSDB 509; HSDB 510; N712M78A8G; UNII-N712M78A8G; UNII-V1I29R0RJQ
DMTL2Y1 PC 5359596
DMTL2Y1 MW 74.921
DMTL2Y1 FM As
DMTL2Y1 IC RQNWIZPPADIBDY-UHFFFAOYSA-N
DMTL2Y1 CS [As]
DMTL2Y1 IK 1S/As
DMTL2Y1 IU arsenic
DMTL2Y1 CA CAS 7440-38-2
DMTL2Y1 CB CHEBI:27563
DMTL2Y1 DE Acute myeloid leukaemia
DM61TA4 ID DM61TA4
DM61TA4 DN Arsenic trioxide
DM61TA4 HS Approved
DM61TA4 SN Arsenox; Arsentrioxide; Naonobin; Trisenox; Trixenox; Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic trioxide [JAN]; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Oxyde Arsenieux; Arsenic trioxide [UN1561] [Poison]; Arsenic oxide (As2O3); Arsenic(III) trioxide; Oxyde Arsenieux [ISO-French]; Trisenox (TN); Arsenic trioxide (JP15/USAN); Arsenic(3+)
DM61TA4 TC Anticancer Agents
DM61TA4 DT Small molecular drug
DM61TA4 PC 14888
DM61TA4 MW 197.841
DM61TA4 FM As2O3
DM61TA4 IC InChI=1S/2As.3O/q2*+3;3*-2
DM61TA4 CS [O-2].[O-2].[O-2].[As+3].[As+3]
DM61TA4 IK QTLQKAJBUDWPIB-UHFFFAOYSA-N
DM61TA4 IU arsenic(3+);oxygen(2-)
DM61TA4 CA CAS 1327-53-3
DM61TA4 DE Acute lymphoblastic leukaemia
DMQLX7O ID DMQLX7O
DMQLX7O DN Arteether
DMQLX7O HS Approved
DMQLX7O SN Beta arteether; Artecef (TN); Artemotil (TN)
DMQLX7O CP Artecef BV
DMQLX7O DT Small molecular drug
DMQLX7O PC 3000469
DMQLX7O MW 312.4
DMQLX7O FM C17H28O5
DMQLX7O IC InChI=1S/C17H28O5/c1-5-18-14-11(3)13-7-6-10(2)12-8-9-16(4)20-15(19-14)17(12,13)22-21-16/h10-15H,5-9H2,1-4H3/t10-,11-,12+,13+,14+,15-,16-,17-/m1/s1
DMQLX7O CS CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)O[C@@](CC3)(OO4)C)C)C
DMQLX7O IK NLYNIRQVMRLPIQ-XQLAAWPRSA-N
DMQLX7O IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DMQLX7O CA CAS 75887-54-6
DMQLX7O CB CHEBI:135335
DMQLX7O DE Malaria
DM48QOT ID DM48QOT
DM48QOT DN Artemether
DM48QOT HS Approved
DM48QOT SN Artemetero; Artemether[inn]; Artemetheri; Artemetherum; Artemos; Artenam; Artesaph; Artesian; Artimist; Artmether; Falcidol; Gvither; Malartem; Paluther; Rither; Arteannuin ether; Artemether [INN]; Artemisininelactol methyl ether; Dihydroartemisinin methyl ether; Dihydroquinghaosu methyl ether; SM 224; SM 229; Alpha-Artemether; Alpha-Dihydroartemisinin methyl ether; Artemetero [INN-Spanish]; Artemether (INN); Artemetherum [INN-Latin]; Beta-Artemether; Beta-Dihydroartemisinin methyl ether; Methyl-dihydroartemisinine; O-Methyldihydroartemisinine; SM-224; Beta-Methylether of 11-epi-dihydroartemisinin; Artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether; (3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
DM48QOT DT Small molecular drug
DM48QOT PC 68911
DM48QOT MW 298.37
DM48QOT FM C16H26O5
DM48QOT IC InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
DM48QOT CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
DM48QOT IK SXYIRMFQILZOAM-HVNFFKDJSA-N
DM48QOT IU (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
DM48QOT CA CAS 71963-77-4
DM48QOT CB CHEBI:195280
DM48QOT DE Malaria
DMOY7W3 ID DMOY7W3
DMOY7W3 DN Artemisinin
DMOY7W3 HS Approved
DMOY7W3 SN Arteannuin; Artemisine; Artemisinina; Artemisinine; Artemisininum; Artesin; Huanghuahaosu; Qinghaosu; Qinghosu; Quinghaosu; Artemisinin [INN]; Artemisinina [Spanish]; Artemisinine [French]; Artemisininum [Latin]; Qing Hau SU; Qing Hau Sau; Qing Hau Sau [Chinese]; Qinghaosu [Chinese]; Quing Hau Sau; Artemisinin (INN); Coartem, Artemisinin; Artemisia annua L., extract; GNF-PF-5671; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (+)-Arteannuin; (+)-Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; (5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; 3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
DMOY7W3 DT Small molecular drug
DMOY7W3 PC 68827
DMOY7W3 MW 282.33
DMOY7W3 FM C15H22O5
DMOY7W3 IC InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
DMOY7W3 CS C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C
DMOY7W3 IK BLUAFEHZUWYNDE-NNWCWBAJSA-N
DMOY7W3 IU (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
DMOY7W3 CA CAS 63968-64-9
DMOY7W3 CB CHEBI:223316
DMOY7W3 DE Malaria
DMFETDK ID DMFETDK
DMFETDK DN Artemisinin SP
DMFETDK HS Approved
DMFETDK SN Isoguvacine; isoguvacine; 1,2,3,6-tetrahydropyridine-4-carboxylic acid; 64603-90-3; 1,2,3,6-Tetrahydro-pyridine-4-carboxylic acid; 1,2,3,6-Tetrahydro-4-pyridinecarboxylic acid; UNII-YTF580771Y; CHEMBL39071; CHEBI:34799; YTF580771Y; 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-; AC1OEMUS; 1,2,3,6-tetrahydropyridinium-4-carboxylate; 1,2,3,6-tetrahydropyridin-1-ium-4-carboxylate; Tocris-0235; Spectrum_001974; Lopac-G-002; AC1L1GNT; Spectrum3_001869; Biomol-NT_000254; AC1Q5QG1; Lopac0_000561; KBioSS_002540; BSPBio_003318; DivK1c_000115
DMFETDK DT Small molecular drug
DMFETDK PC 3765
DMFETDK MW 127.14
DMFETDK FM C6H9NO2
DMFETDK IC InChI=1S/C6H9NO2/c8-6(9)5-1-3-7-4-2-5/h1,7H,2-4H2,(H,8,9)
DMFETDK CS C1CNCC=C1C(=O)O
DMFETDK IK KRVDMABBKYMBHG-UHFFFAOYSA-N
DMFETDK IU 1,2,3,6-tetrahydropyridine-4-carboxylic acid
DMFETDK CA CAS 64603-90-3
DMFETDK CB CHEBI:34799
DMFETDK DE Malaria
DMR27C8 ID DMR27C8
DMR27C8 DN Artesunate
DMR27C8 HS Approved
DMR27C8 SN Arinate; Arsumax; Artesunato; Artesunatum; Artsuna; Dihydroqinghaosusuccinate; Nuartez; Plasmotrim; Plasmotrin; Qinghaozhi; Artesunic acid; Dihydroqinghasu hemsuccinate; Quinghaosu reduced succinate ester; Succinyl dihydroartemisinin; SM 804; WR 256283; Arsumax (TN); Artesunate (USAN); Artesunate (superseded RN); Artesunato [INN-Spanish]; Artesunatum [INN-Latin]; WR-256283; Dihydroartemisinine-12-alpha-succinate; Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid; 4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
DMR27C8 DT Small molecular drug
DMR27C8 PC 6917864
DMR27C8 MW 384.4
DMR27C8 FM C19H28O8
DMR27C8 IC InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1
DMR27C8 CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C
DMR27C8 IK FIHJKUPKCHIPAT-AHIGJZGOSA-N
DMR27C8 IU 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
DMR27C8 CA CAS 88495-63-0
DMR27C8 CB CHEBI:63918
DMR27C8 DE Malaria
DMOKCVI ID DMOKCVI
DMOKCVI DN ARZOXIFENE
DMOKCVI HS Approved
DMOKCVI SN Arzoxifene; 182133-25-1; UNII-E569WG6E60; LY 353381; E569WG6E60; 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol; 2-(4-methoxyphenyl)-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[b]thiophen-6-ol; Arzoxifene [INN]; LY-353381; SCHEMBL285277; CHEMBL226267; BDBM19442; DTXSID10171255; ZINC1544683; AC1L4522; AN-538; AKOS030631785; SB19713; KB-05502; FT-0751607; 124708-EP2295426A1; 124708-EP2295427A1; 124708-EP2292592A1; 124708-EP2292576A2; Benzo(b)thiophene-6-ol, 2-(4-methoxyphenyl)-3-(4-(2-(1-piperidinyl)
DMOKCVI DT Small molecular drug
DMOKCVI PC 179337
DMOKCVI MW 475.6
DMOKCVI FM C28H29NO4S
DMOKCVI IC InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3
DMOKCVI CS COC1=CC=C(C=C1)C2=C(C3=C(S2)C=C(C=C3)O)OC4=CC=C(C=C4)OCCN5CCCCC5
DMOKCVI IK MCGDSOGUHLTADD-UHFFFAOYSA-N
DMOKCVI IU 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol
DMOKCVI CA CAS 182133-25-1
DMOKCVI DE Breast cancer
DMV05SW ID DMV05SW
DMV05SW DN As-1670542
DMV05SW HS Approved
DMV05SW SN AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542
DMV05SW CP Dova Pharmaceuticals
DMV05SW DT Small molecular drug
DMV05SW PC 9852519
DMV05SW MW 649.7
DMV05SW FM C29H34Cl2N6O3S2
DMV05SW IC InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)
DMV05SW CS C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl
DMV05SW IK OFZJKCQENFPZBH-UHFFFAOYSA-N
DMV05SW IU 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
DMV05SW CA CAS 570406-98-3
DMV05SW DE Thrombocytopenia; Idiopathic thrombocytopenic purpura
DMCZIHT ID DMCZIHT
DMCZIHT DN Asasantin
DMCZIHT HS Approved
DMCZIHT SN Aggrenox; Aspirin mixture with Dipyridamole; 87653-67-6; Asasantin Retard; Aspirin / Dipyridamole; aspirin, dipyridamole drug combination; TX-3301; TX 3301; C24H40N8O4.C9H8O4; Aspirin/extended-release dipyridamole; AC1L3AE0; SCHEMBL456521; DTXSID40236543; LS-178622; Benzoic acid, 2-(acetyloxy)-, mixt. with 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis(ethanol)
DMCZIHT CP Boehringer Ingelheim Corp
DMCZIHT DT Small molecular drug
DMCZIHT PC 137329
DMCZIHT MW 684.8
DMCZIHT FM C33H48N8O8
DMCZIHT IC InChI=1S/C24H40N8O4.C9H8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30;1-6(10)13-8-5-3-2-4-7(8)9(11)12/h33-36H,1-18H2;2-5H,1H3,(H,11,12)
DMCZIHT CS CC(=O)OC1=CC=CC=C1C(=O)O.C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMCZIHT IK NOHUXXDTQJPXSB-UHFFFAOYSA-N
DMCZIHT IU 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMCZIHT CA CAS 87653-67-6
DMCZIHT DE Cerebrovascular ischaemia
DMSQZE2 ID DMSQZE2
DMSQZE2 DN Asenapine
DMSQZE2 HS Approved
DMSQZE2 SN Asenapi; Asenapine [INN:BAN]; Saphris (TN); [13C,2H3]-Asenipine; Trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole; 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-met; 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
DMSQZE2 CP Organon BioSciences
DMSQZE2 DT Small molecular drug
DMSQZE2 PC 3036780
DMSQZE2 MW 285.8
DMSQZE2 FM C17H16ClNO
DMSQZE2 IC InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1
DMSQZE2 CS CN1C[C@@H]2[C@@H](C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
DMSQZE2 IK VSWBSWWIRNCQIJ-GJZGRUSLSA-N
DMSQZE2 IU (2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DMSQZE2 CA CAS 65576-45-6
DMSQZE2 CB CHEBI:71246
DMSQZE2 DE Schizophrenia
DMM4FXA ID DMM4FXA
DMM4FXA DN Asfotase alfa
DMM4FXA HS Approved
DMM4FXA SN SPHEX, BioMep; SPHEX, Enobia; PHEX-based enzyme replacement therapy, BioMep; PHEX-based enzyme replacement therapy, Enobia; X-linked hypophosphatemic rickets therapy, BioMep; X-linked hypophosphatemic rickets therapy, Enobia
DMM4FXA CP Enobia Pharma Inc
DMM4FXA SQ Asfotase Alfa Sequence: LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAIQILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTADHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYAHNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHCAPASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDDDDDDDD
DMM4FXA DE Genetic disease
DM672AH ID DM672AH
DM672AH DN Aspirin
DM672AH HS Approved
DM672AH SN ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
DM672AH CP Bayer Pharmaceuticals Corporation
DM672AH TC Analgesics
DM672AH DT Small molecular drug
DM672AH PC 2244
DM672AH MW 180.16
DM672AH FM C9H8O4
DM672AH IC InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
DM672AH CS CC(=O)OC1=CC=CC=C1C(=O)O
DM672AH IK BSYNRYMUTXBXSQ-UHFFFAOYSA-N
DM672AH IU 2-acetyloxybenzoic acid
DM672AH CA CAS 50-78-2
DM672AH CB CHEBI:15365
DM672AH DE Pain; Myocardial infarction; Cardiovascular disease
DMSYRBX ID DMSYRBX
DMSYRBX DN Atazanavir
DMSYRBX HS Approved
DMSYRBX SN 198904-31-3; Latazanavir; Zrivada; Reyataz; BMS-232632; BMS 232632; Atazanavir [INN:BAN]; CGP 73547; Atazanavir Base; UNII-QZU4H47A3S; CGP-73547; HSDB 7339; Reyataz (TN); ATV; QZU4H47A3S; CHEMBL1163; CHEBI:37924; (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER; NCGC00182552-01; AK174307; DSSTox_CID_28617; DSSTox_RID_82887; DSSTox_GSID_48691; DR7; atazanavirum; ATZ; Atazanavirum; Atazanavir (INN); Reyataz, BMS-232632, Atazanavir; Reyataz(TM) (*1:1 sulfate*); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate; METHYL [(1S,4S,5S,10S)-4-BENZYL-1,10-DI-TERT-BUTYL-5-HYDROXY-2,9,12-TRIOXO-7-(4-PYRIDIN-2-YLBENZYL)-13-OXA-3,7,8,11-TETRAAZATETRADEC-1-YL]CARBAMATE; Methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; (2S)-N-(3-{[(2S)-2-(Methoxycarbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycarbonylamino)-3,3-dimethylbutanamide
DMSYRBX CP Bristol-Myers Squibb
DMSYRBX TC Anti-HIV Agents
DMSYRBX DT Small molecular drug
DMSYRBX PC 148192
DMSYRBX MW 704.9
DMSYRBX FM C38H52N6O7
DMSYRBX IC InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
DMSYRBX CS CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
DMSYRBX IK AXRYRYVKAWYZBR-GASGPIRDSA-N
DMSYRBX IU methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMSYRBX CA CAS 198904-31-3
DMSYRBX CB CHEBI:37924
DMSYRBX DE Human immunodeficiency virus infection
DMNKG1Z ID DMNKG1Z
DMNKG1Z DN Atenolol
DMNKG1Z HS Approved
DMNKG1Z SN Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide
DMNKG1Z TC Antihypertensive Agents
DMNKG1Z DT Small molecular drug
DMNKG1Z PC 2249
DMNKG1Z MW 266.34
DMNKG1Z FM C14H22N2O3
DMNKG1Z IC InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
DMNKG1Z CS CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
DMNKG1Z IK METKIMKYRPQLGS-UHFFFAOYSA-N
DMNKG1Z IU 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMNKG1Z CA CAS 29122-68-7
DMNKG1Z CB CHEBI:2904
DMNKG1Z DE Hypertension
DMMF8U0 ID DMMF8U0
DMMF8U0 DN Atezolizumab
DMMF8U0 HS Approved
DMMF8U0 CP Genentech South San Francisco, CA
DMMF8U0 DT Monoclonal antibody
DMMF8U0 DE Melanoma; Breast cancer; Bladder cancer; Colorectal cancer; Haematological malignancy; Myelodysplastic syndrome; Renal cell carcinoma; Squamous cell carcinoma; Urothelial carcinoma; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Acute myeloid leukaemia; Follicular lymphoma; Gastric adenocarcinoma; Multiple myeloma; Pancreatic cancer; Small-cell lung cancer; Solid tumour/cancer; Bronchioalveolar carcinoma; Ulcer; Non-small cell lung cancer
DM5L6HI ID DM5L6HI
DM5L6HI DN Atomoxetine
DM5L6HI HS Approved
DM5L6HI SN Tomoxetina; Tomoxetine; Tomoxetinum; Tomoxetina [Spanish]; Tomoxetine [INN]; Tomoxetinum [Latin]; Atomoxetine (INN); Attentin (TN); Strattera (TN); Tomoxetin (TN); (-)-Tomoxetine; (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI CP Eli Lilly
DM5L6HI DT Small molecular drug
DM5L6HI PC 54841
DM5L6HI MW 255.35
DM5L6HI FM C17H21NO
DM5L6HI IC InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
DM5L6HI CS CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2
DM5L6HI IK VHGCDTVCOLNTBX-QGZVFWFLSA-N
DM5L6HI IU (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
DM5L6HI CA CAS 83015-26-3
DM5L6HI CB CHEBI:127342
DM5L6HI DE Attention deficit hyperactivity disorder
DMF28YC ID DMF28YC
DMF28YC DN Atorvastatin
DMF28YC HS Approved
DMF28YC SN Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID
DMF28YC CP Pfizer Pharmaceuticals
DMF28YC TC Anticholesteremic Agents
DMF28YC DT Small molecular drug
DMF28YC PC 60823
DMF28YC MW 558.6
DMF28YC FM C33H35FN2O5
DMF28YC IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMF28YC CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMF28YC IK XUKUURHRXDUEBC-KAYWLYCHSA-N
DMF28YC IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMF28YC CA CAS 134523-00-5
DMF28YC CB CHEBI:39548
DMF28YC DE Cardiovascular disease
DMY4UMW ID DMY4UMW
DMY4UMW DN Atovaquone
DMY4UMW HS Approved
DMY4UMW SN Acuvel; Atavaquone; Mepron; Pron; Wellvone; Atovaquone GlaxoSmithKline brand; Glaxo Wellcome brand of atovaquone; GlaxoSmithKline brand of atovaquone; Malarone Pediatric; BW 566C; BW 566C80; Hydroxynaphthoquinone 566C80; Atovaquone & Interleukin 12; BW 556C-80; BW 566C-80; BW-A 566C; DRG-0084; Hydroxynaphthoquinone, 566C80; Mepron (TN); Mepron (antipneumocystic); ATO & IL-12; Atovaquone (USP/INN); Atovaquone [USAN:BAN:INN]; CRL-8131 & Atovaquone; 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; 3-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxy-naphthalene-1,2-dione; 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione; 566C80 hydroxynaphthoquinone; 566C80, hydroxynaphthoquinone; ATQ
DMY4UMW CP GlaxoSmithKline
DMY4UMW TC Antifungal Agents
DMY4UMW DT Small molecular drug
DMY4UMW PC 74989
DMY4UMW MW 366.8
DMY4UMW FM C22H19ClO3
DMY4UMW IC InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,24H,5-8H2
DMY4UMW CS C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O
DMY4UMW IK BSJMWHQBCZFXBR-UHFFFAOYSA-N
DMY4UMW IU 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
DMY4UMW CA CAS 94015-53-9
DMY4UMW CB CHEBI:575568
DMY4UMW DE Fungal infection
DM42HXN ID DM42HXN
DM42HXN DN Atracurium
DM42HXN HS Approved
DM42HXN SN Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN CP Burroughs Wellcome Co
DM42HXN TC Neuromuscular Nondepolarizing Agents
DM42HXN DT Small molecular drug
DM42HXN PC 47319
DM42HXN MW 929.1
DM42HXN FM C53H72N2O12+2
DM42HXN IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2
DM42HXN CS C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DM42HXN IK YXSLJKQTIDHPOT-UHFFFAOYSA-N
DM42HXN IU 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DM42HXN CA CAS 64228-79-1
DM42HXN CB CHEBI:2914
DM42HXN DE Anaesthesia
DMEN6X7 ID DMEN6X7
DMEN6X7 DN Atropine
DMEN6X7 HS Approved
DMEN6X7 SN dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate
DMEN6X7 CP Pfizer Pharmaceuticals
DMEN6X7 TC Antiarrhythmic Agents
DMEN6X7 DT Small molecular drug
DMEN6X7 PC 174174
DMEN6X7 MW 289.4
DMEN6X7 FM C17H23NO3
DMEN6X7 IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
DMEN6X7 CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
DMEN6X7 IK RKUNBYITZUJHSG-PJPHBNEVSA-N
DMEN6X7 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMEN6X7 CA CAS 51-55-8
DMEN6X7 CB CHEBI:16684
DMEN6X7 DE Organophosphate poisoning; Poison intoxication
DM79Y2T ID DM79Y2T
DM79Y2T DN ATryn antithrombin
DM79Y2T HS Approved
DM79Y2T CP Revo biologics
DM79Y2T DE Multiple sclerosis
DMWE2N4 ID DMWE2N4
DMWE2N4 DN Auranofin
DMWE2N4 HS Approved
DMWE2N4 SN Ridaura; Ridauran; Ridaura (TN); SK&F 39162; SK&F-39162; Gold, (1-thio-.beta.-D-glucopyranosato)(triethylphosphine)-, 2,3,4,6-tetraacetate; (1-Thio-.beta.-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate
DMWE2N4 TC Antirheumatic Agents
DMWE2N4 DT Small molecular drug
DMWE2N4 PC 24199313
DMWE2N4 MW 678.5
DMWE2N4 FM C20H34AuO9PS
DMWE2N4 IC InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1
DMWE2N4 CS CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
DMWE2N4 IK AUJRCFUBUPVWSZ-UHFFFAOYSA-M
DMWE2N4 IU gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
DMWE2N4 CA CAS 34031-32-8
DMWE2N4 DE Inflammatory arthritis
DM75CXN ID DM75CXN
DM75CXN DN Avanafil
DM75CXN HS Approved
DM75CXN SN Stendra (TN)
DM75CXN CP Vivus
DM75CXN DT Small molecular drug
DM75CXN PC 9869929
DM75CXN MW 483.9
DM75CXN FM C23H26ClN7O3
DM75CXN IC InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
DM75CXN CS COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
DM75CXN IK WEAJZXNPAWBCOA-INIZCTEOSA-N
DM75CXN IU 4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
DM75CXN CA CAS 330784-47-9
DM75CXN CB CHEBI:66876
DM75CXN DE Erectile dysfunction
DMK2GZX ID DMK2GZX
DMK2GZX DN Avapritinib
DMK2GZX HS Approved
DMK2GZX SN 1703793-34-3; UNII-513P80B4YJ; 513P80B4YJ; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; Avapritinib [INN]; BLU-285 (Avapritinib); SCHEMBL16652297; EX-A1366; BCP20175; CS-7577; ACN-051245; HY-101561; (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine
DMK2GZX CP Blueprint Medicines Cambridge, MA
DMK2GZX PC 118023034
DMK2GZX MW 498.6
DMK2GZX FM C26H27FN10
DMK2GZX IC InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
DMK2GZX CS C[C@](C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N
DMK2GZX IK DWYRIWUZIJHQKQ-SANMLTNESA-N
DMK2GZX IU (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine
DMK2GZX CA CAS 1703793-34-3
DMK2GZX DE Mast cell leukaemia; Systemic mastocytosis; Gastrointestinal stromal tumour
DMSZLJR ID DMSZLJR
DMSZLJR DN Avelumab
DMSZLJR HS Approved
DMSZLJR CP Merck KGaA/Pfizer
DMSZLJR DT Monoclonal antibody
DMSZLJR SQ Heavy chain: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMSZLJR DE Melanoma; Ovarian cancer; Solid tumour/cancer; Renal cell carcinoma; Merkel cell carcinoma
DM1AEH4 ID DM1AEH4
DM1AEH4 DN Avibactam
DM1AEH4 HS Approved
DM1AEH4 SN Avibactam; Avibactam (free acid); Avibactam [USAN:INN]; Avibactam free acid; AVE-1330A free acid; NXL 104; NXL104; Q15410251; SCHEMBL1666807; ZINC9302239; (2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; 1,6-Diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1R,2S,5R)-rel-; 1192500-31-4; 396731-14-9; BDBM50339145; CHEBI:85984; CHEMBL1689063; CS-0593; DB09060; HY-14879; UNII-06MFO7817I component NDCUAPJVLWFHHB-UHNVWZDZSA-N; UNII-7352665165
DM1AEH4 PC 9835049
DM1AEH4 MW 265.25
DM1AEH4 FM C7H11N3O6S
DM1AEH4 IC NDCUAPJVLWFHHB-UHNVWZDZSA-N
DM1AEH4 CS C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N
DM1AEH4 IK 1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
DM1AEH4 IU [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DM1AEH4 CA CAS 396731-14-9
DM1AEH4 CB CHEBI:85984
DM1AEH4 DE Infectious cystitis
DMYHN59 ID DMYHN59
DMYHN59 DN Axicabtagene ciloleucel
DMYHN59 HS Approved
DMYHN59 CP Masonic Cancer Center, University of Minnesota
DMYHN59 DT CAR T Cell Therapy
DMYHN59 DE Acute lymphoblastic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; Large B-cell lymphoma
DMGVH6N ID DMGVH6N
DMGVH6N DN Axitinib
DMGVH6N HS Approved
DMGVH6N SN AG 013736; AG013736; AG-013736; AG-13736; AG-013736, Axitinib; N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Axitinib (VEGFR inhibitor)
DMGVH6N CP Pfizer
DMGVH6N TC Anticancer Agents
DMGVH6N DT Small molecular drug
DMGVH6N PC 6450551
DMGVH6N MW 386.5
DMGVH6N FM C22H18N4OS
DMGVH6N IC InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
DMGVH6N CS CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
DMGVH6N IK RITAVMQDGBJQJZ-FMIVXFBMSA-N
DMGVH6N IU N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
DMGVH6N CA CAS 319460-85-0
DMGVH6N CB CHEBI:66910
DMGVH6N DE Renal cell carcinoma
DMTA5OE ID DMTA5OE
DMTA5OE DN Azacitidine
DMTA5OE HS Approved
DMTA5OE SN Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
DMTA5OE CP Celgene
DMTA5OE TC Anticancer Agents
DMTA5OE DT Small molecular drug
DMTA5OE PC 9444
DMTA5OE MW 244.2
DMTA5OE FM C8H12N4O5
DMTA5OE IC InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
DMTA5OE CS C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N
DMTA5OE IK NMUSYJAQQFHJEW-KVTDHHQDSA-N
DMTA5OE IU 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMTA5OE CA CAS 320-67-2
DMTA5OE CB CHEBI:2038
DMTA5OE DE Myelodysplastic syndrome
DMZ80SB ID DMZ80SB
DMZ80SB DN Azatadine
DMZ80SB HS Approved
DMZ80SB SN Azatadina; Azatadinum; Azatidine; Azatadine maleate; Azatadina [INN-Spanish]; Azatadine (INN); Azatadine [INN:BAN]; Azatadinum [INN-Latin]; 11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
DMZ80SB TC Antihistamines
DMZ80SB DT Small molecular drug
DMZ80SB PC 19861
DMZ80SB MW 290.4
DMZ80SB FM C20H22N2
DMZ80SB IC InChI=1S/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3
DMZ80SB CS CN1CCC(=C2C3=CC=CC=C3CCC4=C2N=CC=C4)CC1
DMZ80SB IK SEBMTIQKRHYNIT-UHFFFAOYSA-N
DMZ80SB IU 2-(1-methylpiperidin-4-ylidene)-4-azatricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaene
DMZ80SB CA CAS 3964-81-6
DMZ80SB CB CHEBI:2946
DMZ80SB DE Allergic rhinitis
DMMZSXQ ID DMMZSXQ
DMMZSXQ DN Azathioprine
DMMZSXQ HS Approved
DMMZSXQ SN Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
DMMZSXQ CP GlaxoSmithKline
DMMZSXQ TC Immunosuppressive Agents
DMMZSXQ DT Small molecular drug
DMMZSXQ PC 2265
DMMZSXQ MW 277.27
DMMZSXQ FM C9H7N7O2S
DMMZSXQ IC InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
DMMZSXQ CS CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
DMMZSXQ IK LMEKQMALGUDUQG-UHFFFAOYSA-N
DMMZSXQ IU 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
DMMZSXQ CA CAS 446-86-6
DMMZSXQ CB CHEBI:2948
DMMZSXQ DE Organ transplant rejection
DMHVL0J ID DMHVL0J
DMHVL0J DN Azelaic Acid
DMHVL0J HS Approved
DMHVL0J SN AZA; Azelaic; Azelex; Finacea; Finevin; Skinorem; Skinoren; Acide azelaique; Acide azelaique [French]; Acido azelaico; Acido azelaico [Spanish]; Acidum azelaicum; Acidum azelaicum [Latin]; Anchoic acid; Azalaic Acid; Azelaic acid polyanhydride; Azelaic polyanhydride; Azelainic acid; Azleaic Acid; Heptanedicarboxylic acid; Lepargylic acid; NONANEDIOIC ACID; Nonanedioic acid; Polyazelaic anhydride; AZ1; Dicarboxylic acid C9; Emerox 1110; Emerox 1144; ZK 62498; A-9800; AGN-191861; Azelaic acid [USAN:INN]; Azelaic acid,technical grade; Azelex (TN); Finacea (TN); Finevin (TN); N-Nonanedioic acid; Nonanedioic acid, homopolymer; Poly(azelaic anhydride); SH-441; Skinoren (TN); ZK-62498; AZELAIC ACID, 95%; Azelaic acid (USAN/INN); Emery's L-110; 1,7-Heptanedicarboxylic acid; 1,9-Nonanedioic acid
DMHVL0J TC Dermatologic Agents
DMHVL0J DT Small molecular drug
DMHVL0J PC 2266
DMHVL0J MW 188.22
DMHVL0J FM C9H16O4
DMHVL0J IC InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)
DMHVL0J CS C(CCCC(=O)O)CCCC(=O)O
DMHVL0J IK BDJRBEYXGGNYIS-UHFFFAOYSA-N
DMHVL0J IU nonanedioic acid
DMHVL0J CA CAS 123-99-9
DMHVL0J CB CHEBI:48131
DMHVL0J DE Acne vulgaris
DMXTMBJ ID DMXTMBJ
DMXTMBJ DN Azelastine
DMXTMBJ HS Approved
DMXTMBJ SN Azelastina; Azelastinum; Optivar; Astelin (TN); Astepro (TN); Azelastina [INN-Spanish]; Azelastine (INN); Azelastine [INN:BAN]; Azelastinum [INN-Latin]; Optivar (TN); 4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride; 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl; 4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone; 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ CP Meda Pharmaceuticals Inc
DMXTMBJ TC Antiallergic Agents
DMXTMBJ DT Small molecular drug
DMXTMBJ PC 2267
DMXTMBJ MW 381.9
DMXTMBJ FM C22H24ClN3O
DMXTMBJ IC InChI=1S/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3
DMXTMBJ CS CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
DMXTMBJ IK MBUVEWMHONZEQD-UHFFFAOYSA-N
DMXTMBJ IU 4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
DMXTMBJ CA CAS 58581-89-8
DMXTMBJ CB CHEBI:2950
DMXTMBJ DE Allergic conjunctivitis
DMOIX5S ID DMOIX5S
DMOIX5S DN Azilsartan
DMOIX5S HS Approved
DMOIX5S SN TAK 536; TAK-536; Azilsartan (INN/USAN)
DMOIX5S CP Takeda
DMOIX5S DT Small molecular drug
DMOIX5S PC 135415867
DMOIX5S MW 456.4
DMOIX5S FM C25H20N4O5
DMOIX5S IC InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
DMOIX5S CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O
DMOIX5S IK KGSXMPPBFPAXLY-UHFFFAOYSA-N
DMOIX5S IU 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMOIX5S CA CAS 147403-03-0
DMOIX5S CB CHEBI:68850
DMOIX5S DE Hypertension
DMIR5QP ID DMIR5QP
DMIR5QP DN Azlocillin
DMIR5QP HS Approved
DMIR5QP SN Azlocilina; Azlocilline; Azlocillinum; Securopen; Bayer Brand of Azlocillin; Azlocilina [INN-Spanish]; Azlocillin Sodium (Sterile); Azlocilline [INN-French]; Azlocillinum [INN-Latin]; Bay-e 6905; Azlocillin (USAN/INN); Azlocillin [USAN:BAN:INN]; (2R,5R,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2R,5S,6S)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-((R)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2S)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5S,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2r,5s,6s)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic acid; 3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-7-oxo-6-{[{[(2-oxoimidazolidin-1-yl)carbonyl]amino}(phenyl)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-((R)-2-(2-Oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure
DMIR5QP CP Bayer Pharmaceuticals Corp
DMIR5QP TC Antibiotics
DMIR5QP DT Small molecular drug
DMIR5QP PC 6479523
DMIR5QP MW 461.5
DMIR5QP FM C20H23N5O6S
DMIR5QP IC InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1
DMIR5QP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
DMIR5QP IK JTWOMNBEOCYFNV-NFFDBFGFSA-N
DMIR5QP IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIR5QP CA CAS 37091-66-0
DMIR5QP CB CHEBI:2956
DMIR5QP DE Pseudomonas infection
DMDNJHG ID DMDNJHG
DMDNJHG DN Aztreonam
DMDNJHG HS Approved
DMDNJHG SN Azactam; Primbactam; Azactam (TN); SQ-26776; Monobactam, SQ 26776, Squibb 26776, Aztreonam; [2S-[2alpha,3beta(Z)]]-2-[[[1-(2-Amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid; 2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG CP Bristol-Myers Squibb Company
DMDNJHG TC Antibiotics
DMDNJHG DT Small molecular drug
DMDNJHG PC 5742832
DMDNJHG MW 435.4
DMDNJHG FM C13H17N5O8S2
DMDNJHG IC InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1
DMDNJHG CS C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
DMDNJHG IK WZPBZJONDBGPKJ-VEHQQRBSSA-N
DMDNJHG IU 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid
DMDNJHG CA CAS 78110-38-0
DMDNJHG CB CHEBI:161680
DMDNJHG DE Bacterial infection
DMP54C7 ID DMP54C7
DMP54C7 DN Bacampicillin
DMP54C7 HS Approved
DMP54C7 SN Bacampicilina; Bacampicilline; Bacampicillinum; Penglobe; Bacampicillin hydrochloride; Bacampicilina [INN-Spanish]; Bacampicillin (INN); Bacampicillin [INN:BAN]; Bacampicilline [INN-French]; Bacampicillinum [INN-Latin]; Penglobe (TN); Spectrobid (TN); (2S,5R,6R)-6((R)-(2-Amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid ester with ethyl 1-hydroxyethylcarbonate; 1'-Ethoxycarbonyloxyethyl-(6-D-alpha-aminophenylacetamido)penicillanate; 1-Ethoxycarbonyloxyethyl (2S,5R,6R)-6((R)-(2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carboxylat; 1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-[(ethoxycarbonyl)oxy]ethyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2S)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 6-((R)-2-Amino-2-phenylacetamido)penicillansaeure-(1-(ethoxycarbonyloxy)ethylester
DMP54C7 CP Pfizer Pharmaceuticals
DMP54C7 TC Antibiotics
DMP54C7 DT Small molecular drug
DMP54C7 PC 441397
DMP54C7 MW 465.5
DMP54C7 FM C21H27N3O7S
DMP54C7 IC InChI=1S/C21H27N3O7S/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25)/t11?,13-,14-,15+,18-/m1/s1
DMP54C7 CS CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C
DMP54C7 IK PFOLLRNADZZWEX-FFGRCDKISA-N
DMP54C7 IU 1-ethoxycarbonyloxyethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMP54C7 CA CAS 50972-17-3
DMP54C7 CB CHEBI:2968
DMP54C7 DE Bacterial infection
DM5OHYE ID DM5OHYE
DM5OHYE DN Bacitracin
DM5OHYE HS Approved
DM5OHYE SN Altracin; Baciguent; Baciquent; Citracin; Fortracin; Bacitracin A; Bacitracin A1; Bacitracin A2a; Neosporin (TN); Solu-Tracin 50; Partyl-, (10.4)-lactam; L-Asparagine, N-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-.alpha.-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-.alpha.-as; 11702_FLUKA; 11702_SIGMA
DM5OHYE TC Antibiotics
DM5OHYE DT Small molecular drug
DM5OHYE PC 10909430
DM5OHYE MW 1422.7
DM5OHYE FM C66H103N17O16S
DM5OHYE IC InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1
DM5OHYE CS CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
DM5OHYE IK CLKOFPXJLQSYAH-ABRJDSQDSA-N
DM5OHYE IU (4R)-4-[[(2S)-2-[[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S,3S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-6-(carboxymethyl)-9-(1H-imidazol-5-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM5OHYE CA CAS 1405-87-4
DM5OHYE CB CHEBI:35862
DM5OHYE DE Skin infection
DMD2871 ID DMD2871
DMD2871 DN Bacitracin
DMD2871 HS Approved
DMD2871 SN Bacillus subtilis; Bacitracin Zinc free sample; Bacitracin zinc [USP]; Bacitracins zinc complex; Bacitracins, zinc complex; EPA Pesticide Chemical Code 006309; SC-18930; SCHEMBL543112; Ziba-RX; Zinc bacitracin; 5-((1-((9-((4H-imidazol-4-yl)methyl)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-(sec-butyl)-6-(carboxymethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopent; AKOS015896384; Albac; Caswell No. 909A; EINECS 215-787-8; FT-0622546; FT-0654564
DMD2871 PC 3083711
DMD2871 MW 1488.1
DMD2871 FM C66H103N17O16SZn
DMD2871 IC QSNOBVJFKSQBBD-UHFFFAOYSA-N
DMD2871 CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCCCC(C(=O)NC(C(=O)N1)CCCN)NC(=O)C(C(C)CC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C2CSC(=N2)C(C(C)CC)N)CC(=O)N)CC(=O)O)CC3C=NC=N3)CC4=CC=CC=C4.[Zn]
DMD2871 IK 1S/C66H103N17O16S.Zn/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90;/h12-14,18-19,31,33-37,39-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88);
DMD2871 IU 4-[[2-[[2-(1-amino-2-methylbutyl)-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[1-[[3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-butan-2-yl-6-(carboxymethyl)-9-(4H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid;zinc
DMD2871 CA CAS 1405-89-6
DMD2871 DE Pyothorax
DM0QV1J ID DM0QV1J
DM0QV1J DN Baclofen
DM0QV1J HS Approved
DM0QV1J SN Arbaclofen; (R)-Baclofen; 69308-37-8; (R)-4-Amino-3-(4-chlorophenyl)butanoic acid; d-Baclofen; (-)-Baclofen; (R)-(-)-Baclofen; R-Baclofen; R-(-)-Baclofen; STX209; (3R)-4-amino-3-(4-chlorophenyl)butanoic acid; UNII-NYU6UTW25B; l-Baclofen; STX 209; (R)-4-Amino-3-(4-chlorophenyl)butyric Acid; NYU6UTW25B; CHEMBL301742; AK109161; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-, (R)-; Benzeneporopanoic acid, (beta-(aminomethyl)-4-chloro-, (betaR)-; Arbaclofen [USAN:INN]; R-Baclofen RS; Arbaclofen (USAN); p-chlorophenyl GABA; ApoBaclofen; Atrofen; Baclofene; BaclofeneIrex; Baclofeno; Baclofenum; Baclon; Baclophen; Baclospas; Clofen; Gabalon; GenBaclofen; Genpharm; Kemstro; Lebic; Lioresal; NuBaclo; PMSBaclofen; ASTA Medica Brand of Baclofen; Alphapharm Brand of Baclofen; Apo Baclofen; Apotex Brand of Baclofen; Ashbourne Brand of Baclofen; Athena Brand of Baclofen; Baclofen AWD; Baclofen Alphapharm Brand; Baclofen Apotex Brand; Baclofen Ashbourne Brand; Baclofen Athena Brand; Baclofen Irex Brand; Baclofen Isis Brand; Baclofen Medtronic Brand; Baclofen Novartis Brand; Baclofen Pharmascience Brand; Baclofene Irex; Chlorophenyl GABA; Ciba Geigy Brand of Baclofen; Gen Baclofen; Irex Brand of Baclofen; Isis Brand of Baclofen; Lioresal Intrathecal; Medtronic Brand of Baclofen; Novartis Brand of Baclofen; Nu Baclo; Nu Pharm Brand of Baclofen; PMS Baclofen; Pharmascience Brand of Baclofen; B 5399; Ba 34647; Ba34647; C 34647Ba; AWD, Baclofen; Apo-Baclofen; Ba-34647; Ba34,647; Baclofen Ciba-Geigy Brand; Baclofen Nu-Pharm Brand; Baclofene [INN-French]; Baclofene-Irex; Baclofeno [INN-Spanish]; Baclofenum [INN-Latin]; CIBA34,647BA; Ciba-Geigy Brand of Baclofen; DL-Baclofen; GABA, Chlorophenyl; Gen-Baclofen; Kemstro (TN); Lioresal (TN); Nu-Baclo; Nu-Baclofen; Nu-Pharm Brand of Baclofen; PCP-GABA; Pms-Baclofen; Ba-34,647; Baclofen (R,S); Ciba 34,647-Ba; Baclofen (JP15/USP/INN); Baclofen [USAN:INN:BAN:JAN]; Beta-(4-Chlorophenyl)gaba; CIBA-34,647-BA; Beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; Beta-(Aminomethyl)-p-chlorohydrocinnamic acid; Beta-(p-Chlorophenyl)-gamma-aminobutyric acid; DL-4-Amino-3-p-chlorophenylbutanoic acid; Gamma-Amino-beta-(p-chlorophenyl)butyric acid; Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI); (+-)-Baclofen; (+/-)-BACLOFEN; (+/-)-beta-(Aminoethyl)-4-chlorobenzenepropanoic acid; (+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid; (inverted question mark)-Baclofen; 4-Amino-3-(4-chlorophenyl)butanoic acid; 4-Amino-3-(4-chlorophenyl)butyric acid; (R)-4-Amino-3-(4-chloro-phenyl)-butyric acid
DM0QV1J CP Norvatis Phamaceuticals Corporation
DM0QV1J TC Muscle Relaxants
DM0QV1J DT Small molecular drug
DM0QV1J PC 2284
DM0QV1J MW 213.66
DM0QV1J FM C10H12ClNO2
DM0QV1J IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
DM0QV1J CS C1=CC(=CC=C1C(CC(=O)O)CN)Cl
DM0QV1J IK KPYSYYIEGFHWSV-UHFFFAOYSA-N
DM0QV1J IU 4-amino-3-(4-chlorophenyl)butanoic acid
DM0QV1J CA CAS 1134-47-0
DM0QV1J CB CHEBI:2972
DM0QV1J DE Multiple sclerosis; Fragile X syndrome
DMPWNDB ID DMPWNDB
DMPWNDB DN Balofloxacin
DMPWNDB HS Approved
DMPWNDB SN Baloxin; Balofloxacin [INN]; Q 35; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinoline arboxylic acid; (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)piperidino)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB CP Chugai
DMPWNDB DT Small molecular drug
DMPWNDB PC 65958
DMPWNDB MW 389.4
DMPWNDB FM C20H24FN3O4
DMPWNDB IC InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)
DMPWNDB CS CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPWNDB IK MGQLHRYJBWGORO-UHFFFAOYSA-N
DMPWNDB IU 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMPWNDB CA CAS 127294-70-6
DMPWNDB DE Gram-positive bacterial infection
DM1UV7F ID DM1UV7F
DM1UV7F DN Baloxavir marboxil
DM1UV7F HS Approved
DM1UV7F SN UNII-505CXM6OHG; 505CXM6OHG; Xofluza (TN); Baloxavir marboxil [INN]; Baloxavir marboxil (JAN/INN); SCHEMBL20108731; EX-A1867; HY-109025; CS-0030527
DM1UV7F CP Shionogi/Roche
DM1UV7F PC 124081896
DM1UV7F MW 571.6
DM1UV7F FM C27H23F2N3O7S
DM1UV7F IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DM1UV7F CS COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DM1UV7F IK RZVPBGBYGMDSBG-GGAORHGYSA-N
DM1UV7F IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DM1UV7F CA CAS 1985606-14-1
DM1UV7F DE Influenza virus infection
DMRJ9EN ID DMRJ9EN
DMRJ9EN DN Baloxavir marboxil
DMRJ9EN HS Approved
DMRJ9EN SN (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate; Baloxavir marboxil; Baloxavir marboxil (JAN/INN); Baloxavir marboxil [INN]; Xofluza (TN)
DMRJ9EN TC Antiviral Agents
DMRJ9EN DT Small molecular drug
DMRJ9EN PC 124081896
DMRJ9EN MW 571.552
DMRJ9EN FM C27H23F2N3O7S
DMRJ9EN IC InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
DMRJ9EN CS COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
DMRJ9EN IK RZVPBGBYGMDSBG-GGAORHGYSA-N
DMRJ9EN IU [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
DMRJ9EN CA CAS 1985606-14-1
DMRJ9EN DE Influenza A infection
DM7I1T9 ID DM7I1T9
DM7I1T9 DN Balsalazide
DM7I1T9 HS Approved
DM7I1T9 SN Balsalazida; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazide [INN:BAN]; Balsalazido; Balsalazido [Spanish]; Balsalazidum; Balsalazidum [Latin]; BX-661A; Colazide; BALSALAZIDE; P80AL8J7ZP; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 80573-04-2; C17H15N3O6; CHEBI:267413; UNII-P80AL8J7ZP
DM7I1T9 PC 54585
DM7I1T9 MW 357.32
DM7I1T9 FM C17H15N3O6
DM7I1T9 IC IPOKCKJONYRRHP-UHFFFAOYSA-N
DM7I1T9 CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DM7I1T9 IK 1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DM7I1T9 IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DM7I1T9 CA CAS 80573-04-2
DM7I1T9 CB CHEBI:267413
DM7I1T9 DE Ulcerative colitis
DMO091F ID DMO091F
DMO091F DN Balsalazide
DMO091F HS Approved
DMO091F SN Balsalazida; Balsalazido; Balsalazidum; Colazal; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Balsalazide (INN); Balsalazide [INN:BAN]; Colazal (TN); Colazide (TN); (3Z)-3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazinylidene]-6-oxocyclohexa-1,4-diene-1-carboxylic acid; (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid; 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid; 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid; 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid
DMO091F TC Antiinflammatory Agents
DMO091F DT Small molecular drug
DMO091F PC 54585
DMO091F MW 357.32
DMO091F FM C17H15N3O6
DMO091F IC InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
DMO091F CS C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DMO091F IK IPOKCKJONYRRHP-UHFFFAOYSA-N
DMO091F IU 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DMO091F CA CAS 80573-04-2
DMO091F CB CHEBI:267413
DMO091F DE Inflammatory bowel disease
DMKLSHF ID DMKLSHF
DMKLSHF DN Bambuterol
DMKLSHF HS Approved
DMKLSHF SN Bambec; Bambuterolum; Oxeol; Bambuterolum [Latin]; Terbutaline bisdimethylcarbamate; Bambec (TN); Bambuterol (INN); Bambuterol [BAN:INN]; KWD-2183; Oxeol (TN); Terbutaline bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-3-phenylene bis(dimethylcarbamate); 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate)
DMKLSHF CP AstraZeneca
DMKLSHF TC Bronchodilator Agents
DMKLSHF DT Small molecular drug
DMKLSHF PC 54766
DMKLSHF MW 367.4
DMKLSHF FM C18H29N3O5
DMKLSHF IC InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3
DMKLSHF CS CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
DMKLSHF IK ANZXOIAKUNOVQU-UHFFFAOYSA-N
DMKLSHF IU [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate
DMKLSHF CA CAS 81732-65-2
DMKLSHF CB CHEBI:553827
DMKLSHF DE Asthma
DMXLHYN ID DMXLHYN
DMXLHYN DN Bamifylline
DMXLHYN HS Approved
DMXLHYN SN Bamifylline hydrochloride; Trentadil; Pulmac; Bamifylline HCl; Bamiphylline hydrochloride; 20684-06-4; mono-HCl; Benzetamophylline hydrochloride; UNII-66466QLM3S; 8102 CB; BAX 2793Z; Bamifylline hydrochloride [USAN]; EINECS 243-967-6; AC 3810; CB 8102; 66466QLM3S; 8-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline monohydrochloride; 8'-Benzyl-7-(2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline hydrochloride; 8-Benzyl-7-(N-ethyl-N-(beta-hydroxyethyl)aminoethyl)theophylline hydrochloride
DMXLHYN DT Small molecular drug
DMXLHYN PC 16229
DMXLHYN MW 385.5
DMXLHYN FM C20H27N5O3
DMXLHYN IC InChI=1S/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3
DMXLHYN CS CCN(CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3)CCO
DMXLHYN IK VVUYEFBRTFASAH-UHFFFAOYSA-N
DMXLHYN IU 8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione
DMXLHYN CA CAS 2016-63-9
DMXLHYN CB CHEBI:135605
DMXLHYN DE Chronic obstructive pulmonary disease
DME1DJX ID DME1DJX
DME1DJX DN Baquting
DME1DJX HS Approved
DME1DJX CP China Nuokang Bio-Pharmaceutical Inc
DME1DJX DE Bleeding disorder
DMJ8NMC ID DMJ8NMC
DMJ8NMC DN Barbital
DMJ8NMC HS Approved
DMJ8NMC SN Barbitale; Barbitalum; Barbitone; Barbitonum; DEBA; Diemal; Diemalum; Diethylbarbitone; Diethylmalonylurea; Dormileno; Dormonal; Ethylbarbital; Hypnogene; Malonal; Medinal; Sedeval; Uronal; Veroletten; Verolettin; Veronal; Vesperal; Barbital Faes Brand; Barbitale [DCIT]; Diethylbarbituric acid; Faes Brand of Barbital; Barbital (TN); Barbital (VAN); Barbital [INN:JAN]; Barbitalum [INN-Latin]; Veronal (TN); Barbital (JP15/INN); Kyselina 5,5-diethylbarbiturova; Kyselina 5,5-diethylbarbiturova [Czech]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5,5-diethyl-(9CI); 5,5-Diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethylbarbituric acid; 5,5-diethyl-1,3-diazinane-2,4,6-trione; 5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione; 7979P
DMJ8NMC CP Schering-Plough
DMJ8NMC TC Hypnotics and Sedatives
DMJ8NMC DT Small molecular drug
DMJ8NMC PC 2294
DMJ8NMC MW 184.19
DMJ8NMC FM C8H12N2O3
DMJ8NMC IC InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
DMJ8NMC CS CCC1(C(=O)NC(=O)NC1=O)CC
DMJ8NMC IK FTOAOBMCPZCFFF-UHFFFAOYSA-N
DMJ8NMC IU 5,5-diethyl-1,3-diazinane-2,4,6-trione
DMJ8NMC CA CAS 57-44-3
DMJ8NMC CB CHEBI:31252
DMJ8NMC DE Insomnia
DMJIA6T ID DMJIA6T
DMJIA6T DN Barbiturate
DMJIA6T HS Approved
DMJIA6T SN Barbituric acid; BARBITURIC ACID; 67-52-7; Malonylurea; 6-Hydroxyuracil; 2,4,6(1H,3H,5H)-Pyrimidinetrione; Pyrimidinetrione; pyrimidine-2,4,6(1H,3H,5H)-trione; 2,4,6-Pyrimidinetrione; Malonylharnstoff; 2,4,6-Trioxohexahydropyrimidine; 1,3-diazinane-2,4,6-trione; Barbitursaeure; Hexahydropyrimidine-2,4,6-trione; Hydrouracil, 6-hydroxy-; Barbituric acid (VAN); Urea, N,N'-(1,3-dioxo-1,3-propanediyl)-; NSC 7889; UNII-WQ92Y2793G; 2,4,6-Pyrimidinetrione(1H,3H,5H); Barbituric acid (VAN) (8CI); CHEBI:16294; EINECS 200-658-0; Barbitursaeure; Pyrimidinetriol; Barbiturate anion; Sodiumbarbiturate; AG-670/31547005; Hexahydro-pyrimidine-2,4,6-trione; Pyrimidine-2,4,6(1H,3H,5H)-trione; 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione; 11709_FLUKA; 2,4,6-(1H,3H,5H)-Pyrimidinetrione; 2,4,6-Pyrimidinetriol; 2,4,6-Trihydroxypyrimidine; 2,4,6-trioxotetrahydro-2H-pyrimidin-1-ide; 4,6-dioxo-1H-pyrimidin-2-olate
DMJIA6T DT Small molecular drug
DMJIA6T PC 6211
DMJIA6T MW 128.09
DMJIA6T FM C4H4N2O3
DMJIA6T IC InChI=1S/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9)
DMJIA6T CS C1C(=O)NC(=O)NC1=O
DMJIA6T IK HNYOPLTXPVRDBG-UHFFFAOYSA-N
DMJIA6T IU 1,3-diazinane-2,4,6-trione
DMJIA6T CA CAS 67-52-7
DMJIA6T CB CHEBI:16294
DMJIA6T DE Depression; Anaesthesia
DM4ONW5 ID DM4ONW5
DM4ONW5 DN Baricitinib
DM4ONW5 HS Approved
DM4ONW5 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DM4ONW5 CP Incyte/Eli Lilly
DM4ONW5 DT Small molecular drug
DM4ONW5 PC 44205240
DM4ONW5 MW 371.4
DM4ONW5 FM C16H17N7O2S
DM4ONW5 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DM4ONW5 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM4ONW5 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N
DM4ONW5 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DM4ONW5 CA CAS 1187594-09-7
DM4ONW5 CB CHEBI:95341
DM4ONW5 DE Rheumatoid arthritis
DMWNRZT ID DMWNRZT
DMWNRZT DN Basiliximab
DMWNRZT HS Approved
DMWNRZT SN Simulect (TN)
DMWNRZT CP Norvatis Phamaceuticals Corporation
DMWNRZT TC Immunomodulatory Agents
DMWNRZT DT Monoclonal antibody
DMWNRZT SQ Basiliximab heavy chain: QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Basiliximab light chainQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE
DMWNRZT DE Organ transplant rejection
DMU9C8F ID DMU9C8F
DMU9C8F DN Bavencio
DMU9C8F HS Approved
DMU9C8F CP EMD Serono Rockland, MA Pfizer New York, NY
DMU9C8F DT Monoclonal antibody
DMU9C8F DE Melanoma; Merkel cell carcinoma; Breast cancer; Gastric adenocarcinoma; Haematological malignancy; Head and neck cancer; Squamous cell carcinoma; Urothelial carcinoma; Colon cancer; Testicular cancer
DMLOS5R ID DMLOS5R
DMLOS5R DN Bay 80-6946
DMLOS5R HS Approved
DMLOS5R SN Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS
DMLOS5R CP Bayer HealthCare Pharmaceuticals
DMLOS5R DT Small molecular drug
DMLOS5R PC 135565596
DMLOS5R MW 480.5
DMLOS5R FM C23H28N8O4
DMLOS5R IC InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
DMLOS5R CS COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5
DMLOS5R IK MWYDSXOGIBMAET-UHFFFAOYSA-N
DMLOS5R IU 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide
DMLOS5R CA CAS 1032568-63-0
DMLOS5R DE Follicular lymphoma; Non-hodgkin lymphoma
DMY85QW ID DMY85QW
DMY85QW DN Bazedoxifene
DMY85QW HS Approved
DMY85QW SN Brilence; Conbriza; Viviant; Bazedoxifene acetate; TSE-424; WAY-140424; WAY-TES 424
DMY85QW CP Ligand Pharmaceuticals Inc
DMY85QW DT Small molecular drug
DMY85QW PC 154257
DMY85QW MW 470.6
DMY85QW FM C30H34N2O3
DMY85QW IC InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
DMY85QW CS CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O
DMY85QW IK UCJGJABZCDBEDK-UHFFFAOYSA-N
DMY85QW IU 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
DMY85QW CA CAS 198481-32-2
DMY85QW CB CHEBI:135947
DMY85QW DE Osteopetrosis
DM1R5X4 ID DM1R5X4
DM1R5X4 DN Becaplermin
DM1R5X4 HS Approved
DM1R5X4 SN Regranex; Regranex (TN); Becaplermin (USAN/INN)
DM1R5X4 CP Ortho-McNeil Pharmaceutical
DM1R5X4 TC Antiulcer Agents
DM1R5X4 SQ DB00102 sequence: SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT
DM1R5X4 DE Diabetic complication
DMZPHIK ID DMZPHIK
DMZPHIK DN Beclomethasone
DMZPHIK HS Approved
DMZPHIK SN Anceron; Beclocort; Beclometason; Beclometasona; Beclometasonum; Becloval; Becodisks; Beconasol; Becotide; Inalone; Viarex; Beclometasondipropionat Mikron; Beclometasone [INN]; Vancenase AQ; B 0385; BMJ 5800; Beclometason (TN); Beclometasona [INN-Spanish]; Beclometasone (INN); Beclometasonum [INN-Latin]; Beconase (TN); Clipper (TN); Propaderm (TN); Vancenase (TN); (11beta,16beta)-9-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8R,9S,10S,11S,13R,14R,16R,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9-Chloro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9alpha-Chloro-11beta,17alpha,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9alpha-Chloro-16beta-methyl-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione; 9alpha-Chloro-16beta-methylprednisolone
DMZPHIK CP Shire Pharmaceuticals
DMZPHIK TC Antiasthmatic Agents
DMZPHIK DT Small molecular drug
DMZPHIK PC 20469
DMZPHIK MW 408.9
DMZPHIK FM C22H29ClO5
DMZPHIK IC InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMZPHIK CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C
DMZPHIK IK NBMKJKDGKREAPL-DVTGEIKXSA-N
DMZPHIK IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZPHIK CA CAS 4419-39-0
DMZPHIK CB CHEBI:3001
DMZPHIK DE Allergic rhinitis; Asthma
DM3906J ID DM3906J
DM3906J DN Bedaquiline
DM3906J HS Approved
DM3906J SN SIRTURO (TN)
DM3906J CP Johnson & Johnson
DM3906J DT Small molecular drug
DM3906J PC 5388906
DM3906J MW 555.5
DM3906J FM C32H31BrN2O2
DM3906J IC InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1
DM3906J CS CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O
DM3906J IK QUIJNHUBAXPXFS-XLJNKUFUSA-N
DM3906J IU (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol
DM3906J CA CAS 843663-66-1
DM3906J CB CHEBI:72292
DM3906J DE Multi-drug resistant tuberculosis
DM8WCXM ID DM8WCXM
DM8WCXM DN Befunolol hci
DM8WCXM HS Approved
DM8WCXM SN Bentox (TN)
DM8WCXM DT Small molecular drug
DM8WCXM PC 38286
DM8WCXM MW 327.8
DM8WCXM FM C16H22ClNO4
DM8WCXM IC InChI=1S/C16H21NO4.ClH/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14;/h4-7,10,13,17,19H,8-9H2,1-3H3;1H
DM8WCXM CS CC(C)[NH2+]CC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O.[Cl-]
DM8WCXM IK TVVTWOGRPVJKDJ-UHFFFAOYSA-N
DM8WCXM IU [3-[(2-acetyl-1-benzofuran-7-yl)oxy]-2-hydroxypropyl]-propan-2-ylazanium;chloride
DM8WCXM CA CAS 39543-79-8
DM8WCXM CB CHEBI:31254
DM8WCXM DE Glaucoma/ocular hypertension
DMBT3AI ID DMBT3AI
DMBT3AI DN Belantamab mafodotin
DMBT3AI HS Approved
DMBT3AI DT Antibody drug conjugate
DMBT3AI DE Multiple myeloma
DMXLYQF ID DMXLYQF
DMXLYQF DN Belatacept
DMXLYQF HS Approved
DMXLYQF SN Nulojix (TN); Belatacept (USAN/INN)
DMXLYQF CP Bristol-Myers Squibb
DMXLYQF SQ sequence for belatacept: MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMXLYQF DE Kidney transplant rejection; Heart transplant rejection
DM3OBQF ID DM3OBQF
DM3OBQF DN Belimumab
DM3OBQF HS Approved
DM3OBQF SN Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)
DM3OBQF CP GSK
DM3OBQF DT Antibody
DM3OBQF DE Systemic lupus erythematosus
DM2RBWK ID DM2RBWK
DM2RBWK DN Belladonna
DM2RBWK HS Approved
DM2RBWK DE Colitis
DM3SRJZ ID DM3SRJZ
DM3SRJZ DN Belotecan hydrocholoride
DM3SRJZ HS Approved
DM3SRJZ DE Small-cell lung cancer
DM1CI9R ID DM1CI9R
DM1CI9R DN Bempedoic acid
DM1CI9R HS Approved
DM1CI9R SN ETC-1002; bempedoic acid; 738606-46-7; 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid; ESP-55016; UNII-1EJ6Z6Q368; ETC 1002; Bempedoic acid; ESP-55016; 1EJ6Z6Q368; Bempedoate; Bempedoic acid [USAN:INN]; ETC1002; ESP 55016; Bempedoic acid (USAN/INN); SCHEMBL185768; GTPL8321; CHEMBL3545313; HYHMLYSLQUKXKP-UHFFFAOYSA-N; EX-A1243; ZINC3948738; BCP16083; s7953; AKOS027439916; CS-3952; DB11936; AK499358; AC-29040; AS-49804; HY-12357; Bempedoic Acid(ETC-1002;ESP-55016); D10691; Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-
DM1CI9R CP Esperion Therapeutics
DM1CI9R DT Small molecular drug
DM1CI9R PC 10472693
DM1CI9R MW 344.5
DM1CI9R FM C19H36O5
DM1CI9R IC InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
DM1CI9R CS CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
DM1CI9R IK HYHMLYSLQUKXKP-UHFFFAOYSA-N
DM1CI9R IU 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
DM1CI9R CA CAS 738606-46-7
DM1CI9R CB CHEBI:149601
DM1CI9R DE Cardiovascular disease; Familial hypercholesterolemia
DMH1M9B ID DMH1M9B
DMH1M9B DN Benazepril
DMH1M9B HS Approved
DMH1M9B SN Benazapril; Benazeprilum; Benzazepril; Benazepril Sandoz; Benazeprilum [Latin]; Forteekor [veterinary]; Benazepril (INN); Benazepril Sandoz (TN); Benazepril [INN:BAN]; Forteekor [veterinary] (TN); Fortekor (TN); Lotensin (TN); CGS-14824-A; [(3S)-3-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; [(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid; 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B CP Norvatis Phamaceuticals Corporation
DMH1M9B TC Antihypertensive Agents
DMH1M9B DT Small molecular drug
DMH1M9B PC 5362124
DMH1M9B MW 424.5
DMH1M9B FM C24H28N2O5
DMH1M9B IC InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
DMH1M9B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
DMH1M9B IK XPCFTKFZXHTYIP-PMACEKPBSA-N
DMH1M9B IU 2-[(3S)-3-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMH1M9B CA CAS 86541-75-5
DMH1M9B CB CHEBI:3011
DMH1M9B DE Hypertension
DMFH15Z ID DMFH15Z
DMFH15Z DN Bendamustine hydrochloride
DMFH15Z HS Approved
DMFH15Z SN Treanda (TN)
DMFH15Z CP Cephalon
DMFH15Z DT Small molecular drug
DMFH15Z PC 77082
DMFH15Z MW 394.7
DMFH15Z FM C16H22Cl3N3O2
DMFH15Z IC InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
DMFH15Z CS CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl
DMFH15Z IK ZHSKUOZOLHMKEA-UHFFFAOYSA-N
DMFH15Z IU 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
DMFH15Z CA CAS 3543-75-7
DMFH15Z DE leukaemia
DM7EVLC ID DM7EVLC
DM7EVLC DN Bendroflumethiazide
DM7EVLC HS Approved
DM7EVLC SN Aprinox; BHFT; Bendrofluazide; Bendroflumethazide; Bendroflumethiazidum; Bendroflumetiazida; Bendroflumetiazide; Bendrofumethiazide; Bentride; Benuron; Benzhydroflumethiazide; Benzydroflumethiazide; Benzylhydroflumethiazide; Benzylrodiuran; Berkozide; Bristuric; Bristuron; Centyl; Corzide; Flumersil; Flumesil; Intolex; Livesan; Naigaril; Nateretin; Naturetin; Naturine; Niagaril; Nikion; Orsile; Pluryl; Pluryle; Plusuril; Poliuron; Rauzide; Repicin; Salural; Salures; Sinesalin; Sodiuretic; Thiazidico; Urlea; Bendroflumethiazide [USP]; Bendroflumetiazide [DCIT]; Rautrax N; Relan beta; BL H368; FT 8; FT 81; Be 724-A; Bendroflumethiazidum [INN-Latin]; Bendroflumetiazida [INN-Spanish]; Benzy-rodiuran; NATURETIN-10; NATURETIN-5; Naturetin (TN); Neo-naclex; Neo-rontyl; Naturetin-2.5; Bendroflumethiazide (JAN/USP/INN); (+-)-3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-benzyl-3,4-dihydro-6-(trifluoromethyl)-,1,1-dioxide; 3,4-Dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 3-Benzyl-6-trifluoromethyl-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine, 1,1-dioxide; 6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DM7EVLC CP Crescent Pharmaceuticals
DM7EVLC TC Antihypertensive Agents
DM7EVLC DT Small molecular drug
DM7EVLC PC 2315
DM7EVLC MW 421.4
DM7EVLC FM C15H14F3N3O4S2
DM7EVLC IC InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
DM7EVLC CS C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2
DM7EVLC IK HDWIHXWEUNVBIY-UHFFFAOYSA-N
DM7EVLC IU 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DM7EVLC CA CAS 73-48-3
DM7EVLC CB CHEBI:3013
DM7EVLC DE High blood pressure
DM7P1J4 ID DM7P1J4
DM7P1J4 DN Benralizumab
DM7P1J4 HS Approved
DM7P1J4 CP AstraZeneca
DM7P1J4 DT Monoclonal antibody
DM7P1J4 DE Asthma; Chronic obstructive pulmonary disease
DMRVBWU ID DMRVBWU
DMRVBWU DN Bentazepam
DMRVBWU HS Approved
DMRVBWU DT Small molecular drug
DMRVBWU PC 135412795
DMRVBWU MW 296.4
DMRVBWU FM C17H16N2OS
DMRVBWU IC InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20)
DMRVBWU CS C1CCC2=C(C1)C3=C(S2)NC(=O)CN=C3C4=CC=CC=C4
DMRVBWU IK AIZFEOPQVZBNGH-UHFFFAOYSA-N
DMRVBWU IU 5-phenyl-1,3,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one
DMRVBWU CA CAS 29462-18-8
DMRVBWU CB CHEBI:135252
DMRVBWU DE Anxiety disorder
DMF7EXL ID DMF7EXL
DMF7EXL DN Benzatropine
DMF7EXL HS Approved
DMF7EXL SN Benzatropina; Benzatropina [INN-Spanish]; Benzatropine; Benzatropinum; Benzatropinum [INN-Latin]; Benztropinum; Cobrentin; Cogentin; Cogentine; Akitan; Cogentinol; Tropine benzohydryl ether; benztropine; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 1NHL2J4X8K; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 86-13-5; CHEBI:3048; HSDB 3014; NCGC00159471-02; NK 02; UNII-1NHL2J4X8K
DMF7EXL PC 1201549
DMF7EXL MW 307.4
DMF7EXL FM C21H25NO
DMF7EXL IC GIJXKZJWITVLHI-YOFSQIOKSA-N
DMF7EXL CS CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMF7EXL IK 1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMF7EXL IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMF7EXL CA CAS 86-13-5
DMF7EXL CB CHEBI:3048
DMF7EXL DE Agitation/aggression
DMC3YUA ID DMC3YUA
DMC3YUA DN Benzbromarone
DMC3YUA HS Approved
DMC3YUA SN Acifugan; Azubromaron; Benzbromaron; Benzbromaronratiopharm; Benzbromaronum; Benzobromarona; Besuric; Desuric; Exurate; Harolan; Hipurik; Minuric; Narcaricin; Normurat; Uricovac; Urinorm; Uroleap; Aliud Brand of Benzbromarone; Benzbromaron AL; Benzbromaron ratiopharm; Benzbromarone Aliud Brand; Benzbromarone Heumann Brand; Benzbromarone Sanfer Brand; Benzbromarone ratiopharm Brand; Heumann Brand of Benzbromarone; Ratiopharm Brand of Benzbromarone; Sanfer Brand of Benzbromarone; Sanofi Winthrop Brand of Benzbromarone; L 2214; L2214; MJ 10061; NCI85433; AL, Benzbromaron; Benzbromaron-ratiopharm; Benzbromaronum [INN-Latin]; Benzobromarona [INN-Spanish]; L 2214-Labaz; L-2214; Uroleap (TN); Benzbromarone [USAN:INN:BAN]; Methanone, (3; Benzbromarone (JP15/USAN/INN); KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL; Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl; (2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton; (3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone; (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone; 2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran; 3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone; 3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran; 3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN
DMC3YUA CP Labaz Laboratories
DMC3YUA DT Small molecular drug
DMC3YUA PC 2333
DMC3YUA MW 424.1
DMC3YUA FM C17H12Br2O3
DMC3YUA IC InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
DMC3YUA CS CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
DMC3YUA IK WHQCHUCQKNIQEC-UHFFFAOYSA-N
DMC3YUA IU (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
DMC3YUA CA CAS 3562-84-3
DMC3YUA CB CHEBI:3023
DMC3YUA DE Gout
DMI18HW ID DMI18HW
DMI18HW DN Benzocaine
DMI18HW HS Approved
DMI18HW SN Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester
DMI18HW CP Wyeth Pharmaceuticals
DMI18HW TC Anesthetics
DMI18HW DT Small molecular drug
DMI18HW PC 2337
DMI18HW MW 165.19
DMI18HW FM C9H11NO2
DMI18HW IC InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
DMI18HW CS CCOC(=O)C1=CC=C(C=C1)N
DMI18HW IK BLFLLBZGZJTVJG-UHFFFAOYSA-N
DMI18HW IU ethyl 4-aminobenzoate
DMI18HW CA CAS 94-09-7
DMI18HW CB CHEBI:116735
DMI18HW DE Anaesthesia
DMKB9FI ID DMKB9FI
DMKB9FI DN Benzoic acid
DMKB9FI HS Approved
DMKB9FI SN Phenylformate; benzoate anion; Benzoic acid, ion(1-); 766-76-7; Benzeneformate; Tennplas; Phenylcarboxylate; Benzenemethanoate; Retarded BA; Benzenecarboxylate; Phenyl carboxylic acid; benzoic acid anion; Oracyclic acid; 4-Carboxybenzenide; Benzene formic acid; AC1Q1HDY; AC1Q22CA; AC1L18SS; GTPL4565; DTXSID4043771; CHEBI:16150; BDBM36181; CTK2H9612; WPYMKLBDIGXBTP-UHFFFAOYSA-M; STL483236; ZINC328578076; NCGC00247905-01; ZB000218; CJ-00025; LS-190261; 3230-EP2374454A1; 3230-EP2372017A1; 3230-EP2316825A1; 3230-EP2316457A1
DMKB9FI DT Small molecular drug
DMKB9FI PC 243
DMKB9FI MW 122.12
DMKB9FI FM C7H6O2
DMKB9FI IC InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)
DMKB9FI CS C1=CC=C(C=C1)C(=O)O
DMKB9FI IK WPYMKLBDIGXBTP-UHFFFAOYSA-N
DMKB9FI IU benzoic acid
DMKB9FI CA CAS 65-85-0
DMKB9FI CB CHEBI:30746
DMKB9FI DE Fungal infection
DM9U4FO ID DM9U4FO
DM9U4FO DN Benzonatate
DM9U4FO HS Approved
DM9U4FO SN Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester
DM9U4FO TC Antitussives
DM9U4FO DT Small molecular drug
DM9U4FO PC 7699
DM9U4FO MW 603.7
DM9U4FO FM C30H53NO11
DM9U4FO IC InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3
DM9U4FO CS CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DM9U4FO IK MAFMQEKGGFWBAB-UHFFFAOYSA-N
DM9U4FO IU 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate
DM9U4FO CA CAS 104-31-4
DM9U4FO CB CHEBI:3032
DM9U4FO DE Cough
DMIJATC ID DMIJATC
DMIJATC DN Benzphetamine
DMIJATC HS Approved
DMIJATC SN Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine
DMIJATC CP Pharmacia
DMIJATC DT Small molecular drug
DMIJATC PC 5311017
DMIJATC MW 239.35
DMIJATC FM C17H21N
DMIJATC IC InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
DMIJATC CS C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
DMIJATC IK YXKTVDFXDRQTKV-HNNXBMFYSA-N
DMIJATC IU (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine
DMIJATC CA CAS 156-08-1
DMIJATC CB CHEBI:3044
DMIJATC DE Obesity
DMU4D5Y ID DMU4D5Y
DMU4D5Y DN Benzquinamide
DMU4D5Y HS Approved
DMU4D5Y SN Benzchinamid; Benzchinamide; Benzchinamidum; Benzochinamide; Benzoquinamida; Benzoquinamide; Benzquinamid; Benzquinamida; Benzquinamidum; Emeticon; Promecon; Quantril; Quantryl; P 2647; Benzoquinamida [INN-Spanish]; Benzquinamide (USAN); Benzquinamidum [INN-Latin]; Emete-con; P-2647; Benzquinamide [USAN:INN:BAN]; [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamideacetate; N,N-Diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); N,N-Diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide acetate (ester); 2-(Acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo(a)quinolizine-3-carboxamide; 2-(acetoxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizine-3-carboxamide; 2-Acetoxy-3-(N,N-diethylcarboxamido)-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzopyridocoline; 2-Acetoxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11b-benzo(a)quinolizine; 2-Hydroxy-3-diethylcarbamyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzoquinolizine acetate; 2H-Benzo(a)quinolizine-3-carboxamide, 2-(acetyloxy)-N,N-diethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-, (2alpha,3beta,11balpha)-(9CI); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3,4,6,7,11b-hexahydro-2-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo(a)quinolizine-3-carboxamide, N,N-diethyl-1,3alpha,4,6,7,11bbeta-hexahydro-2beta-hydroxy-9,10-dimethoxy-, acetate (ester); 2H-Benzo[a]quinolizine-3-carboxamide, N,N-diethyl-1,3.alpha.,4,6,7,11b.beta.-hexahydro-2.beta.-hydroxy-9,10-dimethoxy-, acetate (ester); 3-(diethylcarbamoyl)-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate; 3-Diethylcarbamoyl-2,3,4,6,7,11b-hexahydro-9,10-dimethoxy-1H-benzo(a)chinolizin-2-yl acetat; 3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate
DMU4D5Y TC Antiemetics
DMU4D5Y DT Small molecular drug
DMU4D5Y PC 2342
DMU4D5Y MW 404.5
DMU4D5Y FM C22H32N2O5
DMU4D5Y IC InChI=1S/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3
DMU4D5Y CS CCN(CC)C(=O)C1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C)OC)OC
DMU4D5Y IK JSZILQVIPPROJI-UHFFFAOYSA-N
DMU4D5Y IU [3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate
DMU4D5Y CA CAS 63-12-7
DMU4D5Y CB CHEBI:27662
DMU4D5Y DE Nausea
DMQWZ0H ID DMQWZ0H
DMQWZ0H DN Benzthiazide
DMQWZ0H HS Approved
DMQWZ0H SN Aquapres; Aquasec; Aquatag; Benzothiazide; Benzotiazida; Benzthazide; Benzthiazidum; Benztiazide; Dihydrex; Diucen;Diucene; Edemex; Exna; Exosalt; Fouane; Fovane; Freeuril; HyDrine; Lemazide; Proaqua; Regulon; Urazide; Urese; Benztiazide [DCIT]; P 1393; Pfizer 1393; Aqua-Scrip; Aquatag (TN); Benzotiazida [INN-Spanish]; Benzthiazidum [INN-Latin]; Dihydrex (TN); Diucen (TN); Edemax (TN); Exna (TN); Foven (TN); Hy-drine; Pro-aqua; Rid-ema; S-Aqua; Benzthiazide (JAN/INN); Benzthiazide [USAN:INN:BAN]; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)menthyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-((benzylthio)methyl)-6-chloro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(((phenylmethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-[[(phenylmethyl)thio]methyl]-, 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 3-((Benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine-1,1-dioxide; 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1; 3-Benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 3-[(Benzylsulfanyl)methyl]-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(((phenylmethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide; 6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMQWZ0H TC Antihypertensive Agents
DMQWZ0H DT Small molecular drug
DMQWZ0H PC 2343
DMQWZ0H MW 431.9
DMQWZ0H FM C15H14ClN3O4S3
DMQWZ0H IC InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)
DMQWZ0H CS C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N
DMQWZ0H IK NDTSRXAMMQDVSW-UHFFFAOYSA-N
DMQWZ0H IU 3-(benzylsulfanylmethyl)-6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMQWZ0H CA CAS 91-33-8
DMQWZ0H CB CHEBI:3047
DMQWZ0H DE High blood pressure
DMGZOVN ID DMGZOVN
DMGZOVN DN Benztropine
DMGZOVN HS Approved
DMGZOVN SN Akitan; Benzatropina; Benzatropine; Benzatropinum; Benztropinum; Cobrentin; Cogentine; Cogentinol; Benzatropine [INN]; Benzatropine mesilate; Pms Benztropine; Tropine benzohydryl ether; NK 02; Apo-Benztropine; Benzatropina [INN-Spanish]; Benzatropine (INN); Benzatropine [INN:BAN]; Benzatropinum [INN-Latin]; Cogentin (TN); Benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether; (1R,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; (1r,5r)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; (3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane; (5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane; 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3alpha-(Diphenylmethoxy)-1alphaH,5alphaH-tropane; 3alpha-(diphenylmethoxy)tropane; 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane; 3endo-benzhydryloxytropane; 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo-(9CI)
DMGZOVN CP Oak Pharmaceuticals Inc Sub Akorn Inc
DMGZOVN TC Antiparkinson Agents
DMGZOVN DT Small molecular drug
DMGZOVN PC 1201549
DMGZOVN MW 307.4
DMGZOVN FM C21H25NO
DMGZOVN IC InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20?
DMGZOVN CS CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMGZOVN IK GIJXKZJWITVLHI-YOFSQIOKSA-N
DMGZOVN IU (1R,5S)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane
DMGZOVN CA CAS 86-13-5
DMGZOVN CB CHEBI:3048
DMGZOVN DE Parkinson disease
DMBVYDI ID DMBVYDI
DMBVYDI DN Benzyl alcohol
DMBVYDI HS Approved
DMBVYDI SN Ulesfia (TN)
DMBVYDI CP Sciele Pharma
DMBVYDI DT Small molecular drug
DMBVYDI PC 244
DMBVYDI MW 108.14
DMBVYDI FM C7H8O
DMBVYDI IC InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
DMBVYDI CS C1=CC=C(C=C1)CO
DMBVYDI IK WVDDGKGOMKODPV-UHFFFAOYSA-N
DMBVYDI IU phenylmethanol
DMBVYDI CA CAS 100-51-6
DMBVYDI CB CHEBI:17987
DMBVYDI DE Head and body lice
DMDPYI5 ID DMDPYI5
DMDPYI5 DN Benzyl benzoate
DMDPYI5 HS Approved
DMDPYI5 SN BENZYL BENZOATE; 120-51-4; Benylate; Ascabiol; Novoscabin; Benzoic acid, phenylmethyl ester; Benzoic acid benzyl ester; Scobenol; Scabitox; Ascabin; Benzyl phenylformate; Phenylmethyl benzoate; Scabiozon; Scabagen; Peruscabin; Colebenz; Scabanca; Benzylets; Benzoic acid, benzyl ester; Vanzoate; Scabide; Benzyl benzenecarboxylate; benzylbenzoate; Antiscabiosum; Benzylis benzoas; Benzyl alcohol benzoic ester; Peruscabina; Venzonate; Spasmodin; Benzylum benzoicum; Benzylester kyseliny benzoove; Benzoesaeurebenzylester; Caswell No. 082
DMDPYI5 DT Small molecular drug
DMDPYI5 PC 2345
DMDPYI5 MW 212.24
DMDPYI5 FM C14H12O2
DMDPYI5 IC InChI=1S/C14H12O2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10H,11H2
DMDPYI5 CS C1=CC=C(C=C1)COC(=O)C2=CC=CC=C2
DMDPYI5 IK SESFRYSPDFLNCH-UHFFFAOYSA-N
DMDPYI5 IU benzyl benzoate
DMDPYI5 CA CAS 120-51-4
DMDPYI5 CB CHEBI:41237
DMDPYI5 DE Infestations of lice and scabies
DMQHM2D ID DMQHM2D
DMQHM2D DN Benzylpenicilloyl Polylysine
DMQHM2D HS Approved
DMQHM2D SN Benzylpenicilloyl; Benzylpenicilloyl G; Benzylpenicilloyl G polylysine; Benzylpenicilloyl-polylysine; Penicilloyl-polylysine; 2-(2-((5-Carboxypentyl)amino)-2-oxo-1-((phenylacetyl)amino)ethyl)-5,5-dimethyl-4-thiazolidinecarboxylic acid; 2-[2-[(6-hydroxy-6-oxohexyl)amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid
DMQHM2D TC Analgesics
DMQHM2D DT Small molecular drug
DMQHM2D PC 45266800
DMQHM2D MW 626.8
DMQHM2D FM C28H46N6O8S
DMQHM2D IC InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1
DMQHM2D CS CC1([C@@H](N[C@H](S1)C(C(=O)NCCCC[C@H](C(=O)O)N)NC(=O)CC2=CC=CC=C2)C(=O)O)C.C(CCN)C[C@H](C(=O)O)N
DMQHM2D IK IMPVZRLKKKXMKQ-SGDOCVTFSA-N
DMQHM2D IU (2R,4S)-2-[2-[[(5R)-5-amino-5-carboxypentyl]amino]-2-oxo-1-[(2-phenylacetyl)amino]ethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid;(2R)-2,6-diaminohexanoic acid
DMQHM2D CA CAS 31855-75-1
DMQHM2D CB CHEBI:59297
DMQHM2D DE Bacterial infection
DMXDZAQ ID DMXDZAQ
DMXDZAQ DN Bepotastine
DMXDZAQ HS Approved
DMXDZAQ SN Betotastine; Tau 284; TAU-284DS; Talion (TN); (S)-4-(4-((4-Chlorophenyl)(2-pyridil)methoxy)piperidino)butylic acid; 4-((4-Chlorophenyl)-2-pyridinylmethoxy)-1-piperidinebutanoic acid; 4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ CP Tanabe Seiyaku Co
DMXDZAQ TC Antiallergic Agents
DMXDZAQ DT Small molecular drug
DMXDZAQ PC 164522
DMXDZAQ MW 388.9
DMXDZAQ FM C21H25ClN2O3
DMXDZAQ IC InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1
DMXDZAQ CS C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O
DMXDZAQ IK YWGDOWXRIALTES-NRFANRHFSA-N
DMXDZAQ IU 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
DMXDZAQ CA CAS 125602-71-3
DMXDZAQ CB CHEBI:71204
DMXDZAQ DE Allergic rhinitis
DM0RKS4 ID DM0RKS4
DM0RKS4 DN Bepridil
DM0RKS4 HS Approved
DM0RKS4 SN Bepadin; Vascor; CERM 1978; Bepadin (TN); Bepridil (INN); Vascor (TN); N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline; Beta-((2-Methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine; N-Benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-yl-propyl]aniline hydrochloride; N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline; N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline
DM0RKS4 TC Antiarrhythmic Agents
DM0RKS4 DT Small molecular drug
DM0RKS4 PC 2351
DM0RKS4 MW 366.5
DM0RKS4 FM C24H34N2O
DM0RKS4 IC InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
DM0RKS4 CS CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3
DM0RKS4 IK UIEATEWHFDRYRU-UHFFFAOYSA-N
DM0RKS4 IU N-benzyl-N-[3-(2-methylpropoxy)-2-pyrrolidin-1-ylpropyl]aniline
DM0RKS4 CA CAS 64706-54-3
DM0RKS4 CB CHEBI:3061
DM0RKS4 DE Chronic/stable angina
DMEBY2D ID DMEBY2D
DMEBY2D DN Beriplast-P
DMEBY2D HS Approved
DMEBY2D SN Fibrin sealant, Aventis Behring
DMEBY2D CP Aventis Behring LLC
DMEBY2D DE Wound healing
DMWA2DZ ID DMWA2DZ
DMWA2DZ DN Berotralstat
DMWA2DZ HS Approved
DMWA2DZ SN UNII-XZA0KB1BDQ; XZA0KB1BDQ; 1809010-50-1; BCX7353; BCX-7353; Berotralstat (USAN); Berotralstat [USAN]; 1-[3-(aminomethyl)phenyl]-N-(5-{(R)-(3-; cyanophenyl)[(cyclopropylmethyl)amino]methyl}-2-; fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-; Orladeyo; Berotralstat [INN]; Berotralstat [USAN:INN]; SCHEMBL21974728; GTPL11347; WHO 10907; D11673; 1-(3-(Aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1H-pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl); 1H-Pyrazole-5-carboxamide, 1-(3-(aminomethyl)phenyl)-N-(5-((R)-(3-cyanophenyl)((cyclopropylmethyl)amino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-; 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ CP BioCryst Pharmaceuticals
DMWA2DZ DT Small molecular drug
DMWA2DZ PC 137528262
DMWA2DZ MW 562.6
DMWA2DZ FM C30H26F4N6O
DMWA2DZ IC InChI=1S/C30H26F4N6O/c31-24-10-9-22(28(37-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)38-29(41)26-14-27(30(32,33)34)39-40(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28,37H,7-8,16-17,36H2,(H,38,41)/t28-/m1/s1
DMWA2DZ CS C1CC1CN[C@@H](C2=CC(=C(C=C2)F)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)C5=CC=CC(=C5)C#N
DMWA2DZ IK UXNXMBYCBRBRFD-MUUNZHRXSA-N
DMWA2DZ IU 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMWA2DZ CA CAS 1809010-50-1
DMWA2DZ DE Hereditary angioedema
DMPHXMI ID DMPHXMI
DMPHXMI DN Besifloxacin
DMPHXMI HS Approved
DMPHXMI SN Besivance (TN)
DMPHXMI CP Bausch & Lomb
DMPHXMI DT Small molecular drug
DMPHXMI PC 10178705
DMPHXMI MW 393.8
DMPHXMI FM C19H21ClFN3O3
DMPHXMI IC InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1
DMPHXMI CS C1CCN(C[C@@H](C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F
DMPHXMI IK QFFGVLORLPOAEC-SNVBAGLBSA-N
DMPHXMI IU 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMPHXMI CA CAS 141388-76-3
DMPHXMI CB CHEBI:135622
DMPHXMI DE Ocular inflammation
DM8L9D4 ID DM8L9D4
DM8L9D4 DN Bestatin
DM8L9D4 HS Approved
DM8L9D4 SN Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid
DM8L9D4 DT Small molecular drug
DM8L9D4 PC 72172
DM8L9D4 MW 308.37
DM8L9D4 FM C16H24N2O4
DM8L9D4 IC InChI=1S/C16H24N2O4/c1-10(2)8-13(16(21)22)18-15(20)14(19)12(17)9-11-6-4-3-5-7-11/h3-7,10,12-14,19H,8-9,17H2,1-2H3,(H,18,20)(H,21,22)/t12-,13+,14+/m1/s1
DM8L9D4 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
DM8L9D4 IK VGGGPCQERPFHOB-RDBSUJKOSA-N
DM8L9D4 IU (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid
DM8L9D4 CA CAS 58970-76-6
DM8L9D4 DE Acute myeloid leukaemia
DMI6GKT ID DMI6GKT
DMI6GKT DN Beta-acetyldigoxin
DMI6GKT HS Approved
DMI6GKT SN Novodigal (TN)
DMI6GKT DT Small molecular drug
DMI6GKT PC 10350481
DMI6GKT MW 823
DMI6GKT FM C43H66O15
DMI6GKT IC InChI=1S/C43H66O15/c1-20-38(55-23(4)44)30(45)17-36(53-20)57-40-22(3)54-37(18-32(40)47)58-39-21(2)52-35(16-31(39)46)56-26-9-11-41(5)25(14-26)7-8-28-29(41)15-33(48)42(6)27(10-12-43(28,42)50)24-13-34(49)51-19-24/h13,20-22,25-33,35-40,45-48,50H,7-12,14-19H2,1-6H3/t20-,21-,22-,25-,26+,27-,28-,29+,30+,31+,32+,33-,35+,36+,37+,38-,39-,40-,41+,42+,43+/m1/s1
DMI6GKT CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)OC(=O)C)O)O
DMI6GKT IK NREAGDHHMSOWKZ-DXJNJSHLSA-N
DMI6GKT IU [(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl] acetate
DMI6GKT CA CAS 5355-48-6
DMI6GKT CB CHEBI:135892
DMI6GKT DE Cardiovascular disease
DM0RXBT ID DM0RXBT
DM0RXBT DN Beta-carotene
DM0RXBT HS Approved
DM0RXBT SN beta-carotene; 7235-40-7; beta Carotene; beta,beta-Carotene; Betacarotene; Provitamin A; Solatene; Carotaben; Provatene; all-trans-beta-Carotene; Serlabo; Natural Yellow 26; Karotin; KPMK; C.I. Food Orange 5; Solatene (caps); Karotin [Czech]; Food orange 5; Zlut prirodni 26; Betacarotenum [Latin]; Betacaroteno [Spanish]; Lucaratin; BetaVit; beta-Karotin; beta-Carotin; beta;-Carotene; beta-Carotene, all-trans-; .beta. Carotene; .beta.-Carotene; Betacarotenum [INN-Latin]; C.I. 75130; Betacaroteno [INN-Spanish]; Zlut prirodni 26 [Czech]
DM0RXBT DT Small molecular drug
DM0RXBT PC 5280489
DM0RXBT MW 536.9
DM0RXBT FM C40H56
DM0RXBT IC InChI=1S/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+
DM0RXBT CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\\C)\\C)/C)/C
DM0RXBT IK OENHQHLEOONYIE-JLTXGRSLSA-N
DM0RXBT IU 1,3,3-trimethyl-2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene
DM0RXBT CA CAS 7235-40-7
DM0RXBT CB CHEBI:17579
DM0RXBT DE Vitamin deficiency
DMGRZW2 ID DMGRZW2
DMGRZW2 DN Betaine
DMGRZW2 HS Approved
DMGRZW2 SN Cystadane
DMGRZW2 CP Rare Disease Therapeutics Inc
DMGRZW2 DT Small molecular drug
DMGRZW2 PC 247
DMGRZW2 MW 117.15
DMGRZW2 FM C5H11NO2
DMGRZW2 IC InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3
DMGRZW2 CS C[N+](C)(C)CC(=O)[O-]
DMGRZW2 IK KWIUHFFTVRNATP-UHFFFAOYSA-N
DMGRZW2 IU 2-(trimethylazaniumyl)acetate
DMGRZW2 CA CAS 107-43-7
DMGRZW2 CB CHEBI:17750
DMGRZW2 DE Inborn error of metabolism
DMAHJEF ID DMAHJEF
DMAHJEF DN Betamethasone
DMAHJEF HS Approved
DMAHJEF SN betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate
DMAHJEF TC Antiinflammatory Agents
DMAHJEF DT Small molecular drug
DMAHJEF PC 9782
DMAHJEF MW 392.5
DMAHJEF FM C22H29FO5
DMAHJEF IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMAHJEF CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMAHJEF IK UREBDLICKHMUKA-DVTGEIKXSA-N
DMAHJEF IU (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMAHJEF CA CAS 378-44-9
DMAHJEF CB CHEBI:3077
DMAHJEF DE Inflammation
DMRMS1A ID DMRMS1A
DMRMS1A DN Betamethasone Benzoate
DMRMS1A HS Approved
DMRMS1A SN Uticort
DMRMS1A CP Parke Davis Div Warner Lambert Co
DMRMS1A DT Small molecular drug
DMRMS1A PC 5282492
DMRMS1A MW 496.6
DMRMS1A FM C29H33FO6
DMRMS1A IC InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1
DMRMS1A CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)OC(=O)C5=CC=CC=C5)C)O)F)C
DMRMS1A IK SOQJPQZCPBDOMF-YCUXZELOSA-N
DMRMS1A IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] benzoate
DMRMS1A CA CAS 22298-29-9
DMRMS1A CB CHEBI:135798
DMRMS1A DE Inflammation
DMMIAXO ID DMMIAXO
DMMIAXO DN Betamethasone valerate
DMMIAXO HS Approved
DMMIAXO SN Beta-val; Betaderm; Betatrex; Dermabet; Valnac
DMMIAXO CP Schering Corp Sub Schering Plough Corp
DMMIAXO DT Small molecular drug
DMMIAXO PC 16533
DMMIAXO MW 476.6
DMMIAXO FM C27H37FO6
DMMIAXO IC InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1
DMMIAXO CS CCCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CO
DMMIAXO IK SNHRLVCMMWUAJD-SUYDQAKGSA-N
DMMIAXO IU [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DMMIAXO CA CAS 2152-44-5
DMMIAXO CB CHEBI:31277
DMMIAXO DE Dermatological disease
DM6EUL5 ID DM6EUL5
DM6EUL5 DN Betaxolol
DM6EUL5 HS Approved
DM6EUL5 SN Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol
DM6EUL5 CP Lorex Pharmaceuticals
DM6EUL5 TC Antihypertensive Agents
DM6EUL5 DT Small molecular drug
DM6EUL5 PC 2369
DM6EUL5 MW 307.4
DM6EUL5 FM C18H29NO3
DM6EUL5 IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
DM6EUL5 CS CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
DM6EUL5 IK NWIUTZDMDHAVTP-UHFFFAOYSA-N
DM6EUL5 IU 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM6EUL5 CA CAS 63659-18-7
DM6EUL5 CB CHEBI:3082
DM6EUL5 DE Hypertension
DMUFGAY ID DMUFGAY
DMUFGAY DN Betazole
DMUFGAY HS Approved
DMUFGAY SN Ametazole; Betazol; Betazolo; Betazolum; Betazole [INN]; Betazolo [DCIT]; Lilly 96791; Betazol [INN-Spanish]; Betazolum [INN-Latin]; 1H-Pyrazole-3-ethanamine; 2-(1H-Pyrazol-3-yl)ethanamine; 2-(1H-pyrazol-5-yl)ethanamine; 2-(3-Pyrazolyl)ethylamine; 3-(2-Aminoethyl)pyrazole; 3-(beta-aminoethyl)pyrazole
DMUFGAY CP Eli Lilly And Co
DMUFGAY TC Antihistamines
DMUFGAY DT Small molecular drug
DMUFGAY PC 7741
DMUFGAY MW 111.15
DMUFGAY FM C5H9N3
DMUFGAY IC InChI=1S/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)
DMUFGAY CS C1=C(NN=C1)CCN
DMUFGAY IK JXDFEQONERDKSS-UHFFFAOYSA-N
DMUFGAY IU 2-(1H-pyrazol-5-yl)ethanamine
DMUFGAY CA CAS 105-20-4
DMUFGAY CB CHEBI:59170
DMUFGAY DE Gastric secretory disorder
DMCLHO0 ID DMCLHO0
DMCLHO0 DN Bethanechol
DMCLHO0 HS Approved
DMCLHO0 SN Amidopropyldimethylbetaine; Bethanecol; Urabeth; Myotonine chloride; Duvoid (TN); Myotonachol (TN); Urecholine (TN); Carbamoyl-beta-methylcholine; Carbamyl-beta-methylcholine; Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester); (2-Hydroxypropyl)trimethylammonium carbamate; 1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-(9CI); 2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium; 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium; 2-carbamoyloxypropyl(trimethyl)azanium; 2-carbamoyloxypropyl-trimethylazanium
DMCLHO0 CP Merck & Co
DMCLHO0 TC Parasympathomimetics
DMCLHO0 DT Small molecular drug
DMCLHO0 PC 2370
DMCLHO0 MW 161.22
DMCLHO0 FM C7H17N2O2+
DMCLHO0 IC InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1
DMCLHO0 CS CC(C[N+](C)(C)C)OC(=O)N
DMCLHO0 IK NZUPCNDJBJXXRF-UHFFFAOYSA-O
DMCLHO0 IU 2-carbamoyloxypropyl(trimethyl)azanium
DMCLHO0 CA CAS 674-38-4
DMCLHO0 CB CHEBI:3084
DMCLHO0 DE Urinary retention
DM2C4RF ID DM2C4RF
DM2C4RF DN Betrixaban
DM2C4RF HS Approved
DM2C4RF SN Betrixaban; 330942-05-7; Bevyxxa; PRT054021; UNII-74RWP7W0J9; PRT 054021; 74RWP7W0J9; betrixaban maleate; Betrixaban [USAN:INN]; betrixaban/; Betrixaban (USAN); D0J0BU; SCHEMBL158591; QCR-99; GTPL9602; EX-A358; MolPort-009-682-948; ZINC3
DM2C4RF CP Portola Pharmaceuticals
DM2C4RF DT Small molecular drug
DM2C4RF PC 10275777
DM2C4RF MW 451.9
DM2C4RF FM C23H22ClN5O3
DM2C4RF IC InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)
DM2C4RF CS CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
DM2C4RF IK XHOLNRLADUSQLD-UHFFFAOYSA-N
DM2C4RF IU N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
DM2C4RF CA CAS 330942-05-7
DM2C4RF CB CHEBI:140421
DM2C4RF DE Venous thromboembolism; Cerebrovascular ischaemia
DMSD1UN ID DMSD1UN
DMSD1UN DN Bevacizumab
DMSD1UN HS Approved
DMSD1UN SN Bevacizumab (ophthalmic slow-release tissue tablet)
DMSD1UN CP University of London
DMSD1UN DT Monoclonal antibody
DMSD1UN SQ Bevacizumab light chain: DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >"Bevacizumab heavy chain"EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMSD1UN DE Solid tumour/cancer; Colorectal cancer; Lung cancer; Metastatic colorectal cancer; Brain metastases; Ovarian cancer
DMZFICR ID DMZFICR
DMZFICR DN Bevantolol
DMZFICR HS Approved
DMZFICR SN Bevantololum; Bevantolol [INN:BAN]; Bevantololum [INN-Latin]; (+-)-bevantolol; 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol; 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol; 1-(3,4-dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol; 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol; 1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
DMZFICR TC Antihypertensive Agents
DMZFICR DT Small molecular drug
DMZFICR PC 2372
DMZFICR MW 345.4
DMZFICR FM C20H27NO4
DMZFICR IC InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
DMZFICR CS CC1=CC(=CC=C1)OCC(CNCCC2=CC(=C(C=C2)OC)OC)O
DMZFICR IK HXLAFSUPPDYFEO-UHFFFAOYSA-N
DMZFICR IU 1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol
DMZFICR CA CAS 59170-23-9
DMZFICR CB CHEBI:238698
DMZFICR DE Hypertension
DMOBIKY ID DMOBIKY
DMOBIKY DN Bexarotene
DMOBIKY HS Approved
DMOBIKY SN Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
DMOBIKY CP Eisai Inc
DMOBIKY TC Anticancer Agents
DMOBIKY DT Small molecular drug
DMOBIKY PC 82146
DMOBIKY MW 348.5
DMOBIKY FM C24H28O2
DMOBIKY IC InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
DMOBIKY CS CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C
DMOBIKY IK NAVMQTYZDKMPEU-UHFFFAOYSA-N
DMOBIKY IU 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
DMOBIKY CA CAS 153559-49-0
DMOBIKY CB CHEBI:50859
DMOBIKY DE Cutaneous T-cell lymphoma
DMZDCS0 ID DMZDCS0
DMZDCS0 DN Bezafibrate
DMZDCS0 HS Approved
DMZDCS0 SN Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0 TC Antilipemic Agents
DMZDCS0 DT Small molecular drug
DMZDCS0 PC 39042
DMZDCS0 MW 361.8
DMZDCS0 FM C19H20ClNO4
DMZDCS0 IC InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
DMZDCS0 CS CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
DMZDCS0 IK IIBYAHWJQTYFKB-UHFFFAOYSA-N
DMZDCS0 IU 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
DMZDCS0 CA CAS 41859-67-0
DMZDCS0 CB CHEBI:47612
DMZDCS0 DE Hyperlipidaemia
DMTZC5G ID DMTZC5G
DMTZC5G DN Bezlotoxumab
DMTZC5G HS Approved
DMTZC5G SN CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava
DMTZC5G CP Merck & Co.
DMTZC5G DT Monoclonal antibody
DMTZC5G DE C. difficile infection
DMTKD7Q ID DMTKD7Q
DMTKD7Q DN BIBW 2992
DMTKD7Q HS Approved
DMTKD7Q SN Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens
DMTKD7Q CP Boehringer Ingelheim
DMTKD7Q DT Small molecular drug
DMTKD7Q PC 10184653
DMTKD7Q MW 485.9
DMTKD7Q FM C24H25ClFN5O3
DMTKD7Q IC InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
DMTKD7Q CS CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4
DMTKD7Q IK ULXXDDBFHOBEHA-CWDCEQMOSA-N
DMTKD7Q IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
DMTKD7Q CA CAS 850140-72-6
DMTKD7Q CB CHEBI:61390
DMTKD7Q DE Non-small-cell lung cancer
DMZMSPF ID DMZMSPF
DMZMSPF DN Bicalutamide
DMZMSPF HS Approved
DMZMSPF SN Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
DMZMSPF CP AstraZeneca plc
DMZMSPF TC Anticancer Agents
DMZMSPF DT Small molecular drug
DMZMSPF PC 2375
DMZMSPF MW 430.4
DMZMSPF FM C18H14F4N2O4S
DMZMSPF IC InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
DMZMSPF CS CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
DMZMSPF IK LKJPYSCBVHEWIU-UHFFFAOYSA-N
DMZMSPF IU N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
DMZMSPF CA CAS 90357-06-5
DMZMSPF CB CHEBI:91617
DMZMSPF DE Prostate cancer
DMG0H8K ID DMG0H8K
DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K HS Approved
DMG0H8K SN S900007760; Bictegravir mixture with emtricitabine and tenofovir alafenamide
DMG0H8K CP Gilead Sciences
DMG0H8K PC 129626368
DMG0H8K MW 1173.1
DMG0H8K FM C50H57F4N12O13PS
DMG0H8K IC InChI=1S/C21H18F3N3O5.C21H29N6O5P.C8H10FN3O3S/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28;1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30);5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1,5-6,13H,2-3H2,(H2,10,11,14)/t10-,11+,16+;15-,16+,33+;5-,6+/m010/s1
DMG0H8K CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3.C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F.C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMG0H8K IK GMIGIKGMWTUBHA-UKQLQXPXSA-N
DMG0H8K IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMG0H8K DE Human immunodeficiency virus infection
DM3KN7V ID DM3KN7V
DM3KN7V DN Bifonazole
DM3KN7V HS Approved
DM3KN7V SN Amycor; Azolmen; Bifokey; Bifomyk; Bifon; Bifonazol; Bifonazolum; Moldina; Mycospor; Trifonazole; Bayer brand of bifonazole; Bioglan brand of bifonazole; Canesten Extra Bifonazol; Canesten brand of bifonazole; Dermapharm brand of bifonazole; Inkeysa brand of bifonazole; Juventus brand of bifonazole; Merck Lipha Sante brand of bifonazole; Bay H-4502; Bifonazol [INN-Spanish]; Bifonazolum [INN-Latin]; Canespor (TN); Mycospor (TN); Bay-h-4502; Bifonazole (JP15/USAN/INN); Bifonazole [USAN:BAN:INN:JAN]; (+-)-1-([1,1'-Biphenyl]-4-ylphenylmethyl)-1H-imidazole; (+-)-1-(p,alpha-Diphenylbenzyl)imidazole; 1-((4-Biphenylyl)phenylmethyl)-1H-imidazole; 1-(alpha-(4-Biphenylyl)benzyl)imidazole; 1-(p,alpha-Diphenylbenzyl)imidazole; 1-[4,alpha-Diphenylbenzyl]-imidazole; 1-[biphenyl-4-yl(phenyl)methyl]-1H-imidazole; 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V CP Bayer Pharmaceuticals Corporation
DM3KN7V TC Antifungal Agents
DM3KN7V DT Small molecular drug
DM3KN7V PC 2378
DM3KN7V MW 310.4
DM3KN7V FM C22H18N2
DM3KN7V IC InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H
DM3KN7V CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4
DM3KN7V IK OCAPBUJLXMYKEJ-UHFFFAOYSA-N
DM3KN7V IU 1-[phenyl-(4-phenylphenyl)methyl]imidazole
DM3KN7V CA CAS 60628-96-8
DM3KN7V CB CHEBI:78692
DM3KN7V DE Fungal infection
DMX0E5B ID DMX0E5B
DMX0E5B DN Bimatoprost
DMX0E5B HS Approved
DMX0E5B SN Bimatoprost (topical, alopecia)
DMX0E5B CP Allergan Inc
DMX0E5B DT Small molecular drug
DMX0E5B PC 5311027
DMX0E5B MW 415.6
DMX0E5B FM C25H37NO4
DMX0E5B IC InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
DMX0E5B CS CCNC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
DMX0E5B IK AQOKCDNYWBIDND-FTOWTWDKSA-N
DMX0E5B IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
DMX0E5B CA CAS 155206-00-1
DMX0E5B CB CHEBI:51230
DMX0E5B DE Alopecia; Glaucoma/ocular hypertension
DME78OA ID DME78OA
DME78OA DN Biperiden
DME78OA HS Approved
DME78OA SN Akineton; Beperiden; Biperidene; Biperideno; Biperidenum; Biperidine; Biperidene hydrochloride; KL 373; Akineton (TN);Biperidene [INN-French]; Biperideno [INN-Spanish]; Biperidenum [INN-Latin]; Biperiden (JAN/USP/INN); Biperiden [USAN:BAN:INN:JAN]; Biperiden [USAN:INN:BAN:JAN]; Alpha-5-Norbornen-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-Bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol; Alpha-(Bicyclo(2.2.1)hept-5-en-2-yl)-alpha-phenyl-1-piperidino propanol; 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol; 1-(Bicyclo(2.2.1)hept-5-en-2alpha-yl)-1-phenyl-3-piperidinopropanol; 1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1; 1-Piperidinepropanol, .alpha.-bicyclo[2.2.1]hept-5-en-2-yl-.alpha.-phenyl-, hydrochloride; 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1); 3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1) [German]; 3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol
DME78OA CP Knoll Pharma
DME78OA TC Antiparkinson Agents
DME78OA DT Small molecular drug
DME78OA PC 2381
DME78OA MW 311.5
DME78OA FM C21H29NO
DME78OA IC InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2
DME78OA CS C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O
DME78OA IK YSXKPIUOCJLQIE-UHFFFAOYSA-N
DME78OA IU 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol
DME78OA CA CAS 514-65-8
DME78OA CB CHEBI:3112
DME78OA DE Parkinson disease
DMTKU46 ID DMTKU46
DMTKU46 DN Bismuth
DMTKU46 HS Approved
DMTKU46 SN Bismut; Bismuto; Wismut; Bismuth standard for AAS; Bismuth standard for ICP; LTBB002773; Bismuth(III) nitrate solution; Bismuth, elemental; Bismuth-209; BISMUTH, 99.95%; BISMUTH, 99.999%; 83Bi
DMTKU46 TC Antidiarrheals
DMTKU46 DT Small molecular drug
DMTKU46 PC 5359367
DMTKU46 MW 208.98
DMTKU46 FM Bi
DMTKU46 IC InChI=1S/Bi
DMTKU46 CS [Bi]
DMTKU46 IK JCXGWMGPZLAOME-UHFFFAOYSA-N
DMTKU46 IU bismuth
DMTKU46 CA CAS 7440-69-9
DMTKU46 CB CHEBI:33301
DMTKU46 DE Diarrhea
DM3UZ95 ID DM3UZ95
DM3UZ95 DN Bisoprolol
DM3UZ95 HS Approved
DM3UZ95 SN Bisocor; Bisoprololum; Cardicor; Concor; Detensiel; Emconcor; Emcor; Euradal; Isoten; Monocor; Soloc; Soprol; Zebeta; Bisoprolol fumerate; Bisoprolol hemifumarate; Bisoprololum [Latin]; CL-297939; Concor (TN); Concore (TN); EMD-33512; Monocor (TN); Zebeta (TN); Bisoprolol (USAN/INN); Bisoprolol [USAN:BAN:INN]; EMD-33-512; (+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol; (RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol; 1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
DM3UZ95 TC Antihypertensive Agents
DM3UZ95 DT Small molecular drug
DM3UZ95 PC 2405
DM3UZ95 MW 325.4
DM3UZ95 FM C18H31NO4
DM3UZ95 IC InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
DM3UZ95 CS CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O
DM3UZ95 IK VHYCDWMUTMEGQY-UHFFFAOYSA-N
DM3UZ95 IU 1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
DM3UZ95 CA CAS 66722-44-9
DM3UZ95 CB CHEBI:3127
DM3UZ95 DE Hypertension
DMK6XAV ID DMK6XAV
DMK6XAV DN Bitolterol
DMK6XAV HS Approved
DMK6XAV SN Tornalate
DMK6XAV CP Sanofi Aventis Us Llc
DMK6XAV DT Small molecular drug
DMK6XAV PC 35330
DMK6XAV MW 461.5
DMK6XAV FM C28H31NO5
DMK6XAV IC InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
DMK6XAV CS CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C
DMK6XAV IK FZGVEKPRDOIXJY-UHFFFAOYSA-N
DMK6XAV IU [4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyl)oxyphenyl] 4-methylbenzoate
DMK6XAV CA CAS 30392-40-6
DMK6XAV CB CHEBI:3133
DMK6XAV DE Chronic obstructive pulmonary disease; Asthma
DMECRX1 ID DMECRX1
DMECRX1 DN Bivalirudin
DMECRX1 HS Approved
DMECRX1 SN 128270-60-0; Angiomax; Hirulog; bivalirudinum; bivalirudina; Bivalirudin Trifluoroacetate; BG-8967; UNII-TN9BEX005G; BG8967; Bivalirudin Trifluoacetate; TN9BEX005G; D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine; CHEBI:59173; Hirulog-1; Angiox; Bivalirudina; Bivalirudine; Bivalirudinum; The Medicines Company brand of bivalirudin; BG 8967; Angiomax (TN); HS-2004; Bivalirudin [USAN:BAN:INN]; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64); Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
DMECRX1 TC Antithrombotic Agents
DMECRX1 DT Small molecular drug
DMECRX1 PC 16129704
DMECRX1 MW 2180.3
DMECRX1 FM C98H138N24O33
DMECRX1 IC InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1
DMECRX1 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N
DMECRX1 IK OIRCOABEOLEUMC-GEJPAHFPSA-N
DMECRX1 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMECRX1 CA CAS 128270-60-0
DMECRX1 CB CHEBI:59173
DMECRX1 DE Thrombocytopenia
DMR8YD6 ID DMR8YD6
DMR8YD6 DN B-Lactams
DMR8YD6 HS Approved
DMR8YD6 SN Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6 DT Small molecular drug
DMR8YD6 PC 5280445
DMR8YD6 MW 286.24
DMR8YD6 FM C15H10O6
DMR8YD6 IC InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
DMR8YD6 CS C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMR8YD6 IK IQPNAANSBPBGFQ-UHFFFAOYSA-N
DMR8YD6 IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMR8YD6 CA CAS 491-70-3
DMR8YD6 CB CHEBI:15864
DMR8YD6 DE Bacterial infection
DMNER5S ID DMNER5S
DMNER5S DN Bleomycin
DMNER5S HS Approved
DMNER5S SN BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
DMNER5S CP Bristol-Myers Squibb
DMNER5S TC Anticancer Agents
DMNER5S DT Small molecular drug
DMNER5S PC 5360373
DMNER5S MW 1415.6
DMNER5S FM C55H84N17O21S3+
DMNER5S IC InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1
DMNER5S CS CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
DMNER5S IK OYVAGSVQBOHSSS-WXFSZRTFSA-O
DMNER5S IU 3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
DMNER5S CA CAS 11056-06-7
DMNER5S DE Hodgkin lymphoma
DMGECIJ ID DMGECIJ
DMGECIJ DN Blinatumomab
DMGECIJ HS Approved
DMGECIJ SN AMG 103; Blincyto
DMGECIJ CP Amgen
DMGECIJ DT Monoclonal antibody
DMGECIJ SQ single chain variable fragment fusion protein : DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH
DMGECIJ DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma
DMQTAGO ID DMQTAGO
DMQTAGO DN BMS-201038
DMQTAGO HS Approved
DMQTAGO SN AEGR 733; AEGR733; BMS 201038; BMS 201238; BMS201038; AEGR-733; BMS 201038-01
DMQTAGO CP Bristol-Myers Squibb
DMQTAGO DT Small molecular drug
DMQTAGO PC 9853053
DMQTAGO MW 693.7
DMQTAGO FM C39H37F6N3O2
DMQTAGO IC InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)
DMQTAGO CS C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMQTAGO IK MBBCVAKAJPKAKM-UHFFFAOYSA-N
DMQTAGO IU N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMQTAGO CA CAS 182431-12-5
DMQTAGO CB CHEBI:72297
DMQTAGO DE Familial hypercholesterolemia
DMBSHMF ID DMBSHMF
DMBSHMF DN Boceprevir
DMBSHMF HS Approved
DMBSHMF SN Boceprevir; Victrelis; 394730-60-0; SCH 503034; EBP 520; UNII-89BT58KELH; SCH-503034; 89BT58KELH; CHEBI:68621; (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
DMBSHMF DT Small molecular drug
DMBSHMF PC 10324367
DMBSHMF MW 519.7
DMBSHMF FM C27H45N5O5
DMBSHMF IC InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
DMBSHMF CS CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
DMBSHMF IK LHHCSNFAOIFYRV-DOVBMPENSA-N
DMBSHMF IU (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DMBSHMF CA CAS 394730-60-0
DMBSHMF CB CHEBI:68621
DMBSHMF DE Hepatitis C virus infection
DM2EXC5 ID DM2EXC5
DM2EXC5 DN BOL-303259-X
DM2EXC5 HS Approved
DM2EXC5 SN Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
DM2EXC5 CP Bausch and Lomb/Valeant Pharmaceuticals
DM2EXC5 DT Small molecular drug
DM2EXC5 PC 11156438
DM2EXC5 MW 507.6
DM2EXC5 FM C27H41NO8
DM2EXC5 IC InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
DM2EXC5 CS C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O
DM2EXC5 IK LOVMMUBRQUFEAH-UIEAZXIASA-N
DM2EXC5 IU 4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DM2EXC5 CA CAS 860005-21-6
DM2EXC5 DE Open-angle glaucoma; Renal cell carcinoma
DMIFYLX ID DMIFYLX
DMIFYLX DN Bopindolol
DMIFYLX HS Approved
DMIFYLX SN BOPINDOLOL; 62658-63-3; Sandonorm; (+-)-Bopindolol; 1-(tert-Butylamino)-3-((2-methyl-1H-indol-4-yl)oxy)propan-2-yl benzoate; Bopindololum [INN-Latin]; Bopindolol [INN]; UUOJIACWOAYWEZ-UHFFFAOYSA-N; Bopindolol (INN); Wandonorm; 69010-88-4; NCGC00163155-01; Sandonorm (TN); (+-)-4-(2-Benzoyloxy-3-tert-butylaminopropoxy)-2-methylindole; DSSTox_CID_2684; DSSTox_RID_76690; (+-)-1-(tert-Butylamino)-3-((2-methylindol-4-yl)oxy)-2-propanol benzoate (ester); DSSTox_GSID_22684
DMIFYLX DT Small molecular drug
DMIFYLX PC 44112
DMIFYLX MW 380.5
DMIFYLX FM C23H28N2O3
DMIFYLX IC InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
DMIFYLX CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
DMIFYLX IK UUOJIACWOAYWEZ-UHFFFAOYSA-N
DMIFYLX IU [1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl] benzoate
DMIFYLX CA CAS 62658-63-3
DMIFYLX CB CHEBI:143782
DMIFYLX DE Hypertension
DMNO38U ID DMNO38U
DMNO38U DN Bortezomib
DMNO38U HS Approved
DMNO38U SN 179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
DMNO38U CP Takeda
DMNO38U TC Anticancer Agents
DMNO38U DT Small molecular drug
DMNO38U PC 387447
DMNO38U MW 384.2
DMNO38U FM C19H25BN4O4
DMNO38U IC InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
DMNO38U CS B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
DMNO38U IK GXJABQQUPOEUTA-RDJZCZTQSA-N
DMNO38U IU [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
DMNO38U CA CAS 179324-69-7
DMNO38U CB CHEBI:52717
DMNO38U DE Multiple myeloma; Non-hodgkin lymphoma; Mantle cell lymphoma
DMIOGBU ID DMIOGBU
DMIOGBU DN Bosentan
DMIOGBU HS Approved
DMIOGBU SN Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU CP Actelion Pharmaceuticals
DMIOGBU TC Antihypertensive Agents
DMIOGBU DT Small molecular drug
DMIOGBU PC 104865
DMIOGBU MW 551.6
DMIOGBU FM C27H29N5O6S
DMIOGBU IC InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)
DMIOGBU CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC
DMIOGBU IK GJPICJJJRGTNOD-UHFFFAOYSA-N
DMIOGBU IU 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
DMIOGBU CA CAS 147536-97-8
DMIOGBU CB CHEBI:51450
DMIOGBU DE Pulmonary arterial hypertension
DMTI8YE ID DMTI8YE
DMTI8YE DN Bosutinib
DMTI8YE HS Approved
DMTI8YE SN SKI 606; SKI606; Bosutinib (USAN); PF-5208763; SKI-606; Xy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propo; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (BCR-ABL inhibitor 3rd gen)
DMTI8YE CP Wyeth Research
DMTI8YE TC Anticancer Agents
DMTI8YE DT Small molecular drug
DMTI8YE PC 5328940
DMTI8YE MW 530.4
DMTI8YE FM C26H29Cl2N5O3
DMTI8YE IC InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
DMTI8YE CS CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
DMTI8YE IK UBPYILGKFZZVDX-UHFFFAOYSA-N
DMTI8YE IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
DMTI8YE CA CAS 380843-75-4
DMTI8YE CB CHEBI:39112
DMTI8YE DE Breast cancer
DMW67MU ID DMW67MU
DMW67MU DN Botulinum Toxin Type A
DMW67MU HS Approved
DMW67MU SN Botox; Botulinum toxin type A (JAN)
DMW67MU SQ Botulinum Toxin Type A Sequence: MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL
DMW67MU DE Blepharospasm
DM58QS1 ID DM58QS1
DM58QS1 DN Botulinum Toxin Type B
DM58QS1 HS Approved
DM58QS1 SN BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN)
DM58QS1 CP Allergan Inc
DM58QS1 TC Antidystonic Agents
DM58QS1 SQ Botulinum neurotoxin type B - Clostridium botulinum: MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSNYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQYLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLIPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDLSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE
DM58QS1 DE Parkinson disease
DM20LIM ID DM20LIM
DM20LIM DN Bremelanotide
DM20LIM HS Approved
DM20LIM SN Bremelanotide (USAN/INN); PT-141; Rekynda
DM20LIM CP Palatin Technol
DM20LIM DT Small molecular drug
DM20LIM PC 9941379
DM20LIM MW 1025.2
DM20LIM FM C50H68N14O10
DM20LIM IC InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
DM20LIM CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
DM20LIM IK FFHBJDQSGDNCIV-MFVUMRCOSA-N
DM20LIM IU (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
DM20LIM CA CAS 189691-06-3
DM20LIM DE Erectile dysfunction; Hypoactive sexual desire dysfunction
DMWLC57 ID DMWLC57
DMWLC57 DN Brentuximab vedotin
DMWLC57 HS Approved
DMWLC57 SN Adcetris (TN)
DMWLC57 CP Millennium Pharmaceuticals; Seattle Genetics
DMWLC57 DT Monoclonal antibody
DMWLC57 DE Hodgkin lymphoma
DM1FX74 ID DM1FX74
DM1FX74 DN Bretylium
DM1FX74 HS Approved
DM1FX74 SN Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
DM1FX74 CP Hospira Inc
DM1FX74 TC Antiarrhythmic Agents
DM1FX74 DT Small molecular drug
DM1FX74 PC 2431
DM1FX74 MW 243.16
DM1FX74 FM C11H17BrN+
DM1FX74 IC InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
DM1FX74 CS CC[N+](C)(C)CC1=CC=CC=C1Br
DM1FX74 IK AAQOQKQBGPPFNS-UHFFFAOYSA-N
DM1FX74 IU (2-bromophenyl)methyl-ethyl-dimethylazanium
DM1FX74 CA CAS 59-41-6
DM1FX74 CB CHEBI:3172
DM1FX74 DE Ventricular fibrillation
DM7W94S ID DM7W94S
DM7W94S DN Brigatinib
DM7W94S HS Approved
DM7W94S SN 1197953-54-0; UNII-HYW8DB273J; Brigatinib [USAN]; ALUNBRIG; HYW8DB273J; Brigatinib (USAN); Brigatiib; Alunbrig (TN); Brigatinib [USAN:INN]; Brigatinib (AP26113); SCHEMBL11916361; KS-00000TSQ; EX-A775; MolPort-044-561-640; BDBM50185140; ZINC148723177; AKOS030257612; CS-4278; DB12267; HY-12857; AC-29958
DM7W94S CP Ariad Pharmaceuticals/Takeda
DM7W94S DT Small molecular drug
DM7W94S PC 68165256
DM7W94S MW 584.1
DM7W94S FM C29H39ClN7O2P
DM7W94S IC InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
DM7W94S CS CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC
DM7W94S IK AILRADAXUVEEIR-UHFFFAOYSA-N
DM7W94S IU 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine
DM7W94S CA CAS 1197953-54-0
DM7W94S DE Non-small-cell lung cancer; Anaplastic large cell lymphoma
DMBR01X ID DMBR01X
DMBR01X DN Brilinta
DMBR01X HS Approved
DMBR01X SN Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique
DMBR01X CP AstraZeneca
DMBR01X DT Small molecular drug
DMBR01X PC 9871419
DMBR01X MW 522.6
DMBR01X FM C23H28F2N6O4S
DMBR01X IC InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
DMBR01X CS CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
DMBR01X IK OEKWJQXRCDYSHL-FNOIDJSQSA-N
DMBR01X IU (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
DMBR01X CA CAS 274693-27-5
DMBR01X CB CHEBI:68558
DMBR01X DE Myocardial infarction; Arterial thrombosis; Thrombosis
DMQLT4N ID DMQLT4N
DMQLT4N DN Brimonidine
DMQLT4N HS Approved
DMQLT4N SN brimonidine; 59803-98-4; Bromoxidine; UK 14,304; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; AGN 190342; UNII-E6GNX3HHTE; Brimonidine [INN:BAN]; UK 14304; C11H10BrN5; MLS000069370; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; E6GNX3HHTE; CHEMBL844; AGN-190342; BRN 0751629; SMR000058355; CHEBI:3175; LK 14304-18; Brimonidine, 98%; NCGC00016069-09; EN300-50880; DSSTox_RID_80758; Brimonidine (bioerodible, extended release); [3H]brimonidine
DMQLT4N CP PSivida Corp
DMQLT4N DT Small molecular drug
DMQLT4N PC 2435
DMQLT4N MW 292.13
DMQLT4N FM C11H10BrN5
DMQLT4N IC InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
DMQLT4N CS C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
DMQLT4N IK XYLJNLCSTIOKRM-UHFFFAOYSA-N
DMQLT4N IU 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
DMQLT4N CA CAS 59803-98-4
DMQLT4N CB CHEBI:3175
DMQLT4N DE Ocular hypertension; Glaucoma/ocular hypertension
DMBAPFG ID DMBAPFG
DMBAPFG DN Brinzolamide
DMBAPFG HS Approved
DMBAPFG SN Azopt; Birnzolamide; Alcon brand of brinzolamide; Allphar brand of brinzolamide; Brinzolamide [USAN]; AL 4862; AL04862; BZ1; AL-4862; Azopt (TN); Brinzolamide (BRZ); Brinzolamide (JAN/USP/INN); (+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide; 2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
DMBAPFG CP Alcon Laboratories
DMBAPFG TC Antiglaucomic Agents
DMBAPFG DT Small molecular drug
DMBAPFG PC 68844
DMBAPFG MW 383.5
DMBAPFG FM C12H21N3O5S3
DMBAPFG IC InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
DMBAPFG CS CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
DMBAPFG IK HCRKCZRJWPKOAR-JTQLQIEISA-N
DMBAPFG IU (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMBAPFG CA CAS 138890-62-7
DMBAPFG CB CHEBI:3176
DMBAPFG DE Open-angle glaucoma
DMSEPK8 ID DMSEPK8
DMSEPK8 DN Brivaracetam
DMSEPK8 HS Approved
DMSEPK8 SN Rikelta; UCB-34714; Brivaracetam (USAN/INN)
DMSEPK8 CP UCB
DMSEPK8 DT Small molecular drug
DMSEPK8 PC 9837243
DMSEPK8 MW 212.29
DMSEPK8 FM C11H20N2O2
DMSEPK8 IC InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1
DMSEPK8 CS CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N
DMSEPK8 IK MSYKRHVOOPPJKU-BDAKNGLRSA-N
DMSEPK8 IU (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
DMSEPK8 CA CAS 357336-20-0
DMSEPK8 CB CHEBI:133013
DMSEPK8 DE Epilepsy; Pain; Complex partial seizure
DMASDQ6 ID DMASDQ6
DMASDQ6 DN Brodalumab
DMASDQ6 HS Approved
DMASDQ6 SN AMG 827
DMASDQ6 CP Valeant Pharmaceuticals
DMASDQ6 DT Monoclonal antibody
DMASDQ6 DE Plaque psoriasis; Asthma; Psoriasis vulgaris
DMW8QNG ID DMW8QNG
DMW8QNG DN Brolucizumab
DMW8QNG HS Approved
DMW8QNG CP Alcon
DMW8QNG DT Antibody
DMW8QNG DE Wet age-related macular degeneration; Diabetic macular edema
DMY9TCW ID DMY9TCW
DMY9TCW DN Bromazepam
DMY9TCW HS Approved
DMY9TCW SN Bromazepamum; Calmepam; Compedium; Compendium; Creosedin; Durazanil; Lectopam; Lekotam; Lexaurin; Lexilium; Lexomil; Lexotan; Lexotanil; Normoc; Somalium; Ultramidol; Bromazepamum [Latin]; LA Xvii; KL 001; Ro 53350; Apo-Bromazepam; Brazepam (TN); Bromaze (TN); Bromazepam(USAN; Bromazepamum [INN-Latin]; Gen-Bromazepam; KL-001; Lectopam (TN); Lexotan (TN); Novo-bromazepam; Nu-Bromazepam; Ro 4-9253; Ro 5-3350; Bromazepam (JP15/USAN/INN); Bromazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-bromo-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzdiazepin-2-one; 7-Bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one; 7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW CP Hoffmann-La Roche pharmaceutical company
DMY9TCW TC Hypnotics and Sedatives
DMY9TCW DT Small molecular drug
DMY9TCW PC 2441
DMY9TCW MW 316.15
DMY9TCW FM C14H10BrN3O
DMY9TCW IC InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)
DMY9TCW CS C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3
DMY9TCW IK VMIYHDSEFNYJSL-UHFFFAOYSA-N
DMY9TCW IU 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one
DMY9TCW CA CAS 1812-30-2
DMY9TCW CB CHEBI:31302
DMY9TCW DE Panic attacks; Anxiety disorder
DMKB79O ID DMKB79O
DMKB79O DN Bromfenac
DMKB79O HS Approved
DMKB79O SN Bromfenaco; Bromfenacum; Duract; Xibrom; BROMFENAC SODIUM; Bromfenac [INN]; Bromfenaco [Spanish]; Bromfenacum [Latin]; AHR-10282; Bromfenac (INN); Duract (TN); Xibrom (TN); Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate; [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid; {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetic acid; [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid; 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid; 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O TC Antiinflammatory Agents
DMKB79O DT Small molecular drug
DMKB79O PC 60726
DMKB79O MW 334.16
DMKB79O FM C15H12BrNO3
DMKB79O IC InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
DMKB79O CS C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
DMKB79O IK ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
DMKB79O IU 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
DMKB79O CA CAS 91714-94-2
DMKB79O CB CHEBI:240107
DMKB79O DE Postoperative inflammation; Inflammation
DMVE3TK ID DMVE3TK
DMVE3TK DN Bromocriptine
DMVE3TK HS Approved
DMVE3TK SN Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine
DMVE3TK CP Norvatis Phamaceuticals Corporation
DMVE3TK TC Antiparkinson Agents
DMVE3TK DT Small molecular drug
DMVE3TK PC 31101
DMVE3TK MW 654.6
DMVE3TK FM C32H40BrN5O5
DMVE3TK IC InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
DMVE3TK CS CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
DMVE3TK IK OZVBMTJYIDMWIL-AYFBDAFISA-N
DMVE3TK IU (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMVE3TK CA CAS 25614-03-3
DMVE3TK CB CHEBI:3181
DMVE3TK DE Parkinson disease
DMNDJT5 ID DMNDJT5
DMNDJT5 DN Bromodiphenhydramine
DMNDJT5 HS Approved
DMNDJT5 SN Amodryl; Bromanautine; Bromazin; Bromazina; Bromazine; Bromazinum; Bromdiphenhydramine; Bromdiphenhydraminum; Deserol; Histabromamine; Ambodryl hydrochloride; Bromdiphenhydramine hydrochloride; Bromdiphenylhydramine hydrochloride; Bromodiphenhydramine hydrochloride; Ambrodyl (TN); Bromazina [INN-Spanish]; Bromazine [INN:BAN]; Bromazinum [INN-Latin]; Bromo-Benadryl; Bromo-Benzdryl; Neo-Benadryl; Beta-dimethylaminoethyl p-bromobenzhydryl ether; Beta-(p-Bromobenzhydryloxy)ethyldimethylamine; 2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine; 2-[(4-Bromophenyl)(phenyl)methoxy]-N,N-dimethylethanamine; 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine; 2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine
DMNDJT5 TC Antihistamines
DMNDJT5 DT Small molecular drug
DMNDJT5 PC 2444
DMNDJT5 MW 334.2
DMNDJT5 FM C17H20BrNO
DMNDJT5 IC InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3
DMNDJT5 CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)Br
DMNDJT5 IK NUNIWXHYABYXKF-UHFFFAOYSA-N
DMNDJT5 IU 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine
DMNDJT5 CA CAS 118-23-0
DMNDJT5 CB CHEBI:59177
DMNDJT5 DE Hay fever
DM24XYQ ID DM24XYQ
DM24XYQ DN Bromperidol
DM24XYQ HS Approved
DM24XYQ SN bromperidol; 10457-90-6; Impromen; Bromoperidol; Tesoprel; Azurene; 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; UNII-LYH6F7I22E; Bromperidolum [INN-Latin]; R 11333; EINECS 233-943-3; 4-(4-(4-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; CC 2489; BRN 1552256; LYH6F7I22E; 4-(4-(p-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; RKLNONIVDFXQRX-UHFFFAOYSA-N; 4-(4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; NCGC00016692-01; CAS-10457-90-6
DM24XYQ DT Small molecular drug
DM24XYQ PC 2448
DM24XYQ MW 420.3
DM24XYQ FM C21H23BrFNO2
DM24XYQ IC InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM24XYQ CS C1CN(CCC1(C2=CC=C(C=C2)Br)O)CCCC(=O)C3=CC=C(C=C3)F
DM24XYQ IK RKLNONIVDFXQRX-UHFFFAOYSA-N
DM24XYQ IU 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM24XYQ CA CAS 10457-90-6
DM24XYQ CB CHEBI:31305
DM24XYQ DE Schizophrenia
DMFOVSD ID DMFOVSD
DMFOVSD DN Brompheniramine
DMFOVSD HS Approved
DMFOVSD SN Bromfed; Bromfenex; Bromfeniramina; Brotane; Parabromdylamine; BROMFED-DM; Bromfeniramina [INN-Spanish]; Brompheniramine (INN); Brompheniramine [INN:BAN]; Brompheniraminum [INN-Latin]; Brotane (TN); DIMETANE-DX; P-Bromdylamine; Para-Bromdylamine; Brompheniramine Maleate (1:1); [3-(4-Bromophenyl)-3-(2-pyridyl)propyl]dimethylamine; Gamma-(4-Bromophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine; 3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine; 3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
DMFOVSD CP Alpharma Us Pharmaceuticals Division
DMFOVSD TC Antiallergic Agents
DMFOVSD DT Small molecular drug
DMFOVSD PC 6834
DMFOVSD MW 319.24
DMFOVSD FM C16H19BrN2
DMFOVSD IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DMFOVSD CS CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMFOVSD IK ZDIGNSYAACHWNL-UHFFFAOYSA-N
DMFOVSD IU 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMFOVSD CA CAS 86-22-6
DMFOVSD CB CHEBI:3183
DMFOVSD DE Allergic rhinitis
DMXKZT3 ID DMXKZT3
DMXKZT3 DN Buclizine
DMXKZT3 HS Approved
DMXKZT3 SN Bucladin; Buclifen; Buclina; Buclizina; Buclizinum; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Hitabutyzyne; Posdel; Softran; Vibazine; Aphilan R; Buclizine dihydrochloride; Buclizine hydrochloride; Component of Softran; Histabutyzine dihydrochloride; Histabutyzine hydrochloride; Vibazine hydrochloride; AH 2526; UCB 4445; Aphilan-R base; Buclina (TN); Buclizina [INN-Spanish]; Buclizine (INN); Buclizine [INN:BAN]; Buclizine, hydrochloride; Buclizinum [INN-Latin]; Component of Bucladin-S; Migraleve (TN); Buclizine Hydrochloride (*dihydrochloride*); Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-, dihydrochloride; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((4-(1,1-dimethylethyl)phenyl)methyl)-(9CI); 1-(4-Tert-butylbenzyl)-4-((4-chlorophenyl)(phenyl)methyl)piperazine; 1-(4-tert-Butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine; 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine; 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3 CP McNeil Laboratories
DMXKZT3 TC Antihistamines
DMXKZT3 DT Small molecular drug
DMXKZT3 PC 6729
DMXKZT3 MW 433
DMXKZT3 FM C28H33ClN2
DMXKZT3 IC InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
DMXKZT3 CS CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMXKZT3 IK MOYGZHXDRJNJEP-UHFFFAOYSA-N
DMXKZT3 IU 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine
DMXKZT3 CA CAS 82-95-1
DMXKZT3 CB CHEBI:3205
DMXKZT3 DE Nausea
DMJIBAW ID DMJIBAW
DMJIBAW DN Budesonide
DMJIBAW HS Approved
DMJIBAW SN Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
DMJIBAW CP AstraZeneca
DMJIBAW TC Antiinflammatory Agents
DMJIBAW DT Small molecular drug
DMJIBAW PC 5281004
DMJIBAW MW 430.5
DMJIBAW FM C25H34O6
DMJIBAW IC InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
DMJIBAW CS CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
DMJIBAW IK VOVIALXJUBGFJZ-KWVAZRHASA-N
DMJIBAW IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMJIBAW CA CAS 51333-22-3
DMJIBAW CB CHEBI:3207
DMJIBAW DE Asthma
DMODHQI ID DMODHQI
DMODHQI DN Budipine
DMODHQI HS Approved
DMODHQI SN Parkinsan; BY-701
DMODHQI CP ALTANA Pharma AG
DMODHQI DT Small molecular drug
DMODHQI PC 68778
DMODHQI MW 293.4
DMODHQI FM C21H27N
DMODHQI IC InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3
DMODHQI CS CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMODHQI IK QIHLUZAFSSMXHQ-UHFFFAOYSA-N
DMODHQI IU 1-tert-butyl-4,4-diphenylpiperidine
DMODHQI CA CAS 57982-78-2
DMODHQI CB CHEBI:135228
DMODHQI DE Migraine
DMG1OPF ID DMG1OPF
DMG1OPF DN Buflomedil
DMG1OPF HS Approved
DMG1OPF SN Loftyl; Buflomedil hydrochloride
DMG1OPF CP Laboratoire L Lafon SA
DMG1OPF DT Small molecular drug
DMG1OPF PC 2467
DMG1OPF MW 307.4
DMG1OPF FM C17H25NO4
DMG1OPF IC InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
DMG1OPF CS COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC
DMG1OPF IK OWYLAEYXIQKAOL-UHFFFAOYSA-N
DMG1OPF IU 4-pyrrolidin-1-yl-1-(2,4,6-trimethoxyphenyl)butan-1-one
DMG1OPF CA CAS 55837-25-7
DMG1OPF CB CHEBI:94538
DMG1OPF DE Peripheral vascular disease
DMX82DO ID DMX82DO
DMX82DO DN Buformin
DMX82DO HS Approved
DMX82DO SN Buformin; 1-Butylbiguanide; Buformine; Butyldiguanide; Butylbiguanide; Butformin; Butylbiguanidum; Glybigid; 1-Butyldiguanide; Glybigidum; N-Butylbiguanide; Buformina; Buforminum; Buformine [INN-French]; Buforminum [INN-Latin]; Buformina [INN-Spanish]; Silubin; Adebit; BIGUANIDE, 1-BUTYL-; Buformin [USAN:INN]; W 37; Buformin HCl; Imidodicarbonimidic diamide, N-butyl-; Sindiatil; Panformin; Diabrin; Biforon; Andere; UNII-W2115E9C7B; Buformine HCl; N-butylimidodicarbonimidic diamide; DBV hydrochloride; H 224
DMX82DO PC 2468
DMX82DO MW 157.22
DMX82DO FM C6H15N5
DMX82DO IC InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)
DMX82DO CS CCCCN=C(N)N=C(N)N
DMX82DO IK XSEUMFJMFFMCIU-UHFFFAOYSA-N
DMX82DO IU 2-butyl-1-(diaminomethylidene)guanidine
DMX82DO CA CAS 692-13-7
DMX82DO CB CHEBI:3209
DMX82DO DE Type 2 diabetes
DMJUVE6 ID DMJUVE6
DMJUVE6 DN Bulevirtide
DMJUVE6 HS Approved
DMJUVE6 SN Lipopeptide
DMJUVE6 CP MYR Pharma
DMJUVE6 DT Peptide
DMJUVE6 DE Hepatitis D virus infection
DMRV7H0 ID DMRV7H0
DMRV7H0 DN Bumetanide
DMRV7H0 HS Approved
DMRV7H0 SN Aquazone; Bumedyl; Bumetanida; Bumetanidum; Bumethanide; Bumex; Burine; Burinex; Butinat; Cambiex; Diurama; Drenural; Fontego; Fordiuran; Lixil; Lunetoron; Miccil; Segurex; Yurinex; AstraZeneca Brand of Bumetanide; Atlantis Brand of Bumetanide; Bumetanide AstraZeneca Brand; Bumetanide Atlantis Brand; Bumetanide Farmacusi Brand; Bumetanide Grossmann Brand; Bumetanide Leo Brand; Bumetanide Roche Brand; Bumetanide Senosiain Brand; Farmacusi Brand of Bumetanide; Grossmann Brand of Bumetanide; Leo Brand of Bumetanide; Roche Brand of Bumetanide; Senosiain Brand of Bumetanide; B 3023; PF 1593; PF1593; Bumetanida [INN-Spanish]; Bumetanidum [INN-Latin]; Bumex (TN); Bumex, Bumetanide; Lixil-Leo; PF-1593; Ro 10-6338; Bumetanide (JP15/USP); Ro-10-6338; Bumetanide (JP15/USP/INN); Bumetanide [USAN:BAN:INN:JAN]; 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(Butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid; 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
DMRV7H0 CP Hoffmann-La Roche pharmaceutical company
DMRV7H0 TC Diuretics
DMRV7H0 DT Small molecular drug
DMRV7H0 PC 2471
DMRV7H0 MW 364.4
DMRV7H0 FM C17H20N2O5S
DMRV7H0 IC InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
DMRV7H0 CS CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
DMRV7H0 IK MAEIEVLCKWDQJH-UHFFFAOYSA-N
DMRV7H0 IU 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
DMRV7H0 CA CAS 28395-03-1
DMRV7H0 CB CHEBI:3213
DMRV7H0 DE Congestive heart failure
DM4I8O7 ID DM4I8O7
DM4I8O7 DN Bunazosin
DM4I8O7 HS Approved
DM4I8O7 SN Andante; E 015; DE-070; Detantol-R; E-1015; E-643
DM4I8O7 CP Eisai Co Ltd
DM4I8O7 DT Small molecular drug
DM4I8O7 PC 2472
DM4I8O7 MW 373.4
DM4I8O7 FM C19H27N5O3
DM4I8O7 IC InChI=1S/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)
DM4I8O7 CS CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
DM4I8O7 IK RHLJLALHBZGAFM-UHFFFAOYSA-N
DM4I8O7 IU 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one
DM4I8O7 CA CAS 80755-51-7
DM4I8O7 CB CHEBI:135576
DM4I8O7 DE Glaucoma/ocular hypertension
DM4PRFC ID DM4PRFC
DM4PRFC DN Bupivacaine
DM4PRFC HS Approved
DM4PRFC SN Anekain; Bloqueina; Bucaine; Bupivacaina; Bupivacainum; Bupivan; CBupivacaine; Carbostesin; DepoBupivacaine; Marcaina; Marcaine; Sensorcaine; Bupivacaine Carbonate; Bupivacaine HCL; Bupivacaine HCL KIT; Marcaine HCL; Marcaine Spinal; AH 250; Win 11318; Win 11318 HCl; Bucaine (TN); Bupivacaina [INN-Spanish]; Bupivacaine (INN); Bupivacaine Monohydrochloride, Monohydrate; Bupivacaine [INN:BAN]; Bupivacainum [INN-Latin]; DL-Bupivacaine; DUR-843; Marcain (TN); Marcaine (TN); Sensorcaine (TN); Sensorcaine-MPF; Sensorcaine-MPFSpinal; Transdur-Bupivacaine; Vivacaine (TN); Dl-1-Butyl-2',6'-pipecoloxylidide; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (inverted exclamation markA)-bupivacaine; 1-Butyl-2',6'-pipecoloxylidide; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC CP AstraZeneca
DM4PRFC TC Anesthetics
DM4PRFC DT Small molecular drug
DM4PRFC PC 2474
DM4PRFC MW 288.4
DM4PRFC FM C18H28N2O
DM4PRFC IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
DM4PRFC CS CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
DM4PRFC IK LEBVLXFERQHONN-UHFFFAOYSA-N
DM4PRFC IU 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM4PRFC CA CAS 38396-39-3
DM4PRFC CB CHEBI:77431
DM4PRFC DE Anaesthesia; Pain
DMPRI8G ID DMPRI8G
DMPRI8G DN Buprenorphine
DMPRI8G HS Approved
DMPRI8G SN Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M
DMPRI8G CP Reckitt; Colman
DMPRI8G TC Analgesics
DMPRI8G DT Small molecular drug
DMPRI8G PC 644073
DMPRI8G MW 467.6
DMPRI8G FM C29H41NO4
DMPRI8G IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
DMPRI8G CS C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMPRI8G IK RMRJXGBAOAMLHD-IHFGGWKQSA-N
DMPRI8G IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMPRI8G CA CAS 52485-79-7
DMPRI8G CB CHEBI:3216
DMPRI8G DE Pain; Migraine; Psychiatric disorder
DMBQEGT ID DMBQEGT
DMBQEGT DN Buprenorphine + naloxone
DMBQEGT HS Approved
DMBQEGT SN Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461
DMBQEGT CP Orexo
DMBQEGT DT Small molecular drug
DMBQEGT PC 6321408
DMBQEGT MW 467.6
DMBQEGT FM C29H41NO4
DMBQEGT IC InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29?/m1/s1
DMBQEGT CS C[C@]([C@H]1C[C@@]23CCC1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
DMBQEGT IK RMRJXGBAOAMLHD-MLLHIGKASA-N
DMBQEGT IU (1S,2S,6R,14R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMBQEGT CA CAS 52485-79-7
DMBQEGT DE Opioid dependence; Major depressive disorder
DM5PCS7 ID DM5PCS7
DM5PCS7 DN Bupropion
DM5PCS7 HS Approved
DM5PCS7 SN bupropion; Amfebutamone; 34911-55-2; Amfebutamon; 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one; amfebutamonum; Amfebutamona; (+-)-Bupropion; Wellbatrin; Bupropion [INN:BAN]; 34841-39-9; Elontril; Amfebutamonum [INN-Latin]; Zyban; Amfebutamona [INN-Spanish]; Bupropion SR; AMFEBUTAMONE HCl; alpha-(tert-butylamino)-m-chloropropiophenone; CHEMBL894; BRN 2101062; (+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone; CHEBI:3219; SNPPWIUOZRMYNY-UHFFFAOYSA-N; 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one; Amfebutamon; Amfebutamonum; Elont; Bupropion Hcl; Bupropion hydrocloride; Bupropion (INN); Bupropion (Old RN); Bupropion (USAN); Alpha-(tert-Butylamino)-m-chloropropiophenone; Alpha-(tert-butylamino)-m-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chloropropiophenone; (-)-2-(tert-Butylamino)-3'-chlorpropiophenon; 1-Propanone; 2-(Tert-Butylamino)-3'-chloropropiophenone
DM5PCS7 CP GlaxoSmithKline plc
DM5PCS7 DT Small molecular drug
DM5PCS7 PC 444
DM5PCS7 MW 239.74
DM5PCS7 FM C13H18ClNO
DM5PCS7 IC InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM5PCS7 CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DM5PCS7 IK SNPPWIUOZRMYNY-UHFFFAOYSA-N
DM5PCS7 IU 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DM5PCS7 CA CAS 34911-55-2
DM5PCS7 CB CHEBI:3219
DM5PCS7 DE Smoking dependence
DMKUOQV ID DMKUOQV
DMKUOQV DN Burosumab
DMKUOQV HS Approved
DMKUOQV SN Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29
DMKUOQV CP Ultragenyx Pharmaceutical/Kyowa Hakko Kirin
DMKUOQV DT Antibody
DMKUOQV DE X-linked hypophosphataemia
DMBS632 ID DMBS632
DMBS632 DN Buspirone
DMBS632 HS Approved
DMBS632 SN Ansial; Ansiced; Anxiron; Axoren; Bespar; Buspirona; Buspironum; Buspisal; Ansial (TN); Ansiced (TN); Anxiron (TN); Axoren (TN); Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum [INN-Latin]; Buspisal (TN); Gen-Buspirone; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN); Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
DMBS632 CP Bristol-Myers Squibb
DMBS632 TC Antianxiety Agents
DMBS632 DT Small molecular drug
DMBS632 PC 2477
DMBS632 MW 385.5
DMBS632 FM C21H31N5O2
DMBS632 IC InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
DMBS632 CS C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
DMBS632 IK QWCRAEMEVRGPNT-UHFFFAOYSA-N
DMBS632 IU 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
DMBS632 CA CAS 36505-84-7
DMBS632 CB CHEBI:3223
DMBS632 DE Anxiety disorder
DMXYJ9C ID DMXYJ9C
DMXYJ9C DN Busulfan
DMXYJ9C HS Approved
DMXYJ9C SN Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C CP GlaxoSmithKline
DMXYJ9C TC Anticancer Agents
DMXYJ9C DT Small molecular drug
DMXYJ9C PC 2478
DMXYJ9C MW 246.3
DMXYJ9C FM C6H14O6S2
DMXYJ9C IC InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
DMXYJ9C CS CS(=O)(=O)OCCCCOS(=O)(=O)C
DMXYJ9C IK COVZYZSDYWQREU-UHFFFAOYSA-N
DMXYJ9C IU 4-methylsulfonyloxybutyl methanesulfonate
DMXYJ9C CA CAS 55-98-1
DMXYJ9C CB CHEBI:28901
DMXYJ9C DE Myeloproliferative syndrome
DMC5AST ID DMC5AST
DMC5AST DN Butabarbital
DMC5AST HS Approved
DMC5AST SN Butabarb; Butabarbitone; Butalan; Butatab; Butatal; Buticaps; Butisol; Butrate; Medarsed; Nilox; Sarisol; Secbubarbital; Secbutabarbital; Secbutabarbitale; Secbutabarbitalum; Secbutobarbital; Secbutobarbitone; Unicelles; Butabarbital [USAN]; Butisol sodium; Secbutabarbital [INN]; Secbutabarbitale [DCIT]; Sodium butabarbital;Butabarbital (USP); Butabarbital (VAN); Butisol (TN); Sec-Butobarbitone; Secbutabarbitalum [INN-Latin]; 5-(butan-2-yl)-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylpropyl)barbiturate; 5-Ethyl-5-(1-methylpropyl)barbituric acid; 5-Ethyl-5-isobutylbarbituric acid; 5-SEC-BUTYL-5-ETHYL-BARBITURIC ACID; 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-sec-Butyl-5-ethylbarbituric acid; 5-sec-Butyl-5-ethylmalonyl urea; 5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
DMC5AST TC Antianxiety Agents
DMC5AST DT Small molecular drug
DMC5AST PC 2479
DMC5AST MW 212.25
DMC5AST FM C10H16N2O3
DMC5AST IC InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
DMC5AST CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMC5AST IK ZRIHAIZYIMGOAB-UHFFFAOYSA-N
DMC5AST IU 5-butan-2-yl-5-ethyl-1,3-diazinane-2,4,6-trione
DMC5AST CA CAS 125-40-6
DMC5AST CB CHEBI:3228
DMC5AST DE Insomnia
DM584TM ID DM584TM
DM584TM DN Butacaine
DM584TM HS Approved
DM584TM SN Butacaine sulfate; Butelline; Butyn; 149-15-5; Butacaine sulphate; Butacaine sulfate [USP]; UNII-PAU39W3CVB; EINECS 205-733-1; PAU39W3CVB; p-Aminobenzoyldibutylaminopropanol sulfate; Dibutylaminopropyl p-aminobenzoate sulfate; AI3-02405; 3'-Dibutylaminopropyl 4-aminobenzoate sulfate; 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester), sulfate (2:1) (salt); 3-(p-Aminobenzoxy)-1-di-N-butylaminopropane sulfate; 3-(Dibutylamino)-1-propanol p-aminobenzoate (ester) sulfate (2:1)
DM584TM DT Small molecular drug
DM584TM PC 2480
DM584TM MW 306.4
DM584TM FM C18H30N2O2
DM584TM IC InChI=1S/C18H30N2O2/c1-3-5-12-20(13-6-4-2)14-7-15-22-18(21)16-8-10-17(19)11-9-16/h8-11H,3-7,12-15,19H2,1-2H3
DM584TM CS CCCCN(CCCC)CCCOC(=O)C1=CC=C(C=C1)N
DM584TM IK HQFWVSGBVLEQGA-UHFFFAOYSA-N
DM584TM IU 3-(dibutylamino)propyl 4-aminobenzoate
DM584TM CA CAS 149-16-6
DM584TM CB CHEBI:94820
DM584TM DE Pain
DM9J04X ID DM9J04X
DM9J04X DN Butalbital
DM9J04X HS Approved
DM9J04X SN Alisobumal; Alisobumalum; Allylbarbital; Allylbarbitone; Allylisobutylbarbital; Allylisobutylbarbiturate; Butalbarbital;Butalbitale; Butalbitalum; Itobarbital; Profundal; Sandoptal; Tetrallobarbital; Butalbitale [DCIT]; Axocet (TN); Axotal (TN); Bucet (TN); Bupap (TN); Butalbital [USAN:INN]; Butalbitalum [INN-Latin]; Cephadyn (TN); Dolgic (TN); Esgic (TN); Fioricet (TN); Fiorinal (TN); Fiormor (TN); Fiortal (TN); Fortabs (TN); IBS-L0126512; Iso-butylallylbarbituric acid; Laniroif (TN); Phrenilin (TN); Phrenilin Forte (TN); Sandoptal (TN); Sedapap (TN); Butalbital (USP/INN); Esgic-Plus (TN); 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione; 5-Allyl-5-(2'-methyl-n-propyl) barbituric acid; 5-Allyl-5-(2-methylpropyl)barbituric acid; 5-Allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione; 5-Allyl-5-isobutylbarbituric acid
DM9J04X TC Analgesics
DM9J04X DT Small molecular drug
DM9J04X PC 2481
DM9J04X MW 224.26
DM9J04X FM C11H16N2O3
DM9J04X IC InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM9J04X CS CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
DM9J04X IK UZVHFVZFNXBMQJ-UHFFFAOYSA-N
DM9J04X IU 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM9J04X CA CAS 77-26-9
DM9J04X CB CHEBI:102524
DM9J04X DE Anxiety disorder; Headache
DMOJ4ZI ID DMOJ4ZI
DMOJ4ZI DN Butenafine
DMOJ4ZI HS Approved
DMOJ4ZI SN Butenafina; Butenafinum; Mentax; Butenafine HCL; Butenafine [INN]; Butenafine hydrochloride; KP 363; Butenafina [INN-Spanish]; Butenafine (INN); Butenafinum [INN-Latin]; Butop (TN); KP-363; Mentax (TN); N-4-tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride; N-p-tert-Butylbenzyl-N-methyl-1-naphthalenemethylamine; N-(p-tert-Butylbenzyl)-N-methyl-1-naphthalenemethylamine; 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine; 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
DMOJ4ZI CP Schering-Plough
DMOJ4ZI TC Antifungal Agents
DMOJ4ZI DT Small molecular drug
DMOJ4ZI PC 2484
DMOJ4ZI MW 317.5
DMOJ4ZI FM C23H27N
DMOJ4ZI IC InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3
DMOJ4ZI CS CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
DMOJ4ZI IK ABJKWBDEJIDSJZ-UHFFFAOYSA-N
DMOJ4ZI IU 1-(4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
DMOJ4ZI CA CAS 101828-21-1
DMOJ4ZI CB CHEBI:3238
DMOJ4ZI DE Dermatologic infection
DM7JHX0 ID DM7JHX0
DM7JHX0 DN Butethal
DM7JHX0 HS Approved
DM7JHX0 SN Aethylbutylbarbitursaeure; Budorm; Butabarbitol; Butobarbital; Butobarbitalum; Butobarbitone; Butobarbitural; Etoval; Hyperbutal; Longanoct; Meonal; Monodorm; Neonal; Sonerile; Soneryl; Butobarbital [BAN]; Butobarbital (BAN); Neonal (TN); Butyl,5-ethylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-butyl-5-ethyl-(9CI); 5-BUTYL-5-ETHYLBARBITURIC ACID; 5-Butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-butylbarbituric acid; 5-Ethyl-5-n-butylbarbituric acid; 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0 TC Hypnotics and Sedatives
DM7JHX0 DT Small molecular drug
DM7JHX0 PC 6473
DM7JHX0 MW 212.25
DM7JHX0 FM C10H16N2O3
DM7JHX0 IC InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)
DM7JHX0 CS CCCCC1(C(=O)NC(=O)NC1=O)CC
DM7JHX0 IK STDBAQMTJLUMFW-UHFFFAOYSA-N
DM7JHX0 IU 5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
DM7JHX0 CA CAS 77-28-1
DM7JHX0 CB CHEBI:134884
DM7JHX0 DE Insomnia
DM8SY60 ID DM8SY60
DM8SY60 DN Butoconazole
DM8SY60 HS Approved
DM8SY60 SN Butaconazole; Butoconazol; Butoconazolum; Femstat; Gynofort; Duplicate RN for parent cpd; RS 35887; Butoconazol [INN-Spanish]; Butoconazole (INN); Butoconazole [INN:BAN]; Butoconazolum [INN-Latin]; Gynofort (TN); RS 35887-10-3; (+-)-1-[4-(4-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole; (+/-)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole; (-)-1-((4-(p-Chlorophenyl)-2-((2,6-dichlorophenyl)thio)imidazole; 1-(4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl)-1H-imidazole; 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole; 1-{4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl}-1H-imidazole; 1H-Imidazole; 1H-Imidazole, 1-(4-(4-chlorophenyl)-2-((2,6-dichlorophenyl)thio)butyl)-, nitrate
DM8SY60 CP Roche Palo Alto Llc
DM8SY60 TC Antifungal Agents
DM8SY60 DT Small molecular drug
DM8SY60 PC 47472
DM8SY60 MW 411.8
DM8SY60 FM C19H17Cl3N2S
DM8SY60 IC InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2
DM8SY60 CS C1=CC(=C(C(=C1)Cl)SC(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)Cl
DM8SY60 IK SWLMUYACZKCSHZ-UHFFFAOYSA-N
DM8SY60 IU 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)sulfanylbutyl]imidazole
DM8SY60 CA CAS 64872-76-0
DM8SY60 CB CHEBI:3240
DM8SY60 DE Candidiasis
DM5KYPJ ID DM5KYPJ
DM5KYPJ DN Butorphanol
DM5KYPJ HS Approved
DM5KYPJ SN Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
DM5KYPJ CP Apotex Inc
DM5KYPJ TC Analgesics
DM5KYPJ DT Small molecular drug
DM5KYPJ PC 5361092
DM5KYPJ MW 327.5
DM5KYPJ FM C21H29NO2
DM5KYPJ IC InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
DM5KYPJ CS C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
DM5KYPJ IK IFKLAQQSCNILHL-QHAWAJNXSA-N
DM5KYPJ IU (1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
DM5KYPJ CA CAS 42408-82-2
DM5KYPJ CB CHEBI:3242
DM5KYPJ DE Pain
DMZKXB7 ID DMZKXB7
DMZKXB7 DN Butylscopolamine
DMZKXB7 HS Approved
DMZKXB7 SN AC1LCV8Y
DMZKXB7 DT Small molecular drug
DMZKXB7 PC 160883
DMZKXB7 MW 360.5
DMZKXB7 FM C21H30NO4+
DMZKXB7 IC InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15?,16-,17-,18+,19-,20+,22?/m1/s1
DMZKXB7 CS CCCC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DMZKXB7 IK YBCNXCRZPWQOBR-MWGADRMYSA-N
DMZKXB7 IU [(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMZKXB7 CA CAS 7182-53-8
DMZKXB7 CB CHEBI:145701
DMZKXB7 DE Dysmenorrhea
DMPAZHC ID DMPAZHC
DMPAZHC DN Cabazitaxel
DMPAZHC HS Approved
DMPAZHC SN Jevtana; Taxoid XRP6258; Jevtana (TN)
DMPAZHC CP Sanofi-Aventis
DMPAZHC DT Small molecular drug
DMPAZHC PC 9854073
DMPAZHC MW 835.9
DMPAZHC FM C45H57NO14
DMPAZHC IC InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
DMPAZHC CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
DMPAZHC IK BMQGVNUXMIRLCK-OAGWZNDDSA-N
DMPAZHC IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMPAZHC CA CAS 183133-96-2
DMPAZHC CB CHEBI:63584
DMPAZHC DE Breast cancer; Solid tumour/cancer
DMQ4HIN ID DMQ4HIN
DMQ4HIN DN Cabergoline
DMQ4HIN HS Approved
DMQ4HIN SN Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
DMQ4HIN CP Pfizer Pharmaceuticals
DMQ4HIN TC Anticancer Agents
DMQ4HIN DT Small molecular drug
DMQ4HIN PC 54746
DMQ4HIN MW 451.6
DMQ4HIN FM C26H37N5O2
DMQ4HIN IC InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
DMQ4HIN CS CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C
DMQ4HIN IK KORNTPPJEAJQIU-KJXAQDMKSA-N
DMQ4HIN IU (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMQ4HIN CA CAS 81409-90-7
DMQ4HIN CB CHEBI:3286
DMQ4HIN DE Hyperprolactinaemia
DMIYDT4 ID DMIYDT4
DMIYDT4 DN Cabozantinib
DMIYDT4 HS Approved
DMIYDT4 SN Cabometyx; Cometriq
DMIYDT4 CP Exelixis
DMIYDT4 DT Small molecular drug
DMIYDT4 PC 25102847
DMIYDT4 MW 501.5
DMIYDT4 FM C28H24FN3O5
DMIYDT4 IC InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
DMIYDT4 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
DMIYDT4 IK ONIQOQHATWINJY-UHFFFAOYSA-N
DMIYDT4 IU 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMIYDT4 CA CAS 849217-68-1
DMIYDT4 CB CHEBI:72317
DMIYDT4 DE Thyroid cancer; Ovarian cancer
DMKBJWP ID DMKBJWP
DMKBJWP DN Caffeine
DMKBJWP HS Approved
DMKBJWP SN CFF; Cafamil; Cafecon; Cafeina; Cafeine; Caffedrine; Caffein; Caffeina; Caffenium; Caffine; Cafipel; Coffein; Coffeine; Coffeinum; DHCplus; Dasin; Dexitac; Diurex; Durvitan; Enerjets; Ercatab; Guaranine; Hycomine; Kofein; Koffein; Mateina; Methyltheobromide; Methyltheobromine; Miudol; Nodaca; Organex; Percutafeine; Phensal; Stim; Teina; Thein; Theine; Tirend; Vivarin; Anacin Maximum Strength; Anhydrous caffeine; Caffedrine Caplets; Caffeina [Italian]; Caffeine Pure; Caffeine solution; Coffein [German]; Coffeinum N; Coffeinum Purrum; Component of Cafergot; DHC Plus; Dexitac Stay Alert Stimulant; Eldiatric C; GlaxoSmithKline Brand of Caffeine; Hycomine Compound; Keep Alert; Kofein [Czech]; Koffein [German]; Merck dura Brand of Caffeine; Methylxanthine theophylline; Midol Maximum Strength; Monomethyl derivative of Theophylline; Natural Caffeinum; Nix Nap; No Doz; Nodoz Maximum Strength Caplets; Passauer Brand of Caffeine; Percoffedrinol N; Pierre Fabre Brand of Caffeine; Quick Pep; Republic Drug Brand of Caffeine; Seid Brand of Caffeine; Theobromine Me; Theophylline Me; C 0750; Propoxyphene Compound 65; SK 65 Compound; TNP00310; Thompson Brand 1 of Caffeine; Thompson Brand 2 of Caffeine; Alert-pep; Anhydrous caffeine (JP15); Anhydrous caffeine (TN); Berlin-Chemie Brand of Caffeine; Bristol-Myers Squibb Brand of Caffeine; Cafcit (TN); Caffeine (USP); Caffeine (natural); Caffeine [BAN:JAN]; Caffeine, Monohydrate; Caffeine, anhydrous; Caffeine, synthetic; No-Doz; Pep-Back; Propoxyphene Compound-65; Quick-Pep; Refresh'n; SK-65 Compound; Tri-Aqua; Ultra Pep-Back; Wake-Up; CU-01000012617-3; P-A-C Analgesic Tablets; Theophylline, 7-methyl; Xanthine, 1,3,7-trimethyl; 1,3,7-Trimethyl-2,6-dioxopurine; 1,3,7-Trimethylpurine-2,6-dione; 1,3,7-Trimethylxanthine; 1-3-7-TRIMETHYLXANTHINE; 1-methyltheobromine; 3,7-dihydro-1,3,7-trimethyl-1H-purine; 7-Methyltheophylline
DMKBJWP CP Ben Venue Laboratories
DMKBJWP TC Antihypertensive Agents
DMKBJWP DT Small molecular drug
DMKBJWP PC 2519
DMKBJWP MW 194.19
DMKBJWP FM C8H10N4O2
DMKBJWP IC InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DMKBJWP CS CN1C=NC2=C1C(=O)N(C(=O)N2C)C
DMKBJWP IK RYYVLZVUVIJVGH-UHFFFAOYSA-N
DMKBJWP IU 1,3,7-trimethylpurine-2,6-dione
DMKBJWP CA CAS 58-08-2
DMKBJWP CB CHEBI:27732
DMKBJWP DE Orthostatic hypotension
DMQZBXI ID DMQZBXI
DMQZBXI DN Calaspargase pegol
DMQZBXI HS Approved
DMQZBXI SN UNII-T9FVH03HMZ; T9FVH03HMZ; Calaspargase pegol [USAN:INN]; EZN-2285
DMQZBXI CP Servier
DMQZBXI DT Antibody
DMQZBXI DE Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia
DMN4CV5 ID DMN4CV5
DMN4CV5 DN Calcidiol
DMN4CV5 HS Approved
DMN4CV5 SN Calcifediolum; Calcifidiol; Delakmin; VDY; Calcifediol anhydrous; BML2-E02; Calcifediolum [INN-Latin]; Ro 8-8892; U-32070E; (1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 25(OH)D3; 25-(OH)Vitamin D3; 25-Hydroxycholecalciferol; 25-Hydroxycholecalciferol (Calcifediol); 25-Hydroxycholescalciferol; 25-Hydroxyvitamin D; 25-Hydroxyvitamin D3 monohydrate; 25-hydroxyvitamin D3; 3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL; 5,6-cis-25-Hydroxyvitamin D3; 5,6-trans-25-Hydroxycholescalciferol; 5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol; 9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
DMN4CV5 CP United Research Laboratories
DMN4CV5 TC Vitamins
DMN4CV5 DT Small molecular drug
DMN4CV5 PC 5283731
DMN4CV5 MW 400.6
DMN4CV5 FM C27H44O2
DMN4CV5 IC InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
DMN4CV5 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMN4CV5 IK JWUBBDSIWDLEOM-DTOXIADCSA-N
DMN4CV5 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMN4CV5 CA CAS 19356-17-3
DMN4CV5 CB CHEBI:17933
DMN4CV5 DE Vitamin D deficiency
DM03CP7 ID DM03CP7
DM03CP7 DN Calcipotriol
DM03CP7 HS Approved
DM03CP7 SN Calcipotriene; Divonex; Dovonex; BMS-181161; Daivonex (TN); Dovonex (TN); MC-903; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1S,5Z,7Z,17ALPHA,22E)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10,22-TETRAENE-1,3,24-TRIOL; 1-ALPHA,24S-(OH)2-22-ENE-26,27-DEHYDROVITAMIN D3
DM03CP7 CP LEO Pharma Inc
DM03CP7 TC Antipsoriatic Agents
DM03CP7 DT Small molecular drug
DM03CP7 PC 5288783
DM03CP7 MW 412.6
DM03CP7 FM C27H40O3
DM03CP7 IC InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
DM03CP7 CS C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DM03CP7 IK LWQQLNNNIPYSNX-UROSTWAQSA-N
DM03CP7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM03CP7 CA CAS 112965-21-6
DM03CP7 CB CHEBI:50749
DM03CP7 DE Psoriasis vulgaris
DM0N9WA ID DM0N9WA
DM0N9WA DN Calcitonin Human
DM0N9WA HS Approved
DM0N9WA CP Novartis Pharmaceuticals Corp
DM0N9WA TC Anticancer Agents
DM0N9WA PC 45055432
DM0N9WA MW 3417.9
DM0N9WA FM C151H226N40O45S3
DM0N9WA IC InChI=1S/C151H226N40O45S3/c1-17-75(8)118(144(229)163-67-114(205)183-117(74(6)7)143(228)162-64-112(203)165-77(10)150(235)190-50-29-38-106(190)124(158)209)185-125(210)76(9)166-145(230)120(79(12)194)186-131(216)92(45-47-109(155)200)170-142(227)107-39-30-51-191(107)151(236)103(58-85-35-25-20-26-36-85)180-148(233)122(81(14)196)188-139(224)99(59-87-63-159-71-164-87)176-133(218)96(55-83-31-21-18-22-32-83)174-128(213)90(37-27-28-49-152)168-136(221)101(61-111(157)202)177-134(219)97(56-84-33-23-19-24-34-84)175-137(222)102(62-116(207)208)178-129(214)91(44-46-108(154)199)171-147(232)121(80(13)195)187-138(223)98(57-86-40-42-88(198)43-41-86)179-146(231)119(78(11)193)184-115(206)66-161-127(212)94(53-72(2)3)172-130(215)93(48-52-237-16)169-141(226)105-70-239-238-69-89(153)126(211)160-65-113(204)167-100(60-110(156)201)135(220)173-95(54-73(4)5)132(217)181-104(68-192)140(225)189-123(82(15)197)149(234)182-105/h18-26,31-36,40-43,63,71-82,89-107,117-123,192-198H,17,27-30,37-39,44-62,64-70,152-153H2,1-16H3,(H2,154,199)(H2,155,200)(H2,156,201)(H2,157,202)(H2,158,209)(H,159,164)(H,160,211)(H,161,212)(H,162,228)(H,163,229)(H,165,203)(H,166,230)(H,167,204)(H,168,221)(H,169,226)(H,170,227)(H,171,232)(H,172,215)(H,173,220)(H,174,213)(H,175,222)(H,176,218)(H,177,219)(H,178,214)(H,179,231)(H,180,233)(H,181,217)(H,182,234)(H,183,205)(H,184,206)(H,185,210)(H,186,216)(H,187,223)(H,188,224)(H,189,225)(H,207,208)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,117-,118-,119-,120-,121-,122-,123-/m0/s1
DM0N9WA CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]8CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)CO)CC(C)C)CC(=O)N)N
DM0N9WA IK LDVRMNJZLWXJPL-JKQNMTHDSA-N
DM0N9WA IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10-(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM0N9WA CB CHEBI:135973
DM0N9WA DE Postmenopausal osteoporosis; Pain; Paget's disease
DM8ZVJ7 ID DM8ZVJ7
DM8ZVJ7 DN Calcitriol
DM8ZVJ7 HS Approved
DM8ZVJ7 SN calcitriol; Rocaltrol; 32222-06-3; Calcijex; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; Soltriol; 1alpha,25-Dihydroxycholecalciferol; Calcitriolum; Dihydroxyvitamin D3; 1,25-DHCC; 1,25-Dihydroxyvitamin D; Vectical; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1alpha,25-Dihydroxyvitamin D; 1-alpha,25-Dihydroxyvitamin D3; Calcitriolum [INN-Latin]; UNII-FXC9231JVH; 1alpha,25(OH)2D3; DN-101; 1,25-Dihydroxycholecaliferol; CCRIS 5522; Ro 21-5535; HSDB 3482; 1-alpha,25-Dihydroxycholecalciferol; EINECS 250-963-8; DN 101; Calcitriol (chemotherapy-induced alopecia); Calcitriol (chemotherapy-induced alopecia), Cytotech Labs; Calcitriol (API-31543, drug-induced alopecia), Cytotech Labs; 1alpha,25 dihydroxyvitamin D(3)
DM8ZVJ7 CP Cytotech Labs LLC
DM8ZVJ7 DT Small molecular drug
DM8ZVJ7 PC 5280453
DM8ZVJ7 MW 416.6
DM8ZVJ7 FM C27H44O3
DM8ZVJ7 IC InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1
DM8ZVJ7 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM8ZVJ7 IK GMRQFYUYWCNGIN-NKMMMXOESA-N
DM8ZVJ7 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM8ZVJ7 CA CAS 32222-06-3
DM8ZVJ7 CB CHEBI:17823
DM8ZVJ7 DE Congenital alopecia
DM3W15N ID DM3W15N
DM3W15N DN Calcium carbimide
DM3W15N HS Approved
DM3W15N SN Nitrolime; Alzodef; Aero cyanamid granular; USAF CY-2; Aero cyanamid special grade; Nitrolim; Cyanamid; Calcium cyanamid; Lime Nitroget; Cyanamid granular; NCI-C02937; CY-L 500; Cyanamid special grade; UN 1403, Nitrolime; WLN: CA NCN; NSC7078; NSC-7078
DM3W15N DT Small molecular drug
DM3W15N PC 56955933
DM3W15N MW 80.1
DM3W15N FM CCaN2
DM3W15N IC InChI=1S/CN2.Ca/c2-1-3;/q-2;+2
DM3W15N CS C(=[N-])=[N-].[Ca+2]
DM3W15N IK MYFXBBAEXORJNB-UHFFFAOYSA-N
DM3W15N IU calcium;azanidylidenemethylideneazanide
DM3W15N CA CAS 156-62-7
DM3W15N CB CHEBI:64301
DM3W15N DE Alcohol dependence
DMJ3CFY ID DMJ3CFY
DMJ3CFY DN Calcium phosphate dihydrate
DMJ3CFY HS Approved
DMJ3CFY SN Calcium phosphate dihydrate
DMJ3CFY DT Small molecular drug
DMJ3CFY PC 22340838
DMJ3CFY MW 346.204
DMJ3CFY FM Ca3H4O10P2
DMJ3CFY IC InChI=1S/3Ca.2H3O4P.2H2O/c;;;2*1-5(2,3)4;;/h;;;2*(H3,1,2,3,4);2*1H2/q3*+2;;;;/p-6
DMJ3CFY CS O.O.[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMJ3CFY IK WKMXOPXIVBEXRR-UHFFFAOYSA-H
DMJ3CFY IU tricalcium;diphosphate;dihydrate
DMJ3CFY DE Dental Caries
DMWIO46 ID DMWIO46
DMWIO46 DN Camphor
DMWIO46 HS Approved
DMWIO46 SN camphor; 76-22-2; 2-Camphanone; 2-Bornanone; DL-Camphor; (+)-Camphor; l-(-)-Camphor; (+/-)-Camphor; Root bark oil; 1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one; Bornan-2-one; Alphanon; Kampfer; Gum camphor; Spirit of camphor; Formosa camphor; Laurel camphor; 2-Camphonone; Matricaria camphor; Camphor, synthetic; Bornane, 2-oxo-; 1,7,7-Trimethylnorcamphor; Root bark spirit; 2-Keto-1,7,7-trimethylnorcamphane; DL-Bornan-2-one; D-(+)-Camphor; Norcamphor, 1,7,7-trimethyl-; 21368-68-3; Camphor, (1R,4R)-(+)-; Bicyclo[2.2.1]heptan-2-one, 1,7,7-tri
DMWIO46 DT Small molecular drug
DMWIO46 PC 2537
DMWIO46 MW 152.23
DMWIO46 FM C10H16O
DMWIO46 IC InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3
DMWIO46 CS CC1(C2CCC1(C(=O)C2)C)C
DMWIO46 IK DSSYKIVIOFKYAU-UHFFFAOYSA-N
DMWIO46 IU 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
DMWIO46 CA CAS 76-22-2
DMWIO46 CB CHEBI:36773
DMWIO46 DE Acute or chronic pain
DMFRM1I ID DMFRM1I
DMFRM1I DN Canagliflozin
DMFRM1I HS Approved
DMFRM1I SN 842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0
DMFRM1I CP Johnson & Johnson
DMFRM1I DT Small molecular drug
DMFRM1I PC 24812758
DMFRM1I MW 444.5
DMFRM1I FM C24H25FO5S
DMFRM1I IC InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
DMFRM1I CS CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
DMFRM1I IK XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
DMFRM1I IU (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMFRM1I CA CAS 842133-18-0
DMFRM1I CB CHEBI:73274
DMFRM1I DE Type-2 diabetes; Diabetic nephropathy; Type-1 diabetes
DM8HLO5 ID DM8HLO5
DM8HLO5 DN Canakinumab
DM8HLO5 HS Approved
DM8HLO5 SN Ilaris (TN)
DM8HLO5 CP Novartis
DM8HLO5 DT Antibody
DM8HLO5 SQ 8836_H|canakinumab|Homo sapiens||H-GAMMA-1 (VH(1-118)+CH1(119-216)+HINGE-REGION(217-231)+CH2(232-341)+CH3(342-448))|||||||448||||MW 49253.6|MW 49253.6|: QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >8836_L|canakinumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23357.9|MW 23357.9|QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLEIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HLO5 DE Vasculitis; Urticaria; Rheumatoid arthritis; Cryopyrin-associated periodic syndromes
DMRK8OT ID DMRK8OT
DMRK8OT DN Candesartan
DMRK8OT HS Approved
DMRK8OT SN candesartan; 139481-59-7; Blopress; Ratacand; CV-11974; 1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid; CV 11974; UNII-S8Q36MD2XX; 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid; CHEMBL1016; S8Q36MD2XX; 2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid; CHEBI:3347; C24H20N6O3; 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid; NCGC00167474-01; AK-57139; Blopress; Candesartan [BAN]; CV11974; Amias (TN); Atacand (TN); Blopress (TN); Candesartan [USAN:INN]; KS-5003; Ratacand (TN); Candesartan (USAN/INN); Atacand, Blopress, Amias, Ratacand,Candesartan; 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid; 2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid; 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole; [3H]candesartan
DMRK8OT CP AstraZeneca
DMRK8OT TC Antihypertensive Agents
DMRK8OT DT Small molecular drug
DMRK8OT PC 2541
DMRK8OT MW 440.5
DMRK8OT FM C24H20N6O3
DMRK8OT IC InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
DMRK8OT CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMRK8OT IK HTQMVQVXFRQIKW-UHFFFAOYSA-N
DMRK8OT IU 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMRK8OT CA CAS 139481-59-7
DMRK8OT CB CHEBI:3347
DMRK8OT DE Hypertension
DMNZSC1 ID DMNZSC1
DMNZSC1 DN Candicidin
DMNZSC1 HS Approved
DMNZSC1 SN (23E,25E,27E,29E,31E,33E,35E)-22-(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1 TC Antibiotics
DMNZSC1 DT Small molecular drug
DMNZSC1 PC 10079874
DMNZSC1 MW 1109.3
DMNZSC1 FM C59H84N2O18
DMNZSC1 IC InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1
DMNZSC1 CS C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\\2CC(C(C(CC(=O)CC(CC(CC(CC(=O)CCCC(=O)CC(=O)OC(C(/C=C/C=C/C=C/C=C/C=C/C=C/C=C2)C)C(C)CC(C)C(CC(=O)C3=CC=C(C=C3)N)O)O)O)O)O)C(=O)O)O)O)N)O
DMNZSC1 IK OPGSFDUODIJJGF-JBUZINEHSA-N
DMNZSC1 IU (23E,25E,27E,29E,31E,33E,35E)-22-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-38-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-10,12,14,18,20-pentahydroxy-37-methyl-2,4,8,16-tetraoxo-1-oxacyclooctatriaconta-23,25,27,29,31,33,35-heptaene-19-carboxylic acid
DMNZSC1 CA CAS 1403-17-4
DMNZSC1 CB CHEBI:3349
DMNZSC1 DE Bacterial infection
DM8JRH0 ID DM8JRH0
DM8JRH0 DN Cangrelor
DM8JRH0 HS Approved
DM8JRH0 SN Cangrelor; 163706-06-7; Kengreal; UNII-6AQ1Y404U7; AR-C69931XX; CHEMBL334966; 6AQ1Y404U7; kengrexal; 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine; 5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)
DM8JRH0 CP The Medicines Company
DM8JRH0 DT Small molecular drug
DM8JRH0 PC 9854012
DM8JRH0 MW 776.4
DM8JRH0 FM C17H25Cl2F3N5O12P3S2
DM8JRH0 IC InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1
DM8JRH0 CS CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O
DM8JRH0 IK PAEBIVWUMLRPSK-IDTAVKCVSA-N
DM8JRH0 IU [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
DM8JRH0 CA CAS 163706-06-7
DM8JRH0 CB CHEBI:90841
DM8JRH0 DE Thrombosis
DM0659E ID DM0659E
DM0659E DN Cannabidiol
DM0659E HS Approved
DM0659E SN cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E CP GW Pharmaceuticals
DM0659E DT Small molecular drug
DM0659E PC 644019
DM0659E MW 314.5
DM0659E FM C21H30O2
DM0659E IC InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
DM0659E CS CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
DM0659E IK QHMBSVQNZZTUGM-ZWKOTPCHSA-N
DM0659E IU 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DM0659E CA CAS 13956-29-1
DM0659E CB CHEBI:69478
DM0659E DE LennoxGastaut syndrome; Dravet syndrome; Epilepsy; Infantile spasm
DMBP5N3 ID DMBP5N3
DMBP5N3 DN Cantharidin
DMBP5N3 HS Approved
DMBP5N3 SN DSSTox_CID_21752; DSSTox_RID_79835; DSSTox_GSID_41752; CAS-56-25-7; NCGC00016247-01; Spectrum_001114; SpecPlus_000537; Spectrum4_000920; Spectrum2_000630; Prestwick0_000885; Spectrum3_000621; Prestwick1_000885; Spectrum5_001618; Prestwick2_000885; KBioSS_001594; KBioGR_001420; BSPBio_002182; MLS002153505; SCHEMBL152261; DivK1c_006633; SPBio_002889; SPBio_000600; CHEMBL299846; DTXSID7041752; KBio2_006730; KBio3_001682; KBio2_004162; KBio2_001594; KBio1_001577; MolPort-003-665-556; HMS1570B12; Tox21_110326; CCG-39927; Tox21_110326_1
DMBP5N3 DT Small molecular drug
DMBP5N3 PC 5944
DMBP5N3 MW 196.2
DMBP5N3 FM C10H12O4
DMBP5N3 IC InChI=1S/C10H12O4/c1-9-5-3-4-6(13-5)10(9,2)8(12)14-7(9)11/h5-6H,3-4H2,1-2H3/t5-,6+,9+,10-
DMBP5N3 CS C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3
DMBP5N3 IK DHZBEENLJMYSHQ-XCVPVQRUSA-N
DMBP5N3 IU (1S,2R,6S,7R)-2,6-dimethyl-4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
DMBP5N3 CA CAS 56-25-7
DMBP5N3 CB CHEBI:64213
DMBP5N3 DE Molluscum contagiosum infection
DMTS85L ID DMTS85L
DMTS85L DN Capecitabine
DMTS85L HS Approved
DMTS85L SN Capecitabin; Capecitabina; Capecitabinum; Capecitibine; Capiibine; Caxeta; Xabine; Xeloda; Capecitabine [USAN]; R340;R-340; RG-340; Ro 09-1978; Xeloda (TN); Ro 09-1978/000; Ro-09-1978; Xeloda, Captabin, Capecitabine; Capecitabine (JAN/USAN/INN); Ro-09-1978/000; N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine; Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate; Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate; Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester; Pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate; (1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester; 5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine; 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine; Capecitabine (Fluoropyrimidine)
DMTS85L CP Roche
DMTS85L TC Anticancer Agents
DMTS85L DT Small molecular drug
DMTS85L PC 60953
DMTS85L MW 359.35
DMTS85L FM C15H22FN3O6
DMTS85L IC InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
DMTS85L CS CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O
DMTS85L IK GAGWJHPBXLXJQN-UORFTKCHSA-N
DMTS85L IU pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
DMTS85L CA CAS 154361-50-9
DMTS85L CB CHEBI:31348
DMTS85L DE Colorectal cancer; Breast cancer
DMPUKA7 ID DMPUKA7
DMPUKA7 DN Caplacizumab
DMPUKA7 HS Approved
DMPUKA7 DT Antibody
DMPUKA7 DE Thrombotic thrombocytopenic purpura
DMYCXKL ID DMYCXKL
DMYCXKL DN Capmatinib
DMYCXKL HS Approved
DMYCXKL SN 1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O
DMYCXKL CP Incyte
DMYCXKL DT Small molecular drug
DMYCXKL PC 25145656
DMYCXKL MW 412.4
DMYCXKL FM C23H17FN6O
DMYCXKL IC InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
DMYCXKL CS CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
DMYCXKL IK LIOLIMKSCNQPLV-UHFFFAOYSA-N
DMYCXKL IU 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
DMYCXKL CA CAS 1029712-80-8
DMYCXKL DE Hepatocellular carcinoma; Recurrent glioblastoma; Non-small-cell lung cancer
DMNZBRY ID DMNZBRY
DMNZBRY DN Capreomycin
DMNZBRY HS Approved
DMNZBRY SN Capreomycin Sulfate Standard; Capreomycin sulphate; Caprocin (Disulfate); Ogostal (Disulfate); (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY TC Antibiotics
DMNZBRY DT Small molecular drug
DMNZBRY PC 3000502
DMNZBRY MW 1321.4
DMNZBRY FM C50H88N28O15
DMNZBRY IC InChI=1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1
DMNZBRY CS C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N
DMNZBRY IK VCOPTHOUUNAYKQ-WBTCAYNUSA-N
DMNZBRY IU (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
DMNZBRY CA CAS 11003-38-6
DMNZBRY DE Bacterial infection; Mycobacterium infection
DM346QI ID DM346QI
DM346QI DN Capreomycin Sulfate
DM346QI HS Approved
DM346QI SN Capastat Sulfate
DM346QI CP Akorn Inc
DM346QI DE Tuberculosis
DMHERIJ ID DMHERIJ
DMHERIJ DN Capromab
DMHERIJ HS Approved
DMHERIJ SN Prostascint (TN)
DMHERIJ TC Imaging Agents
DMHERIJ DT Antibody
DMHERIJ DE Prostate cancer
DMGMF6V ID DMGMF6V
DMGMF6V DN Capsaicin
DMGMF6V HS Approved
DMGMF6V SN Capsaicin (transdermal patch formulation, neuropathic pain)
DMGMF6V CP Samyang Corp
DMGMF6V DT Small molecular drug
DMGMF6V PC 1548943
DMGMF6V MW 305.4
DMGMF6V FM C18H27NO3
DMGMF6V IC InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+
DMGMF6V CS CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
DMGMF6V IK YKPUWZUDDOIDPM-SOFGYWHQSA-N
DMGMF6V IU (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
DMGMF6V CA CAS 404-86-4
DMGMF6V CB CHEBI:3374
DMGMF6V DE Neuropathic pain
DM458UM ID DM458UM
DM458UM DN Captopril
DM458UM HS Approved
DM458UM SN Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline
DM458UM CP Bristol-Myers Squibb
DM458UM TC Antihypertensive Agents
DM458UM DT Small molecular drug
DM458UM PC 44093
DM458UM MW 217.29
DM458UM FM C9H15NO3S
DM458UM IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DM458UM CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DM458UM IK FAKRSMQSSFJEIM-RQJHMYQMSA-N
DM458UM IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DM458UM CA CAS 62571-86-2
DM458UM CB CHEBI:3380
DM458UM DE Hypertension
DMX9K8F ID DMX9K8F
DMX9K8F DN Carbachol
DMX9K8F HS Approved
DMX9K8F SN Carbach; Carbacholin; Carbacholine; Carbacholinum; Carbacholum; Carbacol; Carbacolina; Carbacolo; Carbamiotin; Carbamoylcholine; Carbastat; Carbochol; Carbocholin; Carbocholine; Carbyl; Carcholin; Coletyl; Doryl; Jestryl; Karbachol; Lentin; Lentine; Miostat; Moryl; Rilentol; Vasoperif; CARBACHOL CHLORIDE; Carbachol hydrochloride; Carbacholine chloride; Carbacholini chloridum; Carbacholinium chloratum; Carbacholum chloratum; Carbacolo [DCIT]; Carbaminocholine chloride; Carbaminoylcholine chloride; Carbamoylcholine chloride; Carbamylcholine chloride; Choline carbamate chloride; Choline chloride carbamate; Choline chlorine carbamate; Isopto Carbachol; Karbachol [Czech]; Karbamoylcholin chlorid; Karbamoylcholin chlorid [Czech]; Lentine [French]; Mistura C; C 4382; TL 457; C-1770; Carbacholum [INN-Latin]; Carbacol [INN-Spanish]; Carbamic acid, ester with choline chloride; Carbamoylcholine-hydrochloride; Carbastat (TN); Carboptic (TN); Choline chloride, carbamate; Doryl (VAN); Doryl (pharmaceutical); Gamma-Carbamoyl choline chloride; Isopto Carbachol (TN); Miostat (TN); Carbachol [INN:BAN:JAN]; Choline, chloride carbamate(ester); Choline, chloride, carbamate; P. V. Carbachol; Carbachol (JAN/USP/INN); Choline, chloride, carbamate, hydrochloride; Ethanaminium, 2-(aminocarbonyl)oxy-N,N,N-trimethyl-, chloride; Ethanaminium, 2-[(aminocarbonyl)oxy]-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride; Ethanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl-, chloride (1:1); (2-Carbamoyloxy-ethyl)-trimethyl-ammonium; (2-Carbamoyloxy-ethyl)-trimethyl-ammonium(Carbachol); (2-Carbamoyloxyethyl)trimethylammonium chloride; (2-Hydroxyethyl)trimethyl ammonium chloride carbamate; (2-Hydroxyethyl)trimethylammonium chloride carbamate; (carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride; 2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride; 2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride; 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride; 2-carbamoyloxyethyl(trimethyl)azanium chloride
DMX9K8F CP Norvatis Phamaceuticals Corporation
DMX9K8F TC Cardiotonic Agents
DMX9K8F DT Small molecular drug
DMX9K8F PC 5831
DMX9K8F MW 182.65
DMX9K8F FM C6H15ClN2O2
DMX9K8F IC InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
DMX9K8F CS C[N+](C)(C)CCOC(=O)N.[Cl-]
DMX9K8F IK AIXAANGOTKPUOY-UHFFFAOYSA-N
DMX9K8F IU 2-carbamoyloxyethyl(trimethyl)azanium;chloride
DMX9K8F CA CAS 51-83-2
DMX9K8F CB CHEBI:3385
DMX9K8F DE Glaucoma/ocular hypertension
DMZOLBI ID DMZOLBI
DMZOLBI DN Carbamazepine
DMZOLBI HS Approved
DMZOLBI SN Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
DMZOLBI CP Lundbeck Inc
DMZOLBI DT Small molecular drug
DMZOLBI PC 2554
DMZOLBI MW 236.27
DMZOLBI FM C15H12N2O
DMZOLBI IC InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
DMZOLBI CS C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
DMZOLBI IK FFGPTBGBLSHEPO-UHFFFAOYSA-N
DMZOLBI IU benzo[b][1]benzazepine-11-carboxamide
DMZOLBI CA CAS 298-46-4
DMZOLBI CB CHEBI:3387
DMZOLBI DE Gastric adenocarcinoma; Epilepsy; Type-1 diabetes
DMLEDNK ID DMLEDNK
DMLEDNK DN Carbenicillin
DMLEDNK HS Approved
DMLEDNK SN CBPC; Carbenicilina; Carbenicillina; Carbenicilline; Carbenicillinum; Carboxybenzylpenicillin; Pyopen; Carbenicillina [DCIT]; Carboxybenzyl Penicillin; Carboxybenzylpenicillin acid; Alpha-Carboxybenzylpencillin; Alpha-Carboxybenzylpenicillin solution; Carbenicilina [INN-Spanish]; Carbenicillin (INN); Carbenicillin [INN:BAN]; Carbenicilline [INN-French]; Carbenicillinum [INN-Latin]; Alpha-Phenyl(carboxymethylpenicillin); N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid;N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid; (2S,5R,6R)-6-[(3-hydroxy-3-oxo-2-phenylpropanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(alpha-Carboxyphenylacetamido)penicillanic acid; 6beta-(2-carboxy-2-phenylacetamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMLEDNK CP Roerig Div Pfizer Inc
DMLEDNK TC Antibiotics
DMLEDNK DT Small molecular drug
DMLEDNK PC 20824
DMLEDNK MW 378.4
DMLEDNK FM C17H18N2O6S
DMLEDNK IC InChI=1S/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1
DMLEDNK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C
DMLEDNK IK FPPNZSSZRUTDAP-UWFZAAFLSA-N
DMLEDNK IU (2S,5R,6R)-6-[(2-carboxy-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMLEDNK CA CAS 4697-36-3
DMLEDNK CB CHEBI:3393
DMLEDNK DE Infection of the upper and lower urinary tract
DME2XG3 ID DME2XG3
DME2XG3 DN Carbenicillin Indanyl Sodium
DME2XG3 HS Approved
DME2XG3 SN Geocillin
DME2XG3 CP Pfizer Laboratories Div Pfizer Inc
DME2XG3 TC Antiinfective Agents
DME2XG3 DT Small molecular drug
DME2XG3 PC 23676503
DME2XG3 MW 516.5
DME2XG3 FM C26H25N2NaO6S
DME2XG3 IC InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1
DME2XG3 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)OC4=CC5=C(CCC5)C=C4)C(=O)[O-])C.[Na+]
DME2XG3 IK QFWPXOXWAUAYAB-XZVIDJSISA-M
DME2XG3 IU sodium;(2S,5R,6R)-6-[[3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DME2XG3 CA CAS 26605-69-6
DME2XG3 CB CHEBI:31358
DME2XG3 DE Bacterial infection
DMUSLW3 ID DMUSLW3
DMUSLW3 DN Carbetocin
DMUSLW3 HS Approved
DMUSLW3 SN Carbetocino [INN-Spanish]; Carbetocinum [INN-Latin]; Duratocin (TN); 1-Buttersaeure-2-(3-(4-methoxyphenyl)-L-alanin)oxytocin; 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-hydroxybenzyl)-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide
DMUSLW3 CP Pfizer Pharmaceuticals
DMUSLW3 TC Antitocolytic Agents
DMUSLW3 DT Small molecular drug
DMUSLW3 PC 16681432
DMUSLW3 MW 988.2
DMUSLW3 FM C45H69N11O12S
DMUSLW3 IC InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
DMUSLW3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMUSLW3 IK NSTRIRCPWQHTIA-DTRKZRJBSA-N
DMUSLW3 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
DMUSLW3 CA CAS 37025-55-1
DMUSLW3 CB CHEBI:59204
DMUSLW3 DE Postpartum haemorrhage
DMHRG8Q ID DMHRG8Q
DMHRG8Q DN Carbidopa
DMHRG8Q HS Approved
DMHRG8Q SN Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
DMHRG8Q TC Antiparkinson Agents
DMHRG8Q DT Small molecular drug
DMHRG8Q PC 34359
DMHRG8Q MW 226.23
DMHRG8Q FM C10H14N2O4
DMHRG8Q IC InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
DMHRG8Q CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
DMHRG8Q IK TZFNLOMSOLWIDK-JTQLQIEISA-N
DMHRG8Q IU (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
DMHRG8Q CA CAS 28860-95-9
DMHRG8Q CB CHEBI:39585
DMHRG8Q DE Parkinson disease
DMULAI4 ID DMULAI4
DMULAI4 DN Carbimazole
DMULAI4 HS Approved
DMULAI4 SN Athyromazole; Atirozidina; Basolest; Carbethoxymethimazole; Carbimazol; Carbimazolum; Carbinazole; Carbotiroid; Mertiran; Neomercazole; TYRAZOL; Thyrostat; Carbimazol henning; Carbimazol spofa; CG1; Cg 1; Carbimazol henning (TN); Carbimazole (INN); Carbimazolum [INN-Latin]; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Carbimazol [INN-Spanish, French]; Carbimazole [INN:BAN:DCF]; Ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate; Ethyl 3-methyl-2-thioimidazoline-1-carboxylate; Ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate; 1-Ethoxycarbonyl-3-methyl-2-thioimidazol; 1-Ethoxycarbonyl-3-methyl-2-thioxo-4-imidazoline; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo, ethyl ester; 1H-Imidazole-1-carboxylic acid, 2,3-dihydro-3-methyl-2-thioxo-, ethyl ester; 3-Methyl-2-thioxo-4-imidazoline-1-carboxylic acid ethyl ester; 4-Imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester
DMULAI4 TC Antithyroid Agents
DMULAI4 DT Small molecular drug
DMULAI4 PC 31072
DMULAI4 MW 186.23
DMULAI4 FM C7H10N2O2S
DMULAI4 IC InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3
DMULAI4 CS CCOC(=O)N1C=CN(C1=S)C
DMULAI4 IK CFOYWRHIYXMDOT-UHFFFAOYSA-N
DMULAI4 IU ethyl 3-methyl-2-sulfanylideneimidazole-1-carboxylate
DMULAI4 CA CAS 22232-54-8
DMULAI4 CB CHEBI:617099
DMULAI4 DE Hyperthyroidism
DMCT31R ID DMCT31R
DMCT31R DN Carbinoxamine
DMCT31R HS Approved
DMCT31R SN Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine
DMCT31R CP McNeil Laboratories
DMCT31R TC Antihistamines
DMCT31R DT Small molecular drug
DMCT31R PC 2564
DMCT31R MW 290.79
DMCT31R FM C16H19ClN2O
DMCT31R IC InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
DMCT31R CS CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DMCT31R IK OJFSXZCBGQGRNV-UHFFFAOYSA-N
DMCT31R IU 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
DMCT31R CA CAS 486-16-8
DMCT31R CB CHEBI:3398
DMCT31R DE Vasomotor/allergic rhinitis
DMG281S ID DMG281S
DMG281S DN Carboplatin
DMG281S HS Approved
DMG281S SN Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
DMG281S CP Bristol-Myers Squibb
DMG281S TC Anticancer Agents
DMG281S DT Small molecular drug
DMG281S PC 426756
DMG281S MW 371.25
DMG281S FM C6H12N2O4Pt
DMG281S IC InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
DMG281S CS C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
DMG281S IK VSRXQHXAPYXROS-UHFFFAOYSA-N
DMG281S IU azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMG281S CA CAS 41575-94-4
DMG281S CB CHEBI:31355
DMG281S DE Ovarian cancer
DMS3508 ID DMS3508
DMS3508 DN Carboprost tromethamine
DMS3508 HS Approved
DMS3508 SN Hemabate; Carboprost Trometanol; Carboprost trometamol; Carboprost tromethamine [USAN]; U 32921E; Hemabate (TN); Prostin / 15M; U-32921E; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9-alpha,11-alpha,13E,15S)-,compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (15S)-15-Methylprostaglandin F(sub 2alpha) tromethamine; (15S)-15-Methylprostaglandin F2alpha tromethamine; (E)-7-[(1S,3S,5R)-3,5-dihydroxy-2-[(Z,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-(3S)-3-hydroxy-3-methyl-1-octenyl)cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); 15(S)15-Methyl pgf2-alpha tromethaminesalt; 15(S)15-Methyl prostaglandin F2-alpha tromethamine; 15-methylprostaglandin F2alpha-tromethamine
DMS3508 TC Abortifacient Agents
DMS3508 DT Small molecular drug
DMS3508 PC 5281074
DMS3508 MW 489.6
DMS3508 FM C25H47NO8
DMS3508 IC InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1
DMS3508 CS CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMS3508 IK UMMADZJLZAPZAW-XOWPVRJPSA-N
DMS3508 IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]cyclopentyl]hept-5-enoic acid
DMS3508 CA CAS 58551-69-2
DMS3508 DE Abortion
DM48K0X ID DM48K0X
DM48K0X DN Carfilzomib
DM48K0X HS Approved
DM48K0X SN Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
DM48K0X CP Onyx Pharmaceuticals
DM48K0X DT Small molecular drug
DM48K0X PC 11556711
DM48K0X MW 719.9
DM48K0X FM C40H57N5O7
DM48K0X IC InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
DM48K0X CS CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
DM48K0X IK BLMPQMFVWMYDKT-NZTKNTHTSA-N
DM48K0X IU (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
DM48K0X CA CAS 868540-17-4
DM48K0X CB CHEBI:65347
DM48K0X DE Multiple myeloma; Small-cell lung cancer
DMCY0TI ID DMCY0TI
DMCY0TI DN Carglumic acid
DMCY0TI HS Approved
DMCY0TI SN Carbaglu (TN)
DMCY0TI CP Orphan Europe
DMCY0TI DT Small molecular drug
DMCY0TI PC 121396
DMCY0TI MW 190.15
DMCY0TI FM C6H10N2O5
DMCY0TI IC InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
DMCY0TI CS C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
DMCY0TI IK LCQLHJZYVOQKHU-VKHMYHEASA-N
DMCY0TI IU (2S)-2-(carbamoylamino)pentanedioic acid
DMCY0TI CA CAS 1188-38-1
DMCY0TI CB CHEBI:71028
DMCY0TI DE Acute hyperammonaemia
DMJYDVK ID DMJYDVK
DMJYDVK DN Cariprazine
DMJYDVK HS Approved
DMJYDVK SN Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH
DMJYDVK CP Forest Laboratories; Gedeon Richter
DMJYDVK DT Small molecular drug
DMJYDVK PC 11154555
DMJYDVK MW 427.4
DMJYDVK FM C21H32Cl2N4O
DMJYDVK IC InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)
DMJYDVK CS CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
DMJYDVK IK KPWSJANDNDDRMB-UHFFFAOYSA-N
DMJYDVK IU 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
DMJYDVK CA CAS 839712-12-8
DMJYDVK CB CHEBI:90933
DMJYDVK DE Bipolar disorder
DMWR1JC ID DMWR1JC
DMWR1JC DN Carisoprodol
DMWR1JC HS Approved
DMWR1JC SN carisoprodol; 78-44-4; Isomeprobamate; Carisoprodate; Carisoprodatum; Isoprotane; Isobamate; Isoprothane; Carisoma; Sanoma; Isopropyl meprobamate; SOMA; Somalgit; Atonalyt; Mioratrina; Mioartrina; Flexartal; Skutamil; Miolisodal; Mioril; Apesan; Relasom; Nospasm; Flexal; Arusal; Somanil; Carlsoprol; Carisoprodolum; Domarax; Stialgin; Somadril; Carsodal; Mioriodol; Mediquil; Izoprotan; Isoprotan; Carisol; Caprodat; Calenfa; Diolene; Carlsoma; Carlsodol; Brianil; Flexidon; Flexagilt; Caridolin; Meprodat; Listaflex; Flexagit; Fibrosona; Chinchen; Carsodol
DMWR1JC DT Small molecular drug
DMWR1JC PC 2576
DMWR1JC MW 260.329
DMWR1JC FM C12H24N2O4
DMWR1JC IC InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
DMWR1JC CS CCCC(C)(COC(=O)N)COC(=O)NC(C)C
DMWR1JC IK OFZCIYFFPZCNJE-UHFFFAOYSA-N
DMWR1JC IU [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate
DMWR1JC CA CAS 78-44-4
DMWR1JC CB CHEBI:3419
DMWR1JC DE Musculoskeletal disorder
DMHTB31 ID DMHTB31
DMHTB31 DN Carphenazine
DMHTB31 HS Approved
DMHTB31 SN Carfenazine; Carphenazin; Procethazine; Proketazin; Carfenazina [INN-Spanish]; Carfenazine [INN:BAN]; Carfenazinum [INN-Latin]; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31 CP Wyeth Ayerst Laboratories
DMHTB31 TC Antipsychotic Agents
DMHTB31 DT Small molecular drug
DMHTB31 PC 18104
DMHTB31 MW 425.6
DMHTB31 FM C24H31N3O2S
DMHTB31 IC InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
DMHTB31 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO
DMHTB31 IK XZSMZRXAEFNJCU-UHFFFAOYSA-N
DMHTB31 IU 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
DMHTB31 CA CAS 2622-30-2
DMHTB31 DE Insomnia; Schizophrenia
DMHMP05 ID DMHMP05
DMHMP05 DN Carprofen
DMHMP05 HS Approved
DMHMP05 SN Carprofene; Carprofeno; Carprofenum; Imadyl; Ridamyl; Rimadyl; Carprofeno [Spanish]; C 5720; Ro 205720; C-5720; Carprofene [INN-French]; Carprofeno [INN-Spanish]; Carprofenum [INN-Latin]; Rimadyl (TN); Ro 20-5720; Carprofen (USAN/INN); Carprofen [USAN:INN:BAN]; Ro 20-5720/000; Ro-20-5720; Ro-20-5720/000; (+-)-6-Chloro-alpha-methylcarbazole-2-acetic acid; (+-)-isomer of carprofen; (+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid; (+/-)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid; (-)-6-Chlor-alpha-methyl-2-carbazolessigsaeure; 2-(6-Chloro-9H-carbazol-2-yl)-propionic acid; 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure; 6-Chlor-alpha-methyl-carbazol-2-essigsaeure [German]; 6-Chloro-alpha-methyl-9H-carbazole-2-acetic acid; 6-Chloro-alpha-methylcarbazole-2-acetic acid; 9H-Carbazole-2-acetic acid, 6-chloro-.al
DMHMP05 CP Pfizer Pharmaceuticals
DMHMP05 TC Analgesics
DMHMP05 DT Small molecular drug
DMHMP05 PC 2581
DMHMP05 MW 273.71
DMHMP05 FM C15H12ClNO2
DMHMP05 IC InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)
DMHMP05 CS CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O
DMHMP05 IK PUXBGTOOZJQSKH-UHFFFAOYSA-N
DMHMP05 IU 2-(6-chloro-9H-carbazol-2-yl)propanoic acid
DMHMP05 CA CAS 53716-49-7
DMHMP05 CB CHEBI:364453
DMHMP05 DE Pain
DMFMDOB ID DMFMDOB
DMFMDOB DN Carteolol
DMFMDOB HS Approved
DMFMDOB SN Carteololum; Carteolol HCl; Carteolol Monohydrochloride; Arteolol (TN); Arteoptic (TN); Calte (TN); Carteol (TN); Carteolol (INN); Carteolol [INN:BAN]; Carteololum [INN-Latin]; Cartrol (TN); Elebloc (TN); Endak (TN); Glauteolol (TN); Mikelan (TN); Ocupress (TN); Poenglaucol (TN); Singlauc (TN); Teoptic (TN); 5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
DMFMDOB CP CIBA Vision Sterile Mfg
DMFMDOB TC Antihypertensive Agents
DMFMDOB DT Small molecular drug
DMFMDOB PC 2583
DMFMDOB MW 292.37
DMFMDOB FM C16H24N2O3
DMFMDOB IC InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)
DMFMDOB CS CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O
DMFMDOB IK LWAFSWPYPHEXKX-UHFFFAOYSA-N
DMFMDOB IU 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
DMFMDOB CA CAS 51781-06-7
DMFMDOB CB CHEBI:3437
DMFMDOB DE Glaucoma/ocular hypertension
DMHTEAO ID DMHTEAO
DMHTEAO DN Carvedilol
DMHTEAO HS Approved
DMHTEAO SN Artist; Carvedilolum; Coreg; Coropres; Coropress; Dibloc; Dilatrend; Eucardic; Kredex; Querto; Atlana Pharma brand of carvedilol; Carvedilolum [Latin]; Coreg CR; GlaxoSmithKline brand of carvedilol; Lakeside brand of carvedilol; Roche brand of carvedilol; BM 14190; DQ 2466; SKF 105517; Artist (TN); BM-14190; Carloc (TN); Coreg (TN); DQ-2466; Dilatrend (TN); EG-P042; Eucardic (TN); BM-14-190; BM-14.190; Carvedilol, 14C-labeled; SK&F-105517; Carvedilol (JAN/USAN/INN); Carvedilol [USAN:INN:BAN:JAN]; Carvedilol, (R)-isomer; Carvedilol, (S)-isomer; Carvedilol, (+-)-isomer; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
DMHTEAO CP GlaxoSmithKline plc
DMHTEAO TC Vasodilator Agents
DMHTEAO DT Small molecular drug
DMHTEAO PC 2585
DMHTEAO MW 406.5
DMHTEAO FM C24H26N2O4
DMHTEAO IC InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
DMHTEAO CS COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
DMHTEAO IK OGHNVEJMJSYVRP-UHFFFAOYSA-N
DMHTEAO IU 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
DMHTEAO CA CAS 72956-09-3
DMHTEAO CB CHEBI:3441
DMHTEAO DE Congestive heart failure
DMZPXRC ID DMZPXRC
DMZPXRC DN Carzinophilin
DMZPXRC HS Approved
DMZPXRC SN CARZINOPHILIN; Cardinophyllin; Cardinophillin; Azinomycin; CARZINOPHILIN A; Carzinophyllin; NSC 20088; Antibiotic from Streptomyces Sahachiroi; BRN 5721373; C31H33N3O11; 1403-28-7; Carzinophilin (8CI); AC1MHU1X; Carzinophilin (8CI)(9CI); LS-52587; LS-52588; 11002-20-3; [(1S)-2-[[(1E)-1-[(3R,4R,5S)-3-acetyloxy-4-hydroxy-1-azabicyclo[3.1.0]hexan-2-ylidene]-2-[[(E)-1-hydroxy-3-oxobut-1-en-2-yl]amino]-2-oxoethyl]amino]-1-[(2S)-2-methyloxiran-2-yl]-2-oxoethyl] 3-methoxy-5-methylnaphthalene-1-carboxylate
DMZPXRC DT Small molecular drug
DMZPXRC PC 227922
DMZPXRC MW 639.6
DMZPXRC FM C31H33N3O12
DMZPXRC IC InChI=1S/C31H33N3O12/c1-14-7-6-8-18-19(14)9-17(43-5)10-20(18)26(40)32-13-30(4)24(39)28(41)45-31(46-30)25(23(38)22-11-34(22)16(3)37)44-27(33-29(31)42)21(12-35)15(2)36/h6-10,12,22-25,38-39H,11,13H2,1-5H3,(H,32,40)(H,33,42)
DMZPXRC CS CC1=C2C=C(C=C(C2=CC=C1)C(=O)NCC3(C(C(=O)OC4(O3)C(OC(=C(C=O)C(=O)C)NC4=O)C(C5CN5C(=O)C)O)O)C)OC
DMZPXRC IK GNGRYODSYNVRFD-UHFFFAOYSA-N
DMZPXRC IU N-[[7-[(1-acetylaziridin-2-yl)-hydroxymethyl]-9-(1,3-dioxobutan-2-ylidene)-3-hydroxy-4-methyl-2,11-dioxo-1,5,8-trioxa-10-azaspiro[5.5]undecan-4-yl]methyl]-3-methoxy-5-methylnaphthalene-1-carboxamide
DMZPXRC DE Solid tumour/cancer
DMGQIPT ID DMGQIPT
DMGQIPT DN Caspofungin
DMGQIPT HS Approved
DMGQIPT SN CASPO; Cancidas; Capsofungin; Caspofungin [INN]; M991; Cancidas (TM); Cancidas (TN); Caspofungin (INN); MK-0991; L-743,872; [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate; Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-(9CI); (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide; 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
DMGQIPT CP Merck & Co
DMGQIPT TC Antifungal Agents
DMGQIPT DT Small molecular drug
DMGQIPT PC 2826718
DMGQIPT MW 1093.3
DMGQIPT FM C52H88N10O15
DMGQIPT IC InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1
DMGQIPT CS CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O
DMGQIPT IK JYIKNQVWKBUSNH-OGZDCFRISA-N
DMGQIPT IU N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMGQIPT CA CAS 162808-62-0
DMGQIPT CB CHEBI:474180
DMGQIPT DE Fungal infection
DMRSZA5 ID DMRSZA5
DMRSZA5 DN Cefacetrile
DMRSZA5 HS Approved
DMRSZA5 SN Cefacetril; Cefacetrilo; Cefacetrilum; Celospor; Cephacetrile; Vetrimast [veterinary]; Cefacetrile (INN); Cefacetrilo [INN-Spanish]; Cefacetrilum [INN-Latin]; Celospor (TN); Celtol (TN); Cristacef (TN); Vetrimast [veterinary] (TN); C-36278-Ba; (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-Acetoxymethyl-7-(2-cyanacetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2-Cyanacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat acetat (ester); 7-Cyanacetylamino-cephalosporansaeure
DMRSZA5 TC Antibiotics
DMRSZA5 DT Small molecular drug
DMRSZA5 PC 91562
DMRSZA5 MW 339.33
DMRSZA5 FM C13H13N3O6S
DMRSZA5 IC InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1
DMRSZA5 CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC#N)SC1)C(=O)O
DMRSZA5 IK RRYMAQUWDLIUPV-BXKDBHETSA-N
DMRSZA5 IU (6R,7R)-3-(acetyloxymethyl)-7-[(2-cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMRSZA5 CA CAS 10206-21-0
DMRSZA5 CB CHEBI:135437
DMRSZA5 DE Bacterial infection
DMJXDGC ID DMJXDGC
DMJXDGC DN Cefaclor
DMJXDGC HS Approved
DMJXDGC SN Alenfral; Alfacet; Alfatil; CCL; Ceclor; Cefaclorum; Distaclor; Kefolor; Panacef; Panoral; Alfatil Kapseln; Cefaclor anhydrous; Cefaclor hydrate; Cefaclor monohydrate; Dystaclor MR; Kefolor Suspension; Muco Panoral; Lilly 99638 hydrate; Alenfral (TN); Ceclor (TN); Cefaclor (JP15); Cefaclor (USP); Distaclor (TN); Keflor (TN); L-Kefral; Raniclor (TN); S-6472; Cefaclor-1-wasser; Cefaclor [USAN:INN:BAN:JAN]; Ceclor, Distaclor, Keflor, Raniclor, Cefaclor; (6R,7R)-7-((R)-2-Amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid; 3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate; 7-(2-Amino-2-phenyl-acetylamino)-3-chloro-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-3,4-didehydrocepham-4-carboxylic acid
DMJXDGC CP Eli Lilly
DMJXDGC TC Antibiotics
DMJXDGC DT Small molecular drug
DMJXDGC PC 51039
DMJXDGC MW 367.8
DMJXDGC FM C15H14ClN3O4S
DMJXDGC IC InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
DMJXDGC CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DMJXDGC IK QYIYFLOTGYLRGG-GPCCPHFNSA-N
DMJXDGC IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJXDGC CA CAS 53994-73-3
DMJXDGC CB CHEBI:3478
DMJXDGC DE Bacterial infection
DMMC345 ID DMMC345
DMMC345 DN Cefadroxil
DMMC345 HS Approved
DMMC345 SN CDX; Cefadroxilo; Cefadroxilum; Cephadroxil; Sumacef; Cefadroxil anhydrous; S 578; BL-S 578; BL-S578; Cefadroxil (JP15); Cefadroxilo [INN-Spanish]; Cefadroxilum [INN-Latin]; Curisafe (TN); D-Cefadroxil; S-578; Sumacef (TN); MJF-11567-3; (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMMC345 CP Pharco B international
DMMC345 TC Antibiotics
DMMC345 DT Small molecular drug
DMMC345 PC 47965
DMMC345 MW 363.4
DMMC345 FM C16H17N3O5S
DMMC345 IC InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
DMMC345 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DMMC345 IK BOEGTKLJZSQCCD-UEKVPHQBSA-N
DMMC345 IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMC345 CA CAS 50370-12-2
DMMC345 CB CHEBI:3479
DMMC345 DE Bacterial infection
DMVYSLE ID DMVYSLE
DMVYSLE DN Cefalotin
DMVYSLE HS Approved
DMVYSLE SN Cefalothin; Cefalotina; Cefalotine; Cefalotinum; Cemastin; Cephalothinum; Cephalotin; Coaxin; Cefalotina fabra; Cephalothin Monosodium Salt; Averon-1; Cefalotin (BAN); Cefalotina [INN-Spanish]; Cefalotina fabra (TN); Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Keflin (TN); (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; 3-ACETOXYMETHYL-8-OXO-7-(2-THIOPHEN-2-YL-ACETYLAMINO)-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; 7-(2-Thienylacetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporanic acid; 7-(Thiophene-2-acetamido)cephalosporin; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid
DMVYSLE CP Eli Lilly
DMVYSLE TC Antibiotics
DMVYSLE DT Small molecular drug
DMVYSLE PC 6024
DMVYSLE MW 396.4
DMVYSLE FM C16H16N2O6S2
DMVYSLE IC InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1
DMVYSLE CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)O
DMVYSLE IK XIURVHNZVLADCM-IUODEOHRSA-N
DMVYSLE IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMVYSLE CA CAS 153-61-7
DMVYSLE CB CHEBI:124991
DMVYSLE DE Bacterial infection
DMNEXZF ID DMNEXZF
DMNEXZF DN Cefamandole
DMNEXZF HS Approved
DMNEXZF SN Cefadole; Cefamandolum; Cefamandole (USAN/INN); (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DMNEXZF CP Eli Lilly
DMNEXZF TC Antibiotics
DMNEXZF DT Small molecular drug
DMNEXZF PC 456255
DMNEXZF MW 462.5
DMNEXZF FM C18H18N6O5S2
DMNEXZF IC InChI=1S/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1
DMNEXZF CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)[C@@H](C4=CC=CC=C4)O)SC2)C(=O)O
DMNEXZF IK OLVCFLKTBJRLHI-AXAPSJFSSA-N
DMNEXZF IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMNEXZF CA CAS 34444-01-4
DMNEXZF CB CHEBI:3480
DMNEXZF DE Microorganisms infection
DMPDYFR ID DMPDYFR
DMPDYFR DN Cefazolin
DMPDYFR HS Approved
DMPDYFR SN CEZ; Cefamezin; Cefamezine; Cefazolina; Cefazoline; Cefazolinum; Cephamezine; Cephazolidin; Cephazolin; Cephazoline; Elzogram; Cephazolin Sodium; Ancef (TN); Cefacidal (TN); Cefamezin (TN); Cefazolin (USP); Cefazolin [USAN:INN]; Cefazolin(usp); Cefazolina [INN-Spanish]; Cefazoline [INN-French]; Cefazolinum [INN-Latin]; Cefrina (TN); Elzogram (TN); Faxilen (TN); Gramaxin (TN); Kefazol (TN); Kefol (TN); Kefzol (TN); Kefzolan (TN); Kezolin (TN); Novaporin (TN); Zolicef (TN); (6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid; 7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid
DMPDYFR CP Fujisawa Pharmaceutical Co
DMPDYFR TC Antibiotics
DMPDYFR DT Small molecular drug
DMPDYFR PC 33255
DMPDYFR MW 454.5
DMPDYFR FM C14H14N8O4S3
DMPDYFR IC InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
DMPDYFR CS CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O
DMPDYFR IK MLYYVTUWGNIJIB-BXKDBHETSA-N
DMPDYFR IU (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPDYFR CA CAS 25953-19-9
DMPDYFR CB CHEBI:474053
DMPDYFR DE Bacterial infection
DMJ7A0H ID DMJ7A0H
DMJ7A0H DN Cefdinir
DMJ7A0H HS Approved
DMJ7A0H SN CFDN; Cefdinirum; Cefdinyl; Cefdirnir; Cefzon; Omnicef; BMY 28488; FK 482; PD 134393; Cefdinir [USAN:INN]; Cefdinirum [INN-Latin]; Cefzon (TN); FK-482; FR-80482; KS-1038; Omnicef (TN); PD-134393; Cefdinir (JP15/USAN/INN); Omnicef, FK-482, BMY-28488, PD 134393, CI-983, Cefdinir; (-)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-oxime; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(2 (2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid; 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMJ7A0H CP Abbott Laboratories
DMJ7A0H TC Antibiotics
DMJ7A0H DT Small molecular drug
DMJ7A0H PC 6915944
DMJ7A0H MW 395.4
DMJ7A0H FM C14H13N5O5S2
DMJ7A0H IC InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
DMJ7A0H CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\O)/C3=CSC(=N3)N)SC1)C(=O)O
DMJ7A0H IK RTXOFQZKPXMALH-GHXIOONMSA-N
DMJ7A0H IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJ7A0H CA CAS 91832-40-5
DMJ7A0H CB CHEBI:3485
DMJ7A0H DE Bacterial infection
DMSUVM1 ID DMSUVM1
DMSUVM1 DN Cefditoren
DMSUVM1 HS Approved
DMSUVM1 SN Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMSUVM1 CP Cornerstone BioPharma
DMSUVM1 TC Antibiotics
DMSUVM1 DT Small molecular drug
DMSUVM1 PC 9870843
DMSUVM1 MW 506.6
DMSUVM1 FM C19H18N6O5S3
DMSUVM1 IC InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
DMSUVM1 CS CC1=C(SC=N1)/C=C\\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMSUVM1 IK KMIPKYQIOVAHOP-YLGJWRNMSA-N
DMSUVM1 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSUVM1 CA CAS 104145-95-1
DMSUVM1 CB CHEBI:59343
DMSUVM1 DE Bacterial infection
DMHVWIK ID DMHVWIK
DMHVWIK DN Cefepime
DMHVWIK HS Approved
DMHVWIK SN Axepim; CFPM; Cefepima; Cefepimum; Cepimax; Cepimex; Maxcef; Maxipime; Cefepima [Spanish]; Cefepimum [Latin]; BMY 28142; Axepim (TN); BMY-28142; Cefepime [USAN:INN]; Cepimax (TN); Cepimex (TN); Maxcef (TN); Maxipime (TN); Cefepime (USAN/INN); (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime); 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
DMHVWIK CP Bristol-Myers Squibb
DMHVWIK TC Antibiotics
DMHVWIK DT Small molecular drug
DMHVWIK PC 5479537
DMHVWIK MW 480.6
DMHVWIK FM C19H24N6O5S2
DMHVWIK IC InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1
DMHVWIK CS C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]
DMHVWIK IK HVFLCNVBZFFHBT-ZKDACBOMSA-N
DMHVWIK IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMHVWIK CA CAS 88040-23-7
DMHVWIK CB CHEBI:478164
DMHVWIK DE Bacterial infection
DMY60I8 ID DMY60I8
DMY60I8 DN Cefixime
DMY60I8 HS Approved
DMY60I8 SN CFIX; Cefixima; Cefiximum; Denvar; Necopen; Tricef; CL-284635; FK-027; FR-17027; Ofex (TN); Suprax (TN); Cefixime (JP15/USP/INN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethyloxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b; 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
DMY60I8 CP Wyeth Pharmaceuticals
DMY60I8 TC Antibiotics
DMY60I8 DT Small molecular drug
DMY60I8 PC 5362065
DMY60I8 MW 453.5
DMY60I8 FM C16H15N5O7S2
DMY60I8 IC InChI=1S/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1
DMY60I8 CS C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
DMY60I8 IK OKBVVJOGVLARMR-QSWIMTSFSA-N
DMY60I8 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY60I8 CA CAS 79350-37-1
DMY60I8 CB CHEBI:472657
DMY60I8 DE Bacterial infection
DMPLY7B ID DMPLY7B
DMPLY7B DN Cefmenoxime
DMPLY7B HS Approved
DMPLY7B SN Cefmax; Cefmenoxima; Cefmenoximum; Tacef; Cefmenoxime [INN]; A 50912; AB 50912; SCE 1365; Abbott-50192; Cefmenoxima [INN-Spanish]; Cefmenoxime (INN); Cefmenoximum [INN-Latin]; Cefmenoxime Hydrochloride (2:1); (6R,7R)-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-(1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (IUPAC); (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMPLY7B TC Antibiotics
DMPLY7B DT Small molecular drug
DMPLY7B PC 9570757
DMPLY7B MW 511.6
DMPLY7B FM C16H17N9O5S3
DMPLY7B IC InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1
DMPLY7B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMPLY7B IK HJJDBAOLQAWBMH-YCRCPZNHSA-N
DMPLY7B IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMPLY7B CA CAS 65085-01-0
DMPLY7B CB CHEBI:55490
DMPLY7B DE Bacterial infection
DM42W1B ID DM42W1B
DM42W1B DN Cefmetazole
DM42W1B HS Approved
DM42W1B SN CMZ; Cefmetazolo; Cefmetazolum; Cefmetazole Monosodium Salt; CS 1170; SKF 83088; U 72791; CS-1170; Cefmetazole [USAN:INN]; Cefmetazolo [INN-Spanish]; Cefmetazolum [INN-Latin]; U-72791A; Cefmetazole (USP/INN); (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-(2-((Cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt; (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 6beta-{[(cyanomethyl)sulfanyl]acetamido}-6alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
DM42W1B CP Pharmacia And Upjohn Co
DM42W1B TC Antibiotics
DM42W1B DT Small molecular drug
DM42W1B PC 42008
DM42W1B MW 471.5
DM42W1B FM C15H17N7O5S3
DM42W1B IC InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1
DM42W1B CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O
DM42W1B IK SNBUBQHDYVFSQF-HIFRSBDPSA-N
DM42W1B IU (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM42W1B CA CAS 56796-20-4
DM42W1B CB CHEBI:3489
DM42W1B DE Bacterial infection
DMORSGU ID DMORSGU
DMORSGU DN Cefodizime
DMORSGU HS Approved
DMORSGU SN AC1NSFIB; CDZM; CHEBI:63214; CHEMBL2303613; Cefodizima; Cefodizima [INN-Spanish]; Cefodizime; Cefodizime (INN); Cefodizime Acid; Cefodizime [INN:BAN]; Cefodizimum; Cefodizimum [INN-Latin]; Cefodizme; DTXSID2022757; Diezime; EC 700-301-3; EX-A1379; HR 221 [AS SODIUM]; HR-221; HR-221 [As Sodium]; J-700161; Modivid; Neucef; S-771221B [As Sodium]; SCHEMBL151101; THR 221 [AS SODIUM]; THR-221; THR-221 [As Sodium]; Timecef; UNII-Z31298J4HQ; Z31298J4HQ
DMORSGU TC Anti-Bacterial Agents
DMORSGU DT Small molecular drug
DMORSGU PC 5361871
DMORSGU MW 584.655
DMORSGU FM C20H20N6O7S4
DMORSGU IC InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1
DMORSGU CS CC1=C(SC(=N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O)CC(=O)O
DMORSGU IK XDZKBRJLTGRPSS-BGZQYGJUSA-N
DMORSGU IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMORSGU CA CAS 69739-16-8
DMORSGU CB CHEBI:63214
DMORSGU DE Bacterial infections
DMTX2BH ID DMTX2BH
DMTX2BH DN Cefonicid
DMTX2BH HS Approved
DMTX2BH SN Cefonicido; Cefonicidum; Monocef; Praticef; Cefonicid Monosodium Salt; Sodium Cefonicid; Cefonicid (INN); Cefonicid [INN:BAN]; Cefonicido [INN-Spanish]; Cefonicidum [INN-Latin]; Monocef (TN); SK&F-75073; SKF-75073-2; (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (7R)-7-(2-Hydroxy-2-phenylacetylamino)-6-oxo-3-{[1-(sulfomethyl)(1,2,3,4-tetraazol-5-ylthio)]methyl}-2H,7H,7aH-azetidino[2,1-b]1,3-thiazine-4-carboxylic acid; 6beta-[(2R)-2-hydroxy-2-phenylacetamido]-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)ceph-3-em-4-carboxylic acid; 7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH CP Glaxosmithkline
DMTX2BH TC Antibiotics
DMTX2BH DT Small molecular drug
DMTX2BH PC 43594
DMTX2BH MW 542.6
DMTX2BH FM C18H18N6O8S3
DMTX2BH IC InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
DMTX2BH CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O
DMTX2BH IK DYAIAHUQIPBDIP-AXAPSJFSSA-N
DMTX2BH IU (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMTX2BH CA CAS 61270-58-4
DMTX2BH CB CHEBI:3491
DMTX2BH DE Bacterial infection
DM53PV8 ID DM53PV8
DM53PV8 DN Cefoperazone
DM53PV8 HS Approved
DM53PV8 SN Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid
DM53PV8 CP Pfizer Pharmaceuticals
DM53PV8 TC Antibiotics
DM53PV8 DT Small molecular drug
DM53PV8 PC 44187
DM53PV8 MW 645.7
DM53PV8 FM C25H27N9O8S2
DM53PV8 IC InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1
DM53PV8 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DM53PV8 IK GCFBRXLSHGKWDP-XCGNWRKASA-N
DM53PV8 IU (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM53PV8 CA CAS 62893-19-0
DM53PV8 CB CHEBI:3493
DM53PV8 DE Bacterial infection
DMSQVD6 ID DMSQVD6
DMSQVD6 DN Ceforanide
DMSQVD6 HS Approved
DMSQVD6 SN Ceforanido; Ceforanidum; Precef; Radacef; Bl s786; BL-S 786; BL-S786; Ceforanido [INN-Spanish]; Ceforanidum [INN-Latin]; Precef (TN); Ceforanide (USP/INN); Ceforanide [USAN:INN:BAN]; (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid; 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid; 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid
DMSQVD6 TC Antibiotics
DMSQVD6 DT Small molecular drug
DMSQVD6 PC 43507
DMSQVD6 MW 519.6
DMSQVD6 FM C20H21N7O6S2
DMSQVD6 IC InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1
DMSQVD6 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O
DMSQVD6 IK SLAYUXIURFNXPG-CRAIPNDOSA-N
DMSQVD6 IU (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSQVD6 CA CAS 60925-61-3
DMSQVD6 CB CHEBI:3495
DMSQVD6 DE Bacterial infection
DMEB837 ID DMEB837
DMEB837 DN Cefotaxime
DMEB837 HS Approved
DMEB837 SN Cefotaxima; Cefotaxima [INN-Spanish]; Cefotaxime [INN:BAN]; Cefotaxime acid; Cefotaximum; Cefotaximum [INN-Latin]; Cephotaxime; E-cefotaxime; Omnatax; RU 24662; RU 24756; cefotaxime; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; 60846-21-1; 63527-52-6; C16H17N5O7S2; CHEBI:204928; EINECS 264-299-1; HR 756; N2GI8B1GK7; Taxim; UNII-N2GI8B1GK7
DMEB837 PC 5742673
DMEB837 MW 455.5
DMEB837 FM C16H17N5O7S2
DMEB837 IC GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMEB837 CS CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
DMEB837 IK 1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMEB837 IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMEB837 CA CAS 60846-21-1
DMEB837 CB CHEBI:204928
DMEB837 DE Meningitis
DMMKHBJ ID DMMKHBJ
DMMKHBJ DN Cefotaxime
DMMKHBJ HS Approved
DMMKHBJ SN Cefotaxim; Cefotaxima; Cefotaximum; Cephotaxim; Cephotaxime; Claforan; Klaforan; Cefotaxim Hikma; Cefotaxime acid; CE3; RU 24662; Cefotaxim Hikma (TN); Cefotaxima [INN-Spanish]; Cefotaxime (INN); Cefotaxime [INN:BAN]; Cefotaximum [INN-Latin]; Claforan (TN); Ru-24756; Claforan (*Sodium salt*)
DMMKHBJ CP Roussel Uclaf
DMMKHBJ TC Antibiotics
DMMKHBJ DT Small molecular drug
DMMKHBJ PC 5742673
DMMKHBJ MW 455.5
DMMKHBJ FM C16H17N5O7S2
DMMKHBJ IC InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
DMMKHBJ CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMMKHBJ IK GPRBEKHLDVQUJE-QSWIMTSFSA-N
DMMKHBJ IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMMKHBJ CA CAS 63527-52-6
DMMKHBJ CB CHEBI:204928
DMMKHBJ DE Bacterial infection
DM07TX3 ID DM07TX3
DM07TX3 DN Cefotetan
DM07TX3 HS Approved
DM07TX3 SN Cefotetanum; Apatef (TN); Cefotan (TN); Cefotetan (JP15/USP/INN); (6R,7S)-7-(4-(carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7alpha-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DM07TX3 CP AstraZeneca
DM07TX3 TC Antibiotics
DM07TX3 DT Small molecular drug
DM07TX3 PC 53025
DM07TX3 MW 575.6
DM07TX3 FM C17H17N7O8S4
DM07TX3 IC InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1
DM07TX3 CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O
DM07TX3 IK SRZNHPXWXCNNDU-RHBCBLIFSA-N
DM07TX3 IU (6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM07TX3 CA CAS 69712-56-7
DM07TX3 CB CHEBI:3499
DM07TX3 DE Bacterial infection
DMF5HU6 ID DMF5HU6
DMF5HU6 DN Cefotiam
DMF5HU6 HS Approved
DMF5HU6 SN Aspil; CTM; Cefotiamum; Ceradolan; Haloapor; CEFOTIAM HYDROCHLORIDE; CGP 14221E; Abbott-48999; Aspil (TN); Cefotiam (INN); Cefotiam [INN:BAN]; Cefotiamum [INN-Latin]; SCE-963; CGP-14221-E; (6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7b-[2-(aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1h-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylic acid; 7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid
DMF5HU6 CP Takeda
DMF5HU6 TC Antibiotics
DMF5HU6 DT Small molecular drug
DMF5HU6 PC 43708
DMF5HU6 MW 525.6
DMF5HU6 FM C18H23N9O4S3
DMF5HU6 IC InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1
DMF5HU6 CS CN(C)CCN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CSC(=N4)N)SC2)C(=O)O
DMF5HU6 IK QYQDKDWGWDOFFU-IUODEOHRSA-N
DMF5HU6 IU (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMF5HU6 CA CAS 61622-34-2
DMF5HU6 CB CHEBI:355510
DMF5HU6 DE Respiratory tract infection
DMY8NC4 ID DMY8NC4
DMY8NC4 DN Cefoxitin
DMY8NC4 HS Approved
DMY8NC4 SN Cefoxitina; Cefoxitine; Cefoxitinum; Cefoxotin; Cenomycin; Mefoxin; Mefoxitin; Rephoxitin; cefoxitin; ceftoxitin; 35607-66-0; CEPHOXITIN; 4kow; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7S)-; 6OEV9DX57Y; AK118716; CAS-35607-66-0; CFX; CHEBI:209807; CHEMBL996; DSSTox_CID_2764; DSSTox_GSID_22764; DSSTox_RID_76721; NCGC00183034-01; UNII-6OEV9DX57Y
DMY8NC4 PC 441199
DMY8NC4 MW 427.5
DMY8NC4 FM C16H17N3O7S2
DMY8NC4 IC WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMY8NC4 CS COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMY8NC4 IK 1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMY8NC4 IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMY8NC4 CA CAS 35607-66-0
DMY8NC4 CB CHEBI:209807
DMY8NC4 DE Peritonitis
DMYTXVR ID DMYTXVR
DMYTXVR DN Cefoxitin
DMYTXVR HS Approved
DMYTXVR SN Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMYTXVR CP Merck & Co
DMYTXVR TC Antibiotics
DMYTXVR DT Small molecular drug
DMYTXVR PC 441199
DMYTXVR MW 427.5
DMYTXVR FM C16H17N3O7S2
DMYTXVR IC InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
DMYTXVR CS CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3
DMYTXVR IK WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
DMYTXVR IU (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYTXVR CA CAS 35607-66-0
DMYTXVR CB CHEBI:209807
DMYTXVR DE Bacterial infection
DMKBTFG ID DMKBTFG
DMKBTFG DN Cefozopran
DMKBTFG HS Approved
DMKBTFG SN CZOP; Cefozopran [INN]; SCE 2787; Cefozopran (INN); (-)-1-(((6R,7R)-7-(2-(5-Amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1H-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(Z)-(O-methyloxime); Imidazo(1,2-b)pyridazinium, 1-((6R,7R)-7-(((2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt
DMKBTFG CP Takeda
DMKBTFG DT Small molecular drug
DMKBTFG PC 9571080
DMKBTFG MW 515.5
DMKBTFG FM C19H17N9O5S2
DMKBTFG IC InChI=1S/C19H17N9O5S2/c1-33-24-11(14-23-19(20)35-25-14)15(29)22-12-16(30)28-13(18(31)32)9(8-34-17(12)28)7-26-5-6-27-10(26)3-2-4-21-27/h2-6,12,17H,7-8H2,1H3,(H3-,20,22,23,25,29,31,32)/b24-11-/t12-,17-/m1/s1
DMKBTFG CS CO/N=C(/C1=NSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-]
DMKBTFG IK QDUIJCOKQCCXQY-WHJQOFBOSA-N
DMKBTFG IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMKBTFG CA CAS 113359-04-9
DMKBTFG CB CHEBI:3502
DMKBTFG DE Gram-positive bacterial infection
DMZ2WL4 ID DMZ2WL4
DMZ2WL4 DN Cefpiramide
DMZ2WL4 HS Approved
DMZ2WL4 SN Cefpiramido; Cefpiramidum; WY 44635; Cefpiramide [USAN:INN]; Cefpiramido [INN-Spanish]; Cefpiramidum [INN-Latin]; WY44,635; Cefpiramide (USP/INN); (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-((R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(p-hydroxyphe-nyl)acetamido)-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6r)-7-{[(2r)-2-(4-hydroxyphenyl)-2-{[(6-methyl-4-oxo-1,4-dihydropyridin-3-yl)carbonyl]amino}acetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-[(2R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMZ2WL4 CP Wyeth Ayerst Laboratories
DMZ2WL4 TC Antibiotics
DMZ2WL4 DT Small molecular drug
DMZ2WL4 PC 636405
DMZ2WL4 MW 612.6
DMZ2WL4 FM C25H24N8O7S2
DMZ2WL4 IC InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1
DMZ2WL4 CS CC1=CC(=O)C(=CN1)C(=O)N[C@H](C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
DMZ2WL4 IK PWAUCHMQEXVFJR-PMAPCBKXSA-N
DMZ2WL4 IU (6R,7R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo-1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMZ2WL4 CA CAS 70797-11-4
DMZ2WL4 CB CHEBI:59213
DMZ2WL4 DE Bacterial infection
DMJUNY5 ID DMJUNY5
DMJUNY5 DN Cefpodoxime
DMJUNY5 HS Approved
DMJUNY5 SN CPDX; Cefpodoxima; Cefpodoximum; Epoxim; Cefpodoxim acid; Cefpodoxima [Spanish]; Cefpodoximum [Latin]; RU 51807; Cefpodoxime (INN); Cefpodoxime [INN:BAN]; Epoxim (TN); Vantin (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5 CP Pfizer Pharmaceuticals
DMJUNY5 TC Antibiotics
DMJUNY5 DT Small molecular drug
DMJUNY5 PC 6335986
DMJUNY5 MW 427.5
DMJUNY5 FM C15H17N5O6S2
DMJUNY5 IC InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
DMJUNY5 CS COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OC)/C3=CSC(=N3)N)SC1)C(=O)O
DMJUNY5 IK WYUSVOMTXWRGEK-HBWVYFAYSA-N
DMJUNY5 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMJUNY5 CA CAS 80210-62-4
DMJUNY5 CB CHEBI:3504
DMJUNY5 DE Bacterial infection
DM7DSYP ID DM7DSYP
DM7DSYP DN Cefprozil
DM7DSYP HS Approved
DM7DSYP SN Arzimol; Brisoral; Cefprozilo; Cefprozilum; Cefzil; Cronocef; Procef; Serozil; Cefprozil anhydrous; BMY 28100; Cefprozil (INN); Cefprozil (TN); Cefprozilo [INN-Spanish]; Cefprozilum [INN-Latin]; Cefzil (TN); Procef (TN); (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP CP Bristol-Myers Squibb
DM7DSYP TC Antibiotics
DM7DSYP DT Small molecular drug
DM7DSYP PC 5281006
DM7DSYP MW 389.4
DM7DSYP FM C18H19N3O5S
DM7DSYP IC InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1
DM7DSYP CS C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O
DM7DSYP IK WDLWHQDACQUCJR-ZAMMOSSLSA-N
DM7DSYP IU (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7DSYP CA CAS 92676-86-3
DM7DSYP CB CHEBI:3506
DM7DSYP DE Bacterial infection
DMUNSWV ID DMUNSWV
DMUNSWV DN Cefradine
DMUNSWV HS Approved
DMUNSWV SN Anspor; Cefradin; Cefradina; Cefradinum; Cephradin; Cephradine; Eskacef; Sefril; Velosef; CEPHRADINE SODIUM; SKF D 39304; SQ 11436; VELOSEF 125; VELOSEF 250; VELOSEF 500; Anspor (TN); Cefradina [INN-Spanish]; Cefradinum [INN-Latin]; Cephradine (USP); Cephradine (anhydrous); Cephradine [USAN:BAN]; SQ-11436; SQ-22022; Velosef (TN); Cefradine (JAN/INN); SK&F D-39304; SK-D-39304; (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid; 7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid; 7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid
DMUNSWV CP Kent Pharms
DMUNSWV TC Antibiotics
DMUNSWV DT Small molecular drug
DMUNSWV PC 38103
DMUNSWV MW 349.4
DMUNSWV FM C16H19N3O4S
DMUNSWV IC InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMUNSWV CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O
DMUNSWV IK RDLPVSKMFDYCOR-UEKVPHQBSA-N
DMUNSWV IU (6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMUNSWV CA CAS 38821-53-3
DMUNSWV CB CHEBI:3547
DMUNSWV DE Bacterial infection
DMQXLF3 ID DMQXLF3
DMQXLF3 DN Cefsulodin
DMQXLF3 HS Approved
DMQXLF3 SN cefsulodin; (6R,7R)-3-{[4-(aminocarbonyl)pyridinium-1-yl]methyl}-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; AC1NR4MP; SCHEMBL65524; DTXSID6022769; Cefsulodin free acid (SCE-129), Antibiotic for Culture Media Use Only
DMQXLF3 DT Small molecular drug
DMQXLF3 PC 656575
DMQXLF3 MW 532.6
DMQXLF3 FM C22H20N4O8S2
DMQXLF3 IC InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1
DMQXLF3 CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N
DMQXLF3 IK SYLKGLMBLAAGSC-QLVMHMETSA-N
DMQXLF3 IU (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMQXLF3 CA CAS 62587-73-9
DMQXLF3 CB CHEBI:3507
DMQXLF3 DE Pseudomonas infection
DM41GRA ID DM41GRA
DM41GRA DN Ceftazidime
DM41GRA HS Approved
DM41GRA SN Ceftazidima; Ceftazidimum; Ceptaz; Fortaz; Ceftazidime Sodium In Plastic Container; Ceftazidime anhydrous; Ceftazidime pentahydrate; Fortaz In Plastic Container; SN 401; CEFTAZIDIME (ARGININE FORMULATION); Ceftazidima [INN-Spanish]; Ceftazidime (INN); Ceftazidime (TN); Ceftazidimum [INN-Latin]; Cefzim (TN); Ceptaz (TN); Fortaz (TN); Fortum (TN); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7-[[2-(2-amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-(pyridinium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
DM41GRA CP GlaxoSmithKline
DM41GRA TC Antibiotics
DM41GRA DT Small molecular drug
DM41GRA PC 5481173
DM41GRA MW 546.6
DM41GRA FM C22H22N6O7S2
DM41GRA IC InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
DM41GRA CS CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]
DM41GRA IK ORFOPKXBNMVMKC-DWVKKRMSSA-N
DM41GRA IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM41GRA CA CAS 72558-82-8
DM41GRA CB CHEBI:3508
DM41GRA DE Bacterial infection
DMWV2AG ID DMWV2AG
DMWV2AG DN Ceftibuten
DMWV2AG HS Approved
DMWV2AG SN CETB; Cedax; Ceftem; Ceftibutene; Ceftibuteno; Ceftibutenum; Cephem; Ceprifran; Isocef; Keimax; Antibiotic 7432S; S 7432; Sch 39720; Cedax (TN); Ceftibutene [INN-French]; Ceftibuteno [INN-Spanish]; Ceftibutenum [INN-Latin]; Cephalosporin 7432-S; Cis-Ceftibutin; Cis-ceftibuten; Sch-39720; Trans-Ceftibuten; Ceftibuten(USAN/INN); Ceftibuten [USAN:INN:BAN]; (+)-(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(E)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-(2-amino-1,3-thiazol-4-yl)-5-hydroxy-5-oxopent-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7432-S; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid
DMWV2AG CP Shionogi USA
DMWV2AG TC Antibiotics
DMWV2AG DT Small molecular drug
DMWV2AG PC 5282242
DMWV2AG MW 410.4
DMWV2AG FM C15H14N4O6S2
DMWV2AG IC InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1
DMWV2AG CS C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\\CC(=O)O)/C3=CSC(=N3)N)C(=O)O
DMWV2AG IK UNJFKXSSGBWRBZ-BJCIPQKHSA-N
DMWV2AG IU (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWV2AG CA CAS 97519-39-6
DMWV2AG CB CHEBI:3510
DMWV2AG DE Chronic bronchitis
DMR2SOZ ID DMR2SOZ
DMR2SOZ DN Ceftiofur
DMR2SOZ HS Approved
DMR2SOZ SN Excede (TN)
DMR2SOZ CP Pfizer
DMR2SOZ DT Small molecular drug
DMR2SOZ PC 6328657
DMR2SOZ MW 523.6
DMR2SOZ FM C19H17N5O7S3
DMR2SOZ IC InChI=1S/C19H17N5O7S3/c1-30-23-11(9-7-34-19(20)21-9)14(25)22-12-15(26)24-13(17(27)28)8(5-32-16(12)24)6-33-18(29)10-3-2-4-31-10/h2-4,7,12,16H,5-6H2,1H3,(H2,20,21)(H,22,25)(H,27,28)/b23-11-/t12-,16-/m1/s1
DMR2SOZ CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O
DMR2SOZ IK ZBHXIWJRIFEVQY-IHMPYVIRSA-N
DMR2SOZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMR2SOZ CA CAS 80370-57-6
DMR2SOZ DE Bacterial infection
DM3VOGS ID DM3VOGS
DM3VOGS DN Ceftizoxime
DM3VOGS HS Approved
DM3VOGS SN Ceftix; Ceftizoxima; Ceftizoximum; Eposerin; Ceftizoxime Monosodium Salt; FK749; FR 13749; Cefizox (TN); Ceftizoxima[INN-Spanish]; Ceftizoxime (INN); Ceftizoxime [INN:BAN]; Ceftizoximum [INN-Latin]; FK-749; FR-13479; FR-13749; SKF-88373; SK&F 88373-2; Syn-7-(2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)-2Z-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxyamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-carbonsaeure-7-(Z)-(O-methyloxim); (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2,3-didehydropenam-2-carboxylic acid
DM3VOGS CP Fujisawa Pharmaceutical Co
DM3VOGS TC Antibiotics
DM3VOGS DT Small molecular drug
DM3VOGS PC 6533629
DM3VOGS MW 383.4
DM3VOGS FM C13H13N5O5S2
DM3VOGS IC InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
DM3VOGS CS CO/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O
DM3VOGS IK NNULBSISHYWZJU-LLKWHZGFSA-N
DM3VOGS IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM3VOGS CA CAS 68401-81-0
DM3VOGS CB CHEBI:553473
DM3VOGS DE Bacterial infection
DM9QWAH ID DM9QWAH
DM9QWAH DN Ceftolozane/tazobactam
DM9QWAH HS Approved
DM9QWAH SN CXA-101/tazobactam; CXA-201; Tazobactam/ceftolozane; Tazobactam/CXA-101; Zerbaxa
DM9QWAH TC Antiinfective Agents
DM9QWAH DE Discovery agent
DMCEW64 ID DMCEW64
DMCEW64 DN Ceftriaxone
DMCEW64 HS Approved
DMCEW64 SN Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
DMCEW64 CP Hoffmann-La Roche pharmaceutical company
DMCEW64 TC Antibiotics
DMCEW64 DT Small molecular drug
DMCEW64 PC 5479530
DMCEW64 MW 554.6
DMCEW64 FM C18H18N8O7S3
DMCEW64 IC InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
DMCEW64 CS CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\OC)/C4=CSC(=N4)N)SC2)C(=O)O
DMCEW64 IK VAAUVRVFOQPIGI-SPQHTLEESA-N
DMCEW64 IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMCEW64 CA CAS 73384-59-5
DMCEW64 CB CHEBI:29007
DMCEW64 DE Bacterial infection
DMSIMD8 ID DMSIMD8
DMSIMD8 DN Cefuroxime
DMSIMD8 HS Approved
DMSIMD8 SN Anaptivan; Biociclin; Biofuroksym; Bioxima; CXM; Cefofix; Cefumax; Cefurex; Cefuril; Cefuroxim; Cefuroximesodium; Cefuroximine; Cefuroximo; Cefuroximum; Cephuroxime; Cetroxil; Colifossim; Curocef; Curoxim; Curoxima; Curoxime; Froxal; Furoxil; Kesint; Ketocef; Lifurox; Medoxim; Sharox; Spectrazolr; Ultroxim; Zinacef;CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER; CEFUROXIME SODIUM; Cefuroxim AJ; Cefuroxim Fresenius; Cefuroxim Genericsn; Cefuroxim Hexal; Cefuroxim Lilly; Cefuroxim MN; Cefuroxim Norcox; Cefuroxim curasan; Cefuroxima Fabra; Cefuroxima Richet; Cefuroxime for Injection and Dextrose for Injection in Duplex Container; Cefuroxime na; Cefuroxime sodium salt; KEFUROX IN PLASTIC CONTAINER; Sodium cefuroxime; ZINACEF IN PLASTIC CONTAINER; Zinacef Danmark; Ceftin (TN); Cefuroxim Norcox [inj.]; Cefuroxime (TN); Cefuroximo [INN-Spanish]; Cefuroximum [INN-Latin]; Cetroxil [inj.]; Froxal [inj.]; KS-1040; Sharox [inj.]; Zinacef (TN); Zinnat (TN); Zinnat [inj.]; Cefuroxime (USAN/INN); Cefuroxime [USAN:INN:BAN]; Cefuroxime sodium (JP15/USP); Cefuroxime sodium [USAN:BAN:JAN]; Sodium (6R-(6alpha,7beta(Z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester); (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid
DMSIMD8 CP GlaxoSmithKline
DMSIMD8 TC Antibiotics
DMSIMD8 DT Small molecular drug
DMSIMD8 PC 5479529
DMSIMD8 MW 424.4
DMSIMD8 FM C16H16N4O8S
DMSIMD8 IC InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
DMSIMD8 CS CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
DMSIMD8 IK JFPVXVDWJQMJEE-IZRZKJBUSA-N
DMSIMD8 IU (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMSIMD8 CA CAS 55268-75-2
DMSIMD8 CB CHEBI:3515
DMSIMD8 DE Acute bronchitis
DM4CHN0 ID DM4CHN0
DM4CHN0 DN Cefuroxime axetil
DM4CHN0 HS Approved
DM4CHN0 SN cefuroxime axetil; Ceftin; Zinnat; Elobact; Zinat; Cefuroxime 1-acetoxyethyl ester; Bioracef; CXM-AX; Coliofossim; Furoxime; Cetoxil; Celocid; Cethixim; Nivador; Medoxm; Kalcef; Zoref; Sharox-500; UNII-Z49QDT0J8Z; DRG-0157; SN 407; CCI 15641; CCI-15641; Cepazine; CCI 1564; BRN 6854419; Z49QDT0J8Z; CHEBI:3516; (RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate; C20H22N4O10S; Cefazine; Altacef
DM4CHN0 PC 6321416
DM4CHN0 MW 510.5
DM4CHN0 FM C20H22N4O10S
DM4CHN0 IC InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
DM4CHN0 CS CC(OC(=O)C)OC(=O)C1=C(CSC2N1C(=O)C2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N
DM4CHN0 IK KEJCWVGMRLCZQQ-YJBYXUATSA-N
DM4CHN0 IU 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM4CHN0 CA CAS 64544-07-6
DM4CHN0 CB CHEBI:3516
DM4CHN0 DE Bacterial infections
DM6LOQU ID DM6LOQU
DM6LOQU DN Celecoxib
DM6LOQU HS Approved
DM6LOQU SN CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU CP Pfizer
DM6LOQU TC Analgesics
DM6LOQU DT Small molecular drug
DM6LOQU PC 2662
DM6LOQU MW 381.4
DM6LOQU FM C17H14F3N3O2S
DM6LOQU IC InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
DM6LOQU CS CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DM6LOQU IK RZEKVGVHFLEQIL-UHFFFAOYSA-N
DM6LOQU IU 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM6LOQU CA CAS 169590-42-5
DM6LOQU CB CHEBI:41423
DM6LOQU DE Rheumatoid arthritis; Pain
DMD5LBX ID DMD5LBX
DMD5LBX DN Celiprolol HCL
DMD5LBX HS Approved
DMD5LBX SN Selectol (TN)
DMD5LBX DT Small molecular drug
DMD5LBX PC 42373
DMD5LBX MW 416
DMD5LBX FM C20H34ClN3O4
DMD5LBX IC InChI=1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
DMD5LBX CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl
DMD5LBX IK VKJHTUVLJYWAEY-UHFFFAOYSA-N
DMD5LBX IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea;hydrochloride
DMD5LBX CA CAS 57470-78-7
DMD5LBX CB CHEBI:31385
DMD5LBX DE Hypertension
DMYT2FP ID DMYT2FP
DMYT2FP DN Cellulose Sodium Phosphate
DMYT2FP HS Approved
DMYT2FP SN Calcibind
DMYT2FP CP Mission Pharmacal Co
DMYT2FP DE Hypercalciuria
DMTIUFA ID DMTIUFA
DMTIUFA DN Celtura
DMTIUFA HS Approved
DMTIUFA SN A/H1N1v; A/H1N1v vaccine (influenza virus infection), Novartis; H1N1 pandemic influenza A vaccine (MF59-adjuvanted, cell culture), Novartis
DMTIUFA CP Novartis AG
DMTIUFA DT Vaccine
DMTIUFA DE Influenza virus infection
DMKMJHE ID DMKMJHE
DMKMJHE DN Cemiplimab
DMKMJHE HS Approved
DMKMJHE SN REGN2810; REGN-2810; REGN 2810
DMKMJHE CP Regeneron/Sanofi
DMKMJHE DT Monoclonal antibody
DMKMJHE DE Cutaneous squamous cell carcinoma
DM8Y2RU ID DM8Y2RU
DM8Y2RU DN Cenegermin
DM8Y2RU HS Approved
DM8Y2RU SN cenegermin; Cenegermin [INN]; UNII-B6E7K36KT8; B6E7K36KT8; Human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli nerve growth factor
DM8Y2RU CP Domp
DM8Y2RU DT Antibody
DM8Y2RU DE Neurotrophic keratitis
DMXQS7K ID DMXQS7K
DMXQS7K DN Cenestin
DMXQS7K HS Approved
DMXQS7K SN Sodium equilin sulfate; Equilin sodium sulfate; Climopax; Estratab; 16680-47-0; Sodium equilin 3-monosulfate; Emopremarin; Novoconestron; Climestrone; Promarit; Primarin; Premarose; Premaril; Menotrol; Ganeake; Estropan; Estrifol; Premarina; Palopause; Menogen; Mannest; Hyphorin; Formatrix; Estromed; Equigyne; Prempak; Oestrilin; Menotab; Kestrin; Glyestrin; Estroate; Equilin 3-Sulfate Sodium Salt; Conjugen; Conestron; Ayerogen; Theogen; Sukingpo
DMXQS7K CP Duramed Pharmaceuticals Inc
DMXQS7K DT Small molecular drug
DMXQS7K PC 23676225
DMXQS7K MW 370.4
DMXQS7K FM C18H19NaO5S
DMXQS7K IC InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1
DMXQS7K CS C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)OS(=O)(=O)[O-])[C@@H]1CCC2=O.[Na+]
DMXQS7K IK QTTMOCOWZLSYSV-QWAPEVOJSA-M
DMXQS7K IU sodium;[(9S,13S,14S)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMXQS7K CA CAS 12126-59-9
DMXQS7K CB CHEBI:32143
DMXQS7K DE Menopause symptom; Osteoporosis
DM8KLU9 ID DM8KLU9
DM8KLU9 DN Cenobamate
DM8KLU9 HS Approved
DM8KLU9 SN Cenobamate; Cenobamate (USAN/INN); Cenobamate [INN]; Cenobamate [USAN:INN]; P85X70RZWS; SCHEMBL1682643; YKP3089; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; 913088-80-9; CHEMBL3989949; CS-0014686; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; HY-17607; UNII-P85X70RZWS
DM8KLU9 PC 11962412
DM8KLU9 MW 267.67
DM8KLU9 FM C10H10ClN5O2
DM8KLU9 IC GFHAXPJGXSQLPT-VIFPVBQESA-N
DM8KLU9 CS C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
DM8KLU9 IK 1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DM8KLU9 IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DM8KLU9 CA CAS 913088-80-9
DM8KLU9 DE Focal seizure
DMGOVHA ID DMGOVHA
DMGOVHA DN Cenobamate
DMGOVHA HS Approved
DMGOVHA SN Xcopri; UNII-P85X70RZWS; 913088-80-9; YKP3089; YKP-3089; P85X70RZWS; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate; (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl carbamate; Cenobamate [INN]; Xcopri (TN); YKP-3089 Cenobamate; Cenobamate (USAN/INN); Cenobamate [USAN:INN]; SCHEMBL1682643; CHEMBL3989949; GTPL10773; EX-A3604; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, 2-carbamate, (alphaR)-; Carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester; DB06119; 2H-Tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; HY-17607; CS-0014686; D11150; Q27286352
DMGOVHA DT Small molecular drug
DMGOVHA PC 11962412
DMGOVHA MW 267.67
DMGOVHA FM C10H10ClN5O2
DMGOVHA IC InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
DMGOVHA CS C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
DMGOVHA IK GFHAXPJGXSQLPT-VIFPVBQESA-N
DMGOVHA IU [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
DMGOVHA CA CAS 913088-80-9
DMGOVHA DE Complex partial seizure
DMD5JU8 ID DMD5JU8
DMD5JU8 DN Cephalexin
DMD5JU8 HS Approved
DMD5JU8 SN Adcadina; Ades[prex; Alcephin; Alexin; Alsporin; Ambal; Aristosporin; Azabort; Bactopenor; Beliam; Biocef; CEX; Carnosporin; Cefablan; Cefacet; Cefadal; Cefadin; Cefadina; Cefalekey; Cefaleksin; Cefalessina; Cefalexgobens; Cefalexin; Cefalexina; Cefalexine; Cefalexinum; Cefalin; Cefalival; Cefaloto; Cefaseptin; Cefax; Ceffanex; Cefibacter; Ceflax; Ceforal; Cefovit; Celexin; Cepastar; Cepexin; Cephacillin; Cephalexine; Cephalexinum; Cephalobene; Cephanasten; Cephaxin; Cephin; Cepol; Ceporex; Ceporexin; Ceporexine; Check; Cophalexin; Domucef; Doriman; Durantel; Efemida; Erocetin; Factagard; Felexin; Fexin; Ibilex; Ibrexin; Inphalex; Karilexina; Kefalospes; Keflet; Keflex; Kefolan; Keforal; Keftab; Kekrinal; Kidolex; Lafarine; Larixin; Lenocef; Lexibiotico; Loisine; Lonflex; Lopilexin; Losporal; Madlexin; Maksipor; Mamalexin; Mamlexin; Medolexin; Medoxine; Neokef; Neolexina; Noveol; Novolexin; Nufex; Oracef; Oriphex; Oroxin; Ortisporina; Ospexin; Palitrex; Pectril; Prindex; Pyassan; Rilexine; Roceph; Rogevil; Sanaxin; Sartosona; Sencephalin; Sepexin; Servicef; Servispor; Sialexin; Sinthecillin; Sintolexyn; Sporicef; Sporidex; Syncl; Syncle; Synecl; Tepaxin; Theratrex; Tokiolexin; Uphalexin; Viosporine; Voxxim; Winlex; Zabytrex; Zozarine; Cefalessina [DCIT]; Cefalexin Scand Pharm; Cefalexin Sodium; Cefalexin generics; Cefalexin hydrate; Cefalexin monohydrate; Cefalexina Northia; Cefalexina Richet; Cephalex von ct; Cephalexin hydrate; Cephalexin monohydrate; Ceporex Forte; Durantel DS; Henina Oral; Panixine Disperdose; Roceph Distab; Lilly 66873; S 6437; SQ 20248; Cefa-iskia; Cefalexin (JP15); Cefalexin.H2O; Cefalexina [INN-Spanish]; Cefalexine [INN-French]; Cefalexinum [INN-Latin]; Cephalexin(USP); Cephalexin (anhydrous); Cephalexin 1-hydrate; Cephalexin 1-wasser; Cephalexin [USAN:BAN]; Cephalexin.H2O; Ceporexin-E; Cusisporina-Cefalox; Ed A-Ceph; KS-1134; Keflex (TN); Keftab (TN); L-Keflex; Panixine disperdose (TN); Sporidex (TN); Cephalexin, (6R-(6alpha,7beta))-Isomer; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta (sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-methyl-delta3-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
DMD5JU8 CP Eli Lilly
DMD5JU8 TC Antibiotics
DMD5JU8 DT Small molecular drug
DMD5JU8 PC 27447
DMD5JU8 MW 347.4
DMD5JU8 FM C16H17N3O4S
DMD5JU8 IC InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
DMD5JU8 CS CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMD5JU8 IK ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
DMD5JU8 IU (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMD5JU8 CA CAS 15686-71-2
DMD5JU8 CB CHEBI:3534
DMD5JU8 DE Bacterial infection
DMYZITL ID DMYZITL
DMYZITL DN Cephaloglycin
DMYZITL HS Approved
DMYZITL SN CEG; Cefaloglicina; Cefaloglycin; Cefaloglycine; Cefaloglycinum; Cephaloglycine; Kafocin; Kefglycin; Cephaloglycinanhdyous; Cephaloglycin anhydrous; Cephaoglycin acid; Lilly 39435; Cefaloglicina [INN-Spanish]; Cefaloglycin (JAN); Cefaloglycine [INN-French]; Cefaloglycinum [INN-Latin]; Cephaloglycin (anhydrous); D-Cephaloglycine; D-(-)-Cephaloglycin; (6R,7R)-3-(acetoxymethyl)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-((Acetyloxy)methyl)-7-((aminophenylacetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-acetoxymethyl-7beta-[(2R)-2-amino-2-phenylacetamido]-3,4-didehydrocepham-4-carboxylic acid; 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester); 7-(2-Amino-2-phenylacetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)octane-2-carboxylic acid, acetate inner salt; 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup 3)-cephem-4-carboxylic acid; 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid; 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid
DMYZITL TC Antibiotics
DMYZITL DT Small molecular drug
DMYZITL PC 19150
DMYZITL MW 405.4
DMYZITL FM C18H19N3O6S
DMYZITL IC InChI=1S/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1
DMYZITL CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
DMYZITL IK FUBBGQLTSCSAON-PBFPGSCMSA-N
DMYZITL IU (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYZITL CA CAS 3577-01-3
DMYZITL CB CHEBI:34613
DMYZITL DE Bacterial infection
DM79XDW ID DM79XDW
DM79XDW DN Cephalosporin
DM79XDW HS Approved
DM79XDW SN Cephalothin (TN)
DM79XDW CP Eli Lilly
DM79XDW TC Antibiotics
DM79XDW DT Small molecular drug
DM79XDW PC 25058126
DM79XDW MW 387.4
DM79XDW FM C15H21N3O7S
DM79XDW IC InChI=1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1
DM79XDW CS C=C1CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)CCCC[C@H](C(=O)O)N
DM79XDW IK JGKXEMYIHDYWCZ-JFUSQASVSA-N
DM79XDW IU (2R)-2-[(R)-[[(6R)-6-amino-6-carboxyhexanoyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DM79XDW DE Bacterial infection
DM51Z9E ID DM51Z9E
DM51Z9E DN Cephalothin sodium
DM51Z9E HS Approved
DM51Z9E SN Cephalothin Sodium W/ Dextrose In Plastic Container; Cephalothin Sodium W/ Sodium Chloride In Plastic Container; Keflin In Plastic Container
DM51Z9E CP Eli Lilly And Co
DM51Z9E TC Antiinfective Agents
DM51Z9E DT Small molecular drug
DM51Z9E PC 23675321
DM51Z9E MW 418.4
DM51Z9E FM C16H15N2NaO6S2
DM51Z9E IC InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1
DM51Z9E CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CC3=CC=CS3)SC1)C(=O)[O-].[Na+]
DM51Z9E IK VUFGUVLLDPOSBC-XRZFDKQNSA-M
DM51Z9E IU sodium;(6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM51Z9E CA CAS 58-71-9
DM51Z9E CB CHEBI:3542
DM51Z9E DE Bacterial infection
DMV2JNY ID DMV2JNY
DMV2JNY DN Cephapirin
DMV2JNY HS Approved
DMV2JNY SN CEPR; Cefa; Cefadyl; Cefapirin; Cefapirina; Cefapirine; Cefapirinum; Cefaprin; Cephapirine; Metricure; CEPHAPIRIN SODIUM; Cefaprinsodium; Cephapirin Monosodium Salt; ANTIBIOTIC BL-P1322; BL-P 1322; Cefa-ak; Cefadyl (TN); Cefapirin (BAN); Cefapirin [INN:BAN]; Cefapirina [INN-Spanish]; Cefapirine [INN-French]; Cefapirinum [INN-Latin]; Metricure (TN); (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-acetoxymethyl-7-[(pyridin-4-ylsulfanyl)acetamido]-3,4-didehydrocepham-4-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamidol-5-thia-1-azabicyclo(4.2.0)oct-2-en-2carbonsaeure acetat; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(4-pyridylthio)acetamido)-, acetate (ester); 7-(2-(4-Pyridylthio)acetamido)cephalosporanic acid
DMV2JNY TC Antibiotics
DMV2JNY DT Small molecular drug
DMV2JNY PC 30699
DMV2JNY MW 423.5
DMV2JNY FM C17H17N3O6S2
DMV2JNY IC InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1
DMV2JNY CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CSC3=CC=NC=C3)SC1)C(=O)O
DMV2JNY IK UQLLWWBDSUHNEB-CZUORRHYSA-N
DMV2JNY IU (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMV2JNY CA CAS 21593-23-7
DMV2JNY CB CHEBI:554446
DMV2JNY DE Sepsis
DM9Y5JB ID DM9Y5JB
DM9Y5JB DN Cepharanthine
DM9Y5JB HS Approved
DM9Y5JB SN CEPHARANTHINE; Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; CCRIS 6539; NSC 623442; BRN 0075231; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); NSC-623442; ecaene (non-preferred name); DSSTox_RID_81253; DSSTox_CID_25957; DSSTox_GSID_45957; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; CAS-481-49-2; SR-01000779734; Cepharanthin,(S)
DM9Y5JB PC 10206
DM9Y5JB MW 606.7
DM9Y5JB FM C37H38N2O6
DM9Y5JB IC InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1
DM9Y5JB CS CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
DM9Y5JB IK YVPXVXANRNDGTA-WDYNHAJCSA-N
DM9Y5JB IU (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
DM9Y5JB CA CAS 481-49-2
DM9Y5JB CB CHEBI:3546
DM9Y5JB DE Thrombocytopenia
DMB920Z ID DMB920Z
DMB920Z DN Ceritinib
DMB920Z HS Approved
DMB920Z SN ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
DMB920Z DT Small molecular drug
DMB920Z PC 57379345
DMB920Z MW 558.1
DMB920Z FM C28H36ClN5O3S
DMB920Z IC InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
DMB920Z CS CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl
DMB920Z IK VERWOWGGCGHDQE-UHFFFAOYSA-N
DMB920Z IU 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
DMB920Z CA CAS 1032900-25-6
DMB920Z CB CHEBI:78432
DMB920Z DE Non-small-cell lung cancer
DMXCM7H ID DMXCM7H
DMXCM7H DN Cerivastatin
DMXCM7H HS Approved
DMXCM7H SN cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
DMXCM7H DT Small molecular drug
DMXCM7H PC 446156
DMXCM7H MW 459.5
DMXCM7H FM C26H34FNO5
DMXCM7H IC InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
DMXCM7H CS CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
DMXCM7H IK SEERZIQQUAZTOL-ANMDKAQQSA-N
DMXCM7H IU (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMXCM7H CA CAS 145599-86-6
DMXCM7H CB CHEBI:3558
DMXCM7H DE Hyperlipidaemia; Multiple myeloma
DM0HAC8 ID DM0HAC8
DM0HAC8 DN Cerliponase Alfa
DM0HAC8 HS Approved
DM0HAC8 SN Brineura
DM0HAC8 CP BioMarin Pharmaceutical
DM0HAC8 DT Recombinant protein
DM0HAC8 SQ Cerliponase alfa Sequence: SYSPEPDQRRTLPPGWVSLGRADPEEELSLTFALRQQNVERLSELVQAVSDPSSPQYGKYLTLENVADLVRPSPLTLHTVQKWLLAAGAQKCHSVITQDFLTCWLSIRQAELLLPGAEFHHYVGGPTETHVVRSPHPYQLPQALAPHVDFVGGLHRFPPTSSLRQRPEPQVTGTVGLHLGVTPSVIRKRYNLTSQDVGSGTSNNSQACAQFLEQYFHDSDLAQFMRLFGGNFAHQASVARVVGQQGRGRAGIEASLDVQYLMSAGANISTWVYSSPGRHEGQEPFLQWLMLLSNESALPHVHTVSYGDDEDSLSSAYIQRVNTELMKAAARGLTLLFASGDSGAGCWSVSGRHQFRPTFPASSPYVTTVGGTSFQEPFLITNEIVDYISGGGFSNVFPRPSYQEEAVTKFLSSSPHLPPSSYFNASGRAYPDVAALSDGYWVVSNRVPIPWVSGTSASTPVFGGILSLINEHRILSGRPPLGFLNPRLYQQHGAGLFDVTRGCHESCLDEEVEGQGFCSGPGWDPVTGWGTPNFPALLKTLLNP
DM0HAC8 DE Tripeptidyl peptidase 1 deficiency; Neuronal ceroid lipofuscinosis
DM5CL9Z ID DM5CL9Z
DM5CL9Z DN Certolizumab
DM5CL9Z HS Approved
DM5CL9Z SN CDP-870; Cimzia; PHA-738144; Simziya
DM5CL9Z CP UCB
DM5CL9Z DT Monoclonal antibody
DM5CL9Z DE Rheumatoid arthritis
DMUR94J ID DMUR94J
DMUR94J DN Certoparin sodium
DMUR94J HS Approved
DMUR94J SN Alphaparin (TN)
DMUR94J DE Deep vein thrombosis
DM6N4PR ID DM6N4PR
DM6N4PR DN Cerulenin
DM6N4PR HS Approved
DM6N4PR SN Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide
DM6N4PR TC Antiinfective Agents
DM6N4PR DT Small molecular drug
DM6N4PR PC 5282054
DM6N4PR MW 223.27
DM6N4PR FM C12H17NO3
DM6N4PR IC InChI=1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+/t10-,11-/m1/s1
DM6N4PR CS C/C=C/C/C=C/CCC(=O)[C@@H]1[C@@H](O1)C(=O)N
DM6N4PR IK GVEZIHKRYBHEFX-NQQPLRFYSA-N
DM6N4PR IU (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide
DM6N4PR CA CAS 17397-89-6
DM6N4PR CB CHEBI:171741
DM6N4PR DE Weight loss
DM2WE5K ID DM2WE5K
DM2WE5K DN Ceruletide
DM2WE5K HS Approved
DM2WE5K SN Caerulein; Cerulein; Ceruletida; Ceruletidum; Ceruletida [INN-Spanish]; Ceruletidum [INN-Latin]; Ceruletide (USAN/INN); Ceruletide [USAN:INN:BAN]; 5-Oxo-L-prolyl-L-glutaminyl-L-alpha-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide; 5-Oxo-L-prolyl-L-glutaminyl-L-aspartyl-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide 4-(hydrogen sulfate) (ester); 5-oxo-L-prolyl-L-glutaminyl-L-a-aspartyl-O-sulfo-L-tyrosyl-L-threonylglycyl-L-tryptophyl-L-methionyl-L-a-aspartyl-L-phenylalaninamide
DM2WE5K CP Pharmacia And Upjohn Co
DM2WE5K TC Diagnostic Agents
DM2WE5K DT Small molecular drug
DM2WE5K PC 16129675
DM2WE5K MW 1352.4
DM2WE5K FM C58H73N13O21S2
DM2WE5K IC InChI=1S/C58H73N13O21S2/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91)/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+/m1/s1
DM2WE5K CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O
DM2WE5K IK YRALAIOMGQZKOW-HYAOXDFASA-N
DM2WE5K IU (3S)-3-[[(2S)-5-amino-5-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-[[(2S)-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DM2WE5K CA CAS 17650-98-5
DM2WE5K CB CHEBI:59219
DM2WE5K DE Caerulein stimulated gastric and pancreatic secretion; Solid tumour/cancer
DMOMP9U ID DMOMP9U
DMOMP9U DN Cetirizine
DMOMP9U HS Approved
DMOMP9U SN Cetiderm; Cetirizin; Cetirizina; Cetirizinum; Cetryn; Setir; Virlix; Ziptek; Zirtek; Zyrlex; Cetirizina [Spanish]; Cetirizinum [Latin]; Cetrizine Hcl; Hitrizin Film Tablet; Cetiderm (TN); Cetirizine (INN); Cetirizine [INN:BAN]; P-071; Reactine (TN); Zyrtec (TN); [(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid; (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid; (2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U CP Pfizer Pharmaceuticals
DMOMP9U TC Antiallergic Agents
DMOMP9U DT Small molecular drug
DMOMP9U PC 2678
DMOMP9U MW 388.9
DMOMP9U FM C21H25ClN2O3
DMOMP9U IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)
DMOMP9U CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMOMP9U IK ZKLPARSLTMPFCP-UHFFFAOYSA-N
DMOMP9U IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMOMP9U CA CAS 83881-51-0
DMOMP9U CB CHEBI:3561
DMOMP9U DE Allergic rhinitis
DMSP4JX ID DMSP4JX
DMSP4JX DN Cetraxate
DMSP4JX HS Approved
DMSP4JX SN Neuer; NeuerCap; NeuerS; Cetraxate hydrochloride; DV-1006
DMSP4JX CP Daiichi Seiyaku Co Ltd
DMSP4JX DT Small molecular drug
DMSP4JX PC 2680
DMSP4JX MW 305.4
DMSP4JX FM C17H23NO4
DMSP4JX IC InChI=1S/C17H23NO4/c18-11-13-1-6-14(7-2-13)17(21)22-15-8-3-12(4-9-15)5-10-16(19)20/h3-4,8-9,13-14H,1-2,5-7,10-11,18H2,(H,19,20)
DMSP4JX CS C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O
DMSP4JX IK FHRSHSOEWXUORL-UHFFFAOYSA-N
DMSP4JX IU 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
DMSP4JX CA CAS 34675-84-8
DMSP4JX CB CHEBI:17340
DMSP4JX DE Peptic ulcer
DMFD9Q6 ID DMFD9Q6
DMFD9Q6 DN Cetrorelix
DMFD9Q6 HS Approved
DMFD9Q6 SN Cetrorelixum; Cetrorelix (INN); Cetrotide (TN); HS-2008; Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2; N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide; N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
DMFD9Q6 CP Merck Serono
DMFD9Q6 TC Infertility Agents
DMFD9Q6 DT Small molecular drug
DMFD9Q6 PC 25074887
DMFD9Q6 MW 1431
DMFD9Q6 FM C70H92ClN17O14
DMFD9Q6 IC InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1
DMFD9Q6 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMFD9Q6 IK SBNPWPIBESPSIF-MHWMIDJBSA-N
DMFD9Q6 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFD9Q6 CA CAS 120287-85-6
DMFD9Q6 CB CHEBI:59224
DMFD9Q6 DE Ovarian stimulation
DMLNCE0 ID DMLNCE0
DMLNCE0 DN Cetuximab
DMLNCE0 HS Approved
DMLNCE0 SN Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors
DMLNCE0 CP Bristol-Myers Squibb
DMLNCE0 TC Anticancer Agents
DMLNCE0 DT Antibody
DMLNCE0 SQ Cetuximab heavy chain: QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Cetuximab light chainDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMLNCE0 DE Colorectal cancer
DMWSMND ID DMWSMND
DMWSMND DN Cevimeline
DMWSMND HS Approved
DMWSMND SN Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
DMWSMND CP Daiichi Sankyo Pharma Development
DMWSMND TC Parasympathomimetics
DMWSMND DT Small molecular drug
DMWSMND PC 83898
DMWSMND MW 199.32
DMWSMND FM C10H17NOS
DMWSMND IC InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1
DMWSMND CS C[C@@H]1O[C@]2(CN3CCC2CC3)CS1
DMWSMND IK WUTYZMFRCNBCHQ-PSASIEDQSA-N
DMWSMND IU (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
DMWSMND CA CAS 107233-08-9
DMWSMND DE Sjogren syndrome
DMKN345 ID DMKN345
DMKN345 DN Charybdotoxin
DMKN345 HS Approved
DMKN345 SN ChTX; CTX Toxin; Quinquestriatus Toxin; Charybdotoxin (reduced); Toxin, CTX; Toxin, Quinquestriatus
DMKN345 DT Small molecular drug
DMKN345 PC 56842037
DMKN345 MW 4296
DMKN345 FM C176H277N57O55S7
DMKN345 IC InChI=1S/C176H277N57O55S7/c1-81(2)58-106-149(263)213-110(62-91-67-191-80-197-91)152(266)215-112(64-127(183)246)156(270)231-135(85(8)240)170(284)219-114(69-234)157(271)200-95(36-25-54-192-174(185)186)138(252)196-68-130(249)199-96(32-17-21-50-177)139(253)222-120-75-291-295-79-124(226-159(273)116(71-236)218-167(281)132(82(3)4)228-155(269)113(65-128(184)247)216-169(283)134(84(7)239)230-154(268)108(59-88-28-13-12-14-29-88)210-145(259)102-44-47-129(248)198-102)166(280)232-137(87(10)242)172(286)233-136(86(9)241)171(285)220-115(70-235)158(272)204-98(34-19-23-52-179)141(255)206-104(45-48-131(250)251)147(261)225-122-77-292-290-74-119(223-143(257)99(35-20-24-53-180)201-140(254)97(33-18-22-51-178)203-153(267)111(63-126(182)245)214-148(262)105(49-57-289-11)208-162(120)276)161(275)205-101(38-27-56-194-176(189)190)144(258)224-121(164(278)211-107(60-89-39-41-92(243)42-40-89)150(264)221-118(73-238)173(287)288)76-293-294-78-123(163(277)207-103(43-46-125(181)244)146(260)202-100(142(256)209-106)37-26-55-193-175(187)188)227-168(282)133(83(5)6)229-160(274)117(72-237)217-151(265)109(212-165(122)279)61-90-66-195-94-31-16-15-30-93(90)94/h12-16,28-31,39-42,66-67,80-87,95-124,132-137,195,234-243H,17-27,32-38,43-65,68-79,177-180H2,1-11H3,(H2,181,244)(H2,182,245)(H2,183,246)(H2,184,247)(H,191,197)(H,196,252)(H,198,248)(H,199,249)(H,200,271)(H,201,254)(H,202,260)(H,203,267)(H,204,272)(H,205,275)(H,206,255)(H,207,277)(H,208,276)(H,209,256)(H,210,259)(H,211,278)(H,212,279)(H,213,263)(H,214,262)(H,215,266)(H,216,283)(H,217,265)(H,218,281)(H,219,284)(H,220,285)(H,221,264)(H,222,253)(H,223,257)(H,224,258)(H,225,261)(H,226,273)(H,227,282)(H,228,269)(H,229,274)(H,230,268)(H,231,270)(H,232,280)(H,233,286)(H,250,251)(H,287,288)(H4,185,186,192)(H4,187,188,193)(H4,189,190,194)/t84-,85-,86-,87-,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,132+,133+,134+,135+,136+,137+/m1/s1
DMKN345 CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCCN)CCCCN)CC(=O)N)CCSC)CCCCN)CCCNC(=N)N)CO)[C@@H](C)O)CC(=O)N)CC6=CN=CN6)CC(C)C)CCCNC(=N)N)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC7=CNC8=CC=CC=C87)CO)C(C)C)C(=O)N[C@@H](CC9=CC=C(C=C9)O)C(=O)N[C@@H](CO)C(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CO)[C@@H](C)O)O
DMKN345 IK CNVQLPPZGABUCM-LIGYZCPXSA-N
DMKN345 IU (2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(1R,4S,7R,12R,15S,18S,21S,24S,27S,30S,33S,36S,42S,45R,50R,53S,56S,59S,62S,65S,68R,75S,78S,81S,84S,89S,92S,95S)-42,62,75,78-tetrakis(4-aminobutyl)-50-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-27,81-bis(2-amino-2-oxoethyl)-15-(3-amino-3-oxopropyl)-4,18,36-tris(3-carbamimidamidopropyl)-65-(2-carboxyethyl)-30,53,56-tris[(1R)-1-hydroxyethyl]-33,59,92-tris(hydroxymethyl)-24-(1H-imidazol-5-ylmethyl)-89-(1H-indol-3-ylmethyl)-21-(2-methylpropyl)-84-(2-methylsulfanylethyl)-2,5,13,16,19,22,25,28,31,34,37,40,43,51,54,57,60,63,66,74,77,80,83,86,87,90,93,96-octacosaoxo-95-propan-2-yl-9,10,47,48,70,71-hexathia-3,6,14,17,20,23,26,29,32,35,38,41,44,52,55,58,61,64,67,73,76,79,82,85,88,91,94,97-octacosazatricyclo[43.27.14.1112,68]heptanonacontane-7-carbonyl]amino]propanoyl]amino]propanoic acid
DMKN345 CA CAS 95751-30-7
DMKN345 DE Scorpion envenoming syndrome
DMQ8JIK ID DMQ8JIK
DMQ8JIK DN Chenodiol
DMQ8JIK HS Approved
DMQ8JIK SN 474-25-9; Chenix; Chenic acid; Chenodeoxycholate; Gallodesoxycholic acid; Chendol; Chenodesoxycholic acid; Cdca; Chenofalk; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Henohol; Chenique Acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum
DMQ8JIK CP Sigma Tau Pharmaceuticals Inc
DMQ8JIK DT Small molecular drug
DMQ8JIK PC 10133
DMQ8JIK MW 392.6
DMQ8JIK FM C24H40O4
DMQ8JIK IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
DMQ8JIK CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMQ8JIK IK RUDATBOHQWOJDD-BSWAIDMHSA-N
DMQ8JIK IU (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMQ8JIK CA CAS 474-25-9
DMQ8JIK CB CHEBI:16755
DMQ8JIK DE Cholelithiasis
DMXGJEI ID DMXGJEI
DMXGJEI DN Chlophedianol
DMXGJEI HS Approved
DMXGJEI SN Abehol; Antitussin; Calmotusin; Chlofedanol; Clofedano; Clofedanol; Clofedanolum; Clofedianolo; Dencyl; Eutus; Tussistop; Clofedianolo [Italian]; Clophedianol base; Ulo base; SL 501 base; Antitussin (TN); Clofedanol (INN); Clofedanol [INN:BAN]; Clofedanolum [INN-Latin]; Ulone (TN); Alpha-(Dimethylaminoethyl)-o-chlorobenzhydrol; Benzenemethanol, 2-chloro-alpha-(2-(dimethylamino)ethyl)-alpha-phenyl-(9CI); 1-(2-Chlorophenyl)-1-phenyl-3-dimethylaminopropanol; 1-(2-Chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol; 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol; 1-(2-chlorophenyl)-3-dimethylamino-1-phenylpropan-1-ol; 1-Phenyl-1-(o-chlorophenyl)-3-dimethylaminopropanol; 2-Chloro-.alpha.-(2-dimethylaminoethyl)benzhydrol; 2-Chloro-alpha-(2-(dimethylamino)ethyl)benzhydrol; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo; 2-Cloro-alpha-(2-dimetilaminoetil)-benzidrolo [Italian]
DMXGJEI CP 3m Pharmaceuticals Inc
DMXGJEI TC Anesthetics
DMXGJEI DT Small molecular drug
DMXGJEI PC 2795
DMXGJEI MW 289.8
DMXGJEI FM C17H20ClNO
DMXGJEI IC InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3
DMXGJEI CS CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O
DMXGJEI IK WRCHFMBCVFFYEQ-UHFFFAOYSA-N
DMXGJEI IU 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol
DMXGJEI CA CAS 791-35-5
DMXGJEI CB CHEBI:135207
DMXGJEI DE Dry cough; Anaesthesia
DMRKE63 ID DMRKE63
DMRKE63 DN Chlorambucil
DMRKE63 HS Approved
DMRKE63 SN Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN)
DMRKE63 CP GlaxoSmithKline
DMRKE63 TC Anticancer Agents
DMRKE63 DT Small molecular drug
DMRKE63 PC 2708
DMRKE63 MW 304.2
DMRKE63 FM C14H19Cl2NO2
DMRKE63 IC InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
DMRKE63 CS C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
DMRKE63 IK JCKYGMPEJWAADB-UHFFFAOYSA-N
DMRKE63 IU 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid
DMRKE63 CA CAS 305-03-3
DMRKE63 CB CHEBI:28830
DMRKE63 DE Chronic lymphocytic leukaemia
DMFXEWT ID DMFXEWT
DMFXEWT DN Chloramphenicol
DMFXEWT HS Approved
DMFXEWT SN Alficetyn; Ambofen; Amphenicol; Amphicol; Amseclor; Anacetin; Aquamycetin; Austracil; Austracol; Biocetin; Biophenicol; CAF; CLM; Catilan; Chemiceticol; Chemicetin; Chemicetina; Chlomin; Chlomycol; Chloramex; Chloramfenikol; Chloramficin; Chloramfilin; Chloramphenicolum; Chloramsaar; Chlorasol; Chloricol; Chlornitromycin; Chloroamphenicol; Chlorocaps; Chlorocid; Chlorocide; Chlorocol; Chlorofair; Chloromax; Chloromycetin; Chloromycetny; Chloromyxin; Chloronitrin; Chloroptic; Chlorovules; Chlorsig; Cidocetine; Ciplamycetin; Cloramfen; Cloramfenicol; Cloramfenicolo; Cloramficin; Cloramical; Cloramicol; Cloramidina; Cloranfenicol; Cloroamfenicolo; Clorocyn; Cloromisan; Cloromissan; Clorosintex; Comycetin; Cylphenicol; Desphen; Detreomycin; Detreomycine; Dextromycetin; Doctamicina; Duphenicol; Econochlor; Embacetin; Emetren; Enicol; Enteromycetin; Erbaplast; Ertilen; Farmicetina; Fenicol; Globenicol; Glorous; Halomycetin; Hortfenicol; Interomycetine; Intramycetin; Intramyctin; Isicetin; Ismicetina; Isophenicol; Juvamycetin; Kamaver; Kemicetina; Kemicetine; Kloramfenikol; Klorita; Laevomycetinum; Leukamycin; Leukomyan; Leukomycin; Levomicetina; Levomitsetin; Levomycetin; Loromicetina; Loromisan; Loromisin; Mastiphen; Mediamycetine; Medichol; Micloretin; Micochlorine; Micoclorina; Microcetina; Mychel; Mycinol; Myscel; Novochlorocap; Novomycetin; Novophenicol; Oftalent; Oleomycetin; Opclor; Opelor; Ophthochlor; Ophtochlor; Optomycin; Otachron; Otophen; Pantovernil; Paraxin; Pentamycetin; Quemicetina; Rivomycin; Romphenil; Ronfenil; Ronphenil; Septicol; Sificetina; Sintomicetina; Stanomycetin; Synthomycetin; Synthomycetine; Synthomycine; Syntomycin; Tevcocin; Tevcosin; Tifomycin; Tifomycine;Tiromycetin; Treomicetina; Unimycetin; Veticol; Viceton; Ch loramex; Chloramfenikol [Czech]; Chloramphenicol crystalline; Chlormycetin R; Chlorocid S; Chlorocidin C; Chlorocidin C tetran; Chloroject L; Chloromycetny [Polish]; Cloramfenicolo [DCIT]; Cloroamfenicolo [Italian]; F armicetina; Isopto fenicol; Klorocid S; Normimycin V; Sintomicetine R; Sno Phenicol; Vice ton; I 337A; Ak-chlor; Alficetyn (TN); Amphicol (TN); Biomicin (TN); Brochlor (TN); CAF (pharmaceutical); Cedoctine (TN); Chlora-tabs; Chloramex (TN); Chloramphenicol & VRC3375; Chloramphenicolum [INN-Latin]; Chlorbiotic (Veterinary); Chlornitromycin (TN); Chloro-25 vetag; Chloromycetin (TN); Chlorsig (TN); Cloramfenicol [INN-Spanish]; D-Chloramphenicol; Dispersadron C (TN); Econochlor (TN); Elase-Chloromycetin; Fenicol (TN); Golden Eye (TN); Isoptophenicol (TN); Kemicetine (TN); Laevomycetin (TN); Medicom (TN); Mychel-Vet; Nevimycin (TN); Oftan Chlora (TN); Optrex Infected Eyes (TN); Orchadexoline (TN); Phenicol (TN); Renicol (TN); Silmycetin (TN); Sno-Phenicol; Synthomycine (TN); Tea-Cetin; Tega-Cetin; Tifomycine (TN); U-6062; Vernacetin (TN); Veticol (TN); C.A.F; CHLOROPTIC S.O.P; Chloramphenicol [INN:BAN:JAN]; Chloromycetin® D-threo-Chloramphenicol; Alficetyn, Chlornitromycin, Chloromycetin, Chloramphenicol; Chloramphenicol (JP15/USP/INN); Chloroptic S.O.P.; D(-)-threo-Chloramphenicol; D-(-)-Chloramphenicol; D-(-)-threo-Chloramphenicol; D(-)-threo-2-dichloroacetamido-1-p-nitrophen yl-propanediol; D(-)-threo-2-dichloroacetamido-1-p-nitrophenyl-propanediol
DMFXEWT CP Aventis Pharmaceuticals Inc.
DMFXEWT TC Antibiotics
DMFXEWT DT Small molecular drug
DMFXEWT PC 5959
DMFXEWT MW 323.13
DMFXEWT FM C11H12Cl2N2O5
DMFXEWT IC InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
DMFXEWT CS C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
DMFXEWT IK WIIZWVCIJKGZOK-RKDXNWHRSA-N
DMFXEWT IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
DMFXEWT CA CAS 56-75-7
DMFXEWT CB CHEBI:17698
DMFXEWT DE Bacterial infection
DMTN5XI ID DMTN5XI
DMTN5XI DN Chlordiazepoxide
DMTN5XI HS Approved
DMTN5XI SN Abboxide; Balance; Chloradiazepoxide; Chlordiazachel; Chlordiazepoxid; Chlordiazepoxidum; Chlordiazepoxydum; Chloridazepoxide; Chloridiazepide; Chloridiazepoxide; Chlorodiazepoxide; Chlozepid; Clopoxide; Clordiazepossido; Clordiazepoxido; Control; Decacil; Disarim; Eden; Elenium; Helogaphen; Ifibrium; Kalmocaps; Librelease; Librinin; Libritabs; Librium; Lygen; Menrium; Mesural; Methaminodiazepoxide; Mildmen; Multum; Napoton; Napton; Psicosan; Radepur; Risolid; Silibrin; Sonimen; Tropium; Viopsicol; Zeisin; Zetran; Chlordiazepoxide Base; Clordiazepossido [Italian]; A-Poxide; Apo-Chlordiazepoxide; Balance (pharmaceutical); Chlordiazepoxidum [INN-Latin]; Clordiazepoxido [INN-Spanish]; Eden-psich; Libritabs (TN); Librium (TN); MENRIUM 10-4; MENRIUM 5-4; Novapam (TN); Novo-Poxide; Tropium (TN); Chlordiazepoxide (JP15/USP/INN); Chlordiazepoxide [USAN:INN:BAN:JAN]; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl, 4-oxide; 3H-1,4-Benzodiazepin-2-amine, 7-chloro-N-methyl-5-phenyl-, 4-oxide; 3H-1,4-Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide; 3H-1,4-benzodiazepin-2-amine,7-chloro-N-methyl-5-phenyl-,4-oxide; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid; 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxid [German]; 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido; 7-Cloro-2-metilamino-5-fenil-3H-1,4-benzodiazepina 4-ossido [Italian]; 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI CP Patheon Pharmaceuticals Inc
DMTN5XI TC Antianxiety Agents
DMTN5XI DT Small molecular drug
DMTN5XI PC 2712
DMTN5XI MW 299.75
DMTN5XI FM C16H14ClN3O
DMTN5XI IC InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3
DMTN5XI CS CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
DMTN5XI IK BUCORZSTKDOEKQ-UHFFFAOYSA-N
DMTN5XI IU 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine
DMTN5XI CA CAS 58-25-3
DMTN5XI CB CHEBI:3611
DMTN5XI DE Anxiety disorder
DMQ9MVG ID DMQ9MVG
DMQ9MVG DN Chlorhexidine
DMQ9MVG HS Approved
DMQ9MVG SN AVAGARD; Chlorhexidin; Chlorhexidinum; Cloresidina; Clorhexidina; Fimeil; Hexadol; Hibiclens; Hibispray; Hibistat;Nolvasan; Novalsan; Peridex; Periogard; Rotersept; Savloclens; Soretol; Sterido; Sterilon; Superspray; Tubulicid; Chlorhexidin [Czech]; Chlorhexidine Base; Chlorhexidine gluconate; Cloresidina [DCIT]; Decanoylacetaldehyde Sodium Sulfide; Dentisept [veterinary]; Savlon babycare; Sebidin A; Sodium Houttuyfonamide; Avagard (TN); BIOPATCH (TN); ChloraPrep (TN); Chlorhexamed (TN); Chlorhexidine (INN);Chlorhexidine [INN:BAN]; Chlorhexidinum [INN-Latin]; Chlorohex (TN); Clohex (TN); Clorexil (TN); Clorhexidina [INN-Spanish]; Corsodyl (TN); Dentisept [veterinary] (TN); Dexidin (TN); Exidine (TN); Hibiclens (TN); Hibiscrub (TN); MK-412A; Merfen-incolore; Oro-Clense; Oronine (TN); Perichlor (TN); Peridex (TN); Peridont (TN); Periochip (TN); Periogard Oral Rinse (TN); Perioxidina (TN); Savacol (TN); Suthol (TN); Dejavu-MW (TN); Merfen-incolore (TN); Lisium (*Dihydrochloride*); Nolvasan (*Diacetate*); SOLU-I.V (TN); N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide; N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]; N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca-nediimidamide; N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]; 1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]; 1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide); 1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide; 1,6-Bis(5-(p-chlorophenyl)biguandino)hexane; 1,6-Bis(p-chlorophenyldiguanido)hexane; 1,6-Di(4'-chlorophenyldiguanido)hexane; 1,6-Di(N-p-chlorophenyldiguanido)hexane
DMQ9MVG CP G. D. Pharmaceuticals
DMQ9MVG TC Antibiotics
DMQ9MVG DT Small molecular drug
DMQ9MVG PC 9552079
DMQ9MVG MW 505.4
DMQ9MVG FM C22H30Cl2N10
DMQ9MVG IC InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)
DMQ9MVG CS C1=CC(=CC=C1N/C(=N/C(=NCCCCCCN=C(/N=C(/NC2=CC=C(C=C2)Cl)\\N)N)N)/N)Cl
DMQ9MVG IK GHXZTYHSJHQHIJ-UHFFFAOYSA-N
DMQ9MVG IU (1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine
DMQ9MVG CA CAS 55-56-1
DMQ9MVG CB CHEBI:3614
DMQ9MVG DE Bacterial infection
DMSF4PR ID DMSF4PR
DMSF4PR DN Chlormerodrin
DMSF4PR HS Approved
DMSF4PR SN Chlormerodrina; Chloromeridin; Neogidrin; Chlormerodrin Hg 197; Chlormerodrin Hg 203; Chlormerodrin (197Hg); Chlormerodrin (203Hg); Chlormerodrin Hg 197 (TN); Chlormerodrin Hg 197 (USAN); Chlormerodrin Hg 197 [USAN:USP XX]; Chlormerodrin Hg 203 (USAN); Hg-203 chlormerodrin; Loro-}; Neohydrin-203; Chlormerodrin (197Hg) (INN); Neohydrin-203 (TN); Mercury, [3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro; Urea, (2-methoxypropyl)-, mercury complex; [3-(carbamoylamino)-2-methoxypropyl](chloro)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury; {[3-(Chloromercuri)-2-methoxypropyl]urea}; {[3-[(Aminocarbonyl)amino]-2-hydroxypropyl]chloromercury}; [3-(carbamoylamino)-2-methoxypropyl](chloro)(203hg)mercury; [3-(carbamoylamino)-2-methoxypropyl]-chloromercury-203; Chloro(2-methoxy-3-ureidopropyl)((203)Hg)mercury(II); Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl]chloro-}; [3-(carbamoylamino)-2-methoxypropyl](chloro)((203)Hg)mercury; Mercury, {[3-[(aminocarbonyl)amino]-2-methoxypropyl-C1,O3]ch; (3-(Chloromercuri)-2-methoxypropyl)urea; 3-Chloromercuri-2-methoxypropylurea; 3-ureido-2-methoxypropyl((203)Hg)mercury(II) chloride
DMSF4PR TC Diagnostic Agents
DMSF4PR DT Small molecular drug
DMSF4PR PC 25210
DMSF4PR MW 367.2
DMSF4PR FM C5H11ClHgN2O2
DMSF4PR IC InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1
DMSF4PR CS COC(CNC(=O)N)C[Hg]Cl
DMSF4PR IK BJFGVYCULWBXKF-UHFFFAOYSA-M
DMSF4PR IU [3-(carbamoylamino)-2-methoxypropyl]-chloromercury
DMSF4PR CA CAS 10375-56-1
DMSF4PR CB CHEBI:59445
DMSF4PR DE Diagnostic imaging
DMTWUXR ID DMTWUXR
DMTWUXR DN Chlormezanone
DMTWUXR HS Approved
DMTWUXR SN Alinam; Banabin; Bisina; Chlomedinon; Chlormethazanone; Chlormethazone; Chlormezanon; Chlormezanona; Chlormezanonum; Clorilax; Clormetazanone; Clormetazon; Clormezanona; Clormezanone; Dichloromethazanone; Dichloromezanone; Lobak; Miorilax; Muskel; Myolespen; Phenarol; Rexan; Rilansyl; Rilaquil; Rilasol; Rilassol; Rilax; Rillasol; Supotran; Suprotan; Tanafol; Trancopal; Trancote; Tranrilax; Transanate; Clormezanone [DCIT]; WIN 4692; Banabil-sintyal; Banabin-sintyal; Banabin-syntyal; C-192; Chlormezanonum [INN-Latin]; Clormezanona [INN-Spanish]; Dl-Chlormezanone; Mio-sed; Muskel-Trancopal; TRANCOPAL (TN); Trancopal (TN); Chlormezanone (JAN/INN); Chlormezanone [BAN:INN:JAN]; Chlormezanone [INN:BAN:JAN]; (+-)-Chlormezanone; 2-(4-Chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide; 2-(4-Chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H,1,3-thiazin-4-one 1,1-Dioxide; 2-(4-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(4-Chlorphenyl)-3-methyl-4-metathiazanon-1,1-dioxid; 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one; 2-(p-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one 1,1-dioxide; 2-(p-Chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxide; 2-(para-Chlorophenyl)tetrahydro-3-methyl-4H-1,3-thiazin-4-one, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1,-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide; 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-1,1-dioxide; 4H-1,3-Thiazin-4-one, tetrahydro-2-(p-chlorophenyl)-3-methyl-, 1,1-dioxide
DMTWUXR TC Analgesics
DMTWUXR DT Small molecular drug
DMTWUXR PC 2717
DMTWUXR MW 273.74
DMTWUXR FM C11H12ClNO3S
DMTWUXR IC InChI=1S/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3
DMTWUXR CS CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl
DMTWUXR IK WEQAYVWKMWHEJO-UHFFFAOYSA-N
DMTWUXR IU 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
DMTWUXR CA CAS 80-77-3
DMTWUXR CB CHEBI:3619
DMTWUXR DE Anxiety disorder
DMSOQK1 ID DMSOQK1
DMSOQK1 DN Chloroprocaine
DMSOQK1 HS Approved
DMSOQK1 SN Chloroprocain; Chloroprocainum; Chlorprocaine; Chlorprocainum; Cloroprocaina; Halestyn; Nesacaine; Piocaine; Chloroprocaine [INN]; Chloroprocaine hydrochloride; Nesacaine MPF; Chlor-procaine; Chloroprocaine (INN); Chloroprocainum [INN-Latin]; Cloroprocaina [INN-Spanish]; Nesacaine (TN); Nesacaine-Ce; Nesacaine-MPF (TN); Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate; 2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate; 2-Chloroprocaine; 2-diethylaminoethyl 4-amino-2-chlorobenzoate; 4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester
DMSOQK1 CP Abbott Laboratories
DMSOQK1 TC Anesthetics
DMSOQK1 DT Small molecular drug
DMSOQK1 PC 8612
DMSOQK1 MW 270.75
DMSOQK1 FM C13H19ClN2O2
DMSOQK1 IC InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
DMSOQK1 CS CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl
DMSOQK1 IK VDANGULDQQJODZ-UHFFFAOYSA-N
DMSOQK1 IU 2-(diethylamino)ethyl 4-amino-2-chlorobenzoate
DMSOQK1 CA CAS 133-16-4
DMSOQK1 CB CHEBI:3636
DMSOQK1 DE Anaesthesia
DMSI5CB ID DMSI5CB
DMSI5CB DN Chloroquine
DMSI5CB HS Approved
DMSI5CB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMSI5CB CP Medreich Sterilab Ltd
DMSI5CB TC Antimalarials
DMSI5CB DT Small molecular drug
DMSI5CB PC 2719
DMSI5CB MW 319.9
DMSI5CB FM C18H26ClN3
DMSI5CB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMSI5CB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMSI5CB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMSI5CB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMSI5CB CA CAS 54-05-7
DMSI5CB CB CHEBI:3638
DMSI5CB DE Malaria
DMLHESP ID DMLHESP
DMLHESP DN Chlorothiazide
DMLHESP HS Approved
DMLHESP SN Aldoclor; Alurene; Chloriazid; Chlorosal; Chlorothiazid; Chlorothiazidum; Chlorotiazida; Chlorthiazid; Chlorthiazide; Chlorthiazidum; Chlortiazid; Chlorurit; Chlotride; Chlrosal; Clorotiazida; Clorotiazide; Clotride; Diupres; Diuresal; Diuril; Diurilix; Diurite; Diutrid; Flumen; Minzil; Salisan; Salunil; Saluretil; Saluric; Thiazide; Urinex; Warduzide; Yadalan; Clorotiazide [DCIT]; Component of Aldoclor; Diuril Boluses; C 4911; Chlorothiazidum [INN-Latin]; Clorotiazida [INN-Spanish]; Diuril (TN); Diuril Boluses, Veterinary; Neo-Dema; Sk-chlorothiazide; Chlorothiazide [USAN:INN:BAN]; Diuril, Chlotride, Chlorothiazide; Chlorothiazide (JAN/USP/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide; 6-Chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMLHESP CP Oak Pharmaceuticals Inc Sub Akorn Inc
DMLHESP TC Antihypertensive Agents
DMLHESP DT Small molecular drug
DMLHESP PC 2720
DMLHESP MW 295.7
DMLHESP FM C7H6ClN3O4S2
DMLHESP IC InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
DMLHESP CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
DMLHESP IK JBMKAUGHUNFTOL-UHFFFAOYSA-N
DMLHESP IU 6-chloro-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMLHESP CA CAS 58-94-6
DMLHESP CB CHEBI:3640
DMLHESP DE Congestive heart failure
DMFZBMQ ID DMFZBMQ
DMFZBMQ DN Chloroxine
DMFZBMQ HS Approved
DMFZBMQ SN chloroxine; 5,7-Dichloroquinolin-8-ol; 773-76-2; 5,7-Dichloro-8-hydroxyquinoline; Chlorquinol; Quixalin; Capitrol; Dichloroxin; Chloroxyquinoline; Dichloroquinolinol; Dikhloroskin; 5,7-Dichloro-8-quinolinol; Endiaron; Clofuzid; Quinolor; Dichlorohydroxyquinoline; Chlofucid; Quesyl; 5,7-Dichloroxine; 5,7-Dichlorooxine; Chlorohydroxyquinoline; 8-QUINOLINOL, 5,7-DICHLORO-; 5,7-Dichloro-8-oxyquinoline; Chloroxine [USAN]; 5,7-Dichlor-8-hydroxychinolin; C9H5Cl2NO; NSC 3904; UNII-2I8BD50I8B; CCRIS 5751; CHQ; Capitrol Cream Shampoo; EINECS 212-2
DMFZBMQ DT Small molecular drug
DMFZBMQ PC 2722
DMFZBMQ MW 214.04
DMFZBMQ FM C9H5Cl2NO
DMFZBMQ IC InChI=1S/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
DMFZBMQ CS C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1
DMFZBMQ IK WDFKMLRRRCGAKS-UHFFFAOYSA-N
DMFZBMQ IU 5,7-dichloroquinolin-8-ol
DMFZBMQ CA CAS 773-76-2
DMFZBMQ CB CHEBI:59477
DMFZBMQ DE Erythema
DM5URA2 ID DM5URA2
DM5URA2 DN Chlorpheniramine
DM5URA2 HS Approved
DM5URA2 SN Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine
DM5URA2 CP Schering-Plough Corporation
DM5URA2 TC Antiallergic Agents
DM5URA2 DT Small molecular drug
DM5URA2 PC 2725
DM5URA2 MW 274.79
DM5URA2 FM C16H19ClN2
DM5URA2 IC InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
DM5URA2 CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM5URA2 IK SOYKEARSMXGVTM-UHFFFAOYSA-N
DM5URA2 IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM5URA2 CA CAS 113-92-8
DM5URA2 CB CHEBI:52010
DM5URA2 DE Allergic rhinitis
DMQRPOS ID DMQRPOS
DMQRPOS DN Chlorphentermine hydrochloride
DMQRPOS HS Approved
DMQRPOS SN Pre-sate
DMQRPOS CP Parke Davis Div Warner Lambert Co
DMQRPOS DT Small molecular drug
DMQRPOS PC 65477
DMQRPOS MW 220.14
DMQRPOS FM C10H15Cl2N
DMQRPOS IC InChI=1S/C10H14ClN.ClH/c1-10(2,12)7-8-3-5-9(11)6-4-8;/h3-6H,7,12H2,1-2H3;1H
DMQRPOS CS CC(C)(CC1=CC=C(C=C1)Cl)N.Cl
DMQRPOS IK WEJDYJKJPUPMLH-UHFFFAOYSA-N
DMQRPOS IU 1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride
DMQRPOS CA CAS 151-06-4
DMQRPOS DE Appetite suppressant
DM1IFGT ID DM1IFGT
DM1IFGT DN Chlorproguanil
DM1IFGT HS Approved
DM1IFGT SN Chlorproguanilum; Clorpreguanile; Clorproguanil; Lapudrine; Clorpreguanile [DCIT]; Unspecified HCl of chlorproguanil; Chlorproguanil [INN:BAN]; Chlorproguanilum [INN-Latin]; Clorproguanil [INN-Spanish]; N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; 1-(3,4-Dichlorophenyl)-5-isopropylbiguanide
DM1IFGT DT Small molecular drug
DM1IFGT PC 9571037
DM1IFGT MW 288.17
DM1IFGT FM C11H15Cl2N5
DM1IFGT IC InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
DM1IFGT CS CC(C)N=C(N)/N=C(\\N)/NC1=CC(=C(C=C1)Cl)Cl
DM1IFGT IK ISZNZKHCRKXXAU-UHFFFAOYSA-N
DM1IFGT IU (1E)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine
DM1IFGT CA CAS 537-21-3
DM1IFGT CB CHEBI:135192
DM1IFGT DE Malaria
DMBGZI3 ID DMBGZI3
DMBGZI3 DN Chlorpromazine
DMBGZI3 HS Approved
DMBGZI3 SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DMBGZI3 CP GlaxoSmithKline
DMBGZI3 TC Antipsychotic Agents
DMBGZI3 DT Small molecular drug
DMBGZI3 PC 2726
DMBGZI3 MW 318.9
DMBGZI3 FM C17H19ClN2S
DMBGZI3 IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DMBGZI3 CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMBGZI3 IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DMBGZI3 IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DMBGZI3 CA CAS 34468-21-8
DMBGZI3 CB CHEBI:3647
DMBGZI3 DE Schizophrenia
DMPHZQE ID DMPHZQE
DMPHZQE DN Chlorpropamide
DMPHZQE HS Approved
DMPHZQE SN Adiaben; Asucrol; Bioglumin; Catanil; Chlorodiabina; Chloronase; Chloropropamide; Chlorporpamide; Chlorpropamid; Chlorpropamidum; Clorpropamid; Clorpropamida; Clorpropamide; Diabaril; Diabechlor; Diabenal; Diabenese; Diabeneza; Diabetoral; Diabexan; Diabinese; Dynalase; Glisema; Glucamide; Insogen; Insulase; Meldian; Melitase; Mellinese; Millinese; Oradian; Prodiaben; Stabinol; Apotex Brand of Chlorpropamide; Byk Gulden Brand of Chlorpropamide; CHLORPROPAMIDE USP; Clorpropamide [DCIT]; Clorpropamide [Italian];Dia benese; Diamel Ex; Farmasierra Brand of Chlorpropamide; Pfizer Brand of Chlorpropamide; C 1290; P 607; Apo-Chlorpropamide; Chlorpropamide Bp/ Usp; Chlorpropamidum [INN-Latin]; Clorpropamida [INN-Spanish]; Diabet-Pages; Diabinese (TN); Novo-Propamide; U-3818; U-9818; Chlorpropamide [INN:BAN:JAN]; Chlorpropamide (JP15/USP/INN); N3-Butyl-N1-p-chlorobenzenesulfonylure a; N3-Butyl-N1-p-chlorobenzenesulfonylurea; N-Propyl-N'-p-chlorophenylsulfonylcarbamide; N-Propyl-N'-p-chlorphenylsulfonylcarbamide; N-propyl-N'-p-chlorophenylsu lfonylcarbamide; N-(4-Chlorophenylsulfonyl)-N'-propylurea; N-(p-Chlorobenzenesulfonyl)-N'-propylurea; N-Propyl-N'-(p-chlorobenzenesulfonyl)urea; 1-((p-Chlorophenyl)sulfonyl)-3-propylurea; 1-(4-Chlorophenylsulfonyl)-3-propylurea; 1-(4-chlorophenyl)sulfonyl-3-propylurea; 1-(p-Chlorobenzenesulfonyl)-3-propylurea; 1-(p-Chlorobenzensulfonyl)-3-propylurea; 1-(p-Chlorophenylsulfonyl)-3-propylurea; 1-(para-Chlorophenylsulfonyl)-3-propylurea; 1-Propyl-3-(p-chlorobenzenesulfonyl)urea; 1-[(4-chlorobenzene)sulfonyl]-3-propylurea; 1-[p-Chlorobenzenesulfonyl]-3-propylurea; 1-p-Chlorophenyl-3-(propylsulfonyl)urea; 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide; 4-Chloro-N-((propylamino)carbonyl)benzenesulfonamide; 4-chloro-N-(propylcarbamoyl)benzenesulfonamide; 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide
DMPHZQE TC Hypoglycemic Agents
DMPHZQE DT Small molecular drug
DMPHZQE PC 2727
DMPHZQE MW 276.74
DMPHZQE FM C10H13ClN2O3S
DMPHZQE IC InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
DMPHZQE CS CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
DMPHZQE IK RKWGIWYCVPQPMF-UHFFFAOYSA-N
DMPHZQE IU 1-(4-chlorophenyl)sulfonyl-3-propylurea
DMPHZQE CA CAS 94-20-2
DMPHZQE CB CHEBI:3650
DMPHZQE DE Non-insulin dependent diabetes
DMY0KGJ ID DMY0KGJ
DMY0KGJ DN Chlorprothixene
DMY0KGJ HS Approved
DMY0KGJ SN Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ TC Antipsychotic Agents
DMY0KGJ DT Small molecular drug
DMY0KGJ PC 667467
DMY0KGJ MW 315.9
DMY0KGJ FM C18H18ClNS
DMY0KGJ IC InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7-
DMY0KGJ CS CN(C)CC/C=C\\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMY0KGJ IK WSPOMRSOLSGNFJ-AUWJEWJLSA-N
DMY0KGJ IU (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
DMY0KGJ CA CAS 113-59-7
DMY0KGJ CB CHEBI:50931
DMY0KGJ DE Psychotic disorder
DM4DMBT ID DM4DMBT
DM4DMBT DN Chlorthalidone
DM4DMBT HS Approved
DM4DMBT SN Chlorothalidone; Chlorphthalidolone; Chlorphthalidone; Chlortalidone; Chlortalidonum; Chlorthalidon; Clortalidona; Clortalidone; Famolin; Higroton; Hygroton; Igroton; Isoren; Natriuran; Oradil; Oxodolin; Oxodoline; Phthalamodine; Phthalamudine; Renon; Saluretin; Thalitone; Urolin; Zambesil; Clortalidone [DCIT]; Racemic chlorthalidone; G 33182; Chlortalidonum [INN-Latin]; Chlorthalidone (USP); Clortalidona [INN-Spanish]; G-33182; Hydro-Long; Hygroton (TN); Oksodolin (oxodolin); Thalitone (TN); Chlortalidone (JAN/INN); Chlorthalidone [USAN:INN:BAN]; (+-)-Chlorthalidone; (+-)-Hygroton; 1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide; 2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide; 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide; 3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine; 3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
DM4DMBT TC Antihypertensive Agents
DM4DMBT DT Small molecular drug
DM4DMBT PC 2732
DM4DMBT MW 338.8
DM4DMBT FM C14H11ClN2O4S
DM4DMBT IC InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
DM4DMBT CS C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
DM4DMBT IK JIVPVXMEBJLZRO-UHFFFAOYSA-N
DM4DMBT IU 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
DM4DMBT CA CAS 77-36-1
DM4DMBT CB CHEBI:3654
DM4DMBT DE Edema; Hypertension
DMCYVDT ID DMCYVDT
DMCYVDT DN Chlorzoxazone
DMCYVDT HS Approved
DMCYVDT SN Biomioran; CLW; Chloroxazone; Chlorsoxazone; Chlorzoxane; Chlorzoxazon; Chlorzoxazona; Chlorzoxazonum; Clorzoxazona; Escoflex; Klorzoxazon; Mioran; Miotran; Myoflexin; Myoflexine; Neoflex; Nyoflex; Paraflex; Parafon; Pathorysin; Relaxazone; Remofleks; Remular; Solaxin; Component of Parafon Forte; McNeil Brand of Chlorzoxazone; Ortho Brand of Chlorzoxazone; Parafon Forte; Parafon Forte DSC; Strifon Forte Dsc; C 4397; Chlorzoxazonum [INN-Latin]; Clorzoxazona [INN-Spanish]; EZE-DS; Muscol (TN); Paraflex (TN); Parafon Forte (TN); Remular-S; Usaf ma-10; Chlorzoxazone [INN:BAN:JAN]; Chlorzoxazone (JAN/USP/INN); 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-1,3-benzoxazol-2(3H)-one; 5-Chloro-2(3H)-benzoxazolone; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol; 5-Chloro-2-benzoxazolone; 5-Chloro-2-hydroxybenzoxazole; 5-Chloro-3(H)-2-benzoxazolone; 5-Chlorobenzoksazolinon-2; 5-Chlorobenzoksazolinon-2 [Polish]; 5-Chlorobenzoksazolon-2; 5-Chlorobenzoksazolon-2 [Polish]; 5-Chlorobenzoxazol-2-one; 5-Chlorobenzoxazolidone; 5-Chlorobenzoxazolone; 5-chloro-1,3-benzoxazol-2-ol; 5-chloro-3H-1,3-benzoxazol-2-one; 5-chlorobenzoxazolin-2-one
DMCYVDT TC Analgesics
DMCYVDT DT Small molecular drug
DMCYVDT PC 2733
DMCYVDT MW 169.56
DMCYVDT FM C7H4ClNO2
DMCYVDT IC InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
DMCYVDT CS C1=CC2=C(C=C1Cl)NC(=O)O2
DMCYVDT IK TZFWDZFKRBELIQ-UHFFFAOYSA-N
DMCYVDT IU 5-chloro-3H-1,3-benzoxazol-2-one
DMCYVDT CA CAS 95-25-0
DMCYVDT CB CHEBI:3655
DMCYVDT DE Acute pain
DMGU74E ID DMGU74E
DMGU74E DN Cholecalciferol
DMGU74E HS Approved
DMGU74E SN Arachitol; Calciol; Cholecalciferolum; Colecalciferol; Colecalciferolo; Colecalciferolum; Colecalcipherol; Delsterol; Deparal; Ebivit; FeraCol; Provitamine; Provitina; Rampage; Ricketon; Trivitan; Vigorsan; Colecalciferolo [DCIT]; VITAMIN D; Duphafral D3 1000; LT00244775; NEO Dohyfral D3; Oleovitamin D3; TNP00266; VITAMIN D3 POWDER; VITAMIN_D3; Vitamin D3; Vitamin D3 emulsifiable; Activated 7-dehydrocholesterol; Cholecalciferol (D3); Cholecalciferol, D3; Colecalciferol (INN); Colecalciferolum [INN-Latin]; D3-Vicotrat; D3-Vigantol; Delta-D; Irradiated 7-dehydrocholesterol; Micro-dee; Vitamin d-3; Cholecalciferol (JP15/USP); Cholecalciferol [USAN:BAN:JAN]; Delta-D (TN); Vitinc Dan-Dee-3; Vi-de-3-hydrosol; (+)-Vitamin D3; (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 25(OH)D; 7-Dehydrocholesterol activated; 7-Dehydrocholesterol, Activated; 7-Dehydrocholesterol, irradiated; 7-Dehydrocholestrol, activated; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
DMGU74E TC Vitamins
DMGU74E DT Small molecular drug
DMGU74E PC 5280795
DMGU74E MW 384.6
DMGU74E FM C27H44O
DMGU74E IC InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMGU74E CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMGU74E IK QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMGU74E IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMGU74E CA CAS 67-97-0
DMGU74E CB CHEBI:28940
DMGU74E DE Vitamin D deficiency
DM7OKQV ID DM7OKQV
DM7OKQV DN Cholic acid
DM7OKQV HS Approved
DM7OKQV SN cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV DT Small molecular drug
DM7OKQV PC 221493
DM7OKQV MW 408.6
DM7OKQV FM C24H40O5
DM7OKQV IC InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1
DM7OKQV CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM7OKQV IK BHQCQFFYRZLCQQ-OELDTZBJSA-N
DM7OKQV IU (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM7OKQV CA CAS 81-25-4
DM7OKQV CB CHEBI:16359
DM7OKQV DE Synthesis disorder; Peroxisomal disorder
DMOI1ZF ID DMOI1ZF
DMOI1ZF DN Choline alfoscerate
DMOI1ZF HS Approved
DMOI1ZF SN Delecit (TN)
DMOI1ZF DT Small molecular drug
DMOI1ZF PC 657272
DMOI1ZF MW 257.22
DMOI1ZF FM C8H20NO6P
DMOI1ZF IC InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
DMOI1ZF CS C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O
DMOI1ZF IK SUHOQUVVVLNYQR-MRVPVSSYSA-N
DMOI1ZF IU [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMOI1ZF CA CAS 28319-77-9
DMOI1ZF CB CHEBI:16870
DMOI1ZF DE Amnesia
DM8P137 ID DM8P137
DM8P137 DN Choline salicylate
DM8P137 HS Approved
DM8P137 SN 2016-36-6; Arthropan; Syrap; Mundisal; Satibon; Actasal; Salicol; Artrobione; Arret; Choline salicylate B; (2-Hydroxyethyl)trimethylammonium salicylate; UNII-KD510K1IQW; Choline salicylic acid salt; Salicylic acid choline salt; Cholini salicylas [INN-Latin]; Salicylic acid, ion(1-), choline; Salicylate de choline [INN-French]; Salicilato de colina [INN-Spanish]; EINECS 217-948-8; KD510K1IQW; Choline salicylate [USAN:INN:BAN:JAN]; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-hydroxybenzoic acid (1:1)
DM8P137 DT Small molecular drug
DM8P137 PC 54686350
DM8P137 MW 241.28
DM8P137 FM C12H19NO4
DM8P137 IC InChI=1S/C7H6O3.C5H14NO/c8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7/h1-4,8H,(H,9,10);7H,4-5H2,1-3H3/q;+1/p-1
DM8P137 CS C[N+](C)(C)CCO.C1=CC=C(C(=C1)C(=O)O)[O-]
DM8P137 IK UDKCHVLMFQVBAA-UHFFFAOYSA-M
DM8P137 IU 2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium
DM8P137 CA CAS 2016-36-6
DM8P137 CB CHEBI:3668
DM8P137 DE Inflammation
DMFMZ3G ID DMFMZ3G
DMFMZ3G DN Choriogonadotropin alfa
DMFMZ3G HS Approved
DMFMZ3G TC Fertility Agents
DMFMZ3G SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
DMFMZ3G DE Female infertility
DMFT73E ID DMFT73E
DMFT73E DN Chorionic Gonadotropin
DMFT73E HS Approved
DMFT73E SN A.P.L.; Chorionic Gonadotropin; Follutein; Pregnyl
DMFT73E CP Ferring Pharmaceuticals Inc
DMFT73E DE Fertility problem
DM2NA4K ID DM2NA4K
DM2NA4K DN Ciclesonide
DM2NA4K HS Approved
DM2NA4K SN Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
DM2NA4K CP Altana Pharma
DM2NA4K TC Antiallergic Agents
DM2NA4K DT Small molecular drug
DM2NA4K PC 6918155
DM2NA4K MW 540.7
DM2NA4K FM C32H44O7
DM2NA4K IC InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
DM2NA4K CS CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6
DM2NA4K IK LUKZNWIVRBCLON-GXOBDPJESA-N
DM2NA4K IU [2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 2-methylpropanoate
DM2NA4K CA CAS 126544-47-6
DM2NA4K CB CHEBI:31397
DM2NA4K DE Obstructive airway disease; Asthma
DMN5T2A ID DMN5T2A
DMN5T2A DN Ciclopirox
DMN5T2A HS Approved
DMN5T2A SN Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A TC Antifungal Agents
DMN5T2A DT Small molecular drug
DMN5T2A PC 2749
DMN5T2A MW 207.27
DMN5T2A FM C12H17NO2
DMN5T2A IC InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
DMN5T2A CS CC1=CC(=O)N(C(=C1)C2CCCCC2)O
DMN5T2A IK SCKYRAXSEDYPSA-UHFFFAOYSA-N
DMN5T2A IU 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
DMN5T2A CA CAS 29342-05-0
DMN5T2A CB CHEBI:453011
DMN5T2A DE Fungal infection
DMAZJFX ID DMAZJFX
DMAZJFX DN Ciclosporin
DMAZJFX HS Approved
DMAZJFX SN Ciclosporin; Ciclosporin (Ciclosporin A); Ciclosporina; Ciclosporina [INN-Spanish]; Ciclosporine; Ciclosporine [INN-French]; Ciclosporinum; Ciclosporinum [INN-Latin]; Cipol N; Consupren; Cyclosporin; Cyclosporine A; Equoral; Antibiotic S 7481F1; Gengraf; Neoplanta; Neoral; Ramihyphin A; Restasis; S-Neoral; Sandimmun; Sandimmun Neoral; Sandimmune; Sang 35; Sang-35; SangCyA; Sigmasporin Microoral; cyclosporin A; cyclosporine; 59865-13-3; 83HN0GTJ6D; CHEBI:4031; CSA; DSSTox_CID_365; DSSTox_RID_75541; MFCD00274558; MLS001333756; UNII-83HN0GTJ6D
DMAZJFX PC 5284373
DMAZJFX MW 1202.6
DMAZJFX FM C62H111N11O12
DMAZJFX IC PMATZTZNYRCHOR-CGLBZJNRSA-N
DMAZJFX CS CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMAZJFX IK 1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
DMAZJFX IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMAZJFX CA CAS 59865-13-3
DMAZJFX CB CHEBI:4031
DMAZJFX DE Viral hepatitis
DMT2KRV ID DMT2KRV
DMT2KRV DN Ciclosporin
DMT2KRV HS Approved
DMT2KRV SN Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
DMT2KRV CP Sandoz
DMT2KRV TC Immunosuppressive Agents
DMT2KRV DT Protein/peptide drug
DMT2KRV PC 24883466
DMT2KRV MW 1202.6
DMT2KRV FM C62H111N11O12
DMT2KRV IC InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
DMT2KRV CS CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMT2KRV IK PMATZTZNYRCHOR-VJRYSDSKSA-N
DMT2KRV IU (3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMT2KRV CA CAS 59865-13-3
DMT2KRV DE Psoriasis vulgaris; Xerophthalmia; Brain injury
DMA13GD ID DMA13GD
DMA13GD DN Cidofovir
DMA13GD HS Approved
DMA13GD SN CDV; Cidofovirum; Forvade; HPMPC; Vistide; Cidofovir anhydrous; GS 0504; GS 504; GS504; Cidofovir (Vistide); Cidofovir (anhydrous); GS-0504; GS-504; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
DMA13GD CP Pfizer Pharmaceuticals
DMA13GD TC Anti-HIV Agents
DMA13GD DT Small molecular drug
DMA13GD PC 60613
DMA13GD MW 279.19
DMA13GD FM C8H14N3O6P
DMA13GD IC InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
DMA13GD CS C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
DMA13GD IK VWFCHDSQECPREK-LURJTMIESA-N
DMA13GD IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
DMA13GD CA CAS 113852-37-2
DMA13GD CB CHEBI:3696
DMA13GD DE Cytomegalovirus infection
DME2H5T ID DME2H5T
DME2H5T DN Cilastatin
DME2H5T HS Approved
DME2H5T SN Cilastatina; Cilastatine; Cilastatinum; Cilastatin Monosodium Salt; Cilastatin acid; Cilastatina [Spanish]; Cilastatine [French]; Cilastatinum [Latin]; MK0791; Cilastatin (INN); Cilastatin [INN:BAN]; MK-791; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T CP Merck
DME2H5T TC Antibiotics
DME2H5T DT Small molecular drug
DME2H5T PC 6435415
DME2H5T MW 358.5
DME2H5T FM C16H26N2O5S
DME2H5T IC InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1
DME2H5T CS CC1(C[C@@H]1C(=O)N/C(=C\\CCCCSC[C@@H](C(=O)O)N)/C(=O)O)C
DME2H5T IK DHSUYTOATWAVLW-WFVMDLQDSA-N
DME2H5T IU (Z)-7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
DME2H5T CA CAS 82009-34-5
DME2H5T CB CHEBI:3697
DME2H5T DE Bacterial infection
DM4V6JA ID DM4V6JA
DM4V6JA DN Cilazapril
DM4V6JA HS Approved
DM4V6JA SN Cilazaprilum; Cilazil; Dynorm; Inhibace; Inibace; Justor; Vascace; CILAZAPRIL MONOHYDRATE; Cilazapril anhydrous;Cilazapril hydrate; Cilazaprilum [Latin]; Cilazapril (INN); Cilazapril (USAN); Cilazapril (anhydrous); Cilazapril hydrate (JAN); Cilazapril, Anhydrous; Inhibace (TN); Ro 31-2848; Ro 31-2848 monohydrate; Ro 34-2848; Ro-312848; Ro-31-2848; Cilazapril [USAN:INN:BAN:JAN]; (1S,9S)-9-(((S)-1-Carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6H-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl estermonohydrate; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid; (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid hydrate
DM4V6JA TC Antihypertensive Agents
DM4V6JA DT Small molecular drug
DM4V6JA PC 56330
DM4V6JA MW 417.5
DM4V6JA FM C22H31N3O5
DM4V6JA IC InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
DM4V6JA CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O
DM4V6JA IK HHHKFGXWKKUNCY-FHWLQOOXSA-N
DM4V6JA IU (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
DM4V6JA CA CAS 88768-40-5
DM4V6JA CB CHEBI:3698
DM4V6JA DE Congestive heart failure
DMZMSCT ID DMZMSCT
DMZMSCT DN Cilostazol
DMZMSCT HS Approved
DMZMSCT SN cilostazol; 73963-72-1; Pletal; Cilostazole; Pletaal; Cilostazolum; OPC-13013; Cilostazolum [INN-Latin]; OPC-21; OPC 13013; OPC 21; UNII-N7Z035406B; CHEBI:31401; C20H27N5O2; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; BRN 3632107; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; MLS000028470; Cilostazole; Otsuka brand of cilostazol; C 0737; CL23867; Cilostazol [INN:JAN]; Pleta (TN); Pletal (TN); Pletal, Cilostazol; Cilostazol (JP15/USAN/INN); 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
DMZMSCT CP Otsuka Pharmaceutical Co
DMZMSCT TC Vasodilator Agents
DMZMSCT DT Small molecular drug
DMZMSCT PC 2754
DMZMSCT MW 369.5
DMZMSCT FM C20H27N5O2
DMZMSCT IC InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
DMZMSCT CS C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
DMZMSCT IK RRGUKTPIGVIEKM-UHFFFAOYSA-N
DMZMSCT IU 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
DMZMSCT CA CAS 73963-72-1
DMZMSCT CB CHEBI:31401
DMZMSCT DE Intermittent claudication
DMH61ZB ID DMH61ZB
DMH61ZB DN Cimetidine
DMH61ZB HS Approved
DMH61ZB SN Acibilin; Acinil; Altramet; Brumetidina; Cimal; Cimetadine; Cimetag; Cimetidina; Cimetidinum; Cimetum; Dyspamet; Edalene; Eureceptor; Evicer; Gastrobitan; Gastromet; Histodil; Magicul; Metracin; Peptol; Sigmetadine; Tagamet; Tametin; Tratul; Ulcedin; Ulcedine; Ulcestop; Ulcimet; Ulcofalk; Ulcomedina; Ulcomet; Ulhys; Valmagen; Venopex; Ci metum; Cimetidine Hcl; Tagamet Hb; Biomet400; C 4522; FPF 1002; SKF 92334; Tagamet Hb 200; CIMETIDINE A/AB; Cimetidina [INN-Spanish]; Cimetidinum [INN-Latin]; DRG-0150; SKF-92334; Tagamet (TN); Tagamet HB (TN); Tagamet HB200 (TN); SK&F-92334; Cimetidine (JP15/USP/INN); Cimetidine [USAN:INN:BAN:JAN]; Tagamet, SKF-92334, Tratul, Tametin, Dyspamet, Acinil, Cimetidine; N-Cyano-N'-methyl-[2-[[[5-methyl-1H-imidazol-4-yl]methyl]thio]ethyl]guanidine; N''-Cyano-N-methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl]guanidine; N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine; N-cyano-N'-methyl-N''-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine; N-Cyano-N'-Methyl-N''-(2-(((5-Methyl-1H-Imidazol-4-YL)Methyl)Thio)Ethyl) Guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1 H-imidazol-4-yl) methyl)thio)ethyl)guanidine; N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine; N''-cyano-N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)-ethyl)guanidine; 1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine; 1-Cyano-2-methyl-3-[2-[[(5-methylimidazol-4-yl)methyl]thio]ethyl]guanidine; 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine; 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine; 2-Cyano-1-methyl-3-[2-(5-methyl-1H-imidazol-4-yl-methylthio)ethyl]guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine; 2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
DMH61ZB CP GlaxoSmithKline
DMH61ZB TC Antiulcer Agents
DMH61ZB DT Small molecular drug
DMH61ZB PC 2756
DMH61ZB MW 252.34
DMH61ZB FM C10H16N6S
DMH61ZB IC InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
DMH61ZB CS CC1=C(N=CN1)CSCCNC(=NC)NC#N
DMH61ZB IK AQIXAKUUQRKLND-UHFFFAOYSA-N
DMH61ZB IU 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
DMH61ZB CA CAS 51481-61-9
DMH61ZB CB CHEBI:3699
DMH61ZB DE Acid-reflux disorder
DMZHPNE ID DMZHPNE
DMZHPNE DN Cimetropium bromide
DMZHPNE HS Approved
DMZHPNE SN Alginor (TN)
DMZHPNE CP DeAngelini
DMZHPNE DT Small molecular drug
DMZHPNE PC 20054870
DMZHPNE MW 438.4
DMZHPNE FM C21H28BrNO4
DMZHPNE IC InChI=1S/C21H28NO4.BrH/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14;/h2-6,13,15-20,23H,7-12H2,1H3;1H/q+1;/p-1/t15?,16-,17-,18+,19-,20+,22?;/m1./s1
DMZHPNE CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5.[Br-]
DMZHPNE IK WDURTRGFUGAJHA-HNHWXVNLSA-M
DMZHPNE IU [(1R,2R,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMZHPNE CA CAS 51598-60-8
DMZHPNE DE Spasm; Gastric motility disorder
DMCX0K3 ID DMCX0K3
DMCX0K3 DN Cinacalcet
DMCX0K3 HS Approved
DMCX0K3 SN Cinacalcet [INN]; AMG 073; AMG073; Cinacalcet (USAN); Mimpara (TN); Sensipar (TN); N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine; N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine; (R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
DMCX0K3 CP Amgen
DMCX0K3 TC Calcimimetics
DMCX0K3 DT Small molecular drug
DMCX0K3 PC 156419
DMCX0K3 MW 357.4
DMCX0K3 FM C22H22F3N
DMCX0K3 IC InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
DMCX0K3 CS C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
DMCX0K3 IK VDHAWDNDOKGFTD-MRXNPFEDSA-N
DMCX0K3 IU N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
DMCX0K3 CA CAS 226256-56-0
DMCX0K3 CB CHEBI:48390
DMCX0K3 DE Hyperparathyroidism; Kidney disease
DMFIC0M ID DMFIC0M
DMFIC0M DN Cinalukast
DMFIC0M HS Approved
DMFIC0M SN Cinalukast [USAN:INN]; Ro 24-5913; Cinalukast (USAN/INN); Ro-24-5913; (E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid; 3'-((E)-2-(4-Cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid; 4-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}amino)-2,2-diethyl-4-oxobutanoic acid; 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M TC Antiarrhythmic Agents
DMFIC0M DT Small molecular drug
DMFIC0M PC 6436135
DMFIC0M MW 412.5
DMFIC0M FM C23H28N2O3S
DMFIC0M IC InChI=1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+
DMFIC0M CS CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C3CCC3)C(=O)O
DMFIC0M IK BZMKNPGKXJAIDV-VAWYXSNFSA-N
DMFIC0M IU 4-[3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid
DMFIC0M CA CAS 128312-51-6
DMFIC0M CB CHEBI:126598
DMFIC0M DE Asthma
DM7U5QJ ID DM7U5QJ
DM7U5QJ DN Cinnarizine
DM7U5QJ HS Approved
DM7U5QJ SN Aplactan; Aplexal; Apotomin; Artate; Carecin; Cerebolan; Cinaperazine; Cinarizina; Cinarizine; Cinazyn; Cinnacet; Cinnageron; Cinnarizinum; Corathiem; Denapol; Dimitron; Dimitronal; Eglen; Folcodal; Giganten; Glanil; Hilactan; Ixertol; Katoseran; Labyrin; Lazeta; Libotasin; Marisan; Midronal; Mitronal; Olamin; Processine; Sedatromin; Senoger; Sepan; Siptazin; Spaderizine; Stugeron; Stutgeron; Stutgin; Toliman; Votegol; Zepamol; Cinnarizine Stugeron; C 5270; MD 516; R 1575; R 516; Cero-Aterin; Cinarizina [INN-Spanish]; Cinnarizinum [INN-Latin]; R-516; Stugeron (TN); Stunarone (TN); Cinnarizine (JAN/USAN/INN); Cinnarizine [USAN:INN:BAN:JAN]; N-Benzhydryl-N'-cinnamylpiperazine; 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine; 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)-piperazine; 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine; 1-Benzhydryl-4-cinnamylpiperazin; 1-Cinnamyl-4-(diphenylmethyl)piperazine; 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine; 1-trans-Cinnamyl-4-diphenylmethylpiperazine
DM7U5QJ CP Janssen Pharmaceutica
DM7U5QJ TC Antiallergic Agents
DM7U5QJ DT Small molecular drug
DM7U5QJ PC 1547484
DM7U5QJ MW 368.5
DM7U5QJ FM C26H28N2
DM7U5QJ IC InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
DM7U5QJ CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4
DM7U5QJ IK DERZBLKQOCDDDZ-JLHYYAGUSA-N
DM7U5QJ IU 1-benzhydryl-4-[(E)-3-phenylprop-2-enyl]piperazine
DM7U5QJ CA CAS 16699-20-0
DM7U5QJ CB CHEBI:31403
DM7U5QJ DE Vertigo meniere disease
DMDX1ZC ID DMDX1ZC
DMDX1ZC DN Cinolazepam
DMDX1ZC HS Approved
DMDX1ZC SN Cinolazepamum; Gerodorm; Cinolazepam [INN]; OX 373; Cinolazepam (INN); Cinolazepamum [INN-Latin]; Gerodorm (TN); OX-373;1-(2-cyanoethyl)-7-chloro-3-hydroxy-5-(2'-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl]propanenitrile; 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile; 7-Chloro-5-(o-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propionitrile; 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo-1H-1,4-benzodiazepine-1-propanenitrile
DMDX1ZC TC Anticonvulsants
DMDX1ZC DT Small molecular drug
DMDX1ZC PC 3033621
DMDX1ZC MW 357.8
DMDX1ZC FM C18H13ClFN3O2
DMDX1ZC IC InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2
DMDX1ZC CS C1=CC=C(C(=C1)C2=NC(C(=O)N(C3=C2C=C(C=C3)Cl)CCC#N)O)F
DMDX1ZC IK XAXMYHMKTCNRRZ-UHFFFAOYSA-N
DMDX1ZC IU 3-[7-chloro-5-(2-fluorophenyl)-3-hydroxy-2-oxo-3H-1,4-benzodiazepin-1-yl]propanenitrile
DMDX1ZC CA CAS 75696-02-5
DMDX1ZC CB CHEBI:59514
DMDX1ZC DE Muscle spasm
DM4EWNS ID DM4EWNS
DM4EWNS DN Cinoxacin
DM4EWNS HS Approved
DM4EWNS SN Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS TC Antiinfective Agents
DM4EWNS DT Small molecular drug
DM4EWNS PC 2762
DM4EWNS MW 262.22
DM4EWNS FM C12H10N2O5
DM4EWNS IC InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
DM4EWNS CS CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
DM4EWNS IK VDUWPHTZYNWKRN-UHFFFAOYSA-N
DM4EWNS IU 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
DM4EWNS CA CAS 28657-80-9
DM4EWNS CB CHEBI:3716
DM4EWNS DE Urinary tract infection
DMVIKJZ ID DMVIKJZ
DMVIKJZ DN Cinryze
DMVIKJZ HS Approved
DMVIKJZ DE Hereditary angioedema
DMGC5DB ID DMGC5DB
DMGC5DB DN Ciprofibrate
DMGC5DB HS Approved
DMGC5DB SN Ciprofibrato; Ciprofibratum; Ciprol; Hiperlipen; Hyperlipen; Lipanor; Modalim; Oroxadin; Sanofi Synthelabo brand of ciprofibrate; Sanofi Winthrop brand of ciprofibrate; C 0330; WIN 35833; Ciprofibrato [INN-Spanish]; Ciprofibratum [INN-Latin]; Win 35,833; Win-35833; Ciprofibrate (USAN/INN); Ciprofibrate [USAN:BAN:INN]; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{4-[2,2-dichlorocyclopropyl]phenoxy}-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid
DMGC5DB TC Anticancer Agents
DMGC5DB DT Small molecular drug
DMGC5DB PC 2763
DMGC5DB MW 289.15
DMGC5DB FM C13H14Cl2O3
DMGC5DB IC InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
DMGC5DB CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl
DMGC5DB IK KPSRODZRAIWAKH-UHFFFAOYSA-N
DMGC5DB IU 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid
DMGC5DB CA CAS 52214-84-3
DMGC5DB CB CHEBI:50867
DMGC5DB DE Hyperlipoproteinemia
DM2NLS9 ID DM2NLS9
DM2NLS9 DN Ciprofloxacin XR
DM2NLS9 HS Approved
DM2NLS9 SN ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciproxan; Ciprofloxacina; Ciprofloxacinum; Ciprofloxacino; Cipro IV; Ciproxina; Ciprinol; Bernoflox; Ciprodar; Cifloxin; Septicide; Bacquinor; Ciproquinol; Cipromycin; Ciprocinol; Cipro XR; Superocin; Ciprowin; Ciprolon; Ciproflox; Ciprecu; BAY q 3939; Spitacin; Quintor; Quinolid; Proflaxin; Probiox; Ipiflox; Zumaflox; Ciproxine; Ciprolin; Roxytal; Italnik; Fimoflox; Corsacin; Citopcin; Ciprogis; Rancif; Ciriax; Ciplus; Baflox; Loxan; Cilab; Cycin; Cixan; Unex; GW1843; Ciprofloxacin Hydrochloride; Ciprofloxacin intratympanic - Otonomy
DM2NLS9 CP Depomed Bayer
DM2NLS9 DT Small molecular drug
DM2NLS9 PC 2764
DM2NLS9 MW 331.34
DM2NLS9 FM C17H18FN3O3
DM2NLS9 IC InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)
DM2NLS9 CS C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DM2NLS9 IK MYSWGUAQZAJSOK-UHFFFAOYSA-N
DM2NLS9 IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DM2NLS9 CA CAS 85721-33-1
DM2NLS9 CB CHEBI:100241
DM2NLS9 DE Bacterial infection; Gram-positive bacterial infection; Biliary cancer; Cystic fibrosis
DMZR26N ID DMZR26N
DMZR26N DN Ciprofloxacin+dexamethasone
DMZR26N HS Approved
DMZR26N SN CIPRODEX; Ciprofloxacin mixture with dexamethasone; 130244-48-3; Ciprodex Otic; Ciprofloxacin / dexamethasone; Ciprofloxacin and dexamethasone; Ciprofloxacin-dexamethasone Mixt.; SCHEMBL2523572; DTXSID50156420; NTRHYMXQWWPZDD-WKSAPEMMSA-N; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, mixt. with 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
DMZR26N CP Alcon
DMZR26N DT Small molecular drug
DMZR26N PC 9961920
DMZR26N MW 723.8
DMZR26N FM C39H47F2N3O8
DMZR26N IC InChI=1S/C22H29FO5.C17H18FN3O3/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24;18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3;7-10,19H,1-6H2,(H,23,24)/t12-,15+,16+,17+,19+,20+,21+,22+;/m1./s1
DMZR26N CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C.C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
DMZR26N IK NTRHYMXQWWPZDD-WKSAPEMMSA-N
DMZR26N IU 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMZR26N CA CAS 130244-48-3
DMZR26N DE Otitis externa; Acute otitis media
DMY7PED ID DMY7PED
DMY7PED DN Cisapride
DMY7PED HS Approved
DMY7PED SN cisapride; Propulsid; Prepulsid; Syspride; Pridesia; Risamal; Acenalin; Alimix; Propulsin; Propulsid Quicksolv; Enteropride; Kinestase; 81098-60-4; Cisawal; Vomiprid; Colinorm; Cisapron; Vomipride; Unipride; Kaudalit; Alipride; Acpulsif; Rapulid; Cipride; Pulsid; Esorid; Dispep; Presid; Unamol; Guptro; Alimix Forte; Cisapridum [Latin]; Cisaprida [Spanish]; R-51619; Cisapridum [INN-Latin]; R 51619; Cisaprida [INN-Spanish]; 104860-73-3; DCSUBABJRXZOMT-UHFFFAOYSA-N; T 1341; DSSTox_CID_2825; Acenalin; Cisaprida; Cisapridum; Risamol; Prepulsid (TN); Propulsid (TN); Cisapride (USAN/INN); Cisapride [USAN:BAN:INN:JAN]; Cis-4-Amino-5-chloro-N-(1-(3-(p-fluorophenoxy)propyl)-3-methoxy-4-piperidyl)-o-anisamide; (+-)-Cisapride; 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; 4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide; 4-amino-5-chloro-N-{1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl}-2-methoxybenzamide; E-1454
DMY7PED CP Janssen Pharmaceutica
DMY7PED TC Gastrointestinal Agents
DMY7PED DT Small molecular drug
DMY7PED PC 6917698
DMY7PED MW 465.9
DMY7PED FM C23H29ClFN3O4
DMY7PED IC InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1
DMY7PED CS CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
DMY7PED IK DCSUBABJRXZOMT-IRLDBZIGSA-N
DMY7PED IU 4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide
DMY7PED CA CAS 81098-60-4
DMY7PED CB CHEBI:3720
DMY7PED DE Gastroesophageal reflux disease; Gastrointestinal disease
DMUZPJ5 ID DMUZPJ5
DMUZPJ5 DN Cisatracurium
DMUZPJ5 HS Approved
DMUZPJ5 SN Cisatracurium Besylate; Cisatracurium Besylate Preservative Free; Nimbex; Nimbex Preservative Free
DMUZPJ5 CP Abbvie Inc
DMUZPJ5 DT Small molecular drug
DMUZPJ5 PC 62887
DMUZPJ5 MW 929.1
DMUZPJ5 FM C53H72N2O12+2
DMUZPJ5 IC InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
DMUZPJ5 CS C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C
DMUZPJ5 IK YXSLJKQTIDHPOT-LJCJQEJUSA-N
DMUZPJ5 IU 5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
DMUZPJ5 CA CAS 96946-41-7
DMUZPJ5 CB CHEBI:140621
DMUZPJ5 DE Muscle spasm
DMRHGI9 ID DMRHGI9
DMRHGI9 DN Cisplatin
DMRHGI9 HS Approved
DMRHGI9 SN Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
DMRHGI9 CP Bristol-Myers Squibb
DMRHGI9 TC Anticancer Agents
DMRHGI9 DT Small molecular drug
DMRHGI9 PC 5702198
DMRHGI9 MW 300.05
DMRHGI9 FM Cl2H6N2Pt
DMRHGI9 IC InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
DMRHGI9 CS N.N.Cl[Pt]Cl
DMRHGI9 IK LXZZYRPGZAFOLE-UHFFFAOYSA-L
DMRHGI9 IU azane;dichloroplatinum
DMRHGI9 CA CAS 15663-27-1
DMRHGI9 DE Solid tumour/cancer; Osteosarcoma
DM2G9AE ID DM2G9AE
DM2G9AE DN Citalopram
DM2G9AE HS Approved
DM2G9AE SN Akarin; Celapram; Celexa; Celius; Ciazil; Cilift; Cipram; Ciprapine; Citabax; Citadur; Citalec; Citalopramum; Citopam; Cytalopram; Dalsan; Humorup; Nitalapram; Oropram; Pramcit; Recital; Seropram; Talam; Talohexal; Temperax; Vodelax; Zentius; Zetalo; Citalopram [Celexa]; [3H]Citalopram; Akarin (TN); Celapram (TN); Celexa (TN); Celius (TN); Ciazil (TN); Cilift (TN); Cipram (TN); Cipramil (TN); Ciprapine (TN); Citabax (TN); Citadur (TN); Citalec (TN); Citalopram [INN:BAN]; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam (TN); Citox (TN); Citrol (TN); Dalsan (TN); Lu 10-171; Recital (TN); Seropram (TN); Talam (TN); Zentius (TN); Zetalo (TN); AE-641/00603021; Citalopram (USP/INN); Lu-10-171; 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE CP Forest Laboratories, Inc
DM2G9AE TC Antidepressants
DM2G9AE DT Small molecular drug
DM2G9AE PC 2771
DM2G9AE MW 324.4
DM2G9AE FM C20H21FN2O
DM2G9AE IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
DM2G9AE CS CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DM2G9AE IK WSEQXVZVJXJVFP-UHFFFAOYSA-N
DM2G9AE IU 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DM2G9AE CA CAS 59729-33-8
DM2G9AE CB CHEBI:77397
DM2G9AE DE Depression
DMI4XBM ID DMI4XBM
DMI4XBM DN Citicoline
DMI4XBM HS Approved
DMI4XBM SN Alphcolin; CerAxon; Citicholine; Hipercol; Neurex; Nicholin; Somazina; Trausan; Citicoline sodium; Cytidil diphosphocholine; CDP-choline; IP-302; Cytidine-5-diphosphocholine
DMI4XBM CP Ferrer Internacional SA
DMI4XBM DT Small molecular drug
DMI4XBM PC 13804
DMI4XBM MW 488.32
DMI4XBM FM C14H26N4O11P2
DMI4XBM IC InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1
DMI4XBM CS C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O
DMI4XBM IK RZZPDXZPRHQOCG-OJAKKHQRSA-N
DMI4XBM IU [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
DMI4XBM CA CAS 987-78-0
DMI4XBM CB CHEBI:16436
DMI4XBM DE Cerebrovascular ischaemia
DMMEBWR ID DMMEBWR
DMMEBWR DN Citric acid, magnesium oxide, sodium picosulfate
DMMEBWR HS Approved
DMMEBWR SN Prepopik (TN)
DMMEBWR CP Ferring Pharmaceuticals
DMMEBWR DT Small molecular drug
DMMEBWR PC 68654
DMMEBWR MW 481.4
DMMEBWR FM C18H13NNa2O8S2
DMMEBWR IC InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
DMMEBWR CS C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)[O-])C3=CC=C(C=C3)OS(=O)(=O)[O-].[Na+].[Na+]
DMMEBWR IK GOZDTZWAMGHLDY-UHFFFAOYSA-L
DMMEBWR IU disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate
DMMEBWR CA CAS 10040-45-6
DMMEBWR CB CHEBI:32147
DMMEBWR DE Crohn disease
DM3JDRP ID DM3JDRP
DM3JDRP DN Cladribine
DM3JDRP HS Approved
DM3JDRP SN Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
DM3JDRP CP EMD Serono Rockland, MA
DM3JDRP TC Anticancer Agents
DM3JDRP DT Small molecular drug
DM3JDRP PC 20279
DM3JDRP MW 285.69
DM3JDRP FM C10H12ClN5O3
DM3JDRP IC InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
DM3JDRP CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
DM3JDRP IK PTOAARAWEBMLNO-KVQBGUIXSA-N
DM3JDRP IU (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
DM3JDRP CA CAS 4291-63-8
DM3JDRP CB CHEBI:567361
DM3JDRP DE Multiple sclerosis; Relapsing-remitting multiple sclerosis; Hairy cell leukaemia
DM4M1SG ID DM4M1SG
DM4M1SG DN Clarithromycin
DM4M1SG HS Approved
DM4M1SG SN Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a
DM4M1SG CP Abbott Laboratories
DM4M1SG TC Antibiotics
DM4M1SG DT Small molecular drug
DM4M1SG PC 84029
DM4M1SG MW 748
DM4M1SG FM C38H69NO13
DM4M1SG IC InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DM4M1SG CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
DM4M1SG IK AGOYDEPGAOXOCK-KCBOHYOISA-N
DM4M1SG IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4M1SG CA CAS 81103-11-9
DM4M1SG CB CHEBI:3732
DM4M1SG DE Bacterial infection
DMPGR1E ID DMPGR1E
DMPGR1E DN Clascoterone
DMPGR1E HS Approved
DMPGR1E SN CB-03-01
DMPGR1E CP Cosmo Pharmaceuticals SpA
DMPGR1E DT Small molecular drug
DMPGR1E PC 11750009
DMPGR1E MW 402.5
DMPGR1E FM C24H34O5
DMPGR1E IC InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1
DMPGR1E CS CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO
DMPGR1E IK GPNHMOZDMYNCPO-PDUMRIMRSA-N
DMPGR1E IU [(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate
DMPGR1E CA CAS 19608-29-8
DMPGR1E DE Acne vulgaris
DM2FGRT ID DM2FGRT
DM2FGRT DN Clavulanate
DM2FGRT HS Approved
DM2FGRT SN Clavulansaeure; Clavulox; Acide clavulanique; Acido clavulanico; Acidum clavulanicum; CLAVULANIC ACID; Clavulansaeure [INN]; Clavulinic Acid; Sodium Clavulanate; Antibiotic MM 14151; MM 14151; Acide clavulanique [INN-French]; Acido clavulanico [INN-Spanish]; Acidum clavulanicum [INN-Latin]; BRL-14151; Clavulanic acid (INN); Clavulanic acid [BAN:INN]; Clavulox (TN); MM-14151; (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Z)-(2R,5R)-3-(2-Hydroxyethyliden)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3008-B; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, (2R-(2alpha,3Z,5alpha))
DM2FGRT CP GlaxoSmithKline
DM2FGRT TC Antibiotics
DM2FGRT DT Small molecular drug
DM2FGRT PC 5280980
DM2FGRT MW 199.16
DM2FGRT FM C8H9NO5
DM2FGRT IC InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
DM2FGRT CS C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O
DM2FGRT IK HZZVJAQRINQKSD-PBFISZAISA-N
DM2FGRT IU (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM2FGRT CA CAS 58001-44-8
DM2FGRT CB CHEBI:48947
DM2FGRT DE Bacterial infection
DMBZWQL ID DMBZWQL
DMBZWQL DN Clemastine
DMBZWQL HS Approved
DMBZWQL SN Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
DMBZWQL CP Norvatis Phamaceuticals Corporation
DMBZWQL TC Antiallergic Agents
DMBZWQL DT Small molecular drug
DMBZWQL PC 26987
DMBZWQL MW 343.9
DMBZWQL FM C21H26ClNO
DMBZWQL IC InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
DMBZWQL CS C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
DMBZWQL IK YNNUSGIPVFPVBX-NHCUHLMSSA-N
DMBZWQL IU (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
DMBZWQL CA CAS 15686-51-8
DMBZWQL CB CHEBI:3738
DMBZWQL DE Allergic rhinitis
DMCKYZ5 ID DMCKYZ5
DMCKYZ5 DN Clenbuterol
DMCKYZ5 HS Approved
DMCKYZ5 SN Clenbuterolum; Contraspasmin; Planipart; Planipart [veterinary]; Clenbuterol (INN); Clenbuterol [BAN:INN]; Clenbuterolum [INN-Latin]; Contraspasmin (TN); NAB-365; Planipart [veterinary] (TN); (+)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; (+-)-clenbuterol; (-)-4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 1-(4-Amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol; 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol; 4-Amino-3,5-dichloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-Amino-alpha-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol
DMCKYZ5 TC Bronchodilator Agents
DMCKYZ5 DT Small molecular drug
DMCKYZ5 PC 2783
DMCKYZ5 MW 277.19
DMCKYZ5 FM C12H18Cl2N2O
DMCKYZ5 IC InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3
DMCKYZ5 CS CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
DMCKYZ5 IK STJMRWALKKWQGH-UHFFFAOYSA-N
DMCKYZ5 IU 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
DMCKYZ5 CA CAS 37148-27-9
DMCKYZ5 CB CHEBI:174690
DMCKYZ5 DE Chronic breathing disorder
DMW4M97 ID DMW4M97
DMW4M97 DN Clevidipine butyrate
DMW4M97 HS Approved
DMW4M97 SN Clevidipine; Cleviprex; 167221-71-8; Clevelox; rac-Clevidipine; H 324/38; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate; Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Cleviprex (TN); 3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; METHYL 5-{[(BUTANOYLOXY)METHOXY]CARBONYL}-4-(2,3-DICHLOROPHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3
DMW4M97 CP The Medicines Company
DMW4M97 DT Small molecular drug
DMW4M97 PC 153994
DMW4M97 MW 456.3
DMW4M97 FM C21H23Cl2NO6
DMW4M97 IC InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
DMW4M97 CS CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMW4M97 IK KPBZROQVTHLCDU-UHFFFAOYSA-N
DMW4M97 IU 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMW4M97 CA CAS 167221-71-8
DMW4M97 CB CHEBI:135738
DMW4M97 DE Hypertension
DMUMQZ0 ID DMUMQZ0
DMUMQZ0 DN Clidinium
DMUMQZ0 HS Approved
DMUMQZ0 SN clidinium; N-Methyl quinuclidinyl benzilate; 7020-55-5; 3-hydroxy-1-methylquinuclidinium benzilate ester; 3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[222]octane; Ro-23773; 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[222]octane; 1-Azoniabicyclo(222)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-; [3H]clidinium; (-)MQNB; Clidinium bromid; (1-methyl-1-azoniabicyclo[222]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate; 3-Hydroxy-1-methylquinuclidinium benzilate (ester); Quinuclidinium,; Librax (TN); Benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium; Quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester); (1-methyl-1-azoniabicyclo[222]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0 CP Hoffmann La Roche Inc
DMUMQZ0 TC Analgesics
DMUMQZ0 DT Small molecular drug
DMUMQZ0 PC 2784
DMUMQZ0 MW 352.4
DMUMQZ0 FM C22H26NO3+
DMUMQZ0 IC InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1
DMUMQZ0 CS C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMUMQZ0 IK HOOSGZJRQIVJSZ-UHFFFAOYSA-N
DMUMQZ0 IU (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
DMUMQZ0 CA CAS 7020-55-5
DMUMQZ0 CB CHEBI:3743
DMUMQZ0 DE Irritable bowel syndrome; Abdominal stomach pain
DM15HL8 ID DM15HL8
DM15HL8 DN Clindamycin
DM15HL8 HS Approved
DM15HL8 SN Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin
DM15HL8 CP Pharmacia And Upjohn Co
DM15HL8 TC Antibiotics
DM15HL8 DT Small molecular drug
DM15HL8 PC 446598
DM15HL8 MW 425
DM15HL8 FM C18H33ClN2O5S
DM15HL8 IC InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
DM15HL8 CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
DM15HL8 IK KDLRVYVGXIQJDK-AWPVFWJPSA-N
DM15HL8 IU (2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DM15HL8 CA CAS 18323-44-9
DM15HL8 DE Acne vulgaris
DMW1OQ0 ID DMW1OQ0
DMW1OQ0 DN Clobazam - Lundbeck
DMW1OQ0 HS Approved
DMW1OQ0 SN Clobazam; Chlorepin; Urbanyl; Frisium; Clorepin; Urbadan; 22316-47-8; Clobazamum; Onfi; LM-2717; HR 376; RU-4723; Clobazamum [INN-Latin]; LM 2717; H-4723; H 4723; 7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione; UNII-2MRO291B4U; 1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl-; NSC 336279; 1-Phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine; CCRIS 7506; 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione; EINECS 244-908-7; BRN 0758410; Onfi
DMW1OQ0 TC Neurology Agents
DMW1OQ0 DT Small molecular drug
DMW1OQ0 PC 2789
DMW1OQ0 MW 300.74
DMW1OQ0 FM C16H13ClN2O2
DMW1OQ0 IC InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMW1OQ0 CS CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMW1OQ0 IK CXOXHMZGEKVPMT-UHFFFAOYSA-N
DMW1OQ0 IU 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
DMW1OQ0 CA CAS 22316-47-8
DMW1OQ0 CB CHEBI:31413
DMW1OQ0 DE Anxiety disorder; Epilepsy
DMUXP52 ID DMUXP52
DMUXP52 DN Clobetasol
DMUXP52 HS Approved
DMUXP52 SN Clobetasolum; Clofenazon; Clobecort Amex; Butavate (TN); Clobecort Amex (TN); Clobetasol (INN); Clobetasol [INN:BAN]; Clobetasolum [INN-Latin]; Clobex (TN); Dermatovate (TN); Dermovate (TN); Movate (TN); Olux (TN); Temovate (TN); Tenovate (TN); (11beta,16beta)-21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 21-chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
DMUXP52 CP Fougera Pharmaceuticals Inc
DMUXP52 TC Antiinflammatory Agents
DMUXP52 DT Small molecular drug
DMUXP52 PC 5311051
DMUXP52 MW 410.9
DMUXP52 FM C22H28ClFO4
DMUXP52 IC InChI=1S/C22H28ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DMUXP52 CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C
DMUXP52 IK FCSHDIVRCWTZOX-DVTGEIKXSA-N
DMUXP52 IU (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUXP52 CA CAS 25122-41-2
DMUXP52 CB CHEBI:205919
DMUXP52 DE Rosacea; Oral lichen planus
DM9ZMQH ID DM9ZMQH
DM9ZMQH DN Clocortolone
DM9ZMQH HS Approved
DM9ZMQH SN Clocortolona; Clocortolonum; Clocortolone (INN); (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione; 9-chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9-chloro-6alpha-fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
DM9ZMQH CP Promius Pharma Llc
DM9ZMQH DT Small molecular drug
DM9ZMQH PC 5311052
DM9ZMQH MW 410.9
DM9ZMQH FM C22H28ClFO4
DM9ZMQH IC InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
DM9ZMQH CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)Cl)C)F
DM9ZMQH IK YMTMADLUXIRMGX-RFPWEZLHSA-N
DM9ZMQH IU (6S,8S,9R,10S,11S,13S,14S,16R,17S)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM9ZMQH CA CAS 4828-27-7
DM9ZMQH CB CHEBI:59582
DM9ZMQH DE Rosacea
DM9Y6X7 ID DM9Y6X7
DM9Y6X7 DN Clodronate
DM9Y6X7 HS Approved
DM9Y6X7 SN Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid)
DM9Y6X7 TC Antihypocalcemic Agents
DM9Y6X7 DT Small molecular drug
DM9Y6X7 PC 25419
DM9Y6X7 MW 244.89
DM9Y6X7 FM CH4Cl2O6P2
DM9Y6X7 IC InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
DM9Y6X7 CS C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
DM9Y6X7 IK ACSIXWWBWUQEHA-UHFFFAOYSA-N
DM9Y6X7 IU [dichloro(phosphono)methyl]phosphonic acid
DM9Y6X7 CA CAS 10596-23-3
DM9Y6X7 CB CHEBI:110423
DM9Y6X7 DE Hypercalcaemia
DMCVJ86 ID DMCVJ86
DMCVJ86 DN Clofarabine
DMCVJ86 HS Approved
DMCVJ86 SN CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
DMCVJ86 TC Anticancer Agents
DMCVJ86 DT Small molecular drug
DMCVJ86 PC 119182
DMCVJ86 MW 303.68
DMCVJ86 FM C10H11ClFN5O3
DMCVJ86 IC InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
DMCVJ86 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N
DMCVJ86 IK WDDPHFBMKLOVOX-AYQXTPAHSA-N
DMCVJ86 IU (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
DMCVJ86 CA CAS 123318-82-1
DMCVJ86 CB CHEBI:681569
DMCVJ86 DE Acute lymphoblastic leukaemia; Myelodysplastic syndrome
DMEBOFW ID DMEBOFW
DMEBOFW DN Clofazimine
DMEBOFW HS Approved
DMEBOFW SN clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine
DMEBOFW CP Norvatis Phamaceuticals Corporation
DMEBOFW TC Antiinflammatory Agents
DMEBOFW DT Small molecular drug
DMEBOFW PC 2794
DMEBOFW MW 473.4
DMEBOFW FM C27H22Cl2N4
DMEBOFW IC InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
DMEBOFW CS CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
DMEBOFW IK WDQPAMHFFCXSNU-UHFFFAOYSA-N
DMEBOFW IU N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
DMEBOFW CA CAS 2030-63-9
DMEBOFW CB CHEBI:3749
DMEBOFW DE Crohn disease; Mycobacterium infection
DMPC1J7 ID DMPC1J7
DMPC1J7 DN Clofibrate
DMPC1J7 HS Approved
DMPC1J7 SN Amotril; Angiokapsul; Anparton; Antilipid; Antilipide; Apolan; Arterioflexin; Arterosol; Artevil; Ateculon; Ateriosan; Athebrate; Atheromide; Atheropront; Athromidin; Atrolen; Atromid; Atromida; Atromidin; Atrovis; Azionyl; Bioscleran; Bresit; CPIB; Cartagyl; Chlorfenisate; Chlorphenisate; Cinnarizin; Citiflus; Claripex; Cloberat; Clobrat; Clofar; Clofibate; Clofibram; Clofibrat; Clofibrato; Clofibratum; Clofinit; Clofipront; Delipid; Deliva; ELPI; EPIB; Fibralem; Gerastop; Hyclorate; Klofibrat; Klofiran; Levatrom; Lipamid; Lipavil; Lipavlon; Lipidsenker; Lipofacton; Lipomid; Liponorm; Liporeduct; Liporil; Liposid; Liprin; Liprinal; Lobetrin; Miscleron; Misclerone; Miskleron; Negalip; Normalip; Normat; Normet; Normolipol; Novofibrate; Persantinat; Recolip; Regardin; Regelan; Robigram; Scrobin; Serofinex; Serotinex; Skerolip; Sklerepmexe; Sklero; Sklerolip; Skleromex; Skleromexe; Ticlobran; Xyduril; Yoclo; Amotril S; Atromid S; Claripex CPIB; Clofibrato [Spanish]; Dura clofibrat; Ethyl chlorophenoxyisobutyrate; Ethyl clofibrate; Regelan N; Vincamin compositum; AY 61123; C 6643; Lipide 500; Oxan 600; AY-61123; Athranid-wirkstoff; Atromid-S; BML2-F02; Chlorophenoxyisobutyrate, Ethyl; Clobren-5F; Clobren-SF; Clofibrate (CLOF); Clofibrato [INN-Spanish]; Clofibratum [INN-Latin]; Clofibric Acid, Ethyl Ester; Ethyl p-chlorophenoxyisobutyrate; Ethyl para-chlorophenoxyisobutyrate; Neo-Atomid; Neo-Atromid; Sklero-Tablinen; Sklero-tablinene; Sklero-tabuls; ATROMID-S (TN); Atromid-S (TN); Atromid-S, Clofibrate; Ethyl alpha-p-chlorophenoxyisobutyrate; Clofibrate (JP15/USP/INN); Clofibrate [USAN:INN:BAN:JAN]; Ethyl 2-(4-chlorophenoxy)isobutyrate; Ethyl 2-(p-chlorophenoxy)isobutyrate; Ethyl alpha-(4-chlorophenoxy)isobutyrate; Ethyl alpha-(p-chlorophenoxy)isobutyrate; Ethyl-alpha-p-chlorophenoxy-isobutyrate
DMPC1J7 CP Ayerst Laboratories Inc
DMPC1J7 TC Antilipemic Agents
DMPC1J7 DT Small molecular drug
DMPC1J7 PC 2796
DMPC1J7 MW 242.7
DMPC1J7 FM C12H15ClO3
DMPC1J7 IC InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3
DMPC1J7 CS CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
DMPC1J7 IK KNHUKKLJHYUCFP-UHFFFAOYSA-N
DMPC1J7 IU ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
DMPC1J7 CA CAS 637-07-0
DMPC1J7 CB CHEBI:3750
DMPC1J7 DE Dysbetalipoproteinemia
DMKI7RB ID DMKI7RB
DMKI7RB DN Clomifene
DMKI7RB HS Approved
DMKI7RB SN Androxal; Chlomaphene; Chloramifene; Cisclomifenum; Cisclomiphene; Clomifen; Clomifeno; Clomifenum; Clomifert; Clomiphene; Clostilbegit; Enclomifene; Enclomifeno; Enclomifenum; Enclomiphen; Enclomiphene; Klostilbegit; Transclomifenum; Transclomiphene; Zuclomifene; Zuclomifeno; Zuclomifenum; Zuclomiphene; Clomiphene B;Enclomiphene [USAN]; ISOMER B; Zuclomiphene [USAN]; Cis-Clomifene; Cis-Clomiphene; Clomid (TN); Clomifene (INN); Clomifene (TN); Clomifene [INN:BAN]; Clomifeno [INN-Spanish]; Clomifenum [INN-Latin]; En-Clomiphene; Enclomifeno [INN-Spanish]; Enclomifenum [INN-Latin]; Enclomiphene (USAN); Milophene (TN); RMI 16,289; RMI-16289; RMI-16312; Serophene (TN); Trans-Clomifene; Trans-Clomiphene; Zuclomifeno [INN-Spanish]; Zuclomifenum [INN-Latin]; Zuclomiphene (USAN); Cis-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Trans-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; Cis-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Trans-2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; (E)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; (Z)-isomer; 1-(p-(beta-Diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene; 2-(4-(2-Chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; 2-(p-(2-Chloro-1,2-diphenylvinyl)phenoxy)triethylamine; 2-(p-(beta-Chloro-alpha-phenylstyryl)phenoxy)-triethylamine; 2-(p-(beta-chloro-alpha-phenylstyryl)phenoxy)triethylamine; 2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine; 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine; 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine; 2-{4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine
DMKI7RB TC Fertility Agents
DMKI7RB DT Small molecular drug
DMKI7RB PC 1548953
DMKI7RB MW 406
DMKI7RB FM C26H28ClNO
DMKI7RB IC InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25+
DMKI7RB CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
DMKI7RB IK GKIRPKYJQBWNGO-OCEACIFDSA-N
DMKI7RB IU 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine
DMKI7RB CA CAS 15690-57-0
DMKI7RB CB CHEBI:3752
DMKI7RB DE Female infertility
DMS51VC ID DMS51VC
DMS51VC DN Clomiphene citrate
DMS51VC HS Approved
DMS51VC SN Clomid; Milophene; Serophene
DMS51VC CP Sanofi Aventis Us Llc
DMS51VC DT Small molecular drug
DMS51VC PC 3033832
DMS51VC MW 598.1
DMS51VC FM C32H36ClNO8
DMS51VC IC InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
DMS51VC CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\Cl)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMS51VC IK PYTMYKVIJXPNBD-OQKDUQJOSA-N
DMS51VC IU 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMS51VC CA CAS 7619-53-6
DMS51VC DE Female infertility
DMINRKW ID DMINRKW
DMINRKW DN Clomipramine
DMINRKW HS Approved
DMINRKW SN Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)
DMINRKW CP Norvatis Phamaceuticals Corporation
DMINRKW TC Antidepressants
DMINRKW DT Small molecular drug
DMINRKW PC 2801
DMINRKW MW 314.9
DMINRKW FM C19H23ClN2
DMINRKW IC InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
DMINRKW CS CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
DMINRKW IK GDLIGKIOYRNHDA-UHFFFAOYSA-N
DMINRKW IU 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DMINRKW CA CAS 303-49-1
DMINRKW CB CHEBI:47780
DMINRKW DE Depression
DM0ZRMQ ID DM0ZRMQ
DM0ZRMQ DN Clomocycline
DM0ZRMQ HS Approved
DM0ZRMQ SN Chlormethylenecycline; Clomociclina; Clomocyclina; Clomocyclinum; Clomociclina [INN-Spanish]; Clomocycline (INN); Clomocycline [INN:BAN]; Clomocyclinum [INN-Latin]; N-2-Hydroxymethylchlortetracycline; N'-Methylolo-chlortetracycline; (2Z,4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(hydroxymethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
DM0ZRMQ TC Antibiotics
DM0ZRMQ DT Small molecular drug
DM0ZRMQ PC 54680675
DM0ZRMQ MW 508.9
DM0ZRMQ FM C23H25ClN2O9
DM0ZRMQ IC InChI=1S/C23H25ClN2O9/c1-22(34)8-6-9-16(26(2)3)18(30)14(21(33)25-7-27)20(32)23(9,35)19(31)12(8)17(29)13-11(28)5-4-10(24)15(13)22/h4-5,8-9,16,27-29,32,34-35H,6-7H2,1-3H3,(H,25,33)/t8-,9-,16-,22-,23-/m0/s1
DM0ZRMQ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)NCO)N(C)C)O
DM0ZRMQ IK BXTHDFJCJQJHKD-KMVLDZISSA-N
DM0ZRMQ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-N-(hydroxymethyl)-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DM0ZRMQ CA CAS 1181-54-0
DM0ZRMQ CB CHEBI:59589
DM0ZRMQ DE Bacterial infection
DMTO13J ID DMTO13J
DMTO13J DN Clonazepam
DMTO13J HS Approved
DMTO13J SN Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
DMTO13J CP Roche Pharmaceuticals
DMTO13J TC Anticonvulsants
DMTO13J DT Small molecular drug
DMTO13J PC 2802
DMTO13J MW 315.71
DMTO13J FM C15H10ClN3O3
DMTO13J IC InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
DMTO13J CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
DMTO13J IK DGBIGWXXNGSACT-UHFFFAOYSA-N
DMTO13J IU 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
DMTO13J CA CAS 1622-61-3
DMTO13J CB CHEBI:3756
DMTO13J DE Epilepsy; Seizure disorder
DM6RZ9Q ID DM6RZ9Q
DM6RZ9Q DN Clonidine
DM6RZ9Q HS Approved
DM6RZ9Q SN clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form); Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
DM6RZ9Q CP Intas Pharmaceuticals
DM6RZ9Q TC Antihypertensive Agents
DM6RZ9Q DT Small molecular drug
DM6RZ9Q PC 2803
DM6RZ9Q MW 230.09
DM6RZ9Q FM C9H9Cl2N3
DM6RZ9Q IC InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
DM6RZ9Q CS C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
DM6RZ9Q IK GJSURZIOUXUGAL-UHFFFAOYSA-N
DM6RZ9Q IU N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
DM6RZ9Q CA CAS 4205-90-7
DM6RZ9Q CB CHEBI:3757
DM6RZ9Q DE Hypertension; Diabetic neuropathy
DMOL54H ID DMOL54H
DMOL54H DN Clopidogrel
DMOL54H HS Approved
DMOL54H SN clopidogrel; 113665-84-2; (S)-Clopidogrel; Plavix; Clopidogrel [INN:BAN]; (+)-(S)-Clopidogrel; (+)-Clopidogrel; UNII-A74586SNO7; HSDB 7430; CLOPIDOGREL SULFATE; CHEBI:37941; GKTWGGQPFAXNFI-HNNXBMFYSA-N; A74586SNO7; CPD000550475; Zyllt; Clopidogrel (TN); SR-25990C; Plavix (TN); methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate; Clopidogrelum; Thrombo; Clopidogrel BMS; Clopidogrel Hexal; Clopidogrel Acino; methyl (2S)-2-(2-chlorophenyl)-2-{4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}acetate; PM-103; Clopidogrel (captisol-enabled); Clopidogrel (captisol-enabled), The Medicines Co; Clopidogrel (captisol-enabled, cardiovascular disease), Cydex; Clopidogrel (captisol-enabled, cardiovascular disease), Prism Pharmaceuticals
DMOL54H CP Prism Pharmaceuticals Inc
DMOL54H DT Small molecular drug
DMOL54H PC 60606
DMOL54H MW 321.8
DMOL54H FM C16H16ClNO2S
DMOL54H IC InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
DMOL54H CS COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
DMOL54H IK GKTWGGQPFAXNFI-HNNXBMFYSA-N
DMOL54H IU methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
DMOL54H CA CAS 113665-84-2
DMOL54H CB CHEBI:37941
DMOL54H DE Thrombosis
DMC3JST ID DMC3JST
DMC3JST DN Clorazepate
DMC3JST HS Approved
DMC3JST SN Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
DMC3JST CP Taro Pharmaceutical Industries Ltd
DMC3JST TC Hypnotics and Sedatives
DMC3JST DT Small molecular drug
DMC3JST PC 2809
DMC3JST MW 314.72
DMC3JST FM C16H11ClN2O3
DMC3JST IC InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
DMC3JST CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O
DMC3JST IK XDDJGVMJFWAHJX-UHFFFAOYSA-N
DMC3JST IU 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
DMC3JST CA CAS 23887-31-2
DMC3JST CB CHEBI:3761
DMC3JST DE Anxiety disorder
DMCEUJD ID DMCEUJD
DMCEUJD DN Clorgyline
DMCEUJD HS Approved
DMCEUJD SN Chlorgyline; Clorgilin; Clorgilina; Clorgiline; Clorgilinum; Clorgiline [INN]; M and B 9302; Clorgilina [INN-Spanish]; Clorgiline (INN); Clorgilinum [INN-Latin]; M & B 9302; N-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-(9CI); 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD TC Antiparkinson Agents
DMCEUJD DT Small molecular drug
DMCEUJD PC 4380
DMCEUJD MW 272.17
DMCEUJD FM C13H15Cl2NO
DMCEUJD IC InChI=1S/C13H15Cl2NO/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15/h1,5-6,10H,4,7-9H2,2H3
DMCEUJD CS CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C
DMCEUJD IK BTFHLQRNAMSNLC-UHFFFAOYSA-N
DMCEUJD IU 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine
DMCEUJD CA CAS 17780-72-2
DMCEUJD CB CHEBI:3763
DMCEUJD DE Skin imperfections; Parkinson disease
DM6K1OA ID DM6K1OA
DM6K1OA DN Clothiapine
DM6K1OA HS Approved
DM6K1OA SN Clothiapine; Clotiapine; 2058-52-8; Entumine; Entumin; Etumine; HF 2159; Clotiapinum [INN-Latin]; Clotiapina [INN-Spanish]; UNII-Z05HCY0X1T; S-805C; Clothiapine [USAN]; EINECS 218-162-8; LW 2159; C18H18ClN3S; BRN 0568276; Z05HCY0X1T; CHEMBL304902; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine; KAAZGXDPUNNEFN-UHFFFAOYSA-N; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo(b,f)(1,4)thiazepine; DIBENZO(b,f)(1,4)THIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; Clothiapine (USAN); HF-2159; NCGC00160387-01
DM6K1OA DT Small molecular drug
DM6K1OA PC 16351
DM6K1OA MW 343.9
DM6K1OA FM C18H18ClN3S
DM6K1OA IC InChI=1S/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM6K1OA CS CN1CCN(CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM6K1OA IK KAAZGXDPUNNEFN-UHFFFAOYSA-N
DM6K1OA IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine
DM6K1OA CA CAS 2058-52-8
DM6K1OA CB CHEBI:31424
DM6K1OA DE Schizophrenia
DM59AZT ID DM59AZT
DM59AZT DN Clotiazepam
DM59AZT HS Approved
DM59AZT SN Clotiazepamum; Clozan; Distensan; Rise; Rize; Rizen; Tienor; Trecalmo; Veratran; Y 6047; Clotiazepam [INN:JAN]; Clotiazepamum [INN-Latin]; Clozan (TN); Distensan (TN); Rize (TN); Rizen (TN); Trecalmo (TN); Veratran (TN); Y-6047; Clotiazepam (JP15/INN); 2H-Thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-(8CI); 5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one; 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one; 5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one
DM59AZT TC Hypnotics and Sedatives
DM59AZT DT Small molecular drug
DM59AZT PC 2811
DM59AZT MW 318.8
DM59AZT FM C16H15ClN2OS
DM59AZT IC InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3
DM59AZT CS CCC1=CC2=C(S1)N(C(=O)CN=C2C3=CC=CC=C3Cl)C
DM59AZT IK CHBRHODLKOZEPZ-UHFFFAOYSA-N
DM59AZT IU 5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one
DM59AZT CA CAS 33671-46-4
DM59AZT CB CHEBI:31425
DM59AZT DE Anxiety disorder
DMMFCIH ID DMMFCIH
DMMFCIH DN Clotrimazole
DMMFCIH HS Approved
DMMFCIH SN Canesten; Canestene; Canestine; Canifug; Chlotrimazole; Cimitidine; Clomatin; Clotrimaderm; Clotrimazol; Clotrimazolum; Clotrimeizol; Cutistad; Empecid; Esparol; FemCare; Gynix; Kanesten; Klotrimazole; Lotrimax; Lotrimin; Monobaycuten; Mycelax; Mycelex; Mycofug; Mycosporin; Mykosporin; Nalbix; Pedisafe; Rimazole; Stiemazol; Tibatin; Trimysten; Canesten Cream; Canesten Solution; Clotrimazole Schering Brand; Desamix F; Fem Care; Gyne lotrimin; Lotrimin AF Cream; Lotrimin AF Lotion; Lotrimin AF Solution; Lotrimin Af; Lotrimin Cream; Lotrimin Lotion; Lotrimin Solution; Mycelex Cream; Mycelex G; Mycelex OTC; Mycelex Solution; Mycelex Troches; Mycelex Twin Pack; Myclo Cream; Myclo Solution; Myclo Spray Solution; Schering Brand of Clotrimazole; B 5097; Bay b 9057; Bayer Brand 1 of Clotrimazole; Bayer Brand 2 of Clotrimazole; C 6019; FB 5097; FB b 5097; Mycelex 7; Trivagizole 3; Bay-B 5097; Candid Vaginal (TN); Candinil (TN); Canesten (TN); Canesten 1-Day Therapy; Canesten 3-Day Therapy; Canesten 6-Day Therapy; Clobrate VT (TN); Clotrimazol [INN-Spanish]; Clotrimazolum [INN-Latin]; DRG-0072; Gino-Lotremine; Gyne-Lotrimin; Gyne-Lotrimin 3; Gyne-Lotrimin 3 Combination Pack; Gyne-Lotrimin Combination Pack; Lotrimin (TN); Lotrimin AF Jock-Itch Cream; Mono-baycuten; Mycelex (TN); Mycelex-7; Mycelex-7 Combination Pack; Mycelex-G; Mycelex: MycosporinRimazole; Myclo-Gyne; Neo-Zol Cream; Pan-Fungex; Cancap-VT (TN); Candid - V Gel (TN); Canesten 1-Day Cream Combi-Pak; Canesten Combi-Pak 1-Day Therapy; Canesten Combi-Pak 3-Day Therapy; Clotrimazole (JP15/USP/INN); Clotrimazole [USAN:INN:BAN:JAN]; (Chlorotrityl)imidazole; 1-(o-Chlorotrityl)imidazole
DMMFCIH CP Bayer Pharmaceuticals Corporation
DMMFCIH TC Antifungal Agents
DMMFCIH DT Small molecular drug
DMMFCIH PC 2812
DMMFCIH MW 344.8
DMMFCIH FM C22H17ClN2
DMMFCIH IC InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
DMMFCIH CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
DMMFCIH IK VNFPBHJOKIVQEB-UHFFFAOYSA-N
DMMFCIH IU 1-[(2-chlorophenyl)-diphenylmethyl]imidazole
DMMFCIH CA CAS 23593-75-1
DMMFCIH CB CHEBI:3764
DMMFCIH DE Fungal infection
DMUTL7O ID DMUTL7O
DMUTL7O DN Cloxacillin
DMUTL7O HS Approved
DMUTL7O SN Chloroxacillin; Clossacillina; Cloxacilina; Cloxacilline; Cloxacillinum; MCIPC; Orbenin; Syntarpen; Tegopen; Clossacillina [DCIT]; Cloxacillin sodium; Methocillin S; BRL 1621; Cloxacilina [INN-Spanish]; Cloxacillin (INN); Cloxacillin [INN:BAN]; Cloxacilline [INN-French]; Cloxacillinum [INN-Latin]; Cloxapen (TN); Cloxapen (sodium monohydrate); Methylchlorphenylisoxazoryl-penicillin; Novo-Cloxin; Nu-Cloxi; Orbenin (TN); Tegopen (sodium monohydrate); BRL-1621 (sodium monohydrate); P-25 (sodium monohydrate); [3-(O-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL]PENICILLIN; (2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (3-(o-Chlorophenyl)-5-methyl-4-isoxazolyl)penicillin; 6-(((3-(2-Chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(o-Chlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid
DMUTL7O CP Beecham phamaceuticals
DMUTL7O TC Antibiotics
DMUTL7O DT Small molecular drug
DMUTL7O PC 6098
DMUTL7O MW 435.9
DMUTL7O FM C19H18ClN3O5S
DMUTL7O IC InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1
DMUTL7O CS CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMUTL7O IK LQOLIRLGBULYKD-JKIFEVAISA-N
DMUTL7O IU (2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMUTL7O CA CAS 61-72-3
DMUTL7O CB CHEBI:49566
DMUTL7O DE Bacterial infection
DMFC71L ID DMFC71L
DMFC71L DN Clozapine
DMFC71L HS Approved
DMFC71L SN Asaleptin; CLOZARIL; Clorazil; Clozapin; Clozapina; Clozapinum; Fazaclo; Iprox; Leponex; Lepotex; Fazaclo ODT; C 6305; HF1854; Clopine (TN); Clozapina [INN-Spanish]; Clozapine(tautomer); Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo (TN); Froidir (TN); HF-1854; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex (TN); W-801; Zaponex (TN); Clozapine [USAN:INN:BAN]; Clozapine (JAN/USP/INN); 3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
DMFC71L CP Sandoz
DMFC71L TC Antipsychotic Agents
DMFC71L DT Small molecular drug
DMFC71L PC 135398737
DMFC71L MW 326.8
DMFC71L FM C18H19ClN4
DMFC71L IC InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
DMFC71L CS CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMFC71L IK QZUDBNBUXVUHMW-UHFFFAOYSA-N
DMFC71L IU 3-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
DMFC71L CA CAS 5786-21-0
DMFC71L CB CHEBI:3766
DMFC71L DE Schizophrenia
DMPC2QY ID DMPC2QY
DMPC2QY DN CNTO-1959
DMPC2QY HS Approved
DMPC2QY SN Guselkumab
DMPC2QY CP Janssen/Johnson & Johnson
DMPC2QY DT Antibody
DMPC2QY SQ Heavy chain: EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainQSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
DMPC2QY DE Plaque psoriasis; Asthma
DM8HBJI ID DM8HBJI
DM8HBJI DN Coagulation Factor IX
DM8HBJI HS Approved
DM8HBJI TC Anticoagulants
DM8HBJI DE Haemophilia B
DM6L4H2 ID DM6L4H2
DM6L4H2 DN Cobicistat
DM6L4H2 HS Approved
DM6L4H2 SN 1004316-88-4; Cobicistat (GS-9350); GS 9350; GS-9350; UNII-LW2E03M5PG; Cobicistat,GS-9350; CHEBI:72291; LW2E03M5PG; Tybost; thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate; 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate; 1,3-thiazol-5-ylmethyl
DM6L4H2 CP GILEAD
DM6L4H2 DT Small molecular drug
DM6L4H2 PC 25151504
DM6L4H2 MW 776
DM6L4H2 FM C40H53N7O5S2
DM6L4H2 IC InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1
DM6L4H2 CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DM6L4H2 IK ZCIGNRJZKPOIKD-CQXVEOKZSA-N
DM6L4H2 IU 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DM6L4H2 CA CAS 1004316-88-4
DM6L4H2 CB CHEBI:72291
DM6L4H2 DE Human immunodeficiency virus infection
DMDKXTO ID DMDKXTO
DMDKXTO DN Cobicistat/darunavir
DMDKXTO HS Approved
DMDKXTO SN Prezcobix; Cobicistat / darunavir; Darunavir / Cobicistat; Cobicistat and darunavir; Cobicistat mixture with darunavir; Darunavir and cobicistat
DMDKXTO CP Gilead Sciences
DMDKXTO DT Small molecular drug
DMDKXTO PC 57327017
DMDKXTO MW 1323.7
DMDKXTO FM C67H90N10O12S3
DMDKXTO IC InChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1
DMDKXTO CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
DMDKXTO IK CXORHDVSJFELCV-HWDLLDTBSA-N
DMDKXTO IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMDKXTO DE Human immunodeficiency virus infection
DMSOX7I ID DMSOX7I
DMSOX7I DN Cocaine
DMSOX7I HS Approved
DMSOX7I SN Allococaine; Allopseudococaine; Badrock; Bazooka; Benzoylethylecgonine; Benzoylmethylecgonine; Bernice; Bernies; Blast; Blizzard; Blow; Burese; COC; Cabello; Candy; Carrie; Caviar; Cecil; Charlie; Cholly; Coca; Cocain; Cocaina; Cocainum; Cocktail; Coke; Cola; Corine; Crack; Eritroxilina; Erytroxylin; Flake; Flex; Freeze; Girl; Goofball; Heaven; Hell; Jam; Kokain; Kokan; Kokayeen; Lady; Leaf; Moonrocks; Neurocaine; Pseudoallococaine; Rock; Sleighride; Snort; Snow; Toke; Toot; Trails; Yeyo; Bernice [Street Name]; Blow [Street Name]; Bouncing Powder; Cecil [Street Name]; Chicken Scratch; Cocaine [BAN]; Cocaine free base; Cocaine solution; Crack cocaine; Dama blanca; Ecgonine methyl ester benzoate; Ecgonine methyl ester benzoate solution; Flake [Street Name]; Florida Snow; Foo Foo; Girl [Street Name]; Gold dust; Gold dust [Street Name]; Green gold; Happy dust; Happy dust [Street Name]; Happy powder; Happy trails; Lady [Street Name]; Methyl Benzoylecgonine; Nose candy; Prime Time; Rock [Street Name]; Sweet Stuff; Toot [Street Name]; White girl or lady; Beta-Cocain; C" Carrie; Cocaine (TN); Cocaine (USP); Cocaine-M; G-Rock; Kibbles n' Bits; L-Cocain; L-Cocaine; Pimp's drug; Snow (birds); Star-spangled powder; Ecgonine, methyl ester, benzoate (ester); Methyl 3beta-hydroxy-1alphaH,5alphaH-tropane-2beta-carboxylate benzoate (ester); Methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl 3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate; Methyl (3S,4R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; Methyl (1S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate; (-)-Cocaine; (-)-Cocaine base; (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate; (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate; (R)-Cocaine; 1-Cocaine; 2-beta-Carbomethoxy-3-beta-benzoxytropane; 2-beta-Tropanecarboxylic acid, 3-beta-hydroxy-, methyl ester, benzoate (ester); 2beta-Carbomethoxy-3beta-benzoxytropane; 3-Tropanylbenzoate-2-carboxylic acid methyl ester; 3beta-Hydroxy-2beta-tropanecarboxylic acid methyl ester benzoate (ester)
DMSOX7I TC Anesthetics
DMSOX7I DT Small molecular drug
DMSOX7I PC 446220
DMSOX7I MW 303.35
DMSOX7I FM C17H21NO4
DMSOX7I IC InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1
DMSOX7I CS CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC
DMSOX7I IK ZPUCINDJVBIVPJ-LJISPDSOSA-N
DMSOX7I IU methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMSOX7I CA CAS 50-36-2
DMSOX7I CB CHEBI:27958
DMSOX7I DE Anaesthesia
DMJX6ZG ID DMJX6ZG
DMJX6ZG DN Codeine
DMJX6ZG HS Approved
DMJX6ZG SN codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate
DMJX6ZG CP Forest Pharmaceuticals
DMJX6ZG TC Analgesics
DMJX6ZG DT Small molecular drug
DMJX6ZG PC 5284371
DMJX6ZG MW 299.4
DMJX6ZG FM C18H21NO3
DMJX6ZG IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMJX6ZG CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
DMJX6ZG IK OROGSEYTTFOCAN-DNJOTXNNSA-N
DMJX6ZG IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMJX6ZG CA CAS 76-57-3
DMJX6ZG CB CHEBI:16714
DMJX6ZG DE Pain; Cough
DM2POTE ID DM2POTE
DM2POTE DN Colchicine
DM2POTE HS Approved
DM2POTE SN Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine
DM2POTE TC Gout Suppressants
DM2POTE DT Small molecular drug
DM2POTE PC 6167
DM2POTE MW 399.4
DM2POTE FM C22H25NO6
DM2POTE IC InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
DM2POTE CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DM2POTE IK IAKHMKGGTNLKSZ-INIZCTEOSA-N
DM2POTE IU N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM2POTE CA CAS 64-86-8
DM2POTE CB CHEBI:27882
DM2POTE DE Acute gouty arthritis
DMJ01D8 ID DMJ01D8
DMJ01D8 DN Colforsin daropate hci
DMJ01D8 HS Approved
DMJ01D8 SN Adehl (TN); Adele (TN)
DMJ01D8 CP Nippon Kayaku
DMJ01D8 DT Small molecular drug
DMJ01D8 PC 444028
DMJ01D8 MW 546.1
DMJ01D8 FM C27H44ClNO8
DMJ01D8 IC InChI=1S/C27H43NO8.ClH/c1-10-24(5)15-18(31)27(33)25(6)17(30)11-13-23(3,4)21(25)20(35-19(32)12-14-28(8)9)22(34-16(2)29)26(27,7)36-24;/h10,17,20-22,30,33H,1,11-15H2,2-9H3;1H/t17-,20-,21-,22-,24-,25-,26+,27-;/m0./s1
DMJ01D8 CS CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C.Cl
DMJ01D8 IK VIRRLEDAYYYTOD-YHEOSNBFSA-N
DMJ01D8 IU [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-5-acetyloxy-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-6-yl] 3-(dimethylamino)propanoate;hydrochloride
DMJ01D8 CA CAS 138605-00-2
DMJ01D8 CB CHEBI:31429
DMJ01D8 DE Asthma
DMZ9BMU ID DMZ9BMU
DMZ9BMU DN Colistimethate
DMZ9BMU HS Approved
DMZ9BMU SN Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable
DMZ9BMU TC Antibiotics
DMZ9BMU DT Small molecular drug
DMZ9BMU PC 216258
DMZ9BMU MW 1749.8
DMZ9BMU FM C58H105N16Na5O28S5
DMZ9BMU IC InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
DMZ9BMU CS CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]
DMZ9BMU IK IQWHCHZFYPIVRV-UHFFFAOYSA-I
DMZ9BMU IU pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate
DMZ9BMU CA CAS 8068-28-8
DMZ9BMU DE Respiratory tract infection
DMMD9QE ID DMMD9QE
DMMD9QE DN Colistin
DMMD9QE HS Approved
DMMD9QE SN Colistin sulphate; Polymyxin E; Colistin sulfate, nonsterile; Polymyxin E. Sulfate; Coly-Mycin M Parenteral (TN)
DMMD9QE CP Parkdale Pharmaceuticals
DMMD9QE TC Antibiotics
DMMD9QE DT Small molecular drug
DMMD9QE PC 5311054
DMMD9QE MW 1155.4
DMMD9QE FM C52H98N16O13
DMMD9QE IC InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1
DMMD9QE CS CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O
DMMD9QE IK YKQOSKADJPQZHB-QNPLFGSASA-N
DMMD9QE IU N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-5-methylheptanamide
DMMD9QE CA CAS 1066-17-7
DMMD9QE DE Pseudomonas infection
DMFJ2OG ID DMFJ2OG
DMFJ2OG DN Collagenase
DMFJ2OG HS Approved
DMFJ2OG TC Antiulcer Agents
DMFJ2OG DE Skin burns; Dermal ulcers
DM1V329 ID DM1V329
DM1V329 DN Conivaptan
DM1V329 HS Approved
DM1V329 SN Conivaptan [INN]; YM 087; YM087; Conivaptan (INN); Vaprisol (TN); YM-087; N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide; N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide; 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
DM1V329 CP Astellas Pharma Inc
DM1V329 DT Small molecular drug
DM1V329 PC 151171
DM1V329 MW 498.6
DM1V329 FM C32H26N4O2
DM1V329 IC InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
DM1V329 CS CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM1V329 IK IKENVDNFQMCRTR-UHFFFAOYSA-N
DM1V329 IU N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
DM1V329 CA CAS 210101-16-9
DM1V329 CB CHEBI:681850
DM1V329 DE Euvolemic hyponatremia
DMLT0E1 ID DMLT0E1
DMLT0E1 DN Conjugated estrogens
DMLT0E1 HS Approved
DMLT0E1 SN Par Estro; evex; Premarin; Conestoral; NSC18313; Sodium estrone 3-monosulfate; Estrone, hydrogen sulfate sodium salt; AC1NS0NL; NSC-18313; sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate; Estra-1,5(10)-trien-17-one, 3-(sulfooxy)-, sodium; Carentil; Congest; Estroplus; Evex; Menotabs; Oestrogen; Prelestrin; Presomil; Progens; Conjugated Equine Estrogens; Conjugated Estrogenic Substances; Conjugated estrogenic hormones; Conjugated oestrogens; Conjugated oestrogens [Steroidal oestrogens]; Steroidal estrogens; ASTA Medica Brand of Estrogens, Conjugated; Almirall Brand of Estrogens, Conjugated; Equine Estrogens, Conjugated; Estro-Feminal; Estrogenic Hormones, Conjugated; Estrogenic substances, conjugated; Estrogens, conjugated USP; Estrogens, conjugated [USP]; Estrogens, conjugated synthetic A; Estrogens, steroidal; Solvay Brand of Estrogens, Conjugated; Trianon Brand of Estrogens, Conjugated; Wyeth Brand of Estrogens, Conjugated; Estrogens, conjugated (USP); Estrogens, conjugated-equine; Mack Brand of Estrogens, Conjugated (USP); Major Brand of Estrogens, Conjugated (USP); Pasadena Brand of Estrogens, Conjugated (USP); Pharmacia Brand of Estrogens, Conjugated (USP); CES; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, sodium salt; Sodium [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMLT0E1 CP Wyeth Pharmaceuticals
DMLT0E1 TC Estrogens
DMLT0E1 DT Small molecular drug
DMLT0E1 PC 45357473
DMLT0E1 MW 372.4
DMLT0E1 FM C18H21NaO5S
DMLT0E1 IC InChI=1S/C18H22O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14?,15?,16?,18-;/m0./s1
DMLT0E1 CS C[C@]12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+]
DMLT0E1 IK VUCAHVBMSFIGAI-TWCWWGPMSA-M
DMLT0E1 IU sodium;[(13S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfate
DMLT0E1 DE Menopause symptom; Vasomotor symptom
DMTPIZC ID DMTPIZC
DMTPIZC DN Conjugated estrogens a
DMTPIZC HS Approved
DMTPIZC SN Conestin (TN)
DMTPIZC DE Hormone replacement therapy
DMU7SF8 ID DMU7SF8
DMU7SF8 DN Conjugated estrogens b
DMU7SF8 HS Approved
DMU7SF8 SN Enjuvia (TN)
DMU7SF8 DE Hormone replacement therapy
DMF29Q5 ID DMF29Q5
DMF29Q5 DN Connexyn
DMF29Q5 HS Approved
DMF29Q5 SN Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1)
DMF29Q5 DT Small molecular drug
DMF29Q5 PC 71401
DMF29Q5 MW 282.5
DMF29Q5 FM C9H10Cl3N3O
DMF29Q5 IC InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
DMF29Q5 CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl
DMF29Q5 IK DGFYECXYGUIODH-UHFFFAOYSA-N
DMF29Q5 IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
DMF29Q5 CA CAS 29110-48-3
DMF29Q5 CB CHEBI:5559
DMF29Q5 DE Attention deficit hyperactivity disorder
DM26KR1 ID DM26KR1
DM26KR1 DN Copper dotatate Cu-64
DM26KR1 HS Approved
DM26KR1 SN UNII-N3858377KC; N3858377KC; Copper 64-DOTA-tate; Copper Cu-64 dotatate; 1426155-87-4; Cuprate(2-)-64Cu, (N-(2-(4,10-bis((carboxy-kappaO)methyl)-7-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN7,kappaN10)acetyl)-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoni
DM26KR1 DT Radioactive diagnostic agent
DM26KR1 PC 124220636
DM26KR1 MW 1497.5
DM26KR1 FM C65H88CuN14O19S2
DM26KR1 IC InChI=1S/C65H90N14O19S2.Cu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+2/p-2/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+0
DM26KR1 CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[64Cu+2]
DM26KR1 IK IJRLLVFQGCCPPI-NVGRTJHCSA-L
DM26KR1 IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-10-(carboxylatomethyl)-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)
DM26KR1 CA CAS 1426155-87-4
DM26KR1 DE Diagnostic imaging
DMP9TWZ ID DMP9TWZ
DMP9TWZ DN Corticotropin
DMP9TWZ HS Approved
DMP9TWZ SN corticotropin; ACTH; Cortrophin; Corticotrophin; Adrenocorticotropic hormone; Corticotrophine; Corticotrofina; Acthargel; Corticotrophinum; beta-Corticotropin; Adrenocorticotrophin; Purified Cortrophin gel; Corticotropin [USP:INN]; 9002-60-2; CHEBI:3892; BDBM82408; ACTH-(1-39); 25-Asp-30-Gln-corticotropin porcine; NCGC00167127-01; CAS_12279-41-3; Adrenocorticotropic Hormone (1-39), human; LS-187380; SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF; J-004856; alpha1-39-Corticotropin (swine), 25-L-aspartic acid-30-L-glutamine
DMP9TWZ CP Questcor pharmaceuticals
DMP9TWZ SQ ACTH(1-39): SYSMEHFRWGKPVGKKRRPVKVYPDGAEDQLAEAFPLEF
DMP9TWZ PC 16132265
DMP9TWZ MW 4541
DMP9TWZ FM C207H308N56O58S
DMP9TWZ IC InChI=1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1
DMP9TWZ CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N
DMP9TWZ IK IDLFZVILOHSSID-OVLDLUHVSA-N
DMP9TWZ IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMP9TWZ CA CAS 12427-33-7
DMP9TWZ CB CHEBI:3892
DMP9TWZ DE Diabetic nephropathy; Cushing disease
DMU5QZX ID DMU5QZX
DMU5QZX DN Cortisone
DMU5QZX HS Approved
DMU5QZX SN 11-dehydro-17-hydroxycorticosterone; 17-hydroxy-11-dehydrocorticosterone
DMU5QZX DT Small molecular drug
DMU5QZX PC 222786
DMU5QZX MW 360.4
DMU5QZX FM C21H28O5
DMU5QZX IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DMU5QZX CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C
DMU5QZX IK MFYSYFVPBJMHGN-ZPOLXVRWSA-N
DMU5QZX IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione
DMU5QZX CA CAS 53-06-5
DMU5QZX CB CHEBI:16962
DMU5QZX DE Atopic dermatitis
DMG8K57 ID DMG8K57
DMG8K57 DN Cortisone acetate
DMG8K57 HS Approved
DMG8K57 SN Cortone
DMG8K57 CP Pharmacia And Upjohn Co
DMG8K57 TC Anticancer Agents
DMG8K57 DT Small molecular drug
DMG8K57 PC 5745
DMG8K57 MW 402.5
DMG8K57 FM C23H30O6
DMG8K57 IC InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
DMG8K57 CS CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMG8K57 IK ITRJWOMZKQRYTA-RFZYENFJSA-N
DMG8K57 IU [2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMG8K57 CA CAS 50-04-4
DMG8K57 CB CHEBI:3897
DMG8K57 DE Solid tumour/cancer
DMUIASK ID DMUIASK
DMUIASK DN Cosyntropin
DMUIASK HS Approved
DMUIASK SN Cortrosyn; Tetracosactide; Cortrosyn (TN); Cosyntropin (USAN); Tetracosactide (INN)
DMUIASK CP Sandoz
DMUIASK TC Diagnostic Agents
DMUIASK PC 16129617
DMUIASK MW 2933.4
DMUIASK FM C136H210N40O31S
DMUIASK IC InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1
DMUIASK CS CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C(CO)N
DMUIASK IK ZOEFCCMDUURGSE-CQVUSSRSSA-N
DMUIASK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
DMUIASK CA CAS 16960-16-0
DMUIASK DE Adrenocortical insufficiency
DMCEZ1B ID DMCEZ1B
DMCEZ1B DN Cotinine
DMCEZ1B HS Approved
DMCEZ1B SN cotinine; (-)-Cotinine; 486-56-6; Cotinina; Cotininum; (S)-(-)-Cotinine; (5S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one; Cotinine (-); (S)-Cotinine; UNII-K5161X06LL; (S)-1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone; 2-Pyrrolidinone, 1-methyl-5-(3-pyridinyl)-, (5S)-; CHEBI:68641; (S)-1-Methyl-5-(3-pyridyl)-2-pyrrolidinone; UIKROCXWUNQSPJ-VIFPVBQESA-N; K5161X06LL; Cotinine [INN]; MFCD00077696; Cotininum [INN-Latin]; Cotinina [INN-Spanish]; S(-)-1-Methyl-5-(3-pyridyl)-2-pyrrolidone; (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B DT Small molecular drug
DMCEZ1B PC 854019
DMCEZ1B MW 176.21
DMCEZ1B FM C10H12N2O
DMCEZ1B IC InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1
DMCEZ1B CS CN1[C@@H](CCC1=O)C2=CN=CC=C2
DMCEZ1B IK UIKROCXWUNQSPJ-VIFPVBQESA-N
DMCEZ1B IU (5S)-1-methyl-5-pyridin-3-ylpyrrolidin-2-one
DMCEZ1B CA CAS 486-56-6
DMCEZ1B CB CHEBI:68641
DMCEZ1B DE Insecticide
DMJ7IQX ID DMJ7IQX
DMJ7IQX DN Crestor/TriLipix
DMJ7IQX HS Approved
DMJ7IQX CP AstraZeneca
DMJ7IQX DE Dyslipidemia
DMNVKU6 ID DMNVKU6
DMNVKU6 DN Crisaborole
DMNVKU6 HS Approved
DMNVKU6 SN Crisaborole ointment 2%; PF-06930164
DMNVKU6 CP Pfizer/Anacor Pharmaceuticals
DMNVKU6 DT Small molecular drug
DMNVKU6 PC 44591583
DMNVKU6 MW 251.05
DMNVKU6 FM C14H10BNO3
DMNVKU6 IC InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
DMNVKU6 CS B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
DMNVKU6 IK USZAGAREISWJDP-UHFFFAOYSA-N
DMNVKU6 IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile
DMNVKU6 CA CAS 906673-24-3
DMNVKU6 CB CHEBI:134677
DMNVKU6 DE Atopic dermatitis
DMAHOVJ ID DMAHOVJ
DMAHOVJ DN Crizanlizumab
DMAHOVJ HS Approved
DMAHOVJ SN SEG101
DMAHOVJ CP Novartis
DMAHOVJ DT Antibody
DMAHOVJ DE Vaso-occlusive crisis; Sickle-cell disorder
DM4F29C ID DM4F29C
DM4F29C DN Crizotinib
DM4F29C HS Approved
DM4F29C SN Xalkori (TN); novel ALK inhibitors
DM4F29C CP Pfizer New York, NY
DM4F29C DT Small molecular drug
DM4F29C PC 11626560
DM4F29C MW 450.3
DM4F29C FM C21H22Cl2FN5O
DM4F29C IC InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
DM4F29C CS C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
DM4F29C IK KTEIFNKAUNYNJU-GFCCVEGCSA-N
DM4F29C IU 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
DM4F29C CA CAS 877399-52-5
DM4F29C CB CHEBI:64310
DM4F29C DE Non-small-cell lung cancer
DM4AMQZ ID DM4AMQZ
DM4AMQZ DN Crofelemer
DM4AMQZ HS Approved
DM4AMQZ SN Fulyzaq (TN)
DM4AMQZ CP Salix
DM4AMQZ DT Small molecular drug
DM4AMQZ PC 17397714
DM4AMQZ MW 308.3
DM4AMQZ FM C18H16N2O3
DM4AMQZ IC InChI=1S/C18H16N2O3/c1-22-16-10-6-5-9-14(16)12-19-18(21)15-11-17(23-20-15)13-7-3-2-4-8-13/h2-11H,12H2,1H3,(H,19,21)
DM4AMQZ CS COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3
DM4AMQZ IK JDNAIBCYTQGWFC-UHFFFAOYSA-N
DM4AMQZ IU N-[(2-methoxyphenyl)methyl]-5-phenyl-1,2-oxazole-3-carboxamide
DM4AMQZ DE HIV-associated diarrhoea
DM74LZK ID DM74LZK
DM74LZK DN Cromoglicate
DM74LZK HS Approved
DM74LZK SN Crolom (TN); Intal (TN); Nasalcrom (TN); Opticrom (TN); Optrex Allergy (TN); Prevalin (TN); Rynacrom (TN)
DM74LZK CP Zambon Group
DM74LZK TC Antiasthmatic Agents
DM74LZK DT Small molecular drug
DM74LZK PC 2882
DM74LZK MW 468.4
DM74LZK FM C23H16O11
DM74LZK IC InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)
DM74LZK CS C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
DM74LZK IK IMZMKUWMOSJXDT-UHFFFAOYSA-N
DM74LZK IU 5-[3-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid
DM74LZK CA CAS 16110-51-3
DM74LZK CB CHEBI:59773
DM74LZK DE Asthma; Allergic rhinitis
DMHCTAL ID DMHCTAL
DMHCTAL DN Cryptenamine Acetates
DMHCTAL HS Approved
DMHCTAL SN Unitensen; Cryptenamine Tannates
DMHCTAL CP Medpointe Pharmaceuticals Medpointe Healthcare Inc
DMHCTAL TC Cardiovascular Agents
DMHCTAL DE Hypertension
DMB8PF3 ID DMB8PF3
DMB8PF3 DN CT-102
DMB8PF3 HS Approved
DMB8PF3 CP Curative Health Services
DMB8PF3 DE Diabetic foot ulcer
DMP0NFQ ID DMP0NFQ
DMP0NFQ DN Cupric Sulfate
DMP0NFQ HS Approved
DMP0NFQ SN Copper sulfate; 7758-98-7; CUPRIC SULFATE; Copper(II) sulfate; Cupric sulfate anhydrous; Copper sulphate; Copper(2+) sulfate; Cupricsulfate; Blue stone; Copper monosulfate; Copper II sulfate; Trinagle; Hylinec; Delcup; Cupric sulphate; Copper(ii) sulfate, anhydrous; Monocopper sulfate; Copper sulfate (1:1); Incracide 10A; Incracide E 51; Sulfuric acid copper(2+) salt (1:1); BCS copper fungicide; Blue copper (VAN); Copper Sulfate Powder; Bonide Root Destroyer; CuSO4; Kupfersulfat [German]; All Clear Root Destroyer; Copper sulfate (CuSO
DMP0NFQ CP Abraxis Pharmaceutical Products
DMP0NFQ TC Antiinfective Agents
DMP0NFQ DT Small molecular drug
DMP0NFQ PC 24462
DMP0NFQ MW 159.61
DMP0NFQ FM CuO4S
DMP0NFQ IC InChI=1S/Cu.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMP0NFQ CS [O-]S(=O)(=O)[O-].[Cu+2]
DMP0NFQ IK ARUVKPQLZAKDPS-UHFFFAOYSA-L
DMP0NFQ IU copper;sulfate
DMP0NFQ CA CAS 7758-98-7
DMP0NFQ CB CHEBI:23414
DMP0NFQ DE Pest attack; Fungal infection; Herbicide
DMHSJB4 ID DMHSJB4
DMHSJB4 DN Cyclacillin
DMHSJB4 HS Approved
DMHSJB4 SN Aminocyclohexylpenicillin; Bastcillin; Calthor; Ciclacilina; Ciclacillin; Ciclacilline; Ciclacillinum; Ciclacillum; Citosarin; Cyclapen; Noblicil; Orfilina; Peamezin; Syngacillin; Ultracillin; Vastcillin; Vipicil; Wyvital; Aminocyclohexyl penicillin; Cyclacillin [USAN]; AC 98; WY 4508; WY4508; C-12104; Ciclacilina [INN-Spanish]; Ciclacilline [INN-French]; Ciclacillinum [INN-Latin]; Cyclacillin (USAN); Cyclapen (TN); Cyclapen-W; Vastcillin (TN); Wy-4508; Ciclacillin (JP15/INN); Cyclapen-W (TN); (1-Aminocyclohexyl)penicillin; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-(8CI); 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMHSJB4 TC Antibiotics
DMHSJB4 DT Small molecular drug
DMHSJB4 PC 19003
DMHSJB4 MW 341.4
DMHSJB4 FM C15H23N3O4S
DMHSJB4 IC InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1
DMHSJB4 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C
DMHSJB4 IK HGBLNBBNRORJKI-WCABBAIRSA-N
DMHSJB4 IU (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMHSJB4 CA CAS 3485-14-1
DMHSJB4 CB CHEBI:31444
DMHSJB4 DE Bacterial infection
DMO0R76 ID DMO0R76
DMO0R76 DN Cyclandelate
DMO0R76 HS Approved
DMO0R76 SN cyclandelate; 456-59-7; Cyclolyt; Cyclomandol; Cyclospasmol; Spasmocyclon; Spasmocyclone; Ciclospasmol; Ciclandelato; Sancyclan; Saiclate; Sepyron; Perebral; Dilatan; Clandilon; Capilan; Spasmione; Arto-espasmol; 3,3,5-Trimethylcyclohexyl mandelate; Cyclandelatum; 3,5,5-Trimethylcyclohexyl amygdalate; Cyclobral; Cyclergine; Cyclandelatum [INN-Latin]; Ciclandelato [INN-Spanish]; 3,5,5-Trimethylcyclohexyl mandelate; Novodil; Natil; Mandelic Acid 3,3,5-Trimethylcyclohexyl Ester; Cyclandelic acid; BS 572; UNII-4139O1OAY2; HSDB 3046; EINECS 207
DMO0R76 DT Small molecular drug
DMO0R76 PC 2893
DMO0R76 MW 276.4
DMO0R76 FM C17H24O3
DMO0R76 IC InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
DMO0R76 CS CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
DMO0R76 IK WZHCOOQXZCIUNC-UHFFFAOYSA-N
DMO0R76 IU (3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate
DMO0R76 CA CAS 456-59-7
DMO0R76 CB CHEBI:3988
DMO0R76 DE Dementia
DM9G7BS ID DM9G7BS
DM9G7BS DN Cyclizine
DM9G7BS HS Approved
DM9G7BS SN Ciclizina; Cyclizinum; Emoquil; Marezine; Nautazine; Valoid; Wellcome; Cyclizine chloride; Cyclizine hydrochloride; Marezine hydrochloride; BW 47-83; Ciclizina [INN-Spanish]; Cyclizine (INN); Cyclizinum [INN-Latin]; Emoquil (TN); Marezine (TN); Marzine (TN); Ne-devomit; Neo-devomit; Reis-fit; Valoid (TN); Wellcome preparation 47-83; Wellcome prepn 47-83; Cyclizine [INN:BAN:DCF]; Wellcome prepn. 47-83; N-Benzhydryl-N'-methylpiperazine; N-Methyl-N'-benzhydrylpiperazine; N-Methyl-N'-benzyhydrylpiperazine; (+-)-1-diphenylmethyl-4-methylpiperazine; (-)-1-Diphenylmethyl-4-methylpiperazine; (N-Benzhydryl)(N'-methyl)diethylenediamine; 1-(Diphenylmethyl)-4-methylpiperazine; 1-Benzhydryl-4-methylpiperazin; 1-Benzhydryl-4-methylpiperazine; 1-Diphenylmethyl-4-methylpiperazine
DM9G7BS CP Seatrace Pharmaceuticals
DM9G7BS TC Antiemetics
DM9G7BS DT Small molecular drug
DM9G7BS PC 6726
DM9G7BS MW 266.4
DM9G7BS FM C18H22N2
DM9G7BS IC InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3
DM9G7BS CS CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
DM9G7BS IK UVKZSORBKUEBAZ-UHFFFAOYSA-N
DM9G7BS IU 1-benzhydryl-4-methylpiperazine
DM9G7BS CA CAS 82-92-8
DM9G7BS CB CHEBI:3994
DM9G7BS DE Nausea
DM1YBRM ID DM1YBRM
DM1YBRM DN Cyclobenzaprine
DM1YBRM HS Approved
DM1YBRM SN Ciclobenzaprina; Cyclobenz; Cyclobenzaprinum; Fexmid; Flexeril; Lisseril; Proeptatriene; Proheptatrien; Proheptatriene; Yurelax; Cyclobenzaprine [INN]; Flexeril hydrochloride; Proeptatriene [Italian]; MK 130; NCI78206; Amrix (TN); Ciclobenzaprina [INN-Spanish]; Cyclobenzaprine (INN); Cyclobenzaprinum [INN-Latin]; Fexmid(TN); Flexeril (TN); MK-130 HCl; Ro 4-1577; Apo-Cyclobenzaprine (TN); N,N-Dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine; N,N-Dimethyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine; N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine; 1-Propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-(9CI); 10,11-Dehydroamitriptyline; 3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene; 5-(3-Dimetilaminopropiliden)-5H-dibenzo-(a,d)-ciclopentene [Italian]; 9715 R.P; 9715 R.P.
DM1YBRM CP Janssen Research And Development Llc
DM1YBRM TC Antidepressants
DM1YBRM DT Small molecular drug
DM1YBRM PC 2895
DM1YBRM MW 275.4
DM1YBRM FM C20H21N
DM1YBRM IC InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
DM1YBRM CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
DM1YBRM IK JURKNVYFZMSNLP-UHFFFAOYSA-N
DM1YBRM IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine
DM1YBRM CA CAS 303-53-7
DM1YBRM CB CHEBI:3996
DM1YBRM DE Depression
DMT5RMB ID DMT5RMB
DMT5RMB DN Cyclofenil
DMT5RMB HS Approved
DMT5RMB SN cyclofenil; 2624-43-3; Ondogyne; Cyclofenyl; Cyclophenyl; Cyclopenil; Fertodur; Sanocrisin; Cyclophenil; Sexovar; Rehibin; Sexadieno; Sexovid; Ondonid; Oginex; (Cyclohexylidenemethylene)bis(4,1-phenylene) diacetate; Neoclym; ICI 48213; Cyclofenilum [INN-Latin]; Ciclofenilo [INN-Spanish]; NSC 86464; H 3452; F 6066; UNII-J468V64WZ1; Cyclofenil [INN:BAN:DCF:JAN]; 4,4'-(Cyclohexylidenemethylene)diphenol diacetate ester; C23H24O4; EINECS 220-089-1; Bis(p-hydroxyphenyl)cyclohexyldienemethane diacetate; BRN 2014687; AI3-52271; F-6066
DMT5RMB DT Small molecular drug
DMT5RMB PC 2898
DMT5RMB MW 364.4
DMT5RMB FM C23H24O4
DMT5RMB IC InChI=1S/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3
DMT5RMB CS CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C
DMT5RMB IK GVOUFPWUYJWQSK-UHFFFAOYSA-N
DMT5RMB IU [4-[(4-acetyloxyphenyl)-cyclohexylidenemethyl]phenyl] acetate
DMT5RMB CA CAS 2624-43-3
DMT5RMB CB CHEBI:31446
DMT5RMB DE Infertility
DMA8LM5 ID DMA8LM5
DMA8LM5 DN Cyclopentolate
DMA8LM5 HS Approved
DMA8LM5 SN Ciclopentolato; Cyclopentoiate; Cyclopentolatum; Cyclopentylate; Cylate; Diopentolate; Mydrilate; Bell Pentolate; Minims Cyclopentolate; Bell Pentolate (TN); Ciclopentolato [INN-Spanish]; Cyclopentolate (INN); Cyclopentolate [INN:BAN]; Cyclopentolatum [INN-Latin]; Ocu-Pentolate; B-dimethylaminoethyl(1-hydroxycyclopentyl)phenylacetate; Beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate; Beta-(Dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate; Alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester; Benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; Benzeneacetic acid, .alpha.-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester; (+-)-cyclopentolate; 1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate; 2-(Dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate; 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-Dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetat; 2-dimethylaminoethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate; 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
DMA8LM5 CP Akorn Inc
DMA8LM5 TC Parasympatholytics
DMA8LM5 DT Small molecular drug
DMA8LM5 PC 2905
DMA8LM5 MW 291.4
DMA8LM5 FM C17H25NO3
DMA8LM5 IC InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
DMA8LM5 CS CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O
DMA8LM5 IK SKYSRIRYMSLOIN-UHFFFAOYSA-N
DMA8LM5 IU 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
DMA8LM5 CA CAS 512-15-2
DMA8LM5 CB CHEBI:4024
DMA8LM5 DE Examination of eyes or vision
DM4O2Z7 ID DM4O2Z7
DM4O2Z7 DN Cyclophosphamide
DM4O2Z7 HS Approved
DM4O2Z7 SN ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
DM4O2Z7 CP Baxter International Inc
DM4O2Z7 TC Anticancer Agents
DM4O2Z7 DT Small molecular drug
DM4O2Z7 PC 2907
DM4O2Z7 MW 261.079
DM4O2Z7 FM C7H15Cl2N2O2P
DM4O2Z7 IC InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
DM4O2Z7 CS C1CNP(=O)(OC1)N(CCCl)CCCl
DM4O2Z7 IK CMSMOCZEIVJLDB-UHFFFAOYSA-N
DM4O2Z7 IU N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DM4O2Z7 CA CAS 50-18-0
DM4O2Z7 CB CHEBI:4027
DM4O2Z7 DE Solid tumour/cancer
DMT1I52 ID DMT1I52
DMT1I52 DN Cycloserine
DMT1I52 HS Approved
DMT1I52 SN D-cycloserine; cycloserine; 68-41-7; Seromycin; orientomycin; Oxamycin; Cyclorin; Cyclo-D-serine; Wasserina; Farmiserina; Tisomycin; Cicloserina; Miroseryn; Closina; D-4-amino-3-isoxazolidinone; (R)-4-AMINOISOXAZOLIDIN-3-ONE; alpha-Cycloserine; (+)-4-Amino-3-isoxazolidinone; Miroserina; Cycloserinum; D-4-amino-3-isoxazolidone; Oxamicina; (4R)-4-aminoisoxazolidin-3-one; PA 94; (+)-Cycloserine; (4R)-4-amino-1,2-oxazolidin-3-one; Oxamicina [Italian]; Cycloserin; Micoserina; Cicloserina [Italian]; PA-94; Tebemicina; Novoserin; D-Oxamycin; Cicloserina; Closerin; Orientomycin; C 3909; Alpha-Cycloserine; C-9390; C-9400; Cicloserina [INN-Spanish]; Cycloserinum [INN-Latin]; D-CS; DRG-0195; I-1431; K-300; SC-49088; Seromycin (TN); Cycloserine [INN:BAN:JAN]; E-733-A; RO-1-9213; Cycloserine (JP15/USP/INN); D-amino-3-isoxazolidinone; D-(+)-Cycloserine; D-4-Amino-3-isossazolidone; D-4-Amino-3-isossazolidone [Italian]; FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09; R-(+)-Cycloserine; R-4-Amino-3-isoxazolidinone; R(+)-4-Amino-3-isoxazolidinone; (4R)-4-Amino-3-isoxazolidinone; (R)-(+)-4-Amino-3-isoxazolidinone; (R)-(+)-Cycloserine; (R)-4-AMINO-ISOXAZOLIDIN-3-ONE; (R)-4-Amino-3-isoxazolidinone; (R)-4-Amino-3-isoxazolidone; (R)-Cycloserine; 3-Isoxazolidinone, 4-amino-, (+)-(8CI); 3-Isoxazolidinone, 4-amino-, (4R)-(9CI); 3-Isoxazolidinone, 4-amino-, (R); 3-Isoxazolidinone, 4-amino-, D; (R)-4-Amino-Isoxazolidin-3-One
DMT1I52 TC Antiinfective Agents
DMT1I52 DT Small molecular drug
DMT1I52 PC 6234
DMT1I52 MW 102.09
DMT1I52 FM C3H6N2O2
DMT1I52 IC InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1
DMT1I52 CS C1[C@H](C(=O)NO1)N
DMT1I52 IK DYDCUQKUCUHJBH-UWTATZPHSA-N
DMT1I52 IU (4R)-4-amino-1,2-oxazolidin-3-one
DMT1I52 CA CAS 68-41-7
DMT1I52 CB CHEBI:40009
DMT1I52 DE Tuberculosis; Bacterial infection; Obsessive compulsive disorder
DMJ4AWC ID DMJ4AWC
DMJ4AWC DN Cyclothiazide
DMJ4AWC HS Approved
DMJ4AWC SN Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMJ4AWC TC Antihypertensive Agents
DMJ4AWC DT Small molecular drug
DMJ4AWC PC 2910
DMJ4AWC MW 389.9
DMJ4AWC FM C14H16ClN3O4S2
DMJ4AWC IC InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
DMJ4AWC CS C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl
DMJ4AWC IK BOCUKUHCLICSIY-UHFFFAOYSA-N
DMJ4AWC IU 3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMJ4AWC CA CAS 2259-96-3
DMJ4AWC CB CHEBI:31448
DMJ4AWC DE Congestive heart failure
DM8C43Q ID DM8C43Q
DM8C43Q DN Cycrimine
DM8C43Q HS Approved
DM8C43Q SN Cicrimina; Cycriminum; Pagitane; Cicrimina [INN-Spanish]; Cycriminum [INN-Latin]; Alpha-Cyclopentyl-alpha-phenyl-1-Piperidinepropanol; (+-)-cycrimine; 1-Phenyl-1-cyclopentyl-3-piperidino-1-propanol; 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol; 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q TC Antiparkinson Agents
DM8C43Q DT Small molecular drug
DM8C43Q PC 2911
DM8C43Q MW 287.4
DM8C43Q FM C19H29NO
DM8C43Q IC InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DM8C43Q CS C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O
DM8C43Q IK SWRUZBWLEWHWRI-UHFFFAOYSA-N
DM8C43Q IU 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DM8C43Q CA CAS 77-39-4
DM8C43Q CB CHEBI:59692
DM8C43Q DE Parkinson disease
DMUY2OR ID DMUY2OR
DMUY2OR DN Cynarin
DMUY2OR HS Approved
DMUY2OR SN 1,3-O-Dicaffeoylquinic acid; 19870-46-3; 1,3-Dicaffeoylquinic acid; Cynarin; 1,5-Dicaffeoylquinic acid; Cynarine; 1,5-di-O-Caffeoylquinic acid; 1,3-di-O-Caffeoylquinic acid; 30964-13-7; (1S,3R,4R,5R)-1,3-Bis[3-(3,4-dihydroxyphenyl)acryloyloxy]-4,5-dihydroxycyclohexanecarboxylic acid; (1S,3R,4R,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxy-cyclohexanecarboxylic acid; AC1O6FEM; 1,5-Dicaffeoylquinic-acid; 1,3-Dicaffeoyl quinic acid; 1,5-Dicaffeoylquinic acid ; CHEMBL478574; 1,5-DCQA
DMUY2OR DT Small molecular drug
DMUY2OR PC 5281769
DMUY2OR MW 516.4
DMUY2OR FM C25H24O12
DMUY2OR IC InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(31)36-20-12-25(24(34)35,11-19(30)23(20)33)37-22(32)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-30,33H,11-12H2,(H,34,35)/b7-3+,8-4+/t19-,20-,23+,25-/m1/s1
DMUY2OR CS C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O
DMUY2OR IK YDDUMTOHNYZQPO-RVXRWRFUSA-N
DMUY2OR IU (1R,3R,4S,5R)-1,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-4,5-dihydroxycyclohexane-1-carboxylic acid
DMUY2OR CA CAS 212891-05-9
DMUY2OR CB CHEBI:520
DMUY2OR DE Vibrio cholerae infection
DM92AH3 ID DM92AH3
DM92AH3 DN Cyproheptadine
DM92AH3 HS Approved
DM92AH3 SN Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
DM92AH3 CP Merck & Co
DM92AH3 TC Antihistamines
DM92AH3 DT Small molecular drug
DM92AH3 PC 2913
DM92AH3 MW 287.4
DM92AH3 FM C21H21N
DM92AH3 IC InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
DM92AH3 CS CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
DM92AH3 IK JJCFRYNCJDLXIK-UHFFFAOYSA-N
DM92AH3 IU 1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
DM92AH3 CA CAS 129-03-3
DM92AH3 CB CHEBI:4046
DM92AH3 DE Rhinitis
DMQXLD2 ID DMQXLD2
DMQXLD2 DN Cyproterone
DMQXLD2 HS Approved
DMQXLD2 SN Ciproterona; Ciproterone; CyPat; Cyproteron; Cyproteronum; Ciproterona Servycal; Ciproterone [DCIT]; SH 80881; Apo-cyproterone; Ciproterona Servycal (TN); Ciproterona [INN-Spanish]; Cyproterone (INN); Cyproterone [INN:BAN]; Cyproteronum [INN-Latin]; Dianette (TN); Gen-Cyproterone; Novo-cyproterone; Diane-35 (TN); (1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one; 6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron; 6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]; 6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
DMQXLD2 CP Schering-Plough
DMQXLD2 TC Anticancer Agents
DMQXLD2 DT Small molecular drug
DMQXLD2 PC 5284537
DMQXLD2 MW 374.9
DMQXLD2 FM C22H27ClO3
DMQXLD2 IC InChI=1S/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1
DMQXLD2 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)O
DMQXLD2 IK DUSHUSLJJMDGTE-ZJPMUUANSA-N
DMQXLD2 IU (1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-15-hydroxy-2,16-dimethylpentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dien-6-one
DMQXLD2 CA CAS 2098-66-0
DMQXLD2 CB CHEBI:50742
DMQXLD2 DE Prostate cancer
DMSYFM8 ID DMSYFM8
DMSYFM8 DN Cysteamine
DMSYFM8 HS Approved
DMSYFM8 SN Becaptan; Cisteamina; Cystavision; Cysteamide; Cysteamin; Cysteinamine; Decarboxycysteine; Ethanethiolamine; Lambraten; Lambratene; MEA; Mecramine; Mercamin; Mercamine; Mercaptamin; Mercaptamina; Mercaptamine; Mercaptaminum; Mercaptoethylamine; Merkamin; Riacon; Thioethanolamine; Aminoethyl mercaptan; Cisteamina [Italian]; Cysteamine bitartate; L 1573; WR 347; Beta-Aminoethanethiol; Beta-Aminoethylthiol; Beta-MEA; Beta-Mercaptoethylamine; C-9500; Cysteamine (USAN); Cysteamine [USAN:BAN]; L-1573; MEA (mercaptan); Mercaptamina [INN-Spanish]; Mercaptamine (INN); Mercaptaminum [INN-Latin]; (2-Mercaptoethyl)amine; (Mercaptoethyl)ammonium toluene-p-sulphonate; 1-Amino-2-mercaptoethylamine; 2-AMINO-ETHANETHIOL; 2-Amino-1-ethanethiol; 2-Aminoethanethiol; 2-Aminoethyl mercaptan; 2-Mercaptoethanamine; 2-Mercaptoethylamine; 2-Mercaptoethylamine, polymer-bound; 641022_ALDRICH
DMSYFM8 CP Mylan Pharmaceuticals Inc
DMSYFM8 TC Nephropathic cystinosis therapy
DMSYFM8 DT Small molecular drug
DMSYFM8 PC 6058
DMSYFM8 MW 77.15
DMSYFM8 FM C2H7NS
DMSYFM8 IC InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2
DMSYFM8 CS C(CS)N
DMSYFM8 IK UFULAYFCSOUIOV-UHFFFAOYSA-N
DMSYFM8 IU 2-aminoethanethiol
DMSYFM8 CA CAS 60-23-1
DMSYFM8 CB CHEBI:17141
DMSYFM8 DE Nephropathic cystinosis
DMZD5QR ID DMZD5QR
DMZD5QR DN Cytarabine
DMZD5QR HS Approved
DMZD5QR SN Alexan; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; Citarabina; Cytarabin; Cytarabina; Cytarabinoside; Cytarabinum; Cytarbel; Cytonal; Cytosar; Cytosinearabinoside; DepoCyte; Depocyt; Erpalfa; Iretin; Spongocytidine; Tarabine; Udicil; Arabinosyl Cytosine; Cytarabine liposome injection; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; AR3; BTB15125; CHX 3311; U 19920A; Ara-C; Ara-Cytidine; Beta-Ara C; Beta-Arabinosylcytosine; Beta-cytosine arabinoside; Citarabina [INN-Spanish]; Cytarabinum [INN-Latin]; Cytosar-U; Cytosine arabinoside (VAN); Depocyt (TN); Depocyt (liposomal); Intrathecal (injected into the spinal fluid) DepoCyt; U-19920; Beta-D-Arabinosylcytosine; Cytosar-U (TN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine-beta-arabinoside; Intrathecal cytarabine (also known as ara-C); U-19,920; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytosine 1-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine-1-beta-D-arabinofuranoside; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; (beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
DMZD5QR CP Upjohn Corporation
DMZD5QR TC Anticancer Agents
DMZD5QR DT Small molecular drug
DMZD5QR PC 6253
DMZD5QR MW 243.22
DMZD5QR FM C9H13N3O5
DMZD5QR IC InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
DMZD5QR CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMZD5QR IK UHDGCWIWMRVCDJ-CCXZUQQUSA-N
DMZD5QR IU 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMZD5QR CA CAS 147-94-4
DMZD5QR CB CHEBI:28680
DMZD5QR DE Acute lymphoblastic leukaemia
DMDI6R4 ID DMDI6R4
DMDI6R4 DN Dabigatran
DMDI6R4 HS Approved
DMDI6R4 SN Pradaxa (TN)
DMDI6R4 CP Boehringer Ingelheim
DMDI6R4 DT Small molecular drug
DMDI6R4 PC 216210
DMDI6R4 MW 471.5
DMDI6R4 FM C25H25N7O3
DMDI6R4 IC InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
DMDI6R4 CS CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
DMDI6R4 IK YBSJFWOBGCMAKL-UHFFFAOYSA-N
DMDI6R4 IU 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
DMDI6R4 CA CAS 211914-51-1
DMDI6R4 CB CHEBI:70752
DMDI6R4 DE Stroke
DMX6OE3 ID DMX6OE3
DMX6OE3 DN Dabrafenib
DMX6OE3 HS Approved
DMX6OE3 SN 1195765-45-7; Dabrafenib (GSK2118436); Tafinlar; GSK2118436A; UNII-QGP4HA4G1B; GSK 2118436; QGP4HA4G1B; N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide; CHEBI:75045; N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide; N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; GSK-2118436A; Dabrafenib [USAN:INN]; GSK2118436
DMX6OE3 DT Small molecular drug
DMX6OE3 PC 44462760
DMX6OE3 MW 519.6
DMX6OE3 FM C23H20F3N5O2S2
DMX6OE3 IC InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
DMX6OE3 CS CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
DMX6OE3 IK BFSMGDJOXZAERB-UHFFFAOYSA-N
DMX6OE3 IU N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
DMX6OE3 CA CAS 1195765-45-7
DMX6OE3 CB CHEBI:75045
DMX6OE3 DE Melanoma
DMNPZL4 ID DMNPZL4
DMNPZL4 DN Dacarbazine
DMNPZL4 HS Approved
DMNPZL4 SN Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
DMNPZL4 CP Bayer Pharmaceuticals Corporation
DMNPZL4 TC Anticancer Agents
DMNPZL4 DT Small molecular drug
DMNPZL4 PC 135398738
DMNPZL4 MW 182.18
DMNPZL4 FM C6H10N6O
DMNPZL4 IC InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
DMNPZL4 CS CN(C)/N=N/C1=C(NC=N1)C(=O)N
DMNPZL4 IK FDKXTQMXEQVLRF-ZHACJKMWSA-N
DMNPZL4 IU 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
DMNPZL4 CA CAS 4342-03-4
DMNPZL4 CB CHEBI:94587
DMNPZL4 DE Melanoma
DMSFK9V ID DMSFK9V
DMSFK9V DN Daclatasvir
DMSFK9V HS Approved
DMSFK9V SN 1009119-64-5; Daclatasvir (BMS-790052); 1214735-16-6; CHEBI:82977; C40H50N8O6; methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate; Daclatasvir (USAN); cc-39; Daclatasvir BMS 790052; MLS006011140; SCHEMBL2756027; CHEMBL2023898; SCHEMBL17897804; KS-00000XPC; EX-A410
DMSFK9V CP Bristol-Myers Squibb
DMSFK9V DT Small molecular drug
DMSFK9V PC 25154714
DMSFK9V MW 738.9
DMSFK9V FM C40H50N8O6
DMSFK9V IC InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
DMSFK9V CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSFK9V IK FKRSSPOQAMALKA-CUPIEXAXSA-N
DMSFK9V IU methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSFK9V CA CAS 1009119-64-5
DMSFK9V CB CHEBI:82977
DMSFK9V DE Hepatitis C virus infection
DM6OZQV ID DM6OZQV
DM6OZQV DN Daclizumab
DM6OZQV HS Approved
DM6OZQV SN DAC HYP; Daclizumab HYP; Daclizumab High Yield Process; Daclizumab (subcutaneous, multiple sclerosis); Daclizumab (subcutaneous, multiple sclerosis), Abbott/Biogen Idec
DM6OZQV CP Biogen
DM6OZQV DT Monoclonal antibody
DM6OZQV SQ Humanized Anti-CD25 Heavy Chain 1: QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Humanized Anti-CD25 Light Chain 1DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM6OZQV DE Multiple sclerosis
DMOH8VY ID DMOH8VY
DMOH8VY DN Dacomitinib
DMOH8VY HS Approved
DMOH8VY SN PF-00299804
DMOH8VY CP Pfizer
DMOH8VY DT Small molecular drug
DMOH8VY PC 11511120
DMOH8VY MW 469.9
DMOH8VY FM C24H25ClFN5O2
DMOH8VY IC InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
DMOH8VY CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
DMOH8VY IK LVXJQMNHJWSHET-AATRIKPKSA-N
DMOH8VY IU (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
DMOH8VY CA CAS 1110813-31-4
DMOH8VY CB CHEBI:91466
DMOH8VY DE Non-small-cell lung cancer
DM2YGNW ID DM2YGNW
DM2YGNW DN Dactinomycin
DM2YGNW HS Approved
DM2YGNW SN Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
DM2YGNW TC Anticancer Agents
DM2YGNW DT Small molecular drug
DM2YGNW PC 457193
DM2YGNW MW 1255.4
DM2YGNW FM C62H86N12O16
DM2YGNW IC InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
DM2YGNW CS C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
DM2YGNW IK RJURFGZVJUQBHK-IIXSONLDSA-N
DM2YGNW IU 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
DM2YGNW CA CAS 50-76-0
DM2YGNW CB CHEBI:27666
DM2YGNW DE Solid tumour/cancer
DMGMNH3 ID DMGMNH3
DMGMNH3 DN Dalbavancin
DMGMNH3 HS Approved
DMGMNH3 SN Zeven; Zeven (TN); Dalbavancin (USAN/INN); Dalvance; Xydalba
DMGMNH3 CP Pfizer
DMGMNH3 DT Small molecular drug
DMGMNH3 PC 16134627
DMGMNH3 MW 1816.7
DMGMNH3 FM C88H100Cl2N10O28
DMGMNH3 IC InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1
DMGMNH3 CS CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
DMGMNH3 IK KGPGQDLTDHGEGT-SZUNQUCBSA-N
DMGMNH3 IU (2S,3S,4R,5R,6S)-6-[[(1S,2R,19R,22R,34S,37R,40R,52S)-5,32-dichloro-52-[3-(dimethylamino)propylcarbamoyl]-2,26,31,44,49-pentahydroxy-22-(methylamino)-21,35,38,54,56,59-hexaoxo-47-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14(63),15,17(62),23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,65-henicosaen-64-yl]oxy]-3,4-dihydroxy-5-(10-methylundecanoylamino)oxane-2-carboxylic acid
DMGMNH3 CA CAS 171500-79-1
DMGMNH3 CB CHEBI:82721
DMGMNH3 DE Bacterial infection
DMM0PDO ID DMM0PDO
DMM0PDO DN Dalfampridine
DMM0PDO HS Approved
DMM0PDO SN Ampyra (TN)
DMM0PDO CP Acorda Therapeutics
DMM0PDO DT Small molecular drug
DMM0PDO PC 1727
DMM0PDO MW 94.11
DMM0PDO FM C5H6N2
DMM0PDO IC InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)
DMM0PDO CS C1=CN=CC=C1N
DMM0PDO IK NUKYPUAOHBNCPY-UHFFFAOYSA-N
DMM0PDO IU pyridin-4-amine
DMM0PDO CA CAS 504-24-5
DMM0PDO CB CHEBI:34385
DMM0PDO DE Multiple sclerosis
DM4LTKV ID DM4LTKV
DM4LTKV DN Dalfopristin
DM4LTKV HS Approved
DM4LTKV SN 5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE
DM4LTKV TC Antibiotics
DM4LTKV DT Small molecular drug
DM4LTKV PC 6323289
DM4LTKV MW 690.8
DM4LTKV FM C34H50N4O9S
DM4LTKV IC InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
DM4LTKV CS CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
DM4LTKV IK SUYRLXYYZQTJHF-VMBLUXKRSA-N
DM4LTKV IU (6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
DM4LTKV CA CAS 112362-50-2
DM4LTKV CB CHEBI:4309
DM4LTKV DE Bacterial infection
DM6CLBN ID DM6CLBN
DM6CLBN DN Danaparoid
DM6CLBN HS Approved
DM6CLBN SN Orgaran (TN)
DM6CLBN CP Schering-Plough
DM6CLBN TC Anticoagulants
DM6CLBN DE Deep venous clot
DML8KTN ID DML8KTN
DML8KTN DN Danazol
DML8KTN HS Approved
DML8KTN SN Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
DML8KTN TC Fertility Agents
DML8KTN DT Small molecular drug
DML8KTN PC 28417
DML8KTN MW 337.5
DML8KTN FM C22H27NO2
DML8KTN IC InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
DML8KTN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
DML8KTN IK POZRVZJJTULAOH-LHZXLZLDSA-N
DML8KTN IU (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
DML8KTN CA CAS 17230-88-5
DML8KTN CB CHEBI:4315
DML8KTN DE Menorrhagia; Breast cancer
DM1D8XY ID DM1D8XY
DM1D8XY DN Dantrolene
DM1D8XY HS Approved
DM1D8XY SN Dantrium; Dantroleno; Dantrolenum; DANTROLENE SODIUM; Dantrium Intravenous; Dantrium (TN); Dantrolen (TN); Dantroleno [INN-Spanish]; Dantrolenum [INN-Latin]; F-368; Dantrolene (USAN/INN); Dantrolene [USAN:BAN:INN]; 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin; 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione; 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY CP Procter & Gamble
DM1D8XY TC Muscle Relaxants
DM1D8XY DT Small molecular drug
DM1D8XY PC 6914273
DM1D8XY MW 314.25
DM1D8XY FM C14H10N4O5
DM1D8XY IC InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
DM1D8XY CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]
DM1D8XY IK OZOMQRBLCMDCEG-VIZOYTHASA-N
DM1D8XY IU 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
DM1D8XY CA CAS 7261-97-4
DM1D8XY DE Hyperthermia
DM28UJG ID DM28UJG
DM28UJG DN Dapagliflozin
DM28UJG HS Approved
DM28UJG SN BMS 512148; BMS-512148; BMS-512148, Dapagliflozin; Dapagliflozin (INN/USAN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
DM28UJG CP AstraZeneca
DM28UJG DT Small molecular drug
DM28UJG PC 9887712
DM28UJG MW 408.9
DM28UJG FM C21H25ClO6
DM28UJG IC InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
DM28UJG CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
DM28UJG IK JVHXJTBJCFBINQ-ADAARDCZSA-N
DM28UJG IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM28UJG CA CAS 461432-26-8
DM28UJG CB CHEBI:85078
DM28UJG DE Type-2 diabetes
DM34TXO ID DM34TXO
DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO HS Approved
DM34TXO SN Saxagliptin Hydrochloride; Qtern
DM34TXO CP Astrazeneca
DM34TXO DT Small molecular drug
DM34TXO DE Type-2 diabetes
DMOXJKF ID DMOXJKF
DMOXJKF DN Dapiprazole
DMOXJKF HS Approved
DMOXJKF SN Dapiprazol; Dapiprazolum; Dapirazol; Dapirazolum; Glamidolo; Remydrial; Reversil; Dapiprazol [German]; Dapiprazole [INN]; Dapiprazole (INN); Dapirazol [INN-Spanish]; Dapirazolum [INN-Latin]; Rev-Eyes; Rev-Eyes (TN); S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride; 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride; 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine; 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine; 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
DMOXJKF CP Abbott Laboratories
DMOXJKF TC Ophthalmologicals
DMOXJKF DT Small molecular drug
DMOXJKF PC 3033538
DMOXJKF MW 325.5
DMOXJKF FM C19H27N5
DMOXJKF IC InChI=1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3
DMOXJKF CS CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
DMOXJKF IK RFWZESUMWJKKRN-UHFFFAOYSA-N
DMOXJKF IU 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
DMOXJKF CA CAS 72822-12-9
DMOXJKF CB CHEBI:51066
DMOXJKF DE Glaucoma/ocular hypertension
DM4LT8A ID DM4LT8A
DM4LT8A DN Dapsone
DM4LT8A HS Approved
DM4LT8A SN Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline
DM4LT8A TC Antiinflammatory Agents
DM4LT8A DT Small molecular drug
DM4LT8A PC 2955
DM4LT8A MW 248.3
DM4LT8A FM C12H12N2O2S
DM4LT8A IC InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
DM4LT8A CS C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
DM4LT8A IK MQJKPEGWNLWLTK-UHFFFAOYSA-N
DM4LT8A IU 4-(4-aminophenyl)sulfonylaniline
DM4LT8A CA CAS 80-08-0
DM4LT8A CB CHEBI:4325
DM4LT8A DE Pneumocystis pneumonia
DMFDQ3I ID DMFDQ3I
DMFDQ3I DN Daptomycin
DMFDQ3I HS Approved
DMFDQ3I SN Dapcin; Daptomicina; Daptomycine; Daptomycinum; LY 146032; LY-146032; LY146032; (2S)-daptomycin; 103060-53-3; C72H101N17O26; Cidecin; Cubicin; DAPTOMYCIN; CHEBI:600103; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; SCHEMBL28102
DMFDQ3I PC 16134395
DMFDQ3I MW 1620.7
DMFDQ3I FM C72H101N17O26
DMFDQ3I IC DOAKLVKFURWEDJ-RWDRXURGSA-N
DMFDQ3I CS CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMFDQ3I IK 1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMFDQ3I IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMFDQ3I CA CAS 103060-53-3
DMFDQ3I CB CHEBI:600103
DMFDQ3I DE Methicillin-resistant staphylococcus infection
DMKDU16 ID DMKDU16
DMKDU16 DN Daptomycin
DMKDU16 HS Approved
DMKDU16 SN Cidecin; Cubicin; Dapcin; Daptomicina; Daptomycine; Daptomycinum; Deptomycin; Daptomicina [Spanish]; Daptomycine [French]; Daptomycinum [Latin]; LY146032; Cubicin (TN); LY-146032; MK-3009; Daptomycin [USAN:INN:BAN]; Daptomycin (JAN/USAN/INN); N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon1-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine epsilon(1)-lactone; N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine 1.13-3.4-lactone; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox
DMKDU16 CP Cubist Pharmaceuticals
DMKDU16 TC Antibiotics
DMKDU16 DT Small molecular drug
DMKDU16 PC 16134395
DMKDU16 MW 1620.7
DMKDU16 FM C72H101N17O26
DMKDU16 IC InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1
DMKDU16 CS CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
DMKDU16 IK DOAKLVKFURWEDJ-RWDRXURGSA-N
DMKDU16 IU (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid
DMKDU16 CA CAS 103060-53-3
DMKDU16 CB CHEBI:600103
DMKDU16 DE Bacterial infection
DMKCIUZ ID DMKCIUZ
DMKCIUZ DN Daratumumab
DMKCIUZ HS Approved
DMKCIUZ CP Genmab Princeton, NJ
DMKCIUZ DT Antibody
DMKCIUZ DE Multiple myeloma
DMMJTYW ID DMMJTYW
DMMJTYW DN Darbepoetin alfa
DMMJTYW HS Approved
DMMJTYW SN Aranesp (TN)
DMMJTYW CP Amgen Inc
DMMJTYW TC Antianemic Agents
DMMJTYW SQ DB00012 sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
DMMJTYW DE Anemia
DMWXLYZ ID DMWXLYZ
DMWXLYZ DN Darifenacin
DMWXLYZ HS Approved
DMWXLYZ SN Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)
DMWXLYZ CP Norvatis Phamaceuticals Corporation
DMWXLYZ TC Urinary antispasmodics
DMWXLYZ DT Small molecular drug
DMWXLYZ PC 444031
DMWXLYZ MW 426.5
DMWXLYZ FM C28H30N2O2
DMWXLYZ IC InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
DMWXLYZ CS C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
DMWXLYZ IK HXGBXQDTNZMWGS-RUZDIDTESA-N
DMWXLYZ IU 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
DMWXLYZ CA CAS 133099-04-4
DMWXLYZ CB CHEBI:391960
DMWXLYZ DE Overactive bladder
DMV7YFT ID DMV7YFT
DMV7YFT DN Darolutamide
DMV7YFT HS Approved
DMV7YFT SN 1297538-32-9; BAY-1841788; N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide; Darolutamide [USAN]; Darolutamide (JAN/USAN/INN); SCHEMBL1814935; SCHEMBL13733117; KS-00000TSX; EX-A759; BLIJXOOIHRSQRB-PXYINDEMSA-N; MolPort-046-033-692; MolPort-044-560-277; AKOS030526387; CS-5174; BAY1841788; DB12941; BAY 1841788; HY-16985; S7559; FT-0700158; J3.501.129C; D11045; J-690121; 1H-Pyrazole-3-carboxamide, N-((1S)-2-(3-(3-chloro-4-cyanophen
DMV7YFT CP Bayer Pharmaceuticals Whippany, NJ
DMV7YFT PC 67171867
DMV7YFT MW 398.8
DMV7YFT FM C19H19ClN6O2
DMV7YFT IC InChI=1S/C19H19ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11-12,27H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-,12?/m0/s1
DMV7YFT CS C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O
DMV7YFT IK BLIJXOOIHRSQRB-PXYINDEMSA-N
DMV7YFT IU N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
DMV7YFT CA CAS 1297538-32-9
DMV7YFT DE Prostate cancer
DMN3GCH ID DMN3GCH
DMN3GCH DN Darunavir
DMN3GCH HS Approved
DMN3GCH SN 206361-99-1; TMC114; Prezista; TMC-114; UIC-94017; Darunavirum; TMC 114; Darunavirum [INN-Latin]; UNII-YO603Y8113; AIDS073035; CHEMBL1323; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE; CHEBI:367163; Darunavir-d9; YO603Y8113; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate; NCGC00168773-01; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl; Darunavirum; Darunavir [USAN]; UIC 94017; Prezista(TM); UIC-96017; Darunavir (USAN/INN); Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester; {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester; N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide; [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester; (3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate; (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate; (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
DMN3GCH CP Tibotec
DMN3GCH TC Antiviral Agents
DMN3GCH DT Small molecular drug
DMN3GCH PC 213039
DMN3GCH MW 547.7
DMN3GCH FM C27H37N3O7S
DMN3GCH IC InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
DMN3GCH CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N
DMN3GCH IK CJBJHOAVZSMMDJ-HEXNFIEUSA-N
DMN3GCH IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMN3GCH CA CAS 206361-99-1
DMN3GCH CB CHEBI:367163
DMN3GCH DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMJV2EK ID DMJV2EK
DMJV2EK DN Dasatinib
DMJV2EK HS Approved
DMJV2EK SN Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
DMJV2EK CP Bristol Myers Squibb
DMJV2EK TC Anticancer Agents
DMJV2EK DT Small molecular drug
DMJV2EK PC 3062316
DMJV2EK MW 488
DMJV2EK FM C22H26ClN7O2S
DMJV2EK IC InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
DMJV2EK CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
DMJV2EK IK ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DMJV2EK IU N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMJV2EK CA CAS 302962-49-8
DMJV2EK CB CHEBI:49375
DMJV2EK DE Chronic myelogenous leukaemia; Multiple myeloma
DM74SVE ID DM74SVE
DM74SVE DN Dasiglucagon
DM74SVE HS Approved
DM74SVE SN UNII-AD4J2O47FQ; AD4J2O47FQ; Dasiglucagon [INN]; Dasiglucagon [USAN]; Dasiglucagon [WHO-DD]; Dasiglucagon [USAN:INN]; ZP-GA-1; ZP4207; ZP-4207; 1544300-84-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr; L-Threonine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-2-methylalanyl-L-alanyl-L-arginyl-L-alanyl-L-alpha-glutamyl-L-alpha
DM74SVE CP Zealand Pharma
DM74SVE DT Peptide
DM74SVE PC 126961379
DM74SVE MW 3381.6
DM74SVE FM C152H222N38O50
DM74SVE IC InChI=1S/C152H222N38O50/c1-73(2)55-99(133(222)171-98(47-51-116(206)207)132(221)183-111(71-194)144(233)189-122(80(11)197)149(238)239)174-137(226)105(61-85-65-161-91-32-21-20-31-89(85)91)178-129(218)93(34-23-25-53-154)172-146(235)119(75(5)6)187-139(228)103(57-81-27-16-14-17-28-81)176-131(220)97(46-50-115(204)205)170-130(219)96(45-49-114(202)203)167-123(212)76(7)164-127(216)94(35-26-54-160-151(157)158)166-124(213)77(8)165-150(240)152(12,13)190-145(234)107(64-118(210)211)180-134(223)100(56-74(3)4)173-135(224)101(59-83-36-40-87(198)41-37-83)175-128(217)92(33-22-24-52-153)168-142(231)109(69-192)184-136(225)102(60-84-38-42-88(199)43-39-84)177-138(227)106(63-117(208)209)179-143(232)110(70-193)185-148(237)121(79(10)196)188-140(229)104(58-82-29-18-15-19-30-82)181-147(236)120(78(9)195)186-113(201)67-162-126(215)95(44-48-112(156)200)169-141(230)108(68-191)182-125(214)90(155)62-86-66-159-72-163-86/h14-21,27-32,36-43,65-66,72-80,90,92-111,119-122,161,191-199H,22-26,33-35,44-64,67-71,153-155H2,1-13H3,(H2,156,200)(H,159,163)(H,162,215)(H,164,216)(H,165,240)(H,166,213)(H,167,212)(H,168,231)(H,169,230)(H,170,219)(H,171,222)(H,172,235)(H,173,224)(H,174,226)(H,175,217)(H,176,220)(H,177,227)(H,178,218)(H,179,232)(H,180,223)(H,181,236)(H,182,214)(H,183,221)(H,184,225)(H,185,237)(H,186,201)(H,187,228)(H,188,229)(H,189,233)(H,190,234)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,238,239)(H4,157,158,160)/t76-,77-,78+,79+,80+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,119-,120-,121-,122-/m0/s1
DM74SVE CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DM74SVE IK RZRMFQMNPDPAIX-AJTOSFMRSA-N
DM74SVE IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-2-methylpropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM74SVE CA CAS 1544300-84-6
DM74SVE DE Hypoglycemia; Hyperinsulinemia
DMLDQFV ID DMLDQFV
DMLDQFV DN Dasotraline
DMLDQFV HS Approved
DMLDQFV SN SEP-225289; SEP-289; Triple reuptake inhibitors (depression), Sepracor
DMLDQFV CP Sunovion pharmaceuticals
DMLDQFV DT Small molecular drug
DMLDQFV PC 9947999
DMLDQFV MW 292.2
DMLDQFV FM C16H15Cl2N
DMLDQFV IC InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
DMLDQFV CS C1C[C@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
DMLDQFV IK SRPXSILJHWNFMK-MEDUHNTESA-N
DMLDQFV IU (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
DMLDQFV CA CAS 675126-05-3
DMLDQFV DE Mood disorder; Attention deficit hyperactivity disorder; Eating disorder
DMQUSBT ID DMQUSBT
DMQUSBT DN Daunorubicin
DMQUSBT HS Approved
DMQUSBT SN daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
DMQUSBT TC Anticancer Agents
DMQUSBT DT Small molecular drug
DMQUSBT PC 30323
DMQUSBT MW 527.5
DMQUSBT FM C27H29NO10
DMQUSBT IC InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
DMQUSBT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
DMQUSBT IK STQGQHZAVUOBTE-VGBVRHCVSA-N
DMQUSBT IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMQUSBT CA CAS 20830-81-3
DMQUSBT CB CHEBI:41977
DMQUSBT DE Acute myeloid leukaemia; Solid tumour/cancer; Kaposi sarcoma
DMC50ME ID DMC50ME
DMC50ME DN Debrisoquin
DMC50ME HS Approved
DMC50ME SN Debrisochinum; Debrisoquina; Debrisoquine; Debrisoquinum; Declinax; Equitonil; Isocaramidine; Tendor; DEBRISOQUIN SULFATE; Debrisoquin hemisulfate; Debrisoquine sulfate; Isocaramidine sulfate; Debrisoquina [INN-Spanish]; Debrisoquine [INN:BAN]; Debrisoquinum [INN-Latin]; Ro 5-3307/1; Sulfuric acid compound with 3,4-dihydro-2(1H)-isoquinolinecarboximidamide (1:1); 1,2,3, 4-Tetrahydro-isoquinoline-2-carboxamidine sulfate; 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-(7CI,8CI); 2(1H)-Isoquinolinecarboxamidine, 3,4-dihydro-, sulfate (2:1); 2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-, sulfate (2:1); 2-Amidino-1,2,3,4-tetrahydroisoquinoline; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine; 3,4-Dihydro-2(1H)-isoquinolinecarboxamidine sulfate (2:1); 3,4-Dihydro-2(1H)-isoquinolinecarboximidamide; 3,4-Dihydro-2(1H;)-isoquinoline carboxamidine sulfate; 3,4-dihydro-1H-isoquinoline-2-carboximidamide; 3,4-dihydroisoquinoline-2(1H)-carboximidamide
DMC50ME TC Antihypertensive Agents
DMC50ME DT Small molecular drug
DMC50ME PC 2966
DMC50ME MW 175.23
DMC50ME FM C10H13N3
DMC50ME IC InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
DMC50ME CS C1CN(CC2=CC=CC=C21)C(=N)N
DMC50ME IK JWPGJSVJDAJRLW-UHFFFAOYSA-N
DMC50ME IU 3,4-dihydro-1H-isoquinoline-2-carboximidamide
DMC50ME CA CAS 1131-64-2
DMC50ME CB CHEBI:34665
DMC50ME DE Hypertension
DMSBRUW ID DMSBRUW
DMSBRUW DN Decamethonium
DMSBRUW HS Approved
DMSBRUW SN Decamethonum; Syncurine; DECAMETHONIUM ION; AIDS351484; AIDS-351484; Decamethylenebis(trimethylammonium)bromide; Syncurine (TN); Syncurine (*dibromide salt*); Trimethyl-[10-(trimethylazaniumyl)decyl]azanium; C 10 (VAN) (*dibromide salt*); N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium; (DM)Br2; 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-(9CI); 1,10-Decanediaminium, N,N,N,N',N',N'-hexamethyl-, dibromide
DMSBRUW TC Neuromuscular Depolarizing Agents
DMSBRUW DT Small molecular drug
DMSBRUW PC 2968
DMSBRUW MW 258.49
DMSBRUW FM C16H38N2+2
DMSBRUW IC InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2
DMSBRUW CS C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C
DMSBRUW IK MTCUAOILFDZKCO-UHFFFAOYSA-N
DMSBRUW IU trimethyl-[10-(trimethylazaniumyl)decyl]azanium
DMSBRUW CA CAS 156-74-1
DMSBRUW CB CHEBI:41934
DMSBRUW DE Muscle spasm
DMQL8XJ ID DMQL8XJ
DMQL8XJ DN Decitabine
DMQL8XJ HS Approved
DMQL8XJ SN AzadC; Dacogen; Dezocitidine; NCGC_5ADOC; Dacogen (TN); E-7373; Decitabine (USAN/INN); Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 5-AZAdC; 5-Aza-2′-Deoxycytidine; 5-Aza-2'-deoxycytidine; 5-Azadeoxycytidine; 5-Deoxy-2′-azacytidine; 5-aza-2-deoxycytidine; 5-aza-CdR; 5-aza-dC; 5A2dc
DMQL8XJ TC Anticancer Agents
DMQL8XJ DT Small molecular drug
DMQL8XJ PC 451668
DMQL8XJ MW 228.21
DMQL8XJ FM C8H12N4O4
DMQL8XJ IC InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
DMQL8XJ CS C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O
DMQL8XJ IK XAUDJQYHKZQPEU-KVQBGUIXSA-N
DMQL8XJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
DMQL8XJ CA CAS 2353-33-5
DMQL8XJ CB CHEBI:50131
DMQL8XJ DE Myelodysplastic syndrome
DM6ETS0 ID DM6ETS0
DM6ETS0 DN Deferasirox
DM6ETS0 HS Approved
DM6ETS0 SN Deferasirox; Deferasirox (Exjade); Deferasiroxum; Deferasiroxum [INN-Latin]; Exjade; V8G4MOF2V9; 201530-41-8; 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid; 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid; 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-; C21H15N3O4; CGP-72670; CHEBI:49005; DSSTox_CID_28522; DSSTox_RID_82794; ICL 670; ICL 670A; ICL-670; ICL-670A; ICL670; ICL670A; NCGC00181754-01; UNII-V8G4MOF2V9
DM6ETS0 PC 214348
DM6ETS0 MW 373.4
DM6ETS0 FM C21H15N3O4
DM6ETS0 IC BOFQWVMAQOTZIW-UHFFFAOYSA-N
DM6ETS0 CS C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 IK C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DM6ETS0 CA C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O
DM6ETS0 CB CHEBI:49005
DM6ETS0 DE Hyperphosphatemia
DMS2M7O ID DMS2M7O
DMS2M7O DN Deferiprone
DMS2M7O HS Approved
DMS2M7O SN Ferriprox (TN)
DMS2M7O CP ApoPharma
DMS2M7O DT Small molecular drug
DMS2M7O PC 2972
DMS2M7O MW 139.15
DMS2M7O FM C7H9NO2
DMS2M7O IC InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
DMS2M7O CS CC1=C(C(=O)C=CN1C)O
DMS2M7O IK TZXKOCQBRNJULO-UHFFFAOYSA-N
DMS2M7O IU 3-hydroxy-1,2-dimethylpyridin-4-one
DMS2M7O CA CAS 30652-11-0
DMS2M7O CB CHEBI:68554
DMS2M7O DE Thalassemia
DMTUKZH ID DMTUKZH
DMTUKZH DN Deferoxamine mesylate
DMTUKZH HS Approved
DMTUKZH SN Desferal
DMTUKZH CP Novartis Pharmaceuticals Corp
DMTUKZH DT Small molecular drug
DMTUKZH PC 62881
DMTUKZH MW 656.8
DMTUKZH FM C26H52N6O11S
DMTUKZH IC InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
DMTUKZH CS CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
DMTUKZH IK IDDIJAWJANBQLJ-UHFFFAOYSA-N
DMTUKZH IU N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid
DMTUKZH CA CAS 138-14-7
DMTUKZH CB CHEBI:31460
DMTUKZH DE Acute iron or aluminum toxicity
DMV0RNS ID DMV0RNS
DMV0RNS DN Deflazacort
DMV0RNS HS Approved
DMV0RNS SN C25H33NO6; Deflazacort (Calcort); Deflazacortum [INN-Latin]; EINECS 238-483-7; Deflan (TN); D09WYX; AC1L1BQ2; Deflazacort [USAN:BAN:INN]; CTK8F9001; MolPort-035-394-927
DMV0RNS CP PTC Therapeutics
DMV0RNS DT Small molecular drug
DMV0RNS PC 189821
DMV0RNS MW 441.5
DMV0RNS FM C25H31NO6
DMV0RNS IC InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
DMV0RNS CS CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C
DMV0RNS IK FBHSPRKOSMHSIF-GRMWVWQJSA-N
DMV0RNS IU [2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-6,14,17-trien-8-yl]-2-oxoethyl] acetate
DMV0RNS CA CAS 14484-47-0
DMV0RNS CB CHEBI:135720
DMV0RNS DE Duchenne dystrophy
DM3O8QY ID DM3O8QY
DM3O8QY DN Degarelix
DM3O8QY HS Approved
DM3O8QY SN Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
DM3O8QY DT Small molecular drug
DM3O8QY PC 16136245
DM3O8QY MW 1632.3
DM3O8QY FM C82H103ClN18O16
DM3O8QY IC InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
DM3O8QY CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DM3O8QY IK MEUCPCLKGZSHTA-XYAYPHGZSA-N
DM3O8QY IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DM3O8QY CA CAS 214766-78-6
DM3O8QY CB CHEBI:135961
DM3O8QY DE Prostate cancer
DM4Q80H ID DM4Q80H
DM4Q80H DN Dehydroepiandrosterone sulfate
DM4Q80H HS Approved
DM4Q80H SN Prasterone sulfate; DHEA sulfate; DEHYDROEPIANDROSTERONE SULFATE; Dehydroisoandrosterone sulfate; DHEAS; Dehydroepiandrosterone sulphate; Dehydroepiandrosterone monosulfate; 3-O-Sulfodehydroepiandrosterone; Dehydroepiandrosterone 3-sulfate; Dehydroandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; 17-Ketoandrost-5-en-3beta-yl sulfate; DHEA-S; Androst-5-en-17-on-3beta-yl sulfuric acid; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; CCRIS 6746; (3-beta)-3-(Sulfooxy)androst-5-en-17-one; DHEA sulphate
DM4Q80H PC 12594
DM4Q80H MW 368.5
DM4Q80H FM C19H28O5S
DM4Q80H IC InChI=1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DM4Q80H CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DM4Q80H IK CZWCKYRVOZZJNM-USOAJAOKSA-N
DM4Q80H IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DM4Q80H CA CAS 651-48-9
DM4Q80H CB CHEBI:16814
DM4Q80H DE Dyspareunia
DMVTU5Q ID DMVTU5Q
DMVTU5Q DN Delafloxacin Meglumine
DMVTU5Q HS Approved
DMVTU5Q SN Baxdela
DMVTU5Q CP Melinta Therapeutics
DMVTU5Q DT Small molecular drug
DMVTU5Q PC 11578213
DMVTU5Q MW 636
DMVTU5Q FM C25H29ClF3N5O9
DMVTU5Q IC InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
DMVTU5Q CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMVTU5Q IK AHJGUEMIZPMAMR-WZTVWXICSA-N
DMVTU5Q IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DMVTU5Q CA CAS 352458-37-8
DMVTU5Q DE Acute bacterial skin infection; Skin infection
DMXE76K ID DMXE76K
DMXE76K DN Delamanid
DMXE76K HS Approved
DMXE76K SN OPC-67683; Nitro-dihydroimidazo-oxazole derivatives (tuberculosis), Otsuka; 2-nitroimidazole derivatives (tuberculosis), Otsuka
DMXE76K CP Otsuka pharmaceutical
DMXE76K DT Small molecular drug
DMXE76K PC 6480466
DMXE76K MW 534.5
DMXE76K FM C25H25F3N4O6
DMXE76K IC InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
DMXE76K CS C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
DMXE76K IK XDAOLTSRNUSPPH-XMMPIXPASA-N
DMXE76K IU (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole
DMXE76K CA CAS 681492-22-8
DMXE76K CB CHEBI:134742
DMXE76K DE Mycobacterium infection; Multi-drug resistant tuberculosis
DM7EUK3 ID DM7EUK3
DM7EUK3 DN Delapril
DM7EUK3 HS Approved
DM7EUK3 SN Adecut (TN)
DM7EUK3 CP Takeda
DM7EUK3 DT Small molecular drug
DM7EUK3 PC 5362116
DM7EUK3 MW 452.5
DM7EUK3 FM C26H32N2O5
DM7EUK3 IC InChI=1S/C26H32N2O5/c1-3-33-26(32)23(14-13-19-9-5-4-6-10-19)27-18(2)25(31)28(17-24(29)30)22-15-20-11-7-8-12-21(20)16-22/h4-12,18,22-23,27H,3,13-17H2,1-2H3,(H,29,30)/t18-,23-/m0/s1
DM7EUK3 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2
DM7EUK3 IK WOUOLAUOZXOLJQ-MBSDFSHPSA-N
DM7EUK3 IU 2-[2,3-dihydro-1H-inden-2-yl-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]amino]acetic acid
DM7EUK3 CA CAS 83435-66-9
DM7EUK3 CB CHEBI:135735
DM7EUK3 DE Cardiovascular disease
DM3NF5G ID DM3NF5G
DM3NF5G DN Delavirdine
DM3NF5G HS Approved
DM3NF5G SN DLV; Rescriptor; SPP; DELAVIRDINE MESYLATE; Delavirdine [INN]; U 90152; BHAP-U 90152; Delavirdine (INN); Rescriptor (TM);Rescriptor (TN); U-90152; U-90152S; PNU-90152-T; Delavirdine (*Mesylate salt*); U90152S (*Mesylate salt*); Delavirdine(U-90152) & .a.IFN; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide; N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide; N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide; N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide; N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon; (1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE; (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide); 1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine; 1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz; 2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
DM3NF5G CP Pfizer Pharmaceuticals
DM3NF5G TC Anti-HIV Agents
DM3NF5G DT Small molecular drug
DM3NF5G PC 5625
DM3NF5G MW 456.6
DM3NF5G FM C22H28N6O3S
DM3NF5G IC InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
DM3NF5G CS CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
DM3NF5G IK WHBIGIKBNXZKFE-UHFFFAOYSA-N
DM3NF5G IU N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
DM3NF5G CA CAS 136817-59-9
DM3NF5G CB CHEBI:119573
DM3NF5G DE Human immunodeficiency virus infection
DMAYEU1 ID DMAYEU1
DMAYEU1 DN Demecarium bromide
DMAYEU1 HS Approved
DMAYEU1 SN Demecarium; Demecastigmine; Frumtosnil; Humorsol; Tonilen; Tosmicil; Tosmilen; Tosmilene; Visumatic; Visumiotic;Bromure de demecarium; Bromuro de demecario; Demecarii bromidum; Demekarium bromide; Demekastigmine bromide; BC 48; Bromure de demecarium [INN-French]; Bromuro de demecario [INN-Spanish]; Demecarii bromidum [INN-Latin]; Demecarium bromide [INN:BAN]; Humorsol (TN); Decamethylenebis[m-dimethylaminophenyl n-methylcarbamate] dimethobromide; Demecarium bromide (USP/INN); Decamethylenebis(N-methylcarbamic acid m-dimethylaminophenyl ester) bromomethylate; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate) dimethobromide; Decamethylenebis(m-dimethylaminophenyl-N-methylcarbamate)dimethobromide;Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate); Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium dibromide; Ammonium, (m-hydroxyphenyl)trimethyl-, bromide, decamethylenebis(methylcarbamate) (2:1); N,N'-Bis(3-trimethylammoniumphenoxycarbonyl)-N,N'-dimethyldecamethylenediamine dibromide; Benzenaminium,3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(N,N,N-trimethyl-, dibromide; (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (2:1); (m-Hydroxyphenyl)trimethylammonium bromide decamethylenebis(methylcarbamate) (7CI); 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(N,N,N-trimethylanilinium) dibromide
DMAYEU1 TC Parasympathomimetics
DMAYEU1 DT Small molecular drug
DMAYEU1 PC 5965
DMAYEU1 MW 716.6
DMAYEU1 FM C32H52Br2N4O4
DMAYEU1 IC InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2
DMAYEU1 CS CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-]
DMAYEU1 IK YHKBUDZECQDYBR-UHFFFAOYSA-L
DMAYEU1 IU trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium;dibromide
DMAYEU1 CA CAS 56-94-0
DMAYEU1 CB CHEBI:4391
DMAYEU1 DE Open-angle glaucoma
DMZEPFJ ID DMZEPFJ
DMZEPFJ DN Demeclocycline
DMZEPFJ HS Approved
DMZEPFJ SN Bioterciclin; Clortetrin; DMCT; DMCTC; Declomycin; Deganol; Demeclociclina; Demeclocyclinum; Demeclor; Demethylchlorotetracycline; Demethylchlortetracyclin; Demethylchlortetracycline; Demethylchlortetracyclinum; Demetraclin; Diuciclin; Ledermycin; Methylchlorotetracycline; Mexocine; Novotriclina; Perciclina; Sumaclina; Demeclocycline Monohydrochloride; Demethylchlortetracycline base; Ledermycin hydrochloride; RP 10192; DMCT (antibiotic); Declomycin (TN); Declostatin (TN); Demeclociclina [INN-Spanish]; Demeclocycline (USP); Demeclocycline [USAN:BAN]; Demeclocyclinum [INN-Latin]; Demethylchlortetracycline (JAN); Ledermycin (TN); Tri-demethylchlortetracycline; [4S-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (2E)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6R,12aR)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2E,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aS,5aS,6S,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; 6-Demethyl-7-chlorotetracycline; 6-Demethyl-7-chlortetracycline; 6-Demethylchlorotetracycline; 6-Demethylchlortetracycline; 6-Demetil-7-clorotetraciclina; 6-Demetil-7-clorotetraciclina [Italian]; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-4-dimethylamino-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide; 7-Chloro-6-demethyltetracycline
DMZEPFJ CP Patheon Pharmaceuticals Inc
DMZEPFJ TC Antibiotics
DMZEPFJ DT Small molecular drug
DMZEPFJ PC 54680690
DMZEPFJ MW 464.9
DMZEPFJ FM C21H21ClN2O8
DMZEPFJ IC InChI=1S/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-27,30,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1
DMZEPFJ CS CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMZEPFJ IK GUXHBMASAHGULD-SEYHBJAFSA-N
DMZEPFJ IU (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMZEPFJ CA CAS 127-33-3
DMZEPFJ CB CHEBI:4392
DMZEPFJ DE Bronchitis; Acne vulgaris; Lyme disease
DMCZQGK ID DMCZQGK
DMCZQGK DN Demecolcine
DMCZQGK HS Approved
DMCZQGK SN colcemid; 1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one; demecolcine,colcemid, n-deacetyl-n-methylcolchicine, n-methyl-n-desacetylcolchicine; Demicolcine; NSC3096; 1,2,3,10-Tetramethoxy-7-(methylamino)-6,7-dihydrobenzo[a]heptalen-9(5H)-one; NCGC00166035-01; AC1L1EKK; MolMap_000011; SCHEMBL8160; AC1Q698E; CHEMBL433632; CTK8E8505; MolPort-003-846-192; 6,7-Dihydro-1,2,3,10-Tetramethoxy-7-(Methylamino) Benzo (alpha) Heptalen-9(5H)-one; HMS3374M04; HSCI1_000384; BBL027927; STL377913; CD0013
DMCZQGK DT Small molecular drug
DMCZQGK PC 220401
DMCZQGK MW 371.4
DMCZQGK FM C21H25NO5
DMCZQGK IC InChI=1S/C21H25NO5/c1-22-15-8-6-12-10-18(25-3)20(26-4)21(27-5)19(12)13-7-9-17(24-2)16(23)11-14(13)15/h7,9-11,15,22H,6,8H2,1-5H3/t15-/m0/s1
DMCZQGK CS CN[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
DMCZQGK IK NNJPGOLRFBJNIW-HNNXBMFYSA-N
DMCZQGK IU (7S)-1,2,3,10-tetramethoxy-7-(methylamino)-6,7-dihydro-5H-benzo[a]heptalen-9-one
DMCZQGK CA CAS 477-30-5
DMCZQGK CB CHEBI:4393
DMCZQGK DE Solid tumour/cancer
DMMHR1U ID DMMHR1U
DMMHR1U DN Denileukin diftitox
DMMHR1U HS Approved
DMMHR1U CP Louisville
DMMHR1U TC Anticancer Agents
DMMHR1U SQ DB00004 sequence: MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
DMMHR1U DE leukaemia; Non-small-cell lung cancer
DM8C3GN ID DM8C3GN
DM8C3GN DN Denopamine
DM8C3GN HS Approved
DM8C3GN SN Kalgut (TN)
DM8C3GN DT Small molecular drug
DM8C3GN PC 5311064
DM8C3GN MW 317.4
DM8C3GN FM C18H23NO4
DM8C3GN IC InChI=1S/C18H23NO4/c1-22-17-8-3-13(11-18(17)23-2)9-10-19-12-16(21)14-4-6-15(20)7-5-14/h3-8,11,16,19-21H,9-10,12H2,1-2H3/t16-/m0/s1
DM8C3GN CS COC1=C(C=C(C=C1)CCNC[C@@H](C2=CC=C(C=C2)O)O)OC
DM8C3GN IK VHSBBVZJABQOSG-INIZCTEOSA-N
DM8C3GN IU 4-[(1R)-2-[2-(3,4-dimethoxyphenyl)ethylamino]-1-hydroxyethyl]phenol
DM8C3GN CA CAS 71771-90-9
DM8C3GN CB CHEBI:135359
DM8C3GN DE Cardiac disease
DMNI0KO ID DMNI0KO
DMNI0KO DN Denosumab
DMNI0KO HS Approved
DMNI0KO SN Denosumab (USAN); Denosumab (genetical recombination); Prolia (TN); Denosumab (genetical recombination) (JAN)
DMNI0KO CP Amgen
DMNI0KO DT Antibody
DMNI0KO SQ Denosumab OPGL-1 heavy chain sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Denosumab OPGL-1 light chain sequenceEIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNI0KO DE Postmenopausal osteoporosis; Rheumatoid arthritis; Prostate cancer
DM3GYAL ID DM3GYAL
DM3GYAL DN Deoxycholic acid
DM3GYAL HS Approved
DM3GYAL SN (3alpha,5beta,12alpha)-3,12-Dihydroxycholan-24-oic acid; 3,12-Dihydroxycholanic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,12alpha-Dihydroxy-5beta-cholanic acid; 5-beta-Deoxycholic acid; 7-Deoxycholic acid; 7alpha-Deoxycholic acid; ATX-101; Choleic acid; Cholerebic; Cholic acid, deoxy-; Cholorebic; DEOXYCHOLIC ACID; Degalol; Deoxy cholic acid; Deoxycholatic acid; Desoxycholic acid; Desoxycholsaeure; Dihydroxycholanoic acid; Droxolan; Pyrochol; Septochol; Sodium deoxycholate; deoxycholate
DM3GYAL DT Small molecular drug
DM3GYAL PC 222528
DM3GYAL MW 392.58
DM3GYAL FM C24H40O4
DM3GYAL IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM3GYAL CS CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
DM3GYAL IK KXGVEGMKQFWNSR-LLQZFEROSA-N
DM3GYAL IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3GYAL CA CAS 83-44-3
DM3GYAL CB CHEBI:28834
DM3GYAL DE Fat below the chin
DMYE5LJ ID DMYE5LJ
DMYE5LJ DN DEOXYCYTIDINE
DMYE5LJ HS Approved
DMYE5LJ SN Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993
DMYE5LJ DT Small molecular drug
DMYE5LJ PC 13711
DMYE5LJ MW 227.22
DMYE5LJ FM C9H13N3O4
DMYE5LJ IC InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-3-5(14)6(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m0/s1
DMYE5LJ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O
DMYE5LJ IK CKTSBUTUHBMZGZ-SHYZEUOFSA-N
DMYE5LJ IU 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMYE5LJ CA CAS 951-77-9
DMYE5LJ CB CHEBI:15698
DMYE5LJ DE Acute myeloid leukaemia
DMRH7CV ID DMRH7CV
DMRH7CV DN Deserpidine
DMRH7CV HS Approved
DMRH7CV SN Canescin; Canescine; Deresperine; Desepridine; Deserpidin; Deserpidina; Deserpidinum; Desmethoxyreserpine; Halmonyl; Harmonyl; Raunormin; Raunormine; Recanescin; Recanescine; Reserpidine; Tranquinil; Lilly 22641; ORETICYL 50; A-11025; Deserpidina [INN-Spanish]; Deserpidine (INN); Deserpidine [INN:BAN]; Deserpidinum [INN-Latin]; Halmonyl (TN); MD-0232; Deserpidic acid, methyl ester, 3,4,5-trimethoxybenzoate; Methyl 17alpha-methoxy-18beta-(3,4,5-trimethoxybenzoyloxy)-3beta,20alpha-yohimban-16beta-carboxylat; Methyl 17alpha-methoxy-18beta-((3,4,5-trimethoxybenzoyl)oxy)-3beta,20alpha-yohimban-16beta-carboxylate; Methyl 18beta-hydroxy-17alpha-methoxy-3beta,20alpha-yohimban-16beta-carboxylate, 3,4,5-trimethoxybenzoate (ester); Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate; Methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate; Benz[g]indolo[2,3-a]quinolizine-1-carboxylic acid, 1,2,3,4,4a,5,7,8,-13,13b,14,14a-dodecahydro-3-hydroxy-2-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate; (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester; 11-Demethoxyreserpine; 11-Desmethoxyreserpine; 17.alpha.-Methoxy-18.beta.-[(3,4,5-trimethoxybenzoyl)oxy]-3.beta.,20.alpha.-yohimban-16.beta.-carboxylic acid methyl ester; 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester); 3-beta,20-alpha-Yohimban-16-beta-carboxylic acid, 18-beta-hydroxy-17-alpha-methoxy-,methyl ester, 3,4,5-trimethoxybenzoate (ester)
DMRH7CV TC Antihypertensive Agents
DMRH7CV DT Small molecular drug
DMRH7CV PC 8550
DMRH7CV MW 578.7
DMRH7CV FM C32H38N2O8
DMRH7CV IC InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1
DMRH7CV CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DMRH7CV IK CVBMAZKKCSYWQR-WCGOZPBSSA-N
DMRH7CV IU methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMRH7CV CA CAS 131-01-1
DMRH7CV CB CHEBI:27478
DMRH7CV DE Hypertension
DM2TO9R ID DM2TO9R
DM2TO9R DN Desflurane
DM2TO9R HS Approved
DM2TO9R SN Desflurano; Desfluranum; Suprane; I 653; I653; PC6781E; Desflurane [USAN:INN]; Desflurano [INN-Spanish]; Desfluranum [INN-Latin]; I-653; R-e 236ea1; Suprane (TN); Desflurane (JAN/USP/INN); Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane; 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R TC Anesthetics
DM2TO9R DT Small molecular drug
DM2TO9R PC 42113
DM2TO9R MW 168.04
DM2TO9R FM C3H2F6O
DM2TO9R IC InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DM2TO9R CS C(C(F)(F)F)(OC(F)F)F
DM2TO9R IK DPYMFVXJLLWWEU-UHFFFAOYSA-N
DM2TO9R IU 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
DM2TO9R CA CAS 57041-67-5
DM2TO9R CB CHEBI:4445
DM2TO9R DE Anaesthesia
DMT2FDC ID DMT2FDC
DMT2FDC DN Desipramine
DMT2FDC HS Approved
DMT2FDC SN Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
DMT2FDC CP Sanofi Aventis Us Llc
DMT2FDC TC Antidepressants
DMT2FDC DT Small molecular drug
DMT2FDC PC 2995
DMT2FDC MW 266.4
DMT2FDC FM C18H22N2
DMT2FDC IC InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
DMT2FDC CS CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DMT2FDC IK HCYAFALTSJYZDH-UHFFFAOYSA-N
DMT2FDC IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMT2FDC CA CAS 50-47-5
DMT2FDC CB CHEBI:47781
DMT2FDC DE Attention deficit hyperactivity disorder; Depression
DM2BTFN ID DM2BTFN
DM2BTFN DN Desirudin Recombinant
DM2BTFN HS Approved
DM2BTFN SN Iprivask
DM2BTFN CP Valeant Pharmaceuticals North America Llc
DM2BTFN TC Cardiovascular Agents
DM2BTFN DE Coagulation defect
DMB3ZSK ID DMB3ZSK
DMB3ZSK DN Deslanoside
DMB3ZSK HS Approved
DMB3ZSK SN Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
DMB3ZSK TC Antiarrhythmic Agents
DMB3ZSK DT Small molecular drug
DMB3ZSK PC 28620
DMB3ZSK MW 943.1
DMB3ZSK FM C47H74O19
DMB3ZSK IC InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
DMB3ZSK CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O
DMB3ZSK IK OBATZBGFDSVCJD-LALPQLPRSA-N
DMB3ZSK IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMB3ZSK CA CAS 17598-65-1
DMB3ZSK CB CHEBI:31468
DMB3ZSK DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DM56YN7 ID DM56YN7
DM56YN7 DN Desloratadine
DM56YN7 HS Approved
DM56YN7 SN Aerius; Allex; Azomyr; Claramax; Clarinex; Denosin; Desalex; Descarboethoxyloratadine; Descarboethoxyoratidine; Desloratidine; Neoclarityn; Opulis; Clarinex RediTabs; Desloratadine [USAN]; Essex brand of desloratadine; Schering brand of desloratadine; Sch 34117; Aerius (TN); Claramax (TN); Clarinex (TN); NeoClarityn (TN); Sch-34117; Schering-Plough brand of desloratadine; Desloratadine (USAN/INN); 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine; 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine; 8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
DM56YN7 CP Schering-Plough
DM56YN7 TC Antiallergic Agents
DM56YN7 DT Small molecular drug
DM56YN7 PC 124087
DM56YN7 MW 310.8
DM56YN7 FM C19H19ClN2
DM56YN7 IC InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
DM56YN7 CS C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
DM56YN7 IK JAUOIFJMECXRGI-UHFFFAOYSA-N
DM56YN7 IU 13-chloro-2-piperidin-4-ylidene-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DM56YN7 CA CAS 100643-71-8
DM56YN7 CB CHEBI:291342
DM56YN7 DE Allergic rhinitis
DMS3GVE ID DMS3GVE
DMS3GVE DN Desmopressin
DMS3GVE HS Approved
DMS3GVE SN Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals
DMS3GVE CP Ferring Pharmaceuticals Inc
DMS3GVE DT Small molecular drug
DMS3GVE PC 5311065
DMS3GVE MW 1069.2
DMS3GVE FM C46H64N14O12S2
DMS3GVE IC InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29+,30+,31+,32+,33+,34+/m1/s1
DMS3GVE CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMS3GVE IK NFLWUMRGJYTJIN-PNIOQBSNSA-N
DMS3GVE IU (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMS3GVE CA CAS 16679-58-6
DMS3GVE CB CHEBI:4450
DMS3GVE DE Diabetic complication
DM27U4Y ID DM27U4Y
DM27U4Y DN Desogestrel
DM27U4Y HS Approved
DM27U4Y SN Cerazette; Desogen; Desogestrelum; Organon Brand of Desogestrel; ORG 2969; Desogestrelum [INN-Latin]; Desogestrel (USAN/INN); Desogestrel [USAN:BAN:INN]; Alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17; (17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol; (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol; 13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol; 13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol; 13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol; 17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
DM27U4Y TC Contraceptive Agents
DM27U4Y DT Small molecular drug
DM27U4Y PC 40973
DM27U4Y MW 310.5
DM27U4Y FM C22H30O
DM27U4Y IC InChI=1S/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DM27U4Y CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34
DM27U4Y IK RPLCPCMSCLEKRS-BPIQYHPVSA-N
DM27U4Y IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
DM27U4Y CA CAS 54024-22-5
DM27U4Y CB CHEBI:4453
DM27U4Y DE Contraception
DMTP2NJ ID DMTP2NJ
DMTP2NJ DN Desonide
DMTP2NJ HS Approved
DMTP2NJ SN Apolar; DesOwen; Desilux; Desonate; Desonida; Desonidum; Flusemidon; Hamiltoderm; Locapred; Prednacinolone; Prenacid; Reticus; Sterax; Steroderm; Topifug; Tridesilon; Tridesonit; Verdeso; Zotinar; Desfluorotriamcinolone acetonide; D 2083; D-2083; Desonida [INN-Spanish]; Desonidum [INN-Latin]; Desowen (TN); Verdeso (TN);Verdeso Foam (TN); Desonide (USAN/INN); Desonide [USAN:INN:BAN]; Locapred, Topifug, Tridesilon, Desonide; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone; 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione; 16-alpha-Hydroxyprednisole-16,17-acetonide; 16alpha,17alpha-isopropylidenedioxyprednisolone; 16alpha-hydroxyprednisole-16,17-acetonide; 16alpha-hydroxyprednisolone-16alpha,17-acetonide
DMTP2NJ TC Antiinflammatory Agents
DMTP2NJ DT Small molecular drug
DMTP2NJ PC 5311066
DMTP2NJ MW 416.5
DMTP2NJ FM C24H32O6
DMTP2NJ IC InChI=1S/C24H32O6/c1-21(2)29-19-10-16-15-6-5-13-9-14(26)7-8-22(13,3)20(15)17(27)11-23(16,4)24(19,30-21)18(28)12-25/h7-9,15-17,19-20,25,27H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMTP2NJ CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O
DMTP2NJ IK WBGKWQHBNHJJPZ-LECWWXJVSA-N
DMTP2NJ IU (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMTP2NJ CA CAS 638-94-8
DMTP2NJ CB CHEBI:204734
DMTP2NJ DE Atopic dermatitis
DM4PXF6 ID DM4PXF6
DM4PXF6 DN Desoximetasone
DM4PXF6 HS Approved
DM4PXF6 SN Desoximetasona; Desoximetasonum; Topicort; HOE-304; R-2113; Topicort (TN); Topicort Emollient (TN); A-41-304; Desoximetasone (USP/INN); (11beta,16alpha)-9-Fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione; (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one; 9-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 9alpha-fluoro-16alpha-methyl-Delta(1)-corticosterone
DM4PXF6 TC Antiinflammatory Agents
DM4PXF6 DT Small molecular drug
DM4PXF6 PC 5311067
DM4PXF6 MW 376.5
DM4PXF6 FM C22H29FO4
DM4PXF6 IC InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
DM4PXF6 CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
DM4PXF6 IK VWVSBHGCDBMOOT-IIEHVVJPSA-N
DM4PXF6 IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4PXF6 CA CAS 140218-14-0
DM4PXF6 CB CHEBI:691037
DM4PXF6 DE Inflammation
DMS0AFE ID DMS0AFE
DMS0AFE DN Desoxycorticosterone acetate
DMS0AFE HS Approved
DMS0AFE SN Doca
DMS0AFE CP Organon Usa Inc
DMS0AFE DT Small molecular drug
DMS0AFE PC 5952
DMS0AFE MW 372.5
DMS0AFE FM C23H32O4
DMS0AFE IC InChI=1S/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1
DMS0AFE CS CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMS0AFE IK VPGRYOFKCNULNK-ACXQXYJUSA-N
DMS0AFE IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DMS0AFE CA CAS 56-47-3
DMS0AFE CB CHEBI:34671
DMS0AFE DE Discovery agent
DMSA4B3 ID DMSA4B3
DMSA4B3 DN Desoxycorticosterone pivalate
DMSA4B3 HS Approved
DMSA4B3 SN DOCP; DTMA; Cortexone M; Deoxycorticosterone pivalate; Deoxycorticosterone trimethylacetate; Deoxycortolone Pivalate; Deoxycortone pivalate; Deoxycortone trimethylacetate; Desoxycorticosterone trimethylacetate; Desoxycortone pivalate; Percorten M; Percorten Pivalate; Desoxycorticosterone pivalate (USP); Neodin-depositum; Percorten (TN); Corticosterone, deoxy-, pivalate (6CI,7CI); [2-(10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] 2,2-dimethylpropanoate; 11-Deoxycorticosterone pivalate; 11-Deoxycorticosterone, pivalate; 11-Deoxycorticosterone, pivalate (8CI); 21-(2,2-Dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione; 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate
DMSA4B3 TC Antiaddison Agents
DMSA4B3 DT Small molecular drug
DMSA4B3 PC 11876263
DMSA4B3 MW 414.6
DMSA4B3 FM C26H38O4
DMSA4B3 IC InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1
DMSA4B3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C
DMSA4B3 IK VVOIQBFMTVCINR-WWMZEODYSA-N
DMSA4B3 IU [2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMSA4B3 CA CAS 808-48-0
DMSA4B3 CB CHEBI:50782
DMSA4B3 DE Addison disease
DMEZFXR ID DMEZFXR
DMEZFXR DN Desoxyribonuclease
DMEZFXR HS Approved
DMEZFXR DE Female genital tract inflammation
DMJE6KO ID DMJE6KO
DMJE6KO DN Desvenalfaxine succinate
DMJE6KO HS Approved
DMJE6KO SN 386750-22-7; Desvenlafaxine succinate monohydrate; Desvenlafaxine (succinate hydrate); Desvenlafaxine succinate hydrate; Desvenlafaxine Succinate [USAN]; Desvenlafaxine succinate (USAN); O-desmethylvenlafaxine Succinate Monohydrate; Desvenlafaxine Succinate Monohydrate (O-Desmethylvenlafaxine Succinate Monohydrate); Pristiq (TN); AC1OCFPN; Desvenlafaxine(succinatehydrate); SCHEMBL1278407; CTK8E8387; HY-B0602A; MolPort-021-783-032
DMJE6KO CP Wyeth
DMJE6KO DT Small molecular drug
DMJE6KO PC 6918664
DMJE6KO MW 399.5
DMJE6KO FM C20H33NO7
DMJE6KO IC InChI=1S/C16H25NO2.C4H6O4.H2O/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8);1H2
DMJE6KO CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O.O
DMJE6KO IK PWPDEXVGKDEKTE-UHFFFAOYSA-N
DMJE6KO IU butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol;hydrate
DMJE6KO CA CAS 386750-22-7
DMJE6KO DE Fibromyalgia
DMHD4PE ID DMHD4PE
DMHD4PE DN Desvenlafaxine
DMHD4PE HS Approved
DMHD4PE SN Norvenlafaxine; Desvenlafaxine (INN); Desvenlafaxine [INN:BAN]; O-Desmethylvenlafaxine; WY 45,233; O-DESMETHYLVENLAFAXINE (ODV); WY-45,233
DMHD4PE CP Wyeth
DMHD4PE DT Small molecular drug
DMHD4PE PC 125017
DMHD4PE MW 263.37
DMHD4PE FM C16H25NO2
DMHD4PE IC InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
DMHD4PE CS CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
DMHD4PE IK KYYIDSXMWOZKMP-UHFFFAOYSA-N
DMHD4PE IU 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
DMHD4PE CA CAS 93413-62-8
DMHD4PE CB CHEBI:83527
DMHD4PE DE Major depressive disorder; Menopause symptom
DMUPFLI ID DMUPFLI
DMUPFLI DN Deutetrabenazine
DMUPFLI HS Approved
DMUPFLI SN Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN]
DMUPFLI CP Teva
DMUPFLI DT Small molecular drug
DMUPFLI PC 73437646
DMUPFLI MW 323.5
DMUPFLI FM C19H27NO3
DMUPFLI IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
DMUPFLI CS [2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
DMUPFLI IK MKJIEFSOBYUXJB-VFJJUKLQSA-N
DMUPFLI IU (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMUPFLI CA CAS 1392826-25-3
DMUPFLI DE Tardive dyskinesia; Huntington disease
DMMWZET ID DMMWZET
DMMWZET DN Dexamethasone
DMMWZET HS Approved
DMMWZET SN Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone
DMMWZET CP Swiss Pharma
DMMWZET TC Antiinflammatory Agents
DMMWZET DT Small molecular drug
DMMWZET PC 5743
DMMWZET MW 392.5
DMMWZET FM C22H29FO5
DMMWZET IC InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DMMWZET CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
DMMWZET IK UREBDLICKHMUKA-CXSFZGCWSA-N
DMMWZET IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMMWZET CA CAS 50-02-2
DMMWZET CB CHEBI:41879
DMMWZET DE Rheumatoid arthritis
DMIG8DW ID DMIG8DW
DMIG8DW DN Dexamethasone sodium phosphate
DMIG8DW HS Approved
DMIG8DW SN EryDex; Dexamethasone sodium phosphate (erythrocyte encapsulated); Dexamethasone sodium phosphate (erythrocyte encapsulated), Urbino University/EryDel; Dex 21-P (red blood cell encapsulated), Urbino University/EryDel; Intra-erythrocyte dexamethasone (inflammatory diseases), Urbino University/EryDel
DMIG8DW CP Universita' Degli Studi Di Urbino
DMIG8DW DT Small molecular drug
DMIG8DW PC 16961
DMIG8DW MW 516.4
DMIG8DW FM C22H28FNa2O8P
DMIG8DW IC InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
DMIG8DW CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+]
DMIG8DW IK PLCQGRYPOISRTQ-FCJDYXGNSA-L
DMIG8DW IU disodium;[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate
DMIG8DW CA CAS 2392-39-4
DMIG8DW CB CHEBI:4462
DMIG8DW DE Ataxia-telangiectasia
DMKVWGE ID DMKVWGE
DMKVWGE DN Dexbrompheniramine
DMKVWGE HS Approved
DMKVWGE SN Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine
DMKVWGE CP Schering Corp Sub Schering Plough Corp
DMKVWGE TC Antihistamines
DMKVWGE DT Small molecular drug
DMKVWGE PC 16960
DMKVWGE MW 319.24
DMKVWGE FM C16H19BrN2
DMKVWGE IC InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
DMKVWGE CS CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2
DMKVWGE IK ZDIGNSYAACHWNL-HNNXBMFYSA-N
DMKVWGE IU (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMKVWGE CA CAS 132-21-8
DMKVWGE CB CHEBI:59269
DMKVWGE DE Hay fever
DMA8DPN ID DMA8DPN
DMA8DPN DN Dexchlorpheniramine maleate
DMA8DPN HS Approved
DMA8DPN SN Polaramine
DMA8DPN CP Schering Corp Sub Schering Plough Corp
DMA8DPN DT Small molecular drug
DMA8DPN PC 5281070
DMA8DPN MW 390.9
DMA8DPN FM C20H23ClN2O4
DMA8DPN IC InChI=1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1
DMA8DPN CS CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DMA8DPN IK DBAKFASWICGISY-DASCVMRKSA-N
DMA8DPN IU (Z)-but-2-enedioic acid;(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DMA8DPN CA CAS 2438-32-6
DMA8DPN CB CHEBI:4465
DMA8DPN DE Rhinitis
DMFYBD0 ID DMFYBD0
DMFYBD0 DN Dexibuprofen
DMFYBD0 HS Approved
DMFYBD0 SN (S)-(+)-Ibuprofen; 51146-56-6; DEXIBUPROFEN; S(+)-Ibuprofen; (S)-2-(4-Isobutylphenyl)propanoic acid; (S)-Ibuprofen; d-Ibuproten; (S)-(+)-2-(4-Isobutylphenyl)propionic acid; (+)-(S)-p-Isobutylhydratropic acid; Seractil; (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid; (S)-(+)-4-Isobutyl-alpha-methylphenylacetic acid; UNII-671DKG7P5S; S-(+)-ibuprofen; (2S)-2-(4-isobutylphenyl)propanoic acid; CHEMBL175; 671DKG7P5S; CHEBI:43415; (S)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; NCGC00016861-05
DMFYBD0 DT Small molecular drug
DMFYBD0 PC 39912
DMFYBD0 MW 206.28
DMFYBD0 FM C13H18O2
DMFYBD0 IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
DMFYBD0 CS C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
DMFYBD0 IK HEFNNWSXXWATRW-JTQLQIEISA-N
DMFYBD0 IU (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
DMFYBD0 CA CAS 51146-56-6
DMFYBD0 CB CHEBI:43415
DMFYBD0 DE Ankylosing spondylitis
DM1DBV5 ID DM1DBV5
DM1DBV5 DN Dexlansoprazole
DM1DBV5 HS Approved
DM1DBV5 SN dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole
DM1DBV5 CP Takeda
DM1DBV5 DT Small molecular drug
DM1DBV5 PC 9578005
DM1DBV5 MW 369.4
DM1DBV5 FM C16H14F3N3O2S
DM1DBV5 IC InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
DM1DBV5 CS CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DM1DBV5 IK MJIHNNLFOKEZEW-RUZDIDTESA-N
DM1DBV5 IU 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DM1DBV5 CA CAS 138530-94-6
DM1DBV5 CB CHEBI:135931
DM1DBV5 DE Non-erosive gastro-esophageal reflux disease; Erosive esophagitis; Peptic ulcer; NSAID-associated gastric ulcer
DM93L4X ID DM93L4X
DM93L4X DN Dexmedetomidine
DM93L4X HS Approved
DM93L4X SN Dexmedetomidina; Dexmedetomidinum; MPV 1440; MPV-1440; Precedex (TN); Dexmedetomidine (USAN/INN); (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X CP Hospira
DM93L4X TC Hypnotics and Sedatives
DM93L4X DT Small molecular drug
DM93L4X PC 5311068
DM93L4X MW 200.28
DM93L4X FM C13H16N2
DM93L4X IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
DM93L4X CS CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C
DM93L4X IK CUHVIMMYOGQXCV-NSHDSACASA-N
DM93L4X IU 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DM93L4X CA CAS 113775-47-6
DM93L4X CB CHEBI:4466
DM93L4X DE Irritability
DMUQE2A ID DMUQE2A
DMUQE2A DN Dexmethylphenidate
DMUQE2A HS Approved
DMUQE2A SN Dexmethylphenidate; Dexmethylphenidate (INN); Dexmethylphenidate [INN]; Focalin; Focalin XR; M32RH9MFGP; Methyl D-phenidate; d-Methylphenidate; Attenade; Dex methylphenidate; d-threo-Methylphenidate; dex-methylphenidate; dexmethylphenidatum; dexmetilfenidato; threo-(+)-Methylphenidate; (+)-threo-Methylphenidate; 40431-64-9; CHEBI:51860; CHEMBL827; D-MPH; D-TMP; UNII-M32RH9MFGP; methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate; methyl (2R)-phenyl[(2R)-piperidin-2-yl]acetate; methyl (R)-phenyl[(R)-piperidin-2-yl]acetate
DMUQE2A PC 154101
DMUQE2A MW 233.31
DMUQE2A FM C14H19NO2
DMUQE2A IC DUGOZIWVEXMGBE-CHWSQXEVSA-N
DMUQE2A CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DMUQE2A IK 1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1
DMUQE2A IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
DMUQE2A CA CAS 40431-64-9
DMUQE2A CB CHEBI:51860
DMUQE2A DE Attention deficit hyperactivity disorder
DM8WBAH ID DM8WBAH
DM8WBAH DN Dexmethylphenidate hydrochloride
DM8WBAH HS Approved
DM8WBAH SN Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06
DM8WBAH DT Small molecular drug
DM8WBAH PC 154100
DM8WBAH MW 269.77
DM8WBAH FM C14H20ClNO2
DM8WBAH IC InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
DM8WBAH CS COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl
DM8WBAH IK JUMYIBMBTDDLNG-OJERSXHUSA-N
DM8WBAH IU methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride
DM8WBAH CA CAS 19262-68-1
DM8WBAH DE Attention deficit hyperactivity disorder
DMD7X1O ID DMD7X1O
DMD7X1O DN Dexrazoxane
DMD7X1O HS Approved
DMD7X1O SN 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dexrazoxano; Dexrazoxanum; Dextrorazoxane; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; Desrazoxane; Eucardion; ADR 529; ICRF 187; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; Dexrazone; ADR-529; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; HSDB 7319; UNII-048L81261F; NSC169780; dyzoxane; BRN 5759131; CHEBI:50223; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; NSC 169780; AK-72797; Razoxanum; Cardioxane; Dyzoxane; Savene; TopoTect; Totect; Dexrazoxane HCl; Dexrazoxane hydrochloride; ICRF 187 hydrochloride; Cardioxane (TN); Dexrazoxane (TN); Totect (TN); Zinecard (TN); Dexrazoxane (USAN/INN); Dexrazoxane [USAN:BAN:INN]; Soluble ICRF (L-isosomer); Razoxane, (S)-Isomer; Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride;(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-(9CI); 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride; Icrf-187
DMD7X1O CP Pfizer Pharmaceuticals
DMD7X1O TC Anticancer Agents
DMD7X1O DT Small molecular drug
DMD7X1O PC 71384
DMD7X1O MW 268.27
DMD7X1O FM C11H16N4O4
DMD7X1O IC InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
DMD7X1O CS C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
DMD7X1O IK BMKDZUISNHGIBY-ZETCQYMHSA-N
DMD7X1O IU 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
DMD7X1O CA CAS 24584-09-6
DMD7X1O CB CHEBI:50223
DMD7X1O DE Breast cancer; Chemoprotection; Respiratory tract disease
DMMIHVP ID DMMIHVP
DMMIHVP DN Dextroamphetamine
DMMIHVP HS Approved
DMMIHVP SN D-Amphetamine; dextroamphetamine; Dexamphetamine; Dexamfetamine; (S)-Amphetamine; Dexadrine; (+)-(S)-Amphetamine; Dexedrine; (2S)-1-phenylpropan-2-amine; (S)-(+)-Amphetamine; Dextrostat; Desamfetamina; (S)-1-Phenyl-2-propylamine; Dexidrine; Sympamin; Dephadren; Amsustain; (+)-Phenaminum; (+)-alpha-Methylphenethylamine; (S)-1-Phenyl-2-aminopropane; (+)-alpha-Methylphenylethylamine; D-(S)-Amphetamine; (S)-(+)-beta-Phenylisopropylamine; 51-64-9; (S)-alpha-Phenylethylamine; (2S)-(+)-Amphetamine; Benzedrine; Dexacaps; Dexamfetamina; Dexamfetaminum; Dexamphetaminum; Dexanfetamina; Isoamycin; Propisamine; Psychedrine; Raphetamine; Rhinalator; Simpatedrin; Sympamine; Sympatedrine; Weckamine; Desamfetamina [DCIT]; Dexedrine Spansule; Dextroamphetamine [USAN]; Dextroamphetamine resin complex; D-AM; Dexamfetamina [INN-Spanish]; Dexamfetamine (INN); Dexamfetaminum [INN-Latin]; Dexamphetaminum [INN-Latin]; Dexanfetamina [INN-Spanish]; Dexedrine (TN); Dextro-Amphetamine; Dextro-Amphetamine Sulfate; Dextroamphetamine (USAN); Dextrostat (TN); Dl-Amphetamine; Dl-Benzedrine; Fenylo-izopropylaminyl; Beta-phenyl-isopropylamine; D-alpha-methylphenethylamine; Alpha-Methylphenethylamine, d-form; S(+)-Amphetamine; D-(+)-Amphetamine; D-1-Phenyl-2-aminopropan; D-1-Phenyl-2-aminopropan [German]; D-1-Phenyl-2-aminopropane; D-2-Amino-1-phenylpropane; Dl-1-Phenyl-2-aminopropane; Benzeneethanamine, alpha-methyl-, (aS)-(9CI); Phenethylamine, alpha-methyl-, (+)-(8CI); (+/-)-Benzedrine; (+/-)-Desoxynorephedrine; (+/-)-beta-Phenylisopropylamine; (S)-1-Phenyl-2-propanamine; (S)-alpha-Methylphenethylamine; (S)-alpha-methylbenzeneethanamine; (alphaS)-alpha-methylbenzeneethanamine; dextroamphetamine sulfate (oral liquid, ADHD), Auriga
DMMIHVP CP GlaxoSmithKline
DMMIHVP TC Central Nervous System Stimulants
DMMIHVP DT Small molecular drug
DMMIHVP PC 5826
DMMIHVP MW 135.21
DMMIHVP FM C9H13N
DMMIHVP IC InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
DMMIHVP CS C[C@@H](CC1=CC=CC=C1)N
DMMIHVP IK KWTSXDURSIMDCE-QMMMGPOBSA-N
DMMIHVP IU (2S)-1-phenylpropan-2-amine
DMMIHVP CA CAS 51-64-9
DMMIHVP CB CHEBI:4469
DMMIHVP DE Narcolepsy; Attention deficit hyperactivity disorder
DMUDJZM ID DMUDJZM
DMUDJZM DN Dextromethorphan
DMUDJZM HS Approved
DMUDJZM SN Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)
DMUDJZM TC Analgesics
DMUDJZM DT Small molecular drug
DMUDJZM PC 5360696
DMUDJZM MW 271.4
DMUDJZM FM C18H25NO
DMUDJZM IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
DMUDJZM CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
DMUDJZM IK MKXZASYAUGDDCJ-NJAFHUGGSA-N
DMUDJZM IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMUDJZM CA CAS 125-71-3
DMUDJZM CB CHEBI:4470
DMUDJZM DE Cough
DMEHCY5 ID DMEHCY5
DMEHCY5 DN Dextromethorphan polistirex
DMEHCY5 HS Approved
DMEHCY5 CP Reckitt Benckiser Llc
DMEHCY5 PC 5464025
DMEHCY5 MW 352.3
DMEHCY5 FM C18H26BrNO
DMEHCY5 IC InChI=1S/C18H25NO.BrH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1
DMEHCY5 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.Br
DMEHCY5 IK MISZALMBODQYFT-URVXVIKDSA-N
DMEHCY5 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrobromide
DMEHCY5 CA CAS 125-69-9
DMEHCY5 DE Dry cough
DM23HCX ID DM23HCX
DM23HCX DN Dextropropoxyphene
DM23HCX HS Approved
DM23HCX SN Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane
DM23HCX TC Analgesics
DM23HCX DT Small molecular drug
DM23HCX PC 10100
DM23HCX MW 339.5
DM23HCX FM C22H29NO2
DM23HCX IC InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
DM23HCX CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C
DM23HCX IK XLMALTXPSGQGBX-GCJKJVERSA-N
DM23HCX IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
DM23HCX CA CAS 469-62-5
DM23HCX CB CHEBI:51173
DM23HCX DE Pain
DMBVEC7 ID DMBVEC7
DMBVEC7 DN Dextrothyroxine Sodium
DMBVEC7 HS Approved
DMBVEC7 SN Choloxin
DMBVEC7 CP Abbvie Inc
DMBVEC7 DT Small molecular drug
DMBVEC7 PC 23690433
DMBVEC7 MW 798.85
DMBVEC7 FM C15H10I4NNaO4
DMBVEC7 IC InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m1./s1
DMBVEC7 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@H](C(=O)[O-])N.[Na+]
DMBVEC7 IK YDTFRJLNMPSCFM-UTONKHPSSA-M
DMBVEC7 IU sodium;(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
DMBVEC7 CA CAS 137-53-1
DMBVEC7 DE High blood cholesterol level
DMJDB0Y ID DMJDB0Y
DMJDB0Y DN Dezocine
DMJDB0Y HS Approved
DMJDB0Y SN SCHEMBL1369581; (5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol
DMJDB0Y TC Analgesics
DMJDB0Y DT Small molecular drug
DMJDB0Y PC 3033053
DMJDB0Y MW 245.36
DMJDB0Y FM C16H23NO
DMJDB0Y IC InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1
DMJDB0Y CS C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O
DMJDB0Y IK VTMVHDZWSFQSQP-VBNZEHGJSA-N
DMJDB0Y IU (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol
DMJDB0Y CA CAS 53648-55-8
DMJDB0Y CB CHEBI:4474
DMJDB0Y DE Pain
DMU3FGB ID DMU3FGB
DMU3FGB DN Dhaq diacetate
DMU3FGB HS Approved
DMU3FGB SN Mitoxantrone diacetate; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate
DMU3FGB TC Anticancer Agents
DMU3FGB DT Small molecular drug
DMU3FGB PC 51151
DMU3FGB MW 564.6
DMU3FGB FM C26H36N4O10
DMU3FGB IC InChI=1S/C22H28N4O6.2C2H4O2/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;2*1-2(3)4/h1-4,23-30H,5-12H2;2*1H3,(H,3,4)
DMU3FGB CS CC(=O)[O-].CC(=O)[O-].C1=CC(=C2C(=C1NCC[NH2+]CCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCC[NH2+]CCO
DMU3FGB IK ZWCKUVMZBKQQRG-UHFFFAOYSA-N
DMU3FGB IU 2-[[5,8-dihydroxy-4-[2-(2-hydroxyethylazaniumyl)ethylamino]-9,10-dioxoanthracen-1-yl]amino]ethyl-(2-hydroxyethyl)azanium;diacetate
DMU3FGB CA CAS 70711-41-0
DMU3FGB DE Solid tumour/cancer
DM08E9O ID DM08E9O
DM08E9O DN Diazepam
DM08E9O HS Approved
DM08E9O SN diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol; Diazepam (intranasal, epilepsy)
DM08E9O CP Archimedes Pharma Ltd
DM08E9O DT Small molecular drug
DM08E9O PC 3016
DM08E9O MW 284.74
DM08E9O FM C16H13ClN2O
DM08E9O IC InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
DM08E9O CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DM08E9O IK AAOVKJBEBIDNHE-UHFFFAOYSA-N
DM08E9O IU 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM08E9O CA CAS 439-14-5
DM08E9O CB CHEBI:49575
DM08E9O DE Epilepsy
DML1538 ID DML1538
DML1538 DN Diazoxide
DML1538 HS Approved
DML1538 SN Aroglycem; Diazossido; Diazoxido; Diazoxidum; Dizoxide; Eudemine; Hyperstat; Hypertonalum; Mutabase; Proglicem; Proglycem; Diazossido [DCIT]; Diazossido [Italian]; D 9035; SRG 95213; Sch 6783; Diazoxido [INN-Spanish]; Diazoxidum [INN-Latin]; Hyperstat (TN); SRG-95213; Sch-6783; Diazoxide [USAN:INN:BAN]; Diazoxide (JAN/USP/INN); 2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide; 7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide; 7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido; 7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]; 7-chloro-3-methyl-4H-1
DML1538 TC Antihypertensive Agents
DML1538 DT Small molecular drug
DML1538 PC 3019
DML1538 MW 230.67
DML1538 FM C8H7ClN2O2S
DML1538 IC InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)
DML1538 CS CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
DML1538 IK GDLBFKVLRPITMI-UHFFFAOYSA-N
DML1538 IU 7-chloro-3-methyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
DML1538 CA CAS 364-98-7
DML1538 CB CHEBI:4495
DML1538 DE Hypertension
DMF9G7L ID DMF9G7L
DMF9G7L DN Dibucaine
DMF9G7L HS Approved
DMF9G7L SN Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L CP Novartis Pharmaceuticals Corp
DMF9G7L TC Anesthetics
DMF9G7L DT Small molecular drug
DMF9G7L PC 3025
DMF9G7L MW 343.5
DMF9G7L FM C20H29N3O2
DMF9G7L IC InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
DMF9G7L CS CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
DMF9G7L IK PUFQVTATUTYEAL-UHFFFAOYSA-N
DMF9G7L IU 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
DMF9G7L CA CAS 85-79-0
DMF9G7L CB CHEBI:247956
DMF9G7L DE Anaesthesia
DMH7IDQ ID DMH7IDQ
DMH7IDQ DN Dichlorphenamide
DMH7IDQ HS Approved
DMH7IDQ SN dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis; Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE
DMH7IDQ TC Antiglaucomic Agents
DMH7IDQ DT Small molecular drug
DMH7IDQ PC 3038
DMH7IDQ MW 305.2
DMH7IDQ FM C6H6Cl2N2O4S2
DMH7IDQ IC InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
DMH7IDQ CS C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
DMH7IDQ IK GJQPMPFPNINLKP-UHFFFAOYSA-N
DMH7IDQ IU 4,5-dichlorobenzene-1,3-disulfonamide
DMH7IDQ CA CAS 120-97-8
DMH7IDQ CB CHEBI:101085
DMH7IDQ DE Chronic glaucoma
DMPIHLS ID DMPIHLS
DMPIHLS DN Diclofenac
DMPIHLS HS Approved
DMPIHLS SN Diclofenac (sodium matrix patch, pain)
DMPIHLS CP Novartis Pharmaceuticals Corp
DMPIHLS TC Neurology Agents
DMPIHLS DT Small molecular drug
DMPIHLS PC 3033
DMPIHLS MW 296.1
DMPIHLS FM C14H11Cl2NO2
DMPIHLS IC InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
DMPIHLS CS C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
DMPIHLS IK DCOPUUMXTXDBNB-UHFFFAOYSA-N
DMPIHLS IU 2-[2-(2,6-dichloroanilino)phenyl]acetic acid
DMPIHLS CA CAS 15307-86-5
DMPIHLS CB CHEBI:47381
DMPIHLS DE Osteoarthritis
DM8EU0Z ID DM8EU0Z
DM8EU0Z DN Dicloxacillin
DM8EU0Z HS Approved
DM8EU0Z SN Dichloroxacillin; Diclossacillina; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilline; Dicloxacillinum; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; Diclossacillina [DCIT]; Dicloxacillin sodium; BRL 1702; Diclocil (TN); Dicloxacilina [INN-Spanish]; Dicloxacilline [INN-French]; Dicloxacillinum [INN-Latin]; R-13423; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin, Monosodium Salt, Mono-Hydrate; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DM8EU0Z CP Sandoz Inc
DM8EU0Z TC Antibiotics
DM8EU0Z DT Small molecular drug
DM8EU0Z PC 18381
DM8EU0Z MW 470.3
DM8EU0Z FM C19H17Cl2N3O5S
DM8EU0Z IC InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DM8EU0Z CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DM8EU0Z IK YFAGHNZHGGCZAX-JKIFEVAISA-N
DM8EU0Z IU (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8EU0Z CA CAS 3116-76-5
DM8EU0Z CB CHEBI:4511
DM8EU0Z DE Bacterial infection
DMFQCB1 ID DMFQCB1
DMFQCB1 DN Dicumarol
DMFQCB1 HS Approved
DMFQCB1 SN Acadyl; Acavyl; Anathrombase; Antitrombosin; Apekumarol; Baracoumin; Bishydroxycoumarin; Cuma; Cumid; Dicoumal; Dicoumarin; Dicoumarol; Dicoumarolum; Dicoumerol; Dicuman; Dicumarine; Dicumarinum; Dicumarolo; Dicumarolum; Dicumol; Dikumarol; Dufalone; Dwukumarol; Kumoran; Melitoxin; Temparin; Trombosan; Dicumaol R; Dicumarol [USAN]; Dicumarolo [DCIT]; Dwukumarol [Polish]; Uncoupler of oxidative respiration; M0216; NC 034; Bis-hydroxycoumarin; Dicoumarol (INN); Dicoumarolum [INN-Latin]; Dicumarol (TN); Dicumarol (USAN); Dicumarol [INN-Spanish]; Symmetric dicoumarol analogue, 1; Bis(4-hydroxycoumarin-3-yl)methane; Di-(4-hydroxy-3-coumarinyl)methane; Bis-3,3'-(4-hydroxycoumarinyl)methane; Bis-3,3'-(4-oxycoumarinyl)ethylacetate; Di-4-hydroxy-3,3'-methylenedicoumarin; Coumarin, 3,3'-methylenebis[4-hydroxy-(8CI); 2-hydroxy-3-[(2-hydroxy-4-oxochromen-3-yl)methyl]chromen-4-one; 2H-1-Benzopyran-2-one, 3,3'-methylenebis[4-hydroxy-(9CI); 3,3′-Methylenebis(4-hydroxycoumarin); 3,3'-Methyleen-bis(4-hydroxy-cumarine); 3,3'-Methyleen-bis(4-hydroxy-cumarine) [Dutch]; 3,3'-Methylen-bis(4-hydroxy-cumarin); 3,3'-Methylen-bis(4-hydroxy-cumarin) [German]; 3,3'-Methylene-bis(4-hydroxycoumarin); 3,3'-Methylene-bis(4-hydroxycoumarine); 3,3'-Methylene-bis(4-hydroxycoumarine) [French]; 3,3'-Methylenebis(4-hydroxy-1,2-benzopyrone); 3,3'-Methylenebis(4-hydroxy-2H-1-benzopyran-2-one); 3,3'-Methylenebis(4-hydroxycoumarin); 3,3'-Methylenebis[4-hydroxy-1,2-benzopyrone]; 3,3'-Methylenebis[4-hydroxy-2H-1-benzopyran-2-one]; 3,3'-Methylenebis[4-hydroxycoumarin]; 3,3'-Metilen-bis(4-idrossi-cumarina); 3,3'-Metilen-bis(4-idrossi-cumarina) [Italian]; 3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one); 3,3'-methylenebis(2-hydroxy-4h-chromen-4-one); 3,3'-methylenebis(4-hydroxy-2H-chromen-2-one); 3,3-Methylene-bis[4-hydroxycoumarin]; 4,4'-Dihydroxy-3,3'-methylene bis coumarin
DMFQCB1 TC Anticoagulants
DMFQCB1 DT Small molecular drug
DMFQCB1 PC 54676038
DMFQCB1 MW 336.3
DMFQCB1 FM C19H12O6
DMFQCB1 IC InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
DMFQCB1 CS C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O
DMFQCB1 IK DOBMPNYZJYQDGZ-UHFFFAOYSA-N
DMFQCB1 IU 4-hydroxy-3-[(4-hydroxy-2-oxochromen-3-yl)methyl]chromen-2-one
DMFQCB1 CA CAS 66-76-2
DMFQCB1 CB CHEBI:4513
DMFQCB1 DE Thrombosis; Bleeding disorder
DMZSDGX ID DMZSDGX
DMZSDGX DN Dicyclomine
DMZSDGX HS Approved
DMZSDGX SN Atumin; Bentomine; Bentylol; Dicicloverina; Dicycloverin; Dicycloverine; Dicycloverinum; Dicymine; Diocyl; Dyspas; Formulex; Mamiesan; Merbentyl; Procyclomin; Sawamin; Spasmoban; Wyovin; Bentyl hydrochloride; Bentylol hydrochloride; Dicyclomine Hcl; Dicycloverin hydrochloride; Diethylaminocarbethoxybicyclohexyl hydrochloride; Diocyl hydrochloride; Kolantyl hydrochloride; Wyovin hydrochloride; GU8471000; Bentyl (TN); Bentylol (TN); Byclomine (TN); Di-syntramine; Dibent (TN); Dicicloverina [INN-Spanish]; Dicycloverine (INN); Dicycloverine [INN:BAN]; Dicycloverinum [INN-Latin]; Dicymine (TN); Dilomine (TN); Formulex (TN); Lomine (TN); Merbentyl (TN); Oxityl-P; Beta-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; Di-Spaz (TN); J.L. 998; Beta-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; Cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER, HYDROCHLORIDE; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 1-Cyclohexylcyclohexanecarboxylic acid 2-(diethylamino)ethyl ester; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride
DMZSDGX CP Peckforton Pharmaceuticals
DMZSDGX TC Anticholinergic Agents
DMZSDGX DT Small molecular drug
DMZSDGX PC 3042
DMZSDGX MW 309.5
DMZSDGX FM C19H35NO2
DMZSDGX IC InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
DMZSDGX CS CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
DMZSDGX IK CURUTKGFNZGFSE-UHFFFAOYSA-N
DMZSDGX IU 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
DMZSDGX CA CAS 77-19-0
DMZSDGX CB CHEBI:4514
DMZSDGX DE Functional bowel syndrome
DMI2QPE ID DMI2QPE
DMI2QPE DN Didanosine
DMI2QPE HS Approved
DMI2QPE SN didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927
DMI2QPE CP Bristol-Myers Squibb
DMI2QPE TC Anti-HIV Agents
DMI2QPE DT Small molecular drug
DMI2QPE PC 135398739
DMI2QPE MW 236.23
DMI2QPE FM C10H12N4O3
DMI2QPE IC InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
DMI2QPE CS C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
DMI2QPE IK BXZVVICBKDXVGW-NKWVEPMBSA-N
DMI2QPE IU 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMI2QPE CA CAS 69655-05-6
DMI2QPE CB CHEBI:490877
DMI2QPE DE Human immunodeficiency virus infection
DMBSXI0 ID DMBSXI0
DMBSXI0 DN Dienestrol
DMBSXI0 HS Approved
DMBSXI0 SN Agaldog; Cycladiene; Dehydrostilbestrol; Dehydrostilboestrol; Dienesterol; Dienestrolo; Dienestrolum; Dienoestrol; Dienol; Dinestrol; Dinovex; Estragard; Estraguard; Estrodienol; Estroral; Follidiene; Follormon; Gynefollin; Hormofemin; Isodienestrol; Oestrasid; Oestrodiene; Oestrodienol; Oestroral; Oestrovis; Restrol; Retalon; Sexadien; Synestrol; Teserene; Willnestrol; Dienestrolo [DCIT]; Dienoestrol [Nonsteroidal oestrogens]; Dienoestrol bp; Alpha-Dienestrol; DV (TN); Dienestrolum [INN-Latin]; Para-Dien; Restrol, Dienestrol; Dienestrol (E,E); Dienestrol (USP/INN); Dienestrol, (E,E)-Isomer; P,p'-(Diethylideneethylene)diphenol; Para,para'-(Diethylideneethylene)diphenol; Di(p-oxyphenyl)-2,4-hexadiene; Di(para-oxyphenyl)-2,4-hexadiene; Phenol, 4,4'-(1,2-diethylidene-1,2-ethanediyl)bis-, (E,E-(9CI); (E,E)-Dienestrol; 3,4-Bis(4-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(p-hydroxyphenyl)-2,4-hexadiene; 3,4-Bis(para-hydroxyphenyl)-2,4-hexadiene; 4,4'-(1,2-Diethylidene-1,2-ethanediyl)bisphenol; 4,4'-(2E,4E)-hexa-2,4-diene-3,4-diyldiphenol; 4,4'-(Diethylideneethylene)diphenol; 4,4'-Dihydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-Hydroxy-gamma,delta-diphenyl-beta,delta-hexadiene; 4,4'-hexa-2,4-diene-3,4-diyldiphenol; 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0 TC Estrogens
DMBSXI0 DT Small molecular drug
DMBSXI0 PC 667476
DMBSXI0 MW 266.3
DMBSXI0 FM C18H18O2
DMBSXI0 IC InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3/b17-3+,18-4+
DMBSXI0 CS C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\\C2=CC=C(C=C2)O
DMBSXI0 IK NFDFQCUYFHCNBW-SCGPFSFSSA-N
DMBSXI0 IU 4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
DMBSXI0 CA CAS 13029-44-2
DMBSXI0 CB CHEBI:4518
DMBSXI0 DE Atrophic vaginitis
DM1TJ8F ID DM1TJ8F
DM1TJ8F DN Diethylcarbamazine
DM1TJ8F HS Approved
DM1TJ8F SN Bitirazine; Camin; Caracide; Carbamazine; Carbilazine; Caricide; Cypip; Decacide; Diaethylcarbamazinum; Diethylcarbamazinum; Dietilcarbamazina; Ethodryl; Luxuran; Notezine; Spatonin; Diethyl carbamazine; Ditrazine Base; Banocide (TN); Camin (TN); Carbilazine (TN); Caricide (TN); Cypip (TN); Diethylcarbamazine (INN); Diethylcarbamazine [INN:BAN]; Diethylcarbamazinum [INN-Latin]; Dietilcarbamazina [INN-Spanish]; Ethodryl (TN); FR-1031; Filaribits (TN); Forte (TN); Hetrazan (TN); Spatonin (TN); N,N-Diethyl-4-methyl-1-piperazinecarboxamide; N,N-diethyl-4-methylpiperazine-1-carboxamide; 1-Diethylcarbamyl-4-methylpiperazine; 84L
DM1TJ8F CP Lederle Laboratories Div American Cyanamid Co
DM1TJ8F TC Anthelmintics
DM1TJ8F DT Small molecular drug
DM1TJ8F PC 3052
DM1TJ8F MW 199.29
DM1TJ8F FM C10H21N3O
DM1TJ8F IC InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3
DM1TJ8F CS CCN(CC)C(=O)N1CCN(CC1)C
DM1TJ8F IK RCKMWOKWVGPNJF-UHFFFAOYSA-N
DM1TJ8F IU N,N-diethyl-4-methylpiperazine-1-carboxamide
DM1TJ8F CA CAS 90-89-1
DM1TJ8F CB CHEBI:4527
DM1TJ8F DE Lymphatic filariasis
DMN3UXQ ID DMN3UXQ
DMN3UXQ DN Diethylstilbestrol
DMN3UXQ HS Approved
DMN3UXQ SN Acnestrol; Agostilben; Antigestil; Apstil; Bufon; Climaterine; Comestrol; Cyren; DES; Desma; Destrol; Diaethylstilboestrolum; Diastyl; Dibestrol; Dicorvin; Diethylstilbesterol; Diethylstilbestrolum; Diethylstilboesterol; Dietilestilbestrol; Dietilstilbestrolo; Distilbene; Domestrol; Dyestrol; Estril; Estrobene; Estrogenine; Estromenin; Estrosyn; Fonatol; Grafestrol; Gynopharm; Hibestrol; Idroestril; Iscovesco; Makarol; Menostilbeen; Micrest; Microest; Milestrol; OeKolp; Oestrogenine; Oestrolmensil; Oestromenin; Oestromensil; Oestromensyl; Oestromienin; Oestromon; Pabestrol; Palestrol; Protectona; Sedestran; Serral; Sexocretin; Sibol; Sintestrol; Stibilium; Stilbestroform; Stilbestrol; Stilbestrone; Stilbetin; Stilboefral; Stilboestroform; Stilboestrol; Stilbofolin; Stilbofollin; Stilbol; Stilkap; Strobene; Synestrin; Synthestrin; Synthoestrin; Synthofolin; Syntofolin; Tampovagan; Tylosterone; Vagestrol; APS Brand of Diethylstilbestrol; Anti gestil; Co Pharma Brand of Diethylstilbestrol; Comestrol estrobene; Cyren A; Diethylstilbestrol BP; Dietilestilbestrol [Spanish]; Dietilstilbestrolo [DCIT]; Estilbin MCO; Gerda Brand of Diethylstilbestrol; Oestrol vetag; Percutatrine oestrogenique iscovesco; ST IL; Stilbene Estrogen; Tampovagan stilboestrol; DiBestrol 2 Premix; MG 137; Rumestrol 1; Rumestrol 2; Cis-Des; Cis-Diethylstilbesterol; Cis-Diethylstilbestrol; Co-Pharma Brand of Diethylstilbestrol; DES (synthetic estrogen); Dawe's destrol; Di-Estryl; Diethylstilbestrol (DES); Diethylstilbestrol [USAN:INN]; Diethylstilbestrol, Disodium Salt; Diethylstilbestrolum [INN-Latin]; Dietilestilbestrol [INN-Spanish]; E-Diethylstilbestrol; Estilbin (MCO); Estrogen, Stilbene; Hi-Bestrol; Neo-Oestranol 1; Neo-Oestranol I; Neo-oe stranol 1; New-Estranol 1; Stil-Rol; Stilbestrol (TN); TRANS-DIETHYSTILBESTEROL; TRANSGENIC MODEL EVALUATION (DES); Trans-Diethylstilbesterol; Trans-Diethylstilbestrol; Trans-Diethylstilboesterol; DiBestrol "2" Premix; Dibestrol '2' premix; Diethylstilbestrol (USP/INN); Alpha,alpha'-Diethylstilbenediol; Diethylstilbestrol, (Z)-Isomer; Alpha,alpha'-Diethyl-4,4'-stilbenediol; (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene; (E)-4,4'-(hex-3-ene-3,4-diyl)diphenol; (E)-Diethylstilbestrol; 3,4'(4,4'-Dihydroxyphenyl)hex-3-ene; 3,4-Bis(p-hydroxyphenyl)-3-hexene; 3,4-bis(4-hydroxyphenyl)hex-3-ene; 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol; 4,4'-Dihydroxydiethylstilbene; 4,4'-hex-3-ene-3,4-diyldiphenol
DMN3UXQ CP Bayer Pharmaceuticals Corp
DMN3UXQ TC Anticancer Agents
DMN3UXQ DT Small molecular drug
DMN3UXQ PC 448537
DMN3UXQ MW 268.3
DMN3UXQ FM C18H20O2
DMN3UXQ IC InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+
DMN3UXQ CS CC/C(=C(/CC)\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O
DMN3UXQ IK RGLYKWWBQGJZGM-ISLYRVAYSA-N
DMN3UXQ IU 4-[(E)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
DMN3UXQ CA CAS 56-53-1
DMN3UXQ CB CHEBI:41922
DMN3UXQ DE Gonorrheal vaginitis
DMI9PRJ ID DMI9PRJ
DMI9PRJ DN Diflorasone
DMI9PRJ HS Approved
DMI9PRJ SN Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
DMI9PRJ CP Pharmacia And Upjohn Co
DMI9PRJ TC Antiinflammatory Agents
DMI9PRJ DT Small molecular drug
DMI9PRJ PC 71415
DMI9PRJ MW 410.5
DMI9PRJ FM C22H28F2O5
DMI9PRJ IC InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
DMI9PRJ CS C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F
DMI9PRJ IK WXURHACBFYSXBI-XHIJKXOTSA-N
DMI9PRJ IU (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMI9PRJ CA CAS 2557-49-5
DMI9PRJ CB CHEBI:59750
DMI9PRJ DE Rosacea
DM7EN8I ID DM7EN8I
DM7EN8I DN Diflunisal
DM7EN8I HS Approved
DM7EN8I SN Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid
DM7EN8I CP Merck & Co
DM7EN8I TC Analgesics
DM7EN8I DT Small molecular drug
DM7EN8I PC 3059
DM7EN8I MW 250.2
DM7EN8I FM C13H8F2O3
DM7EN8I IC InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
DM7EN8I CS C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
DM7EN8I IK HUPFGZXOMWLGNK-UHFFFAOYSA-N
DM7EN8I IU 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
DM7EN8I CA CAS 22494-42-4
DM7EN8I CB CHEBI:39669
DM7EN8I DE Pain
DMMFVB3 ID DMMFVB3
DMMFVB3 DN Difluprednate
DMMFVB3 HS Approved
DMMFVB3 SN Durezol (TN)
DMMFVB3 CP Sirion
DMMFVB3 DT Small molecular drug
DMMFVB3 PC 443936
DMMFVB3 MW 508.5
DMMFVB3 FM C27H34F2O7
DMMFVB3 IC InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
DMMFVB3 CS CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C
DMMFVB3 IK WYQPLTPSGFELIB-JTQPXKBDSA-N
DMMFVB3 IU [(6S,8S,9R,10S,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
DMMFVB3 CA CAS 23674-86-4
DMMFVB3 CB CHEBI:31485
DMMFVB3 DE Ocular pain
DMWVIGP ID DMWVIGP
DMWVIGP DN Digitoxin
DMWVIGP HS Approved
DMWVIGP SN Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]
DMWVIGP TC Antiarrhythmic Agents
DMWVIGP DT Small molecular drug
DMWVIGP PC 441207
DMWVIGP MW 764.9
DMWVIGP FM C41H64O13
DMWVIGP IC InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
DMWVIGP CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
DMWVIGP IK WDJUZGPOPHTGOT-XUDUSOBPSA-N
DMWVIGP IU 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMWVIGP CA CAS 71-63-6
DMWVIGP CB CHEBI:28544
DMWVIGP DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DMQCTIH ID DMQCTIH
DMQCTIH DN Digoxin
DMQCTIH HS Approved
DMQCTIH SN digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin
DMQCTIH CP GlaxoSmithKline
DMQCTIH TC Antiarrhythmic Agents
DMQCTIH DT Small molecular drug
DMQCTIH PC 2724385
DMQCTIH MW 780.9
DMQCTIH FM C41H64O14
DMQCTIH IC InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
DMQCTIH CS C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
DMQCTIH IK LTMHDMANZUZIPE-PUGKRICDSA-N
DMQCTIH IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMQCTIH CA CAS 20830-75-5
DMQCTIH CB CHEBI:4551
DMQCTIH DE Heart failure; Arrhythmia; Congestive cardiac insufficiency
DMZIXU9 ID DMZIXU9
DMZIXU9 DN Dihydralazine
DMZIXU9 HS Approved
DMZIXU9 SN Dihydralazine sulfate; 7327-87-9; Dihydralazine sulphate; 1,4-Dihydrazinophthalazine sulfate; Depressan; Hydralazine sulfate; Ophthazin Sulfate; UNII-1C2B1W91NK; CCRIS 5386; Sulfate de dihydralazine [French]; 1,4-Dihydrazinylphthalazine Sulfate; EINECS 230-808-0; 1C2B1W91NK; Phthalazine, 1,4-dihydrazino-, sulfate (1:1); 1,4-Dihydrazinophthalazine hydrogen sulfate; W-104459; Sulfate de dihydralazine; 1,4-dihydrazinophthalazine sulfate(1:1); Dihydralazinsulfat; C8H10N6.H2O4S; Nepresol (TN); Dihydralazine Sulfate,(S); AC1Q6XE2
DMZIXU9 DT Small molecular drug
DMZIXU9 PC 10230
DMZIXU9 MW 190.21
DMZIXU9 FM C8H10N6
DMZIXU9 IC InChI=1S/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)
DMZIXU9 CS C1=CC=C2C(=C1)C(=NN=C2NN)NN
DMZIXU9 IK VQKLRVZQQYVIJW-UHFFFAOYSA-N
DMZIXU9 IU (4-hydrazinylphthalazin-1-yl)hydrazine
DMZIXU9 CA CAS 484-23-1
DMZIXU9 CB CHEBI:134841
DMZIXU9 DE Hypertension
DMBXVMZ ID DMBXVMZ
DMBXVMZ DN Dihydroartemisinin
DMBXVMZ HS Approved
DMBXVMZ SN Artenimol; Cotecxin; Dihydroartemisinine; Dihydroqinghaosu; Dihydroquinghaosu; Dihydroquinghoasu; VM3352; Artenimol (INN); JAV-110; GNF-PF-5634; (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol; [3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin; 1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)
DMBXVMZ DT Small molecular drug
DMBXVMZ PC 3000518
DMBXVMZ MW 284.35
DMBXVMZ FM C15H24O5
DMBXVMZ IC InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1
DMBXVMZ CS C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C
DMBXVMZ IK BJDCWCLMFKKGEE-ISOSDAIHSA-N
DMBXVMZ IU (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
DMBXVMZ CA CAS 71939-50-9
DMBXVMZ CB CHEBI:135921
DMBXVMZ DE Malaria
DM5SQ1G ID DM5SQ1G
DM5SQ1G DN Dihydroergocristine
DM5SQ1G HS Approved
DM5SQ1G SN Nehydrin
DM5SQ1G CP Sanochemia Pharmazeutika AG
DM5SQ1G DT Small molecular drug
DM5SQ1G PC 107715
DM5SQ1G MW 611.7
DM5SQ1G FM C35H41N5O5
DM5SQ1G IC InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1
DM5SQ1G CS CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5SQ1G IK DEQITUUQPICUMR-HJPBWRTMSA-N
DM5SQ1G IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5SQ1G CA CAS 17479-19-5
DM5SQ1G CB CHEBI:59912
DM5SQ1G DE Alcohol dependence
DM5IKUF ID DM5IKUF
DM5IKUF DN Dihydroergotamine
DM5IKUF HS Approved
DM5IKUF SN Migranal (TN)
DM5IKUF CP Pfizer Pharmaceuticals
DM5IKUF TC Antimigraine Agents
DM5IKUF DT Small molecular drug
DM5IKUF PC 10531
DM5IKUF MW 583.7
DM5IKUF FM C33H37N5O5
DM5IKUF IC InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
DM5IKUF CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
DM5IKUF IK LUZRJRNZXALNLM-JGRZULCMSA-N
DM5IKUF IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM5IKUF CA CAS 511-12-6
DM5IKUF CB CHEBI:4562
DM5IKUF DE Migraine
DM5D6WZ ID DM5D6WZ
DM5D6WZ DN Dihydroergotoxine
DM5D6WZ HS Approved
DM5D6WZ SN Ergotamine, dihydro, methanesulfonate (salt)
DM5D6WZ TC Vasodilator Agents
DM5D6WZ DT Small molecular drug
DM5D6WZ PC 6420006
DM5D6WZ MW 679.8
DM5D6WZ FM C34H41N5O8S
DM5D6WZ IC InChI=1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1
DM5D6WZ CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5CC6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
DM5D6WZ IK ADYPXRFPBQGGAH-WVVAGBSPSA-N
DM5D6WZ IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
DM5D6WZ CA CAS 11032-41-0
DM5D6WZ DE Alzheimer disease
DMFB97P ID DMFB97P
DMFB97P DN Dihydrotachysterol
DMFB97P HS Approved
DMFB97P SN Antitanil; Calcamine; Dichystrolum; Dihidrotaquisterol; Dihydral; Dihydrotachysterolum; Diidrotachisterolo; Dygratyl; Hytakerol; Parterol; Tachyrol; Tachystin; Dht Intensol; Diidrotachisterolo [DCIT]; AT 10; DHT2; Anti-tetany substance 10; Dht(sub 2); Dihidrotaquisterol [INN-Spanish]; Dihydrotachysterol(sub 2); Dihydrotachysterolum [INN-Latin]; Dihydrotachysterol [INN:BAN:JAN]; (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (1S,3E,4S)-3-[(2E)-2-[(3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3E)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; (3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol; (3Z)-3-[(2E)-2-[1-[(E)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol; 9,10-Secoergosta-5,7,22-trien-3beta-ol
DMFB97P TC Antihypoparathyroid Agents
DMFB97P DT Small molecular drug
DMFB97P PC 5311071
DMFB97P MW 398.7
DMFB97P FM C28H46O
DMFB97P IC InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1
DMFB97P CS C[C@H]\\1CC[C@@H](C/C1=C\\C=C\\2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C)O
DMFB97P IK ILYCWAKSDCYMBB-OPCMSESCSA-N
DMFB97P IU (1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
DMFB97P CA CAS 67-96-9
DMFB97P CB CHEBI:4591
DMFB97P DE Hypocalcemia
DMM1LG2 ID DMM1LG2
DMM1LG2 DN Dihydroxyacetone
DMM1LG2 HS Approved
DMM1LG2 SN 1,3-dihydroxyacetone; Dihydroxyacetone; 96-26-4; 1,3-Dihydroxypropan-2-one; Chromelin; 1,3-Dihydroxy-2-propanone; glycerone; Triulose; Viticolor; Soleal; Oxatone; Dihyxal; Oxantin; Otan; 2-Propanone, 1,3-dihydroxy-; 1,3-Dihydroxypropanone; 1,3-Dihydroxydimethyl ketone; NSC-24343; Ketochromin; Bis(hydroxymethyl) ketone; UNII-O10DDW6JOO; dihydroxy-acetone; 2-Propanone, 1,3-dihydroxy; BRN 1740268; CCRIS 4899; AI3-24477; Dihydroxyacetone [USP]; EINECS 202-494-5; O10DDW6JOO; 1,2-Dihydroxy-2-propanone; CHEBI:16016; RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2 DT Small molecular drug
DMM1LG2 PC 670
DMM1LG2 MW 90.08
DMM1LG2 FM C3H6O3
DMM1LG2 IC InChI=1S/C3H6O3/c4-1-3(6)2-5/h4-5H,1-2H2
DMM1LG2 CS C(C(=O)CO)O
DMM1LG2 IK RXKJFZQQPQGTFL-UHFFFAOYSA-N
DMM1LG2 IU 1,3-dihydroxypropan-2-one
DMM1LG2 CA CAS 96-26-4
DMM1LG2 CB CHEBI:16016
DMM1LG2 DE Sunburn
DM8YXKW ID DM8YXKW
DM8YXKW DN Dihydroxyaluminium
DM8YXKW HS Approved
DM8YXKW SN (2-Aminoacetoxy)dihydroxyaluminum; Dihydroxyaluminium glycinate; Dihydroxyaluminum aminoacetate; 41354-48-7; Robalate; Prodexin; Hyperacid; Alilac; (Glycinato)dihydroxyaluminum; Alminate; (T-4)-(Glycinato-N,O)dihydroxyaluminum; Dihydroxyaluminum aminoacetate [USAN:USP]; C2H6AlNO4; Dihydroxoaluminium glycinat; Aluminum glycinate, AldrichCPR; DTXSID3044546; (Glycinato-N,O)dihydroxyaluminum; 51484-68-5 (proacid); MolPort-023-220-319; 13682-92-3 (Parent); (Glycinato)dihydroxyaluminum hydrate; EINECS 237-193-8; Aluminum, (glycinato-N
DM8YXKW TC Antiinflammatory Agents
DM8YXKW DT Small molecular drug
DM8YXKW PC 16683036
DM8YXKW MW 137.07
DM8YXKW FM C2H8AlNO4
DM8YXKW IC InChI=1S/C2H5NO2.Al.2H2O/c3-1-2(4)5;;;/h1,3H2,(H,4,5);;2*1H2/q;+1;;/p-1
DM8YXKW CS C(C(=O)O[Al])N.O.O
DM8YXKW IK RBNPZEHAODHBPZ-UHFFFAOYSA-M
DM8YXKW CA CAS 13682-92-3
DM8YXKW DE Skin inflammation
DMAI7ZV ID DMAI7ZV
DMAI7ZV DN Diltiazem
DMAI7ZV HS Approved
DMAI7ZV SN Acalix; Adizem; Aldizem; Anoheal; Cardil; Cardizem; Citizem; Dilacor; Dilcontin; Dilren; Diltia; Diltiazemum; Dilticard; Diltzac; Dilzen; Endrydil; Viazem; Cardizen LA; Incoril AP; Tiazac Tildiem; Tiazac XC; Adizem (TN); Altiazem (TN); Angiozem (TN); Angizem (TN); Angizem CD (TN); Apo-Diltiaz; Cardizem (Hydrochloride); Cardizem (TN); Cartia XT (TN); Dilacor-XR; Dilatam (TN); Dilatem (TN); Dilcardia (TN); Dilcontin SR (TN); Dilt-cd; Dilta-Hexal; Diltelan (TN); Diltiazem (INN); Diltiazem [INN:BAN]; Diltiazemum [INN-Latin]; Diltime (TN); Dilzem (TN); Dyalec (TN); Filazem (TN); Herben (TN); Nu-Diltiaz; Progor (TN); RG 83606 (Hydrochloride); Surazem (TN); Tiamate (TN); Tiazac (TN); Tiazac XC (TN); Tildiem (TN); Vasmulax (TN); Viazem (TN); Zandil (TN); Zemtrial (TN); D-cis-Diltiazem; MK-793 (Malate); [(2S,3S)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester; (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate; (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
DMAI7ZV CP Valeant International Barbados Srl
DMAI7ZV TC Antihypertensive Agents
DMAI7ZV DT Small molecular drug
DMAI7ZV PC 39186
DMAI7ZV MW 414.5
DMAI7ZV FM C22H26N2O4S
DMAI7ZV IC InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1
DMAI7ZV CS CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMAI7ZV IK HSUGRBWQSSZJOP-RTWAWAEBSA-N
DMAI7ZV IU [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMAI7ZV CA CAS 56209-45-1
DMAI7ZV CB CHEBI:101278
DMAI7ZV DE Hypertension
DM264B3 ID DM264B3
DM264B3 DN Dimenhydrinate
DM264B3 HS Approved
DM264B3 SN Gravamin (TN); Gravol (TN); Vertirosan (TN); Dimenhydrinate (JP15/USP/INN); 2-(diphenylmethoxy)-N,N-dimethylethanaminium 8-chloro-1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide; 2-benzhydryloxyethyl(dimethyl)azanium; 8-chloro-1,3-dimethyl-2-oxopurin-6-olate; 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione-2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
DM264B3 CP Carter-Horner Corp.
DM264B3 TC Antiemetics
DM264B3 DT Small molecular drug
DM264B3 PC 10660
DM264B3 MW 470
DM264B3 FM C24H28ClN5O3
DM264B3 IC InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10)
DM264B3 CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DM264B3 IK NFLLKCVHYJRNRH-UHFFFAOYSA-N
DM264B3 IU 2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione
DM264B3 CA CAS 523-87-5
DM264B3 CB CHEBI:94848
DM264B3 DE Nausea
DM32YAI ID DM32YAI
DM32YAI DN Dimethindene
DM32YAI HS Approved
DM32YAI SN Dimethpyrindene; Dimethylpyrindene; Dimetindene; Dimetindeno; Dimetindenum; Fengel; Fenistil; Forhistal; Foristal; Pecofenil; Triten; Z 2001; Dimetindene (INN); Dimetindene [INN:BAN]; Dimetindeno [INN-Spanish]; Dimetindenum [INN-Latin]; Fenistil (TN); Dimethyl{2-[3-(2-pyridylethyl)inden-2-yl]ethyl}amine; N,N-Dimethyl-3-(1-(2-pyridyl)ethyl)inden-2-ethylamin; N,N-Dimethyl-N-(3-(1-(2-pyridyl)ethyl)-2-indenylethyl)amin; N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine; 1H-Indene-2-ethanamine, N,N-dimethyl-3-(1-(2-pyridinyl)ethyl)-(9CI); 2-(1-(2-(2-Dimethylaminoethyl)inden-3-yl)ethyl)pyridine
DM32YAI TC Antiallergic Agents
DM32YAI DT Small molecular drug
DM32YAI PC 21855
DM32YAI MW 292.4
DM32YAI FM C20H24N2
DM32YAI IC InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3
DM32YAI CS CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
DM32YAI IK MVMQESMQSYOVGV-UHFFFAOYSA-N
DM32YAI IU N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine
DM32YAI CA CAS 5636-83-9
DM32YAI CB CHEBI:135222
DM32YAI DE Respiratory allergy
DMXQKSL ID DMXQKSL
DMXQKSL DN Dinoprost Tromethamine
DMXQKSL HS Approved
DMXQKSL SN Dinolytic; Ensaprost; Lutalyse; Prostamate; Zinoprost; Panacelan F tromethamine salt; Pronalgon F; Prostalmon F; PGF2alpha THAM; PGF2alpha tromethamine; PROSTAGLANDIN F2ALPHA TRIS SALT; Prostaglandin F2a tromethamine; Prostaglandin F2alpha tham; Prostaglandin F2alpha tromethamine; Prostin F2 alpha; U 14585; Dinoprost tromethamine [USAN:JAN]; Dinoprost, trometamol salt; Enzaprost F compd. with trisamine; Lutalyse (Veterinary); PGF2-alpha tham; PGF2-alpha tris salt; PGF2-alpha tromethamine; PGF2-alpha tromethamine salt; PGF2alpha-Tris; Prostaglandin F(sub 2a) tromethamine; Prostaglandin F-2alpha tromethamine salt; Prostaglandin F2-alpha THAM; Prostaglandin F2-alpha THAM salt; Prostaglandin F2-alpha tromethamine; Prostin F2 alpha (TN); THAM PGF2-alpha; Tromethamine prostaglandin F2-alpha; U-14583E; Dinoprost tromethamine (JAN/USP); Protaglandin F2-alpha-tham salt; U-14,583E; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-, compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-,compd. with trimethylolaminomethane; Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9alpha,11alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt; (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1); (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, (5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oate (salt); 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, tham; 7-(3,5-Dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid, tromethamine salt
DMXQKSL TC Abortifacient Agents
DMXQKSL DT Small molecular drug
DMXQKSL PC 5282415
DMXQKSL MW 475.6
DMXQKSL FM C24H45NO8
DMXQKSL IC InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1
DMXQKSL CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
DMXQKSL IK IYGXEHDCSOYNKY-RZHHZEQLSA-N
DMXQKSL IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
DMXQKSL CA CAS 38562-01-5
DMXQKSL CB CHEBI:31502
DMXQKSL DE Abortion
DMTYOPD ID DMTYOPD
DMTYOPD DN Dinoprostone
DMTYOPD HS Approved
DMTYOPD SN Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
DMTYOPD CP Pfizer Pharmaceuticals
DMTYOPD TC Prostaglandins
DMTYOPD DT Small molecular drug
DMTYOPD PC 5280360
DMTYOPD MW 352.5
DMTYOPD FM C20H32O5
DMTYOPD IC InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1
DMTYOPD CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMTYOPD IK XEYBRNLFEZDVAW-ARSRFYASSA-N
DMTYOPD IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMTYOPD CA CAS 363-24-6
DMTYOPD CB CHEBI:15551
DMTYOPD DE Medical abortion
DMXVU6D ID DMXVU6D
DMXVU6D DN Diphemanil Methylsulfate
DMXVU6D HS Approved
DMXVU6D SN Demotil; Diphemanil; Diphemanilum; Diphenatil; Diphenmethanil; Nivelon; Nivelona; Prantal; Prantil; Prentol; Talpran; Vagophemanil; Variton; Diphemanil methosulfate; Diphemanil methyl sulfate; Diphemanil methylsulphate; Diphemanil metilsulfate; Diphemanili metilsulfas; Diphenmanil methyl sulfate; Diphenmanil methylsulfate; Diphenmethanil methyl sulfate; Diphenmethanil methylsulfate; Metilsulfate de diphemanil; Metilsulfato de difemanilo; Prantal methylsulfate; Vagophemanil methyl sulfate; Ban-guard; Diphemanil methylsulfate [INN:BAN]; Diphemanil metilsulfate (INN); Diphemanili metilsulfas [INN-Latin]; Metilsulfate de diphemanil [INN-French]; Metilsulfato de difemanilo [INN-Spanish]; Prantal (TN); Ban-Guard (Veterinary); P-(alpha-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; N,N-Dimethyl-4-piperidylidene-1,1-diphenylmethane methylsulfate; P-(alpha.-Phenylbenzylidene)-1,1-dimethylpiperidinium methyl sulfate; Piperidinium, 4-(diphenylmethylene)-1,1-dimethyl-, methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methyl sulfate; 4-(Diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate; 4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate; 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium
DMXVU6D TC Parasympatholytics
DMXVU6D DT Small molecular drug
DMXVU6D PC 6126
DMXVU6D MW 389.5
DMXVU6D FM C21H27NO4S
DMXVU6D IC InChI=1S/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMXVU6D CS C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-]
DMXVU6D IK BREMLQBSKCSNNH-UHFFFAOYSA-M
DMXVU6D IU 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium;methyl sulfate
DMXVU6D CA CAS 62-97-5
DMXVU6D CB CHEBI:59782
DMXVU6D DE Peptic ulcer
DMKQTBA ID DMKQTBA
DMKQTBA DN Diphenhydramine
DMKQTBA HS Approved
DMKQTBA SN diphenhydramine; 58-73-1; Benadryl; Benzhydramine; Probedryl; Alledryl; Antistominum; Dihidral; 2-(Benzhydryloxy)-N,N-dimethylethanamine; Benzhydraminum; Benzhydroamina; Diphantine; Difenhydramin; Ibiodral; Difedryl; Dibondrin; Mephadryl; Desentol; Dermistina; Betramin; Benzhydril; Benzantine; Benachlor; Bagodryl; Syntedril; Novamina; Medidryl; Hyadrine; Histaxin; Etanautine; Drylistan; Diabylen; Diabenyl; Dermodrin; Benodine; Baramine; Allergical; Debendrin; Benadrin; Dabylen; Antomin; Nausen; Benapon; Dylamon; Benylin; Benylan; Benodin; Amidryl; Aleryl; Allerdryl; Allergeval; Allergina; Allergival; Antitussive; Automin; Banophen; Beldin; Belix; Bena; Benhydramin; Benzhydryl; Compoz; Dibendrin; Dibenil; Difenhidramina; Difenidramina; Dimedrol; Dimedryl; Dimehydrinate; Diphen; Diphenhist; Diphenhydraminum; Diphenylhydramin; Diphenylhydramine; Dryistan; Genahist; Hydramine; Hyrexin; Restamin; Rigidil; Siladryl; Silphen; Syntodril; Allergan B; Allermax Caplets; BENADRYL HCl; Banophen Caplets; Benadryl Allergy; Difenidramina [Italian]; Dimedrol base; Diphen Cough; Diphenhist Captabs; Diphenhydramine Base; Diphenhydramine HCl; Nytol Quickcaps; Nytol Quickgels;Twilite Caplets; Unisom Sleepgels Maximum Strength; Dormarex 2; FAR 90X2; PM 255; S51; Aller-Med; Ben-allergin; Benadryl (TN); Benadryl (hydrochloride); Beta-Dimethylaminoethanol diphenylmethyl ether; Beta-Dimethylaminoethylbenzhydrylether; Beta-dimethylaminoethyl benzhydryl ether; Difenhidramina [INN-Spanish]; Dimedrol (TN); Diphenhydraminum [INN-Latin]; Nervine Nighttime Sleep-Aid; Nytol (TN); O-Benzhydryldimethylaminoethanol; Restamin (TN); Sleep-Eze D; Sleep-Eze D Extra Strength; DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE; Diphenhydramine (JP15/INN); Diphenhydramine [INN:BAN:JAN]; Alpha-(2-Dimethylaminoethoxy)diphenylmethane; N-(Benzhydryloksy-etylo)dwumetyloamina; N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]; Beta-Dimethylamino-aethyl-benzhydryl-aether; Beta-Dimethylamino-aethyl-benzhydryl-aether [German]; N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride; N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE; N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine; 2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride; 2-(Diphenylmethoxy)-N,N-dimethylethylamine; 2-(diphenylmethoxy)-N,N-dimethylethanamine; 2-Diphenylmethoxy-N,N-dimethylethylamine; 2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine; 2-benzhydryloxy-N,N-dimethylethanamine; 2-benzhydryloxyethyl-N,N-dimethylammonium; 2-diphenylmethoxy-N,N-demthylethanamine; 2PM
DMKQTBA CP Johnson & Johnson
DMKQTBA TC Antiallergic Agents
DMKQTBA DT Small molecular drug
DMKQTBA PC 3100
DMKQTBA MW 255.35
DMKQTBA FM C17H21NO
DMKQTBA IC InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
DMKQTBA CS CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
DMKQTBA IK ZZVUWRFHKOJYTH-UHFFFAOYSA-N
DMKQTBA IU 2-benzhydryloxy-N,N-dimethylethanamine
DMKQTBA CA CAS 58-73-1
DMKQTBA CB CHEBI:4636
DMKQTBA DE Meniere disease
DMHPWOM ID DMHPWOM
DMHPWOM DN Diphenidol
DMHPWOM HS Approved
DMHPWOM SN Avomol; Defenidol; Difenidol; Difenidolo; Difenidolum; Nometic; Vontrol; Difenidol HCl; Difenidolo [DCIT]; SKF 478; Difenidolum [INN-Latin]; Diphenidol [USAN:BAN]; SK-478; Diphenidol (USAN/INN); SK&F-478; Alpha,alpha-Diphenyl-1-piperidinebutanol; Diphenyl(3-(1-piperidyl)propyl)carbinol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol; 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol hydrochloride
DMHPWOM DT Small molecular drug
DMHPWOM PC 3055
DMHPWOM MW 309.4
DMHPWOM FM C21H27NO
DMHPWOM IC InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2
DMHPWOM CS C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O
DMHPWOM IK OGAKLTJNUQRZJU-UHFFFAOYSA-N
DMHPWOM IU 1,1-diphenyl-4-piperidin-1-ylbutan-1-ol
DMHPWOM CA CAS 972-02-1
DMHPWOM CB CHEBI:4638
DMHPWOM DE Nausea
DMO5SZX ID DMO5SZX
DMO5SZX DN Diphenoxylate
DMO5SZX HS Approved
DMO5SZX SN Difenossilato; Difenoxilato; Diphenoxalate; Diphenoxylatum; Difenossilato [DCIT]; Difenoxilato [Spanish]; Diphenoxylate HCl; Diphenoxylate Monohydrochloride; Diphenoxylate hydrochloride; Diphenoxylatum [Latin]; NIH 7562; R 1132; Difenoxilato [INN-Spanish]; Diphenoxylate (INN); Diphenoxylate [INN:BAN]; Diphenoxylate hydrochloride (USP); Diphenoxylate hydrochloride(usp); Diphenoxylatum [INN-Latin]; R 1132 (antiperistaltic); R-1132; Co-phenotrope (TN); Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate hydrochloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; Ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidin-1-ium-4-carboxylate chloride; Isonipecotic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, hydrochloride; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenyl-isonipecotic acid ethyl ester; 1-(3-Cyano-3,3-diphenylpropyl)-4-phenylisonipecotic acid ethyl ester hydrochloride; 1-(3-cyano-3,3-diphenylpropyl)-4-(ethoxycarbonyl)-4-phenylpiperidinium chloride; 2,2-Diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile; 4-Ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile, hydrochloride; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester; 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester (9CI); 4-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-4-phenyl-, ethyl ester, monohydrochloride; 4-ethoxycarbonyl-alpha,alpha,4-triphenyl-1-piperidinebutyronitrile hydrochloride
DMO5SZX CP Janssen Pharmaceutica
DMO5SZX TC Analgesics
DMO5SZX DT Small molecular drug
DMO5SZX PC 13505
DMO5SZX MW 452.6
DMO5SZX FM C30H32N2O2
DMO5SZX IC InChI=1S/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3
DMO5SZX CS CCOC(=O)C1(CCN(CC1)CCC(C#N)(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMO5SZX IK HYPPXZBJBPSRLK-UHFFFAOYSA-N
DMO5SZX IU ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
DMO5SZX CA CAS 915-30-0
DMO5SZX CB CHEBI:4639
DMO5SZX DE Diarrhea
DMW4X37 ID DMW4X37
DMW4X37 DN Diphenylpyraline
DMW4X37 HS Approved
DMW4X37 SN Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine
DMW4X37 TC Antihistamines
DMW4X37 DT Small molecular drug
DMW4X37 PC 3103
DMW4X37 MW 281.4
DMW4X37 FM C19H23NO
DMW4X37 IC InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
DMW4X37 CS CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3
DMW4X37 IK OWQUZNMMYNAXSL-UHFFFAOYSA-N
DMW4X37 IU 4-benzhydryloxy-1-methylpiperidine
DMW4X37 CA CAS 147-20-6
DMW4X37 CB CHEBI:59788
DMW4X37 DE Allergic rhinitis
DM0FSIM ID DM0FSIM
DM0FSIM DN Diphtheria-tetanus vaccine
DM0FSIM HS Approved
DM0FSIM SN Diphtheria-tetanus vaccine (im suspension), Finlay Institute
DM0FSIM CP Finlay Institute
DM0FSIM DT Vaccine
DM0FSIM DE Clostridium infection
DMH5W0G ID DMH5W0G
DMH5W0G DN Dipivefrin
DMH5W0G HS Approved
DMH5W0G SN AKPro; Dipivefrina; Dipivefrine; Dipivefrinum; Propine; Dipivalyl epinephrine; Dipivefrin HCL; Dipivefrin [USAN]; K 30081; Dipivefrin (USAN); Dipivefrina [INN-Spanish]; Dipivefrine (INN); Dipivefrinum [INN-Latin]; Ophtho-Dipivefrin; Propine C Cap B.I.D.; [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate; (+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate; (+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; (-)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester; (-)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat; (RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol; 2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat; 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
DMH5W0G CP Allergan Pharmaceutical
DMH5W0G TC Ophthalmologicals
DMH5W0G DT Small molecular drug
DMH5W0G PC 3105
DMH5W0G MW 351.4
DMH5W0G FM C19H29NO5
DMH5W0G IC InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3
DMH5W0G CS CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C
DMH5W0G IK OCUJLLGVOUDECM-UHFFFAOYSA-N
DMH5W0G IU [2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
DMH5W0G CA CAS 52365-63-6
DMH5W0G CB CHEBI:4646
DMH5W0G DE Chronic open-angle glaucoma
DMXY30O ID DMXY30O
DMXY30O DN Dipyridamole
DMXY30O HS Approved
DMXY30O SN Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
DMXY30O CP FISCHER and ROCH
DMXY30O TC Vasodilator Agents
DMXY30O DT Small molecular drug
DMXY30O PC 3108
DMXY30O MW 504.6
DMXY30O FM C24H40N8O4
DMXY30O IC InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
DMXY30O CS C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
DMXY30O IK IZEKFCXSFNUWAM-UHFFFAOYSA-N
DMXY30O IU 2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
DMXY30O CA CAS 58-32-2
DMXY30O CB CHEBI:4653
DMXY30O DE Hypertension
DM0D9YJ ID DM0D9YJ
DM0D9YJ DN Dirithromycin
DM0D9YJ HS Approved
DM0D9YJ SN Dirithromycine; Dirithromycinum; Diritromicina; Divitross; Dynabac; Noriclan; Valodin; Dirithromycine [French]; Dirithromycinum [Latin]; Diritromicina [Spanish]; LY 237216; AS-E 136; ASE-136; Dynabac (TN); LY-237216; Dirithromycin (USP/INN); Dirithromycin [USAN:BAN:INN]; (9S)-9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]erythromycin
DM0D9YJ TC Antibiotics
DM0D9YJ DT Small molecular drug
DM0D9YJ PC 6473883
DM0D9YJ MW 835.1
DM0D9YJ FM C42H78N2O14
DM0D9YJ IC InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1
DM0D9YJ CS CC[C@@H]1[C@@]([C@H]2[C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O
DM0D9YJ IK WLOHNSSYAXHWNR-DWIOZXRMSA-N
DM0D9YJ IU (1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2,10-dihydroxy-7-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-15-(2-methoxyethoxymethyl)-2,6,8,10,12,17-hexamethyl-4,16-dioxa-14-azabicyclo[11.3.1]heptadecan-5-one
DM0D9YJ CA CAS 62013-04-1
DM0D9YJ CB CHEBI:474014
DM0D9YJ DE Bacterial infection
DM5SYZP ID DM5SYZP
DM5SYZP DN Disopyramide
DM5SYZP HS Approved
DM5SYZP SN Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP CP Gd Searle Llc
DM5SYZP TC Antiarrhythmic Agents
DM5SYZP DT Small molecular drug
DM5SYZP PC 3114
DM5SYZP MW 339.5
DM5SYZP FM C21H29N3O
DM5SYZP IC InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
DM5SYZP CS CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
DM5SYZP IK UVTNFZQICZKOEM-UHFFFAOYSA-N
DM5SYZP IU 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
DM5SYZP CA CAS 3737-09-5
DM5SYZP CB CHEBI:4657
DM5SYZP DE Ventricular arrhythmias; Urinary incontinence
DMCL2OK ID DMCL2OK
DMCL2OK DN Disulfiram
DMCL2OK HS Approved
DMCL2OK SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMCL2OK CP Odyssey Pharmaceuticals
DMCL2OK TC Alcohol Deterrents
DMCL2OK DT Small molecular drug
DMCL2OK PC 3117
DMCL2OK MW 296.5
DMCL2OK FM C10H20N2S4
DMCL2OK IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMCL2OK CS CCN(CC)C(=S)SSC(=S)N(CC)CC
DMCL2OK IK AUZONCFQVSMFAP-UHFFFAOYSA-N
DMCL2OK IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMCL2OK CA CAS 97-77-8
DMCL2OK CB CHEBI:4659
DMCL2OK DE Alcohol dependence
DM4RK0G ID DM4RK0G
DM4RK0G DN Divalproex sodium
DM4RK0G HS Approved
DM4RK0G SN Delepsine; Depakote; Divalproate; Divalproex; Epilex; Epival; Sprinkle; Valcote; Valdisoval; Valparin; Depakote CP; Depakote ER; Depakote Sprinkle; Divalproex sodium [USAN]; Sodium divalproate; Sodium hydrogen divalproate; Valproate semisodique; Valproate semisodique [French]; Valproate semisodium; Valproato semisodico; Valproato semisodico [Spanish]; Valproatum seminatricum; Valproatum seminatricum [Latin]; Abbott 50711; Abbott-50711; Depacon (TN); Depakote (TN); Depakote ER (TN); Divalproex sodium (USP); Epival (TN); Ergenyl Chrono (TN); Valance (TN); Valproate semisodium (INN); Divalproex sodium, Depakote, Epival; Natrium hydrogen bis(2-propylvalerat); Sodium hydrogen bis(2-propylpentanoate); Sodium hydrogen bis(2-propylvalerate); Valproic acid semisodium salt (2:1); Zalkote. (TN); Sodium hydrogen bis(2-propylvalerate), oligomer; Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1); Pentanoic acid, 2-propyl-, sodium salt (2:1); Pentanoic acid, 2-propyl-, sodium salt(2:1); 2-propylpentanoate
DM4RK0G CP Abbott Laboratories
DM4RK0G TC Anticonvulsants
DM4RK0G DT Small molecular drug
DM4RK0G PC 23663956
DM4RK0G MW 310.4
DM4RK0G FM C16H31NaO4
DM4RK0G IC InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1
DM4RK0G CS CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
DM4RK0G IK MSRILKIQRXUYCT-UHFFFAOYSA-M
DM4RK0G IU sodium;2-propylpentanoate;2-propylpentanoic acid
DM4RK0G CA CAS 76584-70-8
DM4RK0G CB CHEBI:4667
DM4RK0G DE Seizure disorder
DMD1B8Z ID DMD1B8Z
DMD1B8Z DN Dobutamine
DMD1B8Z HS Approved
DMD1B8Z SN Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z CP Ben Venue Laboratories
DMD1B8Z TC Cardiotonic Agents
DMD1B8Z DT Small molecular drug
DMD1B8Z PC 36811
DMD1B8Z MW 301.4
DMD1B8Z FM C18H23NO3
DMD1B8Z IC InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
DMD1B8Z CS CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
DMD1B8Z IK JRWZLRBJNMZMFE-UHFFFAOYSA-N
DMD1B8Z IU 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
DMD1B8Z CA CAS 34368-04-2
DMD1B8Z CB CHEBI:4670
DMD1B8Z DE Heart failure
DMS5IEB ID DMS5IEB
DMS5IEB DN Docarpamine
DMS5IEB HS Approved
DMS5IEB SN Tanadopa (TN)
DMS5IEB DT Small molecular drug
DMS5IEB PC 71137
DMS5IEB MW 470.5
DMS5IEB FM C21H30N2O8S
DMS5IEB IC InChI=1S/C21H30N2O8S/c1-5-28-20(26)30-17-8-7-15(13-18(17)31-21(27)29-6-2)9-11-22-19(25)16(10-12-32-4)23-14(3)24/h7-8,13,16H,5-6,9-12H2,1-4H3,(H,22,25)(H,23,24)/t16-/m0/s1
DMS5IEB CS CCOC(=O)OC1=C(C=C(C=C1)CCNC(=O)[C@H](CCSC)NC(=O)C)OC(=O)OCC
DMS5IEB IK ZLVMAMIPILWYHQ-INIZCTEOSA-N
DMS5IEB IU [4-[2-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]ethyl]-2-ethoxycarbonyloxyphenyl] ethyl carbonate
DMS5IEB CA CAS 74639-40-0
DMS5IEB CB CHEBI:31513
DMS5IEB DE Hypertension
DMDI269 ID DMDI269
DMDI269 DN Docetaxel
DMDI269 HS Approved
DMDI269 SN EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
DMDI269 CP Sanofi-Aventis
DMDI269 TC Anticancer Agents
DMDI269 DT Small molecular drug
DMDI269 PC 148124
DMDI269 MW 807.9
DMDI269 FM C43H53NO14
DMDI269 IC InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
DMDI269 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
DMDI269 IK ZDZOTLJHXYCWBA-VCVYQWHSSA-N
DMDI269 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDI269 CA CAS 114977-28-5
DMDI269 CB CHEBI:4672
DMDI269 DE Solid tumour/cancer
DMOHK1E ID DMOHK1E
DMOHK1E DN Docosanol
DMOHK1E HS Approved
DMOHK1E SN Abreva; Debat; Doconsanol; Erazaban; Healip; Herepair; Lidakol; Lidavol; Tadenan; Behenic alcohol; Behenyl alcohol; Docosanol [USAN]; Docosyl alcohol; IK 2; Lanette 22; NAA 422; Stenol 1822; Stenol 1822A; Abreva (TN); Docosanol (USAN); Docosanol (VAN); Erazaban (TN); IK.2; N-Docosanol; Nacol 22-97; V-1326;BEHENYL ALCOHOL, 98%; Docosan-1-ol; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 1-DOCOSANOL
DMOHK1E CP Avanir Pharmaceuticals
DMOHK1E TC Antiviral Agents
DMOHK1E DT Small molecular drug
DMOHK1E PC 12620
DMOHK1E MW 326.6
DMOHK1E FM C22H46O
DMOHK1E IC InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3
DMOHK1E CS CCCCCCCCCCCCCCCCCCCCCCO
DMOHK1E IK NOPFSRXAKWQILS-UHFFFAOYSA-N
DMOHK1E IU docosan-1-ol
DMOHK1E CA CAS 661-19-8
DMOHK1E CB CHEBI:31000
DMOHK1E DE Herpes simplex virus infection
DMPN1TW ID DMPN1TW
DMPN1TW DN Dofetilide
DMPN1TW HS Approved
DMPN1TW SN Dofetilida; Dofetilidum; Tikosyn; Xelide; UK 68798; Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin];Tikosyn (TN); UK 68,798; UK-68798; Dofetilide [USAN:BAN:INN]; Tikosyn, UK68798, Dofetilide; UK-68,798; Dofetilide (JAN/USAN/INN); Beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide; N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl); 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane; 1-MSPMPE
DMPN1TW CP Pfizer Pharmaceuticals
DMPN1TW TC Antiarrhythmic Agents
DMPN1TW DT Small molecular drug
DMPN1TW PC 71329
DMPN1TW MW 441.6
DMPN1TW FM C19H27N3O5S2
DMPN1TW IC InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
DMPN1TW CS CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
DMPN1TW IK IXTMWRCNAAVVAI-UHFFFAOYSA-N
DMPN1TW IU N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
DMPN1TW CA CAS 115256-11-6
DMPN1TW CB CHEBI:4681
DMPN1TW DE Sinus rhythm disorder
DMMG26Z ID DMMG26Z
DMMG26Z DN Dolasetron
DMMG26Z HS Approved
DMMG26Z SN Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate
DMMG26Z CP Aventis Pharmaceuticals Inc.
DMMG26Z TC Antiemetics
DMMG26Z DT Small molecular drug
DMMG26Z PC 3033818
DMMG26Z MW 324.4
DMMG26Z FM C19H20N2O3
DMMG26Z IC InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11?,12-,13+,14?
DMMG26Z CS C1[C@@H]2CC(C[C@H]3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54
DMMG26Z IK UKTAZPQNNNJVKR-AKJUYKBHSA-N
DMMG26Z IU [(3S,7R)-10-oxo-8-azatricyclo[5.3.1.03,8]undecan-5-yl] 1H-indole-3-carboxylate
DMMG26Z CA CAS 115956-12-2
DMMG26Z CB CHEBI:94561
DMMG26Z DE Nausea
DMCZGRE ID DMCZGRE
DMCZGRE DN Dolutegravir
DMCZGRE HS Approved
DMCZGRE SN 1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (
DMCZGRE CP GlaxoSmithKline
DMCZGRE DT Small molecular drug
DMCZGRE PC 54726191
DMCZGRE MW 419.4
DMCZGRE FM C20H19F2N3O5
DMCZGRE IC InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
DMCZGRE CS C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMCZGRE IK RHWKPHLQXYSBKR-BMIGLBTASA-N
DMCZGRE IU (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
DMCZGRE CA CAS 1051375-16-6
DMCZGRE CB CHEBI:76010
DMCZGRE DE Human immunodeficiency virus infection
DMBDPY0 ID DMBDPY0
DMBDPY0 DN Domperidone
DMBDPY0 HS Approved
DMBDPY0 SN Domperidon; Domperidona; Domperidonum; Motilium; Nauzelin; KW 5338; NCI299589; Costi (TN); D-122; Domperidona [INN-Spanish]; Domperidonum [INN-Latin]; HS-0067; KW-5338; Motilium (TN); Motillium (TN); Motinorm (TN); R 33,812; R-33812; R-33,812; Domperidone (JAN/USAN/INN); Domperidone [USAN:BAN:INN:JAN]; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone; 5-Chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone; 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one; 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0 CP Janssen Pharmaceutica
DMBDPY0 TC Antiemetics
DMBDPY0 DT Small molecular drug
DMBDPY0 PC 3151
DMBDPY0 MW 425.9
DMBDPY0 FM C22H24ClN5O2
DMBDPY0 IC InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
DMBDPY0 CS C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
DMBDPY0 IK FGXWKSZFVQUSTL-UHFFFAOYSA-N
DMBDPY0 IU 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMBDPY0 CA CAS 57808-66-9
DMBDPY0 CB CHEBI:31515
DMBDPY0 DE Gastrointestinal disease
DMIYG7Z ID DMIYG7Z
DMIYG7Z DN Donepezil
DMIYG7Z HS Approved
DMIYG7Z SN Donepezil (transdermal patch, Alzheimer's disease)
DMIYG7Z CP Nitto Denko Corp
DMIYG7Z TC Neurology Agents
DMIYG7Z DT Small molecular drug
DMIYG7Z PC 3152
DMIYG7Z MW 379.5
DMIYG7Z FM C24H29NO3
DMIYG7Z IC InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3
DMIYG7Z CS COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
DMIYG7Z IK ADEBPBSSDYVVLD-UHFFFAOYSA-N
DMIYG7Z IU 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
DMIYG7Z CA CAS 120014-06-4
DMIYG7Z CB CHEBI:53289
DMIYG7Z DE Alzheimer disease
DMPGUCF ID DMPGUCF
DMPGUCF DN Dopamine
DMPGUCF HS Approved
DMPGUCF SN Dopamin; Dopamina; Dopaminum; Dophamine; Hydroxytyramin; Hydroxytyramine; Intropin; LDP; Oxytyramine; Revimine; ASL 279; IP 498; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine [INN:BAN]; Dopaminum [INN-Latin]; L-DOPAMINE; M-Hydroxytyramine hydrochloride; Medopa (TN); Intropin [*hydrochloride*]; KW-3-060; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamine (USAN)(*hydrochloride*); A-(3,4-Dihydroxyphenyl)-b-aminoethane; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; (3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol
DMPGUCF CP Baxter Healthcare Corp Anesthesia And Critical Care
DMPGUCF TC Cardiotonic Agents
DMPGUCF DT Small molecular drug
DMPGUCF PC 681
DMPGUCF MW 153.18
DMPGUCF FM C8H11NO2
DMPGUCF IC InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
DMPGUCF CS C1=CC(=C(C=C1CCN)O)O
DMPGUCF IK VYFYYTLLBUKUHU-UHFFFAOYSA-N
DMPGUCF IU 4-(2-aminoethyl)benzene-1,2-diol
DMPGUCF CA CAS 51-61-6
DMPGUCF CB CHEBI:18243
DMPGUCF DE Parkinson disease; Hypotension
DMSCIKZ ID DMSCIKZ
DMSCIKZ DN Dopexamine
DMSCIKZ HS Approved
DMSCIKZ SN Dopacard (TN)
DMSCIKZ DT Small molecular drug
DMSCIKZ PC 55483
DMSCIKZ MW 356.5
DMSCIKZ FM C22H32N2O2
DMSCIKZ IC InChI=1S/C22H32N2O2/c25-21-11-10-20(18-22(21)26)13-17-24-15-7-2-1-6-14-23-16-12-19-8-4-3-5-9-19/h3-5,8-11,18,23-26H,1-2,6-7,12-17H2
DMSCIKZ CS C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O
DMSCIKZ IK RYBJORHCUPVNMB-UHFFFAOYSA-N
DMSCIKZ IU 4-[2-[6-(2-phenylethylamino)hexylamino]ethyl]benzene-1,2-diol
DMSCIKZ CA CAS 86197-47-9
DMSCIKZ CB CHEBI:135507
DMSCIKZ DE Cardiac failure
DM9UCJK ID DM9UCJK
DM9UCJK DN Doripenem
DM9UCJK HS Approved
DM9UCJK SN Doribax; S 4661; S-4661; Doripenem (USAN/INN); (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK CP Shionogi; penisula
DM9UCJK DT Small molecular drug
DM9UCJK PC 73303
DM9UCJK MW 420.5
DM9UCJK FM C15H24N4O6S2
DM9UCJK IC InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1
DM9UCJK CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O
DM9UCJK IK AVAACINZEOAHHE-VFZPANTDSA-N
DM9UCJK IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9UCJK CA CAS 148016-81-3
DM9UCJK CB CHEBI:135928
DM9UCJK DE Urinary tract infection; Gram-positive bacterial infection
DM3XU74 ID DM3XU74
DM3XU74 DN Dornase Alfa
DM3XU74 HS Approved
DM3XU74 SN Pulmozyme (TN)
DM3XU74 CP Genentech
DM3XU74 TC Enzyme Replacement Agents
DM3XU74 SQ Dornase alfa sequence: LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK
DM3XU74 DE Cystic fibrosis
DMA17D0 ID DMA17D0
DMA17D0 DN Dorzolamide
DMA17D0 HS Approved
DMA17D0 SN Trusopt; Dorzolamide (DZA); Dorzolamide (INN); Trusopt (TN); (4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide; (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide; (4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; (4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
DMA17D0 CP Merck & Co
DMA17D0 TC Antihypertensive Agents
DMA17D0 DT Small molecular drug
DMA17D0 PC 5284549
DMA17D0 MW 324.4
DMA17D0 FM C10H16N2O4S3
DMA17D0 IC InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1
DMA17D0 CS CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
DMA17D0 IK IAVUPMFITXYVAF-XPUUQOCRSA-N
DMA17D0 IU (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMA17D0 CA CAS 120279-96-1
DMA17D0 CB CHEBI:4702
DMA17D0 DE Open-angle glaucoma
DM78NWP ID DM78NWP
DM78NWP DN Dostarlimab
DM78NWP HS Approved
DM78NWP CP AnaptysBio; GlaxoSmithKline
DM78NWP DT Antibody
DM78NWP DE Endometrial cancer; Multiple myeloma; Breast cancer; Neoplasm
DMKE7L9 ID DMKE7L9
DMKE7L9 DN Doxacurium
DMKE7L9 HS Approved
DMKE7L9 SN Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride
DMKE7L9 CP Abbott Laboratories
DMKE7L9 TC Analgesics
DMKE7L9 DT Small molecular drug
DMKE7L9 PC 60169
DMKE7L9 MW 1035.2
DMKE7L9 FM C56H78N2O16+2
DMKE7L9 IC InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2
DMKE7L9 CS C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C
DMKE7L9 IK GBLRQXKSCRCLBZ-UHFFFAOYSA-N
DMKE7L9 IU bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
DMKE7L9 CA CAS 133814-18-3
DMKE7L9 CB CHEBI:4706
DMKE7L9 DE Spasm
DMCYANK ID DMCYANK
DMCYANK DN Doxapram
DMCYANK HS Approved
DMCYANK SN Docatone; Dopram; Doxapramum; Doxapram HCL; Doxapram hydrochloride; Docatone (TN); Dopram (TN); Doxapram (INN); Doxapram [USP:JAN]; Doxapramum [INN-Latin]; (+-)-doxapram; 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone; 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one; 1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-one; 2-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-(9CI)
DMCYANK TC Central Nervous System Stimulants
DMCYANK DT Small molecular drug
DMCYANK PC 3156
DMCYANK MW 378.5
DMCYANK FM C24H30N2O2
DMCYANK IC InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3
DMCYANK CS CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
DMCYANK IK XFDJYSQDBULQSI-UHFFFAOYSA-N
DMCYANK IU 1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one
DMCYANK CA CAS 309-29-5
DMCYANK CB CHEBI:681848
DMCYANK DE Respiratory disease
DM9PLRH ID DM9PLRH
DM9PLRH DN Doxazosin
DM9PLRH HS Approved
DM9PLRH SN Doxazosina; Doxazosine; Doxazosinum; Normothen; Doxazosina [Spanish]; Doxazosine [French]; Doxazosinum [Latin]; UK 33274; Cardura (TN); Cardura XL (TN); Cardura-1; Cardura-2; Cardura-4; Carduran (TN); Doxazosin (INN); Doxazosin [INN:BAN]; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine; 2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
DM9PLRH CP Pfizer Pharmaceuticals
DM9PLRH TC Antihypertensive Agents
DM9PLRH DT Small molecular drug
DM9PLRH PC 3157
DM9PLRH MW 451.5
DM9PLRH FM C23H25N5O5
DM9PLRH IC InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
DM9PLRH CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
DM9PLRH IK RUZYUOTYCVRMRZ-UHFFFAOYSA-N
DM9PLRH IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
DM9PLRH CA CAS 74191-85-8
DM9PLRH CB CHEBI:4708
DM9PLRH DE Hypertension
DMPI98T ID DMPI98T
DMPI98T DN Doxepin
DMPI98T HS Approved
DMPI98T SN Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin
DMPI98T CP Pfizer Pharmaceuticals
DMPI98T TC Antidepressants
DMPI98T DT Small molecular drug
DMPI98T PC 667477
DMPI98T MW 279.4
DMPI98T FM C19H21NO
DMPI98T IC InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
DMPI98T CS CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31
DMPI98T IK ODQWQRRAPPTVAG-GZTJUZNOSA-N
DMPI98T IU (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
DMPI98T CA CAS 1668-19-5
DMPI98T DE Depression
DM6FG1P ID DM6FG1P
DM6FG1P DN Doxercalciferol
DM6FG1P HS Approved
DM6FG1P SN Doxcercalciferol; Hectorol; Doxercalciferol [INN]; TSA 840; BCI-101; Doxercalciferol (INN); Hectorol (TN); (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol; 1-Hydroxyergocalciferol; 1-alpha-Hydroxyvitamin D2; 1alpha-Hydroxyergocalciferol; 1alpha-OH-D2; 9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5Z,7E,22E)
DM6FG1P CP Genzyme
DM6FG1P DT Small molecular drug
DM6FG1P PC 5281107
DM6FG1P MW 412.6
DM6FG1P FM C28H44O2
DM6FG1P IC InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
DM6FG1P CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM6FG1P IK HKXBNHCUPKIYDM-CGMHZMFXSA-N
DM6FG1P IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM6FG1P CA CAS 54573-75-0
DM6FG1P CB CHEBI:4712
DM6FG1P DE Chronic kidney disease
DMEDKZH ID DMEDKZH
DMEDKZH DN Doxofylline
DMEDKZH HS Approved
DMEDKZH SN Ansimar (TN)
DMEDKZH CP ABC S.p.A.
DMEDKZH DT Small molecular drug
DMEDKZH PC 50942
DMEDKZH MW 266.25
DMEDKZH FM C11H14N4O4
DMEDKZH IC InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
DMEDKZH CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
DMEDKZH IK HWXIGFIVGWUZAO-UHFFFAOYSA-N
DMEDKZH IU 7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
DMEDKZH CA CAS 69975-86-6
DMEDKZH CB CHEBI:94714
DMEDKZH DE Asthma
DMVP5YE ID DMVP5YE
DMVP5YE DN Doxorubicin
DMVP5YE HS Approved
DMVP5YE SN doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
DMVP5YE CP Sequus Pharmaceuticals Inc
DMVP5YE TC Anticancer Agents
DMVP5YE DT Small molecular drug
DMVP5YE PC 31703
DMVP5YE MW 543.5
DMVP5YE FM C27H29NO11
DMVP5YE IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
DMVP5YE CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMVP5YE IK AOJJSUZBOXZQNB-TZSSRYMLSA-N
DMVP5YE IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMVP5YE CA CAS 23214-92-8
DMVP5YE CB CHEBI:28748
DMVP5YE DE Solid tumour/cancer; Tumour; Breast cancer; Hepatocellular carcinoma
DM7ICNU ID DM7ICNU
DM7ICNU DN Doxycycline
DM7ICNU HS Approved
DM7ICNU SN Atridox; Azudoxat; DOXY; Deoxymykoin; Dossiciclina; Doxiciclina; Doxitard; Doxivetin; Doxycen; Doxychel; Doxycin; Doxycyclin; Doxycyclinum; Doxysol; Doxytec; Doxytetracycline; Hydramycin; Investin; Jenacyclin; Liviatin; Monodox; Oracea; Ronaxan; Spanor; Supracyclin; Vibramycin; Vibramycine; Vibravenos; DOXCYCLINE ANHYDROUS; DOXYCYCLINE CALCIUM; DOXYCYCLINE MONOHYDRATE; Dossiciclina [DCIT]; Doxiciclina [Italian]; Doxycycline anhydrous; Doxycycline hyclate; Vibramycin Novum; Alpha-Doxycycline; Alti-Doxycycline; Apo-Doxy; BMY-28689; BU-3839T; Doxiciclina [INN-Spanish]; Doxy-Caps; Doxy-Puren; Doxy-Tabs; Doxychel (TN); Doxycycline (INN); Doxycycline (TN); Doxycycline (anhydrous); Doxycycline (internal use); Doxycycline-Chinoin; Doxycyclinum [INN-Latin]; Novo-Doxylin; Nu-Doxycycline; Periostat (TN); Vibra-tabs; Alpha-6-Deoxyoxytetracycline; DMSC (*Fosfatex); Doxycycline (200mg/day) or Placebo; Monodox (*monohydrate); Vibramycin (*monohydrate); Vivox (*Hyclate); GS-3065 (*monohydrate); Alpha-6-Deoxy-5-hydroxytetracycline; (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS); 5-Hydroxy-alpha-6-deoxytetracycline; 6-Deoxyoxytetracycline; 6-Deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline; 6alpha-Deoxy-5-oxytetracycline
DM7ICNU CP Collagenex
DM7ICNU TC Antiinflammatory Agents
DM7ICNU DT Small molecular drug
DM7ICNU PC 54671203
DM7ICNU MW 444.4
DM7ICNU FM C22H24N2O8
DM7ICNU IC InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25-27,30,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
DM7ICNU CS C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DM7ICNU IK SGKRLCUYIXIAHR-AKNGSSGZSA-N
DM7ICNU IU (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM7ICNU CA CAS 564-25-0
DM7ICNU CB CHEBI:50845
DM7ICNU DE Chronic periodontitis; Advanced gum disease; Diabetic foot ulcer
DMKOXFE ID DMKOXFE
DMKOXFE DN Doxylamine
DMKOXFE HS Approved
DMKOXFE SN Dossilamina; Doxilamina; Doxilminio; Doxylaminum; Dossilamina [DCIT]; Diclectin (TN); Dolased (TN); Donormyl (TN); Dormidina (TN); Doxilminio [INN-Spanish]; Doxylamine (INN); Doxylamine [INN:BAN]; Doxylaminum [INN-Latin]; Dozile (TN); Evanorm (TN); Mersyndol (TN); Restavit (TN); Somnil (TN); Syndol (TN); Unisom-2 (TN); Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether; N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine; N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine; N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine; N,N-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine; 2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine; 2-Dimethylaminoethoxyphenylmethyl-2-picoline
DMKOXFE CP Ion Healthcare
DMKOXFE TC Hypnotics and Sedatives
DMKOXFE DT Small molecular drug
DMKOXFE PC 3162
DMKOXFE MW 270.37
DMKOXFE FM C17H22N2O
DMKOXFE IC InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
DMKOXFE CS CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
DMKOXFE IK HCFDWZZGGLSKEP-UHFFFAOYSA-N
DMKOXFE IU N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
DMKOXFE CA CAS 469-21-6
DMKOXFE CB CHEBI:51380
DMKOXFE DE Morning sickness
DMGOXPQ ID DMGOXPQ
DMGOXPQ DN DP-VPA
DMGOXPQ HS Approved
DMGOXPQ SN TVA; RAP-valproate; SPD-421; Valproic acid prodrug, Shire; RAP-valproate, D-Pharm
DMGOXPQ CP D-Pharm Ltd
DMGOXPQ DE Bipolar disorder
DMF2JDG ID DMF2JDG
DMF2JDG DN Dromostanolone
DMF2JDG HS Approved
DMF2JDG SN Drostanolo; Drostanolon; Drostanolona; Drostanolone; Drostanolonum; Medrosteron; Medrotestron; Methalone; Metholone; Prometholone; Drostanolo [DCIT]; SKI 27719; Drolban (TN); Drostanolona [INN-Spanish]; Drostanolone [INN:BAN]; Drostanolonum [INN-Latin]; Dihydro-2alpha-methyltestosterone; Dihydro-2-alpha-methyltestosterone; Dihydro-2.alpha.-methyltestosterone; Androstan-3-one, 17-hydroxy-2-methyl-, (2alpha,5alpha,17beta)-(9CI); (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; (2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one; 17 beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one; 17-beta-Hydroxy-2-alpha-methyl-5-alpha-androstan-3-one; 17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one; 2-alpha-Methyl-17-beta-hydroxy-5-alpha-androstan-3-one; 2-alpha-Methyldihydrotestosterone; 2.alpha.-Methyldihydrotestosterone; 2a-methylandrostan-17b-ol-3-one; 2alpha-Methyldihydrotestosterone
DMF2JDG CP Eli Lilly And Co
DMF2JDG TC Anabolic Agents
DMF2JDG DT Small molecular drug
DMF2JDG PC 6011
DMF2JDG MW 304.5
DMF2JDG FM C20H32O2
DMF2JDG IC InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1
DMF2JDG CS C[C@@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C)CC1=O)C
DMF2JDG IK IKXILDNPCZPPRV-RFMGOVQKSA-N
DMF2JDG IU (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DMF2JDG CA CAS 58-19-5
DMF2JDG CB CHEBI:34838
DMF2JDG DE Mammary tumour
DMA8FS5 ID DMA8FS5
DMA8FS5 DN Dronedarone
DMA8FS5 HS Approved
DMA8FS5 SN Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide
DMA8FS5 CP Sanofi-Synthelabo
DMA8FS5 DT Small molecular drug
DMA8FS5 PC 208898
DMA8FS5 MW 556.8
DMA8FS5 FM C31H44N2O5S
DMA8FS5 IC InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
DMA8FS5 CS CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
DMA8FS5 IK ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
DMA8FS5 IU N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
DMA8FS5 CA CAS 141626-36-0
DMA8FS5 CB CHEBI:50659
DMA8FS5 DE Angina pectoris; Atrial fibrillation
DM0DXA8 ID DM0DXA8
DM0DXA8 DN Droperidol
DM0DXA8 HS Approved
DM0DXA8 SN DHBP; Dehidrobenzperidol; Dehydrobenzoperidol; Dehydrobenzperidol; Deidrobenzperidolo; Dihidrobenzperidol; Dridol; Droleptan; Droperidolo; Droperidolum; Halkan; Inappin; Inapsin; Inapsine; Innovan; Inopsin; Inoval; Leptanal; Leptofen; Properidol; Sintodril; Sintosian; Thalamanol; Thalamonal; Vetkalm; Component of Innovar; Droperidolo [DCIT]; Janssen Brand of Droperidol; Kern Brand of Droperidol; Taylor Brand of Droperidol; R 4749; R4749; Dridol (TN); Droleptan (TN); Droperidolum [INN-Latin]; Dropletan (TN); HS-0065; INAPSINE (TN); Inapsine (TN); Innovar-vet; McN-JR 4749; R-4749; Ina.psi.n; Ina.psi.ne; Ino.psi.n; McN-JR-4749; Droperidol (JP15/USP/INN); Droperidol [USAN:INN:BAN:JAN]; Luorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-(1-(4-(4-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone; 1-1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl-2-benzimidazolinone; 1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-[1-[4-(p-F; 1-[1-[4-(p-Fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 2-Benzimidazolinone, 1-[1-[3-(p-fluorobenz; 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8 CP Janssen Pharmaceutica
DM0DXA8 TC Antipsychotic Agents
DM0DXA8 DT Small molecular drug
DM0DXA8 PC 3168
DM0DXA8 MW 379.4
DM0DXA8 FM C22H22FN3O2
DM0DXA8 IC InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
DM0DXA8 CS C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
DM0DXA8 IK RMEDXOLNCUSCGS-UHFFFAOYSA-N
DM0DXA8 IU 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one
DM0DXA8 CA CAS 548-73-2
DM0DXA8 CB CHEBI:4717
DM0DXA8 DE Nausea
DM1A9W3 ID DM1A9W3
DM1A9W3 DN Drospirenone
DM1A9W3 HS Approved
DM1A9W3 SN DRSP; Dehydrospirorenone; Dihydrospirorenone; Drospirenona; Drospirenonum; Drospirenone [INN]; ZK 30595; ZK30595; Angeliq, Drospirenone; Drospirenona [INN-Spanish]; Drospirenonum [INN-Latin]; SH-470; ZK-30595; Drospirenone (JAN/USAN/INN); (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6a,7,8,9,10,11,12,13,14,15,15a,16-Hexadecahydro-10,13-dimethylspiro-(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione; 1,2-Dihydrospirorenone; 1,2-dihydro-spirorenone; 17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid, gamma-lactone; 3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-7'H,16'H-dicyclopropa[6,7;15,16]-17alpha-pregn-4-ene-21,17-carbolactone; 6-beta,7-beta;15-beta,16-beta-Dimethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactone; 6beta,7beta,15beta,16beta-dimethylen-3-oxo-17alpha-pregn-4-en-21,17-carbolacton; 6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone; 6beta,7beta;15beta,16beta-Dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone; Spiro(17H-dicyclopropa(6,7:15,16)cyclopenta(a)phenanthrene-17,2'(5'H)-furan)-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (6R-(6alpha,7alpha,8beta,9alpha,10beta,13beta,14alpha,15alpha,16alpha,17beta
DM1A9W3 TC Contraceptive Agents
DM1A9W3 DT Small molecular drug
DM1A9W3 PC 68873
DM1A9W3 MW 366.5
DM1A9W3 FM C24H30O3
DM1A9W3 IC InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
DM1A9W3 CS C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C
DM1A9W3 IK METQSPRSQINEEU-HXCATZOESA-N
DM1A9W3 IU (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
DM1A9W3 CA CAS 67392-87-4
DM1A9W3 CB CHEBI:50838
DM1A9W3 DE Contraception
DM59JCN ID DM59JCN
DM59JCN DN Drotrecogin alfa
DM59JCN HS Approved
DM59JCN SN Xigris; Drotrecogin alfa (activated); Xigris (TN); Drotrecogin alfa (activated) (USAN)
DM59JCN CP Eli Lilly
DM59JCN TC Antisepsis Agents
DM59JCN SQ Heavy chain: LIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP >Light chainSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL
DM59JCN DE Cerebrovascular ischaemia; Severe sepsis
DM5YF4M ID DM5YF4M
DM5YF4M DN Droxidopa
DM5YF4M HS Approved
DM5YF4M SN droxidopa; 23651-95-8; L-DOPS; Northera; (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid; threo-Dopaserine; 3916-18-5; DOPS; DL-threo-DOPS; L-Threodops; DL-threo-3,4-Dihydroxyphenylserine; DL-threo-Droxidopa; DL-threo-Dihydroxyphenylserine; UNII-J7A92W69L7; SM 5688; CHEBI:31524; Droxidopa (L-DOPS); threo-beta,3-Dihydroxy-DL-tyrosine; EINECS 223-480-5; beta,3-Dihydroxy-DL-tyrosine threo-; BRN 2852792; L-threo-dihydroxyphenylserine; DL-threo-3-(3,4-Dihydroxyphenyl)serine; Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-
DM5YF4M CP Chelsea Therapeutics
DM5YF4M DT Small molecular drug
DM5YF4M PC 92974
DM5YF4M MW 213.19
DM5YF4M FM C9H11NO5
DM5YF4M IC InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
DM5YF4M CS C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O
DM5YF4M IK QXWYKJLNLSIPIN-JGVFFNPUSA-N
DM5YF4M IU (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
DM5YF4M CA CAS 23651-95-8
DM5YF4M CB CHEBI:31524
DM5YF4M DE Neurogenic orthostatic hypotension
DMXZRW0 ID DMXZRW0
DMXZRW0 DN DTI-015
DMXZRW0 HS Approved
DMXZRW0 SN Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics
DMXZRW0 CP Direct Therapeutics Inc
DMXZRW0 DT Small molecular drug
DMXZRW0 PC 2578
DMXZRW0 MW 214.05
DMXZRW0 FM C5H9Cl2N3O2
DMXZRW0 IC InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
DMXZRW0 CS C(CCl)NC(=O)N(CCCl)N=O
DMXZRW0 IK DLGOEMSEDOSKAD-UHFFFAOYSA-N
DMXZRW0 IU 1,3-bis(2-chloroethyl)-1-nitrosourea
DMXZRW0 CA CAS 154-93-8
DMXZRW0 CB CHEBI:3423
DMXZRW0 DE Liver cancer; Brain cancer
DMCIJBH ID DMCIJBH
DMCIJBH DN DU-176B
DMCIJBH HS Approved
DMCIJBH SN Edoxaban
DMCIJBH CP Daiichi Sankyo
DMCIJBH DT Small molecular drug
DMCIJBH PC 25022378
DMCIJBH MW 738.3
DMCIJBH FM C31H40ClN7O8S2
DMCIJBH IC InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1
DMCIJBH CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O
DMCIJBH IK PSMMNJNZVZZNOI-SJILXJHISA-N
DMCIJBH IU N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate
DMCIJBH CA CAS 1229194-11-9
DMCIJBH CB CHEBI:85974
DMCIJBH DE Atrial fibrillation
DMYXBV3 ID DMYXBV3
DMYXBV3 DN Dulaglutide
DMYXBV3 HS Approved
DMYXBV3 SN GLP-1 analog
DMYXBV3 CP Eli Lilly
DMYXBV3 SQ Dulaglutide Sequence: HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
DMYXBV3 DE Type-2 diabetes
DM9BI7M ID DM9BI7M
DM9BI7M DN Duloxetine
DM9BI7M HS Approved
DM9BI7M SN Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine
DM9BI7M CP Eli Lilly
DM9BI7M TC Antidepressants
DM9BI7M DT Small molecular drug
DM9BI7M PC 60835
DM9BI7M MW 297.4
DM9BI7M FM C18H19NOS
DM9BI7M IC InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
DM9BI7M CS CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
DM9BI7M IK ZEUITGRIYCTCEM-KRWDZBQOSA-N
DM9BI7M IU (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DM9BI7M CA CAS 116539-59-4
DM9BI7M CB CHEBI:36795
DM9BI7M DE Depression
DMOAD2Y ID DMOAD2Y
DMOAD2Y DN Dupilumab
DMOAD2Y HS Approved
DMOAD2Y SN REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
DMOAD2Y CP Regeneron/Sanofi
DMOAD2Y DT Antibody
DMOAD2Y DE Atopic dermatitis; Asthma
DM4PVDY ID DM4PVDY
DM4PVDY DN Durvalumab
DM4PVDY HS Approved
DM4PVDY CP AstraZeneca
DM4PVDY DT Monoclonal antibody
DM4PVDY SQ Durvalumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Durvalumab light chainEIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM4PVDY DE Pancreatic ductal carcinoma; Solid tumour/cancer; Biliary tract cancer; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Melanoma; Urothelial carcinoma
DMQ4TJK ID DMQ4TJK
DMQ4TJK DN Dutasteride
DMQ4TJK HS Approved
DMQ4TJK SN Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
DMQ4TJK CP GSK
DMQ4TJK TC Anticancer Agents
DMQ4TJK DT Small molecular drug
DMQ4TJK PC 6918296
DMQ4TJK MW 528.5
DMQ4TJK FM C27H30F6N2O2
DMQ4TJK IC InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
DMQ4TJK CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DMQ4TJK IK JWJOTENAMICLJG-QWBYCMEYSA-N
DMQ4TJK IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMQ4TJK CA CAS 164656-23-9
DMQ4TJK CB CHEBI:521033
DMQ4TJK DE Benign prostatic hyperplasia; Prostate cancer
DMU6OFP ID DMU6OFP
DMU6OFP DN Dyclonine
DMU6OFP HS Approved
DMU6OFP SN Diclonia; Diclonina; Dyclocaine; Dyclocainum; Dyclonin; Dycloninum; Dyclothane; Tanaclone; Diclonina [INN-Spanish]; Dyclonine (INN); Dyclonine [INN:BAN]; Dycloninum [INN-Latin]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-(9CI); 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 3-Piperidino-4'-butoxypropiophenone; 4'-Butoxy-3-piperidinopropiophenone; 4-butoxy-beta-piperidinopropiophenone; 4-n-butoxy-beta-(1-piperidyl)propiophenone
DMU6OFP CP Astrazeneca Lp
DMU6OFP TC Anesthetics
DMU6OFP DT Small molecular drug
DMU6OFP PC 3180
DMU6OFP MW 289.4
DMU6OFP FM C18H27NO2
DMU6OFP IC InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
DMU6OFP CS CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2
DMU6OFP IK BZEWSEKUUPWQDQ-UHFFFAOYSA-N
DMU6OFP IU 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one
DMU6OFP CA CAS 586-60-7
DMU6OFP CB CHEBI:4724
DMU6OFP DE Pain
DMAKIDV ID DMAKIDV
DMAKIDV DN Dydrogesterone
DMAKIDV HS Approved
DMAKIDV SN Dehydrogesterone; Didrogesterona; Didrogesterone; Diphaston; Dufaston; Duphaston; Duvaron; Dydrogesterona; Dydrogesteronum; Gestatron; Gynorest; Hydrogesterone; Hydrogestrone; Isopregnenone; Prodel; Retrone; Terolut; Didrogesterone [DCIT]; Solvay Brand of Dydrogesterone; DELTA6-Retroprogesterone; Duphaston (TN); Dydrogesterona [INN-Spanish]; Dydrogesteronum [INN-Latin]; Gynorest (TN); Delta(6)-Retroprogesterone; Delta(sup 6)-Retroprogesterone; Retro-6-dehydroprogesterone; Dydrogesterone (JP15/USP/INN); Dydrogesterone [USAN:INN:BAN:JAN]; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-(9CI); (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; 10alpha-Isopregnenone; 6 Dehydro 9 beta 10 alpha progesterone; 6-Dehydro-9 beta-10 alpha-progesterone; 6-Dehydro-9.beta.,10.alpha.-progesterone; 6-Dehydro-9beta,10alpha-progesterone; 6-Dehydro-retro-progesterone; 6-Dehydroretroprogesterone; 9-.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; 9.beta.,10.alpha.-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI)
DMAKIDV CP Solvay Pharmaceuticals
DMAKIDV TC Progesterones
DMAKIDV DT Small molecular drug
DMAKIDV PC 9051
DMAKIDV MW 312.4
DMAKIDV FM C21H28O2
DMAKIDV IC InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1
DMAKIDV CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C
DMAKIDV IK JGMOKGBVKVMRFX-HQZYFCCVSA-N
DMAKIDV IU (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMAKIDV CA CAS 152-62-5
DMAKIDV CB CHEBI:31527
DMAKIDV DE Menstrual disorder
DM8DZC1 ID DM8DZC1
DM8DZC1 DN Dyphylline
DM8DZC1 HS Approved
DM8DZC1 SN Aristophyllin; Asthmolysin; Astmamasit; Astrophyllin; Circain; Circair; Coronal; Coronarin; Corphyllin; Dihydroxypropyltheophylline; Diprofilina; Diprofillin; Diprofillina; Diprofilline; Diprophyllin; Diprophylline; Diprophyllinum; Dipropylline; Droxine; Dyflex; Glyfyllin; Glyphyllin; Glyphylline; Glyphyllinum; Hidroxiteofillina; Hiphyllin; Hyphylline; Iphyllin; Isophyllen; Liactemin; Lufyllin; Neophyl; Neophyllin; Neophylline; Neostenovasan; Neothylline; Neotilina; Neufil; Neutrafil; Neutrafillina; Neutraphyllin; Neutraphylline; Neutroxantina; Propyphyllin; Protheophylline; Purifilin; Silbephyllin; Silbephylline; Solufilin; Solufyllin; Soluphyllin; Synthophylline; Tefilan; Teofen; Tesfen; Theal; Thefylan; Dihydroxypropyl theophylline; Dihydroxypropyl theopylin; Dilor G; Diprofillina [DCIT]; Dyphylline [USAN]; Neophyllin M; Theal ampules; AFI-Phyllin; COR-theophylline; Dihydroxypropyl theopylin (german); Dilor-400; Diphyllin (VAN); Diprofilina [INN-Spanish]; Diprophyllinum [INN-Latin]; Dyphylline (USP); Lufyllin (TN); Neo-Vasophylline; Diprophylline (JAN/INN); Neothylline, Lufyllin, diprophylline,Dyphylline; (+-)-7-(2,3-Dihydroxypropyl)theophylline; (+-)-diprophylline; (+-)-dyphylline; (1,2-Dihydroxy-3-propyl)thiophyllin; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; 7-(2,3-Dihydroxypropyl)theophylline; 7-(2,3-Dioxypropyl)theophylline; 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; 7-(beta,gamma-Dihydroxypropyl)theophylline; 7-(beta.,.gamma.-Dihydroxypropyl)theophylline; 7-DIHYDROXYPROPYLTHEOPHYLLINE; 7-[2,3-Dihydroxypropyl]-theophylline
DM8DZC1 TC Bronchodilator Agents
DM8DZC1 DT Small molecular drug
DM8DZC1 PC 3182
DM8DZC1 MW 254.24
DM8DZC1 FM C10H14N4O4
DM8DZC1 IC InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
DM8DZC1 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
DM8DZC1 IK KSCFJBIXMNOVSH-UHFFFAOYSA-N
DM8DZC1 IU 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione
DM8DZC1 CA CAS 479-18-5
DM8DZC1 CB CHEBI:4728
DM8DZC1 DE Acute bronchial asthma
DMJDYNQ ID DMJDYNQ
DMJDYNQ DN E-2007
DMJDYNQ HS Approved
DMJDYNQ SN Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
DMJDYNQ CP Eisai Co. Ltd.
DMJDYNQ DT Small molecular drug
DMJDYNQ PC 9924495
DMJDYNQ MW 349.4
DMJDYNQ FM C23H15N3O
DMJDYNQ IC InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
DMJDYNQ CS C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4
DMJDYNQ IK PRMWGUBFXWROHD-UHFFFAOYSA-N
DMJDYNQ IU 2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile
DMJDYNQ CA CAS 380917-97-5
DMJDYNQ CB CHEBI:71013
DMJDYNQ DE Diabetic neuropathy; Parkinson disease
DMOF2C6 ID DMOF2C6
DMOF2C6 DN Ecallantide
DMOF2C6 HS Approved
DMOF2C6 SN FOV-2302; Retinal venous occlusion therapy, Fovea; Ecallantide (ophthalmic formulation/retinal disease); Ecallantide (ophthalmic formulation/retinal disease), Dyax/Fovea; DX-88 (ophthalmic formulation/retinal disease), Dyax/Fovea
DMOF2C6 CP Dyax Corp
DMOF2C6 DT Small molecular drug
DMOF2C6 PC 44152182
DMOF2C6 MW 7054
DMOF2C6 FM C305H442N88O91S8
DMOF2C6 IC InChI=1S/C305H442N88O91S8/c1-16-152(5)241-295(478)377-195(124-168-80-82-172(398)83-81-168)252(435)334-137-227(404)333-138-228(405)345-214-143-487-491-147-218-291(474)351-179(73-47-107-327-301(315)316)255(438)341-154(7)245(428)339-155(8)249(432)379-210(127-171-136-326-150-338-171)299(482)393-113-53-79-221(393)294(477)361-181(75-49-109-329-303(319)320)260(443)372-203(125-169-134-332-175-69-40-39-68-173(169)175)277(460)370-198(119-163-58-29-20-30-59-163)274(457)369-199(120-164-60-31-21-32-61-164)275(458)375-207(130-226(314)403)284(467)389-242(153(6)17-2)296(479)378-202(123-167-66-37-24-38-67-167)283(466)390-243(159(12)396)297(480)362-182(76-50-110-330-304(321)322)258(441)353-186(86-94-223(311)400)267(450)383-217(290(473)359-188(89-98-234(414)415)263(446)354-189(90-99-235(416)417)265(448)368-201(282(465)388-241)122-166-64-35-23-36-65-166)146-490-489-145-216(384-268(451)191(92-101-237(420)421)355-262(445)187(88-97-233(412)413)357-271(454)194(116-151(3)4)366-285(468)212(141-394)381-266(449)190(91-100-236(418)419)358-273(456)197(118-162-56-27-19-28-57-162)367-259(442)180(74-48-108-328-302(317)318)349-280(463)206(129-225(313)402)374-264(447)185(85-93-222(310)399)356-279(462)205(128-224(312)401)344-229(406)139-335-251(434)184(352-288(214)471)87-96-232(410)411)289(472)350-178(72-43-46-106-308)256(439)347-177(71-42-45-105-307)257(440)360-193(103-115-486-15)270(453)385-219(292(475)391-244(160(13)397)298(481)363-183(77-51-111-331-305(323)324)261(444)380-211(300(483)484)133-240(426)427)148-492-488-144-215(386-276(459)200(121-165-62-33-22-34-63-165)371-286(469)213(142-395)382-278(461)204(126-170-135-325-149-337-170)373-269(452)192(102-114-485-14)346-246(429)156(9)340-250(433)174(309)84-95-231(408)409)287(470)343-158(11)247(430)364-196(117-161-54-25-18-26-55-161)272(455)348-176(70-41-44-104-306)254(437)342-157(10)248(431)365-209(132-239(424)425)281(464)376-208(131-238(422)423)253(436)336-140-230(407)392-112-52-78-220(392)293(476)387-218/h18-40,54-69,80-83,134-136,149-160,174,176-221,241-244,332,394-398H,16-17,41-53,70-79,84-133,137-148,306-309H2,1-15H3,(H2,310,399)(H2,311,400)(H2,312,401)(H2,313,402)(H2,314,403)(H,325,337)(H,326,338)(H,333,404)(H,334,435)(H,335,434)(H,336,436)(H,339,428)(H,340,433)(H,341,438)(H,342,437)(H,343,470)(H,344,406)(H,345,405)(H,346,429)(H,347,439)(H,348,455)(H,349,463)(H,350,472)(H,351,474)(H,352,471)(H,353,441)(H,354,446)(H,355,445)(H,356,462)(H,357,454)(H,358,456)(H,359,473)(H,360,440)(H,361,477)(H,362,480)(H,363,481)(H,364,430)(H,365,431)(H,366,468)(H,367,442)(H,368,448)(H,369,457)(H,370,460)(H,371,469)(H,372,443)(H,373,452)(H,374,447)(H,375,458)(H,376,464)(H,377,478)(H,378,479)(H,379,432)(H,380,444)(H,381,449)(H,382,461)(H,383,450)(H,384,451)(H,385,453)(H,386,459)(H,387,476)(H,388,465)(H,389,467)(H,390,466)(H,391,475)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,483,484)(H4,315,316,327)(H4,317,318,328)(H4,319,320,329)(H4,321,322,330)(H4,323,324,331)/t152-,153-,154-,155-,156-,157-,158-,159-,160-,174-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,241-,242-,243-,244-/m0/s1
DMOF2C6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)[C@H](C)O)CC1=CC=CC=C1)[C@@H](C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O
DMOF2C6 IK VBGWSQKGUZHFPS-VGMMZINCSA-N
DMOF2C6 IU (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(1R,2aS,4S,5aS,8aS,11aR,13S,14aS,16S,17aS,19S,20aS,22S,23aS,25S,26aS,28S,29aS,31R,32aS,35aS,36R,38aS,39S,41aS,42S,44aS,45S,48R,50aS,51S,53aS,54S,56aS,57S,59aS,60S,63S,66S,69S,72S,75S,78S,84S,87R,96S,99S)-22,42,45-tris(4-aminobutyl)-31-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-29a,72,78-tris(2-amino-2-oxoethyl)-14a,75-bis(3-amino-3-oxopropyl)-2a,23a,25,32a,35a,66-hexabenzyl-26a,99-bis[(2S)-butan-2-yl]-17a,41a,59a,69-tetrakis(3-carbamimidamidopropyl)-5a,8a,51,54,63,84-hexakis(2-carboxyethyl)-13,16-bis(carboxymethyl)-20a-[(1S)-1-hydroxyethyl]-60-(hydroxymethyl)-96-[(4-hydroxyphenyl)methyl]-50a-(1H-imidazol-5-ylmethyl)-38a-(1H-indol-3-ylmethyl)-19,28,53a,56a-tetramethyl-57-(2-methylpropyl)-39-(2-methylsulfanylethyl)-1a,3,4a,7a,9,10a,12,13a,15,16a,18,19a,21,22a,24,25a,27,28a,30,31a,34a,37a,38,40a,41,43a,44,47,49a,50,52a,53,55a,56,58a,59,61a,62,65,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-33,34,63a,64a,67a,68a-hexathia-a,2,3a,6a,8,9a,11,12a,14,15a,17,18a,20,21a,23,24a,26,27a,29,30a,33a,36a,37,39a,40,42a,43,46,48a,49,51a,52,54a,55,57a,58,60a,61,64,67,70,73,76,79,82,85,88,91,94,97-pentacontazapentacyclo[85.74.4.448,111.04,8.0144,148]nonahexacontahectane-36-carbonyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]butanedioic acid
DMOF2C6 CA CAS 460738-38-9
DMOF2C6 DE Retina venous occlusion
DMSNVGB ID DMSNVGB
DMSNVGB DN Echothiophate Iodide
DMSNVGB HS Approved
DMSNVGB SN Echodide; Phospholine; Diethoxyphosphinylthiocholine iodide; ECOTHIOPATE IODIDE; Ecostigmini jodidum; Ecothiopati iodidum; Ecothiophate iodide; Ioduro de ecotiopato; Phospholine iodide; Diethoxyphosphoryl-thiocholine iodide; Echothiophate iodide (USP); Ecothiopati iodidum [INN-Latin]; Iodide, Echothiophate; Iodide, Ecothiopate; Iodide, Ecothiophate; Iodide, Phospholine; Iodure d'ecothiopate; Ioduro de ecotiopato [INN-Spanish]; Phospholine (the pharmaceutical); Phospholine Iodide (TN); Phospholine iodide (TN); Ecothiopate iodide (JP15/INN); Iodure d'ecothiopate [INN-French]; N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide; O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide; S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate; S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide; S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide; S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide; Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide; Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate; S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide; Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide; (2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate; (2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate; 2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid; 2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]; 2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide; 2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide; 2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide; 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide; 2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide; 217 MI; 217-mi
DMSNVGB CP Wyeth Pharmaceuticals
DMSNVGB TC Parasympathomimetics
DMSNVGB DT Small molecular drug
DMSNVGB PC 10547
DMSNVGB MW 383.23
DMSNVGB FM C9H23INO3PS
DMSNVGB IC InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1
DMSNVGB CS CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-]
DMSNVGB IK OVXQHPWHMXOFRD-UHFFFAOYSA-M
DMSNVGB IU 2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium;iodide
DMSNVGB CA CAS 513-10-0
DMSNVGB CB CHEBI:59849
DMSNVGB DE Chronic glaucoma
DMFSWGH ID DMFSWGH
DMFSWGH DN Econazole
DMFSWGH HS Approved
DMFSWGH SN Ecostatin; Palavale; Pevaryl; Ecostatin Vaginal Ovules; Ecostatin cream; Spectazole cream; SQ 13050; Ecostatin (TN); Gyno-Pevaryl 150; Gyno-pevaryl; Pevaryl (TN); Spectazole (TN); Econazole (USAN/INN); 1-[2,4-Dichloro-.beta.-[(p-chlorobenzyl)oxy]phenethyl]imidazole; 1-[2-[(4-Chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 1-{2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMFSWGH CP Merz Pharmaceuticals Llc
DMFSWGH TC Antifungal Agents
DMFSWGH DT Small molecular drug
DMFSWGH PC 3198
DMFSWGH MW 381.7
DMFSWGH FM C18H15Cl3N2O
DMFSWGH IC InChI=1S/C18H15Cl3N2O/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21/h1-9,12,18H,10-11H2
DMFSWGH CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
DMFSWGH IK LEZWWPYKPKIXLL-UHFFFAOYSA-N
DMFSWGH IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMFSWGH CA CAS 27220-47-9
DMFSWGH CB CHEBI:82873
DMFSWGH DE Tinea versicolor; Cutaneous candidiasis; Tinea corporis; Tinea cruris; Tinea pedis
DMCRQHB ID DMCRQHB
DMCRQHB DN Edrophonium
DMCRQHB HS Approved
DMCRQHB SN EDR; Edrophonum; Edroponium; Reversol; Tensilon; EDROPHONIUM ION; Edrophone Chloride; Enlon Plus; ENLON-PLUS; Enlon (TN); Reversol (TN); Tensilon (TN); Ethyl-(3-hydroxyphenyl)-dimethylazanium; Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium; N-ethyl-3-hydroxy-N,N-dimethylanilinium; N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium; (3-hydroxyphenyl)dimethylethylammonium; 3-hydroxy-N,N-dimethyl-N-ethylanilinium
DMCRQHB TC Antidotes
DMCRQHB DT Small molecular drug
DMCRQHB PC 3202
DMCRQHB MW 166.24
DMCRQHB FM C10H16NO+
DMCRQHB IC InChI=1S/C10H15NO/c1-4-11(2,3)9-6-5-7-10(12)8-9/h5-8H,4H2,1-3H3/p+1
DMCRQHB CS CC[N+](C)(C)C1=CC(=CC=C1)O
DMCRQHB IK VWLHWLSRQJQWRG-UHFFFAOYSA-O
DMCRQHB IU ethyl-(3-hydroxyphenyl)-dimethylazanium
DMCRQHB CA CAS 312-48-1
DMCRQHB CB CHEBI:251408
DMCRQHB DE Myasthenia gravis
DMCKL5V ID DMCKL5V
DMCKL5V DN Efalizumab
DMCKL5V HS Approved
DMCKL5V SN Raptiva; Raptiva (TN); Efalizumab (USAN/INN)
DMCKL5V CP Roche
DMCKL5V TC Immunomodulatory Agents
DMCKL5V DT Antibody
DMCKL5V SQ Heavy Chain Variable Region: EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS >Light Chain Variable RegionDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR
DMCKL5V DE Psoriasis vulgaris; Renal transplantation
DMC0GSJ ID DMC0GSJ
DMC0GSJ DN Efavirenz
DMC0GSJ HS Approved
DMC0GSJ SN EFV; EFZ; Eravirenz; Stocrin; Sustiva; DMP 266; L 743726; DMP-266; L-741211; L-743725; L-743726; Stocrin (TN); Strocin (TM); Sustiva (TM); Sustiva (TN); Efavirenz (JAN/INN); L-743,726; Zoxazin-2-one; Efavirenz, (S)-isomer; Met-SDF-1.beta. & Efavirenz; Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz; (-)-Efavirenz; (4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one; (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one; 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-(9; 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
DMC0GSJ TC Anti-HIV Agents
DMC0GSJ DT Small molecular drug
DMC0GSJ PC 64139
DMC0GSJ MW 315.67
DMC0GSJ FM C14H9ClF3NO2
DMC0GSJ IC InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
DMC0GSJ CS C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
DMC0GSJ IK XPOQHMRABVBWPR-ZDUSSCGKSA-N
DMC0GSJ IU (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
DMC0GSJ CA CAS 154598-52-4
DMC0GSJ CB CHEBI:119486
DMC0GSJ DE Human immunodeficiency virus infection
DMFA9MV ID DMFA9MV
DMFA9MV DN Efinaconazole
DMFA9MV HS Approved
DMFA9MV SN IDP-108; KP-103
DMFA9MV CP Dow
DMFA9MV DT Small molecular drug
DMFA9MV PC 489181
DMFA9MV MW 348.4
DMFA9MV FM C18H22F2N4O
DMFA9MV IC InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1
DMFA9MV CS C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3
DMFA9MV IK NFEZZTICAUWDHU-RDTXWAMCSA-N
DMFA9MV IU (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMFA9MV CA CAS 164650-44-6
DMFA9MV CB CHEBI:82718
DMFA9MV DE Fungal infection
DMJOQM3 ID DMJOQM3
DMJOQM3 DN Eflornithine
DMJOQM3 HS Approved
DMJOQM3 SN EFLORNITHINE; Ornidyl; 70052-12-9; 2-(Difluoromethyl)ornithine; alpha-Difluoromethylornithine; Difluromethylornithine; Eflornitina [Spanish]; Eflornithinum [Latin]; 2,5-diamino-2-(difluoromethyl)pentanoic acid; alpha-(Difluoromethyl)-DL-ornithine; N-Difluoromethylornithine; DFMO (growth regulator); 67037-37-0; Eflornithine [INN:BAN]; 2-(Difluoromethyl)-DL-ornithine; DL-alpha-(Difluoromethyl)ornithine; MDL 71782; CCRIS 3295; Ornithine, 2-(difluoromethyl)-; Eflornithinum; Eflornitina; DFMO hydrochloride; DFMO hydrochloride hydrate; EFLORNITHINE HYDROCHLORIDE; BMS 203522; Alpha-DFMO HCl; Alpha-Difluoromethylornithine; Alpha-Difluoromethylornithine hydrochloride; CPP-1X; Eflornithine (INN); Ornidyl (TN); DL-alpha-Difluoromethylornithine; DL-alpha-Difluoromethylornithine hydrochloride hydrate; D,L-alpha-Difluoromethylornithine; Alpha-(Difluoromethyl)-DL-ornithine; Alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; 2-(Difluoromethyl)-DL-ornithine hydrochloride; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; 2-(Difluoromethyl)ornithine hydrochloride hydrate
DMJOQM3 CP Sanofi-Aventis
DMJOQM3 TC Anticancer Agents
DMJOQM3 DT Small molecular drug
DMJOQM3 PC 3009
DMJOQM3 MW 182.17
DMJOQM3 FM C6H12F2N2O2
DMJOQM3 IC InChI=1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)
DMJOQM3 CS C(CC(C(F)F)(C(=O)O)N)CN
DMJOQM3 IK VLCYCQAOQCDTCN-UHFFFAOYSA-N
DMJOQM3 IU 2,5-diamino-2-(difluoromethyl)pentanoic acid
DMJOQM3 CA CAS 70052-12-9
DMJOQM3 CB CHEBI:41948
DMJOQM3 DE African trypanosomiasis; Trypanosomiasis
DMMUCG4 ID DMMUCG4
DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4 HS Approved
DMMUCG4 SN Docosahexaenoic acid; Doconexent; Cervonic acid; 6217-54-5; all-cis-DHA; Doconexentum; Doconexento; Doxonexent; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; AquaGrow Advantage; all-Z-Docosahexaenoic acid; Martek DHA HM; Ropufa 60; cis-4,7,10,13,16,19-Docosahexaenoic acid; Docosahexaenoate; UNII-ZAD9OKH9JC; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Docosahexaenoic acid (all-Z); CCRIS 7670; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; ZAD9OKH9JC; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; CHEMBL367149; Espanova (TN); DOCOSAHEXAENOIC ACID
DMMUCG4 CP Omthera Pharmaceutials
DMMUCG4 DT Small molecular drug
DMMUCG4 PC 445580
DMMUCG4 MW 328.5
DMMUCG4 FM C22H32O2
DMMUCG4 IC InChI=1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMMUCG4 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMMUCG4 IK MBMBGCFOFBJSGT-KUBAVDMBSA-N
DMMUCG4 IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid
DMMUCG4 CA CAS 6217-54-5
DMMUCG4 CB CHEBI:28125
DMMUCG4 DE Hypertriglyceridemia; Alzheimer disease
DMRDUC0 ID DMRDUC0
DMRDUC0 DN Elagolix sodium
DMRDUC0 HS Approved
DMRDUC0 SN Elagolix sodium salt; UNII-5948VUI423; Elagolix sodium [USAN]; 5948VUI423; Elagolix sodium (USAN); SCHEMBL1641994; NBI 56418NA; NBI-56418-NA; MolPort-003-984-965; NBI-56418 NA; DQYGXRQUFSRDCH-UQIIZPHYSA-M; AKOS030524154; VA12044; KS-0000063K; KB-76766; HY-14369; AC-29671; CS-0003317; D09336
DMRDUC0 CP AbbVie
DMRDUC0 PC 24785956
DMRDUC0 MW 653.6
DMRDUC0 FM C32H29F5N3NaO5
DMRDUC0 IC InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
DMRDUC0 CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
DMRDUC0 IK DQYGXRQUFSRDCH-UQIIZPHYSA-M
DMRDUC0 IU sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
DMRDUC0 CA CAS 832720-36-2
DMRDUC0 DE Endometriosis
DMS7OU8 ID DMS7OU8
DMS7OU8 DN Elapegademase
DMS7OU8 HS Approved
DMS7OU8 SN Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS
DMS7OU8 CP Leadiant Biosciences
DMS7OU8 DE Immunodeficiency; Adenosine deaminase defciency
DMJLE18 ID DMJLE18
DMJLE18 DN Elbasvir
DMJLE18 HS Approved
DMJLE18 SN Elbasvir; Elbasvir [USAN:INN]; Elbasvir(MK-8742); MK 8742; MK-8742; MK8742; SB16741; ZINC150588351; 1370468-36-2; 632L571YDK; A16855; CHEBI:132967; CHEMBL3039514; CS-5332; Carbamic acid, N,N'-(((6S)-6-phenyl-6H-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; DB11574; EX-A2889; HY-15789; SCHEMBL17429773; UNII-632L571YDK
DMJLE18 PC 71661251
DMJLE18 MW 882
DMJLE18 FM C49H55N9O7
DMJLE18 IC BVAZQCUMNICBAQ-PZHYSIFUSA-N
DMJLE18 CS CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
DMJLE18 IK 1S/C49H55N9O7/c1-27(2)41(54-48(61)63-5)45(59)56-20-10-14-37(56)43-50-25-34(52-43)30-17-19-36-32(22-30)23-39-33-18-16-31(24-40(33)65-47(58(36)39)29-12-8-7-9-13-29)35-26-51-44(53-35)38-15-11-21-57(38)46(60)42(28(3)4)55-49(62)64-6/h7-9,12-13,16-19,22-28,37-38,41-42,47H,10-11,14-15,20-21H2,1-6H3,(H,50,52)(H,51,53)(H,54,61)(H,55,62)/t37-,38-,41-,42-,47-/m0/s1
DMJLE18 IU methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMJLE18 CA CAS 1370468-36-2
DMJLE18 CB CHEBI:132967
DMJLE18 DE Viral hepatitis
DMW649X ID DMW649X
DMW649X DN Eletriptan
DMW649X HS Approved
DMW649X SN Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X CP Pfizer Inc
DMW649X TC Antimigraine Agents
DMW649X DT Small molecular drug
DMW649X PC 77993
DMW649X MW 382.5
DMW649X FM C22H26N2O2S
DMW649X IC InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
DMW649X CS CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
DMW649X IK PWVXXGRKLHYWKM-LJQANCHMSA-N
DMW649X IU 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
DMW649X CA CAS 143322-58-1
DMW649X CB CHEBI:50922
DMW649X DE Migraine
DMSRZAO ID DMSRZAO
DMSRZAO DN Eliglustat tartrate
DMSRZAO HS Approved
DMSRZAO SN Fabrazyme (TN)
DMSRZAO CP Genzyme
DMSRZAO DT Small molecular drug
DMSRZAO PC 52918379
DMSRZAO MW 959.2
DMSRZAO FM C50H78N4O14
DMSRZAO IC InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1
DMSRZAO CS CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMSRZAO IK KUBARPMUNHKBIQ-VTHUDJRQSA-N
DMSRZAO IU N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide;(2R,3R)-2,3-dihydroxybutanedioic acid
DMSRZAO CA CAS 928659-70-5
DMSRZAO CB CHEBI:83353
DMSRZAO DE Metabolic disorder
DMZC6GT ID DMZC6GT
DMZC6GT DN Elliptinium acetate
DMZC6GT HS Approved
DMZC6GT SN Celiptium (TN)
DMZC6GT CP Sanofi
DMZC6GT DT Small molecular drug
DMZC6GT PC 42722
DMZC6GT MW 336.4
DMZC6GT FM C20H20N2O3
DMZC6GT IC InChI=1S/C18H16N2O.C2H4O2/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18;1-2(3)4/h4-9,21H,1-3H3;1H3,(H,3,4)
DMZC6GT CS CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C.CC(=O)[O-]
DMZC6GT IK BOMZMNZEXMAQQW-UHFFFAOYSA-N
DMZC6GT IU 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate
DMZC6GT CA CAS 58337-35-2
DMZC6GT DE Solid tumour/cancer
DMRCX8K ID DMRCX8K
DMRCX8K DN Eloctate
DMRCX8K HS Approved
DMRCX8K SN Recombinant human factor VIII-FC
DMRCX8K CP Biogen Idec
DMRCX8K DE Haemophilia A
DMA9REV ID DMA9REV
DMA9REV DN Elosulfase alfa
DMA9REV HS Approved
DMA9REV SN Vimizim
DMA9REV CP Biomarin
DMA9REV SQ Elosulfase-alfa: APQPPNILLLLMDDMGWGDLGVYGEPSRETPLCSPSRAALLTGRLPIRNGFYTTNAHARNLLKKAGYVSKIVGKWHLGHRPQFHPLKHGFNIPVYRDWEMVGRYYEEFPINLKTGEANLTFLYWAVDATHAPVYASKPFLGTSQRGRYGDVADNTFVFFTSDNGAALISAPEQGGSNGPFPGHVTAGQVSHQLGSIMDLFTTSLALAGLTLMDRPIFYYRGDTLMAATLGQHKAHFWTWTVTTHNLEDHTKLPLIFHLGRDPGERFPLSFEALVPAQPQLNVCNWAVMNWAPPGCEKLGKPNLDRMAAEGLLFPNFYSANAYTPQEIVGGIPDSEQLLPEDEWFGSPNCHFGPYDNKARPQIYLQEALDFIKRQARHHPFAVREIDDSIGKILELLQDLHLCGKQTTFEGGMREPALAWWPPSDRAIDGLNLLPTLLQGRNSWENFRQGIDFCPGQNVSGASAEYQEALSRITSVVQQHQCLTPPESIPKKCLWSH
DMA9REV DE Mucopolysaccharidosis
DMEYHG9 ID DMEYHG9
DMEYHG9 DN Elotuzumab
DMEYHG9 HS Approved
DMEYHG9 SN BMS-901608
DMEYHG9 CP Bristol-Myers Squibb
DMEYHG9 DT Antibody
DMEYHG9 SQ Elotuzumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Elotuzumab light chainDIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMEYHG9 DE Multiple myeloma
DMOGFIX ID DMOGFIX
DMOGFIX DN Eltrombopag
DMOGFIX HS Approved
DMOGFIX SN Eltrombopag [INN]; SB 497115; SB497115; SB-497115; [1,1'-Biphenyl]-3-carboxylic acid, 3'-[(2Z)-[1-(3,4-dime; Thylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-(9CI); (E)-3\'-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2\'-hydroxybiphenyl-3-carboxylic acid
DMOGFIX CP GlaxoSmithKline
DMOGFIX DT Small molecular drug
DMOGFIX PC 135449332
DMOGFIX MW 442.5
DMOGFIX FM C25H22N4O4
DMOGFIX IC InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)
DMOGFIX CS CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
DMOGFIX IK SVOQIEJWJCQGDQ-UHFFFAOYSA-N
DMOGFIX IU 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid
DMOGFIX CA CAS 496775-61-2
DMOGFIX CB CHEBI:85010
DMOGFIX DE Thrombocytopenia; Idiopathic thrombocytopenic purpura
DMYZ0P1 ID DMYZ0P1
DMYZ0P1 DN Eluxadoline
DMYZ0P1 HS Approved
DMYZ0P1 SN MuDelta
DMYZ0P1 CP Furiex pharmaceuticals
DMYZ0P1 DT Small molecular drug
DMYZ0P1 PC 11250029
DMYZ0P1 MW 569.6
DMYZ0P1 FM C32H35N5O5
DMYZ0P1 IC InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1
DMYZ0P1 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)[C@@H](C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
DMYZ0P1 IK QFNHIDANIVGXPE-FNZWTVRRSA-N
DMYZ0P1 IU 5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid
DMYZ0P1 CA CAS 864821-90-9
DMYZ0P1 CB CHEBI:85980
DMYZ0P1 DE Diarrhea-predominant irritable bowel syndrome
DMG9B1U ID DMG9B1U
DMG9B1U DN Elvitegravir
DMG9B1U HS Approved
DMG9B1U SN EVG
DMG9B1U DT Small molecular drug
DMG9B1U PC 5277135
DMG9B1U MW 447.9
DMG9B1U FM C23H23ClFNO5
DMG9B1U IC InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1
DMG9B1U CS CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
DMG9B1U IK JUZYLCPPVHEVSV-LJQANCHMSA-N
DMG9B1U IU 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
DMG9B1U CA CAS 697761-98-1
DMG9B1U CB CHEBI:72289
DMG9B1U DE Human immunodeficiency virus infection
DMZG5WL ID DMZG5WL
DMZG5WL DN Emapalumab
DMZG5WL HS Approved
DMZG5WL SN emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X
DMZG5WL CP Novimmune
DMZG5WL DT Antibody
DMZG5WL DE Primary haemophagocytic lymphohistiocytosis
DM36LAJ ID DM36LAJ
DM36LAJ DN Emedastine
DM36LAJ HS Approved
DM36LAJ SN Emadine; Emedastina; Emedastinum; Emedastine [INN]; Emedastine difumarate; KB 2413; KG 2413; Emadine (TN); Emedastina [INN-Spanish]; Emedastine (INN); Emedastine [INN:BAN]; Emedastinum [INN-Latin]; KB-2413; KG-2413; 1-(2-Ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate; 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole; 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole; 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane; 1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
DM36LAJ TC Antiallergic Agents
DM36LAJ DT Small molecular drug
DM36LAJ PC 3219
DM36LAJ MW 302.4
DM36LAJ FM C17H26N4O
DM36LAJ IC InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
DM36LAJ CS CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
DM36LAJ IK KBUZBQVCBVDWKX-UHFFFAOYSA-N
DM36LAJ IU 1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
DM36LAJ CA CAS 87233-61-2
DM36LAJ CB CHEBI:4779
DM36LAJ DE Allergic conjunctivitis
DMCOAVT ID DMCOAVT
DMCOAVT DN Emepronium
DMCOAVT HS Approved
DMCOAVT SN Emepronium Bromide; Restenacht; Cetiprin; Emeprone bromide; Emepron bromide; 3614-30-0; Emeproniumbromid [German]; Emepronium bromide [INN:BAN]; Emepronii bromidum [INN-Latin]; Bromure d'emepronium [INN-French]; Bromuro de emepronio [INN-Spanish]; EINECS 222-786-6; Ethyldimethyl(1-methyl-3,3-diphenylpropyl)ammonium bromide; Dimethylethyl(beta-benzhydrylisopropyl)ammonium bromide; C20H28N; Ammonium, ethyldimethyl(1-methyl-3,3-diphenylpropyl)-, bromide; Emeproniumbromid; Emepronii bromidum; Bromure d'emepronium; Bromuro de emep
DMCOAVT DT Small molecular drug
DMCOAVT PC 34055
DMCOAVT MW 282.4
DMCOAVT FM C20H28N+
DMCOAVT IC InChI=1S/C20H28N/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20H,5,16H2,1-4H3/q+1
DMCOAVT CS CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
DMCOAVT IK JEJBJBKVPOWOQK-UHFFFAOYSA-N
DMCOAVT IU 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium
DMCOAVT CA CAS 27892-33-7
DMCOAVT CB CHEBI:135169
DMCOAVT DE Urinary incontinence
DMCT2YF ID DMCT2YF
DMCT2YF DN Emetine
DMCT2YF HS Approved
DMCT2YF SN Emetine hydrochloride; EMETINE; 14198-59-5; MLS000028478; SMR000058444; NSC-33669; NSC33669; Emetine monohydrochloride; Opera_ID_1460; Cephaeline methyl ether HCl; AC1O7FP4; SCHEMBL636599; CHEMBL513000; DTXSID80424947; MolPort-004-964-890; Cephaeline methyl ether hydrochloride; NSC752340; AKOS024374935; NSC-752340; ST51014995; Emetan,7',10,11-tetramethoxy-, dihydrochloride; Q-100155; 10-[((1R)-6,7-dimethoxy(1,2,3,4-tetrahydroisoquinolyl))methyl](10S,11aS,9R)-9- ethyl-2,3-dimethoxy-5,6,7,11a-tetrahydropiperidino[2,1-a]isoquinolin
DMCT2YF DT Small molecular drug
DMCT2YF PC 10219
DMCT2YF MW 480.6
DMCT2YF FM C29H40N2O4
DMCT2YF IC InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1
DMCT2YF CS CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC
DMCT2YF IK AUVVAXYIELKVAI-CKBKHPSWSA-N
DMCT2YF IU (2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine
DMCT2YF CA CAS 483-18-1
DMCT2YF CB CHEBI:4781
DMCT2YF DE Hepatitis virus infection
DM0AQ83 ID DM0AQ83
DM0AQ83 DN Emicizumab
DM0AQ83 HS Approved
DM0AQ83 CP Roche/Genentech
DM0AQ83 DT Antibody
DM0AQ83 DE Factor VIII deficiency
DMRF9YK ID DMRF9YK
DMRF9YK DN Empagliflozin
DMRF9YK HS Approved
DMRF9YK SN 864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
DMRF9YK CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMRF9YK DT Small molecular drug
DMRF9YK PC 11949646
DMRF9YK MW 450.9
DMRF9YK FM C23H27ClO7
DMRF9YK IC InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
DMRF9YK CS C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMRF9YK IK OBWASQILIWPZMG-QZMOQZSNSA-N
DMRF9YK IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMRF9YK CA CAS 864070-44-0
DMRF9YK CB CHEBI:82720
DMRF9YK DE Type-1 diabetes
DMBMUWZ ID DMBMUWZ
DMBMUWZ DN Emtricitabine
DMBMUWZ HS Approved
DMBMUWZ SN Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
DMBMUWZ CP Gilead; Bristol-Myers Squibb
DMBMUWZ TC Anti-HIV Agents
DMBMUWZ DT Small molecular drug
DMBMUWZ PC 60877
DMBMUWZ MW 247.25
DMBMUWZ FM C8H10FN3O3S
DMBMUWZ IC InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
DMBMUWZ CS C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
DMBMUWZ IK XQSPYNMVSIKCOC-NTSWFWBYSA-N
DMBMUWZ IU 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMBMUWZ CA CAS 143491-57-0
DMBMUWZ CB CHEBI:31536
DMBMUWZ DE Human immunodeficiency virus infection; Hepatitis virus infection; Hepatitis B virus infection
DMNFUZR ID DMNFUZR
DMNFUZR DN Enalapril
DMNFUZR HS Approved
DMNFUZR SN Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR CP Merck & Co
DMNFUZR TC Antihypertensive Agents
DMNFUZR DT Small molecular drug
DMNFUZR PC 5388962
DMNFUZR MW 376.4
DMNFUZR FM C20H28N2O5
DMNFUZR IC InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
DMNFUZR CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
DMNFUZR IK GBXSMTUPTTWBMN-XIRDDKMYSA-N
DMNFUZR IU (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMNFUZR CA CAS 75847-73-3
DMNFUZR CB CHEBI:4784
DMNFUZR DE Hypertension
DMFYAM1 ID DMFYAM1
DMFYAM1 DN Enalaprilat
DMFYAM1 HS Approved
DMFYAM1 SN Extract of ginger root; Ginger extract; Ginger root extract; Ginger, ext; LS-3194; Zingiber officinale extract; Zingiber officinale root extract; CCRIS 7641; EINECS 283-634-2; FEMA No. 2520; FEMA No. 2521; FEMA No. 2523; Ginger extract (Zingiber officinale); ginger, extract (zingiber officinale rosc.)
DMFYAM1 PC 6850776
DMFYAM1 MW 568.8
DMFYAM1 FM C35H52O6
DMFYAM1 IC QCVRFSPGUWEKFC-ILHSMLOTSA-N
DMFYAM1 CS CCCCCC=CC(=O)CCC1=CC(=C(C=C1)O)OC.CCCCCC(C)CC(=O)CCC1=CC(=C(C=C1)O)OC
DMFYAM1 IK 1S/C18H28O3.C17H24O3/c1-4-5-6-7-14(2)12-16(19)10-8-15-9-11-17(20)18(13-15)21-3;1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h9,11,13-14,20H,4-8,10,12H2,1-3H3;7-8,10,12-13,19H,3-6,9,11H2,1-2H3/b;8-7+
DMFYAM1 IU (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-one;1-(4-hydroxy-3-methoxyphenyl)-5-methyldecan-3-one
DMFYAM1 CA CAS 84696-15-1
DMFYAM1 DE Essential hypertension
DMPRBQV ID DMPRBQV
DMPRBQV DN Enalaprilat
DMPRBQV HS Approved
DMPRBQV SN EAL; Enalaprilate; Enalaprilatum; ENALAPRILAT INHIBITOR; Enalapril acid; Enalapril diacid; Enalaprilat anhydrous; Enalaprilic acid; Enalprilat hydrate; Enalprilate hydrate; Enalaprilat (USP); MK-422; Vasotec I.V.; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline; N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline-water (1/2); (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid; (2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate; 1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
DMPRBQV CP Merck & Co
DMPRBQV TC Antihypertensive Agents
DMPRBQV DT Small molecular drug
DMPRBQV PC 5462501
DMPRBQV MW 348.4
DMPRBQV FM C18H24N2O5
DMPRBQV IC InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
DMPRBQV CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O
DMPRBQV IK LZFZMUMEGBBDTC-QEJZJMRPSA-N
DMPRBQV IU (2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMPRBQV CA CAS 76420-72-9
DMPRBQV CB CHEBI:4786
DMPRBQV DE Hypertension
DM8QXOC ID DM8QXOC
DM8QXOC DN Enasidenib
DM8QXOC HS Approved
DM8QXOC SN Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG
DM8QXOC PC 89683805
DM8QXOC MW 473.4
DM8QXOC FM C19H17F6N7O
DM8QXOC IC DYLUUSLLRIQKOE-UHFFFAOYSA-N
DM8QXOC CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DM8QXOC IK 1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DM8QXOC IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DM8QXOC CA CAS 1446502-11-9
DM8QXOC CB CHEBI:145374
DM8QXOC DE Acute myeloid leukaemia
DMPOU5H ID DMPOU5H
DMPOU5H DN ENASIDENIB MESYLATE
DMPOU5H HS Approved
DMPOU5H SN UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541
DMPOU5H CP Celgene/Agios
DMPOU5H PC 90480031
DMPOU5H MW 569.5
DMPOU5H FM C20H21F6N7O4S
DMPOU5H IC InChI=1S/C19H17F6N7O.CH4O3S/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25;1-5(2,3)4/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32);1H3,(H,2,3,4)
DMPOU5H CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O
DMPOU5H IK ORZHZQZYWXEDDL-UHFFFAOYSA-N
DMPOU5H IU methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMPOU5H CA CAS 1650550-25-6
DMPOU5H DE Acute myeloid leukaemia
DM7RNP3 ID DM7RNP3
DM7RNP3 DN Enbrel
DM7RNP3 HS Approved
DM7RNP3 DE Arthritis
DM0YJSB ID DM0YJSB
DM0YJSB DN Enflurane
DM0YJSB HS Approved
DM0YJSB SN Alyrane; Efrane; Enflurano; Enfluranum; Enfran; Enlirane; Ethrane; Etran; Methylflurether; Abbott Brand of Enflurane; AstraZeneca Brand of Enflurane; Baxter Anaesthesia Brand of Enflurane; Pisa Brand of Enflurane; Zeneca Brand of Enflurane; Anesthetic 347; C 347; OHIO 347; Anesthetic Compound No. 347; Enflurane [Anaesthetics,volatile]; Enflurano [INN-Spanish]; Enfluranum [INN-Latin]; Ethrane (TN); Enflurane (JP15/USP/INN); Enflurane [USAN:BAN:INN:JAN]; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB TC Anesthetics
DM0YJSB DT Small molecular drug
DM0YJSB PC 3226
DM0YJSB MW 184.49
DM0YJSB FM C3H2ClF5O
DM0YJSB IC InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H
DM0YJSB CS C(C(OC(F)F)(F)F)(F)Cl
DM0YJSB IK JPGQOUSTVILISH-UHFFFAOYSA-N
DM0YJSB IU 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane
DM0YJSB CA CAS 13838-16-9
DM0YJSB CB CHEBI:4792
DM0YJSB DE Anaesthesia
DMFS63G ID DMFS63G
DMFS63G DN Enfortumab
DMFS63G HS Approved
DMFS63G SN ASG-2ME
DMFS63G CP Astellas Northbrook, IL Seattle Genetics Bothell, WA
DMFS63G DT Antibody drug conjugate
DMFS63G DE Urothelial carcinoma
DM7YPM1 ID DM7YPM1
DM7YPM1 DN Enfuvirtide
DM7YPM1 HS Approved
DM7YPM1 SN Fuzeon; Pentafuside; Enfuvirtide [USAN]; Roche brand of pentafuside; DP178; Dp 178; Peptide T20; T 20; T20 peptide; Fuzeon (TN); T 20 (peptide); T-20; T-20 cpd
DM7YPM1 CP Hoffmann-La Roche pharmaceutical company
DM7YPM1 TC Anti-HIV Agents
DM7YPM1 DT Small molecular drug
DM7YPM1 SQ DB00109 sequence: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
DM7YPM1 PC 24847866
DM7YPM1 MW 4565
DM7YPM1 FM C206H304N52O66
DM7YPM1 IC InChI=1S/C206H304N52O66/c1-20-103(15)168(254-197(315)137(75-101(11)12)239-202(320)151(94-261)252-192(310)143(82-113-90-216-96-221-113)249-205(323)169(104(16)21-2)255-198(316)138(76-102(13)14)240-203(321)152(95-262)253-206(324)170(106(18)263)256-199(317)148(258-257-107(19)264)78-109-45-47-114(265)48-46-109)204(322)234-132(58-68-165(283)284)180(298)229-131(57-67-164(281)282)184(302)251-150(93-260)200(318)233-126(52-62-156(212)269)181(299)246-145(84-158(214)271)193(311)230-125(51-61-155(211)268)177(295)225-123(49-59-153(209)266)175(293)227-127(53-63-160(273)274)178(296)223-121(43-31-33-69-207)174(292)245-144(83-157(213)270)194(312)232-128(54-64-161(275)276)179(297)226-124(50-60-154(210)267)176(294)228-129(55-65-162(277)278)182(300)235-134(72-98(5)6)187(305)237-133(71-97(3)4)186(304)231-130(56-66-163(279)280)183(301)236-135(73-99(7)8)189(307)248-147(86-166(285)286)196(314)224-122(44-32-34-70-208)173(291)242-140(79-110-87-217-118-40-28-25-37-115(110)118)185(303)222-105(17)171(289)250-149(92-259)201(319)238-136(74-100(9)10)188(306)243-142(81-112-89-219-120-42-30-27-39-117(112)120)191(309)247-146(85-159(215)272)195(313)244-141(80-111-88-218-119-41-29-26-38-116(111)119)190(308)241-139(172(290)220-91-167(287)288)77-108-35-23-22-24-36-108/h22-30,35-42,45-48,87-90,96-106,121-152,168-170,217-219,258-263,265H,20-21,31-34,43-44,49-86,91-95,207-208H2,1-19H3,(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,271)(H2,215,272)(H,216,221)(H,220,290)(H,222,303)(H,223,296)(H,224,314)(H,225,295)(H,226,297)(H,227,293)(H,228,294)(H,229,298)(H,230,311)(H,231,304)(H,232,312)(H,233,318)(H,234,322)(H,235,300)(H,236,301)(H,237,305)(H,238,319)(H,239,320)(H,240,321)(H,241,308)(H,242,291)(H,243,306)(H,244,313)(H,245,292)(H,246,299)(H,247,309)(H,248,307)(H,249,323)(H,250,289)(H,251,302)(H,252,310)(H,253,324)(H,254,315)(H,255,316)(H,256,317)(H,257,264)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)/t103-,104-,105-,106+,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,168-,169-,170-/m0/s1
DM7YPM1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NNC(=O)C
DM7YPM1 IK BWVBEUNZTQWGMR-CKVIKZOTSA-N
DM7YPM1 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-(2-acetylhydrazinyl)-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM7YPM1 DE Human immunodeficiency virus infection
DMYTE6L ID DMYTE6L
DMYTE6L DN Enoxacin
DMYTE6L HS Approved
DMYTE6L SN Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
DMYTE6L TC Antiinfective Agents
DMYTE6L DT Small molecular drug
DMYTE6L PC 3229
DMYTE6L MW 320.32
DMYTE6L FM C15H17FN4O3
DMYTE6L IC InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
DMYTE6L CS CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
DMYTE6L IK IDYZIJYBMGIQMJ-UHFFFAOYSA-N
DMYTE6L IU 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
DMYTE6L CA CAS 74011-58-8
DMYTE6L CB CHEBI:157175
DMYTE6L DE Urinary tract infection
DMQVZJD ID DMQVZJD
DMQVZJD DN Enoximone
DMQVZJD HS Approved
DMQVZJD SN ENOXIMONE; Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane; Enoximona; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; FENOXIMONE
DMQVZJD TC Cardiotonic Agents
DMQVZJD DT Small molecular drug
DMQVZJD PC 53708
DMQVZJD MW 248.3
DMQVZJD FM C12H12N2O2S
DMQVZJD IC InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
DMQVZJD CS CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC
DMQVZJD IK ZJKNESGOIKRXQY-UHFFFAOYSA-N
DMQVZJD IU 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one
DMQVZJD CA CAS 77671-31-9
DMQVZJD CB CHEBI:135010
DMQVZJD DE Congestive heart failure
DMFYZKN ID DMFYZKN
DMFYZKN DN Enprofylline
DMFYZKN HS Approved
DMFYZKN SN Enprofilina; Enprofyllinum; Nilyph; Oxeze; P 5679; D-4028; Enprofilina [INN-Spanish]; Enprofylline [USAN:INN]; Enprofyllinum [INN-Latin]; Enprofylline (USAN/INN); 3,7-Dihydro-3-propyl-1H-purine-2,6-dione; 3-Propyl-3,7-dihydro-purine-2,6-dione; 3-Propylxanthine; 3-n-Propylxanthine; 3-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-propyl-7H-purine-2,6-dione
DMFYZKN TC Antiinflammatory Agents
DMFYZKN DT Small molecular drug
DMFYZKN PC 1676
DMFYZKN MW 194.19
DMFYZKN FM C8H10N4O2
DMFYZKN IC InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
DMFYZKN CS CCCN1C2=C(C(=O)NC1=O)NC=N2
DMFYZKN IK SIQPXVQCUCHWDI-UHFFFAOYSA-N
DMFYZKN IU 3-propyl-7H-purine-2,6-dione
DMFYZKN CA CAS 41078-02-8
DMFYZKN CB CHEBI:126237
DMFYZKN DE Asthma
DMLBVKQ ID DMLBVKQ
DMLBVKQ DN Entacapone
DMLBVKQ HS Approved
DMLBVKQ SN Comtan; Comtess; Entacapona; Entacaponum; Novartis brand of entacapone; Orion brand of entacapone; KB475572; OR 611; COM-998; Comtan (TN); Entacapona [INN-Spanish]; Entacapone [USAN:INN]; Entacaponum [INN-Latin]; OR-611; Stalevo (TN); Entacapone (JAN/USAN/INN); N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
DMLBVKQ CP Norvatis Phamaceuticals Corporation
DMLBVKQ TC Antiparkinson Agents
DMLBVKQ DT Small molecular drug
DMLBVKQ PC 5281081
DMLBVKQ MW 305.29
DMLBVKQ FM C14H15N3O5
DMLBVKQ IC InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
DMLBVKQ CS CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N
DMLBVKQ IK JRURYQJSLYLRLN-BJMVGYQFSA-N
DMLBVKQ IU (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
DMLBVKQ CA CAS 130929-57-6
DMLBVKQ CB CHEBI:4798
DMLBVKQ DE Parkinson disease
DM7VTQO ID DM7VTQO
DM7VTQO DN Entecavir
DM7VTQO HS Approved
DM7VTQO SN Baraclude; ETV; Entecavir hydrate; Entecavir monohydrate; BMS-200475; Baraclude (TN); Entecavir (INN); Entecavir (USAN); Entecavir hydrate (JAN); SQ-34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
DM7VTQO CP Bristol-Myers Squibb
DM7VTQO TC Antiviral Agents
DM7VTQO DT Small molecular drug
DM7VTQO PC 135398508
DM7VTQO MW 277.28
DM7VTQO FM C12H15N5O3
DM7VTQO IC InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
DM7VTQO CS C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N
DM7VTQO IK QDGZDCVAUDNJFG-FXQIFTODSA-N
DM7VTQO IU 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one
DM7VTQO CA CAS 142217-69-4
DM7VTQO CB CHEBI:473990
DM7VTQO DE Hepatitis B virus infection
DMK659W ID DMK659W
DMK659W DN Enteric-coated mycophenolate sodium
DMK659W HS Approved
DMK659W SN Myfortic; Mycophenolate sodium; ERL-080; Enteric-coated MPA, Novartis; Enteric-coated mycophenolate sodium, Novartis
DMK659W CP Novartis AG
DMK659W DE Transplant rejection
DMMPTLH ID DMMPTLH
DMMPTLH DN Entrectinib
DMMPTLH HS Approved
DMMPTLH SN 1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
DMMPTLH CP Ignyta
DMMPTLH DT Small molecular drug
DMMPTLH PC 25141092
DMMPTLH MW 560.6
DMMPTLH FM C31H34F2N6O2
DMMPTLH IC InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)
DMMPTLH CS CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMMPTLH IK HAYYBYPASCDWEQ-UHFFFAOYSA-N
DMMPTLH IU N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
DMMPTLH CA CAS 1108743-60-7
DMMPTLH DE Solid tumour/cancer; Colorectal cancer; Neuroblastoma; Mammary analogue secretory carcinoma; Non-small cell lung cancer
DMGL19D ID DMGL19D
DMGL19D DN Enzalutamide
DMGL19D HS Approved
DMGL19D SN MDV3100; Enzalutamide (AR inhibitor)
DMGL19D CP Astellas Pharma
DMGL19D DT Small molecular drug
DMGL19D SQ 5'-CTCCAACATCAAGGAAGATGGCATTTCTAG
DMGL19D PC 15951529
DMGL19D MW 464.4
DMGL19D FM C21H16F4N4O2S
DMGL19D IC InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
DMGL19D CS CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
DMGL19D IK WXCXUHSOUPDCQV-UHFFFAOYSA-N
DMGL19D IU 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
DMGL19D CA CAS 915087-33-1
DMGL19D CB CHEBI:68534
DMGL19D DE Prostate cancer
DM5OGK0 ID DM5OGK0
DM5OGK0 DN Epalrestat
DM5OGK0 HS Approved
DM5OGK0 SN epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono 2235; Ono-2235; Epalrestat [INN]; Epalrestatum [Latin]; ONO-2; 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid; ONO 2; UNII-424DV0807X; C15H13NO3S2; CHEMBL56337; 5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; CHEBI:31539; 5-((Z,E)-beta-Methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; 424DV0807X; Epalrestatum; Aldorin (TN); Kinedak (TN); Epalrestat (JAN/INN); {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid; 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; Ono 2
DM5OGK0 CP Eskayef Bangladesh Limited
DM5OGK0 TC Hypoglycemic Agents
DM5OGK0 DT Small molecular drug
DM5OGK0 PC 1549120
DM5OGK0 MW 319.4
DM5OGK0 FM C15H13NO3S2
DM5OGK0 IC InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
DM5OGK0 CS C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O
DM5OGK0 IK CHNUOJQWGUIOLD-NFZZJPOKSA-N
DM5OGK0 IU 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DM5OGK0 CA CAS 82159-09-9
DM5OGK0 CB CHEBI:31539
DM5OGK0 DE Diabetic neuropathy; Pain
DMHEAGL ID DMHEAGL
DMHEAGL DN Epanova
DMHEAGL HS Approved
DMHEAGL SN Omefas; Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera
DMHEAGL CP Tillotts Pharma AG
DMHEAGL DT Small molecular drug
DMHEAGL PC 56842239
DMHEAGL MW 909.4
DMHEAGL FM C60H92O6
DMHEAGL IC InChI=1S/C22H32O2.C20H30O2.C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22);3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;4-3-,7-6-,10-9-,13-12-,16-15-;4-3-,7-6-,10-9-
DMHEAGL CS CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O
DMHEAGL IK QPEOIOLHJXXJFN-GNGJDXFDSA-N
DMHEAGL IU (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid;(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid;(9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
DMHEAGL DE Hypertriglyceridemia
DMMV0KW ID DMMV0KW
DMMV0KW DN Ephedrine
DMMV0KW HS Approved
DMMV0KW SN Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin
DMMV0KW CP Ben Venue Laboratories Inc
DMMV0KW TC Central Nervous System Stimulants
DMMV0KW DT Small molecular drug
DMMV0KW PC 9294
DMMV0KW MW 165.23
DMMV0KW FM C10H15NO
DMMV0KW IC InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
DMMV0KW CS C[C@@H]([C@@H](C1=CC=CC=C1)O)NC
DMMV0KW IK KWGRBVOPPLSCSI-WPRPVWTQSA-N
DMMV0KW IU (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol
DMMV0KW CA CAS 299-42-3
DMMV0KW CB CHEBI:15407
DMMV0KW DE Asthma
DMVONE6 ID DMVONE6
DMVONE6 DN Epidermal growth factor
DMVONE6 HS Approved
DMVONE6 SN 62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF
DMVONE6 DT Small molecular drug
DMVONE6 PC 56841751
DMVONE6 MW 6046
DMVONE6 FM C257H381N73O83S7
DMVONE6 IC InChI=1S/C257H381N73O83S7/c1-20-123(15)203(245(404)283-103-192(351)285-157(80-127-42-52-135(339)53-43-127)222(381)313-171(104-331)210(369)281-101-191(350)287-167(92-198(360)361)228(387)290-146(37-27-70-273-255(265)266)213(372)318-177(110-414)238(397)292-148(62-65-185(259)344)217(376)327-205(125(17)337)249(408)294-147(38-28-71-274-256(267)268)212(371)309-168(93-199(362)363)229(388)298-153(76-117(3)4)218(377)289-145(36-26-69-272-254(263)264)211(370)303-162(86-133-96-277-144-35-25-23-33-141(133)144)226(385)304-161(85-132-95-276-143-34-24-22-32-140(132)143)225(384)291-149(63-66-195(354)355)214(373)297-154(77-118(5)6)219(378)296-152(253(412)413)39-29-72-275-257(269)270)326-247(406)202(122(13)14)324-242(401)181(114-418)320-227(386)165(90-188(262)347)307-241(400)180(113-417)322-250(409)206(126(18)338)328-231(390)160(83-130-48-58-138(342)59-49-130)302-234(393)174(107-334)315-230(389)169(94-200(364)365)310-221(380)155(78-119(7)8)299-233(392)173(106-333)314-215(374)150(64-67-196(356)357)295-248(407)204(124(16)21-2)325-232(391)163(87-134-97-271-116-284-134)305-216(375)151(68-75-420-19)293-239(398)179(112-416)321-246(405)201(121(11)12)323-194(353)99-278-189(348)98-279-208(367)164(89-187(261)346)306-220(379)156(79-120(9)10)300-240(399)178(111-415)319-223(382)158(81-128-44-54-136(340)55-45-128)286-190(349)100-280-209(368)166(91-197(358)359)308-224(383)159(82-129-46-56-137(341)57-47-129)301-235(394)175(108-335)316-237(396)176(109-336)317-244(403)184-41-31-74-330(184)252(411)182(115-419)288-193(352)102-282-243(402)183-40-30-73-329(183)251(410)170(84-131-50-60-139(343)61-51-131)311-236(395)172(105-332)312-207(366)142(258)88-186(260)345/h22-25,32-35,42-61,95-97,116-126,142,145-184,201-206,276-277,331-343,414-419H,20-21,26-31,36-41,62-94,98-115,258H2,1-19H3,(H2,259,344)(H2,260,345)(H2,261,346)(H2,262,347)(H,271,284)(H,278,348)(H,279,367)(H,280,368)(H,281,369)(H,282,402)(H,283,404)(H,285,351)(H,286,349)(H,287,350)(H,288,352)(H,289,377)(H,290,387)(H,291,384)(H,292,397)(H,293,398)(H,294,408)(H,295,407)(H,296,378)(H,297,373)(H,298,388)(H,299,392)(H,300,399)(H,301,394)(H,302,393)(H,303,370)(H,304,385)(H,305,375)(H,306,379)(H,307,400)(H,308,383)(H,309,371)(H,310,380)(H,311,395)(H,312,366)(H,313,381)(H,314,374)(H,315,389)(H,316,396)(H,317,403)(H,318,372)(H,319,382)(H,320,386)(H,321,405)(H,322,409)(H,323,353)(H,324,401)(H,325,391)(H,326,406)(H,327,376)(H,328,390)(H,354,355)(H,356,357)(H,358,359)(H,360,361)(H,362,363)(H,364,365)(H,412,413)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t123-,124-,125+,126+,142-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,201-,202-,203-,204-,205-,206-/m0/s1
DMVONE6 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N
DMVONE6 IK VBEQCZHXXJYVRD-GACYYNSASA-N
DMVONE6 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMVONE6 CA CAS 62229-50-9
DMVONE6 DE Vulnerary; Wound healing
DMX0K3Q ID DMX0K3Q
DMX0K3Q DN Epinastine
DMX0K3Q HS Approved
DMX0K3Q SN Epinastina; Epinastinum; Purivist; Epinastina [Spanish]; Epinastine [INN]; Epinastinum [Latin]; WAL 80; WAL 801; WAL 801CL; Elestat (TN); Epinastine (INN); Purivist (TN); Relestat (TN); WAL-80 Cl; (+-)-Epinastine; 3-Amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine; 3-amino-9,13b-dihydro-1H-benz(c,f)imidazo(1,5a)azepine; 9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-amine
DMX0K3Q CP Allergan Pharmaceuticals
DMX0K3Q TC Antihistamines
DMX0K3Q DT Small molecular drug
DMX0K3Q PC 3241
DMX0K3Q MW 249.31
DMX0K3Q FM C16H15N3
DMX0K3Q IC InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)
DMX0K3Q CS C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
DMX0K3Q IK WHWZLSFABNNENI-UHFFFAOYSA-N
DMX0K3Q IU 2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine
DMX0K3Q CA CAS 80012-43-7
DMX0K3Q CB CHEBI:51032
DMX0K3Q DE Allergic conjunctivitis
DM3KJBC ID DM3KJBC
DM3KJBC DN Epinephrine
DM3KJBC HS Approved
DM3KJBC SN ADROP; Adnephrine; Adrenal; Adrenalin; Adrenalina; Adrenaline; Adrenalinum; Adrenamine; Adrenan; Adrenapax; Adrenasol; Adrenatrate; Adrenine; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Adrin; Adrine; Antiasthmatique; Asthmanefrin; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Bosmin; Brevirenin; Bronkaid; Chelafrin; Corisol; Drenamist; Dylephrin; Epifrin; Epiglaufrin; Epinefrin; Epinefrina; Epinephran; Epinephrin; Epinephrinum; Epipen; Epirenamine; Epirenan; Epirenin; Epitrate; Eppy; Esphygmogenina; Exadrin; Glaucon; Glaucosan; Glauposine; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hemisine; Hemostasin; Hemostatin; Hypernephrin; Hyporenin; IOP; Intranefrin; Iontocaine; Isoptoepinal; Kidoline; Levoadrenaline; Levoepinephrine; Levorenen; Levorenin; Levorenine; Lyophrin; Metanephrin; Methylaminoethanolcatechol; Methylarterenol; Micronefrin; Micronephrine; Mucidrina; Myosthenine; Mytrate; Nephridine; Nieraline; Paranephrin; Primatene; Racepinephrine; Renagladin; Renaglandin; Renaglandulin; Renaleptine; Renalina; Renoform; Renostypricin; Renostypticin; Renostyptin; Scurenaline; Septocaine; Simplene; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Styptirenal; Supracapsulin; Supradin; Supranefran; Supranephrane; Supranephrine; Supranol; Suprarenaline; Suprarenin; Suprel; Surenine; Surrenine; Susphrine; Takamina; Takamine; Tokamina; Tonogen; Twinject; Vaponefrin; Vasoconstrictine; Vasoconstrictor; Vasodrine; Vasoton; Vasotonin; ADR ADRENALINE; Adrenalin in Oil; Adrenalina [DCIT]; Asmatane Mist; Asthma meter mist; Asthmahaler Mist; Bronkaid Mist; Bronkaid Suspension Mist; Bupivacaine Hcl and Epinephrine; Citanest Forte; EPI E Z PEN JR; EPIPEN E Z PEN; EPIPEN JR; Epi EZ Pen Jr; Epinefrin [Czech]; Epinephrine hydrochloride; Epipen EZ Pen; Primatene Mist; Racemic Epinephrine; Sympathin I; Adrenalin (TN); Adrenalin-Medihaler; Adrenaline (JP15); Adrenaline/Epinephrine; Ana-Guard; Asthma-nefrin; D-Adrenaline; D-Epifrin; D-Epinephrine; Dyspne-Inhal; Epinefrina [INN-Spanish]; Epinephrine (USP); Epinephrinum [INN-Latin]; Epipen (TN); Epipen Auto-Injector; Epipen Jr.; L-Adrenalin; L-Adrenaline; L-Adrenaline Base; L-Epinehphrine; L-Epinephine; L-Epirenamine; L-Methylaminoethanolcatechol; L-epinephrine; Levo-Methylaminoethanolcatechol; Medihaler-Epi; R-Adrenaline; Sus-Phrine; Twinject 0.15; Twinject 0.3; Twinject 0.30; Epinephrine (USP/INN); Epinephrine [USAN:INN:JAN]; Epipen Jr. Auto-Injector; L-Epinephrine (synthetic); SUS-PHRINE SULFITE-FREE; R-(-)-Epinephrine; L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; (-)-(R)-Epinephrine; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; (-)-Adrenalin; (-)-Adrenaline; (-)-R-Epinephrine; (R)-(-)-Adnephrine; (R)-(-)-Adrenaline; (R)-(-)-Epinephrine; (R)-(-)-Epirenamine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; (R)-Adrenaline; (R)-Epinephrine; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; 1-Adrenalin; 1-Epinephrine; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
DM3KJBC TC Vasoconstrictor Agents
DM3KJBC DT Small molecular drug
DM3KJBC PC 5816
DM3KJBC MW 183.2
DM3KJBC FM C9H13NO3
DM3KJBC IC InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1
DM3KJBC CS CNC[C@@H](C1=CC(=C(C=C1)O)O)O
DM3KJBC IK UCTWMZQNUQWSLP-VIFPVBQESA-N
DM3KJBC IU 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
DM3KJBC CA CAS 51-43-4
DM3KJBC CB CHEBI:28918
DM3KJBC DE Allergy
DMPDW6T ID DMPDW6T
DMPDW6T DN Epirubicin
DMPDW6T HS Approved
DMPDW6T SN Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
DMPDW6T CP Pfizer Pharmaceuticals
DMPDW6T TC Anticancer Agents
DMPDW6T DT Small molecular drug
DMPDW6T PC 41867
DMPDW6T MW 543.5
DMPDW6T FM C27H29NO11
DMPDW6T IC InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
DMPDW6T CS C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
DMPDW6T IK AOJJSUZBOXZQNB-VTZDEGQISA-N
DMPDW6T IU (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMPDW6T CA CAS 56420-45-2
DMPDW6T CB CHEBI:47898
DMPDW6T DE Solid tumour/cancer
DMF0NQR ID DMF0NQR
DMF0NQR DN Eplerenone
DMF0NQR HS Approved
DMF0NQR SN Epoxymexrenone; Inspra; Selara; CGP-30083; Inspra (TN); SC-66110; Eplerenone (JAN/USAN/INN); Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone; 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
DMF0NQR CP Pfizer Pharmaceuticals
DMF0NQR TC Antihypertensive Agents
DMF0NQR DT Small molecular drug
DMF0NQR PC 443872
DMF0NQR MW 414.5
DMF0NQR FM C24H30O6
DMF0NQR IC InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
DMF0NQR CS C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMF0NQR IK JUKPWJGBANNWMW-VWBFHTRKSA-N
DMF0NQR IU methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate
DMF0NQR CA CAS 107724-20-9
DMF0NQR CB CHEBI:31547
DMF0NQR DE Heart failure
DMKWB73 ID DMKWB73
DMKWB73 DN Epoetin alfa
DMKWB73 HS Approved
DMKWB73 SN Epogen (TN); Procrit (TN)
DMKWB73 CP Amgen Inc
DMKWB73 TC Antianemic Agents
DMKWB73 DE Anemia
DMUTYR2 ID DMUTYR2
DMUTYR2 DN Epoprostenol
DMUTYR2 HS Approved
DMUTYR2 SN Epoprostanol; Epoprostenolum; Flolan; PGX; Prostacyclin; Prostacycline; Prostacyclins; Vasocyclin; ProstaglandinI; Prostaglandin X; Prostaglandins X; PGI2; Prostacyclin I2; Prostaglandin I2; TRY 200; Epoprostenol (TN); Epoprostenol [USAN:INN]; Epoprostenolum [INN-Latin]; PG-I2; PGI(sub 2); Prostaglandin I(2); Try-200; U 53,217; U-53217; Epoprostenol (USAN/INN); KB-IV-24; (5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; (5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate; (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid; (5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid; (5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid; (Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid; 6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
DMUTYR2 TC Antihypertensive Agents
DMUTYR2 DT Small molecular drug
DMUTYR2 PC 5282411
DMUTYR2 MW 352.5
DMUTYR2 FM C20H32O5
DMUTYR2 IC InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1
DMUTYR2 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/O2)O)O
DMUTYR2 IK KAQKFAOMNZTLHT-OZUDYXHBSA-N
DMUTYR2 IU (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
DMUTYR2 CA CAS 35121-78-9
DMUTYR2 CB CHEBI:15552
DMUTYR2 DE Pulmonary hypertension
DM07K2I ID DM07K2I
DM07K2I DN Eprosartan
DM07K2I HS Approved
DM07K2I SN 133040-01-4; Teveten; F-108566; F 108566; UNII-2KH13Z0S0Y; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEMBL813; SK-108566; 2KH13Z0S0Y; CHEBI:4814; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; SK&F 108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; [3H]eprosartan
DM07K2I CP Abbott Laboratories
DM07K2I TC Antihypertensive Agents
DM07K2I DT Small molecular drug
DM07K2I PC 5281037
DM07K2I MW 424.5
DM07K2I FM C23H24N2O4S
DM07K2I IC InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
DM07K2I CS CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\\CC3=CC=CS3)/C(=O)O
DM07K2I IK OROAFUQRIXKEMV-LDADJPATSA-N
DM07K2I IU 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid
DM07K2I CA CAS 133040-01-4
DM07K2I CB CHEBI:4814
DM07K2I DE Hypertension
DMQXTJS ID DMQXTJS
DMQXTJS DN Eptifibatide
DMQXTJS HS Approved
DMQXTJS SN Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
DMQXTJS CP Millennium Pharmaceuticals
DMQXTJS TC Anticoagulants
DMQXTJS DT Small molecular drug
DMQXTJS PC 448812
DMQXTJS MW 832
DMQXTJS FM C35H49N11O9S2
DMQXTJS IC InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
DMQXTJS CS C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
DMQXTJS IK CZKPOZZJODAYPZ-LROMGURASA-N
DMQXTJS IU 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
DMQXTJS CA CAS 188627-80-7
DMQXTJS CB CHEBI:291902
DMQXTJS DE Acute cardiac ischemic events
DM5LJCI ID DM5LJCI
DM5LJCI DN Eptinezumab
DM5LJCI HS Approved
DM5LJCI CP Alder Biopharmaceuticals Bothell, WA
DM5LJCI DE Migraine
DMI782S ID DMI782S
DMI782S DN Erdafitinib
DMI782S HS Approved
DMI782S SN 1346242-81-6; UNII-890E37NHMV; 890E37NHMV; Erdafitinib [USAN:INN]; Erdafitinib (USAN/INN); GTPL9039; SCHEMBL2583760; CHEMBL3545376; MolPort-044-560-398; JNJ-42756493 (Erdafitinib); s8401; compound 4 [WO2011135376]; ZINC168520308; AKOS030526429; CS-4988; DB12147; AC-30222; 1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-; HY-18708; AS-35040; KB-333716; D10927; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quino
DMI782S CP Janssen Research & Development Raritan, NJ
DMI782S PC 67462786
DMI782S MW 446.5
DMI782S FM C25H30N6O2
DMI782S IC InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3
DMI782S CS CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC
DMI782S IK OLAHOMJCDNXHFI-UHFFFAOYSA-N
DMI782S IU N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine
DMI782S CA CAS 1346242-81-6
DMI782S DE Lymphoma; Urothelial carcinoma; Bladder cancer; Solid tumour/cancer
DM6QFSV ID DM6QFSV
DM6QFSV DN Erdosteine
DM6QFSV HS Approved
DM6QFSV SN Asdigan; Biopulmin; Dostin; Dostol; Drupsan; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdotin; Esteclin; Fluidasa; Flusten; Mucoflux; Mucofor; Mucotec; Mucothera; Mukial; Secresolv; Theovix; Tusselin; Vectrine; KW-9144; RV-144
DM6QFSV CP Edmond Pharma
DM6QFSV DT Small molecular drug
DM6QFSV PC 65632
DM6QFSV MW 249.3
DM6QFSV FM C8H11NO4S2
DM6QFSV IC InChI=1S/C8H11NO4S2/c10-6(3-14-4-7(11)12)9-5-1-2-15-8(5)13/h5H,1-4H2,(H,9,10)(H,11,12)
DM6QFSV CS C1CSC(=O)C1NC(=O)CSCC(=O)O
DM6QFSV IK QGFORSXNKQLDNO-UHFFFAOYSA-N
DM6QFSV IU 2-[2-oxo-2-[(2-oxothiolan-3-yl)amino]ethyl]sulfanylacetic acid
DM6QFSV CA CAS 84611-23-4
DM6QFSV CB CHEBI:135014
DM6QFSV DE Bronchitis
DMWMCN0 ID DMWMCN0
DMWMCN0 DN Erenumab
DMWMCN0 HS Approved
DMWMCN0 SN Aimovig; Erenumab [USAN]; UNII-I5I8VB78VT; I5I8VB78VT
DMWMCN0 CP Amgen/Novartis
DMWMCN0 DE Hyperprolactinaemia
DMHO0AR ID DMHO0AR
DMHO0AR DN Ergocalciferol
DMHO0AR HS Approved
DMHO0AR SN Calciferol; Calciferolum; Condacaps; Condocaps; Condol; Crtron; Crystallina; Daral; Davitin; Decaps; Deltalin; Deratol; Detalup; Diactol; Drisdol; Ercalciol; Ergocalciferolo; Ergocalciferols; Ergocalciferolum; Ergorone; Ertron; Fortodyl; Geltabs; Haliver; Hyperkil; Infron; Metadee; Mulsiferol; Mykostin; Ostelin; Radiostol; Radstein; Radsterin; Rodinec; Sterogyl; Vigantol; Viostdrol; Viosterol; CALCIFEROL IN A GELATIN MATRIX; Component of Geltabs Vitamin D; Davitamon D; Divit urto; Ergocalciferolo [DCIT]; Ergosterol activated; Ergosterol irradiated; Geltabs Vitamin D; Irradiated ergosterol; Oleovitamin D; Rodine C; Synthetic Vitamin D; Viosterol in Oil; Calciferon 2; Mina D2; Oleovitamin D2; VITAMIN D2; VITAMIN_D2; Vitamina D2; Buco-D; Calciferol (TN); Calciferol (vitamin D2); D-Arthin; D-Tracetten; De-rat concentrate; Dee-Osterol; Dee-Ron; Dee-Ronal; Dee-Roual; Deltalin (TN); Drisdol (TN); Ergocalciferol (D2); Ergocalciferol: Vitamin D; Ergocalciferolum [INN-Latin]; Ergosterol, irradiated; Hi-Deratol; Novovitamin-D; Oleovitamin D, Synthetic; Shock-ferol; Shock-ferol sterogyl; Sorex C.R; Uvesterol-D; Vio-D; Vitamin d-2; Vitamin-D2; Vitavel-D; Ergocalciferol (JP15/USP); Ergocalciferol [INN:BAN:JAN]; Sorex C.R.; VITAMIN D2 WATER DISPERSABLE U.S.P.; CALCIFEROL, U.S.P.; Irradiated ergosta-5,7,22-trien-3-beta-ol; Irradiated ergosta-5,7,22-trien-3.beta.-ol; (+)-Vitamin D2; (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol; (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol; (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol; (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol; 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87; 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol;9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol; 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
DMHO0AR CP Eli Lilly
DMHO0AR TC Vitamins
DMHO0AR DT Small molecular drug
DMHO0AR PC 5280793
DMHO0AR MW 396.6
DMHO0AR FM C28H44O
DMHO0AR IC InChI=1S/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
DMHO0AR CS C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](CCC3=C)O)C
DMHO0AR IK MECHNRXZTMCUDQ-RKHKHRCZSA-N
DMHO0AR IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMHO0AR CA CAS 50-14-6
DMHO0AR CB CHEBI:28934
DMHO0AR DE Hypoparathyroidism
DMORPBA ID DMORPBA
DMORPBA DN Ergoloid mesylate
DMORPBA HS Approved
DMORPBA SN Alkergot; Circanol; Gerimal; Hydergin; Ischelium; Redergin; Trigot; Dihydroergotoxin Mesilat; Dihydroergotoxinmesylate; Dihydroergotoxin methanesulfonate; Dihydroergotoxine methanesulfonate; Dihydroergotoxine methanesulphonate; Ergoloid Mesylates [USAN]; Hydergine LC; Hydrogenated Ergot Alkaloids; Alkergot (TN); Cicanol (TN); Deapril-ST; Gerimal (TN); Hydergina (TN); Hydergine (TN); Niloric (TN); Redergin (TN); Redizork (TN)
DMORPBA CP Sandoz
DMORPBA TC Vasodilator Agents
DMORPBA DT Small molecular drug
DMORPBA PC 592735
DMORPBA MW 591.7
DMORPBA FM C33H45N5O5
DMORPBA IC InChI=1S/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39)
DMORPBA CS CCC(C)(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O
DMORPBA IK YLXBZBPHTNJZQE-UHFFFAOYSA-N
DMORPBA IU N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMORPBA DE Alzheimer disease
DM0VEC1 ID DM0VEC1
DM0VEC1 DN Ergonovine
DM0VEC1 HS Approved
DM0VEC1 SN Basergin; Ergobasin; Ergobasine; Ergoklinine; Ergometrin; Ergometrina; Ergometrine; Ergometrinum; Ergostetrine; Ergotocine; Ergotrate; Margonovine; Neofemergen; Secacornin; Secometrin; Ergotrate Maleate; Lysergic acid propanolamide; Ergometrina [INN-Spanish]; Ergometrine (INN); Ergometrine [INN:BAN]; Ergometrinum[INN-Latin]; D-Lysergic acid 1-hydroxymethylethylamide; D-Lysergic acid-L-propanolamide; L-Lysergic-L(beta-hydroxyisopropylamide); N-(1-(Hydroxymethyl)ethyl)-D-lysergamide; N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide; N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide; N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-9,10-didehydroergoline-8beta-carboxamide; [8beta(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide
DM0VEC1 CP Pfizer Pharmaceuticals
DM0VEC1 TC Oxytocics
DM0VEC1 DT Small molecular drug
DM0VEC1 PC 443884
DM0VEC1 MW 325.4
DM0VEC1 FM C19H23N3O2
DM0VEC1 IC InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1
DM0VEC1 CS C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DM0VEC1 IK WVVSZNPYNCNODU-XTQGRXLLSA-N
DM0VEC1 IU (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM0VEC1 CA CAS 60-79-7
DM0VEC1 CB CHEBI:4822
DM0VEC1 DE Postpartum haemorrhage
DMKR3C5 ID DMKR3C5
DMKR3C5 DN Ergotamine
DMKR3C5 HS Approved
DMKR3C5 SN Avetol; Cornutamin; Cornutamine; ETIN; Ergam; Ergate; Ergomar; Ergonsvine; Ergostat; Ergotamin; Ergotartrate; Exmigra; Femergin;Gynergen; Lingraine; Lingran; Migretamine; Rigetamin; Secagyn; Secupan; Temigran; Wigrettes; Ergotamine bitartrate; Ergotamine hemitartrate; Ergotamine tartrate; Gotamine tartrate; Medihaler ergotamine; Ergomar (TN); Ergotamina [INN-Spanish]; Ergotamine (INN); Ergotamine [INN:BAN]; Ergotamine tartrate (VAN); Ergotaminum [INN-Latin]; Ergoton-A; Neo-ergotin; Ergotamine, tartrate (2:1); Ergotamine tartrate, Avetol, Cornutamin, Ergam, Ergotartrate; ERGOTAMINE (SEE ALSO: ERGOTAMINE TARTRATE (CAS 379-79-3)); Ergotamine, tartrate (2:1) (salt) (8CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)-(9CI); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt); (5'A)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman 2,3-dihydroxybutanedioate(2:1); 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione
DMKR3C5 CP Eli Lilly
DMKR3C5 TC Analgesics
DMKR3C5 DT Small molecular drug
DMKR3C5 PC 8223
DMKR3C5 MW 581.7
DMKR3C5 FM C33H35N5O5
DMKR3C5 IC InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
DMKR3C5 CS C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
DMKR3C5 IK XCGSFFUVFURLIX-VFGNJEKYSA-N
DMKR3C5 IU (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMKR3C5 CA CAS 379-79-3
DMKR3C5 CB CHEBI:64318
DMKR3C5 DE Headache
DM78IME ID DM78IME
DM78IME DN Ergotidine
DM78IME HS Approved
DM78IME SN Eramin; Ergamine; Histamine; Histaminum; Istamina; Theramine; Free histamine; Histamine Base; Histamine [USAN]; Istamina [Italian]; H7125_SIGMA; [3H]histamine; ALBB-005968; Beta-Aminoethylglyoxaline; Beta-Aminoethylimidazole; Beta-aminothethylglyoxaline; Histamine (DCF); Histamine, Free Base; Histaminum (TN); L-histamine; ZERO/004089; Imidazole-4-ethylamine; Beta-Imidazolyl-4-ethylamine; F411C768-A159-4FC0-A195-291A08BB03AA; 1H-Imidazole-4-ethanamine; 1H-Imidazole-5-ethanamine; 2-(1H-Imidazol-4-yl)ethanamine; 2-(1H-imidazol-4-yl)ethan-1-amine; 2-(1H-imidazol-5-yl)ethanamine; 2-(3H-Imidazol-4-yl)-ethylamine; 2-(4-Imidazolyl)ethylamine; 2-Imidazol-4-ylethylamine; 2-[4-Imidazolyl]ethylamine; 4-(2-Aminoethyl)-1H-imidazole; 4-Imidazoleethylamine; 5-Imidazoleethylamine
DM78IME TC Antiallergic Agents
DM78IME DT Small molecular drug
DM78IME PC 774
DM78IME MW 111.15
DM78IME FM C5H9N3
DM78IME IC InChI=1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)
DM78IME CS C1=C(NC=N1)CCN
DM78IME IK NTYJJOPFIAHURM-UHFFFAOYSA-N
DM78IME IU 2-(1H-imidazol-5-yl)ethanamine
DM78IME CA CAS 51-45-6
DM78IME CB CHEBI:18295
DM78IME DE Respiratory allergy
DM1DX4Q ID DM1DX4Q
DM1DX4Q DN Eribulin
DM1DX4Q HS Approved
DM1DX4Q CP Eisai
DM1DX4Q DT Small molecular drug
DM1DX4Q PC 11354606
DM1DX4Q MW 729.9
DM1DX4Q FM C40H59NO11
DM1DX4Q IC InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1
DM1DX4Q CS C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
DM1DX4Q IK UFNVPOGXISZXJD-JBQZKEIOSA-N
DM1DX4Q IU (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one
DM1DX4Q CA CAS 253128-41-5
DM1DX4Q CB CHEBI:63587
DM1DX4Q DE Breast cancer
DMCMBHA ID DMCMBHA
DMCMBHA DN Erlotinib
DMCMBHA HS Approved
DMCMBHA SN Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
DMCMBHA CP OSI Pharma
DMCMBHA TC Anticancer Agents
DMCMBHA DT Small molecular drug
DMCMBHA PC 176870
DMCMBHA MW 393.4
DMCMBHA FM C22H23N3O4
DMCMBHA IC InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
DMCMBHA CS COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
DMCMBHA IK AAKJLRGGTJKAMG-UHFFFAOYSA-N
DMCMBHA IU N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
DMCMBHA CA CAS 183321-74-6
DMCMBHA CB CHEBI:114785
DMCMBHA DE Non-small-cell lung cancer; Colon cancer; Pancreatic cancer
DM4S3O8 ID DM4S3O8
DM4S3O8 DN Ertapenem
DM4S3O8 HS Approved
DM4S3O8 SN Ertapenem [INN]; Ertapenem (INN); Invanz (TN); (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM4S3O8 CP Merck & Co
DM4S3O8 TC Antibiotics
DM4S3O8 DT Small molecular drug
DM4S3O8 PC 150610
DM4S3O8 MW 475.5
DM4S3O8 FM C22H25N3O7S
DM4S3O8 IC InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1
DM4S3O8 CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)[C@@H](C)O
DM4S3O8 IK JUZNIMUFDBIJCM-ANEDZVCMSA-N
DM4S3O8 IU (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM4S3O8 CA CAS 153832-46-3
DM4S3O8 CB CHEBI:404903
DM4S3O8 DE Bacterial infection
DMFGQ2S ID DMFGQ2S
DMFGQ2S DN Erythrityl Tetranitrate
DMFGQ2S HS Approved
DMFGQ2S SN Cardilate; Cardiloid; Cardivell; Cardiwell; Erythritetranitrat; Nitroerythrit; Nitroerythrite; Nitroerythrol; Tetranitrin; Tetranitrol; Eritritile tetranitrato; Eritritile tetranitrato [DCIT]; Eritrityl tetranitrate; Eritrityli tetranitras; Erythritol tetranitrate; Erythrityl tetranitrate [USAN]; Erythrol tetranitrate; Tetranitrato de eritritilo; Eritrityli tetranitras [INN-Latin]; Erythritol, tetranitrate; Meso-Erythritol tetranitrate; Tetranitrate d'erithrityle; Tetranitrate d'eritrityle; Tetranitrato de eritritilo [INN-Spanish]; Erythritol, tetranitrate (8CI); Tetranitrate d'eritrityle [INN-French]; 1,2,3,4-Butanetetralyl tetranitrate; 1,3,4-trinitrooxybutan-2-yl nitrate
DMFGQ2S TC Vasodilator Agents
DMFGQ2S DT Small molecular drug
DMFGQ2S PC 5284553
DMFGQ2S MW 302.11
DMFGQ2S FM C4H6N4O12
DMFGQ2S IC InChI=1S/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+
DMFGQ2S CS C([C@H]([C@H](CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMFGQ2S IK SNFOERUNNSHUGP-ZXZARUISSA-N
DMFGQ2S IU [(2R,3S)-1,3,4-trinitrooxybutan-2-yl] nitrate
DMFGQ2S CA CAS 7297-25-8
DMFGQ2S CB CHEBI:60072
DMFGQ2S DE Angina pectoris
DM4K7GQ ID DM4K7GQ
DM4K7GQ DN Erythromycin
DM4K7GQ HS Approved
DM4K7GQ SN Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery
DM4K7GQ CP Eli Lilly
DM4K7GQ TC Antibiotics
DM4K7GQ DT Small molecular drug
DM4K7GQ PC 12560
DM4K7GQ MW 733.9
DM4K7GQ FM C37H67NO13
DM4K7GQ IC InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
DM4K7GQ CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
DM4K7GQ IK ULGZDMOVFRHVEP-RWJQBGPGSA-N
DM4K7GQ IU (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM4K7GQ CA CAS 114-07-8
DM4K7GQ CB CHEBI:42355
DM4K7GQ DE Bacterial infection
DMFK9HG ID DMFK9HG
DMFK9HG DN Escitalopram
DMFK9HG HS Approved
DMFK9HG SN Esertia; Escitalopram [INN]; Cipralex (TN); Escitalopram (INN); Esertia (TN); Lexapro (TN); S(+)-Citalopram; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (S)-Citalopram
DMFK9HG CP Forest Laboratories
DMFK9HG TC Antidepressants
DMFK9HG DT Small molecular drug
DMFK9HG PC 146570
DMFK9HG MW 324.4
DMFK9HG FM C20H21FN2O
DMFK9HG IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
DMFK9HG CS CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DMFK9HG IK WSEQXVZVJXJVFP-FQEVSTJZSA-N
DMFK9HG IU (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DMFK9HG CA CAS 128196-01-0
DMFK9HG CB CHEBI:36791
DMFK9HG DE Major depressive disorder
DMZREFQ ID DMZREFQ
DMZREFQ DN Eslicarbazepine
DMZREFQ HS Approved
DMZREFQ SN Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix
DMZREFQ TC Neurology Agents
DMZREFQ DT Small molecular drug
DMZREFQ PC 9881504
DMZREFQ MW 254.28
DMZREFQ FM C15H14N2O2
DMZREFQ IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
DMZREFQ CS C1[C@@H](C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMZREFQ IK BMPDWHIDQYTSHX-AWEZNQCLSA-N
DMZREFQ IU (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMZREFQ CA CAS 104746-04-5
DMZREFQ DE Seizure disorder
DMREUZV ID DMREUZV
DMREUZV DN Eslicarbazepine acetate
DMREUZV HS Approved
DMREUZV SN Eslicarbazepine acetate; BIA 2-093; Aptiom; Zebinix; Stedesa; Exalief; Eslicarbazepine (acetate); UNII-BEA68ZVB2K; BIA-2-093; (S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate; Sep 0002093; BIA 2093; BEA68ZVB2K; SEP-0002093; CHEMBL87992; Eslicarbazepine acetate [USAN]; CHEBI:87016; exelief; (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide; [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate; Eslicarbazepine acetate (USAN)
DMREUZV PC 179344
DMREUZV MW 296.32
DMREUZV FM C17H16N2O3
DMREUZV IC InChI=1S/C17H16N2O3/c1-11(20)22-16-10-12-6-2-4-8-14(12)19(17(18)21)15-9-5-3-7-13(15)16/h2-9,16H,10H2,1H3,(H2,18,21)/t16-/m0/s1
DMREUZV CS CC(=O)OC1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N
DMREUZV IK QIALRBLEEWJACW-INIZCTEOSA-N
DMREUZV IU [(5S)-11-carbamoyl-5,6-dihydrobenzo[b][1]benzazepin-5-yl] acetate
DMREUZV CA CAS 236395-14-5
DMREUZV CB CHEBI:87016
DMREUZV DE Partial seizures
DM51TYR ID DM51TYR
DM51TYR DN Esmolol
DM51TYR HS Approved
DM51TYR SN ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
DM51TYR CP Bedford Laboratories
DM51TYR TC Antihypertensive Agents
DM51TYR DT Small molecular drug
DM51TYR PC 59768
DM51TYR MW 295.37
DM51TYR FM C16H25NO4
DM51TYR IC InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
DM51TYR CS CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
DM51TYR IK AQNDDEOPVVGCPG-UHFFFAOYSA-N
DM51TYR IU methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
DM51TYR CA CAS 81147-92-4
DM51TYR CB CHEBI:88206
DM51TYR DE Acute supraventricular tachycardia
DM7BN0X ID DM7BN0X
DM7BN0X DN Esomeprazole
DM7BN0X HS Approved
DM7BN0X SN Esomeprazolum; Nexiam; Inexium paranova; Axagon (TN); Esomeprazole (INN); Esomeprazole [INN:BAN]; Esopral (TN); Inexium paranova (TN); Lucen (TN); Nexiam (TN); Nexium (TN); Sompraz (TN); Zoleri (TN); (S)-(-)-Omeprazole; (S)-Omeprazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
DM7BN0X CP AstraZeneca
DM7BN0X TC Antiulcer Agents
DM7BN0X DT Small molecular drug
DM7BN0X PC 9568614
DM7BN0X MW 345.4
DM7BN0X FM C17H19N3O3S
DM7BN0X IC InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
DM7BN0X CS CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C(N2)C=C(C=C3)OC
DM7BN0X IK SUBDBMMJDZJVOS-DEOSSOPVSA-N
DM7BN0X IU 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DM7BN0X CA CAS 119141-88-7
DM7BN0X CB CHEBI:50275
DM7BN0X DE Peptic ulcer
DMZGXUM ID DMZGXUM
DMZGXUM DN Estazolam
DMZGXUM HS Approved
DMZGXUM SN Cannoc; Esilgan; Estazolamum; Eurodin; Julodin; Nemurel; Nuctalon; ProSom; Somnatrol; Tasedan; Abbott Brand of Estazolam; HormonaBrand of Estazolam; Takeda Brand of Estazolam; Abbott 47631; D 40TA; D40TA; U 33737; D-40TA; Estazolamum [INN-Latin]; Eurodin (TN); ProSom (TN); Prosom (TN); Estazolam [USAN:INN:JAN]; Estazolam (JP15/USAN/INN); 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine
DMZGXUM TC Anticonvulsants
DMZGXUM DT Small molecular drug
DMZGXUM PC 3261
DMZGXUM MW 294.74
DMZGXUM FM C16H11ClN4
DMZGXUM IC InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2
DMZGXUM CS C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4
DMZGXUM IK CDCHDCWJMGXXRH-UHFFFAOYSA-N
DMZGXUM IU 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMZGXUM CA CAS 29975-16-4
DMZGXUM CB CHEBI:4858
DMZGXUM DE Insomnia
DM9KZDO ID DM9KZDO
DM9KZDO DN Esterified estrogens
DM9KZDO HS Approved
DM9KZDO DE Breast cancer
DMUNTE3 ID DMUNTE3
DMUNTE3 DN Estradiol
DMUNTE3 HS Approved
DMUNTE3 SN Aerodiol; Alora; Altrad; Aquadiol; Bardiol; Climaderm; Climara; Compudose; Corpagen; Dermestril; Destradiol; Dihydrofolliculin; Dihydromenformon; Dihydrotheelin; Dihydroxyesterin; Dihydroxyestrin; Dihydroxyoestrin; Dimenformon; Diogyn; Diogynets; Divigel; Elestrin; Encore; Esclim; Estrace; Estraderm; Estradiolo; Estradiolum; Estradot; Estraldine; Estrasorb; Estreva; Estrifam; Estring; Estroclim; Estrodiolum; Estrogel; Estrovite; Evamist; Evorel; Extrasorb; Femanest; Femestral; Femestrol; Fempatch; Femtran; Follicyclin; Gelestra; Ginedisc; Ginosedol; GynPolar; Gynergon; Gynestrel; Gynodiol; Gynoestryl; Innofem; Lamdiol; Macrodiol; Macrol; Menest; Menorest; Microdiol; Nordicol; Oesclim; Oestergon; Oestradiol; Oestradiolum; Oestrogel; Oestroglandol; Oestrogynal; Ovahormon; Ovasterol; Ovastevol; Ovociclina; Ovocyclin; Ovocycline; Ovocylin; Perlatanol; Polyestradiol; Primofol; Profoliol; Progynon; Syndiol; Systen; Tradelia; Trocosone; Vagifem; Vivelle; Zerella; Zesteem; Zesteen; Zumenon; Climara Forte; Component of Menrium; Estraderm MX; Estraderm TTS; Estradiolo [DCIT]; Estradiolum [INN]; Estring vaginal ring; Estrofem Forte; Oestradiol Berco; Oestradiol R; Progynon DH; Sandrena Gel; Sisare Gel; Trial SAT; CMC_11154; Compudose 200; Compudose 365; E 2; E 8875; E0025; Epiestriol 50; Estraderm TTS 100; Estraderm TTS 50; Estrapak 50; Estroclim 50; Estrofem 2; Sandrena 1; [3H]]estradiol; Activella (TN); Alora (TN); Alpha-Oestradiol; AngeliQ (TN); B-Estradiol; Beta-Estradiol; Beta-Oestradiol; Beta-estradiol; Cis-Estradiol; Cis-Oestradiol; Climara (TN); D-Estradiol; D-Oestradiol; Divigel (TN); E(sub 2); Elestrin (TN); Estrace (TN); Estraderm (TN); Estraderm TTS (TN); Estradiol [USAN:INN]; Estradiol acetate (TN); Estradiol cypionate (TN); Estradiol valerate (TN); Estradiol-17 beta; Estradiol-17beta; Estrasorb (TN); Estrasorb Topical (TN); Estring (TN); Estrofem (TN); Estrogel (TN); EvaMist (TN); Femring (TN); Innofem (TN); Menostar (TN); Oestradiol-17beta; Progynon-DH; Progynova (TN); S-21400; SK-Estrogens; SL-1100; VIVELLE-DOT; Vagifem (TN); Vivelle (TN); [3H]-estradiol; Estradiol-17-beta; Estradiol-3,17beta; Oestradiol-17-beta; Vivelle-Dot (TN); D-3,17beta-Estradiol; [2,4,6,7-3H]-E2; 17 beta-Estradiol; 17-.BETA.-Estradiol; 17-beta-OH-estradiol; 17-beta-estradiol; 17.beta.-Estradiol; 17.beta.-Oestradiol; 17b-Oestradiol; 17beta oestradiol; 17beta-Estradiol; 17beta-Oestradiol; 3,17-beta-Estradiol; 3,17-beta-Oestradiol; 3,17.beta.-Estradiol; 3,17beta-Estradiol
DMUNTE3 TC Estrogens
DMUNTE3 DT Small molecular drug
DMUNTE3 PC 5757
DMUNTE3 MW 272.4
DMUNTE3 FM C18H24O2
DMUNTE3 IC InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
DMUNTE3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
DMUNTE3 IK VOXZDWNPVJITMN-ZBRFXRBCSA-N
DMUNTE3 IU (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMUNTE3 CA CAS 17916-67-5
DMUNTE3 CB CHEBI:16469
DMUNTE3 DE Breast cancer
DM07U2A ID DM07U2A
DM07U2A DN Estradiol acetate
DM07U2A HS Approved
DM07U2A SN Femring
DM07U2A CP Warner Chilcott Ireland Ltd
DM07U2A DT Small molecular drug
DM07U2A PC 9818306
DM07U2A MW 314.4
DM07U2A FM C20H26O3
DM07U2A IC InChI=1S/C20H26O3/c1-12(21)23-14-4-6-15-13(11-14)3-5-17-16(15)9-10-20(2)18(17)7-8-19(20)22/h4,6,11,16-19,22H,3,5,7-10H2,1-2H3/t16-,17-,18+,19+,20+/m1/s1
DM07U2A CS CC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C
DM07U2A IK FHXBMXJMKMWVRG-SLHNCBLASA-N
DM07U2A IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate
DM07U2A CA CAS 4245-41-4
DM07U2A CB CHEBI:135981
DM07U2A DE Hormone replacement therapy
DM27Z5T ID DM27Z5T
DM27Z5T DN Estradiol cypionate
DM27Z5T HS Approved
DM27Z5T SN Depo-estradiol
DM27Z5T CP Pharmacia And Upjohn Co
DM27Z5T DT Small molecular drug
DM27Z5T PC 9403
DM27Z5T MW 396.6
DM27Z5T FM C26H36O3
DM27Z5T IC InChI=1S/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1
DM27Z5T CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O
DM27Z5T IK UOACKFBJUYNSLK-XRKIENNPSA-N
DM27Z5T IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
DM27Z5T CA CAS 313-06-4
DM27Z5T CB CHEBI:34745
DM27Z5T DE Hormone replacement therapy
DM8MC6O ID DM8MC6O
DM8MC6O DN Estradiol valerate
DM8MC6O HS Approved
DM8MC6O SN Delestrogen
DM8MC6O CP Par Sterile Products Llc
DM8MC6O DT Small molecular drug
DM8MC6O PC 13791
DM8MC6O MW 356.5
DM8MC6O FM C23H32O3
DM8MC6O IC InChI=1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1
DM8MC6O CS CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C
DM8MC6O IK RSEPBGGWRJCQGY-RBRWEJTLSA-N
DM8MC6O IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate
DM8MC6O CA CAS 979-32-8
DM8MC6O CB CHEBI:31561
DM8MC6O DE Hormone replacement therapy
DMLNMEA ID DMLNMEA
DMLNMEA DN Estradiol valerate/dienogest
DMLNMEA HS Approved
DMLNMEA SN Climodien; Climodiene; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme
DMLNMEA DT Small molecular drug
DMLNMEA PC 9874560
DMLNMEA MW 667.9
DMLNMEA FM C43H57NO5
DMLNMEA IC InChI=1S/C23H32O3.C20H25NO2/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2;1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3;12,17-18,23H,2-10H2,1H3/t18-,19-,20+,21+,23+;17-,18+,19+,20-/m11/s1
DMLNMEA CS CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C.C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O
DMLNMEA IK LRHSUZNWLAJWRT-GAJBHWORSA-N
DMLNMEA IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate;2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
DMLNMEA CA CAS 307334-58-3
DMLNMEA DE Discovery agent
DMWTAOI ID DMWTAOI
DMWTAOI DN Estramustine
DMWTAOI HS Approved
DMWTAOI SN Estramustina; Estramustinum; Emcyt (TN); Estramustine (USAN/INN); Estradiol 3-[bis(2-chloroethyl)carbamate]; Ro-22-2296/000; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate]
DMWTAOI CP Pfizer Pharmaceuticals
DMWTAOI TC Anticancer Agents
DMWTAOI DT Small molecular drug
DMWTAOI PC 259331
DMWTAOI MW 440.4
DMWTAOI FM C23H31Cl2NO3
DMWTAOI IC InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1
DMWTAOI CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl
DMWTAOI IK FRPJXPJMRWBBIH-RBRWEJTLSA-N
DMWTAOI IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate
DMWTAOI CA CAS 2998-57-4
DMWTAOI CB CHEBI:4868
DMWTAOI DE Prostate cancer
DMOEM2I ID DMOEM2I
DMOEM2I DN Estriol
DMOEM2I HS Approved
DMOEM2I SN Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene
DMOEM2I CP Pipex Pharmaceuticals
DMOEM2I TC Estrogens
DMOEM2I DT Small molecular drug
DMOEM2I PC 5756
DMOEM2I MW 288.4
DMOEM2I FM C18H24O3
DMOEM2I IC InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1
DMOEM2I CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O
DMOEM2I IK PROQIPRRNZUXQM-ZXXIGWHRSA-N
DMOEM2I IU (8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol
DMOEM2I CA CAS 50-27-1
DMOEM2I CB CHEBI:27974
DMOEM2I DE Hormone deficiency; Multiple sclerosis
DMGY0UT ID DMGY0UT
DMGY0UT DN Estrogen
DMGY0UT HS Approved
DMGY0UT DE Menopause symptom
DM5T6US ID DM5T6US
DM5T6US DN Estrone
DM5T6US HS Approved
DM5T6US SN Aquacrine; Crinovaryl; Cristallovar; Crystogen; Destrone; Disynformon; Endofolliculina; Esterone; Estrin; Estrol; Estron; Estrona; Estronum; Estrovarin; Estrugenone; Estrusol; Femidyn; Fermidyn; Folikrin; Folipex; Folisan; Follestrine; Follestrol; Folliculin; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Hormofollin; Hormovarine; Kestrone; Ketodestrin; Ketohydroxyestrin; Ketohydroxyoestrin; Ketophydroxyestrin; Kolpon; Menagen; Menformon; Mestronaq; OESTRONE; Oestrin; Oestroform; Oestronum; Oestroperos; Ovifollin; Perlatan; Solliculin; Theelin; Thelestrin; Thelykinin; Thynestron; Tokokin; Unden; Unigen; Wehgen; Wynestron; Estrogenic Substance; Estrona [Spanish]; Femestrone injection; Follicular hormone; Folliculine benzoate; Hauck Brand of Estrone; Hyrex Brand of Estrone; Menformon A; Oestrone [Steroidal oestrogens]; Penncap M; Vortech Brand of Estrone; WynestronPencap M; CMC_13458; E 9750; E0026; E(sub 1); Estrona [INN-Spanish]; Estrone (E1); Estrone (TN); Estrone [USAN:INN]; Estrone-A; Estronum [INN-Latin]; Femestrone inj.; Ketohydroxy-Estratriene; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; Oestrone, Estrone; Ovex (tablets); Unden (pharmaceutical); Unden (pharmaceutical) (VAN); Estrone (JAN/USP/INN); Estrone, (8 alpha)-Isomer; Estrone, (9 beta)-Isomer; Estrone, (+-)-Isomer; [2,4,6,7-3H]-E1; Delta-1,3,5-Estratrien-3beta-ol-17-one; Delta-1,3,5-Oestratrien-3beta-ol-17-one; Delta-1,3,5-estratrien-3-beta-ol-17-one; Delta-1,3,5-oestratrien-3-beta-ol-17-one; (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; 1,3,5(10)-Estratrien-3-ol-17-one; 1,3,5(10)-Oestratrien-3-ol-17-one; 3-Hydroxy-1,3,5(10)-estratrien-17-one; 3-Hydroxy-17-keto-estra-1,3,5-triene; 3-Hydroxy-17-keto-oestra-1,3,5-triene; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; 3-hydroxy-estra-1,3,5(10)-trien-17-one
DM5T6US TC Antimenopausal Agents
DM5T6US DT Small molecular drug
DM5T6US PC 5870
DM5T6US MW 270.4
DM5T6US FM C18H22O2
DM5T6US IC InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
DM5T6US CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O
DM5T6US IK DNXHEGUUPJUMQT-CBZIJGRNSA-N
DM5T6US IU (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DM5T6US CA CAS 53-16-7
DM5T6US CB CHEBI:17263
DM5T6US DE Menopausal and postmenopausal disorder
DMVBIZL ID DMVBIZL
DMVBIZL DN Estrone sulfate
DMVBIZL HS Approved
DMVBIZL SN Estrone 3-sulfate; Estrone hydrogen sulfate; Estrone sulphate; [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate; [3H]estrone-3-sulphate
DMVBIZL DT Small molecular drug
DMVBIZL PC 3001028
DMVBIZL MW 350.429
DMVBIZL FM C18H22O5S
DMVBIZL IC InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1
DMVBIZL CS CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
DMVBIZL IK JKKFKPJIXZFSSB-CBZIJGRNSA-N
DMVBIZL IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMVBIZL CA CAS 481-97-0
DMVBIZL CB CHEBI:17474
DMVBIZL DE Menopausal symptoms
DMRMDWA ID DMRMDWA
DMRMDWA DN Estropipate
DMRMDWA HS Approved
DMRMDWA SN Estropipate; 7280-37-7; Piperazine estrone sulfate; Harmogen; Ogen; Ortho-Est; UNII-SVI38UY019; Piperazine estronesulfate; Sulestrex; SVI38UY019; Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, compd. with piperazine (1:1); OGEN 2.5; Estropipate (USP); OGEN 5; Ogen (TN); OGEN .625; OGEN 1.25; EINECS 230-696-3; piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate; Piperazine oestrone sulphate; Conjugated estrogens: piperazine estrone sulfate; Estrone hydrogen sulf
DMRMDWA DT Small molecular drug
DMRMDWA PC 5284555
DMRMDWA MW 436.6
DMRMDWA FM C22H32N2O5S
DMRMDWA IC InChI=1S/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1
DMRMDWA CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1
DMRMDWA IK HZEQBCVBILBTEP-ZFINNJDLSA-N
DMRMDWA IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;piperazine
DMRMDWA CA CAS 7280-37-7
DMRMDWA CB CHEBI:4873
DMRMDWA DE Hypogonadism
DM8RZ9H ID DM8RZ9H
DM8RZ9H DN Eszopiclone
DM8RZ9H HS Approved
DM8RZ9H SN Esopiclone; Estorra; Lunesta; Lunivia; Estorra (TN); Eszopiclone [USAN:INN]; KS-1055; SEP-0227018; SEP-0227108; SEP-190; SEP-225441; Eszopiclone (JAN/USAN/INN); [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate; (S)-Zopiclone; (plus)-Zopiclone; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester
DM8RZ9H CP GSK
DM8RZ9H TC Hypnotics and Sedatives
DM8RZ9H DT Small molecular drug
DM8RZ9H PC 969472
DM8RZ9H MW 388.8
DM8RZ9H FM C17H17ClN6O3
DM8RZ9H IC InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
DM8RZ9H CS CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
DM8RZ9H IK GBBSUAFBMRNDJC-INIZCTEOSA-N
DM8RZ9H IU [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
DM8RZ9H CA CAS 138729-47-2
DM8RZ9H CB CHEBI:53760
DM8RZ9H DE Insomnia
DMCV109 ID DMCV109
DMCV109 DN Etanercept
DMCV109 HS Approved
DMCV109 SN Etanercept (sciatica); Etanercept (sciatica), BioAssets Development; Etanercept (sciatica), Cephalon
DMCV109 CP AstraZeneca
DMCV109 DT Monoclonal antibody
DMCV109 SQ Etanercept Sequence: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMCV109 DE Arthritis; Pemphigus vulgaris; Sciatica
DMHP9BL ID DMHP9BL
DMHP9BL DN Etelcalcetide
DMHP9BL HS Approved
DMHP9BL SN Velcalcetide; Parsabiv; UNII-60ME133FJB; 1262780-97-1; 60ME133FJB; etelcalcetide HCl; Etelcalcetide [USAN:INN]; Etelcalcetide (USAN/INN); Etelcalcetide Hydrochloride(AMG-416)
DMHP9BL CP Amgen/Kai Pharmaceuticals
DMHP9BL DT Small molecular drug
DMHP9BL PC 71511839
DMHP9BL MW 1048.3
DMHP9BL FM C38H73N21O10S2
DMHP9BL IC InChI=1S/C38H73N21O10S2/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52)/t18-,19-,21+,22-,23-,24-,25-,26-/m1/s1
DMHP9BL CS C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@@H](C(=O)O)N)NC(=O)C
DMHP9BL IK ANIAZGVDEUQPRI-ZJQCGQFWSA-N
DMHP9BL IU (2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid
DMHP9BL CA CAS 1262780-97-1
DMHP9BL CB CHEBI:134700
DMHP9BL DE Secondary hyperparathyroidism; Myelodysplastic syndrome
DM2QBHP ID DM2QBHP
DM2QBHP DN Eteplirsen
DM2QBHP HS Approved
DM2QBHP SN AVI-4658
DM2QBHP CP Sarepta Therapeutics
DM2QBHP DE Duchenne dystrophy
DM5M4NT ID DM5M4NT
DM5M4NT DN Ethacrynate sodium
DM5M4NT HS Approved
DM5M4NT CP Aton Pharma Inc
DM5M4NT TC Cardiovascular Agents
DM5M4NT DT Small molecular drug
DM5M4NT PC 23668825
DM5M4NT MW 325.12
DM5M4NT FM C13H11Cl2NaO4
DM5M4NT IC InChI=1S/C13H12Cl2O4.Na/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17;/h4-5H,2-3,6H2,1H3,(H,16,17);/q;+1/p-1
DM5M4NT CS CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])Cl)Cl.[Na+]
DM5M4NT IK CWCSCNSKBSCYCS-UHFFFAOYSA-M
DM5M4NT IU sodium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate
DM5M4NT CA CAS 6500-81-8
DM5M4NT DE High blood pressure
DM60QMR ID DM60QMR
DM60QMR DN Ethacrynic acid
DM60QMR HS Approved
DM60QMR SN Crinuryl; Edecril; Edecrina; Endecril; Ethacrynate; Hidromedin; Hydromedin; Mingit; Otacril; Reomax; Taladren; Uregit; Acide etacrynique; Acido etacrinico; Acidum etacrynicum; Etacrinic acid; Etacrynic Acid; Etakrinic acid; Ethacrinic acid; Ethacryinic Acid; Kyselina ethakrynova; Kyselina ethakrynova [Czech]; Methylenebutyryl phenoxyacetic acid; Methylenebutyrylphenoxyacetic acid; E0526; MK 595; Acide etacrynique [INN-French]; Acido etacrinico [INN-Spanish]; Acidum etacrynicum [INN-Latin]; Edecrin (TN); Ethacrinique (acide); Ethacrynic Acid, Sodium Salt; Ethacrynic acid (USP); Ethacrynic acid [USAN:BAN]; MK-595; Etacrynic acid (JP15/INN); [2,3-Dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylenebutanoyl)phenoxy]acetic acid; [2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid; [4-(2-Methylenebutyryl)-2,3-dichlorophenoxy]acetic acid; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova; Kyselina 4-(2-(1-butenyl)karbonyl)-2,3-dichlorfenoxyoctova [Czech]; [2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-methylenebutyryl)phenoxy)acetic acid; (2,3-Dichloro-4-[2-methylenebutyryl]phenoxy)acetic acid; (4-(2-Methylenebutyryl)-2,3-dichlorophenoxy)acetic acid; 2,3-Dichloro-4(2-methylene-butyryl)phenoxy] acetic acid; 2,3-Dichloro-4-(2-methylenebutyl)phenoxyacetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxy acetic acid; 2,3-Dichloro-4-(2-methylenebutyryl)phenoxyacetic acid; 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
DM60QMR TC Diuretics
DM60QMR DT Small molecular drug
DM60QMR PC 3278
DM60QMR MW 303.13
DM60QMR FM C13H12Cl2O4
DM60QMR IC InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
DM60QMR CS CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
DM60QMR IK AVOLMBLBETYQHX-UHFFFAOYSA-N
DM60QMR IU 2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
DM60QMR CA CAS 58-54-8
DM60QMR CB CHEBI:4876
DM60QMR DE High blood pressure
DMR87LC ID DMR87LC
DMR87LC DN Ethambutol
DMR87LC HS Approved
DMR87LC SN Aethambutolum; Diambutol; EMB; Etambutol; Etambutolo; Ethambutolum; Etibi; Miambutol; Myambutol; Purderal; Servambutol; Tibutol; Etambutolo [DCIT]; CL 40881 (dihydrochloride); D-Ethambutol; Etambutol [INN-Spanish]; Ethambutol & EEP; Ethambutol & Propolis; Ethambutol (INN); Ethambutol [INN:BAN]; Ethambutol, meso form; Ethambutol, racemic mixture; Ethambutolum [INN-Latin]; Myambutol (TN); Myambutol (dihydrochloride); Servambutol (TN); Ethambutol, (-)-isomer; D,N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-N,N'-Bis(1-hydroxymethylpropyl)ethylenediamine; D-2,2'-(Ethylenediimino)bis(1-butanol); D-2,2'-(Ethylenediimino)di-1-butanol; (+)-(S,S)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (+)-2,2'-(Ethylenediimino)di-1-butanol; (+)-N,N'-Bis(1-(hydroxymethyl)propyl)ethylenediamine; (+)-S,S-Ethambutol; (+)-ethambutol; (-)-(R,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (2'S)-2,2'-[Ethane-1,2-diyldi(imino)]dibutan-1-ol; (2R)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2R)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S)-2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol; (2S)-2-[2-[[(2R)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol; (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol; (R)-2,2'-(1,2-Ethanediyldiimino)bis-1-butanol; (S,R)-2,2'-(1,2-Ethylenediimino)-di-1-butanol; (S,S)-ethambutol; 2,2'-(1,2-Ethylenediimino)-di-1-butanol; 2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol; 2-[2-(1-hydroxybutan-2-ylamino)ethylamino]butan-1-ol
DMR87LC CP Macleods Pharmaceutical. Ltd
DMR87LC TC Antitubercular Agents
DMR87LC DT Small molecular drug
DMR87LC PC 14052
DMR87LC MW 204.31
DMR87LC FM C10H24N2O2
DMR87LC IC InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1
DMR87LC CS CC[C@@H](CO)NCCN[C@@H](CC)CO
DMR87LC IK AEUTYOVWOVBAKS-UWVGGRQHSA-N
DMR87LC IU (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol
DMR87LC CA CAS 74-55-5
DMR87LC CB CHEBI:4877
DMR87LC DE Pulmonary tuberculosis
DMDRQZU ID DMDRQZU
DMDRQZU DN Ethanol
DMDRQZU HS Approved
DMDRQZU SN Aethanol; Aethylalkohol; Alcohol; Alcohols; Algrain; Alkohol; Anhydrol; EOH; EOX; EtOH; Etanol; Etanolo; Ethicap; Ethylalcohol; Ethylol; Hinetoless; Hydroxyethane; Jaysol; Methylcarbinol; QMHAIh; Sekundasprit; Spirit; Spirt; Synasol; Tecsol; Thanol; Absolute alcohol; Absolute ethanol; Aethanol [German]; Alcare Hand Degermer; Alcohol [USP]; Alcohol anhydrous; Alcohol dehydrated; Alcohol etilico; Alcool ethylique; Alcool etilico; Alkohol [German]; Alkoholu etylowego; Anhydrous alcohol; Anhydrous ethanol; Cologne Spirit; Colognespirits; Dehydrated alcohol; Dehydrated ethanol; Denatured alcohol; Denatured ethanol; Desinfektol EL; Distilled spirits; Etanolo [Italian]; Ethanol Absolute; Ethanol Absolute Bp; Ethanol Anhydrous; Ethanol Extra Pure; Ethanol Vapor; Ethanol [JAN]; Ethanol solution; Ethanolum anhydricum; Ethyl alc; Ethyl alcohol; Ethyl alcohol usp; Ethyl hydrate; Ethyl hydroxide; Ethylalcohol [Dutch]; Ethyloxy Group; Etylowy alkohol; Fermentation alcohol; Grain alcohol; HYDROXYETHYL GROUP; Infinity Pure; Jaysol S; Methylated spirit; Molasses alcohol; Oxydimethylene Group; Potato alcohol; Reagent Alcohol; SY Fresh M; Spirits of wine; Spiritus vini; Tecsol C; AHD 2000; Anhydrol PM 4085; CDA 19; E7148_ALDRICH; Esumiru WK 88; Ethanol 200 proof; IMS 99; LTBB002977; SDA 3A; Alcohol (USP); Alcohol, Absolute; Alcohol, Grain; Alcohol, anhydrous; Alcohol, dehydrated; Alcohol, diluted; Alcohol, ethyl; Alcohols, C30; CDA 19-200; Ethanol (9CI); Ethanol, undenatured; Ru-Tuss Expectorant; SDA 40-2; SDM No. 37; ALCOHOL 5% IN D5-W; Alcohols, C1-3; Alcohols, C6-9; (C6-C9)Alkyl alcohol; 1-Hydroxyethane; 100C.NPA
DMDRQZU TC Analgesics
DMDRQZU DT Small molecular drug
DMDRQZU PC 702
DMDRQZU MW 46.07
DMDRQZU FM C2H6O
DMDRQZU IC InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3
DMDRQZU CS CCO
DMDRQZU IK LFQSCWFLJHTTHZ-UHFFFAOYSA-N
DMDRQZU IU ethanol
DMDRQZU CA CAS 64-17-5
DMDRQZU CB CHEBI:16236
DMDRQZU DE Cystitis; Chronic pain
DM3B654 ID DM3B654
DM3B654 DN Ethanolamine oleate
DM3B654 HS Approved
DM3B654 SN Ethamolin (TN)
DM3B654 DT Small molecular drug
DM3B654 PC 5282489
DM3B654 MW 343.5
DM3B654 FM C20H41NO3
DM3B654 IC InChI=1S/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-;
DM3B654 CS CCCCCCCC/C=C\\CCCCCCCC(=O)O.C(CO)N
DM3B654 IK KGWDUNBJIMUFAP-KVVVOXFISA-N
DM3B654 IU 2-aminoethanol;(Z)-octadec-9-enoic acid
DM3B654 CA CAS 2272-11-9
DM3B654 DE Bleeding disorder
DM53IP1 ID DM53IP1
DM53IP1 DN Ethchlorvynol
DM53IP1 HS Approved
DM53IP1 SN Alvinol; Arvynol; Etchlorvinolo; Etclorvinol; Ethchlorovynol; Ethchlorvinol; Ethchlorvinyl; Ethchlorvynolum;Ethclorvynol; Ethochlorvynol; Ethychlorvynol; Normonson; Normosan; Normoson; Nostel; Nromoson; Placidil; Placidyl; Roeridorm; Serenesil; Serenil; Serensil; Serensiloline; A 71; Aethyl-chlorvynol; Beta-Chlorovinyl ethyl ethynyl carbinol; Beta-Chlorvinyl ethyl ethynyl carbinol; Etclorvinol [INN-Spanish]; Ethchlorvynolum [INN-Latin]; Ethyl beta-chlorovinyl ethynyl carbinol; Placidyl (TN); Ethchlorvynol [USAN:INN:BAN]; Ethchlorvynol (JAN/USP/INN); (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol; 1-Chloro-3-ethyl-1-penten-4-yn-3-ol; 1-Chloro-3-ethylpent-1-4-yn-3-ol; 1-chloro-3-ethylpent-1-en-4-yn-3-ol; 3-(beta-Chlorovinyl)-1-pentyn-3-ol; 5-Chloro-3-ethylpent-1-yn-4-en-3-ol
DM53IP1 CP Abbott Laboratories
DM53IP1 TC Hypnotics and Sedatives
DM53IP1 DT Small molecular drug
DM53IP1 PC 5281077
DM53IP1 MW 144.6
DM53IP1 FM C7H9ClO
DM53IP1 IC InChI=1S/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5+
DM53IP1 CS CCC(/C=C/Cl)(C#C)O
DM53IP1 IK ZEHYJZXQEQOSON-AATRIKPKSA-N
DM53IP1 IU (E)-1-chloro-3-ethylpent-1-en-4-yn-3-ol
DM53IP1 CA CAS 113-18-8
DM53IP1 CB CHEBI:4882
DM53IP1 DE Insomnia
DMK57GB ID DMK57GB
DMK57GB DN Ethinamate
DMK57GB HS Approved
DMK57GB SN Ethinamat; Ethinamatum; Ethinimate; Etinamate; Etinamato; Valamid; Valamin; Valaminetta; Valaminettae; Valaminetten; Valmid; Valmidate; Volamin; Ethynylcyclohexyl carbamate; Carbamate de L'ethinylcyclohexanol; Carbamate de l'ethinylcyclohexanol [French]; Ethinamatum [INN-Latin]; Etinamato [INN-Spanish]; USAF EL-42; Valamin (TN); Valmid (TN); Aethinyl-cyclohexyl-carbamat; Aethinyl-cyclohexyl-carbamat [German]; Carbamic acid, 1-ethynylcyclohexyl ester; Ethinamate (JAN/INN); Ethinamate [INN:BAN:JAN]; Cyclohexanol, 1-ethynyl-, carbamate; Cyclohexanol, 1-ethynyl-, 1-carbamate; (1-ethynylcyclohexyl) carbamate; 1-Ethinylcyclohexyl carbamate; 1-Ethinylcyclohexyl carbonate; 1-Ethynylcyclohexanol carbamate; 1-Ethynylcyclohexyl carbamate; 1-ethynylcyclohexylcarbamate
DMK57GB TC Hypnotics and Sedatives
DMK57GB DT Small molecular drug
DMK57GB PC 3284
DMK57GB MW 167.2
DMK57GB FM C9H13NO2
DMK57GB IC InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11)
DMK57GB CS C#CC1(CCCCC1)OC(=O)N
DMK57GB IK GXRZIMHKGDIBEW-UHFFFAOYSA-N
DMK57GB IU (1-ethynylcyclohexyl) carbamate
DMK57GB CA CAS 126-52-3
DMK57GB CB CHEBI:4884
DMK57GB DE Insomnia
DMODJ40 ID DMODJ40
DMODJ40 DN Ethinyl estradiol
DMODJ40 HS Approved
DMODJ40 SN Aethinyloestradiolum; Aethinyoestradiol; Amenoron; Amenorone; Anovlar; Certostat; Cyclosa; Dicromil; Diprol; Dyloform; Ertonyl; Esteed; Estigyn; Estinyl; Estopherol; Estoral; Estorals; Ethidol; Ethinoral; Ethinylestradiolum; Ethinylestriol; Ethinyloestradiol; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol; Etinilestradiolo; Etinoestryl; Etistradiol; Etivex; Feminone; Follicoral; Ginestrene; Inestra; Kolpolyn; Linoral; Lynoral; Menolyn; Microfollin; Novestrol; Oradiol; Orestralyn; Orestrayln; Palonyl; Perovex; Primogyn; Prosexol; Spanestrin; Ylestrol; Aethinyoestradiol [German]; Component of Demulen; Component of Oracon; Component of Ortrel; Diogyn E; Effik Brand of Ethinyl Estradiol; Estoral [Orion]; Ethinyl Estradiol Hemihydrate; Ethinyl Estradiol [USP]; Ethinyl Oestradiol Effik; Ethinylestradiol Jenapharm; Ethinyloestradiol [Steroidal oestrogens]; Ethynyl estradiol; Etinilestradiolo [DCIT]; Jenapharm Brand of Ethinyl Estradiol; Microfollin Forte; Organon Brand of Ethinyl Estradiol; PUBERTAL ETHINYL ESTRADIOL STUDY; Primogyn C; Primogyn M; Progynon C; Progynon M; Schering Brand of Ethinyl Estradiol; EE2; Ethinyl E2; Ethy 11; Diognat-E; Diogyn-E; EE(sub 2); Estinyl (TN); Eston-E; Estoral (Orion); Estoral (VAN); Estradiol, Ethinyl; Estradiol, Ethynyl; Ethinyl estradiol (USP); Ethinyl-Oestradiol Effik; Ethinyl-oestranol; Ethinylestradiolum [INN-Latin]; Ethynylestradiol, Ethinyl Estradiol; Etinilestradiol [INN-Spanish]; Hemihydrate, Ethinyl Estradiol; Jenapharm, Ethinylestradiol; Neo-Estrone; Nogest-S; OVULEN-21; OVULEN-28; Ortho-Cyclen; Chee-O-Gen; Chee-O-Genf; Ethinylestradiol (JP15/INN); Ethinylestradiol [INN:BAN:JAN]; Ethinyl Estradiol, (8 alpha)-Isomer; 17 alpha-Ethinylestradiol; 17 alpha-Ethynylestradiol; 17 alpha-Ethynyloestradiol; 17 alpha-ethinyestradiol; 17-Ethinyl-3,17-estradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethinylestradiol; 17-Ethynylestradiol; 17-Ethynyloestradiol; 17-alpha-Ethinyl-17-beta-estradiol; 17-alpha-Ethynyl-17-beta-oestradiol; 17-alpha-Ethynylestradiol; 17-alpha-Ethynylestradiol-17-beta; 17-alpha-Ethynylestradiol-l7-beta; 17-alpha-Ethynyloestradiol-17-beta; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynyl-17.beta.-oestradiol; 17.alpha.-Ethynylestradiol; 17.alpha.-Ethynyloestradiol; 17a-Ethynylestradiol; 17alpha-Ethinyl estradiol; 17alpha-Ethinylestradiol; 17alpha-Ethinylestradiol-17beta; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; 17alpha-Ethynyloestradiol-17beta
DMODJ40 CP Schering-Plough
DMODJ40 TC Estrogens
DMODJ40 DT Small molecular drug
DMODJ40 PC 5991
DMODJ40 MW 296.4
DMODJ40 FM C20H24O2
DMODJ40 IC InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
DMODJ40 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
DMODJ40 IK BFPYWIDHMRZLRN-SLHNCBLASA-N
DMODJ40 IU (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMODJ40 CA CAS 57-63-6
DMODJ40 CB CHEBI:4903
DMODJ40 DE Female hypogonadism
DM8K3EI ID DM8K3EI
DM8K3EI DN Ethionamide
DM8K3EI HS Approved
DM8K3EI SN Aethionamidum; Aetina; Aetiva; Amidazin; Amidazine; Atina; Ethatyl; Ethimide; Ethina; Ethinamide; Ethionamidum; Ethioniamide; Ethylisothiamide; Ethyonomide; Etimid; Etiocidan; Etionamid; Etionamida; Etionamide; Etioniamid; Etionid; Etionizin; Etionizina; Etionizine; Fatoliamid; Iridocin; Iridozin; Isothin; Isotiamida; Itiocide; Nicotion; Nisotin; Nizotin; Rigenicid; Sertinon; Teberus; Thianid; Thianide; Thioamide; Thiomid; Thioniden; Tianid; Tiomid; Trecator; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; Ethionamid prothionamid; Etionamide [DCIT]; Iridocin Bayer; Trecator SC; Wyeth Brand of Ethionamide; Bayer 5312; Bayer5312; E0695; TH 1314; Alpha-Ethylisonicotinic acid thioamide; Alpha-Ethylisonicotinoylthioamide; Alpha-Ethylisothionicotinamide; Alpha-Ethylthioisonicotinamide; Alpha-ethylt hioisonicotinamide; Ethina (VAN); Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; Tio-Mid; Trecator-SC; Alpha-Ethyl-thioisonicotinamide; Trecator-SC (TN); Ethionamide (JP15/USP/INN); Ethionamide [USAN:INN:BAN:JAN]; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; 2-Ethyl-4-thioamidylpyridine; 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 2-Ethylisonicotinic acid thioamide; 2-Ethylisonicotinic thioamide; 2-Ethylisonicotinothioamide; 2-Ethylisonicotinoylthioamide; 2-Ethylisothionicotinamide; 2-Ethylthioisonicotinamide; 2-e thylisothionicotinamide; 2-ethyl-4-aminothiocarbonylpyridine; 2-ethylisonicotinic acid thiomide; 2-ethylpyridine-4-carbothioamide; 2-ethylthioisonicotinamide, Trecator SC, Amidazine, Ethionamide; 3-Ethylisothionicotinamide
DM8K3EI TC Antituberculosis Agents
DM8K3EI DT Small molecular drug
DM8K3EI PC 2761171
DM8K3EI MW 166.25
DM8K3EI FM C8H10N2S
DM8K3EI IC InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
DM8K3EI CS CCC1=NC=CC(=C1)C(=S)N
DM8K3EI IK AEOCXXJPGCBFJA-UHFFFAOYSA-N
DM8K3EI IU 2-ethylpyridine-4-carbothioamide
DM8K3EI CA CAS 536-33-4
DM8K3EI CB CHEBI:4885
DM8K3EI DE Tuberculosis
DM0N3L7 ID DM0N3L7
DM0N3L7 DN Ethopropazine
DM0N3L7 HS Approved
DM0N3L7 SN Aethopropropazin; Athapropazine; Athopropazin; Ethapropazine; Ethopromazine; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothiazine; Lysivane; Parcidol; Pardidol; Parfezine; Parkin; Parkisol; Parsidan; Parsidol; Parsitan; Parsotil; Phenopropazine; Phenoprozine; Prodictazin; Prodierazine; Profenamina; Profenamine; Profenaminum; Prophenamine; Prophenaminum; Rochipel; Rocipel; Rodipal; Profenamina [Italian]; RP 3356; SC 2538; SKF 2538; W 483; Parkin (TN); Parsidan (TN); Parsidol(TN); Profenamina [INN-Spanish]; Profenamine (INN); Profenamine [INN:BAN]; Profenaminum [INN-Latin]; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; 10-(2-Diethylaminopropyl)phenothiazine; 10-[2-(Diethylamino)-1-Propyl]phenothiazine;10-[2-(Diethylamino)-2-methylethyl]phenothiazine; 10-[2-(Diethylamino)propyl]phenothiazine; 2-Diethylamino-1-propyl-N-dibenzoparathiazine
DM0N3L7 TC Antiparkinson Agents
DM0N3L7 DT Small molecular drug
DM0N3L7 PC 3290
DM0N3L7 MW 312.5
DM0N3L7 FM C19H24N2S
DM0N3L7 IC InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3
DM0N3L7 CS CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31
DM0N3L7 IK CDOZDBSBBXSXLB-UHFFFAOYSA-N
DM0N3L7 IU N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine
DM0N3L7 CA CAS 522-00-9
DM0N3L7 CB CHEBI:313639
DM0N3L7 DE Parkinson disease
DMDZ9LT ID DMDZ9LT
DMDZ9LT DN Ethosuximide
DMDZ9LT HS Approved
DMDZ9LT SN Aethosuccimidum; Aethosuximide; Asamid; Atysmal; Capitus; Emeside; Ethosuccimid; Ethosuccimide; Ethosuccinimide; Ethosuxide; Ethosuximidum; Ethylmethylsuccimide; Ethymal; Etomal; Etosuccimide; Etosuximid; Etosuximida; Etosuximide; Mesentol; Pemal; Pemalin; Pentinimid; Peptinimid; Petinimid; Petnidan; Piknolepsin; Pyknolepsinum; Ronton; Simatin; Succimal; Succimitin; Suksilep; Suxilep; Suximal; Suxin; Suxinutin; Thetamid; Thilopemal; Zaraondan; Zarodan; Zarondan; Zarontin; Zartalin; Aethosuximide [German]; Desitin Brand of Ethosuximide; Epileo Petit MAL; Etosuccimide [DCIT]; Etosuximida Faes; Faes Brand of Ethosuximide; Fortbenton Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Katwijk Brand of Ethosuximide; LAB Brand of Ethosuximide; Parke Davis Brand of Ethosuximide; Pfizer Brand of Ethosuximide; United Drug Brand of Ethosuximide; Warner Lambert Brand of Ethosuximide; Wernigerode Brand of Ethosuximide; Cl 366; E 7138; E0746; H 940; PM 671; CN-10395; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; Faes, Etosuximida; H-490; N-Ethyl methylsuccinimide; PM-671; Simatin(E); Warner-Lambert Brand of Ethosuximide; Zarondan-Saft; Zarontin (TN); C.I. 366; CN-10,395; Piknole.psi.n; Pyknole.psi.num; Alpha-Ethyl-alpha-methylsuccinimide; Alpha-Methyl-alpha-ethylsuccinimide; Ethosuximide (JP15/USP/INN); Ethosuximide [USAN:INN:BAN:JAN]; Gamma-Methyl-gamma-ethylsuccinimide; Gamma-Methyl-gamma-ethyl-succinimide; Gamma-ethyl-gamma-methyl-succinimide; (+-)-2-Ethyl-2-methylsuccinimide; 2-Ethyl-2-methylsuccinimide; 2-Methyl-2-ethylsuccinimide; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; 3-Ethyl-3-methylsuccinimide; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Methyl-3-ethylsuccinimide
DMDZ9LT CP Pfizer
DMDZ9LT TC Analgesics
DMDZ9LT DT Small molecular drug
DMDZ9LT PC 3291
DMDZ9LT MW 141.17
DMDZ9LT FM C7H11NO2
DMDZ9LT IC InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
DMDZ9LT CS CCC1(CC(=O)NC1=O)C
DMDZ9LT IK HAPOVYFOVVWLRS-UHFFFAOYSA-N
DMDZ9LT IU 3-ethyl-3-methylpyrrolidine-2,5-dione
DMDZ9LT CA CAS 77-67-8
DMDZ9LT CB CHEBI:4887
DMDZ9LT DE Epilepsy
DMXWOCP ID DMXWOCP
DMXWOCP DN Ethotoin
DMXWOCP HS Approved
DMXWOCP SN Accenon; Ethotoine; Ethotoinum; Etotoina; Peganone; Pegoanone; Abbott brand of ethotoin; Accenon (TN); Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; Peganone (TN); Ethotoin [INN:BAN:JAN]; Ethotoin (JAN/USP/INN); (+-)-3-Ethyl-5-phenylhydantoin; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; 3-Ethyl-5-phenylhydantoin; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 3-ethyl-5-phenylimidazolidine-2,4-dione
DMXWOCP CP Ovation Pharmaceuticals
DMXWOCP TC Anticonvulsants
DMXWOCP DT Small molecular drug
DMXWOCP PC 3292
DMXWOCP MW 204.22
DMXWOCP FM C11H12N2O2
DMXWOCP IC InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)
DMXWOCP CS CCN1C(=O)C(NC1=O)C2=CC=CC=C2
DMXWOCP IK SZQIFWWUIBRPBZ-UHFFFAOYSA-N
DMXWOCP IU 3-ethyl-5-phenylimidazolidine-2,4-dione
DMXWOCP CA CAS 86-35-1
DMXWOCP CB CHEBI:4888
DMXWOCP DE Complex partial seizure
DMVO4ED ID DMVO4ED
DMVO4ED DN Ethoxzolamide
DMVO4ED HS Approved
DMVO4ED SN ethoxzolamide; Ethoxyzolamide; Ethoxazolamide; Ethamide; Etoxzolamide; Cardrase; 6-Ethoxy-2-benzothiazolesulfonamide; 452-35-7; Glaucotensil; Diuretic C; 6-Ethoxy-1,3-benzothiazole-2-sulfonamide; Mingoral; 2-Benzothiazolesulfonamide, 6-ethoxy-; Redupresin; 6-Ethoxybenzo[d]thiazole-2-sulfonamide; 6-Ethoxyzolamide; 6-Ethoxybenzothiazole-2-sulfonamide; 6-Ethoxybenzothiazole-2-sulphonamide; U-4191; NSC 10679; UNII-Z52H4811WX; C9H10N2O3S2; HSDB 3268; CHEMBL18; EINECS 207-199-5; BRN 0212240; MLS000028637; AI3-50805; Cardrase; EZL; Cardrase (TN); Ethoxzolamide (EZA); 6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide; 6-Ethoxy-benzothiazole-2-sulfonic acid amide; 6-ethoxy-1,3-benzothiazole-2-sulfonamide
DMVO4ED TC Diuretics
DMVO4ED DT Small molecular drug
DMVO4ED PC 3295
DMVO4ED MW 258.3
DMVO4ED FM C9H10N2O3S2
DMVO4ED IC InChI=1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)
DMVO4ED CS CCOC1=CC2=C(C=C1)N=C(S2)S(=O)(=O)N
DMVO4ED IK OUZWUKMCLIBBOG-UHFFFAOYSA-N
DMVO4ED IU 6-ethoxy-1,3-benzothiazole-2-sulfonamide
DMVO4ED CA CAS 452-35-7
DMVO4ED CB CHEBI:101096
DMVO4ED DE Glaucoma/ocular hypertension; Duodenal ulcer
DM20VMW ID DM20VMW
DM20VMW DN Ethylestrenol
DM20VMW HS Approved
DM20VMW SN Maxibolin
DM20VMW CP Organon Usa Inc
DM20VMW DT Small molecular drug
DM20VMW PC 13765
DM20VMW MW 288.5
DM20VMW FM C20H32O
DM20VMW IC InChI=1S/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DM20VMW CS CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O
DM20VMW IK AOXRBFRFYPMWLR-XGXHKTLJSA-N
DM20VMW IU (8R,9S,10R,13S,14S,17S)-17-ethyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DM20VMW CA CAS 965-90-2
DM20VMW CB CHEBI:31578
DM20VMW DE Testosterone deficiency
DMZM84R ID DMZM84R
DMZM84R DN Ethynodiol diacetate
DMZM84R HS Approved
DMZM84R SN Cervicundin; Continuin; Femulen; Luteonorm; Metrodiol; Ethinodiol diacetate; Ethyndiol Diacetate; Ethynodiol diacetate [Progestins]; Ethynodiol diacetate [USAN]; Etynodiol Acetate; Metrodiol diacetate; Ovulen 50; SC 11800; Etynodiol di(acetate); Luto-metrodiol; SC-11800; Ethynodiol diacetate (JAN/USP);[(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; (3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diolDiacetate; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol diacetate; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diyl diacetate; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17-alpha-Ethynyl-4-estrene-3-beta,17-beta-diol diacetate; 17-alpha-Ethynylestr-4-ene-3-beta,17-beta-diol acetate; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17-beta-diol diacetate; 17alpha-Ethynyl-3,17-dihydroxy-4-estrene diacetate; 17alpha-Ethynyl-4-estrene-3beta,17beta-diol diacetate; 17alpha-Ethynylestr-4-ene-3beta,17beta-diol acetate; 17alpha-ethynylestr-4-ene-3beta,17beta-diyl diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol diacetate; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol, diacetate; 19-Nor-17alpha-pregn-4-en-20-yne-3beta,17-diol diacetate; 3-beta, 17-beta-Diacetoxy-17-alpha-ethynyl-4-oestrene; 3-beta,17-beta-Diacetoxy-19-nor-17-alpha-pregn-4-en-20-yne; 3beta, 17beta-Diacetoxy-17alpha-ethynyl-4-oestrene; 3beta,17beta-Diacetoxy-17alpha-ethynyl-4-estrene; 3beta,17beta-Diacetoxy-19-nor-17alpha-pregn-4-en-20-yne
DMZM84R TC Contraceptive Agents
DMZM84R DT Small molecular drug
DMZM84R PC 9270
DMZM84R MW 384.5
DMZM84R FM C24H32O4
DMZM84R IC InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1
DMZM84R CS CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C
DMZM84R IK ONKUMRGIYFNPJW-KIEAKMPYSA-N
DMZM84R IU [(3S,8R,9S,10R,13S,14S,17R)-17-acetyloxy-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMZM84R CA CAS 297-76-7
DMZM84R CB CHEBI:31580
DMZM84R DE Contraception
DMBIYNH ID DMBIYNH
DMBIYNH DN ETI-204
DMBIYNH HS Approved
DMBIYNH CP Elusys Therapeutics
DMBIYNH DT Antibody
DMBIYNH DE Anthrax
DMAWJIN ID DMAWJIN
DMAWJIN DN Etidronate Disodium
DMAWJIN HS Approved
DMAWJIN SN Didronel
DMAWJIN CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DMAWJIN DT Small molecular drug
DMAWJIN PC 23894
DMAWJIN MW 249.99
DMAWJIN FM C2H6Na2O7P2
DMAWJIN IC InChI=1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
DMAWJIN CS CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
DMAWJIN IK GWBBVOVXJZATQQ-UHFFFAOYSA-L
DMAWJIN IU disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]ethyl]phosphinate
DMAWJIN CA CAS 7414-83-7
DMAWJIN CB CHEBI:4906
DMAWJIN DE Osteoporosis
DM1XHYJ ID DM1XHYJ
DM1XHYJ DN Etidronic acid
DM1XHYJ HS Approved
DM1XHYJ SN EHDP; Etidronate; Etidronsaeure; HEDP; Osteoscan; Acetodiphosphonic acid; Acide etidronique; Acido etidronico; Acidumetidronicum; Didronel IV; Etidronic acid monohydrate; Hydroxyethanediphosphonic acid; Oxyethylidenediphosphonic acid; Turpinal SL; Dequest2010; Dequest 2015; Dequest Z 010; Ferrofos 510; RP 61; Acide etidronique [INN-French]; Acido etidronico [INN-Spanish]; Acidum etidronicum [INN-Latin]; Diphosphonate (base); Etidronic acid (USAN/INN); Etidronic acid [USAN:INN:BAN]; Hydroxyethane-1,1-diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-bisphosphonic acid; Ethane-1-hydroxy-1,1-diphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester; (1-Hydroxyethylene)diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); (1-Hydroxyethylidene)bisphosphonic acid; (1-Hydroxyethylidene)diphoshonic acid; (1-Hydroxyethylidene)diphosphonic acid; (1-hydroxy-1-phosphonoethyl)phosphonic acid; (1-hydroxyethane-1,1-diyl)bis(phosphonic acid); (Hydroxyethylidene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonate; 1-HYDROXY-1,1-DIPHOSPHONOETHANE; 1-Hydroxyethane-1,1,-diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1-Hydroxyethane-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; 1-Hydroxyethanediphosphonic acid; 1-Hydroxyethylidene 1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-biphosphonate; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonic acid; 1-Hydroxyethylidenediphosphonic acid; 1000SL
DM1XHYJ TC Bone Density Conservation Agents
DM1XHYJ DT Small molecular drug
DM1XHYJ PC 3305
DM1XHYJ MW 206.03
DM1XHYJ FM C2H8O7P2
DM1XHYJ IC InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
DM1XHYJ CS CC(O)(P(=O)(O)O)P(=O)(O)O
DM1XHYJ IK DBVJJBKOTRCVKF-UHFFFAOYSA-N
DM1XHYJ IU (1-hydroxy-1-phosphonoethyl)phosphonic acid
DM1XHYJ CA CAS 2809-21-4
DM1XHYJ CB CHEBI:4907
DM1XHYJ DE Paget's disease
DM6WJO9 ID DM6WJO9
DM6WJO9 DN Etodolac
DM6WJO9 HS Approved
DM6WJO9 SN etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1
DM6WJO9 CP Meda Pharmaceuticals
DM6WJO9 TC Analgesics
DM6WJO9 DT Small molecular drug
DM6WJO9 PC 3308
DM6WJO9 MW 287.35
DM6WJO9 FM C17H21NO3
DM6WJO9 IC InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
DM6WJO9 CS CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
DM6WJO9 IK NNYBQONXHNTVIJ-UHFFFAOYSA-N
DM6WJO9 IU 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
DM6WJO9 CA CAS 41340-25-4
DM6WJO9 CB CHEBI:4909
DM6WJO9 DE Pain
DMZI3WO ID DMZI3WO
DMZI3WO DN Etomidate
DMZI3WO HS Approved
DMZI3WO SN Absele; Amidate; Ethnor; Ethomidate; Etomidato; Etomidatum; Hypnomidate; Radenarcon; Radenarkon; Etomidic acid; R 16659; R 26490; R26490; Amidate (TN); Amidate (pharmaceutical); Amidate, Etomidate; D-Etomidate; Etomidato [INN-Spanish]; Etomidatum [INN-Latin]; R-26490; Etomidate (USAN/INN); Etomidate [USAN:BAN:INN]; Ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (+)-Etomidate; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; (d)-Etomidate; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
DMZI3WO CP Janssen Pharmaceutica
DMZI3WO TC Analgesics
DMZI3WO DT Small molecular drug
DMZI3WO PC 667484
DMZI3WO MW 244.29
DMZI3WO FM C14H16N2O2
DMZI3WO IC InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
DMZI3WO CS CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2
DMZI3WO IK NPUKDXXFDDZOKR-LLVKDONJSA-N
DMZI3WO IU ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate
DMZI3WO CA CAS 33125-97-2
DMZI3WO CB CHEBI:4910
DMZI3WO DE Anaesthesia
DMKA8J4 ID DMKA8J4
DMKA8J4 DN Etonogestrel
DMKA8J4 HS Approved
DMKA8J4 SN Etonogestrelum; Implanon; Implanon (TN); NuvaRing (TN); Etonogestrel (USAN/INN); (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; 17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one; 3-Ketodesogestrel; 3-Oxodesogestrel
DMKA8J4 TC Contraceptive Agents
DMKA8J4 DT Small molecular drug
DMKA8J4 PC 6917715
DMKA8J4 MW 324.5
DMKA8J4 FM C22H28O2
DMKA8J4 IC InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
DMKA8J4 CS CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DMKA8J4 IK GCKFUYQCUCGESZ-BPIQYHPVSA-N
DMKA8J4 IU (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMKA8J4 CA CAS 54048-10-1
DMKA8J4 CB CHEBI:50777
DMKA8J4 DE Contraception
DMNH3PG ID DMNH3PG
DMNH3PG DN Etoposide
DMNH3PG HS Approved
DMNH3PG SN etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
DMNH3PG CP Bristol Myers Squibb Co Pharmaceutical Research Institute
DMNH3PG TC Anticancer Agents
DMNH3PG DT Small molecular drug
DMNH3PG PC 36462
DMNH3PG MW 588.6
DMNH3PG FM C29H32O13
DMNH3PG IC InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
DMNH3PG CS C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
DMNH3PG IK VJJPUSNTGOMMGY-MRVIYFEKSA-N
DMNH3PG IU (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
DMNH3PG CA CAS 33419-42-0
DMNH3PG CB CHEBI:4911
DMNH3PG DE Solid tumour/cancer
DM6A4NW ID DM6A4NW
DM6A4NW DN Etoricoxib
DM6A4NW HS Approved
DM6A4NW SN Algix; Arcoxia; Etoricoxibe; Nucoxia; Tauxib; L791456; MK 0663; MK 663; Algix (TN); Arcoxia (TN); L-791456; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Tauxib (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH
DM6A4NW CP Merck & Co
DM6A4NW TC Antiinflammatory Agents
DM6A4NW DT Small molecular drug
DM6A4NW PC 123619
DM6A4NW MW 358.8
DM6A4NW FM C18H15ClN2O2S
DM6A4NW IC InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
DM6A4NW CS CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
DM6A4NW IK MNJVRJDLRVPLFE-UHFFFAOYSA-N
DM6A4NW IU 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
DM6A4NW CA CAS 202409-33-4
DM6A4NW CB CHEBI:6339
DM6A4NW DE Rheumatoid arthritis
DMGV8QU ID DMGV8QU
DMGV8QU DN Etravirine
DMGV8QU HS Approved
DMGV8QU SN Intelence; DAPY deriv; Diaminopyrimidine deriv; R 165335; R165335; TMC 125; TMC125; Intelence (TN); Intelence(TM); R-165335; R165335-TMC125; TMC-125; Etravirine (JAN/USAN/INN); TMC-125/R-165335; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile; 4-({6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]PYRIMIDIN-4-YL}OXY)-3,5-DIMETHYLBENZONITRILE; 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile; 65B; ETR
DMGV8QU DT Small molecular drug
DMGV8QU PC 193962
DMGV8QU MW 435.3
DMGV8QU FM C20H15BrN6O
DMGV8QU IC InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
DMGV8QU CS CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N
DMGV8QU IK PYGWGZALEOIKDF-UHFFFAOYSA-N
DMGV8QU IU 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
DMGV8QU CA CAS 269055-15-4
DMGV8QU CB CHEBI:63589
DMGV8QU DE Human immunodeficiency virus-1 infection
DM2CZFA ID DM2CZFA
DM2CZFA DN Etretinate
DM2CZFA HS Approved
DM2CZFA SN etretinate; 54350-48-0; Tegison; Ethyl etrinoate; Retinoid; Etretinatum; Etretinato; Ro 10-9359; Etretinatum [INN-Latin]; Etretinato [INN-Spanish]; UNII-65M2UDR9AG; CCRIS 3615; HSDB 7185; EINECS 259-119-3; NSC 297936; 65M2UDR9AG; Ro-10-9359; Tigason; CHEBI:4913; C23H30O3; Ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; Ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate; 3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonanetetraenoic acid ethy
DM2CZFA DT Small molecular drug
DM2CZFA PC 5282375
DM2CZFA MW 354.5
DM2CZFA FM C23H30O3
DM2CZFA IC InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+
DM2CZFA CS CCOC(=O)/C=C(\\C)/C=C/C=C(\\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C
DM2CZFA IK HQMNCQVAMBCHCO-DJRRULDNSA-N
DM2CZFA IU ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
DM2CZFA CA CAS 54350-48-0
DM2CZFA CB CHEBI:4913
DM2CZFA DE Keratosis
DM5GT1M ID DM5GT1M
DM5GT1M DN EVANS BLUE
DM5GT1M HS Approved
DM5GT1M SN tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-5-oxonaphthalene-1,3-disulfonate; AC1NUWHB; AC1O426Q; AN-23389; tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonato-2-naphthylidene)hydrazino]-3-methyl-phenyl]-2-methyl-phenyl]hydrazono]-5-oxo-naphthalene-1,3-disulfonate; 6,6-[(3,3'-Dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalenedisulphonic acid]tetrasodium sa
DM5GT1M DT Small molecular drug
DM5GT1M PC 9409
DM5GT1M MW 960.8
DM5GT1M FM C34H24N6Na4O14S4
DM5GT1M IC InChI=1S/C34H28N6O14S4.4Na/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
DM5GT1M CS CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+].[Na+]
DM5GT1M IK ATNOAWAQFYGAOY-UHFFFAOYSA-J
DM5GT1M IU tetrasodium;4-amino-6-[[4-[4-[(8-amino-1-hydroxy-5,7-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-5-hydroxynaphthalene-1,3-disulfonate
DM5GT1M CA CAS 314-13-6
DM5GT1M CB CHEBI:82467
DM5GT1M DE Abdominal aortic aneurysm
DM8X2EH ID DM8X2EH
DM8X2EH DN Everolimus
DM8X2EH HS Approved
DM8X2EH SN Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
DM8X2EH CP Novartis
DM8X2EH TC Anticancer Agents
DM8X2EH DT Small molecular drug
DM8X2EH PC 6442177
DM8X2EH MW 958.2
DM8X2EH FM C53H83NO14
DM8X2EH IC InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DM8X2EH CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
DM8X2EH IK HKVAMNSJSFKALM-GKUWKFKPSA-N
DM8X2EH IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM8X2EH CA CAS 159351-69-6
DM8X2EH CB CHEBI:68478
DM8X2EH DE Renal cell carcinoma; Kidney cancer
DMBLX7U ID DMBLX7U
DMBLX7U DN Evinacumab
DMBLX7U HS Approved
DMBLX7U SN REGN1500; ANGPTL-1 antibody
DMBLX7U CP Regeneron Pharmaceuticals Tarrytown, NY
DMBLX7U DE Elevated C-reactive protein; Familial hypercholesterolemia; Hypercholesterolaemia
DM9HPW3 ID DM9HPW3
DM9HPW3 DN Exemestane
DM9HPW3 HS Approved
DM9HPW3 SN Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione
DM9HPW3 TC Anticancer Agents
DM9HPW3 DT Small molecular drug
DM9HPW3 PC 60198
DM9HPW3 MW 296.4
DM9HPW3 FM C20H24O2
DM9HPW3 IC InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
DM9HPW3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C
DM9HPW3 IK BFYIZQONLCFLEV-DAELLWKTSA-N
DM9HPW3 IU (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
DM9HPW3 CA CAS 107868-30-4
DM9HPW3 CB CHEBI:4953
DM9HPW3 DE Hormonally-responsive breast cancer
DMYHBKN ID DMYHBKN
DMYHBKN DN Exenatide
DMYHBKN HS Approved
DMYHBKN SN Exenatide Synthetic; AC 2993 LAR; Ex4 peptide; Byetta (TN); Exendin 4 (Heloderma suspectum); Extendin-4; L-Serinamide
DMYHBKN CP Eli Lilly
DMYHBKN TC Hypoglycemic Agents
DMYHBKN DT Small molecular drug
DMYHBKN SQ Exenatide: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
DMYHBKN PC 45588096
DMYHBKN MW 4187
DMYHBKN FM C184H282N50O60S
DMYHBKN IC InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1
DMYHBKN CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC9=CNC=N9)N
DMYHBKN IK HTQBXNHDCUEHJF-XWLPCZSASA-N
DMYHBKN IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMYHBKN CA CAS 141758-74-9
DMYHBKN DE Cardiovascular disease; Type-2 diabetes
DMHPRWG ID DMHPRWG
DMHPRWG DN Exjade
DMHPRWG HS Approved
DMHPRWG SN Deferasirox
DMHPRWG CP Novartis
DMHPRWG DT Small molecular drug
DMHPRWG PC 214348
DMHPRWG MW 373.4
DMHPRWG FM C21H15N3O4
DMHPRWG IC InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
DMHPRWG CS C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
DMHPRWG IK BOFQWVMAQOTZIW-UHFFFAOYSA-N
DMHPRWG IU 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
DMHPRWG CA CAS 201530-41-8
DMHPRWG CB CHEBI:49005
DMHPRWG DE Iron overload disease
DM7A8TW ID DM7A8TW
DM7A8TW DN Ezetimibe
DM7A8TW HS Approved
DM7A8TW SN Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
DM7A8TW CP Schering-Plough
DM7A8TW TC Anticholesteremic Agents
DM7A8TW DT Small molecular drug
DM7A8TW PC 150311
DM7A8TW MW 409.4
DM7A8TW FM C24H21F2NO3
DM7A8TW IC InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
DM7A8TW CS C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O
DM7A8TW IK OLNTVTPDXPETLC-XPWALMASSA-N
DM7A8TW IU (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
DM7A8TW CA CAS 163222-33-1
DM7A8TW CB CHEBI:49040
DM7A8TW DE Hypercholesterolaemia
DMAB6PM ID DMAB6PM
DMAB6PM DN Factor 8
DMAB6PM HS Approved
DMAB6PM SN Wilate (TN)
DMAB6PM DE Hemophilia
DMZUW6P ID DMZUW6P
DMZUW6P DN Factor viia
DMZUW6P HS Approved
DMZUW6P SN Novoseven (TN)
DMZUW6P DE Hemophilia
DM3C5GZ ID DM3C5GZ
DM3C5GZ DN FADROZOLE
DM3C5GZ HS Approved
DM3C5GZ SN 102676-47-1; CGS-16949A; Fadrozole [INN]; Fadrozolum [INN-Latin]; Fadrozol [INN-Spanish]; CHEMBL9298; Fadrozole (INN); 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-; Fadrozolum; Fadrozol; 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-
DM3C5GZ DT Small molecular drug
DM3C5GZ PC 59693
DM3C5GZ MW 223.27
DM3C5GZ FM C14H13N3
DM3C5GZ IC InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2
DM3C5GZ CS C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N
DM3C5GZ IK CLPFFLWZZBQMAO-UHFFFAOYSA-N
DM3C5GZ IU 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
DM3C5GZ CA CAS 102676-47-1
DM3C5GZ CB CHEBI:94355
DM3C5GZ DE Breast cancer
DMBI9ZJ ID DMBI9ZJ
DMBI9ZJ DN Falecalcitrol
DMBI9ZJ HS Approved
DMBI9ZJ SN Falecalcitriol; falecalcitriol; Flocalcitriol; 83805-11-2; calcitriol hexafluoride; Hornel, Fulstan; Falecalcitriol [INN]; ST-630; ST 630; Fulstan; Ro 23-4194; UNII-G70A8514T8; C27H38F6O3; Hornel; 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3; G70A8514T8; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; Hexafluorocalcitriol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol,; Fulstan (TN); Horner (TN)
DMBI9ZJ DT Small molecular drug
DMBI9ZJ PC 5282190
DMBI9ZJ MW 524.6
DMBI9ZJ FM C27H38F6O3
DMBI9ZJ IC InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
DMBI9ZJ CS C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMBI9ZJ IK XPYGGHVSFMUHLH-UUSULHAXSA-N
DMBI9ZJ IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMBI9ZJ CA CAS 83805-11-2
DMBI9ZJ DE Hyperparathyroidism
DMJHLSD ID DMJHLSD
DMJHLSD DN Famciclovir
DMJHLSD HS Approved
DMJHLSD SN FCV; Famciclovirum; Famvir; Oravir; BRL 42810; IN1338; Anti-Farnesyl Rabbit pAb; BRL-42810; Famciclovirum [INN-Latin]; Famvir (TN); Famciclovir [USAN:BAN:INN]; Famciclovir (JAN/USAN/INN); [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine
DMJHLSD CP Schering-Plough
DMJHLSD TC Antiviral Agents
DMJHLSD DT Small molecular drug
DMJHLSD PC 3324
DMJHLSD MW 321.33
DMJHLSD FM C14H19N5O4
DMJHLSD IC InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)
DMJHLSD CS CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
DMJHLSD IK GGXKWVWZWMLJEH-UHFFFAOYSA-N
DMJHLSD IU [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate
DMJHLSD CA CAS 104227-87-4
DMJHLSD CB CHEBI:4974
DMJHLSD DE Virus infection
DMRL3AB ID DMRL3AB
DMRL3AB DN Famotidine
DMRL3AB HS Approved
DMRL3AB SN Pepcid; famotidine; 76824-35-6; Pepcid AC; Pepcidine; Quamatel; Gastridin; Famodil; Dispromil; Pepdine; Digervin; Gaster; Fluxid; Pepdul; Pepcid RPD; Famulcer; Supertidine; Pepcidina; Fagastine; Whitidin; Farmotex; Peptifam; Ferotine; Dispronil; Tairal; Sigafam; Famtac; Durater; Yamarin; Pepzan; Famoxal; Evatin; Weimok; Pepdif; Fudone; Fanosin; Fanobel; Duovel; Fibonel; Fadine; Dipsin; Ganor; Fadin; Dinul; Fanox; Fadyn; Famox; Famo; Nu-Famotidine; Pepcidin Rapitab; Sedanium-R; Dibrit 40; Famotidinum [Latin]; PEPCID; Famotidina [Spanish]; Apogastine; Antodine; Bestidine; Amfamox; Blocacid; Brolin; Cepal; Confobos; Cronol; Cuantin; Famocid; Famodar; Famodin; Famodine; Famogard; Famonit; Famopsin; Famos; Famosan; Famotal; Famotep; Famotin; Famovane; Famowal; Gastridan; Gastrion; Gastro; Gastrodomina; Gastrofam; Gastropen; Gastrosidin; Hacip; Huberdina; Ingastri; Invigan; Lecedil; Logos; Mensoma; Midefam; Mosul; Motiax; Muclox; Neocidine; Nevofam; Notidin; Nulceran; Nulcerin; Panalba; Pepcidac; Pepcidin; Pepfamin; Peptan; Peptidin; Purifam; Quamtel; Renapepsa; Restadin; Rogasti; Rubacina; Tamin; Tipodex; Topcid; Ulcatif; Ulceprax; Ulcofam; Ulfagel; Ulfam; Ulfamid; Ulfinol; Ulgarine; Vagostal; FAMOTIDINE PRESERVATIVE FREE; FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER; Mylanta AR; PEPCID COMPLETE; PEPCID PRESERVATIVE FREE; PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER; Pepcid AC Gelcaps; PepcidRPD; F 6889; F0530; L 643341; MK 208; YM 11170; Apo-Famotidine; HS-0054; MK-208; Novo-Famotidine; Pepcid (TN); Pepcidine (TN); YM-11170; YM-1170; Famotidine [USAN:BAN:INN:JAN]; Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl); N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine; (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide; (1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide; (1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide; 3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide; 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro; 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
DMRL3AB CP Astellas Pharma
DMRL3AB TC Antiulcer Agents
DMRL3AB DT Small molecular drug
DMRL3AB PC 5702160
DMRL3AB MW 337.5
DMRL3AB FM C8H15N7O2S3
DMRL3AB IC InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
DMRL3AB CS C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
DMRL3AB IK XUFQPHANEAPEMJ-UHFFFAOYSA-N
DMRL3AB IU 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
DMRL3AB CA CAS 76824-35-6
DMRL3AB CB CHEBI:4975
DMRL3AB DE Peptic ulcer
DMX7A5V ID DMX7A5V
DMX7A5V DN Faropenem
DMX7A5V HS Approved
DMX7A5V SN FPM; Fropenem; (+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; 6alpha-[(1R)-1-hydroxyethyl]-2-[(2R)-tetrahydrofuran-2-yl]-2,3-didehydropenam-3-carboxylic acid
DMX7A5V CP Suntory
DMX7A5V TC Respiratory Agents
DMX7A5V DT Small molecular drug
DMX7A5V PC 65894
DMX7A5V MW 285.32
DMX7A5V FM C12H15NO5S
DMX7A5V IC InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1
DMX7A5V CS C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)[C@H]3CCCO3)C(=O)O)O
DMX7A5V IK HGGAKXAHAYOLDJ-FHZUQPTBSA-N
DMX7A5V IU (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMX7A5V CA CAS 106560-14-9
DMX7A5V CB CHEBI:51257
DMX7A5V DE Gram-positive bacterial infection
DMDEXQ0 ID DMDEXQ0
DMDEXQ0 DN Febuxostat
DMDEXQ0 HS Approved
DMDEXQ0 SN Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DMDEXQ0 CP Takeda
DMDEXQ0 DT Small molecular drug
DMDEXQ0 PC 134018
DMDEXQ0 MW 316.4
DMDEXQ0 FM C16H16N2O3S
DMDEXQ0 IC InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
DMDEXQ0 CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
DMDEXQ0 IK BQSJTQLCZDPROO-UHFFFAOYSA-N
DMDEXQ0 IU 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DMDEXQ0 CA CAS 144060-53-7
DMDEXQ0 CB CHEBI:31596
DMDEXQ0 DE Hyperuricaemia
DM4ZBK6 ID DM4ZBK6
DM4ZBK6 DN Fedratinib
DM4ZBK6 HS Approved
DM4ZBK6 SN TG101348
DM4ZBK6 CP Targen
DM4ZBK6 DT Small molecular drug
DM4ZBK6 PC 16722836
DM4ZBK6 MW 524.7
DM4ZBK6 FM C27H36N6O3S
DM4ZBK6 IC InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
DM4ZBK6 CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
DM4ZBK6 IK JOOXLOJCABQBSG-UHFFFAOYSA-N
DM4ZBK6 IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
DM4ZBK6 CA CAS 936091-26-8
DM4ZBK6 CB CHEBI:91408
DM4ZBK6 DE Myelofibrosis
DML2DCR ID DML2DCR
DML2DCR DN Fedratinib hydrochloride
DML2DCR HS Approved
DML2DCR SN Fedratinib hydrochloride (USAN); TG101348(2ClH.H2O); UH9J2HBQWJ; 1374744-69-0; BCP24783; D11296; Fedratinib dihydrochloride monohydrate; UNII-UH9J2HBQWJ
DML2DCR PC 67517580
DML2DCR MW 615.6
DML2DCR FM C27H40Cl2N6O4S
DML2DCR IC QAFZLTVOFJHYDF-UHFFFAOYSA-N
DML2DCR CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl
DML2DCR IK 1S/C27H36N6O3S.2ClH.H2O/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4;;;/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31);2*1H;1H2
DML2DCR IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide;hydrate;dihydrochloride
DML2DCR CA CAS 1374744-69-0
DML2DCR DE Myelofibrosis
DM1V5ZS ID DM1V5ZS
DM1V5ZS DN Felbamate
DM1V5ZS HS Approved
DM1V5ZS SN Felbamato; Felbamatum; Felbamyl; Felbatol; Taloxa; Essex brand of felbamate; Felbamato [Spanish]; Felbamatum [Latin]; Schering brand of felbamate; F 0778; W 554; Wallace brand 1 of felbamate; Wallace brand 2 of felbamate; ADD-03055; Carbamic acid 2-phenyltrimethylene ester; Felbamate [USAN:INN]; Felbatol (TN); Schering-Plough brand of felbamate; W-554; Carbamic acid, 2-phenyltrimethylene ester; Felbamate (USAN/INN); (3-carbamoyloxy-2-phenyl-propyl) carbamate; (3-carbamoyloxy-2-phenylpropyl) carbamate; 1,3-Propanediol, 2-phenyl-, dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; 2-Phenylpropane-1,3-diyl dicarbamate
DM1V5ZS CP MedPointe
DM1V5ZS TC Antiepileptic Agents
DM1V5ZS DT Small molecular drug
DM1V5ZS PC 3331
DM1V5ZS MW 238.24
DM1V5ZS FM C11H14N2O4
DM1V5ZS IC InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
DM1V5ZS CS C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
DM1V5ZS IK WKGXYQFOCVYPAC-UHFFFAOYSA-N
DM1V5ZS IU (3-carbamoyloxy-2-phenylpropyl) carbamate
DM1V5ZS CA CAS 25451-15-4
DM1V5ZS CB CHEBI:4995
DM1V5ZS DE Epilepsy
DMKZEIB ID DMKZEIB
DMKZEIB DN Felbinac
DMKZEIB HS Approved
DMKZEIB SN Felbinac); Felbinac, Takeda Chemical Industries Ltd; Seltouch, Takeda
DMKZEIB CP Takeda Pharmaceutical Co Ltd
DMKZEIB DT Small molecular drug
DMKZEIB PC 3332
DMKZEIB MW 212.24
DMKZEIB FM C14H12O2
DMKZEIB IC InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)
DMKZEIB CS C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O
DMKZEIB IK QRZAKQDHEVVFRX-UHFFFAOYSA-N
DMKZEIB IU 2-(4-phenylphenyl)acetic acid
DMKZEIB CA CAS 5728-52-9
DMKZEIB CB CHEBI:31597
DMKZEIB DE Arthritis
DMOSW35 ID DMOSW35
DMOSW35 DN Felodipine
DMOSW35 HS Approved
DMOSW35 SN Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMOSW35 CP AstraZeneca
DMOSW35 TC Antihypertensive Agents
DMOSW35 DT Small molecular drug
DMOSW35 PC 3333
DMOSW35 MW 384.2
DMOSW35 FM C18H19Cl2NO4
DMOSW35 IC InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
DMOSW35 CS CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
DMOSW35 IK RZTAMFZIAATZDJ-UHFFFAOYSA-N
DMOSW35 IU 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMOSW35 CA CAS 72509-76-3
DMOSW35 CB CHEBI:585948
DMOSW35 DE Hypertension
DMHLP9C ID DMHLP9C
DMHLP9C DN Felypressin
DMHLP9C HS Approved
DMHLP9C SN Felipresina; Felipressina; Felypressine; Felypressinum; Octapressin; Octopressin; Phelypressin; Felipressina [DCIT]; Phenylalanine Lysine Vasopressin; Felipresina [INN-Spanish]; Felypressine [INN-French]; Felypressinum [INN-Latin]; Octapressin (TN); PLV-2; Felypressin [USAN:INN:BAN]; Vasopressin, Phenylalanyl-Lysyl; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1-6)disulfide; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide cyclic (1->6)disulfide; 1-{[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyllysylglycinamide; 2-(L-Phenylalanine)-8-L-lysinevasopressin; N-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMHLP9C CP AstraZeneca
DMHLP9C TC Vasoconstrictor Agents
DMHLP9C DT Small molecular drug
DMHLP9C PC 14257662
DMHLP9C MW 1040.2
DMHLP9C FM C46H65N13O11S2
DMHLP9C IC InChI=1S/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMHLP9C CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=CC=C4)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMHLP9C IK SFKQVVDKFKYTNA-DZCXQCEKSA-N
DMHLP9C IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13,16-dibenzyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMHLP9C CA CAS 56-59-7
DMHLP9C CB CHEBI:60564
DMHLP9C DE Localisation
DMXGDFK ID DMXGDFK
DMXGDFK DN Fenbufen
DMXGDFK HS Approved
DMXGDFK SN fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a
DMXGDFK DT Small molecular drug
DMXGDFK PC 3335
DMXGDFK MW 254.28
DMXGDFK FM C16H14O3
DMXGDFK IC InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
DMXGDFK CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCC(=O)O
DMXGDFK IK ZPAKPRAICRBAOD-UHFFFAOYSA-N
DMXGDFK IU 4-oxo-4-(4-phenylphenyl)butanoic acid
DMXGDFK CA CAS 36330-85-5
DMXGDFK CB CHEBI:31599
DMXGDFK DE Arthritis
DM0LRU9 ID DM0LRU9
DM0LRU9 DN Fendrix
DM0LRU9 HS Approved
DM0LRU9 SN Fendrix Extra Strength; New hepatitis B prophylactic vaccine, GlaxoSmithKline; HBV prophylactic vaccine (new), GlaxoSmithKline; Hepatitis B prophylactic vaccine (extra strength), GlaxoSmithKline; MPL hepatitis B vaccine, GSK/Corixa; SBAS4-adjuvanted hepatitis B vaccine, GlaxoSmithKline; SBAS4-adjuvanted hepatitis B vaccine, SmithKline Beecham; SBAS4/MPL (HBV vaccine), GlaxoSmithKline/Ribi; SBAS4/MPL (HBV vaccine), SmithKline Beecham/Ribi
DM0LRU9 CP GlaxoSmithKline Biologicals
DM0LRU9 DT Vaccine
DM0LRU9 DE Hepatitis B virus infection
DMFKXDY ID DMFKXDY
DMFKXDY DN Fenofibrate
DMFKXDY HS Approved
DMFKXDY SN Ankebin; Antara; Controlip; Durafenat; Elasterate; Elasterin; FNF; Fenobeta; Fenobrate; Fenofanton; Fenofibrato; Fenofibratum; Fenogal; Fenoglide; Fenomax; Fenotard; Finofibrate; Fulcro; Lipanthyl; Lipantil; Liparison; Lipidex; Lipidil; Lipifen; Lipirex; Lipoclar; Lipofen; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Pharmavit; Phenofibrate; Procetofen; Procetofene; Proctofene; Protolipan; Secalip; Sedufen; Supralip; Tricor; Triglide; AbZ Brand of Procetofen; Abbott Brand of Procetofen; Aliud Brand of Procetofen; Antara Micronized Procetofen; Anto Brand of Procetofen; Apo Feno Micro; Apo Fenofibrate; Apotex Brand of Procetofen; Azupharma Brand of Procetofen; Betapharm Brand of Procetofen; Bouchara Brand of Procetofen; Ct Arzneimittel Brand of Procetofen; Fenofibrat AL; Fenofibrat AZU; Fenofibrat AbZ; Fenofibrat FPh; Fenofibrat Heumann; Fenofibrat Hexal; Fenofibrat Stada; Fenofibrat ratiopharm; Fenofibrat von ct; Fenofibrate Debat; Fenofibrate MSD; Fournier Brand of Procetofen; GNR Pharma Brand of Procetofen; Gate Brand of Procetofen; Gen Fenofibrate; Genpharm Brand of Procetofen; Heumann Brand of Procetofen; Hexal Brand of Procetofen; Knoll Brand of Procetofen; Lichtenstein Brand of Procetofen; Lipidil Micro; Lipidil Supra; Lipidil Ter; MTW Brand of Procetofen; MTW Fenofibrat; Merck dura Brand of Procetofen; Novartis Brand of Procetofen; Novo Fenofibrate; Novopharm Brand of Procetofen; Nu Fenofibrate; Nu Pharm Brand of Procetofen; PMS Fenofibrate Micro;Pharmascience Brand of Procetofen; Procetofen Reliant Brand; Q Pharm Brand of Procetofen; Ratiopharm Brand of Procetofen; Reliant Brand of Procetofen; Schering Plough Brand of Procetofen; Stadapharm Brand of Procetofen; United Drug Brand of Procetofen; F 6020; LF 178; LF178; AZU, Fenofibrat; Antara (TN); Antara (micronized); Apo-Fenofibrate; CIP-Fenofibrate; Ct-Arzneimittel Brand of Procetofen; Debat, Fenofibrate; FENOFIBRATE (MICRONIZED); Fenofibrat-ratiopharm; Fenofibrate IDD-P; Fenofibrate [INN:BAN]; Fenofibrato [INN-Spanish]; Fenofibratum [INN-Latin]; Fenogal (TN); GNR-Pharma Brand of Procetofen; GRS-027; Gen-Fenofibrate; Heumann, Fenofibrat; Hexal, Fenofibrat; LCP-Feno; LCP-FenoChol; LF-178; Lipanthyl (TN); Lipantil (TN); Lipidil (TN); Lipidil-Ter; Lipofen (TN); Lofibra (TN); MTW-Fenofibrat; Micronized Procetofen, Antara; Novo-Fenofibrate; Nu-Fenofibrate; Nu-Pharm Brand of Procetofen; PMS-Fenofibrate Micro; Procetofen, Antara Micronized; Q-Pharm Brand of Procetofen; Schering-Plough Brand of Procetofen; Stada, Fenofibrat; TRICOR (MICRONIZED); Tricor (TN); Triglide (TN); Trilipix (TN); Apo-Feno-Micro; Fenocor-67 (TN); Fenofibrate (JAN/INN); Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate
DMFKXDY CP Abbott Laboratories
DMFKXDY TC Antilipemic Agents
DMFKXDY DT Small molecular drug
DMFKXDY PC 3339
DMFKXDY MW 360.8
DMFKXDY FM C20H21ClO4
DMFKXDY IC InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
DMFKXDY CS CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
DMFKXDY IK YMTINGFKWWXKFG-UHFFFAOYSA-N
DMFKXDY IU propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
DMFKXDY CA CAS 49562-28-9
DMFKXDY CB CHEBI:5001
DMFKXDY DE High cholesterol level
DMGO2MC ID DMGO2MC
DMGO2MC DN Fenofibric acid
DMGO2MC HS Approved
DMGO2MC SN Fenofibric acid; 42017-89-0; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; alpha 1081; NSC 281318; LF 178 acid; UNII-BGF9MN2HU1; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; LF 153; FNF Acid; C17H15ClO4; Trilipix; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; AK117112; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; W-106287
DMGO2MC DT Small molecular drug
DMGO2MC PC 64929
DMGO2MC MW 318.7
DMGO2MC FM C17H15ClO4
DMGO2MC IC InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
DMGO2MC CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
DMGO2MC IK MQOBSOSZFYZQOK-UHFFFAOYSA-N
DMGO2MC IU 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid
DMGO2MC CA CAS 42017-89-0
DMGO2MC CB CHEBI:83469
DMGO2MC DE Cardiovascular disease
DMFAOKP ID DMFAOKP
DMFAOKP DN Fenoldopam
DMFAOKP HS Approved
DMFAOKP SN Carlacor; Fenoldopamum; Fenodopam mesylate; Fenoldopamum [Latin]; SKF 82526; Carlacor (TN); Corlopam (TN); Fenoldopam (INN);Fenoldopam [INN:BAN]; SKF 82526-J; SKF-82526J; SK&F-82526; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMFAOKP CP Ben Venue Laboratories
DMFAOKP TC Antihypertensive Agents
DMFAOKP DT Small molecular drug
DMFAOKP PC 3341
DMFAOKP MW 305.75
DMFAOKP FM C16H16ClNO3
DMFAOKP IC InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
DMFAOKP CS C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O
DMFAOKP IK TVURRHSHRRELCG-UHFFFAOYSA-N
DMFAOKP IU 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMFAOKP CA CAS 67227-56-9
DMFAOKP CB CHEBI:5002
DMFAOKP DE Hypertension
DML5VQ0 ID DML5VQ0
DML5VQ0 DN Fenoprofen
DML5VQ0 HS Approved
DML5VQ0 SN Fenoprofene; Fenoprofeno; Fenoprofenum; Feprona; Nalfon; Nalgesic; Feneprofen calcium salt dihydrate; Fenoprofen calcium; Fenoprofen calcium hydrate; Lilly 53838; Fenoprofen Dihydrate, Calcium Salt; Fenoprofene [INN-French]; Fenoprofeno [INN-Spanish]; Fenoprofenum [INN-Latin]; Fenopron (TN); Fenoprofen (USAN/INN); Fenoprofen [USAN:BAN:INN]; Alpha-(m-phenoxyphenyl)propionic acid; Alpha-Methyl-3-phenoxybenzeneacetic acid; (+-)-2-(3-Phenoxyphenyl)propionic acid; (+-)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-phenoxyphenyl)propionic acid; 2-[3-(phenyloxy)phenyl]propanoic acid
DML5VQ0 CP Typharm Limited
DML5VQ0 TC Antiinflammatory Agents
DML5VQ0 DT Small molecular drug
DML5VQ0 PC 3342
DML5VQ0 MW 242.27
DML5VQ0 FM C15H14O3
DML5VQ0 IC InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
DML5VQ0 CS CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
DML5VQ0 IK RDJGLLICXDHJDY-UHFFFAOYSA-N
DML5VQ0 IU 2-(3-phenoxyphenyl)propanoic acid
DML5VQ0 CA CAS 29679-58-1
DML5VQ0 CB CHEBI:5004
DML5VQ0 DE Rheumatoid arthritis
DMIP3ZV ID DMIP3ZV
DMIP3ZV DN Fenoterol
DMIP3ZV HS Approved
DMIP3ZV SN Berotec; Berotek; Fenoterolum; Phenoterol; TH 1165A; Berotec (TN); Fenoterolum [INN-Latin]; P-Hydroxyphenylorciprenaline; Th-1165a; Fenoterol (USAN/INN); Fenoterol [USAN:BAN:INN]; P-Hydroxyphenyl-orciprenaline; 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane; 1-(p-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane; 3,5-Dihydroxy-alpha-(((p-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 5-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethyl)benzene-1,3-diol; 5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol; 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol; 5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol
DMIP3ZV CP Boehriger Ingelheim
DMIP3ZV TC Bronchodilator Agents
DMIP3ZV DT Small molecular drug
DMIP3ZV PC 3343
DMIP3ZV MW 303.35
DMIP3ZV FM C17H21NO4
DMIP3ZV IC InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3
DMIP3ZV CS CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O
DMIP3ZV IK LSLYOANBFKQKPT-UHFFFAOYSA-N
DMIP3ZV IU 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol
DMIP3ZV CA CAS 13392-18-2
DMIP3ZV CB CHEBI:149226
DMIP3ZV DE Asthma
DM8WAHT ID DM8WAHT
DM8WAHT DN Fentanyl
DM8WAHT HS Approved
DM8WAHT SN fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals
DM8WAHT CP Janssen Pharmaceuticals Inc
DM8WAHT TC Neurology Agents
DM8WAHT DT Small molecular drug
DM8WAHT PC 3345
DM8WAHT MW 336.5
DM8WAHT FM C22H28N2O
DM8WAHT IC InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3
DM8WAHT CS CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
DM8WAHT IK PJMPHNIQZUBGLI-UHFFFAOYSA-N
DM8WAHT IU N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
DM8WAHT CA CAS 437-38-7
DM8WAHT CB CHEBI:119915
DM8WAHT DE Analgesia; Pain; Cancer related pain; Chronic pain
DM13495 ID DM13495
DM13495 DN Fesoterodine fumarate
DM13495 HS Approved
DM13495 SN Toviaz (TN)
DM13495 CP Pfizer
DM13495 DT Small molecular drug
DM13495 PC 9849808
DM13495 MW 527.6
DM13495 FM C30H41NO7
DM13495 IC InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1
DM13495 CS CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\\C(=O)O
DM13495 IK MWHXMIASLKXGBU-RNCYCKTQSA-N
DM13495 IU (E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
DM13495 CA CAS 286930-03-8
DM13495 DE Overactive bladder
DM17ONX ID DM17ONX
DM17ONX DN Fexofenadine
DM17ONX HS Approved
DM17ONX SN Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
DM17ONX CP Sanofi-Aventis
DM17ONX TC Antiallergic Agents
DM17ONX DT Small molecular drug
DM17ONX PC 3348
DM17ONX MW 501.7
DM17ONX FM C32H39NO4
DM17ONX IC InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
DM17ONX CS CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
DM17ONX IK RWTNPBWLLIMQHL-UHFFFAOYSA-N
DM17ONX IU 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
DM17ONX CA CAS 83799-24-0
DM17ONX CB CHEBI:5050
DM17ONX DE Allergic rhinitis
DM9Q8SO ID DM9Q8SO
DM9Q8SO DN Fibrinolysin
DM9Q8SO HS Approved
DM9Q8SO SQ Fibrinolysin heavy chain: DLLDDYVNTQGASLLSLSRKNLAGRSVEDCAAKCEEETDFVCRAFQYHSKEQQCVVMAENSKNTPVFRMRDVILYEKRIYLLECKTGNGQTYRGTTAETKSGVTCQKWSATSPHVPKFSPEKFPLAGLEENYCRNPDNDENGPWCYTTDPDKRYDYCDIPECEDKCMHCSGENYEGKIAKTMSGRDCQAWDSQSPHAHGYIPSKFPNKNLKMNYCRNPDGEPRPWCFTTDPQKRWEFCDIPRCTTPPPSSGPKYQCLKGTGKNYGGTVAVTESGHTCQRWSEQTPHKHNRTPENFPCKNLEENYCRNPNGEKAPWCYTTNSEVRWEYCTIPSCESSPLSTERMDVPVPPEQTPVPQDCYHGNGQSYRGTSSTTITGRKCQSWSSMTPHRHLKTPENYPNAGLTMNYCRNPDADKSPWCYTTDPRVRWEFCNLKKCSETPEQVPAAPQAPGVENPPEADCMIGTGKSYRGKKATTVAGVPCQEWAAQEPHQHSIFTPETNPQSGLERNYCRNPDGDVNGPWCYTMNPRKPFDYCDVPQCESSFDCGKPKVEPKKCSGR >Fibrinolysin light chainIVGGCVSKPHSWPWQVSLRRSSRHFCGGTLISPKWVLTAAHCLDNILALSFYKVILGAHNEKVREQSVQEIPVSRLFREPSQADIALLKLSRPAIITKEVIPACLPPPNYMVAARTECYITGWGETQGTFGEGLLKEAHLPVIENKVCNRNEYLDGRVKPTELCAGHLIGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSPYVPWIEETMRRN
DM9Q8SO DE Wound healing
DMFP6MV ID DMFP6MV
DMFP6MV DN Fidaxomicin
DMFP6MV HS Approved
DMFP6MV SN Dificid (TN)
DMFP6MV CP Astellas
DMFP6MV DT Small molecular drug
DMFP6MV PC 10034073
DMFP6MV MW 1058
DMFP6MV FM C52H74Cl2O18
DMFP6MV IC InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1
DMFP6MV CS CC[C@H]1/C=C(/[C@H](C/C=C/C=C(/C(=O)O[C@@H](C/C=C(/C=C(/[C@@H]1O[C@H]2[C@H]([C@H]([C@@H](C(O2)(C)C)OC(=O)C(C)C)O)O)\\C)\\C)[C@@H](C)O)\\CO[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)\\C
DMFP6MV IK ZVGNESXIJDCBKN-UUEYKCAUSA-N
DMFP6MV IU [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
DMFP6MV CA CAS 873857-62-6
DMFP6MV DE Clostridium difficile associated diarrhea
DMZEONG ID DMZEONG
DMZEONG DN Finafloxacin
DMZEONG HS Approved
DMZEONG SN Finafloxacin hydrochloride; Antibacterial (Helicobacter pylori infection/ bacterial urinary tract infection), Combinature; Finafloxacin (iv, bacterial infection), MerLion/Alcon; Finafloxacin (oral, bacterial infection), MerLion/Alcon
DMZEONG CP Alcon
DMZEONG DT Small molecular drug
DMZEONG PC 11567473
DMZEONG MW 398.4
DMZEONG FM C20H19FN4O4
DMZEONG IC InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
DMZEONG CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
DMZEONG IK FYMHQCNFKNMJAV-HOTGVXAUSA-N
DMZEONG IU 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMZEONG CA CAS 209342-40-5
DMZEONG CB CHEBI:85176
DMZEONG DE Urinary tract infection
DMWV3TZ ID DMWV3TZ
DMWV3TZ DN Finasteride
DMWV3TZ HS Approved
DMWV3TZ SN Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
DMWV3TZ CP Merck
DMWV3TZ TC Antihyperplasia Agents
DMWV3TZ DT Small molecular drug
DMWV3TZ PC 57363
DMWV3TZ MW 372.5
DMWV3TZ FM C23H36N2O2
DMWV3TZ IC InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
DMWV3TZ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
DMWV3TZ IK DBEPLOCGEIEOCV-WSBQPABSSA-N
DMWV3TZ IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
DMWV3TZ CA CAS 98319-26-7
DMWV3TZ CB CHEBI:5062
DMWV3TZ DE Benign prostatic hyperplasia
DM5JVAN ID DM5JVAN
DM5JVAN DN Fingolimod
DM5JVAN HS Approved
DM5JVAN SN 2-Amino-2-(4-octylphenethyl)propane-1,3-diol
DM5JVAN CP Novartis
DM5JVAN DT Small molecular drug
DM5JVAN PC 107970
DM5JVAN MW 307.5
DM5JVAN FM C19H33NO2
DM5JVAN IC InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
DM5JVAN CS CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
DM5JVAN IK KKGQTZUTZRNORY-UHFFFAOYSA-N
DM5JVAN IU 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
DM5JVAN CA CAS 162359-55-9
DM5JVAN CB CHEBI:63115
DM5JVAN DE Primary progressive multiple sclerosis
DMKV4NL ID DMKV4NL
DMKV4NL DN Flavoxate
DMKV4NL HS Approved
DMKV4NL SN Bladuril; Flavossato; Flavoxato; Flavoxatum; Urispas; Flavossato [DCIT]; Flavoxate HCI; Flavoxate HCL; Spasuret hydrochloride; AK 123; Bladderon (TN); Bladuril (TN); DW-61; Flavoxate (INN); Flavoxate [INN:BAN]; Flavoxato [INN-Spanish]; Flavoxatum [INN-Latin]; Urispas (TN); Uritac (TN); Zopyran-8-carboxylate; Beta-piperidinoethyl 3-methylflavone-8-carboxylate; Piperidinoethyl-3-methylflavone-8-carboxylate; 1-Piperidinoethanol, 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-(1-Piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-(piperidin-1-yl)ethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylat; 2-Piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate; 2-Piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-ben; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate; 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate; 2-piperidinoethyl 3-methylflavone-8-carboxylate; 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester
DMKV4NL CP Nippon Shinyaku
DMKV4NL TC Parasympatholytics
DMKV4NL DT Small molecular drug
DMKV4NL PC 3354
DMKV4NL MW 391.5
DMKV4NL FM C24H25NO4
DMKV4NL IC InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3
DMKV4NL CS CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
DMKV4NL IK SPIUTQOUKAMGCX-UHFFFAOYSA-N
DMKV4NL IU 2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
DMKV4NL CA CAS 15301-69-6
DMKV4NL CB CHEBI:5088
DMKV4NL DE Suprapubic pain; Nocturia; Urgency; Dysuria
DMSQDLE ID DMSQDLE
DMSQDLE DN Flecainide
DMSQDLE HS Approved
DMSQDLE SN flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide
DMSQDLE CP 3M pharmaceuticals
DMSQDLE TC Antiarrhythmic Agents
DMSQDLE DT Small molecular drug
DMSQDLE PC 3356
DMSQDLE MW 414.34
DMSQDLE FM C17H20F6N2O3
DMSQDLE IC InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
DMSQDLE CS C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
DMSQDLE IK DJBNUMBKLMJRSA-UHFFFAOYSA-N
DMSQDLE IU N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
DMSQDLE CA CAS 54143-55-4
DMSQDLE CB CHEBI:75984
DMSQDLE DE Tachyarrhythmias; Atrial fibrillation; Paroxysmal atrial fibrillation
DMXGQYZ ID DMXGQYZ
DMXGQYZ DN Fleroxacin
DMXGQYZ HS Approved
DMXGQYZ SN FLRX; Fleroxacine; Fleroxacino; Fleroxacinum; Fleroxicin; Megalocin; Megalone; Megalosin; Quinodis; Fleroxacine [French]; Fleroxacino [Spanish]; Fleroxacinum [Latin]; AM 833; F0646; AM-833; Megalocin (TN); Megalone (TN); Quinodis (TN); Ro 23-6240; Ro-236240; Ro 23-6240/000; Fleroxacin (JAN/USAN/INN); Fleroxacin [USAN:BAN:INN:JAN]; Ro-23-6240/000; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid; 6,8-Difluoro-1-(2-fluoroethyl)1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMXGQYZ TC Antiinfective Agents
DMXGQYZ DT Small molecular drug
DMXGQYZ PC 3357
DMXGQYZ MW 369.34
DMXGQYZ FM C17H18F3N3O3
DMXGQYZ IC InChI=1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
DMXGQYZ CS CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
DMXGQYZ IK XBJBPGROQZJDOJ-UHFFFAOYSA-N
DMXGQYZ IU 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMXGQYZ CA CAS 79660-72-3
DMXGQYZ CB CHEBI:31810
DMXGQYZ DE Bacterial infection
DM70DTN ID DM70DTN
DM70DTN DN Flibanserin
DM70DTN HS Approved
DM70DTN SN Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
DM70DTN CP Boehringer Ingelheim
DM70DTN DT Small molecular drug
DM70DTN PC 6918248
DM70DTN MW 390.4
DM70DTN FM C20H21F3N4O
DM70DTN IC InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
DM70DTN CS C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
DM70DTN IK PPRRDFIXUUSXRA-UHFFFAOYSA-N
DM70DTN IU 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
DM70DTN CA CAS 167933-07-5
DM70DTN CB CHEBI:90865
DM70DTN DE Mood disorder; Female sexual arousal dysfunction
DMJ8A3Z ID DMJ8A3Z
DMJ8A3Z DN Florbetapir F-18
DMJ8A3Z HS Approved
DMJ8A3Z SN Amyvid (TN)
DMJ8A3Z CP Avid Radiopharmaceuticals
DMJ8A3Z DT Small molecular drug
DMJ8A3Z PC 24822371
DMJ8A3Z MW 359.4
DMJ8A3Z FM C20H25FN2O3
DMJ8A3Z IC InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1
DMJ8A3Z CS CNC1=CC=C(C=C1)/C=C/C2=CN=C(C=C2)OCCOCCOCC[18F]
DMJ8A3Z IK YNDIAUKFXKEXSV-CRYLGTRXSA-N
DMJ8A3Z IU 4-[(E)-2-[6-[2-[2-(2-(18F)fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-N-methylaniline
DMJ8A3Z CA CAS 956103-76-7
DMJ8A3Z CB CHEBI:66880
DMJ8A3Z DE Diagnostic imaging
DM04LR2 ID DM04LR2
DM04LR2 DN Floxuridine
DM04LR2 HS Approved
DM04LR2 SN floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside; Sterile fudr (TN); Floxuridine/5-fluorouracil
DM04LR2 CP Heidelberger
DM04LR2 DT Small molecular drug
DM04LR2 PC 5790
DM04LR2 MW 246.19
DM04LR2 FM C9H11FN2O5
DM04LR2 IC InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DM04LR2 CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O
DM04LR2 IK ODKNJVUHOIMIIZ-RRKCRQDMSA-N
DM04LR2 IU 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM04LR2 CA CAS 50-91-9
DM04LR2 CB CHEBI:60761
DM04LR2 DE Solid tumour/cancer; Colorectal cancer
DMNUWST ID DMNUWST
DMNUWST DN Flucloxacillin
DMNUWST HS Approved
DMNUWST SN FLOXACILLIN; Floxapen; Fluclox; Flucloxacilina; Flucloxacilline; Flucloxacillinum; Fluorochloroxacillin; MFIPC; Floxacillin [USAN]; Flucloxacillin sodium; BRL 2039; Flopen (TN); Floxacillin (USAN); Floxapen (TN); Flucloxacilina [INN-Spanish]; Flucloxacillin (INN); Flucloxacillin-Sodium; Flucloxacilline [INN-French]; Flucloxacillinum [INN-Latin]; Rel-(2R,6S)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylato; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S(2alpha,5alpha,6beta)); 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic acid
DMNUWST CP GlaxoSmithKline
DMNUWST TC Antibiotics
DMNUWST DT Small molecular drug
DMNUWST PC 21319
DMNUWST MW 453.9
DMNUWST FM C19H17ClFN3O5S
DMNUWST IC InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
DMNUWST CS CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMNUWST IK UIOFUWFRIANQPC-JKIFEVAISA-N
DMNUWST IU (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMNUWST CA CAS 5250-39-5
DMNUWST CB CHEBI:5098
DMNUWST DE Bacterial infection
DMOWZ6B ID DMOWZ6B
DMOWZ6B DN Fluconazole
DMOWZ6B HS Approved
DMOWZ6B SN Afungil; Alflucoz; Baten; Beagyne; Biocanol; Biozolene; Canzol; Cryptal; Diflazon; Diflucan; Dimycon; Elazor; FCZ; FLCZ; Flucazol; FlucoLich; Flucobeta; Fluconazol; Fluconazolum; Flucostat; Flukezol; Flunazul; Flunizol; Fluzone; Forcan; Fuconal; Fungata; Lavisa; Loitin; Mutum; Neofomiral; Oxifugol; Oxifungol; Pritenzol; Solacap; Syscan; TPF; Triflucan; Zemyc; Zoltec; Zonal; AbZ Brand of Fluconazole; Aliud Brand of Fluconazole; Alpharma Brand of Fluconazole; Apo Fluconazole; Apotex Brand of Fluconazole; Armstrong Brand of Fluconazole; Betapharm Brand of Fluconazole; Chemia Brand of Fluconazole; Ct Arzneimittel Brand of Fluconazole; Effik Brand of Fluconazole; Fluc Hexal; Fluconazol AL; Fluconazol AbZ; Fluconazol Isis; Fluconazol Stada; Fluconazol [Spanish]; Fluconazol ratiopharm; Fluconazol von ct; Fluconazolum [Latin]; Hexal Brand of Fluconazole; Lesvi Brand of Fluconazole; Lichtenstein Brand of Fluconazole; Mack Brand of Fluconazole; Pfizer Brand of Fluconazole; Pfleger Brand of Fluconazole; Ratiopharm Brand of Fluconazole; SAT Brand of Fluconazole; Silanes Brand of Fluconazole; Stada Brand of Fluconazole; Vita Brand of Fluconazole; F0677; Fluconazole in combination with MGCD290; UK 49858; UK49858; Alfumet (TN); Apo-Fluconazole; Ct-Arzneimittel Brand of Fluconazole; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; DRG-0005; Diflucan (TN); Fluconazol-Isis; Fluconazol-ratiopharm; Fluconazole & Bovine Lactoferrin; Fluconazole & Human recombinant granulocyte colony stimulating factor; Fluconazole & hGCSF; Fluconazole in dextrose 5% in plastic container; Flucytosine & Nyotran; GL663142 & Fluconazole; KS-1059; Trican (TN); UK-49858; DIFLUCAN IN SODIUM CHLORIDE 0.9%; DIFLUCAN IN SODIUM CHLORIDE 0.9%IN PLASTIC CONTAINER; Fluconazole in sodium chloride 0.9%; Fluconazole in sodium chloride 0.9% in plastic container; Flucytosine & Nyotran(Liposomal Nystatin); XMP.284 & Fluconazole; XMP.366 & Fluconazole; XMP.391 & Fluconazole; Diflucan, Trican, Alfumet, Fluconazole; Fluconazole & MC-510,011; Fluconazole (JAN/USAN/INN); Fluconazole [USAN:INN:BAN:JAN]; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
DMOWZ6B CP Pfizer
DMOWZ6B TC Antifungal Agents
DMOWZ6B DT Small molecular drug
DMOWZ6B PC 3365
DMOWZ6B MW 306.27
DMOWZ6B FM C13H12F2N6O
DMOWZ6B IC InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
DMOWZ6B CS C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
DMOWZ6B IK RFHAOTPXVQNOHP-UHFFFAOYSA-N
DMOWZ6B IU 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
DMOWZ6B CA CAS 86386-73-4
DMOWZ6B CB CHEBI:46081
DMOWZ6B DE Fungal infection
DM13VTW ID DM13VTW
DM13VTW DN Flucytosine
DM13VTW HS Approved
DM13VTW SN Alcobon; Ancobon; Ancotil; Ancotyl; Flucitosina; Flucystine; Flucytosin; Flucytosinum; Flucytosone; Fluocytosine; Fluorcytosine; Fluorocytosine; Flucitosina [DCIT]; F0321; LT00771985; Ancobon (TN); Flucytosinum [INN-Latin]; GL663142 & 5FC; Ro 2-9915; Ro 29915 E/265601; Ro-2-9915; Flucytosine (JP15/USP/INN); Flucytosine [USAN:INN:BAN:JAN]; Cytosine, 5-fluoro-(6CI,7CI,8CI); GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone, 4-amino-5-fluoro-); 2-Hydroxy-4-amino-5-fluoropyrimidine; 4-Amino-5-fluoro-2(1H)-pyrimidinone; 4-Amino-5-fluoro-2-hydroxypyrimidine; 4-Amino-5-fluoro-2-hyroxypyrimidine; 4-Amino-5-fluoropyrimidin-2(1H)-one; 5-FC; 5-Flucytosine; 5-Fluorocystosine; 5-Fluorocytosin; 5-Fluorocytosine; 5-Fluorocytosine-6-3H; 5-Flurocytosine; 5-fluoro cytosine; 5987P; 6-Amino-2-oxo-5-fluoropyrimidine; 6-amino-5-fluoro-1H-pyrimidin-2-one; 9074P
DM13VTW TC Antifungal Agents
DM13VTW DT Small molecular drug
DM13VTW PC 3366
DM13VTW MW 129.09
DM13VTW FM C4H4FN3O
DM13VTW IC InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
DM13VTW CS C1=NC(=O)NC(=C1F)N
DM13VTW IK XRECTZIEBJDKEO-UHFFFAOYSA-N
DM13VTW IU 6-amino-5-fluoro-1H-pyrimidin-2-one
DM13VTW CA CAS 2022-85-7
DM13VTW CB CHEBI:5100
DM13VTW DE Endocarditis
DMVRLT7 ID DMVRLT7
DMVRLT7 DN Fludarabine
DMVRLT7 HS Approved
DMVRLT7 SN FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)
DMVRLT7 CP Genzyme Corp
DMVRLT7 TC Anticancer Agents
DMVRLT7 DT Small molecular drug
DMVRLT7 PC 657237
DMVRLT7 MW 285.23
DMVRLT7 FM C10H12FN5O4
DMVRLT7 IC InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
DMVRLT7 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
DMVRLT7 IK HBUBKKRHXORPQB-FJFJXFQQSA-N
DMVRLT7 IU (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMVRLT7 CA CAS 21679-14-1
DMVRLT7 CB CHEBI:94701
DMVRLT7 DE Haematological malignancy
DMD2K4I ID DMD2K4I
DMD2K4I DN Fludiazepam
DMD2K4I HS Approved
DMD2K4I SN Erispan; Fludiazepamum; ID 540; Erispan (TN); Fludiazepam [INN:JAN]; Fludiazepamum [INN-Latin]; ID-540; Fludiazepam (JP15/INN); 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-(9CI); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMD2K4I CP Dainippon Sumitomo Pharma
DMD2K4I TC Antianxiety Agents
DMD2K4I DT Small molecular drug
DMD2K4I PC 3369
DMD2K4I MW 302.73
DMD2K4I FM C16H12ClFN2O
DMD2K4I IC InChI=1S/C16H12ClFN2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
DMD2K4I CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
DMD2K4I IK ROYOYTLGDLIGBX-UHFFFAOYSA-N
DMD2K4I IU 7-chloro-5-(2-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMD2K4I CA CAS 3900-31-0
DMD2K4I CB CHEBI:31618
DMD2K4I DE Anxiety disorder
DMUDIR8 ID DMUDIR8
DMUDIR8 DN Fludrocortisone
DMUDIR8 HS Approved
DMUDIR8 SN fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF; Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone
DMUDIR8 TC Antiinflammatory Agents
DMUDIR8 DT Small molecular drug
DMUDIR8 PC 31378
DMUDIR8 MW 380.4
DMUDIR8 FM C21H29FO5
DMUDIR8 IC InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
DMUDIR8 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F
DMUDIR8 IK AAXVEMMRQDVLJB-BULBTXNYSA-N
DMUDIR8 IU (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMUDIR8 CA CAS 127-31-1
DMUDIR8 CB CHEBI:50885
DMUDIR8 DE Cerebral salt-wasting syndrome
DMC8VNH ID DMC8VNH
DMC8VNH DN Flufenamic Acid
DMC8VNH HS Approved
DMC8VNH SN flufenamic acid; 530-78-9; Fluphenamic acid; Nichisedan; Achless; Arlef; Tecramine; Paraflu; Lanceat; Flufacid; Plostene; Fullsafe; Parlef; Surika; Parlif; Flufenaminsaeure; Reumajust A; Acido flufenamico; N-(3-Trifluoromethylphenyl)anthranilic acid; Ristogen; Sastridex; Meralen; Ansatin; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; Fluore-200; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; ANT-1; Acide flufenamique; Acidum flufenamicum; TVX 916; INF 1837; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; NSC-82699; CI 440
DMC8VNH DT Small molecular drug
DMC8VNH PC 3371
DMC8VNH MW 281.23
DMC8VNH FM C14H10F3NO2
DMC8VNH IC InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)
DMC8VNH CS C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F
DMC8VNH IK LPEPZBJOKDYZAD-UHFFFAOYSA-N
DMC8VNH IU 2-[3-(trifluoromethyl)anilino]benzoic acid
DMC8VNH CA CAS 530-78-9
DMC8VNH CB CHEBI:42638
DMC8VNH DE Dysmenorrhea
DMPCG2L ID DMPCG2L
DMPCG2L DN Flumazenil
DMPCG2L HS Approved
DMPCG2L SN flumazenil; 78755-81-4; Anexate; Flumazepil; Romazicon; Lanexat; Mazicon; Ro 15-1788; Flumazenilum; Flumazenilo; Flumazenilum [Latin]; Flumazenilo [Spanish]; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; [11C]flumazenil; Ro 151788; Flumazenil (Ro 15-1788); Ro-15-1788; UNII-40P7XK9392; C15H14FN3O3; CHEMBL407; Ro15-1788; BRN 4763661; MLS000028850; Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; CHEBI:5103; OFBIFZUFASYYRE-UHFFFAOYSA-N; FlumUP TD; Flumazenil (transdermal patch formulation); Flumazenil (transdermal patch formulation), Coeruleus
DMPCG2L CP Coeruleus Ltd
DMPCG2L DT Small molecular drug
DMPCG2L PC 3373
DMPCG2L MW 303.29
DMPCG2L FM C15H14FN3O3
DMPCG2L IC InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3
DMPCG2L CS CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C
DMPCG2L IK OFBIFZUFASYYRE-UHFFFAOYSA-N
DMPCG2L IU ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMPCG2L CA CAS 78755-81-4
DMPCG2L CB CHEBI:5103
DMPCG2L DE Benzodiazepine overdose
DMUNG4A ID DMUNG4A
DMUNG4A DN Flumethasone
DMUNG4A HS Approved
DMUNG4A SN Flucorticin; Flumetasona; Flumetasona [INN-Spanish]; Flumetasone; Flumetasone [INN]; Flumetasonum; Flumetasonum [INN-Latin]; Flumethason; Flumethasonum; Fluvet; LR3CD8SX89; Methagon; RS 2177; RS-2177; U-10974; flumethasone; 2135-17-3; Anaprime; Aniprime; Cortexilar; Flucort (Veterinary); 6-alpha-Fluorodexamethasone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; 6alpha,9alpha-Difluoro-16alpha-methylprednisolone; 6alpha-Fluorodexamethasone; CHEBI:34764; MLS000028618; NSC 54702; UNII-LR3CD8SX89
DMUNG4A PC 16490
DMUNG4A MW 410.5
DMUNG4A FM C22H28F2O5
DMUNG4A IC WXURHACBFYSXBI-GQKYHHCASA-N
DMUNG4A CS CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C)F
DMUNG4A IK 1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
DMUNG4A IU (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMUNG4A CA CAS 2135-17-3
DMUNG4A CB CHEBI:34764
DMUNG4A DE Atopic dermatitis
DMU0YP6 ID DMU0YP6
DMU0YP6 DN Flumethasone Pivalate
DMU0YP6 HS Approved
DMU0YP6 SN Locacorten; Locorten; Lorinden; Flumetasone pivalate; Flumethasone pivalate (USP); KS-1138; Locorten (TN); Flumetasone pivalate (JAN/BAN); Lpha.-methylpregna-1,4-diene-3,20-dione 21-pivalate; [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate; 6,9-Difluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl pivalate; 6.Alpha.,9-Difluoro-11.beta.,17,21-trihydroxy-16.a; 6.Alpha.,9.alpha.-Difluoro-16.alpha.-methylprednisolone 21-pivalate; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(2,2-dimethylpropionate); 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl 2,2-dimethylpropanoate
DMU0YP6 TC Antiinflammatory Agents
DMU0YP6 DT Small molecular drug
DMU0YP6 PC 443980
DMU0YP6 MW 494.6
DMU0YP6 FM C27H36F2O6
DMU0YP6 IC InChI=1S/C27H36F2O6/c1-14-9-16-17-11-19(28)18-10-15(30)7-8-24(18,5)26(17,29)20(31)12-25(16,6)27(14,34)21(32)13-35-22(33)23(2,3)4/h7-8,10,14,16-17,19-20,31,34H,9,11-13H2,1-6H3/t14-,16+,17+,19+,20+,24+,25+,26+,27+/m1/s1
DMU0YP6 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F
DMU0YP6 IK JWRMHDSINXPDHB-OJAGFMMFSA-N
DMU0YP6 IU [2-[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
DMU0YP6 CA CAS 2002-29-1
DMU0YP6 CB CHEBI:31620
DMU0YP6 DE Contact dermatitis
DMZU5JP ID DMZU5JP
DMZU5JP DN Flunarizine
DMZU5JP HS Approved
DMZU5JP SN Flufenal; Flunarizin; Flunarizina; Flunarizinum; Fluvert; Issium; Sibelium; Vertix; Zinasen; Apo-flunarizine capsules; Flunarizina [INN-Spanish]; Flunarizine (INN); Flunarizine [INN:BAN]; Flunarizinum [INN-Latin]; Novo-Flunarizine; R-14950; Sibelium (TN); (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
DMZU5JP CP Janssen Pharmaceutica
DMZU5JP TC Anticonvulsants
DMZU5JP DT Small molecular drug
DMZU5JP PC 941361
DMZU5JP MW 404.5
DMZU5JP FM C26H26F2N2
DMZU5JP IC InChI=1S/C26H26F2N2/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21/h1-15,26H,16-20H2/b7-4+
DMZU5JP CS C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMZU5JP IK SMANXXCATUTDDT-QPJJXVBHSA-N
DMZU5JP IU 1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine
DMZU5JP CA CAS 52468-60-7
DMZU5JP CB CHEBI:92209
DMZU5JP DE Migraine
DMZSWQC ID DMZSWQC
DMZSWQC DN Flunisolide
DMZSWQC HS Approved
DMZSWQC SN Aerobid; Aerospan; Bronalide; Flunisolida; Flunisolidum; Lunis; Nasalide; Nasarel; Nisolid; Rhinalar; Rhinolar; Soluzione; Synaclyn; Syntaris; Aerobid M; Aerospan HFA; Flunisolide HFA; Flunisolide [INN]; Flunisolide [anhydrous]; Flunisolide anhydrous; F0437; RS 3999; AeroBid (TN); Flunisolida [INN-Spanish]; Flunisolide (anhydrous); Flunisolidum [INN-Latin]; Nasalide (TN); Nasarel (TN); RS-3999; AeroBid, Nasalide, Nasarel,Flunisolide; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-,cyclic 16,17-acetal with acetone; 6 alpha-fluoro-11 beta,16 alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20-dione; 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone; 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione
DMZSWQC TC Antiasthmatic Agents
DMZSWQC DT Small molecular drug
DMZSWQC PC 82153
DMZSWQC MW 434.5
DMZSWQC FM C24H31FO6
DMZSWQC IC InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMZSWQC CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O
DMZSWQC IK XSFJVAJPIHIPKU-XWCQMRHXSA-N
DMZSWQC IU (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMZSWQC CA CAS 3385-03-3
DMZSWQC CB CHEBI:5106
DMZSWQC DE Allergic rhinitis
DMGR5Z3 ID DMGR5Z3
DMGR5Z3 DN Flunitrazepam
DMGR5Z3 HS Approved
DMGR5Z3 SN Flunibeta; Flunimerck; Fluninoc; Flunitrazepamum; Fluridrazepam; Narcozep; Primun; Rohipnol; Rohypnol; Roipnol; Betapharm Brand of Flunitrazepam; Ct Arzneimittel Brand of Flunitrazepam; Flunitrazepam Teva; Flunitrazepam neuraxpharm; Flunitrazepam ratiopharm; Flunizep von ct; Hexal Brand of Flunitrazepam; Merck dura Brand ofFlunitrazepam; Neuraxpharm Brand of Flunitrazepam; Ratiopharm Brand of Flunitrazepam; Roche Brand of Flunitrazepam; Teva Brand of Flunitrazepam; Fluni 1A Pharma; RO54200; [3H]flunitrazepam; Ct-Arzneimittel Brand of Flunitrazepam; Darkene (TN); Flunipam (TN); Flunitrazepam-Teva; Flunitrazepam-neuraxpharm; Flunitrazepam-ratiopharm; Flunitrazepamum [INN-Latin]; Hipnosedon (TN); Hypnodorm (TN); Ilman(TN); Insom (TN); Nilium (TN); Ro 5-4200; Rohypnol (TN); Rufinol (TN); Silece (TN); Vulbegal (TN); RO-5-4200; Flunitrazepam (JP15/USAN/INN); Flunitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-5-(o-fluorophenyl)-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; 1-Methyl-7-nitro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one; 1A Brand of Flunitrazepam; 5-(2-Fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one; 5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one
DMGR5Z3 CP Roche Laboratories Inc
DMGR5Z3 TC Hypnotics and Sedatives
DMGR5Z3 DT Small molecular drug
DMGR5Z3 PC 3380
DMGR5Z3 MW 313.28
DMGR5Z3 FM C16H12FN3O3
DMGR5Z3 IC InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3
DMGR5Z3 CS CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F
DMGR5Z3 IK PPTYJKAXVCCBDU-UHFFFAOYSA-N
DMGR5Z3 IU 5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one
DMGR5Z3 CA CAS 1622-62-4
DMGR5Z3 CB CHEBI:31622
DMGR5Z3 DE Insomnia
DMG2KI4 ID DMG2KI4
DMG2KI4 DN Fluocinolone acetonide
DMG2KI4 HS Approved
DMG2KI4 SN Coriphate; Cortiplastol; Dermalar; Flucinar; Flucinolone; Flucort; Fluocet; Fluocinolonacetonidum; Fluonid; Fluotrex; Fluovitif; Flupollon; Jellin; Localyn; Medidur; Omniderm; Percutina; Prodermin; Radiocin; Retisert; Sinalar; Synalar; Synamol; Synandone; Synandrone; Synemol; Synotic; Synsac; Tefunote;Acetonida de fluocinolona; Acetonide de fluocinolone; Fluocinolone acetonide [DCIT]; Fluocinoloni acetonidum; Fluortriamcinolone Acetonide; Fs Shampoo; Localyn Syntex; F0657; RS 1401AT; Acetonida de fluocinolona [INN-Spanish]; Acetonide de fluocinolone [INN-French]; Component of Neo-Synalar; Dermatin (steroid); Fluocet (TN); Fluocinoloni acetonidum [INN-Latin]; Neo-Synalar; RS-1401 AT; Retisert (TN); Synalar (TN); Synalar-HP; Derma-smoothe/fs; Flucort-N (TN); Fluocinolone 16,17-acetonide; Fluocinolone acetonide [USAN:INN:JAN]; Ydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI); Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; 6.Alpha., 9.alpha.-Difluoro-16.alpha.-h; 6.Alpha.,9-Difluoro; 6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; 6.alpha.-Fluorotriamcinolone acetonide; 6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; 6alpha-Fluorotriamcinolone acetonide
DMG2KI4 TC Antiinflammatory Agents
DMG2KI4 DT Small molecular drug
DMG2KI4 PC 6215
DMG2KI4 MW 452.5
DMG2KI4 FM C24H30F2O6
DMG2KI4 IC InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
DMG2KI4 CS C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O
DMG2KI4 IK FEBLZLNTKCEFIT-VSXGLTOVSA-N
DMG2KI4 IU (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
DMG2KI4 CA CAS 67-73-2
DMG2KI4 CB CHEBI:31623
DMG2KI4 DE Inflammation
DM65KL8 ID DM65KL8
DM65KL8 DN Fluocinonide
DM65KL8 HS Approved
DM65KL8 SN Bestasone; Biscosal; Cortalar; Fluocinolide; Fluocinonido; Fluocinonidum; Fluonex; Fluzon; Lidex; Lonide; Lyderm;Metosyn; Straderm; Topsymin; Topsyn; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide FAPG; Lidex E; Synalar acetate; Fluocinolone acetonide 21-acetate; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]; Fluonex (TN); LIDEX (TN); LIDEX-E; Lidex (TN); Lonide (TN); Lyderm (TN); Vanos (TN); Lidex-E (TN); Fluocinonide (JP15/USP/INN); Fluocinonide [USAN:BAN:INN:JAN]; Fluocinonide [USAN:INN:BAN:JAN]; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate
DM65KL8 CP Taro Pharmaceuticals Inc
DM65KL8 TC Antiinflammatory Agents
DM65KL8 DT Small molecular drug
DM65KL8 PC 9642
DM65KL8 MW 494.5
DM65KL8 FM C26H32F2O7
DM65KL8 IC InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
DM65KL8 CS CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C
DM65KL8 IK WJOHZNCJWYWUJD-IUGZLZTKSA-N
DM65KL8 IU [2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate
DM65KL8 CA CAS 356-12-7
DM65KL8 CB CHEBI:5109
DM65KL8 DE Inflammation
DMQTFAO ID DMQTFAO
DMQTFAO DN Fluorescein
DMQTFAO HS Approved
DMQTFAO SN Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070
DMQTFAO DT Small molecular drug
DMQTFAO PC 16850
DMQTFAO MW 332.3
DMQTFAO FM C20H12O5
DMQTFAO IC InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
DMQTFAO CS C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O
DMQTFAO IK GNBHRKFJIUUOQI-UHFFFAOYSA-N
DMQTFAO IU 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
DMQTFAO CA CAS 2321-07-5
DMQTFAO CB CHEBI:31624
DMQTFAO DE Ocular disease
DM2HKC4 ID DM2HKC4
DM2HKC4 DN Fluorometholone
DM2HKC4 HS Approved
DM2HKC4 SN Cortilet; Cortisdin; Delmeson; Efflumidex; FML; Fluaton; Flucon; Flumetholon; Fluormetholon; Fluormetholone; Fluormetholonum; Fluoromethalone; Fluorometholonum; Fluorometolona; Fluorometolone; Fluoropos; Loticort; Oxylone; Trilcin; Ursnon; Alcon Brand of Fluorometholone; FML Forte; FML Liquifilm; Fluor Op; Fluoro Ophtal; Fluorometolone [DCIT]; Isdin Brand of Fluorometholone; Isopto Flucon; Novartis Brand of Fluorometholone; PMS Fluorometholone; Pharm Allergan Brand of Fluorometholone; Pharmascience Brand of Fluorometholone; Ursapharm Brand of Fluorometholone; Winzer Brand of Fluorometholone; Allergan Brand 1 of Fluorometholone; Allergan Brand 2 of Fluorometholone; Allergan Brand 3 of Fluorometholone; F0414; U 8614; Component of Neo-Oxylone; FML (TN); FML-S Liquifilm; Flarex (TN); Flucon, Isopto; Fluor-Op; Fluoro-Ophtal; Fluorometholonum [INN-Latin]; Fluorometolona [INN-Spanish]; Fml (TN); Neo-Oxylone; Oxylone (TN); PMS-Fluorometholone; Pharm-Allergan Brand of Fluorometholone; FML S.O.P; Fluor-op (TN); Fluorometholone [INN:BAN:JAN]; Fluorometholone (JP15/USP/INN); Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl-(8CI); (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
DM2HKC4 CP Alcon Laboratories
DM2HKC4 TC Antiallergic Agents
DM2HKC4 DT Small molecular drug
DM2HKC4 PC 9878
DM2HKC4 MW 376.5
DM2HKC4 FM C22H29FO4
DM2HKC4 IC InChI=1S/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
DM2HKC4 CS C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
DM2HKC4 IK FAOZLTXFLGPHNG-KNAQIMQKSA-N
DM2HKC4 IU (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM2HKC4 CA CAS 426-13-1
DM2HKC4 CB CHEBI:31625
DM2HKC4 DE Chronic obstructive pulmonary disease
DMUM7HZ ID DMUM7HZ
DMUM7HZ DN Fluorouracil
DMUM7HZ HS Approved
DMUM7HZ SN 5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU
DMUM7HZ CP Hoffmann-La Roche pharmaceutical company
DMUM7HZ TC Immunosuppressive Agents
DMUM7HZ DT Small molecular drug
DMUM7HZ PC 3385
DMUM7HZ MW 130.08
DMUM7HZ FM C4H3FN2O2
DMUM7HZ IC InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
DMUM7HZ CS C1=C(C(=O)NC(=O)N1)F
DMUM7HZ IK GHASVSINZRGABV-UHFFFAOYSA-N
DMUM7HZ IU 5-fluoro-1H-pyrimidine-2,4-dione
DMUM7HZ CA CAS 51-21-8
DMUM7HZ CB CHEBI:46345
DMUM7HZ DE Solid tumour/cancer; Tumour; Colorectal cancer
DM3PD2C ID DM3PD2C
DM3PD2C DN Fluoxetine
DM3PD2C HS Approved
DM3PD2C SN Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
DM3PD2C CP Eli Lilly
DM3PD2C TC Antidepressants
DM3PD2C DT Small molecular drug
DM3PD2C PC 3386
DM3PD2C MW 309.33
DM3PD2C FM C17H18F3NO
DM3PD2C IC InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
DM3PD2C CS CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
DM3PD2C IK RTHCYVBBDHJXIQ-UHFFFAOYSA-N
DM3PD2C IU N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DM3PD2C CA CAS 54910-89-3
DM3PD2C CB CHEBI:86990
DM3PD2C DE Depression
DMUHCF1 ID DMUHCF1
DMUHCF1 DN Fluoxymesterone
DMUHCF1 HS Approved
DMUHCF1 SN Androfluorene; Androfluorone; Androsterolo; Fluossimesterone; Fluosterone; Fluotestin; Fluoximesteron; Fluoximesterona; Fluoximesterone; Fluoximesteronum; Fluoxymesteronum; Fluoxymestrone; Flusteron; Flutestos; Halotestin; Oralsterone; Oratestin; Testoral; Ultandren; Ultandrene; Component of Halodrin; Fluossimesterone [DCIT]; Ora Testryl; U 6040; Anadroid-F; Android-f; Fluoximesterona [INN-Spanish]; Fluoxymesteronum [INN-Latin]; Halotestin (TN); Neo-Ormonal; Ora-Testryl; Fluoxymesterone [INN:BAN:JAN]; Fluoxymesterone (JP15/USP/INN); Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3; Fluoro-9-alpha dihydroxy-11-beta,17-beta methyl-17-alpha androstene-4 one-3 [French]; Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN); Androst-4-en-3-one, 9-fluoro-11beta,17beta-dihydroxy-17-methyl-(VAN) (8CI); (11beta,17beta)-9-fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one; (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 11-beta,17-beta-Dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androsten-3-one; 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one; 17-alpha-Methyl-9-alpha-fluoro-11-beta-hydroxytesterone; 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone; 9-Fluoro-11-beta,17-beta-dihydroxy-17-methylandrost-4-en-3-one; 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one; 9-alpha-Fluoro-11-beta,17-beta-dihydroxy-17-alpha-methyl-4-androstene-3-one; 9-alpha-Fluoro-11-beta-hydroxy-17-methyltestosterone; 9-alpha-Fluoro-17-alpha-methyl-11-beta,17-dihydroxy-4-androsten-3-one;9-fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9.alpha.-Fluoro-11.beta.,17.beta.-dihydroxy-17.alpha.-methyl-4-androstene-3-one; 9.alpha.-Fluoro-11.beta.-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methyl-4-androstene-3-one; 9alpha-Fluoro-11beta,17beta-dihydroxy-17alpha-methylandrost-4-en-3-one; 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone; 9alpha-Fluoro-11beta-hydroxy-17alpha-methyltestosterone; 9alpha-Fluoro-17alpha-methyl-11beta,17-dihydroxy-4-androsten-3-one
DMUHCF1 TC Anabolic Agents
DMUHCF1 DT Small molecular drug
DMUHCF1 PC 6446
DMUHCF1 MW 336.4
DMUHCF1 FM C20H29FO3
DMUHCF1 IC InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
DMUHCF1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F
DMUHCF1 IK YLRFCQOZQXIBAB-RBZZARIASA-N
DMUHCF1 IU (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMUHCF1 CA CAS 76-43-7
DMUHCF1 CB CHEBI:5120
DMUHCF1 DE Breast cancer
DM0DJ9O ID DM0DJ9O
DM0DJ9O DN Flupentixol
DM0DJ9O HS Approved
DM0DJ9O SN 2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 53772-82-0; ALPHA-FLUPENTHIXOL; EINECS 220-304-9; EINECS 258-756-4; Emergil; FA0UYH6QUO; FLUPENTHIXOL; Fluanxol; Flupenthixole; Flupentixol; Flupentixolum [INN-Latin]; Fluphenthixol; Fluxanxol; LC 44; N 7009; Siplaril; Siplarol; UNII-FA0UYH6QUO; cis-(Z)-Flupenthixol; cis-(Z)-Flupenthixol dihydrochloride; cis-Flupenthixol; cis-Flupentixol; flupentixolum
DM0DJ9O TC Antipsychotic Neuroleptic drug
DM0DJ9O DT Small molecular drug
DM0DJ9O PC 5281881
DM0DJ9O MW 434.521
DM0DJ9O FM C23H25F3N2OS
DM0DJ9O IC InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
DM0DJ9O CS C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DM0DJ9O IK NJMYODHXAKYRHW-DVZOWYKESA-N
DM0DJ9O IU 2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DM0DJ9O CA CAS 2709-56-0
DM0DJ9O CB CHEBI:10454
DM0DJ9O DE Depression; Schizophrenia
DMIT8LX ID DMIT8LX
DMIT8LX DN Fluphenazine
DMIT8LX HS Approved
DMIT8LX SN FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
DMIT8LX CP Bristol-Myers Squibb
DMIT8LX TC Antipsychotic Agents
DMIT8LX DT Small molecular drug
DMIT8LX PC 3372
DMIT8LX MW 437.5
DMIT8LX FM C22H26F3N3OS
DMIT8LX IC InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
DMIT8LX CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMIT8LX IK PLDUPXSUYLZYBN-UHFFFAOYSA-N
DMIT8LX IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
DMIT8LX CA CAS 69-23-8
DMIT8LX CB CHEBI:5123
DMIT8LX DE Psychotic disorder
DMZWBKG ID DMZWBKG
DMZWBKG DN Fluprednisolone
DMZWBKG HS Approved
DMZWBKG SN Alphadrol
DMZWBKG CP Pharmacia And Upjohn Co
DMZWBKG DT Small molecular drug
DMZWBKG PC 5876
DMZWBKG MW 378.4
DMZWBKG FM C21H27FO5
DMZWBKG IC InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1
DMZWBKG CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O
DMZWBKG IK MYYIMZRZXIQBGI-HVIRSNARSA-N
DMZWBKG IU (6S,8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMZWBKG CA CAS 53-34-9
DMZWBKG CB CHEBI:34474
DMZWBKG DE Asthma
DMHCI9S ID DMHCI9S
DMHCI9S DN Flurandrenolide
DMHCI9S HS Approved
DMHCI9S SN Cordran; Drenison; Drocort; Floudroxycortide; Fludrossicortide; Fludroxicortida; Fludroxicortidum; Fludroxycortide; Fludroxycortidum; Fluorandrenolone; Fluradrenolide; Flurandrenolone; Haelan; Sermaka; CORDRAN SP; Fludrossicortide [DCIT]; Fluorandrenolone acetonide; Flurandrenolide [USAN]; Flurandrenolone acetonide; L 33379; Alondra-F; CORDRAN (TN); Cordran tape (TN); Fludroxicortida [INN-Spanish]; Fludroxycortidum [INN-Latin]; Flurandrenolide (USP); Haldrone-F; Fludroxycortide (JAN/INN); Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide
DMHCI9S CP Watson Laboratories
DMHCI9S TC Antiinflammatory Agents
DMHCI9S DT Small molecular drug
DMHCI9S PC 15209
DMHCI9S MW 436.5
DMHCI9S FM C24H33FO6
DMHCI9S IC InChI=1S/C24H33FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h7,13-14,16-17,19-20,26,28H,5-6,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
DMHCI9S CS C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F
DMHCI9S IK POPFMWWJOGLOIF-XWCQMRHXSA-N
DMHCI9S IU (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMHCI9S CA CAS 1524-88-5
DMHCI9S CB CHEBI:5127
DMHCI9S DE Inflammation
DMAL4G0 ID DMAL4G0
DMAL4G0 DN Flurazepam
DMAL4G0 HS Approved
DMAL4G0 SN Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
DMAL4G0 CP West-ward Pharmaceutical Corp
DMAL4G0 TC Hypnotics and Sedatives
DMAL4G0 DT Small molecular drug
DMAL4G0 PC 3393
DMAL4G0 MW 387.9
DMAL4G0 FM C21H23ClFN3O
DMAL4G0 IC InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
DMAL4G0 CS CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
DMAL4G0 IK SAADBVWGJQAEFS-UHFFFAOYSA-N
DMAL4G0 IU 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
DMAL4G0 CA CAS 17617-23-1
DMAL4G0 CB CHEBI:5128
DMAL4G0 DE Insomnia
DMGN4BY ID DMGN4BY
DMGN4BY DN Flurbiprofen
DMGN4BY HS Approved
DMGN4BY SN Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid
DMGN4BY CP Abbott Laboratories
DMGN4BY TC Antiinflammatory Agents
DMGN4BY DT Small molecular drug
DMGN4BY PC 3394
DMGN4BY MW 244.26
DMGN4BY FM C15H13FO2
DMGN4BY IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
DMGN4BY CS CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMGN4BY IK SYTBZMRGLBWNTM-UHFFFAOYSA-N
DMGN4BY IU 2-(3-fluoro-4-phenylphenyl)propanoic acid
DMGN4BY CA CAS 5104-49-4
DMGN4BY CB CHEBI:5130
DMGN4BY DE Rheumatoid arthritis
DMFO843 ID DMFO843
DMFO843 DN Fluspirilene
DMFO843 HS Approved
DMFO843 SN Fluspirilen; Fluspirileno; Fluspirilenum; Imap; Redeptin; Spirodiflamine; R 6218; F-100; Fluspirileno [INN-Spanish]; Fluspirilenum [INN-Latin]; Imap (TN); Spiropiperidine analogue, 1; Fluspirilene (USAN/INN); Fluspirilene [USAN:INN:BAN]; McN-JR-6218; 1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane; 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one; 8-[4,4-bis (p-fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4,5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; 8-[4,4-bis(4-fluorophenyl)butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one; 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one
DMFO843 CP Janssen Pharmaceutica
DMFO843 TC Antipsychotic Agents
DMFO843 DT Small molecular drug
DMFO843 PC 3396
DMFO843 MW 475.6
DMFO843 FM C29H31F2N3O
DMFO843 IC InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
DMFO843 CS C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
DMFO843 IK QOYHHIBFXOOADH-UHFFFAOYSA-N
DMFO843 IU 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMFO843 CA CAS 1841-19-6
DMFO843 CB CHEBI:93369
DMFO843 DE Schizophrenia
DMK0O7U ID DMK0O7U
DMK0O7U DN Flutamide
DMK0O7U HS Approved
DMK0O7U SN Apimid; ApoFlutamide; Cebatrol; Chimax; Cytamid; Drogenil; Eulexin; Eulexine; Fluken; Flulem; Flumid; FlutaGRY; Flutacell; Flutamida; Flutamidum; Flutamin; Flutandrona; Flutaplex; Flutexin; Fugerel; METHOXYCHLOR; NFBA; Niftholide; Niftolid; Niftolide; NovoFlutamide; Odyne; Oncosal; Prostacur; Prostandril; Prostica; Prostogenat; Testotard; Alphapharm Brand of Flutamide; Apo Flutamide; Apogepha Brand of Flutamide; Apotex Brand of Flutamide; Azupharma Brand of Flutamide; Cell pharm Brand of Flutamide; Chephasaar Brand of Flutamide; Chiron Brand of Flutamide; Ciclum Brand of Flutamide; Esparma Brand of Flutamide; Essex Brand of Flutamide; Fluta GRY; Fluta cell; Gry Brand of Flutamide; Hexal Brand of Flutamide; InibsaBrand of Flutamide; Ipsen Brand of Flutamide; Juta Brand of Flutamide; Kendrick Brand of Flutamide; Lemery Brand of Flutamide; Novo Flutamide; Novopharm Brand of Flutamide; PMS Flutamide; Pharmascience Brand of Flutamide; Prasfarma Brand of Flutamide; Q Pharm Brand of Flutamide; Schering Brand of Flutamide; Schering Plough Brand of Flutamide; TAD Brand of Flutamide; Tedec Meiji Brand of Flutamide; F 9397; F0663; Fluta 1A Pharma; Flutamide USP25; SCH13521; Sch 13521; Apo-Flutamide; Cebatrol, veterinary; Eulexin (TN); Fluta-GRY; Fluta-cell; Flutamida [INN-Spanish]; Flutamide(pubertal study); Flutamidum [INN-Latin]; NK-601; Novo-Flutamide; PMS-Flutamide; PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN; Q-Pharm Brand of Flutamide; Sch-13521; Schering-Plough Brand of Flutamide; Flutamide [USAN:BAN:INN]; Ham's F-12 medium; Eulexin, Flutamin, Drogenil,Flutamide; Flutamide (JAN/USP/INN); Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide; M-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro; M-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro-(8CI); 1A Brand of Flutamide; 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide; 4'-Nitro-3'-(trifluoromethyl)isobutyranilide; 4'-Nitro-3'-trifluoromethylisobutyramilide; 4'-Nitro-3'-trifluoromethylisobutyranilide; 4-Nitro-3-(trifluoromethyl)isobutyranilide; Flutamide (AR inhibitor)
DMK0O7U CP Schering-Plough Corporation
DMK0O7U TC Anticancer Agents
DMK0O7U DT Small molecular drug
DMK0O7U PC 3397
DMK0O7U MW 276.21
DMK0O7U FM C11H11F3N2O3
DMK0O7U IC InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
DMK0O7U CS CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
DMK0O7U IK MKXKFYHWDHIYRV-UHFFFAOYSA-N
DMK0O7U IU 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMK0O7U CA CAS 13311-84-7
DMK0O7U CB CHEBI:5132
DMK0O7U DE Prostate cancer
DMGCSVF ID DMGCSVF
DMGCSVF DN Fluticasone
DMGCSVF HS Approved
DMGCSVF SN Fluticaps; Fluticaps (TN); Fluticasone (INN); S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMGCSVF CP Fougera Pharmaceuticals Inc
DMGCSVF TC Antiinflammatory Agents
DMGCSVF DT Small molecular drug
DMGCSVF PC 5311101
DMGCSVF MW 444.5
DMGCSVF FM C22H27F3O4S
DMGCSVF IC InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
DMGCSVF CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F
DMGCSVF IK MGNNYOODZCAHBA-GQKYHHCASA-N
DMGCSVF IU S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMGCSVF CA CAS 90566-53-3
DMGCSVF CB CHEBI:5134
DMGCSVF DE Allergic rhinitis
DMRWLB2 ID DMRWLB2
DMRWLB2 DN Fluticasone propionate
DMRWLB2 HS Approved
DMRWLB2 SN FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W
DMRWLB2 PC 444036
DMRWLB2 MW 500.6
DMRWLB2 FM C25H31F3O5S
DMRWLB2 IC InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
DMRWLB2 CS CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
DMRWLB2 IK WMWTYOKRWGGJOA-CENSZEJFSA-N
DMRWLB2 IU [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DMRWLB2 CA CAS 80474-14-2
DMRWLB2 CB CHEBI:31441
DMRWLB2 DE Asthma
DMU54C3 ID DMU54C3
DMU54C3 DN Flutropium bromide
DMU54C3 HS Approved
DMU54C3 SN Flubron (TN)
DMU54C3 DT Small molecular drug
DMU54C3 PC 656602
DMU54C3 MW 478.4
DMU54C3 FM C24H29BrFNO3
DMU54C3 IC InChI=1S/C24H29FNO3.BrH/c1-26(15-14-25)20-12-13-21(26)17-22(16-20)29-23(27)24(28,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,20-22,28H,12-17H2,1H3;1H/q+1;/p-1/t20-,21+,22?,26?;
DMU54C3 CS C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF.[Br-]
DMU54C3 IK FNUZASGZEHGWQM-QCERWEEGSA-M
DMU54C3 IU [(1S,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide
DMU54C3 CA CAS 63516-07-4
DMU54C3 CB CHEBI:31630
DMU54C3 DE Cough
DM4MDJY ID DM4MDJY
DM4MDJY DN Fluvastatin
DM4MDJY HS Approved
DM4MDJY SN Canef; Cranoc; Fluindostatin; Fluvas; Fluvastatina; Fluvastatine; Fluvastatinum; Lescol; Lescol XL; XU 62320; Canef(TN); Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]; Lescol (TN); Vastin (TN); XU-62320; (+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
DM4MDJY TC Anticholesteremic Agents
DM4MDJY DT Small molecular drug
DM4MDJY PC 446155
DM4MDJY MW 411.5
DM4MDJY FM C24H26FNO4
DM4MDJY IC InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1
DM4MDJY CS CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F
DM4MDJY IK FJLGEFLZQAZZCD-MCBHFWOFSA-N
DM4MDJY IU (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
DM4MDJY CA CAS 93957-54-1
DM4MDJY CB CHEBI:38565
DM4MDJY DE Hypercholesterolaemia
DMQTJSX ID DMQTJSX
DMQTJSX DN Fluvoxamine
DMQTJSX HS Approved
DMQTJSX SN Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
DMQTJSX CP IVAX Pharmaceuticals
DMQTJSX TC Antidepressants
DMQTJSX DT Small molecular drug
DMQTJSX PC 5324346
DMQTJSX MW 318.33
DMQTJSX FM C15H21F3N2O2
DMQTJSX IC InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
DMQTJSX CS COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F
DMQTJSX IK CJOFXWAVKWHTFT-XSFVSMFZSA-N
DMQTJSX IU 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
DMQTJSX CA CAS 54739-18-3
DMQTJSX CB CHEBI:5138
DMQTJSX DE Depression
DM2PSBE ID DM2PSBE
DM2PSBE DN Focetria A(H1N1)
DM2PSBE HS Approved
DM2PSBE SN Focetria (H1N1); H1N1 pandemic influenza A vaccine (MF59-adjuvanted, egg-based), Novartis
DM2PSBE CP Novartis AG
DM2PSBE DT Vaccine
DM2PSBE DE Influenza virus infection
DMEMBJC ID DMEMBJC
DMEMBJC DN Folic acid
DMEMBJC HS Approved
DMEMBJC SN folic acid; 59-30-3; Folate; Pteroylglutamic acid; Vitamin M; Folacin; Folacid; PteGlu; Vitamin B9; Folvite; Pteroyl-L-glutamic acid; Vitamin Bc; Acifolic; Cytofol; Incafolic; Foliamin; Folsaure; Folicet; Millafol; Folipac; Folettes; Folsan; Folbal; Folsav; Vitamin Be; Pteroyl-L-monoglutamic acid; Mittafol; Folan; Facid; Pteroylmonoglutamic acid; Antianemia factor; Factor U; Folico (Italy); Folina (Italy); Foldine [France]; Pteroylmonoglutamate; Acfol (Spain); Foldine; Folcysteine; Folasic (Australia); Folcidin; Folaemin [Netherlands]; Nifolin; [3H]folic acid
DMEMBJC TC Vitamins
DMEMBJC DT Small molecular drug
DMEMBJC PC 135398658
DMEMBJC MW 441.4
DMEMBJC FM C19H19N7O6
DMEMBJC IC InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
DMEMBJC CS C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMEMBJC IK OVBPIULPVIDEAO-LBPRGKRZSA-N
DMEMBJC IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMEMBJC CA CAS 59-30-3
DMEMBJC CB CHEBI:27470
DMEMBJC DE Vitamin deficiency; Folate-deficiency anemia
DM2JTS5 ID DM2JTS5
DM2JTS5 DN Follitropin beta
DM2JTS5 HS Approved
DM2JTS5 TC Fertility Agents
DM2JTS5 SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DM2JTS5 DE Female infertility
DM6VOWQ ID DM6VOWQ
DM6VOWQ DN Fomepizole
DM6VOWQ HS Approved
DM6VOWQ SN Antizol; Fomepizol; Fomepizolum; Orphan brand of fomepizole; Paladin brand of fomepizole; M0774; Antizol (TN); Fomepizol [INN-Spanish]; Fomepizole [USAN:INN]; Fomepizolum [INN-Latin]; S14-0570; Fomepizole (USAN/INN); 4-Methyl-1H-pyrazole; 4-Methylpyrazol; 4-Methylpyrazole; 4-methylpyrazole monohydrochloride
DM6VOWQ TC Antidotes
DM6VOWQ DT Small molecular drug
DM6VOWQ PC 3406
DM6VOWQ MW 82.1
DM6VOWQ FM C4H6N2
DM6VOWQ IC InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)
DM6VOWQ CS CC1=CNN=C1
DM6VOWQ IK RIKMMFOAQPJVMX-UHFFFAOYSA-N
DM6VOWQ IU 4-methyl-1H-pyrazole
DM6VOWQ CA CAS 7554-65-6
DM6VOWQ CB CHEBI:5141
DM6VOWQ DE Athylene glycol or methanol poisoning
DMBEP7G ID DMBEP7G
DMBEP7G DN Fomivirsen sodium
DMBEP7G HS Approved
DMBEP7G SN Vitravene; Vitravene Preservative Free; DRG-0234; Vitravene (TN); DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G), eicosasodium salt
DMBEP7G CP Novartis AG; Isis Pharmaceuticals
DMBEP7G TC Antisense
DMBEP7G DT Small molecular drug
DMBEP7G PC 71587550
DMBEP7G MW 7122
DMBEP7G FM C204H243N63Na20O114P20S20
DMBEP7G IC InChI=1S/C204H263N63O114P20S20.20Na/c1-80-44-253(195(291)237-169(80)270)145-31-98(119(349-145)62-328-387(306,407)367-97-30-144(252-22-16-137(210)226-194(252)290)348-118(97)61-327-400(319,420)380-109-42-157(266-78-219-162-167(266)230-187(214)235-182(162)283)361-131(109)74-340-398(317,418)378-107-40-154(262-53-89(10)178(279)246-204(262)300)357-127(107)70-336-395(314,415)375-104-37-151(259-50-86(7)175(276)243-201(259)297)355-125(104)68-334-396(315,416)376-105-38-152(260-51-87(8)176(277)244-202(260)298)358-128(105)71-337-401(320,421)381-110-43-158(267-79-220-163-168(267)231-188(215)236-183(163)284)359-129(110)72-338-388(307,408)368-93-26-140(248-18-12-133(206)222-190(248)286)343-113(93)56-322-383(302,403)362-91-24-155(341-111(91)54-268)264-76-217-160-165(264)228-185(212)233-180(160)281)369-389(308,409)323-58-115-94(27-141(345-115)249-19-13-134(207)223-191(249)287)364-384(303,404)329-63-120-101(34-148(350-120)256-47-83(4)172(273)240-198(256)294)372-392(311,412)332-66-123-99(32-146(353-123)254-45-81(2)170(271)238-196(254)292)370-390(309,410)324-59-116-95(28-142(346-116)250-20-14-135(208)224-192(250)288)365-385(304,405)330-64-121-102(35-149(351-121)257-48-84(5)173(274)241-199(257)295)373-393(312,413)333-67-124-100(33-147(354-124)255-46-82(3)171(272)239-197(255)293)371-391(310,411)325-60-117-96(29-143(347-117)251-21-15-136(209)225-193(251)289)366-386(305,406)331-65-122-103(36-150(352-122)258-49-85(6)174(275)242-200(258)296)374-394(313,414)335-69-126-106(39-153(356-126)261-52-88(9)177(278)245-203(261)299)377-397(316,417)339-73-130-108(41-156(360-130)265-77-218-161-166(265)229-186(213)234-181(161)282)379-399(318,419)326-57-114-92(25-139(344-114)247-17-11-132(205)221-189(247)285)363-382(301,402)321-55-112-90(269)23-138(342-112)263-75-216-159-164(263)227-184(211)232-179(159)280;;;;;;;;;;;;;;;;;;;;/h11-22,44-53,75-79,90-131,138-158,268-269H,23-43,54-74H2,1-10H3,(H,301,402)(H,302,403)(H,303,404)(H,304,405)(H,305,406)(H,306,407)(H,307,408)(H,308,409)(H,309,410)(H,310,411)(H,311,412)(H,312,413)(H,313,414)(H,314,415)(H,315,416)(H,316,417)(H,317,418)(H,318,419)(H,319,420)(H,320,421)(H2,205,221,285)(H2,206,222,286)(H2,207,223,287)(H2,208,224,288)(H2,209,225,289)(H2,210,226,290)(H,237,270,291)(H,238,271,292)(H,239,272,293)(H,240,273,294)(H,241,274,295)(H,242,275,296)(H,243,276,297)(H,244,277,298)(H,245,278,299)(H,246,279,300)(H3,211,227,232,280)(H3,212,228,233,281)(H3,213,229,234,282)(H3,214,230,235,283)(H3,215,231,236,284);;;;;;;;;;;;;;;;;;;;/q;20*+1/p-20/t90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,382?,383?,384?,385?,386?,387?,388?,389?,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?;;;;;;;;;;;;;;;;;;;;/m0..................../s1
DMBEP7G CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)O)[S-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMBEP7G IK DLKYYJFLRUUGHJ-SSJCJZGYSA-A
DMBEP7G IU icosasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-sulfidophosphoryl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMBEP7G CA CAS 160369-77-7
DMBEP7G DE Cytomegalovirus retinitis
DMWS3FH ID DMWS3FH
DMWS3FH DN Fondaparinux sodium
DMWS3FH HS Approved
DMWS3FH SN Arixtra; Quixidar; Fondaparin sodium; Arixtra (TN); GSK-576428; SR-90107; SR-90107A; Fondaparinux sodium (JAN/USAN/INN)
DMWS3FH CP GSK
DMWS3FH TC Anticoagulants
DMWS3FH DT Small molecular drug
DMWS3FH PC 636380
DMWS3FH MW 1728.1
DMWS3FH FM C31H43N3Na10O49S8
DMWS3FH IC InChI=1S/C31H53N3O49S8.10Na/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56;;;;;;;;;;/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68);;;;;;;;;;/q;10*+1/p-10/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-;;;;;;;;;;/m1........../s1
DMWS3FH CS CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMWS3FH IK XEKSTYNIJLDDAZ-JASSWCPGSA-D
DMWS3FH IU decasodium;(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxylato-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dihydroxyoxane-2-carboxylate
DMWS3FH CA CAS 114870-03-0
DMWS3FH DE Venous thrombosis
DMRBJNZ ID DMRBJNZ
DMRBJNZ DN Forasartan
DMRBJNZ HS Approved
DMRBJNZ SN SC 52458; SC-52458; Forasartan (USAN/INN); 5-((3,5-Dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-ylphenyl))pyridine; 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine
DMRBJNZ TC Antihypertensive Agents
DMRBJNZ DT Small molecular drug
DMRBJNZ PC 132706
DMRBJNZ MW 416.5
DMRBJNZ FM C23H28N8
DMRBJNZ IC InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
DMRBJNZ CS CCCCC1=NN(C(=N1)CCCC)CC2=CN=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMRBJNZ IK YONOBYIBNBCDSJ-UHFFFAOYSA-N
DMRBJNZ IU 5-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-tetrazol-5-yl)phenyl]pyridine
DMRBJNZ CA CAS 145216-43-9
DMRBJNZ CB CHEBI:141552
DMRBJNZ DE Hypertension
DMSOURV ID DMSOURV
DMSOURV DN Formoterol
DMSOURV HS Approved
DMSOURV SN Foradile; Formoterol tartrate; Oxeze Turbuhaler Foradil; MOLI000351; Atimos (TN); Atock (TN); Foradil (TN); Foradile (TN); Formoterol (INN); Modulite (TN); Oxeze (TN); Oxis (TN); Perforomist (TN); Formoterol, ((R*,R*)-(+-)-)-isomer; N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide; N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide; N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide; (+-)-2'-Hydroxy-5'-((RS)-1-hydroxy-2-(((RS)-p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide; 3-formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
DMSOURV CP Norvatis Phamaceuticals Corporation
DMSOURV TC Sympathomimetics
DMSOURV DT Small molecular drug
DMSOURV PC 3410
DMSOURV MW 344.4
DMSOURV FM C19H24N2O4
DMSOURV IC InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)
DMSOURV CS CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
DMSOURV IK BPZSYCZIITTYBL-UHFFFAOYSA-N
DMSOURV IU N-[2-hydroxy-5-[1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]phenyl]formamide
DMSOURV CA CAS 73573-87-2
DMSOURV CB CHEBI:63082
DMSOURV DE Asthma
DM4W9B3 ID DM4W9B3
DM4W9B3 DN Fosamprenavir
DM4W9B3 HS Approved
DM4W9B3 SN Telzir; Amprenavir phosphate; Fosamprenavir [INN]; GW 433908; GW433908; VX 175; Fosamprenavir (INN); Lexiva (TM); Lexiva (TN); Telzir (TN); Telzir(TM); VX-175; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester; ((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-benzyl-2-(phosphonooxy)propyl)carboxamide; (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester
DM4W9B3 CP GlaxoSmithKline
DM4W9B3 TC Anti-HIV Agents
DM4W9B3 DT Small molecular drug
DM4W9B3 PC 131536
DM4W9B3 MW 585.6
DM4W9B3 FM C25H36N3O9PS
DM4W9B3 IC InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
DM4W9B3 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N
DM4W9B3 IK MLBVMOWEQCZNCC-OEMFJLHTSA-N
DM4W9B3 IU [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate
DM4W9B3 CA CAS 226700-79-4
DM4W9B3 CB CHEBI:82941
DM4W9B3 DE Human immunodeficiency virus infection
DM9KJLZ ID DM9KJLZ
DM9KJLZ DN Foscavir
DM9KJLZ HS Approved
DM9KJLZ SN Foscarmet; Foscarnet; Phosphonoformate; Triapten; Virudin; Carboxyphosphonic acid; Dihydroxyphosphanecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide; Dihydroxyphosphinecarboxylic acid oxide trisodium salt; Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate; FOSCARNET SODIUM; Forscarnet sodium; Foscarnet sodico; Foscarnet sodico [Spanish]; Foscarnet sodique; Foscarnet sodique [French]; Foscarnet sodium hexahydrate; Foscarnet sodium hydrate; Foscarneto sodico; Foscarnetum natricum; Foscarnetum natricum [Latin]; Phgosphonocarboxylic acid; Phosphonoformic acid; Phosphonomethanoic acid; Trisodium carboxyphosphate; Trisodium dioxidophosphanecarboxylate oxide; Trisodium dioxidophosphinecarboxylate oxide; Trisodium phosphonatoformate; Trisodium phosphonatoformate hexahydrate; Trisodium phosphonoformate; Trisodium phosphonoformate hexahydrate; Trisodium phosphonoformte hexahydrate; A 29622; EHB 776; A-29622; DRG-0017; Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody; EHB-776; Foscarnet sodique [INN-French]; Foscarnet sodium hydrate (JAN); Foscarneto sodico [INN-Spanish]; Foscarnetum natricum [INN-Latin]; Foscavir (TN); HS-0008; MSL & PFA; Phosphonoformic acid, trisodium salt; Trisodium carboxyphosphate (anhydrous); Trisodium phosphonoformate (anhydrous); Foscarnet & IFN-ALPHA; Foscarnet sodium (USAN/INN); Foscarnet sodium [USAN:INN:BAN]; Phosphonoformic acid & IFN-ALPHA; Phosphonoformic acid, trisodium salt, hexahydrate; PFA & rIFN.alpha.A; Phosphinecarboxylic acid, dihydroxy-, oxide; Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon; Sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6); Formic acid, phosphono-, trisodium salt, hexahydrate; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt; Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
DM9KJLZ CP AstraZeneca
DM9KJLZ TC Antiviral Agents
DM9KJLZ DT Small molecular drug
DM9KJLZ PC 44561
DM9KJLZ MW 191.95
DM9KJLZ FM CNa3O5P
DM9KJLZ IC InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3
DM9KJLZ CS C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
DM9KJLZ IK DFHAXXVZCFXGOQ-UHFFFAOYSA-K
DM9KJLZ IU trisodium;phosphonatoformate
DM9KJLZ CA CAS 63585-09-1
DM9KJLZ CB CHEBI:141644
DM9KJLZ DE Cytomegalovirus retinitis
DMR0TYK ID DMR0TYK
DMR0TYK DN Fosdenopterin
DMR0TYK HS Approved
DMR0TYK SN CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
DMR0TYK CP Orphatec Pharmaceuticals GmbH
DMR0TYK DT Small molecular drug
DMR0TYK PC 135463437
DMR0TYK MW 363.22
DMR0TYK FM C10H14N5O8P
DMR0TYK IC InChI=1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1
DMR0TYK CS C1[C@@H]2[C@@H](C([C@H]3[C@@H](O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O
DMR0TYK IK CZAKJJUNKNPTTO-AJFJRRQVSA-N
DMR0TYK IU (1R,10R,12S,17R)-5-amino-11,11,14-trihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),4-dien-7-one
DMR0TYK CA CAS 150829-29-1
DMR0TYK CB CHEBI:60210
DMR0TYK DE Encephalopathy; Molybdenum cofactor deficiency
DMD072M ID DMD072M
DMD072M DN Fosfestrol
DMD072M HS Approved
DMD072M SN fosfestrol; Diethylstilbestrol diphosphate; 522-40-7; Phosphestrol; Phosphoestrolum; Honvan; Stilbestrol diphosphate; Desdp; Diethylstilbestryl diphosphate; Diethylstilbesterol diphosphate; ST52-Asta; Fosfestrolum [INN-Latin]; UNII-A0E0NMA80F; CCRIS 2778; (E)-Hex-3-ene-3,4-diylbis(4,1-phenylene) bis(dihydrogen phosphate); C18H22O8P2; EINECS 208-328-8; A0E0NMA80F; CHEBI:4532; Diethylstilbestrol diphosphate [USP]; NCGC00181335-01; Stilphostrol (TN); alpha,alpha'-Diethyl-(E)-4,4'-stilbenediol bis(dihydrogen phosphate)
DMD072M DT Small molecular drug
DMD072M PC 3032325
DMD072M MW 428.3
DMD072M FM C18H22O8P2
DMD072M IC InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24)/b18-17+
DMD072M CS CC/C(=C(/CC)\\C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O
DMD072M IK NLORYLAYLIXTID-ISLYRVAYSA-N
DMD072M IU [4-[(E)-4-(4-phosphonooxyphenyl)hex-3-en-3-yl]phenyl] dihydrogen phosphate
DMD072M CA CAS 522-40-7
DMD072M CB CHEBI:4532
DMD072M DE Solid tumour/cancer
DMVGPMX ID DMVGPMX
DMVGPMX DN Fosfomycin
DMVGPMX HS Approved
DMVGPMX SN FCM; Phosphomycin; Phosphonemycin; Phosphonomycin; Priomicina; Veramina; Disodium fosfomycin; Disodium phosphonomycin; Fosfocina disodium salt; Fosfomycin disodium; Fosfomycin disodium salt; Fosfomycin sodium; Fosfomycin sodium salt; Fosmicin S; Phosphomycin disodium salt; Phosphonomycin disodium salt; Phosphonomycin sodium; Sodium fosfomycin; MK 955; FOM-Na; Fosfomycin sodium (JP15); Fosmicin S (TN); Fosfomycin (USAN/INN); L-cis-1,2-epoxypropylphosphonic acid; Disodium (1R,2S)-(1,2-epoxypropyl)phosphonate; Disodium[(2r,3s)-3-methyloxiran-2-yl]phosphonate; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, disodium salt, (2R-cis)-(9CI); (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonicacid; (1R,2S)(-)-(1,2-Epoxypropyl)phosphonic acid disodium salt; (1R,2S)-(1,2-Epoxypropyl)phosphonic acid; (1R,2S)-epoxypropylphosphonate; (1R,2S)-epoxypropylphosphonic acid; (2R-cis)-(3-Methyloxiranyl)phosphonic acid disodium salt
DMVGPMX TC Antibiotics
DMVGPMX DT Small molecular drug
DMVGPMX PC 446987
DMVGPMX MW 138.06
DMVGPMX FM C3H7O4P
DMVGPMX IC InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
DMVGPMX CS C[C@H]1[C@H](O1)P(=O)(O)O
DMVGPMX IK YMDXZJFXQJVXBF-STHAYSLISA-N
DMVGPMX IU [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid
DMVGPMX CA CAS 23155-02-4
DMVGPMX CB CHEBI:28915
DMVGPMX DE Bacterial infection
DMDIC39 ID DMDIC39
DMDIC39 DN Fosfosal
DMDIC39 HS Approved
DMDIC39 SN Disdolen (TN)
DMDIC39 DT Small molecular drug
DMDIC39 PC 3418
DMDIC39 MW 218.1
DMDIC39 FM C7H7O6P
DMDIC39 IC InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12)
DMDIC39 CS C1=CC=C(C(=C1)C(=O)O)OP(=O)(O)O
DMDIC39 IK FFKUDWZICMJVPA-UHFFFAOYSA-N
DMDIC39 IU 2-phosphonooxybenzoic acid
DMDIC39 CA CAS 6064-83-1
DMDIC39 CB CHEBI:94564
DMDIC39 DE Pain
DM9NJ52 ID DM9NJ52
DM9NJ52 DN Fosinopril
DM9NJ52 HS Approved
DM9NJ52 SN Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
DM9NJ52 CP Bristol-Myers Squibb
DM9NJ52 TC Antihypertensive Agents
DM9NJ52 DT Small molecular drug
DM9NJ52 PC 55891
DM9NJ52 MW 563.7
DM9NJ52 FM C30H46NO7P
DM9NJ52 IC InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
DM9NJ52 CS CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3
DM9NJ52 IK BIDNLKIUORFRQP-FKDWWROVSA-N
DM9NJ52 IU (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
DM9NJ52 CA CAS 98048-97-6
DM9NJ52 CB CHEBI:5163
DM9NJ52 DE Hypertension
DM7G0EP ID DM7G0EP
DM7G0EP DN Fosmidomycin
DM7G0EP HS Approved
DM7G0EP SN FOM; Fosmidomycina; Fosmidomycine; Fosmidomycinum; FR-31564; Fosmidomycina [INN-Spanish]; Fosmidomycine [INN-French]; Fosmidomycinum [INN-Latin]; {3-[formyl(hydroxy)amino]propyl}phosphonic acid; (3-(Formylhydroxyamino)propyl)phosphonic acid, monosodium salt; (3-(N-Hydroxyformamido)propyl)phosphonic acid; 3-(Formyl-hydroxy-amino)propylphosphonic acid; 3-(N-Formyl-N-hydroxyamino)-propylphosphonic acid; 3-(N-hydroxyformamido)propylphosphonic acid; 3-[FORMYL(HYDROXY)AMINO]PROPYLPHOSPHONIC ACID
DM7G0EP TC Antimalarials
DM7G0EP DT Small molecular drug
DM7G0EP PC 572
DM7G0EP MW 183.1
DM7G0EP FM C4H10NO5P
DM7G0EP IC InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
DM7G0EP CS C(CN(C=O)O)CP(=O)(O)O
DM7G0EP IK GJXWDTUCERCKIX-UHFFFAOYSA-N
DM7G0EP IU 3-[formyl(hydroxy)amino]propylphosphonic acid
DM7G0EP CA CAS 66508-53-0
DM7G0EP CB CHEBI:443725
DM7G0EP DE Malaria
DMOX3LB ID DMOX3LB
DMOX3LB DN Fosphenytoin
DMOX3LB HS Approved
DMOX3LB SN Fosfenitoina; Fosphenytoine; Fosphenytoinum; HMPDP; Prodilantin; ACC-9653; Cerebyx (TN); Fosfenitoina [INN-Spanish]; Fosphenytoin (INN); Fosphenytoin [INN:BAN]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; Prodilantin (TN); (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; (3-Phosphoryloxymethyl)phenytoin; 3-(hydroxymethyl)phenytoin disodium phosphate; 3-(hydroxymethyl)phenytoin phosphate ester
DMOX3LB CP Pfizer Pharmaceuticals
DMOX3LB TC Anticonvulsants
DMOX3LB DT Small molecular drug
DMOX3LB PC 56339
DMOX3LB MW 362.27
DMOX3LB FM C16H15N2O6P
DMOX3LB IC InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)
DMOX3LB CS C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3
DMOX3LB IK XWLUWCNOOVRFPX-UHFFFAOYSA-N
DMOX3LB IU (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate
DMOX3LB CA CAS 93390-81-9
DMOX3LB CB CHEBI:5165
DMOX3LB DE Epilepsy
DM8J5XT ID DM8J5XT
DM8J5XT DN Fospropofol
DM8J5XT HS Approved
DM8J5XT SN Fospropofol; Fospropofol [INN]; LZ257RZP7K; SCHEMBL3821874; ZINC2519740; 258516-89-1; AC1MI4YI; ACM258516891; CHEBI:135193; CHEMBL1201766; DB06716; DEA No. 2138; DTXSID50870295; FT-0727559; GTPL7475; UNII-LZ257RZP7K; [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
DM8J5XT PC 3038498
DM8J5XT MW 288.28
DM8J5XT FM C13H21O5P
DM8J5XT IC QVNNONOFASOXQV-UHFFFAOYSA-N
DM8J5XT CS CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)(O)O
DM8J5XT IK 1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)
DM8J5XT IU [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate
DM8J5XT CA CAS 258516-89-1
DM8J5XT CB CHEBI:135193
DM8J5XT DE Neuropathic pain
DMKLJRD ID DMKLJRD
DMKLJRD DN Fospropofol disodium
DMKLJRD HS Approved
DMKLJRD SN Lusedra (TN)
DMKLJRD CP Eisai
DMKLJRD DT Small molecular drug
DMKLJRD PC 3038497
DMKLJRD MW 332.24
DMKLJRD FM C13H19Na2O5P
DMKLJRD IC InChI=1S/C13H21O5P.2Na/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16;;/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16);;/q;2*+1/p-2
DMKLJRD CS CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)([O-])[O-].[Na+].[Na+]
DMKLJRD IK LWYLQNWMSGFCOZ-UHFFFAOYSA-L
DMKLJRD IU disodium;[2,6-di(propan-2-yl)phenoxy]methyl phosphate
DMKLJRD CA CAS 258516-87-9
DMKLJRD DE Monitored anaesthesia care
DM6AUHV ID DM6AUHV
DM6AUHV DN Fostamatinib
DM6AUHV HS Approved
DM6AUHV SN 901119-35-5; R788; Tavalisse; UNII-SQ8A3S5101; R-788 Free acid; R 788; R-788; R-935788 Free acid; SQ8A3S5101; R7935788; Fostamatinib [USAN:INN]
DM6AUHV CP Rigel Pharmaceuticals
DM6AUHV DT Small molecular drug
DM6AUHV PC 11671467
DM6AUHV MW 580.5
DM6AUHV FM C23H26FN6O9P
DM6AUHV IC InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
DM6AUHV CS CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C
DM6AUHV IK GKDRMWXFWHEQQT-UHFFFAOYSA-N
DM6AUHV IU [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate
DM6AUHV CA CAS 901119-35-5
DM6AUHV DE Immune thrombocytopenic purpura; Rheumatoid arthritis
DM50ILT ID DM50ILT
DM50ILT DN Fostemsavir
DM50ILT HS Approved
DM50ILT SN BMS-216; BMS-248; BMS-378806; BMS-626529; BMS-705; BMS-806; BMS-806 series; BMS-853; HIV-1 attachment inhibitors, BMS; HIV-1 entry inhibitors, BMS; BMS-488043 follow-on compounds, BMS; HIV-1 attachment inhibitors, Bristol-Myers Squibb
DM50ILT CP Bristol-myers squibb
DM50ILT DT Small molecular drug
DM50ILT PC 11319217
DM50ILT MW 583.5
DM50ILT FM C25H26N7O8P
DM50ILT IC InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38)
DM50ILT CS CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC
DM50ILT IK SWMDAPWAQQTBOG-UHFFFAOYSA-N
DM50ILT IU [3-[2-(4-benzoylpiperazin-1-yl)-2-oxoacetyl]-4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)pyrrolo[2,3-c]pyridin-1-yl]methyl dihydrogen phosphate
DM50ILT CA CAS 864953-29-7
DM50ILT DE Human immunodeficiency virus infection
DMV62ED ID DMV62ED
DMV62ED DN Fotemustine
DMV62ED HS Approved
DMV62ED SN Fotemustine; 92118-27-9; Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Muphoran; Mustophorane; Servier-10036; Fotemustinum [Latin]; Fotemustina [Spanish]; S 10036; C9H19ClN3O5P; CCRIS 6337; S-10036; Fotemustinum; Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate; (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate; Mustoforan; 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea; Fotemustine [BAN:INN]
DMV62ED DT Small molecular drug
DMV62ED PC 104799
DMV62ED MW 315.69
DMV62ED FM C9H19ClN3O5P
DMV62ED IC InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
DMV62ED CS CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
DMV62ED IK YAKWPXVTIGTRJH-UHFFFAOYSA-N
DMV62ED IU 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea
DMV62ED CA CAS 92118-27-9
DMV62ED CB CHEBI:131852
DMV62ED DE Solid tumour/cancer
DMF8DNE ID DMF8DNE
DMF8DNE DN Framycetin
DMF8DNE HS Approved
DMF8DNE SN Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy
DMF8DNE TC Antibiotics
DMF8DNE DT Small molecular drug
DMF8DNE PC 8378
DMF8DNE MW 614.6
DMF8DNE FM C23H46N6O13
DMF8DNE IC InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
DMF8DNE CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
DMF8DNE IK PGBHMTALBVVCIT-VCIWKGPPSA-N
DMF8DNE IU (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
DMF8DNE CA CAS 119-04-0
DMF8DNE CB CHEBI:7508
DMF8DNE DE Alcoholic cirrhosis of liver; Acute liver failure; Bacterial infection
DMDZY54 ID DMDZY54
DMDZY54 DN Fremanezumab
DMDZY54 HS Approved
DMDZY54 SN Fremanezumab [INN]; Fremanezumab [USAN]; UNII-PF8K38CG54; PF8K38CG54; TEV-48125; PF-04472429
DMDZY54 CP Teva
DMDZY54 DT Antibody
DMDZY54 DE Hyperprolactinaemia
DM7RE8P ID DM7RE8P
DM7RE8P DN Frovatriptan
DM7RE8P HS Approved
DM7RE8P SN Allegro; Auradol; Frova; Frovelan; Migard; Miguard; Rilamig; Allergo filmtabletten; SB 209509; Allergo filmtabletten(TN); Frova (TN); Frovatriptan (INN); SB-209509; (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide; (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (R)-5,6,7,8-Tetrahydro-6-(methylamino)carbazole-3-carboxamide
DM7RE8P CP Vernalis
DM7RE8P TC Antimigraine Agents
DM7RE8P DT Small molecular drug
DM7RE8P PC 77992
DM7RE8P MW 243.3
DM7RE8P FM C14H17N3O
DM7RE8P IC InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1
DM7RE8P CS CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N
DM7RE8P IK XPSQPHWEGNHMSK-SECBINFHSA-N
DM7RE8P IU (6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
DM7RE8P CA CAS 158747-02-5
DM7RE8P CB CHEBI:134991
DM7RE8P DE Migraine
DM43AN2 ID DM43AN2
DM43AN2 DN Fructose
DM43AN2 HS Approved
DM43AN2 SN D-(-)-Fructose; 57-48-7; D(-)-Fructose; (3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one; 53188-23-1; D-(-)-Levulose; D-Levulose; Nevulose; Furucton; arabino-Hexulose; Sugar, fruit; Fructose, D-; Krystar 300; Hi-Fructo 970; keto-D-fructose; Fructose, pure; Fructose solution; CCRIS 3335; 30237-26-4; EINECS 200-333-3; AI3-23514; DL-Fructose; MFCD00148910; D(-)-Fructose, 99%; Fructon; D-(-)-Fructose, > Methose; Levulosa; Levulosa Baxter; Levulosa Braun; Apir Levulosa; Levulosa Mein; Levulosa Ibys; Levulosa Ife; Levulosado Braun; D-fructose
DM43AN2 DT Small molecular drug
DM43AN2 PC 2723872
DM43AN2 MW 180.16
DM43AN2 FM C6H12O6
DM43AN2 IC InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6?/m1/s1
DM43AN2 CS C1[C@H]([C@H]([C@@H](C(O1)(CO)O)O)O)O
DM43AN2 IK LKDRXBCSQODPBY-VRPWFDPXSA-N
DM43AN2 IU (3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM43AN2 CA CAS 6347-01-9
DM43AN2 CB CHEBI:37714
DM43AN2 DE Vomiting
DM0YZC6 ID DM0YZC6
DM0YZC6 DN Fulvestrant
DM0YZC6 HS Approved
DM0YZC6 SN Faslodex; AstraZeneca brand of fulvestrant; Fulvestrant [USAN]; Ici 182780; ZD 182780; ZM 182780; Faslodex (TN); ZD-182780; ZD-9238; ZM-182780; Faslodex(ICI 182,780); Faslodex, ICI 182780, Fulvestrant; Fulvestrant (JAN/USAN/INN); (7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; (7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol; 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol; 7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol; 7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol; ICI
DM0YZC6 CP AstraZeneca
DM0YZC6 TC Anticancer Agents
DM0YZC6 DT Small molecular drug
DM0YZC6 PC 104741
DM0YZC6 MW 606.8
DM0YZC6 FM C32H47F5O3S
DM0YZC6 IC InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
DM0YZC6 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
DM0YZC6 IK VWUXBMIQPBEWFH-WCCTWKNTSA-N
DM0YZC6 IU (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM0YZC6 CA CAS 129453-61-8
DM0YZC6 CB CHEBI:31638
DM0YZC6 DE Breast cancer
DM3P6V7 ID DM3P6V7
DM3P6V7 DN Furazolidone
DM3P6V7 HS Approved
DM3P6V7 SN Bifuron; Corizium; Coryzium; Diafuron; Enterotoxon; Furall; Furaxon; Furaxone; Furazol; Furazolidine; Furazolidon; Furazolidona; Furazolidonum; Furazolum; Furazon; Furidon; Furovag; Furox; Furoxal; Furoxane; Furoxon; Furoxone; Furozolidine; Giardil; Giarlam; Medaron; Neftin; Nicolen; Nifulidone; Nifuran; Nifurazolidone; Nifurazolidonum; Nitrofurazolidone; Nitrofurazolidonum; Nitrofuroxon; Optazol; Ortazol; Puradin; Roptazol; Sclaventerol; Tikofuran; Topazone; Trichofuron; Tricofuron; Tricoron; Trifurox; Viofuragyn; Fiurox aerosol powder; Furoxone Liquid; Furoxone Swine Mix; NF 180 custom mix ten; F-8900; Furazolidona [INN-Spanish]; Furazolidone [INN:BAN]; Furazolidonum [INN-Latin]; Furox Aerosol Powder (Veterinary); Furoxone (TN); NF-180; Usaf ea-1; Dependal-M (TN); Furazolidone (USP/INN); N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone; N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one; 3-(((5-Nitro-2-furanyl)methylene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidinone; 3-((5-Nitrofurfurylidene)amino)-2-oxazolidone; 3-((5-Nitrofurylidene)amino)-2-oxazolidone; 3-(5'-Nitrofurfuralamino)-2-oxazolidone; 3-(5-Nitrofurfurylideneamino)-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone; 3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone; 3-[(5-Nitrofurylidene)amino]-2-oxazolidone; 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one; 3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone; 3-{[(5-Nitro-2-furanyl)methylene]amino}-2-oxazolidinone; 3-{[(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one; 3-{[(E)-(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one; 5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
DM3P6V7 CP GlaxoSmithKline
DM3P6V7 TC Antiinfective Agents
DM3P6V7 DT Small molecular drug
DM3P6V7 PC 5323714
DM3P6V7 MW 225.16
DM3P6V7 FM C8H7N3O5
DM3P6V7 IC InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2/b9-5+
DM3P6V7 CS C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DM3P6V7 IK PLHJDBGFXBMTGZ-WEVVVXLNSA-N
DM3P6V7 IU 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
DM3P6V7 CA CAS 67-45-8
DM3P6V7 CB CHEBI:5195
DM3P6V7 DE Diarrhea
DMMQ8ZG ID DMMQ8ZG
DMMQ8ZG DN Furosemide
DMMQ8ZG HS Approved
DMMQ8ZG SN Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
DMMQ8ZG CP Sanofi-Aventis
DMMQ8ZG TC Diuretics
DMMQ8ZG DT Small molecular drug
DMMQ8ZG PC 3440
DMMQ8ZG MW 330.74
DMMQ8ZG FM C12H11ClN2O5S
DMMQ8ZG IC InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
DMMQ8ZG CS C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
DMMQ8ZG IK ZZUFCTLCJUWOSV-UHFFFAOYSA-N
DMMQ8ZG IU 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
DMMQ8ZG CA CAS 54-31-9
DMMQ8ZG CB CHEBI:47426
DMMQ8ZG DE Congestive heart failure
DMWVCF3 ID DMWVCF3
DMWVCF3 DN Fusidic acid
DMWVCF3 HS Approved
DMWVCF3 SN FUCIDIN; Fucidate; Fucithalmic; Fusidate; Fusidine; Ramycin; Diethanolamine fusidate; Fucidate Sodium; Fucidic acid; Fucidin acid; Fuci (TN); Fucibet (TN); Fucicort (TN); Fucidin (TN); Fucidin Cream 2%; Fucidine (TN); Fucithalmic (TN); Fucizon (TN); Fudic (TN); Fusiderm (TN); Fusidin (TN); SQ 16,603; Fusidic acid (USAN/INN); C.A.S. 62,602; (2Z)-2-[(17Z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid; (2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid; 16-(Acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic acid; 3.alpha.,11.alpha.,16.beta.-Trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic acid 16-acetate
DMWVCF3 CP Leo Laboratories
DMWVCF3 TC Antibiotics
DMWVCF3 DT Small molecular drug
DMWVCF3 PC 3000226
DMWVCF3 MW 516.7
DMWVCF3 FM C31H48O6
DMWVCF3 IC InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
DMWVCF3 CS C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\\C(=O)O)OC(=O)C)C)O)C
DMWVCF3 IK IECPWNUMDGFDKC-MZJAQBGESA-N
DMWVCF3 IU (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
DMWVCF3 CA CAS 6990-06-3
DMWVCF3 CB CHEBI:29013
DMWVCF3 DE Bacterial infection; MRSA infection
DMZ0P95 ID DMZ0P95
DMZ0P95 DN Ga-68-DOTATOC
DMZ0P95 HS Approved
DMZ0P95 DT radioactive diagnostic agent
DMZ0P95 DE Diagnostic imaging
DM6T924 ID DM6T924
DM6T924 DN Gabapentin
DM6T924 HS Approved
DM6T924 SN Aclonium; GBN; Gabapen; Gabapentina; Gabapentine; Gabapentinium; Gabapentino; Gabapentinum; Gabapetin; Neurontin; Serada; Vultin; Apotex brand of gabapentin; Aventis brand of gabapentin; Gabapentin GR; Gabapentin Hexal; Gabapentin Stada; Gabapentino [Spanish]; Hexal brand of gabapentin; Novopharm brand of gabapentin; Parke Davis brand of gabapentin; Pfizer brand of gabapentin; Pharmascience brand of gabapentin; Ratiopharm brand of gabapentin; Stadapharm brand of gabapentin; GOE 2450; Go 3450; Apo-Gabapentin; DDS-2003; DM-1796; DM-5689; G-154; Gabapentin (Neurontin); Gabapentin-ratiopharm; Gabapentine [INN-French]; Gabapentino [INN-Spanish]; Gabapentinum [INN-Latin]; Goe-3450; Neurontin (TN); Novo-Gabapentin; PMS-Gabapentin; Warner-Lambert brand of gabapentin; Gabapentin [USAN:INN:BAN]; [1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID; Gabapentin (JAN/USAN/INN); 1-(Aminomethyl)-cyclohexaneacetic acid; 1-(Aminomethyl)cyclohexaneacetic acid; 2-[1-(aminomethyl)cyclohexyl]acetic acid
DM6T924 CP Pfizer
DM6T924 TC Analgesics
DM6T924 DT Small molecular drug
DM6T924 PC 3446
DM6T924 MW 171.24
DM6T924 FM C9H17NO2
DM6T924 IC InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)
DM6T924 CS C1CCC(CC1)(CC(=O)O)CN
DM6T924 IK UGJMXCAKCUNAIE-UHFFFAOYSA-N
DM6T924 IU 2-[1-(aminomethyl)cyclohexyl]acetic acid
DM6T924 CA CAS 60142-96-3
DM6T924 CB CHEBI:42797
DM6T924 DE Complex partial seizure; Solid tumour/cancer
DMU9D2F ID DMU9D2F
DMU9D2F DN Gabexate
DMU9D2F HS Approved
DMU9D2F SN gabexate; Gabexate [INN]; 39492-01-8; Gabexatum [INN-Latin]; Gabexato [INN-Spanish]; UNII-4V7M9137X9; CHEMBL87563; C16H23N3O4; Gabexate (INN); 4V7M9137X9; Ethyl p-hydroxybenzoate 6-guanidinohexanoate; ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate; Gabexatum; Gabexato; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester; p-carbethoxyphenyl e-guanidinocaproate; AC1L1FYH; Prestwick3_001008; Prestwick2_001008; Prestwick0_001008; Prestwick1_001008; BSPBio_001135; SCHEMBL446024; SPBio_003016; GTPL7863
DMU9D2F DT Small molecular drug
DMU9D2F PC 3447
DMU9D2F MW 321.37
DMU9D2F FM C16H23N3O4
DMU9D2F IC InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)
DMU9D2F CS CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N
DMU9D2F IK YKGYIDJEEQRWQH-UHFFFAOYSA-N
DMU9D2F IU ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate
DMU9D2F CA CAS 39492-01-8
DMU9D2F CB CHEBI:93036
DMU9D2F DE Pancreatitis
DMI53FU ID DMI53FU
DMI53FU DN Gaboxadol
DMI53FU HS Approved
DMI53FU SN Gaboxadolum; Gaboxadolum [Latin]; LU 2030; Gaboxadol [USAN:INN]; Lu 02-030; MK-0928; Gaboxadol (USAN/INN); LU-2-030; Lu-02-030; Isoxazolo(5,4-c)pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, hydrate; 4,5,6,7-Tetrahydroisoxazole(5,4-c)pyridin-3-ol; 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
DMI53FU CP Merck & Co
DMI53FU TC Hypnotics and Sedatives
DMI53FU DT Small molecular drug
DMI53FU PC 3448
DMI53FU MW 140.14
DMI53FU FM C6H8N2O2
DMI53FU IC InChI=1S/C6H8N2O2/c9-6-4-1-2-7-3-5(4)10-8-6/h7H,1-3H2,(H,8,9)
DMI53FU CS C1CNCC2=C1C(=O)NO2
DMI53FU IK ZXRVKCBLGJOCEE-UHFFFAOYSA-N
DMI53FU IU 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one
DMI53FU CA CAS 64603-91-4
DMI53FU CB CHEBI:34373
DMI53FU DE Insomnia
DM4VAOG ID DM4VAOG
DM4VAOG DN Gadobenate dimeglumine
DM4VAOG HS Approved
DM4VAOG SN Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)
DM4VAOG TC Contrast Media
DM4VAOG DT Small molecular drug
DM4VAOG PC 6918204
DM4VAOG MW 1058.1
DM4VAOG FM C36H62GdN5O21
DM4VAOG IC InChI=1S/C22H31N3O11.2C7H17NO5.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1
DM4VAOG CS CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)O.[Gd+3]
DM4VAOG IK OCDAWJYGVOLXGZ-VPVMAENOSA-K
DM4VAOG IU 2-[2-[carboxylatomethyl-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl]amino]ethyl-(carboxymethyl)amino]-3-phenylmethoxypropanoate;gadolinium(3+);(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
DM4VAOG CA CAS 127000-20-8
DM4VAOG DE Schizophrenia
DM5V9U1 ID DM5V9U1
DM5V9U1 DN Gadofosveset
DM5V9U1 HS Approved
DM5V9U1 SN Vasovist (TN)
DM5V9U1 CP Epix
DM5V9U1 DT Small molecular drug
DM5V9U1 PC 73415770
DM5V9U1 MW 891.9
DM5V9U1 FM C33H41GdN3O14P
DM5V9U1 IC InChI=1S/C33H44N3O14P.Gd/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);/q;+3/p-3/t26-;/m1./s1
DM5V9U1 CS [H+].[H+].[H+].C1CC(CCC1OP(=O)([O-])OC[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Gd+3]
DM5V9U1 IK ZSDLYSDDELEVDD-UFTMZEDQSA-K
DM5V9U1 IU 2-[[(2R)-2-[bis(carboxylatomethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;gadolinium(3+);hydron
DM5V9U1 CA CAS 201688-00-8
DM5V9U1 DE Imaging
DMEO794 ID DMEO794
DMEO794 DN Galantamine
DMEO794 HS Approved
DMEO794 SN GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
DMEO794 CP Janssen Pharmaceutica
DMEO794 TC Parasympathomimetics
DMEO794 DT Small molecular drug
DMEO794 PC 9651
DMEO794 MW 287.35
DMEO794 FM C17H21NO3
DMEO794 IC InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
DMEO794 CS CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
DMEO794 IK ASUTZQLVASHGKV-JDFRZJQESA-N
DMEO794 IU (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMEO794 CA CAS 357-70-0
DMEO794 CB CHEBI:42944
DMEO794 DE Alzheimer disease
DMIZ1E8 ID DMIZ1E8
DMIZ1E8 DN Galcanezumab
DMIZ1E8 HS Approved
DMIZ1E8 SN Galcanezumab [USAN:INN]; UNII-55KHL3P693; 55KHL3P693
DMIZ1E8 CP Eli Lilly
DMIZ1E8 DT Antibody
DMIZ1E8 DE Hyperprolactinaemia
DMPO0MS ID DMPO0MS
DMPO0MS DN Gallamine Triethiodide
DMPO0MS HS Approved
DMPO0MS SN Benzkurin; Flaxedil; Gallaflex; Parexyl; Pirolakson; Pyrolaxon; Relaxan; Remyolan; Retensin; Sincurarine; Syncurarine; Tricuran; Benzcurine iodide; Gallamin triethiodide; Gallamina triodoetilato; Gallamina triodoetilato [DCIT]; Gallamine iodide; Gallamine triethiodide [INN]; Gallamine triiodoethylate; Gallamini triethiodidum; Gallaminii iodidum; Gallaminum triaethjodidum; Gallaminum triaethoiodatum; Gallamone triethiodide; Gallamoni jodidum; Miowas G; Triethiodure de gallamine; Triethiodurode galamina; Triiodoethylate de gallamine; Triiodoethylate de gallamine [French]; F 2559; Fourneau 2559; G 8134; HL 8583; RP 3697; Flaxedil (TN); Gallamine triethiodide (USP); Gallamine-3ETI; Gallamini triethiodidum [INN-Latin]; Triethiodure de gallamine [INN-French]; Triethioduro de galamina [INN-Spanish]; Pyrogallol 1,2,3-(diethylaminoethyl ether) trisethyl iodide; Pyrogallol 1,2,3-(diethylaminoethyl ether) tris(ethyliodide); Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene; Tri(iodoethylate) de tri (beta diethylaminoethoxy)-1,2,3 benzene [French]; Triiodoethylate of tri(diethylaminoethyloxy)-1,2,3-benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene; Triiodure de tri(beta-triethylammoniumethoxy)-1,2,3 benzene [French]; Ammonium, (v-phenenyltris(oxyethylene))tris(triethyl-, triiodide; Ammonium, (v-phenenyltris(oxyethylene)tris(triethyl-, triiodide; Tri(beta-diethylaminoethoxy)-1,2,3-benzene tri-iodoethylate; Ethanaminium, 2,2',2'-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl)-, triiodide; Ethanaminium, 2,2',2''-(1,2,3-benzenetriyltris(oxy))tris(N,N,N-triethyl-, triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammonium iodide); (v-Phenenyltris(oxyethylene))tris(triethylammonium) triiodide; (v-Phenenyltris(oxyethylene))tris(triethylammoniumiodide); 1,2,3-Tri(beta-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene triethiodide; 1,2,3-Tris(2-diethylaminoethoxy)benzene tris(ethyliodide); 1,2,3-Tris(2-triethylammonium ethoxy)benzene triiodide; 1,2,3-Tris(diethylaminoethoxy)benzene triethiodide; 2,2',2''-(1,2,3-Benzenetriyltris(oxy))tris(N,N,N-triethylethanaminium) triiodide; 2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethylethanaminium) triiodide; 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium triiodide
DMPO0MS TC Skeletal Muscle Relaxants
DMPO0MS DT Small molecular drug
DMPO0MS PC 6172
DMPO0MS MW 891.5
DMPO0MS FM C30H60I3N3O3
DMPO0MS IC InChI=1S/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3
DMPO0MS CS CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-]
DMPO0MS IK REEUVFCVXKWOFE-UHFFFAOYSA-K
DMPO0MS IU 2-[2,3-bis[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl-triethylazanium;triiodide
DMPO0MS CA CAS 65-29-2
DMPO0MS DE Stabilize muscle contraction
DMF9O6B ID DMF9O6B
DMF9O6B DN Gallium nitrate
DMF9O6B HS Approved
DMF9O6B SN Ganite (TN)
DMF9O6B TC Anticancer Agents
DMF9O6B DT Small molecular drug
DMF9O6B PC 61635
DMF9O6B MW 255.74
DMF9O6B FM GaN3O9
DMF9O6B IC InChI=1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1
DMF9O6B CS [N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ga+3]
DMF9O6B IK CHPZKNULDCNCBW-UHFFFAOYSA-N
DMF9O6B IU gallium;trinitrate
DMF9O6B CA CAS 13494-90-1
DMF9O6B DE Hypercalcaemia
DMER9YA ID DMER9YA
DMER9YA DN Galsulfase
DMER9YA HS Approved
DMER9YA SN Aryplase; Aryplase (TN); Galsulfase (genetical recombination); Galsulfase (USAN/INN); Galsulfase (genetical recombination) (JAN)
DMER9YA TC Enzyme Replacement Agents
DMER9YA SQ Galsulfase: SGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWNNTVFIFSTDNGGQTLAGGNNWPLRGRKWSLWEGGVRGVGFVASPLLKQKGVKNRELIHISDWLPTLVKLARGHTNGTKPLDGFDVWKTISEGSPSPRIELLHNIDPNFVDSSPCPRNSMAPAKDDSSLPEYSAFNTSVHAAIRHGNWKLLTGYPGCGYWFPPPSQYNVSEIPSSDPPTKTLWLFDIDRDPEERHDLSREYPHIVTKLLSRLQFYHKHSVPVYFPAQDPRCDPKATGVWGPWM
DMER9YA DE Mucopolysaccharidosis
DMGBKVD ID DMGBKVD
DMGBKVD DN Gamma hydroxybutyric acid
DMGBKVD HS Approved
DMGBKVD SN Anetamin; GHB; Hydroxyb; Oxybate; SHB; Somsanit; Xyrem; Gamma OH; Oxybate sodium; Utyric acid monosodium salt; EB 27; WY 3478; Gam-OH; Gamma-Hydroxy butyrate; Gamma-Hydroxy sodium butyrate; Gamma-Hydroxybutanoic acid; Gamma-Hydroxybutyrate sodium; Gamma-Hydroxybutyric acid; Gamma-Hydroxybutyric acid decomposition product; Gamma-Hydroxybutyric acid monosodium salt; Gamma-OH; Xyrem (TN); Gamma-Hydroxybutyric acid, sodium salt; Oxy-n-butyric acid; Sodium Oxybate (4-hydroxybutanoic acid); Sodium .gamma.-hydroxybutyrate; Sodium .gamma.-oxybutyrate; AA3E2AF0-AB7A-4A1E-A391-199C049D7162; Butanoic acid, 4-hydroxy-, monosodium salt; Butanoic acid, 4-hydroxy-, sodium salt; Butyric acid, 4-hydroxy-, monosodium salt; Butyric acid, 4-hydroxy-, sodium salt; 3-carboxypropoxy acid; 4 HB; 4-Hydroxy; 4-Hydroxyacid; 4-Hydroxyalkanoic acid; 4-Hydroxybutanoic acid; 4-Hydroxybuttersaeure; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid; 4-Hydroxybutyric acid monosodium salt; 4-Hydroxycarboxylic acid; 4-OHB; 4-hydroxy-butyric acid
DMGBKVD CP Jazz Pharmaceuticals
DMGBKVD TC Anesthetics
DMGBKVD DT Small molecular drug
DMGBKVD PC 10413
DMGBKVD MW 104.1
DMGBKVD FM C4H8O3
DMGBKVD IC InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)
DMGBKVD CS C(CC(=O)O)CO
DMGBKVD IK SJZRECIVHVDYJC-UHFFFAOYSA-N
DMGBKVD IU 4-hydroxybutanoic acid
DMGBKVD CA CAS 591-81-1
DMGBKVD CB CHEBI:30830
DMGBKVD DE Narcolepsy
DMSXKYG ID DMSXKYG
DMSXKYG DN Gamma-homolinolenic acid
DMSXKYG HS Approved
DMSXKYG SN DGLA; BML3-B11; Ro 12-1989; Star GLA (GNC); Bishomo-gamma-linolenic acid; C 20:3 n-6; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Homo-gamma-linolensaeure; Tona-lean 1000 CLA (Action Labs); Cis-8,11,14-Eicosatrienoic Acid; Eicosa-8Z,11Z,14Z-trienoic acid; All-cis-8,11,14-Eicosatrienoic acid; All-cis-8,11,14-icosatrienoic acid; All-cis-Eicosa-8,11,14-triensaeure; Cis,cis,cis-8,11,14-Eicosatrienoic acid; Cis-8,cis-11,cis-14-Eicosatrienoic acid; (8E,11E,14E)-8,11,14-Icosatrienoic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoate; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoicacid; 20:3, n-6,9,12 all-cis; 8, 11, 14-eicosatrienoic acid; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)-(9CI); 8,11,14-Eicosatrienoic acid, (Z,Z,Z)-(8CI); 8,11,14-Icosatrienoate; 8,11,14-all-cis-Eicosatrienoic acid; 8c,11c,14c-Eicosatriensaeure; 8c,11c,14c-eicosatrienoic acid
DMSXKYG TC Dietary supplement
DMSXKYG DT Small molecular drug
DMSXKYG PC 5280581
DMSXKYG MW 306.5
DMSXKYG FM C20H34O2
DMSXKYG IC InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-
DMSXKYG CS CCCCC/C=C\\C/C=C\\C/C=C\\CCCCCCC(=O)O
DMSXKYG IK HOBAELRKJCKHQD-QNEBEIHSSA-N
DMSXKYG IU (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid
DMSXKYG CA CAS 1783-84-2
DMSXKYG CB CHEBI:53486
DMSXKYG DE Malnutrition
DMQN30Z ID DMQN30Z
DMQN30Z DN Gamolenic acid
DMQN30Z HS Approved
DMQN30Z SN gamma-Linolenic acid; GAMOLENIC ACID; 506-26-3; (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid; (Z,Z,Z)-6,9,12-Octadecatrienoic acid; CCRIS 7668; UNII-78YC2MAX4O; Acidum gamolenicum [Latin]; Acido gamolenico [Spanish]; Acide gamolenique [French]; 6,9,12-Octadecatrienoic acid, (Z,Z,Z)-; Gamolenic acid [INN:BAN]; (6,9,12)-linolenic acid; all-cis-6,9,12-Octadecatrienoic acid; cis,cis,cis-6,9,12-Octadecatrienoic acid; 6Z,9Z,12Z-octadecatrienoic acid; 78YC2MAX4O; cis-Delta(6,9,12)-octadecatrienoic acid; CHEMBL464982; CHEBI:28661; Epogam (TN); gamma-linolenic acid
DMQN30Z DT Small molecular drug
DMQN30Z PC 5280933
DMQN30Z MW 278.4
DMQN30Z FM C18H30O2
DMQN30Z IC InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13H,2-5,8,11,14-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-
DMQN30Z CS CCCCC/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O
DMQN30Z IK VZCCETWTMQHEPK-QNEBEIHSSA-N
DMQN30Z IU (6Z,9Z,12Z)-octadeca-6,9,12-trienoic acid
DMQN30Z CA CAS 506-26-3
DMQN30Z CB CHEBI:28661
DMQN30Z DE Allergy
DM1MBYQ ID DM1MBYQ
DM1MBYQ DN Ganciclovir
DM1MBYQ HS Approved
DM1MBYQ SN ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512
DM1MBYQ CP Bausch & Lomb Pharmaceuticals, Inc.
DM1MBYQ TC Antiviral Agents
DM1MBYQ DT Small molecular drug
DM1MBYQ PC 135398740
DM1MBYQ MW 255.23
DM1MBYQ FM C9H13N5O4
DM1MBYQ IC InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
DM1MBYQ CS C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
DM1MBYQ IK IRSCQMHQWWYFCW-UHFFFAOYSA-N
DM1MBYQ IU 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one
DM1MBYQ CA CAS 82410-32-0
DM1MBYQ CB CHEBI:465284
DM1MBYQ DE Virus infection
DMGMB30 ID DMGMB30
DMGMB30 DN Ganirelix
DMGMB30 HS Approved
DMGMB30 SN Ganirelixum; Orgalutran; Ganirelix acetate; Antagon (TN); Ganirelix (INN); Ganirelix [INN:BAN]; Ganirelixum [INN-Latin]; Orgalutran (TN); RS-26306
DMGMB30 CP Organon International
DMGMB30 TC Abortifacient Agents
DMGMB30 DT Small molecular drug
DMGMB30 PC 16130957
DMGMB30 MW 1570.3
DMGMB30 FM C80H113ClN18O13
DMGMB30 IC InChI=1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1
DMGMB30 CS CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC
DMGMB30 IK GJNXBNATEDXMAK-PFLSVRRQSA-N
DMGMB30 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGMB30 CA CAS 124904-93-4
DMGMB30 CB CHEBI:135910
DMGMB30 DE Ovulation dysfunction
DMSL679 ID DMSL679
DMSL679 DN Gatifloxacin
DMSL679 HS Approved
DMSL679 SN Bonoq; GTFX; Gaity; Gatiflo; Gatilox; Gatiquin; Gatispan; Tequin; Zymar; Zymaxid; Zymer; AM 1155; CG 5501;PD 135432; PD135432; AM-1155; BMS 206584-01; BMS-206584; CG-5501; Gatiflo (TN); Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; PD-135432; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar (TN); Zymer (TN); BMS-206584-01; Gatiflo,Tequin and Zymar, Gatifloxacin; AM-1155 (*Sesquihydrate*); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMSL679 CP Bristol-Myers Squibb
DMSL679 TC Antiinfective Agents
DMSL679 DT Small molecular drug
DMSL679 PC 5379
DMSL679 MW 375.4
DMSL679 FM C19H22FN3O4
DMSL679 IC InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
DMSL679 CS CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
DMSL679 IK XUBOMFCQGDBHNK-UHFFFAOYSA-N
DMSL679 IU 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMSL679 CA CAS 112811-59-3
DMSL679 CB CHEBI:5280
DMSL679 DE Respiratory tract infection
DMH0QKA ID DMH0QKA
DMH0QKA DN GDC-0199
DMH0QKA HS Approved
DMH0QKA CP AbbVie
DMH0QKA DT Small molecular drug
DMH0QKA PC 49846579
DMH0QKA MW 868.4
DMH0QKA FM C45H50ClN7O7S
DMH0QKA IC InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
DMH0QKA CS CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
DMH0QKA IK LQBVNQSMGBZMKD-UHFFFAOYSA-N
DMH0QKA IU 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DMH0QKA CA CAS 1257044-40-8
DMH0QKA CB CHEBI:133021
DMH0QKA DE Chronic lymphocytic leukaemia; Solid tumour/cancer
DM15F0X ID DM15F0X
DM15F0X DN Gefitinib
DM15F0X HS Approved
DM15F0X SN Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
DM15F0X CP AstraZeneca
DM15F0X TC Anticancer Agents
DM15F0X DT Small molecular drug
DM15F0X PC 123631
DM15F0X MW 446.9
DM15F0X FM C22H24ClFN4O3
DM15F0X IC InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
DM15F0X CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
DM15F0X IK XGALLCVXEZPNRQ-UHFFFAOYSA-N
DM15F0X IU N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
DM15F0X CA CAS 184475-35-2
DM15F0X CB CHEBI:49668
DM15F0X DE Solid tumour/cancer; Urethral cancer; Head and neck cancer
DMSE3I7 ID DMSE3I7
DMSE3I7 DN Gemcitabine
DMSE3I7 HS Approved
DMSE3I7 SN Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)
DMSE3I7 CP Eli Lilly
DMSE3I7 TC Anticancer Agents
DMSE3I7 DT Small molecular drug
DMSE3I7 PC 60750
DMSE3I7 MW 263.2
DMSE3I7 FM C9H11F2N3O4
DMSE3I7 IC InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
DMSE3I7 CS C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
DMSE3I7 IK SDUQYLNIPVEERB-QPPQHZFASA-N
DMSE3I7 IU 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMSE3I7 CA CAS 95058-81-4
DMSE3I7 CB CHEBI:175901
DMSE3I7 DE Solid tumour/cancer
DMD8Q3J ID DMD8Q3J
DMD8Q3J DN Gemfibrozil
DMD8Q3J HS Approved
DMD8Q3J SN ApoGemfibrozil; Ausgem; Bolutol; Brozil; Cholespid; Clearol; Decrelip; Elmogan; Fetinor; Fibratol; Fibrocit; GFZ; Gemd; Gemfibril; Gemfibromax; Gemfibrosil; Gemfibrozilo; Gemfibrozilum; Gemhexal; Gemlipid; Gemnpid; GenGemfibrozil; Genlip; Gozid; Hidil; Hipolixan; Innogem; Innogen; Ipolipid; Jezil; Lanaterom; Lifibron; Lipazil; Lipigem; Lipira; Lipizyl; Lipozid; Lipur; Litarek; Lopid; Micolip; Normolip; NuGemfibrozil; Pilder; Polyxit; Progemzal; Reducel; Regulip; Renabrazin; Sinelip; Synbrozil; Taborcil; Tentroc; Trialmin; Alphapharm Brand of Gemfibrozil; Apo Gemfibrozil; Apotex Brand of Gemfibrozil; Bayvit Brand of Gemfibrozil; Bexal Brand of Gemfibrozil; Biochemie Brand of Gemfibrozil; Bull Brand of Gemfibrozil; Cantabria Brand of Gemfibrozil; Chem mart Brand of Gemfibrozil; Chem mart Gemfibrozil; DBL Gemfibrozil; Douglas Brand of Gemfibrozil; Farmasierra Brand of Gemfibrozil; Faulding Brand of Gemfibrozil;Ferrer Brand of Gemfibrozil; Gemfibrozilo Bayvit; Gemfibrozilo Bexal; Gemfibrozilo Ur; Gen Gemfibrozil; GenRX Gemfibrozil; Genpharm Brand of Gemfibrozil; Gevilon Uno; Healthsense Brand of Gemfibrozil; Healthsense Gemfibrozil; Hexal Brand of Gemfibrozil; Ipsen Brand of Gemfibrozil; Lipox Gemfi; Lopid R; Menarini Brand of Gemfibrozil; Novo Gemfibrozil; Novopharm Brand of Gemfibrozil; Nu Gemfibrozil; Nu Pharm Brand of Gemfibrozil; PMS Gemfibrozil; Parke Davis Brand of Gemfibrozil; Pfizer Brand of Gemfibrozil; Pharmascience Brand of Gemfibrozil; Quimifar Brand of Gemfibrozil; SBPA Gemfibrozil; Sigma Brand of Gemfibrozil; TAD Brand of Gemfibrozil; Terry White Chemists Brand of Gemfibrozil; Terry White Chemists Gemfibrozil; United Drug Brand of Gemfibrozil; Warner Lambert Brand of Gemfibrozil; CI719; Gemfi 1A Pharma; Apo-Gemfibrozil; Bayvit, Gemfibrozilo; Gem-S; Gemfibrozil, GenRX; Gemfibrozil, Healthsense; Gemfibrozil, SBPA; Gemfibrozilo [INN-Spanish]; Gemfibrozilum [INN-Latin]; Gen-Fibro;Gen-Gemfibrozil; Jezil (TN); Lopid (TN); Low-Lip; Novo-Gemfibrozil; Nu-Gemfibrozil; Nu-Pharm Brand of Gemfibrozil; PMS-Gemfibrozil; TEVA-A; WL-Gemfibrozil; Warner-Lambert Brand of Gemfibrozil; GEMFIBROZIL (SEE ALSO PEROXISOME PROJECT (GEMFIBROZIL)); Gemfibrozil [USAN:BAN:INN]; Gen-Fibro (TN); PEROXISOME PROJECT (GEMFIBROZIL) (SEE ALSO GEMFIBROZIL); Gemfibrozil (JAN/USP/INN); Gemcor, Lopid, Jezil,Gen-Fibro, Gemfibrozil; 1A Brand of Gemfibrozil; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 5-(2,5-Dimethyl-Phenoxy)-2,2-Dimethyl-Pentanoic Acid; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid
DMD8Q3J CP Pfizer Pharmaceuticals
DMD8Q3J TC Antilipemic Agents
DMD8Q3J DT Small molecular drug
DMD8Q3J PC 3463
DMD8Q3J MW 250.33
DMD8Q3J FM C15H22O3
DMD8Q3J IC InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
DMD8Q3J CS CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
DMD8Q3J IK HEMJJKBWTPKOJG-UHFFFAOYSA-N
DMD8Q3J IU 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
DMD8Q3J CA CAS 25812-30-0
DMD8Q3J CB CHEBI:5296
DMD8Q3J DE Hyperlipidaemia
DMHT34O ID DMHT34O
DMHT34O DN Gemifloxacin
DMHT34O HS Approved
DMHT34O SN Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DMHT34O CP Oscient Pharmaceuticals
DMHT34O TC Antibiotics
DMHT34O DT Small molecular drug
DMHT34O PC 9571107
DMHT34O MW 389.4
DMHT34O FM C18H20FN5O4
DMHT34O IC InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
DMHT34O CS CO/N=C/1\\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
DMHT34O IK ZRCVYEYHRGVLOC-HYARGMPZSA-N
DMHT34O IU 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMHT34O CA CAS 175463-14-6
DMHT34O CB CHEBI:101853
DMHT34O DE Bacterial infection
DMJ2O7B ID DMJ2O7B
DMJ2O7B DN Gemtuzumab ozogamicin
DMJ2O7B HS Approved
DMJ2O7B SN Mylotarg (TN)
DMJ2O7B CP Wyeth Pharmaceuticals
DMJ2O7B TC Anticancer Agents
DMJ2O7B DT Antibody
DMJ2O7B SQ Light Chain No. 1: QIVLTQSPAIMSASPGEKVTITCSASSSISYMHWFQQKPGTSPKLWIYTTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCHQRSTYPLTFGSGTKLELK > Light Chain No. 2DIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLMYKASSLESGVPSRFIGSGSGTEFTLTISSLQPDDFATYYCQQYNSDSKMFGQGTKVEVK > Heavy Chain No. 1QVQLQQSGAELAKPGASVKMSCKASGYTFTSYRMHWVKQRPGQGLEWIGYINPSTGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTFEDSAVYYCARGGGVFDYWGQGTTLTVSS > Heavy Chain No. 2QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAIIWVRQAPGQGLEWMGGIVPMFGPPNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGIYSPEEYNGGLVTVSS
DMJ2O7B DE Acute myeloid leukaemia
DMKINJO ID DMKINJO
DMKINJO DN Gentamicin
DMKINJO HS Approved
DMKINJO SN Alcomicin; Apogen; Bristagen; Cidomycin; GENTAMYCIN; Garamycin; Garasol; Gentacidin; Gentacycol; Gentafair; Gentak; Gentamar; Gentamicina; Gentamicine; Gentamicins; Gentamicinum; Gentamycinum; Gentavet; Gentocin; Jenamicin; Refobacin; Uromycine; Garamycin Otic Solution; Genoptic Liquifilm; Gentamcin Sulfate; Gentamicin sulphate sterile; Refobacin TM; Gentamicin C1; G-Mycin; G-Myticin; Garamycin (TN); Gentamicin (BAN); Gentamicin (TN); Gentamicina [INN-Spanish]; Gentamicine [INN-French]; Gentamicinum [INN-Latin];Gentamycin-creme; Gentamycin-creme [German]; Ocu-Mycin; Spectro-Genta; U-Gencin; Genoptic S.O.P.; O-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-ribo-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-2-deoxy-D-streptamine; (1R,2S,3S,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-beta-L-lyxo-heptopyranoside; (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4,6-diamino-3-{[3-deoxy-4-c-methyl-3-(methylamino)pentopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside
DMKINJO CP Sandoz
DMKINJO TC Antibiotics
DMKINJO DT Small molecular drug
DMKINJO PC 3467
DMKINJO MW 477.6
DMKINJO FM C21H43N5O7
DMKINJO IC InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3
DMKINJO CS CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
DMKINJO IK CEAZRRDELHUEMR-UHFFFAOYSA-N
DMKINJO IU 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMKINJO CA CAS 1403-66-3
DMKINJO DE Bacterial infection
DMBT7MI ID DMBT7MI
DMBT7MI DN Gentamicine sulfate
DMBT7MI HS Approved
DMBT7MI SN SCH-9724; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMBT7MI TC Antibiotics
DMBT7MI DT Small molecular drug
DMBT7MI PC 6419933
DMBT7MI MW 1488.8
DMBT7MI FM C60H125N15O25S
DMBT7MI IC InChI=1S/C21H43N5O7.C20H41N5O7.C19H39N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19;1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;8-19,25-28H,4-7,21-24H2,1-3H3;8-18,24-27H,3-7,20-23H2,1-2H3;(H2,1,2,3,4)/t9-,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+;8-,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+;8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-;/m110./s1
DMBT7MI CS C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O.OS(=O)(=O)O
DMBT7MI IK RDEIXVOBVLKYNT-HDZPSJEVSA-N
DMBT7MI IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[(1R)-1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
DMBT7MI CA CAS 1405-41-0
DMBT7MI DE Bacterial infection
DMP0OVQ ID DMP0OVQ
DMP0OVQ DN Gestrinone
DMP0OVQ HS Approved
DMP0OVQ SN Dimetrose (TN)
DMP0OVQ CP Sarsa
DMP0OVQ DT Small molecular drug
DMP0OVQ PC 27812
DMP0OVQ MW 308.4
DMP0OVQ FM C21H24O2
DMP0OVQ IC InChI=1S/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1
DMP0OVQ CS CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C#C)O
DMP0OVQ IK BJJXHLWLUDYTGC-ANULTFPQSA-N
DMP0OVQ IU (8S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMP0OVQ CA CAS 16320-04-0
DMP0OVQ CB CHEBI:89642
DMP0OVQ DE Breast cancer
DMKGH0R ID DMKGH0R
DMKGH0R DN GHRP-2
DMKGH0R HS Approved
DMKGH0R SN Pralmorelin; D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide; KP-102; UNII-E6S6E1F19M; E6S6E1F19M; KP 102; WAY-GPA-748; L-Lysinamide, D-alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-; (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; KP-102D; Pralmorelin [INN]; GHRP-2 Acetate/; GHRP Kaken 100; AC1OCF7D; (2R)-2-methyl-4-deoxy and 2,4-dideoxy
DMKGH0R DT Small molecular drug
DMKGH0R PC 6918245
DMKGH0R MW 818
DMKGH0R FM C45H55N9O6
DMKGH0R IC InChI=1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
DMKGH0R CS C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N
DMKGH0R IK HRNLPPBUBKMZMT-RDRUQFPZSA-N
DMKGH0R IU (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMKGH0R CA CAS 158861-67-7
DMKGH0R CB CHEBI:135890
DMKGH0R DE Growth hormone deficiency
DMTI0ZO ID DMTI0ZO
DMTI0ZO DN Gilteritinib
DMTI0ZO HS Approved
DMTI0ZO SN 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide; ASP 2215; Gilteritinib; Gilteritinib (ASP-2215); Gilteritinib (ASP2215); Gilteritinib (USAN/INN); Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Xospata
DMTI0ZO TC Anticancer Agents
DMTI0ZO DT Small molecular drug
DMTI0ZO PC 49803313
DMTI0ZO MW 552.724
DMTI0ZO FM C29H44N8O3
DMTI0ZO IC InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
DMTI0ZO CS CCC1=NC(=C(N=C1NC2CCOCC2)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC)C(=O)N
DMTI0ZO IK GYQYAJJFPNQOOW-UHFFFAOYSA-N
DMTI0ZO IU 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
DMTI0ZO CA CAS 1254053-43-4
DMTI0ZO DE Acute myeloid leukemia
DMWQ4MZ ID DMWQ4MZ
DMWQ4MZ DN Gilteritinib
DMWQ4MZ HS Approved
DMWQ4MZ SN UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199
DMWQ4MZ CP Astellas
DMWQ4MZ PC 49803313
DMWQ4MZ MW 552.7
DMWQ4MZ FM C29H44N8O3
DMWQ4MZ IC InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
DMWQ4MZ CS CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5
DMWQ4MZ IK GYQYAJJFPNQOOW-UHFFFAOYSA-N
DMWQ4MZ IU 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
DMWQ4MZ CA CAS 1254053-43-4
DMWQ4MZ CB CHEBI:145372
DMWQ4MZ DE Acute myeloid leukaemia
DM5PFIJ ID DM5PFIJ
DM5PFIJ DN Givosiran
DM5PFIJ HS Approved
DM5PFIJ SN 1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280
DM5PFIJ CP Alnylam Pharmaceuticals
DM5PFIJ DT Small interfering RNA
DM5PFIJ PC 119058042
DM5PFIJ MW 1711
DM5PFIJ FM C78H139N11O30
DM5PFIJ IC InChI=1S/C78H139N11O30/c1-50-42-54(96)43-89(50)65(104)26-12-10-8-6-5-7-9-11-25-64(103)88-78(47-111-39-27-61(100)82-33-19-30-79-58(97)22-13-16-36-114-75-66(85-51(2)93)72(108)69(105)55(44-90)117-75,48-112-40-28-62(101)83-34-20-31-80-59(98)23-14-17-37-115-76-67(86-52(3)94)73(109)70(106)56(45-91)118-76)49-113-41-29-63(102)84-35-21-32-81-60(99)24-15-18-38-116-77-68(87-53(4)95)74(110)71(107)57(46-92)119-77/h50,54-57,66-77,90-92,96,105-110H,5-49H2,1-4H3,(H,79,97)(H,80,98)(H,81,99)(H,82,100)(H,83,101)(H,84,102)(H,85,93)(H,86,94)(H,87,95)(H,88,103)/t50-,54-,55-,56-,57-,66-,67-,68-,69+,70+,71+,72-,73-,74-,75-,76-,77-/m1/s1
DM5PFIJ CS C[C@@H]1C[C@H](CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(=O)C)O
DM5PFIJ IK RUPXJRIDSUCQAN-PQNNUJSWSA-N
DM5PFIJ IU N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide
DM5PFIJ CA CAS 1639325-43-1
DM5PFIJ DE Acute intermittent hepatic porphyria
DM83MOK ID DM83MOK
DM83MOK DN Glassia
DM83MOK HS Approved
DM83MOK SN Glassia (TN)
DM83MOK CP Baxter
DM83MOK DE Emphysema
DMAPV1B ID DMAPV1B
DMAPV1B DN Glatiramer acetate
DMAPV1B HS Approved
DMAPV1B SN Glatiramer acetate; Copaxone; 147245-92-9; Copolymer 1; Copolymer-1; COP-1; Protiramer; Glatopa; L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt); L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1); (2S)-2,6-diaminohexanoic acid; TV 5010; UNII-5M691HL4BO; Glatirameracetat; Glatiramer acetate [USAN:BAN]; AC1MIXQC; 5M691HL4BO
DMAPV1B CP Teva Pharmaceuticals
DMAPV1B TC Immunosuppressive Agents
DMAPV1B DT Small molecular drug
DMAPV1B SQ Example Glatiramer peptide: EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK
DMAPV1B PC 3081884
DMAPV1B MW 623.7
DMAPV1B FM C25H45N5O13
DMAPV1B IC InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)/t8-;5-;3-;2-;/m0000./s1
DMAPV1B CS C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N
DMAPV1B IK FHEAIOHRHQGZPC-KIWGSFCNSA-N
DMAPV1B IU acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid
DMAPV1B CA CAS 147245-92-9
DMAPV1B DE Multiple sclerosis
DM31YVO ID DM31YVO
DM31YVO DN Glecaprevir
DM31YVO HS Approved
DM31YVO SN Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; glecaprevirum; 1365970-03-1; A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CHEMBL3545363; CS-8098; D10814; DB13879; EX-A1940; HY-17634; UNII-K6BUU8J72P
DM31YVO PC 66828839
DM31YVO MW 838.9
DM31YVO FM C38H46F4N6O9S
DM31YVO IC MLSQGNCUYAMAHD-ITNVBOSISA-N
DM31YVO CS CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DM31YVO IK 1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
DM31YVO IU (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
DM31YVO CA CAS 1365970-03-1
DM31YVO DE Viral hepatitis
DMF6Z5T ID DMF6Z5T
DMF6Z5T DN Glecaprevir; pibrentasvir
DMF6Z5T HS Approved
DMF6Z5T SN pibrentasvir; Maviret; Mavyret; Glecaprevir / pibrentasvir; Glecaprevir and pibrentasvir; ABT-493/ABT-530; Glecaprevir mixture with pibrentasvir; ABT-493 / ABT-530; S900007520
DMF6Z5T CP AbbVie
DMF6Z5T DT Combination drug
DMF6Z5T PC 66828839; 58031952
DMF6Z5T DE Hepatitis C virus infection
DM8JXPZ ID DM8JXPZ
DM8JXPZ DN Glibenclamide
DM8JXPZ HS Approved
DM8JXPZ SN Abbenclamide; Adiab; Azuglucon; Bastiverit; Benclamin; Betanase; Calabren; Cytagon; Daonil; Debtan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglykon; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamida; Glibenclamidum; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glycolande; Glycomin; Glynase; Hexaglucon; Humedia; Lederglib; Libanil; Lisaglucon; Maninil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Normoglucon; Orabetic; Pira; Praeciglucon; PresTab; Prodiabet; Renabetic; Sugril; Suraben; Tiabet; Yuglucon; Euglucon N; Glibenclamid AL; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M; Glyburide [USAN]; Micronized glyburide; Betanese 5; Euglucon 5; G 0639; GBN 5; HB 419; HB 420; HB419; HB420; Norglicem 5; U 26452; UR 606; Apo-Glibenclamide; Daonil (TN); Dia-basan; Diabeta (TN); Euglucon (TN); Gen-Glybe; Gliben-Puren N; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [INN-Spanish]; Glibenclamidum [INN-Latin]; Gluco-Tablimen; Glyburide (USP); Glyburide (micronized); Glynase (TN); HB-419; HB-420; Hemi-Daonil; Med-Glionil; Micronase (TN); Novo-Glyburide; Semi-Euglucon; Semi-daonil; U-26452; Glibenclamide (JP15/INN); Semi-Daonil (TN); Semi-Gliben-Puren N; N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N'-cyclohexylurea; N-p-[2-(5-Chloro-2-methoxybenzamido)-ethyl]benzene-sulfonyl-N-cyclohexylurea; N-(4-(2-(5-Chloro-2-methoxybenzamido)ethyl)phenylsulfonyl)-N'-cyclohexylurea; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea; 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea; 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide; 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
DM8JXPZ CP Nigerian-German Chemicals
DM8JXPZ TC Hypoglycemic Agents
DM8JXPZ DT Small molecular drug
DM8JXPZ PC 3488
DM8JXPZ MW 494
DM8JXPZ FM C23H28ClN3O5S
DM8JXPZ IC InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
DM8JXPZ CS COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
DM8JXPZ IK ZNNLBTZKUZBEKO-UHFFFAOYSA-N
DM8JXPZ IU 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
DM8JXPZ CA CAS 10238-21-8
DM8JXPZ CB CHEBI:5441
DM8JXPZ DE Diabetic complication; Stroke
DMN6QO5 ID DMN6QO5
DMN6QO5 DN Gliclazide
DMN6QO5 HS Approved
DMN6QO5 SN Diaikron; Diamicron; Gliclazida; Gliclazidum; Gliklazid; Glimicron; Glyclazide; Nordialex; S 1702; S 852; SE 1702; Diamicron (TN); Dianorm (TN); Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; Glimicron (TN); S-1702; S-852; Gliclazide (JAN/INN); Glubitor-OD (TN); Gliclazide [BAN:INN:DCF:JAN]; N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
DMN6QO5 TC Hypoglycemic Agents
DMN6QO5 DT Small molecular drug
DMN6QO5 PC 3475
DMN6QO5 MW 323.4
DMN6QO5 FM C15H21N3O3S
DMN6QO5 IC InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
DMN6QO5 CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
DMN6QO5 IK BOVGTQGAOIONJV-UHFFFAOYSA-N
DMN6QO5 IU 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea
DMN6QO5 CA CAS 21187-98-4
DMN6QO5 CB CHEBI:31654
DMN6QO5 DE Diabetic complication
DM5FSJA ID DM5FSJA
DM5FSJA DN Glimepiride
DM5FSJA HS Approved
DM5FSJA SN Amarel; Amaryl; Endial; Glimepirid; Glimepirida; Glimepiridum; Glimepride; Glimer; Glymepirid; Roname; Solosa; Glimepirida [Spanish]; Glimepiridum [Latin]; Sandoz glimepiride; HOE 490; Amaryl (TN); Hoe-490; Novo-glimepiride; PMS-glimepiride; Ratio-glimepiride; Amaryl, Glista OD, Glimepiride; Glimepiride [USAN:BAN:INN]; Glimepiride (JAN/USP/INN); 1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea; 1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea; 3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide; 3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro; 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide; 64598P
DM5FSJA CP Sanofi-Aventis
DM5FSJA TC Hypoglycemic Agents
DM5FSJA DT Small molecular drug
DM5FSJA PC 3476
DM5FSJA MW 490.6
DM5FSJA FM C24H34N4O5S
DM5FSJA IC InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)
DM5FSJA CS CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
DM5FSJA IK WIGIZIANZCJQQY-UHFFFAOYSA-N
DM5FSJA IU 4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
DM5FSJA CA CAS 261361-60-8
DM5FSJA CB CHEBI:5383
DM5FSJA DE Diabetic complication
DMZA5PQ ID DMZA5PQ
DMZA5PQ DN Glipizide
DMZA5PQ HS Approved
DMZA5PQ SN Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea
DMZA5PQ CP Pfizer Pharmaceuticals
DMZA5PQ TC Hypoglycemic Agents
DMZA5PQ DT Small molecular drug
DMZA5PQ PC 3478
DMZA5PQ MW 445.5
DMZA5PQ FM C21H27N5O4S
DMZA5PQ IC InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
DMZA5PQ CS CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
DMZA5PQ IK ZJJXGWJIGJFDTL-UHFFFAOYSA-N
DMZA5PQ IU N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide
DMZA5PQ CA CAS 29094-61-9
DMZA5PQ CB CHEBI:5384
DMZA5PQ DE Diabetic complication
DMB0EUX ID DMB0EUX
DMB0EUX DN Gliquidone
DMB0EUX HS Approved
DMB0EUX SN Beglynor; Beglynora; Glikvidon; Gliquidona; Gliquidonum; Glurenorm; Glycvidon; ARDF 26; ARDF 26 SE; AR-DF 26; Gliquidona [INN-Spanish]; Gliquidone (INN); Gliquidone [BAN:INN]; Gliquidonum [INN-Latin]; Glurenorm (TN); N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide; 1-Cyclohexyl-3-((p-(2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinolyl)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-(p-beta-(4,4-dimethyl-2-methoxy-1,3-(2H,4H)-isoquinolinedione-2-yl)phenethyl)sulfonylurea; 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
DMB0EUX CP Boehriger Ingelheim
DMB0EUX TC Hypoglycemic Agents
DMB0EUX DT Small molecular drug
DMB0EUX PC 91610
DMB0EUX MW 527.6
DMB0EUX FM C27H33N3O6S
DMB0EUX IC InChI=1S/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
DMB0EUX CS CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C
DMB0EUX IK LLJFMFZYVVLQKT-UHFFFAOYSA-N
DMB0EUX IU 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxoisoquinolin-2-yl)ethyl]phenyl]sulfonylurea
DMB0EUX CA CAS 33342-05-1
DMB0EUX CB CHEBI:93416
DMB0EUX DE Diabetic complication
DMJPR2B ID DMJPR2B
DMJPR2B DN Glisoxepide
DMJPR2B HS Approved
DMJPR2B SN Glisepin; Glisoxepid; Glisoxepida; Glisoxepidum; Glisoxepida [Spanish]; BS 4231; Bay B 4231; FBB 4231; RP22410; Glisoxepida [INN-Spanish]; Glisoxepide (INN); Glisoxepidum [INN-Latin]; Pro-Diaban; Glisoxepide [INN:BAN:DCF]; N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide; N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide; 1-(Hexahydro-1H-azepin-1-yl)-3-((p-(2-(5-methyl-3-isoxazolecarboxamido)ethyl)phenyl)sulfonyl)urea
DMJPR2B TC Hypoglycemic Agents
DMJPR2B DT Small molecular drug
DMJPR2B PC 32778
DMJPR2B MW 449.5
DMJPR2B FM C20H27N5O5S
DMJPR2B IC InChI=1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
DMJPR2B CS CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3
DMJPR2B IK ZKUDBRCEOBOWLF-UHFFFAOYSA-N
DMJPR2B IU N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
DMJPR2B CA CAS 25046-79-1
DMJPR2B CB CHEBI:135731
DMJPR2B DE Non-insulin dependent diabetes
DMFLUTR ID DMFLUTR
DMFLUTR DN Glucagon recombinant
DMFLUTR HS Approved
DMFLUTR SN Glucagon recombinant; GTPL1136; CHEMBL266481
DMFLUTR TC Antihypoglycemic Agents
DMFLUTR DT Small molecular drug
DMFLUTR SQ Glucagon for Injection Sequence : HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
DMFLUTR PC 44278361
DMFLUTR MW 3482.7
DMFLUTR FM C153H225N43O49S
DMFLUTR IC InChI=1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1
DMFLUTR CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)N)O
DMFLUTR IK MASNOZXLGMXCHN-ZLPAWPGGSA-N
DMFLUTR IU (3S)-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMFLUTR CB CHEBI:5391
DMFLUTR DE Hypoglycemia
DM6EL5Q ID DM6EL5Q
DM6EL5Q DN Glucarpidase
DM6EL5Q HS Approved
DM6EL5Q SN Voraxaze (TN)
DM6EL5Q CP BTG International
DM6EL5Q DT Small molecular drug
DM6EL5Q SQ Glucarpidase: ALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNIDDKAKNLRFNWTIAKAGNVSNIIPASATLNADVRYARNEDFDAAMKTLEERAQQKKLPEADVKVIVTRGRPAFNAGEGGKKLVDKAVAYYKEAGGTLGVEERTGGGTDAAYAALSGKPVIESLGLPGFGYHSDKAEYVDISAIPRRLYMAARLIMDLGAGK
DM6EL5Q PC 21195079
DM6EL5Q MW 261.5
DM6EL5Q FM Zn4+8
DM6EL5Q IC InChI=1S/4Zn/q4*+2
DM6EL5Q CS [Zn+2].[Zn+2].[Zn+2].[Zn+2]
DM6EL5Q IK LZQXMCNBQHANEY-UHFFFAOYSA-N
DM6EL5Q IU zinc(2+)
DM6EL5Q DE Delayed methotrexate clearance
DM4ZLFD ID DM4ZLFD
DM4ZLFD DN Glucosamine
DM4ZLFD HS Approved
DM4ZLFD SN Chitosamine; GCS; Glucosamina; Glucosaminum; D-glucosamine; Glucosamina [INN-Spanish]; Glucosamine [USAN:INN]; Glucosaminum [INN-Latin]; Viartril-S; Beta-D-Glucosamine; Glucosamine (USAN/INN); Partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; 2-Amino-2-deoxy-D-glucose; 2-Amino-2-deoxy-beta-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose; 2-amino-2-deoxyglucose
DM4ZLFD TC Antiinflammatory Agents
DM4ZLFD DT Small molecular drug
DM4ZLFD PC 439213
DM4ZLFD MW 179.17
DM4ZLFD FM C6H13NO5
DM4ZLFD IC InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6?/m1/s1
DM4ZLFD CS C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)N)O)O)O
DM4ZLFD IK MSWZFWKMSRAUBD-IVMDWMLBSA-N
DM4ZLFD IU (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
DM4ZLFD CA CAS 3416-24-8
DM4ZLFD CB CHEBI:47977
DM4ZLFD DE Osteoarthritis
DMAHMT9 ID DMAHMT9
DMAHMT9 DN Glutathione
DMAHMT9 HS Approved
DMAHMT9 SN glutathione; 70-18-8; Glutathion; Isethion; Tathion; Glutathione-SH; Glutinal; reduced glutathione; Neuthion; Deltathione; Copren; L-Glutathione reduced; Glutide; Tathione; Triptide; Ledac; Glutatione; GSH; Glutatiol; Panaron; gamma-L-Glutamyl-L-cysteinylglycine; Glutathione SH; L-Glutatione; Glutathione (reduced); Agifutol S; L-gamma-glutamyl-L-cysteinylglycine; gamma-L-glutamyl-L-cysteinyl-glycine; 5-L-Glutamyl-L-cysteinylglycine; Glutathione [JAN]; glutathione red; gamma-L-Glutamylcysteinylglycine; red. glutathione
DMAHMT9 DT Small molecular drug
DMAHMT9 PC 124886
DMAHMT9 MW 307.33
DMAHMT9 FM C10H17N3O6S
DMAHMT9 IC InChI=1S/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1
DMAHMT9 CS C(CC(=O)N[C@@H](CS)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
DMAHMT9 IK RWSXRVCMGQZWBV-WDSKDSINSA-N
DMAHMT9 IU (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
DMAHMT9 CA CAS 70-18-8
DMAHMT9 CB CHEBI:16856
DMAHMT9 DE Human immunodeficiency virus infection
DMGE0CW ID DMGE0CW
DMGE0CW DN Glutethimide
DMGE0CW HS Approved
DMGE0CW SN Alfimid; Doriden; Dorimide; Elrodorm; Gimid; Glimid; Glutathimid; Glutethimid; Glutethimidum; Glutetimid; Glutetimida; Glutetimide; Glutetimidu; Gluthetimide; Noxiron; Noxyron; Ondasil; Rigenox; Sarodormin; Glutetimide [DCIT]; Glutetimidu [Polish]; CC 11511; LT00114358; Doriden (TN); Doriden-sed; Glutethimide [INN:BAN]; Glutethimidum [INN-Latin]; Glutetimida [INN-Spanish]; Glutethimide (JAN/INN); Phenyl-aethyl-glutarsaeureimid; Phenyl-aethyl-glutarsaeureimid [German]; Alpha-Ethyl-alpha-phenylglutarimide; Alpha-Phenyl-alpha-ethylglutaric acid imide; Alpha-Phenyl-alpha-ethylglutarimide; 2-Ethyl-2-phenylglutarimide; 2-Phenyl-2-ethylglutaric acid imide; 3-Ethyl-3-phenyl-2,6-diketopiperidine; 3-Ethyl-3-phenyl-2,6-dioxopiperidine; 3-Ethyl-3-phenyl-2,6-piperidinedione; 3-Phenyl-3-ethyl-2,6-diketopiperidine; 3-Phenyl-3-ethyl-2,6-dioxopiperidine; 3-ethyl-3-phenylpiperidine-2,6-dione
DMGE0CW TC Hypnotics and Sedatives
DMGE0CW DT Small molecular drug
DMGE0CW PC 3487
DMGE0CW MW 217.26
DMGE0CW FM C13H15NO2
DMGE0CW IC InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)
DMGE0CW CS CCC1(CCC(=O)NC1=O)C2=CC=CC=C2
DMGE0CW IK JMBQKKAJIKAWKF-UHFFFAOYSA-N
DMGE0CW IU 3-ethyl-3-phenylpiperidine-2,6-dione
DMGE0CW CA CAS 77-21-4
DMGE0CW CB CHEBI:5439
DMGE0CW DE Insomnia
DMDGRQO ID DMDGRQO
DMDGRQO DN Glycerol phenylbutyrate
DMDGRQO HS Approved
DMDGRQO SN GT4P; HPN-100; Glyceryl tri-(4-phenylbutyrate)
DMDGRQO CP Ucyclyd Pharma Inc
DMDGRQO DT Small molecular drug
DMDGRQO PC 10482134
DMDGRQO MW 530.6
DMDGRQO FM C33H38O6
DMDGRQO IC InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2
DMDGRQO CS C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3
DMDGRQO IK ZSDBFLMJVAGKOU-UHFFFAOYSA-N
DMDGRQO IU 2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate
DMDGRQO CA CAS 611168-24-2
DMDGRQO CB CHEBI:134745
DMDGRQO DE Hepatic encephalopathy
DMIOZ29 ID DMIOZ29
DMIOZ29 DN Glycine
DMIOZ29 HS Approved
DMIOZ29 SN Aciport; Aminoazijnzuur; Aminoessigsaeure; Amitone; Corilin; Glicina; Glicoamin; Gly; Glycin; Glycinum; Glycocoll; Glycolixir; Glycosthene; Glykokoll; Glyzin; Hgly; Leimzucker; Padil; Polyglycine; Acide aminoacetique; Acido aminoacetico; Acidum aminoaceticum; Aminoacetic acid; Aminoethanoic acid; An alpha amino acid ester; Glycine [INN]; Hampshire glycine; Polyglycine II; Sucre de gelatine; Acide aminoacetique [INN-French]; Acido aminoacetico [INN-Spanish]; Acidum aminoaceticum [INN-Latin]; GLY (IUPAC abbrev); GLYCINE, ACS; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Gyn-hydralin; L-Glycine; S04-0135; AB-131/40217813; AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER; GLYCINE 1.5% IN PLASTIC CONTAINER; Glycine (JP15/USP); Glycine iron sulphate (1:1); Glycine, homopolymer (VAN); Glycine, labeled with carbon-14; Glycine, non-medical; Glycine-UL-14C hydrochloride; H-Gly-OH; H2N-CH2-COOH; L-alpha-amino acids; (1-13c)glycinato; (15N)Glycine; 2,2-dialkylglycines; 2-Aminoacetic acid
DMIOZ29 TC Dietary supplement
DMIOZ29 DT Small molecular drug
DMIOZ29 PC 750
DMIOZ29 MW 75.07
DMIOZ29 FM C2H5NO2
DMIOZ29 IC InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)
DMIOZ29 CS C(C(=O)O)N
DMIOZ29 IK DHMQDGOQFOQNFH-UHFFFAOYSA-N
DMIOZ29 IU 2-aminoacetic acid
DMIOZ29 CA CAS 56-40-6
DMIOZ29 CB CHEBI:15428
DMIOZ29 DE Malnutrition
DM1WL9O ID DM1WL9O
DM1WL9O DN Glycodiazine
DM1WL9O HS Approved
DM1WL9O SN GLYMIDINE; Glidiazine; Glycodiazin; Glymidinum; Glycodiazin [German]; Gondafon (TN); N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulfonamide; N-(5-(2-Methoxyethoxy)-2-pyrimidinyl)benzenesulphonamide; N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide; 2-Benzolsulfonamido-5-.beta.-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine; 2-Benzolsulfonamido-5-beta-methoxy-aethoxy-pyrimidine [German]; 5-beta-(Methoxyethoxy)-2-(phenylsulfonylamido)pyrimidine
DM1WL9O TC Hypoglycemic Agents
DM1WL9O DT Small molecular drug
DM1WL9O PC 9565
DM1WL9O MW 309.34
DM1WL9O FM C13H15N3O4S
DM1WL9O IC InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)
DM1WL9O CS COCCOC1=CN=C(N=C1)NS(=O)(=O)C2=CC=CC=C2
DM1WL9O IK QFWPJPIVLCBXFJ-UHFFFAOYSA-N
DM1WL9O IU N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide
DM1WL9O CA CAS 339-44-6
DM1WL9O CB CHEBI:146188
DM1WL9O DE Diabetic complication
DM2M3ZA ID DM2M3ZA
DM2M3ZA DN Glycopyrrolate
DM2M3ZA HS Approved
DM2M3ZA SN GLYCOPYRROLATE; 596-51-0; Glycopyrrolate bromide; Robinul; Gastrodyn; Tarodyl; Nodapton; Tarodyn; Asecryl; Copyrrolate; Cuvposa; Glycopyrronii bromidum; AHR-504; ROBINUL FORTE; Robinal; Robanul; Bromuro de glicopirronio; Bromure de glycopyrronium; NVA-237; AHR 504; Glycopyrronii bromidum [INN-Latin]; EINECS 209-887-0; Bromure de glycopyrronium [INN-French]; Bromuro de glicopirronio [INN-Spanish]; 3-Hydroxy-1,1-dimethylpyrrolidinium bromide
DM2M3ZA CP Novartis
DM2M3ZA TC Anticholinergic Agents
DM2M3ZA DT Small molecular drug
DM2M3ZA PC 11693
DM2M3ZA MW 398.3
DM2M3ZA FM C19H28BrNO3
DM2M3ZA IC InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1
DM2M3ZA CS C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DM2M3ZA IK VPNYRYCIDCJBOM-UHFFFAOYSA-M
DM2M3ZA IU (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DM2M3ZA CA CAS 596-51-0
DM2M3ZA CB CHEBI:90972
DM2M3ZA DE Anaesthesia; Chronic obstructive pulmonary disease
DMGVJLB ID DMGVJLB
DMGVJLB DN GMA-161
DMGVJLB HS Approved (orphan drug)
DMGVJLB CP MacroGenics & Genzyme
DMGVJLB DE Idiopathic thrombocytopenic purpura
DMHZV7X ID DMHZV7X
DMHZV7X DN Golimumab
DMHZV7X HS Approved
DMHZV7X SN Simponi (TN); Golimumab (USAN/INN)
DMHZV7X CP Takeda
DMHZV7X DT Antibody
DMHZV7X DE Rheumatoid arthritis; Inflammatory bowel disease
DMAQ469 ID DMAQ469
DMAQ469 DN Gonadorelin
DMAQ469 HS Approved
DMAQ469 SN Dirigestran; Factrel; Fertagyl; Gonadorelina; Gonadorelinum; Hypocrine; Kryptocur; LFRH; LHFSHRH; Luforan; Luliberin; Lutal; Lutamin; Lutrefact; Relefact; Relisorm; Dirigestran Spofa; Gonadoliberin I; Gonadotropin releasing hormone; LHFSH Releasing Hormone; LUTEINIZING HORMONE; Lutrepulse KIT; MammalianGnRH; Relisorm l; Synthetic LRF; Synthetic gonadoliberin; HOE 471; AY-24031; FSH-Releasing Hormone; Fertagyl (TN); GnRH-I; Gonadorelin (INN); Gonadorelin [INN:BAN]; Gonadorelina [INN-Spanish]; Gonadorelinum [INN-Latin]; Gonadotropin-releasing factor; Gonadotropin-releasing hormone; Gonadotropin-releasing hormone I; Human LH-RH; LH-FSH Releasing Hormone; LH-Releasing hormone; Luteinizing hormone-releasing hormone; Mammalian LH-RH; Mammalian gonadotropin-releasing hormone; Ovine LH-RH; Ovine gonadotropin-releasing hormone; Porchine LH-RH; Porcine LH-releasing factor; Synthetic Gn-RH; Synthetic LH-FSH releasing hormone; Synthetic LH-RF; Synthetic LH-RH; Synthetic LH-releasing factor; Synthetic LH-releasing hormone; Synthetic gonadotropic hormone-releasing hormone; Synthetic gonadotropin-releasing hormone; LH-RH (swine); LH-Releasing factor (pig); LH-Releasing hormone (porcine); Luteinizing hormone-releasing factor (human); Luteinizing hormone-releasing factor (pig); Luteinizing hormone-releasing factor (rat); Luteinizing hormone-releasing factor (sheep); Luteinizing hormone-releasing factor (swine); Luteinizing hormone-releasing hormone (swin); Synthetic LH-FSH-RH; Synthetic decapeptide FSH/LH-RH; Follicle-stimulating hormone-releasing factor (pig); Gonadotropin, luteinizing hormone-releasing hormone, synthetic; Synthetic LH-RH/FSH-RH; Synthetic LH-releasing hormone/FSH-releasing hormone; PyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
DMAQ469 CP Hikma (Maple) Ltd
DMAQ469 TC Fertility Agents
DMAQ469 DT Small molecular drug
DMAQ469 PC 638793
DMAQ469 MW 1182.3
DMAQ469 FM C55H75N17O13
DMAQ469 IC InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
DMAQ469 CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DMAQ469 IK XLXSAKCOAKORKW-AQJXLSMYSA-N
DMAQ469 IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAQ469 CA CAS 9034-40-6
DMAQ469 CB CHEBI:5520
DMAQ469 DE Hypothalamic hypogonadism
DMAT8CG ID DMAT8CG
DMAT8CG DN Goserelin
DMAT8CG HS Approved
DMAT8CG SN AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN)
DMAT8CG CP Zeneca Pharmaceuticals
DMAT8CG TC Anticancer Agents
DMAT8CG DT Small molecular drug
DMAT8CG PC 5311128
DMAT8CG MW 1269.4
DMAT8CG FM C59H84N18O14
DMAT8CG IC InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
DMAT8CG CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DMAT8CG IK BLCLNMBMMGCOAS-URPVMXJPSA-N
DMAT8CG IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAT8CG CA CAS 65807-02-5
DMAT8CG CB CHEBI:5523
DMAT8CG DE Breast cancer
DMPT74U ID DMPT74U
DMPT74U DN Gramicidin D
DMPT74U HS Approved
DMPT74U SN Gramicidins; Gramoderm; Gramacidine S; Gramicidin C; Gramicidin Dubos; Gramicidin J; Gramicidin K; Gramicidin P; Gramicidin S; Gramicidin S [INN]; Gramicidina D; Gramicidina S; Gramicidinum S; Neosporin Ophthalmic Solution; Gramicin S 1; Gramacidine S [INN-French]; Gramicidin A(1); Gramicidin [INN:BAN]; Gramicidina S [INN-Spanish]; Gramicidina [INN-Spanish]; Gramicidine [INN-French]; Gramicidinum S [INN-Latin]; Gramicidinum [INN-Latin]; Gramicin S-A; Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl); 1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine)
DMPT74U TC Antibiotics
DMPT74U DT Small molecular drug
DMPT74U PC 45267103
DMPT74U MW 1811.2
DMPT74U FM C96H135N19O16
DMPT74U IC InChI=1S/C96H135N19O16/c1-50(2)36-71(105-79(118)48-102-93(128)80(54(9)10)103-49-117)86(121)104-58(17)84(119)113-82(56(13)14)95(130)115-83(57(15)16)96(131)114-81(55(11)12)94(129)112-78(43-62-47-101-70-33-25-21-29-66(62)70)92(127)108-74(39-53(7)8)89(124)111-77(42-61-46-100-69-32-24-20-28-65(61)69)91(126)107-73(38-52(5)6)88(123)110-76(41-60-45-99-68-31-23-19-27-64(60)68)90(125)106-72(37-51(3)4)87(122)109-75(85(120)97-34-35-116)40-59-44-98-67-30-22-18-26-63(59)67/h18-33,44-47,49-58,71-78,80-83,98-101,116H,34-43,48H2,1-17H3,(H,97,120)(H,102,128)(H,103,117)(H,104,121)(H,105,118)(H,106,125)(H,107,126)(H,108,127)(H,109,122)(H,110,123)(H,111,124)(H,112,129)(H,113,119)(H,114,131)(H,115,130)/t58-,71+,72+,73+,74+,75-,76-,77-,78-,80-,81+,82+,83-/m0/s1
DMPT74U CS C[C@@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)NCCO)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@H](C(C)C)NC=O
DMPT74U IK NDAYQJDHGXTBJL-MWWSRJDJSA-N
DMPT74U IU (2R)-2-[[2-[[(2S)-2-formamido-3-methylbutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-(2-hydroxyethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]-4-methylpentanamide
DMPT74U CA CAS 1405-97-6
DMPT74U DE Bacterial infection
DMIUW25 ID DMIUW25
DMIUW25 DN Granisetron
DMIUW25 HS Approved
DMIUW25 SN BRL-43694; Kytril (TN); Granisetron (USAN/INN); 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide; 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
DMIUW25 CP Roche Pharmaceuticals
DMIUW25 TC Antiemetics
DMIUW25 DT Small molecular drug
DMIUW25 PC 5284566
DMIUW25 MW 312.4
DMIUW25 FM C18H24N4O
DMIUW25 IC InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12?,13-,14+
DMIUW25 CS CN1[C@@H]2CCC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMIUW25 IK MFWNKCLOYSRHCJ-AGUYFDCRSA-N
DMIUW25 IU 1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
DMIUW25 CA CAS 109889-09-0
DMIUW25 CB CHEBI:5537
DMIUW25 DE Nausea and vomiting
DMGLX0T ID DMGLX0T
DMGLX0T DN Grepafloxacin
DMGLX0T HS Approved
DMGLX0T SN Raxar; Grepafloxacin [INN]; Grepafloxacin (unspecified); Raxar (TN); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMGLX0T CP GlaxoSmithKline
DMGLX0T TC Antibiotics
DMGLX0T DT Small molecular drug
DMGLX0T PC 72474
DMGLX0T MW 359.4
DMGLX0T FM C19H22FN3O3
DMGLX0T IC InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)
DMGLX0T CS CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F
DMGLX0T IK AIJTTZAVMXIJGM-UHFFFAOYSA-N
DMGLX0T IU 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMGLX0T CA CAS 119914-60-2
DMGLX0T CB CHEBI:5543
DMGLX0T DE Chronic bronchitis; Bacterial infection
DMK54YG ID DMK54YG
DMK54YG DN Griseofulvin
DMK54YG HS Approved
DMK54YG SN Amudane; Delmofulvina; Fulcin; Fulcine; Fulvicin; FulvicinUF; Fulvina; Fulvinil; Fulvistatin; Fungivin; Greosin;Gresfeed; Gricin; Grifulin; Grifulvin; GrisPEG; Grisactin; Griscofulvin; Grisefuline; Griseo; Griseofulvina; Griseofulvine; Griseofulvinum; Griseomix; Griseostatin; Grisetin; Grisofulvin; Grisovin; Grizeofulvin; Grysio; Guservin; Lamoryl; Likuden; Likunden; Murfulvin; Poncyl; Spirofulvin; Sporostatin; Xuanjing; Curling fact or; Curling factor; Fulvican grisactin; Fulvicin U F; Grifulvin V; Gris PEG; Grisactin Ultra; Grise ostatin; Griseofulvin forte; Grisovin FP; Interacts with polymerized microtubules and associated proteins; Sporostatin xan; Biogrisin-FP; FULVICIN P/G 165; FULVICIN P/G 330;Fulvicin Bolus (Veterinary); Fulvicin P/G; Fulvicin U/F; Fulvidex (Veterinary); GRISEOFULVIN, MICROCRYSTALLINE; GRISEOFULVIN, ULTRAMICROCRYSTALLINE; Gris-PEG; Griseofulvin and Alpha-IFN; Griseofulvin-forte; Griseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]; Grisovin (TN); NP-002466; Neo-Fulcin; ULTRAGRIS-165; ULTRAGRIS-330; USAF SC-2; Fulvicin-P/G; Fulvicin-U-F; Fulvicin-U/F; Fulvicin-U/F (Veterinary); Griseofulvin [USAN:INN:BAN:JAN]; (+)-Griseofulvin; 7-Chloro-4,6,2'-trimethoxy-6'-methylgris-2'-en-3,4'-dione
DMK54YG TC Antifungal Agents
DMK54YG DT Small molecular drug
DMK54YG PC 441140
DMK54YG MW 352.8
DMK54YG FM C17H17ClO6
DMK54YG IC InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1
DMK54YG CS C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
DMK54YG IK DDUHZTYCFQRHIY-RBHXEPJQSA-N
DMK54YG IU (2S,5'R)-7-chloro-3',4,6-trimethoxy-5'-methylspiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
DMK54YG CA CAS 126-07-8
DMK54YG CB CHEBI:27779
DMK54YG DE Ringworm infection
DM1ECNJ ID DM1ECNJ
DM1ECNJ DN GS-7340
DM1ECNJ HS Approved
DM1ECNJ SN Tenofovir alafenamide; Vemlidy
DM1ECNJ CP Gilead Sciences
DM1ECNJ DT Small molecular drug
DM1ECNJ PC 9574768
DM1ECNJ MW 476.5
DM1ECNJ FM C21H29N6O5P
DM1ECNJ IC InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DM1ECNJ CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3
DM1ECNJ IK LDEKQSIMHVQZJK-CAQYMETFSA-N
DM1ECNJ IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DM1ECNJ CA CAS 379270-37-8
DM1ECNJ CB CHEBI:90926
DM1ECNJ DE Human immunodeficiency virus infection; Hepatitis B virus infection
DM8QB0T ID DM8QB0T
DM8QB0T DN GSK2592984A
DM8QB0T HS Approved
DM8QB0T SN GSK-2340269A; GSK-2340272A; Pandemrix (H1N1); H1N1 pandemic influenzavaccine (AS03 adjuvanted) 1, GlaxoSmithKline; H1N1 pandemic influenza vaccine 1 (AS03 adjuvanted), GSK; Influenza vaccines (intramuscular, influenza virus infection), GlaxoSmithKline
DM8QB0T CP GlaxoSmithKline plc
DM8QB0T DT Vaccine
DM8QB0T DE Influenza virus infection
DM5QWEL ID DM5QWEL
DM5QWEL DN Guanabenz
DM5QWEL HS Approved
DM5QWEL SN GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
DM5QWEL CP Eon Labs Manufacturing
DM5QWEL TC Sympatholytics
DM5QWEL DT Small molecular drug
DM5QWEL PC 5702063
DM5QWEL MW 231.08
DM5QWEL FM C8H8Cl2N4
DM5QWEL IC InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
DM5QWEL CS C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
DM5QWEL IK WDZVGELJXXEGPV-YIXHJXPBSA-N
DM5QWEL IU 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
DM5QWEL CA CAS 60329-03-5
DM5QWEL CB CHEBI:5553
DM5QWEL DE High blood pressure
DM6S157 ID DM6S157
DM6S157 DN Guanadrel Sulfate
DM6S157 HS Approved
DM6S157 SN Hylorel; Hyloride; Guanadrel sulfate [USAN]; CL 1388R; U 28288D; CL-1388R; Guanadrel sulfate (USP); Hylorel (TN); U 28,288D; U-28288D; Guanadrel sulfate (2:1); Guanidine (1,4-dioxaspiro(4.5)dec-2-ylmethyl)-, sulfate (2:1); (1,4-Dioxaspiro(4.5)dec-2-ylmethyl)guanidine sulfate (2:1); 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine
DM6S157 TC Antihypertensive Agents
DM6S157 DT Small molecular drug
DM6S157 PC 68552
DM6S157 MW 524.6
DM6S157 FM C20H40N6O8S
DM6S157 IC InChI=1S/2C10H19N3O2.H2O4S/c2*11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10;1-5(2,3)4/h2*8H,1-7H2,(H4,11,12,13);(H2,1,2,3,4)
DM6S157 CS C1CCC2(CC1)OCC(O2)CN=C(N)N.C1CCC2(CC1)OCC(O2)CN=C(N)N.OS(=O)(=O)O
DM6S157 IK RTEVGQJRTFFMLL-UHFFFAOYSA-N
DM6S157 IU 2-(1,4-dioxaspiro[4.5]decan-3-ylmethyl)guanidine;sulfuric acid
DM6S157 CA CAS 22195-34-2
DM6S157 CB CHEBI:5556
DM6S157 DE Hypertension
DM9NSWT ID DM9NSWT
DM9NSWT DN Guanethidine
DM9NSWT HS Approved
DM9NSWT SN Abapresin; Dopam; Dopom; Eutensol; Guanethidinum; Guanetidina; Ismelin; Isobarin; Octadin; Octadine; Octatensin; Octatensine; Oktadin; Oktatensin; Oktatenzin; Sanotensin; Guanethidine Sulphae; Guanethidine sulfate; Ismelin sulfate; Apo-Guanethidine; Guanethidine (INN); Guanethidine [INN:BAN]; Guanethidinum [INN-Latin]; Guanetidina [INN-Spanish]; Apo-Guanethidine (TN); Beta-1-Azacyclooctylethylguanidine; Guanethidine Sulfate (1:1); Guanethidine Sulfate (2:1); Su 5864 sulfate (1:1); N-(2-Perhydroazocin-1-ylethyl)guanidine; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; (2-(Octahydro-1-azocinyl)ethyl)guanidine; 1-(2-azocan-1-ylethyl)guanidine; 1-[2-(azocan-1-yl)ethyl]guanidine; 2-(1'-Azacyclooctyl)ethylguanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; 2-[2-(azocan-1-yl)ethyl]guanidine
DM9NSWT CP Norvatis Phamaceuticals Corporation
DM9NSWT TC Antihypertensive Agents
DM9NSWT DT Small molecular drug
DM9NSWT PC 3518
DM9NSWT MW 198.31
DM9NSWT FM C10H22N4
DM9NSWT IC InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)
DM9NSWT CS C1CCCN(CCC1)CCN=C(N)N
DM9NSWT IK ACGDKVXYNVEAGU-UHFFFAOYSA-N
DM9NSWT IU 2-[2-(azocan-1-yl)ethyl]guanidine
DM9NSWT CA CAS 55-65-2
DM9NSWT CB CHEBI:5557
DM9NSWT DE Moderate and severe hypertension
DMB1CZ8 ID DMB1CZ8
DMB1CZ8 DN Guanfacine extended release
DMB1CZ8 HS Approved
DMB1CZ8 SN Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Impulsin; Palmitamide MEA; Hydroxyethylpalmitamide; N-palmitoylethanolamine; N-(2-Hydroxyethyl)palmitamide; Palmitic acid monoethanolamide; Palmitoyl-EA; Loramine P 256; Palmitoyl ethanolamide; Palmidrolum; palmitylethanolamide; HEXADECANAMIDE, N-(2-HYDROXYETHYL)-; Palmidrol [INN]; Palmidrolum [INN-Latin]; UNII-6R8T1UDM3V; Palmitinsaeure-beta-hydroxyethylamid; Monoethanolamine palmitic acid amide; NSC 23320; hexadecanoyl ethanolamide; Anandamide (16:0)
DMB1CZ8 CP Shire
DMB1CZ8 DT Small molecular drug
DMB1CZ8 PC 4671
DMB1CZ8 MW 299.5
DMB1CZ8 FM C18H37NO2
DMB1CZ8 IC InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
DMB1CZ8 CS CCCCCCCCCCCCCCCC(=O)NCCO
DMB1CZ8 IK HXYVTAGFYLMHSO-UHFFFAOYSA-N
DMB1CZ8 IU N-(2-hydroxyethyl)hexadecanamide
DMB1CZ8 CA CAS 544-31-0
DMB1CZ8 CB CHEBI:71464
DMB1CZ8 DE Attention deficit hyperactivity disorder
DM0P63W ID DM0P63W
DM0P63W DN Guanidine Hydrochloride
DM0P63W HS Approved
DM0P63W SN Guanidine hydrochloride; 1950/1/1; Guanidinium chloride; Guanidine, monohydrochloride; guanidine HCl; Aminoformamidine hydrochloride; Aminomethanamidine hydrochloride; GUANIDINE MONOHYDROCHLORIDE; Guanidine chloride; Iminourea hydrochloride; Carbamidine hydrochloride; Guanidinium hydrochloride; Guanidine (hydrochloride); UNII-3YQC9ZY4YB; Guanidium chloride; USAF EK-749; Guanidine, hydrochloride (1:1); EINECS 200-002-3; 3YQC9ZY4YB; AI3-19014; MFCD00013026; Guanidine Hydrochloride, ULTROL& Grade; Guanidinehydrochloride
DM0P63W CP Merck Sharp And Dohme Corp
DM0P63W TC Neurology Agents
DM0P63W DT Small molecular drug
DM0P63W PC 5742
DM0P63W MW 95.53
DM0P63W FM CH6ClN3
DM0P63W IC InChI=1S/CH5N3.ClH/c2-1(3)4;/h(H5,2,3,4);1H
DM0P63W CS C(=N)(N)N.Cl
DM0P63W IK PJJJBBJSCAKJQF-UHFFFAOYSA-N
DM0P63W IU guanidine;hydrochloride
DM0P63W CA CAS 50-01-1
DM0P63W CB CHEBI:32735
DM0P63W DE Muscle fatigue
DMP7LK1 ID DMP7LK1
DMP7LK1 DN Guggulsterone
DMP7LK1 HS Approved
DMP7LK1 SN Guggulsterone E; (E)-Guggulsterone; E-Guggulsterone; Guggulsterones E; trans-Guggulsterone; 39025-24-6; Pregna-4,17-diene-3,16-dione; UNII-9B259YE66O; (17E)-Pregna-4,17(20)-diene-3,16-dione; Z-Guggulsterone; CHEMBL402063; 95975-55-6; 9B259YE66O; (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; E-Guggulsteron; Pregna-4,17(20)-diene-3,16-dione; Guggulsterone, (E)-; Guglip; Z/E-Guggulsterone; Pregna-4,17(20)-diene-3,16-dione, (17E)-; Guggulsterone E; Guggulsterones Z; Cis-Guggulsterone; Trans-Guggulsterone; (17E)-pregna-4,17-diene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; (17Z)-pregna-4,17-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (Z)-Guggulsterone; 4,17(20)-cis-Pregnadiene-3,16-dione; E-GUGGULSTERONE
DMP7LK1 TC Antiinflammatory Agents
DMP7LK1 DT Small molecular drug
DMP7LK1 PC 6450278
DMP7LK1 MW 312.4
DMP7LK1 FM C21H28O2
DMP7LK1 IC InChI=1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1
DMP7LK1 CS C/C=C/1\\C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMP7LK1 IK WDXRGPWQVHZTQJ-OSJVMJFVSA-N
DMP7LK1 IU (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione
DMP7LK1 CA CAS 39025-23-5
DMP7LK1 CB CHEBI:135338
DMP7LK1 DE Osteoarthritis
DMV4KOA ID DMV4KOA
DMV4KOA DN GW642444
DMV4KOA HS Approved
DMV4KOA SN Fumagillinum; Fumagilline; Fumagilina; Fumidil; Fugillin; UNII-7OW73204U1; Amebacillin; Fugilin; CHEMBL32838; Fumagillin DCH; CHEBI:48635; Fumagillina [DCIT]; 7OW73204U1; Fumagillinum [INN-Latin]; Fumagilline [INN-French]; Fumagilina [INN-Spanish]; DSSTox_RID_79580; DSSTox_CID_20736; DSSTox_GSID_40736; Fumagillin [INN:BAN:DCF]; 2,4,6,8-Decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester
DMV4KOA CP GSK
DMV4KOA DT Small molecular drug
DMV4KOA PC 21880659
DMV4KOA MW 486.4
DMV4KOA FM C24H33Cl2NO5
DMV4KOA IC InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2
DMV4KOA CS C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl
DMV4KOA IK DAFYYTQWSAWIGS-UHFFFAOYSA-N
DMV4KOA IU 4-[2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMV4KOA DE Asthma
DML72VJ ID DML72VJ
DML72VJ DN GW685698X
DML72VJ HS Approved
DML72VJ SN Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
DML72VJ CP GSK
DML72VJ DT Small molecular drug
DML72VJ PC 9854489
DML72VJ MW 538.6
DML72VJ FM C27H29F3O6S
DML72VJ IC InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
DML72VJ CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
DML72VJ IK XTULMSXFIHGYFS-VLSRWLAYSA-N
DML72VJ IU [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
DML72VJ CA CAS 397864-44-7
DML72VJ CB CHEBI:74899
DML72VJ DE Asthma
DMFUAXT ID DMFUAXT
DMFUAXT DN H1N1 pandemic influenza A vaccine
DMFUAXT HS Approved
DMFUAXT SN Panflu; H1N1 pandemic influenza A vaccine, Sinovac; Panflu.1; Split viron vaccine (H1N1 influenza), Sinovac; Split viron vaccine + adjuvant (H1N1 influenza), Sinovac; Whole viron vaccine + adjuvant (H1N1 influenza), Sinovac
DMFUAXT CP Sinovac Biotech Ltd
DMFUAXT DT Vaccine
DMFUAXT DE Influenza virus infection
DMMHYLB ID DMMHYLB
DMMHYLB DN H5N1 influenza vaccine
DMMHYLB HS Approved
DMMHYLB SN IPSIV; Inactivated Polymer-Subunit H5N1 Influenza Vaccine; H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant); H5N1 influenza vaccine (protein subunit, Polyoxidonium adjuvant), Microgen
DMMHYLB CP Glaxosmithkline; novavax; vaxart
DMMHYLB DT Vaccine
DMMHYLB DE Human immunodeficiency virus infection
DM7JNTV ID DM7JNTV
DM7JNTV DN Halaven
DM7JNTV HS Approved
DM7JNTV SN Eribulin mesylate; Eribulin (mesylate); Eribulin mesilate; UNII-AV9U0660CW; Eribulin mesylate [USAN]; 441045-17-6; AV9U0660CW; CHEBI:70710; E 7389; E7389; Eribulin mesylate (USAN); B-1939; NSC-707389; Eribulin mesilate (JAN); CHEMBL1683544; QAMYWGZHLCQOOJ-WRNBYXCMSA-N; HY-13442A; AKOS030238218; CS-2803; D08914; 2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopent
DM7JNTV CP Eisai Woodcliff Lake, NJ
DM7JNTV PC 17755248
DM7JNTV MW 826
DM7JNTV FM C41H63NO14S
DM7JNTV IC InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1
DM7JNTV CS C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O
DM7JNTV IK QAMYWGZHLCQOOJ-WRNBYXCMSA-N
DM7JNTV IU (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one;methanesulfonic acid
DM7JNTV CA CAS 441045-17-6
DM7JNTV CB CHEBI:70710
DM7JNTV DE Bladder cancer; Breast cancer
DMPFWO6 ID DMPFWO6
DMPFWO6 DN Halazepam
DMPFWO6 HS Approved
DMPFWO6 SN Halazepamum; Pacinone; Paxipam; Sch 12041; Schering 12041; Alapryl (TN); Halazepamum [INN-Latin]; Pacinone (TN); Paxipam (TN); Sch-12041; Halazepam (USAN/INN); Halazepam [USAN:BAN:INN]; 7-Chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one; 7=Chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1H-1,4-benzodiazepin-2(3H)-on
DMPFWO6 TC Antianxiety Agents
DMPFWO6 DT Small molecular drug
DMPFWO6 PC 31640
DMPFWO6 MW 352.7
DMPFWO6 FM C17H12ClF3N2O
DMPFWO6 IC InChI=1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2
DMPFWO6 CS C1C(=O)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3)CC(F)(F)F
DMPFWO6 IK WYCLKVQLVUQKNZ-UHFFFAOYSA-N
DMPFWO6 IU 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-2-one
DMPFWO6 CA CAS 23092-17-3
DMPFWO6 CB CHEBI:5603
DMPFWO6 DE Anxiety disorder
DMGLAX1 ID DMGLAX1
DMGLAX1 DN Halcinonide
DMGLAX1 HS Approved
DMGLAX1 SN Halog; Halog-e
DMGLAX1 CP Ranbaxy Laboratories Inc
DMGLAX1 DT Small molecular drug
DMGLAX1 PC 443943
DMGLAX1 MW 455
DMGLAX1 FM C24H32ClFO5
DMGLAX1 IC InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
DMGLAX1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F
DMGLAX1 IK MUQNGPZZQDCDFT-JNQJZLCISA-N
DMGLAX1 IU (1S,2S,4R,8S,9S,11S,12R,13S)-8-(2-chloroacetyl)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMGLAX1 CA CAS 3093-35-4
DMGLAX1 CB CHEBI:31663
DMGLAX1 DE Skin disease
DM3GB6S ID DM3GB6S
DM3GB6S DN Halobetasol propionate
DM3GB6S HS Approved
DM3GB6S SN Halobetasol; Miracorten; Ultravate; Halobetasol propionate [USAN]; Ulobetasol cream; Ulobetasol propionate; BMY 30056; CGP 14 458; CGP 14458; BMY-30056; CGP-14458; Halobetasol propionate (USAN); Ultravate (TN); [(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate; 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; 6 alpha-fluoroclobetasol 17-propionate; 6-fluoroclobetasol 17-propionate
DM3GB6S TC Antiinflammatory Agents
DM3GB6S DT Small molecular drug
DM3GB6S PC 6918178
DM3GB6S MW 485
DM3GB6S FM C25H31ClF2O5
DM3GB6S IC InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
DM3GB6S CS CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl
DM3GB6S IK BDSYKGHYMJNPAB-LICBFIPMSA-N
DM3GB6S IU [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DM3GB6S CA CAS 66852-54-8
DM3GB6S CB CHEBI:135782
DM3GB6S DE Inflammation
DMOMK1V ID DMOMK1V
DMOMK1V DN Halofantrine
DMOMK1V HS Approved
DMOMK1V SN Halfan; Halofantrino; HALOFANTRINE HYDROCHLORIDE; Halofantrine HCl; Halofantrine Hydrochloride [USAN]; Halofantrine [USAN]; Halofantrino [Spanish]; WR 171669; Dl-WR 171669; Halfan (TN); Halofantrine hydrochloride (USAN); WR 171,699; WR-171669; WR-171699; SK&F-102866; WR-171,669; (+-)-Halofantrine hydrochloride; (1)-Halofantrine; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol; 1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenathrenemethanol; 1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride; 1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride; 1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride; 1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride; 9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1); 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride; 9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
DMOMK1V CP GlaxoSmithKline
DMOMK1V TC Antimalarials
DMOMK1V DT Small molecular drug
DMOMK1V PC 37393
DMOMK1V MW 500.4
DMOMK1V FM C26H30Cl2F3NO
DMOMK1V IC InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
DMOMK1V CS CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O
DMOMK1V IK FOHHNHSLJDZUGQ-UHFFFAOYSA-N
DMOMK1V IU 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol
DMOMK1V CA CAS 69756-53-2
DMOMK1V CB CHEBI:94392
DMOMK1V DE Malaria
DM96SE0 ID DM96SE0
DM96SE0 DN Haloperidol
DM96SE0 HS Approved
DM96SE0 SN Aldo; Aloperidin; Aloperidol; Aloperidolo; Aloperidon; Bioperidolo; Brotopon; Dozic; Dozix; Eukystol; Fortunan; Galoperidol; Haldol; Halidol; Halojust; Halol; Halopal; Haloperido; Haloperidolum; Halopidol; Halopoidol; Halosten; Keselan; Linton; Mixidol; Pekuces; Peluces; Peridol; Pernox; Serenace; Serenase; Serenelfi; Sernas; Sernel; Sigaperidol; Ulcolind; Uliolind; Vesalium; Aloperidolo [DCIT]; Aloperidolo [Italian]; Einalon S; Haldol La; Haldol Solutab; Lealgin compositum; Pms Haloperidol; H 1512; R 1625; Aloperidin (TN); Apo-Haloperidol; Bioperidolo (TN); Brotopon (TN); Dozic (TN); Duraperidol (TN); Einalon S (TN); Eukystol (TN); Haldol (TN); Haloperidolum [INN-Latin]; Halosten (TN); Keselan (TN); Linton (TN);Novo-Peridol; Peluces (TN); R-1625; Serenace (TN); Serenase (TN); Sigaperidol (TN); Haloperidol (JP15/USP); McN-JR-1625; Haloperidol (JP15/USP/INN); Haloperidol [USAN:INN:BAN:JAN]
DM96SE0 CP Janssen Pharmaceutica
DM96SE0 TC Antipsychotic Agents
DM96SE0 DT Small molecular drug
DM96SE0 PC 3559
DM96SE0 MW 375.9
DM96SE0 FM C21H23ClFNO2
DM96SE0 IC InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DM96SE0 CS C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
DM96SE0 IK LNEPOXFFQSENCJ-UHFFFAOYSA-N
DM96SE0 IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DM96SE0 CA CAS 52-86-8
DM96SE0 CB CHEBI:5613
DM96SE0 DE Schizophrenia
DMH4IVU ID DMH4IVU
DMH4IVU DN Haloprogin
DMH4IVU HS Approved
DMH4IVU SN Aloprogen; Haloprogina; Haloprogine; Haloproginum; Halotex; Mycanden; Mycilan; Polik; Component of Halotex; M 1028; Haloprogina [INN-Spanish]; Haloprogine [INN-French]; Haloproginum [INN-Latin]; Halotex (TN); Mycanden (TN); Mycilan (TN); Polik (TN); Haloprogin [USAN:INN:JAN]; M-1028 (Meiji); Haloprogin (JAN/USAN/INN); Ether, 3-iodo-2-propynyl 2,4,5-trichlorophenyl; Benzene,1,2,4-trichloro-5-[(3-iodo-2-propynyl)oxy]; (3-Iod-2-propinyl)-(2,4,5-trichlorphenyl)ether; 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene; 1,2,4-trichloro-5-[(3-iodo-2-propynyl) oxy]benzene; 2,4,5-Trichlorophenyl .gamma.-iodopropargil ether; 2,4,5-Trichlorophenyl .gamma.-iodopropargyl ether; 2,4,5-Trichlorophenyl gamma-iodopropargil ether; 2,4,5-Trichlorophenyl iodopropargyl ether; 2,4,5-Trichlorophenyl-gamma-iodopropargyl ether; 3-Iodo-2-propynyl 2,4,5-trichlorophenyl ether
DMH4IVU TC Antifungal Agents
DMH4IVU DT Small molecular drug
DMH4IVU PC 3561
DMH4IVU MW 361.4
DMH4IVU FM C9H4Cl3IO
DMH4IVU IC InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
DMH4IVU CS C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI
DMH4IVU IK CTETYYAZBPJBHE-UHFFFAOYSA-N
DMH4IVU IU 1,2,4-trichloro-5-(3-iodoprop-2-ynoxy)benzene
DMH4IVU CA CAS 777-11-7
DMH4IVU CB CHEBI:5614
DMH4IVU DE Dermatophytosis; Candidiasis
DM80OZ5 ID DM80OZ5
DM80OZ5 DN Halothane
DM80OZ5 HS Approved
DM80OZ5 SN Alotano; Anestan; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Chalothane; Fluktan; Fluorotane; Fluothane; Ftorotan; Ftuorotan; Halan; Halotan; Halotano; Halothan; Halothanum; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan; Alotano [DCIT]; Ftorotan [Russian]; CF3CHClBr; Freon 123B1; Fluothane (TN); Halotano [INN-Spanish]; Halothane [Anaesthetics, volatile]; Halothanum [INN-Latin]; Narcotann NE-spofa [Russian]; Narcotann ne-spofa; Halothane [INN:BAN:JAN]; Halothane (JP15/USP/INN); (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; 2-Brom-2-chlor-1,1,1-trifluorethan
DM80OZ5 TC Anesthetics
DM80OZ5 DT Small molecular drug
DM80OZ5 PC 3562
DM80OZ5 MW 197.38
DM80OZ5 FM C2HBrClF3
DM80OZ5 IC InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
DM80OZ5 CS C(C(F)(F)F)(Cl)Br
DM80OZ5 IK BCQZXOMGPXTTIC-UHFFFAOYSA-N
DM80OZ5 IU 2-bromo-2-chloro-1,1,1-trifluoroethane
DM80OZ5 CA CAS 151-67-7
DM80OZ5 CB CHEBI:5615
DM80OZ5 DE Anaesthesia
DMN0S1G ID DMN0S1G
DMN0S1G DN HEGF
DMN0S1G HS Approved
DMN0S1G CP Bharat Biotech
DMN0S1G DE Diabetic foot ulcer
DMEVXY6 ID DMEVXY6
DMEVXY6 DN Heparin Calcium
DMEVXY6 HS Approved
DMEVXY6 SN Calciparine
DMEVXY6 CP Sanofi Aventis Us Llc
DMEVXY6 TC Cardiovascular Agents
DMEVXY6 DE Coagulation defect
DM9KHZL ID DM9KHZL
DM9KHZL DN Heparin Sodium
DM9KHZL HS Approved
DM9KHZL SN (2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid; HepFlush; GTPL4214; CHEMBL526514; Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container
DM9KHZL CP Hospira Inc
DM9KHZL TC Cardiovascular Agents
DM9KHZL PC 92044406
DM9KHZL MW 1157.9
DM9KHZL FM C26H42N2NaO37S5+
DM9KHZL IC InChI=1S/C26H42N2O37S5.Na/c1-4(30)27-7-9(31)13(6(56-23(7)39)3-55-67(43,44)45)58-26-19(65-70(52,53)54)12(34)16(20(62-26)22(37)38)60-24-8(28-66(40,41)42)15(63-68(46,47)48)14(5(2-29)57-24)59-25-18(64-69(49,50)51)11(33)10(32)17(61-25)21(35)36;/h5-20,23-26,28-29,31-34,39H,2-3H2,1H3,(H,27,30)(H,35,36)(H,37,38)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);/q;+1
DM9KHZL CS CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
DM9KHZL IK JRTRSJGZMRQDHI-UHFFFAOYSA-N
DM9KHZL IU sodium;6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KHZL DE Deep vein thrombosis; Coagulation defect
DMOB2F3 ID DMOB2F3
DMOB2F3 DN Heptabarbital
DMOB2F3 HS Approved
DMOB2F3 SN Cycloheptenylethylmalonylurea; Heptabarb; Heptabarbe; Heptabarbitone; Heptabarbo; Heptabarbum; Heptadorm; Heptamal; Heptamalum; Heptbarbital; Medapan; Medomin; Medomine; Noctyn; Cycloheptenylethylbarbituric acid; G 475; Heptabarbe [INN-French]; Heptabarbo [INN-Spanish]; Heptabarbum [INN-Latin]; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohepten-1-yl)-5-ethyl-(9CI); 5-(1-CYCLOHEPTEN-1-YL)-5-ETHYLBARBITURIC ACID; 5-(1-Cyclohepten-1-yl)-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cycloheptenyl)-5-ethylbarbitursaeure; 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione; 5-Ethyl-5-(1'-cycloheptenyl)-barbituric acid; 5-Ethyl-5-cycloheptenylbarbituric acid
DMOB2F3 DT Small molecular drug
DMOB2F3 PC 10518
DMOB2F3 MW 250.29
DMOB2F3 FM C13H18N2O3
DMOB2F3 IC InChI=1S/C13H18N2O3/c1-2-13(9-7-5-3-4-6-8-9)10(16)14-12(18)15-11(13)17/h7H,2-6,8H2,1H3,(H2,14,15,16,17,18)
DMOB2F3 CS CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2
DMOB2F3 IK PAZQYDJGLKSCSI-UHFFFAOYSA-N
DMOB2F3 IU 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
DMOB2F3 CA CAS 509-86-4
DMOB2F3 CB CHEBI:81297
DMOB2F3 DE Anaesthesia
DM6YWBF ID DM6YWBF
DM6YWBF DN Herbimycin A
DM6YWBF HS Approved
DM6YWBF SN Herbimycin; Herbimycin A from Streptomyces hygroscopicus; Antibiotic Tan 420F; [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(2R,3S,5S,6R,7S,8E,10S,11S,12Z,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate
DM6YWBF TC Anticancer Agents
DM6YWBF DT Small molecular drug
DM6YWBF PC 5311102
DM6YWBF MW 574.7
DM6YWBF FM C30H42N2O9
DM6YWBF IC InChI=1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1
DM6YWBF CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)/C)OC)OC(=O)N)\\C)C)OC)OC
DM6YWBF IK MCAHMSDENAOJFZ-BVXDHVRPSA-N
DM6YWBF IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DM6YWBF CA CAS 70563-58-5
DM6YWBF CB CHEBI:5674
DM6YWBF DE Solid tumour/cancer
DMDBWHY ID DMDBWHY
DMDBWHY DN Heroin diacetylmorphine
DMDBWHY HS Approved
DMDBWHY SN Diamorphine (TN)
DMDBWHY CP Bayer company
DMDBWHY DT Small molecular drug
DMDBWHY PC 5462328
DMDBWHY MW 369.4
DMDBWHY FM C21H23NO5
DMDBWHY IC InChI=1S/C21H23NO5/c1-11(23)25-16-6-4-13-10-15-14-5-7-17(26-12(2)24)20-21(14,8-9-22(15)3)18(13)19(16)27-20/h4-7,14-15,17,20H,8-10H2,1-3H3/t14-,15+,17-,20-,21-/m0/s1
DMDBWHY CS CC(=O)O[C@H]1C=C[C@H]2[C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)OC(=O)C)CCN3C
DMDBWHY IK GVGLGOZIDCSQPN-PVHGPHFFSA-N
DMDBWHY IU [(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] acetate
DMDBWHY CA CAS 561-27-3
DMDBWHY CB CHEBI:27808
DMDBWHY DE Neurological disorder
DMKER83 ID DMKER83
DMKER83 DN Hesperetin
DMKER83 HS Approved
DMKER83 SN Hesperin; Hesperitin; TNP00238; YSO2; Cyanidanon 4'-methyl ether 1626; Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN); Flavanone, 3',5,7-trihydroxy-4'-methoxy-(VAN) (8CI); (-)-hesperetin; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 3',5,7-Trihydroxy-4'-methoxyflavanone; 3',5,7-Trihydroxy-4-methoxyflavanone; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-(9CI); 5,7,3'-Trihydroxy-4'-methoxyflavanone
DMKER83 TC Anticholesteremic Agents
DMKER83 DT Small molecular drug
DMKER83 PC 72281
DMKER83 MW 302.28
DMKER83 FM C16H14O6
DMKER83 IC InChI=1S/C16H14O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
DMKER83 CS COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMKER83 IK AIONOLUJZLIMTK-AWEZNQCLSA-N
DMKER83 IU (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMKER83 CA CAS 520-33-2
DMKER83 CB CHEBI:28230
DMKER83 DE High blood cholesterol level
DMI5DW1 ID DMI5DW1
DMI5DW1 DN Hesperidin
DMI5DW1 HS Approved
DMI5DW1 SN hesperidin; 520-26-3; Cirantin; Hesperidoside; Hesper bitabs; Hesperetin-rutinosid; Hesperidine; UNII-E750O06Y6O; CCRIS 3940; (S)-(-)-Hesperidin; EINECS 208-288-1; NSC 44184; BRN 0075140; Hesperidin, (2S)-; Hesperetin 7-rutinoside; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; CHEBI:28775; USAF CF-3; Hesperidin, (S)-(-)-; Hesperitin-7-rhamnoglucoside; E750O06Y6O; C28H34O15; HESPERIDINE
DMI5DW1 DT Small molecular drug
DMI5DW1 PC 10621
DMI5DW1 MW 610.6
DMI5DW1 FM C28H34O15
DMI5DW1 IC InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
DMI5DW1 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
DMI5DW1 IK QUQPHWDTPGMPEX-QJBIFVCTSA-N
DMI5DW1 IU (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
DMI5DW1 CA CAS 520-26-3
DMI5DW1 CB CHEBI:28775
DMI5DW1 DE Vascular purpura
DMPXITB ID DMPXITB
DMPXITB DN Hetacillin
DMPXITB HS Approved
DMPXITB SN Etacillina; Hetacilina; Hetacilline; Hetacillinum; Phenazacillin; Versapen; Etacillina [DCIT]; HETACILLIN POTASSIUM; BRL 804; BL-P 804; BRL-804; Hetacilina [INN-Spanish]; Hetacilline [INN-French]; Hetacillinum [INN-Latin]; Versapen (TN); Hetacillin (USAN/INN); Hetacillin [USAN:INN:BAN]; N,N'-Isopropylidene-A-amino-benzyl penicillin; (2S,%R,6R)-6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure; (2S,5R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure; 6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid
DMPXITB CP Bristol Laboratories Inc Div Bristol Myers Co
DMPXITB TC Antibiotics
DMPXITB DT Small molecular drug
DMPXITB PC 443387
DMPXITB MW 389.5
DMPXITB FM C19H23N3O4S
DMPXITB IC InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1
DMPXITB CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)C4=CC=CC=C4)C(=O)O)C
DMPXITB IK DXVUYOAEDJXBPY-NFFDBFGFSA-N
DMPXITB IU (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMPXITB CA CAS 3511-16-8
DMPXITB CB CHEBI:5683
DMPXITB DE Bacterial infection
DMGUC9T ID DMGUC9T
DMGUC9T DN HEV-239
DMGUC9T HS Approved
DMGUC9T SN Hecolin; Bacterially-expressed hepatitis E vaccine, Xiamen Innovax Biotech; Hepatitis E vaccine (recombinant), Xiamen Innovax Biotech; Hepatitis E vaccine (alum-adjuvanted), Xiamen Innovax Biotech
DMGUC9T CP Beijing Wantai Biological Pharmacy Enterprise Co Ltd
DMGUC9T DT Vaccine
DMGUC9T DE Hepatitis E virus infection
DMLKSE0 ID DMLKSE0
DMLKSE0 DN Hexachlorophene
DMLKSE0 HS Approved
DMLKSE0 SN Acigena; Almederm; Armohex; Bilevon; Bivelon; Cotofilm; Dermadex; Distodin; Eleven; Esaclorofene; Exofene; Fascol; Fomac; Fostril; Gamophen; Gamophene; Hexabalm; Hexachlorofen; Hexachlorophane; Hexachlorophen; Hexachlorophenum; Hexaclorofeno; Hexafen; Hexascrub; Hexide; Hexophene; Hexosan; Isobac; Nabac; PHisoHex; Phisodan; Ritosept; Septisol; Septofen; Steral; Steraskin; Surofene; TRICHLOROPHENE; Tersaseptic; Trisophen; Turgex; Blockade Anti Bacterial Finish; Brevity Blue Liquid Bacteriostatic Scouring Cream; Brevity Blue Liquid Sanitizing Scouring Cream; Enditch Pet Shampoo; Esaclorofene [DCIT]; Fo stril; Hexachlorofen [Czech]; Hexachlorophene [INN]; Hilo Cat Flea Powder; Hilo Flea Powder; Neosept V; Pedigree Dog Shampoo Bar; Scrubteam Surgical Spongebrush; Staphene O; AT 7; B 32; H3P; Hexachlorophene [UN2875] [Poison]; KUC106447N; M0219; Nabac 25 ec; AT-7; AT17 (TN); AT7 (TN); Acigena (TN); Almederm (TN); At-17; B & b Flea Kontroller for Dogs Only; B 32 (VAN); Bilevon (TN); E-Z Scrub; En-Viron D Concentrated Phenolic Disinfectant; Exofene (TN); Fesia-sin; Fostril (TN); G-11; G-Eleven; G-II; Gamophen (TN); Germa-Medica; Hexa-Germ; Hexachlorophene, Pharma; Hexachlorophenum [INN-Latin]; Hexaclorofeno [INN-Spanish]; Hexaphene-LV; Hexosan (TN); PRE-OP II; Phiso-Scrub; Phisohex(TN); Pre-Op; Septi-Soft; Septisol (TN); Solu-Heks; Soy-dome; Ster-zac; Surgi-Cen; Surgi-Cin; Surofene (TN); Thera-Groom Pet Shampoo for Dogs for Veterinary Use Only; G-11 (TN); GERMA-MEDICA (MG); Germa-Medica (TN); Hexachlorophene (USP/INN); KSC-19-051; Methylenebis(3,4,6-trichlorophenol); Bis(2,3,5-tric hloro-6-hydroxyphenyl)methane; Bis(2,3,5-trichloro-6-hydroxyphenyl)methane; Bis(2-hydroxy-3,5,6-trichlorophenyl)methane; Bis(3,5,6-trichloro-2-hydroxyphenyl)methane; Bis-2,3,5-trichlor-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan; Bis-2,3,5-trichloro-6-hydroxyfenylmethan [Czech]; Bis(3,5,6-trichloro-2-hydroxyphenyl)-methane; Methane, bis(2,3,5-trichloro-6-hydroxyphenyl); 2,2',3,3',5,5'-Hexachloro-6,6'-dihydroxydiphenylmethane; 2,2'-Dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane; 2,2'-Methylene bis(3,4,6-trichlorophenol); 2,2'-Methylenebis(3,4,6-trichlorophenol); 2,2'-Methylenebis[3,4,6-trichlorophenol]; 2,2'-methanediylbis(3,4,6-trichlorophenol); 2,2-Methylene-bis-[3,4,6-trichlorophenol]; 3,3',5,5',6,6'-Hexachloro-2,2'-dihydroxydiphenylmethane; 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol
DMLKSE0 TC Antiinfective Agents
DMLKSE0 DT Small molecular drug
DMLKSE0 PC 3598
DMLKSE0 MW 406.9
DMLKSE0 FM C13H6Cl6O2
DMLKSE0 IC InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2
DMLKSE0 CS C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl
DMLKSE0 IK ACGUYXCXAPNIKK-UHFFFAOYSA-N
DMLKSE0 IU 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol
DMLKSE0 CA CAS 70-30-4
DMLKSE0 CB CHEBI:5693
DMLKSE0 DE Bacterial infection
DMFY307 ID DMFY307
DMFY307 DN Hexafluronium bromide
DMFY307 HS Approved
DMFY307 SN Hexafluorenium; Milaxen; Mylaxen; Bromuro de hexafluronio; Esafluronio bromuro; Esafluronio bromuro [DCIT]; Hexafluorenium bromide; Hexafluorenium bromide [USAN]; Hexafluorenium dibromide; Hexafluorenium dibromide salt; Hexafluronii bromidum; Bromure d'hexafluronium; Bromuro de hexafluronio [INN-Spanish]; Hexafluorenium bromide (USAN); Hexafluronii bromidum [INN-Latin]; Hexafluronium bromide (INN); IN-117; Mylaxen (TN); Bromure d'hexafluronium [INN-French]; Hexamethylene bis(9-fluorenyldimethylammonium)dibromide; Hexamethylenebis(9-fluorenyldimethylammonium bromide); Hexamethylenebis(dimethyl-9-fluorenylammonium bromide); Hexamethylenebis(fluoren-9-yldimethylammonium) dibromide; AMMONIUM, HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYL-, DIBROMIDE; Ammonium, hexamethylenebis(fluoren-9-yldimethyl-, bromide; N,N'-Di(9-fluorenyl)-N,N,N',N'-tetramethyly-hexamethylendi(ammoniumbromid); 1,6-Bis(9 fluorenyldimethyl-ammonium)hexane bromide; 1,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-, dibromide; 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium dibromide
DMFY307 TC Analgesics
DMFY307 DT Small molecular drug
DMFY307 PC 9434
DMFY307 MW 662.5
DMFY307 FM C36H42Br2N2
DMFY307 IC InChI=1S/C36H42N2.2BrH/c1-37(2,35-31-21-11-7-17-27(31)28-18-8-12-22-32(28)35)25-15-5-6-16-26-38(3,4)36-33-23-13-9-19-29(33)30-20-10-14-24-34(30)36;;/h7-14,17-24,35-36H,5-6,15-16,25-26H2,1-4H3;2*1H/q+2;;/p-2
DMFY307 CS C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C3=CC=CC=C13)C4C5=CC=CC=C5C6=CC=CC=C46.[Br-].[Br-]
DMFY307 IK WDEFPRUEZRUYNW-UHFFFAOYSA-L
DMFY307 IU 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide
DMFY307 CA CAS 317-52-2
DMFY307 DE Spasm
DMQ314B ID DMQ314B
DMQ314B DN Hexobarbital
DMQ314B HS Approved
DMQ314B SN Barbidorm; Citodon; Citopan; Cyclonal; Cyclopan; Dorico; Enhexymal; Enhexymalum; Esobarbitale; Evipal; Evipan; Hexabarbital;Hexobarbitalum; Hexobarbitone; Hexobarbitonum; Methexenyl; Methylhexabarbital; Methylhexabital; Narcosan; Noctivane; Sombucaps; Sombulex; Somnalert; Esobarbitale [DCIT]; Esobarbitale [Italian]; Hexanastab oral; Sodium hexobarbital; Citopan (TN); Evipan (TN); Hexenal (barbiturate); Hexobarbital (VAN); Hexobarbital [INN:JAN]; Hexobarbitalum [INN-Latin]; Hexobarbital (JAN/INN); N-Methyl-5-cyclohexenyl-5-methylbarbituric acid; (+-)-Hexobarbital; 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl; 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cyclohexenyl)-1,5-dimethylbarbituric acid; 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid; 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German]; 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-(delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione
DMQ314B TC Hypnotics and Sedatives
DMQ314B DT Small molecular drug
DMQ314B PC 3608
DMQ314B MW 236.27
DMQ314B FM C12H16N2O3
DMQ314B IC InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
DMQ314B CS CC1(C(=O)NC(=O)N(C1=O)C)C2=CCCCC2
DMQ314B IK UYXAWHWODHRRMR-UHFFFAOYSA-N
DMQ314B IU 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
DMQ314B CA CAS 56-29-1
DMQ314B CB CHEBI:5706
DMQ314B DE Anaesthesia
DMEADRK ID DMEADRK
DMEADRK DN Hexylcaine
DMEADRK HS Approved
DMEADRK SN Hexilcaina; Hexylcainum; Osmocaine; Hexylcaine [INN]; Cyclaine (TN); Hexilcaina [INN-Spanish]; Hexylcainum [INN-Latin]; Osmocaine (TN); (2-Cyclohexylamino-1-methylethyl) benzoate; 1-(Cyclohexylamino)-2-propanol benzoate (ester); 1-(cyclohexylamino)propan-2-yl benzoate; 2-Propanol, 1-(cyclohexylamino)-, benzoate (ester)
DMEADRK CP Merck & Co
DMEADRK TC Anesthetics
DMEADRK DT Small molecular drug
DMEADRK PC 10770
DMEADRK MW 261.36
DMEADRK FM C16H23NO2
DMEADRK IC InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3
DMEADRK CS CC(CNC1CCCCC1)OC(=O)C2=CC=CC=C2
DMEADRK IK DKLKMKYDWHYZTD-UHFFFAOYSA-N
DMEADRK IU 1-(cyclohexylamino)propan-2-yl benzoate
DMEADRK CA CAS 532-77-4
DMEADRK CB CHEBI:34791
DMEADRK DE Anaesthesia
DMV7IM6 ID DMV7IM6
DMV7IM6 DN Histamine Phosphate
DMV7IM6 HS Approved
DMV7IM6 SN Histamine acid phosphate; Histamine biphosphate; Histamine dihydrogen phosphate; Histamine diphosphate; Histamine phosphate [USP]; Histamine positive; H0147; Histamine phosphate (TN); Histamine phosphate (USP); Histamine phosphate (1:2); 1H-Imidazole-4-ethanamine, phosphate (1:2); 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2); 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate); 4-(2-Aminoethyl)imidazole di-acid phosphate; 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
DMV7IM6 TC Diagnostic Agents
DMV7IM6 DT Small molecular drug
DMV7IM6 PC 65513
DMV7IM6 MW 307.14
DMV7IM6 FM C5H15N3O8P2
DMV7IM6 IC InChI=1S/C5H9N3.2H3O4P/c6-2-1-5-3-7-4-8-5;2*1-5(2,3)4/h3-4H,1-2,6H2,(H,7,8);2*(H3,1,2,3,4)
DMV7IM6 CS C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O
DMV7IM6 IK ZHIBQGJKHVBLJJ-UHFFFAOYSA-N
DMV7IM6 IU 2-(1H-imidazol-5-yl)ethanamine;phosphoric acid
DMV7IM6 CA CAS 51-74-1
DMV7IM6 CB CHEBI:51193
DMV7IM6 DE Diagnostic imaging
DMGBPSH ID DMGBPSH
DMGBPSH DN Homatropine Methylbromide
DMGBPSH HS Approved
DMGBPSH SN Arkitropin; Camatropine; Equipin; Esopin; Homapin; Homatromide; Malcotran; Mesopin; Methylhomatropine; Novatrin; Novatrine; Novatropine; Npvatropine; Sethyl; Homatropine methobromide; Homatropine methyl bromide; Homatropini methylbromidum; Humulon lead salt; Methyl Bromide Homatropine; Methylhomatropine bromide; Methylhomatropinum bromatum; Metilbromuro de homatropina; Omatropina metilbromuro; Omatropina metilbromuro [DCIT]; Tropinium methobromide mandelate; DL-Homatropine methyl bromide; DL-Methylbromide; Equipin (TN); Homapin-10; Homapin-5; Homatropine DL-methylbromide; Homatropine methylbromide (USP); Homatropine methylbromide [INN:BAN]; Homatropini methylbromidum [INN-Latin]; Hycodan, probilagol; Isopto Homatropine (TN); Methylbromure d'homatropine; Metilbromuro de homatropina [INN-Spanish]; N-Methylhomatropinium Bromide; Sed-Tems; Methylbromure d'homatropine [INN-French]; HOMATROPINIUM, 8-METHYL-, BROMIDE; [(5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate bromide; (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate bromide; 3-[2-hydroxy(phenyl)acetoxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate; 3-{[hydroxy(phenyl)acetyl]oxy}-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide mandelate; 8-Methylhomatropinium bromide
DMGBPSH TC Antiulcer Agents
DMGBPSH DT Small molecular drug
DMGBPSH PC 10429215
DMGBPSH MW 370.3
DMGBPSH FM C17H24BrNO3
DMGBPSH IC InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1/t13-,14+,15?,16?;
DMGBPSH CS C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-]
DMGBPSH IK FUFVKLQESJNNAN-ZZJGABIISA-M
DMGBPSH IU [(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide
DMGBPSH CA CAS 80-49-9
DMGBPSH DE Uveitis; Peptic ulcer
DM78G6F ID DM78G6F
DM78G6F DN HTF 919
DM78G6F HS Approved
DM78G6F DT Small molecular drug
DM78G6F PC 60918
DM78G6F MW 301.39
DM78G6F FM C16H23N5O
DM78G6F IC InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)
DM78G6F CS CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC
DM78G6F IK IKBKZGMPCYNSLU-UHFFFAOYSA-N
DM78G6F IU 1-[(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
DM78G6F CA CAS 145158-71-0
DM78G6F DE Constipation
DMA5OBU ID DMA5OBU
DMA5OBU DN Human neutral insulin
DMA5OBU HS Approved
DMA5OBU DT Small molecular drug
DMA5OBU PC 16129672
DMA5OBU MW 5808
DMA5OBU FM C257H383N65O77S6
DMA5OBU IC InChI=1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1
DMA5OBU CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMA5OBU IK PBGKTOXHQIOBKM-FHFVDXKLSA-N
DMA5OBU IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMA5OBU DE Diabetic complication
DMPHVQ1 ID DMPHVQ1
DMPHVQ1 DN Human prothrombin complex concentrate
DMPHVQ1 HS Approved
DMPHVQ1 CP Octapharma usa
DMPHVQ1 SQ sp|P00734|THRB_HUMAN Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2: MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
DMPHVQ1 DE Bleeding disorder
DMMAWLU ID DMMAWLU
DMMAWLU DN Huperzine A
DMMAWLU HS Approved
DMMAWLU SN Fordine; ( inverted exclamation markA)-Huperazine A; ( inverted exclamation markA)-Huperzine A; C15H18N2O; 5,9-Methanocycloocta(b)pyridin-2(1H)-one, 5-amino-11-ethylidene-5,6,9,10-tetrahydro-7-methyl-; rac-huperzine A; NCGC00159362-02; SCHEMBL679315; SCHEMBL1047469; CHEMBL394259; CHEBI:91724; MolPort-003-941-680
DMMAWLU DT Small molecular drug
DMMAWLU PC 854026
DMMAWLU MW 242.32
DMMAWLU FM C15H18N2O
DMMAWLU IC InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15+/m0/s1
DMMAWLU CS C/C=C/1\\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3
DMMAWLU IK ZRJBHWIHUMBLCN-YQEJDHNASA-N
DMMAWLU IU (1R,9R,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMMAWLU CA CAS 102518-79-6
DMMAWLU CB CHEBI:78330
DMMAWLU DE Alzheimer disease
DMX8M26 ID DMX8M26
DMX8M26 DN Hyaluronate sodium
DMX8M26 HS Approved
DMX8M26 DT Small molecular drug
DMX8M26 PC 3084049
DMX8M26 MW 799.6
DMX8M26 FM C28H44N2NaO23+
DMX8M26 IC InChI=1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1
DMX8M26 CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O.[Na+]
DMX8M26 IK YWIVKILSMZOHHF-QJZPQSOGSA-N
DMX8M26 IU sodium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMX8M26 CA CAS 9067-32-7
DMX8M26 DE Joint lubricant; Pancytopenia; Enthesopathy
DMETWAU ID DMETWAU
DMETWAU DN Hyaluronidase (ovine)
DMETWAU HS Approved
DMETWAU SN Hyaluronidase; Hydase; Vitragan; Vitrase; Hyaluronidase Injection; Hyaluronidase (vitreous hemorrhage), ISTA
DMETWAU CP PrimaPharm; Primapharm
DMETWAU SQ Hyaluronidase Sequence: MWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDMKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHVEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQYEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQLSWLWAESTALFPSVYLEETLASSTHGRNFVSFRVQEALRVADVHHANHALPVYVFTRPTYSRGLTGLSEMDLISTIGESAALGAAGVILWGDAGFTTSNETCRRLKDYLTRSLVPYVVNVSWAAQYCSWAQCHGHGRCVRRDPNAHTFLHLSASSFRLVPSHAPDEPRLRPEGELSWADRNHLQTHFRCQCYLGWGGEQCQWDRRRAAGGASGAWAGFHLTGLLAVAVLAFTWTS
DMETWAU DE Resorption of radiopaque agents
DMU8JGH ID DMU8JGH
DMU8JGH DN Hydralazine
DMU8JGH HS Approved
DMU8JGH SN Apresolin; Apresoline; Apressin; Apressoline; Aprezolin; HLZ; Hidral; Hidralazin; Hidralazina; Hipoftalin; Hydralazin; Hydralazinum; Hydrallazin; Hydrallazine; Hydrazinophthalazine; Hypophthalin; Idralazina; Hidralazina [Spanish]; Idralazina [DCIT]; Idralazina [Italian]; BA 5968; C 5968; Ciba 5968; Praparat 5968; Apresoline (TN); Apressin (pharmaceutical); C-5068; C-5968; Hidral (TN); Hidralazina [INN-Spanish]; Hydralazine (INN); Hydralazine [INN:BAN]; Hydralazinum [INN-Latin]; Hydrazone 1(2H)-phthalazinone; Phthalazin-1-ylhydrazine; [2H-Phthalazin-(1Z)-Ylidene]-Hydrazine Hydrochloride; (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone hydrazone; 1(2H)-Phthalazinone, hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine
DMU8JGH TC Antihypertensive Agents
DMU8JGH DT Small molecular drug
DMU8JGH PC 3637
DMU8JGH MW 160.18
DMU8JGH FM C8H8N4
DMU8JGH IC InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
DMU8JGH CS C1=CC=C2C(=C1)C=NN=C2NN
DMU8JGH IK RPTUSVTUFVMDQK-UHFFFAOYSA-N
DMU8JGH IU phthalazin-1-ylhydrazine
DMU8JGH CA CAS 86-54-4
DMU8JGH CB CHEBI:5775
DMU8JGH DE Hypertension
DMUSZHD ID DMUSZHD
DMUSZHD DN Hydrochlorothiazide
DMUSZHD HS Approved
DMUSZHD SN Acesistem; Acuilix; Acuretic; Aldazida; Aldoril; Apresazide; Aquarills; Aquarius; Bremil; Briazide; Caplaril; Carozide; Catiazida; Chlorizide; Chlorosulthiadil; Chlorzide; Chlothia; Cidrex; Clorana; Condiuren; Diaqua; Dichlorosal; Dichlorotride; Dichlothiazide; Dichlotiazid; Dichlotride; Diclotride; Dicyclotride; Didral; Dihydran; Dihydrochlorothiazid; Dihydrochlorothiazide; Dihydrochlorothiazidum; Dihydrochlorurit; Dihydrochlorurite; Dihydroxychlorothiazidum; Direma; Disalunil; Disothiazid; Diurogen; Dixidrasi; Drenol; Esidrex; Esidrix; Esoidrina; Fluvin; HCT; HCTZ; HCZ; Hidril; Hidrochlortiazid; Hidroclorotiazida; Hidroronol; Hidrosaluretil; Hidrotiazida; Hyclosid; Hydril; HydroDIURIL; Hydrochlorat; Hydrochlorot; Hydrochlorothiazid; Hydrochlorothiazidum; Hydrochlorthiazide; Hydrochlorthiazidum; Hydrocot; Hydrodiuretic; Hydropres; Hydrosaluric; Hydrothide; Hydrozide; Hypothiazid; Hypothiazide; Hytrid; Idroclorotiazide; Idrotiazide; Indroclor; Ivaugan; Manuril; Maschitt; Medozide; Megadiuril; Microzide; Mictrin; Mikorten; Modurcen; Moduretic; Natrinax; Nefrix; Nefrol; Neoflumen; Newtolide; Novodiurex; Oretic; Pantemon; Panurin; Roxane; Saldiuril; Sectrazide; Selozide; Servithiazid; Spironazide; Tandiur; Thiaretic; Thiuretic; Thlaretic; Timolide; Unazid; Urodiazin; Urozide; Vaseretic; Vetidrex; Aquazide H; Chlorsulfonamidodihydrobenzothiadiazine dioxide; Component of Aldactazide; Component of Aldoril; Component of Butizide Prestabs; Component of Caplaril; Component of Cyclex; Component of Dyazide; Component of Esimil; Concor Plus; Diclot ride; Hydro Par; Hydrochlorothiazide Intensol; Idroclorotiazide [DCIT]; Lotensin HCT; Panurin dichloride; Raunova Plus; Diu 25 Vigt; H 4759; MaybridgeCompound 10; Mazide 25 mg; Su 5879; Aldactazide 25/25; Aldectazide 50/50; Apo-Hydro; Aquazide H (TN); Aquazide-H; Dichlotride (TN); Diu-melusin; Esidrex (TN); Esidrix (TN); HCT-Isis; Hidro-Niagrin; Hidroclorotiazida [INN-Spanish]; Hydrex-semi; Hydro-Aquil; Hydro-D; Hydro-Diuril; Hydro-Saluric; Hydro-T; Hydro-chlor; HydroSaluric (TN); Hydrochlorothiazidum [INN-Latin]; Hydrodiuril (TN); Hydrozide Injection, Veterinary; Jen-Diril; Microzide (TN); Neo-Flumen; Neo-Minzil; Neo-codema; Oretic (TN); Ro-hydrazide; AF-614/30832002; Apo-Hydro (TN); Hydrochlorothiazide [INN:BAN:JAN]; Hydrochlorothiazide (JP15/USP/INN); Dro-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-6-chloro-7-sulfamyl-1,2, 4-benzothi; 3,4-Dihydrochlorothiazide; 6-Chloro-7-sulfamoyl-3, 4-dihy
DMUSZHD TC Diuretics
DMUSZHD DT Small molecular drug
DMUSZHD PC 3639
DMUSZHD MW 297.7
DMUSZHD FM C7H8ClN3O4S2
DMUSZHD IC InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
DMUSZHD CS C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
DMUSZHD IK JZUFKLXOESDKRF-UHFFFAOYSA-N
DMUSZHD IU 6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMUSZHD CA CAS 58-93-5
DMUSZHD CB CHEBI:5778
DMUSZHD DE Hypertension
DMQ2JO5 ID DMQ2JO5
DMQ2JO5 DN Hydrocodone
DMQ2JO5 HS Approved
DMQ2JO5 SN HYDROCODONE; Dihydrocodeinone; Hydrocodon; Hydrocone; Hydroconum; Codinovo; Dicodid; Multacodin; Bekadid; hidrocodona; Idrocodone; Hydrocodonum; Idrocodone [DCIT]; DICO; (-)-Dihydrocodeinone; Hydrocodonum [INN-Latin]; 125-29-1; Hidrocodona [INN-Spanish]; Codeinone, dihydro-; Hydrocodone polistirex; Hydrocodone [INN:BAN]; UNII-6YKS4Y3WQ7; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; HSDB 3097; EINECS 204-733-9; BRN 0094193; Bekadid; Hidrocodona; Hydrocodeinonebitartrate; Hydrocon; Anexsia (TN); Dicodid (TN); Duodin (TN); Hycet (TN); Hycodan (TN); Hycomine (TN); Hydrocodone (INN); Hydrokon (TN); Hydrovo (TN); Kolikodol (TN); Lorcet (TN); Lortab (TN); Mercodinone (TN); Norco (TN); Norgan (TN); Novahistex (TN); Orthoxycol (TN); Symtan (TN); Synkonin (TN); Vicodin (TN); Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-(8CI); Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-(9CI); (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; KP-201 hydrocodone prodrug
DMQ2JO5 CP Abbott Laboratories
DMQ2JO5 TC Analgesics
DMQ2JO5 DT Small molecular drug
DMQ2JO5 PC 5284569
DMQ2JO5 MW 299.4
DMQ2JO5 FM C18H21NO3
DMQ2JO5 IC InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
DMQ2JO5 CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
DMQ2JO5 IK LLPOLZWFYMWNKH-CMKMFDCUSA-N
DMQ2JO5 IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMQ2JO5 CA CAS 125-29-1
DMQ2JO5 CB CHEBI:5779
DMQ2JO5 DE Pain
DMIAPBE ID DMIAPBE
DMIAPBE DN Hydrocodone bitartrate
DMIAPBE HS Approved
DMIAPBE SN Hydrocodon; Hydrocodone [INN:BAN]; Hydrocodone polistirex; Hydrocodonum; Hydrocodonum [INN-Latin]; Hydrocone; Hydroconum; Idrocodone; Idrocodone [DCIT]; Multacodin; hidrocodona; (-)-Dihydrocodeinone; 125-29-1; 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one; 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan; BRN 0094193; DICO; EINECS 204-733-9; HSDB 3097; UNII-6YKS4Y3WQ7; Bekadid; Codeinone, dihydro-; Codinovo; Dicodid; Dihydrocodeinone; HYDROCODONE; Hidrocodona [INN-Spanish]; HYDROCODONE BITARTRATE; OJHZNMVJJKMFGX-RNWHKREASA-N; SCHEMBL154972; .codon; 143-71-5; API0002943; CHEMBL2062267; MFCD00078557
DMIAPBE PC 20831824
DMIAPBE MW 449.4
DMIAPBE FM C22H27NO9
DMIAPBE IC OJHZNMVJJKMFGX-RNWHKREASA-N
DMIAPBE CS CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4.C(C(C(=O)O)O)(C(=O)O)O
DMIAPBE IK 1S/C18H21NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,17-,18-;/m0./s1
DMIAPBE IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2,3-dihydroxybutanedioic acid
DMIAPBE CA CAS 143-71-5
DMIAPBE DE Neuropathic pain
DM8K1XO ID DM8K1XO
DM8K1XO DN Hydrocortamate
DM8K1XO HS Approved
DM8K1XO SN Hidrocortamato; Hydrocortamatum; Idrocortamato; Magnacort; Hydrocortamate [INN]; Idrocortamato [DCIT]; Hidrocortamato [INN-Spanish]; Hydrocortamatum [INN-Latin]; Hydrocortisone 21-(diethylamino)acetate; Hyddrocortison-21-(beta-diethylaminoacetat); Glycine, N,N-diethyl-, 21-ester with cortisol; Glycine, N,N-diethyl-, (11beta)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl ester; [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate; 11beta,17-Dihydroxy-3,20-dioxo-4-pregnen-21-yl 2-(diethylamino)acetat; 11beta,17-dihydroxy-3,20-dioxopregn-4-en-21-yl N,N-diethylglycinate; 11beta,17alpha,21-Trihydroxypregn-4-ene-3,20-dione 21-diethylaminoacetate; 17-Hydroxycorticosterone, 21-(diethylamino)acetate
DM8K1XO TC Antiinflammatory Agents
DM8K1XO DT Small molecular drug
DM8K1XO PC 84088
DM8K1XO MW 475.6
DM8K1XO FM C27H41NO6
DM8K1XO IC InChI=1S/C27H41NO6/c1-5-28(6-2)15-23(32)34-16-22(31)27(33)12-10-20-19-8-7-17-13-18(29)9-11-25(17,3)24(19)21(30)14-26(20,27)4/h13,19-21,24,30,33H,5-12,14-16H2,1-4H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1
DM8K1XO CS CCN(CC)CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)O
DM8K1XO IK FWFVLWGEFDIZMJ-FOMYWIRZSA-N
DM8K1XO IU [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-(diethylamino)acetate
DM8K1XO CA CAS 76-47-1
DM8K1XO CB CHEBI:50851
DM8K1XO DE Inflammation
DMGEMB7 ID DMGEMB7
DMGEMB7 DN Hydrocortisone
DMGEMB7 HS Approved
DMGEMB7 SN Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone
DMGEMB7 CP Merck And Co Inc
DMGEMB7 TC Antiinflammatory Agents
DMGEMB7 DT Small molecular drug
DMGEMB7 PC 5754
DMGEMB7 MW 362.5
DMGEMB7 FM C21H30O5
DMGEMB7 IC InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
DMGEMB7 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
DMGEMB7 IK JYGXADMDTFJGBT-VWUMJDOOSA-N
DMGEMB7 IU (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMGEMB7 CA CAS 50-23-7
DMGEMB7 CB CHEBI:17650
DMGEMB7 DE Inflammation; Congenital adrenal hyperplasia
DMVPUQI ID DMVPUQI
DMVPUQI DN Hydroflumethiazide
DMVPUQI HS Approved
DMVPUQI SN Bristab; Bristurin; Dihydroflumethazide; Dihydroflumethiazide; Diucardin; Diuredemina; Diurometon; Elodrin; Elodrine; Enjit; Finuret; Flutizide; Glomerulin; HFZ; Hidroalogen; Hidroflumetiazid; Hidroflumetiazida; Hydol; Hydrenox; Hydroflumethazide; Hydroflumethiazidum; Hydroflumethizide; Idroflumetiazide; Leodrine; Metflorylthiazidine; Metforylthiadiazin; Metforylthiazidin; Methforylthiazidine; NaClex; Olmagran; Rivosil; Robezon; Rodiuran; Rontyl; Saluron; Sisuril; Spandiuril; Trifluoromethylhydrazide; Trifluoromethylhydrothiazide; Vergonil; Component of Salutensin; Idroflumetiazide [DCIT]; SB01887; Di-ademil; Di-adenil; Hidroflumetiazida [INN-Spanish]; Hydroflumethiazidum [INN-Latin]; Naciex (glaxo); Saluron (TN); Hydroflumethiazide [INN:BAN:JAN]; Hydroflumethiazide (JAN/USP/INN); Ethyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Fluoromethyl-3, 4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1; 2H-1,2, 4-Benzothiadiazine-7-sulfonamide, 3, 4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-(trifluoromethyl)-, 1,1-dioxide; 3, 4-Dihydro-6-trifluorom; 3, 4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1, 1-dioxide; 3,4-Dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3,4-Dihydro-6-trifluoromethyl-7-sulfamoylbenzo-1,2,4-thiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2, 4-benzothi; 3,4-Dihydro-7-sulfamoyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 3,4-Dihydro-7-sulfamyl-6-trifluoromethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-(Trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Trifluoromethyl-3, 4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-3,4-dihydro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2, 4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 6-Trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 7-Sulfamoyl-6-tri; 7-Sulfamoyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1, 1-dioxide; 7-Sulfamyl-6-trifluoromethyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
DMVPUQI TC Diuretics
DMVPUQI DT Small molecular drug
DMVPUQI PC 3647
DMVPUQI MW 331.3
DMVPUQI FM C8H8F3N3O4S2
DMVPUQI IC InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
DMVPUQI CS C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1
DMVPUQI IK DMDGGSIALPNSEE-UHFFFAOYSA-N
DMVPUQI IU 1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMVPUQI CA CAS 135-09-1
DMVPUQI CB CHEBI:5784
DMVPUQI DE Congestive heart failure
DM1NG5W ID DM1NG5W
DM1NG5W DN Hydrogen peroxide
DM1NG5W HS Approved
DM1NG5W SN perhydrol; oxydol; 7722-84-1; Superoxol; Interox; Hydrogen dioxide; hydroperoxide; Peroxaan; Inhibine; Kastone; Hioxyl; Albone; Albone 35; Dihydrogen dioxide; Albone DS; T-Stuff; Lensept; Perone; Elawox; Albone 70; Perone 50; Albone 50; Albone 35CG; Albone 70CG; Albone 50CG; H2O2; Hydrogen peroxide (H2O2); Peroxide; Peroxan; Hydrogen peroxide, 30%; Hydrogen dioxide solution; Hydrogen peroxide, 90%; Perone 35; Perone 30; Hydrogen peroxide, solution; Waterstofperoxyde; Wasserstoffperoxid; Hydrogen peroxide, 3%; Caswell No. 486AA
DM1NG5W DT Small molecular drug
DM1NG5W PC 784
DM1NG5W MW 34.015
DM1NG5W FM H2O2
DM1NG5W IC InChI=1S/H2O2/c1-2/h1-2H
DM1NG5W CS OO
DM1NG5W IK MHAJPDPJQMAIIY-UHFFFAOYSA-N
DM1NG5W IU hydrogen peroxide
DM1NG5W CA CAS 7722-84-1
DM1NG5W CB CHEBI:16240
DM1NG5W DE Infectious disease
DMHP21E ID DMHP21E
DMHP21E DN Hydromorphone
DMHP21E HS Approved
DMHP21E SN hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug
DMHP21E CP Knoll
DMHP21E TC Analgesics
DMHP21E DT Small molecular drug
DMHP21E PC 5284570
DMHP21E MW 285.34
DMHP21E FM C17H19NO3
DMHP21E IC InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
DMHP21E CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4
DMHP21E IK WVLOADHCBXTIJK-YNHQPCIGSA-N
DMHP21E IU (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMHP21E CA CAS 466-99-9
DMHP21E CB CHEBI:5790
DMHP21E DE Pain; Chronic pain
DM6AVR4 ID DM6AVR4
DM6AVR4 DN Hydroquinone
DM6AVR4 HS Approved
DM6AVR4 SN hydroquinone; 1,4-benzenediol; Benzene-1,4-diol; 123-31-9; 1,4-Dihydroxybenzene; Quinol; p-Benzenediol; p-Hydroxyphenol; p-Hydroquinone; 4-Hydroxyphenol; Eldoquin; Benzoquinol; p-Dihydroxybenzene; hydroquinol; Eldopaque; Phiaquin; p-Dioxybenzene; Hydroquinole; Dihydroquinone; Tecquinol; Idrochinone; Benzohydroquinone; Tequinol; Hidroquinone; Arctuvin; Dihydroxybenzene; Solaquin forte; Derma-Blanch; Tenox HQ; Hydrochinone; Hydrochinon; Artra; Eldoquin Forte; Eldopaque Forte; Diak 5; Benzene, p-dihydroxy-; 1,4-Dihydroxy-benzol; Usaf ek-356; Accutin
DM6AVR4 DT Small molecular drug
DM6AVR4 PC 785
DM6AVR4 MW 110.11
DM6AVR4 FM C6H6O2
DM6AVR4 IC InChI=1S/C6H6O2/c7-5-1-2-6(8)4-3-5/h1-4,7-8H
DM6AVR4 CS C1=CC(=CC=C1O)O
DM6AVR4 IK QIGBRXMKCJKVMJ-UHFFFAOYSA-N
DM6AVR4 IU benzene-1,4-diol
DM6AVR4 CA CAS 123-31-9
DM6AVR4 CB CHEBI:17594
DM6AVR4 DE Melasma
DMGKV9D ID DMGKV9D
DMGKV9D DN Hydroxocobalamin
DMGKV9D HS Approved
DMGKV9D SN AlphaRedisol; Axion; Axlon; Cobalex; Codroxomin; Cyanokit; Depogamma; Docclan; Docelan; Docelvita; Docevita; Duradoce; Hidroxocobalamina; Hydrobamine; Hydrocobalamin; Hydrogrisevit; Hydrovit; Hydroxocobalaminacetat; Hydroxocobalamine; Hydroxocobalaminum; Hydroxocobemine; Hydroxomin; Hydroxycobalamin; Hydroxycobalamine; Hyxobamine; Idrogrisevit; Idrossocobalamina; Oxobemin; Vibeden; Vitadurin; Alpha Cobione; Ciplamin H; Hydro Cobex; Hydroxocobalamin acetate; Hydroxocobalamin monohydrochloride; Hydroxy Cobal; Idrossocobalamina [DCIT]; Primabalt RP; Hydroxocobalamin Vitamin B12; Hydroxy vitamin B12; Ohb12; Vitamin B12a; Vitamin B12b; Acti-B12; AlphaRedisol (TN); Benzimidazolyl ribofuranosyl phosphate deriv.; Cyanokit (TN); Ducobee-Hy; Duralta-12; Hidroxocobalamina [INN-Spanish]; Hydroxocobalamine [INN-French]; Hydroxocobalaminum [INN-Latin]; Hydroxycob(lll)alamin; Lyovit-H; Neo-Betalin 12; Neo-cytamen; Neo-macrabin; Neo-rojamin; OH-Cbl; OH-Duphar; Oxolamine (arcum); Redisol-H; Sytobex-H; Vitamin B(sub 12a); Vitamin B-12b; Hydroxocobalamin (JAN/USP/INN); Hydroxocobalamin [USAN:INN:BAN:JAN]; Alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide; Hydroxocobalamin(alkaline soln.), OH-replaces CN-in Cyanocobalamin); Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide; Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt; Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole; Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole; Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3); Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
DMGKV9D TC Vitamins
DMGKV9D DT Small molecular drug
DMGKV9D PC 70689311
DMGKV9D MW 1347.4
DMGKV9D FM C62H90CoN13O15P
DMGKV9D IC InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+2;/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1
DMGKV9D CS CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@@]\\4([C@H]([C@@H]5[C@]6([C@@]([C@@H](C(=N6)/C(=C\\7/[C@@]([C@@H](C(=N7)/C=C\\8/C([C@@H](C(=N8)/C(=C4\\[N-]5)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2]
DMGKV9D IK DQOCFCZRZOAIBN-WZHZPDAFSA-L
DMGKV9D IU cobalt(2+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2R)-1-[3-[(1R,2R,3R,4Z,7S,9Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl] phosphate;hydrate
DMGKV9D CA CAS 13422-51-0
DMGKV9D DE Vitamin B12 deficiency; Lung injury
DMJAS3O ID DMJAS3O
DMJAS3O DN Hydroxyamphetamine
DMJAS3O HS Approved
DMJAS3O SN Hydroxyamfetamine; Hydroxyamphetamide; Norpholedrine; Norveritol; Nov-Pholedrin; Oksamfetamin; Oxamfetamin; Oxamphetamine; Oxamphetaminium; Paradrine; Paredrine; Paredrinex; Pedrolon; Phenol, 4-(2-aminopropyl)-; Phenol, p-(2-aminopropyl)-; Phenol,4-(2-aminopropyl)-; Pulsoton; alpha-Methyltyramine; hydroxyamphetamine; p-(2-Aminopropyl)phenol; p-HYDROXYAMPHETAMINE; .alpha.-Methyltyramine; 1-p-Hydroxyphenyl-2-propylamine; 103-86-6; 2-Amino-1-(p-hydroxyphenyl)propane; 4-(2-Aminopropyl)phenol; 4-Hydroxyamphetamine
DMJAS3O PC 3651
DMJAS3O MW 151.21
DMJAS3O FM C9H13NO
DMJAS3O IC GIKNHHRFLCDOEU-UHFFFAOYSA-N
DMJAS3O CS CC(CC1=CC=C(C=C1)O)N
DMJAS3O IK 1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3
DMJAS3O IU 4-(2-aminopropyl)phenol
DMJAS3O CA CAS 103-86-6
DMJAS3O CB CHEBI:103855
DMJAS3O DE Horner syndrome
DMQSGM0 ID DMQSGM0
DMQSGM0 DN Hydroxyamphetamine Hydrobromide
DMQSGM0 HS Approved
DMQSGM0 SN Paredrine; 4-hydroxyamphetamine
DMQSGM0 CP Pharmics Inc
DMQSGM0 DT Small molecular drug
DMQSGM0 PC 9377
DMQSGM0 MW 232.12
DMQSGM0 FM C9H14BrNO
DMQSGM0 IC InChI=1S/C9H13NO.BrH/c1-7(10)6-8-2-4-9(11)5-3-8;/h2-5,7,11H,6,10H2,1H3;1H
DMQSGM0 CS CC(CC1=CC=C(C=C1)O)N.Br
DMQSGM0 IK RZCJLMTXBMNRAD-UHFFFAOYSA-N
DMQSGM0 IU 4-(2-aminopropyl)phenol;hydrobromide
DMQSGM0 CA CAS 306-21-8
DMQSGM0 DE Horner syndrome
DMSIVND ID DMSIVND
DMSIVND DN Hydroxychloroquine
DMSIVND HS Approved
DMSIVND SN Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
DMSIVND CP Concordia Pharmaceuticals Inc
DMSIVND TC Antimalarials
DMSIVND DT Small molecular drug
DMSIVND PC 3652
DMSIVND MW 335.9
DMSIVND FM C18H26ClN3O
DMSIVND IC InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DMSIVND CS CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
DMSIVND IK XXSMGPRMXLTPCZ-UHFFFAOYSA-N
DMSIVND IU 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
DMSIVND CA CAS 118-42-3
DMSIVND CB CHEBI:5801
DMSIVND DE Malaria
DMGIZF5 ID DMGIZF5
DMGIZF5 DN Hydroxyflutamide
DMGIZF5 HS Approved
DMGIZF5 SN HFT; Hydroxyniphtholide; PC1193; Sch 16423; Hydroxy-flutamide; OH-flutamide; Sch-16423; Alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; Alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide; 2-Hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide; 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMGIZF5 TC Anticancer Agents
DMGIZF5 DT Small molecular drug
DMGIZF5 PC 91649
DMGIZF5 MW 292.21
DMGIZF5 FM C11H11F3N2O4
DMGIZF5 IC InChI=1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)
DMGIZF5 CS CC(C)(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)O
DMGIZF5 IK YPQLFJODEKMJEF-UHFFFAOYSA-N
DMGIZF5 IU 2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMGIZF5 CA CAS 52806-53-8
DMGIZF5 DE Prostate cancer
DMIKQH5 ID DMIKQH5
DMIKQH5 DN Hydroxyprogesterone
DMIKQH5 HS Approved
DMIKQH5 SN Delalutin (TN); Proluton depot (TN)
DMIKQH5 CP Bristol Myers Squibb
DMIKQH5 DT Small molecular drug
DMIKQH5 PC 6238
DMIKQH5 MW 330.5
DMIKQH5 FM C21H30O3
DMIKQH5 IC InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h12,16-18,24H,4-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
DMIKQH5 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
DMIKQH5 IK DBPWSSGDRRHUNT-CEGNMAFCSA-N
DMIKQH5 IU (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMIKQH5 CA CAS 68-96-2
DMIKQH5 CB CHEBI:17252
DMIKQH5 DE Solid tumour/cancer
DMR5QS6 ID DMR5QS6
DMR5QS6 DN Hydroxystilbamidine Isethionate
DMR5QS6 HS Approved
DMR5QS6 SN Hydroxystilbamide; Hydroxystilbamidine diisethionate; FluoroGold (TN); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1); Ethanesulfonic acid, 2-hydroxy-, compd. with 2-hydroxy-4,4'-stilbenedicarboxamidine (2:1) (8CI); Benzenecarboximidamide, 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxy-, bis(2-hydroxyethanesulfonate) (salt); Ethanesulfonic acid, 2-hydroxy-, compd. with 4-(2-(4-(aminoiminomethyl)phenyl)ethenyl)-3-hydroxybenzenecarboximidamide (2:1); (4E)-4-[2-[4-(diaminomethylidene)cyclohexa-2,5-dien-1-ylidene]ethylidene]-3-oxocyclohexa-1,5-diene-1-carboximidamide; 2-Hydroxy-4,4'-diamidinostilbene di(beta-hydroxyethanesulfonate); 2-Hydroxy-4,4'-diguanylstilbene diisethionate; 2-Hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulfonate) (salt); 2-Hydroxy-4,4'-stilbenedicarboxamidine diisethionate; 2-Hydroxyethanesulphonic acid, compoundwith 4-(2-(4-amidinophenyl)vinyl)-3-hydroxybenzenecarboxamidine (2:1); 2-Hydroxystilbamidine diisethionate; 2-Hydroxystilbamidine isethionate; 2-hydroxyethanesulfonic acid
DMR5QS6 TC Antifungal Agents
DMR5QS6 DT Small molecular drug
DMR5QS6 PC 135460345
DMR5QS6 MW 406.5
DMR5QS6 FM C18H22N4O5S
DMR5QS6 IC InChI=1S/C16H16N4O.C2H6O4S/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21;3-1-2-7(4,5)6/h1-9,21H,(H3,17,18)(H3,19,20);3H,1-2H2,(H,4,5,6)/b4-1+;
DMR5QS6 CS C1=CC(=CC=C1/C=C/C2=C(C=C(C=C2)C(=N)N)O)C(=N)N.C(CS(=O)(=O)O)O
DMR5QS6 IK HPLUMRXCPMTSQW-DYVSEJHDSA-N
DMR5QS6 IU 4-[(E)-2-(4-carbamimidoylphenyl)ethenyl]-3-hydroxybenzenecarboximidamide;2-hydroxyethanesulfonic acid
DMR5QS6 CA CAS 533-22-2
DMR5QS6 DE Blastomycosis
DMOQVU9 ID DMOQVU9
DMOQVU9 DN Hydroxyurea
DMOQVU9 HS Approved
DMOQVU9 SN Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
DMOQVU9 TC Anticancer Agents
DMOQVU9 DT Small molecular drug
DMOQVU9 PC 3657
DMOQVU9 MW 76.055
DMOQVU9 FM CH4N2O2
DMOQVU9 IC InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
DMOQVU9 CS C(=O)(N)NO
DMOQVU9 IK VSNHCAURESNICA-UHFFFAOYSA-N
DMOQVU9 IU hydroxyurea
DMOQVU9 CA CAS 127-07-1
DMOQVU9 CB CHEBI:44423
DMOQVU9 DE Chronic myelogenous leukaemia
DMF8Y74 ID DMF8Y74
DMF8Y74 DN Hydroxyzine
DMF8Y74 HS Approved
DMF8Y74 SN Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
DMF8Y74 CP Pfizer Pharmaceuticals
DMF8Y74 TC Hypnotics and Sedatives
DMF8Y74 DT Small molecular drug
DMF8Y74 PC 3658
DMF8Y74 MW 374.9
DMF8Y74 FM C21H27ClN2O2
DMF8Y74 IC InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
DMF8Y74 CS C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMF8Y74 IK ZQDWXGKKHFNSQK-UHFFFAOYSA-N
DMF8Y74 IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
DMF8Y74 CA CAS 68-88-2
DMF8Y74 CB CHEBI:5818
DMF8Y74 DE Anxiety disorder
DMVAIH4 ID DMVAIH4
DMVAIH4 DN Hylenex
DMVAIH4 HS Approved
DMVAIH4 CP Halozyme therapeutics; baxter healthcare
DMVAIH4 DE Solid tumour/cancer
DM804UR ID DM804UR
DM804UR DN Hyoscyamine
DM804UR HS Approved
DM804UR SN L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine
DM804UR TC Antiarrhythmic Agents
DM804UR DT Small molecular drug
DM804UR PC 154417
DM804UR MW 289.4
DM804UR FM C17H23NO3
DM804UR IC InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1
DM804UR CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3
DM804UR IK RKUNBYITZUJHSG-VFSICIBPSA-N
DM804UR IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
DM804UR CA CAS 101-31-5
DM804UR CB CHEBI:17486
DM804UR DE Gastrointestinal disease
DM0RXF5 ID DM0RXF5
DM0RXF5 DN Hyqvia
DM0RXF5 HS Approved
DM0RXF5 SN Immunoglobulin infusion with recombinant hyaluronidase
DM0RXF5 CP Baxter
DM0RXF5 DE Immunodeficiency
DMV67QO ID DMV67QO
DMV67QO DN Ibalizumab
DMV67QO HS Approved
DMV67QO SN Hu5A8; TNX-355
DMV67QO CP TaiMed Biologics/Theratechnologies
DMV67QO DT Antibody
DMV67QO DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DM0QZBN ID DM0QZBN
DM0QZBN DN Ibandronate
DM0QZBN HS Approved
DM0QZBN SN BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate
DM0QZBN CP Roche; GlaxoSmithKline
DM0QZBN TC Bone Density Conservation Agents
DM0QZBN DT Small molecular drug
DM0QZBN PC 60852
DM0QZBN MW 319.23
DM0QZBN FM C9H23NO7P2
DM0QZBN IC InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
DM0QZBN CS CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
DM0QZBN IK MPBVHIBUJCELCL-UHFFFAOYSA-N
DM0QZBN IU [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
DM0QZBN CA CAS 114084-78-5
DM0QZBN DE Osteoporosis
DMGUX67 ID DMGUX67
DMGUX67 DN Ibopamine hci
DMGUX67 HS Approved
DMGUX67 SN Inopamil (TN); Scandine (TN)
DMGUX67 DT Small molecular drug
DMGUX67 PC 156320
DMGUX67 MW 343.8
DMGUX67 FM C17H26ClNO4
DMGUX67 IC InChI=1S/C17H25NO4.ClH/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4;/h6-7,10-12,18H,8-9H2,1-5H3;1H
DMGUX67 CS CC(C)C(=O)OC1=C(C=C(C=C1)CCNC)OC(=O)C(C)C.Cl
DMGUX67 IK ALIXRWKJZYLBJI-UHFFFAOYSA-N
DMGUX67 IU [4-[2-(methylamino)ethyl]-2-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate;hydrochloride
DMGUX67 CA CAS 75011-65-3
DMGUX67 DE Cardiac disease
DMG594T ID DMG594T
DMG594T DN Ibritumomab
DMG594T HS Approved
DMG594T SN Zevalin (TN)
DMG594T CP Bayer Pharmaceuticals Corporation
DMG594T TC Anticancer Agents
DMG594T DT Antibody
DMG594T SQ Ibritumomab tiuxetan heavy chain: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR >Ibritumomab tiuxetan light chainQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN
DMG594T DE Non-hodgkin lymphoma; Mantle cell lymphoma
DMHZCPO ID DMHZCPO
DMHZCPO DN Ibrutinib
DMHZCPO HS Approved
DMHZCPO SN PCI-32765; Ibrutinib (BTK inhibitor)
DMHZCPO CP Janssen Biotech; Pharmacyclics
DMHZCPO DT Small molecular drug
DMHZCPO PC 24821094
DMHZCPO MW 440.5
DMHZCPO FM C25H24N6O2
DMHZCPO IC InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
DMHZCPO CS C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMHZCPO IK XYFPWWZEPKGCCK-GOSISDBHSA-N
DMHZCPO IU 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
DMHZCPO CA CAS 936563-96-1
DMHZCPO CB CHEBI:76612
DMHZCPO DE B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma; Pancreatic cancer; Solid tumour/cancer
DM4LSPN ID DM4LSPN
DM4LSPN DN Ibudilast
DM4LSPN HS Approved
DM4LSPN SN Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
DM4LSPN CP Avigen
DM4LSPN DT Small molecular drug
DM4LSPN PC 3671
DM4LSPN MW 230.31
DM4LSPN FM C14H18N2O
DM4LSPN IC InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
DM4LSPN CS CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C
DM4LSPN IK ZJVFLBOZORBYFE-UHFFFAOYSA-N
DM4LSPN IU 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
DM4LSPN CA CAS 50847-11-5
DM4LSPN CB CHEBI:31684
DM4LSPN DE Amyotrophic lateral sclerosis; Alcohol dependence; Methamphetamine dependence; Opioid dependence; Multiple sclerosis; Castleman's disease
DM8VCBE ID DM8VCBE
DM8VCBE DN Ibuprofen
DM8VCBE HS Approved
DM8VCBE SN ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Nuprin; Liptan; Ibuprocin; Buburone; Medipren; Butylenin; Ibumetin; Anflagen; Lamidon; Ebufac; Mynosedin; Trendar; Roidenin; Apsifen; Haltran; Epobron; Nobgen; Adran; Nobfen; Rufen; PediaProfen; Andran; Bluton; Nobfelon; Pantrop; Brufort; Suspren; Rebugen; Tabalon; Inabrin; (RS)-Ibuprofen; Urem; Anco; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Ibu-slo; Napacetin; Brufanic; Ibuprohm; Ibufen; Ibren; 4-Isobutylhydratropic acid; p-Isobutylhydratropic acid; Actiprofen; Alaxan; Algofen; Amelior; Amersol; Amibufen; Anafen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Artril; Balkaprofen; Betaprofen; Bloom; Brofen; Bruflam; Bufeno; Bufigen; Bukrefen; Bupron; Buracaps; Burana; Carol;Cesra; Citalgan; Cobo; Codral; Combiflam; Cunil; Daiprophen; Dalsy; Dansida; Dentigoa; Dibufen; Dignoflex; Dolgirid; Dolibu; Dolmaral; Dolocyl; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Dolormin; Doltibil; Dolven; Dorival; Drin; Duafen; Duobrus; Dysdolen; Easifon; Emflam; Eputex; Ergix; Esprenit; Exneural; Faspic; Femadon; Femafen; Femapirin; Femidol; Fenbid;Fendol; Fenspan; Fibraflex; Gelufene; Gofen; Grefen; Gynofug; Ibol; Ibu; Ibubest; Ibubeta; Ibucasen; Ibudol; Ibudolor; Ibuflamar; Ibufug; Ibugel; Ibugen; Ibugesic; Ibuhexal; Ibulagic; Ibular; Ibulav; Ibuleve; Ibulgan; Ibumed; Ibumerck; Ibupirac; Ibuprin; Ibuprofene; Ibuprofeno; Ibuprofenum; Ibuprophen; Ibusal; Ibutid; Ifen; Inflam; Inoven; Ipren; Irfen; Isodol; Jenaprofen; Junifen; Kesan; Kratalgin; Lebrufen; Librofem; Lidifen; Lopane; Malafene; Manypren; Melfen; Mensoton; Midol; Moment; Narfen; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Norton; Novadol; Novogent; Novoprofen; Nuprilan; Optifen; Opturem; Oralfene; Ostarin; Ostofen; Ozonol; Paduden; Panafen; Paxofen; Perofen; Proartinal; Profen; Proflex; Provon; Quadrax; Rafen; Ranofen; Relcofen; Rhinadvil; Rofen; Rufin; Rupan; Sadefen; Salivia; Salprofen; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Solufen; Stelar; Sugafen; Suprafen; Syntofene; Tatanal; Tempil; Tofen; Tonal; Unipron; Upfen; Uprofen; Zafen; Zofen; DOLO PUREN; Deep Relief; Donjust B; Motrin IB; Novogent N; Togal N; Adex 200; Artril 300; Brufen 400; I 4883; IP 82; IP82; Midol 200; RD 13621; Tabalon 400; U 18573; UCB 79171; VUFB 9649; Act-3; Advil (TN); Ak+C2278tren; Aktre (TN); Alaxan (TN); Algoflex (TN); Alivium (TN); Am-Fam 400; Apsifen-F; Arthrofen (TN); Bonifen (TN); Brufen (TN); Bugesic (TN); Burana (TN); Caldolor (TN); Calprofen (TN); Cap-Profen; Dalsy (TN); Dismenol (TN); Diverin (TN); Dolgit (TN); Dolo-Dolgit; Dolofen-F; Dolofort (TN); Doloraz (TN); Dolormin (TN); Dorival (TN); Dura-Ibu; Ebufac (TN); Emflam-200; EmuProfen (TN); Espidifen (TN); Eve (TN); Fenbid (TN); Fenpaed (TN); Finalflex (TN); Galprofen (TN); Hedex (TN); Herron Blue (TN); IB-100; IBUFEN (TN); IP-82; Ibalgin (TN); Ibu-Attritin; Ibu-Tab; Ibu-Tab 200; Ibu-slow; IbuHEXAL (TN); Ibugel (TN); Ibuleve (TN); Ibum (TN); Ibumax (TN); Ibumetin (TN); Ibuprom (TN); Ibuprosyn (TN); Ibux (TN); Ibuxin (TN); Ipren (TN); Kratalgin (TN); Medicol (TN); Moment (TN); Motrin (TN); Nagifen-D; Narfen (TN); Neo-Helvagit; Neo-Mindol; Neobrufen (TN); Neofen (TN); Norvectan (TN); Novo-Profen; Nuprin (TN); Nureflex (TN); Nurofen (TN); Orbifen (TN); Panafen (TN); Pedia-Profen; Perifar (TN); Profin (TN); Ratiodolor (TN); Retard (TN); Rimafen (TN); Salvarina (TN); Solpaflex (TN); Spedifen (TN); Speedpain NANO (TN); Spidifen (TN); Tab-Profen; U-18573; Upfen (TN); ACHES-N-PAIN; Act-3 (TN); Dolo-Spedifen (TN); I-profen (TN); IBU-Ratiopharm (TN); Ibu-Vivimed (TN); U-18,573; IBUPROPHEN
DM8VCBE TC Analgesics
DM8VCBE DT Small molecular drug
DM8VCBE PC 3672
DM8VCBE MW 206.28
DM8VCBE FM C13H18O2
DM8VCBE IC InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
DM8VCBE CS CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
DM8VCBE IK HEFNNWSXXWATRW-UHFFFAOYSA-N
DM8VCBE IU 2-[4-(2-methylpropyl)phenyl]propanoic acid
DM8VCBE CA CAS 15687-27-1
DM8VCBE CB CHEBI:5855
DM8VCBE DE Pain
DMFJ8LT ID DMFJ8LT
DMFJ8LT DN Ibutamoren
DMFJ8LT HS Approved
DMFJ8LT SN L 163191; MK-0667; MK-677; 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMFJ8LT CP Merck
DMFJ8LT DT Small molecular drug
DMFJ8LT PC 178024
DMFJ8LT MW 528.7
DMFJ8LT FM C27H36N4O5S
DMFJ8LT IC InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1
DMFJ8LT CS CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N
DMFJ8LT IK UMUPQWIGCOZEOY-JOCHJYFZSA-N
DMFJ8LT IU 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMFJ8LT CA CAS 159634-47-6
DMFJ8LT DE Fibromyalgia
DMKXY2R ID DMKXY2R
DMKXY2R DN Ibutilide
DMKXY2R HS Approved
DMKXY2R SN Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate
DMKXY2R CP Pfizer Pharmaceuticals
DMKXY2R TC Antiarrhythmic Agents
DMKXY2R DT Small molecular drug
DMKXY2R PC 60753
DMKXY2R MW 384.6
DMKXY2R FM C20H36N2O3S
DMKXY2R IC InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
DMKXY2R CS CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
DMKXY2R IK ALOBUEHUHMBRLE-UHFFFAOYSA-N
DMKXY2R IU N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
DMKXY2R CA CAS 122647-31-8
DMKXY2R CB CHEBI:5856
DMKXY2R DE Atrial fibrillation
DMQPTOZ ID DMQPTOZ
DMQPTOZ DN Icatibant
DMQPTOZ HS Approved
DMQPTOZ SN Firazyr; Icatibant [INN]; HOE 140; HOE140; JE049; WIN 65365; Hoe-140; WIN-65365; D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DMQPTOZ CP Jerini AG
DMQPTOZ TC Antiinflammatory Agents
DMQPTOZ DT Small molecular drug
DMQPTOZ PC 6918173
DMQPTOZ MW 1304.5
DMQPTOZ FM C59H89N19O13S
DMQPTOZ IC InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1
DMQPTOZ CS C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMQPTOZ IK QURWXBZNHXJZBE-SKXRKSCCSA-N
DMQPTOZ IU (2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMQPTOZ CA CAS 130308-48-4
DMQPTOZ DE Hereditary angioedema
DM648X9 ID DM648X9
DM648X9 DN Icodextrin
DM648X9 HS Approved
DM648X9 SN Extraneal
DM648X9 CP Innovata plc
DM648X9 DT Small molecular drug
DM648X9 PC 3517
DM648X9 MW 231.08
DM648X9 FM C8H8Cl2N4
DM648X9 IC InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)
DM648X9 CS C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl
DM648X9 IK WDZVGELJXXEGPV-UHFFFAOYSA-N
DM648X9 IU 2-[(2,6-dichlorophenyl)methylideneamino]guanidine
DM648X9 CA CAS 5051-62-7
DM648X9 DE Kidney disease
DMJHN0A ID DMJHN0A
DMJHN0A DN Icosapent
DMJHN0A HS Approved
DMJHN0A TC Dietary supplement
DMJHN0A DT Small molecular drug
DMJHN0A PC 446284
DMJHN0A MW 302.5
DMJHN0A FM C20H30O2
DMJHN0A IC InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMJHN0A CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O
DMJHN0A IK JAZBEHYOTPTENJ-JLNKQSITSA-N
DMJHN0A IU (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
DMJHN0A CA CAS 10417-94-4
DMJHN0A CB CHEBI:28364
DMJHN0A DE Thrombin deficiency; Hyperglyceridemia; Hypertriglyceridemia
DMM0XGL ID DMM0XGL
DMM0XGL DN Idarubicin
DMM0XGL HS Approved
DMM0XGL SN DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
DMM0XGL CP Ben Venue Laboratories
DMM0XGL TC Anticancer Agents
DMM0XGL DT Small molecular drug
DMM0XGL PC 42890
DMM0XGL MW 497.5
DMM0XGL FM C26H27NO9
DMM0XGL IC InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
DMM0XGL CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
DMM0XGL IK XDXDZDZNSLXDNA-TZNDIEGXSA-N
DMM0XGL IU (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DMM0XGL CA CAS 58957-92-9
DMM0XGL CB CHEBI:42068
DMM0XGL DE Acute myeloid leukaemia
DMXEACF ID DMXEACF
DMXEACF DN Idarucizumab
DMXEACF HS Approved
DMXEACF SN Praxbind
DMXEACF CP Boehringer Ingelheim
DMXEACF DT Antibody
DMXEACF DE Reversal of the anticoagulant effects of dabigatran
DMQFDRC ID DMQFDRC
DMQFDRC DN Idebenone
DMQFDRC HS Approved
DMQFDRC SN idebenone; 58186-27-9; Idebenona; Idebenonum; CV 2619; Idebenonum [Latin]; Idebenona [Spanish]; Idebenone [INN:JAN]; CV-2619; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; UNII-HB6PN45W4J; BRN 2001459; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; HB6PN45W4J; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; CHEBI:31687; JGPMMRGNQUBGND-UHFFFAOYSA-N; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; NCGC00160514-01; AK161748
DMQFDRC CP Santhera Pharmaceuticals
DMQFDRC DT Small molecular drug
DMQFDRC PC 3686
DMQFDRC MW 338.4
DMQFDRC FM C19H30O5
DMQFDRC IC InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3
DMQFDRC CS CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
DMQFDRC IK JGPMMRGNQUBGND-UHFFFAOYSA-N
DMQFDRC IU 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
DMQFDRC CA CAS 58186-27-9
DMQFDRC CB CHEBI:31687
DMQFDRC DE Cognitive impairment; Friedreich's ataxia
DMP1QTS ID DMP1QTS
DMP1QTS DN Idecabtagene vicleucel
DMP1QTS HS Approved
DMP1QTS SN Bb2121
DMP1QTS CP Celgene
DMP1QTS DT CAR T Cell Therapy
DMP1QTS DE Multiple myeloma
DM602WT ID DM602WT
DM602WT DN Idelalisib
DM602WT HS Approved
DM602WT SN Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
DM602WT CP Gilead Sciences
DM602WT DT Small molecular drug
DM602WT PC 11625818
DM602WT MW 415.4
DM602WT FM C22H18FN7O
DM602WT IC InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
DM602WT CS CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DM602WT IK IFSDAJWBUCMOAH-HNNXBMFYSA-N
DM602WT IU 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
DM602WT CA CAS 870281-82-6
DM602WT CB CHEBI:82701
DM602WT DE Chronic lymphocytic leukaemia
DMDRT0E ID DMDRT0E
DMDRT0E DN Idoxuridine
DMDRT0E HS Approved
DMDRT0E SN Emanil; Herpesil; Herpidu; Idossuridina; Iododeoxyuridine; Kerecide; Ophthalmadine; Synmiol; ID2; LT00440811; SKF 14287; Dendrid (TN); HERPLEX (TN); Herpe-Gel; Herpes-Gel; Iododeoxyuridine-125I; Oftan-IDU; SK&F 14287; SK&F-14287; Idoxuridine (JP15/USP/INN); Idoxuridine [USAN:INN:BAN:JAN]; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; 1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 2'-Deoxy-5-(iodo-125I)uridine; 2'-deoxy-5-(125i)iodouridine; 5-(125-I)-Iodo-2-deoxyuridine; 5-I-2'-dUrd; 5-Iododesoxyuridine; 5IdU
DMDRT0E TC Antiviral Agents
DMDRT0E DT Small molecular drug
DMDRT0E PC 5905
DMDRT0E MW 354.1
DMDRT0E FM C9H11IN2O5
DMDRT0E IC InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DMDRT0E CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O
DMDRT0E IK XQFRJNBWHJMXHO-RRKCRQDMSA-N
DMDRT0E IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DMDRT0E CA CAS 54-42-2
DMDRT0E CB CHEBI:147675
DMDRT0E DE Herpes simplex virus infection
DM30SXV ID DM30SXV
DM30SXV DN Idursulfase
DM30SXV HS Approved
DM30SXV SN Elaprase (TN)
DM30SXV SQ Idursulfase heavy chain: SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPG >Idursulfase light chainNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP
DM30SXV DE Infertility; Hunter syndrome
DMCT3I8 ID DMCT3I8
DMCT3I8 DN Ifosfamide
DMCT3I8 HS Approved
DMCT3I8 SN Cyfos; Holoxan; Ifex; Ifosfamid; Ifosfamida; Ifosfamidum; Ifosphamide; Ifsofamide; Iphosphamid; Iphosphamide; Isoendoxan; Isofosfamide; Isophosphamide; Isosfamide; Mitoxana; Naxamide; Ifosfamide Sterile; Iso Endoxan; A 4942; ASTA Z 4942; Holoxan 1000; MJF 9325; Z 4942; Z4942; I-Phosphamide; IFEX (TN); Ifex (TN); Ifosfamida [INN-Spanish]; Ifosfamidum [INN-Latin]; Iphosphamid(e); Iso-Endoxan; MJF-9325; Mitoxana (TN); NPFAPI-04; Z-4942; Mitoxana, Ifex, Ifosfamide; Ifosfamide (JAN/USP/INN); Ifosfamide [USAN:INN:BAN:JAN]; N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide; N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide; N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid; N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]; N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine; (+-)-Ifosfamid; (+-)-Ifosphamide; (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; (D,L)-Ifosfamide; (R,S)-Ifosphamide; (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd; 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd; 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI); 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide; 3,} 2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide; 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
DMCT3I8 TC Anticancer Agents
DMCT3I8 DT Small molecular drug
DMCT3I8 PC 3690
DMCT3I8 MW 261.079
DMCT3I8 FM C7H15Cl2N2O2P
DMCT3I8 IC InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
DMCT3I8 CS C1CN(P(=O)(OC1)NCCCl)CCCl
DMCT3I8 IK HOMGKSMUEGBAAB-UHFFFAOYSA-N
DMCT3I8 IU N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DMCT3I8 CA CAS 3778-73-2
DMCT3I8 CB CHEBI:5864
DMCT3I8 DE Solid tumour/cancer
DM6AUFY ID DM6AUFY
DM6AUFY DN Iloperidone
DM6AUFY HS Approved
DM6AUFY SN Fanapt; Fanapta; Fiapta; Zomaril; HP 873; Fanapt (TN); HP-873; ILO-522; Iloperidone [USAN:INN]; Fanapta, Zomaril, Iloperidone; Iloperidone (USAN/INN); 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone; 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
DM6AUFY CP Vanda Pharmaceuticals
DM6AUFY DT Small molecular drug
DM6AUFY PC 71360
DM6AUFY MW 426.5
DM6AUFY FM C24H27FN2O4
DM6AUFY IC InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
DM6AUFY CS CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
DM6AUFY IK XMXHEBAFVSFQEX-UHFFFAOYSA-N
DM6AUFY IU 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone
DM6AUFY CA CAS 133454-47-4
DM6AUFY CB CHEBI:65173
DM6AUFY DE Schizophrenia
DMVPZBE ID DMVPZBE
DMVPZBE DN Iloprost
DMVPZBE HS Approved
DMVPZBE SN Ciloprost; Endoprost; Ilomedin; Ilomedine; Iloprostum; Ventavis; Iloprostum [Latin]; ZK 36374; E-1030; Iloprost (INN); Iloprost [BAN:INN]; SH-401; Ventavis (TN); ZK-36374; ZK-363775; [3H]-Iloprost; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
DMVPZBE CP Actelion Pharmaceuticals
DMVPZBE TC Antihypertensive Agents
DMVPZBE DT Small molecular drug
DMVPZBE PC 5311181
DMVPZBE MW 360.5
DMVPZBE FM C22H32O4
DMVPZBE IC InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
DMVPZBE CS CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
DMVPZBE IK HIFJCPQKFCZDDL-ACWOEMLNSA-N
DMVPZBE IU (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMVPZBE CA CAS 78919-13-8
DMVPZBE CB CHEBI:63916
DMVPZBE DE Pulmonary arterial hypertension
DM7RJXL ID DM7RJXL
DM7RJXL DN Imatinib
DM7RJXL HS Approved
DM7RJXL SN Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
DM7RJXL CP Novartis AG
DM7RJXL TC Anticancer Agents
DM7RJXL DT Small molecular drug
DM7RJXL PC 5291
DM7RJXL MW 493.6
DM7RJXL FM C29H31N7O
DM7RJXL IC InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
DM7RJXL CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DM7RJXL IK KTUFNOKKBVMGRW-UHFFFAOYSA-N
DM7RJXL IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DM7RJXL CA CAS 152459-95-5
DM7RJXL CB CHEBI:45783
DM7RJXL DE Chronic myelogenous leukaemia; Systemic mastocytosis; Lung cancer; Intestinal cancer; Acute lymphoblastic leukaemia
DMUL7T1 ID DMUL7T1
DMUL7T1 DN Imidapril
DMUL7T1 HS Approved
DMUL7T1 SN Tanatil (TN)
DMUL7T1 CP Tanabe
DMUL7T1 DT Small molecular drug
DMUL7T1 PC 5464343
DMUL7T1 MW 405.4
DMUL7T1 FM C20H27N3O6
DMUL7T1 IC InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
DMUL7T1 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O
DMUL7T1 IK KLZWOWYOHUKJIG-BPUTZDHNSA-N
DMUL7T1 IU (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
DMUL7T1 CA 89371-37-9
DMUL7T1 DE Cardiovascular disease
DM3VS7Z ID DM3VS7Z
DM3VS7Z DN Imidazole salicylate
DM3VS7Z HS Approved
DM3VS7Z SN Salizolo; Selezen; ITF-182
DM3VS7Z CP Italfarmaco SpA
DM3VS7Z DT Small molecular drug
DM3VS7Z PC 37425
DM3VS7Z MW 206.2
DM3VS7Z FM C10H10N2O3
DM3VS7Z IC InChI=1S/C7H6O3.C3H4N2/c8-6-4-2-1-3-5(6)7(9)10;1-2-5-3-4-1/h1-4,8H,(H,9,10);1-3H,(H,4,5)
DM3VS7Z CS C1=CC=C(C(=C1)C(=O)O)O.C1=CN=CN1
DM3VS7Z IK XCHHJFVNQPPLJK-UHFFFAOYSA-N
DM3VS7Z IU 2-hydroxybenzoic acid;1H-imidazole
DM3VS7Z CA CAS 36364-49-5
DM3VS7Z DE Inflammation
DMI9FBP ID DMI9FBP
DMI9FBP DN Imipenem
DMI9FBP HS Approved
DMI9FBP SN Imipemide; Tienamycin; Imipenem anhydrous; Imipenem (INN); N-Formimidoylthienamycin; Primaxin (TN); Imipenem, N-Formimidoyl thienamycin; [5R-[5.alpha.,6.alpha.(R*)]]-6-(1-Hydroxyethyl)-3-[[2-[(iminomethyl)amino]ethyl]thio]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate; (5R,6S)-3-(2-Formimidoylamino-ethylsulfanyl)-6-((R)-1-hydroxy-ethyl)-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5R,6S)-6-((R)-1-Hydroxyethyl)-3-(2-(iminomethylamino)ethylthio)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carbonsaeure; (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMI9FBP CP Merck & Co
DMI9FBP TC Antibiotics
DMI9FBP DT Small molecular drug
DMI9FBP PC 104838
DMI9FBP MW 299.35
DMI9FBP FM C12H17N3O4S
DMI9FBP IC InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1
DMI9FBP CS C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O
DMI9FBP IK ZSKVGTPCRGIANV-ZXFLCMHBSA-N
DMI9FBP IU (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMI9FBP CA CAS 64221-86-9
DMI9FBP CB CHEBI:471744
DMI9FBP DE Bacterial infection
DM2NUH3 ID DM2NUH3
DM2NUH3 DN Imipramine
DM2NUH3 HS Approved
DM2NUH3 SN Antideprin; Berkomine; Censtim; Censtin; Declomipramine; Dimipressin; Dpid; Dynaprin; Eupramin; Imavate; Imidobenzyle; Imipramin; Imipramina; Imipraminum; Imiprin; Imizin; Imizinum; Impramine; Intalpram; Iramil; Irmin; Janimine; Melipramin; Melipramine; Nelipramin; Norchlorimipramine; Norfranil; Pramine; Prazepine; Promiben;Psychoforin; Surplix; Timolet; Tofranil; Imipramina [Italian]; Tofraniln A; Antideprin (TN); Deprimin (TN); Deprinol (TN); Depsonil (TN); Dyna-zina; Dynaprin (TN); Eupramin (TN); G-22355; Imipramil (TN); Imipramina [INN-Spanish]; Imipramine (INN); Imipramine [INN:BAN]; Imipraminum [INN-Latin]; Irmin (TN); Janimine (TN); Janimine (hydrochloride); Melipramin (TN); SK-Pramine; Surplix (TN); Tofranil(TN); Tofranil (free base); Tofranil (hydrochloride); Tofranil, base; N-(gamma-Dimethylaminopropyl)iminodibenzyl; N-(gamma.-Dimethylaminopropyl)iminodibenzyl; N-(3-Dimethylaminopropyl)-o-iminodibenzyl; 1-(3-Dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine; 10,11-Dihydro-5-(3-(dimethylamino)propyl)-5H-dibenz[b,f]azepine; 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2,2'-(3-Dimethylaminopropylimino)bibenzyl; 2,2'-(3-Dimethylaminopropylimino)dibenzyl; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 5,6-Dihydro-N-(3-(dimethylamino)propyl)-11H-dibenz(b,e)azepine; 5,6-Dihydro-N-[3-(dimethylamino)propyl]-11H-dibenz[b,e]azepine; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(3-Dimethylaminopropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine,5-[3-(dimethylamino)propyl]-10,11-dihydro-mixed with ethyl alcohol; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-(9CI)
DM2NUH3 CP Novartis Pharmaceuticals Corp
DM2NUH3 TC Antidepressants
DM2NUH3 DT Small molecular drug
DM2NUH3 PC 3696
DM2NUH3 MW 280.4
DM2NUH3 FM C19H24N2
DM2NUH3 IC InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
DM2NUH3 CS CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
DM2NUH3 IK BCGWQEUPMDMJNV-UHFFFAOYSA-N
DM2NUH3 IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
DM2NUH3 CA CAS 50-49-7
DM2NUH3 CB CHEBI:47499
DM2NUH3 DE Depression
DM1TMA3 ID DM1TMA3
DM1TMA3 DN Imiquimod
DM1TMA3 HS Approved
DM1TMA3 SN Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
DM1TMA3 CP INova Pharmaceuticals
DM1TMA3 TC Antiviral Agents
DM1TMA3 DT Small molecular drug
DM1TMA3 PC 57469
DM1TMA3 MW 240.3
DM1TMA3 FM C14H16N4
DM1TMA3 IC InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
DM1TMA3 CS CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
DM1TMA3 IK DOUYETYNHWVLEO-UHFFFAOYSA-N
DM1TMA3 IU 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
DM1TMA3 CA CAS 99011-02-6
DM1TMA3 CB CHEBI:36704
DM1TMA3 DE Skin cancer
DMRMFP4 ID DMRMFP4
DMRMFP4 DN Inamrinone Lactate
DMRMFP4 HS Approved
DMRMFP4 SN Amrinone; inamrinone; 60719-84-8; Wincoram; Inocor; Cordemcura; Cartonic; 5-Amino-[3,4'-bipyridin]-6(1H)-one; Amrinonum [INN-Latin]; Amrinonum; Amrinona; Amrinona [INN-Spanish]; 3-Amino-5-(4-pyridinyl)-2(1H)-pyridinone; Win-40680; Amcoral; 5-Amino-(3,4'-bipyridin)-6(1H)-one; WIN 40680; AWD 08-250; 3-amino-5-pyridin-4-yl-1H-pyridin-2-one; UNII-JUT23379TN; CCRIS 3794; Amrinone lactate; MLS000069829; EINECS 262-390-0; 5-amino-3,4'-bipyridin-6(1H)-one; BRN 0744819; 5-Amino(3,4'-bipyridin)-6(1H)-one; SMR000058850; CHEMBL12856; JUT23379TN; Amrinone Lactate
DMRMFP4 CP Sanofi Aventis Us Llc
DMRMFP4 TC Cardiovascular Agents
DMRMFP4 DT Small molecular drug
DMRMFP4 PC 3035194
DMRMFP4 MW 277.28
DMRMFP4 FM C13H15N3O4
DMRMFP4 IC InChI=1S/C10H9N3O.C3H6O3/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7;1-2(4)3(5)6/h1-6H,11H2,(H,13,14);2,4H,1H3,(H,5,6)
DMRMFP4 CS CC(C(=O)O)O.C1=CN=CC=C1C2=CNC(=O)C(=C2)N
DMRMFP4 IK DOSIONJFGDSKCQ-UHFFFAOYSA-N
DMRMFP4 IU 3-amino-5-pyridin-4-yl-1H-pyridin-2-one;2-hydroxypropanoic acid
DMRMFP4 CA CAS 75898-90-7
DMRMFP4 DE Congestive heart failure; Cardiac disease
DM3DSVJ ID DM3DSVJ
DM3DSVJ DN Incadronate
DM3DSVJ HS Approved
DM3DSVJ SN Incadronate; 138330-18-4; Disodium Cycloheptylaminomethylene diphosphonate; Bisphonal; Cimadronate sodium; AC1OCF1R; Incadronic acid sodium salt; C8H17NNa2O6P2; CTK8F9264; RT-012376; YM-21175-1; J-007120; disodium [(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate
DM3DSVJ DT Small molecular drug
DM3DSVJ PC 6918123
DM3DSVJ MW 331.15
DM3DSVJ FM C8H17NNa2O6P2
DM3DSVJ IC InChI=1S/C8H19NO6P2.2Na/c10-16(11,12)8(17(13,14)15)9-7-5-3-1-2-4-6-7;;/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2
DM3DSVJ CS C1CCCC(CC1)NC(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
DM3DSVJ IK PCSJAAWOSGCAFV-UHFFFAOYSA-L
DM3DSVJ IU disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate
DM3DSVJ DE Hypercalcaemia
DMKE6YT ID DMKE6YT
DMKE6YT DN Incobotulinum toxin A
DMKE6YT HS Approved
DMKE6YT SN IncobotulinumtoxinA; Xeomin; NT-201; Botulinum toxin type A extract (blepharospasm), Merz/BioteCon
DMKE6YT CP Merz
DMKE6YT DE Cervical cancer
DM32GSJ ID DM32GSJ
DM32GSJ DN Incruse ellipta
DM32GSJ HS Approved
DM32GSJ SN Umeclidinium bromide; 869113-09-7; Umeclidinium (bromide); GSK573719A; Incruse Ellipta; UNII-7AN603V4JV; 7AN603V4JV; GSK-573719; 1-[2-(Benzyloxy)ethyl]-4-(hydroxydiphenylmethyl)-1-quinuclidinium Bromide; 1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide; CHEMBL523299; Umeclidinium brom; Umeclidinium bromide [USAN:INN]; umeclidinii bromidum; 1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1); 1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2
DM32GSJ CP Glaxosmithkline
DM32GSJ DT Small molecular drug
DM32GSJ PC 11519069
DM32GSJ MW 508.5
DM32GSJ FM C29H34BrNO2
DM32GSJ IC InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
DM32GSJ CS C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
DM32GSJ IK PEJHHXHHNGORMP-UHFFFAOYSA-M
DM32GSJ IU diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide
DM32GSJ CA CAS 869113-09-7
DM32GSJ CB CHEBI:79040
DM32GSJ DE Chronic obstructive pulmonary disease
DMQJHR7 ID DMQJHR7
DMQJHR7 DN Indacaterol
DMQJHR7 HS Approved
DMQJHR7 SN 312753-06-3; QAB149; Arcapta; Onbrez; QAB-149; QAB 149; UNII-8OR09251MQ; 753498-25-8; CHEMBL1095777; CHEBI:68575; 8OR09251MQ; (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one; Indacaterol Maleic Acid Salt; Indacaterol (USAN/INN); Indacaterol [USAN:INN:BAN]; 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one; QAB-149; 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one; Indacaterol/mometasone
DMQJHR7 CP Novartis
DMQJHR7 DT Small molecular drug
DMQJHR7 PC 6918554
DMQJHR7 MW 392.5
DMQJHR7 FM C24H28N2O3
DMQJHR7 IC InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
DMQJHR7 CS CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
DMQJHR7 IK QZZUEBNBZAPZLX-QFIPXVFZSA-N
DMQJHR7 IU 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
DMQJHR7 CA CAS 312753-06-3
DMQJHR7 CB CHEBI:68575
DMQJHR7 DE Chronic obstructive pulmonary disease; Asthma
DMGN1PW ID DMGN1PW
DMGN1PW DN Indapamide
DMGN1PW HS Approved
DMGN1PW SN Arifon; Bajaten; Cormil; Damide; Fludex; Idapamide; Indaflex; Indamol; Indapamida; Indapamidum; Ipamix; Lozide; Lozol; Metindamide; Natrilix; Natrix; Noranat; Pressurai; Tandix; Tertensif; Veroxil; RHC 2555; SE 1520; USV 2555; Apo-Indapamide; Indapamida [INN-Spanish]; Indapamide (USP); Indapamidum [INN-Latin]; Lozol (TN); Natrilix (TN); Natrix (TN); Novo-Indapamide; Nu-Indapamide; S-1520; SE-1520; Indapamide (JAN/USP); Indapamide [USAN:INN:BAN:JAN]; N-[4-Chloro-3-sulfamoylbenzamido]-2-methylindoline; NLozol, Arifon, Fludex, Noranat, Veroxil, Tertensif, Indapamide; N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-(9CI); 1-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline; 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide; 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide; 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
DMGN1PW CP Servier Laboratories
DMGN1PW TC Antihypertensive Agents
DMGN1PW DT Small molecular drug
DMGN1PW PC 3702
DMGN1PW MW 365.8
DMGN1PW FM C16H16ClN3O3S
DMGN1PW IC InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
DMGN1PW CS CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
DMGN1PW IK NDDAHWYSQHTHNT-UHFFFAOYSA-N
DMGN1PW IU 4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
DMGN1PW CA CAS 26807-65-8
DMGN1PW CB CHEBI:5893
DMGN1PW DE Hypertension
DMUV8OR ID DMUV8OR
DMUV8OR DN Indecainide
DMUV8OR HS Approved
DMUV8OR SN Indecainida; Indecainidum; Ricainid; Ricainide; Indecainida [Spanish]; Indecainide [INN]; Indecainidum [Latin]; Decabid (TN); LY-135837; 9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl))fluorene-9-carboxamide; 9-(3-(Isopropylamino)propyl)-9-fluorenylcarboxamid; 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
DMUV8OR CP Eli Lilly And Co
DMUV8OR TC Antidysrhythmic Agents
DMUV8OR DT Small molecular drug
DMUV8OR PC 52195
DMUV8OR MW 308.4
DMUV8OR FM C20H24N2O
DMUV8OR IC InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)
DMUV8OR CS CC(C)NCCCC1(C2=CC=CC=C2C3=CC=CC=C31)C(=O)N
DMUV8OR IK UCEWGESNIULAGX-UHFFFAOYSA-N
DMUV8OR IU 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide
DMUV8OR CA CAS 74517-78-5
DMUV8OR CB CHEBI:135314
DMUV8OR DE Dysrhythmias
DMWO3N6 ID DMWO3N6
DMWO3N6 DN Indeloxazine
DMWO3N6 HS Approved
DMWO3N6 SN Elen; Noin; Indeloxazine hydrochloride; YM-08054
DMWO3N6 CP Yamanouchi Pharmaceutical Co Ltd
DMWO3N6 DT Small molecular drug
DMWO3N6 PC 3704
DMWO3N6 MW 231.29
DMWO3N6 FM C14H17NO2
DMWO3N6 IC InChI=1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2
DMWO3N6 CS C1COC(CN1)COC2=CC=CC3=C2CC=C3
DMWO3N6 IK MADRVGBADLFHMO-UHFFFAOYSA-N
DMWO3N6 IU 2-(3H-inden-4-yloxymethyl)morpholine
DMWO3N6 CA CAS 60929-23-9
DMWO3N6 CB CHEBI:5894
DMWO3N6 DE Dementia
DM0T3YH ID DM0T3YH
DM0T3YH DN Indinavir
DM0T3YH HS Approved
DM0T3YH SN Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
DM0T3YH CP Merck & Co
DM0T3YH TC Anti-HIV Agents
DM0T3YH DT Small molecular drug
DM0T3YH PC 5362440
DM0T3YH MW 613.8
DM0T3YH FM C36H47N5O4
DM0T3YH IC InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1
DM0T3YH CS CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
DM0T3YH IK CBVCZFGXHXORBI-PXQQMZJSSA-N
DM0T3YH IU (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
DM0T3YH CA CAS 150378-17-9
DM0T3YH CB CHEBI:44032
DM0T3YH DE Human immunodeficiency virus infection
DMOPGHQ ID DMOPGHQ
DMOPGHQ DN Indiplon
DMOPGHQ HS Approved
DMOPGHQ SN NBI 34060; NBI-34060; Indiplon (USAN/INN); N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide
DMOPGHQ CP Neurocrine Biosciences
DMOPGHQ DT Small molecular drug
DMOPGHQ PC 6450813
DMOPGHQ MW 376.4
DMOPGHQ FM C20H16N4O2S
DMOPGHQ IC InChI=1S/C20H16N4O2S/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18/h3-12H,1-2H3
DMOPGHQ CS CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4
DMOPGHQ IK CBIAWPMZSFFRGN-UHFFFAOYSA-N
DMOPGHQ IU N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide
DMOPGHQ CA CAS 325715-02-4
DMOPGHQ DE Insomnia; Fibromyalgia
DM2NQUY ID DM2NQUY
DM2NQUY DN Indocyanine green
DM2NQUY HS Approved
DM2NQUY SN indocyanine green; Cardiogreen; 3599-32-4; AC1L2DMU; GTPL4844; KS-00000YFZ; MOLI001001; F9995-0163; sodium 4-(2-((1E,3E,5E,7E)-7-(1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-2(3H)-ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1H-benzo[e]indolium-3-yl)butane-1-sulfonate; sodium 4-[2-[(1E,3E,5E,7Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate; sodium 4-[2-[7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4
DM2NQUY DT Small molecular drug
DM2NQUY PC 11967809
DM2NQUY MW 775
DM2NQUY FM C43H47N2NaO6S2
DM2NQUY IC InChI=1S/C43H48N2O6S2.Na/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51;/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51);/q;+1/p-1
DM2NQUY CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+]
DM2NQUY IK MOFVSTNWEDAEEK-UHFFFAOYSA-M
DM2NQUY IU sodium;4-[(2E)-2-[(2E,4E,6E)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate
DM2NQUY CA CAS 3599-32-4
DM2NQUY DE Gastrointestinal disease
DMSC4A7 ID DMSC4A7
DMSC4A7 DN Indomethacin
DMSC4A7 HS Approved
DMSC4A7 SN Aconip; Amuno; Arthrexin; Artracin; Artrinovo; Artrivia; Bonidin; Bonidon; Catlep; Confortid; Dolcidium; Dolovin; Durametacin; Elmetacin; Hicin; IMN; Idomethine; Imbrilon; Inacid; Indacin; Indameth; Indmethacine; Indocid; Indocin; Indomecol; Indomed; Indomee; Indometacin; Indometacina; Indometacine; Indometacinum; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethegan; Indomethine; Indometicina; Indomo; Indomod; Indoptic; Indoptol; Indorektal; Indoxen; Inflazon; Infrocin; Lausit; Liometacen; Metacen; Metartril; Methazine; Metindol; Mezolin; Miametan; Mikametan; Mobilan; Novomethacin; Reumacide; Sadoreum; Tannex; Vonum; Bonidon Gel; DESMETHYL INDOMETHACIN; Dolcidium PL;Flexin continus; Indocid Pda; Indocid Sr; Indocin Sr; Indolar SR; Indometacyna [Polish]; Indometicina [Spanish]; Inteban sp; Rhemacin LA; Rheumacin LA; I 7378; IN1454; Indomet 140; Aconip (TN); Apo-Indomethacin; Chibro-amuno; Chrono-indicid; Chrono-indocid; Indo-Lemmon; Indo-Spray; Indo-phlogont; Indo-rectolmin; Indo-tablinen; Indocid (TN); Indocid (pharmaceutical); Indocin (TN); Indocin I.V; Indometacina [INN-Spanish]; Indometacine [INN-French]; Indometacinum [INN-Latin]; Indomethacin (USP); Indomethacin [USAN:BAN]; Novo-Methacin; Indochron E-R (TN); Indocin I.V.; Indocin-SR (TN); Indometacin (JP15/INN); Indomethacin & MAP-30; Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
DMSC4A7 CP Recordati Rare Diseases Inc
DMSC4A7 TC Antiinflammatory Agents
DMSC4A7 DT Small molecular drug
DMSC4A7 PC 3715
DMSC4A7 MW 357.8
DMSC4A7 FM C19H16ClNO4
DMSC4A7 IC InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
DMSC4A7 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
DMSC4A7 IK CGIGDMFJXJATDK-UHFFFAOYSA-N
DMSC4A7 IU 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
DMSC4A7 CA CAS 53-86-1
DMSC4A7 CB CHEBI:49662
DMSC4A7 DE Rheumatoid arthritis
DMI0RHA ID DMI0RHA
DMI0RHA DN Inebilizumab
DMI0RHA HS Approved
DMI0RHA CP MedImmune Gaithersburg, MD
DMI0RHA DE Neuromyelitis optica spectrum disorder
DMH7OIA ID DMH7OIA
DMH7OIA DN Infliximab
DMH7OIA HS Approved
DMH7OIA SN Remicade (TN)
DMH7OIA CP Samsung Bioepsis
DMH7OIA TC Immunosuppressive Agents
DMH7OIA DT Antibody
DMH7OIA DE Plaque psoriasis; Rheumatoid arthritis; Asthma
DMK1CZJ ID DMK1CZJ
DMK1CZJ DN Ingenol mebutate
DMK1CZJ HS Approved
DMK1CZJ SN Picato; Ingenol 3-angelate; 75567-37-2; PEP-005; PEP005; 3-Angeloylingenol; UNII-7686S50JAH; PEP 005; 3-Ingenyl angelate; Ingenol-3-angelate; 7686S50JAH; Picato (TN); Euphorbia factor H1; Euphorbia factor An1; Ingenol mebutate [USAN:INN]; [dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[ ]yl] (Z)-2-methylbut-2-enoate; I3A; Ingenol-3- angelate; Ingenol mebutate (USAN); (Z)-2-methylbut-2-enoate; SCHEMBL2526605; GTPL7443; CHEMBL1863513; HSDB 8308; VDJHFHXMUKFKET-WDUFCVPESA-N; MolPort-003-941-761; AN-262; POL-103A
DMK1CZJ CP LEO Pharma
DMK1CZJ DT Small molecular drug
DMK1CZJ PC 6918670
DMK1CZJ MW 430.5
DMK1CZJ FM C25H34O6
DMK1CZJ IC InChI=1S/C25H34O6/c1-7-12(2)22(29)31-21-13(3)10-24-14(4)8-17-18(23(17,5)6)16(20(24)28)9-15(11-26)19(27)25(21,24)30/h7,9-10,14,16-19,21,26-27,30H,8,11H2,1-6H3/b12-7-/t14-,16+,17-,18+,19-,21+,24+,25+/m1/s1
DMK1CZJ CS C/C=C(/C)\\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C
DMK1CZJ IK VDJHFHXMUKFKET-WDUFCVPESA-N
DMK1CZJ IU [(1S,4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] (Z)-2-methylbut-2-enoate
DMK1CZJ CA CAS 75567-37-2
DMK1CZJ CB CHEBI:66913
DMK1CZJ DE Actinic keratosis; Melanoma
DMJ93CT ID DMJ93CT
DMJ93CT DN Inotersen
DMJ93CT HS Approved
DMJ93CT SN UNII-0IEO0F56LV; 0IEO0F56LV; Inotersen [USAN]; ISIS 420915
DMJ93CT CP Ionis Pharmaceuticals
DMJ93CT PC 121492004
DMJ93CT MW 7183
DMJ93CT FM C230H318N69O121P19S19
DMJ93CT IC InChI=1S/C230H318N69O121P19S19/c1-98-53-280(219(312)262-178(98)231)140-43-110(121(382-140)66-364-425(328,444)406-114-47-144(292-90-254-150-183(236)244-85-249-188(150)292)387-126(114)71-368-423(326,442)404-112-45-142(282-59-104(7)197(303)274-225(282)318)383-122(112)67-363-421(324,440)403-111-44-141(281-58-103(6)196(302)273-224(281)317)385-124(111)69-366-427(330,446)410-119-52-149(297-95-260-156-194(297)268-217(242)271-204(156)310)391-130(119)75-372-431(334,450)419-167-139(401-215(177(167)362-42-32-352-22)299-97-261-157-195(299)269-218(243)272-205(157)311)84-381-438(341,457)418-165-136(398-213(175(165)360-40-30-350-20)291-64-109(12)202(308)279-230(291)323)82-379-437(340,456)417-163-135(397-211(173(163)358-38-28-348-18)289-62-107(10)200(306)277-228(289)321)81-378-435(338,454)414-161-132(394-209(171(161)356-36-26-346-16)286-56-101(4)181(234)265-222(286)315)78-375-433(336,452)412-159-120(65-300)392-207(169(159)354-34-24-344-14)288-61-106(9)199(305)276-227(288)320)402-422(325,441)367-70-125-115(48-145(386-125)293-91-255-151-184(237)245-86-250-189(151)293)407-426(329,445)365-68-123-113(46-143(384-123)283-60-105(8)198(304)275-226(283)319)405-424(327,443)371-74-129-118(51-148(390-129)296-94-259-155-193(296)267-216(241)270-203(155)309)409-429(332,448)370-72-127-116(49-146(388-127)294-92-256-152-185(238)246-87-251-190(152)294)408-428(331,447)369-73-128-117(50-147(389-128)295-93-257-153-186(239)247-88-252-191(153)295)411-430(333,449)374-77-138-166(176(361-41-31-351-21)214(400-138)298-96-258-154-187(240)248-89-253-192(154)298)420-439(342,458)380-83-137-164(174(359-39-29-349-19)212(399-137)290-63-108(11)201(307)278-229(290)322)416-436(339,455)377-80-134-162(172(357-37-27-347-17)210(396-134)287-57-102(5)182(235)266-223(287)316)415-434(337,453)376-79-133-160(170(355-35-25-345-15)208(395-133)285-55-100(3)180(233)264-221(285)314)413-432(335,451)373-76-131-158(301)168(353-33-23-343-13)206(393-131)284-54-99(2)179(232)263-220(284)313/h53-64,85-97,110-149,158-177,206-215,300-301H,23-52,65-84H2,1-22H3,(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H,342,458)(H2,231,262,312)(H2,232,263,313)(H2,233,264,314)(H2,234,265,315)(H2,235,266,316)(H2,236,244,249)(H2,237,245,250)(H2,238,246,251)(H2,239,247,252)(H2,240,248,253)(H,273,302,317)(H,274,303,318)(H,275,304,319)(H,276,305,320)(H,277,306,321)(H,278,307,322)(H,279,308,323)(H3,241,267,270,309)(H3,242,268,271,310)(H3,243,269,272,311)/t110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,206+,207+,208+,209+,210+,211+,212+,213+,214+,215+,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?/m0/s1
DMJ93CT CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)O[C@@H]8[C@H](O[C@H]([C@@H]8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
DMJ93CT IK KLEGMTRDCCDFJK-XDQSQZFTSA-N
DMJ93CT IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[hydroxy-[(2R,3R,4R,5R)-2-(hydroxymethyl)-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJ93CT CA CAS 1492984-65-2
DMJ93CT DE Hereditary amyloidosis
DMAC130 ID DMAC130
DMAC130 DN Inotuzumab ozogamicin
DMAC130 HS Approved
DMAC130 CP Pfizer
DMAC130 DT Antibody
DMAC130 DE Acute lymphocytic leukaemia; Acute lymphoblastic leukaemia
DMB7CE0 ID DMB7CE0
DMB7CE0 DN Insulin
DMB7CE0 HS Approved
DMB7CE0 SN BrioDurance; Insulin (agglomerated vesicle technology, diabetes), Cense Biosciences; Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes); Insulin (subcutaneous/nanoparticle/suspension/sustained release formulation, diabetes), Cense Biosciences
DMB7CE0 CP Cense Biosciences Inc
DMB7CE0 SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKT
DMB7CE0 DE Diabetic complication
DMPL395 ID DMPL395
DMPL395 DN Insulin degludec
DMPL395 HS Approved
DMPL395 SN Tresiba (TN)
DMPL395 CP Novo Nordisk
DMPL395 SQ A Chain: FVNQHLCGSHLVEALYLVCGERGFFYTPK >B ChainGIVEQCCTSICSLYQLENYCN
DMPL395 PC 118984462
DMPL395 MW 6104
DMPL395 FM C274H411N65O81S6
DMPL395 IC InChI=1S/C274H411N65O81S6/c1-28-146(23)223(331-210(357)119-275)268(412)335-222(145(21)22)264(408)305-172(89-97-218(369)370)234(378)300-169(84-92-204(279)351)238(382)326-198-131-424-425-132-199-259(403)323-193(126-341)256(400)312-177(103-138(7)8)241(385)313-183(110-154-66-74-160(345)75-67-154)244(388)301-167(82-90-202(277)349)235(379)308-176(102-137(5)6)239(383)303-171(88-96-217(367)368)237(381)320-189(116-205(280)352)251(395)316-185(112-156-70-78-162(347)79-71-156)247(391)327-197(258(402)322-191(273(419)420)118-207(282)354)130-423-422-129-196(231(375)290-122-211(358)295-166(86-94-215(363)364)233(377)299-165(62-53-99-288-274(283)284)229(373)289-123-212(359)297-181(108-152-57-45-41-46-58-152)243(387)315-182(109-153-59-47-42-48-60-153)246(390)317-186(113-157-72-80-163(348)81-73-157)254(398)338-226(150(27)344)270(414)339-100-54-63-201(339)262(406)306-173(271(415)416)61-51-52-98-287-208(355)93-85-174(272(417)418)296-209(356)64-49-38-36-34-32-30-31-33-35-37-39-50-65-214(361)362)329-266(410)221(144(19)20)334-252(396)179(105-140(11)12)310-245(389)184(111-155-68-76-161(346)77-69-155)314-240(384)175(101-136(3)4)307-227(371)148(25)294-232(376)170(87-95-216(365)366)304-263(407)220(143(17)18)333-253(397)180(106-141(13)14)311-249(393)188(115-159-121-286-135-293-159)319-255(399)192(125-340)298-213(360)124-291-230(374)195(128-421-426-133-200(328-260(198)404)261(405)337-225(149(26)343)269(413)324-194(127-342)257(401)336-224(147(24)29-2)267(411)330-199)325-242(386)178(104-139(9)10)309-248(392)187(114-158-120-285-134-292-158)318-236(380)168(83-91-203(278)350)302-250(394)190(117-206(281)353)321-265(409)219(142(15)16)332-228(372)164(276)107-151-55-43-40-44-56-151/h40-48,55-60,66-81,120-121,134-150,164-201,219-226,340-348H,28-39,49-54,61-65,82-119,122-133,275-276H2,1-27H3,(H2,277,349)(H2,278,350)(H2,279,351)(H2,280,352)(H2,281,353)(H2,282,354)(H,285,292)(H,286,293)(H,287,355)(H,289,373)(H,290,375)(H,291,374)(H,294,376)(H,295,358)(H,296,356)(H,297,359)(H,298,360)(H,299,377)(H,300,378)(H,301,388)(H,302,394)(H,303,383)(H,304,407)(H,305,408)(H,306,406)(H,307,371)(H,308,379)(H,309,392)(H,310,389)(H,311,393)(H,312,400)(H,313,385)(H,314,384)(H,315,387)(H,316,395)(H,317,390)(H,318,380)(H,319,399)(H,320,381)(H,321,409)(H,322,402)(H,323,403)(H,324,413)(H,325,386)(H,326,382)(H,327,391)(H,328,404)(H,329,410)(H,330,411)(H,331,357)(H,332,372)(H,333,397)(H,334,396)(H,335,412)(H,336,401)(H,337,405)(H,338,398)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,415,416)(H,417,418)(H,419,420)(H4,283,284,288)/t146-,147-,148-,149+,150+,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,219-,220-,221-,222-,223-,224-,225-,226-/m0/s1
DMPL395 CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMPL395 IK FYZPCMFQCNBYCY-WIWKJPBBSA-N
DMPL395 IU 16-[[(1S)-4-[[(5S)-5-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carboxypentyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid
DMPL395 CA CAS 844439-96-9
DMPL395 DE Type-1/2 diabetes
DM79NZ5 ID DM79NZ5
DM79NZ5 DN Insulin determir
DM79NZ5 HS Approved
DM79NZ5 SN Levemir (TN)
DM79NZ5 DE Diabetic complication
DM5XHVR ID DM5XHVR
DM5XHVR DN Insulin Lyspro recombinant
DM5XHVR HS Approved
DM5XHVR TC Hypoglycemic Agents
DM5XHVR DE Diabetic complication
DMYVP5G ID DMYVP5G
DMYVP5G DN Insulin recombinant
DMYVP5G HS Approved
DMYVP5G SN 9004-10-8; Exubera; Insulin recombinant; Endopancrine; Humilin; Dermulin; Decurvon; Musulin; Iszilin; Insulyl; Insular; Iletin; insulin-human; Dal-insulinum; Intesulin B; Insulin, dalanated; Insulina dalanatada; AERx; Insulinum dalanatum; insulin (recombinant); Imusay-131; INSULIN INJECTION; Insulini injectio neutralis; Insulina iniettabile neutra; Injectable insulini neutrale; Inyectable neutro de insulina; CHEBI:5931; CCRIS 5464; Insulinum dalanatum [INN-Latin]; HSDB 3102; Insulin, dalanated [USAN:INN]; AERx [Insulin management system]
DMYVP5G TC Hypoglycemic Agents
DMYVP5G DT Small molecular drug
DMYVP5G PC 70678557
DMYVP5G MW 5794
DMYVP5G FM C256H381N65O77S6
DMYVP5G IC InChI=1S/C256H381N65O77S6/c1-29-130(23)202(311-190(337)103-258)250(391)315-200(128(19)20)246(387)286-158(75-82-197(347)348)216(357)281-154(70-77-186(261)333)220(361)306-181-115-402-403-116-182-241(382)303-176(110-323)238(379)293-161(88-122(7)8)224(365)294-167(95-139-53-61-145(328)62-54-139)227(368)282-153(69-76-185(260)332)217(358)289-160(87-121(5)6)222(363)283-157(74-81-196(345)346)219(360)301-173(101-188(263)335)233(374)297-169(97-141-57-65-147(330)66-58-141)230(371)307-180(240(381)302-174(254(395)396)102-189(264)336)114-401-400-113-179(213(354)272-106-191(338)277-152(72-79-194(341)342)215(356)280-150(51-42-84-270-256(266)267)211(352)271-107-192(339)278-165(93-137-46-36-32-37-47-137)226(367)296-166(94-138-48-38-33-39-49-138)229(370)298-170(98-142-59-67-148(331)68-60-142)236(377)318-205(134(27)326)253(394)321-85-43-52-184(321)244(385)284-151(50-40-41-83-257)221(362)319-206(135(28)327)255(397)398)309-247(388)199(127(17)18)314-234(375)163(90-124(11)12)291-228(369)168(96-140-55-63-146(329)64-56-140)295-223(364)159(86-120(3)4)288-209(350)132(25)276-214(355)156(73-80-195(343)344)285-245(386)198(126(15)16)313-235(376)164(91-125(13)14)292-232(373)172(100-144-105-269-119-275-144)300-237(378)175(109-322)279-193(340)108-273-212(353)178(112-399-404-117-183(308-242(181)383)243(384)317-204(133(26)325)251(392)304-177(111-324)239(380)316-203(131(24)30-2)249(390)310-182)305-225(366)162(89-123(9)10)290-231(372)171(99-143-104-268-118-274-143)299-218(359)155(71-78-187(262)334)287-252(393)207(208(265)349)320-248(389)201(129(21)22)312-210(351)149(259)92-136-44-34-31-35-45-136/h31-39,44-49,53-68,104-105,118-135,149-184,198-207,322-331H,29-30,40-43,50-52,69-103,106-117,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,349)(H,268,274)(H,269,275)(H,271,352)(H,272,354)(H,273,353)(H,276,355)(H,277,338)(H,278,339)(H,279,340)(H,280,356)(H,281,357)(H,282,368)(H,283,363)(H,284,385)(H,285,386)(H,286,387)(H,287,393)(H,288,350)(H,289,358)(H,290,372)(H,291,369)(H,292,373)(H,293,379)(H,294,365)(H,295,364)(H,296,367)(H,297,374)(H,298,370)(H,299,359)(H,300,378)(H,301,360)(H,302,381)(H,303,382)(H,304,392)(H,305,366)(H,306,361)(H,307,371)(H,308,383)(H,309,388)(H,310,390)(H,311,337)(H,312,351)(H,313,376)(H,314,375)(H,315,391)(H,316,380)(H,317,384)(H,318,377)(H,319,362)(H,320,389)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,395,396)(H,397,398)(H4,266,267,270)/t130-,131-,132+,133+,134+,135+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182-,183+,184+,198+,199+,200+,201+,202+,203+,204+,205+,206+,207+/m1/s1
DMYVP5G CS CC[C@@H](C)[C@H]1C(=O)N[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](C)CC)NC(=O)CN
DMYVP5G IK YAJCHEVQCOHZDC-QMMNLEPNSA-N
DMYVP5G IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-oxopropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2R)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1S)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S,2S)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMYVP5G CA CAS 9004-10-8
DMYVP5G DE Diabetic complication
DMW8KI7 ID DMW8KI7
DMW8KI7 DN Insulin Susp Isophane Recombinant Human
DMW8KI7 HS Approved
DMW8KI7 SN Nph Insulin; Nph Iletin I (Beef-pork); Nph Iletin Ii; Insulin Insulatard Nph Nordisk; Nph Iletin Ii (Pork); Nph Purified Pork Isophane Insulin; Humulin N; Novolin N; Insulatard Nph Human; Insulin Susp Isophane Beef; Insulin Susp Isophane Beef/Pork; Insulin Susp Isophane Purified Beef; Insulin Susp Isophane Purified Pork; Insulin Susp Isophane Semisynthetic Purified Human
DMW8KI7 CP Eli Lilly And Co
DMW8KI7 DE Diabetic complication
DM0NATE ID DM0NATE
DM0NATE DN Insulin Susp Protamine Zinc Beef/Pork
DM0NATE HS Approved
DM0NATE SN Protamine Zinc & Iletin I (Beef-pork); Protamine Zinc And Iletin Ii; Protamine Zinc Insulin; Protamine Zinc And Iletin Ii (Pork); Insulin Susp Protamine Zinc Purified Beef; Insulin Susp Protamine Zinc Purified Pork
DM0NATE CP Eli Lilly And Co
DM0NATE DE Diabetic complication
DM6MO9X ID DM6MO9X
DM6MO9X DN Insulin Zinc Susp Recombinant Human
DM6MO9X HS Approved
DM6MO9X SN Humulin L; Humulin U; Lentard; Lente; Lente Iletin Ii; Lente Iletin Ii (Pork); Lente Insulin; Novolin L; Semilente; Semilente Insulin; Ultralente; Ultralente Insulin; Insulin Zinc Susp Beef; Insulin Zinc Susp Extended Beef; Insulin Zinc Susp Extended Purified Beef; Insulin Zinc Susp Extended Recombinant Human; Insulin Zinc Susp Prompt Beef; Insulin Zinc Susp Prompt Purified Pork; Insulin Zinc Susp Purified Beef; Insulin Zinc Susp Purified Beef/Pork; Insulin Zinc Susp Purified Pork; Insulin Zinc Susp Semisynthetic Purified Human
DM6MO9X CP Eli Lilly And Co
DM6MO9X DE Diabetic complication
DMO95XI ID DMO95XI
DMO95XI DN Insulin, porcine
DMO95XI HS Approved
DMO95XI SN Velosulin; Hog insulin; Insulin [pig]; Insulin porcine; Neutral insulin; Pig insulin; Porcine insulin; Swine insulin; A neutral, buffered solution of pork insulin; Insulin (Alopex lagopus); Insulin (Canis familiaris); Insulin (Physeter catodon); Insulin (dog); Insulin (ox); Insulin (pig); Insulin (porcine); Insulin (sperm whale); Insulin (swine); Insulin [USAN:JAN]; Insulin, neutral; Insulin,pig; Insulin (Ox), 8A-L-threonine-10A-L-isoleucine-(9CI); 8A-L-Threonine-10A-L-isoleucineinsulin (ox)
DMO95XI TC Hypoglycemic Agents
DMO95XI DT Small molecular drug
DMO95XI PC 16131098
DMO95XI MW 5778
DMO95XI FM C256H381N65O76S6
DMO95XI IC InChI=1S/C256H381N65O76S6/c1-29-131(23)205(313-193(337)104-258)251(391)317-204(130(21)22)247(387)288-159(75-82-200(347)348)217(357)282-156(71-78-189(262)333)221(361)308-183-116-401-402-117-184-242(382)305-178(111-323)239(379)294-162(88-123(7)8)224(364)295-168(95-140-53-61-146(327)62-54-140)227(367)283-154(69-76-187(260)331)218(358)290-161(87-122(5)6)222(362)285-158(74-81-199(345)346)220(360)302-174(101-190(263)334)234(374)298-170(97-142-57-65-148(329)66-58-142)230(370)309-182(241(381)304-176(255(396)397)103-192(265)336)115-400-399-114-181(213(353)272-107-194(338)278-153(72-79-197(341)342)216(356)281-151(51-42-84-270-256(266)267)211(351)271-108-195(339)279-166(93-138-46-36-32-37-47-138)226(366)297-167(94-139-48-38-33-39-49-139)229(369)299-171(98-143-59-67-149(330)68-60-143)237(377)320-208(136(28)326)253(393)321-85-43-52-186(321)245(385)286-152(50-40-41-83-257)214(354)277-134(26)254(394)395)311-249(389)203(129(19)20)316-235(375)164(90-125(11)12)292-228(368)169(96-141-55-63-147(328)64-56-141)296-223(363)160(86-121(3)4)289-209(349)133(25)276-215(355)157(73-80-198(343)344)287-246(386)202(128(17)18)315-236(376)165(91-126(13)14)293-232(372)173(100-145-106-269-120-275-145)301-238(378)177(110-322)280-196(340)109-273-212(352)180(113-398-403-118-185(310-243(183)383)244(384)319-207(135(27)325)252(392)306-179(112-324)240(380)318-206(132(24)30-2)250(390)312-184)307-225(365)163(89-124(9)10)291-231(371)172(99-144-105-268-119-274-144)300-219(359)155(70-77-188(261)332)284-233(373)175(102-191(264)335)303-248(388)201(127(15)16)314-210(350)150(259)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-208,322-330H,29-30,40-43,50-52,69-104,107-118,257-259H2,1-28H3,(H2,260,331)(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H,268,274)(H,269,275)(H,271,351)(H,272,353)(H,273,352)(H,276,355)(H,277,354)(H,278,338)(H,279,339)(H,280,340)(H,281,356)(H,282,357)(H,283,367)(H,284,373)(H,285,362)(H,286,385)(H,287,386)(H,288,387)(H,289,349)(H,290,358)(H,291,371)(H,292,368)(H,293,372)(H,294,379)(H,295,364)(H,296,363)(H,297,366)(H,298,374)(H,299,369)(H,300,359)(H,301,378)(H,302,360)(H,303,388)(H,304,381)(H,305,382)(H,306,392)(H,307,365)(H,308,361)(H,309,370)(H,310,383)(H,311,389)(H,312,390)(H,313,337)(H,314,350)(H,315,376)(H,316,375)(H,317,391)(H,318,380)(H,319,384)(H,320,377)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,394,395)(H,396,397)(H4,266,267,270)/t131-,132-,133-,134-,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1
DMO95XI CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMO95XI IK NOESYZHRGYRDHS-ZYCCASTOSA-N
DMO95XI IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-5-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(1S)-1-carboxyethyl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMO95XI CA CAS 12584-58-6
DMO95XI DE Diabetic complication
DMX7V28 ID DMX7V28
DMX7V28 DN Insulin-aspart
DMX7V28 HS Approved
DMX7V28 SN Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human)
DMX7V28 TC Hypoglycemic Agents
DMX7V28 DT Small molecular drug
DMX7V28 SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVNQHLCGSHLVEALYLVCGERGFFYTDKT
DMX7V28 PC 118984445
DMX7V28 MW 5826
DMX7V28 FM C256H381N65O79S6
DMX7V28 IC InChI=1S/C256H381N65O79S6/c1-29-129(23)204(313-191(338)102-258)251(394)317-203(128(21)22)247(390)287-157(73-80-198(348)349)216(359)282-154(69-76-187(262)334)220(363)308-182-114-404-405-115-183-243(386)305-177(109-323)240(383)293-160(85-121(7)8)224(367)294-166(92-138-51-59-144(328)60-52-138)227(370)283-152(67-74-185(260)332)217(360)289-159(84-120(5)6)222(365)285-156(72-79-197(346)347)219(362)301-172(98-188(263)335)234(377)297-168(94-140-55-63-146(330)64-56-140)230(373)309-181(242(385)304-175(254(397)398)100-190(265)337)113-403-402-112-180(213(356)272-105-192(339)277-151(70-77-195(342)343)215(358)280-149(50-42-82-270-256(266)267)211(354)271-106-193(340)278-164(90-136-45-36-32-37-46-136)226(369)296-165(91-137-47-38-33-39-48-137)229(372)298-169(95-141-57-65-147(331)66-58-141)238(381)319-206(132(26)325)252(395)303-174(101-199(350)351)235(378)281-150(49-40-41-81-257)221(364)321-208(134(28)327)255(399)400)311-249(392)202(127(19)20)316-236(379)162(87-123(11)12)291-228(371)167(93-139-53-61-145(329)62-54-139)295-223(366)158(83-119(3)4)288-209(352)131(25)276-214(357)155(71-78-196(344)345)286-246(389)201(126(17)18)315-237(380)163(88-124(13)14)292-232(375)171(97-143-104-269-118-275-143)300-239(382)176(108-322)279-194(341)107-273-212(355)179(111-401-406-116-184(310-244(182)387)245(388)320-207(133(27)326)253(396)306-178(110-324)241(384)318-205(130(24)30-2)250(393)312-183)307-225(368)161(86-122(9)10)290-231(374)170(96-142-103-268-117-274-142)299-218(361)153(68-75-186(261)333)284-233(376)173(99-189(264)336)302-248(391)200(125(15)16)314-210(353)148(259)89-135-43-34-31-35-44-135/h31-39,43-48,51-66,103-104,117-134,148-184,200-208,322-331H,29-30,40-42,49-50,67-102,105-116,257-259H2,1-28H3,(H2,260,332)(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H,268,274)(H,269,275)(H,271,354)(H,272,356)(H,273,355)(H,276,357)(H,277,339)(H,278,340)(H,279,341)(H,280,358)(H,281,378)(H,282,359)(H,283,370)(H,284,376)(H,285,365)(H,286,389)(H,287,390)(H,288,352)(H,289,360)(H,290,374)(H,291,371)(H,292,375)(H,293,383)(H,294,367)(H,295,366)(H,296,369)(H,297,377)(H,298,372)(H,299,361)(H,300,382)(H,301,362)(H,302,391)(H,303,395)(H,304,385)(H,305,386)(H,306,396)(H,307,368)(H,308,363)(H,309,373)(H,310,387)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,380)(H,316,379)(H,317,394)(H,318,384)(H,319,381)(H,320,388)(H,321,364)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,266,267,270)/t129-,130-,131-,132+,133+,134+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,200-,201-,202-,203-,204-,205-,206-,207-,208-/m0/s1
DMX7V28 CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC8=CC=C(C=C8)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC9=CNC=N9)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMX7V28 IK WEDIKSVWBUKTRA-WTKGVUNUSA-N
DMX7V28 IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMX7V28 CA CAS 116094-23-6
DMX7V28 DE Diabetic complication
DMOA4VW ID DMOA4VW
DMOA4VW DN Insulin-detemir
DMOA4VW HS Approved
DMOA4VW SN Insulin detemir; UNII-4FT78T86XV; 4FT78T86XV; NN-304; Levemir; Levemir Penfill; Levemir Insulin; Levemir Innolet; Levemir Flexpen; 169148-63-4; Insulin detemir [USAN:INN:BAN]; NN304; NN 304; CHEMBL2104391; INSULIN DETEMIR RECOMBINANT; 29B-(N6-Myristoyl-L-lysine)-30B-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-Myristoyl-L-lysine)-30(sup B)-de-L-threonineinsulin (human); 29(sup B)-(N(sup 6)-(1-Oxotetradecyl)-L-lysine)-(1(sup A)-21(sup A)),(1(sup B)-29(sup B))-insulin (human); 270588-25-5
DMOA4VW TC Hypoglycemic Agents
DMOA4VW DT Small molecular drug
DMOA4VW SQ GIVEQCCTSICSLYQLENYCNFVNQHLCGSHLVEALYLVCGERGFFYTPK
DMOA4VW PC 16137271
DMOA4VW MW 5917
DMOA4VW FM C267H402N64O76S6
DMOA4VW IC InChI=1S/C267H402N64O76S6/c1-29-32-33-34-35-36-37-38-39-40-50-64-204(347)280-95-52-51-61-170(265(404)405)298-256(395)197-63-54-97-331(197)264(403)220(147(28)336)330-248(387)182(110-154-71-79-160(340)80-72-154)309-240(379)178(106-150-59-48-43-49-60-150)307-237(376)177(105-149-57-46-42-47-58-149)289-207(350)120-282-223(362)162(62-53-96-281-267(276)277)291-227(366)163(84-91-209(352)353)288-206(349)119-283-225(364)192-126-409-410-127-193(252(391)314-187(266(406)407)115-203(275)346)319-241(380)181(109-153-69-77-159(339)78-70-153)308-245(384)185(113-201(273)344)312-231(370)168(86-93-211(356)357)295-233(372)172(99-134(6)7)300-229(368)164(81-88-198(270)341)293-238(377)179(107-151-65-73-157(337)74-66-151)305-235(374)173(100-135(8)9)304-250(389)189(123-333)315-253(392)195-129-412-411-128-194(318-232(371)166(83-90-200(272)343)292-228(367)169(87-94-212(358)359)297-258(397)216(142(22)23)327-262(401)217(143(24)30-2)323-205(348)116-268)254(393)320-196(255(394)329-219(146(27)335)263(402)316-190(124-334)251(390)328-218(144(25)31-3)261(400)322-195)130-413-408-125-191(317-236(375)174(101-136(10)11)301-242(381)183(111-155-117-278-131-285-155)310-230(369)165(82-89-199(271)342)294-244(383)186(114-202(274)345)313-259(398)213(139(16)17)324-222(361)161(269)104-148-55-44-41-45-56-148)224(363)284-121-208(351)290-188(122-332)249(388)311-184(112-156-118-279-132-286-156)243(382)303-176(103-138(14)15)247(386)325-214(140(18)19)257(396)296-167(85-92-210(354)355)226(365)287-145(26)221(360)299-171(98-133(4)5)234(373)306-180(108-152-67-75-158(338)76-68-152)239(378)302-175(102-137(12)13)246(385)326-215(141(20)21)260(399)321-192/h41-49,55-60,65-80,117-118,131-147,161-197,213-220,332-340H,29-40,50-54,61-64,81-116,119-130,268-269H2,1-28H3,(H2,270,341)(H2,271,342)(H2,272,343)(H2,273,344)(H2,274,345)(H2,275,346)(H,278,285)(H,279,286)(H,280,347)(H,282,362)(H,283,364)(H,284,363)(H,287,365)(H,288,349)(H,289,350)(H,290,351)(H,291,366)(H,292,367)(H,293,377)(H,294,383)(H,295,372)(H,296,396)(H,297,397)(H,298,395)(H,299,360)(H,300,368)(H,301,381)(H,302,378)(H,303,382)(H,304,389)(H,305,374)(H,306,373)(H,307,376)(H,308,384)(H,309,379)(H,310,369)(H,311,388)(H,312,370)(H,313,398)(H,314,391)(H,315,392)(H,316,402)(H,317,375)(H,318,371)(H,319,380)(H,320,393)(H,321,399)(H,322,400)(H,323,348)(H,324,361)(H,325,386)(H,326,385)(H,327,401)(H,328,390)(H,329,394)(H,330,387)(H,352,353)(H,354,355)(H,356,357)(H,358,359)(H,404,405)(H,406,407)(H4,276,277,281)/t143-,144-,145-,146+,147+,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,213-,214-,215-,216-,217-,218-,219-,220-/m0/s1
DMOA4VW CS CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)C(C)C)CC(C)C)CC7=CC=C(C=C7)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC8=CNC=N8)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC9=CNC=N9)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)[C@@H](C)CC)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN)CO)CC(C)C)CC1=CC=C(C=C1)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O
DMOA4VW IK UGOZVNFCFYTPAZ-IOXYNQHNSA-N
DMOA4VW IU (2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-6-(tetradecanoylamino)hexanoic acid
DMOA4VW CA CAS 169148-63-4
DMOA4VW DE Type-1/2 diabetes
DMR4HIW ID DMR4HIW
DMR4HIW DN Insulin-glargine
DMR4HIW HS Approved
DMR4HIW SN Glargine; Lantus; SoloStar; SoloStar [Insulin delivery pen]; A21-Gly-B31-Arg-B32-Arg-insulin
DMR4HIW TC Hypoglycemic Agents
DMR4HIW DT Small molecular drug
DMR4HIW SQ A chain: GIVEQCCTSICSLYQLENYCG >B chainFVNQHLCGSHLVEALYLVCGERGFFYTPKTRR
DMR4HIW PC 118984454
DMR4HIW MW 6063
DMR4HIW FM C267H404N72O78S6
DMR4HIW IC InChI=1S/C267H404N72O78S6/c1-29-137(23)212(330-199(355)109-269)260(412)334-211(136(21)22)256(408)305-166(79-86-206(365)366)226(378)298-163(75-82-196(273)352)230(382)326-190-122-421-422-123-191-251(403)322-185(117-341)249(401)312-170(94-129(7)8)234(386)313-176(101-146-57-65-152(346)66-58-146)237(389)299-161(73-80-194(271)350)227(379)308-169(93-128(5)6)232(384)301-165(78-85-205(363)364)229(381)320-182(107-197(274)353)244(396)316-178(103-148-61-69-154(348)70-62-148)240(392)325-188(222(374)290-115-207(367)368)120-418-420-121-189(221(373)288-112-200(356)294-160(76-83-203(359)360)225(377)297-157(53-42-88-284-265(276)277)219(371)287-113-201(357)295-174(99-144-48-36-32-37-49-144)236(388)315-175(100-145-50-38-33-39-51-145)239(391)317-179(104-149-63-71-155(349)72-64-149)247(399)338-216(142(28)345)263(415)339-91-45-56-193(339)254(406)302-158(52-40-41-87-268)231(383)336-214(140(26)343)261(413)303-159(54-43-89-285-266(278)279)224(376)306-167(264(416)417)55-44-90-286-267(280)281)328-258(410)210(135(19)20)333-245(397)172(96-131(11)12)310-238(390)177(102-147-59-67-153(347)68-60-147)314-233(385)168(92-127(3)4)307-217(369)139(25)293-223(375)164(77-84-204(361)362)304-255(407)209(134(17)18)332-246(398)173(97-132(13)14)311-242(394)181(106-151-111-283-126-292-151)319-248(400)184(116-340)296-202(358)114-289-220(372)187(119-419-423-124-192(327-252(190)404)253(405)337-215(141(27)344)262(414)323-186(118-342)250(402)335-213(138(24)30-2)259(411)329-191)324-235(387)171(95-130(9)10)309-241(393)180(105-150-110-282-125-291-150)318-228(380)162(74-81-195(272)351)300-243(395)183(108-198(275)354)321-257(409)208(133(15)16)331-218(370)156(270)98-143-46-34-31-35-47-143/h31-39,46-51,57-72,110-111,125-142,156-193,208-216,340-349H,29-30,40-45,52-56,73-109,112-124,268-270H2,1-28H3,(H2,271,350)(H2,272,351)(H2,273,352)(H2,274,353)(H2,275,354)(H,282,291)(H,283,292)(H,287,371)(H,288,373)(H,289,372)(H,290,374)(H,293,375)(H,294,356)(H,295,357)(H,296,358)(H,297,377)(H,298,378)(H,299,389)(H,300,395)(H,301,384)(H,302,406)(H,303,413)(H,304,407)(H,305,408)(H,306,376)(H,307,369)(H,308,379)(H,309,393)(H,310,390)(H,311,394)(H,312,401)(H,313,386)(H,314,385)(H,315,388)(H,316,396)(H,317,391)(H,318,380)(H,319,400)(H,320,381)(H,321,409)(H,322,403)(H,323,414)(H,324,387)(H,325,392)(H,326,382)(H,327,404)(H,328,410)(H,329,411)(H,330,355)(H,331,370)(H,332,398)(H,333,397)(H,334,412)(H,335,402)(H,336,383)(H,337,405)(H,338,399)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,416,417)(H4,276,277,284)(H4,278,279,285)(H4,280,281,286)/t137-,138-,139-,140+,141+,142+,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,208-,209-,210-,211-,212-,213-,214-,215-,216-/m0/s1
DMR4HIW CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NCC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMR4HIW IK COCFEDIXXNGUNL-RFKWWTKHSA-N
DMR4HIW IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-47-(carboxymethylcarbamoyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMR4HIW CA CAS 160337-95-1
DMR4HIW DE Malaria; Type-1 diabetes; Type-2 diabetes; Diabetic complication
DMQI0FU ID DMQI0FU
DMQI0FU DN Insulin-glulisine
DMQI0FU HS Approved
DMQI0FU TC Hypoglycemic Agents
DMQI0FU SQ A chain: GIVEQCCTSICSLYQLENYCN >B chainFVKQHLCGSHLVEALYLVCGERGFFYTPET
DMQI0FU PC 16136701
DMQI0FU MW 5823
DMQI0FU FM C258H384N64O78S6
DMQI0FU IC InChI=1S/C258H384N64O78S6/c1-29-132(23)206(313-193(338)105-260)253(394)317-205(131(21)22)250(391)289-160(75-83-200(348)349)219(360)283-157(71-79-190(264)335)223(364)308-184-117-404-405-118-185-244(385)305-179(112-324)241(382)295-164(90-124(7)8)227(368)296-170(97-141-53-61-147(329)62-54-141)230(371)284-156(70-78-189(263)334)220(361)291-163(89-123(5)6)225(366)285-159(74-82-199(346)347)222(363)303-176(103-191(265)336)236(377)299-172(99-143-57-65-149(331)66-58-143)233(374)309-183(243(384)304-177(256(397)398)104-192(266)337)116-403-402-115-182(215(356)273-108-194(339)278-154(72-80-197(342)343)218(359)281-152(51-42-86-271-258(267)268)213(354)272-109-195(340)279-168(95-139-46-36-32-37-47-139)229(370)298-169(96-140-48-38-33-39-49-140)232(373)300-173(100-144-59-67-150(332)68-60-144)239(380)320-209(136(27)327)255(396)322-87-43-52-187(322)247(388)286-161(76-84-201(350)351)224(365)321-210(137(28)328)257(399)400)311-251(392)204(130(19)20)316-237(378)166(92-126(11)12)293-231(372)171(98-142-55-63-148(330)64-56-142)297-226(367)162(88-122(3)4)290-211(352)134(25)277-216(357)158(73-81-198(344)345)288-249(390)203(129(17)18)315-238(379)167(93-127(13)14)294-235(376)175(102-146-107-270-121-276-146)302-240(381)178(111-323)280-196(341)110-274-214(355)181(114-401-406-119-186(310-245(184)386)246(387)319-208(135(26)326)254(395)306-180(113-325)242(383)318-207(133(24)30-2)252(393)312-185)307-228(369)165(91-125(9)10)292-234(375)174(101-145-106-269-120-275-145)301-221(362)155(69-77-188(262)333)282-217(358)153(50-40-41-85-259)287-248(389)202(128(15)16)314-212(353)151(261)94-138-44-34-31-35-45-138/h31-39,44-49,53-68,106-107,120-137,151-187,202-210,323-332H,29-30,40-43,50-52,69-105,108-119,259-261H2,1-28H3,(H2,262,333)(H2,263,334)(H2,264,335)(H2,265,336)(H2,266,337)(H,269,275)(H,270,276)(H,272,354)(H,273,356)(H,274,355)(H,277,357)(H,278,339)(H,279,340)(H,280,341)(H,281,359)(H,282,358)(H,283,360)(H,284,371)(H,285,366)(H,286,388)(H,287,389)(H,288,390)(H,289,391)(H,290,352)(H,291,361)(H,292,375)(H,293,372)(H,294,376)(H,295,382)(H,296,368)(H,297,367)(H,298,370)(H,299,377)(H,300,373)(H,301,362)(H,302,381)(H,303,363)(H,304,384)(H,305,385)(H,306,395)(H,307,369)(H,308,364)(H,309,374)(H,310,386)(H,311,392)(H,312,393)(H,313,338)(H,314,353)(H,315,379)(H,316,378)(H,317,394)(H,318,383)(H,319,387)(H,320,380)(H,321,365)(H,342,343)(H,344,345)(H,346,347)(H,348,349)(H,350,351)(H,397,398)(H,399,400)(H4,267,268,271)/t132-,133-,134-,135+,136+,137+,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,202-,203-,204-,205-,206-,207-,208-,209-,210-/m0/s1
DMQI0FU CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DMQI0FU IK RCHHVVGSTHAVPF-ZPHPLDECSA-N
DMQI0FU IU (4S)-4-[[2-[[(1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,77S,80S,83S,88R)-88-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-47-[[(1S)-3-amino-1-carboxy-3-oxopropyl]carbamoyl]-53-(2-amino-2-oxoethyl)-62-(3-amino-3-oxopropyl)-77-[(2S)-butan-2-yl]-24,56-bis(2-carboxyethyl)-83-[(1R)-1-hydroxyethyl]-12,71,80-tris(hydroxymethyl)-33,50,65-tris[(4-hydroxyphenyl)methyl]-15-(1H-imidazol-4-ylmethyl)-27-methyl-18,30,36,59,68-pentakis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,39-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-42-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQI0FU CA CAS 207748-29-6
DMQI0FU DE Diabetic complication
DM4O90W ID DM4O90W
DM4O90W DN Insulin-lispro
DM4O90W HS Approved
DM4O90W SN WNRQPCUGRUFHED-DETKDSODSA-N; Insulin lispro [USAN:BAN:INN]; Humalog (TN); Insulin Lispro
DM4O90W CP Eli Lilly
DM4O90W TC Hypoglycemic Agents
DM4O90W DT Small molecular drug
DM4O90W PC 16132438
DM4O90W MW 5814
DM4O90W FM C257H389N65O77S6
DM4O90W IC InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
DM4O90W CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN.C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O
DM4O90W IK WNRQPCUGRUFHED-DETKDSODSA-N
DM4O90W IU (4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM4O90W CA CAS 133107-64-9
DM4O90W DE Diabetic complication
DMSTA36 ID DMSTA36
DMSTA36 DN Intedanib
DMSTA36 HS Approved
DMSTA36 SN Nintedanib; Vargatef; 656247-17-5; BIBF-1120; BIBF 1120; 928326-83-4; BIBF1120; Nintedanib (BIBF 1120); OFEV; UNII-G6HRD2P839; (Z)-methyl 3-((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate; G6HRD2P839; CHEBI:85164; 1160294-26-7; Methyl (3z)-3-{[(4-{methyl[(4-Methylpiperazin-1-Yl)acetyl]amino}phenyl)amino](Phenyl)methylidene}-2-Oxo-2,3-Dihydro-1h-Indole-6-Carboxylate
DMSTA36 CP Boehringer Ingelheim Pharmaceuticals
DMSTA36 DT Small molecular drug
DMSTA36 PC 135423438
DMSTA36 MW 539.6
DMSTA36 FM C31H33N5O4
DMSTA36 IC InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,33,38H,15-18,20H2,1-3H3
DMSTA36 CS CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
DMSTA36 IK CPMDPSXJELVGJG-UHFFFAOYSA-N
DMSTA36 IU methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate
DMSTA36 CA CAS 656247-17-5
DMSTA36 CB CHEBI:85164
DMSTA36 DE Colorectal cancer; Idiopathic pulmonary fibrosis; Ovarian cancer; Non-small-cell lung cancer; Mesothelioma
DMUTZ8S ID DMUTZ8S
DMUTZ8S DN Interferon Alfa-2a, Recombinant
DMUTZ8S HS Approved
DMUTZ8S SN Roferon A (TN)
DMUTZ8S TC Anticancer Agents
DMUTZ8S SQ DB00034 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMUTZ8S DE Chronic HCV-1 infection
DMWCQP4 ID DMWCQP4
DMWCQP4 DN Interferon alfa-2B
DMWCQP4 HS Approved
DMWCQP4 SN Intron A; Viraferon
DMWCQP4 CP Schering-plough
DMWCQP4 TC Anticancer Agents
DMWCQP4 DT Small molecular drug
DMWCQP4 PC 71306834
DMWCQP4 MW 746.5
DMWCQP4 FM C16H17Cl3I2N3NaO5S
DMWCQP4 IC InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1
DMWCQP4 CS CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
DMWCQP4 IK MIXCUJKCXRNYFM-UHFFFAOYSA-M
DMWCQP4 IU sodium;diiodomethanesulfonate;N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide
DMWCQP4 CA CAS 98530-12-2
DMWCQP4 DE Melanoma
DM3TPY8 ID DM3TPY8
DM3TPY8 DN Interferon Alfa-2b, Recombinant
DM3TPY8 HS Approved
DM3TPY8 SN Alpharona (TN); Genferon (TN); Gerpferon (TN); Grippferon (TN); Infagel (TN); Intron A (TN); Kipferon (TN); Realderon (TN); Recolin (TN); Teva (TN); Viferon (TN)
DM3TPY8 CP Schering-Plough
DM3TPY8 TC Anticancer Agents
DM3TPY8 SQ DB00105 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DM3TPY8 DE Hairy cell leukaemia
DM90WJH ID DM90WJH
DM90WJH DN Interferon alfacon-1
DM90WJH HS Approved
DM90WJH SN Advaferon; Infergen; Advaferon (TN); Infergen (TN); Interferon alfacon-1 (genetical recombination); Interferon alfacon-1 (USAN/INN); Interferon alfacon-1 (genetical recombination) (JAN)
DM90WJH TC Anticancer Agents
DM90WJH SQ Interferon alfacon-1: MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE
DM90WJH DE Hepatitis C
DM4AK0Q ID DM4AK0Q
DM4AK0Q DN Interferon alfa-n1
DM4AK0Q HS Approved
DM4AK0Q SN Well-feron; Interferon alfa-n1 (USAN); Well-feron (TN)
DM4AK0Q TC Antiviral Agents
DM4AK0Q SQ DB00011 sequence: CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DM4AK0Q DE Chronic myelogenous leukaemia
DMTZNQ9 ID DMTZNQ9
DMTZNQ9 DN Interferon alfa-n3
DMTZNQ9 HS Approved
DMTZNQ9 SN Alferon LDO; Interferon alfa-n3 (oral); Interferon alfa-n3 (oral), Hemispherx; Interferon alfa-n3 (oral), InterferonSciences
DMTZNQ9 CP Interferon Sciences Inc
DMTZNQ9 SQ DB00018 sequence (alpha-2A): CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE >DB00018 sequence (alpha-2B)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE >DB00018 sequence (alpha-2C)CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMTZNQ9 DE Human immunodeficiency virus infection
DM1A6RV ID DM1A6RV
DM1A6RV DN Interferon beta-1a
DM1A6RV HS Approved
DM1A6RV SN Avonex; Avonex (TN); Cinnovex (TN); Interferon beta-1a (USAN); Interferon beta-1a (genetical recombination); Interferon beta-1a (genetical recombination) (JAN); Rebif (TN)
DM1A6RV TC Immunomodulatory Agents
DM1A6RV DT Protein/peptide drug
DM1A6RV SQ MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DM1A6RV DE Multiple sclerosis
DMCN61Z ID DMCN61Z
DMCN61Z DN Interferon beta-1b
DMCN61Z HS Approved
DMCN61Z SN Betaferon (TN); Betaseron (TN)
DMCN61Z TC Immunomodulatory Agents
DMCN61Z SQ DB00068 sequence: SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DMCN61Z DE Multiple sclerosis
DMWUMRL ID DMWUMRL
DMWUMRL DN Interferon gamma-1b
DMWUMRL HS Approved
DMWUMRL TC Immunomodulatory Agents
DMWUMRL SQ DB00033 sequence: CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ
DMWUMRL DE Chronic granulomatous disease
DM1Y69Q ID DM1Y69Q
DM1Y69Q DN Interleukin-3
DM1Y69Q HS Approved
DM1Y69Q DE Aplastic anemia
DM1Y2JH ID DM1Y2JH
DM1Y2JH DN Inulin
DM1Y2JH HS Approved
DM1Y2JH SN Inulin [BAN]; Inulin and sodium chloride; Inulin from Jerusalem artichokes; Inulin USP 27
DM1Y2JH TC Hypoglycemic Agents
DM1Y2JH DT Small molecular drug
DM1Y2JH PC 24763
DM1Y2JH MW 6179
DM1Y2JH FM C228H382O191
DM1Y2JH IC InChI=1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
DM1Y2JH CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO[C@]7([C@H]([C@@H]([C@H](O7)CO)O)O)CO[C@]8([C@H]([C@@H]([C@H](O8)CO)O)O)CO[C@]9([C@H]([C@@H]([C@H](O9)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO)O)O)O)O
DM1Y2JH IK JYJIGFIDKWBXDU-MNNPPOADSA-N
DM1Y2JH IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM1Y2JH CA CAS 9005-80-5
DM1Y2JH DE Measure kidney function
DMS6ZI0 ID DMS6ZI0
DMS6ZI0 DN Inulin
DMS6ZI0 HS Approved
DMS6ZI0 SN Inulin [BAN]; Inulin [USP:BAN]; Inulin and sodium chloride; Inulin-oligofructose enriched; JOS53KRJ01; LS-186416; LS-187349; Liquid Agave Inulin; Agave Inulin; Inulin - Liquid; Inulin Powder; 78089-EP2272846A1; 78089-EP2277868A1; 78089-EP2277869A1; 78089-EP2308866A1; 78089-EP2374791A1; AI3-19506; DB00638; EINECS 232-684-3; UNII-JOS53KRJ01
DMS6ZI0 PC 24763
DMS6ZI0 MW 6179
DMS6ZI0 FM C228H382O191
DMS6ZI0 IC JYJIGFIDKWBXDU-MNNPPOADSA-N
DMS6ZI0 CS C(C1C(C(C(C(O1)OC2(C(C(C(O2)CO)O)O)COC3(C(C(C(O3)CO)O)O)COC4(C(C(C(O4)CO)O)O)COC5(C(C(C(O5)CO)O)O)COC6(C(C(C(O6)CO)O)O)COC7(C(C(C(O7)CO)O)O)COC8(C(C(C(O8)CO)O)O)COC9(C(C(C(O9)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)COC1(C(C(C(O1)CO)O)O)CO)O)O)O)O
DMS6ZI0 IK 1S/C228H382O191/c229-1-76-114(268)152(306)153(307)191(381-76)419-228(190(344)151(305)113(38-266)418-228)75-380-227(189(343)150(304)112(37-265)417-227)74-379-226(188(342)149(303)111(36-264)416-226)73-378-225(187(341)148(302)110(35-263)415-225)72-377-224(186(340)147(301)109(34-262)414-224)71-376-223(185(339)146(300)108(33-261)413-223)70-375-222(184(338)145(299)107(32-260)412-222)69-374-221(183(337)144(298)106(31-259)411-221)68-373-220(182(336)143(297)105(30-258)410-220)67-372-219(181(335)142(296)104(29-257)409-219)66-371-218(180(334)141(295)103(28-256)408-218)65-370-217(179(333)140(294)102(27-255)407-217)64-369-216(178(332)139(293)101(26-254)406-216)63-368-215(177(331)138(292)100(25-253)405-215)62-367-214(176(330)137(291)99(24-252)404-214)61-366-213(175(329)136(290)98(23-251)403-213)60-365-212(174(328)135(289)97(22-250)402-212)59-364-211(173(327)134(288)96(21-249)401-211)58-363-210(172(326)133(287)95(20-248)400-210)57-362-209(171(325)132(286)94(19-247)399-209)56-361-208(170(324)131(285)93(18-246)398-208)55-360-207(169(323)130(284)92(17-245)397-207)54-359-206(168(322)129(283)91(16-244)396-206)53-358-205(167(321)128(282)90(15-243)395-205)52-357-204(166(320)127(281)89(14-242)394-204)51-356-203(165(319)126(280)88(13-241)393-203)50-355-202(164(318)125(279)87(12-240)392-202)49-354-201(163(317)124(278)86(11-239)391-201)48-353-200(162(316)123(277)85(10-238)390-200)47-352-199(161(315)122(276)84(9-237)389-199)46-351-198(160(314)121(275)83(8-236)388-198)45-350-197(159(313)120(274)82(7-235)387-197)44-349-196(158(312)119(273)81(6-234)386-196)43-348-195(157(311)118(272)80(5-233)385-195)42-347-194(156(310)117(271)79(4-232)384-194)41-346-193(155(309)116(270)78(3-231)383-193)40-345-192(39-267)154(308)115(269)77(2-230)382-192/h76-191,229-344H,1-75H2/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152+,153-,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181+,182+,183+,184+,185+,186+,187+,188+,189+,190+,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228+/m1/s1
DMS6ZI0 IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMS6ZI0 CA CAS 9005-80-5
DMS6ZI0 DE Acute kidney failure
DM80OEZ ID DM80OEZ
DM80OEZ DN Iobenguane I-123
DM80OEZ HS Approved
DM80OEZ SN Iobenguane (123I); UNII-P2TH1XYZ84; m-Iodobenzylguanidine-123I; P2TH1XYZ84; Adreview; Iobenguane I 123; 123I-MIBG; 2-[(3-iodanylphenyl)methyl]guanidine; 76924-93-1; Iodine-123 metaiodobenzylguanidine; m-(123I)Iodobenzylguanidine; Iobenguane I 123 [USAN]; MyoMIBG-I 123 (TN); (123I)-m-Iodobenzylguanidine; AC1L367T; AC1Q50E3; CHEMBL1615777; SCHEMBL13158600; (123)I-MIBG; CHEBI:135134; 123 iodine metaiodobenzylguanidine; MOLI000966; 3-Iodobenzylguanidine (123I) (JAN); Guanidine, ((3-iodo(123I)phenyl)methyl)-; D01729
DM80OEZ CP GE Healthcare
DM80OEZ DT Small molecular drug
DM80OEZ PC 135326
DM80OEZ MW 271.09
DM80OEZ FM C8H10IN3
DM80OEZ IC InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9-4
DM80OEZ CS C1=CC(=CC(=C1)[123I])CN=C(N)N
DM80OEZ IK PDWUPXJEEYOOTR-IUAIQHPESA-N
DM80OEZ IU 2-[(3-(123I)iodanylphenyl)methyl]guanidine
DM80OEZ CA CAS 76924-93-1
DM80OEZ CB CHEBI:135134
DM80OEZ DE Neuroendocrine cancer
DMXIQYS ID DMXIQYS
DMXIQYS DN Iodipamide
DMXIQYS HS Approved
DMXIQYS SN Adipiodon; Adipiodona; Adipiodone; Adipiodonum; Bilignost; Bilignostum; Biligrafin; Cholografin; Cholospect; IDB; Transbilix; Iodipamic acid; Iodipamide [USAN]; Adipiodona [INN-Spanish]; Adipiodonum [INN-Latin]; Iodipamide (USP); Adipiodone (JAN/INN); N,N''-Adipoyl-bis(3-amino-2,4,6-triiodbenzoesaeure); 3,3'(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-(Adipoyldiimino)bis(2,4,6-triiodobenzoic acid); 3,3'-Adipoyldiiminobis(2,4,6-triiodobenzoic Acid); 3,3'-[(1,6-DIOXOHEXANE-1,6-DIYL)DIIMINO]BIS(2,4,6-TRIIODOBENZOIC ACID); 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID; 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
DMXIQYS TC Contrast Media
DMXIQYS DT Small molecular drug
DMXIQYS PC 3739
DMXIQYS MW 1139.8
DMXIQYS FM C20H14I6N2O6
DMXIQYS IC InChI=1S/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)
DMXIQYS CS C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I
DMXIQYS IK FFINMCNLQNTKLU-UHFFFAOYSA-N
DMXIQYS IU 3-[[6-(3-carboxy-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoic acid
DMXIQYS CA CAS 606-17-7
DMXIQYS CB CHEBI:31176
DMXIQYS DE Gallbladder disease
DMNARJT ID DMNARJT
DMNARJT DN Ioflupane I-123
DMNARJT HS Approved
DMNARJT SN Datscan (TN)
DMNARJT CP GE Healthcare
DMNARJT DT Small molecular drug
DMNARJT PC 3086674
DMNARJT MW 427.3
DMNARJT FM C18H23FINO2
DMNARJT IC InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4
DMNARJT CS COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1C3=CC=C(C=C3)[123I]
DMNARJT IK HXWLAJVUJSVENX-HFIFKADTSA-N
DMNARJT IU methyl (1R,2S,3S,5S)-8-(3-fluoropropyl)-3-(4-(123I)iodanylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DMNARJT CA CAS 155798-07-5
DMNARJT CB CHEBI:68855
DMNARJT DE Parkinson disease
DMLZTP9 ID DMLZTP9
DMLZTP9 DN Ipecac
DMLZTP9 HS Approved
DMLZTP9 SN Ipecac syrup
DMLZTP9 DE Poison intoxication
DMWA24P ID DMWA24P
DMWA24P DN IPI-145
DMWA24P HS Approved
DMWA24P SN Duvelisib; 1201438-56-3; INK-1197; UNII-610V23S0JI;
DMWA24P CP Verastem
DMWA24P DT Small molecular drug
DMWA24P PC 50905713
DMWA24P MW 416.9
DMWA24P FM C22H17ClN6O
DMWA24P IC InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
DMWA24P CS C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DMWA24P IK SJVQHLPISAIATJ-ZDUSSCGKSA-N
DMWA24P IU 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
DMWA24P CA CAS 1201438-56-3
DMWA24P CB CHEBI:131169
DMWA24P DE Small lymphocytic lymphoma; Follicular lymphoma; Arthritis
DMJTIYK ID DMJTIYK
DMJTIYK DN Ipilimumab
DMJTIYK HS Approved
DMJTIYK SN BMS-734016; MDX-010; MDX-101; Yervoy (TN)
DMJTIYK CP Bristol-Myers Squibb
DMJTIYK DT Monoclonal antibody
DMJTIYK SQ Ipilimumab heavy chain (patent appl. US20150283234) : QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Ipilimumab light chain EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMJTIYK DE Melanoma
DMFQ320 ID DMFQ320
DMFQ320 DN Ipratropium
DMFQ320 HS Approved
DMFQ320 SN Aerodose; Atrovent; Atrovent Hfa; Ipatropium Bromide; Ipratropium bromide; X8M; Apo-Ipravent; Apovent (TN); Atrovent (TN); Kendral-Ipratropium; [(5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] (2R)-3-hydroxy-2-phenylpropanoate; (3-endo,8-syn)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octane; (8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate; 3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azoniabicyclo[3.2.1]octane
DMFQ320 TC Bronchodilator Agents
DMFQ320 DT Small molecular drug
DMFQ320 PC 657309
DMFQ320 MW 332.5
DMFQ320 FM C20H30NO3+
DMFQ320 IC InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18?,19?,21?
DMFQ320 CS CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C
DMFQ320 IK OEXHQOGQTVQTAT-BZQJJPTISA-N
DMFQ320 IU [(1S,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
DMFQ320 CA CAS 60205-81-4
DMFQ320 CB CHEBI:5956
DMFQ320 DE Obstructive lung disease
DM0IO13 ID DM0IO13
DM0IO13 DN Ipriflavone
DM0IO13 HS Approved
DM0IO13 SN Osten (TN)
DM0IO13 DT Small molecular drug
DM0IO13 PC 3747
DM0IO13 MW 280.3
DM0IO13 FM C18H16O3
DM0IO13 IC InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
DM0IO13 CS CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
DM0IO13 IK SFBODOKJTYAUCM-UHFFFAOYSA-N
DM0IO13 IU 3-phenyl-7-propan-2-yloxychromen-4-one
DM0IO13 CA CAS 35212-22-7
DM0IO13 CB CHEBI:31719
DM0IO13 DE Osteoporosis
DMTP1DC ID DMTP1DC
DMTP1DC DN Irbesartan
DMTP1DC HS Approved
DMTP1DC SN irbesartan; 138402-11-6; Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; Irbesartan [USAN:INN]; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one; CHEBI:5959; C25H28N6O; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Aprovel; Irbesarran; Irbetan; Lrbesartan; BMS Brand of Irbesartan; Bristol Myers Brand of Irbesartan; SanofiWinthrop Brand of Irbesartan; Aprovel (TN); Avalide (TN); Avapro (TN); Karvea (TN); Irbesartan (JAN/USAN/INN); BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan; 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(44)non-1-en-4-one; 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[44]non-1-en-4-one; 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one; 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[44]non-1-en-4-one; 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one; 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one; [3H]irbesartan
DMTP1DC CP Bristol-Myers Squibb
DMTP1DC TC Antihypertensive Agents
DMTP1DC DT Small molecular drug
DMTP1DC PC 3749
DMTP1DC MW 428.5
DMTP1DC FM C25H28N6O
DMTP1DC IC InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
DMTP1DC CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMTP1DC IK YOSHYTLCDANDAN-UHFFFAOYSA-N
DMTP1DC IU 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
DMTP1DC CA CAS 138402-11-6
DMTP1DC CB CHEBI:5959
DMTP1DC DE Hypertension
DMP6SC2 ID DMP6SC2
DMP6SC2 DN Irinotecan
DMP6SC2 HS Approved
DMP6SC2 SN Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde
DMP6SC2 CP Pfizer Pharmaceuticals
DMP6SC2 TC Anticancer Agents
DMP6SC2 DT Small molecular drug
DMP6SC2 PC 60838
DMP6SC2 MW 586.7
DMP6SC2 FM C33H38N4O6
DMP6SC2 IC InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
DMP6SC2 CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
DMP6SC2 IK UWKQSNNFCGGAFS-XIFFEERXSA-N
DMP6SC2 IU [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
DMP6SC2 CA CAS 97682-44-5
DMP6SC2 CB CHEBI:80630
DMP6SC2 DE Colorectal cancer
DMAP8MV ID DMAP8MV
DMAP8MV DN Iron
DMAP8MV HS Approved
DMAP8MV SN Eisen; Feronate; Ferretts; Ferrousal; Ferrum; Hemocyte; Hierro; LOHA; PZhO; Remko; Siderol; Yieronia; Ancor B; Armco iron; Carbonyl iron; Ferrous iron; Ferrovac E; Hoeganaes EH; Iron monocation; Iron standard for AAS; ATW 230; ATW 432; Atomel 28; Atomel 300M200; Atomel 500M; Atomel 95; Atomiron 44MR; Atomiron 5M; Atomiron AFP 25; Atomiron AFP 5; DSP 1000; DSP 128B; DSP 135; DSP 135C; DSP 138; EF 1000; EF 250; EFV 250; GS 6; HS 4849; Hoeganaes ATW 230; NC 100; PZh1M1; PZh2M; PZh2M1; PZh2M2; PZh3; PZh3M; PZh4M; Ancoren 80/150; Copy Powder CS 105-175; Diseases, iron overload; EFV 200/300; EFV 250/400; F 60 (metal); FT 3 (element); Fe-40; Fe1+; Ferro-Caps; Ferro-Time; HF 2 (element); HL (iron); HQ (metal); HS (iron); Iron (Fe); Iron(III) nitrate solution; Iron, elemental; PZh-1M3; PZh-2; SUY-B 2; Vitedyn-Slo; Diseases (animal), iron overload; Ed-In-Sol; Iron (Fe1+); Iron ion (Fe+); Iron ion(1+); Iron(1+); Iron(1+) ion; Iron, ion (Fe1+); Iron, ion (Fe1+) (8CI,9CI); 3ZhP
DMAP8MV TC Iron Supplement
DMAP8MV DT Small molecular drug
DMAP8MV PC 23925
DMAP8MV MW 55.84
DMAP8MV FM Fe
DMAP8MV IC InChI=1S/Fe
DMAP8MV CS [Fe]
DMAP8MV IK XEEYBQQBJWHFJM-UHFFFAOYSA-N
DMAP8MV IU iron
DMAP8MV CA CAS 7439-89-6
DMAP8MV CB CHEBI:18248
DMAP8MV DE Iron-deficiency anemia
DM5OY70 ID DM5OY70
DM5OY70 DN Iron Dextran
DM5OY70 HS Approved
DM5OY70 SN Chinofer; Dexferrum; Dextrofer; Eisendextran; Fenate; Ferridextran; Ferrodextran; Ferroglucin; Hematran; Icar; Imfergen; Imferon; Imperon; Imposil; Infed; Norferan; Polyfer; Proferdex; Prolongal; Ursoferran; Dextran iron complex; Eisendextran [German]; Fero Gradumet; Ferric dextran; Iron dextran complex; Iron dextran injection; Iron hydrogenated dextran; Ironorm injection; B 75; Dextrofer 75; Ferdex 100; Ferroglukin 75; Myofer 100; A 100 (Pharmaceutical); American Regent Brand of Iron-Dextran Complex; Dextran-Iron Complex; Fe-Dextran; GlaxoSmithKline Brand of Iron-Dextran Complex; Goldline Brand of Iron-Dextran Complex; Hauck Brand of Iron-Dextran Complex; Hawthron Brand of Iron-Dextran Complex; Iro-Jex; Iron-dextran complex; Sanofi Brand of Iron-Dextran Complex; Sulfuric acid, iron salt; Sulphuric acid, iron salt; Vortech Brand of Iron-Dextran Complex; Watson Brand of Iron-Dextran Complex; Sulfuric acid iron salt (1:1); Sulfuric acid, iron salt (1:); Sulfuric acid iron(2+) salt (1:1)
DM5OY70 TC Iron Supplement
DM5OY70 DT Small molecular drug
DM5OY70 PC 105075
DM5OY70 MW 153.93
DM5OY70 FM FeH2O4S
DM5OY70 IC InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
DM5OY70 CS OS(=O)(=O)O.[Fe]
DM5OY70 IK MVZXTUSAYBWAAM-UHFFFAOYSA-N
DM5OY70 IU iron;sulfuric acid
DM5OY70 CA CAS 9004-66-4
DM5OY70 DE Iron-deficiency anemia
DMD45S9 ID DMD45S9
DMD45S9 DN Isavuconazonium
DMD45S9 HS Approved
DMD45S9 SN Isavuconazonium; Isavuconazonium (USAN); Isavuconazonium [USAN]; Isavuconazonium ion; VH2L779W8Q; 742049-41-8; AC1OCFMR; ACN-048059; BCP23773; BAL 8557-000; BAL-8557; BAL8557-000; CHEBI:85978; CHEMBL1183349; DB06636; DTXSID70225203; Glycine, N-methyl-, (2-(((1-(1-((2R,3R)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-1H-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl ester; SCHEMBL13133195; UNII-VH2L779W8Q
DMD45S9 PC 6918606
DMD45S9 MW 717.8
DMD45S9 FM C35H35F2N8O5S+
DMD45S9 IC RSWOJTICKMKTER-QXLBVTBOSA-N
DMD45S9 CS CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=[N+](C=N3)C(C)OC(=O)N(C)C4=C(C=CC=N4)COC(=O)CNC)(C5=C(C=CC(=C5)F)F)O
DMD45S9 IK 1S/C35H35F2N8O5S/c1-22(33-42-30(18-51-33)25-9-7-24(15-38)8-10-25)35(48,28-14-27(36)11-12-29(28)37)19-45-21-44(20-41-45)23(2)50-34(47)43(4)32-26(6-5-13-40-32)17-49-31(46)16-39-3/h5-14,18,20-23,39,48H,16-17,19H2,1-4H3/q+1/t22-,23?,35+/m0/s1
DMD45S9 IU [2-[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazol-4-ium-4-yl]ethoxycarbonyl-methylamino]pyridin-3-yl]methyl 2-(methylamino)acetate
DMD45S9 CA CAS 742049-41-8
DMD45S9 CB CHEBI:85978
DMD45S9 DE Allergic bronchopulmonary aspergillosis
DMJ9G23 ID DMJ9G23
DMJ9G23 DN ISIS 1570
DMJ9G23 HS Approved
DMJ9G23 CP Isis Pharmaceuticals
DMJ9G23 DT Antisense drug
DMJ9G23 DE Lleum inflammation
DMAF1NB ID DMAF1NB
DMAF1NB DN Isocarboxazid
DMAF1NB HS Approved
DMAF1NB SN BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide
DMAF1NB CP Hoffmann-La Roche pharmaceutical company
DMAF1NB TC Antidepressants
DMAF1NB DT Small molecular drug
DMAF1NB PC 3759
DMAF1NB MW 231.25
DMAF1NB FM C12H13N3O2
DMAF1NB IC InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
DMAF1NB CS CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2
DMAF1NB IK XKFPYPQQHFEXRZ-UHFFFAOYSA-N
DMAF1NB IU N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
DMAF1NB CA CAS 59-63-2
DMAF1NB CB CHEBI:93635
DMAF1NB DE Depression
DMITSEH ID DMITSEH
DMITSEH DN Isoetharine
DMITSEH HS Approved
DMITSEH SN Bronkosol; Dilabron; Etyprenaline; Etyprenalinum; Isoetarin; Isoetarina; Isoetarine; Isoetarinum; Neoisuprel; Isoetharine Hcl; Win 3406; Bronkometer (TN); Bronkosol (TN); Dey-Lute Isoetharine; Isoetarina [INN-Spanish]; Isoetarine (INN); Isoetarinum [INN-Latin]; Isoetharine (USP); Isoetharine HCl S/F; Isoetharine [USAN:BAN]; 3,4-Dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol; 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol
DMITSEH TC Bronchodilator Agents
DMITSEH DT Small molecular drug
DMITSEH PC 3762
DMITSEH MW 239.31
DMITSEH FM C13H21NO3
DMITSEH IC InChI=1S/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3
DMITSEH CS CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C
DMITSEH IK HUYWAWARQUIQLE-UHFFFAOYSA-N
DMITSEH IU 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol
DMITSEH CA CAS 530-08-5
DMITSEH CB CHEBI:6005
DMITSEH DE Asthma
DMY6T31 ID DMY6T31
DMY6T31 DN Isoflurane
DMY6T31 HS Approved
DMY6T31 SN Aerrane; Forane; Forene; IsoFlo; Isoflurano; Isofluranum; AErrane (Veterinary); Forane (TN); Isoflurane [Anaesthetics, volatile]; Isoflurano [INN-Spanish]; Isofluranum [INN-Latin]; R-E 235dal; Isoflurane (JP15/USP/INN); Isoflurane [USAN:BAN:INN:JAN]; Isoflurane [USAN:INN:BAN:JAN]; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane
DMY6T31 TC Anesthetics
DMY6T31 DT Small molecular drug
DMY6T31 PC 3763
DMY6T31 MW 184.49
DMY6T31 FM C3H2ClF5O
DMY6T31 IC InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H
DMY6T31 CS C(C(F)(F)F)(OC(F)F)Cl
DMY6T31 IK PIWKPBJCKXDKJR-UHFFFAOYSA-N
DMY6T31 IU 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane
DMY6T31 CA CAS 26675-46-7
DMY6T31 CB CHEBI:6015
DMY6T31 DE Anaesthesia
DMBSK7X ID DMBSK7X
DMBSK7X DN Isoflurophate
DMBSK7X HS Approved
DMBSK7X SN DFP; DIFP; Diflupyl; Diflurophate; Diisopropylfluorfosfat; Diisopropylfluorophosphate; Diisopropylfluorphosphorsaeureester; Diisopropylphosphofluoridate; Diisopropylphosphorofluoridate; Dyflos; Floropryl; Fluoropryl; Fluorostigmine; Fluostigmine; Fluropryl; Isofluorophate; Isofluorphate; Isoflurophosphate; Neoglaucit; Di isopropylphosphorofluoridate; Diisopropoxyphosphoryl fluoride; Diisopropyl fluoridophosphate; Diisopropyl fluorophosphate; Diisopropyl fluorophosphonate; Diisopropyl phosphofluoridate; Diisopropyl phosphorofluoridate; Diisopropylfluorfosfat [Czech]; Diisopropylfluorophosphoric acid ester; Diisopropylfluorphosphorsaeureester [German]; Disiopropyl fluorophosphonate; Fluorodiisopropyl phosphate; Isoflurophate [USP]; Isopropyl fluophosphate; Isopropyl phosphorofluoridate; Merck Brand of Isoflurophate; Phosphoric acid diisopropyl ester fluoride; EA 1152; TL 466; DIISOPROPYL-FLUOROPHOSPHATE; Di-isopropylphosphorofluoridate; Floropryl (TN); Fluophosphoric acid, diisopropyl ester; Fluorophosphoric acid, diisopropyl ester; Isoflurophate (USP); PF-3; Phosphorofluoridic acid, diisopropyl ester; T-1703; Bis(1-methylethyl) Phosphorofluoridate; Dipropan-2-yl phosphorofluoridoate; O,O-Diisopropyl fluorophosphate; Bis(propan-2-yl) fluorophosphate; O,O'-Diisopropyl phosphoryl fluoride; Phosphorofluoridic acid, bis(1-methylethyl) ester; 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane
DMBSK7X TC Antiglaucomic Agents
DMBSK7X DT Small molecular drug
DMBSK7X PC 5936
DMBSK7X MW 184.15
DMBSK7X FM C6H14FO3P
DMBSK7X IC InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3
DMBSK7X CS CC(C)OP(=O)(OC(C)C)F
DMBSK7X IK MUCZHBLJLSDCSD-UHFFFAOYSA-N
DMBSK7X IU 2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane
DMBSK7X CA CAS 55-91-4
DMBSK7X CB CHEBI:17941
DMBSK7X DE Glaucoma/ocular hypertension
DM5JVS3 ID DM5JVS3
DM5JVS3 DN Isoniazid
DM5JVS3 HS Approved
DM5JVS3 SN Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.
DM5JVS3 CP Roche Pharmaceuticals
DM5JVS3 TC Antitubercular Agents
DM5JVS3 DT Small molecular drug
DM5JVS3 PC 3767
DM5JVS3 MW 137.14
DM5JVS3 FM C6H7N3O
DM5JVS3 IC InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
DM5JVS3 CS C1=CN=CC=C1C(=O)NN
DM5JVS3 IK QRXWMOHMRWLFEY-UHFFFAOYSA-N
DM5JVS3 IU pyridine-4-carbohydrazide
DM5JVS3 CA CAS 54-85-3
DM5JVS3 CB CHEBI:6030
DM5JVS3 DE Tuberculosis
DMQYV60 ID DMQYV60
DMQYV60 DN Isopropamide iodide
DMQYV60 HS Approved
DMQYV60 SN Isopropamide Iodide; 71-81-8; Darbid; Isoproponum iodide; Priamide Eupharma; Priamide; Tyrimide; Dipramide; Priazimide; Piaccamide; Sanulcin; Dipramid; Isamid; Marygin-M; UNII-E0KNA372SZ; Isopropamide ioduro [DCIT]; Isopropamidi iodidum [INN-Latin]; SKF 4740; Iodure d'isopropamide [INN-French]; EINECS 200-766-8; NSC 15521; Ioduro de isopropamida [INN-Spanish]; 5579 MD; E0KNA372SZ; R 79; MLS000069749; (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; Benzenepropanaminium, gamma-(aminocarbonyl)-N-methyl-N,N-bis(1-methyl
DMQYV60 DT Small molecular drug
DMQYV60 PC 6284
DMQYV60 MW 480.4
DMQYV60 FM C23H33IN2O
DMQYV60 IC InChI=1S/C23H32N2O.HI/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21;/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26);1H
DMQYV60 CS CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[I-]
DMQYV60 IK BFSMWENDZZIWPW-UHFFFAOYSA-N
DMQYV60 IU (4-amino-4-oxo-3,3-diphenylbutyl)-methyl-di(propan-2-yl)azanium;iodide
DMQYV60 CA CAS 71-81-8
DMQYV60 CB CHEBI:6044
DMQYV60 DE Allergic rhinitis
DMK7MEY ID DMK7MEY
DMK7MEY DN Isoproterenol
DMK7MEY HS Approved
DMK7MEY SN isoproterenol; Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isadrine; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Neo-Epinine; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409
DMK7MEY CP Abbott Laboratories
DMK7MEY TC Cardiotonic Agents
DMK7MEY DT Small molecular drug
DMK7MEY PC 3779
DMK7MEY MW 211.26
DMK7MEY FM C11H17NO3
DMK7MEY IC InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
DMK7MEY CS CC(C)NCC(C1=CC(=C(C=C1)O)O)O
DMK7MEY IK JWZZKOKVBUJMES-UHFFFAOYSA-N
DMK7MEY IU 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol
DMK7MEY CA CAS 7683-59-2
DMK7MEY CB CHEBI:64317
DMK7MEY DE Heart block; Melanoma
DMBI4JG ID DMBI4JG
DMBI4JG DN Isosorbide dinitrate
DMBI4JG HS Approved
DMBI4JG SN Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol
DMBI4JG CP Biovail Corporation
DMBI4JG TC Vasodilator Agents
DMBI4JG DT Small molecular drug
DMBI4JG PC 6883
DMBI4JG MW 236.14
DMBI4JG FM C6H8N2O8
DMBI4JG IC InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
DMBI4JG CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-]
DMBI4JG IK MOYKHGMNXAOIAT-JGWLITMVSA-N
DMBI4JG IU [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
DMBI4JG CA CAS 87-33-2
DMBI4JG CB CHEBI:6061
DMBI4JG DE Anal fissure; Angina pectoris
DMYLMU0 ID DMYLMU0
DMYLMU0 DN Isosorbide mononitrate
DMYLMU0 HS Approved
DMYLMU0 SN Conpin; Corangin; Duride; Edistol; Elantan; Epicordin; Etimonis; IHD; ISMN; ISMO; Imazin; Imdur; Imodur; Imtrate; Ismexin; Ismox; Isomon; Isomonat; Isomonit; Iturol; Medocor; Monicor; Monis; Monisid; Monit; Monizid; MonoSigma; Monocedocard; Monocinque; Monoclair; Monocord; Monoket; Monolong; Monomax; Mononit; Monopront; Monosorb; Monosorbitrate; Monosordil; Monotrate; Multitab; Nitex; Nitramin; Olicard; Olicardin; Orasorbil; Percorina; Pertil; Plodin; Promocard; Sigacora; Sorbimon; Titarane; Turimonit; Uniket; Vasdilat; Vasotrate; Conpin Retardkaps; Corangin SR; Elantan Long; Elantan Retard; ISMN AL; ISMN AbZ; ISMN Apogepha; ISMN Atid; ISMN Basics; ISMN Heumann; ISMN Hexal; ISMN Lannacher; ISMN Stada; Imdur Durules; Isosorbidi mononitras; Isosorbidi mononitras [Latin]; Mono Corax; Mono Corax Retard; Mono Mack; Monodur Durules; Monoket OD; Monoket Retard; Mononitrato de isosorbida; Mononitrato de isosorbida [Spanish]; AHR 4698; IS 5MN; Imdur 60; Monit 20; Mono Mac 50D; Monocord 20; Monocord 40; Monocord 50 SR; Monolong 40; Monolong 60; Mononit 20; Mononit 40; Mononit Retard 50; Monosorb XL 60;Olicard 40; Pentacard 20; AHR-4698; BM 22-145; BM 22.145; Chemydur (TN); Fem-Mono; IS 5-MN; Imdur (TN); Ismo (TN); Ismo-20; Isopen-20; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Mono-Mack; Mono-Sanorania; Mononitrate d'isosorbide; Mononitrate d'isosorbide [French]; Olicard-retard; BM-22-145; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Isosorbide-5-mononitrate; Isosorbide-5-nitrate; Isosorbide mononitrate (JAN/USP/INN); Isosorbide mononitrate [USAN:BAN:INN:JAN]; Isosorbide mononitrate [USAN:INN:BAN:JAN]; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; 5-ISMN Durules; 5-Ismn
DMYLMU0 CP AstraZeneca
DMYLMU0 TC Vasodilator Agents
DMYLMU0 DT Small molecular drug
DMYLMU0 PC 27661
DMYLMU0 MW 191.14
DMYLMU0 FM C6H9NO6
DMYLMU0 IC InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
DMYLMU0 CS C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O
DMYLMU0 IK YWXYYJSYQOXTPL-SLPGGIOYSA-N
DMYLMU0 IU [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
DMYLMU0 CA CAS 16051-77-7
DMYLMU0 CB CHEBI:6062
DMYLMU0 DE Hydrocephalus
DM4QTBN ID DM4QTBN
DM4QTBN DN Isotretinoin
DM4QTBN HS Approved
DM4QTBN SN Accutane; Amnesteem; Claravis; Isotane; Isotretinoine; Isotretinoino; Isotretinoinum; Isotrex; Roaccutan; Roaccutane; Roacutan; Sotret; Teriosal; Neovitamin A acid; R 3255; Ro 4 3780; Ro 43780; Accutane (TN); Amnesteem (TN); BML2-E07; CIP-Isotretinoin; Claravi (TN); Clarus (TN); Decutan (TN); Isotane (TN); Isotretinoin (USP); Isotretinoin Zinc Salt, 13 cis Isomer; Isotretinoine [INN-French]; Isotretinoino [INN-Spanish]; Isotretinoinum [INN-Latin]; Izotek (TN); Oratane (TN); Ro 4-3780; Ro-43780; Roaccutane (TN); Sotret (TN); Isotretinoin [USAN:INN:BAN]; Ro-4-3780; Isotretinoin Zinc Salt, 13-cis-Isomer; (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid; (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid; (7E,9E,11E,13Z)-retinoic acid; 13-RA; 13-cis RA; 13-cis-Vitamin A acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
DM4QTBN CP Roche Pharmaceuticals
DM4QTBN TC Antiacne Agents
DM4QTBN DT Small molecular drug
DM4QTBN PC 5282379
DM4QTBN MW 300.4
DM4QTBN FM C20H28O2
DM4QTBN IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
DM4QTBN CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C
DM4QTBN IK SHGAZHPCJJPHSC-XFYACQKRSA-N
DM4QTBN IU (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DM4QTBN CA CAS 4759-48-2
DM4QTBN CB CHEBI:6067
DM4QTBN DE Acne vulgaris
DMX7LKS ID DMX7LKS
DMX7LKS DN Isovanillin
DMX7LKS HS Approved
DMX7LKS SN Isovanilin; Isovanilline; Iso-Vanillin; Oxy-3 methoxy-4 benzaldehyde; Oxy-3 methoxy-4 benzaldehyde [French]; P-Anisaldehyde, 3-hydroxy-(8CI); 3-Hydroxy-4-methoxybenzaldehyde; 3-Hydroxy-p-anisaldehyde; 3-Hydroxyanisaldehyde; 3-hydroxy-4-anisaldehyde; 4-Methoxy-3-hydroxybenzaldehyde; 5-Formylguaiacol
DMX7LKS TC Anticancer Agents
DMX7LKS DT Small molecular drug
DMX7LKS PC 12127
DMX7LKS MW 152.15
DMX7LKS FM C8H8O3
DMX7LKS IC InChI=1S/C8H8O3/c1-11-8-3-2-6(5-9)4-7(8)10/h2-5,10H,1H3
DMX7LKS CS COC1=C(C=C(C=C1)C=O)O
DMX7LKS IK JVTZFYYHCGSXJV-UHFFFAOYSA-N
DMX7LKS IU 3-hydroxy-4-methoxybenzaldehyde
DMX7LKS CA CAS 621-59-0
DMX7LKS DE Solid tumour/cancer
DMJL10P ID DMJL10P
DMJL10P DN Isoxyl
DMJL10P HS Approved
DMJL10P SN Tiocarlide; Thiocarlide; Tiocarlid; 910-86-1; Disocarban; Datanil; Tiocarlidum [INN-Latin]; Tiocarlida [INN-Spanish]; 4,4'-Diisoamyloxythiocarbanilide; 4,4'-Bis(isopentyloxy)thiocarbanilide; Tiocarlide [INN:BAN:DCF]; UNII-43M23X81Y2; C23H32N2O2S; N,N'-Bis(4-(3-methylbutoxy)phenyl)thiourea; EINECS 213-006-5; CARBANILIDE, 4,4'-BIS(ISOPENTYLOXY)THIO-; BRN 2546347; Thiourea, N,N'-bis[4-(3-methylbutoxy)phenyl]-; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-; NSC742400; 43M23X81Y2; Amixyl; Disoxyl; Tiocarlida; Tiocarlidum; BRN2546347; Tiocarlide (INN); Tiocarlide [INN:DCF]; Thiourea, N,N'-bis(4-(3-methylbutoxy)phenyl)-(9CI)
DMJL10P DT Small molecular drug
DMJL10P PC 3001386
DMJL10P MW 400.6
DMJL10P FM C23H32N2O2S
DMJL10P IC InChI=1S/C23H32N2O2S/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28)
DMJL10P CS CC(C)CCOC1=CC=C(C=C1)NC(=S)NC2=CC=C(C=C2)OCCC(C)C
DMJL10P IK BWBONKHPVHMQHE-UHFFFAOYSA-N
DMJL10P IU 1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
DMJL10P CA CAS 910-86-1
DMJL10P CB CHEBI:135637
DMJL10P DE Bacterial infection
DMWCRN1 ID DMWCRN1
DMWCRN1 DN Ispaghula
DMWCRN1 HS Approved
DMWCRN1 SN Fiberall; Metamucil; PSYLLIUM; Plantaglucide; Psyllium Husk [USP]; Psyllium gum; Psyllium seed gum; Psyllium seed husk
DMWCRN1 CP Reckitt; Colman
DMWCRN1 DE Irritable bowel syndrome
DMA5XGH ID DMA5XGH
DMA5XGH DN Isradipine
DMA5XGH HS Approved
DMA5XGH SN Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
DMA5XGH CP Norvatis Phamaceuticals Corporation
DMA5XGH TC Antihypertensive Agents
DMA5XGH DT Small molecular drug
DMA5XGH PC 3784
DMA5XGH MW 371.4
DMA5XGH FM C19H21N3O5
DMA5XGH IC InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
DMA5XGH CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
DMA5XGH IK HMJIYCCIJYRONP-UHFFFAOYSA-N
DMA5XGH IU 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMA5XGH CA CAS 75695-93-1
DMA5XGH CB CHEBI:6073
DMA5XGH DE Hypertension; Herpes simplex virus infection
DM20VSK ID DM20VSK
DM20VSK DN Istradefylline
DM20VSK HS Approved
DM20VSK SN KW 6002; Istradefylline [USAN:INN]; Istradefylline (JAN/USAN/INN); (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine; 8-((1E)-2-(3,4-Dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
DM20VSK CP Kyowa Hakko Pharmaceuticals
DM20VSK DT Small molecular drug
DM20VSK PC 5311037
DM20VSK MW 384.4
DM20VSK FM C20H24N4O4
DM20VSK IC InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
DM20VSK CS CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C
DM20VSK IK IQVRBWUUXZMOPW-PKNBQFBNSA-N
DM20VSK IU 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione
DM20VSK CA CAS 155270-99-8
DM20VSK CB CHEBI:134726
DM20VSK DE Substance use disorder; Parkinson disease
DMCR1MV ID DMCR1MV
DMCR1MV DN Itraconazole
DMCR1MV HS Approved
DMCR1MV SN Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
DMCR1MV CP Janssen Pharmaceutica
DMCR1MV TC Antifungal Agents
DMCR1MV DT Small molecular drug
DMCR1MV PC 55283
DMCR1MV MW 705.6
DMCR1MV FM C35H38Cl2N8O4
DMCR1MV IC InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
DMCR1MV CS CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
DMCR1MV IK VHVPQPYKVGDNFY-ZPGVKDDISA-N
DMCR1MV IU 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
DMCR1MV CA CAS 84625-61-6
DMCR1MV CB CHEBI:6076
DMCR1MV DE Fungal infection
DM0L594 ID DM0L594
DM0L594 DN Ivabradine
DM0L594 HS Approved
DM0L594 SN Ivabradine; 155974-00-8; Procoralan; Corlanor; Corlentor; UNII-3H48L0LPZQ; S 16257; S-16257; S-16257-2; S 16257-2; 3H48L0LPZQ; CHEMBL471737; CHEBI:85966; C27H36N2O5; 7,8-Dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one; S-16260-2; s16257; (S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one; Ivabradine [INN]
DM0L594 CP Servier
DM0L594 DT Small molecular drug
DM0L594 PC 132999
DM0L594 MW 468.6
DM0L594 FM C27H36N2O5
DM0L594 IC InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1
DM0L594 CS CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC
DM0L594 IK ACRHBAYQBXXRTO-OAQYLSRUSA-N
DM0L594 IU 3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM0L594 CA CAS 155974-00-8
DM0L594 CB CHEBI:85966
DM0L594 DE Angina pectoris
DMZC1HS ID DMZC1HS
DMZC1HS DN Ivacaftor
DMZC1HS HS Approved
DMZC1HS SN Kalydeco (TN)
DMZC1HS CP Vertex
DMZC1HS DT Small molecular drug
DMZC1HS PC 16220172
DMZC1HS MW 392.5
DMZC1HS FM C24H28N2O3
DMZC1HS IC InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
DMZC1HS CS CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
DMZC1HS IK PURKAOJPTOLRMP-UHFFFAOYSA-N
DMZC1HS IU N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide
DMZC1HS CA CAS 873054-44-5
DMZC1HS CB CHEBI:66901
DMZC1HS DE Cystic fibrosis
DMDBX5F ID DMDBX5F
DMDBX5F DN Ivermectin
DMDBX5F HS Approved
DMDBX5F SN I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN)
DMDBX5F CP Merck & Co
DMDBX5F TC Antiprotozoal Agents
DMDBX5F DT Small molecular drug
DMDBX5F PC 6321424
DMDBX5F MW 875.1
DMDBX5F FM C48H74O14
DMDBX5F IC InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
DMDBX5F CS CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\\C)C
DMDBX5F IK AZSNMRSAGSSBNP-XPNPUAGNSA-N
DMDBX5F IU (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DMDBX5F CA CAS 71827-03-7
DMDBX5F CB CHEBI:63941
DMDBX5F DE Intestinal strongyloidiasis due to nematode parasite
DM8S6T7 ID DM8S6T7
DM8S6T7 DN Ivosidenib
DM8S6T7 HS Approved
DM8S6T7 SN UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
DM8S6T7 CP Agios Pharmaceuticals
DM8S6T7 PC 71657455
DM8S6T7 MW 583
DM8S6T7 FM C28H22ClF3N6O3
DM8S6T7 IC InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
DM8S6T7 CS C1CC(=O)N([C@@H]1C(=O)N(C2=CC(=CN=C2)F)[C@@H](C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
DM8S6T7 IK WIJZXSAJMHAVGX-DHLKQENFSA-N
DM8S6T7 IU (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
DM8S6T7 CA CAS 1448347-49-6
DM8S6T7 CB CHEBI:145430
DM8S6T7 DE Haematological malignancy; Acute myeloid leukaemia; Cholangiocarcinoma
DMRVITQ ID DMRVITQ
DMRVITQ DN Ivosidenib
DMRVITQ HS Approved
DMRVITQ SN (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; Ivosidenib; Ivosidenib (USAN/INN); Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; Tibsovo
DMRVITQ TC Anticancer Agents
DMRVITQ DT Small molecular drug
DMRVITQ PC 71657455
DMRVITQ MW 582.968
DMRVITQ FM C28H22ClF3N6O3
DMRVITQ IC InChI=1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
DMRVITQ CS C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
DMRVITQ IK WIJZXSAJMHAVGX-DHLKQENFSA-N
DMRVITQ IU (2S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
DMRVITQ CA CAS 1448347-49-6
DMRVITQ DE Acute myeloid leukemia; Cholangiocarcinoma
DM2OZ3G ID DM2OZ3G
DM2OZ3G DN Ixabepilone
DM2OZ3G HS Approved
DM2OZ3G SN Azaepothilone B; BMS-247550; Ixempra (TN)
DM2OZ3G CP Bristol-Myers Squibb
DM2OZ3G DT Small molecular drug
DM2OZ3G PC 6445540
DM2OZ3G MW 506.7
DM2OZ3G FM C27H42N2O5S
DM2OZ3G IC InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
DM2OZ3G CS C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C
DM2OZ3G IK FABUFPQFXZVHFB-PVYNADRNSA-N
DM2OZ3G IU (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione
DM2OZ3G CA CAS 219989-84-1
DM2OZ3G CB CHEBI:63605
DM2OZ3G DE Breast cancer
DMXW92T ID DMXW92T
DMXW92T DN Ixekizumab
DMXW92T HS Approved
DMXW92T SN LY2439821
DMXW92T CP Eli Lilly
DMXW92T DT Monoclonal antibody
DMXW92T SQ Heavy Chain Sequence: QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG >Light Chain SequenceDIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMXW92T DE Plaque psoriasis; Psoriatic arthritis
DMKJ8LB ID DMKJ8LB
DMKJ8LB DN Josamycin
DMKJ8LB HS Approved
DMKJ8LB SN Josacine; Josamicina; Josamycine; Josamycinum; EN 141; Kitasamycin A3; Leucomycin A3; Turimycin A5; Antibiotic yl-704 A3; Iosalide (TN); Josacine (TN); Josalid (TN); Josamicina [INN-Spanish]; Josamina (TN); Josamy (TN); Josamycin (TN); Josamycine [INN-French]; Josamycinum [INN-Latin]; Wilprafen (TN); Yl-704 A3; Josamycin [USAN:INN:JAN]; Josamycin (JP15/USAN/INN); Dro-2H-pyran-3-yl 3-methylbutanoate; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); Leucomycin V,3-acetate 4(sup beta)-(3-methylbutanoate)
DMKJ8LB TC Antibiotics
DMKJ8LB DT Small molecular drug
DMKJ8LB PC 5282165
DMKJ8LB MW 828
DMKJ8LB FM C42H69NO15
DMKJ8LB IC InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
DMKJ8LB CS C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)OC(=O)C)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O
DMKJ8LB IK XJSFLOJWULLJQS-NGVXBBESSA-N
DMKJ8LB IU [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate
DMKJ8LB CA CAS 16846-24-5
DMKJ8LB CB CHEBI:31739
DMKJ8LB DE Bacterial infection
DM2DMPO ID DM2DMPO
DM2DMPO DN Kanamycin
DM2DMPO HS Approved
DM2DMPO SN Aspidium; KAN; Kanamicina; Kanamycine; Kanamycinum; Kantrex; Klebcil; KANAMYCIN A; Kanamicina [Italian]; Kanamycin A tetracation; Kanamycin Base; Kanamycin monosulfate; Kanamycin sulfate; Kenamycin A; Liposomal Kanamycin; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin monosulfate (JP15); Kanamycinsulfate (JP15); Kanamycin sulfate (TN); Kanamycin sulfate (USP); Kanamycine [INN-French]; Kanamycinum [INN-Latin]; Kantrex (TN); Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diazaniumyl-3-(6-azaniumyl-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-azaniumyl-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside
DM2DMPO CP Sigma Chemical Company
DM2DMPO TC Antibiotics
DM2DMPO DT Small molecular drug
DM2DMPO PC 6032
DM2DMPO MW 484.5
DM2DMPO FM C18H36N4O11
DM2DMPO IC InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
DM2DMPO CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N
DM2DMPO IK SBUJHOSQTJFQJX-NOAMYHISSA-N
DM2DMPO IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
DM2DMPO CA CAS 59-01-8
DM2DMPO CB CHEBI:17630
DM2DMPO DE Bacterial infection
DMITFB8 ID DMITFB8
DMITFB8 DN Kanamycin
DMITFB8 HS Approved
DMITFB8 SN Kanamicina; Kanamicina [Italian]; Kanamycin Base; EQK9Q303C5; KANAMYCIN A; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycin sulfate; Kanamycine; Kanamycine [INN-French]; Kanamycinum; Kanamycinum [INN-Latin]; kanamycin; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; BRN 0061647; C18H36N4O11; CHEBI:17630; EINECS 200-411-7; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; HSDB 3107; KAN; UNII-EQK9Q303C5
DMITFB8 PC 6032
DMITFB8 MW 484.5
DMITFB8 FM C18H36N4O11
DMITFB8 IC SBUJHOSQTJFQJX-NOAMYHISSA-N
DMITFB8 CS C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)O)O)OC3C(C(C(C(O3)CO)O)N)O)N
DMITFB8 IK 1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
DMITFB8 IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol
DMITFB8 CA CAS 59-01-8
DMITFB8 CB CHEBI:17630
DMITFB8 DE Pulmonary tuberculosis
DMT5HA4 ID DMT5HA4
DMT5HA4 DN Ketamine
DMT5HA4 HS Approved
DMT5HA4 SN Calypsol; Cetamina; Green; Ketaject; Ketalar; Ketaminum; Ketanest; Ketoject; Ketolar; Tekam; KETAMINE HCL; Ketalar base; Ketamine Base; Special K; Special K [street name]; CLSTA 20; T385; Cetamina [INN-Spanish]; Dl-Ketamine; Ketalar (TN); Ketamine (INN); Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Ketanest (TN); Ketaset (TN); Tekam (TN); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-(9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-(9CI); Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)-(8CI); (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
DMT5HA4 CP Pfizer Pharmaceuticals
DMT5HA4 TC Analgesics
DMT5HA4 DT Small molecular drug
DMT5HA4 PC 3821
DMT5HA4 MW 237.72
DMT5HA4 FM C13H16ClNO
DMT5HA4 IC InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
DMT5HA4 CS CNC1(CCCCC1=O)C2=CC=CC=C2Cl
DMT5HA4 IK YQEZLKZALYSWHR-UHFFFAOYSA-N
DMT5HA4 IU 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
DMT5HA4 CA CAS 6740-88-1
DMT5HA4 CB CHEBI:6121
DMT5HA4 DE Anaesthesia
DMVLMW6 ID DMVLMW6
DMVLMW6 DN Ketanserin
DMVLMW6 HS Approved
DMVLMW6 SN Ketanserina; Ketanserine; Ketanserinum; Ketaserin; Perketal; Serefrex; Sufrexal; Taseron; Ketanserina [INN-Spanish]; Ketanserine [INN-French]; Ketanserinum [INN-Latin]; R 41,468; R-41468; [3H]-Ketanserin; Ketanserin (USAN/INN); Ketanserin [USAN:BAN:INN]; R-41,468; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione
DMVLMW6 CP Janssen Pharmaceutica
DMVLMW6 TC Antihypertensive Agents
DMVLMW6 DT Small molecular drug
DMVLMW6 PC 3822
DMVLMW6 MW 395.4
DMVLMW6 FM C22H22FN3O3
DMVLMW6 IC InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
DMVLMW6 CS C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O
DMVLMW6 IK FPCCSQOGAWCVBH-UHFFFAOYSA-N
DMVLMW6 IU 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione
DMVLMW6 CA CAS 74050-98-9
DMVLMW6 CB CHEBI:6123
DMVLMW6 DE Hypertension
DMM3L6Z ID DMM3L6Z
DMM3L6Z DN Ketobemidone
DMM3L6Z HS Approved
DMM3L6Z SN Ketobemidone hydrochloride; Cliradon hydrochloride; Ketobimedon hydrochloride; UNII-U9U6LTV80K; 5965-49-1; EINECS 227-749-8; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; Ketobemidone HCl; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; Ketogan (TN); AC1L2YOJ; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); AC1Q5G7W; SCHEMBL9706814; 469-79-4 (Parent); DTXSID00208327; LS-123062; D08101
DMM3L6Z DT Small molecular drug
DMM3L6Z PC 10101
DMM3L6Z MW 247.33
DMM3L6Z FM C15H21NO2
DMM3L6Z IC InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3
DMM3L6Z CS CCC(=O)C1(CCN(CC1)C)C2=CC(=CC=C2)O
DMM3L6Z IK ALFGKMXHOUSVAD-UHFFFAOYSA-N
DMM3L6Z IU 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one
DMM3L6Z CA CAS 469-79-4
DMM3L6Z CB CHEBI:6125
DMM3L6Z DE Pain
DMPZI3Q ID DMPZI3Q
DMPZI3Q DN Ketoconazole
DMPZI3Q HS Approved
DMPZI3Q SN KCZ; KTZ; K 1003; R 41400; R41400; KS-1205; KW-1414; Perkhotal (TN); R 41,400; R-41400; R41,400; Ketoconazole [USAN:INN:BAN:JAN]; Nizoral, Extina, Xolegel, Kuric, Ketoconazole; Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine; Cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE; (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine; (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine; (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine; 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone; 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
DMPZI3Q CP Johnson & Johnson
DMPZI3Q TC Antifungal Agents
DMPZI3Q DT Small molecular drug
DMPZI3Q PC 456201
DMPZI3Q MW 531.4
DMPZI3Q FM C26H28Cl2N4O4
DMPZI3Q IC InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1
DMPZI3Q CS CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
DMPZI3Q IK XMAYWYJOQHXEEK-OZXSUGGESA-N
DMPZI3Q IU 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
DMPZI3Q CA CAS 65277-42-1
DMPZI3Q CB CHEBI:48336
DMPZI3Q DE Fungal infection
DMRKXPT ID DMRKXPT
DMRKXPT DN Ketoprofen
DMRKXPT HS Approved
DMRKXPT SN Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid
DMRKXPT CP ProEthic Pharmaceuticals
DMRKXPT TC Analgesics
DMRKXPT DT Small molecular drug
DMRKXPT PC 3825
DMRKXPT MW 254.28
DMRKXPT FM C16H14O3
DMRKXPT IC InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
DMRKXPT CS CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
DMRKXPT IK DKYWVDODHFEZIM-UHFFFAOYSA-N
DMRKXPT IU 2-(3-benzoylphenyl)propanoic acid
DMRKXPT CA CAS 22071-15-4
DMRKXPT CB CHEBI:6128
DMRKXPT DE Pain; Osteoarthritis; Musculoskeletal pain; Migraine
DMI4EL5 ID DMI4EL5
DMI4EL5 DN Ketorolac
DMI4EL5 HS Approved
DMI4EL5 SN Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
DMI4EL5 CP Laboratorios Syntex SA
DMI4EL5 TC Analgesics
DMI4EL5 DT Small molecular drug
DMI4EL5 PC 3826
DMI4EL5 MW 255.27
DMI4EL5 FM C15H13NO3
DMI4EL5 IC InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
DMI4EL5 CS C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
DMI4EL5 IK OZWKMVRBQXNZKK-UHFFFAOYSA-N
DMI4EL5 IU 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
DMI4EL5 CA CAS 74103-06-3
DMI4EL5 CB CHEBI:76223
DMI4EL5 DE Postoperative inflammation
DM74XKS ID DM74XKS
DM74XKS DN Ketotifen
DM74XKS HS Approved
DM74XKS SN Ketotifen [INN:BAN]; Ketotifene; Ketotifene [INN-French]; Ketotifeno; Ketotifeno [INN-Spanish]; Ketotifenum; Ketotifenum [INN-Latin]; HC 20-511; ZCVMWBYGMWKGHF-UHFFFAOYSA-N; Zaditor; ketotifen; 34580-13-7; 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one; BRN 3983897; CHEMBL534; EINECS 252-099-7; HSDB 7283; UNII-X49220T18G
DM74XKS PC 3827
DM74XKS MW 309.4
DM74XKS FM C19H19NOS
DM74XKS IC ZCVMWBYGMWKGHF-UHFFFAOYSA-N
DM74XKS CS CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
DM74XKS IK 1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
DM74XKS IU 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DM74XKS CA CAS 34580-13-7
DM74XKS CB CHEBI:92511
DM74XKS DE Conjunctivitis
DMOVY05 ID DMOVY05
DMOVY05 DN Ketotifen
DMOVY05 HS Approved
DMOVY05 SN Ketotifene; Ketotifeno; Ketotifenum; Ketotifin; Ketotiphen; Ketotiphene; Zaditor; Ketotifene fumarate; Alaway (TN); HC 20-511; Ketotifen (INN); Ketotifen [INN:BAN]; Ketotifene [INN-French]; Ketotifeno [INN-Spanish]; Ketotifenum [INN-Latin]; Zaditor (TN); 10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2E)-2-butenedioate (1:1); 4,9-Dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one; 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one; 4-(1-Methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one; 4-(1-Methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one; 4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
DMOVY05 CP Norvatis Phamaceuticals Corporation
DMOVY05 TC Antiallergic Agents
DMOVY05 DT Small molecular drug
DMOVY05 PC 3827
DMOVY05 MW 309.4
DMOVY05 FM C19H19NOS
DMOVY05 IC InChI=1S/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3
DMOVY05 CS CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
DMOVY05 IK ZCVMWBYGMWKGHF-UHFFFAOYSA-N
DMOVY05 IU 2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DMOVY05 CA CAS 34580-13-7
DMOVY05 CB CHEBI:92511
DMOVY05 DE Allergic conjunctivitis
DM0KAE6 ID DM0KAE6
DM0KAE6 DN Kombiglyze XR/Komboglyze FDC
DM0KAE6 HS Approved
DM0KAE6 SN Metformin mixture with saxagliptin; 1198772-17-6; Kombiglyze; Komboglyze; Kombiglyze XR; Saxagliptin / metformin; Metformin / saxagliptin
DM0KAE6 CP AstraZeneca
DM0KAE6 DT Small molecular drug
DM0KAE6 PC 56842229
DM0KAE6 MW 444.6
DM0KAE6 FM C22H36N8O2
DM0KAE6 IC InChI=1S/C18H25N3O2.C4H11N5/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;1-9(2)4(7)8-3(5)6/h10-15,23H,1-7,9,20H2;1-2H3,(H5,5,6,7,8)/t10?,11?,12?,13-,14-,15+,17?,18?;/m1./s1
DM0KAE6 CS CN(C)C(=N)N=C(N)N.C1[C@@H](N([C@H]2C1C2)C(=O)[C@@H](C34CC5CC(C3)CC(C5)(C4)O)N)C#N
DM0KAE6 IK QUKZWYNGKYRRKE-RIKNOMPASA-N
DM0KAE6 IU (1R,3R)-2-[(2R)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;3-(diaminomethylidene)-1,1-dimethylguanidine
DM0KAE6 CA CAS 1198772-17-6
DM0KAE6 DE Diabetic complication
DMSA4HZ ID DMSA4HZ
DMSA4HZ DN KU-0058948
DMSA4HZ HS Approved
DMSA4HZ SN CHEMBL380648; KU-0058948; 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; 4-(3-(1,4-diazepane-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; Homopiperazine analogue, 14; SCHEMBL864319; BDBM27533; HGEPGGJUGUMFHT-UHFFFAOYSA-N; ZINC3821234; DB08058; NCGC00386677-01; KU-58948; FT-0670691; TL80090044; 4-[3-([1,4]diazepane-1-carbonyl)-4 -fluorobenzyl]-2H-phthalazin-1-one; 4-[3-([1,4]diazepane-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
DMSA4HZ DT Small molecular drug
DMSA4HZ PC 11291932
DMSA4HZ MW 380.4
DMSA4HZ FM C21H21FN4O2
DMSA4HZ IC InChI=1S/C21H21FN4O2/c22-18-7-6-14(12-17(18)21(28)26-10-3-8-23-9-11-26)13-19-15-4-1-2-5-16(15)20(27)25-24-19/h1-2,4-7,12,23H,3,8-11,13H2,(H,25,27)
DMSA4HZ CS C1CNCCN(C1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F
DMSA4HZ IK HGEPGGJUGUMFHT-UHFFFAOYSA-N
DMSA4HZ IU 4-[[3-(1,4-diazepane-1-carbonyl)-4-fluorophenyl]methyl]-2H-phthalazin-1-one
DMSA4HZ DE Ovarian cancer
DMK8U72 ID DMK8U72
DMK8U72 DN Labetalol
DMK8U72 HS Approved
DMK8U72 SN Albetol; Ibidomide; Labetalolum; Labetolol; NORMOZIDE; AH 5158; AH-5158; Labetalol (INN); Labetalol [INN:BAN]; Labetalolum [INN-Latin]; Normodyne (TN); Sch-19927; Trandate (TN); 2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide; 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide; 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide; 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol; 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
DMK8U72 CP Allen & Handbury
DMK8U72 TC Antihypertensive Agents
DMK8U72 DT Small molecular drug
DMK8U72 PC 3869
DMK8U72 MW 328.4
DMK8U72 FM C19H24N2O3
DMK8U72 IC InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
DMK8U72 CS CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
DMK8U72 IK SGUAFYQXFOLMHL-UHFFFAOYSA-N
DMK8U72 IU 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide
DMK8U72 CA CAS 36894-69-6
DMK8U72 CB CHEBI:6343
DMK8U72 DE Hypertension
DMVM6QR ID DMVM6QR
DMVM6QR DN Lacosamide
DMVM6QR HS Approved
DMVM6QR SN Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide
DMVM6QR CP Schwarz Pharma
DMVM6QR TC Analgesics
DMVM6QR DT Small molecular drug
DMVM6QR PC 219078
DMVM6QR MW 250.29
DMVM6QR FM C13H18N2O3
DMVM6QR IC InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
DMVM6QR CS CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1
DMVM6QR IK VPPJLAIAVCUEMN-GFCCVEGCSA-N
DMVM6QR IU (2R)-2-acetamido-N-benzyl-3-methoxypropanamide
DMVM6QR CA CAS 175481-36-4
DMVM6QR CB CHEBI:135939
DMVM6QR DE Convulsion; Diabetic neuropathy; Epilepsy
DMA7QTC ID DMA7QTC
DMA7QTC DN Lactoferrin
DMA7QTC HS Approved
DMA7QTC SN Lactoferroxin B; Lactoferroxin-B; AC1L4UTC; Arg-tyr-tyr-gly-tyr-och3; AC1Q5JP4; methyl n5-(diaminomethylidene)-l-ornithyl-l-tyrosyl-l-tyrosylglycyl-l-tyrosinate; 117667-26-2; L-Tyrosine, N-(N-(N-(N-L-arginyl-L-tyrosyl)-L-tyrosyl)glycyl)-, methyl ester; methyl (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoate
DMA7QTC DT Small molecular drug
DMA7QTC PC 126456119
DMA7QTC MW 3125.8
DMA7QTC FM C141H226N46O29S3
DMA7QTC IC InChI=1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1
DMA7QTC CS CC[C@H](C)[C@@H](C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CS)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](C)C(=N[C@@H](CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C([C@H](CO)N=C([C@@H]2CCCN2C(=O)[C@H](C)N=C(CN=C([C@H](CC(C)C)N=C([C@H](CCCCN)N=C([C@H](CCCCN)N=C([C@H](CCSC)N=C([C@H](CCCNC(=N)N)N=C([C@H](CC3=CNC4=CC=CC=C43)N=C([C@H](CCC(=N)O)N=C([C@H](CC5=CNC6=CC=CC=C65)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCCNC(=N)N)N=C([C@H](CS)N=C([C@H](CCCCN)N=C([C@H](CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O
DMA7QTC IK CSSYQJWUGATIHM-IKGCZBKSSA-N
DMA7QTC IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-4-methylsulfanylbutylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-1-hydroxyethylidene]amino]propanoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-methylpentylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxypropylidene]amino]-3-phenylpropanoic acid
DMA7QTC CA CAS 151186-19-5
DMA7QTC DE Solid tumour/cancer
DMV7OPN ID DMV7OPN
DMV7OPN DN Lactulose
DMV7OPN HS Approved
DMV7OPN SN Lactulosa; Lactulosa [INN-Spanish]; Lactulosa [Spanish]; Lactulosum; Lactulosum [INN-Latin]; Lactulosum [Latin]; Laevolac; Lattulosio [Italian]; Laxilose; Portalac; lactulose; 4-O-beta-D-Galactopyranosyl-D-fructofuranose; 4-O-beta-D-Galactopyranosyl-D-fructose; Acilac; Bifiteral; Cephulac; Cholac; Chronulac; Constilac; Constulose; D-Lactulose; Duphalac; Enulose; Generlac; Heptalac; Isolactose; 4-O-beta-D-galactopyranosyl-beta-D-fructofuranose; 9XH2P2N8EP; BRN 0093773; BRN 6278818; EINECS 225-027-7; UNII-9XH2P2N8EP
DMV7OPN PC 11333
DMV7OPN MW 342.3
DMV7OPN FM C12H22O11
DMV7OPN IC JCQLYHFGKNRPGE-FCVZTGTOSA-N
DMV7OPN CS C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O
DMV7OPN IK 1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1
DMV7OPN IU (2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMV7OPN CA CAS 4618-18-2
DMV7OPN CB CHEBI:6359
DMV7OPN DE Hepatic encephalopathy
DMZDN4W ID DMZDN4W
DMZDN4W DN L-alanine
DMZDN4W HS Approved
DMZDN4W SN ALA; Alaninum; LPG; Polyalanine; A-Alanine; A-Aminopropionic acid; Alanina [DCIT,Spanish]; Alanine (USP); L-A-Aminopropionicacid; L-Alanine (9CI); L-Alanine (JAN); L-Alanine, homopolymer; L-Alanine, labeled with tritium; L-a-Alanine; L-a-Aminopropionic acid; Poly-DL-alanine; L-Alanine, labeled with carbon-14; Alanine, L-(7CI,8CI); F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine, N-coco alkyl derivs.; Propanoic acid, 2-amino-, (S); (C14)L-Alanine; (S)-2-Aminopropionic acid; 14C-L-Alanine
DMZDN4W TC Dietary supplement
DMZDN4W DT Small molecular drug
DMZDN4W PC 5950
DMZDN4W MW 89.09
DMZDN4W FM C3H7NO2
DMZDN4W IC InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m0/s1
DMZDN4W CS C[C@@H](C(=O)O)N
DMZDN4W IK QNAYBMKLOCPYGJ-REOHCLBHSA-N
DMZDN4W IU (2S)-2-aminopropanoic acid
DMZDN4W CA CAS 56-41-7
DMZDN4W CB CHEBI:16977
DMZDN4W DE Glioma; Dietary shortage
DMANBR7 ID DMANBR7
DMANBR7 DN L-alanyl-l-glutamine
DMANBR7 HS Approved
DMANBR7 SN Dipeptiven (TN)
DMANBR7 DT Small molecular drug
DMANBR7 PC 123935
DMANBR7 MW 217.22
DMANBR7 FM C8H15N3O4
DMANBR7 IC InChI=1S/C8H15N3O4/c1-4(9)7(13)11-5(8(14)15)2-3-6(10)12/h4-5H,2-3,9H2,1H3,(H2,10,12)(H,11,13)(H,14,15)/t4-,5-/m0/s1
DMANBR7 CS C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMANBR7 IK HJCMDXDYPOUFDY-WHFBIAKZSA-N
DMANBR7 IU (2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoic acid
DMANBR7 CA CAS 39537-23-0
DMANBR7 CB CHEBI:73788
DMANBR7 DE Mucositis
DMI347A ID DMI347A
DMI347A DN Lamivudine
DMI347A HS Approved
DMI347A SN lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate
DMI347A CP Glaxo Smith Kline Pharmaceuticals
DMI347A TC Anti-HIV Agents
DMI347A DT Small molecular drug
DMI347A PC 60825
DMI347A MW 229.26
DMI347A FM C8H11N3O3S
DMI347A IC InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
DMI347A CS C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
DMI347A IK JTEGQNOMFQHVDC-NKWVEPMBSA-N
DMI347A IU 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
DMI347A CA CAS 134678-17-4
DMI347A CB CHEBI:63577
DMI347A DE Chronic HBV infection; Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DM8SXYG ID DM8SXYG
DM8SXYG DN Lamotrigine
DM8SXYG HS Approved
DM8SXYG SN Crisomet; Labileno; Lamictal; Lamictin; Lamiktal; Lamitor; Lamotrigina; Lamotriginum; Desitin Brand of Lamotrigine; Faes Brand of Lamotrigine; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; Lamictal Cd; Lamictal ODT; Lamictal XR; Lamotrigina [Spanish]; Lamotriginum [Latin]; BW 430C; GI 267119X; GW 273293; L 3791; BW-430C; EUR-1048; Lamictal (TN); Lamictin (TN); Lamotrigine [USAN:INN:BAN]; Lamotrigine (JAN/USAN/INN); 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
DM8SXYG CP GSK
DM8SXYG TC Anticonvulsants
DM8SXYG DT Small molecular drug
DM8SXYG PC 3878
DM8SXYG MW 256.089
DM8SXYG FM C9H7Cl2N5
DM8SXYG IC InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
DM8SXYG CS C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
DM8SXYG IK PYZRQGJRPPTADH-UHFFFAOYSA-N
DM8SXYG IU 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
DM8SXYG CA CAS 84057-84-1
DM8SXYG CB CHEBI:6367
DM8SXYG DE Bipolar disorder; Epilepsy
DMEH7YU ID DMEH7YU
DMEH7YU DN Lanadelumab
DMEH7YU HS Approved
DMEH7YU SN Lanadelumab [USAN]; UNII-2372V1TKXK; 2372V1TKXK; DX-2930
DMEH7YU CP Dyax/Shire
DMEH7YU DE Hereditary angioedema
DMG6ZU4 ID DMG6ZU4
DMG6ZU4 DN Lanreotide acetate
DMG6ZU4 HS Approved
DMG6ZU4 SN Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel
DMG6ZU4 CP Beaufour-Ipsen
DMG6ZU4 DT Small molecular drug
DMG6ZU4 PC 71349
DMG6ZU4 MW 1096.3
DMG6ZU4 FM C54H69N11O10S2
DMG6ZU4 IC InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)
DMG6ZU4 CS CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
DMG6ZU4 IK PUDHBTGHUJUUFI-UHFFFAOYSA-N
DMG6ZU4 IU 10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMG6ZU4 CA CAS 108736-35-2
DMG6ZU4 DE Acromegaly
DMXYLQ3 ID DMXYLQ3
DMXYLQ3 DN Lansoprazole
DMXYLQ3 HS Approved
DMXYLQ3 SN Lancid; Lanproton; Lansopep; Lansoprazol; Lansoprazol [INN-Spanish]; Lansoprazole [USAN:BAN:INN]; Lansoprazolum; Lansoprazolum [INN-Latin]; Lansox; Lanston; Lanzol-30; Lanzopral; Lanzor; Lasoprol; Limpidex; Mesactol; Monolitum; Ogastro; Opiren; Agopton; Aprazol; Bamalite; Blason; Compraz; Ilsatec; Ketian; Prevacid; Prevacid 24HR; Prevacid Iv; Prevacid NapraPAC; Prevacid SoluTab; Prezal; Pro Ulco; Prosogan; Suprecid; Takepron; Zoprol; lansoprazole; 103577-45-3; A-65006; AG 1749; AG-1749; CHEBI:6375; Dakar; HSDB 7204; Lanz; Lanzo; Ogast; Promp; Ulpax; Zoton
DMXYLQ3 PC 3883
DMXYLQ3 MW 369.4
DMXYLQ3 FM C16H14F3N3O2S
DMXYLQ3 IC MJIHNNLFOKEZEW-UHFFFAOYSA-N
DMXYLQ3 CS CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
DMXYLQ3 IK 1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
DMXYLQ3 IU 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMXYLQ3 CA CAS 103577-45-3
DMXYLQ3 CB CHEBI:6375
DMXYLQ3 DE Duodenal ulcer
DMMJQSH ID DMMJQSH
DMMJQSH DN Lanthanum carbonate
DMMJQSH HS Approved
DMMJQSH SN Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey
DMMJQSH CP Shire Pharm
DMMJQSH DT Small molecular drug
DMMJQSH PC 168924
DMMJQSH MW 457.84
DMMJQSH FM C3La2O9
DMMJQSH IC InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6
DMMJQSH CS C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]
DMMJQSH IK NZPIUJUFIFZSPW-UHFFFAOYSA-H
DMMJQSH IU lanthanum(3+);tricarbonate
DMMJQSH CA CAS 587-26-8
DMMJQSH DE Hypophosphatasia
DM3BH1Y ID DM3BH1Y
DM3BH1Y DN Lapatinib
DM3BH1Y HS Approved
DM3BH1Y SN FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)
DM3BH1Y CP GlaxoSmithKline
DM3BH1Y TC Anticancer Agents
DM3BH1Y DT Small molecular drug
DM3BH1Y PC 208908
DM3BH1Y MW 581.1
DM3BH1Y FM C29H26ClFN4O4S
DM3BH1Y IC InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
DM3BH1Y CS CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
DM3BH1Y IK BCFGMOOMADDAQU-UHFFFAOYSA-N
DM3BH1Y IU N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
DM3BH1Y CA CAS 231277-92-2
DM3BH1Y CB CHEBI:49603
DM3BH1Y DE Breast cancer
DM26CQR ID DM26CQR
DM26CQR DN Larotrectinib
DM26CQR HS Approved
DM26CQR SN UNII-PF9462I9HX; PF9462I9HX; ARRY 470; Larotrectinib [USAN:INN]; GTPL8909; SCHEMBL2241012; NYNZQNWKBKUAII-KBXCAEBGSA-N; BDBM136597; ZINC118399834; AKOS027338709; example 14 [US8865698 B2]; CS-5722; HY-12866; AS-35231; J3.628.138C; US8865698, 14; ARRY470; ARRY-470
DM26CQR CP Loxo Oncology/Bayer
DM26CQR PC 46188928
DM26CQR MW 428.4
DM26CQR FM C21H22F2N6O2
DM26CQR IC InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
DM26CQR CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F
DM26CQR IK NYNZQNWKBKUAII-KBXCAEBGSA-N
DM26CQR IU (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
DM26CQR CA CAS 1223403-58-4
DM26CQR DE Solid tumour/cancer
DMSQ1JV ID DMSQ1JV
DMSQ1JV DN LAS-34273
DMSQ1JV HS Approved
DMSQ1JV SN Bretaris; Eklira; Aclidinium bromide; LAS-W-330; [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oct-8-yl] 2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide
DMSQ1JV CP Almirall
DMSQ1JV DT Small molecular drug
DMSQ1JV PC 11519741
DMSQ1JV MW 564.6
DMSQ1JV FM C26H30BrNO4S2
DMSQ1JV IC InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
DMSQ1JV CS C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-]
DMSQ1JV IK XLAKJQPTOJHYDR-QTQXQZBYSA-M
DMSQ1JV IU [(3R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
DMSQ1JV CA CAS 320345-99-1
DMSQ1JV CB CHEBI:65344
DMSQ1JV DE Chronic obstructive pulmonary disease
DMXLVDT ID DMXLVDT
DMXLVDT DN Lasmiditan
DMXLVDT HS Approved
DMXLVDT SN COL-144; LY-573144; Migraine therapy, CoLucid
DMXLVDT CP Colucid pharmaceuticals
DMXLVDT DT Small molecular drug
DMXLVDT PC 11610526
DMXLVDT MW 377.4
DMXLVDT FM C19H18F3N3O2
DMXLVDT IC InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
DMXLVDT CS CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F
DMXLVDT IK XEDHVZKDSYZQBF-UHFFFAOYSA-N
DMXLVDT IU 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide
DMXLVDT CA CAS 439239-90-4
DMXLVDT DE Migraine
DMHA18P ID DMHA18P
DMHA18P DN Lasofoxifene
DMHA18P HS Approved
DMHA18P SN Oporia; 180916-16-9; rac-Lasofoxifene; CP 336156; Fablyn; UNII-337G83N988; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CHEMBL328190; 337G83N988; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 180915-78-0; CP-336,156; LASOFOXIFENE HCL; Lasofoxifene [INN:BAN]; AC1L50OI; SCHEMBL26815; GTPL7542; CTK8F1062; BDBM20606; DTXSID50171037; GXESHMAMLJKROZ-IAPPQJPRSA-N; ZINC3918428; BCP03626; AKOS030241621; AN-3516; BCP9000842; DB06202; Oporia; Lasofoxifene [INN]; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; AZD9639
DMHA18P CP Pfizer
DMHA18P DT Small molecular drug
DMHA18P PC 216416
DMHA18P MW 413.5
DMHA18P FM C28H31NO2
DMHA18P IC InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1
DMHA18P CS C1CCN(C1)CCOC2=CC=C(C=C2)[C@H]3[C@H](CCC4=C3C=CC(=C4)O)C5=CC=CC=C5
DMHA18P IK GXESHMAMLJKROZ-IAPPQJPRSA-N
DMHA18P IU (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
DMHA18P CA CAS 180916-16-9
DMHA18P CB CHEBI:135938
DMHA18P DE Osteoporosis; Virus infection
DMANL0D ID DMANL0D
DMANL0D DN Latamoxef
DMANL0D HS Approved
DMANL0D SN Festamoxin; LMOX; Lamoxactam; Latamoxefum; Moxalactam; Disodium Moxalactam; Lilly 127935; Ly127935; Sid 734787; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum [INN-Latin]; Oxa-cephem; S-6059; (6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid
DMANL0D TC Antibiotics
DMANL0D DT Small molecular drug
DMANL0D PC 47499
DMANL0D MW 520.5
DMANL0D FM C20H20N6O9S
DMANL0D IC InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
DMANL0D CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O
DMANL0D IK JWCSIUVGFCSJCK-CAVRMKNVSA-N
DMANL0D IU (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMANL0D CA CAS 64952-97-2
DMANL0D CB CHEBI:599928
DMANL0D DE Bacterial infection
DMI5OXG ID DMI5OXG
DMI5OXG DN Latanoprost
DMI5OXG HS Approved
DMI5OXG SN Catioprost; Xalatan; Latanoprost free acid; L1167_SIGMA; PhXA41; XA41; AR-202; Nova-21027; PHXA-41; XA-41; Xalatan (TN); Latanoprost (JAN/USAN/INN); PhXA34 [as 15(R,S)-isomer]; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
DMI5OXG CP Pfizer Pharmaceuticals
DMI5OXG TC Antihypertensive Agents
DMI5OXG DT Small molecular drug
DMI5OXG PC 5311221
DMI5OXG MW 432.6
DMI5OXG FM C26H40O5
DMI5OXG IC InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
DMI5OXG CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
DMI5OXG IK GGXICVAJURFBLW-CEYXHVGTSA-N
DMI5OXG IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DMI5OXG CA CAS 130209-82-4
DMI5OXG CB CHEBI:6384
DMI5OXG DE Open-angle glaucoma; Glaucoma/ocular hypertension; Ocular disease
DMLFX7K ID DMLFX7K
DMLFX7K DN LCZ696
DMLFX7K HS Approved
DMLFX7K SN DTXSID50239500
DMLFX7K CP Novartis Pharmaceuticals
DMLFX7K DT Small molecular drug
DMLFX7K PC 71300864
DMLFX7K MW 970
DMLFX7K FM C48H64N6Na3O11+3
DMLFX7K IC InChI=1S/C24H29N5O3.C24H29NO5.3Na.3H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;3*1H2/q;;3*+1;;;/t22-;17-,21+;;;;;;/m01....../s1
DMLFX7K CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O.O.O.O.[Na+].[Na+].[Na+]
DMLFX7K IK ACXLNSLRLQLEAL-HWSDWTSLSA-N
DMLFX7K IU trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid;trihydrate
DMLFX7K DE Heart failure
DME6G97 ID DME6G97
DME6G97 DN Lefamulin
DME6G97 HS Approved
DME6G97 SN UNII-21904A5386; 1061337-51-6; CHEMBL3291398; 21904A5386; Lefamulin [INN]; Acetic acid, 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3ah-cyclopentacycloocten-8-yl ester; Lefamulin(BC-3781); Lefamulin [USAN:INN]; Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten
DME6G97 CP Nabriva Therapeutics King of Prussia, PA
DME6G97 PC 25185057
DME6G97 MW 507.7
DME6G97 FM C28H45NO5S
DME6G97 IC InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1
DME6G97 CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C
DME6G97 IK KPVIXBKIJXZQJX-FCEONZPQSA-N
DME6G97 IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanylacetate
DME6G97 CA CAS 1061337-51-6
DME6G97 DE Acute bacterial skin infection; Community-acquired pneumonia
DMR8ONJ ID DMR8ONJ
DMR8ONJ DN Leflunomide
DMR8ONJ HS Approved
DMR8ONJ SN Arava; Leflunomid; Leflunomida; Leflunomidum; Lefunamide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; Hoechst Brand of Leflunomide; HWA 486; L 5025; SU 101; SU101; Arava (TN); Arava, Leflunomide; HWA-486; Leflunomida [INN-Spanish]; Leflunomide [USAN:INN]; Leflunomidum [INN-Latin]; Lefunomide [Inn-Spanish]; RS-34821; SU 101 (pharmaceutical); SU-101; AP-501/42475599; Leflunomide (JAN/USAN/INN); N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
DMR8ONJ CP Sanofi-Aventis
DMR8ONJ TC Antiinflammatory Agents
DMR8ONJ DT Small molecular drug
DMR8ONJ PC 3899
DMR8ONJ MW 270.21
DMR8ONJ FM C12H9F3N2O2
DMR8ONJ IC InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
DMR8ONJ CS CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
DMR8ONJ IK VHOGYURTWQBHIL-UHFFFAOYSA-N
DMR8ONJ IU 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
DMR8ONJ CA CAS 75706-12-6
DMR8ONJ CB CHEBI:6402
DMR8ONJ DE Arthritis; Multiple sclerosis
DM6Q7U4 ID DM6Q7U4
DM6Q7U4 DN Lenalidomide
DM6Q7U4 HS Approved
DM6Q7U4 SN Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
DM6Q7U4 CP Celgene Corporation
DM6Q7U4 TC Anticancer Agents
DM6Q7U4 DT Small molecular drug
DM6Q7U4 PC 216326
DM6Q7U4 MW 259.26
DM6Q7U4 FM C13H13N3O3
DM6Q7U4 IC InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
DM6Q7U4 CS C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
DM6Q7U4 IK GOTYRUGSSMKFNF-UHFFFAOYSA-N
DM6Q7U4 IU 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
DM6Q7U4 CA CAS 191732-72-6
DM6Q7U4 CB CHEBI:63791
DM6Q7U4 DE Multiple myeloma
DMB1IU4 ID DMB1IU4
DMB1IU4 DN Lenvatinib
DMB1IU4 HS Approved
DMB1IU4 SN E 7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
DMB1IU4 CP Eisai Co. Ltd.
DMB1IU4 DT Small molecular drug
DMB1IU4 PC 9823820
DMB1IU4 MW 426.9
DMB1IU4 FM C21H19ClN4O4
DMB1IU4 IC InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
DMB1IU4 CS COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
DMB1IU4 IK WOSKHXYHFSIKNG-UHFFFAOYSA-N
DMB1IU4 IU 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
DMB1IU4 CA CAS 417716-92-8
DMB1IU4 CB CHEBI:85994
DMB1IU4 DE Ovarian cancer; Hepatocellular carcinoma; Melanoma; Solid tumour/cancer; Non-small-cell lung cancer; Renal cell carcinoma; Thyroid cancer
DM1I3D5 ID DM1I3D5
DM1I3D5 DN Lepirudin
DM1I3D5 HS Approved
DM1I3D5 SN Refludan; Refludin; Aventis Behring Brand of Lepirudin; Aventis Brand Lepirudin; Aventis Pharma Brand of Lepirudin; Berlex Brand of Lepirudin; Hoechst Brand of Lepirudin; Lepirudin recombinant; Pharmion Brand of Lepirudin; Schering Brand of Lepirudin; Hbw 023; Hbw-023; 1-L-Leucine-2-L-threonine-63-desulfohirudin (Hirudomedicinalis isoform HV1); 1-Leu-2-thr-63-desulfohirudin
DM1I3D5 TC Antithrombotic Agents
DM1I3D5 DT Small molecular drug
DM1I3D5 SQ DB00001 sequence: LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ
DM1I3D5 PC 118856773
DM1I3D5 MW 6979
DM1I3D5 FM C287H440N80O111S6
DM1I3D5 IC InChI=1S/C287H440N80O111S6/c1-24-132(17)225-280(470)345-162(87-126(5)6)236(426)306-111-209(396)320-181(116-370)267(457)344-176(101-220(416)417)238(428)307-105-203(390)316-152(61-74-213(402)403)243(433)321-146(40-29-32-80-288)241(431)339-171(96-198(298)385)259(449)326-153(56-69-194(294)381)250(440)351-186(121-482-479-118-183-240(430)310-107-202(389)313-148(54-67-192(292)379)233(423)303-108-206(393)317-170(95-197(297)384)258(448)322-147(41-30-33-81-289)242(432)350-187(272(462)359-225)122-483-480-119-184(269(459)323-150(60-73-212(400)401)235(425)304-110-208(395)319-180(115-369)266(456)342-174(99-201(301)388)265(455)357-223(130(13)14)278(468)355-183)352-254(444)165(90-129(11)12)335-270(460)185-120-481-484-123-188(354-263(453)178(103-222(420)421)347-283(473)230(137(22)375)362-264(454)168(93-141-48-52-144(378)53-49-141)346-282(472)228(135(20)373)361-232(422)145(291)86-125(3)4)273(463)363-229(136(21)374)281(471)330-158(65-78-217(410)411)249(439)348-179(114-368)239(429)309-106-204(391)315-151(55-68-193(293)380)244(434)340-172(97-199(299)386)260(450)334-164(89-128(9)10)253(443)353-185)271(461)358-224(131(15)16)279(469)364-227(134(19)372)277(467)311-112-205(392)314-149(59-72-211(398)399)234(424)305-113-210(397)356-231(138(23)376)286(476)367-85-37-45-191(367)276(466)331-160(42-31-34-82-290)284(474)365-83-35-43-189(365)274(464)328-154(57-70-195(295)382)248(438)349-182(117-371)268(458)338-169(94-142-104-302-124-312-142)257(447)341-173(98-200(300)387)261(451)343-175(100-219(414)415)237(427)308-109-207(394)318-177(102-221(418)419)262(452)337-166(91-139-38-27-26-28-39-139)255(445)327-155(62-75-214(404)405)245(435)325-159(66-79-218(412)413)251(441)360-226(133(18)25-2)285(475)366-84-36-44-190(366)275(465)329-157(64-77-216(408)409)246(436)324-156(63-76-215(406)407)247(437)336-167(92-140-46-50-143(377)51-47-140)256(446)333-163(88-127(7)8)252(442)332-161(287(477)478)58-71-196(296)383/h26-28,38-39,46-53,104,124-138,145-191,223-231,368-378H,24-25,29-37,40-45,54-103,105-123,288-291H2,1-23H3,(H2,292,379)(H2,293,380)(H2,294,381)(H2,295,382)(H2,296,383)(H2,297,384)(H2,298,385)(H2,299,386)(H2,300,387)(H2,301,388)(H,302,312)(H,303,423)(H,304,425)(H,305,424)(H,306,426)(H,307,428)(H,308,427)(H,309,429)(H,310,430)(H,311,467)(H,313,389)(H,314,392)(H,315,391)(H,316,390)(H,317,393)(H,318,394)(H,319,395)(H,320,396)(H,321,433)(H,322,448)(H,323,459)(H,324,436)(H,325,435)(H,326,449)(H,327,445)(H,328,464)(H,329,465)(H,330,471)(H,331,466)(H,332,442)(H,333,446)(H,334,450)(H,335,460)(H,336,437)(H,337,452)(H,338,458)(H,339,431)(H,340,434)(H,341,447)(H,342,456)(H,343,451)(H,344,457)(H,345,470)(H,346,472)(H,347,473)(H,348,439)(H,349,438)(H,350,432)(H,351,440)(H,352,444)(H,353,443)(H,354,453)(H,355,468)(H,356,397)(H,357,455)(H,358,461)(H,359,462)(H,360,441)(H,361,422)(H,362,454)(H,363,463)(H,364,469)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,477,478)/t132-,133-,134+,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1
DM1I3D5 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CNC=N7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C
DM1I3D5 IK FIBJDTSHOUXTKV-BRHMIFOHSA-N
DM1I3D5 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM1I3D5 CA CAS 138068-37-8
DM1I3D5 CB CHEBI:142437
DM1I3D5 DE Thrombocytopenia
DMPWSEM ID DMPWSEM
DMPWSEM DN Lercanidipine
DMPWSEM HS Approved
DMPWSEM SN Lercanil; Masnidipine; Lercanidipine [INN]; Lercanidipine (INN); Lercanil (TN); REC 15-2375; Zanidip (TN); REC-15-2375; Methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-2-((3,3-Diphenylpropyl)methylamino)-1,1-dimethylethyl methyl1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester; 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMPWSEM CP Forest Laboratories
DMPWSEM TC Antihypertensive Agents
DMPWSEM DT Small molecular drug
DMPWSEM PC 65866
DMPWSEM MW 611.7
DMPWSEM FM C36H41N3O6
DMPWSEM IC InChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
DMPWSEM CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMPWSEM IK ZDXUKAKRHYTAKV-UHFFFAOYSA-N
DMPWSEM IU 5-O-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMPWSEM CA CAS 100427-26-7
DMPWSEM CB CHEBI:135930
DMPWSEM DE Hypertension
DMUR64T ID DMUR64T
DMUR64T DN Lesinurad
DMUR64T HS Approved
DMUR64T SN LESINURAD; 878672-00-5; RDEA594; Zurampic; RDEA 594; UNII-09ERP08I3W; RDEA-594; 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid; 09ERP08I3W; AK323774; C17H14BrN3O2S; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid; 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
DMUR64T CP Ardea Biosciences
DMUR64T DT Small molecular drug
DMUR64T PC 53465279
DMUR64T MW 404.3
DMUR64T FM C17H14BrN3O2S
DMUR64T IC InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)
DMUR64T CS C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O
DMUR64T IK FGQFOYHRJSUHMR-UHFFFAOYSA-N
DMUR64T IU 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
DMUR64T CA CAS 878672-00-5
DMUR64T CB CHEBI:90929
DMUR64T DE Hyperuricaemia
DMQ2AIJ ID DMQ2AIJ
DMQ2AIJ DN Lestaurtinib
DMQ2AIJ HS Approved (orphan drug)
DMQ2AIJ SN A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
DMQ2AIJ CP Cephalon; Kyowa Hakko Kogyo
DMQ2AIJ TC Anticancer Agents
DMQ2AIJ DT Small molecular drug
DMQ2AIJ PC 126565
DMQ2AIJ MW 439.5
DMQ2AIJ FM C26H21N3O4
DMQ2AIJ IC InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1
DMQ2AIJ CS C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
DMQ2AIJ IK UIARLYUEJFELEN-LROUJFHJSA-N
DMQ2AIJ IU (15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
DMQ2AIJ CA CAS 111358-88-4
DMQ2AIJ CB CHEBI:91471
DMQ2AIJ DE Acute myeloid leukaemia; Psoriasis vulgaris; Myeloid leukaemia
DMH07Y3 ID DMH07Y3
DMH07Y3 DN Letrozole
DMH07Y3 HS Approved
DMH07Y3 SN Femara; Femera; Letoval; Letrozol; Novartis Brand of Letrozole; CGS 20267; CGS-20267; FEM-345; Femara (TN); Letrozole [USAN:INN]; CGS 20267, Femara, Piroxicam, Letrozole; Letrozole (JAN/USP/INN); 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
DMH07Y3 TC Anticancer Agents
DMH07Y3 DT Small molecular drug
DMH07Y3 PC 3902
DMH07Y3 MW 285.3
DMH07Y3 FM C17H11N5
DMH07Y3 IC InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
DMH07Y3 CS C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
DMH07Y3 IK HPJKCIUCZWXJDR-UHFFFAOYSA-N
DMH07Y3 IU 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
DMH07Y3 CA CAS 112809-51-5
DMH07Y3 CB CHEBI:6413
DMH07Y3 DE Hormonally-responsive breast cancer
DMUAZWG ID DMUAZWG
DMUAZWG DN Leucovorin
DMUAZWG HS Approved
DMUAZWG SN 5-formyltetrahydrofolate; Citrovorum factor; Folinic acid
DMUAZWG TC Vitamins
DMUAZWG DT Small molecular drug
DMUAZWG PC 135403648
DMUAZWG MW 473.446
DMUAZWG FM C20H23N7O7
DMUAZWG IC InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
DMUAZWG CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DMUAZWG IK VVIAGPKUTFNRDU-ABLWVSNPSA-N
DMUAZWG IU (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMUAZWG CA CAS 58-05-9
DMUAZWG CB CHEBI:15640
DMUAZWG DE Colorectal cancer
DMNWZJG ID DMNWZJG
DMNWZJG DN Leucovorin Calcium
DMNWZJG HS Approved
DMNWZJG SN Leucovorin Calcium Preservative Free; Wellcovorin
DMNWZJG CP Hospira Inc
DMNWZJG TC Anticancer Agents
DMNWZJG DT Small molecular drug
DMNWZJG PC 135403647
DMNWZJG MW 511.5
DMNWZJG FM C20H21CaN7O7
DMNWZJG IC InChI=1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12?,13-;/m0./s1
DMNWZJG CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2]
DMNWZJG IK KVUAALJSMIVURS-ZEDZUCNESA-L
DMNWZJG IU calcium;(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioate
DMNWZJG CA CAS 1492-18-8
DMNWZJG CB CHEBI:31340
DMNWZJG DE Solid tumour/cancer
DMZT4N7 ID DMZT4N7
DMZT4N7 DN Leucovorin/5-fluorouracil
DMZT4N7 HS Approved
DMZT4N7 TC Vitamins
DMZT4N7 DT Small molecular drug
DMZT4N7 PC 54575
DMZT4N7 DE Colon cancer
DM5XPIJ ID DM5XPIJ
DM5XPIJ DN Leuprolide
DM5XPIJ HS Approved
DM5XPIJ SN Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
DM5XPIJ CP Abbott Laboratories
DM5XPIJ TC Anticancer Agents
DM5XPIJ DT Small molecular drug
DM5XPIJ SQ Leuprolide: PHWSYLLR
DM5XPIJ PC 657181
DM5XPIJ MW 1209.4
DM5XPIJ FM C59H84N16O12
DM5XPIJ IC InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
DM5XPIJ CS CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
DM5XPIJ IK GFIJNRVAKGFPGQ-LIJARHBVSA-N
DM5XPIJ IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM5XPIJ CA CAS 53714-56-0
DM5XPIJ CB CHEBI:6427
DM5XPIJ DE Prostate cancer
DM15HAT ID DM15HAT
DM15HAT DN Leuprorelin acetate
DM15HAT HS Approved
DM15HAT SN Leuprolide acetate; Leuplin (TN); Leuprorelin acetate (JAN); 5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
DM15HAT CP Takeda
DM15HAT DT Small molecular drug
DM15HAT PC 657180
DM15HAT MW 1269.4
DM15HAT FM C61H88N16O14
DM15HAT IC InChI=1S/C59H84N16O12.C2H4O2/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40;1-2(3)4/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64);1H3,(H,3,4)/t40-,41-,42-,43+,44-,45-,46-,47-,48-;/m0./s1
DM15HAT CS CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O
DM15HAT IK RGLRXNKKBLIBQS-XNHQSDQCSA-N
DM15HAT IU acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM15HAT CA CAS 74381-53-6
DM15HAT CB CHEBI:63597
DM15HAT DE Prostate cancer
DMJBOCR ID DMJBOCR
DMJBOCR DN Levacecarnine HCL
DMJBOCR HS Approved
DMJBOCR SN Levocarnitine; L-carnitine; 541-15-1; vitamin BT; (R)-Carnitine; Carnitor; (-)-Carnitine; Carnitine; Karnitin; (-)-L-Carnitine; L-(-)-Carnitine; Levocarnitina; Carnitene; Levocarnitinum; Metina; L-Carnitine inner salt; Carniking; Carnovis; Carnitolo; Carnilean; Carrier; Lefcar; Carnitine, (-)-; L-carnitine Base; Levocarnitinum [Latin]; Levocarnitina [Spanish]; ST 198; L(-)-Carnitine; Carniking 50; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; Levocarnitine [USAN:INN]; gamma-Trimethyl-beta-hydroxybutyrobetaine; bicarnesine; Nicetile (TN); L-Carnitine
DMJBOCR DT Small molecular drug
DMJBOCR PC 10917
DMJBOCR MW 161.2
DMJBOCR FM C7H15NO3
DMJBOCR IC InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1
DMJBOCR CS C[N+](C)(C)C[C@@H](CC(=O)[O-])O
DMJBOCR IK PHIQHXFUZVPYII-ZCFIWIBFSA-N
DMJBOCR IU (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate
DMJBOCR CA CAS 541-15-1
DMJBOCR CB CHEBI:16347
DMJBOCR DE Nutritional deficiency; Cognitive impairment
DM5YBO1 ID DM5YBO1
DM5YBO1 DN Levalbuterol
DM5YBO1 HS Approved
DM5YBO1 SN Levosalbutamol; 34391-04-3; (R)-salbutamol; Xopenex; R-Salbutamol; R-Albuterol; (r)-(-)-salbutamol; UNII-EDN2NBH5SS; 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; EDN2NBH5SS; CHEBI:8746; Levosalbutamol (INN); Levosalbutamol [INN]; (R)-albuterol; m-Xylene-alpha,alpha'-diol, alpha(sup 1)-((tert-butylamino)methyl)-4-hydroxy-, (R)-(-)-; (-)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
DM5YBO1 DT Small molecular drug
DM5YBO1 PC 123600
DM5YBO1 MW 239.31
DM5YBO1 FM C13H21NO3
DM5YBO1 IC InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1
DM5YBO1 CS CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O
DM5YBO1 IK NDAUXUAQIAJITI-LBPRGKRZSA-N
DM5YBO1 IU 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DM5YBO1 CA CAS 34391-04-3
DM5YBO1 CB CHEBI:8746
DM5YBO1 DE Asthma
DMCOLUP ID DMCOLUP
DMCOLUP DN Levallorphan
DMCOLUP HS Approved
DMCOLUP SN Levallofano; Levallorphane; Levallorphanum; Levalorfano; Naloxiphan; Levallofano [DCIT]; Levallorphan [INN:BAN]; Levallorphane [INN-French]; Levallorphanum [INN-Latin]; Levalorfano [INN-Spanish]; Lorfan (TN); Ro-1-7700; N-Allyl-3-hydroxymorphinan; L-N-Allyl-3-hydroxymorphinan; Levo-3-hydroxy-N-allyl morphinan; (-)-3-Hydroxy-N-allylmorphinan; 17-Allylmorphinan-3-ol; 17-prop-2-en-1-ylmorphinan-3-ol
DMCOLUP CP Hoffmann La Roche Inc
DMCOLUP TC Antinarcotic Agents
DMCOLUP DT Small molecular drug
DMCOLUP PC 5359371
DMCOLUP MW 283.4
DMCOLUP FM C19H25NO
DMCOLUP IC InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1
DMCOLUP CS C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMCOLUP IK OZYUPQUCAUTOBP-QXAKKESOSA-N
DMCOLUP IU (1R,9R,10R)-17-prop-2-enyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMCOLUP CA CAS 152-02-3
DMCOLUP CB CHEBI:6431
DMCOLUP DE Narcotic depression
DM5EN79 ID DM5EN79
DM5EN79 DN Levamisole
DM5EN79 HS Approved
DM5EN79 SN Ketrax; LEVOMYSOL; Lepuron; Levamisol; Levamisolum; Levotetramisole; Tetramisol; Wormicid; Levamisole Base;Nilverm base; P00039; Vermisol 150; Dl-Tetramisol; Dl-Tetramisole; Ergamisol (TN); Ketrax (TN); L-Tetramisole; Levamisol [INN-Spanish]; Levamisole (INN); Levamisole [INN:BAN]; Levamisolum [INN-Latin]; TCMDC-125847; L(-)-Levamisole; L-2,3,5,6-Tetrahyro-6-phenylimidazo(2,1-b)thiazole; (-)-Tetramisole; (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole; (S)-(-)-Levamisole
DM5EN79 CP Janssen Pharmaceutica
DM5EN79 TC Anticancer Agents
DM5EN79 DT Small molecular drug
DM5EN79 PC 26879
DM5EN79 MW 204.29
DM5EN79 FM C11H12N2S
DM5EN79 IC InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1
DM5EN79 CS C1CSC2=N[C@H](CN21)C3=CC=CC=C3
DM5EN79 IK HLFSDGLLUJUHTE-SNVBAGLBSA-N
DM5EN79 IU (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole
DM5EN79 CA CAS 14769-73-4
DM5EN79 CB CHEBI:6432
DM5EN79 DE Parasitic infection; Colon cancer
DMTGDN8 ID DMTGDN8
DMTGDN8 DN Levetiracetam
DMTGDN8 HS Approved
DMTGDN8 SN 102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Keppra; Leviteracetam; Torleva; Levetiracetam [INN]; Ucb L060; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam
DMTGDN8 CP UCB Pharmaceuticals Inc
DMTGDN8 TC Anticonvulsants
DMTGDN8 DT Small molecular drug
DMTGDN8 PC 5284583
DMTGDN8 MW 170.21
DMTGDN8 FM C8H14N2O2
DMTGDN8 IC InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
DMTGDN8 CS CC[C@@H](C(=O)N)N1CCCC1=O
DMTGDN8 IK HPHUVLMMVZITSG-LURJTMIESA-N
DMTGDN8 IU (2S)-2-(2-oxopyrrolidin-1-yl)butanamide
DMTGDN8 CA CAS 102767-28-2
DMTGDN8 CB CHEBI:6437
DMTGDN8 DE Fibromyalgia; Epilepsy
DMSREPX ID DMSREPX
DMSREPX DN Levobetaxolol
DMSREPX HS Approved
DMSREPX SN Levobetaxolol [INN]; Betaxon (TN); (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol
DMSREPX CP Alcon Pharmaceuticals Ltd
DMSREPX TC Cardiotonic Agents
DMSREPX DT Small molecular drug
DMSREPX PC 60657
DMSREPX MW 307.4
DMSREPX FM C18H29NO3
DMSREPX IC InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
DMSREPX CS CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O
DMSREPX IK NWIUTZDMDHAVTP-KRWDZBQOSA-N
DMSREPX IU (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMSREPX CA CAS 93221-48-8
DMSREPX CB CHEBI:59254
DMSREPX DE Chronic open-angle glaucoma
DMTNFCQ ID DMTNFCQ
DMTNFCQ DN Levobunolol
DMTNFCQ HS Approved
DMTNFCQ SN Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one
DMTNFCQ CP Allergan Pharmaceuticals
DMTNFCQ TC Sympatholytics
DMTNFCQ DT Small molecular drug
DMTNFCQ PC 39468
DMTNFCQ MW 291.4
DMTNFCQ FM C17H25NO3
DMTNFCQ IC InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
DMTNFCQ CS CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O
DMTNFCQ IK IXHBTMCLRNMKHZ-LBPRGKRZSA-N
DMTNFCQ IU 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one
DMTNFCQ CA CAS 47141-42-4
DMTNFCQ CB CHEBI:6438
DMTNFCQ DE Open-angle glaucoma
DM783CH ID DM783CH
DM783CH DN Levobupivacaine
DM783CH HS Approved
DM783CH SN Novabupi; Chirocaine (TN); Levobupivacaine (INN); Levobupivacaine [INN:BAN]; Novabupi (TN); L(-)-Bupivacaine; L-(-)-bupivacaine; L-(-)-1-Butyl-2',6'-pipecoloxylidide; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; (S)-1-Butyl-2',6'-pipecoloxylidide; (S)-bupivacaine
DM783CH CP AstraZeneca
DM783CH TC Anesthetics
DM783CH DT Small molecular drug
DM783CH PC 92253
DM783CH MW 288.4
DM783CH FM C18H28N2O
DM783CH IC InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1
DM783CH CS CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
DM783CH IK LEBVLXFERQHONN-INIZCTEOSA-N
DM783CH IU (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DM783CH CA CAS 27262-47-1
DM783CH CB CHEBI:6149
DM783CH DE Anaesthesia
DMMZPWT ID DMMZPWT
DMMZPWT DN Levocabastine
DMMZPWT HS Approved
DMMZPWT SN Levocabastin; Levocabastina; Levocabastinum; Livostin; Levocabastina [Spanish]; Levocabastinum [Latin]; Levocabastine (INN); Levocabastine [INN:BAN]; Livostin (TN); (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid; 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid
DMMZPWT CP Janssen Pharmaceutica
DMMZPWT TC Antiallergic Agents
DMMZPWT DT Small molecular drug
DMMZPWT PC 54385
DMMZPWT MW 420.5
DMMZPWT FM C26H29FN2O2
DMMZPWT IC InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23?,25?,26-/m1/s1
DMMZPWT CS C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F
DMMZPWT IK ZCGOMHNNNFPNMX-YHYDXASRSA-N
DMMZPWT IU (3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid
DMMZPWT CA CAS 79449-98-2
DMMZPWT CB CHEBI:92584
DMMZPWT DE Allergic conjunctivitis
DMQYLGP ID DMQYLGP
DMQYLGP DN Levocetirizine
DMQYLGP HS Approved
DMQYLGP SN (-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
DMQYLGP DT Small molecular drug
DMQYLGP PC 1549000
DMQYLGP MW 388.892
DMQYLGP FM C21H25ClN2O3
DMQYLGP IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
DMQYLGP CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMQYLGP IK ZKLPARSLTMPFCP-OAQYLSRUSA-N
DMQYLGP IU 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMQYLGP CA CAS 130018-77-8
DMQYLGP CB CHEBI:94559
DMQYLGP DE Allergy
DMW6ZJI ID DMW6ZJI
DMW6ZJI DN Levocetirizine dihydrochloride
DMW6ZJI HS Approved
DMW6ZJI SN Xyzal; Xyzall; Levocetirizine HCl; Levocetirizine dihydrochloride [USAN]; Levocetirizine hydrochloride; Levocetirizine 2HCl; KS-1177; Levocetirizine hydrochloride (JAN); Vozet (TN); Xozal (TN); Xusal (TN); Xuzal (TN); Xyzal (TN); Xyzall (TN); Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride; (2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
DMW6ZJI CP GlaxoSmithKline
DMW6ZJI TC Antiallergic Agents
DMW6ZJI DT Small molecular drug
DMW6ZJI PC 9955977
DMW6ZJI MW 461.8
DMW6ZJI FM C21H27Cl3N2O3
DMW6ZJI IC InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H/t21-;;/m1../s1
DMW6ZJI CS C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
DMW6ZJI IK PGLIUCLTXOYQMV-GHVWMZMZSA-N
DMW6ZJI IU 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
DMW6ZJI CA CAS 130018-87-0
DMW6ZJI DE Allergic rhinitis
DMN3E57 ID DMN3E57
DMN3E57 DN Levodopa
DMN3E57 HS Approved
DMN3E57 SN Levodopa (optimized formulation, Parkinson's disease); More effective levodopa (Parkinson's disease), Orion; Levodopa (optimized formulation, Parkinson's disease), Orion
DMN3E57 CP Orion Corp
DMN3E57 DT Small molecular drug
DMN3E57 PC 6047
DMN3E57 MW 197.19
DMN3E57 FM C9H11NO4
DMN3E57 IC InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
DMN3E57 CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
DMN3E57 IK WTDRDQBEARUVNC-LURJTMIESA-N
DMN3E57 IU (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
DMN3E57 CA CAS 59-92-7
DMN3E57 CB CHEBI:15765
DMN3E57 DE Parkinson disease
DMS60RB ID DMS60RB
DMS60RB DN Levofloxacin
DMS60RB HS Approved
DMS60RB SN Aeroquin; Cravit; Elequine; Floxacin; Floxel; Iquix; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levofloxacine; Levofloxacino; Levofloxacinum; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Oftaquix; Quixin; Reskuin; Tavanic; Volequin; Cravit Ophthalmic; DR 3354; DR3355; HR 355; Cravit (TN); D-Levofloxacin; DR-3355; HR-355; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Levaquin (TN); Levofloxacin (INN); Levofloxacin tablet, suspension or intravenous; Levofloxacine [INN-French]; Levofloxacino [INN-Spanish]; Levofloxacinum [INN-Latin]; MP-376; Oftaquix (TN); Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Tavanic (TN); Levofloxacin [USAN:INN:JAN]; DR-3355: L-isomer of ofloxacin; Ofloxacin S-(-)-form; S-(-)-Ofloxacin; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin
DMS60RB CP Sanofi-Aventis
DMS60RB TC Antibiotics
DMS60RB DT Small molecular drug
DMS60RB PC 149096
DMS60RB MW 361.4
DMS60RB FM C18H20FN3O4
DMS60RB IC InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
DMS60RB CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
DMS60RB IK GSDSWSVVBLHKDQ-JTQLQIEISA-N
DMS60RB IU (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMS60RB CA CAS 100986-85-4
DMS60RB CB CHEBI:63598
DMS60RB DE Bacterial infection
DMUV5JB ID DMUV5JB
DMUV5JB DN Levomefolic acid
DMUV5JB HS Approved
DMUV5JB SN Levomefolic acid; Levomefolinic acid; Metafolin; Metafolin (TN); L-5-Methyltetrahydrofolate; LEVOMEFOLATE; (6s)-5-methyltetrahydrofolic acid; (S)-2-(4-((((S)-2-Amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzamido)pentanedioic acid; 31690-09-2; 5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID; 5-Methyltetrahydrofolate; 8S95DH25XC; C20H25N7O6; CHEBI:15641; LMSR; N-(5-methyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid; UNII-8S95DH25XC; [(6S)-5-methyl-5,6,7,8-tetrahydropteroyl]glutamate
DMUV5JB PC 135398561
DMUV5JB MW 459.5
DMUV5JB FM C20H25N7O6
DMUV5JB IC ZNOVTXRBGFNYRX-STQMWFEESA-N
DMUV5JB CS CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DMUV5JB IK 1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12-,13-/m0/s1
DMUV5JB IU (2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DMUV5JB CA CAS 31690-09-2
DMUV5JB CB CHEBI:15641
DMUV5JB DE Contraception
DMIKFEL ID DMIKFEL
DMIKFEL DN Levomepromazine
DMIKFEL HS Approved
DMIKFEL SN METHOTRIMEPRAZINE; Nozinan; 60-99-1; Levoprome; Levomepromazina; Levomepromazinum; Levomepromazin; Nosinan; UNII-9G0LAW7ATQ; 2-Methoxytrimeprazine; Neozine; Levotomin; Minozinan; Milezin; 9G0LAW7ATQ; RP-7044; Levopromazioni; Veractil; Nomizan; Hirnamine; Dedoran; Nocinan; Nirnamine; CHEBI:6838; XP03; Methoxytrimeprazine; F-5116; Methotrimeprazine [USP]; Methotrimeprazine (USP); Bayer 1213; Arc-VI-C-5; CL 36467; CL 39743; Levomepromazinum [INN-Latin]; Levomepromazina [INN-Spanish]; EINECS 200-495-5; Methotrimeprazine
DMIKFEL CP Immunex Corp
DMIKFEL DT Small molecular drug
DMIKFEL PC 72287
DMIKFEL MW 328.5
DMIKFEL FM C19H24N2OS
DMIKFEL IC InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1
DMIKFEL CS C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C
DMIKFEL IK VRQVVMDWGGWHTJ-CQSZACIVSA-N
DMIKFEL IU (2R)-3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
DMIKFEL CA CAS 60-99-1
DMIKFEL CB CHEBI:6838
DMIKFEL DE Psychotic disorder; Bipolar disorder
DM06HG5 ID DM06HG5
DM06HG5 DN Levomethadyl Acetate
DM06HG5 HS Approved
DM06HG5 SN LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)
DM06HG5 CP Roxane Laboratories
DM06HG5 TC Analgesics
DM06HG5 DT Small molecular drug
DM06HG5 PC 15130
DM06HG5 MW 353.5
DM06HG5 FM C23H31NO2
DM06HG5 IC InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
DM06HG5 CS CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
DM06HG5 IK XBMIVRRWGCYBTQ-AVRDEDQJSA-N
DM06HG5 IU [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
DM06HG5 CA CAS 1477-40-3
DM06HG5 CB CHEBI:6441
DM06HG5 DE Opioid dependence
DM429AE ID DM429AE
DM429AE DN Levomethadyl acetate hydrochloride
DM429AE HS Approved
DM429AE SN Levacetilmetadol; Levacetilmetadol [INN-Spanish]; Levacetylmethadol; Levacetylmethadol (INN); Levacetylmethadol [INN]; Levacetylmethadolum; Levacetylmethadolum [INN-Latin]; Levomethadyl; Levomethadyl acetate; Levacetyl methadol hydrochloride; LAAM hydrochloride; Levomethadyl acetate HCl; MK 790; MK-790 hydrochloride; ORLAAM hydrochloride; l-Acetylmethadol hydrochloride; (-)-(3S,6S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), hydrochloride; 43033-72-3; 6-Dimethylamino-4,4-diphenyl-3-heptanolacetate.HCl; B54CW5KG52; CCRIS 3321; Levomethadyl acetate hydrochloride; Levomethadyl acetate hydrochloride [USAN]; UNII-B54CW5KG52; alpha-l-Acetylmethadol hydrochloride; l-alpha-Acetylmethadol hydrochloride; N-alpha-Acetylmethadol; Orlaam; alpha-l-Acetylmethadol; l-alpha-Acetylmethadol; levo-Alphacetylmethadol; levo-Methadyl acetate; levo-alpha-Acetylmethadol; (-)-alpha-Acetylmethadol; 1-alpha-Acetylmethadol; 1477-40-3; DEA No. 9648; LAAM; UNII-R3B637Y991; alpha-(-)-Acetylmethadol
DM429AE PC 39371
DM429AE MW 390
DM429AE FM C23H32ClNO2
DM429AE IC UXBPQRGCVJOTNT-COBSGTNCSA-N
DM429AE CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.Cl
DM429AE IK 1S/C23H31NO2.ClH/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21;/h7-16,18,22H,6,17H2,1-5H3;1H/t18-,22-;/m0./s1
DM429AE IU [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate;hydrochloride
DM429AE CA CAS 43033-72-3
DM429AE CB CHEBI:6442
DM429AE DE Opiate dependence
DMV26S8 ID DMV26S8
DMV26S8 DN Levomilnacipran
DMV26S8 HS Approved
DMV26S8 SN Fetzima; UNII-UGM0326TXX; Levomilnacipran HCl; 96847-54-0; UGM0326TXX; CHEMBL99946; F-2695; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; Levomilnacipran [USAN:INN]; Milnacipram; AC1OCEN8; F 2695; Levomilnacipran (USAN/INN); ZINC506; SCHEMBL1414867; GTPL7435; GJJFMKBJSRMPLA-DZGCQCFKSA-N; CHEBI:136040; BDBM50032379; SB17447; DB08918; f2-695; D10072
DMV26S8 CP Forest Laboratories
DMV26S8 DT Small molecular drug
DMV26S8 PC 6917779
DMV26S8 MW 246.35
DMV26S8 FM C15H22N2O
DMV26S8 IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1
DMV26S8 CS CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2
DMV26S8 IK GJJFMKBJSRMPLA-DZGCQCFKSA-N
DMV26S8 IU (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMV26S8 CA CAS 96847-54-0
DMV26S8 CB CHEBI:136040
DMV26S8 DE Fibromyalgia
DM1DP7T ID DM1DP7T
DM1DP7T DN Levonorgestrel
DM1DP7T HS Approved
DM1DP7T SN norgestrel; 797-63-7; D-Norgestrel; (-)-Norgestrel; Microval; Levonova; Postinor; Mirena; Ovrette; Neogest; Jadelle; Plan B; NORPLANT; Norplant 2; Microlution; Follistrel; Trivora; Monovar; Triciclor; Microgyn; Ovranette; Triagynon; Microlut; Nordet; Trigoa; 18-Methylnorethisterone; Levonorgestrelum; Microgynon CD; Microgest ED; Norplant II; Ovral-Lo; Logynon ED; Levlen ED; Trinordiol 28; Trinordiol 21; Microgynon 28; Microgynon 21; d(-)-Norgestrel; Neogynon 21; Monofeme 28; Nordette 28; Minivlar 30; Stediril 30; Nordette 21; Trifeme; Capronor; DNorgestrel; Levlen; Levonelle; Methylnorethindrone; Microluton; NorLevo; Norgeston; Norgestrel; Norgestrelum; Preven; Tetragynon; LD norgestrel [French]; Ld norgestrel; Levonorgestrel implants; Norgestrel [Progestins]; Norplant System in Plastic Container; Triquilar ED; Microgynon 30 ED; SH 70850; SH 850; Trifeme 28; Triphasil 21; Triphasil 28; Wy 3707; Alpha-Norgestrel; Component of Lo/ovral; Dl-Norgestrel; FH 122-A; LO/Ovral; Levonorgestrelum [INN-Latin]; Levora-21; Levora-28; Mirena (TN); Norgestrelum [INN-Latin]; Norplant (TN); Norplant-2; Ovoplex 30-150; Ovrette (TN); Postinor-2; Rigevidon 21+7; SOH-075; Tri-Levlen 21; Wy-3707; Wy-5104; E-Gen-C; Levonorgestrel [USAN:INN:BAN]; D(-)-Norgestrel; Levonorgestrel (JAN/USP/INN); Norgestrel (JP15/USP/INN); Norgestrel [USAN:BAN:INN:JAN]; Norgestrel [USAN:INN:BAN:JAN]; D-(-)-Norgestrel; Levonelle, D-Norgestrel, Levonova, Levonorgestrel; Norgestrel-(-)-D; Dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; 13-BETA-ETHYL-17-ALPHA-ETHYNYL-17-BETA-HYDROXYGON-4-EN-3-ONE; 13-Ehyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 17-Ethynyl-18-methyl-19-nortestosterone; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; 17alpha-Ethynyl-18-homo-19-nor-testosterone; 17alpha-Ethynyl-18-homo-19-nortestosterone; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; 18,19-Dinor-4-pregnen-20-yn-3-one; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; 72-HOURS
DM1DP7T TC Contraceptive Agents
DM1DP7T DT Small molecular drug
DM1DP7T PC 13109
DM1DP7T MW 312.4
DM1DP7T FM C21H28O2
DM1DP7T IC InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
DM1DP7T CS CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DM1DP7T IK WWYNJERNGUHSAO-XUDSTZEESA-N
DM1DP7T IU (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM1DP7T CA CAS 797-63-7
DM1DP7T CB CHEBI:6443
DM1DP7T DE Contraception
DMECB4H ID DMECB4H
DMECB4H DN Levopropoxyphene Napsylate Anhydrous
DMECB4H HS Approved
DMECB4H SN Novrad
DMECB4H CP Eli Lilly Industries Inc
DMECB4H DT Small molecular drug
DMECB4H PC 6604497
DMECB4H MW 547.7
DMECB4H FM C32H37NO5S
DMECB4H IC InChI=1S/C22H29NO2.C10H8O3S/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13)/t18-,22+;/m0./s1
DMECB4H CS CCC(=O)O[C@@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@@H](C)CN(C)C.C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O
DMECB4H IK VZPXFHVJUUSVLH-VNJAQMQMSA-N
DMECB4H IU [(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;naphthalene-2-sulfonic acid
DMECB4H CA CAS 5714-90-9
DMECB4H DE Cough
DM2XVNI ID DM2XVNI
DM2XVNI DN Levormeloxifene
DM2XVNI HS Approved
DM2XVNI SN Centchroman; Centron; Levormeloxifene; Ormeloxifene; Saheli; NNC-46-0020; Non-steroidal (oral, contraception/cancer); Non-steroidal (oral, contraception/cancer), Central Drug Research Institute (CDRI)
DM2XVNI CP Novo Nordisk A/S; Central Drug Research Institute
DM2XVNI DT Small molecular drug
DM2XVNI PC 35805
DM2XVNI MW 457.6
DM2XVNI FM C30H35NO3
DM2XVNI IC InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1
DM2XVNI CS CC1([C@H]([C@@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
DM2XVNI IK XZEUAXYWNKYKPL-WDYNHAJCSA-N
DM2XVNI IU 1-[2-[4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine
DM2XVNI CA 78994-23-7
DM2XVNI DE Breast cancer
DMGS80V ID DMGS80V
DMGS80V DN Levorphanol
DMGS80V HS Approved
DMGS80V SN levorphanol; Levorphan; Methorphinan; Aromarone; Racemethorphanum; Dromoran; Cetarin; Antalgin; Levo-Dromoran; Racemic dromoran; Methorfinan [Czech]; Levorfanolo [DCIT]; Levorphanolum; Levorfanol; Orphan; Levorfanol [INN-Spanish]; Levorphanolum [INN-Latin]; Racemorfano [INN-Spanish]; 17-Methylmorphinan-3-ol; N-Methyl-3-hydroxymorphinan; Racemorphan; Racemorphan [INN:BAN]; Racemorphane [INN-French]; Racemorphanum [INN-Latin]; (-)-N-Methylmorphinan-3-ol; Morphinan-3-ol, 17-methyl-; Levorphanal; dl-3-Hydroxy-N-methylmorphinan; DEA No; Antalgin; DEXTRORPHAN; Levodroman; Levorfanolo; Methorfinan; Racemorfano; Racemorphane; Racemorphanum; NU 2206; L-Dromoran; Levorphanol (INN); Ro 1-5431; Levo-Dromoran (TN); Dl-3-Hydroxy-N-methylmorphinan; (+)-3-Hydroxy-17-methylmorphinan; (+-)-17-Methylmorphinan-3-ol; (+-)-3-Hydroxy-N-methylmorphinan; (-)-3-Hydroxy-N-methylmorphinan; 1,3,4,9,10,10a-Hexahydro-11-methyl-2H-10,4a-iminoethanophenanthren-6-ol, dl-mixture; 1,3,4,9,10,10a-Hexahydro-6-hydroxy-2H-10,4a-(iminoethano)-11-methylphenanthrene; 3-Hydroxy-N-methylmorphinan; Dextrorphan
DMGS80V CP Roxane Laboratories
DMGS80V TC Analgesics
DMGS80V DT Small molecular drug
DMGS80V PC 5359272
DMGS80V MW 257.37
DMGS80V FM C17H23NO
DMGS80V IC InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1
DMGS80V CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMGS80V IK JAQUASYNZVUNQP-USXIJHARSA-N
DMGS80V IU (1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMGS80V CA CAS 297-90-5
DMGS80V CB CHEBI:6444
DMGS80V DE Pain; Ischemic stroke
DMKBOS2 ID DMKBOS2
DMKBOS2 DN Levosimendan
DMKBOS2 HS Approved
DMKBOS2 SN Levosimedan; Levosimendanum; Simdax; Levosimendan [INN]; Simdax (TN); Levosimendan (USAN/INN); Mesoxalonitrile(p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; (-)-OR-1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
DMKBOS2 CP Abbott Laboratories
DMKBOS2 TC Cardiotonic Agents
DMKBOS2 DT Small molecular drug
DMKBOS2 PC 3033825
DMKBOS2 MW 280.28
DMKBOS2 FM C14H12N6O
DMKBOS2 IC InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1
DMKBOS2 CS C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N
DMKBOS2 IK WHXMKTBCFHIYNQ-SECBINFHSA-N
DMKBOS2 IU 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
DMKBOS2 CA CAS 141505-33-1
DMKBOS2 CB CHEBI:50567
DMKBOS2 DE Cardiac output syndrome; Pulmonary hypertension; Congestive heart failure; Heart failure
DMHN027 ID DMHN027
DMHN027 DN Levothyroxine
DMHN027 HS Approved
DMHN027 SN Eltroxin; Euthyrox; Forthyron; Laevothyroxinum; Laevoxin; Levolet; Levothroid; Levothyrox; Levothyroxin; Levoxyl; Oroxine; Synthroid; THX; Tetraiodothyronine; Thyratabs; Thyrax; Thyreoideum; Thyroxevan; Thyroxin; Thyroxinal; Levothyroxine sodium; Synthroid sodium; Thyroxine [BAN]; Thyroxine iodine; LT00440967; T4 levothyroxine; DL-Thyroxin; Eltroxin (TN); Euthyrox (TN); Eutirox (TN); Forthyron (TN); L-Thryoxin; L-Thyroxin; L-thyroxine; Laevothyroxinum (acid); Levaxin (TN); Levo-T; Levothyroxine (BAN); Levothyroxinum (acid); Levoxyl (TN); Synthroid (TN); T-3850; T4 (Hormone); Thyrax (TN); Thyrox (TN); Thyroxine (VAN); Thyroxine (l); L-thyroxine (TN); Levothyroxine Sodium (L-thyroxine); Levothroid (*Sodiumsalt*); Synthroid (*Sodium salt*); Thyroxine, L-(8CI); L-3,5,3',5'-Tetraiodothyronine; O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine; Beta-((3,5-Diiodo-4-hydroxyphenoxy)-3,5-diiodophenyl)alanine; O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine; O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine; (-)-Thyroxine; (125I)T4; (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid; 2-amino-3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propanoic acid; 3,3',5,5"-Tetraiodo-L-thyronine; 3,3',5,5''-Tetraiodo-L-thyronine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 3,5,3'5'-Tetraiodo-L-thyronine; 3-(4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)alanine; 3-[4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-L-alanine; 4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine
DMHN027 CP Abbott Laboratories
DMHN027 TC Antithyroid Agents
DMHN027 DT Small molecular drug
DMHN027 PC 5819
DMHN027 MW 776.87
DMHN027 FM C15H11I4NO4
DMHN027 IC InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
DMHN027 CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N
DMHN027 IK XUIIKFGFIJCVMT-LBPRGKRZSA-N
DMHN027 IU (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
DMHN027 CA CAS 51-48-9
DMHN027 CB CHEBI:18332
DMHN027 DE Hypothyroidism
DM4PUDW ID DM4PUDW
DM4PUDW DN L-glutamic acid
DM4PUDW HS Approved
DM4PUDW SN Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid
DM4PUDW TC Dietary supplement
DM4PUDW DT Small molecular drug
DM4PUDW PC 33032
DM4PUDW MW 147.13
DM4PUDW FM C5H9NO4
DM4PUDW IC InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DM4PUDW CS C(CC(=O)O)[C@@H](C(=O)O)N
DM4PUDW IK WHUUTDBJXJRKMK-VKHMYHEASA-N
DM4PUDW IU (2S)-2-aminopentanedioic acid
DM4PUDW CA CAS 56-86-0
DM4PUDW CB CHEBI:16015
DM4PUDW DE Schizophrenia
DM69G8X ID DM69G8X
DM69G8X DN L-glutamine
DM69G8X HS Approved
DM69G8X SN NutreStore; AES-14; Aesgen-14; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles
DM69G8X CP Nutritional Restart
DM69G8X DT Small molecular drug
DM69G8X PC 5961
DM69G8X MW 146.14
DM69G8X FM C5H10N2O3
DM69G8X IC InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
DM69G8X CS C(CC(=O)N)[C@@H](C(=O)O)N
DM69G8X IK ZDXPYRJPNDTMRX-VKHMYHEASA-N
DM69G8X IU (2S)-2,5-diamino-5-oxopentanoic acid
DM69G8X CA CAS 56-85-9
DM69G8X CB CHEBI:18050
DM69G8X DE Short bowel syndrome
DMNQXV8 ID DMNQXV8
DMNQXV8 DN LGX818
DMNQXV8 HS Approved
DMNQXV8 SN Encorafenib; 1269440-17-6; LGX-818; Encorafenib (LGX818); UNII-8L7891MRB6; LGX 818; 8L7891MRB6; Encorafenib [USAN:INN]; LGX-818(Encorafenib)
DMNQXV8 CP Array BioPharma
DMNQXV8 DT Small molecular drug
DMNQXV8 PC 50922675
DMNQXV8 MW 540
DMNQXV8 FM C22H27ClFN7O4S
DMNQXV8 IC InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
DMNQXV8 CS C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC
DMNQXV8 IK CMJCXYNUCSMDBY-ZDUSSCGKSA-N
DMNQXV8 IU methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
DMNQXV8 CA CAS 1269440-17-6
DMNQXV8 DE Melanoma
DML4ZOT ID DML4ZOT
DML4ZOT DN Lidocaine
DML4ZOT HS Approved
DML4ZOT SN Alphacaine; Anestacon; Cappicaine; Cuivasil; Dalcaine; Dentipatch; DermaFlex; Dilocaine; Duncaine; EMBOLEX; Esracaine; Gravocain; Isicaina; Isicaine; Jetocaine; LIDOPEN; LQZ; Lanabiotic; Leostesin; Lidocaina; Lidocainum; Lidocaton; Lidoderm; Lignocaine; Lignocainum; Lingocaine; Maricaine; Octocaine; Remicaine; Rucaina; Solcain; Xilina; Xilocaina; Xllina; Xycaine; Xylestesin; Xylesthesin; Xylocain; Xylocaine; Xylocard; Xylocitin; Xylotox; Zingo; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Anestacon Jelly; Cito optadren; Emla Cream; Lidocaine Carbonate; Lidocaine Hydrocarbonate; Lidocaine Monohydrochloride; Norwood Sunburn Spray; Rocephin Kit; Solarcaine aloe extraburn relief cream; Xilocaina [Italian]; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Test Dose; Xylocaine Viscous; CDS1_000283; L1026_SIGMA; Xylocaine CO2; Dentipatch (TN); ELA-Max; L-Caine; Lida-Mantle; Lidocaina [INN-Spanish]; Lidocaine (VAN); Lidocainum [INN-Latin]; Lidoject-1; Lidoject-2; Octocaine-100; Octocaine-50; Xylocaine (TN); Xylocaine 5% Spinal; Xylocaine-Mpf; Xylocaine-Mpf with Glucose; Xyloneural (free base); Zilactin-L; Lidocaine [USAN:INN:JAN]; Diethylaminoaceto-2,6-xylidide; Lidocaine (JP15/USP/INN); Alfa-Dietilamino-2,6-dimetilacetanilide; Alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Alpha-Diethylamino-2,6-dimethylacetanilide; Alpha-Diethylaminoaceto-2,6-xylidide; LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE); Omega-Diethylamino-2,6-dimethylacetanilide; Alpha-(Diethylamino)-2,6-acetoxylidide; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; 2-(Diethylamino)-2',6'-acetoxylidide; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
DML4ZOT CP Endo Pharmaceuticals
DML4ZOT TC Anesthetics
DML4ZOT DT Small molecular drug
DML4ZOT PC 3676
DML4ZOT MW 234.34
DML4ZOT FM C14H22N2O
DML4ZOT IC InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
DML4ZOT CS CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
DML4ZOT IK NNJVILVZKWQKPM-UHFFFAOYSA-N
DML4ZOT IU 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
DML4ZOT CA CAS 137-58-6
DML4ZOT CB CHEBI:6456
DML4ZOT DE Anaesthesia; Dysmenorrhea
DMV23GL ID DMV23GL
DMV23GL DN Lidoflazine
DMV23GL HS Approved
DMV23GL SN LIDOFLAZINE; Ordiflazine; Corflazine; Clinium; Lidoflazinum; Lidoflazin; 3416-26-0; Klinium; Angex; Lidoflazina [Italian]; McN-JR 7904; UNII-J4ZHN3HBTE; Lidoflazinum [INN-Latin]; Lidoflazina [INN-Spanish]; Lidoflazine [USAN:INN:BAN]; C30H35F2N3O; J4ZHN3HBTE; EINECS 222-312-8; R 7904; BRN 0904339; CHEMBL92870; MCN-JR-7904; 4-(4,4-Bis(p-fluorophenyl)butyl)-1-piperazineaceto-2',6'-xylidide; 1-Piperazineacetamide, 4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dimethylphenyl)-; NCGC00016627-01; NCGC00016627-04; CAS-3416-26-0
DMV23GL DT Small molecular drug
DMV23GL PC 3926
DMV23GL MW 491.6
DMV23GL FM C30H35F2N3O
DMV23GL IC InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
DMV23GL CS CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMV23GL IK ZBIAKUMOEKILTF-UHFFFAOYSA-N
DMV23GL IU 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide
DMV23GL CA CAS 3416-26-0
DMV23GL CB CHEBI:93095
DMV23GL DE Angina pectoris
DM4WVC5 ID DM4WVC5
DM4WVC5 DN Lifitegrast
DM4WVC5 HS Approved
DM4WVC5 SN Lifitegrast; Xiidra; 1025967-78-5; SAR-1118; SAR 1118; UNII-038E5L962W; CHEMBL2048028; 038E5L962W; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid;(S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; SAR-1118; SAR-1119; SHP606; SPD606
DM4WVC5 CP Shire Pharmaceuticals
DM4WVC5 DT Small molecular drug
DM4WVC5 PC 11965427
DM4WVC5 MW 615.5
DM4WVC5 FM C29H24Cl2N2O7S
DM4WVC5 IC InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
DM4WVC5 CS CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
DM4WVC5 IK JFOZKMSJYSPYLN-QHCPKHFHSA-N
DM4WVC5 IU (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
DM4WVC5 CA CAS 1025967-78-5
DM4WVC5 CB CHEBI:133023
DM4WVC5 DE Dry eye disease; Allergic conjunctivitis
DM4EGV0 ID DM4EGV0
DM4EGV0 DN Linaclotide
DM4EGV0 HS Approved
DM4EGV0 SN Linaclotide (USAN)
DM4EGV0 CP Microbia
DM4EGV0 DT Small molecular drug
DM4EGV0 PC 16158208
DM4EGV0 MW 1526.8
DM4EGV0 FM C59H79N15O21S6
DM4EGV0 IC InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
DM4EGV0 CS C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O
DM4EGV0 IK KXGCNMMJRFDFNR-WDRJZQOASA-N
DM4EGV0 IU (2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4EGV0 CA CAS 851199-59-2
DM4EGV0 CB CHEBI:68551
DM4EGV0 DE Irritable bowel syndrome
DMWFJTR ID DMWFJTR
DMWFJTR DN Linagliptin
DMWFJTR HS Approved
DMWFJTR SN Ondero; BI 1356; BI-1356; Ondero (TN); BI-1356-BS; (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
DMWFJTR CP Boehringer Ingelheim
DMWFJTR DT Small molecular drug
DMWFJTR PC 10096344
DMWFJTR MW 472.5
DMWFJTR FM C25H28N8O2
DMWFJTR IC InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
DMWFJTR CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
DMWFJTR IK LTXREWYXXSTFRX-QGZVFWFLSA-N
DMWFJTR IU 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
DMWFJTR CA CAS 668270-12-0
DMWFJTR CB CHEBI:68610
DMWFJTR DE Type-2 diabetes
DMVTHER ID DMVTHER
DMVTHER DN Lincomycin
DMVTHER HS Approved
DMVTHER SN Cillimycin; Epilincomycin; Jiemycin; LCM; Lincocin; Lincocine; Lincolcina; Lincolnensin; Lincomicina; Lincomix; Lincomycine; Lincomycinum; Lincomyocin; Lincorex; Mycivin; Lincomycin A; Lincomycine [French]; CBMicro_021584; Lincomix 20; Pura Ject 100; Lincocin (TN); Lincomicina [INN-Spanish]; Lincomycine [INN-French]; Lincomycinum [INN-Latin]; U 10,149A; Lincomycin (USAN/INN); Lincomycin [USAN:INN:BAN]; Lincomycin, (2S-cis)-Isomer; Methyl 6,8-dideoxy-6-[(1-methyl-4-propylprolyl)amino]-1-thiooctopyranoside
DMVTHER TC Antibiotics
DMVTHER DT Small molecular drug
DMVTHER PC 3000540
DMVTHER MW 406.5
DMVTHER FM C18H34N2O6S
DMVTHER IC InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1
DMVTHER CS CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
DMVTHER IK OJMMVQQUTAEWLP-KIDUDLJLSA-N
DMVTHER IU (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
DMVTHER CA CAS 154-21-2
DMVTHER CB CHEBI:6472
DMVTHER DE Gram-positive bacterial infection
DMB8CNL ID DMB8CNL
DMB8CNL DN Lindane
DMB8CNL HS Approved
DMB8CNL SN Aalindan; Aficide; Agrocide; Agronexit; Ameisenatod; Ameisentod; Aparasin; Aphtiria; Aphtitria; Aplidal; Arbitex; BBH; Benhexachlor; Benhexol; Benzanex; Benzex; Bexol; Celanex; Chloresene; Codechine; Devoran; Dolmix; Entomoxan; Esoderm; Exagama; Forlin; Gallogama; Gamacarbatox; Gamacid; Gamacide; Gamaphex; Gamene; Gamiso; Gammahexa; Gammahexane; Gammalin; Gammasan; Gammaterr; Gammex; Gammexane; Gammopaz; Gamtox; Geobilan; Gexane; Gyben; HCH; Hcch; Heclotox; Hecoltox; Hexa; Hexablanc; Hexachlor; Hexachloran; Hexachlorane; Hexamul; Hexapoudre; Hexatox; Hexaverm; Hexcidum; Hexicide; Hexit; Hexyclan; Hilbeech; Hortex; Inexit; Isatox; Isotox; Jacutin; Kokotine; Kwell; Lasochron; Lendine; Lentox; Lidenal; Lindafor; Lindagam; Lindagrain; Lindagranox; Lindalo; Lindamul; Lindan; Lindano; Lindanum; Lindapoudre; Lindaterra; Lindatox; Lindex; Lindosep; Lintox; Linvur; Lorexane; Mszycol; Nexit; Nicochloran; Novigam; Novigan; Omnitox; Ovadziak; Owadziak; PLK; Pedraczak; Pflanzol; Quellada; Scabene; Silvanol; Streunex; Submar; Viton; Agrocide III; Agrocide WP; Am eisenatod; Arcotal S; BHCor HCH; Borer Spray; DOL GRANULE; Eso derm; Gamma BHC; HCH [BSI]; HCH [ISO]; Hilbeec h; Isot ox; Lacco HI lin; Lindam ul; Mglawik L; New kotol; Nexen fb; PMS Lindane; Sang gamma; Agrocide 2; Agrocide6G; Agrocide 7; Bentox 10; Detox 25; Gamacide 20; Gammalin 20; Geolin G 3; Hungaria L7; Latka 666; Milbol 49; PS71_SUPELCO; TAP 85; Agrisol G-20; Alpha-BHC; Alpha-HCH; Ben-Hex; Beta-BHC; Beta-HCH; Beta-Lindane; Beta-isomer; D-BHC; Delta-BHC; Delta-HCH; ENT 7,796; ENT 8,601; ENT 9,232; ENT 9,233; ENT 9,234; Epsilon-HCH; Forst-nexen; Gamma-BHC; Gamma-HCH; Gamma-col; HCH (alpha); HCH (beta); KWELL (TN); Kwell-R; Nexen-fb; Nexi t-stark; Nexit-stark; Nexol-E; Sang-gamma; T-HCH; TRI-6; Trives-T
DMB8CNL CP Morton Grove Pharmaceuticals
DMB8CNL TC Antiscabies Agent
DMB8CNL DT Small molecular drug
DMB8CNL PC 727
DMB8CNL MW 290.8
DMB8CNL FM C6H6Cl6
DMB8CNL IC InChI=1S/C6H6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H
DMB8CNL CS C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
DMB8CNL IK JLYXXMFPNIAWKQ-UHFFFAOYSA-N
DMB8CNL IU 1,2,3,4,5,6-hexachlorocyclohexane
DMB8CNL CB CHEBI:24536
DMB8CNL DE Infestations of lice and scabies
DMGFPU2 ID DMGFPU2
DMGFPU2 DN Linezolid
DMGFPU2 HS Approved
DMGFPU2 SN Linezlid; ZLD; Zyvox; Zyvoxa; Zyvoxam; Zyvoxid; PNU 100766; U 100766; Linezolid & VRC3375; Linezolid [USAN:INN]; PNU-100766; U-100766; Zyvox (TN); Zyvoxam (TN); Zyvoxid (TN); NDA 21-130 Zyvox (linezolid tablets); NDA 21-131 Zyvox for injection (linezolid injection); NDA 21-132 Zyvox oral suspension (linzolid oral suspension); Linezolid (JAN/USAN/INN); PNU-100766, U-100766, Zyvoxid, Zyvoxam, Linezolid; N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide; N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide; N-({5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide, N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide; 111GE017
DMGFPU2 CP Pfizer Pharmaceuticals
DMGFPU2 TC Antibiotics
DMGFPU2 DT Small molecular drug
DMGFPU2 PC 441401
DMGFPU2 MW 337.35
DMGFPU2 FM C16H20FN3O4
DMGFPU2 IC InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
DMGFPU2 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
DMGFPU2 IK TYZROVQLWOKYKF-ZDUSSCGKSA-N
DMGFPU2 IU N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMGFPU2 CA CAS 165800-03-3
DMGFPU2 CB CHEBI:63607
DMGFPU2 DE Bacterial infection
DM6IR3P ID DM6IR3P
DM6IR3P DN Liothyronine
DM6IR3P HS Approved
DM6IR3P SN liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine
DM6IR3P CP King Pharmaceuticals, Inc
DM6IR3P TC Hormone Replacement Agents
DM6IR3P DT Small molecular drug
DM6IR3P PC 5920
DM6IR3P MW 650.97
DM6IR3P FM C15H12I3NO4
DM6IR3P IC InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1
DM6IR3P CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O
DM6IR3P IK AUYYCJSJGJYCDS-LBPRGKRZSA-N
DM6IR3P IU (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
DM6IR3P CA CAS 15785-49-6
DM6IR3P CB CHEBI:18258
DM6IR3P DE Hypothyroidism; Congestive heart failure
DMSTXWR ID DMSTXWR
DMSTXWR DN Liotrix
DMSTXWR HS Approved
DMSTXWR SN Liotrix; Novothyral; Thyrolar; Combithyrex; Diotroxin; Euthroid; W 1782; 8065-29-0; L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, mixt. with O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine monosodium salt; Levothyroxine Sodium mixture with Liothyronine Sodium; Liothyronine Sodium and Levothyroxine Sodium; Monosodium L-thyroxine hydrate mixt. with monosodium L-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine
DMSTXWR PC 71371
DMSTXWR MW 1471.8
DMSTXWR FM C30H21I7N2Na2O8
DMSTXWR IC LKYWLLWWYBVUPP-XOCLESOZSA-L
DMSTXWR CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)[O-])N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)[O-])N.[Na+].[Na+]
DMSTXWR IK 1S/C15H11I4NO4.C15H12I3NO4.2Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);1-4,6,12,20H,5,19H2,(H,21,22);;/q;;2*+1/p-2/t2*12-;;/m00../s1
DMSTXWR IU disodium;(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
DMSTXWR CA CAS 8065-29-0
DMSTXWR CB CHEBI:6485
DMSTXWR DE Hypothyroidism
DM3FXPS ID DM3FXPS
DM3FXPS DN Liraglutide
DM3FXPS HS Approved
DM3FXPS SN Liraglutida; Liraglutidum; Victoza; NN 2211; NN2211; Liraglutida [INN-Spanish]; Liraglutide [USAN:INN]; Liraglutidum [INN-Latin]; NN-2211; Victoza (TN); N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
DM3FXPS CP Novo Nordisk Massachusetts General Hospital
DM3FXPS DT Small molecular drug
DM3FXPS SQ Liraglutide Sequence: HAEGTFTSDVSSYLEGQAAKEEFIIAWLVKGRG
DM3FXPS PC 16134956
DM3FXPS MW 3751
DM3FXPS FM C172H265N43O51
DM3FXPS IC InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1
DM3FXPS CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
DM3FXPS IK YSDQQAXHVYUZIW-QCIJIYAXSA-N
DM3FXPS IU (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DM3FXPS CA CAS 204656-20-2
DM3FXPS CB CHEBI:71193
DM3FXPS DE Type-2 diabetes; Obesity
DM6W8V5 ID DM6W8V5
DM6W8V5 DN Lisdexamfetamine
DM6W8V5 HS Approved
DM6W8V5 SN NRP104; Lisdexamfetamine (INN); Vyvanse (TN)
DM6W8V5 CP New River Pharmaceuticals
DM6W8V5 DT Small molecular drug
DM6W8V5 PC 11597698
DM6W8V5 MW 263.38
DM6W8V5 FM C15H25N3O
DM6W8V5 IC InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
DM6W8V5 CS C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N
DM6W8V5 IK VOBHXZCDAVEXEY-JSGCOSHPSA-N
DM6W8V5 IU (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
DM6W8V5 CA CAS 608137-32-2
DM6W8V5 CB CHEBI:135925
DM6W8V5 DE Attention deficit hyperactivity disorder
DMUOK4C ID DMUOK4C
DMUOK4C DN Lisinopril
DMUOK4C HS Approved
DMUOK4C SN Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
DMUOK4C CP Merck & Co
DMUOK4C TC Antihypertensive Agents
DMUOK4C DT Small molecular drug
DMUOK4C PC 5362119
DMUOK4C MW 405.5
DMUOK4C FM C21H31N3O5
DMUOK4C IC InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
DMUOK4C CS C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
DMUOK4C IK RLAWWYSOJDYHDC-BZSNNMDCSA-N
DMUOK4C IU (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
DMUOK4C CA CAS 76547-98-3
DMUOK4C CB CHEBI:43755
DMUOK4C DE Hypertension
DMP45ME ID DMP45ME
DMP45ME DN Lisocabtagene maraleucel
DMP45ME HS Approved
DMP45ME SN JCAR017
DMP45ME CP Celgene
DMP45ME DT CAR T Cell Therapy
DMP45ME DE Central nervous system lymphoma; Precursor B-lymphoblastic neoplasm; Follicular lymphoma; Richter syndrome; Non-hodgkin lymphoma; Large B-cell lymphoma
DMCME17 ID DMCME17
DMCME17 DN Lisuride
DMCME17 HS Approved
DMCME17 SN Lisurida; Lisuridum; Lysurid; Lysuride; Lisuride [INN]; Lysuride Hydrogen Maleate; Methylergol Carbamide; Arolac (TN); Cuvalit (TN); Dipergon (TN); Dopergin (TN); Dopergine (TN); Lisurida [INN-Spanish]; Lisuride (INN); Lisuridum [INN-Latin]; Lysenyl Forte (TN); Prolacam (TN); Revanil (TN); Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
DMCME17 CP IVAX Pharmaceuticals
DMCME17 TC Antiparkinson Agents
DMCME17 DT Small molecular drug
DMCME17 PC 28864
DMCME17 MW 338.4
DMCME17 FM C20H26N4O
DMCME17 IC InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1
DMCME17 CS CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMCME17 IK BKRGVLQUQGGVSM-KBXCAEBGSA-N
DMCME17 IU 3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMCME17 CA CAS 18016-80-3
DMCME17 CB CHEBI:51164
DMCME17 DE Parkinson disease; Fibrosis
DMX9PIA ID DMX9PIA
DMX9PIA DN Live attenuated influenza vaccine
DMX9PIA HS Approved
DMX9PIA SN Influenza vaccine, BioDiem; Influenza vaccine, St Petersburg Institute of Experimental Medicine; Live attenuated influenza vaccine (CoVaccine adjuvant); SCH-900795; Cold-adapted flu virus vaccine, St Petersburg Institute of Experimental Medicine; Influenza vaccine (live attenuated, nasal), BioDiem; Influenza vaccine, BioDiem/Merck & Co; LAIV (CoVaccine adjuvant), Nobilon/NV Organon; Live attenuated influenza vaccine (CoVaccine adjuvant), BioDiem/ Serum Institute of India; Live attenuated influenza vaccine (CoVaccine adjuvant), Schering Plough/BioDiem; Live attenuated influenza vaccine (CoVaccine adjuvant), Merck & Co/BioDiem
DMX9PIA CP St Petersburg Institute of Experimental Medicine
DMX9PIA DT Vaccine
DMX9PIA DE Influenza virus infection
DM0QJDC ID DM0QJDC
DM0QJDC DN Lixisenatide
DM0QJDC HS Approved
DM0QJDC SN Lyxumia (TN)
DM0QJDC CP Sanofi
DM0QJDC DT Small molecular drug
DM0QJDC PC 90472060
DM0QJDC MW 4858
DM0QJDC FM C215H347N61O65S
DM0QJDC IC InChI=1S/C215H347N61O65S/c1-16-115(10)173(210(337)256-141(68-74-170(299)300)194(321)261-148(94-122-98-232-126-50-24-23-49-124(122)126)199(326)258-143(89-111(2)3)196(323)247-134(58-32-40-83-223)189(316)262-149(96-160(226)285)180(307)235-100-161(286)233-104-165(290)274-85-42-60-156(274)207(334)267-154(108-280)206(333)265-151(105-277)181(308)237-101-162(287)239-117(12)213(340)276-87-44-62-158(276)214(341)275-86-43-61-157(275)208(335)268-153(107-279)204(331)249-132(56-30-38-81-221)187(314)246-131(55-29-37-80-220)186(313)245-130(54-28-36-79-219)185(312)244-129(53-27-35-78-218)184(311)243-128(52-26-34-77-217)183(310)242-127(176(227)303)51-25-33-76-216)272-201(328)146(92-120-45-19-17-20-46-120)260-197(324)144(90-112(4)5)257-190(317)135(59-41-84-231-215(228)229)255-209(336)172(114(8)9)271-177(304)116(11)240-182(309)138(65-71-167(293)294)251-192(319)139(66-72-168(295)296)252-193(320)140(67-73-169(297)298)253-195(322)142(75-88-342-15)254-191(318)137(63-69-159(225)284)250-188(315)133(57-31-39-82-222)248-203(330)152(106-278)266-198(325)145(91-113(6)7)259-200(327)150(97-171(301)302)263-205(332)155(109-281)269-212(339)175(119(14)283)273-202(329)147(93-121-47-21-18-22-48-121)264-211(338)174(118(13)282)270-164(289)103-236-179(306)136(64-70-166(291)292)241-163(288)102-234-178(305)125(224)95-123-99-230-110-238-123/h17-24,45-50,98-99,110-119,125,127-158,172-175,232,277-283H,16,25-44,51-97,100-109,216-224H2,1-15H3,(H2,225,284)(H2,226,285)(H2,227,303)(H,230,238)(H,233,286)(H,234,305)(H,235,307)(H,236,306)(H,237,308)(H,239,287)(H,240,309)(H,241,288)(H,242,310)(H,243,311)(H,244,312)(H,245,313)(H,246,314)(H,247,323)(H,248,330)(H,249,331)(H,250,315)(H,251,319)(H,252,320)(H,253,322)(H,254,318)(H,255,336)(H,256,337)(H,257,317)(H,258,326)(H,259,327)(H,260,324)(H,261,321)(H,262,316)(H,263,332)(H,264,338)(H,265,333)(H,266,325)(H,267,334)(H,268,335)(H,269,339)(H,270,289)(H,271,304)(H,272,328)(H,273,329)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H4,228,229,231)/t115-,116-,117-,118+,119+,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,172-,173-,174-,175-/m0/s1
DM0QJDC CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC8=CNC=N8)N
DM0QJDC IK XVVOERDUTLJJHN-IAEQDCLQSA-N
DM0QJDC IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM0QJDC CA CAS 320367-13-3
DM0QJDC CB CHEBI:85662
DM0QJDC DE Type-2 diabetes
DMJPD06 ID DMJPD06
DMJPD06 DN Lmw heparin
DMJPD06 HS Approved
DMJPD06 SN Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)
DMJPD06 DT Small molecular drug
DMJPD06 PC 25244225
DMJPD06 MW 591.5
DMJPD06 FM C12H17NO20S3-4
DMJPD06 IC InChI=1S/C12H21NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/p-4/t2-,3?,4-,5?,6+,7?,8?,9?,11?,12-/m1/s1
DMJPD06 CS C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]
DMJPD06 IK OHJKXVLJWUPWQG-IUYNYSEKSA-J
DMJPD06 IU (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
DMJPD06 DE Hematologic disease; Coagulation defect
DMHY3IP ID DMHY3IP
DMHY3IP DN Lobeglitazone
DMHY3IP HS Approved
DMHY3IP SN Lobeglitazone sulfate; CKD-501; Dual PPARalpha/delta (type 2 diabetes), Chong Kun Dang
DMHY3IP CP Chong Kun Dang Pharmaceutical Corp
DMHY3IP DT Small molecular drug
DMHY3IP PC 9826451
DMHY3IP MW 480.5
DMHY3IP FM C24H24N4O5S
DMHY3IP IC InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)
DMHY3IP CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC
DMHY3IP IK CHHXEZSCHQVSRE-UHFFFAOYSA-N
DMHY3IP IU 5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMHY3IP CA CAS 607723-33-1
DMHY3IP CB CHEBI:136052
DMHY3IP DE Type-2 diabetes
DM1WXA6 ID DM1WXA6
DM1WXA6 DN Lofexidine
DM1WXA6 HS Approved
DM1WXA6 SN Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole
DM1WXA6 CP US WorldMeds
DM1WXA6 TC Antihypertensive Agents
DM1WXA6 DT Small molecular drug
DM1WXA6 PC 30668
DM1WXA6 MW 259.13
DM1WXA6 FM C11H12Cl2N2O
DM1WXA6 IC InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)
DM1WXA6 CS CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl
DM1WXA6 IK KSMAGQUYOIHWFS-UHFFFAOYSA-N
DM1WXA6 IU 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
DM1WXA6 CA CAS 31036-80-3
DM1WXA6 CB CHEBI:51368
DM1WXA6 DE Opioid dependence; Heroin and opiate withdrawal
DMVRH9C ID DMVRH9C
DMVRH9C DN Lomefloxacin
DMVRH9C HS Approved
DMVRH9C SN LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride
DMVRH9C CP Pharmacia Corp
DMVRH9C TC Antibiotics
DMVRH9C DT Small molecular drug
DMVRH9C PC 3948
DMVRH9C MW 351.35
DMVRH9C FM C17H19F2N3O3
DMVRH9C IC InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
DMVRH9C CS CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
DMVRH9C IK ZEKZLJVOYLTDKK-UHFFFAOYSA-N
DMVRH9C IU 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMVRH9C CA CAS 98079-51-7
DMVRH9C CB CHEBI:116278
DMVRH9C DE Bacterial infection
DME0TC8 ID DME0TC8
DME0TC8 DN Lomerizine
DME0TC8 HS Approved
DME0TC8 SN lomerizine; 101477-55-8; Lomerizine [INN]; UNII-DEE37CY4VO; 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine; C27H30F2N2O3; DEE37CY4VO; CHEMBL29188; Terranas; 1-(Bis(p-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; 1-(Bis(p-fluorophenyl)-methyl)-4-(2,3,4-trimethoxybenzyl)piperazine; NCGC00164543-01; iomerizine; 1-(2,3,4-trimethoxybenzyl)-4-[bis(4-fluorophenyl)methyl]piperazine; 1-(2,3,4-trimethoxybenzyl)-4-(bis(4-fluorophenyl)methyl)piperazine; AC1Q4NME
DME0TC8 DT Small molecular drug
DME0TC8 PC 3949
DME0TC8 MW 468.5
DME0TC8 FM C27H30F2N2O3
DME0TC8 IC InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3
DME0TC8 CS COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC
DME0TC8 IK JQSAYKKFZOSZGJ-UHFFFAOYSA-N
DME0TC8 IU 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine
DME0TC8 CA CAS 101477-55-8
DME0TC8 CB CHEBI:94682
DME0TC8 DE Migraine
DMLB4PE ID DMLB4PE
DMLB4PE DN Lomitapide mesylate
DMLB4PE HS Approved
DMLB4PE SN Lomitapide (mesylate); Lomitapide mesylate; Lomitapide mesylate (USAN); Lomitapide mesylate [USAN]; X4S83CP54E; lomitapide-mesylate; 202914-84-9; BMS 201038-04; BMS-201038-04; CHEBI:72299; N-(2,2,2-trifluoroethyl)-9-(4-(4-(4'-(trifluoromethyl)biphenyl-2-ylcarboxamido)piperidin-1-yl)butyl)-9H-fluorene-9-carboxamide methanesulfonate; UNII-X4S83CP54E; Juxtapid (TN)
DMLB4PE PC 11274333
DMLB4PE MW 789.8
DMLB4PE FM C40H41F6N3O5S
DMLB4PE IC QKVKOFVWUHNEBX-UHFFFAOYSA-N
DMLB4PE CS CS(=O)(=O)O.C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
DMLB4PE IK 1S/C39H37F6N3O2.CH4O3S/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45;1-5(2,3)4/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49);1H3,(H,2,3,4)
DMLB4PE IU methanesulfonic acid;N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
DMLB4PE CA CAS 202914-84-9
DMLB4PE CB CHEBI:72299
DMLB4PE DE Hypertriglyceridaemia
DMMWSUL ID DMMWSUL
DMMWSUL DN Lomustine
DMMWSUL HS Approved
DMMWSUL SN Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea
DMMWSUL TC Anticancer Agents
DMMWSUL DT Small molecular drug
DMMWSUL PC 3950
DMMWSUL MW 233.69
DMMWSUL FM C9H16ClN3O2
DMMWSUL IC InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)
DMMWSUL CS C1CCC(CC1)NC(=O)N(CCCl)N=O
DMMWSUL IK GQYIWUVLTXOXAJ-UHFFFAOYSA-N
DMMWSUL IU 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
DMMWSUL CA CAS 13010-47-4
DMMWSUL CB CHEBI:6520
DMMWSUL DE Brain cancer
DMGM2Z6 ID DMGM2Z6
DMGM2Z6 DN Lonafarnib
DMGM2Z6 HS Approved
DMGM2Z6 SN Sarasar; Lonafarnib [USAN]; Sch 66336; Sch66336; SCH-066336; Sch-66336; Lonafarnib (USAN/INN); (+)-4-(2-(4-(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-piperidin-1-yl))-2-oxoethyl)-piperidine-1-carboxamide; (+)-4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide; 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide; 4-{2-[4-(3,10-DIBROMO-8-CHLORO-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDIN-11-YL)PIPERIDIN-1-YL]-2-OXOETHYL}PIPERIDINE-1-CARBOXAMIDE
DMGM2Z6 CP Schering-Plough
DMGM2Z6 TC Anticancer Agents
DMGM2Z6 DT Small molecular drug
DMGM2Z6 PC 148195
DMGM2Z6 MW 638.8
DMGM2Z6 FM C27H31Br2ClN4O2
DMGM2Z6 IC InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1
DMGM2Z6 CS C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
DMGM2Z6 IK DHMTURDWPRKSOA-RUZDIDTESA-N
DMGM2Z6 IU 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
DMGM2Z6 CA CAS 193275-84-2
DMGM2Z6 CB CHEBI:47097
DMGM2Z6 DE Non-small-cell lung cancer; Hepatitis D virus infection; Myelodysplastic syndrome; Hutchinson-Gilford progeria syndrome
DMXSVGI ID DMXSVGI
DMXSVGI DN Loncastuximab tesirine
DMXSVGI HS Approved
DMXSVGI CP ADC Therapeutics
DMXSVGI DT Antibody drug conjugate
DMXSVGI DE Diffuse large B-cell lymphoma; Follicular lymphoma
DMOJZQ9 ID DMOJZQ9
DMOJZQ9 DN Loperamide
DMOJZQ9 HS Approved
DMOJZQ9 SN Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide
DMOJZQ9 CP Janssen Pharmaceutica
DMOJZQ9 TC Antidiarrheals
DMOJZQ9 DT Small molecular drug
DMOJZQ9 PC 3955
DMOJZQ9 MW 477
DMOJZQ9 FM C29H33ClN2O2
DMOJZQ9 IC InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
DMOJZQ9 CS CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
DMOJZQ9 IK RDOIQAHITMMDAJ-UHFFFAOYSA-N
DMOJZQ9 IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
DMOJZQ9 CA CAS 53179-11-6
DMOJZQ9 CB CHEBI:6532
DMOJZQ9 DE Diarrhea
DMITQS0 ID DMITQS0
DMITQS0 DN Lopinavir
DMITQS0 HS Approved
DMITQS0 SN AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378
DMITQS0 CP Abbott Laboratories
DMITQS0 TC Anti-HIV Agents
DMITQS0 DT Small molecular drug
DMITQS0 PC 92727
DMITQS0 MW 628.8
DMITQS0 FM C37H48N4O5
DMITQS0 IC InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
DMITQS0 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
DMITQS0 IK KJHKTHWMRKYKJE-SUGCFTRWSA-N
DMITQS0 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
DMITQS0 CA CAS 192725-17-0
DMITQS0 CB CHEBI:31781
DMITQS0 DE Human immunodeficiency virus infection
DM4L8H3 ID DM4L8H3
DM4L8H3 DN Loracarbef
DM4L8H3 HS Approved
DM4L8H3 SN Lorabid; Loracarbefum; Lorafem; Loracarbef hydrate; KT-3777; LY-163892; Lorabid (TN); (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate; (6R,7S)-7-{[(2R)-2-ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate; 7beta-[(2R)-2-amino-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylic acid; 7beta-[(2R)-2-ammonio-2-phenylacetyl]nitrilo-3-chloro-3,4-didehydrocepham-4-carboxylate
DM4L8H3 CP Eli Lilly
DM4L8H3 TC Antibiotics
DM4L8H3 DT Small molecular drug
DM4L8H3 PC 5284585
DM4L8H3 MW 349.77
DM4L8H3 FM C16H16ClN3O4
DM4L8H3 IC InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1
DM4L8H3 CS C1CC(=C(N2[C@H]1[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
DM4L8H3 IK JAPHQRWPEGVNBT-UTUOFQBUSA-N
DM4L8H3 IU (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM4L8H3 CA CAS 76470-66-1
DM4L8H3 CB CHEBI:47544
DM4L8H3 DE Bacterial infection
DMF3AN7 ID DMF3AN7
DMF3AN7 DN Loratadine
DMF3AN7 HS Approved
DMF3AN7 SN Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
DMF3AN7 CP Schering-Plough Corporation
DMF3AN7 TC Antihistamines
DMF3AN7 DT Small molecular drug
DMF3AN7 PC 3957
DMF3AN7 MW 382.9
DMF3AN7 FM C22H23ClN2O2
DMF3AN7 IC InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
DMF3AN7 CS CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
DMF3AN7 IK JCCNYMKQOSZNPW-UHFFFAOYSA-N
DMF3AN7 IU ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate
DMF3AN7 CA CAS 79794-75-5
DMF3AN7 CB CHEBI:6538
DMF3AN7 DE Allergy; Allergic rhinitis
DM84ZXF ID DM84ZXF
DM84ZXF DN Lorazepam
DM84ZXF HS Approved
DM84ZXF SN Almazine; Alzapam; Anxiedin; Anxira; Anzepam; Aplacasse; Aplacassee; ApoLorazepam; Aripax; Ativan; Azurogen; Bonatranquan; Bonton; Delormetazepam; Demethyllormetazepam; Donix; Duralozam; Durazolam; Efasedan; Emotion; Emotival; Equitam; Idalprem; Kalmalin; Larpose; Laubeel; Lomesta; Lopam; Lorabenz; Lorafen; Loram; Lorans; Lorapam; Lorat; Lorax; Loraz; Lorazene; Lorazep; Lorazepamum; Lorazin; Lorazon; Lorenin; Loridem; Lorivan; Lorsedal; Lorsilan; Lorzem; Lozepam; Merlit; Nervistopl; Norlormetazepam; Novhepar; Novolorazem; NuLoraz; Orfidal; Punktyl; Quait; Renaquil; Rocosgen; Securit; Sedatival; Sedazin; Sedicepan; Sedizepan; Sidenar; Silence; Sinestron; Somagerol; Stapam; Tavor; Temesta; Tolid; Tranqipam; Trapax; Upan; Vigiten; Wypax; AHP Brand of Lorazepam; Apo Lorazepam; Apotex Brand of Lorazepam; Baxter Brand of Lorazepam; Ct Arzneimittel Brand of Lorazepam; Desitin Brand of Lorazepam; Dolorgiet Brand of Lorazepam; Llorens Brand of Lorazepam; Lorazep von ct; Lorazepam AHP Brand; Lorazepam Apotex Brand; Lorazepam Baxter Brand; Lorazepam Desitin Brand; Lorazepam Dolorgiet Brand; Lorazepam Fabra; Lorazepam Genericon; Lorazepam Intensol; Lorazepam Lannacher; Lorazepam Llorens Brand; Lorazepam Medical; Lorazepam Medical Brand; Lorazepam Medix Brand; Lorazepam Novartis Brand; Lorazepam Novopharm Brand; Lorazepam Riemser Brand; Lorazepam Wyeth Brand; Lorazepam neuraxpharm; Lorazepam neuraxpharm Brand; Lorazepam preservative free; Lorazepam ratiopharm; Lorazepam ratiopharm Brand; Lorazepan Chobet; Lorazepan Richet; Max Pax; Medical Brand of Lorazepam; Medix Brand of Lorazepam; Merck dura Brand of Lorazepam; Nervistop L; Neuraxpharm Brand of Lorazepam; Novartis Brand of Lorazepam; Novo Lorazem; Novopharm Brand of Lorazepam; Nu Loraz; Nu Pharm Brand of Lorazepam; Orfidal Wyeth; Pro dorm; Ratiopharm Brand of Lorazepam; Riemser Brand of Lorazepam; Serra Pamies Brand of Lorazepam; Wyeth Brand of Lorazepam; L1764_SIGMA; WY4036; Wy 4036; Apo-Lorazepam; Ativan (TN); Ct-Arzneimittel Brand of Lorazepam; Lorazepam (Ativan); Lorazepam Nu-Pharm Brand; Lorazepam ct-Arzneimittel Brand; Lorazepam-Efeka; Lorazepam-neuraxpharm; Lorazepam-ratiopharm; Lorazepamum [INN-Latin]; Medical, Lorazepam; Novo-Lorazem; Nu-Loraz; Nu-Pharm Brand of Lorazepam; O-Chlorooxazepam; O-Chloroxazepam; Temesta (TN); Wy-4036; Wyeth, Orfidal; Lorazepam (JP15/USP/INN); Lorazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; (+/-)-Lorazepam; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
DM84ZXF CP Wyeth Pharmaceuticals
DM84ZXF TC Antianxiety Agents
DM84ZXF DT Small molecular drug
DM84ZXF PC 3958
DM84ZXF MW 321.2
DM84ZXF FM C15H10Cl2N2O2
DM84ZXF IC InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
DM84ZXF CS C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
DM84ZXF IK DIWRORZWFLOCLC-UHFFFAOYSA-N
DM84ZXF IU 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
DM84ZXF CA CAS 846-49-1
DM84ZXF CB CHEBI:6539
DM84ZXF DE Anxiety disorder
DMG6OYJ ID DMG6OYJ
DMG6OYJ DN Lorcaserin
DMG6OYJ HS Approved
DMG6OYJ SN APD 356; APD356; AR-10A; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; 10-chloro-2-methyl-4-azabicyclo[5.4.0]undeca-8,10,12-triene
DMG6OYJ CP Arena Pharmaceuticals Inc.
DMG6OYJ DT Small molecular drug
DMG6OYJ PC 11658860
DMG6OYJ MW 195.69
DMG6OYJ FM C11H14ClN
DMG6OYJ IC InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
DMG6OYJ CS C[C@H]1CNCCC2=C1C=C(C=C2)Cl
DMG6OYJ IK XTTZERNUQAFMOF-QMMMGPOBSA-N
DMG6OYJ IU (5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
DMG6OYJ CA CAS 616202-92-7
DMG6OYJ CB CHEBI:65353
DMG6OYJ DE Obesity; Drug abuse
DMICDLV ID DMICDLV
DMICDLV DN Lorlatinib
DMICDLV HS Approved
DMICDLV SN Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39
DMICDLV CP Pfizer
DMICDLV PC 71731823
DMICDLV MW 406.4
DMICDLV FM C21H19FN6O2
DMICDLV IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DMICDLV CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DMICDLV IK IIXWYSCJSQVBQM-LLVKDONJSA-N
DMICDLV IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DMICDLV CA CAS 1454846-35-5
DMICDLV CB CHEBI:143117
DMICDLV DE Non-small-cell lung cancer
DMYZFXN ID DMYZFXN
DMYZFXN DN Lornoxicam
DMYZFXN HS Approved
DMYZFXN SN CTX; Chlortenoxicam; Lorcam; Safem; Telos; Xefo; Xefo Rapid; HN-10000; TS-110; Ro-13-9297
DMYZFXN CP Roche Holding AG
DMYZFXN DT Small molecular drug
DMYZFXN PC 54690031
DMYZFXN MW 371.8
DMYZFXN FM C13H10ClN3O4S2
DMYZFXN IC InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,18H,1H3,(H,15,16,19)
DMYZFXN CS CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3
DMYZFXN IK WLHQHAUOOXYABV-UHFFFAOYSA-N
DMYZFXN IU 6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
DMYZFXN CA CAS 70374-39-9
DMYZFXN CB CHEBI:31783
DMYZFXN DE Migraine
DM72JXH ID DM72JXH
DM72JXH DN Losartan
DM72JXH HS Approved
DM72JXH SN Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
DM72JXH CP Merck & Co
DM72JXH TC Antihypertensive Agents
DM72JXH DT Small molecular drug
DM72JXH PC 3961
DM72JXH MW 422.9
DM72JXH FM C22H23ClN6O
DM72JXH IC InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
DM72JXH CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
DM72JXH IK PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DM72JXH IU [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DM72JXH CA CAS 114798-26-4
DM72JXH CB CHEBI:6541
DM72JXH DE Hypertension
DM8QTJI ID DM8QTJI
DM8QTJI DN Loteprednol etabonate
DM8QTJI HS Approved
DM8QTJI SN Alrex; Locort; Loteflam; Lotemax; Loterox; CDDD-5604; HGP-1; IDR-90102; IDR-90103; Lotemax (TN); P-5604; Alrex, Lotemax, Loteprednol etabonate; Loteprednol etabonate (JAN/USAN); Chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate; Chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM8QTJI CP Bausch & Lomb Pharmaceuticals, Inc.
DM8QTJI TC Antiallergic Agents
DM8QTJI DT Small molecular drug
DM8QTJI PC 444025
DM8QTJI MW 466.9
DM8QTJI FM C24H31ClO7
DM8QTJI IC InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1
DM8QTJI CS CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
DM8QTJI IK DMKSVUSAATWOCU-HROMYWEYSA-N
DM8QTJI IU chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM8QTJI CA CAS 82034-46-6
DM8QTJI CB CHEBI:31784
DM8QTJI DE Eye inflammation
DM9OZWQ ID DM9OZWQ
DM9OZWQ DN Lovastatin
DM9OZWQ HS Approved
DM9OZWQ SN lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
DM9OZWQ CP Atos Pharma
DM9OZWQ TC Anticholesteremic Agents
DM9OZWQ DT Small molecular drug
DM9OZWQ PC 53232
DM9OZWQ MW 404.5
DM9OZWQ FM C24H36O5
DM9OZWQ IC InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
DM9OZWQ CS CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
DM9OZWQ IK PCZOHLXUXFIOCF-BXMDZJJMSA-N
DM9OZWQ IU [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM9OZWQ CA CAS 75330-75-5
DM9OZWQ CB CHEBI:40303
DM9OZWQ DE Hypercholesterolaemia; Cardiovascular disease
DMGCQ4E ID DMGCQ4E
DMGCQ4E DN Lovastatin acid
DMGCQ4E HS Approved
DMGCQ4E SN Lovastatin acid; Mevinolinic acid; Monacolinic K acid; MSD 803 acid; MSD 803 free acid; UNII-5CLV35Y90C; MK 819; L-154819; L 154819; 5CLV35Y90C; CHEBI:82985; (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DMGCQ4E PC 64727
DMGCQ4E MW 422.6
DMGCQ4E FM C24H38O6
DMGCQ4E IC InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
DMGCQ4E CS CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C
DMGCQ4E IK QLJODMDSTUBWDW-BXMDZJJMSA-N
DMGCQ4E IU (3R,5R)-7-[(1S,2S,6R,8S,8aR)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DMGCQ4E CA CAS 75225-51-3
DMGCQ4E CB CHEBI:82985
DMGCQ4E DE Hypercholesterolemia
DM8AI9U ID DM8AI9U
DM8AI9U DN Loxapine
DM8AI9U HS Approved
DM8AI9U SN Cloxazepine; Dibenzacepin; Dibenzoazepine; Lossapina; Loxapin; Loxapina; Loxapinsuccinate; Loxapinum; Loxepine; Oxilapine; Lossapina [DCIT]; Loxitane IM; CL 62362; HF 3170; HF3170; Hydrofluoride 3170; LW 3170; S 805; SUM 3170; CL-62362; Loxapac (TN); Loxapina [INN-Spanish]; Loxapinum [INN-Latin]; Loxitane (TN); S-805;SUM-3170; CL-71,563; Loxapine (USAN/INN); Loxapine [USAN:BAN:INN]; Loxapine [USAN:INN:BAN]; 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine; 2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
DM8AI9U CP Watson Laboratories
DM8AI9U TC Antipsychotic Agents
DM8AI9U DT Small molecular drug
DM8AI9U PC 3964
DM8AI9U MW 327.8
DM8AI9U FM C18H18ClN3O
DM8AI9U IC InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
DM8AI9U CS CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
DM8AI9U IK XJGVXQDUIWGIRW-UHFFFAOYSA-N
DM8AI9U IU 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DM8AI9U CA CAS 1977-10-2
DM8AI9U CB CHEBI:50841
DM8AI9U DE Schizophrenia
DMQMGXV ID DMQMGXV
DMQMGXV DN Loxoprofen gel
DMQMGXV HS Approved
DMQMGXV SN Loxonin; Loxoprofen; Loxonin Pap; Loxonin Tape; CS-600G; LX-A; LX-P; Loxonin Gel 1%; Lipoxin A, Daiichi Sankyo/Lead Chemical; Lipoxin A, Sankyo/ Lead Chemical; Loxoprofen (gel, pain/ inflammation), Daiichi Sankyo; Loxoprofen (gel, pain/ inflammation), Sankyo; Loxoprofen (patch, pain/inflammation), Daiichi Sankyo/ Lead Chemical; Loxoprofen (patch, pain/inflammation), Sankyo/ Lead Chemical
DMQMGXV CP Sankyo Co Ltd
DMQMGXV DT Small molecular drug
DMQMGXV PC 3965
DMQMGXV MW 246.3
DMQMGXV FM C15H18O3
DMQMGXV IC InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
DMQMGXV CS CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
DMQMGXV IK YMBXTVYHTMGZDW-UHFFFAOYSA-N
DMQMGXV IU 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
DMQMGXV CA 68767-14-6
DMQMGXV DE Inflammation
DMQXI9F ID DMQXI9F
DMQXI9F DN L-Phenylalanine
DMQXI9F HS Approved
DMQXI9F SN Endophenyl; Fenilalanina; Phe; Phenylalanine; Phenylalaninum; Fenilalanina [Spanish]; Phenylalaninum [Latin]; Antibiotic FN 1636; CB 3208; NCI9959; Alpha-Aminohydrocinnamic acid; Beta-Phenylalanine; L-Antibiotic FN 1636; L-PHENYLALININE; N-Formylmelphalan; Phenylalanine (VAN); H-Phe-OH; L-Phenylalanine (JP15); Phenylalanine (USP/INN); Phenylalanine [USAN:INN:JAN]; Beta-Phenyl-L-alanine; N-Formyl-L-sarcolysin; N-Formyl-L-p-sarcolysin; L-PHENYL ALANINE (SEE ALSO 22839-47-0, ASPARTAME; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)-N-formylalanine; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-N-formyl-(9CI); (2S)-2-amino-3-phenylpropanoic acid; (L)-Phenylalanine; (S)-(-)-Phenylalanine; (S)-2-Amino-3-phenylpropanoic acid; (S)-2-Amino-3-phenylpropionic acid; (S)-Phenylalanine; (S)-alpha-Amino-benzenepropanoic acid; (S)-alpha-Amino-beta-phenylpropionic acid; (S)-alpha-Aminohydrocinnamic acid; 1F9436B3-8B0D-4AC6-A004-4249B0BDA436; 3-Phenyl-L-alanine; 3-Phenylalanine; 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid
DMQXI9F TC Dietary supplement
DMQXI9F DT Small molecular drug
DMQXI9F PC 6140
DMQXI9F MW 165.19
DMQXI9F FM C9H11NO2
DMQXI9F IC InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
DMQXI9F CS C1=CC=C(C=C1)C[C@@H](C(=O)O)N
DMQXI9F IK COLNVLDHVKWLRT-QMMMGPOBSA-N
DMQXI9F IU (2S)-2-amino-3-phenylpropanoic acid
DMQXI9F CA CAS 63-91-2
DMQXI9F CB CHEBI:17295
DMQXI9F DE Malnutrition
DMKSTWR ID DMKSTWR
DMKSTWR DN L-Proline
DMKSTWR HS Approved
DMKSTWR SN Carboxypyrrolidine; Pro; Prolina; Prolinum; Prolina [Spanish]; Prolinum [Latin]; CB 1707; L-Prolin; PRO (IUPACabbreviation); Proline (USP); Proline (VAN); Proline [USAN:INN]; H-Pro-OH; L-Proline (JAN); L-Proline-15N; L-alpha-Pyrrolidinecarboxylic acid; L-Proline, labeled with carbon-14; L-Pyrrolidine-2-carboxylic acid; L-(2,3-3H)Proline; (-)-(S)-Proline; (-)-2-Pyrrolidinecarboxylic acid; (-)-Proline (S)-2-Carboxypyrrolidine; (2S)-pyrrolidine-2-carboxylic acid; (S)-2-Carboxypyrrolidine; (S)-2-Pyrrolidinecarboxylic acid; (S)-Proline; (S)-Pyrrolidine-2-carboxylic acid; 2-pyrrolidinecarboxylic acid
DMKSTWR TC Dietary supplement
DMKSTWR DT Small molecular drug
DMKSTWR PC 145742
DMKSTWR MW 115.13
DMKSTWR FM C5H9NO2
DMKSTWR IC InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1
DMKSTWR CS C1C[C@H](NC1)C(=O)O
DMKSTWR IK ONIBWKKTOPOVIA-BYPYZUCNSA-N
DMKSTWR IU (2S)-pyrrolidine-2-carboxylic acid
DMKSTWR CA CAS 4305-67-3
DMKSTWR CB CHEBI:17203
DMKSTWR DE Malnutrition
DMIBH7M ID DMIBH7M
DMIBH7M DN L-tryptophan
DMIBH7M HS Approved
DMIBH7M SN Ardeytropin; Kalma; LTR; Lyphan; Optimax; Pacitron; Sedanoct; Triptofano; Trofan; Trp; Tryptacin; Tryptan; Tryptophane; Tryptophanum; Triptofano [Spanish]; Tryptophane [French]; Tryptophanum [Latin]; EH 121; MT1; T 0254; Alti-Tryptophan; L-TRYPTOPHAN SIGMA GRADE; L-Trp; L-Tryptofan; L-Tryptophane; L-Ttp; TRP NH3+ COOH; TRP-01; Tryptophan (VAN); Tryptophan [USAN:INN]; H-Trp-oh; Indole-3-alanine; L-Tryptophan (9CI); L-Tryptophan (JP15); Tryptophan (H-3); Tryptophan (USP/INN); L-b-3-Indolylalanine; L-beta-3-Indolylalanine; Tryptophan, L-(8CI); Alanine, 3-indol-3-yl; Alpha'-Amino-3-indolepropionic acid; L-(-)-Tryptophan; L-(-)-Tryptophane; L-a-Aminoindole-3-propionic acid; L-alpha-Aminoindole-3-propionic acid; L-alpha-amino-3-indolepropionic acid; Alpha-Amino-beta-(3-indolyl)-propionic acid; Alpha-amino-beta-(3-indolyl)-pr opionic acid; Propionic acid, 2-amino-3-indol-3-yl; S(-)-1-alpha-Aminoindole-3-propionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; (L)-TRYPTOPHAN; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-(-)-Tryptopha n; (S)-(-)-Tryptophan; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; (S)-Tryptophan; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; (S)-alpha-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; (S)-alpha-Aminoindole-3-propionic acid; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; 1-beta-3-Indolylalanine; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; 1H-Indole-3-alanine; 1H-Indole-3-alanine (VAN); 1beta-3-Indolylalanine; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; 2-Amino-3-indolylpropanoic acid; 2-amino-3-indol-3-ylpropionic acid; 3-Indol-3-ylalanine
DMIBH7M TC Antidepressants
DMIBH7M DT Small molecular drug
DMIBH7M PC 6305
DMIBH7M MW 204.22
DMIBH7M FM C11H12N2O2
DMIBH7M IC InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
DMIBH7M CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N
DMIBH7M IK QIVBCDIJIAJPQS-VIFPVBQESA-N
DMIBH7M IU (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
DMIBH7M CA CAS 73-22-3
DMIBH7M CB CHEBI:16828
DMIBH7M DE Depression
DM9O8DT ID DM9O8DT
DM9O8DT DN L-tyrosine
DM9O8DT HS Approved
DM9O8DT SN DTY; Rxosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Tirosina [Spanish]; Tyrosine Power; Tyrosinum [Latin]; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; L-Tyrosin; L-Tyrosine hydrochloride; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; P-Tyrosine; TYR NH3+ COOH; Tyrosine (VAN); Tyrosine [USAN:INN]; Free-Form L-Tyrosine; H-Tyr-OH; L-Tyrosine (9CI); L-Tyrosine (JAN); L-Tyrosine, homopolymer; L-Tyrosine, monomer; L-p-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Tyrosine (USP/INN); Beta-(p-Hydroxyphenyl)alanine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine, L-(8CI); DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; L-(-)-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; Alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-Tyrosine; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; 3-(p-Hydroxyphenyl)alanine; 4-Hydroxy-L-phenylalanine; 4ts1
DM9O8DT TC Dietary supplement
DM9O8DT DT Small molecular drug
DM9O8DT PC 6057
DM9O8DT MW 181.19
DM9O8DT FM C9H11NO3
DM9O8DT IC InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
DM9O8DT CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)O
DM9O8DT IK OUYCCCASQSFEME-QMMMGPOBSA-N
DM9O8DT IU (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
DM9O8DT CA CAS 60-18-4
DM9O8DT CB CHEBI:17895
DM9O8DT DE Malnutrition
DMMJVXZ ID DMMJVXZ
DMMJVXZ DN LU302146
DMMJVXZ HS Approved
DMMJVXZ DE Pulmonary hypertension
DMJTEMW ID DMJTEMW
DMJTEMW DN Lubiprostone
DMJTEMW HS Approved
DMJTEMW SN Amitiza; Lubiprostone [USAN]; RU 0211; RU0211; SPI 0211; SPI0211; AMITIZA (TN); RU-0211; SPI-0211; Amitiza, RU-0211, SPI-0211, Lubiprostone; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta (b)pyran-5-yl)heptanoic acid; (-)-7-((2R,4aR,5R,7aR)-2-(1,1-Difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta(b)pyran-5-yl)heptanoic acid; 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
DMJTEMW CP Takeda
DMJTEMW TC Anticonstipation Agents
DMJTEMW DT Small molecular drug
DMJTEMW PC 157920
DMJTEMW MW 390.5
DMJTEMW FM C20H32F2O5
DMJTEMW IC InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1
DMJTEMW CS CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F
DMJTEMW IK WGFOBBZOWHGYQH-MXHNKVEKSA-N
DMJTEMW IU 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoic acid
DMJTEMW CA CAS 333963-40-9
DMJTEMW DE Chronic idiopathic constipation
DMZLBUO ID DMZLBUO
DMZLBUO DN Lucanthone
DMZLBUO HS Approved
DMZLBUO SN Lucanthon; Lucanthonum; Lucantona; Miracol; Nilodin; Scapuren; Tixantone; LUCANTHONE HYDROCHLORIDE; Lucanthone monohydrochloride; Miracil D; BW 57223; CBC 900139; DR-15771; Lucanthone [INN:BAN]; Lucanthonum [INN-Latin]; Lucantona [INN-Spanish]; 1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one; 1-(2-diethylaminoethylamino)-4-methylthioxanthen-9-one; 1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone; 1-{[2-(Diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one; 9H-Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methyl-(9CI)
DMZLBUO CP Spectrum
DMZLBUO TC Anticancer Agents
DMZLBUO DT Small molecular drug
DMZLBUO PC 10180
DMZLBUO MW 340.5
DMZLBUO FM C20H24N2OS
DMZLBUO IC InChI=1S/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3
DMZLBUO CS CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O
DMZLBUO IK FBQPGGIHOFZRGH-UHFFFAOYSA-N
DMZLBUO IU 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one
DMZLBUO CA CAS 479-50-5
DMZLBUO CB CHEBI:51052
DMZLBUO DE Solid tumour/cancer
DMT73J8 ID DMT73J8
DMT73J8 DN Luliconazole
DMT73J8 HS Approved
DMT73J8 SN Lulicon; Lulifin; JA-004; JA-005; NND-502; PR-2699
DMT73J8 CP Medicis
DMT73J8 DT Small molecular drug
DMT73J8 PC 3003141
DMT73J8 MW 354.3
DMT73J8 FM C14H9Cl2N3S2
DMT73J8 IC InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1
DMT73J8 CS C1[C@H](S/C(=C(\\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl
DMT73J8 IK YTAOBBFIOAEMLL-REQDGWNSSA-N
DMT73J8 IU (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile
DMT73J8 CA CAS 187164-19-8
DMT73J8 CB CHEBI:34825
DMT73J8 DE Tinea pedis; Dry eye disease
DMUPOGR ID DMUPOGR
DMUPOGR DN Lumacaftor + Ivacaftor
DMUPOGR HS Approved
DMUPOGR CP Vertex
DMUPOGR DE Cystic fibrosis; Acute lung injury
DMEBQAO ID DMEBQAO
DMEBQAO DN Lumasiran
DMEBQAO HS Approved
DMEBQAO CP Alnylam Pharmaceuticals
DMEBQAO DT Small interfering RNA
DMEBQAO DE Hyperoxaluria
DMQ8HOJ ID DMQ8HOJ
DMQ8HOJ DN lumateperone tosylate
DMQ8HOJ HS Approved
DMQ8HOJ SN lumateperone Tosylate; lumateperone (Tosylate); 1187020-80-9; UNII-JIE88N006O; ITI-007 tosylate; JIE88N006O; 1187020-80-9 (tosylate); ITI007; ITI 007; ITI-007; Lumateperone tosylate (USAN); Lumateperone tosylate [USAN]; CHEMBL3233142; 1-(4-fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]butan-1-one toluenesulfonic acid; Caplyta (TN); SCHEMBL1769664; CS-5540; HY-19733; D11170; Q27281520; 1-(4-Fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one tosylate salt
DMQ8HOJ DT Small molecular drug
DMQ8HOJ PC 44241743
DMQ8HOJ MW 565.7
DMQ8HOJ FM C31H36FN3O4S
DMQ8HOJ IC InChI=1S/C24H28FN3O.C7H8O3S/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17;1-6-2-4-7(5-3-6)11(8,9)10/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3;2-5H,1H3,(H,8,9,10)/t20-,21-;/m0./s1
DMQ8HOJ CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
DMQ8HOJ IK LHAPOGAFBLSJJQ-GUTACTQSSA-N
DMQ8HOJ IU 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one;4-methylbenzenesulfonic acid
DMQ8HOJ CA CAS 1187020-80-9
DMQ8HOJ DE Schizophrenia
DM29GAD ID DM29GAD
DM29GAD DN Lumefantrine
DM29GAD HS Approved
DM29GAD SN Benflumetol; Coartem; Dl-Benflumelol; Lumefantrine (INN); Lumefantrine [INN:BAN]; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol; (+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol; 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol; 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol; 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
DM29GAD DT Small molecular drug
DM29GAD PC 6437380
DM29GAD MW 528.9
DM29GAD FM C30H32Cl3NO
DM29GAD IC InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
DM29GAD CS CCCCN(CCCC)CC(C1=CC(=CC\\2=C1C3=C(/C2=C/C4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O
DM29GAD IK DYLGFOYVTXJFJP-MYYYXRDXSA-N
DM29GAD IU 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
DM29GAD CA CAS 82186-77-4
DM29GAD CB CHEBI:156095
DM29GAD DE Malaria
DM1S4AG ID DM1S4AG
DM1S4AG DN Lumiracoxib
DM1S4AG HS Approved
DM1S4AG SN Joicela; Prexige; Novartis brand of lumiracoxib; COX 189; COX189; COX-189; Lumiracoxib [USAN:INN]; Prexige (Novartis); Prexige (TN); Lumiracoxib (USAN/INN); 2-((2-Chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid; 2-((2-Chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid; 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid; 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
DM1S4AG CP Norvatis Phamaceuticals Corporation
DM1S4AG TC Antiinflammatory Agents
DM1S4AG DT Small molecular drug
DM1S4AG PC 151166
DM1S4AG MW 293.72
DM1S4AG FM C15H13ClFNO2
DM1S4AG IC InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
DM1S4AG CS CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O
DM1S4AG IK KHPKQFYUPIUARC-UHFFFAOYSA-N
DM1S4AG IU 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
DM1S4AG CA CAS 220991-20-8
DM1S4AG CB CHEBI:73044
DM1S4AG DE Knee osteoarthritis
DMCVPXO ID DMCVPXO
DMCVPXO DN Lurasidone hydrochloride
DMCVPXO HS Approved
DMCVPXO SN Lurasidone HCl; SM 13496; Lurasidone hydrochloride (USAN); MK-3756; SM-13496; SMP-13496; N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
DMCVPXO CP Sumitomo
DMCVPXO DT Small molecular drug
DMCVPXO PC 11237860
DMCVPXO MW 529.1
DMCVPXO FM C28H37ClN4O2S
DMCVPXO IC InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
DMCVPXO CS C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl
DMCVPXO IK NEKCRUIRPWNMLK-SCIYSFAVSA-N
DMCVPXO IU (1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione;hydrochloride
DMCVPXO CA CAS 367514-88-3
DMCVPXO CB CHEBI:70732
DMCVPXO DE Schizophrenia
DMEFRTZ ID DMEFRTZ
DMEFRTZ DN Lurbinectedin
DMEFRTZ HS Approved
DMEFRTZ SN UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B
DMEFRTZ CP PharmaMar
DMEFRTZ DT Small molecular drug
DMEFRTZ PC 57327016
DMEFRTZ MW 784.9
DMEFRTZ FM C41H44N4O10S
DMEFRTZ IC InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
DMEFRTZ CS CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
DMEFRTZ IK YDDMIZRDDREKEP-HWTBNCOESA-N
DMEFRTZ IU [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
DMEFRTZ CA CAS 497871-47-3
DMEFRTZ DE leukaemia; Solid tumour/cancer; Endometrial cancer; Ovarian cancer; Small-cell lung cancer
DMH6IKO ID DMH6IKO
DMH6IKO DN Lusutrombopag
DMH6IKO HS Approved
DMH6IKO SN LUSUTROMBOPAG; mulpleta; UNII-6LL5JFU42F; 6LL5JFU42F; 2-Propenoic acid, Lusutrombopag [USAN:INN]; SCHEMBL3062
DMH6IKO CP Shionogi
DMH6IKO PC 49843517
DMH6IKO MW 591.5
DMH6IKO FM C29H32Cl2N2O5S
DMH6IKO IC InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1
DMH6IKO CS CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\\C)/C(=O)O)Cl
DMH6IKO IK NOZIJMHMKORZBA-KJCUYJGMSA-N
DMH6IKO IU (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
DMH6IKO CA CAS 1110766-97-6
DMH6IKO CB CHEBI:136051
DMH6IKO DE Thrombocytopenia; Liver disease
DMN1XVC ID DMN1XVC
DMN1XVC DN Lutetium Lu 177 dotatate
DMN1XVC HS Approved
DMN1XVC SN UNII-AE221IM3BB; Dotatate lutenium Lu-177; AE221IM3BB; Lu-DOTA-TATE; 177Lu-DOTA-octreotate; Lutetium Lu 177 Dotatate; 177Lu-DOTA-Tyr3-octreotate
DMN1XVC CP Advanced Accelerator Applications/Novartis
DMN1XVC PC 132274234
DMN1XVC MW 1609.5
DMN1XVC FM C65H87LuN14O19S2
DMN1XVC IC InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2
DMN1XVC CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3]
DMN1XVC IK MXDPZUIOZWKRAA-PRDSJKGBSA-K
DMN1XVC IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)
DMN1XVC CA CAS 437608-50-9
DMN1XVC DE Neuroendocrine cancer
DM7K5GD ID DM7K5GD
DM7K5GD DN Lutropin alfa
DM7K5GD HS Approved
DM7K5GD SN Luveris; Luveris (TN); Lutropin alfa (USAN/INN)
DM7K5GD TC Fertility Agents
DM7K5GD SQ Alpha Chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta Chain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL
DM7K5GD DE Female infertility
DMJKROX ID DMJKROX
DMJKROX DN Luvox
DMJKROX HS Approved
DMJKROX SN FLUVOXAMINE MALEATE; 61718-82-9; Fevarin; Luvox CR; Fluvoxamine (maleate); UNII-5LGN83G74V; DU23000; DU-23000; SME 3110; 5LGN83G74V; MK-264; 54739-18-3; 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate; 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1); 54739-20-7; 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1); C19H25F3N2O6
DMJKROX DT Small molecular drug
DMJKROX PC 9560989
DMJKROX MW 434.4
DMJKROX FM C19H25F3N2O6
DMJKROX IC InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
DMJKROX CS COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F.C(=C\\C(=O)O)\\C(=O)O
DMJKROX IK LFMYNZPAVPMEGP-PIDGMYBPSA-N
DMJKROX IU (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
DMJKROX CA CAS 61718-82-9
DMJKROX CB CHEBI:5139
DMJKROX DE Anxiety disorder
DM93VBZ ID DM93VBZ
DM93VBZ DN LY2835219
DM93VBZ HS Approved
DM93VBZ SN Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);
DM93VBZ CP Eli Lilly
DM93VBZ DT Small molecular drug
DM93VBZ PC 46220502
DM93VBZ MW 506.6
DM93VBZ FM C27H32F2N8
DM93VBZ IC InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
DM93VBZ CS CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
DM93VBZ IK UZWDCWONPYILKI-UHFFFAOYSA-N
DM93VBZ IU N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
DM93VBZ CA CAS 1231929-97-7
DM93VBZ DE Breast cancer; Solid tumour/cancer
DMOMLHJ ID DMOMLHJ
DMOMLHJ DN Lymecycline
DMOMLHJ HS Approved
DMOMLHJ SN Aureociclin; Aureomicina; Aurofac; Biovetin; Centraureo; Chlortetracyclin; Chrusomykine; Limeciclina; Lymecyclinum; Orospray; Acronize PD; Aurofac 10; Tetrlysal 300; Lymecycline (INN); Tetralysal 300 (TN); N(2)-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline; N(6)-[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]carbonyl}amino)methyl]-L-lysine; (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
DMOMLHJ CP Galderma
DMOMLHJ TC Antibiotics
DMOMLHJ DT Small molecular drug
DMOMLHJ PC 54707177
DMOMLHJ MW 602.6
DMOMLHJ FM C29H38N4O10
DMOMLHJ IC InChI=1S/C29H38N4O10/c1-28(42)13-7-6-9-17(34)18(13)22(35)19-14(28)11-15-21(33(2)3)23(36)20(25(38)29(15,43)24(19)37)26(39)32-12-31-10-5-4-8-16(30)27(40)41/h6-7,9,14-16,21,31,34-35,38,42-43H,4-5,8,10-12,30H2,1-3H3,(H,32,39)(H,40,41)/t14-,15-,16-,21-,28+,29-/m0/s1
DMOMLHJ CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCNCCCC[C@@H](C(=O)O)N)N(C)C)O
DMOMLHJ IK PZTCVADFMACKLU-UEPZRUIBSA-N
DMOMLHJ IU (2S)-6-[[[(4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carbonyl]amino]methylamino]-2-aminohexanoic acid
DMOMLHJ CA CAS 992-21-2
DMOMLHJ CB CHEBI:59040
DMOMLHJ DE Bacterial infection
DM154EB ID DM154EB
DM154EB DN Lypressin
DM154EB HS Approved
DM154EB SN Lysine-vasopressin; Lysine-8-vasopressin
DM154EB DT Small molecular drug
DM154EB PC 644076
DM154EB MW 1056.2
DM154EB FM C46H65N13O12S2
DM154EB IC InChI=1S/C46H65N13O12S2/c47-17-5-4-9-29(40(65)52-22-38(51)63)54-45(70)35-10-6-18-59(35)46(71)34-24-73-72-23-28(48)39(64)55-31(20-26-11-13-27(60)14-12-26)43(68)56-32(19-25-7-2-1-3-8-25)42(67)53-30(15-16-36(49)61)41(66)57-33(21-37(50)62)44(69)58-34/h1-3,7-8,11-14,28-35,60H,4-6,9-10,15-24,47-48H2,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,67)(H,54,70)(H,55,64)(H,56,68)(H,57,66)(H,58,69)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DM154EB CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DM154EB IK BJFIDCADFRDPIO-DZCXQCEKSA-N
DM154EB IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM154EB CA CAS 50-57-7
DM154EB CB CHEBI:94802
DM154EB DE Amnesia
DMQYJIR ID DMQYJIR
DMQYJIR DN Macimorelin
DMQYJIR HS Approved
DMQYJIR SN Solorel; AEZS-130; ARD-07; ARD-0705; EP-01572; EP-1572; JMV-1843
DMQYJIR CP Aeterna Zentaris
DMQYJIR DT Small molecular drug
DMQYJIR PC 9804938
DMQYJIR MW 474.6
DMQYJIR FM C26H30N6O3
DMQYJIR IC InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1
DMQYJIR CS CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N
DMQYJIR IK UJVDJAPJQWZRFR-DHIUTWEWSA-N
DMQYJIR IU 2-amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DMQYJIR CA CAS 381231-18-1
DMQYJIR DE Somatotropin deficiency; Growth hormone deficiency
DMP79A1 ID DMP79A1
DMP79A1 DN Macitentan
DMP79A1 HS Approved
DMP79A1 SN Macitentan; 441798-33-0; Opsumit; ACT-064992; ACT 064992; UNII-Z9K9Y9WMVL; ACT064992; Z9K9Y9WMVL; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide; CHEBI:76607; Actelion-1; Macitentan [USAN:INN]; macitentanum; zlchem 5; Opsumit (TN); Macitentan (JAN/USAN); (non-labelled)Macitentan-d7; MLS006011174; C19H20Br2N6O4S; SCHEMBL1445625; GTPL7352; CHEMBL2103873; ZLA0005; EX-A544; DTXSID50196063
DMP79A1 CP Actelion Pharmaceuticals
DMP79A1 DT Small molecular drug
DMP79A1 PC 16004692
DMP79A1 MW 588.3
DMP79A1 FM C19H20Br2N6O4S
DMP79A1 IC InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
DMP79A1 CS CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
DMP79A1 IK JGCMEBMXRHSZKX-UHFFFAOYSA-N
DMP79A1 IU 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine
DMP79A1 CA CAS 441798-33-0
DMP79A1 CB CHEBI:76607
DMP79A1 DE Cardiovascular disease
DM3BS97 ID DM3BS97
DM3BS97 DN Macrolides
DM3BS97 HS Approved
DM3BS97 SN Tylosin; tylosin tartrate; Tilosina; Tylosinum; UNII-YEF4JXN031; Tylosine; Tylocine; Tylan; Tylosin A; 1401-69-0; YEF4JXN031; Fradizine; CHEBI:17658; Vubityl 200; Tylosinum [INN-Latin]; Tylosine [INN-French]; Tilosina [INN-Spanish]; HSDB 7022; EINECS 215-754-8; AI3-29799; SR-05000002057; Tylosin [USP:INN:BAN]; Tylan (TN); Tylosin (USP/INN); AC1NQX0W
DM3BS97 DT Small molecular drug
DM3BS97 PC 5280440
DM3BS97 MW 916.1
DM3BS97 FM C46H77NO17
DM3BS97 IC InChI=1S/C46H77NO17/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3/b15-14+,23-18+/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-/m1/s1
DM3BS97 CS CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)\\C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC
DM3BS97 IK WBPYTXDJUQJLPQ-VMXQISHHSA-N
DM3BS97 IU 2-[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
DM3BS97 CA CAS 1401-69-0
DM3BS97 CB CHEBI:17658
DM3BS97 DE Bacterial infection
DMU4ORS ID DMU4ORS
DMU4ORS DN Magnesium
DMU4ORS HS Approved
DMU4ORS SN Magnesio; Magnesio [Italian]; Magnesium Matrix Modifier; Magnesium modifier; Magnesium powdered; Magnesium preparation; Magnesium sheet; LTBB002624; Magnesium hydride [UN2010] [Dangerous when wet]; MAGNESIUM NITRATE, ACS; Magnesium nitrate-nitric acid solution; Rieke's active magnesium; MAGNESIUM, ATOMIZED POWDER,18MICRON; Magnesium granules, coated particle size not50% magnesium in pellets, turnings or ribbons [UN1869] [Flammable solid]; Magnesium, powder or magnesium alloys, powder [UN1418] [Dangerous when wet, Spontaneously combustible]; AQUANAL-plus magnesium (Mg) 100-1500 mg/L; AQUANAL(R)-plus magnesium (Mg) 100-1500 mg/L;12Mg
DMU4ORS CP AstraZeneca
DMU4ORS DT Small molecular drug
DMU4ORS PC 5462224
DMU4ORS MW 24.305
DMU4ORS FM Mg
DMU4ORS IC InChI=1S/Mg
DMU4ORS CS [Mg]
DMU4ORS IK FYYHWMGAXLPEAU-UHFFFAOYSA-N
DMU4ORS IU magnesium
DMU4ORS CA CAS 7439-95-4
DMU4ORS CB CHEBI:25107
DMU4ORS DE Ischemic stroke
DMVEK07 ID DMVEK07
DMVEK07 DN Magnesium Sulfate
DMVEK07 HS Approved
DMVEK07 SN Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt
DMVEK07 CP Mitsuwa Kinzoku Co
DMVEK07 TC Analgesics
DMVEK07 DT Small molecular drug
DMVEK07 PC 24083
DMVEK07 MW 120.37
DMVEK07 FM MgO4S
DMVEK07 IC InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
DMVEK07 CS [O-]S(=O)(=O)[O-].[Mg+2]
DMVEK07 IK CSNNHWWHGAXBCP-UHFFFAOYSA-L
DMVEK07 IU magnesium;sulfate
DMVEK07 CA CAS 7487-88-9
DMVEK07 CB CHEBI:32599
DMVEK07 DE Acute pain
DMXZ84M ID DMXZ84M
DMXZ84M DN Malathion
DMXZ84M HS Approved
DMXZ84M SN Calmathion; Camathion; Carbafos; Carbetovur; Carbetox; Carbofos; Carbophos; Celthion; Chemathion; Cimexan; Cleensheen; Cythion; Dorthion; Emmatos; Ethiolacar; Etiol; Extermathion; Flair; Forthion; Fosfothion; Fosfotion; Fyfanon; Hilthion; Karbofos; Kypfos; Malacide; Malafor; Malagran; Malakill; Malamar; Malaphele; Malaphos; Malasol; Malaspray; Malataf; Malathiazol; Malathione; Malathiozoo; Malathon; Malathyl; Malation; Malatol; Malatox; Maldison; Malmed; Malphos; Maltox; Mercaptothion; Mercaptotion; Moscarda; Oleophosphothion; Organoderm; Ovide; Paladin; Phosphothion; Prioderm; Sadofos; Sadophos; Sumitox; TAK; Taskil; Vetiol; Zithiol; Carbethoxy malathion; Detm ol ma; Detmol MA; Emmatos extra; Lice Rid;Malathion LV Concentrate; Malathion [USP]; Malation [Polish]; Maltox MLT; Mercaptosuccinic acid diethyl ester; Mercaptotion [Spanish]; Ortho Malathion; Siptox I; Vegfru malatox; AC 26691; EL 4049; Experimental insecticide 4049; Fog 3; Fosfotion 550; Hilthion 25wdp; IFO 13140; Latka 4049; Latka 4049 [Czech]; MET86C_SUPELCO; Malamar 50; Malathion 60; Malathion E50; OMS 1; PS86_SUPELCO; SF 60; Sadofos 30; American cyanamid 4,049; Derbac-M; ENT 17,034; Four thousand forty-nine; Insecticide no. 4049; Kop-Thionkypfosmalacide; Kop-thion; Malathion (USP); Malathion (old ID); Ovide (TN); Staeubol-Puder; Suleo-M; TM-4049; Kill-A-Mite; MALATHION, 96%; Malathion-2,3-14C; 8059HC
DMXZ84M TC Parasympathomimetics
DMXZ84M DT Small molecular drug
DMXZ84M PC 4004
DMXZ84M MW 330.4
DMXZ84M FM C10H19O6PS2
DMXZ84M IC InChI=1S/C10H19O6PS2/c1-5-15-9(11)7-8(10(12)16-6-2)19-17(18,13-3)14-4/h8H,5-7H2,1-4H3
DMXZ84M CS CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC
DMXZ84M IK JXSJBGJIGXNWCI-UHFFFAOYSA-N
DMXZ84M IU diethyl 2-dimethoxyphosphinothioylsulfanylbutanedioate
DMXZ84M CA CAS 121-75-5
DMXZ84M CB CHEBI:6651
DMXZ84M DE Pediculus capitis infestation
DMSCDY9 ID DMSCDY9
DMSCDY9 DN Mannitol
DMSCDY9 HS Approved
DMSCDY9 SN Diosmol; Hexahydroxyhexane; Invenex; Isotol; MTL; Manita; Mannazucker; Mannidex; Mannigen; Mannistol; Mannit; Mannite; Osmitrol; Osmofundin; Osmosal; Resectisol; Cordycepic acid; Cpd without stereochemical designation; Manna sugar; Mannitol [USAN]; Marine Crystal; Resectisol In Plastic Container; M0044; Mannidex 16700; Mannogem 2080; D-mannite; D-mannitol; DL-Mannitol; MANNITOL 25%; Maniton-S; Mannitol (USP); Mannitol (VAN); Mannitol 10%; Mannitol 10% In Plastic Container; Mannitol 15%; Mannitol 15% In Plastic Container; Mannitol 20%; Mannitol 20% In Plastic Container; Mannitol 5%; Mannitol 5% In Plastic Container; OSMITROL 10% IN WATER IN PLASTIC CONTAINER; OSMITROL 15% IN WATER IN PLASTIC CONTAINER; OSMITROL 20% IN WATER IN PLASTIC CONTAINER; OSMITROL 5% IN WATER IN PLASTIC CONTAINER; Osmitrol (TN); Osmitrol 10% In Water; Osmitrol 15% In Water; Osmitrol 20% In Water; Osmitrol 5% In Water; SDM No. 35; SORBITOL-MANNITOL IN PLASTIC CONTAINER; Sorbitol-Mannitol; D-Mannitol (JP15); MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER; D-(-)-Mannitol; ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D; MANNITOL 15% DEXTROSE 5% IN SODIUM CHLORIDE 0.45%; MANNITOL 5% DEXTROSE 5% IN SODIUM CHLORIDE 0.12%; (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol; (L)-Mannitol
DMSCDY9 TC Sweetening Agents
DMSCDY9 DT Small molecular drug
DMSCDY9 PC 6251
DMSCDY9 MW 182.17
DMSCDY9 FM C6H14O6
DMSCDY9 IC InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
DMSCDY9 CS C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
DMSCDY9 IK FBPFZTCFMRRESA-KVTDHHQDSA-N
DMSCDY9 IU (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
DMSCDY9 CA CAS 69-65-8
DMSCDY9 CB CHEBI:16899
DMSCDY9 DE Bronchiectasis; Renal failure
DMPWB7T ID DMPWB7T
DMPWB7T DN Maprotiline
DMPWB7T HS Approved
DMPWB7T SN Deprilept; Dibencycladine; Maprotilin; Maprotilina; Maprotilinum; Maprotylina; Maprotylina [Polish]; TBB066626; BA-34276; Deprilept (TN); Ludiomil (TN); Maprotilina [INN-Spanish]; Maprotiline (USAN); Maprotilinum [INN-Latin]; Psymion (TN); Ba-34,276; Maprotiline [USAN:BAN:INN]; N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine; N-Methyl-9,10-ethanoanthracene-9(10H)-propylamine; 3-(9,10-Dihydro-9,10-ethanoanthracen-9-yl)propylmethylamine; 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylpropan-1-amine
DMPWB7T CP Norvatis Phamaceuticals Corporation
DMPWB7T TC Antidepressants
DMPWB7T DT Small molecular drug
DMPWB7T PC 4011
DMPWB7T MW 277.4
DMPWB7T FM C20H23N
DMPWB7T IC InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
DMPWB7T CS CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
DMPWB7T IK QSLMDECMDJKHMQ-UHFFFAOYSA-N
DMPWB7T IU N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine
DMPWB7T CA CAS 10262-69-8
DMPWB7T CB CHEBI:6690
DMPWB7T DE Major depressive disorder
DMTL94F ID DMTL94F
DMTL94F DN Maraviroc
DMTL94F HS Approved
DMTL94F SN 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc
DMTL94F CP Pfizer; AstraZeneca
DMTL94F TC Anti-HIV Agents
DMTL94F DT Small molecular drug
DMTL94F PC 3002977
DMTL94F MW 513.7
DMTL94F FM C29H41F2N5O
DMTL94F IC InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
DMTL94F CS CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
DMTL94F IK GSNHKUDZZFZSJB-HLMSNRGBSA-N
DMTL94F IU 4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
DMTL94F CA CAS 376348-65-1
DMTL94F CB CHEBI:63608
DMTL94F DE Human immunodeficiency virus infection; Chronic obstructive pulmonary disease
DMKEY6S ID DMKEY6S
DMKEY6S DN Margetuximab
DMKEY6S HS Approved
DMKEY6S CP Macrogenics
DMKEY6S DT Antibody
DMKEY6S DE Gastrointestinal cancer; Gastric adenocarcinoma; HER2-positive breast cancer
DM70IK5 ID DM70IK5
DM70IK5 DN Marinol
DM70IK5 HS Approved
DM70IK5 SN Dronabinol; TETRAHYDROCANNABINOL; delta9-Tetrahydrocannabinol; delta9-THC; Deltanyne; Dronabinolum; delta-9-tetrahydrocannabinol; Abbott 40566; delta-9-THC; delta(9)-THC; 1972/8/3; delta1-THC; delta(sup 1)-Thc; delta(sup 9)-Thc; 1-trans-delta-9-Tetrahydrocannabinol; THC; Namisol; Dronabinolum [Latin]; 9-tetrahydrocannabinol; delta(9)-Tetrahydrocannabinol; delta(1)-Tetrahydrocannabinol; (-)-delta9-trans-Tetrahydrocannabinol; delta1-Tetrahydrocannabinol; 1-trans-delta9-Tetrahydrocannabinol; delta(9)-Tetrahydrocannibinol; SP; Compassia; Ganja; Hashish; Marincap; MaxEPA; Omegaven; Promega; Relivar; Sonergx; Tetranabinex; Cannabis resin; Drona binol; QCD 84924; SP 104; Tetrahydrocannabinol delta9; CAT-310; DELTA1-THC; DELTA1-Tetrahydrocannabinol;DELTA9-THC; DRG-0138; Delta-THC; Delta1-THC; Delta1-Tetrahydrocannabinol; Delta9-THC; Delta9-Tetrahydrocannabinol; Delta9-Tetrahydrocannabinol solution; Dronabinol [USAN:INN]; Marinol (TN); Pro-Mega;QCD-84924; Trans-tetrahydrocannabinol; DELTA9-trans-Tetrahydrocannabinol; Delta(1)-THC; Delta(1)-Tetrahydrocannabinol; Delta(9)-THC; Delta(9)-Tetrahydrocannabinol; Delta(9)-Tetrahydrocannibinol; Delta(sup 1)-Tetrahydrocannabinol; Delta(sup 1)-Thc; Delta(sup 9)-Tetrahydrocannabinol; Delta(sup 9)-Thc; Delta(sup9)-THC; Delta-9-THC; Delta-9-tetrahydrocannabinol; Delta1-Tetrahydrocannabinol (VAN); Delta9-Tetrahydrocannabinol (VAN); Delta9-trans-Tetrahydrocannabinol; Dronabinol (USP/INN); Omega-3-Fatty acid; THC-delta-9; Trans-delta9-Tetrahydrocannabinol; Cannabinol, tetrahydro-(6CI); Fish oils, n-3 fatty acid-high; Fish oils, omega-3 fatty acid-high; L-delta(sup 1)-tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol; L-trans-delta9-Tetrahydrocannabinol; Trans-delta-9-Tetrahydrocannabinol; Cannabinol, Delta1-tetrahydro-(7CI); Fats and Glyceridic oils, fish, n-3 fatty acid-high; L-delta1-Tetrahydrocannabinol; Trans-DELTA9-Tetrahydrocannabinol; L-delta1-trans-Tetrahydrocannabinol;L-trans-delta9-Tetrahydrocannabinol; Tetrahydrocannabinols (-)-delta1-3,4-trans-form; (-)-DELTA1-Tetrahydrocannabinol; (-)-DELTA9-THC; (-)-DELTA9-Tetrahydrocannabinol; (-)-DELTA9-trans-Tetrahydrocannabinol; (-)-delta(sup9)-trans-Tetrahydrocannabinol; (-)-3,4-trans-Delta1-Tetrahydrocannabinol; (-)-delta(sup 1)-3,4-trans-Tetrahydrocannabinol; (-)-delta1-Tetrahydrocannabinol; (-)-delta9-(trans)-Tetrahydrocannabinol; (-)-delta9-Tetrahydrocannabinol; (-)-trans-DELTA9-Tetrahydrocannabinol; (-)-trans-Delta1-Tetrahydrocannabinol; (-)-trans-Delta9-THC; (-)-trans-delta9-Tetrahydrocannabinol; (L)-delta1-Tetrahydrocannabinol; (l)-delta(sup 1)-Tetrahydrocannabinol; (l)-delta1-Tetrahydrocannabinol; 1-trans-delta(sup9)-tetrahydrocannabinol; 1-trans-D9-Tetrahydrocannabinol; 1-trans-delta(sup 9)-Tetrahydrocannabinol; 14C-DELTA1-Tetrahydrocannabinol; 6H-Dibenzo; 9-delta-Tetrahydrocannabinol; 9-ene-Tetrahydrocannabinol; Delta(9)-tetrahydrocannabinol
DM70IK5 CP Unimed Pharmaceuticals
DM70IK5 TC Analgesics
DM70IK5 DT Small molecular drug
DM70IK5 PC 16078
DM70IK5 MW 314.5
DM70IK5 FM C21H30O2
DM70IK5 IC InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1
DM70IK5 CS CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DM70IK5 IK CYQFCXCEBYINGO-IAGOWNOFSA-N
DM70IK5 IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
DM70IK5 CA CAS 1972-08-3
DM70IK5 CB CHEBI:66964
DM70IK5 DE Anorexia nervosa cachexia; Chemotherapy-induced nausea
DMMVNZ0 ID DMMVNZ0
DMMVNZ0 DN Masoprocol
DMMVNZ0 HS Approved
DMMVNZ0 SN NDGA; N 5023; TNP00263; Actinex (TN); Nordihydroguaiaretic acid (meso-form); (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol; 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMMVNZ0 TC Anticancer Agents
DMMVNZ0 DT Small molecular drug
DMMVNZ0 PC 71398
DMMVNZ0 MW 302.4
DMMVNZ0 FM C18H22O4
DMMVNZ0 IC InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
DMMVNZ0 CS C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O
DMMVNZ0 IK HCZKYJDFEPMADG-TXEJJXNPSA-N
DMMVNZ0 IU 4-[(2S,3R)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMMVNZ0 CA CAS 27686-84-6
DMMVNZ0 CB CHEBI:73468
DMMVNZ0 DE Prostate cancer
DMZ36RN ID DMZ36RN
DMZ36RN DN Mazindol
DMZ36RN HS Approved
DMZ36RN SN mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547; Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol
DMZ36RN TC Central Nervous System Stimulants
DMZ36RN DT Small molecular drug
DMZ36RN PC 4020
DMZ36RN MW 284.74
DMZ36RN FM C16H13ClN2O
DMZ36RN IC InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
DMZ36RN CS C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
DMZ36RN IK ZPXSCAKFGYXMGA-UHFFFAOYSA-N
DMZ36RN IU 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
DMZ36RN CA CAS 22232-71-9
DMZ36RN CB CHEBI:6702
DMZ36RN DE Obesity
DM0R4Z5 ID DM0R4Z5
DM0R4Z5 DN MCB-3837
DM0R4Z5 HS Approved
DM0R4Z5 SN Oxaquin
DM0R4Z5 CP Biovertis
DM0R4Z5 DT Small molecular drug
DM0R4Z5 PC 44201350
DM0R4Z5 MW 706.6
DM0R4Z5 FM C31H33F2N4O11P
DM0R4Z5 IC InChI=1S/C31H33F2N4O11P/c1-17(38)34-13-20-14-37(30(42)47-20)19-4-5-27(24(33)10-19)46-16-31(48-49(43,44)45)6-8-35(9-7-31)26-12-25-21(11-23(26)32)28(39)22(29(40)41)15-36(25)18-2-3-18/h4-5,10-12,15,18,20H,2-3,6-9,13-14,16H2,1H3,(H,34,38)(H,40,41)(H2,43,44,45)/t20-/m0/s1
DM0R4Z5 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)OCC3(CCN(CC3)C4=C(C=C5C(=C4)N(C=C(C5=O)C(=O)O)C6CC6)F)OP(=O)(O)O)F
DM0R4Z5 IK MNABRWLVTSGIMU-FQEVSTJZSA-N
DM0R4Z5 IU 7-[4-[[4-[(5S)-5-(acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenoxy]methyl]-4-phosphonooxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM0R4Z5 CA CAS 790704-50-6
DM0R4Z5 DE Malaria
DM8ZHP1 ID DM8ZHP1
DM8ZHP1 DN MCI-186
DM8ZHP1 HS Approved
DM8ZHP1 SN Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one
DM8ZHP1 CP Mitsubishi Tanabe
DM8ZHP1 DT Small molecular drug
DM8ZHP1 PC 4021
DM8ZHP1 MW 174.2
DM8ZHP1 FM C10H10N2O
DM8ZHP1 IC InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
DM8ZHP1 CS CC1=NN(C(=O)C1)C2=CC=CC=C2
DM8ZHP1 IK QELUYTUMUWHWMC-UHFFFAOYSA-N
DM8ZHP1 IU 5-methyl-2-phenyl-4H-pyrazol-3-one
DM8ZHP1 CA CAS 89-25-8
DM8ZHP1 CB CHEBI:31530
DM8ZHP1 DE Amyotrophic lateral sclerosis
DM4IAKR ID DM4IAKR
DM4IAKR DN MD-1100
DM4IAKR HS Approved
DM4IAKR SN Linaclotide acetate; Linaclotide acetate (USAN); MM-416775
DM4IAKR CP Microbia
DM4IAKR DT Small molecular drug
DM4IAKR PC 16158207
DM4IAKR MW 1586.8
DM4IAKR FM C61H83N15O23S6
DM4IAKR IC InChI=1S/C59H79N15O21S6.C2H4O2/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29;1-2(3)4/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95);1H3,(H,3,4)/t26-,27+,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,46-;/m0./s1
DM4IAKR CS C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O.CC(=O)O
DM4IAKR IK KWFNVZFWXXEJKL-YZDVLOIKSA-N
DM4IAKR IU acetic acid;(2S)-2-[[(1R,4S,7S,13S,16R,21R,24R,27S,30S,33R,38R,44S)-21-amino-13-(2-amino-2-oxoethyl)-27-(2-carboxyethyl)-44-[(1R)-1-hydroxyethyl]-30-[(4-hydroxyphenyl)methyl]-4-methyl-3,6,12,15,22,25,28,31,40,43,46,51-dodecaoxo-18,19,35,36,48,49-hexathia-2,5,11,14,23,26,29,32,39,42,45,52-dodecazatetracyclo[22.22.4.216,33.07,11]dopentacontane-38-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4IAKR CA CAS 851199-60-5
DM4IAKR DE Constipation; Irritable bowel syndrome
DMO14SG ID DMO14SG
DMO14SG DN Mebendazole
DMO14SG HS Approved
DMO14SG SN Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
DMO14SG CP Janssen Pharmaceutica
DMO14SG TC Antinematodal Agents
DMO14SG DT Small molecular drug
DMO14SG PC 4030
DMO14SG MW 295.29
DMO14SG FM C16H13N3O3
DMO14SG IC InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
DMO14SG CS COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
DMO14SG IK OPXLLQIJSORQAM-UHFFFAOYSA-N
DMO14SG IU methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
DMO14SG CA CAS 31431-39-7
DMO14SG CB CHEBI:6704
DMO14SG DE Worm infection
DMNOBFQ ID DMNOBFQ
DMNOBFQ DN Mebeverine
DMNOBFQ HS Approved
DMNOBFQ SN Arluy; Mebeverina; Mebeverinum; Arluy (TN); Mebeverina [INN-Spanish]; Mebeverine (INN); Mebeverine [INN:BAN]; Mebeverinum [INN-Latin]; Mebeverine (USAN)(*hydrochloride*); Veratric acid, 4-[ethyl(p-me; Veratric acid, 4-((ethyl(p-methoxy-alpha-methylphenethyl))amino)butyl ester; Veratric acid, 4-((ethyl(p-methoxy-.alpha.-methylphenethyl))amino)butyl ester; Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester; Benzoic acid, 3,4-dimethoxy-, {4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl} ester; Benzoic acid, 3,4-dimethoxy-, 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl ester; 4-(Ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate;4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate; 4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate; 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
DMNOBFQ CP Reckitt; Colman
DMNOBFQ DT Small molecular drug
DMNOBFQ PC 4031
DMNOBFQ MW 429.5
DMNOBFQ FM C25H35NO5
DMNOBFQ IC InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
DMNOBFQ CS CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC
DMNOBFQ IK VYVKHNNGDFVQGA-UHFFFAOYSA-N
DMNOBFQ IU 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
DMNOBFQ CA CAS 3625-06-7
DMNOBFQ CB CHEBI:91514
DMNOBFQ DE Irritable bowel syndrome
DM0KYI4 ID DM0KYI4
DM0KYI4 DN Mebutamate
DM0KYI4 HS Approved
DM0KYI4 SN Dormate
DM0KYI4 CP Medpointe Pharmaceuticals Medpointe Healthcare Inc
DM0KYI4 DT Small molecular drug
DM0KYI4 PC 6151
DM0KYI4 MW 232.28
DM0KYI4 FM C10H20N2O4
DM0KYI4 IC InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)
DM0KYI4 CS CCC(C)C(C)(COC(=O)N)COC(=O)N
DM0KYI4 IK LEROTMJVBFSIMP-UHFFFAOYSA-N
DM0KYI4 IU [2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate
DM0KYI4 CA CAS 64-55-1
DM0KYI4 CB CHEBI:31804
DM0KYI4 DE Anxiety disorder
DMGQFYB ID DMGQFYB
DMGQFYB DN Mecamylamine
DMGQFYB HS Approved
DMGQFYB SN Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane
DMGQFYB CP Mecamylamine
DMGQFYB TC Antihypertensive Agents
DMGQFYB DT Small molecular drug
DMGQFYB PC 4032
DMGQFYB MW 167.29
DMGQFYB FM C11H21N
DMGQFYB IC InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
DMGQFYB CS CC1(C2CCC(C2)C1(C)NC)C
DMGQFYB IK IMYZQPCYWPFTAG-UHFFFAOYSA-N
DMGQFYB IU N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
DMGQFYB CA CAS 60-40-2
DMGQFYB CB CHEBI:6706
DMGQFYB DE Essential hypertension
DM1O3BY ID DM1O3BY
DM1O3BY DN Mecasermin
DM1O3BY HS Approved
DM1O3BY SN Increlex (TN)
DM1O3BY TC Immunomodulatory Agents
DM1O3BY SQ Mecasermin: GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
DM1O3BY DE Growth failure
DM0CVXA ID DM0CVXA
DM0CVXA DN Mechlorethamine
DM0CVXA HS Approved
DM0CVXA SN Antimit; Carolysine; Caryolysin; Caryolysine; Chlorethazine; Chlormethine; Cloramin; Clormetina; Dichloren; Embechine; Embichin; MBA; Mebichloramine; Mechlorethanamine; Mechloroethamine; Mecloretamina; Mustargen; Mustine; Mutagen; Nitrogranulogen; Thyldiethylamine; Dichlor amine; Me chloroethamine; Mecloretamina [Italian]; Mustine note; Nitrogen mustard; HN2; T 1024; TL 146; Chloramine (the nitrogen mustard); Chlormethine (INN); Chlormethine [INN:BAN]; Chlormethinum [INN-Latin]; Clormetina [INN-Spanish]; ENT-25294; HN-2; IBS-L0033631; Mustargen (TN); N-Lost; N-Methyl lost; Stickstofflost (ebewe); T-1024; Bis(2-chloroethyl)methylamine; Bis(beta-chloroethyl) methylamine; Bis(beta-chloroethyl)methylamine; Di(2-chloroethyl)methylamine; Methylbis(2-chloroethyl)amine; Methylbis(beta-chloroethyl)amine; Methyldi(2-chloroethyl)amine; N-Methyl-lost; N-Methyl-lost [German]; Nitrogen mustard (HN-2); Mitoxine (*Hydrochloride*); N,N-Di(chloroethyl)methylamine; N-Methyl-bis-chloraethylamin; N-Methyl-bis-chloraethylamin [German]; Nitol (*Hydrochloride*); Stickstofflost (*Hydrochloride*); N,N-Bis(2-chloroethyl)methylamine; N-Methyl-bis(2-chloroethyl)amine; N-Methyl-bis(beta-chloroethyl)amine; Beta,beta'-Dichlorodiethyl-N-methylamine; N-Methyl-2,2'-dichlorodiethylamine; N,N-Bis(2-chloroethyl)-N-methylamine; 1,5-Dichloro-3-methyl-3-azapentane hydrochloride; 2,2'-Dichloro-N-me; 2,2'-Dichloro-N-methyldiethylamine; 2,2'-Dichlorodiethyl-methylamine; 2-Chloro-N-(2-chloroethyl)-N-methylethanamine
DM0CVXA CP Recordati Rare Diseases Inc
DM0CVXA TC Anticancer Agents
DM0CVXA DT Small molecular drug
DM0CVXA PC 4033
DM0CVXA MW 156.05
DM0CVXA FM C5H11Cl2N
DM0CVXA IC InChI=1S/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3
DM0CVXA CS CN(CCCl)CCCl
DM0CVXA IK HAWPXGHAZFHHAD-UHFFFAOYSA-N
DM0CVXA IU 2-chloro-N-(2-chloroethyl)-N-methylethanamine
DM0CVXA CA CAS 51-75-2
DM0CVXA CB CHEBI:28925
DM0CVXA DE T-cell lymphoma; Hodgkin lymphoma
DMS7T13 ID DMS7T13
DMS7T13 DN Meclizine
DMS7T13 HS Approved
DMS7T13 SN Ancolan; Ancolon; Antivert; Bonadettes; Bonine; Calmonal; Chiclida; Diadril; Histamethine; Histamethizine; Histametizine; Histametizyn; Histametizyne; Itinerol; Marex; Meclicot; Meclozina; Meclozine; Meclozinum; Medivert; Monamine; Navicalm; Nevidoxine; Parachloramine; Peremesin; Postafene; Ravelon; Sabari; Siguran; Subari; Suprimal; Travelon; Veritab; Vomisseis; Vomissels; Dramamine II; Meclizine Hcl; UCB 170; UCB 5052; UCB 5062; Antivert (TN); Antivert/25; Antivert/50; Bonamine (TN); Bonine (TN); Meclizine [INN:BAN]; Meclozina [INN-Spanish]; Meclozine (BAN); Meclozinum [INN-Latin]; Neo-istafene; Neo-suprimal; Neo-suprimel; Nevidoxine (TN); Postafen (TN); Sea-Legs; Ru-Vert-M; U. C. B. 5062; U.C.B. 5062; (+-)-Meclizine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine
DMS7T13 CP Citron Pharma Llc
DMS7T13 TC Antiallergic Agents
DMS7T13 DT Small molecular drug
DMS7T13 PC 4034
DMS7T13 MW 390.9
DMS7T13 FM C25H27ClN2
DMS7T13 IC InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
DMS7T13 CS CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMS7T13 IK OCJYIGYOJCODJL-UHFFFAOYSA-N
DMS7T13 IU 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine
DMS7T13 CA CAS 569-65-3
DMS7T13 CB CHEBI:6709
DMS7T13 DE Dizziness
DMSFQ8I ID DMSFQ8I
DMSFQ8I DN Meclocycline
DMSFQ8I HS Approved
DMSFQ8I SN Meclociclina; Meclocyclinum; Meclosorb; Samil; Meclociclina [Italian]; GS 2989; GS-2989; Meclociclina [INN-Spanish]; Meclocycline(USAN); Meclocyclinum [INN-Latin]; Meclocycline (USAN/INN); Meclocycline [USAN:INN:BAN]; (2E,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4aR,5S,5aS,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4a.alpha.,5.alpha.,5a.alpha.,12a.alpha.)]-(9CI); 2-Naphthacenecarboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-, [4S-(4.alpha.,4aal; 2-[amino(hydroxy)methylidene]-7-chloro-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; 7-Chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 7-Chloro-6-methylene-5-oxytetracycline; 7-Cloro-6-metilene-5-ossitetraciclina; 7-Cloro-6-metilene-5-ossitetraciclina [Italian]; 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacene carboxamide
DMSFQ8I CP Johnson And Johnson Consumer Companies Inc
DMSFQ8I TC Antibiotics
DMSFQ8I DT Small molecular drug
DMSFQ8I PC 54676539
DMSFQ8I MW 476.9
DMSFQ8I FM C22H21ClN2O8
DMSFQ8I IC InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,14-15,17,26-28,31,33H,1H2,2-3H3,(H2,24,32)/t10-,14-,15+,17+,22+/m1/s1
DMSFQ8I CS CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O
DMSFQ8I IK RNIADBXQDMCFEN-IWVLMIASSA-N
DMSFQ8I IU (4S,4aR,5S,5aR,12aR)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMSFQ8I CA CAS 2013-58-3
DMSFQ8I CB CHEBI:135772
DMSFQ8I DE Bacterial infection
DMNL98G ID DMNL98G
DMNL98G DN Meclofenamate sodium
DMNL98G HS Approved
DMNL98G CP Parke Davis Div Warner Lambert Co
DMNL98G DT Small molecular drug
DMNL98G PC 4038
DMNL98G MW 318.1
DMNL98G FM C14H10Cl2NNaO2
DMNL98G IC InChI=1S/C14H11Cl2NO2.Na/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;/h2-7,17H,1H3,(H,18,19);/q;+1/p-1
DMNL98G CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.[Na+]
DMNL98G IK OGPIIGMUPMPMNT-UHFFFAOYSA-M
DMNL98G IU sodium;2-(2,6-dichloro-3-methylanilino)benzoate
DMNL98G CA CAS 6385-02-0
DMNL98G CB CHEBI:6711
DMNL98G DE Arthritis
DM05FXR ID DM05FXR
DM05FXR DN Meclofenamic acid
DM05FXR HS Approved
DM05FXR SN Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
DM05FXR TC Analgesics
DM05FXR DT Small molecular drug
DM05FXR PC 4037
DM05FXR MW 296.1
DM05FXR FM C14H11Cl2NO2
DM05FXR IC InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
DM05FXR CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
DM05FXR IK SBDNJUWAMKYJOX-UHFFFAOYSA-N
DM05FXR IU 2-(2,6-dichloro-3-methylanilino)benzoic acid
DM05FXR CA CAS 644-62-2
DM05FXR CB CHEBI:6710
DM05FXR DE Ankylosing spondylitis; Joint pain
DMBGWPH ID DMBGWPH
DMBGWPH DN Medroxyprogesterone
DMBGWPH HS Approved
DMBGWPH SN Asconale; Colirest; Hematrol; Hydroxymethylprogesterone; Lunelle; Medrossiprogesterone; Medroxiprogesterona; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteronum; Methylhydroxyprogesterone; Adgyn Medro; Farlutal inyectable; Medroprogesterone Acetate; Medrossiprogesterone [DCIT]; Medroxyprogesteron acetate; Medroxyprogesterone Strakan Brand; Sodelut G; Strakan Brand of Medroxyprogesterone; MPA Gyn 5; U 8840; CBP-1011; Farlutal inyectable (TN); G-Farlutal; Medroxiprogesterona [INN-Spanish]; Medroxyprogesterone (INN); Medroxyprogesterone [INN:BAN]; Medroxyprogesteronum [INN-Latin]; Novo-Medrone; Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-(9CI); Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)-(9CI); (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; (6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione; 17 alpha Hydroxy 6 alpha Methylprogesterone; 17 alpha-Hydroxy-6 alpha-Methylprogesterone; 17-Hydroxy-6.alpha.-methylprogesterone; 17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione; 17-Hydroxy-6alpha-methylprogesterone; 17.alpha.-Hydroxy-6.alpha.-methylprogesterone; 17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 17alpha-Hydroxy-6alpha-methylprogesterone; 6-Dihydromegestrol; 6-alpha-Methyl-17-alpha-hydroxyprogesterone; 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone; 6alpha-Methyl-17alpha-hydroxyprogesterone; 6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione; 6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
DMBGWPH CP Pharmacia And Upjohn Co
DMBGWPH TC Contraceptive Agents
DMBGWPH DT Small molecular drug
DMBGWPH PC 10631
DMBGWPH MW 344.5
DMBGWPH FM C22H32O3
DMBGWPH IC InChI=1S/C22H32O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h12-13,16-18,25H,5-11H2,1-4H3/t13-,16+,17-,18-,20+,21-,22-/m0/s1
DMBGWPH CS C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
DMBGWPH IK FRQMUZJSZHZSGN-HBNHAYAOSA-N
DMBGWPH IU (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMBGWPH CA CAS 520-85-4
DMBGWPH CB CHEBI:6715
DMBGWPH DE Solid tumour/cancer
DMJ90O5 ID DMJ90O5
DMJ90O5 DN Medrysone
DMJ90O5 HS Approved
DMJ90O5 SN Hydroxymesterone; Medrifar; Medritonic; Medrocort; Visudrisone; Medrysone (USAN); U-8471; (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 11.beta.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione; 11.beta.-Hydroxy-6.alpha.-methylprogesterone; 11beta-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione; 11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione; 6.alpha.-Methyl-11.beta.-hydroxyprogesterone
DMJ90O5 DT Small molecular drug
DMJ90O5 PC 247839
DMJ90O5 MW 344.5
DMJ90O5 FM C22H32O3
DMJ90O5 IC InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1
DMJ90O5 CS C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)CC4)C)O)C)C(=O)C
DMJ90O5 IK GZENKSODFLBBHQ-ILSZZQPISA-N
DMJ90O5 IU (6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMJ90O5 CA CAS 2668-66-8
DMJ90O5 CB CHEBI:34829
DMJ90O5 DE Eye inflammation
DMK7HFI ID DMK7HFI
DMK7HFI DN Mefenamic acid
DMK7HFI HS Approved
DMK7HFI SN ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid
DMK7HFI TC Antiinflammatory Agents
DMK7HFI DT Small molecular drug
DMK7HFI PC 4044
DMK7HFI MW 241.28
DMK7HFI FM C15H15NO2
DMK7HFI IC InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
DMK7HFI CS CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
DMK7HFI IK HYYBABOKPJLUIN-UHFFFAOYSA-N
DMK7HFI IU 2-(2,3-dimethylanilino)benzoic acid
DMK7HFI CA CAS 61-68-7
DMK7HFI CB CHEBI:6717
DMK7HFI DE Dysmenorrhea
DMWT905 ID DMWT905
DMWT905 DN Mefloquine
DMWT905 HS Approved
DMWT905 SN Lariam; Mefloquin; Mefloquina; Mefloquinone; Mefloquinum; Mephloquine; Racemic mefloquine; Ro 215998; WR 142490; Lariam (Hydrochloride); Lariam (TN); Mefaquin (TN); Mefloquina [INN-Spanish]; Mefloquinum [INN-Latin]; RO 13-7224; RO 13-7225; Ro 21-5998; SPB-80406; WR-142490; Mefloquine (USAN/INN); Mefloquine [USAN:INN:BAN]; RTI1169-1-1; RTI1172-1-1; RTI1173-1-1; RTI1174-1-1; RTI1188-1-1; RTI1189-1-1; Ro 21-5998 (Hydrochloride); WR-142,490; WR-177,602; Ro-21-5998-001; Alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; Alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol; [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol; Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol; (+)-(11R,2'S)-erythro-Mefloquine; (+)-Mefloquine; (+)-Threo-Mefloquine; (-)-(11S,2'R)-erythro-Mefloquine; (-)-Mefloquine; (-)-Threo-Mefloquine; (DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol; (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol
DMWT905 CP Hoffmann-La Roche pharmaceutical company
DMWT905 TC Antimalarials
DMWT905 DT Small molecular drug
DMWT905 PC 4046
DMWT905 MW 378.31
DMWT905 FM C17H16F6N2O
DMWT905 IC InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
DMWT905 CS C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
DMWT905 IK XEEQGYMUWCZPDN-UHFFFAOYSA-N
DMWT905 IU [2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
DMWT905 CA CAS 49752-90-1
DMWT905 CB CHEBI:63681
DMWT905 DE Malaria
DMDH9KX ID DMDH9KX
DMDH9KX DN Megestrol
DMDH9KX HS Approved
DMDH9KX SN Chronopil; Megestrolo; Megestrolo [DCIT]; Chronopil (TN); Megace (TN); Megestrol (INN); Megestrol [INN:BAN]; Megestrolum [INN-Latin]; (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
DMDH9KX CP Bristol Myers Squibb
DMDH9KX TC Anticancer Agents
DMDH9KX DT Small molecular drug
DMDH9KX PC 19090
DMDH9KX MW 342.5
DMDH9KX FM C22H30O3
DMDH9KX IC InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11-12,16-18,25H,5-10H2,1-4H3/t16-,17+,18+,20-,21+,22+/m1/s1
DMDH9KX CS CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C
DMDH9KX IK VXIMPSPISRVBPZ-NWUMPJBXSA-N
DMDH9KX IU (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DMDH9KX CA CAS 3562-63-8
DMDH9KX DE Breast cancer
DM1OFHN ID DM1OFHN
DM1OFHN DN Meglitinides
DM1OFHN HS Approved
DM1OFHN DT Small molecular drug
DM1OFHN PC 3033769
DM1OFHN MW 347.2
DM1OFHN FM C15H20Cl2N2O3
DM1OFHN IC InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
DM1OFHN CS CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O
DM1OFHN IK WAOQONBSWFLFPE-VIFPVBQESA-N
DM1OFHN IU 3,5-dichloro-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
DM1OFHN CA CAS 84225-95-6
DM1OFHN CB CHEBI:92070
DM1OFHN DE Type-2 diabetes; Psychotic disorder
DMGUZ0W ID DMGUZ0W
DMGUZ0W DN MELARSOPROL
DMGUZ0W HS Approved
DMGUZ0W SN MELARSOPROL; Mel B; Arsobal; 494-79-1; Melarsoprolum [INN-Latin]; EINECS 207-793-4; Melarsoprol [INN:BAN:DCF]; RP 3854; CHEBI:6729; [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol; 1,3,2-Dithiarsolane-4-methanol, 2-(4-((4,6-diamino-1,3,5-triazin-2-yl)amino)phenyl)-; Melarsoprolum; Melarsenoxid-BAL; 2-(p-(4,6-Diamino-s-triazin-2-ylamino)phenyl)-1,3,2-dithiarsolane-4-methanol; C12H15AsN6OS2; Specia; UNII-ZF3786Q2E8; Melarsoprol (INN); AC1L1UXN; Mel B (TN); CHEMBL166; SCHEMBL61707; ZF3786Q2E8
DMGUZ0W DT Small molecular drug
DMGUZ0W PC 10311
DMGUZ0W MW 398.3
DMGUZ0W FM C12H15AsN6OS2
DMGUZ0W IC InChI=1S/C12H15AsN6OS2/c14-10-17-11(15)19-12(18-10)16-8-3-1-7(2-4-8)13-21-6-9(5-20)22-13/h1-4,9,20H,5-6H2,(H5,14,15,16,17,18,19)
DMGUZ0W CS C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO
DMGUZ0W IK JCYZMTMYPZHVBF-UHFFFAOYSA-N
DMGUZ0W IU [2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiarsolan-4-yl]methanol
DMGUZ0W CA CAS 494-79-1
DMGUZ0W CB CHEBI:6729
DMGUZ0W DE Trypanosomiasis
DMKWFBT ID DMKWFBT
DMKWFBT DN Melatonin
DMKWFBT HS Approved
DMKWFBT SN 73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; Circadin; 5-Methoxy-N-acetyltryptamine; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melatol; Melovine; Melatonex; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; UNII-JL5DK93RCL; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; N-acetyl-5-methoxy-tryptamine; NSC 113928; CCRIS 3472; CHEMBL45; EINECS 200-797-7; JL5DK93RCL; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; BRN 0205542; Circadin; Melapure; Melatonina; Posidorm; Vivitas; Night Rest; Pineal Hormone; Revital Melatonin; Rx Balance; Sleep Right; IN1244; M 5250; M1105; ML1; MT6; TNP00300; M-1200; M-1250; Mela-T; Melatonex, Melatonin; Melatonina (TN); NMR/14327425; Nature'S Harmony; PREVENTION 2 (MELATONIN); PREVENTION 3 (MELATONIN); PREVENTION 4 (MELATONIN); PREVENTION 5 (MELATONIN); PREVENTION 1 (MELATONIN) (PREVENTION 1); Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-(6CI,8CI); N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-(9CI); Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-(9CI); 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; [3H]melatonin; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKWFBT TC Central Nervous System Stimulants
DMKWFBT DT Small molecular drug
DMKWFBT PC 896
DMKWFBT MW 232.28
DMKWFBT FM C13H16N2O2
DMKWFBT IC InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)
DMKWFBT CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
DMKWFBT IK DRLFMBDRBRZALE-UHFFFAOYSA-N
DMKWFBT IU N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKWFBT CA CAS 73-31-4
DMKWFBT CB CHEBI:16796
DMKWFBT DE Insomnia
DM2AR7L ID DM2AR7L
DM2AR7L DN Meloxicam
DM2AR7L HS Approved
DM2AR7L SN Meloxicam (SoluMatrix/arthritis); Meloxicam nanoformulation capsules (arthritis), iCeutica; Meloxicam (SoluMatrix/arthritis), iCeutica
DM2AR7L CP Iroko pharmaceuticals
DM2AR7L DT Small molecular drug
DM2AR7L PC 54677470
DM2AR7L MW 351.4
DM2AR7L FM C14H13N3O4S2
DM2AR7L IC InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
DM2AR7L CS CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
DM2AR7L IK ZRVUJXDFFKFLMG-UHFFFAOYSA-N
DM2AR7L IU 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
DM2AR7L CA CAS 71125-38-7
DM2AR7L CB CHEBI:6741
DM2AR7L DE Arthritis
DMOLNHF ID DMOLNHF
DMOLNHF DN Melphalan
DMOLNHF HS Approved
DMOLNHF SN Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); Alkeran (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
DMOLNHF TC Anticancer Agents
DMOLNHF DT Small molecular drug
DMOLNHF PC 460612
DMOLNHF MW 305.2
DMOLNHF FM C13H18Cl2N2O2
DMOLNHF IC InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
DMOLNHF CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl
DMOLNHF IK SGDBTWWWUNNDEQ-LBPRGKRZSA-N
DMOLNHF IU (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
DMOLNHF CA CAS 148-82-3
DMOLNHF CB CHEBI:28876
DMOLNHF DE Multiple myeloma; Intrahepatic cholangiocarcinoma
DMWF5R4 ID DMWF5R4
DMWF5R4 DN Melphalan flufenamide
DMWF5R4 HS Approved
DMWF5R4 SN J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides
DMWF5R4 CP Oncopeptides AB
DMWF5R4 DT Small molecular drug
DMWF5R4 PC 9935639
DMWF5R4 MW 498.4
DMWF5R4 FM C24H30Cl2FN3O3
DMWF5R4 IC InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1
DMWF5R4 CS CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N
DMWF5R4 IK YQZNKYXGZSVEHI-VXKWHMMOSA-N
DMWF5R4 IU ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate
DMWF5R4 CA CAS 380449-51-4
DMWF5R4 DE Ovarian cancer; Plasma cell myeloma; Multiple myeloma
DMD9WSC ID DMD9WSC
DMD9WSC DN Memantine
DMD9WSC HS Approved
DMD9WSC SN Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest
DMD9WSC CP Merz & Co GmbH
DMD9WSC DT Small molecular drug
DMD9WSC PC 4054
DMD9WSC MW 179.3
DMD9WSC FM C12H21N
DMD9WSC IC InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
DMD9WSC CS CC12CC3CC(C1)(CC(C3)(C2)N)C
DMD9WSC IK BUGYDGFZZOZRHP-UHFFFAOYSA-N
DMD9WSC IU 3,5-dimethyladamantan-1-amine
DMD9WSC CA CAS 19982-08-2
DMD9WSC CB CHEBI:64312
DMD9WSC DE Alzheimer disease
DMP9N85 ID DMP9N85
DMP9N85 DN Menadiol sodium diphosphate
DMP9N85 HS Approved
DMP9N85 SN Kappadione; Synkavit; Procoagulo; Synkavite; Thylokay; Kipca water soluble; Synkayvite; Menadiol sodium diphosphate; Menadione sodium phosphate; Sodium menadione diphosphate; Menadiol Sodium Diphosphate Anhydrous; UNII-R2L46WE615; Menadiol tetrasodium diphosphate; EINECS 205-012-1; Menadione diphosphate tetrasodium salt; 1:4-Naphthaquinol-bisdisodium phosphate; 131-13-5; Menadiol sodium diphosphate anhydrous [USAN]; R2L46WE615; 2-Methyl-1,4-naphthaquinol bis(disodium phosphate); Tetrasodium 2-methyl-1,4-naphthalenediol diphosp
DMP9N85 DT Small molecular drug
DMP9N85 PC 8555
DMP9N85 MW 422.08
DMP9N85 FM C11H8Na4O8P2
DMP9N85 IC InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4
DMP9N85 CS CC1=C(C2=CC=CC=C2C(=C1)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
DMP9N85 IK GZBACHSOZNEZOG-UHFFFAOYSA-J
DMP9N85 IU tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate
DMP9N85 CA CAS 131-13-5
DMP9N85 DE Coagulation defect
DMSJDTY ID DMSJDTY
DMSJDTY DN Menadione
DMSJDTY HS Approved
DMSJDTY SN menadione; 58-27-5; Vitamin K3; 2-Methyl-1,4-naphthoquinone; Menaphthone; 2-methylnaphthalene-1,4-dione; 2-Methylnaphthoquinone; Thyloquinone; Panosine; Klottone; Kayquinone; Kappaxin; Kayklot; Kolklot; 2-Methyl-1,4-naphthalenedione; Menaphthon; Menadion; Kipca; Kanone; Mitenone; Kativ-G; Kaergona; Aquinone; Prokayvit; Mitenon; Koaxin; Kaykot; Kareon; Hemodal; Aquakay; Synkay; Karcon; K-Thrombyl; K-Vitan; Kipca-Oil Soluble; Juva-K; Vitamin K2(0); Vitamin K0; Menaquinone 0; Vitamin K 3; Menaphtone; Menadionum; 2-Methyl-1,4-naphthochinon; Usaf; Aquakay; Klottone;Koaxin; Memodol; Methylnaphthoquinone; Vicasol; Menadione semiquinone; M0373; VK3; Kappaxan (VAN); Kappaxin (TN); Kipca, oil soluble; Menadione (K3); Menadione (USP); Menadione [USAN:BAN]; Usaf ek-5185; Vitamin-K3; Methyl-1,4-naphthalenedione; Methyl-1,4-naphthoquinone; Vitamin K3 : 2-Methyl-1,4-naphthoquinone; 1,4-Naphthalenedione, 2-methyl-,radical ion(1-); 2-Methyl-1,4-naftochinon; 2-Methyl-1,4-naftochinon [Czech]; 2-Methyl-1,4-naphthochinon [German]; 2-methyl-1,4-naphthoquinone, 5; 3-Methyl-1,4-naphthoquinone; Ascorbic acid/menadione; Triglycyl-lysine-vasopressin
DMSJDTY TC Vitamins
DMSJDTY DT Small molecular drug
DMSJDTY PC 4055
DMSJDTY MW 172.18
DMSJDTY FM C11H8O2
DMSJDTY IC InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3
DMSJDTY CS CC1=CC(=O)C2=CC=CC=C2C1=O
DMSJDTY IK MJVAVZPDRWSRRC-UHFFFAOYSA-N
DMSJDTY IU 2-methylnaphthalene-1,4-dione
DMSJDTY CA CAS 58-27-5
DMSJDTY CB CHEBI:28869
DMSJDTY DE Vitamin K deficiency; Prostate cancer
DM2SR1J ID DM2SR1J
DM2SR1J DN Meningococcal groups A, C, Y and W-135 conjugate vaccine
DM2SR1J HS Approved
DM2SR1J SN Menveo (TN)
DM2SR1J CP Novartis
DM2SR1J DE Meningococcal infection
DM4CF18 ID DM4CF18
DM4CF18 DN Menotropins
DM4CF18 HS Approved
DM4CF18 SN Humegon; Human Menopausal Gonadotrophin; Human Menopausal Gonadotrophin (JP15); Humegon (TN); Menotropins (USP)
DM4CF18 TC Fertility Agents
DM4CF18 SQ AlphaChain (LH): APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >BetaChain (LH)SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYRDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLFL >AlphaChain (FSH)APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >BetaChain (FSH)NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DM4CF18 DE Female infertility
DMG2KW7 ID DMG2KW7
DMG2KW7 DN Menthol
DMG2KW7 HS Approved
DMG2KW7 SN Hexahydrothymol; Levomenthol; Levomentholum; Menthacamphor; Menthomenthol; Neoisomenthol; Racementhol; Racementholum; Racementol; Headache crystals; Menthol natural; Menthol racemic; Menthol racemique; Menthol racemique [French]; Menthol solution; Menthyl alcohol; Peppermint camphor; Racemic menthol; Robitussin Cough Drops; M0321; M0545; D-Menthol; D-Neomenthol; Dl-Menthol; Fisherman's friend lozenges; L-Menthol; Levomenthol [INN:BAN]; Levomentholum [INN-Latin]; Menthol (USP); Menthol (VAN); Menthol natural, brazilian; NOOLISFMXDJSKH-KXUCPTDWBX; Rac-Menthol; Racementhol [INN:BAN]; Racementholum [INN-Latin]; Racementol [INN-Spanish]; Tra-kill tracheal mite killer; D,l-Menthol; Dl-Menthol (JP15); Fisherman's friendlozenges (TN); L-Menthol (JP15); L-Menthol (TN); L-Menthol (natural); Dl-3-p-Menthanol; P-Menthan-3-ol; RACEMIC MENTHOL U.S.P.; U.S.P. Menthol; D-(-)-Menthol; D-p-Menthan-3-ol; L-(-)-Menthol; Menthol, (1alpha,2beta,5alpha)-Isomer; Cis-1 ,3-trans-1,4-(+-)-menthol; Cis-1,3-trans-1,4-(+-)-menthol; (+)-Neo-menthol; (+)-p-Menthan-3-ol; (+-)-(1R*,3R*,4S*)-Menthol; (+-)-Menthol; (+/-)-Menthol; (+/-)-p-Menthan-3-ol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-p-Menthan-3-ol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-Menthol; (1R,3R,4S)-(-)-MENTHOL; (1S, 2S, 5R)-(+)-Neomenthol; (1S,2R,5R)-(+)-Isomenthol; (1S,2R,5S)-(+)-Menthol; (1S,2R,5S)-Menthol; (1r,2s,5r)-(-)-menthol; (L)-MENTHOL; (R)-(-)-Menthol; 2-Isopropyl-5-methylcyclohexanol; 3-p-Menthol; 4-Isopropyl-1-methylcyclohexan-3-ol; 5-Methyl-2-(1-methylethyl)-cyclohexanol; 5-Methyl-2-(1-methylethyl)cyclohexanol; 5-methyl-2-(propan-2-yl)cyclohexanol; 5-methyl-2-propan-2-ylcyclohexan-1-ol
DMG2KW7 TC Antipruritics
DMG2KW7 DT Small molecular drug
DMG2KW7 PC 1254
DMG2KW7 MW 156.26
DMG2KW7 FM C10H20O
DMG2KW7 IC InChI=1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3
DMG2KW7 CS CC1CCC(C(C1)O)C(C)C
DMG2KW7 IK NOOLISFMXDJSKH-UHFFFAOYSA-N
DMG2KW7 IU 5-methyl-2-propan-2-ylcyclohexan-1-ol
DMG2KW7 CA CAS 89-78-1
DMG2KW7 CB CHEBI:25187
DMG2KW7 DE Throat irritation
DM8YU2F ID DM8YU2F
DM8YU2F DN Mepenzolate
DM8YU2F HS Approved
DM8YU2F SN Cantil; Cantilaque; Cantilon; Cantril; Colibantil; Colopiril; Colum; Delevil; Eftoron; Gastropidil; Glycophenylate; Mepenzolon; Tralanta; Trancolon; Trokonil; Bromure de mepenzolate; Bromuro de mepenzolato; MEPENZOLATE BROMIDE; Mepenzolate Methylbromide; Mepenzolati bromidum; Mepenzolic acid; Mepenzolone Bromide; JB 340; Bromure de mepenzolate [INN-French]; Bromuro de mepenzolato [INN-Spanish]; Cantil (TN); Mepenzolati bromidum [INN-Latin]; Mepenzolic acid, bromine salt; Mepenzolate bromide (JP15/INN); Mepenzolate bromide [INN:BAN:JAN]; N-Methyl-3-piperidyl benzilate methobromide; N-Methyl-3-piperidyl benzilate methyl bromide; N-Methyl-3-piperidyldiphenylglycolate methobromide; N-methyl-3-piperidylbenzilate methyl bromide; Benzilic acid, 1-methyl-3-piperidyl ester methobromide; Benzilic acid, ester with 3-hydroxy-1,1-dimethylpiperidinium bromide; Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-, bromide; Piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester); Piperidinium, 3-hydroxy-1,1-dimethyl-, bromide, benzilate; Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-(VAN); Piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-, bromide; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate; (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide; 1-Methyl-3-piperidyl benzilate methyl bromide; 1-Methyl-3-piperidyl benzilate methylbromide; 2-(1,1-dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate; 2-[(1,1-dimethylpiperidinium-3-yl)oxy]-2-oxo-1,1-diphenylethanolate; 3-((Hydroxydiphenylacetyl)oxy)-1,1-dimethylpiperidinium bromide; 3-Hydroxy-1,1-dimethylpiperidinium bromide benzilate; 3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide
DM8YU2F TC Parasympatholytics
DM8YU2F DT Small molecular drug
DM8YU2F PC 4057
DM8YU2F MW 340.4
DM8YU2F FM C21H26NO3+
DM8YU2F IC InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1
DM8YU2F CS C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C
DM8YU2F IK GKNPSSNBBWDAGH-UHFFFAOYSA-N
DM8YU2F IU (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
DM8YU2F CA CAS 25990-43-6
DM8YU2F CB CHEBI:94411
DM8YU2F DE Gastrointestinal disease; Peptic ulcer
DMX4GND ID DMX4GND
DMX4GND DN Meperidine
DMX4GND HS Approved
DMX4GND SN Demarol; Demerol; Dolcontral; Dolosal; Dolsin; Isonipecain; Isonipecaine; Lidol; Lydol; Meperidol; Nemerol; Pethanol; Pethidin; Pethidine; Pethidineter; Pethidinum; Petidina; Petydyna; Phetidine; Piperosal; Pipersal; Meperidine solution; Methyl phenylpiperidine carbonic acid ethyl ester; Operidine EPJ I; Pethidine DBL; Petydyna [Polish]; Demerol (TN); Operidine EPJ-I; Pethidine (INN); Pethidine DBL (TN); Pethidinum [INN-Latin]; Petidina [INN-Spanish]; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; N-Methyl-4-phenyl-4-carbethoxypiperidine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI); 1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
DMX4GND CP Apotex Inc
DMX4GND TC Anesthetics
DMX4GND DT Small molecular drug
DMX4GND PC 4058
DMX4GND MW 247.33
DMX4GND FM C15H21NO2
DMX4GND IC InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
DMX4GND CS CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2
DMX4GND IK XADCESSVHJOZHK-UHFFFAOYSA-N
DMX4GND IU ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
DMX4GND CA CAS 57-42-1
DMX4GND CB CHEBI:6754
DMX4GND DE Pain
DMFJH5Q ID DMFJH5Q
DMFJH5Q DN Mephentermine
DMFJH5Q HS Approved
DMFJH5Q SN Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane
DMFJH5Q CP Baxter Healthcare Corp Anesthesia Critical Care
DMFJH5Q TC Vasoconstrictor Agents
DMFJH5Q DT Small molecular drug
DMFJH5Q PC 3677
DMFJH5Q MW 163.26
DMFJH5Q FM C11H17N
DMFJH5Q IC InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
DMFJH5Q CS CC(C)(CC1=CC=CC=C1)NC
DMFJH5Q IK RXQCGGRTAILOIN-UHFFFAOYSA-N
DMFJH5Q IU N,2-dimethyl-1-phenylpropan-2-amine
DMFJH5Q CA CAS 100-92-5
DMFJH5Q CB CHEBI:6755
DMFJH5Q DE High blood pressure
DM5UGDK ID DM5UGDK
DM5UGDK DN Mephenytoin
DM5UGDK HS Approved
DM5UGDK SN Epiazin; Epilan; Fenantoin; Insulton; Mefenetoin; Mefenitoina; Mephenetoinum; Mephentoin; Mephenytoine; Mephenytoinum; Mesantoin; Mesdontoin; Mesontoin; Methoin; Methylphenetoin; Metydan; Phenantoin; Phenylethylmethylhydantoin; Sacerno; Sedantional; Sedantoin; Sedantoinal; Triantoin; Ydantoin; Methyl Phenetoin; Methyl hydantoin; MU2276000; Gerot-epilan; L-Mephenytoin; Mefenitoina [INN-Spanish]; Mephenytoin [USAN:INN]; Mephenytoine [INN-French]; Mephenytoinum [INN-Latin]; Mesantoin (TN); Phenetoin, Methyl;Mephenytoin (USP/INN); L-3-Methyl-5-ethyl-5-phenylhydantoin; (+-)-5-Ethyl-3-methyl-5-phenylhydantoin; (+-)-Mephenytoin; (-)-5-Ethyl-3-methyl-5-phenylhydantoin; 3-Ethylnirvanol; 3-Methyl-5, 5-ethylphenylhydantoin; 3-Methyl-5,5-ethylphenylhydantoin; 3-Methyl-5,5-phenylethylhydantoin; 3-Methyl-5-ethyl-5-phenylh; 3-Methyl-5-ethyl-5-phenylhydantoin; 5 Ethyl 3 Methyl 5 Phenylhydantoin; 5-Ethyl-3-methyl-5-phenyl-2,4(3H,5H)-imidazoledione; 5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione; 5-Ethyl-3-methyl-5-phenylhydantoin; 5-Ethyl-3-methyl-5-phenylimidazolidin-2,4-dione; 5-Ethyl-5-fenyl-3-methylhydantoin; 5-Ethyl-5-fenyl-3-methylhydantoin [Czech]; 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
DM5UGDK CP Norvatis Phamaceuticals Corporation
DM5UGDK TC Anticonvulsants
DM5UGDK DT Small molecular drug
DM5UGDK PC 4060
DM5UGDK MW 218.25
DM5UGDK FM C12H14N2O2
DM5UGDK IC InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
DM5UGDK CS CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2
DM5UGDK IK GMHKMTDVRCWUDX-UHFFFAOYSA-N
DM5UGDK IU 5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
DM5UGDK CA CAS 50-12-4
DM5UGDK CB CHEBI:6757
DM5UGDK DE Epilepsy
DMUDWP9 ID DMUDWP9
DMUDWP9 DN Mepindolol
DMUDWP9 HS Approved
DMUDWP9 SN Mepindolol Bio Tsd; PH-851; Mepindolol, Pharmed/SB
DMUDWP9 CP Pharmed Dr Liedtke GmbH
DMUDWP9 DT Small molecular drug
DMUDWP9 PC 71698
DMUDWP9 MW 262.35
DMUDWP9 FM C15H22N2O2
DMUDWP9 IC InChI=1S/C15H22N2O2/c1-10(2)16-8-12(18)9-19-15-6-4-5-14-13(15)7-11(3)17-14/h4-7,10,12,16-18H,8-9H2,1-3H3
DMUDWP9 CS CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)C)O
DMUDWP9 IK NXWGWUVGUSFQJC-UHFFFAOYSA-N
DMUDWP9 IU 1-[(2-methyl-1H-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol
DMUDWP9 CA CAS 23694-81-7
DMUDWP9 CB CHEBI:135082
DMUDWP9 DE Angina pectoris
DMH2NMY ID DMH2NMY
DMH2NMY DN Mepivacaine
DMH2NMY HS Approved
DMH2NMY SN Carbocaine; Mepivacaina; Mepivacainum; Mepivicaine; Scandicain; Scandicaine; Scandicane; Arestocaine HCL; Carboplyin Dental; Isocaine HCL; Carbocaine (TN); Carboplyin Dental (TN); D-mepivacaine; DL-Mepivacaine; Mepivacaina [INN-Spanish]; Mepivacaine (INN); Mepivacaine [INN:BAN]; Mepivacainum [INN-Latin]; Polocaine (TN); Polocaine-Mpf; S-Ropivacaine Mesylate; D(-)-Mepivacaine; N-Methyl-2-pipecolic acid, 2,6-dimethylanilide; N-Methyl-2-pipecolic acid, 2,6-xylidide; N-Methylhexahydro-2-picolinic acid, 2,6-dimethylanilide; N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide; (+-)-1-Methyl-2',6'-pipecoloxylidide; 1-METHYL-2',6'-PIPECOLOXYLIDIDE
DMH2NMY CP Eastman Kodak Co
DMH2NMY TC Anesthetics
DMH2NMY DT Small molecular drug
DMH2NMY PC 4062
DMH2NMY MW 246.35
DMH2NMY FM C15H22N2O
DMH2NMY IC InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
DMH2NMY CS CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
DMH2NMY IK INWLQCZOYSRPNW-UHFFFAOYSA-N
DMH2NMY IU N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
DMH2NMY CA CAS 96-88-8
DMH2NMY CB CHEBI:6759
DMH2NMY DE Analgesia
DMW2GEJ ID DMW2GEJ
DMW2GEJ DN Mepolizumab
DMW2GEJ HS Approved
DMW2GEJ SN Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
DMW2GEJ CP MedImmune
DMW2GEJ DT Monoclonal antibody
DMW2GEJ DE Severe asthma; Asthma
DMTL9IP ID DMTL9IP
DMTL9IP DN Meprednisone
DMTL9IP HS Approved
DMTL9IP SN Betapar
DMTL9IP CP Schering Corp Sub Schering Plough Corp
DMTL9IP DT Small molecular drug
DMTL9IP PC 5284587
DMTL9IP MW 372.5
DMTL9IP FM C22H28O5
DMTL9IP IC InChI=1S/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1
DMTL9IP CS C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C
DMTL9IP IK PIDANAQULIKBQS-RNUIGHNZSA-N
DMTL9IP IU (8S,9S,10R,13S,14S,16S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
DMTL9IP CA CAS 1247-42-3
DMTL9IP CB CHEBI:135573
DMTL9IP DE Chronic obstructive pulmonary disease
DMHM93Y ID DMHM93Y
DMHM93Y DN Meprobamate
DMHM93Y HS Approved
DMHM93Y SN meprobamate; Meprospan; Meprobamat; Equanil; Miltown; Amepromat; Meprocompren; Meproban; Tranmep; Meprobam; Dapaz; Metractyl; Meprotabs; Meprosin; Meprodil; Mepiosine; Libiolan; Crestanil; Calmiren; Ayeramate; Andaksin; Anatimon; Anathylmon; Holbamate; Despasmol; Cirponyl; Biobamat; Neuramate; Metranquil; Meprocon; Mepantin; Lepetown; Ipsotian; Equilium; Equatrate; Carbaxin; Biobamate; Ansiatan; Anastress; Miltamato; Meprotil; Meprotan; Meprosan; Meproleaf; Meprindon; Mepranil; Mepavlon; Margonil; Harmonin; Dicandiol; Calmadin; Auxietil; Anxietil; Ansiowas; Amepromat; Amosene; Andaxin; Aneural; Aneurol; Aneusral; Aneuxal; Aneuxral; Ansietan; Ansil; Anural; Anzil; Apascil; Apasil; Appetrol; Arcoban; Arpon; Artolon; Ataraxine; Atraxin; Ayermate; Bamate; Brobamate; Calmax; Cirpon; Coprobate; Cypron; Cyrpon; Deprol; Diron; Diurnal; Diurnaldiverondormabrol; Diveron; Dormabrol; Ecuanil; Edenal; Enorden; Epicur; Epikur; Equinil; Equitar; Erina; Estasil; Gadexyl; Gagexyl; Hartol; Kessobamate; Klort; Larten; Lepenil; Letyl; Mendel; Mepamtin; Meposed; Mepriam; Meprin; Meprobamato; Meprobamatum; Meprodiol; Meprol; Meprosa; Meprotanum; Meproten; Meprovan; Meprovanmeprozine; Meprozine; Meptran; Meptranactylmilprem; Micrainin; Milpath; Milprem; Miltann; Miltaun; Miltuan; Miltwon; Misedant; Morbam; Multaun; Nephentine; Nervonus; Oasil; Optarket;Orlevol; Orolevol; Pancalma; Panediol; Pankalma; Pathibamate; Paxin; Pensive; Perequietil; Perequil; Perquietil; Pertranquil; Pimal; Placidon; Placitate; Prequil; Probamato; Probamyl; Probate; Procalmadiol; Procalmadol; Procalmidol; Procarbamide; Promate; Promato; Proquanil; Protran; Quaname; Quanane; Quanil; Quietidon; Quivet; Rastenil; Reostral; Restenil; Restenyl; Restinal; Restinil; Robamate;Sadanyl; Scolazil; Sedabamate; Sedanil; Sedanyl; Sedazil; Sedoquil; Sedoselecta; Selene; Seril; Setran; Shalvaton; Sowell; Spantran; Stensolo; Tamate; Tensol; Tensonal; Trancot; Trankvilan; Tranlisant; Tranquilan; Tranquilate; Tranquilax; Tranquiline; Tranquilsan; Tranquinol; Trelmar; Urbil; Urbilat; Vistabamate; Wardamate; Wyseals; Zirpon; Component of Appetrol; Component of Bamadex; Component of Equalysen; Component of Milpath; Component of Milprem; Component of Miltrate; Equanil suspension; Meprobamat [German]; Meprobamate and Aspirin Tablets; Meprobamato [Italian]; Meprobamic acid; Meprocon CMC; Solevione anastress; Bamd 400; Bamo 400; Canquil 400; Miltown 600; PMB 200; PMB 400; Apo-Meprobamate; Appetrol-Sr; Canquil-400; Component of PMB-400; Equanil (TN); Equazine-M; Fas-Cile; Fas-Cile 200; Kesso-Bamate; Mar-Bate; Meprin (VAN); Mepro-Aspirin; Mepro-analgesic; Meprobamato [INN-Spanish]; Meprobamatum [INN-Latin]; Meprospan (TN); Meprospan-200; Meprospan-400; Milprem-200; Milprem-400; Miltown (TN); My-trans; Neo-Tran; PMB-200; PMB-400; Pan-tranquil; Q-Gesic; SK-Bamate; Tranquiline (Intra); Vio-Bamate; Cap-O-Tran; Carbamic acid 2-methyl-2-propyltrimethylene ester; Meprobamate (JAN/USP/INN); Meprobamate [USAN:INN:BAN:JAN]; Carbamic acid, 2-methyl-2-propyltrimethylene ester; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate; {2-[(carbamoyloxy)methyl]-2-methylpentyl} carbamate; 1,3-Propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate; 1,3-Propanediol, 2-methyl-2-propyl-, dicarbamate; 2,2-Di(carbamoyloxymethyl)pentane; 2-Methyl-2-n-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propyl-1,3-propanediol dicarbamate; 2-Methyl-2-propylpropane-1,3-diol dicarbamate; 2-Methyl-2-propyltrimethylene carbamate; 2-Metil-2-n-propil-1,3-propanediol dicarbamato; 2-Metil-2-n-propil-1,3-propanediol dicarbamato [Spanish]; 2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate; 3P Bamate; KAI-1455
DMHM93Y CP Wyeth Pharmaceuticals
DMHM93Y TC Antianxiety Agents
DMHM93Y DT Small molecular drug
DMHM93Y PC 4064
DMHM93Y MW 218.25
DMHM93Y FM C9H18N2O4
DMHM93Y IC InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
DMHM93Y CS CCCC(C)(COC(=O)N)COC(=O)N
DMHM93Y IK NPPQSCRMBWNHMW-UHFFFAOYSA-N
DMHM93Y IU [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate
DMHM93Y CA CAS 57-53-4
DMHM93Y CB CHEBI:6761
DMHM93Y DE Malaria; Anxiety disorder; Ischemic reperfusion injury
DMPSB8F ID DMPSB8F
DMPSB8F DN MEPTAZINOL
DMPSB8F HS Approved
DMPSB8F SN MEPTAZINOL HYDROCHLORIDE; 59263-76-2; Meptazinol HCl; Meptazinol (hydrochloride); 3-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Meptazinol hydrochloride [USAN]; EINECS 261-683-0; WY-22811 hydrochloride; IL-22811 hydrochloride; WY 22811; IL 22811; 3-(3-ethyl-1-methylazepan-3-yl)phenol hydrochloride; m-(3-Ethyl-1-methyl-hexahydro-1H-azepin-3-yl)phenol hydrochloride; m-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Phenol, m-(3-ethyl-1-methyl-hexahydro-1H-azepin-3-yl)-, hydrochloride
DMPSB8F DT Small molecular drug
DMPSB8F PC 41049
DMPSB8F MW 233.35
DMPSB8F FM C15H23NO
DMPSB8F IC InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3
DMPSB8F CS CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O
DMPSB8F IK JLICHNCFTLFZJN-UHFFFAOYSA-N
DMPSB8F IU 3-(3-ethyl-1-methylazepan-3-yl)phenol
DMPSB8F CA CAS 54340-58-8
DMPSB8F CB CHEBI:91484
DMPSB8F DE Pain
DMB4SFH ID DMB4SFH
DMB4SFH DN Mepyramine
DMB4SFH HS Approved
DMB4SFH SN Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine
DMB4SFH TC Antiasthmatic Agents
DMB4SFH DT Small molecular drug
DMB4SFH PC 4992
DMB4SFH MW 285.4
DMB4SFH FM C17H23N3O
DMB4SFH IC InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3
DMB4SFH CS CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
DMB4SFH IK YECBIJXISLIIDS-UHFFFAOYSA-N
DMB4SFH IU N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DMB4SFH CA CAS 91-84-9
DMB4SFH CB CHEBI:6762
DMB4SFH DE Allergy
DM7F5OW ID DM7F5OW
DM7F5OW DN Mepyramine maleate
DM7F5OW HS Approved
DM7F5OW SN Pyrilamine maleate; PYRILAMINE MALEATE; 59-33-6; Anisopyradamine; Histosol; Minihist; Diaminide maleate; Paraminyl maleate; Renstamin; Histatex; Pyraninyl; Pymafed; Paramal; Histine; Antihist; Histan; Pyramal maleate; Stangen maleate; Thylogen maleate; Anthisan maleate; Statomin maleate; Pyra-Maleate; Pyrilamine maleate salt; Neoantergan maleate; Pyranisamine maleate; Pyranilamine maleate; Kriptin maleate; Neo-Antergan maleate; Pyra maleate; Prefrin A; Dorantamin maleate; 2786 RP maleate; Histavet-P (veterinary); Mepyramine hydrogen; Enrumay; Pyma; Component of Pyrdex; Mepiramine maleate; Mepyramine hydrogen maleinate; Mepyramine maleate salt; Midol Maximum Strength PMS; Pyranilamine m aleate; Pyrilamine maleate [USAN]; P 5514; Component of Endotussin-NN; Histavet-P; Pymafed (TN); Pyrilamine maleate (USP); PYRILAMINE MALEATE (SEE ALSO PYRILAMINE, CAS 91-84-9); N-Dimethylaminoethyl-N-p-methoxy-alpha-aminopyridine maleate; N-(dimethylaminoethyl)-N-(p-methoxyphenyl)-alpha-aminopyridine maleate; N-(Dimethylamino)ethyl-N-(p-methoxy)-alpha-aminopyridine maleate; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-, maleate (1:1); N,N-Dimethyl-N'-(4-methoxybenzyl)-N'-(2-pyridyl)ethylenediamine maleate; N-(p-me thoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; N-(p-methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine maleate; Pyridine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)-, maleate (1:1); N-(4-Methoxyphenyl)methyl-N inverted exclamation marka,Ninverted exclamation marka-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-alpha-pyridylethylenediamine maleate; N-(p-Methoxybenzyl)-N,N'-dimethyl-N-2-pyridyl-1,2-ethanediamine, maleic acid salt; N-(4-Methoxyphenyl)methyl-N',N'-dimethyl-N-(2-pyridinyl)-1,2-ethanediamine maleate salt; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine but-2-enedioate; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine (2Z)-but-2-enedioate; 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1); 1,2-Ethanediamine, N1-((4-methoxyphenyl)methyl)-N2,N2-dimethyl-N1-2-pyridinyl-, (2Z)-2-butenedioate (1:1); 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine bimaleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-((2-(Dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate (1:1); 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)pyridine maleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine bimaleate; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine maleate; Pyrilamine Maleate
DM7F5OW TC Antiasthmatic Agents
DM7F5OW DT Small molecular drug
DM7F5OW PC 5284451
DM7F5OW MW 401.5
DM7F5OW FM C21H27N3O5
DM7F5OW IC InChI=1S/C17H23N3O.C4H4O4/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15;5-3(6)1-2-4(7)8/h4-11H,12-14H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DM7F5OW CS CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2.C(=C\\C(=O)O)\\C(=O)O
DM7F5OW IK JXYWFNAQESKDNC-BTJKTKAUSA-N
DM7F5OW IU (Z)-but-2-enedioic acid;N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DM7F5OW CA CAS 59-33-6
DM7F5OW DE Headache; Allergy
DMAFBCY ID DMAFBCY
DMAFBCY DN Mequitazine
DMAFBCY HS Approved
DMAFBCY SN Butix; Instotal; Kitazemin; Mequitazina; Mequitazinum; Metaplexan; Mircol; Primalan; Quitadrill; Vigigan; Virginan; Zesulan; Italfarmaco brand of mequitazine; Mequitazina [Spanish]; Mequitazine hydrochloride; Pierre Fabre brand of mequitazine; LM 209; Kitazemin (TN); LM-209; Mequitazina [INN-Spanish]; Mequitazinum [INN-Latin]; Mequitazine (JP15/INN); Mequitazine [INN:BAN:DCF:JAN]; Mequitazine tartrate, (R-(R*,R*))-isomer; 10-(1-Azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine; 10-(1-azabicyclo(2.2.2)oct-8-ylmethyl)phenothiazine; 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine; 10-(3-Quinuclidinylmethyl)phenothiazine; 10H-Phenothiazine, 10-(1-azabicyclo(2.2.2)oct-3-ylmethyl)-(9CI); 3-Methylquinuclidinyl-10-phenothiazine
DMAFBCY CP Pierre Fabre SA
DMAFBCY TC Antihistamines
DMAFBCY DT Small molecular drug
DMAFBCY PC 4066
DMAFBCY MW 322.5
DMAFBCY FM C20H22N2S
DMAFBCY IC InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
DMAFBCY CS C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
DMAFBCY IK HOKDBMAJZXIPGC-UHFFFAOYSA-N
DMAFBCY IU 10-(1-azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine
DMAFBCY CA CAS 29216-28-2
DMAFBCY CB CHEBI:31821
DMAFBCY DE Allergic rhinitis; Respiratory disease
DMTM2IK ID DMTM2IK
DMTM2IK DN Mercaptopurine
DMTM2IK HS Approved
DMTM2IK SN 6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)
DMTM2IK CP Novopharm
DMTM2IK TC Anticancer Agents
DMTM2IK DT Small molecular drug
DMTM2IK PC 667490
DMTM2IK MW 152.18
DMTM2IK FM C5H4N4S
DMTM2IK IC InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMTM2IK CS C1=NC2=C(N1)C(=S)N=CN2
DMTM2IK IK GLVAUDGFNGKCSF-UHFFFAOYSA-N
DMTM2IK IU 3,7-dihydropurine-6-thione
DMTM2IK CA CAS 50-44-2
DMTM2IK CB CHEBI:2208
DMTM2IK DE Acute lymphoblastic leukaemia; Crohn disease
DM0HS92 ID DM0HS92
DM0HS92 DN Merimepodib
DM0HS92 HS Approved
DM0HS92 SN Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
DM0HS92 CP GSK
DM0HS92 DT Small molecular drug
DM0HS92 PC 153241
DM0HS92 MW 452.5
DM0HS92 FM C23H24N4O6
DM0HS92 IC InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
DM0HS92 CS COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4
DM0HS92 IK JBPUGFODGPKTDW-SFHVURJKSA-N
DM0HS92 IU [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
DM0HS92 CA CAS 198821-22-6
DM0HS92 DE Hepatitis C virus infection; Breast cancer; Hepatitis virus infection; Head and neck cancer; Gastric adenocarcinoma
DM62UHC ID DM62UHC
DM62UHC DN Meropenem
DM62UHC HS Approved
DM62UHC SN MEPM; MERONEM; Meropen; Merrem; Meropenem anhydrous; Mepem (TN); Meronem (TN); Meropen (TN); Meropenem (INN); Merrem (TN); Neopenem (TN); SM-7338; Meronem; Merrem I.V. (TN); (1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate; (2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid; (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid; (6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
DM62UHC CP AstraZeneca
DM62UHC TC Antibiotics
DM62UHC DT Small molecular drug
DM62UHC PC 441130
DM62UHC MW 383.5
DM62UHC FM C17H25N3O5S
DM62UHC IC InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
DM62UHC CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
DM62UHC IK DMJNNHOOLUXYBV-PQTSNVLCSA-N
DM62UHC IU (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM62UHC CA CAS 96036-03-2
DM62UHC CB CHEBI:43968
DM62UHC DE Bacterial infection
DMOVAIX ID DMOVAIX
DMOVAIX DN Meropenem + vaborbactam
DMOVAIX HS Approved
DMOVAIX SN Vabomere; Meropenem / vaborbactam; Meropenem and vaborbactam; Meropenem mixture with vaborbactam; Carbavance
DMOVAIX CP The Medicines Company/Rempex Pharmaceuticals
DMOVAIX PC 86298703
DMOVAIX MW 680.6
DMOVAIX FM C29H41BN4O10S2
DMOVAIX IC InChI=1S/C17H25N3O5S.C12H16BNO5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t7-,8-,9+,10+,11-,12-;8-,10-/m10/s1
DMOVAIX CS B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O.C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
DMOVAIX IK SDJYWZHQLNEXKV-SSHSFQATSA-N
DMOVAIX IU (4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
DMOVAIX CA CAS 2031124-72-6
DMOVAIX DE Urinary tract infection; Intra-abdominal infection
DMOL5IU ID DMOL5IU
DMOL5IU DN Mesalazine
DMOL5IU HS Approved
DMOL5IU SN Apriso; Asacol; Asacolitin; Asacolon; Asalit; Ascolitin; Canasa; Claversal; Fisalamine; Fivasa; Iialda; Ipocol; Lialda; Lixacol; Mesacol; Mesalamine; Mesalazina; Mesalazinum; Mesasal; Mesavance; Mesavancol; Mezavant; Pentacol; Pentasa; Rowasa; Salofalk; Salozinal; SfRowasa; Allphar Brand of Mesalamine; Antigen Brand of Mesalamine; Asacol HD; Axcan Brand of Mesalamine; Byk Brand of Mesalamine; Celltech Brand of Mesalamine; Falk Brand of Mesalamine; Farmasa Brand of Mesalamine; Ferring Brand of Mesalamine; GlaxoSmithKline Brand of Mesalamine; Henning Berlin Brand of Mesalamine; M Aminosalicylic Acid; Merckle Brand of Mesalamine; Mesalamine Hydrochloride; Mesalamine Monosodium Salt; Mesalamine [USAN]; Mesalazina[Spanish]; Mesalazine MMX; Mesalazinum [Latin]; Meta Aminosalicylic Acid; Mezavant XL; Minosalicylic acid; Norgine Brand of Mesalamine; Novopharm Brand of Mesalamine; Provalis Brand of Mesalamine; Sanofi Synthelabo Brand of Mesalamine; Schering Plough Brand of Mesalamine; SmithKline Brand of Mesalamine; Solvay Brand of Mesalamine; Yamanouchi Brand of Mesalamine; Novo 5 ASA; Novo5 ASA; AJG-501; Apriso (TN); Asacol (TN); Canasa (TN); Hydrochloride, Mesalamine; Iialda (TN); Ipocal (TN); Lialda (TN); M-A; M-Aminosalicylic acid; MAX-002; MD-0901; Masacol (TN); Mesalamine (USP); Meta-AminosalicylicAcid; Monosodium Salt, Mesalamine; Novo-5 ASA; P-Aminosalicylsaeure; P-Aminosalicylsaeure [German]; Pentasa (TN); Procter & Gamble Brand of Mesalamine; Rowasa (TN); SPD-476; SPD-480; Salofalk (TN); Salofalk Granu-Stix; Schering-Plough Brand of Mesalamine; Z-206; Mesalazine (JAN/INN); Salicylic acid, 5-amino-(8CI); 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; 5 Aminosalicylate; 5 Aminosalicylic Acid; 5-AS; 5-ASA; 5-Amino-2-hydroxybenzoic acid; 5-Aminosalicylate; 5-Aminosalicylic acid; 5-amino-2-hydroxy-benzoic acid; 5-aminosalicylic acid, Mesalazine, Asacol, Pentasa, Canasa, Mesalamine
DMOL5IU TC Antiinflammatory Agents
DMOL5IU DT Small molecular drug
DMOL5IU PC 4075
DMOL5IU MW 153.14
DMOL5IU FM C7H7NO3
DMOL5IU IC InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
DMOL5IU CS C1=CC(=C(C=C1N)C(=O)O)O
DMOL5IU IK KBOPZPXVLCULAV-UHFFFAOYSA-N
DMOL5IU IU 5-amino-2-hydroxybenzoic acid
DMOL5IU CA CAS 89-57-6
DMOL5IU CB CHEBI:6775
DMOL5IU DE Ulcerative colitis
DM2ZGAN ID DM2ZGAN
DM2ZGAN DN Mesoridazine
DM2ZGAN HS Approved
DM2ZGAN SN Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
DM2ZGAN CP Norvatis Phamaceuticals Corporation
DM2ZGAN TC Antipsychotic Agents
DM2ZGAN DT Small molecular drug
DM2ZGAN PC 4078
DM2ZGAN MW 386.6
DM2ZGAN FM C21H26N2OS2
DM2ZGAN IC InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
DM2ZGAN CS CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C
DM2ZGAN IK SLVMESMUVMCQIY-UHFFFAOYSA-N
DM2ZGAN IU 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
DM2ZGAN CA CAS 5588-33-0
DM2ZGAN CB CHEBI:6780
DM2ZGAN DE Schizophrenia
DMG3F94 ID DMG3F94
DMG3F94 DN Mestranol
DMG3F94 HS Approved
DMG3F94 SN Devocin; Menophase; Mestranolo; Mestranolum; Norquen; Ovastol; Component of Norinyl; Component of Norquen; Component of Ovulen; Ethynylestradiol methyl ether; Mestranol [Steroidal oestrogens]; Mestranolo [DCIT]; EE3ME; Ethinyl Estradiol 3 Methyl Ether; SC 4725; Component of Ortho-Novum; Delta-MVE; EE(sub3)ME; EthinylEstradiol 3-Methyl Ether; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynylestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; Inostral (steroid); Mestranolum [INN-Latin]; Mestranol (JP15/USP/INN); Mestranol [USAN:INN:BAN:JAN]; Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 17-Ethynylestradiol 3-methyl ether; 17-Ethynyloestradiol 3-methyl ether; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 17-alpha-Ethynyloestradiol methyl ether; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; 17alpha-Ethinyl estradiol 3-methyl ether; 17alpha-Ethinyl oestradiol 3-methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 17alpha-Ethynylestradiol 3-methyl ether; 17alpha-Ethynylestradiol methyl ether; 17alpha-Ethynyloestradiol 3-methyl ether; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynylestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; 3-Methoxy-17-ethynyloestradiol-17-beta; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 3-Methoxy-17alpha-ethynylestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; 3-Methoxyethynylestradiol; 3-Methoxyethynyloestradiol; 3-Methylethynylestradiol; 3-Methylethynyloestradiol; 3-O-Methylethynylestradiol
DMG3F94 TC Estrogens
DMG3F94 DT Small molecular drug
DMG3F94 PC 6291
DMG3F94 MW 310.4
DMG3F94 FM C21H26O2
DMG3F94 IC InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1
DMG3F94 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC
DMG3F94 IK IMSSROKUHAOUJS-MJCUULBUSA-N
DMG3F94 IU (8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
DMG3F94 CA CAS 72-33-3
DMG3F94 CB CHEBI:6784
DMG3F94 DE Contraception
DMM4QOJ ID DMM4QOJ
DMM4QOJ DN Metadoxine
DMM4QOJ HS Approved
DMM4QOJ SN MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra
DMM4QOJ CP Alcobra
DMM4QOJ DT Small molecular drug
DMM4QOJ PC 115198
DMM4QOJ MW 298.29
DMM4QOJ FM C13H18N2O6
DMM4QOJ IC InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
DMM4QOJ CS CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)N[C@@H]1C(=O)O
DMM4QOJ IK RYKKQQUKJJGFMN-HVDRVSQOSA-N
DMM4QOJ IU 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2S)-5-oxopyrrolidine-2-carboxylic acid
DMM4QOJ CA CAS 74536-44-0
DMM4QOJ DE Multiple myeloma
DMTQS9A ID DMTQS9A
DMTQS9A DN Metaproterenol sulfate
DMTQS9A HS Approved
DMTQS9A SN Metaproterenol; metaproterenol; ORCIPRENALINE; Alupent; 586-06-1; Orciprenalinum; Metaproterenol sulfate; Orciprenalina; Orciprenalinum [INN-Latin]; Orciprenalina [INN-Spanish]; Metaproterenol polistirex; Metaprel; Alotec; Prometa; Orciprenaline [INN]; CCRIS 9017; Orciprenaline (INN); EINECS 209-569-1; CHEMBL776; BRN 2807247; (RS)-1-(3,5-Dihydroxyphenyl)-2-isopropylaminoethanol; CHEBI:6792; 3,5-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol; Alupent; Orciprenaline
DMTQS9A CP Boehringer Ingelheim Pharmaceuticals Inc
DMTQS9A DT Small molecular drug
DMTQS9A PC 441333
DMTQS9A MW 520.6
DMTQS9A FM C22H36N2O10S
DMTQS9A IC InChI=1S/2C11H17NO3.H2O4S/c2*1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8;1-5(2,3)4/h2*3-5,7,11-15H,6H2,1-2H3;(H2,1,2,3,4)
DMTQS9A CS CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O
DMTQS9A IK MKFFGUZYVNDHIH-UHFFFAOYSA-N
DMTQS9A IU 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;sulfuric acid
DMTQS9A CA CAS 5874-97-5
DMTQS9A DE Asthma
DMWIX23 ID DMWIX23
DMWIX23 DN Metaraminol
DMWIX23 HS Approved
DMWIX23 SN Araminol; Hydroxynorephedrine; Isophenylephrine; Metaradrin; Metaradrine; Metaraminolum; Pressonex; Pressorol; Icoral B; Metaraminolum [Latin]; Aramine (TN); L-Metaraminol; M-Hydroxy norephedrine; M-Hydroxynorephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; Meta-Hydroxynorephedrine; Metaraminol (INN); Metaraminol [INN:BAN]; Metaraminolum [INN-Latin]; Alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol; Alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; Alpha-(m-Hydroxyphenyl)-beta-aminopropanol; M-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol; Benzenemethanol, alpha-(1-aminoethyl)-3-hydroxy-, (R-(R*,S*))-(9CI); (-)-Erythro-metaraminol; 1-(m-Hydroxyphenyl)-2-amino-1-propanol; 1-Metaraminol; 1-alpha-(1-Aminoethyl)-m-hydroxybenzyl alcohol; 2-Amino-1-(m-hydroxyphenyl)-1-propanol; 3-Hydroxyphenylisopropanolamine; 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
DMWIX23 CP Merck Sharp & Dohme Pharmaceuticals
DMWIX23 TC Antihypertensive Agents
DMWIX23 DT Small molecular drug
DMWIX23 PC 5906
DMWIX23 MW 167.2
DMWIX23 FM C9H13NO2
DMWIX23 IC InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1
DMWIX23 CS C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N
DMWIX23 IK WXFIGDLSSYIKKV-RCOVLWMOSA-N
DMWIX23 IU 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
DMWIX23 CA CAS 54-49-9
DMWIX23 CB CHEBI:6794
DMWIX23 DE Hypotension
DMJFP6G ID DMJFP6G
DMJFP6G DN Metergolin
DMJFP6G HS Approved
DMJFP6G SN Metergoline; metergoline; Liserdol; 17692-51-2; Methergoline; Metergolina; Metergolinum; Metergolina [DCIT]; Metergolinum [Latin]; Metergolina [Spanish]; Substance 355/255; Metergoline [INN:BAN]; Metergolinum [INN-Latin]; 1-Methyl-N-carbobenzyloxydihydro-D-lysergamin; FI-6337; MLS000069437; UNII-1501393LY5; C25H29N3O2; AHR 3009; 1-Methyl-8-beta-carbobenzyloxyaminomethyl-10-alpha-ergoline; EINECS 241-686-3; 1,6-Dimethyl-8-beta-carbobenzyloxaminomethyl-10-alpha-ergoline; FI 6337; Liserdol (TN)
DMJFP6G DT Small molecular drug
DMJFP6G PC 28693
DMJFP6G MW 403.5
DMJFP6G FM C25H29N3O2
DMJFP6G IC InChI=1S/C25H29N3O2/c1-27-14-18(13-26-25(29)30-16-17-7-4-3-5-8-17)11-21-20-9-6-10-22-24(20)19(12-23(21)27)15-28(22)2/h3-10,15,18,21,23H,11-14,16H2,1-2H3,(H,26,29)/t18-,21+,23+/m0/s1
DMJFP6G CS CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5
DMJFP6G IK WZHJKEUHNJHDLS-QTGUNEKASA-N
DMJFP6G IU benzyl N-[[(6aR,9S,10aR)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl]methyl]carbamate
DMJFP6G CA CAS 17692-51-2
DMJFP6G CB CHEBI:64216
DMJFP6G DE Hyperprolactinaemia
DM89QE1 ID DM89QE1
DM89QE1 DN Metformin
DM89QE1 HS Approved
DM89QE1 SN 657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin
DM89QE1 CP Bristol-Myers Squibb
DM89QE1 TC Hypoglycemic Agents
DM89QE1 DT Small molecular drug
DM89QE1 PC 4091
DM89QE1 MW 129.16
DM89QE1 FM C4H11N5
DM89QE1 IC InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
DM89QE1 CS CN(C)C(=N)N=C(N)N
DM89QE1 IK XZWYZXLIPXDOLR-UHFFFAOYSA-N
DM89QE1 IU 3-(diaminomethylidene)-1,1-dimethylguanidine
DM89QE1 CA CAS 657-24-9
DM89QE1 CB CHEBI:6801
DM89QE1 DE Type-2 diabetes
DMTPAM3 ID DMTPAM3
DMTPAM3 DN Metformin arginine-hemisuccinimide
DMTPAM3 HS Approved
DMTPAM3 SN Diap-2; Metformin arginine-hemisuccinate-hemisuccinamide; Metformin arginine-hemisuccinimide (type 2 diabetes); Diap-2 (type 2 diabetes), Arteria; Metformin arginine-hemisuccinimide (type 2 diabetes), Arteria
DMTPAM3 CP Boehringer Ingelheim Pharmaceuticals; Merck; Depomed; Janssen Research & Development; AstraZeneca; Bristol-Myers Squibb
DMTPAM3 DE Type-2 diabetes
DMGS4QH ID DMGS4QH
DMGS4QH DN Methacholine Chloride
DMGS4QH HS Approved
DMGS4QH SN Methacholine; methacholine; Acetylmethylcholine; Methacholin; Mecholine; Mecholin; Provocholine; Methacholinum; beta-Methylacetylcholine; 55-92-5; Choline, acetyl-beta-methyl-; Acetyl-beta-methylcholine; BRN 1769932; CHEBI:6804; 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-; AMMONIUM, (2-HYDROXYPROPYL)TRIMETHYL-, ACETATE (ESTER); 2-acetyloxypropyl(trimethyl)azanium; C8H18NO2; AC1Q5XYD; AC1L1COQ; Prestwick2_000759; Prestwick0_000759; Prestwick3_000759; Prestwick1_000759; CHEMBL978; 2-(acetyloxy)-n,n,n-trimethylpropan-1-aminium; METHACHOLINE
DMGS4QH CP Methapharm Inc
DMGS4QH DT Small molecular drug
DMGS4QH PC 6114
DMGS4QH MW 195.69
DMGS4QH FM C8H18ClNO2
DMGS4QH IC InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1
DMGS4QH CS CC(C[N+](C)(C)C)OC(=O)C.[Cl-]
DMGS4QH IK JHPHVAVFUYTVCL-UHFFFAOYSA-M
DMGS4QH IU 2-acetyloxypropyl(trimethyl)azanium;chloride
DMGS4QH CA CAS 62-51-1
DMGS4QH CB CHEBI:50142
DMGS4QH DE bronchial hyperreactivity; Asthma
DMAY96V ID DMAY96V
DMAY96V DN Methacycline
DMAY96V HS Approved
DMAY96V SN Bialatan; Metaciclina; Metacycline; Metacyclinum; Methacyclin; Methacyclinum; Methylenecycline; Methyleneoxytetracycline; Rondomycin; Methacycline amphoteric; Methacycline base; GS 2876; GS-2876; Metaciclina [INN-Spanish]; Metacycline (INN); Metacyclinum [INN-Latin]; Methacycline (USAN); Methacycline [USAN:BAN]; Tri-methacycline; (2Z,4S,4aR,5S,5aR,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methylidene-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxo-2-naphthacenecarboxamide; 6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline; 6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline; 6-Methylene-5-hydroxytetracycline; 6-Methylene-5-oxytetracycline; 6-Methyleneoxytetracycline
DMAY96V TC Antibiotics
DMAY96V DT Small molecular drug
DMAY96V PC 54675785
DMAY96V MW 442.4
DMAY96V FM C22H22N2O8
DMAY96V IC InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25-27,30,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1
DMAY96V CS CN(C)[C@H]1[C@@H]2[C@H]([C@@H]3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O
DMAY96V IK XIYOPDCBBDCGOE-IWVLMIASSA-N
DMAY96V IU (4S,4aR,5S,5aR,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMAY96V CA CAS 914-00-1
DMAY96V CB CHEBI:6805
DMAY96V DE Bacterial infection
DMTW6IU ID DMTW6IU
DMTW6IU DN Methadone
DMTW6IU HS Approved
DMTW6IU SN Adanon; Algovetin; Althose; Amidon; Amidone; Biscuits; Dextromethadone; Diaminon; Dollies; Dolly; Dolophin; Dolophine; Heptadone; Heptanon; Ketalgin; Levometadona; Levomethadonum; Levothyl; Metadona; Metadone; Metasedin; Methadon; Methadona; Methadonum; Methaquaione; Phenadone; Polamidone; Polamivet; Westadone; Dolophine HCL; Levomethadone [INN]; Metadona [Spanish]; Metadone [DCIT]; Methadona [Spanish]; Methadone HCL Intensol; Methadone M; Methadonum [Latin]; Racemic methadone; A 4624; AN 148; Hoechst 10820; K 174; Amidone (TN); D-Methadone; Dl-Methadone; Dolophine (TN); Heptadon (TN); Heptanon (pharmaceutical); L-Methadone; L-Polamidon; L-Polamivet; Levometadona [INN-Spanish]; Levomethadonum [INN-Latin]; Metadona [INN-Spanish]; Methadone (BAN); Methadone [INN:BAN]; Methadonum [INN-Latin]; Methadose (TN); Physeptone (TN); Sedo-Rapide; Symoron (TN); Dolophine (*Hydrochloride*); Fenadone (*Hydrochloride*); Heptadone (*Hydrochloride*); Heptanon (*Hydrochloride*); Hoescht 10820 (*Hydrochloride*); Phenadone (*Hydrochloride*); AN-148 (*Hydrochloride*); L-(+)-Methadone; S-(+)-Methadone; D-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (+)-Methadone; (+-)-Methadone; (+/-)-Methadone; (+/-)-Tussal; (-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (-)-Methadone; (6R)-Methadone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; (R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; 3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)-(9CI); 6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture; 6-(dimethylamino)-4,4-diphenylheptan-3-one; 6-Dimethylamino-4,4-diphenyl-3-heptanone; 6-dimethylamino-4,4-di(phenyl)heptan-3-one; 6S-Methadone
DMTW6IU CP Eli Lilly
DMTW6IU TC Analgesics
DMTW6IU DT Small molecular drug
DMTW6IU PC 4095
DMTW6IU MW 309.4
DMTW6IU FM C21H27NO
DMTW6IU IC InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
DMTW6IU CS CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
DMTW6IU IK USSIQXCVUWKGNF-UHFFFAOYSA-N
DMTW6IU IU 6-(dimethylamino)-4,4-diphenylheptan-3-one
DMTW6IU CA CAS 76-99-3
DMTW6IU CB CHEBI:6807
DMTW6IU DE Dry cough
DMIRMVB ID DMIRMVB
DMIRMVB DN Methadyl Acetate
DMIRMVB HS Approved
DMIRMVB SN ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate
DMIRMVB TC Narcotics
DMIRMVB DT Small molecular drug
DMIRMVB PC 10517
DMIRMVB MW 353.5
DMIRMVB FM C23H31NO2
DMIRMVB IC InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3
DMIRMVB CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
DMIRMVB IK XBMIVRRWGCYBTQ-UHFFFAOYSA-N
DMIRMVB IU [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
DMIRMVB CA CAS 509-74-0
DMIRMVB CB CHEBI:135491
DMIRMVB DE Opioid dependence
DMPM4SK ID DMPM4SK
DMPM4SK DN Methamphetamine
DMPM4SK HS Approved
DMPM4SK SN METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; d-N-Methylamphetamine; Metamphetamine; L-Methamphetamine; d-Methylamphetamine; Methylamphetamine; d-Phenylisopropylmethylamine; N-Methylamphetamine; (S)-Methamphetamine; Norodin; (+)-Methylamphetamine; d-(S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Metamfetaminum; Desyphed; (+)-N-Methylamphetamine; (S)-Methylamphetamine; (+)-(S)-Deoxyephedrine; Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylaminopropane; (S)-(+)-Deoxyephedrine; Crank; Desohyephedrine; Metamfetamina; Meth; Methamphetaminum; Speed; Stimulex; Crank [Street Name]; Crystal Meth; Crystal Meth [Street Name]; Desyphed hydrochloride; ICE [Street Name]; Metamfetamine [INN];Metamfetaminum [Latin]; Metanfetamina [Spanish]; Methamphetaminum [JP]; Speed [Street Name]; D-Deoxyephedrine; D-Desoxyephedrine; D-Methamphetamine; D-Methylamphetamine; D-Phenylisopropylmethylamine;Desoxyn (TN); Metamfetamina [INN-Spanish]; Metamfetamine (INN); Metamfetamine-m; Metamfetaminum [INN-Latin]; Metanfetamina [INN-Spanish]; Meth (Street Name); Methamphetaminum [INN-Latin]; D-N-Methylamphetamine; D-(S)-Methamphetamine; D-N,alpha-dimethylphenethylamine; Methamphetamine, its salts, isomers, and salts of its isomers; N-Methyl-beta-phenylisopropylamin; N-Methyl-beta-phenylisopropylamin [German]; N-Methyl-beta-phenylisopropylamine; D-1-Phenyl-2-methylaminopropan; D-1-Phenyl-2-methylaminopropan [German]; S-(+)-Methamphetamine; D-N,alpha-Dimethylphenethylamine; N-Methyl-1-phenyl-2-propanamine; Benzeneethanamine, N,alpha-dimethyl-, (S)-(9CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-(9CI); Phenethylamine, N,alpha-dimethyl-, (S)-(+)-(8CI); (+)-(S)-N-alpha-Dimethylphenethylamine; (+)-2-(N-Methylamino)-1-phenylpropane; (+)-N,alpha-Dimethyl-beta-phenylethylamine; (+)-N,alpha-Dimethylphenethylamine; (+)-methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (S)-(+)-Methamphetamine; (S)-(+)-N,alpha,dimethylphenethylamine; (S)-N,alpha-Dimethylbenzeneethanamine; (S)-N,alpha-Dimethylbenzeneethanoamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; 1-Phenyl-2-methylamino-propan; 1-Phenyl-2-methylamino-propan [German]; 2S-(+)-Methamphetamine; Methamfetamine
DMPM4SK CP Ovation Pharma
DMPM4SK TC Central Nervous System Stimulants
DMPM4SK DT Small molecular drug
DMPM4SK PC 10836
DMPM4SK MW 149.23
DMPM4SK FM C10H15N
DMPM4SK IC InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1
DMPM4SK CS C[C@@H](CC1=CC=CC=C1)NC
DMPM4SK IK MYWUZJCMWCOHBA-VIFPVBQESA-N
DMPM4SK IU (2S)-N-methyl-1-phenylpropan-2-amine
DMPM4SK CA CAS 537-46-2
DMPM4SK CB CHEBI:6809
DMPM4SK DE Pain; Attention deficit hyperactivity disorder
DMO2JBC ID DMO2JBC
DMO2JBC DN Methamphetamine hydrochloride
DMO2JBC HS Approved
DMO2JBC SN Methamphetamine HCL; Methamphetamine hydrochloride; Methamphetaminium chloride; Methylamphetamine hydrochloride; Methylisomyn; Norodin hydrochloride; Adipex; Chestox; Deofed; Des-O-E; Desepin; Desodex; Desoxo-5; Desoxyfed; Desoxyne; Destim; Dexoval; Dexstim; Dextim; Dosoxy; Doxyfed; Drinalfa; Efroxine; Eufodrinal; Gerovit; Hyphet; Isophen; Isophen (VAN); Obedrin-LA; Pervitin; Philopon; Soxysympamine; Syndrox; Tonedron; d-Methaphetamine hydrochloride; (+)-Methamphetamine hydrochloride; 51-57-0; S-(+)-Methamphetamine hydrochloride
DMO2JBC PC 66124
DMO2JBC MW 185.69
DMO2JBC FM C10H16ClN
DMO2JBC IC TWXDDNPPQUTEOV-FVGYRXGTSA-N
DMO2JBC CS CC(CC1=CC=CC=C1)NC.Cl
DMO2JBC IK 1S/C10H15N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h3-7,9,11H,8H2,1-2H3;1H/t9-;/m0./s1
DMO2JBC IU (2S)-N-methyl-1-phenylpropan-2-amine;hydrochloride
DMO2JBC CA CAS 51-57-0
DMO2JBC CB CHEBI:35340
DMO2JBC DE Attention deficit hyperactivity disorder
DM8X4A1 ID DM8X4A1
DM8X4A1 DN Methantheline
DM8X4A1 HS Approved
DM8X4A1 SN Mantheline; Methanide; Methanthelinium; Methanthelinum; Banthine bromide; Gastrin I; Methanthine bromide; Gastrin-1 Human; Diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; N,N-Diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium
DM8X4A1 CP Shire Development Inc
DM8X4A1 TC Anticholinergic Agents
DM8X4A1 DT Small molecular drug
DM8X4A1 PC 4097
DM8X4A1 MW 340.4
DM8X4A1 FM C21H26NO3+
DM8X4A1 IC InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1
DM8X4A1 CS CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13
DM8X4A1 IK GZHFODJQISUKAY-UHFFFAOYSA-N
DM8X4A1 IU diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
DM8X4A1 CA CAS 5818-17-7
DM8X4A1 CB CHEBI:6817
DM8X4A1 DE Gastritis; Pancreatitis; Irritable bowel syndrome; Peptic ulcer
DM5A38V ID DM5A38V
DM5A38V DN Metharbital
DM5A38V HS Approved
DM5A38V SN Endiemal; Endiemalum; Gemonal; Gemonil; Gemonit; Metabarbital; Metarbital; Metarbitale; Methabarbital; Methabarbitone; Metharbitalum; Metharbitone; Metharbutal; Methylbarbital; Metarbitale [DCIT]; AN 23; Sch 412; Gemonil (TN); Metarbital [INN-Spanish]; Metharbital [INN:JAN]; Metharbitalum [INN-Latin]; N-Methylbarbital; Metharbital (JAN/INN); 1-Methylbarbital; 5,5-Diethyl-1-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5,5-Diethyl-1-methylbarbituric acid; 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione; 5,5-diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione
DM5A38V CP Abbott Laboratories
DM5A38V TC Anticonvulsants
DM5A38V DT Small molecular drug
DM5A38V PC 4099
DM5A38V MW 198.22
DM5A38V FM C9H14N2O3
DM5A38V IC InChI=1S/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)
DM5A38V CS CCC1(C(=O)NC(=O)N(C1=O)C)CC
DM5A38V IK FWJKNZONDWOGMI-UHFFFAOYSA-N
DM5A38V IU 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione
DM5A38V CA CAS 50-11-3
DM5A38V CB CHEBI:31827
DM5A38V DE Epilepsy
DM7J2TA ID DM7J2TA
DM7J2TA DN Methazolamide
DM7J2TA HS Approved
DM7J2TA SN Methazolamide (oral, sustained release)
DM7J2TA CP Effcon Laboratories Inc
DM7J2TA DT Small molecular drug
DM7J2TA PC 4100
DM7J2TA MW 236.3
DM7J2TA FM C5H8N4O3S2
DM7J2TA IC InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)
DM7J2TA CS CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C
DM7J2TA IK FLOSMHQXBMRNHR-UHFFFAOYSA-N
DM7J2TA IU N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
DM7J2TA CA CAS 554-57-4
DM7J2TA CB CHEBI:6822
DM7J2TA DE Glaucoma/ocular hypertension
DMAUHQX ID DMAUHQX
DMAUHQX DN Methdilazine
DMAUHQX HS Approved
DMAUHQX SN Disyncram; Methdilazinum; Methodilazine; Metodilazina; Tacaryl; Tacazyl; Tacryl; Methilazine hydrochloride; Methdilazine (INN); Methdilazinum [INN-Latin]; Metodilazina [INN-Spanish]; Tacaryl (TN); Methdilazine [USAN:INN:BAN]; 10-((1-Methyl-3-pyrrolidinyl)methyl)phenothiazine; 10-((1-methyl-3-pyrrolidinyl)methyl)-10H-phenothiazine; 10-[(1-Methylpyrrolidin-3-yl)methyl]phenothiazine; 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine
DMAUHQX TC Antihistamines
DMAUHQX DT Small molecular drug
DMAUHQX PC 14677
DMAUHQX MW 296.4
DMAUHQX FM C18H20N2S
DMAUHQX IC InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3
DMAUHQX CS CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
DMAUHQX IK HTMIBDQKFHUPSX-UHFFFAOYSA-N
DMAUHQX IU 10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine
DMAUHQX CA CAS 1982-37-2
DMAUHQX CB CHEBI:6823
DMAUHQX DE Allergic rhinitis
DM25FL8 ID DM25FL8
DM25FL8 DN Methimazole
DM25FL8 HS Approved
DM25FL8 SN methimazole; 60-56-0; thiamazole; Tapazole; 2-Mercapto-1-methylimidazole; Mercazolyl; 1-Methylimidazole-2-thiol; Thymidazole; Mercazole; Methimazol; Thymidazol; Thiamazol; Metazolo; Thycapzol; Metothyrine; Metothyrin; Merkazolil; Mercaptazole; Strumazol; Favistan; Basolan; Thycapsol; Metotirin; Danantizol; Thacapzol; Merkastan; Frentirox; Metizol; Tiamazol; Mercasolyl; 1-Methyl-1H-imidazole-2-thiol; Methylmercaptoimidazole; 1-Methyl-2-mercaptoimidazole; Methiamazole; Usaf el-30; Methimazolum; Mercazolylum; Tapuzole; Metimazol; Thimazole; Basolan; MMZ; Mercazol; Methamazole; Methizol; Methymazol; Metisol; Strumazole; Thiamazole; Thiamazolum; Thimazol; Thyrozol; Tiamazolo; Tirodril; EliLilly Brand of Methimazole; Estedi Brand of Methimazole; Henning Berlin Brand of Methimazole; Hexal Brand of Methimazole; Jones Brand of Methimazole; Merck Brand of Methimazole; Nourypharma Brand of Methimazole; Philopharm Brand of Methimazole; Sanofi Synthelabo Brand of Methimazole; Temmler Brand of Methimazole; Thiamazol Henning; Thiamazol Hexal; Tiamazolo [DCIT]; M0868; Henning, Thiamazol; Hexal, Thiamazol; Methimazole (USP); Methimazole [USAN:BAN]; Tapazole (TN); Thiamazol [INN-French]; Thiamazolum [INN-Latin]; Tiamazol [INN-Spanish]; Mestinon, Regonol, Pyridostigmine Bromide;Thiamazole (JP15/INN); N-Methyl-2-mercaptoimidazole; 1 Methyl 2 mercaptoimidazole; 1,3-Dihydro-1-Methyl-2H-Imidazol-2-Thione; 1,3-Dihydro-1-methyl-2H-imidazole-2-thione; 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE; 1-Methyl-1,3-dihydroimidazole-2-thione; 1-Methyl-2-Imidazolethione; 1-Methyl-2-imidazolethiol; 1-Methyl-imidazole-2-thiol; 1-Methylimidazole-2(3H)-thione; 1-Metylo 2 merkaptoimidazolem; 1-Metylo 2 merkaptoimidazolem [Polish]; 2-Mercaptomethylimidazole; 3-methyl-1H-imidazole-2-thione
DM25FL8 TC Antithyroid Agents
DM25FL8 DT Small molecular drug
DM25FL8 PC 1349907
DM25FL8 MW 114.17
DM25FL8 FM C4H6N2S
DM25FL8 IC InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
DM25FL8 CS CN1C=CNC1=S
DM25FL8 IK PMRYVIKBURPHAH-UHFFFAOYSA-N
DM25FL8 IU 3-methyl-1H-imidazole-2-thione
DM25FL8 CA CAS 60-56-0
DM25FL8 CB CHEBI:50673
DM25FL8 DE Hyperthyroidism
DM3Z217 ID DM3Z217
DM3Z217 DN Methimazole
DM3Z217 HS Approved
DM3Z217 SN Mercaptazole; Mercasolyl; Mercazole; Mercazolyl; Mercazolylum; Merkastan; Merkazolil; Metazolo; Methiamazole; Methimazol; Methimazolum; Methylmercaptoimidazole; Metizol; Metothyrin; Metothyrine; Metotirin; Strumazol; Tapazole; Thacapzol; Basolan; Danantizol; Favistan; Frentirox; Thiamazol; Thycapsol; Thycapzol; Thymidazol; Thymidazole; Tiamazol; Usaf el-30; methimazole; thiamazole; 1-Methyl-1H-imidazole-2-thiol; 1-Methyl-2-mercaptoimidazole; 1-Methylimidazole-2-thiol; 2-Mercapto-1-methylimidazole; 3-methyl-1H-imidazole-2-thione; 60-56-0
DM3Z217 PC 1349907
DM3Z217 MW 114.17
DM3Z217 FM C4H6N2S
DM3Z217 IC PMRYVIKBURPHAH-UHFFFAOYSA-N
DM3Z217 CS CN1C=CNC1=S
DM3Z217 IK 1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
DM3Z217 IU 3-methyl-1H-imidazole-2-thione
DM3Z217 CA CAS 60-56-0
DM3Z217 CB CHEBI:50673
DM3Z217 DE Thyrotoxicosis
DM7YMIT ID DM7YMIT
DM7YMIT DN Methohexital
DM7YMIT HS Approved
DM7YMIT SN Brevital; Brietal; Enallynymall; Enallynymalum; Methodrexitone; Methohexitalum; Methohexitone; Metoesital; Metohexital; Metoesital [DCIT]; Brevital (TN); Methohexital, Monosodium Salt; Methohexitalum [INN-Latin]; Metohexital [INN-Spanish]; Methohexital (USP/INN); Alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituricacid; (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione; 1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione; 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid; 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM7YMIT CP Par Sterile Products Llc
DM7YMIT TC Anesthetics
DM7YMIT DT Small molecular drug
DM7YMIT PC 9034
DM7YMIT MW 262.3
DM7YMIT FM C14H18N2O3
DM7YMIT IC InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
DM7YMIT CS CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C
DM7YMIT IK NZXKDOXHBHYTKP-UHFFFAOYSA-N
DM7YMIT IU 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM7YMIT CA CAS 151-83-7
DM7YMIT CB CHEBI:102216
DM7YMIT DE Anaesthesia
DM2TEOL ID DM2TEOL
DM2TEOL DN Methotrexate
DM2TEOL HS Approved
DM2TEOL SN methotrexate; 1959/5/2; Rheumatrex; Amethopterin; Metatrexan; Hdmtx; Abitrexate; Mexate; Methylaminopterinum; Methotrexatum; Antifolan; Metotrexato; Methylaminopterin; MTX; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexat; Amethopterine; Maxtrex; Rasuvo; L-Amethopterin; A-Methopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; N-Bismethylpteroylglutamic acid; Methotrexate, L-; Metotressato [DCIT]; Methotextrate; Mexate-Aq; [3H]methotrexate
DM2TEOL DT Small molecular drug
DM2TEOL PC 126941
DM2TEOL MW 454.4
DM2TEOL FM C20H22N8O5
DM2TEOL IC InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
DM2TEOL CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM2TEOL IK FBOZXECLQNJBKD-ZDUSSCGKSA-N
DM2TEOL IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
DM2TEOL CA CAS 59-05-2
DM2TEOL CB CHEBI:44185
DM2TEOL DE leukaemia; Solid tumour/cancer; Prostate cancer; Rheumatoid arthritis; Proliferative vitreoretinopathy
DM5XH2C ID DM5XH2C
DM5XH2C DN Methotrexate Sodium
DM5XH2C HS Approved
DM5XH2C SN Methotrexate disodium salt; 7413-34-5; Sodium methotrexate; MTX disodium; methotrexate disodium; UNII-3IG1E710ZN; 3IG1E710ZN; CHEBI:50679; Amethopterin sodium; Disodium methotrexate; Methotrexat dinatrium; Mexate-Aq Preserved; Methotrexate sodium salt; EINECS 231-022-0; 59-05-2 (Parent); Methotrexate Preservative Free; 4-Amino-N(sup 10)-methylpteroylglutamic acid disodium salt; METHOTREXATE SODIUM PRESERVATIVE FREE
DM5XH2C CP Hospira Inc
DM5XH2C TC Anticancer Agents
DM5XH2C DT Small molecular drug
DM5XH2C PC 11329481
DM5XH2C MW 498.4
DM5XH2C FM C20H20N8Na2O5
DM5XH2C IC InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1
DM5XH2C CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+]
DM5XH2C IK DASQOOZCTWOQPA-GXKRWWSZSA-L
DM5XH2C IU disodium;(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioate
DM5XH2C CA CAS 7413-34-5
DM5XH2C CB CHEBI:50679
DM5XH2C DE Solid tumour/cancer
DMF5XQH ID DMF5XQH
DMF5XQH DN Methoxamine
DMF5XQH HS Approved
DMF5XQH SN Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol
DMF5XQH CP Glaxosmithkline
DMF5XQH TC Antihypertensive Agents
DMF5XQH DT Small molecular drug
DMF5XQH PC 6082
DMF5XQH MW 211.26
DMF5XQH FM C11H17NO3
DMF5XQH IC InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3
DMF5XQH CS CC(C(C1=C(C=CC(=C1)OC)OC)O)N
DMF5XQH IK WJAJPNHVVFWKKL-UHFFFAOYSA-N
DMF5XQH IU 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol
DMF5XQH CA CAS 390-28-3
DMF5XQH CB CHEBI:6839
DMF5XQH DE Hypertension
DME8FZ9 ID DME8FZ9
DME8FZ9 DN Methoxsalen
DME8FZ9 HS Approved
DME8FZ9 SN Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one
DME8FZ9 TC Anticancer Agents
DME8FZ9 DT Small molecular drug
DME8FZ9 PC 4114
DME8FZ9 MW 216.19
DME8FZ9 FM C12H8O4
DME8FZ9 IC InChI=1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3
DME8FZ9 CS COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
DME8FZ9 IK QXKHYNVANLEOEG-UHFFFAOYSA-N
DME8FZ9 IU 9-methoxyfuro[3,2-g]chromen-7-one
DME8FZ9 CA CAS 298-81-7
DME8FZ9 CB CHEBI:18358
DME8FZ9 DE Cutaneous T-cell lymphoma; Psoriasis vulgaris
DMK1LZD ID DMK1LZD
DMK1LZD DN Methoxy polyethylene glycol-epoetin beta
DMK1LZD HS Approved
DMK1LZD SN Mircera (TN)
DMK1LZD DE Kidney transplant rejection
DML0RAE ID DML0RAE
DML0RAE DN Methoxyflurane
DML0RAE HS Approved
DML0RAE SN Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether
DML0RAE TC Anesthetics
DML0RAE DT Small molecular drug
DML0RAE PC 4116
DML0RAE MW 164.96
DML0RAE FM C3H4Cl2F2O
DML0RAE IC InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
DML0RAE CS COC(C(Cl)Cl)(F)F
DML0RAE IK RFKMCNOHBTXSMU-UHFFFAOYSA-N
DML0RAE IU 2,2-dichloro-1,1-difluoro-1-methoxyethane
DML0RAE CA CAS 76-38-0
DML0RAE CB CHEBI:6843
DML0RAE DE Anaesthesia
DMHP8FI ID DMHP8FI
DMHP8FI DN Methscopolamine bromide
DMHP8FI HS Approved
DMHP8FI SN Pamine Forte
DMHP8FI CP Private Formulations Inc
DMHP8FI DT Small molecular drug
DMHP8FI PC 5459110
DMHP8FI MW 398.3
DMHP8FI FM C18H24BrNO4
DMHP8FI IC InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14-,15+,16-,17+;/m1./s1
DMHP8FI CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
DMHP8FI IK CXYRUNPLKGGUJF-OZVSTBQFSA-M
DMHP8FI IU [(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DMHP8FI CA CAS 155-41-9
DMHP8FI CB CHEBI:61276
DMHP8FI DE Nausea and vomiting
DM6L5VO ID DM6L5VO
DM6L5VO DN Methsuximide
DM6L5VO HS Approved
DM6L5VO SN Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
DM6L5VO CP Pfizer Pharmaceuticals
DM6L5VO TC Anticonvulsants
DM6L5VO DT Small molecular drug
DM6L5VO PC 6476
DM6L5VO MW 203.24
DM6L5VO FM C12H13NO2
DM6L5VO IC InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
DM6L5VO CS CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2
DM6L5VO IK AJXPJJZHWIXJCJ-UHFFFAOYSA-N
DM6L5VO IU 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
DM6L5VO CA CAS 77-41-8
DM6L5VO CB CHEBI:6846
DM6L5VO DE Epileptic seizures
DMN7SDE ID DMN7SDE
DMN7SDE DN Methyclothiazide
DMN7SDE HS Approved
DMN7SDE SN Aquaresen; Aquatensen; Duretic; Enduron; Enduronum; METHYLCLOTHIAZIDE; Methychlothiazide; Methyclothiazid; Methyclothiazidum;Methycyclothiazide; Methylchlorothiazide; Methylcyclothiazide; Meticlotiazida; Meticlotiazide; Naturon; Meticlotiazide [DCIT]; Ciba 7272-Su; Enduron (TN); Methyclothiazidum [INN-Latin]; Meticlotiazida [INN-Spanish]; Naturon (VAN); Methyclothiazide (JAN/USP/INN); Methyclothiazide [USAN:INN:BAN:JAN]; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxid;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1
DMN7SDE TC Antihypertensive Agents
DMN7SDE DT Small molecular drug
DMN7SDE PC 4121
DMN7SDE MW 360.2
DMN7SDE FM C9H11Cl2N3O4S2
DMN7SDE IC InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
DMN7SDE CS CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl
DMN7SDE IK CESYKOGBSMNBPD-UHFFFAOYSA-N
DMN7SDE IU 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMN7SDE CA CAS 135-07-9
DMN7SDE CB CHEBI:6847
DMN7SDE DE Edema; Hypertension
DMIUX3D ID DMIUX3D
DMIUX3D DN Methyl aminolevulinate
DMIUX3D HS Approved
DMIUX3D SN Metvix; Aminolevulinic acid methyl ester; Methyl 5-aminolevulinate; Methyl delta-aminolevulinate; Methyl5-amino-4-oxopentanoate; Levulinic acid, 5-amino-, methyl ester; Pentanoic acid, 5-amino-4-oxo-, methyl ester; 5-Aminolevulinic acid methyl ester
DMIUX3D TC Anticancer Agents
DMIUX3D DT Small molecular drug
DMIUX3D PC 157922
DMIUX3D MW 145.16
DMIUX3D FM C6H11NO3
DMIUX3D IC InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3
DMIUX3D CS COC(=O)CCC(=O)CN
DMIUX3D IK YUUAYBAIHCDHHD-UHFFFAOYSA-N
DMIUX3D IU methyl 5-amino-4-oxopentanoate
DMIUX3D CA CAS 33320-16-0
DMIUX3D CB CHEBI:724125
DMIUX3D DE Acne vulgaris
DM5I621 ID DM5I621
DM5I621 DN Methyldopa
DM5I621 HS Approved
DM5I621 SN AMD; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine
DM5I621 CP Ivax pharmaceutical
DM5I621 TC Antihypertensive Agents
DM5I621 DT Small molecular drug
DM5I621 PC 38853
DM5I621 MW 211.21
DM5I621 FM C10H13NO4
DM5I621 IC InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1
DM5I621 CS C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N
DM5I621 IK CJCSPKMFHVPWAR-JTQLQIEISA-N
DM5I621 IU (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
DM5I621 CA CAS 555-30-6
DM5I621 CB CHEBI:61058
DM5I621 DE Hypertension
DM8XI09 ID DM8XI09
DM8XI09 DN Methyldopate Hydrochloride
DM8XI09 HS Approved
DM8XI09 CP Merck And Co Inc
DM8XI09 TC Cardiovascular Agents
DM8XI09 DT Small molecular drug
DM8XI09 PC 17276
DM8XI09 MW 275.73
DM8XI09 FM C12H18ClNO4
DM8XI09 IC InChI=1S/C12H17NO4.ClH/c1-3-17-11(16)12(2,13)7-8-4-5-9(14)10(15)6-8;/h4-6,14-15H,3,7,13H2,1-2H3;1H/t12-;/m0./s1
DM8XI09 CS CCOC(=O)[C@](C)(CC1=CC(=C(C=C1)O)O)N.Cl
DM8XI09 IK QSRVZCCJDKYRRF-YDALLXLXSA-N
DM8XI09 IU ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate;hydrochloride
DM8XI09 CA CAS 2508-79-4
DM8XI09 DE Hypertension
DMJAPE7 ID DMJAPE7
DMJAPE7 DN Methylene blue
DMJAPE7 HS Approved
DMJAPE7 SN methylene blue; 61-73-4; Methylthioninium chloride; Swiss Blue; Chromosmon; Methylene Blue N; Methylenium ceruleum; Urolene blue; Methylene Blue chloride; Solvent blue 8; Bleu de methylene; Methylene Blue G; Methylene Blue A; External Blue 1; Methylene Blue D; Methylene Blue B; Methylene Blue anhydrous; CI Basic Blue 9; Methylene Blue ZF; Methylene Blue SP; Methylene Blue NZ; Methylene Blue BX; Methylene Blue BD; Methylene Blue SG; Tetramethylene Blue; Methylene Blue ZX; Methylene Blue FZ; Methylene Blue BP; Calcozine; 3,7-Bis-dimethylamino-phenothiazin-5-ylium
DMJAPE7 PC 6099
DMJAPE7 MW 319.9
DMJAPE7 FM C16H18ClN3S
DMJAPE7 IC InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1
DMJAPE7 CS CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-]
DMJAPE7 IK CXKWCBBOMKCUKX-UHFFFAOYSA-M
DMJAPE7 IU [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride
DMJAPE7 CA CAS 61-73-4
DMJAPE7 CB CHEBI:6872
DMJAPE7 DE Acquired methemoglobinemia
DMBEX4O ID DMBEX4O
DMBEX4O DN Methylergonovine
DMBEX4O HS Approved
DMBEX4O SN Basofortina; Ergotyl; Metenarin; Methergen; Methergin; Methergine; Methylergobasin; Methylergobasine; Methylergobrevin; Methylergometrin; Methylergometrine; Methylergometrinum; Methylergonovin; Metilergometrina; Metilergometrinio; Partergin; Ryegonovin; Lysergic acid butanolamide; Methylergometrine maleate; Metilergometrina [DCIT]; ME 277; Ergotyl (TN); Methergine (TN); Methylergometrine (INN); Methylergometrine [INN:BAN]; Methylergometrinum [INN-Latin]; Metilergometrinio [INN-Spanish]; Spametrin-M; D-Lysergic acid-dl-hydroxybutylamide-2; N-(alpha-(Hydroxymethyl)propyl)-D-lysergamide; D-Lysergic acid-(+)-butanolamide-(2); (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-6-methylergoline-8-carboxamide; 9,10-Didehydro-N-(alpha-(hydroxymethyl)propyl)-6-methyl-ergoline-8-beta-carboxamide
DMBEX4O CP Edison Therapeutics Llc
DMBEX4O TC Oxytocics
DMBEX4O DT Small molecular drug
DMBEX4O PC 8226
DMBEX4O MW 339.4
DMBEX4O FM C20H25N3O2
DMBEX4O IC InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1
DMBEX4O CS CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMBEX4O IK UNBRKDKAWYKMIV-QWQRMKEZSA-N
DMBEX4O IU (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMBEX4O CA CAS 113-42-8
DMBEX4O CB CHEBI:92607
DMBEX4O DE Spontaneous abortion
DMZTGN2 ID DMZTGN2
DMZTGN2 DN Methylnaltrexone bromide
DMZTGN2 HS Approved
DMZTGN2 SN Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, > W-5330; CHIR-01020
DMZTGN2 CP Progenics
DMZTGN2 DT Small molecular drug
DMZTGN2 PC 5361917
DMZTGN2 MW 436.3
DMZTGN2 FM C21H26BrNO4
DMZTGN2 IC InChI=1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1
DMZTGN2 CS C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-]
DMZTGN2 IK IFGIYSGOEZJNBE-KNLJMPJLSA-N
DMZTGN2 IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one;bromide
DMZTGN2 CA CAS 73232-52-7
DMZTGN2 DE Opioid-induced constipation; Obesity
DM7SJD6 ID DM7SJD6
DM7SJD6 DN Methylphenidate
DM7SJD6 HS Approved
DM7SJD6 SN Calocain; Centedein; Centedrin; Centredin; Concerta; Daytrana; Meridil; Metadate; Methylfenidan; Methylin; Methylofenidan; Methylphen; Methylphenidan; Methylphenidatum; Metilfenidato; Phenidylate; Plimasine; Riphenidate; Ritalin; Ritaline; Tsentedrin; Metadate CD; Metadate ER; Methyl phenidate; Methyl phenidyl acetate; Methyl phenidylacetate; Methylin ER; Metilfenidato [Italian]; Ritalin LA; Ritalin SR; Ritcher works; C 4311; Attenta (TN); Biphentin (TN); Concerta (TN); D-methylphenidate HCl; Daytrana (TN); Equasym (TN); Metadate ER (TN); Methylin (TN); Methylphenidate [INN:BAN]; Methylphenidatum [INN-Latin]; Metilfenidato [INN-Spanish]; Motiron (TN); PMS-Methylphenidate; Ritalin (TN); Ritalin LA (TN); Ritalin-SR; Rubifen (TN); Methylphenidate (USAN/INN); Alpha-Phenyl-2-piperidineacetic acid methyl ester; Methyl phenyl(piperidin-2-yl)acetate; Methyl alpha-phenyl-alpha-2-piperidinylacetate; Alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester; Methyl 2-phenyl-2-piperidin-2-ylacetate; Methyl alpha-phenyl-alpha-(2-piperidyl)acetate; Methyl (2-phenyl-2-(2-piperidyl)acetate); METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R); 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester
DM7SJD6 CP Novartis
DM7SJD6 TC Central Nervous System Stimulants
DM7SJD6 DT Small molecular drug
DM7SJD6 PC 4158
DM7SJD6 MW 233.31
DM7SJD6 FM C14H19NO2
DM7SJD6 IC InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3
DM7SJD6 CS COC(=O)C(C1CCCCN1)C2=CC=CC=C2
DM7SJD6 IK DUGOZIWVEXMGBE-UHFFFAOYSA-N
DM7SJD6 IU methyl 2-phenyl-2-piperidin-2-ylacetate
DM7SJD6 CA CAS 113-45-1
DM7SJD6 CB CHEBI:84276
DM7SJD6 DE Attention deficit hyperactivity disorder; Traumatic brain injury
DMDSWAG ID DMDSWAG
DMDSWAG DN Methylphenobarbital
DMDSWAG HS Approved
DMDSWAG SN Enfenemal; Enphenemal; Enphenemalum; Mebaral; Meberal; Mebroin; Mephobarbital; Mephobarbitone; Mephytal; Methylphenobarbitalum; Methylphenobarbitone; Methylphenobarbitonum; Methylphenolbarbital; Metilfenobarbital; Metilfenobarbitale; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal; Prominaletten; Prominalum; Mephobarbital [JAN]; Methyl phenobarbitone; Methylphenylbarbituric acid; Metilfenobarbitale [DCIT]; Sanofi Brand of Mephobarbital; Sanofi Synthelabo Brand of Mephobarbital; Isonal (roussel); Mebaral (TN); Menta-Bal; Methyl-calminal; Methylphenobarbital (INN); Methylphenobarbitalum [INN-Latin]; Metilfenobarbital [INN-Spanish]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Mephobarbital (JAN/USP); N-Methyl-5-phenyl-5-ethylbarbital; 1-Methyl-5-ethyl-5-phenylbarbituric acid; 1-Methyl-5-phenyl-5-ethylbarbituric acid; 1-Methylphenobarbital; 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric acid; 5-Ethyl-5-phenyl-N-methyl-bartituric acid; 5-Ethyl-N-methyl-5-phenylbarbituric acid; 5-Phenyl-5-ethyl-3-methylbarbituric acid; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
DMDSWAG CP Ovation Pharmaceuticals
DMDSWAG TC Hypnotics and Sedatives
DMDSWAG DT Small molecular drug
DMDSWAG PC 8271
DMDSWAG MW 246.26
DMDSWAG FM C13H14N2O3
DMDSWAG IC InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
DMDSWAG CS CCC1(C(=O)NC(=O)N(C1=O)C)C2=CC=CC=C2
DMDSWAG IK ALARQZQTBTVLJV-UHFFFAOYSA-N
DMDSWAG IU 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMDSWAG CA CAS 115-38-8
DMDSWAG CB CHEBI:6758
DMDSWAG DE Anxiety disorder
DM4BDON ID DM4BDON
DM4BDON DN Methylprednisolone
DM4BDON HS Approved
DM4BDON SN Depo-medrol; M-predrol; Medrol; Medrol Acetate
DM4BDON CP Pharmacia And Upjohn Co
DM4BDON TC Anticancer Agents
DM4BDON DT Small molecular drug
DM4BDON PC 6741
DM4BDON MW 374.5
DM4BDON FM C22H30O5
DM4BDON IC InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
DM4BDON CS C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
DM4BDON IK VHRSUDSXCMQTMA-PJHHCJLFSA-N
DM4BDON IU (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM4BDON CA CAS 83-43-2
DM4BDON CB CHEBI:6888
DM4BDON DE Solid tumour/cancer; Spinal cord injury
DM5VWOB ID DM5VWOB
DM5VWOB DN Methylscopolamine
DM5VWOB HS Approved
DM5VWOB SN Methscopolamine; methscopolamine; N-Methylscopolamine; N-methyl scopolamine; UNII-VDR09VTQ8U; VDR09VTQ8U; 13265-10-6; CHEMBL376897; (1r,2r,4s,5s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane; Metylskopolamin; 56552-70-6; 3-Oxa-9-azoniatricyclo[33102,4]nonane, 7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, (1a,2b,4b,5a,7b); HSDB 5420; [3H]N-methylscopolamine; [3H]N-methyl scopolamine; [3H]NMS; Methyl scopolamine; 3C0
DM5VWOB TC Anticholinergic Agents
DM5VWOB DT Small molecular drug
DM5VWOB PC 71183
DM5VWOB MW 318.4
DM5VWOB FM C18H24NO4+
DM5VWOB IC InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12?,13-,14-,15+,16-,17+/m1/s1
DM5VWOB CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C
DM5VWOB IK LZCOQTDXKCNBEE-XJMZPCNVSA-N
DM5VWOB IU [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DM5VWOB CA CAS 13265-10-6
DM5VWOB CB CHEBI:135361
DM5VWOB DE Peptic ulcer
DMWLFGO ID DMWLFGO
DMWLFGO DN Methyltestosterone
DMWLFGO HS Approved
DMWLFGO SN Android (TN)
DMWLFGO CP Valeant Pharmaceuticals
DMWLFGO DT Small molecular drug
DMWLFGO PC 6010
DMWLFGO MW 302.5
DMWLFGO FM C20H30O2
DMWLFGO IC InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
DMWLFGO CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C
DMWLFGO IK GCKMFJBGXUYNAG-HLXURNFRSA-N
DMWLFGO IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMWLFGO CA CAS 58-18-4
DMWLFGO CB CHEBI:27436
DMWLFGO DE Solid tumour/cancer
DMBW7VH ID DMBW7VH
DMBW7VH DN Methyprylon
DMBW7VH HS Approved
DMBW7VH SN Dimerin; Methprylon; Methyprolon; Methyprylone; Methyprylonum; Metiprilon; Metiprilona; Metiprilone; Noctan; Nodular; Noludar; Methyprylon [INN]; Methyprylone [INN-French]; Methyprylonum [INN-Latin]; Metiprilona [INN-Spanish]; Noludar (TN); Ro 1-6463; Methyprylon (JAN/INN); 2,4-Dioxo-3,3-diethyl-5-methylpiperidine; 2,4-Dioxy-3,3-diethyl-5-methylpiperidine; 3,3-Diethyl-2,4-dioxo-5-methylpiperidine; 3,3-Diethyl-5-methyl-2,4-piperidinedione; 3,3-Diethyl-5-methylpiperidine-2,4-dione
DMBW7VH TC Sedatives and Hypnotics
DMBW7VH DT Small molecular drug
DMBW7VH PC 4162
DMBW7VH MW 183.25
DMBW7VH FM C10H17NO2
DMBW7VH IC InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)
DMBW7VH CS CCC1(C(=O)C(CNC1=O)C)CC
DMBW7VH IK SIDLZWOQUZRBRU-UHFFFAOYSA-N
DMBW7VH IU 3,3-diethyl-5-methylpiperidine-2,4-dione
DMBW7VH CA CAS 125-64-4
DMBW7VH CB CHEBI:31837
DMBW7VH DE Insomnia
DM1EF73 ID DM1EF73
DM1EF73 DN Methysergide
DM1EF73 HS Approved
DM1EF73 SN Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
DM1EF73 CP Norvatis Phamaceuticals Corporation
DM1EF73 TC Vasoconstrictor Agents
DM1EF73 DT Small molecular drug
DM1EF73 PC 9681
DM1EF73 MW 353.5
DM1EF73 FM C21H27N3O2
DM1EF73 IC InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1
DM1EF73 CS CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
DM1EF73 IK KPJZHOPZRAFDTN-ZRGWGRIASA-N
DM1EF73 IU (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
DM1EF73 CA CAS 361-37-5
DM1EF73 CB CHEBI:92629
DM1EF73 DE Migraine
DMIKHN0 ID DMIKHN0
DMIKHN0 DN Meticillin
DMIKHN0 HS Approved
DMIKHN0 SN Dimocillin; MII; Metacillin; Methicillin; Methicillinum; Methycillin; Meticilina; Meticillina; Meticilline; Meticillinum; Staphcillin; Methicillin [BAN]; Meticillin [INN]; Meticillina [DCIT]; BRL 1241; Methicillin Monohydrate, Monosodium Salt; Meticilina [INN-Spanish]; Meticilline [INN-French]; Meticillinum [INN-Latin]; Penicillin, Dimethoxyphenyl; (2,6-Dimethoxyphenyl)penicillin; (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2,3-Dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(2,6-Dimethoxybenzamido)penicillanic acid; 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-(2,6-dimethoxybenzamido)penicillanic acid
DMIKHN0 CP Beecham phamaceuticals
DMIKHN0 TC Antibiotics
DMIKHN0 DT Small molecular drug
DMIKHN0 PC 6087
DMIKHN0 MW 380.4
DMIKHN0 FM C17H20N2O6S
DMIKHN0 IC InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1
DMIKHN0 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)O)C
DMIKHN0 IK RJQXTJLFIWVMTO-TYNCELHUSA-N
DMIKHN0 IU (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMIKHN0 CA CAS 61-32-5
DMIKHN0 CB CHEBI:6827
DMIKHN0 DE Bacterial infection; Neurological disorder
DMJMVKI ID DMJMVKI
DMJMVKI DN Metipranolol
DMJMVKI HS Approved
DMJMVKI SN Disorat; Methypranol; Metipranololum; Trimepranol; Turoptin; BM-01004; Betanol (TN); Disorat (TN); Metipranololum [INN-Latin]; OptiPranolol (TN); Trimepranol (TN); VUAB-6453; VUFB-6453; Metipranolol (USAN/INN); Metipranolol [USAN:BAN:INN]; [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate (9CI); Phenol,4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, (+-)-, 1-acetate; (+-)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; (RS)-4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetat; 1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; 1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate; 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate; 4-(2-Hydroxy-3-((1-methylethyl)-amino)propoxy)-2,3,6-trimethylphenol 1-acetate; 4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate; 62164P
DMJMVKI TC Antihypertensive Agents
DMJMVKI DT Small molecular drug
DMJMVKI PC 31477
DMJMVKI MW 309.4
DMJMVKI FM C17H27NO4
DMJMVKI IC InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
DMJMVKI CS CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O
DMJMVKI IK BQIPXWYNLPYNHW-UHFFFAOYSA-N
DMJMVKI IU [4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate
DMJMVKI CA CAS 22664-55-7
DMJMVKI CB CHEBI:6897
DMJMVKI DE Open-angle glaucoma
DM0JE6N ID DM0JE6N
DM0JE6N DN Metixene
DM0JE6N HS Approved
DM0JE6N SN Atosil; Contalyl; Dalpan; METHIXENE; Methixart; Methixen; Methyloxan; Metisene; Metixeno; Metixenum; Raunana; Tremaril;Tremarit; Tremonil; Tremoquil; Trest; Methixen [German]; Methixene hydrochloride; Metisene [DCIT]; Metixene hydrochloride; Tremaril hydrochloride; Metixene (INN); Metixene (TN); Metixene [INN:BAN]; Metixeno [INN-Spanish]; Metixenum [INN-Latin]; Methixene (*hydrochloride*); Metixene (*hydrochloride*); Tremonil (*hydrochloride*); 1-Methyl-3-(9H-thioxanthen-9-yl-methyl)piperidine; 1-Methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl) piperidine; 1-Methyl-3-(thioxanthen-9-ylmethyl)-1-piperidine; 1-methyl-3-(thioxanthen-9-ylmethyl)-piperidine hydrochloride; 60 SJ 1977; 60 SJ 1977 (*hydrochloride*); 9-(1'-Methylpiperidine-3'-methyl)thioxanthene
DM0JE6N CP Norvatis Phamaceuticals Corporation
DM0JE6N TC Antiparkinson Agents
DM0JE6N DT Small molecular drug
DM0JE6N PC 4167
DM0JE6N MW 309.5
DM0JE6N FM C20H23NS
DM0JE6N IC InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3
DM0JE6N CS CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24
DM0JE6N IK MJFJKKXQDNNUJF-UHFFFAOYSA-N
DM0JE6N IU 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine
DM0JE6N CA CAS 4969-02-2
DM0JE6N CB CHEBI:51024
DM0JE6N DE Parkinson disease
DMFA5MY ID DMFA5MY
DMFA5MY DN Metoclopramide
DMFA5MY HS Approved
DMFA5MY SN Cerucal; Clopra; Clopromate; Duraclamid; Elieten; Emetid; Emitasol; Emperal; Eucil; Gastrese; Gastrobid; Gastromax; Gastronerton; Gastrosil; Gastrotablinen; Gastrotem; Imperan; Maxeran; Maxolon; Meclopran; Metaclopramide; Metaclopromide; Metamide; Methochlopramide; Methoclopramide; Metochlopramide; Metoclol; Metoclopramida; Metoclopramidum; Metocobil; Metramid; Moriperan; Mygdalon; Octamide; Parmid; Paspertin; Peraprin; Plasil; Pramidin; Pramiel; Pramin; Primperan; Reclomide; Reglan; Reliveran; Terperan; Metoclopramide Omega; DEL 1267; Apo-Metoclop; CLOPRA-YELLOW; Clopra-Yellow; Degan (TN); Elieten (TN); Gastro-Timelets; Maxeran (TN); Maxolon (TN); Metoclopramida [INN-Spanish]; Metoclopramide Monohydrochloride, Monohydrate; Metoclopramidum [INN-Latin]; Neu-Sensamide; Nu-Metoclopramide; Plasil (pharmaceutical); Pms-Metoclopramide; Primperan (TN); Pylomid (TN); Reglan (TN); Terperan (TN); Metoclopramide (JP15/INN); Metoclopramide [INN:BAN:JAN]; N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide; O-Anisamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-(8CI); Benzamide, 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxy-(9CI); (metaclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; (metoclopramide)4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 1,5-Dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethyl)benzamide; 2-Methoxy-5-chloroprocainamide; 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide; 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-2-methoxy-N-(beta-diethylaminoethyl)benzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide; 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide; 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (Mcp); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide (metoclopramide); 4-Amino-5-chloro-N-(2-diethylamino-ethyl)-2-methoxy-benzamide(Metoclopramide); 4-amino-5-chloro-N-(2-diethylaminoethyl)-2-methoxybenzamide; 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide; 5-Chloro-2-methoxyprocainamide
DMFA5MY CP Sanofi-Aventis
DMFA5MY TC Antiemetics
DMFA5MY DT Small molecular drug
DMFA5MY PC 4168
DMFA5MY MW 299.79
DMFA5MY FM C14H22ClN3O2
DMFA5MY IC InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
DMFA5MY CS CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
DMFA5MY IK TTWJBBZEZQICBI-UHFFFAOYSA-N
DMFA5MY IU 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
DMFA5MY CA CAS 364-62-5
DMFA5MY CB CHEBI:107736
DMFA5MY DE Nausea
DMZJYBW ID DMZJYBW
DMZJYBW DN Metocurine Iodide
DMZJYBW HS Approved
DMZJYBW SN Metokuriinijodidi; Metokurinjodid; Metubine; Dimethyl tubocurarine iodide; Dimethylchondrocurarine iodide; Dimethyltubocurarine Iodide; Metocurine diiodide; Metocurine iodide [USAN]; Metocurini Iodidum; Metubine iodide; Mutubine Iodide; Trimethyltubocurarine Iodide; Dimethylether of d-tubocurarine iodide; Dimetiltubocurarinio, ioduro de; Methyl-curarin; Methyl-curarin [German]; Metocurine iodide (USAN); Metubine iodide (TN); O,O'-Dimethylchondrocurarine diiodide; Tubocurarine, O,O'-dimethyl-, diiodide; Tubocuraranium, 6,6',7',12'-tetramethoxy-2,2,2',2'-tetramethyl-, diiodide; (+)-O,O'-Dimethylchondrocurarine Di-iodide; (+)-O,O'-Dimethylchondrocurarine diiodide; 2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium diiodide; 6,6',7',12'-Tetramethoxy-2,2,2',2'-tetramethyltubocuraranium diiodide
DMZJYBW TC Anesthetics
DMZJYBW DT Small molecular drug
DMZJYBW PC 24244
DMZJYBW MW 906.6
DMZJYBW FM C40H48I2N2O6
DMZJYBW IC InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1
DMZJYBW CS C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[I-].[I-]
DMZJYBW IK DIGFQJFCDPKEPF-OIUSMDOTSA-L
DMZJYBW IU (1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene;diiodide
DMZJYBW CA CAS 7601-55-0
DMZJYBW CB CHEBI:6901
DMZJYBW DE Anaesthesia
DMB39LO ID DMB39LO
DMB39LO DN Metolazone
DMB39LO HS Approved
DMB39LO SN Diulo; Metalazone; Metalozone; Metenix; Metolazona; Metolazonum; Microx; Mykrox; Oldren; Xuret; Zaroxolyn; Metolazona [INN-Spanish]; Metolazonum [INN-Latin]; Mykrox (TN); SR 720-22; Zaroxolyn (TN); SR-720-22; Metolazone (JAN/USP/INN); Metolazone [USAN:BAN:INN:JAN]; Mykrox, Zaroxolyn, Diulo, Metolazone; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
DMB39LO TC Antihypertensive Agents
DMB39LO DT Small molecular drug
DMB39LO PC 4170
DMB39LO MW 365.8
DMB39LO FM C16H16ClN3O3S
DMB39LO IC InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
DMB39LO CS CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
DMB39LO IK AQCHWTWZEMGIFD-UHFFFAOYSA-N
DMB39LO IU 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
DMB39LO CA CAS 17560-51-9
DMB39LO CB CHEBI:64354
DMB39LO DE Edema; Hypertension
DMOJ0V6 ID DMOJ0V6
DMOJ0V6 DN Metoprolol
DMOJ0V6 HS Approved
DMOJ0V6 SN Beatrolol; BelocDuriles; Betaloc; BetalocAstra; Betalok; Dutoprol; LOPRESSIDONE; Lopresor; Lopresoretic; Lopressor; Meijoprolol; Metohexal; Metoprololum; Metroprolol; Preblok; Presolol; Seloken; Seroken; Spesicor; Spesikor; Toprol; AstraZeneca Brand of Metaoprolol Tartrate; AstraZeneca Brand of Seloken; Beloc Duriles; Betaloc Astra; Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate; Metoprolol succinate; Novartis Brand of Metprolol Tartrate; Seloken AstraZeneca Brand; CGP 2175; CGP2175; H 93 26; H 9326; Beloc-Duriles; Betaloc (TN); Betaloc-Astra; CGP-2175; Corvitol (TN); Dl-Metoprolol; H 93-26; Lopressor (TN); Metoprololum [INN-Latin]; Metrol (TN); Minax (TN); Neobloc (TN); Selo-Zok; Selokeen (TN); TOPROL-XL; Tartrate, Metoprolol; Metoprolol (USAN/INN); Metoprolol [USAN:INN:BAN]; Toprol-XL (TN); (RS)-Metoprolol; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; 3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
DMOJ0V6 CP AstraZeneca
DMOJ0V6 TC Antihypertensive Agents
DMOJ0V6 DT Small molecular drug
DMOJ0V6 PC 4171
DMOJ0V6 MW 267.36
DMOJ0V6 FM C15H25NO3
DMOJ0V6 IC InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
DMOJ0V6 CS CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
DMOJ0V6 IK IUBSYMUCCVWXPE-UHFFFAOYSA-N
DMOJ0V6 IU 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMOJ0V6 CA CAS 51384-51-1
DMOJ0V6 CB CHEBI:6904
DMOJ0V6 DE Hypertension
DM1NOEK ID DM1NOEK
DM1NOEK DN Metreleptin
DM1NOEK HS Approved
DM1NOEK CP Amylin Pharmaceuticals
DM1NOEK SQ Peptide Sequence : MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC
DM1NOEK DE Diabetic complication
DMTIVEN ID DMTIVEN
DMTIVEN DN Metronidazole
DMTIVEN HS Approved
DMTIVEN SN APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ
DMTIVEN CP Pfizer Pharmaceuticals
DMTIVEN TC Antiinfective Agents
DMTIVEN DT Small molecular drug
DMTIVEN PC 4173
DMTIVEN MW 171.15
DMTIVEN FM C6H9N3O3
DMTIVEN IC InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
DMTIVEN CS CC1=NC=C(N1CCO)[N+](=O)[O-]
DMTIVEN IK VAOCPAMSLUNLGC-UHFFFAOYSA-N
DMTIVEN IU 2-(2-methyl-5-nitroimidazol-1-yl)ethanol
DMTIVEN CA CAS 443-48-1
DMTIVEN CB CHEBI:6909
DMTIVEN DE Amoebiasis; Crohn disease; Perianal crohn disease
DMI7FVQ ID DMI7FVQ
DMI7FVQ DN Metyrapone
DMI7FVQ HS Approved
DMI7FVQ SN MYT; Mepyrapone; Metapirone; Metapyron; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metirapona; Metopiron; Metopirone; Metopyrone; Metroprione; Metyrapon; Metyraponum; Alliance Brand of Metyrapone; Metyrapone Alliance Brand; Metyrapone Novartis Brand; Novartis Brand of Metyrapone; Su 4885; METOPIRONE (TN); Metirapona [INN-Spanish]; Metopirone (TN); Metyraponum [INN-Latin]; Su-4885; Metyrapone (JP15/USP/INN); Metyrapone [USAN:INN:BAN:JAN]; 1,2-Di-3-pyridyl-2-methyl-1-propanone; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; 2-Methyl-1,2-di-3-pyridyl-1-propanone; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; 2-methyl-1,2-dipyridin-3-ylpropan-1-one
DMI7FVQ CP Norvatis Phamaceuticals Corporation
DMI7FVQ TC Antimetabolites
DMI7FVQ DT Small molecular drug
DMI7FVQ PC 4174
DMI7FVQ MW 226.27
DMI7FVQ FM C14H14N2O
DMI7FVQ IC InChI=1S/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3
DMI7FVQ CS CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2
DMI7FVQ IK FJLBFSROUSIWMA-UHFFFAOYSA-N
DMI7FVQ IU 2-methyl-1,2-dipyridin-3-ylpropan-1-one
DMI7FVQ CA CAS 54-36-4
DMI7FVQ CB CHEBI:44241
DMI7FVQ DE Cushing disease
DMBYCU0 ID DMBYCU0
DMBYCU0 DN Metyrosine
DMBYCU0 HS Approved
DMBYCU0 SN Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine
DMBYCU0 TC Anticancer Agents
DMBYCU0 DT Small molecular drug
DMBYCU0 PC 441350
DMBYCU0 MW 195.21
DMBYCU0 FM C10H13NO3
DMBYCU0 IC InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
DMBYCU0 CS C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N
DMBYCU0 IK NHTGHBARYWONDQ-JTQLQIEISA-N
DMBYCU0 IU (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
DMBYCU0 CA CAS 672-87-7
DMBYCU0 CB CHEBI:6912
DMBYCU0 DE Pheochromocytoma
DMCTE9R ID DMCTE9R
DMCTE9R DN Mexiletine
DMCTE9R HS Approved
DMCTE9R SN Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene
DMCTE9R CP Boehringer Ingelheim
DMCTE9R TC Antiarrhythmic Agents
DMCTE9R DT Small molecular drug
DMCTE9R PC 4178
DMCTE9R MW 179.26
DMCTE9R FM C11H17NO
DMCTE9R IC InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
DMCTE9R CS CC1=C(C(=CC=C1)C)OCC(C)N
DMCTE9R IK VLPIATFUUWWMKC-UHFFFAOYSA-N
DMCTE9R IU 1-(2,6-dimethylphenoxy)propan-2-amine
DMCTE9R CA CAS 31828-71-4
DMCTE9R CB CHEBI:6916
DMCTE9R DE Ventricular tachycardia
DMY5JEP ID DMY5JEP
DMY5JEP DN Mezlocillin
DMY5JEP HS Approved
DMY5JEP SN Mezlin; Mezlocilina; Mezlocillinum; Mezlocillin (USAN/INN); (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid; 6beta-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid
DMY5JEP TC Antibiotics
DMY5JEP DT Small molecular drug
DMY5JEP PC 656511
DMY5JEP MW 539.6
DMY5JEP FM C21H25N5O8S2
DMY5JEP IC InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1
DMY5JEP CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCN(C4=O)S(=O)(=O)C)C(=O)O)C
DMY5JEP IK YPBATNHYBCGSSN-VWPFQQQWSA-N
DMY5JEP IU (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMY5JEP CA CAS 51481-65-3
DMY5JEP CB CHEBI:6919
DMY5JEP DE Urinary tract infection
DMVKA4O ID DMVKA4O
DMVKA4O DN Mianserin
DMVKA4O HS Approved
DMVKA4O SN Mianserina; Mianserine; Mianserinum; Mianseryna; Norval; Tolvan; Tolvon; Mianserin Monohydrochloride; Mianseryna [Polish]; Bolvidon (TN); Mianserin (INN); Mianserin [INN:BAN]; Mianserina [INN-Spanish]; Mianserine [INN-French]; Mianserinum [INN-Latin]; Norval (TN); Tolvin (TN); Tolvon (TN); 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
DMVKA4O CP GlaxoSmithKline
DMVKA4O TC Antidepressants
DMVKA4O DT Small molecular drug
DMVKA4O PC 4184
DMVKA4O MW 264.4
DMVKA4O FM C18H20N2
DMVKA4O IC InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
DMVKA4O CS CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
DMVKA4O IK UEQUQVLFIPOEMF-UHFFFAOYSA-N
DMVKA4O IU 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene
DMVKA4O CA CAS 24219-97-4
DMVKA4O CB CHEBI:51137
DMVKA4O DE Depression
DM6Y3AN ID DM6Y3AN
DM6Y3AN DN Micafungin
DM6Y3AN HS Approved
DM6Y3AN SN Mycamine; FK463; FK-463; Mycamine (TN); Mycamine(TM)
DM6Y3AN CP Astellas Pharma
DM6Y3AN TC Antifungal Agents
DM6Y3AN DT Small molecular drug
DM6Y3AN PC 477468
DM6Y3AN MW 1270.3
DM6Y3AN FM C56H71N9O23S
DM6Y3AN IC InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
DM6Y3AN CS CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O
DM6Y3AN IK PIEUQSKUWLMALL-YABMTYFHSA-N
DM6Y3AN IU [5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
DM6Y3AN CA CAS 235114-32-6
DM6Y3AN CB CHEBI:600520
DM6Y3AN DE Candidiasis
DM3O6CY ID DM3O6CY
DM3O6CY DN Micardis telmisartan
DM3O6CY HS Approved
DM3O6CY CP Boehringer-Ingelheim Pharmaceuticals
DM3O6CY DE Hypertension
DMPMYE8 ID DMPMYE8
DMPMYE8 DN Miconazole
DMPMYE8 HS Approved
DMPMYE8 SN Dactarin; MCZ; Miconazol; Miconazolo; Miconazolum; Micozole; Minostate; Monistat; Vusion; Zimycan; Daktarin IV; Miconasil Nitrate; Miconazole nitrate salt; Miconazolo [DCIT]; Monistat IV; MJR 1762; Miconazole 3; Miconazole 3 Combination Pack; Miconazole 7 Combination Pack; Monazole 7; Monistat 1 Combination Pack; Monistat 3 Vaginal Ovules; Monistat 5 Tampon; Monistat 7 Vaginal Suppositories; R 18134; Aflorix(nitrate); Albistat(nitrate); Andergin(nitrate); Conofite(nitrate); Daktarin (TN); Femizol (TN); Femizol-M; Florid(nitrate); Lotrimin AF(nitrate); Micantin (nitrate); Micatin (TN); Miconazex (TN); Miconazol [INN-Spanish]; Miconazole-7; Miconazolum [INN-Latin]; Monista (nitrate); Monistat (TN); Monistat 3 Dual-Pak; Monistat 7 Dual-Pak; Monistat Dual-PAK; Monistat iv (TN); Monistat-Derm; Novo-Miconazole Vaginal Ovules; Epi-Monistat(nitrate); Gyno-Daktar(nitrate); Monistat-Derm (TN); R-14,889; Miconazole (JP15/USP/INN); Miconazole [USAN:BAN:INN:JAN]; Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)-(9CI); Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-(9CI); (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole; 1-[2,4-Dichloro-beta-([2,4-dichloro-benzyl]oxy)phenethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole; 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole; 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
DMPMYE8 CP Janssen Pharmaceutica
DMPMYE8 TC Antifungal Agents
DMPMYE8 DT Small molecular drug
DMPMYE8 PC 4189
DMPMYE8 MW 416.1
DMPMYE8 FM C18H14Cl4N2O
DMPMYE8 IC InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
DMPMYE8 CS C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl
DMPMYE8 IK BYBLEWFAAKGYCD-UHFFFAOYSA-N
DMPMYE8 IU 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
DMPMYE8 CA CAS 22916-47-8
DMPMYE8 CB CHEBI:82892
DMPMYE8 DE Fungal infection
DMXOELT ID DMXOELT
DMXOELT DN Midazolam
DMXOELT HS Approved
DMXOELT SN Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
DMXOELT CP Roche Pharmaceuticals
DMXOELT TC Hypnotics and Sedatives
DMXOELT DT Small molecular drug
DMXOELT PC 4192
DMXOELT MW 325.8
DMXOELT FM C18H13ClFN3
DMXOELT IC InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
DMXOELT CS CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F
DMXOELT IK DDLIGBOFAVUZHB-UHFFFAOYSA-N
DMXOELT IU 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
DMXOELT CA CAS 59467-70-8
DMXOELT CB CHEBI:6931
DMXOELT DE Irritability; Epilepsy
DME2PY5 ID DME2PY5
DME2PY5 DN Midodrine
DME2PY5 HS Approved
DME2PY5 SN Alphamine; Amatine; Gutron; Hipertan; Metligene; Midamine; Midodrin; Midodrina; Midodrinum; ProAmatine; MIDODRINE HYDROCHLORIDE; Midodrine HCL; Midodrine Monohydrochloride; Midodrine hydrochloride [USAN]; A 4020 Linz; St 1085; TS 701; A-4020 Linz; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride [USAN:JAN]; Midodrinum [INN-Latin]; Pro-Amatine; Proamatine (TN); ST-1085; St. Peter 224; Midodrine hydrochloride (JAN/USAN); Pro-Amatine (TN); DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; (+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride
DME2PY5 CP Shire Canada Inc
DME2PY5 TC Vasoconstrictor Agents
DME2PY5 DT Small molecular drug
DME2PY5 PC 4195
DME2PY5 MW 254.28
DME2PY5 FM C12H18N2O4
DME2PY5 IC InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
DME2PY5 CS COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
DME2PY5 IK PTKSEFOSCHHMPD-UHFFFAOYSA-N
DME2PY5 IU 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide
DME2PY5 CA CAS 42794-76-3
DME2PY5 CB CHEBI:6933
DME2PY5 DE Orthostatic hypotension
DMI6E0R ID DMI6E0R
DMI6E0R DN Midostaurin
DMI6E0R HS Approved
DMI6E0R SN PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251
DMI6E0R CP Novartis
DMI6E0R TC Anticancer Agents
DMI6E0R DT Small molecular drug
DMI6E0R PC 9829523
DMI6E0R MW 570.6
DMI6E0R FM C35H30N4O4
DMI6E0R IC InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
DMI6E0R CS C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
DMI6E0R IK BMGQWWVMWDBQGC-IIFHNQTCSA-N
DMI6E0R IU N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
DMI6E0R CA CAS 120685-11-2
DMI6E0R CB CHEBI:63452
DMI6E0R DE Acute myeloid leukaemia; Systemic mastocytosis; Colorectal cancer; Chronic myelomonocytic leukaemia
DMGZQEF ID DMGZQEF
DMGZQEF DN Mifepristone
DMGZQEF HS Approved
DMGZQEF SN Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma
DMGZQEF CP HRA Pharma
DMGZQEF DT Small molecular drug
DMGZQEF PC 55245
DMGZQEF MW 429.6
DMGZQEF FM C29H35NO2
DMGZQEF IC InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
DMGZQEF CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
DMGZQEF IK VKHAHZOOUSRJNA-GCNJZUOMSA-N
DMGZQEF IU (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMGZQEF CA CAS 84371-65-3
DMGZQEF CB CHEBI:50692
DMGZQEF DE Cushing disease
DMFIQ2H ID DMFIQ2H
DMFIQ2H DN Migalastat
DMFIQ2H HS Approved
DMFIQ2H SN DDIG; D-Galactitol, 1,5-dideoxy-1,5-imino; (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-iminogalactitol; 2-(Hydroxymethyl)-3,4,5-piperidinetriol hydrochloride
DMFIQ2H CP Amicus Therapeutics
DMFIQ2H DT Small molecular drug
DMFIQ2H PC 176077
DMFIQ2H MW 163.17
DMFIQ2H FM C6H13NO4
DMFIQ2H IC InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5+,6-/m1/s1
DMFIQ2H CS C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O
DMFIQ2H IK LXBIFEVIBLOUGU-DPYQTVNSSA-N
DMFIQ2H IU (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMFIQ2H CA CAS 108147-54-2
DMFIQ2H CB CHEBI:135923
DMFIQ2H DE Fabry disease
DMXBQAM ID DMXBQAM
DMXBQAM DN Miglitol
DMXBQAM HS Approved
DMXBQAM SN Diastabol; Glyset; Plumarol; Seibule; Glyset (TN); SK-983; Bay-m-1099; Miglitol (JAN/USAN/INN); (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMXBQAM TC Hypoglycemic Agents
DMXBQAM DT Small molecular drug
DMXBQAM PC 441314
DMXBQAM MW 207.22
DMXBQAM FM C8H17NO5
DMXBQAM IC InChI=1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
DMXBQAM CS C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O
DMXBQAM IK IBAQFPQHRJAVAV-ULAWRXDQSA-N
DMXBQAM IU (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
DMXBQAM CA CAS 72432-03-2
DMXBQAM CB CHEBI:6935
DMXBQAM DE Diabetic complication
DM5J64S ID DM5J64S
DM5J64S DN Miglustat
DM5J64S HS Approved
DM5J64S SN BuDNJ; Butyldeoxynojirimycin; Miglustatum; NBV; Vevesca; Zavesca; Miglustat [USAN]; OGT 918; SC 48334; SC48334; Miglustat, Hydrochloride; N-Butyl deoxynojirimycin; N-Butyl dnj; N-Butyldeoxynojirimycin; N-Butylmoranoline; NB-DNJ; OGT-918; SC-48334; Zavesca (TN); Miglustat (USAN/INN); N-Bu-DNJ; N-Butyl-DNJ; N-Butyl-deoxynojirimycin; N-(n-Butyl)deoxynojirimycin; N-butyl-1-deoxynojirimycin; N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Dideoxy-1,5-N-butylimino-D-glucitol
DM5J64S TC Anti-HIV Agents
DM5J64S DT Small molecular drug
DM5J64S PC 51634
DM5J64S MW 219.28
DM5J64S FM C10H21NO4
DM5J64S IC InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1
DM5J64S CS CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
DM5J64S IK UQRORFVVSGFNRO-UTINFBMNSA-N
DM5J64S IU (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
DM5J64S CA CAS 72599-27-0
DM5J64S CB CHEBI:50381
DM5J64S DE Type 1 gaucher disease
DMBFE74 ID DMBFE74
DMBFE74 DN Milnacipran
DMBFE74 HS Approved
DMBFE74 SN Ixel; Midalcipran; Milnacipranum; Toledomin; Milnacipran [INN]; Milnacipranum [Latin]; F 2207; F-2207; Ixel (TN); Milnacipran(INN); Savella (TN); (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; 1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
DMBFE74 CP Silesia Laboratories
DMBFE74 TC Antidepressants
DMBFE74 DT Small molecular drug
DMBFE74 PC 65833
DMBFE74 MW 246.35
DMBFE74 FM C15H22N2O
DMBFE74 IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1
DMBFE74 CS CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2
DMBFE74 IK GJJFMKBJSRMPLA-HIFRSBDPSA-N
DMBFE74 IU (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMBFE74 CA CAS 96847-55-1
DMBFE74 CB CHEBI:94468
DMBFE74 DE Depression
DM8TUPF ID DM8TUPF
DM8TUPF DN Milrinone
DM8TUPF HS Approved
DM8TUPF SN Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
DM8TUPF CP Sanofi-Synthelabo Inc
DM8TUPF TC Cardiotonic Agents
DM8TUPF DT Small molecular drug
DM8TUPF PC 4197
DM8TUPF MW 211.22
DM8TUPF FM C12H9N3O
DM8TUPF IC InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)
DM8TUPF CS CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
DM8TUPF IK PZRHRDRVRGEVNW-UHFFFAOYSA-N
DM8TUPF IU 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
DM8TUPF CA CAS 78415-72-2
DM8TUPF CB CHEBI:50693
DM8TUPF DE Congestive heart failure
DMND304 ID DMND304
DMND304 DN Miltefosine
DMND304 HS Approved
DMND304 SN HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
DMND304 CP Aeterna Zentaris
DMND304 TC Antifungal Agents
DMND304 DT Small molecular drug
DMND304 PC 3599
DMND304 MW 407.6
DMND304 FM C21H46NO4P
DMND304 IC InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
DMND304 CS CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
DMND304 IK PQLXHQMOHUQAKB-UHFFFAOYSA-N
DMND304 IU hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
DMND304 CA CAS 58066-85-6
DMND304 CB CHEBI:75283
DMND304 DE Leishmaniasis; Visceral leishmaniasis
DM0EP7M ID DM0EP7M
DM0EP7M DN Minaprine
DM0EP7M HS Approved
DM0EP7M SN Brantur; Cantor; Minaprina; Minaprinum; Minaprine dihydrochloride; AGR 1240; CB 30038; Cantor (TN); Minaprina [INN-Spanish]; Minaprinum [INN-Latin]; Minaprine (USAN/INN); Minaprine [USAN:BAN:INN]; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
DM0EP7M TC Antidepressants
DM0EP7M DT Small molecular drug
DM0EP7M PC 4199
DM0EP7M MW 298.4
DM0EP7M FM C17H22N4O
DM0EP7M IC InChI=1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
DM0EP7M CS CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
DM0EP7M IK LDMWSLGGVTVJPG-UHFFFAOYSA-N
DM0EP7M IU 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
DM0EP7M CA CAS 25905-77-5
DM0EP7M CB CHEBI:51038
DM0EP7M DE Depression
DMVN5OH ID DMVN5OH
DMVN5OH DN Minocycline
DMVN5OH HS Approved
DMVN5OH SN Borymycin; MINO; MIY; Minociclina; Minociclinum; Minocin; Minocline; Minocyclin; Minocyclinum; Minocycline Monohydrochloride; CL 59806; Lactoferrin B & Minocycline; Lactoferrin H & Minocycline; Minociclina [INN-Spanish]; Minocin (Hydrochloride); Minocin (TN); Minocyclinum [INN-Latin]; Vectrin (Hydrochloride); CRL-1605 & Minocycline; Minocycline (USAN/INN); Minocycline [USAN:BAN:INN]; (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; 7-Dimethylamino-6-demethyl-6-deoxytetracycline
DMVN5OH CP Lederle Laboratories
DMVN5OH TC Antibiotics
DMVN5OH DT Small molecular drug
DMVN5OH PC 54675783
DMVN5OH MW 457.5
DMVN5OH FM C23H27N3O7
DMVN5OH IC InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
DMVN5OH CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
DMVN5OH IK FFTVPQUHLQBXQZ-KVUCHLLUSA-N
DMVN5OH IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMVN5OH CA CAS 10118-90-8
DMVN5OH CB CHEBI:50694
DMVN5OH DE Bacterial infection; Rosacea
DM50PMY ID DM50PMY
DM50PMY DN Minodronate
DM50PMY HS Approved
DM50PMY SN Minodronic acid; 180064-38-4; (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid; Recalbon; Bonoteo; BPH 261; ONO 5920; YH 529; Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-; UNII-40SGR63TGL; YM 529; 40SGR63TGL; Ono-5920; NSC725590; YH-529; 127657-42-5; NCGC00183829-01; AK119862; Phosphonic acid, (1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-; (1-hydroxy-2-{imidazo[1,2-a]pyridin-3-yl}-1-phosphonoethyl)phosphonic acid; minodronic acid
DM50PMY DT Small molecular drug
DM50PMY PC 130956
DM50PMY MW 322.15
DM50PMY FM C9H12N2O7P2
DM50PMY IC InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)
DM50PMY CS C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM50PMY IK VMMKGHQPQIEGSQ-UHFFFAOYSA-N
DM50PMY IU (1-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid
DM50PMY CA CAS 180064-38-4
DM50PMY DE Osteoporosis
DMA2Z4F ID DMA2Z4F
DMA2Z4F DN Minoxidil
DMA2Z4F HS Approved
DMA2Z4F SN Alopexil; Alostil; Loniten; Lonolox; Minodyl; Minossidile; Minoxidilum; Minoxigaine; Minoximen; Neoxidil; Normoxidil; Pierminox; Prexidil; Regaine; RiUP; Rogaine; Theroxidil; Tricoxidil; Trocoxidil; MINOXIDIL EXTRA STRENGTH FOR MEN; Men s Rogaine Foam; Mens Rogaine Foam; Minossidile [Italian]; Minoxidil Pfizer Brand; PfizerBrand of Minoxidil; Rogaine Extra Strength for Men; Rogaine for Men; Rogaine for Women; M 4145; M1389; U 10858; Apo-Gain; Gen-Minoxidil; Loniten (TN); MINOXIDIL (FOR MEN); MINOXIDIL (FOR WOMEN); MINOXIDIL EXTRA STRENGTH (FOR MEN); Men's Rogaine; Minoxidilum [INN-Latin]; ROGAINE (FOR MEN); ROGAINE (FOR WOMEN); ROGAINE EXTRA STRENGTH (FOR MEN); Regaine (TN); Riup (TN); Rogaine (TN); TM-160; U-10858; Minoxidil (USP/INN); Minoxidil [USAN:BAN:INN]; U-10,858; Rogaine, Regaine, Avacor and Mintop, Minoxidil; Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide; 2,3-Dihydro-3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine; 2,4-Diamino-6-piperidinilpirimidina-3-ossido; 2,4-Diamino-6-piperidinilpirimidina-3-ossido [Italian]; 2,4-Diamino-6-piperidino-pyrimidine-3-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-N-oxide; 2,4-Diamino-6-piperidinopyrimidine 3-oxide; 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide; 2,6-Diamino-4-piperidinopyrimidin-1-oxid; 3-hydroxy-2-imino-6-(1-piperidyl)pyrimidin-4-amine; 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine; 6-(1-Piperidinyl)-2,4-pyrimidinediamine 3-oxide; 6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide; 6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine; 6-Piperidino-2,4-diaminopyrimidine 3-oxide; 6-[1-Piperidinyl]pyrimidine-2,4-diamine 3 oxide
DMA2Z4F CP Upjohn Corporation
DMA2Z4F TC Antihypertensive Agents
DMA2Z4F DT Small molecular drug
DMA2Z4F PC 4201
DMA2Z4F MW 209.25
DMA2Z4F FM C9H15N5O
DMA2Z4F IC InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6,11,15H,1-5,10H2
DMA2Z4F CS C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
DMA2Z4F IK ZIMGGGWCDYVHOY-UHFFFAOYSA-N
DMA2Z4F IU 3-hydroxy-2-imino-6-piperidin-1-ylpyrimidin-4-amine
DMA2Z4F CA CAS 38304-91-5
DMA2Z4F CB CHEBI:6942
DMA2Z4F DE Hypertension
DMGSRN1 ID DMGSRN1
DMGSRN1 DN Mipomersen
DMGSRN1 HS Approved
DMGSRN1 SN Mipomersen
DMGSRN1 CP Isis Pharmaceuticals
DMGSRN1 TC Antisense
DMGSRN1 DT Antisense drug
DMGSRN1 SQ 5'-GCCUCAGTCTGCTTCGCACC
DMGSRN1 PC 71301230
DMGSRN1 MW 7158
DMGSRN1 FM C230H305N67O122P19S19-19
DMGSRN1 IC InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-131(112(400-141)70-381-422(327,328)442-136-50-146(283-66-108(12)196(302)275-228(283)320)406-118(136)76-387-427(337,338)448-140-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)409-120(140)78-389-428(339,340)446-138-52-148(292-91-250-151-186(240)246-89-248-188(151)292)407-121(138)79-390-430(343,344)450-169-124(413-204(160(169)373-37-27-363-17)286-59-101(5)181(235)260-221(286)313)83-394-435(353,354)455-174-128(417-209(165(174)378-42-32-368-22)291-68-110(14)198(304)277-230(291)322)87-396-434(351,352)453-172-126(415-207(163(172)376-40-30-366-20)289-62-104(8)184(238)263-224(289)316)85-395-433(349,350)452-171-123(412-206(162(171)375-39-29-365-19)288-61-103(7)183(237)262-223(288)315)82-393-432(347,348)449-168-111(69-298)410-211(159(168)372-36-26-362-16)296-95-254-155-192(296)267-215(244)271-201(155)307)439-420(323,324)384-74-117-137(51-147(405-117)284-67-109(13)197(303)276-229(284)321)444-425(333,334)388-77-119-139(53-149(408-119)293-92-252-153-190(293)265-213(242)269-199(153)305)447-426(335,336)386-71-113-132(46-142(401-113)279-56-98(2)178(232)257-218(279)310)440-421(325,326)383-73-115-135(49-145(403-115)282-65-107(11)195(301)274-227(282)319)443-424(331,332)385-75-116-134(48-144(404-116)281-64-106(10)194(300)273-226(281)318)441-423(329,330)382-72-114-133(47-143(402-114)280-57-99(3)179(233)258-219(280)311)445-429(341,342)392-81-129-176(167(380-44-34-370-24)212(419-129)297-96-255-156-193(297)268-216(245)272-202(156)308)457-438(359,360)398-86-127-173(164(377-41-31-367-21)208(416-127)290-63-105(9)185(239)264-225(290)317)454-436(355,356)399-88-130-175(166(379-43-33-369-23)210(418-130)295-94-251-152-187(241)247-90-249-189(152)295)456-437(357,358)397-84-125-170(161(374-38-28-364-18)205(414-125)287-60-102(6)182(236)261-222(287)314)451-431(345,346)391-80-122-157(299)158(371-35-25-361-15)203(411-122)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)/p-19/t111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123-,124-,125+,126-,127+,128-,129-,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,157+,158+,159-,160-,161+,162-,163-,164+,165-,166+,167-,168-,169-,170+,171-,172-,173+,174-,175+,176-,203+,204-,205+,206-,207-,208+,209-,210+,211-,212-/m1/s1
DMGSRN1 CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)([O-])S[C@H]3C[C@@H](O[C@@H]3COP(=O)([O-])S[C@H]4C[C@@H](O[C@@H]4COP(=O)([O-])S[C@H]5C[C@@H](O[C@@H]5COP(=O)([O-])S[C@H]6C[C@@H](O[C@@H]6COP(=O)([O-])S[C@H]7C[C@@H](O[C@@H]7COP(=O)([O-])S[C@H]8C[C@@H](O[C@@H]8COP(=O)([O-])S[C@H]9C[C@@H](O[C@@H]9COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=O)([O-])S[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)SP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)SP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)SP(=O)([O-])OC[C@H]1[C@@H]([C@@H]([C@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)O
DMGSRN1 IK TZRFSLHOCZEXCC-HIVFKXHNSA-A
DMGSRN1 IU [(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2R,3R,4S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4S,5R)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4R,5S)-3-[[(2S,3S,4R,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2S,3S,4S,5S)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyloxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-oxidophosphoryl]sulfanyl-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-[(2R,3R,4S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]sulfanylphosphinate
DMGSRN1 CA CAS 1000120-98-8
DMGSRN1 DE Familial hypercholesterolemia
DMS1GYT ID DMS1GYT
DMS1GYT DN Mirabegron
DMS1GYT HS Approved
DMS1GYT SN Myrbetriq (TN)
DMS1GYT CP Astellas
DMS1GYT DT Small molecular drug
DMS1GYT PC 9865528
DMS1GYT MW 396.5
DMS1GYT FM C21H24N4O2S
DMS1GYT IC InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
DMS1GYT CS C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
DMS1GYT IK PBAPPPCECJKMCM-IBGZPJMESA-N
DMS1GYT IU 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide
DMS1GYT CA CAS 223673-61-8
DMS1GYT CB CHEBI:65349
DMS1GYT DE Overactive bladder
DML53ZJ ID DML53ZJ
DML53ZJ DN Mirtazapine
DML53ZJ HS Approved
DML53ZJ SN Avanza; Axit; Azamianserin; Mepirzapin; Mepirzepine; Mirtabene; Mirtaz; Mirtazapina; Mirtazapinum; Mirtazepine; Mirtazipine; Mirtazon; Norset; Promyrtil; Remergil; Remergon; Remeron; Rexer; Zispin; Celltech brand of mirtazapine; Mundogen brand of mirtazapine; Organon brand of mirtazapine; Remeron SolTab; ORG 3770; Afloyan (TN); Alphamirt (TN); Alphazagen (TN); Amirel (TN); Arintapin (TN); Arintapina (TN); Avanza (TN); Axit (TN); Bexzis (TN); Calixta (TN); Ciblex (TN); Combar (TN); Comenter (TN); Divaril (TN); Esprital (TN); Finmirtaza (TN); Finpharma (TN); Finscope (TN); Genamirt (TN); Hexazipin (TN); Loxozapin (TN); ME-2040; Medizapin (TN); Miralix (TN); Mirap (TN); Mirazep (TN); Miro (TN); Miron (TN); Mirta (TN); Mirtabene (TN); Mirtachem (TN); Mirtacur (TN); Mirtadepi (TN); Mirtagamma (TN); Mirtal (TN); Mirtalich (TN); Mirtalphagen (TN); Mirtamed (TN); Mirtamerck (TN); Mirtapax (TN); Mirtapharm (TN); Mirtapin(TN); Mirtaratio (TN); Mirtaril (TN); Mirtaron (TN); Mirtascope (TN); Mirtasole (TN); Mirtastad (TN); Mirtastada (TN); Mirtatifi (TN); Mirtatsapiini (TN); Mirtawin (TN); Mirtaz (TN); Mirtazapin (TN);Mirtazapina (TN); Mirtazapina [INN-Spanish]; Mirtazapinum [INN-Latin]; Mirtazelon (TN); Mirtazen (TN); Mirtazep (TN); Mirtazepin (TN); Mirtazon (TN); Mirtazza (TN); Mirtel (TN); Mirtoral (TN); Mirzagen (TN); Mirzalux (TN); Mirzaten (TN); Mitrazen (TN); Mizapin (TN); Mizapin Sol (TN); Norset (TN); Noxibel (TN); Pharmasole (TN); Pharmazepine (TN); Promyrtil (TN); Remergil (TN); Remergon (TN); Remeron (TN); Remeron SolTab (TN); Remirta (TN); Rexer (TN); SolTab (TN); Tarzapine (TN); Tazamel (TN); Tazapin (TN); Tazascope (TN); Tirzamed (TN); Valdren (TN); Vastat (TN); Zapex (TN); Zicomber (TN); Zismirt (TN); Zispin (TN); Zispin SolTab (TN); Zuleptan (TN); Mirtazapine [USAN:BAN:INN]; Mirtazapine [USAN:INN:BAN]; Mirzaten Q-Tab (TN); Zistap. (TN); Mirtazapine (JAN/USAN/INN); (1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; (N-methyl-11C)mirtazapine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine; 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; 6-Azamianserin
DML53ZJ CP Organon International
DML53ZJ TC Antidepressants
DML53ZJ DT Small molecular drug
DML53ZJ PC 4205
DML53ZJ MW 265.35
DML53ZJ FM C17H19N3
DML53ZJ IC InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
DML53ZJ CS CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
DML53ZJ IK RONZAEMNMFQXRA-UHFFFAOYSA-N
DML53ZJ IU 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
DML53ZJ CA CAS 85650-52-8
DML53ZJ CB CHEBI:6950
DML53ZJ DE Depression
DMHVJFK ID DMHVJFK
DMHVJFK DN Misoprostol
DMHVJFK HS Approved
DMHVJFK SN Cytotec; GyMiso; Isprelor; Misopess; Misoprostolum; Misotol; SC 29333; Cytotec (TN); Misoprostolum [INN-Latin]; SC-29333; XP-16J; Misoprostol (JAN/USAN/INN); Methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate; Methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate; (+/-)-15-Deoxy-(16RS)-16-hydroxy-16-methylprostaglandin E1 methyl ester; (11-alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester
DMHVJFK CP Pfizer Pharmaceuticals
DMHVJFK TC Abortifacient Agents
DMHVJFK DT Small molecular drug
DMHVJFK PC 5282381
DMHVJFK MW 382.5
DMHVJFK FM C22H38O5
DMHVJFK IC InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
DMHVJFK CS CCCCC(C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O
DMHVJFK IK OJLOPKGSLYJEMD-URPKTTJQSA-N
DMHVJFK IU methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
DMHVJFK CA CAS 59122-46-2
DMHVJFK CB CHEBI:94387
DMHVJFK DE Medical abortion
DMP8HEL ID DMP8HEL
DMP8HEL DN Mitiglinide
DMP8HEL HS Approved
DMP8HEL SN Mitiglinide calcium; Mitiglinide calcium hydrate; KAD 1229; S21403; Glufast (TN); Kad-1229; Calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate; Calcium (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate; (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid; 2-Benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate
DMP8HEL CP Elixir Pharmaceuticals
DMP8HEL TC Hypoglycemic Agents
DMP8HEL DT Small molecular drug
DMP8HEL PC 121891
DMP8HEL MW 315.4
DMP8HEL FM C19H25NO3
DMP8HEL IC InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
DMP8HEL CS C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O
DMP8HEL IK WPGGHFDDFPHPOB-BBWFWOEESA-N
DMP8HEL IU (2S)-4-[(3aR,7aS)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid
DMP8HEL CA CAS 145375-43-5
DMP8HEL CB CHEBI:135349
DMP8HEL DE Diabetic complication
DMH0ZJE ID DMH0ZJE
DMH0ZJE DN Mitomycin
DMH0ZJE HS Approved
DMH0ZJE SN Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free
DMH0ZJE TC Anticancer Agents
DMH0ZJE DT Small molecular drug
DMH0ZJE PC 5746
DMH0ZJE MW 334.33
DMH0ZJE FM C15H18N4O5
DMH0ZJE IC InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
DMH0ZJE CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
DMH0ZJE IK NWIBSHFKIJFRCO-WUDYKRTCSA-N
DMH0ZJE IU [(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
DMH0ZJE CA CAS 50-07-7
DMH0ZJE CB CHEBI:27504
DMH0ZJE DE Breast cancer; Gastrointestinal cancer; Solid tumour/cancer
DM4PF81 ID DM4PF81
DM4PF81 DN Mitomycin A
DM4PF81 HS Approved
DM4PF81 SN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester); [(1ar,8r,8as,8br)-6,8a-dimethoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aR-(1aalpha,8beta,8aalpha,8balpha))-(9CI)
DM4PF81 TC Anticancer Agents
DM4PF81 DT Small molecular drug
DM4PF81 PC 19972
DM4PF81 MW 349.34
DM4PF81 FM C16H19N3O6
DM4PF81 IC InChI=1S/C16H19N3O6/c1-6-11(20)10-9(12(21)13(6)23-2)7(5-25-15(17)22)16(24-3)14-8(18-14)4-19(10)16/h7-8,14,18H,4-5H2,1-3H3,(H2,17,22)/t7-,8+,14+,16-/m1/s1
DM4PF81 CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)OC
DM4PF81 IK HYFMSAFINFJTFH-NGSRAFSJSA-N
DM4PF81 IU [(4S,6S,7R,8S)-7,11-dimethoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
DM4PF81 CA CAS 4055-39-4
DM4PF81 CB CHEBI:85412
DM4PF81 DE Solid tumour/cancer
DMU1GX0 ID DMU1GX0
DMU1GX0 DN Mitotane
DMU1GX0 HS Approved
DMU1GX0 SN Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
DMU1GX0 CP Bristol Myers Squibb
DMU1GX0 TC Anticancer Agents
DMU1GX0 DT Small molecular drug
DMU1GX0 PC 4211
DMU1GX0 MW 320
DMU1GX0 FM C14H10Cl4
DMU1GX0 IC InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
DMU1GX0 CS C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
DMU1GX0 IK JWBOIMRXGHLCPP-UHFFFAOYSA-N
DMU1GX0 IU 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
DMU1GX0 CA CAS 53-19-0
DMU1GX0 CB CHEBI:6954
DMU1GX0 DE Adrenocortical carcinoma
DMM39BF ID DMM39BF
DMM39BF DN Mitoxantrone
DMM39BF HS Approved
DMM39BF SN DHAD; DHAQ; Dihydroxyanthraquinone; MIX; Misostol; Mitoxanthrone; Mitoxantron; Mitoxantrona; Mitoxantronum; Mitozantrone; DHAQ HCl; Mitoxantrone [INN]; Mitozantrone hydrochloride; Mitoxantrone 2HCl; Liposome Encapsulated Mitoxantrone (LEM); Misostol (TN); Mitoxantrona [INN-Spanish]; Mitoxantrone (INN); Mitoxantrone (free base); Mitoxantronum [INN-Latin]; Novantrone (TN); AN-584/42007670; Novantrone(R) (mitoxantrone for injection concentrate); DHAQ (*Diacetate salt*); MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI)
DMM39BF CP Serono
DMM39BF TC Analgesics
DMM39BF DT Small molecular drug
DMM39BF PC 4212
DMM39BF MW 444.5
DMM39BF FM C22H28N4O6
DMM39BF IC InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
DMM39BF CS C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
DMM39BF IK KKZJGLLVHKMTCM-UHFFFAOYSA-N
DMM39BF IU 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
DMM39BF CA CAS 65271-80-9
DMM39BF CB CHEBI:50729
DMM39BF DE Solid tumour/cancer; Non-hodgkin lymphoma
DM473VD ID DM473VD
DM473VD DN Mivacurium
DM473VD HS Approved
DM473VD SN Mivacron; Chlorure de mivacurium; Chlorure de mivacurium [French]; Cloruro de mivacurio; Cloruro de mivacurio [Spanish]; MIVACURIUM CHLORIDE; Mivacurii chloridum; Mivacurii chloridum [Latin]; BW B109OU dichloride; BWB109OU; BW-B1090U; BW-B109OU; MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER; Mivacron (TN); Mivacurium chloride(USAN/INN); Mivacurium chloride [USAN:INN:BAN]; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate; Bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride; (R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
DM473VD TC Neuromuscular Nondepolarizing Agents
DM473VD DT Small molecular drug
DM473VD PC 5281042
DM473VD MW 1029.3
DM473VD FM C58H80N2O14+2
DM473VD IC InChI=1S/C58H80N2O14/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10/h13-14,31-38,45-46H,15-30H2,1-12H3/q+2/b14-13+/t45-,46-,59?,60?/m1/s1
DM473VD CS C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C
DM473VD IK ILVYCEVXHALBSC-OTBYEXOQSA-N
DM473VD IU bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
DM473VD CA CAS 133814-19-4
DM473VD CB CHEBI:6958
DM473VD DE Anaesthesia
DM1FDN8 ID DM1FDN8
DM1FDN8 DN Mizolastine
DM1FDN8 HS Approved
DM1FDN8 SN Mistalin; Mistamine; Mizolastina; Mizolastinum; Mizolen; Mizollen; Zolim; Zolistam; Zolistan; Allphar brand of mizolastine; Galderma brand of mizolastine; Mizolastine [INN]; Novag brand of mizolastine; Sanofi Synthelabo brand of mizolastine; Schwarz brand of mizolastine; MKC-431; Mizolastina [INN-Spanish]; Mizolastinum [INN-Latin]; Mizollen (TN); SL 85.0324; Mizolastine (JAN/INN); SL-85.0324; 2-((1-(1-(p-Fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3H)-pyrimidinone; 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
DM1FDN8 TC Antiallergic Agents
DM1FDN8 DT Small molecular drug
DM1FDN8 PC 65906
DM1FDN8 MW 432.5
DM1FDN8 FM C24H25FN6O
DM1FDN8 IC InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32)
DM1FDN8 CS CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
DM1FDN8 IK PVLJETXTTWAYEW-UHFFFAOYSA-N
DM1FDN8 IU 2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1H-pyrimidin-6-one
DM1FDN8 CA CAS 108612-45-9
DM1FDN8 CB CHEBI:31857
DM1FDN8 DE Allergic rhinitis
DMW6F0S ID DMW6F0S
DMW6F0S DN Mizoribine
DMW6F0S HS Approved
DMW6F0S SN Bredinin; Bredinine; MZR; Mizoribina; Mizoribinum; M 3047; Bredinin (TN); HE-69; HS-0046; Mizoribina [INN-Spanish]; Mizoribine [INN:JAN]; Mizoribinum [INN-Latin]; Mizoribine (JAN/INN); Bredinin, HE 69, NSC 289637, MZB, Mizoribine; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide;4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; 4-carbamoyl-1-b-d-ribofuranosylimidazolium-5-olate; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide
DMW6F0S TC Antimetabolites
DMW6F0S DT Small molecular drug
DMW6F0S PC 104762
DMW6F0S MW 259.22
DMW6F0S FM C9H13N3O6
DMW6F0S IC InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
DMW6F0S CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)N
DMW6F0S IK HZQDCMWJEBCWBR-UUOKFMHZSA-N
DMW6F0S IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide
DMW6F0S CA CAS 50924-49-7
DMW6F0S CB CHEBI:31858
DMW6F0S DE Transplant rejection
DM215WE ID DM215WE
DM215WE DN MK-1439
DM215WE HS Approved
DM215WE SN Doravirine; 1338225-97-0; UNII-913P6LK81M; MK1439; 913P6LK81M; MK 1439
DM215WE CP Merck & Co.
DM215WE DT Small molecular drug
DM215WE PC 58460047
DM215WE MW 425.7
DM215WE FM C17H11ClF3N5O3
DM215WE IC InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
DM215WE CS CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F
DM215WE IK ZIAOVIPSKUPPQW-UHFFFAOYSA-N
DM215WE IU 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile
DM215WE CA CAS 1338225-97-0
DM215WE DE Human immunodeficiency virus infection
DMBYNW0 ID DMBYNW0
DMBYNW0 DN MK-3475
DMBYNW0 HS Approved
DMBYNW0 CP Merck
DMBYNW0 DT Monoclonal antibody
DMBYNW0 DE Melanoma
DMOB58Q ID DMOB58Q
DMOB58Q DN MK-8228
DMOB58Q HS Approved
DMOB58Q SN Letermovir
DMOB58Q CP Merck & Co.
DMOB58Q DT Small molecular drug
DMOB58Q PC 45138674
DMOB58Q MW 572.5
DMOB58Q FM C29H28F4N4O4
DMOB58Q IC InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
DMOB58Q CS COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
DMOB58Q IK FWYSMLBETOMXAG-QHCPKHFHSA-N
DMOB58Q IU 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
DMOB58Q CA CAS 917389-32-3
DMOB58Q DE Cytomegalovirus Disease; Cytomegalovirus infection
DMP2LZ8 ID DMP2LZ8
DMP2LZ8 DN MLN0002
DMP2LZ8 HS Approved
DMP2LZ8 SN Vedolizumab
DMP2LZ8 CP Takeda
DMP2LZ8 SQ Heavy Chain Sequence: QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain SequenceDVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMP2LZ8 DE Crohn disease
DMCMETN ID DMCMETN
DMCMETN DN MLN9708
DMCMETN HS Approved
DMCMETN CP Millennium Pharmaceuticals
DMCMETN DT Small molecular drug
DMCMETN PC 49867936
DMCMETN MW 517.1
DMCMETN FM C20H23BCl2N2O9
DMCMETN IC InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1
DMCMETN CS B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
DMCMETN IK YTXSYWAKVMZICI-PVCZSOGJSA-N
DMCMETN IU 4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid
DMCMETN CA CAS 1201902-80-8
DMCMETN DE Amyloidosis; Multiple myeloma
DMNZWL7 ID DMNZWL7
DMNZWL7 DN Moclobemide
DMNZWL7 HS Approved
DMNZWL7 SN Arima; Aurorex; Aurorix; Deprenorm; Feraken; Manerix; Moclaime; Moclamide; Moclamine; Moclix; Moclobamide; Moclobemid; Moclobemida; Moclobemidum; Moclobeta; Moclodura; Moclonorm; NovoMoclobemide; NuMoclobemide; Rimoc; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo Moclobemide; Apotex Brand of Moclobemide; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Betapharm Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; Ct Arzneimittel Brand of Moclobemide; DBL Moclobemide; Esparma Brand of Moclobemide; Faulding Brand of Moclobemide; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclobemid AZU; Moclobemid Puren; Moclobemid Stada; Moclobemid ratiopharm; Moclobemid von ct; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Novo Moclobemide; Novopharm Brand of Moclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; PMS Moclobemide; Pharmascience Brand of Moclobemide; Ratiopharm Brand of Moclobemide; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; CBMicro_048319; Moclobemid 1A Pharma; Moclobemid1A Pharma; Moclobemide 1A Brand; Ro 11 1163; AZU, Moclobemid; Apo-Moclobemide; Aurorix (TN); Ct-Arzneimittel Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Manerix (TN); Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobemida [INN-Spanish]; Moclobemide Nu-Pharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Moclobemidum [INN-Latin]; Novo-Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Ro 11-1163; Stada, Moclobemid; Von ct, Moclobemid; GNF-PF-695; Moclobemide (USAN/INN); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Ro 11-1163/000; Ro-11-1163; P-Chloro-N-(2-morpholinoethyl)benzamide; 1A Brand of Moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
DMNZWL7 CP Hoffmann-La Roche pharmaceutical company
DMNZWL7 TC Antidepressants
DMNZWL7 DT Small molecular drug
DMNZWL7 PC 4235
DMNZWL7 MW 268.74
DMNZWL7 FM C13H17ClN2O2
DMNZWL7 IC InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
DMNZWL7 CS C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
DMNZWL7 IK YHXISWVBGDMDLQ-UHFFFAOYSA-N
DMNZWL7 IU 4-chloro-N-(2-morpholin-4-ylethyl)benzamide
DMNZWL7 CA CAS 71320-77-9
DMNZWL7 CB CHEBI:83531
DMNZWL7 DE Skin imperfections; Depression
DMYILBE ID DMYILBE
DMYILBE DN Modafinil
DMYILBE HS Approved
DMYILBE SN Provigil; Modiodal
DMYILBE CP Cephalon Inc
DMYILBE TC Neurology Agents
DMYILBE DT Small molecular drug
DMYILBE PC 4236
DMYILBE MW 273.4
DMYILBE FM C15H15NO2S
DMYILBE IC InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)
DMYILBE CS C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
DMYILBE IK YFGHCGITMMYXAQ-UHFFFAOYSA-N
DMYILBE IU 2-benzhydrylsulfinylacetamide
DMYILBE CA CAS 68693-11-8
DMYILBE CB CHEBI:77585
DMYILBE DE Narcolepsy; Brain injury; Bipolar disorder
DM26E4B ID DM26E4B
DM26E4B DN Moexipril
DM26E4B HS Approved
DM26E4B SN Moexiprilum; Uniretic; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum [INN-Latin]; Perdix (TN); Univasc (TN); (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM26E4B CP Ucb Inc
DM26E4B TC Antihypertensive Agents
DM26E4B DT Small molecular drug
DM26E4B PC 91270
DM26E4B MW 498.6
DM26E4B FM C27H34N2O7
DM26E4B IC InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
DM26E4B CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC
DM26E4B IK UWWDHYUMIORJTA-HSQYWUDLSA-N
DM26E4B IU (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM26E4B CA CAS 103775-10-6
DM26E4B CB CHEBI:6960
DM26E4B DE Hypertension
DMISH0Z ID DMISH0Z
DMISH0Z DN Mogamulizumab
DMISH0Z HS Approved
DMISH0Z CP Kyowa Hakko Kirin
DMISH0Z DT Monoclonal antibody
DMISH0Z DE Cutaneous T-cell lymphoma; Solid tumour/cancer; T-cell leukaemia; Sezary syndrome; Mycosis fungoides
DMAH70G ID DMAH70G
DMAH70G DN Molindone
DMAH70G HS Approved
DMAH70G SN Molindona; Molindonum; Molindone Monohydrochloride; Molindona [INN-Spanish]; Molindone (INN); Molindone (MOL); Molindone [INN:BAN]; Molindonum [INN-Latin]; (+-)-Molindone; 3-Ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-4H-indol-4-one; 3-Ethyl-6,7-dihydro-2-methyl-5-(morpholinomethyl)indol-4(5H)-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one; 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-4,5,6,7-tetrahydro-1H-indol-4-one
DMAH70G TC Antipsychotic Agents
DMAH70G DT Small molecular drug
DMAH70G PC 23897
DMAH70G MW 276.37
DMAH70G FM C16H24N2O2
DMAH70G IC InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3
DMAH70G CS CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
DMAH70G IK KLPWJLBORRMFGK-UHFFFAOYSA-N
DMAH70G IU 3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one
DMAH70G CA CAS 7416-34-4
DMAH70G CB CHEBI:6965
DMAH70G DE Schizophrenia
DM9MA8O ID DM9MA8O
DM9MA8O DN Molsidomine
DM9MA8O HS Approved
DM9MA8O SN molsidomine; morsydomine; Corvaton; 25717-80-0; Molsidolat; Motazomin; SIN-10; Sydnopharm; Morial; N-Ethoxycarbonyl-3-morpholinosydnonimine; Molsidominum [INN-Latin]; Molsidomina [INN-Spanish]; Molsidomin; MLS000028573; UNII-D46583G77X; CAS 276; EINECS 247-207-4; BRN 3999414; SMR000058990; Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-; N-Carboxy-3-morpholinosydnonimine ethyl ester; N-Carboxy-3-morpholinosydnone imine ethyl ester; N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine; Corvasal; Coruno; Sydnone imine, N-carboxy-3-m
DM9MA8O DT Small molecular drug
DM9MA8O PC 5353788
DM9MA8O MW 242.23
DM9MA8O FM C9H14N4O4
DM9MA8O IC InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
DM9MA8O CS CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-]
DM9MA8O IK XLFWDASMENKTKL-UHFFFAOYSA-N
DM9MA8O IU (1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
DM9MA8O CA CAS 25717-80-0
DM9MA8O CB CHEBI:92623
DM9MA8O DE Angina pectoris
DM45OJN ID DM45OJN
DM45OJN DN Mometasone
DM45OJN HS Approved
DM45OJN SN Elocom; Mometasona; Mometasonum; Mometasona [Spanish]; Mometasonum [Latin]; Asmanex (TN); Elocon (TN); Mometasone (INN); Nasonex (TN); Twisthaler (TN); (+)-Mometasone; (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
DM45OJN CP Schering-Plough
DM45OJN TC Antiinflammatory Agents
DM45OJN DT Small molecular drug
DM45OJN PC 441335
DM45OJN MW 427.4
DM45OJN FM C22H28Cl2O4
DM45OJN IC InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
DM45OJN CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C
DM45OJN IK QLIIKPVHVRXHRI-CXSFZGCWSA-N
DM45OJN IU (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM45OJN CA CAS 105102-22-5
DM45OJN CB CHEBI:6970
DM45OJN DE Skin allergy
DMVJS2K ID DMVJS2K
DMVJS2K DN Monobenzone
DMVJS2K HS Approved
DMVJS2K SN Agerite; Alba; Benoquin; Benzoquin; Carmifal; Depigman; Dermochinona; Leucodinine; Monobenzon; Monobenzona; Monobenzonum; PBP; Pigmex; Superlite; Agerite alba; Benzyl hydroquinone; Hydrochinon monobenzylether; Hydrochinon monobenzylether [Czech]; Hydroquinone benzyl ether; Hydroquinone monobenzyl ether; ICN brand of monobenzone; Monobenzone [INN]; Monobenzyl Ether of Hydroquinone; Monobenzyl ether hydroquinone; Monobenzyl hydroquinone; Alba-Dome; Benoquin (TN); Benoquin, Monobenzone; Benzyl p-hydroxyphenyl ether; Carmifal(TN); Depigman (TN); Dermochinona (TN); HYDROQUINONE MONOBENZYL ETHER, N F; Leucodinine (TN); Monobenzon (TN); Monobenzona [INN-Spanish]; Monobenzonum [INN-Latin]; Novo-depigman; P-BENZYLOXYPHENOL; P-Hydroxyphenyl benzyl ether; Pigmex (TN); Superlite (TN); Superlite (antioxidant); Monobenzone (USP/INN); P-(BENZYLOXY)PHENOL; 4-(Benzyl-Oxy)Phenol; 4-(Benzyloxy)phenol; 4-(Benzyloxyl)phenol; 4-(Phenylmethoxy)phenol; 4-Benzyloxyphenol; 4-benzyloxy phenol; 4-phenylmethoxy-phenol; 4-phenylmethoxyphenol
DMVJS2K TC Dermatologic Agents
DMVJS2K DT Small molecular drug
DMVJS2K PC 7638
DMVJS2K MW 200.23
DMVJS2K FM C13H12O2
DMVJS2K IC InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2
DMVJS2K CS C1=CC=C(C=C1)COC2=CC=C(C=C2)O
DMVJS2K IK VYQNWZOUAUKGHI-UHFFFAOYSA-N
DMVJS2K IU 4-phenylmethoxyphenol
DMVJS2K CA CAS 103-16-2
DMVJS2K CB CHEBI:34380
DMVJS2K DE Vitiligo
DMD157S ID DMD157S
DMD157S DN Montelukast
DMD157S HS Approved
DMD157S SN Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMD157S CP Schering-Plough Corporation
DMD157S TC Antiasthmatic Agents
DMD157S DT Small molecular drug
DMD157S PC 5281040
DMD157S MW 586.2
DMD157S FM C35H36ClNO3S
DMD157S IC InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
DMD157S CS CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
DMD157S IK UCHDWCPVSPXUMX-TZIWLTJVSA-N
DMD157S IU 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMD157S CA CAS 158966-92-8
DMD157S CB CHEBI:50730
DMD157S DE Asthma
DM560Y3 ID DM560Y3
DM560Y3 DN Morantel tartrate
DM560Y3 HS Approved
DM560Y3 SN Paratect; Banminth II; MORANTEL TARTRATE SALT; Morantel tartrate [USAN]; Morantel tartrate hydrate; CP 12009-18; Morantel tartrate (USP); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-, tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)-, (E)-,tartrate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)ethenyl)-, (E)-,(R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); (E)-1,4,5,6-Tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine tartrate (1:1); 1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine; 2,3-dihydroxybutanedioic acid
DM560Y3 TC Anthelmintics
DM560Y3 DT Small molecular drug
DM560Y3 PC 6433951
DM560Y3 MW 370.4
DM560Y3 FM C16H22N2O6S
DM560Y3 IC InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/b5-4+;/t;1-,2-/m.1/s1
DM560Y3 CS CC1=C(SC=C1)/C=C/C2=NCCCN2C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DM560Y3 IK GGXQONWGCAQGNA-UUSVNAAPSA-N
DM560Y3 IU (2R,3R)-2,3-dihydroxybutanedioic acid;1-methyl-2-[(E)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4H-pyrimidine
DM560Y3 CA CAS 26155-31-7
DM560Y3 DE Mature gastrointestinal nematode infection
DMOMBJW ID DMOMBJW
DMOMBJW DN Moricizine
DMOMBJW HS Approved
DMOMBJW SN Moracizin; Moracizina; Moracizine; Moracizinum; Moricizine [USAN]; G 214; EN-313; Moracizina [INN-Spanish]; Moracizine (INN); Moracizinum [INN-Latin]; Moricizine (USAN); Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate; Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate; Ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate; Phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester; Ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate; Ethyl {10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl N-{10-[3-(morpholin-4-yl)propanoyl]-10H-phenothiazin-2-yl}carbamate; Ethyl (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)carbamate; Carbamic acid, (10-(3-(4-morpholinyl)-1-oxopropyl)-10H-phenothiazin-2-yl)-, ethyl ester
DMOMBJW CP Shire Development Inc
DMOMBJW TC Antiarrhythmic Agents
DMOMBJW DT Small molecular drug
DMOMBJW PC 34633
DMOMBJW MW 427.5
DMOMBJW FM C22H25N3O4S
DMOMBJW IC InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)
DMOMBJW CS CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4
DMOMBJW IK FUBVWMNBEHXPSU-UHFFFAOYSA-N
DMOMBJW IU ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate
DMOMBJW CA CAS 31883-05-3
DMOMBJW CB CHEBI:6997
DMOMBJW DE Arrhythmia; Heart arrhythmia
DM9UTDE ID DM9UTDE
DM9UTDE DN Morniflumate
DM9UTDE HS Approved
DM9UTDE SN morniflumate; 65847-85-0; UNII-R133MWH7X1; 2-Morpholinoethyl 2-((3-(trifluoromethyl)phenyl)amino)nicotinate; R133MWH7X1; Morniflumatum; Morniflumato; 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate; Morniflumate [USAN:INN]; Morniflumatum [INN-Latin]; Morniflumato [INN-Spanish]; Nifluminsaeure 2-morpholinoethylester; UP 164; Morniflumate (USAN); Niflumic acid beta-morpholinoethyl ester; AC1Q4JLB; AC1L2HFJ; DSSTox_RID_97471; DSSTox_CID_31587; DSSTox_GSID_57798; SCHEMBL50683; CHEMBL2105059; DTXSID6057798
DM9UTDE DT Small molecular drug
DM9UTDE PC 72106
DM9UTDE MW 395.4
DM9UTDE FM C19H20F3N3O3
DM9UTDE IC InChI=1S/C19H20F3N3O3/c20-19(21,22)14-3-1-4-15(13-14)24-17-16(5-2-6-23-17)18(26)28-12-9-25-7-10-27-11-8-25/h1-6,13H,7-12H2,(H,23,24)
DM9UTDE CS C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F
DM9UTDE IK LDXSPUSKBDTEKA-UHFFFAOYSA-N
DM9UTDE IU 2-morpholin-4-ylethyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate
DM9UTDE CA CAS 65847-85-0
DM9UTDE CB CHEBI:136018
DM9UTDE DE Otitis media
DMRMS0L ID DMRMS0L
DMRMS0L DN Morphine
DMRMS0L HS Approved
DMRMS0L SN Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr
DMRMS0L CP Eurohealth International Sarl
DMRMS0L TC Analgesics
DMRMS0L DT Small molecular drug
DMRMS0L PC 5288826
DMRMS0L MW 285.34
DMRMS0L FM C17H19NO3
DMRMS0L IC InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
DMRMS0L CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
DMRMS0L IK BQJCRHHNABKAKU-KBQPJGBKSA-N
DMRMS0L IU (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DMRMS0L CA CAS 57-27-2
DMRMS0L CB CHEBI:17303
DMRMS0L DE Chronic pain
DMEJKRF ID DMEJKRF
DMEJKRF DN Motexafin gadolinium
DMEJKRF HS Approved
DMEJKRF SN Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)
DMEJKRF CP Pharmacyclics, Inc
DMEJKRF TC Anticancer Agents
DMEJKRF DT Small molecular drug
DMEJKRF PC 158385
DMEJKRF MW 1148.4
DMEJKRF FM C52H72GdN5O14
DMEJKRF IC InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2
DMEJKRF CS CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3]
DMEJKRF IK VAZLWPAHMORDGR-UHFFFAOYSA-L
DMEJKRF IU 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;gadolinium(3+);diacetate
DMEJKRF CA CAS 246252-06-2
DMEJKRF DE Brain cancer; Human immunodeficiency virus infection
DMYKUNR ID DMYKUNR
DMYKUNR DN Moxalactam Disodium
DMYKUNR HS Approved
DMYKUNR SN Moxam; Shiomarin
DMYKUNR CP Eli Lilly And Co
DMYKUNR TC Antiinfective Agents
DMYKUNR DT Small molecular drug
DMYKUNR PC 441242
DMYKUNR MW 564.4
DMYKUNR FM C20H18N6Na2O9S
DMYKUNR IC InChI=1S/C20H20N6O9S.2Na/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9;;/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32);;/q;2*+1/p-2/t12?,18-,20+;;/m1../s1
DMYKUNR CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)[O-])OC)OC2)C(=O)[O-].[Na+].[Na+]
DMYKUNR IK GRIXGZQULWMCLU-HUTAOCTPSA-L
DMYKUNR IU disodium;(6R,7R)-7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMYKUNR CA CAS 64953-12-4
DMYKUNR DE Bacterial infection
DMN63DZ ID DMN63DZ
DMN63DZ DN Moxetumomab pasudotox
DMN63DZ HS Approved
DMN63DZ SN CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment)
DMN63DZ CP AstraZeneca
DMN63DZ TC Anticancer Agents
DMN63DZ DT Monoclonal antibody
DMN63DZ SQ RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1)
DMN63DZ DE Haematological malignancy; Hairy cell leukaemia
DMYGHX5 ID DMYGHX5
DMYGHX5 DN Moxidectin
DMYGHX5 HS Approved
DMYGHX5 SN Moxidectin; ProHeart 6; UNII-NGU5H31YO9; Cydectin; NGU5H31YO9; Moxidectine [INN-French]; Moxidectinum [INN-Latin]; Moxidectina [INN-Spanish]; C37H53NO8; Moxidectina; Moxidectine; Moxidectinum; Moxidectin [USAN:INN:BAN]
DMYGHX5 CP Medicines Development for Global Health
DMYGHX5 PC 9832912
DMYGHX5 MW 639.8
DMYGHX5 FM C37H53NO8
DMYGHX5 IC InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1
DMYGHX5 CS C[C@@H]\\1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N\\OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C
DMYGHX5 IK YZBLFMPOMVTDJY-LSGXYNIPSA-N
DMYGHX5 IU (1R,4S,4'E,5'S,6R,6'S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DMYGHX5 CA CAS 113507-06-5
DMYGHX5 DE River blindness; Onchocerciasis
DMU8V4S ID DMU8V4S
DMU8V4S DN Moxifloxacin
DMU8V4S HS Approved
DMU8V4S SN Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMU8V4S CP Bayer AG
DMU8V4S TC Antibiotics
DMU8V4S DT Small molecular drug
DMU8V4S PC 152946
DMU8V4S MW 401.4
DMU8V4S FM C21H24FN3O4
DMU8V4S IC InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
DMU8V4S CS COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
DMU8V4S IK FABPRXSRWADJSP-MEDUHNTESA-N
DMU8V4S IU 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMU8V4S CA CAS 151096-09-2
DMU8V4S CB CHEBI:63611
DMU8V4S DE Bacterial infection
DMFCLYW ID DMFCLYW
DMFCLYW DN Moxisylyte
DMFCLYW HS Approved
DMFCLYW SN Thymoxamine
DMFCLYW DT Small molecular drug
DMFCLYW PC 4260
DMFCLYW MW 279.37
DMFCLYW FM C16H25NO3
DMFCLYW IC InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
DMFCLYW CS CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C
DMFCLYW IK VRYMTAVOXVTQEF-UHFFFAOYSA-N
DMFCLYW IU [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] acetate
DMFCLYW CA CAS 54-32-0
DMFCLYW CB CHEBI:94754
DMFCLYW DE Erectile dysfunction
DMGFB0E ID DMGFB0E
DMGFB0E DN MOXONIDINE
DMGFB0E HS Approved
DMGFB0E SN BDF-5895; BE-5895; Normoxin; AC1OCENE; SCHEMBL1230620; Moxonidine hydrochloride hydrate; moxonidine hydrochloride monohydrate; LY-326869; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine hydrate hydrochloride
DMGFB0E DT Small molecular drug
DMGFB0E PC 4810
DMGFB0E MW 241.68
DMGFB0E FM C9H12ClN5O
DMGFB0E IC InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
DMGFB0E CS CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
DMGFB0E IK WPNJAUFVNXKLIM-UHFFFAOYSA-N
DMGFB0E IU 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine
DMGFB0E CA CAS 75438-57-2
DMGFB0E CB CHEBI:7009
DMGFB0E DE Alcohol dependence
DMZ905C ID DMZ905C
DMZ905C DN Mozavaptan
DMZ905C HS Approved
DMZ905C SN 137975-06-5; Opc-31260; Opc 31260; Mozavaptan [INN]; CHEMBL420762; OPC31260; 5-Dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide; N-(4-((5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; N-(4-(((5RS)-5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; C27H29N3O2; OPC-31260
DMZ905C DT Small molecular drug
DMZ905C PC 119369
DMZ905C MW 427.5
DMZ905C FM C27H29N3O2
DMZ905C IC InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
DMZ905C CS CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
DMZ905C IK WRNXUQJJCIZICJ-UHFFFAOYSA-N
DMZ905C IU N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide
DMZ905C CA CAS 137975-06-5
DMZ905C CB CHEBI:135694
DMZ905C DE Hyponatraemia
DMWX683 ID DMWX683
DMWX683 DN Mupirocin
DMWX683 HS Approved
DMWX683 SN Bactoderm; Bactroban; Centany; MRC; Mupirocina; Mupirocine; Mupirocinum; Plasimine; Bactroban Nasal; Mupirocina [Spanish]; Mupirocine [French]; Mupirocinum [Latin]; Pseudomonic acid; Pseudomonic acid A; BRL 4910A; BRL-4910A; Bactroban (TN); Centany (TN); Mupirocin (USP/INN); Mupirocin, 14C-Labeled; 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S); 8-Carboxyoctyl (E)-4-(2S,3R,4R,5S)-5-((2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2H-pyran-2-yl)-3-methylcrotonat; 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
DMWX683 CP GlaxoSmithKline
DMWX683 TC Antibiotics
DMWX683 DT Small molecular drug
DMWX683 PC 446596
DMWX683 MW 500.6
DMWX683 FM C26H44O9
DMWX683 IC InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1
DMWX683 CS C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O
DMWX683 IK MINDHVHHQZYEEK-HBBNESRFSA-N
DMWX683 IU 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
DMWX683 CA CAS 12650-69-0
DMWX683 CB CHEBI:7025
DMWX683 DE Bacterial infection
DM8ANCF ID DM8ANCF
DM8ANCF DN Muromonab
DM8ANCF HS Approved
DM8ANCF TC Immunomodulatory Agents
DM8ANCF SQ Muromonab-CD3 light chain: QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC >Muromonab-CD3 heavy chainQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSAKTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DM8ANCF DE Organ transplant rejection
DMPQAGE ID DMPQAGE
DMPQAGE DN Mycophenolate mofetil
DMPQAGE HS Approved
DMPQAGE SN mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
DMPQAGE CP Roche
DMPQAGE TC Immunosuppressive Agents
DMPQAGE DT Small molecular drug
DMPQAGE PC 5281078
DMPQAGE MW 433.5
DMPQAGE FM C23H31NO7
DMPQAGE IC InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
DMPQAGE CS CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)OCCN3CCOCC3)O
DMPQAGE IK RTGDFNSFWBGLEC-SYZQJQIISA-N
DMPQAGE IU 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
DMPQAGE CA CAS 128794-94-5
DMPQAGE CB CHEBI:8764
DMPQAGE DE Organ transplant rejection; Immune System disease; Pemphigus vulgaris
DMRBMAU ID DMRBMAU
DMRBMAU DN Mycophenolic acid
DMRBMAU HS Approved
DMRBMAU SN Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; mycophenolic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; Lilly-68618; Ly 68618; Melbex; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 24280-93-1; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; CCRIS 5565; NSC 129185; NSC-129185; UNII-HU9DX48N0T
DMRBMAU PC 446541
DMRBMAU MW 320.3
DMRBMAU FM C17H20O6
DMRBMAU IC HPNSFSBZBAHARI-RUDMXATFSA-N
DMRBMAU CS CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O
DMRBMAU IK 1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMRBMAU IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMRBMAU CA CAS 483-60-3
DMRBMAU CB CHEBI:168396
DMRBMAU DE Crohn disease
DMYTN18 ID DMYTN18
DMYTN18 DN Mycophenolic acid
DMYTN18 HS Approved
DMYTN18 SN (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; Acide mycophenolique; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenoic acid; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T; mycophenolic acid
DMYTN18 DT Small molecular drug
DMYTN18 PC 446541
DMYTN18 MW 320.341
DMYTN18 FM C17H20O6
DMYTN18 IC InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMYTN18 CS CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)O)OC
DMYTN18 IK HPNSFSBZBAHARI-RUDMXATFSA-N
DMYTN18 IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMYTN18 CA CAS 483-60-3
DMYTN18 CB CHEBI:168396
DMYTN18 DE Organ transplant rejection
DMSOAJ2 ID DMSOAJ2
DMSOAJ2 DN N-0923
DMSOAJ2 HS Approved
DMSOAJ2 SN ent-Rotigotine; 92206-54-7; N-0437; 6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; 112835-48-0; 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-; 2-(N-n-Propyl-N-2-thienylethylamino)-5-hydroxytetralin; PubChem16422; AC1Q7ALS; rotigotine transdermal patch; AC1L1N7C; SCHEMBL50425; CHEMBL104383; CTK8E7910
DMSOAJ2 CP National Cancer Institute (NCI)
DMSOAJ2 DT Small molecular drug
DMSOAJ2 PC 57537
DMSOAJ2 MW 315.5
DMSOAJ2 FM C19H25NOS
DMSOAJ2 IC InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3
DMSOAJ2 CS CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
DMSOAJ2 IK KFQYTPMOWPVWEJ-UHFFFAOYSA-N
DMSOAJ2 IU 6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMSOAJ2 CA CAS 92206-54-7
DMSOAJ2 DE Parkinson disease
DMHJVOL ID DMHJVOL
DMHJVOL DN Nabi-HB
DMHJVOL HS Approved
DMHJVOL SN Reformulated HBV therapy, Nabi; Hepatitis B virus immune globulin (intramuscular), Nabi; H-BIG 5%iv formulation, Nabi
DMHJVOL CP Nabi Biologics
DMHJVOL DE Hepatitis B virus infection
DMVRYT2 ID DMVRYT2
DMVRYT2 DN Nabilone
DMVRYT2 HS Approved
DMVRYT2 SN Nabilone; Nabilona; Nabilonum; Cesamet; 51022-71-0; CHEMBL947; GECBBEABIDMGGL-RTBURBONSA-N; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; DEA No. 7379; Nabilon; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-
DMVRYT2 DT Small molecular drug
DMVRYT2 PC 5284592
DMVRYT2 MW 372.5
DMVRYT2 FM C24H36O3
DMVRYT2 IC InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
DMVRYT2 CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=O)CC[C@H]3C(OC2=C1)(C)C)O
DMVRYT2 IK GECBBEABIDMGGL-RTBURBONSA-N
DMVRYT2 IU (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-9-one
DMVRYT2 CA CAS 51022-71-0
DMVRYT2 DE Insomnia
DMAT2XH ID DMAT2XH
DMAT2XH DN Nabumetone
DMAT2XH HS Approved
DMAT2XH SN NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex
DMAT2XH CP Nobex Corp
DMAT2XH DT Small molecular drug
DMAT2XH PC 4409
DMAT2XH MW 228.29
DMAT2XH FM C15H16O2
DMAT2XH IC InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
DMAT2XH CS CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
DMAT2XH IK BLXXJMDCKKHMKV-UHFFFAOYSA-N
DMAT2XH IU 4-(6-methoxynaphthalen-2-yl)butan-2-one
DMAT2XH CA CAS 42924-53-8
DMAT2XH CB CHEBI:7443
DMAT2XH DE Pain
DM1XBWR ID DM1XBWR
DM1XBWR DN N-acetyl-D-glucosamine
DM1XBWR HS Approved
DM1XBWR SN Aflexa; GlcNAc; NAcGlc; NDG; Crab Shell Chitin; Glucosamine Complex; Maxi GS; Natures Blend Glucosamine; Pharmaceutical aid; JFD00446; SB01966; GS-500; N-Acetylchitosamine; N-Acetylchondrosamine; N-Acetylgalactosamine; N-Acetylhexosamine; Glucosamine, N-acetyl; N-Acetyl-D-Allosamine; N-Acetyl-D-galactosamine; N-Acetyl-D-hexosamine; N-acetyl-D-mannosamine; N-Acetyl-D-glucosamine-Agarose; N-Acetyl-alpha-D-glucosamine; N-acetyl-alpha-D-glucosaminides; N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 2-(Acetylamino)-2-deoxyhexopyranose; 2-ACETAMIDO-2-DEOXY-D-ALLOSE; 2-Acetamido-2-deoxy-D-glucose; 2-Acetamido-2-deoxyglucose; 2-Acetamido-D-glucose; 2-acetamido-2-deoxy-D-glucopyranose; 2-acetamido-2-deoxyhexopyranose; 6-Acetamido-6-deoxy-.alpha.-D-glucopyranose; 6-Acetamido-6-deoxy-acpha-D-glucopyranose
DM1XBWR TC Antiinflammatory Agents
DM1XBWR DT Small molecular drug
DM1XBWR PC 439174
DM1XBWR MW 221.21
DM1XBWR FM C8H15NO6
DM1XBWR IC InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8?/m1/s1
DM1XBWR CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O
DM1XBWR IK OVRNDRQMDRJTHS-RTRLPJTCSA-N
DM1XBWR IU N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DM1XBWR CA CAS 72-87-7
DM1XBWR CB CHEBI:506227
DM1XBWR DE Autoimmune diabetes
DM5NM6E ID DM5NM6E
DM5NM6E DN NADH
DM5NM6E HS Approved
DM5NM6E SN DPNH; Dihydrodiphosphopyridine nucleotide; Dihydronicotinamide adenine dinucleotide; Diphosphopyridine nucleotide reduced; NADH dianion; Nicotinamide adenine dinucleotide reduced; Reduced Nicotinamide Adenine Dinucleotide; NADH2; Beta-DPNH; Beta-NADH; Coenzyme I, reduced; Cozymase I, reduced; Diphosphopyridine nucleotide,reduced form; NAD-reduced; Nicotinamide adenine dinucleotide, reduced form; Reduced nicotinamide-adenine dinucleotide; Beta-Nicotinamide adenine dinucleotide, reduced dipotassium salt; NADH+H+; Nicotinaminde-Adenine-Dinucleotide; Adenosine pyrophosphate, 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (7CI); Adenosine 5'-(trihydrogen pyrophosphate), 5'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosylnicotinamide (8CI); Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamide (9CI); Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] dihydrogen diphosphate}; Adenosine 5'-{3-[1-(3-carbamoyl-1,4-dihydropyridin-1-yl)-1,4-anhydro-D-ribitol-5-yl] diphosphate}; [5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-phosphinic acid
DM5NM6E TC Dietary supplement
DM5NM6E DT Small molecular drug
DM5NM6E PC 439153
DM5NM6E MW 665.4
DM5NM6E FM C21H29N7O14P2
DM5NM6E IC InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM5NM6E CS C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DM5NM6E IK BOPGDPNILDQYTO-NNYOXOHSSA-N
DM5NM6E IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM5NM6E CA CAS 58-68-4
DM5NM6E CB CHEBI:16908
DM5NM6E DE Parkinson disease
DMW6GVL ID DMW6GVL
DMW6GVL DN Nadolol
DMW6GVL HS Approved
DMW6GVL SN Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol
DMW6GVL CP Apotex Inc
DMW6GVL TC Antihypertensive Agents
DMW6GVL DT Small molecular drug
DMW6GVL PC 39147
DMW6GVL MW 309.4
DMW6GVL FM C17H27NO4
DMW6GVL IC InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
DMW6GVL CS CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O
DMW6GVL IK VWPOSFSPZNDTMJ-UCWKZMIHSA-N
DMW6GVL IU (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
DMW6GVL CA CAS 220045-89-6
DMW6GVL DE High blood pressure
DMBNKST ID DMBNKST
DMBNKST DN Nadroparin calcium
DMBNKST HS Approved
DMBNKST SN Fraxiparine (TN)
DMBNKST DE Coagulation defect
DMU1XOD ID DMU1XOD
DMU1XOD DN Nafamostat
DMU1XOD HS Approved
DMU1XOD SN FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
DMU1XOD DT Small molecular drug
DMU1XOD PC 4413
DMU1XOD MW 347.4
DMU1XOD FM C19H17N5O2
DMU1XOD IC InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
DMU1XOD CS C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
DMU1XOD IK MQQNFDZXWVTQEH-UHFFFAOYSA-N
DMU1XOD IU (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
DMU1XOD CA CAS 81525-10-2
DMU1XOD CB CHEBI:135466
DMU1XOD DE Pancreatitis; Sepsis
DMAHEFY ID DMAHEFY
DMAHEFY DN Nafarelin
DMAHEFY HS Approved
DMAHEFY SN Nafarelina; Nafareline; Nafarelinum; Synarel; NAFARELIN ACETATE; Nafarelina [Spanish]; Nafareline [French]; Nafarelinum [Latin]; HS-2018; Nafarelin (INN); Nafarelin Acetate, Hydrate; Nafarelin [INN:BAN]; Synarel (TN); RS-94991-298; 6-(3-(2-Naphthalenyl)-D-alanine)luteinizing hormone-releasing factor (pig)
DMAHEFY CP Pfizer Pharmaceuticals
DMAHEFY TC Fertility Agents
DMAHEFY DT Small molecular drug
DMAHEFY PC 25077405
DMAHEFY MW 1322.5
DMAHEFY FM C66H83N17O13
DMAHEFY IC InChI=1S/C66H83N17O13/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71)/t46-,47-,48-,49-,50+,51-,52-,53-,54-/m0/s1
DMAHEFY CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
DMAHEFY IK RWHUEXWOYVBUCI-ITQXDASVSA-N
DMAHEFY IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMAHEFY CA CAS 76932-56-4
DMAHEFY DE Endometriosis
DMN9RPO ID DMN9RPO
DMN9RPO DN Nafcillin
DMN9RPO HS Approved
DMN9RPO SN Nafcilina; Nafcilline; Nafcillinum; Nallpen; Naphcillin; Naphthamidopenicillin; Unipen; NAFCILLIN SODIUM; Nafcillin sodium for injection; Nallpen In Plastic Container; Nafcilin-1; Nafcilina [INN-Spanish]; Nafcillin & VRC3375; Nafcillin (INN); Nafcillin [INN:BAN]; Nafcilline [INN-French]; Nafcillinum [INN-Latin]; Nafcillin, Monosodium Salt, Anhydrous; (2-Ethoxy-1-naphthyl)penicillin; (2-ethoxy-1-naphthalenyl)penicillin; (2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(2-ethoxy-1-naphthamido)penicillanic acid; 6-[(2-Ethoxy-naphthalene-1-carbonyl)-amino]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid anion; 6beta-(2-ethoxynaphthalene-1-carboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid
DMN9RPO TC Antibiotics
DMN9RPO DT Small molecular drug
DMN9RPO PC 8982
DMN9RPO MW 414.5
DMN9RPO FM C21H22N2O5S
DMN9RPO IC InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1
DMN9RPO CS CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMN9RPO IK GPXLMGHLHQJAGZ-JTDSTZFVSA-N
DMN9RPO IU (2S,5R,6R)-6-[(2-ethoxynaphthalene-1-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMN9RPO CA CAS 147-52-4
DMN9RPO CB CHEBI:7447
DMN9RPO DE Arthritis
DMVMQ1L ID DMVMQ1L
DMVMQ1L DN Nafronyl
DMVMQ1L HS Approved
DMVMQ1L SN Nafronyl oxalate; 3200-06-4; Naftidrofuryl oxalate; Nafronyl oxalate salt; 2-(Diethylamino)ethyl 3-(naphthalen-1-yl)-2-((tetrahydrofuran-2-yl)methyl)propanoate oxalate; Naftidrofuryl (oxalate); Dusodril; Dubimax; Praxilene; Iridus; LS-121; EU-1806; DSSTox_RID_80935; DSSTox_CID_25533; DSSTox_GSID_45533; naftidrofuryl hydrogen oxalate; CHEMBL1439099; alpha-[1-Naphthylmethyl]-2-tetrahydrofuranpropionic acid diethylaminoethyl ester; SMR000539007; Nafronyl oxalate salt, analytical standard; CAS-3200-06-4; NSC225233; LS 121
DMVMQ1L DT Small molecular drug
DMVMQ1L PC 4417
DMVMQ1L MW 383.5
DMVMQ1L FM C24H33NO3
DMVMQ1L IC InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
DMVMQ1L CS CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C32
DMVMQ1L IK KBAFPSLPKGSANY-UHFFFAOYSA-N
DMVMQ1L IU 2-(diethylamino)ethyl 2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoate
DMVMQ1L CA CAS 31329-57-4
DMVMQ1L CB CHEBI:91817
DMVMQ1L DE Cerebrovascular ischaemia
DMHVBG1 ID DMHVBG1
DMHVBG1 DN Naftifine
DMHVBG1 HS Approved
DMHVBG1 SN Naftifin; Naftifina; Naftifinum; Naftifine HCl; Naftifina [INN-Spanish]; Naftifine (INN); Naftifine [INN:BAN]; Naftifinum[INN-Latin]; Naftin (TN); SN 105-843; N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride; N-Methyl-N-(1-naphthyl methyl)-3-phenyl-2-propen-1-amine(E), hydrochloride; (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine; (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine; (E)-N-Cinnamyl-N-methyl-1-naphthalinmethylamin; (E)-N-Cinnamyl-N-methyl-1-naphthylmethylamin; (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
DMHVBG1 CP Merz Pharmaceuticals Llc
DMHVBG1 TC Antifungal Agents
DMHVBG1 DT Small molecular drug
DMHVBG1 PC 47641
DMHVBG1 MW 287.4
DMHVBG1 FM C21H21N
DMHVBG1 IC InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+
DMHVBG1 CS CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32
DMHVBG1 IK OZGNYLLQHRPOBR-DHZHZOJOSA-N
DMHVBG1 IU (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine
DMHVBG1 CA CAS 65472-88-0
DMHVBG1 CB CHEBI:7451
DMHVBG1 DE Dermatomycosis
DMQ8R4E ID DMQ8R4E
DMQ8R4E DN Naftopidil
DMQ8R4E HS Approved
DMQ8R4E SN naftopidil; 57149-07-2; Flivas; KT-611; Naftopidil [INN]; Avishot; Naftopidilum [Latin]; Naftopidil (Flivas); BM-15275; Naftopidil (unspecified); BRN 0629965; CHEMBL142635; C24H28N2O3; 1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol; NCGC00015718-06; (+-)-1-(4-(2-Methoxyphenyl)piperazinyl)-3-(1-naphthyloxy)propan-2-ol; 4-(2-Methoxyphenyl)-alpha-((1-naphthalenyloxy)methyl)-1-pioerazineethanol; (RS)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol; DSSTox_RID_80725; DSSTox_CID_25176
DMQ8R4E DT Small molecular drug
DMQ8R4E PC 4418
DMQ8R4E MW 392.5
DMQ8R4E FM C24H28N2O3
DMQ8R4E IC InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
DMQ8R4E CS COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O
DMQ8R4E IK HRRBJVNMSRJFHQ-UHFFFAOYSA-N
DMQ8R4E IU 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol
DMQ8R4E CA CAS 57149-07-2
DMQ8R4E CB CHEBI:31891
DMQ8R4E DE Hypertension
DMOSQGU ID DMOSQGU
DMOSQGU DN Nalbuphine
DMOSQGU HS Approved
DMOSQGU SN Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol
DMOSQGU CP Endo Pharmaceuticals
DMOSQGU TC Analgesics
DMOSQGU DT Small molecular drug
DMOSQGU PC 5311304
DMOSQGU MW 357.4
DMOSQGU FM C21H27NO4
DMOSQGU IC InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
DMOSQGU CS C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O
DMOSQGU IK NETZHAKZCGBWSS-CEDHKZHLSA-N
DMOSQGU IU (4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMOSQGU CA CAS 20594-83-6
DMOSQGU CB CHEBI:7454
DMOSQGU DE Prurigo nodularis; Uremic pruritus; Pain
DMGD3YH ID DMGD3YH
DMGD3YH DN Naldemedine Tosylate
DMGD3YH HS Approved
DMGD3YH CP Shionogi
DMGD3YH DT Small molecular drug
DMGD3YH PC 56837137
DMGD3YH MW 742.8
DMGD3YH FM C39H42N4O9S
DMGD3YH IC InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1
DMGD3YH CS CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
DMGD3YH IK WCYDLROFMZJJLE-RTMHEQJQSA-N
DMGD3YH IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide;4-methylbenzenesulfonic acid
DMGD3YH CA CAS 1345728-04-2
DMGD3YH DE Opioid-induced constipation
DMA9DHW ID DMA9DHW
DMA9DHW DN Nalfurafine hcl
DMA9DHW HS Approved
DMA9DHW SN Nalfurafine hydrochloride; Nalfurafine HCl; TRK-820; Remitch; Nalfurafine (hydrochloride); 152658-17-8; UNII-25CC4N0P8J; 25CC4N0P8J; CHEMBL490665; AC 820; Nalfurafine hydrochloride [USAN:JAN]; (-)-17-(Cyclopropylmethyl)-3,14; A-dihydroxy-4,5; A-epoxy-6; A-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan Hydrochloride; (2E)-N-[(5; A)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide Hydrochloride; SCHEMBL19856501; DTXSID70426071; DJSFYNINGIMKAG-FQJQBBMWSA-N; BCP15625; Remitch (TN)
DMA9DHW DT Small molecular drug
DMA9DHW PC 6918287
DMA9DHW MW 513
DMA9DHW FM C28H33ClN2O5
DMA9DHW IC InChI=1S/C28H32N2O5.ClH/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17;/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3;1H/b7-4+;/t20-,22-,26+,27+,28-;/m1./s1
DMA9DHW CS CN([C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)/C=C/C7=COC=C7.Cl
DMA9DHW IK DJSFYNINGIMKAG-FQJQBBMWSA-N
DMA9DHW IU (E)-N-[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]-3-(furan-3-yl)-N-methylprop-2-enamide;hydrochloride
DMA9DHW CA CAS 152658-17-8
DMA9DHW DE Uremic pruritus
DMRM0JV ID DMRM0JV
DMRM0JV DN Nalidixic acid
DMRM0JV HS Approved
DMRM0JV SN Betaxina; Cybis; Dixiben; Dixinal; Eucistin; Innoxalon; Jicsron; Kusnarin; Nalidicron; Nalidixan; Nalidixane; Nalidixate; Nalidixic; Nalidixin; Nalitucsan; Nalix; Nalurin; Narigix; Naxuril; NegGram; Negram; Nevigramon; Nicelate; Nogram; Poleon; Sicmylon; Specifen; Specifin; Unaserus; Uralgin; Uriben; Uriclar; Urisal; Urodixin; Uroman; Uroneg; Uronidix; Uropan; Wintomylon; Wintron; Acide nalidixico; Acide nalidixico [Italian]; Acide nalidixique; Acide nalidixique [French]; Acido nalidissico; Acido nalidissico [DCIT]; Acido nalidixico; Acidum nalidixicum; NALIDIXATE SODIUM; Naladixic acid; Naldixic acid; Nalidic acid; Nalidixinic acid; Nalidixic acid USP27; WIN 183203; Acid, Nalidixic; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; N-1200; NegGram (TN); Neggram (TN); Sodium Nalidixic Acid, Anhydrous; Sodium Nalidixic Acid, Monohydrate; Sodium,Nalidixate; WIN 18,320; WIN-18320; Wil 18,320; Wintomylon (TN); ZERO/002632; WIN-18320 (TN); Nalidixic acid (JP15/USP/INN); Nalidixic acid [USAN:INN:BAN:JAN]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
DMRM0JV TC Antibiotics
DMRM0JV DT Small molecular drug
DMRM0JV PC 4421
DMRM0JV MW 232.23
DMRM0JV FM C12H12N2O3
DMRM0JV IC InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)
DMRM0JV CS CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)O
DMRM0JV IK MHWLWQUZZRMNGJ-UHFFFAOYSA-N
DMRM0JV IU 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMRM0JV CA CAS 389-08-2
DMRM0JV CB CHEBI:100147
DMRM0JV DE Urinary tract infection
DM4YWCZ ID DM4YWCZ
DM4YWCZ DN Nalmefene
DM4YWCZ HS Approved
DM4YWCZ SN Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol
DM4YWCZ CP Eurohealth International Sarl
DM4YWCZ TC Anticraving Agents
DM4YWCZ DT Small molecular drug
DM4YWCZ PC 5284594
DM4YWCZ MW 339.4
DM4YWCZ FM C21H25NO3
DM4YWCZ IC InChI=1S/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1
DM4YWCZ CS C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O
DM4YWCZ IK WJBLNOPPDWQMCH-MBPVOVBZSA-N
DM4YWCZ IU (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DM4YWCZ CA CAS 55096-26-9
DM4YWCZ CB CHEBI:7457
DM4YWCZ DE Opioid dependence
DML0B41 ID DML0B41
DML0B41 DN Naloxegol
DML0B41 HS Approved
DML0B41 SN NKTR-118
DML0B41 CP AstraZeneca
DML0B41 DT Small molecular drug
DML0B41 PC 56959087
DML0B41 MW 651.8
DML0B41 FM C34H53NO11
DML0B41 IC InChI=1S/C34H53NO11/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2/h3-5,28-29,32,36-37H,1,6-25H2,2H3/t28-,29+,32-,33-,34+/m0/s1
DML0B41 CS COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O
DML0B41 IK XNKCCCKFOQNXKV-ZRSCBOBOSA-N
DML0B41 IU (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DML0B41 CA CAS 854601-70-0
DML0B41 CB CHEBI:82975
DML0B41 DE Opioid-induced constipation
DM3FXMA ID DM3FXMA
DM3FXMA DN Naloxone
DM3FXMA HS Approved
DM3FXMA SN Nalone; Nalossone; Naloxona; Naloxonum; Narcan; Narcanti; Narcon; DBL Naloxone; Nalossone [DCIT]; Naloxone HCl; EN 1530base; DBL Naloxone (TN); L-Naloxone; N-Allylnoroxymorphone; Nalone (TN); Naloxona [INN-Spanish]; Naloxone (INN); Naloxone [INN:BAN]; Naloxonum [INN-Latin]; Narcan (TN); Narcanti (TN); N-Allyl-noroxymorphone; L-N-Allyl-14-hydroxynordihydromorphinone; L-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon; Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy-(8CI); Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)-(9CI); (-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one; (-)-Naloxone; (5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one; (5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; 1-N-Allyl-14-hydroxynordihydromorphinone; 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one; 17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; 17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one; 3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
DM3FXMA CP Bristol Meyers Squibb
DM3FXMA TC Antinarcotic Agents
DM3FXMA DT Small molecular drug
DM3FXMA PC 5284596
DM3FXMA MW 327.4
DM3FXMA FM C19H21NO4
DM3FXMA IC InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
DM3FXMA CS C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM3FXMA IK UZHSEJADLWPNLE-GRGSLBFTSA-N
DM3FXMA IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM3FXMA CA CAS 465-65-6
DM3FXMA CB CHEBI:7459
DM3FXMA DE Narcotic depression; Opioid dependence; Respiratory depression; Pruritus
DMUL45H ID DMUL45H
DMUL45H DN Naltrexone
DMUL45H HS Approved
DMUL45H SN Depotrex; Naltrel; Vivitrex; Vivitrol; Naltrexone Depot; IBS therapy, Pain Therapeutics; Irritable bowel syndrome therapy, Pain Therapeutics; PTI-901; XR-NTX; Naltrexone (sustained release), DAS; Naltrexone (sustained release), elbion; Naltrexone depot (injectable suspension), DrugAbuse Sciences; Naltrexone depot (injectable suspension), elbion; Opioid antagonists (irritable bowel syndrome), Pain Therapeutics; Naltrexone (low-dose), Pain Therapeutics; Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek; Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma; Naltrexone (once-monthly controlled-release, Medisorb), Alkermes
DMUL45H CP Tni biotech; DrugAbuse Sciences; Alkermes Inc
DMUL45H DT Small molecular drug
DMUL45H PC 5360515
DMUL45H MW 341.4
DMUL45H FM C20H23NO4
DMUL45H IC InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
DMUL45H CS C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
DMUL45H IK DQCKKXVULJGBQN-XFWGSAIBSA-N
DMUL45H IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMUL45H CA CAS 16590-41-3
DMUL45H CB CHEBI:7465
DMUL45H DE Alcohol dependence; Human immunodeficiency virus infection
DMFWKG1 ID DMFWKG1
DMFWKG1 DN Nandrolone
DMFWKG1 HS Approved
DMFWKG1 SN Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one
DMFWKG1 CP Aspen Global Inc
DMFWKG1 TC Anabolic Agents
DMFWKG1 DT Small molecular drug
DMFWKG1 PC 9904
DMFWKG1 MW 274.4
DMFWKG1 FM C18H26O2
DMFWKG1 IC InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
DMFWKG1 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34
DMFWKG1 IK NPAGDVCDWIYMMC-IZPLOLCNSA-N
DMFWKG1 IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
DMFWKG1 CA CAS 434-22-0
DMFWKG1 CB CHEBI:7466
DMFWKG1 DE Osteoporosis
DMJFZDL ID DMJFZDL
DMJFZDL DN Naphazoline
DMJFZDL HS Approved
DMJFZDL SN Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
DMJFZDL CP Allergan Inc
DMJFZDL TC Anticancer Agents
DMJFZDL DT Small molecular drug
DMJFZDL PC 4436
DMJFZDL MW 210.27
DMJFZDL FM C14H14N2
DMJFZDL IC InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
DMJFZDL CS C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
DMJFZDL IK CNIIGCLFLJGOGP-UHFFFAOYSA-N
DMJFZDL IU 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
DMJFZDL CA CAS 835-31-4
DMJFZDL CB CHEBI:93363
DMJFZDL DE Itching; Hyperaemia
DMZ5RGV ID DMZ5RGV
DMZ5RGV DN Naproxen
DMZ5RGV HS Approved
DMZ5RGV SN NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex
DMZ5RGV CP Iroko pharmaceuticals; PLx Pharma; CeNeS Pharmaceuticals plc
DMZ5RGV DT Small molecular drug
DMZ5RGV PC 156391
DMZ5RGV MW 230.26
DMZ5RGV FM C14H14O3
DMZ5RGV IC InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
DMZ5RGV CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
DMZ5RGV IK CMWTZPSULFXXJA-VIFPVBQESA-N
DMZ5RGV IU (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
DMZ5RGV CA CAS 22204-53-1
DMZ5RGV CB CHEBI:7476
DMZ5RGV DE Osteoarthritis; Endometriosis; Pain
DMO50U2 ID DMO50U2
DMO50U2 DN Naratriptan
DMO50U2 HS Approved
DMO50U2 SN Colatan; Naramig; Naratriptanum; Amerge (TN); Naramig (TN); Naratriptan (INN); Amerge, Naramig,Naratriptan; N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
DMO50U2 CP GlaxoSmithKline
DMO50U2 TC Vasoconstrictor Agents
DMO50U2 DT Small molecular drug
DMO50U2 PC 4440
DMO50U2 MW 335.5
DMO50U2 FM C17H25N3O2S
DMO50U2 IC InChI=1S/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3
DMO50U2 CS CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
DMO50U2 IK AMKVXSZCKVJAGH-UHFFFAOYSA-N
DMO50U2 IU N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
DMO50U2 CA CAS 121679-13-8
DMO50U2 CB CHEBI:7478
DMO50U2 DE Migraine
DMFEHXD ID DMFEHXD
DMFEHXD DN Natamycin
DMFEHXD HS Approved
DMFEHXD SN Delvocid; Delvolan; Delvopos; Mycophyt; Myprozine; Natacyn; Natafucin; Natamicina; Natamycine; Natamycinum; Pimafucin; Pimaricin; Pimaricine; Pimarizin; Synogil; Tennecetin; Natamycin preparation; Pimaricin preparation; Pimarizin [German]; CL 12625; Antibiotic A-5283; CL 12,625; CL-12625; Natacyn (TN); Natamicina [INN-Spanish]; Natamycine [INN-French]; Natamycinum [INN-Latin]; Pimaricin (JP15); Natamycin (USP/INN); Natamycin [USAN:INN:BAN]; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure; 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-, (1R,3S,5R,7R,8E,12R,14
DMFEHXD TC Antifungal Agents
DMFEHXD DT Small molecular drug
DMFEHXD PC 5284447
DMFEHXD MW 665.7
DMFEHXD FM C33H47NO13
DMFEHXD IC InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1
DMFEHXD CS C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O
DMFEHXD IK NCXMLFZGDNKEPB-FFPOYIOWSA-N
DMFEHXD IU (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
DMFEHXD CA CAS 7681-93-8
DMFEHXD DE Conjunctivitis
DMLK2QH ID DMLK2QH
DMLK2QH DN Nateglinide
DMLK2QH HS Approved
DMLK2QH SN Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
DMLK2QH CP Norvatis Phamaceuticals Corporation
DMLK2QH TC Hypoglycemic Agents
DMLK2QH DT Small molecular drug
DMLK2QH PC 5311309
DMLK2QH MW 317.4
DMLK2QH FM C19H27NO3
DMLK2QH IC InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
DMLK2QH CS CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O
DMLK2QH IK OELFLUMRDSZNSF-OFLPRAFFSA-N
DMLK2QH IU (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid
DMLK2QH CA CAS 105816-04-4
DMLK2QH CB CHEBI:31897
DMLK2QH DE Diabetic complication
DM7F1PA ID DM7F1PA
DM7F1PA DN Nebivolol
DM7F1PA HS Approved
DM7F1PA SN Bystolic; Lobivon; Nebilet; Nebilong; Nebipill; Nebivololum; Nubeta; Nebivololum [Latin]; R 67555; Bystolic (TN); Nebicard-5;Nebilet (TN); Nebilong (TN); Nodon (TN); Nubeta (TN); PI-21858; R-67555; R65,824; Nebicard-5 (TN); Nebivolol (USAN/INN); Nebivolol [USAN:INN:BAN]; Alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
DM7F1PA CP Forest Laboratories
DM7F1PA TC Antihypertensive Agents
DM7F1PA DT Small molecular drug
DM7F1PA PC 71301
DM7F1PA MW 405.4
DM7F1PA FM C22H25F2NO4
DM7F1PA IC InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
DM7F1PA CS C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
DM7F1PA IK KOHIRBRYDXPAMZ-UHFFFAOYSA-N
DM7F1PA IU 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
DM7F1PA CA CAS 99200-09-6
DM7F1PA CB CHEBI:64019
DM7F1PA DE Hypertension
DMKOJSN ID DMKOJSN
DMKOJSN DN Necitumumab
DMKOJSN HS Approved
DMKOJSN SN LY3012211
DMKOJSN CP Lilly
DMKOJSN DT Monoclonal antibody
DMKOJSN SQ Sequence A: QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Sequence A'QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Sequence BEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Sequence B'EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMKOJSN DE Colorectal cancer
DM4ZS8M ID DM4ZS8M
DM4ZS8M DN Nefazodone
DM4ZS8M HS Approved
DM4ZS8M SN Nefazodona; Nefazodonum; Nefazodona [Spanish]; Nefazodone Hcl; Nefazodonum [Latin]; Nefadar (TN); Nefazodone (INN); Nefazodone [INN:BAN]; Serzone (TN); 1-(3-(4-(3-Chlorpheyl-1-piperazinylpropyl)-3-ethyl-4,5-dihydro-4-(2-phenoxyethyl)-1,2,4-triazol-5-on; 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one; 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
DM4ZS8M CP Bristol-Myers Squibb
DM4ZS8M TC Antidepressants
DM4ZS8M DT Small molecular drug
DM4ZS8M PC 4449
DM4ZS8M MW 470
DM4ZS8M FM C25H32ClN5O2
DM4ZS8M IC InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
DM4ZS8M CS CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
DM4ZS8M IK VRBKIVRKKCLPHA-UHFFFAOYSA-N
DM4ZS8M IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
DM4ZS8M CA CAS 83366-66-9
DM4ZS8M CB CHEBI:7494
DM4ZS8M DE Major depressive disorder; Depression
DMB6VEG ID DMB6VEG
DMB6VEG DN Nelarabine
DMB6VEG HS Approved
DMB6VEG SN Arranon; ArranonG; Atriance; Nelzarabine; Nelarabine [USAN]; Nelzarabine [USAN]; GW 506U78; GW506U78; U78; Arranon (GlaxoSmithKline); Arranon (TN); Arranon, Nelarabine; Atriance (TN); GW-506U; GW-506U78; Nelarabine (INN); Nelzarabine (USAN); O-Methoxydeoxyguanosine; O-Methylguanosine; Nelarabine (JAN/USAN); (2R,3R,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; 2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-Amino-6-methoxypurine arabinoside; 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine; 6'-O-Methylguanosine; 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine; 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
DMB6VEG CP GlaxoSmithKline
DMB6VEG TC Anticancer Agents
DMB6VEG DT Small molecular drug
DMB6VEG PC 3011155
DMB6VEG MW 297.27
DMB6VEG FM C11H15N5O5
DMB6VEG IC InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1
DMB6VEG CS COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
DMB6VEG IK IXOXBSCIXZEQEQ-UHTZMRCNSA-N
DMB6VEG IU (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMB6VEG CA CAS 121032-29-9
DMB6VEG CB CHEBI:63612
DMB6VEG DE leukaemia
DMFX6G8 ID DMFX6G8
DMFX6G8 DN Nelfinavir mesylate
DMFX6G8 HS Approved
DMFX6G8 SN Nelfin; Nelfinavir (Mesylate); Nelfinavir Mesylate [USAN]; Nelfinavir Methanesulfonate; Nelfinavir mesilate; Nelfinavir mesylate; Nelfinavir mesylate hydrate; Nelfinavir; NELFINAVIR MESYLATE AG1343; Nelfinavir [INN:BAN]; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; 159989-64-7; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; C32H45N3O4S; CHEBI:7496; HO3OGH5D7I; NLF; UNII-HO3OGH5D7I; 98D603VP8V; C32H45N3O4S.CH4O3S; CHEBI:7497; CHEMBL1205; DSSTox_CID_10777; DSSTox_GSID_33736; DSSTox_RID_79093; HSDB 7159; MFCD00931436; Nelfinavir methanesulfonate hydrate; UNII-98D603VP8V
DMFX6G8 PC 64142
DMFX6G8 MW 663.9
DMFX6G8 FM C33H49N3O7S2
DMFX6G8 IC NQHXCOAXSHGTIA-SKXNDZRYSA-N
DMFX6G8 CS CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
DMFX6G8 IK 1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1
DMFX6G8 IU (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide;methanesulfonic acid
DMFX6G8 CA CAS 159989-65-8
DMFX6G8 CB CHEBI:7497
DMFX6G8 DE Human immunodeficiency virus infection
DMY0EKH ID DMY0EKH
DMY0EKH DN Nemonapride
DMY0EKH HS Approved
DMY0EKH SN Emilace (TN); Nemonapride (JAN/INN); Nemonapride, (cis)-isomer
DMY0EKH CP Astellas
DMY0EKH DT Small molecular drug
DMY0EKH PC 156333
DMY0EKH MW 387.9
DMY0EKH FM C21H26ClN3O2
DMY0EKH IC InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1
DMY0EKH CS C[C@@H]1[C@@H](CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl
DMY0EKH IK KRVOJOCLBAAKSJ-RDTXWAMCSA-N
DMY0EKH IU N-[(2R,3R)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide
DMY0EKH CA CAS 187139-87-3
DMY0EKH CB CHEBI:64219
DMY0EKH DE Schizophrenia
DM0S9Z1 ID DM0S9Z1
DM0S9Z1 DN Nemonoxacin
DM0S9Z1 HS Approved
DM0S9Z1 SN Nemonoxacin; 378746-64-6; UNII-P94L0PVO94; TG-873870; P94L0PVO94; Nemonoxacin [INN]; 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(3S,5S)-3-Amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; SCHEMBL1006373; CHEMBL1213456; CHEBI:136053; ZINC40435195; SB16570; FT-0700967; 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
DM0S9Z1 CP TaiGen Biotechnology
DM0S9Z1 DT Small molecular drug
DM0S9Z1 PC 11993740
DM0S9Z1 MW 371.4
DM0S9Z1 FM C20H25N3O4
DM0S9Z1 IC InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
DM0S9Z1 CS C[C@H]1C[C@@H](CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N
DM0S9Z1 IK AVPQPGFLVZTJOR-RYUDHWBXSA-N
DM0S9Z1 IU 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid
DM0S9Z1 CA CAS 378746-64-6
DM0S9Z1 CB CHEBI:136053
DM0S9Z1 DE infection associated with diabetic foot ulcers; Community-acquired pneumonia
DMPWCTH ID DMPWCTH
DMPWCTH DN Neocarzinostatin
DMPWCTH HS Approved
DMPWCTH SN ZINOSTATIN; Neocarzinostatin (JAN); Zinostatin (USAN/INN); SCHEMBL1347615; D02046; 33862-EP2311453A1; 33862-EP2298765A1; 33862-EP2295426A1; 33862-EP2298764A1; 33862-EP2298748A2; 33862-EP2295427A1; 33862-EP2295055A2; 33862-EP2272832A1; 33862-EP2311829A1; 33862-EP2305642A2; 33862-EP2275420A1; 33862-EP2311808A1; 33862-EP2298768A1; 33862-EP2295416A2; 120130-EP2272832A1
DMPWCTH DT Small molecular drug
DMPWCTH PC 5282473
DMPWCTH MW 661.6
DMPWCTH FM C35H35NO12
DMPWCTH IC InChI=1S/C35H35NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h8-9,12-14,17,21,24-26,28-31,33,36-39H,6,15H2,1-4H3/t17-,21?,24-,25-,26-,28-,29+,30-,31-,33-,35+/m1/s1
DMPWCTH CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](C=C3C2CC#C[C@@H]4[C@@](O4)(C#C3)[C@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)O)NC)O)O
DMPWCTH IK BLXZMHNVKCEIJX-PNKAXBHOSA-N
DMPWCTH IU [(4S,6R,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]tridec-1(13)-en-2,7-diyn-12-yl] 2-hydroxy-7-methoxy-5-methylnaphthalene-1-carboxylate
DMPWCTH CA CAS 9014-02-2
DMPWCTH DE Solid tumour/cancer
DM6T2J3 ID DM6T2J3
DM6T2J3 DN Neostigmine
DM6T2J3 HS Approved
DM6T2J3 SN Eustigmin; Eustigmine; Intrastigmina; Juvastigmin; Neostigmin; Neostigminum; Prostigmin; Prostigmine; Prozerin; Sulfonatooxymethane; Synstigmin; Syntostigmine; Vagostigmin; Vagostigmine; Neostigmine [BAN]; Neostigmine omega; M-Trimethylammoniumphenyldimethylcarbamate; Neostigmine (BAN); Prostigmin (TN); Vagostigmin (TN); [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium; [3-(dimethylcarbamoyloxy)phenyl]-trimethyl-azanium bromide; Ammonium, (m-hydroxyphenyl)trimethyl-, dimethylcarbamate (ester); Benzenaminium, 3-(((dimethylamino)carbonyl)oxy)-N,N,N-trimethyl-(9CI); (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate; (m-Hydroxyphenyl)trimethylammonium dimethylcarbamate (ester); 3-Trimethylammoniumphenyl N,N-dimethylcarbamate; 3-[(dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium; 3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium
DM6T2J3 TC Parasympathomimetics
DM6T2J3 DT Small molecular drug
DM6T2J3 PC 4456
DM6T2J3 MW 223.29
DM6T2J3 FM C12H19N2O2+
DM6T2J3 IC InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
DM6T2J3 CS CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
DM6T2J3 IK ALWKGYPQUAPLQC-UHFFFAOYSA-N
DM6T2J3 IU [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium
DM6T2J3 CA CAS 59-99-4
DM6T2J3 CB CHEBI:7514
DM6T2J3 DE Myasthenia gravis
DMYK490 ID DMYK490
DMYK490 DN Nepafenac
DMYK490 HS Approved
DMYK490 SN Nevanac; AHR-9434; AL-6515
DMYK490 CP Alcon
DMYK490 DT Small molecular drug
DMYK490 PC 151075
DMYK490 MW 254.28
DMYK490 FM C15H14N2O2
DMYK490 IC InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
DMYK490 CS C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N
DMYK490 IK QEFAQIPZVLVERP-UHFFFAOYSA-N
DMYK490 IU 2-(2-amino-3-benzoylphenyl)acetamide
DMYK490 CA CAS 78281-72-8
DMYK490 CB CHEBI:75922
DMYK490 DE Osteoarthritis
DMEDU7B ID DMEDU7B
DMEDU7B DN NERATINIB MALEATE
DMEDU7B HS Approved
DMEDU7B SN Neratinib maleate; UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892
DMEDU7B CP Puma Biotechnology
DMEDU7B PC 67307512
DMEDU7B MW 673.1
DMEDU7B FM C34H33ClN6O7
DMEDU7B IC InChI=1S/C30H29ClN6O3.C4H4O4/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22;5-3(6)1-2-4(7)8/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38);1-2H,(H,5,6)(H,7,8)/b9-7+;2-1-
DMEDU7B CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\\C(=O)O)\\C(=O)O
DMEDU7B IK VXZCUHNJXSIJIM-MEBGWEOYSA-N
DMEDU7B IU (Z)-but-2-enedioic acid;(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DMEDU7B CA CAS 915942-22-2
DMEDU7B DE HER2/NEU overexpressing breast cancer
DMMPG5V ID DMMPG5V
DMMPG5V DN NERIDRONIC ACID
DMMPG5V HS Approved
DMMPG5V SN Neridronic acid; 79778-41-9; Nerixia; Neridronic acid [INN]; (6-Amino-1-hydroxyhexane-1,1-diyl)diphosphonic acid; UNII-8U27U3RIN4; Acide neridronique [INN-French]; Acido neridronico [INN-Spanish]; Acidum neridronicum [INN-Latin]; CHEMBL55214; 8U27U3RIN4; NERIDRONATE SODIUM HYDRATE; (6-Amino-1-hydroxyhexylidene)diphosphonic acid; 6-Amino-1-hydroxyhexane-1,1-diphosphonate; 6-amino-1-hydroxyhexane-1,1-diyldiphosphonic acid; W-203821; Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis-
DMMPG5V DT Small molecular drug
DMMPG5V PC 71237
DMMPG5V MW 277.15
DMMPG5V FM C6H17NO7P2
DMMPG5V IC InChI=1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
DMMPG5V CS C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN
DMMPG5V IK PUUSSSIBPPTKTP-UHFFFAOYSA-N
DMMPG5V IU (6-amino-1-hydroxy-1-phosphonohexyl)phosphonic acid
DMMPG5V CA CAS 79778-41-9
DMMPG5V CB CHEBI:135145
DMMPG5V DE Bone disease; Complex regional pain syndrome
DMFOIA8 ID DMFOIA8
DMFOIA8 DN Nesiritide
DMFOIA8 HS Approved
DMFOIA8 SN Natrecor (TN)
DMFOIA8 CP Scios Llc
DMFOIA8 DT Small molecular drug
DMFOIA8 SQ DB04899: Natriuretic peptides B: SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH
DMFOIA8 PC 71308561
DMFOIA8 MW 3464
DMFOIA8 FM C143H244N50O42S4
DMFOIA8 IC InChI=1S/C143H244N50O42S4/c1-13-76(10)112-137(232)189-99(68-199)131(226)188-98(67-198)130(225)187-97(66-197)129(224)186-96(65-196)117(212)166-59-105(202)169-90(52-72(2)3)114(209)163-61-107(204)171-100(132(227)177-83(32-19-22-44-146)124(219)190-111(75(8)9)136(231)184-91(53-73(4)5)127(222)175-84(34-24-46-159-141(151)152)121(216)174-85(35-25-47-160-142(153)154)122(217)185-94(139(234)235)55-78-57-157-71-167-78)69-238-239-70-101(172-108(205)62-165-116(211)95(64-195)170-106(203)60-162-113(208)87(38-39-103(148)200)181-135(230)110(74(6)7)191-126(221)89(41-51-237-12)179-120(215)82(31-18-21-43-145)180-134(229)102-37-27-49-193(102)138(233)79(147)63-194)133(228)182-92(54-77-28-15-14-16-29-77)115(210)164-58-104(201)168-80(33-23-45-158-140(149)150)118(213)173-81(30-17-20-42-144)119(214)178-88(40-50-236-11)123(218)183-93(56-109(206)207)128(223)176-86(125(220)192-112)36-26-48-161-143(155)156/h14-16,28-29,57,71-76,79-102,110-112,194-199H,13,17-27,30-56,58-70,144-147H2,1-12H3,(H2,148,200)(H,157,167)(H,162,208)(H,163,209)(H,164,210)(H,165,211)(H,166,212)(H,168,201)(H,169,202)(H,170,203)(H,171,204)(H,172,205)(H,173,213)(H,174,216)(H,175,222)(H,176,223)(H,177,227)(H,178,214)(H,179,215)(H,180,229)(H,181,230)(H,182,228)(H,183,218)(H,184,231)(H,185,217)(H,186,224)(H,187,225)(H,188,226)(H,189,232)(H,190,219)(H,191,221)(H,192,220)(H,206,207)(H,234,235)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t76-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,110-,111-,112-/m0/s1
DMFOIA8 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC=N4)C(=O)O)CC(C)C)CO)CO)CO)CO
DMFOIA8 IK HPNRHPKXQZSDFX-OAQDCNSJSA-N
DMFOIA8 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(4R,10S,16S,19S,22S,25S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
DMFOIA8 CB CHEBI:135919
DMFOIA8 DE Congestive heart failure
DM0LPI9 ID DM0LPI9
DM0LPI9 DN Netarsudil
DM0LPI9 HS Approved
DM0LPI9 SN UNII-W6I5QDT7QI; W6I5QDT7QI; Netarsudil mesylate; Netarsudil [USAN]; AR-11324 free base; Netarsudil [USAN:INN]; Netarsudil (USAN/INN); GTPL9322; SCHEMBL16036278; ZINC113149554; AR11324; AR-11324; ester 60; 1628418-15-4
DM0LPI9 CP Aerie Pharmaceuticals
DM0LPI9 PC 66599893
DM0LPI9 MW 453.5
DM0LPI9 FM C28H27N3O3
DM0LPI9 IC InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1
DM0LPI9 CS CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
DM0LPI9 IK OURRXQUGYQRVML-AREMUKBSSA-N
DM0LPI9 IU [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
DM0LPI9 CA CAS 1254032-66-0
DM0LPI9 DE Open-angle glaucoma; Glaucoma/ocular hypertension
DMRD1QK ID DMRD1QK
DMRD1QK DN Netilmicin
DMRD1QK HS Approved
DMRD1QK SN NTL; Netilmicina; Netilmicine; Netilmicinum; Netilyn; Netira; Nettacin; Vectacin; NETILMICIN SULFATE; Sch 20569; Netilmicin (INN); Netilmicin [INN:BAN]; Netilmicina [INN-Spanish]; Netilmicine [INN-French]; Netilmicinum [INN-Latin]; Netira (TN); Nettacin (TN); Sch-20569; O-(2,6-Diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-O-(3-desoxy-4-C-methyl-3-methylamino-beta-L-arabinopyranosyl-(1-6)-2-desoxy-N1-ethyl-D-streptamin; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; (2R,3S,4S,5S)-2-[(1S,2R,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 1-N-Aethylsisomicin; 1-N-Ethylsisomicin; 2-[4-amino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol; 4-amino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside
DMRD1QK CP Abbott Laboratories
DMRD1QK TC Antibiotics
DMRD1QK DT Small molecular drug
DMRD1QK PC 441306
DMRD1QK MW 475.6
DMRD1QK FM C21H41N5O7
DMRD1QK IC InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1
DMRD1QK CS CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N
DMRD1QK IK CIDUJQMULVCIBT-MQDUPKMGSA-N
DMRD1QK IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMRD1QK CA CAS 56391-56-1
DMRD1QK DE Bacterial infection
DM6HX9B ID DM6HX9B
DM6HX9B DN Nevirapine
DM6HX9B HS Approved
DM6HX9B SN NEV; NVP; Viramune; Cahill May Roberts Brand of Nevirapine; Promeco Brand of Nevirapine; BI RG 587; BIRG 0587; BIRG 587; BIRG587; BIRG-0587; BIRG-587; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Nevirapine & PRO 140; Nevirapine [USAN:INN]; Viramune (TN); Viramune(TM); BI-RG-587; Nevirapine & CD4-IgG; Nevirapine (JAN/USP/INN); Viramune, BI-RG 587, Nevirapine; BI-RG-587 & CD4-IgG; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
DM6HX9B CP Boehringer Ingelheim
DM6HX9B TC Anti-HIV Agents
DM6HX9B DT Small molecular drug
DM6HX9B PC 4463
DM6HX9B MW 266.3
DM6HX9B FM C15H14N4O
DM6HX9B IC InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
DM6HX9B CS CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
DM6HX9B IK NQDJXKOVJZTUJA-UHFFFAOYSA-N
DM6HX9B IU 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
DM6HX9B CA CAS 129618-40-2
DM6HX9B CB CHEBI:63613
DM6HX9B DE Human immunodeficiency virus infection
DMCDYW7 ID DMCDYW7
DMCDYW7 DN Nicardipine
DMCDYW7 HS Approved
DMCDYW7 SN Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMCDYW7 CP Chiesi Usa Inc
DMCDYW7 TC Antihypertensive Agents
DMCDYW7 DT Small molecular drug
DMCDYW7 PC 4474
DMCDYW7 MW 479.5
DMCDYW7 FM C26H29N3O6
DMCDYW7 IC InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
DMCDYW7 CS CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMCDYW7 IK ZBBHBTPTTSWHBA-UHFFFAOYSA-N
DMCDYW7 IU 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMCDYW7 CA CAS 55985-32-5
DMCDYW7 CB CHEBI:7550
DMCDYW7 DE High blood pressure
DMBCM8L ID DMBCM8L
DMBCM8L DN Nicergoline
DMBCM8L HS Approved
DMBCM8L SN MNE; Nargoline; Nicergolin; Nicergolina; Nicergolinum; Nicotergoline; Nimergoline; Sermion; Nicergolin [German]; Nicergolina [DCIT]; Nimergoline base; FI 6714; RP 19651; Nicergolinum [INN-Latin]; Sermion (TN); Nicergoline (JP15/USAN/INN); Nicergoline [USAN:BAN:INN:JAN]; Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester); Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester) (8CI); Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester); Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester); (+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; 1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether; 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat); 10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]; 10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester); 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate; 10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester); 5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester; 8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline
DMBCM8L TC Vasodilator Agents
DMBCM8L DT Small molecular drug
DMBCM8L PC 34040
DMBCM8L MW 484.4
DMBCM8L FM C24H26BrN3O3
DMBCM8L IC InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
DMBCM8L CS CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br
DMBCM8L IK YSEXMKHXIOCEJA-FVFQAYNVSA-N
DMBCM8L IU [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
DMBCM8L CA CAS 27848-84-6
DMBCM8L CB CHEBI:31902
DMBCM8L DE Brain ischaemia; Senile dementia
DMJAGXQ ID DMJAGXQ
DMJAGXQ DN Niclosamide
DMJAGXQ HS Approved
DMJAGXQ SN niclosamide; 50-65-7; Niclocide; 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide; Tredemine; Bayluscid; Phenasal; Yomesan; Fenasal; Dichlosale; Helmiantin; Sagimid; Iomezan; Devermine; Atenase; Vermitid; Radeverm; Mansonil; Iomesan; Devermin; Cestocid; Sulqui; Lintex; Nasemo; Mato; Fedal-Telmin; Bayer 73; Radewerm; Zestocarp; Bayer 2353; 2',5-Dichloro-4'-nitrosalicylanilide; Chemagro 2353; BAY 2353; Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-; 5-Chloro-2'-chloro-4'-nitrosalicylanilide; nicolsamide; HL 2447; Niclosamidum [I
DMJAGXQ DT Small molecular drug
DMJAGXQ PC 4477
DMJAGXQ MW 327.12
DMJAGXQ FM C13H8Cl2N2O4
DMJAGXQ IC InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19)
DMJAGXQ CS C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O
DMJAGXQ IK RJMUSRYZPJIFPJ-UHFFFAOYSA-N
DMJAGXQ IU 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide
DMJAGXQ CA CAS 50-65-7
DMJAGXQ CB CHEBI:7553
DMJAGXQ DE Cestodes infection
DMIYJFV ID DMIYJFV
DMIYJFV DN Nicorandil
DMIYJFV HS Approved
DMIYJFV SN Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat
DMIYJFV CP Chugai; Roche; Sanofi-Aventis; Merk KGaA; Pfizer; 3M Pharmaceutical
DMIYJFV TC Vasodilator Agents
DMIYJFV DT Small molecular drug
DMIYJFV PC 47528
DMIYJFV MW 211.17
DMIYJFV FM C8H9N3O4
DMIYJFV IC InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
DMIYJFV CS C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
DMIYJFV IK LBHIOVVIQHSOQN-UHFFFAOYSA-N
DMIYJFV IU 2-(pyridine-3-carbonylamino)ethyl nitrate
DMIYJFV CA CAS 65141-46-0
DMIYJFV CB CHEBI:31905
DMIYJFV DE Angina pectoris
DMUPE07 ID DMUPE07
DMUPE07 DN Nicotinamide
DMUPE07 HS Approved
DMUPE07 SN Aminicotin; Amixicotyn; Amnicotin; Benicot; Dipegyl; Endobion; Enduramide; Hansamid; Mediatric; Niacevit; Niacinamide; Niacotinamide; Niamide; Nicamina; Nicamindon; Nicasir; Nicobion; Nicofort; Nicogen; Nicomidol; Nicosylamide; Nicota; Nicotamide; Nicotilamide; Nicotililamido; Nicotinamid; Nicotinamida; Nicotinamidum; Nicotinsaeureamid; Nicotinsaureamid; Nicotol; Nicotylamide; Nicotylamidum; Nicovit; Nicovitina; Nicovitol; Nicozymin; Nikasan; Nikazan; Nikotinamid; Nikotinsaeureamid; Niocinamide; Niozymin; Papulex; Pelmin; Pelmine; Savacotyl; Amid kyseliny nikotinove; Amid kyseliny nikotinove [Czech]; Amide PP; Astra Brand of Niacinamide; Austrovit PP; Delonin amide; Factor pp; Inovitan PP; Jenapharm Brand of Niacinamide; Merck Brand of Niacinamide; Niacinamide Astra Brand; Niacinamide Jenapharm Brand; Niacinamide Merck Brand; Niacinamide Pharmagenix Brand; Niacinamide [USAN]; Niavit PP; Nicotine acid amide; Nicotine amide; Nicotinic acid amide; Nicotinic amide; Nicotinsaureamid Jenapharm; Nicotinsaureamid [German]; Nikotinsaeureamid [German]; Pelonin amide; Pharmagenix Brand of Niacinamide; Vitamin B; Vitamin PP; Witamina PP; Nicosan 2; Vitamin H1; B 3, Vitamin; B3, Vitamin; Beta-Pyridinecarboxamide; Jenapharm, Nicotinsaureamid; Nandervit-N; Niacin-Vitamin B3; Niacinamide (USP); Nicotinamida [INN-Spanish]; Nicotinamide (Niacinamide); Nicotinamidum [INN-Latin]; Niko-tamin; PP-Faktor; Vi-Nicotyl; Vitamin B (VAN); M-(Aminocarbonyl)pyridine; Niacinamide, Nicotinic acid amide, Nicotinamide; Nicotinamide (JP15/INN); Nicotinamide, niacin, vitamin B3; Nicotinamide-carbonyl-14C; Pyridine-3-carboxamide; Pyridine-3-carboxylic acid amide; 3 Pyridinecarboxamide; 3-Carbamoylpyridine; 3-Pyridinecarboxamide; 3-Pyridinecarboxylic acid amide
DMUPE07 TC Antiinflammatory Agents
DMUPE07 DT Small molecular drug
DMUPE07 PC 936
DMUPE07 MW 122.12
DMUPE07 FM C6H6N2O
DMUPE07 IC InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
DMUPE07 CS C1=CC(=CN=C1)C(=O)N
DMUPE07 IK DFPAKSUCGFBDDF-UHFFFAOYSA-N
DMUPE07 IU pyridine-3-carboxamide
DMUPE07 CA CAS 98-92-0
DMUPE07 CB CHEBI:17154
DMUPE07 DE Inflammatory skin condition
DMWX5CO ID DMWX5CO
DMWX5CO DN Nicotine
DMWX5CO HS Approved
DMWX5CO SN Habitrol; Micotine; NCT; NICOTINE AND SALTS; Nicoderm Patch; Nicotina [Italian]; Nicotine Patch; Nicotine [USAN]; Nicotine replacement patch; Nicotine solution; Nictoine patch; Nikotin [German]; Nikotyna [Polish]; Transdermal Nicotine; Nicotine [UN1654] [Poison]; ENT 3,424; Habitrol (TN); Nicorette (TN); Nicotine (USP); Nicotine (compounds related to); Nicotine [BSI:ISO]; L(-)-nicotine; Beta-Pyridyl-alpha-N-methyl pyrrolidine; (-)-Nicotine solution; (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; (S)-(-)-Nicotine; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; (S)-Nicotine; 3-(2-(N-methylpyrrolidinyl))pyridine; 3-(N-Methylpyrollidino)pyridine; 3-(N-Methylpyrrolidino)pyridine; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMWX5CO CP Upjohn Corporation
DMWX5CO DT Small molecular drug
DMWX5CO PC 89594
DMWX5CO MW 162.23
DMWX5CO FM C10H14N2
DMWX5CO IC InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3/t10-/m0/s1
DMWX5CO CS CN1CCC[C@H]1C2=CN=CC=C2
DMWX5CO IK SNICXCGAKADSCV-JTQLQIEISA-N
DMWX5CO IU 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMWX5CO CA CAS 54-11-5
DMWX5CO CB CHEBI:17688
DMWX5CO DE Nicotine dependence; Tobacco dependence
DMSVOZT ID DMSVOZT
DMSVOZT DN Nifedipine
DMSVOZT HS Approved
DMSVOZT SN Adalat; Adalate; Adapine; Adapress; Afeditab; Alat; Aldipin; Alfadal; Alonix; Angipec; Anifed; Anpine; Aprical; Bonacid; Calcibloc; Calcigard; Calcilat; Camont; Cardifen; Cardilat; Cardionorm; Chronadalate; Citilat; Coracten; Coral; Cordafen; Cordaflex; Cordalat; Cordicant; Cordilan; Cordipin; Cordipine; Corinfar; Corotrend; Corynphar; Depin; Dignokonstant; Dilafed; Dipinkor; Duranifin; Ecodipi; Ecodipin; Emaberin; Fedcor; Fenamon; Fenigidin; Fenihidin; Fenihidine; Glopir; Hadipin; Hexadilat; Infedipin; Introcar; Kordafen; Korinfar; Macorel; Megalat; Myogard; Nedipin; Nicardia; Nifangin; Nifar; Nifdemin; Nifebene; Nifecard; Nifecor; Nifedepat; Nifediac; Nifedical; Nifedicor; Nifedin; Nifedine; Nifedipino; Nifedipinum; Nifedipres; Nifelan; Nifelat; Nifelate; Nificard; Nifidine; Nifipen; Niphedipine; Orix; Oxcord; Pidilat; Procardia; Sepamit; Tibricol; Vascard; Zenusin; AWD Pharma Brand of Nifedipine; Adalat CC; Adalat CR; Adalat Crono; Adalat FT; Adalat GITS; Adalat LA; Adalat LP; Adalat Oros; Adalat PA; Adalat Retard; Adalat XL; Adalate LP; Adcock Ingram Brand of Nifedipine; Adipine XL; Afeditab CR; Alonix S; Aprical long; Bayer Brand of Nifedipine; Chronadalate LP; Coracten XL; Ecodipin E; Fedcor Retard; Fenamon SR; Fortipine LA; KRKA Brand of Nifedipine; Nifedical XL; Nifedipine Bayer Brand; Nifedipine GTIS; Nifedipine KRKA Brand; Nifedipine Monohydrochloride; Nifedipine Orion Brand; Nifedipine Pfizer Brand; Nifedipine Retard; Nifedirex LP; Nifelat Q; Nifensar XL; Orion Brand of Nifedipine; Pfizer Brand of Nifedipine; Procardia XL; Slofedipine XL; Tensipine MR; Adalat 10; Adalat 20; Adalat 5; Adalat GITS 30; Bay1040; N 7634; N1fedilat; Adalat (TN); Afeditab CR (TN); Alpha-Nifedipine Retard;Apo-Nifed; Bay-1040; KB-1712P; Monohydrochloride, Nifedipine; Nifedical (TN); Nifedipine-GTIS; Nifedipino [INN-Spanish]; Nifedipinum [INN-Latin]; Procardia (TN); Bay-a-1040; Nifedipine (JP15/USP/INN); Nifedipine [USAN:BAN:INN:JAN]
DMSVOZT CP Bayer
DMSVOZT TC Analgesics
DMSVOZT DT Small molecular drug
DMSVOZT PC 4485
DMSVOZT MW 346.3
DMSVOZT FM C17H18N2O6
DMSVOZT IC InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
DMSVOZT CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
DMSVOZT IK HYIMSNHJOBLJNT-UHFFFAOYSA-N
DMSVOZT IU dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMSVOZT CA CAS 21829-25-4
DMSVOZT CB CHEBI:7565
DMSVOZT DE Angina pectoris
DMJ3I1Q ID DMJ3I1Q
DMJ3I1Q DN Niflumic acid
DMJ3I1Q HS Approved
DMJ3I1Q SN Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A
DMJ3I1Q TC Antiinflammatory Agents
DMJ3I1Q DT Small molecular drug
DMJ3I1Q PC 4488
DMJ3I1Q MW 282.22
DMJ3I1Q FM C13H9F3N2O2
DMJ3I1Q IC InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
DMJ3I1Q CS C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
DMJ3I1Q IK JZFPYUNJRRFVQU-UHFFFAOYSA-N
DMJ3I1Q IU 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid
DMJ3I1Q CA CAS 4394-00-7
DMJ3I1Q CB CHEBI:34888
DMJ3I1Q DE Rheumatoid arthritis
DMSQLZJ ID DMSQLZJ
DMSQLZJ DN Nifurtimox
DMSQLZJ HS Approved
DMSQLZJ SN NIFURTIMOX; Lampit; Bayer 2502; 23256-30-6; BAY 2502; Nifurtimox [INN:BAN]; Nifurtimoxum [INN-Latin]; CCRIS 2201; EINECS 245-531-0; CHEBI:7566; C10H13N3O5S; 4-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide; 4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide; 3-Methyl-N-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide; 3-Methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4H-1,4-thiazine-1,1-dioxide
DMSQLZJ CP Bayer healthcare pharmaceuticals
DMSQLZJ DT Small molecular drug
DMSQLZJ PC 6842999
DMSQLZJ MW 287.29
DMSQLZJ FM C10H13N3O5S
DMSQLZJ IC InChI=1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+
DMSQLZJ CS CC1CS(=O)(=O)CCN1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DMSQLZJ IK ARFHIAQFJWUCFH-IZZDOVSWSA-N
DMSQLZJ IU (E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine
DMSQLZJ CA CAS 23256-30-6
DMSQLZJ CB CHEBI:7566
DMSQLZJ DE Trypanosomiasis; Chagas disease
DM7HXWT ID DM7HXWT
DM7HXWT DN Nilotinib
DM7HXWT HS Approved
DM7HXWT SN NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
DM7HXWT CP Novartis AG
DM7HXWT TC Anticancer Agents
DM7HXWT DT Small molecular drug
DM7HXWT PC 644241
DM7HXWT MW 529.5
DM7HXWT FM C28H22F3N7O
DM7HXWT IC InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
DM7HXWT CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DM7HXWT IK HHZIURLSWUIHRB-UHFFFAOYSA-N
DM7HXWT IU 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
DM7HXWT CA CAS 641571-10-0
DM7HXWT CB CHEBI:52172
DM7HXWT DE Chronic myelogenous leukaemia
DMFN07X ID DMFN07X
DMFN07X DN Nilutamide
DMFN07X HS Approved
DMFN07X SN Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
DMFN07X CP Aventis Pharmaceuticals Inc.
DMFN07X TC Anticancer Agents
DMFN07X DT Small molecular drug
DMFN07X PC 4493
DMFN07X MW 317.22
DMFN07X FM C12H10F3N3O4
DMFN07X IC InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
DMFN07X CS CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
DMFN07X IK XWXYUMMDTVBTOU-UHFFFAOYSA-N
DMFN07X IU 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
DMFN07X CA CAS 63612-50-0
DMFN07X CB CHEBI:7573
DMFN07X DE Prostate cancer
DMQ0RKZ ID DMQ0RKZ
DMQ0RKZ DN Nimodipine
DMQ0RKZ HS Approved
DMQ0RKZ SN Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide
DMQ0RKZ CP Bayer Pharmaceuticals Corporation
DMQ0RKZ TC Vasodilator Agents
DMQ0RKZ DT Small molecular drug
DMQ0RKZ PC 4497
DMQ0RKZ MW 418.4
DMQ0RKZ FM C21H26N2O7
DMQ0RKZ IC InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
DMQ0RKZ CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
DMQ0RKZ IK UIAGMCDKSXEBJQ-UHFFFAOYSA-N
DMQ0RKZ IU 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMQ0RKZ CA CAS 66085-59-4
DMQ0RKZ CB CHEBI:7575
DMQ0RKZ DE Cerebral vasospasm
DMA65ER ID DMA65ER
DMA65ER DN Nipradilol
DMA65ER HS Approved
DMA65ER SN Nipradilol; Nipradolol; Hypadil; 81486-22-8; Nipradilolum [Latin]; Nipradilol [INN:JAN]; UNII-FVM336I71Y; Hypadil (TN); CCRIS 2515; K 351; BRN 3566879; FVM336I71Y; 8-(2-Hydroxy-3-(isopropylamino)propoxy)chroman-3-yl nitrate; C15H22N2O6; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanyl nitrat; 8-(2-Hydroxy-3-(isopropylamino)propoxy)-3-chromanol 3-nitrate; K-351; 3,4-Dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-benzopyran; 3,4-Dihydro-8-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2H-1-benzopyran-3-ol 3-nitra
DMA65ER DT Small molecular drug
DMA65ER PC 72006
DMA65ER MW 326.34
DMA65ER FM C15H22N2O6
DMA65ER IC InChI=1S/C15H22N2O6/c1-10(2)16-7-12(18)8-21-14-5-3-4-11-6-13(23-17(19)20)9-22-15(11)14/h3-5,10,12-13,16,18H,6-9H2,1-2H3
DMA65ER CS CC(C)NCC(COC1=CC=CC2=C1OCC(C2)O[N+](=O)[O-])O
DMA65ER IK OMCPLEZZPVJJIS-UHFFFAOYSA-N
DMA65ER IU [8-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3,4-dihydro-2H-chromen-3-yl] nitrate
DMA65ER CA CAS 81486-22-8
DMA65ER CB CHEBI:31682
DMA65ER DE Angina pectoris
DMLPSWQ ID DMLPSWQ
DMLPSWQ DN Niraparib Tosylate
DMLPSWQ HS Approved
DMLPSWQ SN 1038915-73-9; MK-4827 (tosylate); MK-4827 tosylate; UNII-75KE12AY9U; MK-4827(Niraparib) tosylate; 75KE12AY9U; MK-4827-tosylate; MK 4827 tosylate; Niraparib(MK-4827) tosylate; KS-00000TSH; MolPort-044-556-849; s7625; HY-10619B; AKOS030632785; CS-2283; AC-30383; KB-335358; AX8326059
DMLPSWQ CP Tesaro
DMLPSWQ TC Antihypertensive Agents
DMLPSWQ DT Small molecular drug
DMLPSWQ PC 78357761
DMLPSWQ MW 492.6
DMLPSWQ FM C26H28N4O4S
DMLPSWQ IC InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
DMLPSWQ CS CC1=CC=C(C=C1)S(=O)(=O)O.C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
DMLPSWQ IK LCPFHXWLJMNKNC-PFEQFJNWSA-N
DMLPSWQ IU 4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
DMLPSWQ CA CAS 1038915-73-9
DMLPSWQ DE Peritoneal cancer; Fallopian tube cancer
DM7ISKJ ID DM7ISKJ
DM7ISKJ DN Nisoldipine
DM7ISKJ HS Approved
DM7ISKJ SN Baymycard; Nisocor; Nisoldipin; Nisoldipino; Nisoldipinum; Sular; Syscor; Zadipina; Bay k 5552; Nisoldipino [INN-Spanish]; Nisoldipinum [INN-Latin]; Sular (TN); Bay-k-5552; Nisoldipine (JAN/USAN/INN); Nisoldipine [USAN:BAN:INN:JAN]; Isobutyl 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(2-nitrophenyl)-3-pyridincarboxylat;Methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester; 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM7ISKJ TC Antihypertensive Agents
DM7ISKJ DT Small molecular drug
DM7ISKJ PC 4499
DM7ISKJ MW 388.4
DM7ISKJ FM C20H24N2O6
DM7ISKJ IC InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
DM7ISKJ CS CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
DM7ISKJ IK VKQFCGNPDRICFG-UHFFFAOYSA-N
DM7ISKJ IU 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM7ISKJ CA CAS 63675-72-9
DM7ISKJ CB CHEBI:76917
DM7ISKJ DE Hypertension
DMOWLVG ID DMOWLVG
DMOWLVG DN Nitazoxanide
DMOWLVG HS Approved
DMOWLVG SN Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanid; Nitazoxanida; Nitazoxanidum; Taenitaz; Tizoxanide glucuronide; AZT + Nitazoxanide; Alinia (TN); Annita (TN); Azt+ nitazoxanide; Daxon (TN); Dexidex (TN); Kidonax (TN); Nitax (TN); Nitazox (TN); Nitazoxanida [INN-Spanish]; Nitazoxanide [USAN:INN]; Nitazoxanidum [INN-Latin]; Pacovanton (TN); Paramix (TN); Phavic-1; Zox (TN); Nitazoxanide (USAN/INN); Daxon, Dexidex, Kidonax, Pacovanton, Paramix, Nitax, Zox, Nitazoxanide
DMOWLVG CP Unimed Pharmaceuticals
DMOWLVG TC Antiparasitic Agents
DMOWLVG DT Small molecular drug
DMOWLVG PC 41684
DMOWLVG MW 307.28
DMOWLVG FM C12H9N3O5S
DMOWLVG IC InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
DMOWLVG CS CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]
DMOWLVG IK YQNQNVDNTFHQSW-UHFFFAOYSA-N
DMOWLVG IU [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] acetate
DMOWLVG CA CAS 55981-09-4
DMOWLVG CB CHEBI:94807
DMOWLVG DE Diarrhea
DMVS9WQ ID DMVS9WQ
DMVS9WQ DN Nitisinone
DMVS9WQ HS Approved
DMVS9WQ SN Nitisinona; Nitisinonum; Nitisone; Orfadin; Nitisinone [INN]; SC 0735; FE-0200; Nitisinone (NTBC); Nitisinone [USAN:INN]; Orfadin (TN); Nitisinone (JAN/USAN/INN); 2-(2-Nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione; 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione; 2-(Alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione; 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione; 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
DMVS9WQ TC Anticancer Agents
DMVS9WQ DT Small molecular drug
DMVS9WQ PC 115355
DMVS9WQ MW 329.23
DMVS9WQ FM C14H10F3NO5
DMVS9WQ IC InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2
DMVS9WQ CS C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
DMVS9WQ IK OUBCNLGXQFSTLU-UHFFFAOYSA-N
DMVS9WQ IU 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
DMVS9WQ CA CAS 104206-65-7
DMVS9WQ CB CHEBI:50378
DMVS9WQ DE Hereditary tyrosinemia type 1
DMEGIQ6 ID DMEGIQ6
DMEGIQ6 DN Nitrazepam
DMEGIQ6 HS Approved
DMEGIQ6 SN Alodorm; Apodorm; Benzalin; Calsamin; Calsmin; Cerson; Dormalon; Dumolid; Eatan; Epibenzalin; Epinelbon; Eunoctin; Eunoktin; Gerson; Hipnax; Hipsal; Ibrovek; Imadorm; Imeson; Imesont; Ipersed; Magadon; Megadon; Mitidin; Mogadan; Mogadon; Mogadone; Nelbon; Nelmat; Neozepam; Neuchlonic; Nitrados; Nitravet; Nitrazadon; Nitrazep; Nitrazepamum; Nitrempax; Nitrenpax; Nitrodiazepam; Noctesed; Novanox; Pacisyn; Paxisyn; Pelson; Persopit; Radedorm; Relact; Remnos; Serenade; Somitran; Somnased; Somnibel; Somnite; Sonebon; Sonnolin; Surem; Trazenin; Unisomnia; Aliud Brand of Nitrazepam; Allphar Brand of Nitrazepam; Alphapharma Brand of Nitrazepam; Alpharma Brand of Nitrazepam; Alter Brand of Nitrazepam; CSP Brand of Nitrazepam; DDSA Brand of Nitrazepam; Dermatech Brand of Nitrazepam; Desitin Brand of Nitrazepam; Dormicum Brand of Nitrazepam; Eatan N; ICN Brand of Nitrazepam; Neuraxpharm Brand of Nitrazepam; Nitrazepam AL; Norgine Brand of Nitrazepam; Pfleger Brand of Nitrazepam; Protea Brand of Nitrazepam; Rhoxalpharma Brand of Nitrazepam; Sandoz nitrazepam; Scheurich Brand of Nitrazepam; Sonebon Tofraniln A; Taurus Brandof Nitrazepam; United Drug Brand of Nitrazepam; Wernigerode Brand of Nitrazepam; LA 1; S 2000; Alodorm (TN); Apo-nitrazepam tablets BP; Apodorm (TN); Arem (TN); Benzalin (TN); Cavodan (TN); Ct-Arzneimittel Brand of Nitrazepam; Dima (TN); Dormalon (TN); Dormicum (anticonvulsant); Dormigen (TN); Dormin-5; Dormo-Puren; Dumolid (TN); Eatan N (TN); Eunoctin (TN); Hypnotex (TN); ISOPROPYLACETATE/NITRAZEPAM; Imeson (TN); Insoma (TN); Insomin (TN); Ipersed (TN); LA 1 (VAN); Mitidin (TN); Mogadan (TN); Mogadon (TN); N-Desmethylnimetazepam; Nitavan (TN); Nitepam (TN); Nitrados (TN); Nitrapan (TN); Nitravet (TN); Nitrazadon (TN); Nitrazep (TN); Nitrazepam (TN); Nitrazepam Capsules BP 1993 (TN); Nitrazepam Oral Suspension BP 1993 (TN); Nitrazepam Tablets BP 1993 (TN); Nitrazepam-10; Nitrazepam-5; Nitrazepam-neuraxpharm; Nitrazepamum [INN-Latin]; Nitrazepan (TN); Nitrazepol (TN); Nitredon (TN); Nitrosun (TN); Novanox (TN); Numbon (TN); Onirema (TN); Ormodon (TN); Pacisyn (TN); Paxadorm (TN); Pelson (TN); Pelsonfilina (TN); Protraz (TN); Radedorm (TN); Remnos (TN); Rhoxal-nitrazepam; Ro 4-5360; Ro 5-3059; Ro 53-60; Serenade (TN); Somnibel N (TN); Somnipar (TN); Somnite (TN); Sonebon (TN); Sonotrat (TN); Surem (TN); Tri (TN); Unisomnia (TN); Dormo-Puren (TN); Nitrazepam (JP15/USAN/INN); Nitrazepam [USAN:INN:BAN:JAN]; 1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; 2,3-Dihydro-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2-on; 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMEGIQ6 TC Antianxiety Agents
DMEGIQ6 DT Small molecular drug
DMEGIQ6 PC 4506
DMEGIQ6 MW 281.27
DMEGIQ6 FM C15H11N3O3
DMEGIQ6 IC InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
DMEGIQ6 CS C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3
DMEGIQ6 IK KJONHKAYOJNZEC-UHFFFAOYSA-N
DMEGIQ6 IU 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMEGIQ6 CA CAS 146-22-5
DMEGIQ6 CB CHEBI:7581
DMEGIQ6 DE Epilepsy; Insomnia
DM21C09 ID DM21C09
DM21C09 DN Nitrendipine
DM21C09 HS Approved
DM21C09 SN Baylotensin; Bayotensin; Baypress; Bylotensin; Deiten; Gericin; Jutapress; Nidrel; Niprina; NitrePuren; Nitregamma; Nitrendepat; Nitrendidoc; Nitrendimerck; Nitrendipin; Nitrendipincorax; Nitrendipino; Nitrendipinum; Nitrensal; Nitrepin; Nitrepress; Tensogradal; Trendinol; Vastensium; Nitre AbZ; Nitre Puren; Nitren Lich;Nitren acis; Nitrend KSK; Nitrendi Biochemie; Nitrendipin AL; Nitrendipin Apogepha; Nitrendipin Atid; Nitrendipin Basics; Nitrendipin Heumann; Nitrendipin Lindo; Nitrendipin Stada; Nitrendipin beta; Nitrendipin corax; Nitrendipin von ct; Nitrendipino Bayvit; Nitren 1A Pharma; AL, Nitrendipin; AbZ, Nitre; Acis, Nitren; Atid, Nitrendipin; Basics, Nitrendipin; Baypress (TN); Bayvit, Nitrendipino; Beta, Nitrendipin; Biochemie, Nitrendi; Ct, nitrendipin von; Heumann, Nitrendipin; KSK, Nitrend; Lich, Nitren; Lindo, Nitrendipin; N-144; Nitre-Puren; Nitrendipin-corax; Pharma, Nitren 1A; Stada, Nitrendipin; Von ct, nitrendipin; Bay-e-5009; 1A Pharma, Nitren
DM21C09 TC Antihypertensive Agents
DM21C09 DT Small molecular drug
DM21C09 PC 4507
DM21C09 MW 360.4
DM21C09 FM C18H20N2O6
DM21C09 IC InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
DM21C09 CS CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C
DM21C09 IK PVHUJELLJLJGLN-UHFFFAOYSA-N
DM21C09 IU 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM21C09 CA CAS 39562-70-4
DM21C09 CB CHEBI:7582
DM21C09 DE Hypertension
DM1RBYG ID DM1RBYG
DM1RBYG DN Nitric Oxide
DM1RBYG HS Approved
DM1RBYG SN Nitric oxide; nitric oxide; nitrogen monoxide; Mononitrogen monoxide; 10102-43-9; nitrogen monooxide; nitrogen protoxide; nitrosyl; Nitrosyl radical; EDRF; CHEBI:16480; endothelium-derived relaxing factor; monoxyde d'azote; oxoazanyl; oxyde azotique; oxido nitrico; Stickstoffmonoxid; Nitric oxide trimer; monoxido de nitrogeno; Stickstoff(II)-oxid; Nitric oxide (JAN); INOmax (TN); oxido de nitrogeno(II); Nitrosoradical; [NO]; oxidonitrogen(); Nitrogen(II) oxide; OHM 11771; AC1L3QHF; Nitric oxide, 985%; DTXSID1020938; CHEMBL1200689; CTK0H7679; ()NO; HNO; INOmax; Nitrosyl; Nitroxyl; Oxoazanyl; Stickmonoxyd; Endogenous Nitrate Vasodilator; Monoxido de nitrogeno; Nitrogen monooxide; Nitrogen monoxide; Nitrosyl hydride; Nitroxide radical; Oxido nitrico; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd [German]; Bioxyde d'azote; Bioxyde d'azote [French]; Endothelium-Derived Nitric Oxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric oxide 10% by volume or more; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen oxide (NO); Oxide, Nitric; Oxido de nitrogeno(II); Oxidonitrogen(); Vasodilator, Endogenous Nitrate; Nitric Oxide, Endothelium-Derived; Nitrosyl hydride ((NO)H); Endothelium-derived relaxing factor (EDRF)
DM1RBYG CP NB therapeutics; University of Akron
DM1RBYG TC Bronchodilator Agents
DM1RBYG DT Small molecular drug
DM1RBYG PC 145068
DM1RBYG MW 30.006
DM1RBYG FM NO
DM1RBYG IC InChI=1S/NO/c1-2
DM1RBYG CS [N]=O
DM1RBYG IK MWUXSHHQAYIFBG-UHFFFAOYSA-N
DM1RBYG IU nitric oxide
DM1RBYG CA CAS 10102-43-9
DM1RBYG CB CHEBI:16480
DM1RBYG DE Respiratory failure; Solid tumour/cancer; Tinea pedis
DM7PQIK ID DM7PQIK
DM7PQIK DN Nitrofurantoin
DM7PQIK HS Approved
DM7PQIK SN Alfuran; Benkfuran; Berkfuran; Berkfurin; Ceduran; Chemiofuran; Cistofuran; Cyantin; Cystit; Dantafur; Furabid; Furachel; Furadantin; Furadantine; Furadantoin; Furadoine; Furadonin; Furadonine; Furadoninum; Furadontin; Furalan; Furaloid; Furantoin; Furatoin; Furedan; Furina; Furobactina; Furodantin; Furophen; Gerofuran; Ituran; Macpac; Macrobid; Macrodantin; Macrodantina; Macrofuran; Macrofurin; NITROFURANTION; Nierofu; Nifurantin; Nifuretten; Nitoin; Nitrex; Nitrofuradantin; Nitrofurantoina; Nitrofurantoine; Nitrofurantoinum; Novofuran; Orafuran; Parfuran; Phenurin; PiyEloseptyl; Siraliden; Trantoin; Uerineks; Urantoin; Urizept; Urodil; Urodin; Urofuran; Urofurin; Urolisa; Urolong; Welfurin; Zoofurin; Fua Med; Furadantin Retard; Furadantina MC; Furadantine mc; Furophen T; NITROFURANTOIN MACROCRYSTALLINE; Nitrofurantoina [DCIT]; Fua-med; Fur-ren; Furadantin (TN); Furadantine-MC; Macrobid (TN); Macrodantin (TN); N-Toin; ND-3320; ND-7248; NITROFURANTOIN, MACROCRYSTALLINE; Nitro Macro (TN); Nitrofur-C; Nitrofurantoine [INN-French]; Nitrofurantoinum [INN-Latin]; Ro-Antoin; Urantoin (TN); Uro-Selz; Uro-Tablinen; Uro-tablineu; Usaf ea-2; Nitrofurantoin (JAN/USP/INN); Nitrofurantoin [USAN:INN:BAN:JAN]; N-(5-Nitrofurfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylidene)-1-aminohydantoin; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina; N-(5-Nitro-2-furfurylideno)-1-aminohydantoina [Polish]; N-(5-nitro-2-furfurylidene)-1-aminohyda ntoin; 1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione; 1-((5-Nitrofurfurylidene)amino)hydantoin; 1-(5-Nitro-2-furfurylidenamino)hydantoin; 1-(5-Nitro-2-furfurylideneamino)hydantoin; 1-[(5-:nitrofurfurylidene)amino]hydantoin; 1-[(5-Nitrofurfurylidene)amino]hydantoin; 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione; 1-[[(5-Nitro-2-furanyl)methylene]amino]-2,4-imidazolidinedione; 1-{[(1E)-(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione; 1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione; 5-Nitrofurantoin
DM7PQIK CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DM7PQIK TC Antiinfective Agents
DM7PQIK DT Small molecular drug
DM7PQIK PC 6604200
DM7PQIK MW 238.16
DM7PQIK FM C8H6N4O5
DM7PQIK IC InChI=1S/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+
DM7PQIK CS C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
DM7PQIK IK NXFQHRVNIOXGAQ-YCRREMRBSA-N
DM7PQIK IU 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
DM7PQIK CA CAS 67-20-9
DM7PQIK CB CHEBI:71415
DM7PQIK DE Urinary tract infection
DMSM2KE ID DMSM2KE
DMSM2KE DN Nitrofurazone
DMSM2KE HS Approved
DMSM2KE SN nitrofurazone; Nitrofural; Furacilin; 59-87-0; Furacin; Furacillin; Furacine; Aldomycin; Furaldon; Nifuzon; Actin-N; Furacycline; Furacoccid; Otofuran; Nitrofurazan; Monafuracin; Furaziline; Furacinetten; Babrocid; Nitrozone; Mastofuran; Furazone; Chemofuran; Mammex; Amifur; Alfucin; Furesol; Furazol W; 5-Nitro-2-furaldehyde semicarbazone; Monofuracin; Dermofural; Monafuracis; Furaseptyl; Furatsilin; Nitrofurol; Fuvacillin; Furametral; Biofuracina; Becafurazone; Nifucin; Ibiofural; Hemofuran; Furalone; Furacort; Eldezol; Vadrocid; Vabrocid; Furazyme
DMSM2KE DT Small molecular drug
DMSM2KE PC 5447130
DMSM2KE MW 198.14
DMSM2KE FM C6H6N4O4
DMSM2KE IC InChI=1S/C6H6N4O4/c7-6(11)9-8-3-4-1-2-5(14-4)10(12)13/h1-3H,(H3,7,9,11)/b8-3+
DMSM2KE CS C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)N
DMSM2KE IK IAIWVQXQOWNYOU-FPYGCLRLSA-N
DMSM2KE IU [(E)-(5-nitrofuran-2-yl)methylideneamino]urea
DMSM2KE CA CAS 59-87-0
DMSM2KE CB CHEBI:44368
DMSM2KE DE Skin burns; Bacterial infection
DMQ2491 ID DMQ2491
DMQ2491 DN Nitroglycerin
DMQ2491 HS Approved
DMQ2491 SN nitroglycerin; Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Nitro-dur (TN); Transderm-nitro (TN); DWP-401
DMQ2491 TC Vasodilator Agents
DMQ2491 DT Small molecular drug
DMQ2491 PC 4510
DMQ2491 MW 227.09
DMQ2491 FM C3H5N3O9
DMQ2491 IC InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
DMQ2491 CS C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMQ2491 IK SNIOPGDIGTZGOP-UHFFFAOYSA-N
DMQ2491 IU 1,3-dinitrooxypropan-2-yl nitrate
DMQ2491 CA CAS 55-63-0
DMQ2491 CB CHEBI:28787
DMQ2491 DE Diabetic foot ulcer; Angina pectoris
DMLUA2J ID DMLUA2J
DMLUA2J DN Nitroprusside
DMLUA2J HS Approved
DMLUA2J SN Nitropress (TN); Nitroprusside sodium; Sodium nitroprusside (USP); Tox21_110314; Tox21_110314_1; 13755-38-9; 7304AF; A-8282; C07695; NITROPRUSSIDE SODIUM DIHYDRATE; C5FeN6O.2Na.2H2O; CAS-13755-38-9; CHEBI:9179; D00614; DSSTox_CID_21126; DSSTox_GSID_41126; DSSTox_RID_79630; DTXSID7041126; MFCD00149192; NCGC00166055-03; Na2[Fe(CN)5(NO)].2H2O; Sodium nitroferricyanide dihydrate, 99+%; Sodium nitroferricyanide dihydrate, reagent ACS; Sodium nitroferricyanide(III) dihydrate; Sodium nitroprusside hydrate (JAN)
DMLUA2J PC 11953895
DMLUA2J MW 297.95
DMLUA2J FM C5H4FeN6Na2O3
DMLUA2J IC XRKMNJXYOFSTBE-UHFFFAOYSA-N
DMLUA2J CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
DMLUA2J IK 1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;
DMLUA2J IU disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
DMLUA2J CA CAS 13755-38-9
DMLUA2J CB CHEBI:9179
DMLUA2J DE Congestive heart failure
DMM765C ID DMM765C
DMM765C DN Nitroprusside
DMM765C HS Approved
DMM765C SN C07269; LS-187044
DMM765C TC Antihypertensive Agents
DMM765C DT Small molecular drug
DMM765C PC 11953891
DMM765C MW 215.94
DMM765C FM C5FeN6O
DMM765C IC InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q5*-1;+6;-1
DMM765C CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Fe+6]
DMM765C IK CDLSWOALPINAJL-UHFFFAOYSA-N
DMM765C IU iron(6+);nitroxyl anion;pentacyanide
DMM765C DE Hypertension
DMTHWBI ID DMTHWBI
DMTHWBI DN Nitrous oxide
DMTHWBI HS Approved
DMTHWBI SN Distickstoffmonoxid; Lachgas; Stickdioxyd; Dinitrogen monoxide; Dinitrogen oxide; Factitious air; Gaz hilarant; Hyponitrous acid anhydride; Laughing gas; Nitrogen hypoxide; Nitrogenium oxydulatum; Nitrous oxide [JAN]; Oxido nitroso; Oxido nitroso [Spanish]; Oxyde nitreux; Stickdioxyd [German]; N2O; Nitrous oxide [UN1070] [Nonflammable gas]; Diazyne 1-oxide; Gas, Laughing; NITROUS-OXIDE; Nitrogen oxide (N2O); Nitrous oxide (TN); Nitrous oxide [Anaesthetics, volatile]; Nitrous oxide, compressed; Nitrous oxide, refrigerated liquid; Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]; Oxide, Nitrous; Protoxyde d'azote; Protoxyde d'azote [French]; Nitrous oxide (JP15/USP); Oxidodinitrogen(N-N); Stickstoff(I)-oxid
DMTHWBI DT Small molecular drug
DMTHWBI PC 948
DMTHWBI MW 44.013
DMTHWBI FM N2O
DMTHWBI IC InChI=1S/N2O/c1-2-3
DMTHWBI CS [N-]=[N+]=O
DMTHWBI IK GQPLMRYTRLFLPF-UHFFFAOYSA-N
DMTHWBI IU nitrous oxide
DMTHWBI CA CAS 10024-97-2
DMTHWBI CB CHEBI:17045
DMTHWBI DE Anxiety disorder
DMAB9QE ID DMAB9QE
DMAB9QE DN Nivolumab
DMAB9QE HS Approved
DMAB9QE CP Bristol-Myers Squibb
DMAB9QE DT Monoclonal antibody
DMAB9QE SQ Heavy Chain Sequence: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMAB9QE DE Central nervous system lymphoma; Chronic myelogenous leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Malignant pleural mesothelioma; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small-cell lung cancer; Esophageal cancer; Gastric adenocarcinoma; Recurrent glioblastoma; Renal cell carcinoma; Triple negative breast cancer; Melanoma; Non-small-cell lung cancer
DMGFV3Z ID DMGFV3Z
DMGFV3Z DN Nizatidine
DMGFV3Z HS Approved
DMGFV3Z SN Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
DMGFV3Z CP Eli Lilly
DMGFV3Z TC Antiulcer Agents
DMGFV3Z DT Small molecular drug
DMGFV3Z PC 3033637
DMGFV3Z MW 331.5
DMGFV3Z FM C12H21N5O2S2
DMGFV3Z IC InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
DMGFV3Z CS CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C
DMGFV3Z IK SGXXNSQHWDMGGP-IZZDOVSWSA-N
DMGFV3Z IU (E)-1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
DMGFV3Z CA CAS 76963-41-2
DMGFV3Z CB CHEBI:7601
DMGFV3Z DE Acid-reflux disorder
DMRJ7D1 ID DMRJ7D1
DMRJ7D1 DN Nomegestrol acetate
DMRJ7D1 HS Approved
DMRJ7D1 SN Lutenyl (TN)
DMRJ7D1 CP Theramex
DMRJ7D1 DT Small molecular drug
DMRJ7D1 PC 91668
DMRJ7D1 MW 370.5
DMRJ7D1 FM C23H30O4
DMRJ7D1 IC InChI=1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
DMRJ7D1 CS CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4
DMRJ7D1 IK IIVBFTNIGYRNQY-YQLZSBIMSA-N
DMRJ7D1 IU [(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
DMRJ7D1 CA CAS 58652-20-3
DMRJ7D1 CB CHEBI:135564
DMRJ7D1 DE Breast cancer
DMOUC09 ID DMOUC09
DMOUC09 DN Norepinephrine
DMOUC09 HS Approved
DMOUC09 SN norepinephrine; L-Noradrenaline; Levarterenol; 51-41-2; L-Norepinephrine; Levophed; (-)-Norepinephrine; L-arterenol; (R)-Noradrenaline; (R)-Norepinephrine; Levonor; Levonorepinephrine; Adrenor; Aktamin; Levonoradrenaline; Sympathin E; (R)-(-)-Norepinephrine; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; Noradrenalin; Norepirenamine; norepinephrinum; Noradrenalinum; Levoarterenol; Norartrinal; Nor-Epirenan; L-3,4-dihydroxyphenylethanolamine; Levarterenolo; Noreinefrina; Norepinefrina; Norepinephrinum; Levarterenolo [DCIT]; Nor adrenalin; Noradrenalina [Italian]; Norepinephrine Noradrenalin; LT03330026; ALBB-006229; Nor adrenalin (TN); Noradrenaline (JP15); Noreinefrina [INN-Spanish]; Norepinephrine (INN); Norepinephrine [INN:JAN]; Norepinephrinum [INN-Latin]; Norepinephrine l-Tartrate (1:1); D-(-)-Noradrenaline; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; L-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; (-)-(R)-Norepinephrine; (-)-Arterenol free base; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(9CI); 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Ecteinascidins
DMOUC09 CP Bedford Laboratories
DMOUC09 TC Vasoconstrictor Agents
DMOUC09 DT Small molecular drug
DMOUC09 PC 439260
DMOUC09 MW 169.18
DMOUC09 FM C8H11NO3
DMOUC09 IC InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1
DMOUC09 CS C1=CC(=C(C=C1[C@H](CN)O)O)O
DMOUC09 IK SFLSHLFXELFNJZ-QMMMGPOBSA-N
DMOUC09 IU 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
DMOUC09 CA CAS 51-41-2
DMOUC09 CB CHEBI:18357
DMOUC09 DE Sepsis
DMTY169 ID DMTY169
DMTY169 DN Norethindrone
DMTY169 HS Approved
DMTY169 SN Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one
DMTY169 CP Parke Davis Div Warner Lambert Co
DMTY169 TC Contraceptive Agents
DMTY169 DT Small molecular drug
DMTY169 PC 6230
DMTY169 MW 298.4
DMTY169 FM C20H26O2
DMTY169 IC InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DMTY169 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DMTY169 IK VIKNJXKGJWUCNN-XGXHKTLJSA-N
DMTY169 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMTY169 CA CAS 68-22-4
DMTY169 CB CHEBI:7627
DMTY169 DE Solid tumour/cancer
DMDGCQP ID DMDGCQP
DMDGCQP DN Norethindrone acetate
DMDGCQP HS Approved
DMDGCQP SN Noresthisterone; Norethadrone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Norpregneninlone; Norpregneninolone; Primolut-N; Proluteasi; Synphase; Triella; Utovlan; Utovlar; norethindrone; 19-Nor-ethindrone; 19-Norethisterone; 68-22-4; Anovulatorio; Anovule; Camila; Ciclovulan; Conludaf; Conludag; Ethinylnortestosterone; Gestest; Microneth; Micronett; Micronor; Micronovum; Mini-Pe; Mini-pill; Minovlar; Nor-QD; Noralutin; Norcolut; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
DMDGCQP PC 5832
DMDGCQP MW 340.5
DMDGCQP FM C22H28O3
DMDGCQP IC IMONTRJLAWHYGT-ZCPXKWAGSA-N
DMDGCQP CS CC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)C#C
DMDGCQP IK 1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1
DMDGCQP IU [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
DMDGCQP CA CAS 51-98-9
DMDGCQP CB CHEBI:7628
DMDGCQP DE Menorrhagia
DMIZ6W2 ID DMIZ6W2
DMIZ6W2 DN Norfloxacin
DMIZ6W2 HS Approved
DMIZ6W2 SN Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DMIZ6W2 TC Antibiotics
DMIZ6W2 DT Small molecular drug
DMIZ6W2 PC 4539
DMIZ6W2 MW 319.33
DMIZ6W2 FM C16H18FN3O3
DMIZ6W2 IC InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
DMIZ6W2 CS CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
DMIZ6W2 IK OGJPXUAPXNRGGI-UHFFFAOYSA-N
DMIZ6W2 IU 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
DMIZ6W2 CA CAS 70458-96-7
DMIZ6W2 CB CHEBI:100246
DMIZ6W2 DE Bacterial infection
DMYP4XC ID DMYP4XC
DMYP4XC DN Norgestimate
DMYP4XC HS Approved
DMYP4XC SN Norgestimato; Norgestimatum; Dexnorgestrel acetime; Norgestrel oxime acetate; D 138; ORF 10131; RWJ 10131; Norgestimato [INN-Spanish]; Norgestimatum [INN-Latin]; ORF-10131; Ortho-Prefest; RWJ-10131; Norgestimate (USP/INN); Norgestimate [USAN:INN:BAN]; D-13beta-Ethyl-17alpha-ethynyl-17beta-acetoxygon-4-en-3-oneoxime; D-13-beta-Ethyl-17-alpha-ethynyl-17-beta-acetoxygon-4-en-3-one oxime; [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate; (+)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one oxime acetate (ester); (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (17alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime; (3E)-17alpha-ethynyl-3-(hydroxyimino)-18a-homoestr-4-en-17beta-yl acetate
DMYP4XC TC Contraceptive Agents
DMYP4XC DT Small molecular drug
DMYP4XC PC 6540478
DMYP4XC MW 369.5
DMYP4XC FM C23H31NO3
DMYP4XC IC InChI=1S/C23H31NO3/c1-4-22-12-10-19-18-9-7-17(24-26)14-16(18)6-8-20(19)21(22)11-13-23(22,5-2)27-15(3)25/h2,14,18-21,26H,4,6-13H2,1,3H3/b24-17+/t18-,19+,20+,21-,22-,23-/m0/s1
DMYP4XC CS CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34
DMYP4XC IK KIQQMECNKUGGKA-NMYWJIRASA-N
DMYP4XC IU [(3E,8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
DMYP4XC CA CAS 20799-27-3
DMYP4XC CB CHEBI:50815
DMYP4XC DE Contraception
DM4KDYJ ID DM4KDYJ
DM4KDYJ DN Nortriptyline
DM4KDYJ HS Approved
DM4KDYJ SN Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
DM4KDYJ TC Antidepressants
DM4KDYJ DT Small molecular drug
DM4KDYJ PC 4543
DM4KDYJ MW 263.4
DM4KDYJ FM C19H21N
DM4KDYJ IC InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
DM4KDYJ CS CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
DM4KDYJ IK PHVGLTMQBUFIQQ-UHFFFAOYSA-N
DM4KDYJ IU N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
DM4KDYJ CA CAS 72-69-5
DM4KDYJ CB CHEBI:7640
DM4KDYJ DE Depression
DMRFWGK ID DMRFWGK
DMRFWGK DN Novobiocin
DMRFWGK HS Approved
DMRFWGK SN Albamix; Albamycin; Cardelmycin; Cathocin; Cathomycin; Inamycin; NOV; Novobiocina; Novobiocine; Novobiocinum; Robiocina; Sirbiocina; Spheromycin; Stilbiocina; Streptonivicin; Crystallinic acid; Novobiocin sodium salt; PA 93; U 6391; Albamycin (TN); Antibiotic PA-93; Novo-R; Novobiocin [INN:BAN]; Novobiocina [INN-Spanish]; Novobiocine [INN-French]; Novobiocinum [INN-Latin]; Streptonivicin (*Sodium salt*); [(3R,4S,5R,6R)-5-hydroxy-6-[2-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate; N-[7-[[3-O-(Aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-.beta.-L-lyxo-hexopyranosyl]oxy]-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butenyl); (3R,4S,5R,6R)-5-hydroxy-6-{[4-hydroxy-3-({[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]carbonyl}amino)-8-methyl-2-oxo-2H-chromen-7-yl]oxy}-3-methoxy-2,2-dimethyltetrahydro-2H-pyran-4-yl carbamate; (3r,4s,5r,6r)-5-hydroxy-6-[(2-hydroxy-3-{[4-hydroxy-3-(3-methylbut-2-en-1-yl)benzoyl]amino}-8-methyl-4-oxo-4h-chromen-7-yl)oxy]-3-methoxy-2,2-dimethyltetrahydro-2h-pyran-4-yl carbamate(non-preferred name); 7-(3-(O-Carbamoyl)-4-(O-methyl)-5,5-dimethyl-alpha-L-lyxopyranosyloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamidol)-8-methylcumarin; 7-(Carbamoyltetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(3-methylbut-2-enyl)benzamide)-8-methyl-2H-chromen-2-one
DMRFWGK CP Pfizer Pharmaceuticals
DMRFWGK TC Antibiotics
DMRFWGK DT Small molecular drug
DMRFWGK PC 54675769
DMRFWGK MW 612.6
DMRFWGK FM C31H36N2O11
DMRFWGK IC InChI=1S/C31H36N2O11/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37)/t23-,25+,26-,29-/m1/s1
DMRFWGK CS CC1=C(C=CC2=C1OC(=O)C(=C2O)NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O
DMRFWGK IK YJQPYGGHQPGBLI-KGSXXDOSSA-N
DMRFWGK IU [(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] carbamate
DMRFWGK CA CAS 303-81-1
DMRFWGK CB CHEBI:28368
DMRFWGK DE Bacterial infection
DM6ZPLQ ID DM6ZPLQ
DM6ZPLQ DN Novolimus
DM6ZPLQ HS Approved
DM6ZPLQ CP Elixir Medical
DM6ZPLQ PC 9854320
DM6ZPLQ MW 900.1
DM6ZPLQ FM C50H77NO13
DM6ZPLQ IC InChI=1S/C50H77NO13/c1-29-15-11-10-12-16-30(2)40(53)27-37-20-18-35(7)50(60,64-37)47(57)48(58)51-22-14-13-17-38(51)49(59)63-42(32(4)25-36-19-21-39(52)43(26-36)61-8)28-41(54)31(3)24-34(6)45(56)46(62-9)44(55)33(5)23-29/h10-12,15-16,24,29,31-33,35-40,42-43,45-46,52-53,56,60H,13-14,17-23,25-28H2,1-9H3/b12-10+,15-11+,30-16+,34-24+/t29-,31-,32-,33-,35-,36+,37+,38+,39-,40+,42+,43-,45-,46+,50-/m1/s1
DM6ZPLQ CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)O
DM6ZPLQ IK ZHYGVVKSAGDVDY-QQQXYHJWSA-N
DM6ZPLQ IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18,30-trihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM6ZPLQ CA CAS 151519-50-5
DM6ZPLQ DE Artery stenosis
DMRSX53 ID DMRSX53
DMRSX53 DN nusinersen
DMRSX53 HS Approved
DMRSX53 SN BIIB 058; IONIS-SMNRx; ISIS-396443; Spinraza
DMRSX53 CP Biogen/Ionis Pharmaceuticals
DMRSX53 DT Antisense drug
DMRSX53 SQ 5'-UCACUUUCAUAAUGCUGG
DMRSX53 DE Spinal muscular atrophy
DM63QS9 ID DM63QS9
DM63QS9 DN Nystatin
DM63QS9 HS Approved
DM63QS9 SN Biofanal; Comycin; Diastatin; Fungicidin; Herniocid; Korostatin; Moronal; Myconystatin; Mycostatin; Mykinac; Mykostatyna; Nilstat; Nistatin; Nistatina; Nyamyc; Nyotran; Nystaform; Nystan; Nystatine; Nystatinum; Nystatyna; Nystavescent; Nystex; Nystop; Stamicin; Stamycin; Terrastatin; Candex Lotion; Mycostatin Pastilles; Nystatin A; Nystatin G; Nystatin preparation; Nystatyna [Polish]; Zydin E; Barstatin 100; Mycostatin 20; Nystatin A1; Nystatin A2; Nystatin A3; Animax (TN); Candio-hermal; Flagystatin II (TN); Infestat (TN); Korostatin (TN); Lystin (TN); Moronal (antibiotic); Mycostatin (TN); Mykacet (TN); Mykinac (TN); Mytrex (TN); Nidoflor (TN); Nilstat (TN); Nistatina (TN); Nistatina [INN-Spanish]; Nysert (TN);Nystaform (TN); Nystalocal (TN); Nystamont (TN); Nystan (TN); Nystatin LF (liposome); Nystatine [INN-French]; Nystatinum [INN-Latin]; Nystex (TN); Nystop (TN); O-V Statin; Myco-Triacet II (TN); Mycolog-II (TN); Nystatin A1, A2, A3 complex; Nystatin [INN:BAN:JAN]; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-a-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(3-amino-3,6-dideoxy-alpha-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid; (4E,6E,8E,10E,14E,16E)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid; (4E,6E,8E,10E,14E,16E,18S,19R,21S,35S)-3-[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid
DM63QS9 CP Bristol-Myers Squibb
DM63QS9 TC Antifungal Agents
DM63QS9 DT Small molecular drug
DM63QS9 PC 6433272
DM63QS9 MW 926.1
DM63QS9 FM C47H75NO17
DM63QS9 IC InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1
DM63QS9 CS C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/C(CC2C(C(C[C@](O2)(CC(C(CCC(CC(CC(CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
DM63QS9 IK VQOXZBDYSJBXMA-RKEBNKJGSA-N
DM63QS9 IU (1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
DM63QS9 CA CAS 1400-61-9
DM63QS9 CB CHEBI:473992
DM63QS9 DE Fungal infection
DM3Q1SM ID DM3Q1SM
DM3Q1SM DN Obeticholic acid
DM3Q1SM HS Approved
DM3Q1SM SN INT747; INT-747; 6-ethylchenodeoxycholic acid; 6-ECDCA; OCA; 6-Et CDCA
DM3Q1SM CP Intercept
DM3Q1SM DT Small molecular drug
DM3Q1SM PC 447715
DM3Q1SM MW 420.6
DM3Q1SM FM C26H44O4
DM3Q1SM IC InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
DM3Q1SM CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O
DM3Q1SM IK ZXERDUOLZKYMJM-ZWECCWDJSA-N
DM3Q1SM IU (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM3Q1SM CA CAS 459789-99-2
DM3Q1SM CB CHEBI:43602
DM3Q1SM DE Primary biliary cholangitis; Insomnia
DM3BVAE ID DM3BVAE
DM3BVAE DN Obinutuzumab
DM3BVAE HS Approved
DM3BVAE SN GA101/RG7159
DM3BVAE CP Biogen Idec; Genentech
DM3BVAE DT Antibody
DM3BVAE DE Chronic lymphocytic leukaemia; Haematological malignancy
DMEZ2KH ID DMEZ2KH
DMEZ2KH DN Ocrelizumab
DMEZ2KH HS Approved
DMEZ2KH SN Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
DMEZ2KH CP Roche/Genentech
DMEZ2KH DT Antibody
DMEZ2KH DE Multiple sclerosis; Diffuse large B-cell lymphoma
DM7AVGW ID DM7AVGW
DM7AVGW DN Ocriplasmin
DM7AVGW HS Approved
DM7AVGW CP ThromboGenics
DM7AVGW SQ Protein sequence for the truncated heavy chain: APSFDCGKPQVEPKKCPGR >Protein sequence for the light chain VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN
DM7AVGW DE Symptomatic vitreomacular adhesion
DMHIDCJ ID DMHIDCJ
DMHIDCJ DN Octreotide
DMHIDCJ HS Approved
DMHIDCJ SN Longastatin; Octreotida; Octreotidum; Sandostatine; Octreotida [Spanish]; Octreotide Acetate Salt; Octreotidum [Latin]; DRG-0115; HS-2020; Octreotide-LAR; SAN 201-995; SM 201-995; SMS 201-995; Sandostatin (TN); Sandoz 201-995; Octreotide (USAN/INN); Octreotide [USAN:INN:BAN]; SMS-201-995; Zacycloicosane-4-carboxamide acetate; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide; L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide; D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide; 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide; 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMHIDCJ CP Norvatis Phamaceuticals Corporation
DMHIDCJ TC Anabolic Agents
DMHIDCJ DT Small molecular drug
DMHIDCJ PC 448601
DMHIDCJ MW 1019.2
DMHIDCJ FM C49H66N10O10S2
DMHIDCJ IC InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
DMHIDCJ CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
DMHIDCJ IK DEQANNDTNATYII-OULOTJBUSA-N
DMHIDCJ IU (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMHIDCJ CA CAS 83150-76-9
DMHIDCJ DE Acromegaly
DMZK0FQ ID DMZK0FQ
DMZK0FQ DN Oestradiol valerate and dienogest
DMZK0FQ HS Approved
DMZK0FQ SN Dienogest; 65928-58-7; Dienogestrel; Dienogestum; Dienogestril; Dinagest; Natazia; Endometrion; Visanne; STS-557; STS 557; Dienogestum [Latin]; UNII-46M3EV8HHE; MJR-35; 17alpha-17-Hydroxy-3-oxo-19-norpregna-4,9-diene-21-nitrile; BAY86-5258; BAY 86-5258; 46M3EV8HHE; CHEBI:70708; 17-alpha-Cyanomethyl-17-beta-hydroxy-estra-4,9(10)-dien-3-one; 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile; 17-alpha-Cyanomethyl-17-beta-hydroxyestra-4,9(10)-diene-3-one; Natazia (TN)
DMZK0FQ CP Bayer
DMZK0FQ DT Small molecular drug
DMZK0FQ PC 68861
DMZK0FQ MW 311.4
DMZK0FQ FM C20H25NO2
DMZK0FQ IC InChI=1S/C20H25NO2/c1-19-8-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(19)7-9-20(19,23)10-11-21/h12,17-18,23H,2-10H2,1H3/t17-,18+,19+,20-/m1/s1
DMZK0FQ CS C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O
DMZK0FQ IK AZFLJNIPTRTECV-FUMNGEBKSA-N
DMZK0FQ IU 2-[(8S,13S,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile
DMZK0FQ CA CAS 65928-58-7
DMZK0FQ CB CHEBI:70708
DMZK0FQ DE Endometriosis; Contraception
DM295PR ID DM295PR
DM295PR DN Ofatumumab
DM295PR HS Approved
DM295PR SN Arzerra (TN)
DM295PR CP GlaxoSmithKline
DM295PR DT Antibody
DM295PR SQ Ofatumumab Heavy Chain: EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP >Ofatumumab Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DM295PR DE Chronic lymphocytic leukaemia; Rheumatoid arthritis; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DM0VQN3 ID DM0VQN3
DM0VQN3 DN Ofloxacin
DM0VQN3 HS Approved
DM0VQN3 SN Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
DM0VQN3 CP Janssen Pharmaceutica
DM0VQN3 TC Antibiotics
DM0VQN3 DT Small molecular drug
DM0VQN3 PC 4583
DM0VQN3 MW 361.4
DM0VQN3 FM C18H20FN3O4
DM0VQN3 IC InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
DM0VQN3 CS CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
DM0VQN3 IK GSDSWSVVBLHKDQ-UHFFFAOYSA-N
DM0VQN3 IU 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DM0VQN3 CA CAS 82419-36-1
DM0VQN3 CB CHEBI:7731
DM0VQN3 DE Bacterial infection
DMQ4PKA ID DMQ4PKA
DMQ4PKA DN Olamufloxacin
DMQ4PKA HS Approved
DMQ4PKA SN Olamufloxacin; HSR-903; UNII-LJG8KL1435; HSR 903; LJG8KL1435; J-502473; (S)-5-Amino-7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; (S)-(-)-5-Amino-7-(7-amino-5-azaspiro[2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid; 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-quinoline-3-carboxylic acid; Olamufloxacin [INN]; AC1Q5RCW; AC1L9XAZ; SCHEMBL1851976
DMQ4PKA PC 477670
DMQ4PKA MW 386.4
DMQ4PKA FM C20H23FN4O3
DMQ4PKA IC InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1
DMQ4PKA CS CC1=C2C(=C(C(=C1N3CC(C4(C3)CC4)N)F)N)C(=O)C(=CN2C5CC5)C(=O)O
DMQ4PKA IK LEILBPMISZFZQK-GFCCVEGCSA-N
DMQ4PKA IU 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid
DMQ4PKA CA CAS 167887-97-0
DMQ4PKA DE Bacterial infections
DMPFN6Y ID DMPFN6Y
DMPFN6Y DN Olanzapine
DMPFN6Y HS Approved
DMPFN6Y SN Lanzac; Midax; Olansek; Olanzapina; Olanzapinum; Symbyax; Zalasta; Zydis; Zyprexa; Eli Lilly brand of olanzapine; Lilly brand of olanzapine; Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis; LY 170053; ALKS-7921; KS-1090; LY-170052; LY-170053; Olanzapine (OLA); Olanzapine [USAN:INN]; Olzapin (TN); Rexapin (TN); Zalasta (TN); Zolafren (TN); Zydis (TN); Zyprexa (TN); Olanzapine (JAN/USAN/INN); 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
DMPFN6Y CP Eli Lilly
DMPFN6Y TC Antipsychotic Agents
DMPFN6Y DT Small molecular drug
DMPFN6Y PC 135398745
DMPFN6Y MW 312.4
DMPFN6Y FM C17H20N4S
DMPFN6Y IC InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
DMPFN6Y CS CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
DMPFN6Y IK KVWDHTXUZHCGIO-UHFFFAOYSA-N
DMPFN6Y IU 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
DMPFN6Y CA CAS 132539-06-1
DMPFN6Y CB CHEBI:7735
DMPFN6Y DE Schizophrenia
DM0Y49P ID DM0Y49P
DM0Y49P DN Olanzapine/fluoxetine combination
DM0Y49P HS Approved
DM0Y49P SN Symbyax (Zyprexa/Prozac)
DM0Y49P CP Eli Lilly; Eli Lilly & Co
DM0Y49P DT Small molecular drug
DM0Y49P PC 24848071
DM0Y49P DE Depression
DM8QB1D ID DM8QB1D
DM8QB1D DN Olaparib
DM8QB1D HS Approved
DM8QB1D SN AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
DM8QB1D CP AstraZeneca
DM8QB1D DT Small molecular drug
DM8QB1D PC 23725625
DM8QB1D MW 434.5
DM8QB1D FM C24H23FN4O3
DM8QB1D IC InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
DM8QB1D CS C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
DM8QB1D IK FDLYAMZZIXQODN-UHFFFAOYSA-N
DM8QB1D IU 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
DM8QB1D CA CAS 763113-22-0
DM8QB1D CB CHEBI:83766
DM8QB1D DE Ovarian cancer; Pancreatic cancer; Prostate cancer
DMNYOIX ID DMNYOIX
DMNYOIX DN Olaratumab
DMNYOIX HS Approved
DMNYOIX SN LY3012207
DMNYOIX CP Eli Lilly
DMNYOIX DT Monoclonal antibody
DMNYOIX SQ Heavy Chain: QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMNYOIX DE Soft tissue sarcoma; Non-small-cell lung cancer
DM6MDCF ID DM6MDCF
DM6MDCF DN Oliceridine
DM6MDCF HS Approved
DM6MDCF SN TRV130A
DM6MDCF DT Small molecular drug
DM6MDCF PC 66553195
DM6MDCF MW 386.6
DM6MDCF FM C22H30N2O2S
DM6MDCF IC InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1
DM6MDCF CS COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4
DM6MDCF IK DMNOVGJWPASQDL-OAQYLSRUSA-N
DM6MDCF IU N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine
DM6MDCF CA CAS 1401028-24-7
DM6MDCF DE Thyroid disease; Acute pain
DMWBHRY ID DMWBHRY
DMWBHRY DN Olmesartan medoxomil
DMWBHRY HS Approved
DMWBHRY SN Benevas; Benicar; Olmetec; Olvance; Forest Brand of Olmesartan Medoxomil; Olmesartan medoximil; Sankyo Brand of Olmesartan Medoxomil; Cs 866; Benicar (TN); Berlin-Chemie Brand of Olmesartan Medoxomil; CS-866; CS-866DM; CS-866RN; DE-092; KS-1182; Olmetec (TN); Benicar, Olmetec,Olmesartan; Olmesartan medoxomil (JAN/USAN); (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester; 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
DMWBHRY TC Antihypertensive Agents
DMWBHRY DT Small molecular drug
DMWBHRY PC 130881
DMWBHRY MW 558.6
DMWBHRY FM C29H30N6O6
DMWBHRY IC InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
DMWBHRY CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
DMWBHRY IK UQGKUQLKSCSZGY-UHFFFAOYSA-N
DMWBHRY IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
DMWBHRY CA CAS 144689-63-4
DMWBHRY CB CHEBI:31932
DMWBHRY DE High blood pressure
DM62B78 ID DM62B78
DM62B78 DN Olodaterol
DM62B78 HS Approved
DM62B78 SN BI-1744
DM62B78 CP Boehringer Ingelheim Pharmaceuticals
DM62B78 DT Small molecular drug
DM62B78 PC 11504295
DM62B78 MW 386.4
DM62B78 FM C21H26N2O5
DM62B78 IC InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1
DM62B78 CS CC(C)(CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C(=CC(=C2)O)NC(=O)CO3)O
DM62B78 IK COUYJEVMBVSIHV-SFHVURJKSA-N
DM62B78 IU 6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one
DM62B78 CA CAS 868049-49-4
DM62B78 CB CHEBI:82700
DM62B78 DE Chronic obstructive pulmonary disease
DMKMWQG ID DMKMWQG
DMKMWQG DN Olopatadine
DMKMWQG HS Approved
DMKMWQG SN Allelock; Opatanol; Pataday; Patanase; Patanol; OLOPATADINE HCl; OLOPATADINE HYDROCHLORIDE; ALO4943A; HCl of KW 4679; KW 4679; O0361; AL-4943A; ALO-4943A; Allelock (TN); KW-4679; KW-4943A; Olopatadine [INN:BAN]; Pataday (TN); Patanase (TN); Patanol S (TN); {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid hydrochloride; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid, hydrochloride; 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid hydrochloride
DMKMWQG CP Alcon
DMKMWQG TC Antiallergic Agents
DMKMWQG DT Small molecular drug
DMKMWQG PC 5281071
DMKMWQG MW 337.4
DMKMWQG FM C21H23NO3
DMKMWQG IC InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
DMKMWQG CS CN(C)CC/C=C\\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
DMKMWQG IK JBIMVDZLSHOPLA-LSCVHKIXSA-N
DMKMWQG IU 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
DMKMWQG CA CAS 113806-05-6
DMKMWQG CB CHEBI:94593
DMKMWQG DE Allergic conjunctivitis; Ocular allergy
DMWBQKU ID DMWBQKU
DMWBQKU DN Olprinone
DMWBQKU HS Approved
DMWBQKU SN Olprinone; 106730-54-5; loprinone; Coretec; Olprinone [INN]; UNII-4Y8BMI9YGC; 4Y8BMI9YGC; C14H10N4O; Olprinone (INN); 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile; 1,2-Dihydro-5-imidazo(1,2-alpha)pyridin-6-yl-6-methyl-2-oxonicotinonitrile; 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridinecarbonitrile; AC1L1IIG; AC1Q4Q1U; SCHEMBL27661; DTXSID1048461; CHEMBL1474900; KS-00000EYK; MolPort-006-394-808; JPAWFIIYTJQOKW-UHFFFAOYSA-N; CHEBI:135019; BCP09781; ZINC38192538; HY-14254A; 3950AH
DMWBQKU DT Small molecular drug
DMWBQKU PC 4593
DMWBQKU MW 250.25
DMWBQKU FM C14H10N4O
DMWBQKU IC InChI=1S/C14H10N4O/c1-9-12(6-11(7-15)14(19)17-9)10-2-3-13-16-4-5-18(13)8-10/h2-6,8H,1H3,(H,17,19)
DMWBQKU CS CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2
DMWBQKU IK JPAWFIIYTJQOKW-UHFFFAOYSA-N
DMWBQKU IU 5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
DMWBQKU CA CAS 106730-54-5
DMWBQKU CB CHEBI:135019
DMWBQKU DE Heart failure
DMZW9HA ID DMZW9HA
DMZW9HA DN Olsalazine
DMZW9HA HS Approved
DMZW9HA SN Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine
DMZW9HA CP Pharmacia & Upjohn AB
DMZW9HA DT Small molecular drug
DMZW9HA PC 22419
DMZW9HA MW 302.24
DMZW9HA FM C14H10N2O6
DMZW9HA IC InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
DMZW9HA CS C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
DMZW9HA IK QQBDLJCYGRGAKP-UHFFFAOYSA-N
DMZW9HA IU 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
DMZW9HA CA CAS 15722-48-2
DMZW9HA CB CHEBI:7770
DMZW9HA DE Ulcerative colitis
DMPU2WX ID DMPU2WX
DMPU2WX DN Omacetaxine mepesuccinate
DMPU2WX HS Approved
DMPU2WX SN Synribo (TN)
DMPU2WX CP Ivax
DMPU2WX DT Small molecular drug
DMPU2WX PC 285033
DMPU2WX MW 545.6
DMPU2WX FM C29H39NO9
DMPU2WX IC InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
DMPU2WX CS CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
DMPU2WX IK HYFHYPWGAURHIV-JFIAXGOJSA-N
DMPU2WX IU 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
DMPU2WX CA CAS 26833-87-4
DMPU2WX CB CHEBI:71019
DMPU2WX DE Chronic myeloid leukaemia
DMR2J95 ID DMR2J95
DMR2J95 DN Omadacycline
DMR2J95 HS Approved
DMR2J95 SN UNII-090IP5RV8F; 090IP5RV8F; Omadacycline [USAN:INN]; Omadacycline (USAN); AC1NUY3H; Amadacycline methanesulfonate; SCHEMBL152
DMR2J95 CP Paratek Pharmaceuticals
DMR2J95 PC 54697325
DMR2J95 MW 556.6
DMR2J95 FM C29H40N4O7
DMR2J95 IC InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
DMR2J95 CS CC(C)(C)CNCC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMR2J95 IK VJYKVCURWJGLPG-IQZGDKDPSA-N
DMR2J95 IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMR2J95 CA CAS 389139-89-3
DMR2J95 DE Acute bacterial skin infection; Bacterial pneumonia; Bacterial infection
DMU5G01 ID DMU5G01
DMU5G01 DN Omadacycline
DMU5G01 HS Approved
DMU5G01 SN Amadacycline; Amadacycline (intravenous), Merck & Co; Amadacycline (intravenous), Paratek/Novartis; Amadacycline (oral), Merck & Co; Amadacycline (oral), Paratek/ Novartis; Antibacterial aminomethycyclines, Paratek/Bayer; MK-2764; Omadacycline; Omadacycline (intravenous), Merck & Co; Omadacycline (intravenous), Paratek; Omadacycline (intravenous), Paratek/ Novartis; Omadacycline (oral), Merck & Co; Omadacycline (oral), Paratek; Omadacycline (oral), Paratek/ Novartis; Omadacycline tosylate; P-000538; P-000642; P-001075; P-001207; P-001221; P-00136; P-002352; PTK-0796; PTK-796; Sancycline derivatives, Paratek; Tetracycline analogs, GlaxoSmithKline/Paratek; Tetracycline analogs, Paratek/Merck & Co;Tetracycline analogs (multi-drug-resistant infections), Paratek/Bayer
DMU5G01 TC Antibiotics
DMU5G01 DT Small molecular drug
DMU5G01 PC 54697325
DMU5G01 MW 556.66
DMU5G01 FM C29H40N4O7
DMU5G01 IC InChI=1S/C29H40N4O7/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39)/t13-,16-,21-,29-/m0/s1
DMU5G01 CS CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMU5G01 IK VJYKVCURWJGLPG-IQZGDKDPSA-N
DMU5G01 IU (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMU5G01 CA CAS 389139-89-3
DMU5G01 DE Acute skin infections; Community-acquired bacterial pneumonia
DMETVFJ ID DMETVFJ
DMETVFJ DN Omalizumab
DMETVFJ HS Approved
DMETVFJ SN Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
DMETVFJ CP National University Hospital, Singapore|National University, Singapore
DMETVFJ TC Antiasthmatic Agents
DMETVFJ DT Monoclonal antibody
DMETVFJ SQ Omalizumab heavy chain: EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Omalizumab light chainDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMETVFJ DE Asthma; Chronic idiopathic urticaria
DML9TI0 ID DML9TI0
DML9TI0 DN Ombitasvir + paritaprevir + ritonavir
DML9TI0 HS Approved
DML9TI0 SN ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); Viekirax
DML9TI0 TC Antiinfective Agents
DML9TI0 DE Hepatitis C virus infection
DM471KJ ID DM471KJ
DM471KJ DN Omeprazole
DM471KJ HS Approved
DM471KJ SN Losec (TN)
DM471KJ CP AstraZeneca
DM471KJ TC Antiulcer Agents
DM471KJ DT Small molecular drug
DM471KJ PC 4594
DM471KJ MW 345.4
DM471KJ FM C17H19N3O3S
DM471KJ IC InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
DM471KJ CS CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
DM471KJ IK SUBDBMMJDZJVOS-UHFFFAOYSA-N
DM471KJ IU 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DM471KJ CA CAS 73590-58-6
DM471KJ CB CHEBI:77260
DM471KJ DE Gastroesophageal reflux disease
DMOTQ1I ID DMOTQ1I
DMOTQ1I DN Ondansetron
DMOTQ1I HS Approved
DMOTQ1I SN DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMOTQ1I CP GlaxoSmithKline
DMOTQ1I TC Antiemetics
DMOTQ1I DT Small molecular drug
DMOTQ1I PC 4595
DMOTQ1I MW 293.4
DMOTQ1I FM C18H19N3O
DMOTQ1I IC InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
DMOTQ1I CS CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
DMOTQ1I IK FELGMEQIXOGIFQ-UHFFFAOYSA-N
DMOTQ1I IU 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMOTQ1I CA CAS 99614-02-5
DMOTQ1I CB CHEBI:7773
DMOTQ1I DE Chemotherapy-induced nausea; Alcohol dependence
DMHG57U ID DMHG57U
DMHG57U DN OPC-34712
DMHG57U HS Approved
DMHG57U SN Brexpiprazole
DMHG57U CP Lundbeck; Otsuka America Pharmaceutical
DMHG57U DT Small molecular drug
DMHG57U PC 11978813
DMHG57U MW 433.6
DMHG57U FM C25H27N3O2S
DMHG57U IC InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)
DMHG57U CS C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4
DMHG57U IK ZKIAIYBUSXZPLP-UHFFFAOYSA-N
DMHG57U IU 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one
DMHG57U CA CAS 913611-97-9
DMHG57U CB CHEBI:134716
DMHG57U DE Major depressive disorder
DM1BKA6 ID DM1BKA6
DM1BKA6 DN Opicapone
DM1BKA6 HS Approved
DM1BKA6 SN BIA-9-1067
DM1BKA6 CP Portela & Ca SA
DM1BKA6 PC 135565903
DM1BKA6 MW 413.2
DM1BKA6 FM C15H10Cl2N4O6
DM1BKA6 IC InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
DM1BKA6 CS CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
DM1BKA6 IK ASOADIZOVZTJSR-UHFFFAOYSA-N
DM1BKA6 IU 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
DM1BKA6 CA CAS 923287-50-7
DM1BKA6 CB CHEBI:134699
DM1BKA6 DE Parkinson disease
DMPUOXF ID DMPUOXF
DMPUOXF DN Opipramol
DMPUOXF HS Approved
DMPUOXF SN Opipramolo; Opipramolum; Opipramol dihydrochloride; Opipramol hydrochloride; Opipramoli hydrochloridum; G 33 040
DMPUOXF DT Small molecular drug
DMPUOXF PC 9417
DMPUOXF MW 363.5
DMPUOXF FM C23H29N3O
DMPUOXF IC InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2
DMPUOXF CS C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO
DMPUOXF IK YNZFUWZUGRBMHL-UHFFFAOYSA-N
DMPUOXF IU 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol
DMPUOXF CA CAS 315-72-0
DMPUOXF CB CHEBI:94614
DMPUOXF DE Anxiety disorder
DMTSRI6 ID DMTSRI6
DMTSRI6 DN Oprelvekin
DMTSRI6 HS Approved
DMTSRI6 SN Neumega; Neumega (TN); Oprelvekin (genetical recombination); Oprelvekin (USAN/INN); Oprelvekin (genetical recombination) (JAN)
DMTSRI6 CP Wyeth Pharmaceuticals
DMTSRI6 TC Anticoagulants
DMTSRI6 SQ DB00038 sequence: GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL
DMTSRI6 DE Thrombocytopenia
DM28D05 ID DM28D05
DM28D05 DN Oritavancin
DM28D05 HS Approved
DM28D05 SN Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin
DM28D05 CP Eli Lilly
DM28D05 DT Small molecular drug
DM28D05 PC 16136912
DM28D05 MW 1793.1
DM28D05 FM C86H97Cl3N10O26
DM28D05 IC InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
DM28D05 CS C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
DM28D05 IK VHFGEBVPHAGQPI-LXKZPTCJSA-N
DM28D05 IU (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
DM28D05 CA CAS 171099-57-3
DM28D05 CB CHEBI:82699
DM28D05 DE Bacterial infection; Gram-positive bacterial infection
DMRJSP8 ID DMRJSP8
DMRJSP8 DN Orlistat
DMRJSP8 HS Approved
DMRJSP8 SN orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum; Orlipastatum [INN-Latin]; THLP; Ro-18-0647; UNII-95M8R751W8; C29H53NO5; Ro 18-0647/002; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; Orlistat (Alli, Xenical); MLS002207022; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; CHEMBL175247; Alli; GlaxoSmithKline brand of orlistat; Roche brand of orlistat; Alli (TN); Hoffmann-La Roche brand of orlistat; KS-1183; Orlistat [USAN:INN]; R-212; Xenical (TN); Orlistat (USAN/INN); Ro 18-0647/008; Alli, Xenical, Tetrahydrolipstatin, Orlistat; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; TETRAHYDROLIPSTATIN
DMRJSP8 CP GlaxoSmithKline plc
DMRJSP8 TC Antiobesity Agents
DMRJSP8 DT Small molecular drug
DMRJSP8 PC 3034010
DMRJSP8 MW 495.7
DMRJSP8 FM C29H53NO5
DMRJSP8 IC InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
DMRJSP8 CS CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
DMRJSP8 IK AHLBNYSZXLDEJQ-FWEHEUNISA-N
DMRJSP8 IU [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
DMRJSP8 CA CAS 96829-58-2
DMRJSP8 CB CHEBI:94686
DMRJSP8 DE Obesity
DM6QHDJ ID DM6QHDJ
DM6QHDJ DN Ornidazole
DM6QHDJ HS Approved
DM6QHDJ DT Small molecular drug
DM6QHDJ PC 28061
DM6QHDJ MW 219.62
DM6QHDJ FM C7H10ClN3O3
DM6QHDJ IC InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
DM6QHDJ CS CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-]
DM6QHDJ IK IPWKIXLWTCNBKN-UHFFFAOYSA-N
DM6QHDJ IU 1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
DM6QHDJ CA CAS 16773-42-5
DM6QHDJ CB CHEBI:75176
DM6QHDJ DE Amoebiasis
DMW542E ID DMW542E
DMW542E DN Orphenadrine
DMW542E HS Approved
DMW542E SN Antiflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Lysantin; Mefenamine; Mephenamine; Methyldiphenylhydramine; Myolin; Myotrol; ORP; Orfenadrina; Orfro; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrinum; Orphenate; Orphenedrine; Norflex Orphenadrine Citrate; Sodium Mefenamine; WS 2434; Banflex (TN); Biorphen (TN); Brocasipal (TN); Disipal (TN); Flexon (TN); Mephenamin (TN); Mialgin (TN); Norflex (TN); O-Methyldiphenhydramine; O-Monomethyldiphenhydramine; Orfenadrina [INN-Spanish]; Orphenadrine(INN); Orphenadrine [INN:BAN]; Orphenadrinum [INN-Latin]; Beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Phenyl-o-tolylmethyl dimethyaminoethyl ether; Beta-Dimethylaminoethyl-2-methylbenzhydryl ether; N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin; N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine; N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine; N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine; N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine; N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine; N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine
DMW542E CP 3M Pharmaceuticals
DMW542E TC Antiparkinson Agents
DMW542E DT Small molecular drug
DMW542E PC 4601
DMW542E MW 269.4
DMW542E FM C18H23NO
DMW542E IC InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3
DMW542E CS CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
DMW542E IK QVYRGXJJSLMXQH-UHFFFAOYSA-N
DMW542E IU N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
DMW542E CA CAS 83-98-7
DMW542E CB CHEBI:7789
DMW542E DE Parkinson disease
DMFIQ20 ID DMFIQ20
DMFIQ20 DN Orphenadrine citrate
DMFIQ20 HS Approved
DMFIQ20 SN Orfenadrina; Orfenadrina [INN-Spanish]; Orphenadine; Orphenadinum; Orphenadrin; Orphenadrine [INN:BAN]; Orphenadrinum; Orphenadrinum [INN-Latin]; Orphenate; Orphenedrine; WS 2434; o-Methyldiphenhydramine; o-Monomethyldiphenhydramine; orphenadrine; 2-(Phenyl-o-tolylmethoxy)ethyldimethylamine; 2-Methyldiphenhydramine; 83-98-7; EINECS 201-509-2; HSDB 3139; Phenyl-o-tolylmethyl dimethyaminoethyl ether; beta-Dimethylaminoethyl 2-methylbenzhydryl ether; Biorphen; Brocadisipal; Brocasipal; Disipal; Invagesic; Mephenamine; Norgesic; Banflex; Euflex; Flexoject; Flexon; Flexor; Norflex; Norflex (pharmaceutical); Orphenadrine (Citrate); Orphenadrine citrate; Orphenadrine citrate (Norflex); Orphenadrine citrate [USP]; Orphenadrine citrate salt; Orphenadrine dihydrogen citrate; Plenactol; Tega-Flex; X-Otag; 2-hydroxypropane-1,2,3-tricarboxylic acid; 4596-23-0; 4682-36-4; CHEBI:7790; EINECS 225-137-5; N,N-Dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine citrate (1:1); NCGC00094745-01; dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
DMFIQ20 PC 83823
DMFIQ20 MW 461.5
DMFIQ20 FM C24H31NO8
DMFIQ20 IC MMMNTDFSPSQXJP-UHFFFAOYSA-N
DMFIQ20 CS CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMFIQ20 IK 1S/C18H23NO.C6H8O7/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-12,18H,13-14H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMFIQ20 IU N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMFIQ20 CA CAS 4682-36-4
DMFIQ20 CB CHEBI:7790
DMFIQ20 DE Myalgia
DMGO72P ID DMGO72P
DMGO72P DN Oseltamivir
DMGO72P HS Approved
DMGO72P SN Tamiflu (*Phosphate salt 1:1*); Agucort; Oseltamivirum; Tamvir; GS 4104; GS4104; Agucort (TN); GS-4104; Oseltamivir (INN); Oseltamivir [INN:BAN]; Ro-640796; Tamiflu (TN); Tamiflu-Free; Ro-64-0796; OTV
DMGO72P CP Hoffmann-La Roche pharmaceutical company
DMGO72P TC Antiviral Agents
DMGO72P DT Small molecular drug
DMGO72P PC 65028
DMGO72P MW 312.4
DMGO72P FM C16H28N2O4
DMGO72P IC InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1
DMGO72P CS CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC
DMGO72P IK VSZGPKBBMSAYNT-RRFJBIMHSA-N
DMGO72P IU ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
DMGO72P CA CAS 196618-13-0
DMGO72P CB CHEBI:7798
DMGO72P DE Influenza virus infection
DMIJC9X ID DMIJC9X
DMIJC9X DN Osilodrostat
DMIJC9X HS Approved
DMIJC9X SN LCI699; 928134-65-0; LCI-699; UNII-5YL4IQ1078; CHEMBL3099695; 5YL4IQ1078; Osilodrostat;4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile; 1304733-26-3; Osilodrostat [USAN:INN]; LCI 699; Osilodrostat (USAN/INN); LCI699-NX; GTPL8310; SCHEMBL12460772; DTXSID40156570; MolPort-044-560-410; EX-A1397; ZINC72318114; s7456; BDBM50444549; AKOS027323750; DB11837; CS-6896; HY-16276; KB-78108; Z-3271; D11061; 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile
DMIJC9X CP Novartis Pharmaceuticals
DMIJC9X DT Small molecular drug
DMIJC9X PC 44139752
DMIJC9X MW 227.24
DMIJC9X FM C13H10FN3
DMIJC9X IC InChI=1S/C13H10FN3/c14-12-5-9(6-15)1-3-11(12)13-4-2-10-7-16-8-17(10)13/h1,3,5,7-8,13H,2,4H2/t13-/m1/s1
DMIJC9X CS C1CC2=CN=CN2[C@H]1C3=C(C=C(C=C3)C#N)F
DMIJC9X IK USUZGMWDZDXMDG-CYBMUJFWSA-N
DMIJC9X IU 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
DMIJC9X CA CAS 928134-65-0
DMIJC9X DE Cushing disease
DMRJLAT ID DMRJLAT
DMRJLAT DN Osimertinib
DMRJLAT HS Approved
DMRJLAT SN Tagrisso
DMRJLAT CP Astrazeneca
DMRJLAT DT Small molecular drug
DMRJLAT PC 71496458
DMRJLAT MW 499.6
DMRJLAT FM C28H33N7O2
DMRJLAT IC InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
DMRJLAT CS CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
DMRJLAT IK DUYJMQONPNNFPI-UHFFFAOYSA-N
DMRJLAT IU N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
DMRJLAT CA CAS 1421373-65-0
DMRJLAT CB CHEBI:90943
DMRJLAT DE Non-small-cell lung cancer; Melanoma
DMF5ZB3 ID DMF5ZB3
DMF5ZB3 DN OspA lipoprotein
DMF5ZB3 HS Approved
DMF5ZB3 TC Vaccines
DMF5ZB3 DT Vaccine
DMF5ZB3 SQ OspA lipoprotein: MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDNVDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKSTTEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVEIKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNGTITVQNYDSAGTKLEGSAAEIKKLDELKNALR
DMF5ZB3 DE Lyme disease
DMC4GEI ID DMC4GEI
DMC4GEI DN Ospemifene
DMC4GEI HS Approved
DMC4GEI SN Ospemifene; 128607-22-7; Osphena; FC-1271a; Deamino-hydroxytoremifene; Fc-1271; 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; UNII-B0P231ILBK; CCRIS 9205; B0P231ILBK; CHEBI:73275; 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; senshio; Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethanol; Ophena; Ospemifene [USAN:INN:BAN]; Deaminotoremifene; Osphena (TN); Deaminohydroxytoremifene; AC1MI19T; C24H23ClO2
DMC4GEI CP Shionogi; QuatRx
DMC4GEI DT Small molecular drug
DMC4GEI PC 3036505
DMC4GEI MW 378.9
DMC4GEI FM C24H23ClO2
DMC4GEI IC InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
DMC4GEI CS C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C3=CC=C(C=C3)OCCO)/CCCl
DMC4GEI IK LUMKNAVTFCDUIE-VHXPQNKSSA-N
DMC4GEI IU 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol
DMC4GEI CA CAS 128607-22-7
DMC4GEI CB CHEBI:73275
DMC4GEI DE Dyspareunia; Postmenopausal vaginal atrophy
DM05968 ID DM05968
DM05968 DN Otilonium bromide
DM05968 HS Approved
DM05968 SN Otilonium Bromide; 26095-59-0; Octylonium bromide; Spasmomen; Octylonium; Otilonium (bromide); SP63; Ottilonio bromuro [Italian]; UNII-21HN3N72PV; Otilonium bromide [INN:BAN]; Otilonii bromidum [INN-Latin]; Bromure d'otilonium [INN-French]; Bromuro de otilonio [INN-Spanish]; EINECS 247-457-4; 21HN3N72PV; Diethyl(2-hydroxyethyl)methylammonium bromide p-(o-(octyloxy)benzamido)benzoate; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, bromide; DSSTox_CID_26357; DSSTox_RID_81559
DM05968 CP Menarini
DM05968 DT Small molecular drug
DM05968 PC 72092
DM05968 MW 563.6
DM05968 FM C29H43BrN2O4
DM05968 IC InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H
DM05968 CS CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-]
DM05968 IK VWZPIJGXYWHBOW-UHFFFAOYSA-N
DM05968 IU diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium;bromide
DM05968 CA CAS 26095-59-0
DM05968 DE Gastric motility disorder
DMQNI7O ID DMQNI7O
DMQNI7O DN OTL-200
DMQNI7O HS Approved
DMQNI7O SN Libmeldy
DMQNI7O CP Orchard Therapeutics
DMQNI7O DT Gene therapy
DMQNI7O DE Metachromatic leukodystrophy
DME0F98 ID DME0F98
DME0F98 DN Ovine corticotropin-releasing hormone
DME0F98 HS Approved
DME0F98 SN Ovine CRF; Ovine CRH; Ovine CRF 41; Ovine corticotropin-releasing factor; Ovine ACTH releasing factor; 79804-71-0; Corticotropin-releasing factor (sheep); Sheep corticotropin-releasing factor (1-41); Corticotropin-releasing factor (sheep hypothalamus); Amunine; Amunin; Corticorelin ovine; oCRH; Corticorelin triflutate; AC1Q2C7A; CRF(OVINE)TRIFLUOROACETATE; Sheep corticotropin-releasing factor; Corticotropin-releasing hormone, ovine; Corticotropin-releasing f
DME0F98 DT Small molecular drug
DME0F98 PC 16132344
DME0F98 MW 4670
DME0F98 FM C205H339N59O63S
DME0F98 IC InChI=1S/C205H339N59O63S/c1-30-104(21)159(198(322)225-106(23)163(214)287)259-193(317)142(87-157(285)286)253-184(308)132(77-99(11)12)246-182(306)130(75-97(7)8)244-172(296)117(46-36-38-67-207)231-170(294)118(47-39-68-221-204(215)216)233-189(313)139(84-151(213)274)251-194(318)143(91-266)256-188(312)137(82-113-88-219-93-223-113)241-165(289)108(25)227-169(293)120(51-58-147(209)270)234-173(297)121(52-59-148(210)271)229-164(288)107(24)228-179(303)128(73-95(3)4)243-176(300)123(54-61-150(212)273)236-190(314)140(85-155(281)282)242-166(290)109(26)226-168(292)116(45-35-37-66-206)239-200(324)161(110(27)268)261-178(302)126(65-72-328-29)238-174(298)124(55-62-152(275)276)237-181(305)134(79-101(15)16)254-197(321)158(103(19)20)258-177(301)125(56-63-153(277)278)235-171(295)119(48-40-69-222-205(217)218)232-180(304)129(74-96(5)6)245-183(307)131(76-98(9)10)247-187(311)138(83-114-89-220-94-224-114)250-186(310)136(81-112-43-33-32-34-44-112)255-201(325)162(111(28)269)262-192(316)135(80-102(17)18)248-191(315)141(86-156(283)284)252-185(309)133(78-100(13)14)249-195(319)144(92-267)257-199(323)160(105(22)31-2)260-196(320)145-49-41-70-263(145)203(327)146-50-42-71-264(146)202(326)127(57-64-154(279)280)240-175(299)122(53-60-149(211)272)230-167(291)115(208)90-265/h32-34,43-44,88-89,93-111,115-146,158-162,265-269H,30-31,35-42,45-87,90-92,206-208H2,1-29H3,(H2,209,270)(H2,210,271)(H2,211,272)(H2,212,273)(H2,213,274)(H2,214,287)(H,219,223)(H,220,224)(H,225,322)(H,226,292)(H,227,293)(H,228,303)(H,229,288)(H,230,291)(H,231,294)(H,232,304)(H,233,313)(H,234,297)(H,235,295)(H,236,314)(H,237,305)(H,238,298)(H,239,324)(H,240,299)(H,241,289)(H,242,290)(H,243,300)(H,244,296)(H,245,307)(H,246,306)(H,247,311)(H,248,315)(H,249,319)(H,250,310)(H,251,318)(H,252,309)(H,253,308)(H,254,321)(H,255,325)(H,256,312)(H,257,323)(H,258,301)(H,259,317)(H,260,320)(H,261,302)(H,262,316)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H4,215,216,221)(H4,217,218,222)/t104-,105-,106-,107-,108-,109-,110+,111+,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,158-,159-,160-,161-,162-/m0/s1
DME0F98 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N
DME0F98 IK QEEJLLNYQOBRRM-KSHGRFHLSA-N
DME0F98 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoic acid
DME0F98 CA CAS 79804-71-0
DME0F98 DE Cushing disease; Diagnostic imaging
DMTAFY4 ID DMTAFY4
DMTAFY4 DN Oxacillin
DMTAFY4 HS Approved
DMTAFY4 SN Bactocill; Ossacillina; Oxacilina; Oxacilline; Oxacillinum; Oxazocillin; Oxazocilline; Prostaphlin; Prostaphlyn; OXACILLIN SODIUM; Ossacillina [DCIT]; Sodium oxacillin; Bactocill (TN); MPI-penicillin; MPi-PC; Oxacilina (TN); Oxacilina [INN-Spanish]; Oxacillin (INN); Oxacillin [INN:BAN]; Oxacilline [INN-French]; Oxacillinum [INN-Latin]; Penicillin, Methylphenylisoxazolyl; Oxacillin, Monosodium Salt, Anhydrous; (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (5-methyl-3-phenyl-4-isoxazolyl)penicillin; 2,2-dimethyl-6beta-(5-methyl-3-phenyl-1,2-oxazole-4-carboxamido)penam-3alpha-carboxylic acid; 5-Methyl-3-phenyl-4-isoxazolyl-penicillin; 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid
DMTAFY4 CP Sandoz Inc
DMTAFY4 TC Antibiotics
DMTAFY4 DT Small molecular drug
DMTAFY4 PC 6196
DMTAFY4 MW 401.4
DMTAFY4 FM C19H19N3O5S
DMTAFY4 IC InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1
DMTAFY4 CS CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMTAFY4 IK UWYHMGVUTGAWSP-JKIFEVAISA-N
DMTAFY4 IU (2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMTAFY4 CA CAS 66-79-5
DMTAFY4 CB CHEBI:7809
DMTAFY4 DE Bacterial infection
DMQNWRD ID DMQNWRD
DMQNWRD DN Oxaliplatin
DMQNWRD HS Approved
DMQNWRD SN Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
DMQNWRD CP Sanofi-Aventis
DMQNWRD TC Anticancer Agents
DMQNWRD DT Small molecular drug
DMQNWRD PC 9887053
DMQNWRD MW 397.29
DMQNWRD FM C8H14N2O4Pt
DMQNWRD IC InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
DMQNWRD CS C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
DMQNWRD IK DRMCATBEKSVAPL-BNTLRKBRSA-N
DMQNWRD IU [(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
DMQNWRD CA CAS 61825-94-3
DMQNWRD DE Colorectal cancer
DM2QDX1 ID DM2QDX1
DM2QDX1 DN Oxamniquine
DM2QDX1 HS Approved
DM2QDX1 SN Mansil; Oxaminiquine; Oxamniquina; Oxamniquinum; Vansil; UK 4261; UK 4271; Mansil (TN); Oxamniquina [INN-Spanish]; Oxamniquinum [INN-Latin]; UK-4271; Vansil (TN); Oxamniquine (USAN/INN); Oxamniquine [USAN:BAN:INN]; {2-[(Isopropylamino)methyl]-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl}methanol; [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol; (2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol; 1,2,3,4-Tetrahydro-2-(((1-methylethyl)amino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol; 1,2,3,4-Tetrahydro-2-[(isopropylamino)methyl]-7-nitro-6-quinolinemethanol; 2-((Isopropylamino)methyl)-7-nitro-1,2,3,4-tetrahydro-6-quinolinemethanol; 2-(Isopropylaminomethyl)-7-nitro-1,2,3,4-tetrahydroquinoline-6-methanol; 6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-1,2,3,4-tetrahydroquinoline
DM2QDX1 CP Pfizer Pharmaceuticals
DM2QDX1 TC Schistosomicides
DM2QDX1 DT Small molecular drug
DM2QDX1 PC 4612
DM2QDX1 MW 279.33
DM2QDX1 FM C14H21N3O3
DM2QDX1 IC InChI=1S/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3
DM2QDX1 CS CC(C)NCC1CCC2=CC(=C(C=C2N1)[N+](=O)[O-])CO
DM2QDX1 IK XCGYUJZMCCFSRP-UHFFFAOYSA-N
DM2QDX1 IU [7-nitro-2-[(propan-2-ylamino)methyl]-1,2,3,4-tetrahydroquinolin-6-yl]methanol
DM2QDX1 CA CAS 21738-42-1
DM2QDX1 CB CHEBI:78416
DM2QDX1 DE Schistosomiasis
DMU9MYJ ID DMU9MYJ
DMU9MYJ DN Oxandrolone
DMU9MYJ HS Approved
DMU9MYJ SN Anavar; Lonavar; Ossandrolone; Oxandrin; Oxandrolona; Oxandrolonum; Protivar; Provitar; Vasorome; Ossandrolone [DCIT]; SC 11585; Anavar (TN); Oxandrin (TN); Oxandrolona [INN-Spanish]; Oxandrolonum [INN-Latin]; SC-11585; Oxandrin, Anavar, Oxandrolone; Oxandrolone (JAN/USP/INN); Oxandrolone [USAN:INN:BAN:JAN]; Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone; (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one; (4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one; 17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI); 17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one; 17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one; 2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-(8CI); 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-(9CI)
DMU9MYJ CP Pfizer Pharmaceuticals
DMU9MYJ DT Small molecular drug
DMU9MYJ PC 5878
DMU9MYJ MW 306.4
DMU9MYJ FM C19H30O3
DMU9MYJ IC InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
DMU9MYJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C
DMU9MYJ IK QSLJIVKCVHQPLV-PEMPUTJUSA-N
DMU9MYJ IU (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
DMU9MYJ CA CAS 53-39-4
DMU9MYJ CB CHEBI:7820
DMU9MYJ DE Alcoholic hepatitis
DMZ30JT ID DMZ30JT
DMZ30JT DN Oxantel pamoate
DMZ30JT HS Approved
DMZ30JT SN Telopar; Oxantel embonate; CP-14445; Oxantel pamoate (USAN); Telopar (TN); CP-14445-16; Phenol, 3-(2-(1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)ethenyl), (E)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (1:1) (salt); 4,4'-Methylenebis(3-hydroxy-2-naphthoic) acid, compound with (E)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1)
DMZ30JT TC Anthelmintics
DMZ30JT DT Small molecular drug
DMZ30JT PC 5281086
DMZ30JT MW 604.6
DMZ30JT FM C36H32N2O7
DMZ30JT IC InChI=1S/C23H16O6.C13H16N2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-7,10,16H,3,8-9H2,1H3/b;7-6+
DMZ30JT CS CN1CCCN=C1/C=C/C2=CC(=CC=C2)O.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O
DMZ30JT IK CCOAINFUFGBHBA-UETGHTDLSA-N
DMZ30JT IU 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol
DMZ30JT CA CAS 68813-55-8
DMZ30JT CB CHEBI:7821
DMZ30JT DE Trichuris trichiura infection
DM9UB0P ID DM9UB0P
DM9UB0P DN Oxaprozin
DM9UB0P HS Approved
DM9UB0P SN Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid
DM9UB0P CP Gd Searle Llc
DM9UB0P TC Antiinflammatory Agents
DM9UB0P DT Small molecular drug
DM9UB0P PC 4614
DM9UB0P MW 293.3
DM9UB0P FM C18H15NO3
DM9UB0P IC InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
DM9UB0P CS C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
DM9UB0P IK OFPXSFXSNFPTHF-UHFFFAOYSA-N
DM9UB0P IU 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
DM9UB0P CA CAS 21256-18-8
DM9UB0P CB CHEBI:7822
DM9UB0P DE Rheumatoid arthritis
DM1F42Z ID DM1F42Z
DM1F42Z DN Oxatomide
DM1F42Z HS Approved
DM1F42Z SN Celtect; Oxatimide; Oxatomida; Oxatomidum; Oxetal; Tinset; CBMicro_024634; KW 4354; O 9387; R 35443; R35443; Celtect (TN); KW-4354; McN-JR 35443; Oxatomida [INN-Spanish]; Oxatomide (tinset); Oxatomidum [INN-Latin]; R 35,443; R-35443; Oxatomide (JAN/USAN/INN); Oxatomide [USAN:BAN:INN:JAN]; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
DM1F42Z CP Janssen Pharmaceutica
DM1F42Z TC Antiallergic Agents
DM1F42Z DT Small molecular drug
DM1F42Z PC 4615
DM1F42Z MW 426.6
DM1F42Z FM C27H30N4O
DM1F42Z IC InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
DM1F42Z CS C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM1F42Z IK BAINIUMDFURPJM-UHFFFAOYSA-N
DM1F42Z IU 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
DM1F42Z CA CAS 60607-34-3
DM1F42Z CB CHEBI:31943
DM1F42Z DE Hay fever
DMXNZM4 ID DMXNZM4
DMXNZM4 DN Oxazepam
DMXNZM4 HS Approved
DMXNZM4 SN Abboxampam; Abboxapam; Adumbran; Alepam; Ansioxacepam; Anxiolit; Aplakil; Astress; Azutranguil; Azutranquil; Bonare; Drimuel; Droxacepam; Durazepam; Hilong; Isodin; Lederpam; Limbial; Murelax; Nesontil; Noctazepam; Nortemazepam; Nozepam; Ossazepam; Oxanid; Oxazepamum; Oxazipam; Oxozepam; Pacienx; Praxiten; Propax; Psicopax; Psiquiwas; QUEN; Quilibrex; Rondar; Sedigoa; Serax; Serenal; Serenid; Serepax; Seresta; Serpax; Sigacalm; Sobril; Tacepam; Tarchomin; Tazepam; Uskan; Vaben; Zaxopam; Anxiolit retard; Ossazepam [DCIT]; P acienx; CB 8092; DF2371850; O5254_SIGMA; Wy 3498; Z 10 tr; Alepam (TN); Apo-astress; Hi-Long; Medopam (TN); Murelax (TN); N-Desmethyltemazepam; Noripam (TN); Oxa-puren; Oxazepamum [INN-Latin]; Purata (TN); Ro 5-6789; Serax (TN); Serenid-D; Serepax (TN); WY-3498; Wy-3498 stic; Z10-Tr; Ox-Pam (TN); Tranquo-buscopan-wirkstoff; Oxazepam (JAN/USP/INN); Oxazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; (+-)-Oxazepam; (RS)-Oxazepam; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMXNZM4 CP Genus Pharms
DMXNZM4 TC Hypnotics and Sedatives
DMXNZM4 DT Small molecular drug
DMXNZM4 PC 4616
DMXNZM4 MW 286.71
DMXNZM4 FM C15H11ClN2O2
DMXNZM4 IC InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)
DMXNZM4 CS C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
DMXNZM4 IK ADIMAYPTOBDMTL-UHFFFAOYSA-N
DMXNZM4 IU 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
DMXNZM4 CA CAS 604-75-1
DMXNZM4 CB CHEBI:7823
DMXNZM4 DE Anxiety disorder
DM5PU6O ID DM5PU6O
DM5PU6O DN Oxcarbazepine
DM5PU6O HS Approved
DM5PU6O SN Epilexter; Epliga; Oxacarbazepine; Oxcarbamazepine; Oxcarbazepime; Oxcarbazepina; Oxcarbazepinum; Timox; Trileptal; Desitin brand of oxcarbazepine; Novartis brand of oxcarbazepine; Oxcarbazepine [INN]; GP 47680; O0363; GP-47680; KIN-493; Oxaleptal (TN); Oxcarbazepina [INN-Spanish]; Oxcarbazepinum [INN-Latin]; SPN-804; Trileptal (TN); Oxcarbazepine (USAN/INN); 10,11-Dihydro-10-oxo-5H-debenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; 10,11-Dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
DM5PU6O CP Norvatis Phamaceuticals Corporation
DM5PU6O TC Anticonvulsants
DM5PU6O DT Small molecular drug
DM5PU6O PC 34312
DM5PU6O MW 252.27
DM5PU6O FM C15H12N2O2
DM5PU6O IC InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
DM5PU6O CS C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
DM5PU6O IK CTRLABGOLIVAIY-UHFFFAOYSA-N
DM5PU6O IU 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide
DM5PU6O CA CAS 28721-07-5
DM5PU6O CB CHEBI:7824
DM5PU6O DE Epilepsy
DME7KRM ID DME7KRM
DME7KRM DN Oxiconazole
DME7KRM HS Approved
DME7KRM SN Oxiconazol; Oxiconazolum; Oxyconazole; Oxiconazol [INN-Spanish]; Oxiconazole (INN); Oxiconazole [INN:BAN]; Oxiconazolum [INN-Latin]; Ro 13-8996; Sgd 301-76; RO-13-8996; (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-(2,4-dichlorobenzyl) ethanone oxime nitrate; 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine; 2',4'-Dichlor-O-(2,4-dichlorbenzyl)-2-(1-imidazolyl)-(Z)-acetophenonoxim; 2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-(O-(2,4-dichlorobenzyl)oxime)
DME7KRM CP Fougera Pharmaceuticals Inc
DME7KRM TC Antifungal Agents
DME7KRM DT Small molecular drug
DME7KRM PC 5353853
DME7KRM MW 429.1
DME7KRM FM C18H13Cl4N3O
DME7KRM IC InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18+
DME7KRM CS C1=CC(=C(C=C1Cl)Cl)CO/N=C(\\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl
DME7KRM IK QRJJEGAJXVEBNE-HKOYGPOVSA-N
DME7KRM IU (Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine
DME7KRM CA CAS 64211-45-6
DME7KRM CB CHEBI:7825
DME7KRM DE Tinea pedis
DM9EQC0 ID DM9EQC0
DM9EQC0 DN Oxidized glutathione
DM9EQC0 HS Approved
DM9EQC0 DT Small molecular drug
DM9EQC0 PC 65359
DM9EQC0 MW 612.6
DM9EQC0 FM C20H32N6O12S2
DM9EQC0 IC InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
DM9EQC0 CS C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
DM9EQC0 IK YPZRWBKMTBYPTK-BJDJZHNGSA-N
DM9EQC0 IU (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM9EQC0 CA CAS 27025-41-8
DM9EQC0 CB CHEBI:17858
DM9EQC0 DE Breast cancer; Bacterial infection
DMRKOS1 ID DMRKOS1
DMRKOS1 DN Oxilofrine
DMRKOS1 HS Approved
DMRKOS1 SN Oxilofrine hydrochloride; Carnigen (TN)
DMRKOS1 DT Small molecular drug
DMRKOS1 PC 688009
DMRKOS1 MW 181.23
DMRKOS1 FM C10H15NO2
DMRKOS1 IC InChI=1S/C10H15NO2/c1-7(11-2)10(13)8-3-5-9(12)6-4-8/h3-7,10-13H,1-2H3/t7-,10-/m0/s1
DMRKOS1 CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NC
DMRKOS1 IK OXFGTKPPFSCSMA-XVKPBYJWSA-N
DMRKOS1 IU 4-[(1R,2S)-1-hydroxy-2-(methylamino)propyl]phenol
DMRKOS1 CA CAS 365-26-4
DMRKOS1 CB CHEBI:134822
DMRKOS1 DE Orthostatic hypotension
DM9FKSR ID DM9FKSR
DM9FKSR DN Oxitropium bromide
DM9FKSR HS Approved
DM9FKSR SN Oxivent (TN)
DM9FKSR CP Dieckmann
DM9FKSR DT Small molecular drug
DM9FKSR PC 6917865
DM9FKSR MW 412.3
DM9FKSR FM C19H26BrNO4
DM9FKSR IC InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13?,14-,15-,16+,17-,18+,20?;/m1./s1
DM9FKSR CS CC[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
DM9FKSR IK LCELQERNWLBPSY-YAYGZGPXSA-M
DM9FKSR IU [(1R,2R,4S,5S)-9-ethyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
DM9FKSR CA CAS 30286-75-0
DM9FKSR DE Asthma
DM51OQW ID DM51OQW
DM51OQW DN Oxprenolol
DM51OQW HS Approved
DM51OQW SN Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol
DM51OQW TC Antihypertensive Agents
DM51OQW DT Small molecular drug
DM51OQW PC 4631
DM51OQW MW 265.35
DM51OQW FM C15H23NO3
DM51OQW IC InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
DM51OQW CS CC(C)NCC(COC1=CC=CC=C1OCC=C)O
DM51OQW IK CEMAWMOMDPGJMB-UHFFFAOYSA-N
DM51OQW IU 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol
DM51OQW CA CAS 6452-71-7
DM51OQW CB CHEBI:91704
DM51OQW DE Hypertension
DMLHSE3 ID DMLHSE3
DMLHSE3 DN Oxtriphylline
DMLHSE3 HS Approved
DMLHSE3 SN Choledyl; Cholegyl; Cholinophyllin; Cholinophylline; Filoral; Oxtrimethylline; Sabidal; Soliphylline; Teofilcolina; Teokolin; Theoxylline; Choline theophylline salt; Cholini theophyllinas; Colina teofillinato; Colina teofillinato [DCIT]; Oxtriphylline [USAN]; Oxtriphylline pediatric; Teofilinato de colina; Theophyllinate de choline; Theophylline cholinate; Theophylline salt of choline; Choledyl SA 400; Zy 15061; Choledyl (TN); Cholini theophyllinas [INN-Latin]; Teofilinato de colina [INN-Spanish]; Theophyllinate de choline[INN-French]; Choline salt with theophylline (1:1); Theophylline, compd. with choline; Choline, compd. with theophylline (1:1); Choline, hydroxide, compd. with theophylline (1:1); Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethylpurine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1); (2-Hydroxyethyl)trimethylammonium compound with theophylline; 1,3-dimethyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, ion(1-), 2-hydroxy-N,N,N-trimethylethanaminium
DMLHSE3 TC Bronchodilator Agents
DMLHSE3 DT Small molecular drug
DMLHSE3 PC 656652
DMLHSE3 MW 283.33
DMLHSE3 FM C12H21N5O3
DMLHSE3 IC InChI=1S/C7H8N4O2.C5H14NO/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;1-6(2,3)4-5-7/h3,12H,1-2H3;7H,4-5H2,1-3H3/q;+1/p-1
DMLHSE3 CS CN1C(=C2C(=NC=N2)N(C1=O)C)[O-].C[N+](C)(C)CCO
DMLHSE3 IK SOELXOBIIIBLRJ-UHFFFAOYSA-M
DMLHSE3 IU 1,3-dimethyl-2-oxopurin-6-olate;2-hydroxyethyl(trimethyl)azanium
DMLHSE3 CA CAS 4499-40-5
DMLHSE3 DE Cough
DMI0GDH ID DMI0GDH
DMI0GDH DN Oxybuprocaine
DMI0GDH HS Approved
DMI0GDH SN Benoxil; Benoxinate; Butoxyaminobenzoyldiethylaminoethanol; Butoxyprocaine; Conjucain; Dorsacain; Novescine; Novesinol; Oxibuprocaina; Oxibuprocainum; Oxibuprokain; Oxybucaine; Oxybuprocainum; Oxyriprocaine; Prescaina; Benoxinate hydrochloride; Monofree oxybuprocaine; Oxybuprocaine HCL; Oxybuprocaine hydrochloride; S 749;Monofree oxybuprocaine (TN); Novesin (TN); Novesine (TN); Oxibuprocaina [INN-Spanish]; Oxybuprocaine (INN); Oxybuprocaine [INN:BAN]; Oxybuprocainum [INN-Latin]; Diethylaminoethyl-4-amino-3-butoxybenzoate; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; 4-Amino-3-butoxybenzoicacid 2-diethylaminoethyl ester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]
DMI0GDH CP Norvatis Phamaceuticals Corporation
DMI0GDH TC Anesthetics
DMI0GDH DT Small molecular drug
DMI0GDH PC 4633
DMI0GDH MW 308.4
DMI0GDH FM C17H28N2O3
DMI0GDH IC InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
DMI0GDH CS CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N
DMI0GDH IK CMHHMUWAYWTMGS-UHFFFAOYSA-N
DMI0GDH IU 2-(diethylamino)ethyl 4-amino-3-butoxybenzoate
DMI0GDH CA CAS 99-43-4
DMI0GDH CB CHEBI:309594
DMI0GDH DE Anaesthesia
DMF2KLU ID DMF2KLU
DMF2KLU DN Oxybutynin hydrochloride
DMF2KLU HS Approved
DMF2KLU SN HOB-294; Oxybutynin hydrochloride (transdermal patch, overactive bladder); Oxybutynin hydrochloride (transdermal patch, overactive bladder), Hisamitsu
DMF2KLU CP Watson Pharmaceuticals
DMF2KLU DT Small molecular drug
DMF2KLU PC 91505
DMF2KLU MW 393.9
DMF2KLU FM C22H32ClNO3
DMF2KLU IC InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
DMF2KLU CS CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl
DMF2KLU IK SWIJYDAEGSIQPZ-UHFFFAOYSA-N
DMF2KLU IU 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate;hydrochloride
DMF2KLU CA CAS 1508-65-2
DMF2KLU CB CHEBI:7857
DMF2KLU DE Urinary incontinence
DMXLKHV ID DMXLKHV
DMXLKHV DN Oxycodone
DMXLKHV HS Approved
DMXLKHV CP Watson Laboratories
DMXLKHV TC Analgesics
DMXLKHV DT Small molecular drug
DMXLKHV PC 5284603
DMXLKHV MW 315.4
DMXLKHV FM C18H21NO4
DMXLKHV IC InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
DMXLKHV CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
DMXLKHV IK BRUQQQPBMZOVGD-XFKAJCMBSA-N
DMXLKHV IU (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMXLKHV CA CAS 76-42-6
DMXLKHV CB CHEBI:7852
DMXLKHV DE Pain; Back pain
DM8ZXT6 ID DM8ZXT6
DM8ZXT6 DN Oxymetazoline
DM8ZXT6 HS Approved
DM8ZXT6 SN Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
DM8ZXT6 CP Schein Pharmaceutical
DM8ZXT6 TC Nasal Decongestants
DM8ZXT6 DT Small molecular drug
DM8ZXT6 PC 4636
DM8ZXT6 MW 260.37
DM8ZXT6 FM C16H24N2O
DM8ZXT6 IC InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)
DM8ZXT6 CS CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C
DM8ZXT6 IK WYWIFABBXFUGLM-UHFFFAOYSA-N
DM8ZXT6 IU 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
DM8ZXT6 CA CAS 1491-59-4
DM8ZXT6 CB CHEBI:7862
DM8ZXT6 DE Eye inflammation; Nasal congestion
DMFXUT8 ID DMFXUT8
DMFXUT8 DN Oxymetholone
DMFXUT8 HS Approved
DMFXUT8 SN oxymetholone; Anasterone; 434-07-1; HMS3393H15
DMFXUT8 CP Solvay Pharmaceuticals
DMFXUT8 DT Small molecular drug
DMFXUT8 PC 5281034
DMFXUT8 MW 332.5
DMFXUT8 FM C21H32O3
DMFXUT8 IC InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
DMFXUT8 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
DMFXUT8 IK ICMWWNHDUZJFDW-DHODBPELSA-N
DMFXUT8 IU (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMFXUT8 CA CAS 434-07-1
DMFXUT8 CB CHEBI:7864
DMFXUT8 DE Aplastic anemia
DM65AGJ ID DM65AGJ
DM65AGJ DN Oxymorphone
DM65AGJ HS Approved
DM65AGJ SN Oxymorphone (abuse-resistant, pain); Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals; Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer
DM65AGJ CP Pain Therapeutics Inc
DM65AGJ TC Neurology Agents
DM65AGJ DT Small molecular drug
DM65AGJ PC 5284604
DM65AGJ MW 301.34
DM65AGJ FM C17H19NO4
DM65AGJ IC InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
DM65AGJ CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DM65AGJ IK UQCNKQCJZOAFTQ-ISWURRPUSA-N
DM65AGJ IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM65AGJ CA CAS 76-41-5
DM65AGJ CB CHEBI:7865
DM65AGJ DE Pain
DMPZS7U ID DMPZS7U
DMPZS7U DN Oxyphenbutazone
DMPZS7U HS Approved
DMPZS7U SN Tandearil
DMPZS7U CP Novartis Pharmaceuticals Corp
DMPZS7U DT Small molecular drug
DMPZS7U PC 4641
DMPZS7U MW 324.4
DMPZS7U FM C19H20N2O3
DMPZS7U IC InChI=1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3
DMPZS7U CS CCCCC1C(=O)N(N(C1=O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMPZS7U IK HFHZKZSRXITVMK-UHFFFAOYSA-N
DMPZS7U IU 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
DMPZS7U CA CAS 129-20-4
DMPZS7U CB CHEBI:76258
DMPZS7U DE Arthritis
DM3TABW ID DM3TABW
DM3TABW DN Oxyphencyclimine
DM3TABW HS Approved
DM3TABW SN Antulcus; Caridan; Daricol; Manir; Naridan; Oxifencicliminum; Oxiphencycliminum; Oxyphencycliminum; Zamanil; Oxifencicliminum [INN-Spanish]; Oxyphencyclimine (INN); Oxyphencyclimine [INN:BAN]; Oxyphencycliminum [INN-Latin]; Benzeneacetic acid, .alpha.-cyclohexyl-.alpha.-hydroxy-, (1,4,5,6-tetrahydro-1-methyl-2-pyrimidinyl)methyl ester; (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate; (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinemethanol-alpha-phenylcyclohexaneglycolate; 1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinylmethyl alpha-cyclohexyl-alpha-phenylglycolat; 1-Methyl-1,4,5,6-tetrahydro-2-pyrimidinylmethyl-alpha-cyclohexylmandelat
DM3TABW CP Pfizer Laboratories Div Pfizer Inc
DM3TABW TC Anticholinergic Agents
DM3TABW DT Small molecular drug
DM3TABW PC 4642
DM3TABW MW 344.4
DM3TABW FM C20H28N2O3
DM3TABW IC InChI=1S/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3
DM3TABW CS CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O
DM3TABW IK DUDKAZCAISNGQN-UHFFFAOYSA-N
DM3TABW IU (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
DM3TABW CA CAS 125-53-1
DM3TABW CB CHEBI:7868
DM3TABW DE Peptic ulcer
DMMQHOZ ID DMMQHOZ
DMMQHOZ DN Oxyphenonium
DMMQHOZ HS Approved
DMMQHOZ SN Argicillin; Atrenyl; Hydroxymethylgramicidin; Methacin; Methocidin; Methocidine; Methocidinum; Metocidina; Oxiphenonum; Spastrex;Oxyphenonium Chloride; Oxyphenonium Iodide; Methocidin [DCF:INN]; Methocidine [INN-French]; Methocidinum [INN-Latin]; Metocidina [INN-Spanish]; [2-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-ethyl]-diethyl-methyl-ammonium; 2-((Cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methylethanaminium; 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium; 2-[2-cyclohexyl(hydroxy)phenylacetoxy]-n,n-diethyl-n-methylethanaminium
DMMQHOZ CP Novartis Pharmaceuticals Corp
DMMQHOZ TC Parasympatholytics
DMMQHOZ DT Small molecular drug
DMMQHOZ PC 5749
DMMQHOZ MW 348.5
DMMQHOZ FM C21H34NO3+
DMMQHOZ IC InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1
DMMQHOZ CS CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
DMMQHOZ IK GFRUPHOKLBPHTQ-UHFFFAOYSA-N
DMMQHOZ IU 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium
DMMQHOZ CA CAS 14214-84-7
DMMQHOZ CB CHEBI:94329
DMMQHOZ DE Visceral spasms
DMOVH1M ID DMOVH1M
DMOVH1M DN Oxytetracycline
DMOVH1M HS Approved
DMOVH1M SN Adamycin; Biostat; Dabicycline; Dalimycin; Fanterrin; Geomycin; Geotilin; Hydroxytetracycline; Imperacin; Lenocycline; Macocyn; OTC; Oksisyklin; Ossitetraciclina; Oxacycline; Oxitetraciclina; Oxitetracyclin; Oxitetracycline; Oxitetracyclinum; Oxymycin; Oxymykoin; Oxypam; Oxyterracin; Oxyterracine; Oxyterracyne; Oxytetracid; Oxytetracyclin; Oxytetracyclinum; Proteroxyna; Riomitsin; Ryomycin; Solkaciclina; Tarocyn; Tarosin; Teravit; Terrafungine; Terramitsin; Terramycin; Tetran; Unimycin; Ursocyclin; Ursocycline; Vendarcin; Biostat PA; Ossitetraciclina [DCIT]; Oxytetracycline HCl; Oxytetracycline [INN]; Oxytetracycline amphoteric; Oxytetracycline anhydrous; Oxytetracycline calcium; Terramycin im; Antibiotic TM 25; LA 200; Liquamycin LA 200; Mycoshield TMQTHC 20; Pennox 200; TM 5; Terramycin Q50; Geomycin (Streptomyces vimosus); OTC (antibiotic); Oxitetraciclina [INN-Spanish]; Oxytetracycline (anhydrous); Oxytetracycline (internal use); Oxytetracyclinum [INN-Latin]; Terramycin, Liquamycin, Oxytetracycline; (2E,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2E,4S,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aR,5S,5aR,6S,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,6,10,11,12a-pentahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 5-Hydroxytetracycline
DMOVH1M CP Pfizer Pharmaceuticals
DMOVH1M TC Antibiotics
DMOVH1M DT Small molecular drug
DMOVH1M PC 54675779
DMOVH1M MW 460.4
DMOVH1M FM C22H24N2O9
DMOVH1M IC InChI=1S/C22H24N2O9/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29/h4-6,12-14,17,25-26,28,30,32-33H,1-3H3,(H2,23,31)/t12-,13-,14+,17+,21-,22+/m1/s1
DMOVH1M CS C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O
DMOVH1M IK OWFJMIVZYSDULZ-PXOLEDIWSA-N
DMOVH1M IU (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMOVH1M CA CAS 2058-46-0
DMOVH1M CB CHEBI:27701
DMOVH1M DE Bacterial infection
DMDL27I ID DMDL27I
DMDL27I DN Oxytocin
DMDL27I HS Approved
DMDL27I SN OXYTOCIN; Pitocin; 50-56-6; Ocytocin; Endopituitrina; Orasthin; Syntocinon; Oxytocine; Oxitocina; Oxytocinum; (1-Hemicystine)oxytocin; Piton S; Oxytocic hormone; UNII-1JQS135EYN; 3-Isoleucine-8-leucine vasopressin; Partocon; Oxystin; alpha-Hypophamine; Synthetic oxytocin; 1JQS135EYN; Ocytocinum; Syntocinone; Utedrin; Oxtocin; Uteracon; Syntocin; Synpitan; Presoxin; Di-sipidin; CHEMBL395429; CHEBI:7872; Nobitocin S; Atonin O; Oxetakain [Czech]; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; Posterior; Oxytocin (intranasal/ muco system, autism); [3H]OT (human, mouse, rat)
DMDL27I CP Pastorus Pharma Llc
DMDL27I DT Small molecular drug
DMDL27I SQ DB00107 sequence: CYIQNCPLG
DMDL27I PC 439302
DMDL27I MW 1007.2
DMDL27I FM C43H66N12O12S2
DMDL27I IC InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1
DMDL27I CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMDL27I IK XNOPRXBHLZRZKH-DSZYJQQASA-N
DMDL27I IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMDL27I CA CAS 50-56-6
DMDL27I CB CHEBI:7872
DMDL27I DE Autism spectrum disorder; Lactation failure
DM1YB0R ID DM1YB0R
DM1YB0R DN OZ277
DM1YB0R HS Approved
DM1YB0R SN Arterolane; UNII-3N1TN351VB; 664338-39-0; OZ277; 3N1TN351VB; OZ-277; C22H36N2O4; Arterolane [INN]; RBx11160; OZ 277; SCHEMBL4547841; CHEMBL404431; CHEMBL580910; CHEMBL221773; SCHEMBL12612733; CHEMBL1197433; SCHEMBL13951812; SCHEMBL11379522; SCHEMBL10307589; VXYZBLXGCYNIHP-BBMJWGJISA-N; VXYZBLXGCYNIHP-CAGINOIPSA-N; ZINC14191464; RBX-11160; NCGC00274173-01; HY-10852; Y1261
DM1YB0R DT Small molecular drug
DM1YB0R PC 10475633
DM1YB0R MW 392.5
DM1YB0R FM C22H36N2O4
DM1YB0R IC InChI=1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25)
DM1YB0R CS CC(C)(CNC(=O)CC1CCC2(CC1)OC3(C4CC5CC(C4)CC3C5)OO2)N
DM1YB0R IK VXYZBLXGCYNIHP-UHFFFAOYSA-N
DM1YB0R CA CAS 664338-39-0
DM1YB0R CB CHEBI:136054
DM1YB0R DE Malaria
DMT6AM2 ID DMT6AM2
DMT6AM2 DN Ozanimod
DMT6AM2 HS Approved
DMT6AM2 SN 1306760-87-1; Ozanimod (RPC1063); UNII-Z80293URPV; Z80293URPV; (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile; Ozanimod [USAN:INN]; Ozanimod (USAN/INN); SCHEMBL2195490; GTPL8709; CHEMBL3707247; 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile; EX-A1316; s7952; ZINC116109867; AKOS026674086; DB12612; CS-5070; HY-12288; AC-29883; Benzonitrile, 5-(3-((1
DMT6AM2 CP Receptos San Diego, CA
DMT6AM2 PC 52938427
DMT6AM2 MW 404.5
DMT6AM2 FM C23H24N4O3
DMT6AM2 IC InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
DMT6AM2 CS CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N
DMT6AM2 IK XRVDGNKRPOAQTN-FQEVSTJZSA-N
DMT6AM2 IU 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile
DMT6AM2 CA CAS 1306760-87-1
DMT6AM2 DE Crohn disease; Ulcerative colitis; Non-small-cell lung cancer; Multiple sclerosis
DM6KZMG ID DM6KZMG
DM6KZMG DN Ozenoxacin
DM6KZMG HS Approved
DM6KZMG SN T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer
DM6KZMG CP Ferrer Internacional
DM6KZMG PC 9863827
DM6KZMG MW 363.4
DM6KZMG FM C21H21N3O3
DM6KZMG IC InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
DM6KZMG CS CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
DM6KZMG IK XPIJWUTXQAGSLK-UHFFFAOYSA-N
DM6KZMG IU 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid
DM6KZMG CA CAS 245765-41-7
DM6KZMG CB CHEBI:136050
DM6KZMG DE Impetigo; Bacterial infection
DMNKT8Z ID DMNKT8Z
DMNKT8Z DN Pachycarpine
DMNKT8Z HS Approved
DMNKT8Z SN (+)-sparteine
DMNKT8Z DT Small molecular drug
DMNKT8Z PC 7014
DMNKT8Z MW 234.38
DMNKT8Z FM C15H26N2
DMNKT8Z IC InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m1/s1
DMNKT8Z CS C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4
DMNKT8Z IK SLRCCWJSBJZJBV-TUVASFSCSA-N
DMNKT8Z IU (1R,2S,9R,10R)-7,15-diazatetracyclo[7.7.1.02,7.010,15]heptadecane
DMNKT8Z CA CAS 492-08-0
DMNKT8Z DE Postpartum haemorrhage
DMLB81S ID DMLB81S
DMLB81S DN Paclitaxel
DMLB81S HS Approved
DMLB81S SN 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel
DMLB81S TC Anticancer Agents
DMLB81S DT Small molecular drug
DMLB81S PC 36314
DMLB81S MW 853.918
DMLB81S FM C47H51NO14
DMLB81S IC InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DMLB81S CS CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
DMLB81S IK RCINICONZNJXQF-MZXODVADSA-N
DMLB81S IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMLB81S CA CAS 33069-62-4
DMLB81S CB ChEBI:45863
DMLB81S DE Breast cancer
DMD7L94 ID DMD7L94
DMD7L94 DN Palbociclib
DMD7L94 HS Approved
DMD7L94 SN 571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
DMD7L94 CP Onyx Pharmaceuticals; Pfizer
DMD7L94 TC Anticancer Agents
DMD7L94 DT Small molecular drug
DMD7L94 PC 5330286
DMD7L94 MW 447.5
DMD7L94 FM C24H29N7O2
DMD7L94 IC InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
DMD7L94 CS CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
DMD7L94 IK AHJRHEGDXFFMBM-UHFFFAOYSA-N
DMD7L94 IU 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
DMD7L94 CA CAS 571190-30-2
DMD7L94 CB CHEBI:85993
DMD7L94 DE Solid tumour/cancer; Schizophrenia; Breast cancer
DM9JOYP ID DM9JOYP
DM9JOYP DN Palifermin
DM9JOYP HS Approved
DM9JOYP SN Kepivance; Kepivance (TN); Palifermin (USAN/INN)
DM9JOYP TC Antimucositis Agents
DM9JOYP SQ Palifermin sequence: SYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT
DM9JOYP DE Oral mucositis
DM7NPJS ID DM7NPJS
DM7NPJS DN Paliperidone
DM7NPJS HS Approved
DM7NPJS SN Xeplion; Invega Sustenna; Paliperidone palmitate; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (injectable, NanoCrystal), Elan; Paliperidone (depot injection, NanoCrystal), Johnson & Johnson
DM7NPJS CP Johnson & Johnson
DM7NPJS DT Small molecular drug
DM7NPJS PC 115237
DM7NPJS MW 426.5
DM7NPJS FM C23H27FN4O3
DM7NPJS IC InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
DM7NPJS CS CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DM7NPJS IK PMXMIIMHBWHSKN-UHFFFAOYSA-N
DM7NPJS IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DM7NPJS CA CAS 144598-75-4
DM7NPJS CB CHEBI:83804
DM7NPJS DE Schizophrenia
DMQM9S0 ID DMQM9S0
DMQM9S0 DN Palivizumab
DMQM9S0 HS Approved
DMQM9S0 SN Synagis; Abbosynagis (TN); Palivizumab (INN); Palivizumab (genetical recombination); Synagis (TN); Palivizumab (genetical recombination) (JAN)
DMQM9S0 CP Medlmmune
DMQM9S0 TC Antiviral Agents
DMQM9S0 DT Monoclonal antibody
DMQM9S0 SQ VH region MEDI-493: QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS >VH RegionQVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
DMQM9S0 DE Respiratory syncytial virus infection
DMBHMOX ID DMBHMOX
DMBHMOX DN Palonosetron
DMBHMOX HS Approved
DMBHMOX SN Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
DMBHMOX CP Eisai Inc
DMBHMOX TC Antiemetics
DMBHMOX DT Small molecular drug
DMBHMOX PC 6337614
DMBHMOX MW 296.4
DMBHMOX FM C19H24N2O
DMBHMOX IC InChI=1S/C19H24N2O/c22-19-16-6-2-4-14-3-1-5-15(18(14)16)11-21(19)17-12-20-9-7-13(17)8-10-20/h2,4,6,13,15,17H,1,3,5,7-12H2/t15-,17-/m1/s1
DMBHMOX CS C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5
DMBHMOX IK CPZBLNMUGSZIPR-NVXWUHKLSA-N
DMBHMOX IU (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one
DMBHMOX CA CAS 135729-61-2
DMBHMOX CB CHEBI:85161
DMBHMOX DE Nausea
DMK2PBD ID DMK2PBD
DMK2PBD DN Palonosetron + fosnetupitant
DMK2PBD HS Approved
DMK2PBD CP Helsinn Group
DMK2PBD DT Antibody
DMK2PBD DE Chemotherapy-induced nausea
DMB4AVP ID DMB4AVP
DMB4AVP DN Pamidronate
DMB4AVP HS Approved
DMB4AVP SN AHPrBP; Amidronate; Aminomux; Aminopropanehydroxydiphosphonate; Aredia; Ribodroat; Acide pamidronique; Acido pamidronico; Acidum pamidronicum; Aminohydroxypropylidene diphosphonate; Novartis brand of pamidronate disodium salt; PAMIDRONATE DISODIUM; PAMIDRONIC ACID; Pamidronate calcium; Pamidronate monosodium; Bisphosphonate 6; Acide pamidronique [INN-French]; Acido pamidronico [INN-Spanish]; Acidum pamidronicum [INN-Latin]; Pamidronic acid (INN); Pamidronic acid [INN:BAN]; Ribodroat (TN); Amino-1-hydroxypropane-1,1-diphosphonate; (3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID; (3-Amino-1-hydroxypropylidene)bisphosphonic acid; (3-Amino-1-hydroxypropylidene)diphosphonic acid; (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid; (3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid); (3-amino-1-hydroxypropylidene)-1,1-biphosphonate; (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate; 1-hydroxy-3-aminopropane-1,1-diphosphonic acid; 3-Amino-1-hydroxypropylidene-1,1-diphosphonate
DMB4AVP TC Antiinflammatory Agents
DMB4AVP DT Small molecular drug
DMB4AVP PC 4674
DMB4AVP MW 235.07
DMB4AVP FM C3H11NO7P2
DMB4AVP IC InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
DMB4AVP CS C(CN)C(O)(P(=O)(O)O)P(=O)(O)O
DMB4AVP IK WRUUGTRCQOWXEG-UHFFFAOYSA-N
DMB4AVP IU (3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
DMB4AVP CA CAS 40391-99-9
DMB4AVP CB CHEBI:7903
DMB4AVP DE Hypercalcaemia
DMB0VY8 ID DMB0VY8
DMB0VY8 DN Pancuronium
DMB0VY8 HS Approved
DMB0VY8 SN Mioblock; Pavulon; Bromure de pancuronium; Bromuro de pancuronio; PANCURONIUM BROMIDE; Pancuronii bromidum; Pancuronium dibromide; Poncuronium bromide; NA 97; ORG NA 97; P 1918; Bromure de pancuronium [INN-French]; Bromuro de pancuronio [INN-Spanish]; ORG-NA 97; Pancuronii bromidum [INN-Latin]; Pavulon (TN); Pancuronium bromide (JP15/USAN/INN); Pancuronium bromide [USAN:BAN:INN:JAN]; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI); Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide; Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide; Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate; Piperidinium, 1,1'-[(2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide; (2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate dibromide; 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate; 1,1'-([2beta,3alpha,5alpha,16beta,17beta]-3,17-Bis[acetyloxy]androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide; 1,1'-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(Acetyloxy)androstane-2,16-diyl]bis(1-methylpiperidinium) dibromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide; 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide; 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide; 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane; 3alpha,17beta-diacetoxy-2beta,16beta-bis(1-methylpiperidinium-1-yl)-5alpha-androstane dibromide; 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate
DMB0VY8 CP Organon International
DMB0VY8 TC Neuromuscular Nondepolarizing Agents
DMB0VY8 DT Small molecular drug
DMB0VY8 PC 441289
DMB0VY8 MW 572.9
DMB0VY8 FM C35H60N2O4+2
DMB0VY8 IC InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMB0VY8 CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C
DMB0VY8 IK GVEAYVLWDAFXET-XGHATYIMSA-N
DMB0VY8 IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMB0VY8 CA CAS 16974-53-1
DMB0VY8 CB CHEBI:7907
DMB0VY8 DE Anaesthesia
DMQPD1F ID DMQPD1F
DMQPD1F DN Panitumumab
DMQPD1F HS Approved
DMQPD1F SN Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor)
DMQPD1F CP Amgen & Takeda
DMQPD1F TC Anticancer Agents
DMQPD1F DT Monoclonal antibody
DMQPD1F DE Colorectal cancer; Head and neck cancer
DM58WKG ID DM58WKG
DM58WKG DN Panobinostat
DM58WKG HS Approved
DM58WKG SN Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
DM58WKG CP Novartis
DM58WKG DT Small molecular drug
DM58WKG PC 6918837
DM58WKG MW 349.4
DM58WKG FM C21H23N3O2
DM58WKG IC InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
DM58WKG CS CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
DM58WKG IK FPOHNWQLNRZRFC-ZHACJKMWSA-N
DM58WKG IU (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
DM58WKG CA CAS 404950-80-7
DM58WKG CB CHEBI:85990
DM58WKG DE Multiple myeloma; Primary myelofibrosis; Type-2 diabetes
DMSVOCZ ID DMSVOCZ
DMSVOCZ DN Pantoprazole
DMSVOCZ HS Approved
DMSVOCZ SN Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DMSVOCZ CP Wyeth; Altana; Solvay
DMSVOCZ TC Antiulcer Agents
DMSVOCZ DT Small molecular drug
DMSVOCZ PC 4679
DMSVOCZ MW 383.4
DMSVOCZ FM C16H15F2N3O4S
DMSVOCZ IC InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
DMSVOCZ CS COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
DMSVOCZ IK IQPSEEYGBUAQFF-UHFFFAOYSA-N
DMSVOCZ IU 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
DMSVOCZ CA CAS 102625-70-7
DMSVOCZ CB CHEBI:7915
DMSVOCZ DE Gastroesophageal reflux disease
DM091H2 ID DM091H2
DM091H2 DN Pantothenic acid
DM091H2 HS Approved
DM091H2 SN D-pantothenic acid; pantothenic acid; vitamin B5; 79-83-4; pantothenate; Chick antidermatitis factor; (+)-Pantothenic acid; PANTOTHENOIC ACID; (R)-pantothenate; (D)-(+)-Pantothenic acid; Kyselina pantothenova [Czech]; HSDB 1020; Pantothenic Acid [BAN]; D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-beta-alanine; BRN 1727064; UNII-19F5HK2737; (R)-pantothenic acid; beta-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-; EINECS 201-229-0; (D,+)-N(alpha-gamma-Dihydroxy-beta,beta-dimethylbutyryl)-beta-alanine
DM091H2 DT Small molecular drug
DM091H2 PC 6613
DM091H2 MW 219.23
DM091H2 FM C9H17NO5
DM091H2 IC InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1
DM091H2 CS CC(C)(CO)[C@H](C(=O)NCCC(=O)O)O
DM091H2 IK GHOKWGTUZJEAQD-ZETCQYMHSA-N
DM091H2 IU 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid
DM091H2 CA CAS 79-83-4
DM091H2 CB CHEBI:46905
DM091H2 DE Vitamin deficiency
DMCA9QP ID DMCA9QP
DMCA9QP DN Papaverine
DMCA9QP HS Approved
DMCA9QP SN papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE
DMCA9QP TC Vasodilator Agents
DMCA9QP DT Small molecular drug
DMCA9QP PC 4680
DMCA9QP MW 339.4
DMCA9QP FM C20H21NO4
DMCA9QP IC InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
DMCA9QP CS COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
DMCA9QP IK XQYZDYMELSJDRZ-UHFFFAOYSA-N
DMCA9QP IU 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
DMCA9QP CA CAS 58-74-2
DMCA9QP CB CHEBI:28241
DMCA9QP DE Spasm
DMOC1BX ID DMOC1BX
DMOC1BX DN Paraldehyde
DMOC1BX HS Approved
DMOC1BX SN UNII-S6M3YBG8QA; S6M3YBG8QA
DMOC1BX DT Small molecular drug
DMOC1BX PC 31264
DMOC1BX MW 132.16
DMOC1BX FM C6H12O3
DMOC1BX IC InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3
DMOC1BX CS CC1OC(OC(O1)C)C
DMOC1BX IK SQYNKIJPMDEDEG-UHFFFAOYSA-N
DMOC1BX IU 2,4,6-trimethyl-1,3,5-trioxane
DMOC1BX CA CAS 123-63-7
DMOC1BX CB CHEBI:27909
DMOC1BX DE Insomnia
DMR5ZUP ID DMR5ZUP
DMR5ZUP DN Paramethadione
DMR5ZUP HS Approved
DMR5ZUP SN Isoethadione; Paradione; Parametadiona; Parametadione; Paramethadionum; Parametadione [DCIT]; A 348; Paradione (TN); Parametadiona [INN-Spanish]; Paramethadione (INN); Paramethadione [BAN:INN]; Paramethadione [INN:BAN]; Paramethadionum [INN-Latin]; 3,5-Dimethyl-5-ethyloxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione; 5-Ethyl-3,5-dimethyl-2,4-oxazolidinedione
DMR5ZUP TC Anticonvulsants
DMR5ZUP DT Small molecular drug
DMR5ZUP PC 8280
DMR5ZUP MW 157.17
DMR5ZUP FM C7H11NO3
DMR5ZUP IC InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3
DMR5ZUP CS CCC1(C(=O)N(C(=O)O1)C)C
DMR5ZUP IK VQASKUSHBVDKGU-UHFFFAOYSA-N
DMR5ZUP IU 5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione
DMR5ZUP CA CAS 115-67-3
DMR5ZUP CB CHEBI:7921
DMR5ZUP DE Seizure disorder; Fetal trimethadione syndrome
DM6PR40 ID DM6PR40
DM6PR40 DN Paramethasone
DM6PR40 HS Approved
DM6PR40 SN Cassenne; Cortiden; Dillar; Flumethone; Metilar; Parametasona; Parametasone; Paramethasonum; Paramezone; Parametasone [DCIT]; CS 1483; Dillar (TN); Parametasona [INN-Spanish]; Paramethasone (INN); Paramethasone [INN:BAN]; Paramethasonum [INN-Latin]; (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; (6alpha,11beta,16alpha)-6-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 16alpha-Methyl-6alpha-fluoroprednisolone; 6alpha-Fluoro-16alpha-methylprednisolone
DM6PR40 CP Eli Lilly And Co
DM6PR40 TC Antiinflammatory Agents
DM6PR40 DT Small molecular drug
DM6PR40 PC 5875
DM6PR40 MW 392.5
DM6PR40 FM C22H29FO5
DM6PR40 IC InChI=1S/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1
DM6PR40 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)C)F
DM6PR40 IK MKPDWECBUAZOHP-AFYJWTTESA-N
DM6PR40 IU (6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DM6PR40 CA CAS 53-33-8
DM6PR40 CB CHEBI:7922
DM6PR40 DE Inflammation; Diabetic macular edema
DMM0HR1 ID DMM0HR1
DMM0HR1 DN Pargyline
DMM0HR1 HS Approved
DMM0HR1 SN Benzylmethylpropargylamine; Benzylmethylpropynylamine; Eudatin; Eutron; Methylbenzylpropynylamine; Paragyline; Pargilina; Pargylamine; Pargylin; Pargylinum; Supirdyl; A 19120; MO 911; Pargilina [INN-Spanish]; Pargyline (INN); Pargyline [INN:BAN]; Pargylinum [INN-Latin]; Benzyl-methyl-2-propinylamin; Benzyl-methyl-2-propinylamin [Czech]; N-Methyl-N-benzylpropynylamine; N-Methyl-N-propargylbenzylamine; N-Methyl-N-2-propynylbenzylamine; N-Benzyl-N-methyl-2-propynylamine; N-Benzyl-N-methyl-2-propyn-1; N-Benzyl-N-methyl-2-propyn-1-amine; N-benzyl-N-methylprop-2-yn-1-amine; N-methyl-N-(phenylmethyl)prop-2-yn-1-amine
DMM0HR1 CP Abbott Laboratories Pharmaceutical Products Div
DMM0HR1 TC Antihypertensive Agents
DMM0HR1 DT Small molecular drug
DMM0HR1 PC 4688
DMM0HR1 MW 159.23
DMM0HR1 FM C11H13N
DMM0HR1 IC InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
DMM0HR1 CS CN(CC#C)CC1=CC=CC=C1
DMM0HR1 IK DPWPWRLQFGFJFI-UHFFFAOYSA-N
DMM0HR1 IU N-benzyl-N-methylprop-2-yn-1-amine
DMM0HR1 CA CAS 555-57-7
DMM0HR1 CB CHEBI:7930
DMM0HR1 DE Skin imperfections; Muscular dystrophy; Hypertension
DMYBV3G ID DMYBV3G
DMYBV3G DN Paricalcitol
DMYBV3G HS Approved
DMYBV3G SN Paracalcin; Zemplar; Abbott brand of paricalcitol; Paricalcitol [USAN]; Ab 122358; ABT-358; Zemplar (TN); Paricalcitol (USAN/INN); Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; 19-Nor-1,25-(OH)2D2; 19-Nor-1-alpha,25-dihydroxyvitamin D2; 19-Nor-1alpha,25-dihydroxyvitamin D2; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
DMYBV3G CP Abbott Laboratories
DMYBV3G TC Parasympathomimetics
DMYBV3G DT Small molecular drug
DMYBV3G PC 5281104
DMYBV3G MW 416.6
DMYBV3G FM C27H44O3
DMYBV3G IC InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1
DMYBV3G CS C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C
DMYBV3G IK BPKAHTKRCLCHEA-UBFJEZKGSA-N
DMYBV3G IU (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
DMYBV3G CA CAS 131918-61-1
DMYBV3G CB CHEBI:7931
DMYBV3G DE Hyperparathyroidism
DM1AGXN ID DM1AGXN
DM1AGXN DN Paromomycin
DM1AGXN HS Approved
DM1AGXN SN Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine
DM1AGXN CP King Pharmaceuticals
DM1AGXN TC Antibiotics
DM1AGXN DT Small molecular drug
DM1AGXN PC 165580
DM1AGXN MW 615.6
DM1AGXN FM C23H45N5O14
DM1AGXN IC InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
DM1AGXN CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
DM1AGXN IK UOZODPSAJZTQNH-LSWIJEOBSA-N
DM1AGXN IU (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol
DM1AGXN CA CAS 7542-37-2
DM1AGXN CB CHEBI:7934
DM1AGXN DE Intestinal amebiasis
DM5PVQE ID DM5PVQE
DM5PVQE DN Paroxetine
DM5PVQE HS Approved
DM5PVQE SN Seroxat (TN)
DM5PVQE CP GlaxoSmithKline
DM5PVQE TC Antidepressants
DM5PVQE DT Small molecular drug
DM5PVQE PC 43815
DM5PVQE MW 329.4
DM5PVQE FM C19H20FNO3
DM5PVQE IC InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
DM5PVQE CS C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
DM5PVQE IK AHOUBRCZNHFOSL-YOEHRIQHSA-N
DM5PVQE IU (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
DM5PVQE CA CAS 61869-08-7
DM5PVQE CB CHEBI:7936
DM5PVQE DE Depression
DMHM7JS ID DMHM7JS
DMHM7JS DN Pasireotide
DMHM7JS HS Approved
DMHM7JS SN Signifor; UNII-I4P76SY3N4; Pasireotide diaspartate; I4P76SY3N4; SOM230; 820232-50-6; pasireotide aspartate; Pasireotide diaspartate [EMA EPAR]; CHEBI:72313; Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate; Signifor (TN); SOM 230; SOM-230
DMHM7JS CP Novartis
DMHM7JS DT Small molecular drug
DMHM7JS PC 9941444
DMHM7JS MW 1047.2
DMHM7JS FM C58H66N10O9
DMHM7JS IC InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1
DMHM7JS CS C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
DMHM7JS IK VMZMNAABQBOLAK-DBILLSOUSA-N
DMHM7JS IU [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
DMHM7JS CA CAS 396091-73-9
DMHM7JS CB CHEBI:72312
DMHM7JS DE Cushing disease
DMMIQ20 ID DMMIQ20
DMMIQ20 DN Patiromer calcium
DMMIQ20 HS Approved
DMMIQ20 SN Patiromer; RLY-5016; Potassium binder (hyperkalemia), Relypsa
DMMIQ20 CP Relypsa Inc
DMMIQ20 DE Hyperkalemia
DMWSA0V ID DMWSA0V
DMWSA0V DN Patisiran
DMWSA0V HS Approved
DMWSA0V SN Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328
DMWSA0V CP Alnylam Pharmaceuticals
DMWSA0V DT siRNA drug
DMWSA0V SQ RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA(G-Um-A-A-Cm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1)
DMWSA0V DE Amyloidosis; Amyloid cardiomyopathy; Hereditary amyloidosis; Transthyretin familial amyloid cardiomyopathy
DMF57DM ID DMF57DM
DMF57DM DN Pazopanib
DMF57DM HS Approved
DMF57DM SN Pazopanib; Pazopanib (GW-786034); 444731-52-6; 5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; CHEBI:71219; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; UNII-7RN5DR86CK
DMF57DM PC 10113978
DMF57DM MW 437.5
DMF57DM FM C21H23N7O2S
DMF57DM IC CUIHSIWYWATEQL-UHFFFAOYSA-N
DMF57DM CS CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
DMF57DM IK 1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
DMF57DM IU 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
DMF57DM CA CAS 444731-52-6
DMF57DM CB CHEBI:71219
DMF57DM DE Renal cell carcinoma
DM6U9CQ ID DM6U9CQ
DM6U9CQ DN Pazopanib HCl
DM6U9CQ HS Approved
DM6U9CQ SN Votrient (TN)
DM6U9CQ CP GlaxoSmithKline
DM6U9CQ DT Small molecular drug
DM6U9CQ PC 11525740
DM6U9CQ MW 474
DM6U9CQ FM C21H24ClN7O2S
DM6U9CQ IC InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
DM6U9CQ CS CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
DM6U9CQ IK MQHIQUBXFFAOMK-UHFFFAOYSA-N
DM6U9CQ IU 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride
DM6U9CQ CA CAS 635702-64-6
DM6U9CQ CB CHEBI:71217
DM6U9CQ DE Renal cell carcinoma
DM49IGF ID DM49IGF
DM49IGF DN Pefloxacin
DM49IGF HS Approved
DM49IGF SN Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo
DM49IGF TC Antiinfective Agents
DM49IGF DT Small molecular drug
DM49IGF PC 51081
DM49IGF MW 333.36
DM49IGF FM C17H20FN3O3
DM49IGF IC InChI=1S/C17H20FN3O3/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21/h8-10H,3-7H2,1-2H3,(H,23,24)
DM49IGF CS CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
DM49IGF IK FHFYDNQZQSQIAI-UHFFFAOYSA-N
DM49IGF IU 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM49IGF CA CAS 70458-92-3
DM49IGF CB CHEBI:50199
DM49IGF DE Gonococcal urethritis
DMOWEBU ID DMOWEBU
DMOWEBU DN Pegaptanib
DMOWEBU HS Approved
DMOWEBU SN Macugen (TN); Pegaptanib Octasodium; Pegaptanib sodium; EYE 001; NX 1838; NX1838
DMOWEBU CP Eyetech pharmaceuticals and Pfizer
DMOWEBU TC Antiangiogenic Agents
DMOWEBU DT Aptamer
DMOWEBU PC 56603655
DMOWEBU MW 541.6
DMOWEBU FM C22H44N3O10P
DMOWEBU IC InChI=1S/C22H44N3O10P/c1-31-15-17-33-21(27)24-13-9-7-11-19(25-22(28)34-18-16-32-2)20(26)23-12-8-5-4-6-10-14-35-36(3,29)30/h19H,4-18H2,1-3H3,(H,23,26)(H,24,27)(H,25,28)(H,29,30)/t19-/m0/s1
DMOWEBU CS COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
DMOWEBU IK WLCZTRVUXYALDD-IBGZPJMESA-N
DMOWEBU IU 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid
DMOWEBU DE Neovascular age-related macular degeneration
DM7UP8X ID DM7UP8X
DM7UP8X DN Pegfilgrastim
DM7UP8X HS Approved
DM7UP8X SN Neulasta; Neulasta (TN); Pegfilgrastim (INN)
DM7UP8X CP Amgen Inc
DM7UP8X TC Immunomodulatory Agents
DM7UP8X DT Small molecular drug
DM7UP8X SQ Pegfilgrastim sequence: MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP
DM7UP8X PC 70683024
DM7UP8X MW 730.7
DM7UP8X FM C27H46N4O19
DM7UP8X IC InChI=1S/C27H46N4O19/c1-10(16(28)23(40)41)48-24-18(30-11(2)33)21(39)20(38)14(49-24)9-47-27(25(42)43)6-12(34)17(22(50-27)19(37)13(35)8-32)31-15(36)7-29-26(44)46-5-4-45-3/h10,12-14,16-22,24,32,34-35,37-39H,4-9,28H2,1-3H3,(H,29,44)(H,30,33)(H,31,36)(H,40,41)(H,42,43)/t10-,12+,13-,14-,16+,17-,18-,19-,20+,21-,22-,24+,27-/m1/s1
DM7UP8X CS C[C@H]([C@@H](C(=O)O)N)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@@]2(C[C@@H]([C@H]([C@@H](O2)[C@@H]([C@@H](CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C
DM7UP8X IK GAQMWPRWVIGRRV-IVDGIBIRSA-N
DM7UP8X IU (2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DM7UP8X DE Malignant solid tumour
DMJI3BA ID DMJI3BA
DMJI3BA DN Peginterferon alfa-2a
DMJI3BA HS Approved
DMJI3BA SN Pegasys; Peginterferon alfa-2a (genetical recombination); Peginterferon alfa-2a (USAN/INN); Peginterferon alfa-2a (genetical recombination) (JAN)
DMJI3BA CP Hoffmann-La Roche pharmaceutical company
DMJI3BA TC Anticancer Agents
DMJI3BA SQ Peginterferon alfa-2a sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMJI3BA DE Hairy cell leukaemia
DMAP58Y ID DMAP58Y
DMAP58Y DN Peginterferon alfa-2b
DMAP58Y HS Approved
DMAP58Y SN PegIntron; Peginterferon alfa-2b (INN); Peginterferon alfa-2b (generical recombination); Peginterferon alfa-2b (generical recombination) (JAN)
DMAP58Y CP Schering-Plough
DMAP58Y TC Antiviral Agents
DMAP58Y SQ DB00022 sequence: CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
DMAP58Y DE Hepatitis C virus infection
DMCLR6G ID DMCLR6G
DMCLR6G DN Pegloticase
DMCLR6G HS Approved
DMCLR6G SN Krystexxa (TN)
DMCLR6G CP Savient
DMCLR6G SQ Pegloticase: TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL
DMCLR6G DE Gout
DM6NZ2P ID DM6NZ2P
DM6NZ2P DN Pegvaliase
DM6NZ2P HS Approved
DM6NZ2P SN BMN 165; Pegvaliase [INN]; UNII-N6UAH27EUV; N6UAH27EUV
DM6NZ2P CP BioMarin Pharmaceutical
DM6NZ2P PC 86278362
DM6NZ2P MW 318.41
DM6NZ2P FM C15H30N2O5
DM6NZ2P IC InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1
DM6NZ2P CS COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N
DM6NZ2P IK NPOCDVAOUKODSQ-ZDUSSCGKSA-N
DM6NZ2P IU (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanoylamino]hexanoic acid
DM6NZ2P CA CAS 1585984-95-7
DM6NZ2P DE Phenylketonuria
DMDEZI3 ID DMDEZI3
DMDEZI3 DN Pegvisomant
DMDEZI3 HS Approved
DMDEZI3 SN Somavent; Pegvisomant (genetical recombination); Somavent (TN); Somavert (TN); Pegvisomant (USAN/INN); Pegvisomant (genetical recombination) (JAN)
DMDEZI3 CP Abbott Laboratories
DMDEZI3 TC Anabolic Agents
DMDEZI3 SQ DB00082 sequence: FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
DMDEZI3 DE Acromegaly
DMRH0D5 ID DMRH0D5
DMRH0D5 DN PEGylated IFN beta 1-a
DMRH0D5 HS Approved
DMRH0D5 SN BIIB-017; PEG-Avonex; PEGylated IFN beta 1-a (multiple sclerosis); PEGylated IFN beta 1-a (multiple sclerosis), Biogen Idec; PEGylated interferon beta 1-a (multiple sclerosis), Biogen Idec
DMRH0D5 CP Biogen idec
DMRH0D5 DE Type-2 diabetes
DM8DQV9 ID DM8DQV9
DM8DQV9 DN Pelubiprofen
DM8DQV9 HS Approved
DM8DQV9 SN Pelubi; Rubione; CS-670; DW-330; RS-2131
DM8DQV9 CP Sankyo Co Ltd
DM8DQV9 DT Small molecular drug
DM8DQV9 PC 5282203
DM8DQV9 MW 258.31
DM8DQV9 FM C16H18O3
DM8DQV9 IC InChI=1S/C16H18O3/c1-11(16(18)19)13-8-6-12(7-9-13)10-14-4-2-3-5-15(14)17/h6-11H,2-5H2,1H3,(H,18,19)/b14-10+
DM8DQV9 CS CC(C1=CC=C(C=C1)/C=C/2\\CCCCC2=O)C(=O)O
DM8DQV9 IK AUZUGWXLBGZUPP-GXDHUFHOSA-N
DM8DQV9 IU 2-[4-[(E)-(2-oxocyclohexylidene)methyl]phenyl]propanoic acid
DM8DQV9 CA CAS 69956-77-0
DM8DQV9 DE Back pain
DMD1VZL ID DMD1VZL
DMD1VZL DN Pemafibrate
DMD1VZL HS Approved
DMD1VZL SN K-877
DMD1VZL CP Kowa Co Ltd
DMD1VZL PC 11526038
DMD1VZL MW 490.5
DMD1VZL FM C28H30N2O6
DMD1VZL IC InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
DMD1VZL CS CC[C@H](C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3
DMD1VZL IK ZHKNLJLMDFQVHJ-RUZDIDTESA-N
DMD1VZL IU (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid
DMD1VZL CA CAS 848259-27-8
DMD1VZL DE Lipid metabolism disorder; Cardiovascular disease; Hyperlipidemia
DMFQEA6 ID DMFQEA6
DMFQEA6 DN Pembrolizumab
DMFQEA6 HS Approved
DMFQEA6 CP Merck Kenilworth, NJ
DMFQEA6 DT Monoclonal antibody
DMFQEA6 SQ Heavy Chain Sequence: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >Light Chain SequenceEIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMFQEA6 DE Solid tumour/cancer; Hepatocellular carcinoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Prostate cancer; Renal cell carcinoma; Small-cell lung cancer; Breast cancer; Colorectal cancer; Cutaneous squamous cell carcinoma; Esophageal cancer; Melanoma
DMMX2E6 ID DMMX2E6
DMMX2E6 DN Pemetrexed
DMMX2E6 HS Approved
DMMX2E6 SN Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
DMMX2E6 CP Eli Lilly
DMMX2E6 TC Anticancer Agents
DMMX2E6 DT Small molecular drug
DMMX2E6 PC 135410875
DMMX2E6 MW 427.4
DMMX2E6 FM C20H21N5O6
DMMX2E6 IC InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
DMMX2E6 CS C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMMX2E6 IK WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
DMMX2E6 IU (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
DMMX2E6 CA CAS 137281-23-3
DMMX2E6 CB CHEBI:63616
DMMX2E6 DE Malignant pleural mesothelioma
DM819JF ID DM819JF
DM819JF DN Pemigatinib
DM819JF HS Approved
DM819JF SN Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828
DM819JF CP Incyte Wilmington, DE
DM819JF PC 86705695
DM819JF MW 487.5
DM819JF FM C24H27F2N5O4
DM819JF IC InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)
DM819JF CS CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5
DM819JF IK HCDMJFOHIXMBOV-UHFFFAOYSA-N
DM819JF IU 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
DM819JF CA CAS 1513857-77-6
DM819JF DE Bladder cancer; Myeloproliferative syndrome; Cholangiocarcinoma
DML97WV ID DML97WV
DML97WV DN Pemirolast
DML97WV HS Approved
DML97WV SN Pemirolastum; Pemirox; Pemirolast [INN]; Pemiroplast Potassium; Alamast (TN); Alegysal (TN); Pemirolast (INN); Pemirolastum [INN-Latin]; Pemirox (TN); 9-TBX; 9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DML97WV TC Antiallergic Agents
DML97WV DT Small molecular drug
DML97WV PC 57697
DML97WV MW 228.21
DML97WV FM C10H8N6O
DML97WV IC InChI=1S/C10H8N6O/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8/h2-5H,1H3,(H,12,13,14,15)
DML97WV CS CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3
DML97WV IK HIANJWSAHKJQTH-UHFFFAOYSA-N
DML97WV IU 9-methyl-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DML97WV CA CAS 69372-19-6
DML97WV CB CHEBI:134936
DML97WV DE Allergic conjunctivitis
DM4ES8F ID DM4ES8F
DM4ES8F DN Penbutolol
DM4ES8F HS Approved
DM4ES8F SN Betapressin; Levatol; Levatolol; Levopenbutol; Lobeta; Paginol; Penbutololum; PENBUTOLOL SULFATE; HOE 893; HOE 893d; Betapressin (TN); Hostabloc (TN); L-Penbutolol; Levatol (TN); Levatolol (TN); Lobeta (TN); Paginol (TN); Penbutolol (INN); Penbutolol [INN:BAN]; Penbutololum [INN-Latin]; Penbutolol Sulfate (2:1); S(-)-Penbutolol; (-)-Penbutolol; (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol; 1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol
DM4ES8F TC Antihypertensive Agents
DM4ES8F DT Small molecular drug
DM4ES8F PC 37464
DM4ES8F MW 291.4
DM4ES8F FM C18H29NO2
DM4ES8F IC InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1
DM4ES8F CS CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O
DM4ES8F IK KQXKVJAGOJTNJS-HNNXBMFYSA-N
DM4ES8F IU (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol
DM4ES8F CA CAS 38363-40-5
DM4ES8F CB CHEBI:7954
DM4ES8F DE Hypertension
DMOUMDV ID DMOUMDV
DMOUMDV DN Penciclovir
DMOUMDV HS Approved
DMOUMDV SN penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2
DMOUMDV TC Antiviral Agents
DMOUMDV DT Small molecular drug
DMOUMDV PC 135398748
DMOUMDV MW 253.26
DMOUMDV FM C10H15N5O3
DMOUMDV IC InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
DMOUMDV CS C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
DMOUMDV IK JNTOCHDNEULJHD-UHFFFAOYSA-N
DMOUMDV IU 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one
DMOUMDV CA CAS 39809-25-1
DMOUMDV CB CHEBI:7956
DMOUMDV DE Human immunodeficiency virus infection
DMG1DTE ID DMG1DTE
DMG1DTE DN Penfluridol
DMG1DTE HS Approved
DMG1DTE SN PENFLURIDOL; 26864-56-2; Semap; 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-4-ol; TLP-607; McN-JR-16,341; 1-[4,4-Bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol; Penfluridolum [INN-Latin]; C28H27ClF5NO; UNII-25TLU22Q8H; R 16341; EINECS 248-074-5; R-16341; BRN 1558826; CHEMBL47050; 25TLU22Q8H; MDLAAYDRRZXJIF-UHFFFAOYSA-N; 4-Piperidinol, 1-(4,4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)-; 4-Piperidinol,; Hydroxamates
DMG1DTE DT Small molecular drug
DMG1DTE PC 33630
DMG1DTE MW 524
DMG1DTE FM C28H27ClF5NO
DMG1DTE IC InChI=1S/C28H27ClF5NO/c29-26-12-7-21(18-25(26)28(32,33)34)27(36)13-16-35(17-14-27)15-1-2-24(19-3-8-22(30)9-4-19)20-5-10-23(31)11-6-20/h3-12,18,24,36H,1-2,13-17H2
DMG1DTE CS C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMG1DTE IK MDLAAYDRRZXJIF-UHFFFAOYSA-N
DMG1DTE IU 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol
DMG1DTE CA CAS 26864-56-2
DMG1DTE CB CHEBI:92278
DMG1DTE DE Schizophrenia
DM40EF6 ID DM40EF6
DM40EF6 DN Penicillamine
DM40EF6 HS Approved
DM40EF6 SN D-Penicillamine; penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; D-Mercaptovaline; Mercaptovaline; Perdolat; Penicillamin; Pendramine; Kuprenil; Depamine; Mercaptyl; Trolovol; Metalcaptase; Artamine; Cupripen; (S)-3,3-Dimethylcysteine; D-Valine, 3-mercapto-; Penicillaminum; Penicilamina; Sufirtan; beta-Thiovaline; Dimethylcysteine; D-beta,beta-Dimethylcysteine; D-3-Mercaptovaline; beta,beta-Dimethylcysteine; Penicillamina; Penicilllamine; Sufortan; Copper penicillaminate; D Penicillamine; Penicillamina [DCIT]; Reduced penicillamine; D 3 Mercaptovaline; TBB068824; Beta,beta Dimethylcysteine; Beta-Thiovaline; Cuprimine (TN); D-Penicilamine; D-Penicyllamine; Depen (TN); P-1280; Penicilamina [INN-Spanish]; Penicillaminate, Copper; Penicillaminum [INN-Latin]; Reduced D-penicillamine; Beta,beta-Dimethylcysteine; D,3-Mercaptovaline; D-beta-Mercaptovaline; Distamine (*Hydrochloride*); Metalcaptase (*Hydrochloride*); Penicillamine (JAN/USP/INN); Penicillamine [USAN:INN:BAN:JAN]; Alpha-Amino-beta-methyl-beta-mercaptobutyric acid; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; (D)-PENICILLAMINE; (S)-Penicillamin; (S)-Penicillamine; 2-Amino-3-mercapto-3-methylbutanoic acid; 3,3-Dimethyl-D-cysteine; 3-Mercaptovaline; 3-sulfanyl-D-valine; D-penicillamine
DM40EF6 TC Antidotes
DM40EF6 DT Small molecular drug
DM40EF6 PC 5852
DM40EF6 MW 149.21
DM40EF6 FM C5H11NO2S
DM40EF6 IC InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1
DM40EF6 CS CC(C)([C@H](C(=O)O)N)S
DM40EF6 IK VVNCNSJFMMFHPL-VKHMYHEASA-N
DM40EF6 IU (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid
DM40EF6 CA CAS 771431-20-0
DM40EF6 CB CHEBI:7959
DM40EF6 DE Rheumatoid arthritis
DMNMHBV ID DMNMHBV
DMNMHBV DN Penicillin
DMNMHBV HS Approved
DMNMHBV SN Cillin; Pentids; 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (Phenylmethyl)penicillin; 7005-30-3; NSC131815; (Phenylmethyl)penicillinic acid; 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; AC1L1DHC; AC1Q5UVJ; Penicilline G sodium salt; Oprea1_713794; Oprea1_861345; CHEMBL300052; SCHEMBL2109546; CTK2H5530
DMNMHBV DT Small molecular drug
DMNMHBV PC 2349
DMNMHBV MW 334.4
DMNMHBV FM C16H18N2O4S
DMNMHBV IC InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)
DMNMHBV CS CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
DMNMHBV IK JGSARLDLIJGVTE-UHFFFAOYSA-N
DMNMHBV IU 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMNMHBV CA CAS 61-33-6
DMNMHBV DE Bacterial infection
DM49VEW ID DM49VEW
DM49VEW DN Penicillin G Benzathine
DM49VEW HS Approved
DM49VEW SN Bicillin L-a; Permapen; Bicillin
DM49VEW CP King Pharmaceuticals Inc
DM49VEW TC Antiinfective Agents
DM49VEW DT Small molecular drug
DM49VEW PC 656811
DM49VEW MW 981.2
DM49VEW FM C48H64N6O12S2
DM49VEW IC InChI=1S/2C16H18N2O4S.C16H20N2.4H2O/c2*1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-7-15(8-4-1)13-17-11-12-18-14-16-9-5-2-6-10-16;;;;/h2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);1-10,17-18H,11-14H2;4*1H2/t2*11-,12+,14-;;;;;/m11...../s1
DM49VEW CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1=CC=C(C=C1)CNCCNCC2=CC=CC=C2.O.O.O.O
DM49VEW IK WIDKTXGNSOORHA-CJHXQPGBSA-N
DM49VEW IU N,N'-dibenzylethane-1,2-diamine;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate
DM49VEW CA CAS 41372-02-5
DM49VEW DE Bacterial infection
DMU4JLB ID DMU4JLB
DMU4JLB DN Penicillin G Procaine
DMU4JLB HS Approved
DMU4JLB SN Duracillin A.S.; Pfizerpen-as
DMU4JLB CP Eli Lilly And Co
DMU4JLB TC Antiinfective Agents
DMU4JLB DT Small molecular drug
DMU4JLB PC 22502
DMU4JLB MW 588.7
DMU4JLB FM C29H40N4O7S
DMU4JLB IC InChI=1S/C16H18N2O4S.C13H20N2O2.H2O/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);5-8H,3-4,9-10,14H2,1-2H3;1H2/t11-,12+,14-;;/m1../s1
DMU4JLB CS CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.O
DMU4JLB IK KZDCMKVLEYCGQX-UDPGNSCCSA-N
DMU4JLB IU 2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate
DMU4JLB CA CAS 6130-64-9
DMU4JLB DE Bacterial infection
DMY18XK ID DMY18XK
DMY18XK DN Penicillin G Sodium
DMY18XK HS Approved
DMY18XK SN Penicillin G sodium salt; 69-57-8; Benzylpenicillin sodium; Crystapen; American penicillin; Pencillin G sodium; Sodium penicillin G; BENZYLPENICILLIN SODIUM SALT; Sodium penicillin; Sodium benzylpenicillinate; Sodium penicillin II; Veticillin; Penilaryn; Mycofarm; Novocillin; Sodium benzylpenicillin; Kesso-Pen; Pen-A-Brasive; Sodium benzylpenicillin G; Monosodium benzylpenicillin; Benzylpenicillinic acid sodium salt; Sugracillin sodium salt; Penicillin G Sodium, Crystalline; Sodium benzylp
DMY18XK CP Bristol Myers Squibb Spa
DMY18XK TC Antiinfective Agents
DMY18XK DT Small molecular drug
DMY18XK PC 23668834
DMY18XK MW 356.4
DMY18XK FM C16H17N2NaO4S
DMY18XK IC InChI=1S/C16H18N2O4S.Na/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
DMY18XK CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)[O-])C.[Na+]
DMY18XK IK FCPVYOBCFFNJFS-LQDWTQKMSA-M
DMY18XK IU sodium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMY18XK CA CAS 69-57-8
DMY18XK CB CHEBI:51765
DMY18XK DE Bacterial infection
DMKVOYF ID DMKVOYF
DMKVOYF DN Penicillin V
DMKVOYF HS Approved
DMKVOYF SN Apocillin; Apopen; Beromycin; Calcipen; Fenacilin; Fenospen; Fenossimetilpenicillina; Fenoximetilpenicilina; Fenoxymethylpenicillin; Fenoxypen; Meropenin; Oracillin; Oratren; Ospen; PNV; PVA; Phenocillin; Phenomycilline; Phenopenicillin; Phenoximethylpenicillinum; Phenoxomethylpenicillanyl; Phenoxomethylpenicillin; Phenoxymethylpenicillanyl; Phenoxymethylpenicillin; Phenoxymethylpenicilline; Phenoxymethylpenicillinum; Robicillin; Rocilin; Stabicillin; Vebecillin; Vegacillin; Acipen V; Compocillin V; Crystapen V; Distaquaine V; Eskacillian V; Eskacillin V; Fenossimetilpenicillina [DCIT]; Penicillin V [USAN]; Penicillin phenoxymethyl; Phenoxymethyl penicillin; Phenoxymethylenepenicillinic acid; Phenoxymethylpenicillinic acid; Phenoxymethylpenicillinic acid potassium salt; Acipen-v; Beromycin, Penicillin; Berromycin, Penicillin; Fenoximetilpenicilina [INN-Spanish]; Pen-Oral; Pen-V; Pen-vee; Penicillin V (USP); Penicillin, Phenoxymethyl; Phenoxymethylpenicillin (INN); Phenoxymethylpenicilline [INN-French]; Phenoxymethylpenicillinum [INN-Latin]; V-Cil; V-Cillin; V-Cylina; V-Cyline; V-Tablopen; P-Mega-Tablinen; V-Cillin (TN); (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carbonyl; 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid; 3,3-Dimethyl-7-oxo-6-((phenyloxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN); 6-Phenoxyacetamidopenicillanic acid
DMKVOYF TC Antibiotics
DMKVOYF DT Small molecular drug
DMKVOYF PC 6869
DMKVOYF MW 350.4
DMKVOYF FM C16H18N2O5S
DMKVOYF IC InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
DMKVOYF CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C
DMKVOYF IK BPLBGHOLXOTWMN-MBNYWOFBSA-N
DMKVOYF IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMKVOYF CA CAS 87-08-1
DMKVOYF CB CHEBI:27446
DMKVOYF DE Bacterial infection
DM8LX76 ID DM8LX76
DM8LX76 DN Penicillin V Potassium
DM8LX76 HS Approved
DM8LX76 SN Ledercillin Vk; Pen-vee K; Pfizerpen Vk; Veetids; Veetids '125'; Veetids '250'; Uticillin Vk; Veetids '500'
DM8LX76 CP Glaxosmithkline
DM8LX76 TC Antiinfective Agents
DM8LX76 DT Small molecular drug
DM8LX76 PC 23676814
DM8LX76 MW 388.5
DM8LX76 FM C16H17KN2O5S
DM8LX76 IC InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
DM8LX76 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)[O-])C.[K+]
DM8LX76 IK HCTVWSOKIJULET-LQDWTQKMSA-M
DM8LX76 IU potassium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DM8LX76 CA CAS 132-98-9
DM8LX76 CB CHEBI:7967
DM8LX76 DE Bacterial infection
DMZ9MO5 ID DMZ9MO5
DMZ9MO5 DN Pentaerythritol tetranitrate
DMZ9MO5 HS Approved
DMZ9MO5 SN PENTAERYTHRITOL TETRANITRATE; PETN; Penthrite; Nitropentaerythrite; Nitropentaerythritol; Nitropenta; Pentaerithrityl tetranitrate; Vasodiatol; Pentanitrine; Pentanitrol; Quintrate; Corpent; Baritrate; Angicap; Perityl; Peritrate; Penthrit; Antora; Erinit; Peridex-LA; 78-11-5; Deltrate-20; Neopentanetetrayl nitrate; Tetrasule; Pergitral; Pentritol; Pentrite; Nitrotalans; Kaytrate; Duotrate; Subicard; Rythritol; Prevangor; Pentryate; Nitropenton; Nitropent; Pentrate; Pentitrate; Pentafin; Nitrinal; Niperyth; Mycardol; Metranil; Lowetrate; Arcotrate
DMZ9MO5 DT Small molecular drug
DMZ9MO5 PC 6518
DMZ9MO5 MW 316.14
DMZ9MO5 FM C5H8N4O12
DMZ9MO5 IC InChI=1S/C5H8N4O12/c10-6(11)18-1-5(2-19-7(12)13,3-20-8(14)15)4-21-9(16)17/h1-4H2
DMZ9MO5 CS C(C(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])O[N+](=O)[O-]
DMZ9MO5 IK TZRXHJWUDPFEEY-UHFFFAOYSA-N
DMZ9MO5 IU [3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate
DMZ9MO5 CA CAS 78-11-5
DMZ9MO5 CB CHEBI:25879
DMZ9MO5 DE Angina pectoris
DMRCLZB ID DMRCLZB
DMRCLZB DN Pentagastrin
DMRCLZB HS Approved
DMRCLZB SN Peptavlon; Peptavlon (TN); Pentagastrin (JAN/USAN/INN); (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-(2-methylpropoxycarbonylamino)propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMRCLZB TC Diagnostic Agents
DMRCLZB DT Small molecular drug
DMRCLZB PC 9853654
DMRCLZB MW 767.9
DMRCLZB FM C37H49N7O9S
DMRCLZB IC InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
DMRCLZB CS CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N
DMRCLZB IK NEYNJQRKHLUJRU-DZUOILHNSA-N
DMRCLZB IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMRCLZB CA CAS 5534-95-2
DMRCLZB CB CHEBI:31974
DMRCLZB DE Diagnostic imaging
DMHZJCG ID DMHZJCG
DMHZJCG DN Pentamidine
DMHZJCG HS Approved
DMHZJCG SN Lomidine; Nebupent; PENTAM; PNT; Pentacarinat; Pentamide; Pentamidin; Pentamidina; Pentamidinum; Pneumopent; PENTAMIDINE ISETHIONATE; Pentamidina [DCIT]; Pentamidine isetionate; Pentamidine mesylate; MB 800; Pentam 300; Lomidine (TN); MB-800; Nebupent (as isethionate); Pentacarinat (as isethionate); Pentam 300 (as isethionate); Pentamidine (INN); Pentamidinum [INN-Latin]; RP-2512; Nebupent (*Isethionate); Pentacarinat (*Isethionate); Pentam 300 (*Isethionate); Pentamidine Isethionate 2-Hydroxy-Ethanesulfonic Acid;Pentamidine [INN:BAN:DCF]; RP 2512 (*Isethionate); P,p'-(Pentamethylenedioxy)bis[benzamidine]; P,p'-(Pentamethylenedioxy)dibenzamidine; P,p'-(Pentamethylene-dioxy)bis-benzamidine; Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis-(9CI); 1,3-BIS(4-AMIDINOPHENOXY)PENTANE; 4, 4'-Diamidinodiphenoxypentane; 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide; 4,4'-(Pentamethylenedioxy)dibenzamide; 4,4'-(Pentamethylenedioxy)dibenzamidine; 4,4'-Diamidino-.alpha.,.omega.-diphenoxypentane; 4,4'-Diamidinodiphenoxypentane; 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide; 4-[5-(4-Carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
DMHZJCG TC Antifungal Agents
DMHZJCG DT Small molecular drug
DMHZJCG PC 4735
DMHZJCG MW 340.4
DMHZJCG FM C19H24N4O2
DMHZJCG IC InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
DMHZJCG CS C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
DMHZJCG IK XDRYMKDFEDOLFX-UHFFFAOYSA-N
DMHZJCG IU 4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarboximidamide
DMHZJCG CA CAS 100-33-4
DMHZJCG CB CHEBI:45081
DMHZJCG DE Fungal infection; Human immunodeficiency virus infection
DM1XBHS ID DM1XBHS
DM1XBHS DN Pentazocine
DM1XBHS HS Approved
DM1XBHS SN Fortalgesic; Fortalin; Fortral; Lexir; Liticon; Pentagin; Pentazocaine; Pentazocin; Pentazocina; Pentazocinum; Sosegon; Soseton; Sosigon; Talacen; Talwan; Pentazocina [DCIT]; NIH 7958; WIN 20228; Algopent (free base); Fortal (TN); Fortral (TN); Fortwin (TN); KF-1820; L-pentazocine; Pentazocinum [INN-Latin]; Talacen (TN); Talwin (TN); Talwin NX (TN); Talwin PX (TN); II-C-2; Pentazocine (JP15/USP/INN); Pentazocine [USAN:INN:BAN:JAN]; Pentazocine, Pentazocin, Sosegon, WIN 20228; (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; (2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; (2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol; 1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol; 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan; 2-(3,3-Dimethylallyl)-2',2'-hydroxy-5,9-dimethyl-6,7-benzomorphan; 2-(3,3-Dimethylallyl)cyclazocine; 2-Dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan; 3-(3-Methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
DM1XBHS CP Sterling Drug Company
DM1XBHS TC Anesthetics
DM1XBHS DT Small molecular drug
DM1XBHS PC 441278
DM1XBHS MW 285.4
DM1XBHS FM C19H27NO
DM1XBHS IC InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1
DM1XBHS CS C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O
DM1XBHS IK VOKSWYLNZZRQPF-GDIGMMSISA-N
DM1XBHS IU (1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM1XBHS CA CAS 359-83-1
DM1XBHS CB CHEBI:7982
DM1XBHS DE Pain
DMFNH7L ID DMFNH7L
DMFNH7L DN Pentobarbital
DMFNH7L HS Approved
DMFNH7L SN Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
DMFNH7L CP Oak Pharmaceuticals Inc
DMFNH7L TC Hypnotics and Sedatives
DMFNH7L DT Small molecular drug
DMFNH7L PC 4737
DMFNH7L MW 226.27
DMFNH7L FM C11H18N2O3
DMFNH7L IC InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DMFNH7L CS CCCC(C)C1(C(=O)NC(=O)NC1=O)CC
DMFNH7L IK WEXRUCMBJFQVBZ-UHFFFAOYSA-N
DMFNH7L IU 5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
DMFNH7L CA CAS 76-74-4
DMFNH7L CB CHEBI:7983
DMFNH7L DE Insomnia
DM38VYQ ID DM38VYQ
DM38VYQ DN Pentolinium
DM38VYQ HS Approved
DM38VYQ SN Pentolineum; Pentolonium; Pentolonum; 1,1'-pentane-1,5-diylbis(1-methylpyrrolidinium); 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
DM38VYQ CP Wyeth Ayerst Laboratories
DM38VYQ TC Antihypertensive Agents
DM38VYQ DT Small molecular drug
DM38VYQ PC 5850
DM38VYQ MW 240.43
DM38VYQ FM C15H32N2+2
DM38VYQ IC InChI=1S/C15H32N2/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17/h3-15H2,1-2H3/q+2
DM38VYQ CS C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C
DM38VYQ IK XSBSKEQEUFOSDD-UHFFFAOYSA-N
DM38VYQ IU 1-methyl-1-[5-(1-methylpyrrolidin-1-ium-1-yl)pentyl]pyrrolidin-1-ium
DM38VYQ CA CAS 144-44-5
DM38VYQ CB CHEBI:347401
DM38VYQ DE Hypotension
DM2HRKE ID DM2HRKE
DM2HRKE DN Pentosan polysulfate
DM2HRKE HS Approved
DM2HRKE SN Elmiron; Pentosan sulfuric polyester; Polypentose sulfate; Elmiron (TN); Xylan,hydrogen sulfate; [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
DM2HRKE CP Ortho-McNeil Pharmaceutical
DM2HRKE TC Anticoagulants
DM2HRKE DT Small molecular drug
DM2HRKE PC 37720
DM2HRKE MW 602.5
DM2HRKE FM C10H18O21S4
DM2HRKE IC InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
DM2HRKE CS C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O
DM2HRKE IK FCCNSUIJIOOXEZ-SJYYZXOBSA-N
DM2HRKE IU [(2R,3R,4S,5R)-2-hydroxy-5-[(2S,3R,4S,5R)-5-hydroxy-3,4-disulfooxyoxan-2-yl]oxy-3-sulfooxyoxan-4-yl] hydrogen sulfate
DM2HRKE CA CAS 37300-21-3
DM2HRKE DE Painful bladder syndrome; Interstitial cystitis
DM0HXDS ID DM0HXDS
DM0HXDS DN Pentostatin
DM0HXDS HS Approved
DM0HXDS SN Coforin; Covidarabine; Deoxycoformycin; Nipent; Oncopent; Vidarbine; Vira A deaminase inhibitor; CL-67310465; CO-Vidarabine; Co-V; Nipent (TN); PD-81565; PD-ADI; Pentostatin (JAN/USAN/INN); (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol; (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol; 2'-DCF; 2'-Deoxycoformycin; 2'-Dexoycoformycin
DM0HXDS TC Anticancer Agents
DM0HXDS DT Small molecular drug
DM0HXDS PC 439693
DM0HXDS MW 268.27
DM0HXDS FM C11H16N4O4
DM0HXDS IC InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
DM0HXDS CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC=NC[C@H]3O)CO)O
DM0HXDS IK FPVKHBSQESCIEP-JQCXWYLXSA-N
DM0HXDS IU (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
DM0HXDS CA CAS 53910-25-1
DM0HXDS DE Hairy cell leukaemia
DMU3DNC ID DMU3DNC
DMU3DNC DN Pentoxifylline
DMU3DNC HS Approved
DMU3DNC SN Agapurin; Azupentat; Dimethyloxohexylxanthine; Durapental; Hemovas; Ikomio; Oxpentifylline; PENTOXYPHYLINE;PNX; Pentoxifilina; Pentoxifyllin; Pentoxifyllinum; Pentoxil; Pentoxiphyllin; Pentoxiphylline; Pentoxiphyllium; Pentoxyfylline; Pentoxyphyllin; Pentoxyphylline; Ralofect; Rentylin; Torental; Trental;Vasofirin; Vazofirin; Agapurin Retard; BL 191; BL191; EHT 0201; EHT0201; IN1161; P 1784; Artal (TN); BL-191; EHT-0201; EHT-201; Flexital (TN); Pentox (TN); Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Pentoxin (TN); Trental (TN); Cis-9-Octadecenoyl coenzyme A; Pentoxifylline [USAN:INN:JAN]; Pentoxifylline (JAN/USP/INN); 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 1-(5-Oxohexyl)-3,7-dimethylxanthine; 1-(5-Oxohexyl)theobromine; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl) xantine; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMU3DNC CP Aventis Pharmaceuticals Inc.
DMU3DNC TC Vasodilator Agents
DMU3DNC DT Small molecular drug
DMU3DNC PC 4740
DMU3DNC MW 278.31
DMU3DNC FM C13H18N4O3
DMU3DNC IC InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
DMU3DNC CS CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMU3DNC IK BYPFEZZEUUWMEJ-UHFFFAOYSA-N
DMU3DNC IU 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMU3DNC CA CAS 6493-05-6
DMU3DNC CB CHEBI:7986
DMU3DNC DE Intermittent claudication
DMNXY5K ID DMNXY5K
DMNXY5K DN Peramivir
DMNXY5K HS Approved
DMNXY5K SN PeramiFlu; S-021812; (1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid; PRV
DMNXY5K CP BioCryst Pharmaceuticals
DMNXY5K DT Small molecular drug
DMNXY5K PC 154234
DMNXY5K MW 328.41
DMNXY5K FM C15H28N4O4
DMNXY5K IC InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
DMNXY5K CS CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C
DMNXY5K IK XRQDFNLINLXZLB-CKIKVBCHSA-N
DMNXY5K IU (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DMNXY5K CA CAS 330600-85-6
DMNXY5K CB CHEBI:85202
DMNXY5K DE Influenza virus infection
DM2AOTZ ID DM2AOTZ
DM2AOTZ DN Perazine
DM2AOTZ HS Approved
DM2AOTZ SN Perazine maleate; Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, maleate; 84-97-9 (Parent); 10H-Phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-, (Z)-2-butenedioate; SCHEMBL220704; AC1O6123; LS-105593; 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM2AOTZ DT Small molecular drug
DM2AOTZ PC 4744
DM2AOTZ MW 339.5
DM2AOTZ FM C20H25N3S
DM2AOTZ IC InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3
DM2AOTZ CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=CC=CC=C42
DM2AOTZ IK WEYVCQFUGFRXOM-UHFFFAOYSA-N
DM2AOTZ IU 10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM2AOTZ CA CAS 84-97-9
DM2AOTZ CB CHEBI:59118
DM2AOTZ DE Psychotic disorder
DM14MAE ID DM14MAE
DM14MAE DN Pergolide
DM14MAE HS Approved
DM14MAE SN Pergolida; Pergolidum; Permax; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum [INN-Latin]; Permax (TN); LY-127,809; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; (8beta)-8-[(methylthio)methyl]-6-propylergoline
DM14MAE CP Valeant Pharmaceuticals
DM14MAE TC Antiparkinson Agents
DM14MAE DT Small molecular drug
DM14MAE PC 47811
DM14MAE MW 314.5
DM14MAE FM C19H26N2S
DM14MAE IC InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1
DM14MAE CS CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
DM14MAE IK YEHCICAEULNIGD-MZMPZRCHSA-N
DM14MAE IU (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DM14MAE CA CAS 66104-22-1
DM14MAE CB CHEBI:63617
DM14MAE DE Parkinson disease
DM5GKOV ID DM5GKOV
DM5GKOV DN Pergolide mesylate
DM5GKOV HS Approved
DM5GKOV SN Pergolida; Pergolide (mesylate); Pergolide Methanesulfonate; Pergolide mesilate; Permax (TN); LY127809; PERGOLIDE MESYLATE; PERGOLIDE MESYLATE SALT; 55B9HQY616; 66104-23-2; 8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate; 8-beta-((Methylthio)methyl)-6-propylergoline monomethane sulfonate; 8beta-((Methylthio)methyl)-6-propylergoline monomethanesulfonate; CHEBI:8021; CHEMBL1275; CPD000058504; DSSTox_CID_20583; DSSTox_GSID_40583; DSSTox_RID_77029; MLS000069837; MPE; SMR000058504; UNII-55B9HQY616; LY-127,809; LY-127809; Pergolida [INN-Spanish]; Pergolide (INN); Pergolide [INN:BAN]; Pergolidum; Pergolidum [INN-Latin]; Permax; Prestwick0_000295; Prestwick1_000295; Prestwick2_000295; Prestwick3_000295; SR-01000721840; Spectrum2_001970; Spectrum4_000835; Spectrum5_001649; Spectrum_001647; TNP00315; pergolide; (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; 24MJ822NZ9; 66104-22-1; CHEBI:63617; CHEMBL531; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; NCGC00017366-04; UNII-24MJ822NZ9
DM5GKOV PC 47812
DM5GKOV MW 410.6
DM5GKOV FM C20H30N2O3S2
DM5GKOV IC UWCVGPLTGZWHGS-ZORIOUSZSA-N
DM5GKOV CS CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O
DM5GKOV IK 1S/C19H26N2S.CH4O3S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21;1-5(2,3)4/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3;1H3,(H,2,3,4)/t13-,16-,18-;/m1./s1
DM5GKOV IU (6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid
DM5GKOV CA CAS 66104-23-2
DM5GKOV CB CHEBI:8021
DM5GKOV DE Parkinsonism
DMINO7Z ID DMINO7Z
DMINO7Z DN Perhexiline
DMINO7Z HS Approved
DMINO7Z SN Perhexilene; Perhexilina; Perhexilinum; Perhexilline; Perhexilina [INN-Spanish]; Perhexiline (INN); Perhexiline [INN:BAN]; Perhexilinum [INN-Latin]; (+)-2-(2,2-Dicyclohexylethyl)piperidine; (-)-2-(2,2-Dicyclohexylethyl)piperidine; 2-(2,2-Dicyclohexylethyl)piperidine
DMINO7Z TC Vasodilator Agents
DMINO7Z DT Small molecular drug
DMINO7Z PC 4746
DMINO7Z MW 277.5
DMINO7Z FM C19H35N
DMINO7Z IC InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2
DMINO7Z CS C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
DMINO7Z IK CYXKNKQEMFBLER-UHFFFAOYSA-N
DMINO7Z IU 2-(2,2-dicyclohexylethyl)piperidine
DMINO7Z CA CAS 39648-47-0
DMINO7Z CB CHEBI:35553
DMINO7Z DE Angina pectoris
DMOPZDT ID DMOPZDT
DMOPZDT DN Perindopril
DMOPZDT HS Approved
DMOPZDT SN ACEON; Coverex; Coversum; Coversyl; Prestarium; Coverene Cor; Cpd with unspecified MF; Aceon (TN); Acertil (TN); Armix (TN); Coverene (TN); Coverex (TN); Coversum (TN); DW-7950; Prestarium (TN); Prexanil (TN); Prexum (TN); Procaptan (TN); S-9490; SED-9490; McN-A-2833; Perindopril (USAN/INN); Ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate; (2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
DMOPZDT TC Antihypertensive Agents
DMOPZDT DT Small molecular drug
DMOPZDT PC 107807
DMOPZDT MW 368.5
DMOPZDT FM C19H32N2O5
DMOPZDT IC InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1
DMOPZDT CS CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O
DMOPZDT IK IPVQLZZIHOAWMC-QXKUPLGCSA-N
DMOPZDT IU (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DMOPZDT CA CAS 82834-16-0
DMOPZDT CB CHEBI:8024
DMOPZDT DE Hypertension
DMZ0Q1G ID DMZ0Q1G
DMZ0Q1G DN Permethrin
DMZ0Q1G HS Approved
DMZ0Q1G SN Ambush; PerFoam; Transpermethrin; Acticin Cream; Elimite Cream; Nix Cream Rinse; Transpermethrin [ISO];FMC 35171; NRDC 146; NRDC 148; PS758_SUPELCO; Permethrin (isomers); Permethrin (isomers) solution; Permethrine,c&t; Trans-(+-)-Permethrin; [3-(phenyloxy)phenyl]methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (+)-CIS-PERMETHRIN; (+)-trans-Permethrin; (+-)-cis-Fmc 33297; (+-)-cis-Permethrin; (+-)-trans-Permethrin; (3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate; (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate; 1RS,cis-Permethrin; 1RS-trans-Permethrin; 3-Phenoxybenzyle (1RS)-cis, trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylate; 3-phenoxybenzyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
DMZ0Q1G TC Insecticides
DMZ0Q1G DT Small molecular drug
DMZ0Q1G PC 40326
DMZ0Q1G MW 391.3
DMZ0Q1G FM C21H20Cl2O3
DMZ0Q1G IC InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3
DMZ0Q1G CS CC1(C(C1C(=O)OCC2=CC(=CC=C2)OC3=CC=CC=C3)C=C(Cl)Cl)C
DMZ0Q1G IK RLLPVAHGXHCWKJ-UHFFFAOYSA-N
DMZ0Q1G IU (3-phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate
DMZ0Q1G CA CAS 52645-53-1
DMZ0Q1G CB CHEBI:34911
DMZ0Q1G DE Sarcoptes scabiei infection
DMVHJLX ID DMVHJLX
DMVHJLX DN Perospirone
DMVHJLX HS Approved
DMVHJLX SN Lullan; SM-9018
DMVHJLX CP Sumitomo Pharmaceuticals Co Ltd
DMVHJLX DT Small molecular drug
DMVHJLX PC 115368
DMVHJLX MW 426.6
DMVHJLX FM C23H30N4O2S
DMVHJLX IC InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+
DMVHJLX CS C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54
DMVHJLX IK FBVFZWUMDDXLLG-HDICACEKSA-N
DMVHJLX IU (3aR,7aS)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
DMVHJLX CA CAS 150915-41-6
DMVHJLX CB CHEBI:94777
DMVHJLX DE Psychotic disorder
DMA4MRX ID DMA4MRX
DMA4MRX DN Perphenazine
DMA4MRX HS Approved
DMA4MRX SN Chlorperphenazine; Chlorpiprazine; Decentan; Emesinal; Etaperazin; Etaperazine; Ethaperazine; Fentazin;PZC; Perfenazina; Perfenazine; Perphenan; Perphenazin; Perphenazinum; Thilatazin; Tranquisan; Trifaron; Trilafon; Trilifan; Triphenot; Perfenazina [Italian]; Perphenazine [Trilafon]; Perphenazine maleate; P 6402; Sch 3940; Apo-Perphenazine; F-mon; Perfenazina [INN-Spanish]; Perphenazinum [INN-Latin]; SCH-3940; Siquil (TN); Triavil (TN); Perphenazine [INN:BAN:JAN]; Perphenazine (JP15/USP/INN); Gamma-[4-(beta-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine; Gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina; 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]; 1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine; 1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine; 1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride; 2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol; 2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine; 2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine; 2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine; 2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine; 2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine; 2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol; 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol; 4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol; 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
DMA4MRX CP Schering-Plough Corporation
DMA4MRX TC Antipsychotic Agents
DMA4MRX DT Small molecular drug
DMA4MRX PC 4748
DMA4MRX MW 404
DMA4MRX FM C21H26ClN3OS
DMA4MRX IC InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
DMA4MRX CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
DMA4MRX IK RGCVKNLCSQQDEP-UHFFFAOYSA-N
DMA4MRX IU 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol
DMA4MRX CA CAS 58-39-9
DMA4MRX CB CHEBI:8028
DMA4MRX DE Schizophrenia
DMHJV0X ID DMHJV0X
DMHJV0X DN Pertuzumab
DMHJV0X HS Approved
DMHJV0X SN Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
DMHJV0X CP Roche; Genentech
DMHJV0X DT Monoclonal antibody
DMHJV0X SQ Amino acid sequence for pertuzumab light chain : DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Amino acid sequence for pertuzumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
DMHJV0X DE Breast cancer
DMS2J0Z ID DMS2J0Z
DMS2J0Z DN Pexidartinib
DMS2J0Z HS Approved
DMS2J0Z SN PLX-3397
DMS2J0Z CP Plexxikon Inc
DMS2J0Z PC 25151352
DMS2J0Z MW 417.8
DMS2J0Z FM C20H15ClF3N5
DMS2J0Z IC InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)
DMS2J0Z CS C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F
DMS2J0Z IK JGWRKYUXBBNENE-UHFFFAOYSA-N
DMS2J0Z IU 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyridin-2-amine
DMS2J0Z CA CAS 1029044-16-3
DMS2J0Z CB CHEBI:145373
DMS2J0Z DE Alzheimer disease; Pigmented villonodular synovitis; Neurofibromatosis type 1; Tenosynovial giant cell tumour
DMSB068 ID DMSB068
DMSB068 DN PF-04449913
DMSB068 HS Approved
DMSB068 SN Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2
DMSB068 CP Pfizer
DMSB068 DT Small molecular drug
DMSB068 PC 25166913
DMSB068 MW 374.4
DMSB068 FM C21H22N6O
DMSB068 IC InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1
DMSB068 CS CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N
DMSB068 IK SFNSLLSYNZWZQG-VQIMIIECSA-N
DMSB068 IU 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea
DMSB068 CA CAS 1095173-27-5
DMSB068 CB CHEBI:145428
DMSB068 DE Chronic myelomonocytic leukaemia; Solid tumour/cancer
DM79VXT ID DM79VXT
DM79VXT DN PF-04971729
DM79VXT HS Approved
DM79VXT SN Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7; PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729
DM79VXT CP Merck & Co./Pfizer
DM79VXT DT Small molecular drug
DM79VXT PC 44814423
DM79VXT MW 436.9
DM79VXT FM C22H25ClO7
DM79VXT IC InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
DM79VXT CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O)Cl
DM79VXT IK MCIACXAZCBVDEE-CUUWFGFTSA-N
DM79VXT IU (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
DM79VXT CA CAS 1210344-57-2
DM79VXT DE Type-2 diabetes
DMOHS9P ID DMOHS9P
DMOHS9P DN Phenacemide
DMOHS9P HS Approved
DMOHS9P SN Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemida; Fenacemide;Fenacetamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacemidum; Phenacereum; Phenacerum; Phenacetur; Phenacetylcarbamide; Phenacetylurea; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenylacetylurea; Phenylacetyluree; Phenyrit; Phetylureum; Carbamide phenylacetate; Fenacemide [DCIT]; Fenylacetylmocovina [Czech]; Phenylacetyluree [French]; A-1348; Alpha-Phenylacetylurea; Fenacemida [INN-Spanish]; Fenacetil-karbamide; Phenacemide [INN:BAN]; Phenacemidum [INN-Latin]; Phenurone (TN); Sym-PHENYLACETYLUREA; N-(Aminocarbonyl)benzeneacetamide; Phenacemide (JAN/INN); N-carbamoyl-2-phenylacetamide; N-(aminocarbonyl)-2-phenylacetamide; (2-phenylacetyl)urea; (Phenylacetyl)urea
DMOHS9P TC Anticonvulsants
DMOHS9P DT Small molecular drug
DMOHS9P PC 4753
DMOHS9P MW 178.19
DMOHS9P FM C9H10N2O2
DMOHS9P IC InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
DMOHS9P CS C1=CC=C(C=C1)CC(=O)NC(=O)N
DMOHS9P IK XPFRXWCVYUEORT-UHFFFAOYSA-N
DMOHS9P IU N-carbamoyl-2-phenylacetamide
DMOHS9P CA CAS 63-98-9
DMOHS9P CB CHEBI:8049
DMOHS9P DE Epilepsy
DM6TS1N ID DM6TS1N
DM6TS1N DN Phendimetrazine
DM6TS1N HS Approved
DM6TS1N SN Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine
DM6TS1N CP Sandoz Inc
DM6TS1N TC Anorexigenic Agents
DM6TS1N DT Small molecular drug
DM6TS1N PC 30487
DM6TS1N MW 191.27
DM6TS1N FM C12H17NO
DM6TS1N IC InChI=1S/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3/t10-,12+/m0/s1
DM6TS1N CS C[C@H]1[C@@H](OCCN1C)C2=CC=CC=C2
DM6TS1N IK MFOCDFTXLCYLKU-CMPLNLGQSA-N
DM6TS1N IU (2S,3S)-3,4-dimethyl-2-phenylmorpholine
DM6TS1N CA CAS 634-03-7
DM6TS1N CB CHEBI:8059
DM6TS1N DE Obesity
DMHIDUE ID DMHIDUE
DMHIDUE DN Phenelzine
DMHIDUE HS Approved
DMHIDUE SN Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine
DMHIDUE CP Parke Davis Div Warner Lambert Co
DMHIDUE TC Antidepressants
DMHIDUE DT Small molecular drug
DMHIDUE PC 3675
DMHIDUE MW 136.19
DMHIDUE FM C8H12N2
DMHIDUE IC InChI=1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
DMHIDUE CS C1=CC=C(C=C1)CCNN
DMHIDUE IK RMUCZJUITONUFY-UHFFFAOYSA-N
DMHIDUE IU 2-phenylethylhydrazine
DMHIDUE CA CAS 51-71-8
DMHIDUE CB CHEBI:8060
DMHIDUE DE Skin imperfections; Depression
DMDTC7R ID DMDTC7R
DMDTC7R DN Phenindamine
DMDTC7R HS Approved
DMDTC7R SN Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
DMDTC7R CP Amarin Pharmaceuticals
DMDTC7R TC Antihistamines
DMDTC7R DT Small molecular drug
DMDTC7R PC 11291
DMDTC7R MW 261.399
DMDTC7R FM C19H19N
DMDTC7R IC InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3
DMDTC7R CS CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4
DMDTC7R IK ISFHAYSTHMVOJR-UHFFFAOYSA-N
DMDTC7R IU 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
DMDTC7R CA CAS 82-88-2
DMDTC7R CB CHEBI:8065
DMDTC7R DE Common cold
DM2PYNR ID DM2PYNR
DM2PYNR DN Phenindione
DM2PYNR HS Approved
DM2PYNR SN Athrombon; Bindan; Cronodione; Danedion; Danilon; Danilone; Diadilan; Dindevan; Dineval; Diophindane; Emandion; Emandione; Eridione; Fenhydren; Fenilin; Fenindion; Fenindiona; Hedulin; Hemolidione; Indema; Indion; Indon; Phenhydren; Phenillin; Phenindionum; Phenylen; Phenylin; Phenylindanedione; Phenylindione; Phenyline; Phenyllin; Pindione; Rectadione; Theradione; Thrombasal; Tromazal; Trombol; Boots Brand of Phenindione; Goldshield Brand of Phenindione; Merck Lipha Sante Brand of Phenindione; P1029; P26406_ALDRICH; Fenindiona [INN-Spanish]; Hedulin (TN); Phenindione (INN); Phenindione [INN:BAN]; Phenindionum [INN-Latin]; 2 Phenyl 1,3 indandione; 2-Fenyloindandion-1,3; 2-Fenyloindandion-1,3 [Polish]; 2-Phenyl-1,3-diketohydrindene; 2-Phenyl-1,3-indandione; 2-Phenyl-1,3-indanedione; 2-Phenyl-1H-indene-1,3(2H)-dione; 2-Phenylindan-1,3-dione; 2-Phenylindandione; 2-phenyl-1,3(2H)-Indenedione; 2-phenyl-2,3-dihydro-1H-indene-1,3-dione; 2-phenylindene-1,3-dione
DM2PYNR TC Anticoagulants
DM2PYNR DT Small molecular drug
DM2PYNR PC 4760
DM2PYNR MW 222.24
DM2PYNR FM C15H10O2
DM2PYNR IC InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H
DM2PYNR CS C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
DM2PYNR IK NFBAXHOPROOJAW-UHFFFAOYSA-N
DM2PYNR IU 2-phenylindene-1,3-dione
DM2PYNR CA CAS 83-12-5
DM2PYNR CB CHEBI:8066
DM2PYNR DE Coagulation defect; Pulmonary embolism
DMCH7RU ID DMCH7RU
DMCH7RU DN Pheniramine
DMCH7RU HS Approved
DMCH7RU SN Avil; Feniramina; Feniramine; Histapyridamine; Metron; Pheniraminum; Propheniramine; Prophenpyridamine; Pyriton; Trimeton; Tripoton; Pheniramine Bimaleate; Avil (TN); Feniramina [INN-Spanish]; P-Aminosalicylsaures salz; Pheniramine (INN); Pheniramine [INN:BAN]; Pheniraminum [INN-Latin]; PHENIRAMINE (SEE ALSO PHENIRAMINE MALEATE 132-20-7); Dimethyl(3-phenyl-3-(2-pyridyl)propyl)amine; N,N-Dimethyl-3-phenyl-3-(2-pyridyl)propylamine; N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine; 1-Phenyl-1-(2-pyridyl)-3-dimethylaminopropane; 2-(3-Dimethylamino-1-phenylpropyl)pyridine; 2-(alpha-(2-Dimethylaminoethyl)benzyl)pyridine; 2-Pyridinepropanamine, N,N-dimethyl-gamma-phenyl-(9CI); 2-[.alpha.-(2-Dimethylaminoethyl)benzyl]pyridine; 2-[.alpha.-[2-(Dimethylamino)ethyl]benzyl]pyridine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylamine; 3-Phenyl-3-(2-pyridyl)-N,N-dimethylpropylanine
DMCH7RU CP Aventis Pharmaceuticals Inc.
DMCH7RU TC Antiallergic Agents
DMCH7RU DT Small molecular drug
DMCH7RU PC 4761
DMCH7RU MW 240.34
DMCH7RU FM C16H20N2
DMCH7RU IC InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3
DMCH7RU CS CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2
DMCH7RU IK IJHNSHDBIRRJRN-UHFFFAOYSA-N
DMCH7RU IU N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine
DMCH7RU CA CAS 86-21-5
DMCH7RU CB CHEBI:91591
DMCH7RU DE Hay fever
DMXYTN9 ID DMXYTN9
DMXYTN9 DN Phenmetrazine
DMXYTN9 HS Approved
DMXYTN9 SN Cafilon; Defenmetrazin; Dexphenmetrazine; Fenmetrazin; Fenmetrazina; Oxazimedrine; Phenmetraline; Phenmetrazin; Phenmetrazinum; Preludin hydrochloride; A 66; Psychamine A 66; Defenmetrazin (TN); Fenmetrazin (TN); Fenmetrazina [INN-Spanish]; Oxazimedrine (TN); Phenmetraline (TN); Phenmetrazine [INN:BAN]; Phenmetrazinum [INN-Latin]; Dl-2-Phenyl-3-methyltetrahydro-1,4-oxazine; 2-Fenyl-3-methylmorfolin; 2-Fenyl-3-methylmorfolin [Czech]; 2-Phenyl-3-methylmorpholine; 3-Methyl-2-phenylmorpholine; 3-Methyl-2-phenyltetrahydro-2H-1,4-oxazine
DMXYTN9 CP Boehringer Ingelheim GmbH
DMXYTN9 TC Appetite Depressants
DMXYTN9 DT Small molecular drug
DMXYTN9 PC 4762
DMXYTN9 MW 177.24
DMXYTN9 FM C11H15NO
DMXYTN9 IC InChI=1S/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3
DMXYTN9 CS CC1C(OCCN1)C2=CC=CC=C2
DMXYTN9 IK OOBHFESNSZDWIU-UHFFFAOYSA-N
DMXYTN9 IU 3-methyl-2-phenylmorpholine
DMXYTN9 CA CAS 134-49-6
DMXYTN9 CB CHEBI:8067
DMXYTN9 DE Obesity
DMXZOCG ID DMXZOCG
DMXZOCG DN Phenobarbital
DMXZOCG HS Approved
DMXZOCG SN Adonal; Aephenal; Agrypnal; Amylofene; Antrocol; Aphenylbarbit; Aphenyletten; Austrominal; Barbapil; Barbellen; Barbellon; Barbenyl; Barbilehae; Barbinal; Barbipenyl; Barbiphen; Barbiphenyl; Barbipil; Barbita; Barbivis; Barbonal; Barbophen; Bardorm; Bartol; Bialminal; Cabronal; Calmetten; Calminal; Cardenal; Chinoin; Codibarbita; Coronaletta; Cratecil; Damoral; Dezibarbitur; Donphen; Dormina; Dormiral; Dormital; Doscalun; Duneryl; Ensobarb; Ensodorm; Epanal; Epidorm; Epilol; Episedal; Epsylone; Eskabarb; Etilfen; Euneryl; Ezibarbitur; Fenbital; Fenemal; Fenobarbital; Fenobarbitale; Fenosed; Fenylettae; Gardenal; Gardepanyl; Glysoletten; Haplopan; Haplos; Helional; Hennoletten; Henotal; Hypnaletten; Hypnette; Hypnogen; Hypnolone; Hypnoltol; Hysteps; Lefebar; Leonal; Lephebar; Lepinal; Lepinaletten; Linasen; Liquital; Lixophen; Lubergal; Lubrokal; Lumen; Lumesettes; Lumesyn; Luminal; Lumofridetten; Luphenil; Luramin; Molinal; Neurobarb; Nirvonal; Noptil; Nunol; PHOB; Parkotal; Pharmetten; Phenaemal; Phenemal; Phenemalum; Phenobal; Phenobarb; Phenobarbitalum; Phenobarbitol; Phenobarbitone; Phenobarbitonum; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenylaethylbarbitursaeure; Phenylethylbarbiturate; Phenylethylbarbitursaeure; Phenylethylmalonylurea; Phenyletten; Phenylral; Phenyral; Polcominal; Promptonal; Sedabar; Sedicat; Sedizorin; Sedlyn; Sedofen; Sedonal; Sedonettes; Sedophen; Sevenal; Solfoton; Sombutol; Somnolens; Somnoletten; Somnosan; Somonal; Spasepilin; Starifen; Starilettae; Stental; Talpheno; Teolaxin; Teoloxin; Thenobarbital; Theoloxin; Theominal; Triabarb; Tridezibarbitur; Triphenatol; Versomnal; Zadoletten; Zadonal; Aephe nal; Component of Antrocol; Component of Bronkotabs; Component of Hecadrol; Component of Primatene P; Component of Slowten; Component of Tedral; Elixir of phenobarbital; Fen osed; Fenobarbitale [DCIT]; Le phebar; Levsin PB Drops and Tablets; PUBERTAL PHENOBARBITAL STUDY; Pamine PB; Phenobarbitalum [INN]; Phenobarbituric acid; Phenylethyl barbituric acid; Phenylethylbarbituric acid; Solfoton talpheno; Stental Extentabs; Stental exte ntabs; Arco-Lase Plus; Barbilehae (barbilettae); Blu-phen; Chardonna-2; Component of Valpin 50-PB; Fenobarbital [INN-Spanish]; Gustase-Plus; Hypno-Tablinetten; Luminal (TN); Nova-Pheno; Phazyme-PB; Phen-Bar; Phenobarbital (PB); Phenobarbital, Monosodium Salt; Phenobarbitalum [INN-Latin]; SK-Phenobarbital; Seda-Tablinen; Seda-tabl inen; Sedonal (sedative); Solu-Barb; Valprin 50-PB; Phenobarbital [USAN:INN:JAN]; Phenyl-ethyl-barbituric acid; Acido 5-fenil-5-etilbarbiturico; Acido 5-fenil-5-etilbarbiturico [Italian]; Phenobarbital (JP15/USP/INN); 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione;5-Ethyl-5-phenyl-2,4,6-(1H,3H,5H)pyrimidinetrione; 5-Ethyl-5-phenyl-2,4,6-pyrimidinetrione; 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione; 5-Ethyl-5-phenylbarbituric acid; 5-Phenyl-5-ethylbarbituric acid;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione; 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
DMXZOCG CP FISCHER and ROCH
DMXZOCG TC Anticonvulsants
DMXZOCG DT Small molecular drug
DMXZOCG PC 4763
DMXZOCG MW 232.23
DMXZOCG FM C12H12N2O3
DMXZOCG IC InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
DMXZOCG CS CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DMXZOCG IK DDBREPKUVSBGFI-UHFFFAOYSA-N
DMXZOCG IU 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMXZOCG CA CAS 50-06-6
DMXZOCG CB CHEBI:8069
DMXZOCG DE Seizure disorder
DM8KSQH ID DM8KSQH
DM8KSQH DN Phenoxybenzamine
DM8KSQH HS Approved
DM8KSQH SN Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A
DM8KSQH CP Concordia Pharmaceuticals Inc
DM8KSQH TC Antihypertensive Agents
DM8KSQH DT Small molecular drug
DM8KSQH PC 4768
DM8KSQH MW 303.8
DM8KSQH FM C18H22ClNO
DM8KSQH IC InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
DM8KSQH CS CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2
DM8KSQH IK QZVCTJOXCFMACW-UHFFFAOYSA-N
DM8KSQH IU N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
DM8KSQH CA CAS 59-96-1
DM8KSQH CB CHEBI:8077
DM8KSQH DE Malignant essential hypertension
DMDO279 ID DMDO279
DMDO279 DN Phenprocoumon
DMDO279 HS Approved
DMDO279 SN Falithiom; Falithrom; Fencumar; Fenprocoumona; Fenprocumon; Fenprocumone; Liquamar; Marcoumar; Marcumar; Marcuphen; Phenprocoumalol; Phenprocoumarol; Phenprocoumarole; Phenprocoumone; Phenprocoumonum; Phenprocumone; Phenprocumonum; Phenprogramma; Phenylpropylhydroxycumarinum; Fenprocumone [DCIT]; Hexal Brand of Phenprocoumon; Roche Brand of Phenprocoumon; Worwag Brand of Phenprocoumon; U29342; Falithrom (TN); Fenprocoumona [INN-Spanish]; Liquamar (TN); Marcoumar (TN); Marcumar (TN); Phenprocoumone [INN-French]; Phenprocoumonum [INN-Latin]; Ro 1-4849; Phenprocoumon (USAN/INN); Phenprocoumon [USAN:INN:BAN]; 2-hydroxy-3-(1-phenylpropyl)chromen-4-one; 3-(1'-Phenyl-propyl)-4-oxycoumarin; 3-(1'-Phenyl-propyl)-4-oxycoumarin [German]; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(alpha-Ethylbenzyl)-4-hydroxycoumarin; 3-(alpha-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
DMDO279 TC Anticoagulants
DMDO279 DT Small molecular drug
DMDO279 PC 54680692
DMDO279 MW 280.3
DMDO279 FM C18H16O3
DMDO279 IC InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
DMDO279 CS CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
DMDO279 IK DQDAYGNAKTZFIW-UHFFFAOYSA-N
DMDO279 IU 4-hydroxy-3-(1-phenylpropyl)chromen-2-one
DMDO279 CA CAS 435-97-2
DMDO279 CB CHEBI:50438
DMDO279 DE Thrombosis
DMG60XN ID DMG60XN
DMG60XN DN Phentermine
DMG60XN HS Approved
DMG60XN SN Duromine; Fastin; Fentermina; Inoamin; Ionamin; Ionamine; Linyl; Lipopill; Lonamin; Mirapront; Normephentermine; Obenix; Obermine; Omnibex; Ortetamin; Ortetamina; Ortetaminum; Phentercot; Phenterminum; Phentride; Phentrol; Wilpo; Zantryl; Ona Mast; Ortetamine [INN]; Phentermine HCl; Phentermine resin complex; AmbkkkkK744; Phentermine Resin 30; Phentrol 2; Phentrol 3; Phentrol 4; Adipex P (TN); Adipex-P; Alpha-Benzylisopropylamine; Duromine (TN); Fastin (TN); Fentermina [INN-Spanish]; Ionamin (TN); Mirapront (TN); Obenix (TN); Obephen (TN); Obermine (TN); Oby-Trim; Panbesy (TN); Phenterex (TN); Phentermine (TN); Phenterminum [INN-Latin]; Phentremene (TN); Phentrol (TN); Phentromin (TN); Pro-Fast; Redusa (TN); Sinpet (TN); Supremin (TN); Teramine (TN); Trenker (TN); Umine (TN); Weltmine (TN); Zantryl (TN); Alpha,alpha-Dimethylbenzeneethanamine; Alpha,alpha-Dimethylphenethylamine; Anoxine-AM (TN); Obestin-30 (TN); Oby-Trim (TN); Phentermine (USAN/INN); Phentermine [USAN:INN:BAN]; Phenyl-tert-butylamine; Phenyl-tertiary-butylamine; Pro-Fast SA (TN); Alpha,alpha-Dimethyl-beta-phenylethylamine; Alpha.,.alpha.-dimethyl-Benzeneethanamine; (alpha,alpha)-Dimethylphenethylamine; 1,1-Dimethyl-2-phenylethylamine; 1-(2-Methylphenyl)-2-propylamin; 1-(2-Tolyl)-2-propylamine; 2-Amino-2-methyl-1-phenylpropane; 2-Methyl-1-phenyl-2-propanamine; 2-Phenyl-tert-butylamine
DMG60XN CP Medeva Pharmaceuticals
DMG60XN TC Appetite Depressants
DMG60XN DT Small molecular drug
DMG60XN PC 4771
DMG60XN MW 149.23
DMG60XN FM C10H15N
DMG60XN IC InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
DMG60XN CS CC(C)(CC1=CC=CC=C1)N
DMG60XN IK DHHVAGZRUROJKS-UHFFFAOYSA-N
DMG60XN IU 2-methyl-1-phenylpropan-2-amine
DMG60XN CA CAS 122-09-8
DMG60XN CB CHEBI:8080
DMG60XN DE Obesity
DMXYJOB ID DMXYJOB
DMXYJOB DN Phentolamine
DMXYJOB HS Approved
DMXYJOB SN Dibasin; Fentolamin; Fentolamina; Phenotolamine; Phentalamine; Phentolaminum; Regitin; Regitine; Regitipe; Regityn; Rogitine; Phentolamine mesylate [USAN]; Phentolamine methanesulfonate; C 7337; C 7337 Ciba; Fentolamina [INN-Spanish]; Phentolamine (INN); Phentolamine [INN:BAN]; Phentolamine, methyl sulfonate; Phentolaminum [INN-Latin]; Vasomax (TN); 2-((N-(m-Hydroxyphenyl)-p-toluidino)methyl)-2-imidazoline; 2-(N'-p-Tolyl-N'-m-hydroxyphenylaminomethyl)-2-imidazoline; 2-(N-(m-Hydroxyphenyl)-p-toluidinomethyl)imidazoline; 2-(m-Hydroxy-N-p-tolylanilinomethyl)-2-imidazoline; 3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol; 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
DMXYJOB CP Bedford Laboratories
DMXYJOB TC Antihypertensive Agents
DMXYJOB DT Small molecular drug
DMXYJOB PC 5775
DMXYJOB MW 281.35
DMXYJOB FM C17H19N3O
DMXYJOB IC InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)
DMXYJOB CS CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
DMXYJOB IK MRBDMNSDAVCSSF-UHFFFAOYSA-N
DMXYJOB IU 3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol
DMXYJOB CA CAS 50-60-2
DMXYJOB CB CHEBI:8081
DMXYJOB DE Dermal necrosis
DMQ95GE ID DMQ95GE
DMQ95GE DN Phenylacetic acid
DMQ95GE HS Approved
DMQ95GE SN .alpha.-Toluic acid; .omega.-Phenylacetic acid; 2-Phenylacetic acid; Acetic acid, phenyl-; Benzenacetic acid; Benzeneacetic acid; Benzylcarboxylic acid; Benzylformic acid; Kyselina fenyloctova; Kyselina fenyloctova [Czech]; PHENYL ACETIC ACID; PHENYL-ACETIC ACID; PHENYLACETIC ACID; Phenylacetic acid (natural); Phenylethanoic acid; Phenyllacetic acid; alpha-Toluic acid; omega-Phenylacetic acid; phenylacetate
DMQ95GE DT Small molecular drug
DMQ95GE PC 999
DMQ95GE MW 136.15
DMQ95GE FM C8H8O2
DMQ95GE IC InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)
DMQ95GE CS C1=CC=C(C=C1)CC(=O)O
DMQ95GE IK WLJVXDMOQOGPHL-UHFFFAOYSA-N
DMQ95GE IU 2-phenylacetic acid
DMQ95GE CA CAS 103-82-2
DMQ95GE CB ChEBI:30745
DMQ95GE DE Hyperammonemia
DMAYL0T ID DMAYL0T
DMAYL0T DN Phenylbutazone
DMAYL0T HS Approved
DMAYL0T SN Alindor; Alkabutazona; Alqoverin; Anerval; Anpuzone; Antadol; Anuspiramin; Arthrizon; Artizin; Artrizin; Artrizone; Artropan; Azdid; Azobutyl; Azolid; Benzone; Betazed; Bizolin; Bunetzone; Busone; Butacompren; Butacote; Butadion; Butadiona; Butadione; Butadionum; Butagesic; Butalgina; Butalidon; Butaluy; Butaphen; Butapirazol; Butapirazole; Butapyrazole; Butarecbon; Butartril; Butartrina; Butatron; Butazina; Butazolidin; Butazolidine; Butazona; Bute; Butidiona; Butone; Butoz; Butylpyrin; Buvetzone; Buzon;Chembutazone; Cotylbutazone; Digibutina; Diossidone; Diozol; Diphebuzol; Diphenylbutazone; Ecobutazone; Elmedal; Equipalazone; Equiphen; Eributazone; Esteve; Febuzina; Fenartil; Fenibutal; Fenibutasan; Fenibutazona; Fenibutol; Fenilbutazon; Fenilbutazona; Fenilbutazone; Fenilbutina; Fenilbutine; Fenilidina; Fenotone; Fenylbutazon; Flexazone; Intalbut; Intrabutazone; Intrazone; Ipsoflame; Kadol; Lingel; Malgesic; Mephabutazon; Mephabutazone; Merizone; Nadazone; Nadozone; Novophenyl; Phebuzin; Phebuzine; Phenbutazol; Phenbutazone; Phenopyrine; Phenylbutaz; Phenylbutazon; Phenylbutazonum; Phenyzene; Phenyzone; Praecirheumin; Pyrabutol; Pyrazolidin; Rectofasa; Reudo; Reudox; Reumasyl; Reumazin; Reumazol; Reumune; Reumuzol; Reupolar; Robizone; Rubatone; Scanbutazone; Schemergen; Schemergin; Shigrodin; Tazone; Tencodyne; Tetnor; Tevcodyne; Therazone; Ticinil; Todalgil; Uzone; Wescozone; Zolaphen; Zolidinum; Alka Butazolidin; Art rizin; Buta phen; Butyl pyrin; Equi bute; Exrheudon N; Fe nilbutine; Fenilbutazone [DCIT]; Phenyl butazone; Phenylbutazon [German]; Pirarreumol B; A 7514; Bizolin 200; G 13871; P 8386; P1686; P1Z; AZOLID (TN); Apo-Phenylbutazone; Butiwas-Simple; Component of Azolid-A; DA-192; Fenilbutazona [INN-Spanish]; G 13,871; Ia-But; Mepha-Butazon; Neo-zoline; Phenyl-Mobuzon; Phenylbutazonum [INN-Latin]; Robizon-V; Robizone-V; Usaf ge-15; VAC-10; B.T.Z; Phen-Buta-Vet; R-3-ZON; B.t.z.; Bute, Butazolidin, Butatron, Phenylbutazone; Phenylbutazone (JP15/USP/INN); Phenylbutazone [USAN:INN:BAN:JAN]; 1,2-Diphenyl-2,3-dioxo-4-N-butylpyrazoline; 1,2-Diphenyl-3,5-dioxo-4-butylpyrazolidine; 1,2-Diphenyl-4-butyl-3,5-dioxopyrazolidine; 1,2-Diphenyl-4-butyl-3,5-pyrazolidinedione; 1,2-diphenyl-3,5-dioxo-4-n-butylpyrazoline; 3,5-Dioxe-4 buty-1, diphenyl-pyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-N-butylpyrazolidine; 3,5-Dioxo-1,2-diphenyl-4-n-butyl-pyrazolidin; 3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine; 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE; 4-Butyl-1,2-diphenyl-3,5-dioxopyrazolidine; 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione; 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione; 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
DMAYL0T TC Analgesics
DMAYL0T DT Small molecular drug
DMAYL0T PC 4781
DMAYL0T MW 308.4
DMAYL0T FM C19H20N2O2
DMAYL0T IC InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3
DMAYL0T CS CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
DMAYL0T IK VYMDGNCVAMGZFE-UHFFFAOYSA-N
DMAYL0T IU 4-butyl-1,2-diphenylpyrazolidine-3,5-dione
DMAYL0T CA CAS 50-33-9
DMAYL0T CB CHEBI:48574
DMAYL0T DE Chronic pain
DMZHUO5 ID DMZHUO5
DMZHUO5 DN Phenylephrine
DMZHUO5 HS Approved
DMZHUO5 SN Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
DMZHUO5 CP Alcon Canada Inc
DMZHUO5 TC Ophthalmologicals
DMZHUO5 DT Small molecular drug
DMZHUO5 PC 6041
DMZHUO5 MW 167.2
DMZHUO5 FM C9H13NO2
DMZHUO5 IC InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
DMZHUO5 CS CNC[C@@H](C1=CC(=CC=C1)O)O
DMZHUO5 IK SONNWYBIRXJNDC-VIFPVBQESA-N
DMZHUO5 IU 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
DMZHUO5 CA CAS 61-76-7
DMZHUO5 CB CHEBI:8093
DMZHUO5 DE Fecal incontinence; Ophthalmic graves disease
DMKAEQW ID DMKAEQW
DMKAEQW DN Phenyltoloxamine
DMKAEQW HS Approved
DMKAEQW SN Bristamin hydrochloride; Phenyltoloxamine hydrochloride; HL 2153; (2-(Dimethylamino)ethyl) (o-benzylphenoxy)ether hydrochloride; N,N-Dimethyl-2-(alpha-phenyl-o-toloxy)-ethylamine hydrochloride; ETHYLAMINE, 2-(o-BENZYLPHENOXY)-N,N-DIMETHYL-, HYDROCHLORIDE; Ethylamine, N,N-dimethyl-2-((alpha-phenyl-o-tolyl)oxy)-, hydrochloride; N-(2'-Dimethylaminoaethyl)-(o-benzylphenol)-aether hydrochlorid [German]; AC1L2KJQ; 92-12-6 (Parent); LS-67923; 2-(2-benzylphenoxy)ethyl-dimethylazanium chloride
DMKAEQW DT Small molecular drug
DMKAEQW PC 7077
DMKAEQW MW 255.35
DMKAEQW FM C17H21NO
DMKAEQW IC InChI=1S/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
DMKAEQW CS CN(C)CCOC1=CC=CC=C1CC2=CC=CC=C2
DMKAEQW IK IZRPKIZLIFYYKR-UHFFFAOYSA-N
DMKAEQW IU 2-(2-benzylphenoxy)-N,N-dimethylethanamine
DMKAEQW CA CAS 92-12-6
DMKAEQW CB CHEBI:135047
DMKAEQW DE Allergy
DMNOKBV ID DMNOKBV
DMNOKBV DN Phenytoin
DMNOKBV HS Approved
DMNOKBV SN Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoine; Denyl; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dihydantoin; Dilabid; Dilantin; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Diphenylhydantoin; Diphenylhydantoine; Diphenylhydatanoin; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epelin; Epifenyl; Epihydan; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenitoin; Fenitoina; Fentoin; Fenylepsin; Fenytoine; Hidan; Hidantal; Hidantilo; Hidantina; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoinal; Hydantol; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Minetoin; Neosidantoina; Novantoina; Novophenytoin; Oxylan; PHENYTEK; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoine; Phenytoinum; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic;TOIN; Tacosal; Thilophenyl; Zentronal; Zentropil; Component of Mebroin; Dantoinal klinos; Difenilhidantoina [Spanish]; Dihydan toin; Dilantin acid; Diphenylhydantoine [French]; Ekko capsules; Elepsi ndon; Epdantoin Simple; Epdantoine simple; Epilan D; Extended Phenytoin Sodium; Fen toin; Fenantoin Mn Pharma; Fenidantoin s; Fenytoin Dak; Hidantina senosian; Hidantina vitoria; Ictalis simp le; Ictalis simple; Om hidantoina simple; Phenat ine; Phenytoin AWD; Sodium Diphenylhydantoinate; Taco sal; Toin unicelles; CL12003; D 4007; D4007_SIGMA; Didan TDC 250; Epasmir 5; IFLab1_000214; DILANTIN-30; DPH (VAN); Di-Hydan; Di-Lan; Di-Phetine; Dilantin (TN); Dilantin Infatabs (TN); Dilantin Kapseals (TN); Dilantin-125; Diphenylhydantoin (VAN); Epanutin (TN); Epasmir (5); Epilan-D; Eptoin (TN); Fenidantoin (s); Fenitoina [INN-Spanish]; Neos-Hidantoina; Om-Hydantoine; PHENYTOIN SODIUM, EXTENDED; Phenytek (TN); Phenytoin (PHN); Phenytoin-Gerot; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Di-Lan (VAN); Didan-tdc-250; Gerot-epilan-D; PHENYTOIN (5,5-DIPHENYLHYDANTOIN); Phenytoin (JP15/USP/INN); Phenytoin [USAN:INN:BAN:JAN]; Hydantoin, 5,5-diphenyl-(8CI); 2,4-Imidazolidinedione, 5,5-diphenyl-(9CI); 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; 5,5-DIPHENYLHYDANTOIN; 5,5-Diphenyl-2,4-imidazolidinedione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Diphenylhydantoin (phenytoin); 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Dwufenylohydantoina; 5,5-Dwufenylohydantoina [Polish]; 5,5-diphenylimidazolidine-2,4-dione
DMNOKBV CP Mylan Laboratories
DMNOKBV TC Anticonvulsants
DMNOKBV DT Small molecular drug
DMNOKBV PC 1775
DMNOKBV MW 252.27
DMNOKBV FM C15H12N2O2
DMNOKBV IC InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)
DMNOKBV CS C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
DMNOKBV IK CXOFVDLJLONNDW-UHFFFAOYSA-N
DMNOKBV IU 5,5-diphenylimidazolidine-2,4-dione
DMNOKBV CA CAS 57-41-0
DMNOKBV CB CHEBI:8107
DMNOKBV DE Epilepsy
DMUKMC8 ID DMUKMC8
DMUKMC8 DN Phloroglucinol
DMUKMC8 HS Approved
DMUKMC8 SN phloroglucinol; 108-73-6; Benzene-1,3,5-triol; 1,3,5-trihydroxybenzene; 1,3,5-benzenetriol; Phloroglucin; Phloroglucine; Spasfon-Lyoc; s-Trihydroxybenzene; 5-Hydroxyresorcinol; Benzene-s-triol; 3,5-Dihydroxyphenol; Benzene, trihydroxy; sym-Trihydroxybenzene; 5-Oxyresorcinol; Dilospan S; Floroglucinol; Floroglucin; Phloroglucinol anhydrous; 5-Oxyresorcinolphloroglucin; 1,3,5-THB; 1,3,5-Trihydroxycyclohexatriene; 1,3,5-Triol; Floroglucin [Czech]; Floroglucinol [Czech]; Benzene, 1,3,5-trihydroxy-; UNII-DHD7FFG6YS; 5-Benzenetriol; NSC 157
DMUKMC8 DT Small molecular drug
DMUKMC8 PC 359
DMUKMC8 MW 126.11
DMUKMC8 FM C6H6O3
DMUKMC8 IC InChI=1S/C6H6O3/c7-4-1-5(8)3-6(9)2-4/h1-3,7-9H
DMUKMC8 CS C1=C(C=C(C=C1O)O)O
DMUKMC8 IK QCDYQQDYXPDABM-UHFFFAOYSA-N
DMUKMC8 IU benzene-1,3,5-triol
DMUKMC8 CA CAS 108-73-6
DMUKMC8 CB CHEBI:16204
DMUKMC8 DE Urinary tract disease
DMUXQG7 ID DMUXQG7
DMUXQG7 DN Phosphate
DMUXQG7 HS Approved
DMUXQG7 SN orthophosphate; Phosphate ion; 14265-44-2; O-Phosphate; UNII-NK08V8K8HR; NK08V8K8HR; Phosphates; Phosphate ions; PO4; a phosphate group; tetraoxophosphate(V); tetraoxophosphate(3-); Phosphoric acid trianion; tetraoxidophosphate(3-); phosphoric acid, ion(3-); AC1L1AN2; DTXSID7039672; CHEBI:18367; CTK0H5978; NBIIXXVUZAFLBC-UHFFFAOYSA-K; BDBM50155537; AKOS015903596; PO4(3-); CREATINE PHOSPHATE; N-PHOSPHOCREATINE; [PO4](3-); I14-18227
DMUXQG7 DT Small molecular drug
DMUXQG7 PC 1061
DMUXQG7 MW 94.971
DMUXQG7 FM O4P-3
DMUXQG7 IC InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3
DMUXQG7 CS [O-]P(=O)([O-])[O-]
DMUXQG7 IK NBIIXXVUZAFLBC-UHFFFAOYSA-K
DMUXQG7 IU phosphate
DMUXQG7 CA CAS 14265-44-2
DMUXQG7 CB CHEBI:18367
DMUXQG7 DE Constipation
DM8HDOL ID DM8HDOL
DM8HDOL DN Phytonadione
DM8HDOL HS Approved
DM8HDOL SN Phyllochinon; Phyllohydroquinone; Phytomenadione; Fitomenadione [DCIT]; Phyllochinon [German]; LT00452032; Fitomenadiona [INN-Spanish]; Mephyton (TN); Phylloquinone (8CI); Phytomenadione (INN); Phytomenadionum [INN-Latin]; Phytonadione [USAN:JAN]; Vitamin K1 (TN); Vitamin K1 (VAN); Vitamin K1 (generic); Phythyl-menadion (GERMAN); Phytonadione (JP15/USP); 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-); 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened-ione; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon; 2-Methyl-3-phytyl-1,4-naphthochinon [German]; 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; 3-Phytylmenadione
DM8HDOL TC Vitamins
DM8HDOL DT Small molecular drug
DM8HDOL PC 5284607
DM8HDOL MW 450.7
DM8HDOL FM C31H46O2
DM8HDOL IC InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1
DM8HDOL CS CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C
DM8HDOL IK MBWXNTAXLNYFJB-NKFFZRIASA-N
DM8HDOL IU 2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
DM8HDOL CA CAS 79083-00-4
DM8HDOL CB CHEBI:18067
DM8HDOL DE Bleeding disorder; Vitamin K deficiency
DM27BL1 ID DM27BL1
DM27BL1 DN Pibrentasvir
DM27BL1 HS Approved
DM27BL1 SN 2WU922TK3L; A-1325912.0; ABT 530; ABT-530; ABT-530;Pibrentasvir; CHEMBL3545123; CS-8135; D10816; DB13878; Dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1H-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate; EX-A865; J-690144; J3.646.121G; Pibrentasvir; Pibrentasvir (JAN/USAN/INN); Pibrentasvir [USAN]; SCHEMBL17639956; SCHEMBL2756579; UNII-2WU922TK3L
DM27BL1 TC Antiviral Agent
DM27BL1 DT Small molecular drug
DM27BL1 PC 58031952
DM27BL1 MW 1113.201
DM27BL1 FM C57H65F5N10O8
DM27BL1 IC InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1
DM27BL1 CS CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC
DM27BL1 IK VJYSBPDEJWLKKJ-NLIMODCCSA-N
DM27BL1 IU methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
DM27BL1 CA CAS 1353900-92-1
DM27BL1 DE Hepatitis C virus infection
DMIBNG2 ID DMIBNG2
DMIBNG2 DN Picrotoxin
DMIBNG2 HS Approved
DMIBNG2 SN Cocculin; Cocculus; Picrotox; Picrotoxine; Picrotoxinum; Sesquiterpene; Coques du levant; Coques du levant [French];Fish berry; Indian berry; Oriental berry; P 1675; Picrotin-Picrotoxinin; Picrotoxin (Compound of one mole Picrotoxinin and one mole Picrotin); Picrotoxinin-picrotin; Picrotin, compound with picrotoxinin (1:1); Picrotin, compd. with picrotoxinin (1:1); Picrotoxinin, compd. with picrotin (1:1); 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR,2aR,3S,6R,6aS,8aS,8bR,9S)-& (1aR,2aR,3S,6R,6aS,8aS,8bR,9R; 3,6-Methano-8H-1,5,7-trioxacyclopenta[ij]cycloprop[a]azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, [1aR-(1a.alpha.,2
DMIBNG2 TC Central Nervous System Stimulants
DMIBNG2 DT Small molecular drug
DMIBNG2 PC 31304
DMIBNG2 MW 602.6
DMIBNG2 FM C30H34O13
DMIBNG2 IC InChI=1S/C15H18O7.C15H16O6/c1-12(2,18)6-7-10(16)20-8(6)9-13(3)14(7,19)4-5-15(13,22-5)11(17)21-9;1-5(2)7-8-11(16)19-9(7)10-13(3)14(8,18)4-6-15(13,21-6)12(17)20-10/h5-9,18-19H,4H2,1-3H3;6-10,18H,1,4H2,2-3H3/t5-,6+,7?,8?,9-,13-,14-,15+;6?,7-,8?,9?,10+,13+,14+,15-/m10/s1
DMIBNG2 CS CC(=C)[C@@H]1C2[C@@H]3[C@@]4([C@](C1C(=O)O2)(CC5[C@]4(O5)C(=O)O3)O)C.C[C@@]12[C@H]3C4[C@H](C([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O
DMIBNG2 IK VJKUPQSHOVKBCO-ZTYBEOBUSA-N
DMIBNG2 IU (1R,3R,5S,8S,13R,14S)-1-hydroxy-14-(2-hydroxypropan-2-yl)-13-methyl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione;(1R,5S,8S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione
DMIBNG2 CA CAS 124-87-8
DMIBNG2 DE Respiratory distress syndrome
DMV9ADG ID DMV9ADG
DMV9ADG DN Pilocarpine
DMV9ADG HS Approved
DMV9ADG SN Adsorbocarpine; Almocarpine; Epicar; Isopilocarpine; Isoptocarpine; Miocarpine; Ocusert; Pilagan; Pilocarpin; Pilocarpol; Pilokarpin; Pilokarpol; Pilostat; Salagen; Spersacarpine; Syncarpine; Amistura P; Isopto carpine; Minims Pilocarpine; Ocusert pilo; Pilocarpine HCl; Pilocarpine chloride; Pilocarpine nitrate; Ocusert P 20;Beta-Pilocarpine hydrochloride; Diocarpine (TN); Isopto Carpine (TN); Mi-Pilo; Miocarpine (TN); Ocu-Carpine; Ocusert Pilo-40; Ocusert pilo-20; Pilocarpine (TN); Pilopine HS (TN); Piloptic-1; Piloptic-2; Piloptic-3; Piloptic-4; Piloptic-6; Salagen (TN); Scheinpharm (TN); Timpilo (TN); Ocusert Pilo-20 (TN); Ocusert pilo-20 (TN); P.V. Carpine Liquifilm; Pilocarpine (JAN/USP); Pilocarpine [USAN:BAN:JAN]; Piloptic-1/2; Pilocarpine Mononitrate, (3S-cis)-Isomer; Pilocarpine, Monohydrochloride, (3S-cis)-Isomer; Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone; (+)-Pilocarpine; (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one; (3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone; (3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone; 3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone; 3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one; 3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone; 3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
DMV9ADG CP Alcon Laboratories
DMV9ADG TC Cholinergic Agents
DMV9ADG DT Small molecular drug
DMV9ADG PC 5910
DMV9ADG MW 208.26
DMV9ADG FM C11H16N2O2
DMV9ADG IC InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
DMV9ADG CS CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C
DMV9ADG IK QCHFTSOMWOSFHM-WPRPVWTQSA-N
DMV9ADG IU (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
DMV9ADG CA CAS 92-13-7
DMV9ADG CB CHEBI:8207
DMV9ADG DE Glaucoma/ocular hypertension
DMZ65K8 ID DMZ65K8
DMZ65K8 DN Pilsicainide
DMZ65K8 HS Approved
DMZ65K8 SN SUNRYTHM; Sunrhythm; Pilsicainide hydrochloride; DU-6552; SUN-1165; SUN-1165i
DMZ65K8 CP Suntory Ltd
DMZ65K8 DT Small molecular drug
DMZ65K8 PC 4820
DMZ65K8 MW 272.4
DMZ65K8 FM C17H24N2O
DMZ65K8 IC InChI=1S/C17H24N2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20)
DMZ65K8 CS CC1=C(C(=CC=C1)C)NC(=O)CC23CCCN2CCC3
DMZ65K8 IK BCQTVJKBTWGHCX-UHFFFAOYSA-N
DMZ65K8 IU N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide
DMZ65K8 CA CAS 88069-67-4
DMZ65K8 CB CHEBI:135127
DMZ65K8 DE Heart arrhythmia
DMR7IVC ID DMR7IVC
DMR7IVC DN Pimavanserin
DMR7IVC HS Approved
DMR7IVC SN ST51054136; AC-5273; I14-1981; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMR7IVC CP Acadia Pharmaceuticals
DMR7IVC DT Small molecular drug
DMR7IVC PC 10071196
DMR7IVC MW 427.6
DMR7IVC FM C25H34FN3O2
DMR7IVC IC InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
DMR7IVC CS CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
DMR7IVC IK RKEWSXXUOLRFBX-UHFFFAOYSA-N
DMR7IVC IU 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMR7IVC CA CAS 706779-91-1
DMR7IVC CB CHEBI:133017
DMR7IVC DE Parkinson disease
DMZLGRB ID DMZLGRB
DMZLGRB DN Pimecrolimus
DMZLGRB HS Approved
DMZLGRB SN Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin
DMZLGRB CP Norvatis Phamaceuticals Corporation
DMZLGRB TC Dermatologic Agents
DMZLGRB DT Small molecular drug
DMZLGRB PC 6509979
DMZLGRB MW 810.4
DMZLGRB FM C43H68ClNO11
DMZLGRB IC InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
DMZLGRB CS CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)Cl)/C)O)C)OC)OC)C)\\C
DMZLGRB IK KASDHRXLYQOAKZ-XDSKOBMDSA-N
DMZLGRB IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(E)-1-[(1R,3R,4S)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl]-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZLGRB CA CAS 137071-32-0
DMZLGRB CB CHEBI:135888
DMZLGRB DE Atopic dermatitis
DMW83TP ID DMW83TP
DMW83TP DN Pimozide
DMW83TP HS Approved
DMW83TP SN Antalon; Neoperidole; Opiran; Orap; Pimozida; Pimozidum; Primozida; ASTA Medica Brand of Pimozide; Janssen Brand of Pimozide;Orap forte; Pharmascience Brand of Pimozide; P 1793; R 6238; McN-JR 6238; Orap (TN); Pimozida [INN-Spanish]; Pimozidum [INN-Latin]; Primozida [INN-Spanish]; R-6238; McN-JR-6238; Pimozide (JAN/USP/INN); Pimozide [USAN:INN:BAN:JAN]; 1-(1-(4,4-Bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone; 1-(4,4-Bis(p-fluorophenyl)butyl)-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-[1-[4,4-Bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[1-[4,4-Bis(p-fluorophenyl)butyl]-4-piperidyl]-2-benzimidazolinone; 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[4,4-Bis(p-fluorophenyl)butyl]-4-(2-oxo-1-benzimidazolinyl)piperidine; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMW83TP CP Janssen Pharmaceutica
DMW83TP TC Antipsychotic Agents
DMW83TP DT Small molecular drug
DMW83TP PC 16362
DMW83TP MW 461.5
DMW83TP FM C28H29F2N3O
DMW83TP IC InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
DMW83TP CS C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
DMW83TP IK YVUQSNJEYSNKRX-UHFFFAOYSA-N
DMW83TP IU 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMW83TP CA CAS 2062-78-4
DMW83TP CB CHEBI:8212
DMW83TP DE Schizophrenia
DMRADYL ID DMRADYL
DMRADYL DN Pinacidil
DMRADYL HS Approved
DMRADYL SN Pinacidilum; P 1134; S 1230; P-154; Pinacidil (anhydrous); Pinacidilum [INN-Latin]; S-1230; N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)guanidine; Guanidine, 2-cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)-, monohydrate; Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-, monohydrate; (+-)-Pinacidil; (+/-)-N-Cyano-N'-4-pyridinyl-N"-(1,2,2-trimethylpropyl)guanidine; (R,S)-Pinacidil; (inverted question mark)-N-Cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-guanidine; 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine; 2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine; 2-Cyano-3-(4-pyridyl)-1-(1,2,2-trimethylpropyl)guanidine monohydrate
DMRADYL TC Antihypertensive Agents
DMRADYL DT Small molecular drug
DMRADYL PC 4826
DMRADYL MW 245.32
DMRADYL FM C13H19N5
DMRADYL IC InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)
DMRADYL CS CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1
DMRADYL IK IVVNZDGDKPTYHK-UHFFFAOYSA-N
DMRADYL IU 1-cyano-2-(3,3-dimethylbutan-2-yl)-3-pyridin-4-ylguanidine
DMRADYL CA CAS 60560-33-0
DMRADYL CB CHEBI:91706
DMRADYL DE High blood pressure
DMD2NV7 ID DMD2NV7
DMD2NV7 DN Pindolol
DMD2NV7 HS Approved
DMD2NV7 SN Betapindol; Blocklin; Calvisken; Carvisken; Decreten; Durapindol; Pectobloc; Pinbetol; Pindololum; Prindolol; Prinodolol; Pynastin; Visken; Blockin L; Blocklin L; LB 46; LB46; P 0778; Betapindol (TN); Blockin L (TN); Blocklin L (TN); Blocklin-L; Calvisken (TN); Cardilate (TN); Carvisken (TN); DL-LB 46; DL-Pindolol; Decreten (TN); Durapindol (TN); Glauco-Viskin; Glauco-visken; LB-46; P-6820; Pectobloc (TN); Pinbetol (TN); Pindololum [INN-Latin]; Prindolol (TN); Pynastin (TN); Visken (TN); Blocklin-L (TN); Glauco-Visken (TN); Pindolol (JP15/USP/INN); Pindolol [USAN:INN:BAN:JAN]; DL-4-[2-Hydroxy-3-(isopropylamino)propoxy]indole; (+-)-Pindolol; (1)-1-(1H-Indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(4-indolyloxy)-2-propanol; 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol; 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol; 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol; 1-(1H-indol-4-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-indole; 4-(3-(Isopropylamino)-2-hydroxypropoxy)indole
DMD2NV7 CP Tocris Bioscience
DMD2NV7 TC Antihypertensive Agents
DMD2NV7 DT Small molecular drug
DMD2NV7 PC 4828
DMD2NV7 MW 248.32
DMD2NV7 FM C14H20N2O2
DMD2NV7 IC InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
DMD2NV7 CS CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
DMD2NV7 IK JZQKKSLKJUAGIC-UHFFFAOYSA-N
DMD2NV7 IU 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DMD2NV7 CA CAS 13523-86-9
DMD2NV7 CB CHEBI:8214
DMD2NV7 DE Hypertension
DMKJ485 ID DMKJ485
DMKJ485 DN Pioglitazone
DMKJ485 HS Approved
DMKJ485 SN 111025-46-8; Actos; Pioglitazona; Pioglitazonum; Glustin; Zactos; 105355-27-9; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; Duetact; Pioglitazone [INN:BAN]; Pioglitazone [BAN:INN]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; AD-4833; U 72107; CHEBI:8228; Pioglitazone (Actos); HSDB 7322; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; C19H20N2O3S; AD 4833; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U 72107A; Actos; Actost; Glustin (TN); HS-0047; Pioglitazone (INN); U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; Linagliptin + pioglitazone; PCG1
DMKJ485 CP Takeda Pharmaceuticals
DMKJ485 TC Hypoglycemic Agents
DMKJ485 DT Small molecular drug
DMKJ485 PC 4829
DMKJ485 MW 356.4
DMKJ485 FM C19H20N2O3S
DMKJ485 IC InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
DMKJ485 CS CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMKJ485 IK HYAFETHFCAUJAY-UHFFFAOYSA-N
DMKJ485 IU 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMKJ485 CA CAS 111025-46-8
DMKJ485 CB CHEBI:8228
DMKJ485 DE Diabetic complication; Obesity; Type-2 diabetes
DM5F84A ID DM5F84A
DM5F84A DN Pipecuronium
DM5F84A HS Approved
DM5F84A SN Arduan; Pipecurium; Arduan (TN); Piperazinium, 4,4'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1,1-dimethyl); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DM5F84A TC Analgesics
DM5F84A DT Small molecular drug
DM5F84A PC 50192
DM5F84A MW 602.9
DM5F84A FM C35H62N4O4+2
DM5F84A IC InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DM5F84A CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C
DM5F84A IK OWWLUIWOFHMHOQ-XGHATYIMSA-N
DM5F84A IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DM5F84A CA CAS 68399-58-6
DM5F84A CB CHEBI:8230
DM5F84A DE Spasm
DMGQU0Y ID DMGQU0Y
DMGQU0Y DN Piperacetazine
DMGQU0Y HS Approved
DMGQU0Y SN Quide
DMGQU0Y CP Dow Pharmaceutical Corp Sub Dow Chemical Co
DMGQU0Y DT Small molecular drug
DMGQU0Y PC 19675
DMGQU0Y MW 410.6
DMGQU0Y FM C24H30N2O2S
DMGQU0Y IC InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3
DMGQU0Y CS CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO
DMGQU0Y IK BTFMCMVEUCGQDX-UHFFFAOYSA-N
DMGQU0Y IU 1-[10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone
DMGQU0Y CA CAS 3819-00-9
DMGQU0Y CB CHEBI:92293
DMGQU0Y DE Schizophrenia
DMTBKF3 ID DMTBKF3
DMTBKF3 DN Piperacillin
DMTBKF3 HS Approved
DMTBKF3 SN PIPC; Peperacillin; Peracin; Pipercillin; Pipracil; Pipril; PIPERACILLIN SODIUM; Piperacillin Monosodium Salt; Piperacillin anhydrous; Cl-227193; Peracin (TN); Piperacillin (INN); Piperacillin (anhydrous); Pipracil, Piper; T-1220; Zobactin (TN); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 4-ethyl-2,3-dioxopiperazine carbonyl ampicillin; 6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanicacid; 6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
DMTBKF3 CP Wyeth
DMTBKF3 TC Antibiotics
DMTBKF3 DT Small molecular drug
DMTBKF3 PC 43672
DMTBKF3 MW 517.6
DMTBKF3 FM C23H27N5O7S
DMTBKF3 IC InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1
DMTBKF3 CS CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
DMTBKF3 IK IVBHGBMCVLDMKU-GXNBUGAJSA-N
DMTBKF3 IU (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMTBKF3 CA CAS 61477-96-1
DMTBKF3 CB CHEBI:8232
DMTBKF3 DE Bacterial infection
DMT70RC ID DMT70RC
DMT70RC DN Piperaquine
DMT70RC HS Approved
DMT70RC SN Piperaquinoline; Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-(9CI); 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine); 4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline); 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
DMT70RC DT Small molecular drug
DMT70RC PC 122262
DMT70RC MW 535.5
DMT70RC FM C29H32Cl2N6
DMT70RC IC InChI=1S/C29H32Cl2N6/c30-22-2-4-24-26(20-22)32-8-6-28(24)36-16-12-34(13-17-36)10-1-11-35-14-18-37(19-15-35)29-7-9-33-27-21-23(31)3-5-25(27)29/h2-9,20-21H,1,10-19H2
DMT70RC CS C1CN(CCN1CCCN2CCN(CC2)C3=C4C=CC(=CC4=NC=C3)Cl)C5=C6C=CC(=CC6=NC=C5)Cl
DMT70RC IK UCRHFBCYFMIWHC-UHFFFAOYSA-N
DMT70RC IU 7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
DMT70RC CA CAS 4085-31-8
DMT70RC CB CHEBI:91231
DMT70RC DE Malaria
DMTY9LU ID DMTY9LU
DMTY9LU DN Piperazine
DMTY9LU HS Approved
DMTY9LU SN Anthalazine; Antiren; Diethylenediamine; Diethyleneimine; Dispermine; Eraverm; Hexahydropyrazine; Lumbrical; PZE; Piperazidine; Piperazin; Pipersol; Upixon; Uvilon; Vermex; Vermizine; Wurmirazin; Piperazin [German]; Piperazin [Germany]; Piperazine Dihydrochloride Dihydrochloride Hydrate; Piperazine [USAN]; Piperazine anhydrous; Piperazinium oleate; Pyrazine hexahydride; LTBB000432; Piperazine [UN2579] [Corrosive]; Eraverm (VAN); PIPERAZINE (HEXAHYDRATE); Piperazine (USP); Piperazine Hexa-Hydrate; Piperazine, anhydrous; Pyrazine, hexahy; Vermizine (TN); Worm-away; Asca-Trol No. 3; Worm-A-Ton; Hexahydro-1,4-diazine; 1,4-Diazacyclohexane; 1,4-Diethylenediamine; 1,4-Piperazine
DMTY9LU CP Glaxosmithkline
DMTY9LU TC Antinematodal Agents
DMTY9LU DT Small molecular drug
DMTY9LU PC 4837
DMTY9LU MW 86.14
DMTY9LU FM C4H10N2
DMTY9LU IC InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2
DMTY9LU CS C1CNCCN1
DMTY9LU IK GLUUGHFHXGJENI-UHFFFAOYSA-N
DMTY9LU IU piperazine
DMTY9LU CA CAS 110-85-0
DMTY9LU CB CHEBI:28568
DMTY9LU DE Enterobiasis; Ascariasis
DMNL0E6 ID DMNL0E6
DMNL0E6 DN Pipobroman
DMNL0E6 HS Approved
DMNL0E6 SN Amedel; Pipobromanum; Vercyte; A 1803; A-8103; Pipobroman [USAN:INN]; Pipobromanum [INN-Latin]; VERCYTE (TN); Pipobroman (JAN/USAN/INN); N,N'-Bis(3-bromopropionyl)piperazine; N,N-Bis-(3-bromopropionyl)-piperazine; 1,4-Bis(3-bromopropanoyl)piperazine; 1,4-Bis(3-bromopropionyl)piperazine; 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
DMNL0E6 TC Anticancer Agents
DMNL0E6 DT Small molecular drug
DMNL0E6 PC 4842
DMNL0E6 MW 356.05
DMNL0E6 FM C10H16Br2N2O2
DMNL0E6 IC InChI=1S/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2
DMNL0E6 CS C1CN(CCN1C(=O)CCBr)C(=O)CCBr
DMNL0E6 IK NJBFOOCLYDNZJN-UHFFFAOYSA-N
DMNL0E6 IU 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
DMNL0E6 CA CAS 54-91-1
DMNL0E6 CB CHEBI:8242
DMNL0E6 DE Refractory chronic myeloid leukaemia
DMC68DF ID DMC68DF
DMC68DF DN Pipotiazine
DMC68DF HS Approved
DMC68DF SN Pipotiazine; Pipothiazine; Pipotiazina; Pipotiazinum; 39860-99-6; Piportil; Pipotiazinum [INN-Latin]; Pipotiazina [INN-Spanish]; UNII-L903J9JPYV; L903J9JPYV; 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide; Pipotiazine [INN:BAN]; Piportil depot; Piportil (TN); Pipotiazine (INN); EINECS 254-659-6; Pipotiazine; ; ; Piportil; AC1L1XY4; SCHEMBL123275; GTPL7557; CHEMBL398880; BDBM81798; DTXSID40192913; ZINC3813024; BCP23973; PDSP2_000525; PDSP1_000527; NSC_62867; AKOS030527554; DB01621; ACM39860996
DMC68DF DT Small molecular drug
DMC68DF PC 62867
DMC68DF MW 475.7
DMC68DF FM C24H33N3O3S2
DMC68DF IC InChI=1S/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
DMC68DF CS CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO
DMC68DF IK JOMHSQGEWSNUKU-UHFFFAOYSA-N
DMC68DF IU 10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]-N,N-dimethylphenothiazine-2-sulfonamide
DMC68DF CA CAS 39860-99-6
DMC68DF DE Schizophrenia
DMGTW1I ID DMGTW1I
DMGTW1I DN Pirarubicin
DMGTW1I HS Approved
DMGTW1I SN Pinorubicin (TN); Therarubucin (TN)
DMGTW1I CP Sanraku and Meiji Seika
DMGTW1I DT Small molecular drug
DMGTW1I PC 636397
DMGTW1I MW 627.6
DMGTW1I FM C32H37NO12
DMGTW1I IC InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21-,22-,31+,32-/m0/s1
DMGTW1I CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O[C@H]6CCCCO6
DMGTW1I IK KMSKQZKKOZQFFG-HSUXVGOQSA-N
DMGTW1I IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2S)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMGTW1I CA CAS 72496-41-4
DMGTW1I CB CHEBI:32011
DMGTW1I DE Breast cancer
DMI5678 ID DMI5678
DMI5678 DN Pirbuterol
DMI5678 HS Approved
DMI5678 SN Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
DMI5678 CP 3M Pharmaceuticals
DMI5678 TC Bronchodilator Agents
DMI5678 DT Small molecular drug
DMI5678 PC 4845
DMI5678 MW 240.3
DMI5678 FM C12H20N2O3
DMI5678 IC InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
DMI5678 CS CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
DMI5678 IK VQDBNKDJNJQRDG-UHFFFAOYSA-N
DMI5678 IU 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
DMI5678 CA CAS 38677-81-5
DMI5678 CB CHEBI:8245
DMI5678 DE Asthma
DMP6M1N ID DMP6M1N
DMP6M1N DN Pirenzepine
DMP6M1N HS Approved
DMP6M1N SN Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
DMP6M1N CP Boehringer Ingelheim
DMP6M1N TC Antiulcer Agents
DMP6M1N DT Small molecular drug
DMP6M1N PC 4848
DMP6M1N MW 351.4
DMP6M1N FM C19H21N5O2
DMP6M1N IC InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
DMP6M1N CS CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMP6M1N IK RMHMFHUVIITRHF-UHFFFAOYSA-N
DMP6M1N IU 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMP6M1N CA CAS 28797-61-7
DMP6M1N CB CHEBI:8247
DMP6M1N DE Peptic ulcer
DM6VZFQ ID DM6VZFQ
DM6VZFQ DN Pirfenidone
DM6VZFQ HS Approved
DM6VZFQ SN Deskar; Esbriet; Pirespa; Pirfenidona; Pirfenidonum; AMR 69; P 2116; AMR-69; F-647; KS-5041; Pirfenidona [INN-Spanish]; Pirfenidone (Deskar); Pirfenidone [USAN:INN]; Pirfenidonum [INN-Latin]; S-7701; Pirfenidone (JAN/USAN/INN); 5-Methyl-1-phenyl-1H-pyridin-2-one; 5-Methyl-1-phenyl-2(1H)-pyridone; 5-Methyl-1-phenyl-2-(1H)-pyridone; 5-methyl-1-phenylpyridin-2(1H)-one; 5-methyl-1-phenylpyridin-2-one
DM6VZFQ CP InterMune
DM6VZFQ DT Small molecular drug
DM6VZFQ PC 40632
DM6VZFQ MW 185.22
DM6VZFQ FM C12H11NO
DM6VZFQ IC InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
DM6VZFQ CS CC1=CN(C(=O)C=C1)C2=CC=CC=C2
DM6VZFQ IK ISWRGOKTTBVCFA-UHFFFAOYSA-N
DM6VZFQ IU 5-methyl-1-phenylpyridin-2-one
DM6VZFQ CA CAS 53179-13-8
DM6VZFQ CB CHEBI:32016
DM6VZFQ DE Idiopathic pulmonary fibrosis
DMBCYF5 ID DMBCYF5
DMBCYF5 DN Pirmenol
DMBCYF5 HS Approved
DMBCYF5 SN Pimenol; Pirmavar; Pirmenol hydrochloride
DMBCYF5 CP Pfizer Inc
DMBCYF5 DT Small molecular drug
DMBCYF5 PC 65502
DMBCYF5 MW 338.5
DMBCYF5 FM C22H30N2O
DMBCYF5 IC InChI=1S/C22H30N2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3/t18-,19+,22?
DMBCYF5 CS C[C@@H]1CCC[C@@H](N1CCCC(C2=CC=CC=C2)(C3=CC=CC=N3)O)C
DMBCYF5 IK APUDBKTWDCXQJA-QIDMFYOTSA-N
DMBCYF5 IU 4-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-1-phenyl-1-pyridin-2-ylbutan-1-ol
DMBCYF5 CA CAS 68252-19-7
DMBCYF5 CB CHEBI:135436
DMBCYF5 DE Heart arrhythmia
DMTK234 ID DMTK234
DMTK234 DN Piroxicam
DMTK234 HS Approved
DMTK234 SN Akten; Artroxicam; Bruxicam; Caliment; Erazon; Felden; Feldene; Flogobene; Geldene; Improntal; Larapam; Pipoxicam; Pirkam; Piroflex; Piroftal; Piroxicamum; Pyroxycam; Reudene; Riacen; Roxicam; Roxiden; Sasulen; Solocalm; Zunden; Feldene Fast; Feldene Gel; Piroxicam usp; AK1015; CHF 1251; CP 16171; CP16171; P 5654; Apo-Piroxicam; Brexidol (TN); Brexin (TN); CP-16171; Erazon (TN); Exipan (TN); Felden (TN); Feldene (TN); Feldoral (TN); Hotemin (TN); Mobilis (TN); Pirox von ct (TN); Piroxicamum [INN-Latin]; Proponol (TN); Reumador (TN); Tracam (TN); Veral (TN); Vurdon (TN); Feldene, Roxam, Piroxicam; Piroxicam (JP15/USP/INN); Piroxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxo-1; (4-Hydroxy-2-methyl-1,1-dioxobenzo[e]1,2-thiazin-3-yl)-N-(2-pyridyl)carboxamide; 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy(pyridin-2-ylamino)methylidene]-2-methyl-3,4-dihydro-2H-1; 4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazine 1,1-dioxide; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid [German]; 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-pyridin-2-yl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
DMTK234 CP Pfizer Pharmaceuticals
DMTK234 TC Analgesics
DMTK234 DT Small molecular drug
DMTK234 PC 54676228
DMTK234 MW 331.3
DMTK234 FM C15H13N3O4S
DMTK234 IC InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
DMTK234 CS CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
DMTK234 IK QYSPLQLAKJAUJT-UHFFFAOYSA-N
DMTK234 IU 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1lambda6,2-benzothiazine-3-carboxamide
DMTK234 CA CAS 36322-90-4
DMTK234 CB CHEBI:8249
DMTK234 DE Pain
DMMOFHT ID DMMOFHT
DMMOFHT DN Pirprofen
DMMOFHT HS Approved
DMMOFHT SN Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei
DMMOFHT DT Small molecular drug
DMMOFHT PC 35935
DMMOFHT MW 251.71
DMMOFHT FM C13H14ClNO2
DMMOFHT IC InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
DMMOFHT CS CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O
DMMOFHT IK PIDSZXPFGCURGN-UHFFFAOYSA-N
DMMOFHT IU 2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid
DMMOFHT CA CAS 31793-07-4
DMMOFHT CB CHEBI:135028
DMMOFHT DE Dysmenorrhea
DMJH792 ID DMJH792
DMJH792 DN Pitavastatin
DMJH792 HS Approved
DMJH792 SN Pitavastatin; Itavastatin; Livalo; NK 104; Pitavastatin [INN]; Pitavastatin calcium; UNII-M5681Q5F9P; NK-104; C25H24FNO4; M5681Q5F9P; Zypitamag; Flovas; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; P 872441; P-872441; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; ( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid; NK 104 (acid); Pitavastatin calcium (JAN)
DMJH792 PC 5282452
DMJH792 MW 421.5
DMJH792 FM C25H24FNO4
DMJH792 IC InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1
DMJH792 CS C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F
DMJH792 IK VGYFMXBACGZSIL-MCBHFWOFSA-N
DMJH792 IU (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
DMJH792 CA CAS 147511-69-1
DMJH792 CB CHEBI:32020
DMJH792 DE Primary hyperlipidemia and mixed dyslipidemia
DM1UJO0 ID DM1UJO0
DM1UJO0 DN Pitavastatin calcium
DM1UJO0 HS Approved
DM1UJO0 SN Livalo; Pitavastatin calcium; 147526-32-7; Pitavastatin hemicalcium; NK-104; Nisvastatin; UNII-IYD54XEG3W; Flovas; IYD54XEG3W; 2C25H23FNO4Ca; CHEBI:71258; NK 104 (acid); Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate; AK-50694; Itavastatin calcium; Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt; Pitavastatin calcium (JAN); Alipza; Livazo; P-872441; P 872441; 6-Heptenoic acid,
DM1UJO0 DT Small molecular drug
DM1UJO0 PC 5282451
DM1UJO0 MW 881
DM1UJO0 FM C50H46CaF2N2O8
DM1UJO0 IC InChI=1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1
DM1UJO0 CS C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2]
DM1UJO0 IK RHGYHLPFVJEAOC-FFNUKLMVSA-L
DM1UJO0 IU calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
DM1UJO0 CA CAS 147526-32-7
DM1UJO0 CB CHEBI:71258
DM1UJO0 DE Dyslipidemia
DM8RFNJ ID DM8RFNJ
DM8RFNJ DN Pitolisant
DM8RFNJ HS Approved
DM8RFNJ SN Pitolisant; 362665-56-3; TIPROLISANT; BF2.649; UNII-4BC83L4PIY; 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine; Pitolisant (BF2.649); 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine; 4BC83L4PIY; Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-; CHEMBL462605; wakix; 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride; 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine; Tirolisant; Pitolisant (INN); tiprolisant [USAN]; Wakix (TN); Pitolisant [USAN:INN]; SCHEMBL117648; GTPL8924; CTK1B6404; HBS-101
DM8RFNJ CP Bioprojet; Ferrer
DM8RFNJ DT Small molecular drug
DM8RFNJ PC 9948102
DM8RFNJ MW 295.8
DM8RFNJ FM C17H26ClNO
DM8RFNJ IC InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2
DM8RFNJ CS C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
DM8RFNJ IK NNACHAUCXXVJSP-UHFFFAOYSA-N
DM8RFNJ IU 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
DM8RFNJ CA CAS 362665-56-3
DM8RFNJ CB CHEBI:134709
DM8RFNJ DE Schizophrenia; Excessive daytime sleepiness
DMX8CVY ID DMX8CVY
DMX8CVY DN Pivampicillin
DMX8CVY HS Approved
DMX8CVY SN Pivaloylampicillin; Pivampicilina; Pivampicilline; Pivampicillinum; Pondocillin; Ampicillin Pivaloyl Ester; Ampicillin pivaloyloxymethyl ester; Pivaloyloxymethyl ampicillinate; Pivampicillin Monohydrochloride; MK 191; Pivampicilina [INN-Spanish]; Pivampicillin (INN); Pivampicillin [INN:BAN]; Pivampicilline [INN-French]; Pivampicillinum [INN-Latin]; Pondocillin (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylate; 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMX8CVY TC Antibiotics
DMX8CVY DT Small molecular drug
DMX8CVY PC 33478
DMX8CVY MW 463.5
DMX8CVY FM C22H29N3O6S
DMX8CVY IC InChI=1S/C22H29N3O6S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26)/t13-,14-,15+,18-/m1/s1
DMX8CVY CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OCOC(=O)C(C)(C)C)C
DMX8CVY IK ZEMIJUDPLILVNQ-ZXFNITATSA-N
DMX8CVY IU 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMX8CVY CA CAS 33817-20-8
DMX8CVY CB CHEBI:8255
DMX8CVY DE Bacterial infection
DMDU0BV ID DMDU0BV
DMDU0BV DN Pivmecillinam
DMDU0BV HS Approved
DMDU0BV SN Coactabs; PMPC; Pivamdinocillin; Pivmecilinamo; Pivmecillinamum; Selexid; Amdinocillin Pivoxil; Amdinocillin pivoxil [USAN]; Mecillinam Pivaloyl Ester; Amdinocillin pivoxil (USAN); Amdinocillin, pivaloyloxymethyl ester; Coactabs (TN); Penomax (TN); Pivmecilinamo [INN-Spanish]; Pivmecillinam (INN); Pivmecillinamum [INN-Latin]; Ro 10-9071; Selexid (TN); [(2,2-dimethylpropanoyl)oxy]methyl 6beta-[(azepan-1-ylmethylidene)amino]-2,2-dimethylpenam-3alpha-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-[(azepan-1-ylmethylidene)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; [(2,2-dimethylpropanoyl)oxy]methyl(2s,5r,6r)-6-{[(e)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; Hydroxymethyl (2S,5R,6R)-6-(((hexahydro-1H-azepin-1-yl)methylene)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate pivalate (ester); 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 2,2-dimethylpropanoyloxymethyl (5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMDU0BV TC Antibiotics
DMDU0BV DT Small molecular drug
DMDU0BV PC 115163
DMDU0BV MW 439.6
DMDU0BV FM C21H33N3O5S
DMDU0BV IC InChI=1S/C21H33N3O5S/c1-20(2,3)19(27)29-13-28-18(26)15-21(4,5)30-17-14(16(25)24(15)17)22-12-23-10-8-6-7-9-11-23/h12,14-15,17H,6-11,13H2,1-5H3/t14-,15+,17-/m1/s1
DMDU0BV CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C
DMDU0BV IK NPGNOVNWUSPMDP-HLLBOEOZSA-N
DMDU0BV IU 2,2-dimethylpropanoyloxymethyl (2S,5R,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMDU0BV CA CAS 32886-97-8
DMDU0BV CB CHEBI:51210
DMDU0BV DE Urinary tract infection
DMV74ZH ID DMV74ZH
DMV74ZH DN Pizotyline
DMV74ZH HS Approved
DMV74ZH SN Pizotifen; PIZOTYLINE; 15574-96-6; Sandomigran; Litec; Sandomygran; Pizotifenum; Pizotifeno; Polomigran; Pizotifene; BC-105; BC 105; Pizotyline [USAN]; Pizotifan; Pizotifene [INN-French]; Pizotifenum [INN-Latin]; Pizotifeno [INN-Spanish]; UNII-0BY8440V3N; EINECS 239-632-9; BRN 0753534; C19H21NS; CHEBI:50212; FIADGNVRKBPQEU-UHFFFAOYSA-N; Pizotifen (INN); Pizotifen [INN]; 0BY8440V3N; Pizotyline (USAN); 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)-1-methylpiperidine
DMV74ZH DT Small molecular drug
DMV74ZH PC 27400
DMV74ZH MW 295.4
DMV74ZH FM C19H21NS
DMV74ZH IC InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3
DMV74ZH CS CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1
DMV74ZH IK FIADGNVRKBPQEU-UHFFFAOYSA-N
DMV74ZH IU 1-methyl-4-(6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-2-ylidene)piperidine
DMV74ZH CA CAS 15574-96-6
DMV74ZH CB CHEBI:50212
DMV74ZH DE Headache
DMKMBES ID DMKMBES
DMKMBES DN Plazomicin
DMKMBES HS Approved
DMKMBES SN ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,
DMKMBES CP Achaogen
DMKMBES DT Small molecular drug
DMKMBES PC 42613186
DMKMBES MW 592.7
DMKMBES FM C25H48N6O10
DMKMBES IC InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1
DMKMBES CS C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O
DMKMBES IK IYDYFVUFSPQPPV-PEXOCOHZSA-N
DMKMBES IU (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
DMKMBES CA CAS 1154757-24-0
DMKMBES DE Urinary tract infection; Prostate disease; Bronchitis; Pancreatic cancer
DMKEX7O ID DMKEX7O
DMKEX7O DN Plecanatide
DMKEX7O HS Approved
DMKEX7O SN Trulance
DMKEX7O CP Synergy Pharmaceuticals
DMKEX7O DT Small molecular drug
DMKEX7O PC 70693500
DMKEX7O MW 1681.9
DMKEX7O FM C65H104N18O26S4
DMKEX7O IC InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1
DMKEX7O CS C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N
DMKEX7O IK NSPHQWLKCGGCQR-DLJDZFDSSA-N
DMKEX7O IU (2S)-2-[[(1R,4S,7S,10S,13S,16R,19S,22S,25R,32S,38R)-10-(2-amino-2-oxoethyl)-25-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-22-(2-carboxyethyl)-32-[(1R)-1-hydroxyethyl]-4-methyl-19-(2-methylpropyl)-3,6,9,12,15,18,21,24,30,33,36-undecaoxo-7,13-di(propan-2-yl)-27,28,40,41-tetrathia-2,5,8,11,14,17,20,23,31,34,37-undecazabicyclo[14.13.13]dotetracontane-38-carbonyl]amino]-4-methylpentanoic acid
DMKEX7O CA CAS 467426-54-6
DMKEX7O DE Irritable bowel syndrome; Chronic idiopathic constipation; Crohn disease
DMAKXW9 ID DMAKXW9
DMAKXW9 DN PLEGRIDY
DMAKXW9 HS Approved
DMAKXW9 SN Peginterferon beta-1a
DMAKXW9 CP Biogen Idec
DMAKXW9 SQ Sequence: MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
DMAKXW9 DE Multiple sclerosis
DMCJN1P ID DMCJN1P
DMCJN1P DN Plerixafor
DMCJN1P HS Approved
DMCJN1P SN Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
DMCJN1P CP Genzyme
DMCJN1P DT Small molecular drug
DMCJN1P PC 65015
DMCJN1P MW 502.8
DMCJN1P FM C28H54N8
DMCJN1P IC InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
DMCJN1P CS C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3
DMCJN1P IK YIQPUIGJQJDJOS-UHFFFAOYSA-N
DMCJN1P IU 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
DMCJN1P CA CAS 110078-46-1
DMCJN1P CB CHEBI:125354
DMCJN1P DE Non-hodgkin lymphoma
DM7C8YV ID DM7C8YV
DM7C8YV DN Plicamycin
DM7C8YV HS Approved
DM7C8YV SN A-2371; NSC24559; PA-144; MTM A; AC1O3EQZ; CHEMBL413720; SCHEMBL14066059; NSC-24559; AKOS030213136; EC-7071; CCG-208236; NCGC00160390-01; NCI60_004287; AB01273958-01
DM7C8YV DT Small molecular drug
DM7C8YV PC 163659
DM7C8YV MW 1085.1
DM7C8YV FM C52H76O24
DM7C8YV IC InChI=1S/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27+,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43-,44-,45+,49+,50+,51-,52+/m1/s1
DM7C8YV CS C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@H]([C@H](O7)C)O)O[C@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O
DM7C8YV IK CFCUWKMKBJTWLW-BKHRDMLASA-N
DM7C8YV IU (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one
DM7C8YV CA CAS 18378-89-7
DM7C8YV CB CHEBI:31856
DM7C8YV DE Lung cancer; Ovarian cancer; Testicular cancer; Hypercalcaemia; Solid tumour/cancer
DMG8MLJ ID DMG8MLJ
DMG8MLJ DN Pneumococcal 13-valent conjugate vaccine
DMG8MLJ HS Approved
DMG8MLJ SN Prevnar 13 (TN)
DMG8MLJ CP Pfizer
DMG8MLJ DE Streptococcus infection
DMT2EJP ID DMT2EJP
DMT2EJP DN Podofilox
DMT2EJP HS Approved
DMT2EJP SN podophyllotoxin; 518-28-5; Condylox; Condyline; Wartec; Podophyllotoxin 7; Podophyllinic acid lactone; Warticon; (-)-Podophyllotoxin; Podofilox [USAN]; CCRIS 565; UNII-L36H50F353; Podophyllotoxin, 95%; HSDB 7238; NSC24818; CHEMBL61; EINECS 208-250-4; NSC 24818; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; MLS000069495; AI3-50456; CHEBI:50305; Podofilox (USAN); L36H50F353; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,; Podophyllotoxin
DMT2EJP CP Actavis Laboratories Ut Inc
DMT2EJP DT Small molecular drug
DMT2EJP PC 10607
DMT2EJP MW 414.4
DMT2EJP FM C22H22O8
DMT2EJP IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1
DMT2EJP CS COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
DMT2EJP IK YJGVMLPVUAXIQN-XVVDYKMHSA-N
DMT2EJP IU (5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMT2EJP CA CAS 518-28-5
DMT2EJP CB CHEBI:50305
DMT2EJP DE External genital and perianal wart; Condyloma; Verruca vulgaris
DMF6Y0L ID DMF6Y0L
DMF6Y0L DN Polatuzumab vedotin
DMF6Y0L HS Approved
DMF6Y0L CP Genentech
DMF6Y0L DT Antibody
DMF6Y0L DE Follicular lymphoma; Haematological malignancy; Diffuse large B-cell lymphoma
DMH1KMT ID DMH1KMT
DMH1KMT DN Polidocanol
DMH1KMT HS Approved
DMH1KMT SN Asclera (TN)
DMH1KMT CP Chemisch FBRK KRSSLR
DMH1KMT DT Small molecular drug
DMH1KMT PC 656641
DMH1KMT MW 582.8
DMH1KMT FM C30H62O10
DMH1KMT IC InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3
DMH1KMT CS CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
DMH1KMT IK ONJQDTZCDSESIW-UHFFFAOYSA-N
DMH1KMT IU 2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
DMH1KMT CA CAS 3055-99-0
DMH1KMT CB CHEBI:46859
DMH1KMT DE Reticular veins; Spider veins
DMUCWEX ID DMUCWEX
DMUCWEX DN Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
DMUCWEX HS Approved
DMUCWEX SN Aethoxysklerol; Asclera
DMUCWEX DT Small molecular drug
DMUCWEX PC 24750
DMUCWEX MW 230.39
DMUCWEX FM C14H30O2
DMUCWEX IC InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3
DMUCWEX CS CCCCCCCCCCCCOCCO
DMUCWEX IK SFNALCNOMXIBKG-UHFFFAOYSA-N
DMUCWEX IU 2-dodecoxyethanol
DMUCWEX CA CAS 4536-30-5
DMUCWEX CB CHEBI:78770
DMUCWEX DE Varicose veins
DM0PMGJ ID DM0PMGJ
DM0PMGJ DN Polyestradiol Phosphate
DM0PMGJ HS Approved
DM0PMGJ SN Estradurin
DM0PMGJ CP Wyeth Ayerst Laboratories
DM0PMGJ TC Anticancer Agents
DM0PMGJ DT Small molecular drug
DM0PMGJ PC 66435
DM0PMGJ MW 352.4
DM0PMGJ FM C18H25O5P
DM0PMGJ IC InChI=1S/C18H25O5P/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(20,21)22/h3,5,10,14-17,19H,2,4,6-9H2,1H3,(H2,20,21,22)/t14-,15-,16+,17+,18+/m1/s1
DM0PMGJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)O
DM0PMGJ IK BBWXLCKRYRQQPL-ZBRFXRBCSA-N
DM0PMGJ IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] dihydrogen phosphate
DM0PMGJ CA CAS 4995-43-1
DM0PMGJ DE Prostate cancer
DM4I1JP ID DM4I1JP
DM4I1JP DN Polyethylene glycol
DM4I1JP HS Approved
DM4I1JP SN ETHYLENE GLYCOL; Ethane-1,2-diol; 1,2-ethanediol; 107-21-1; glycol; monoethylene glycol; 1,2-Dihydroxyethane; 2-hydroxyethanol; Glycol alcohol; polyethylene glycol; Ethylene alcohol; Macrogol; Fridex; Tescol; Ethylene dihydrate; Norkool; Macrogol 400 BPC; Dowtherm SR 1; Zerex; Ucar 17; Lutrol-9; ethyleneglycol; ethanediol; Aethylenglykol; Polyethylene glycol 200; Glycol, ethylene-; 1,2-Ethandiol; Glycols, polyethylene; Caswell No. 441; Ethylenglycol; Lutrol; Aethylenglykol [German]; Polyethylene glycol 600; 146AR; UNII-FC72KVT52F
DM4I1JP DT Small molecular drug
DM4I1JP PC 174
DM4I1JP MW 62.07
DM4I1JP FM C2H6O2
DM4I1JP IC InChI=1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2
DM4I1JP CS C(CO)O
DM4I1JP IK LYCAIKOWRPUZTN-UHFFFAOYSA-N
DM4I1JP IU ethane-1,2-diol
DM4I1JP CA CAS 107-21-1
DM4I1JP CB CHEBI:30742
DM4I1JP DE Constipation
DMN0LP8 ID DMN0LP8
DMN0LP8 DN Polymyxin B Sulfate
DMN0LP8 HS Approved
DMN0LP8 SN Aerosporin; Polimixina B; Polymixin B sulfate; Polymxin B sulfate; Polymyxin b; Polymyxine B; Polymyxinum B; Terramycin Ophthalmic; Polimixina B [INN-Spanish]; Polymyxin B Sulfate [USAN:JAN]; Polymyxin B, sulfate; Polymyxine B [INN-French]; Polymyxinum B [INN-Latin]; Aerosporin, PMB, Poly-RX,Polymyxin B sulphate; 4-amino-N-[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(2-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-4-hydroxy-1-oxobutan-2-yl]-2-formamidobutanamide
DMN0LP8 TC Antibiotics
DMN0LP8 DT Small molecular drug
DMN0LP8 PC 5702105
DMN0LP8 MW 1301.6
DMN0LP8 FM C56H100N16O17S
DMN0LP8 IC InChI=1S/C56H98N16O13.H2O4S/c1-7-32(4)13-11-12-16-44(75)63-36(17-23-57)51(80)72-46(34(6)74)56(85)68-39(20-26-60)48(77)67-41-22-28-62-55(84)45(33(5)73)71-52(81)40(21-27-61)65-47(76)37(18-24-58)66-53(82)42(29-31(2)3)69-54(83)43(30-35-14-9-8-10-15-35)70-49(78)38(19-25-59)64-50(41)79;1-5(2,3)4/h8-10,14-15,31-34,36-43,45-46,73-74H,7,11-13,16-30,57-61H2,1-6H3,(H,62,84)(H,63,75)(H,64,79)(H,65,76)(H,66,82)(H,67,77)(H,68,85)(H,69,83)(H,70,78)(H,71,81)(H,72,80);(H2,1,2,3,4)
DMN0LP8 CS CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O.OS(=O)(=O)O
DMN0LP8 IK HFMDLUQUEXNBOP-UHFFFAOYSA-N
DMN0LP8 IU N-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide;sulfuric acid
DMN0LP8 CA CAS 1405-20-5
DMN0LP8 DE Pseudomonas infection
DMJAOT1 ID DMJAOT1
DMJAOT1 DN Polyoxidonium
DMJAOT1 HS Approved
DMJAOT1 CP Immutic Group
DMJAOT1 DE Infectious disease
DMCH80F ID DMCH80F
DMCH80F DN Polythiazide
DMCH80F HS Approved
DMCH80F SN Drenusil; Nephril; Politiazida; Polythiazidum; Renese; P 2525; P-2525; Politiazida [INN-Spanish]; Polythiazidum [INN-Latin]; Renese (TN); Polythiazide (JAN/USAN/INN); Polythiazide [USAN:INN:BAN:JAN]; 2-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide (8CI, 9CI); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-2-methyl-7-sulphamoyl-3-(2,2,2-trifluoroethylthiomethyl)-2H-benzo-1,2,4-thiadiazine 1,1-dioxide; 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1; 6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)thio]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
DMCH80F TC Antihypertensive Agents
DMCH80F DT Small molecular drug
DMCH80F PC 4870
DMCH80F MW 439.9
DMCH80F FM C11H13ClF3N3O4S3
DMCH80F IC InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)
DMCH80F CS CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F
DMCH80F IK CYLWJCABXYDINA-UHFFFAOYSA-N
DMCH80F IU 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMCH80F CA CAS 346-18-9
DMCH80F CB CHEBI:8327
DMCH80F DE Edema; Hypertension
DMTGBAX ID DMTGBAX
DMTGBAX DN Pomalidomide
DMTGBAX HS Approved
DMTGBAX SN Actimid (TN); Pomalidomide (Immunomodulator)
DMTGBAX CP Celgene
DMTGBAX DT Small molecular drug
DMTGBAX PC 134780
DMTGBAX MW 273.24
DMTGBAX FM C13H11N3O4
DMTGBAX IC InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
DMTGBAX CS C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
DMTGBAX IK UVSMNLNDYGZFPF-UHFFFAOYSA-N
DMTGBAX IU 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DMTGBAX CA CAS 19171-19-8
DMTGBAX CB CHEBI:72690
DMTGBAX DE Systemic sclerosis
DMYGJQO ID DMYGJQO
DMYGJQO DN Ponatinib
DMYGJQO HS Approved
DMYGJQO SN Iclusig (TN)
DMYGJQO CP ARIAD Pharmaceuticals
DMYGJQO DT Small molecular drug
DMYGJQO PC 24826799
DMYGJQO MW 532.6
DMYGJQO FM C29H27F3N6O
DMYGJQO IC InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
DMYGJQO CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
DMYGJQO IK PHXJVRSECIGDHY-UHFFFAOYSA-N
DMYGJQO IU 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMYGJQO CA CAS 943319-70-8
DMYGJQO CB CHEBI:78543
DMYGJQO DE Acute lymphoblastic leukaemia
DMEAOYJ ID DMEAOYJ
DMEAOYJ DN Ponesimod
DMEAOYJ HS Approved
DMEAOYJ SN 854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-
DMEAOYJ CP Actelion Pharmaceuticals South San Francisco, CA
DMEAOYJ DT Small molecular drug
DMEAOYJ PC 11363176
DMEAOYJ MW 461
DMEAOYJ FM C23H25ClN2O4S
DMEAOYJ IC InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
DMEAOYJ CS CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
DMEAOYJ IK LPAUOXUZGSBGDU-ULCCENQXSA-N
DMEAOYJ IU (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
DMEAOYJ CA CAS 854107-55-4
DMEAOYJ DE Psoriasis vulgaris; Multiple sclerosis
DM7ZWNY ID DM7ZWNY
DM7ZWNY DN Porfimer Sodium
DM7ZWNY HS Approved
DM7ZWNY SN Photofrin
DM7ZWNY CP Concordia Laboratories Inc
DM7ZWNY DT Small molecular drug
DM7ZWNY DE Non-small-cell lung cancer
DMUL5EW ID DMUL5EW
DMUL5EW DN Posaconazole
DMUL5EW HS Approved
DMUL5EW SN Noxafil; Spriafil; Posaconazole SP; Posaconazole in combination with MGCD290; SCH56592; Sch 56592; X2N; Noxafil (TN); Noxafil, Posaconazole; SCH-56592; Posaconazole (USAN/INN); Posaconazole [USAN:INN:BAN]; 1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one; 4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one; 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
DMUL5EW CP Schering-Plough
DMUL5EW TC Antifungal Agents
DMUL5EW DT Small molecular drug
DMUL5EW PC 468595
DMUL5EW MW 700.8
DMUL5EW FM C37H42F2N8O4
DMUL5EW IC InChI=1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
DMUL5EW CS CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMUL5EW IK RAGOYPUPXAKGKH-XAKZXMRKSA-N
DMUL5EW IU 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one
DMUL5EW CA CAS 171228-49-2
DMUL5EW CB CHEBI:64355
DMUL5EW DE Aspergillosis
DMMTAJC ID DMMTAJC
DMMTAJC DN Potassium chloride
DMMTAJC HS Approved
DMMTAJC SN Acronitol; Celeka; Chloropotassuril; Chlorvescent; Durekal; Durules; Enpott; Enseal; Infalyte; KCL; KSR; Kadalex; Kalcorid; Kaleorid; Kaleorod; Kaliduron; Kaliglutol; Kalilente; Kalinorm; Kaliolite; Kalipor; Kalipoz; Kalitabs; Kaliumchlorid; Kaochlor; Kaskay; Kato; Kayback; Kayciel; Kaysiel; Keylyte; Kloren; Klorvess; Klotrix; Kolyum; Miopotasio; Neobakasal; Pfiklor; Potasion; Potasol; Potavescent; Rekawan; Selora; Steropotassium; Sylvite; [KCl]; Chlorid draselny; Chlorid draselny [Czech]; Chloride of potash; Conductance standard solution; Dipotassium dichloride; Emplets potassium chloride; K Tab; KCL Retard; KM potassium chloride; Kalinorm Depottab; Kalitrans Retard; Kalium Duriles; Kalium Durules; Kalium Retard; Kalium SR; Kaon Cl; Kaon Ultra; Kay Ciel; Kelp salt; Leo K; Monopotassium chloride; Muriate of potash; Natural sylvite; Plus Kalium Retard; Potassium Chloride BP; Potassium Chloride in Plastic Container; Potassium Cl; Potassium chloride [JAN]; Potassium chloride solution; Potassium chloride standard; Potassium monochloride; Potassium muriate; Rekawan Retard; Repone K; Sal digestnum sylvii; Super K; Tripotassium trichloride; Trona muriate of potash; Trona potassium chloride; Ultra K Chlor; IN2900; Potassium Chloride 10meq in Plastic Container; Potassium chloride 20meq inplastic container; Potassium chloride 30meq in plastic container; Potassium chloride 40meq in plastic container; Addi-K; Apo-K; Cena-K; Chloride, Potassium; Chloropotassuril diffu-K; Diffu-K; Duffi-K; Durules-K; K+10; K+8; K-10; K-Care; K-Contin; K-Dur; K-Grad; K-Lease; K-Lor; K-Lyte Cl; K-Norm; K-SR; K-Sol; K-Tab; K. tab; KCL (TN); KCl-retard Zyma; Kalinor-Retard P; Kalium S.R; Kalium-Durettes; Kalium-R; Kalium-duriles; Kaon Cl-10; Kaon-Cl; Kaon-Cl 10; Kaon-Cl TABS; Kaon-ci; Kay-Ciel; Kay-EM; Klor-Con; Klor-Con M10; Klor-Con M15; Klor-Con M20; Klor-Lyte; Klotrix (TN); Lento-K; Lento-Kalium; Leo-K; Micro-K; Micro-K 10; Micro-K Extentcaps; Micro-K LS; Micro-Kalium Retard; Nu-K; POTASSIUM CHLORIDE, ACS; Peter-kal; Potassium atomic spectroscopy standard concentrate 1.00 g K; Potassium chloride (K3Cl3); Potassium chloride (KCl); Potassium standard concentrate 10.00 g K; Potassium thallium chloride (KTlCl); Repone-K; Rum-K; Sando-K; Slow-K; Slow-K tablets; Span-K; Super K (salt); Ten-K; Clor-K-Zaf; Hydrochloric acid potassium salt (1:1); ISA (ionic strength adjustment solution: 1 M KCl); K-Lyte/Cl; K-Predne-Dome; K-dur (TN); K-lyte/C1; Kalium S.R.; Kaon-Cl (TN); Kay-Cee-L; Klor-con (TN); Potassium chloride (JP15/USP); Ultra-K-Chlor; Conductivity Standard Solution, 1413-S/cm; Conductivity Standard Solution, 500-S/cm; POTASSIUM CHLORIDE, U.S.P.; 11118_FLUKA
DMMTAJC TC Dietary supplement
DMMTAJC DT Small molecular drug
DMMTAJC PC 4873
DMMTAJC MW 74.55
DMMTAJC FM ClK
DMMTAJC IC InChI=1S/ClH.K/h1H;/q;+1/p-1
DMMTAJC CS [Cl-].[K+]
DMMTAJC IK WCUXLLCKKVVCTQ-UHFFFAOYSA-M
DMMTAJC IU potassium;chloride
DMMTAJC CA CAS 7447-40-7
DMMTAJC CB CHEBI:32588
DMMTAJC DE Hypokalemia
DMGLZ26 ID DMGLZ26
DMGLZ26 DN Practolol
DMGLZ26 HS Approved
DMGLZ26 SN Dalzic; Eraldin; Practololo; Practololum; Praktololu; Teranol; Eralzdin Practolol; Practololo [DCIT]; Praktololu [Polish]; AY 21011; Cardiol (TN); Cordialina (TN); Dalzic (TN); Eraldin (TN); Eraldina (TN); Practololum [INN-Latin]; Praktol (TN); Pralon (TN); Teranol (TN); Practolol [USAN:BAN:INN]; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; (+-)-Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide
DMGLZ26 TC Antiarrhythmic Agents
DMGLZ26 DT Small molecular drug
DMGLZ26 PC 4883
DMGLZ26 MW 266.34
DMGLZ26 FM C14H22N2O3
DMGLZ26 IC InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
DMGLZ26 CS CC(C)NCC(COC1=CC=C(C=C1)NC(=O)C)O
DMGLZ26 IK DURULFYMVIFBIR-UHFFFAOYSA-N
DMGLZ26 IU N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
DMGLZ26 CA CAS 6673-35-4
DMGLZ26 CB CHEBI:258351
DMGLZ26 DE Cardiac arrhythmias
DMAO80I ID DMAO80I
DMAO80I DN Pralatrexate
DMAO80I HS Approved
DMAO80I SN Folotyn (TN)
DMAO80I CP Allos Therapeutics
DMAO80I DT Small molecular drug
DMAO80I PC 148121
DMAO80I MW 477.5
DMAO80I FM C23H23N7O5
DMAO80I IC InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
DMAO80I CS C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMAO80I IK OGSBUKJUDHAQEA-WMCAAGNKSA-N
DMAO80I IU (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid
DMAO80I CA CAS 146464-95-1
DMAO80I CB CHEBI:71223
DMAO80I DE Breast cancer; Peripheral T-cell lymphoma
DMGQ0ZI ID DMGQ0ZI
DMGQ0ZI DN Pralidoxime chloride
DMGQ0ZI HS Approved
DMGQ0ZI SN Protopam Chloride
DMGQ0ZI CP Baxter Healthcare Corp Anesthesia And Critical Care
DMGQ0ZI DT Small molecular drug
DMGQ0ZI PC 135445761
DMGQ0ZI MW 172.61
DMGQ0ZI FM C7H9ClN2O
DMGQ0ZI IC InChI=1S/C7H8N2O.ClH/c1-9-5-3-2-4-7(9)6-8-10;/h2-6H,1H3;1H
DMGQ0ZI CS C[N+]1=CC=CC=C1/C=N/O.[Cl-]
DMGQ0ZI IK HIGSLXSBYYMVKI-UHFFFAOYSA-N
DMGQ0ZI IU (NE)-N-[(1-methylpyridin-1-ium-2-yl)methylidene]hydroxylamine;chloride
DMGQ0ZI CA CAS 51-15-0
DMGQ0ZI CB CHEBI:8355
DMGQ0ZI DE Poisoning due to pesticides and chemicals
DMWU0I2 ID DMWU0I2
DMWU0I2 DN Pralsetinib
DMWU0I2 HS Approved
DMWU0I2 SN GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
DMWU0I2 CP Blueprint Medicines Cambridge, MA
DMWU0I2 PC 129073603
DMWU0I2 MW 533.6
DMWU0I2 FM C27H32FN9O2
DMWU0I2 IC InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
DMWU0I2 CS CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC
DMWU0I2 IK GBLBJPZSROAGMF-SIYOEGHHSA-N
DMWU0I2 IU N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
DMWU0I2 CA CAS 2097132-94-8
DMWU0I2 DE Solid tumour/cancer; Non-small-cell lung cancer
DMNMW9R ID DMNMW9R
DMNMW9R DN Pramipexole
DMNMW9R HS Approved
DMNMW9R SN Mirapex; Pramipexol; Pramipexolum; SUD919CL2Y; Mirapex (TN); Mirapexin (TN); Pramipexole [USAN:INN]; SND-919; Sifrol(TN); U-98528E; Pramipexole (USAN/INN); (-)-Pramipexole; (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole; 111GE001; 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole; 2-amino-6-propylaminotetrahydrobenzothiazole
DMNMW9R CP Intas Pharma
DMNMW9R TC Antiparkinson Agents
DMNMW9R DT Small molecular drug
DMNMW9R PC 119570
DMNMW9R MW 211.33
DMNMW9R FM C10H17N3S
DMNMW9R IC InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
DMNMW9R CS CCCN[C@H]1CCC2=C(C1)SC(=N2)N
DMNMW9R IK FASDKYOPVNHBLU-ZETCQYMHSA-N
DMNMW9R IU (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMNMW9R CA CAS 104632-26-0
DMNMW9R CB CHEBI:8356
DMNMW9R DE Parkinson disease
DM2FHG3 ID DM2FHG3
DM2FHG3 DN Pramiracetam
DM2FHG3 HS Approved (orphan drug)
DM2FHG3 SN Amacetam; Ectapram; Neupramir; Remen; Amacetam hydrochloride; Amacetam sulfate; Pramiracetam hydrochloride; Pramiracetam sulfate; CNS-1879
DM2FHG3 CP Warner-Lambert Co
DM2FHG3 DT Small molecular drug
DM2FHG3 PC 51712
DM2FHG3 MW 269.38
DM2FHG3 FM C14H27N3O2
DM2FHG3 IC InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)
DM2FHG3 CS CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C
DM2FHG3 IK ZULJGOSFKWFVRX-UHFFFAOYSA-N
DM2FHG3 IU N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
DM2FHG3 CA CAS 68497-62-1
DM2FHG3 CB CHEBI:135110
DM2FHG3 DE Brain disease
DM0EZ9Q ID DM0EZ9Q
DM0EZ9Q DN Pramlintide
DM0EZ9Q HS Approved
DM0EZ9Q SN Symlin; Triproamylin; Pramlintide [USAN]; Pramlintide acetate; Pramlintide acetate [USAN]; Pramlintide acetate hydrate; AC 0137
DM0EZ9Q CP Amylin Pharmaceuticals
DM0EZ9Q DT Small molecular drug
DM0EZ9Q SQ Pramlintide: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY
DM0EZ9Q PC 70691388
DM0EZ9Q MW 3949
DM0EZ9Q FM C171H267N51O53S2
DM0EZ9Q IC InChI=1S/C171H267N51O53S2/c1-21-81(12)130(163(268)207-110(56-78(6)7)169(274)222-53-33-42-118(222)170(275)221-52-32-41-117(221)160(265)219-135(89(20)230)167(272)206-109(66-125(180)238)151(256)212-128(79(8)9)161(266)186-68-126(239)192-111(70-223)154(259)203-107(64-123(178)236)152(257)218-134(88(19)229)166(271)195-98(136(181)241)57-92-43-45-94(231)46-44-92)214-159(264)116-40-31-51-220(116)127(240)69-187-141(246)101(58-90-34-24-22-25-35-90)199-148(253)105(62-121(176)234)201-149(254)106(63-122(177)235)202-155(260)112(71-224)209-156(261)113(72-225)208-146(251)103(60-93-67-184-75-188-93)205-162(267)129(80(10)11)213-150(255)100(55-77(4)5)198-145(250)102(59-91-36-26-23-27-37-91)200-147(252)104(61-120(175)233)196-137(242)82(13)189-144(249)99(54-76(2)3)197-142(247)96(39-30-50-185-171(182)183)193-143(248)97(47-48-119(174)232)194-165(270)132(86(17)227)215-138(243)83(14)190-157(262)114-73-276-277-74-115(210-140(245)95(173)38-28-29-49-172)158(263)204-108(65-124(179)237)153(258)217-131(85(16)226)164(269)191-84(15)139(244)216-133(87(18)228)168(273)211-114/h22-27,34-37,43-46,67,75-89,95-118,128-135,223-231H,21,28-33,38-42,47-66,68-74,172-173H2,1-20H3,(H2,174,232)(H2,175,233)(H2,176,234)(H2,177,235)(H2,178,236)(H2,179,237)(H2,180,238)(H2,181,241)(H,184,188)(H,186,266)(H,187,246)(H,189,249)(H,190,262)(H,191,269)(H,192,239)(H,193,248)(H,194,270)(H,195,271)(H,196,242)(H,197,247)(H,198,250)(H,199,253)(H,200,252)(H,201,254)(H,202,260)(H,203,259)(H,204,263)(H,205,267)(H,206,272)(H,207,268)(H,208,251)(H,209,261)(H,210,245)(H,211,273)(H,212,256)(H,213,255)(H,214,264)(H,215,243)(H,216,244)(H,217,258)(H,218,257)(H,219,265)(H4,182,183,185)/t81-,82-,83-,84-,85+,86+,87+,88+,89+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,128-,129-,130-,131-,132-,133-,134-,135-/m0/s1
DM0EZ9Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
DM0EZ9Q IK TZIRZGBAFTZREM-MKAGXXMWSA-N
DM0EZ9Q IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide
DM0EZ9Q CA CAS 151126-32-8
DM0EZ9Q CB CHEBI:135922
DM0EZ9Q DE Type-1/2 diabetes
DMYHDCA ID DMYHDCA
DMYHDCA DN Pranlukast
DMYHDCA HS Approved
DMYHDCA SN Azlaire; Azlaire (TN); Pranlukast (INN); N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
DMYHDCA TC Antiasthmatic Agents
DMYHDCA DT Small molecular drug
DMYHDCA PC 4887
DMYHDCA MW 481.5
DMYHDCA FM C27H23N5O4
DMYHDCA IC InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
DMYHDCA CS C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5
DMYHDCA IK NBQKINXMPLXUET-UHFFFAOYSA-N
DMYHDCA IU N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide
DMYHDCA CA CAS 103177-37-3
DMYHDCA CB CHEBI:94810
DMYHDCA DE Asthma
DM67VKL ID DM67VKL
DM67VKL DN Prasterone
DM67VKL HS Approved
DM67VKL SN Dehydroepiandrosterone; DHEA; 53-43-0; PRASTERONE; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone
DM67VKL DT Small molecular drug
DM67VKL PC 5881
DM67VKL MW 288.4
DM67VKL FM C19H28O2
DM67VKL IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
DM67VKL CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)O)C
DM67VKL IK FMGSKLZLMKYGDP-USOAJAOKSA-N
DM67VKL IU (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DM67VKL CA CAS 53-43-0
DM67VKL CB CHEBI:28689
DM67VKL DE Chronic obstructive pulmonary disease; Cardiovascular disease
DM7MT6E ID DM7MT6E
DM7MT6E DN Prasugrel
DM7MT6E HS Approved
DM7MT6E SN Effient (TN)
DM7MT6E CP Lilly; Daiichi Sankyo
DM7MT6E DT Small molecular drug
DM7MT6E PC 6918456
DM7MT6E MW 373.4
DM7MT6E FM C20H20FNO3S
DM7MT6E IC InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
DM7MT6E CS CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
DM7MT6E IK DTGLZDAWLRGWQN-UHFFFAOYSA-N
DM7MT6E IU [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
DM7MT6E CA CAS 150322-43-3
DM7MT6E CB CHEBI:87723
DM7MT6E DE Acute coronary syndrome
DM6A0X7 ID DM6A0X7
DM6A0X7 DN Pravastatin
DM6A0X7 HS Approved
DM6A0X7 SN Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
DM6A0X7 CP Bristol-Myers Squibb
DM6A0X7 TC Anticholesteremic Agents
DM6A0X7 DT Small molecular drug
DM6A0X7 PC 54687
DM6A0X7 MW 424.5
DM6A0X7 FM C23H36O7
DM6A0X7 IC InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
DM6A0X7 CS CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
DM6A0X7 IK TUZYXOIXSAXUGO-PZAWKZKUSA-N
DM6A0X7 IU (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DM6A0X7 CA CAS 81093-37-0
DM6A0X7 CB CHEBI:63618
DM6A0X7 DE Hypercholesterolaemia
DMEWC7N ID DMEWC7N
DMEWC7N DN Prazepam
DMEWC7N HS Approved
DMEWC7N SN Centrax; Demetrin; Lysanxia; Prazeene; Prazene; Prazepamum; Sedapran; Settima; Trepidan; Verstran; W 4020; Centrac (TN); Centrax (TN); Demetrin (TN); K-373; Lysanxia (TN); Mono Demetrin (TN); Pozapam (TN); Prasepine (TN); Prazene (TN); Prazepamum [INN-Latin]; Reapam (TN); Trepidan (TN); W-4020; Prazepam (JP15/USAN/INN); Prazepam [USAN:INN:BAN:JAN]; 7-Chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one; 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
DMEWC7N TC Antianxiety Agents
DMEWC7N DT Small molecular drug
DMEWC7N PC 4890
DMEWC7N MW 324.8
DMEWC7N FM C19H17ClN2O
DMEWC7N IC InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
DMEWC7N CS C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4
DMEWC7N IK MWQCHHACWWAQLJ-UHFFFAOYSA-N
DMEWC7N IU 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
DMEWC7N CA CAS 2955-38-6
DMEWC7N CB CHEBI:8362
DMEWC7N DE Anxiety disorder
DMOU1PK ID DMOU1PK
DMOU1PK DN Praziquantel
DMOU1PK HS Approved
DMOU1PK SN Azinox; Biliricide; Biltricide; Cesol; Cisticid; Cutter; Cysticide; Droncit; Drontsit; Prasiquantel; Praziquantelum; Pyquiton; Traziquantel; Bayer Brand of Praziquantel; Cutter Tape Tabs; Merck Brand of Praziquantel; Embay 8440; P 4668; Bay-8440; Biltricide (TN); EMBAY-8440; NPFAPI-02; Praziquantelum [INN-Latin]; Biltricide, Droncit, Praziquantel; Praziquantel (JAN/USP/INN); Praziquantel [USAN:INN:BAN:JAN]; Praziquantel, (R)-Isomer; Praziquantel, (S)-Isomer; Praziquantel, (+-)-Isomer; (+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; (11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one; 8440, EMBAY
DMOU1PK CP Bayer Pharmaceuticals Corporation
DMOU1PK TC Anthelmintics
DMOU1PK DT Small molecular drug
DMOU1PK PC 4891
DMOU1PK MW 312.4
DMOU1PK FM C19H24N2O2
DMOU1PK IC InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
DMOU1PK CS C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
DMOU1PK IK FSVJFNAIGNNGKK-UHFFFAOYSA-N
DMOU1PK IU 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one
DMOU1PK CA CAS 55268-74-1
DMOU1PK CB CHEBI:91583
DMOU1PK DE Flatworm infection
DMCD9YG ID DMCD9YG
DMCD9YG DN Prazosin
DMCD9YG HS Approved
DMCD9YG SN Furazosin; Justac; Lentopres; Prazocin; Prazosina; Prazosine; Prazosinum; Prazosin HCl; TNP00312; CP-12299; Hypovase (TN); Minipress (TN); Prazosin (INN); Prazosin [INN:BAN]; Prazosina [INN-Spanish]; Prazosine [INN-French]; Prazosinum [INN-Latin]; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone; Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); 1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
DMCD9YG CP Pfizer Pharmaceuticals
DMCD9YG TC Antihypertensive Agents
DMCD9YG DT Small molecular drug
DMCD9YG PC 4893
DMCD9YG MW 383.4
DMCD9YG FM C19H21N5O4
DMCD9YG IC InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
DMCD9YG CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
DMCD9YG IK IENZQIKPVFGBNW-UHFFFAOYSA-N
DMCD9YG IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
DMCD9YG CA CAS 19216-56-9
DMCD9YG CB CHEBI:8364
DMCD9YG DE Congestive heart failure; Benign prostatic hyperplasia; Hypertension
DMBUNVW ID DMBUNVW
DMBUNVW DN Prednicarbate
DMBUNVW HS Approved
DMBUNVW SN Dermatop; Peitel; Dermatop (TN); Hoe-777; S-77 0777; S-770777; Prednicarbate (USP/INN); [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DMBUNVW TC Antiinflammatory Agents
DMBUNVW DT Small molecular drug
DMBUNVW PC 6714002
DMBUNVW MW 488.6
DMBUNVW FM C27H36O8
DMBUNVW IC InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1
DMBUNVW CS CCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)OCC
DMBUNVW IK FNPXMHRZILFCKX-KAJVQRHHSA-N
DMBUNVW IU [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DMBUNVW CA CAS 73771-04-7
DMBUNVW CB CHEBI:135791
DMBUNVW DE Inflammation
DMQ8FR2 ID DMQ8FR2
DMQ8FR2 DN Prednisolone
DMQ8FR2 HS Approved
DMQ8FR2 SN Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
DMQ8FR2 CP Schering Corp Sub Schering Plough Corp
DMQ8FR2 TC Anticancer Agents
DMQ8FR2 DT Small molecular drug
DMQ8FR2 PC 5755
DMQ8FR2 MW 360.4
DMQ8FR2 FM C21H28O5
DMQ8FR2 IC InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
DMQ8FR2 CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O
DMQ8FR2 IK OIGNJSKKLXVSLS-VWUMJDOOSA-N
DMQ8FR2 IU (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMQ8FR2 CA CAS 50-24-8
DMQ8FR2 CB CHEBI:8378
DMQ8FR2 DE Solid tumour/cancer; Multiple sclerosis
DM2HG4X ID DM2HG4X
DM2HG4X DN Prednisone
DM2HG4X HS Approved
DM2HG4X SN Adasone; Ancortone; Bicortone; Cartancyl; Colisone; Cortan; Cortidelt; Cotone; Dacorten; Dacortin; Decortancyl; Decortin; Decortisyl; Dehydrocortisone; Dekortin; Dellacort; Deltacortene; Deltacortisone; Deltacortone; Deltasone; Deltison; Deltisona; Deltisone; Deltra; Diadreson; Econosone; Encorton; Encortone; Enkortolon; Enkorton; Fiasone; Hostacortin; Incocortyl; Juvason; Kortancyl; Lisacort; Lodotra; Metacortandracin; Meticorten; Nisona; Nizon; Novoprednisone; Nurison; Orasone; Panafcort; Panasol; Paracort; Parmenison; Pehacort; Precort; Predeltin; Prednicorm; Prednicort; Prednicot; Prednidib; Prednilonga; Prednison; Prednisona; Prednisonum; Prednitone; Prednizon; Prednovister; Presone; Pronison; Pronisone; Rectodelt; Retrocortine; Servisone; Sone; Sterapred; Supercortil; Ultracorten; Ultracortene; Winpred; Wojtab; Zenadrid; Dellacort A; Delta E; Delta cortelan; Liquid Pred; Origen Prednisone; Prednisone Intensol; Zenadrid [veterinary]; P1276; U 6020; Apo-Prednisone; Delta E.; Delta-Cortelan; Delta-Cortisone; Delta-Cortone; Delta-Dome; Delta-E; Delta1-Cortisone; Delta1-Dehydrocortisone; Di-Adreson; In-Sone; Me-Korti; Meticortelone (TN); Meticorten (TN); Meticorten (Veterinary); Metrevet (Veterinary); Prednicen-M; Prednisona [INN-Spanish]; Prednisone [INN:BAN]; Prednisonum [INN-Latin]; SK-Prednisone; Zenadrid (veterinary); Delta(sup 1)-Cortisone; Delta(sup 1)-Dehydrocortisone; Delta(sup1)-Cortisone; Delta-1-Cortisone; Delta-1-Dehydrocortisone; Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone; (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione; (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione; (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione; 1,2-Dehydrocortisone; 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione; 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione; 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione; 1-Cortisone; 1-Dehydrocortisone; 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione; 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
DM2HG4X CP Schering-Plough
DM2HG4X TC Antiinflammatory Agents
DM2HG4X DT Small molecular drug
DM2HG4X PC 5865
DM2HG4X MW 358.4
DM2HG4X FM C21H26O5
DM2HG4X IC InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
DM2HG4X CS C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
DM2HG4X IK XOFYZVNMUHMLCC-ZPOLXVRWSA-N
DM2HG4X IU (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
DM2HG4X CA CAS 53-03-2
DM2HG4X CB CHEBI:8382
DM2HG4X DE Atopic dermatitis; Eczema; Inflammation
DMDVP3B ID DMDVP3B
DMDVP3B DN Pregabalin
DMDVP3B HS Approved
DMDVP3B SN Pregabalin CR; Pregabalin (controlled-release, oral); Pregabalin (controlled-release, oral), Pfizer
DMDVP3B CP Pfizer
DMDVP3B DT Small molecular drug
DMDVP3B PC 5486971
DMDVP3B MW 159.23
DMDVP3B FM C8H17NO2
DMDVP3B IC InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)/t7-/m0/s1
DMDVP3B CS CC(C)C[C@@H](CC(=O)O)CN
DMDVP3B IK AYXYPKUFHZROOJ-ZETCQYMHSA-N
DMDVP3B IU (3S)-3-(aminomethyl)-5-methylhexanoic acid
DMDVP3B CA CAS 148553-50-8
DMDVP3B CB CHEBI:64356
DMDVP3B DE Chronic obstructive pulmonary disease
DMYQVGN ID DMYQVGN
DMYQVGN DN Premarin/Trimegestone
DMYQVGN HS Approved
DMYQVGN SN Conjugated estrogen tablets
DMYQVGN CP Wyeth
DMYQVGN DE Menopause symptom
DMDYA31 ID DMDYA31
DMDYA31 DN Pretomanid
DMDYA31 HS Approved
DMDYA31 SN PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011
DMDYA31 DT Small molecular drug
DMDYA31 PC 456199
DMDYA31 MW 359.26
DMDYA31 FM C14H12F3N3O5
DMDYA31 IC InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
DMDYA31 CS C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
DMDYA31 IK ZLHZLMOSPGACSZ-NSHDSACASA-N
DMDYA31 IU (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
DMDYA31 CA CAS 187235-37-6
DMDYA31 DE Mycobacterium infection; Tuberculosis
DMQ0C2Z ID DMQ0C2Z
DMQ0C2Z DN Prevnar
DMQ0C2Z HS Approved
DMQ0C2Z SN Prevenar; PNCRM7; PCV-7; Polyvalent pneumococcal vaccine, Praxis; Pneumococcus/CRM-197 conjugate vaccine, Pfizer; Vaccine (pneumococcal), Praxis/American Home Products; 7vPnC, Pfizer
DMQ0C2Z CP Pfizer Vaccines
DMQ0C2Z DT Vaccine
DMQ0C2Z DE Otitis media
DMMZB0K ID DMMZB0K
DMMZB0K DN Prifinium
DMMZB0K HS Approved
DMMZB0K SN Prifinium; 10236-81-4; 3-(Benzhydrylidene)-1,1-diethyl-2-methylpyrrolidinium; Prifinum; NCGC00183859-01; EINECS 233-568-5; AC1Q1ITK; AC1L1J7T; SCHEMBL14672576; 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium; CHEMBL1229214; CTK4A0968; 3-Diphenylmethylene-1,1-diethyl-2-methylpyrrolidinium
DMMZB0K DT Small molecular drug
DMMZB0K PC 4905
DMMZB0K MW 306.5
DMMZB0K FM C22H28N+
DMMZB0K IC InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1
DMMZB0K CS CC[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)C1C)CC
DMMZB0K IK ZYEPZINLLPPBMI-UHFFFAOYSA-N
DMMZB0K IU 3-benzhydrylidene-1,1-diethyl-2-methylpyrrolidin-1-ium
DMMZB0K CA CAS 10236-81-4
DMMZB0K DE Irritable bowel syndrome
DMI7DZ2 ID DMI7DZ2
DMI7DZ2 DN Prilocaine
DMI7DZ2 HS Approved
DMI7DZ2 SN Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide
DMI7DZ2 CP Astrazeneca Lp
DMI7DZ2 TC Anesthetics
DMI7DZ2 DT Small molecular drug
DMI7DZ2 PC 4906
DMI7DZ2 MW 220.31
DMI7DZ2 FM C13H20N2O
DMI7DZ2 IC InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)
DMI7DZ2 CS CCCNC(C)C(=O)NC1=CC=CC=C1C
DMI7DZ2 IK MVFGUOIZUNYYSO-UHFFFAOYSA-N
DMI7DZ2 IU N-(2-methylphenyl)-2-(propylamino)propanamide
DMI7DZ2 CA CAS 721-50-6
DMI7DZ2 CB CHEBI:8404
DMI7DZ2 DE Pain
DMWQ16I ID DMWQ16I
DMWQ16I DN Primaquine
DMWQ16I HS Approved
DMWQ16I SN Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline
DMWQ16I CP Sanofi-Aventis
DMWQ16I TC Antimalarials
DMWQ16I DT Small molecular drug
DMWQ16I PC 4908
DMWQ16I MW 259.35
DMWQ16I FM C15H21N3O
DMWQ16I IC InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
DMWQ16I CS CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
DMWQ16I IK INDBQLZJXZLFIT-UHFFFAOYSA-N
DMWQ16I IU 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
DMWQ16I CA CAS 90-34-6
DMWQ16I CB CHEBI:8405
DMWQ16I DE Malaria
DM0WX6I ID DM0WX6I
DM0WX6I DN Primidone
DM0WX6I HS Approved
DM0WX6I SN Cyral; Desoxyphenobarbital; Desoxyphenobarbitone; Hexadiona; Lepimidin; Lepsiral; Liskantin; Majsolin; Midone; Milepsin; Misodine; Misolyne; Mizodin; Mizolin; Myidone; Mylepsin; Mylepsinum; Mysedon; Mysoline; Neurosyn; Prilepsin; Primacione; Primaclone; Primacone; Primakton; Primidon; Primidona; Primidonum; Primoline; Prysoline; Resimatil; Sertan; Apotex Brand of Primidone; Astra Brand of Primidone; AstraZeneca Brand of Primidone; Desitin Brand of Primidone; Draxis Brand of Primidone; Holsten Brand of Primidone; Pms Primidone; Primidon Holsten; Primidone Methanol Solution; Xcel Brand of Primidone; Zeneca Brand of Primidone; P 7295; Roe 101; Apo-Primidone; Hexamidine (the antispasmodic); Hexamidine(the antispasmodic); Liskantin (TN); Medi-Pets; Mylepsinum (TN); Mysoline (TN); Primidona [INN-Spanish]; Primidone (primaclone); Primidonum [INN-Latin]; Prysoline (TN); Pyrimidone Medi-pets; Resimatil (TN); Sanofi-Synthelabo Brand of Primidone; Sertan (TN); Apo-Primidone (TN); Pyrimidone (Medi-pets); Primidone (JP15/USP/INN); Primidone [USAN:INN:BAN:JAN]; 2-Deoxyphenobarbital; 2-Desoxyphenobarbital; 4,4'-(Hexamethylenedioxy)dibenzamidine; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion; 5-Aethyl-5-phenyl-hexahydropyrimidin-4,6-dion [German]; 5-Ethyl-5-phenylhexahydropyrimidine-4,6-dione; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione; 5-Ethylhexahydro-4,6-dioxo-5-phenylpyrimidine; 5-Ethylhexahydro-5-phenylpyrimidine-4,6-dione; 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6); 5-Phenyl-5-aethylhexahydropyrimidindion-(4,6) [German]; 5-Phenyl-5-ethyl-hexahydropyrimidine-4,6-dione; 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione; 5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione; 5-ethylhe xahydro-4,6-dioxo-5-phenylpyrimidine
DM0WX6I CP Rekah Pharmaceutical
DM0WX6I TC Anticonvulsants
DM0WX6I DT Small molecular drug
DM0WX6I PC 4909
DM0WX6I MW 218.25
DM0WX6I FM C12H14N2O2
DM0WX6I IC InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)
DM0WX6I CS CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
DM0WX6I IK DQMZLTXERSFNPB-UHFFFAOYSA-N
DM0WX6I IU 5-ethyl-5-phenyl-1,3-diazinane-4,6-dione
DM0WX6I CA CAS 125-33-7
DM0WX6I CB CHEBI:8412
DM0WX6I DE Epilepsy
DM9HOKG ID DM9HOKG
DM9HOKG DN Prinomastat
DM9HOKG HS Approved
DM9HOKG SN AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
DM9HOKG CP Pfizer
DM9HOKG TC Anticancer Agents
DM9HOKG DT Small molecular drug
DM9HOKG PC 466151
DM9HOKG MW 423.5
DM9HOKG FM C18H21N3O5S2
DM9HOKG IC InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
DM9HOKG CS CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=NC=C3)C(=O)NO)C
DM9HOKG IK YKPYIPVDTNNYCN-INIZCTEOSA-N
DM9HOKG IU (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
DM9HOKG CA CAS 192329-42-3
DM9HOKG CB CHEBI:138885
DM9HOKG DE Lung cancer; Brain cancer
DMMFWOJ ID DMMFWOJ
DMMFWOJ DN Probenecid
DMMFWOJ HS Approved
DMMFWOJ SN Apurina; Bencid; Benecid; Benemid; Benemide; Benuryl; Panuric; Parabenem; Probalan; Probampacin; Probecid; Proben; Probenecida; Probenecide; Probenecidum; Probenemid; Probenicid; Probenid; Probexin; Prolongine; Robenecid; Sulprin; Tubophan; Uricosid; Urocid; Biokanol Brand of Probenecid; ICN Brand of Probenecid; IDIS Brand of Probenecid; Major Brand of Probenecid; Martec Brand of Probenecid; Merck Brand of Probenecid; Ophthalmic Brand of Probenecid; Parmed Brand of Probenecid; Probenecid Major Brand; Probenecid Martec Brand; Probenecid Parmed Brand; Probenecid Weimer; Probenecid Zenith Brand; Probenecid acid; Synergid R; Valdecasas Brand of Probenecid; Zenith Brand of Probenecid; Benemid (TN); Benuryl (TN); Col-BENEMID; ColBenemid (co mponent of); ColBenemid (component of); P-[Dipropylsulfamoyl]benzoic acid; Polycillin-BRB; Pro-Cid; Probenecida [INN-Spanish]; Probenecide [INN-French]; Probenecidum [INN-Latin]; P-(Dipropylsulfamoyl)benzoic acid; P-(Dipropylsulfamyl)benzoic acid; Polycillin-PRB (component of); Probenecid [INN:BAN:JAN]; Probenecid (JP15/USP/INN); 4-((Dipropylamino)sulfonyl)benzoic acid;4-(Di-n-propylsulfamoyl)benzoesaeure; 4-(Dipropylsulfamoyl)benzoic acid; 4-(N,N-Dipropylsulfamoyl)benzoesaeure; 4-[(dipropylamino)sulfonyl]benzoic acid
DMMFWOJ TC Uricosuric Agents
DMMFWOJ DT Small molecular drug
DMMFWOJ PC 4911
DMMFWOJ MW 285.36
DMMFWOJ FM C13H19NO4S
DMMFWOJ IC InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
DMMFWOJ CS CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O
DMMFWOJ IK DBABZHXKTCFAPX-UHFFFAOYSA-N
DMMFWOJ IU 4-(dipropylsulfamoyl)benzoic acid
DMMFWOJ CA CAS 57-66-9
DMMFWOJ CB CHEBI:8426
DMMFWOJ DE Hyperuricaemia; Gout
DMVZQ2M ID DMVZQ2M
DMVZQ2M DN Probucol
DMVZQ2M HS Approved
DMVZQ2M SN Biphenabid; Bisbid; Bisphenabid; Lesterol; Lorelco; Lursell; Lurselle; Panavir; Probucolum; Sinlestal; Superlipid; Almirall Brand of Probucol; Aventis Brand of Probucol; Hoechst Brand of Probucol; DH 581; DH581; DE-3872; DH-581; LORELCO (TN); Probucolum [INN-Latin]; ZERO/001429; Probucol (JAN/USP/INN); Probucol [USAN:BAN:INN:JAN]; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol; 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; 4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]; 4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol); 4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]
DMVZQ2M TC Anticholesteremic Agents
DMVZQ2M DT Small molecular drug
DMVZQ2M PC 4912
DMVZQ2M MW 516.799
DMVZQ2M FM C31H48O2S2
DMVZQ2M IC InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3
DMVZQ2M CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
DMVZQ2M IK FYPMFJGVHOHGLL-UHFFFAOYSA-N
DMVZQ2M IU 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
DMVZQ2M CA CAS 23288-49-5
DMVZQ2M CB CHEBI:8427
DMVZQ2M DE Coronary artery disease
DMNMXR8 ID DMNMXR8
DMNMXR8 DN Procainamide
DMNMXR8 HS Approved
DMNMXR8 SN Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide
DMNMXR8 TC Antiarrhythmic Agents
DMNMXR8 DT Small molecular drug
DMNMXR8 PC 4913
DMNMXR8 MW 235.33
DMNMXR8 FM C13H21N3O
DMNMXR8 IC InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
DMNMXR8 CS CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
DMNMXR8 IK REQCZEXYDRLIBE-UHFFFAOYSA-N
DMNMXR8 IU 4-amino-N-[2-(diethylamino)ethyl]benzamide
DMNMXR8 CA CAS 51-06-9
DMNMXR8 CB CHEBI:8428
DMNMXR8 DE Ventricular arrhythmias
DM4LSNE ID DM4LSNE
DM4LSNE DN Procaine
DM4LSNE HS Approved
DM4LSNE SN Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester
DM4LSNE CP Wyeth Pharmaceuticals
DM4LSNE TC Anesthetics
DM4LSNE DT Small molecular drug
DM4LSNE PC 4914
DM4LSNE MW 236.31
DM4LSNE FM C13H20N2O2
DM4LSNE IC InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3
DM4LSNE CS CCN(CC)CCOC(=O)C1=CC=C(C=C1)N
DM4LSNE IK MFDFERRIHVXMIY-UHFFFAOYSA-N
DM4LSNE IU 2-(diethylamino)ethyl 4-aminobenzoate
DM4LSNE CA CAS 59-46-1
DM4LSNE CB CHEBI:8430
DM4LSNE DE Anaesthesia
DMIK367 ID DMIK367
DMIK367 DN Procarbazine
DMIK367 HS Approved
DMIK367 SN Ibenzmethyzin; Ibenzmethyzine; MBH; MIH; Natulan; Natulanar; PCX; Procarbazin; Procarbazina; Procarbazinum; Procarbazin [German]; Procarbazine Monohydrochloride; CB 400-497; Indicarb (TN); Matulane (TN); Natulan (TN); Procarbazina [INN-Spanish]; Procarbazine (INN); Procarbazine [INN:BAN]; Procarbazinum [INN-Latin];Ro 4-6467; SRI-10847; Ro 4-6467/1; N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine; N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide; P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide; N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide; P-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide; N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide; N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide; N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide; Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-(9CI); 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine; 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine; 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide; 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
DMIK367 CP Sigma-Tau Pharmaceuticals
DMIK367 TC Anticancer Agents
DMIK367 DT Small molecular drug
DMIK367 PC 4915
DMIK367 MW 221.3
DMIK367 FM C12H19N3O
DMIK367 IC InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
DMIK367 CS CC(C)NC(=O)C1=CC=C(C=C1)CNNC
DMIK367 IK CPTBDICYNRMXFX-UHFFFAOYSA-N
DMIK367 IU 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
DMIK367 CA CAS 671-16-9
DMIK367 CB CHEBI:71417
DMIK367 DE Hodgkin lymphoma
DM1M0Q4 ID DM1M0Q4
DM1M0Q4 DN Procaterol
DM1M0Q4 HS Approved
DM1M0Q4 SN Meptin; Procaterolo; Procaterolum; Procaterol Monohydrochloride; Procaterolo [DCIT]; Procaterolum [Latin]; Meptin (TN); OPC-2009; Procaterol (INN); Procaterol [INN:BAN]; Procaterolum [INN-Latin]; (R*,S*)-(+-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 5-[1-hydroxy-2-(propan-2-ylamino)butyl]quinoline-2,8-diol; 8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone; 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
DM1M0Q4 TC Bronchodilator Agents
DM1M0Q4 DT Small molecular drug
DM1M0Q4 PC 4916
DM1M0Q4 MW 290.36
DM1M0Q4 FM C16H22N2O3
DM1M0Q4 IC InChI=1S/C16H22N2O3/c1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15/h5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20)
DM1M0Q4 CS CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C
DM1M0Q4 IK FKNXQNWAXFXVNW-UHFFFAOYSA-N
DM1M0Q4 IU 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one
DM1M0Q4 CA CAS 60443-17-6
DM1M0Q4 CB CHEBI:91585
DM1M0Q4 DE Asthma
DM53SRA ID DM53SRA
DM53SRA DN Prochlorperazine
DM53SRA HS Approved
DM53SRA SN CHLOPERAZINE; Capazine; Chlormeprazine; Chlorperazine; Combid; Compazine; Compro; Emelent; Eskatrol; Kronocin; Meterazin; Meterazine; Nipodal; Novamin; Prochloroperazine; Prochlorpemazine; Prochlorperazin; Prochlorperazinum; Prochlorpermazine; Prochlorpromazine; Procloperazine; Proclorperazina; Proclorperazine; Stemetil; Tementil; Temetid; Vertigon; Compazine Suppositories; Prochlorperazine Edisylate Salt; Prochlorperazine dihydrobromide; Prochlorperazine dimaleate; Prochlorperazine maleate; Prochlorperazine mesilate; Bayer A 173; P77; RP 6140; SKF 4657; Buccastem (TN); Compazine (TN); Compro (TN); Phenotil (TN); Prochlorperazinum [INN-Latin]; Proclorperazina [INN-Spanish]; Stemetil (TN); Stemzine (TN); Compazine (*Maleate*); Prochlorperazine (JAN/USP/INN); Prochlorperazine [USAN:INN:BAN:JAN]; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine; Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine [French]; N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine; 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10H-phenothiazine; 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 2-Chloro-10-[3-(4-methyl-1-piper-azinyl)propyl]-10H-pheno-thiazine dimaleate; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine; 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine; 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine; 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine; 6140 RP
DM53SRA CP GlaxoSmithKline
DM53SRA TC Antipsychotic Agents
DM53SRA DT Small molecular drug
DM53SRA PC 4917
DM53SRA MW 373.9
DM53SRA FM C20H24ClN3S
DM53SRA IC InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
DM53SRA CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
DM53SRA IK WIKYUJGCLQQFNW-UHFFFAOYSA-N
DM53SRA IU 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DM53SRA CA CAS 58-38-8
DM53SRA CB CHEBI:8435
DM53SRA DE Nausea
DMHFJDT ID DMHFJDT
DMHFJDT DN Procyclidine
DMHFJDT HS Approved
DMHFJDT SN Arpicolin; Elorine; Kemadrin; Kemadrine; Lergine; Metanin; Osnervan; Prociclidina; Procidlidina; Procyclid; Procyclidinum; Procyklidin; Prosyklidin; Spamol; Triciclidina; Triciloid; Tricoloid; Tricyclamol; Vagosin; Prociclidina [INN-Spanish]; Procyclidine (INN); Procyclidine [INN:BAN]; Procyclidinum [INN-Latin]; 1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol; 1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
DMHFJDT TC Antiparkinson Agents
DMHFJDT DT Small molecular drug
DMHFJDT PC 4919
DMHFJDT MW 287.4
DMHFJDT FM C19H29NO
DMHFJDT IC InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
DMHFJDT CS C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O
DMHFJDT IK WYDUSKDSKCASEF-UHFFFAOYSA-N
DMHFJDT IU 1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
DMHFJDT CA CAS 77-37-2
DMHFJDT CB CHEBI:8448
DMHFJDT DE Parkinson disease
DMF1X5P ID DMF1X5P
DMF1X5P DN Proflavine
DMF1X5P HS Approved
DMF1X5P SN PRL; Proflavin; Proflavina; Proflavinum; Profura; Progarmed; Isoflav base; Proflavine [INN]; Proflavine hemisulfate; Proflavina [INN-Spanish]; Proflavine Hemi-Sulfate; Proflavinum [INN-Latin]; AE-562/12222295; Acridine-3,6-diamine; 2,8-Diaminoacridine; 2,8-Diaminoacridine (European); 2,8-Diaminoacridinium; 3,6-ACRIDINEDIAMINE; 3,6-Acridinediamine hydrochloride; 3,6-Diamino-acridinium; 3,6-Diaminoacridine; 3,6-Diaminoacridine sulfate; 3,6-Diaminoacridinium; 3,7-Diamino-5-azaanthracene
DMF1X5P TC Antiinfective Agents
DMF1X5P DT Small molecular drug
DMF1X5P PC 7099
DMF1X5P MW 209.25
DMF1X5P FM C13H11N3
DMF1X5P IC InChI=1S/C13H11N3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7H,14-15H2
DMF1X5P CS C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N
DMF1X5P IK WDVSHHCDHLJJJR-UHFFFAOYSA-N
DMF1X5P IU acridine-3,6-diamine
DMF1X5P CA CAS 92-62-6
DMF1X5P CB CHEBI:8452
DMF1X5P DE Sepsis
DM671NG ID DM671NG
DM671NG DN Progabide
DM671NG HS Approved
DM671NG SN Gabren; Gabrene; Halogabide; Progabida; Progabidum; SL 76002; Gabren (TN); Gabrene (TN); Progabida [INN-Spanish]; Progabidum [INN-Latin]; SL 76-002; SL-76002; Progabide (USAN/INN); Progabide [USAN:BAN:INN]; Progabide [USAN:INN:BAN]; 4-(((4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide; 4-((alpha-(p-Chlorophenyl)-5-fluorosalicylidene)amino)butyramide; 4-(alpha-(p-Chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide; 4-[[(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(Z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide
DM671NG CP Sanofi-Aventis
DM671NG TC Antidepressants
DM671NG DT Small molecular drug
DM671NG PC 44115
DM671NG MW 334.8
DM671NG FM C17H16ClFN2O2
DM671NG IC InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,22H,1-2,9H2,(H2,20,23)
DM671NG CS C1=CC(=CC=C1C(=NCCCC(=O)N)C2=C(C=CC(=C2)F)O)Cl
DM671NG IK IBALRBWGSVJPAP-UHFFFAOYSA-N
DM671NG IU 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide
DM671NG CA CAS 62666-20-0
DM671NG CB CHEBI:135422
DM671NG DE Depression
DMUY35B ID DMUY35B
DMUY35B DN Progesterone
DMUY35B HS Approved
DMUY35B SN progesterone; 57-83-0; Agolutin; Pregn-4-ene-3,20-dione; Luteohormone; Crinone; 4-Pregnene-3,20-dione; Utrogestan; Syngesterone; Progestin; Luteol; Corpus luteum hormone; Progesterol; Progesteronum; Pregnenedione; Glanducorpin; Prometrium; Corlutin; Cyclogest; Progestron; Gestormone; Progestone; Gestone; Progestasert; Progestronol; Methylpregnone; Hormoflaveine; Syngestrets; Proluton; Progekan; Nalutron; Lutoform; Gynlutin; Gesterol; Fologenon; Corporin; Corlutina; Syntolutan; Prolidon; Membrettes; Lutocyclin; Luteodyn; Lucorteum; Corluvite; LPCN-1107; Progesterone (oral, preterm labor); Progesterone (oral, preterm labor), Lipocine
DMUY35B CP Lipocine Inc
DMUY35B DT Small molecular drug
DMUY35B PC 5994
DMUY35B MW 314.5
DMUY35B FM C21H30O2
DMUY35B IC InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
DMUY35B CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMUY35B IK RJKFOVLPORLFTN-LEKSSAKUSA-N
DMUY35B IU (8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMUY35B CA CAS 57-83-0
DMUY35B CB CHEBI:17026
DMUY35B DE Premature labour; Contraception
DMBL79I ID DMBL79I
DMBL79I DN Proguanil
DMBL79I HS Approved
DMBL79I SN Bigumal; Chlorguanid; Chlorguanide; Chloriguane; Chloroguanide; Paludrin; Proguanile; Proguanilum; Proguanile [DCIT]; Diguanyl (hydrochloride); Drinupal (hydrochloride); Paludrine (TN); Paludrine (hydrochloride); Palusil (hydrochloride); Proguanil [INN:BAN]; Proguanilum [INN-Latin]; RP-3359; Tirian (hydrochloride); M-4888 (hydrochloride); SN-12837 (hydrochloride); N1-p-Chlorophenyl-N5-isopropylbiguanide; N-(4-Chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide; N-(4-Chlorophenyl)-N'-(isopropyl)-imidodicarbonimidic diamide; N-(4-chlorophenyl)-N'-(propan-2-yl)imidodicarbonimidic diamide; (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine; 1-(p-Chlorophenyl)-5-isopropylbiguanide; 1-Isopropyl-5-(4-chlorophenyl)biguanide
DMBL79I CP AstraZeneca
DMBL79I TC Antimalarials
DMBL79I DT Small molecular drug
DMBL79I PC 6178111
DMBL79I MW 253.73
DMBL79I FM C11H16ClN5
DMBL79I IC InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)
DMBL79I CS CC(C)N=C(N)/N=C(\\N)/NC1=CC=C(C=C1)Cl
DMBL79I IK SSOLNOMRVKKSON-UHFFFAOYSA-N
DMBL79I IU (1E)-1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine
DMBL79I CA CAS 500-92-5
DMBL79I CB CHEBI:8455
DMBL79I DE Malaria
DMYSCIL ID DMYSCIL
DMYSCIL DN Prolastin
DMYSCIL HS Approved
DMYSCIL SN Prolastin-C; TAL-6004; Alpha-1 antitrypsin, Bayer; Alpha-1 antitrypsin, Talecris/Crucell; Alpha-1 proteinaseinhibitor (human), Bayer
DMYSCIL CP Bayer AG
DMYSCIL DE Alpha-1 antitrypsin deficiency
DMMJ1IS ID DMMJ1IS
DMMJ1IS DN Prolixin decanoate
DMMJ1IS HS Approved
DMMJ1IS SN Modecate; Dapotum D; Flufenazine decanoate; Fluorophenazine decanoate; Fluphenaline decanoate; Fluphenazine decanoate; Fluphenazine depot; Moditen depot; Fluphenazine O-decanoate; Moditen-depo; Prolixin decanoate (TN); SQ 10,733; Fluphenazine decanoate (JAN/USP); Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester; 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl decanoate; 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate; 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
DMMJ1IS TC Antipsychotic Agents
DMMJ1IS DT Small molecular drug
DMMJ1IS PC 3388
DMMJ1IS MW 591.8
DMMJ1IS FM C32H44F3N3O2S
DMMJ1IS IC InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3
DMMJ1IS CS CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
DMMJ1IS IK VIQCGTZFEYDQMR-UHFFFAOYSA-N
DMMJ1IS IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate
DMMJ1IS CA CAS 5002-47-1
DMMJ1IS CB CHEBI:5124
DMMJ1IS DE Schizophrenia
DMZAL7W ID DMZAL7W
DMZAL7W DN Promazine
DMZAL7W HS Approved
DMZAL7W SN Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
DMZAL7W CP Wyeth Pharmaceuticals
DMZAL7W TC Antipsychotic Agents
DMZAL7W DT Small molecular drug
DMZAL7W PC 4926
DMZAL7W MW 284.4
DMZAL7W FM C17H20N2S
DMZAL7W IC InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
DMZAL7W CS CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
DMZAL7W IK ZGUGWUXLJSTTMA-UHFFFAOYSA-N
DMZAL7W IU N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine
DMZAL7W CA CAS 58-40-2
DMZAL7W CB CHEBI:8459
DMZAL7W DE Psychomotor agitation
DMK4S8I ID DMK4S8I
DMK4S8I DN Promegestone
DMK4S8I HS Approved
DMK4S8I SN Surgestone (TN)
DMK4S8I CP Labs. Cassenne
DMK4S8I DT Small molecular drug
DMK4S8I PC 36709
DMK4S8I MW 326.5
DMK4S8I FM C22H30O2
DMK4S8I IC InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1
DMK4S8I CS CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C
DMK4S8I IK QFFCYTLOTYIJMR-XMGTWHOFSA-N
DMK4S8I IU (8S,13S,14S,17S)-13,17-dimethyl-17-propanoyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMK4S8I CA CAS 34184-77-5
DMK4S8I CB CHEBI:73390
DMK4S8I DE Gynecological disease
DMU92F8 ID DMU92F8
DMU92F8 DN Promestriene
DMU92F8 HS Approved
DMU92F8 SN BCP9000134; VA11593; A824465; I06-0300
DMU92F8 DT Small molecular drug
DMU92F8 PC 9883915
DMU92F8 MW 328.5
DMU92F8 FM C22H32O2
DMU92F8 IC InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1
DMU92F8 CS CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC)C
DMU92F8 IK IUWKNLFTJBHTSD-AANPDWTMSA-N
DMU92F8 IU (8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene
DMU92F8 CA CAS 39219-28-8
DMU92F8 CB CHEBI:135402
DMU92F8 DE Acne vulgaris
DM6I5GR ID DM6I5GR
DM6I5GR DN Promethazine
DM6I5GR HS Approved
DM6I5GR SN Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)
DM6I5GR CP Wyeth Pharmaceuticals
DM6I5GR TC Antiallergic Agents
DM6I5GR DT Small molecular drug
DM6I5GR PC 4927
DM6I5GR MW 284.4
DM6I5GR FM C17H20N2S
DM6I5GR IC InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
DM6I5GR CS CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
DM6I5GR IK PWWVAXIEGOYWEE-UHFFFAOYSA-N
DM6I5GR IU N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
DM6I5GR CA CAS 60-87-7
DM6I5GR CB CHEBI:8461
DM6I5GR DE Nausea
DMPIBJK ID DMPIBJK
DMPIBJK DN Propafenone
DMPIBJK HS Approved
DMPIBJK SN Propafenona; Propafenonum; Rythmol; Propafenon Hexal; Propafenon hexal (TN); Propafenona [INN-Spanish]; Propafenone (INN); Propafenone [INN:BAN]; Propafenone-HCl; Propafenonum [INN-Latin]; Rythmol SR (TN); Rytmonorm (TN); 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone; 1-(2-(2-Hydroxy-3-propylaminopropoxy)phenyl)-3-phenylpropan-1-one; 1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride; 1-[2-(2-Hydroxy-3-[propylamino]-propoxy)phenyl]-3-phenyl-1-propanone; 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
DMPIBJK CP Reliant Pharmaceuticals
DMPIBJK TC Antiarrhythmic Agents
DMPIBJK DT Small molecular drug
DMPIBJK PC 4932
DMPIBJK MW 341.4
DMPIBJK FM C21H27NO3
DMPIBJK IC InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
DMPIBJK CS CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
DMPIBJK IK JWHAUXFOSRPERK-UHFFFAOYSA-N
DMPIBJK IU 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
DMPIBJK CA CAS 54063-53-5
DMPIBJK CB CHEBI:63619
DMPIBJK DE Tachyarrhythmias
DM2EN6G ID DM2EN6G
DM2EN6G DN Propantheline
DM2EN6G HS Approved
DM2EN6G SN Corrigast; Ercorax; Ercotina; Ketaman; Kivatin; Neometantyl; Neopepulsan; Pantas; Pantheline; Pervagal; Probanthine; Probantine; Prodixamon; Propantel; Propanthel; Propanthelinium; Propanthelinum; Bromure de propantheline; Bromuro de proantelina; PROPANTHELINE BROMIDE; Propantelina bromuro; Propantelina bromuro [DCIT];Propanthelini bromidum; P 8891; Bromure de propantheline [INN-French]; Bromuro de proantelina [INN-Spanish]; Pro-Banthine; Pro-Gastron; Propanthelini bromidum [INN-Latin]; SC-3171; Pro-Banthine (TN);Propantheline bromide (JP15/USP/INN); Propantheline bromide [USAN:INN:BAN:JAN]; Diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate; Xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide; Ammonium, (2-hydroxyethyl)diisopropylmethyl-, xanthene-9-carboxylate (ester); Ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium; Methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide; N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate; (2-Hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide; 2-Hydroxyethyl]diisopropylmethyl-ammonium bromide xanthene-9-carboxylate; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide; 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-(2-((9H-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)
DM2EN6G TC Antispasmodics
DM2EN6G DT Small molecular drug
DM2EN6G PC 4934
DM2EN6G MW 368.5
DM2EN6G FM C23H30NO3+
DM2EN6G IC InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1
DM2EN6G CS CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C
DM2EN6G IK VVWYOYDLCMFIEM-UHFFFAOYSA-N
DM2EN6G IU methyl-di(propan-2-yl)-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
DM2EN6G CA CAS 298-50-0
DM2EN6G CB CHEBI:8481
DM2EN6G DE Stomach ulcer; Excessive sweating
DMLS39E ID DMLS39E
DMLS39E DN Proparacaine
DMLS39E HS Approved
DMLS39E SN Alcaine; Diocaine; Kainair; Ophthaine; Ophthetic; Paracaine; Prossimetacaina; Proximetacaina; Proximetacainum; Proxymetacaine; Proxymetacainum; Prossimetacaina [DCIT]; Proxymetacaine Hcl; Ak-taine; Alcaine (TN); Ocu-Caine; Proximetacaina [INN-Spanish]; Proxymetacaine (INN); Proxymetacaine [INN:BAN]; Proxymetacainum [INN-Latin]; Spectro-Caine; Ak-Taine (TN); Beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; 2-diethylaminoethyl 3-amino-4-propoxybenzoate; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester
DMLS39E TC Anesthetics
DMLS39E DT Small molecular drug
DMLS39E PC 4935
DMLS39E MW 294.39
DMLS39E FM C16H26N2O3
DMLS39E IC InChI=1S/C16H26N2O3/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3/h7-8,12H,4-6,9-11,17H2,1-3H3
DMLS39E CS CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N
DMLS39E IK KCLANYCVBBTKTO-UHFFFAOYSA-N
DMLS39E IU 2-(diethylamino)ethyl 3-amino-4-propoxybenzoate
DMLS39E CA CAS 499-67-2
DMLS39E CB CHEBI:8485
DMLS39E DE Anaesthesia
DM6JQ2I ID DM6JQ2I
DM6JQ2I DN Propentofylline propionate
DM6JQ2I HS Approved
DM6JQ2I SN Hextol (TN)
DM6JQ2I DT Small molecular drug
DM6JQ2I PC 4938
DM6JQ2I MW 306.36
DM6JQ2I FM C15H22N4O3
DM6JQ2I IC InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3
DM6JQ2I CS CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C
DM6JQ2I IK RBQOQRRFDPXAGN-UHFFFAOYSA-N
DM6JQ2I IU 3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione
DM6JQ2I CA CAS 55242-55-2
DM6JQ2I CB CHEBI:32061
DM6JQ2I DE Alzheimer disease
DME9JNL ID DME9JNL
DME9JNL DN Propericiazine
DME9JNL HS Approved
DME9JNL SN Aolept; Nemactil; Neulactil; Neuleptil; PERICYAZINE; Periciazina; Periciazine; Periciazinum; Piperocyanomazine;Periciazine [INN]; Bayer 1409; IC 6002; RP 8908; WH 7508; Neulactil (TN); Neuleptil (TN); Periciazina [INN-Spanish]; Periciazinum [INN-Latin]; Propericiazine (JAN); Propericiazine(jan); SKF 20,716; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine; Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine [French]; 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile; 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile; 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine; 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine; 6909 RP
DME9JNL CP Sanofi-Aventis
DME9JNL TC Antipsychotic Agents
DME9JNL DT Small molecular drug
DME9JNL PC 4747
DME9JNL MW 365.5
DME9JNL FM C21H23N3OS
DME9JNL IC InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
DME9JNL CS C1CN(CCC1O)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C#N
DME9JNL IK LUALIOATIOESLM-UHFFFAOYSA-N
DME9JNL IU 10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile
DME9JNL CA CAS 2622-26-6
DME9JNL CB CHEBI:31981
DME9JNL DE Psychiatric disorder
DMWDHUZ ID DMWDHUZ
DMWDHUZ DN Propicillin
DMWDHUZ HS Approved
DMWDHUZ SN Propicillin; propicilline; Propicilina; Propicillinum; 551-27-9; UNII-8X1R260V33; phenoxypropylpenicillin; CHEBI:52429; 8X1R260V33; 6beta-(2-phenoxybutanamido)-2,2-dimethylpenam-3alpha-carboxylic acid; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxybutanoyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (1-Phenoxypropyl)penicillin; Propicillinum [INN-Latin]; Propicilina [INN-Spanish]; Propicilline [INN-French]; Propicillin [INN:BAN:DCF]; Propicillin (BAN); EINECS 208-995-5; AC1Q5QWR; NCGC00160673-01; AC1L3P0Y
DMWDHUZ DT Small molecular drug
DMWDHUZ PC 92879
DMWDHUZ MW 378.4
DMWDHUZ FM C18H22N2O5S
DMWDHUZ IC InChI=1S/C18H22N2O5S/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24)/t11?,12-,13+,16-/m1/s1
DMWDHUZ CS CCC(C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)OC3=CC=CC=C3
DMWDHUZ IK HOCWPKXKMNXINF-XQERAMJGSA-N
DMWDHUZ IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxybutanoylamino)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMWDHUZ CA CAS 551-27-9
DMWDHUZ CB CHEBI:52429
DMWDHUZ DE Bacterial infection
DMKY8V1 ID DMKY8V1
DMKY8V1 DN Propiomazine
DMKY8V1 HS Approved
DMKY8V1 SN Phenoctyl; Propiomazina; Propiomazinum; Propionylpromethazine; Dorevan (TN); Dorevane (TN); Indorm (TN); Largon (TN); Propavan (TN); Propiomazina [INN-Spanish]; Propiomazinum [INN-Latin]; Serentin (TN); Wy-1359; Propiomazine (USAN/INN); Propiomazine [USAN:BAN:INN]; Propiomazine [USAN:INN:BAN]; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 3-Propionyl-10-dimethylaminoisopropylphenothiazine
DMKY8V1 CP Hikma Maple Ltd
DMKY8V1 TC Sedatives and Hypnotics
DMKY8V1 DT Small molecular drug
DMKY8V1 PC 4940
DMKY8V1 MW 340.5
DMKY8V1 FM C20H24N2OS
DMKY8V1 IC InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
DMKY8V1 CS CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C
DMKY8V1 IK UVOIBTBFPOZKGP-UHFFFAOYSA-N
DMKY8V1 IU 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one
DMKY8V1 CA CAS 362-29-8
DMKY8V1 CB CHEBI:8491
DMKY8V1 DE Insomnia
DMUWBIJ ID DMUWBIJ
DMUWBIJ DN Propiverine
DMUWBIJ HS Approved
DMUWBIJ SN propiverine hydrochloride; 54556-98-8; Propiverine HCl; Mictonorm; Propiverine Hydrochlorride; UNII-DC4GZD10H3; (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride; DSSTox_RID_81957; DSSTox_CID_26847; DSSTox_GSID_46847; C23H29NO3.HCl; DC4GZD10H3; CAS-54556-98-8; NCGC00181103-01; Mictonetten; Pollarine; Mictonorm (TN); propiverin hydrochloride; Bup-4 (TN); AC1L9B4A; CHEBI:8494; SCHEMBL1034248; DTXSID1046847; CHEMBL2359059; Propiverine hydrochloride (JP17); KFUJMHHNLGCTIJ-UHFFFAOYSA-N; BCP09576; Tox21_112719; NSC172140
DMUWBIJ DT Small molecular drug
DMUWBIJ PC 4942
DMUWBIJ MW 367.5
DMUWBIJ FM C23H29NO3
DMUWBIJ IC InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3
DMUWBIJ CS CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C
DMUWBIJ IK QPCVHQBVMYCJOM-UHFFFAOYSA-N
DMUWBIJ IU (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate
DMUWBIJ CA CAS 60569-19-9
DMUWBIJ CB CHEBI:8493
DMUWBIJ DE Urinary incontinence
DMB4OLE ID DMB4OLE
DMB4OLE DN Propofol
DMB4OLE HS Approved
DMB4OLE SN Ampofol; Aquafol; Diisopropylphenol; Dipravan; Diprivan; Disoprivan; Disoprofol; Fresofol; Ivofol; PFL; Propofolum; Rapinovet; Recofol; Abbott Brand of Propofol; Alpha Brand of Propofol; Astra Brand of Propofol; AstraZeneca Brand of Propofol; Braun Brand of Propofol; Curamed Brand of Propofol; Diprivan Injectable emulsion; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Juste Brand of Propofol; Parnell Brand of Propofol; Pisa Brand of Propofol; Propofol Abbott; Propofol Fresenius; Propofol MCT; Propofol Rovi; Propofolum [Latin]; Rovi Brand of Propofol; Schering Brand of Propofol; Zeneca Brand of Propofol; AM-149; DDS-04F; Diprivan (TN); Propofol IDD-D; Propofol-Lipuro; ZD-0859; Ghl.PD_Mitscher_leg0.558; Propofol [USAN:INN:BAN]; Propofol (JAN/USAN/INN); Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; 2,6 Diisopropylphenol; 2,6-Bis(1-methylethyl)phenol; 2,6-Bis(Isopropyl)-phenol; 2,6-DIISOPROPYLPHENOL; 2,6-Diisopropyl phenol; 2,6-Diisopropylphenol; 2,6-bis(1-methylethyl)-phenol; 2,6-di(propan-2-yl)phenol
DMB4OLE CP AstraZeneca
DMB4OLE TC Hypnotics and Sedatives
DMB4OLE DT Small molecular drug
DMB4OLE PC 4943
DMB4OLE MW 178.27
DMB4OLE FM C12H18O
DMB4OLE IC InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3
DMB4OLE CS CC(C)C1=C(C(=CC=C1)C(C)C)O
DMB4OLE IK OLBCVFGFOZPWHH-UHFFFAOYSA-N
DMB4OLE IU 2,6-di(propan-2-yl)phenol
DMB4OLE CA CAS 2078-54-8
DMB4OLE CB CHEBI:44915
DMB4OLE DE Anaesthesia
DMMSOLA ID DMMSOLA
DMMSOLA DN Propoxyphene Hydrochloride
DMMSOLA HS Approved
DMMSOLA SN Darvon; Dolene; Kesso-gesic; Prophene 65; Propoxyphene Hydrochloride 65; Darvon-n; Propoxyphene Napsylate
DMMSOLA CP Xanodyne Pharmaceutics Inc
DMMSOLA TC Neurology Agents
DMMSOLA DT Small molecular drug
DMMSOLA PC 15424
DMMSOLA MW 375.9
DMMSOLA FM C22H30ClNO2
DMMSOLA IC InChI=1S/C22H29NO2.ClH/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;/h6-15,18H,5,16-17H2,1-4H3;1H/t18-,22+;/m1./s1
DMMSOLA CS CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C.Cl
DMMSOLA IK QMQBBUPJKANITL-MYXGOWFTSA-N
DMMSOLA IU [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;hydrochloride
DMMSOLA CA CAS 1639-60-7
DMMSOLA CB CHEBI:8498
DMMSOLA DE Pain
DM79NTF ID DM79NTF
DM79NTF DN Propranolol
DM79NTF HS Approved
DM79NTF SN Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
DM79NTF CP AstraZeneca plc
DM79NTF TC Antianxiety Agents
DM79NTF DT Small molecular drug
DM79NTF PC 4946
DM79NTF MW 259.339
DM79NTF FM C16H21NO2
DM79NTF IC InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
DM79NTF CS CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
DM79NTF IK AQHHHDLHHXJYJD-UHFFFAOYSA-N
DM79NTF IU 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
DM79NTF CA CAS 525-66-6
DM79NTF CB CHEBI:8499
DM79NTF DE Migraine
DMTBW2O ID DMTBW2O
DMTBW2O DN Propylhexedrine
DMTBW2O HS Approved
DMTBW2O SN Propylhexedrine hydrochloride; Eggobesin; Eventin hydrochloride; Benzedrex hydrochloride; Pernsator-wirkstoff; dl-Propylhexedrine Hydrochloride; 1007-33-6; Cyclohexylisopropylmethylamine hydrochloride; NSC 27110; NSC 170998; Cyclohexyl(isopropyl)methylammonium chloride; 1-Cyclohexyl-2-methylaminopropane hydrochloride; EINECS 213-753-7; (+-)-Propylhexedrine hydrochloride; N,alpha-Dimethylcyclohexaneethylamine hydrochloride; Propylhexedrine dl-form hydrochloride; Cyclohexaneethylamine, N,alpha-dimethyl-, hydrochloride
DMTBW2O DT Small molecular drug
DMTBW2O PC 7558
DMTBW2O MW 155.28
DMTBW2O FM C10H21N
DMTBW2O IC InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3
DMTBW2O CS CC(CC1CCCCC1)NC
DMTBW2O IK JCRIVQIOJSSCQD-UHFFFAOYSA-N
DMTBW2O IU 1-cyclohexyl-N-methylpropan-2-amine
DMTBW2O CA CAS 101-40-6
DMTBW2O CB CHEBI:134783
DMTBW2O DE Obesity
DM6D7N8 ID DM6D7N8
DM6D7N8 DN Propylthiouracil
DM6D7N8 HS Approved
DM6D7N8 SN propylthiouracil; 51-52-5; 6-Propyl-2-thiouracil; Propacil; Prothyran; Prothiurone; Procasil; Propycil; Thiuragyl; Protiural; Prothiucil; Prothycil; Propyl-Thiorist; Propyl-Thyracil; 2-Mercapto-6-propylpyrimidin-4-ol; 6-N-Propylthiouracil; Propythiouracil; Propilthiouracil; Propyl-Thiorit; Propylthiorit; 6-Propylthiouracil; Propylthiouracile; Thyreostat II; 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one; Propiltiouracilo; 6-N-Propyl-2-thiouracil; 6-Thio-4-propyluracil; PTU (thyreostatic); Propylthiouracilum; 4-Propyl-2-thiouracil; Procasil; Propiltiouracile; PROPYL THIOURACIL; Propiltiouracile [DCIT]; Thyreos tat ii; HC210060; Propiltiouracilo [INN-Spanish]; Propylthiouracil (TN); Propylthiouracile [INN-French]; Propylthiouracilum [INN-Latin]; Ptu(thyreostatic); T0517-6237; Thyreostat propyl-thyracil; Propylthiouracil [INN:BAN:JAN]; Propylthiouracil (JP15/USP/INN); 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone; 2-Mercapto-4-hydroxy-6-n-propylpyrimidine; 2-Mercapto-6-propyl-4-pyrimidone; 2-Mercapto-6-propylpyrimid-4-one; 2-Thio-4-oxo-6-propyl-1,3-pyrimidine; 2-Thio-6-propyl-1,3-pyrimidin-4-one; 4-Hydroxy-2-mercapto-6-propylpyrimidine; 6 Propyl 2 Thiouracil; 6-(n-Propyl)-2-thiouracil; 6-Prop yl-2-thiouracil; 6-Propil-tiouracile; 6-Propil-tiouracile [Italian]; 6-Propyl-2-thio-2,4(1H,3H)-pyrimidinedione; 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione; 6-n-PROPYL-2-MERCAPTO-4-HYDROXYPYRIMIDINE; 6-propyl-2 thiouracil; 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one; 6-propyl-2-thiopyrimidine-2,4(1H,3H)-dione; Propyl thiouracile
DM6D7N8 TC Antithyroid Agents
DM6D7N8 DT Small molecular drug
DM6D7N8 PC 657298
DM6D7N8 MW 170.23
DM6D7N8 FM C7H10N2OS
DM6D7N8 IC InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)
DM6D7N8 CS CCCC1=CC(=O)NC(=S)N1
DM6D7N8 IK KNAHARQHSZJURB-UHFFFAOYSA-N
DM6D7N8 IU 6-propyl-2-sulfanylidene-1H-pyrimidin-4-one
DM6D7N8 CA CAS 51-52-5
DM6D7N8 CB CHEBI:8502
DM6D7N8 DE Hyperthyroidism
DMX0EZJ ID DMX0EZJ
DMX0EZJ DN Prothionamide
DMX0EZJ HS Approved
DMX0EZJ SN Ektebin; Peteha; Prothionamidum; Protionamid; Protionamida; Protionamide; Protionamidum; Protionizina; Tebeform; Trevintix; Tuberex; RP 9778; TH 1321; Prothionamide (JP15); Protionamida [INN-Spanish]; Protionamide (INN); Protionamide [INN:DCF]; Protionamidum [INN-Latin]; TH-1321; Trevintix (TN); 2-Propyl-4-pyridinecarbothioamide; 2-Propyl-4-thiocarbamoylpyridine; 2-Propyl-thioisonicotinamide; 2-Propylisonicotinylthioamide; 2-Propylthioisonicotinamide; 2-propylpyridine-4-carbothioamide; 4-Pyridinecarbothioamide, 2-propyl-(9CI); 9778 R.P; 9778 R.P.
DMX0EZJ TC Antituberculosis Agents
DMX0EZJ DT Small molecular drug
DMX0EZJ PC 666418
DMX0EZJ MW 180.27
DMX0EZJ FM C9H12N2S
DMX0EZJ IC InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)
DMX0EZJ CS CCCC1=NC=CC(=C1)C(=S)N
DMX0EZJ IK VRDIULHPQTYCLN-UHFFFAOYSA-N
DMX0EZJ IU 2-propylpyridine-4-carbothioamide
DMX0EZJ CA CAS 14222-60-7
DMX0EZJ CB CHEBI:32066
DMX0EZJ DE Tuberculosis
DMGN5QD ID DMGN5QD
DMGN5QD DN Protirelin
DMGN5QD HS Approved
DMGN5QD SN 24305-27-9; Hirtonin; TRH-SR, Takeda; protirelin
DMGN5QD CP Abbott Laboratories Pharmaceutical Products Div
DMGN5QD TC Neurology Agents
DMGN5QD DT Small molecular drug
DMGN5QD PC 638678
DMGN5QD MW 362.38
DMGN5QD FM C16H22N6O4
DMGN5QD IC InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1
DMGN5QD CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N
DMGN5QD IK XNSAINXGIQZQOO-SRVKXCTJSA-N
DMGN5QD IU (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMGN5QD CA CAS 24305-27-9
DMGN5QD CB CHEBI:35940
DMGN5QD DE Central nervous system disease
DMAHZKR ID DMAHZKR
DMAHZKR DN Protokylol Hydrochloride
DMAHZKR HS Approved
DMAHZKR SN Ventaire
DMAHZKR CP Sanofi Aventis Us Llc
DMAHZKR DT Small molecular drug
DMAHZKR PC 8699
DMAHZKR MW 367.8
DMAHZKR FM C18H22ClNO5
DMAHZKR IC InChI=1S/C18H21NO5.ClH/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13;/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3;1H
DMAHZKR CS CC(CC1=CC2=C(C=C1)OCO2)NCC(C3=CC(=C(C=C3)O)O)O.Cl
DMAHZKR IK LOVXREQUMZKFCM-UHFFFAOYSA-N
DMAHZKR IU 4-[2-[1-(1,3-benzodioxol-5-yl)propan-2-ylamino]-1-hydroxyethyl]benzene-1,2-diol;hydrochloride
DMAHZKR CA CAS 136-69-6
DMAHZKR DE Asthma
DMNHTZI ID DMNHTZI
DMNHTZI DN Protriptyline
DMNHTZI HS Approved
DMNHTZI SN Amimetilina; Impril; Maximed; Novopramine; Protriptilina; Protriptylinum; Protryptyline; Rhotrimine; Triptil; Triptyl; Vivactil; Vivactyl; Triptil hydrochloride; Normethyl EX4442; Triadapin 5; Apo-Imipramine; Apo-Trimip; Novo-Doxepin; Novo-Tripramine; Protriptilina [INN-Spanish]; Protriptyline (INN); Protriptyline [INN:BAN]; Protriptylinum [INN-Latin]; Vivactil (TN); N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine; N-Methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine; N-Methyl-5H-dibenzo(a,d)cycloheptene-5-propylamine; N-3-(5H-Dibenzo(a,d)cyclohepten-5-yl)propyl-N-methylamine; 3-(5H-Dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine; 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine; 5-(3-Methylaminopropyl)-5H-Dibenzo[a,d]cycloheptene; 5-(3-Methylaminopropyl)-5H-dibenzo(a,d)cycloheptene; 5H-Dibenzo[a, d]cycloheptene-5-propanamine, N-methyl-, hydrochloride; 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
DMNHTZI CP Teva Womens Health Inc
DMNHTZI TC Antidepressants
DMNHTZI DT Small molecular drug
DMNHTZI PC 4976
DMNHTZI MW 263.4
DMNHTZI FM C19H21N
DMNHTZI IC InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
DMNHTZI CS CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13
DMNHTZI IK BWPIARFWQZKAIA-UHFFFAOYSA-N
DMNHTZI IU N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)propan-1-amine
DMNHTZI CA CAS 438-60-8
DMNHTZI CB CHEBI:8597
DMNHTZI DE Depression
DMGKT2L ID DMGKT2L
DMGKT2L DN Pro-urokinase
DMGKT2L HS Approved
DMGKT2L SN Thrombolyse (TN)
DMGKT2L DE Thrombin deficiency
DMOK965 ID DMOK965
DMOK965 DN Prulifloxacin
DMOK965 HS Approved
DMOK965 SN 123447-62-1; NM441; NM 441; NM-441; Prulifloxacin (hydrochloride); 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; NCGC00164615-01; Quisnon; DSSTox_CID_26480; DSSTox_RID_81651; DSSTox_GSID_46480; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-; 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; Prulifloxacin [INN]; Pruvel; Sword; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; CCRIS 7686; CAS-123447-62-1; Pufloxacin dioxolil; 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; MLS006011767; CHEMBL422648; NAD-441A; OPT-99; SCHEMBL1650794; DTXSID0046480; CHEBI:32071; AOB5600; BCP12727; HY-B0024; Tox21_112235; BBL034010; MFCD00864847; s2071; STK626148; AKOS005559236; Prulifloxacin (NM441, AF 3013); Tox21_112235_1; AC-2012; DB11892; MCULE-8435182996; SB18983; NCGC00164615-02; NCGC00164615-03; (+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate; AK144730; AS-13607; I926; SMR000046722; AB0013936; FT-0651733; P2058; Prulifloxacin 100 microg/mL in Acetonitrile; K-1771; 447P621; Prulifloxacin, >=98% (perchloric acid titration); SR-01000872596; Prulifloxacin, Antibiotic for Culture Media Use Only; Q-101929; Q3924793; SR-01000872596-1; BRD-A92341659-001-01-6
DMOK965 DT Small molecular drug
DMOK965 PC 65947
DMOK965 MW 461.5
DMOK965 FM C21H20FN3O6S
DMOK965 IC InChI=1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DMOK965 CS CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
DMOK965 IK PWNMXPDKBYZCOO-UHFFFAOYSA-N
DMOK965 IU 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DMOK965 CA CAS 123447-62-1
DMOK965 CB CHEBI:32071
DMOK965 DE Urinary tract infection
DMIVJ0D ID DMIVJ0D
DMIVJ0D DN Pseudoephedrine
DMIVJ0D HS Approved
DMIVJ0D SN Balminil Decongestant Syrup; Dimetapp Decongestant; Dimetapp Decongestant Pediatric Drops; Drixoral Nasal Decongestant; Pseudoephedrine Ephedrine; Sudafed Decongestant Extra Strength; Triaminic AM Decongestant Formula; Triaminic Infant Oral Decongestant Drops; Efidac 24 PseudoephedrineHcl; Sudafed Decongestant 12 Hour; Pseudoefedrina [INN-Spanish]; Pseudoephedrine (INN); Pseudoephedrine [INN:BAN]; Pseudoephedrine d-form; Pseudoephedrinum [INN-Latin]; Sudafed (TN); Alpha-(1-(Methylamino)ethyl)benzyl alcohol; D-psi-2-Methylamino-1-phenyl-1-propanol; Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)-(9CI); (+)-(1S,2S)-Pseudoephedrine; (1S,2S)-(+)-Pseudoephedrine; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; (1S,2S)-2-Methylamino-1-phenyl-1-propanol; (1S,2S)-Pseudoephedrine; (1S,2S)-Pseudoephedrine, polymer-bound
DMIVJ0D CP Pfizer Pharmaceuticals
DMIVJ0D DT Small molecular drug
DMIVJ0D PC 7028
DMIVJ0D MW 165.23
DMIVJ0D FM C10H15NO
DMIVJ0D IC InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1
DMIVJ0D CS C[C@@H]([C@H](C1=CC=CC=C1)O)NC
DMIVJ0D IK KWGRBVOPPLSCSI-WCBMZHEXSA-N
DMIVJ0D IU (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
DMIVJ0D CA CAS 90-82-4
DMIVJ0D CB CHEBI:51209
DMIVJ0D DE Nasal congestion
DMLSUWZ ID DMLSUWZ
DMLSUWZ DN PSI-7977
DMLSUWZ HS Approved
DMLSUWZ SN 1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R,
DMLSUWZ CP Gilead Sciences
DMLSUWZ DT Small molecular drug
DMLSUWZ PC 45375808
DMLSUWZ MW 529.5
DMLSUWZ FM C22H29FN3O9P
DMLSUWZ IC InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
DMLSUWZ CS C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DMLSUWZ IK TTZHDVOVKQGIBA-IQWMDFIBSA-N
DMLSUWZ IU propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMLSUWZ CA CAS 1190307-88-0
DMLSUWZ CB CHEBI:85083
DMLSUWZ DE HCV 1-6 infection; Hepatitis C virus infection
DMWLTU2 ID DMWLTU2
DMWLTU2 DN PSMA-11 Ga-68
DMWLTU2 HS Approved
DMWLTU2 SN UNII-ZJ0EKR6M10; ZJ0EKR6M10; Prostamedix; (68Ga)Hbed-psma; 68ga-psma-hbed-cc; (68ga)psma-hbed-cc; 68Ga-Psma-11; Gallium Ga-68 gozetotide; Gallium gozetotide Ga-68; Ga-Psma-hbed-CC Ga-68; Gallium (68Ga) gozetotide; Ga-68-Labeled PSMA-11; Ga-68 PSMA-11; PSMA-11 Ga 68; DKFZ-PSMA-11 GA-68; Gallium (68Ga) gozetotide [INN]; Glu-urea-Lys(ahx)-hbed-CC Ga-68; (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 68Ga-Labelled Glu-urea-Lys(ahx)-hbed-CC; Glu-NH-CO-NH-Lys-(ahx)-(68Ga(hbed-CC)); (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC; Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC; 1906894-20-9
DMWLTU2 DT Radioactive diagnostic agent
DMWLTU2 PC 154572876
DMWLTU2 MW 1011.9
DMWLTU2 FM C44H59GaN6O17
DMWLTU2 IC InChI=1S/C44H62N6O17.Ga/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58;/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67);/q;+3/p-3/t32-,33-;/m0./s1/i;1-2
DMWLTU2 CS [H+].C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)[O-])CC(=O)[O-])CC(=O)[O-])[O-].[68Ga+3]
DMWLTU2 IK AEBYHKKMCWUMKX-LNTZDJBBSA-K
DMWLTU2 IU 2-[[5-[3-[[6-[[(5S)-5-carboxy-5-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentyl]amino]-6-oxohexyl]amino]-3-oxopropyl]-2-oxidophenyl]methyl-[2-[[5-(2-carboxyethyl)-2-oxidophenyl]methyl-(carboxylatomethyl)amino]ethyl]amino]acetate;gallium-68(3+);hydron
DMWLTU2 CA CAS 1906894-20-9
DMWLTU2 DE Diagnostic imaging
DMG2X3E ID DMG2X3E
DMG2X3E DN Pyrantel
DMG2X3E HS Approved
DMG2X3E SN PYRANTEL; Pyrequan; 15686-83-6; Strongid; Pirantele [DCIT]; Pyrantelum; Pirantel; Pyrantel [INN:BAN]; Pyrantelum [INN-Latin]; Pirantel [INN-Spanish]; UNII-4QIH0N49E7; HSDB 3252; EINECS 239-774-1; CHEBI:8654; 4QIH0N49E7; (E)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine; E-1,4,5,6-Tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine; Pirantele; 1-methyl-2-[(E)-2-(2-thienyl)vinyl]-5,6-dihydro-4H-pyrimidine; Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (E)-; Pin-X
DMG2X3E DT Small molecular drug
DMG2X3E PC 708857
DMG2X3E MW 206.31
DMG2X3E FM C11H14N2S
DMG2X3E IC InChI=1S/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+
DMG2X3E CS CN1CCCN=C1/C=C/C2=CC=CS2
DMG2X3E IK YSAUAVHXTIETRK-AATRIKPKSA-N
DMG2X3E IU 1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine
DMG2X3E CA CAS 15686-83-6
DMG2X3E CB CHEBI:8654
DMG2X3E DE Worm infection
DM4IF32 ID DM4IF32
DM4IF32 DN Pyrazinamide
DM4IF32 HS Approved
DM4IF32 SN Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-carbamyl pyrazine
DM4IF32 TC Antitubercular Agents
DM4IF32 DT Small molecular drug
DM4IF32 PC 1046
DM4IF32 MW 123.11
DM4IF32 FM C5H5N3O
DM4IF32 IC InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
DM4IF32 CS C1=CN=C(C=N1)C(=O)N
DM4IF32 IK IPEHBUMCGVEMRF-UHFFFAOYSA-N
DM4IF32 IU pyrazine-2-carboxamide
DM4IF32 CA CAS 98-96-4
DM4IF32 CB CHEBI:45285
DM4IF32 DE Mycobacterium infection
DM8HO1L ID DM8HO1L
DM8HO1L DN Pyridostigmine
DM8HO1L HS Approved
DM8HO1L SN Pyridostigminum; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium
DM8HO1L CP Valeant Pharmaceuticals
DM8HO1L TC Parasympathomimetics
DM8HO1L DT Small molecular drug
DM8HO1L PC 4991
DM8HO1L MW 181.21
DM8HO1L FM C9H13N2O2+
DM8HO1L IC InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1
DM8HO1L CS C[N+]1=CC=CC(=C1)OC(=O)N(C)C
DM8HO1L IK RVOLLAQWKVFTGE-UHFFFAOYSA-N
DM8HO1L IU (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate
DM8HO1L CA CAS 155-97-5
DM8HO1L CB CHEBI:8665
DM8HO1L DE Myasthenia gravis
DMO2K0J ID DMO2K0J
DMO2K0J DN Pyridoxal Phosphate
DMO2K0J HS Approved
DMO2K0J SN Pyridoxal phosphate; pyridoxal phosphate; Codecarboxylase; pyridoxal 5-phosphate; 54-47-7; pyridoxal 5'-phosphate; Pyridoxal P; Pyromijin; Hairoxal; Vitazechs; Biosechs; Pyridoxal-5'-phosphate; Hiadelon; Pidopidon; Himitan; Phosphopyridoxal; Sechvitan; Pydoxal; Piodel; Pyridoxyl phosphate; Apolon B6; (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate; HI-Pyridoxin; Pal-P; PYRIDOXAL-5-PHOSPHATE; pyridoxal-P; Phosphopyridoxal coenzyme; Vitahexin P; Hexermin P; Coenzyme B6; Pyridoxal monophosphate; Pyridoxaldehyde phosphate; Apolon B(sub 6); Biosechs; PLP; Pyrido; Phosphoridoxal coenzyme; Pyridoxal phosphate [JAN]; SRI 2392; VITAMIN B6 COMPLEX; Vitamin B6 phosphate; Hexermin-P; Pyridoxal 5-monophosphoric acid ester; Pyridoxal 5-phosphate; Pyridoxal phosphate (6CI); Pyridoxal-5P; Pyridoxal-P; Sechvitan, Vitahexin P; Vitahexin-P; Vitamin B6 phosphate (ester); Pyridoxal 5'-phosphate; Pyridoxal 5'-phosphate hydrate; Pyridoxal-5-Phosphate Hydrate; Pyridoxal-5-monophosphate; P-5'-P; Pyridoxal 5'-(dihydrogen phosphate); Pyridoxal 5'-phosphate monohydrate, vitamin B6; Pyridoxal 5'-phosphate monohydrate-Vitamin B6; Pyridoxal phosphate treated beta-lactoglobulin from bovine whey; Pyridoxal, 5-(dihydrogen phosphate); Pyridoxal, 5-(dihydrogenphosphate); Pyridoxal, 5-(dihydrogen phosphate) (8CI); Phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester; Isonicotinaldehyde, 3-hydroxy-5-(hydroxymethyl)-2-methyl-, 5-(dihydrogen phosphate); (4-Formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate; (4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate; 2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate; 2-Methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid; 3-Hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde; 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate; 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; 4-Formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid; 4-Pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-(9CI); Lepirudine
DMO2K0J TC Dietary supplement
DMO2K0J DT Small molecular drug
DMO2K0J PC 1051
DMO2K0J MW 247.14
DMO2K0J FM C8H10NO6P
DMO2K0J IC InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14)
DMO2K0J CS CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O
DMO2K0J IK NGVDGCNFYWLIFO-UHFFFAOYSA-N
DMO2K0J IU (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate
DMO2K0J CA CAS 54-47-7
DMO2K0J CB CHEBI:18405
DMO2K0J DE Malnutrition
DM5X7VY ID DM5X7VY
DM5X7VY DN Pyrimethamine
DM5X7VY HS Approved
DM5X7VY SN Chloridin; Chloridine; Chloridyn; Darachlor; Daraclor; Darapram; Daraprim; Daraprime; Daraprin; Diaminopyritamin; Erbaprelina; Ethylpyrimidine; Khloridin; Malacid; Malocid; Malocide; Maloprim; Pirimecidan; Pirimetamin; Pirimetamina; Primethamine; Pyremethamine; Pyrimethamin; Pyrimethaminum; Tindurin; Tindurine; Tinduring; Aventis Brand of Pyrimethamine; Glaxo Wellcome Brand of Pyrimethamine; GlaxoSmithKline Brand of Pyrimethamine; M alocid; Pirimetamina [Spanish]; Pyrimethamine Hcl; Wellcome Brand of Pyrimethamine; BW 5063; RP 4753; WR 2978; AZT + Pyrimethamine combination; BW 50-63; Daraprim (TN); EXR-101; Lactoferrin B & Pyrimethamine; Lactoferrin H & Pyrimethamine; Pirimetamina [INN-Spanish]; Pyrimethamine (Pyr); Pyrimethaminum [INN-Latin]; TCMDC-123831; TCMDC-125860; CRL-8131 & Pyrimethamine; CRL-8142 & Pyrimethamine; Fansidar (Pyrimethamine/Sulfadoxine); Pyrimethamine (JAN/USP/INN); Pyrimethamine [USAN:INN:BAN:JAN]; 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine; 2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine; 5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE; 5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE; 5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine; 5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine; 5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine; 5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
DM5X7VY TC Antimalarials
DM5X7VY DT Small molecular drug
DM5X7VY PC 4993
DM5X7VY MW 248.71
DM5X7VY FM C12H13ClN4
DM5X7VY IC InChI=1S/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)
DM5X7VY CS CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl
DM5X7VY IK WKSAUQYGYAYLPV-UHFFFAOYSA-N
DM5X7VY IU 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
DM5X7VY CA CAS 58-14-0
DM5X7VY CB CHEBI:8673
DM5X7VY DE Malaria
DMNA8HM ID DMNA8HM
DMNA8HM DN Pyrithione Zinc
DMNA8HM HS Approved
DMNA8HM SN Head & Shoulders Conditioner
DMNA8HM CP Warner Chilcott Co Llc
DMNA8HM DT Small molecular drug
DMNA8HM PC 3005837
DMNA8HM MW 317.7
DMNA8HM FM C10H8N2O2S2Zn
DMNA8HM IC InChI=1S/2C5H4NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4H;/q2*-1;+2
DMNA8HM CS C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2]
DMNA8HM IK PICXIOQBANWBIZ-UHFFFAOYSA-N
DMNA8HM IU zinc;1-oxidopyridine-2-thione
DMNA8HM CA CAS 13463-41-7
DMNA8HM CB CHEBI:32076
DMNA8HM DE Seborrhoeic dermatitis
DMUWAM2 ID DMUWAM2
DMUWAM2 DN Pyronaridine
DMUWAM2 HS Approved
DMUWAM2 SN Malaridine; Pyronaridine phosphate salt; Benzonaphthyridine 7351; 2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine; 4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol; 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one; 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DMUWAM2 DT Small molecular drug
DMUWAM2 PC 107771
DMUWAM2 MW 518
DMUWAM2 FM C29H32ClN5O2
DMUWAM2 IC InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
DMUWAM2 CS COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6
DMUWAM2 IK DJUFPMUQJKWIJB-UHFFFAOYSA-N
DMUWAM2 IU 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
DMUWAM2 CA CAS 74847-35-1
DMUWAM2 CB CHEBI:135951
DMUWAM2 DE Malaria
DM7Q41G ID DM7Q41G
DM7Q41G DN Pyruvic acid
DM7Q41G HS Approved
DM7Q41G SN BTS; Brenztraubensaeure; Acetylformic acid; Acide pyruvique; Pyroracemic acid; CH3COCOOH; A-Ketopropionic acid; Alpha-Ketopropionic acid; Alpha-Oxopropionsaeure; Alpha-keto propionic acid; Alpha-ketopropionic acid; P-9250; Pyruvic acid (8CI); Pyruvic acid (natural); Propanoic acid, 2-oxo-(9CI); 2-Ketopropionic acid; 2-Oxopropanoate; 2-Oxopropanoic acid; 2-Oxopropansaeure; 2-Oxopropionic acid; 2-Oxopropionsaeure; 2-oxo(1-14c)propanoic acid; 2-oxo-propionic acid
DM7Q41G TC Dietary supplement
DM7Q41G DT Small molecular drug
DM7Q41G PC 1060
DM7Q41G MW 88.06
DM7Q41G FM C3H4O3
DM7Q41G IC InChI=1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)
DM7Q41G CS CC(=O)C(=O)O
DM7Q41G IK LCTONWCANYUPML-UHFFFAOYSA-N
DM7Q41G IU 2-oxopropanoic acid
DM7Q41G CA CAS 127-17-3
DM7Q41G CB CHEBI:32816
DM7Q41G DE Malnutrition
DMGAZHU ID DMGAZHU
DMGAZHU DN Quattvaxem
DMGAZHU HS Approved
DMGAZHU SN DTwPHib-CRM197 conjugate vaccine; DPT-Hib vaccine, Chiron; DTP-Hib vaccine, Chiron; Diphtheria, tetanus, pertussis, Haemophilus influenzae b vaccine (CRM-197 adjuvant), Chiron
DMGAZHU CP Chiron Corp
DMGAZHU DT Vaccine
DMGAZHU DE Bordetella pertussis infection
DMY4D87 ID DMY4D87
DMY4D87 DN Quazepam
DMY4D87 HS Approved
DMY4D87 SN Cetrane; Doral; Dormalin; Oniria; Prosedar; Quazapam; Quazepamum; Quazium; Selepam; Sch 16134; Doral (TN); Dormalin (TN); Quazepamum [INN-Latin]; Sch-161; Sch-16134; Quazepam (JAN/USP); Quazepam [USAN:BAN:INN]; Quazepam (JAN/USP/INN); 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-Chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione; 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
DMY4D87 CP Schering-Plough
DMY4D87 TC Hypnotics and Sedatives
DMY4D87 DT Small molecular drug
DMY4D87 PC 4999
DMY4D87 MW 386.8
DMY4D87 FM C17H11ClF4N2S
DMY4D87 IC InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
DMY4D87 CS C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F
DMY4D87 IK IKMPWMZBZSAONZ-UHFFFAOYSA-N
DMY4D87 IU 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione
DMY4D87 CA CAS 36735-22-5
DMY4D87 CB CHEBI:8694
DMY4D87 DE Insomnia
DM3NC4M ID DM3NC4M
DM3NC4M DN Quercetin
DM3NC4M HS Approved
DM3NC4M SN Kvercetin; Meletin; QUE; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; Xanthaurine; Flavin meletin; Kvercetin [Czech]; Quercetin content; Quercetin dihydrate; CI Natural Yellow 10; Cyanidelonon 1522; KUC104418N; KUC107684N; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; TNP00070; TNP00089; LIM-5662; LNS-5662; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; CU-01000012502-3; KSC-10-126; KSC-23-76; T-Gelb bzw. grun 1; C.I. Natural yellow 10 & 13; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one
DM3NC4M TC Hypoglycemic Agents
DM3NC4M DT Small molecular drug
DM3NC4M PC 5280343
DM3NC4M MW 302.23
DM3NC4M FM C15H10O7
DM3NC4M IC InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
DM3NC4M CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DM3NC4M IK REFJWTPEDVJJIY-UHFFFAOYSA-N
DM3NC4M IU 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DM3NC4M CA CAS 117-39-5
DM3NC4M CB CHEBI:16243
DM3NC4M DE Obesity
DM1N62C ID DM1N62C
DM1N62C DN Quetiapine
DM1N62C HS Approved
DM1N62C SN quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760
DM1N62C CP AstraZeneca
DM1N62C TC Antipsychotic Agents
DM1N62C DT Small molecular drug
DM1N62C PC 5002
DM1N62C MW 383.5
DM1N62C FM C21H25N3O2S
DM1N62C IC InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
DM1N62C CS C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
DM1N62C IK URKOMYMAXPYINW-UHFFFAOYSA-N
DM1N62C IU 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
DM1N62C CA CAS 111974-69-7
DM1N62C CB CHEBI:8707
DM1N62C DE Schizophrenia; Alcohol dependence
DM7WI4Q ID DM7WI4Q
DM7WI4Q DN Quinagolide
DM7WI4Q HS Approved
DM7WI4Q SN Norprolac; 87056-78-8; Quinagolidum; SDZ 205-502; Quinagolide (INN/BAN); AC1MJ64J; SCHEMBL143485; CHEMBL290962; CHEBI:135627; ZINC3778441; BDBM50225362; DB09097; D07217; 056Q788; UNII-80Q9QWN15M component GDFGTRDCCWFXTG-ZIFCJYIRSA-N; (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM7WI4Q CP Ferring Pharmaceuticals
DM7WI4Q TC Fertility Agents
DM7WI4Q DT Small molecular drug
DM7WI4Q PC 3086401
DM7WI4Q MW 395.6
DM7WI4Q FM C20H33N3O3S
DM7WI4Q IC InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1
DM7WI4Q CS CCCN1C[C@H](C[C@H]2[C@H]1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC
DM7WI4Q IK GDFGTRDCCWFXTG-ZIFCJYIRSA-N
DM7WI4Q IU (3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM7WI4Q CA CAS 87056-78-8
DM7WI4Q CB CHEBI:135627
DM7WI4Q DE Hyperprolactinaemia
DMR8H31 ID DMR8H31
DMR8H31 DN Quinapril
DMR8H31 HS Approved
DMR8H31 SN Ectren; Koretic; Quinaprilum; QUINAPRIL HCL; Quinaprilum [Latin]; Accupril (TN); Quinapril [INN:BAN]; Quinapril (USP/INN); [3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-Isoquinolinecarboxylic acid; (3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; (3S)-2-{(2S)-2-[(1S)-1-ethoxycarbonyl-3-phenylpropylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-{N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
DMR8H31 CP Pfizer Pharmaceuticals
DMR8H31 TC Antihypertensive Agents
DMR8H31 DT Small molecular drug
DMR8H31 PC 54892
DMR8H31 MW 438.5
DMR8H31 FM C25H30N2O5
DMR8H31 IC InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
DMR8H31 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O
DMR8H31 IK JSDRRTOADPPCHY-HSQYWUDLSA-N
DMR8H31 IU (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMR8H31 CA CAS 85441-61-8
DMR8H31 CB CHEBI:8713
DMR8H31 DE Hypertension
DMJ6H1Z ID DMJ6H1Z
DMJ6H1Z DN Quinestrol
DMJ6H1Z HS Approved
DMJ6H1Z SN EECPE; Eston; Estrovis; Estrovister; Plestrovis; Quilea; Quinestrolo; Quinestrolum; Quinestrolo [DCIT]; Estrovis 4000; W 3566; Estrovis (TN); Ethinyl Estradiol 3-Cyclopentyl Ether; Qui-Lea; Quinestrolum [INN-Latin]; W-3566; Quinestrol (USAN/INN); Quinestrol [USAN:INN:BAN]; Estradiol-17-beta 3-cyclopentyl ether; (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; 17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17ALPHA-ETHYLNYL-1,3,5[10]ESTRATRIENE-3,17BETA-DIOL 3-CYCLOPENTYL ETHER; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; 3-(Cyclopentyloxy)-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(Cyclopentyloxy)-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-(cyclopentyloxy)-17beta-ethynylestra-1,3,5(10)-trien-17-ol; 3-Cyclopentyloxy-17alpha-ethynylestra-1,3,5(10)-trien-17beta-ol
DMJ6H1Z TC Anticancer Agents
DMJ6H1Z DT Small molecular drug
DMJ6H1Z PC 9046
DMJ6H1Z MW 364.5
DMJ6H1Z FM C25H32O2
DMJ6H1Z IC InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1
DMJ6H1Z CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5
DMJ6H1Z IK PWZUUYSISTUNDW-VAFBSOEGSA-N
DMJ6H1Z IU (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
DMJ6H1Z CA CAS 152-43-2
DMJ6H1Z CB CHEBI:8716
DMJ6H1Z DE Breast cancer
DMWCOSR ID DMWCOSR
DMWCOSR DN Quinethazone
DMWCOSR HS Approved
DMWCOSR SN Aquamox; Chinetazone; Chinethazone; Chinethazonum; Hydromox; Idrokin; Quinetazona; Quinethazon; Quinethazonum; Chinetazone[DCIT]; CL 36010; Hydromox (TN); Quinetazona [INN-Spanish]; Quinethazone (aquamox); Quinethazonum [INN-Latin]; Quinethazone (JAN/INN); Quinethazone [INN:BAN:JAN]; 2-Ethyl-7-chloro-1,2,3,4-tetrahydro-4-oxochinazolin-6-sulfonamid; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulfonamide; 7-Chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-sulfamoylquinazoline; 7-Chloro-2-ethyl-6-sulfamoyl-1,2,3,4-tetrahydro-4-quinazolinone; 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide; 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
DMWCOSR TC Antihypertensive Agents
DMWCOSR DT Small molecular drug
DMWCOSR PC 6307
DMWCOSR MW 289.74
DMWCOSR FM C10H12ClN3O3S
DMWCOSR IC InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)
DMWCOSR CS CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl
DMWCOSR IK AGMMTXLNIQSRCG-UHFFFAOYSA-N
DMWCOSR IU 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide
DMWCOSR CA CAS 73-49-4
DMWCOSR CB CHEBI:8717
DMWCOSR DE Hypertension
DMLPICK ID DMLPICK
DMLPICK DN Quinidine
DMLPICK HS Approved
DMLPICK SN Quinact; Quinaglute; Quinalan; Quinatime; Quindine; Quinicardine; Quinidex; Quinidine sulfate; Quiniduran; Quinora; beta-Quinine; Cardioquin; Chinidin; Chinidine; Cin-Quin; Cinchonan-9-ol, 6'-methoxy-, (9S)-; Conchinin; Conchinine; Conquinine; Duraquin; ITX08688JL; Kinidin; Pitayine; chinidinum; quinidina; quinidine; (+)-Quinidine; (8R,9S)-Quinidine; (9S)-6'-Methoxycinchonan-9-ol; (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; 56-54-2; CHEBI:28593; CHEMBL1294; MFCD00135581; UNII-ITX08688JL
DMLPICK PC 441074
DMLPICK MW 324.4
DMLPICK FM C20H24N2O2
DMLPICK IC LOUPRKONTZGTKE-LHHVKLHASA-N
DMLPICK CS COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
DMLPICK IK 1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
DMLPICK IU (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
DMLPICK CA CAS 56-54-2
DMLPICK CB CHEBI:28593
DMLPICK DE Ventricular tachyarrhythmia
DMSWYF5 ID DMSWYF5
DMSWYF5 DN Quinine
DMSWYF5 HS Approved
DMSWYF5 SN Aflukin; Chinin; Chinine; Chininum; Conchinin; Conquinine; Quindan; Quinidex; Quinidine; Quinimax; Quinina; Quinineanhydrous; Quinora; Quniacridine; Chinin [German]; Kinder Quinina; QUININE MONO HCL; Quinine Dab; Quinine [BAN]; Quinine anhydrous; Quinine bisulfate; Quinine sulfate; Quinine sulphate; Quinoline alkaloid; LT00645788;Q0028; SB01652; Beta-Quinine; Cin-Quin; Coco-Quinine; IBS-L0034250; Kinder Quinina (TN); Legatrin (TN); Quinine (BAN); Quinine, Anhydrous; Quinine, polymers; Quinine, tannate; Biquinate (*Bisulfate heptathydrate*); Dentojel (*Bisulfate heptathydrate*); Quinamm (*2:1 Sulfate salt*), dihydrate; Quine (*2:1 Sulfate salt*, dihydrate); Quinsan (*2:1 Sulfate salt*), dihydrate; Alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; (+)-Quinidine; (-)-Quinine; (1R)-(6-Methoxyquinolin-4-yl)((1S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (3A,8A,9r)-6'-methoxycinchonan-9-ol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-6'-Methoxycinchonan-9-ol; (8S,9R)-Quinine; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-(-)-Quinine, 6-methoxycinchonidine; (R)-(-)-quinine; (R)-(6-Methoxy-quinolin-4-yl)-((2S,5S)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; (R)-[(2S,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (R)-[(2S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; (S)-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 6'-Methoxycinchonan-9-ol; 6'-Methoxycinchonidine; 6'-Methoxycinchonine; 6-Methoxycinchonine
DMSWYF5 CP Pfizer Pharmaceuticals
DMSWYF5 TC Antimalarials
DMSWYF5 DT Small molecular drug
DMSWYF5 PC 3034034
DMSWYF5 MW 324.4
DMSWYF5 FM C20H24N2O2
DMSWYF5 IC InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1
DMSWYF5 CS COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O
DMSWYF5 IK LOUPRKONTZGTKE-WZBLMQSHSA-N
DMSWYF5 IU (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
DMSWYF5 CA CAS 72402-53-0
DMSWYF5 CB CHEBI:15854
DMSWYF5 DE Malaria
DM5GVHU ID DM5GVHU
DM5GVHU DN Quinolones
DM5GVHU HS Approved
DM5GVHU SN AC1MI0KP
DM5GVHU DT Small molecular drug
DM5GVHU PC 6038
DM5GVHU MW 145.16
DM5GVHU FM C9H7NO
DM5GVHU IC InChI=1S/C9H7NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H,(H,10,11)
DM5GVHU CS C1=CC=C2C(=C1)C=CC(=O)N2
DM5GVHU IK LISFMEBWQUVKPJ-UHFFFAOYSA-N
DM5GVHU IU 1H-quinolin-2-one
DM5GVHU CA CAS 59-31-4
DM5GVHU CB CHEBI:16365
DM5GVHU DE Bacterial infection; Tuberculosis
DMLKFC4 ID DMLKFC4
DMLKFC4 DN Quinupristin
DMLKFC4 HS Approved
DMLKFC4 SN Quinupristina; Quinupristine; Quinupristinum; SYB; RP 57669; Quinupristin [USAN:INN]; Quinupristina [INN-Spanish]; Quinupristine [INN-French]; Quinupristinum [INN-Latin]; RP-57669; Synercid (TN); Quinupristin (JAN/USAN/INN); 4-[4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANINE]-5-[(2S,5R)-5-[[[(3S)-1-AZABICYCLO-[2.2.2]OCT-3-YL]THIO]METHYL]-4-OXO-2-PIPERIDINECARBOXYLIC ACID]VIRGINIAMYCIN; 5delta-(3-quinuclidinyl)thiomethylpristinamycin IA
DMLKFC4 TC Antibiotics
DMLKFC4 DT Small molecular drug
DMLKFC4 PC 5388937
DMLKFC4 MW 1022.2
DMLKFC4 FM C53H67N9O10S
DMLKFC4 IC InChI=1S/C53H67N9O10S/c1-6-37-50(68)61-23-11-14-38(61)51(69)59(5)40(26-32-16-18-36(19-17-32)58(3)4)52(70)62-28-35(30-73-43-29-60-24-20-33(43)21-25-60)42(64)27-39(62)47(65)57-45(34-12-8-7-9-13-34)53(71)72-31(2)44(48(66)55-37)56-49(67)46-41(63)15-10-22-54-46/h7-10,12-13,15-19,22,31,33,35,37-40,43-45,63H,6,11,14,20-21,23-30H2,1-5H3,(H,55,66)(H,56,67)(H,57,65)/t31-,35+,37-,38+,39+,40+,43-,44+,45+/m1/s1
DMLKFC4 CS CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C
DMLKFC4 IK WTHRRGMBUAHGNI-LCYNINFDSA-N
DMLKFC4 IU N-[(3S,6S,12R,15S,16R,19S,22S,25R)-25-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]sulfanylmethyl]-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
DMLKFC4 CA CAS 120138-50-3
DMLKFC4 DE Bacterial infection
DMM4U9G ID DMM4U9G
DMM4U9G DN R0-93877
DMM4U9G HS Approved
DMM4U9G SN Prucalopride; 179474-81-8; UNII-0A09IUW5TP; 4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide; 0A09IUW5TP; C18H26ClN3O3; CHEMBL117287; R-093877; 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide; R 093877; 4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide; 4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide; R093877; Motegrity; Prucalopride [USAN:INN:BAN]
DMM4U9G CP Shire/Takeda
DMM4U9G DT Small molecular drug
DMM4U9G PC 3052762
DMM4U9G MW 367.9
DMM4U9G FM C18H26ClN3O3
DMM4U9G IC InChI=1S/C18H26ClN3O3/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14/h11-12H,2-10,20H2,1H3,(H,21,23)
DMM4U9G CS COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl
DMM4U9G IK ZPMNHBXQOOVQJL-UHFFFAOYSA-N
DMM4U9G IU 4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide
DMM4U9G CA CAS 179474-81-8
DMM4U9G CB CHEBI:135552
DMM4U9G DE Irritable bowel syndrome; Constipation
DMMZXIW ID DMMZXIW
DMMZXIW DN Rabeprazole
DMMZXIW HS Approved
DMMZXIW SN Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMMZXIW CP Eisai; Johnson & Johnson
DMMZXIW TC Antiulcer Agents
DMMZXIW DT Small molecular drug
DMMZXIW PC 5029
DMMZXIW MW 359.4
DMMZXIW FM C18H21N3O3S
DMMZXIW IC InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
DMMZXIW CS CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
DMMZXIW IK YREYEVIYCVEVJK-UHFFFAOYSA-N
DMMZXIW IU 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
DMMZXIW CA CAS 117976-89-3
DMMZXIW CB CHEBI:8768
DMMZXIW DE Bacterial infection
DMFOTZ7 ID DMFOTZ7
DMFOTZ7 DN Racecadotril
DMFOTZ7 HS Approved
DMFOTZ7 SN Acetorphan; Hidrasec; Tiorfan
DMFOTZ7 CP BioProjet; Societe Civile de Recherche
DMFOTZ7 DT Small molecular drug
DMFOTZ7 PC 107751
DMFOTZ7 MW 385.5
DMFOTZ7 FM C21H23NO4S
DMFOTZ7 IC InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25)
DMFOTZ7 CS CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2
DMFOTZ7 IK ODUOJXZPIYUATO-UHFFFAOYSA-N
DMFOTZ7 IU benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate
DMFOTZ7 CA CAS 81110-73-8
DMFOTZ7 CB CHEBI:91508
DMFOTZ7 DE Diarrhea
DMXTCVF ID DMXTCVF
DMXTCVF DN Radium-223-Dichloride
DMXTCVF HS Approved
DMXTCVF CP Bayer HealthCare Pharmaceuticals
DMXTCVF DE Prostate cancer
DMDKF3M ID DMDKF3M
DMDKF3M DN Raloxifene
DMDKF3M HS Approved
DMDKF3M SN Raloxifene (extended-release, CDT)
DMDKF3M CP SCOLR Pharma Inc
DMDKF3M DT Small molecular drug
DMDKF3M PC 5035
DMDKF3M MW 473.6
DMDKF3M FM C28H27NO4S
DMDKF3M IC InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
DMDKF3M CS C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DMDKF3M IK GZUITABIAKMVPG-UHFFFAOYSA-N
DMDKF3M IU [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
DMDKF3M CA CAS 84449-90-1
DMDKF3M CB CHEBI:8772
DMDKF3M DE Osteoporosis
DMYURI6 ID DMYURI6
DMYURI6 DN Raltegravir
DMYURI6 HS Approved
DMYURI6 SN RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL
DMYURI6 CP Merck
DMYURI6 DT Small molecular drug
DMYURI6 PC 54671008
DMYURI6 MW 444.4
DMYURI6 FM C20H21FN6O5
DMYURI6 IC InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
DMYURI6 CS CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
DMYURI6 IK CZFFBEXEKNGXKS-UHFFFAOYSA-N
DMYURI6 IU N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
DMYURI6 CA CAS 518048-05-0
DMYURI6 DE Human immunodeficiency virus infection
DMT9K8G ID DMT9K8G
DMT9K8G DN Raltitrexed
DMT9K8G HS Approved
DMT9K8G SN Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482
DMT9K8G CP AstraZeneca
DMT9K8G TC Anticancer Agents
DMT9K8G DT Small molecular drug
DMT9K8G PC 135400182
DMT9K8G MW 458.5
DMT9K8G FM C21H22N4O6S
DMT9K8G IC InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
DMT9K8G CS CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1
DMT9K8G IK IVTVGDXNLFLDRM-HNNXBMFYSA-N
DMT9K8G IU (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid
DMT9K8G CA CAS 112887-68-0
DMT9K8G CB CHEBI:5847
DMT9K8G DE Rectal adenocarcinoma
DM7IW9J ID DM7IW9J
DM7IW9J DN Ramelteon
DM7IW9J HS Approved
DM7IW9J SN Rozerem; Ramelteon [USAN]; Rozerem (TN); TAK-375; Ramelteon (JAN/USAN/INN); Rozerem, TAK-375, Ramelteon; N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide; N-{2-[(8s)-1,6,7,8-tetrahydro-2h-indeno[5,4-b]fur-8-yl]ethyl}propanamid; (-)-N-(2-(((8S)-1,6,7,8-Tetrahydro-2H-indeno(5,4-b)furan-8-yl)ethyl)propanamide; (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide
DM7IW9J CP Takeda
DM7IW9J TC Hypnotics and Sedatives
DM7IW9J DT Small molecular drug
DM7IW9J PC 208902
DM7IW9J MW 259.339
DM7IW9J FM C16H21NO2
DM7IW9J IC InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
DM7IW9J CS CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3
DM7IW9J IK YLXDSYKOBKBWJQ-LBPRGKRZSA-N
DM7IW9J IU N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide
DM7IW9J CA CAS 196597-26-9
DM7IW9J CB CHEBI:109549
DM7IW9J DE Insomnia; Circadian rhythm sleep disorder
DM2R68E ID DM2R68E
DM2R68E DN Ramipril
DM2R68E HS Approved
DM2R68E SN Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
DM2R68E CP Sanofi-Aventis
DM2R68E TC Antihypertensive Agents
DM2R68E DT Small molecular drug
DM2R68E PC 5362129
DM2R68E MW 416.5
DM2R68E FM C23H32N2O5
DM2R68E IC InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
DM2R68E CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
DM2R68E IK HDACQVRGBOVJII-JBDAPHQKSA-N
DM2R68E IU (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
DM2R68E CA CAS 87333-19-5
DM2R68E CB CHEBI:8774
DM2R68E DE Congestive heart failure
DMH7GN8 ID DMH7GN8
DMH7GN8 DN Ramosetron
DMH7GN8 HS Approved
DMH7GN8 SN 132036-88-5; UNII-7ZRO0SC54Y; Ramosetron [INN]; 7ZRO0SC54Y; CHEMBL1643895; Ramosetron (INN); (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone; Nor-YM 060; SCHEMBL16701; GTPL2301; DTXSID0043842; NTHPAPBPFQJABD-LLVKDONJSA-N; MolPort-019-991-383; CHEBI:135156; ZINC5116719; AC1L3355; BDBM50334454; 8235AH; AKOS015896003; SB19072; DB09290; SC-92398; AJ-53160; LS-187182; TL8000762; R-146; FT-0651831; D08466; A806353; (-)-(R)-1-Methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone; Nasea (TN); YM060
DMH7GN8 DT Small molecular drug
DMH7GN8 PC 108000
DMH7GN8 MW 279.34
DMH7GN8 FM C17H17N3O
DMH7GN8 IC InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1
DMH7GN8 CS CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
DMH7GN8 IK NTHPAPBPFQJABD-LLVKDONJSA-N
DMH7GN8 IU (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone
DMH7GN8 CA CAS 132036-88-5
DMH7GN8 CB CHEBI:135156
DMH7GN8 DE Nausea and vomiting; Irritable bowel syndrome
DMWUFQ4 ID DMWUFQ4
DMWUFQ4 DN Ramucirumab
DMWUFQ4 HS Approved
DMWUFQ4 SN LY3009806
DMWUFQ4 CP Lilly
DMWUFQ4 DT Monoclonal antibody
DMWUFQ4 SQ 9098_H|ramucirumab|Homo sapiens||H-GAMMA-1 (VH(1-116)+CH1(117-214)+HINGE-REGION(215-229)+CH2(230-339)+CH3(340-446))|||||||446||||MW 48696.0|MW 48696.0|: EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >9098_L|ramucirumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(109-214))|||||||214||||MW 23124.7|MW 23124.7|DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMWUFQ4 DE Gastric adenocarcinoma
DMSYPNW ID DMSYPNW
DMSYPNW DN Ranibizumab
DMSYPNW HS Approved
DMSYPNW SN Ranibizumab (nasal spray, hereditary hemorrhagic telangiectasia)
DMSYPNW CP Genentech Inc
DMSYPNW DT Antibody
DMSYPNW SQ Ranibizumab Light Chain: DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Ranibizumab Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL
DMSYPNW DE Hereditary hemorrhagic telangiectasia
DM0GUSX ID DM0GUSX
DM0GUSX DN Ranitidine
DM0GUSX HS Approved
DM0GUSX SN Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
DM0GUSX CP GlaxoSmithKline
DM0GUSX TC Antiulcer Agents
DM0GUSX DT Small molecular drug
DM0GUSX PC 3001055
DM0GUSX MW 314.41
DM0GUSX FM C13H22N4O3S
DM0GUSX IC InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
DM0GUSX CS CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
DM0GUSX IK VMXUWOKSQNHOCA-UKTHLTGXSA-N
DM0GUSX IU (E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
DM0GUSX CA CAS 82530-72-1
DM0GUSX CB CHEBI:8776
DM0GUSX DE Peptic ulcer
DM0C9IL ID DM0C9IL
DM0C9IL DN Ranolazine
DM0C9IL HS Approved
DM0C9IL SN RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination
DM0C9IL CP CV Therapeutics
DM0C9IL TC Analgesics
DM0C9IL DT Small molecular drug
DM0C9IL PC 56959
DM0C9IL MW 427.5
DM0C9IL FM C24H33N3O4
DM0C9IL IC InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)
DM0C9IL CS CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
DM0C9IL IK XKLMZUWKNUAPSZ-UHFFFAOYSA-N
DM0C9IL IU N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
DM0C9IL CA CAS 95635-55-5
DM0C9IL CB CHEBI:87690
DM0C9IL DE Chronic/stable angina; Paroxysmal atrial fibrillation
DM3WKQ4 ID DM3WKQ4
DM3WKQ4 DN Rasagiline
DM3WKQ4 HS Approved
DM3WKQ4 SN RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
DM3WKQ4 CP Teva Pharmaceutical Industries Ltd
DM3WKQ4 TC Antiparkinson Agents
DM3WKQ4 DT Small molecular drug
DM3WKQ4 PC 3052776
DM3WKQ4 MW 171.24
DM3WKQ4 FM C12H13N
DM3WKQ4 IC InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
DM3WKQ4 CS C#CCN[C@@H]1CCC2=CC=CC=C12
DM3WKQ4 IK RUOKEQAAGRXIBM-GFCCVEGCSA-N
DM3WKQ4 IU (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
DM3WKQ4 CA CAS 136236-51-6
DM3WKQ4 CB CHEBI:63620
DM3WKQ4 DE Skin cancer; Skin imperfections; Parkinson disease
DMWTVAN ID DMWTVAN
DMWTVAN DN Rauwolfia serpentina root
DMWTVAN HS Approved
DMWTVAN SN Raubasine; 483-04-5; Ajmalicin; Circolene; Sarpan; py-Tetrahydroserpentine; Tetrahydroserpentine; UNII-4QJL8OX71Z; EINECS 207-589-5; BRN 0097268; 4QJL8OX71Z; CHEBI:2524; CHEMBL123325; Methyl 16,17-didehydro-19alpha-methyl-18-oxayohimban-16-carboxylat; 16,17-Didehydro-19-methyloxayohimban-16-carboxylic acid m
DMWTVAN DT Small molecular drug
DMWTVAN DE Discovery agent
DMSWNJF ID DMSWNJF
DMSWNJF DN Ravulizumab
DMSWNJF HS Approved
DMSWNJF SN Ravulizumab [USAN]; UNII-C3VX249T6L; C3VX249T6L; ALXN1210
DMSWNJF CP Alexion
DMSWNJF DT Antibody
DMSWNJF DE Paroxysmal nocturnal haemoglobinuria
DM7QG0M ID DM7QG0M
DM7QG0M DN Raxibacumab
DM7QG0M HS Approved
DM7QG0M CP GlaxoSmithKline
DM7QG0M DT Monoclonal antibody
DM7QG0M DE Anthrax
DM26PRD ID DM26PRD
DM26PRD DN Reboxetine
DM26PRD HS Approved
DM26PRD SN 71620-89-8; (2r)-2-[(R)-(2-Ethoxyphenoxy)(Phenyl)methyl]morpholine; Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,R*)-; Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel-; Reboxetine [INN:BAN]; Morpholine, 2-((R)-(2-ethoxyphenoxy)phenylmethyl)-, (2R)-rel-; HSDB 7701; Edronax (TN); (R,R)-Reboxetine; AC1L2RJ0; SCHEMBL34533; CHEMBL383921; DTXSID1048257; MolPort-005-943-618; CHEBI:135342; ZINC3996032; BCP12060; AKOS015966368; DB00234; AN-34535; AK431803; AJ-47614
DM26PRD CP Pfizer Pharmaceuticals
DM26PRD TC Antidepressants
DM26PRD DT Small molecular drug
DM26PRD PC 127151
DM26PRD MW 313.4
DM26PRD FM C19H23NO3
DM26PRD IC InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
DM26PRD CS CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
DM26PRD IK CBQGYUDMJHNJBX-RTBURBONSA-N
DM26PRD IU (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
DM26PRD CA CAS 71620-89-8
DM26PRD CB CHEBI:135342
DM26PRD DE Depression
DMY7ESM ID DMY7ESM
DMY7ESM DN Recombinant Factor IX
DMY7ESM HS Approved
DMY7ESM SN RFIX, Baxter; Recombinant Factor IX, Baxter
DMY7ESM CP Baxter 1nternational
DMY7ESM DE Factor IX deficiency; Bleeding disorder
DMMPCFX ID DMMPCFX
DMMPCFX DN Recombinant human endostatin
DMMPCFX HS Approved
DMMPCFX SN Endostar; Endu; Recombinant human endostatin (cancer); YH-16; Recombinant human endostatin (cancer), Shandong Simcere Medgenn
DMMPCFX CP Shandong Simcere Medgenn Bio- Pharmaceutical Co Ltd
DMMPCFX DE Solid tumour/cancer
DM76VHG ID DM76VHG
DM76VHG DN Regadenoson
DM76VHG HS Approved
DM76VHG SN Lexiscan (TN)
DM76VHG CP CV Therapeutics
DM76VHG DT Small molecular drug
DM76VHG PC 219024
DM76VHG MW 390.35
DM76VHG FM C15H18N8O5
DM76VHG IC InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
DM76VHG CS CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM76VHG IK LZPZPHGJDAGEJZ-AKAIJSEGSA-N
DM76VHG IU 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide
DM76VHG CA CAS 313348-27-5
DM76VHG CB CHEBI:135613
DM76VHG DE Radionuclide imaging
DM87XSN ID DM87XSN
DM87XSN DN REGN-727
DM87XSN HS Approved
DM87XSN SN Alirocumab; Alirocumab); RENG-727; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis
DM87XSN CP Sanofi; Novo Nordisk
DM87XSN DT Antibody
DM87XSN DE Familial hypercholesterolemia; Hypercholesterolaemia
DMHSY1I ID DMHSY1I
DMHSY1I DN Regorafenib
DMHSY1I HS Approved
DMHSY1I SN Regorafenib; 755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
DMHSY1I CP Bayer HealthCare Pharmaceuticals
DMHSY1I DT Small molecular drug
DMHSY1I PC 11167602
DMHSY1I MW 482.8
DMHSY1I FM C21H15ClF4N4O3
DMHSY1I IC InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
DMHSY1I CS CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
DMHSY1I IK FNHKPVJBJVTLMP-UHFFFAOYSA-N
DMHSY1I IU 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMHSY1I CA CAS 755037-03-7
DMHSY1I CB CHEBI:68647
DMHSY1I DE Metastatic colorectal cancer
DMK7IWL ID DMK7IWL
DMK7IWL DN Relugolix
DMK7IWL HS Approved
DMK7IWL SN 737789-87-6; TAK-385; TAK 385; UNII-P76B05O5V6; CHEMBL1800159; TAK-385/TAK385; P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; Relugolix [USAN:INN]; TAK385; Relugolix (JAN/INN); SCHEMBL778416; GTPL5586; DTXSID40224167; MolPort-044-567-649; AOMXMOCNKJTRQP-UHFFFAOYSA-N; EX-A1083; BCP21587; ZINC43206033; BDBM50347982; AKOS027440398; SB16721; DB11853; CS-5917
DMK7IWL CP Takeda
DMK7IWL DT Small molecular drug
DMK7IWL PC 10348973
DMK7IWL MW 623.6
DMK7IWL FM C29H27F2N7O5S
DMK7IWL IC InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
DMK7IWL CS CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
DMK7IWL IK AOMXMOCNKJTRQP-UHFFFAOYSA-N
DMK7IWL IU 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
DMK7IWL CA CAS 737789-87-6
DMK7IWL DE Endometriosis; Prostate cancer
DMBFZ6L ID DMBFZ6L
DMBFZ6L DN Remdesivir
DMBFZ6L HS Approved
DMBFZ6L SN L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
DMBFZ6L CP Gilead Sciences, Foster City, CA
DMBFZ6L DT Small molecular drug
DMBFZ6L PC 121304016
DMBFZ6L MW 602.6
DMBFZ6L FM C27H35N6O8P
DMBFZ6L IC InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
DMBFZ6L CS CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
DMBFZ6L IK RWWYLEGWBNMMLJ-YSOARWBDSA-N
DMBFZ6L IU 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMBFZ6L CA CAS 1809249-37-3
DMBFZ6L CB CHEBI:145994
DMBFZ6L DE Ebola virus infection; Coronavirus Disease 2019 (COVID-19)
DMZTXCH ID DMZTXCH
DMZTXCH DN Remifentanil
DMZTXCH HS Approved
DMZTXCH SN Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
DMZTXCH CP Abbott Laboratories
DMZTXCH TC Hypnotics and Sedatives
DMZTXCH DT Small molecular drug
DMZTXCH PC 60815
DMZTXCH MW 376.4
DMZTXCH FM C20H28N2O5
DMZTXCH IC InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
DMZTXCH CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC
DMZTXCH IK ZTVQQQVZCWLTDF-UHFFFAOYSA-N
DMZTXCH IU methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DMZTXCH CA CAS 132875-61-7
DMZTXCH CB CHEBI:8802
DMZTXCH DE Anaesthesia
DMNAKLY ID DMNAKLY
DMNAKLY DN Remikiren
DMNAKLY HS Approved
DMNAKLY SN REM; Remikiren [INN]; Remikiren (INN); Ro 42-5892; Ro-42-5892; (2R)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide; (S)-alpha-((S)-alpha-((t-butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; (alphaS)-alpha-((alphaS)-alpha-((tert-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; 2-benzyl-3-tert-butylsulfonyl-N-[1-[(1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl)amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
DMNAKLY CP Hoffmann-La Roche pharmaceutical company
DMNAKLY TC Antihypertensive Agents
DMNAKLY DT Small molecular drug
DMNAKLY PC 6324659
DMNAKLY MW 630.8
DMNAKLY FM C33H50N4O6S
DMNAKLY IC InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1
DMNAKLY CS CC(C)(C)S(=O)(=O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3CCCCC3)[C@H]([C@H](C4CC4)O)O
DMNAKLY IK UXIGZRQVLGFTOU-VQXQMPIVSA-N
DMNAKLY IU (2S)-2-benzyl-3-tert-butylsulfonyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]propanamide
DMNAKLY CA CAS 126222-34-2
DMNAKLY CB CHEBI:8803
DMNAKLY DE Hypertension
DMLVSYX ID DMLVSYX
DMLVSYX DN Remimazolam
DMLVSYX HS Approved
DMLVSYX SN CNS-7054; CNS-7056; CNS-7056B; CNS-7056X; GW-351564X; GW-418259X; GW-457837A; GW-502056X; ONO-2745; Short-acting sedatives, Therasci; GABA A agonist (anesthesia, sedation) CeNeS/Ono; Sedatives (short acting), CeNeS/Ono; Sedatives (short acting), PAION/Ono; Sedatives (short-acting), TheraSci; Short-acting sedatives, Therasci/GSK; Sedatives (short-acting), TheraSci/GSK
DMLVSYX CP GlaxoSmithKline plc
DMLVSYX DT Small molecular drug
DMLVSYX PC 9867812
DMLVSYX MW 439.3
DMLVSYX FM C21H19BrN4O2
DMLVSYX IC InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1
DMLVSYX CS CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
DMLVSYX IK CYHWMBVXXDIZNZ-KRWDZBQOSA-N
DMLVSYX IU methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
DMLVSYX CA CAS 308242-62-8
DMLVSYX DE Anaesthesia; Procedural sedation
DM5SXUV ID DM5SXUV
DM5SXUV DN Repaglinide
DM5SXUV HS Approved
DM5SXUV SN Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
DM5SXUV CP Novo Nordisk
DM5SXUV TC Hypoglycemic Agents
DM5SXUV DT Small molecular drug
DM5SXUV PC 65981
DM5SXUV MW 452.6
DM5SXUV FM C27H36N2O4
DM5SXUV IC InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
DM5SXUV CS CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
DM5SXUV IK FAEKWTJYAYMJKF-QHCPKHFHSA-N
DM5SXUV IU 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
DM5SXUV CA CAS 135062-02-1
DM5SXUV CB CHEBI:8805
DM5SXUV DE Diabetic complication
DM6KI0D ID DM6KI0D
DM6KI0D DN Repirinast
DM6KI0D HS Approved
DM6KI0D SN MY-1250; MY-5116; MY-6116
DM6KI0D CP Mitsubishi-Tokyo Pharmaceuticals Inc
DM6KI0D DT Small molecular drug
DM6KI0D PC 5050
DM6KI0D MW 355.4
DM6KI0D FM C20H21NO5
DM6KI0D IC InChI=1S/C20H21NO5/c1-10(2)7-8-25-20(24)15-9-14(22)16-18(26-15)13-6-5-11(3)12(4)17(13)21-19(16)23/h5-6,9-10H,7-8H2,1-4H3,(H,21,23)
DM6KI0D CS CC1=C(C2=C(C=C1)C3=C(C(=O)C=C(O3)C(=O)OCCC(C)C)C(=O)N2)C
DM6KI0D IK NFQIAEMCQGTTIR-UHFFFAOYSA-N
DM6KI0D IU 3-methylbutyl 7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylate
DM6KI0D CA CAS 73080-51-0
DM6KI0D CB CHEBI:32092
DM6KI0D DE Asthma
DMG7SQK ID DMG7SQK
DMG7SQK DN Rescinnamine
DMG7SQK HS Approved
DMG7SQK SN Anapral; Anaprel; Apolon; Apoterin; Cartric; Cinamine; Cinatabs; Cinnaloid; Cinnasil; Moderil; Normorescina; Paresinan; Raupyrol; Raurescin; Raurescine; Recinnamine; Recitensina; Rescaloid; Rescamin; Rescidan; Rescin; Rescinamina; Rescinnamin; Rescinnamina; Rescinnaminum; Rescinpal; Rescisan; Rescitens; Resealoid; Reserpinene; Reserpinin; Reserpinine; Resipal; Reskinnamin; Rozex; Scinnamina; Tenamine; Tuareg; Apoterin S; Methyl trimethoxycinnamoylreserpate; Rescinnamina [DCIT]; Trimethoxy cinnamoyl reserpate de methyl; Trimethoxy cinnamoyl reserpate de methyl [French]; Trimethoxycinnamoyl methyl reserpate; Tsuruselpi S; Anaprel (TN); Cinnasil (TN); Moderil (TN); NP-011016; Rescinamina [INN-Spanish]; Rescinnamine (VAN); Rescinnaminum [INN-Latin]; Resepinine (C35 alkaloid); Reserpinine (C35 alkaloid); Reserpinine (VAN); Tsuruselpi S (TN); Rescinnamine (JAN/INN); Rescinnamine [BAN:INN:JAN]; Methyl reserpate 3,4,5-trimethoxycinnamic acid ester; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Methyl 18-O-(3,4,5-trimethoxycinnamoyl)reserpate; O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; 3,4,5-Trimethoxycinnamic acid, methyl reserpate; 3,4,5-Trimethoxycinnamoyl methyl reserpate; 3,4,5-Trimethylcinnamic acid, ester with methyl reserpate; 3,4,5-Trimethylcinnamoyl methyl reserpate
DMG7SQK TC Antihypertensive Agents
DMG7SQK DT Small molecular drug
DMG7SQK PC 5280954
DMG7SQK MW 634.7
DMG7SQK FM C35H42N2O9
DMG7SQK IC InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
DMG7SQK CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)/C=C/C6=CC(=C(C(=C6)OC)OC)OC
DMG7SQK IK SZLZWPPUNLXJEA-QEGASFHISA-N
DMG7SQK IU methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMG7SQK CA CAS 24815-24-5
DMG7SQK CB CHEBI:28572
DMG7SQK DE Hypertension
DM6VM38 ID DM6VM38
DM6VM38 DN Reserpine
DM6VM38 HS Approved
DM6VM38 SN Abesta; Abicol; Adelfan; Adelphin; Alkarau; Alkaserp; Alserin; Apoplon; Apsical; Ascoserp; Ascoserpina; Austrapine; Banasil; Banisil; Benazyl; Bioserpine; Brinderdin; Briserine; Broserpine; Cardioserpin; Carditivo; Carpacil; Carrserp; Darebon; Deserpine; Dralserp; Eberpine; Eberspine; Ebserpine; Elfanex; Elserpine; Enipresser; Escaspere; Eserpine; Eskaserp; Eskaserpine; Gammaserpine; Gilucard; Helfoserpin; Hexaplin; Hiposerpil; Hiserpia; Hydropine; Hydroserp; Hypersil; Hypersine; Hypertensan; Idoserp; Idsoserp; Interpina; Kitine; Klimanosid; Lemiserp; Loweserp; Mallopress; Maviserpin; Mayserpine; Mephaserpin; Modenol; Naquival; Nembuserpin; Neoserfin; Neoserp; Neoslowten; Orthoserpina; Perskleran; Pressimedin; Purserpine; Quiescin; Raucap; Raudiford; Raudixin; Raudixoid; Raugal; Raulen; Rauloydin; Raumorine; Raunervil; Raunorine; Raunova; Raupasil; Raupoid; Raurine; Rausan; Rausedan; Rausedil; Rausedyl; Rauserpin; Rauserpine; Rauserpol; Rausingle; Rautrin; Rauvlid; Rauwasedin; Rauwilid; Rauwiloid; Rauwipur; Rauwita; Rauwoleaf; Rawilid; Recipin; Regroton; Resaltex; Resedrex; Resedril; Reserbal; Resercaps; Resercen; Reserfia; Reserjen; Reserlor; Reserp; Reserpal; Reserpamed; Reserpanca; Reserpene; Reserpex; Reserpidefe; Reserpil; Reserpin; Reserpina; Reserpinum; Reserpka; Reserpoid; Reserpur; Reserutin; Resiatric; Residin; Residine; Resine; Resocalm; Resperin; Resperine; Respital; Restran; Rezerpin; Riserpa; Rivased; Rivasin; Rolserp; Roxel; Roxinoid; Roxynoid; Ryser; Salupres; Sandril; Sandron; Sedaraupin; Sedaraupina; Sederaupin; Sedserp; Seominal; Serfin; Serfolia; Serolfia; Serpalan; Serpaloid; Serpaneurona; Serpanray; Serpasil; Serpasol; Serpate; Serpazil; Serpazol; Serpedin; Serpen; Serpena; Serpentil; Serpentin; Serpentina; Serpicon; Serpil; Serpiloid; Serpilum; Serpine; Serpipur; Serpivate; Serpivite; Serpogen; Serpoid; Serpone; Serpyrit; Sertabs; Sertens; Sertensin; Sertina; Supergan; Tefaserpina; Temposerpine; Tensanyl; Tenserpinie; Tensional; Tensionorme; Tepserpine; Terbolan; Transerpin; Triserpin; Tylandril; Unilord; Unipres; VIXO; Esc aspere; Hydromox R; Hypercal B; Loweser p; Neose rfin; Rau sedyl; Renese R; Rese rpamed; Se rpate; V Serp; VI XO; Diupres 250; Diupres 500; ENT 50146; H 520; Hydropres 25; Hydropres 50; Hydrosine 25; R 0875; Apoplon (TN); Diupres-250; Diupres-500; Diurese-R; Diutensen-R; HYDRO-RESERP; Hydrap-ES; Hydromox-R; Key-serpine; L-Carpserp; Neo-serp; Rau-Sed; Renese-R; Rese-lar; Reser-ar; SK-Reserpine; T-Serp; Usaf cb-27; V-Serp; Vio-Serpine; Cam-Ap-Es; L"-Carpserp; R-e-s; Ser-A-Gen; 3P Reserp
DM6VM38 TC Antihypertensive Agents
DM6VM38 DT Small molecular drug
DM6VM38 PC 5770
DM6VM38 MW 608.7
DM6VM38 FM C33H40N2O9
DM6VM38 IC InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1
DM6VM38 CS CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
DM6VM38 IK QEVHRUUCFGRFIF-MDEJGZGSSA-N
DM6VM38 IU methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DM6VM38 CA CAS 50-55-5
DM6VM38 CB CHEBI:28487
DM6VM38 DE Hypertension
DM0AUCH ID DM0AUCH
DM0AUCH DN Reslizumab
DM0AUCH HS Approved
DM0AUCH CP Teva
DM0AUCH DT Monoclonal antibody
DM0AUCH DE Severe asthma; Asthma; Eosinophilic asthma
DM9JXB7 ID DM9JXB7
DM9JXB7 DN Retapamulin
DM9JXB7 HS Approved
DM9JXB7 SN Altabax; Altargo; SB 275833; Altabax (Glaxo); Altabax (TN); Altargo (TN); Retapamulin (USAN/INN)
DM9JXB7 CP GlaxoSmithKline
DM9JXB7 TC Antibiotics
DM9JXB7 DT Small molecular drug
DM9JXB7 PC 6918462
DM9JXB7 MW 517.799
DM9JXB7 FM C30H47NO4S
DM9JXB7 IC InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29+,30+/m1/s1
DM9JXB7 CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4C[C@H]5CC[C@@H](C4)N5C)C
DM9JXB7 IK STZYTFJPGGDRJD-FJJJPKKESA-N
DM9JXB7 IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl]acetate
DM9JXB7 CA CAS 224452-66-8
DM9JXB7 CB CHEBI:166679
DM9JXB7 DE Impetigo
DML0D1P ID DML0D1P
DML0D1P DN Reteplase
DML0D1P HS Approved
DML0D1P SN Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)
DML0D1P TC Thrombolytic Agents
DML0D1P SQ DB00015 sequence: SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DML0D1P DE Heart attack
DMGNYIH ID DMGNYIH
DMGNYIH DN Retigabine
DMGNYIH HS Approved
DMGNYIH SN Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester
DMGNYIH CP GSK
DMGNYIH TC Anticonvulsants
DMGNYIH DT Small molecular drug
DMGNYIH PC 121892
DMGNYIH MW 303.33
DMGNYIH FM C16H18FN3O2
DMGNYIH IC InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
DMGNYIH CS CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N
DMGNYIH IK PCOBBVZJEWWZFR-UHFFFAOYSA-N
DMGNYIH IU ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
DMGNYIH CA CAS 150812-12-7
DMGNYIH CB CHEBI:68584
DMGNYIH DE Epilepsy; Behcet disease
DMMP5SI ID DMMP5SI
DMMP5SI DN Revefenacin
DMMP5SI HS Approved
DMMP5SI SN UNII-G2AE2VE07O; G2AE2VE07O; Revefenacin [INN]; Revefenacin [WHO-DD]; Revefenacin [USAN:INN]; Revefenacin (USAN/INN); SCHEMBL356480; EX-A1722; DB11855; GSK1160724; CS-7743; GSK-1160724; HY-15851; D10978; 1211931-83-7
DMMP5SI CP Theravance Biopharma/Mylan
DMMP5SI PC 11753673
DMMP5SI MW 597.7
DMMP5SI FM C35H43N5O4
DMMP5SI IC InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
DMMP5SI CS CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
DMMP5SI IK FYDWDCIFZSGNBU-UHFFFAOYSA-N
DMMP5SI IU [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
DMMP5SI CA CAS 864750-70-9
DMMP5SI DE Chronic obstructive pulmonary disease
DM8LRU2 ID DM8LRU2
DM8LRU2 DN Revolade/Promacta
DM8LRU2 HS Approved
DM8LRU2 SN AC1OC7GM
DM8LRU2 CP GSK
DM8LRU2 DT Small molecular drug
DM8LRU2 PC 6913084
DM8LRU2 MW 330.9
DM8LRU2 FM C22H31Cl
DM8LRU2 IC InChI=1S/C22H31Cl/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20/h8,12,15-18,20H,1-7,9-11,13-14H2/b12-8-
DM8LRU2 CS C1CCCC(CC1)C/C=C\\C2=CC(=C(C=C2)C3CCCCC3)Cl
DM8LRU2 IK NDXQJQCGBAIFER-WQLSENKSSA-N
DM8LRU2 IU [(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane
DM8LRU2 DE Idiopathic thrombocytopenic purpura; Thrombocytopenia; Chronic liver disease
DM69XMQ ID DM69XMQ
DM69XMQ DN RG-7446
DM69XMQ HS Approved
DM69XMQ CP Genentech
DM69XMQ DT Monoclonal antibody
DM69XMQ DE Urothelial carcinoma; Bladder cancer
DMNF0G8 ID DMNF0G8
DMNF0G8 DN Rh-alphaglucosidase
DMNF0G8 HS Approved
DMNF0G8 SN Pompase (TN)
DMNF0G8 DE Pompe disease
DM3ADGP ID DM3ADGP
DM3ADGP DN Rhucin
DM3ADGP HS Approved
DM3ADGP SN sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil
DM3ADGP CP Pfizer
DM3ADGP DT Small molecular drug
DM3ADGP PC 135398744
DM3ADGP MW 474.6
DM3ADGP FM C22H30N6O4S
DM3ADGP IC InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
DM3ADGP CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
DM3ADGP IK BNRNXUUZRGQAQC-UHFFFAOYSA-N
DM3ADGP IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DM3ADGP CA CAS 139755-83-2
DM3ADGP CB CHEBI:9139
DM3ADGP DE Hereditary angioedema; Erectile dysfunction
DMALNG0 ID DMALNG0
DMALNG0 DN RHuEPO
DMALNG0 HS Approved
DMALNG0 CP Bio-Gal Advanced Biotechnology
DMALNG0 DE Solid tumour/cancer
DMEYLH9 ID DMEYLH9
DMEYLH9 DN Ribavirin
DMEYLH9 HS Approved
DMEYLH9 SN ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus); Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin
DMEYLH9 CP Hoffmann-La Roche pharmaceutical company
DMEYLH9 TC Antiviral Agents
DMEYLH9 DT Small molecular drug
DMEYLH9 PC 37542
DMEYLH9 MW 244.2
DMEYLH9 FM C8H12N4O5
DMEYLH9 IC InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
DMEYLH9 CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DMEYLH9 IK IWUCXVSUMQZMFG-AFCXAGJDSA-N
DMEYLH9 IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
DMEYLH9 CA CAS 36791-04-5
DMEYLH9 CB CHEBI:63580
DMEYLH9 DE Hepatitis C virus infection
DM9CIUW ID DM9CIUW
DM9CIUW DN Ribociclib succinate
DM9CIUW HS Approved
DM9CIUW SN 1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739
DM9CIUW CP Novartis
DM9CIUW DT Small molecular drug
DM9CIUW PC 57334219
DM9CIUW MW 552.6
DM9CIUW FM C27H36N8O5
DM9CIUW IC InChI=1S/C23H30N8O.C4H6O4/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30;5-3(6)1-2-4(7)8/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28);1-2H2,(H,5,6)(H,7,8)
DM9CIUW CS CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5.C(CC(=O)O)C(=O)O
DM9CIUW IK NHANOMFABJQAAH-UHFFFAOYSA-N
DM9CIUW IU butanedioic acid;7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DM9CIUW CA CAS 1374639-75-4
DM9CIUW DE Hormone receptor positive and HER2-negative advanced or metastatic breast cancer; Breast cancer
DM8YMWE ID DM8YMWE
DM8YMWE DN Riboflavin
DM8YMWE HS Approved
DM8YMWE SN riboflavin; vitamin B2; Lactoflavin; Riboflavine; Vitamin G; 83-88-5; Lactoflavine; (-)-riboflavin; Beflavine; Beflavin; Riboflavina; Flavaxin; Vitaflavine; Riboflavinum; Ribocrisina; Ribovel; Lactobene; Ribotone; Flaxain; Ribosyn; Riboderm; Ribipca; Flavin BB; Vitasan B2; Fiboflavin; Dermadram; Hyflavin; HYRE; Vitamin Bi; Aqua-Flave; 7,8-Dimethyl-10-ribitylisoalloxazine; Russupteridine Yellow III; 6,7-Dimethyl-9-D-ribitylisoalloxazine; Riboflavinequinone; Riboflavinum [INN-Latin]; Riboflavine [INN-French]; Riboflavina [INN-Spanish]
DM8YMWE DT Small molecular drug
DM8YMWE PC 493570
DM8YMWE MW 376.4
DM8YMWE FM C17H20N4O6
DM8YMWE IC InChI=1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1
DM8YMWE CS CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O
DM8YMWE IK AUNGANRZJHBGPY-SCRDCRAPSA-N
DM8YMWE IU 7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione
DM8YMWE CA CAS 83-88-5
DM8YMWE CB CHEBI:17015
DM8YMWE DE Acne vulgaris
DMWH9CN ID DMWH9CN
DMWH9CN DN Ridogrel
DMWH9CN HS Approved
DMWH9CN SN Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
DMWH9CN TC Gastrointestinal Agents
DMWH9CN DT Small molecular drug
DMWH9CN PC 5362391
DMWH9CN MW 366.3
DMWH9CN FM C18H17F3N2O3
DMWH9CN IC InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+
DMWH9CN CS C1=CC(=CC(=C1)C(F)(F)F)/C(=N\\OCCCCC(=O)O)/C2=CN=CC=C2
DMWH9CN IK GLLPUTYLZIKEGF-HAVVHWLPSA-N
DMWH9CN IU 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
DMWH9CN CA CAS 110140-89-1
DMWH9CN CB CHEBI:135542
DMWH9CN DE Acute myocardial infarction
DM1YBHK ID DM1YBHK
DM1YBHK DN Rifabutin
DM1YBHK HS Approved
DM1YBHK SN Alfacid; Ansamycin; Ansatipin; Ansatipine; Assatipin; Mycobutin; RBT; Rifabutina; Rifabutine; Rifabutinum; Grunenthal Brand of Rifabutin; Kenfarma Brand of Rifabutin; Pfizer Brand of Rifabutin; Rifabutin Pfizer Brand; Rifabutina [Spanish]; Rifabutine [French]; Rifabutinum [Latin]; Antibiotic LM 427; LM 427; LM427; DRG-0085; LM-427; Mycobutin (TN); Rifabutin [USAN:BAN:INN]; Rifabutin (JAN/USP/INN); Mycobutin, Ansamycin, LM 427, Ansatipine, Rifabutin; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptameth; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; 4-N-isobutylspiropiperidylrifamycin S
DM1YBHK CP Adria Laboratories
DM1YBHK TC Antibiotics
DM1YBHK DT Small molecular drug
DM1YBHK PC 135398743
DM1YBHK MW 847
DM1YBHK FM C46H62N4O11
DM1YBHK IC InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
DM1YBHK CS C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C
DM1YBHK IK ZWBTYMGEBZUQTK-PVLSIAFMSA-N
DM1YBHK IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate
DM1YBHK CA CAS 72559-06-9
DM1YBHK DE Mycobacterium infection; Tuberculosis
DM5DSFZ ID DM5DSFZ
DM5DSFZ DN Rifampicin
DM5DSFZ HS Approved
DM5DSFZ SN Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifamor; Rifampicin; Rifampicin SV; Rifampicina; Rifampicina [INN-Spanish]; Rifampicine [French]; Rifampicinum; Rifampicinum [INN-Latin]; Rifamycin AMP; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Sinerdol; Tubocin; Archidyn; Arficin; Arzide; Benemicin; Dione 21-acetate; Doloresum; Eremfat; Fenampicin; L-5103 Lepetit; rifampin; 13292-46-1; Abrifam; Ba 41166/E; R/AMP; Rifa; Rifam
DM5DSFZ PC 135398735
DM5DSFZ MW 822.9
DM5DSFZ FM C43H58N4O12
DM5DSFZ IC JQXXHWHPUNPDRT-WLSIYKJHSA-N
DM5DSFZ CS CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C
DM5DSFZ IK 1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
DM5DSFZ IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DM5DSFZ CA CAS 13292-46-1
DM5DSFZ CB CHEBI:27470
DM5DSFZ DE Osteoporosis
DMA8J1G ID DMA8J1G
DMA8J1G DN Rifampin
DMA8J1G HS Approved
DMA8J1G SN Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI)
DMA8J1G CP Norvatis Phamaceuticals Corporation
DMA8J1G TC Antituberculosis Agents
DMA8J1G DT Small molecular drug
DMA8J1G PC 135398735
DMA8J1G MW 822.9
DMA8J1G FM C43H58N4O12
DMA8J1G IC InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
DMA8J1G CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C
DMA8J1G IK JQXXHWHPUNPDRT-WLSIYKJHSA-N
DMA8J1G IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMA8J1G CA CAS 13292-46-1
DMA8J1G CB CHEBI:28077
DMA8J1G DE Tuberculosis
DMEH3O7 ID DMEH3O7
DMEH3O7 DN Rifamycin
DMEH3O7 HS Approved
DMEH3O7 SN Rifamycin SV; Rifamycin SV MMX; Rifamycin sodium; CB-01-11; Rifamycin (oral controlled-release, gastrointestinal-specific); Rifamycin (oral controlled-release, gastrointestinal-specific), Cosmo/Dr Falk/Santarus
DMEH3O7 CP Cosmo Technologies
DMEH3O7 DT Small molecular drug
DMEH3O7 PC 6324616
DMEH3O7 MW 697.8
DMEH3O7 FM C37H47NO12
DMEH3O7 IC InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
DMEH3O7 CS C[C@H]1/C=C/C=C(\\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C
DMEH3O7 IK HJYYPODYNSCCOU-ODRIEIDWSA-N
DMEH3O7 IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMEH3O7 CA CAS 6998-60-3
DMEH3O7 CB CHEBI:29673
DMEH3O7 DE Diarrhea; Infectious disease
DMCHV4I ID DMCHV4I
DMCHV4I DN Rifapentine
DMCHV4I HS Approved
DMCHV4I SN RIFAPENTINE; Rifapentina; Rifapentinum; Cyclopentylrifampicin; Rifamycin AF/ACPP; Antibiotic DL 473IT; KTC 1; 61379-65-5; MDL 473; DRG-0283; DL 473; R-773; R 77-3; 3-(N-(4-Cyclopentyl-1-piperazinyl)formimidoyl)rifamycin; 3-(4-Cyclopentyl-1-piperazinyl)iminomethylrifamycin SV; 3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; Rifapentin,(S); NCGC00167431-01; ZINC169621228; NCGC00167431-03; AN-15578; RPE
DMCHV4I CP Sanofi-Aventis
DMCHV4I TC Antituberculosis Agents
DMCHV4I DT Small molecular drug
DMCHV4I PC 135403821
DMCHV4I MW 877
DMCHV4I FM C47H64N4O12
DMCHV4I IC InChI=1S/C47H64N4O12/c1-24-13-12-14-25(2)46(59)49-37-32(23-48-51-20-18-50(19-21-51)31-15-10-11-16-31)41(56)34-35(42(37)57)40(55)29(6)44-36(34)45(58)47(8,63-44)61-22-17-33(60-9)26(3)43(62-30(7)52)28(5)39(54)27(4)38(24)53/h12-14,17,22-24,26-28,31,33,38-39,43,53-57H,10-11,15-16,18-21H2,1-9H3,(H,49,59)/b13-12+,22-17+,25-14-,48-23+/t24-,26+,27+,28+,33-,38-,39+,43+,47-/m0/s1
DMCHV4I CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C
DMCHV4I IK WDZCUPBHRAEYDL-GZAUEHORSA-N
DMCHV4I IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
DMCHV4I CA CAS 61379-65-5
DMCHV4I CB CHEBI:45304
DMCHV4I DE Tuberculosis; Macular degeneration
DMW1TV2 ID DMW1TV2
DMW1TV2 DN Rifaximin
DMW1TV2 HS Approved
DMW1TV2 SN RCIFAX; Rifaximin (bioadhesive/ gastrointestinal extended release); Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals
DMW1TV2 CP Salix Pharmaceuticals Ltd
DMW1TV2 DT Small molecular drug
DMW1TV2 PC 6436173
DMW1TV2 MW 785.9
DMW1TV2 FM C43H51N3O11
DMW1TV2 IC InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
DMW1TV2 CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C
DMW1TV2 IK NZCRJKRKKOLAOJ-XRCRFVBUSA-N
DMW1TV2 IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate
DMW1TV2 CA CAS 80621-81-4
DMW1TV2 CB CHEBI:75246
DMW1TV2 DE Bacterial infection
DM13PQW ID DM13PQW
DM13PQW DN Rilmenidine
DM13PQW HS Approved
DM13PQW SN Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid
DM13PQW DT Small molecular drug
DM13PQW PC 68712
DM13PQW MW 180.25
DM13PQW FM C10H16N2O
DM13PQW IC InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
DM13PQW CS C1CC1C(C2CC2)NC3=NCCO3
DM13PQW IK CQXADFVORZEARL-UHFFFAOYSA-N
DM13PQW IU N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
DM13PQW CA CAS 54187-04-1
DM13PQW CB CHEBI:8862
DM13PQW DE Hypertension
DMGLUQS ID DMGLUQS
DMGLUQS DN Rilonacept
DMGLUQS HS Approved
DMGLUQS SN Rilonacept (USAN/INN)
DMGLUQS CP Regeneron
DMGLUQS SQ 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|: SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKKVTSEDLKRSYVCHARSAKGEVAKAAKVKQKVPAPRYTVEKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKDDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNLCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDRLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDLGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISEIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNSGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMGLUQS DE Arthritis; Acute gout flare
DMJ0QOW ID DMJ0QOW
DMJ0QOW DN Rilpivirine
DMJ0QOW HS Approved
DMJ0QOW SN 500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888; RPV; Mu O-conotoxin
DMJ0QOW DT Small molecular drug
DMJ0QOW PC 6451164
DMJ0QOW MW 366.4
DMJ0QOW FM C22H18N6
DMJ0QOW IC InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
DMJ0QOW CS CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N
DMJ0QOW IK YIBOMRUWOWDFLG-ONEGZZNKSA-N
DMJ0QOW IU 4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile
DMJ0QOW CA CAS 500287-72-9
DMJ0QOW CB CHEBI:68606
DMJ0QOW DE Human immunodeficiency virus infection; Pain
DMECBWN ID DMECBWN
DMECBWN DN Riluzole
DMECBWN HS Approved
DMECBWN SN Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine
DMECBWN CP Sanofi-Aventis
DMECBWN TC Anticonvulsants
DMECBWN DT Small molecular drug
DMECBWN PC 5070
DMECBWN MW 234.2
DMECBWN FM C8H5F3N2OS
DMECBWN IC InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
DMECBWN CS C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
DMECBWN IK FTALBRSUTCGOEG-UHFFFAOYSA-N
DMECBWN IU 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
DMECBWN CA CAS 1744-22-5
DMECBWN CB CHEBI:8863
DMECBWN DE Amyotrophic lateral sclerosis
DM5DWMU ID DM5DWMU
DM5DWMU DN Rimantadine
DM5DWMU HS Approved
DM5DWMU SN Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine
DM5DWMU CP Forest Laboratories Inc
DM5DWMU TC Antiviral Agents
DM5DWMU DT Small molecular drug
DM5DWMU PC 5071
DM5DWMU MW 179.3
DM5DWMU FM C12H21N
DM5DWMU IC InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3
DM5DWMU CS CC(C12CC3CC(C1)CC(C3)C2)N
DM5DWMU IK UBCHPRBFMUDMNC-UHFFFAOYSA-N
DM5DWMU IU 1-(1-adamantyl)ethanamine
DM5DWMU CA CAS 13392-28-4
DM5DWMU CB CHEBI:94440
DM5DWMU DE Influenza A virus infection
DMHOAUG ID DMHOAUG
DMHOAUG DN Rimegepant
DMHOAUG HS Approved
DMHOAUG SN BMS-927711; 1289023-67-1; UNII-997WVV895X; BMS 927711; CHEMBL2178422; 997WVV895X; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Rimegepant (USAN/INN); SCHEMBL1670580; DTXSID70156003; C28H28F2N6O3; EX-A1922; 3504AH; ZINC68267814; BDBM50400098; AKOS030526382; DB12457; CS-1027; NCGC00378677-01; HY-15498; KB-145921; W-5991
DMHOAUG CP Labrys Biologics
DMHOAUG DT Small molecular drug
DMHOAUG PC 51049968
DMHOAUG MW 534.6
DMHOAUG FM C28H28F2N6O3
DMHOAUG IC InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
DMHOAUG CS C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
DMHOAUG IK KRNAOFGYEFKHPB-ANJVHQHFSA-N
DMHOAUG IU [(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
DMHOAUG CA CAS 1289023-67-1
DMHOAUG DE Migraine
DMTAREC ID DMTAREC
DMTAREC DN Rimexolone
DMTAREC HS Approved
DMTAREC SN Rimexolone (sustained release intra-articular steroid suspension, Plexis, arthritis)
DMTAREC CP Auritec Pharmaceuticals Inc
DMTAREC DT Small molecular drug
DMTAREC PC 5311412
DMTAREC MW 370.5
DMTAREC FM C24H34O3
DMTAREC IC InChI=1S/C24H34O3/c1-6-20(27)24(5)14(2)11-18-17-8-7-15-12-16(25)9-10-22(15,3)21(17)19(26)13-23(18,24)4/h9-10,12,14,17-19,21,26H,6-8,11,13H2,1-5H3/t14-,17+,18+,19+,21-,22+,23+,24-/m1/s1
DMTAREC CS CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C
DMTAREC IK QTTRZHGPGKRAFB-OOKHYKNYSA-N
DMTAREC IU (8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
DMTAREC CA CAS 49697-38-3
DMTAREC CB CHEBI:135566
DMTAREC DE Arthritis
DMA47C6 ID DMA47C6
DMA47C6 DN Rimiterol
DMA47C6 HS Approved
DMA47C6 SN Rimiterol Hydrobromide; EINECS 250-834-6; WG-253; 31842-61-2; R 798; (R*,S*)-4-(Hydroxypiperidin-2-ylmethyl)pyrocatechol hydrobromide; erythro-alpha-(3,4-Dihydroxyphenyl)-2-piperidinemethanol hydrobromide; 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol hydrobromide; 2-Piperidinemethanol, alpha-(3,4-dihydroxyphenyl)-, (R*,S*)-, hydrobromide; API0025612; UNII-I29DRR8S3R component QPYZEEKXUYXZBK-PKKHVXKMSA-N; 1,2-Benzenediol, 4-(hydroxy-2-piperidinylmethyl)-, hydrobromide, (R*,S*)- (9CI)
DMA47C6 DT Small molecular drug
DMA47C6 PC 36283
DMA47C6 MW 223.27
DMA47C6 FM C12H17NO3
DMA47C6 IC InChI=1S/C12H17NO3/c14-10-5-4-8(7-11(10)15)12(16)9-3-1-2-6-13-9/h4-5,7,9,12-16H,1-3,6H2/t9-,12+/m1/s1
DMA47C6 CS C1CCN[C@H](C1)[C@H](C2=CC(=C(C=C2)O)O)O
DMA47C6 IK IYMMESGOJVNCKV-SKDRFNHKSA-N
DMA47C6 IU 4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol
DMA47C6 CA CAS 32953-89-2
DMA47C6 DE Asthma
DMXBLMP ID DMXBLMP
DMXBLMP DN Riociguat
DMXBLMP HS Approved
DMXBLMP SN Riociguat; 625115-55-1; Adempas; Riociguat (BAY 63-2521); BAY 63-2521; riociguatum; UNII-RU3FE2Y4XI; RU3FE2Y4XI; CHEBI:76018; Methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)(methyl)carbamate; Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate; N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester
DMXBLMP CP Bayer HealthCare Pharmaceuticals
DMXBLMP DT Small molecular drug
DMXBLMP PC 11304743
DMXBLMP MW 422.4
DMXBLMP FM C20H19FN8O2
DMXBLMP IC InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
DMXBLMP CS CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC
DMXBLMP IK WXXSNCNJFUAIDG-UHFFFAOYSA-N
DMXBLMP IU methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate
DMXBLMP CA CAS 625115-55-1
DMXBLMP CB CHEBI:76018
DMXBLMP DE Pulmonary arterial hypertension
DM958QB ID DM958QB
DM958QB DN Ripretinib
DM958QB HS Approved
DM958QB SN 1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
DM958QB CP Deciphera Pharmaceuticals Waltham, MA
DM958QB PC 71584930
DM958QB MW 510.4
DM958QB FM C24H21BrFN5O2
DM958QB IC InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
DM958QB CS CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
DM958QB IK CEFJVGZHQAGLHS-UHFFFAOYSA-N
DM958QB IU 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea
DM958QB CA CAS 1442472-39-0
DM958QB DE Glioma; Solid tumour/cancer; Systemic mastocytosis; Gastrointestinal stromal tumour
DMM32GT ID DMM32GT
DMM32GT DN Risankizumab
DMM32GT HS Approved
DMM32GT CP AbbVie North Chicago, IL Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DMM32GT DE Psoriatic arthritis; Plaque psoriasis
DMIMF8J ID DMIMF8J
DMIMF8J DN Risdiplam
DMIMF8J HS Approved
DMIMF8J SN UNII-76RS4S2ET1; 76RS4S2ET1; 1825352-65-5; Risdiplam [INN]; SCHEMBL17260852; EX-A2074; RG-7916; HY-109101; RO7034067; CS-0039501; 4H-Pyrido(1,2-a)pyrimidin-4-one, 7-(4,7-diazaspiro(2.5)oct-7-yl)-2-(2,8-dimethylimidazo(1,2-b)pyridazin-6-yl)-; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
DMIMF8J CP PTC Therapeutics South Plainfield, NJ Roche Basel, Switzerland
DMIMF8J PC 118513932
DMIMF8J MW 401.5
DMIMF8J FM C22H23N7O
DMIMF8J IC InChI=1S/C22H23N7O/c1-14-9-18(26-29-11-15(2)24-21(14)29)17-10-20(30)28-12-16(3-4-19(28)25-17)27-8-7-23-22(13-27)5-6-22/h3-4,9-12,23H,5-8,13H2,1-2H3
DMIMF8J CS CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6
DMIMF8J IK ASKZRYGFUPSJPN-UHFFFAOYSA-N
DMIMF8J IU 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one
DMIMF8J CA CAS 1825352-65-5
DMIMF8J DE Spinal muscular atrophy
DM5FLTY ID DM5FLTY
DM5FLTY DN Risedronate
DM5FLTY HS Approved
DM5FLTY SN Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,; Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID
DM5FLTY CP Procter & Gamble; Sanofi-Aventis
DM5FLTY TC Bone Density Conservation Agents
DM5FLTY DT Small molecular drug
DM5FLTY PC 5245
DM5FLTY MW 283.11
DM5FLTY FM C7H11NO7P2
DM5FLTY IC InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
DM5FLTY CS C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM5FLTY IK IIDJRNMFWXDHID-UHFFFAOYSA-N
DM5FLTY IU (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
DM5FLTY CA CAS 105462-24-6
DM5FLTY CB CHEBI:8869
DM5FLTY DE Paget's disease
DMN6DXL ID DMN6DXL
DMN6DXL DN Risperidone
DMN6DXL HS Approved
DMN6DXL SN Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
DMN6DXL CP Janssen-Cilag
DMN6DXL TC Antipsychotic Agents
DMN6DXL DT Small molecular drug
DMN6DXL PC 5073
DMN6DXL MW 410.5
DMN6DXL FM C23H27FN4O2
DMN6DXL IC InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
DMN6DXL CS CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DMN6DXL IK RAPZEAPATHNIPO-UHFFFAOYSA-N
DMN6DXL IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DMN6DXL CB CHEBI:8871
DMN6DXL DE Schizophrenia
DM4V6RL ID DM4V6RL
DM4V6RL DN Ritodrine
DM4V6RL HS Approved
DM4V6RL SN Prepar; Ritodrina; Ritodrinium; Utopar; Yutopar; RITODRINE HCL; DU-21220; Ritodrina [INN-Spanish]; Ritodrinium [INN-Latin]; Yutopar (TN); Yutopar S.R; Ritodrine (USAN/INN); Ritodrine [USAN:BAN:INN]; P-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; Erythro-p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol; 2-(4-Hydroxyphenethylamino)-1-(4-hydroxyphenyl)propanol; 4-[2-[[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2R)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol; 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
DM4V6RL TC Sympathomimetics
DM4V6RL DT Small molecular drug
DM4V6RL PC 33572
DM4V6RL MW 287.35
DM4V6RL FM C17H21NO3
DM4V6RL IC InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1
DM4V6RL CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O
DM4V6RL IK IOVGROKTTNBUGK-SJCJKPOMSA-N
DM4V6RL IU 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
DM4V6RL CA CAS 26652-09-5
DM4V6RL CB CHEBI:8872
DM4V6RL DE Premature labour
DMU764S ID DMU764S
DMU764S DN Ritonavir
DMU764S HS Approved
DMU764S SN Norvir; RIT; RTV; Norvir Sec; Ritonavir [USAN]; ABT 538; ABT 84538; ABT538; Abbott 84538; A-84538; ABBOTT-84538; ABT-538; DRG-0244; Norvir (TM); Norvir (TN); Ritonavir (JAN/USAN/INN); N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT
DMU764S CP Abbott Laboratories
DMU764S TC Anti-HIV Agents
DMU764S DT Small molecular drug
DMU764S PC 392622
DMU764S MW 720.9
DMU764S FM C37H48N6O5S2
DMU764S IC InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
DMU764S CS CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
DMU764S IK NCDNCNXCDXHOMX-XGKFQTDJSA-N
DMU764S IU 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMU764S CA CAS 155213-67-5
DMU764S CB CHEBI:45409
DMU764S DE Human immunodeficiency virus infection
DM1YVZT ID DM1YVZT
DM1YVZT DN Rituximab
DM1YVZT HS Approved
DM1YVZT CP Genentech
DM1YVZT DT Antibody
DM1YVZT DE Non-hodgkin lymphoma; Pemphigus vulgaris
DMBUH26 ID DMBUH26
DMBUH26 DN Rituximab
DMBUH26 HS Approved
DMBUH26 SN MAbThera (TN)
DMBUH26 CP Roche
DMBUH26 TC Anticancer Agents
DMBUH26 DT Antibody
DMBUH26 SQ Rituximab heavy chain chimeric: QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Rituximab light chain chimericQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMBUH26 DE Non-hodgkin lymphoma; Haematological malignancy
DMQMBZ1 ID DMQMBZ1
DMQMBZ1 DN Rivaroxaban
DMQMBZ1 HS Approved
DMQMBZ1 SN XARELTO (TN)
DMQMBZ1 CP Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
DMQMBZ1 DT Small molecular drug
DMQMBZ1 PC 9875401
DMQMBZ1 MW 435.9
DMQMBZ1 FM C19H18ClN3O5S
DMQMBZ1 IC InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
DMQMBZ1 CS C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
DMQMBZ1 IK KGFYHTZWPPHNLQ-AWEZNQCLSA-N
DMQMBZ1 IU 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
DMQMBZ1 CA CAS 366789-02-8
DMQMBZ1 CB CHEBI:68579
DMQMBZ1 DE Deep vein thrombosis
DMG629M ID DMG629M
DMG629M DN Rivastigmine
DMG629M HS Approved
DMG629M SN Rivastigmine (transdermal patch)
DMG629M CP Samyang Corp
DMG629M DT Small molecular drug
DMG629M PC 77991
DMG629M MW 250.34
DMG629M FM C14H22N2O2
DMG629M IC InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
DMG629M CS CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
DMG629M IK XSVMFMHYUFZWBK-NSHDSACASA-N
DMG629M IU [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
DMG629M CA CAS 123441-03-2
DMG629M CB CHEBI:8874
DMG629M DE Alzheimer disease
DMDJMA3 ID DMDJMA3
DMDJMA3 DN Rizatriptan
DMDJMA3 HS Approved
DMDJMA3 SN Risatriptan; Rizatriptanum; Rizatriptan benzoat; MK 462 free base; Maxalt (TN); Rizaliv (TN); Rizalt (TN); Rizatriptan (INN); Rizatriptan [INN:BAN]; N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine; N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine; N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine; N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
DMDJMA3 CP Merck & Co
DMDJMA3 TC Antiinflammatory Agents
DMDJMA3 DT Small molecular drug
DMDJMA3 PC 5078
DMDJMA3 MW 269.34
DMDJMA3 FM C15H19N5
DMDJMA3 IC InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
DMDJMA3 CS CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3
DMDJMA3 IK ULFRLSNUDGIQQP-UHFFFAOYSA-N
DMDJMA3 IU N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
DMDJMA3 CA CAS 144034-80-0
DMDJMA3 CB CHEBI:48273
DMDJMA3 DE Migraine
DMY9BMK ID DMY9BMK
DMY9BMK DN Rocuronium
DMY9BMK HS Approved
DMY9BMK SN Esmeron (TN); Zemuron (TN); (2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMY9BMK CP Gland Pharma Ltd
DMY9BMK TC Neuromuscular Nondepolarizing Agents
DMY9BMK DT Small molecular drug
DMY9BMK PC 441290
DMY9BMK MW 529.8
DMY9BMK FM C32H53N2O4+
DMY9BMK IC InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
DMY9BMK CS CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C
DMY9BMK IK YXRDKMPIGHSVRX-OOJCLDBCSA-N
DMY9BMK IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMY9BMK CA CAS 143558-00-3
DMY9BMK CB CHEBI:8884
DMY9BMK DE Muscle spasm
DM3P5DA ID DM3P5DA
DM3P5DA DN Rofecoxib
DM3P5DA HS Approved
DM3P5DA SN Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
DM3P5DA CP Merck & Co
DM3P5DA TC Antiinflammatory Agents
DM3P5DA DT Small molecular drug
DM3P5DA PC 5090
DM3P5DA MW 314.4
DM3P5DA FM C17H14O4S
DM3P5DA IC InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
DM3P5DA CS CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
DM3P5DA IK RZJQGNCSTQAWON-UHFFFAOYSA-N
DM3P5DA IU 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
DM3P5DA CA CAS 162011-90-7
DM3P5DA CB CHEBI:8887
DM3P5DA DE Osteoarthritis
DMPGHY8 ID DMPGHY8
DMPGHY8 DN Roflumilast
DMPGHY8 HS Approved
DMPGHY8 SN 162401-32-3; DAXAS; Daliresp; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; BY217; BYK20869; UNII-0P6C6ZOP5U; BY-217; Roflumilast (Daxas); B9302-107; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEMBL193240; CHEBI:47657; BYK-20869; ROF; Libertek; AK110425; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; DAXAS; Roflumilast [USAN]; APTA-2217; Roflumilast (JAN/USAN/INN); 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide; Alogliptin/roflumilast
DMPGHY8 CP Nycomed US Inc; Altana
DMPGHY8 DT Small molecular drug
DMPGHY8 PC 449193
DMPGHY8 MW 403.2
DMPGHY8 FM C17H14Cl2F2N2O3
DMPGHY8 IC InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
DMPGHY8 CS C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
DMPGHY8 IK MNDBXUUTURYVHR-UHFFFAOYSA-N
DMPGHY8 IU 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
DMPGHY8 CA CAS 162401-32-3
DMPGHY8 CB CHEBI:47657
DMPGHY8 DE Asthma; Atopic dermatitis; Type-2 diabetes; Chronic obstructive pulmonary disease
DMCZWOK ID DMCZWOK
DMCZWOK DN Rokitamycin
DMCZWOK HS Approved
DMCZWOK SN Ricamycin (TN)
DMCZWOK CP Toyo Jozo Co Ltd
DMCZWOK DT Small molecular drug
DMCZWOK PC 5282211
DMCZWOK MW 828
DMCZWOK FM C42H69NO15
DMCZWOK IC InChI=1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
DMCZWOK CS CCCC(=O)O[C@H]1[C@@H](O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)O[C@H]3[C@H](C[C@H]([C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]3OC)O)C)O)C)CC=O)C)C
DMCZWOK IK VYWWNRMSAPEJLS-MDWYKHENSA-N
DMCZWOK IU [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-2,4-dimethyl-4-propanoyloxyoxan-3-yl] butanoate
DMCZWOK CA CAS 74014-51-0
DMCZWOK CB CHEBI:32103
DMCZWOK DE Bacterial infection
DM8XP26 ID DM8XP26
DM8XP26 DN Rolapitant
DM8XP26 HS Approved
DM8XP26 SN Rolapitant; 552292-08-7; Sch 619734; Varubi; UNII-NLE429IZUC; SCH-619734; NLE429IZUC; 914462-92-3; (5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one; (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one; Rolapitant [USAN:INN]; Varuby; Varubi (TN); Rolapitant (USAN/INN); Rolapitant(sch619734); SCHEMBL354305; GTPL5749; CHEMBL3707331; CHEBI:90908; DTXSID90203740; MolPort-035-942-975; EX-A1288; BCP09609; ZINC3816514
DM8XP26 CP TESARO
DM8XP26 DT Small molecular drug
DM8XP26 PC 10311306
DM8XP26 MW 500.5
DM8XP26 FM C25H26F6N2O2
DM8XP26 IC InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1
DM8XP26 CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)C4=CC=CC=C4
DM8XP26 IK FIVSJYGQAIEMOC-ZGNKEGEESA-N
DM8XP26 IU (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one
DM8XP26 CA CAS 552292-08-7
DM8XP26 CB CHEBI:90908
DM8XP26 DE Chemotherapy-induced nausea
DMBR5Q7 ID DMBR5Q7
DMBR5Q7 DN Rolitetracycline
DMBR5Q7 HS Approved
DMBR5Q7 SN Bristacin; Kinteto; Pyrrolidinomethyltetracycline; Reverin; Revrin; Rolitetraciclina; Rolitetracyclinum; Solvocillin; Superciclin; Synotodecin; Synterin; Syntetrex; Syntetrin; Tetraverin; Transcycline; Velacicline; Velacycline; AAT 4; SQ 15659; Pirrolidinometil-tetraciclina; Pirrolidinometil-tetraciclina [Italian]; Prm-TC; Rolitetraciclina [INN-Spanish]; Rolitetracyclinum [INN-Latin]; SQ 15,659; Synterin (TN); N-(Pyrrolidinomethyl)tetracycline; Pyrrolidino-methyl-tetracycline; N-Pyrrolidino-methyl-tetracycline; Rolitetracycline (JAN/USAN/INN); Rolitetracycline [USAN:INN:BAN:JAN]; N-(1-Pyrrolidinylmethyl)-tetracycline; (2Z,4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,4aS,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (2Z,4S,6S,12aS)-4-(dimethylamino)-6,10,11,12a-tetrahydroxy-2-[hydroxy-(pyrrolidin-1-ylmethylamino)methylidene]-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione; (4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
DMBR5Q7 TC Antibiotics
DMBR5Q7 DT Small molecular drug
DMBR5Q7 PC 54682938
DMBR5Q7 MW 527.6
DMBR5Q7 FM C27H33N3O8
DMBR5Q7 IC InChI=1S/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,20,31-32,35,37-38H,4-5,9-12H2,1-3H3,(H,28,36)/t14-,15-,20-,26+,27-/m0/s1
DMBR5Q7 CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)NCN5CCCC5)N(C)C)O
DMBR5Q7 IK IKQRPFTXKQQLJF-IAHYZSEUSA-N
DMBR5Q7 IU (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-N-(pyrrolidin-1-ylmethyl)-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMBR5Q7 CA CAS 751-97-3
DMBR5Q7 CB CHEBI:63334
DMBR5Q7 DE Acne vulgaris
DMT5GNL ID DMT5GNL
DMT5GNL DN Romidepsin
DMT5GNL HS Approved
DMT5GNL SN Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
DMT5GNL CP Gloucester Pharmaceuticals; Fujisawa Pharmaceutical Ltd.
DMT5GNL DT Small molecular drug
DMT5GNL PC 5352062
DMT5GNL MW 540.7
DMT5GNL FM C24H36N4O6S2
DMT5GNL IC InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
DMT5GNL CS C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C
DMT5GNL IK OHRURASPPZQGQM-GCCNXGTGSA-N
DMT5GNL IU (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
DMT5GNL CA CAS 128517-07-7
DMT5GNL CB CHEBI:61080
DMT5GNL DE Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Renal cell carcinoma
DM3U7SZ ID DM3U7SZ
DM3U7SZ DN Romiplostim
DM3U7SZ HS Approved
DM3U7SZ CP Amgen
DM3U7SZ DT Small molecular drug
DM3U7SZ SQ Thrombopoietin receptor binding domain amino acid sequence : IEGPTLRQWLAARA >Amino acid sequence for Fc fusion compoundMDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGGIEGPTLRQWLAARA
DM3U7SZ PC 5329098
DM3U7SZ MW 238.28
DM3U7SZ FM C15H14N2O
DM3U7SZ IC InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
DM3U7SZ CS CC1=CC(=C(N1)/C=C\\2/C3=CC=CC=C3NC2=O)C
DM3U7SZ IK WUWDLXZGHZSWQZ-WQLSENKSSA-N
DM3U7SZ IU (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
DM3U7SZ CA CAS 194413-58-6
DM3U7SZ CB CHEBI:91083
DM3U7SZ DE Thrombocytopenia; Multiple myeloma; Myelodysplastic syndrome
DMFJZN0 ID DMFJZN0
DMFJZN0 DN Romosozumab
DMFJZN0 HS Approved
DMFJZN0 SN AMG 785
DMFJZN0 CP Amgen
DMFJZN0 DT Antibody
DMFJZN0 DE Postmenopausal osteoporosis
DMA6S1D ID DMA6S1D
DMA6S1D DN Ropinirole
DMA6S1D HS Approved
DMA6S1D SN Ropinirol; Ropinirolum; Ropitor; ReQuip CR; ReQuip XL; SKF 101468; Adartrel (TN); Requip (TN); Ropark (TN); Ropinirol[INN-Spanish]; Ropinirole (INN); Ropinirole [INN:BAN]; Ropinirolum [INN-Latin]; Ropitor (TN); SK&F 101468; SK&F-101,468; 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
DMA6S1D CP GlaxoSmithKline plc
DMA6S1D TC Antiparkinson Agents
DMA6S1D DT Small molecular drug
DMA6S1D PC 5095
DMA6S1D MW 260.37
DMA6S1D FM C16H24N2O
DMA6S1D IC InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)
DMA6S1D CS CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
DMA6S1D IK UHSKFQJFRQCDBE-UHFFFAOYSA-N
DMA6S1D IU 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
DMA6S1D CA CAS 91374-21-9
DMA6S1D CB CHEBI:8888
DMA6S1D DE Parkinson disease
DMSPJG2 ID DMSPJG2
DMSPJG2 DN Ropivacaine
DMSPJG2 HS Approved
DMSPJG2 SN Naropin; ROPIVACAINE HCl; Ropivacaine hydrochloride; Ropivacaine monohydrochloride; Naropin (TN); Ropivacaine monohydrochloride, (S)-isomer; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride
DMSPJG2 CP AstraZeneca
DMSPJG2 TC Anesthetics
DMSPJG2 DT Small molecular drug
DMSPJG2 PC 175805
DMSPJG2 MW 274.4
DMSPJG2 FM C17H26N2O
DMSPJG2 IC InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1
DMSPJG2 CS CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
DMSPJG2 IK ZKMNUMMKYBVTFN-HNNXBMFYSA-N
DMSPJG2 IU (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
DMSPJG2 CA CAS 84057-95-4
DMSPJG2 CB CHEBI:8890
DMSPJG2 DE Anaesthesia
DMILWZR ID DMILWZR
DMILWZR DN Rosiglitazone
DMILWZR HS Approved
DMILWZR PC 77999
DMILWZR FM C18H19N3O3S
DMILWZR IC InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
DMILWZR CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
DMILWZR IK YASAKCUCGLMORW-UHFFFAOYSA-N
DMILWZR IU 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMILWZR CA CAS 122320-73-4
DMILWZR CB CHEBI:50122
DMILWZR DE Type 2 diabetes
DMY6EAO ID DMY6EAO
DMY6EAO DN Rosiglitazone
DMY6EAO HS Approved
DMY6EAO SN Rosigilitazone; Rosiglitazone [INN:BAN]; Rosiglitazone maleate; Rosiglizole; TDZ 01; YASAKCUCGLMORW-UHFFFAOYSA-N; Avandamet; Avandaryl; Avandia; rosiglitazona; rosiglitazone; rosiglitazone (Avandia); rosiglitazonum; 122320-73-4; 5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL49653; Brl 49653; Brl-49653; C18H19N3O3S; CHEBI:50122
DMY6EAO PC 77999
DMY6EAO MW 357.4
DMY6EAO FM C18H19N3O3S
DMY6EAO IC YASAKCUCGLMORW-UHFFFAOYSA-N
DMY6EAO CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
DMY6EAO IK 1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
DMY6EAO IU 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMY6EAO CA CAS 122320-73-4
DMY6EAO CB CHEBI:50122
DMY6EAO DE Diabetes mellitus
DMT45MU ID DMT45MU
DMT45MU DN Rosiglitazone XR
DMT45MU HS Approved
DMT45MU SN Avandia; Nyracta; Venvia; Rosiglitazone Maleate [USAN]; Rosiglitazone maleate; BRL 49653C; Avandia (TN); Avandiaadministration for 6-12 weeks; BRL 49653-C; BRL-49653C; SB-206846; SB-210232; Rosiglitazone maleate (JAN/USAN); (+-)-5-(p-(2-(Methyl-2-pyridylamino)ethoxy)benzyl)-2,4-thiazolidinedione maleate (1:1); (+-)-5-[[4-2-(methyl]-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,(Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1); 2,4-Thiazolidinedione,5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-,(2Z)-2-butenedioate; 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate
DMT45MU CP GSK
DMT45MU DT Small molecular drug
DMT45MU PC 5281055
DMT45MU MW 473.5
DMT45MU FM C22H23N3O7S
DMT45MU IC InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMT45MU CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=C\\C(=O)O)\\C(=O)O
DMT45MU IK SUFUKZSWUHZXAV-BTJKTKAUSA-N
DMT45MU IU (Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMT45MU CA CAS 155141-29-0
DMT45MU CB CHEBI:8892
DMT45MU DE Type-2 diabetes; Alzheimer disease
DMVOIK1 ID DMVOIK1
DMVOIK1 DN Rosoxacin
DMVOIK1 HS Approved
DMVOIK1 SN Acrosoxacin; Eracine; Eradacil; Eradacin; Rosoxacine; Rosoxacino; Rosoxacinum; Roxadyl; Winuron; PD 107522; WIN 35213;Eradacil (TN); Rosoxacin [USAN:INN]; Rosoxacine [INN-French]; Rosoxacino [INN-Spanish]; Rosoxacinum [INN-Latin]; Roxadyl (TN); Win 35,213; Win-35123; Rosoxacin (USAN/INN); 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; 1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMVOIK1 CP Sanofi-Aventis
DMVOIK1 TC Antiinfective Agents
DMVOIK1 DT Small molecular drug
DMVOIK1 PC 287180
DMVOIK1 MW 294.3
DMVOIK1 FM C17H14N2O3
DMVOIK1 IC InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)
DMVOIK1 CS CCN1C=C(C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3)C(=O)O
DMVOIK1 IK XBPZXDSZHPDXQU-UHFFFAOYSA-N
DMVOIK1 IU 1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMVOIK1 CA CAS 40034-42-2
DMVOIK1 CB CHEBI:131715
DMVOIK1 DE Bacterial infection
DMMIQ7G ID DMMIQ7G
DMMIQ7G DN Rosuvastatin
DMMIQ7G HS Approved
DMMIQ7G SN Astende; Cirantan; Cresadex; Creston; Crestor; Provisacor; Razel; Rosedex; Rosimol; Rosumed; Rosustatin; Rosuvas; Rosuvast; Rosvel; Rovartal; Simestat; Sinlip; Vivacor; Rosuvastatin [INN]; Rosuvastatin calcium; Rosuvastatin calcium [USAN]; Rosuvastatin hemicalcium; S 4522; ZD 4522; ZD4522; AZD-4522; Creston (TN);Crestor (TN); Pyrimidine Compound, 26; Rosuvastatin (INN); S-4522; ZD 4522, calcium salt; ZD-4522; Rosuvastatin calcium (JAN/USAN); Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhelpt-6-enoic acid] calcium salt; Calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate; (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid; (E,3R,5R)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid; (S-((R*,S*-(E)))-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl) amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); (S-(R*,S*-(E)))-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, calcium salt (2:1); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (3R,5S,6E); 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)
DMMIQ7G CP AstraZeneca
DMMIQ7G TC Anticholesteremic Agents
DMMIQ7G DT Small molecular drug
DMMIQ7G PC 446157
DMMIQ7G MW 481.5
DMMIQ7G FM C22H28FN3O6S
DMMIQ7G IC InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
DMMIQ7G CS CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
DMMIQ7G IK BPRHUIZQVSMCRT-VEUZHWNKSA-N
DMMIQ7G IU (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
DMMIQ7G CA CAS 287714-41-4
DMMIQ7G CB CHEBI:38545
DMMIQ7G DE Hypercholesterolaemia; Elevated C-reactive protein
DMP7X6Q ID DMP7X6Q
DMP7X6Q DN Rotigotine
DMP7X6Q HS Approved
DMP7X6Q SN Rotigotine; Rotigotine CDS; Rotigotine CDS Patch; SPM 962; SPM-962; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; Leganto; N 0923; Neupro; (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 87T4T8BO2E; 99755-59-6; C19H25NOS; CHEMBL1303; DSSTox_CID_26772; DSSTox_RID_81893; NCGC00168748-01; UNII-87T4T8BO2E
DMP7X6Q PC 59227
DMP7X6Q MW 315.5
DMP7X6Q FM C19H25NOS
DMP7X6Q IC KFQYTPMOWPVWEJ-INIZCTEOSA-N
DMP7X6Q CS CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
DMP7X6Q IK 1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
DMP7X6Q IU (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMP7X6Q CA CAS 99755-59-6
DMP7X6Q CB CHEBI:135351
DMP7X6Q DE Parkinsonism
DM9PVX8 ID DM9PVX8
DM9PVX8 DN Rucaparib
DM9PVX8 HS Approved
DM9PVX8 SN RUCAPARIB; 283173-50-2; Rubraca; AG-14447; UNII-8237F3U7EH; 8237F3U7EH; AK317822; 8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one; 8-FLUORO-2-(4-((METHYLAMINO)METHYL)PHENYL)-4,5-DIHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-6(3H)-ONE; 6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-; 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
DM9PVX8 CP Clovis Oncology
DM9PVX8 DT Small molecular drug
DM9PVX8 PC 9931954
DM9PVX8 MW 323.4
DM9PVX8 FM C19H18FN3O
DM9PVX8 IC InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
DM9PVX8 CS CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
DM9PVX8 IK HMABYWSNWIZPAG-UHFFFAOYSA-N
DM9PVX8 IU 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
DM9PVX8 CA CAS 283173-50-2
DM9PVX8 CB CHEBI:94311
DM9PVX8 DE Ovarian cancer
DMWE60C ID DMWE60C
DMWE60C DN Rufinamide
DMWE60C HS Approved
DMWE60C SN 106308-44-5; Inovelon; Banzel; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; CGP-33101; Cgp 33101; Xilep; 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide; RUF-331; UNII-WFW942PR79; RUF 331; 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide; WFW942PR79; C10H8F2N4O; E 2080; POGQSBRIGCQNEG-UHFFFAOYSA-N; 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-; NCGC00165883-02; E2080; DSSTox_CID_26506; DSSTox_RID_81675; DSSTox_GSID_46506; Banzel; Banzel, Rufinamide; E-2080; SYN-111; Rufinamide (USAN/INN); Inovelon/Banzel
DMWE60C CP Eisai
DMWE60C DT Small molecular drug
DMWE60C PC 129228
DMWE60C MW 238.19
DMWE60C FM C10H8F2N4O
DMWE60C IC InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
DMWE60C CS C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
DMWE60C IK POGQSBRIGCQNEG-UHFFFAOYSA-N
DMWE60C IU 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
DMWE60C CA CAS 106308-44-5
DMWE60C CB CHEBI:134966
DMWE60C DE Seizure disorder; Pediatric lennox-gastaut syndrome; Epilepsy
DM7Q98D ID DM7Q98D
DM7Q98D DN Ruxolitinib
DM7Q98D HS Approved
DM7Q98D SN Ruxolitinib (JAK inhibitor)
DM7Q98D CP Incyte
DM7Q98D DT Small molecular drug
DM7Q98D PC 25126798
DM7Q98D MW 306.4
DM7Q98D FM C17H18N6
DM7Q98D IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
DM7Q98D CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM7Q98D IK HFNKQEVNSGCOJV-OAHLLOKOSA-N
DM7Q98D IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DM7Q98D CA CAS 941678-49-5
DM7Q98D CB CHEBI:66919
DM7Q98D DE High-risk myelofibrosis; Pancreatic cancer; Essential thrombocythemia; Atopic dermatitis; Vitiligo
DMOFP18 ID DMOFP18
DMOFP18 DN Ryzodeq
DMOFP18 HS Approved
DMOFP18 CP Novo nordisk
DMOFP18 DE Type-2 diabetes
DM0YWJC ID DM0YWJC
DM0YWJC DN Safinamide
DM0YWJC HS Approved
DM0YWJC SN 133865-89-1; Xadago; (S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; Fce-26743; UNII-90ENL74SIG; (2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide; EMD 1195686; 90ENL74SIG; CHEMBL396778; EMD-1195686; AK-77847; 2(s)-(4-(3-fluorobenzyloxy)benzylamino)propionamide; CHEMBL48582; Safinamide [USAN:INN]; 2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide; AC1L2ZLK; Safinamide (USAN/INN); (S)-2-(((4-((3-Fluorophenyl)methoxy)phenyl)methyl)amino)propanamide; EC 603-772-2; SCHEMBL69350; Fce 26743; ON 019190.Na
DM0YWJC CP Us Worldmeds
DM0YWJC DT Small molecular drug
DM0YWJC PC 131682
DM0YWJC MW 302.34
DM0YWJC FM C17H19FN2O2
DM0YWJC IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DM0YWJC CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
DM0YWJC IK NEMGRZFTLSKBAP-LBPRGKRZSA-N
DM0YWJC IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DM0YWJC CA CAS 133865-89-1
DM0YWJC CB CHEBI:134718
DM0YWJC DE Parkinson disease; Idiopathic parkinson disease
DM0J2ZT ID DM0J2ZT
DM0J2ZT DN Safinamide mesylate
DM0J2ZT HS Approved
DM0J2ZT SN Safinamide mesylate; Safinamide mesilate; PNU-151774E; UNII-YS90V3DTX0; FCE-28073; NW-1015; Safinamide mesylate [USAN]; YS90V3DTX0; FCE-28073(R-isomer); Safinamide mesylate (USAN); safinamide methanesulfonate; PNU 151774E; Xadago (TN); NW 1015; AC1MI4YU; Safinamide mesilate (JAN)
DM0J2ZT CP US WorldMeds
DM0J2ZT PC 3038502
DM0J2ZT MW 398.5
DM0J2ZT FM C18H23FN2O5S
DM0J2ZT IC InChI=1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1
DM0J2ZT CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F.CS(=O)(=O)O
DM0J2ZT IK YKOCHIUQOBQIAC-YDALLXLXSA-N
DM0J2ZT IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid
DM0J2ZT CA CAS 202825-46-5
DM0J2ZT DE Parkinson disease
DMN9CWF ID DMN9CWF
DMN9CWF DN Salbutamol
DMN9CWF HS Approved
DMN9CWF SN Aerolin; Airomir; Almotex; Anebron; Asmadil; Asmanil; Asmasal; Asmatol; Asmaven; Asmidon; Asmol; Asthalin; Asthavent; Broncovaleas; Bronter; Bugonol; Bumol; Butamol; Butohaler; Butotal; Butovent; Buventol; Cetsim; Cobutolin; Dilatamol; Ecovent; Farcolin; Gerivent; Grafalin; Libretin; Medolin; Mozal; Novosalmol; Parasma; Pneumolat; Proventil; Respax; Respolin; Rotahaler; Sabutal; Sabutamol; Salamol; Salbetol; Salbron; Salbuhexal; Salbulin; Salbupur; Salbusian; Salbutalan; Salbutamolum; Salbutan; Salbutard; Salbutine; Salbutol; Salbuven; Salbuvent; Sallbupp; Salmaplon; Salomol; Salvent; Saventol; Servitamol; Solbutamol; Spreor; Sultanol; Suprasma; Suxar; Theosal; Tobybron; Vencronyl; Ventamol; Ventilan; Ventiloboi; Ventodisks; Ventoline; Volma; Volmax; Zaperin; Albuterol Sulphate; Albuterol [USAN]; Albuterol hemisulfate; Proventil HFA; Proventil Inhaler; Salbutamol Sulphate; Salbutamol sulfate; Sultanol N; Ventalin inhaler; Ventolin Inhaler; Ventolin Rotacaps; Volare albuterol HFA; AH 3365; S 8260; Aerolin (TN); Albuterol (USP); Alti-Salbutamol; Arubendol-Salbutamol; Asmol Uni-Dose; Asthalin (TN); Broncho-Spray; Buto-Asma; Dl-Albuterol; Dl-Salbutamol; ProAi (TN); Proventil (TN); Racemic-Salbutamol; Salbu-BASF; Salbu-Fatol; Salbutamolum [INN-Latin]; Ventolin (TN); Volare easi-breathe; R,S-Albuterol; Alpha-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha-diol; Alpha-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol; DL-N-tert-Butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine; Alpha'-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; Alpha(sup 1)-((tert-Butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol; (alpha1-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha-diol); 1-(tert-Butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol; 2-(tert-Butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol; 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol; 4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol; 4-[2-(tert-Butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol; 4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
DMN9CWF CP GlaxoSmithKline
DMN9CWF TC Bronchodilator Agents
DMN9CWF DT Small molecular drug
DMN9CWF PC 2083
DMN9CWF MW 239.31
DMN9CWF FM C13H21NO3
DMN9CWF IC InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
DMN9CWF CS CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
DMN9CWF IK NDAUXUAQIAJITI-UHFFFAOYSA-N
DMN9CWF IU 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMN9CWF CA CAS 18559-94-9
DMN9CWF CB CHEBI:2549
DMN9CWF DE Acute asthma
DM1T2LS ID DM1T2LS
DM1T2LS DN Salicin
DM1T2LS HS Approved
DM1T2LS SN salicin; 138-52-3; Salicoside; Salicine; Salicyl alcohol glucoside; D-(-)-Salicin; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; 2-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Saligenin beta-D-glucopyranoside; D-Salicin; Saligenin-beta-D-glucopyranoside; 2-(Hydroxymethyl)phenyl-beta-d-glucopyranoside; Salicin (6CI,8CI); D(-)-Salicin; o-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Benzyl alcohol, o-hydroxy-, o-glucoside; UNII-4649620TBZ; AI3-19099; alpha-Hydroxy-o-tolyl beta
DM1T2LS DT Small molecular drug
DM1T2LS PC 439503
DM1T2LS MW 286.28
DM1T2LS FM C13H18O7
DM1T2LS IC InChI=1S/C13H18O7/c14-5-7-3-1-2-4-8(7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2/t9-,10-,11+,12-,13-/m1/s1
DM1T2LS CS C1=CC=C(C(=C1)CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM1T2LS IK NGFMICBWJRZIBI-UJPOAAIJSA-N
DM1T2LS IU (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol
DM1T2LS CA CAS 138-52-3
DM1T2LS CB CHEBI:17814
DM1T2LS DE Analgesia
DM2F8XZ ID DM2F8XZ
DM2F8XZ DN Salicyclic acid
DM2F8XZ HS Approved
DM2F8XZ SN Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart; Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE
DM2F8XZ TC Antiinflammatory Agents
DM2F8XZ DT Small molecular drug
DM2F8XZ PC 338
DM2F8XZ MW 138.12
DM2F8XZ FM C7H6O3
DM2F8XZ IC InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
DM2F8XZ CS C1=CC=C(C(=C1)C(=O)O)O
DM2F8XZ IK YGSDEFSMJLZEOE-UHFFFAOYSA-N
DM2F8XZ IU 2-hydroxybenzoic acid
DM2F8XZ CA CAS 69-72-7
DM2F8XZ CB CHEBI:16914
DM2F8XZ DE Seborrhoeic dermatitis
DMIEU69 ID DMIEU69
DMIEU69 DN Salmeterol
DMIEU69 HS Approved
DMIEU69 SN Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
DMIEU69 CP GlaxoSmithKline
DMIEU69 TC Bronchodilator Agents
DMIEU69 DT Small molecular drug
DMIEU69 PC 5152
DMIEU69 MW 415.6
DMIEU69 FM C25H37NO4
DMIEU69 IC InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
DMIEU69 CS C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O
DMIEU69 IK GIIZNNXWQWCKIB-UHFFFAOYSA-N
DMIEU69 IU 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
DMIEU69 CA CAS 89365-50-4
DMIEU69 CB CHEBI:64064
DMIEU69 DE Chronic obstructive pulmonary disease
DMEWUPF ID DMEWUPF
DMEWUPF DN Salmon Calcitonin
DMEWUPF HS Approved
DMEWUPF SN Astronin; Biocalcin; Bionocalcin; Cadens; Calciben; Calcihexal; Calcimar; Calcimonta; Calcinil; Calcioton; Calcitonina; Calcitoran; Calco; Calogen; Calsynar; Caltine; Casalm; Catonin; Cibacalcine; Citonina; Eptacalcin; Forcaltonin; Fortical; Ipocalcin; Kalsimin; Karil; Miacalcic; Miacalcin; Miracalcic; Oseototal; Osseocalcina; Osteobion; Osteovis; Ostosalm; Ostostabil; Porostenina; Prontocalcin; Quosten; Riostin; Rulicalcin; Salcat; Salcatonin; Salcatyn; Salmocalcin; Salmofar; Sical; Stalcin; Staporos; Steocin; Tonocalcin; Ucecal; Calcitonin salmon; Calcitonin vom lachs; Calcitonine de saumon; Calsynar Lyo L; Recombinant salmon calcitonin; Salmon calcitonin I; Synthetic salmon calcitonin; CALCITONIN, SALMON; Calcimar (TN); Calcitonin (salmon); Calcitonin salmon (synthesis); Calcitonin, salmar; Calcitonin,salmon; Calcitonin-salmon; Fortical (TN); Isi-calcin; Miacalcin (TN); TZ-CT; Thyrocalcitonin (salmon); Calcitonin salmon (USAN/INN); Calcitonin salmon (synthesis) (JAN); Calcitonin, salmon, for bioassay; Salmon calcitonin (1-32); Calcitonin [USAN:INN:BAN:JAN]; Salmon calcitonin-(I-32)
DMEWUPF TC Antiosteporotic Agents
DMEWUPF DT Small molecular drug
DMEWUPF SQ DB00017 sequence: CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP
DMEWUPF PC 16129616
DMEWUPF MW 3431.9
DMEWUPF FM C145H240N44O48S2
DMEWUPF IC InChI=1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)
DMEWUPF CS CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)N)CO)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N4CCCC4C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)N)C(C)O)CO
DMEWUPF IK BBBFJLBPOGFECG-UHFFFAOYSA-N
DMEWUPF IU 4-[[5-amino-2-[[2-[[2-[[6-amino-2-[[2-[[2-[[2-[[22-amino-16-(2-amino-2-oxoethyl)-7-(1-hydroxyethyl)-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[1-[[1-[[6-amino-1-[[1-[[5-amino-1-[[1-[[1-[2-[[1-[[1-[[4-amino-1-[[1-[[2-[[1-[[2-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMEWUPF CA CAS 9007-12-9
DMEWUPF DE Osteoporosis
DM13P4C ID DM13P4C
DM13P4C DN Salsalate
DM13P4C HS Approved
DM13P4C SN Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid
DM13P4C TC Antiinflammatory Agents
DM13P4C DT Small molecular drug
DM13P4C PC 5161
DM13P4C MW 258.23
DM13P4C FM C14H10O5
DM13P4C IC InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
DM13P4C CS C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
DM13P4C IK WVYADZUPLLSGPU-UHFFFAOYSA-N
DM13P4C IU 2-(2-hydroxybenzoyl)oxybenzoic acid
DM13P4C CA CAS 552-94-3
DM13P4C CB CHEBI:9014
DM13P4C DE Rheumatoid arthritis
DM62MUZ ID DM62MUZ
DM62MUZ DN Samarium Sm-153 Lexidronam Pentasodium
DM62MUZ HS Approved
DM62MUZ CP Lantheus Medical Imaging Inc
DM62MUZ TC Neurology Agents
DM62MUZ DT Small molecular drug
DM62MUZ PC 9810246
DM62MUZ MW 695.93
DM62MUZ FM C6H12N2Na5O12P4Sm
DM62MUZ IC InChI=1S/C6H20N2O12P4.5Na.Sm/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20;;;;;;/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20);;;;;;/q;5*+1;+3/p-8/i;;;;;;1+3
DM62MUZ CS C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3]
DM62MUZ IK SZZACTGRBZTAKY-NKNBZPHVSA-F
DM62MUZ IU pentasodium;samarium-153(3+);N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine
DM62MUZ DE Cancer related pain
DMDINFS ID DMDINFS
DMDINFS DN Sanguinarine
DMDINFS HS Approved
DMDINFS SN SANGUINARINE; 2447-54-3; Pseudochelerythrine; Sanguinarin; sangvinarin; Veadent; Sanguiritrin; SANGUINARIUM; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; C20H14NO4; EINECS 219-503-3; Benzophenanthridine alkaloid; BRN 3915507; AV9VK043SS; CHEBI:17183; NCGC00015959-03; CAS-2447-54-3; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; DSSTox_RID_80748; DSSTox_CID_25204; DSSTox_GSID_45204; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; Sangrovit; y-Chelerythrine; SR-01000075650
DMDINFS DT Small molecular drug
DMDINFS PC 5154
DMDINFS MW 332.3
DMDINFS FM C20H14NO4+
DMDINFS IC InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1
DMDINFS CS C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6
DMDINFS IK INVGWHRKADIJHF-UHFFFAOYSA-N
DMDINFS IU 24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene
DMDINFS CA CAS 2447-54-3
DMDINFS CB CHEBI:17183
DMDINFS DE Dental plaque
DM5VP0F ID DM5VP0F
DM5VP0F DN Saphris
DM5VP0F HS Approved
DM5VP0F SN Asenapine maleate; Saphris; Asenapine (maleate); Org 5222; Sycrest; Org-5222; Asenapine maleate [USAN]; C17H16ClNO.C4H4O4; Asenapine/; Saphris (TN); EINECS 288-064-8; Org 5222 maleate; trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate; (S,S)-Asenapine Maleate; SCHEMBL175228; Asenapine maleate (JAN/USAN); CHEBI:71248; GMDCDXMAFMEDAG-CHHFXETESA-N; ABP000604; s1283; MFCD00900588; Asenapine maleate, >=98% (HPLC); AKOS015951084; SCH-900274; MK-8274; CS-0859; HY-11100; AC-24116
DM5VP0F PC 6917875
DM5VP0F MW 401.8
DM5VP0F FM C21H20ClNO5
DM5VP0F IC InChI=1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1
DM5VP0F CS CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24.C(=CC(=O)O)C(=O)O
DM5VP0F IK GMDCDXMAFMEDAG-CHHFXETESA-N
DM5VP0F IU (Z)-but-2-enedioic acid;(2S,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
DM5VP0F CA CAS 85650-56-2
DM5VP0F CB CHEBI:71248
DM5VP0F DE Schizophrenia
DM4087K ID DM4087K
DM4087K DN Saprisartan
DM4087K HS Approved
DM4087K SN Saprisartan potassium; GR 138950; GR-138950; GR-138950C; GR-138950X; 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
DM4087K TC Antihypertensive Agents
DM4087K DT Small molecular drug
DM4087K PC 60921
DM4087K MW 611.4
DM4087K FM C25H22BrF3N4O4S
DM4087K IC InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
DM4087K CS CCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4NS(=O)(=O)C(F)(F)F)C(=O)N)C5CC5
DM4087K IK DUEWVPTZCSAMNB-UHFFFAOYSA-N
DM4087K IU 3-[[3-bromo-2-[2-(trifluoromethylsulfonylamino)phenyl]-1-benzofuran-5-yl]methyl]-5-cyclopropyl-2-ethylimidazole-4-carboxamide
DM4087K CA CAS 146623-69-0
DM4087K DE Hypertension
DM90TJP ID DM90TJP
DM90TJP DN Sapropterin hydrochloride
DM90TJP HS Approved
DM90TJP SN Biopten (TN)
DM90TJP DT Small molecular drug
DM90TJP PC 135409471
DM90TJP MW 314.17
DM90TJP FM C9H17Cl2N5O3
DM90TJP IC InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1
DM90TJP CS C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl
DM90TJP IK RKSUYBCOVNCALL-NTVURLEBSA-N
DM90TJP IU (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one;dihydrochloride
DM90TJP CA CAS 69056-38-8
DM90TJP CB CHEBI:32120
DM90TJP DE Hyperphenylalaninemia
DMG814N ID DMG814N
DMG814N DN Saquinavir
DMG814N HS Approved
DMG814N SN Fortovase; Invirase; ROC; SQV; Saguinavir; Ro 318959; Fortovase (TN); Fortovase(TM); Invirase (TN); Ro 31-8959; Invirase(TM)(monomesylate); Ro-31-8959; Saquinavir (JAN/USP/INN); QNC-ASN-HPH-DIQ-NTB; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
DMG814N CP Hoffmann-La Roche pharmaceutical company
DMG814N TC Anti-HIV Agents
DMG814N DT Small molecular drug
DMG814N PC 441243
DMG814N MW 670.8
DMG814N FM C38H50N6O5
DMG814N IC InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
DMG814N CS CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
DMG814N IK QWAXKHKRTORLEM-UGJKXSETSA-N
DMG814N IU (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
DMG814N CA CAS 127779-20-8
DMG814N CB CHEBI:63621
DMG814N DE Human immunodeficiency virus infection
DMKS1DV ID DMKS1DV
DMKS1DV DN SARALASIN
DMKS1DV HS Approved
DMKS1DV SN Saralasin; 34273-10-4; UNII-H2AFV2HE66; (Sar1,Val5,Ala8)-Angiotensin II; CHEMBL938; H2AFV2HE66; Saralasinum [INN-Latin]; Saralasin [INN:BAN]; Saralasine [INN-French]; Saralasina [INN-Spanish]; Saralasinum; Saralasine; Saralasina; (1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II; Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-; NCGC00166135-01; N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine; SCHEMBL23; AC1O44IX; DSSTox_RID_81710
DMKS1DV DT Small molecular drug
DMKS1DV PC 6324663
DMKS1DV MW 912
DMKS1DV FM C42H65N13O10
DMKS1DV IC InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1
DMKS1DV CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMKS1DV IK PFGWGEPQIUAZME-NXSMLHPHSA-N
DMKS1DV IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMKS1DV CA CAS 34273-10-4
DMKS1DV CB CHEBI:135894
DMKS1DV DE Hypertension
DMKZROL ID DMKZROL
DMKZROL DN Saralasin Acetate
DMKZROL HS Approved
DMKZROL SN Saralasin acetate; Sarenin; Saralasin acetate [USAN]; Saralasin acetate (USAN); 39698-78-7; UNII-FO21Z580M4; Sarenin (TN); SCHEMBL2200145; CHEMBL1200670; FO21Z580M4; 34273-10-4 (Parent); D04126; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate; [Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate, >
DMKZROL CP Procter And Gamble Pharmaceuticals Inc Sub Procter And Gamble Co
DMKZROL DT Small molecular drug
DMKZROL PC 11954381
DMKZROL MW 990.1
DMKZROL FM C44H71N13O13
DMKZROL IC InChI=1S/C42H65N13O10.C2H4O2.H2O/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65;1-2(3)4;/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47);1H3,(H,3,4);1H2/t24-,28-,29-,30-,31-,33-,34-;;/m0../s1
DMKZROL CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC.CC(=O)O.O
DMKZROL IK YBZYNINTWCLDQA-UHKVWXOHSA-N
DMKZROL IU acetic acid;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;hydrate
DMKZROL CA CAS 39698-78-7
DMKZROL DE Hypertension
DMLZNIQ ID DMLZNIQ
DMLZNIQ DN Sarecycline
DMLZNIQ HS Approved
DMLZNIQ SN Sarecycline; UNII-94O110CX2E; 94O110CX2E; Sarecycline [USAN:INN]; Sarecycline (USAN/INN); P005672; SCHEMBL2699170; ZINC72319783; ZINC198637385; DB12035; FT-0772434; D10666
DMLZNIQ CP Allergan
DMLZNIQ PC 54681908
DMLZNIQ MW 487.5
DMLZNIQ FM C24H29N3O8
DMLZNIQ IC InChI=1S/C24H29N3O8/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33/h5-6,11,13,18,28-29,32,34H,7-9H2,1-4H3,(H2,25,33)/t11-,13-,18-,24-/m0/s1
DMLZNIQ CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC
DMLZNIQ IK AYUMVPHUMFKFPJ-SBAJWEJLSA-N
DMLZNIQ IU (4S,4aS,5aR,12aR)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMLZNIQ CA CAS 1035654-66-0
DMLZNIQ DE Acne vulgaris
DMY0M8J ID DMY0M8J
DMY0M8J DN Sargramostim
DMY0M8J HS Approved
DMY0M8J SN Leukine; Leukine (TN); Sargramostim (genetical recombination); Sargramostim (USAN/INN); Sargramostim (genetical recombination) (JAN)
DMY0M8J CP Bayer Pharmaceuticals Corporation
DMY0M8J TC Immunomodulatory Agents
DMY0M8J SQ DB00020 sequence: APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE
DMY0M8J DE Bone marrow transplantation
DMOGNXY ID DMOGNXY
DMOGNXY DN Sarilumab
DMOGNXY HS Approved
DMOGNXY SN Kevzara
DMOGNXY CP Sanofi/Regeneron
DMOGNXY DT Monoclonal antibody
DMOGNXY SQ Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMOGNXY DE Rheumatoid arthritis
DMGLP6S ID DMGLP6S
DMGLP6S DN Sarpogrelate
DMGLP6S HS Approved
DMGLP6S SN Sarpogrelate [INN]; Sarpogrelate (INN); Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester; 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid; 4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
DMGLP6S TC Hypoglycemic Agents
DMGLP6S DT Small molecular drug
DMGLP6S PC 5160
DMGLP6S MW 429.5
DMGLP6S FM C24H31NO6
DMGLP6S IC InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
DMGLP6S CS CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O
DMGLP6S IK FFYNAVGJSYHHFO-UHFFFAOYSA-N
DMGLP6S IU 4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
DMGLP6S CA CAS 125926-17-2
DMGLP6S CB CHEBI:135697
DMGLP6S DE Diabetic complication
DMRSKMZ ID DMRSKMZ
DMRSKMZ DN Satumomab Pendetide
DMRSKMZ HS Approved
DMRSKMZ TC Imaging Agents
DMRSKMZ DT Monoclonal antibody
DMRSKMZ DE Breast cancer
DMGXENV ID DMGXENV
DMGXENV DN Saxagliptin
DMGXENV HS Approved
DMGXENV SN Onglyza; BMS 477118-11; BMS-477118; Kombiglyze XR (TN); OPC-262; Onglyza (TN); BMS-477118-11; (1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3
DMGXENV CP Bristol-Myers Squibb; AstraZeneca
DMGXENV DT Small molecular drug
DMGXENV PC 11243969
DMGXENV MW 315.4
DMGXENV FM C18H25N3O2
DMGXENV IC InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
DMGXENV CS C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N
DMGXENV IK QGJUIPDUBHWZPV-SGTAVMJGSA-N
DMGXENV IU (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
DMGXENV CA CAS 361442-04-8
DMGXENV CB CHEBI:71272
DMGXENV DE Type-2 diabetes
DMDK7T9 ID DMDK7T9
DMDK7T9 DN SBC-102
DMDK7T9 HS Approved
DMDK7T9 SN Sebelipase alfa; Enzyme replacement therapy (protein recombinant, lysosomal acid lipase deficiency), Synageva BioPharma
DMDK7T9 CP Synageva biopharma
DMDK7T9 SQ Sebelipase alfa protein sequence: SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYNQSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGLDAPWRLYNKIINLMRKYQ
DMDK7T9 DE Enzyme deficiency
DMOM8AL ID DMOM8AL
DMOM8AL DN Scopolamine
DMOM8AL HS Approved
DMOM8AL SN Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate
DMOM8AL CP Norvatis Phamaceuticals Corporation
DMOM8AL TC Antispasmodics
DMOM8AL DT Small molecular drug
DMOM8AL PC 3000322
DMOM8AL MW 303.35
DMOM8AL FM C17H21NO4
DMOM8AL IC InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1
DMOM8AL CS CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4
DMOM8AL IK STECJAGHUSJQJN-USLFZFAMSA-N
DMOM8AL IU [(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
DMOM8AL CA CAS 114-49-8
DMOM8AL CB CHEBI:16794
DMOM8AL DE Addictive disorder; Nausea
DMJ18YL ID DMJ18YL
DMJ18YL DN Secnidazole
DMJ18YL HS Approved
DMJ18YL SN 3366-95-8; Secnidazol; Secnidazolum; Flagentyl; Secnidazolum [INN-Latin]; Solosec; RP 14539; Secnidazol [INN-Spanish]; PM 185184;Secnidazole (Flagentyl); SYM-1219; EINECS 222-134-0; seknidazol; MLS000559043; PM-185184; NCGC00095158-01; SMR000149359; RP-14539
DMJ18YL CP Lupin
DMJ18YL DT Small molecular drug
DMJ18YL PC 71815
DMJ18YL MW 185.18
DMJ18YL FM C7H11N3O3
DMJ18YL IC InChI=1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3
DMJ18YL CS CC1=NC=C(N1CC(C)O)[N+](=O)[O-]
DMJ18YL IK KPQZUUQMTUIKBP-UHFFFAOYSA-N
DMJ18YL IU 1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
DMJ18YL CA CAS 3366-95-8
DMJ18YL CB CHEBI:94433
DMJ18YL DE Bacterial vaginosis; Amoebiasis
DM14RF5 ID DM14RF5
DM14RF5 DN Secobarbital
DM14RF5 HS Approved
DM14RF5 SN Barbosec; Evronal; Hypotrol; Hyptran; Meballymal; Meballymalum; Pramil; Quinalbarbital; Quinalbarbitone; Secobarbitale; Secobarbitalum; Secobarbitone; Seconal; Seotal; Somosal; Secobarbital solution; Secobarbital suppository dosage form; Secobarbitale [DCIT]; Secobarbital [USAN:INN]; Secobarbitalum [INN-Latin]; Seconal (TN);Secobarbital (USP/INN); (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid; (+-)-Secobarbital; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI); 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione; 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID; 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Allyl-5-(1-methylbutyl)barbiturate; 5-Allyl-5-(1-methylbutyl)malonylurea; 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione; 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM14RF5 CP Eli Lilly
DM14RF5 TC Hypnotics and Sedatives
DM14RF5 DT Small molecular drug
DM14RF5 PC 5193
DM14RF5 MW 238.28
DM14RF5 FM C12H18N2O3
DM14RF5 IC InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
DM14RF5 CS CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DM14RF5 IK KQPKPCNLIDLUMF-UHFFFAOYSA-N
DM14RF5 IU 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM14RF5 CA CAS 76-73-3
DM14RF5 CB CHEBI:9073
DM14RF5 DE Intractable insomnia
DMDKE4N ID DMDKE4N
DMDKE4N DN Secretin
DMDKE4N HS Approved
DMDKE4N SN SECREFLO; SecreFlow; Secrepan; Secretina; Secretine; Secretinum; Secretolin; Vitrum; Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level; Human secretin; RG 1068; L-Valinamide; SECRETIN-FERRING; Secretin (human); Secretin (porcine); Secretin-Kabi; Secretina [INN-Spanish]; Secretine [INN-French]; Secretinum [INN-Latin]; Secretin [INN:BAN:DCF:JAN]
DMDKE4N TC Diagnostic Agents
DMDKE4N DT Small molecular drug
DMDKE4N SQ DB00021 sequence: HSDGTFTSELSRLRDSARLQRLLQGLV
DMDKE4N PC 16129665
DMDKE4N MW 3056.4
DMDKE4N FM C130H219N43O42
DMDKE4N IC InChI=1S/C130H219N43O42/c1-59(2)43-78(118(206)172-99(65(13)14)126(214)215)151-94(182)53-148-104(192)75(31-34-91(132)180)156-113(201)81(46-62(7)8)163-115(203)82(47-63(9)10)161-107(195)72(28-22-38-145-128(136)137)153-110(198)76(32-35-92(133)181)157-114(202)80(45-61(5)6)159-106(194)71(27-21-37-144-127(134)135)152-102(190)66(15)150-120(208)87(55-174)168-117(205)86(52-98(188)189)165-109(197)73(29-23-39-146-129(138)139)154-112(200)79(44-60(3)4)160-108(196)74(30-24-40-147-130(140)141)155-121(209)89(57-176)169-116(204)83(48-64(11)12)162-111(199)77(33-36-96(184)185)158-122(210)90(58-177)170-125(213)101(68(17)179)173-119(207)84(49-69-25-19-18-20-26-69)166-124(212)100(67(16)178)171-95(183)54-149-105(193)85(51-97(186)187)164-123(211)88(56-175)167-103(191)70(131)50-93-142-41-42-143-93/h18-20,25-26,41-42,59-68,70-90,99-101,174-179H,21-24,27-40,43-58,131H2,1-17H3,(H2,132,180)(H2,133,181)(H,142,143)(H,148,192)(H,149,193)(H,150,208)(H,151,182)(H,152,190)(H,153,198)(H,154,200)(H,155,209)(H,156,201)(H,157,202)(H,158,210)(H,159,194)(H,160,196)(H,161,195)(H,162,199)(H,163,203)(H,164,211)(H,165,197)(H,166,212)(H,167,191)(H,168,205)(H,169,204)(H,170,213)(H,171,183)(H,172,206)(H,173,207)(H,184,185)(H,186,187)(H,188,189)(H,214,215)(H4,134,135,144)(H4,136,137,145)(H4,138,139,146)(H4,140,141,147)
DMDKE4N CS CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=NC=CN2)N
DMDKE4N IK KKNIUBFRGPFELP-UHFFFAOYSA-N
DMDKE4N IU 5-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[5-amino-1-[[2-[[1-[(1-carboxy-2-methylpropyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-amino-3-(1H-imidazol-2-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMDKE4N CA CAS 1393-25-5
DMDKE4N DE Pancreatic exocrine dysfunction; Gastrinoma
DMFEGB0 ID DMFEGB0
DMFEGB0 DN Segesterone acetate; ethinyl estradiol
DMFEGB0 HS Approved
DMFEGB0 CP TherapeuticsMD
DMFEGB0 DE Contraception
DM6034S ID DM6034S
DM6034S DN Selegiline
DM6034S HS Approved
DM6034S SN selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic
DM6034S CP Syntropharma
DM6034S DT Small molecular drug
DM6034S PC 26757
DM6034S MW 187.28
DM6034S FM C13H17N
DM6034S IC InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
DM6034S CS C[C@H](CC1=CC=CC=C1)N(C)CC#C
DM6034S IK MEZLKOACVSPNER-GFCCVEGCSA-N
DM6034S IU (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
DM6034S CA CAS 14611-51-9
DM6034S CB CHEBI:9086
DM6034S DE Skin imperfections; Major depressive disorder; Chemotherapy-induced nausea
DM3VR1L ID DM3VR1L
DM3VR1L DN Selegiline hydrochloride
DM3VR1L HS Approved
DM3VR1L SN Selegiline hydrochloride; 14611-52-0; Selegiline Hcl; (-)-Deprenyl hydrochloride; l-Deprenyl hydrochloride; Jumex hydrochloride; Eldepryl hydrochloride; (-)-Deprenil hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; (-)-E-250 hydrochloride; UNII-6W731X367Q; HSDB 7183; R-(-)-Deprenyl (hydrochloride); FPF1100; (-)-Phenylisopropylmethylpropynylamine; 6W731X367Q; (-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine hydrochloride; Zydis selegiline
DM3VR1L CP Somerset Pharmaceuticals Inc
DM3VR1L TC Neurology Agents
DM3VR1L DT Small molecular drug
DM3VR1L PC 26758
DM3VR1L MW 223.74
DM3VR1L FM C13H18ClN
DM3VR1L IC InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
DM3VR1L CS C[C@H](CC1=CC=CC=C1)N(C)CC#C.Cl
DM3VR1L IK IYETZZCWLLUHIJ-UTONKHPSSA-N
DM3VR1L IU (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride
DM3VR1L CA CAS 14611-52-0
DM3VR1L CB CHEBI:9087
DM3VR1L DE Parkinson disease; Motor symptoms
DM25CGV ID DM25CGV
DM25CGV DN Selenium
DM25CGV HS Approved
DM25CGV SN Selenium; Selenium alloy; Selenium and compounds; Selenium anhydride; Selenium base; Selenium dihydride; Selenium dust; Selenium elemental; Selenium homopolymer; Selenium hydride; Selenium metallicum; Selenium, colloidal; Selenium, elemental; Selenium, metallic; Vandex; selenio; 7782-49-2; CCRIS 4250; Caswell No. 732; EINECS 231-957-4; Colloidal selenium; Electronic E-2; Elemental selenium; Gray selenium; Hydrogen selenide (H2Se); SELENIUM ATOM; SELENIUM COMPOUNDS; SELENIUM POWDER; Selen [Polish]; HSDB 4493; Se; Selen; UNII-H6241UJ22B
DM25CGV PC 6326970
DM25CGV MW 78.97
DM25CGV FM Se
DM25CGV IC BUGBHKTXTAQXES-UHFFFAOYSA-N
DM25CGV CS [Se]
DM25CGV IK 1S/Se
DM25CGV IU selenium
DM25CGV CA CAS 7782-49-2
DM25CGV CB CHEBI:27568
DM25CGV DE Seborrhoeic dermatitis
DMAHSU0 ID DMAHSU0
DMAHSU0 DN Selexipag
DMAHSU0 HS Approved
DMAHSU0 SN Selexipag; NS-304; 475086-01-2; Uptravi; NS 304; ACT-293987; UNII-5EXC0E384L; Selexipag(NS-304); ACT 293987; 5EXC0E384L; 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide; 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide; 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide; Selexipag [USAN:INN]; 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide; Uptravi (TN)
DMAHSU0 CP Actelion Pharmaceuticals
DMAHSU0 DT Small molecular drug
DMAHSU0 PC 9913767
DMAHSU0 MW 496.6
DMAHSU0 FM C26H32N4O4S
DMAHSU0 IC InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)
DMAHSU0 CS CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMAHSU0 IK QXWZQTURMXZVHJ-UHFFFAOYSA-N
DMAHSU0 IU 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide
DMAHSU0 CA CAS 475086-01-2
DMAHSU0 CB CHEBI:90844
DMAHSU0 DE Pulmonary arterial hypertension
DMZR15V ID DMZR15V
DMZR15V DN Selpercatinib
DMZR15V HS Approved
DMZR15V SN MFOVQWYFURMVKU-IWAAJCSBSA-N; 2222755-14-6; LOXO292; ARRY-192; LOXO 292; EX-A2636
DMZR15V CP Loxo Oncology Stamford, CT
DMZR15V PC 134823904
DMZR15V MW 542.6
DMZR15V FM C29H34N8O3
DMZR15V IC InChI=1S/C29H34N8O3/c1-19-9-34-37-17-23(40-18-24-11-30-5-6-39-24)8-25(29(19)37)26-12-32-27(13-31-26)35-15-21-7-22(16-35)36(21)14-20-3-4-28(38-2)33-10-20/h3-4,8-10,12-13,17,21-22,24,30H,5-7,11,14-16,18H2,1-2H3/t21?,22?,24-/m0/s1
DMZR15V CS CC1=C2C(=CC(=CN2N=C1)OC[C@@H]3CNCCO3)C4=CN=C(C=N4)N5CC6CC(C5)N6CC7=CN=C(C=C7)OC
DMZR15V IK MFOVQWYFURMVKU-IWAAJCSBSA-N
DMZR15V IU (2S)-2-[[4-[5-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyrazin-2-yl]-3-methylpyrazolo[1,5-a]pyridin-6-yl]oxymethyl]morpholine
DMZR15V DE Non-small-cell lung cancer; Colon cancer; Thyroid cancer
DMAGFOD ID DMAGFOD
DMAGFOD DN Semaglutide
DMAGFOD HS Approved
DMAGFOD SN NN9535
DMAGFOD CP Novo Nordisk
DMAGFOD DT Small molecular drug
DMAGFOD PC 56843331
DMAGFOD MW 4114
DMAGFOD FM C187H291N45O59
DMAGFOD IC InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1
DMAGFOD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
DMAGFOD IK DLSWIYLPEUIQAV-CCUURXOWSA-N
DMAGFOD IU 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
DMAGFOD CA CAS 910463-68-2
DMAGFOD DE Type-2 diabetes
DM25HP1 ID DM25HP1
DM25HP1 DN Sermorelin
DM25HP1 HS Approved
DM25HP1 SN Sermorelina; Sermoreline; Sermorelinum; Sermorelina [Spanish]; Sermoreline [French]; Sermorelinum [Latin]; Geref (TN); Sermorelin (INN); Sermorelin [INN:BAN]; GROWTH HORMONE RELEASING FACTOR, Fragment 1-29 Amide; Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
DM25HP1 CP Emd Serono Inc
DM25HP1 TC Hormone Replacement Agents
DM25HP1 DT Small molecular drug
DM25HP1 SQ DB00010 sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSRQ
DM25HP1 PC 16132413
DM25HP1 MW 3357.9
DM25HP1 FM C149H246N44O42S
DM25HP1 IC InChI=1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1
DM25HP1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM25HP1 IK WGWPRVFKDLAUQJ-MITYVQBRSA-N
DM25HP1 IU (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
DM25HP1 CA CAS 86168-78-7
DM25HP1 DE Pediatric growth disorder
DM1A9XO ID DM1A9XO
DM1A9XO DN Sertaconazole
DM1A9XO HS Approved
DM1A9XO SN Sertaconazol; Sertaconazolum; Sertaconazol [Spanish]; Sertaconazole [INN]; Sertaconazolum [Latin]; FI-7045; Sertaconazole (INN); (+-)-1-(2,4-Dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole; (inverted exclamation markA)-1-[2,4-dichloro-b-[(7-chlorobenzo[b]thien-3-yl)methoxy]phenethyl]imidazole;1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 7-Chloro-3-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene; 7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [Spanish]
DM1A9XO TC Antifungal Agents
DM1A9XO DT Small molecular drug
DM1A9XO PC 65863
DM1A9XO MW 437.8
DM1A9XO FM C20H15Cl3N2OS
DM1A9XO IC InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2
DM1A9XO CS C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl
DM1A9XO IK JLGKQTAYUIMGRK-UHFFFAOYSA-N
DM1A9XO IU 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DM1A9XO CA CAS 99592-32-2
DM1A9XO CB CHEBI:83682
DM1A9XO DE Fungal infection
DM0FB1J ID DM0FB1J
DM0FB1J DN Sertraline
DM0FB1J HS Approved
DM0FB1J SN Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
DM0FB1J CP Pfizer Inc
DM0FB1J TC Antidepressants
DM0FB1J DT Small molecular drug
DM0FB1J PC 68617
DM0FB1J MW 306.2
DM0FB1J FM C17H17Cl2N
DM0FB1J IC InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
DM0FB1J CS CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DM0FB1J IK VGKDLMBJGBXTGI-SJCJKPOMSA-N
DM0FB1J IU (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
DM0FB1J CA CAS 79617-96-2
DM0FB1J CB CHEBI:9123
DM0FB1J DE Depression
DMPVRN9 ID DMPVRN9
DMPVRN9 DN Setmelanotide
DMPVRN9 HS Approved
DMPVRN9 SN RM-493; UNII-N7T15V1FUY; BIM-22493; N7T15V1FUY; 920014-72-8; Setmelanotide [USAN:INN]; GTPL9272; CHEMBL3301624; CS-6399; DB11700; HY-19870; L-Cysteinamide, N2-acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-> 8)-disulfide; (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-d
DMPVRN9 CP Rhythm Metabolics Boston, MA
DMPVRN9 PC 11993702
DMPVRN9 MW 1117.3
DMPVRN9 FM C49H68N18O9S2
DMPVRN9 IC InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1
DMPVRN9 CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMPVRN9 IK HDHDTKMUACZDAA-PHNIDTBTSA-N
DMPVRN9 IU (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
DMPVRN9 CA CAS 920014-72-8
DMPVRN9 DE Diabetic complication; Obesity; Prader-Willi syndrome; Bardet biedl syndrome
DMC9O43 ID DMC9O43
DMC9O43 DN Sevoflurane
DMC9O43 HS Approved
DMC9O43 SN Sevofluran; Sevoflurano; Sevofluranum; Sevofrane; Sevorane; Sojourn; Ultane; Fluoromethyl hexafluoroisopropyl ether; Bax 3084; F0691; MR6S4; MR_6S4; PC4681; Sevoflurano [INN-Spanish]; Sevofluranum [INN-Latin]; Ultane (TN); Sevoflurane (JAN/USAN/INN); Sevoflurane [USAN:INN:BAN:JAN]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
DMC9O43 CP Abbott Laboratories
DMC9O43 TC Anesthetics
DMC9O43 DT Small molecular drug
DMC9O43 PC 5206
DMC9O43 MW 200.05
DMC9O43 FM C4H3F7O
DMC9O43 IC InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
DMC9O43 CS C(OC(C(F)(F)F)C(F)(F)F)F
DMC9O43 IK DFEYYRMXOJXZRJ-UHFFFAOYSA-N
DMC9O43 IU 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
DMC9O43 CA CAS 28523-86-6
DMC9O43 CB CHEBI:9130
DMC9O43 DE Anaesthesia
DMFJTDI ID DMFJTDI
DMFJTDI DN Sibutramine
DMFJTDI HS Approved
DMFJTDI SN Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
DMFJTDI CP Abbott Laboratories
DMFJTDI TC Appetite Depressants
DMFJTDI DT Small molecular drug
DMFJTDI PC 5210
DMFJTDI MW 279.8
DMFJTDI FM C17H26ClN
DMFJTDI IC InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
DMFJTDI CS CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
DMFJTDI IK UNAANXDKBXWMLN-UHFFFAOYSA-N
DMFJTDI IU 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
DMFJTDI CA CAS 106650-56-0
DMFJTDI CB CHEBI:9137
DMFJTDI DE Obesity
DM1BS03 ID DM1BS03
DM1BS03 DN Sifalimumab
DM1BS03 HS Approved
DM1BS03 SN Cci 779; CHEBI:79699; Torisel (TN); 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin; Temsirolimus (JAN/USAN/INN); 162635-04-3; DB06287; C15182; D06068; J-524319; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0; {4,9}]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
DM1BS03 CP AstraZeneca; MedImmune
DM1BS03 DT Antibody
DM1BS03 DE Renal cell carcinoma; Systemic lupus erythematosus
DMSWJ5X ID DMSWJ5X
DMSWJ5X DN Sildenafil citrate
DMSWJ5X HS Approved
DMSWJ5X SN Sildenafil (citrate); Sildenafil citrate; Sildenafil citrate [USAN]; Sildenafil citrate salt; UK 92480; UK-92480-10; UNII-BW9B0ZE037; Sildenafilcitrate; Sildenafil; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; 139755-83-2; 3M7OB98Y7H; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; BNRNXUUZRGQAQC-UHFFFAOYSA-N; C22H30N6O4S; CHEBI:9139; CHEMBL192; HSDB 7305; Sildenafil [INN:BAN]; UK-92,480-10; UK-92480; UNII-3M7OB98Y7H; 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1); 171599-83-0; BW9B0ZE037; CHEBI:58987; Caverta; DSSTox_CID_26076; DSSTox_GSID_46076; DSSTox_RID_81321
DMSWJ5X PC 135413523
DMSWJ5X MW 666.7
DMSWJ5X FM C28H38N6O11S
DMSWJ5X IC DEIYFTQMQPDXOT-UHFFFAOYSA-N
DMSWJ5X CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMSWJ5X IK 1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMSWJ5X IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;2-hydroxypropane-1,2,3-tricarboxylic acid
DMSWJ5X CA CAS 171599-83-0
DMSWJ5X CB CHEBI:31307
DMSWJ5X DE Erectile dysfunction
DMJSBT6 ID DMJSBT6
DMJSBT6 DN Silodosin
DMJSBT6 HS Approved
DMJSBT6 SN Silodosin; 160970-54-7; Rapaflo; Urief; Silodyx; Urorec; KMD-3213; Silodosin-d6; UNII-CUZ39LUY82; KMD 3213; KAD 3213; CUZ39LUY82; CHEMBL24778; KAD-3213; (R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; Q-102517; Rapflo
DMJSBT6 DT Small molecular drug
DMJSBT6 PC 5312125
DMJSBT6 MW 495.5
DMJSBT6 FM C25H32F3N3O4
DMJSBT6 IC InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
DMJSBT6 CS C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
DMJSBT6 IK PNCPYILNMDWPEY-QGZVFWFLSA-N
DMJSBT6 IU 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide
DMJSBT6 CA CAS 160970-54-7
DMJSBT6 CB CHEBI:135929
DMJSBT6 DE Benign prostatic hyperplasia
DMGEATB ID DMGEATB
DMGEATB DN Siltuximab
DMGEATB HS Approved
DMGEATB CP Janssen Biotech
DMGEATB DT Antibody
DMGEATB SQ Heavy Chain Sequence: EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain SequenceQIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMGEATB DE Anemia; Multiple myeloma
DMVTHWQ ID DMVTHWQ
DMVTHWQ DN Silver sulfadiazine
DMVTHWQ HS Approved
DMVTHWQ SN Brandiazin; Dermazin; Dermazine; Flamazine; Flammazine; Geben; Sicazine; Silbertone; Silvederma; Silver; Sulfargen; Abbott Brand of Silver Sulfadiazine; Aldo Brand of Silver Sulfadiazine; Major Brand of Silver Sulfadiazine; Medphano Brand of Silver Sulfadiazine; MonarchBrand of Silver Sulfadiazine; Pharmascience Brand of Silver Sulfadiazine; Rhone Poulenc Rorer Brand of Silver Sulfadiazine; SSD AF; SULFADIAZINE SILVER; Sherwood Brand of Silver Sulfadiazine; Silver Sulfafdiazine; Silver sulfadiazinate; Silver sulphadiazine; Solvay Brand of Silver Sulfadiazine; Sulfadiazin silber; Sulfadiazine silver salt; Sulfadiazine silverSilvadene; Zenith Brand of Silver Sulfadiazine; Par Brand 1 of Silver Sulfadiazine; Par Brand 2 of Silver Sulfadiazine; Par Brand 3 of Silver Sulfadiazine; Flamazine (TN); Rhone-Poulenc Rorer Brand of Silver Sulfadiazine; Silvadene (TN); Silver(I) sulfadiazine; Smith & Nephew Brand of Silver Sulfadiazine; Sulfadiazin, silbersalz; Sulfadiazine silver (JP15); Sulfadiazine, Silver [USAN]; Sulfadiazine, silver; Sulfafdiazine, Silver; Thermazene (TN); SSD (1% Silver Sulfadiazine Cream USP); Sulfadiazine, silver (USP); N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt; N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt; Silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide; Silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex; Silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide; Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt; Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt; (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
DMVTHWQ TC Antiinfective Agents
DMVTHWQ DT Small molecular drug
DMVTHWQ PC 441244
DMVTHWQ MW 357.14
DMVTHWQ FM C10H9AgN4O2S
DMVTHWQ IC InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
DMVTHWQ CS C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+]
DMVTHWQ IK UEJSSZHHYBHCEL-UHFFFAOYSA-N
DMVTHWQ IU silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
DMVTHWQ CA CAS 22199-08-2
DMVTHWQ CB CHEBI:9142
DMVTHWQ DE Bacterial infection
DMLUA9D ID DMLUA9D
DMLUA9D DN Simeprevir
DMLUA9D HS Approved
DMLUA9D SN TMC436
DMLUA9D CP Johnson & Johnson
DMLUA9D TC Antiinfective Agents
DMLUA9D DT Small molecular drug
DMLUA9D PC 24873435
DMLUA9D MW 749.9
DMLUA9D FM C38H47N5O7S2
DMLUA9D IC InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1
DMLUA9D CS CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C\\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC
DMLUA9D IK JTZZSQYMACOLNN-VDWJNHBNSA-N
DMLUA9D IU (1R,4R,6S,7Z,15R,17R)-N-cyclopropylsulfonyl-17-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxamide
DMLUA9D CA CAS 923604-59-5
DMLUA9D CB CHEBI:134743
DMLUA9D DE Chronic HCV-1 infection
DM30SGU ID DM30SGU
DM30SGU DN Simvastatin
DM30SGU HS Approved
DM30SGU SN Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
DM30SGU CP Merck & Co
DM30SGU TC Anticholesteremic Agents
DM30SGU DT Small molecular drug
DM30SGU PC 54454
DM30SGU MW 418.6
DM30SGU FM C25H38O5
DM30SGU IC InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
DM30SGU CS CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
DM30SGU IK RYMZZMVNJRMUDD-HGQWONQESA-N
DM30SGU IU [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
DM30SGU CA CAS 79902-63-9
DM30SGU CB CHEBI:9150
DM30SGU DE Hypercholesterolaemia
DMGWR0C ID DMGWR0C
DMGWR0C DN Sintilimab
DMGWR0C HS Approved
DMGWR0C SN Tyvyt
DMGWR0C CP Innovent Biologics
DMGWR0C DT Antibody
DMGWR0C DE Hodgkin lymphoma
DM2R86O ID DM2R86O
DM2R86O DN Siponimod
DM2R86O HS Approved
DM2R86O SN BAF312
DM2R86O CP Novartis
DM2R86O DT Small molecular drug
DM2R86O PC 44599207
DM2R86O MW 516.6
DM2R86O FM C29H35F3N2O3
DM2R86O IC InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
DM2R86O CS CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O
DM2R86O IK KIHYPELVXPAIDH-HNSNBQBZSA-N
DM2R86O IU 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
DM2R86O CA CAS 1230487-00-9
DM2R86O DE Hepatocellular carcinoma; Rheumatoid arthritis; Multiple sclerosis
DMVCMUJ ID DMVCMUJ
DMVCMUJ DN Siponimod
DMVCMUJ HS Approved
DMVCMUJ SN Siponimod; Siponimod [INN]; Siponimod [WHO-DD]; BAF-312; BAF312; BAF312 (Siponimod); RR6P8L282I; 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid; 1230487-00-9; 3-Azetidinecarboxylic acid, 1-((4-((1E)-1-(((4-cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-; CHEMBL2336071; UNII-RR6P8L282I
DMVCMUJ PC 44599207
DMVCMUJ MW 516.6
DMVCMUJ FM C29H35F3N2O3
DMVCMUJ IC KIHYPELVXPAIDH-HNSNBQBZSA-N
DMVCMUJ CS CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O
DMVCMUJ IK 1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+
DMVCMUJ IU 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid
DMVCMUJ CA CAS 1230487-00-9
DMVCMUJ DE Multiple sclerosis
DMGW1ID ID DMGW1ID
DMGW1ID DN Sirolimus
DMGW1ID HS Approved
DMGW1ID SN 53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
DMGW1ID CP Wyeth
DMGW1ID TC Immunosuppressive Agents
DMGW1ID DT Small molecular drug
DMGW1ID PC 5284616
DMGW1ID MW 914.2
DMGW1ID FM C51H79NO13
DMGW1ID IC InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DMGW1ID CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DMGW1ID IK QFJCIRLUMZQUOT-HPLJOQBZSA-N
DMGW1ID IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMGW1ID CA CAS 53123-88-9
DMGW1ID CB CHEBI:9168
DMGW1ID DE Organ transplant rejection; Dutch elm disease; Multiple myeloma
DM92P0F ID DM92P0F
DM92P0F DN Sisomicin
DM92P0F HS Approved
DM92P0F SN Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ
DM92P0F PC 36119
DM92P0F MW 447.5
DM92P0F FM C19H37N5O7
DM92P0F IC URWAJWIAIPFPJE-YFMIWBNJSA-N
DM92P0F CS CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CN)N)N)N)O
DM92P0F IK 1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1
DM92P0F IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DM92P0F CA CAS 32385-11-8
DM92P0F CB CHEBI:9169
DM92P0F DE Infectious cystitis
DMGDKXN ID DMGDKXN
DMGDKXN DN Sitagliptin
DMGDKXN HS Approved
DMGDKXN SN 486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin
DMGDKXN CP Merck & Co
DMGDKXN TC Hypoglycemic Agents
DMGDKXN DT Small molecular drug
DMGDKXN PC 4369359
DMGDKXN MW 407.31
DMGDKXN FM C16H15F6N5O
DMGDKXN IC InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
DMGDKXN CS C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
DMGDKXN IK MFFMDFFZMYYVKS-SECBINFHSA-N
DMGDKXN IU (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
DMGDKXN CA CAS 486460-32-6
DMGDKXN CB CHEBI:40237
DMGDKXN DE Type-2 diabetes; Peripheral arterial disease
DMQ8E9R ID DMQ8E9R
DMQ8E9R DN SKI-758
DMQ8E9R HS Approved
DMQ8E9R SN SCHEMBL3992463; CHEMBL219557; BDBM13047; SKI-758; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile
DMQ8E9R DT Small molecular drug
DMQ8E9R PC 11341869
DMQ8E9R MW 552.4
DMQ8E9R FM C28H27Cl2N5O3
DMQ8E9R IC InChI=1S/C28H27Cl2N5O3/c1-34-4-6-35(7-5-34)15-19-8-17(16-38-19)20-9-24-21(10-26(20)36-2)28(18(13-31)14-32-24)33-25-12-27(37-3)23(30)11-22(25)29/h8-12,14,16H,4-7,15H2,1-3H3,(H,32,33)
DMQ8E9R CS CN1CCN(CC1)CC2=CC(=CO2)C3=C(C=C4C(=C3)N=CC(=C4NC5=CC(=C(C=C5Cl)Cl)OC)C#N)OC
DMQ8E9R IK ANUHLKPVOXDYSK-UHFFFAOYSA-N
DMQ8E9R IU 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile
DMQ8E9R DE Ischemia
DMDIZCS ID DMDIZCS
DMDIZCS DN S-licarbazepine
DMDIZCS HS Approved
DMDIZCS SN Eslicarbazepine; (S)-10-Hydroxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; S-licarbazepine; UNII-S5VXA428R4; BIA 2-194; S-10-Monohydroxy-dihydro-carbamazepin; S5VXA428R4; S-(+)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide; (10S)-10,11-Dihydro-10-hydroxy-5H-Dibenz[b,f]azepine-5-carboxamide; (S)-Licarbazepine; S(+)-Liscarbazepine; (10S)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide
DMDIZCS PC 9881504
DMDIZCS MW 254.28
DMDIZCS FM 15H14N2O2
DMDIZCS IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
DMDIZCS CS C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMDIZCS IK BMPDWHIDQYTSHX-AWEZNQCLSA-N
DMDIZCS IU (5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMDIZCS CA CAS 104746-04-5
DMDIZCS DE Partial seizures
DMFX9O6 ID DMFX9O6
DMFX9O6 DN SM-101
DMFX9O6 HS Approved (orphan drug)
DMFX9O6 SN SMP-534
DMFX9O6 CP SuppreMol
DMFX9O6 DT Small molecular drug
DMFX9O6 PC 445629
DMFX9O6 DE Idiopathic thrombocytopenic purpura; Diabetic nephropathy; Systemic lupus erythematosus
DM1I93C ID DM1I93C
DM1I93C DN SMT-D002
DM1I93C HS Approved
DM1I93C SN DL-06003
DM1I93C CP DanioLabs Ltd
DM1I93C DE Seborrhea
DMH21E0 ID DMH21E0
DMH21E0 DN Sodium acetate anhydrous
DMH21E0 HS Approved
DMH21E0 SN Sodium Acetate In Plastic Container
DMH21E0 CP Hospira Inc
DMH21E0 DT Small molecular drug
DMH21E0 PC 517045
DMH21E0 MW 82.03
DMH21E0 FM C2H3NaO2
DMH21E0 IC InChI=1S/C2H4O2.Na/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
DMH21E0 CS CC(=O)[O-].[Na+]
DMH21E0 IK VMHLLURERBWHNL-UHFFFAOYSA-M
DMH21E0 IU sodium;acetate
DMH21E0 CA CAS 127-09-3
DMH21E0 CB CHEBI:32954
DMH21E0 DE Hyponatraemia
DMMU6BJ ID DMMU6BJ
DMMU6BJ DN Sodium bicarbonate
DMMU6BJ HS Approved
DMMU6BJ SN Acidosan; Colovage; Glycoprep; Golytely; Jusonin; Meylon; Natriumhydrogenkarbonat; Natron; Neut; Nulytely; Soludal; BSS plus; Baking soda; Bicarbonate of soda; Carbonic acid monosodium salt; Gripe water; Lithium bicarbonate; Monosodium hydrogen carbonate; Natrii hydrogencarbonas; Natrium bicarbonicum; Natrium hydrogencarbonicum; Natrum bicarbonicum; Sandoz sodium bicarbonate; Sel De vichy; Soda Mint; Sodium acid carbonate; Sodium bicarbonate in plastic container; Sodium bicarbonate liquid concentrate; Sodium bicarbonate solution; Sodium hydrocarbonate; Sodium hydrogen carbonate; Sodium hydrogencarbonate; NaHCO3; Bicarbonate, Sodium; Carbonic acid, monosodium salt; Co-lav; Col-evac; Go-evac; Hema BP-38; Hydrogen Carbonate, Sodium; Meylon (TN); Neut (TN); Peg-lyte; Soda (van); Soda, Baking; Sodium bicarbonate [USAN:JAN]; Carbonic acid sodium salt (1:1); E-Z-EM Prep Lyte; Sodium bicarbonate (1:1); Sodium bicarbonate (JP15/USP); Sodium carbonate (Na(HCO3)); 800 Sodium Bicarbonate Powder
DMMU6BJ TC Antidiarrheals
DMMU6BJ DT Small molecular drug
DMMU6BJ PC 516892
DMMU6BJ MW 84.007
DMMU6BJ FM CHNaO3
DMMU6BJ IC InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
DMMU6BJ CS C(=O)(O)[O-].[Na+]
DMMU6BJ IK UIIMBOGNXHQVGW-UHFFFAOYSA-M
DMMU6BJ IU sodium;hydrogen carbonate
DMMU6BJ CA CAS 144-55-8
DMMU6BJ CB CHEBI:32139
DMMU6BJ DE Metabolic acidosis
DMM3950 ID DMM3950
DMM3950 DN Sodium chloride
DMM3950 HS Approved
DMM3950 SN sodium chloride; 7647-14-5; Halite; Salt; Table salt; Saline; Rock salt; Common salt; Dendritis; Purex; Sodium chloric; Top flake; Sodium chloride (NaCl); Hyposaline; Flexivial; Gingivyl; Iodized salt; Slow Sodium; Sea salt; SS salt; Sodium monochloride; Natriumchlorid; Hypersal; Adsorbanac; Trisodium trichloride; White crystal; NaCl; HG blending; Salt (ingredient); sodiumchloride; Colyte; Sodium chloride (Na4Cl4); Caswell No 754; Extra Fine 325 Salt; Extra Fine 200 Salt; Sodium chloride brine, purified; Arm-A-Vial; CCRIS 982; sterling
DMM3950 DT Small molecular drug
DMM3950 PC 5234
DMM3950 MW 58.44
DMM3950 FM ClNa
DMM3950 IC InChI=1S/ClH.Na/h1H;/q;+1/p-1
DMM3950 CS [Na+].[Cl-]
DMM3950 IK FAPWRFPIFSIZLT-UHFFFAOYSA-M
DMM3950 IU sodium;chloride
DMM3950 CA CAS 7647-14-5
DMM3950 CB CHEBI:26710
DMM3950 DE Skin burns
DMLJ634 ID DMLJ634
DMLJ634 DN Sodium lauryl sulfate
DMLJ634 HS Approved
DMLJ634 SN Anticerumen; Dreft; Dupanal; Duponal; Duponol; Gardinol; Irium; NALS; Natriumlaurylsulfat; Neutrazyme; SDS; SLS; Syntapon; WAQE; Akyposal SDS; Aquarex ME; Aquarex methyl; Carsonol SLS; Carsonol SLS Paste B; Carsonol SLS Special; Conco Sulfate WAG; Conco Sulfate WAN; Conco Sulfate WAS; Conco sulfate WA; Conco sulfate WN; DODECYL SULFATE; Dupanol WAQ; Duponal WAQE; Duponol C; Duponol Me; Duponol QC; Duponol WA; Duponol WA dry; Duponol WAQ; Duponol WAQE; Duponol WAQM; Duponol methyl; Duponol qx; Duponol waqa; EMAL O; Empicol LPZ; Hexamol SLS; Incronol SLS; Laurylsiran sodny; Lauyl sodium sulfate; Maprobix NEU; Maprofix LK; Maprofix NEU; Maprofix WAC; Melanol CL; Montopol La Paste; Nikkol SLS; Orvus WA Paste; Perlandrol L; Perlankrol L; Richonol A; Richonol C; Richonol af; SDS Running Buffer; Sintapon L; Sipex OP; Sipex SP; Sipex UB; Sipex sb; Sipex sd; Sipon LS; Sipon LSB; Sipon PD; Sipon WD; Sodium Laurylsulfate; Solsol needles; Standapol WAQ; Stepanol ME; Stepanol ME Dry AW; Stepanol WA; Stepanol WA Paste; Stepanol me dry; Stepanol methyl; Stepanol wac; Stepanol waq; Sterling wa paste; Sulfotex wa; Texapon DL; Trepenol WA; Avirol 101; Avirol 118; Avirol 118 conc; Berol 452; CP 75424; Cycloryl 21; Cycloryl 31; Cycloryl 580; Cycloryl 585N; Detergent 66; Emal 10; Emersal 6400; Empicol LS 30; Empicol LX 28; Finasol osr2; MP SILICA RP 18; Maprofix 563; Melanol CL 30; Monagen Y 100; Monogen Y 100; Odoripon Al 95; Perklankrol ESD 60; Rewopol NLS 30; Sinnopon LS 100; Sinnopon LS 95; Sipon LS 100; Standapol 112; Standapol 112 conc; Standapol was 100; Steinapol NLS 90; Stepanol T 28; Sulfetal L 95; Sulfopon wa 1; Swascol 3L; Tarapon K 12; Tvm 474; Emulsifier no. 104; Finasol osr(sub 2); IPC-SDS;Jordanol SL-300; Lanette Wax-S; Maprofix WAC-LA; Product no. 161; Product no. 75; Quolac EX-UB; S-4600; Standapol wa-ac; Stepanol WA-100; Sterling WAQ-CH; Ultra sulfate sl-1
DMLJ634 DT Small molecular drug
DMLJ634 PC 3423265
DMLJ634 MW 288.38
DMLJ634 FM C12H25NaO4S
DMLJ634 IC InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1
DMLJ634 CS CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
DMLJ634 IK DBMJMQXJHONAFJ-UHFFFAOYSA-M
DMLJ634 IU sodium;dodecyl sulfate
DMLJ634 CA CAS 151-21-3
DMLJ634 CB CHEBI:8984
DMLJ634 DE Constipation
DMGA9X0 ID DMGA9X0
DMGA9X0 DN Sodium nitroprusside
DMGA9X0 HS Approved
DMGA9X0 SN Nitroprusside (Sodium); Sodium nitroprusside anhydrous; 14402-89-2; C5FeN6O.2Na; Nitropruss; Nitroprusid-natrium; Sodium nitroprussate; Nitroprussidnatrium [German]; C5FeN6O.2H2O.2Na; Sodium nitroprusside [USAN]; Na2[Fe(CN)5(NO)]; Sodium nitroprussiate dihydrate; Sodium nitrosylpentacyanoferrate; SCHEMBL3020702; CCRIS 1912; Sodium Nitroprusside (anhydrous); Disodium nitrosylpentacyanoferrate; Disodium pentacyanonitrosylferrate; CHEBI:29321; Nitroprussiate de sodium [French]; MolPort-003-926-312; disodium pentacyanidonitrosylfer
DMGA9X0 DT Small molecular drug
DMGA9X0 PC 11953895
DMGA9X0 MW 297.95
DMGA9X0 FM C5H4FeN6Na2O3
DMGA9X0 IC InChI=1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;
DMGA9X0 CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
DMGA9X0 IK XRKMNJXYOFSTBE-UHFFFAOYSA-N
DMGA9X0 IU disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
DMGA9X0 CA CAS 13755-38-9
DMGA9X0 CB CHEBI:9179
DMGA9X0 DE Hypertension
DMCIWZL ID DMCIWZL
DMCIWZL DN Sodium oxybate
DMCIWZL HS Approved
DMCIWZL SN Sodium Oxybate [USAN]; Sodium gamma-hydroxybutyrate; Sodium oxybate; Sodium-4-hydroxybutyrate; Somsanit; gamma-Hydroxy sodium butyrate; Anetamin; Gamma OH; Natrium 4-hydroxybutyrat; Oxybate (sodium); Oxybate sodium; Sodium 4-hydroxybutyrate; gamma-Hydroxybutyrate sodium; gamma-Hydroxybutyrate sodium salt; sodium 4-hydroxybutanoate; 4-Hydroxybuttersaeure natriumsalz; 4-Hydroxybutyrate sodium; 4-Hydroxybutyric acid sodium salt; 502-85-2; Butanoic acid, 4-hydroxy-, monosodium salt; EINECS 207-953-3; NSC 84223; UNII-7G33012534
DMCIWZL PC 23663870
DMCIWZL MW 126.09
DMCIWZL FM C4H7NaO3
DMCIWZL IC XYGBKMMCQDZQOZ-UHFFFAOYSA-M
DMCIWZL CS C(CC(=O)[O-])CO.[Na+]
DMCIWZL IK 1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1
DMCIWZL IU sodium;4-hydroxybutanoate
DMCIWZL CA CAS 502-85-2
DMCIWZL DE Narcolepsy
DMXLBCQ ID DMXLBCQ
DMXLBCQ DN Sodium phenylbutyrate
DMXLBCQ HS Approved
DMXLBCQ SN Ammonaps; Buphenyl; EL-532; Sodium 4-phenylbutyrate; Sodium phenylbutyrate, Elan; Sodium phenylbutyrate, Medicis; Sodium phenylbutyrate, Ucyclyd; VP-101; Sodium 4-phenylbutyrate, Elan; Sodium 4-phenylbutyrate, Ucyclyd; Sodium phenylbutyrate (cancer), MacroChem/Access; Sodium phenylbutyrate (cancer), Virium/ Somanta; Sodium phenylbutyrate (cancer), Virium/Access Pharmaceuticals; Sodium 4-phenyibutyrate (cancer), MacroChem/Access; Sodium 4-phenylbutyrate (cancer), Virium/ Somanta; Sodium 4-phenylbutyrate (cancer), Virium/Access Pharmaceuticals
DMXLBCQ CP Ucyclyd Pharma Inc; Elan Corp plc
DMXLBCQ DT Small molecular drug
DMXLBCQ PC 5258
DMXLBCQ MW 186.18
DMXLBCQ FM C10H11NaO2
DMXLBCQ IC InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
DMXLBCQ CS C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
DMXLBCQ IK VPZRWNZGLKXFOE-UHFFFAOYSA-M
DMXLBCQ IU sodium;4-phenylbutanoate
DMXLBCQ CA CAS 1716-12-7
DMXLBCQ CB CHEBI:75316
DMXLBCQ DE Spinal muscular atrophy
DMKY27B ID DMKY27B
DMKY27B DN Sodium phosphate dibasic/sodium phosphate monobasic
DMKY27B HS Approved
DMKY27B SN Anhydrous sodium acid phosphate; Dipotassium phosphate anhydrous; Monobasic potassium acid phosphate; Monobasic sodium phosphate; Potassium phosphate; Sodium phosphate
DMKY27B DE Multiple sclerosis
DM4QFXJ ID DM4QFXJ
DM4QFXJ DN Sodium Tetradecyl Sulfate
DM4QFXJ HS Approved
DM4QFXJ SN STDS; Trombavar; Monotetradecylsulfate sodium salt; Natri tetradecylsulfas; Natrii tetradecyclis sulfas; Sodium myristyl sulfate; Sodium tetradecyl sulphate; Sodium tetradecylsulfate; Sotradecol Sodium; Tetradecyl sodium sulfate; Niaproof 4; Tesapon K 14; Texapon K 14; Myristyl sulfate, sodium salt; Natrii tetradecyclis sulfas [INN-Latin]; Tetradecilsulfato sodico [INN-Spanish]; Tetradecyl sulfate de sodium [INN-French]; Tetradecyl sulfate, sodium salt; Fibro-Vein (TN); S.T.D; Sulfuric acid, monotetradecyl ester, sodium salt; Sulfuric acid, myristyl ester, sodium salt; S.T.D.; 1-Tetradecanol, 1-(hydrogen sulfate), sodium salt (1:1); 1-Tetradecanol, hydrogen sulfate, sodium salt
DM4QFXJ TC Sclerosing Agents
DM4QFXJ DT Small molecular drug
DM4QFXJ PC 23665770
DM4QFXJ MW 316.43
DM4QFXJ FM C14H29NaO4S
DM4QFXJ IC InChI=1S/C14H30O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-18-19(15,16)17;/h2-14H2,1H3,(H,15,16,17);/q;+1/p-1
DM4QFXJ CS CCCCCCCCCCCCCCOS(=O)(=O)[O-].[Na+]
DM4QFXJ IK UPUIQOIQVMNQAP-UHFFFAOYSA-M
DM4QFXJ IU sodium;tetradecyl sulfate
DM4QFXJ CA CAS 1191-50-0
DM4QFXJ DE Hemangioma; Varicose and spider veins of leg
DMCSLZ4 ID DMCSLZ4
DMCSLZ4 DN Sodium zirconium cyclosilicate
DMCSLZ4 HS Approved
DMCSLZ4 SN UZSi 9; ZS-9 compound; Sodium zirconium silicate (Na2ZrSi3O9); UZSi-9; CBTCHTJSGLCFMY-UHFFFAOYSA-N; 543686-27-7
DMCSLZ4 CP AstraZeneca
DMCSLZ4 PC 91799284
DMCSLZ4 MW 371.5
DMCSLZ4 FM H6Na2O9Si3Zr+2
DMCSLZ4 IC InChI=1S/2Na.H6O9Si3.Zr/c;;1-10(2)7-11(3,4)9-12(5,6)8-10;/h;;1-6H;/q2*+1;;
DMCSLZ4 CS O[Si]1(O[Si](O[Si](O1)(O)O)(O)O)O.[Na+].[Na+].[Zr]
DMCSLZ4 IK CBTCHTJSGLCFMY-UHFFFAOYSA-N
DMCSLZ4 IU disodium;2,2,4,4,6,6-hexahydroxy-1,3,5,2,4,6-trioxatrisilinane;zirconium
DMCSLZ4 CA CAS 17141-74-1
DMCSLZ4 DE Hyperkalemia
DMQI86A ID DMQI86A
DMQI86A DN Sofosbuvir
DMQI86A HS Approved
DMQI86A SN HSDB 8226; Hepcinat; Hepcvir; Resof; SOFOSBUVIR; Sofosbuvir (PSI-7977, GS-7977); Sofosbuvir [USAN:INN]; Sovaldi (TN); SoviHep
DMQI86A TC Antiviral Agents
DMQI86A DT Small molecular drug
DMQI86A PC 45375808
DMQI86A MW 529.458
DMQI86A FM C22H29FN3O9P
DMQI86A IC InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
DMQI86A CS CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DMQI86A IK TTZHDVOVKQGIBA-IQWMDFIBSA-N
DMQI86A IU propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMQI86A CA CAS 1190307-88-0
DMQI86A CB CHEBI:85083
DMQI86A DE Chronic hepatitis C infection
DM5F47O ID DM5F47O
DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O HS Approved
DM5F47O SN Vosevi; Sofosbuvir / velpatasvir / voxilaprevir; Sofosbuvir mixture with velpatasvir and voxilaprevir; S900007740
DM5F47O CP Gilead Sciences
DM5F47O PC 129011857
DM5F47O MW 2281.4
DM5F47O FM C111H135F5N17O26PS
DM5F47O IC InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1
DM5F47O CS CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC.C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
DM5F47O IK FMWRYUBVSONSCK-ZYTFCPLVSA-N
DM5F47O IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide;methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate;propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM5F47O DE Hepatitis C virus infection
DMG592Q ID DMG592Q
DMG592Q DN Solifenacin
DMG592Q HS Approved
DMG592Q SN Vesicare; Vesikur; Solifenacin succinate; Solifenacin succinate [USAN]; YM 905; Solifenacin (INN); Solifenacin [INN:BAN]; Vesicare (TN); YM-53705; YM-67905; YM-905; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1); 1-azabicyclo[2.2.2]oct-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
DMG592Q CP GlaxoSmithKline
DMG592Q TC Antispasmodics
DMG592Q DT Small molecular drug
DMG592Q PC 154059
DMG592Q MW 362.5
DMG592Q FM C23H26N2O2
DMG592Q IC InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1
DMG592Q CS C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5
DMG592Q IK FBOUYBDGKBSUES-VXKWHMMOSA-N
DMG592Q IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
DMG592Q CA CAS 242478-37-1
DMG592Q CB CHEBI:135530
DMG592Q DE Overactive bladder
DMZ9FAO ID DMZ9FAO
DMZ9FAO DN Somatomedin-1
DMZ9FAO HS Approved
DMZ9FAO SN Igef (TN)
DMZ9FAO DE Hormone deficiency
DMF3GM2 ID DMF3GM2
DMF3GM2 DN Somatropin recombinant
DMF3GM2 HS Approved
DMF3GM2 SN Genotropin (TN); Humatrope (TN); Norditropin (TN); Nutropin (TN); Saizen (TN)
DMF3GM2 CP Pfizer Pharmaceuticals
DMF3GM2 TC Hormone Replacement Agents
DMF3GM2 DE Growth hormone deficiency
DM72409 ID DM72409
DM72409 DN Sonidegib phosphate
DM72409 HS Approved
DM72409 SN Sonidegib phosphate; Sonidegib phosphate (USAN); Sonidegib phosphate [USAN:INN]; UNII-W421AI34UW; W421AI34UW; sonidegib bisphosphate; sonidegib diphosphate; 1218778-77-8; 3888AH; AKOS015994565; AOB87343; BCP11860; C26H26F3N3O3.2H3O4P; CHEBI:90864; CHEMBL3137317; CS-1175; DTXSID90669468; EX-A1556; Erismodegib Diphosphate; FE-0016; HY-16582; KS-00002WSZ; LDE-225 Diphosphate; LDE225 (Diphosphate); LDE225 Diphosphate; NVP-LDE225 Diphosphate; NVP-LDE225 Diphosphate salt; Odomzo (TN); SB16677
DM72409 PC 45138699
DM72409 MW 681.5
DM72409 FM C26H32F3N3O11P2
DM72409 IC RWIVSVMMGFFZIJ-VWDRLOGHSA-N
DM72409 CS CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O
DM72409 IK 1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;;
DM72409 IU N-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide;phosphoric acid
DM72409 CA CAS 1218778-77-8
DM72409 CB CHEBI:90864
DM72409 DE Basal cell carcinoma
DMS8IFC ID DMS8IFC
DMS8IFC DN Sorafenib
DMS8IFC HS Approved
DMS8IFC SN Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
DMS8IFC CP Bayer AG; Onyx Pharmaceuticals
DMS8IFC TC Anticancer Agents
DMS8IFC DT Small molecular drug
DMS8IFC PC 216239
DMS8IFC MW 464.8
DMS8IFC FM C21H16ClF3N4O3
DMS8IFC IC InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
DMS8IFC CS CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
DMS8IFC IK MLDQJTXFUGDVEO-UHFFFAOYSA-N
DMS8IFC IU 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
DMS8IFC CA CAS 284461-73-0
DMS8IFC CB CHEBI:50924
DMS8IFC DE Renal cell carcinoma; Myelodysplastic syndrome; Hepatocellular carcinoma
DMAN0DE ID DMAN0DE
DMAN0DE DN Sorbitol
DMAN0DE HS Approved
DMAN0DE SN D-Sorbitol; sorbitol; D-Glucitol; 50-70-4; glucitol; L-Gulitol; (-)-Sorbitol; Glucarine; Sorbilande; Diakarmon; Sorbostyl; Multitol; Nivitin; Karion; Esasorb; Neosorb; D-(-)-Sorbitol; Sorbol; Cholaxine; Sorbite; Sionit; Sionite; Siosan; Sionon; Karion instant; Sorbitol F; Sorbitol FP; Sorbex Rp; Sorbitol syrup C; Sorbex X; Sorbex R; Sorbex M; Sorbex S; Sionit K; D-Sorbol; Hexahydric alcohol; Sorbicolan; Sorvilande; Neosorb P 60; D-Sorbite; Foodol D 70; Neosorb 20/60DC; Neosorb 70/70; Neosorb 70/02; Neosorb P 20/60; d-Sorbit; Karion (carbohydrate)
DMAN0DE CP Pharmaxis
DMAN0DE DT Small molecular drug
DMAN0DE PC 5780
DMAN0DE MW 182.17
DMAN0DE FM C6H14O6
DMAN0DE IC InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
DMAN0DE CS C([C@H]([C@H]([C@@H]([C@H](CO)O)O)O)O)O
DMAN0DE IK FBPFZTCFMRRESA-JGWLITMVSA-N
DMAN0DE IU (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol
DMAN0DE CA CAS 50-70-4
DMAN0DE CB CHEBI:17924
DMAN0DE DE Constipation
DMUJGR1 ID DMUJGR1
DMUJGR1 DN Sorivudine
DMUJGR1 HS Approved
DMUJGR1 SN Usevir (TN)
DMUJGR1 DT Small molecular drug
DMUJGR1 PC 5282192
DMUJGR1 MW 349.13
DMUJGR1 FM C11H13BrN2O6
DMUJGR1 IC InChI=1S/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1
DMUJGR1 CS C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br
DMUJGR1 IK GCQYYIHYQMVWLT-HQNLTJAPSA-N
DMUJGR1 IU 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMUJGR1 CA CAS 77181-69-2
DMUJGR1 CB CHEBI:32152
DMUJGR1 DE Virus infection
DML60TN ID DML60TN
DML60TN DN Sotalol
DML60TN HS Approved
DML60TN SN Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid
DML60TN CP Bristol-Myers Squibb
DML60TN TC Antiarrhythmic Agents
DML60TN DT Small molecular drug
DML60TN PC 5253
DML60TN MW 272.37
DML60TN FM C12H20N2O3S
DML60TN IC InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
DML60TN CS CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
DML60TN IK ZBMZVLHSJCTVON-UHFFFAOYSA-N
DML60TN IU N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
DML60TN CA CAS 3930-20-9
DML60TN CB CHEBI:63622
DML60TN DE Sinus rhythm disorder
DMB4HCT ID DMB4HCT
DMB4HCT DN Sparfloxacin
DMB4HCT HS Approved
DMB4HCT SN Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMB4HCT CP Square pharma
DMB4HCT TC Antibiotics
DMB4HCT DT Small molecular drug
DMB4HCT PC 60464
DMB4HCT MW 392.4
DMB4HCT FM C19H22F2N4O3
DMB4HCT IC InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
DMB4HCT CS C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
DMB4HCT IK DZZWHBIBMUVIIW-DTORHVGOSA-N
DMB4HCT IU 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMB4HCT CA CAS 110871-86-8
DMB4HCT CB CHEBI:9212
DMB4HCT DE Bacterial infection
DM0MQ35 ID DM0MQ35
DM0MQ35 DN Spectinomycin
DM0MQ35 HS Approved
DM0MQ35 SN Actinospectacin; Actinospectacina; Adspec; Espectinomicina; Prospec; SCM; SPCM; Spectam; Spectinomicina; Spectinomycine; Spectinomycinum; Spectogard; Stanilo; Togamycin; Trobicin; Actinospectacina [Italian]; Spectam Scour Halt; Spectinomicina [Italian]; Spectinomycin Di HCl; Spectinomycin HCl; Spectinomycin dihydrochloride; Spectinomycin hydrochloride; Spectinomycin hydrochloride anhydrous; Spectinomycin monohydrochloride; Spectinomycin sulfate; Antibiotic 2233wp; M 141; U 18409; U 18409 E; Actinospectacin, hydrochloride; Adspec (TN); Espectinomicina [INN-Spanish]; M-141; Prospec (TN); Spectinomycin (INN); Spectinomycin Dihydrochloride, Anhydrous; Spectinomycin Dihydrochloride, Pentahydrate; SpectinomycinHCl/ Sulphate; Spectinomycin Hydrochloride (anhydrous); Spectinomycin [INN:BAN]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Trobicin (TN); U-18409AE; XK 43-1; Togamycin sulfate (1:1); ACTINOSPECTACIN, ESPECTINOMICINA, CHX-3101; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))-Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano(2,3-b)(1,4)benzodioxin-4-one monohydrochloride; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, [2R-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.)]-, sulfate (1:1) (salt)
DM0MQ35 CP Pharmacia & Upjohn Company
DM0MQ35 TC Antibiotics
DM0MQ35 DT Small molecular drug
DM0MQ35 PC 15541
DM0MQ35 MW 332.35
DM0MQ35 FM C14H24N2O7
DM0MQ35 IC InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DM0MQ35 CS C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O
DM0MQ35 IK UNFWWIHTNXNPBV-WXKVUWSESA-N
DM0MQ35 IU (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
DM0MQ35 CA CAS 1695-77-8
DM0MQ35 CB CHEBI:9215
DM0MQ35 DE Bacterial infection
DM6CMJD ID DM6CMJD
DM6CMJD DN Spectinomycin
DM6CMJD HS Approved
DM6CMJD SN Specitinomycin; Spectam; Spectinomicina; Spectinomicina [Italian]; Spectinomycin; Spectinomycin [INN:BAN]; Spectinomycin hydrochloride; Spectinomycine; Spectinomycine [INN-French]; Spectinomycinum; Spectinomycinum [INN-Latin]; Togamycin; Actinospectacina [Italian]; Antibiotic 2233wp; CHX-3101; Espectinomicina; Espectinomicina [INN-Spanish]; Trobicin; U 18409 E; UNFWWIHTNXNPBV-WXKVUWSESA-N; actinospectacin; 1695-77-8; 93AKI1U6QF; BRN 2171701; C14H24N2O7; CHEBI:9215; EINECS 216-911-3; M-141; SCM; UNII-93AKI1U6QF
DM6CMJD PC 15541
DM6CMJD MW 332.35
DM6CMJD FM C14H24N2O7
DM6CMJD IC UNFWWIHTNXNPBV-WXKVUWSESA-N
DM6CMJD CS CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O
DM6CMJD IK 1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
DM6CMJD IU (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
DM6CMJD CA CAS 1695-77-8
DM6CMJD CB CHEBI:9215
DM6CMJD DE Gonococcal infection
DM6XFHS ID DM6XFHS
DM6XFHS DN SPI-1005
DM6XFHS HS Approved
DM6XFHS SN Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520
DM6XFHS TC Fibrinolytic Agents
DM6XFHS DT Small molecular drug
DM6XFHS PC 3194
DM6XFHS MW 274.19
DM6XFHS FM C13H9NOSe
DM6XFHS IC InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DM6XFHS CS C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DM6XFHS IK DYEFUKCXAQOFHX-UHFFFAOYSA-N
DM6XFHS IU 2-phenyl-1,2-benzoselenazol-3-one
DM6XFHS CA CAS 60940-34-3
DM6XFHS CB CHEBI:77543
DM6XFHS DE Reperfusion injury
DM0BQRS ID DM0BQRS
DM0BQRS DN Spinosad
DM0BQRS HS Approved
DM0BQRS SN Natroba (TN)
DM0BQRS CP ParaPRO
DM0BQRS DT Small molecular drug
DM0BQRS PC 24721309
DM0BQRS MW 732
DM0BQRS FM C41H65NO10
DM0BQRS IC InChI=1S/C41H65NO10/c1-10-26-12-11-13-34(52-36-17-16-33(42(5)6)23(3)48-36)22(2)37(44)32-20-30-28(31(32)21-35(43)50-26)15-14-25-18-27(19-29(25)30)51-41-40(47-9)39(46-8)38(45-7)24(4)49-41/h14-15,20,22-31,33-34,36,38-41H,10-13,16-19,21H2,1-9H3/t22-,23-,24+,25-,26+,27-,28+,29-,30-,31?,33+,34+,36+,38+,39-,40-,41+/m1/s1
DM0BQRS CS CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C
DM0BQRS IK SRJQTHAZUNRMPR-MGGCLMNKSA-N
DM0BQRS IU (2S,5S,7R,9R,10S,14R,15S,19S)-15-[(2R,5S,6R)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-19-ethyl-14-methyl-7-[(2R,3R,4R,5S,6S)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy-20-oxatetracyclo[10.10.0.02,10.05,9]docosa-3,11-diene-13,21-dione
DM0BQRS CA CAS 168316-95-8
DM0BQRS DE Head and body lice
DM20R5F ID DM20R5F
DM20R5F DN Spiramycin
DM20R5F HS Approved
DM20R5F SN spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard
DM20R5F DT Small molecular drug
DM20R5F PC 6419898
DM20R5F MW 843.1
DM20R5F FM C43H74N2O14
DM20R5F IC InChI=1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26?,27?,28?,29+,30?,31-,32+,34?,35?,36?,37?,38?,39+,40+,41?,42?,43?/m1/s1
DM20R5F CS C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C
DM20R5F IK ACTOXUHEUCPTEW-JMRHEKERSA-N
DM20R5F IU 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
DM20R5F CA CAS 8025-81-8
DM20R5F DE Bacterial infection
DM5XLTY ID DM5XLTY
DM5XLTY DN Spirapril
DM5XLTY HS Approved
DM5XLTY SN Renormax; Sandopril; Setrilan; Espirapril [Spanish]; Not established; Spiraprilum [Latin]; Sch-33844; Spirapril (INN); Spirapril [INN:BAN]; TI-211-950; (2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid
DM5XLTY TC Antihypertensive Agents
DM5XLTY DT Small molecular drug
DM5XLTY PC 5311447
DM5XLTY MW 466.6
DM5XLTY FM C22H30N2O5S2
DM5XLTY IC InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
DM5XLTY CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3
DM5XLTY IK HRWCVUIFMSZDJS-SZMVWBNQSA-N
DM5XLTY IU (8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
DM5XLTY CA CAS 83647-97-6
DM5XLTY CB CHEBI:135756
DM5XLTY DE Hypertension
DM2AQ5N ID DM2AQ5N
DM2AQ5N DN Spironolactone
DM2AQ5N HS Approved
DM2AQ5N SN Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
DM2AQ5N CP Pfizer Pharmaceuticals
DM2AQ5N TC Diuretics
DM2AQ5N DT Small molecular drug
DM2AQ5N PC 5833
DM2AQ5N MW 416.6
DM2AQ5N FM C24H32O4S
DM2AQ5N IC InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
DM2AQ5N CS CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
DM2AQ5N IK LXMSZDCAJNLERA-ZHYRCANASA-N
DM2AQ5N IU S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
DM2AQ5N CA CAS 52-01-7
DM2AQ5N CB CHEBI:9241
DM2AQ5N DE Congestive heart failure
DMCO5JZ ID DMCO5JZ
DMCO5JZ DN SR141716A
DMCO5JZ HS Approved
DMCO5JZ SN Riobant; Slimona; [3H]SR141716A; Acomplia (TN); Bethin (TN); Monaslim (TN); Remonabent (TN); Rimonabant [USAN:INN]; Rimoslim (TN); Riobant (TN); Riomont (TN); Slimona (TN); Zimulti (TN); Rimonabant (JAN/USAN/INN); 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
DMCO5JZ CP Sanofi-Aventis
DMCO5JZ TC Antiobesity Agents
DMCO5JZ DT Small molecular drug
DMCO5JZ PC 104850
DMCO5JZ MW 463.8
DMCO5JZ FM C22H21Cl3N4O
DMCO5JZ IC InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMCO5JZ CS CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMCO5JZ IK JZCPYUJPEARBJL-UHFFFAOYSA-N
DMCO5JZ IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMCO5JZ CA CAS 168273-06-1
DMCO5JZ CB CHEBI:34967
DMCO5JZ DE Obesity
DM6DEK9 ID DM6DEK9
DM6DEK9 DN Stavudine
DM6DEK9 HS Approved
DM6DEK9 SN DdeThd; DdeTyd; Dideoxydidehydrothymidine; Estavudina; STV; Sanilvudine; Stavudinum; Zent; Zerit; Zerit Xr; Zerut XR; BMY 27857; BMY27857; D 1413; D 4T; BMY-27857; Bristol-Myers Brand of Stavudine; Bristol-Myers Squibb Brand of Stavudine; D 4T (nucleoside); Estavudina [INN-Spanish]; Sanilvudine (JAN); Stavudine, Monosodium Salt; Stavudinum [INN-Latin]; Zerit (TN); Zerit(TM); D4T & GM-CSF; D4TMBY-27857-3; Stavudine (USAN/INN); Stavudine [USAN:BAN:INN]; Stavudine [USAN:INN:BAN]; Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)-(7CI,8CI); 1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine; 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione; 1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2; 2',3' Didehydro 3' deoxythymidine; 2',3'-Anhydrothymidine; 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI); 2',3'-Didehydro-2',3'-dideoxythmidine; 2',3'-Didehydro-3'-deoxythimidine; 2',3'-Didehydro-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Deoxy-2',3'-didehydrothymidine; 3'-Deoxy-2'-thymidinene; D4T
DM6DEK9 CP Aurobindo Pharma
DM6DEK9 TC Anti-HIV Agents
DM6DEK9 DT Small molecular drug
DM6DEK9 PC 18283
DM6DEK9 MW 224.21
DM6DEK9 FM C10H12N2O4
DM6DEK9 IC InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
DM6DEK9 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO
DM6DEK9 IK XNKLLVCARDGLGL-JGVFFNPUSA-N
DM6DEK9 IU 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DM6DEK9 CA CAS 3056-17-5
DM6DEK9 CB CHEBI:63581
DM6DEK9 DE Human immunodeficiency virus infection
DMMSDOY ID DMMSDOY
DMMSDOY DN Stiripentol
DMMSDOY HS Approved
DMMSDOY SN Diacomit; ME-2080; Stiripentol (oral); Stiripentol (oral), Laboratoires Biocodex
DMMSDOY CP Biocodex
DMMSDOY DT Small molecular drug
DMMSDOY PC 5311454
DMMSDOY MW 234.29
DMMSDOY FM C14H18O3
DMMSDOY IC InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+
DMMSDOY CS CC(C)(C)C(/C=C/C1=CC2=C(C=C1)OCO2)O
DMMSDOY IK IBLNKMRFIPWSOY-FNORWQNLSA-N
DMMSDOY IU (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
DMMSDOY CA CAS 49763-96-4
DMMSDOY CB CHEBI:94435
DMMSDOY DE Dravet syndrome; Epilepsy
DM5JQ0D ID DM5JQ0D
DM5JQ0D DN Streptokinase
DM5JQ0D HS Approved
DM5JQ0D SN Awelysin; Estreptoquinasa; Kabikinase; Streptase; Streptochinasi; Streptokinasum; Streptochinasi [DCIT]; Streptococcal fibrinolysin; Estreptoquinasa [INN-Spanish]; Streptase (TN); Streptokinasum [INN-Latin]; 4-cyclohexylpyrrolidine-2-carboxylic Acid
DM5JQ0D CP Alpes Selection
DM5JQ0D TC Thrombolytic Agents
DM5JQ0D DT Small molecular drug
DM5JQ0D SQ Streptokinase Sequence DB00086: MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK
DM5JQ0D PC 9815560
DM5JQ0D MW 197.27
DM5JQ0D FM C11H19NO2
DM5JQ0D IC InChI=1S/C11H19NO2/c13-11(14)10-6-9(7-12-10)8-4-2-1-3-5-8/h8-10,12H,1-7H2,(H,13,14)
DM5JQ0D CS C1CCC(CC1)C2CC(NC2)C(=O)O
DM5JQ0D IK XRZWVSXEDRYQGC-UHFFFAOYSA-N
DM5JQ0D IU 4-cyclohexylpyrrolidine-2-carboxylic acid
DM5JQ0D CA CAS 9002-01-1
DM5JQ0D DE Pulmonary embolism
DME1LQN ID DME1LQN
DME1LQN DN Streptomycin
DME1LQN HS Approved
DME1LQN SN Agrept; Agrimycin; Gerox; Neodiestreptopab; SRY; Strepcen; Streptomicina; Streptomycine; Streptomycinum; Streptomyzin; Liposomal Streptomycin; Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin Sesquisulfate Hydrate; Streptomycin sulfate; Streptomycin sulphate; Streptomyzin [German]; Agrept (TN); Estreptomicina [INN-Spanish]; Hokko-mycin; Plantomycin (TN); Rimosidin (TN); Streptomycin & EEP; Streptomycin & Propolis; Streptomycin (INN); Streptomycin (TN); Streptomycin [INN:BAN]; Streptomycin, Sulfate Salt; AS-50 (TN); STREPTOMYCIN SULFATE (2:3) SALT; Agri-mycin-17 (TN); O-2-Deoxy-2-(methylamino)-.alpha.-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-.alpha.-L-lyxofuranosyl-(1->4)-N,N'-bis(aminoiminomethyl)-D-streptamine and Liposome; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2S,3S,4S,5R)-3-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine; 2-[(1S,4S)-5-(diaminomethylideneamino)-2-[(2R,5S)-3-[(2S,5R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-3,4,6-trihydroxycyclohexyl]guanidine; [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
DME1LQN CP Merck & Co
DME1LQN TC Antibiotics
DME1LQN DT Small molecular drug
DME1LQN PC 19649
DME1LQN MW 581.6
DME1LQN FM C21H39N7O12
DME1LQN IC InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DME1LQN CS C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O
DME1LQN IK UCSJYZPVAKXKNQ-HZYVHMACSA-N
DME1LQN IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DME1LQN CA CAS 57-92-1
DME1LQN CB CHEBI:17076
DME1LQN DE Bacterial infection
DMSRXVM ID DMSRXVM
DMSRXVM DN Streptomycin
DMSRXVM HS Approved
DMSRXVM SN Streptomicina [Italian]; Streptomycin A; Streptomycin A sulfate; Streptomycin [INN:BAN]; Streptomycin sulfate; Streptomycin sulphate; Streptomycine; Streptomycinum; Streptomyzin [German]; Agrept; Agrimycin; Chemform; Estreptomicina [INN-Spanish]; Hokko-mycin; Neodiestreptopab; Strepcen; Y45QSO73OB; streptomycin; 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside; 57-92-1; CHEBI:17076; Caswell No. 804; Gerox; NSC-14083; UNII-Y45QSO73OB
DMSRXVM PC 19649
DMSRXVM MW 581.6
DMSRXVM FM C21H39N7O12
DMSRXVM IC UCSJYZPVAKXKNQ-HZYVHMACSA-N
DMSRXVM CS CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O
DMSRXVM IK 1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DMSRXVM IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DMSRXVM CA CAS 57-92-1
DMSRXVM CB CHEBI:17076
DMSRXVM DE Infectious endocarditis
DMOF7AT ID DMOF7AT
DMOF7AT DN Streptozocin
DMOF7AT HS Approved
DMOF7AT SN Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
DMOF7AT CP Pfizer Pharmaceuticals
DMOF7AT TC Anticancer Agents
DMOF7AT DT Small molecular drug
DMOF7AT PC 29327
DMOF7AT MW 265.22
DMOF7AT FM C8H15N3O7
DMOF7AT IC InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
DMOF7AT CS CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O
DMOF7AT IK ZSJLQEPLLKMAKR-GKHCUFPYSA-N
DMOF7AT IU 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
DMOF7AT CA CAS 18883-66-4
DMOF7AT CB CHEBI:9288
DMOF7AT DE Pancreatic cancer
DME81IY ID DME81IY
DME81IY DN Succimer
DME81IY HS Approved
DME81IY SN Succimer; meso-2,3-Dimercaptosuccinic acid; 304-55-2; DMSA; (2R,3S)-rel-2,3-Dimercaptosuccinic acid; meso-Dimercaptosuccinic acid; Chemet; Dim-sa; Succimerum; Succimero; Dimercaptosuccinic acid; Succimerum [INN-Latin]; Succimero [INN-Spanish]; (R*,S*)-2,3-Dimercaptobutanedioic acid; Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-; UNII-DX1U2629QE; Succimer [USAN:INN:BAN]; HSDB 6783; EINECS 206-155-2; Ro 1-7977; BRN 1725150; DX1U2629QE; CHEBI:63623; Butanedioic acid, 2,3-dimercapto-, (R*,S*)-; meso-2,3-Dimercaptobernsteinsaeure
DME81IY DT Small molecular drug
DME81IY PC 2724354
DME81IY MW 182.2
DME81IY FM C4H6O4S2
DME81IY IC InChI=1S/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/t1-,2+
DME81IY CS [C@@H]([C@@H](C(=O)O)S)(C(=O)O)S
DME81IY IK ACTRVOBWPAIOHC-XIXRPRMCSA-N
DME81IY IU (2S,3R)-2,3-bis(sulfanyl)butanedioic acid
DME81IY CA CAS 304-55-2
DME81IY CB CHEBI:63623
DME81IY DE Metal intoxication
DMDWICP ID DMDWICP
DMDWICP DN Succinic acid
DMDWICP HS Approved
DMDWICP SN Asuccin; Bernsteinsaeure; Bernsteinsaure; Butandisaeure; Katasuccin; SIN; Succ; Succinellite; Wormwood; Acid of amber; Acide butanedioique; Acide succinique; Acidum succinicum; Amber acid; Bernsteinsaure [German]; Butanedioic acid diammonium salt; Butanedionic acid; Dihydrofumaric acid; Ethanedicarboxylic acid; Ethylene dicarboxylic acid; Ethylene succinic acid; Ethylenesuccinic acid; Kyselina jantarova; Kyselina jantarova [Czech]; Potassium Succinate; Sal succini; Spirit of amber; Succinicum acidum; Succinicun acidum; Wormwood acid; A 12084; Butanedioic acid (9CI); SUCCINIC ACID, ACS; Succinate, 9; Succinic acid (8CI); Amber acid, Butanedioic acid, Ethylenesuccinic acid; 1,2-Ethanedicarboxylic acid; 1,4-BUTANEDIOIC ACID (SUCCINIC ACID); 1,4-Butanedioic acid
DMDWICP TC Dietary supplement
DMDWICP DT Small molecular drug
DMDWICP PC 1110
DMDWICP MW 118.09
DMDWICP FM C4H6O4
DMDWICP IC InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)
DMDWICP CS C(CC(=O)O)C(=O)O
DMDWICP IK KDYFGRWQOYBRFD-UHFFFAOYSA-N
DMDWICP IU butanedioic acid
DMDWICP CA CAS 110-15-6
DMDWICP CB CHEBI:15741
DMDWICP DE Malnutrition
DM2ET1M ID DM2ET1M
DM2ET1M DN Succinylcholine
DM2ET1M HS Approved
DM2ET1M SN Anectine; Diacetylcholine; Ditilin; Ditiline; Listenon; Lysthenon; Quelicin; SCK; Succicuran; Succinocholine; Succinoylcholine; Succinylbischoline; Succinyldicholine; Sucostrin; Suxamethonium; Dicholine succinate; Succinyl choline; Anectine (TN); Scoline (TN); Succinic acid, diester with choline; Succinic acid, diester with choline chloride; Choline, succinate (ester); Choline, succinate (2:1) (ester); Trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio; Trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium; 2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
DM2ET1M CP Sandoz Canada Inc
DM2ET1M TC Analgesics
DM2ET1M DT Small molecular drug
DM2ET1M PC 5314
DM2ET1M MW 290.4
DM2ET1M FM C14H30N2O4+2
DM2ET1M IC InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
DM2ET1M CS C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
DM2ET1M IK AXOIZCJOOAYSMI-UHFFFAOYSA-N
DM2ET1M IU trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
DM2ET1M CA CAS 306-40-1
DM2ET1M CB CHEBI:45652
DM2ET1M DE Spasm
DMP9HBO ID DMP9HBO
DMP9HBO DN Sucralfate
DMP9HBO HS Approved
DMP9HBO SN SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova
DMP9HBO CP Scios Inc
DMP9HBO PC 121494085
DMP9HBO MW 1577.9
DMP9HBO FM C12H54Al9O55S8
DMP9HBO IC InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
DMP9HBO CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
DMP9HBO IK YZPQNHUVIVIUCT-JTJNLBSYSA-F
DMP9HBO CA CAS 54182-58-0
DMP9HBO DE Acne vulgaris
DMU7YEL ID DMU7YEL
DMU7YEL DN Sufentanil
DMU7YEL HS Approved
DMU7YEL SN Chronogesic; Sufentanilum; Sufentanyl; Sulfentanil; Sulfentanyl; R 30730; R-30730; Sufenta (TN); Sufentanilum [INN-Latin]; Sufentil (TN); Sufentanil (USAN/INN); Sufentanil [USAN:BAN:INN]; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide; N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide; N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
DMU7YEL CP Janssen Pharmaceutica
DMU7YEL TC Anesthetics
DMU7YEL DT Small molecular drug
DMU7YEL PC 41693
DMU7YEL MW 386.6
DMU7YEL FM C22H30N2O2S
DMU7YEL IC InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
DMU7YEL CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC
DMU7YEL IK GGCSSNBKKAUURC-UHFFFAOYSA-N
DMU7YEL IU N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMU7YEL CA CAS 56030-54-7
DMU7YEL CB CHEBI:9316
DMU7YEL DE Analgesia
DMZ6VEY ID DMZ6VEY
DMZ6VEY DN Sulfacetamide
DMZ6VEY HS Approved
DMZ6VEY SN Acetocid; Acetosulfamin; Acetosulfamine; Albamine; Albucid; Alesten; Cetamide; Formosulfacetamide; Klaron; Oclucid; Ophthacet; Region; SULSTER; Sebizon; Solfacetamide; Steramide; Sulamyd; Sulfacet; Sulfacetamida; Sulfacetamidum; Sulfacetimide; Sulfacil; Sulfacyl; Sulfacylum; Sulfair; Sulfanilacetamide; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; Sulphasil; Sultrin; Urosulfon; Urosulfone; Isopto cetamide; Sodium sulamyd; Sodium sulfacetamide; Solfacetamide [DCIT]; Sulfacetamide Monosodium Salt; Sulfacetamide Sodium Usp; Sulfacetamide sodium; Sulfacetamide sodium anhydrous; Sulfanilazetamid [German]; Sulphacetamide sodium; Sulfair 15; A-500; Ak-Sulf; Bleph-10; Bleph-10 liquifilm; FML-S; I-Sulfacet; Isopto-Cetamide; Klaron (TN); N-Acetylsulfanilamide; N-Acetylsulfanilamine; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N1-Acetylsulfanilamide; OP-Sulfa 30; Ocusulf-10; Ophthel-S; P-Aminobenzenesulfonacetamide; P-Aminobenzenesulfonoacetamide; Steri-Units Sulfacetamide; Sulf-10; Sulf-15; Sulfacel-15; Sulfacetamida [INN-Spanish]; Sulfacetamide [USAN:INN]; Sulfacetamidum [INN-Latin]; Sulfacyl (VAN); Sulfair-15; Sulten-10; N'-Acetylsulfanilamide; N(sup 1)-Acetylsulfanilamide; N(sup1)-Acetylsulfanilamide; Sulfacetamide (USP/INN); N-(4-Aminobenzenesulfonyl)acetamide; N-(4-Aminophenylsulfonyl)acetamide; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N(sup 1)-Acetyl-4-aminophenylsulfonamide; N-((4-Aminophenyl)sulfonyl)acetamide; N-((p-Aminophenyl)sulfonyl)acetamide
DMZ6VEY TC Antibiotics
DMZ6VEY DT Small molecular drug
DMZ6VEY PC 5320
DMZ6VEY MW 214.24
DMZ6VEY FM C8H10N2O3S
DMZ6VEY IC InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)
DMZ6VEY CS CC(=O)NS(=O)(=O)C1=CC=C(C=C1)N
DMZ6VEY IK SKIVFJLNDNKQPD-UHFFFAOYSA-N
DMZ6VEY IU N-(4-aminophenyl)sulfonylacetamide
DMZ6VEY CA CAS 144-80-9
DMZ6VEY CB CHEBI:63845
DMZ6VEY DE Acne vulgaris
DMKI2XC ID DMKI2XC
DMKI2XC DN Sulfacytine
DMKI2XC HS Approved
DMKI2XC SN Renoquid; Sulfacitina; Sulfacitine; Sulfacitinum; CL 636; Renoquid (TN); Sulfacitina [INN-Spanish]; Sulfacitinum [INN-Latin]; Sulfacytine (USAN); Sulfacytine [USAN:BAN]; N-Sulfanilyl-l-ethylcytosine; Nl-sulfanilyl-1-ethylcytosine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-(8CI); 1-Ethyl N4-sulfanilylcytosin; 1-Ethyl-N-sulfanilylcytosine; 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
DMKI2XC TC Antiinfective Agents
DMKI2XC DT Small molecular drug
DMKI2XC PC 5322
DMKI2XC MW 294.33
DMKI2XC FM C12H14N4O3S
DMKI2XC IC InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)
DMKI2XC CS CCN1C=CC(=NC1=O)NS(=O)(=O)C2=CC=C(C=C2)N
DMKI2XC IK SIBQAECNSSQUOD-UHFFFAOYSA-N
DMKI2XC IU 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
DMKI2XC CA CAS 17784-12-2
DMKI2XC CB CHEBI:135230
DMKI2XC DE Cystitis; Urinary tract infection
DMTW3R8 ID DMTW3R8
DMTW3R8 DN Sulfadiazine
DMTW3R8 HS Approved
DMTW3R8 SN Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ
DMTW3R8 CP Lilly
DMTW3R8 TC Antiinfective Agents
DMTW3R8 DT Small molecular drug
DMTW3R8 PC 5215
DMTW3R8 MW 250.28
DMTW3R8 FM C10H10N4O2S
DMTW3R8 IC InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
DMTW3R8 CS C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMTW3R8 IK SEEPANYCNGTZFQ-UHFFFAOYSA-N
DMTW3R8 IU 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
DMTW3R8 CA CAS 68-35-9
DMTW3R8 CB CHEBI:9328
DMTW3R8 DE Rheumatic fever
DMKM3SX ID DMKM3SX
DMKM3SX DN Sulfamerazine
DMKM3SX HS Approved
DMKM3SX SN Cremomerazine; Kelamerazine; Mebacid; Mesulfa; Methylpyrimal; Methylsulfadiazine; Methylsulfazin; Methylsulfazine;Metilsulfadiazin; Metilsulfazin; Percoccide; Pyralcid; Romezin; Septacil; Septosyl; Solfamerazina; Solumedin; Sulfameradine; Sulfamerazin; Sulfamerazina; Sulfamerazinum; Sulfamethyldiazine; Sulphamerazine; Sumedine; Pyrimal M; Solfamerazina [DCIT]; RP 2632; A-310; Debenal-M; Pirimal-M; Sulfamerazina [INN-Spanish]; Sulfamerazine (INN); Sulfamerazinum [INN-Latin]; Veta-Merazine; Sulfamerazine [USAN:INN:BAN]; N-(4-Methyl-2-pyrimidyl)sulfanilamide; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; N1-(4-Methylpyrimidin-2-yl)sulfanilamide; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-(8CI); (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; 2-(Sulfanilamido)-4-methylpyrimidine; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; 2-Sulfa-4-methylpyrimidine; 2-Sulfanilamido-4-methylpyrimidine; 2643-RP; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
DMKM3SX TC Antiinfective Agents
DMKM3SX DT Small molecular drug
DMKM3SX PC 5325
DMKM3SX MW 264.31
DMKM3SX FM C11H12N4O2S
DMKM3SX IC InChI=1S/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
DMKM3SX CS CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMKM3SX IK QPPBRPIAZZHUNT-UHFFFAOYSA-N
DMKM3SX IU 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
DMKM3SX CA CAS 127-79-7
DMKM3SX CB CHEBI:102130
DMKM3SX DE Bacterial infection
DMRGZ16 ID DMRGZ16
DMRGZ16 DN Sulfamethazine
DMRGZ16 HS Approved
DMRGZ16 SN Azolmetazin; Cremomethazine; Diazil; Dimezathine; Intradine; Kelametazine; Mermeth; Neasina; Neazina; Pirmazin; Primazin; Solfadimidina; Spanbolet; Sulfadimerazine; Sulfadimesin; Sulfadimesine; Sulfadimethyldiazine; Sulfadimethylpyrimidine; Sulfadimezin; Sulfadimezine; Sulfadimezinum; Sulfadimidin; Sulfadimidina; Sulfadimidine; Sulfadimidinum; Sulfadine; Sulfametazina; Sulfametazyny; Sulfamethiazine; Sulfamezathine; Sulfodimesin; Sulfodimezine; Sulphadimethylpyrimidine; Sulphadimidine; Sulphamethasine; Sulphamethazine; Sulphamezathine; Sulphamidine; Sulphodimezine; Superseptil; Superseptyl; Vertolan; Calfspan Tablets; Sa III; Solfadimidina [DCIT]; SulfaSURE SR Bolus; Sulfadimidine solution; Sulfametazina[Italian]; Sulfametazyny [Polish]; Sulfamethazine solution; Sulka S Boluses; BN 2409; HC210279; A-502; Diazil (the sulfanilamide); Dimidin-R; Hava-Span; Sulfa-Isodimerazine; Sulfadimidina [INN-Spanish]; Sulfadimidine (INN); Sulfadimidine [INN:BAN]; Sulfadimidinum [INN-Latin]; Sulfamethazine (USP); Sulfamezathine (TN); N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-Sulfanilamido-4,6-dimethylpyrimidine; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 4,6-Dimethylsulfadiazine; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; 4-Amino-N-[4,6-dimethyl-2-pyrimidinyl]-benzenesulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]
DMRGZ16 TC Antiinfective Agents
DMRGZ16 DT Small molecular drug
DMRGZ16 PC 5327
DMRGZ16 MW 278.33
DMRGZ16 FM C12H14N4O2S
DMRGZ16 IC InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)
DMRGZ16 CS CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C
DMRGZ16 IK ASWVTGNCAZCNNR-UHFFFAOYSA-N
DMRGZ16 IU 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
DMRGZ16 CA CAS 57-68-1
DMRGZ16 CB CHEBI:102265
DMRGZ16 DE Bacterial infection
DMGCHDS ID DMGCHDS
DMGCHDS DN Sulfamethizole
DMGCHDS HS Approved
DMGCHDS SN Ayerlucil; Famet; Lucosil; Methazol; Microsul; Proklar; Renasul; Rufol; SULFAMETHIAZOLE; Salimol; Solfametizolo; Sulamethizole; Sulfamethazole; Sulfamethizol; Sulfamethizolum; Sulfamethylthiadiazole; Sulfametizol; Sulfapyelon; Sulfstat; Sulfurine; Sulphamethizole; Sulphamethyltiadiazole; Tetracid; Thidicur;Thiosulfil; Ultrasul; Urocydal; Urodiaton; Urolucosil; Urosulfin; Uroz; Solfametizolo [DCIT]; Sulfa gram; Thiosulfil Forte; RP 2145; VK 53; Sulfamethizolum [INN-Latin]; Sulfametizol [INN-Spanish]; Thiosulfil (TN); Sulfamethizole [USAN:INN:JAN]; Thiosulfil-A-Forte; Sulfamethizole (JP15/USP/INN); N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; 4-Amino-N-[5-methyl-1,3,4-thiadiazol-2-yl]benzenesulfonamide; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole
DMGCHDS TC Antiinfective Agents
DMGCHDS DT Small molecular drug
DMGCHDS PC 5328
DMGCHDS MW 270.3
DMGCHDS FM C9H10N4O2S2
DMGCHDS IC InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)
DMGCHDS CS CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N
DMGCHDS IK VACCAVUAMIDAGB-UHFFFAOYSA-N
DMGCHDS IU 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide
DMGCHDS CA CAS 144-82-1
DMGCHDS CB CHEBI:9331
DMGCHDS DE Urinary tract infection
DMB08GE ID DMB08GE
DMB08GE DN Sulfamethoxazole
DMB08GE HS Approved
DMB08GE SN sulfamethoxazole; 723-46-6; Gantanol; Sulphamethoxazole; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Bactrimel; Gamazole; Sulphisomezole; Sulfametoxazol; Solfametossazolo; Sulfamethoxazolum; Ro 4-2130; SMX; Septran; Sulphamethalazole; Trib; Solfametossazolo [DCIT]; Sulfamethoxazole sodium; MS 53; Sulphamethoxazole BP 98; ALBB-002089; Apo-Sulfamethoxazole; Bactrim (TN); Septra (TN); Septrin (TN); Sulfamethoxazolum [INN-Latin]; Sulfametoxazol [INN-Spanish]; Ro 6-2580/11; Ro-4-2130; Sulfamethoxazole [USAN:INN:JAN]; Sulfamethoxazole (JP15/USP/INN); N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); N'-(5-Methyl-3-isoxazole)sulfanilamide; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-(8CI); 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; 3-Sulphanilamido-5-methylisoxazole; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; 4-Amino-N-[5-methyl-3-isoxazolyl]benzenesulfonamide; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; 5-Methyl-3-sulphanil-amidoisoxazole; Sulphameth oxazole
DMB08GE TC Antiinfective Agents
DMB08GE DT Small molecular drug
DMB08GE PC 5329
DMB08GE MW 253.28
DMB08GE FM C10H11N3O3S
DMB08GE IC InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
DMB08GE CS CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
DMB08GE IK JLKIGFTWXXRPMT-UHFFFAOYSA-N
DMB08GE IU 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
DMB08GE CA CAS 723-46-6
DMB08GE CB CHEBI:9332
DMB08GE DE Bacterial infection; Infection of P. falciparum
DMIO1K0 ID DMIO1K0
DMIO1K0 DN Sulfamylon
DMIO1K0 HS Approved
DMIO1K0 SN Mafenide; mafenide; 138-39-6; 4-(Aminomethyl)benzenesulfonamide; 4-Aminomethylbenzenesulfonamide; Ambamide; Emilene; Maphenide; Maphenid; Malfamin; Homosul; Homonal; Benzamsulfonamide; Homosulfanilamide; Marprontil; Mesudrin; Septicid; Neofamid; Mesudin; Paramenyl; 4-Homosulfanilamide; Benzenesulfonamide, 4-(aminomethyl)-; Homosulfaminum; 4-(aminomethyl)benzene-1-sulfonamide; p-(Aminomethyl)benzenesulfonamide; 4-sulfamoylbenzylamine; Bensulfamide; Mafenidum [INN-Latin]; Mafenida [INN-Spanish]; 4-(aminosulfonyl)benzylamine; Mafenide acetate; MAFENIDE
DMIO1K0 CP Mylan Inc
DMIO1K0 DT Small molecular drug
DMIO1K0 PC 3998
DMIO1K0 MW 186.23
DMIO1K0 FM C7H10N2O2S
DMIO1K0 IC InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)
DMIO1K0 CS C1=CC(=CC=C1CN)S(=O)(=O)N
DMIO1K0 IK TYMRLRRVMHJFTF-UHFFFAOYSA-N
DMIO1K0 IU 4-(aminomethyl)benzenesulfonamide
DMIO1K0 CA CAS 138-39-6
DMIO1K0 CB CHEBI:6633
DMIO1K0 DE Bacterial infection
DMABVE9 ID DMABVE9
DMABVE9 DN Sulfanilamide
DMABVE9 HS Approved
DMABVE9 SN AAS; AVC; Albexan; Albosal; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Desseptyl; Dipron; Ergaseptine; Gerison; Gombardol; Infepan; Lusil; Lysococcine; Neococcyl; Orgaseptine; PABS; Prontalbin; Prontylin; Proseptal; Proseptine; Pysococcine; SAN; Sanamid; Septanilam; Septolix; Septoplex; Septoplix; Solfanilamide; Stramid; Strepamide; Streptagol; Streptamid; Streptocid; Streptocide; Streptocidum; Streptocom; Streptol; Strepton; Streptopan; Streptrocide; Sulfanilamida; Sulfanilamidum; Sulfocidin; Therapol; Tolder; Prontosil I; Prontosil White; Pronzin Album; Rubiazol A; Septamide Album; Solfanilamide [DCIT]; Stopton Album; Streptocid album; Streptocide White; Sulfanilamide Vaginal Cream; Sulphanilamide Extra Pure; Sulphanilamide Gr; White streptocide; F 1162; Fourneau 1162; Ro13354; A-349; AVC (TN); Aromatic/heteroaromatic sulfonamide 2; F-1162; P-Aminobenzenesulfonylamide; P-Aminobenzensulfonamide; Streptocid (TN); Streptocide (VAN); Sulfanilamida [INN-Spanish]; Sulfanilamide (INN); Sulfanilamide [INN:DCF]; Sulfanilamidum [INN-Latin]; Aniline-p-sulfonic amide; I.C. 56; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; N4,N4-Bis(2-bromoethyl)sulfanilamide; N(sup 4),N(sup 4)-Bis(2-bromoethyl)sulfanilamide; N(sup4),N(sup4)-Bis(2-bromoethyl)sulfanilamide; Benzenesulfonamide, 4-(bis(2-bromoethyl)amino)-(9CI); Sulfanilamide, N4,N4-bis(2-bromoethyl)-(8CI); 1162 F; 4-(Bis(2-bromoethyl)amino)benzenesulfonamide; 4-Aminobenzene-1-Sulfonamide; 4-Aminophenylsulfonamide; 4-Sulfamoylaniline; 4-[bis(2-bromoethyl)amino]benzenesulfonamide
DMABVE9 TC Antibiotics
DMABVE9 DT Small molecular drug
DMABVE9 PC 5333
DMABVE9 MW 172.21
DMABVE9 FM C6H8N2O2S
DMABVE9 IC InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DMABVE9 CS C1=CC(=CC=C1N)S(=O)(=O)N
DMABVE9 IK FDDDEECHVMSUSB-UHFFFAOYSA-N
DMABVE9 IU 4-aminobenzenesulfonamide
DMABVE9 CA CAS 63-74-1
DMABVE9 CB CHEBI:45373
DMABVE9 DE Bacterial infection
DMFNAEM ID DMFNAEM
DMFNAEM DN Sulfaphenazole
DMFNAEM HS Approved
DMFNAEM SN Sulfabid
DMFNAEM CP Pharmaceutical Research Assoc Inc
DMFNAEM TC Antiinfective Agents
DMFNAEM DT Small molecular drug
DMFNAEM PC 5335
DMFNAEM MW 314.4
DMFNAEM FM C15H14N4O2S
DMFNAEM IC InChI=1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2
DMFNAEM CS C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N
DMFNAEM IK QWCJHSGMANYXCW-UHFFFAOYSA-N
DMFNAEM IU 4-amino-N-(2-phenylpyrazol-3-yl)benzenesulfonamide
DMFNAEM CA CAS 526-08-9
DMFNAEM CB CHEBI:77780
DMFNAEM DE Bacterial infection
DMIUYFH ID DMIUYFH
DMIUYFH DN Sulfapyridine
DMIUYFH HS Approved
DMIUYFH SN Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Piridazol; Plurazol; Pyriamid; Pyridazol; Relbapiridina; Ronin;Septipulmon; Solfapiridina; Streptosilpyridine; Sulfapiridina; Sulfapyridinum; Sulfidin; Sulfidine; Sulphapyridin; Sulphapyridine; Thioseptal; Trianon; Solfapiridina [DCIT]; M and B 693; A-499; ALBB-006215; M + B 693; M&B 693; M+B 693; Sulfapiridina [INN-Spanish]; Sulfapyridine (TN); Sulfapyridinum [INN-Latin]; AO-801/41077453; N(1)-Pyridylsulfanilamide; N(sup1)-Pyridylsulfanilamide; N-2-Pyridylsulfanilamide; N1-2-Pyridylsulfanilamide; Sulfapyridine (USP/INN); Sulfapyridine [USAN:INN:BAN]; N'-2-Pyridylsulfanilide; N(1)-2-Pyridylsulfanilamide; N(sup 1)-2-Pyridylsulfanilamide; N1-(Pyridin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyridyl-(8CI); 2-(4-Aminobenzenesulfonamido)pyridine; 2-(p-Aminobenzenesulphonamido)pyridine; 2-Sulfanilamidopyridin; 2-Sulfanilamidopyridin [German]; 2-Sulfanilamidopyridine; 2-Sulfanilyl aminopyridine; 2-Sulfanilylaminopyridine; 2-Sulfapyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N,2-pyridinylbenzenesulfonamide; 4-Amino-N-2-pyridinyl-benzenesulfonamide; 4-Amino-N-[2-pyridyl]benzene sulfonamide; 4-[(2-Pyridylamino)sulfonyl]aniline; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; 4-amino-N-pyridin-2-yl-benzenesulfonamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide
DMIUYFH TC Dermatologic Agents
DMIUYFH DT Small molecular drug
DMIUYFH PC 5336
DMIUYFH MW 249.29
DMIUYFH FM C11H11N3O2S
DMIUYFH IC InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)
DMIUYFH CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMIUYFH IK GECHUMIMRBOMGK-UHFFFAOYSA-N
DMIUYFH IU 4-amino-N-pyridin-2-ylbenzenesulfonamide
DMIUYFH CA CAS 144-83-2
DMIUYFH CB CHEBI:132842
DMIUYFH DE Dermatitis herpetiformis
DMICA9H ID DMICA9H
DMICA9H DN Sulfasalazine
DMICA9H HS Approved
DMICA9H SN sulfasalazine; 599-79-1; Salicylazosulfapyridine; Salazosulfapyridine; Azulfidine; Asulfidine; Salazopyridin; Sulcolon; Azopyrin; Accucol; Colo-Pleon; Salazopiridazin; Salisulf; Reupirin; Benzosulfa; Azopyrine; Salazosulfapyridin; Sulfasalazina; w-t Sasp oral; Sulfasalazinum; Sulfasalazin; Azulfidine EN; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Sas-500; Salazosulfapyridinum; Azosulfidin; SASP; Salazo-sulfapyridinum; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; SAS-500; Sulfasalizine
DMICA9H CP Watson Laboratories
DMICA9H TC Antiinflammatory Agents
DMICA9H DT Small molecular drug
DMICA9H PC 5339
DMICA9H MW 398.4
DMICA9H FM C18H14N4O5S
DMICA9H IC InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)
DMICA9H CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
DMICA9H IK NCEXYHBECQHGNR-UHFFFAOYSA-N
DMICA9H IU 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
DMICA9H CA CAS 599-79-1
DMICA9H CB CHEBI:9334
DMICA9H DE Rheumatoid arthritis; Irritable bowel syndrome
DMEV954 ID DMEV954
DMEV954 DN Sulfinpyrazone
DMEV954 HS Approved
DMEV954 SN Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
DMEV954 TC Uricosuric Agents
DMEV954 DT Small molecular drug
DMEV954 PC 5342
DMEV954 MW 404.5
DMEV954 FM C23H20N2O3S
DMEV954 IC InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
DMEV954 CS C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
DMEV954 IK MBGGBVCUIVRRBF-UHFFFAOYSA-N
DMEV954 IU 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
DMEV954 CA CAS 57-96-5
DMEV954 CB CHEBI:9342
DMEV954 DE Gout
DMXLT8C ID DMXLT8C
DMXLT8C DN Sulfisoxazole
DMXLT8C HS Approved
DMXLT8C SN Accuzole; Alphazole; Amidoxal; Astrazolo; Azosulfizin; Bactesulf; Barazae; Chemouag; Cosoxazole; Dorsulfan; ERYZOLE; Entusil; Entusul; Ganda; Gantrisin; Gantrisine; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazoi; Neoxazol; Novazolo; Novosaxazole; Pancid; Renosulfan; Resoxol; Roxosul; Roxoxol; SOXO; Saxosozine; Sodizole; Solfafurazolo; Sosol; Soxamide; Soxazole; Soxisol; Soxitabs; Soxomide; Stansin; Sulbio; Sulfadimethylisoxazole; Sulfafurazol; Sulfafurazole; Sulfafurazolum; Sulfagan; Sulfagen; Sulfaisoxazole; Sulfalar; Sulfapolar; Sulfasol; Sulfasoxazole; Sulfasoxizole; Sulfazin; Sulfisin; Sulfisonazole; Sulfisoxasole; Sulfisoxazol; Sulfisoxazolum; Sulfizin; Sulfizol; Sulfizole; Sulfofurazole; Sulfoxol; Suloxsol; Sulphadimethylisoxazole; Sulphafuraz; Sulphafurazol; Sulphafurazole; Sulphafurazolum; Sulphaisoxazole; Sulphisoxazol; Sulphisoxazole; Sulphofurazole; Sulsoxin; Thiasin; Unisulf; Urisoxin; Uritrisin; Urogan; Vagilia; Azo Gantrisin; Component of Azo Gantrisin; Component of Azo Gantrisin Accuzole; Dorsulfan warthausen; Roxosul tablets; Solfafurazolo [DCIT]; Sulfafuraz ole; Sulfisoxazole [USAN]; Sulfisoxazole dialamine; NU 445; Component of Azo-Sulfizin; G-sox; Gantrisin (TN); J-Sul; Koro-sulf; Norilgan-S; SK-Soxazole; Sulfafurazole (INN); Sulfafurazolum [INN-Latin]; Sulfazin (VAN); Sulfisoxazole-Carc; Tl-azole; US-67; V-Sul; Sulfisoxazole (JP15/USP); U.S.-67; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxale-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulfanilamide; 3,4-Dimethylisoxazole-5-sulphanilamide; 3,4-dimethylisoaxazole-5-sulfanilimide; 5-Sulfanilamido-3,4-dimethyl-isoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; 5-Sulphanilamido-3,4-dimethyl-isoxazole
DMXLT8C CP Hoffmann La Roche Inc
DMXLT8C TC Antiinfective Agents
DMXLT8C DT Small molecular drug
DMXLT8C PC 5344
DMXLT8C MW 267.31
DMXLT8C FM C11H13N3O3S
DMXLT8C IC InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
DMXLT8C CS CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
DMXLT8C IK NHUHCSRWZMLRLA-UHFFFAOYSA-N
DMXLT8C IU 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
DMXLT8C CA CAS 127-69-5
DMXLT8C CB CHEBI:102484
DMXLT8C DE Urinary tract infection
DM1YA7M ID DM1YA7M
DM1YA7M DN Sulfonamides
DM1YA7M HS Approved
DM1YA7M SN Sulfonamide Mixtures; Mixtures, Sulfonamide
DM1YA7M DT Small molecular drug
DM1YA7M PC 91392493
DM1YA7M MW 347.4
DM1YA7M FM C17H17NO5S
DM1YA7M IC InChI=1S/C17H17NO5S/c1-2-23-17(20)12-18(16-11-7-6-8-14(16)13-19)24(21,22)15-9-4-3-5-10-15/h3-11,13H,2,12H2,1H3
DM1YA7M CS CCOC(=O)CN(C1=CC=CC=C1C=O)S(=O)(=O)C2=CC=CC=C2
DM1YA7M IK DFRPGUIKXDWHSA-UHFFFAOYSA-N
DM1YA7M IU ethyl 2-[N-(benzenesulfonyl)-2-formylanilino]acetate
DM1YA7M DE Bacterial infection
DMAYX6P ID DMAYX6P
DMAYX6P DN Sulfoxone
DMAYX6P HS Approved
DMAYX6P SN Aldapsone; Aldesulfon; Diamidin; Diason; Diazon; Novotrone; Adesulfone sodium; Diasone sodium enterab; Sodium aldesulphone; Sodium sulfoxone; [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid; [sulfonylbis(4,1-phenyleneimino)]dimethanesulfinic acid
DMAYX6P CP Abbvie Inc
DMAYX6P TC Antibiotics
DMAYX6P DT Small molecular drug
DMAYX6P PC 5351
DMAYX6P MW 404.5
DMAYX6P FM C14H16N2O6S3
DMAYX6P IC InChI=1S/C14H16N2O6S3/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20)
DMAYX6P CS C1=CC(=CC=C1NCS(=O)O)S(=O)(=O)C2=CC=C(C=C2)NCS(=O)O
DMAYX6P IK NEDPPCHNEOMTJV-UHFFFAOYSA-N
DMAYX6P IU [4-[4-(sulfinomethylamino)phenyl]sulfonylanilino]methanesulfinic acid
DMAYX6P CA CAS 144-76-3
DMAYX6P CB CHEBI:135651
DMAYX6P DE Dermatitis herpetiformis
DM2QHZU ID DM2QHZU
DM2QHZU DN Sulindac
DM2QHZU HS Approved
DM2QHZU SN Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
DM2QHZU CP Merck & Co
DM2QHZU TC Antiinflammatory Agents
DM2QHZU DT Small molecular drug
DM2QHZU PC 1548887
DM2QHZU MW 356.4
DM2QHZU FM C20H17FO3S
DM2QHZU IC InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
DM2QHZU CS CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
DM2QHZU IK MLKXDPUZXIRXEP-MFOYZWKCSA-N
DM2QHZU IU 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
DM2QHZU CA CAS 38194-50-2
DM2QHZU CB CHEBI:9352
DM2QHZU DE Rheumatoid arthritis
DMNUC42 ID DMNUC42
DMNUC42 DN Sulodexide
DMNUC42 HS Approved
DMNUC42 TC Antithrombotic Agents
DMNUC42 PC 6453528
DMNUC42 MW 295.29
DMNUC42 FM C12H17N5O4
DMNUC42 IC InChI=1S/C12H17N5O4/c1-13-10-7-11(15-4-14-10)17(5-16-7)12-9(20-2)8(19)6(3-18)21-12/h4-6,8-9,12,18-19H,3H2,1-2H3,(H,13,14,15)/t6-,8-,9-,12-/m1/s1
DMNUC42 CS CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)OC
DMNUC42 IK GRYSXUXXBDSYRT-WOUKDFQISA-N
DMNUC42 IU (2R,3R,4R,5R)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol
DMNUC42 CA CAS 57817-83-1
DMNUC42 DE Tinnitus
DMZI2UF ID DMZI2UF
DMZI2UF DN Sulphadoxine
DMZI2UF HS Approved
DMZI2UF SN 2447-57-6; Sulforthomidine; Fanasil; Sulphormethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxinum; Sulfadoxina; Sulfadoxin; Fanzil; Solfadossina; Ro 4-4393; Solfadossina [DCIT]; Sulfadoxinum [INN-Latin]; Sulfadoxina [INN-Spanish]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; Orthosulfin; Sulformethoxine; Sulformetoxine; Sulphormetoxin; Sulphorthodimethoxine; WR 4073; Ro-4-4393; Sanasil: Sulfadoxine: Sulformetoxin; Sulfadoxine (JAN/USP/INN); Sulfadoxine [USAN:INN:BAN:JAN]; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; RS-1653
DMZI2UF DT Small molecular drug
DMZI2UF PC 17134
DMZI2UF MW 310.33
DMZI2UF FM C12H14N4O4S
DMZI2UF IC InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
DMZI2UF CS COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N
DMZI2UF IK PJSFRIWCGOHTNF-UHFFFAOYSA-N
DMZI2UF IU 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
DMZI2UF CA CAS 2447-57-6
DMZI2UF CB CHEBI:9329
DMZI2UF DE Malaria
DMF54ZG ID DMF54ZG
DMF54ZG DN Sulpiride
DMF54ZG HS Approved
DMF54ZG SN Abilit; Aiglonyl; Alimoral; Arminol; Calmoflorine; Championyl; Coolspan; Darleton; Deponerton; Desisulpid; Desmenat; Digton; Dobren; Dogmatil; Dogmatyl; Dolmatil; Dresent; Eglonil; Eglonyl; Ekilid; Enimon; Equilid; Eusulpid; Fardalan; Fidelan; Guastil; Isnamide; Kylistro; Lebopride; Levobren; Levopraid; Levosulpirida; Levosulpiridum; Lisopiride; Mariastel; Meresa; Miradol; Mirbanil; Misulvan; Neogama; Norestran; Normum; Nufarol; Omiryl; Omperan; Ozoderpin; Pontiride; Psicocen; Pyrikappl; Pyrkappl; Restful; Sernevin; Splotin; Stamonevrol; Sulp; Sulperide; Sulpirid; Sulpirida; Sulpiridum; Sulpitil; Sulpivert; Sulpor; Sulpride; Sulpyrid; Suprium; Sursumid; Synedil; Tepavil; Valirem; Zemorcon; Allphar Brand of Sulpiride; Almirall Brand of Sulpiride; Areu Brand of Sulpiride; Centrum Brand of Sulpiride; Desitin Brand of Sulpiride; Dolorgiet Brand of Sulpiride; Erempharma Brand of Sulpiride; Fumouzer Brand of Sulpiride; Hennig Brand of Sulpiride; Hexal Brand of Sulpiride; Hoechst Brand of Sulpiride; Hormosan Brand of Sulpiride; Krewel Brand of Sulpiride; Levosulpiride [INN]; Magnetic resonance imaging sulpiride; Pharmacia Brand of Sulpiride; Psicofarma Brand of Sulpiride; Rosemont Brand of Sulpiride; Sanofi Synthelabo Brand of Sulpiride; Spyfarma Brand of Sulpiride; Uriach Brand of Sulpiride; Vertigo Meresa; Vertigo neogama; RD 1403; S 8010; Bosnyl (TN); Dogmatil (TN); Dogmatyl (TN); Eglonyl (TN); Levosulpirida [INN-Spanish]; Levosulpiridum [INN-Latin]; Meresa (TN); Neuraxpharm (TN); RV-12309; Ratiopharm (TN); Sanofi-Synthelabo Brand of Sulpiride; Sulpirid (TN); Sulpirida [INN-Spanish]; Sulpiridum [INN-Latin]; Sulpiryd (TN); Vertigo-Meresa; Vertigo-neogama; R. D. 1403; R.D. 1403; Sulpiride (JP15/USAN/INN); Sulpiride [USAN:INN:BAN:JAN]; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (+/-)-Sulpiride; (RS)-(+/-)-sulpiride; (inverted question mark)-Sulpiride
DMF54ZG CP Arrow Generics
DMF54ZG TC Antipsychotic Agents
DMF54ZG DT Small molecular drug
DMF54ZG PC 5355
DMF54ZG MW 341.4
DMF54ZG FM C15H23N3O4S
DMF54ZG IC InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)
DMF54ZG CS CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
DMF54ZG IK BGRJTUBHPOOWDU-UHFFFAOYSA-N
DMF54ZG IU N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
DMF54ZG CA CAS 15676-16-1
DMF54ZG CB CHEBI:32168
DMF54ZG DE Schizophrenia
DMVYXR8 ID DMVYXR8
DMVYXR8 DN Sumatriptan
DMVYXR8 HS Approved
DMVYXR8 SN Sumatran; Sumatriptanum; Sumax; GR 43175; GR 43175X; NP101; GR-43175; Imigran (TN); Imitrex (TN); KS-1116; Sumatriptanum [INN-Latin]; Sumatriptan (JAN/USP/INN); (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide; 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide; 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide; 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
DMVYXR8 CP GlaxoSmithKline
DMVYXR8 TC Vasoconstrictor Agents
DMVYXR8 DT Small molecular drug
DMVYXR8 PC 5358
DMVYXR8 MW 295.4
DMVYXR8 FM C14H21N3O2S
DMVYXR8 IC InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
DMVYXR8 CS CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
DMVYXR8 IK KQKPFRSPSRPDEB-UHFFFAOYSA-N
DMVYXR8 IU 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DMVYXR8 CA CAS 103628-46-2
DMVYXR8 CB CHEBI:10650
DMVYXR8 DE Migraine
DMCBJSR ID DMCBJSR
DMCBJSR DN Sunitinib
DMCBJSR HS Approved
DMCBJSR SN Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
DMCBJSR CP Pfizer
DMCBJSR TC Anticancer Agents
DMCBJSR DT Small molecular drug
DMCBJSR PC 5329102
DMCBJSR MW 398.5
DMCBJSR FM C22H27FN4O2
DMCBJSR IC InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
DMCBJSR CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
DMCBJSR IK WINHZLLDWRZWRT-ATVHPVEESA-N
DMCBJSR IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMCBJSR CA CAS 557795-19-4
DMCBJSR CB CHEBI:38940
DMCBJSR DE Gastrointestinal stromal tumour; Gastrointestinal cancer
DMN8E5D ID DMN8E5D
DMN8E5D DN Sunitinib malate
DMN8E5D HS Approved
DMN8E5D SN (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate; LVX8N1UT73; MFCD08282795; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; PHA-290940AD; SU 011248; SU010398; SU011248; SU011248 L-malate salt; SUNITINIB MALEATE; Sunitinib malate; Sunitinib malate [USAN]; UNII-LVX8N1UT73
DMN8E5D TC Anticancer Agents
DMN8E5D DT Small molecular drug
DMN8E5D PC 6456015
DMN8E5D MW 532.569
DMN8E5D FM C26H33FN4O7
DMN8E5D IC InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1
DMN8E5D CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O
DMN8E5D IK LBWFXVZLPYTWQI-IPOVEDGCSA-N
DMN8E5D IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid
DMN8E5D CA CAS 341031-54-7
DMN8E5D DE Gastrointestinal stromal tumor; Renal cell carcinoma
DMOGREH ID DMOGREH
DMOGREH DN Suplatast tosilate
DMOGREH HS Approved
DMOGREH SN IPD; IPD-1151T; YM-672
DMOGREH CP Taiho Pharmaceutical Co Ltd
DMOGREH DT Small molecular drug
DMOGREH PC 71773
DMOGREH MW 499.6
DMOGREH FM C23H33NO7S2
DMOGREH IC InChI=1S/C16H25NO4S.C7H8O3S/c1-4-20-11-14(18)12-21-15-7-5-13(6-8-15)17-16(19)9-10-22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h5-8,14,18H,4,9-12H2,1-3H3;2-5H,1H3,(H,8,9,10)
DMOGREH CS CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-]
DMOGREH IK RYVJQEZJUFRANT-UHFFFAOYSA-N
DMOGREH IU [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate
DMOGREH CA CAS 94055-76-2
DMOGREH DE Allergy
DMKXJZ7 ID DMKXJZ7
DMKXJZ7 DN Suprofen
DMKXJZ7 HS Approved
DMKXJZ7 SN Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure
DMKXJZ7 TC Antiinflammatory Agents
DMKXJZ7 DT Small molecular drug
DMKXJZ7 PC 5359
DMKXJZ7 MW 260.31
DMKXJZ7 FM C14H12O3S
DMKXJZ7 IC InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
DMKXJZ7 CS CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O
DMKXJZ7 IK MDKGKXOCJGEUJW-UHFFFAOYSA-N
DMKXJZ7 IU 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
DMKXJZ7 CA CAS 40828-46-4
DMKXJZ7 CB CHEBI:9362
DMKXJZ7 DE Miosis
DM0E6S3 ID DM0E6S3
DM0E6S3 DN Suvorexant
DM0E6S3 HS Approved
DM0E6S3 SN Suvorexant; 1030377-33-3; MK-4305; BELSOMRA; MK 4305; MK4305; UNII-081L192FO9; Suvorexant (MK-4305); [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; CHEMBL1083659; CHEBI:82698; 081L192FO9; C23H23ClN6O2; ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
DM0E6S3 DT Small molecular drug
DM0E6S3 PC 24965990
DM0E6S3 MW 450.9
DM0E6S3 FM C23H23ClN6O2
DM0E6S3 IC InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
DM0E6S3 CS C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
DM0E6S3 IK JYTNQNCOQXFQPK-MRXNPFEDSA-N
DM0E6S3 IU [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
DM0E6S3 CA CAS 1030377-33-3
DM0E6S3 CB CHEBI:82698
DM0E6S3 DE Insomnia
DM6S0HB ID DM6S0HB
DM6S0HB DN TachoComb
DM6S0HB HS Approved
DM6S0HB SN Collagen fleece, Nycomed; Collagen fleece, Torii; TO-193; Fibrin/thrombin/aprotinin collagen fleece, Nycomed/Torii
DM6S0HB CP Nycomed
DM6S0HB DE Wound healing
DM51FY6 ID DM51FY6
DM51FY6 DN Tacrine
DM51FY6 HS Approved
DM51FY6 SN Cognex; Romotal; Tacrina; Tacrinal; Tacrinum; Tenakrin; Tetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; Tha; Tacrine hydrochloride; BBL001044; CS 12602; Cognex (TN); Tacrina [INN-Spanish]; Tacrinal (TN); Tacrine (INN); Tacrine [INN:BAN]; Tacrinum [INN-Latin]; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE; 1,2,3,4-TETRAHYDRO-9-ACRIDINAMINE (SEE ALSO 1684-40-8); 1,2,3,4-Tetrahydro-9-acridineamine; 1,2,3,4-Tetrahydro-acridin-9-ylamine; 1,2,3,4-Tetrahydroaminoacridine; 1,2,3,4-tetrahydroacridin-9-amine; 5-Amino-6,7,8,9-tetrahydroacridine (European); 9-AMINOTETRAHYDROACRIDINE; 9-Acridinamine, 1,2,3,4-tetrahydro-(9CI); 9-Amino-1,2,3,4-Tetrahydroacridine Hydrate Hydrochloride Hydrate; 9-amino-1,2,3,4-tetrahydroacridine
DM51FY6 TC Parasympathomimetics
DM51FY6 DT Small molecular drug
DM51FY6 PC 1935
DM51FY6 MW 198.26
DM51FY6 FM C13H14N2
DM51FY6 IC InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
DM51FY6 CS C1CCC2=NC3=CC=CC=C3C(=C2C1)N
DM51FY6 IK YLJREFDVOIBQDA-UHFFFAOYSA-N
DM51FY6 IU 1,2,3,4-tetrahydroacridin-9-amine
DM51FY6 CA CAS 321-64-2
DM51FY6 CB CHEBI:45980
DM51FY6 DE Alzheimer disease
DMZ7XNQ ID DMZ7XNQ
DMZ7XNQ DN Tacrolimus
DMZ7XNQ HS Approved
DMZ7XNQ SN Advagraf; Fujimycin; Graceptor; Modigraf; Prograf; Protopic; Protopy; Tacarolimus; Tsukubaenolide; Tacrolimus anhydrous; FK 506; FK5; FK506; FR 900506; FR900506; K506; L 679934; Advagraf (TN); FR-900506; Fk-506; L-679934; LCP-Tacro; Prograf (TN); Protopic (TN); Tacrolimus (INN); Tacrolimus (Prograf); Tacrolimus (anhydrous); (-)-FK 506; 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone; 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
DMZ7XNQ CP Fujisawa; Sucampo
DMZ7XNQ TC Immunosuppressive Agents
DMZ7XNQ DT Small molecular drug
DMZ7XNQ PC 445643
DMZ7XNQ MW 804
DMZ7XNQ FM C44H69NO12
DMZ7XNQ IC InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
DMZ7XNQ CS C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
DMZ7XNQ IK QJJXYPPXXYFBGM-LFZNUXCKSA-N
DMZ7XNQ IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZ7XNQ CA CAS 104987-11-3
DMZ7XNQ CB CHEBI:61049
DMZ7XNQ DE Organ transplant rejection; Ocular allergy
DMJZHT1 ID DMJZHT1
DMJZHT1 DN Tadalafil
DMJZHT1 HS Approved
DMJZHT1 SN ADCIRCA; Acdirca; Cialis; Tadanafil; Lilly brand of tadalafil; Tadalafil [USAN]; GF 196960; IC 351; ICOS 351; Ic351; Cialis (TN); GF-196960; IC-351; KS-1117; Tadalafil (JAN/USAN/INN); Cialis, GF 196960, IC 351, ICOS 351, Tadalafil; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione; (6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
DMJZHT1 CP Eli Lilly
DMJZHT1 TC Antiimpotence Agents
DMJZHT1 DT Small molecular drug
DMJZHT1 PC 110635
DMJZHT1 MW 389.4
DMJZHT1 FM C22H19N3O4
DMJZHT1 IC InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
DMJZHT1 CS CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36
DMJZHT1 IK WOXKDUGGOYFFRN-IIBYNOLFSA-N
DMJZHT1 IU (2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
DMJZHT1 CA CAS 171596-29-5
DMJZHT1 CB CHEBI:71940
DMJZHT1 DE Erectile dysfunction
DM1XT4N ID DM1XT4N
DM1XT4N DN Tafenoquine
DM1XT4N HS Approved
DM1XT4N SN 106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN
DM1XT4N CP Medicines for Malaria Venture/GlaxoSmithKline
DM1XT4N DT Small molecular drug
DM1XT4N PC 115358
DM1XT4N MW 463.5
DM1XT4N FM C24H28F3N3O3
DM1XT4N IC InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3
DM1XT4N CS CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC
DM1XT4N IK LBHLFPGPEGDCJG-UHFFFAOYSA-N
DM1XT4N IU 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
DM1XT4N CA CAS 106635-80-7
DM1XT4N CB CHEBI:141487
DM1XT4N DE Plasmodium vivax malaria; Malaria
DMFC41K ID DMFC41K
DMFC41K DN Tafluprost
DMFC41K HS Approved
DMFC41K SN Zioptan (TN)
DMFC41K CP Merck
DMFC41K DT Small molecular drug
DMFC41K PC 9868491
DMFC41K MW 452.5
DMFC41K FM C25H34F2O5
DMFC41K IC InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1
DMFC41K CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O
DMFC41K IK WSNODXPBBALQOF-VEJSHDCNSA-N
DMFC41K IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
DMFC41K CA CAS 209860-87-7
DMFC41K CB CHEBI:66899
DMFC41K DE Glaucoma/ocular hypertension
DM9HQ5U ID DM9HQ5U
DM9HQ5U DN Tagraxofusp
DM9HQ5U HS Approved
DM9HQ5U SN Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DM9HQ5U CP Stemline Therapeutics
DM9HQ5U DE Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia
DM1KS78 ID DM1KS78
DM1KS78 DN Talazoparib
DM1KS78 HS Approved
DM1KS78 SN Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ
DM1KS78 CP Pfizer
DM1KS78 DT Small molecular drug
DM1KS78 PC 135565082
DM1KS78 MW 380.4
DM1KS78 FM C19H14F2N6O
DM1KS78 IC InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
DM1KS78 CS CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DM1KS78 IK HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DM1KS78 IU (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
DM1KS78 CA CAS 1207456-01-6
DM1KS78 DE Breast cancer; Psoriatic arthritis
DM2M3OC ID DM2M3OC
DM2M3OC DN Talazoparib
DM2M3OC HS Approved
DM2M3OC SN (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-3H-pyrido[4,3,2-de]phthalazine-3-one; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one; (8s,9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1h-1,2,4-Triazol-5-Yl)-2,7,8,9-Tetrahydro-3h-Pyrido[4,3,2-De]phthalazin-3-One; LT-673; Talazoparib; Talazoparib (BMN 673); Talazoparib [USAN:INN]
DM2M3OC TC Poly (ADP-ribose) polymerase (PARP) inhibitor
DM2M3OC DT Small molecular drug
DM2M3OC PC 135565082
DM2M3OC MW 380.359
DM2M3OC FM C19H14F2N6O
DM2M3OC IC InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
DM2M3OC CS CN1C(=NC=N1)C2C(NC3=C4C2=NNC(=O)C4=CC(=C3)F)C5=CC=C(C=C5)F
DM2M3OC IK HWGQMRYQVZSGDQ-HZPDHXFCSA-N
DM2M3OC IU (11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
DM2M3OC CA CAS 1207456-01-6
DM2M3OC DE Breast cancer
DM214Q8 ID DM214Q8
DM214Q8 DN Talbutal
DM214Q8 HS Approved
DM214Q8 SN Lotusate; Profundol; Talbumalum; Talbutale; Talbutalum; Talbutal [INN]; Talbutale [DCIT]; WIN 5095; Lotusate (TN); Sec-Butyl allylbarbituric acid; Talbutal (INN); Talbutalum [INN-Latin]; 5-(1-Methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-Allyl-5-(1-methylpropyl) barbituric acid; 5-Allyl-5-sec-butylbarbituric acid; 5-Isobutyl-5-allylbarbituric acid; 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM214Q8 TC Hypnotics and Sedatives
DM214Q8 DT Small molecular drug
DM214Q8 PC 8275
DM214Q8 MW 224.26
DM214Q8 FM C11H16N2O3
DM214Q8 IC InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
DM214Q8 CS CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
DM214Q8 IK BJVVMKUXKQHWJK-UHFFFAOYSA-N
DM214Q8 IU 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
DM214Q8 CA CAS 115-44-6
DM214Q8 CB CHEBI:134923
DM214Q8 DE Irritability
DM3PZXN ID DM3PZXN
DM3PZXN DN Taliglucerase alfa
DM3PZXN HS Approved
DM3PZXN SN Elelyso (TN)
DM3PZXN CP Pfizer
DM3PZXN DE Metabolic disorder
DMKBW5C ID DMKBW5C
DMKBW5C DN Talimogene Laherparepvec
DMKBW5C HS Approved
DMKBW5C SN IMLYGIC
DMKBW5C CP Amgen
DMKBW5C TC Anticancer Agents
DMKBW5C DT Vaccine
DMKBW5C DE Melanoma
DMLB0EZ ID DMLB0EZ
DMLB0EZ DN Tamoxifen
DMLB0EZ HS Approved
DMLB0EZ SN tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen
DMLB0EZ CP AstraZeneca plc
DMLB0EZ TC Anticancer Agents
DMLB0EZ DT Small molecular drug
DMLB0EZ PC 2733526
DMLB0EZ MW 371.5
DMLB0EZ FM C26H29NO
DMLB0EZ IC InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
DMLB0EZ CS CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
DMLB0EZ IK NKANXQFJJICGDU-QPLCGJKRSA-N
DMLB0EZ IU 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMLB0EZ CA CAS 10540-29-1
DMLB0EZ CB CHEBI:41774
DMLB0EZ DE Breast cancer
DM5QF9V ID DM5QF9V
DM5QF9V DN Tamsulosin
DM5QF9V HS Approved
DM5QF9V SN Flomax; Flowmax; Harnal; Tamsolusin; Tamsulon; Tamsulosina; Tamsulosine; Tamsulosinum; Flomax (TN); Flomaxtra (TN); Tamsulon (TN); Tamsulosin (INN); Tamsulosin [INN:BAN]; Tamsulosina [INN-Spanish]; Tamsulosine [INN-French]; Tamsulosinum [INN-Latin]; Urimax (TN); (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide; 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide; 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide; 5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide; 5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
DM5QF9V CP Yamanouchi Pharmaceuticals
DM5QF9V TC Anticancer Agents
DM5QF9V DT Small molecular drug
DM5QF9V PC 129211
DM5QF9V MW 408.5
DM5QF9V FM C20H28N2O5S
DM5QF9V IC InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1
DM5QF9V CS CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N
DM5QF9V IK DRHKJLXJIQTDTD-OAHLLOKOSA-N
DM5QF9V IU 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
DM5QF9V CA CAS 106133-20-4
DM5QF9V CB CHEBI:9398
DM5QF9V DE Benign prostatic hyperplasia
DMPHWU6 ID DMPHWU6
DMPHWU6 DN Tandospirone
DMPHWU6 HS Approved
DMPHWU6 SN Sediel (TN)
DMPHWU6 DT Small molecular drug
DMPHWU6 PC 91273
DMPHWU6 MW 383.5
DMPHWU6 FM C21H29N5O2
DMPHWU6 IC InChI=1S/C21H29N5O2/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21/h3,6-7,15-18H,1-2,4-5,8-14H2/t15-,16+,17+,18-
DMPHWU6 CS C1C[C@H]2C[C@@H]1[C@H]3[C@@H]2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5
DMPHWU6 IK CEIJFEGBUDEYSX-FZDBZEDMSA-N
DMPHWU6 IU (1S,2R,6S,7R)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
DMPHWU6 CA CAS 87760-53-0
DMPHWU6 CB CHEBI:145673
DMPHWU6 DE Anxiety disorder
DMXLSH3 ID DMXLSH3
DMXLSH3 DN Tapentadol hydrochloride
DMXLSH3 HS Approved
DMXLSH3 SN Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL
DMXLSH3 CP Ortho-McNell Pharmaceutical
DMXLSH3 DT Small molecular drug
DMXLSH3 PC 9838021
DMXLSH3 MW 257.8
DMXLSH3 FM C14H24ClNO
DMXLSH3 IC InChI=1S/C14H23NO.ClH/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12;/h6-9,11,14,16H,5,10H2,1-4H3;1H/t11-,14+;/m0./s1
DMXLSH3 CS CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C.Cl
DMXLSH3 IK ZELFLGGRLLOERW-YECZQDJWSA-N
DMXLSH3 IU 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride
DMXLSH3 CA CAS 175591-09-0
DMXLSH3 DE Acute pain
DMLOQ1V ID DMLOQ1V
DMLOQ1V DN Tasimelteon
DMLOQ1V HS Approved
DMLOQ1V SN Tasimelteon; 609799-22-6; Hetlioz; VEC-162; BMS-214778; VEC 162; UNII-SHS4PU80D9; BMS 214778; SHS4PU80D9; CHEBI:79042; N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide; Tasimelteon [USAN:INN]; tasimelteonum; N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide; N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide; N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide; Hetlioz (TN); Tasimelteon (USAN/INN); SCHEMBL3505912; GTPL7393
DMLOQ1V CP Vanda Pharmaceuticals
DMLOQ1V DT Small molecular drug
DMLOQ1V PC 10220503
DMLOQ1V MW 245.32
DMLOQ1V FM C15H19NO2
DMLOQ1V IC InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
DMLOQ1V CS CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
DMLOQ1V IK PTOIAAWZLUQTIO-GXFFZTMASA-N
DMLOQ1V IU N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
DMLOQ1V CA CAS 609799-22-6
DMLOQ1V CB CHEBI:79042
DMLOQ1V DE Insomnia
DMM13DI ID DMM13DI
DMM13DI DN Tasosartan
DMM13DI HS Approved
DMM13DI SN Verdia; ANA-756; WAY-126756; Tasosartan (USAN/INN); WAY-ANA-756; 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one; 2,4-dimethyl-8-{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6h)-one
DMM13DI TC Antihypertensive Agents
DMM13DI DT Small molecular drug
DMM13DI PC 60919
DMM13DI MW 411.5
DMM13DI FM C23H21N7O
DMM13DI IC InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)
DMM13DI CS CC1=C2CCC(=O)N(C2=NC(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMM13DI IK ADXGNEYLLLSOAR-UHFFFAOYSA-N
DMM13DI IU 2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[2,3-d]pyrimidin-7-one
DMM13DI CA CAS 145733-36-4
DMM13DI CB CHEBI:135666
DMM13DI DE Hypertension
DM3ED1A ID DM3ED1A
DM3ED1A DN Tavaborole
DM3ED1A HS Approved
DM3ED1A SN Kerydin; AN2690; AN-2690; AN-2690); SCH-900340; Topical antifungal (onychomycosis), Merck & Co; Trichophyton-targeting antifungal (onychomycosis), Merck & Co; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough; Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor; Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
DM3ED1A CP Anacor; Anacor Pharmaceuticals Inc
DM3ED1A DT Small molecular drug
DM3ED1A PC 11499245
DM3ED1A MW 151.93
DM3ED1A FM C7H6BFO2
DM3ED1A IC InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
DM3ED1A CS B1(C2=C(CO1)C=C(C=C2)F)O
DM3ED1A IK LFQDNHWZDQTITF-UHFFFAOYSA-N
DM3ED1A IU 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
DM3ED1A CA CAS 174671-46-6
DM3ED1A CB CHEBI:77942
DM3ED1A DE Onychomycosis
DMUOT9V ID DMUOT9V
DMUOT9V DN Taxol
DMUOT9V HS Approved
DMUOT9V SN C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
DMUOT9V DT Small molecular drug
DMUOT9V PC 36314
DMUOT9V MW 853.9
DMUOT9V FM C47H51NO14
DMUOT9V IC InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
DMUOT9V CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
DMUOT9V IK RCINICONZNJXQF-MZXODVADSA-N
DMUOT9V IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMUOT9V CA CAS 33069-62-4
DMUOT9V CB CHEBI:45863
DMUOT9V DE Gastric adenocarcinoma; Ovarian cancer; Solid tumour/cancer; Breast cancer; Pancreatic cancer
DM8SMD1 ID DM8SMD1
DM8SMD1 DN Tazarotene
DM8SMD1 HS Approved
DM8SMD1 SN Avage; Suretin; Tazaroteno; Tazarotenum; Tazorac; Tazoral; Zorac; AGN 190168; AGN-190168; Avage (TN); Tazarotene [USAN:INN]; Tazorac (TN); Zorac (TN); Tazarotene (JAN/USAN/INN); Tazorac, Avage, Zora, Tazarotene; Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate; Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate; Ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester; 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester
DM8SMD1 CP Allergan Pharmaceuticals
DM8SMD1 TC Dermatologic Agents
DM8SMD1 DT Small molecular drug
DM8SMD1 PC 5381
DM8SMD1 MW 351.5
DM8SMD1 FM C21H21NO2S
DM8SMD1 IC InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
DM8SMD1 CS CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
DM8SMD1 IK OGQICQVSFDPSEI-UHFFFAOYSA-N
DM8SMD1 IU ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
DM8SMD1 CA CAS 118292-40-3
DM8SMD1 CB CHEBI:32184
DM8SMD1 DE Psoriasis vulgaris
DMWP1BH ID DMWP1BH
DMWP1BH DN Tazemetostat
DMWP1BH HS Approved
DMWP1BH SN EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
DMWP1BH CP Epizyme
DMWP1BH DT Small molecular drug
DMWP1BH PC 66558664
DMWP1BH MW 572.7
DMWP1BH FM C34H44N4O4
DMWP1BH IC InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40)
DMWP1BH CS CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
DMWP1BH IK NSQSAUGJQHDYNO-UHFFFAOYSA-N
DMWP1BH IU N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide
DMWP1BH CA CAS 1403254-99-8
DMWP1BH DE Malignant rhabdoid tumour; Brain and central nervous system tumour; Diffuse large B-cell lymphoma; Mesothelioma; Solid tumour/cancer; Synovial sarcoma; Follicular lymphoma
DM3XNUI ID DM3XNUI
DM3XNUI DN Tazobactam
DM3XNUI HS Approved
DM3XNUI SN TAZ; CL298741; YTR830H; CL-298741; Piprataz (TN); YTR-830H; Tazobactam (JAN/USAN/INN); (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4; (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
DM3XNUI CP Gepach International
DM3XNUI TC Antiinfective Agents
DM3XNUI DT Small molecular drug
DM3XNUI PC 123630
DM3XNUI MW 300.29
DM3XNUI FM C10H12N4O5S
DM3XNUI IC InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1
DM3XNUI CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
DM3XNUI IK LPQZKKCYTLCDGQ-WEDXCCLWSA-N
DM3XNUI IU (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM3XNUI CA CAS 89786-04-9
DM3XNUI CB CHEBI:9421
DM3XNUI DE Bacterial infection
DML6OE7 ID DML6OE7
DML6OE7 DN Tbo-Filgrastim
DML6OE7 HS Approved
DML6OE7 SN Neutroval (TN)
DML6OE7 CP Sicor Biotech
DML6OE7 DE Neutropenia
DMQ5S6C ID DMQ5S6C
DMQ5S6C DN Tebipenem pivoxil
DMQ5S6C HS Approved
DMQ5S6C SN 161715-24-8; Orapenem; TBPM-PI; L-084; ME1211; UNII-95AK1A52I8; LJC 11,084; 95AK1A52I8; LJC-11084; ME-1211; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; Tebipenempivoxil; Tebipenem [INN]; (4R,5S,6S)-(Pivaloyloxy)methyl 3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)-; Tebipenem pivoxil (L-084); Tebipenem pivoxil(L-084); Orapenem (TN); (1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester; MLS006011128; SCHEMBL305541; Tebipenem pivoxil [USAN:INN]; CHEMBL2107486; GTPL10864; DTXSID00167228; CHEBI:135799; EX-A1256; HY-B0396; WHO 7924; ZINC4217736; Tebipenem pivoxil (JAN/USAN/INN); 2748AH; CT0255; LJC 11084; MFCD17215369; s2159; AKOS015899532; CCG-269673; LJC-11,084; NCGC00346570-01; NCGC00346570-04; (pivaloyloxy)methyl (4R,5S,6S)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate; [(4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carbonyloxy]methyl 2,2-dimethylpropanoate; AC-22712; AS-75334; L-084;ME1211; SMR004702908; L 084; D09598; AB01566835_01; Q1623593; (4R,5R,6S)-3-((1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy) methyl ester; 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMQ5S6C CP Meiji Seika Pharma
DMQ5S6C DT Small molecular drug
DMQ5S6C PC 9892071
DMQ5S6C MW 497.6
DMQ5S6C FM C22H31N3O6S2
DMQ5S6C IC InChI=1S/C22H31N3O6S2/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21/h11-15,26H,6-10H2,1-5H3/t11-,12-,14-,15-/m1/s1
DMQ5S6C CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O
DMQ5S6C IK SNUDIPVBUUXCDG-QHSBEEBCSA-N
DMQ5S6C IU 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMQ5S6C CA CAS 161715-24-8
DMQ5S6C CB CHEBI:135799
DMQ5S6C DE Respiratory tract infection
DMYQCWT ID DMYQCWT
DMYQCWT DN Tecartus
DMYQCWT HS Approved
DMYQCWT SN Brexucabtagene autoleucel; KTE-X19
DMYQCWT CP Gilead Sciences; Kite Pharma
DMYQCWT DT CAR T Cell Therapy
DMYQCWT DE Mantle cell lymphoma
DM2OVDT ID DM2OVDT
DM2OVDT DN Tecfidera
DM2OVDT HS Approved
DM2OVDT SN DIMETHYL FUMARATE
DM2OVDT CP Biogen Idec
DM2OVDT DT Small molecular drug
DM2OVDT PC 637568
DM2OVDT MW 144.12
DM2OVDT FM C6H8O4
DM2OVDT IC InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+
DM2OVDT CS COC(=O)/C=C/C(=O)OC
DM2OVDT IK LDCRTTXIJACKKU-ONEGZZNKSA-N
DM2OVDT IU dimethyl (E)-but-2-enedioate
DM2OVDT CA CAS 624-49-7
DM2OVDT CB CHEBI:76004
DM2OVDT DE Multiple sclerosis
DMUEWM3 ID DMUEWM3
DMUEWM3 DN Technetium (99MTC) mebrofenin
DMUEWM3 HS Approved
DMUEWM3 SN F2NQ468L52; Glycine, N-(2-((3-bromo-2,4,6-trimethylphenyl)amino)-2-oxoethyl)-N-(carboxymethyl)-, technetium-99Tc salt; Mebrofenin / 99Tc; Mebrofenin / technetium-99Tc; Mebrofenin mixture with technetium-99Tc; TECHNETIUM TC-99M MEBROFENIN KIT; Technetium (99Mtc) Mebrofenin; Technetium TC-99M mebrofenin kit; Technetium Tc 99m DISIDA; Technetium Tc 99m diisopropyl-iminodiacetic acid; Technetium Tc 99m mebrofenin; Technetium Tc-99m mebrofenin; UNII-F2NQ468L52
DMUEWM3 TC Diagnostic Radiopharmaceutical Agents
DMUEWM3 DT Small molecular drug
DMUEWM3 PC 11431716
DMUEWM3 MW 486.136
DMUEWM3 FM C15H19BrN2O5Tc
DMUEWM3 IC InChI=1S/C15H19BrN2O5.Tc/c1-8-4-9(2)15(10(3)14(8)16)17-11(19)5-18(6-12(20)21)7-13(22)23;/h4H,5-7H2,1-3H3,(H,17,19)(H,20,21)(H,22,23);/i;1+1
DMUEWM3 CS CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C.[Tc]
DMUEWM3 IK JLJSYHOPCNWUNE-IEOVAKBOSA-N
DMUEWM3 IU 2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid;technetium-99
DMUEWM3 CA CAS 1415247-71-0
DMUEWM3 DE Imaging of liver and gallbladder
DMW5ML9 ID DMW5ML9
DMW5ML9 DN Tecovirimat
DMW5ML9 HS Approved
DMW5ML9 SN Tecovirimat; ST 246; SIGA-246; UNII-F925RR824R; 816458-31-8; F925RR824R; ST-246; TPOXX; Tecovirimat [USAN:INN]; SIGA 246
DMW5ML9 CP SIGA Technologies
DMW5ML9 PC 16124688
DMW5ML9 MW 376.3
DMW5ML9 FM C19H15F3N2O3
DMW5ML9 IC InChI=1S/C19H15F3N2O3/c20-19(21,22)9-3-1-8(2-4-9)16(25)23-24-17(26)14-10-5-6-11(13-7-12(10)13)15(14)18(24)27/h1-6,10-15H,7H2,(H,23,25)/t10-,11+,12+,13-,14-,15+
DMW5ML9 CS C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F
DMW5ML9 IK CSKDFZIMJXRJGH-VWLPUNTISA-N
DMW5ML9 IU N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide
DMW5ML9 CA CAS 869572-92-9
DMW5ML9 DE Virus infection; Smallpox
DMG2SKR ID DMG2SKR
DMG2SKR DN Tedizolid
DMG2SKR HS Approved
DMG2SKR SN Tedizolid; Torezolid; 856866-72-3; TR-700; Da 7157; UNII-97HLQ82NGL; DA-7157; TR 700; 97HLQ82NGL; CHEBI:82717; (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)-3-pyridyl]phenyl]-5-(hydroxymethyl)oxazolidin-2-one; Tedizolid [USAN:INN]; Tedizolid (USAN/INN); SCHEMBL440398; CHEMBL1257051; DTXSID10234975; XFALPSLJIHVRKE-GFCCVEGCSA-N; MolPort-042-624-220; AI025; BCP02830; ZINC43100956; AKOS025401974; CS-0687; NCGC00379072-02; AN-27109; AK322133; AC-27738; BC600578; HY-14855
DMG2SKR CP Bayer HealthCare Pharmaceuticals
DMG2SKR DT Small molecular drug
DMG2SKR PC 11234049
DMG2SKR MW 370.3
DMG2SKR FM C17H15FN6O3
DMG2SKR IC InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
DMG2SKR CS CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4C[C@@H](OC4=O)CO)F
DMG2SKR IK XFALPSLJIHVRKE-GFCCVEGCSA-N
DMG2SKR IU (5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
DMG2SKR CA CAS 856866-72-3
DMG2SKR CB CHEBI:82717
DMG2SKR DE Skin infection
DMYOAKS ID DMYOAKS
DMYOAKS DN Teduglutide
DMYOAKS HS Approved
DMYOAKS SN Gattex (TN)
DMYOAKS CP NPS
DMYOAKS DT Small molecular drug
DMYOAKS SQ Protein sequence for teduglutide: HGDGSFSDEMNTILDNLAARDFINWLIQTKITD
DMYOAKS PC 16139605
DMYOAKS MW 3752.1
DMYOAKS FM C164H252N44O55S
DMYOAKS IC InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1
DMYOAKS CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N
DMYOAKS IK CILIXQOJUNDIDU-ASQIGDHWSA-N
DMYOAKS IU (2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]butanedioic acid
DMYOAKS CA CAS 197922-42-2
DMYOAKS DE Short bowel syndrome
DM31ZQM ID DM31ZQM
DM31ZQM DN Tegafur
DM31ZQM HS Approved
DM31ZQM SN Tegafur (Fluoropyrimidine)
DM31ZQM DT Small molecular drug
DM31ZQM PC 5386
DM31ZQM MW 200.17
DM31ZQM FM C8H9FN2O3
DM31ZQM IC InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
DM31ZQM CS C1CC(OC1)N2C=C(C(=O)NC2=O)F
DM31ZQM IK WFWLQNSHRPWKFK-UHFFFAOYSA-N
DM31ZQM IU 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
DM31ZQM CA CAS 17902-23-7
DM31ZQM CB CHEBI:32188
DM31ZQM DE Solid tumour/cancer
DM3XYD1 ID DM3XYD1
DM3XYD1 DN Tegaserod
DM3XYD1 HS Approved
DM3XYD1 SN Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine
DM3XYD1 CP Novartis
DM3XYD1 DT Small molecular drug
DM3XYD1 PC 135409453
DM3XYD1 MW 301.39
DM3XYD1 FM C16H23N5O
DM3XYD1 IC InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
DM3XYD1 CS CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC
DM3XYD1 IK IKBKZGMPCYNSLU-RGVLZGJSSA-N
DM3XYD1 IU 1-[(E)-(5-methoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
DM3XYD1 CA CAS 145158-71-0
DM3XYD1 CB CHEBI:51043
DM3XYD1 DE Irritable bowel syndrome; Gastro-oesophageal reflux; Dyspepsia
DMAQ2LK ID DMAQ2LK
DMAQ2LK DN Teicoplanin
DMAQ2LK HS Approved
DMAQ2LK SN Targocid (TN)
DMAQ2LK CP Sanofi-Aventis
DMAQ2LK DT Small molecular drug
DMAQ2LK PC 133065662
DMAQ2LK MW 1879.7
DMAQ2LK FM C88H97Cl2N9O33
DMAQ2LK IC InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1
DMAQ2LK CS CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O
DMAQ2LK IK BJNLLBUOHPVGFT-CAYRISATSA-N
DMAQ2LK IU (1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid
DMAQ2LK CA CAS 61036-62-2
DMAQ2LK DE Bacterial infection
DMMRV29 ID DMMRV29
DMMRV29 DN Telaprevir
DMMRV29 HS Approved
DMMRV29 SN 402957-28-2; VX-950; Incivek; Telaprevir (VX-950); Incivo; MP-424; VX 950; Telavic; VX-950(Telaprevir); LY-570310; UNII-655M5O3W0U; VRT-111950; CHEMBL231813; CHEBI:68595; 655M5O3W0U; S-Telaprevir; (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-6-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)-octahydrocyclopenta[c]pyrrole-1-carboxamide
DMMRV29 DT Small molecular drug
DMMRV29 PC 3010818
DMMRV29 MW 679.8
DMMRV29 FM C36H53N7O6
DMMRV29 IC InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1
DMMRV29 CS CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5
DMMRV29 IK BBAWEDCPNXPBQM-GDEBMMAJSA-N
DMMRV29 IU (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
DMMRV29 CA CAS 402957-28-2
DMMRV29 CB CHEBI:68595
DMMRV29 DE Hepatitis C virus infection
DM58VQX ID DM58VQX
DM58VQX DN Telavancin
DM58VQX HS Approved
DM58VQX SN telavancinum; telavancina; telavancine; 372151-71-8; UNII-XK134822Z0; CHEBI:71229; XK134822Z0; Telavancin [INN]; HSDB 8194; AC1MIWRX; SCHEMBL8287015; CHEMBL507870; DB06402; LS-192933; T-1455; Telavancin, Antibiotic for Culture Media Use Only; Vancomycin, N3''-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-
DM58VQX DT Small molecular drug
DM58VQX PC 3081362
DM58VQX MW 1755.6
DM58VQX FM C80H106Cl2N11O27P
DM58VQX IC InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1
DM58VQX CS CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C
DM58VQX IK ONUMZHGUFYIKPM-MXNFEBESSA-N
DM58VQX IU (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
DM58VQX CA CAS 372151-71-8
DM58VQX CB CHEBI:71229
DM58VQX DE Staphylococcus infection
DMSWUGE ID DMSWUGE
DMSWUGE DN Telbivudine
DMSWUGE HS Approved
DMSWUGE SN Epavudine; LLT; LdT; Sebivo; Telbivudin; Tyzeka; Telbivudine [USAN]; LDT600; NB 02B; NV 02B; L-Deoxythymidine; L-Thymidine; L-dT; LDT-600; NV-02B; Tyzeka (TN); Beta-L-Thymidine; Telbivudine (USAN/INN); Tyzake/Sebivo (TN); Tyzeka, Sebivo, Telbivudine; 1-(2-Deoxy-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; 2'-Deoxy-L-thymidine
DMSWUGE CP Idenix
DMSWUGE TC Antiviral Agents
DMSWUGE DT Small molecular drug
DMSWUGE PC 159269
DMSWUGE MW 242.23
DMSWUGE FM C10H14N2O5
DMSWUGE IC InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
DMSWUGE CS CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O
DMSWUGE IK IQFYYKKMVGJFEH-CSMHCCOUSA-N
DMSWUGE IU 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMSWUGE CA CAS 3424-98-4
DMSWUGE CB CHEBI:63624
DMSWUGE DE Hepatitis B virus infection
DMZ4P3A ID DMZ4P3A
DMZ4P3A DN Telithromycin
DMZ4P3A HS Approved
DMZ4P3A SN Ketek; Levviax; TEL; HMR 3647; HMR3647; RU 66647; RU66647; HMR-3647; Ketek (TN); RU-66647; Telithromycin [USAN:BAN:INN]; Telithromycin (JAN/USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6R,7R,8R,10S,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2S,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-6-methoxy-2,4,6,8,10,14-hexamethyl-17-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; 11,12-Dideoxy-3-des(2,6-dideoxy-3-C,3-O-dimethyl-alpha-L-altropyranosyloxy)-6-O-methyl-3-oxo-12,11-(oxycarbonylimino)-N11-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]erythromycin A
DMZ4P3A CP Sanofi-Aventis
DMZ4P3A TC Antibiotics
DMZ4P3A DT Small molecular drug
DMZ4P3A PC 3002190
DMZ4P3A MW 812
DMZ4P3A FM C43H65N5O10
DMZ4P3A IC InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
DMZ4P3A CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
DMZ4P3A IK LJVAJPDWBABPEJ-PNUFFHFMSA-N
DMZ4P3A IU (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMZ4P3A CA CAS 191114-48-4
DMZ4P3A CB CHEBI:29688
DMZ4P3A DE Bacterial infection
DMS3GX2 ID DMS3GX2
DMS3GX2 DN Telmisartan
DMS3GX2 HS Approved
DMS3GX2 SN Kinzal; Kinzalmono; Micardis; Pritor; Abbott brand of telmisartan; Boehringer Ingelheim brand of telmisartan; Glaxo Wellcome brand of telmisartan; GlaxoSmithKline brand of telmisartan; BIBR 277; BIBR 277SE; BIBR-277; BIBR-277SE; Bay 68-9291; Micardis (TN); Telmisartan [USAN:INN]; YM-086; BIBR-277-SE; Telmisartan (JAN/USAN/INN); Micardis, Targit, Temax, BIBR277, Telmisartan; 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid; 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid; 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid; 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid; 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
DMS3GX2 CP Boehringer Ingelheim
DMS3GX2 TC Antihypertensive Agents
DMS3GX2 DT Small molecular drug
DMS3GX2 PC 65999
DMS3GX2 MW 514.6
DMS3GX2 FM C33H30N4O2
DMS3GX2 IC InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
DMS3GX2 CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
DMS3GX2 IK RMMXLENWKUUMAY-UHFFFAOYSA-N
DMS3GX2 IU 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
DMS3GX2 CA CAS 144701-48-4
DMS3GX2 CB CHEBI:9434
DMS3GX2 DE Hypertension
DMDIYFZ ID DMDIYFZ
DMDIYFZ DN Telotristat ethyl
DMDIYFZ HS Approved
DMDIYFZ SN Telotristat; Telotristat etiprate; LP-778902; LX-1032; LX-1606; Serotonin modulator (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon; Tryptophan hydroxylase inhibitor (oral, GI disorder/hypertension/carcinoid syndrome), Lexicon
DMDIYFZ CP Lexicon Pharmaceuticals
DMDIYFZ DT Small molecular drug
DMDIYFZ PC 25181577
DMDIYFZ MW 575
DMDIYFZ FM C27H26ClF3N6O3
DMDIYFZ IC InChI=1S/C27H26ClF3N6O3/c1-3-39-25(38)20(32)12-16-4-6-17(7-5-16)21-14-23(35-26(33)34-21)40-24(27(29,30)31)19-9-8-18(28)13-22(19)37-11-10-15(2)36-37/h4-11,13-14,20,24H,3,12,32H2,1-2H3,(H2,33,34,35)/t20-,24+/m0/s1
DMDIYFZ CS CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N
DMDIYFZ IK MDSQOJYHHZBZKA-GBXCKJPGSA-N
DMDIYFZ IU ethyl (2S)-2-amino-3-[4-[2-amino-6-[(1R)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate
DMDIYFZ CA CAS 1033805-22-9
DMDIYFZ DE Carcinoid syndrome diarrhea; Carcinoid syndrome
DM02A65 ID DM02A65
DM02A65 DN Temazepam
DM02A65 HS Approved
DM02A65 SN Cerepax; Crisonar; Dasuen; Euhypnos; Euipnos; Gelthix; Hydroxydiazepam; Lenal; Levanxene; Levanxol; Levanzene; Mabertin; Methyloxazepam; Nocturne; Nomapam; Normison; Normitab; Nortem; Oxydiazepam; Perdorm; Planum; Remestan; Restoril; Signopam; Temador; Temaz; Temaze; Temazepamum; Temtabs; Tenox; AHP Brand of Temazepam; Alphapharm Brand of Temazepam; Apo Temazepam; Apotex Brand of Temazepam; Ct Arzneimittel Brand of Temazepam; Desitin Brand of Temazepam; Gen Temazepam; Genopharm Brand of Temazepam; Genpharm Brand of Temazepam; ICN Brand of Temazepam; Katwijk Brand of Temazepam; Knoll Brand of Temazepam; Mallinckrodt Brand of Temazepam; Neodorm SP; Norkotral Tema; Norton Brand of Temazepam; Novartis Brand of Temazepam; Novo Temazepam; Novopharm Brand of Temazepam; Nu Pharm Brand of Temazepam; Nu Temazepam; Orion Brand of Temazepam; PMS Temazepam; Pharmascience Brand of Temazepam; Pronervon T; Scheffler Brand of Temazepam; Sigma Brand of Temazepam; Temazep von ct; Uvamin Retard; Wyeth Brand of Temazepam; ER 115; K3917; Pfizer Brand 1 of Temazepam; Pfizer Brand 2 of Temazepam; Ro 5 5345; Ro55345; SaH 47 603; SaH 47603; WY 2917; WY 3917; WY3917; Apo-Temazepam; Ct-Arzneimittel Brand of Temazepam; Euhypnos (TN); Gen-Temazepam; K-3917; N-Methyloxazepam; Norkotral (TN); Normison (TN); Novo-Temazepam; Nu-Pharm Brand of Temazepam; Nu-Temazepam; PMS-Temazepam; Remestan (TN); Restoril (TN); Ro 5-5345; SaH 47-603; Tema, Norkotral; Temazepam, pharmaceutical grade; Temazepamum [INN-Latin]; Temtabs (TN); Tenox (TN); Wy-3917; Ro-5-5345; Temazepam (USP/INN); Temazepam [USAN:INN:BAN]; 1,3-Dihydro-7-chloro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 3 Hydroxydiazepam; 3-Hydroxydiazepam; 7-CHLORO-1,3-DIHYDRO-3-HYDROXY-1-METHYL-5-PHENYL-2H-1,4-BENZODIAZEPIN-2-ONE; 7-Chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM02A65 CP Mylan Inc
DM02A65 TC Hypnotics and Sedatives
DM02A65 DT Small molecular drug
DM02A65 PC 5391
DM02A65 MW 300.74
DM02A65 FM C16H13ClN2O2
DM02A65 IC InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
DM02A65 CS CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3
DM02A65 IK SEQDDYPDSLOBDC-UHFFFAOYSA-N
DM02A65 IU 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DM02A65 CA CAS 846-50-4
DM02A65 CB CHEBI:9435
DM02A65 DE Insomnia
DM1A79H ID DM1A79H
DM1A79H DN Temocapril
DM1A79H HS Approved
DM1A79H SN Temocapril; Temocaprilum; 2-((2S,6R)-6-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)acetic acid; UNII-18IZ008EU6; 18IZ008EU6; Temocapril [INN:BAN]; Temocaprilum [INN-Latin]; C23H28N2O5S2; 2-((2S,6R)-6-((S)-1-ETHOXY-1-OXO-4-PHENYLBUTAN-2-YLAMINO)-5-OXO-2-(THIOPHEN-2-YL)-1,4-THIAZEPAN-4-YL)ACETIC ACID; (2S-(2alpha,6beta(R*)))-6-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; Temocapril (INN); AC1L9FDI
DM1A79H PC 443874
DM1A79H MW 476.6
DM1A79H FM C23H28N2O5S2
DM1A79H IC InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
DM1A79H CS CCOC(=O)C(CCC1=CC=CC=C1)NC2CSC(CN(C2=O)CC(=O)O)C3=CC=CS3
DM1A79H IK FIQOFIRCTOWDOW-BJLQDIEVSA-N
DM1A79H IU 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
DM1A79H CA CAS 111902-57-9
DM1A79H CB CHEBI:135771
DM1A79H DE High blood pressure
DM0JXFL ID DM0JXFL
DM0JXFL DN Temocapril hydrochloride
DM0JXFL HS Approved
DM0JXFL SN Acecol (TN)
DM0JXFL CP Sankyo
DM0JXFL DT Small molecular drug
DM0JXFL PC 443873
DM0JXFL MW 513.1
DM0JXFL FM C23H29ClN2O5S2
DM0JXFL IC InChI=1S/C23H28N2O5S2.ClH/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27;/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27);1H/t17-,18-,20-;/m0./s1
DM0JXFL CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl
DM0JXFL IK XDDQNOKKZKHBIX-ASBZXGSUSA-N
DM0JXFL IU 2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid;hydrochloride
DM0JXFL CA CAS 110221-44-8
DM0JXFL CB CHEBI:32190
DM0JXFL DE Cardiovascular disease
DMNX2QI ID DMNX2QI
DMNX2QI DN Temocaprilate
DMNX2QI HS Approved
DMNX2QI SN (+)-(2S,6R)-6-(((1S)-1-carboxy-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic acid; 2-(4-Carboxymethyl-5-oxo-2-thiophen-2-yl-[1,4]thiazepan-6-ylamino)-4-phenyl-butyric acid; 2D6A12Q12R; AC1L9E45; AJ-48035; AK116088; AKOS016010295; API0000849; AX8152551; BDBM50024710; O437; RNH 5139; RNH-5139; RS 5139; RS-5139; RT-015901; SCHEMBL498916; TL8000320; Temocapril Diacid; Temocaprilat; Temocaprilat [INN:BAN]; ZINC4099102; temocaprilate
DMNX2QI PC 443151
DMNX2QI MW 448.552
DMNX2QI FM C21H24N2O5S2
DMNX2QI IC InChI=1S/C21H24N2O5S2/c24-19(25)12-23-11-18(17-7-4-10-29-17)30-13-16(20(23)26)22-15(21(27)28)9-8-14-5-2-1-3-6-14/h1-7,10,15-16,18,22H,8-9,11-13H2,(H,24,25)(H,27,28)/t15-,16-,18-/m0/s1
DMNX2QI CS C1C(SCC(C(=O)N1CC(=O)O)NC(CCC2=CC=CC=C2)C(=O)O)C3=CC=CS3
DMNX2QI IK KZVWEOXAPZXAFB-BQFCYCMXSA-N
DMNX2QI IU (2S)-2-[[(2S,6R)-4-(carboxymethyl)-5-oxo-2-thiophen-2-yl-1,4-thiazepan-6-yl]amino]-4-phenylbutanoic acid
DMNX2QI CA CAS 110221-53-9
DMNX2QI CB CHEBI:9436
DMNX2QI DE High blood pressure
DMKECZD ID DMKECZD
DMKECZD DN Temozolomide
DMKECZD HS Approved
DMKECZD SN Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ
DMKECZD CP Schering-Plough
DMKECZD TC Anticancer Agents
DMKECZD DT Small molecular drug
DMKECZD PC 5394
DMKECZD MW 194.15
DMKECZD FM C6H6N6O2
DMKECZD IC InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
DMKECZD CS CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
DMKECZD IK BPEGJWRSRHCHSN-UHFFFAOYSA-N
DMKECZD IU 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
DMKECZD CA CAS 85622-93-1
DMKECZD CB CHEBI:72564
DMKECZD DE Grade IV astrocytoma
DMS104F ID DMS104F
DMS104F DN Temsirolimus
DMS104F HS Approved
DMS104F SN Torisel
DMS104F CP Wyeth
DMS104F DT Small molecular drug
DMS104F PC 6918289
DMS104F MW 1030.3
DMS104F FM C56H87NO16
DMS104F IC InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
DMS104F CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC
DMS104F IK CBPNZQVSJQDFBE-FUXHJELOSA-N
DMS104F IU [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
DMS104F CA CAS 162635-04-3
DMS104F CB CHEBI:79699
DMS104F DE Renal cell carcinoma
DMCOZJY ID DMCOZJY
DMCOZJY DN Tenapanor
DMCOZJY HS Approved
DMCOZJY SN 1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506
DMCOZJY CP AstraZeneca
DMCOZJY DT Small molecular drug
DMCOZJY PC 71587953
DMCOZJY MW 1145
DMCOZJY FM C50H66Cl4N8O10S2
DMCOZJY IC InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
DMCOZJY CS CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C
DMCOZJY IK DNHPDWGIXIMXSA-CXNSMIOJSA-N
DMCOZJY IU 1-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethyl]-3-[4-[2-[2-[2-[[3-[(4S)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethylcarbamoylamino]butyl]urea
DMCOZJY CA CAS 1234423-95-0
DMCOZJY DE Kidney disease; Constipation; Irritable bowel syndrome
DMJYN25 ID DMJYN25
DMJYN25 DN Tenecteplase
DMJYN25 HS Approved
DMJYN25 SN Tnkase; Tnkase (TN); Tenecteplase (USAN/INN)
DMJYN25 TC Thrombolytic Agents
DMJYN25 SQ DB00031 sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAASPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
DMJYN25 DE Myocardial infarction
DMLW57T ID DMLW57T
DMLW57T DN Teniposide
DMLW57T HS Approved
DMLW57T SN PTG; Teniposido; Teniposidum; Vehem; Vumon; Demethyl Epipodophyllotoxin Thenylidine Glucoside; VM 26; Teniposido [INN-Spanish]; Teniposidum [INN-Latin]; VM-26; Vee M-26; Veham-Sandoz; Vumon (TN); Teniposide (USAN/INN); Teniposide [USAN:BAN:INN]; VM-26 (TN); Vumon, VM-26, Vehem, NSC 122819, Teniposide; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin thenylidene glucoside; 4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside; 4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin; 4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
DMLW57T TC Anticancer Agents
DMLW57T DT Small molecular drug
DMLW57T PC 452548
DMLW57T MW 656.7
DMLW57T FM C32H32O13S
DMLW57T IC InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
DMLW57T CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O
DMLW57T IK NRUKOCRGYNPUPR-QBPJDGROSA-N
DMLW57T IU (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
DMLW57T CA CAS 29767-20-2
DMLW57T DE Acute lymphoblastic leukaemia
DM1IS6U ID DM1IS6U
DM1IS6U DN Tenofovir
DM1IS6U HS Approved
DM1IS6U SN Apropovir; PMPA; TFV; Tenefovir; GS 1275; GS 1278; GS1278; GNA & Tenofovir; HHA & Tenofovir; KS-5021; Viread (TN); Viread, Tenofovir; D,L-Tenofovir; PMPA-(R); Phosphonic acid, [[2-(6-amino-9H-purin-9; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid; Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA
DM1IS6U CP Gilead Sciences
DM1IS6U TC Anti-HIV Agents
DM1IS6U DT Small molecular drug
DM1IS6U PC 464205
DM1IS6U MW 287.21
DM1IS6U FM C9H14N5O4P
DM1IS6U IC InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
DM1IS6U CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
DM1IS6U IK SGOIRFVFHAKUTI-ZCFIWIBFSA-N
DM1IS6U IU [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
DM1IS6U CA CAS 147127-20-6
DM1IS6U CB CHEBI:63625
DM1IS6U DE Human immunodeficiency virus infection
DMTQF4A ID DMTQF4A
DMTQF4A DN Tenofovir alafenamide
DMTQF4A HS Approved
DMTQF4A SN Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy; Tenofovir; UNII-W4HFE001U5; W4HFE001U5; (R)-(((1-(6-AMINO-9H-PURIN-9-YL)PROPAN-2-YL)OXY)METHYL)PHOSPHONIC ACID; (R)-(1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid; (R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-[2-(Phosphonomethoxy)propyl]adenine; (R)-PMPA; ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid; 147127-20-6; 9-[(R)-2-(phosphonomethoxy)propyl]adenine; Apropovir; CHEBI:63625; D,L-Tenofovir; GS-1278; PMPA; PMPA gel; (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; 379270-37-8; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE
DMTQF4A PC 9574768
DMTQF4A MW 476.5
DMTQF4A FM C21H29N6O5P
DMTQF4A IC LDEKQSIMHVQZJK-CAQYMETFSA-N
DMTQF4A CS CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OC3=CC=CC=C3
DMTQF4A IK 1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DMTQF4A IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMTQF4A CA CAS 379270-37-8
DMTQF4A CB CHEBI:90926
DMTQF4A DE Viral hepatitis
DMSY4ZG ID DMSY4ZG
DMSY4ZG DN Tenofovir disoproxil fumarate
DMSY4ZG HS Approved
DMSY4ZG SN Bis-POC-PMPA; GSK548470; PMPA-oral; Tenofovir DF; Tenozet; Viread
DMSY4ZG TC Antiinfective Agents
DMSY4ZG DT Small molecular drug
DMSY4ZG PC 6398764
DMSY4ZG MW 635.5
DMSY4ZG FM C23H34N5O14P
DMSY4ZG IC InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1
DMSY4ZG CS C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\\C(=O)O
DMSY4ZG IK VCMJCVGFSROFHV-WZGZYPNHSA-N
DMSY4ZG IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(E)-but-2-enedioic acid
DMSY4ZG CA CAS 202138-50-9
DMSY4ZG CB CHEBI:63718
DMSY4ZG DE Discovery agent
DMVAZP9 ID DMVAZP9
DMVAZP9 DN Tenoxicam
DMVAZP9 HS Approved
DMVAZP9 SN Artriunic; Liman; Mobiflex; Reutenox; Tenoxicamum; Tilcotil; Apotex brand of tenoxicam; Novag brand of tenoxicam; Novopharm brand of tenoxicam; Roche brand of tenoxicam; Solvay brand of tenoxicam; Apo-Tenoxicam; Mobiflex (TN); Novo-Tenoxicam; Ro 12-0068; Ro-120068; Tenoxicamum [INN-Latin]; Tilcotil (TN); Ro 12-0068/000; Ro-12-0068; Tenoxicam (JAN/USAN/INN); Tenoxicam [USAN:BAN:INN:JAN]; (3E)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; (3Z)-3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide; 3-[hydroxy-(pyridin-2-ylamino)methylidene]-2-methyl-1,1-dioxothieno[2,3-e]thiazin-4-one; 4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE; 4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide1,1-dioxide; 4-Hydroxy-2-methyl-N-2-pyridyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide; 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide
DMVAZP9 CP Roche Laboratories Inc
DMVAZP9 TC Antiinflammatory Agents
DMVAZP9 DT Small molecular drug
DMVAZP9 PC 54677971
DMVAZP9 MW 337.4
DMVAZP9 FM C13H11N3O4S2
DMVAZP9 IC InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
DMVAZP9 CS CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3
DMVAZP9 IK LZNWYQJJBLGYLT-UHFFFAOYSA-N
DMVAZP9 IU 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide
DMVAZP9 CA CAS 59804-37-4
DMVAZP9 CB CHEBI:32192
DMVAZP9 DE Rheumatoid arthritis
DMUQ0E8 ID DMUQ0E8
DMUQ0E8 DN Tepotinib
DMUQ0E8 HS Approved
DMUQ0E8 SN 1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo
DMUQ0E8 CP EMD Serono
DMUQ0E8 DT Small molecular drug
DMUQ0E8 PC 25171648
DMUQ0E8 MW 492.6
DMUQ0E8 FM C29H28N6O2
DMUQ0E8 IC InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
DMUQ0E8 CS CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N
DMUQ0E8 IK AHYMHWXQRWRBKT-UHFFFAOYSA-N
DMUQ0E8 IU 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
DMUQ0E8 CA CAS 1100598-32-0
DMUQ0E8 DE Solid tumour/cancer; Hepatocellular carcinoma; Non-small cell lung cancer
DM4L59B ID DM4L59B
DM4L59B DN Teprotumumab
DM4L59B HS Approved
DM4L59B SN RV001
DM4L59B CP River vision
DM4L59B DE Diabetic macular edema; Graves disease
DM3JCVS ID DM3JCVS
DM3JCVS DN Terazosin
DM3JCVS HS Approved
DM3JCVS SN Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
DM3JCVS CP Abbott Laboratories
DM3JCVS TC Anticancer Agents
DM3JCVS DT Small molecular drug
DM3JCVS PC 5401
DM3JCVS MW 387.4
DM3JCVS FM C19H25N5O4
DM3JCVS IC InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
DM3JCVS CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
DM3JCVS IK VCKUSRYTPJJLNI-UHFFFAOYSA-N
DM3JCVS IU [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
DM3JCVS CA CAS 63590-64-7
DM3JCVS CB CHEBI:9445
DM3JCVS DE Benign prostatic hyperplasia
DMI6HUW ID DMI6HUW
DMI6HUW DN Terbinafine
DMI6HUW HS Approved
DMI6HUW SN Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
DMI6HUW CP Celtic Pharma
DMI6HUW TC Antifungal Agents
DMI6HUW DT Small molecular drug
DMI6HUW PC 1549008
DMI6HUW MW 291.4
DMI6HUW FM C21H25N
DMI6HUW IC InChI=1S/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+
DMI6HUW CS CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
DMI6HUW IK DOMXUEMWDBAQBQ-WEVVVXLNSA-N
DMI6HUW IU (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
DMI6HUW CA CAS 91161-71-6
DMI6HUW CB CHEBI:9448
DMI6HUW DE Fungal infection; Onychomycosis
DMD4381 ID DMD4381
DMD4381 DN Terbutaline
DMD4381 HS Approved
DMD4381 SN Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
DMD4381 CP Ben Venue Laboratories
DMD4381 TC Bronchodilator Agents
DMD4381 DT Small molecular drug
DMD4381 PC 5403
DMD4381 MW 225.28
DMD4381 FM C12H19NO3
DMD4381 IC InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
DMD4381 CS CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
DMD4381 IK XWTYSIMOBUGWOL-UHFFFAOYSA-N
DMD4381 IU 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
DMD4381 CA CAS 23031-25-6
DMD4381 CB CHEBI:9449
DMD4381 DE Asthma
DMVPWLZ ID DMVPWLZ
DMVPWLZ DN Terbutyline
DMVPWLZ HS Approved
DMVPWLZ DE Hypertension
DMJ13KI ID DMJ13KI
DMJ13KI DN Terconazole
DMJ13KI HS Approved
DMJ13KI SN Fungistat; Terazol; Terconazol; Terconazolum; Tercospor; Triaconazole; Zazole; R 42470; Terazol 3; Terazol 7; Terazol 73; Tetrazol 3; Tetrazol 7; Gyno-Terazol; R 42,470; R-42470; Terazol 3 (TN); Terazol 7 & 3; Terazol Cream & Suppositories; Terconazol [INN-Spanish]; Terconazolum [INN-Latin]; Terconazole (USAN/INN); Terconazole [USAN:INN:BAN]; Cis-1-(p-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine; Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, rel-(2R,4S); 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine; 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[(4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine; 1-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
DMJ13KI TC Antifungal Agents
DMJ13KI DT Small molecular drug
DMJ13KI PC 441383
DMJ13KI MW 532.5
DMJ13KI FM C26H31Cl2N5O3
DMJ13KI IC InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1
DMJ13KI CS CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl
DMJ13KI IK BLSQLHNBWJLIBQ-OZXSUGGESA-N
DMJ13KI IU 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine
DMJ13KI CA CAS 67915-31-5
DMJ13KI CB CHEBI:82980
DMJ13KI DE Candidiasis
DMQ2FKJ ID DMQ2FKJ
DMQ2FKJ DN Teriflunomide
DMQ2FKJ HS Approved
DMQ2FKJ CP Sanofi-Aventis
DMQ2FKJ DT Small molecular drug
DMQ2FKJ PC 54684141
DMQ2FKJ MW 270.21
DMQ2FKJ FM C12H9F3N2O2
DMQ2FKJ IC InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
DMQ2FKJ CS C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C(F)(F)F)/O
DMQ2FKJ IK UTNUDOFZCWSZMS-YFHOEESVSA-N
DMQ2FKJ IU (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
DMQ2FKJ CA CAS 163451-81-8
DMQ2FKJ CB CHEBI:68540
DMQ2FKJ DE Hyperlipidaemia; Multiple sclerosis; Hepatitis B virus infection; Rheumatoid arthritis
DMMC45B ID DMMC45B
DMMC45B DN Teriparatide
DMMC45B HS Approved
DMMC45B SN Forteo; Forteo (TN); Teriparatide (genetical recombination); Teriparatide (USAN/INN); Teriparatide (genetical recombination) (JAN)
DMMC45B CP Eli Lilly
DMMC45B TC Bone Density Conservation Agents
DMMC45B DT Peptide
DMMC45B SQ Parathyroid hormone precursor - Homo sapiens (1-34): SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF
DMMC45B PC 16133850
DMMC45B MW 4118
DMMC45B FM C181H291N55O51S2
DMMC45B IC InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1
DMMC45B CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N
DMMC45B IK OGBMKVWORPGQRR-UMXFMPSGSA-N
DMMC45B IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMMC45B CA CAS 52232-67-4
DMMC45B CB CHEBI:135983
DMMC45B DE Osteogenesis imperfecta; Psoriatic disorder
DMT9FH3 ID DMT9FH3
DMT9FH3 DN Terlipressin
DMT9FH3 HS Approved
DMT9FH3 SN Glypressin; Lucassin; Terlipressina; Terlipressine; Terlipressinum; Glypressin (TN); HS-2028; Terlipressin [BAN:INN]; Terlipressina [INN-Spanish]; Terlipressine [INN-French]; Terlipressinum [INN-Latin]; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin
DMT9FH3 CP Ferring Pharmaceuticals
DMT9FH3 TC Vasoconstrictor Agents
DMT9FH3 DT Small molecular drug
DMT9FH3 PC 72081
DMT9FH3 MW 1227.4
DMT9FH3 FM C52H74N16O15S2
DMT9FH3 IC InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
DMT9FH3 CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMT9FH3 IK BENFXAYNYRLAIU-QSVFAHTRSA-N
DMT9FH3 IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DMT9FH3 CA CAS 14636-12-5
DMT9FH3 CB CHEBI:135905
DMT9FH3 DE Hypertension
DM2L3D5 ID DM2L3D5
DM2L3D5 DN Tertatolol
DM2L3D5 HS Approved
DM2L3D5 SN (-)-tertatolol; (+)-Tertatolol; GTPL64; ZINC748; PDSP2_001696; PDSP1_001713; 117305-34-7; UNII-9ZO341YQXP component HTWFXPCUFWKXOP-CYBMUJFWSA-N
DM2L3D5 DT Small molecular drug
DM2L3D5 PC 36920
DM2L3D5 MW 295.4
DM2L3D5 FM C16H25NO2S
DM2L3D5 IC InChI=1S/C16H25NO2S/c1-16(2,3)17-10-13(18)11-19-14-8-4-6-12-7-5-9-20-15(12)14/h4,6,8,13,17-18H,5,7,9-11H2,1-3H3
DM2L3D5 CS CC(C)(C)NCC(COC1=CC=CC2=C1SCCC2)O
DM2L3D5 IK HTWFXPCUFWKXOP-UHFFFAOYSA-N
DM2L3D5 IU 1-(tert-butylamino)-3-(3,4-dihydro-2H-thiochromen-8-yloxy)propan-2-ol
DM2L3D5 CA CAS 83688-84-0
DM2L3D5 CB CHEBI:135244
DM2L3D5 DE Hypertension
DM9GP85 ID DM9GP85
DM9GP85 DN Tesamorelin
DM9GP85 HS Approved
DM9GP85 SN Egrifta (TN)
DM9GP85 CP Theratechnologies
DM9GP85 DT Small molecular drug
DM9GP85 PC 16137828
DM9GP85 MW 5136
DM9GP85 FM C221H366N72O67S
DM9GP85 IC InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1
DM9GP85 CS CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N
DM9GP85 IK QBEPNUQJQWDYKU-BMGKTWPMSA-N
DM9GP85 IU (4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM9GP85 CA CAS 804475-66-9
DM9GP85 DE HIV-associated lipodystrophy
DMVY4GN ID DMVY4GN
DMVY4GN DN Testolactone
DMVY4GN HS Approved
DMVY4GN SN Fludestrin; Teolit; Teslac; Teslak; Testolacton; Testolactona; Testolactonum; Testolattone; Bristol Myers SquibbBrand of Testolactone; Testolattone [DCIT]; SQ 9538; Bristol-Myers Squibb Brand of Testolactone; DELTA1-Dehydrotestolactone; DELTA1-Dehydrotestololactone; DELTA1-Testololactone; SQ-9538; TESLAC (TN);Teslac (TN); Testolactona [INN-Spanish]; Testolactone [USAN:INN]; Testolactonum [INN-Latin]; Delta(1)-Dehydrotestolactone; Delta(1)-Testolactone; Delta(1)-Testololactone; Delta(1)-testololactone; Delta-1-testololactone; Testolactone (USP/INN); D-Homo-17A-oxaandrosta-1,4-diene-3,17-dione; D-homo-17a-oxaandrosta-1,4-diene-3,17-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione; (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione; 1 Dehydrotestolactone; 1,2,3,4,4a,4b,7,9,10,10a-Decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone; 1,2-Dehydrotestololactone; 1,2-Didehydrotestololactone; 1,2-didehydrotestololactone; 1-Dehydrotestolactone; 1-Dehydrotestololactone; 1-dehydrotestololactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, .delta.-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, delta-lactone (8CI); 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, lactone; 13,17-Secoandrosta-1,4-dien-17-oic acid, 13.alpha.-hydroxy-3-oxo-, .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid .delta.-lactone; 13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone; 17a-Oxa-D-homoandrosta-1,4-diene-3,17-dione; 17alpha-Oxo-D-homo-1,4-androstadiene-3,17-dione; 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, lactone; 3-oxo-13,17-secoandrosta-1,4-dieno-17,13alpha-lactone
DMVY4GN TC Anticancer Agents
DMVY4GN DT Small molecular drug
DMVY4GN PC 13769
DMVY4GN MW 300.4
DMVY4GN FM C19H24O3
DMVY4GN IC InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1
DMVY4GN CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C
DMVY4GN IK BPEWUONYVDABNZ-DZBHQSCQSA-N
DMVY4GN IU (4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-4,4a,4b,5,6,10b,11,12-octahydro-3H-naphtho[2,1-f]chromene-2,8-dione
DMVY4GN CA CAS 968-93-4
DMVY4GN CB CHEBI:9460
DMVY4GN DE Breast cancer
DM7HUNW ID DM7HUNW
DM7HUNW DN Testosterone
DM7HUNW HS Approved
DM7HUNW SN AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one
DM7HUNW CP Ardana Bioscience
DM7HUNW DT Small molecular drug
DM7HUNW PC 6013
DM7HUNW MW 288.4
DM7HUNW FM C19H28O2
DM7HUNW IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
DM7HUNW CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C
DM7HUNW IK MUMGGOZAMZWBJJ-DYKIIFRCSA-N
DM7HUNW IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DM7HUNW CA CAS 58-22-0
DM7HUNW CB CHEBI:17347
DM7HUNW DE Osteoporosis; Male hormonal deficiency; Hormone deficiency
DMC1TEV ID DMC1TEV
DMC1TEV DN Testosterone cypionate
DMC1TEV HS Approved
DMC1TEV SN Testodrin prolongatum; Testosterone 17beta-cyclopentylpropionate; Testosterone 17beta-cypionate; Testosterone cyclopentanepropionate; Testosterone cyclopentylpropionate; Testosterone cypionate [USP]; Testandrone; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testrone; Testryl; Virormone; Virosterone; testosterone; trans-Testosterone; 58-22-0; AndroGel; Androderm; Androlin; Andronaq; Andropatch; Andrusol; Cristerona T; Cristerone T; Homosteron; Homosterone; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Sustanon; Sustanone; Synandrol F; Teslen; UNII-M0XW1UBI14; depAndro 100; depAndro 200; 58-20-8; Andro-Cyp; Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-; CHEBI:9463; DEPO; Dep-Test; Depo-Testadiol; Depo-Testosterone; Depotest; Depovirin; Durandro; Jectatest; M0XW1UBI14; Malogen CYP; NSC 9157; Pertestis; T-Ionate-P.A; TESTOSTERONE CYPIONATE
DMC1TEV PC 441404
DMC1TEV MW 412.6
DMC1TEV FM C27H40O3
DMC1TEV IC HPFVBGJFAYZEBE-ZLQWOROUSA-N
DMC1TEV CS CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C
DMC1TEV IK 1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1
DMC1TEV IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
DMC1TEV CA CAS 58-20-8
DMC1TEV CB CHEBI:9463
DMC1TEV DE Testosterone deficiency
DMB6871 ID DMB6871
DMB6871 DN Testosterone enanthate
DMB6871 HS Approved
DMB6871 SN Testanthate; Testate; Testenate; Testinon; Testoenant; Testonenant; Testosterone 17-enanthate; Testosterone enantate; Testosterone heptanoate; Testosterone heptoate; Testosterone heptylate; Testosterone oenanthate; Testostroval; testosterone enanthate; 17-Hydroxyandrost-4-en-3-one, 17-heptanoate; 315-37-7; Andro L.A. 200; Andropository; Androtardyl; Atlatest; DePatestrye; Delatest; Depo-Testro Med; Ditate; Durathate; Everone; Exten test; Malogen L.A.; Malogen L.A.200; NSC-17591; Orquisteron-E; Primotestone; Reposo TMD; Reposo-TMD
DMB6871 PC 9416
DMB6871 MW 400.6
DMB6871 FM C26H40O3
DMB6871 IC VOCBWIIFXDYGNZ-IXKNJLPQSA-N
DMB6871 CS CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
DMB6871 IK 1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1
DMB6871 IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
DMB6871 CA CAS 315-37-7
DMB6871 CB CHEBI:9464
DMB6871 DE Testosterone deficiency
DMZO10Y ID DMZO10Y
DMZO10Y DN Testosterone Undecanoate
DMZO10Y HS Approved
DMZO10Y SN Restandol (TN)
DMZO10Y CP Organon Greece
DMZO10Y DT Small molecular drug
DMZO10Y PC 65157
DMZO10Y MW 456.7
DMZO10Y FM C30H48O3
DMZO10Y IC InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
DMZO10Y CS CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
DMZO10Y IK UDSFVOAUHKGBEK-CNQKSJKFSA-N
DMZO10Y IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
DMZO10Y CA CAS 5949-44-0
DMZO10Y CB CHEBI:135741
DMZO10Y DE Hypogonadism
DMYWQ0O ID DMYWQ0O
DMYWQ0O DN Tetrabenazine
DMYWQ0O HS Approved
DMYWQ0O SN Nitoman; Rubigen; Tetrabenazina; Tetrabenazinum; Tetrabenzaine; Tetrabenzine; Xenazine; Tetra Benazin; Nitoman (TN); Ro 1-9569; Tetrabenazina [INN-Spanish]; Tetrabenazine (INN); Tetrabenazine [INN:BAN]; Tetrabenazinum [INN-Latin]; Xenazine (TN); Nitoman, Xenazine, Tetrabenazine; Ro 1-9569/12; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-(9CI); 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMYWQ0O TC Nephropathic cystinosis therapy
DMYWQ0O DT Small molecular drug
DMYWQ0O PC 6018
DMYWQ0O MW 317.4
DMYWQ0O FM C19H27NO3
DMYWQ0O IC InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
DMYWQ0O CS CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
DMYWQ0O IK MKJIEFSOBYUXJB-UHFFFAOYSA-N
DMYWQ0O IU 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
DMYWQ0O CA CAS 718635-93-9
DMYWQ0O CB CHEBI:64028
DMYWQ0O DE Hyperkinetic movement disorder; Huntington disease
DM9J6C2 ID DM9J6C2
DM9J6C2 DN Tetracaine
DM9J6C2 HS Approved
DM9J6C2 SN Amethocaine; Anetain; Contralgin; Dicain; Dicaine; Dikain; Fissucain; Intercain; Laudocaine; Medicaine; Meethobalm; Metraspray; Mucaesthin; Niphanoid; Pontocaine; Rexocaine; Tetracaina; Tetracainum; Tetrakain; Uromucaesthin; Tetrakain [Czech]; Amethocaine (TN); Diaethylaminoaethanol ester der p-butylaminobenzoesaeure;Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]; Medihaler-Tetracaine; Pontocaine (TN); Tetracaina [INN-Spanish]; Tetracaine [USAN:INN]; Tetracainum [INN-Latin]; Dimethylaminoethyl p-butyl-aminobenzoate; Tetracaine (USP/INN); P-Butylaminobenzoyl-2-dimethylaminoethanol; BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE; P-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester; BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester; 2-(Dimethylamino)ethyl 4-(butylamino)benzoate; 2-(Dimethylamino)ethyl p-(butylamino)benzoate; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove; 2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]; 2-dimethylaminoethyl 4-(butylamino)benzoate; 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester; 4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester
DM9J6C2 TC Anesthetics
DM9J6C2 DT Small molecular drug
DM9J6C2 PC 5411
DM9J6C2 MW 264.36
DM9J6C2 FM C15H24N2O2
DM9J6C2 IC InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
DM9J6C2 CS CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
DM9J6C2 IK GKCBAIGFKIBETG-UHFFFAOYSA-N
DM9J6C2 IU 2-(dimethylamino)ethyl 4-(butylamino)benzoate
DM9J6C2 CA CAS 94-24-6
DM9J6C2 CB CHEBI:9468
DM9J6C2 DE Spinal anesthesia; Pain
DMZA017 ID DMZA017
DMZA017 DN Tetracycline
DMZA017 HS Approved
DMZA017 SN Amycin; Biocycline; Bristaciclin; Bristaciclina; Bristacycline; Ciclibion; Copharlan; Cyclomycin; Cytome; Dumocyclin; Enterocycline; Medocycline; Resteclin; Robitet; Sanclomycine; Tetrachel; Veracin; Bristaciclin alpha; Cefracycline suspension; Component of Tetrastatin; Sumycin syrup; Tetracycline Free Base; Tetracycline I; Tetracycline II; Tetracycline Monohydrochloride; Achromycin (naphthacene derivative); Achromycin, naphthacene derivative; Centet (base); Lemtrex (base); Liquamycin (Veterinary); Liquamycin, veterinary; Panmycin (TN); Piracaps (base); Polycycline (VAN); Polycycline (antibiotic); Polycycline, antibiotic; SK-Tetracycline; Sumycin (TN); T-125; Tetra-Co; Tetraciclina [INN-Spanish]; Tetracycline & VRC3375; Tetracycline (internal use); Tetracyclinum [INN-Latin]; Tetracyn (TN); Vetquamycin-324 (free base); Tetracycline (JAN/USP/INN); Tetracycline [USAN:INN:BAN:JAN]; Methyl-1,11-dioxo-2-naphthacenecarboxamide; 6-Methyl-1,11-dioxy-2-naphthacenecarboxamide
DMZA017 CP Pfizer Inc
DMZA017 TC Antibiotics
DMZA017 DT Small molecular drug
DMZA017 PC 54675776
DMZA017 MW 444.4
DMZA017 FM C22H24N2O8
DMZA017 IC InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25-26,29,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1
DMZA017 CS C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
DMZA017 IK NWXMGUDVXFXRIG-WESIUVDSSA-N
DMZA017 IU (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide
DMZA017 CA CAS 60-54-8
DMZA017 CB CHEBI:27902
DMZA017 DE Bacterial infection
DMINZ4W ID DMINZ4W
DMINZ4W DN Tetrahydrobiopterin
DMINZ4W HS Approved
DMINZ4W SN tetrahydrobiopterin; 17528-72-2; 5,6,7,8-tetrahydrobiopterin; BRN 0544742; CHEBI:15372; 5,6,7,8-Tetrahydro-2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone; L-erythro-2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinon; (1R,2S)-(2-Amino-3,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)-1,2-propandiol; 5,6,7,8-erythro-tetrahydrobiopterin; 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydropteridin-4(3H)-one; Dapropterin; Phenoptin
DMINZ4W TC Dietary supplement
DMINZ4W DT Small molecular drug
DMINZ4W PC 135402045
DMINZ4W MW 241.25
DMINZ4W FM C9H15N5O3
DMINZ4W IC InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)
DMINZ4W CS CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMINZ4W IK FNKQXYHWGSIFBK-UHFFFAOYSA-N
DMINZ4W IU 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMINZ4W CA CAS 17528-72-2
DMINZ4W CB CHEBI:15372
DMINZ4W DE Malnutrition
DMH15UV ID DMH15UV
DMH15UV DN Tetrahydrofolic acid
DMH15UV HS Approved
DMH15UV SN Tetrahydrafolate; Tetrahydrofolate; Tetrahydropteroylglutamate; Tetrahydropteroylglutamic acid; BIT3012; FH4; H4PteGlu; Folate-H4; Th-folate; Tetra-H-folate; Tetrahydropteroyl mono-L-glutamate; N-(5,6,7,8-tetrahydropteroyl)-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)glutamic acid; N-[4-{[(2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}benzoyl]-L-glutamic acid; N-(4-(((2-Amino-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; N-[4-({[(6S)-2-AMINO-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID; N-[4-({[(6S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid; (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid; (6S)-5,6,7,8-tetrahydropteroylglutamate; (6S)-H4folate; (6S)-THFA; (6S)-Tetrahydrofolic acid; (6S)-tetrahydrofolate; 2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 5,6,7,8-Tetrahydropteroyl-L-glutamic acid; 5,6,7,8-tetrahydrofolate; 5,6,7,8-tetrahydrofolic acid
DMH15UV TC Dietary supplement
DMH15UV DT Small molecular drug
DMH15UV PC 135444742
DMH15UV MW 445.4
DMH15UV FM C19H23N7O6
DMH15UV IC InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1
DMH15UV CS C1C(NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMH15UV IK MSTNYGQPCMXVAQ-KIYNQFGBSA-N
DMH15UV IU (2S)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMH15UV CA CAS 135-16-0
DMH15UV CB CHEBI:20506
DMH15UV DE Malnutrition
DMT57WC ID DMT57WC
DMT57WC DN Tetrahydrozoline
DMT57WC HS Approved
DMT57WC SN Tyzine
DMT57WC CP Fougera Pharmaceuticals Inc
DMT57WC DT Small molecular drug
DMT57WC PC 5419
DMT57WC MW 200.28
DMT57WC FM C13H16N2
DMT57WC IC InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
DMT57WC CS C1CC(C2=CC=CC=C2C1)C3=NCCN3
DMT57WC IK BYJAVTDNIXVSPW-UHFFFAOYSA-N
DMT57WC IU 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole
DMT57WC CA CAS 84-22-0
DMT57WC CB CHEBI:28674
DMT57WC DE Ocular disease
DMWMPRG ID DMWMPRG
DMWMPRG DN Tetrodotoxin
DMWMPRG HS Approved
DMWMPRG SN Maculotoxin; Spheroidine; TTX; Tarichatoxin; Tetradotoxin; Tetrodontoxin; Tetrodotoxine; Tetrodoxin; Fugu Toxin; Fugu poison; BJT 1; Babylonia japonica toxin 1; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10adimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol; (1R,5R,6R,7R,9S,11R,12R,13S,14S)-14-(hydroxymethyl)-3-imino-8,10-dioxa-2,4-diazatetracyclo[7.3.1.1(7,11).0(1,6)]tetradecane-5,9,12,13,14-pentol; (1r,5r,6r,9r,11s,13s,14s)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol(non-preferred name); (4R-(4alpha,4aalpha,5alpha,7alpha,9alpha,10alpha,10abeta,11S*,12S*))-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-(1,3)dioxocino(6,5-d) pyrimidine-4,7,10,11,12-pentol
DMWMPRG TC Antibiotics
DMWMPRG DT Small molecular drug
DMWMPRG PC 11174599
DMWMPRG MW 319.27
DMWMPRG FM C11H17N3O8
DMWMPRG IC InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3-,4-,5+,6-,7+,9+,10-,11+/m1/s1
DMWMPRG CS C([C@@]1([C@H]2[C@@H]3[C@H](N=C(N[C@@]34[C@@H]([C@@H]1O[C@]([C@H]4O)(O2)O)O)N)O)O)O
DMWMPRG IK CFMYXEVWODSLAX-QOZOJKKESA-N
DMWMPRG IU (1R,5R,6R,7R,9S,11S,12S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol
DMWMPRG CA CAS 4368-28-9
DMWMPRG DE Bacterial infection
DMY62FC ID DMY62FC
DMY62FC DN Tezacaftor And Ivacaftor
DMY62FC HS Approved
DMY62FC SN Ivacaftor / Tezacaftor; Tezacaftor / Ivacaftor; Ivacaftor and Tezacaftor; Ivacaftor regimen with Tezacaftor
DMY62FC CP Vertex Pharmaceuticals
DMY62FC PC 72722243
DMY62FC MW 913
DMY62FC FM C50H55F3N4O9
DMY62FC IC InChI=1S/C26H27F3N2O6.C24H28N2O3/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35);7-13,27H,1-6H3,(H,25,28)(H,26,29)/t16-;/m1./s1
DMY62FC CS CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C.CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
DMY62FC IK NETGOEWJJZQLCO-PKLMIRHRSA-N
DMY62FC IU N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
DMY62FC CA CAS 1969264-35-4
DMY62FC DE Acute lung injury
DM70BU5 ID DM70BU5
DM70BU5 DN Thalidomide
DM70BU5 HS Approved
DM70BU5 SN Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
DM70BU5 TC Immunosuppressive Agents
DM70BU5 DT Small molecular drug
DM70BU5 PC 5426
DM70BU5 MW 258.23
DM70BU5 FM C13H10N2O4
DM70BU5 IC InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
DM70BU5 CS C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
DM70BU5 IK UEJJHQNACJXSKW-UHFFFAOYSA-N
DM70BU5 IU 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DM70BU5 CA CAS 50-35-1
DM70BU5 CB CHEBI:74947
DM70BU5 DE Multiple myeloma
DMM8D3F ID DMM8D3F
DMM8D3F DN Theobromine
DMM8D3F HS Approved
DMM8D3F SN theobromine; 83-67-0; 3,7-Dimethylxanthine; Diurobromine; Teobromin; Theostene; Theosalvose; Santheose; Thesodate; Thesal; 3,7-dimethylpurine-2,6-dione; 3,7-Dimethyl-3,7-dihydro-1H-purine-2,6-dione; Theobromin; Xanthine, 3,7-dimethyl-; 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-; SC 15090; 2,6-Dihydroxy-3,7-dimethylpurine; Theobromine (natural); UNII-OBD445WZ5P; NSC 5039; 7-Dimethylxanthine; 2,6-Dihydroxy-3,7-dimethyl-purine; BRN 0016464; FEMA No. 3591; CCRIS 2350; HSDB 7332
DMM8D3F DT Small molecular drug
DMM8D3F PC 5429
DMM8D3F MW 180.16
DMM8D3F FM C7H8N4O2
DMM8D3F IC InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)
DMM8D3F CS CN1C=NC2=C1C(=O)NC(=O)N2C
DMM8D3F IK YAPQBXQYLJRXSA-UHFFFAOYSA-N
DMM8D3F IU 3,7-dimethylpurine-2,6-dione
DMM8D3F CA CAS 83-67-0
DMM8D3F CB CHEBI:28946
DMM8D3F DE Asthma
DMRJFN9 ID DMRJFN9
DMRJFN9 DN Theophylline
DMRJFN9 HS Approved
DMRJFN9 SN Bronchoretard; Cetraphylline; Chronophyllin; Dimethylxanthine; Elixophylline; Liquophylline; Pseudotheophylline; Afonilum Retard; Bronchodid Duracap; Elixophyllin SR; Somophyllin CRT; Spophyllin retard; Telbans DrySyrup; Teofilina [Polish]; Theal tablets; Theobid Duracap; Theodur Dry Syrup; Uniphyllin continus; Elixophyllin (TN); Elixophyllin(e); Pulmo-Timelets; Somophyllin-CRT; Somophyllin-DF; Theo-Organidin; Theoclear-200; Theodur G (TN); Theolair (TN); Theophylline (JP15); Theophylline-SR; Quibron-t (TN); Theo-Dur-Sprinkle; Theophylline-[8-3H; Theoclear L.A.-130; 1,3 Dimethylxanthine; 1,3-Dimethylxanthine; 1H-purine-2,6-dione
DMRJFN9 CP Purdue Pharma
DMRJFN9 TC Bronchodilator Agents
DMRJFN9 DT Small molecular drug
DMRJFN9 PC 2153
DMRJFN9 MW 180.16
DMRJFN9 FM C7H8N4O2
DMRJFN9 IC InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
DMRJFN9 CS CN1C2=C(C(=O)N(C1=O)C)NC=N2
DMRJFN9 IK ZFXYFBGIUFBOJW-UHFFFAOYSA-N
DMRJFN9 IU 1,3-dimethyl-7H-purine-2,6-dione
DMRJFN9 CA CAS 58-55-9
DMRJFN9 CB CHEBI:28177
DMRJFN9 DE Chronic obstructive pulmonary disease
DM7YCK3 ID DM7YCK3
DM7YCK3 DN Thiabendazole
DM7YCK3 HS Approved
DM7YCK3 SN Biogard; Bioguard; Bovizole; Cropasal; Drawipas; Eprofil; Equizole; Hymush; Lombristop; Mertec; Mertect; Mintesol; Mintezol; Mintezole; Minzolum; Mycozol; Nemacin; Nemapan; Omnizole; Ormogal; Pitrizet; Polival; RPH; Sistesan; Storite; Tbdz; Tebuzate; Tecto; Testo; Thiaben; Thiabendazol; Thiabendazolum; Thiabendole; Thiabenzazole; Thiabenzole; Thibendole; Thibenzol; Thibenzole; Thiprazole; Tiabenda; Tiabendazol; Tiabendazole; Tiabendazolum; Tobaz; Tresaderm; Triasox; Tubazole; Captan T; Equivet TZ; Equizole A; Helmindrax octelmin; Hokustar HP; Mertect lsp; RTU Flowable Fungicide; Tecto B; Tecto rph; Thibenzole att; Top Form Wormer; Chemviron TK 100; G 491; MK 360; Mertect 160; Mertect 340f; Metasol TK 100; Metasol tk 10; PS1057_SUPELCO; Sanaizol 100; Syntol M100; TBZ 6; TBZ 60W; Tecto 10P; Tecto 40F; Tecto 60; Thibenzole 200; Tibimix 20; APL-luster; Arbotect (TN); MK-360; Metasol TK-100; Mintezol (TN); TBZ-6; Thiabendazole (USP); Thiabendazole [BSI:ISO]; Thiabendazole [USAN:BAN]; Tiabendazolum [INN-Latin]; Tresaderm (TN); E-Z-Ex; Mintezol, Equizole, Thiabendazole; Tiabendazol [INN-Spanish, French]; Tiabendazole (JAN/INN); 2-(1,3-Thiazol-4-yl)-1H-benzimidazole; 2-(1,3-Thiazol-4-yl)benzimidazole; 2-(1,3-thiazol-4-yl)-1H-1,3-benzodiazole; 2-(4'-Thiazolyl)benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazole; 2-(4-Thiazolyl)benzimidazole; 2-(Thiazol-4-yl)benzimidazole; 2-Thiazol-4-yl-1H-benzoimidazole; 2-Thiazole-4-ylbenzimidazole; 2-[4-Thiazoly]benzimidazole; 4-(1H-benzimidazol-2-yl)-1,3-thiazole; 4-(2-Benzimidazolyl)thiazole
DM7YCK3 TC Antinematodal Agents
DM7YCK3 DT Small molecular drug
DM7YCK3 PC 5430
DM7YCK3 MW 201.25
DM7YCK3 FM C10H7N3S
DM7YCK3 IC InChI=1S/C10H7N3S/c1-2-4-8-7(3-1)12-10(13-8)9-5-14-6-11-9/h1-6H,(H,12,13)
DM7YCK3 CS C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3
DM7YCK3 IK WJCNZQLZVWNLKY-UHFFFAOYSA-N
DM7YCK3 IU 4-(1H-benzimidazol-2-yl)-1,3-thiazole
DM7YCK3 CA CAS 148-79-8
DM7YCK3 CB CHEBI:45979
DM7YCK3 DE Helminth infection; Dutch elm disease
DMDRKH2 ID DMDRKH2
DMDRKH2 DN Thiamphenicol
DMDRKH2 HS Approved
DMDRKH2 SN thiamphenicol; 15318-45-3; Thiophenicol; Thiamcol; (+)-Thiamphenicol; Raceophenidol; Dextrosulphenidol; Thiamphenicolum; D-Thiocymetin; D-Thiophenicol; Thiocymetin (TN); Armai (TN); Thiocymetin; Tiamfenicolo [DCIT]; UNII-FLQ7571NPM; Tiamfenicol [INN-Spanish]; Thiamphenicol (Thiophenicol); Macphenicol; C12H15Cl2NO5S; Urfamycine; Igralin; Hyrazin; Dexawin; Rincrol; Neomyson; Urfamicina; Thiamphenicolum [INN-Latin]; Descocin; Masatirin; Efnicol; SW 5063; Unaseran-D; Thiamphenicol [USAN:INN:BAN:JAN]; EINECS 239-355-3; RACEPHENICOL; WIN-5063-2
DMDRKH2 DT Small molecular drug
DMDRKH2 PC 27200
DMDRKH2 MW 356.2
DMDRKH2 FM C12H15Cl2NO5S
DMDRKH2 IC InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1
DMDRKH2 CS CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O
DMDRKH2 IK OTVAEFIXJLOWRX-NXEZZACHSA-N
DMDRKH2 IU 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide
DMDRKH2 CA CAS 15318-45-3
DMDRKH2 CB CHEBI:32215
DMDRKH2 DE Bacterial infection
DMHDF7B ID DMHDF7B
DMHDF7B DN Thiamylal
DMHDF7B HS Approved
DMHDF7B SN Surital; Thioquinalbarbitone; Thioseconal; Thiamylal [USAN]; Surital (TN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN); Barbituric acid, 5-allyl-5-(1-methylbutyl)-2-thio-(VAN) (8CI); Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione; Dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-4,6-(1H,5H)-pyrimidinedione; 4,6(1H,5H)-Pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo-(9CI); 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione; 5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-Allyl-5-(1-methylbutyl)-2-thiobarbitursaeure; 5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione; 5-allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMHDF7B TC Hypnotics and Sedatives
DMHDF7B DT Small molecular drug
DMHDF7B PC 3032285
DMHDF7B MW 254.35
DMHDF7B FM C12H18N2O2S
DMHDF7B IC InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
DMHDF7B CS CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C
DMHDF7B IK XLOMZPUITCYLMJ-UHFFFAOYSA-N
DMHDF7B IU 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMHDF7B CA CAS 77-27-0
DMHDF7B CB CHEBI:9536
DMHDF7B DE Anaesthesia
DMC1NBW ID DMC1NBW
DMC1NBW DN Thiazolidinedione
DMC1NBW HS Approved
DMC1NBW SN 2295-31-0; 1,3-Thiazolidine-2,4-dione; thiazolidine-2,4-dione; 2,4-Dioxothiazolidine; 2,4(3H,5H)-Thiazoledione; USAF EK-5496; Thiazolidindione; UNII-AA68LXK93C; Thiazolidinedione-2,4; NSC 6745; EINECS 218-941-2; BRN 0110700; AA68LXK93C; AI3-61185; CHEBI:50992; NSC6745; ZOBPZXTWZATXDG-UHFFFAOYSA-N; MFCD00005478; 2,4-Thiazolidinedione, 99%; C3H3NO2S; thiazolidine-dione; 2,4-thiazolidindione; 2,5H)-Thiazoledione; PubChem17487
DMC1NBW DT Small molecular drug
DMC1NBW PC 5437
DMC1NBW MW 117.13
DMC1NBW FM C3H3NO2S
DMC1NBW IC InChI=1S/C3H3NO2S/c5-2-1-7-3(6)4-2/h1H2,(H,4,5,6)
DMC1NBW CS C1C(=O)NC(=O)S1
DMC1NBW IK ZOBPZXTWZATXDG-UHFFFAOYSA-N
DMC1NBW IU 1,3-thiazolidine-2,4-dione
DMC1NBW CA CAS 2295-31-0
DMC1NBW CB CHEBI:50992
DMC1NBW DE Alzheimer disease
DMU3IET ID DMU3IET
DMU3IET DN Thiethylperazine
DMU3IET HS Approved
DMU3IET SN ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*)
DMU3IET CP Norvatis Phamaceuticals Corporation
DMU3IET TC Antiemetics
DMU3IET DT Small molecular drug
DMU3IET PC 5440
DMU3IET MW 399.6
DMU3IET FM C22H29N3S2
DMU3IET IC InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3
DMU3IET CS CCSC1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)C
DMU3IET IK XCTYLCDETUVOIP-UHFFFAOYSA-N
DMU3IET IU 2-ethylsulfanyl-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine
DMU3IET CA CAS 1420-55-9
DMU3IET CB CHEBI:9544
DMU3IET DE Nausea
DMEPWYA ID DMEPWYA
DMEPWYA DN THIOCOLCHICOSIDE
DMEPWYA HS Approved
DMEPWYA SN Thiocolchicoside; 602-41-5; Coltramyl; UNII-T1X8S697GT; Thiocolchicine 2-glucoside analog; NSC 147755; Musco-ril; T1X8S697GT; 10-Thiocolchicoside; Tiocolchicoside [DCIT]; Colchicoside, 10-thio-; Thiocolchicoside [INN:DCF]; Q-201823; Thiocolchicosidum [INN-Latin]; Tiocolchicosido [INN-Spanish]; C27H33NO10S; Tiocolchicosido; Tiocolchicoside; Muscoril; Thiocolchicosidum; EINECS 210-017-7; BRN 0072205; R. 271; 2-10-Di(demethoxy)-2-glucosyloxy-10-methylthiocolchicine; Miotens; Coltrax; NSC147755; Coltramyl (TN); NCGC00016519-01
DMEPWYA DT Small molecular drug
DMEPWYA PC 9915886
DMEPWYA MW 563.6
DMEPWYA FM C27H33NO10S
DMEPWYA IC InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
DMEPWYA CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMEPWYA IK LEQAKWQJCITZNK-AXHKHJLKSA-N
DMEPWYA IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMEPWYA CA CAS 602-41-5
DMEPWYA CB CHEBI:94557
DMEPWYA DE Muscle spasm
DM7NKEV ID DM7NKEV
DM7NKEV DN Thioguanine
DM7NKEV HS Approved
DM7NKEV SN 6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
DM7NKEV CP Glaxo Smith Kline Pharmaceuticals
DM7NKEV TC Anticancer Agents
DM7NKEV DT Small molecular drug
DM7NKEV PC 2723601
DM7NKEV MW 167.19
DM7NKEV FM C5H5N5S
DM7NKEV IC InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DM7NKEV CS C1=NC2=C(N1)C(=S)N=C(N2)N
DM7NKEV IK WYWHKKSPHMUBEB-UHFFFAOYSA-N
DM7NKEV IU 2-amino-3,7-dihydropurine-6-thione
DM7NKEV CA CAS 154-42-7
DM7NKEV CB CHEBI:9555
DM7NKEV DE Acute myeloid leukaemia
DMGP8AX ID DMGP8AX
DMGP8AX DN Thiopental
DMGP8AX HS Approved
DMGP8AX SN Intraval; Penthiobarbital; Pentothiobarbital; Thiomebumal; Thionembutal; Thiopentobarbital; Thiopentobarbitone; Thiopentone; Thiothal; Tiopentale; Trapanal; Thiopental [BAN]; Thiopental solution; Thiopentobarbituric acid; Tiopentale [Italian]; Sodium Pentothal (TN); Thiopental (TN); Thiopentone sodium (TN); Trapanal (TN); (+-)-Thiopental; (+/-)-THIOPENTAL; (+/-)-Thiopental solution; 2-Thio-5-ethyl-5-sec-pentylbarbituric acid; 4,6,(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-(1-methylbutyl)-2-thioxo-(9CI); 5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione; 5-Ethyl-5-(1-methylbutyl)-2-thiobarbituric acid; 5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMGP8AX CP Abbott Laboratories
DMGP8AX TC Hypnotics and Sedatives
DMGP8AX DT Small molecular drug
DMGP8AX PC 3000715
DMGP8AX MW 242.34
DMGP8AX FM C11H18N2O2S
DMGP8AX IC InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
DMGP8AX CS CCCC(C)C1(C(=O)NC(=S)NC1=O)CC
DMGP8AX IK IUJDSEJGGMCXSG-UHFFFAOYSA-N
DMGP8AX IU 5-ethyl-5-pentan-2-yl-2-sulfanylidene-1,3-diazinane-4,6-dione
DMGP8AX CA CAS 76-75-5
DMGP8AX CB CHEBI:102166
DMGP8AX DE Anaesthesia
DM35M8J ID DM35M8J
DM35M8J DN Thioridazine
DM35M8J HS Approved
DM35M8J SN Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
DM35M8J CP Norvatis Phamaceuticals Corporation
DM35M8J TC Antipsychotic Agents
DM35M8J DT Small molecular drug
DM35M8J PC 5452
DM35M8J MW 370.6
DM35M8J FM C21H26N2S2
DM35M8J IC InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
DM35M8J CS CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
DM35M8J IK KLBQZWRITKRQQV-UHFFFAOYSA-N
DM35M8J IU 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
DM35M8J CA CAS 50-52-2
DM35M8J CB CHEBI:9566
DM35M8J DE Schizophrenia
DMIZKOP ID DMIZKOP
DMIZKOP DN Thiotepa
DMIZKOP HS Approved
DMIZKOP SN thiotepa; THIO-TEPA; 52-24-4; Triethylenethiophosphoramide; Thiophosphamide; Tiofosyl; Tiofosfamid; Thiofozil; Tiofozil; Thioplex; Tespamin; Oncotepa; Tespamine; Girostan; Thiotef; Stepa; Tio-tef; Thio-Tep; Oncotiotepa; Tifosyl; Oncothio-tepa; TESPA; TSPA; Thio-tepa S; Ledertepa; Thiotriethylenephosphoramide; TIO TEF; N,N',N''-Triethylenethiophosphoramide; Tris(1-aziridinyl)phosphine sulfide; Thiophosphamidum; 1,1',1''-phosphorothioyltriaziridine; Triethylene thiophosphoramide; Triaziridinylphosphine sulfide
DMIZKOP DT Small molecular drug
DMIZKOP PC 5453
DMIZKOP MW 189.22
DMIZKOP FM C6H12N3PS
DMIZKOP IC InChI=1S/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2
DMIZKOP CS C1CN1P(=S)(N2CC2)N3CC3
DMIZKOP IK FOCVUCIESVLUNU-UHFFFAOYSA-N
DMIZKOP IU tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane
DMIZKOP CA CAS 52-24-4
DMIZKOP CB CHEBI:9570
DMIZKOP DE Breast cancer
DMDINC4 ID DMDINC4
DMDINC4 DN Thiothixene
DMDINC4 HS Approved
DMDINC4 SN Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene
DMDINC4 CP Pfizer Pharmaceuticals
DMDINC4 TC Antipsychotic Agents
DMDINC4 DT Small molecular drug
DMDINC4 PC 941651
DMDINC4 MW 443.6
DMDINC4 FM C23H29N3O2S2
DMDINC4 IC InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
DMDINC4 CS CN1CCN(CC1)CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
DMDINC4 IK GFBKORZTTCHDGY-UWVJOHFNSA-N
DMDINC4 IU (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
DMDINC4 CA CAS 3313-26-6
DMDINC4 CB CHEBI:9571
DMDINC4 DE Schizophrenia
DM2P6VD ID DM2P6VD
DM2P6VD DN Thrombin/fibrinogen matrix patch
DM2P6VD HS Approved
DM2P6VD SN Evicel; Thrombin; Biological Hemostatic Dressing; Fibrin Fleece; Fibrin Pad; Fibrin Patch; Fleece Fibrin Patch; Fibrin sealant, Omrix/ Ethicon; Fibrinogen, Omrix/Ethicon; Thrombin/fibrinogen matrix patch (surgical bleeding); Fibrin matrix patch (surgical bleeding), Omrix/Ethicon; Thrombin/fibrinogen matrixpatch (surgical bleeding), Omrix/Ethicon
DM2P6VD CP OMRIX Biopharmaceuticals SA
DM2P6VD DE Bleeding disorder
DMJ47QC ID DMJ47QC
DMJ47QC DN Thyrotropin
DMJ47QC HS Approved
DMJ47QC SN Thytropar
DMJ47QC CP Sanofi Aventis Us Llc
DMJ47QC DE Hypothyroidism
DMMYLTI ID DMMYLTI
DMMYLTI DN Thyrotropin Alfa
DMMYLTI HS Approved
DMMYLTI TC Diagnostic Agents
DMMYLTI SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY
DMMYLTI DE Thyroid cancer
DMKSQG0 ID DMKSQG0
DMKSQG0 DN Tiagabine
DMKSQG0 HS Approved
DMKSQG0 SN tiagabine; 115103-54-3; Gabitril; Tiagabinum; Tiagabina; (R)-Tiagabine; Tiagabinum [INN-Latin]; Tiagabina [INN-Spanish]; Tiagabine [INN:BAN]; Tiagabine [INN]; Abbott-70569; UNII-Z80I64HMNP; Tiagabine (INN); ABBOTT-70569-1; Gabitril (TN); CHEMBL1027; Z80I64HMNP; ABT-569; CHEBI:9586; NO-328; (-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid; A-70569-1; (R)-1-(4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid; Gabatril; NO 329; Gabitril; NO-329; Tiagabina [INN-Spanish];Tiagabine (INN); N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid; (3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid; (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid; [3H]tiagabine
DMKSQG0 CP Cephalon
DMKSQG0 TC Anticonvulsants
DMKSQG0 DT Small molecular drug
DMKSQG0 PC 60648
DMKSQG0 MW 375.6
DMKSQG0 FM C20H25NO2S2
DMKSQG0 IC InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
DMKSQG0 CS CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C
DMKSQG0 IK PBJUNZJWGZTSKL-MRXNPFEDSA-N
DMKSQG0 IU (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid
DMKSQG0 CA CAS 115103-54-3
DMKSQG0 CB CHEBI:9586
DMKSQG0 DE Epilepsy; Anxiety disorder
DMYN8MA ID DMYN8MA
DMYN8MA DN Tianeptine
DMYN8MA HS Approved
DMYN8MA SN Tianeptina; Tianeptinum; Tianeptine Acid; Tianeptine [INN]; Stablon (TN); Tianeptine (INN); (1)-7-((3-Chloro-6,11-dihydro-6-methyldibenzo(c,f)(1,2)thiazepin-11-yl)amino)heptanoic acid S,S-dioxide; 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
DMYN8MA DT Small molecular drug
DMYN8MA PC 68870
DMYN8MA MW 437
DMYN8MA FM C21H25ClN2O4S
DMYN8MA IC InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26)
DMYN8MA CS CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O
DMYN8MA IK JICJBGPOMZQUBB-UHFFFAOYSA-N
DMYN8MA IU 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid
DMYN8MA CA CAS 72797-41-2
DMYN8MA CB CHEBI:91749
DMYN8MA DE Major depressive disorder
DMN6CAG ID DMN6CAG
DMN6CAG DN Tiapride
DMN6CAG HS Approved
DMN6CAG SN tiapride; 51012-32-9; Thiapride; Tiapridal; N-(2-(Diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamide; Tiapridum [INN-Latin]; Tiaprida [INN-Spanish]; UNII-LAH70H9JPH; FLO 1347; Tiapride [INN:BAN:DCF]; Tiapride HCl; EINECS 256-907-9; LAH70H9JPH; BRN 2390588; JTVPZMFULRWINT-UHFFFAOYSA-N; BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-; N-(2-(Diethylamino)ethyl)-5-(methylsulfonyl)-o-anisamide; Tiapridum; Tiaprida; Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-; NCGC00015996-02; SPI-860
DMN6CAG DT Small molecular drug
DMN6CAG PC 5467
DMN6CAG MW 328.4
DMN6CAG FM C15H24N2O4S
DMN6CAG IC InChI=1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)
DMN6CAG CS CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
DMN6CAG IK JTVPZMFULRWINT-UHFFFAOYSA-N
DMN6CAG IU N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide
DMN6CAG CA CAS 51012-32-9
DMN6CAG CB CHEBI:94666
DMN6CAG DE Alcohol dependence; Neuropathic pain
DM23D7J ID DM23D7J
DM23D7J DN Tiaprofenic acid
DM23D7J HS Approved
DM23D7J SN Surgam; Tiaprofensaeure; Acide tiaprofenique; Acido tiaprofenico; Acidum tiaprofenicum; Surgam SR; FC 3001; RU 15060; Acide tiaprofenique [INN-French]; Acido tiaprofenico [INN-Spanish]; Acidum tiaprofenicum [INN-Latin]; Apo-Tiaprofenic Tablets; Dom-tiaprofenic; Surgam (TN); Surgamyl (TN); Tiaprofen (TN); Tiaprofenic acid (JAN/INN); Tiaprofenic-200-Tab; Tiaprofenic-300-Tab; Tiaprofenic acid [INN:BAN:DCF:JAN]; Alpha-methyl-5-benzoyl-2-thienylacetic acid; 2-(5-Benzyl-2-thienyl)propionsaeure; 2-(5-benzoylthiophen-2-yl)propanoic acid; 2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid; 5-Benzoyl-alpha-methyl-2-thiopheneacetic acid; 5-benzoyl-alpha-methylthiophene-2-acetic acid
DM23D7J TC Analgesics
DM23D7J DT Small molecular drug
DM23D7J PC 5468
DM23D7J MW 260.31
DM23D7J FM C14H12O3S
DM23D7J IC InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
DM23D7J CS CC(C1=CC=C(S1)C(=O)C2=CC=CC=C2)C(=O)O
DM23D7J IK GUHPRPJDBZHYCJ-UHFFFAOYSA-N
DM23D7J IU 2-(5-benzoylthiophen-2-yl)propanoic acid
DM23D7J CA CAS 33005-95-7
DM23D7J CB CHEBI:32221
DM23D7J DE Pain
DM5JWV9 ID DM5JWV9
DM5JWV9 DN Tiazofurin
DM5JWV9 HS Approved
DM5JWV9 SN Riboxamide; TCAR; TIZ; Tiazofurina; Tiazofurine; Tiazofurinum; Tiazole; Tiazofurin [USAN]; Tiazofurina [Spanish]; Tiazofurinum [Latin]; Cpd-5825; Tiazofurin (USAN); Tiazofurine (INN); 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide; 2-beta-D-Ribofuranosyl-4-thiazolecarboxamide; 2-ribofuranosylthiazole-4-carboxamide
DM5JWV9 TC Anticancer Agents
DM5JWV9 DT Small molecular drug
DM5JWV9 PC 457954
DM5JWV9 MW 260.269
DM5JWV9 FM C9H12N2O5S
DM5JWV9 IC InChI=1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1
DM5JWV9 CS C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DM5JWV9 IK FVRDYQYEVDDKCR-DBRKOABJSA-N
DM5JWV9 IU 2-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide
DM5JWV9 CA CAS 60084-10-8
DM5JWV9 CB CHEBI:90239
DM5JWV9 DE Solid tumour/cancer
DM78XFG ID DM78XFG
DM78XFG DN Tibolone
DM78XFG HS Approved
DM78XFG SN Livial (TN)
DM78XFG DT Small molecular drug
DM78XFG PC 444008
DM78XFG MW 312.4
DM78XFG FM C21H28O2
DM78XFG IC InChI=1S/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1
DM78XFG CS C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
DM78XFG IK WZDGZWOAQTVYBX-XOINTXKNSA-N
DM78XFG IU (7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM78XFG CA CAS 5630-53-5
DM78XFG CB CHEBI:32223
DM78XFG DE Anabolic metabolism
DM4ME02 ID DM4ME02
DM4ME02 DN Ticarcillin
DM4ME02 HS Approved
DM4ME02 SN TIPC; Ticarcilina; Ticarcilline; Ticarcillinum; Ticarcillin Supplement; Ticillin [veterinary]; BRL-2288; Ticarcilina[INN-Spanish]; Ticarcillin (INN); Ticarcillin [INN:BAN]; Ticarcilline [INN-French]; Ticarcillinum [INN-Latin]; Ticillin [veterinary] (TN); Timentin (TN); A-carboxy-3-thienylmethylpenicillin; Alpha-carboxy-3-thienylmethylpenicillin; (2S,5R,6R)-6-[[(2R)-3-hydroxy-3-oxo-2-thiophen-3-ylpropanoyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-{[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino}-2,2-dimethylpenam-3alpha-carboxylic acid
DM4ME02 CP GlaxoSmithKline
DM4ME02 TC Antibiotics
DM4ME02 DT Small molecular drug
DM4ME02 PC 36921
DM4ME02 MW 384.4
DM4ME02 FM C15H16N2O6S2
DM4ME02 IC InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1
DM4ME02 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C
DM4ME02 IK OHKOGUYZJXTSFX-KZFFXBSXSA-N
DM4ME02 IU (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM4ME02 CA CAS 34787-01-4
DM4ME02 CB CHEBI:9587
DM4ME02 DE Bacterial infection
DMO946V ID DMO946V
DMO946V DN Ticlopidine
DMO946V HS Approved
DMO946V SN Ticlid; Ticlopidina; Ticlopidinum; PCR 5332; Ticlid (TN); Ticlopidin-Puren; Ticlopidina [INN-Spanish]; Ticlopidine (INN); Ticlopidine [INN:BAN]; Ticlopidinum [INN-Latin]; Ticlopidin-Puren (TN); 5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine; 5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
DMO946V TC Fibrinolytic Agents
DMO946V DT Small molecular drug
DMO946V PC 5472
DMO946V MW 263.8
DMO946V FM C14H14ClNS
DMO946V IC InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
DMO946V CS C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
DMO946V IK PHWBOXQYWZNQIN-UHFFFAOYSA-N
DMO946V IU 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
DMO946V CA CAS 55142-85-3
DMO946V CB CHEBI:9588
DMO946V DE Stroke
DMLE7IO ID DMLE7IO
DMLE7IO DN Tigecycline
DMLE7IO HS Approved
DMLE7IO SN Tigilcycline; Tygacil; Tigecycline [USAN]; GAR 936; GAR-936; TBG-MINO; Tygacil (TN); Tygacil(TM); GAR-936,Tigecycline; Tigecycline (JAN/USAN); WAY-GAR-936; Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline; N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide; (4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide; (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide; 9-t-Butylglycylamido minocycline
DMLE7IO CP Wyeth Pharmaceuticals
DMLE7IO TC Antibiotics
DMLE7IO DT Small molecular drug
DMLE7IO PC 54686904
DMLE7IO MW 585.6
DMLE7IO FM C29H39N5O8
DMLE7IO IC InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36-37,40,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
DMLE7IO CS CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C
DMLE7IO IK SOVUOXKZCCAWOJ-HJYUBDRYSA-N
DMLE7IO IU (4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMLE7IO CA CAS 220620-09-7
DMLE7IO CB CHEBI:149836
DMLE7IO DE Skin infection
DMLW9HG ID DMLW9HG
DMLW9HG DN Tildrakizumab
DMLW9HG HS Approved
DMLW9HG SN UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222
DMLW9HG CP Sun Pharma
DMLW9HG DT Antibody
DMLW9HG DE Plaque psoriasis
DMJW0VS ID DMJW0VS
DMJW0VS DN Tilidine
DMJW0VS HS Approved
DMJW0VS SN Valoron; Tilidine hydrochloride hemihydrate; 255733-17-6; Tilidine hydrochloride hemihydrate [EP]; DTXSID70180262; Ethyl (1RS,2SR)-2-(dimethylamino)-1-phenylcyclohex-3-enecarboxylate hydrochloride hemihydrate; 3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, hydrochloride, hydrate (2:2:1), (1R,2S)-rel-; UNII-Y757T3419R component WHYVWQHDUOALSV-UMJMSJQKSA-N
DMJW0VS DT Small molecular drug
DMJW0VS PC 30131
DMJW0VS MW 273.37
DMJW0VS FM C17H23NO2
DMJW0VS IC InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1
DMJW0VS CS CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2
DMJW0VS IK WDEFBBTXULIOBB-WBVHZDCISA-N
DMJW0VS IU ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate
DMJW0VS CA CAS 51931-66-9
DMJW0VS CB CHEBI:77822
DMJW0VS DE Pain
DM3NXRU ID DM3NXRU
DM3NXRU DN Timolol
DM3NXRU HS Approved
DM3NXRU SN Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol
DM3NXRU CP Merck Frosst
DM3NXRU TC Antiarrhythmic Agents
DM3NXRU DT Small molecular drug
DM3NXRU PC 33624
DM3NXRU MW 316.42
DM3NXRU FM C13H24N4O3S
DM3NXRU IC InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
DM3NXRU CS CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
DM3NXRU IK BLJRIMJGRPQVNF-JTQLQIEISA-N
DM3NXRU IU (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
DM3NXRU CA CAS 26839-75-8
DM3NXRU CB CHEBI:9599
DM3NXRU DE High blood pressure
DM3OWT4 ID DM3OWT4
DM3OWT4 DN Tindamax
DM3OWT4 HS Approved
DM3OWT4 SN Tinidazole (oral), Mission Pharmacal
DM3OWT4 CP Presutti Laboratories
DM3OWT4 DT Small molecular drug
DM3OWT4 PC 5479
DM3OWT4 MW 247.27
DM3OWT4 FM C8H13N3O4S
DM3OWT4 IC InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
DM3OWT4 CS CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C
DM3OWT4 IK HJLSLZFTEKNLFI-UHFFFAOYSA-N
DM3OWT4 IU 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
DM3OWT4 CA CAS 148159-84-6
DM3OWT4 CB CHEBI:63627
DM3OWT4 DE Bacterial infection
DMNYPGS ID DMNYPGS
DMNYPGS DN Tioconazole
DMNYPGS HS Approved
DMNYPGS SN Fungibacid; GyneCure; Tioconazol; Tioconazolum; Trosyd; Trosyl; Vagistat; Zoniden; Trosyd AF; Trosyd J; Monistat 1; UK 20349; Gyno-trosyd; Tioconazol [INN-Spanish]; Tioconazolum [INN-Latin]; Tz-3; UK 20,349; UK-20349; Vagistat-1; Vagistat-1 (TN); Tioconazole (JAN/USP/INN); Tioconazole [USAN:BAN:INN:JAN]; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMNYPGS TC Antifungal Agents
DMNYPGS DT Small molecular drug
DMNYPGS PC 5482
DMNYPGS MW 387.7
DMNYPGS FM C16H13Cl3N2OS
DMNYPGS IC InChI=1S/C16H13Cl3N2OS/c17-12-1-2-13(14(18)7-12)15(8-21-5-4-20-10-21)22-9-11-3-6-23-16(11)19/h1-7,10,15H,8-9H2
DMNYPGS CS C1=CC(=C(C=C1Cl)Cl)C(CN2C=CN=C2)OCC3=C(SC=C3)Cl
DMNYPGS IK QXHHHPZILQDDPS-UHFFFAOYSA-N
DMNYPGS IU 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
DMNYPGS CA CAS 65899-73-2
DMNYPGS CB CHEBI:77898
DMNYPGS DE Onychomycosis
DMFDC0Q ID DMFDC0Q
DMFDC0Q DN Tiotropium
DMFDC0Q HS Approved
DMFDC0Q SN 186691-13-4; UNII-0EB439235F; 0EB439235F; [3H]tiotropium; (1r,2r,4s,5s,7s)-7-{[hydroxy(Dithiophen-2-Yl)acetyl]oxy}-9,9-Dimethyl-3-Oxa-9-Azoniatricyclo[3310~2,4~]nonane; NCGC00167971-01; 0HK; (1R,2R,4S,5S)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3310^{2,4}]nonan-9-ium; GTPL367; SCHEMBL4662461; GTPL8592; DTXSID5044281; CHEMBL3305968; Spiriva (TN); Tiotropium bromide [USAN:INN]; (1A,2A,4A,5A,7A)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatri-cyclo[331024]nonane bromide; (1a,2,4,5a,7)-7-[(2-Hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide; 7-{[hydroxy(dithiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[33102,4]nonane bromide
DMFDC0Q CP Boehringer Ingelheim
DMFDC0Q TC Bronchodilator Agents
DMFDC0Q DT Small molecular drug
DMFDC0Q PC 5487427
DMFDC0Q MW 392.5
DMFDC0Q FM C19H22NO4S2+
DMFDC0Q IC InChI=1S/C19H22NO4S2/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15/h3-8,11-13,16-17,22H,9-10H2,1-2H3/q+1/t11?,12-,13+,16-,17+
DMFDC0Q CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C
DMFDC0Q IK LERNTVKEWCAPOY-FPISHFTHSA-N
DMFDC0Q IU [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate
DMFDC0Q CA CAS 186691-13-4
DMFDC0Q CB CHEBI:90960
DMFDC0Q DE Chronic obstructive pulmonary disease
DM8HJX6 ID DM8HJX6
DM8HJX6 DN Tipranavir
DM8HJX6 HS Approved
DM8HJX6 SN Aptivus; TPV; PNU 140690; U 140690; Aptivus (Boehringer Ingelheim); Aptivus (TN); Aptivus(TM); PNU-140690; PNU-140690E; Tipranavir (INN); U-140690; N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide; N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
DM8HJX6 CP Boehriger Ingelheim
DM8HJX6 TC Anti-HIV Agents
DM8HJX6 DT Small molecular drug
DM8HJX6 PC 54682461
DM8HJX6 MW 602.7
DM8HJX6 FM C31H33F3N2O5S
DM8HJX6 IC InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
DM8HJX6 CS CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4
DM8HJX6 IK SUJUHGSWHZTSEU-FYBSXPHGSA-N
DM8HJX6 IU N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
DM8HJX6 CA CAS 174484-41-4
DM8HJX6 CB CHEBI:63628
DM8HJX6 DE Human immunodeficiency virus infection
DMJNV4O ID DMJNV4O
DMJNV4O DN Tirbanibulin
DMJNV4O HS Approved
DMJNV4O SN KX2-391; 897016-82-9; KX-01; UNII-4V9848RS5G; N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide; KX-2-391; CHEMBL571546; 4V9848RS5G; KX2391; KX 01; KX-2391; MLS006011272; SCHEMBL153779; KX01; GTPL7957; DTXSID30237862; MolPort-023-293-512; HUNGUWOZPQBXGX-UHFFFAOYSA-N; HMS3656J15; EX-A2434; BCP02845; ZINC43152787; s2700; BDBM50303801; AKOS027276392; KX2-391; KX-01; SB16619; CS-0248; KX2-391 (KX01); BCP9000828; 2-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-; NCGC00346644-05; NCGC00346644-01; KX 2
DMJNV4O CP Kinex Pharmaceuticals
DMJNV4O DT Small molecular drug
DMJNV4O PC 23635314
DMJNV4O MW 431.5
DMJNV4O FM C26H29N3O3
DMJNV4O IC InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)
DMJNV4O CS C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4
DMJNV4O IK HUNGUWOZPQBXGX-UHFFFAOYSA-N
DMJNV4O IU N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide
DMJNV4O CA CAS 897016-82-9
DMJNV4O DE Prostate cancer; Actinic keratosis
DMQG17S ID DMQG17S
DMQG17S DN Tirofiban
DMQG17S HS Approved
DMQG17S SN AGG; Aggrastat; Agrastat; Tirofibanum; Aggrastat (TN); Agrastat (TN); L-700462; MK-383; Tirofiban (INN); Tirofiban[BAN:INN]; Tirofiban [INN:BAN]; L-700,462; N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE; N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine; N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine; N-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine; (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
DMQG17S CP Medicure Pharma
DMQG17S TC Fibrinolytic Agents
DMQG17S DT Small molecular drug
DMQG17S PC 60947
DMQG17S MW 440.6
DMQG17S FM C22H36N2O5S
DMQG17S IC InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1
DMQG17S CS CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O
DMQG17S IK COKMIXFXJJXBQG-NRFANRHFSA-N
DMQG17S IU (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
DMQG17S CA CAS 144494-65-5
DMQG17S CB CHEBI:9605
DMQG17S DE Acute coronary syndrome
DMM9BJD ID DMM9BJD
DMM9BJD DN Tisagenlecleucel
DMM9BJD HS Approved
DMM9BJD SN Tisagenlecleucel-T
DMM9BJD CP Novartis Pharmaceuticals East Hanover, NJ
DMM9BJD DT CAR T Cell Therapy
DMM9BJD DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Acute lymphoblastic leukaemia; Acute myeloid leukaemia
DMGVUO5 ID DMGVUO5
DMGVUO5 DN Tislelizumab
DMGVUO5 HS Approved
DMGVUO5 CP BeiGene
DMGVUO5 DT Monoclonal antibody
DMGVUO5 DE Hepatocellular carcinoma; Hodgkin lymphoma
DMUKC5L ID DMUKC5L
DMUKC5L DN Tivozanib
DMUKC5L HS Approved
DMUKC5L SN ASP4130/AV-951
DMUKC5L CP Astellas Pharma US; AVEO Pharmaceuticals
DMUKC5L DT Small molecular drug
DMUKC5L PC 9911830
DMUKC5L MW 454.9
DMUKC5L FM C22H19ClN4O5
DMUKC5L IC InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
DMUKC5L CS CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
DMUKC5L IK SPMVMDHWKHCIDT-UHFFFAOYSA-N
DMUKC5L IU 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea
DMUKC5L CA CAS 475108-18-0
DMUKC5L CB CHEBI:91327
DMUKC5L DE Renal cell carcinoma
DMR2IQ4 ID DMR2IQ4
DMR2IQ4 DN Tizanidine
DMR2IQ4 HS Approved
DMR2IQ4 SN Sirdalud; Ternelin; Tizanidina; Tizanidinum; Sirdalud (TN); Tizanidina [INN-Spanish]; Tizanidine (INN); Tizanidine [INN:BAN]; Tizanidinum [INN-Latin]; Zanaflex (TN); 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole; 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole; 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
DMR2IQ4 CP Elan Pharmaceuticals
DMR2IQ4 TC Analgesics
DMR2IQ4 DT Small molecular drug
DMR2IQ4 PC 5487
DMR2IQ4 MW 253.71
DMR2IQ4 FM C9H8ClN5S
DMR2IQ4 IC InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)
DMR2IQ4 CS C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
DMR2IQ4 IK XFYDIVBRZNQMJC-UHFFFAOYSA-N
DMR2IQ4 IU 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine
DMR2IQ4 CA CAS 51322-75-9
DMR2IQ4 CB CHEBI:63629
DMR2IQ4 DE Spasm
DMUI0CH ID DMUI0CH
DMUI0CH DN Tobramycin
DMUI0CH HS Approved
DMUI0CH SN Aktob; Brulamycin; Distobram; Gotabiotic; NEBRAMYCIN; Nebcin; Nebicin; Obracin; Obramycin; Sybryx; TOY; Tenebrimycin;Tenemycin; Tobacin; Tobi; Tobracin; Tobradex; Tobradistin; Tobralex; Tobramaxin; Tobramicin; Tobramicina; Tobramitsetin; Tobramycetin; Tobramycine; Tobramycinum; Tobrased; Tobrasone; Tobrex; Deoxykanamycin B; Nebramycin VI; TOBRAMYCIN SULFATE; Tobramycin for Inhalation; Tobramycin solution for inhalation; A 12253A; Lilly 47663; NF 6; Nebramycin 6; Nebramycin factir 6; Nebramycin factor 6; Nebcin (Sulfate); SPRC-AB01; TobraDex (TN); Tobracin (TN); Tobramicina [INN-Spanish]; Tobramycin, Free Base; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobrex (TN); Tobramycin (JP15/USP); Tobramycin[USAN:BAN:INN:JAN]; TOA-(1-6)2TB-(4-1)TOC; TOA-(1-6)TOB-(4-1)TOC; 1-Epitobramycin; 3'-Deoxykanamycin B
DMUI0CH CP Bausch & Lomb Pharmaceuticals, Inc.
DMUI0CH TC Antibiotics
DMUI0CH DT Small molecular drug
DMUI0CH PC 36294
DMUI0CH MW 467.5
DMUI0CH FM C18H37N5O9
DMUI0CH IC InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
DMUI0CH CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
DMUI0CH IK NLVFBUXFDBBNBW-PBSUHMDJSA-N
DMUI0CH IU (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
DMUI0CH CA CAS 32986-56-4
DMUI0CH CB CHEBI:28864
DMUI0CH DE Bacterial infection
DMYNMDP ID DMYNMDP
DMYNMDP DN Tocainide
DMYNMDP HS Approved
DMYNMDP SN Taquidil; Tocainida; Tocainidum; Tonocard; Astra W 36095; Tocainida [INN-Spanish]; Tocainidum [INN-Latin]; W-36095; Tocainide (USAN/INN); Tocainide [USAN:BAN:INN]; Alanyl-2,6-xylidide; N-(2,6-dimethylphenyl)alaninamide; (-)-2-Amino-N-(2,6-dimethylphenyl)propanamide; 2-AMINO-N-(2,6-DIMETHYLPHENYL)PROPANAMIDE; 2-Amino-2',6'-propionoxylidide; 2-Amino-N-(2,6-dimethylphenyl)propionamid
DMYNMDP TC Antiarrhythmic Agents
DMYNMDP DT Small molecular drug
DMYNMDP PC 38945
DMYNMDP MW 192.26
DMYNMDP FM C11H16N2O
DMYNMDP IC InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)
DMYNMDP CS CC1=C(C(=CC=C1)C)NC(=O)C(C)N
DMYNMDP IK BUJAGSGYPOAWEI-UHFFFAOYSA-N
DMYNMDP IU 2-amino-N-(2,6-dimethylphenyl)propanamide
DMYNMDP CA CAS 41708-72-9
DMYNMDP CB CHEBI:9611
DMYNMDP DE Ventricular arrhythmias
DM7J6OR ID DM7J6OR
DM7J6OR DN Tocilizumab
DM7J6OR HS Approved
DM7J6OR SN Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
DM7J6OR CP Roche; Genentech
DM7J6OR DT Monoclonal antibody
DM7J6OR DE Rheumatoid arthritis; Juvenile idiopathic arthritis
DM1UE67 ID DM1UE67
DM1UE67 DN TOCOTRIENOL
DM1UE67 HS Approved
DM1UE67 SN 2-Methyl-2-[[4,8,12-trimethyl-3(E),7(E),11(E)]-tridecatrienyl]-3,4-dihydro-2H-benzo[b]pyran-6-ol
DM1UE67 DT Small molecular drug
DM1UE67 PC 9929901
DM1UE67 MW 382.6
DM1UE67 FM C26H38O2
DM1UE67 IC InChI=1S/C26H38O2/c1-20(2)9-6-10-21(3)11-7-12-22(4)13-8-17-26(5)18-16-23-19-24(27)14-15-25(23)28-26/h9,11,13-15,19,27H,6-8,10,12,16-18H2,1-5H3/b21-11+,22-13+
DM1UE67 CS CC(=CCC/C(=C/CC/C(=C/CCC1(CCC2=C(O1)C=CC(=C2)O)C)/C)/C)C
DM1UE67 IK GJJVAFUKOBZPCB-ZGRPYONQSA-N
DM1UE67 IU 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
DM1UE67 CA CAS 6829-55-6
DM1UE67 DE Hyperlipidaemia
DMBS370 ID DMBS370
DMBS370 DN Tofacitinib
DMBS370 HS Approved
DMBS370 SN Tasocitinib; 477600-75-2; 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; CP-690550; CP 690550; racemic-tofacitinib; 1259404-17-5; tofacitinibum; CP-690,550; UNII-87LA6FU830; 3-((3R,4R)-rel-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; Tofacitinib (CP-690550,Tasocitinib); CHEMBL221959; CHEBI:71200; Xeljanz (TN)
DMBS370 CP Pfizer
DMBS370 DT Small molecular drug
DMBS370 PC 9926791
DMBS370 MW 312.37
DMBS370 FM C16H20N6O
DMBS370 IC InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
DMBS370 CS C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
DMBS370 IK UJLAWZDWDVHWOW-YPMHNXCESA-N
DMBS370 IU 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
DMBS370 CA CAS 477600-75-2
DMBS370 CB CHEBI:71200
DMBS370 DE Rheumatoid arthritis
DMIHRNA ID DMIHRNA
DMIHRNA DN Tolazamide
DMIHRNA HS Approved
DMIHRNA SN Diabewas; Norglycin; Tolamide; Tolanase; Tolazamida; Tolazamidum; Tolazolamide; Tolinase; Pharmacia Brand of Tolazamide; T 2408; U 17835; Tolazamida [INN-Spanish]; Tolazamidum [INN-Latin]; Tolinase (TN); U-17835; Tolazamide (JP15/USP/INN); Tolazamide [USAN:INN:BAN:JAN]; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; 4-(p-Tolylsulfonyl)-1,1-hexamethylene; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; 59866P
DMIHRNA TC Hypoglycemic Agents
DMIHRNA DT Small molecular drug
DMIHRNA PC 5503
DMIHRNA MW 311.4
DMIHRNA FM C14H21N3O3S
DMIHRNA IC InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
DMIHRNA CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
DMIHRNA IK OUDSBRTVNLOZBN-UHFFFAOYSA-N
DMIHRNA IU 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea
DMIHRNA CA CAS 1156-19-0
DMIHRNA CB CHEBI:9613
DMIHRNA DE Diabetic complication
DMI40NL ID DMI40NL
DMI40NL DN Tolazoline
DMI40NL HS Approved
DMI40NL SN Artonil; Benzalolin; Benzazoline; Benzidazol; Benzolin; Benzylimidazoline; Divascol; Imidalin; Imidaline; Kasimid;Lambril; Olitensol; Peripherine; Phenylmethylimidazoline; Prefaxil; Pridazole; Priscol; Priscoline; Tolazolin; Tolazolina; Tolazolinum; Vasimid; Vasodil; Vasodilatan; Dilatol ASI; Tolazine [veterinary]; Tolazoline Monohydrochloride; Ciba 3259; Benzolin (VAN); Benzolin (vasodilator); Tolazine [veterinary] (TN); Tolazolina [INN-Spanish]; Tolazoline (INN); Tolazoline [INN:BAN]; Tolazolinum [INN-Latin]; Benzolin (vasodilator) (VAN); 1H-Imidazole, 4,5-dihydro-2-(phenylmethyl)-(9CI); 2-(phenylmethyl)-4,5-dihydro-1H-imidazole; 2-BENZYL-4,5-IMIDAZOLINE HCl; 2-Benzyl-2-imidazoline; 2-Benzyl-4,5-dihydro-1H-imidazole; 2-Benzyl-4,5-imidazoline; 2-Benzylimidazoline; 4,5-Dihydro-2-(phenylmethyl)-1H-imidazole
DMI40NL TC Vasodilator Agents
DMI40NL DT Small molecular drug
DMI40NL PC 5504
DMI40NL MW 160.22
DMI40NL FM C10H12N2
DMI40NL IC InChI=1S/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
DMI40NL CS C1CN=C(N1)CC2=CC=CC=C2
DMI40NL IK JIVZKJJQOZQXQB-UHFFFAOYSA-N
DMI40NL IU 2-benzyl-4,5-dihydro-1H-imidazole
DMI40NL CA CAS 59-98-3
DMI40NL CB CHEBI:28502
DMI40NL DE Pulmonary hypertension
DM02AWV ID DM02AWV
DM02AWV DN Tolbutamide
DM02AWV HS Approved
DM02AWV SN Aglicid; Arcosal; Arkozal; Artosin; Artozin; Beglucin; Butamid; Butamide; Butamidum; Diaben; Diabesan; Diabetamid; Diabetol; Diabuton; Diasulfon; Diaval; Dirastan; Dolipol; Drabet; Glyconon; Ipoglicone; Mobenol; Orabet; Oralin; Oramide; Orezan; Orinase; Orinaz; Oterben; Pramidex; Rastinon; Restinon; Tarasina; Tolbet;Tolbusal; Tolbutamid; Tolbutamida; Tolbutamidum; Tolbutone; Toluina; Tolumid; Toluran; Toluvan; Tolylsulfonylbutylurea; Willbutamide; Apotex Brand of Tolbutamide; Aventis Brand of Tolbutamide; BerlinChemie Brand of Tolbutamide; Butamide Brand of Tolbutamide; Hoechst Brand of Tolbutamide; Pfizer Brand of Tolbutamide; TOLBUTAMIDE USP; Tolbutamide Aventis Brand; Tolbutamide Butamide Brand; Tolbutamide Hoechst Brand; Tolbutamide Pfizer Brand; Valdecasas Brand of Tolbutamide; Yamanouchi Brand of Tolbutamide; D 860; HLS 831; T 0891; U 2043; Apo-Tolbutamide; Berlin-Chemie Brand of Tolbutamide; Novo-Butamide; Orinase (TN); Sk-tolbutamide; Tol-Tab; Tolbutamida [INN-Spanish]; Tolbutamidum [INN-Latin]; Tolbutamide [INN:BAN:JAN]; R.A.N. Brand of Tolbutamide; Tolbutamid R.A.N.; Tolbutamide (JP15/USP/INN); N-4-Methylbenzolsulfonyl-N-butylurea; N-4-(Methylbenzolsulfonyl)-n-butylurea; N-Butyl-N'-p-toluenesulfonylurea; N-n-Butyl-N'-tosylurea; N-(4-Methylbenzenesulfonyl)-N'-butylurea; N-(4-Methylphenylsulfonyl)-N'-butylurea; N-(p-Tolylsulfonyl)-N'-butylcarbamide; N-Butyl-N'-(4-methylphenylsulfonyl)urea; N-Butyl-N'-(p-tolylsulfonyl)urea; N-Butyl-N'-toluene-p-sulfonylurea; N-(p-tolylsulfonyl)-N'-n-butylurea; 1-Butyl-3-(4-methylphenylsulfonyl)urea; 1-Butyl-3-(p-methylphenylsulfonyl)urea; 1-Butyl-3-(p-tolylsulfonyl)urea; 1-Butyl-3-(para-tolylsulfonyl) urea; 1-Butyl-3-tosylurea; 1-butyl-3-(4-methylphenyl)sulfonylurea; 1-p-Toluenesulfonyl-3-butylurea; 3-(p-Tolyl-4-sulfonyl)-1-butylurea; 3-(p-tolylsulfonyl)-1-butylurea; 3-[p-Tolyl-4-sulfonyl]-1-butylurea
DM02AWV CP Pharmacia And Upjohn Co
DM02AWV TC Hypoglycemic Agents
DM02AWV DT Small molecular drug
DM02AWV PC 5505
DM02AWV MW 270.35
DM02AWV FM C12H18N2O3S
DM02AWV IC InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
DM02AWV CS CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C
DM02AWV IK JLRGJRBPOGGCBT-UHFFFAOYSA-N
DM02AWV IU 1-butyl-3-(4-methylphenyl)sulfonylurea
DM02AWV CA CAS 64-77-7
DM02AWV CB CHEBI:27999
DM02AWV DE Non-insulin dependent diabetes
DM8MNVO ID DM8MNVO
DM8MNVO DN Tolcapone
DM8MNVO HS Approved
DM8MNVO SN Tasmar; Roche brand of tolcapone; Ro 40-7592; Tasmar (TN); Tolcapone [USAN:INN]; Ro-40-7592; Tolcapone (JAN/USAN/INN); Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl); (3,4-Dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone; (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone; 3,4-Dihydroxy-4'-methyl-5-nitrobenzophenone; 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone
DM8MNVO TC Antiparkinson Agents
DM8MNVO DT Small molecular drug
DM8MNVO PC 4659569
DM8MNVO MW 273.24
DM8MNVO FM C14H11NO5
DM8MNVO IC InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
DM8MNVO CS CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DM8MNVO IK MIQPIUSUKVNLNT-UHFFFAOYSA-N
DM8MNVO IU (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
DM8MNVO CA CAS 134308-13-7
DM8MNVO CB CHEBI:63630
DM8MNVO DE Parkinson disease
DMWUIJE ID DMWUIJE
DMWUIJE DN Tolmetin
DMWUIJE HS Approved
DMWUIJE SN Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid
DMWUIJE CP Ortho Mcneil Janssen Pharmaceuticals Inc
DMWUIJE TC Antiinflammatory Agents
DMWUIJE DT Small molecular drug
DMWUIJE PC 5509
DMWUIJE MW 257.279
DMWUIJE FM C15H15NO3
DMWUIJE IC InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
DMWUIJE CS CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
DMWUIJE IK UPSPUYADGBWSHF-UHFFFAOYSA-N
DMWUIJE IU 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
DMWUIJE CA CAS 26171-23-3
DMWUIJE CB CHEBI:71941
DMWUIJE DE Rheumatoid arthritis
DM28MU7 ID DM28MU7
DM28MU7 DN Tolnaftate
DM28MU7 HS Approved
DM28MU7 SN Aftate; Breezee; Chinofungin; Dermoxin; Dungistop; Focusan; Fungistop; Genaspor; Micoisdin; Phytoderm; Pitrex; Separin; Sorgoa; Sporiline; Timoped; Tinactin; Tinaderm; Tinatox; Tinavet; Ting; Tniaderm; Tolnaftato; Tolnaftatum; Tolnaphthate; Tolsanil; Tonoftal; Tritin; ZeaSorb; Aftate for jock itch aerosol spray powder; Aftate for jock itch gel; Aftate for jock itch sprinkle powder; Bioglan Brand of Tolnaftate; Carter Wallace Brand of Tolnaftate; Chinosol Brand of Tolnaftate; Douglas Brand of Tolnaftate; Essex Brand of Tolnaftate; Genaspore cream; Insight Brand of Tolnaftate; Isdin Brand of Tolnaftate; Naphthiomate T; Ony Clear; Pitrex cream; Schering Brand of Tolnaftate; Stiefel Brand of Tolnaftate; Thompson Brand of Tolnaftate; Tinactin aerosol liquid; Tinactin aerosol powder; Tinactin antifungal deodorant powder aerosol; Tinactin cream; Tinactin jock itch aerosol powder; Tinactin jock itch cream;Tinactin jock itch spray powder; Tinactin plus aerosol powder; Tinactin plus powder; Tinactin powder; Tinactin solution; Ting Products; Ting antifungal cream; Ting antifungal powder; Ting antifungal spray liquid; Ting antifungal spray powder; Tolnaftat Purder N; Tolnaftate Douglas Brand; Tolnaftate Schering Brand; Tolnaftato [DCIT]; Wernigerode Brand of Tolnaftate; Zenith Brand of Tolnaftate; NP 27; NP27; Pedinol Brand 1 of Tolnaftate; Pedinol Brand 2 of Tolnaftate; Sch 10144; Absorbine (TN); Aftate (TN); Aftate for athlete's foot aerosol spray liquid; Aftate for athlete's foot aerosol spray powder; Aftate for athlete's foot gel; Aftate for athlete's foot sprinkle powder; Genaspor (TN); HI-Alazin; Hi-alarzin; Lamasil AF (TN); NP 27 (TN); NP-27 Cream; NP-27 Powder; NP-27 Solution; NP-27 Spray Powder; Naphthiomate-T; Odor Eaters (TN); Ony-Clear; Purder N, Tolnaftat; Schering-Plough Brand 1 of Tolnaftate; Schering-Plough Brand 2 of Tolnaftate; Scholl (TN); Separin (TN); Tinactin (TN); Tinavet (Veterinary); Ting (TN); Tolnaftate(USAN); Tolnaftato [INN-Spanish]; Tolnaftatum [INN-Latin]; Zeasorb-AF powder; Tolnaftate (JP14/USP); Tolnaftate (JP15/USP); Dr. Scholl's athlete's foot spray; Tolnaftate (JP15/USP/INN); Tolnaftate [USAN:BAN:INN:JAN]; Tolnaftate [USAN:INN:BAN:JAN]; M,N-Dimethylthiocarbanilic acid O-2-naphthyl ester; Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester; O-2-Naphthyl N,N-dimethylthiocarbanilate; O-2-Naphthyl m,N-dimethylthiocarbanilate; Methyl-(3-methylphenyl)carbamothioic acid O-2-naphthyl ester; Methyl-[3-methylphenyl]-carbamothioic acid O-2-naphthyl ester; O-(2-Naphthyl) methyl(3-methylphenyl)thiocarbamate; O-naphthalen-2-yl methyl(3-methylphenyl)carbamothioate; Carbamothioic acid, methyl(3-methylphenyl)-, O-2-naphthalenyl ester; Carbanilic acid, N,m-dimethylthio-, O-2-naphthyl ester; Carbanilic acid, m,N-dimethylthio-, O-2-naphthyl ester; N-Methyl-(3-methylphenyl)-carbamothioic acid, O-2-naphthalenyl ester; O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate; Carbamothioic acid, N-methyl-N-(3-methylphenyl)-, O-2-naphthalenyl ester; 2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate
DM28MU7 CP Schering-Plough
DM28MU7 TC Antifungal Agents
DM28MU7 DT Small molecular drug
DM28MU7 PC 5510
DM28MU7 MW 307.4
DM28MU7 FM C19H17NOS
DM28MU7 IC InChI=1S/C19H17NOS/c1-14-6-5-9-17(12-14)20(2)19(22)21-18-11-10-15-7-3-4-8-16(15)13-18/h3-13H,1-2H3
DM28MU7 CS CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2
DM28MU7 IK FUSNMLFNXJSCDI-UHFFFAOYSA-N
DM28MU7 IU O-naphthalen-2-yl N-methyl-N-(3-methylphenyl)carbamothioate
DM28MU7 CA CAS 2398-96-1
DM28MU7 CB CHEBI:9620
DM28MU7 DE Dermatophytosis; Jock itch
DMA2GHJ ID DMA2GHJ
DMA2GHJ DN Tolperisone
DMA2GHJ HS Approved
DMA2GHJ SN Agileo; Viveo; AV-650; SPH-3047; Tolperisone (controlled-release); Tolperisone (controlled-release), Sanochemia; Tolperisone (controlled-release), Sanochemia/Avigen
DMA2GHJ CP Sanochemia Pharmazeutika AG
DMA2GHJ DT Small molecular drug
DMA2GHJ PC 5511
DMA2GHJ MW 245.36
DMA2GHJ FM C16H23NO
DMA2GHJ IC InChI=1S/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3
DMA2GHJ CS CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
DMA2GHJ IK FSKFPVLPFLJRQB-UHFFFAOYSA-N
DMA2GHJ IU 2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one
DMA2GHJ CA CAS 728-88-1
DMA2GHJ CB CHEBI:93835
DMA2GHJ DE Muscle spasm
DMSHPW8 ID DMSHPW8
DMSHPW8 DN Tolterodine
DMSHPW8 HS Approved
DMSHPW8 SN Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol
DMSHPW8 CP Pfizer Pharmaceuticals
DMSHPW8 TC Antispasmodics
DMSHPW8 DT Small molecular drug
DMSHPW8 PC 443879
DMSHPW8 MW 325.5
DMSHPW8 FM C22H31NO
DMSHPW8 IC InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
DMSHPW8 CS CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2
DMSHPW8 IK OOGJQPCLVADCPB-HXUWFJFHSA-N
DMSHPW8 IU 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
DMSHPW8 CA CAS 124937-51-5
DMSHPW8 CB CHEBI:9622
DMSHPW8 DE Overactive bladder
DMIWFRL ID DMIWFRL
DMIWFRL DN Tolvaptan
DMIWFRL HS Approved
DMIWFRL SN Samsca; OPC 41061; Benzazepine derivative, 32; OPC-41061; Samsca (TN); N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide; (-)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide; 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine
DMIWFRL CP Otsuka; Winston Laboratories & Otsuka
DMIWFRL DT Small molecular drug
DMIWFRL PC 216237
DMIWFRL MW 448.9
DMIWFRL FM C26H25ClN2O3
DMIWFRL IC InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
DMIWFRL CS CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C
DMIWFRL IK GYHCTFXIZSNGJT-UHFFFAOYSA-N
DMIWFRL IU N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide
DMIWFRL CA CAS 150683-30-0
DMIWFRL CB CHEBI:32246
DMIWFRL DE Hyponatraemia; Heart failure
DMAE6LK ID DMAE6LK
DMAE6LK DN Topetecan
DMAE6LK HS Approved
DMAE6LK SN TOPOTECAN HYDROCHLORIDE; 119413-54-6; Topotecan Hcl; Hycamptamine hydrochloride; Topotecan (Hydrochloride); Topotecan monohydrochloride; UNII-956S425ZCY; Topotecan hydrochloride [USAN]; Nogitecan hydrochloride; DRG-0288; F S-104864-A; NSC-609699; NSC 609699; NSC609699; 956S425ZCY; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione monohydrochloride; NCGC00095189-01; AK-48920; DSSTox_RID_81248; DSSTox_CID_25952
DMAE6LK CP GSK
DMAE6LK DT Small molecular drug
DMAE6LK PC 60699
DMAE6LK MW 457.9
DMAE6LK FM C23H24ClN3O5
DMAE6LK IC InChI=1S/C23H23N3O5.ClH/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20;/h5-8,27,30H,4,9-11H2,1-3H3;1H/t23-;/m0./s1
DMAE6LK CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl
DMAE6LK IK DGHHQBMTXTWTJV-BQAIUKQQSA-N
DMAE6LK IU (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione;hydrochloride
DMAE6LK CA CAS 119413-54-6
DMAE6LK DE Small-cell lung cancer
DM82Z30 ID DM82Z30
DM82Z30 DN Topiramate
DM82Z30 HS Approved
DM82Z30 SN Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
DM82Z30 CP Ortho-McNell Pharmaceutical
DM82Z30 TC Anticonvulsants
DM82Z30 DT Small molecular drug
DM82Z30 PC 5284627
DM82Z30 MW 339.36
DM82Z30 FM C12H21NO8S
DM82Z30 IC InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
DM82Z30 CS CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C
DM82Z30 IK KJADKKWYZYXHBB-XBWDGYHZSA-N
DM82Z30 IU [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
DM82Z30 CA CAS 97240-79-4
DM82Z30 CB CHEBI:63631
DM82Z30 DE Alcohol dependence; Epilepsy; Seizure disorder
DMP6G8T ID DMP6G8T
DMP6G8T DN Topotecan
DMP6G8T HS Approved
DMP6G8T SN Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin
DMP6G8T CP GlaxoSmithKline
DMP6G8T TC Anticancer Agents
DMP6G8T DT Small molecular drug
DMP6G8T PC 60700
DMP6G8T MW 421.4
DMP6G8T FM C23H23N3O5
DMP6G8T IC InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
DMP6G8T CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
DMP6G8T IK UCFGDBYHRUNTLO-QHCPKHFHSA-N
DMP6G8T IU (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMP6G8T CA CAS 123948-87-8
DMP6G8T CB CHEBI:63632
DMP6G8T DE Small-cell lung cancer; Ovarian cancer; Solid tumour/cancer
DMXKJ6C ID DMXKJ6C
DMXKJ6C DN Torasemide
DMXKJ6C HS Approved
DMXKJ6C SN Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea
DMXKJ6C TC Diuretics
DMXKJ6C DT Small molecular drug
DMXKJ6C PC 41781
DMXKJ6C MW 348.4
DMXKJ6C FM C16H20N4O3S
DMXKJ6C IC InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
DMXKJ6C CS CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
DMXKJ6C IK NGBFQHCMQULJNZ-UHFFFAOYSA-N
DMXKJ6C IU 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
DMXKJ6C CA CAS 56211-40-6
DMXKJ6C CB CHEBI:9637
DMXKJ6C DE Congestive heart failure
DMQYUWG ID DMQYUWG
DMQYUWG DN Toremifene
DMQYUWG HS Approved
DMQYUWG SN Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
DMQYUWG CP Prostrakan Inc
DMQYUWG TC Anticancer Agents
DMQYUWG DT Small molecular drug
DMQYUWG PC 3005573
DMQYUWG MW 406
DMQYUWG FM C26H28ClNO
DMQYUWG IC InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
DMQYUWG CS CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3
DMQYUWG IK XFCLJVABOIYOMF-QPLCGJKRSA-N
DMQYUWG IU 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
DMQYUWG CA CAS 89778-26-7
DMQYUWG CB CHEBI:9635
DMQYUWG DE Breast cancer
DMMYZ3D ID DMMYZ3D
DMMYZ3D DN Tositumomab
DMMYZ3D HS Approved
DMMYZ3D SN Bexxar (TN)
DMMYZ3D CP GlaxoSmithKline
DMMYZ3D TC Anticancer Agents
DMMYZ3D DT Antibody
DMMYZ3D SQ Mouse-Human chimeric Anti-CD20 Heavy Chain 1: QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Mouse-Human chimeric Anti-CD20 Light Chain 1QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR >Mouse-Human chimeric Anti-CD20 Heavy Chain 2QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Mouse-Human chimeric Anti-CD20 Light Chain 2QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
DMMYZ3D DE Non-hodgkin lymphoma
DM5A31S ID DM5A31S
DM5A31S DN TP-434
DM5A31S HS Approved
DM5A31S SN TP-038; TP-120; TP-170; TP-221; TP-271; TP-787; Tetracycline analogs (bacterial infection), Tetraphase Pharmaceuticals; Tetracycline derivatives (bacterial infection), Tetraphase Pharmaceuticals; Fluorocycline antibiotic (oral, bacterial infection), Tetraphase Pharmaceuticals; Tetracycline analogs (iv, antibiotic), Tetraphase Pharmaceuticals; TP-434 (oral, multidrug-resistant bacterial infections); TP-434 (oral, multidrug-resistant bacterial infections), Tetraphase Pharmaceuticals
DM5A31S CP Tetraphase Pharmaceuticals
DM5A31S DT Small molecular drug
DM5A31S PC 54726192
DM5A31S MW 558.6
DM5A31S FM C27H31FN4O8
DM5A31S IC InChI=1S/C27H31FN4O8/c1-31(2)20-13-8-11-7-12-14(28)9-15(30-16(33)10-32-5-3-4-6-32)21(34)18(12)22(35)17(11)24(37)27(13,40)25(38)19(23(20)36)26(29)39/h9,11,13,20,34-35,38,40H,3-8,10H2,1-2H3,(H2,29,39)(H,30,33)/t11-,13-,20-,27-/m0/s1
DM5A31S CS CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=C(C(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)NC(=O)CN5CCCC5)F
DM5A31S IK AKLMFDDQCHURPW-ISIOAQNYSA-N
DM5A31S IU (4S,4aS,5aR,12aR)-4-(dimethylamino)-7-fluoro-1,10,11,12a-tetrahydroxy-3,12-dioxo-9-[(2-pyrrolidin-1-ylacetyl)amino]-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DM5A31S CA CAS 1207283-85-9
DM5A31S DE Intra-abdominal infection; Influenza virus infection
DMG3Y89 ID DMG3Y89
DMG3Y89 DN Trabectedin
DMG3Y89 HS Approved
DMG3Y89 SN Ecteinascidin; Ecteinascidin-743; Et-743; Yondelis (TN)
DMG3Y89 CP PharmaMar
DMG3Y89 DT Small molecular drug
DMG3Y89 PC 108150
DMG3Y89 MW 761.8
DMG3Y89 FM C39H43N3O11S
DMG3Y89 IC InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
DMG3Y89 CS CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O
DMG3Y89 IK PKVRCIRHQMSYJX-AIFWHQITSA-N
DMG3Y89 IU [(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate
DMG3Y89 CA CAS 114899-77-3
DMG3Y89 CB CHEBI:84050
DMG3Y89 DE Solid tumour/cancer; Ovarian cancer
DMRQD04 ID DMRQD04
DMRQD04 DN Tramadol
DMRQD04 HS Approved
DMRQD04 SN Conzip; Ryzolt; Tramadol Hydrochloride; Ultram Er; Rybix Odt; Ultram
DMRQD04 CP Chemie Grunenthal of Stolberg-am-Rhein
DMRQD04 TC Analgesics
DMRQD04 DT Small molecular drug
DMRQD04 PC 33741
DMRQD04 MW 263.37
DMRQD04 FM C16H25NO2
DMRQD04 IC InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
DMRQD04 CS CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)OC)O
DMRQD04 IK TVYLLZQTGLZFBW-ZBFHGGJFSA-N
DMRQD04 IU (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
DMRQD04 CA CAS 123154-38-1
DMRQD04 CB CHEBI:75725
DMRQD04 DE Pain
DM2JGQ3 ID DM2JGQ3
DM2JGQ3 DN Trametinib
DM2JGQ3 HS Approved
DM2JGQ3 SN GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN
DM2JGQ3 CP GlaxoSmithKline
DM2JGQ3 DT Small molecular drug
DM2JGQ3 PC 11707110
DM2JGQ3 MW 615.4
DM2JGQ3 FM C26H23FIN5O4
DM2JGQ3 IC InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
DM2JGQ3 CS CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
DM2JGQ3 IK LIRYPHYGHXZJBZ-UHFFFAOYSA-N
DM2JGQ3 IU N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
DM2JGQ3 CA CAS 871700-17-3
DM2JGQ3 CB CHEBI:75998
DM2JGQ3 DE Melanoma
DM4L6EU ID DM4L6EU
DM4L6EU DN Trandolapril
DM4L6EU HS Approved
DM4L6EU SN Gopten; Mavik; Odric; Odrik; Preran; Trandolaprilum; Udrik; Trandolaprilum [Latin]; RU 44570; RU44570; Mavik (TN); RU-44570; Trandolapril [INN:BAN]; Trandolapril (JAN/INN); (2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester; (2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid; (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylicacid; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
DM4L6EU CP Abbott Laboratories
DM4L6EU TC Antihypertensive Agents
DM4L6EU DT Small molecular drug
DM4L6EU PC 5484727
DM4L6EU MW 430.5
DM4L6EU FM C24H34N2O5
DM4L6EU IC InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
DM4L6EU CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O
DM4L6EU IK VXFJYXUZANRPDJ-WTNASJBWSA-N
DM4L6EU IU (2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DM4L6EU CA CAS 87679-37-6
DM4L6EU CB CHEBI:9649
DM4L6EU DE Hypertension
DMFI8A7 ID DMFI8A7
DMFI8A7 DN Tranexamic acid
DMFI8A7 HS Approved
DMFI8A7 SN AMCA; AMCHA; AMH; Amikapron; Amstat; Anvitoff; Carxamin; Cyclocapron; Cyklokapron; Emorhalt; Exacyl; Frenolyse; Hexapromin; Hexatron; Mastop; Rikavarin; Spiramin; Tamcha; Tranex; Tranexamsaeure; Tranexan; Transamin; Transamlon; Trasamlon; Ugurol; Acide tranexamique; Acido tranexamico; Acidum tranexamicum; Tranexmic acid; Tranhexamic acid; Trans AMCHA; CL 65336; DV 79; DV79; KABI 2161; LT00159441; ALBB-006013; Acide tranexamique [INN-French]; Acido tranexamico [INN-Spanish]; Acidum tranexamicum [INN-Latin]; CL-65336; Cis-AMCHA; Cyklokapron (TN); DV-79; RP 18,429; Rikavarin (TN); Rikavarin-S; T-AMCHA; Tranexamic acid cis-form; Trans-Amcha; Trans-Tranexamic acid; Cis-4-(Aminomethyl)cyclohexanecarboxylic acid; Tranexamic acid (JP15/USAN/INN); Tranexamic acid [USAN:INN:BAN:JAN]; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester; Trans-p-(Aminomethyl)cyclohexanecarboxylic; Trans-p-(Aminomethyl)cyclohexanecarboxylic acid; Cis-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-Aminomethylcyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)cyclohexane-carboxylic acid; Trans-4-Aminomethylcyclohexane-1-carboxylic acid; Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid; Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid; Trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid; 4-(Aminomethyl)-Cyclohexanecarboxylic Acid; 4-(Aminomethyl)cyclohexanecarboxylic acid; 4-(aminomethyl)cyclohexane-1-carboxylic acid
DMFI8A7 CP Daiichi Sankyo Pharma Development
DMFI8A7 TC Antifibrinolytic Agents
DMFI8A7 DT Small molecular drug
DMFI8A7 PC 5526
DMFI8A7 MW 157.21
DMFI8A7 FM C8H15NO2
DMFI8A7 IC InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)
DMFI8A7 CS C1CC(CCC1CN)C(=O)O
DMFI8A7 IK GYDJEQRTZSCIOI-UHFFFAOYSA-N
DMFI8A7 IU 4-(aminomethyl)cyclohexane-1-carboxylic acid
DMFI8A7 CA CAS 701-54-2
DMFI8A7 CB CHEBI:48669
DMFI8A7 DE Excessive bleeding
DME5Y64 ID DME5Y64
DME5Y64 DN Tranilast
DME5Y64 HS Approved
DME5Y64 SN tranilast; 53902-12-8; Rizaben; trans-Tranilast; Tranilastum; 70806-55-2; MK 341; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; Tranilastum [INN-Latin]; Tranilast [USAN:INN:JAN]; Tranpro; UNII-HVF50SMY6E; SB-252218; MK-341; Tranilast (SB 252218); 3,4-DAA; n-(3',4'-dimethoxycinnamoyl) anthranilic acid; HVF50SMY6E; MLS000028468; CHEBI:77572; C18H17NO5; Anthranilic acid, N-(3,4-dimethoxycinnamoyl)-; NZHGWWWHIYHZNX-CSKARUKUSA-N; 2-((3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid; MFCD00864787; T 0318; NU-3450; Rizaben (TN); Tranilast (JAN/USAN/INN); Rizaben, SB 252218, MK 341, Tranpro ,Tranilast; N-(3',4'-dimethoxycinnamoyl) anthranilic acid; N-(3′ -Dimethoxycinnamoyl)anthranilic Acid; 2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid; 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid; 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; Molecule 20
DME5Y64 CP Kissei
DME5Y64 DT Small molecular drug
DME5Y64 PC 5282230
DME5Y64 MW 327.3
DME5Y64 FM C18H17NO5
DME5Y64 IC InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
DME5Y64 CS COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
DME5Y64 IK NZHGWWWHIYHZNX-CSKARUKUSA-N
DME5Y64 IU 2-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]benzoic acid
DME5Y64 CA CAS 53902-12-8
DME5Y64 CB CHEBI:77572
DME5Y64 DE Ocular allergy
DMGB5RE ID DMGB5RE
DMGB5RE DN Tranylcypromine
DMGB5RE HS Approved
DMGB5RE SN GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine
DMGB5RE CP GlaxoSmithKline plc
DMGB5RE TC Antidepressants
DMGB5RE DT Small molecular drug
DMGB5RE PC 19493
DMGB5RE MW 133.19
DMGB5RE FM C9H11N
DMGB5RE IC InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
DMGB5RE CS C1[C@H]([C@@H]1N)C2=CC=CC=C2
DMGB5RE IK AELCINSCMGFISI-DTWKUNHWSA-N
DMGB5RE IU (1R,2S)-2-phenylcyclopropan-1-amine
DMGB5RE CA CAS 3721-26-4
DMGB5RE CB CHEBI:94631
DMGB5RE DE Prostate cancer; Major depressive disorder
DMZQOUX ID DMZQOUX
DMZQOUX DN Trastuzumab
DMZQOUX HS Approved
DMZQOUX SN Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)
DMZQOUX CP Roche; Genentech
DMZQOUX TC Anticancer Agents
DMZQOUX DT Antibody
DMZQOUX SQ Anti-HER2 Light chain (1 and 2): DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >Anti-HER2 Heavy chain (1 and 2)EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DMZQOUX DE Breast cancer; Gastric adenocarcinoma; HER2-positive breast cancer
DM20K91 ID DM20K91
DM20K91 DN Travoprost
DM20K91 HS Approved
DM20K91 SN Travatan; Travatanz; Travatan Alcon; Travatan Z; Travoprost [USAN]; AL6221; AL-6221; Travatan (TN); Travatan Z (TN); Travatan, Travoprost; Travoprost (JAN/USAN/INN); Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (+)-Fluprostenol isopropyl ester; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
DM20K91 CP Alcon Canada Inc
DM20K91 TC Ophthalmologicals
DM20K91 DT Small molecular drug
DM20K91 PC 5282226
DM20K91 MW 500.5
DM20K91 FM C26H35F3O6
DM20K91 IC InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
DM20K91 CS CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
DM20K91 IK MKPLKVHSHYCHOC-AHTXBMBWSA-N
DM20K91 IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
DM20K91 CA CAS 157283-68-6
DM20K91 CB CHEBI:746859
DM20K91 DE Open-angle glaucoma
DMK1GBJ ID DMK1GBJ
DMK1GBJ DN Trazodone
DMK1GBJ HS Approved
DMK1GBJ SN Beneficat; Desirel; Sideril; Tradozone; Trazalon; Trazodil; Trazodon; Trazodona; Trazodonum; Trazolan; Trazonil; Trialodine; Trittico; Desyrel Dividose; Trazodona [Spanish]; Trazodone Hcl; Trazodonum [Latin]; Beneficat (TN); Deprax (TN); Desirel (TN); Desyrel (TN); Desyrel(trazodone hcl salt); Molipaxin (TN); Thombran (TN); Trazodona [INN-Spanish]; Trazodone (Desyrel); Trazodone (INN); Trazodone [INN:BAN]; Trazodonum [INN-Latin]; Trazorel (TN); Trialodine (TN); Trittico (TN); 2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; 8-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-1,7,8-triazabicyclo[4.3.0]nona-2,4,6-trien-9-one hydrochloride
DMK1GBJ CP Angelini research laboratories
DMK1GBJ TC Antidepressants
DMK1GBJ DT Small molecular drug
DMK1GBJ PC 5533
DMK1GBJ MW 371.9
DMK1GBJ FM C19H22ClN5O
DMK1GBJ IC InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
DMK1GBJ CS C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
DMK1GBJ IK PHLBKPHSAVXXEF-UHFFFAOYSA-N
DMK1GBJ IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one
DMK1GBJ CA CAS 19794-93-5
DMK1GBJ CB CHEBI:9654
DMK1GBJ DE Depression
DMTIQF3 ID DMTIQF3
DMTIQF3 DN Treprostinil
DMTIQF3 HS Approved
DMTIQF3 SN Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
DMTIQF3 TC Antihypertensive Agents
DMTIQF3 DT Small molecular drug
DMTIQF3 PC 6918140
DMTIQF3 MW 390.5
DMTIQF3 FM C23H34O5
DMTIQF3 IC InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
DMTIQF3 CS CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
DMTIQF3 IK PAJMKGZZBBTTOY-ZFORQUDYSA-N
DMTIQF3 IU 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
DMTIQF3 CA CAS 81846-19-7
DMTIQF3 CB CHEBI:50861
DMTIQF3 DE Pulmonary arterial hypertension
DM49DUI ID DM49DUI
DM49DUI DN Tretinoin
DM49DUI HS Approved
DM49DUI SN Retinoic acid; tretinoin; 302-79-4; Vitamin A acid; all-trans-Retinoic acid; trans-Retinoic acid; ATRA; Airol; Retin-A; Vesanoid; Renova; Dermairol; Aknoten; Eudyna; Aberel; all-trans-Vitamin A acid; Aknefug; All-trans Retinoic Acid; Cordes vas; Epi-aberel; Atralin; Vitamin A1 acid, all-trans-; Tretin M; Retin-A Micro; all-trans-Vitamin A1 acid; Vitamin A acid, all-trans-; all-trans-Tretinoin; Effederm; Retionic acid; TRETINON; Retinoic acid, all-trans-; Alltrans-retinoic acid; beta-Ra; all-(E)-Retinoic acid; beta-Retinoic acid; Avitoin; Aberela; Acnavit; Atragen; Betarretin; Lsotretinoin; Nexret; Panretyn; REA; Retacnyl; Retinoate; Retinova; Solage; Tretinoina; Tretinoine; Tretinoino; Tretinoinum; Vesnaroid; Vitinoin; Aberela [Norway]; Accutane Roche; Acnavit [Denmark]; All Trans Retinoic Acid; Avita Gel; Avitoin [Norway]; Beta all trans Retinoic Acid; Cordes VAS [Germany]; Effederm [France]; Panretin Gel; Retin A; Trans Retinoic Acid; Tretinoin Potassium Salt; Tretinoin Sodium Salt; Tretinoin Zinc Salt; Tretinoin liposome; AGN100335; AGN 192013; ALRT 1057; BAL4079; LGD 100057; R 2625; [3H]Retinoic acid; A-Vitaminsyre; A-Vitaminsyre [Denmark]; AT-RA; Aberela (TN); Acid, Retinoic; Acid, Vitamin A; All trans-Retinoic acid; Atra-IV; Avita (TN); B-Retinoic acid; BML2-E05; Beta-Ra; Beta-Retinoic acid; Potassium Salt, Tretinoin; RETINOIC ACID, ALL TRANS; Renova (TN); Retin A (TN); Retisol-A; Ro 1-5488; Salt, Tretinoin Potassium; Salt, Tretinoin Sodium; Salt, Tretinoin Zinc; Sodium Salt, Tretinoin; Stieva-A; Stieva-a Forte; Trans-Retinoicacid; Tretinoin (TN); Tretinoina [INN-Spanish]; Tretinoine [INN-French]; Tretinoino [INN-Spanish]; Tretinoinum [INN-Latin]; Tri-Luma; Vesanoid (TN); Zinc Salt, Tretinoin; A-Acido (Argentina); Acid A Vit (Belgium, Netherlands); Acid, trans-Retinoic; Acide retinoique (French) (DSL); All-trans-Retinoic acid; All-trans-Tretinoin; All-trans-Vitamin A acid; All-trans-Vitamin A1 acid; PDT-002-002; Retin-A (TN); Stieva-A (TN); Tretinoin 01% cream or placebo; Tretinoin [USAN:INN:BAN]; Tretinoin/All-Trans Retinoic Acid; Tretinoine (French) (EINECS); Acid, all-trans-Retinoic; All-(E)-Retinoic acid; All-trans-b-Retinoic acid; All-trans-beta-Retinoic acid; Beta-all-trans-Retinoic acid; Tretinoin (JAN/USP/INN); Acid, beta-all-trans-Retinoic; Retinoic acid, all-trans-(8CI); Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin; 15-Apo-beta-caroten-15-oic acid; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; 9(Z)-Retinoic acid; 9-cis-RA; 9-trans-retinoic acid
DM49DUI CP Roche Pharmaceuticals
DM49DUI TC Keratolytic Agents
DM49DUI DT Small molecular drug
DM49DUI PC 444795
DM49DUI MW 300.4
DM49DUI FM C20H28O2
DM49DUI IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
DM49DUI CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DM49DUI IK SHGAZHPCJJPHSC-YCNIQYBTSA-N
DM49DUI IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DM49DUI CA CAS 302-79-4
DM49DUI CB CHEBI:15367
DM49DUI DE Acne vulgaris; Acute promyelocytic leukaemia
DMU54QB ID DMU54QB
DMU54QB DN Treximet
DMU54QB HS Approved
DMU54QB SN Trexima; Naproxen mixture with sumatriptan; Naproxen sodium mixture with sumatriptan succinate; Sumatriptan mixture with naproxen;Sumatriptan succinate and naproxen sodium; Sumatriptan succinate mixture with naproxen sodium; Naproxen / sumatriptan
DMU54QB CP GSK
DMU54QB DT Small molecular drug
DMU54QB PC 23709079
DMU54QB MW 665.7
DMU54QB FM C32H40N3NaO9S
DMU54QB IC InChI=1S/C14H21N3O2S.C14H14O3.C4H6O4.Na/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;5-3(6)1-2-4(7)8;/h4-5,8-9,15-16H,6-7,10H2,1-3H3;3-9H,1-2H3,(H,15,16);1-2H2,(H,5,6)(H,7,8);/q;;;+1/p-1/t;9-;;/m.0../s1
DMU54QB CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O.[Na+]
DMU54QB IK IGRAQVLKCQVBQA-DBQHITQZSA-M
DMU54QB IU sodium;butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DMU54QB CA CAS 811794-26-0
DMU54QB DE Migraine
DM0AEPG ID DM0AEPG
DM0AEPG DN Triacetin
DM0AEPG HS Approved
DM0AEPG SN triacetin; 102-76-1; Glyceryl triacetate; Glycerol triacetate; Enzactin; Glycerin triacetate; Triacetine; Triacetylglycerol; Fungacetin; Glyped; Triacetyl glycerine; Vanay; Kesscoflex TRA; Kodaflex triacetin; 1,2,3-Propanetriol, triacetate; Acetin, tri-; Triacetinum; Triacetina; 1,2,3-triacetoxypropane; 1,2,3-Propanetriol triacetate; propane-1,2,3-triyl triacetate; Triacetyl glycerin; Triacetyl glycerol; 1,2,3-Propanetriyl triacetate; Triacetin [INN]; 1,2,3-Triacetylglycerol; 1,2,3-Propanetriol, 1,2,3-triacetate; FEMA Number 2007
DM0AEPG DT Small molecular drug
DM0AEPG PC 5541
DM0AEPG MW 218.2
DM0AEPG FM C9H14O6
DM0AEPG IC InChI=1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
DM0AEPG CS CC(=O)OCC(COC(=O)C)OC(=O)C
DM0AEPG IK URAYPUMNDPQOKB-UHFFFAOYSA-N
DM0AEPG IU 2,3-diacetyloxypropyl acetate
DM0AEPG CA CAS 102-76-1
DM0AEPG CB CHEBI:9661
DM0AEPG DE Onychomycosis
DM98IXF ID DM98IXF
DM98IXF DN Triamcinolone
DM98IXF HS Approved
DM98IXF SN Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone
DM98IXF CP Aventis Pharmaceuticals Inc.
DM98IXF TC Antiinflammatory Agents
DM98IXF DT Small molecular drug
DM98IXF PC 31307
DM98IXF MW 394.4
DM98IXF FM C21H27FO6
DM98IXF IC InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
DM98IXF CS C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
DM98IXF IK GFNANZIMVAIWHM-OBYCQNJPSA-N
DM98IXF IU (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DM98IXF CA CAS 124-94-7
DM98IXF CB CHEBI:9667
DM98IXF DE Allergic rhinitis
DM7LRKD ID DM7LRKD
DM7LRKD DN Triamcinolone diacetate
DM7LRKD HS Approved
DM7LRKD SN Aristocort diacetate; Polcortolon; Tedarol; Aristocort Forte; Triamcinolone 16,21-diacetate; Orion; Aristocort Parenterals; Kenacort Diacetate Syrup; Aristocort diacetate forte; Aristocort Forte Parenteral; TRIAMCINOLONE DIACETATE; UNII-A73MM2Q32P; Kenacourt; Aristocort syrup; CHEBI:9669; 357RP; EINECS 200-669-0; Triamcinolone 16-alpha,21-di(acetate); A73MM2Q32P; 16alpha-Hydroxy-9alpha-fluoroprednisolone diacetate; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone diacetate; NCGC00159320-03; delta1,9alpha-Fluoro-16alpha-hydroxyhydrocortisone diacetate; delta11,16alpha-Hydroxy-9alpha-fluorohydrocortisone diacetate; 16alpha,21-Diacetoxy-9alpha-fluoro-11beta,17alpha-dihydroxy-1,4-pregnadiene-3,20-dione; 9-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,21-diacetate; DSSTox_CID_28639; DSSTox_RID_82909; DSSTox_GSID_48713; Pregna-1,4-diene-3,20-dione, 16,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-, (11beta,16alpha)-; Polcartolone; CAS-67-78-7; Triamcinolone diacetate [JAN]; Triamcinolone diacetate [USP:JAN]; SCHEMBL12549; 67-78-7
DM7LRKD PC 6216
DM7LRKD MW 478.5
DM7LRKD FM C25H31FO8
DM7LRKD IC XGMPVBXKDAHORN-RBWIMXSLSA-N
DM7LRKD CS CC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)OC(=O)C)O
DM7LRKD IK 1S/C25H31FO8/c1-13(27)33-12-20(31)25(32)21(34-14(2)28)10-18-17-6-5-15-9-16(29)7-8-22(15,3)24(17,26)19(30)11-23(18,25)4/h7-9,17-19,21,30,32H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22-,23-,24-,25+/m0/s1
DM7LRKD IU [2-[(8S,9R,10S,11S,13S,14S,16R,17S)-16-acetyloxy-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
DM7LRKD CA CAS 67-78-7
DM7LRKD CB CHEBI:9669
DM7LRKD DE Allergy
DM2HU9I ID DM2HU9I
DM2HU9I DN Triamterene
DM2HU9I HS Approved
DM2HU9I SN Ademin; Ademine; Amteren; Anjal; Dazid; Diarol; Dinazide; Diren; Ditak; Diucelpin; Diurene; Diutensat; Diuteren; Dyberzide; Dyren; Dyrenium; Dytac; Dytenzide; Esiteren; Hidiurese; Hydrene; Hypertorr; Isobar; Jatropur; Jenateren; Kalspare; Masuharmin; Nephral; Noridil; Noridyl; Pterofen; Pterophene; Renezide; Reviten; Taturil; Teriam; Teridin; Triamizide; Triampur; Triamteren; Triamterena; Triamterenum; Triamteril; Triamterine; Triamthiazid; Tricilone; Trispan; Triteren; Triurene; Trizid; Turfa; Uretren; Urocaudal; Goldshield Brand of Triamterene; Jorba Brand of Triamterene; Pter ophene; SmithKline Beecham Brand of Triamterene; TRIAMTERENE USP; Thiazid Wolff; Triamteril complex; Wellspring Brand of Triamterene; Fluss 40; SKF 8542; T 4143; Ademin(e); Apo-triazide; Dyrenium (TN); Pteridine deriv. 11; SALI-PUREN; SK&F 8542; SK-8542; Tri-Span; Triamterena [INN-Spanish]; Triamterenum [INN-Latin]; SK&F-8542; Triamterene (JP15/USP/INN); Triamterene [USAN:INN:BAN:JAN]; 2,4,7-Triamino-6-fenilpteridina; 2,4,7-Triamino-6-fenilpteridina [Italian]; 2,4,7-Triamino-6-phenylpteridine; 6-PHENYL-2,4,7-TRIAMINO PTERIDINE; 6-Phenyl-2,4,7-pteridinetriamine; 6-Phenyl-2,4,7-triaminopteridine; 6-phenylpteridine-2,4,7-triamine
DM2HU9I TC Diuretics
DM2HU9I DT Small molecular drug
DM2HU9I PC 5546
DM2HU9I MW 253.26
DM2HU9I FM C12H11N7
DM2HU9I IC InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
DM2HU9I CS C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
DM2HU9I IK FNYLWPVRPXGIIP-UHFFFAOYSA-N
DM2HU9I IU 6-phenylpteridine-2,4,7-triamine
DM2HU9I CA CAS 396-01-0
DM2HU9I CB CHEBI:9671
DM2HU9I DE Congestive heart failure; Edema; Hypertension
DMETYK5 ID DMETYK5
DMETYK5 DN Triazolam
DMETYK5 HS Approved
DMETYK5 SN Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMETYK5 CP Upjohn Corporation
DMETYK5 TC Hypnotics and Sedatives
DMETYK5 DT Small molecular drug
DMETYK5 PC 5556
DMETYK5 MW 343.2
DMETYK5 FM C17H12Cl2N4
DMETYK5 IC InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
DMETYK5 CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl
DMETYK5 IK JOFWLTCLBGQGBO-UHFFFAOYSA-N
DMETYK5 IU 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMETYK5 CA CAS 28911-01-5
DMETYK5 CB CHEBI:9674
DMETYK5 DE Insomnia
DMHAQCO ID DMHAQCO
DMHAQCO DN Trichlormethiazide
DMHAQCO HS Approved
DMHAQCO SN Achletin; Anistadin; Aponorin; Aquazide; Carvacron; Chlopolidine; Cretonin; Diurazida; Diurese; Diuroral;Esmarin; Eurinol; Fluitran; Flurese; Flutra; Gangesol; Hydrotrichlorothiazide; Intromene; Isestran; Kubacron; Metahydrin; Metatensin; Nakva; Naqua; Naquasone; Schebitran; Tachionin; Tolcasone; Trichlordiuride; Trichlorex; Trichlormas; Trichlormetazid; Trichlormethiazid; Trichlormethiazidum; Trichloromethiadiazide; Trichloromethiazide; Triclordiuride; Triclormetiazida; Triclormetiazide; Triflumen;American Urologicals Brand of Trichloromethiazide; Jones Brand of Trichloromethiazide; Schering Brand of Trichlormethiazide; Triclormetiazide [DCIT]; Triclormetiazide [Italian]; Achletin (TN); Ciba 7057-Su; Diu-Hydrin; Flurese (VAN); Naqua (TN); Salurin (wadel); Trichlormethiazide W/ Reserpine; Trichlormethiazide [INN:JAN]; Trichlormethiazidum [INN-Latin]; Trichloromethiazide, 6; Triclormetiazida[INN-Spanish]; Triflumen (TN); Diu-Hydrin (TN); Trichlormethiazide (JP15/USP/INN); (+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide; 3-Dichloromethylhydrochlorothiazide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide; 6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide; 6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide; 6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide
DMHAQCO CP Hoechst Marion Roussel
DMHAQCO TC Antihypertensive Agents
DMHAQCO DT Small molecular drug
DMHAQCO PC 5560
DMHAQCO MW 380.7
DMHAQCO FM C8H8Cl3N3O4S2
DMHAQCO IC InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
DMHAQCO CS C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl
DMHAQCO IK LMJSLTNSBFUCMU-UHFFFAOYSA-N
DMHAQCO IU 6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DMHAQCO CA CAS 133-67-5
DMHAQCO CB CHEBI:9683
DMHAQCO DE Hypertension
DMPWGBR ID DMPWGBR
DMPWGBR DN Triclabendazole
DMPWGBR HS Approved
DMPWGBR SN Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; C14H9Cl3N2OS; Triclabendazolum [INN-Latin]; Triclabendazol [INN-Spanish]; CCRIS 8988; UNII-4784C8E03O; CGA 89317; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; CPD000466357; MLS001424101; CHEMBL1086440; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; SMR000466357; AK-68238; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole
DMPWGBR DT Small molecular drug
DMPWGBR PC 50248
DMPWGBR MW 359.7
DMPWGBR FM C14H9Cl3N2OS
DMPWGBR IC InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
DMPWGBR CS CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl
DMPWGBR IK NQPDXQQQCQDHHW-UHFFFAOYSA-N
DMPWGBR IU 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
DMPWGBR CA CAS 68786-66-3
DMPWGBR CB CHEBI:94759
DMPWGBR DE Helminth infection
DMZUR4N ID DMZUR4N
DMZUR4N DN Triclosan
DMZUR4N HS Approved
DMZUR4N SN triclosan; 3380-34-5; 5-CHLORO-2-(2,4-DICHLOROPHENOXY)PHENOL; 2,4,4'-Trichloro-2'-hydroxydiphenyl ether; Irgasan; Cloxifenolum; Triclosanum; Irgasan DP300; Stri-Dex Face Wash; Phenol, 5-chloro-2-(2,4-dichlorophenoxy)-; Lexol 300; Stri-Dex Cleansing Bar; 5-Chloro-2-(2,4-dichloro-phenoxy)-phenol; Triclosanum [INN-Latin]; CH 3565; DP-300; Caswell No 186A; C12H7Cl3O2; UNII-4NM5039Y5X; HSDB 7194; CHEBI:164200; Ether, 2'-hydroxy-2,4,4'-trichlorodiphenyl; Phenyl ether, 2'-hydroxy-2,4,4'-trichloro-; EINECS 222-182-2; CHEMBL849; EPA; Aquasept; Cliniclean; Cloxifenol; Manusept; Sapoderm; TCL; Trisan; Clearasil DailyFace Wash; Dermtek Brand of Triclosan; GlaxoSmithKline Brand of Triclosan; Microshield T; Oxy Skin Wash; Pharmachem Brand of Triclosan; Reckitt Brand of Triclosan; SSL Brand of Triclosan; Ster Zac Bath Concentrate; SterZac Bath Concentrate; Trans Canaderm Brand of Triclosan; Triclosan Pharmachem Brand; Triclosan Reckitt Brand; IN1424; Irgasan DP 300; CH-3565; Johnson & Johnson Brand of Triclosan; Procter & Gamble Brand of Triclosan; Ster-Zac Bath Concentrate; Stri-Dex cleansing bar (TN); Triclosan (USP/INN); Triclosan [USAN:BAN:INN]; 2,4,4'-Trichloro-2'-hydroxy diphenyl ether; 2-Hydroxy-2',4,4'-trichlorodiphenyl Ether; WL-1001
DMZUR4N TC Antibiotics
DMZUR4N DT Small molecular drug
DMZUR4N PC 5564
DMZUR4N MW 289.5
DMZUR4N FM C12H7Cl3O2
DMZUR4N IC InChI=1S/C12H7Cl3O2/c13-7-1-3-11(9(15)5-7)17-12-4-2-8(14)6-10(12)16/h1-6,16H
DMZUR4N CS C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl
DMZUR4N IK XEFQLINVKFYRCS-UHFFFAOYSA-N
DMZUR4N IU 5-chloro-2-(2,4-dichlorophenoxy)phenol
DMZUR4N CA CAS 3380-34-5
DMZUR4N CB CHEBI:164200
DMZUR4N DE Trypanosomiasis; Infection of P. falciparum; Malaria
DMVLHNI ID DMVLHNI
DMVLHNI DN Tridihexethyl
DMVLHNI HS Approved
DMVLHNI SN Pathilon; Propethonum; (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium; 3-cyclohexyl-N,N,N-triethyl-3-hydroxy-3-phenylpropan-1-aminium
DMVLHNI TC Anticholinergic Agents
DMVLHNI DT Small molecular drug
DMVLHNI PC 20299
DMVLHNI MW 318.5
DMVLHNI FM C21H36NO+
DMVLHNI IC InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1
DMVLHNI CS CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O
DMVLHNI IK NPRHVSBSZMAEIN-UHFFFAOYSA-N
DMVLHNI IU (3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium
DMVLHNI CA CAS 60-49-1
DMVLHNI CB CHEBI:9701
DMVLHNI DE Acquired nystagmus
DMD2WPG ID DMD2WPG
DMD2WPG DN Trientine
DMD2WPG HS Approved
DMD2WPG SN Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride
DMD2WPG DT Small molecular drug
DMD2WPG PC 5565
DMD2WPG MW 146.23
DMD2WPG FM C6H18N4
DMD2WPG IC InChI=1S/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2
DMD2WPG CS C(CNCCNCCN)N
DMD2WPG IK VILCJCGEZXAXTO-UHFFFAOYSA-N
DMD2WPG IU N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine
DMD2WPG CA CAS 112-24-3
DMD2WPG CB CHEBI:39501
DMD2WPG DE Inborn error of metabolism
DMOL793 ID DMOL793
DMOL793 DN Trifarotene
DMOL793 HS Approved
DMOL793 SN Trifarotene; UNII-0J8RN2W0HK; 895542-09-3; CD5789; 0J8RN2W0HK; Trifarotene [USAN:INN]; CD 5789; SCHEMBL381493; GTPL9962; CHEMBL3707313; DTXSID30237781; EX-A2704; DB12808; compound 15b [PMID: 29706423]; 3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic acid; HY-100256; CS-0018407; 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid; [1,1':3',1''-Terphenyl]-4-carboxylic acid, 3''-(1,1-dimethylethyl)-4'-(2-hydroxyethoxy)-4''-(1-pyrrolidinyl)-
DMOL793 CP Galderma
DMOL793 DT Small molecular drug
DMOL793 PC 11518241
DMOL793 MW 459.6
DMOL793 FM C29H33NO4
DMOL793 IC InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
DMOL793 CS CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
DMOL793 IK MFBCDACCJCDGBA-UHFFFAOYSA-N
DMOL793 IU 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
DMOL793 CA CAS 895542-09-3
DMOL793 DE Acne vulgaris
DMKBYWI ID DMKBYWI
DMKBYWI DN Trifluoperazine
DMKBYWI HS Approved
DMKBYWI SN Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
DMKBYWI CP GlaxoSmithKline plc
DMKBYWI TC Antipsychotic Agents
DMKBYWI DT Small molecular drug
DMKBYWI PC 5566
DMKBYWI MW 407.5
DMKBYWI FM C21H24F3N3S
DMKBYWI IC InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
DMKBYWI CS CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
DMKBYWI IK ZEWQUBUPAILYHI-UHFFFAOYSA-N
DMKBYWI IU 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
DMKBYWI CA CAS 117-89-5
DMKBYWI CB CHEBI:45951
DMKBYWI DE Schizophrenia
DMKFQJP ID DMKFQJP
DMKFQJP DN Triflupromazine
DMKFQJP HS Approved
DMKFQJP SN Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN)
DMKFQJP CP Bristol-Myers Squibb
DMKFQJP TC Antipsychotic Agents
DMKFQJP DT Small molecular drug
DMKFQJP PC 5568
DMKFQJP MW 352.4
DMKFQJP FM C18H19F3N2S
DMKFQJP IC InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
DMKFQJP CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
DMKFQJP IK XSCGXQMFQXDFCW-UHFFFAOYSA-N
DMKFQJP IU N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
DMKFQJP CA CAS 146-54-3
DMKFQJP CB CHEBI:9711
DMKFQJP DE Psychotic disorder
DMG2YBD ID DMG2YBD
DMG2YBD DN Trifluridine
DMG2YBD HS Approved
DMG2YBD SN Fluridine; TFDU; TRIFLUOROTHYMIDINE; Trifluoridine; Trifluoromethyldeoxyuridine; Trifluridina; Trifluridinum; Virophta; Viroptic; Trifluorothymine deoxyriboside; CF3dUrd; F3DThd; F3T; F3TDR; HS-0007; Trifluridina [INN-Spanish]; Trifluridine [USAN:INN]; Trifluridinum [INN-Latin]; Viroptic (TN); Trifluridine (USP/INN);Viroptic, Trifluorothymidine, Trifluridine; Alpha,alpha,alpha-Trifluorothymidine; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione; 2'-Deoxy-5-(trifluoromethyl)uridine; 2'-Deoxy-5-trifluoromethyluridine; 5-(Trifluoromethyl)-2'-deoxyuridine; 5-(Trifluoromethyl)deoxyuridine; 5-Trifluoro-2'-deoxythymidine; 5-Trifluoromethyl-2'-deoxyuridine; 5-Trifluoromethyl-2-deoxyuridine; 5-Trifluorothymidine
DMG2YBD CP Monarch Pharmaceuticals
DMG2YBD TC Antiviral Agents
DMG2YBD DT Small molecular drug
DMG2YBD PC 6256
DMG2YBD MW 296.2
DMG2YBD FM C10H11F3N2O5
DMG2YBD IC InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
DMG2YBD CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
DMG2YBD IK VSQQQLOSPVPRAZ-RRKCRQDMSA-N
DMG2YBD IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
DMG2YBD CA CAS 70-00-8
DMG2YBD CB CHEBI:75179
DMG2YBD DE Virus infection
DMB19L8 ID DMB19L8
DMB19L8 DN Trihexyphenidyl
DMB19L8 HS Approved
DMB19L8 SN trihexyphenidyl; Benzhexol; Triphenidyl; Trihexyphenidyle; Parkinane retard; Benzhexolum; 144-11-6; Trihexyphenidylum; Sedrena (free base); Trihexifenidilo; Trihexyphenidyle [INN-French]; Trihexifenidilo [INN-Spanish]; Trihexyphenidylum [INN-Latin]; Artane; Trihexylphenizyl; Trihexylphenidyl; Trihexylphenidyle; Trihexyphenidyl [INN:BAN]; Trihexylphenedyl; HSDB 3196; EINECS 205-614-4; NSC 12268; 1-Piperidinepropanol, alpha-cyclohexyl-alpha-phenyl-; 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol; BRN 0088959; Benzhexol; Trihexane; Trihexy; Artane Sequels; PMS Trihexyphenidyl; Apo-Trihex; Artane (TN); Trihexyphenidyl (INN); Apo-Trihex (TN); Apo-trihex (TN); SWR-0342SA
DMB19L8 CP Lederle Laboratories Div American Cyanamid Co
DMB19L8 TC Antiparkinson Agents
DMB19L8 DT Small molecular drug
DMB19L8 PC 5572
DMB19L8 MW 301.5
DMB19L8 FM C20H31NO
DMB19L8 IC InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2
DMB19L8 CS C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
DMB19L8 IK HWHLPVGTWGOCJO-UHFFFAOYSA-N
DMB19L8 IU 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol
DMB19L8 CA CAS 144-11-6
DMB19L8 CB CHEBI:9720
DMB19L8 DE Dystonia; Parkinson disease; Obesity
DMP5A4T ID DMP5A4T
DMP5A4T DN Trilaciclib
DMP5A4T HS Approved
DMP5A4T SN G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
DMP5A4T CP G1 Therapeutics Research Triangle Park, NC
DMP5A4T PC 68029831
DMP5A4T MW 446.5
DMP5A4T FM C24H30N8O
DMP5A4T IC InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
DMP5A4T CS CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
DMP5A4T IK PDGKHKMBHVFCMG-UHFFFAOYSA-N
DMP5A4T IU 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DMP5A4T CA CAS 1374743-00-6
DMP5A4T DE Triple negative breast cancer; Small-cell lung cancer
DMQZ9GF ID DMQZ9GF
DMQZ9GF DN Trilostane
DMQZ9GF HS Approved
DMQZ9GF SN Desopan; Desopan (TN); Modrenal (TN); Vetoryl (TN); Vetoryl, Trilostane; Win-24540; Trilostane (JAN/USAN); (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile; 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile
DMQZ9GF CP Dechra Pharmaceuticals
DMQZ9GF DT Small molecular drug
DMQZ9GF PC 656583
DMQZ9GF MW 329.4
DMQZ9GF FM C20H27NO3
DMQZ9GF IC InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
DMQZ9GF CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C
DMQZ9GF IK KVJXBPDAXMEYOA-CXANFOAXSA-N
DMQZ9GF IU (1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
DMQZ9GF CA CAS 13647-35-3
DMQZ9GF CB CHEBI:32260
DMQZ9GF DE Cushing disease
DM1QLST ID DM1QLST
DM1QLST DN Trimazosin
DM1QLST HS Approved
DM1QLST SN Trimazosin hydrochloride; Trimazosin HCl; 53746-46-6; UNII-827T79ILE7; Trimazosin hydrochloride [USAN]; 827T79ILE7; Trimazosin hydrochloride monohydrate; Trimazosin hydrochloride (USAN); 35795-16-5 (Parent); Cardovar; Supres; Trimazosin hydrochlorid-1-wasser; AC1Q3ECH; CP 19106-1; AC1L21UN; SCHEMBL10363255; CHEMBL3989848; DTXSID40202021; Trimazosin monohydrochloride monohydrate; 2-Hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylate monohydrochloride monohydrate; 1-Piperazinecarboxylic aci
DM1QLST DT Small molecular drug
DM1QLST PC 37264
DM1QLST MW 435.5
DM1QLST FM C20H29N5O6
DM1QLST IC InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)
DM1QLST CS CC(C)(COC(=O)N1CCN(CC1)C2=NC3=C(C(=C(C=C3C(=N2)N)OC)OC)OC)O
DM1QLST IK YNZXWQJZEDLQEG-UHFFFAOYSA-N
DM1QLST IU (2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
DM1QLST CA CAS 35795-16-5
DM1QLST CB CHEBI:135710
DM1QLST DE Congestive heart failure
DMPYQ7B ID DMPYQ7B
DMPYQ7B DN Trimebutine
DMPYQ7B HS Approved
DMPYQ7B SN Trimebutine maleate; Trimedat; Dromostat; Ibutin; Digerent polifarma; EINECS 251-845-9; TM 906; (1-Ethyl-1-phenyl-2-(3,4,5-trimethoxybenzoyloxy)ethyl)dimethylammonium hydrogen maleate; AC1O5HFA; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethylphenethyl ester, maleate (1:1); 34140-59-5; SCHEMBL1652810; C22H29NO5.C4H4O4; AKOS026750056; LS-38470; dimethyl-[2-phenyl-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azanium; (E)-4-hydroxy-4-oxobut-2-enoate; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethyl
DMPYQ7B DT Small molecular drug
DMPYQ7B PC 5573
DMPYQ7B MW 387.5
DMPYQ7B FM C22H29NO5
DMPYQ7B IC InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
DMPYQ7B CS CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
DMPYQ7B IK LORDFXWUHHSAQU-UHFFFAOYSA-N
DMPYQ7B IU [2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
DMPYQ7B CA CAS 58997-89-0
DMPYQ7B CB CHEBI:94458
DMPYQ7B DE Irritable bowel syndrome
DMEMV9D ID DMEMV9D
DMEMV9D DN Trimeprazine
DMEMV9D HS Approved
DMEMV9D SN Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine
DMEMV9D CP Allergan Herbert Skin Care Div Allergan Inc
DMEMV9D TC Antihistamines
DMEMV9D DT Small molecular drug
DMEMV9D PC 5574
DMEMV9D MW 298.4
DMEMV9D FM C18H22N2S
DMEMV9D IC InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
DMEMV9D CS CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C
DMEMV9D IK ZZHLYYDVIOPZBE-UHFFFAOYSA-N
DMEMV9D IU N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine
DMEMV9D CA CAS 84-96-8
DMEMV9D CB CHEBI:9725
DMEMV9D DE Allergic rhinitis
DM0Q8MZ ID DM0Q8MZ
DM0Q8MZ DN Trimethadione
DM0Q8MZ HS Approved
DM0Q8MZ SN Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
DM0Q8MZ TC Anticonvulsants
DM0Q8MZ DT Small molecular drug
DM0Q8MZ PC 5576
DM0Q8MZ MW 143.14
DM0Q8MZ FM C6H9NO3
DM0Q8MZ IC InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
DM0Q8MZ CS CC1(C(=O)N(C(=O)O1)C)C
DM0Q8MZ IK IRYJRGCIQBGHIV-UHFFFAOYSA-N
DM0Q8MZ IU 3,5,5-trimethyl-1,3-oxazolidine-2,4-dione
DM0Q8MZ CA CAS 127-48-0
DM0Q8MZ CB CHEBI:9727
DM0Q8MZ DE Pancreatic cancer; Epilepsy
DMHF4IQ ID DMHF4IQ
DMHF4IQ DN Trimethaphan
DMHF4IQ HS Approved
DMHF4IQ SN Thimethaphan; Trimetaphan; Trimetaphanum; Arfonad (TN); Thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium, decahydro-2-oxo-1,3-bis(phenylmethyl)-(VAN); 1,3-dibenzyl-2-oxodecahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium
DMHF4IQ CP Hoffmann La Roche Inc
DMHF4IQ TC Antihypertensive Agents
DMHF4IQ DT Small molecular drug
DMHF4IQ PC 23576
DMHF4IQ MW 365.5
DMHF4IQ FM C22H25N2OS+
DMHF4IQ IC InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1
DMHF4IQ CS C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5
DMHF4IQ IK CHQOEHPMXSHGCL-UHFFFAOYSA-N
DMHF4IQ IU 3,5-dibenzyl-8-thionia-3,5-diazatricyclo[6.3.0.02,6]undecan-4-one
DMHF4IQ CA CAS 7187-66-8
DMHF4IQ CB CHEBI:9728
DMHF4IQ DE Aneurysm; Hypertensive emergency
DMM7CHK ID DMM7CHK
DMM7CHK DN Trimethoprim
DMM7CHK HS Approved
DMM7CHK SN Abaprim; Alprim; Anitrim; Antrima; Antrimox; Bacdan; Bacidal; Bacide; Bacin; Bacta; Bacterial; Bacticel; Bactin; Bactoprim; Bactramin; Bencole; Bethaprim; Biosulten; Briscotrim; Chemotrin; Cidal; Colizole; Conprim; Cotrimel; Deprim; Duocide; Esbesul; Espectrin; Euctrim; Exbesul; Fermagex; Fortrim; Futin; Idotrim; Ikaprim; Instalac; Kombinax; Lagatrim; Lastrim; Methoprim; Metoprim; Monoprim; Monotrim; Monotrimin; Novotrimel; Omstat; Oraprim; Pancidim; Polytrim; Priloprim; Primosept; Primsol; Proloprim; Protrin; Purbal; Resprim; Roubac; Roubal; Salvatrim; Setprin; Sinotrim; Stopan; Streptoplus; Sugaprim; Sulfamar; Sulfamethoprim; Sulfoxaprim; Sulmeprim; Sulthrim; Sultrex; Syraprim; Tiempe; Toprim; Trimanyl; Trimethioprim; Trimethoprime; Trimethoprimum; Trimethopriom; Trimetoprim; Trimetoprima; Trimexazole; Trimexol; Trimezol; Trimogal; Trimono; Trimopan; Trimpex; Triprim; Trisul; Trisulcom; Trisulfam; Trisural; Uretrim; Urobactrim; Utetrin; Velaten; Wellcoprim; Wellcoprin; Xeroprim; Zamboprim; Bacterial [Antibiotic]; Colizole DS; Component of Bactrim; Component of Septra; Lagatrim Forte; ResprimForte; Septrin DS; Septrin Forte; Septrin S; Trimetoprim [DCIT]; Trimetoprim [Polish]; BW 5672; KUC103659N; NIH 204; T 7883; Trimpex 200; WR 5949; Alcorim-F; Apo-Sulfatrim; BW 56-72; Co-Trimoxizole; Monotrim (TN); NIH 204 (VAN); Proloprim (TN); Smz-Tmp; Sulfamethoxazole & Trimethoprim; TCMDC-125538; Tmp-Ratiopharm; Trimeth/Sulfa; Trimethopim(TMP); Trimethoprim & VRC3375; Trimethoprime [INN-French]; Trimethoprimum [INN-Latin]; Trimetoprima [INN-Spanish]; Trimez-IFSA; Trimpex (TN); Triprim (TN); U-Prin; Uro-D S; BW-56-72; KSC-4-158; AZT + TMP/SMX (mixture) combination; Trimethoprim (JAN/USP/INN); Trimethoprim [USAN:BAN:INN:JAN]
DMM7CHK CP GlaxoSmithKline
DMM7CHK TC Antiinfective Agents
DMM7CHK DT Small molecular drug
DMM7CHK PC 5578
DMM7CHK MW 290.32
DMM7CHK FM C14H18N4O3
DMM7CHK IC InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
DMM7CHK CS COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
DMM7CHK IK IEDVJHCEMCRBQM-UHFFFAOYSA-N
DMM7CHK IU 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMM7CHK CA CAS 738-70-5
DMM7CHK CB CHEBI:45924
DMM7CHK DE Urinary tract infection
DMDEA85 ID DMDEA85
DMDEA85 DN Trimetrexate
DMDEA85 HS Approved
DMDEA85 SN TMQ; Trimetrexato; Trimetrexatum; JB 11; Jb-11; Trimetrexato [INN-Spanish]; Trimetrexatum [INN-Latin]; Trimetrexate (USAN/INN); Trimetrexate [USAN:BAN:INN]; 2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline; 5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine; 5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine; 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine
DMDEA85 CP Medimmune Oncology Inc
DMDEA85 TC Antifungal Agents
DMDEA85 DT Small molecular drug
DMDEA85 PC 5583
DMDEA85 MW 369.4
DMDEA85 FM C19H23N5O3
DMDEA85 IC InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)
DMDEA85 CS CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC
DMDEA85 IK NOYPYLRCIDNJJB-UHFFFAOYSA-N
DMDEA85 IU 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine
DMDEA85 CA CAS 52128-35-5
DMDEA85 CB CHEBI:9737
DMDEA85 DE Toxoplasmosis
DM1SC8M ID DM1SC8M
DM1SC8M DN Trimipramine
DM1SC8M HS Approved
DM1SC8M SN Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP
DM1SC8M CP Odyssey Pharmaceuticals Inc
DM1SC8M TC Antidepressants
DM1SC8M DT Small molecular drug
DM1SC8M PC 5584
DM1SC8M MW 294.4
DM1SC8M FM C20H26N2
DM1SC8M IC InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
DM1SC8M CS CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
DM1SC8M IK ZSCDBOWYZJWBIY-UHFFFAOYSA-N
DM1SC8M IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
DM1SC8M CA CAS 3564-75-8
DM1SC8M CB CHEBI:9738
DM1SC8M DE Major depressive disorder
DMZBU15 ID DMZBU15
DMZBU15 DN Tripelennamine
DMZBU15 HS Approved
DMZBU15 SN Benzoxale; Cizaron; Dehistin; Piribenzil; Pyribenzamin; Pyribenzamine; Pyridbenzamine; Resistamine; Tonaril; Tripelannamine; Tripelenamina; Tripelenamine; Tripelennamin; Tripelennamina; Tripelennaminum; Tripellenamine; Triplennamine; Vetibenzamina; Pyrinamine base; Tripelennamina [Italian]; Tripelennamine [BAN]; Tripelennamine [INN]; Ts and Blues; Pyribenzamine (TN); Pyristine (piristina); Tripelenamina [INN-Spanish]; Tripelennamine (INN); Tripelennaminum [INN-Latin]; Tripelennamine Citrate (1:1); Beta-Dimethylaminoethyl-2-pyridylaminotoluene; Beta-Dimethylaminoethyl-2-pyridylbenzylamine; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(alpha.-pyridyl)-dimethylaethylendiamin; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha.-pyridyl)ethylenediamine; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-(9CI); 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine
DMZBU15 CP Norvatis Phamaceuticals Corporation
DMZBU15 TC Antiallergic Agents
DMZBU15 DT Small molecular drug
DMZBU15 PC 5587
DMZBU15 MW 255.36
DMZBU15 FM C16H21N3
DMZBU15 IC InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
DMZBU15 CS CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
DMZBU15 IK UFLGIAIHIAPJJC-UHFFFAOYSA-N
DMZBU15 IU N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
DMZBU15 CA CAS 91-81-6
DMZBU15 CB CHEBI:9741
DMZBU15 DE Hypersensitivity
DM7SWIA ID DM7SWIA
DM7SWIA DN Triprolidine
DM7SWIA HS Approved
DM7SWIA SN Actidil; Actidilat; Entra; Histafed; Myidyl; Tripolidina; Triprolidin; Triprolidinum; Venen; Triprolidine HCL; Triprolidine Monohydrochloride; Triprolidine hydrochloride; Triprolidine hydrochloride anhydrous; T 6764; Actidil (TN); Myidil (TN); Pro-Actidil; Pro-Entra; Tripolidina [INN-Spanish]; Triprolidine (INN); Triprolidine Hydrochloride (anhydrous); Triprolidine Monohydrochloride, Monohydrate; Triprolidine [INN:BAN]; Triprolidinum [INN-Latin]; Venen (TN); Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine; Trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine monohydrochloride; Trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene; Trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene; Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, monohydrochloride, monohydrate, stereoisomer; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)-, monohydrochloride; Pyridine, 2-((1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl)-, hydrochloride (1:1); (E)-2-(1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl)pyridine; (E)-2-[3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]pyridine hydrochloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ium-1-ylprop-1-enyl]pyridine chloride; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine; 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine hydrochloride
DM7SWIA TC Antiallergic Agents
DM7SWIA DT Small molecular drug
DM7SWIA PC 5282443
DM7SWIA MW 278.4
DM7SWIA FM C19H22N2
DM7SWIA IC InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
DM7SWIA CS CC1=CC=C(C=C1)/C(=C\\CN2CCCC2)/C3=CC=CC=N3
DM7SWIA IK CBEQULMOCCWAQT-WOJGMQOQSA-N
DM7SWIA IU 2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine
DM7SWIA CA CAS 486-12-4
DM7SWIA CB CHEBI:84116
DM7SWIA DE Hay fever
DMTK4LS ID DMTK4LS
DMTK4LS DN Triptorelin
DMTK4LS HS Approved
DMTK4LS SN Gonapeptyl depot (TN)
DMTK4LS CP Tulane University
DMTK4LS DT Small molecular drug
DMTK4LS PC 25074470
DMTK4LS MW 1311.4
DMTK4LS FM C64H82N18O13
DMTK4LS IC InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1
DMTK4LS CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
DMTK4LS IK VXKHXGOKWPXYNA-PGBVPBMZSA-N
DMTK4LS IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMTK4LS CA CAS 57773-63-4
DMTK4LS CB CHEBI:63633
DMTK4LS DE Solid tumour/cancer; Prostate cancer
DMHB2C3 ID DMHB2C3
DMHB2C3 DN Trofosfamide
DMHB2C3 HS Approved
DMHB2C3 SN Trofosfamide; Trophosphamide; Ixoten; 22089-22-1; Trofosfamid; Triphosphamide; Trilofosfamida; Trifosfamide; Trisfosfamide; Trilophosphamide; Trofosfamidum; Z 4828; Trofosfamide [INN]; ASTA Z 4828; Trofosfamida [Spanish]; A-4828; Trofosfamidum [INN-Latin]; NSC 109723; Trofosfamido [INN-Spanish]; MLS002704177; CCRIS 4442; Z-4828; EINECS 244-770-8; Trofosfamide (INN); BRN 0532530; N,N,3-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; N,N-3'-Tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide
DMHB2C3 DT Small molecular drug
DMHB2C3 PC 65702
DMHB2C3 MW 323.6
DMHB2C3 FM C9H18Cl3N2O2P
DMHB2C3 IC InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
DMHB2C3 CS C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
DMHB2C3 IK UMKFEPPTGMDVMI-UHFFFAOYSA-N
DMHB2C3 IU N,N,3-tris(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
DMHB2C3 CA CAS 22089-22-1
DMHB2C3 CB CHEBI:135381
DMHB2C3 DE Non-hodgkin lymphoma
DM3VFPD ID DM3VFPD
DM3VFPD DN Troglitazone
DM3VFPD HS Approved
DM3VFPD SN Noscal; Prelay; Resulin; Rezulin; Romglizone; Romozin; Troglitazona; Troglitazonum; Parke Davis brand of troglitazone; CS 045; GR 92132X; CS-045; GR-92132X; Resulin (TN); Rezulin (TN); Romozin (TN); Warner-Lambert brand of troglitazone; Troglitazone [USAN:BAN:INN]; Troglitazone (JAN/USAN/INN); (+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione; (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-(9CI); 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione); 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; 5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
DM3VFPD CP Daiichi Sankyo Pharma Development
DM3VFPD TC Antiinflammatory Agents
DM3VFPD DT Small molecular drug
DM3VFPD PC 5591
DM3VFPD MW 441.5
DM3VFPD FM C24H27NO5S
DM3VFPD IC InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)
DM3VFPD CS CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
DM3VFPD IK GXPHKUHSUJUWKP-UHFFFAOYSA-N
DM3VFPD IU 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM3VFPD CA CAS 97322-87-7
DM3VFPD CB CHEBI:9753
DM3VFPD DE Diabetic complication
DMUZNIG ID DMUZNIG
DMUZNIG DN Troleandomycin
DMUZNIG HS Approved
DMUZNIG SN Aovine; Cyclamycin; Evramicina; Matromicina; Oleandocetin; Oleandocetine; TAO; Treolmicina; Triacetyloleandomycin; Triacetyloleandomycinum; Tribiocillina; Triocetin; Triolan; Troleandomicina; Troleandomycine; Troleandomycinum; Viamicina; Wytrion; Matromycin T; Oleandomycin triacetate; Oleandomycin triacetyl ester; Triacetyl ester of oleandomycin; WY 651; Tao (TN); Tao (VAN); Tekmisin (TN); Treis-Micina; Triacetyloleandomycin (JAN); Triocetin (TN); Troleandomicina [INN-Spanish]; Troleandomycin (TAO); Troleandomycin [USAN:INN]; Troleandomycine [INN-French]; Troleandomycinum [INN-Latin]; Oleandomycin, triacetate (ester); T.A.O; Troleandomycin (USP/INN); T.A.O.
DMUZNIG CP Bayer Pharmaceuticals Corporation
DMUZNIG TC Antibiotics
DMUZNIG DT Small molecular drug
DMUZNIG PC 202225
DMUZNIG MW 814
DMUZNIG FM C41H67NO15
DMUZNIG IC InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1
DMUZNIG CS C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C
DMUZNIG IK LQCLVBQBTUVCEQ-QTFUVMRISA-N
DMUZNIG IU [(3R,5S,6S,7R,8S,9R,12R,13S,14S,15R)-6-[(2S,3R,4S,6R)-3-acetyloxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-8-[(2R,4S,5S,6S)-5-acetyloxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-10,16-dioxo-1,11-dioxaspiro[2.13]hexadecan-14-yl] acetate
DMUZNIG CA CAS 2751-09-9
DMUZNIG CB CHEBI:45735
DMUZNIG DE Bacterial infection
DMOBLGK ID DMOBLGK
DMOBLGK DN Tromethamine
DMOBLGK HS Approved
DMOBLGK SN Trometamol; 77-86-1; TROMETHAMINE; Tris; Tris(Hydroxymethyl)aminomethane; Tham; Trisamine; 2-Amino-2-(hydroxymethyl)-1,3-propanediol; Trizma; Tris buffer; Tris base; Tromethane; Trisaminol; Talatrol; Trispuffer; Trisamin; Pehanorm; Tutofusin tris; Tris-steril; Apiroserum Tham; Addex-tham; Tris-base; Tris, free base; Trimethylolaminomethane; 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-; Tris Amino; Aminotrimethylolmethane; Aminotris(hydroxymethyl)methane; THAM-E; Tris (buffering agent); Tris(Hydroxymethyl)Aminomethane
DMOBLGK DT Small molecular drug
DMOBLGK PC 6503
DMOBLGK MW 121.14
DMOBLGK FM C4H11NO3
DMOBLGK IC InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
DMOBLGK CS C(C(CO)(CO)N)O
DMOBLGK IK LENZDBCJOHFCAS-UHFFFAOYSA-N
DMOBLGK IU 2-amino-2-(hydroxymethyl)propane-1,3-diol
DMOBLGK CA CAS 77-86-1
DMOBLGK CB CHEBI:9754
DMOBLGK DE Acidosis
DM1D90W ID DM1D90W
DM1D90W DN Tropicamide
DM1D90W HS Approved
DM1D90W SN Bistropamide; Epitromina; Mydral; Mydriacyl; Mydriafair; Mydriaticum; Mydrum; OcuTropic; Opticyl; Paremyd; Tropicacyl; Tropicamida; Tropicamidum; Tropikamid; Tropimil; Visumidriatic; Akorn Brand of Tropicamide; Alcon Brand of Tropicamide; Bournonville Brand of Tropicamide; Cahill May Roberts Brand of Tropicamide; Chauvin Brand of Tropicamide; Colircusi Tropicamida; Medical Ophthalmics Brand of Tropicamide; Minims tropicamide; Novartis Brand of Tropicamide; Ocu Tropic; Ocumed Brand of Tropicamide; Ocusoft Brand of Tropicamide; Pharmafair Brand of Tropicamide; Rivex Brand of Tropicamide; Triaminic DM; Tropicamide Alcon Brand; Tropicamide Chauvin Brand; Tropicamide Faure; Tropicamide Minims; Tropicamide Monofree; Tropicamide Novartis Brand; Tropicamide Ocumed Brand; Tropicamide Pharmafair Brand; Tropicamide Rivex Brand; Stulln Brand 1 of Tropicamide; Stulln Brand 2 of Tropicamide; T 9778; I-Picamide; Mydriacyl (TN); Ocu-Tropic; Ro 1-7683; Spectro-Cyl; Tropicamida [INN-Spanish]; Tropicamidum [INN-Latin]; Tropicamide [USAN:INN:BANJAN]; Tropicamide (JP15/USP/INN); Tropicamide Monohydrochloride, (R)-Isomer; Tropicamide Monohydrochloride, (S)-Isomer; Tropicamide, (R)-Isomer; Tropicamide, (S)-Isomer; N-Ethyl-N-(4-pyridylmethyl)tropamid; N-Ethyl-N-(4-pyridylmethyl)tropamide; N-ethyl-n-(g-picolyl)tropamide; Tropicamide, (+-)-Isomer; N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide; N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide; N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide; N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide; (+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide
DM1D90W CP Alcon Laboratories Inc
DM1D90W TC Diagnostic Agents
DM1D90W DT Small molecular drug
DM1D90W PC 5593
DM1D90W MW 284.35
DM1D90W FM C17H20N2O2
DM1D90W IC InChI=1S/C17H20N2O2/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15/h3-11,16,20H,2,12-13H2,1H3
DM1D90W CS CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2
DM1D90W IK BGDKAVGWHJFAGW-UHFFFAOYSA-N
DM1D90W IU N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide
DM1D90W CA CAS 1508-75-4
DM1D90W CB CHEBI:9757
DM1D90W DE Mydriasis
DMNSJ7V ID DMNSJ7V
DMNSJ7V DN Tropisetron
DMNSJ7V HS Approved
DMNSJ7V SN Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate
DMNSJ7V CP Novartis International AG
DMNSJ7V DT Small molecular drug
DMNSJ7V PC 656665
DMNSJ7V MW 284.35
DMNSJ7V FM C17H20N2O2
DMNSJ7V IC InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?
DMNSJ7V CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
DMNSJ7V IK ZNRGQMMCGHDTEI-FUNVUKJBSA-N
DMNSJ7V IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate
DMNSJ7V CA CAS 89565-68-4
DMNSJ7V CB CHEBI:32269
DMNSJ7V DE Fibromyalgia
DMX6RTG ID DMX6RTG
DMX6RTG DN Trospium
DMX6RTG HS Approved
DMX6RTG SN Spasmex; Spasmoplex; Trosec; Regurin (TN); Sanctura (TN); Spasmex (TN); Spasmoplex (TN); Trosec (TN); Trospium chloride (JAN/USAN/INN); Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-hydroxy-, chloride, benzilate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate; Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate chloride; 3-Hydroxyspiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium) chloride benzilate; 6,10-Ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate; 8-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
DMX6RTG CP Allergan Pharmaceuticals
DMX6RTG TC Parasympatholytics
DMX6RTG DT Small molecular drug
DMX6RTG PC 5284632
DMX6RTG MW 392.5
DMX6RTG FM C25H30NO3+
DMX6RTG IC InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23?
DMX6RTG CS C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O
DMX6RTG IK OYYDSUSKLWTMMQ-AIZNXBIQSA-N
DMX6RTG IU [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate
DMX6RTG CA CAS 47608-32-2
DMX6RTG CB CHEBI:145791
DMX6RTG DE Spasm; Overactive bladder
DM32XZT ID DM32XZT
DM32XZT DN Trospium chloride
DM32XZT HS Approved
DM32XZT SN Regurin; Sanctura
DM32XZT TC Respiratory Agents
DM32XZT DT Small molecular drug
DM32XZT PC 5284631
DM32XZT MW 428
DM32XZT FM C25H30ClNO3
DM32XZT IC InChI=1S/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22+,23?;
DM32XZT CS C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-]
DM32XZT IK RVCSYOQWLPPAOA-DHWZJIOFSA-M
DM32XZT IU [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride
DM32XZT CA CAS 10405-02-4
DM32XZT CB CHEBI:32270
DM32XZT DE Discovery agent
DM6AN32 ID DM6AN32
DM6AN32 DN Trovafloxacin
DM6AN32 HS Approved
DM6AN32 SN TVFX; Trovan; Fluorinated quinolone; Trovafloxacin [INN]; CP 99219; CP99219; CP 99,219; CP-99219;Trovafloxacin (INN); Trovan (TN); Trovan (oral); Turvel (TN); CP-99,219; (1alpha,5alpha,6alpha)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-((1R,5S)-6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 7-[(1R,5S,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 7-[(1r,5s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DM6AN32 CP Pfizer Pharmaceuticals
DM6AN32 TC Antiinfective Agents
DM6AN32 DT Small molecular drug
DM6AN32 PC 62959
DM6AN32 MW 416.4
DM6AN32 FM C20H15F3N4O3
DM6AN32 IC InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
DM6AN32 CS C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
DM6AN32 IK WVPSKSLAZQPAKQ-SOSAQKQKSA-N
DM6AN32 IU 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DM6AN32 CA CAS 147059-72-1
DM6AN32 CB CHEBI:9763
DM6AN32 DE Bacterial infection
DMDHCK9 ID DMDHCK9
DMDHCK9 DN Trumenba
DMDHCK9 HS Approved
DMDHCK9 SN Meningococcal Group B Vaccine
DMDHCK9 CP Wyeth; pfizer
DMDHCK9 DT Vaccine
DMDHCK9 DE Meningitis
DM4NTMO ID DM4NTMO
DM4NTMO DN TRYPAN BLUE
DM4NTMO HS Approved
DM4NTMO SN AC1O6WJ7; tetrasodium (3E)-5-amino-3-[[4-[4-[(2Z)-2-(8-amino-1-oxo-3,6-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-4-oxonaphthalene-2,7-disulfonate; 3,3',3,3'-[(3,3'-Dimethylbiphenyl-4,4'-diyl)bis(iminonitrilo)]bis(3,4-dihydro-4-oxo-5-amino-2,7-naphthalenedisulfonic acid disodium) salt
DM4NTMO DT Small molecular drug
DM4NTMO PC 6296
DM4NTMO MW 960.8
DM4NTMO FM C34H24N6Na4O14S4
DM4NTMO IC InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4
DM4NTMO CS CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])N)O)C)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])N)O.[Na+].[Na+].[Na+].[Na+]
DM4NTMO IK GLNADSQYFUSGOU-UHFFFAOYSA-J
DM4NTMO IU tetrasodium;5-amino-3-[[4-[4-[(8-amino-1-hydroxy-3,6-disulfonatonaphthalen-2-yl)diazenyl]-3-methylphenyl]-2-methylphenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonate
DM4NTMO CA CAS 72-57-1
DM4NTMO CB CHEBI:78897
DM4NTMO DE Ophthalmic surgery injury
DMBZIVP ID DMBZIVP
DMBZIVP DN Tubocurarine
DMBZIVP HS Approved
DMBZIVP SN Amelizol; Delacurarine; Jexin; Tubadil; Tubaine; Tubarine; Tubocurarin; Tubocurarinum; Chlorure de tubocurarine; Cloruro de tubocurarina; Dextrotubocurarine chloride; Intocostrine T; Isoquinoline alkaloid; Tubocurarina cloruro; Tubocurarina cloruro [DCIT]; Tubocurarine chloride; Tubocurarine hydrochloride; Tubocurarini chloridum; Chlorure de tubocurarine [INN-French]; Cloruro de tubocurarina [INN-Spanish]; Curarin-haf; D-Paracurarine chloride; D-Tubocurarine; D-Tubocurarine chloride; D-Tubocurarine dichloride; D-Tubocurarine hydrochloride; Delacurarine (TN); Jex (TN); Metubine (TN); Tubaine (TN); Tubarine (TN); Tubocurarine chloride (INN); Tubocurarine chloride (TN); Tubocurarine chloride (anhydrous); Tubocurarini chloridum [INN-Latin]; Tubocurarinum (TN); D-(+)-Tubocurarine chloride; Tubocurarine, chloride, hydrochloride, (+)-(8CI); D-7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium chloride; Tubocuraranium, 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyl-, chloride, hydrochloride; (+)-Tubocurarine; (+)-Tubocurarine chloride; (+)-Tubocurarine chloride hydrochloride; 2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride; 7',12'-Dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium; 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraran-2'-ium
DMBZIVP TC Neuromuscular Nondepolarizing Agents
DMBZIVP DT Small molecular drug
DMBZIVP PC 6000
DMBZIVP MW 609.7
DMBZIVP FM C37H41N2O6+
DMBZIVP IC InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
DMBZIVP CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC
DMBZIVP IK JFJZZMVDLULRGK-URLMMPGGSA-O
DMBZIVP IU (1S,16R)-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-30-aza-15-azoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol
DMBZIVP CA CAS 57-95-4
DMBZIVP CB CHEBI:9774
DMBZIVP DE Anaesthesia; Smoking dependence
DMBESUA ID DMBESUA
DMBESUA DN Tucatinib
DMBESUA HS Approved
DMBESUA SN Irbinitinib; 937263-43-9; ONT-380; UNII-234248D0HH; 234248D0HH; N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-; ONT 380; 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; Tucatinib [USAN:INN]; 6-DIAMINE
DMBESUA CP Seattle Genetics Bothell, WA
DMBESUA PC 51039094
DMBESUA MW 480.5
DMBESUA FM C26H24N8O2
DMBESUA IC InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
DMBESUA CS CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5
DMBESUA IK SDEAXTCZPQIFQM-UHFFFAOYSA-N
DMBESUA IU 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
DMBESUA CA CAS 937263-43-9
DMBESUA DE Gastric adenocarcinoma; HER2-positive breast cancer
DM749I3 ID DM749I3
DM749I3 DN Ubrogepant
DM749I3 HS Approved
DM749I3 SN 1374248-77-7; UNII-AD0O8X2QJR; MK-1602; AD0O8X2QJR; Ubrogepant [USAN:INN]; Ubrogepant (USAN/INN); SCHEMBL3698428; CHEMBL2364638; GTPL10176; DTXSID00160178; DDOOFTLHJSMHLN-ZQHRPCGSSA-N; MK1602; ZINC95598454; SB19741; HY-12366; CS-0011109; D10673; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DM749I3 CP Merck
DM749I3 DT Small molecular drug
DM749I3 PC 68748835
DM749I3 MW 549.5
DM749I3 FM C29H26F3N5O3
DM749I3 IC InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
DM749I3 CS C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
DM749I3 IK DDOOFTLHJSMHLN-ZQHRPCGSSA-N
DM749I3 IU (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DM749I3 CA CAS 1374248-77-7
DM749I3 DE Migraine
DM1IQRP ID DM1IQRP
DM1IQRP DN Udenafil
DM1IQRP HS Approved
DM1IQRP SN Zydena; DA 8159; DA-8159; Zydena (TN); 3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide; 5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one
DM1IQRP CP Dong-A Pharmaceutical
DM1IQRP TC Vasodilator Agents
DM1IQRP DT Small molecular drug
DM1IQRP PC 135413547
DM1IQRP MW 516.7
DM1IQRP FM C25H36N6O4S
DM1IQRP IC InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
DM1IQRP CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
DM1IQRP IK IYFNEFQTYQPVOC-UHFFFAOYSA-N
DM1IQRP IU 3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
DM1IQRP CA CAS 268203-93-6
DM1IQRP CB CHEBI:135926
DM1IQRP DE Erectile dysfunction
DMX3O0D ID DMX3O0D
DMX3O0D DN UFT
DMX3O0D HS Approved
DMX3O0D SN Futraful; Orzel; UFUR; Tegafur + uracil; UFT + leucovorin; BMS-200604-01; Tegafur + uracil, Taiho/Bristol-Myers Squibb
DMX3O0D CP Taiho Pharmaceutical Co Ltd
DMX3O0D DT Small molecular drug
DMX3O0D PC 104747
DMX3O0D MW 312.25
DMX3O0D FM C12H13FN4O5
DMX3O0D IC InChI=1S/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)
DMX3O0D CS C1CC(OC1)N2C=C(C(=O)NC2=O)F.C1=CNC(=O)NC1=O
DMX3O0D IK DHMYGZIEILLVNR-UHFFFAOYSA-N
DMX3O0D IU 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione
DMX3O0D CA CAS 74578-38-4
DMX3O0D DE Solid tumour/cancer
DMBNI20 ID DMBNI20
DMBNI20 DN Ulipristal
DMBNI20 HS Approved
DMBNI20 SN Ella (TN)
DMBNI20 CP HRA Pharma
DMBNI20 DT Small molecular drug
DMBNI20 PC 13559281
DMBNI20 MW 433.6
DMBNI20 FM C28H35NO3
DMBNI20 IC InChI=1S/C28H35NO3/c1-17(30)28(32)14-13-25-23-11-7-19-15-21(31)10-12-22(19)26(23)24(16-27(25,28)2)18-5-8-20(9-6-18)29(3)4/h5-6,8-9,15,23-25,32H,7,10-14,16H2,1-4H3/t23-,24+,25-,27-,28-/m0/s1
DMBNI20 CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
DMBNI20 IK HKDLNTKNLJPAIY-WKWWZUSTSA-N
DMBNI20 IU (8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMBNI20 CA CAS 159811-51-5
DMBNI20 DE Contraception
DMYRBO1 ID DMYRBO1
DMYRBO1 DN Umbralisib
DMYRBO1 HS Approved
DMYRBO1 SN RP5264; TGR-1202
DMYRBO1 CP Tg therapeutics
DMYRBO1 PC 72950888
DMYRBO1 MW 571.5
DMYRBO1 FM C31H24F3N5O3
DMYRBO1 IC InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
DMYRBO1 CS C[C@@H](C1=C(C(=O)C2=C(O1)C=CC(=C2)F)C3=CC(=CC=C3)F)N4C5=NC=NC(=C5C(=N4)C6=CC(=C(C=C6)OC(C)C)F)N
DMYRBO1 IK IUVCFHHAEHNCFT-INIZCTEOSA-N
DMYRBO1 IU 2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one
DMYRBO1 CA CAS 1532533-67-7
DMYRBO1 DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Marginal zone lymphoma
DM4E8O9 ID DM4E8O9
DM4E8O9 DN Umeclidinium
DM4E8O9 HS Approved
DM4E8O9 SN 573719
DM4E8O9 CP GlaxoSmithKline
DM4E8O9 DT Small molecular drug
DM4E8O9 PC 11519070
DM4E8O9 MW 428.6
DM4E8O9 FM C29H34NO2+
DM4E8O9 IC InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1
DM4E8O9 CS C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5
DM4E8O9 IK FVTWTVQXNAJTQP-UHFFFAOYSA-N
DM4E8O9 IU diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol
DM4E8O9 CA CAS 869185-19-3
DM4E8O9 CB CHEBI:79041
DM4E8O9 DE Chronic obstructive pulmonary disease
DMXNR04 ID DMXNR04
DMXNR04 DN Unoprostone
DMXNR04 HS Approved
DMXNR04 DT Small molecular drug
DMXNR04 PC 5311236
DMXNR04 MW 382.5
DMXNR04 FM C22H38O5
DMXNR04 IC InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1
DMXNR04 CS CCCCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O
DMXNR04 IK TVHAZVBUYQMHBC-SNHXEXRGSA-N
DMXNR04 IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
DMXNR04 CA CAS 120373-36-6
DMXNR04 CB CHEBI:39455
DMXNR04 DE Glaucoma/ocular hypertension
DM32B5U ID DM32B5U
DM32B5U DN Upadacitinib
DM32B5U HS Approved
DM32B5U SN ABT-494
DM32B5U CP Abbvie
DM32B5U PC 58557659
DM32B5U MW 380.4
DM32B5U FM C17H19F3N6O
DM32B5U IC InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
DM32B5U CS CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
DM32B5U IK WYQFJHHDOKWSHR-MNOVXSKESA-N
DM32B5U IU (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
DM32B5U CA CAS 1310726-60-3
DM32B5U DE Atopic dermatitis; Psoriatic arthritis; Crohn disease; Ulcerative colitis; Rheumatoid arthritis
DM8T2OI ID DM8T2OI
DM8T2OI DN Upadacitinib
DM8T2OI HS Approved
DM8T2OI SN Upadacitinib, ABT-494; J3.590.729G; Rinvoq; SB19218; SCHEMBL9991056; Upadacitinib; Upadacitinib (USAN/INN); Upadacitinib [USAN:INN]; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; 1310726-59-0; 1310726-60-3; 4RA0KN46E0; ABT 494; ABT-494; ABT-494 enantiomer; AC-30326; BCP19011; CHEMBL3622821; CS-6150; D10994; EX-A1628; GTPL9246; HY-19569; MFCD30502663; UNII-4RA0KN46E0
DM8T2OI PC 58557659
DM8T2OI MW 380.4
DM8T2OI FM C17H19F3N6O
DM8T2OI IC WYQFJHHDOKWSHR-MNOVXSKESA-N
DM8T2OI CS CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
DM8T2OI IK 1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
DM8T2OI IU (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
DM8T2OI CA CAS 1310726-60-3
DM8T2OI DE Rheumatoid arthritis
DMHL7OB ID DMHL7OB
DMHL7OB DN Uracil mustard
DMHL7OB HS Approved
DMHL7OB SN Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol
DMHL7OB TC Anticancer Agents
DMHL7OB DT Small molecular drug
DMHL7OB PC 6194
DMHL7OB MW 252.09
DMHL7OB FM C8H11Cl2N3O2
DMHL7OB IC InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)
DMHL7OB CS C1=C(C(=O)NC(=O)N1)N(CCCl)CCCl
DMHL7OB IK IDPUKCWIGUEADI-UHFFFAOYSA-N
DMHL7OB IU 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione
DMHL7OB CA CAS 66-75-1
DMHL7OB CB CHEBI:9884
DMHL7OB DE Acute myeloid leukaemia
DMD59GI ID DMD59GI
DMD59GI DN Urapidil
DMD59GI HS Approved
DMD59GI SN urapidil; 34661-75-1; Ebrantil; Eupressyl; Mediatensyl; Uraprene; Urapidilum [INN-Latin]; UNII-A78GF17HJS; NSC 310405; B-66256; C20H29N5O3; EINECS 252-130-4; BRN 0725782; A78GF17HJS; MLS003115907; 6-(3-(4-(o-Methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil; NCGC00016066-07; Ebrantil (TN); 6-((3-(4-(o-Methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyluracil; W-106718; Urapidilum; urapidil(jan); TgAAV-TNFR:Fc
DMD59GI DT Small molecular drug
DMD59GI PC 5639
DMD59GI MW 387.5
DMD59GI FM C20H29N5O3
DMD59GI IC InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
DMD59GI CS CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC
DMD59GI IK ICMGLRUYEQNHPF-UHFFFAOYSA-N
DMD59GI IU 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione
DMD59GI CA CAS 34661-75-1
DMD59GI CB CHEBI:32278
DMD59GI DE Hypertension; Inflammation
DMUK75B ID DMUK75B
DMUK75B DN Urea
DMUK75B HS Approved
DMUK75B SN carbamide; 57-13-6; Isourea; Carbonyldiamide; Ureophil; Carbonyldiamine; Carbamimidic acid; Pseudourea; Ureaphil; Urevert; Carbaderm; Alphadrate; Keratinamin; Calmurid; Aquadrate; Carbonyl diamide; Pastaron; Urepearl; Carbamide resin; Ultra Mide; Varioform ii; Aqua Care; Prespersion, 75 urea; carmol; basodexan; Harnstoff; Nutraplus; Mocovina; Urea solution; Supercel 3000; Aqua Care HP; Ureacin-20; Ureacin-40 Creme; Ureacin-10 lotion; Polyurea; Panafil; Onychomal; Hyanit; Caswell No. 902; Carbonyl Diamine; Mocovina [Czech]; Harnstoff [Ge
DMUK75B DT Small molecular drug
DMUK75B PC 1176
DMUK75B MW 60.056
DMUK75B FM CH4N2O
DMUK75B IC InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4)
DMUK75B CS C(=O)(N)N
DMUK75B IK XSQUKJJJFZCRTK-UHFFFAOYSA-N
DMUK75B IU urea
DMUK75B CA CAS 57-13-6
DMUK75B CB CHEBI:16199
DMUK75B DE Dermatological disease
DMQTREB ID DMQTREB
DMQTREB DN Uridine
DMQTREB HS Approved
DMQTREB SN uridine; 58-96-8; Uridin; Uracil riboside; beta-Uridine; d-uridine; CHEBI:16704; b-Uridine; UNII-WHI7HQ7H85; Urd; AI3-52690; EINECS 200-407-5; WHI7HQ7H85; MLS000069625; Uracil-1-beta-d-ribofuranoside; C9H12N2O6; DRTQHJPVMGBUCF-XVFCMESISA-N; SMR000058222; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-beta-D-ribofuranosylpyrimidine-2,4(1H,3H)-dione
DMQTREB DT Small molecular drug
DMQTREB PC 6029
DMQTREB MW 244.2
DMQTREB FM C9H12N2O6
DMQTREB IC InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
DMQTREB CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMQTREB IK DRTQHJPVMGBUCF-XVFCMESISA-N
DMQTREB IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMQTREB CA CAS 58-96-8
DMQTREB CB CHEBI:16704
DMQTREB DE Depression
DMG9HIA ID DMG9HIA
DMG9HIA DN Urofollitropin
DMG9HIA HS Approved
DMG9HIA SN Bravelle; Fertinex; Metrodin; Urofollitrophin; Fertinorm HP; Bravelle (TN); Fertinex (TN); Follistim (TN); Gonal-F(TN); (4-Threonine)oxytocin; 1,2-Dithia-5,8,11,14,17-penaazacycloeicosane, cyclic peptide deriv.; 4-(L-Threonine)oxytocin
DMG9HIA TC Fertility Agents
DMG9HIA DT Small molecular drug
DMG9HIA SQ Alpha chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta chainNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
DMG9HIA PC 62819
DMG9HIA MW 980.2
DMG9HIA FM C42H65N11O12S2
DMG9HIA IC InChI=1S/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)
DMG9HIA CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O
DMG9HIA IK ZDRRIRUAESZNIH-UHFFFAOYSA-N
DMG9HIA IU 1-[19-amino-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMG9HIA DE Female infertility
DM0GOUD ID DM0GOUD
DM0GOUD DN Urokinase
DM0GOUD HS Approved
DM0GOUD TC Thrombolytic Agents
DM0GOUD SQ DB00013 sequence: KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL
DM0GOUD DE Myocardial infarction
DMCUT21 ID DMCUT21
DMCUT21 DN Ursodeoxycholic acid
DMCUT21 HS Approved
DMCUT21 SN Actigall; Antigall; Arsacol; Delursan; Destolit; Deursil; Litursol; Lyeton; Peptarom; Solutrat; UDCA; UDCS; UrSO; Urosiol; Ursacol; Ursobilin; Ursochol; Ursodamor; Ursodeoxycholate; Ursodiol; Ursofalk; Ursolvan; Ursosan; Acide ursodesoxycholique; Acido ursodeossicolico; Acido ursodeossicolico [Italian]; Acido ursodeoxicolico; Acidum ursodeoxycholicum; Deoxyursocholic Acid; Sodium Ursodeoxycholate; Ursacholic Acid; Urso DS; Urso Forte; Ursodeoxy cholic acid; Ursodesoxycholicacid; Ursodexycholic Acid; Ursodiol [USAN]; IU5; U0030; Urso 250; Acide ursodesoxycholique [INN-French]; Acido ursodeoxicolico [INN-Spanish]; Acidum ursodeoxycholicum [INN-Latin]; Actigall (TN); Cholit-ursan; Deursil (TN); Dom-ursodiol c; ISO-URSODEOXYCHOLIC ACID; PHL-ursodiol c; PMS-ursodiol c; U-9000; Urso (TN); Urso Forte (TN); Ursodiol (USP); Ursosan (TN); Ursodeoxycholic acid (JP15/INN); Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)-(9CI); (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid; (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid; (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol; 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid; 3,7-Dihydroxycholan-24-oic acid; 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid; 3-alpha,7-beta-Dihydroxycholanic acid; 3-alpha,7-beta-Dioxycholanic acid; 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,7beta-Dihydroxy-5beta-cholanic acid; 5beta-Cholan-24-oic acid-3alpha,7beta-diol; 5beta-Cholanic Acid-3alpha,7beta-diol; 7-beta-Hydroxylithocholic acid; 7beta-Hydroxylithocholic acid
DMCUT21 CP Axcan Pharma
DMCUT21 TC Cholagogues and Choleretics
DMCUT21 DT Small molecular drug
DMCUT21 PC 31401
DMCUT21 MW 392.6
DMCUT21 FM C24H40O4
DMCUT21 IC InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1
DMCUT21 CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMCUT21 IK RUDATBOHQWOJDD-UZVSRGJWSA-N
DMCUT21 IU (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMCUT21 CA CAS 128-13-2
DMCUT21 CB CHEBI:9907
DMCUT21 DE Primary biliary cirrhosis
DMHTYK3 ID DMHTYK3
DMHTYK3 DN Ustekinumab
DMHTYK3 HS Approved
DMHTYK3 SN 6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN)
DMHTYK3 CP Centocor Ortho Biotech
DMHTYK3 DT Antibody
DMHTYK3 DE Plaque psoriasis; Malaria; Inflammatory bowel disease; Psoriasis vulgaris
DMA630M ID DMA630M
DMA630M DN Vaccinia immune globulin
DMA630M HS Approved
DMA630M CP DynPort Vaccine Company LLC
DMA630M DE Vaccination
DMHKS94 ID DMHKS94
DMHKS94 DN Valaciclovir
DMHKS94 HS Approved
DMHKS94 SN Talavir; VACV; ValACV; Valacyclovir; Virval; Zelitrex; Valaciclovir Hcl; Valacyclover Hydrochloric; Valacyclover Hydrochloride; BW256U87; TBB067866; Acyclovir-valine; BW-256U; Valaciclovir (INN); Valaciclovir [INN:BAN]; Valaciclovir, Valtrex; Valtrex (TN); Zelitrex (TN); Valacyclovir, (L)-isomer; L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester; L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9 H-purin-9-yl)methoxy]ethyl ester, monohydrochloride; 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl L-valinate; 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate; 2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate
DMHKS94 CP GlaxoSmithKline
DMHKS94 TC Antiviral Agents
DMHKS94 DT Small molecular drug
DMHKS94 PC 135398742
DMHKS94 MW 324.34
DMHKS94 FM C13H20N6O4
DMHKS94 IC InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1
DMHKS94 CS CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N
DMHKS94 IK HDOVUKNUBWVHOX-QMMMGPOBSA-N
DMHKS94 IU 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate
DMHKS94 CA CAS 124832-26-4
DMHKS94 CB CHEBI:35854
DMHKS94 DE Virus infection
DM5I1CE ID DM5I1CE
DM5I1CE DN Valacyclovir Hydrochloride
DM5I1CE HS Approved
DM5I1CE CP Glaxosmithkline
DM5I1CE TC Antiinfective Agents
DM5I1CE DT Small molecular drug
DM5I1CE PC 135398741
DM5I1CE MW 360.8
DM5I1CE FM C13H21ClN6O4
DM5I1CE IC InChI=1S/C13H20N6O4.ClH/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H/t8-;/m0./s1
DM5I1CE CS CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N.Cl
DM5I1CE IK ZCDDBUOENGJMLV-QRPNPIFTSA-N
DM5I1CE IU 2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM5I1CE CA CAS 124832-27-5
DM5I1CE CB CHEBI:9919
DM5I1CE DE Herpes simplex virus infection
DMQSA2V ID DMQSA2V
DMQSA2V DN Valbenazine tosylate
DMQSA2V HS Approved
DMQSA2V SN Valbenazine ditosylate; UNII-5SML1T733B; 5SML1T733B; Valbenazine tosylate [USAN]; Valbenazine tosylate (USAN); 1639208-54-0; NBI-98854 ditosylate
DMQSA2V CP Neurocrine Biosciences
DMQSA2V DT Small molecular drug
DMQSA2V PC 92042922
DMQSA2V MW 763
DMQSA2V FM C38H54N2O10S2
DMQSA2V IC InChI=1S/C24H38N2O4.2C7H8O3S/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4;2*1-6-2-4-7(5-3-6)11(8,9)10/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3;2*2-5H,1H3,(H,8,9,10)/t17-,19-,20-,23+;;/m1../s1
DMQSA2V CS CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
DMQSA2V IK BXGKAGLZHGYAMW-TZYFFPFWSA-N
DMQSA2V IU [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate;4-methylbenzenesulfonic acid
DMQSA2V CA CAS 1639208-54-0
DMQSA2V DE Tardive dyskinesia
DMAY7H4 ID DMAY7H4
DMAY7H4 DN Valdecoxib
DMAY7H4 HS Approved
DMAY7H4 SN Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide
DMAY7H4 TC Antiinflammatory Agents
DMAY7H4 DT Small molecular drug
DMAY7H4 PC 119607
DMAY7H4 MW 314.4
DMAY7H4 FM C16H14N2O3S
DMAY7H4 IC InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
DMAY7H4 CS CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
DMAY7H4 IK LNPDTQAFDNKSHK-UHFFFAOYSA-N
DMAY7H4 IU 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
DMAY7H4 CA CAS 181695-72-7
DMAY7H4 CB CHEBI:63634
DMAY7H4 DE Osteoarthritis
DMS2IUH ID DMS2IUH
DMS2IUH DN Valganciclovir
DMS2IUH HS Approved
DMS2IUH SN Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
DMS2IUH CP Roche Laboratories Inc
DMS2IUH TC Antiviral Agents
DMS2IUH DT Small molecular drug
DMS2IUH PC 135413535
DMS2IUH MW 354.36
DMS2IUH FM C14H22N6O5
DMS2IUH IC InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1
DMS2IUH CS CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
DMS2IUH IK WPVFJKSGQUFQAP-GKAPJAKFSA-N
DMS2IUH IU [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
DMS2IUH CA CAS 175865-60-8
DMS2IUH CB CHEBI:63635
DMS2IUH DE Virus infection
DMCFE9I ID DMCFE9I
DMCFE9I DN Valproate
DMCFE9I HS Approved
DMCFE9I SN 99-66-1; Dipropylacetic acid; Depakine; Depakene; 2-Propylvaleric acid; Ergenyl; Di-n-propylacetic acid; Mylproin; Pentanoic acid, 2-propyl-; 4-Heptanecarboxylic acid; Propylvaleric acid; n-Dipropylacetic acid; Myproic Acid; Di-n-propylessigsaure; n-DPA; Dipropylacetate; Convulex; Depakin; Vupral; Acido valproico; Acide valproique; Acidum valproicum; Stavzor; Avugane; Baceca; Kyselina 2-propylvalerova; 2-n-Propyl-n-valeric acid; Acetic acid, dipropyl-; Abbott 44090; Valproinsaeure; Savicol; Convulsofin; Deproic; VPA; Depakin chrono; Dipropyl Acetate; Med Valproic; Valproic acid USP; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylessigsaeure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base)
DMCFE9I CP Abbot Phamaceuticals
DMCFE9I TC Neurology Agents
DMCFE9I DT Small molecular drug
DMCFE9I PC 3121
DMCFE9I MW 144.21
DMCFE9I FM C8H16O2
DMCFE9I IC InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
DMCFE9I CS CCCC(CCC)C(=O)O
DMCFE9I IK NIJJYAXOARWZEE-UHFFFAOYSA-N
DMCFE9I IU 2-propylpentanoic acid
DMCFE9I CA CAS 99-66-1
DMCFE9I CB CHEBI:39867
DMCFE9I DE Epilepsy; Alcohol dependence
DMOYJFK ID DMOYJFK
DMOYJFK DN Valrubicin
DMOYJFK HS Approved
DMOYJFK SN Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester
DMOYJFK TC Anticancer Agents
DMOYJFK DT Small molecular drug
DMOYJFK PC 454216
DMOYJFK MW 723.6
DMOYJFK FM C34H36F3NO13
DMOYJFK IC InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
DMOYJFK CS CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O
DMOYJFK IK ZOCKGBMQLCSHFP-KQRAQHLDSA-N
DMOYJFK IU [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate
DMOYJFK CA CAS 56124-62-0
DMOYJFK CB CHEBI:135876
DMOYJFK DE Bladder cancer; Psoriasis vulgaris
DMREUQ6 ID DMREUQ6
DMREUQ6 DN Valsartan
DMREUQ6 HS Approved
DMREUQ6 SN valsartan; 137862-53-4; Diovan; Tareg; Provas; L-Valsartan; CGP 48933; Exforge; CGP-48933; (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid; UNII-80M03YXJ7I; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; CHEMBL1069; 80M03YXJ7I; CHEBI:9927; C24H29N5O3; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; 137863-60-6; AK-58790; Kalpress; Miten; Nisis; Diovan; Vals; Valsarran; Walsartan; Aventis brand of valsartan; CEPA brand of valsartan; Esteve brand of valsartan; Lacer brand of valsartan; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Diovan (TN); Diovan, Valsartan; Valsartan [USAN:INN]; Valtan (TN); Valzaar (TN); Valsartan (JAN/USAN/INN); N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; [3H]valsartan
DMREUQ6 CP Norvatis Phamaceuticals Corporation
DMREUQ6 TC Antihypertensive Agents
DMREUQ6 DT Small molecular drug
DMREUQ6 PC 60846
DMREUQ6 MW 435.5
DMREUQ6 FM C24H29N5O3
DMREUQ6 IC InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
DMREUQ6 CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
DMREUQ6 IK ACWBQPMHZXGDFX-QFIPXVFZSA-N
DMREUQ6 IU (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
DMREUQ6 CA CAS 137862-53-4
DMREUQ6 CB CHEBI:9927
DMREUQ6 DE Hypertension
DMK7T1Q ID DMK7T1Q
DMK7T1Q DN Vancomycin
DMK7T1Q HS Approved
DMK7T1Q SN Vancocin; Vancoled; Vancomicina; Vancomicina [INN-Spanish]; Vancomycin (USP); Vancomycin [USAN:INN:BAN]; Vancomycin [USP:INN:BAN]; Vancomycine; Vancomycine [INN-French]; Vancomycinum; Vancomycinum [INN-Latin]; Viomycin derivative; VANCOMYCIN; VANCOR; vancomicin; vanomycin; 1404-90-6; 6Q205EH1VU; C66H75Cl2N9O24; CHEBI:28001; CHEMBL262777; EINECS 215-772-6; HSDB 3262; UNII-6Q205EH1VU; Vancomycin hydrochloride from Streptomyces orientalis
DMK7T1Q PC 14969
DMK7T1Q MW 1449.2
DMK7T1Q FM C66H75Cl2N9O24
DMK7T1Q IC MYPYJXKWCTUITO-LYRMYLQWSA-N
DMK7T1Q CS CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMK7T1Q IK 1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
DMK7T1Q IU (1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
DMK7T1Q CA CAS 1404-90-6
DMK7T1Q CB CHEBI:28001
DMK7T1Q DE Methicillin-resistant staphylococcus infection
DMRICNP ID DMRICNP
DMRICNP DN Vandetanib
DMRICNP HS Approved
DMRICNP SN Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
DMRICNP CP AstraZeneca
DMRICNP TC Anticancer Agents
DMRICNP DT Small molecular drug
DMRICNP PC 3081361
DMRICNP MW 475.4
DMRICNP FM C22H24BrFN4O2
DMRICNP IC InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
DMRICNP CS CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
DMRICNP IK UHTHHESEBZOYNR-UHFFFAOYSA-N
DMRICNP IU N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
DMRICNP CA CAS 443913-73-3
DMRICNP CB CHEBI:49960
DMRICNP DE Solid tumour/cancer
DMTBGW8 ID DMTBGW8
DMTBGW8 DN Vardenafil
DMTBGW8 HS Approved
DMTBGW8 SN VDN; Levitra (TN); VARDENAFIL, LEVITRA; Vardenafil (INN); 1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine; 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one; 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one; 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4-ol
DMTBGW8 CP Bayer Pharmaceuticals Corporation
DMTBGW8 TC Antiimpotence Agents
DMTBGW8 DT Small molecular drug
DMTBGW8 PC 135400189
DMTBGW8 MW 488.6
DMTBGW8 FM C23H32N6O4S
DMTBGW8 IC InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
DMTBGW8 CS CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C
DMTBGW8 IK SECKRCOLJRRGGV-UHFFFAOYSA-N
DMTBGW8 IU 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
DMTBGW8 CA CAS 224785-90-4
DMTBGW8 CB CHEBI:46295
DMTBGW8 DE Erectile dysfunction
DMMUOLJ ID DMMUOLJ
DMMUOLJ DN Varenicline
DMMUOLJ HS Approved
DMMUOLJ SN CP 526555; Champix (TN); Chantix (TN); Varenicline (INN); 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine; 7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
DMMUOLJ CP Pfizer Pharmaceuticals
DMMUOLJ DT Small molecular drug
DMMUOLJ PC 170361
DMMUOLJ MW 211.26
DMMUOLJ FM C13H13N3
DMMUOLJ IC InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2
DMMUOLJ CS C1C2CNCC1C3=CC4=NC=CN=C4C=C23
DMMUOLJ IK JQSHBVHOMNKWFT-UHFFFAOYSA-N
DMMUOLJ IU 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
DMMUOLJ CA CAS 249296-44-4
DMMUOLJ DE Smoking dependence
DMQ2FPC ID DMQ2FPC
DMQ2FPC DN Vasopressin
DMQ2FPC HS Approved
DMQ2FPC SN Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP)
DMQ2FPC CP Astellas Pharma
DMQ2FPC TC Vasoconstrictor Agents
DMQ2FPC DT Small molecular drug
DMQ2FPC PC 644077
DMQ2FPC MW 1084.2
DMQ2FPC FM C46H65N15O12S2
DMQ2FPC IC InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMQ2FPC CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMQ2FPC IK KBZOIRJILGZLEJ-LGYYRGKSSA-N
DMQ2FPC IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMQ2FPC CA CAS 113-79-1
DMQ2FPC CB CHEBI:34543
DMQ2FPC DE Diabetes insipidus; Polyuria; Enuresis
DMP0UK2 ID DMP0UK2
DMP0UK2 DN Vecuronium
DMP0UK2 HS Approved
DMP0UK2 SN Norcuron (TN); (2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMP0UK2 CP Bedford Laboratories
DMP0UK2 TC Analgesics
DMP0UK2 DT Small molecular drug
DMP0UK2 PC 39765
DMP0UK2 MW 557.8
DMP0UK2 FM C34H57N2O4+
DMP0UK2 IC InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMP0UK2 CS CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C
DMP0UK2 IK BGSZAXLLHYERSY-XQIGCQGXSA-N
DMP0UK2 IU [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
DMP0UK2 CA CAS 86029-43-8
DMP0UK2 CB CHEBI:9939
DMP0UK2 DE Spasm
DMV3YMX ID DMV3YMX
DMV3YMX DN Vedolizmab
DMV3YMX HS Approved
DMV3YMX SN 4168-17-6
DMV3YMX CP Millennium Pharmaceuticals
DMV3YMX DT Monoclonal antibody
DMV3YMX DE Crohn disease; Ulcerative colitis
DM4BOAS ID DM4BOAS
DM4BOAS DN Velaglucerase alfa
DM4BOAS HS Approved
DM4BOAS SN Vpriv (TN)
DM4BOAS CP Shire
DM4BOAS SQ VPRIV Sequence: ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ
DM4BOAS DE Metabolic disorder
DMGF8ZQ ID DMGF8ZQ
DMGF8ZQ DN Velpatasvir
DMGF8ZQ HS Approved
DMGF8ZQ SN Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; KCU0C7RS7Z; 1377049-84-7; GS 5816; GS-5816; GS5816; UNII-KCU0C7RS7Z; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
DMGF8ZQ PC 67683363
DMGF8ZQ MW 883
DMGF8ZQ FM C49H54N8O8
DMGF8ZQ IC FHCUMDQMBHQXKK-CDIODLITSA-N
DMGF8ZQ CS CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
DMGF8ZQ IK 1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
DMGF8ZQ IU methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
DMGF8ZQ CA CAS 1377049-84-7
DMGF8ZQ CB CHEBI:133009
DMGF8ZQ DE Viral hepatitis
DM62UG5 ID DM62UG5
DM62UG5 DN Vemurafenib
DM62UG5 HS Approved
DM62UG5 SN PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
DM62UG5 CP Daiichi Sankyo group; Genentech
DM62UG5 DT Small molecular drug
DM62UG5 PC 42611257
DM62UG5 MW 489.9
DM62UG5 FM C23H18ClF2N3O3S
DM62UG5 IC InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
DM62UG5 CS CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
DM62UG5 IK GPXBXXGIAQBQNI-UHFFFAOYSA-N
DM62UG5 IU N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide
DM62UG5 CA CAS 918504-65-1
DM62UG5 CB CHEBI:63637
DM62UG5 DE Melanoma
DM8I94Y ID DM8I94Y
DM8I94Y DN Venetoclax
DM8I94Y HS Approved
DM8I94Y SN Venclexta
DM8I94Y DT Small molecular drug
DM8I94Y PC 49846579
DM8I94Y MW 868.447
DM8I94Y FM C45H50ClN7O7S
DM8I94Y IC InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)
DM8I94Y CS CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
DM8I94Y IK LQBVNQSMGBZMKD-UHFFFAOYSA-N
DM8I94Y IU 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DM8I94Y CA CAS 1257044-40-8
DM8I94Y CB CHEBI:133021
DM8I94Y DE Chronic lymphocytic leukemia
DMR6QH0 ID DMR6QH0
DMR6QH0 DN Venlafaxine
DMR6QH0 HS Approved
DMR6QH0 SN Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol
DMR6QH0 CP Wyeth
DMR6QH0 TC Antidepressants
DMR6QH0 DT Small molecular drug
DMR6QH0 PC 5656
DMR6QH0 MW 277.4
DMR6QH0 FM C17H27NO2
DMR6QH0 IC InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
DMR6QH0 CS CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
DMR6QH0 IK PNVNVHUZROJLTJ-UHFFFAOYSA-N
DMR6QH0 IU 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
DMR6QH0 CA CAS 93413-69-5
DMR6QH0 CB CHEBI:9943
DMR6QH0 DE Depression
DMA7PEW ID DMA7PEW
DMA7PEW DN Verapamil
DMA7PEW HS Approved
DMA7PEW SN Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)
DMA7PEW CP Pfizer Inc
DMA7PEW TC Analgesics
DMA7PEW DT Small molecular drug
DMA7PEW PC 2520
DMA7PEW MW 454.6
DMA7PEW FM C27H38N2O4
DMA7PEW IC InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
DMA7PEW CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DMA7PEW IK SGTNSNPWRIOYBX-UHFFFAOYSA-N
DMA7PEW IU 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DMA7PEW CA CAS 52-53-9
DMA7PEW CB CHEBI:77733
DMA7PEW DE Hypertension
DM7MDBE ID DM7MDBE
DM7MDBE DN Vericiguat
DM7MDBE HS Approved
DM7MDBE SN Vericiguat; 1350653-20-1; UNII-LV66ADM269; BAY-1021189; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate; BAY1021189; LV66ADM269; MK-1242; Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate; methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate; Methyl (4,6-diamino-2-(5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridin-3-yl)pyrimidin-5-yl)carbam
DM7MDBE CP Bayer HealthCare Pharmaceuticals
DM7MDBE DT Small molecular drug
DM7MDBE PC 54674461
DM7MDBE MW 426.4
DM7MDBE FM C19H16F2N8O2
DM7MDBE IC InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
DM7MDBE CS COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
DM7MDBE IK QZFHIXARHDBPBY-UHFFFAOYSA-N
DM7MDBE IU methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
DM7MDBE CA CAS 1350653-20-1
DM7MDBE CB CHEBI:142432
DM7MDBE DE Heart failure
DMIY6DB ID DMIY6DB
DMIY6DB DN Verteporfin
DMIY6DB HS Approved
DMIY6DB SN Visudyne (TN)
DMIY6DB DT Small molecular drug
DMIY6DB PC 11980904
DMIY6DB MW 1437.6
DMIY6DB FM C82H84N8O16
DMIY6DB IC InChI=1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/t2*38-,41+/m00/s1
DMIY6DB CS CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C
DMIY6DB IK NJLRKAMQPVVOIU-IDLGWYNRSA-N
DMIY6DB IU 3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid;3-[(23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-5-yl]propanoic acid
DMIY6DB DE Psoriasis vulgaris
DMBKX3C ID DMBKX3C
DMBKX3C DN VESNARINONE
DMBKX3C HS Approved
DMBKX3C SN vesnarinone; 81840-15-5; Arkin-Z; Piteranometozine; OPC-8212; Arkin; Vesnarinonum [Latin]; Vesnarinona [Spanish]; UNII-5COW40EV8M; OPC 8212; Vesnarinone [USAN:INN:JAN]; CCRIS 1451; DRG-0210; BRN 5644229; 5COW40EV8M; CHEMBL17423; 6-(4-(3,4-Dimethoxybenzoyl)-1-piperazinyl)-3,4-dihydro-2(1H)-; 1-(1,2,3,4-Tetrahydro-2-oxo-6-quinolyl)-4-veratroylpiperazine; 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one; 3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2(1H)-quinolinone
DMBKX3C DT Small molecular drug
DMBKX3C PC 5663
DMBKX3C MW 395.5
DMBKX3C FM C22H25N3O4
DMBKX3C IC InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
DMBKX3C CS COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
DMBKX3C IK ZVNYJIZDIRKMBF-UHFFFAOYSA-N
DMBKX3C IU 6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
DMBKX3C CA CAS 81840-15-5
DMBKX3C CB CHEBI:31237
DMBKX3C DE Cardiac failure
DM4UHZF ID DM4UHZF
DM4UHZF DN Vestronidase alfa
DM4UHZF HS Approved
DM4UHZF CP Ultragenyx
DM4UHZF DE Mucopolysaccharidosis
DMFR201 ID DMFR201
DMFR201 DN Vibegron
DMFR201 HS Approved
DMFR201 SN MK-4618
DMFR201 CP Merck
DMFR201 PC 44472635
DMFR201 MW 444.5
DMFR201 FM C26H28N4O3
DMFR201 IC InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
DMFR201 CS C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O
DMFR201 IK DJXRIQMCROIRCZ-XOEOCAAJSA-N
DMFR201 IU (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
DMFR201 CA CAS 1190389-15-1
DMFR201 CB CHEBI:142418
DMFR201 DE Overactive bladder
DM0N85H ID DM0N85H
DM0N85H DN Vidarabine
DM0N85H HS Approved
DM0N85H SN Araadenosine; Arabinosyladenine; Armes; RAB; Spongoadenosine; VIRDARABINE; Vidarabin; Vidarabina; Vidarabinum; Xylosyladenine; Adenine arabinoside; Adenine xyloside; Adenosine arabinose; Ara A; Arabinoside adenine; Arabinosyl adenine; Vidarabina [DCIT]; Vidarabine anhydrous; Vira ATM; Xylosyl A; A 9251; ARA-A NSC 247519; Alpha-Ara A; Ara-A; Arabinosyl-adenine; Arasena-A; Armes (TN); Beta-Ara A; Vidarabine (JAN); Vira-A; Adenosine-8-14C; Vira-A, Vidarabine; ADENOSINE, U.S.P.; (+)-Cyclaradine; 9-Arabinosyladenine
DM0N85H TC Antiviral Agents
DM0N85H DT Small molecular drug
DM0N85H PC 21704
DM0N85H MW 267.24
DM0N85H FM C10H13N5O4
DM0N85H IC InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
DM0N85H CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N
DM0N85H IK OIRDTQYFTABQOQ-UHTZMRCNSA-N
DM0N85H IU (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM0N85H CA CAS 5536-17-4
DM0N85H CB CHEBI:45327
DM0N85H DE Herpes simplex virus infection
DMYT0OG ID DMYT0OG
DMYT0OG DN Vigabatrin
DMYT0OG HS Approved
DMYT0OG SN GVG; Sabril; Sabrilex; Vigabatrina; Vigabatrine; Vigabatrinum; Aventis Brand of Vigabatrin; Gamma Vinyl GABA; Gamma Vinyl gamma Aminobutyric Acid; Hoechst Brand of Vigabatrin; Vigabatrin Aventis Brand; Vigabatrin Hoechst Brand; Vigabatrin Yamanouchi Brand; Vigabatrina [Spanish]; Vigabatrine [French]; Vigabatrinum [Latin]; Yamanouchi Brand of Vigabatrin; M071754; MDL 71754; RMI 71754; V 8261; V8261_SIGMA; CPP-109; Gamma-Vinyl GABA; MDL 71,754; MDL-71754; RMI-71754; RMI-71890; Sabril (TN); Sabrilex (TN); Gamma-Vinyl-GABA; Hexenoic acid, 4-amino; Vigabatrin [USAN:BAN:INN]; Vigabatrin [USAN:INN:BAN]; Gamma-Vinyl-gamma-Aminobutyric Acid; Gamma-Vinyl-gamma-aminobutyric acid; Vigabatrin (JAN/USAN/INN); Acid, gamma-Vinyl-gamma-Aminobutyric; (R,S)-4-Amino-5-hexenoic acid; (inverted question mark)-gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; 4-aminohex-5-enoic acid
DMYT0OG CP Ovation Pharma; Lundbeck
DMYT0OG TC Anticonvulsants
DMYT0OG DT Small molecular drug
DMYT0OG PC 5665
DMYT0OG MW 129.16
DMYT0OG FM C6H11NO2
DMYT0OG IC InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
DMYT0OG CS C=CC(CCC(=O)O)N
DMYT0OG IK PJDFLNIOAUIZSL-UHFFFAOYSA-N
DMYT0OG IU 4-aminohex-5-enoic acid
DMYT0OG CA CAS 68506-86-5
DMYT0OG CB CHEBI:63638
DMYT0OG DE Complex partial seizure; Infantile spasm; Epilepsy
DMF5EK1 ID DMF5EK1
DMF5EK1 DN Vilanterol
DMF5EK1 HS Approved
DMF5EK1 SN 503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair
DMF5EK1 CP GlaxoSmithKline
DMF5EK1 DT Small molecular drug
DMF5EK1 PC 10184665
DMF5EK1 MW 486.4
DMF5EK1 FM C24H33Cl2NO5
DMF5EK1 IC InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
DMF5EK1 CS C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl
DMF5EK1 IK DAFYYTQWSAWIGS-DEOSSOPVSA-N
DMF5EK1 IU 4-[(1R)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol
DMF5EK1 CA CAS 503068-34-6
DMF5EK1 CB CHEBI:75037
DMF5EK1 DE Chronic obstructive pulmonary disease
DM4LECQ ID DM4LECQ
DM4LECQ DN Vilazodone
DM4LECQ HS Approved
DM4LECQ SN Vilazodone [INN]; Vilazodone (TN); 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide; 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide
DM4LECQ CP Genaissance and Merck KGaA
DM4LECQ DT Small molecular drug
DM4LECQ PC 6918314
DM4LECQ MW 441.5
DM4LECQ FM C26H27N5O2
DM4LECQ IC InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)
DM4LECQ CS C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N
DM4LECQ IK SGEGOXDYSFKCPT-UHFFFAOYSA-N
DM4LECQ IU 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
DM4LECQ CA CAS 163521-12-8
DM4LECQ CB CHEBI:70707
DM4LECQ DE Major depressive disorder
DMYN59P ID DMYN59P
DMYN59P DN Vildagliptin
DMYN59P HS Approved
DMYN59P SN Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
DMYN59P CP Novartis
DMYN59P DT Small molecular drug
DMYN59P PC 6918537
DMYN59P MW 303.4
DMYN59P FM C17H25N3O2
DMYN59P IC InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
DMYN59P CS C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
DMYN59P IK SYOKIDBDQMKNDQ-XWTIBIIYSA-N
DMYN59P IU (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
DMYN59P CA CAS 274901-16-5
DMYN59P CB CHEBI:135285
DMYN59P DE Type-2 diabetes
DM5TVS3 ID DM5TVS3
DM5TVS3 DN Vinblastine
DM5TVS3 HS Approved
DM5TVS3 SN Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid
DM5TVS3 CP Eli Lilly And Co
DM5TVS3 TC Anticancer Agents
DM5TVS3 DT Small molecular drug
DM5TVS3 PC 13342
DM5TVS3 MW 811
DM5TVS3 FM C46H58N4O9
DM5TVS3 IC InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
DM5TVS3 CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
DM5TVS3 IK JXLYSJRDGCGARV-CFWMRBGOSA-N
DM5TVS3 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DM5TVS3 CA CAS 865-21-4
DM5TVS3 DE Solid tumour/cancer
DMK1ZOR ID DMK1ZOR
DMK1ZOR DN Vincamine
DMK1ZOR HS Approved
DMK1ZOR SN vincamine; 1617-90-9; Pervincamine; Devincan; Minorine; Vincamidol; Novicet; Monorin; Methyl vincaminate; Arteriovinca; Vincasaunier; Vinkametrin; Devinkan; Decincan; Vincapront; Vincafolina; Vincadar; Tripervan; Angiopac; Anasclerol; (+)-Vincamine; Equipur; Pervone; Oxygeron; Vincafor; Perval; Ocu-vinc; Vincamina [DCIT]; Vincimax; Vincamine base; Vincaminum [INN-Latin]; UNII-996XVD0JHT; Vincamine [INN:BAN:DCF]; Minorin; Vincachron; Vincapan; Vincamin; Vincagil; Vinca; Vinodrel retard; Vinca-Minor; Vinca-Ecobi; HSDB 7150; Anasclerol (base)
DMK1ZOR DT Small molecular drug
DMK1ZOR PC 15376
DMK1ZOR MW 354.4
DMK1ZOR FM C21H26N2O3
DMK1ZOR IC InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
DMK1ZOR CS CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@](C2)(C(=O)OC)O
DMK1ZOR IK RXPRRQLKFXBCSJ-GIVPXCGWSA-N
DMK1ZOR IU methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
DMK1ZOR CA CAS 1617-90-9
DMK1ZOR CB CHEBI:9985
DMK1ZOR DE Cerebrovascular disease
DMINOX3 ID DMINOX3
DMINOX3 DN Vincristine
DMINOX3 HS Approved
DMINOX3 SN LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine
DMINOX3 CP Mayne Pharma Limited
DMINOX3 TC Anticancer Agents
DMINOX3 DT Small molecular drug
DMINOX3 PC 5978
DMINOX3 MW 825
DMINOX3 FM C46H56N4O10
DMINOX3 IC InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
DMINOX3 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
DMINOX3 IK OGWKCGZFUXNPDA-XQKSVPLYSA-N
DMINOX3 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DMINOX3 CA CAS 57-22-7
DMINOX3 CB CHEBI:28445
DMINOX3 DE Acute lymphoblastic leukaemia
DMVR628 ID DMVR628
DMVR628 DN Vindesine
DMVR628 HS Approved
DMVR628 SN DAVA; Vindesin; Vindesina; Vindesinum; Desacetylvinblastine amide; Lilly 112531; Vindesina [INN-Spanish]; Vindesinum [INN-Latin]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; 3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
DMVR628 TC Anticancer Agents
DMVR628 DT Small molecular drug
DMVR628 PC 40839
DMVR628 MW 753.9
DMVR628 FM C43H55N5O7
DMVR628 IC InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
DMVR628 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
DMVR628 IK HHJUWIANJFBDHT-KOTLKJBCSA-N
DMVR628 IU methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
DMVR628 CA CAS 53643-48-4
DMVR628 CB CHEBI:36373
DMVR628 DE Acute lymphoblastic leukaemia
DMVXFYE ID DMVXFYE
DMVXFYE DN Vinorelbine
DMVXFYE HS Approved
DMVXFYE SN Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
DMVXFYE CP GlaxoSmithKline
DMVXFYE TC Anticancer Agents
DMVXFYE DT Small molecular drug
DMVXFYE PC 5311497
DMVXFYE MW 778.9
DMVXFYE FM C45H54N4O8
DMVXFYE IC InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
DMVXFYE CS CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
DMVXFYE IK GBABOYUKABKIAF-IELIFDKJSA-N
DMVXFYE IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
DMVXFYE CA CAS 71486-22-1
DMVXFYE CB CHEBI:480999
DMVXFYE DE Solid tumour/cancer
DMVN2E6 ID DMVN2E6
DMVN2E6 DN Vinpocetine
DMVN2E6 HS Approved
DMVN2E6 SN Bravinton; Cavinton; Ceractin; Vinpocetinum; Apovincaminic acid ethyl ester; AY 27255; RGH 4405; TCV 3B; V 6383; V6383_SIGMA; AY 27,255; Apovincaminate d'ethyle; Apovincaminate d'ethyle [French]; Cavinton (TN); Cis-Apovincaminic acid ethyl ester; Intelectol (TN); RGH-4405; TCV-3B; Ultra-Vinca; Vinpocetine-ethyl apovincaminate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid ethyl ester; Ethyl apovincamin-22-oate; Vinpocetine [USAN:INN:JAN]; Ethyl (+)-apovincaminate; Vinpocetine (JAN/USAN/INN); Ethyl(+)-cis-apovincaminate; Ethyl apovincaminate, (3alpha,16alpha)-isomer; Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; (+)-Apovincaminic acid ethyl ester; (+)-cis-Apovincaminic acid ethyl ester; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; 3-alpha,16-alpha-Apovincaminic acid ethyl ester
DMVN2E6 TC Vasodilator Agents
DMVN2E6 DT Small molecular drug
DMVN2E6 PC 443955
DMVN2E6 MW 350.5
DMVN2E6 FM C22H26N2O2
DMVN2E6 IC InChI=1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
DMVN2E6 CS CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC
DMVN2E6 IK DDNCQMVWWZOMLN-IRLDBZIGSA-N
DMVN2E6 IU ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
DMVN2E6 CA CAS 42971-09-5
DMVN2E6 CB CHEBI:32297
DMVN2E6 DE Ischemic stroke
DMZYLFC ID DMZYLFC
DMZYLFC DN Viomycin sulfate
DMZYLFC HS Approved
DMZYLFC SN Viocin (TN)
DMZYLFC DT Small molecular drug
DMZYLFC PC 135524783
DMZYLFC MW 783.8
DMZYLFC FM C25H45N13O14S
DMZYLFC IC InChI=1S/C25H43N13O10.H2O4S/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43;1-5(2,3)4/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48);(H2,1,2,3,4)/b13-7-;/t10-,11+,12-,14-,15-,17-,18-;/m0./s1
DMZYLFC CS C1[C@@H](N=C(N[C@H]1O)N)[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H](CCCN)N.OS(=O)(=O)O
DMZYLFC IK AQONYROJHRNYQQ-QMAPKBLTSA-N
DMZYLFC IU (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide;sulfuric acid
DMZYLFC CA CAS 37883-00-4
DMZYLFC DE Bacterial infection
DM0REZS ID DM0REZS
DM0REZS DN Virulizin
DM0REZS HS Approved
DM0REZS SN Virulizin (TN)
DM0REZS CP Lorus Therapeutics
DM0REZS DE Breast cancer
DM5IXKQ ID DM5IXKQ
DM5IXKQ DN Vismodegib
DM5IXKQ HS Approved
DM5IXKQ SN 879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449
DM5IXKQ CP Genentech
DM5IXKQ DT Small molecular drug
DM5IXKQ PC 24776445
DM5IXKQ MW 421.3
DM5IXKQ FM C19H14Cl2N2O3S
DM5IXKQ IC InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
DM5IXKQ CS CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
DM5IXKQ IK BPQMGSKTAYIVFO-UHFFFAOYSA-N
DM5IXKQ IU 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
DM5IXKQ CA CAS 879085-55-9
DM5IXKQ CB CHEBI:66903
DM5IXKQ DE Basal cell carcinoma; Primitive neuroectodermal tumour medulloblastoma
DMJ2AH4 ID DMJ2AH4
DMJ2AH4 DN Vitamin A
DMJ2AH4 HS Approved
DMJ2AH4 SN Retinol; retinol; all-trans-Retinol; 68-26-8; Vitamin A1; Alphalin; Axerophthol; Afaxin; Oleovitamin A; Chocola A; Ophthalamin; Epiteliol; Biosterol; Aquasynth; Apostavit; Alphasterol; Veroftal; Testavol; Anatola; Prepalin; Myvpack; Agoncal; Agiolan; Vogan; Axerol; Vitpex; Avibon; Apexol; Aoral; Vaflol; Dofsol; Avitol; Vitamin A alcohol; Disatabs Tabs; Lard Factor; Bentavit A; Dohyfral A; all-trans-Retinyl alcohol; Alcovit A; Vogan-Neu; Anatola A; Plivit A; A-Mulsal; Vi-Alpha; A-Vitan; All-trans retinol; Atars; Vafol; trans-retinol; all-trans-Vitamin A; ACON; ATAV; Alin; Avita; Axerophtholum; Cylasphere; LPK; Retinolo; Retinolum; TROL; Thalasphere; Wachstumsvitamin; All Trans Retinol; Antixerophthalmic vitamin; Antixerophthalmisches Vitamin; Aquasol A Parenteral; Homagenets Aoral; Homagenets aorl; Hydrovit A; Mvc Plus; Retinol solution; Retinolo [DCIT]; Retrovitamin A; Sehkraft A; Super A; Testavol S; Vitamin A cryst; Vitamine A; Vitaminum A; Vitavel A; Zinosan N; Rovimix A 500; Vitamin A1 alcohol; A-Sol; Anti-infective vitamin; Beta-Retinol; Retinol [INN:BAN]; Retinolum [INN-Latin]; Solu-A; Trans-Vitamin A alcohol; Trans-retinol; Vi-a; Vi-alpha; Vio-A; Vitamin A (Feed); Vitamin A (USP); Vitamin A alcohol (VAN); Vitamin A1 alcohol, all trans; Vitamin-A; Vitamin-A alcohol; Vitamin-A alcohol solution; Vitamin-A1; Vitavel-A; Vogan-nu; A-Vi-Pel; ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1); All-trans-Retinol; All-trans-Retinyl alcohol; All-trans-Vitamin A; All-trans-Vitamin A alcohol; All-trans-Vitamin A1; Del-VI-A; Hi-A-Vita; Nio-A-Let; Ro-a-vit; Trans-Retinol acid (Vitamin A); Vi-Dom-A; [11,12-3H]-Retinol; MVC 9+3; MVI-12; Retinol, all-trans-(8CI); Retin-11,12-t2-ol (9CI); Retinol-(cellular-retinol-binding-protein); Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol; All-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol; (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol; (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol; 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer; Tricyclics
DMJ2AH4 TC Vitamins
DMJ2AH4 DT Small molecular drug
DMJ2AH4 PC 445354
DMJ2AH4 MW 286.5
DMJ2AH4 FM C20H30O
DMJ2AH4 IC InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
DMJ2AH4 CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C
DMJ2AH4 IK FPIPGXGPPPQFEQ-OVSJKPMPSA-N
DMJ2AH4 IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
DMJ2AH4 CA CAS 11103-57-4
DMJ2AH4 CB CHEBI:17336
DMJ2AH4 DE Night blindness; Kinetoplastids
DMZ1WXJ ID DMZ1WXJ
DMZ1WXJ DN Vitamin B1
DMZ1WXJ HS Approved
DMZ1WXJ SN 59-43-8; Thiamine monochloride; Aneurine; 3-((4-Amino-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride; Tiamina; Oryzanin; Thiaminum; Oryzanine; Bethiamin; Vitaneurin; Beivon; Apatate drape; Thiamine, chloride; B-Amin; Thiamine [INN:BAN]; Tiamina [INN-Spanish]; Thiaminum [INN-Latin]; UNII-X66NSO3N35; CCRIS 5823; HSDB 220; thiamine(1+) chloride; EINECS 200-425-3; X66NSO3N35; CHEBI:33283; AK109288; Thiamine (Vit B1); Thiazolium,
DMZ1WXJ TC Vitamins
DMZ1WXJ DT Small molecular drug
DMZ1WXJ PC 6042
DMZ1WXJ MW 300.81
DMZ1WXJ FM C12H17ClN4OS
DMZ1WXJ IC InChI=1S/C12H17N4OS.ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1
DMZ1WXJ CS CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Cl-]
DMZ1WXJ IK MYVIATVLJGTBFV-UHFFFAOYSA-M
DMZ1WXJ IU 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride
DMZ1WXJ CA CAS 59-43-8
DMZ1WXJ CB CHEBI:33283
DMZ1WXJ DE Vitamin B1 deficiency
DMQVRZH ID DMQVRZH
DMQVRZH DN Vitamin B3
DMQVRZH HS Approved
DMQVRZH SN Niacin (TN); Niacinamide (TN); Nicotinamide (TN)
DMQVRZH CP Anmar
DMQVRZH DT Small molecular drug
DMQVRZH PC 938
DMQVRZH MW 123.11
DMQVRZH FM C6H5NO2
DMQVRZH IC InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
DMQVRZH CS C1=CC(=CN=C1)C(=O)O
DMQVRZH IK PVNIIMVLHYAWGP-UHFFFAOYSA-N
DMQVRZH IU pyridine-3-carboxylic acid
DMQVRZH CA CAS 59-67-6
DMQVRZH CB CHEBI:15940
DMQVRZH DE Lipid metabolism disorder
DMDBZMV ID DMDBZMV
DMDBZMV DN Vitamin B6
DMDBZMV HS Approved
DMDBZMV SN Aderoxin; Alestrol; Becilan; Beesix; Benadon; Bonasanit; Godabion; Hexavibex; Hexermin; Hexermine; Hexobion; Nestrex; Paxadon; Pydox; Pyridipca; Pyridox; Spondylonal; Vitaped; Adermin hydrochloride; Adermine hydrochloride; Aderomine hydrochloride; Component of Alestrol; Hexabione hydrochloride; PN HCl; PYRIDOXINE HYDROCHLORIDE; Pyridoxin hydrochloride; Pyridoxine HCl; Pyridoxine chloride; Pyridoxine hydrogen chloride; Pyridoxine monohydrochloride; Pyridoxinium chloride; Pyridoxinum hydrochloricum; Pyridoxol hydrochloride; Rodex TD; AIDS006784; Campoviton 6; Vitamin V6; AIDS-006784; Cernevit-12; Pyridoxine (INN); Pyridoxine Hydrochloride (B6); Pyridoxine hydrochloride[USAN:JAN]; Pyridoxine, hydrochloride; Pyridoxine-HCl Microencapsulated; Pyridoxinum hydrochloricum (Hungarian); Pyridoxol, hydrochloride; Rodex (R); Vitamin B6-hydrochloride; Vitamin V6 (TN); Vitamin-B6 hydrochloride; Hexa-Betalin (R); Hexa-betalin (TN); Pyridoxine hydrochloride (JP15/USP); Tex Six T.R.; PYRIDOXINE HYDROCHLORIDE, U.S.P.; (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; 2-methyl-4,5-dimethylol-pyridin-3-ol; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride; 3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride; 3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride; 4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; 4-Deoxypyridoxine 5'-phosphate; 5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
DMDBZMV TC Vitamins
DMDBZMV DT Small molecular drug
DMDBZMV PC 1054
DMDBZMV MW 169.18
DMDBZMV FM C8H11NO3
DMDBZMV IC InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
DMDBZMV CS CC1=NC=C(C(=C1O)CO)CO
DMDBZMV IK LXNHXLLTXMVWPM-UHFFFAOYSA-N
DMDBZMV IU 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
DMDBZMV CA CAS 65-23-6
DMDBZMV CB CHEBI:16709
DMDBZMV DE Vitamin B6 deficiency
DMXJ7O8 ID DMXJ7O8
DMXJ7O8 DN Vitamin C
DMXJ7O8 HS Approved
DMXJ7O8 SN l-ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; Ascorbicap; Cevitamic acid; Ascoltin; Hybrin; Secorbate; Proscorbin; Lemascorb; Ascorteal; Ascorbajen; Vitascorbol; Vitamisin; Natrascorb; Citriscorb; Cescorbat; Ascorbutina; Testascorbic; Cevitamin; Cetemican; Allercorb; Vitacimin; Roscorbic; Laroscorbine; Viscorin; Redoxon; Cenetone; Cegiolan; Cebicure; Ascorvit; Viforcit; Concemin; Cevital; Cergona; Cemagyl; Cebione; Cantaxin; Ascorin; Vitacee; Vicelat; Cevimin; Cetamid; Cenolate; Celaskon; Vitacin; Adenex; Ascorb; Ascorbicab; Ascorbicin; Ascorbinsaeure; Cantan; Cebid; Cebion; Cecon; Ceglion; Celin; Cemill; Cereon; Cetebe; Cevalin; Cevatine; Cevex; Cevibid; Cevitan; Cevitex; Cewin; Ciamin; Cipca; Colascor; Cortalex; Duoscorb; Ferancee; Hicee; Magnorbin; Ribena; Scorbacid; Semidehydroascorbate; Sodascorbate; Stuartinic; Sunkist; Tolfrinic; Vitace; Xitix; Acid Ascorbic; Acide ascorbique; Acido ascorbico; Acidum ascorbicum; Acidum ascorbinicum; Antiscorbic vita min; Antiscorbic vitamin; Antiscorbutic factor; Antiscorbutic vitamin; Ascorbyl radical; Catavin C; Ce lent; Component of Cortalex; Component of Endoglobin Forte; Component of Ferancee; Davitamon C; Ferrous ascorbate; Kyselina askorbova; Kyselina askorbova [Czech]; Magnesium Ascorbicum; Monodehydroascorbic acid; Natrascorb injectable; Oral Vitamin C; Planavit C; Roscorbi c; Vicomin C; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; Arco-cee; Ascoltin (TN); Ascorbic Acid, Monosodium Salt; Ascorbicap (TN); C-Level; C-Long; C-Quin; C-Span; C-Vimin; Cee-Caps TD; Cee-Vite; Cee-caps td; Cetane-Caps TC; Cetane-Caps TD; Cevi-Bid; Component of E and C-Level; IDO-C; Iron(II) ascorbate; Iron-ascorbic acid complexes; L-Ascorbic acid; L-Lyxoascorbic acid; L-Xyloascorbic acid; L-ascorbic acid; Liqui-Cee; Meri-C; Sodium Ascorbate (Ascorbic Acid); Vitamin-C; Ascorbic acid [BAN:INN:JAN]; Ascorbic acid [INN:BAN:JAN]; CE-VI-Sol; Ce-Mi-Lin; Dora-C-500; L-3-Ketothreohexuronic acid lactone; L-3-ketothreohexuronic acid; L-Ascorbic acid, free radical form; Ascor-bid; Ascorbic acid (JP15/USP/INN); Ascor-BID; L-(+)-Ascorbic Acid; L-threo-Hex-2-enonic acid, gamma-lactone; L-threo-hex-1-eofuranos-3-ulose; L-threo-hex-2-enono-1,4-lactone; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; 3-Keto-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone; 3-Oxo-L-gulofuranolactone (enol form); [14C]ascorbic acid
DMXJ7O8 TC Vitamins
DMXJ7O8 DT Small molecular drug
DMXJ7O8 PC 54670067
DMXJ7O8 MW 176.12
DMXJ7O8 FM C6H8O6
DMXJ7O8 IC InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1
DMXJ7O8 CS C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O
DMXJ7O8 IK CIWBSHSKHKDKBQ-JLAZNSOCSA-N
DMXJ7O8 IU (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one
DMXJ7O8 CA CAS 50-81-7
DMXJ7O8 CB CHEBI:29073
DMXJ7O8 DE Vitamin C deficiency; Urinary tract infection
DMWQUC9 ID DMWQUC9
DMWQUC9 DN Vitamin D
DMWQUC9 HS Approved
DMWQUC9 SN Vigantol; Vigorsan; Vitamin D3; Vitinc Dan-Dee-3; cholecalciferol; vitamin d-3; (+)-Vitamin D3; Activated 7-dehydrocholesterol; Arachitol; Calciol; Cholecalciferol, D3; Cholecalciferolum; Colecalciferol; Colecalciferolo [DCIT]; Colecalciferolum; Colecalciferolum [INN-Latin]; Colecalcipherol; D3-Vicotrat; D3-Vigantol; Delsterol; Deparal; Duphafral D3 1000; Ebivit; FeraCol; NEO Dohyfral D3; Oleovitamin D3; Quintox; Rampage; Ricketon; Trivitan; VITAMIN D; Vi-De3; Vi-de-3-hydrosol; 1406-16-2; 67-97-0; 7-Dehydrocholestrol, activated;; MFCD00078131
DMWQUC9 PC 5280795
DMWQUC9 MW 384.6
DMWQUC9 FM C27H44O
DMWQUC9 IC QYSXJUFSXHHAJI-YRZJJWOYSA-N
DMWQUC9 CS CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
DMWQUC9 IK 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
DMWQUC9 IU (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
DMWQUC9 CA CAS 67-97-0
DMWQUC9 CB CHEBI:28940
DMWQUC9 DE Hyperparathyroidism
DMZC90K ID DMZC90K
DMZC90K DN Vitamin E
DMZC90K HS Approved
DMZC90K SN Covi-ox; VITAMIN E; E-Vimin; Syntopherol; Profecundin; Evitaminum; Viprimol; Vascuals; Etamican; Viteolin; Tokopharm; Vitayonon; Epsilan; Emipherol; Denamone; Almefrol; Verrol; Ilitia; Etavit; 77171-98-3; Evion; Esorb; alpha-Tokoferol; alpha Tocopherol; Vitaplex E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; Spavit E; Vita E; Endo E; Med-E; Lan-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; (R)-2,5,7,8-tetramethyl-2-((4S,8S)-4,8,12-trimethyltridecyl)chroman-6-ol; Rhenogran Ronotec 50; Vi-E; Covitol F 1000; E 307 (tocopherol)
DMZC90K DT Small molecular drug
DMZC90K PC 14985
DMZC90K MW 430.7
DMZC90K FM C29H50O2
DMZC90K IC InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1
DMZC90K CS CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C
DMZC90K IK GVJHHUAWPYXKBD-IEOSBIPESA-N
DMZC90K IU (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
DMZC90K CA CAS 59-02-9
DMZC90K CB CHEBI:18145
DMZC90K DE Cardiovascular disease
DMWIJTN ID DMWIJTN
DMWIJTN DN Voclosporin
DMWIJTN HS Approved
DMWIJTN SN Luveniq; ISAtx-247; ISA-247; UNII-2PN063X6B1; ISATX247; 515814-01-4; ISA247; 2PN063X6B1; ISA 247; trans-ISA-247; LX211; Voclosporin (USAN/INN); Voclosporin [USAN:INN]; Voclera; 3odi; LX-211; LX-214; ISA247, Luveniq; AC1OCFHS; R-1524; SCHEMBL12632344; CHEBI:135957; (E)-ISA-247; DB11693; 515814-00-3; HY-106638; CS-0026210; D09033; Cyclosporin A, 6-((2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic acid)-; 368455-04-3; Luveniq; Voclosporin [USAN]; R 1524; Trans-ISA 247; Trans-ISA-247; TrkA-IgG
DMWIJTN CP Isotechnika
DMWIJTN DT Small molecular drug
DMWIJTN PC 6918486
DMWIJTN MW 1214.6
DMWIJTN FM C63H111N11O12
DMWIJTN IC InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1
DMWIJTN CS CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMWIJTN IK BICRTLVBTLFLRD-PTWUADNWSA-N
DMWIJTN IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMWIJTN CA CAS 515814-00-3
DMWIJTN CB CHEBI:135957
DMWIJTN DE Kidney disease; Psoriasis vulgaris; Lupus nephritis
DMUBP9O ID DMUBP9O
DMUBP9O DN Voglibose
DMUBP9O HS Approved
DMUBP9O SN Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol
DMUBP9O CP Takeda
DMUBP9O TC Hypoglycemic Agents
DMUBP9O DT Small molecular drug
DMUBP9O PC 444020
DMUBP9O MW 267.28
DMUBP9O FM C10H21NO7
DMUBP9O IC InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
DMUBP9O CS C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
DMUBP9O IK FZNCGRZWXLXZSZ-CIQUZCHMSA-N
DMUBP9O IU (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
DMUBP9O CA CAS 83480-29-9
DMUBP9O CB CHEBI:32300
DMUBP9O DE Diabetic complication
DM1YEPS ID DM1YEPS
DM1YEPS DN Volanesorsen
DM1YEPS HS Approved
DM1YEPS CP Akcea Therapeutics Cambridge, MA, Ionis Pharmaceuticals Carlsbad, CA
DM1YEPS DT Antisense oligonucleotide
DM1YEPS PC 121494123
DM1YEPS MW 7165
DM1YEPS FM C230H320N63O125P19S19
DM1YEPS IC InChI=1S/C230H320N63O125P19S19/c1-98-55-274(217(308)254-178(98)231)142-45-112(400-419(322,438)361-70-124-113(46-143(381-124)275-56-99(2)179(232)255-218(275)309)401-423(326,442)367-76-130-119(52-149(387-130)288-92-248-152-183(236)242-89-245-186(152)288)407-427(330,446)369-78-132-121(54-151(389-132)290-94-252-156-190(290)260-215(240)263-202(156)306)408-425(328,444)365-72-125-114(47-144(382-125)276-57-100(3)180(233)256-219(276)310)406-428(331,447)372-81-134-160(171(354-38-28-344-18)206(393-134)283-64-107(10)196(300)269-226(283)317)412-432(335,451)375-84-137-163(173(356-40-30-346-20)208(395-137)285-66-109(12)198(302)271-228(285)319)415-435(338,454)377-86-139-165(175(358-42-32-348-22)210(397-139)287-68-111(14)200(304)273-230(287)321)416-436(339,455)379-87-140-166(176(359-43-33-349-23)212(398-140)292-96-250-154-185(238)244-91-247-188(154)292)417-430(333,449)371-80-133-158(295)168(351-35-25-341-15)204(391-133)282-63-106(9)195(299)268-225(282)316)123(380-142)71-362-421(324,440)403-117-50-147(279-61-104(7)193(297)266-223(279)314)386-128(117)75-366-426(329,445)409-120-53-150(289-93-251-155-189(289)259-214(239)262-201(155)305)388-131(120)77-368-424(327,443)405-118-51-148(280-62-105(8)194(298)267-224(280)315)385-127(118)74-364-422(325,441)404-116-49-146(278-60-103(6)192(296)265-222(278)313)384-126(116)73-363-420(323,439)402-115-48-145(277-58-101(4)181(234)257-220(277)311)383-129(115)79-370-429(332,448)411-162-136(394-207(172(162)355-39-29-345-19)284-65-108(11)197(301)270-227(284)318)83-374-434(337,453)414-164-138(396-209(174(164)357-41-31-347-21)286-67-110(13)199(303)272-229(286)320)85-376-433(336,452)413-161-135(392-205(170(161)353-37-27-343-17)281-59-102(5)182(235)258-221(281)312)82-378-437(340,456)418-167-141(399-213(177(167)360-44-34-350-24)293-97-253-157-191(293)261-216(241)264-203(157)307)88-373-431(334,450)410-159-122(69-294)390-211(169(159)352-36-26-342-16)291-95-249-153-184(237)243-90-246-187(153)291/h55-68,89-97,112-151,158-177,204-213,294-295H,25-54,69-88H2,1-24H3,(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H2,231,254,308)(H2,232,255,309)(H2,233,256,310)(H2,234,257,311)(H2,235,258,312)(H2,236,242,245)(H2,237,243,246)(H2,238,244,247)(H,265,296,313)(H,266,297,314)(H,267,298,315)(H,268,299,316)(H,269,300,317)(H,270,301,318)(H,271,302,319)(H,272,303,320)(H,273,304,321)(H3,239,259,262,305)(H3,240,260,263,306)(H3,241,261,264,307)/t112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,204+,205+,206+,207+,208+,209+,210+,211+,212+,213+,419?,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?/m0/s1
DM1YEPS CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OCCOC)N6C=C(C(=O)NC6=O)C)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OCCOC)N8C=C(C(=O)NC8=O)C)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)CO)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O
DM1YEPS IK IJUQCWMZCMFFJP-GQSLRNSLSA-N
DM1YEPS IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM1YEPS DE Familial chylomicronemia syndrome; Hyperlipoproteinemia; Hypertriglyceridemia
DMO6315 ID DMO6315
DMO6315 DN Vonoprazan
DMO6315 HS Approved
DMO6315 SN TAK-438
DMO6315 CP Takeda
DMO6315 DT Small molecular drug
DMO6315 PC 45375887
DMO6315 MW 461.5
DMO6315 FM C21H20FN3O6S
DMO6315 IC InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMO6315 CS CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=C/C(=O)O)\\C(=O)O
DMO6315 IK ROGSHYHKHPCCJW-WLHGVMLRSA-N
DMO6315 IU (E)-but-2-enedioic acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
DMO6315 CA CAS 881681-01-2
DMO6315 DE Gastroesophageal reflux disease; Helicobacter infection
DMI783H ID DMI783H
DMI783H DN Vonvendi
DMI783H HS Approved
DMI783H SN Vonicog alfa
DMI783H CP Vonvendi
DMI783H DT Recombinant protein
DMI783H DE Von willebrand disease
DMA16BR ID DMA16BR
DMA16BR DN Vorapaxar
DMA16BR HS Approved
DMA16BR SN Vorapaxar; 618385-01-6; Zontivity; SCH-530348; SCH530348; UNII-ZCE93644N2; CHEMBL493982; CHEBI:82702; ZCE93644N2; MK-5348; ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate; Ethyl [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(E)-2-[5-(3-Fluorophenyl)pyridin-2-Yl]ethenyl}-1-Methyl-3-Oxododecahydronaphtho[2,3-C]furan-6-Yl]carbamate; Vorapaxar [USAN:INN]; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]etheny
DMA16BR CP Schering-Plough
DMA16BR DT Small molecular drug
DMA16BR PC 10077130
DMA16BR MW 492.6
DMA16BR FM C29H33FN2O4
DMA16BR IC InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1
DMA16BR CS CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C
DMA16BR IK ZBGXUVOIWDMMJE-QHNZEKIYSA-N
DMA16BR IU ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
DMA16BR CA CAS 618385-01-6
DMA16BR CB CHEBI:82702
DMA16BR DE Myocardial infarction
DMAOL2S ID DMAOL2S
DMAOL2S DN Voriconazole
DMAOL2S HS Approved
DMAOL2S SN VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC
DMAOL2S CP Pfizer
DMAOL2S TC Antifungal Agents
DMAOL2S DT Small molecular drug
DMAOL2S PC 71616
DMAOL2S MW 349.31
DMAOL2S FM C16H14F3N5O
DMAOL2S IC InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
DMAOL2S CS C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
DMAOL2S IK BCEHBSKCWLPMDN-MGPLVRAMSA-N
DMAOL2S IU (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
DMAOL2S CA CAS 188416-29-7
DMAOL2S CB CHEBI:10023
DMAOL2S DE Invasive aspergillosis
DMWMPD4 ID DMWMPD4
DMWMPD4 DN Vorinostat
DMWMPD4 HS Approved
DMWMPD4 SN NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)
DMWMPD4 CP Merck
DMWMPD4 TC Anticancer Agents
DMWMPD4 DT Small molecular drug
DMWMPD4 PC 5311
DMWMPD4 MW 264.32
DMWMPD4 FM C14H20N2O3
DMWMPD4 IC InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
DMWMPD4 CS C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
DMWMPD4 IK WAEXFXRVDQXREF-UHFFFAOYSA-N
DMWMPD4 IU N'-hydroxy-N-phenyloctanediamide
DMWMPD4 CA CAS 149647-78-9
DMWMPD4 CB CHEBI:45716
DMWMPD4 DE Cutaneous T-cell lymphoma
DM6F1PU ID DM6F1PU
DM6F1PU DN Vortioxetine
DM6F1PU HS Approved
DM6F1PU SN VORTIOXETINE; 508233-74-7; 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine; Lu AA21004; UNII-3O2K1S3WQV; 3O2K1S3WQV; CHEBI:76016; Trintellix; 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine; Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-; Brintellix (TN); 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine; 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine; 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine; CHEMBL2204360; 1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine; Lu-AA21004
DM6F1PU CP Lundbeck; Takeda Pharmaceuticals
DM6F1PU DT Small molecular drug
DM6F1PU PC 9966051
DM6F1PU MW 298.4
DM6F1PU FM C18H22N2S
DM6F1PU IC InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
DM6F1PU CS CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
DM6F1PU IK YQNWZWMKLDQSAC-UHFFFAOYSA-N
DM6F1PU IU 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine
DM6F1PU CA CAS 508233-74-7
DM6F1PU CB CHEBI:76016
DM6F1PU DE Major depressive disorder; Mood disorder
DMCS6M5 ID DMCS6M5
DMCS6M5 DN Voxelotor
DMCS6M5 HS Approved
DMCS6M5 SN Hemoglobin Modulators-1; 1446321-46-5; UNII-3ZO554A4Q8; GBT 440; 3ZO554A4Q8; 2-hydroxy-6-([2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl]methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; 2-hydroxy-6-((2-(1-(propan-2-yl)-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde; Voxelotor [USAN]; SCHEMBL15065529; Voxelotor(GBT440, GTx011); GTX-011; GBT-440; MolPort-044-830-677; FWCVZAQENIZVMY-UHFFFAOYSA-N; AKOS030526545; ZINC145969085; CS-5317; HY-18681; DA-44587; S
DMCS6M5 CP Global Blood Therapeutics South San Francisco, CA
DMCS6M5 PC 71602803
DMCS6M5 MW 337.4
DMCS6M5 FM C19H19N3O3
DMCS6M5 IC InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
DMCS6M5 CS CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
DMCS6M5 IK FWCVZAQENIZVMY-UHFFFAOYSA-N
DMCS6M5 IU 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
DMCS6M5 CA CAS 1446321-46-5
DMCS6M5 DE Sickle-cell disorder
DMAI83D ID DMAI83D
DMAI83D DN Voxilaprevir
DMAI83D HS Approved
DMAI83D SN Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]; 0570F37359;J3.665.048F; 1535212-07-7; CS-0017027; D10899; DB12026; GS-9857; HY-19840; L9P; SCHEMBL15412621; UNII-0570F37359
DMAI83D PC 89921642
DMAI83D MW 868.9
DMAI83D FM C40H52F4N6O9S
DMAI83D IC MZBLZLWXUBZHSL-FZNJKFJKSA-N
DMAI83D CS CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DMAI83D IK 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DMAI83D IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DMAI83D CA CAS 1535212-07-7
DMAI83D DE Viral hepatitis
DMIO4V5 ID DMIO4V5
DMIO4V5 DN VRX496
DMIO4V5 HS Approved
DMIO4V5 SN Nelfinavir; nelfinavir; 159989-64-7; Viracept; Nelfinavir [INN:BAN]; AG1343; UNII-HO3OGH5D7I; AG-1343; C32H45N3O4S; NELFINAVIR MESYLATE AG1343; Viracept (TN); HO3OGH5D7I; CHEBI:7496; AG 1343; NLF; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NFV; NFV; Nelfinavir Monomethane Sulfonate; AG1346; Nelfinavir (INN); Nelfinavir [BAN:INN]; AG1343 (*Mesylate salt*); Viracept (TM)(*Mesylate salt*); Met-SDF-1beta & Nelfinavir; Met-Stromal Cell-derived Factor-1beta (Human) & Nelfinavir; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
DMIO4V5 CP VIRxSYS Corporation
DMIO4V5 TC Antisense
DMIO4V5 DT Antisense drug
DMIO4V5 DE Acquired immune deficiency syndrome; Coronavirus infection
DMJYCVW ID DMJYCVW
DMJYCVW DN Warfarin
DMJYCVW HS Approved
DMJYCVW SN Brumolin; Choice; Coumadin; Coumafen; Coumafene; Coumaphen; Coumaphene; Coumarins; Coumefene; Dethmor; Dethnel; Kumader; Kumadu; Kumatox; Kypfarin; Maveran; Panwarfin; Prothromadin; RAX; Ratorex; Ratoxin; Ratron; Rattentraenke; Rattunal; Rodafarin; Rosex; Sofarin; Solfarin; Warfarat; Warfarina; Warfarine; Warfarinum; Warficide; Zoocoumarin; Arab Rat Death; Arab rat deth; Coumafene [French]; Dicusat E; Eastern states duocide; Fasco fascrat powder; Maag Rattentod Cum; Mouse pak; Ratron G; Rattenstreupulver Neu Schacht; Rattenstreupulver new schacht; Rodafarin C; Rodex blox; Sorexa plus; Temus W; Twin light rat away; Vampirinip II; Vampirinip iii; Warfarin Q; Warfarin plus; Warfarin plus [discontinued]; Zoocoumarin [Netherlands and USSR]; Zoocoumarin [Russian]; CBKinase1_000192; CBKinase1_012592; Latka 42; Latka 42 [Czech]; PS104_SUPELCO; WARF compound 42; Warf 10; Warf 42; Athrombine-K; CO-Rax; Choice (TN); Coumadin (TN); D-Con; Frass-Ratron; Jantoven (TN); Liqua-tox; Mar-Frin; Marevan (TN); Place-pax; Rac-Warfarin; Rat & mice bait; Rat-Gard; Rat-Kill; Rat-Mix; Rat-Ola; Rat-Trol; Ratten-Koederrohr; Ro-Deth; Rough & ready mouse mix; Tox-hid; Waran (TN); Warfarin (INN); Warfarin (and salts of); Warfarin [BSI:ISO]; Warfarin [INN:BAN]; Warfarin(R); Warfarina [INN-Spanish]; Warfarine [INN-French]; Warfarine [ISO-French]; Warfarinum [INN-Latin]; Cov-R-Tox; Martin's mar-frin; Rat-B-gon; Rat-a-way; Rats-no-more; Spray-trol brand roden-trol; Rat-o-cide #2; Warfarin titrated to an INR of 2.5-3.0; W.A.R.F. 42; (-)-Warfarin; (S)-Warfarin; 200 coumarin
DMJYCVW CP Pharmaceutical Research Assoc Inc
DMJYCVW TC Anticoagulants
DMJYCVW DT Small molecular drug
DMJYCVW PC 54678486
DMJYCVW MW 308.3
DMJYCVW FM C19H16O4
DMJYCVW IC InChI=1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3
DMJYCVW CS CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
DMJYCVW IK PJVWKTKQMONHTI-UHFFFAOYSA-N
DMJYCVW IU 4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
DMJYCVW CA CAS 81-81-2
DMJYCVW CB CHEBI:87732
DMJYCVW DE Atrial fibrillation; Thrombosis
DMLHOA0 ID DMLHOA0
DMLHOA0 DN Xatral
DMLHOA0 HS Approved
DMLHOA0 SN Alfetim; Alfoten; Urion; Uroxatral; Alfuzosin HCl; Alfuzosin Hydrochloride; Alfuzosin hydrochloride [USAN]; Xatral OD; Xatral Retard; Xatral SR; Xatral XL; SL 77 499-10; SL 77499-10; SL-7749910; Uroxatral, Alfuzosin hydrochloride; Alfuzosin hydrochloride (JAN/USAN); SL-77499-10; SL-77.0499-10; N-[3-[4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide hydrochloride; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide hydrochloride; N-{3-[(4-amino-6,7-dimethoxychinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamidhydrochlorid; (+-)-N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furamide monohydrochloride
DMLHOA0 CP Sanofi-Aventis
DMLHOA0 DT Small molecular drug
DMLHOA0 PC 71764
DMLHOA0 MW 425.9
DMLHOA0 FM C19H28ClN5O4
DMLHOA0 IC InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
DMLHOA0 CS CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl
DMLHOA0 IK YTNKWDJILNVLGX-UHFFFAOYSA-N
DMLHOA0 IU N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride
DMLHOA0 CA CAS 81403-68-1
DMLHOA0 CB CHEBI:32286
DMLHOA0 DE Benign prostatic hyperplasia
DMU8ANS ID DMU8ANS
DMU8ANS DN Ximelegatran
DMU8ANS HS Approved
DMU8ANS SN Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide; Y-27632
DMU8ANS CP AstraZeneca
DMU8ANS DT Small molecular drug
DMU8ANS PC 448042
DMU8ANS MW 247.34
DMU8ANS FM C14H21N3O
DMU8ANS IC InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1
DMU8ANS CS C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
DMU8ANS IK IYOZTVGMEWJPKR-VOMCLLRMSA-N
DMU8ANS IU 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide
DMU8ANS CA CAS 146986-50-7
DMU8ANS CB CHEBI:75393
DMU8ANS DE Myocardial infarction; Asthma
DMAR467 ID DMAR467
DMAR467 DN Xylose
DMAR467 HS Approved
DMAR467 SN D-Xylose; D-Xylopyranose; Xyloside; D-xylopentose; (3R,4S,5R)-oxane-2,3,4,5-tetrol; 7261-26-9; CHEBI:53455; Xylopyranoside; D-Xylopyranoside; Xylomed; D-Xyl; 10257-31-5; (3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrol; (3R,4S,5R)-Tetrahydro-2H-pyran-2,3,4,5-tetraol; D-(+)-Xylose, > Xyl; Xylose (USP); Xylo-Pfan (TN); DSSTox_CID_3745; Epitope ID:114701; AC1L35YW; DSSTox_RID_77180; SCHEMBL39891; DSSTox_GSID_23745; MLS001361339; cid_135191; CHEMBL502135; DTXSID0023745; CTK0H1735; BDBM16234; MolPort-003-934-029; D-xylose
DMAR467 DT Small molecular drug
DMAR467 PC 135191
DMAR467 MW 150.13
DMAR467 FM C5H10O5
DMAR467 IC InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5?/m1/s1
DMAR467 CS C1[C@H]([C@@H]([C@H](C(O1)O)O)O)O
DMAR467 IK SRBFZHDQGSBBOR-IOVATXLUSA-N
DMAR467 IU (3R,4S,5R)-oxane-2,3,4,5-tetrol
DMAR467 CA CAS 10257-31-5
DMAR467 CB CHEBI:53455
DMAR467 DE Gastrointestinal disease
DMDPM7R ID DMDPM7R
DMDPM7R DN Y-25130
DMDPM7R HS Approved
DMDPM7R SN Azasetron; Nazasetron; Azasetron [INN]; C17H20ClN3O3; 123039-99-6; WUKZPHOXUVCQOR-UHFFFAOYSA-N; Azasetron (INN); 6-Chloro-4-methyl-3-oxo-N-(quinuclidin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide; NCGC00024563-02; DSSTox_RID_81029; DSSTox_CID_25651; DSSTox_GSID_45651; (- )-6-Chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-carboxamide; N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
DMDPM7R DT Small molecular drug
DMDPM7R PC 2264
DMDPM7R MW 349.8
DMDPM7R FM C17H20ClN3O3
DMDPM7R IC InChI=1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23)
DMDPM7R CS CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4
DMDPM7R IK WUKZPHOXUVCQOR-UHFFFAOYSA-N
DMDPM7R IU N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
DMDPM7R CA CAS 123040-69-7
DMDPM7R CB CHEBI:91712
DMDPM7R DE Nausea and vomiting
DMNZCI1 ID DMNZCI1
DMNZCI1 DN YM443
DMNZCI1 HS Approved
DMNZCI1 SN Acofide; Acotiamide
DMNZCI1 CP Astellas
DMNZCI1 DT Small molecular drug
DMNZCI1 PC 6918406
DMNZCI1 MW 541.1
DMNZCI1 FM C21H37ClN4O8S
DMNZCI1 IC InChI=1S/C21H30N4O5S.ClH.3H2O/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26;;;;/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27);1H;3*1H2
DMNZCI1 CS CC(C)N(CCNC(=O)C1=CSC(=N1)NC(=O)C2=CC(=C(C=C2O)OC)OC)C(C)C.O.O.O.Cl
DMNZCI1 IK NPTDXIXCQCFGKC-UHFFFAOYSA-N
DMNZCI1 IU N-[2-[di(propan-2-yl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;trihydrate;hydrochloride
DMNZCI1 CA CAS 773092-05-0
DMNZCI1 DE Functional dyspepsia
DMMP3Y2 ID DMMP3Y2
DMMP3Y2 DN Yn-968D1
DMMP3Y2 HS Approved
DMMP3Y2 SN Apatinib; Apatinib mesylate; VEGF receptor inhibitor (cancer), Advenchen; VEGFR2 receptor inhibitor (cancer), LSK/ Jiangsu Henrui/ Bukwang
DMMP3Y2 CP Advenchen Laboratories LLC
DMMP3Y2 DT Small molecular drug
DMMP3Y2 PC 45139106
DMMP3Y2 MW 493.6
DMMP3Y2 FM C25H27N5O4S
DMMP3Y2 IC InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)
DMMP3Y2 CS CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4
DMMP3Y2 IK FYJROXRIVQPKRY-UHFFFAOYSA-N
DMMP3Y2 IU N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid
DMMP3Y2 CA CAS 1218779-75-9
DMMP3Y2 DE Breast cancer
DMJCP1Y ID DMJCP1Y
DMJCP1Y DN Yohimbine
DMJCP1Y HS Approved
DMJCP1Y SN APHRODINE; Actibine; Aphrodyne; Aphrosol; Corynine; Johimbin; Quebrachin; Quebrachine; Thybine; Yocon; Yohimar; Yohimbin; Yohimex; Yoman; Yovital; Dayto himbin; Yohimbic acid methyl ester; Baron-X; Trans-Quinolizidine yohimbine; Yohimbine (DCF); Methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-(9CI); Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; (+)-Yohimbin; (+)-Yohimbine; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
DMJCP1Y CP Palisades Pharmaceuticals Inc
DMJCP1Y TC Mydriatics
DMJCP1Y DT Small molecular drug
DMJCP1Y PC 8969
DMJCP1Y MW 354.4
DMJCP1Y FM C21H26N2O3
DMJCP1Y IC InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1
DMJCP1Y CS COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
DMJCP1Y IK BLGXFZZNTVWLAY-SCYLSFHTSA-N
DMJCP1Y IU methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMJCP1Y CA CAS 146-48-5
DMJCP1Y CB CHEBI:10093
DMJCP1Y DE Erectile dysfunction
DMHNQOG ID DMHNQOG
DMHNQOG DN Zafirlukast
DMHNQOG HS Approved
DMHNQOG SN Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide
DMHNQOG CP AstraZeneca plc
DMHNQOG TC Antiasthmatic Agents
DMHNQOG DT Small molecular drug
DMHNQOG PC 5717
DMHNQOG MW 575.7
DMHNQOG FM C31H33N3O6S
DMHNQOG IC InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
DMHNQOG CS CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
DMHNQOG IK YEEZWCHGZNKEEK-UHFFFAOYSA-N
DMHNQOG IU cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
DMHNQOG CA CAS 107753-78-6
DMHNQOG CB CHEBI:10100
DMHNQOG DE Asthma
DMH7MUV ID DMH7MUV
DMH7MUV DN Zalcitabine
DMH7MUV HS Approved
DMH7MUV SN zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; ddC; Cytidine, 2',3'-dideoxy-; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2,3-dideoxycytidine; NSC 606170; UNII-6L3XT8CB3I; CCRIS 692; HSDB 7156; C9H13N3O3; Ro-24-2027/000; Ro 24-2027/000; CHEMBL853; BRN 0654956; 6L3XT8CB3I; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; WREGKURFCTUGRC-POYBYMJQSA-N; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; MFCD00012188; DdC; DdCyd; D 5782; DDC (DDC); DdC & Interferon alpha; DdC & sCD4; DdC (Antiviral); Hivid (TN); Hivid(TM); Interferon AD + ddC; KS-1130; SRI-7707; Beta-D-DDC; DS-4152 & ddC; DdC & GM-CSF; DdC & IFN-alpha; DdC & NP (from PHCA or HSA); PC-SOD & ddC; Zalcitabine [USAN:INN:BAN]; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Zalcitabine (JAN/USP/INN); Beta-D-2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy & Interferon alpha; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Lecithinized superoxide dismutase & beta-D-2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; DdC
DMH7MUV CP Hoffmann-La Roche pharmaceutical company
DMH7MUV TC Anti-HIV Agents
DMH7MUV DT Small molecular drug
DMH7MUV PC 24066
DMH7MUV MW 211.22
DMH7MUV FM C9H13N3O3
DMH7MUV IC InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
DMH7MUV CS C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N
DMH7MUV IK WREGKURFCTUGRC-POYBYMJQSA-N
DMH7MUV IU 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMH7MUV CA CAS 7481-89-2
DMH7MUV CB CHEBI:10101
DMH7MUV DE Human immunodeficiency virus infection
DMGFWSM ID DMGFWSM
DMGFWSM DN Zaleplon
DMGFWSM HS Approved
DMGFWSM SN Sonata; Zalaplon; Zerene; CL 284846; L 846; L846; LJC 10846; ZAL 846; AZ-007; CL 284,846; CL-284846; CL284,846; L-846; LJC-10846; SKP-1041; Sonata (TN); Staccato-zaleplon; Starnoc (TN); ZAL-846; Zaleplon [USAN:INN]; Zaleplon (JAN/USAN/INN); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide
DMGFWSM CP King Pharm
DMGFWSM TC Hypnotics and Sedatives
DMGFWSM DT Small molecular drug
DMGFWSM PC 5719
DMGFWSM MW 305.33
DMGFWSM FM C17H15N5O
DMGFWSM IC InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
DMGFWSM CS CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
DMGFWSM IK HUNXMJYCHXQEGX-UHFFFAOYSA-N
DMGFWSM IU N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
DMGFWSM CA CAS 151319-34-5
DMGFWSM CB CHEBI:10102
DMGFWSM DE Insomnia
DMFMBZ4 ID DMFMBZ4
DMFMBZ4 DN Zanamivir
DMFMBZ4 HS Approved
DMFMBZ4 SN zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7; GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir
DMFMBZ4 CP GlaxoSmithKline
DMFMBZ4 TC Antiviral Agents
DMFMBZ4 DT Small molecular drug
DMFMBZ4 PC 60855
DMFMBZ4 MW 332.31
DMFMBZ4 FM C12H20N4O7
DMFMBZ4 IC InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
DMFMBZ4 CS CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N=C(N)N
DMFMBZ4 IK ARAIBEBZBOPLMB-UFGQHTETSA-N
DMFMBZ4 IU (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMFMBZ4 CA CAS 139110-80-8
DMFMBZ4 CB CHEBI:50663
DMFMBZ4 DE Influenza virus infection
DMJWRQP ID DMJWRQP
DMJWRQP DN Zanubrutinib
DMJWRQP HS Approved
DMJWRQP SN RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27
DMJWRQP CP BeiGene Cambridge, MA
DMJWRQP PC 135905454
DMJWRQP MW 471.5
DMJWRQP FM C27H29N5O3
DMJWRQP IC InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)
DMJWRQP CS C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
DMJWRQP IK RNOAOAWBMHREKO-UHFFFAOYSA-N
DMJWRQP IU 2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
DMJWRQP DE B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma; Waldenstrom macroglobulinemia; Mantle cell lymphoma
DMUR5NG ID DMUR5NG
DMUR5NG DN Zanubrutinib
DMUR5NG HS Approved
DMUR5NG SN Zanubrutinib; Zanubrutinib (USAN/INN); Zanubrutinib [INN]; Zanubrutinib [USAN]; compound 27b [US9447106]; (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide; 1691249-45-2; BDBM250082; BGB3111; CHEMBL3936761; CS-0021869; D11422; GTPL9861; HY-101474A; Pyrazolo(1,5-a)pyrimidine-3-carboxamide, 4,5,6,7-tetrahydro-7-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-, (7S)-; SCHEMBL17842597; AG9MHG098Z; US9447106, 27b (peak 2); ZINC584641430; UNII-AG9MHG098Z
DMUR5NG PC 135565884
DMUR5NG MW 471.5
DMUR5NG FM C27H29N5O3
DMUR5NG IC RNOAOAWBMHREKO-QFIPXVFZSA-N
DMUR5NG CS C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
DMUR5NG IK 1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
DMUR5NG IU (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide
DMUR5NG CA CAS 1691249-45-2
DMUR5NG DE Mantle cell lymphoma
DMA5QPM ID DMA5QPM
DMA5QPM DN Zemaira
DMA5QPM HS Approved
DMA5QPM SN Alpha-1-antitrypsin
DMA5QPM CP CSL Behring
DMA5QPM DT Recombinant protein
DMA5QPM DE Emphysema
DMSLJP4 ID DMSLJP4
DMSLJP4 DN Ziconotide
DMSLJP4 HS Approved
DMSLJP4 SN Prialt; Ziconotide [USAN]; SNX 111; DRG-0250; Omega-Conotoxin M VIIA; Omega-conotoxin MVIIA; Prialt (TN); SNX-111; Omega-ConopeptideMVIIA (Conus); Omega-Conotoxin mviia, conus magus; Omega-Conotoxin M VIIA (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide)
DMSLJP4 CP Neurox/Parke Davis
DMSLJP4 TC Analgesics
DMSLJP4 DT Small molecular drug
DMSLJP4 PC 16135415
DMSLJP4 MW 2639.2
DMSLJP4 FM C102H172N36O32S7
DMSLJP4 IC InChI=1S/C102H172N36O32S7/c1-50(2)34-63-91(161)127-62(26-33-171-5)90(160)129-64(35-53-22-24-54(143)25-23-53)92(162)130-65(36-78(148)149)93(163)135-72-48-175-173-45-69(80(108)150)133-86(156)58(18-8-12-29-105)121-76(146)39-117-85(155)66(41-139)131-88(158)61(21-15-32-114-102(111)112)126-96(166)70-46-176-177-47-71(97(167)132-68(43-141)95(165)125-60(87(157)128-63)20-14-31-113-101(109)110)134-89(159)59(19-9-13-30-106)123-81(151)51(3)119-74(144)37-115-83(153)56(16-6-10-27-103)120-75(145)38-116-84(154)57(17-7-11-28-104)124-82(152)55(107)44-172-174-49-73(137-98(72)168)99(169)138-79(52(4)142)100(170)118-40-77(147)122-67(42-140)94(164)136-70/h22-25,50-52,55-73,79,139-143H,6-21,26-49,103-107H2,1-5H3,(H2,108,150)(H,115,153)(H,116,154)(H,117,155)(H,118,170)(H,119,144)(H,120,145)(H,121,146)(H,122,147)(H,123,151)(H,124,152)(H,125,165)(H,126,166)(H,127,161)(H,128,157)(H,129,160)(H,130,162)(H,131,158)(H,132,167)(H,133,156)(H,134,159)(H,135,163)(H,136,164)(H,137,168)(H,138,169)(H,148,149)(H4,109,110,113)(H4,111,112,114)/t51-,52+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,79-/m0/s1
DMSLJP4 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN
DMSLJP4 IK BPKIMPVREBSLAJ-QTBYCLKRSA-N
DMSLJP4 IU 2-[(1R,4S,7S,13S,16R,21R,24S,27S,30S,33S,36S,39S,42R,45S,48S,54S,60S,63R,68R,71S,77S)-63-amino-13,45,54,60-tetrakis(4-aminobutyl)-4,36-bis(3-carbamimidamidopropyl)-16-carbamoyl-71-[(1R)-1-hydroxyethyl]-7,39,77-tris(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-48-methyl-33-(2-methylpropyl)-30-(2-methylsulfanylethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl]acetic acid
DMSLJP4 CA CAS 107452-89-1
DMSLJP4 CB CHEBI:135912
DMSLJP4 DE Pain; Traumatic brain injury
DM4KI7O ID DM4KI7O
DM4KI7O DN Zidovudine
DM4KI7O HS Approved
DM4KI7O SN zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Zidovudinum; Compound S; Thymidine, 3'-azido-3'-deoxy-; ZIDOVUDINE [AZT]; zidovudin; BW A509U; Zidovudinum [Latin]; Zidovudina [Spanish]; BWA509U; DRG-0004; 3'-Azido-2',3'-Dideoxythymidine; ZDV; UNII-4B9XT59T7S; 3'-Deoxy-3'-azidothymidine; CCRIS 105; Aztec; BW-A509U; BW-A-509U; HSDB 6515; 3'-Azido-3'-deoxythymidine (AIDS); CHEMBL129; NSC 602670; BW-A 509U; MLS000028548; 4B9XT59T7S; AZT; Antiviral; Azidodeoxythymidine; ZVD; Zidovudin; Zidovudina; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; Zidovudine EP III; BWA 509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BWA-509U; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFNalpha2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFNalphaA; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-alpha-2; Met-SDF-1beta & AZT; Met-SDF-1beta & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; Dendrigen; CTCE-0422
DM4KI7O CP GlaxoSmithKline
DM4KI7O TC Anti-HIV Agents
DM4KI7O DT Small molecular drug
DM4KI7O PC 35370
DM4KI7O MW 267.24
DM4KI7O FM C10H13N5O4
DM4KI7O IC InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
DM4KI7O CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]
DM4KI7O IK HBOMLICNUCNMMY-XLPZGREQSA-N
DM4KI7O IU 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM4KI7O CA CAS 30516-87-1
DM4KI7O CB CHEBI:10110
DM4KI7O DE Human immunodeficiency virus infection; Virus infection
DMVRIC2 ID DMVRIC2
DMVRIC2 DN Zileuton
DMVRIC2 HS Approved
DMVRIC2 SN Leutrol; Zileutonum; Ziluton; Zyflo; Abbott brand of zileuton; Zyflo CR; Zyflo Filmtab; A 64077; Abbot 64077; Abbott 64077; A-64077; ABBOTT-64077; ABT-077; CTI-02; ZYFLO (TN); ZYFLO, Zileuton; Zileutonum [INN-Latin]; Zyflo (TN); Zileuton (USP/INN); Zileuton [USAN:INN:BAN]; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
DMVRIC2 CP Cornerstone Therapeutics Inc
DMVRIC2 TC Antiinflammatory Agents
DMVRIC2 DT Small molecular drug
DMVRIC2 PC 60490
DMVRIC2 MW 236.29
DMVRIC2 FM C11H12N2O2S
DMVRIC2 IC InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
DMVRIC2 CS CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
DMVRIC2 IK MWLSOWXNZPKENC-UHFFFAOYSA-N
DMVRIC2 IU 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
DMVRIC2 CA CAS 111406-87-2
DMVRIC2 CB CHEBI:10112
DMVRIC2 DE Asthma
DMZ4R3Q ID DMZ4R3Q
DMZ4R3Q DN Zinc salts
DMZ4R3Q HS Approved
DMZ4R3Q DE Arthritis
DMK4OL7 ID DMK4OL7
DMK4OL7 DN Zinostatin stimalamer
DMK4OL7 HS Approved
DMK4OL7 SN Smancs (TN)
DMK4OL7 DT Small molecular drug
DMK4OL7 PC 70682998
DMK4OL7 MW 657.7
DMK4OL7 FM C36H35NO11
DMK4OL7 IC InChI=1S/C36H35NO11/c1-17-9-10-22-18(2)13-21(42-5)15-24(22)28(17)33(40)45-25-14-20-11-12-36(27-16-43-35(41)46-27)26(48-36)8-6-7-23(20)32(25)47-34-29(37-4)31(39)30(38)19(3)44-34/h7,9-10,13-15,19,25-27,29-32,34,37-39H,16H2,1-5H3/b23-7+/t19-,25-,26-,27+,29-,30+,31-,32?,34-,36+/m1/s1
DMK4OL7 CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)OC\\2[C@@H](C=C3/C2=C\\C#C[C@@H]4[C@@](O4)(C#C3)[C@@H]5COC(=O)O5)OC(=O)C6=C(C=CC7=C6C=C(C=C7C)OC)C)NC)O)O
DMK4OL7 IK FYQZGCBXYVWXSP-STTFAQHVSA-N
DMK4OL7 IU [(4S,6R,9E,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4S)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-2,5-dimethylnaphthalene-1-carboxylate
DMK4OL7 DE Brain cancer
DMM58JY ID DMM58JY
DMM58JY DN Ziprasidone
DMM58JY HS Approved
DMM58JY SN 146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280
DMM58JY CP Pfizer
DMM58JY TC Antipsychotic Agents
DMM58JY DT Small molecular drug
DMM58JY PC 60854
DMM58JY MW 412.9
DMM58JY FM C21H21ClN4OS
DMM58JY IC InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
DMM58JY CS C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
DMM58JY IK MVWVFYHBGMAFLY-UHFFFAOYSA-N
DMM58JY IU 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
DMM58JY CA CAS 146939-27-7
DMM58JY CB CHEBI:10119
DMM58JY DE Schizophrenia
DMN4H2O ID DMN4H2O
DMN4H2O DN Zithromax
DMN4H2O HS Approved
DMN4H2O SN azithromycin; Zithromax; 83905-01-5; Azithromycinum; Azithromycine; Sumamed; Zitromax; Zmax; Hemomycin; Azitrocin; Azasite; Azenil; Aritromicina; Zitrotek; Zithrax; Mixoterin; Setron; Aziwok; Zitrim; Aztrin; Zifin; Tobil; Zmas; Zeto; Azithromycinum [Latin]; Azithromycine [French]; Zithromax IV; AZITHROMYCIN DIHYDRATE; Misultina; Azitromax; Z-Pak; Tromix; Aritromicina [Spanish]; Azitromicina; CP-62993; UNII-J2KLZ20U1M; DRG-0104; CCRIS 1961; HSDB 7205; Azithromycin (anhydrous); C38H72N2O12; BRN 5387583; J2KLZ20U1M; Azythromycin; CHEBI:2955
DMN4H2O DT Small molecular drug
DMN4H2O PC 447043
DMN4H2O MW 749
DMN4H2O FM C38H72N2O12
DMN4H2O IC InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
DMN4H2O CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
DMN4H2O IK MQTOSJVFKKJCRP-BICOPXKESA-N
DMN4H2O IU (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
DMN4H2O CA CAS 83905-01-5
DMN4H2O CB CHEBI:2955
DMN4H2O DE Syphilis infection
DMIXC7G ID DMIXC7G
DMIXC7G DN Zoledronate
DMIXC7G HS Approved
DMIXC7G SN Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
DMIXC7G CP Norvatis Phamaceuticals Corporation
DMIXC7G TC Bone Density Conservation Agents
DMIXC7G DT Small molecular drug
DMIXC7G PC 68740
DMIXC7G MW 272.09
DMIXC7G FM C5H10N2O7P2
DMIXC7G IC InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
DMIXC7G CS C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMIXC7G IK XRASPMIURGNCCH-UHFFFAOYSA-N
DMIXC7G IU (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
DMIXC7G CA CAS 118072-93-8
DMIXC7G CB CHEBI:46557
DMIXC7G DE Hypercalcaemia
DM57O90 ID DM57O90
DM57O90 DN Zolgensma
DM57O90 HS Approved
DM57O90 SN Onasemnogene abeparvovec-xioi
DM57O90 CP AveXis
DM57O90 DT Gene therapy
DM57O90 DE Spinal muscular atrophy
DM1IB4Q ID DM1IB4Q
DM1IB4Q DN Zolmitriptan
DM1IB4Q HS Approved
DM1IB4Q SN AscoTop; Flezol; Zolmitriptane; Zolmitriptanum; Zomig; Zomigon; Zolmitriptan RapidFilm; Zolmitriptan [USAN]; Zomig Nasal Spray; Zomig ZMT; AscoTop (TN); BW-311C90; KS-5072; Zomig (TN); Zomig-ZMT; Zomigon (TN); Zomigoro (TN); Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan; (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; (S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; (S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone; (S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one; (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
DM1IB4Q CP AstraZeneca
DM1IB4Q TC Antimigraine Agents
DM1IB4Q DT Small molecular drug
DM1IB4Q PC 60857
DM1IB4Q MW 287.36
DM1IB4Q FM C16H21N3O2
DM1IB4Q IC InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
DM1IB4Q CS CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3
DM1IB4Q IK ULSDMUVEXKOYBU-ZDUSSCGKSA-N
DM1IB4Q IU (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
DM1IB4Q CA CAS 139264-17-8
DM1IB4Q CB CHEBI:10124
DM1IB4Q DE Migraine
DMWOSKJ ID DMWOSKJ
DMWOSKJ DN Zolpidem
DMWOSKJ HS Approved
DMWOSKJ SN zolpidem; 82626-48-0; Ambien; Zolpidemum; Lorex; Zolpidemum [Latin]; Zolpidem [INN:BAN]; UNII-7K383OQI23; N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide; CHEMBL911; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide; DEA No 2783; CHEBI:10125; ZAFYATHCZYHLPB-UHFFFAOYSA-N; 7K383OQI23; NCGC00095179-01; N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide; SL-800750; N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; ZolpiMist; Zolpidem tartrate; Zolpidem (low-dose oral spray, middle-of-the-night awakenings); Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel; [3H]zolpidem
DMWOSKJ CP NovaDel Pharma Inc
DMWOSKJ DT Small molecular drug
DMWOSKJ PC 5732
DMWOSKJ MW 307.4
DMWOSKJ FM C19H21N3O
DMWOSKJ IC InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
DMWOSKJ CS CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C
DMWOSKJ IK ZAFYATHCZYHLPB-UHFFFAOYSA-N
DMWOSKJ IU N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
DMWOSKJ CA CAS 82626-48-0
DMWOSKJ CB CHEBI:10125
DMWOSKJ DE Insomnia
DM0DTF7 ID DM0DTF7
DM0DTF7 DN Zonisamide
DM0DTF7 HS Approved
DM0DTF7 SN Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole
DM0DTF7 CP Eisai
DM0DTF7 TC Analgesics
DM0DTF7 DT Small molecular drug
DM0DTF7 PC 5734
DM0DTF7 MW 212.23
DM0DTF7 FM C8H8N2O3S
DM0DTF7 IC InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
DM0DTF7 CS C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
DM0DTF7 IK UBQNRHZMVUUOMG-UHFFFAOYSA-N
DM0DTF7 IU 1,2-benzoxazol-3-ylmethanesulfonamide
DM0DTF7 CA CAS 68291-97-4
DM0DTF7 DE Epilepsy
DMPI6Z0 ID DMPI6Z0
DMPI6Z0 DN Zopiclone
DMPI6Z0 HS Approved
DMPI6Z0 SN Amoban; Amovane; Imovance; Imovane; Limovan; Optidorm; Rhovane; Siaten; Sopivan; Ximovan; Zileze; Zimoclone; Zimovane; Zopicalm; Zopicalma; Zopiclodura; Zopiclona; Zopiclonum; Zopitan; Zorclone; AbZ brand of zopiclone; Aliud brand of zopiclone; Alpharma brand of zopiclone; Aventis Pharma brand of zopiclone; Aventis brand of zopiclone; Azupharma brand of zopiclone; Betapharm brand of zopiclone; Ciclum brand of zopiclone; Clonmel brand of zopiclone; Dolorgeit brand of zopiclone; Gerard brand of zopiclone; Hexal brand of zopiclone; Hormosan brand of zopiclone; Italfarmaco brand of zopiclone; Merck dura brand of zopiclone; Neuraxpharm brand of zopiclone; Norton brand of zopiclone; Opus brand of zopiclone; Pinewood brand of zopiclone; Ratiopharm brand of zopiclone; Rhodiapharm brand of zopiclone; Stadapharm brand of zopiclone; TAD brand of zopiclone; Temmler brand of zopiclone; Teva brand of zopiclone; Zopiclon AL; Zopiclon AZU; Zopiclon AbZ; Zopiclon Stada; Zopiclon TAD; Zopiclon beta; Zopiclon von ct; RP 27 267; RP 27267; Z 4900; Z4900_SIGMA; Amoban (TN); Ct-Arzneimittel brand of zopiclone; Imovane (TN); Novo-zopiclone; Nu-Pharm brand of zopiclone; Nu-Zopiclone; RP-27267; Ran-zopiclone; Ratio-Zopiclone; Rhone-Poulenc Rorer brand of zopiclone; Zimovane (TN); Zopi-Puren; Zopiclon-TEVA; Zopiclon-neuraxpharm; Zopiclon-ratiopharm; Zopiclona [INN-Spanish]; Zopiclone (TN); Zopiclonum [INN-Latin]; Zopinox (TN); Zopiclone (JAN/INN); Zopiclone [BAN:INN:JAN]; Zopiclone, Imovane, Zimovane, Lunesta; [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; 1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; 4-Methyl-1-piperazinecarboxylic acid ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo(3,4-b)pyrazin-5-one; 6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1-piperazinecarboxylate; 6-(5-chloropyrid-2-yl)-5-(4-methylpiperazin-1-yl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine; 6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
DMPI6Z0 CP Sanofi-Aventis
DMPI6Z0 TC Hypnotics and Sedatives
DMPI6Z0 DT Small molecular drug
DMPI6Z0 PC 5735
DMPI6Z0 MW 388.8
DMPI6Z0 FM C17H17ClN6O3
DMPI6Z0 IC InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3
DMPI6Z0 CS CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl
DMPI6Z0 IK GBBSUAFBMRNDJC-UHFFFAOYSA-N
DMPI6Z0 IU [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
DMPI6Z0 CA CAS 43200-80-2
DMPI6Z0 CB CHEBI:32315
DMPI6Z0 DE Insomnia
DMRMCXW ID DMRMCXW
DMRMCXW DN Zotarolimus
DMRMCXW HS Approved
DMRMCXW SN Abt-578; Zotarolimus (TN)
DMRMCXW CP Medtronic
DMRMCXW DT Small molecular drug
DMRMCXW PC 9876378
DMRMCXW MW 966.2
DMRMCXW FM C52H79N5O12
DMRMCXW IC InChI=1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1
DMRMCXW CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)C)/C)O)OC)C)C)/C)OC
DMRMCXW IK CGTADGCBEXYWNE-JUKNQOCSSA-N
DMRMCXW IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMRMCXW CA CAS 221877-54-9
DMRMCXW CB CHEBI:135897
DMRMCXW DE Solid tumour/cancer
DMF3VXA ID DMF3VXA
DMF3VXA DN Zotepine
DMF3VXA HS Approved
DMF3VXA SN zotepine; 26615-21-4; Nipolept; Lodopin; Zoleptil; Zotepina; Zotepinum; Compound-4; Zotepina [Spanish]; Zotepinum [INN-Latin]; Zotepina [INN-Spanish]; UNII-U29O83JAZW; 2-Chloro-11-(2-(dimethylamino)ethoxy)dibenzo(b,f)thiepin; 2-Chlor-11-(2-dimethylaminoaethoxy)-dibenzo(b,f)-thiepin; C18H18ClNOS; BRN 1435710; U29O83JAZW; CHEMBL285802; CHEBI:32316; HDOZVRUNCMBHFH-UHFFFAOYSA-N; 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine; 2-Chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine; NCGC00182081-02
DMF3VXA DT Small molecular drug
DMF3VXA PC 5736
DMF3VXA MW 331.9
DMF3VXA FM C18H18ClNOS
DMF3VXA IC InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3
DMF3VXA CS CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DMF3VXA IK HDOZVRUNCMBHFH-UHFFFAOYSA-N
DMF3VXA IU 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine
DMF3VXA CA CAS 26615-21-4
DMF3VXA CB CHEBI:32316
DMF3VXA DE Anxiety disorder
DMKYD5N ID DMKYD5N
DMKYD5N DN Zuclopenthixol
DMKYD5N HS Approved
DMKYD5N SN Acuphase; CLOPENTHIXOL; Cisordinol; Clopenthixolum; Clopentixol; Clopixol; Zuclopenthixolum; Zuclopentixol; Alpha Clopenthixol; Zuclopenthixolum [Latin]; Zuclopentixol [Spanish]; Acuphase (TN); Alpha-Clopenthixol; Cisordinol (TN); Clopenthixol (USAN); Clopixol (TN); Zuclopenthixol (INN); Zuclopenthixol [BAN:INN]; (Z)-4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol; 2-{4-[(3Z)-3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 2-{4-[3-(2-chloro-10H-dibenzo[b,e]thiopyran-10-ylidene)propyl]piperazin-1-yl}ethanol; 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol
DMKYD5N CP Lundbeck pharmaceutical company
DMKYD5N TC Antipsychotic Agents
DMKYD5N DT Small molecular drug
DMKYD5N PC 5311507
DMKYD5N MW 401
DMKYD5N FM C22H25ClN2OS
DMKYD5N IC InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
DMKYD5N CS C1CN(CCN1CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
DMKYD5N IK WFPIAZLQTJBIFN-DVZOWYKESA-N
DMKYD5N IU 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol
DMKYD5N CA CAS 53772-83-1
DMKYD5N CB CHEBI:51364
DMKYD5N DE Schizophrenia
DMRCOU5 ID DMRCOU5
DMRCOU5 DN Dicycloplatin
DMRCOU5 HS Registered
DMRCOU5 CP Peking University
DMRCOU5 PC 44475103
DMRCOU5 MW 515.38
DMRCOU5 FM C12H20N2O8Pt
DMRCOU5 IC InChI=1S/2C6H8O4.2H3N.Pt/c2*7-4(8)6(5(9)10)2-1-3-6;;;/h2*1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;;+2/p-2
DMRCOU5 CS C1CC(C1)(C(=O)O)C(=O)O.C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2]
DMRCOU5 IK IIJQICKYWPGJDT-UHFFFAOYSA-L
DMRCOU5 IU azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
DMRCOU5 CA CAS 287402-09-9
DMRCOU5 DE Prostate cancer
DMBZ27L ID DMBZ27L
DMBZ27L DN Favipiravir
DMBZ27L HS Registered
DMBZ27L SN AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
DMBZ27L CP Toyama Chemical
DMBZ27L DT Small molecular drug
DMBZ27L PC 492405
DMBZ27L MW 157.1
DMBZ27L FM C5H4FN3O2
DMBZ27L IC InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
DMBZ27L CS C1=C(N=C(C(=O)N1)C(=O)N)F
DMBZ27L IK ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DMBZ27L IU 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
DMBZ27L CA CAS 259793-96-9
DMBZ27L CB CHEBI:134722
DMBZ27L DE Influenza virus infection
DMDWYUN ID DMDWYUN
DMDWYUN DN HBI-8000
DMDWYUN HS Registered
DMDWYUN SN CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
DMDWYUN CP HUYA Bioscience International; Quintiles
DMDWYUN DT Small molecular drug
DMDWYUN PC 12136798
DMDWYUN MW 390.4
DMDWYUN FM C22H19FN4O2
DMDWYUN IC InChI=1S/C22H19FN4O2/c23-18-8-9-20(19(24)12-18)27-22(29)17-6-3-16(4-7-17)14-26-21(28)10-5-15-2-1-11-25-13-15/h1-13H,14,24H2,(H,26,28)(H,27,29)/b10-5+
DMDWYUN CS C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N
DMDWYUN IK SZMJVTADHFNAIS-BJMVGYQFSA-N
DMDWYUN IU N-(2-amino-4-fluorophenyl)-4-[[[(E)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
DMDWYUN CA CAS 1616493-44-7
DMDWYUN CB CHEBI:135918
DMDWYUN DE Solid tumour/cancer; Melanoma; Merkel cell carcinoma; Renal cell carcinoma; Non-small-cell lung cancer
DM5GFIK ID DM5GFIK
DM5GFIK DN Icotinib hydrochloride
DM5GFIK HS Registered
DM5GFIK SN Conmana; Conmanna; Icotinib; BPI-2009-H
DM5GFIK CP Beta Pharma Inc
DM5GFIK DT Small molecular drug
DM5GFIK PC 44609731
DM5GFIK MW 427.9
DM5GFIK FM C22H22ClN3O4
DM5GFIK IC InChI=1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H
DM5GFIK CS C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4.Cl
DM5GFIK IK PNNGXMJMUUJHAV-UHFFFAOYSA-N
DM5GFIK IU N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine;hydrochloride
DM5GFIK CA CAS 1204313-51-8
DM5GFIK DE Non-small-cell lung cancer
DM5GIWZ ID DM5GIWZ
DM5GIWZ DN Mirogabalin
DM5GIWZ HS Registered
DM5GIWZ SN Mirogabalin; 1138245-13-2; UNII-S7LK2KDM5U; DS-5565; S7LK2KDM5U; Bicyclo[3.2.0]hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; Bicyclo(3.2.0)hept-3-ene-6-acetic acid, 6-(aminomethyl)-3-ethyl-, (1R,5S,6S)-; 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetic acid; ((1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo(3.2.0)hept-3-en-6-yl)acetic acid; Mirogabalin [INN]; Mirogabalin [USAN:INN]; [(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid; DS5565; DS 5565; GTPL8303
DM5GIWZ DT Small molecular drug
DM5GIWZ PC 59509752
DM5GIWZ MW 209.28
DM5GIWZ FM C12H19NO2
DM5GIWZ IC InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1
DM5GIWZ CS CCC1=C[C@@H]2[C@H](C1)C[C@@]2(CC(=O)O)CN
DM5GIWZ IK FTBQORVNHOIASH-CKYFFXLPSA-N
DM5GIWZ IU 2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid
DM5GIWZ CA CAS 1138245-13-2
DM5GIWZ DE Fibromyalgia; Cancer related pain; Cardiovascular disease; Peripheral neuropathy
DMY67U8 ID DMY67U8
DMY67U8 DN Trapidil
DMY67U8 HS Phase 4
DMY67U8 SN trapidil; Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
DMY67U8 DT Small molecular drug
DMY67U8 PC 5531
DMY67U8 MW 205.26
DMY67U8 FM C10H15N5
DMY67U8 IC InChI=1S/C10H15N5/c1-4-14(5-2)9-6-8(3)13-10-11-7-12-15(9)10/h6-7H,4-5H2,1-3H3
DMY67U8 CS CCN(CC)C1=CC(=NC2=NC=NN12)C
DMY67U8 IK GSNOZLZNQMLSKJ-UHFFFAOYSA-N
DMY67U8 IU N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
DMY67U8 CA CAS 15421-84-8
DMY67U8 CB CHEBI:32254
DMY67U8 DE Multiple myeloma; Coronary artery disease; Acute coronary syndrome
DMVZL26 ID DMVZL26
DMVZL26 DN 3,4-Dihydroxycinnamic Acid
DMVZL26 HS Phase 4
DMVZL26 SN Caffeic acid; caffeic acid; 3,4-Dihydroxycinnamic acid; 331-39-5; 3-(3,4-dihydroxyphenyl)acrylic acid; 501-16-6; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; 3,4-Dihydroxybenzeneacrylic acid; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; trans-caffeic acid; trans-Caffeate; 3,4-Dihydroxy-trans-cinnamate; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; Cinnamic acid, 3,4-dihydroxy-; 3-(3,4-Dihydroxyphenyl)propenoic acid; UNII-U2S3A33KVM; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene
DMVZL26 DT Small molecular drug
DMVZL26 PC 689043
DMVZL26 MW 180.16
DMVZL26 FM C9H8O4
DMVZL26 IC InChI=1S/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2+
DMVZL26 CS C1=CC(=C(C=C1/C=C/C(=O)O)O)O
DMVZL26 IK QAIPRVGONGVQAS-DUXPYHPUSA-N
DMVZL26 IU (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
DMVZL26 CA CAS 331-39-5
DMVZL26 CB CHEBI:16433
DMVZL26 DE Thrombocytopenia
DML6CN4 ID DML6CN4
DML6CN4 DN Acemetacin
DML6CN4 HS Phase 4
DML6CN4 SN Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin
DML6CN4 PC 1981
DML6CN4 MW 415.8
DML6CN4 FM C21H18ClNO6
DML6CN4 IC FSQKKOOTNAMONP-UHFFFAOYSA-N
DML6CN4 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
DML6CN4 IK 1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
DML6CN4 IU 2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyacetic acid
DML6CN4 CA CAS 53164-05-9
DML6CN4 CB CHEBI:31162
DML6CN4 DE Osteoarthritis
DM4UE3K ID DM4UE3K
DM4UE3K DN Acetylcarnitine
DM4UE3K HS Phase 4
DM4UE3K SN (-)-Acetylcarnitine; (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate; (R)-Acetylcarnitine; 3040-38-8; 6DH1W9VH8Q; ALCAR; Acetyl-L-(-)-carnitine; Acetyl-L-carnitine; Acetylcarnitine, L-; CAR(2:0); CHEBI:57589; Carnitine, acetyl-, L-; HSDB 7587; L-ACETYLCARNITINE; L-Acetyl carnitine; L-Carnitine acetyl ester; L-O-Acetylcarnitine; Levocarnitine acetyl; Nicetile; O-Acetyl-L-carnitine; R-Acetylcarnitine; RDHQFKQIGNGIED-MRVPVSSYSA-N; UNII-6DH1W9VH8Q; acetyl l-carnitine; acetyl-carnitine; acetylcarnitine
DM4UE3K DT Small molecular drug
DM4UE3K PC 7045767
DM4UE3K MW 203.238
DM4UE3K FM C9H17NO4
DM4UE3K IC InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
DM4UE3K CS CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
DM4UE3K IK RDHQFKQIGNGIED-MRVPVSSYSA-N
DM4UE3K IU (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate
DM4UE3K CA CAS 3040-38-8
DM4UE3K CB CHEBI:57589
DM4UE3K DE Migraine
DM1237M ID DM1237M
DM1237M DN Alfacalcidol
DM1237M HS Phase 4
DM1237M SN Alfacalcidol [INN:BAN:JAN]; Alfacalcidolum; Alfacalcidolum [INN-Latin]; Alfarol; Alpha D 3; Alphacalcidol; Alsiodol; Bondiol; EinsAlpha; One-Alpha; Oxydevit; Sinovul; URQ2517572; Un-Alpha; Vitamin D3, 1alpha-Hydroxy-; alfacalcidol; alpha-Calcidol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol; 1-Hydroxycholecalciferol; 1-Hydroxyvitamin D3; 1alpha-Hydroxy-vitamin D3; 1alpha-Hydroxycholecalciferol; 1alpha-Hydroxyvitamin D3; 1alpha-OH-D3; 41294-56-8; CCRIS 3341; CHEBI:31186; UNII-URQ2517572
DM1237M PC 5282181
DM1237M MW 400.6
DM1237M FM C27H44O2
DM1237M IC OFHCOWSQAMBJIW-AVJTYSNKSA-N
DM1237M CS CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
DM1237M IK 1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
DM1237M IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM1237M CA CAS 41294-56-8
DM1237M CB CHEBI:31186
DM1237M DE Diabetes mellitus
DMY2AH1 ID DMY2AH1
DMY2AH1 DN Aminophenazone
DMY2AH1 HS Phase 4
DMY2AH1 SN AMINOPYRINE; Amidazofen; Amidazophen; Amidazophene; Amidofebrin; Amidofen; Amidophen; Amidophenazone; Amidopyrazoline; Amidopyrin; Amidopyrine; Aminofenazone; Aminophenazon; Aminopyrin; Anafebrina; Brufaneuxol; Dereuma; Dimapyrin; Dimethylaminoantipyrine; Dimethylaminoazophene; Dimethylaminophenazone; Dipirin; Dipyrin; Dipyrine; Eufibron; Febrinina; Febron; Hyparon; Itamidone; Mamallet-A; Novamidon; Piramidon; Pirazon; Piridol; Piromidina; Polinalin; Pyradone; Pyramidon; Pyramidone; aminophenazone; 4-Dimethylaminoantipyrine; 58-15-1
DMY2AH1 PC 6009
DMY2AH1 MW 231.29
DMY2AH1 FM C13H17N3O
DMY2AH1 IC RMMXTBMQSGEXHJ-UHFFFAOYSA-N
DMY2AH1 CS CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)C
DMY2AH1 IK 1S/C13H17N3O/c1-10-12(14(2)3)13(17)16(15(10)4)11-8-6-5-7-9-11/h5-9H,1-4H3
DMY2AH1 IU 4-(dimethylamino)-1,5-dimethyl-2-phenylpyrazol-3-one
DMY2AH1 CA CAS 58-15-1
DMY2AH1 CB CHEBI:160246
DMY2AH1 DE Anaesthesia
DMWDEN0 ID DMWDEN0
DMWDEN0 DN Amylin
DMWDEN0 HS Phase 4
DMWDEN0 SN Amlintide; Pancreatic amylin; IAPP; Islet amyloid polypeptide; Insulinoma amyloid peptide; Diabetes-associated peptide; Insulinoma amyloid polypeptide; Amylin (human); Amlintide [USAN:INN]; 122384-88-7; Human islet amyloid peptide; AC001; AC 001; SCHEMBL374892; C8H16N2O4.C4H10; LS-172011; FT-0688968
DMWDEN0 DT Small molecular drug
DMWDEN0 PC 16132430
DMWDEN0 MW 3903.3
DMWDEN0 FM C165H261N51O55S2
DMWDEN0 IC InChI=1S/C165H261N51O55S2/c1-22-75(12)124(159(266)200-95(47-71(4)5)140(247)203-108(64-219)153(260)206-110(66-221)154(261)216-129(84(21)226)163(270)202-105(58-119(174)234)147(254)209-122(73(8)9)157(264)181-61-121(236)187-106(62-217)150(257)198-103(56-117(172)232)148(255)215-128(83(20)225)162(269)190-93(130(175)237)49-87-38-40-89(227)41-39-87)211-132(239)76(13)183-120(235)60-180-136(243)97(50-85-32-25-23-26-33-85)194-144(251)101(54-115(170)230)196-145(252)102(55-116(171)231)197-151(258)107(63-218)205-152(259)109(65-220)204-142(249)99(52-88-59-178-69-182-88)201-158(265)123(74(10)11)210-146(253)96(48-72(6)7)193-141(248)98(51-86-34-27-24-28-35-86)195-143(250)100(53-114(169)229)191-131(238)77(14)184-139(246)94(46-70(2)3)192-137(244)91(37-31-45-179-165(176)177)188-138(245)92(42-43-113(168)228)189-161(268)126(81(18)223)212-133(240)78(15)185-155(262)111-67-272-273-68-112(207-135(242)90(167)36-29-30-44-166)156(263)199-104(57-118(173)233)149(256)214-125(80(17)222)160(267)186-79(16)134(241)213-127(82(19)224)164(271)208-111/h23-28,32-35,38-41,59,69-84,90-112,122-129,217-227H,22,29-31,36-37,42-58,60-68,166-167H2,1-21H3,(H2,168,228)(H2,169,229)(H2,170,230)(H2,171,231)(H2,172,232)(H2,173,233)(H2,174,234)(H2,175,237)(H,178,182)(H,180,243)(H,181,264)(H,183,235)(H,184,246)(H,185,262)(H,186,267)(H,187,236)(H,188,245)(H,189,268)(H,190,269)(H,191,238)(H,192,244)(H,193,248)(H,194,251)(H,195,250)(H,196,252)(H,197,258)(H,198,257)(H,199,263)(H,200,266)(H,201,265)(H,202,270)(H,203,247)(H,204,249)(H,205,259)(H,206,260)(H,207,242)(H,208,271)(H,209,254)(H,210,253)(H,211,239)(H,212,240)(H,213,241)(H,214,256)(H,215,255)(H,216,261)(H4,176,177,179)/t75-,76-,77-,78-,79-,80+,81+,82+,83+,84+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,122-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMWDEN0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
DMWDEN0 IK PLOPBXQQPZYQFA-AXPWDRQUSA-N
DMWDEN0 IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S,3R)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]pentanediamide
DMWDEN0 CA CAS 106602-62-4
DM8EKSV ID DM8EKSV
DM8EKSV DN Anti-MIF antibodies
DM8EKSV HS Phase 4
DM8EKSV SN Antimacrophage inhibitory factor, Baxter; Anti-MIF antibodies (inflammation); Anti-MIF antibodies (inflammation), Baxter; Anti-MIF technology, Cytokine/IDEC; Anti-inflammatories, Cytokine/IDEC; Anti-macrophage inhibitory factor, Cytokine/IDEC
DM8EKSV CP Baxter healthcare
DM8EKSV DE Autoimmune diabetes
DML1VXW ID DML1VXW
DML1VXW DN Arotinolol
DML1VXW HS Phase 4
DML1VXW SN Arotinolol; Arotinolol (INN); Arotinolol [INN]; Arotinololum; Arotinololum [Latin]; (+-)-5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide; 2-(3-tert-Butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)thiazole; 5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)thiazol-4-yl)thiophene-2-carboxamide; 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide; 68377-92-4; AK129719; C15H21N3O2S3; S-596
DML1VXW PC 2239
DML1VXW MW 371.5
DML1VXW FM C15H21N3O2S3
DML1VXW IC BHIAIPWSVYSKJS-UHFFFAOYSA-N
DML1VXW CS CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O
DML1VXW IK 1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
DML1VXW IU 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide
DML1VXW CA CAS 68377-92-4
DML1VXW CB CHEBI:135569
DML1VXW DE Essential tremor
DMB7WYM ID DMB7WYM
DMB7WYM DN ATOSIBAN
DMB7WYM HS Phase 4
DMB7WYM SN Atosiban; Tractocile; 90779-69-4; Atosiban acetate; Antocin; UNII-081D12SI0Z; Rwj 22164; Orf-22164; RWJ-22164; CHEMBL382301; 1-Deamino-2D-tyr-(OEt)-4-thr-8-orn-oxytocin; dTVT; 081D12SI0Z; 1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin; 1-(3-Mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithineoxytocin; NCGC00165718-01; Atosibanum [INN-Latin]; ORF 22164; deTVT; Atosibanum; Antocin II; Atosiban [USAN:INN:BAN]; RWJ22164; 1-(3-Mercaptopropionic acid)-2-(3-(p-ethoxyphenyl)-D-alanine)-4-L-threonine-8-L-ornithineox
DMB7WYM DT Small molecular drug
DMB7WYM PC 5311010
DMB7WYM MW 994.2
DMB7WYM FM C43H67N11O12S2
DMB7WYM IC InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1
DMB7WYM CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O
DMB7WYM IK VWXRQYYUEIYXCZ-OBIMUBPZSA-N
DMB7WYM IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMB7WYM CA CAS 90779-69-4
DMB7WYM CB CHEBI:135899
DMA12HL ID DMA12HL
DMA12HL DN Azelnidipine
DMA12HL HS Phase 4
DMA12HL SN Azelnidipine; Azelnidipine [INN]; Calblock; RS-9054; 123524-52-7; 3,5-PYRIDINEDICARBOXYLIC ACID, 2-AMINO-1,4-DIHYDRO-6-METHYL-4-(3-NITROPHENYL)-, 3-[1-(DIPHENYLMETHYL)-3-AZETIDINYL] 5-(1-METHYLETHYL) ESTER; 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; C33H34N4O6; CS 905; CS-905; DSSTox_CID_120; DSSTox_GSID_20120; DSSTox_RID_75382; MFCD00865803; NCGC00167436-01; NCGC00167436-02
DMA12HL PC 65948
DMA12HL MW 582.6
DMA12HL FM C33H34N4O6
DMA12HL IC ZKFQEACEUNWPMT-UHFFFAOYSA-N
DMA12HL CS CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C
DMA12HL IK 1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3
DMA12HL IU 3-O-(1-benzhydrylazetidin-3-yl) 5-O-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMA12HL CA CAS 123524-52-7
DMA12HL CB CHEBI:31247
DMA12HL DE Essential hypertension
DMJSDBE ID DMJSDBE
DMJSDBE DN Barnidipine
DMJSDBE HS Phase 4
DMJSDBE SN Barnidipine [INN]; Barnidipine HCl; Barnidipino; Barnidipino [INN-Spanish]; Barnidipinum; Barnidipinum [INN-Latin]; Libradin; Mepirodipine; VXMOONUMYLCFJD-DHLKQENFSA-N; Vasexten (TN); YM 09730; barnidipine; (S)-3-((S)-1-Benzylpyrrolidin-3-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 104713-75-9; 2VBY96ASWJ; AC1L9FD3; BCP07244; C27H29N3O6; CHEBI:135793; CHEMBL2103761; CHEMBL2110040; CTK8B6661; SCHEMBL49302; UNII-2VBY96ASWJ
DMJSDBE PC 443869
DMJSDBE MW 491.5
DMJSDBE FM C27H29N3O6
DMJSDBE IC VXMOONUMYLCFJD-DHLKQENFSA-N
DMJSDBE CS CC1=C(C(C(=C(N1)C)C(=O)OC2CCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMJSDBE IK 1S/C27H29N3O6/c1-17-23(26(31)35-3)25(20-10-7-11-21(14-20)30(33)34)24(18(2)28-17)27(32)36-22-12-13-29(16-22)15-19-8-5-4-6-9-19/h4-11,14,22,25,28H,12-13,15-16H2,1-3H3/t22-,25-/m0/s1
DMJSDBE IU 5-O-[(3S)-1-benzylpyrrolidin-3-yl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMJSDBE CA CAS 104713-75-9
DMJSDBE CB CHEBI:135793
DMJSDBE DE Essential hypertension
DMLKUG7 ID DMLKUG7
DMLKUG7 DN Beclabuvir
DMLKUG7 HS Phase 4
DMLKUG7 SN Beclabuvir; Beclabuvir (USAN/INN); Beclabuvir(BMS-791325); SB16521; 958002-33-0; BDBM50448498; BMS-791325; CHEMBL3126842; CS-6041; HY-12429; SCHEMBL11951525; cyclohexyl-N-(dimethylsulfamoyl)-methoxy-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)[?]carboxamide
DMLKUG7 PC 49773361
DMLKUG7 MW 659.8
DMLKUG7 FM C36H45N5O5S
DMLKUG7 IC ZTTKEBYSXUCBSE-VSBZUFFNSA-N
DMLKUG7 CS CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8
DMLKUG7 IK 1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24?,25?,30-,36-/m0/s1
DMLKUG7 IU (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
DMLKUG7 CA CAS 958002-33-0
DMLKUG7 DE Viral hepatitis
DM5NW1E ID DM5NW1E
DM5NW1E DN Beclomethasone dipropionate
DM5NW1E HS Phase 4
DM5NW1E SN BECLOMETHASONE DIPROPIONATE; Beclometasone dipropionate; Beconase; Beclovent; Vancenase; Beclorhinol; Becloforte; Sanasthmyl; Beclazone; Sanasthmax; Propaderm; Beclomet; Vanceril; Aerobec; Becloturmant; Beclacin; Respocort; Entyderma; Korbutone; Viarox; Rino-clenil; Clenil-A; Beclometasone 17,21-dipropionate; Becotide; Aldecin; Turbinal; Aldecina; Rhinosol; Beclate; Atomase; Alanase; Benconase; Aldecine; Clenil; Spir; Beclocort Nasel; Beclomet Nasal; Propaderm Forte; Rhino Clenil; Inalone O; Inalone R; Qvar; QNASL; Beconase AQ; Qvar 80
DM5NW1E PC 21700
DM5NW1E MW 521
DM5NW1E FM C28H37ClO7
DM5NW1E IC InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1
DM5NW1E CS CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)Cl)O)C)C)OC(=O)CC
DM5NW1E IK KUVIULQEHSCUHY-XYWKZLDCSA-N
DM5NW1E IU [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
DM5NW1E CA CAS 5534-09-8
DM5NW1E CB CHEBI:3002
DM5NW1E DE Allergic rhinitis
DMWNP6B ID DMWNP6B
DMWNP6B DN Benidipine
DMWNP6B HS Phase 4
DMWNP6B SN Benidipene; Benidipine; Benidipine (INN); Benidipine [INN]; Benidipino; Benidipino [Spanish]; Benidipinum; Benidipinum [Latin]; ZINC100014880; ZINC21992076; (+-)-(R*)-3-((R*)-1-Benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 105979-17-7; 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AC1LCVDP; AKOS015895389; C28H31N3O6; CHEMBL2105555; CHEMBL3303980; CTK8E8626; DTXSID0022648; NCGC00185768-01; SCHEMBL24516
DMWNP6B PC 656668
DMWNP6B MW 505.6
DMWNP6B FM C28H31N3O6
DMWNP6B IC QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
DMWNP6B CS CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMWNP6B IK 1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1
DMWNP6B IU 5-O-[(3R)-1-benzylpiperidin-3-yl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMWNP6B CA CAS 105979-17-7
DMWNP6B DE Diabetic nephropathy
DMHKZX1 ID DMHKZX1
DMHKZX1 DN Benzethonium
DMHKZX1 HS Phase 4
DMHKZX1 SN Benzethonii chloridum [INN-Latin]; Benzetonio cloruro [DCIT]; Formula 144; Inactisol; Phemerol; Phemersol chloride; Sanizol; Antiseptol (quarternary compound); Solamin; benzethonium; 10172-60-8; 1VU15B70BP; 498-77-1; BZT (VAN); CCRIS 4748; CHEMBL221753; Caswell No. 614B; Chlorure de benzethonium [INN-French]; Cloruro de benzetonio [INN-Spanish]; EINECS 204-479-9; HSDB 567; NCI-C61494; NSC 20200; NSC20200; UNII-1VU15B70BP; benzyl-dimethyl-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]ammonium
DMHKZX1 PC 2335
DMHKZX1 MW 412.6
DMHKZX1 FM C27H42NO2+
DMHKZX1 IC SIYLLGKDQZGJHK-UHFFFAOYSA-N
DMHKZX1 CS CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2
DMHKZX1 IK 1S/C27H42NO2/c1-26(2,3)22-27(4,5)24-13-15-25(16-14-24)30-20-19-29-18-17-28(6,7)21-23-11-9-8-10-12-23/h8-16H,17-22H2,1-7H3/q+1
DMHKZX1 IU benzyl-dimethyl-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]azanium
DMHKZX1 CA CAS 10172-60-8
DMHKZX1 CB CHEBI:94725
DMHKZX1 DE Methicillin-resistant staphylococcus infection
DML634R ID DML634R
DML634R DN Beraprost
DML634R HS Phase 4
DML634R SN Beraprost [USAN:INN]; Beraprostum; Beraprostum [INN-Latin]; MDL-201229; ML-1229; beraprost; (+-)-(1R,2R,3aS,8bS)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butyric acid; 2-Hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-5-butanoic acid; 88430-50-6; AC1OCEUA; CHEBI:135633; CHEMBL1207745; CTPOHARTNNSRSR-APJZLKAGSA-N; DTXSID7049136; SCHEMBL16904620; SCHEMBL34593
DML634R PC 6917951
DML634R MW 398.5
DML634R FM C24H30O5
DML634R IC CTPOHARTNNSRSR-APJZLKAGSA-N
DML634R CS CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DML634R IK 1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1
DML634R IU 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DML634R CA CAS 88430-50-6
DML634R CB CHEBI:135633
DML634R DE Influenza virus infection
DMWL182 ID DMWL182
DMWL182 DN Beraprost
DMWL182 HS Phase 4
DMWL182 SN beraprost; 88430-50-6; 88430-50-6 (free acid); 1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-; Beraprost (USAN); GTPL1967; SCHEMBL1554142; SCHEMBL1554145; BDBM85181; CAS_2352; NSC_2352; 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid; K578; D02720; L024061; Q5977854; (E)-4-(2-hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1H-benzo[d]cyclopenta[b]furan-5-yl)butanoic acid; 4-(2-Hydroxy-1-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-5-yl)butanoic acid; 4-{4-hydroxy-3-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(12),8,10-trien-9-yl}butanoic acid
DMWL182 DT Small molecular drug
DMWL182 PC 5282428
DMWL182 MW 398.5
DMWL182 FM C24H30O5
DMWL182 IC InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+
DMWL182 CS CC#CCC(C)C(/C=C/C1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DMWL182 IK CTPOHARTNNSRSR-OUKQBFOZSA-N
DMWL182 IU 4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DMWL182 CA CAS 88430-50-6
DMWL182 DE Pulmonary hypertension
DMC5Q8X ID DMC5Q8X
DMC5Q8X DN Berberine
DMC5Q8X HS Phase 4
DMC5Q8X SN berberine; 2086-83-1; Berberin; Umbellatine; UNII-0I8Y3P32UF; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; Berberal; BRN 3570374; ST055798; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; Berbamine sulphate acid; CHEMBL12089; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLE
DMC5Q8X DT Small molecular drug
DMC5Q8X PC 2353
DMC5Q8X MW 336.4
DMC5Q8X FM C20H18NO4+
DMC5Q8X IC InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1
DMC5Q8X CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC
DMC5Q8X IK YBHILYKTIRIUTE-UHFFFAOYSA-N
DMC5Q8X IU 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMC5Q8X CA CAS 2086-83-1
DMC5Q8X CB CHEBI:16118
DMGXD5T ID DMGXD5T
DMGXD5T DN Brotizolam
DMGXD5T HS Phase 4
DMGXD5T SN Brotizolamum; Brotizolamum [INN-Latin]; Lendorm; Lendormin; Mederantil; Sintonal; UMSGKTJDUHERQW-UHFFFAOYSA-N; WE 941; WE-941; brotizolam; 2-Bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 2-Bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine; 2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 57801-81-7; 5XZM1R3DKF; BRN 0839277; C15H10BrClN4S; CHEMBL32479; EINECS 260-964-5; NCGC00183872-01; UNII-5XZM1R3DKF
DMGXD5T PC 2451
DMGXD5T MW 393.7
DMGXD5T FM C15H10BrClN4S
DMGXD5T IC UMSGKTJDUHERQW-UHFFFAOYSA-N
DMGXD5T CS CC1=NN=C2N1C3=C(C=C(S3)Br)C(=NC2)C4=CC=CC=C4Cl
DMGXD5T IK 1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
DMGXD5T IU 4-bromo-7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DMGXD5T CA CAS 57801-81-7
DMGXD5T CB CHEBI:31308
DMGXD5T DE Insomnia
DMXZU73 ID DMXZU73
DMXZU73 DN Carbapenem
DMXZU73 HS Phase 4
DMXZU73 SN Carbapenem; Cis-carbapenem; (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one; 2,3-didehydro-1-carbapenam; 67836-EP2275424A1; 67836-EP2295402A2; 67836-EP2305219A1; 67836-EP2308874A1; CHEBI:46765; SCHEMBL37243
DMXZU73 PC 13293131
DMXZU73 MW 109.13
DMXZU73 FM C6H7NO
DMXZU73 IC YZBQHRLRFGPBSL-RXMQYKEDSA-N
DMXZU73 CS C1C=CN2C1CC2=O
DMXZU73 IK 1S/C6H7NO/c8-6-4-5-2-1-3-7(5)6/h1,3,5H,2,4H2/t5-/m1/s1
DMXZU73 IU (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one
DMXZU73 CB CHEBI:46765
DMXZU73 DE Infectious cystitis
DMJKWPZ ID DMJKWPZ
DMJKWPZ DN Cefpirome
DMJKWPZ HS Phase 4
DMJKWPZ SN Cefpiroma; Cefpiroma [Spanish]; Cefpirome (INN); Cefpirome [INN:BAN]; Cefpiromum; Cefpiromum [Latin]; Cefrom; Cerfpirome; Keiten; Broact; CEFPIROME; S72Q2F09HY; cefpirome sulfate; cefpirome sulphate; (6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 84957-29-9; C22H22N6O5S2; CHEBI:3503; HR 810; HR-810; NCGC00181339-01; UNII-S72Q2F09HY
DMJKWPZ PC 5479539
DMJKWPZ MW 514.6
DMJKWPZ FM C22H22N6O5S2
DMJKWPZ IC DKOQGJHPHLTOJR-WHRDSVKCSA-N
DMJKWPZ CS CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-]
DMJKWPZ IK 1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1
DMJKWPZ IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMJKWPZ CA CAS 84957-29-9
DMJKWPZ CB CHEBI:3503
DMJKWPZ DE Pseudomonas infection
DMPZTRC ID DMPZTRC
DMPZTRC DN Ceftazidine
DMPZTRC HS Phase 4
DMPZTRC SN Ceftazidine [INN]; Ceftazidine [USAN]; Ceftazidine [IBAN]; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide
DMPZTRC PC 13505813
DMPZTRC MW 564.6
DMPZTRC FM C22H24N6O8S2
DMPZTRC IC GCZOCVAKBHTGOL-ROMZVAKDSA-N
DMPZTRC CS CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)O.[OH-]
DMPZTRC IK 1S/C22H22N6O7S2.H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);1H2/b26-13-;/t14-,18-;/m1./s1
DMPZTRC IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydroxide
DMPZTRC DE Meningitis
DMYGEH7 ID DMYGEH7
DMYGEH7 DN Ceftolozane sulfate
DMYGEH7 HS Phase 4
DMYGEH7 SN Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist
DMYGEH7 CP Fujisawa Pharmaceutical Co Ltd; Calixa Therapeutics Inc
DMYGEH7 DT Small molecular drug
DMYGEH7 PC 11592969
DMYGEH7 MW 764.8
DMYGEH7 FM C23H32N12O12S3
DMYGEH7 IC InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1
DMYGEH7 CS CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]
DMYGEH7 IK UJDQGRLTPBVSFN-GZGOMJRCSA-N
DMYGEH7 IU (6R,7R)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate
DMYGEH7 DE Respiratory tract infection
DMYTGW0 ID DMYTGW0
DMYTGW0 DN Celiprolol
DMYTGW0 HS Phase 4
DMYTGW0 SN Celectol; Celiprolol [INN:BAN]; Celiprololum; Celiprololum [INN-Latin]; RHC 5320 A; RHC-5320A; ST-1396; Selectol; UL/1677; celiprolol; 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea; 56980-93-9; BRN 2776298; CCRIS 3400; EINECS 260-497-7; N'-(3-Acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethylurea; Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-
DMYTGW0 PC 2663
DMYTGW0 MW 379.5
DMYTGW0 FM C20H33N3O4
DMYTGW0 IC JOATXPAWOHTVSZ-UHFFFAOYSA-N
DMYTGW0 CS CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C
DMYTGW0 IK 1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)
DMYTGW0 IU 3-[3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1,1-diethylurea
DMYTGW0 CA CAS 56980-93-9
DMYTGW0 CB CHEBI:94461
DMYTGW0 DE Essential hypertension
DM6C4YJ ID DM6C4YJ
DM6C4YJ DN Chlorphenamine
DM6C4YJ HS Phase 4
DM6C4YJ SN Chloropheniramine; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamin; Chlorphenamine; Chlorphenaminum; Chlorpheniramine maleate; Chlorpheniramine polistirex; Chlorpheniraminum; Chlorprophenpyridamine; Clorfenamina; Clorfeniramina; Clorfeniramina [Italian]; Cloropiril; Aller-Chlor; Allergican; Allergisan; Antagonate; Chlor-trimeton; Haynon; Histadur; Kloromin; Phenetron; Polaramine; Polaronil; Telachlor; Teldrin; chlorpheniramine; 132-22-9; 4-Chloropheniramine
DM6C4YJ PC 2725
DM6C4YJ MW 274.79
DM6C4YJ FM C16H19ClN2
DM6C4YJ IC SOYKEARSMXGVTM-UHFFFAOYSA-N
DM6C4YJ CS CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
DM6C4YJ IK 1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m1/s1
DM6C4YJ IU 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
DM6C4YJ CA CAS 132-22-9
DM6C4YJ CB CHEBI:52010
DM6C4YJ DE Allergy
DM0N19Y ID DM0N19Y
DM0N19Y DN Chondroitin sulfate
DM0N19Y HS Phase 4
DM0N19Y SN Chondritinsulfate; Chondritinsulphate; Chondroitin 4 and 6 sulfate; Chondroitin 4-sulfate; Chondroitin 6-sulfate; Chondroitin polysulfate; Chondroitin sulfate; Chondroitin sulfuric acid; Chondroitin sulfuric acids; Chondroitin sulphate; Chondroitin, CHONDROITIN SULFATES; hydrogen sulfate; Chondroitine sulfate; Chondroitinsulfate C; Chondroitinsulfuric acids; Chondron; Chonsurid; Condrosan; Condrosulf; Sodium chondroitin sulfate; Structum; Uropol S; chondroitin sulfate C; 9007-28-7; EINECS 232-696-9; Gepan; UNII-6IC1M3OG5Z
DM0N19Y PC 24766
DM0N19Y MW 463.37
DM0N19Y FM C13H21NO15S
DM0N19Y IC KXKPYJOVDUMHGS-OSRGNVMNSA-N
DM0N19Y CS CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O
DM0N19Y IK 1S/C13H21NO15S/c1-2(15)14-3-8(7(19)13(28-11(3)22)29-30(23,24)25)26-12-6(18)4(16)5(17)9(27-12)10(20)21/h3-9,11-13,16-19,22H,1H3,(H,14,15)(H,20,21)(H,23,24,25)/t3-,4+,5+,6-,7-,8-,9+,11-,12-,13-/m1/s1
DM0N19Y IU (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DM0N19Y CA CAS 9007-28-7
DM0N19Y DE Osteoarthritis
DMBG0N4 ID DMBG0N4
DMBG0N4 DN Cibenzoline
DMBG0N4 HS Phase 4
DMBG0N4 SN Cibenzolina; Cibenzolina [INN-Spanish]; Cibenzoline; Cibenzoline (INN); Cibenzoline [INN]; Cibenzolinum; Cibenzolinum [INN-Latin]; Cifenline; Cifenline (USAN); Cifenline [USAN]; Ro 22-7796; Ro 227796; UP 33901; (+-)-2-(2,2-Diphenylcyclopropyl)-2-imidazoline; 1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-, (+-)-; 2-(2,2-Diphenyl-cyclopropyl)-4,5-dihydro-1H-imidazole; 2-(2,2-diphenylcyclopropyl)-2-imidazoline; 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole; 53267-01-9; C18H18N2; CHEMBL87045; EINECS 258-453-7
DMBG0N4 PC 2747
DMBG0N4 MW 262.3
DMBG0N4 FM C18H18N2
DMBG0N4 IC IPOBOOXFSRWSHL-UHFFFAOYSA-N
DMBG0N4 CS C1CN=C(N1)C2CC2(C3=CC=CC=C3)C4=CC=CC=C4
DMBG0N4 IK 1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)
DMBG0N4 IU 2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole
DMBG0N4 CA CAS 53267-01-9
DMBG0N4 CB CHEBI:135083
DMBG0N4 DE Atrial fibrillation
DMSW5QP ID DMSW5QP
DMSW5QP DN Cotrimoxazole
DMSW5QP HS Phase 4
DMSW5QP SN Centran; Centrin; Cotrim.L.U.T; Eslectin; Insozalin; Biseptol-480; LS-2191; Metomide; Trimedin; Trimethoprim/Sulfamethoxazol; Trimezole; CHEMBL195591; Sulfamethoxazole-Trimethoprim Combination
DMSW5QP PC 24719
DMSW5QP MW 542.6
DMSW5QP FM C25H30N6O6S
DMSW5QP IC CTNTUFQBOKZSPI-UHFFFAOYSA-N
DMSW5QP CS CC1=CC(=NO1)CS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N
DMSW5QP IK 1S/C14H18N4O3.C11H12N2O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-8-6-10(13-16-8)7-17(14,15)11-4-2-9(12)3-5-11/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,7,12H2,1H3
DMSW5QP IU 4-[(5-methyl-1,2-oxazol-3-yl)methylsulfonyl]aniline;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMSW5QP DE Human immunodeficiency virus infection
DMLMOIJ ID DMLMOIJ
DMLMOIJ DN Cyproterone acetate
DMLMOIJ HS Phase 4
DMLMOIJ SN Cyprosterone acetate; Cyproteron acetate; Cyproteron-R acetate; Cyproterone 17-O-acetate; Cyproterone 17.alpha.-acetate; Cyproterone 17alpha-acetate; Cyproterone acetate [USAN:JAN]; Androcur; CYPROTERONE ACETATE; Cyproteroneacetate; SH 714; SH 80714; SH-714; 3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-; 427-51-0; 4KM2BN5JHF; C24H29ClO4; CCRIS 4385; CHEBI:50743; CHEMBL139835; EINECS 207-048-3; HSDB 3592; MLS000859908; NSC 81430; NSC-81430; UNII-4KM2BN5JHF
DMLMOIJ PC 9880
DMLMOIJ MW 416.9
DMLMOIJ FM C24H29ClO4
DMLMOIJ IC UWFYSQMTEOIJJG-FDTZYFLXSA-N
DMLMOIJ CS CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C
DMLMOIJ IK 1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1
DMLMOIJ IU [(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate
DMLMOIJ CA CAS 427-51-0
DMLMOIJ CB CHEBI:50743
DMLMOIJ DE Polycystic ovary syndrome
DMV6KFY ID DMV6KFY
DMV6KFY DN Dapoxetine
DMV6KFY HS Phase 4
DMV6KFY SN Priligy (TN)
DMV6KFY CP Furiex pharmaceuticals
DMV6KFY DT Small molecular drug
DMV6KFY PC 71353
DMV6KFY MW 305.4
DMV6KFY FM C21H23NO
DMV6KFY IC InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
DMV6KFY CS CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3
DMV6KFY IK USRHYDPUVLEVMC-FQEVSTJZSA-N
DMV6KFY IU (1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine
DMV6KFY CA CAS 119356-77-3
DMV6KFY CB CHEBI:135962
DMV6KFY DE Premature ejaculation
DMV5KTJ ID DMV5KTJ
DMV5KTJ DN Demegestone
DMV5KTJ HS Phase 4
DMV5KTJ SN Demegestona; Demegestona [INN-Spanish]; Demegestone; Demegestone (INN); Demegestone [INN:DCF]; Demegestonum; Demegestonum [INN-Latin]; Lutionex; R 2453; R-2453; RU 2453; SCHEMBL146550; ZINC4215548; 10116-22-0; 17-Methyl-19-norpregna-4,9-diene-3,20-dione; 17alpha-Methyl-19-demethylpregna-4,9-diene-3,20-dione; 19-Norpregna-4,9-diene-3,20-dione, 17-methyl- (8CI)(9CI); 6E89AM91SZ; AC1L3PEV; CHEBI:135339; CHEMBL2104231; D07223; DTXSID20878581; EINECS 233-320-6; NSC 118189; UNII-6E89AM91SZ
DMV5KTJ PC 93057
DMV5KTJ MW 312.4
DMV5KTJ FM C21H28O2
DMV5KTJ IC JWAHBTQSSMYISL-MHTWAQMVSA-N
DMV5KTJ CS CC(=O)C1(CCC2C1(CCC3=C4CCC(=O)C=C4CCC23)C)C
DMV5KTJ IK 1S/C21H28O2/c1-13(22)20(2)11-9-19-18-6-4-14-12-15(23)5-7-16(14)17(18)8-10-21(19,20)3/h12,18-19H,4-11H2,1-3H3/t18-,19+,20-,21+/m1/s1
DMV5KTJ IU (8S,13S,14S,17S)-17-acetyl-13,17-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMV5KTJ CA CAS 10116-22-0
DMV5KTJ CB CHEBI:135339
DMV5KTJ DE Corpus luteum cyst
DMN2Q5I ID DMN2Q5I
DMN2Q5I DN Diacerein
DMN2Q5I HS Phase 4
DMN2Q5I SN Diacerein; 13739-02-1; Diacetylrhein; Diacerhein; Fisiodar; Artrodar; 1,8-DIACETOXY-3-CARBOXYANTHRAQUINONE; DIACERIN; 4,5-Diacetylrhein; Diacereinum [Latin]; Diacereine [French]; Diacereina [Spanish]; UNII-4HU6J11EL5; Diacerein [INN]; SF-277; C19H12O8; EINECS 237-310-2; BRN 2184909; 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid; MLS000028577; 4HU6J11EL5; 1,8-Diacetoxyanthraquinone-3-carboxylic acid; Diacerein (INN); 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid; NCGC00018274-04; SMR000058958; AK468692
DMN2Q5I DT Small molecular drug
DMN2Q5I PC 26248
DMN2Q5I MW 368.3
DMN2Q5I FM C19H12O8
DMN2Q5I IC InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
DMN2Q5I CS CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O
DMN2Q5I IK TYNLGDBUJLVSMA-UHFFFAOYSA-N
DMN2Q5I IU 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid
DMN2Q5I CA CAS 13739-02-1
DMN2Q5I CB CHEBI:94708
DMTX0PZ ID DMTX0PZ
DMTX0PZ DN Dibekacin
DMTX0PZ HS Phase 4
DMTX0PZ SN Debecacin; Dibekacin sulfate; Dibekacina; Dibekacina [INN-Spanish]; Dibekacine; Dibekacine [INN-French]; Dibekacinum; Dibekacinum [INN-Latin]; Dideoxykanamycin B; Kappati; Panamicin; dibekacin; 3',4'-Dideoxykanamycin B; 34493-98-6; 45ZFO9E525; BRN 1441606; CHEBI:37945; DKB; DKM; EINECS 252-064-6; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; UNII-45ZFO9E525
DMTX0PZ PC 470999
DMTX0PZ MW 451.5
DMTX0PZ FM C18H37N5O8
DMTX0PZ IC JJCQSGDBDPYCEO-XVZSLQNASA-N
DMTX0PZ CS C1CC(C(OC1CN)OC2C(CC(C(C2O)OC3C(C(C(C(O3)CO)O)N)O)N)N)N
DMTX0PZ IK 1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
DMTX0PZ IU (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
DMTX0PZ CA CAS 34493-98-6
DMTX0PZ CB CHEBI:37945
DMTX0PZ DE Acute lower respiratory infection
DMZ5Y1P ID DMZ5Y1P
DMZ5Y1P DN Dichloroacetate
DMZ5Y1P HS Phase 4
DMZ5Y1P SN 2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050
DMZ5Y1P DT Small molecular drug
DMZ5Y1P PC 25975
DMZ5Y1P MW 127.93
DMZ5Y1P FM C2HCl2O2-
DMZ5Y1P IC InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
DMZ5Y1P CS C(C(=O)[O-])(Cl)Cl
DMZ5Y1P IK JXTHNDFMNIQAHM-UHFFFAOYSA-M
DMZ5Y1P IU 2,2-dichloroacetate
DMZ5Y1P CA CAS 13425-80-4
DMZ5Y1P CB CHEBI:28240
DMZ5Y1P DE Pulmonary fibrosis; Pyruvate dehydrogenase complex deficiency; Insulin-resistant disorder
DMB0FWL ID DMB0FWL
DMB0FWL DN Dihydrocodeine
DMB0FWL HS Phase 4
DMB0FWL SN Dihydrocodeine bitartrate; DF 118; Dihydrocodeine (oral); S-8115; Dihydrocodeine (oral), Shionogi; (-)-Dihydrocodeine
DMB0FWL CP Mundipharma AG
DMB0FWL DT Small molecular drug
DMB0FWL PC 5284543
DMB0FWL MW 301.4
DMB0FWL FM C18H23NO3
DMB0FWL IC InChI=1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
DMB0FWL CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)O
DMB0FWL IK RBOXVHNMENFORY-DNJOTXNNSA-N
DMB0FWL IU (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DMB0FWL CA CAS 125-28-0
DMB0FWL CB CHEBI:135276
DMB0FWL DE Cancer related pain
DM3S8XC ID DM3S8XC
DM3S8XC DN Dihydrotestosterone
DM3S8XC HS Phase 4
DM3S8XC SN Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone
DM3S8XC DT Small molecular drug
DM3S8XC PC 10635
DM3S8XC MW 290.4
DM3S8XC FM C19H30O2
DM3S8XC IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
DM3S8XC CS C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C
DM3S8XC IK NVKAWKQGWWIWPM-ABEVXSGRSA-N
DM3S8XC IU (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DM3S8XC CA CAS 521-18-6
DM3S8XC CB CHEBI:16330
DM3S8XC DE Prostate hyperplasia
DM3YH4I ID DM3YH4I
DM3YH4I DN D-Serine
DM3YH4I HS Phase 4
DM3YH4I SN D-serine; 312-84-5; (R)-2-amino-3-hydroxypropanoic acid; (2R)-2-amino-3-hydroxypropanoic acid; Serine D-form; (R)-Serine; Serine, D-; d-(+)-serine; D-2-Amino-3-hydroxypropionic Acid; D-Serin; D-Ser; UNII-1K77H2Z9B1; EINECS 206-229-4; MFCD00004269; NSC 77689; (2R)-2-amino-3-hydroxy-propanoic acid; AI3-18476; CHEMBL285123; CHEBI:16523; MTCFGRXMJLQNBG-UWTATZPHSA-N; 1K77H2Z9B1; (R)-2-Amino-3-hydroxypropionic acid; DSN; NCGC00094363-03; D-Serine, 98%; D-2-Amino-3-hydroxypropanoic acid; NSC77689; serine d-; [3h]-d-serine; (2R)-serine
DM3YH4I DT Small molecular drug
DM3YH4I PC 71077
DM3YH4I MW 105.09
DM3YH4I FM C3H7NO3
DM3YH4I IC InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1
DM3YH4I CS C([C@H](C(=O)O)N)O
DM3YH4I IK MTCFGRXMJLQNBG-UWTATZPHSA-N
DM3YH4I IU (2R)-2-amino-3-hydroxypropanoic acid
DM3YH4I CA CAS 312-84-5
DM3YH4I CB CHEBI:16523
DMH21D9 ID DMH21D9
DMH21D9 DN Ebastine
DMH21D9 HS Phase 4
DMH21D9 SN ebastine; Kestine; Ebastel; Ebastin; Evastel; Kestin; Bactil; Ebastinum [Latin]; LAS W-090; Ebastina [Spanish]; Estivan; UNII-TQD7Q784P1; RP 64305; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; TQD7Q784P1; CHEMBL305660; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; C32H39NO2; MFCD00865661; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; NCGC00164603-01; RP-64305; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone
DMH21D9 PC 3191
DMH21D9 MW 469.7
DMH21D9 FM C32H39NO2
DMH21D9 IC InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
DMH21D9 CS CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMH21D9 IK MJJALKDDGIKVBE-UHFFFAOYSA-N
DMH21D9 IU 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
DMH21D9 CA CAS 90729-43-4
DMH21D9 CB CHEBI:31528
DMH21D9 DE Irritable bowel syndrome
DMQRX24 ID DMQRX24
DMQRX24 DN Ebastine
DMQRX24 HS Phase 4
DMQRX24 SN Ebastel; Ebastin; Ebastina [Spanish]; Ebastinum [Latin]; Estivan; Evastel; Kestin; Kestine; LAS W-090; RP 64305; Bactil; RP-64305; TQD7Q784P1; ebastine; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; 1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; 4'-tert-Butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; 90729-43-4; C32H39NO2; CHEMBL305660; MFCD00865661; NCGC00164603-01; UNII-TQD7Q784P1
DMQRX24 PC 3191
DMQRX24 MW 469.7
DMQRX24 FM C32H39NO2
DMQRX24 IC MJJALKDDGIKVBE-UHFFFAOYSA-N
DMQRX24 CS CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
DMQRX24 IK 1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3
DMQRX24 IU 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one
DMQRX24 CA CAS 90729-43-4
DMQRX24 CB CHEBI:31528
DMQRX24 DE Irritable bowel syndrome
DM9WPIH ID DM9WPIH
DM9WPIH DN Ergonovine maleate
DM9WPIH HS Phase 4
DM9WPIH SN Ergomet; Ergometrin maleate; Ergometrine acid maleate; Ergometrine hydrogen maleate; Ergometrine maleate (1:1); Ergonovine hydrogen maleate; Ergonovine maleate; Ergonovine maleate (USP); Ergonovine maleate [USP]; Ergonovine maleate salt; Ergonovine, maleate (1:1); Ergonovine, maleate (1:1) (salt); Ergotocin maleate; Ermetrin; Metriclavin; Oxytocic; Cornocentin; Crude ergot; D-Ergonovine maleate; YMH3D0ZJWV; ergometrine maleate; 129-51-1; CHEBI:31554; EINECS 204-953-5; NSC 93752; UNII-YMH3D0ZJWV
DM9WPIH PC 6437065
DM9WPIH MW 441.5
DM9WPIH FM C23H27N3O6
DM9WPIH IC YREISLCRUMOYAY-IIPCNOPRSA-N
DM9WPIH CS CC(CO)NC(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=CC(=O)O)C(=O)O
DM9WPIH IK 1S/C19H23N3O2.C4H4O4/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;5-3(6)1-2-4(7)8/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24);1-2H,(H,5,6)(H,7,8)/b;2-1-/t11-,13+,17+;/m0./s1
DM9WPIH IU (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid
DM9WPIH CA CAS 129-51-1
DM9WPIH CB CHEBI:31554
DM9WPIH DE Abnormal vaginal bleeding
DMKEGI3 ID DMKEGI3
DMKEGI3 DN Esmirtazapine
DMKEGI3 HS Phase 4
DMKEGI3 SN Esmirtazapine; Esmirtazapine [INN]; Org 44-20; Org-44-20; ZINC968310; (+)-Mirtazapine; (S)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine; 4685R51V7M; 61337-87-9; AC1MJ43F; BIDD:PXR0200; CHEMBL1366933; DB06678; EINECS 262-714-0; PDSP1_001530; PDSP2_001514; SCHEMBL49330; UNII-4685R51V7M
DMKEGI3 PC 3085218
DMKEGI3 MW 265.35
DMKEGI3 FM C17H19N3
DMKEGI3 IC RONZAEMNMFQXRA-MRXNPFEDSA-N
DMKEGI3 CS CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
DMKEGI3 IK 1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3/t16-/m1/s1
DMKEGI3 IU (7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
DMKEGI3 CA CAS 61337-87-9
DMKEGI3 DE Depression
DM7ITZK ID DM7ITZK
DM7ITZK DN Ethinylestradiol propanesulfonate
DM7ITZK HS Phase 4
DM7ITZK SN Ethinylestradiol propanesulfonate; Ethinyl estradiol isopropylsulfonate; SCHEMBL457480; Turisteron; Turisteron (TN); XF48685MYR; ethinylestradiol sulfonate; (17; 17-Hydroxy-19-norpregna-1(10),2,4-trien-20-yn-3-yl propane-2-sulfonate; 17alpha-Ethinyl-3-isopropylsulfonyloxyestradiol; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17alpha)-; 28913-23-7; A)-17-ethynyl-17-hydroxyestra-1,3,5(10)-trien-3-yl propane-2-sulfonate; AC1L2A1G; AC1Q6XYI; CHEBI:135643; D07928; DTXSID20951545; J-96; UNII-XF48685MYR
DM7ITZK PC 68582
DM7ITZK MW 402.5
DM7ITZK FM C23H30O4S
DM7ITZK IC KPEUDULLQDHKAZ-VROINQGHSA-N
DM7ITZK CS CC(C)S(=O)(=O)OC1=CC2=C(C=C1)C3CCC4(C(C3CC2)CCC4(C#C)O)C
DM7ITZK IK 1S/C23H30O4S/c1-5-23(24)13-11-21-20-8-6-16-14-17(27-28(25,26)15(2)3)7-9-18(16)19(20)10-12-22(21,23)4/h1,7,9,14-15,19-21,24H,6,8,10-13H2,2-4H3/t19-,20-,21+,22+,23+/m1/s1
DM7ITZK IU [(8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] propane-2-sulfonate
DM7ITZK CA CAS 28913-23-7
DM7ITZK CB CHEBI:135643
DM7ITZK DE Prostate cancer
DM8TNX3 ID DM8TNX3
DM8TNX3 DN Etizolam
DM8TNX3 HS Phase 4
DM8TNX3 SN Etizolam [INN:JAN]; Etizolamum [INN-Latin]; VMZUTJCNQWMAGF-UHFFFAOYSA-N; Y 7131; Y-7131; etizolam; 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 40054-69-1; 6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine; 8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine; A76XI0HL37; AHR 3219; BRN 0572740; C17H15ClN4S; Depas; NCGC00182031-01; UNII-A76XI0HL37
DM8TNX3 PC 3307
DM8TNX3 MW 342.8
DM8TNX3 FM C17H15ClN4S
DM8TNX3 IC VMZUTJCNQWMAGF-UHFFFAOYSA-N
DM8TNX3 CS CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C
DM8TNX3 IK 1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3
DM8TNX3 IU 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DM8TNX3 CA CAS 40054-69-1
DM8TNX3 CB CHEBI:31583
DM8TNX3 DE Insomnia
DMR7U8F ID DMR7U8F
DMR7U8F DN Etoperidone
DMR7U8F HS Phase 4
DMR7U8F SN Etoperidona; Etoperidona [INN-Spanish]; Etoperidona [Spanish]; Etoperidone [INN]; Etoperidonum; Etoperidonum [INN-Latin]; ETOPERIDONE; IZBNNCFOBMGTQX-UHFFFAOYSA-N; KAI6MVO39Z; L001188; ZINC3830815; 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one; 52942-31-1; AC1L242J; AC1Q3SR1; ACM52942311; BDBM82438; CAS_52942-31-1; CHEBI:135589; CHEMBL1743259; DB09194; DTXSID0023034; NSC_40589; PDSP1_000523; PDSP2_000521; SCHEMBL49314; UNII-KAI6MVO39Z
DMR7U8F PC 40589
DMR7U8F MW 377.9
DMR7U8F FM C19H28ClN5O
DMR7U8F IC IZBNNCFOBMGTQX-UHFFFAOYSA-N
DMR7U8F CS CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl
DMR7U8F IK 1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3
DMR7U8F IU 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one
DMR7U8F CA CAS 52942-31-1
DMR7U8F CB CHEBI:135589
DMR7U8F DE Depression
DM9R1YU ID DM9R1YU
DM9R1YU DN Gestodene
DM9R1YU HS Phase 4
DM9R1YU SN Gestinol; Gestoden; Gestodene [USAN:INN:BAN]; Gestodeno; Gestodeno [INN-Spanish]; Gestodenum; Gestodenum [INN-Latin]; SH B 331; GESTODENE; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregna-4,15-dien-20-yn-3-one; 1664P6E6MI; 17-alpha-Ethinyl-13-ethyl-17-beta-hydroxy-4,15-gonadien-3-one; 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-; 60282-87-3; BRN 4237181; CCRIS 9189; DSSTox_CID_26478; DSSTox_GSID_46478; DSSTox_RID_81649; EINECS 262-145-8; HSDB 3594; UNII-1664P6E6MI
DM9R1YU PC 3033968
DM9R1YU MW 310.4
DM9R1YU FM C21H26O2
DM9R1YU IC SIGSPDASOTUPFS-XUDSTZEESA-N
DM9R1YU CS CCC12CCC3C(C1C=CC2(C#C)O)CCC4=CC(=O)CCC34
DM9R1YU IK 1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
DM9R1YU IU (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one
DM9R1YU CA CAS 60282-87-3
DM9R1YU CB CHEBI:135323
DM9R1YU DE Contraception
DMDN4A1 ID DMDN4A1
DMDN4A1 DN Glitazone
DMDN4A1 HS Phase 4
DMDN4A1 SN 74772-78-4; 5-(4-Hydroxybenzyl)thiazolidine-2,4-dione; 5-(4-Hydroxybenzyl)-2,4-thiazolidinedione; 5-(4-HYDROXYBENZYL)-1,3-THIAZOLIDINE-2,4-DIONE; U-90441; 2,4-dioxo-5-[(p-hydroxyphenyl)-methyl]thiazolidine; 5-[(4-Hydroxyphenyl)methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[(4-hydroxyphenyl)methyl]-; Glitazone; 5-(4-Hydroxybenzyl)thiazolidin-2,4-dione; ACMC-1BF0J; Pioglitazone Metabolite M1; SCHEMBL623021; SCHEMBL18174924; CTK5E0483; MolPort-006-394-329; NKOHRVBBQISBSB-UHFFFAOYSA-N; ZX-AT015682; KM1640; CH-087
DMDN4A1 DT Small molecular drug
DMDN4A1 PC 10198397
DMDN4A1 MW 223.25
DMDN4A1 FM C10H9NO3S
DMDN4A1 IC InChI=1S/C10H9NO3S/c12-7-3-1-6(2-4-7)5-8-9(13)11-10(14)15-8/h1-4,8,12H,5H2,(H,11,13,14)
DMDN4A1 CS C1=CC(=CC=C1CC2C(=O)NC(=O)S2)O
DMDN4A1 IK NKOHRVBBQISBSB-UHFFFAOYSA-N
DMDN4A1 IU 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione
DMDN4A1 CA CAS 74772-78-4
DMF72W3 ID DMF72W3
DMF72W3 DN Glyceryl trinitrate
DMF72W3 HS Phase 4
DMF72W3 SN Gilustenon; Glycerol trinitrate; Glyceryl trinitrate; Lenitral; Minitran; Natispray; Nitro-Bid; Nitro-dur; Nitrocine; Nitroderm; Cordipatch; Corditrine; Epinitril; Nitroderm TTS; Nitroglicerina; Nitroglycerine; Nitroglycerol; Nitroglyn; Nitrolan; Nitrolingual; Nitronet; Nitrong; Nitroplast; Nitrorectal; Nitroretard; Nitrospan; Nitrostat; Perglottal; Perlinganit; Rectogesic; Susadrin; Sustonit; Transderm Nitro; Transderm-nitro; Tridil; Trinitrin; Trinitroglycerin; Trinitroglycerol; Trinitrolong; Trinitrosan; nitroglycerin; 55-63-0; Niong
DMF72W3 PC 4510
DMF72W3 MW 227.09
DMF72W3 FM C3H5N3O9
DMF72W3 IC SNIOPGDIGTZGOP-UHFFFAOYSA-N
DMF72W3 CS C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-]
DMF72W3 IK 1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
DMF72W3 IU 1,3-dinitrooxypropan-2-yl nitrate
DMF72W3 CA CAS 55-63-0
DMF72W3 CB CHEBI:28787
DMF72W3 DE Acute coronary syndrome
DM0OX31 ID DM0OX31
DM0OX31 DN Glypromate
DM0OX31 HS Phase 4
DM0OX31 SN Glypromate; Glycyl-prolyl-glutamic acid; Gly-Pro-Glu, >=98% (HPLC); Gly-pro-glu; SCHEMBL1170125; ZINC3776571; ZYK4RVV5LS; glycyl-l-prolyl-l-glutamic acid; 32302-76-4; CHEMBL371315; DB05633; DTXSID80186038; UNII-ZYK4RVV5LS
DM0OX31 PC 3080768
DM0OX31 MW 301.3
DM0OX31 FM C12H19N3O6
DM0OX31 IC JJGBXTYGTKWGAT-YUMQZZPRSA-N
DM0OX31 CS C1CC(N(C1)C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O
DM0OX31 IK 1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1
DM0OX31 IU (2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid
DM0OX31 CA CAS 32302-76-4
DM0OX31 DE Epilepsy
DM9BPLW ID DM9BPLW
DM9BPLW DN Grazoprevir
DM9BPLW HS Phase 4
DM9BPLW SN Grazoprevir; Grazoprevir [INN]; Grazoprevir anhydrous; MK 5172; MK-5172; MK5172; OBMNJSNZOWALQB-NCQNOWPTSA-N; SCHEMBL2175313; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; 1350514-68-9; 8YE81R1X1J; CHEBI:132975; CHEMBL2063090; DTXSID50159234; EX-A2253; UNII-8YE81R1X1J
DM9BPLW PC 44603531
DM9BPLW MW 766.9
DM9BPLW FM C38H50N6O9S
DM9BPLW IC OBMNJSNZOWALQB-NCQNOWPTSA-N
DM9BPLW CS CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1
DM9BPLW IK 1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1
DM9BPLW IU (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DM9BPLW CA CAS 1350514-68-9
DM9BPLW CB CHEBI:132975
DM9BPLW DE Viral hepatitis
DMPN5IH ID DMPN5IH
DMPN5IH DN Guanfacine
DMPN5IH HS Phase 4
DMPN5IH SN GUANFACINE; Tenex; Guanfacinum [INN-Latin]; Guanfacina [INN-Spanish]; Estulic; Intuniv; N-amidino-2-(2,6-dichlorophenyl)acetamide; CHEBI:5558; INJOMKTZOLKMBF-UHFFFAOYSA-N; SPD 503; C9H9Cl2N3O; N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide; Guanfacine Monohydrochloride; NCGC00015469-05; Lon798; Guanfacine (INN); Estulic (TN); Tenex (Salt/Mix); Estulic (Salt/Mix); Tocris-1030; Prestwick1_000339; Prestwick3_000339; Prestwick2_000339; Prestwick0_000339; Lopac-G-1043
DMPN5IH PC 3519
DMPN5IH MW 246.09
DMPN5IH FM C9H9Cl2N3O
DMPN5IH IC InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
DMPN5IH CS C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
DMPN5IH IK INJOMKTZOLKMBF-UHFFFAOYSA-N
DMPN5IH IU N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
DMPN5IH CA CAS 29110-47-2
DMPN5IH CB CHEBI:5558
DMPN5IH DE Primary liver cancer
DMLYXBF ID DMLYXBF
DMLYXBF DN Guanoxan
DMLYXBF HS Phase 4
DMLYXBF SN Guanoxan; Guanoxan [INN:BAN]; Guanoxane; Guanoxano; Guanoxano [INN-Spanish]; Guanoxanum; Guanoxanum [INN-Latin]; Guanoxon; ((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; (1,4-Benzodioxan-2-ylmethyl)guanidine; 2165-19-7; Envacar (Salt/Mix); BRN 1251616; DSSTox_CID_26166; DSSTox_RID_81397; GUANIDINE, (1,4-BENZODIOXAN-2-YLMETHYL)-; Guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-; N-((2,3-Dihydro-1,4-benzodioxin-2-yl)methyl)guanidine; N-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]guanidine; NCGC00160462-01
DMLYXBF PC 16564
DMLYXBF MW 207.23
DMLYXBF FM C10H13N3O2
DMLYXBF IC HIUVKVDQFXDZHU-UHFFFAOYSA-N
DMLYXBF CS C1C(OC2=CC=CC=C2O1)CN=C(N)N
DMLYXBF IK 1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13)
DMLYXBF IU 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine
DMLYXBF CA CAS 2165-19-7
DMLYXBF CB CHEBI:134871
DMLYXBF DE Essential hypertension
DM4OQRD ID DM4OQRD
DM4OQRD DN HIF-1alpha
DM4OQRD HS Phase 4
DM4OQRD SN Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; UNII-NA856793UT; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
DM4OQRD CP Enzon
DM4OQRD TC Anticancer Agents
DM4OQRD DT Small molecular drug
DM4OQRD PC 5328127
DM4OQRD MW 396.4
DM4OQRD FM C20H24N6O3
DM4OQRD IC InChI=1S/C20H24N6O3/c1-20(2,3)26-19(27)25-17-15(8-12-10-22-18(21)24-16(12)23-17)11-6-13(28-4)9-14(7-11)29-5/h6-10H,1-5H3,(H4,21,22,23,24,25,26,27)
DM4OQRD CS CC(C)(C)NC(=O)NC1=C(C=C2C=NC(=NC2=N1)N)C3=CC(=CC(=C3)OC)OC
DM4OQRD IK NHJSWORVNIOXIT-UHFFFAOYSA-N
DM4OQRD IU 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea
DM4OQRD CA CAS 192705-79-6
DM4OQRD CB CHEBI:156259
DM4OQRD DE Lymphoma
DMYOC29 ID DMYOC29
DMYOC29 DN Hirudin
DMYOC29 HS Phase 4
DMYOC29 SN Hirudin (53-64); 135546-61-1; Hirudin 53-64; DTXSID20159463; L-Alanine, L-asparaginylglycyl-L-alpha-aspartyl-L-pheylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-
DMYOC29 DT Small molecular drug
DMYOC29 PC 72941487
DMYOC29 MW 7044
DMYOC29 FM C287H440N80O113S7
DMYOC29 IC InChI=1S/C287H440N80O113S7/c1-25-133(19)226-281(469)345-161(87-125(3)4)235(423)306-111-208(394)320-180(116-370)266(454)344-175(101-219(414)415)237(425)307-105-202(388)316-151(62-75-212(400)401)242(430)321-145(41-30-33-81-288)240(428)339-170(96-197(297)383)258(446)326-152(57-70-193(293)379)249(437)351-185(121-484-481-118-182-239(427)310-107-201(387)313-147(55-68-191(291)377)232(420)303-108-205(391)317-169(95-196(296)382)257(445)322-146(42-31-34-82-289)241(429)350-186(271(459)360-226)122-485-482-119-183(268(456)323-149(61-74-211(398)399)234(422)304-110-207(393)319-179(115-369)265(453)342-173(99-200(300)386)264(452)357-223(130(13)14)279(467)355-182)352-253(441)164(90-128(9)10)335-269(457)184-120-483-486-123-187(354-262(450)177(103-221(418)419)347-283(471)230(137(23)374)362-263(451)167(92-140-47-51-143(376)52-48-140)346-278(466)224(131(15)16)359-276(464)222(301)129(11)12)272(460)363-229(136(22)373)282(470)330-157(66-79-216(408)409)248(436)348-178(114-368)238(426)309-106-203(389)315-150(56-69-192(292)378)243(431)340-171(97-198(298)384)259(447)334-163(89-127(7)8)252(440)353-184)270(458)358-225(132(17)18)280(468)364-228(135(21)372)277(465)311-112-204(390)314-148(60-73-210(396)397)233(421)305-113-209(395)356-231(138(24)375)286(474)367-86-38-46-190(367)275(463)331-159(43-32-35-83-290)284(472)365-84-36-44-188(365)273(461)328-153(58-71-194(294)380)247(435)349-181(117-371)267(455)338-168(94-142-104-302-124-312-142)256(444)341-172(98-199(299)385)260(448)343-174(100-218(412)413)236(424)308-109-206(392)318-176(102-220(416)417)261(449)337-165(91-139-39-28-27-29-40-139)254(442)327-154(63-76-213(402)403)244(432)325-158(67-80-217(410)411)250(438)361-227(134(20)26-2)285(473)366-85-37-45-189(366)274(462)329-156(65-78-215(406)407)245(433)324-155(64-77-214(404)405)246(434)336-166(93-141-49-53-144(54-50-141)480-487(477,478)479)255(443)333-162(88-126(5)6)251(439)332-160(287(475)476)59-72-195(295)381/h27-29,39-40,47-54,104,124-138,145-190,222-231,368-376H,25-26,30-38,41-46,55-103,105-123,288-290,301H2,1-24H3,(H2,291,377)(H2,292,378)(H2,293,379)(H2,294,380)(H2,295,381)(H2,296,382)(H2,297,383)(H2,298,384)(H2,299,385)(H2,300,386)(H,302,312)(H,303,420)(H,304,422)(H,305,421)(H,306,423)(H,307,425)(H,308,424)(H,309,426)(H,310,427)(H,311,465)(H,313,387)(H,314,390)(H,315,389)(H,316,388)(H,317,391)(H,318,392)(H,319,393)(H,320,394)(H,321,430)(H,322,445)(H,323,456)(H,324,433)(H,325,432)(H,326,446)(H,327,442)(H,328,461)(H,329,462)(H,330,470)(H,331,463)(H,332,439)(H,333,443)(H,334,447)(H,335,457)(H,336,434)(H,337,449)(H,338,455)(H,339,428)(H,340,431)(H,341,444)(H,342,453)(H,343,448)(H,344,454)(H,345,469)(H,346,466)(H,347,471)(H,348,436)(H,349,435)(H,350,429)(H,351,437)(H,352,441)(H,353,440)(H,354,450)(H,355,467)(H,356,395)(H,357,452)(H,358,458)(H,359,464)(H,360,459)(H,361,438)(H,362,451)(H,363,460)(H,364,468)(H,396,397)(H,398,399)(H,400,401)(H,402,403)(H,404,405)(H,406,407)(H,408,409)(H,410,411)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,475,476)(H,477,478,479)/t133-,134-,135+,136+,137+,138+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,222-,223-,224-,225-,226-,227-,228-,229-,230-,231-/m0/s1
DMYOC29 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)OS(=O)(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C
DMYOC29 IK WQPDUTSPKFMPDP-OUMQNGNKSA-N
DMYOC29 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-15,76-bis(4-aminobutyl)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9,67-bis(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-18,47-bis(2-carboxyethyl)-24-(carboxymethyl)-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMYOC29 CA CAS 8001-27-2
DM0WD1V ID DM0WD1V
DM0WD1V DN Human calcitonin
DM0WD1V HS Phase 4
DM0WD1V SN Calcitonin (human synthetic); Calcitonin (human); Calcitonin human; Calcitonin, human; Calcitonin, human synthetic
DM0WD1V PC 16220016
DM0WD1V IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19S,22R)-22-amino-16-(2-amino-2-oxoethyl)-7-[(1R)-1-hydroxyethyl]-10,19-bis(hydroxymethyl)-13-(2-methylpropyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM0WD1V DE Hyperparathyroidism
DMABXOZ ID DMABXOZ
DMABXOZ DN Hyaluronic acid
DMABXOZ HS Phase 4
DMABXOZ SN Hyaluronic Acid [BAN]; Hylan G-F 20; Hyvisc; Luronit; Mucoitin; Amo Vitrax; Amvisc; Biolon; Etamucine; Sepracoat; Sofast; Synvisc; C33H54N2O23; EINECS 232-678-0; HSDB 7240; Hyaluronate Sodium (hyaluronic acid)
DMABXOZ PC 24847767
DMABXOZ MW 846.8
DMABXOZ FM C33H54N2O23
DMABXOZ IC BVOZFCOTOYGLGD-VPQOAABJSA-N
DMABXOZ CS CC(=O)NC1C(C(C(OC1COCC2C(OC(C(C2O)(C)O)OCC3C(C(OC(C3O)CO)O)NC(=O)C)C(=O)O)CO)O)COC4C(C(C(C(O4)C(=O)O)O)O)O
DMABXOZ IK 1S/C33H54N2O23/c1-10(38)34-18-12(7-53-31-24(44)22(42)23(43)26(57-31)29(48)49)20(40)15(4-36)55-17(18)9-52-6-14-25(28(46)47)58-32(33(3,51)27(14)45)54-8-13-19(35-11(2)39)30(50)56-16(5-37)21(13)41/h12-27,30-32,36-37,40-45,50-51H,4-9H2,1-3H3,(H,34,38)(H,35,39)(H,46,47)(H,48,49)/t12-,13-,14+,15?,16?,17-,18?,19?,20-,21-,22+,23-,24?,25?,26?,27+,30+,31+,32+,33?/m0/s1
DMABXOZ IU (3S,4R,6R)-3-[[(2R,4R,5S)-3-acetamido-4-[[(2R,4R,5S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxymethyl]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]methoxymethyl]-6-[[(2R,4R,5S)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]methoxy]-4,5-dihydroxy-5-methyloxane-2-carboxylic acid
DMABXOZ DE Osteoarthritis
DM8NWFD ID DM8NWFD
DM8NWFD DN Hypericum
DM8NWFD HS Phase 4
DM8NWFD SN 6-formamidopenicillanic acid; UNII-2TC14ZH3A5; CHEBI:59004; CTK2F8101; 6-formamido-2,2-dimethylpenam-3alpha-carboxylic acid; 2TC14ZH3A5; 64527-04-4; (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-Formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; PAB 141; 141a/2A; HIS-1201; Epitope ID:119700; SCHEMBL11176911; DTXSID90429524; 6beta-formylaminopenicillanic acid; 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-(formylamino)-3,3-d
DM8NWFD DT Small molecular drug
DM8NWFD PC 9548591
DM8NWFD MW 244.27
DM8NWFD FM C9H12N2O4S
DM8NWFD IC InChI=1S/C9H12N2O4S/c1-9(2)5(8(14)15)11-6(13)4(10-3-12)7(11)16-9/h3-5,7H,1-2H3,(H,10,12)(H,14,15)/t4-,5+,7-/m1/s1
DM8NWFD CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC=O)C(=O)O)C
DM8NWFD IK MDQGTDMBVJCTBN-JCGDXUMPSA-N
DM8NWFD IU (2S,5R,6R)-6-formamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DM8NWFD CA CAS 64527-04-4
DM8NWFD CB CHEBI:59004
DMVXLOD ID DMVXLOD
DMVXLOD DN Imrecoxib
DMVXLOD HS Phase 4
DMVXLOD SN Imrecoxib; UNII-SGW6W5758V; SGW6W5758V; CHEMBL504535; 395683-14-4; Imricoxib; BAP-909; SCHEMBL3034253; BDBM50293282; AKOS032954049; DB12354; LS-194053; 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-1-propyl-; BAP-909; ;
DMVXLOD DT Small molecular drug
DMVXLOD PC 11682175
DMVXLOD MW 369.5
DMVXLOD FM C21H23NO3S
DMVXLOD IC InChI=1S/C21H23NO3S/c1-4-13-22-14-19(16-9-11-18(12-10-16)26(3,24)25)20(21(22)23)17-7-5-15(2)6-8-17/h5-12H,4,13-14H2,1-3H3
DMVXLOD CS CCCN1CC(=C(C1=O)C2=CC=C(C=C2)C)C3=CC=C(C=C3)S(=O)(=O)C
DMVXLOD IK AXMZZGKKZDJGAZ-UHFFFAOYSA-N
DMVXLOD IU 4-(4-methylphenyl)-3-(4-methylsulfonylphenyl)-1-propyl-2H-pyrrol-5-one
DMVXLOD CA CAS 395683-14-4
DM2R496 ID DM2R496
DM2R496 DN Indenolol
DM2R496 HS Phase 4
DM2R496 SN Indenolol; Indenolol [INN]; Indenolol [BAN:INN]; Indenolol [INN:BAN]; Indenololum; Indenololum [INN-Latin]; Sch 28316 Z; Sch 28316Z; Securpres; 1-(4-Indenyloxy)-3-isopropylamino-2-propanol; 1-(Inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol; 106656-86-4; 2-Propanol, 1-(1H-inden-4-yloxy)-3-((1-methylethyl)amino)-; 2-Propanol, 1-(1H-inden-4-yloxy)-3-[(1-methylethyl)amino]-; 4-(2-Hydroxy-3-isopropylaminopropoxy)indene; 60607-68-3; AC1L2H51; AC1Q77JA; ACMC-20macf; C15H27NO2; CHEMBL153585; EINECS 262-323-5; SCHEMBL79021; YB-2
DM2R496 PC 71955
DM2R496 MW 247.33
DM2R496 FM C15H21NO2
DM2R496 IC MPGBPFMOOXKQRX-UHFFFAOYSA-N
DM2R496 CS CC(C)NCC(COC1=CC=CC2=C1C=CC2)O
DM2R496 IK 1S/C15H21NO2/c1-11(2)16-9-13(17)10-18-15-8-4-6-12-5-3-7-14(12)15/h3-4,6-8,11,13,16-17H,5,9-10H2,1-2H3
DM2R496 IU 1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DM2R496 CA CAS 60607-68-3
DM2R496 DE Cardiac arrhythmia
DMVPLNC ID DMVPLNC
DMVPLNC DN Ingrezza
DMVPLNC HS Phase 4
DMVPLNC SN Valbenazine; 1025504-45-3; UNII-54K37P50KH; Valbenazine free base; NBI 98854; 54K37P50KH; 1025504-45-3 (free base); (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester; Valbenazine [USAN:INN]; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester; ValbenazineNBI-98854; Valbenazine (USAN/INN); GTPL8694; CHEMBL2364639; SCHEMBL15932979; EX-A2002; MFCD28963976; ZINC43195697; CS-5908; DB11915; SB17456; NCGC00522306-02; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; AC-30929; AS-35294; HY-16771; D10675; NBI-98854;NBI98854;NBI 98854; Q27089118; (2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate; (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate; Valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester
DMVPLNC CP Neurocrine Biosciences
DMVPLNC DT Small molecular drug
DMVPLNC PC 24795069
DMVPLNC MW 418.6
DMVPLNC FM C24H38N2O4
DMVPLNC IC InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1
DMVPLNC CS CC(C)C[C@@H]1CN2CCC3=CC(=C(C=C3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC
DMVPLNC IK GEJDGVNQKABXKG-CFKGEZKQSA-N
DMVPLNC IU [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate
DMVPLNC CA CAS 1025504-45-3
DMVPLNC DE Tourette syndrome; Tardive dyskinesia
DM7U58J ID DM7U58J
DM7U58J DN Isoflavone
DM7U58J HS Phase 4
DM7U58J SN Isoflavone; Isoflavone (8CI); Isoflavone skeleton; LS-191186; MCULE-2586547916; OVO2KUW8H8; SBB068618; SCHEMBL8028; ST098957; VN10014; ZINC895390; isoflavon; 3-Phenylchromone; 3-phenyl-4H-1-benzopyran-4-one; 3-phenyl-4H-chromen-4-one; 3-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 3-phenyl-; 574-12-9; AC-12802; AK114020; AKOS015918505; AX8135136; BCP22856; BCP9000133; CCG-214095; CHEBI:18220; CHEMBL366460; CS-W006405; DB12007; DS-6374; DTXSID90205986; KS-00000GFW; NSC 135405; NSC-135405; NSC135405; GOMNOOKGLZYEJT-UHFFFAOYSA-N; UNII-OVO2KUW8H8
DM7U58J PC 72304
DM7U58J MW 222.24
DM7U58J FM C15H10O2
DM7U58J IC GOMNOOKGLZYEJT-UHFFFAOYSA-N
DM7U58J CS C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O
DM7U58J IK 1S/C15H10O2/c16-15-12-8-4-5-9-14(12)17-10-13(15)11-6-2-1-3-7-11/h1-10H
DM7U58J IU 3-phenylchromen-4-one
DM7U58J CA CAS 574-12-9
DM7U58J CB CHEBI:18220
DM7U58J DE Asthma
DM170OH ID DM170OH
DM170OH DN Ketazolam
DM170OH HS Phase 4
DM170OH SN Ketazolamum; Ketazolamum [INN-Latin]; Loftran; U 28774; U-28,774; Unakalm; Anseren; Ansieten; KETAZOLAM; 11-Chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-(1,3)-oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)dione; 27223-35-4; 4H-(1,3)Oxazino(3,2-d)(1,4)benzodiazepine-4,7(6H)-dione, 8,12b-dihydro-11-chloro-2,8-dimethyl-12b-phenyl-; 4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-; Anxon; EINECS 248-346-3; NSC 338158
DM170OH PC 33746
DM170OH MW 368.8
DM170OH FM C20H17ClN2O3
DM170OH IC PWAJCNITSBZRBL-UHFFFAOYSA-N
DM170OH CS CC1=CC(=O)N2CC(=O)N(C3=C(C2(O1)C4=CC=CC=C4)C=C(C=C3)Cl)C
DM170OH IK 1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
DM170OH IU 11-chloro-2,8-dimethyl-12b-phenyl-6H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione
DM170OH CA CAS 27223-35-4
DM170OH CB CHEBI:135556
DM170OH DE Anxiety disorder
DMQP5I3 ID DMQP5I3
DMQP5I3 DN Lacidipine
DMQP5I3 HS Phase 4
DMQP5I3 SN Lacidipine; Lacidipine (Lacipil, Motens); Lacidipino; Lacidipino [Spanish]; Lacidipinum [Latin]; Lacimen; Lacipil; Motens; trans Lacidipine; 103890-78-4; 260080034N; 4-(o-((E)-2-Carboxyvinyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 4-tert-butyl diethyl ester; C26H33NO6; DSSTox_CID_26429; DSSTox_GSID_46429; DSSTox_RID_81607; GR 43659 X; GR 43659X; GR-43659X; GX-1048; UNII-260080034N; diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMQP5I3 PC 5311217
DMQP5I3 MW 455.5
DMQP5I3 FM C26H33NO6
DMQP5I3 IC GKQPCPXONLDCMU-CCEZHUSRSA-N
DMQP5I3 CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C
DMQP5I3 IK 1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
DMQP5I3 IU diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMQP5I3 CA CAS 103890-78-4
DMQP5I3 CB CHEBI:94480
DMQP5I3 DE Essential hypertension
DM5FABJ ID DM5FABJ
DM5FABJ DN LAROPIPRANT
DM5FABJ HS Phase 4
DM5FABJ SN Laropiprant; 571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B
DM5FABJ DT Small molecular drug
DM5FABJ PC 9867642
DM5FABJ MW 435.9
DM5FABJ FM C21H19ClFNO4S
DM5FABJ IC InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
DM5FABJ CS CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F
DM5FABJ IK NXFFJDQHYLNEJK-CYBMUJFWSA-N
DM5FABJ IU 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
DM5FABJ CA CAS 571170-77-9
DM5FABJ CB CHEBI:135942
DM5FABJ DE Arteriosclerosis; Coronary heart disease
DM92S6N ID DM92S6N
DM92S6N DN Levamlodipine
DM92S6N HS Phase 4
DM92S6N SN Levamlodipine (hypertension); S-amlodipine gentisate; Levamlodipine (hypertension), SK Chemicals; S-amlodipine (hypertension), SK Chemicals
DM92S6N CP SK Chemicals Co Ltd
DM92S6N DT Small molecular drug
DM92S6N PC 9822750
DM92S6N MW 408.9
DM92S6N FM C20H25ClN2O5
DM92S6N IC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3/t17-/m0/s1
DM92S6N CS CCOC(=O)C1=C(NC(=C([C@@H]1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
DM92S6N IK HTIQEAQVCYTUBX-KRWDZBQOSA-N
DM92S6N IU 3-O-ethyl 5-O-methyl (4S)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DM92S6N CA CAS 103129-82-4
DM92S6N CB CHEBI:53796
DM92S6N DE Hypertension
DM82JP0 ID DM82JP0
DM82JP0 DN Lynestrenol
DM82JP0 HS Phase 4
DM82JP0 SN Linestrenol; Linestrenol [INN-Spanish]; Linestrenolo [DCIT]; Lynenol; Lynestrenolum [INN-Latin]; Lynoestrenol; Lynoestrenol [Progestins]; Lynstranol; Endometril; Ethinyl oestrenol; Ethinylestrenol; Ethinyloestranol; Ethynloestrenol; Ethynylestrenol; Exluten; Exlution; Exluton; Exlutona; IND 1006; LYNESTRENOL; Org 485-50; Orgametil; Orgametril; Orgametrol; 17-alpha-Ethynylestrenol; 17-alpha-Ethynyloestrenol; 17alpha-Ethynylestrenol; 3-Desoxynorlutin; 52-76-6; CCRIS 9093; EINECS 200-151-4; NSC 37725; NSC-37725; UNII-N2Z8ALG4U5
DM82JP0 PC 5857
DM82JP0 MW 284.4
DM82JP0 FM C20H28O
DM82JP0 IC YNVGQYHLRCDXFQ-XGXHKTLJSA-N
DM82JP0 CS CC12CCC3C(C1CCC2(C#C)O)CCC4=CCCCC34
DM82JP0 IK 1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
DM82JP0 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DM82JP0 CA CAS 52-76-6
DM82JP0 CB CHEBI:31790
DM82JP0 DE Transsexualism
DM0UGYX ID DM0UGYX
DM0UGYX DN Medifoxamine
DM0UGYX HS Phase 4
DM0UGYX SN Medifoxamina; Medifoxamina [INN-Spanish]; Medifoxamine; Medifoxamine (INN); Medifoxamine [INN:DCF]; Medifoxaminum; Medifoxaminum [INN-Latin]; KWU7C2A1NT; ZX-AT022754; (Dimethylamino)acetaldehyde diphenyl acetal; 32359-34-5; AC1L1V3V; Acetaldehyde, (dimethylamino)-, diphenyl acetal; BRN 2054310; C16H19NO2; CHEBI:135061; CHEMBL85231; CTK4G8876; DTXSID80186078; EINECS 251-011-4; Ethanamine, N,N-dimethyl-2,2-diphenoxy-; N,N-Dimethyl-2,2-diphenoxyethanamine; N,N-Dimethyl-2,2-diphenoxyethylamine; SCHEMBL49319; UNII-KWU7C2A1NT
DM0UGYX PC 36109
DM0UGYX MW 257.329
DM0UGYX FM C16H19NO2
DM0UGYX IC QNMGHBMGNRQPNL-UHFFFAOYSA-N
DM0UGYX CS CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2
DM0UGYX IK 1S/C16H19NO2/c1-17(2)13-16(18-14-9-5-3-6-10-14)19-15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
DM0UGYX IU N,N-dimethyl-2,2-diphenoxyethanamine
DM0UGYX CA CAS 32359-34-5
DM0UGYX CB CHEBI:135061
DM0UGYX DE Depression
DME1X96 ID DME1X96
DME1X96 DN Mexazolam
DME1X96 HS Phase 4
DME1X96 SN Melex (TN); Mexazolam (JAN/INN); Mexazolam [INN:JAN]; Mexazolamum; Mexazolamum [INN-Latin]; Sedoxil; mexazolam; 10-Chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 10-Chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one; 31868-18-5; AC1L1HL4; BRN 1091849; C18H16Cl2N2O2; CHEBI:31842; CS 386; CS-386; DSSTox_CID_31504; Melex; Oxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyl-
DME1X96 PC 4177
DME1X96 MW 363.2
DME1X96 FM C18H16Cl2N2O2
DME1X96 IC ANUCDXCTICZJRH-UHFFFAOYSA-N
DME1X96 CS CC1COC2(N1CC(=O)NC3=C2C=C(C=C3)Cl)C4=CC=CC=C4Cl
DME1X96 IK 1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)
DME1X96 IU 10-chloro-11b-(2-chlorophenyl)-3-methyl-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one
DME1X96 CA CAS 31868-18-5
DME1X96 CB CHEBI:31842
DME1X96 DE Anxiety disorder
DM2VOQ3 ID DM2VOQ3
DM2VOQ3 DN Mosapride
DM2VOQ3 HS Phase 4
DM2VOQ3 SN Mosapride; 112885-41-3; 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide; Mosapride [INN]; CHEMBL60889; Mosapride (INN); 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamide; AK-41276; 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; Q-201413; 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide
DM2VOQ3 DT Small molecular drug
DM2VOQ3 PC 119584
DM2VOQ3 MW 421.9
DM2VOQ3 FM C21H25ClFN3O3
DM2VOQ3 IC InChI=1S/C21H25ClFN3O3/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27)
DM2VOQ3 CS CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
DM2VOQ3 IK YPELFRMCRYSPKZ-UHFFFAOYSA-N
DM2VOQ3 IU 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide
DM2VOQ3 CA CAS 112885-41-3
DM2VOQ3 CB CHEBI:94373
DMVILAD ID DMVILAD
DMVILAD DN MOTILIN
DMVILAD HS Phase 4
DMVILAD SN Motilin (human, porcine); UNII-D85V250YSI; D85V250YSI; 9072-41-7; Human motilin; 52906-92-0; Motilin (swine); Motilin (human); Motilin (porcine); Motilin [MI]; Human motilin [MI]; Motilin porcine; h-Motilin; Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln; GTPL1458; CHEMBL525634; Motilin porcine, >
DMVILAD DT Small molecular drug
DMVILAD PC 16136567
DMVILAD MW 2699.1
DMVILAD FM C120H188N34O35S
DMVILAD IC InChI=1S/C120H188N34O35S/c1-9-64(6)97(152-114(184)86-31-22-53-154(86)117(187)96(63(4)5)151-99(169)70(123)56-66-23-12-10-13-24-66)115(185)150-84(57-67-25-14-11-15-26-67)113(183)153-98(65(7)155)116(186)149-83(58-68-32-34-69(156)35-33-68)101(171)135-60-91(161)136-75(39-45-93(163)164)105(175)147-82(55-62(2)3)111(181)145-77(37-43-88(125)158)106(176)140-73(29-20-51-132-119(128)129)103(173)146-80(48-54-190-8)110(180)142-76(36-42-87(124)157)107(177)144-79(41-47-95(167)168)108(178)139-72(28-17-19-50-122)102(172)143-78(40-46-94(165)166)109(179)141-74(30-21-52-133-120(130)131)104(174)148-85(59-90(127)160)112(182)138-71(27-16-18-49-121)100(170)134-61-92(162)137-81(118(188)189)38-44-89(126)159/h10-15,23-26,32-35,62-65,70-86,96-98,155-156H,9,16-22,27-31,36-61,121-123H2,1-8H3,(H2,124,157)(H2,125,158)(H2,126,159)(H2,127,160)(H,134,170)(H,135,171)(H,136,161)(H,137,162)(H,138,182)(H,139,178)(H,140,176)(H,141,179)(H,142,180)(H,143,172)(H,144,177)(H,145,181)(H,146,173)(H,147,175)(H,148,174)(H,149,186)(H,150,185)(H,151,169)(H,152,184)(H,153,183)(H,163,164)(H,165,166)(H,167,168)(H,188,189)(H4,128,129,132)(H4,130,131,133)/t64-,65+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,96-,97-,98-/m0/s1
DMVILAD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMVILAD IK LVRVABPNVHYXRT-BQWXUCBYSA-N
DMVILAD IU (2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMVILAD CA CAS 9072-41-7
DMHEAB1 ID DMHEAB1
DMHEAB1 DN Neupro
DMHEAB1 HS Phase 4
DMHEAB1 SN Rotigotine; 99755-59-6; Leganto; SPM 962; (S)-6-(propyl(2-(thiophen-2-yl)ethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; (6S)-rotigotine; UNII-87T4T8BO2E; (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-962; N 0923; CHEMBL1303; 87T4T8BO2E; 99755-59-6 (free base); (6S)-6-(Propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol; NCGC00168748-01; Rotigotine CDS Patch; (6s)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol; DSSTox_CID_26772; DSSTox_RID_81893; DSSTox_GSID_46772; C19H25NOS; Rotigotine CDS; (S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; (S)-6-[Propyl-(2-thiophen-2-yl-ethyl)-amino]-5,6,7,8-tetrahydro-naphthalen-1-ol; CAS-99755-59-6; Neupro (TN); N-0923; Rotigotine [USAN:INN:BAN]; (S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol; (S)-6-[Propyl[2-(thiophen-2-yl)ethyl]amino]-5,6,7,8-tetrahydronaphthalen-1-ol; SPM-936; SPM-937; PubChem16423; (-)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol; GTPL941; cc-129; Rotigotine (JAN/USAN/INN); (-)-N-0437; SCHEMBL1088585; ZINC4028; DTXSID5046772; HSDB 8254; (2S)-2-[propyl-[2-(2-thienyl)ethyl]amino]tetralin-5-ol; CHEBI:135351; HMS3885D17; EX-A1164; Tox21_112627; 2696AH; BDBM50123626; MFCD00870193; s4274; AKOS016340728; Tox21_112627_1; AC-3547; CCG-267650; CS-0376; DB05271; SB19528; SS-4572; 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl (2-(2-thienyl)ethyl)amino-(6S)-; NCGC00168748-02; HY-75502; AB0088886; SW220014-1; D05768; W-5179; 572R932; A846076; Q411985; J-502471; UNII-5QTR54Z0E1 component KFQYTPMOWPVWEJ-INIZCTEOSA-N; (6S)-6-(propyl-(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol; 1-Naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-, (6S)-
DMHEAB1 CP UCB
DMHEAB1 DT Small molecular drug
DMHEAB1 PC 59227
DMHEAB1 MW 315.5
DMHEAB1 FM C19H25NOS
DMHEAB1 IC InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1
DMHEAB1 CS CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O
DMHEAB1 IK KFQYTPMOWPVWEJ-INIZCTEOSA-N
DMHEAB1 IU (6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMHEAB1 CA CAS 99755-59-6
DMHEAB1 CB CHEBI:135351
DMHEAB1 DE Parkinson disease; Restless legs syndrome
DMRP8XB ID DMRP8XB
DMRP8XB DN Nomegestrol
DMRP8XB HS Phase 4
DMRP8XB SN Nomegestrol; Nomegestrol (USAN/INN); Nomegestrol [USAN:INN:BAN]; Nomegestrolum; Nomegestrolum [Latin]; SCHEMBL139763; Thermex; nomegestrol[inn]; Monaco; (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 10F89177CO; 17-Hydroxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione; 17-Hydroxy-6-methyl-19-norpregna-4,6-diene-3,20-dione; 58691-88-6; AC1L2AFS; AC1Q6OH0; CHEBI:135993; CHEMBL2105722; UNII-10F89177CO
DMRP8XB PC 68783
DMRP8XB MW 328.4
DMRP8XB FM C21H28O3
DMRP8XB IC KZUIYQJTUIACIG-YBZCJVABSA-N
DMRP8XB CS CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4C1=CC(=O)CC4
DMRP8XB IK 1S/C21H28O3/c1-12-10-18-16(15-5-4-14(23)11-17(12)15)6-8-20(3)19(18)7-9-21(20,24)13(2)22/h10-11,15-16,18-19,24H,4-9H2,1-3H3/t15-,16-,18-,19+,20+,21+/m1/s1
DMRP8XB IU (8S,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,13-dimethyl-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMRP8XB CA CAS 58691-88-6
DMRP8XB CB CHEBI:135993
DMRP8XB DE Hypercoagulability
DMVAOME ID DMVAOME
DMVAOME DN Oleandomycin
DMVAOME HS Phase 4
DMVAOME SN Oleandomycin A; Amimycin; Landomycin; Matromycin; Antibiotic PA 105; LMPK04000007; P8ZQ646136; PA 105; Prestwick3_000152; RZPAKFUAFGMUPI-QESOVKLGSA-N; Romicil; SCHEMBL3717; ZINC85432018; oleandomycin; 3922-90-5; AB00513809; AC1L2I65; BDBM234401; BPBio1_000314; BSPBio_000284; C01946; CHEBI:16869; CHEMBL606258; CS-0063452; E704; HY-116010; NCGC00179617-01; UNII-P8ZQ646136
DMVAOME PC 72493
DMVAOME MW 687.9
DMVAOME FM C35H61NO12
DMVAOME IC RZPAKFUAFGMUPI-QESOVKLGSA-N
DMVAOME CS CC1CC(C(C(O1)OC2C(CC3(CO3)C(=O)C(C(C(C(OC(=O)C(C(C2C)OC4CC(C(C(O4)C)O)OC)C)C)C)O)C)C)O)N(C)C
DMVAOME IK 1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1
DMVAOME IU (3R,5S,6S,7R,8S,9R,12R,13R,14S,15R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione
DMVAOME CA CAS 3922-90-5
DMVAOME CB CHEBI:16869
DMVAOME DE Acute upper respiratory infection
DMQIMTK ID DMQIMTK
DMQIMTK DN Ombitasvir
DMQIMTK HS Phase 4
DMQIMTK SN 2302768XJ8; ABT 267; ABT-267; ABT-267;ABT267;ABT 267; ABT267; CHEBI:85183; CHEMBL3127326; CS-5330; DB09296; Ombitasvir; Ombitasvir (USAN); Ombitasvir [USAN:INN]; Ombitasvir pound>>ABT-267; Ombitasvir(ABT-267); SB16895; SCHEMBL8542284; UNII-2302768XJ8; ZINC150601177; dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
DMQIMTK TC Antiviral Agent
DMQIMTK DT Small molecular drug
DMQIMTK PC 54767916
DMQIMTK MW 894.127
DMQIMTK FM C50H67N7O8
DMQIMTK IC InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
DMQIMTK CS CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
DMQIMTK IK PIDFDZJZLOTZTM-KHVQSSSXSA-N
DMQIMTK IU methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMQIMTK CA CAS 1258226-87-7
DMQIMTK CB CHEBI:85183
DMQIMTK DE Hepatitis C virus infection
DMPSKA5 ID DMPSKA5
DMPSKA5 DN Ortho-phosphate
DMPSKA5 HS Phase 4
DMPSKA5 SN Acide phosphorique; Acide phosphorique [French]; Acido fosforico; Acido fosforico [Italian]; Acidum phosphoricum; Fosforzuuroplossingen; Fosforzuuroplossingen [Dutch]; ORTHOPHOSPHORIC ACID; POLYPHOSPHORIC ACID; Phosphoric acid; Phosphoric acid 75%; Phosphoric acid, ortho-; Phosphorsaeure; Phosphorsaeureloesungen; Phosphorsaeureloesungen [German]; Superphosphoric acid; Wc-reiniger; White phosphoric acid; o-Phosphoric acid; ortho-phosphoric acid; 7664-38-2; Caswell No. 662; Evits; FEMA No. 2900; Sonac; UNII-E4GA8884NN
DMPSKA5 PC 1004
DMPSKA5 MW 97.995
DMPSKA5 FM H3O4P
DMPSKA5 IC NBIIXXVUZAFLBC-UHFFFAOYSA-N
DMPSKA5 CS OP(=O)(O)O
DMPSKA5 IK 1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
DMPSKA5 IU phosphoric acid
DMPSKA5 CA CAS 7664-38-2
DMPSKA5 CB CHEBI:26078.
DMPSKA5 DE Thyroid cancer
DMU1JVW ID DMU1JVW
DMU1JVW DN Otilonium
DMU1JVW HS Phase 4
DMU1JVW SN LS-187100; OTILONIUM; ZINC8214636; 105360-89-2; 6330179ARU; AB01566869_01; AC1L2HEM; AC1Q65RN; CHEBI:135780; CHEMBL1433361; CTK8G5037; DTXSID0048391; Diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium; Ethanaminium, N,N-diethyl-N-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-; N,N-Diethyl-N-methyl-2-(4-(2-(octyloxy)benzamido)benzoyloxy)ethanaminium; NCGC00163507-01; NCGC00163507-02; SCHEMBL20352274; UNII-6330179ARU
DMU1JVW PC 72093
DMU1JVW MW 483.7
DMU1JVW FM C29H43N2O4+
DMU1JVW IC NQHNLNLJPDMBFN-UHFFFAOYSA-O
DMU1JVW CS CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC
DMU1JVW IK 1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1
DMU1JVW IU diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium
DMU1JVW CA CAS 105360-89-2
DMU1JVW CB CHEBI:135780
DMU1JVW DE Irritable bowel syndrome
DMIGKA1 ID DMIGKA1
DMIGKA1 DN Ozagrel
DMIGKA1 HS Phase 4
DMIGKA1 SN Ozagrel (ophthalmic, eye disorders); Ozagrel (ophthalmic, eye disorders), Kissei/ Teika
DMIGKA1 CP Kissei Pharmaceutical Co Ltd
DMIGKA1 DT Small molecular drug
DMIGKA1 PC 5282440
DMIGKA1 MW 228.25
DMIGKA1 FM C13H12N2O2
DMIGKA1 IC InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+
DMIGKA1 CS C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
DMIGKA1 IK SHZKQBHERIJWAO-AATRIKPKSA-N
DMIGKA1 IU (E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid
DMIGKA1 CA CAS 82571-53-7
DMIGKA1 CB CHEBI:92359
DMIGKA1 DE Chronic obstructive pulmonary disease; Xerophthalmia
DMY2AEF ID DMY2AEF
DMY2AEF DN PAI-1
DMY2AEF HS Phase 4
DMY2AEF SN PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
DMY2AEF DT Small molecular drug
DMY2AEF PC 3246941
DMY2AEF MW 297.39
DMY2AEF FM C16H27NO4
DMY2AEF IC InChI=1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)/t14-/m0/s1
DMY2AEF CS CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O
DMY2AEF IK PHSRRHGYXQCRPU-AWEZNQCLSA-N
DMY2AEF IU 3-oxo-N-[(3S)-2-oxooxolan-3-yl]dodecanamide
DMY2AEF CA CAS 168982-69-2
DMY2AEF CB CHEBI:44534
DMIV8CT ID DMIV8CT
DMIV8CT DN Parecoxib
DMIV8CT HS Phase 4
DMIV8CT SN Parecoxib; SC-69124; Dynastat; Valus-P; Vorth-P; SC 69124; UNII-9TUW81Y3CE; 9TUW81Y3CE; Parecoxib [USAN:INN:BAN]; CHEBI:73038; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; Parocoxib; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Valdecoxib Impurity J; Parecoxib (
DMIV8CT DT Small molecular drug
DMIV8CT PC 119828
DMIV8CT MW 370.4
DMIV8CT FM C19H18N2O4S
DMIV8CT IC InChI=1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
DMIV8CT CS CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
DMIV8CT IK TZRHLKRLEZJVIJ-UHFFFAOYSA-N
DMIV8CT IU N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide
DMIV8CT CA CAS 198470-84-7
DMIV8CT CB CHEBI:73038
DMQY873 ID DMQY873
DMQY873 DN Pentifylline
DMQY873 HS Phase 4
DMQY873 SN Pentifilina [INN-Spanish]; Pentifyllin; Pentifylline; Pentifylline [INN:BAN:DCF]; Pentifyllinum [INN-Latin]; Cosadon; Cosaldon; Hexyltheobromine; MBM1C4K26S; SK 7 (Pharmaceutical); Theobromine, 1-hexyl-; 1-Hexyl-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1-Hexyl-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione; 1-Hexyl-3,7-dimethylxanthine; 1-Hexyltheobromine; 1-n-hexyltheobromine; 1028-33-7; 3,7-Dimethyl-1-hexyl-1H,3H-purin-2,6-dione; BRN 0270632; C13H20N4O2; EINECS 213-842-0; MFCD00041424; SK 7; UNII-MBM1C4K26S
DMQY873 PC 70569
DMQY873 MW 264.32
DMQY873 FM C13H20N4O2
DMQY873 IC MRWQRJMESRRJJB-UHFFFAOYSA-N
DMQY873 CS CCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMQY873 IK 1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3
DMQY873 IU 1-hexyl-3,7-dimethylpurine-2,6-dione
DMQY873 CA CAS 1028-33-7
DMQY873 CB CHEBI:135091
DMQY873 DE Cerebrovascular dementia
DM4OIMZ ID DM4OIMZ
DM4OIMZ DN Pinaverium
DM4OIMZ HS Phase 4
DM4OIMZ SN Pinaverium; LS-176056; SCHEMBL312166; U2368VVE7O; 59995-65-2; AC1L24AP; BDBM50101975; C26H41BrNO4; CHEBI:135811; CHEMBL1909324; DB09090; Morpholinium, 4-((2-bromo-4,5-dimethoxyphenyl)methyl)-4-(2-(2-(6,6-dimethylbicyclo(3.1.1)hept-2-yl)ethoxy)ethyl)-; NCGC00181763-01; UNII-U2368VVE7O
DM4OIMZ PC 40704
DM4OIMZ MW 511.5
DM4OIMZ FM C26H41BrNO4+
DM4OIMZ IC DDHUTBKXLWCZCO-UHFFFAOYSA-N
DM4OIMZ CS CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C
DM4OIMZ IK 1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1
DM4OIMZ IU 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium
DM4OIMZ CA CAS 59995-65-2
DM4OIMZ CB CHEBI:135811
DM4OIMZ DE Irritable bowel syndrome
DMWRYUH ID DMWRYUH
DMWRYUH DN Prasterone sulfate
DMWRYUH HS Phase 4
DMWRYUH SN Prasterone sulfate; Prasterone sulphate; 17-Ketoandrost-5-en-3beta-yl sulfate; 3-O-Sulfodehydroepiandrosterone; 3beta-Hydroxyandrost-5-en-17-one 3-sulfate; 651-48-9; DEHYDROEPIANDROSTERONE SULFATE; DHEA sulfate; DHEA sulphate; DHEA-S; Dehydroandrosterone sulfate; Dehydroepiandrosterone 3-sulfate; Dehydroepiandrosterone monosulfate; Dehydroepiandrosterone sulphate; Dehydroisoandrosterone sulfate; Dehydroisoandrosterone-3-sulfate; Androst-5-en-17-on-3beta-yl sulfuric acid; CCRIS 6746; DHEAS; UNII-57B09Q7FJR
DMWRYUH PC 12594
DMWRYUH MW 368.5
DMWRYUH FM C19H28O5S
DMWRYUH IC CZWCKYRVOZZJNM-USOAJAOKSA-N
DMWRYUH CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)O)C
DMWRYUH IK 1S/C19H28O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h3,13-16H,4-11H2,1-2H3,(H,21,22,23)/t13-,14-,15-,16-,18-,19-/m0/s1
DMWRYUH IU [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMWRYUH CA CAS 651-48-9
DMWRYUH CB CHEBI:16814
DMWRYUH DE Adrenocortical deficiency
DM6VFO1 ID DM6VFO1
DM6VFO1 DN Pregnenolone
DM6VFO1 HS Phase 4
DM6VFO1 SN Pregnenolone (schizophrenia); Neurosteroid (schizophrenia), Neuroscience; Pregnenolone (schizophrenia), Neuroscience
DM6VFO1 CP Duke University
DM6VFO1 DT Small molecular drug
DM6VFO1 PC 8955
DM6VFO1 MW 316.5
DM6VFO1 FM C21H32O2
DM6VFO1 IC InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1
DM6VFO1 CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DM6VFO1 IK ORNBQBCIOKFOEO-QGVNFLHTSA-N
DM6VFO1 IU 1-[(3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DM6VFO1 CA CAS 145-13-1
DM6VFO1 CB CHEBI:16581
DM6VFO1 DE Schizophrenia
DM8PTSY ID DM8PTSY
DM8PTSY DN Prenylamine
DM8PTSY HS Phase 4
DM8PTSY SN Prenilamina; Prenilamina [INN-Spanish]; Prenylamine (vasodilator); Prenylamine [USAN:INN:BAN]; Prenylaminum; Prenylaminum [INN-Latin]; Bismethin; Carditin; Corontin; Corpax; DL-Prenylamine; Difril; Elecor; Falliocor; Hostaginan; PRENYLAMINE; SAN 13-194; Sandoz 13-194; Segontin; Synadrin; Valecor; 1-Phenyl-2-(1',1'-diphenylpropyl-3'-amino)propane; 390-64-7; B-436; BRN 2060323; CHEMBL24072; EINECS 206-869-4; N-(1-Methyl-2-phenylethyl)-gamma-phenylbenzenepropanamine; N-(3,3-Diphenylpropyl)-alpha-methylphenethylamine
DM8PTSY PC 9801
DM8PTSY MW 329.5
DM8PTSY FM C24H27N
DM8PTSY IC IFFPICMESYHZPQ-UHFFFAOYSA-N
DM8PTSY CS CC(CC1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DM8PTSY IK 1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3
DM8PTSY IU 3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-amine
DM8PTSY CA CAS 390-64-7
DM8PTSY CB CHEBI:8397
DM8PTSY DE Angina pectoris
DM37FKA ID DM37FKA
DM37FKA DN Primovist
DM37FKA HS Phase 4
DM37FKA SN Eovist; Primovist; gadoxate disodium; AC1L9OPS; gadolinium ethoxybenzyl-DTPA; MOLI000482; 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid; gadolinium(3+)
DM37FKA PC 450096
DM37FKA MW 684.8
DM37FKA FM C23H33GdN3O11+3
DM37FKA IC InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3
DM37FKA CS CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O.[Gd+3]
DM37FKA IK PCZHWPSNPWAQNF-UHFFFAOYSA-N
DM37FKA IU 2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid;gadolinium(3+)
DM37FKA DE Lung cancer
DMXL43T ID DMXL43T
DMXL43T DN Prulifloxacin
DMXL43T HS Phase 4
DMXL43T SN Prulifloxacin; Prulifloxacin [INN]; Pruvel; Q-101929; Quisnon; NM 441; NM-441; 123447-62-1; 1H,4H-(1,3)Thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-; 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid; AK144730; CCRIS 7686; DSSTox_CID_26480; DSSTox_GSID_46480; DSSTox_RID_81651; NCGC00164615-01; NM441; Sword
DMXL43T PC 65947
DMXL43T MW 461.5
DMXL43T FM C21H20FN3O6S
DMXL43T IC PWNMXPDKBYZCOO-UHFFFAOYSA-N
DMXL43T CS CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C
DMXL43T IK 1S/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
DMXL43T IU 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
DMXL43T CA CAS 123447-62-1
DMXL43T CB CHEBI:32071
DMXL43T DE Chronic obstructive pulmonary disease
DMF8CJ9 ID DMF8CJ9
DMF8CJ9 DN Pyridine
DMF8CJ9 HS Phase 4
DMF8CJ9 SN Azabenzene; 110-86-1; Azine; Pyridin; Pirydyna; Piridina; Pyridin [German]; Pirydyna [Polish]; Piridina [Italian]; RCRA waste number U196; NCI-C55301; Caswell No. 717; CCRIS 2926; HSDB 118; pyridine-ring; CHEBI:16227; FEMA Number 2966; CP 32; UNII-NH9L3PP67S; EINECS 203-809-9; UN1282; NSC 406123; FEMA No. 2966; RCRA waste no. U196; EPA Pesticide Chemical Code 069202; NH9L3PP67S; AI3-01240; pyridine fraction; JUJWROOIHBZHMG-UHFFFAOYSA-N; MFCD00011732; Pentadeuteropyridine; Pyridine [UN1282] [Flammable liquid]; 7291-22-7
DMF8CJ9 DT Small molecular drug
DMF8CJ9 PC 1049
DMF8CJ9 MW 79.1
DMF8CJ9 FM C5H5N
DMF8CJ9 IC InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H
DMF8CJ9 CS C1=CC=NC=C1
DMF8CJ9 IK JUJWROOIHBZHMG-UHFFFAOYSA-N
DMF8CJ9 IU pyridine
DMF8CJ9 CA CAS 110-86-1
DMF8CJ9 CB CHEBI:16227
DMBPN7T ID DMBPN7T
DMBPN7T DN Rupatadine
DMBPN7T HS Phase 4
DMBPN7T SN Rupatadine trihydrochloride; UNII-G61C8NZY2T; G61C8NZY2T; 156611-76-6; Rupatadine HCl; Rupatadine hydrochloride; UR 12592; AC1L320L; DTXSID90166109; BQFOTHHRVVHLEW-UHFFFAOYSA-N; 8-Chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine trihydrochloride; 5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridinyl)methyl)-4-piperidinylidene)-, trihydrochloride
DMBPN7T DT Small molecular drug
DMBPN7T PC 133017
DMBPN7T MW 416
DMBPN7T FM C26H26ClN3
DMBPN7T IC InChI=1S/C26H26ClN3/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3
DMBPN7T CS CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2
DMBPN7T IK WUZYKBABMWJHDL-UHFFFAOYSA-N
DMBPN7T IU 13-chloro-2-[1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene]-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene
DMBPN7T CA CAS 158876-82-5
DMBPN7T CB CHEBI:135673
DMXBYQR ID DMXBYQR
DMXBYQR DN Silymarin
DMXBYQR HS Phase 4
DMXBYQR SN Milk thistle extract; Sabal serrulata extract; 84604-20-6; AN-35849; FT-0656490; A835184; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one
DMXBYQR DT Small molecular drug
DMXBYQR PC 5213
DMXBYQR MW 482.4
DMXBYQR FM C25H22O10
DMXBYQR IC InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3
DMXBYQR CS COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
DMXBYQR IK SEBFKMXJBCUCAI-UHFFFAOYSA-N
DMXBYQR IU 3,5,7-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
DMXBYQR CA CAS 65666-07-1
DMXBYQR CB CHEBI:125451
DMOSJD0 ID DMOSJD0
DMOSJD0 DN Sivelestat sodium hydrate
DMOSJD0 HS Phase 4
DMOSJD0 SN sivelestat sodium hydrate; Sivelestat sodium tetrahydrate; 201677-61-4; Elaspol; Sodium sivelestat; EI546 sodium; UNII-737RR8Y409; Sivelestat (sodium tetrahydrate); LY544349 sodium; Sivelestat sodium [USAN]; Sivelestat sodium (USAN); 737RR8Y409; DSSTox_CID_26727; DSSTox_RID_81857; DSSTox_GSID_46727; sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; LY544349 Sodium Hydrate; Elaspol (TN); CAS-201677-61-4; NCGC00167577-01; AC1L4KMF; Sivelestat sodium hydrate (JAN); Sodium 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate tetrahydrate; Sodium ((2-(((4-((2,2-dimethylpropanoyl)oxy)phenyl)sulfonyl)amino)benzoyl)amino)acetate tetrahydrate; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-, monosodium salt, tetrahydrate
DMOSJD0 CP ONO Pharmaceuticals
DMOSJD0 DT Small molecular drug
DMOSJD0 PC 23663985
DMOSJD0 MW 528.5
DMOSJD0 FM C20H29N2NaO11S
DMOSJD0 IC InChI=1S/C20H22N2O7S.Na.4H2O/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24;;;;;/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24);;4*1H2/q;+1;;;;/p-1
DMOSJD0 CS CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)[O-].O.O.O.O.[Na+]
DMOSJD0 IK PLHREJBSQUSUCW-UHFFFAOYSA-M
DMOSJD0 IU sodium;2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate;tetrahydrate
DMOSJD0 CA CAS 201677-61-4
DMOSJD0 CB CHEBI:32133
DMOSJD0 DE Community-acquired pneumonia; Acute lung injury
DMTV7XH ID DMTV7XH
DMTV7XH DN SPN-812
DMTV7XH HS Phase 4
DMTV7XH SN Viloxazine hydrochloride; 35604-67-2; 2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride; Emovit; 2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride; ICI 58,834; Viloxazine hydrochloride [USAN]; 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride; 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, hydrochloride; Vicilan; Vivalan; 2-[(2-ethoxy phenoxy)methyl]morpholine hydrochloride; Morpholine, 2-((2-ethoxyphenoxy)methyl)-, hydrochloride; Viloxazine hydrochloride (USAN); Viloxazine HCl; CCRIS 1915; Viloxacina clorhidrato; ICI-58834; Viloxacina clorhidrato [Spanish]; EINECS 252-638-6; Prestwick_734; 2-((o-Ethoxyphenoxy)methyl)morpholine hydrochloride; Vivalan (TN); 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride; 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine hydrochloride; rac Viloxazine Hydrochloride; DSSTox_CID_31511; DSSTox_RID_97396; DSSTox_GSID_57722; SCHEMBL300741; CHEMBL2106483; DTXSID8057722; Tox21_113955; 1478AE; AKOS015847050; CCG-220828; NCGC00262964-01; CAS-35604-67-2; A6217; FT-0675815; FT-0675816; FT-0675817; FT-0675818; FT-0675819; D02572; Z-1958; 2-(o-ethoxyphenoxymethyl)morpholine hydrochloride; 604E672; SR-01000872636; SR-01000872636-1; W-110863; 2-(2-Ethoxy-phenoxymethyl)-morpholine; hydrochloride; 2-[(2-Ethoxyphenoxy)-methyl]morpholine hydrochloride; Q27285797; 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine hydrochloride
DMTV7XH CP Supernus Pharmaceuticals
DMTV7XH DT Small molecular drug
DMTV7XH PC 71424
DMTV7XH MW 273.75
DMTV7XH FM C13H20ClNO3
DMTV7XH IC InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
DMTV7XH CS CCOC1=CC=CC=C1OCC2CNCCO2.Cl
DMTV7XH IK HJOCKFVCMLCPTP-UHFFFAOYSA-N
DMTV7XH IU 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride
DMTV7XH CA CAS 35604-67-2
DMTV7XH DE Attention deficit hyperactivity disorder
DM4TX7J ID DM4TX7J
DM4TX7J DN Talipexole
DM4TX7J HS Phase 4
DM4TX7J SN Talipexole; 101626-70-4; Talipexole [INN]; Talipexolum [Latin]; Talipexol [Spanish]; UNII-7AM2J46Z1Y; Domin; 7AM2J46Z1Y; CHEMBL279085; Talipexole (INN); NCGC00163160-01; DSSTox_CID_26321; DSSTox_RID_81537; DSSTox_GSID_46321; Talipexolum; Talipexol; 6-Allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo(4,5-d)azepine; 6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin-2-amine; 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine; 4H-Thiazolo[4,5-d]azepin-2-amine,5,6,7,8-tetrahydro-6-(2-propen-1-yl)-; BHT920
DM4TX7J DT Small molecular drug
DM4TX7J PC 5374
DM4TX7J MW 209.31
DM4TX7J FM C10H15N3S
DM4TX7J IC InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)
DM4TX7J CS C=CCN1CCC2=C(CC1)SC(=N2)N
DM4TX7J IK DHSSDEDRBUKTQY-UHFFFAOYSA-N
DM4TX7J IU 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine
DM4TX7J CA CAS 101626-70-4
DM4TX7J CB CHEBI:93327
DM62IPN ID DM62IPN
DM62IPN DN Tenofovir disoproxil
DM62IPN HS Phase 4
DM62IPN SN Tenofovir (Disoproxil); Tenofovir disoproxil; 201341-05-1; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; Bis(POC)PMPA; PMPA prodrug; CHEBI:63717; F4YU4LON7I; UNII-F4YU4LON7I; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate; tenofovir bis(isopropyloxycarbonyloxymethyl) ester
DM62IPN PC 5481350
DM62IPN MW 519.4
DM62IPN FM C19H30N5O10P
DM62IPN IC JFVZFKDSXNQEJW-CQSZACIVSA-N
DM62IPN CS CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
DM62IPN IK 1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DM62IPN IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
DM62IPN CA CAS 201341-05-1
DM62IPN CB CHEBI:63717
DM62IPN DE Human immunodeficiency virus infection
DMC40UY ID DMC40UY
DMC40UY DN Tenofovir disoproxil
DMC40UY HS Phase 4
DMC40UY SN Tenofovir disoproxil; PMPA prodrug; Bis(POC)PMPA; Tenofovir (Disoproxil); UNII-F4YU4LON7I; 9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine; F4YU4LON7I; CHEBI:63717; tenofovir bis(isopropyloxycarbonyloxymethyl) ester; Tenofovir Disoproxil Fumarate; [[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate
DMC40UY PC 5481350
DMC40UY MW 519.4
DMC40UY FM C19H30N5O10P
DMC40UY IC InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1
DMC40UY CS CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OCOC(=O)OC(C)C
DMC40UY IK JFVZFKDSXNQEJW-CQSZACIVSA-N
DMC40UY IU [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
DMC40UY CA CAS 201341-05-1
DMC40UY CB CHEBI:63717
DMC40UY DE Chronic hepatitis B infection
DM2M47Y ID DM2M47Y
DM2M47Y DN TKM-ApoB
DM2M47Y HS Phase 4
DM2M47Y CP Tekmira Pharmaceuticals
DM2M47Y DT siRNA drug
DM2M47Y DE Hypercholesterolaemia
DM7NSI0 ID DM7NSI0
DM7NSI0 DN Urethane
DM7NSI0 HS Phase 4
DM7NSI0 SN Uretan; Uretan etylowy; Uretano [DCIT]; Urethan; Urethanum; Urethanum [INN-Latin]; Aethylcarbamat; Aethylcarbamat [German]; Aethylurethan; Aethylurethan [German]; Carbamic acid ethyl ester; Carbamic acid, ethyl ester; Carbamidsaeure-aethylester; ETHYL CARBAMATE; Estane 5703; Ethyl urethan; Ethyl urethane; Ethylcarbamate; Ethylester kyseliny karbaminove; Ethylurethan; Ethylurethane; Leucethane; Leucothane; O-Ethyl urethane; O-Ethylurethane; Pracarbamin; Pracarbamine; U-Compound; ethyl aminoformate; urethane; 51-79-6; NSC 746
DM7NSI0 PC 5641
DM7NSI0 MW 89.09
DM7NSI0 FM C3H7NO2
DM7NSI0 IC JOYRKODLDBILNP-UHFFFAOYSA-N
DM7NSI0 CS CCOC(=O)N
DM7NSI0 IK 1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
DM7NSI0 IU ethyl carbamate
DM7NSI0 CA CAS 51-79-6
DM7NSI0 CB CHEBI:17967
DM7NSI0 DE Lung cancer
DMCOJPS ID DMCOJPS
DMCOJPS DN Vonoprazan
DMCOJPS HS Phase 4
DMCOJPS SN Vonoprazan; Vonoprazan [INN]; TAK-438 (free base); TAK-438 free base; SCHEMBL194487; 1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonyl-pyrrol-3-yl]-~{N}-methyl-methanamine; 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine; 1R5L3J156G; 881681-00-1; BCP13240; CHEBI:136048; CHEMBL2079130; DTXSID20236869; KS-00000TU1; UNII-1R5L3J156G
DMCOJPS PC 15981397
DMCOJPS MW 345.4
DMCOJPS FM C17H16FN3O2S
DMCOJPS IC BFDBKMOZYNOTPK-UHFFFAOYSA-N
DMCOJPS CS CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3
DMCOJPS IK 1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
DMCOJPS IU 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
DMCOJPS CA CAS 881681-00-1
DMCOJPS CB CHEBI:136048
DMCOJPS DE Gastro-oesophageal reflux disease
DMKV32D ID DMKV32D
DMKV32D DN Xylometazoline
DMKV32D HS Phase 4
DMKV32D SN Xylometazoline (nasal mucoadhesive/MucoAd, congestion); Decongestant (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences; Xylometazoline (nasal mucoadhesive/MucoAd, congestion), Strategic BioSciences
DMKV32D CP Fortune Apex Development Ltd
DMKV32D DT Small molecular drug
DMKV32D PC 5709
DMKV32D MW 244.37
DMKV32D FM C16H24N2
DMKV32D IC InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
DMKV32D CS CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C
DMKV32D IK HUCJFAOMUPXHDK-UHFFFAOYSA-N
DMKV32D IU 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
DMKV32D CA CAS 526-36-3
DMKV32D CB CHEBI:10082
DMKV32D DE Allergic rhinitis
DM9RJH7 ID DM9RJH7
DM9RJH7 DN Zaltoprofen
DM9RJH7 HS Phase 4
DM9RJH7 SN Zaltoprofen (unspecified); Zaltoprofene; Zaltoprofeno; Zaltoprofenum; CN 100; CN-100; Soleton; zaltoprofen; (+-)-2-(10,11-Dihydro-10-oxodibenzo(b,f)thiepin-2-yl)propionic acid; 10,11-Dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid; 2-(10,11-Dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic Acid; 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid; 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid; 74711-43-6; 89482-00-8; AK-77321; C17H14O3S; EINECS 277-973-5; NCGC00183878-01; Peon
DM9RJH7 PC 5720
DM9RJH7 MW 298.4
DM9RJH7 FM C17H14O3S
DM9RJH7 IC MUXFZBHBYYYLTH-UHFFFAOYSA-N
DM9RJH7 CS CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O
DM9RJH7 IK 1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
DM9RJH7 IU 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid
DM9RJH7 CA CAS 74711-43-6
DM9RJH7 CB CHEBI:32306
DM9RJH7 DE Anaesthesia
DMXIRA0 ID DMXIRA0
DMXIRA0 DN RLX030
DMXIRA0 HS Approval submitted
DMXIRA0 SN Serelaxin
DMXIRA0 CP Novartis
DMXIRA0 DT Small molecular drug
DMXIRA0 PC 71300755
DMXIRA0 MW 5963
DMXIRA0 FM C256H408N74O74S8
DMXIRA0 IC InChI=1S/C256H408N74O74S8/c1-32-128(20)198-246(396)286-135(27)207(357)326-199(129(21)33-2)248(398)321-180(210(360)279-106-189(343)289-161(79-88-405-30)221(371)315-177(111-334)239(389)329-202(137(29)337)250(400)312-171(232(382)317-178(112-335)251(401)402)98-141-103-277-148-57-41-39-55-145(141)148)114-408-412-118-184(252(403)404)322-230(380)168(95-138-52-36-35-37-53-138)308-215(365)154(63-50-86-274-255(267)268)291-203(353)132(24)283-226(376)164(91-121(6)7)307-238(388)176(110-333)314-216(366)155(64-51-87-275-256(269)270)293-213(363)151(59-43-46-82-258)301-249(399)201(136(28)336)330-242(392)181-115-409-411-117-183(319-217(367)150(58-42-45-81-257)294-233(383)173(101-186(262)340)303-206(356)133(25)284-225(375)163(90-120(4)5)302-205(355)134(26)285-236(386)174(108-331)316-229(379)169(96-139-65-67-143(338)68-66-139)309-227(377)165(92-122(8)9)305-218(368)156-70-75-187(341)287-156)241(391)320-182(240(390)311-172(99-142-104-271-119-281-142)235(385)323-195(125(14)15)243(393)280-107-190(344)290-181)116-410-407-113-179(209(359)278-105-188(342)288-149(61-48-84-272-253(263)264)212(362)295-159(72-77-192(347)348)220(370)306-167(94-124(12)13)234(384)325-196(126(16)17)244(394)299-153(62-49-85-273-254(265)266)211(361)282-131(23)204(354)292-157(224(374)327-198)69-74-185(261)339)318-228(378)166(93-123(10)11)304-214(364)152(60-44-47-83-259)300-247(397)200(130(22)34-3)328-245(395)197(127(18)19)324-223(373)160(73-78-193(349)350)297-219(369)158(71-76-191(345)346)296-222(372)162(80-89-406-31)298-231(381)170(97-140-102-276-147-56-40-38-54-144(140)147)310-237(387)175(109-332)313-208(358)146(260)100-194(351)352/h35-41,52-57,65-68,102-104,119-137,146,149-184,195-202,276-277,331-338H,32-34,42-51,58-64,69-101,105-118,257-260H2,1-31H3,(H2,261,339)(H2,262,340)(H,271,281)(H,278,359)(H,279,360)(H,280,393)(H,282,361)(H,283,376)(H,284,375)(H,285,386)(H,286,396)(H,287,341)(H,288,342)(H,289,343)(H,290,344)(H,291,353)(H,292,354)(H,293,363)(H,294,383)(H,295,362)(H,296,372)(H,297,369)(H,298,381)(H,299,394)(H,300,397)(H,301,399)(H,302,355)(H,303,356)(H,304,364)(H,305,368)(H,306,370)(H,307,388)(H,308,365)(H,309,377)(H,310,387)(H,311,390)(H,312,400)(H,313,358)(H,314,366)(H,315,371)(H,316,379)(H,317,382)(H,318,378)(H,319,367)(H,320,391)(H,321,398)(H,322,380)(H,323,385)(H,324,373)(H,325,384)(H,326,357)(H,327,374)(H,328,395)(H,329,389)(H,330,392)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,401,402)(H,403,404)(H4,263,264,272)(H4,265,266,273)(H4,267,268,274)(H4,269,270,275)/t128-,129-,130-,131-,132-,133-,134-,135-,136+,137+,146-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,195-,196-,197-,198-,199-,200-,201-,202-/m0/s1
DMXIRA0 CS CC[C@H](C)[C@H]1C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C)[C@@H](C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]7CCC(=O)N7)[C@@H](C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC9=CNC1=CC=CC=C19)C(=O)N[C@@H](CO)C(=O)O
DMXIRA0 IK DTLOVISJEFBXLX-REAFJZEQSA-N
DMXIRA0 IU (1R,6R,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,50S,53S,56S,59S,62S,65S,68S,71S,74R,80S,83S,88R)-6-[[(2S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-88-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-68-(4-aminobutyl)-30-(3-amino-3-oxopropyl)-50-benzyl-33,39-bis[(2S)-butan-2-yl]-12,24,53,65-tetrakis(3-carbamimidamidopropyl)-15-(2-carboxyethyl)-42-[[2-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-2-oxoethyl]carbamoyl]-71-[(1R)-1-hydroxyethyl]-62-(hydroxymethyl)-83-(1H-imidazol-5-ylmethyl)-27,36,56-trimethyl-18,59-bis(2-methylpropyl)-7,10,13,16,19,22,25,28,31,34,37,40,49,52,55,58,61,64,67,70,73,76,79,82,85,87-hexacosaoxo-21,80-di(propan-2-yl)-3,4,44,45,90,91-hexathia-8,11,14,17,20,23,26,29,32,35,38,41,48,51,54,57,60,63,66,69,72,75,78,81,84,86-hexacosazabicyclo[72.11.7]dononacontane-47-carboxylic acid
DMXIRA0 CA CAS 99489-94-8
DMXIRA0 DE Acute heart failure
DMOML9Q ID DMOML9Q
DMOML9Q DN Pancrecarb
DMOML9Q HS NDA filed
DMOML9Q SN Pancrelipase (Digestive Care)
DMOML9Q CP Digestive Care Inc
DMOML9Q SQ Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL >Chymotrypsin BGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFCGGSLISEDWVVTAAHCGVRTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNNDITLLKLATPARFSQTVSAVCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPLLSNAECKKSWGRRITDVMICAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCSTSSPGVYARVTKLIPWVQKILAAN >pancreatic triacylglycerol lipaseMLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTNENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCICVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGRRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGFPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVSVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWYNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC
DMOML9Q DE Pancreatic malfunction
DMF2O4T ID DMF2O4T
DMF2O4T DN (S)-FLURBIPROFEN
DMF2O4T HS Preregistration
DMF2O4T SN 51543-39-6; esflurbiprofen; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; UNII-J5ZZK9P7MX; (S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (S)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid; (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid; J5ZZK9P7MX; CHEMBL435298; CHEBI:42446; SYTBZMRGLBWNTM-JTQLQIEISA-N; (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid; BTS-24332; (S)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic ac
DMF2O4T CP Taisho Pharmaceutical; TOKUHON
DMF2O4T DT Small molecular drug
DMF2O4T PC 72099
DMF2O4T MW 244.26
DMF2O4T FM C15H13FO2
DMF2O4T IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m0/s1
DMF2O4T CS C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMF2O4T IK SYTBZMRGLBWNTM-JTQLQIEISA-N
DMF2O4T IU (2S)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMF2O4T CA CAS 51543-39-6
DMF2O4T CB CHEBI:42446
DMF2O4T DE Myalgia; Scapulohumeral periarthritis; Osteoarthritis
DMBRFUQ ID DMBRFUQ
DMBRFUQ DN B-cell lymphoma vaccine
DMBRFUQ HS Preregistration
DMBRFUQ SN BiovaxID (TN)
DMBRFUQ CP BioVest International
DMBRFUQ DT Vaccine
DMBRFUQ DE Follicular lymphoma
DMP5O1U ID DMP5O1U
DMP5O1U DN GSK2696273
DMP5O1U HS Preregistration
DMP5O1U CP Glaxosmithkline; molmed
DMP5O1U DE Chronic pain; Immunodeficiency
DMXSDJU ID DMXSDJU
DMXSDJU DN MPL-containing Pollinex allergy desensitization vaccine
DMXSDJU HS Preregistration
DMXSDJU SN Pollinex Quattro (ragweed allergy vaccine); Quattro MPL (ragweed allergy vaccine); MPL-containing Pollinex allergy desensitization vaccine (ragweed); Ragweed SC vaccine, Allergy Therapeutics/AllerPharma; MPL-containing Pollinex allergy desensitization vaccine (ragweed), AllergyTherapeutics/AllerPharma
DMXSDJU CP Allergy therapeutics
DMXSDJU DT Vaccine
DMXSDJU DE Allergy
DMLRKJX ID DMLRKJX
DMLRKJX DN Neugranin
DMLRKJX HS Preregistration
DMLRKJX SN Albugranin; CG-10639; Granulocyte colony stimulating factor (long-acting), CoGenesys; Granulocyte colony stimulating factor (long-acting), Teva Pharmaceutical; Long-acting G-CSF, HGS; Long-acting G-CSF, Teva Pharmaceutical; G-SCF (long-acting), CoGenesys
DMLRKJX CP Aventis Behring LLC
DMLRKJX DE Neutropenia
DMUY09W ID DMUY09W
DMUY09W DN SK-NBP601
DMUY09W HS Preregistration
DMUY09W SN NBP-601
DMUY09W CP SK Chemicals Co Ltd
DMUY09W DE Hemophilia
DM26I8H ID DM26I8H
DM26I8H DN TK-DLI
DM26I8H HS Preregistration
DM26I8H SN TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara
DM26I8H CP Molmed
DM26I8H DE Graft-versus-host disease
DMYA6TR ID DMYA6TR
DMYA6TR DN Human coagulation factor X
DMYA6TR HS BLA submitted
DMYA6TR CP Bio products laboratory
DMYA6TR DE Renal cell carcinoma
DMNCY1I ID DMNCY1I
DMNCY1I DN (-)-Phenserine
DMNCY1I HS Phase 3
DMNCY1I SN (-)-Phenserine; CHEMBL54727; SCHEMBL5464366; BDBM10622; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate
DMNCY1I DT Small molecular drug
DMNCY1I PC 192706
DMNCY1I MW 337.4
DMNCY1I FM C20H23N3O2
DMNCY1I IC InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1
DMNCY1I CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
DMNCY1I IK PBHFNBQPZCRWQP-QUCCMNQESA-N
DMNCY1I IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate
DMNCY1I CA CAS 101246-66-6
DMNCY1I DE Alzheimer disease
DMLRHM5 ID DMLRHM5
DMLRHM5 DN [3H](R)-(-)-baclofen
DMLRHM5 HS Phase 3
DMLRHM5 SN AC1OCG0F; ZB000014
DMLRHM5 DT Small molecular drug
DMLRHM5 PC 44602
DMLRHM5 MW 213.66
DMLRHM5 FM C10H12ClNO2
DMLRHM5 IC InChI=1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1
DMLRHM5 CS C1=CC(=CC=C1[C@@H](CC(=O)O)CN)Cl
DMLRHM5 IK KPYSYYIEGFHWSV-QMMMGPOBSA-N
DMLRHM5 IU (3R)-4-amino-3-(4-chlorophenyl)butanoic acid
DMLRHM5 CA CAS 69308-37-8
DMLRHM5 DE Multiple sclerosis
DM3YEV0 ID DM3YEV0
DM3YEV0 DN 131I-labelled aCD45
DM3YEV0 HS Phase 3
DM3YEV0 CP Actinium Pharmaceuticals
DM3YEV0 DT Radiopharmaceutical therapy agent
DM3YEV0 DE Acute myeloid leukaemia
DMTZ1A5 ID DMTZ1A5
DMTZ1A5 DN 13-cis-retinoic acid
DMTZ1A5 HS Phase 3
DMTZ1A5 SN CRA, UCSD
DMTZ1A5 CP University of California San Diego
DMTZ1A5 DE Glioma; Infertility; Azoospermia
DMP5L8S ID DMP5L8S
DMP5L8S DN 177Lu-DOTA-octreotate
DMP5L8S HS Phase 3
DMP5L8S SN Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate
DMP5L8S CP Advanced accelerator applications
DMP5L8S DE Melanoma; Neuroendocrine cancer
DMQ0IZ6 ID DMQ0IZ6
DMQ0IZ6 DN 177Lu-labelled PSMA-617
DMQ0IZ6 HS Phase 3
DMQ0IZ6 CP Novartis/Endocyte
DMQ0IZ6 DT Radiopharmaceutical therapy agent
DMQ0IZ6 DE Prostate cancer
DMMZS2T ID DMMZS2T
DMMZS2T DN 177-Lu-oxodotreotide
DMMZS2T HS Phase 3
DMMZS2T CP Millburn
DMMZS2T DT Small molecular drug
DMMZS2T DE Neuroendocrine cancer
DMX178V ID DMX178V
DMX178V DN 177-Lu-PSMA-617
DMX178V HS Phase 3
DMX178V CP Advanced Accelerator Applications
DMX178V DT Small molecular drug
DMX178V DE Prostate cancer
DME2A8X ID DME2A8X
DME2A8X DN 5-methoxypsoralen
DME2A8X HS Phase 3
DME2A8X SN 5-MOP
DME2A8X CP Oclassen Pharmaceuticals Inc
DME2A8X DT Small molecular drug
DME2A8X PC 2355
DME2A8X MW 216.19
DME2A8X FM C12H8O4
DME2A8X IC InChI=1S/C12H8O4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6H,1H3
DME2A8X CS COC1=C2C=CC(=O)OC2=CC3=C1C=CO3
DME2A8X IK BGEBZHIAGXMEMV-UHFFFAOYSA-N
DME2A8X IU 4-methoxyfuro[3,2-g]chromen-7-one
DME2A8X CA CAS 484-20-8
DME2A8X CB CHEBI:18293
DME2A8X DE Psoriasis vulgaris
DM4OHMP ID DM4OHMP
DM4OHMP DN A-3309
DM4OHMP HS Phase 3
DM4OHMP SN Elobixibat; ALBI-3309; Ileal bile acid transporter inhibitors, AstraZeneca; ASBT inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitor (oral, chronic idiopathic constipation), Albireo; Apical sodium-dependent bile acid transporter inhibitor (oral, chronic idiopathic constipation), Albireo; IBAT inhibitors (1,5-benzothiazepine derivatives), AstraZeneca
DM4OHMP CP AstraZeneca plc
DM4OHMP DE Lipid metabolism disorder
DMJNSLU ID DMJNSLU
DMJNSLU DN AAV2-hRPE65v2
DMJNSLU HS Phase 3
DMJNSLU SN RPE65 AAV gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second University of Naples; RPE65 adeno-associated viral vector gene therapy (Leber's congenital amaurosis), Children's Hospital of Philadelphia/Second Univerity of Naples
DMJNSLU CP Childrens Hospital of Philadelphia
DMJNSLU DE Ocular disease
DMPDQ8T ID DMPDQ8T
DMPDQ8T DN AB-103
DMPDQ8T HS Phase 3
DMPDQ8T SN Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem
DMPDQ8T CP Atoxbio; fast-track drugs & biologics
DMPDQ8T DT Small molecular drug
DMPDQ8T PC 16111
DMPDQ8T MW 281.25
DMPDQ8T FM C12H16N3O3P
DMPDQ8T IC InChI=1S/C12H16N3O3P/c16-12(18-10-11-4-2-1-3-5-11)13-19(17,14-6-7-14)15-8-9-15/h1-5H,6-10H2,(H,13,16,17)
DMPDQ8T CS C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3
DMPDQ8T IK VFIUCBTYGKMLCM-UHFFFAOYSA-N
DMPDQ8T IU benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate
DMPDQ8T CA CAS 1980-45-6
DMPDQ8T DE Necrotizing soft tissue infection
DMUES7Y ID DMUES7Y
DMUES7Y DN AB154
DMUES7Y HS Phase 3
DMUES7Y SN Domvanalimab
DMUES7Y CP Arcus Biosciences; Gilead Sciences
DMUES7Y DT Antibody
DMUES7Y DE Solid tumour/cancer; Non-small cell lung cancer
DMMWO7V ID DMMWO7V
DMMWO7V DN ABBV-951
DMMWO7V HS Phase 3
DMMWO7V SN Foslevodopa; UNII-37NQZ0J76I; 37NQZ0J76I; 3-hydroxy-O-phosphono-L-tyrosine; 101141-95-1; 97321-87-4; Dopa 4-phosphate; Levodopa-4'-monophosphate; 3-Hydroxy-O-phosphonotyrosine; Foslevodopa (JAN/USAN/INN); CHEMBL4594379; SCHEMBL17685899; DTXSID70905957; HY-109132; CS-0086774; D11839; (S)-2-amino-3-(3-hydroxy-4-(phosphonooxy)phenyl)propanoic acid
DMMWO7V CP AbbVie
DMMWO7V DT Small molecular drug
DMMWO7V PC 127766
DMMWO7V MW 277.17
DMMWO7V FM C9H12NO7P
DMMWO7V IC InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1
DMMWO7V CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)OP(=O)(O)O
DMMWO7V IK YNDMEEULGSTYJT-LURJTMIESA-N
DMMWO7V IU (2S)-2-amino-3-(3-hydroxy-4-phosphonooxyphenyl)propanoic acid
DMMWO7V CA CAS 97321-87-4
DMMWO7V DE Parkinson disease
DMCKPG4 ID DMCKPG4
DMCKPG4 DN ABC294640
DMCKPG4 HS Phase 3
DMCKPG4 SN ABC294640; 915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8; ABC294640; 915385-81-8; ABC-294640
DMCKPG4 CP Apogee Biotechnology
DMCKPG4 DT Small molecular drug
DMCKPG4 PC 15604015
DMCKPG4 MW 380.9
DMCKPG4 FM C23H25ClN2O
DMCKPG4 IC InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
DMCKPG4 CS C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
DMCKPG4 IK CAOTVXGYTWCKQE-UHFFFAOYSA-N
DMCKPG4 IU 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
DMCKPG4 CA CAS 915385-81-8
DMCKPG4 CB CHEBI:124965
DMCKPG4 DE Advanced solid tumour; Hepatocellular carcinoma; Cholangiocarcinoma; Multiple myeloma
DM91LGU ID DM91LGU
DM91LGU DN Abexinostat
DM91LGU HS Phase 3
DM91LGU SN PCI-24781; 783355-60-2; ABEXINOSTAT; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide
DM91LGU CP Pharmacyclics
DM91LGU DT Small molecular drug
DM91LGU PC 11749858
DM91LGU MW 397.4
DM91LGU FM C21H23N3O5
DM91LGU IC InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
DM91LGU CS CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO
DM91LGU IK MAUCONCHVWBMHK-UHFFFAOYSA-N
DM91LGU IU 3-[(dimethylamino)methyl]-N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide
DM91LGU CA CAS 783355-60-2
DM91LGU CB CHEBI:92223
DM91LGU DE Acute myeloid leukaemia; Breast cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Gynecologic cancer; Peripheral T-cell lymphoma; Solid tumour/cancer; Renal cell carcinoma
DMMF5K4 ID DMMF5K4
DMMF5K4 DN ABL 001
DMMF5K4 HS Phase 3
DMMF5K4 CP Novartis pharmaceuticals
DMMF5K4 DE leukaemia; Chronic myeloid leukaemia; Promyelocytic leukaemia
DM7EVUF ID DM7EVUF
DM7EVUF DN ABL001
DM7EVUF HS Phase 3
DM7EVUF SN asciminib; ABL-001; 1492952-76-7; Asciminib free base; ABL001-NX; UNII-L1F3R18W77; L1F3R18W77; NVP-ABL001; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; 1492952-76-7 (free base); N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; Asciminib [USAN]; Asciminib (ABL001); Asciminib (USAN/INN); GTPL8962; CHEMBL4208229; SCHEMBL15388306; TQP0925; EX-A3030; BDBM50459091; NSC789925; s8555; ZINC150275965; CCG-269232; CS-7655; DB12597; NSC-789925; SB18878; BS-15538; HY-104010; D11403; Q27074535; (R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; AY7
DM7EVUF CP Novartis
DM7EVUF DT Small molecular drug
DM7EVUF PC 72165228
DM7EVUF MW 449.8
DM7EVUF FM C20H18ClF2N5O3
DM7EVUF IC InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1
DM7EVUF CS C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4
DM7EVUF IK VOVZXURTCKPRDQ-CQSZACIVSA-N
DM7EVUF IU N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
DM7EVUF CA CAS 1492952-76-7
DM7EVUF DE Chronic myeloid leukaemia
DM2J4YB ID DM2J4YB
DM2J4YB DN ABP 501
DM2J4YB HS Phase 3
DM2J4YB CP Amgen
DM2J4YB DT Antibody
DM2J4YB DE Rheumatoid arthritis; Plaque psoriasis
DMDXE4I ID DMDXE4I
DMDXE4I DN ABP959
DMDXE4I HS Phase 3
DMDXE4I CP Amgen
DMDXE4I DT Small molecular drug
DMDXE4I DE Paroxysmal nocturnal haemoglobinuria
DMNE56X ID DMNE56X
DMNE56X DN ABT-263
DMNE56X HS Phase 3
DMNE56X SN Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
DMNE56X CP Roche; Genentech
DMNE56X DT Small molecular drug
DMNE56X PC 24978538
DMNE56X MW 974.6
DMNE56X FM C47H55ClF3N5O6S3
DMNE56X IC InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1
DMNE56X CS CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
DMNE56X IK JLYAXFNOILIKPP-KXQOOQHDSA-N
DMNE56X IU 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
DMNE56X CA CAS 923564-51-6
DMNE56X CB CHEBI:94128
DMNE56X DE Relapsed or refractory chronic lymphocytic leukaemia; Solid tumour/cancer; Myelofibrosis
DMNQ869 ID DMNQ869
DMNQ869 DN ABT-267
DMNQ869 HS Phase 3
DMNQ869 SN HCV therapeutic, Abbott
DMNQ869 CP Abbott Laboratories
DMNQ869 DT Small molecular drug
DMNQ869 PC 54767916
DMNQ869 MW 894.1
DMNQ869 FM C50H67N7O8
DMNQ869 IC InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
DMNQ869 CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC2=CC=C(C=C2)[C@@H]3CC[C@H](N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMNQ869 IK PIDFDZJZLOTZTM-KHVQSSSXSA-N
DMNQ869 IU methyl N-[(2S)-1-[(2S)-2-[[4-[(2S,5S)-1-(4-tert-butylphenyl)-5-[4-[[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]phenyl]pyrrolidin-2-yl]phenyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMNQ869 CA CAS 1258226-87-7
DMNQ869 CB CHEBI:85183
DMNQ869 DE Hepatitis C virus infection
DMJFD2I ID DMJFD2I
DMJFD2I DN ABT-492
DMJFD2I HS Phase 3
DMJFD2I SN Delafloxacin; 189279-58-1; ABT-492; WQ-3034; Abt 492; 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; ABT492; RX-3341; UNII-6315412YVF; 6315412YVF; 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid; Delafloxacin [USAN:INN]; Delafloxacinum; Delafloxacin (USAN)
DMJFD2I DT Small molecular drug
DMJFD2I PC 487101
DMJFD2I MW 440.8
DMJFD2I FM C18H12ClF3N4O4
DMJFD2I IC InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30)
DMJFD2I CS C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O
DMJFD2I IK DYDCPNMLZGFQTM-UHFFFAOYSA-N
DMJFD2I IU 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid
DMJFD2I CA CAS 189279-58-1
DMJFD2I DE Bacterial infection
DM3FIC2 ID DM3FIC2
DM3FIC2 DN ABT-761
DM3FIC2 HS Phase 3
DM3FIC2 SN Atreleuton; Atreleuton [USAN]; ABT 761; A-85761; Atreleuton (USAN/INN); 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM3FIC2 CP Abbott Laboratories
DM3FIC2 DT Small molecular drug
DM3FIC2 PC 3086671
DM3FIC2 MW 318.4
DM3FIC2 FM C16H15FN2O2S
DM3FIC2 IC InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1
DM3FIC2 CS C[C@H](C#CC1=CC=C(S1)CC2=CC=C(C=C2)F)N(C(=O)N)O
DM3FIC2 IK MMSNEKOTSJRTRI-LLVKDONJSA-N
DM3FIC2 IU 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM3FIC2 CA CAS 154355-76-7
DM3FIC2 DE Asthma
DMREDYP ID DMREDYP
DMREDYP DN ABT-869
DMREDYP HS Phase 3
DMREDYP SN Linifanib; ABT 869; S1003_Selleck; AL-39324; RG-3635; ABT869, Linifanib, AL-39324, RG3635; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea; N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea
DMREDYP CP Abbott Laboratories
DMREDYP TC Anticancer Agents
DMREDYP DT Small molecular drug
DMREDYP PC 11485656
DMREDYP MW 375.4
DMREDYP FM C21H18FN5O
DMREDYP IC InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)
DMREDYP CS CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
DMREDYP IK MPVGZUGXCQEXTM-UHFFFAOYSA-N
DMREDYP IU 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea
DMREDYP CA CAS 796967-16-3
DMREDYP CB CHEBI:91435
DMREDYP DE Solid tumour/cancer
DMYHSO2 ID DMYHSO2
DMYHSO2 DN ABT-874
DMYHSO2 HS Phase 3
DMYHSO2 CP Abbott; Astra Zeneca
DMYHSO2 DE Crohn disease; Rheumatoid arthritis; Plaque psoriasis
DM4HYMS ID DM4HYMS
DM4HYMS DN ABT-888
DM4HYMS HS Phase 3
DM4HYMS SN Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride
DM4HYMS DT Small molecular drug
DM4HYMS PC 45480520
DM4HYMS MW 317.21
DM4HYMS FM C13H18Cl2N4O
DM4HYMS IC InChI=1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1
DM4HYMS CS C[C@@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl
DM4HYMS IK DSBSVDCHFMEYBX-FFXKMJQXSA-N
DM4HYMS IU 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide;dihydrochloride
DM4HYMS CA CAS 912445-05-7
DM4HYMS DE Breast cancer; Epithelial ovarian cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer
DMQRL2Y ID DMQRL2Y
DMQRL2Y DN AC0010
DMQRL2Y HS Phase 3
DMQRL2Y SN Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-
DMQRL2Y CP ACEA BiosciencesSan Diego, CA
DMQRL2Y PC 72734520
DMQRL2Y MW 487.5
DMQRL2Y FM C26H26FN7O2
DMQRL2Y IC InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
DMQRL2Y CS CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
DMQRL2Y IK UOFYSRZSLXWIQB-UHFFFAOYSA-N
DMQRL2Y IU N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
DMQRL2Y CA CAS 1557267-42-1
DMQRL2Y DE Non-small-cell lung cancer
DMXZ9T3 ID DMXZ9T3
DMXZ9T3 DN AC-170
DMXZ9T3 HS Phase 3
DMXZ9T3 SN 88139-91-7; 5-Bromo-2-hydroxymethylpyridine; (5-Bromopyridin-2-yl)methanol; 2-hydroxymethyl-5-bromopyridine; 5-Bromo-2-(hydroxymethyl)pyridine; (5-bromopyrid-2-yl)methanol; 5-Bromo-2-pyridinemethanol; (5-Bromo-pyridin-2-yl)-methanol; 2-PYRIDINEMETHANOL, 5-BROMO-; 5-BROMOPYRIDINE-2-METHANOL; (5-bromo-2-pyridyl)methanol; (5-bromo-2-pyridyl)methan-1-ol; AC-170; (5-Bromo-pyridin-2-yl)methanol (5-Bromo-2-hydroxymethylpyridine); zlchem 391; PubChem7710; PubChem12387; ACMC-209qrb; AC1NP90H; 5-bromo-2-pyridine methanol; KSC494K9D
DMXZ9T3 CP Aciex Therapeutics Inc
DMXZ9T3 DT Small molecular drug
DMXZ9T3 PC 5200169
DMXZ9T3 MW 188.02
DMXZ9T3 FM C6H6BrNO
DMXZ9T3 IC InChI=1S/C6H6BrNO/c7-5-1-2-6(4-9)8-3-5/h1-3,9H,4H2
DMXZ9T3 CS C1=CC(=NC=C1Br)CO
DMXZ9T3 IK RUCZFWMEACWFER-UHFFFAOYSA-N
DMXZ9T3 IU (5-bromopyridin-2-yl)methanol
DMXZ9T3 CA CAS 88139-91-7
DMXZ9T3 DE Allergic conjunctivitis
DM8Y4JS ID DM8Y4JS
DM8Y4JS DN AC220
DM8Y4JS HS Phase 3
DM8Y4JS SN Quizartinib
DM8Y4JS CP Ambit Biosciences; Astellas Pharma US
DM8Y4JS DT Small molecular drug
DM8Y4JS PC 24889392
DM8Y4JS MW 560.7
DM8Y4JS FM C29H32N6O4S
DM8Y4JS IC InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
DM8Y4JS CS CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3
DM8Y4JS IK CVWXJKQAOSCOAB-UHFFFAOYSA-N
DM8Y4JS IU 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
DM8Y4JS CA CAS 950769-58-1
DM8Y4JS CB CHEBI:90217
DM8Y4JS DE leukaemia; Acute myeloid leukaemia
DM1RMF5 ID DM1RMF5
DM1RMF5 DN Acadesine
DM1RMF5 HS Phase 3
DM1RMF5 SN AICAR; Acadra; ADV-P1; ATH-001; Acadesine (intravenous formulation, leukemia); Acadesine (intravenous formulation, leukemia), Advanced In Vitro Cell Technologies
DM1RMF5 CP Schering-Plough
DM1RMF5 DT Small molecular drug
DM1RMF5 PC 17513
DM1RMF5 MW 258.23
DM1RMF5 FM C9H14N4O5
DM1RMF5 IC InChI=1S/C9H14N4O5/c10-7-4(8(11)17)12-2-13(7)9-6(16)5(15)3(1-14)18-9/h2-3,5-6,9,14-16H,1,10H2,(H2,11,17)/t3-,5-,6-,9-/m1/s1
DM1RMF5 CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N
DM1RMF5 IK RTRQQBHATOEIAF-UUOKFMHZSA-N
DM1RMF5 IU 5-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide
DM1RMF5 CA CAS 2627-69-2
DM1RMF5 CB CHEBI:28498
DM1RMF5 DE Diabetic complication
DMY96O3 ID DMY96O3
DMY96O3 DN acelarin
DMY96O3 HS Phase 3
DMY96O3 SN NUC-1031
DMY96O3 DT Small molecular drug
DMY96O3 PC 11169170
DMY96O3 MW 580.5
DMY96O3 FM C25H27F2N4O8P
DMY96O3 IC InChI=1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40?/m0/s1
DMY96O3 CS C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C([C@@H](O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4
DMY96O3 IK NHTKGYOMICWFQZ-KKQYNPQSSA-N
DMY96O3 IU benzyl (2S)-2-[[[(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMY96O3 CA CAS 840506-29-8
DMY96O3 DE Alzheimer disease; Ovarian cancer; Biliary tract cancer
DM3UQ9K ID DM3UQ9K
DM3UQ9K DN Acolbifene
DM3UQ9K HS Phase 3
DM3UQ9K SN Acolbifene; EM-652; 182167-02-8; UNII-815LJ9X0D1; 815LJ9X0D1; EM 652; Acolbifene [INN:BAN]; SCH 57068; AC1L4EAA; SCHEMBL406183; CHEMBL68055; CTK4F5320; SCH-57068; HY-16023A; ( )-(2S)-3-(4-Hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-1-benzopyran-7-ol; CS-0007143; (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol; (S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-chromen-7-ol
DM3UQ9K CP EndoCeutics
DM3UQ9K DT Small molecular drug
DM3UQ9K PC 155435
DM3UQ9K MW 457.6
DM3UQ9K FM C29H31NO4
DM3UQ9K IC InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1
DM3UQ9K CS CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
DM3UQ9K IK DUYNJNWVGIWJRI-LJAQVGFWSA-N
DM3UQ9K IU (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol
DM3UQ9K CA CAS 182167-02-8
DM3UQ9K DE Breast cancer
DMXYRPO ID DMXYRPO
DMXYRPO DN Act1
DMXYRPO HS Phase 3
DMXYRPO SN 51-34-3; UNII-DL48G20X8X; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; DL48G20X8X; CHEBI:16794
DMXYRPO DT Small molecular drug
DMXYRPO DE Wound healing
DMVLWG7 ID DMVLWG7
DMVLWG7 DN Ad5FGF-4
DMVLWG7 HS Phase 3
DMVLWG7 DE Angina pectoris
DMFIP35 ID DMFIP35
DMFIP35 DN Adhexil
DMFIP35 HS Phase 3
DMFIP35 CP OMRIX Biopharmaceuticals SA
DMFIP35 DE Injury
DMLBYRA ID DMLBYRA
DMLBYRA DN ADX N05
DMLBYRA HS Phase 3
DMLBYRA CP Aerial BioPharma
DMLBYRA DE Excessive daytime sleepiness; Mood disorder
DMAYO46 ID DMAYO46
DMAYO46 DN AEZS-108
DMAYO46 HS Phase 3
DMAYO46 SN Zoptarelin doxorubicin; AEZS-108; AN-152; UNII-27844X2J29; ZEN-008; 27844X2J29; Zoptrex; Zoptarelin doxorubicin [INN]; Zoptarelin doxorubicin [USAN]; AEZS 108; CHEMBL3544954; AN 152; Luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D-lysine)-, (2S-cis)-
DMAYO46 CP AEterna Zentaris
DMAYO46 DT Small molecular drug
DMAYO46 PC 16134409
DMAYO46 MW 1893
DMAYO46 FM C91H117N19O26
DMAYO46 IC InChI=1S/C91H117N19O26/c1-44(2)31-58(83(125)104-57(17-11-29-98-90(94)95)89(131)110-30-12-18-63(110)88(130)100-40-67(93)114)105-81(123)55(16-7-8-28-97-68(115)20-10-21-70(117)134-42-66(113)91(132)36-52-73(65(37-91)136-71-35-53(92)76(118)45(3)135-71)80(122)75-74(78(52)120)77(119)51-14-9-19-64(133-4)72(51)79(75)121)103-84(126)59(32-46-22-24-49(112)25-23-46)106-87(129)62(41-111)109-85(127)60(33-47-38-99-54-15-6-5-13-50(47)54)107-86(128)61(34-48-39-96-43-101-48)108-82(124)56-26-27-69(116)102-56/h5-6,9,13-15,19,22-25,38-39,43-45,53,55-63,65,71,76,99,111-112,118,120,122,132H,7-8,10-12,16-18,20-21,26-37,40-42,92H2,1-4H3,(H2,93,114)(H,96,101)(H,97,115)(H,100,130)(H,102,116)(H,103,126)(H,104,125)(H,105,123)(H,106,129)(H,107,128)(H,108,124)(H,109,127)(H4,94,95,98)/t45-,53-,55+,56-,57-,58-,59-,60-,61-,62-,63-,65-,71-,76+,91-/m0/s1
DMAYO46 CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)O)N)O
DMAYO46 IK OOUACICUAVTCEC-LZHWUUGESA-N
DMAYO46 IU [2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate
DMAYO46 CA CAS 139570-93-7
DMAYO46 DE Acute lymphoblastic leukaemia
DMS0ZBI ID DMS0ZBI
DMS0ZBI DN Ag-221
DMS0ZBI HS Phase 3
DMS0ZBI SN AG-221 (IDH2 inhibitor)
DMS0ZBI CP Agios pharmaceuticals; celgene
DMS0ZBI PC 89683805
DMS0ZBI MW 473.4
DMS0ZBI FM C19H17F6N7O
DMS0ZBI IC InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32)
DMS0ZBI CS CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O
DMS0ZBI IK DYLUUSLLRIQKOE-UHFFFAOYSA-N
DMS0ZBI IU 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
DMS0ZBI CA CAS 1446502-11-9
DMS0ZBI CB CHEBI:145374
DMS0ZBI DE Acute myeloid leukaemia; Acute myelogenous leukaemia
DMIE1WY ID DMIE1WY
DMIE1WY DN AG-881
DMIE1WY HS Phase 3
DMIE1WY SN Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop
DMIE1WY CP Agios Pharmaceuticals Cambridge, MA Celgene Summit, NJ
DMIE1WY PC 117817422
DMIE1WY MW 414.74
DMIE1WY FM C14H13ClF6N6
DMIE1WY IC InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1
DMIE1WY CS C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F
DMIE1WY IK QCZAWDGAVJMPTA-RNFRBKRXSA-N
DMIE1WY IU 6-(6-chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine
DMIE1WY CA CAS 1644545-52-7
DMIE1WY DE Acute myeloid leukaemia; Glioma
DMYN3IH ID DMYN3IH
DMYN3IH DN AGI-1067
DMYN3IH HS Phase 3
DMYN3IH SN AGZ-1067; Succinic acid 2,6-di-tert-butyl-4-[1-(3,5-di-tert-butyl-4-hydroxyphenylsulfanyl)-1-methylethylsulfanyl]phenyl monoester
DMYN3IH CP AtheroGenics
DMYN3IH DT Small molecular drug
DMYN3IH PC 216325
DMYN3IH MW 616.9
DMYN3IH FM C35H52O5S2
DMYN3IH IC InChI=1S/C35H52O5S2/c1-31(2,3)23-17-21(18-24(29(23)39)32(4,5)6)41-35(13,14)42-22-19-25(33(7,8)9)30(26(20-22)34(10,11)12)40-28(38)16-15-27(36)37/h17-20,39H,15-16H2,1-14H3,(H,36,37)
DMYN3IH CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C
DMYN3IH IK RKSMVPNZHBRNNS-UHFFFAOYSA-N
DMYN3IH IU 4-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]-4-oxobutanoic acid
DMYN3IH CA CAS 216167-82-7
DMYN3IH DE Artery stenosis
DMJRQDG ID DMJRQDG
DMJRQDG DN AG-SPT201
DMJRQDG HS Phase 3
DMJRQDG SN SPT201; S-pantoprazole sodium trihydrate (ulcer), Ahn-Gook; (S)-pantoprazole sodium trihydrate
DMJRQDG CP Ahn-Gook Pharmaceuticals Co Ltd
DMJRQDG DE Ulcerative colitis
DMS2WV3 ID DMS2WV3
DMS2WV3 DN AIDSVAX
DMS2WV3 HS Phase 3
DMS2WV3 SN AIDSVAX B/B; AIDSVAX B/E; Bivalent gp120 HIV vaccines, GSID; Bivalent gp120 HIV vaccines, Global Solutions for Infectious Diseases; Bivalent gp120 HIV vaccines, VaxGen
DMS2WV3 CP DiaDexus Inc
DMS2WV3 DT Vaccine
DMS2WV3 DE Human immunodeficiency virus infection
DM8SYTE ID DM8SYTE
DM8SYTE DN AIR-insulin
DM8SYTE HS Phase 3
DM8SYTE SN HIIP
DM8SYTE CP Alkermes
DM8SYTE DE Diabetic complication
DM5K6J4 ID DM5K6J4
DM5K6J4 DN AJM-300
DM5K6J4 HS Phase 3
DM5K6J4 SN Alpha-4 integrin antagonist (inflammatory bowel disease), Ajinomoto
DM5K6J4 CP Ajinomoto Co Inc
DM5K6J4 DE Crohn disease; Ulcerative colitis
DM2EJM3 ID DM2EJM3
DM2EJM3 DN AKB-6548
DM2EJM3 HS Phase 3
DM2EJM3 CP Akebia therapeutics
DM2EJM3 PC 23634441
DM2EJM3 MW 306.7
DM2EJM3 FM C14H11ClN2O4
DM2EJM3 IC InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
DM2EJM3 CS C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DM2EJM3 IK JGRXMPYUTJLTKT-UHFFFAOYSA-N
DM2EJM3 IU 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
DM2EJM3 CA CAS 1000025-07-9
DM2EJM3 DE Anaemia
DM3WP0N ID DM3WP0N
DM3WP0N DN Al3818
DM3WP0N HS Phase 3
DM3WP0N SN Anlotinib; 1058156-90-3; UNII-GKF8S4C432; GKF8S4C432; AL-3818; SCHEMBL2063386; GTPL9601; KSMZEXLVHXZPEF-UHFFFAOYSA-N; MolPort-044-567-604; ZINC117924202; AKOS030526233; DB11885; CS-5396; AL 3818; HY-19716; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine; 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine; Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
DM3WP0N CP Advenchen Laboratories Moorpark, CA
DM3WP0N PC 25017411
DM3WP0N MW 407.4
DM3WP0N FM C23H22FN3O3
DM3WP0N IC InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
DM3WP0N CS CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
DM3WP0N IK KSMZEXLVHXZPEF-UHFFFAOYSA-N
DM3WP0N IU 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine
DM3WP0N CA CAS 1058156-90-3
DM3WP0N DE Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cavity cancer; Synovial sarcoma
DMK0QW6 ID DMK0QW6
DMK0QW6 DN Albinterferon alfa-2b
DMK0QW6 HS Phase 3
DMK0QW6 SN Albuferon; Joulferon; Zalbin; ABF-656; Albuferon-alpha; Interferon alpha-albumin fusion protein, HGS; Albumin-based fusion protein (viral disease), Principia; Interferon alpha-albumin fusion protein, HGS/Novartis
DMK0QW6 CP Human Genome Sciences
DMK0QW6 DE Hepatitis C virus infection
DMWAL73 ID DMWAL73
DMWAL73 DN Albutropin
DMWAL73 HS Phase 3
DMWAL73 SN Albumin-based fusion protein (growth deficiency), Teva Pharmaceutical; Recombinant human growth hormone (HGH, long acting),Human Genome Sciences; Albumin-based fusion protein (growth deficiency), Principia (HGS); Recombinant human growth hormone (HGH, long-acting), Teva Pharmaceutical
DMWAL73 CP Aventis Behring LLC
DMWAL73 DE Growth failure
DMHKCIS ID DMHKCIS
DMHKCIS DN Aldoxorubicin
DMHKCIS HS Phase 3
DMHKCIS SN 1361644-26-9; ALDOXORUBICIN; Doxorubicin-EMCH; 151038-96-9; Aldoxorubicin (USAN); CHEMBL2107818; SCHEMBL15221892; OBMJQRLIQQTJLR-LBMCFUDOSA-N; ZINC163337436; AKOS030526452; CS-1186; HY-16261; D10383; W-5595; (8S)-1-Methoxy-6,8alpha,11-trihydroxy-8-[1-[2-[6-(2,5-dioxo-3-pyrroline-1-yl)hexanoyl]hydrazono]-2-hydroxyethyl]-10alpha-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione
DMHKCIS CP CytRx, Los Angeles, CA
DMHKCIS PC 9810709
DMHKCIS MW 750.7
DMHKCIS FM C37H42N4O13
DMHKCIS IC InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
DMHKCIS CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O
DMHKCIS IK OBMJQRLIQQTJLR-USGQOSEYSA-N
DMHKCIS IU N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
DMHKCIS CA CAS 1361644-26-9
DMHKCIS DE Soft tissue sarcoma; Pancreatic ductal carcinoma; Glioblastoma multiforme; Small-cell lung cancer; Solid tumour/cancer
DMPH1RK ID DMPH1RK
DMPH1RK DN Alferminogene tadenovec
DMPH1RK HS Phase 3
DMPH1RK SN Generx (TN)
DMPH1RK CP Cardium Therapeutics
DMPH1RK DE Heart disease; Angina pectoris
DMVHRL8 ID DMVHRL8
DMVHRL8 DN Alfimeprase
DMVHRL8 HS Phase 3
DMVHRL8 SN Thrombolytic fibrolase derivative (cardiovascular diseases), Nuvelo; Thrombolytic fibrolase derivative (cerebrovascular ischemia), Nuvelo; Thrombolytic fibrolase derivative (peripheral arterial occlusive diseases), Nuvelo
DMVHRL8 CP Nuvelo
DMVHRL8 SQ Alfimeprase Sequence: SFPQRYVQLVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIQFTLVGLEIWSNQDLITVTSVSHDTLASFGNWRETDLLRRQRHDNAQLLTAIDFDGDTVGLAYVGGMCQLKHSTGVIQDHSAINLLVALTMAHELGHNLGMNHDGNQCHCGANSCVMAAMLSDQPSKLFSDCSKKDYQTFLTVNNPQCILNKP
DMVHRL8 DE Peripheral vascular disease
DMBQK0X ID DMBQK0X
DMBQK0X DN Algenpantucel-L
DMBQK0X HS Phase 3
DMBQK0X SN HyperAcute pancreas (TN)
DMBQK0X CP NewLink Genetics
DMBQK0X DT Vaccine
DMBQK0X DE Pancreatic cancer
DMQ509J ID DMQ509J
DMQ509J DN Alicaforsen
DMQ509J HS Phase 3
DMQ509J SN Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)
DMQ509J CP ISIS & Atlantic Healthcare
DMQ509J TC Antisense
DMQ509J DT Antisense drug
DMQ509J PC 16197725
DMQ509J MW 6349
DMQ509J FM C192H225N75O98P19S19-19
DMQ509J IC InChI=1S/C192H244N75O98P19S19/c1-76-40-256(190(286)245-169(76)270)136-30-89(357-376(299,395)314-50-106-84(25-131(334-106)251-15-7-122(196)230-185(251)281)351-370(293,389)312-49-105-87(28-134(333-105)254-18-10-125(199)233-188(254)284)355-374(297,393)323-59-115-97(38-145(343-115)266-74-225-154-167(266)238-180(208)243-175(154)276)364-381(304,400)319-55-111-90(31-137(339-111)257-41-77(2)170(271)246-191(257)287)356-375(298,394)313-46-102-81(22-128(330-102)248-12-4-119(193)227-182(248)278)348-366(289,385)308-44-100-79(269)20-127(328-100)259-67-218-147-156(201)210-63-214-160(147)259)110(338-136)54-318-380(303,399)359-92-33-139(260-68-219-148-157(202)211-64-215-161(148)260)340-112(92)56-320-373(296,392)354-88-29-135(255-19-11-126(200)234-189(255)285)336-108(88)52-316-379(302,398)363-96-37-144(265-73-224-153-166(265)237-179(207)242-174(153)275)346-118(96)62-326-384(307,403)365-98-39-146(267-75-226-155-168(267)239-181(209)244-176(155)277)344-116(98)60-324-377(300,396)358-91-32-138(258-42-78(3)171(272)247-192(258)288)337-109(91)53-317-371(294,390)352-85-26-132(252-16-8-123(197)231-186(252)282)335-107(85)51-315-378(301,397)362-95-36-143(264-72-223-152-165(264)236-178(206)241-173(152)274)345-117(95)61-325-383(306,402)361-94-35-141(262-70-221-150-159(204)213-66-217-163(150)262)342-114(94)58-322-382(305,401)360-93-34-140(261-69-220-149-158(203)212-65-216-162(149)261)341-113(93)57-321-372(295,391)353-86-27-133(253-17-9-124(198)232-187(253)283)332-104(86)48-311-369(292,388)350-83-24-130(250-14-6-121(195)229-184(250)280)331-103(83)47-310-368(291,387)349-82-23-129(249-13-5-120(194)228-183(249)279)329-101(82)45-309-367(290,386)347-80-21-142(327-99(80)43-268)263-71-222-151-164(263)235-177(205)240-172(151)273/h4-19,40-42,63-75,79-118,127-146,268-269H,20-39,43-62H2,1-3H3,(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H2,193,227,278)(H2,194,228,279)(H2,195,229,280)(H2,196,230,281)(H2,197,231,282)(H2,198,232,283)(H2,199,233,284)(H2,200,234,285)(H2,201,210,214)(H2,202,211,215)(H2,203,212,216)(H2,204,213,217)(H,245,270,286)(H,246,271,287)(H,247,272,288)(H3,205,235,240,273)(H3,206,236,241,274)(H3,207,237,242,275)(H3,208,238,243,276)(H3,209,239,244,277)/p-19/t79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?/m0/s1
DMQ509J CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=S)([O-])O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)O
DMQ509J IK ZMJWRJKGPUDEOX-LMXUULCNSA-A
DMQ509J IU 1-[(2R,4S,5R)-4-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-[[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMQ509J CA CAS 185229-68-9
DMQ509J DE Ulcerative colitis; Crohn disease; Lleum inflammation
DM9R2SD ID DM9R2SD
DM9R2SD DN Alilusem
DM9R2SD HS Phase 3
DM9R2SD SN M-12285; M-17000; M-17055; MD-31
DM9R2SD CP Mochida Pharmaceutical Co Ltd
DM9R2SD DT Small molecular drug
DM9R2SD PC 6338015
DM9R2SD MW 394.8
DM9R2SD FM C17H15ClN2O5S
DM9R2SD IC InChI=1S/C17H15ClN2O5S/c1-11-4-2-3-5-13(11)17(21)20-9-8-15(19-25-26(22,23)24)14-7-6-12(18)10-16(14)20/h2-7,10H,8-9H2,1H3,(H,22,23,24)/b19-15+
DM9R2SD CS CC1=CC=CC=C1C(=O)N2CC/C(=N\\OS(=O)(=O)O)/C3=C2C=C(C=C3)Cl
DM9R2SD IK QQCSUWGQBREWRO-XDJHFCHBSA-N
DM9R2SD IU [(E)-[7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4-ylidene]amino] hydrogen sulfate
DM9R2SD CA CAS 791024-52-7
DM9R2SD DE Diuretic vasodilator
DM83EBP ID DM83EBP
DM83EBP DN Alisporivir
DM83EBP HS Phase 3
DM83EBP SN DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
DM83EBP CP Novartis pharmaceuticals
DM83EBP DT Protein/peptide drug
DM83EBP PC 11513676
DM83EBP MW 1216.6
DM83EBP FM C63H113N11O12
DM83EBP IC InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1
DM83EBP CS CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
DM83EBP IK OLROWHGDTNFZBH-XEMWPYQTSA-N
DM83EBP IU (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM83EBP CA CAS 254435-95-5
DM83EBP DE Duchenne dystrophy
DMCHA27 ID DMCHA27
DMCHA27 DN Almonertinib
DMCHA27 HS Phase 3
DMCHA27 SN HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
DMCHA27 CP EQRx
DMCHA27 DT Small molecular drug
DMCHA27 PC 121280087
DMCHA27 MW 525.6
DMCHA27 FM C30H35N7O2
DMCHA27 IC InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)
DMCHA27 CS CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC
DMCHA27 IK DOEOECWDNSEFDN-UHFFFAOYSA-N
DMCHA27 IU N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
DMCHA27 CA CAS 1899921-05-1
DMCHA27 DE Non-small-cell lung cancer
DMFUOM7 ID DMFUOM7
DMFUOM7 DN ALN-TTRsc
DMFUOM7 HS Phase 3
DMFUOM7 SN SAR438714
DMFUOM7 CP Alnylam pharmaceuticals
DMFUOM7 DE Cardiomyopathy
DMKLBHX ID DMKLBHX
DMKLBHX DN ALO-02
DMKLBHX HS Phase 3
DMKLBHX SN ALO-02 Oxycodone-naltrexone core
DMKLBHX CP Elite Pharmaceuticals; pfizer
DMKLBHX DE Pain
DM2RTGP ID DM2RTGP
DM2RTGP DN Alpha-glucosidase
DM2RTGP HS Phase 3
DM2RTGP SN Pompes disease therapy, Pharming; Alpha-glucosidase (transgenic); Alpha-glucosidase, Pharming; GD-halpha-GLU; Alpha-glucosidase (transgenic), Pharming/Genzyme
DM2RTGP CP Pharming Group NV
DM2RTGP DE Muscle disease
DM7EBH9 ID DM7EBH9
DM7EBH9 DN ALX-0081
DM7EBH9 HS Phase 3
DM7EBH9 CP Ablynx
DM7EBH9 DE Thrombocytopenia; Thrombotic thrombocytopenic purpura
DMG5BTD ID DMG5BTD
DMG5BTD DN ALZT-OP1
DMG5BTD HS Phase 3
DMG5BTD SN ALZT-OP1a+ALZT-OP1b; cromolyn + ibuprofen
DMG5BTD CP AZTherapies Boston, MA
DMG5BTD DE Alzheimer disease
DMGMNUE ID DMGMNUE
DMGMNUE DN AM0010
DMGMNUE HS Phase 3
DMGMNUE CP Armo biosciences
DMGMNUE DE Solid tumour/cancer; Pancreatic ductal carcinoma; Renal cell carcinoma; Non-small-cell lung cancer; Pancreatic cancer
DM4E9PK ID DM4E9PK
DM4E9PK DN AM-111
DM4E9PK HS Phase 3
DM4E9PK SN UNII-FU288768DP; FU288768DP; XG102 peptide; AM111 peptide; D-JNKI-1; D-JNKI 1 peptide; XG 102; AM 111; D-JNKI 1; TAT-IB1 fusion peptide XG-102 (synthetic); HIV TAT-JIP-1 fusion peptide XG-102 (synthetic); 1198367-70-2; 1148126-36-6; Glycine, D-alpha-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-D-asparaginyl-D-leucyl-D-threonyl-D-threonyl-D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginyl-
DM4E9PK CP Auris Medical
DM4E9PK PC 72941992
DM4E9PK MW 3823.4
DM4E9PK FM C164H285N65O41
DM4E9PK IC InChI=1S/C164H285N65O41/c1-84(2)77-106(216-139(254)108(79-89-33-10-9-11-34-89)219-146(261)112-48-28-72-225(112)153(268)105(55-58-119(171)235)215-148(263)123(86(5)6)221-147(262)115-51-29-73-226(115)151(266)103(45-25-69-198-163(187)188)213-142(257)110(83-230)220-137(252)100(53-56-117(169)233)201-126(241)90(168)80-121(237)238)138(253)218-109(81-120(172)236)140(255)217-107(78-85(3)4)141(256)222-124(87(7)231)149(264)223-125(88(8)232)155(270)228-75-31-50-114(228)144(259)211-99(44-24-68-197-162(185)186)135(250)212-102(37-14-17-61-167)150(265)224-71-27-47-111(224)145(260)214-104(46-26-70-199-164(189)190)152(267)229-76-32-52-116(229)154(269)227-74-30-49-113(227)143(258)210-98(43-23-67-196-161(183)184)134(249)207-95(40-20-64-193-158(177)178)131(246)206-97(42-22-66-195-160(181)182)133(248)209-101(54-57-118(170)234)136(251)208-96(41-21-65-194-159(179)180)132(247)205-94(39-19-63-192-157(175)176)130(245)204-93(36-13-16-60-166)129(244)203-92(35-12-15-59-165)128(243)202-91(38-18-62-191-156(173)174)127(242)200-82-122(239)240/h9-11,33-34,84-88,90-116,123-125,230-232H,12-32,35-83,165-168H2,1-8H3,(H2,169,233)(H2,170,234)(H2,171,235)(H2,172,236)(H,200,242)(H,201,241)(H,202,243)(H,203,244)(H,204,245)(H,205,247)(H,206,246)(H,207,249)(H,208,251)(H,209,248)(H,210,258)(H,211,259)(H,212,250)(H,213,257)(H,214,260)(H,215,263)(H,216,254)(H,217,255)(H,218,253)(H,219,261)(H,220,252)(H,221,262)(H,222,256)(H,223,264)(H,237,238)(H,239,240)(H4,173,174,191)(H4,175,176,192)(H4,177,178,193)(H4,179,180,194)(H4,181,182,195)(H4,183,184,196)(H4,185,186,197)(H4,187,188,198)(H4,189,190,199)/t87-,88-,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,123+,124+,125+/m0/s1
DM4E9PK CS C[C@@H]([C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N3CCC[C@@H]3C(=O)N4CCC[C@@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@H]6CCCN6C(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H]7CCCN7C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC(=O)O)N)O
DM4E9PK IK HRMVIAFZYCCHGF-BMCUWHFPSA-N
DM4E9PK IU (3R)-3-amino-4-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[(2R)-2-[[(2R)-1-[[(2R)-5-amino-1-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-4-amino-1-[[(2R)-1-[[(2R,3S)-1-[[(2R,3S)-1-[(2R)-2-[[(2R)-1-[[(2R)-6-amino-1-[(2R)-2-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[[(2R)-6-amino-1-[[(2R)-6-amino-1-[[(2R)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DM4E9PK CA CAS 1198367-70-2
DM4E9PK DE Neurological disorder
DMVOY6B ID DMVOY6B
DMVOY6B DN AMD-070
DMVOY6B HS Phase 3
DMVOY6B SN AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
DMVOY6B CP Genzyme
DMVOY6B DT Small molecular drug
DMVOY6B PC 11256587
DMVOY6B MW 349.5
DMVOY6B FM C21H27N5
DMVOY6B IC InChI=1S/C21H27N5/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25)/t19-/m0/s1
DMVOY6B CS C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3
DMVOY6B IK WVLHHLRVNDMIAR-IBGZPJMESA-N
DMVOY6B IU N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine
DMVOY6B CA CAS 558447-26-0
DMVOY6B CB CHEBI:138865
DMVOY6B DE Human immunodeficiency virus infection; Renal cell carcinoma; Melanoma; Merkel cell carcinoma; Solid tumour/cancer; Whim syndrome
DM4FPM3 ID DM4FPM3
DM4FPM3 DN Amediplase
DM4FPM3 HS Phase 3
DM4FPM3 SN Amediplase [INN]; Trans,trans-3,4:12,13-Tetrahydroxy-3,4,12,13-tetrahydro-dibenz(a,h)anthracene; (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
DM4FPM3 CP Menarini
DM4FPM3 DT Small molecular drug
DM4FPM3 PC 154656
DM4FPM3 MW 346.4
DM4FPM3 FM C22H18O4
DM4FPM3 IC InChI=1S/C22H18O4/c23-19-8-7-13-15(20(19)24)6-5-11-9-17-12-3-1-2-4-14(12)21(25)22(26)18(17)10-16(11)13/h1-10,19-26H/t19-,20-,21-,22-/m0/s1
DM4FPM3 CS C1=CC=C2C(=C1)[C@@H]([C@H](C3=C2C=C4C=CC5=C(C4=C3)C=C[C@@H]([C@H]5O)O)O)O
DM4FPM3 IK YQINXCSNGCDFCQ-CMOCDZPBSA-N
DM4FPM3 IU (3S,4S,12S,13S)-3,4,12,13-tetrahydronaphtho[1,2-b]phenanthrene-3,4,12,13-tetrol
DM4FPM3 CA CAS 151910-75-7
DM4FPM3 DE Thrombosis; Myocardial infarction
DMG324Y ID DMG324Y
DMG324Y DN AMG 145
DMG324Y HS Phase 3
DMG324Y CP Amgen Thousand
DMG324Y DE Hypercholesterolaemia
DMQJXL4 ID DMQJXL4
DMQJXL4 DN AMG 386
DMQJXL4 HS Phase 3
DMQJXL4 SN 7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930
DMQJXL4 CP Amgen
DMQJXL4 DT Small molecular drug
DMQJXL4 PC 5360545
DMQJXL4 MW 22.989
DMQJXL4 FM Na
DMQJXL4 IC InChI=1S/Na
DMQJXL4 CS [Na]
DMQJXL4 IK KEAYESYHFKHZAL-UHFFFAOYSA-N
DMQJXL4 IU sodium
DMQJXL4 CA CAS 7440-23-5
DMQJXL4 CB CHEBI:26708
DMQJXL4 DE Alzheimer disease; Neuropathic pain; Sexual dysfunction; Breast cancer; Asthma
DMS1X67 ID DMS1X67
DMS1X67 DN Amitifadine
DMS1X67 HS Phase 3
DMS1X67 SN EB-1010
DMS1X67 CP Euthymics Bioscience
DMS1X67 DT Small molecular drug
DMS1X67 PC 11658655
DMS1X67 MW 228.11
DMS1X67 FM C11H11Cl2N
DMS1X67 IC InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m1/s1
DMS1X67 CS C1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl
DMS1X67 IK BSMNRYCSBFHEMQ-KCJUWKMLSA-N
DMS1X67 IU (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
DMS1X67 CA CAS 410074-73-6
DMS1X67 DE Obesity; Alcohol dependence; Mood disorder
DMF50XJ ID DMF50XJ
DMF50XJ DN Amitriptyline+ketamine
DMF50XJ HS Phase 3
DMF50XJ SN AmiKet
DMF50XJ CP EpiCept Pharmaceuticals
DMF50XJ TC Analgesics
DMF50XJ DT Small molecular drug
DMF50XJ PC 24784105
DMF50XJ MW 412.9
DMF50XJ FM C20H17ClN4O2S
DMF50XJ IC InChI=1S/C20H16N4O2S.ClH/c1-13(25)23(2)15-6-3-5-14(11-15)17-8-9-21-20-16(12-22-24(17)20)19(26)18-7-4-10-27-18;/h3-12H,1-2H3;1H
DMF50XJ CS CC(=O)N(C)C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4.Cl
DMF50XJ IK HPYLZBPCIBFRAI-UHFFFAOYSA-N
DMF50XJ IU N-methyl-N-[3-[3-(thiophene-2-carbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]acetamide;hydrochloride
DMF50XJ DE Neuropathic pain; Diabetic neuropathy; Postherpetic neuralgia
DMZ7AMY ID DMZ7AMY
DMZ7AMY DN Amivantamab
DMZ7AMY HS Phase 3
DMZ7AMY CP Janssen
DMZ7AMY DT Antibody
DMZ7AMY DE Non-small-cell lung cancer
DMB9587 ID DMB9587
DMB9587 DN Amocarzine
DMB9587 HS Phase 3
DMB9587 SN Phenthiourezine; Thiocarbamazine; CGP-6140; S-80016
DMB9587 CP Novartis AG
DMB9587 DT Small molecular drug
DMB9587 PC 5464102
DMB9587 MW 371.5
DMB9587 FM C18H21N5O2S
DMB9587 IC InChI=1S/C18H21N5O2S/c1-21-10-12-22(13-11-21)18(26)20-16-4-2-14(3-5-16)19-15-6-8-17(9-7-15)23(24)25/h2-9,19H,10-13H2,1H3,(H,20,26)
DMB9587 CS CN1CCN(CC1)C(=S)NC2=CC=C(C=C2)NC3=CC=C(C=C3)[N+](=O)[O-]
DMB9587 IK UFLRJROFPAGRPN-UHFFFAOYSA-N
DMB9587 IU 4-methyl-N-[4-(4-nitroanilino)phenyl]piperazine-1-carbothioamide
DMB9587 CA CAS 36590-19-9
DMB9587 CB CHEBI:38946
DMB9587 DE Helminth infection
DM6SGUB ID DM6SGUB
DM6SGUB DN Amrubicin
DM6SGUB HS Phase 3
DM6SGUB SN 110267-81-7; Amrubicin [INN]; SCHEMBL119022; AC1L4374; (+-)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; BC677604; AN-16624; LS-183761; FT-0662134; ( -)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-9-amino-7-(4,5-dihydroxytetrahydropyran-2-yl)oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DM6SGUB CP Celgene
DM6SGUB DT Small molecular drug
DM6SGUB PC 3035016
DM6SGUB MW 483.5
DM6SGUB FM C25H25NO9
DM6SGUB IC InChI=1S/C25H25NO9/c1-10(27)25(26)7-13-18(16(8-25)35-17-6-14(28)15(29)9-34-17)24(33)20-19(23(13)32)21(30)11-4-2-3-5-12(11)22(20)31/h2-5,14-17,28-29,32-33H,6-9,26H2,1H3/t14-,15+,16-,17-,25-/m0/s1
DM6SGUB CS CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N
DM6SGUB IK VJZITPJGSQKZMX-XDPRQOKASA-N
DM6SGUB IU (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
DM6SGUB CA CAS 110267-81-7
DM6SGUB CB CHEBI:135779
DM6SGUB DE Small-cell lung cancer
DM8QIRN ID DM8QIRN
DM8QIRN DN AMT-011
DM8QIRN HS Phase 3
DM8QIRN SN Alipogene tiparvovec
DM8QIRN CP Amsterdam Molecular Therapeutics
DM8QIRN DE Blood forming organ disorder
DMSO02K ID DMSO02K
DMSO02K DN AMT-061
DMSO02K HS Phase 3
DMSO02K SN etranacogene dezaparvovec
DMSO02K CP uniQure
DMSO02K DT Gene therapy
DMSO02K DE Haemophilia B
DMP2BFG ID DMP2BFG
DMP2BFG DN Anacetrapib
DMP2BFG HS Phase 3
DMP2BFG SN MK0859; Anacetrapib (USAN); MK-0859
DMP2BFG CP Merck
DMP2BFG DT Small molecular drug
DMP2BFG PC 11556427
DMP2BFG MW 637.5
DMP2BFG FM C30H25F10NO3
DMP2BFG IC InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
DMP2BFG CS C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMP2BFG IK MZZLGJHLQGUVPN-HAWMADMCSA-N
DMP2BFG IU (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
DMP2BFG CA CAS 875446-37-0
DMP2BFG DE Hyperlipidaemia; Arteriosclerosis
DM2F9YO ID DM2F9YO
DM2F9YO DN Anakinra
DM2F9YO HS Phase 3
DM2F9YO SN Antril
DM2F9YO TC Antiviral Agents
DM2F9YO DT Protein/peptide drug
DM2F9YO DE Coronavirus Disease 2019 (COVID-19)
DM6HXTS ID DM6HXTS
DM6HXTS DN Anamorelin
DM6HXTS HS Phase 3
DM6HXTS SN 249921-19-5; UNII-DD5RBA1NKF; DD5RBA1NKF; RC 1291; Anamorelin [INN]; ONO-7643; SCHEMBL935751; CHEMBL2110579; EX-A154; DTXSID20179702; C31H42N6O3; BCP06108; 3444AH; ZINC43130908; AKOS030526752; SB16911; API0008642; RC-1291; NCGC00378854-01; KB-80338; HY-14734; BC600755; (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide; AB0165721; FT-0773543; W-5500; 921A195; CS 1036
DM6HXTS CP Sapphire Therape.
DM6HXTS DT Small molecular drug
DM6HXTS PC 9828911
DM6HXTS MW 546.7
DM6HXTS FM C31H42N6O3
DM6HXTS IC InChI=1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
DM6HXTS CS CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N
DM6HXTS IK VQPFSIRUEPQQPP-MXBOTTGLSA-N
DM6HXTS IU 2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DM6HXTS CA CAS 249921-19-5
DM6HXTS DE Carbohydrate metabolism disorder
DMK2Y4V ID DMK2Y4V
DMK2Y4V DN Ancrod
DMK2Y4V HS Phase 3
DMK2Y4V SN Arvin; Arwin; Venacil; Viprinex; Agkistrodon rhodostoma venom proteinase; Agkistrodon serine proteinase; Snake venom, Knoll
DMK2Y4V CP Knoll GmbH; Neurobiological Technologies
DMK2Y4V DE Blood forming organ disorder
DMLDB1X ID DMLDB1X
DMLDB1X DN Andecaliximab
DMLDB1X HS Phase 3
DMLDB1X CP Gilead Sciences Foster City, CA
DMLDB1X DE Solid tumour/cancer; Gastric adenocarcinoma
DMX36BH ID DMX36BH
DMX36BH DN Andolast
DMX36BH HS Phase 3
DMX36BH SN Dizolast; CR-2039; Calcium-activated potassium channel opener (inhaled powder, asthma), Rottapharm
DMX36BH CP Rottapharm Madaus
DMX36BH DT Small molecular drug
DMX36BH PC 65970
DMX36BH MW 333.31
DMX36BH FM C15H11N9O
DMX36BH IC InChI=1S/C15H11N9O/c25-15(11-3-1-9(2-4-11)13-17-21-22-18-13)16-12-7-5-10(6-8-12)14-19-23-24-20-14/h1-8H,(H,16,25)(H,17,18,21,22)(H,19,20,23,24)
DMX36BH CS C1=CC(=CC=C1C2=NNN=N2)C(=O)NC3=CC=C(C=C3)C4=NNN=N4
DMX36BH IK VXEBMQZDPONDFB-UHFFFAOYSA-N
DMX36BH IU 4-(2H-tetrazol-5-yl)-N-[4-(2H-tetrazol-5-yl)phenyl]benzamide
DMX36BH CA CAS 132640-22-3
DMX36BH DE Rhinitis
DMITJAK ID DMITJAK
DMITJAK DN Androsterone
DMITJAK HS Phase 3
DMITJAK SN androsterone; 53-41-8; Androkinine; Androtine; 5alpha-Androsterone; Atromide ICI; 3alpha-Hydroxy-5alpha-androstan-17-one; 3-Epihydroxyetioallocholan-17-one; cis-Androsterone; 3alpha-Hydroxyetioallocholan-17-one; 5alpha-Androstane-3alpha-ol-17-one; 3alpha-Hydroxy-17-androstanone; Androstanon-3-alpha-ol-17-one; 3-alpha-Hydroxy-17-androstanone; 3-alpha-Hydroxyetioallocholan-17-one; 3-alpha-Hydroxy-5-alpha-androstan-17-one; 5-alpha-Androstan-3-alpha-ol-17-one; Caswell No. 051G; Androstan-17-one, 3-hydroxy-, (3alpha,5alpha)-
DMITJAK DT Small molecular drug
DMITJAK PC 5879
DMITJAK MW 290.4
DMITJAK FM C19H30O2
DMITJAK IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,18-,19-/m0/s1
DMITJAK CS C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMITJAK IK QGXBDMJGAMFCBF-HLUDHZFRSA-N
DMITJAK IU (3R,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMITJAK CA CAS 53-41-8
DMITJAK CB CHEBI:16032
DM76GZ0 ID DM76GZ0
DM76GZ0 DN Angiotensin-(1-7)
DM76GZ0 HS Phase 3
DM76GZ0 SN Ang (1-7); Angiotensin (1-7); Angiotensin-(1-7) (cancer); Angiotensin-(1-7) (cancer), Wake Forest University
DM76GZ0 CP Tarix pharmaceuticals
DM76GZ0 DT Small molecular drug
DM76GZ0 PC 123805
DM76GZ0 MW 899
DM76GZ0 FM C41H62N12O11
DM76GZ0 IC InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
DM76GZ0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DM76GZ0 IK PVHLMTREZMEJCG-GDTLVBQBSA-N
DM76GZ0 IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
DM76GZ0 CA CAS 39386-80-6
DM76GZ0 CB CHEBI:55438
DM76GZ0 DE Lymphoma; Chemotherapy-induced nausea; Sarcoma; Duchenne dystrophy; Muscular dystrophy
DM3FPAQ ID DM3FPAQ
DM3FPAQ DN Anifrolumab
DM3FPAQ HS Phase 3
DM3FPAQ CP MedImmune Gaithersburg, MD
DM3FPAQ DE Systemic lupus erythematosus
DMX0PWV ID DMX0PWV
DMX0PWV DN Anti-IL-23
DMX0PWV HS Phase 3
DMX0PWV SN Anti-IL-23 (chronic inflammation); Anti-IL-23 (chronic inflammation), Merck & Co; Anti-IL-23 (chronic inflammation), Schering-Plough; Anti-interleukin-23 antibody (chronic inflammation), Merck & Co
DMX0PWV CP Schering-Plough Corp
DMX0PWV DT Antibody
DMX0PWV DE Inflammation
DMUYOC8 ID DMUYOC8
DMUYOC8 DN AP12009
DMUYOC8 HS Phase 3
DMUYOC8 CP Antisense therapeutics
DMUYOC8 TC Antisense
DMUYOC8 DT Antisense drug
DMUYOC8 DE Colorectal cancer
DMD8QTC ID DMD8QTC
DMD8QTC DN Apadenoson
DMD8QTC HS Phase 3
DMD8QTC SN Stedivaze (TN)
DMD8QTC CP PGx Health
DMD8QTC DT Small molecular drug
DMD8QTC PC 9805430
DMD8QTC MW 486.5
DMD8QTC FM C23H30N6O6
DMD8QTC IC InChI=1S/C23H30N6O6/c1-3-25-21(32)18-16(30)17(31)22(35-18)29-11-26-15-19(24)27-14(28-20(15)29)6-4-5-12-7-9-13(10-8-12)23(33)34-2/h11-13,16-18,22,30-31H,3,5,7-10H2,1-2H3,(H,25,32)(H2,24,27,28)/t12?,13?,16-,17+,18-,22+/m0/s1
DMD8QTC CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CCC4CCC(CC4)C(=O)OC)N)O)O
DMD8QTC IK FLEVIENZILQUKB-DMJMAAGCSA-N
DMD8QTC IU methyl 4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]cyclohexane-1-carboxylate
DMD8QTC CA CAS 250386-15-3
DMD8QTC DE Coronary artery disease
DMVY0BU ID DMVY0BU
DMVY0BU DN Apaziquone
DMVY0BU HS Phase 3
DMVY0BU SN EOquin; 114560-48-4; Apaziquonum; NOR-701; EO 9 (pharmaceutical); EO-9; Apaziquone [USAN:INN]; NSC-382459; Apaziquonum [INN-Latin]; E 09; NSC 382459; UNII-H464ZO600O; E-85/053; E-09; EO9; NSC 382456; H464ZO600O; 5-(Azridin-1-yl)-3-(hydroxymethyl)-2-((1E)-3-hydroxyprop-1-enyl)-methyl-1H-indole-4,7-dione; (E)-5-(1-Azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione; E09; 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)-; Neoquin; Qapzola; Apaziquonum; EO 9; Eoquin (TN); Apaziquone (USAN/INN); E-85/050; 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol; 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione; Apaziquone/EOquin
DMVY0BU CP Spectrum
DMVY0BU DT Small molecular drug
DMVY0BU PC 5813717
DMVY0BU MW 288.3
DMVY0BU FM C15H16N2O4
DMVY0BU IC InChI=1S/C15H16N2O4/c1-16-10(3-2-6-18)9(8-19)13-14(16)12(20)7-11(15(13)21)17-4-5-17/h2-3,7,18-19H,4-6,8H2,1H3/b3-2+
DMVY0BU CS CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)/C=C/CO
DMVY0BU IK MXPOCMVWFLDDLZ-NSCUHMNNSA-N
DMVY0BU IU 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methylindole-4,7-dione
DMVY0BU CA CAS 114560-48-4
DMVY0BU DE Non-muscle invasive bladder cancer; Bladder cancer
DMT0A3Y ID DMT0A3Y
DMT0A3Y DN APD-334
DMT0A3Y HS Phase 3
DMT0A3Y SN S1P1 receptor agonists (autoimmune diseases), Arena Pharmaceuticals
DMT0A3Y CP Arena Pharmaceuticals Inc
DMT0A3Y PC 44623998
DMT0A3Y MW 457.5
DMT0A3Y FM C26H26F3NO3
DMT0A3Y IC InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1
DMT0A3Y CS C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F
DMT0A3Y IK MVGWUTBTXDYMND-QGZVFWFLSA-N
DMT0A3Y IU 2-[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
DMT0A3Y CA CAS 1206123-37-6
DMT0A3Y DE Autoimmune diabetes; Pyoderma gangrenosum; Ulcerative colitis
DM4HQ52 ID DM4HQ52
DM4HQ52 DN APL-2
DM4HQ52 HS Phase 3
DM4HQ52 CP Apellis Pharmaceuticals
DM4HQ52 DE Paroxysmal nocturnal haemoglobinuria
DMBRQF5 ID DMBRQF5
DMBRQF5 DN ApoC-III
DMBRQF5 HS Phase 3
DM1K78U ID DM1K78U
DM1K78U DN Apricitabine
DM1K78U HS Phase 3
DM1K78U SN Apricitabine; 160707-69-7; AVX754; AVX 754; UNII-K1YX059ML1; BCH 10618; (-)-dOTC; (-)-BCH 10652; K1YX059ML1; AVX-754; SPD-754; BCH-10618; 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one; 4-Amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]-2(1H)-pyrimidinone; BCH-10652; 2(1H)-Pyrimidinone, 4-amino-1-((2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-; 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl)-, (2R-cis)-; Apricitabine [INN]; SPD754; BCH-10619; SPD 754; AC1L9S1I; (+/-)dOTC
DM1K78U DT Small molecular drug
DM1K78U PC 455041
DM1K78U MW 229.26
DM1K78U FM C8H11N3O3S
DM1K78U IC InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m1/s1
DM1K78U CS C1[C@@H](S[C@@H](O1)CO)N2C=CC(=NC2=O)N
DM1K78U IK RYMCFYKJDVMSIR-RNFRBKRXSA-N
DM1K78U IU 4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2-one
DM1K78U CA CAS 160707-69-7
DM1K78U DE Human immunodeficiency virus infection
DM2YQK8 ID DM2YQK8
DM2YQK8 DN AR-301
DM2YQK8 HS Phase 3
DM2YQK8 CP Aridis Pharmaceuticals
DM2YQK8 DT Antibody
DM2YQK8 DE Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pneumonia
DMZB9RI ID DMZB9RI
DMZB9RI DN Arabaclofen
DMZB9RI HS Phase 3
DMZB9RI DT Small molecular drug
DMZB9RI DE Fragile X syndrome
DMO628K ID DMO628K
DMO628K DN Arbaclofen placarbil
DMO628K HS Phase 3
DMO628K SN AP; R-baclofen - XenoPort; XP-19986
DMO628K CP Genentech
DMO628K DT Small molecular drug
DMO628K PC 11281011
DMO628K MW 399.9
DMO628K FM C19H26ClNO6
DMO628K IC InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
DMO628K CS CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl
DMO628K IK JXTAALBWJQJLGN-KSSFIOAISA-N
DMO628K IU (3R)-3-(4-chlorophenyl)-4-[[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino]butanoic acid
DMO628K CA CAS 847353-30-4
DMO628K DE Fragile X syndrome; Alcohol dependence
DMYNJHI ID DMYNJHI
DMYNJHI DN Arc029
DMYNJHI HS Phase 3
DMYNJHI SN Nilvadipine; nilvadipine; 75530-68-6; Escor; Nivadil; Nivadipine; FR-34235; Nilvadipinum [Latin]; Nilvadipino [Spanish]; FR 34235; FK 235; Nilvadipine [USAN:INN:JAN]; Nilvadipine (ARC029); FK-235; F-102362; BRN 3572609; F 102,362; CL-287389; CL 287,389; FAIIFDPAEUKBEP-UHFFFAOYSA-N; C19H19N3O6; NCGC00167435-01; 5-Isopropyl 3-methyl 2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester; Nilvadipino; NILVADIPINE
DMYNJHI CP Archer Pharmaceuticals
DMYNJHI DT Small molecular drug
DMYNJHI PC 4494
DMYNJHI MW 385.4
DMYNJHI FM C19H19N3O6
DMYNJHI IC InChI=1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
DMYNJHI CS CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
DMYNJHI IK FAIIFDPAEUKBEP-UHFFFAOYSA-N
DMYNJHI IU 3-O-methyl 5-O-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMYNJHI CA CAS 75530-68-6
DMYNJHI CB CHEBI:31911
DMYNJHI DE Alzheimer disease
DM180DM ID DM180DM
DM180DM DN ARGX-113
DM180DM HS Phase 3
DM180DM CP Argenx
DM180DM DT Small molecular drug
DM180DM DE Myasthenia gravis
DM84AD1 ID DM84AD1
DM84AD1 DN Arofylline
DM84AD1 HS Phase 3
DM84AD1 SN Arofyllin; KM09088; Arofylline (USAN/INN); 3-(4-chlorophenyl)-1-propyl-3,7-dihydro-1H-purine-2,6-dione; 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione
DM84AD1 CP Almiral Prodesfarma
DM84AD1 DT Small molecular drug
DM84AD1 PC 166553
DM84AD1 MW 304.73
DM84AD1 FM C14H13ClN4O2
DM84AD1 IC InChI=1S/C14H13ClN4O2/c1-2-7-18-13(20)11-12(17-8-16-11)19(14(18)21)10-5-3-9(15)4-6-10/h3-6,8H,2,7H2,1H3,(H,16,17)
DM84AD1 CS CCCN1C(=O)C2=C(N=CN2)N(C1=O)C3=CC=C(C=C3)Cl
DM84AD1 IK GVTLDPJNRVMCAL-UHFFFAOYSA-N
DM84AD1 IU 3-(4-chlorophenyl)-1-propyl-7H-purine-2,6-dione
DM84AD1 CA CAS 136145-07-8
DM84AD1 DE Chronic obstructive pulmonary disease
DM02BVQ ID DM02BVQ
DM02BVQ DN ARQ-087
DM02BVQ HS Phase 3
DM02BVQ CP ArQule Inc
DM02BVQ PC 46834118
DM02BVQ MW 468.6
DM02BVQ FM C29H29FN4O
DM02BVQ IC InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
DM02BVQ CS COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
DM02BVQ IK KPJDVVCDVBFRMU-AREMUKBSSA-N
DM02BVQ IU (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
DM02BVQ CA CAS 1234356-69-4
DM02BVQ DE Solid tumour/cancer; Cholangiocarcinoma; Intrahepatic cholangiocarcinoma
DML61S4 ID DML61S4
DML61S4 DN ARQ-151
DML61S4 HS Phase 3
DML61S4 CP Arcutis Biotherapeutics
DML61S4 DT Small molecular drug
DML61S4 DE Plaque psoriasis; Psoriasis vulgaris; Atopic dermatitis
DMD7XWS ID DMD7XWS
DMD7XWS DN AS-013
DMD7XWS HS Phase 3
DMD7XWS SN Circulase; Ecraprost; Prostaglandin E1 (liposomal), Mitsubishi Pharma/Asahi Glass
DMD7XWS CP Taisho Pharmaceutical Co Ltd
DMD7XWS DT Small molecular drug
DMD7XWS PC 6917049
DMD7XWS MW 480.7
DMD7XWS FM C28H48O6
DMD7XWS IC InChI=1S/C28H48O6/c1-4-7-11-15-22(29)18-19-23-24(26(21-25(23)30)34-28(32)14-6-3)16-12-9-10-13-17-27(31)33-20-8-5-2/h18-19,22-23,25,29-30H,4-17,20-21H2,1-3H3/b19-18+/t22-,23+,25+/m0/s1
DMD7XWS CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O
DMD7XWS IK HITYEEHTEOQBAC-OSIGYOHNSA-N
DMD7XWS IU butyl 7-[(4R,5R)-2-butanoyloxy-4-hydroxy-5-[(E,3S)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate
DMD7XWS CA CAS 136892-64-3
DMD7XWS DE Thrombosis
DMIV1WR ID DMIV1WR
DMIV1WR DN AS-12141
DMIV1WR HS Phase 3
DMIV1WR SN D-GalNAc; GalNAc; N-Acetyl-D-Galactosamine; N-acetyl-galactosamine; N-Acetyl-Galactosamine; 14215-68-0; 2-Acetamido-2-Deoxy-D-Galactopyranose; 2-Acetamido-2-Deoxy-D-Galactopyranoside; 2-Acetamido-2-Deoxy-D-Galactose; 2-Acetamido-2-Deoxy-Galactopyranose; 2-Acetamido-2-Deoxy-Galactopyranoside; 2-Acetamido-2-Deoxy-Galactose; 2-Deoxy-2-Acetamido-D-Galactopyranose; 2-Deoxy-2-Acetamido-D-Galactopyranoside; 2-Deoxy-2-Acetamido-D-Galactose; 2-Deoxy-2-Acetamido-Galactopyranose; 2-Deoxy-2-Acetamido-Galactopyranoside; 2-Deoxy-2-Acetamido-Galactose
DMIV1WR PC 35717
DMIV1WR MW 221.21
DMIV1WR FM C8H15NO6
DMIV1WR IC OVRNDRQMDRJTHS-KEWYIRBNSA-N
DMIV1WR CS CC(=O)NC1C(C(C(OC1O)CO)O)O
DMIV1WR IK 1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8?/m1/s1
DMIV1WR IU N-[(3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMIV1WR CA CAS 1136-42-1
DMIV1WR CB CHEBI:28037
DMIV1WR DE Gaucher disease
DMK09D4 ID DMK09D4
DMK09D4 DN ASC09 + ritonavir
DMK09D4 HS Phase 3
DMK09D4 SN TMC-310911 + norvir; ASC09F
DMK09D4 TC Antiviral Agents
DMK09D4 DT Combination drug
DMK09D4 DE Coronavirus Disease 2019 (COVID-19)
DMWE3SC ID DMWE3SC
DMWE3SC DN ASC09 + ritonavir + oseltamivir
DMWE3SC HS Phase 3
DMWE3SC SN TMC-310911 + norvir + tamiflu
DMWE3SC TC Antiviral Agents
DMWE3SC DT Combination drug
DMWE3SC DE Coronavirus Disease 2019 (COVID-19)
DMND3AB ID DMND3AB
DMND3AB DN Asimadoline
DMND3AB HS Phase 3
DMND3AB SN Asimadoline [INN]; EMD 61753; N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
DMND3AB CP Merck
DMND3AB DT Small molecular drug
DMND3AB PC 179340
DMND3AB MW 414.5
DMND3AB FM C27H30N2O2
DMND3AB IC InChI=1S/C27H30N2O2/c1-28(25(21-11-5-2-6-12-21)20-29-18-17-24(30)19-29)27(31)26(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,24-26,30H,17-20H2,1H3/t24-,25+/m0/s1
DMND3AB CS CN([C@H](CN1CC[C@@H](C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMND3AB IK JHLHNYVMZCADTC-LOSJGSFVSA-N
DMND3AB IU N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
DMND3AB CA CAS 153205-46-0
DMND3AB DE Diarrhea-predominant irritable bowel syndrome; Pruritus
DMVA8KU ID DMVA8KU
DMVA8KU DN ASP0113
DMVA8KU HS Phase 3
DMVA8KU SN VCL-CB01
DMVA8KU CP Astellas
DMVA8KU DT Vaccine
DMVA8KU DE Cytomegalovirus infection
DMZ1UOI ID DMZ1UOI
DMZ1UOI DN Asp-015K
DMZ1UOI HS Phase 3
DMZ1UOI SN Peficitinib; ASP015K; UNII-HPH1166CKX; 944118-01-8; ASP-015K; HPH1166CKX; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; 4-[[(1S,3R)-5-oxidanyl-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; Peficitinib [USAN:INN]; ASP 015K; JNJ-54781532; 9T6; Peficitinib (USAN/INN); SCHEMBL1154421; SCHEMBL9990248; SCHEMBL4447032; GTPL8315; SCHEMBL9990240; SCHEMBL1154418; CHEMBL3137308; SCHEMBL17645135; BCP18465; BDBM50124208; SB16834; DB11708; SC-17960; ASP015K; JNJ-54781532; D10653; Peficitinib pound A
DMZ1UOI CP Astellas Pharma Inc
DMZ1UOI DT Small molecular drug
DMZ1UOI PC 57928403
DMZ1UOI MW 326.4
DMZ1UOI FM C18H22N4O2
DMZ1UOI IC InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14?,18?
DMZ1UOI CS C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O
DMZ1UOI IK DREIJXJRTLTGJC-JQCLMNFQSA-N
DMZ1UOI IU 4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
DMZ1UOI CA CAS 944118-01-8
DMZ1UOI DE Psoriasis vulgaris; Rheumatoid arthritis
DMR71ST ID DMR71ST
DMR71ST DN ASP1929
DMR71ST HS Phase 3
DMR71ST SN Cetuximab sarotalocan
DMR71ST CP Rakuten Medical
DMR71ST DT Antibody
DMR71ST DE Solid tumour/cancer; Head and neck cancer
DMGQ1TV ID DMGQ1TV
DMGQ1TV DN ASP1941
DMGQ1TV HS Phase 3
DMGQ1TV SN Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200
DMGQ1TV CP Astellas Pharma US
DMGQ1TV DT Small molecular drug
DMGQ1TV PC 10453870
DMGQ1TV MW 404.5
DMGQ1TV FM C21H21FO5S
DMGQ1TV IC InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
DMGQ1TV CS C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F
DMGQ1TV IK AHFWIQIYAXSLBA-RQXATKFSSA-N
DMGQ1TV IU (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMGQ1TV CA CAS 761423-87-4
DMGQ1TV CB CHEBI:134724
DMGQ1TV DE Liver disease
DM5N1OB ID DM5N1OB
DM5N1OB DN Asp-2151
DM5N1OB HS Phase 3
DM5N1OB SN Helicase-primase inhibitor (herpes infection), Astellas
DM5N1OB CP Astellas Pharma Inc
DM5N1OB DT Small molecular drug
DM5N1OB PC 11397521
DM5N1OB MW 482.6
DM5N1OB FM C24H26N4O5S
DM5N1OB IC InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
DM5N1OB CS CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4
DM5N1OB IK MNHNIVNAFBSLLX-UHFFFAOYSA-N
DM5N1OB IU N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
DM5N1OB CA CAS 841301-32-4
DM5N1OB DE Herpes simplex virus infection
DMLY0H5 ID DMLY0H5
DMLY0H5 DN Astuprotimut-R
DMLY0H5 HS Phase 3
DMLY0H5 CP GlaxoSmithKline
DMLY0H5 DE Non-small-cell lung cancer
DM4HK8Z ID DM4HK8Z
DM4HK8Z DN ASTX727
DM4HK8Z HS Phase 3
DM4HK8Z CP Astex Pharmaceuticals Pleasanton, CA
DM4HK8Z DE Chronic myelogenous leukaemia; Myelodysplastic syndrome
DMRV4DT ID DMRV4DT
DMRV4DT DN AT1001
DMRV4DT HS Phase 3
DMRV4DT SN Larazotide acetate; Larazotide acetate [USAN]; AT-1001; 881851-50-9; Larazotide acetate (USAN); UNII-FO8S2IW40N; AT 1001; FO8S2IW40N; CHEMBL2103815; NYGCNONRVCGHAT-UFIKZEAMSA-N; HY-106268A; CS-8047; D09352; Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine acetate; Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-, monoacetate
DMRV4DT DT Small molecular drug
DMRV4DT PC 44146842
DMRV4DT MW 785.9
DMRV4DT FM C34H59N9O12
DMRV4DT IC InChI=1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1
DMRV4DT CS CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN.CC(=O)O
DMRV4DT IK NYGCNONRVCGHAT-UFIKZEAMSA-N
DMRV4DT IU acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid
DMRV4DT CA CAS 881851-50-9
DMRV4DT DE Autoimmune diabetes
DMVJW0S ID DMVJW0S
DMVJW0S DN AT-406
DMVJW0S HS Phase 3
DMVJW0S SN 1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143
DMVJW0S CP Ascenta Therapeutics; Debiopharm
DMVJW0S DT Small molecular drug
DMVJW0S PC 25022340
DMVJW0S MW 561.7
DMVJW0S FM C32H43N5O4
DMVJW0S IC InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1
DMVJW0S CS C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC
DMVJW0S IK LSXUTRRVVSPWDZ-MKKUMYSQSA-N
DMVJW0S IU (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMVJW0S CA CAS 1071992-99-8
DMVJW0S DE Acute myeloid leukaemia; Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom
DMQ94CT ID DMQ94CT
DMQ94CT DN AT9283
DMQ94CT HS Phase 3
DMQ94CT CP Astex Therape.
DMQ94CT TC Anticancer Agents
DMQ94CT DT Small molecular drug
DMQ94CT PC 135398495
DMQ94CT MW 381.4
DMQ94CT FM C19H23N7O2
DMQ94CT IC InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)
DMQ94CT CS C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5
DMQ94CT IK LOLPPWBBNUVNQZ-UHFFFAOYSA-N
DMQ94CT IU 1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea
DMQ94CT CA CAS 896466-04-9
DMQ94CT CB CHEBI:125514
DMQ94CT DE Solid tumour/cancer
DM8GFEV ID DM8GFEV
DM8GFEV DN Atacicept
DM8GFEV HS Phase 3
DM8GFEV CP ZymoGenetics; Serono
DM8GFEV DE Multiple sclerosis; Rheumatoid arthritis; Lymphoma; Systemic lupus erythematosus; Lupus
DM4GXW3 ID DM4GXW3
DM4GXW3 DN Ataluren
DM4GXW3 HS Phase 3
DM4GXW3 SN Ataluren; 775304-57-9; PTC124; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; PTC124 (Ataluren); PTC 124; UNII-K16AME9I3V; Ataluren (PTC124); K16AME9I3V; NCGC00168759-02; Translarna; AK-31904; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DSSTox_CID_26776; DSSTox_RID_81895; DSSTox_GSID_46776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; CAS-775304-57-9; Ataluren [USAN:INN]; Translarna (TN); PTC124,Ataluren; Ataluren(ptc124)
DM4GXW3 CP Genzyme; PTC Therapeutics
DM4GXW3 DT Small molecular drug
DM4GXW3 PC 11219835
DM4GXW3 MW 284.24
DM4GXW3 FM C15H9FN2O3
DM4GXW3 IC InChI=1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)
DM4GXW3 CS C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F
DM4GXW3 IK OOUGLTULBSNHNF-UHFFFAOYSA-N
DM4GXW3 IU 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
DM4GXW3 CA CAS 775304-57-9
DM4GXW3 CB CHEBI:94805
DM4GXW3 DE Aniridia; Cystic fibrosis; Mucopolysaccharidosis; Dravet syndrome; Duchenne dystrophy; Muscular dystrophy
DM3QLK2 ID DM3QLK2
DM3QLK2 DN Atamestane + Toremifene
DM3QLK2 HS Phase 3
DM3QLK2 SN Atamestane-plus-toremifene
DM3QLK2 CP Intarcia Therapeutics
DM3QLK2 DE Breast cancer
DM4VJ5Q ID DM4VJ5Q
DM4VJ5Q DN ATG-Fresenius S
DM4VJ5Q HS Phase 3
DM4VJ5Q CP Enzon
DM4VJ5Q DT Antibody
DM4VJ5Q DE Transplant rejection
DMBR0QK ID DMBR0QK
DMBR0QK DN Atorvastatin
DMBR0QK HS Phase 3
DMBR0QK SN atorvastatin; 134523-00-5; Cardyl; Xavator; Tozalip; Lipitor; Torvast; Sotis; ATORVASTATIN CALCIUM; Atorvastatin [INN:BAN]; 110862-48-1; UNII-A0JWA85V8F; CCRIS 7159; C33H35FN2O5; HSDB 7039; CI 981; Lipitor (TN); CHEMBL1487; A0JWA85V8F; CHEBI:39548; (betaR,deltaR)-2-(p-Fluorophenyl)-b; Atorvastatin
DMBR0QK TC Antiviral Agents
DMBR0QK DT Small molecular drug
DMBR0QK PC 60823
DMBR0QK MW 558.6
DMBR0QK FM C33H35FN2O5
DMBR0QK IC InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
DMBR0QK CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMBR0QK IK XUKUURHRXDUEBC-KAYWLYCHSA-N
DMBR0QK IU (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
DMBR0QK CA CAS 134523-00-5
DMBR0QK CB CHEBI:39548
DMBR0QK DE Coronavirus Disease 2019 (COVID-19)
DMM74PK ID DMM74PK
DMM74PK DN Atrasentan
DMM74PK HS Phase 3
DMM74PK SN Xinlay; Atrasentan [INN]; A 127722; A 147627; ABT 627; A-127722; A-147627; ABT-627; Xinlay (TN); A-127722.5; (+)-A 127722; (+)-A-127722; (11C)ABT-627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid
DMM74PK CP Abbott
DMM74PK DT Small molecular drug
DMM74PK PC 159594
DMM74PK MW 510.6
DMM74PK FM C29H38N2O6
DMM74PK IC InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
DMM74PK CS CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4
DMM74PK IK MOTJMGVDPWRKOC-QPVYNBJUSA-N
DMM74PK IU (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
DMM74PK CA CAS 173937-91-2
DMM74PK CB CHEBI:135810
DMM74PK DE Prostate cancer; Diabetic nephropathy
DM64WYC ID DM64WYC
DM64WYC DN Atx-101
DM64WYC HS Phase 3
DM64WYC SN ATX-101, APIM Therapeutics; Proliferating cell nuclear antigen (peptide, cancer), APIM
DM64WYC CP Bayer HealthCare Pharmaceuticals
DM64WYC PC 222528
DM64WYC MW 392.6
DM64WYC FM C24H40O4
DM64WYC IC InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1
DM64WYC CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DM64WYC IK KXGVEGMKQFWNSR-LLQZFEROSA-N
DM64WYC IU (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM64WYC CA CAS 83-44-3
DM64WYC CB CHEBI:28834
DM64WYC DE Obesity
DM0EQ9X ID DM0EQ9X
DM0EQ9X DN Av 133
DM0EQ9X HS Phase 3
DM0EQ9X CP Avid Radiopharmaceuticals
DM0EQ9X DE Alzheimer disease
DMPW5UF ID DMPW5UF
DMPW5UF DN Avalglucosidase alfa
DMPW5UF HS Phase 3
DMPW5UF CP Sanofi
DMPW5UF DT Recombinant protein
DMPW5UF DE Pompe disease
DMA86FL ID DMA86FL
DMA86FL DN Avastin+/-Tarceva
DMA86FL HS Phase 3
DMA86FL SN Juglone; juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS; JUGLONE
DMA86FL CP Genentech
DMA86FL DT Small molecular drug
DMA86FL PC 3806
DMA86FL MW 174.15
DMA86FL FM C10H6O3
DMA86FL IC InChI=1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H
DMA86FL CS C1=CC2=C(C(=O)C=CC2=O)C(=C1)O
DMA86FL IK KQPYUDDGWXQXHS-UHFFFAOYSA-N
DMA86FL IU 5-hydroxynaphthalene-1,4-dione
DMA86FL CA CAS 481-39-0
DMA86FL CB CHEBI:15794
DMA86FL DE Non-small-cell lung cancer; Nasopharyngeal carcinoma
DMRJK3U ID DMRJK3U
DMRJK3U DN Avotermin
DMRJK3U HS Phase 3
DMRJK3U SN Juvista; RN-1001; SPD-538; TGF3, Renovo; RN-1, Renovo
DMRJK3U CP Renovo, UK (Shire, UK)
DMRJK3U DE Sarcoidosis
DMV1SOR ID DMV1SOR
DMV1SOR DN AVP-786
DMV1SOR HS Phase 3
DMV1SOR CP Avanir pharmaceuticals
DMV1SOR PC 25052519
DMV1SOR MW 277.4
DMV1SOR FM C18H25NO
DMV1SOR IC InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1/i1D3,2D3
DMV1SOR CS [2H]C([2H])([2H])N1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC([2H])([2H])[2H]
DMV1SOR IK MKXZASYAUGDDCJ-QNNIAVNKSA-N
DMV1SOR IU (1S,9S,10S)-4-(trideuteriomethoxy)-17-(trideuteriomethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMV1SOR CA CAS 1079043-55-2
DMV1SOR DE Pain; Alzheimer disease; Neurobehavioral disorder; Schizophrenia
DM6WZG8 ID DM6WZG8
DM6WZG8 DN AXS-05
DM6WZG8 HS Phase 3
DM6WZG8 CP Axsome Therapeutics
DM6WZG8 DT Small molecular drug
DM6WZG8 DE Alzheimer disease; Depression
DMM6G5D ID DMM6G5D
DMM6G5D DN AZD0914
DMM6G5D HS Phase 3
DMM6G5D SN Zoliflodacin
DMM6G5D CP Astrazeneca
DMM6G5D PC 76685216
DMM6G5D MW 487.4
DMM6G5D FM C22H22FN5O7
DMM6G5D IC InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
DMM6G5D CS C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
DMM6G5D IK ZSWMIFNWDQEXDT-ZESJGQACSA-N
DMM6G5D IU (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
DMM6G5D CA CAS 1620458-09-4
DMM6G5D DE Bacterial infection; Neisseria gonorrhoeae infection
DM9SKW8 ID DM9SKW8
DM9SKW8 DN AZD5363
DM9SKW8 HS Phase 3
DM9SKW8 SN AZD5363; 1143532-39-1; AZD-5363; capivasertib; AZD 5363; UNII-WFR23M21IE; WFR23M21IE; cc-638; 4-Amino-N-[(1s)-1-(4-Chlorophenyl)-3-Hydroxypropyl]-1-(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)piperidine-4-Carboxamide; C21H25ClN6O2; (S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide; 4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1
DM9SKW8 CP Astex Pharmaceuticals
DM9SKW8 DT Small molecular drug
DM9SKW8 PC 25227436
DM9SKW8 MW 428.9
DM9SKW8 FM C21H25ClN6O2
DM9SKW8 IC InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
DM9SKW8 CS C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4
DM9SKW8 IK JDUBGYFRJFOXQC-KRWDZBQOSA-N
DM9SKW8 IU 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
DM9SKW8 CA CAS 1143532-39-1
DM9SKW8 DE Solid tumour/cancer; Triple negative breast cancer
DMLY9F1 ID DMLY9F1
DMLY9F1 DN Azetirelin
DMLY9F1 HS Phase 3
DMLY9F1 SN Azetirelin; YM-14673 (dihydrate); Nalpha-[(S)-2-Azetidinone-4-carbonyl]-L-histidyl-L-prolinamide
DMLY9F1 DT Small molecular drug
DMLY9F1 PC 65841
DMLY9F1 MW 348.36
DMLY9F1 FM C15H20N6O4
DMLY9F1 IC InChI=1S/C15H20N6O4/c16-13(23)11-2-1-3-21(11)15(25)10(4-8-6-17-7-18-8)20-14(24)9-5-12(22)19-9/h6-7,9-11H,1-5H2,(H2,16,23)(H,17,18)(H,19,22)(H,20,24)/t9-,10-,11-/m0/s1
DMLY9F1 CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CC(=O)N3)C(=O)N
DMLY9F1 IK WBGUMUGCONUXFK-DCAQKATOSA-N
DMLY9F1 IU (2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-4-oxoazetidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carboxamide
DMLY9F1 CA CAS 95729-65-0
DMLY9F1 DE Pain
DMUIBV8 ID DMUIBV8
DMUIBV8 DN Azimilide
DMUIBV8 HS Phase 3
DMUIBV8 SN Azimilide [INN:BAN]; 1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
DMUIBV8 CP Procter & Gamble
DMUIBV8 DT Small molecular drug
DMUIBV8 PC 9571004
DMUIBV8 MW 458
DMUIBV8 FM C23H28ClN5O3
DMUIBV8 IC InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+
DMUIBV8 CS CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)/N=C/C3=CC=C(O3)C4=CC=C(C=C4)Cl
DMUIBV8 IK MREBEPTUUMTTIA-PCLIKHOPSA-N
DMUIBV8 IU 1-[(E)-[5-(4-chlorophenyl)furan-2-yl]methylideneamino]-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione
DMUIBV8 CA CAS 149908-53-2
DMUIBV8 CB CHEBI:34545
DMUIBV8 DE Atrial fibrillation
DM5Y4Q2 ID DM5Y4Q2
DM5Y4Q2 DN Azithromycin + hydroxychloroquine
DM5Y4Q2 HS Phase 3
DM5Y4Q2 SN Zithromax + oxichloroquine
DM5Y4Q2 TC Antiviral Agents
DM5Y4Q2 DT Combination drug
DM5Y4Q2 DE Coronavirus Disease 2019 (COVID-19)
DMPV6B2 ID DMPV6B2
DMPV6B2 DN BA-058
DMPV6B2 HS Phase 3
DMPV6B2 SN BA-058 Microneedle Patch; BA-058 (transdermal microneedle patch, osteoporosis); BA-058 (transdermal microneedle patch, osteoporosis), Radius Health
DMPV6B2 CP Radius Health Inc
DMPV6B2 DE Osteoporosis
DMXBHR6 ID DMXBHR6
DMXBHR6 DN Balaglitazone
DMXBHR6 HS Phase 3
DMXBHR6 SN DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
DMXBHR6 CP Dr Reddy's Research Foundation
DMXBHR6 DT Small molecular drug
DMXBHR6 PC 9889200
DMXBHR6 MW 395.4
DMXBHR6 FM C20H17N3O4S
DMXBHR6 IC InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)
DMXBHR6 CS CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMXBHR6 IK IETKPTYAGKZLKY-UHFFFAOYSA-N
DMXBHR6 IU 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMXBHR6 CA CAS 199113-98-9
DMXBHR6 DE Type-1 diabetes
DMUOFAC ID DMUOFAC
DMUOFAC DN Balixafortide
DMUOFAC HS Phase 3
DMUOFAC SN 1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide
DMUOFAC CP Polyphor
DMUOFAC DT Peptide
DMUOFAC PC 91864511
DMUOFAC MW 1782
DMUOFAC FM C80H112N22O21S2
DMUOFAC IC InChI=1S/C80H112N22O21S2/c1-42(82)65(108)98-59-39-124-125-40-60(99-70(113)55(34-45-16-22-49(105)23-17-45)93-66(109)51(10-5-29-87-80(84)85)91-74(117)61-11-6-30-100(61)76(119)43(2)89-71(114)58(38-103)97-73(59)116)72(115)94-54(33-44-14-20-48(104)21-15-44)68(111)90-52(26-27-64(83)107)67(110)92-53(9-3-4-28-81)77(120)102-32-8-13-63(102)78(121)101-31-7-12-62(101)75(118)95-56(35-46-18-24-50(106)25-19-46)69(112)96-57(79(122)123)36-47-37-86-41-88-47/h14-25,37,41-43,51-63,103-106H,3-13,26-36,38-40,81-82H2,1-2H3,(H2,83,107)(H,86,88)(H,89,114)(H,90,111)(H,91,117)(H,92,110)(H,93,109)(H,94,115)(H,95,118)(H,96,112)(H,97,116)(H,98,108)(H,99,113)(H,122,123)(H4,84,85,87)/t42-,43-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m0/s1
DMUOFAC CS C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC=N7)C(=O)O)CC8=CC=C(C=C8)O)CCCNC(=N)N
DMUOFAC IK UUTLJGUXRVWOSI-YYXAXUJHSA-N
DMUOFAC IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(3S,6S,9R,14R,17S,20S,23S)-9-[[(2S)-2-aminopropanoyl]amino]-20-(3-carbamimidamidopropyl)-6-(hydroxymethyl)-17-[(4-hydroxyphenyl)methyl]-3-methyl-2,5,8,16,19,22-hexaoxo-11,12-dithia-1,4,7,15,18,21-hexazabicyclo[21.3.0]hexacosane-14-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid
DMUOFAC DE Metastatic breast cancer
DMKMTDG ID DMKMTDG
DMKMTDG DN Balovaptan
DMKMTDG HS Phase 3
DMKMTDG SN 1228088-30-9; UNII-RAX5D5AGV6; RG7314; RAX5D5AGV6; RO5285119; 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-5-methyl-1-{trans-4-[(pyridin-2-yl)oxy]cyclohexyl}-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Balovaptan [INN]; Balovaptan [USAN]; Balovaptan (USAN/INN); Balovaptan [USAN:INN]; SCHEMBL2471320; SCHEMBL3329710; SCHEMBL3332136; CHEMBL4297183; GTPL10615; compound 1 [PMID: 31951127]; DB14823; RG-7314; SB19643; Ro-5285119; BS-14780; HY-109024; CS-0030526; D11476; 12-chloro-8-methyl-3-[(1r,4r)-4-(pyridin-2-yloxy)cyclohexyl]-2,4,5,8-tetraazatricyclo[8.4.0.0,tetradeca-1(10),3,5,11,13-pentaene; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-; 8-Chloro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-5,6-dihydro-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine
DMKMTDG CP Genentech
DMKMTDG DT Small molecular drug
DMKMTDG PC 46200932
DMKMTDG MW 409.9
DMKMTDG FM C22H24ClN5O
DMKMTDG IC InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3
DMKMTDG CS CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCC(CC4)OC5=CC=CC=N5)C1
DMKMTDG IK GMPZPHGHNDMRKL-UHFFFAOYSA-N
DMKMTDG IU 8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
DMKMTDG CA CAS 1228088-30-9
DMKMTDG DE Autism spectrum disorder
DMHQ5GK ID DMHQ5GK
DMHQ5GK DN Bapineuzumab
DMHQ5GK HS Phase 3
DMHQ5GK SN AAB-001; Monoclonal antibody (Alzheimer's disease), Elan/Pfizer; Monoclonal antibody (Alzheimer's disease), Elan/Wyeth; Monoclonal antibody (Alzheimer's disease), Wyeth/Elan
DMHQ5GK CP Elan Corp plc
DMHQ5GK DT Antibody
DMHQ5GK DE Alzheimer disease
DMODA2X ID DMODA2X
DMODA2X DN Bardoxolone methyl
DMODA2X HS Phase 3
DMODA2X SN BARD; WPTTVJLTNAWYAO-OYWPANLISA-N; 218600-53-4
DMODA2X CP Reata Pharmaceuticals Irving, TX
DMODA2X DT Small molecular drug
DMODA2X PC 400769
DMODA2X MW 505.7
DMODA2X FM C32H43NO4
DMODA2X IC InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1
DMODA2X CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC
DMODA2X IK WPTTVJLTNAWYAO-KPOXMGGZSA-N
DMODA2X IU methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate
DMODA2X CA CAS 218600-53-4
DMODA2X DE Mixed connective tissue disease; Pulmonary arterial hypertension; Pulmonary hypertension
DMPRI14 ID DMPRI14
DMPRI14 DN Baricitinib
DMPRI14 HS Phase 3
DMPRI14 SN Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
DMPRI14 CP Incyte/Eli Lilly
DMPRI14 TC Antiviral Agents
DMPRI14 DT Small molecular drug
DMPRI14 PC 44205240
DMPRI14 MW 371.4
DMPRI14 FM C16H17N7O2S
DMPRI14 IC InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
DMPRI14 CS CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DMPRI14 IK XUZMWHLSFXCVMG-UHFFFAOYSA-N
DMPRI14 IU 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DMPRI14 CA CAS 1187594-09-7
DMPRI14 CB CHEBI:95341
DMPRI14 DE Asthma; Atopic dermatitis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus; Coronavirus Disease 2019 (COVID-19)
DMB147A ID DMB147A
DMB147A DN BAX-817
DMB147A HS Phase 3
DMB147A CP Baxter International Inc
DMB147A DE Hemophilia
DM407I6 ID DM407I6
DM407I6 DN BAY 853934
DM407I6 HS Phase 3
DM407I6 SN Molidustat; 1154028-82-6; BAY 85-3934; Molidustat (BAY85-3934); BAY85-3934; UNII-9JH486CZ13; Molidustat(BAY 85-3934); 9JH486CZ13; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one; 3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-; 2-(6-Morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one; 2-[6-(4-Morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol; 2-(6-Morpholin-4-Ylpyrimidin-4-Yl)-4-(1,2,3-Triazol-1-Yl)-1~{h}-Pyrazol-3-One; Molidustat [INN]; Molidustat(BAY85-3934); Molidustat (BAY 85-3934); QEQ; GTPL8456; SCHEMBL2569970; SCHEMBL6114312; CHEMBL3646118; CHEMBL3991036; DTXSID80151089; EX-A562; BDBM118339; AOB87194; BCP14477; MFCD28411428; AKOS026750584; ZINC167006010; BAY-853934; CCG-267626; SB17156; NCGC00388364-04; AK323698; AS-74456; HY-12654; QC-11791; DB-092822; B5861; S8138; A14404; BAY 85-3934;BAY-85-3934; US8653111, 72; Q27087553; OC1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1; 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol; Molidustat;BAY 85-3934;BAY-85-3934; BAY 853934; BAY-853934; BAY853934; 2-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one; A1H
DM407I6 CP Bayer
DM407I6 DT Small molecular drug
DM407I6 PC 59603622
DM407I6 MW 314.3
DM407I6 FM C13H14N8O2
DM407I6 IC InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2
DM407I6 CS C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4
DM407I6 IK IJMBOKOTALXLKS-UHFFFAOYSA-N
DM407I6 IU 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one
DM407I6 CA CAS 1154028-82-6
DM407I6 DE Anaemia
DMPW5SB ID DMPW5SB
DMPW5SB DN Bay 86-9766
DMPW5SB HS Phase 3
DMPW5SB SN 923032-37-5; RDEA119; BAY 869766; RDEA 119; UNII-JPX07AFM0N; RDEA-119; Refametinib (RDEA119, Bay 86-9766); JPX07AFM0N; (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide; Refametinib [INN]; 923032-38-6; BAY-869766; BAY 8697661; 3e8n; Refametinib R enantiomer; Refametinib (RDEA119); SCHEMBL345333
DMPW5SB CP Ardea Biosciences
DMPW5SB DT Small molecular drug
DMPW5SB PC 44182295
DMPW5SB MW 572.3
DMPW5SB FM C19H20F3IN2O5S
DMPW5SB IC InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1
DMPW5SB CS COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F
DMPW5SB IK RDSACQWTXKSHJT-NSHDSACASA-N
DMPW5SB IU N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
DMPW5SB CA CAS 923032-37-5
DMPW5SB DE Solid tumour/cancer
DM09M3H ID DM09M3H
DM09M3H DN BAY 94-9027
DM09M3H HS Phase 3
DM09M3H SN Peg rFVIII
DM09M3H CP Bayer HealthCare Pharmaceuticals
DM09M3H DE Stroke; Hemophilia
DMWYPZF ID DMWYPZF
DMWYPZF DN BAY-35-3377
DMWYPZF HS Phase 3
DMWYPZF SN BY-377; Gastroquinolone antibacterial, Altana; Gastroquinolone antibacterial, Bayer; Quinolone antibacterials, Bayer
DMWYPZF CP Bayer AG
DMWYPZF DT Small molecular drug
DMWYPZF PC 11662028
DMWYPZF MW 434.8
DMWYPZF FM C20H20ClFN4O4
DMWYPZF IC InChI=1S/C20H19FN4O4.ClH/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15;/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28);1H/t15-,16-;/m0./s1
DMWYPZF CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O.Cl
DMWYPZF IK CQMSQUOHWYYEKM-MOGJOVFKSA-N
DMWYPZF IU 7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride
DMWYPZF CA CAS 209342-41-6
DMWYPZF DE Otitis media
DMQG7ZM ID DMQG7ZM
DMQG7ZM DN Belagenpumatucel-L
DMQG7ZM HS Phase 3
DMQG7ZM SN Lucanix (TN)
DMQG7ZM CP NovaRx
DMQG7ZM DT Vaccine
DMQG7ZM DE Small-cell lung cancer; Non-small-cell lung cancer
DM71CK8 ID DM71CK8
DM71CK8 DN Beloranib
DM71CK8 HS Phase 3
DM71CK8 SN 251111-30-5; CKD-732; UNII-FI471K8BU6; ZGN-433; FI471K8BU6; O-(4-(2-Dimethylaminoethoxy)-trans-cinnamoyl)fumagillol; Beloranib [INN]; ZGN 433; AC1OCFID; ZGN-440(Beloranib); US9682965, Compound A; GTPL8445; SCHEMBL14648763; DTXSID40179800; BDBM148430; ZINC3982162; AKOS027326543; DB12671; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(25)octan-6-yl (2E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate; O-(4-Dimethylaminoethoxycinnamoyl)fumagillol; CKD-731; Fumagillin analogs, Chong Kun Dang; HRK-429; HRK-512
DM71CK8 CP Zafgen
DM71CK8 DT Small molecular drug
DM71CK8 PC 6918502
DM71CK8 MW 499.6
DM71CK8 FM C29H41NO6
DM71CK8 IC InChI=1S/C29H41NO6/c1-20(2)7-13-24-28(3,36-24)27-26(32-6)23(15-16-29(27)19-34-29)35-25(31)14-10-21-8-11-22(12-9-21)33-18-17-30(4)5/h7-12,14,23-24,26-27H,13,15-19H2,1-6H3/b14-10+/t23-,24-,26-,27-,28+,29+/m1/s1
DM71CK8 CS CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C4=CC=C(C=C4)OCCN(C)C)OC)C
DM71CK8 IK ZEZFKUBILQRZCK-MJSCXXSSSA-N
DM71CK8 IU [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate
DM71CK8 CA CAS 251111-30-5
DM71CK8 DE Obesity; Solid tumour/cancer
DMLU8NX ID DMLU8NX
DMLU8NX DN Benserazide
DMLU8NX HS Phase 3
DMLU8NX SN benserazide; Serazide; 322-35-0; Benseraszide; Benserazida; Benserazidum; Ro 4-4602; Ro 44602; DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide; Benserazidum [INN-Latin]; Benserazida [INN-Spanish]; Benserazide [USAN:INN:BAN]; DL-Seryltrihydroxybenzylhydrazine; C10H15N3O5; BRN 3984490; DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; CHEBI:64187; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, DL-; DL-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide
DMLU8NX DT Small molecular drug
DMLU8NX PC 2327
DMLU8NX MW 257.24
DMLU8NX FM C10H15N3O5
DMLU8NX IC InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)
DMLU8NX CS C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O
DMLU8NX IK BNQDCRGUHNALGH-UHFFFAOYSA-N
DMLU8NX IU 2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
DMLU8NX CA CAS 322-35-0
DMLU8NX CB CHEBI:64187
DMS9503 ID DMS9503
DMS9503 DN Benzylpenicillin
DMS9503 HS Phase 3
DMS9503 SN penicillin g; Benzylpenicillinic acid; Free penicillin II; Pencillin G; 61-33-6; Benzylpenicillin G; Bencilpenicilina; Benzylpenicillinum; Benzyl penicillin; Free penicillin G; Dropcillin; Pharmacillin; Gelacillin; Liquacillin; Benzopenicillin; Cilopen; Pradupen; Benzylpenicilline; Specilline G; Cilloral; Cosmopen; Ursopen; Galofak; Free benzylpenicillin; Compocillin G; Phenylacetamidopenicillanic acid; 6-(2-Phenylacetamido)penicillanic acid; Pfizerpen; Benzyl-6-aminopenicillinic acid
DMS9503 DT Small molecular drug
DMS9503 PC 5904
DMS9503 MW 334.4
DMS9503 FM C16H18N2O4S
DMS9503 IC InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1
DMS9503 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
DMS9503 IK JGSARLDLIJGVTE-MBNYWOFBSA-N
DMS9503 IU (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMS9503 CA CAS 61-33-6
DMS9503 CB CHEBI:18208
DM6RWBN ID DM6RWBN
DM6RWBN DN Beperminogene perplasmid
DM6RWBN HS Phase 3
DM6RWBN CP AnGes; Daiichi
DM6RWBN DE Heart disease; Critical limb ischemia
DMLVNTA ID DMLVNTA
DMLVNTA DN Besipirdine
DMLVNTA HS Phase 3
DMLVNTA SN Besipirdine hydrochloride; HP-749; P86-7480
DMLVNTA CP Hoechst Marion Roussel Inc
DMLVNTA DT Small molecular drug
DMLVNTA PC 60691
DMLVNTA MW 251.33
DMLVNTA FM C16H17N3
DMLVNTA IC InChI=1S/C16H17N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h3-11,13H,2,12H2,1H3
DMLVNTA CS CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMLVNTA IK OTPPJICEBWOCKD-UHFFFAOYSA-N
DMLVNTA IU N-propyl-N-pyridin-4-ylindol-1-amine
DMLVNTA CA CAS 119257-34-0
DMLVNTA DE Cognitive impairment
DM0MI81 ID DM0MI81
DM0MI81 DN Bevacizumab + Erlotinib
DM0MI81 HS Phase 3
DM0MI81 CP Roche
DM0MI81 DE Metastatic colorectal cancer; Non-small-cell lung cancer; Hypopharyngeal squamous cell carcinoma; Hepatocellular carcinoma
DM9EXGI ID DM9EXGI
DM9EXGI DN Bevacizumab + Rituximab
DM9EXGI HS Phase 3
DM9EXGI CP Roche
DM9EXGI DT Combination drug (Antibody)
DM9EXGI PC 24801580
DM9EXGI MW 396.2
DM9EXGI FM C14H18ILiN2O3
DM9EXGI IC InChI=1S/C14H19IN2O3.Li/c1-3-17(4-2)8-7-16-13(18)10-5-6-11(14(19)20)12(15)9-10;/h5-6,9H,3-4,7-8H2,1-2H3,(H,16,18)(H,19,20);/q;+1/p-1
DM9EXGI CS [Li+].CCN(CC)CCNC(=O)C1=CC(=C(C=C1)C(=O)[O-])I
DM9EXGI IK CNMYRBKJCDLCHB-UHFFFAOYSA-M
DM9EXGI IU lithium;4-[2-(diethylamino)ethylcarbamoyl]-2-iodobenzoate
DM9EXGI DE Non-hodgkin lymphoma; Lymphoma
DM9CEI5 ID DM9CEI5
DM9CEI5 DN Bevacizumab + Trastuzumab
DM9CEI5 HS Phase 3
DM9CEI5 SN Lithocholic acid; LITHOCHOLIC ACID; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,
DM9CEI5 CP Roche
DM9CEI5 DT Combination drug (Antibody)
DM9CEI5 PC 9903
DM9CEI5 MW 376.6
DM9CEI5 FM C24H40O3
DM9CEI5 IC InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
DM9CEI5 CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C
DM9CEI5 IK SMEROWZSTRWXGI-HVATVPOCSA-N
DM9CEI5 IU (4R)-4-[(3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM9CEI5 CA CAS 434-13-9
DM9CEI5 DE Breast cancer
DMK56G0 ID DMK56G0
DMK56G0 DN Bexagliflozin
DMK56G0 HS Phase 3
DMK56G0 SN UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo
DMK56G0 CP Theracos Marlborough, MA
DMK56G0 PC 25195624
DMK56G0 MW 464.9
DMK56G0 FM C24H29ClO7
DMK56G0 IC InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1
DMK56G0 CS C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
DMK56G0 IK BTCRKOKVYTVOLU-SJSRKZJXSA-N
DMK56G0 IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DMK56G0 CA CAS 1118567-05-7
DMK56G0 DE Type-2 diabetes
DM7NJYC ID DM7NJYC
DM7NJYC DN BGB-A317
DM7NJYC HS Phase 3
DM7NJYC CP BeiGene Cambridge, MA
DM7NJYC DE Hepatocellular carcinoma; Solid tumour/cancer; Squamous cell carcinoma
DMNKBEC ID DMNKBEC
DMNKBEC DN BGJ398
DMNKBEC HS Phase 3
DMNKBEC SN Infigratinib
DMNKBEC DT Small molecular drug
DMNKBEC PC 53235510
DMNKBEC MW 560.5
DMNKBEC FM C26H31Cl2N7O3
DMNKBEC IC InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
DMNKBEC CS CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
DMNKBEC IK QADPYRIHXKWUSV-UHFFFAOYSA-N
DMNKBEC IU 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
DMNKBEC CA CAS 872511-34-7
DMNKBEC CB CHEBI:63451
DMNKBEC DE Solid tumour/cancer; Cholangiocarcinoma
DM3MXT8 ID DM3MXT8
DM3MXT8 DN BI 201335
DM3MXT8 HS Phase 3
DM3MXT8 SN Faldaprevir; BI-201335; UNII-958X4J301A; CHEMBL1241348; 958X4J301A; N-[(Cyclopentyloxy)carbonyl]-3-Methyl-L-Valyl-(4r)-4-[(8-Bromo-7-Methoxy-2-{2-[(2-Methylpropanoyl)amino]-1,3-Thiazol-4-Yl}quinolin-4-Yl)oxy]-N-[(1r,2s)-1-Carboxy-2-Ethenylcyclopropyl]-L-Prolinamide; BI 201335; 801283-95-4; BI201335; Faldaprevir [USAN:INN]; SCHEMBL222429; BDBM50336545; SB16712; DB11808
DM3MXT8 CP Boehringer Ingelheim Pharma
DM3MXT8 DT Small molecular drug
DM3MXT8 PC 42601552
DM3MXT8 MW 869.8
DM3MXT8 FM C40H49BrN6O9S
DM3MXT8 IC InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1
DM3MXT8 CS CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)O[C@@H]4C[C@H](N(C4)C(=O)[C@H](C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)O
DM3MXT8 IK LLGDPTDZOVKFDU-XUHJSTDZSA-N
DM3MXT8 IU (1R,2S)-1-[[(2S,4R)-4-[8-bromo-7-methoxy-2-[2-(2-methylpropanoylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-1-[(2S)-2-(cyclopentyloxycarbonylamino)-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-2-ethenylcyclopropane-1-carboxylic acid
DM3MXT8 CA CAS 801283-95-4
DM3MXT8 DE Hepatitis C virus infection
DMH3XDR ID DMH3XDR
DMH3XDR DN BI 425809
DMH3XDR HS Phase 3
DMH3XDR CP Boehringer Ingelheim
DMH3XDR DT Small molecular drug
DMH3XDR DE Schizophrenia
DMBH4FL ID DMBH4FL
DMBH4FL DN BI 655066
DMBH4FL HS Phase 3
DMBH4FL CP Boehringer ingelheim pharmaceuticals
DMBH4FL DT Antibody
DMBH4FL DE Ankylosing spondylitis; Chronic plaque psoriasis; Crohn disease; Psoriatic arthritis
DM42GP9 ID DM42GP9
DM42GP9 DN Bicifadine
DM42GP9 HS Phase 3
DM42GP9 SN BICIFADINE; 71195-57-8; 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane; 1-p-tolyl-3-azabicyclo[3.1.0]hexane; 5-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-; CL-220075; PubChem18323; AC1L2J2O; SCHEMBL38793; AZA001; CHEMBL511099; OFYVIGTWSQPCLF-UHFFFAOYSA-N; NIH-9542; MCV-4147; BDBM50417944; AKOS006271730; DOV-220075; AN-3206; DB04889; KB-13207; 5-(p-tolyl)-3-azabicyclo[3.1.0]hexane; AM20041063; FT-0718156; 1-(p-tolyl)-3-azabicyclo[3.1.0]-hexane
DM42GP9 CP Dov Pharmaceutical
DM42GP9 TC Analgesics
DM42GP9 DT Small molecular drug
DM42GP9 PC 47953
DM42GP9 MW 173.25
DM42GP9 FM C12H15N
DM42GP9 IC InChI=1S/C12H15N/c1-9-2-4-10(5-3-9)12-6-11(12)7-13-8-12/h2-5,11,13H,6-8H2,1H3
DM42GP9 CS CC1=CC=C(C=C1)C23CC2CNC3
DM42GP9 IK OFYVIGTWSQPCLF-UHFFFAOYSA-N
DM42GP9 IU 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane
DM42GP9 CA CAS 71195-57-8
DM42GP9 DE Neuropathic pain; Chronic low back pain
DM57B9J ID DM57B9J
DM57B9J DN Biferonex
DM57B9J HS Phase 3
DM57B9J SN Beneferon; Beneserin; Interferon beta 1a, BioPartners; Interferon beta 1a, Rentschler/Berlex/Schering; Beta-interferon (1a), Schering/Dr Rentschler
DM57B9J CP Dr Rentschler Biotechnologie GmbH
DM57B9J DE Multiple sclerosis
DM51JW4 ID DM51JW4
DM51JW4 DN BIIB037
DM51JW4 HS Phase 3
DM51JW4 CP Biogen Idec
DM51JW4 DE Alzheimer disease
DM0AEDT ID DM0AEDT
DM0AEDT DN BIIB067
DM0AEDT HS Phase 3
DM0AEDT SN IONIS-SOD1RX; Tofersen
DM0AEDT CP Ionis Pharmaceuticals
DM0AEDT DT Antisense oligonucleotide
DM0AEDT DE Amyotrophic lateral sclerosis
DMR9TF1 ID DMR9TF1
DMR9TF1 DN Bimekizumab
DMR9TF1 HS Phase 3
DMR9TF1 CP UCB Atlanta, GA
DMR9TF1 DE Psoriatic arthritis; Plaque psoriasis
DMS2GA1 ID DMS2GA1
DMS2GA1 DN Bindarit
DMS2GA1 HS Phase 3
DMS2GA1 SN Bindarit, Angelini Pharmaceuticals; CCL2 inhibitor (inflammatory disorders/kidney disease), Angelini Pharmaceuticals; MCP-1 inhibitor (inflammatory disorder/kidney disease), Angelini Pharmaceuticals
DMS2GA1 CP Angelini Pharmaceuticals SpA
DMS2GA1 DT Small molecular drug
DMS2GA1 PC 71354
DMS2GA1 MW 324.4
DMS2GA1 FM C19H20N2O3
DMS2GA1 IC InChI=1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)
DMS2GA1 CS CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3
DMS2GA1 IK MTHORRSSURHQPZ-UHFFFAOYSA-N
DMS2GA1 IU 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid
DMS2GA1 CA CAS 130641-38-2
DMS2GA1 DE Nephritis
DMVHF8G ID DMVHF8G
DMVHF8G DN Binodenoson
DMVHF8G HS Phase 3
DMVHF8G SN CorVue; MRE-0470; MRE-0479; MRE-470; SHA-174; WRC-0470
DMVHF8G CP Aderis Pharmaceuticals Inc
DMVHF8G DT Small molecular drug
DMVHF8G PC 9576912
DMVHF8G MW 391.4
DMVHF8G FM C17H25N7O4
DMVHF8G IC InChI=1S/C17H25N7O4/c18-14-11-15(22-17(21-14)23-20-6-9-4-2-1-3-5-9)24(8-19-11)16-13(27)12(26)10(7-25)28-16/h6,8-10,12-13,16,25-27H,1-5,7H2,(H3,18,21,22,23)/b20-6+/t10-,12-,13-,16-/m1/s1
DMVHF8G CS C1CCC(CC1)/C=N/NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMVHF8G IK XJFMHMFFBSOEPR-DNZQAUTHSA-N
DMVHF8G IU (2R,3R,4S,5R)-2-[6-amino-2-[(2E)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMVHF8G CA CAS 144348-08-3
DMVHF8G DE Hypertension
DME76AP ID DME76AP
DME76AP DN Bis(olanzapine) pamoate monohydrate
DME76AP HS Phase 3
DME76AP SN Bis[2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine] 4,4'-methylenebis(3-hydroxynaphthalen-2-carboxylic acid) salt monohydrate
DME76AP DE Psychotic disorder
DMW34B1 ID DMW34B1
DMW34B1 DN BL-8040
DMW34B1 HS Phase 3
DMW34B1 CP BioLineRx
DMW34B1 DT Peptide
DMW34B1 PC 91865076
DMW34B1 MW 2159.5
DMW34B1 FM C97H144FN33O19S2
DMW34B1 IC InChI=1S/C97H144FN33O19S2/c98-60-33-31-58(32-34-60)78(135)119-65(19-8-42-113-93(104)105)79(136)121-68(21-10-44-115-95(108)109)83(140)126-73(51-56-25-30-57-14-1-2-15-59(57)48-56)87(144)130-75-53-152-151-52-74(88(145)118-63(77(101)134)18-7-41-112-92(102)103)129-84(141)69(23-12-46-117-97(111)150)122-81(138)66(20-9-43-114-94(106)107)124-86(143)72(50-55-28-37-62(133)38-29-55)128-90(147)76-24-13-47-131(76)91(148)70(17-4-6-40-100)125-82(139)64(16-3-5-39-99)120-80(137)67(22-11-45-116-96(110)149)123-85(142)71(127-89(75)146)49-54-26-35-61(132)36-27-54/h1-2,14-15,25-38,48,63-76,132-133H,3-13,16-24,39-47,49-53,99-100H2,(H2,101,134)(H,118,145)(H,119,135)(H,120,137)(H,121,136)(H,122,138)(H,123,142)(H,124,143)(H,125,139)(H,126,140)(H,127,146)(H,128,147)(H,129,141)(H,130,144)(H4,102,103,112)(H4,104,105,113)(H4,106,107,114)(H4,108,109,115)(H3,110,116,149)(H3,111,117,150)/t63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-/m0/s1
DMW34B1 CS C1C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC5=CC=CC=C5C=C4)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O
DMW34B1 IK JJVZSYKFCOBILL-MKMRYRNGSA-N
DMW34B1 IU (3S,6S,9S,12S,15R,20R,23S,26S,29S,32S)-3,6-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-15-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-5-carbamimidamido-2-[(4-fluorobenzoyl)amino]pentanoyl]amino]pentanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-26-(3-carbamimidamidopropyl)-9,23-bis[3-(carbamoylamino)propyl]-12,29-bis[(4-hydroxyphenyl)methyl]-2,5,8,11,14,22,25,28,31-nonaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-20-carboxamide
DMW34B1 CA CAS 664334-36-5
DMW34B1 CB CHEBI:145536
DMW34B1 DE Acute myeloid leukaemia; Pancreatic cancer; Myelodysplastic syndrome; Multiple myeloma
DM7V9LH ID DM7V9LH
DM7V9LH DN Blisibimod
DM7V9LH HS Phase 3
DM7V9LH CP Anthera Pharmaceuticals Hayward, CA
DM7V9LH DE Systemic lupus erythematosus
DM36C17 ID DM36C17
DM36C17 DN Blonanserin
DM36C17 HS Phase 3
DM36C17 SN Lonasen; Blonanserin [INN]; AD 5423; AD-5423; Blonanserin (JAN/INN); 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine; 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
DM36C17 CP Dainippon
DM36C17 DT Small molecular drug
DM36C17 PC 125564
DM36C17 MW 367.5
DM36C17 FM C23H30FN3
DM36C17 IC InChI=1S/C23H30FN3/c1-2-26-13-15-27(16-14-26)23-17-21(18-9-11-19(24)12-10-18)20-7-5-3-4-6-8-22(20)25-23/h9-12,17H,2-8,13-16H2,1H3
DM36C17 CS CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F
DM36C17 IK XVGOZDAJGBALKS-UHFFFAOYSA-N
DM36C17 IU 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
DM36C17 CA CAS 132810-10-7
DM36C17 CB CHEBI:31296
DM36C17 DE Schizophrenia
DMBXR23 ID DMBXR23
DMBXR23 DN BMN-110
DMBXR23 HS Phase 3
DMBXR23 SN Enzyme replacement therapy (iv infusion, MPS IVA), BioMarin; Enzyme replacement therapy (iv infusion, Morquio A syndrome), BioMarin; Enzyme replacement therapy (iv infusion, mucopolysaccharidosis IVA), BioMarin; N-acetylgalactosamine-6-sulfatase (GALNS) (Morquio A syndrome), BioMarin
DMBXR23 CP Biomarin pharmaceutical
DMBXR23 DE Morquio syndrome
DMM9XL2 ID DMM9XL2
DMM9XL2 DN BMN-111
DMM9XL2 HS Phase 3
DMM9XL2 SN C-type natriuretic peptide analog (achondroplasia), BioMarin
DMM9XL2 CP Biomarin pharmaceutical
DMM9XL2 PC 119058036
DMM9XL2 MW 4103
DMM9XL2 FM C176H290N56O51S3
DMM9XL2 IC InChI=1S/C176H290N56O51S3/c1-14-95(10)143-172(280)201-84-138(245)209-125(86-234)168(276)221-113(54-65-284-13)159(267)229-124(85-233)152(260)200-81-135(242)206-114(66-91(2)3)150(258)198-83-140(247)211-128(174(282)283)89-286-285-88-127(170(278)224-118(70-98-34-16-15-17-35-98)151(259)199-80-137(244)207-115(67-92(4)5)162(270)217-108(41-23-29-60-182)155(263)223-117(69-94(8)9)164(272)226-122(75-142(250)251)167(275)219-110(160(268)231-143)44-32-63-193-176(188)189)210-139(246)82-197-149(257)105(38-20-26-57-179)215-169(277)126(87-235)230-163(271)116(68-93(6)7)208-136(243)79-196-147(255)103(36-18-24-55-177)213-153(261)106(39-21-27-58-180)218-166(274)121(74-132(185)239)222-144(252)96(11)203-133(240)77-195-148(256)104(37-19-25-56-178)214-165(273)119(71-99-46-48-101(236)49-47-99)225-156(264)107(40-22-28-59-181)216-154(262)109(43-31-62-192-175(186)187)212-145(253)97(12)204-161(269)120(73-131(184)238)227-171(279)129-45-33-64-232(129)173(281)123(72-100-76-190-90-202-100)228-158(266)112(51-53-141(248)249)220-157(265)111(50-52-130(183)237)205-134(241)78-194-146(254)102-42-30-61-191-102/h15-17,34-35,46-49,76,90-97,102-129,143,191,233-236H,14,18-33,36-45,50-75,77-89,177-182H2,1-13H3,(H2,183,237)(H2,184,238)(H2,185,239)(H,190,202)(H,194,254)(H,195,256)(H,196,255)(H,197,257)(H,198,258)(H,199,259)(H,200,260)(H,201,280)(H,203,240)(H,204,269)(H,205,241)(H,206,242)(H,207,244)(H,208,243)(H,209,245)(H,210,246)(H,211,247)(H,212,253)(H,213,261)(H,214,273)(H,215,277)(H,216,262)(H,217,270)(H,218,274)(H,219,275)(H,220,265)(H,221,276)(H,222,252)(H,223,263)(H,224,278)(H,225,264)(H,226,272)(H,227,279)(H,228,266)(H,229,267)(H,230,271)(H,231,268)(H,248,249)(H,250,251)(H,282,283)(H4,186,187,192)(H4,188,189,193)/t95-,96-,97-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,143-/m0/s1
DMM9XL2 CS CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO
DMM9XL2 IK IGYWDDBBJPSOTG-WBAGYEQSSA-N
DMM9XL2 IU (4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-5-amino-5-oxo-2-[[2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-[(2S)-butan-2-yl]-31-(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,22-bis(hydroxymethyl)-10,37,43-tris(2-methylpropyl)-19-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carboxylic acid
DMM9XL2 CA CAS 1480724-61-5
DMM9XL2 DE Achondroplasia
DM94Y6O ID DM94Y6O
DM94Y6O DN BMN-701
DM94Y6O HS Phase 3
DM94Y6O SN IGF2-GAA; XC-701; ZC-701; Enzyme replacement therapy (GILT, Pompe disease), BioMarin/ZyStor
DM94Y6O CP Biomarin pharmaceutical
DM94Y6O DE Pompe disease; Type 2 glycogen storage disease
DMDAN8H ID DMDAN8H
DMDAN8H DN BMS-582664
DMDAN8H HS Phase 3
DMDAN8H SN Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester
DMDAN8H CP Bristol Myers Squibb
DMDAN8H TC Anticancer Agents
DMDAN8H DT Small molecular drug
DMDAN8H PC 11154925
DMDAN8H MW 441.5
DMDAN8H FM C22H24FN5O4
DMDAN8H IC InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
DMDAN8H CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C
DMDAN8H IK LTEJRLHKIYCEOX-OCCSQVGLSA-N
DMDAN8H IU [(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate
DMDAN8H CA CAS 649735-63-7
DMDAN8H DE Hepatocellular carcinoma
DMAR1YS ID DMAR1YS
DMAR1YS DN BMS-986165
DMAR1YS HS Phase 3
DMAR1YS CP Bristol-Myers Squibb Princeton, NJ
DMAR1YS PC 134821691
DMAR1YS MW 425.5
DMAR1YS FM C20H22N8O3
DMAR1YS IC InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
DMAR1YS CS [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4
DMAR1YS IK BZZKEPGENYLQSC-FIBGUPNXSA-N
DMAR1YS IU 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
DMAR1YS CA CAS 1609392-27-9
DMAR1YS DE Plaque psoriasis; Psoriasis vulgaris
DM3MAYQ ID DM3MAYQ
DM3MAYQ DN BMS-986205
DM3MAYQ HS Phase 3
DM3MAYQ SN KRTIYQIPSAGSBP-KLAILNCOSA-N; 1923833-60-6; BMS986205; UNII-0A7729F42K; 0A7729F42K; GTPL9707; SCHEMBL18826792; SCHEMBL17740982; SCHEMBL19105151; EX-A2606; AKOS032954040; HY-101560; CS-0021719; Q29213697; (R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide; (2R)-N-(4-Chlorophenyl)-2-(4-(6-fluoro-4-quinolyl)cyclohexyl)propanamide, cis; Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-alpha-methyl-, cis-(alphaR)-
DM3MAYQ CP Bristol-Myers Squibb Princeton, NJ
DM3MAYQ PC 121328278
DM3MAYQ MW 410.9
DM3MAYQ FM C24H24ClFN2O
DM3MAYQ IC InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16?,17?/m1/s1
DM3MAYQ CS C[C@H](C1CCC(CC1)C2=C3C=C(C=CC3=NC=C2)F)C(=O)NC4=CC=C(C=C4)Cl
DM3MAYQ IK KRTIYQIPSAGSBP-KLAILNCOSA-N
DM3MAYQ IU (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
DM3MAYQ CA CAS 1923833-60-6
DM3MAYQ DE Advanced cancer; Gastric adenocarcinoma; Melanoma; Renal cell carcinoma; Solid tumour/cancer
DM2OBNW ID DM2OBNW
DM2OBNW DN Bococizumab
DM2OBNW HS Phase 3
DM2OBNW CP Pfizer
DM2OBNW DT Antibody
DM2OBNW DE Chronic obstructive pulmonary disease
DM6KRLW ID DM6KRLW
DM6KRLW DN BQ788
DM6KRLW HS Phase 3
DM6KRLW SN (2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752
DM6KRLW DT Small molecular drug
DM6KRLW PC 16759603
DM6KRLW MW 663.8
DM6KRLW FM C34H50N5NaO7
DM6KRLW IC InChI=1S/C34H51N5O7.Na/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3;/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43);/q;+1/p-1/t21-,22+,25-,26-,27+;/m1./s1
DM6KRLW CS CCCC[C@H](C(=O)[O-])NC(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](CCC[C@@H]3C)C.[Na+]
DM6KRLW IK QCVIFBRTTLMEOV-FUKQNADPSA-M
DM6KRLW IU sodium;(2R)-2-[[(2R)-2-[[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]-3-(1-methoxycarbonylindol-3-yl)propanoyl]amino]hexanoate
DM6KRLW CA CAS 156161-89-6
DM6KRLW DE Hypertension; Acute kidney injury; Encephalopathy; Myasthenia gravis; Neuromyelitis optica
DM942HP ID DM942HP
DM942HP DN Brivanib
DM942HP HS Phase 3
DM942HP SN Brivanib; 649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
DM942HP CP Bristol-Myers Squibb
DM942HP DT Small molecular drug
DM942HP PC 11234052
DM942HP MW 370.4
DM942HP FM C19H19FN4O3
DM942HP IC InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
DM942HP CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
DM942HP IK WCWUXEGQKLTGDX-LLVKDONJSA-N
DM942HP IU (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
DM942HP CA CAS 649735-46-6
DM942HP CB CHEBI:94562
DM942HP DE Liver cancer; Breast cancer
DMM0VO3 ID DMM0VO3
DMM0VO3 DN BSI-201
DMM0VO3 HS Phase 3
DMM0VO3 SN Iniparib; NIBA; INO2BA; IND-71677; SAR-240550; Iniparib, NSC-746045, IND-71677, BSI201, BSI-201; 4-Iodo-3-nitrobenzamide; 4-iodo-3-nitro-benzamide
DMM0VO3 CP Sanofi-Aventis
DMM0VO3 DT Small molecular drug
DMM0VO3 PC 9796068
DMM0VO3 MW 292.03
DMM0VO3 FM C7H5IN2O3
DMM0VO3 IC InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
DMM0VO3 CS C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I
DMM0VO3 IK MDOJTZQKHMAPBK-UHFFFAOYSA-N
DMM0VO3 IU 4-iodo-3-nitrobenzamide
DMM0VO3 CA CAS 160003-66-7
DMM0VO3 CB CHEBI:95067
DMM0VO3 DE Solid tumour/cancer
DM50SNX ID DM50SNX
DM50SNX DN Bucelipase alfa
DM50SNX HS Phase 3
DM50SNX SN Exinalda; Kiobrina; BSSL, Biovitrum; Bile salt stimulated lipase, Arexis; Bile salt stimulated lipase, Biovitrum; Bile salt stimulated lipase, PPL Therapeutics; HrBSSL, Biovitrum; Human recombinant bile salt stimulated lipase, Biovitrum; TgBSSL, PPL Therapeutics
DM50SNX CP Astra Hassle AB
DM50SNX DE Exocrine pancreatic insufficiency
DM1WEHC ID DM1WEHC
DM1WEHC DN Buparlisib
DM1WEHC HS Phase 3
DM1WEHC SN BKM120
DM1WEHC CP Novartis
DM1WEHC DT Small molecular drug
DM1WEHC PC 16654980
DM1WEHC MW 410.4
DM1WEHC FM C18H21F3N6O2
DM1WEHC IC InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
DM1WEHC CS C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
DM1WEHC IK CWHUFRVAEUJCEF-UHFFFAOYSA-N
DM1WEHC IU 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
DM1WEHC CA CAS 944396-07-0
DM1WEHC CB CHEBI:71954
DM1WEHC DE Breast cancer
DMAR9ND ID DMAR9ND
DMAR9ND DN Bupropion+Naltrexone
DMAR9ND HS Phase 3
DMAR9ND SN Mysimba; Contrave; Naltrexone/bupropion; Naltrexone / bupropion; Bupropion / naltrexone; Bupropion mixture with naltrexone; SCHEMBL15633271; 1201668-08-7
DMAR9ND CP Orexigen Therapeutics
DMAR9ND DT Small molecular drug
DMAR9ND PC 11556075
DMAR9ND MW 581.1
DMAR9ND FM C33H41ClN2O5
DMAR9ND IC InChI=1S/C20H23NO4.C13H18ClNO/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h3-4,11,15,18,22,24H,1-2,5-10H2;5-9,15H,1-4H3/t15-,18+,19+,20-;/m1./s1
DMAR9ND CS CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
DMAR9ND IK KVNBDVQGENTICK-ITLPAZOVSA-N
DMAR9ND IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
DMAR9ND CA CAS 1201668-08-7
DMAR9ND DE Obesity
DM6RUKX ID DM6RUKX
DM6RUKX DN BVT.2733
DM6RUKX HS Phase 3
DM6RUKX SN CHEMBL553071; AC1OCFOV; 376641-65-5; SCHEMBL5692696; MolPort-042-665-756; 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide hydrochloride
DM6RUKX DT Small molecular drug
DM6RUKX PC 6918651
DM6RUKX MW 429
DM6RUKX FM C17H21ClN4O3S2
DM6RUKX IC InChI=1S/C17H21ClN4O3S2/c1-12-14(18)4-3-5-15(12)27(24,25)20-17-19-13(11-26-17)10-16(23)22-8-6-21(2)7-9-22/h3-5,11H,6-10H2,1-2H3,(H,19,20)
DM6RUKX CS CC1=C(C=CC=C1Cl)S(=O)(=O)NC2=NC(=CS2)CC(=O)N3CCN(CC3)C
DM6RUKX IK YDPRNGAPPNPYQQ-UHFFFAOYSA-N
DM6RUKX IU 3-chloro-2-methyl-N-[4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1,3-thiazol-2-yl]benzenesulfonamide
DM6RUKX CA CAS 376640-41-4
DM6RUKX DE Non-insulin dependent diabetes; Lupus; Myasthenia gravis; Systemic lupus erythematosus
DM1ARHT ID DM1ARHT
DM1ARHT DN BYM338
DM1ARHT HS Phase 3
DM1ARHT CP Novartis
DM1ARHT DE Acute myeloid leukaemia; Inclusion body myositis; Muscle atrophy
DMPTCYB ID DMPTCYB
DMPTCYB DN Cadi-05
DMPTCYB HS Phase 3
DMPTCYB SN Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila
DMPTCYB CP Cadila Pharmaceuticals Ltd
DMPTCYB DT Vaccine
DMPTCYB DE Prostate cancer
DM6CHNJ ID DM6CHNJ
DM6CHNJ DN Camptothecin
DM6CHNJ HS Phase 3
DM6CHNJ SN camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; d-Camptothecin; (+)-Camptothecine; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; (S)-Camptothecin; Camptothecine (8CI); 20(S)-Camptothecin; Camptothecine (S,+); CHEMBL65; UNII-XT3Z54Z28A; MLS000766223; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; XT3Z54Z28A; CHEBI:27656; VSJKWCGYPAHWDS-FQEVSTJZSA-N; Camptothecin, Camptotheca acuminata; NSC-94600; Camptothecin derivat
DM6CHNJ DT Small molecular drug
DM6CHNJ PC 24360
DM6CHNJ MW 348.4
DM6CHNJ FM C20H16N2O4
DM6CHNJ IC InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1
DM6CHNJ CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
DM6CHNJ IK VSJKWCGYPAHWDS-FQEVSTJZSA-N
DM6CHNJ IU (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DM6CHNJ CA CAS 7689-03-4
DM6CHNJ CB CHEBI:27656
DM6CHNJ DE Solid tumour/cancer
DMHJCGV ID DMHJCGV
DMHJCGV DN Candoxatril
DMHJCGV HS Phase 3
DMHJCGV SN UK 79300; Candoxatril [USAN:INN:BAN]; UK-79,300; Candoxatril (JAN/USAN/INN); Cyclohexanecarboxylic acid, 4-(((1-(2-carboxy-3-(2-methoxyethoxy)propyl)cyclopentyl)carbonyl)-amino)-, (4(S)-cis); [4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; Cis-4-{[(1-{(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl}cyclopentyl)carbonyl]amino}cyclohexanecarboxylic acid; (alphaS)-1-((cis-4-Carboxycyclohexyl)carbamoyl)-alpha-((2-methoxyethoxy)methyl)cyclopentanepropionic acid; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid; 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMHJCGV TC Antihypertensive Agents
DMHJCGV DT Small molecular drug
DMHJCGV PC 5362417
DMHJCGV MW 515.6
DMHJCGV FM C29H41NO7
DMHJCGV IC InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1
DMHJCGV CS COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3
DMHJCGV IK ZTWZVMIYIIVABD-RZMWZJFBSA-N
DMHJCGV IU 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMHJCGV CA CAS 123122-55-4
DMHJCGV CB CHEBI:3353
DMHJCGV DE Hypertension
DM4FHQR ID DM4FHQR
DM4FHQR DN Canfosfamide
DM4FHQR HS Phase 3
DM4FHQR SN Telcyta (TN)
DM4FHQR CP Telik
DM4FHQR DT Small molecular drug
DM4FHQR PC 5312109
DM4FHQR MW 787.5
DM4FHQR FM C26H40Cl4N5O10PS
DM4FHQR IC InChI=1S/C26H40Cl4N5O10PS/c27-8-12-34(13-9-28)46(42,35(14-10-29)15-11-30)45-16-17-47(43,44)18-21(32-22(36)7-6-20(31)25(38)39)24(37)33-23(26(40)41)19-4-2-1-3-5-19/h1-5,20-21,23H,6-18,31H2,(H,32,36)(H,33,37)(H,38,39)(H,40,41)/t20-,21-,23+/m0/s1
DM4FHQR CS C1=CC=C(C=C1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N
DM4FHQR IK OJLHWPALWODJPQ-QNWVGRARSA-N
DM4FHQR IU (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM4FHQR CA CAS 158382-37-7
DM4FHQR CB CHEBI:135883
DM4FHQR DE Solid tumour/cancer
DMMZDJ6 ID DMMZDJ6
DMMZDJ6 DN Captopril
DMMZDJ6 HS Phase 3
DMMZDJ6 SN captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Dilabar; Acepress; Captoril; Tenosbon; Hypertil; Garranil; Alopresin; Lopril; Acepril; Captoprilum; Aceplus; Acediur; Tensobon; Isopresol;Apopril; Asisten; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; SQ 14,225; SA 333; Captopril
DMMZDJ6 TC Antiviral Agents
DMMZDJ6 DT Small molecular drug
DMMZDJ6 PC 44093
DMMZDJ6 MW 217.29
DMMZDJ6 FM C9H15NO3S
DMMZDJ6 IC InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
DMMZDJ6 CS C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
DMMZDJ6 IK FAKRSMQSSFJEIM-RQJHMYQMSA-N
DMMZDJ6 IU (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
DMMZDJ6 CA CAS 62571-86-2
DMMZDJ6 CB CHEBI:3380
DMMZDJ6 DE Coronavirus Disease 2019 (COVID-19)
DMUVMWZ ID DMUVMWZ
DMUVMWZ DN Carebastine
DMUVMWZ HS Phase 3
DMUVMWZ SN Carebastina; Carebastinum; Carebastina [Spanish]; Carebastine [INN]; Carebastinum [Latin]; E00013; P-(4-(4-(Diphenylmethoxy)piperidino)butyryl)-alpha-methylhydratropic acid; 2-(4-(4-(4-Benzhydryloxypiperidino)butyryl)phenyl)-2-methylpropionsaeure; 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid
DMUVMWZ CP Almirall Prodesfarma
DMUVMWZ DT Small molecular drug
DMUVMWZ PC 65820
DMUVMWZ MW 499.6
DMUVMWZ FM C32H37NO4
DMUVMWZ IC InChI=1S/C32H37NO4/c1-32(2,31(35)36)27-17-15-24(16-18-27)29(34)14-9-21-33-22-19-28(20-23-33)37-30(25-10-5-3-6-11-25)26-12-7-4-8-13-26/h3-8,10-13,15-18,28,30H,9,14,19-23H2,1-2H3,(H,35,36)
DMUVMWZ CS CC(C)(C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)O
DMUVMWZ IK XGHOVGYJHWQGCC-UHFFFAOYSA-N
DMUVMWZ IU 2-[4-[4-(4-benzhydryloxypiperidin-1-yl)butanoyl]phenyl]-2-methylpropanoic acid
DMUVMWZ CA CAS 90729-42-3
DMUVMWZ DE Ocular allergy
DM4Y1SP ID DM4Y1SP
DM4Y1SP DN Carisbamate
DM4Y1SP HS Phase 3
DM4Y1SP SN Comfyde; JNJ 10234094; RWJ 333369; YKP 509; Carisbamate (USAN); JNJ-10234094; RWJ-333369; YKP-509; S-2-O-Carbamoyl-1-o-chlorophenyl-ethanol; [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
DM4Y1SP CP Johnson & Johnson
DM4Y1SP DT Small molecular drug
DM4Y1SP PC 6918474
DM4Y1SP MW 215.63
DM4Y1SP FM C9H10ClNO3
DM4Y1SP IC InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
DM4Y1SP CS C1=CC=C(C(=C1)[C@@H](COC(=O)N)O)Cl
DM4Y1SP IK OLBWFRRUHYQABZ-MRVPVSSYSA-N
DM4Y1SP IU [(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate
DM4Y1SP CA CAS 194085-75-1
DM4Y1SP CB CHEBI:135966
DM4Y1SP DE Seizure disorder; Focal dystonia; Epilepsy
DMPG4OM ID DMPG4OM
DMPG4OM DN CAZ AVI
DMPG4OM HS Phase 3
DMPG4OM SN CAZ104
DMPG4OM CP AstraZeneca
DMPG4OM DE Serious infection
DM097UP ID DM097UP
DM097UP DN CBT-1
DM097UP HS Phase 3
DM097UP CP National Institutes of Health Clinical Center (CC)
DM097UP DE Non-small-cell lung cancer; Solid tumour/cancer
DMV7WSN ID DMV7WSN
DMV7WSN DN CC-25430
DMV7WSN HS Phase 3
DMV7WSN SN Caroverin; Caroverina; Caroverina [INN-Spanish]; Caroverine; Caroverine (INN); Caroverine [INN]; Caroverinum; Caroverinum [INN-Latin]; P 201-1; Spasmium; Spasmium (TN); Tox21_113512; XJ73B0K6KB; ZINC4212360; 1-Diethylaminoethyl-3-(p-methoxybenzyl)quinoxalone-2; 23465-76-1; AC1L23SW; BRD-K70161083-003-01-4; C-23692; CAS-23465-76-1; CC-25430; CHEBI:135541; CHEMBL1729803; D07098; DSSTox_CID_28936; DSSTox_GSID_49010; DSSTox_RID_83202; DTXSID6049010; FT-0716182; MFCD00865257; NCGC00186046-01; NCGC00186046-02; SCHEMBL25946; UNII-XJ73B0K6KB; P-201
DMV7WSN PC 65709
DMV7WSN MW 365.5
DMV7WSN FM C22H27N3O2
DMV7WSN IC MSPRUJDUTKRMLM-UHFFFAOYSA-N
DMV7WSN CS CCN(CC)CCN1C2=CC=CC=C2N=C(C1=O)CC3=CC=C(C=C3)OC
DMV7WSN IK 1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3
DMV7WSN IU 1-[2-(diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]quinoxalin-2-one
DMV7WSN CA CAS 23465-76-1
DMV7WSN CB CHEBI:135541
DMV7WSN DE Tinnitus
DMTNQB0 ID DMTNQB0
DMTNQB0 DN CC-486
DMTNQB0 HS Phase 3
DMTNQB0 SN AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
DMTNQB0 CP Celgene
DMTNQB0 DT Small molecular drug
DMTNQB0 PC 9840076
DMTNQB0 MW 320.4
DMTNQB0 FM C19H20N4O
DMTNQB0 IC InChI=1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)
DMTNQB0 CS CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O
DMTNQB0 IK SEKJSSBJKFLZIT-UHFFFAOYSA-N
DMTNQB0 IU 2-[4-[(dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one
DMTNQB0 CA CAS 328543-09-5
DMTNQB0 CB CHEBI:92015
DMTNQB0 DE Myelodysplastic syndrome; Acute myeloid leukaemia; Diffuse large B-cell lymphoma
DM5LQHB ID DM5LQHB
DM5LQHB DN CCX-168
DM5LQHB HS Phase 3
DM5LQHB SN Avacopan
DM5LQHB CP ChemoCentryx
DM5LQHB PC 49841217
DM5LQHB MW 581.6
DM5LQHB FM C33H35F4N3O2
DM5LQHB IC InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1
DM5LQHB CS CC1=C(C(=CC=C1)F)C(=O)N2CCC[C@@H]([C@@H]2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F
DM5LQHB IK PUKBOVABABRILL-YZNIXAGQSA-N
DM5LQHB IU (2R,3S)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-N-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide
DM5LQHB CA CAS 1346623-17-3
DM5LQHB DE Eosinophilic granulomatosis with polyangiitis; Hereditary haemolytic anemia; Anca-associated vasculitis
DMWO5ZR ID DMWO5ZR
DMWO5ZR DN Cediranib
DMWO5ZR HS Phase 3
DMWO5ZR SN Recentin; AZD 2171; AZD2171; M6294; AZD-2171; ZD-2171; AZD2171, Recentin, Cediranib; Cediranib (USAN/INN); 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
DMWO5ZR CP AstraZeneca
DMWO5ZR TC Anticancer Agents
DMWO5ZR DT Small molecular drug
DMWO5ZR PC 9933475
DMWO5ZR MW 450.5
DMWO5ZR FM C25H27FN4O3
DMWO5ZR IC InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
DMWO5ZR CS CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5
DMWO5ZR IK XXJWYDDUDKYVKI-UHFFFAOYSA-N
DMWO5ZR IU 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
DMWO5ZR CA CAS 288383-20-0
DMWO5ZR CB CHEBI:94782
DMWO5ZR DE Peritoneal cavity cancer
DMLWIU4 ID DMLWIU4
DMLWIU4 DN Cefluprenam
DMLWIU4 HS Phase 3
DMLWIU4 SN E-1077
DMLWIU4 CP Eisai Co Ltd
DMLWIU4 DT Small molecular drug
DMLWIU4 PC 6536774
DMLWIU4 MW 556.6
DMLWIU4 FM C20H25FN8O6S2
DMLWIU4 IC InChI=1S/C20H25FN8O6S2/c1-3-29(2,7-11(22)30)6-4-5-10-8-36-18-13(17(32)28(18)14(10)19(33)34)24-16(31)12(26-35-9-21)15-25-20(23)37-27-15/h4-5,13,18H,3,6-9H2,1-2H3,(H5-,22,23,24,25,27,30,31,33,34)/b5-4+,26-12-/t13-,18-,29?/m1/s1
DMLWIU4 CS CC[N+](C)(C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\\OCF)/C3=NSC(=N3)N)SC1)C(=O)[O-])CC(=O)N
DMLWIU4 IK XAKKNLNAJBNLPC-MAYKBZFQSA-N
DMLWIU4 IU (6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMLWIU4 CA CAS 116853-25-9
DMLWIU4 CB CHEBI:3488
DMLWIU4 DE Bacterial infection
DMM76GL ID DMM76GL
DMM76GL DN Ceftobiprole
DMM76GL HS Phase 3
DMM76GL SN BAL 9141; BAL 9141-000; BAL-9141; Ro 63-9141; Ro-63-9141; Ro-63-9141/000; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMM76GL CP Johnson & Johnson
DMM76GL DT Small molecular drug
DMM76GL PC 135413542
DMM76GL MW 534.6
DMM76GL FM C20H22N8O6S2
DMM76GL IC InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
DMM76GL CS C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O
DMM76GL IK VOAZJEPQLGBXGO-SDAWRPRTSA-N
DMM76GL IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMM76GL CA CAS 209467-52-7
DMM76GL CB CHEBI:140407
DMM76GL DE Community-acquired pneumonia; Skin and skin-structure infection
DMWLF2X ID DMWLF2X
DMWLF2X DN Ceftobiprole medocaril
DMWLF2X HS Phase 3
DMWLF2X SN UNII-YXV28V1B07; YXV28V1B07; BAL5788; 376653-43-9; ceftobiprolemedocaril; Ceftobiprole Medocaril [INN]; SCHEMBL2671859; SCHEMBL19236293; CHEBI:135968; DB14733; 653C439; (6R,7R)-7-((2Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)((3'R)-1'-((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl)-2-oxo-(1,3'-bipyrrolidin)-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DMWLF2X CP Basilea Pharmaceutica
DMWLF2X DT Small molecular drug
DMWLF2X PC 135413544
DMWLF2X MW 690.7
DMWLF2X FM C26H26N8O11S2
DMWLF2X IC InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31)/b11-6+,30-15-/t13-,16-,22-/m1/s1
DMWLF2X CS CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O
DMWLF2X IK HFTSMHTWUFCYMJ-YIOMYIDASA-N
DMWLF2X IU (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-hydroxyiminoacetyl]amino]-3-[(E)-[1-[(3R)-1-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxycarbonyl]pyrrolidin-3-yl]-2-oxopyrrolidin-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMWLF2X CA CAS 376653-43-9
DMWLF2X CB CHEBI:135968
DMWLF2X DE Skin and skin-structure infection
DMIGX84 ID DMIGX84
DMIGX84 DN Cethromycin
DMIGX84 HS Phase 3
DMIGX84 SN Restanza; Cethromycin [USAN]; ABT 773; A-195773; ABT-773; Abbott-195773; A-195773.0; Cethromycin (USAN/INN); (1R,2R,4R,6R,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1R,2R,4R,6S,7R,8R,10R,13R,14S)-7-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-13-ethyl-2,4,6,8,10,14-hexamethyl-6-[(E)-3-quinolin-3-ylprop-2-enoxy]-12,15-dioxa-17-azabicyclo[12.3.0]heptadecane-3,9,11,16-tetrone; (1S,2R,5R,7R,8R,9R,11R,13R,14R)-2-Ethyl-1,5,7,9,11,13-Hexamethyl-9-[3-(3-quinolyl)-2(E)-propenyloxy]-8-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-glucopyranosyloxy]-3,17-dioxa-15-azabicyclo[12.3.0]hepta; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15 hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone; (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyl-3a,7,9,11,13,15-hexamethyl-11-((3-(quinolin-3-yl)prop-2-enyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)octahydro-2H-oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone
DMIGX84 CP Advanced life sciences
DMIGX84 DT Small molecular drug
DMIGX84 PC 447451
DMIGX84 MW 765.9
DMIGX84 FM C42H59N3O10
DMIGX84 IC InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1
DMIGX84 CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC/C=C/C4=CC5=CC=CC=C5N=C4)C)C)NC(=O)O2)C
DMIGX84 IK PENDGIOBPJLVBT-ONLVEXIXSA-N
DMIGX84 IU (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMIGX84 CA CAS 205110-48-1
DMIGX84 CB CHEBI:29506
DMIGX84 DE Bacterial infection; Pneumonia
DMWAHTN ID DMWAHTN
DMWAHTN DN Cetilistat
DMWAHTN HS Phase 3
DMWAHTN SN Cametor; Cetilistat [INN]; ATL 962; ATL962; ATL-962; Cetilistat (JAN/USAN/INN); 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
DMWAHTN CP Alizyme; Takeda; Norgine B.V.
DMWAHTN DT Small molecular drug
DMWAHTN PC 9952916
DMWAHTN MW 401.6
DMWAHTN FM C25H39NO3
DMWAHTN IC InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3
DMWAHTN CS CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1
DMWAHTN IK MVCQKIKWYUURMU-UHFFFAOYSA-N
DMWAHTN IU 2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one
DMWAHTN CA CAS 282526-98-1
DMWAHTN CB CHEBI:134721
DMWAHTN DE Obesity; Diabetic complication
DMX9K3W ID DMX9K3W
DMX9K3W DN Cetraxal Otic
DMX9K3W HS Phase 3
DMX9K3W SN Ciprofloxacin otic
DMX9K3W CP Salvat Laboratories
DMX9K3W DE Otitis externa
DMIKMA9 ID DMIKMA9
DMIKMA9 DN CG-100649
DMIKMA9 HS Phase 3
DMIKMA9 SN Polmacoxib; 301692-76-2; UNII-IJ34D6YPAO; CG100649; IJ34D6YPAO; 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide; 4-[3-(3-Fluorophenyl)-5,5-Dimethyl-4-Oxidanylidene-Furan-2-Yl]benzenesulfonamide; 4-(3-(3-Fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide; Polmacoxib [USAN:INN]; CG-100649; Acelex (S. Korea); CG 100649; Polmacoxib (USAN/INN); SCHEMBL3233093; CHEMBL166863; GTPL8316; EX-A601; IJWPAFMIFNSIGD-UHFFFAOYSA-N; ZINC589683; BCP15550; AKOS025149767; SB17177; DB12399
DMIKMA9 CP CG Pharmaceuticals
DMIKMA9 DT Small molecular drug
DMIKMA9 PC 9841854
DMIKMA9 MW 361.4
DMIKMA9 FM C18H16FNO4S
DMIKMA9 IC InChI=1S/C18H16FNO4S/c1-18(2)17(21)15(12-4-3-5-13(19)10-12)16(24-18)11-6-8-14(9-7-11)25(20,22)23/h3-10H,1-2H3,(H2,20,22,23)
DMIKMA9 CS CC1(C(=O)C(=C(O1)C2=CC=C(C=C2)S(=O)(=O)N)C3=CC(=CC=C3)F)C
DMIKMA9 IK IJWPAFMIFNSIGD-UHFFFAOYSA-N
DMIKMA9 IU 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide
DMIKMA9 CA CAS 301692-76-2
DMIKMA9 DE Arthritis
DM1TJXA ID DM1TJXA
DM1TJXA DN Chloride
DM1TJXA HS Phase 3
DM1TJXA SN chloride ion; 16887-00-6; Chloride(1-); Chloride anion; Chlorine, ion; UNII-Q32ZN48698; Hydrochloric acid, ion(1-); Chlorid; CHEMBL19429; Cl-; CHEBI:17996; Q32ZN48698; Chlorides; Chloride ions; Chloride (ion); Perchloride; Chlorine anion; Chlorine ion; Chloride (Cl-); Chlorine(1-); Chlorine ion(1-); Chloride ion (1-); Chlorine, ion (Cl1-); AC1L18YJ; Cl(-); CTK0H5734; BDBM26979; VEXZGXHMUGYJMC-UHFFFAOYSA-M; c0884; AKOS015903642; FT-0755769; 3-Carbamoyl-1-ethoxymethylpyridinium chloride; 1-Butoxymethyl-3-carbamoyl-pyridinium
DM1TJXA DT Small molecular drug
DM1TJXA PC 312
DM1TJXA MW 35.45
DM1TJXA FM Cl-
DM1TJXA IC InChI=1S/ClH/h1H/p-1
DM1TJXA CS [Cl-]
DM1TJXA IK VEXZGXHMUGYJMC-UHFFFAOYSA-M
DM1TJXA IU chloride
DM1TJXA CA CAS 16887-00-6
DM1TJXA CB CHEBI:17996
DM1TJXA DE Solid tumour/cancer
DMORSFB ID DMORSFB
DMORSFB DN Chloroquine
DMORSFB HS Phase 3
DMORSFB SN Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
DMORSFB CP Medreich Sterilab Ltd
DMORSFB TC Antiviral Agents
DMORSFB DT Small molecular drug
DMORSFB PC 2719
DMORSFB MW 319.9
DMORSFB FM C18H26ClN3
DMORSFB IC InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
DMORSFB CS CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
DMORSFB IK WHTVZRBIWZFKQO-UHFFFAOYSA-N
DMORSFB IU 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMORSFB CA CAS 54-05-7
DMORSFB CB CHEBI:3638
DMORSFB DE Malaria; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM5X7DJ ID DM5X7DJ
DM5X7DJ DN Chlorpromazine
DM5X7DJ HS Phase 3
DM5X7DJ SN Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
DM5X7DJ CP GlaxoSmithKline
DM5X7DJ TC Antiviral Agents
DM5X7DJ DT Small molecular drug
DM5X7DJ PC 2726
DM5X7DJ MW 318.9
DM5X7DJ FM C17H19ClN2S
DM5X7DJ IC InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
DM5X7DJ CS CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
DM5X7DJ IK ZPEIMTDSQAKGNT-UHFFFAOYSA-N
DM5X7DJ IU 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
DM5X7DJ CA CAS 34468-21-8
DM5X7DJ CB CHEBI:3647
DM5X7DJ DE Schizophrenia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM0Q6CM ID DM0Q6CM
DM0Q6CM DN CIGB-300
DM0Q6CM HS Phase 3
DM0Q6CM SN P15; IGBC-300; P15-Tat
DM0Q6CM CP Center for Genetic Engineering and Biotechnology
DM0Q6CM PC 86290205
DM0Q6CM MW 3060.6
DM0Q6CM FM C127H215N53O30S3
DM0Q6CM IC InChI=1S/C127H215N53O30S3/c1-66(2)55-84-100(189)157-61-97(187)177-98(67(3)182)116(205)176-89(120(209)210)64-213-212-63-88(113(202)173-85(56-68-59-156-71-22-6-5-21-70(68)71)111(200)168-82(40-54-211-4)110(199)175-87(62-181)118(207)178-51-18-32-90(178)114(203)169-79(30-16-48-154-126(143)144)108(197)174-86(112(201)172-84)57-69-60-147-65-158-69)160-95(185)39-50-148-99(188)80(35-37-93(131)183)170-115(204)91-33-19-52-179(91)119(208)92-34-20-53-180(92)117(206)83(31-17-49-155-127(145)146)171-107(196)78(29-15-47-153-125(141)142)165-105(194)76(27-13-45-151-123(137)138)166-109(198)81(36-38-94(132)184)167-106(195)77(28-14-46-152-124(139)140)164-104(193)75(26-12-44-150-122(135)136)163-103(192)74(24-8-10-42-129)162-102(191)73(23-7-9-41-128)161-101(190)72(159-96(186)58-130)25-11-43-149-121(133)134/h5-6,21-22,59-60,65-67,72-92,98,156,181-182H,7-20,23-58,61-64,128-130H2,1-4H3,(H2,131,183)(H2,132,184)(H,147,158)(H,148,188)(H,157,189)(H,159,186)(H,160,185)(H,161,190)(H,162,191)(H,163,192)(H,164,193)(H,165,194)(H,166,198)(H,167,195)(H,168,200)(H,169,203)(H,170,204)(H,171,196)(H,172,201)(H,173,202)(H,174,197)(H,175,199)(H,176,205)(H,177,187)(H,209,210)(H4,133,134,149)(H4,135,136,150)(H4,137,138,151)(H4,139,140,152)(H4,141,142,153)(H4,143,144,154)(H4,145,146,155)/t67-,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,98+/m1/s1
DM0Q6CM CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC(C)C)CC3=CNC=N3)CCCNC(=N)N)CO)CCSC)CC4=CNC5=CC=CC=C54)NC(=O)CCNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]6CCCN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)O)O
DM0Q6CM IK RNELHWXSRSKXRD-QNKYCTLBSA-N
DM0Q6CM IU (3S,6S,9S,12R,17R,20S,26S,29S,32S,35S)-12-[3-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]propanoylamino]-32-(3-carbamimidamidopropyl)-20-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-29-(1H-imidazol-4-ylmethyl)-9-(1H-indol-3-ylmethyl)-26-(2-methylpropyl)-6-(2-methylsulfanylethyl)-2,5,8,11,19,22,25,28,31,34-decaoxo-14,15-dithia-1,4,7,10,18,21,24,27,30,33-decazabicyclo[33.3.0]octatriacontane-17-carboxylic acid
DM0Q6CM CB CHEBI:83696
DM0Q6CM DE Cervical cancer
DMP0NGX ID DMP0NGX
DMP0NGX DN Cilansetron
DMP0NGX HS Phase 3
DMP0NGX SN Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN)
DMP0NGX CP Solvay Pharma
DMP0NGX DT Small molecular drug
DMP0NGX PC 6918107
DMP0NGX MW 319.4
DMP0NGX FM C20H21N3O
DMP0NGX IC InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1
DMP0NGX CS CC1=NC=CN1C[C@H]2CCC3=C(C2=O)C4=CC=CC5=C4N3CCC5
DMP0NGX IK NCNFDKWULDWJDS-OAHLLOKOSA-N
DMP0NGX IU (12R)-12-[(2-methylimidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.05,16.010,15]hexadeca-5(16),6,8,10(15)-tetraen-11-one
DMP0NGX CA CAS 120635-74-7
DMP0NGX DE Irritable bowel syndrome
DMEAOZ0 ID DMEAOZ0
DMEAOZ0 DN Cilengitide
DMEAOZ0 HS Phase 3
DMEAOZ0 SN Cilengitide; 188968-51-6; EMD-121974; Cilengitide [USAN:INN]; UNII-4EDF46E4GI; EMD121974; EMD-12192; EMD 121974; 4EDF46E4GI; CHEMBL429876; 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid; Cyclo(L-arginylglycyl-L-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl); Cilengitide (TFA salt)
DMEAOZ0 DT Small molecular drug
DMEAOZ0 PC 176873
DMEAOZ0 MW 588.7
DMEAOZ0 FM C27H40N8O7
DMEAOZ0 IC InChI=1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
DMEAOZ0 CS CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMEAOZ0 IK AMLYAMJWYAIXIA-VWNVYAMZSA-N
DMEAOZ0 IU 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMEAOZ0 CA CAS 188968-51-6
DMEAOZ0 DE Rheumatoid arthritis
DM1975O ID DM1975O
DM1975O DN Cilnidipine
DM1975O HS Phase 3
DM1975O SN Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM1975O CP Fuji Viscera Pharmaceutical
DM1975O DT Small molecular drug
DM1975O PC 5282138
DM1975O MW 492.5
DM1975O FM C27H28N2O7
DM1975O IC InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
DM1975O CS CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC
DM1975O IK KJEBULYHNRNJTE-DHZHZOJOSA-N
DM1975O IU 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM1975O CA CAS 132203-70-4
DM1975O CB CHEBI:31399
DM1975O DE High blood pressure
DMU2J7Y ID DMU2J7Y
DMU2J7Y DN Ciltacabtagene autoleucel
DMU2J7Y HS Phase 3
DMU2J7Y SN JNJ-68284528
DMU2J7Y CP Janssen
DMU2J7Y DT CAR T Cell Therapy
DMU2J7Y DE Multiple myeloma
DMEGFYD ID DMEGFYD
DMEGFYD DN Cinitapride
DMEGFYD HS Phase 3
DMEGFYD SN Cinitapride; 66564-14-5; Cidine; cinitapride tartrate; Blaston; Cinitapride [INN]; C21H30N4O4; Cinitapride hydrogen tartrate; Cinitapride (INN); 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide; Cinitapridum; Cinitaprida; Paxapride; Cinitapridum [INN-Latin]; Cinitaprida [INN-Spanish]; cidin; Cintapro; Cinmove; UNII-R8I97I2L24; Paxapride (TN); AC1Q1YMD; AC1L2AM4; (non-labelled)Cinitapride-d5; SCHEMBL476454; SCHEMBL19235643; CHEMBL2104523; CHEBI:135642; R8I97I2L24; BCP04096; AKOS015909742; DB08810
DMEGFYD CP Eisai
DMEGFYD DT Small molecular drug
DMEGFYD PC 68867
DMEGFYD MW 402.5
DMEGFYD FM C21H30N4O4
DMEGFYD IC InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)
DMEGFYD CS CCOC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3CCC=CC3)[N+](=O)[O-])N
DMEGFYD IK ZDLBNXXKDMLZMF-UHFFFAOYSA-N
DMEGFYD IU 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
DMEGFYD CA CAS 66564-14-5
DMEGFYD CB CHEBI:135642
DMEGFYD DE Functional dyspepsia
DM803GL ID DM803GL
DM803GL DN CIPEMASTAT
DM803GL HS Phase 3
DM803GL SN Cipemastat; Trocade; Ro 32-3555; 190648-49-8; UNII-02HQ4TYQ60; 02HQ4TYQ60; GFUITADOEPNRML-SJORKVTESA-N; Cipemastat [USAN:INN]; Ro 32-3555/000; Trocade (TN); Cipemastat (USAN/INN); GTPL6466; CHEMBL115653; SCHEMBL7088217; CTK8F1312; BDBM30344; MolPort-023-276-601; ZINC600699; (alphaR,betaR)-beta-(Cyclopentylmethyl)-gamma-oxo-alpha-((3,4,4-piperidinebutyrohydroxamic acid; AKOS024457333; HY-19677; Ro-32-03555; Ro-323555000; RT-015421; RO32-3555; CS-0016192; D03517; J-012306
DM803GL DT Small molecular drug
DM803GL PC 9824350
DM803GL MW 436.5
DM803GL FM C22H36N4O5
DM803GL IC InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1
DM803GL CS CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C
DM803GL IK GFUITADOEPNRML-SJORKVTESA-N
DM803GL IU (2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide
DM803GL CA CAS 190648-49-8
DM803GL DE Rheumatoid arthritis
DMJ9ZIY ID DMJ9ZIY
DMJ9ZIY DN CK-2017357
DMJ9ZIY HS Phase 3
DMJ9ZIY SN Tirasemtiv; 1005491-05-3; Tirasemtiv(CK-2017357); CK-2017357; UNII-G8WSM7R635; G8WSM7R635; 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one; CK 2017357; 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2-ol; 2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-;2H-Imidazo[4,5-b]pyrazin-2-one, 1-(1-ethylpropyl)-6-ethynyl-1,3-dihydro-; Tirasemtiv [USAN:INN]; Tirasemtiv (USAN/INN); SCHEMBL976988; GTPL8280; tiraseMtiv (CK-2017357); CHEMBL3039529; EX-A367; DTXSID90143379; RSQGZEAXODVTOL-UHFFFAOYSA-N
DMJ9ZIY CP Cytokinetics
DMJ9ZIY DT Small molecular drug
DMJ9ZIY PC 23729157
DMJ9ZIY MW 230.27
DMJ9ZIY FM C12H14N4O
DMJ9ZIY IC InChI=1S/C12H14N4O/c1-4-8-7-13-10-11(14-8)16(12(17)15-10)9(5-2)6-3/h1,7,9H,5-6H2,2-3H3,(H,13,15,17)
DMJ9ZIY CS CCC(CC)N1C2=NC(=CN=C2NC1=O)C#C
DMJ9ZIY IK RSQGZEAXODVTOL-UHFFFAOYSA-N
DMJ9ZIY IU 5-ethynyl-3-pentan-3-yl-1H-imidazo[4,5-b]pyrazin-2-one
DMJ9ZIY CA CAS 1005491-05-3
DMJ9ZIY DE Muscle fatigue; Amyotrophic lateral sclerosis
DMTSONL ID DMTSONL
DMTSONL DN Claritin/Singulair
DMTSONL HS Phase 3
DMTSONL SN Loratadine/montelukast sodium
DMTSONL CP Schering-Plough
DMTSONL DE Allergic rhinitis
DMPQR1D ID DMPQR1D
DMPQR1D DN Claudiximab
DMPQR1D HS Phase 3
DMPQR1D SN IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed
DMPQR1D CP Ganymed Pharmaceuticals AG
DMPQR1D DT Antibody
DMPQR1D DE Esophageal cancer; Gastric adenocarcinoma
DMQSBX4 ID DMQSBX4
DMQSBX4 DN Clazosentan
DMQSBX4 HS Phase 3
DMQSBX4 SN Clazosentan; 180384-56-9; Ro-61-1790; VML-588; UNII-3DRR0X4728; AXV-343434; CHEMBL109648; 3DRR0X4728; Clazosentan [INN]; VML 588; AXV 034; AXV-034343; Ro 61-1790; AXV-034; AXV 034343; AC1O5FK3; SCHEMBL1652657; CTK4D7597; DTXSID60170955; ZINC3939238; BDBM50066370; AKOS032946377; SB18855; N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE; DB-065318; FT-0765561
DMQSBX4 CP Actelion Pharmaceuticals
DMQSBX4 DT Small molecular drug
DMQSBX4 PC 6433095
DMQSBX4 MW 577.6
DMQSBX4 FM C25H23N9O6S
DMQSBX4 IC InChI=1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34)
DMQSBX4 CS CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
DMQSBX4 IK LFWCJABOXHSRGC-UHFFFAOYSA-N
DMQSBX4 IU N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
DMQSBX4 CA CAS 180384-56-9
DMQSBX4 DE Vasospasm; Cerebral vasospasm
DMR21Q3 ID DMR21Q3
DMR21Q3 DN Clevudine
DMR21Q3 HS Phase 3
DMR21Q3 SN Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN)
DMR21Q3 CP Bukwang; Eisai
DMR21Q3 DT Small molecular drug
DMR21Q3 PC 73115
DMR21Q3 MW 260.22
DMR21Q3 FM C10H13FN2O5
DMR21Q3 IC InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
DMR21Q3 CS CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F
DMR21Q3 IK GBBJCSTXCAQSSJ-XQXXSGGOSA-N
DMR21Q3 IU 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR21Q3 CA CAS 163252-36-6
DMR21Q3 CB CHEBI:135964
DMR21Q3 DE Hepatitis B virus infection
DMSPN58 ID DMSPN58
DMSPN58 DN Clomethiazole
DMSPN58 HS Phase 3
DMSPN58 SN Clomethiazole; 533-45-9; Chlormethiazole; 5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE; Distraneurin; Emineurina; Clomethiazolum; Chlormethiazol; Chlorethiazol; Chlorethiazole; Somnevrin; Clometiazole; Clomethiazol; 5-(2-Chloroethyl)-4-methyl-1,3-thiazole; Thiazole, 5-(2-chloroethyl)-4-methyl-; Clometiazolo [DCIT]; Chloro-S.C.T.Z.; C6H8ClNS; UNII-0C5DBZ19HV; Clometiazol [INN-Spanish]; Clomethiazolum [INN-Latin]; WY 1485; Clomethiazole [INN]; SCTZ [as edisylate]; EINECS 208-565-7; 4-Methyl-5-(beta-chloroethyl)thiazole; BRN 0114244; 0C5DBZ19HV
DMSPN58 DT Small molecular drug
DMSPN58 PC 10783
DMSPN58 MW 161.65
DMSPN58 FM C6H8ClNS
DMSPN58 IC InChI=1S/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3
DMSPN58 CS CC1=C(SC=N1)CCCl
DMSPN58 IK PCLITLDOTJTVDJ-UHFFFAOYSA-N
DMSPN58 IU 5-(2-chloroethyl)-4-methyl-1,3-thiazole
DMSPN58 CA CAS 533-45-9
DMSPN58 CB CHEBI:92875
DMSPN58 DE Stroke
DMFQ1WX ID DMFQ1WX
DMFQ1WX DN CLS006
DMFQ1WX HS Phase 3
DMFQ1WX CP Cutanea Wayne, PA
DMFQ1WX DE Verruca vulgaris
DMASPWR ID DMASPWR
DMASPWR DN CM-2395
DMASPWR HS Phase 3
DMASPWR CP Cenomed BioSciences
DMASPWR DE Schizophrenia
DMLMN2F ID DMLMN2F
DMLMN2F DN CM-AT
DMLMN2F HS Phase 3
DMLMN2F DE Autism spectrum disorder; Attention deficit hyperactivity disorder
DMC4X7L ID DMC4X7L
DMC4X7L DN CMS-024-02
DMC4X7L HS Phase 3
DMC4X7L SN Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
DMC4X7L CP Shenzhen Kangzhe Pharmaceutical Co Ltd
DMC4X7L PC 11303106
DMC4X7L MW 367.4
DMC4X7L FM C17H25N3O6
DMC4X7L IC InChI=1S/C17H25N3O6/c1-9(2)14(17(25)26)20-16(24)13(8-21)19-15(23)12(18)7-10-3-5-11(22)6-4-10/h3-6,9,12-14,21-22H,7-8,18H2,1-2H3,(H,19,23)(H,20,24)(H,25,26)/t12-,13-,14-/m0/s1
DMC4X7L CS CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMC4X7L IK TYFLVOUZHQUBGM-IHRRRGAJSA-N
DMC4X7L IU (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid
DMC4X7L CA CAS 154039-16-4
DMC4X7L CB CHEBI:165974
DMC4X7L DE Solid tumour/cancer
DM9Y3B5 ID DM9Y3B5
DM9Y3B5 DN CMX-001
DM9Y3B5 HS Phase 3
DM9Y3B5 SN Brincidofovir; CMX001; 444805-28-1; Hexadecyloxypropyl-cidofovir; CMX 001; Hexadecyloxypropyl cidofovir; UNII-6794O900AX; 6794O900AX; HDP-Cidofovir; Cidofovir-HDP; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid; Brincidofovir [USAN:INN]; Hexadecyloxypropyl - cidofovir; Cidofovir prodrug; HDP-HPMPC; Brincidofovir (USAN); AC1LA8GF; 3-(hexadecyloxy)propyl hydrogen ((((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)
DM9Y3B5 CP Chimerix
DM9Y3B5 DT Small molecular drug
DM9Y3B5 PC 483477
DM9Y3B5 MW 561.7
DM9Y3B5 FM C27H52N3O7P
DM9Y3B5 IC InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
DM9Y3B5 CS CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O
DM9Y3B5 IK WXJFKKQWPMNTIM-VWLOTQADSA-N
DM9Y3B5 IU [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
DM9Y3B5 CA CAS 444805-28-1
DM9Y3B5 DE Solid tumour/cancer
DMB4JPG ID DMB4JPG
DMB4JPG DN CNTX-4975
DMB4JPG HS Phase 3
DMB4JPG CP Centrexion Therapeutics Boston, MA
DMB4JPG DE Pain; Morton neuroma; Knee osteoarthritis
DMWZ2TU ID DMWZ2TU
DMWZ2TU DN CO-1686
DMWZ2TU HS Phase 3
DMWZ2TU SN 1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284
DMWZ2TU CP Clovis Oncology
DMWZ2TU DT Small molecular drug
DMWZ2TU PC 57335384
DMWZ2TU MW 555.6
DMWZ2TU FM C27H28F3N7O3
DMWZ2TU IC InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)
DMWZ2TU CS CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC
DMWZ2TU IK HUFOZJXAKZVRNJ-UHFFFAOYSA-N
DMWZ2TU IU N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
DMWZ2TU CA CAS 1374640-70-6
DMWZ2TU DE Lung cancer; Non-small-cell lung cancer
DMN9ETB ID DMN9ETB
DMN9ETB DN Contusugene ladenovec
DMN9ETB HS Phase 3
DMN9ETB SN Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
DMN9ETB CP Introgen Therapeutics
DMN9ETB DE Oral cancer; Liver metastasis
DMA0WEK ID DMA0WEK
DMA0WEK DN Coprexa
DMA0WEK HS Phase 3
DMA0WEK SN Tetrathiomolybdate
DMA0WEK CP Pipex Pharmaceuticals
DMA0WEK DT Small molecular drug
DMA0WEK PC 5245480
DMA0WEK MW 226.2
DMA0WEK FM H2MoS4-2
DMA0WEK IC InChI=1S/Mo.2H2S.2S/h;2*1H2;;/p-2
DMA0WEK CS [SH-].[SH-].S=[Mo]=S
DMA0WEK IK VVRHUOPINLMZBL-UHFFFAOYSA-L
DMA0WEK IU bis(sulfanylidene)molybdenum;sulfanide
DMA0WEK CA CAS 16330-92-0
DMA0WEK CB CHEBI:30703
DMA0WEK DE Neurological disorder
DMBS3UG ID DMBS3UG
DMBS3UG DN CORT-125134
DMBS3UG HS Phase 3
DMBS3UG SN relacorilant; Relacorilant; UNII-2158753C7E; 2158753C7E; 1496510-51-0; Relacorilant [INN]; Relacorilant [WHO-DD]; Relacorilant [USAN:INN]; SCHEMBL15454999; WANIDIGFXJFFEL-SANMLTNESA-N; CORT125134; ZINC141949519; AKOS032945759; J3.651.009I; ((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone; Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoqui
DMBS3UG CP Corcept TherapeuticsMenlo Park, CA
DMBS3UG PC 73051463
DMBS3UG MW 586.6
DMBS3UG FM C27H22F4N6O3S
DMBS3UG IC InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
DMBS3UG CS CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
DMBS3UG IK WANIDIGFXJFFEL-SANMLTNESA-N
DMBS3UG IU [(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
DMBS3UG CA CAS 1496510-51-0
DMBS3UG DE Alcohol dependence; Solid tumour/cancer; Cushing disease
DMMEAOL ID DMMEAOL
DMMEAOL DN Coversin
DMMEAOL HS Phase 3
DMMEAOL CP Akari Therapeutics
DMMEAOL DT Recombinant?protein
DMMEAOL DE Paroxysmal nocturnal haemoglobinuria
DMZIM37 ID DMZIM37
DMZIM37 DN CP-868596
DMZIM37 HS Phase 3
DMZIM37 SN Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMZIM37 CP Pfizer
DMZIM37 TC Anticancer Agents
DMZIM37 DT Small molecular drug
DMZIM37 PC 10366136
DMZIM37 MW 443.5
DMZIM37 FM C26H29N5O2
DMZIM37 IC InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3
DMZIM37 CS CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
DMZIM37 IK DYNHJHQFHQTFTP-UHFFFAOYSA-N
DMZIM37 IU 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMZIM37 CA CAS 670220-88-9
DMZIM37 CB CHEBI:145365
DMZIM37 DE Gastrointestinal cancer; Acute myelogenous leukaemia; Malignant glioma; Acute myeloid leukaemia; Gastrointestinal stromal tumour
DM2EO5M ID DM2EO5M
DM2EO5M DN CPC-211
DM2EO5M HS Phase 3
DM2EO5M SN Dichloracetate; Dichloroacetate; Dichloroacetate ion; Dichloroacetic acid ion(1-); LS-11597; STL483470; 13425-80-4; 2,2-bis(chloranyl)ethanoate; 2,2-dichloroacetate; 2q8h; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; ACETIC ACID, DICHLORO-, ION(1-); Acetic acid,2,2-dichloro-, ion(1-); BRN 3903873; CHEBI:28240; CTK4B9070; DCA; DTXSID40158610; GTPL4518; NCGC00241105-01
DM2EO5M PC 25975
DM2EO5M MW 127.93
DM2EO5M FM C2HCl2O2-
DM2EO5M IC JXTHNDFMNIQAHM-UHFFFAOYSA-M
DM2EO5M CS C(C(=O)[O-])(Cl)Cl
DM2EO5M IK 1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
DM2EO5M IU 2,2-dichloroacetate
DM2EO5M CA CAS 13425-80-4
DM2EO5M CB CHEBI:28240
DM2EO5M DE Dehydrogenase PDC deficiency
DMPXOYJ ID DMPXOYJ
DMPXOYJ DN CPI-0610
DMPXOYJ HS Phase 3
DMPXOYJ CP Constellation pharmaceuticals
DMPXOYJ PC 57389999
DMPXOYJ MW 365.8
DMPXOYJ FM C20H16ClN3O2
DMPXOYJ IC InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1
DMPXOYJ CS CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl
DMPXOYJ IK GCWIQUVXWZWCLE-INIZCTEOSA-N
DMPXOYJ IU 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide
DMPXOYJ CA CAS 1380087-89-7
DMPXOYJ DE Acute myeloid leukaemia; Myelodysplastic neoplasm; Myeloproliferative neoplasm; Myelofibrosis
DM5XUQL ID DM5XUQL
DM5XUQL DN CPI-613
DM5XUQL HS Phase 3
DM5XUQL SN CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
DM5XUQL CP Cornerstone Pharmaceuticals
DM5XUQL DT Small molecular drug
DM5XUQL PC 24770514
DM5XUQL MW 388.6
DM5XUQL FM C22H28O2S2
DM5XUQL IC InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
DM5XUQL CS C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
DM5XUQL IK ZYRLHJIMTROTBO-UHFFFAOYSA-N
DM5XUQL IU 6,8-bis(benzylsulfanyl)octanoic acid
DM5XUQL CA CAS 95809-78-2
DM5XUQL DE Acute myeloid leukaemia; Myelodysplastic syndrome; B-cell lymphoma; Metastatic colorectal cancer; Recurrent adult burkitt lymphoma; T-cell lymphoma; Pancreatic cancer
DM62E7C ID DM62E7C
DM62E7C DN CPL-7075
DM62E7C HS Phase 3
DM62E7C SN Ajulemic acid; Lenabasum; IP-751; CT-3; 137945-48-3; IP 751; UNII-OGN7X90BT8; CPL7075; JBT-101; OGN7X90BT8; Resunab; (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid; (6ar,10ar)-3-(1,1-Dimethylheptyl)-1-Hydroxy-6,6-Dimethyl-6a,7,10,10a-Tetrahydro-6h-Benzo[c]chromene-9-Carboxylic Acid; DMH-THC-11-OIC; AB-III-56; CT 3; CPL 7075; Lenabasum [USAN]; HU-239; AC1MJ0SY; SCHEMBL26441; CHEMBL456341; GTPL9772; IP751; Mixed CB agonist/sodim channel blocker (pain), Cervelo
DM62E7C CP Cervelo Pharmaceuticals Ltd
DM62E7C DT Small molecular drug
DM62E7C PC 3083542
DM62E7C MW 400.5
DM62E7C FM C25H36O4
DM62E7C IC InChI=1S/C25H36O4/c1-6-7-8-9-12-24(2,3)17-14-20(26)22-18-13-16(23(27)28)10-11-19(18)25(4,5)29-21(22)15-17/h10,14-15,18-19,26H,6-9,11-13H2,1-5H3,(H,27,28)/t18-,19-/m1/s1
DM62E7C CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C(=O)O)O
DM62E7C IK YCHYFHOSGQABSW-RTBURBONSA-N
DM62E7C IU (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid
DM62E7C CA CAS 137945-48-3
DM62E7C DE Cystic fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis; Diffuse systemic sclerosis
DM60TVK ID DM60TVK
DM60TVK DN CQA 206-291
DM60TVK HS Phase 3
DM60TVK SN Cqa 206-291; Cqa-206-291; 93822-42-5; UNII-9I4I0M95U7; 9I4I0M95U7; N,N-Diethyl-N-(1-ethyl-6-methylergoline-8-yl)sulfamide; AC1L3TWB; SCHEMBL8195741; Sulfamide, N,N-diethyl-N'-((8alpha)-1-ethyl-6-methylergolin-8-yl)-
DM60TVK DT Small molecular drug
DM60TVK PC 9953076
DM60TVK MW 404.6
DM60TVK FM C21H32N4O2S
DM60TVK IC InChI=1S/C21H32N4O2S/c1-5-24-13-15-11-20-18(17-9-8-10-19(24)21(15)17)12-16(14-23(20)4)22-28(26,27)25(6-2)7-3/h8-10,13,16,18,20,22H,5-7,11-12,14H2,1-4H3/t16-,18+,20+/m0/s1
DM60TVK CS CCN1C=C2C[C@@H]3[C@H](C[C@@H](CN3C)NS(=O)(=O)N(CC)CC)C4=C2C1=CC=C4
DM60TVK IK ARTRTLXKTHJPRW-ILZDJORESA-N
DM60TVK IU (6aR,9S,10aR)-9-(diethylsulfamoylamino)-4-ethyl-7-methyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline
DM60TVK CA CAS 93822-42-5
DM60TVK DE Parkinson disease
DMKD2BQ ID DMKD2BQ
DMKD2BQ DN Creatine ALS-08
DMKD2BQ HS Phase 3
DMKD2BQ SN Creatine; ALS-02; ALS-05; ALS-08; HD-02; PD-02; PD-04; PD-06; Creatine (ALS), Avicena; Creatine (amyotrophic lateral sclerosis), Avicena; PD-01, Avicena; AL-02 (ALS), Avicena; AL-08 (ALS), Avicena; Creatine (Huntington's disease), Avicena; Creatine (Parkinson's disease), Avicena
DMKD2BQ CP Avicena Group Inc; Avicena
DMKD2BQ DT Small molecular drug
DMKD2BQ PC 586
DMKD2BQ MW 131.13
DMKD2BQ FM C4H9N3O2
DMKD2BQ IC InChI=1S/C4H9N3O2/c1-7(4(5)6)2-3(8)9/h2H2,1H3,(H3,5,6)(H,8,9)
DMKD2BQ CS CN(CC(=O)O)C(=N)N
DMKD2BQ IK CVSVTCORWBXHQV-UHFFFAOYSA-N
DMKD2BQ IU 2-[carbamimidoyl(methyl)amino]acetic acid
DMKD2BQ CA CAS 57-00-1
DMKD2BQ CB CHEBI:16919
DMKD2BQ DE Motor neurone disease
DM7QI29 ID DM7QI29
DM7QI29 DN Crenezumab
DM7QI29 HS Phase 3
DM7QI29 SN MABT5102A; RG7412
DM7QI29 CP Genentech
DM7QI29 DT Monoclonal antibody
DM7QI29 DE Alzheimer disease
DM5F24X ID DM5F24X
DM5F24X DN Crocin
DM5F24X HS Phase 3
DM5F24X DE Knee osteoarthritis
DM67P0F ID DM67P0F
DM67P0F DN CS-038
DM67P0F HS Phase 3
DM67P0F SN Chiglitazar; CS-00098; PPAR alpha/gamma agonist (diabetes), Chipscreen Biosciences
DM67P0F CP Shenzhen Chipscreen Biosciences Ltd
DM67P0F DT Small molecular drug
DM67P0F PC 71402018
DM67P0F MW 572.6
DM67P0F FM C36H29FN2O4
DM67P0F IC InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
DM67P0F CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C[C@@H](C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
DM67P0F IK QNLWMPLUWMWDMQ-YTTGMZPUSA-N
DM67P0F IU (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid
DM67P0F CA CAS 743438-45-1
DM67P0F DE Type-2 diabetes
DMSY0NE ID DMSY0NE
DMSY0NE DN CS1001
DMSY0NE HS Phase 3
DMSY0NE CP CStone Pharmaceuticals
DMSY0NE DT Antibody
DMSY0NE DE Non-small cell lung cancer
DM1PV4Y ID DM1PV4Y
DM1PV4Y DN CS-600G
DM1PV4Y HS Phase 3
DM1PV4Y SN Koloxo; Loxoprofen; Loxoprofen (INN); Loxoprofen [INN]; Loxoprofen sodium hydrate; Loxoprofene; Loxoprofene [French]; Loxoprofeno; Loxoprofeno [Spanish]; Loxoprofenum; Loxoprofenum [Latin]; YMBXTVYHTMGZDW-UHFFFAOYSA-N; sodium loxoprofen; yl]-propionic acid; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; 68767-14-6; CHEBI:76172; CHEMBL19299; CS-600; MFCD00864331; Oxeno
DM1PV4Y PC 3965
DM1PV4Y MW 246.3
DM1PV4Y FM C15H18O3
DM1PV4Y IC YMBXTVYHTMGZDW-UHFFFAOYSA-N
DM1PV4Y CS CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
DM1PV4Y IK 1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
DM1PV4Y IU 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid
DM1PV4Y CA CAS 68767-14-6
DM1PV4Y CB CHEBI:76172
DM1PV4Y DE Epilepsy
DM4CSDH ID DM4CSDH
DM4CSDH DN CS-8958
DM4CSDH HS Phase 3
DM4CSDH SN Inavir; Laninamivir octanoate; R-118958
DM4CSDH CP Biota
DM4CSDH DT Small molecular drug
DM4CSDH PC 9847629
DM4CSDH MW 472.5
DM4CSDH FM C21H36N4O8
DM4CSDH IC InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1
DM4CSDH CS CCCCCCCC(=O)OC[C@H]([C@H]([C@H]1[C@@H]([C@H](C=C(O1)C(=O)O)N=C(N)N)NC(=O)C)OC)O
DM4CSDH IK UKTIJASCFRNWCB-RMIBSVFLSA-N
DM4CSDH IU (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2-hydroxy-1-methoxy-3-octanoyloxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4CSDH CA CAS 203120-46-1
DM4CSDH CB CHEBI:134741
DM4CSDH DE Influenza virus infection
DMV574J ID DMV574J
DMV574J DN CSL312
DMV574J HS Phase 3
DMV574J SN Garadacimab
DMV574J CP CSL Behring
DMV574J DT Antibody
DMV574J DE Hereditary angioedema
DMZJGVL ID DMZJGVL
DMZJGVL DN CSL-654
DMZJGVL HS Phase 3
DMZJGVL SN RIX-FP; Recombinant coagulation factor IX (iv, hemophilia B), CSL Behring; Recombinant coagulation factor IX (extended half-life, hemophilia B), CSL Behring
DMZJGVL CP Csl behring
DMZJGVL SQ DB00100 sequence: YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT
DMZJGVL DE Factor IX deficiency
DMU2ZFK ID DMU2ZFK
DMU2ZFK DN CT-2584
DMU2ZFK HS Phase 3
DMU2ZFK SN Apra (Cell Therapeutics, US, US); 1-[11-(Dodecylamino)-10-hydroxyundecyl]-3,7-dimethylxanthine
DMU2ZFK CP Cell Therapeutics
DMU2ZFK DT Small molecular drug
DMU2ZFK PC 3081346
DMU2ZFK MW 533.8
DMU2ZFK FM C30H55N5O3
DMU2ZFK IC InChI=1S/C30H55N5O3/c1-4-5-6-7-8-9-10-13-16-19-22-31-24-26(36)21-18-15-12-11-14-17-20-23-35-29(37)27-28(32-25-33(27)2)34(3)30(35)38/h25-26,31,36H,4-24H2,1-3H3
DMU2ZFK CS CCCCCCCCCCCCNCC(CCCCCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
DMU2ZFK IK MZNMZWZGUGFQJP-UHFFFAOYSA-N
DMU2ZFK IU 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethylpurine-2,6-dione
DMU2ZFK CA CAS 166981-13-1
DMU2ZFK DE Solid tumour/cancer
DMQPH29 ID DMQPH29
DMQPH29 DN Curcumin
DMQPH29 HS Phase 3
DMQPH29 SN curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
DMQPH29 DT Small molecular drug
DMQPH29 PC 969516
DMQPH29 MW 368.4
DMQPH29 FM C21H20O6
DMQPH29 IC InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
DMQPH29 CS COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
DMQPH29 IK VFLDPWHFBUODDF-FCXRPNKRSA-N
DMQPH29 IU (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
DMQPH29 CA CAS 458-37-7
DMQPH29 CB CHEBI:3962
DMQPH29 DE Solid tumour/cancer
DMIQ31Y ID DMIQ31Y
DMIQ31Y DN Custirsen
DMIQ31Y HS Phase 3
DMIQ31Y SN OGX-001/TV-1011; OGX-011
DMIQ31Y CP OncoGenex Pharmaceuticals
DMIQ31Y DT Small molecular drug
DMIQ31Y PC 72941942
DMIQ31Y MW 7346
DMIQ31Y FM C231H312N78O119P20S20
DMIQ31Y IC InChI=1S/C231H312N78O119P20S20/c1-97-52-295(224(324)273-181(97)235)210-174(361-32-24-353-10)166(118(60-310)401-210)422-444(347,464)383-78-136-171(179(366-37-29-358-15)215(406-136)308-95-265-160-189(243)253-86-259-195(160)308)427-448(351,468)387-80-138-172(180(367-38-30-359-16)216(408-138)309-96-269-164-199(309)279-220(247)283-208(164)320)428-447(350,467)385-76-134-168(175(362-33-25-354-11)211(403-134)296-53-98(2)182(236)274-225(296)325)423-442(345,462)380-73-131-114(48-151(397-131)303-90-263-158-187(241)251-84-257-193(158)303)417-439(342,459)379-72-128-115(49-152(398-128)304-91-266-161-196(304)276-217(244)280-205(161)317)418-435(338,455)370-63-121-107(41-144(390-121)291-22-19-141(234)272-223(291)323)411-430(333,450)374-67-125-111(45-148(394-125)300-87-260-155-184(238)248-81-254-190(155)300)415-437(340,457)378-71-130-117(51-154(400-130)306-93-268-163-198(306)278-219(246)282-207(163)319)420-440(343,460)376-68-126-112(46-149(395-126)301-88-261-156-185(239)249-82-255-191(156)301)416-438(341,458)377-70-129-116(50-153(399-129)305-92-267-162-197(305)277-218(245)281-206(162)318)419-436(339,456)373-66-124-109(43-146(393-124)293-56-101(5)201(313)285-228(293)328)413-433(336,453)368-61-119-105(39-142(388-119)289-20-17-139(232)270-221(289)321)409-429(332,449)371-64-122-110(44-147(391-122)294-57-102(6)202(314)286-229(294)329)414-434(337,454)372-65-123-108(42-145(392-123)292-55-100(4)200(312)284-227(292)327)412-432(335,452)369-62-120-106(40-143(389-120)290-21-18-140(233)271-222(290)322)410-431(334,451)375-69-127-113(47-150(396-127)302-89-262-157-186(240)250-83-256-192(157)302)421-441(344,461)382-75-133-167(177(364-35-27-356-13)213(405-133)299-59-104(8)204(316)288-231(299)331)424-445(348,465)384-77-135-169(176(363-34-26-355-12)212(404-135)297-54-99(3)183(237)275-226(297)326)425-446(349,466)386-79-137-170(178(365-36-28-357-14)214(407-137)307-94-264-159-188(242)252-85-258-194(159)307)426-443(346,463)381-74-132-165(311)173(360-31-23-352-9)209(402-132)298-58-103(7)203(315)287-230(298)330/h17-22,52-59,81-96,105-138,142-154,165-180,209-216,310-311H,23-51,60-80H2,1-16H3,(H,332,449)(H,333,450)(H,334,451)(H,335,452)(H,336,453)(H,337,454)(H,338,455)(H,339,456)(H,340,457)(H,341,458)(H,342,459)(H,343,460)(H,344,461)(H,345,462)(H,346,463)(H,347,464)(H,348,465)(H,349,466)(H,350,467)(H,351,468)(H2,232,270,321)(H2,233,271,322)(H2,234,272,323)(H2,235,273,324)(H2,236,274,325)(H2,237,275,326)(H2,238,248,254)(H2,239,249,255)(H2,240,250,256)(H2,241,251,257)(H2,242,252,258)(H2,243,253,259)(H,284,312,327)(H,285,313,328)(H,286,314,329)(H,287,315,330)(H,288,316,331)(H3,244,276,280,317)(H3,245,277,281,318)(H3,246,278,282,319)(H3,247,279,283,320)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,209+,210+,211+,212+,213+,214+,215+,216+,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?,441?,442?,443?,444?,445?,446?,447?,448?/m0/s1
DMIQ31Y CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OCCOC)N1C=C(C(=NC1=O)N)C)CO)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O)S
DMIQ31Y IK RCFZILUHCNXXFY-DEDWCYLFSA-N
DMIQ31Y IU 1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-[hydroxy-[[(2R,3R,4R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMIQ31Y CA CAS 890056-27-6
DMIQ31Y DE Lung cancer; Breast cancer; Prostate cancer
DM0JA9N ID DM0JA9N
DM0JA9N DN Cyrtominetin
DM0JA9N HS Phase 3
DM0JA9N SN IdB-1031; D,L-5,7,3',4'-Tetrahydroxy-6,8-dimethylflavanone; Rac-5,7-Dihydroxy-2-(3,4-dihydroxyphenyl)-6,8-dimethyl-2,3-dihydro-4H-1-benzopyran-4-one
DM0JA9N DT Small molecular drug
DM0JA9N PC 125309
DM0JA9N MW 316.3
DM0JA9N FM C17H16O6
DM0JA9N IC InChI=1S/C17H16O6/c1-7-15(21)8(2)17-14(16(7)22)12(20)6-13(23-17)9-3-4-10(18)11(19)5-9/h3-5,13,18-19,21-22H,6H2,1-2H3
DM0JA9N CS CC1=C(C(=C2C(=C1O)C(=O)CC(O2)C3=CC(=C(C=C3)O)O)C)O
DM0JA9N IK AESMRHCYHARBLU-UHFFFAOYSA-N
DM0JA9N IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6,8-dimethyl-2,3-dihydrochromen-4-one
DM0JA9N CA CAS 95272-99-4
DM0JA9N DE Phlegmy cough
DMUF0BJ ID DMUF0BJ
DMUF0BJ DN CYTISINE
DMUF0BJ HS Phase 3
DMUF0BJ SN CYTISINE; 485-35-8; Sophorine; Baptitoxine; (-)-Cytisine; Laburnin; Baptitoxin; Tabex; Ulexin; Cytiton; Ulexine; Tsitizin; Cytitone; Cystisine; Cytizin; Citizin; Tabax; (1R,5S)-3,4,5,6-Tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Baphitoxine; UNII-53S5U404NU; Cytisine (-); HSDB 3560; EINECS 207-616-0; NSC 407282; BRN 0083882; Cytisin; (1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One; CHEBI:4055; CHEMBL497939; 53S5U404NU; Cytisine, 98%
DMUF0BJ DT Small molecular drug
DMUF0BJ PC 10235
DMUF0BJ MW 190.24
DMUF0BJ FM C11H14N2O
DMUF0BJ IC InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1
DMUF0BJ CS C1[C@H]2CNC[C@@H]1C3=CC=CC(=O)N3C2
DMUF0BJ IK ANJTVLIZGCUXLD-DTWKUNHWSA-N
DMUF0BJ IU (1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
DMUF0BJ CA CAS 485-35-8
DMUF0BJ CB CHEBI:4055
DMUF0BJ DE Tobacco dependence
DMYJ2QB ID DMYJ2QB
DMYJ2QB DN D2A21
DMYJ2QB HS Phase 3
DMYJ2QB SN Demegel (Demegen, US, US); Alanyl-L-phenylalanyl-L-alanyl-L-phenylalanine
DMYJ2QB PC 16199213
DMYJ2QB MW 2775.4
DMYJ2QB FM C144H212N32O24
DMYJ2QB IC InChI=1S/C144H212N32O24/c1-91(155-128(183)105(154)83-97-49-15-7-16-50-97)122(177)161-106(65-31-40-74-145)129(184)165-111(70-36-45-79-150)134(189)172-117(86-100-55-21-10-22-56-100)139(194)156-93(3)124(179)163-108(67-33-42-76-147)131(186)167-114(73-39-48-82-153)137(192)175-120(89-103-61-27-13-28-62-103)143(198)169-110(69-35-44-78-149)132(187)168-113(72-38-47-81-152)136(191)174-119(88-102-59-25-12-26-60-102)140(195)157-92(2)123(178)162-107(66-32-41-75-146)130(185)166-112(71-37-46-80-151)135(190)173-118(87-101-57-23-11-24-58-101)141(196)158-94(4)125(180)164-109(68-34-43-77-148)133(188)171-116(85-99-53-19-9-20-54-99)142(197)159-95(5)126(181)170-115(84-98-51-17-8-18-52-98)138(193)160-96(6)127(182)176-121(144(199)200)90-104-63-29-14-30-64-104/h7-30,49-64,91-96,105-121H,31-48,65-90,145-154H2,1-6H3,(H,155,183)(H,156,194)(H,157,195)(H,158,196)(H,159,197)(H,160,193)(H,161,177)(H,162,178)(H,163,179)(H,164,180)(H,165,184)(H,166,185)(H,167,186)(H,168,187)(H,169,198)(H,170,181)(H,171,188)(H,172,189)(H,173,190)(H,174,191)(H,175,192)(H,176,182)(H,199,200)/t91-,92-,93-,94-,95-,96-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-/m0/s1
DMYJ2QB CS C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](C)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)O)NC(=O)[C@H](CC8=CC=CC=C8)N
DMYJ2QB IK WVRNJUBRGDUHNI-CPOCOYSOSA-N
DMYJ2QB IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoic acid
DMYJ2QB DE Burn and burn infection
DM9FAJM ID DM9FAJM
DM9FAJM DN D-5519
DM9FAJM HS Phase 3
DM9FAJM DE Asthma
DM6S4R2 ID DM6S4R2
DM6S4R2 DN DA-3031
DM6S4R2 HS Phase 3
DM6S4R2 SN Long-acting agent (neutropenia), Dong-A; PEG-GCSF (neutropenia), Dong-A; PEG-granulocyte colony stimulating factor (neutropenia),Dong-A
DM6S4R2 CP Dong-A Pharmaceutical Co Ltd
DM6S4R2 DT Small molecular drug
DM6S4R2 PC 168302
DM6S4R2 MW 185.26
DM6S4R2 FM C10H19NO2
DM6S4R2 IC InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
DM6S4R2 CS CC(=C)C(=O)OCCN(C)C.C=C
DM6S4R2 IK PNMYDOBPCBCQIA-UHFFFAOYSA-N
DM6S4R2 IU 2-(dimethylamino)ethyl 2-methylprop-2-enoate;ethene
DM6S4R2 CA CAS 25134-54-7
DM6S4R2 DE Neutropenia
DMP2SGN ID DMP2SGN
DMP2SGN DN Dabelotine
DMP2SGN HS Phase 3
DMP2SGN SN Dabelotine mesilate; S-12024; S-12024-2
DMP2SGN CP Servier
DMP2SGN DT Small molecular drug
DMP2SGN PC 177949
DMP2SGN MW 262.35
DMP2SGN FM C15H22N2O2
DMP2SGN IC InChI=1S/C15H22N2O2/c1-17-8-3-5-12-4-2-6-14(15(12)17)19-11-13-10-16-7-9-18-13/h2,4,6,13,16H,3,5,7-11H2,1H3
DMP2SGN CS CN1CCCC2=C1C(=CC=C2)OCC3CNCCO3
DMP2SGN IK VXQWMLATWQSCBE-UHFFFAOYSA-N
DMP2SGN IU 2-[(1-methyl-3,4-dihydro-2H-quinolin-8-yl)oxymethyl]morpholine
DMP2SGN CA CAS 118976-38-8
DMP2SGN DE Cognitive impairment
DMRDZ4X ID DMRDZ4X
DMRDZ4X DN Dabigatran etexilate
DMRDZ4X HS Phase 3
DMRDZ4X SN BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504
DMRDZ4X CP Boehringer Ingelheim Ridgefield, CT
DMRDZ4X PC 135565674
DMRDZ4X MW 627.7
DMRDZ4X FM C34H41N7O5
DMRDZ4X IC InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
DMRDZ4X CS CCCCCCOC(=O)NC(=N)C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4
DMRDZ4X IK KSGXQBZTULBEEQ-UHFFFAOYSA-N
DMRDZ4X IU ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate
DMRDZ4X CA CAS 211915-06-9
DMRDZ4X DE Venous thromboembolism
DMKNCVM ID DMKNCVM
DMKNCVM DN Dalcetrapib
DMKNCVM HS Phase 3
DMKNCVM SN JTT 705; JTT-705; R-1658; RG-1658; RO-4607381; S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
DMKNCVM CP Roche
DMKNCVM DT Small molecular drug
DMKNCVM PC 6918540
DMKNCVM MW 389.6
DMKNCVM FM C23H35NO2S
DMKNCVM IC InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26)
DMKNCVM CS CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
DMKNCVM IK YZQLWPMZQVHJED-UHFFFAOYSA-N
DMKNCVM IU S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
DMKNCVM CA CAS 211513-37-0
DMKNCVM CB CHEBI:95001
DMKNCVM DE Hyperlipidaemia; Acute coronary syndrome
DM1C95G ID DM1C95G
DM1C95G DN DARE-BV1
DM1C95G HS Phase 3
DM1C95G CP Dare Bioscience
DM1C95G DT Small molecular drug
DM1C95G DE Bacterial vaginosis
DMR2JD4 ID DMR2JD4
DMR2JD4 DN Darotropium + 642444
DMR2JD4 HS Phase 3
DMR2JD4 CP GSK
DMR2JD4 DT Combination drug
DMR2JD4 PC 25195533; 642444
DMR2JD4 DE Chronic obstructive pulmonary disease
DM2FV5N ID DM2FV5N
DM2FV5N DN Darunavir + cobicistat
DM2FV5N HS Phase 3
DM2FV5N SN Prezcobix; Prezista + GS-9350
DM2FV5N TC Antiviral Agents
DM2FV5N DT Combination drug
DM2FV5N DE Coronavirus Disease 2019 (COVID-19)
DMF3V01 ID DMF3V01
DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01 HS Phase 3
DMF3V01 SN Prezista + norvir + T-705 + oxichloroquine
DMF3V01 TC Antiviral Agents
DMF3V01 DT Combination drug
DMF3V01 DE Coronavirus Disease 2019 (COVID-19)
DMN9BO3 ID DMN9BO3
DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3 HS Phase 3
DMN9BO3 SN Prezista + norvir + rseltamivir + oxichloroquine
DMN9BO3 TC Antiviral Agents
DMN9BO3 DT Combination drug
DMN9BO3 DE Coronavirus Disease 2019 (COVID-19)
DMN8DQH ID DMN8DQH
DMN8DQH DN Darusentan
DMN8DQH HS Phase 3
DMN8DQH SN Endothelin antagonist, BASF; HMR-4005; LU-127043; LU-135252
DMN8DQH CP Gilead Sciences; Knoll GmbH
DMN8DQH DT Small molecular drug
DMN8DQH PC 177236
DMN8DQH MW 410.4
DMN8DQH FM C22H22N2O6
DMN8DQH IC InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
DMN8DQH CS COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
DMN8DQH IK FEJVSJIALLTFRP-LJQANCHMSA-N
DMN8DQH IU (2S)-2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
DMN8DQH CA CAS 171714-84-4
DMN8DQH DE Hypotension
DMD7K9X ID DMD7K9X
DMD7K9X DN Davunetide
DMD7K9X HS Phase 3
DMD7K9X SN Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
DMD7K9X CP Allon Therapeutics Inc
DMD7K9X DE Cognitive impairment; Alzheimer disease
DMUX7Z8 ID DMUX7Z8
DMUX7Z8 DN DE-117
DMUX7Z8 HS Phase 3
DMUX7Z8 PC 44230999
DMUX7Z8 MW 520.6
DMUX7Z8 FM C26H28N6O4S
DMUX7Z8 IC InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
DMUX7Z8 CS CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4
DMUX7Z8 IK VIQCWEGEHRBLAC-UHFFFAOYSA-N
DMUX7Z8 IU propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate
DMUX7Z8 CA CAS 1187451-19-9
DMUX7Z8 DE Glaucoma/ocular hypertension
DM0GUV2 ID DM0GUV2
DM0GUV2 DN DE-766
DM0GUV2 HS Phase 3
DM0GUV2 CP Daiichi Sankyo
DM0GUV2 DE Non-small-cell lung cancer; Gastric adenocarcinoma; Nasopharyngeal carcinoma
DM2R15Q ID DM2R15Q
DM2R15Q DN DENBUFYLLINE
DM2R15Q HS Phase 3
DM2R15Q SN denbufylline; 57076-71-8; Denbufyllinum [Latin]; Denbufilina [Spanish]; BRL 30892; BRL-30892; UNII-04B949KO6F; 1,3-Di-n-butyl-7-(2-oxopropyl)xanthine; CHEMBL277465; 7-Acetonyl-1,3-dibutylxanthine; C16H24N4O3; 04B949KO6F; 3,7-Dihydro-1,3-dibutyl-7-(2-oxopropyl)-1H-purine-2,6-dione; 1,3-Di-n-butyl-7-(2& -oxopropyl)xanthine; Denbufyllinum; Denbufilina; 1H-Purine-2,6-dione,1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-; Denbufylline [INN:BAN]; Denbufylline [BAN:INN
DM2R15Q DT Small molecular drug
DM2R15Q PC 2984
DM2R15Q MW 320.39
DM2R15Q FM C16H24N4O3
DM2R15Q IC InChI=1S/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3
DM2R15Q CS CCCCN1C2=C(C(=O)N(C1=O)CCCC)N(C=N2)CC(=O)C
DM2R15Q IK HJPRDDKCXVCFOH-UHFFFAOYSA-N
DM2R15Q IU 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione
DM2R15Q CA CAS 57076-71-8
DM2R15Q CB CHEBI:92669
DM2R15Q DE Cognitive impairment
DM2ATZB ID DM2ATZB
DM2ATZB DN Deoxynojirimycin
DM2ATZB HS Phase 3
DM2ATZB SN 1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; deoxynojirimycin; Moranoline; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; UNII-FZ56898FLE; D-1-deoxynojirimycin; 1,5-Dideoxy-1,5-imino-D-glucitol; CHEMBL307429; C6H13NO4; FZ56898FLE; CHEBI:44369; 1-Deoxy-Nojirimycin; 5-Amino-1,5-dideoxy-D-glucopyranose; DNJ; AK151410; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-
DM2ATZB DT Small molecular drug
DM2ATZB PC 29435
DM2ATZB MW 163.17
DM2ATZB FM C6H13NO4
DM2ATZB IC InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1
DM2ATZB CS C1[C@@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O
DM2ATZB IK LXBIFEVIBLOUGU-JGWLITMVSA-N
DM2ATZB IU (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol
DM2ATZB CA CAS 19130-96-2
DM2ATZB CB CHEBI:44369
DM2ATZB DE Pompe disease
DMDLU4Z ID DMDLU4Z
DMDLU4Z DN Desmoteplase
DMDLU4Z HS Phase 3
DMDLU4Z CP Lundbeck Research
DMDLU4Z SQ P98119|URT1_DESRO Salivary plasminogen activator alpha 1 precursor - Desmodus rotundus: MVNTMKTKLLCVLLLCGAVFSLPRQETYRQLARGSRAYGVACKDEITQMTYRRQESWLRPEVRSKRVEHCQCDRGQARCHTVPVNSCSEPRCFNGGTCWQAVYFSDFVCQCPAGYTGKRCEVDTRATCYEGQGVTYRGTWSTAESRVECINWNSSLLTRRTYNGRMPDAFNLGLGNHNYCRNPNGAPKPWCYVIKAGKFTSESCSVPVCSKATCGLRKYKEPQLHSTGGLFTDITSHPWQAAIFAQNRRSSGERFLCGGILISSCWVLTAAHCFQESYLPDQLKVVLGRTYRVKPGEEEQTFKVKKYIVHKEFDDDTYNNDIALLQLKSDSPQCAQESDSVRAICLPEANLQLPDWTECELSGYGKHKSSSPFYSEQLKEGHVRLYPSSRCAPKFLFNKTVTNNMLCAGDTRSGEIYPNVHDACQGDSGGPLVCMNDNHMTLLGIISWGVGCGEKDVPGVYTKVTNYLGWIRDNMHL
DMDLU4Z DE Ischemic stroke
DMRH291 ID DMRH291
DMRH291 DN Dexanabinol
DMRH291 HS Phase 3
DMRH291 SN Sinnabidiol; HU 211; HU-211; PRS 211007-000; (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; 1,1-Dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol; 11-Hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-Hydroxy-delta-8-dmh-thc; 11-Hydroxymethyl-delta(8)-tetrahydrocannabinol-dimethylheptyl; 11-OH-delta(8)-Thc-dmh; 5'(1,1-Dimethylheptyl)-7-hydroxyhexahydrocannabinol; 7-Hydroxy-delta-6-tetrahydrocannabinoldimethylheptyl
DMRH291 CP Pharmos
DMRH291 DT Small molecular drug
DMRH291 PC 107778
DMRH291 MW 386.6
DMRH291 FM C25H38O3
DMRH291 IC InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m0/s1
DMRH291 CS CCCCCCC(C)(C)C1=CC(=C2[C@H]3CC(=CC[C@@H]3C(OC2=C1)(C)C)CO)O
DMRH291 IK SSQJFGMEZBFMNV-PMACEKPBSA-N
DMRH291 IU (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMRH291 CA CAS 112924-45-5
DMRH291 DE Traumatic brain injury
DM1WNGJ ID DM1WNGJ
DM1WNGJ DN DFP-10917
DM1WNGJ HS Phase 3
DM1WNGJ CP Delta-Fly Pharma
DM1WNGJ DT Small molecular drug
DM1WNGJ PC 119184
DM1WNGJ MW 252.23
DM1WNGJ FM C10H12N4O4
DM1WNGJ IC InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
DM1WNGJ CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N
DM1WNGJ IK DCYBPMFXJCWXNB-JWIUVKOKSA-N
DM1WNGJ IU (2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile
DM1WNGJ CA CAS 135598-68-4
DM1WNGJ CB CHEBI:145435
DM1WNGJ DE Acute lymphoblastic leukaemia; Solid tumour/cancer; Acute myeloid leukaemia
DMOUGX1 ID DMOUGX1
DMOUGX1 DN Diamyd
DMOUGX1 HS Phase 3
DMOUGX1 SN Oramyd; Human glutamate decarboxylase 65 kDa isoform; RhGAD-65; GAD65 (diabetes), Biosyn; GAD65 (diabetes), Diamyd; GAD65 (diabetes), OMJPI; GAD65 antigen-based therapy (diabetes), Johnson and Johnson; GAD65 (diabetes), Ortho-McNeil-Janssen Pharmaceuticals
DMOUGX1 CP Diamyd medical
DMOUGX1 DE Type-1 diabetes
DM4XBM7 ID DM4XBM7
DM4XBM7 DN DiaPep-277
DM4XBM7 HS Phase 3
DM4XBM7 SN Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor
DM4XBM7 CP Andromeda biotech
DM4XBM7 DT Small molecular drug
DM4XBM7 PC 16138701
DM4XBM7 MW 2390.7
DM4XBM7 FM C106H180N28O34
DM4XBM7 IC InChI=1S/C106H180N28O34/c1-23-55(18)83(131-102(164)82(54(16)17)130-90(152)60(27-24-32-111-106(109)110)118-91(153)65(38-50(8)9)123-92(154)63(36-48(4)5)121-87(149)58(21)117-101(163)81(53(14)15)129-76(140)45-113-74(138)43-112-75(139)44-114-88(150)62(35-47(2)3)126-100(162)80(108)52(12)13)103(165)133-33-25-28-71(133)98(160)115-56(19)85(147)120-64(37-49(6)7)93(155)125-68(41-78(143)144)95(157)128-70(46-135)97(159)124-66(39-51(10)11)96(158)132-84(59(22)136)104(166)134-34-26-29-72(134)99(161)116-57(20)86(148)122-67(40-73(107)137)94(156)119-61(30-31-77(141)142)89(151)127-69(105(167)168)42-79(145)146/h47-72,80-84,135-136H,23-46,108H2,1-22H3,(H2,107,137)(H,112,139)(H,113,138)(H,114,150)(H,115,160)(H,116,161)(H,117,163)(H,118,153)(H,119,156)(H,120,147)(H,121,149)(H,122,148)(H,123,154)(H,124,159)(H,125,155)(H,126,162)(H,127,151)(H,128,157)(H,129,140)(H,130,152)(H,131,164)(H,132,158)(H,141,142)(H,143,144)(H,145,146)(H,167,168)(H4,109,110,111)/t55-,56-,57-,58-,59+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,80-,81-,82-,83-,84-/m0/s1
DM4XBM7 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N
DM4XBM7 IK VGGRNGOEDNBLPH-YJHCMWSWSA-N
DM4XBM7 IU (2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]butanedioic acid
DM4XBM7 CA CAS 179822-83-4
DM4XBM7 DE Autoimmune diabetes
DMHZBEO ID DMHZBEO
DMHZBEO DN Difelikefalin
DMHZBEO HS Phase 3
DMHZBEO SN UNII-NA1U919MRO; NA1U919MRO; MR13A9; 1024828-77-0; FE202845; Difelikefalin [INN]; Difelikefalin [USAN:INN]; SEQ ID NO: 2; GTPL9044; CHEMBL3989915; SCHEMBL10316464; BDBM235785; DB11938; FE-202845; US9359399, 2; D-Phe-D-Phe-D-Leu-D-Lys-[gamma-(4-N-piperidinyl)amino carboxylic acid]; 4-Piperidinecarboylic acid, 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-; 4-Piperidinecarboxylic acid, N1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-4-amino-; 4-Piperidinecarboxylic acid, N1-(D
DMHZBEO CP Cara Therapeutics Stamford, CT
DMHZBEO PC 24794466
DMHZBEO MW 679.8
DMHZBEO FM C36H53N7O6
DMHZBEO IC InChI=1S/C36H53N7O6/c1-24(2)21-29(32(45)40-28(15-9-10-18-37)34(47)43-19-16-36(39,17-20-43)35(48)49)42-33(46)30(23-26-13-7-4-8-14-26)41-31(44)27(38)22-25-11-5-3-6-12-25/h3-8,11-14,24,27-30H,9-10,15-23,37-39H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)(H,48,49)/t27-,28-,29-,30-/m1/s1
DMHZBEO CS CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
DMHZBEO IK FWMNVWWHGCHHJJ-SKKKGAJSSA-N
DMHZBEO IU 4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid
DMHZBEO CA CAS 1024828-77-0
DMHZBEO DE Pruritus
DMU4T9Y ID DMU4T9Y
DMU4T9Y DN Dimesna
DMU4T9Y HS Phase 3
DMU4T9Y SN Tavocept (TN)
DMU4T9Y CP BioNumerik Pharmaceuticals
DMU4T9Y DT Small molecular drug
DMU4T9Y PC 65625
DMU4T9Y MW 326.4
DMU4T9Y FM C4H8Na2O6S4
DMU4T9Y IC InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2
DMU4T9Y CS C(CS(=O)(=O)[O-])SSCCS(=O)(=O)[O-].[Na+].[Na+]
DMU4T9Y IK KQYGMURBTJPBPQ-UHFFFAOYSA-L
DMU4T9Y IU disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate
DMU4T9Y CA CAS 16208-51-8
DMU4T9Y DE Diabetic nephropathy; Lung cancer
DM19CFZ ID DM19CFZ
DM19CFZ DN DIMS-0150
DM19CFZ HS Phase 3
DM19CFZ SN Kappaproct; Antisense NF-kBp65 oligonucleotide (IBD), InDex Pharmaceuticals; Antisense NF-kBp65 oligonucleotide (IBD), Serono; Antisense NF-kBp65 oligonucleotide (inflammatory bowel disease), Serono
DM19CFZ CP Karolinska Institute
DM19CFZ DT Antisense drug
DM19CFZ DE Ulcerative colitis
DMG8U6M ID DMG8U6M
DMG8U6M DN DIPROTEVERINE HYDROCHLORIDE
DMG8U6M HS Phase 3
DMG8U6M SN UNII-T587ZFV6UM; T587ZFV6UM; Isoquinoline, 3,4-dihydro-6,7-bis(1-methylethoxy)-1-((3,4-diethoxyphenyl)methyl)-, hydrochloride; 69373-88-2; 1-(3',4'-Diethoxybenzyl)-6,7-diisoprooxy-3,4-dihydroisoquinoline hydrochloride; DIPROTEVERINE HYDROCHLORIDE; AC1MHK6D; SCHEMBL7313181; DTXSID30219461; AWQPJKUSDUHYIX-UHFFFAOYSA-N; 69373-95-1 (Parent); LS-85505; 1-(3'4'-diethoxybenzyl)-6,7-diisopropoxy-3,4-dihydroisoquinoline hydrochloride; 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline hydrochloride
DMG8U6M DT Small molecular drug
DMG8U6M PC 3052867
DMG8U6M MW 462
DMG8U6M FM C26H36ClNO4
DMG8U6M IC InChI=1S/C26H35NO4.ClH/c1-7-28-23-10-9-19(14-24(23)29-8-2)13-22-21-16-26(31-18(5)6)25(30-17(3)4)15-20(21)11-12-27-22;/h9-10,14-18H,7-8,11-13H2,1-6H3;1H
DMG8U6M CS CCOC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OC(C)C)OC(C)C)OCC.Cl
DMG8U6M IK AWQPJKUSDUHYIX-UHFFFAOYSA-N
DMG8U6M IU 1-[(3,4-diethoxyphenyl)methyl]-6,7-di(propan-2-yloxy)-3,4-dihydroisoquinoline;hydrochloride
DMG8U6M CA CAS 69373-88-2
DMG8U6M DE Angina pectoris
DM64QG9 ID DM64QG9
DM64QG9 DN Diquafosol
DM64QG9 HS Phase 3
DM64QG9 SN UppppU; Diquafosol [INN]; KPY 998; Diquafosol [INN:BAN]; INS-365; P1,P4-Bis(5'-uridyl) tetrahydrogen tetraphosphate; P1,P4-Bis(5'-uridyl) tetraphosphate; [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DM64QG9 CP Santen Pharmaceutical
DM64QG9 DT Small molecular drug
DM64QG9 PC 148197
DM64QG9 MW 790.3
DM64QG9 FM C18H26N4O23P4
DM64QG9 IC InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
DM64QG9 CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O
DM64QG9 IK NMLMACJWHPHKGR-NCOIDOBVSA-N
DM64QG9 IU [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DM64QG9 CA CAS 59985-21-6
DM64QG9 CB CHEBI:27791
DM64QG9 DE Dry eye disease
DMJS8V3 ID DMJS8V3
DMJS8V3 DN Disufenton sodium
DMJS8V3 HS Phase 3
DMJS8V3 SN Cerovive; ARL-16556; CPI-22; CXY-059; HPN-07; NXY-059; NXY-059G; OKN-007; S-PBN; Nitrones (cancer), Oklahoma Medical Research Foundation; Nitrones, Renovis/AstraZeneca; PBN derivatives, Renovis/AstraZeneca; Spin trap agents, Renovis/AstraZeneca
DMJS8V3 CP AstraZeneca
DMJS8V3 DT Small molecular drug
DMJS8V3 PC 6440181
DMJS8V3 MW 381.3
DMJS8V3 FM C11H13NNa2O7S2
DMJS8V3 IC InChI=1S/C11H15NO7S2.2Na/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19;;/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19);;/q;2*+1/p-2/b12-7-;;
DMJS8V3 CS CC(C)(C)/[N+](=C/C1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])/[O-].[Na+].[Na+]
DMJS8V3 IK XLZOVRYBVCMCGL-BPNVQINPSA-L
DMJS8V3 IU disodium;4-[(Z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate
DMJS8V3 DE Ischemia; Recurrent glioblastoma
DMMKGBP ID DMMKGBP
DMMKGBP DN D-Methionine
DMMKGBP HS Phase 3
DMMKGBP SN D-Methionine-(methyl-13C); D-Methionine-(methyl-13C), 99 atom % 13C
DMMKGBP DT Small molecular drug
DMMKGBP PC 84815
DMMKGBP MW 149.21
DMMKGBP FM C5H11NO2S
DMMKGBP IC InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DMMKGBP CS CSCC[C@H](C(=O)O)N
DMMKGBP IK FFEARJCKVFRZRR-SCSAIBSYSA-N
DMMKGBP IU (2R)-2-amino-4-methylsulfanylbutanoic acid
DMMKGBP CA CAS 348-67-4
DMMKGBP CB CHEBI:16867
DMO7BQS ID DMO7BQS
DMO7BQS DN DMP-444
DMO7BQS HS Phase 3
DMO7BQS CP Bristol-Myers Squibb Pharma Co
DMO7BQS DE Coronary artery disease
DMQLSMB ID DMQLSMB
DMQLSMB DN Dociparstat sodium
DMQLSMB HS Phase 3
DMQLSMB SN DSTAT
DMQLSMB CP Chimerix
DMQLSMB DE Acute myeloid leukaemia
DMH8IT5 ID DMH8IT5
DMH8IT5 DN Donaperminogene seltoplasmid
DMH8IT5 HS Phase 3
DMH8IT5 SN VM202
DMH8IT5 CP ViroMed
DMH8IT5 DT Gene therapy
DMH8IT5 DE Amyotrophic lateral sclerosis; Diabetic foot ulcer; Diabetic neuropathy
DM97S10 ID DM97S10
DM97S10 DN DP-b99
DM97S10 HS Phase 3
DM97S10 SN DP-b99; 343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid
DM97S10 CP D-Pharm
DM97S10 DT Small molecular drug
DM97S10 PC 9810955
DM97S10 MW 789
DM97S10 FM C42H64N2O12
DM97S10 IC InChI=1S/C42H64N2O12/c1-3-5-7-9-11-17-23-51-25-27-55-41(49)33-43(31-39(45)46)35-19-13-15-21-37(35)53-29-30-54-38-22-16-14-20-36(38)44(32-40(47)48)34-42(50)56-28-26-52-24-18-12-10-8-6-4-2/h13-16,19-22H,3-12,17-18,23-34H2,1-2H3,(H,45,46)(H,47,48)
DM97S10 CS CCCCCCCCOCCOC(=O)CN(CC(=O)O)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(=O)O)CC(=O)OCCOCCCCCCCC
DM97S10 IK FTGBVHPWUIHWRH-UHFFFAOYSA-N
DM97S10 IU 2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-N-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid
DM97S10 CA CAS 343340-21-6
DM97S10 DE Stroke
DMWUN1S ID DMWUN1S
DMWUN1S DN Drisapersen
DMWUN1S HS Phase 3
DMWUN1S SN 2402968
DMWUN1S CP GlaxoSmithKline
DMWUN1S DT Antisense drug
DMWUN1S PC 121494119
DMWUN1S MW 6978
DMWUN1S FM C211H275N76O119P19S19
DMWUN1S IC InChI=1S/C211H275N76O119P19S19/c1-329-136-116(295)77(369-178(136)271-33-24-99(289)252-206(271)304)40-349-407(310,426)389-118-79(371-180(138(118)331-3)268-30-21-96(212)249-203(268)301)42-351-409(312,428)392-121-81(373-183(141(121)334-6)273-35-26-101(291)254-208(273)306)44-352-410(313,429)393-122-82(374-184(142(122)335-7)274-36-27-102(292)255-209(274)307)45-353-411(314,430)394-123-83(375-185(143(123)336-8)275-37-28-103(293)256-210(275)308)46-355-415(318,434)396-125-85(377-187(145(125)338-10)277-65-238-105-156(215)226-59-232-162(105)277)48-358-413(316,432)391-120-80(372-182(140(120)333-5)270-32-23-98(214)251-205(270)303)43-354-417(320,436)402-131-94(386-193(151(131)344-16)283-71-244-111-168(283)258-198(221)263-173(111)296)57-366-424(327,443)405-132-91(383-194(152(132)345-17)284-72-245-112-169(284)259-199(222)264-174(112)297)54-363-414(317,433)395-124-84(376-186(144(124)337-9)276-38-29-104(294)257-211(276)309)47-356-416(319,435)397-126-89(381-188(146(126)339-11)278-66-239-106-157(216)227-60-233-163(106)278)52-361-422(325,441)403-133-92(384-195(153(133)346-18)285-73-246-113-170(285)260-200(223)265-175(113)298)55-364-420(323,439)400-130-88(380-192(150(130)343-15)282-70-243-110-161(220)231-64-237-167(110)282)51-360-419(322,438)399-128-90(382-190(148(128)341-13)280-68-241-108-159(218)229-62-235-165(108)280)53-362-423(326,442)404-134-95(387-196(154(134)347-19)286-74-247-114-171(286)261-201(224)266-176(114)299)58-367-425(328,444)406-135-93(385-197(155(135)348-20)287-75-248-115-172(287)262-202(225)267-177(115)300)56-365-421(324,440)401-129-87(379-191(149(129)342-14)281-69-242-109-160(219)230-63-236-166(109)281)50-359-418(321,437)398-127-86(378-189(147(127)340-12)279-67-240-107-158(217)228-61-234-164(107)279)49-357-412(315,431)390-119-78(370-181(139(119)332-4)269-31-22-97(213)250-204(269)302)41-350-408(311,427)388-117-76(39-288)368-179(137(117)330-2)272-34-25-100(290)253-207(272)305/h21-38,59-95,116-155,178-197,288,295H,39-58H2,1-20H3,(H,310,426)(H,311,427)(H,312,428)(H,313,429)(H,314,430)(H,315,431)(H,316,432)(H,317,433)(H,318,434)(H,319,435)(H,320,436)(H,321,437)(H,322,438)(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H2,212,249,301)(H2,213,250,302)(H2,214,251,303)(H2,215,226,232)(H2,216,227,233)(H2,217,228,234)(H2,218,229,235)(H2,219,230,236)(H2,220,231,237)(H,252,289,304)(H,253,290,305)(H,254,291,306)(H,255,292,307)(H,256,293,308)(H,257,294,309)(H3,221,258,263,296)(H3,222,259,264,297)(H3,223,260,265,298)(H3,224,261,266,299)(H3,225,262,267,300)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,407?,408?,409?,410?,411?,412?,413?,414?,415?,416?,417?,418?,419?,420?,421?,422?,423?,424?,425?/m1/s1
DMWUN1S CS CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=S)(O)O[C@@H]3[C@H](O[C@H]([C@@H]3OC)N4C=CC(=NC4=O)N)COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=CC(=O)NC8=O)COP(=S)(O)O[C@@H]9[C@H](O[C@H]([C@@H]9OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=NC2=C(N=CN=C21)N)COP(=O)(O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=NC1=O)N)COP(=S)(O)O[C@@H]1[C@H](O[C@H]([C@@H]1OC)N1C=CC(=O)NC1=O)CO)S)O
DMWUN1S IK HUGILZFVSVLCAO-XVKRXUDYSA-N
DMWUN1S IU 1-[(2R,3R,4R,5R)-5-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxy-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione
DMWUN1S CA CAS 1251830-50-8
DMWUN1S DE Duchenne dystrophy
DMM0HAE ID DMM0HAE
DMM0HAE DN DSC-127
DMM0HAE HS Phase 3
DMM0HAE SN aclerastide; UNII-YYD6UT8T47; YYD6UT8T47; Aclerastide [INN]; DSC-127; Norleu3-a(1-7); Asp-arg-nle-tyr-ile-his-pro; DSC127; USB-001; 227803-63-6; 1-7-Angiotensin II, 3-L-norleucine-5-L-isoleucine
DMM0HAE CP Derma Sciences
DMM0HAE DT Small molecular drug
DMM0HAE PC 9811551
DMM0HAE MW 913
DMM0HAE FM C42H64N12O11
DMM0HAE IC InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1
DMM0HAE CS CCCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
DMM0HAE IK RUBMHAHMIJSMHA-LBWFYSSPSA-N
DMM0HAE IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid
DMM0HAE CA CAS 227803-63-6
DMM0HAE DE Diabetic foot ulcer
DM6P8HU ID DM6P8HU
DM6P8HU DN Dutasteride + tamsulosin
DM6P8HU HS Phase 3
DM6P8HU SN Jalyn; Dutasteride / tamsulosin; Tamsulosin / Dutasteride; Dutasteride mixture with tamsulosin
DM6P8HU CP GSK
DM6P8HU DT Combination drug (small molecular drug)
DM6P8HU PC 11679580
DM6P8HU MW 937
DM6P8HU FM C47H58F6N4O7S
DM6P8HU IC InChI=1S/C27H30F6N2O2.C20H28N2O5S/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33;1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36);5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-,16-,17-,19+,21+,24-,25+;15-/m01/s1
DM6P8HU CS CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DM6P8HU IK SHHCJPKACHSWFP-NMXGMQNUSA-N
DM6P8HU IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
DM6P8HU DE Benign prostatic hyperplasia; Prostate cancer
DMM5VTA ID DMM5VTA
DMM5VTA DN Dutogliptin
DMM5VTA HS Phase 3
DMM5VTA SN Dutogliptin tartrate; PHX-1004; PHX-1149; PHX-1149T; DPP IV inhibitors (diabetes), Phenomix; DPP IV program (diabetes), Phenomix
DMM5VTA CP Phenomix Corp
DMM5VTA PC 11253490
DMM5VTA MW 241.1
DMM5VTA FM C10H20BN3O3
DMM5VTA IC InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1
DMM5VTA CS B([C@@H]1CCCN1C(=O)CN[C@@H]2CCNC2)(O)O
DMM5VTA IK DVJAMEIQRSHVKC-BDAKNGLRSA-N
DMM5VTA IU [(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid
DMM5VTA CA CAS 852329-66-9
DMM5VTA DE Type-2 diabetes
DMAFUIR ID DMAFUIR
DMAFUIR DN DWP-431
DMAFUIR HS Phase 3
DMAFUIR SN Recombinant bone morphogenetic protein 2 (bone synthesis), Daewoong; RBMP-2 (bone synthesis), Daewoong
DMAFUIR CP Daewoong Pharmaceutical Co Ltd
DMAFUIR DE Bone development disorder
DMM1YC4 ID DMM1YC4
DMM1YC4 DN E-101
DMM1YC4 HS Phase 3
DMM1YC4 SN Myeloperoxidase; Glucose oxidase; Human myeloperoxidase, dimer; E-101 (infections); Myeloperoxidase formulations (nosocomial infections), Exoxemis; E-101 (infections), Exoxemis; MPO enzyme system (hospital-acquiredl infections), Exoxemis; Myeloperoxidase + glucose oxidase (infections), Exoxemis
DMM1YC4 CP Exoxemis
DMM1YC4 DT Small molecular drug
DMM1YC4 PC 11973707
DMM1YC4 MW 377.3
DMM1YC4 FM C17H26Cl2N2O3
DMM1YC4 IC InChI=1S/C17H25ClN2O3.ClH/c1-4-12-8-13(18)16(23-3)14(15(12)21)17(22)19-9-11-6-7-20(5-2)10-11;/h8,11,21H,4-7,9-10H2,1-3H3,(H,19,22);1H/t11-;/m0./s1
DMM1YC4 CS CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCN(C2)CC)OC)Cl.Cl
DMM1YC4 IK RDZXYWICCLALQM-MERQFXBCSA-N
DMM1YC4 IU 5-chloro-3-ethyl-N-[[(3S)-1-ethylpyrrolidin-3-yl]methyl]-2-hydroxy-6-methoxybenzamide;hydrochloride
DMM1YC4 DE Infectious disease
DMTNUJ8 ID DMTNUJ8
DMTNUJ8 DN E-2609
DMTNUJ8 HS Phase 3
DMTNUJ8 SN Beta secretase inhibitor (Alzheimer's disease), Eisai
DMTNUJ8 CP Eisai Co Ltd
DMTNUJ8 PC 57827330
DMTNUJ8 MW 437.4
DMTNUJ8 FM C19H18F3N5O2S
DMTNUJ8 IC InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1
DMTNUJ8 CS C[C@@H]1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N
DMTNUJ8 IK AACUJFVOHGRMTR-DPXNYUHVSA-N
DMTNUJ8 IU N-[3-[(4aS,5R,7aS)-2-amino-5-methyl-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-(difluoromethyl)pyrazine-2-carboxamide
DMTNUJ8 CA CAS 1388651-30-6
DMTNUJ8 DE Alzheimer disease
DM42PFT ID DM42PFT
DM42PFT DN E-3810
DM42PFT HS Phase 3
DM42PFT SN Lucitanib; AL-3810; E-3810, EOS
DM42PFT CP Clovis oncology
DM42PFT DT Small molecular drug
DM42PFT PC 25031915
DM42PFT MW 443.5
DM42PFT FM C26H25N3O4
DM42PFT IC InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)
DM42PFT CS CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
DM42PFT IK CUDVHEFYRIWYQD-UHFFFAOYSA-N
DM42PFT IU 6-[7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl]oxy-N-methylnaphthalene-1-carboxamide
DM42PFT CA CAS 1058137-23-7
DM42PFT CB CHEBI:65209
DM42PFT DE Solid tumour/cancer
DMUHS5Q ID DMUHS5Q
DMUHS5Q DN E-913
DMUHS5Q HS Phase 3
DMUHS5Q SN E913; E 913; 342394-93-8; 1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-; 11-butyl-9-(cyclohexylmethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-3,8,11-triazaspiro[5.5]undecane-7,10-dione; 1,4,9-Triazaspiro[5.5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-; AC1LANMM; E-913; SCHEMBL1649664; GTPL3500; CHEMBL1196395; e9-13; BDBM50190513; LS-184716
DMUHS5Q DT Small molecular drug
DMUHS5Q PC 491774
DMUHS5Q MW 483.6
DMUHS5Q FM C28H41N3O4
DMUHS5Q IC InChI=1S/C28H41N3O4/c1-2-3-13-31-26(32)23(18-21-7-5-4-6-8-21)29-27(33)28(31)11-14-30(15-12-28)20-22-9-10-24-25(19-22)35-17-16-34-24/h9-10,19,21,23H,2-8,11-18,20H2,1H3,(H,29,33)
DMUHS5Q CS CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC4=C(C=C3)OCCO4)CC5CCCCC5
DMUHS5Q IK VBONNDPACFTZMX-UHFFFAOYSA-N
DMUHS5Q IU 1-butyl-3-(cyclohexylmethyl)-9-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane-2,5-dione
DMUHS5Q CA CAS 342394-93-8
DMUHS5Q DE Human immunodeficiency virus infection
DMLA1ER ID DMLA1ER
DMLA1ER DN EC20
DMLA1ER HS Phase 3
DMLA1ER SN Technetium Tc-99m etarfolatide
DMLA1ER CP Endocyte
DMLA1ER DT Small molecular drug
DMLA1ER PC 135428923
DMLA1ER MW 745.7
DMLA1ER FM C29H35N11O11S
DMLA1ER IC InChI=1S/C29H35N11O11S/c30-15(24(45)37-17(7-20(42)43)25(46)38-18(11-52)28(50)51)10-33-19(41)6-5-16(27(48)49)36-23(44)12-1-3-13(4-2-12)32-8-14-9-34-22-21(35-14)26(47)40-29(31)39-22/h1-4,9,15-18,32,52H,5-8,10-11,30H2,(H,33,41)(H,36,44)(H,37,45)(H,38,46)(H,42,43)(H,48,49)(H,50,51)(H3,31,34,39,40,47)/t15-,16+,17-,18-/m0/s1
DMLA1ER CS C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)NC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMLA1ER IK RKGPQAGUQDVJHG-MHORFTMASA-N
DMLA1ER IU (2R)-5-[[(2S)-2-amino-3-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]amino]-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-oxopentanoic acid
DMLA1ER CA CAS 479578-27-3
DMLA1ER DE Ovarian cancer
DMS9R43 ID DMS9R43
DMS9R43 DN Ecopipam
DMS9R43 HS Phase 3
DMS9R43 SN Sch-39166; Sch 39166; 112108-01-7; Ecopipam [INN]; Sch39166; UNII-0X748O646K; CHEMBL298406; 0X748O646K; DSSTox_RID_80075; DSSTox_CID_23814; 6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(d)naphtho(2,1b)azepine; DSSTox_GSID_43814; 5H-Benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)-; (6aS,13bR)-11-chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepin-12-ol; 5H-Benzo[d]naphth[2,1-b]azepin-12-ol,; ecopipam (controlled-release, Lesch Nyhan syndrome/Tourette's syndrome/compulsive gambling). Psyadon Pharmaceuticals
DMS9R43 DT Small molecular drug
DMS9R43 PC 107930
DMS9R43 MW 313.8
DMS9R43 FM C19H20ClNO
DMS9R43 IC InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1
DMS9R43 CS CN1CCC2=CC(=C(C=C2[C@@H]3[C@@H]1CCC4=CC=CC=C34)O)Cl
DMS9R43 IK DMJWENQHWZZWDF-PKOBYXMFSA-N
DMS9R43 IU (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol
DMS9R43 CA CAS 112108-01-7
DMS9R43 CB CHEBI:93645
DMS9R43 DE Cocaine addiction; Tourette syndrome
DMRLXAI ID DMRLXAI
DMRLXAI DN ED-71
DMRLXAI HS Phase 3
DMRLXAI SN Edirol; Eldecalcitol; (5Z,7E)-(1R,2R,3R)-2-(3-hydroxypropoxy)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; 104121-92-8; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)cholecalciferol; 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3; 2-(3-Hydroxypropoxy)-1,25-dihydroxyvitamin D3; ED 71; ED-71; I2JP8UE90H; UNII-I2JP8UE90H
DMRLXAI PC 6918141
DMRLXAI MW 490.7
DMRLXAI FM C30H50O5
DMRLXAI IC FZEXGDDBXLBRTD-AYIMTCTASA-N
DMRLXAI CS CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C
DMRLXAI IK 1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26-,27-,28-,30-/m1/s1
DMRLXAI IU (1R,2R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
DMRLXAI CA CAS 104121-92-8
DMRLXAI CB CHEBI:73927
DMRLXAI DE Osteoporosis
DMYVBF6 ID DMYVBF6
DMYVBF6 DN Edasalonexent
DMYVBF6 HS Phase 3
DMYVBF6 SN UNII-AF3Z6434KS; AF3Z6434KS; 1204317-86-1; Edasalonexent [INN]; SCHEMBL1823117; CHEMBL3786673; JQLBBYLGWHUHRW-KUBAVDMBSA-N; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide; Benzamide, 2-hydroxy-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl)amino)ethyl)-; N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16, 19-hexaenamidoethyl)-2-hydroxybenzamide
DMYVBF6 CP Catabasis Pharmaceuticals Cambridge, MA
DMYVBF6 PC 44626120
DMYVBF6 MW 490.7
DMYVBF6 FM C31H42N2O3
DMYVBF6 IC InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
DMYVBF6 CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)NCCNC(=O)C1=CC=CC=C1O
DMYVBF6 IK JQLBBYLGWHUHRW-KUBAVDMBSA-N
DMYVBF6 IU N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide
DMYVBF6 CA CAS 1204317-86-1
DMYVBF6 DE Duchenne dystrophy
DM3ZL7D ID DM3ZL7D
DM3ZL7D DN Edotecarin
DM3ZL7D HS Phase 3
DM3ZL7D SN ED-749; Edotecarin < Prop INN; J-107088; PF-804950; 12-(beta-D-Glucopyranosyl)-2,10-dihydroxy-6-[2-hydroxy-1-(hydroxymethyl)ethylamino]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DM3ZL7D CP Pfizer
DM3ZL7D DT Small molecular drug
DM3ZL7D PC 9808998
DM3ZL7D MW 608.6
DM3ZL7D FM C29H28N4O11
DM3ZL7D IC InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1
DM3ZL7D CS C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C=C(C=C6)O
DM3ZL7D IK QMVPQBFHUJZJCS-NTKFZFFISA-N
DM3ZL7D IU 13-(1,3-dihydroxypropan-2-ylamino)-6,20-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DM3ZL7D CA CAS 174402-32-5
DM3ZL7D DE Gastric adenocarcinoma
DMX7BM4 ID DMX7BM4
DMX7BM4 DN Efaproxyn
DMX7BM4 HS Phase 3
DMX7BM4 SN Efaproxiral; RSR13
DMX7BM4 CP Allos Therapeutics
DMX7BM4 DT Small molecular drug
DMX7BM4 PC 122335
DMX7BM4 MW 341.4
DMX7BM4 FM C20H23NO4
DMX7BM4 IC InChI=1S/C20H23NO4/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24)
DMX7BM4 CS CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)O)C
DMX7BM4 IK BNFRJXLZYUTIII-UHFFFAOYSA-N
DMX7BM4 IU 2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoic acid
DMX7BM4 CA CAS 131179-95-8
DMX7BM4 DE Lung cancer
DMKA2PI ID DMKA2PI
DMKA2PI DN Efpeglenatide
DMKA2PI HS Phase 3
DMKA2PI SN Langlenatide; Efpeglenatide [INN]; Langlenatide [WHO-DD]; UNII-3M1V5Z2270; SCHEMBL19712179; 3M1V5Z2270; 1296200-77-5
DMKA2PI CP Sanofi US Bridgewater, NJ
DMKA2PI PC 86278345
DMKA2PI MW 403.5
DMKA2PI FM C19H37N3O6
DMKA2PI IC InChI=1S/C19H37N3O6/c20-16(18(23)24)6-1-2-8-21-9-4-12-27-14-15-28-13-5-11-22-10-3-7-17(22)19(25)26/h16-17,21H,1-15,20H2,(H,23,24)(H,25,26)/t16-,17-/m0/s1
DMKA2PI CS C1C[C@H](N(C1)CCCOCCOCCCNCCCC[C@@H](C(=O)O)N)C(=O)O
DMKA2PI IK OJQLGILETRTDGQ-IRXDYDNUSA-N
DMKA2PI IU (2S)-1-[3-[2-[3-[[(5S)-5-amino-5-carboxypentyl]amino]propoxy]ethoxy]propyl]pyrrolidine-2-carboxylic acid
DMKA2PI DE Type-2 diabetes
DMCMJRA ID DMCMJRA
DMCMJRA DN EGF816
DMCMJRA HS Phase 3
DMCMJRA CP Novartis pharmaceuticals
DMCMJRA PC 72703790
DMCMJRA MW 495
DMCMJRA FM C26H31ClN6O2
DMCMJRA IC InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1
DMCMJRA CS CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)C(=CC=C3)Cl
DMCMJRA IK IOMMMLWIABWRKL-WUTDNEBXSA-N
DMCMJRA IU N-[7-chloro-1-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]benzimidazol-2-yl]-2-methylpyridine-4-carboxamide
DMCMJRA CA CAS 1508250-71-2
DMCMJRA DE Non-small-cell lung cancer
DMB2C0E ID DMB2C0E
DMB2C0E DN Elagolix
DMB2C0E HS Phase 3
DMB2C0E SN Elagolix; 834153-87-6; UNII-5B2546MB5Z; NBI-56418; 5B2546MB5Z; NBI56418; NBI 56418; Elagolix [USAN:INN]; Orilissa; ELA gOLIX; Elagolix (USAN/INN); SCHEMBL1642523; GTPL8362; CHEMBL1208155; DTXSID40232348; ABT-620; 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid; EX-A1765; BCP08827; ZINC49888891; CS-5329; SB16700; DB11979; compound 10b [PMID 19006286]; HY-14789; AN-27202; D09335; Z-3253; 153E876; Butanoic acid, 4-(((1R)-2-(5-(2-flu
DMB2C0E CP Abbott Laboratories Abbott; Neurocrine Biosciences
DMB2C0E DT Small molecular drug
DMB2C0E PC 11250647
DMB2C0E MW 631.6
DMB2C0E FM C32H30F5N3O5
DMB2C0E IC InChI=1S/C32H30F5N3O5/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42)/t25-/m0/s1
DMB2C0E CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F
DMB2C0E IK HEAUOKZIVMZVQL-VWLOTQADSA-N
DMB2C0E IU 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid
DMB2C0E CA CAS 834153-87-6
DMB2C0E DE Uterine fibroids
DMW6C81 ID DMW6C81
DMW6C81 DN Eltoprazine
DMW6C81 HS Phase 3
DMW6C81 SN Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
DMW6C81 CP Amarantus bioscience; psychogenics
DMW6C81 DT Small molecular drug
DMW6C81 PC 65853
DMW6C81 MW 220.27
DMW6C81 FM C12H16N2O2
DMW6C81 IC InChI=1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2
DMW6C81 CS C1CN(CCN1)C2=C3C(=CC=C2)OCCO3
DMW6C81 IK WVLHGCRWEHCIOT-UHFFFAOYSA-N
DMW6C81 IU 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine
DMW6C81 CA CAS 98224-03-4
DMW6C81 DE Non-hodgkin lymphoma; Alzheimer disease; Attention deficit hyperactivity disorder; Dyskinesia; Parkinson disease
DMZKTYJ ID DMZKTYJ
DMZKTYJ DN Enmetazobactam
DMZKTYJ HS Phase 3
DMZKTYJ SN AAI-101; AAI101; 1001404-83-6; UNII-80VUN7L00C; 80VUN7L00C; (2S,3S,5R)-3-methyl-3-((3-methyl-1H-1,2,3-triazol-3-ium-1-yl)methyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide; CHEMBL4458276; SCHEMBL18110082; OCID-5090; CS-7557; HY-103095; J3.628.087E; (2S,3S,5R)-3-Methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate; (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate; 1H-1,2,3-Triazolium, 3-(((2S,3S,5R)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt
DMZKTYJ CP Allecra Therapeutics
DMZKTYJ DT Small molecular drug
DMZKTYJ PC 23653540
DMZKTYJ MW 314.32
DMZKTYJ FM C11H14N4O5S
DMZKTYJ IC InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
DMZKTYJ CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=C[N+](=N3)C
DMZKTYJ IK HFZITXBUTWITPT-YWVKMMECSA-N
DMZKTYJ IU (2S,3S,5R)-3-methyl-3-[(3-methyltriazol-3-ium-1-yl)methyl]-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMZKTYJ CA CAS 1001404-83-6
DMZKTYJ DE Urinary tract infection
DMIKDCQ ID DMIKDCQ
DMIKDCQ DN Ensartinib
DMIKDCQ HS Phase 3
DMIKDCQ CP Xcovery Palm Beach Gardens, FL
DMIKDCQ PC 56960363
DMIKDCQ MW 561.4
DMIKDCQ FM C26H27Cl2FN6O3
DMIKDCQ IC InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1
DMIKDCQ CS C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N
DMIKDCQ IK GLYMPHUVMRFTFV-QLFBSQMISA-N
DMIKDCQ IU 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3S,5R)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide
DMIKDCQ CA CAS 1370651-20-9
DMIKDCQ DE Non-small-cell lung cancer
DM7EOBQ ID DM7EOBQ
DM7EOBQ DN Entacapone+levodopa+carbidopa
DM7EOBQ HS Phase 3
DM7EOBQ CP Orion; Novartis
DM7EOBQ DE Restless legs syndrome; Parkinson disease
DMTWLXY ID DMTWLXY
DMTWLXY DN Entresto
DMTWLXY HS Phase 3
DMTWLXY SN Sacubitril valsartan sodium hydrate; UNII-WB8FT61183; Sacubitril mixture with valsartan; WB8FT61183; Entresto (TN); Valsartan mixture with AHU-377; MolPort-042-624-138; C96H120N12Na6O21; 9052AF; AKOS026670199; ACN-036829; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; AK198922; AC-29037; Sacubitril valsartan sodium hydrate (JAN); FT-0700025; D10226; L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. wi
DMTWLXY CP Novartis East Hanover, NJ
DMTWLXY PC 71449007
DMTWLXY MW 1916
DMTWLXY FM C96H120N12Na6O21
DMTWLXY IC InChI=1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1
DMTWLXY CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMTWLXY IK ZASXKEGREHRXDL-CAWNUZPDSA-H
DMTWLXY IU hexasodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate
DMTWLXY CA CAS 936623-90-4
DMTWLXY DE Acute myocardial infarction; Heart failure
DM5H0R9 ID DM5H0R9
DM5H0R9 DN Enzastaurin
DM5H0R9 HS Phase 3
DM5H0R9 SN LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
DM5H0R9 CP Eli Lilly
DM5H0R9 TC Anticancer Agents
DM5H0R9 DT Small molecular drug
DM5H0R9 PC 176167
DM5H0R9 MW 515.6
DM5H0R9 FM C32H29N5O2
DM5H0R9 IC InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
DM5H0R9 CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7
DM5H0R9 IK AXRCEOKUDYDWLF-UHFFFAOYSA-N
DM5H0R9 IU 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
DM5H0R9 CA CAS 170364-57-5
DM5H0R9 CB CHEBI:91368
DM5H0R9 DE Central nervous system disease; Glioblastoma multiforme; Non-hodgkin lymphoma; Diffuse large B-cell lymphoma
DMEX86V ID DMEX86V
DMEX86V DN Epcoritamab
DMEX86V HS Phase 3
DMEX86V CP Genmab
DMEX86V DT Antibody
DMEX86V DE Diffuse large B-cell lymphoma
DM1SMAI ID DM1SMAI
DM1SMAI DN Eperisone
DM1SMAI HS Phase 3
DM1SMAI SN EMPP; Myonal; Myorelark; E-0646; E-2000; E-646; Eperisone (transdermal patch); Eperisone (oral), Eisai; Eperisone (transdermalpatch), Eisai; E-2000 (oral), Eisai; E-2000 (transdermal patch), Eisai
DM1SMAI CP Eisai Co Ltd
DM1SMAI DT Small molecular drug
DM1SMAI PC 3236
DM1SMAI MW 259.399
DM1SMAI FM C17H25NO
DM1SMAI IC InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3
DM1SMAI CS CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
DM1SMAI IK SQUNAWUMZGQQJD-UHFFFAOYSA-N
DM1SMAI IU 1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one
DM1SMAI CA CAS 64840-90-0
DM1SMAI CB CHEBI:77070
DM1SMAI DE Muscle spasm
DM08XIN ID DM08XIN
DM08XIN DN EPIANDROSTERONE
DM08XIN HS Phase 3
DM08XIN SN EPIANDROSTERONE; 481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2
DM08XIN DT Small molecular drug
DM08XIN PC 441302
DM08XIN MW 290.4
DM08XIN FM C19H30O2
DM08XIN IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,18-,19-/m0/s1
DM08XIN CS C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DM08XIN IK QGXBDMJGAMFCBF-LUJOEAJASA-N
DM08XIN IU (3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DM08XIN CA CAS 481-29-8
DM08XIN CB CHEBI:541975
DMCGWBJ ID DMCGWBJ
DMCGWBJ DN Epigallocatechin gallate
DMCGWBJ HS Phase 3
DMCGWBJ SN (-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin 3-gallate; Epigallocatechin-3-gallate; Tea catechin; (-)-Epigallocatechin-3-o-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechol gallate; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv; UNII-BQM438CTEL; Green tea extract; CCRIS 3729; (-)-epigallocatechin 3-gallate; C22H18O11; BQM438CTEL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl; EGCG analogs; EGCG, Anagen; Epigallocatechin gallate analogs, Anagen; Epigallocatechin gallate, Anagen; GTPs,Anagen; Green tea polyphenols, Anagen; EPIGALOCATECHIN GALLATE
DMCGWBJ CP Anagen Therapeutics Inc; Enzo Life Sciences
DMCGWBJ DT Small molecular drug
DMCGWBJ PC 65064
DMCGWBJ MW 458.4
DMCGWBJ FM C22H18O11
DMCGWBJ IC InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMCGWBJ CS C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMCGWBJ IK WMBWREPUVVBILR-WIYYLYMNSA-N
DMCGWBJ IU [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMCGWBJ CA CAS 989-51-5
DMCGWBJ CB CHEBI:4806
DMCGWBJ DE Hepatic fibrosis
DM9QPOU ID DM9QPOU
DM9QPOU DN Epoetin zeta
DM9QPOU HS Phase 3
DM9QPOU CP Hospira
DM9QPOU DE Anemia
DMITJRU ID DMITJRU
DMITJRU DN Epothilon
DMITJRU HS Phase 3
DMITJRU CP Bayer AG
DMITJRU DE Ovarian cancer
DMI1ZXV ID DMI1ZXV
DMI1ZXV DN Epratuzumab
DMI1ZXV HS Phase 3
DMI1ZXV SN LymphoCide; Lymphocide (TN); Epratuzumab (USAN/INN)
DMI1ZXV CP Immunomedics
DMI1ZXV DT Antibody
DMI1ZXV DE Graft rejection in heart transplantation; Systemic lupus erythematosus; Acute lymphoblastic leukaemia
DM35T1O ID DM35T1O
DM35T1O DN Epristeride
DM35T1O HS Phase 3
DM35T1O SN Zariflo; ONO-9302; SKB-105657; SKF-105657
DM35T1O CP SmithKline Beecham plc
DM35T1O DT Small molecular drug
DM35T1O PC 68741
DM35T1O MW 399.6
DM35T1O FM C25H37NO3
DM35T1O IC InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1
DM35T1O CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC=C4[C@@]3(CCC(=C4)C(=O)O)C
DM35T1O IK VAPSMQAHNAZRKC-PQWRYPMOSA-N
DM35T1O IU (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
DM35T1O CA CAS 119169-78-7
DM35T1O CB CHEBI:31552
DM35T1O DE Hirsutism
DMTV7ZM ID DMTV7ZM
DMTV7ZM DN Eptastigmine
DMTV7ZM HS Phase 3
DMTV7ZM SN heptastigmine; Heptylphysostigmine; Physostigmine heptyl; Eptastigmine [INN]; (-)-Heptylphysostigmine; Eptastigminum [INN-Latin]; Eptastigmina [INN-Spanish]; UNII-6PZZ52D76Q; N-Demethyl-N-heptylphysostigmine; 101246-68-8; BRN 4883778; CHEMBL433041; 6PZZ52D76Q; Heptylstigmine; heptyl-physostigmine; Eptastigminum; Eptastigmina; heptyl physostigmine; Carbamic acid, heptyl-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-; AC1Q60XA; SCHEMBL195028; BDBM10972; Epiastigmine; Eptastigmine tartrate; Heptylstigmine tartrate; Heptyl-physostigmine; L-693487; MF-201; HEPTYPHYSOSTIGMINE
DMTV7ZM CP Consiglio Nazionale delle Ricerche
DMTV7ZM DT Small molecular drug
DMTV7ZM PC 65872
DMTV7ZM MW 359.5
DMTV7ZM FM C21H33N3O2
DMTV7ZM IC InChI=1S/C21H33N3O2/c1-5-6-7-8-9-13-22-20(25)26-16-10-11-18-17(15-16)21(2)12-14-23(3)19(21)24(18)4/h10-11,15,19H,5-9,12-14H2,1-4H3,(H,22,25)/t19-,21+/m1/s1
DMTV7ZM CS CCCCCCCNC(=O)OC1=CC2=C(C=C1)N([C@@H]3[C@]2(CCN3C)C)C
DMTV7ZM IK RRGMXBQMCUKRLH-CTNGQTDRSA-N
DMTV7ZM IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-heptylcarbamate
DMTV7ZM CA CAS 101246-68-8
DMTV7ZM DE Cognitive impairment
DM6BU57 ID DM6BU57
DM6BU57 DN Eraxis/Vfend
DM6BU57 HS Phase 3
DM6BU57 CP Pfizer
DM6BU57 DE Fungal infection
DM9YI2C ID DM9YI2C
DM9YI2C DN ErepoXen
DM9YI2C HS Phase 3
DM9YI2C CP Lipoxen plc
DM9YI2C DE Anemia
DMKQZ0L ID DMKQZ0L
DMKQZ0L DN ERITORAN
DMKQZ0L HS Phase 3
DMKQZ0L SN ERITORAN; UNII-551541VI0Y; E5564; CHEMBL501259; CHEBI:68609; 185955-34-4; 551541VI0Y; Eritoran [INN]; 3-O-decyl-2-deoxy-6-O-{2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11E)-octadec-11-enoylamino]-4-O-phosphonato-beta-D-glucopyranosyl}-2-[(3-oxotetradecanoyl)amino]-1-O-phosphono-alpha-D-glucopyranose; 3-O-Decyl-2-Deoxy-6-O-{2-Deoxy-3-O-[(3r)-3-Methoxydecyl]-6-O-Methyl-2-[(11z)-Octadec-11-Enoylamino]-4-O-Phosphono-Beta-D-Glucopyranosyl}-2-[(3-Oxotetradecanoyl)amino]-1-O-Phosphono-Alpha-D-Glucopyranose; B1287
DMKQZ0L DT Small molecular drug
DMKQZ0L PC 6912404
DMKQZ0L MW 1313.7
DMKQZ0L FM C66H126N2O19P2
DMKQZ0L IC InChI=1S/C66H126N2O19P2/c1-7-11-15-19-22-25-26-27-28-29-30-32-34-38-42-46-57(70)67-60-64(82-49-47-54(80-6)45-41-36-18-14-10-4)62(86-88(73,74)75)56(51-79-5)85-65(60)83-52-55-61(72)63(81-48-43-39-35-24-21-17-13-9-3)59(66(84-55)87-89(76,77)78)68-58(71)50-53(69)44-40-37-33-31-23-20-16-12-8-2/h25-26,54-56,59-66,72H,7-24,27-52H2,1-6H3,(H,67,70)(H,68,71)(H2,73,74,75)(H2,76,77,78)/b26-25-/t54-,55-,56-,59-,60-,61-,62-,63-,64-,65-,66-/m1/s1
DMKQZ0L CS CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC)NC(=O)CCCCCCCCC/C=C\\CCCCCC)O)OCCCCCCCCCC
DMKQZ0L IK BPSMYQFMCXXNPC-MFCPCZTFSA-N
DMKQZ0L IU [(2R,3R,4R,5S,6R)-4-decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-[[(Z)-octadec-11-enoyl]amino]-5-phosphonooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] dihydrogen phosphate
DMKQZ0L CA CAS 185955-34-4
DMKQZ0L CB CHEBI:68609
DMKQZ0L DE Sepsis
DMVU687 ID DMVU687
DMVU687 DN Esketamine
DMVU687 HS Phase 3
DMVU687 SN (S)-Ketamine; l-Ketamine; (S)-(-)-Ketamine; 33643-46-8; S-Ketamine; UNII-50LFG02TXD; 50LFG02TXD; (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone; CHEBI:60799; esketamine HCl; (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (2S)-; 6740-88-1 (Parent); Esketamine [USAN:INN:BAN]; S-Ketamin; S-(-)-Ketamine; Esketamine (USAN/INN); AC1L4AD8; DSSTox_CID_27787; DSSTox_RID_82562; DSSTox_GSID_47810; SCHEMBL5512024; GTPL9152; CHEMBL395091; DTXSID6047810; YQEZ
DMVU687 CP Janssen Research & Development Raritan, NJ
DMVU687 PC 182137
DMVU687 MW 237.72
DMVU687 FM C13H16ClNO
DMVU687 IC InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3/t13-/m0/s1
DMVU687 CS CN[C@@]1(CCCCC1=O)C2=CC=CC=C2Cl
DMVU687 IK YQEZLKZALYSWHR-ZDUSSCGKSA-N
DMVU687 IU (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
DMVU687 CA CAS 33643-46-8
DMVU687 CB CHEBI:60799
DMVU687 DE Depression
DM8RBHJ ID DM8RBHJ
DM8RBHJ DN Esomeprazole magnesium + Aspirin
DM8RBHJ HS Phase 3
DM8RBHJ CP AstraZeneca
DM8RBHJ DE Peptic ulcer
DM4YGWA ID DM4YGWA
DM4YGWA DN Esonarimod
DM4YGWA HS Phase 3
DM4YGWA SN Sonatimod; KE-298; KE-749; KE-758; NE-298; (R)-KE-298; (S)-KE-298
DM4YGWA CP Taisho Pharmaceutical Co Ltd
DM4YGWA DT Small molecular drug
DM4YGWA PC 127998
DM4YGWA MW 280.34
DM4YGWA FM C14H16O4S
DM4YGWA IC InChI=1S/C14H16O4S/c1-9-3-5-11(6-4-9)13(16)7-12(14(17)18)8-19-10(2)15/h3-6,12H,7-8H2,1-2H3,(H,17,18)
DM4YGWA CS CC1=CC=C(C=C1)C(=O)CC(CSC(=O)C)C(=O)O
DM4YGWA IK YRSSFEUQNAXQMX-UHFFFAOYSA-N
DM4YGWA IU 2-(acetylsulfanylmethyl)-4-(4-methylphenyl)-4-oxobutanoic acid
DM4YGWA CA CAS 101973-77-7
DM4YGWA CB CHEBI:31559
DM4YGWA DE Arthritis
DMXLGED ID DMXLGED
DMXLGED DN esuberaprost
DMXLGED HS Phase 3
DMXLGED SN APS-314D free acid; BPS-314d
DMXLGED DT Small molecular drug
DMXLGED PC 10501053
DMXLGED MW 398.5
DMXLGED FM C24H30O5
DMXLGED IC InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15-,17-,19+,20+,21-,23-/m0/s1
DMXLGED CS CC#CC[C@H](C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O
DMXLGED IK CTPOHARTNNSRSR-NOQAJONNSA-N
DMXLGED IU 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
DMXLGED CA CAS 94132-88-4
DMXLGED DE Gout; Pulmonary arterial hypertension
DMQHX1Y ID DMQHX1Y
DMQHX1Y DN Etirinotecan pegol
DMQHX1Y HS Phase 3
DMQHX1Y SN NKTR-102
DMQHX1Y CP Nektar Therapeutics
DMQHX1Y DT Small molecular drug
DMQHX1Y PC 56935717
DMQHX1Y MW 3047.4
DMQHX1Y FM C161H192N20O40
DMQHX1Y IC InChI=1S/C161H192N20O40/c1-9-105-109-69-101(214-153(198)174-53-37-97(38-54-174)170-45-21-17-22-46-170)29-33-125(109)166-141-113(105)81-178-129(141)73-121-117(145(178)190)85-210-149(194)158(121,13-5)218-137(186)77-162-133(182)89-202-61-65-206-93-157(94-207-66-62-203-90-134(183)163-78-138(187)219-159(14-6)122-74-130-142-114(82-179(130)146(191)118(122)86-211-150(159)195)106(10-2)110-70-102(30-34-126(110)167-142)215-154(199)175-55-39-98(40-56-175)171-47-23-18-24-48-171,95-208-67-63-204-91-135(184)164-79-139(188)220-160(15-7)123-75-131-143-115(83-180(131)147(192)119(123)87-212-151(160)196)107(11-3)111-71-103(31-35-127(111)168-143)216-155(200)176-57-41-99(42-58-176)172-49-25-19-26-50-172)96-209-68-64-205-92-136(185)165-80-140(189)221-161(16-8)124-76-132-144-116(84-181(132)148(193)120(124)88-213-152(161)197)108(12-4)112-72-104(32-36-128(112)169-144)217-156(201)177-59-43-100(44-60-177)173-51-27-20-28-52-173/h29-36,69-76,97-100H,9-28,37-68,77-96H2,1-8H3,(H,162,182)(H,163,183)(H,164,184)(H,165,185)/t158-,159-,160-,161-/m0/s1
DMQHX1Y CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)OC(=O)N3CCC(CC3)N3CCCCC3)N=C8C7=C6)CC)CC)(COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)COCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)OC(=O)N6CCC(CC6)N6CCCCC6)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)OC(=O)N1CCC(CC1)N1CCCCC1
DMQHX1Y IK SELCJVNOEBVTAC-HLDPIHRNSA-N
DMQHX1Y IU [(19S)-19-[2-[[2-[2-[3-[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]-2,2-bis[2-[2-[[2-[[(19S)-10,19-diethyl-14,18-dioxo-7-(4-piperidin-1-ylpiperidine-1-carbonyl)oxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxymethyl]propoxy]ethoxy]acetyl]amino]acetyl]oxy-10,19-diethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
DMQHX1Y DE Breast cancer; Ovarian cancer
DMCDZ15 ID DMCDZ15
DMCDZ15 DN Evacetrapib
DMCDZ15 HS Phase 3
DMCDZ15 SN LY2484595
DMCDZ15 CP Lilly
DMCDZ15 DT Small molecular drug
DMCDZ15 PC 49836058
DMCDZ15 MW 638.6
DMCDZ15 FM C31H36F6N6O2
DMCDZ15 IC InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
DMCDZ15 CS CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C
DMCDZ15 IK IHIUGIVXARLYHP-UXNJHFGPSA-N
DMCDZ15 IU 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid
DMCDZ15 CA CAS 1186486-62-3
DMCDZ15 DE Cardiovascular disease
DMG4UJ6 ID DMG4UJ6
DMG4UJ6 DN EVK-001
DMG4UJ6 HS Phase 3
DMG4UJ6 CP Evoke Pharma
DMG4UJ6 DE Diabetic gastroparesis
DMLQO7F ID DMLQO7F
DMLQO7F DN EVP-6124
DMLQO7F HS Phase 3
DMLQO7F SN Encenicline; EVP-6124; 550999-75-2; UNII-5FI5376A0X; EVP6124; EVP 6124; CHEMBL2151572; (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide; 5FI5376A0X; C16H17ClN2OS; 550999-74-1; Encenicline [USAN:INN]; FRM-6124; Encenicline (USAN/INN); SCHEMBL744767; GTPL6926; SSRDSYXGYPJKRR-ZDUSSCGKSA-N; ZINC95579362; BDBM50393255; 3662AH; AKOS027322165; DB11726; CS-0933; MT-4666; Benzo(b)thiophene-2-carboxamide, N-(3R)-1-azabicyclo(2.2.2)oct-3-yl-7-chloro-; NCGC00378871-01; HY-15430; W-5978; D10626
DMLQO7F CP EnVivo Pharmaceuticals
DMLQO7F DT Small molecular drug
DMLQO7F PC 46196517
DMLQO7F MW 320.8
DMLQO7F FM C16H17ClN2OS
DMLQO7F IC InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1
DMLQO7F CS C1CN2CCC1[C@H](C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl
DMLQO7F IK SSRDSYXGYPJKRR-ZDUSSCGKSA-N
DMLQO7F IU N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
DMLQO7F CA CAS 550999-75-2
DMLQO7F DE Schizophrenia; Alzheimer disease
DMCA7FN ID DMCA7FN
DMCA7FN DN Exatecan
DMCA7FN HS Phase 3
DMCA7FN SN Exatecan mesylate; DX-8951; DX-8951a; DX-8951f; UM-1; UM-2
DMCA7FN CP Daiichi Seiyaku Co Ltd
DMCA7FN DT Small molecular drug
DMCA7FN PC 151115
DMCA7FN MW 435.4
DMCA7FN FM C24H22FN3O4
DMCA7FN IC InChI=1S/C24H22FN3O4/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19/h6-7,16,31H,3-5,8-9,26H2,1-2H3/t16-,24-/m0/s1
DMCA7FN CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O
DMCA7FN IK ZVYVPGLRVWUPMP-FYSMJZIKSA-N
DMCA7FN IU (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione
DMCA7FN CA CAS 171335-80-1
DMCA7FN CB CHEBI:135709
DMCA7FN DE Solid tumour/cancer
DMBY56U ID DMBY56U
DMBY56U DN EXISULIND
DMBY56U HS Phase 3
DMBY56U SN Aposulind; Aptosyn; Sulindac sulfone; FGN-1; Prevatac (former Brand Name); Exisulind; (Z)-5-Fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-indene-3-acetic acid
DMBY56U CP OSI Pharmaceuticals
DMBY56U DT Small molecular drug
DMBY56U PC 5472495
DMBY56U MW 372.4
DMBY56U FM C20H17FO4S
DMBY56U IC InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
DMBY56U CS CC\\1=C(C2=C(/C1=C\\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O
DMBY56U IK MVGSNCBCUWPVDA-MFOYZWKCSA-N
DMBY56U IU 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]acetic acid
DMBY56U CA CAS 59973-80-7
DMBY56U CB CHEBI:64212
DMBY56U DE Colorectal cancer
DMOKT7Y ID DMOKT7Y
DMOKT7Y DN FARGLITAZAR
DMOKT7Y HS Phase 3
DMOKT7Y SN Farglitazar; GI-262570; GI262570; 196808-45-4; GI 262570; UNII-3433GY7132; CHEMBL107367; GI-262570X; 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID; 3433GY7132; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-; L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl); N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; Farglitazar [USAN]; Farglitazar [USAN:INN]; L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-
DMOKT7Y DT Small molecular drug
DMOKT7Y PC 170364
DMOKT7Y MW 546.6
DMOKT7Y FM C34H30N2O5
DMOKT7Y IC InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1
DMOKT7Y CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=CC=CC=C4C(=O)C5=CC=CC=C5
DMOKT7Y IK ZZCHHVUQYRMYLW-HKBQPEDESA-N
DMOKT7Y IU (2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
DMOKT7Y CA CAS 196808-45-4
DMOKT7Y DE Type-1 diabetes
DM83SEB ID DM83SEB
DM83SEB DN Faricimab
DM83SEB HS Phase 3
DM83SEB SN RO6867461; RG7716
DM83SEB DT Antibody
DM83SEB DE Diabetic macular edema
DMFLWX1 ID DMFLWX1
DMFLWX1 DN Farletuzumab
DMFLWX1 HS Phase 3
DMFLWX1 CP Morphotek
DMFLWX1 DT Monoclonal antibody
DMFLWX1 SQ 9067_H|farletuzumab|||H-GAMMA-1 (VH(1-119)+CH1(120-217)+HINGE-REGION(218-232)+CH2(233-342)+CH3(343-449))|||||||449||||MW 48946.2|MW 48946.2|: EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >9067_L|farletuzumab|||L-KAPPA (V-KAPPA(1-110)+C-KAPPA(111-217))|||||||217||||MW 23755.2|MW 23755.2|DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DMFLWX1 DE Ovarian cancer; Non-small-cell lung cancer
DMTGYSO ID DMTGYSO
DMTGYSO DN Fasiglifam hemihydrate
DMTGYSO HS Phase 3
DMTGYSO SN Fasiglifam hemihydrate; 1374598-80-7; UNII-8LDT91CH8A; 8LDT91CH8A; TAK-875 Hemihydrate; Fasiglifam hydrate (JAN); DTXSID80160191; MolPort-035-395-707; EX-A2165; s2637; AKOS025404925; 3-Benzofuranacetic acid, 6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)(1,1'-biphenyl)-3-yl)methoxy)-2,3-dihydro-, hydrate (2:1), (3S)-; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy) biphenyl-3-yl)methoxy)-2,3-dihydro-l-benzofuran-3-yl)acetic acid hydrate; SC-95595; BC600332; (3S)-6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)
DMTGYSO CP Apollo Scientific
DMTGYSO DT Small molecular drug
DMTGYSO PC 57339446
DMTGYSO MW 1067.3
DMTGYSO FM C58H66O15S2
DMTGYSO IC InChI=1S/2C29H32O7S.H2O/c2*1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24;/h2*4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31);1H2/t2*23-;/m11./s1
DMTGYSO CS CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C.O
DMTGYSO IK OJXYMYYDAVXPIK-IWKNALKQSA-N
DMTGYSO IU 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid;hydrate
DMTGYSO CA CAS 1374598-80-7
DMTGYSO DE Type-2 diabetes
DM5PRLA ID DM5PRLA
DM5PRLA DN Fasinumab
DM5PRLA HS Phase 3
DM5PRLA CP Regeneron Pharmaceuticals Tarrytown, NY Teva Pharmaceuticals USA North Wales, PA
DM5PRLA DE Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis
DM8E51L ID DM8E51L
DM8E51L DN FASORACETAM
DM8E51L HS Phase 3
DM8E51L SN LAM-105; NS-105; Fasoracetam; (R)-1-[(5-Oxo-2-pyrrolidinyl)carbonyl]piperidine; (R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one
DM8E51L DT Small molecular drug
DM8E51L PC 198695
DM8E51L MW 196.25
DM8E51L FM C10H16N2O2
DM8E51L IC InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
DM8E51L CS C1CCN(CC1)C(=O)[C@H]2CCC(=O)N2
DM8E51L IK GOWRRBABHQUJMX-MRVPVSSYSA-N
DM8E51L IU (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
DM8E51L CA CAS 110958-19-5
DM8E51L CB CHEBI:31592
DM8E51L DE Cognitive impairment
DM35GBS ID DM35GBS
DM35GBS DN Favipiravir
DM35GBS HS Phase 3
DM35GBS SN AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705
DM35GBS CP Toyama Chemical
DM35GBS TC Antiviral Agents
DM35GBS DT Small molecular drug
DM35GBS PC 492405
DM35GBS MW 157.1
DM35GBS FM C5H4FN3O2
DM35GBS IC InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
DM35GBS CS C1=C(N=C(C(=O)N1)C(=O)N)F
DM35GBS IK ZCGNOVWYSGBHAU-UHFFFAOYSA-N
DM35GBS IU 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
DM35GBS CA CAS 259793-96-9
DM35GBS CB CHEBI:134722
DM35GBS DE Influenza virus infection; Coronavirus Disease 2019 (COVID-19)
DM0762O ID DM0762O
DM0762O DN Fenfluramine
DM0762O HS Phase 3
DM0762O SN Acino; Adifax; Adipomin; Fenfluramina; Fenfluraminum; Isomeride; Obedrex; Pesos; Ponderex; Rotondin; Dexfenfluramina [Spanish]; Dexfenfluraminum [Latin]; Fenfluramina [DCIT]; Fenfluramine hydrochloride; Levofenfluramine [INN]; Ponderax PA; S 768; D-Fenfluramine; Dexfenfluramine [INN:BAN]; Fenfluramine (INN); Fenfluramine [INN:BAN]; Fenfluraminum [INN-Latin]; Ponderax (TN); Fenfluramine, (+-)-Isomer; N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine; D-N-Ethyl-alpha-methyl-m-trifluoromethylphenethylamine; N-Ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine; N-Ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine; N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-(9CI); Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-(9CI);Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (+-)-(9CI); (+)-Fenfluramine; (+-)-Fenfluramine; (+/-)-Fenfluramine hydrochloride; (S)-Fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; 1-(meta-Trifluoromethyl-phenyl)-2 ethylaminopropane; 2-Ethylamino-1-(3-trifluoromethylphenyl)propane; 3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine
DM0762O CP Zogenix Emeryville, CA
DM0762O DT Small molecular drug
DM0762O PC 3337
DM0762O MW 231.26
DM0762O FM C12H16F3N
DM0762O IC InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
DM0762O CS CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
DM0762O IK DBGIVFWFUFKIQN-UHFFFAOYSA-N
DM0762O IU N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DM0762O CA CAS 458-24-2
DM0762O CB CHEBI:5000
DM0762O DE Dravet syndrome; LennoxGastaut syndrome; Obesity
DMRD5SP ID DMRD5SP
DMRD5SP DN Fenretinide
DMRD5SP HS Phase 3
DMRD5SP SN RT-101; ST-602; SYT-101; Fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University; LXS/4-HPR; Fenretinide (Ewing's sarcoma), Cancer Research UK; Fenretinide (ILE formulation), Children's Hospital LA; Fenretinide (intralipid emulsion formulation), Children's Hospital of Los Angeles; Fenretinide (intravenous, cancer), SciTech Development; Fenretinide (iv), Children's Hospital LA; Fenretinide (oral, AMD), Sytera; Fenretinide (soft gel capsule, AMD), ReVision Therapeutics; Fenretinide (soft gel capsule, AMD), Sirion; Fenretinide (topical, actinic keratosis and cancer), SciTech Development; N-(4-hydroxyphenyl)retinamide; Fenretinide (intravenous emulsion, lymphoma/solid tumors/pediatric neuroblastomas/pediatric leukemia), CerRx; Fenretinide (oral powder/Lym-X-Sorb, neuroblastoma), BioMolecular Products; 4-HPR
DMRD5SP CP Sirion Therapeutics; cerrx; Sytera Inc
DMRD5SP DT Small molecular drug
DMRD5SP PC 5288209
DMRD5SP MW 391.5
DMRD5SP FM C26H33NO2
DMRD5SP IC InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
DMRD5SP CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)NC2=CC=C(C=C2)O)/C)/C
DMRD5SP IK AKJHMTWEGVYYSE-FXILSDISSA-N
DMRD5SP IU (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
DMRD5SP CA CAS 65646-68-6
DMRD5SP CB CHEBI:42588
DMRD5SP DE Lymphoma; Peripheral T-cell lymphoma; Solid tumour/cancer; Tumour; Macular degeneration
DM4NX0C ID DM4NX0C
DM4NX0C DN Fevipiprant
DM4NX0C HS Phase 3
DM4NX0C SN 872365-14-5; NVP-QAW039; QAW039; UNII-2PEX5N7DQ4; 2PEX5N7DQ4; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid; 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid; Fevipiprant [INN]; Fevipiprant [USAN:INN]; QAW 039; Fevipiprant (JAN/USAN/INN); GTPL8995; SCHEMBL1940595; CHEMBL3137332; QAW-039; HMS3743E19; BCP25015; EX-A2495; BDBM50233520; ZINC43101772; AB85348; CS-5956; DB12011; Fevipiprant; NVP-QAW039; QAW039; SB16897; (1-(4-((Methane)sulfonyl)-2-trifluoromethylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; 2-(1-((4-Methanesulfonyl-2-(trifluoromethyl)phenyl)methyl(-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; AC-31956; AS-74870; HY-16768; DS-022511; FT-0774596; D10631; Q27077292; 1-(4-methanesulfonylbenzyl)-2-methyl-1H-pyrrolo(2,3-b)pyridin-3-yl)acetic acid; (2-methyl-1-{[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl}-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid; [2-METHYL-1-[4-(METHYLSULFONYL)-2-(TRIFLUOROMETHYL)BENZYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID; 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid; 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[5,4-b]pyridin-3-yl]acetic acid; FSY
DM4NX0C CP Novartis
DM4NX0C DT Small molecular drug
DM4NX0C PC 23582412
DM4NX0C MW 426.4
DM4NX0C FM C19H17F3N2O4S
DM4NX0C IC InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
DM4NX0C CS CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
DM4NX0C IK GFPPXZDRVCSVNR-UHFFFAOYSA-N
DM4NX0C IU 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid
DM4NX0C CA CAS 872365-14-5
DM4NX0C DE Asthma
DM4XSQ2 ID DM4XSQ2
DM4XSQ2 DN FG-4592
DM4XSQ2 HS Phase 3
DM4XSQ2 SN FG-4592; 808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid
DM4XSQ2 CP FibroGen
DM4XSQ2 DT Small molecular drug
DM4XSQ2 PC 11256664
DM4XSQ2 MW 352.3
DM4XSQ2 FM C19H16N2O5
DM4XSQ2 IC InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
DM4XSQ2 CS CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
DM4XSQ2 IK YOZBGTLTNGAVFU-UHFFFAOYSA-N
DM4XSQ2 IU 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
DM4XSQ2 CA CAS 808118-40-3
DM4XSQ2 CB CHEBI:132774
DM4XSQ2 DE Kidney disease; Anaemia
DMFZ81T ID DMFZ81T
DMFZ81T DN Fidanacogene elaparvovec
DMFZ81T HS Phase 3
DMFZ81T SN AAV8-hFIX19
DMFZ81T CP Pfizer
DMFZ81T DT Gene therapy
DMFZ81T DE Haemophilia B
DMZL1I8 ID DMZL1I8
DMZL1I8 DN Fidarestat
DMZL1I8 HS Phase 3
DMZL1I8 SN Aldos; FID; Fidaresstat; SK 860; Snk 860; Aldos (TN); SNK-860; Fidarestat (JAN/INN); (+)-(2S,4S)-6-Fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (+)-(2s,4s)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide; (2S,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; (2S,4S)-6-Fluoro-2',5'-dioxospiro(3,4-dihydro-2H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide; (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMZL1I8 CP Sanwa Kagaku
DMZL1I8 DT Small molecular drug
DMZL1I8 PC 160024
DMZL1I8 MW 279.22
DMZL1I8 FM C12H10FN3O4
DMZL1I8 IC InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1
DMZL1I8 CS C1[C@H](OC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N
DMZL1I8 IK WAAPEIZFCHNLKK-UFBFGSQYSA-N
DMZL1I8 IU (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMZL1I8 CA CAS 136087-85-9
DMZL1I8 DE Diabetic complication
DMM4FJ3 ID DMM4FJ3
DMM4FJ3 DN Finerenone
DMM4FJ3 HS Phase 3
DMM4FJ3 SN UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho
DMM4FJ3 CP Bayer HealthCare Pharmaceuticals, Plainsboro, NJ
DMM4FJ3 PC 60150535
DMM4FJ3 MW 378.4
DMM4FJ3 FM C21H22N4O3
DMM4FJ3 IC InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
DMM4FJ3 CS CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
DMM4FJ3 IK BTBHLEZXCOBLCY-QGZVFWFLSA-N
DMM4FJ3 IU (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
DMM4FJ3 CA CAS 1050477-31-0
DMM4FJ3 DE Diabetic nephropathy
DMMQ7BY ID DMMQ7BY
DMMQ7BY DN Fitusiran
DMMQ7BY HS Phase 3
DMMQ7BY SN ALN-AT3SC
DMMQ7BY CP Sanofi
DMMQ7BY DT Small interfering RNA
DMMQ7BY DE Hemophilia
DM6R2XF ID DM6R2XF
DM6R2XF DN FKB238
DM6R2XF HS Phase 3
DM6R2XF CP Fujifilm; Centus Biotherapeutics
DM6R2XF DT Antibody
DM6R2XF DE Non-small-cell lung cancer
DMPSG4D ID DMPSG4D
DMPSG4D DN Flobufen
DMPSG4D HS Phase 3
DMPSG4D SN VUFB-16066; VUFB-17203
DMPSG4D CP VUFB
DMPSG4D DT Small molecular drug
DMPSG4D PC 159476
DMPSG4D MW 304.29
DMPSG4D FM C17H14F2O3
DMPSG4D IC InChI=1S/C17H14F2O3/c1-10(17(21)22)8-16(20)12-4-2-11(3-5-12)14-7-6-13(18)9-15(14)19/h2-7,9-10H,8H2,1H3,(H,21,22)
DMPSG4D CS CC(CC(=O)C1=CC=C(C=C1)C2=C(C=C(C=C2)F)F)C(=O)O
DMPSG4D IK FIKVYIRIUOFLLR-UHFFFAOYSA-N
DMPSG4D IU 4-[4-(2,4-difluorophenyl)phenyl]-2-methyl-4-oxobutanoic acid
DMPSG4D CA CAS 112344-52-2
DMPSG4D DE Rheumatoid arthritis
DMKL5AT ID DMKL5AT
DMKL5AT DN Flurpiridaz F 18
DMKL5AT HS Phase 3
DMKL5AT SN Flurpiridaz (18F); PET myocardial perfusion imaging agents, Bristol-Myers Squibb Medical Imaging; RP-1003-18; RP-1004-18; RP-1005-18; [18F]-RP-1003; [18F]-RP-1004; [18F]-RP-1005; [18F]-labeled PET myocardial perfusion imaging agents, Lantheus Medical Imaging; BMS-747158-02-[18F]; Fluorine-18-BMS-747158; [18F]-labeled MC-1 inhibitors (MPIAs), Lantheus Medical Imaging; [18F]-labeled MC-1 inhibitors, Bristol-Myers Squibb Medical Imaging; [18fluorine]-labeled mitochondrial complex-1 inhibitors, Bristol-Myers Squibb Medical Imaging; 18F-BMS-747158-02
DMKL5AT CP Lantheus medical imaging
DMKL5AT DT Small molecular drug
DMKL5AT PC 11405965
DMKL5AT MW 367.8
DMKL5AT FM C18H22ClFN2O3
DMKL5AT IC InChI=1S/C18H22ClFN2O3/c1-18(2,3)22-17(23)16(19)15(10-21-22)25-12-14-6-4-13(5-7-14)11-24-9-8-20/h4-7,10H,8-9,11-12H2,1-3H3/i20-1
DMKL5AT CS CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCC[18F])Cl
DMKL5AT IK RMXZKEPDYBTFOS-LRFGSCOBSA-N
DMKL5AT IU 2-tert-butyl-4-chloro-5-[[4-(2-(18F)fluoranylethoxymethyl)phenyl]methoxy]pyridazin-3-one
DMKL5AT CA CAS 863887-89-2
DMKL5AT DE Myocardial disease
DM5S4DL ID DM5S4DL
DM5S4DL DN Forigerimod
DM5S4DL HS Phase 3
DM5S4DL SN CEP-33457
DM5S4DL CP Cephalon
DM5S4DL DT Small molecular drug
DM5S4DL PC 56841982
DM5S4DL MW 2638.9
DM5S4DL FM C117H181N34O32PS
DM5S4DL IC InChI=1S/C117H181N34O32PS/c1-9-64(5)94(148-99(163)75(120)24-18-47-128-115(121)122)112(176)144-85(56-71-57-127-62-132-71)106(170)139-80(44-51-185-8)103(167)147-93(63(3)4)110(174)143-83(54-69-32-38-73(154)39-33-69)105(169)146-87(60-152)108(172)138-78(25-14-16-45-118)101(165)137-76(27-19-48-129-116(123)124)96(160)97(161)88(150-184(180,181)182)61-183-133-59-91(157)135-81(26-15-17-46-119)113(177)151-50-21-29-89(151)109(173)140-77(28-20-49-130-117(125)126)100(164)131-58-90(156)136-82(53-68-30-36-72(153)37-31-68)104(168)134-66(7)98(162)142-84(52-67-22-12-11-13-23-67)107(171)149-95(65(6)10-2)111(175)141-79(42-43-92(158)159)102(166)145-86(114(178)179)55-70-34-40-74(155)41-35-70/h11-13,22-23,30-41,57,62-66,75-89,93-95,133,152-155H,9-10,14-21,24-29,42-56,58-61,118-120H2,1-8H3,(H,127,132)(H,131,164)(H,134,168)(H,135,157)(H,136,156)(H,137,165)(H,138,172)(H,139,170)(H,140,173)(H,141,175)(H,142,162)(H,143,174)(H,144,176)(H,145,166)(H,146,169)(H,147,167)(H,148,163)(H,149,171)(H,158,159)(H,178,179)(H4,121,122,128)(H4,123,124,129)(H4,125,126,130)(H3,150,180,181,182)/t64-,65-,66-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,93-,94-,95-/m0/s1
DM5S4DL CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)C(=O)[C@H](CONCC(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)O)NP(=O)(O)O)NC(=O)[C@H](CCCNC(=N)N)N
DM5S4DL IK LSLBZWAEEUGETG-GGVFYUGVSA-N
DM5S4DL IU (4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S,5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-amino-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-8-carbamimidamido-3,4-dioxo-2-(phosphonoamino)octoxy]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-5-oxopentanoic acid
DM5S4DL CA CAS 497156-60-2
DM5S4DL DE Systemic lupus erythematosus
DM8L3JU ID DM8L3JU
DM8L3JU DN Fosclin
DM8L3JU HS Phase 3
DM8L3JU SN Fosmidomycin + clindamycin (oral, malaria), Jomaa; Fosmidomycin + clindamycin fixed-dose combination (oral, malaria), Jomaa
DM8L3JU CP Jomaa Pharma GmbH
DM8L3JU DE Malaria
DM3274D ID DM3274D
DM3274D DN Fostamatinib disodium
DM3274D HS Phase 3
DM3274D SN 1025687-58-4; R788(prodrug of R406); R788 (Fostamatinib) Disodium; UNII-X9417132K8; R 788 sodium; R788(Fostamatinib disodium); R 935788 sodium; R935788 (Fostamatinib disodium, R788); R788 disodium; X9417132K8; R788 disodium hexahydrate; R788 SODIUM; R-788 disodium; R788, Fostamatinib; Tube731; sodium (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl phosphate; Disodium (6-(5-fluoro-2-(3
DM3274D CP Rigel Pharmaceuticals South San Francisco, CA
DM3274D PC 25008120
DM3274D MW 624.4
DM3274D FM C23H24FN6Na2O9P
DM3274D IC InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
DM3274D CS CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+]
DM3274D IK HSYBQXDGYCYSGA-UHFFFAOYSA-L
DM3274D IU disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate
DM3274D CA CAS 1025687-58-4
DM3274D DE Thrombocytopenia
DM823WQ ID DM823WQ
DM823WQ DN FP-1201
DM823WQ HS Phase 3
DM823WQ SN Traumagen; Traumakine; MR-11-A-8; CD73 agonist (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/MaruishiPharmaceutical; Interferon beta-1a (intravenous, ALI/ARDS/neonatal RDS/ischemia), Faron Pharmaceuticals/Maruishi Pharmaceutical
DM823WQ CP Faron Pharmaceuticals Ltd
DM823WQ DE Acute lung injury
DMGF8MZ ID DMGF8MZ
DMGF8MZ DN FPL-62064
DMGF8MZ HS Phase 3
DMGF8MZ SN N-(4-Methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine
DMGF8MZ DT Small molecular drug
DMGF8MZ PC 128268
DMGF8MZ MW 265.31
DMGF8MZ FM C16H15N3O
DMGF8MZ IC InChI=1S/C16H15N3O/c1-20-15-9-7-13(8-10-15)17-16-11-12-19(18-16)14-5-3-2-4-6-14/h2-12H,1H3,(H,17,18)
DMGF8MZ CS COC1=CC=C(C=C1)NC2=NN(C=C2)C3=CC=CC=C3
DMGF8MZ IK WKLGNFJHVJIZPK-UHFFFAOYSA-N
DMGF8MZ IU N-(4-methoxyphenyl)-1-phenylpyrazol-3-amine
DMGF8MZ CA CAS 103141-09-9
DMGF8MZ DE Inflammation
DMHOSCQ ID DMHOSCQ
DMHOSCQ DN Fruquintinib
DMHOSCQ HS Phase 3
DMHOSCQ SN HMPL-013
DMHOSCQ CP Hutchison Medipharma Enterprises Ltd
DMHOSCQ PC 44480399
DMHOSCQ MW 393.4
DMHOSCQ FM C21H19N3O5
DMHOSCQ IC InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)
DMHOSCQ CS CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC
DMHOSCQ IK BALLNEJQLSTPIO-UHFFFAOYSA-N
DMHOSCQ IU 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide
DMHOSCQ CA CAS 1194506-26-7
DMHOSCQ DE Solid tumour/cancer
DM1YVLM ID DM1YVLM
DM1YVLM DN FST-201
DM1YVLM HS Phase 3
DM1YVLM SN Dexamethasone + povidone iodine (otitis), Foresight Biotherapeutics; Otic anti-infective (otitis), Foresight Biotherapeutics
DM1YVLM CP Foresight Biotherapeutics Inc
DM1YVLM DE Otitis externa
DMDKYVE ID DMDKYVE
DMDKYVE DN FT-0624878
DMDKYVE HS Phase 3
DMDKYVE SN Cellulosepulver; DEAE-CELLULOSE; DEAE-Sephacel(R); Diethylaminoethyl cellulose; Diethylaminoethyl-Sephacel(R); SBB058705; SC-21746; cellulose; 9004-34-6; AKOS015895024; Cellulose, 2-(diethylamino)ethyl ether; Diethylaminoethyl-Sephacel(R), aqueous ethanol suspension, 40-160 mum (wet), exclusion limit ~1,000,000 Da; Express-Ion(TM) exchanger?? D free base, 60-130 mum; FT-0624878; M158
DMDKYVE PC 16211032
DMDKYVE MW 342.3
DMDKYVE FM C12H22O11
DMDKYVE IC GUBGYTABKSRVRQ-WFVLMXAXSA-N
DMDKYVE CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DMDKYVE IK 1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3?,4?,5?,6?,7?,8?,9?,10-,11?,12+/m1/s1
DMDKYVE IU (6S)-2-(hydroxymethyl)-6-[(3S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMDKYVE CA CAS 9004-34-6
DMDKYVE DE Human immunodeficiency virus infection
DMF4I1V ID DMF4I1V
DMF4I1V DN FT-0710230
DMF4I1V HS Phase 3
DMF4I1V SN Meconic acid; Mekonsaure; NSC 805; NSC-805; NSC805; Opium acid; Poppy acid; Q421116; SCHEMBL546968; SCHEMBL600257; UNII-V502I79516; V502I79516; ZEGRKMXCOCRTCS-UHFFFAOYSA-N; ZINC1587602; Opio; Papaver somniferum exudate; Papaver somniferum resin; 3-HYDROXY-4-OXO-4H-PYRAN-2,6-DICARBOXYLIC ACID; 3-Hydroxy-4-oxo-1,4-pyran-2,6-dicarboxylic acid; 3-Hydroxy-4-oxopyran-2,6-dicarboxylic acid; 3-hydroxy-4-oxo-pyran-2,6-dicarboxylic acid; 3-hydroxy-4-pyrone-2,6-dicarboxylic acid; 497-59-6; 4H-Pyran-2, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylic acid, 3-hydroxy-4-oxo-; 4H-Pyran-2,6-dicarboxylicacid, 3-hydroxy-4-oxo-; BDBM50147502; C20209; CHEMBL109516; CTK1D7773; DB-083476; DTXSID2060096; EINECS 207-848-2
DMF4I1V PC 10347
DMF4I1V IU 3-hydroxy-4-oxopyran-2,6-dicarboxylic acid
DMF4I1V DE Opiate dependence
DMK38MV ID DMK38MV
DMK38MV DN Fulranumab
DMK38MV HS Phase 3
DMK38MV CP Johnson & Johnson Pharmaceutical Research & Development
DMK38MV DT Monoclonal antibody
DMK38MV DE Cancer related pain; Back pain; Arthralgia
DMP83UZ ID DMP83UZ
DMP83UZ DN Fumaric acid
DMP83UZ HS Phase 3
DMP83UZ SN Fum; Fumarsaeure; Acidum fumaricum; Allomaleic acid; Allomalenic acid; Ammonium fumarate; Boletic acid; Butenedioic acid; Kyselina fumarova; Kyselina fumarova [Czech]; Lichenic acid; Tumaric acid; F0067; OR17920; FC 33 (acid); Fumarate, 10; Fumaric acid (8CI); Fumaric acid (NF); Lichenic acid (VAN); S04-0167; Trans-Butenedioic acid; U-1149; E-2-Butenedioic acid; Trans-2-Butenedioic acid; USAF EK-P-583; Trans-1,2-Ethylenedicarboxylic acid; Trans-but-2-enedioic acid; (2E)-2-butenedioic acid; (2E)-but-2-enedioic acid; (E)-2-Butenedioic acid; 1,2-Ethylenedicarboxylic acid, (E); 2-(E)-Butenedioic acid; 2-Butenedioic acid; 2-Butenedioic acid (2E-(9CI)
DMP83UZ CP Biogen Idec
DMP83UZ DT Small molecular drug
DMP83UZ PC 444972
DMP83UZ MW 116.07
DMP83UZ FM C4H4O4
DMP83UZ IC InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+
DMP83UZ CS C(=C/C(=O)O)\\C(=O)O
DMP83UZ IK VZCYOOQTPOCHFL-OWOJBTEDSA-N
DMP83UZ IU (E)-but-2-enedioic acid
DMP83UZ CA CAS 110-17-8
DMP83UZ CB CHEBI:18012
DMP83UZ DE Multiple sclerosis; Pustular palmoplantar psoriasis
DMZARP1 ID DMZARP1
DMZARP1 DN FV-100
DMZARP1 HS Phase 3
DMZARP1 SN CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy
DMZARP1 CP Welsh School of Pharmacy
DMZARP1 DT Small molecular drug
DMZARP1 PC 71587897
DMZARP1 MW 534
DMZARP1 FM C27H36ClN3O6
DMZARP1 IC InChI=1S/C27H35N3O6.ClH/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3;/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3;1H/t20-,22+,23+,24-;/m0./s1
DMZARP1 CS CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)COC(=O)[C@H](C(C)C)N)O.Cl
DMZARP1 IK CAHTYTZOAVUCIU-ZMQZINMSSA-N
DMZARP1 IU [(2R,3S,5R)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3-yl]oxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DMZARP1 CA CAS 956483-03-7
DMZARP1 DE Varicella zoster virus infection
DMMNP2F ID DMMNP2F
DMMNP2F DN G17DT
DMMNP2F HS Phase 3
DMMNP2F SN Gastrimmune; Insegia
DMMNP2F CP Receptor Biologix
DMMNP2F DT Antibody
DMMNP2F DE Gastric adenocarcinoma
DMXJMKF ID DMXJMKF
DMXJMKF DN Ganaxolone
DMXJMKF HS Phase 3
DMXJMKF SN Ganaxolone [USAN]; CCD 1042; CCD-1042; Ganaxolone (USAN/INN); (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one; 1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one; 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one
DMXJMKF CP Marinus
DMXJMKF DT Small molecular drug
DMXJMKF PC 6918305
DMXJMKF MW 332.5
DMXJMKF FM C22H36O2
DMXJMKF IC InChI=1S/C22H36O2/c1-14(23)17-7-8-18-16-6-5-15-13-20(2,24)11-12-21(15,3)19(16)9-10-22(17,18)4/h15-19,24H,5-13H2,1-4H3/t15-,16-,17+,18-,19-,20+,21-,22+/m0/s1
DMXJMKF CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C
DMXJMKF IK PGTVWKLGGCQMBR-FLBATMFCSA-N
DMXJMKF IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMXJMKF CA CAS 38398-32-2
DMXJMKF DE Postpartum depression; Complex partial seizure
DMWX90U ID DMWX90U
DMWX90U DN Gantenerumab
DMWX90U HS Phase 3
DMWX90U SN RG1450
DMWX90U CP Roche
DMWX90U DT Monoclonal antibody
DMWX90U DE Alzheimer disease
DMO3ITF ID DMO3ITF
DMO3ITF DN GASTRAZOLE
DMO3ITF HS Phase 3
DMO3ITF SN JB-95008; 5-[N-[5-[N-(Cycloheptylmethyl)carbamoyl]-1H-benzimidazol-6-ylcarbonyl]-2-fluoro-L-phenylalanylamino]isophthalic acid
DMO3ITF DT Small molecular drug
DMO3ITF PC 71587829
DMO3ITF MW 687.6
DMO3ITF FM C34H32FN5Na2O7
DMO3ITF IC InChI=1S/C34H34FN5O7.2Na/c35-26-10-6-5-9-20(26)14-29(32(43)39-23-12-21(33(44)45)11-22(13-23)34(46)47)40-31(42)25-16-28-27(37-18-38-28)15-24(25)30(41)36-17-19-7-3-1-2-4-8-19;;/h5-6,9-13,15-16,18-19,29H,1-4,7-8,14,17H2,(H,36,41)(H,37,38)(H,39,43)(H,40,42)(H,44,45)(H,46,47);;/q;2*+1/p-2/t29-;;/m0../s1
DMO3ITF CS C1CCCC(CC1)CNC(=O)C2=CC3=C(C=C2C(=O)N[C@@H](CC4=CC=CC=C4F)C(=O)NC5=CC(=CC(=C5)C(=O)[O-])C(=O)[O-])N=CN3.[Na+].[Na+]
DMO3ITF IK VHAXHRARUCKASM-UJXPALLWSA-L
DMO3ITF IU disodium;5-[[(2S)-2-[[6-(cycloheptylmethylcarbamoyl)-1H-benzimidazole-5-carbonyl]amino]-3-(2-fluorophenyl)propanoyl]amino]benzene-1,3-dicarboxylate
DMO3ITF CA CAS 862583-15-1
DMO3ITF DE Duodenal ulcer
DMT4QHD ID DMT4QHD
DMT4QHD DN GDC-0032
DMT4QHD HS Phase 3
DMT4QHD SN Taselisib; 1282512-48-4; GDC 0032; UNII-L08J2O299M; 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide; CHEMBL2387080; GDC0032; L08J2O299M; Taselisib [INN]; 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide; Taselisib [USAN:INN]; GTPL7794; SCHEMBL1485247; SYN1202; DTXSID00155842; BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DMT4QHD CP Genentech
DMT4QHD DT Small molecular drug
DMT4QHD PC 51001932
DMT4QHD MW 460.5
DMT4QHD FM C24H28N8O2
DMT4QHD IC InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)
DMT4QHD CS CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
DMT4QHD IK BEUQXVWXFDOSAQ-UHFFFAOYSA-N
DMT4QHD IU 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide
DMT4QHD CA CAS 1282512-48-4
DMT4QHD DE Solid tumour/cancer; Breast cancer
DMWBZJD ID DMWBZJD
DMWBZJD DN GDC-0068
DMWBZJD HS Phase 3
DMWBZJD SN RG7440
DMWBZJD CP Genentech
DMWBZJD DT Small molecular drug
DMWBZJD PC 24788740
DMWBZJD MW 458
DMWBZJD FM C24H32ClN5O2
DMWBZJD IC InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
DMWBZJD CS C[C@@H]1C[C@H](C2=C1C(=NC=N2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)C4=CC=C(C=C4)Cl)O
DMWBZJD IK GRZXWCHAXNAUHY-NSISKUIASA-N
DMWBZJD IU (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one
DMWBZJD CA CAS 1001264-89-6
DMWBZJD CB CHEBI:95089
DMWBZJD DE Solid tumour/cancer; Breast cancer; Colorectal cancer; Gastric adenocarcinoma; Prostate cancer
DMBEL3Q ID DMBEL3Q
DMBEL3Q DN GDC-0853
DMBEL3Q HS Phase 3
DMBEL3Q SN Fenebrutinib
DMBEL3Q CP GenentechSouth San Francisco, CA
DMBEL3Q PC 86567195
DMBEL3Q MW 664.8
DMBEL3Q FM C37H44N8O4
DMBEL3Q IC InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1
DMBEL3Q CS C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8
DMBEL3Q IK WNEODWDFDXWOLU-QHCPKHFHSA-N
DMBEL3Q IU 10-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7-dien-9-one
DMBEL3Q CA CAS 1434048-34-6
DMBEL3Q DE Solid tumour/cancer; Autoimmune disease; Chronic idiopathic urticaria; Multiple sclerosis
DMTUV7L ID DMTUV7L
DMTUV7L DN GED-0301
DMTUV7L HS Phase 3
DMTUV7L SN SMAD-7 inhibitor (oligonucleotide, Crohn's disease), Giuliani
DMTUV7L CP Giuliani SpA
DMTUV7L DE Crohn disease; Ulcerative colitis
DM4GWL7 ID DM4GWL7
DM4GWL7 DN Gefapixant
DM4GWL7 HS Phase 3
DM4GWL7 SN UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid
DM4GWL7 CP Merck, Roche
DM4GWL7 PC 24764487
DM4GWL7 MW 353.4
DM4GWL7 FM C14H19N5O4S
DM4GWL7 IC InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
DM4GWL7 CS CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
DM4GWL7 IK HLWURFKMDLAKOD-UHFFFAOYSA-N
DM4GWL7 IU 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
DM4GWL7 CA CAS 1015787-98-0
DM4GWL7 DE Overactive bladder; Cough
DMZKGPV ID DMZKGPV
DMZKGPV DN Gemigliptin
DMZKGPV HS Phase 3
DMZKGPV SN 911637-19-9; UNII-5DHU18M5D6; 5DHU18M5D6; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; PB11419; DB12412; API0013914; AK170799; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-
DMZKGPV CP LG Life Sciences Ltd
DMZKGPV DT Small molecular drug
DMZKGPV PC 11953153
DMZKGPV MW 489.4
DMZKGPV FM C18H19F8N5O2
DMZKGPV IC InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1
DMZKGPV CS C1CC(CN(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
DMZKGPV IK ZWPRRQZNBDYKLH-VIFPVBQESA-N
DMZKGPV IU 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one
DMZKGPV CA CAS 911637-19-9
DMZKGPV CB CHEBI:134731
DMZKGPV DE Diabetic complication; Type-2 diabetes
DM1WMOK ID DM1WMOK
DM1WMOK DN Generx
DM1WMOK HS Phase 3
DM1WMOK SN Alferminogene tadenovec
DM1WMOK CP Angionetics
DM1WMOK DT Gene therapy
DM1WMOK DE Angina pectoris
DM7ZOAE ID DM7ZOAE
DM7ZOAE DN GFT-505
DM7ZOAE HS Phase 3
DM7ZOAE SN GFT-1007; PPAR activator (dyslipidemia/type 2 diabetes), Genfit
DM7ZOAE CP Genfit SA
DM7ZOAE PC 9864881
DM7ZOAE MW 384.5
DM7ZOAE FM C22H24O4S
DM7ZOAE IC InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
DM7ZOAE CS CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
DM7ZOAE IK AFLFKFHDSCQHOL-IZZDOVSWSA-N
DM7ZOAE IU 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
DM7ZOAE CA CAS 923978-27-2
DM7ZOAE DE Type-2 diabetes; Non-alcoholic steatohepatitis
DMR6YH3 ID DMR6YH3
DMR6YH3 DN GLP-1
DMR6YH3 HS Phase 3
DMR6YH3 SN Glucagon-like peptide 1; Glucagon-like-peptide-1; Glucagon-like peptide-1; Proglucagon (72-108); Proglucagon (78-107)amide; Glucagon-related peptide I; 89750-14-1; GLP-1 (7-36) amide (human, bovine, guinea pig, mouse,; Oral GLP (diabetes, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes); Glucagon-like peptides (oral, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes), Emisphere; NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-CONH2
DMR6YH3 CP Emisphere Technologies Inc
DMR6YH3 PC 16135499
DMR6YH3 MW 3297.6
DMR6YH3 FM C149H226N40O45
DMR6YH3 IC InChI=1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMR6YH3 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMR6YH3 IK DTHNMHAUYICORS-KTKZVXAJSA-N
DMR6YH3 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMR6YH3 CA CAS 89750-14-1
DMR6YH3 DE Diabetic complication
DMEFCTP ID DMEFCTP
DMEFCTP DN Glufosfamide
DMEFCTP HS Phase 3
DMEFCTP SN Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMEFCTP CP Threshold Pharmaceuticals
DMEFCTP DT Small molecular drug
DMEFCTP PC 123628
DMEFCTP MW 383.16
DMEFCTP FM C10H21Cl2N2O7P
DMEFCTP IC InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
DMEFCTP CS C(CCl)NP(=O)(NCCCl)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMEFCTP IK PSVUJBVBCOISSP-SPFKKGSWSA-N
DMEFCTP IU (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMEFCTP CA CAS 132682-98-5
DMEFCTP DE Ovarian cancer; Pancreatic cancer
DMOUT89 ID DMOUT89
DMOUT89 DN Glutamic acid
DMOUT89 HS Phase 3
DMOUT89 SN D(-)-Glutamic acid; D-(-)-Glutamic acid; D-2-Aminoglutaric acid; D-2-Aminopentanedioic acid; D-Glutamicacid; D-Glutaminic acid; D-Glutaminsaeure; D-glutamate; D-glutamic acid; Gamma-D-Glutamic Acid; Glutamic acid D-form; Glutamic acid, D-; H-D-Glu-OH; L(+)-Glutamic acid; Lopac-G-2128; Q479989WEA; R-(-)-Glutamic acid; Tocris-0217; WHUUTDBJXJRKMK-GSVOUGTGSA-N; glutamate; (2R)-2-aminopentanedioic acid; (R)-2-aminopentanedioic acid; (r)-glutamic acid; 6893-26-1; CHEBI:15966; CHEMBL76232; D-Glu; DGL; MFCD00063112; UNII-Q479989WEA
DMOUT89 PC 23327
DMOUT89 MW 147.13
DMOUT89 FM C5H9NO4
DMOUT89 IC WHUUTDBJXJRKMK-GSVOUGTGSA-N
DMOUT89 CS C(CC(=O)O)C(C(=O)O)N
DMOUT89 IK 1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m1/s1
DMOUT89 IU (2R)-2-aminopentanedioic acid
DMOUT89 CA CAS 6893-26-1
DMOUT89 CB CHEBI:15966
DMOUT89 DE Follicular lymphoma
DM8M2N3 ID DM8M2N3
DM8M2N3 DN Glycyrrhizin
DM8M2N3 HS Phase 3
DM8M2N3 SN Glycyrrhizic acid; glycyrrhizin; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-
DM8M2N3 DT Small molecular drug
DM8M2N3 PC 14982
DM8M2N3 MW 822.9
DM8M2N3 FM C42H62O16
DM8M2N3 IC InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1
DM8M2N3 CS C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O
DM8M2N3 IK LPLVUJXQOOQHMX-QWBHMCJMSA-N
DM8M2N3 IU (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DM8M2N3 CA CAS 1405-86-3
DM8M2N3 CB CHEBI:15939
DM8M2N3 DE Influenza virus infection
DMQCZ4N ID DMQCZ4N
DMQCZ4N DN Glyminox
DMQCZ4N HS Phase 3
DMQCZ4N SN Savvy
DMQCZ4N CP Biosyn Inc
DMQCZ4N DT Small molecular drug
DMQCZ4N PC 56842993
DMQCZ4N MW 599
DMQCZ4N FM C36H74N2O4
DMQCZ4N IC InChI=1S/C20H39NO3.C16H35NO/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(22)21(2,3)18-20(23)24;1-4-5-6-7-8-9-10-11-12-13-14-15-16-17(2,3)18/h4-18H2,1-3H3;4-16H2,1-3H3
DMQCZ4N CS CCCCCCCCCCCCCCCC(=O)[N+](C)(C)CC(=O)[O-].CCCCCCCCCCCCCC[N+](C)(C)[O-]
DMQCZ4N IK KALYGJOYPFFBRF-UHFFFAOYSA-N
DMQCZ4N IU N,N-dimethyltetradecan-1-amine oxide;2-[hexadecanoyl(dimethyl)azaniumyl]acetate
DMQCZ4N CA CAS 664323-11-9
DMQCZ4N DE Sexually transmitted infection
DMOHUR2 ID DMOHUR2
DMOHUR2 DN GLYX-13
DMOHUR2 HS Phase 3
DMOHUR2 SN Rapastinel; 117928-94-6; GLYX-13; GLYX 13; GLYX13; UNII-6A1X56B95E; L-Threoninamide, L-threonyl-L-prolyl-L-prolyl-; 6A1X56B95E; (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide; GLYX-13 trifluoroacetate; TPPT-amide trifluoroacetate; TPPT-amide; GLYX-13 peptide; Rapastinel [USAN:INN]; GLYX13;Rapastinel; Rapastinel(GLYX-13); L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate; Thr-Pro-Pro-Thr-NH2 trifluoroacetate
DMOHUR2 CP Naurex
DMOHUR2 DT Small molecular drug
DMOHUR2 PC 14539800
DMOHUR2 MW 413.5
DMOHUR2 FM C18H31N5O6
DMOHUR2 IC InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
DMOHUR2 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DMOHUR2 IK GIBQQARAXHVEGD-BSOLPCOYSA-N
DMOHUR2 IU (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMOHUR2 CA CAS 117928-94-6
DMOHUR2 DE Major depressive disorder
DMQIE7U ID DMQIE7U
DMQIE7U DN GMA102
DMQIE7U HS Phase 3
DMQIE7U CP Gmax Biopharm
DMQIE7U DT Antibody
DMQIE7U DE Type-2 diabetes; Obesity
DM2XSG0 ID DM2XSG0
DM2XSG0 DN GMA105
DM2XSG0 HS Phase 3
DM2XSG0 CP Gmax Biopharm
DM2XSG0 DT Antibody
DM2XSG0 DE Type-2 diabetes; Obesity
DMJ432G ID DMJ432G
DMJ432G DN GMI-1070
DMJ432G HS Phase 3
DMJ432G SN GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics
DMJ432G CP Glycomimetics; pfizer
DMJ432G DT Small molecular drug
DMJ432G PC 44232546
DMJ432G MW 1447.4
DMJ432G FM C58H74N6O31S3
DMJ432G IC InChI=1S/C58H74N6O31S3/c1-27-45(69)47(71)48(72)56(90-27)95-49-35(62-53(74)36-23-41(66)64-58(78)63-36)19-31(20-37(49)92-57-51(94-55(77)29-10-6-3-7-11-29)50(46(70)39(24-65)93-57)91-38(54(75)76)16-28-8-4-2-5-9-28)52(73)60-13-12-59-42(67)25-88-14-15-89-26-43(68)61-34-21-32(96(79,80)81)17-30-18-33(97(82,83)84)22-40(44(30)34)98(85,86)87/h3,6-7,10-11,17-18,21-23,27-28,31,35,37-39,45-51,56-57,65,69-72H,2,4-5,8-9,12-16,19-20,24-26H2,1H3,(H,59,67)(H,60,73)(H,61,68)(H,62,74)(H,75,76)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H2,63,64,66,78)/t27-,31+,35-,37+,38-,39+,45+,46-,47+,48-,49+,50-,51+,56-,57+/m0/s1
DMJ432G CS C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](C[C@H](C[C@H]2O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O
DMJ432G IK VXBNTHRZPJLRSS-PTCSXESPSA-N
DMJ432G IU (2S)-2-[(2R,3R,4S,5S,6R)-3-benzoyloxy-2-[(1R,2R,3S,5R)-3-[(2,4-dioxo-1H-pyrimidine-6-carbonyl)amino]-5-[2-[[2-[2-[2-oxo-2-[(3,6,8-trisulfonaphthalen-1-yl)amino]ethoxy]ethoxy]acetyl]amino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid
DMJ432G CA CAS 927881-99-0
DMJ432G DE Asthma; Vaso-occlusive crisis
DMDTGWQ ID DMDTGWQ
DMDTGWQ DN GMI-1271
DMDTGWQ HS Phase 3
DMDTGWQ SN Uproleselan
DMDTGWQ CP Glycomimetics
DMDTGWQ DT ?
DMDTGWQ PC 71600085
DMDTGWQ MW 1304.5
DMDTGWQ FM C60H109N3O27
DMDTGWQ IC InChI=1S/C60H109N3O27/c1-5-44-38-45(39-46(55(44)90-60-54(70)53(69)51(67)41(2)86-60)88-59-50(63-42(3)65)56(52(68)48(40-64)89-59)87-47(58(72)73)37-43-9-7-6-8-10-43)57(71)62-13-12-61-49(66)11-14-75-17-18-77-21-22-79-25-26-81-29-30-83-33-34-85-36-35-84-32-31-82-28-27-80-24-23-78-20-19-76-16-15-74-4/h41,43-48,50-56,59-60,64,67-70H,5-40H2,1-4H3,(H,61,66)(H,62,71)(H,63,65)(H,72,73)/t41-,44-,45+,46+,47-,48+,50+,51+,52-,53+,54-,55+,56+,59+,60-/m0/s1
DMDTGWQ CS CC[C@H]1C[C@H](C[C@H]([C@@H]1O[C@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)C)O)O)O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC
DMDTGWQ IK LYSYOXNOOPBOSC-NGSKMYNLSA-N
DMDTGWQ IU (2S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2-[(1R,2R,3S,5R)-3-ethyl-5-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid
DMDTGWQ CA CAS 1983970-12-2
DMDTGWQ DE Multiple myeloma; Acute myeloid leukaemia
DM0LQ94 ID DM0LQ94
DM0LQ94 DN GnRH
DM0LQ94 HS Phase 3
DM0LQ94 SN Lutrepatch; GnRH (Lutrepatch, female fertility); GnRH (Lutrepatch, female fertility), Ferring; GnRH (Lutrepatch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Ferring/Vyteris; GnRH (Smart Patch, female infertility), Vyteris/Ferring; Iontophoretic anti-infertility peptide (Smart Patch), Ferring/Vyteris; Iontophoretic anti-infertility peptide (Smart Patch), Vyteris/Ferring; Anti-infertility peptide (iontophoretic/Smart Patch), Ferring/Vyteris; Anti-infertility peptide (iontophoretic/Smart Patch), Vyteris/Ferring; Gonadotropin-releasing hormone (Smart Patch, female infertility), Ferring/Vyteris; Gonadotropin-releasing hormone (Smart Patch, female infertility), Vyteris/Ferring
DM0LQ94 CP Ferring Pharmaceuticals Inc
DM0LQ94 PC 16132914
DM0LQ94 MW 1212.3
DM0LQ94 FM C60H73N15O13
DM0LQ94 IC InChI=1S/C60H73N15O13/c1-32(2)20-47(60(88)75-19-7-12-49(75)59(87)65-28-50(61)78)73-55(83)44(22-34-25-63-40-10-5-3-8-38(34)40)69-52(80)29-66-53(81)43(21-33-13-15-37(77)16-14-33)70-58(86)48(30-76)74-56(84)45(23-35-26-64-41-11-6-4-9-39(35)41)71-57(85)46(24-36-27-62-31-67-36)72-54(82)42-17-18-51(79)68-42/h3-6,8-11,13-16,25-27,31-32,42-49,63-64,76-77H,7,12,17-24,28-30H2,1-2H3,(H2,61,78)(H,62,67)(H,65,87)(H,66,81)(H,68,79)(H,69,80)(H,70,86)(H,71,85)(H,72,82)(H,73,83)(H,74,84)
DM0LQ94 CS CC(C)CC(C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
DM0LQ94 IK NMJREATYWWNIKX-UHFFFAOYSA-N
DM0LQ94 IU N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM0LQ94 DE Female infertility
DMKWV4B ID DMKWV4B
DMKWV4B DN Golnerminogene pradenovac
DMKWV4B HS Phase 3
DMKWV4B SN TNFerade (TN)
DMKWV4B CP GenVec
DMKWV4B DE Esophageal cancer
DMZS2R7 ID DMZS2R7
DMZS2R7 DN Granexin gel
DMZS2R7 HS Phase 3
DMZS2R7 SN alphaCT1
DMZS2R7 CP FirstString Research
DMZS2R7 DE Diabetic foot ulcer; Keloidal surgical scar; Radiation syndrome
DM4Y7WV ID DM4Y7WV
DM4Y7WV DN GRASPA
DM4Y7WV HS Phase 3
DM4Y7WV SN L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
DM4Y7WV CP Erytech Pharma
DM4Y7WV DT Protein
DM4Y7WV SQ Elspar Sequence: QMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDETHELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMERVSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTGGMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAEACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTVATQ >sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGATTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY
DM4Y7WV DE Pancreatic cancer; Acute lymphoblastic leukaemia
DM71GPM ID DM71GPM
DM71GPM DN Grippol Plus
DM71GPM HS Phase 3
DM71GPM SN Egg-based adjuvanted seasonal influenza vaccine, Solvay
DM71GPM CP Solvay SA
DM71GPM DT Vaccine
DM71GPM DE Influenza virus infection
DMB34TZ ID DMB34TZ
DMB34TZ DN Grippol TC
DMB34TZ HS Phase 3
DMB34TZ SN Grippol; Grippol Neo; Cell-based adjuvanted seasonal influenza vaccine, Solvay/Petrovax; Seasonal influenza vaccine (tissue culture), Solvay/Petrovax
DMB34TZ CP Solvay SA
DMB34TZ DT Vaccine
DMB34TZ DE Influenza virus infection
DMHN3PG ID DMHN3PG
DMHN3PG DN GRT-6005
DMHN3PG HS Phase 3
DMHN3PG SN Cebranopadol; 863513-91-1; GRT6005; UNII-7GDW9S3GN3; GRT 6005; 7GDW9S3GN3; Cebranopadol [USAN:INN]; Cebranopadol (USAN/INN); Cebranopadol(GRT-6005); SCHEMBL566256; SCHEMBL154336; GTPL8866; CHEMBL3545616; CHEMBL2364605; SCHEMBL10035739; CHEMBL3962932; SCHEMBL19336241; SCHEMBL14183935; MolPort-039-063-422; BDBM177926; ZINC3950145; EX-A1095; BCP09612; BDBM50101095; BDBM50101112; AKOS032953927; AKOS025402576; AKOS025290738; DB12830; CS-1323; SB16531; NCGC00378895-01; AK170452; HY-15536; AS-35183; Centrally-acting nociceptin agonist analgesic (oral liquid, pain/diabetic neuropathy), Grunenthal; GRT 6005/06
DMHN3PG CP Forest laboratories
DMHN3PG DT Small molecular drug
DMHN3PG PC 11848225
DMHN3PG MW 378.5
DMHN3PG FM C24H27FN2O
DMHN3PG IC InChI=1S/C24H27FN2O/c1-27(2)23(17-6-4-3-5-7-17)11-13-24(14-12-23)22-19(10-15-28-24)20-16-18(25)8-9-21(20)26-22/h3-9,16,26H,10-15H2,1-2H3
DMHN3PG CS CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5
DMHN3PG IK CSMVOZKEWSOFER-UHFFFAOYSA-N
DMHN3PG IU 6-fluoro-N,N-dimethyl-1'-phenylspiro[4,9-dihydro-3H-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine
DMHN3PG CA CAS 863513-91-1
DMHN3PG DE Diabetic neuropathy
DMNZO7M ID DMNZO7M
DMNZO7M DN GS-441524
DMNZO7M HS Phase 3
DMNZO7M SN EVO984; EVO-984; EVO 984; GS 441524; GS441524
DMNZO7M TC Antiviral Agents
DMNZO7M DT Small molecular drug
DMNZO7M PC 44468216
DMNZO7M MW 291.26
DMNZO7M FM C12H13N5O4
DMNZO7M IC InChI=1S/C12H13N5O4/c13-4-12(10(20)9(19)7(3-18)21-12)8-2-1-6-11(14)15-5-16-17(6)8/h1-2,5,7,9-10,18-20H,3H2,(H2,14,15,16)/t7-,9-,10-,12+/m1/s1
DMNZO7M CS C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N
DMNZO7M IK BRDWIEOJOWJCLU-LTGWCKQJSA-N
DMNZO7M IU (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile
DMNZO7M CA CAS 1191237-69-0
DMNZO7M CB CHEBI:147281
DMNZO7M DE Coronavirus Disease 2019 (COVID-19)
DMP8MDW ID DMP8MDW
DMP8MDW DN GS-5745
DMP8MDW HS Phase 3
DMP8MDW CP GILEAD
DMP8MDW PC 56776542
DMP8MDW MW 250.02
DMP8MDW FM C7H5BrFNO3
DMP8MDW IC InChI=1S/C7H5BrFNO3/c1-13-5-3-2-4(8)6(9)7(5)10(11)12/h2-3H,1H3
DMP8MDW CS COC1=C(C(=C(C=C1)Br)F)[N+](=O)[O-]
DMP8MDW IK LJJAOMRFFXQENV-UHFFFAOYSA-N
DMP8MDW IU 1-bromo-2-fluoro-4-methoxy-3-nitrobenzene
DMP8MDW CA CAS 1352317-80-6
DMP8MDW DE Ulcerative colitis; Solid tumour/cancer; Crohn disease; Gastric adenocarcinoma; Rheumatoid arthritis
DMGJQVI ID DMGJQVI
DMGJQVI DN GS-6615
DMGJQVI HS Phase 3
DMGJQVI SN Eleclazine; 1443211-72-0; GS-6615; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C
DMGJQVI CP GILEAD
DMGJQVI DT Small molecular drug
DMGJQVI PC 71183216
DMGJQVI MW 415.4
DMGJQVI FM C21H16F3N3O3
DMGJQVI IC InChI=1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2
DMGJQVI CS C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4
DMGJQVI IK YNUAEEJQYHYLMS-UHFFFAOYSA-N
DMGJQVI IU 4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
DMGJQVI CA CAS 1443211-72-0
DMGJQVI DE Ischemic heart disease; Long QT syndrome
DM936V7 ID DM936V7
DM936V7 DN GS-9674
DM936V7 HS Phase 3
DM936V7 SN Cilofexor; 1418274-28-8; UNII-YUN2306954; PX104; 1418274-28-8 (free acid); YUN2306954; 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)-3-hydroxyazetidin-1-yl)isonicotinic acid; GS 9674; 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid; Cilofexor [INN]; Cilofexor (GS(c)\\9674); CHEMBL4297613; SCHEMBL14641986; GTPL10644; BCP29283; BDBM50511109; GS9674; s6547; DB15168; example 13/9 [US10485795B2]; HY-109083; CS-0039260; 2-(3-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-4-pyridinecarboxylic acid; 4-Pyridinecarboxylic acid, 2-(3-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)-3-hydroxy-1-azetidinyl)-
DM936V7 DT Small molecular drug
DM936V7 PC 71228883
DM936V7 MW 586.8
DM936V7 FM C28H22Cl3N3O5
DM936V7 IC InChI=1S/C28H22Cl3N3O5/c29-20-2-1-3-21(30)24(20)25-18(26(39-33-25)15-4-5-15)12-38-17-6-7-19(22(31)11-17)28(37)13-34(14-28)23-10-16(27(35)36)8-9-32-23/h1-3,6-11,15,37H,4-5,12-14H2,(H,35,36)
DM936V7 CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl
DM936V7 IK KZSKGLFYQAYZCO-UHFFFAOYSA-N
DM936V7 IU 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid
DM936V7 CA CAS 1418274-28-8
DM936V7 DE Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
DMT8J0I ID DMT8J0I
DMT8J0I DN GSK1265744
DMT8J0I HS Phase 3
DMT8J0I SN Cabotegravir; 1051375-10-0; GSK1265744; UNII-HMH0132Z1Q; GSK744; GSK1265744A; GSK-1265744; HMH0132Z1Q; Cabotegravir (GSK744, GSK1265744); CAB; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; Cabotegravir [USAN:INN]; GSK744 LAP; GSK744 LA; S/GSK1265744; GSK 744; 744 LA; GSK 1265
DMT8J0I CP GSK
DMT8J0I DT Small molecular drug
DMT8J0I PC 54713659
DMT8J0I MW 405.4
DMT8J0I FM C19H17F2N3O5
DMT8J0I IC InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
DMT8J0I CS C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
DMT8J0I IK WCWSTNLSLKSJPK-LKFCYVNXSA-N
DMT8J0I IU (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
DMT8J0I CA CAS 1051375-10-0
DMT8J0I DE Human immunodeficiency virus infection
DMRNGD2 ID DMRNGD2
DMRNGD2 DN GSK1278863
DMRNGD2 HS Phase 3
DMRNGD2 SN Daprodustat; 960539-70-2; GSK1278863; UNII-JVR38ZM64B; GSK-1278863; JVR38ZM64B; N-((1,3-Dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl)glycine; Daprodustat [USAN:INN]; GSK 1278863; Daprodustat(GSK1278863); Daprodustat; GSK1278863; Daprodustat (JAN/USAN/INN); GTPL8455; Daprodustat (GSK1278863); CHEMBL3544988; KS-00000M8Z; EX-A1121; BCP16766; s8171; AKOS027439964; Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-; ZINC231226004; CS-5453; SB19761; DB11682; HY-17608; J3.560.573H; D10874
DMRNGD2 CP GSK
DMRNGD2 DT Small molecular drug
DMRNGD2 PC 91617630
DMRNGD2 MW 393.4
DMRNGD2 FM C19H27N3O6
DMRNGD2 IC InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)
DMRNGD2 CS C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O
DMRNGD2 IK RUEYEZADQJCKGV-UHFFFAOYSA-N
DMRNGD2 IU 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid
DMRNGD2 CA CAS 960539-70-2
DMRNGD2 DE Autism spectrum disorder; Diabetic foot ulcer; Anaemia
DMSMFN2 ID DMSMFN2
DMSMFN2 DN GSK2140944
DMSMFN2 HS Phase 3
DMSMFN2 SN Gepotidacin
DMSMFN2 CP Glaxosmithkline
DMSMFN2 PC 25101874
DMSMFN2 MW 448.5
DMSMFN2 FM C24H28N6O3
DMSMFN2 IC InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1
DMSMFN2 CS C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6
DMSMFN2 IK PZFAZQUREQIODZ-LJQANCHMSA-N
DMSMFN2 IU (3R)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione
DMSMFN2 CA CAS 1075236-89-3
DMSMFN2 DE Acute bacterial skin infection; Urinary tract infection; Neisseria gonorrhoeae infection
DMWL2XD ID DMWL2XD
DMWL2XD DN GSK2402968
DMWL2XD HS Phase 3
DMWL2XD CP GlaxoSmithKline; Prosensa
DMWL2XD DE Duchenne dystrophy
DMUVZAO ID DMUVZAO
DMUVZAO DN GSK642444
DMUVZAO HS Phase 3
DMUVZAO SN threo isoleucyl thiazolidide, 1; BDBM17299
DMUVZAO CP Theravance; GlaxoSmithKline
DMUVZAO DT Small molecular drug
DMUVZAO PC 23647689
DMUVZAO MW 203.33
DMUVZAO FM C9H19N2OS+
DMUVZAO IC InChI=1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/p+1/t7-,8-/m0/s1
DMUVZAO CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)[NH3+]
DMUVZAO IK WCRLBFHWFPELKW-YUMQZZPRSA-O
DMUVZAO IU [(2S,3S)-3-methyl-1-oxo-1-(1,3-thiazolidin-3-yl)pentan-2-yl]azanium
DMUVZAO DE Chronic obstructive pulmonary disease
DMPS7U2 ID DMPS7U2
DMPS7U2 DN GTPL-9088
DMPS7U2 HS Phase 3
DMPS7U2 SN Clobetasona; Clobetasona [INN-Spanish]; Clobetasone; Clobetasone (INN); Clobetasone [INN:BAN]; Clobetasonum; Clobetasonum [INN-Latin]; LT69WY1J6D; SCHEMBL3581; XXIFVOHLGBURIG-OZCCCYNHSA-N; ZINC5752185; (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione; 21-Chlor-9-fluor-17-hydroxy-16beta-methyl-1,4-pregnadien-3,11,20-trion; 54063-32-0; AC1L2G2H; API0002061; D07717; DB13158; EINECS 258-953-5; GTPL9088; UNII-LT69WY1J6D
DMPS7U2 PC 71387
DMPS7U2 MW 408.9
DMPS7U2 FM C22H26ClFO4
DMPS7U2 IC XXIFVOHLGBURIG-OZCCCYNHSA-N
DMPS7U2 CS CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(=O)CC2(C1(C(=O)CCl)O)C)F)C
DMPS7U2 IK 1S/C22H26ClFO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-16,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19-,20-,21-,22-/m0/s1
DMPS7U2 IU (8S,9R,10S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-17-hydroxy-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthrene-3,11-dione
DMPS7U2 CA CAS 54063-32-0
DMPS7U2 DE Atopic dermatitis
DM9Y3EG ID DM9Y3EG
DM9Y3EG DN Guadecitabine
DM9Y3EG HS Phase 3
DM9Y3EG SN UNII-2KT4YN1DP7; 929901-49-5; 2KT4YN1DP7; SGI-110 free acid; Guadecitabine [USAN:INN]; GuadecitabineSGI-110; Guadecitabine (USAN/INN); CHEMBL3544916; Guanosine, 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxy-; ZINC43203165; AKOS027321496; AKOS030238181; DB11918; CS-3089; HY-13542; D10877; 2'-deoxy-5-azacytidylyl-(3'-5')-2'-deoxyguanosine
DM9Y3EG CP Astex Pharmaceuticals Pleasanton, CA
DM9Y3EG PC 135564655
DM9Y3EG MW 557.4
DM9Y3EG FM C18H24N9O10P
DM9Y3EG IC InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1
DM9Y3EG CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O
DM9Y3EG IK GUWXKKAWLCENJA-WGWHJZDNSA-N
DM9Y3EG IU [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DM9Y3EG CA CAS 929901-49-5
DM9Y3EG DE Myelodysplastic syndrome
DMN4E7T ID DMN4E7T
DMN4E7T DN Guaiacol
DMN4E7T HS Phase 3
DMN4E7T SN guaiacol; 2-Methoxyphenol; 90-05-1; o-Methoxyphenol; 2-Hydroxyanisole; Phenol, 2-methoxy-; Pyrocatechol monomethyl ether; Methylcatechol; Guaiastil; Guaicol; 1-Hydroxy-2-methoxybenzene; Pyroguaiac acid; o-Guaiacol; o-Hydroxyanisole; Guaicolina; Guajol; Guasol; Anastil; Phenol, o-methoxy-; Catechol monomethyl ether; O-Methyl catechol; CREOSOTE, WOOD; Methoxyphenol; Guajakol; Wood creosote; 2-Methoxy-Phenol; Creosote, beechwood; Guajacol; Methyl Catechol; Phenol, methoxy-; Guajakol [Czech]; Guaiacol (natural); 8021-39-4; Methylcatachol
DMN4E7T DT Small molecular drug
DMN4E7T PC 460
DMN4E7T MW 124.14
DMN4E7T FM C7H8O2
DMN4E7T IC InChI=1S/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3
DMN4E7T CS COC1=CC=CC=C1O
DMN4E7T IK LHGVFZTZFXWLCP-UHFFFAOYSA-N
DMN4E7T IU 2-methoxyphenol
DMN4E7T CA CAS 8021-39-4
DMN4E7T CB CHEBI:28591
DMIWLJE ID DMIWLJE
DMIWLJE DN Guanine
DMIWLJE HS Phase 3
DMIWLJE DT Small molecular drug
DMIWLJE PC 135398634
DMIWLJE MW 151.13
DMIWLJE FM C5H5N5O
DMIWLJE IC InChI=1S/C5H5N5O/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DMIWLJE CS C1=NC2=C(N1)C(=O)NC(=N2)N
DMIWLJE IK UYTPUPDQBNUYGX-UHFFFAOYSA-N
DMIWLJE IU 2-amino-1,7-dihydropurin-6-one
DMIWLJE CA CAS 73-40-5
DMIWLJE CB CHEBI:16235
DMHULRK ID DMHULRK
DMHULRK DN GV1001
DMHULRK HS Phase 3
DMHULRK SN GV1001
DMHULRK CP KAEL-GemVax
DMHULRK DT Vaccine
DMHULRK DE Pancreatic cancer
DMAXTFO ID DMAXTFO
DMAXTFO DN H1N1 influenza vaccine
DMAXTFO HS Phase 3
DMAXTFO SN Humenza; H1N1 influenza vaccine (AF-03-adjuvanted, EU market); H1N1 influenza vaccine (AF-03-adjuvanted, EU market), Sanofi Pasteur
DMAXTFO CP Sanofi Pasteur
DMAXTFO DT Vaccine
DMAXTFO DE Influenza virus infection
DM9CMI3 ID DM9CMI3
DM9CMI3 DN H5N1 influenza vaccine
DM9CMI3 HS Phase 3
DM9CMI3 SN KIB-PIA; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted); Avian influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato; H5N1 influenza vaccine (inactivated whole virion, egg-cultured, alum-adjuvanted), Kitasato
DM9CMI3 CP Kitasato Institute
DM9CMI3 DT Vaccine
DM9CMI3 DE Influenza virus infection
DMQ38JZ ID DMQ38JZ
DMQ38JZ DN HB-AS02V
DMQ38JZ HS Phase 3
DMQ38JZ SN HBV vaccine (adjuvanted), Henogen; Hepatitis B virus vaccine (adjuvanted), Henogen
DMQ38JZ CP Henogen SA
DMQ38JZ DT Vaccine
DMQ38JZ DE Hepatitis B virus infection
DMB06MU ID DMB06MU
DMB06MU DN HC-1119
DMB06MU HS Phase 3
DMB06MU SN Enzalutamide D3; UNII-3OKI556HC2; 3OKI556HC2; HC 1119; 1443331-82-5; CHEMBL4594421; SCHEMBL18789402; HY-70002S; CS-0019855; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-
DMB06MU CP Hinova Pharmaceuticals
DMB06MU DT Small molecular drug
DMB06MU PC 71580408
DMB06MU MW 467.5
DMB06MU FM C21H16F4N4O2S
DMB06MU IC InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
DMB06MU CS [2H]C([2H])([2H])NC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)F
DMB06MU IK WXCXUHSOUPDCQV-HPRDVNIFSA-N
DMB06MU IU 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-(trideuteriomethyl)benzamide
DMB06MU CA CAS 1443331-82-5
DMB06MU DE Prostate cancer
DMB9U5E ID DMB9U5E
DMB9U5E DN HE3286
DMB9U5E HS Phase 3
DMB9U5E SN Triolex; HE3286; UNII-PH8858757I; PH8858757I; 1004264-32-7; HE 3286; HE-3286; 1001100-69-1; SCHEMBL512549; 3beta,7beta,17beta-Trihydroxy-17alpha-ethynylandrost-5-ene; DB05212; Pregn-5-en-20-yne-3,7,17-triol, (3beta,7beta,17alpha)-
DMB9U5E CP Hollis-Eden Pharmaceuticals
DMB9U5E DT Small molecular drug
DMB9U5E PC 16739648
DMB9U5E MW 330.5
DMB9U5E FM C21H30O3
DMB9U5E IC InChI=1S/C21H30O3/c1-4-21(24)10-7-16-18-15(6-9-20(16,21)3)19(2)8-5-14(22)11-13(19)12-17(18)23/h1,12,14-18,22-24H,5-11H2,2-3H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1
DMB9U5E CS C[C@]12CC[C@@H](CC1=C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O)O
DMB9U5E IK JJKOQZHWYLMASZ-FJWDNACWSA-N
DMB9U5E IU (3S,7R,8R,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,7,17-triol
DMB9U5E CA CAS 1001100-69-1
DMB9U5E DE Type-2 diabetes
DMQTLVB ID DMQTLVB
DMQTLVB DN Hebergel
DMQTLVB HS Phase 3
DMQTLVB SN Interferon alpha 2b gel (viral infection), CIGB
DMQTLVB CP Center for Genetic Engineering and Biotechnology
DMQTLVB DE Virus infection
DMUE843 ID DMUE843
DMUE843 DN Hematide
DMUE843 HS Phase 3
DMUE843 CP Affymax Inc; Takeda Pharmaceutical Co Ltd.
DMUE843 DE Anemia
DMGFULM ID DMGFULM
DMGFULM DN Heparin low molecular weight
DMGFULM HS Phase 3
DMGFULM SN Heparin low molecular weight, Watson Laboratories; Heparin transmucosal, TheraTech
DMGFULM CP Watson Laboratories Inc
DMGFULM DE Thrombosis
DMXAZ47 ID DMXAZ47
DMXAZ47 DN HGH-CTP
DMXAZ47 HS Phase 3
DMXAZ47 SN MOD-401; MOD-4023; Human growth hormone (injectable, CTP, growth disorder), Modigene; Long-acting hGH (injectable, CTP, growth disorder), Modigene
DMXAZ47 CP Prolor biotech; chiasma
DMXAZ47 DE Growth hormone deficiency
DM6QOVN ID DM6QOVN
DM6QOVN DN HKI-272
DM6QOVN HS Phase 3
DM6QOVN SN Neratinib (ERBB2 inhibitor)
DM6QOVN CP Wyeth Research
DM6QOVN TC Anticancer Agents
DM6QOVN DT Small molecular drug
DM6QOVN PC 9915743
DM6QOVN MW 557
DM6QOVN FM C30H29ClN6O3
DM6QOVN IC InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
DM6QOVN CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C
DM6QOVN IK JWNPDZNEKVCWMY-VQHVLOKHSA-N
DM6QOVN IU (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DM6QOVN CA CAS 698387-09-6
DM6QOVN CB CHEBI:61397
DM6QOVN DE Breast cancer
DM29XGY ID DM29XGY
DM29XGY DN HMPL-004
DM29XGY HS Phase 3
DM29XGY SN Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
DM29XGY CP Hutchison Medipharma Enterprises Ltd
DM29XGY DE Inflammatory bowel disease
DMAVIPZ ID DMAVIPZ
DMAVIPZ DN HSR-803
DMAVIPZ HS Phase 3
DMAVIPZ SN Ganaton; ITOPRIDE HCl; Itopride (hydrochloride); Q-201260; itopride hydrochloride; 122892-31-3; 2H9NV66W0I; C20H27ClN2O4; DSSTox_CID_26693; DSSTox_GSID_46693; DSSTox_RID_81827; HSR-803; HSR803; Hsr 803; Itax; MFCD00881710; N-((4-(2-(Dimethylamino)ethoxy)phenyl)methyl)-3,4-dimethoxybenzamide monohydrochloride; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxidebenzamide hydrochloride; N-(4-(2-(dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzmide; UNII-2H9NV66W0I; n-[4-(2-dimethylaminoethoxy)benzyl]-3,4-dimethoxybenzamide hcl
DMAVIPZ PC 129791
DMAVIPZ MW 394.9
DMAVIPZ FM C20H27ClN2O4
DMAVIPZ IC ZTOUXLLIPWWHSR-UHFFFAOYSA-N
DMAVIPZ CS CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC.Cl
DMAVIPZ IK 1S/C20H26N2O4.ClH/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4;/h5-10,13H,11-12,14H2,1-4H3,(H,21,23);1H
DMAVIPZ IU N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide;hydrochloride
DMAVIPZ CA CAS 122892-31-3
DMAVIPZ DE Functional nausea/vomiting
DMBER0Q ID DMBER0Q
DMBER0Q DN Hu5F9-G4
DMBER0Q HS Phase 3
DMBER0Q CP Forty Seven Menlo Park, CA
DMBER0Q DE Solid tumour/cancer; Acute myeloid leukaemia; Colorectal cancer; B-cell non-hodgkin lymphoma; Myelodysplastic syndrome
DMXZAL2 ID DMXZAL2
DMXZAL2 DN Hydroxychloroquine
DMXZAL2 HS Phase 3
DMXZAL2 SN Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258
DMXZAL2 CP Concordia Pharmaceuticals Inc
DMXZAL2 TC Antiviral Agents
DMXZAL2 DT Small molecular drug
DMXZAL2 PC 3652
DMXZAL2 MW 335.9
DMXZAL2 FM C18H26ClN3O
DMXZAL2 IC InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
DMXZAL2 CS CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
DMXZAL2 IK XXSMGPRMXLTPCZ-UHFFFAOYSA-N
DMXZAL2 IU 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
DMXZAL2 CA CAS 118-42-3
DMXZAL2 CB CHEBI:5801
DMXZAL2 DE Malaria; Coronavirus Disease 2019 (COVID-19)
DMIGFOR ID DMIGFOR
DMIGFOR DN I3C
DMIGFOR HS Phase 3
DMIGFOR SN Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165
DMIGFOR DT Small molecular drug
DMIGFOR PC 3712
DMIGFOR MW 147.17
DMIGFOR FM C9H9NO
DMIGFOR IC InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2
DMIGFOR CS C1=CC=C2C(=C1)C(=CN2)CO
DMIGFOR IK IVYPNXXAYMYVSP-UHFFFAOYSA-N
DMIGFOR IU 1H-indol-3-ylmethanol
DMIGFOR CA CAS 700-06-1
DMIGFOR CB CHEBI:24814
DMIGFOR DE Breast cancer
DM5KL8E ID DM5KL8E
DM5KL8E DN IBI-308
DM5KL8E HS Phase 3
DM5KL8E CP Innovent Biologics
DM5KL8E DT Monoclonal antibody
DM5KL8E DE Bronchioalveolar carcinoma
DM9G5XD ID DM9G5XD
DM9G5XD DN IB-MECA
DM9G5XD HS Phase 3
DM9G5XD SN IB-Meca; 152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine; UNII-30679UMI0N; N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide; 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; 3-iodobenzyl-5'-N-methylcarboxamidoadenosine; N(6)-(3-iodo-benzyl)adenosine-5'-N-methyluronamide; 3-IB-MECA
DM9G5XD DT Small molecular drug
DM9G5XD PC 123683
DM9G5XD MW 510.3
DM9G5XD FM C18H19IN6O4
DM9G5XD IC InChI=1S/C18H19IN6O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
DM9G5XD CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O
DM9G5XD IK HUJXGQILHAUCCV-MOROJQBDSA-N
DM9G5XD IU (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide
DM9G5XD CA CAS 152918-18-8
DM9G5XD CB CHEBI:73286
DM9G5XD DE Solid tumour/cancer; Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis
DMT67EH ID DMT67EH
DMT67EH DN Ibodutant
DMT67EH HS Phase 3
DMT67EH SN MEN-15596; Tachykinin NK2 receptor antagonist (irritable bowel syndrome), Menarini
DMT67EH CP The Menarini Group
DMT67EH DT Small molecular drug
DMT67EH PC 11527495
DMT67EH MW 644.9
DMT67EH FM C37H48N4O4S
DMT67EH IC InChI=1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1
DMT67EH CS CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6
DMT67EH IK YQYSVMKCMIUCHY-WJOKGBTCSA-N
DMT67EH IU 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4-yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
DMT67EH CA CAS 522664-63-7
DMT67EH DE Irritable bowel syndrome
DMOJQGT ID DMOJQGT
DMOJQGT DN ICARIIN
DMOJQGT HS Phase 3
DMOJQGT SN Icariin; 489-32-7; Ieariline; UNII-VNM47R2QSQ; CHEBI:78420; VNM47R2QSQ; Icariine; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Icarin; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(be
DMOJQGT DT Small molecular drug
DMOJQGT PC 5318997
DMOJQGT MW 676.7
DMOJQGT FM C33H40O15
DMOJQGT IC InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32-,33+/m0/s1
DMOJQGT CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O
DMOJQGT IK TZJALUIVHRYQQB-XLRXWWTNSA-N
DMOJQGT IU 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMOJQGT CA CAS 489-32-7
DMOJQGT CB CHEBI:78420
DM3OU54 ID DM3OU54
DM3OU54 DN ICI 118,551
DM3OU54 HS Phase 3
DM3OU54 SN Ici 118551; (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; CHEMBL198059; CHEBI:73289; ICI-118551; ICI118551; erythro-DL-1-(7-Methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; (2R,3S)-3-(isopropylamino)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]butan-2-ol; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (2R,3S)-rel-; 2-Butanol, 1-((2,3-dihydro-7-methyl-1H-inden-4-yl)oxy)-3-((1-methylethyl)amino)-, (R*,S*)-(+-)-; ICI-118,551; Ici 111,581; AC1NUNSO
DM3OU54 DT Small molecular drug
DM3OU54 PC 3682
DM3OU54 MW 277.4
DM3OU54 FM C17H27NO2
DM3OU54 IC InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3
DM3OU54 CS CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O
DM3OU54 IK VFIDUCMKNJIJTO-UHFFFAOYSA-N
DM3OU54 IU 1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol
DM3OU54 CB CHEBI:91879
DM3OU54 DE Gastric adenocarcinoma; HER2-positive breast cancer
DM7YNV9 ID DM7YNV9
DM7YNV9 DN Iclaprim
DM7YNV9 HS Phase 3
DM7YNV9 SN 192314-93-5; AR-100; 5-[(2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-yl)methyl]pyrimidine-2,4-diamine; RO-48-2622; Mersarex; 5-((2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl)pyrimidine-2,4-diamine; Iclaprim [USAN:INN]; Iclaprim (USAN/INN); 2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-; 2,4-Pyrimidinediamine, 5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]-; AR 100; AC1Q4WM5; SCHEMBL379386; CHEMBL134561; AC1L4U54; SCHEMBL12899446; CTK4E0971; BDBM18070; Iclaprim [INN]; AR-102; AR-100001; 5-((2RS)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-ylmethyl)pyrimidine-2,4-diamine
DM7YNV9 CP Arpida
DM7YNV9 DT Small molecular drug
DM7YNV9 PC 213043
DM7YNV9 MW 354.4
DM7YNV9 FM C19H22N4O3
DM7YNV9 IC InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)
DM7YNV9 CS COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC
DM7YNV9 IK HWJPWWYTGBZDEG-UHFFFAOYSA-N
DM7YNV9 IU 5-[(2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine
DM7YNV9 CA CAS 192314-93-5
DM7YNV9 CB CHEBI:131751
DM7YNV9 DE Pneumonia; Bacterial infection; Acute bacterial skin infection
DMU72KL ID DMU72KL
DMU72KL DN ICP-022
DMU72KL HS Phase 3
DMU72KL SN Orelabrutinib; 1655504-04-3; UNII-WJA5UO9E10; WJA5UO9E10; 4-yl]pyridine-3-carboxamide; ICP022; 2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-; 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide; Orelabrutinib [INN]; orelabrutinib (proposed INN); SCHEMBL16597834; US9951056, Example 3; GTPL10629; BDBM389631; EX-A3442; NSC826039; s9600; NSC-826039; example 3 [WO2015048662A2]; DB-091042; HY-129390; CS-0105163; 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide; 3-Pyridinecarboxamide, 6-(1-(1-oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-; 6-(1-(1-Oxo-2-propen-1-yl)-4-piperidinyl)-2-(4-phenoxyphenyl)-3-pyridinecarboxamide
DMU72KL CP InnoCare Pharma
DMU72KL DT Small molecular drug
DMU72KL PC 91667513
DMU72KL MW 427.5
DMU72KL FM C26H25N3O3
DMU72KL IC InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
DMU72KL CS C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4
DMU72KL IK MZPVEMOYADUARK-UHFFFAOYSA-N
DMU72KL IU 2-(4-phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide
DMU72KL CA CAS 1655504-04-3
DMU72KL DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMBIZ7H ID DMBIZ7H
DMBIZ7H DN ICT-107
DMBIZ7H HS Phase 3
DMBIZ7H CP ImmunoCellular Therapeutics
DMBIZ7H DT Vaccine
DMBIZ7H DE Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma
DMSP0X8 ID DMSP0X8
DMSP0X8 DN IDAZOXAN HYDROCHLORIDE
DMSP0X8 HS Phase 3
DMSP0X8 SN IDAZOXAN HYDROCHLORIDE; 79944-56-2; Idazoxan HCl; RX 781094; MLS000069708; SMR000058458; SR-01000000206; Opera_ID_847; Idazoxan (hydrochloride); AC1L4CEL; MLS001148081; SCHEMBL707367; CHEMBL543467; CTK8G0263; MolPort-003-941-824; MYUBYOVCLMEAOH-UHFFFAOYSA-N; (+/-)-Idazoxan Monohydrochloride; Pharmakon1600-01506073; HMS1570J14; Tox21_500652; NSC759867; MFCD00069293; BN0267; AKOS024458652; NSC-759867; RX 781094A; LP00652; CCG-214002; 1H-Imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-,monohydrochloride; 1H-Imidazole, 2-(2,3-d
DMSP0X8 DT Small molecular drug
DMSP0X8 PC 154494
DMSP0X8 MW 240.68
DMSP0X8 FM C11H13ClN2O2
DMSP0X8 IC InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H
DMSP0X8 CS C1CN=C(N1)C2COC3=CC=CC=C3O2.Cl
DMSP0X8 IK MYUBYOVCLMEAOH-UHFFFAOYSA-N
DMSP0X8 IU 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole;hydrochloride
DMSP0X8 CA CAS 79944-56-2
DMSP0X8 DE Neurological disorder
DMV3DHQ ID DMV3DHQ
DMV3DHQ DN IDDBCP161883
DMV3DHQ HS Phase 3
DMV3DHQ CP Mitsubishi Tanabe
DMV3DHQ DE Type-2 diabetes
DM3A701 ID DM3A701
DM3A701 DN IDP-122
DM3A701 HS Phase 3
DM3A701 CP Valeant Pharmaceuticals Bridgewater, NJ
DM3A701 DE Plaque psoriasis
DMRLVUD ID DMRLVUD
DMRLVUD DN Imagabalin
DMRLVUD HS Phase 3
DMRLVUD SN Imagabalin hydrochloride; PD-0332334; PD-332334; PF-00195889
DMRLVUD CP Pfizer Inc
DMRLVUD DT Small molecular drug
DMRLVUD PC 10236037
DMRLVUD MW 173.25
DMRLVUD FM C9H19NO2
DMRLVUD IC InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
DMRLVUD CS CCC[C@@H](C)C[C@@H](CC(=O)O)N
DMRLVUD IK JXEHXYFSIOYTAH-SFYZADRCSA-N
DMRLVUD IU (3S,5R)-3-amino-5-methyloctanoic acid
DMRLVUD CA CAS 610300-07-7
DMRLVUD DE Generalized anxiety disorder
DMM9JEF ID DMM9JEF
DMM9JEF DN Imatinib
DMM9JEF HS Phase 3
DMM9JEF SN Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI
DMM9JEF CP Novartis AG
DMM9JEF TC Antiviral Agents
DMM9JEF DT Small molecular drug
DMM9JEF PC 5291
DMM9JEF MW 493.6
DMM9JEF FM C29H31N7O
DMM9JEF IC InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
DMM9JEF CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DMM9JEF IK KTUFNOKKBVMGRW-UHFFFAOYSA-N
DMM9JEF IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMM9JEF CA CAS 152459-95-5
DMM9JEF CB CHEBI:45783
DMM9JEF DE Chronic myelogenous leukaemia; Intestinal cancer; Lung cancer; Systemic mastocytosis; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM7BCWT ID DM7BCWT
DM7BCWT DN Imiglitazar
DM7BCWT HS Phase 3
DM7BCWT SN TAK-559
DM7BCWT CP Takeda Pharmaceutical Co Ltd
DM7BCWT DT Small molecular drug
DM7BCWT PC 9890879
DM7BCWT MW 470.5
DM7BCWT FM C28H26N2O5
DM7BCWT IC InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+
DM7BCWT CS CC1=C(N=C(O1)C2=CC=CC=C2)COC3=CC=C(C=C3)CO/N=C(\\CCC(=O)O)/C4=CC=CC=C4
DM7BCWT IK ULVDFHLHKNJICZ-QCWLDUFUSA-N
DM7BCWT IU (4E)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid
DM7BCWT CA CAS 250601-04-8
DM7BCWT DE Type-2 diabetes
DM735FA ID DM735FA
DM735FA DN IMO-2125
DM735FA HS Phase 3
DM735FA CP Idera Pharmaceuticals
DM735FA DE Hepatitis C virus infection; Melanoma; Solid tumour/cancer
DMIJGT9 ID DMIJGT9
DMIJGT9 DN INCB24360
DMIJGT9 HS Phase 3
DMIJGT9 SN Epacadostat
DMIJGT9 CP Incyte
DMIJGT9 DT Small molecular drug
DMIJGT9 PC 135564890
DMIJGT9 MW 438.24
DMIJGT9 FM C11H13BrFN7O4S
DMIJGT9 IC InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
DMIJGT9 CS C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F
DMIJGT9 IK FBKMWOJEPMPVTQ-UHFFFAOYSA-N
DMIJGT9 IU N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide
DMIJGT9 CA CAS 1204669-58-8
DMIJGT9 DE Recurrent glioblastoma; Melanoma; B-cell lymphoma; Colorectal cancer; Head and neck cancer; Lung cancer; Lymphoma; Merkel cell carcinoma; Ovarian cancer; Solid tumour/cancer; Urothelial carcinoma
DMZA2K0 ID DMZA2K0
DMZA2K0 DN INCSHR1210
DMZA2K0 HS Phase 3
DMZA2K0 SN Camrelizumab
DMZA2K0 CP Incyte Wilmington, DE
DMZA2K0 DT Monoclonal antibody
DMZA2K0 DE Solid tumour/cancer; Bronchioalveolar carcinoma; Esophageal squamous cell carcinoma
DMLG96Z ID DMLG96Z
DMLG96Z DN INM-176
DMLG96Z HS Phase 3
DMLG96Z SN WIN-026; Win-025; Alzheimer's therapeutic, Whanin Pharmaceuticals; KR-WAP-026; Anti-beta amyloid/AChE inhibitor (Alzheimer's), WhanIn; Anti-beta amyloid/acetylcholinesterase inhibitor (Alzheimer's), WhanIn
DMLG96Z CP Scigenic & Scigen Harvest Co Ltd
DMLG96Z DE Alzheimer disease
DM5L8QT ID DM5L8QT
DM5L8QT DN INO-1001
DM5L8QT HS Phase 3
DM5L8QT SN Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
DM5L8QT CP Inotek Pharma.
DM5L8QT TC Anticancer Agents
DM5L8QT DT Small molecular drug
DM5L8QT PC 6708742
DM5L8QT DE Brain cancer
DMUS1F8 ID DMUS1F8
DMUS1F8 DN Inolimomab
DMUS1F8 HS Phase 3
DMUS1F8 CP EUSA Pharma
DMUS1F8 DT Monoclonal antibody
DMUS1F8 DE Heart transplant rejection
DMOTH6V ID DMOTH6V
DMOTH6V DN Interferon alpha 2a
DMOTH6V HS Phase 3
DMOTH6V SN LBSI-5535; Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV); Interferon alpha 2a (Biohydrix sustained release/weekly dosing, HCV), LG Life Sciences; Sr-IFN alpha (Biohydrix sustained release/weekly dosing, HCV), LGLS
DMOTH6V CP LG Life Sciences Ltd
DMOTH6V DE Hepatitis C virus infection
DMZA47Y ID DMZA47Y
DMZA47Y DN Iomab-B
DMZA47Y HS Phase 3
DMZA47Y SN Iomab-B (TN)
DMZA47Y CP Actinium Pharmaceuticals
DMZA47Y DT Antibody
DMZA47Y DE Acute myeloid leukaemia; Bone marrow transplantation
DMSV12M ID DMSV12M
DMSV12M DN Isavuconazole
DMSV12M HS Phase 3
DMSV12M SN Isavuconazole; 241479-67-4; isavuconazol; BAL 4815; BAL-4815; UNII-60UTO373KE; Isavuconazole [INN]; 60UTO373KE; Isavuconazole(BAL-4815; RO-0094815); RO 0094815; CHEBI:85979; Isavuconazole (INN); RO-0094815; 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; 1286730-05-9; 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
DMSV12M CP Astellas
DMSV12M DT Small molecular drug
DMSV12M PC 6918485
DMSV12M MW 437.5
DMSV12M FM C22H17F2N5OS
DMSV12M IC InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
DMSV12M CS C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O
DMSV12M IK DDFOUSQFMYRUQK-RCDICMHDSA-N
DMSV12M IU 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
DMSV12M CA CAS 241479-67-4
DMSV12M CB CHEBI:85979
DMSV12M DE Invasive aspergillosis; Invasive candidiasis; Candidemia
DMQZI7K ID DMQZI7K
DMQZI7K DN ISIS 23722
DMQZI7K HS Phase 3
DMQZI7K CP Isis Pharmaceuticals
DMQZI7K SQ TGTGCTATTCTGTGAATT
DMQZI7K DE Solid tumour/cancer
DMKWBJR ID DMKWBJR
DMKWBJR DN ISIS-PKK
DMKWBJR HS Phase 3
DMKWBJR SN ISIS-PKKRx
DMKWBJR DT Antisense drug
DMKWBJR DE Amyloid cardiomyopathy
DM4U5NF ID DM4U5NF
DM4U5NF DN ISIS-TTR
DM4U5NF HS Phase 3
DM4U5NF CP ISIS Pharm
DM4U5NF DT Antisense drug
DM4U5NF DE Amyloidosis
DMBJTVL ID DMBJTVL
DMBJTVL DN Isotretinoin
DMBJTVL HS Phase 3
DMBJTVL SN Accutane; 13-cis-Retinoic acid; Roaccutane; Neovitamin A acid; 13-cis-Vitamin A acid; 13-cis retinoic acid; Claravis; Amnesteem; Isotrex; Teriosal; Sotret; isotretinoino; Isotretinoinum; Isotretinoine; Roaccutan; 13-RA; Roacutan; Absorica; ISOTRETINON; Isotretinoine [INN-French]; Isotretinoinum [INN-Latin]; Isotretinoino [INN-Spanish]; CIP-Isotretinoin; Accutane (TN); Isotretinoin (USP); Ro-4-3780; UNII-EH28UP18IF; CCRIS 4286; HSDB 3929
DMBJTVL TC Antiviral Agents
DMBJTVL DT Small molecular drug
DMBJTVL PC 5282379
DMBJTVL MW 300.4
DMBJTVL FM C20H28O2
DMBJTVL IC InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-
DMBJTVL CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\\C(=O)O)/C)/C
DMBJTVL IK SHGAZHPCJJPHSC-XFYACQKRSA-N
DMBJTVL IU (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMBJTVL CA CAS 4759-48-2
DMBJTVL CB CHEBI:6067
DMBJTVL DE Coronavirus Disease 2019 (COVID-19)
DMP61YB ID DMP61YB
DMP61YB DN ISRAPAFANT
DMP61YB HS Phase 3
DMP61YB SN Y-24180; Israpafant; Pafnol (Mitsubishi Pharma, JP); Rac-4-(2-Chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
DMP61YB DT Small molecular drug
DMP61YB PC 119175
DMP61YB MW 489.1
DMP61YB FM C28H29ClN4S
DMP61YB IC InChI=1S/C28H29ClN4S/c1-17(2)15-21-11-9-20(10-12-21)13-14-22-16-24-26(23-7-5-6-8-25(23)29)30-18(3)27-32-31-19(4)33(27)28(24)34-22/h5-12,16-18H,13-15H2,1-4H3
DMP61YB CS CC1C2=NN=C(N2C3=C(C=C(S3)CCC4=CC=C(C=C4)CC(C)C)C(=N1)C5=CC=CC=C5Cl)C
DMP61YB IK RMSWMRJVUJSDGN-UHFFFAOYSA-N
DMP61YB IU 7-(2-chlorophenyl)-9,13-dimethyl-4-[2-[4-(2-methylpropyl)phenyl]ethyl]-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
DMP61YB CA CAS 117279-73-9
DMP61YB DE Asthma
DMNDGWE ID DMNDGWE
DMNDGWE DN IT-101
DMNDGWE HS Phase 3
DMNDGWE CP Insert Therapeutics
DMNDGWE DE Solid tumour/cancer
DMFZBNE ID DMFZBNE
DMFZBNE DN ITF2357
DMFZBNE HS Phase 3
DMFZBNE SN Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
DMFZBNE CP Italfarmaco
DMFZBNE DT Small molecular drug
DMFZBNE PC 9804992
DMFZBNE MW 421.5
DMFZBNE FM C24H27N3O4
DMFZBNE IC InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
DMFZBNE CS CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO
DMFZBNE IK YALNUENQHAQXEA-UHFFFAOYSA-N
DMFZBNE IU [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate
DMFZBNE CA CAS 497833-27-9
DMFZBNE CB CHEBI:94187
DMFZBNE DE Polycythemia vera; Essential thrombocythemia; Myelofibrosis; Duchenne dystrophy
DMUQ1DO ID DMUQ1DO
DMUQ1DO DN ITI-007
DMUQ1DO HS Phase 3
DMUQ1DO CP Intra-Cellular Therapies
DMUQ1DO DT Small molecular drug
DMUQ1DO PC 21302490
DMUQ1DO MW 393.5
DMUQ1DO FM C24H28FN3O
DMUQ1DO IC InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1
DMUQ1DO CS CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
DMUQ1DO IK HOIIHACBCFLJET-SFTDATJTSA-N
DMUQ1DO IU 1-(4-fluorophenyl)-4-[(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one
DMUQ1DO CA CAS 313369-37-8
DMUQ1DO DE Insomnia; Schizophrenia; Depression; Major depressive disorder
DMGWVLX ID DMGWVLX
DMGWVLX DN Itolizumab
DMGWVLX HS Phase 3
DMGWVLX SN T-1h-mAb; T-1h-mAb); Anti-CD6 humanized monoclonal antibody, Center of Molecular Immunology/Biocon Biopharmaceuticals; Anti-CD6 humanized monoclonal antibody (rheumatoid arthritis/ psoriasis/ T-cell lymphoma), CIM/Biocon Biopharmaceuticals
DMGWVLX CP Dermatology; The Center of Molecular Immunology
DMGWVLX DT Antibody
DMGWVLX DE Type-1 diabetes
DM7MLTR ID DM7MLTR
DM7MLTR DN Itopride
DM7MLTR HS Phase 3
DM7MLTR SN Itopride; Itopride (INN); Itopride [INN]; QQQIECGTIMUVDS-UHFFFAOYSA-N; SCHEMBL311309; SR-01000763470; 122898-67-3; 81BMQ80QRL; AC1L1GQ2; AC1Q5DLT; DTXSID7048320; N-(4-(2-(Dimethylamino)ethoxy)benzyl)-3,4-dimethoxybenzamide; N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide; N-[4-[2-(Dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide; N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide; NCGC00167529-01; UNII-81BMQ80QRL; n-{4-[2-(dimethylamino)ethoxy]benzyl}-3,4-dimethoxybenzamide
DM7MLTR PC 3792
DM7MLTR MW 358.4
DM7MLTR FM C20H26N2O4
DM7MLTR IC QQQIECGTIMUVDS-UHFFFAOYSA-N
DM7MLTR CS CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC
DM7MLTR IK 1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)
DM7MLTR IU N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxybenzamide
DM7MLTR CA CAS 122898-67-3
DM7MLTR CB CHEBI:94809
DM7MLTR DE Functional nausea/vomiting
DMNORK8 ID DMNORK8
DMNORK8 DN Jakafi
DMNORK8 HS Phase 3
DMNORK8 SN Ruxolitinib phosphate; 1092939-17-7; Ruxolitinib (phosphate); Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; UNII-436LRU32H5; Ruxolitinib phosphate salt; Ruxolitinib phosphate(INCB018424); CHEBI:66917; 436LRU32H5; J-501793; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate; Ruxolitinib phosphate [USAN]; Jaka
DMNORK8 CP Incyte, Wilmington, DE
DMNORK8 PC 25127112
DMNORK8 MW 404.4
DMNORK8 FM C17H21N6O4P
DMNORK8 IC InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
DMNORK8 CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
DMNORK8 IK JFMWPOCYMYGEDM-XFULWGLBSA-N
DMNORK8 IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
DMNORK8 CA CAS 1092939-17-7
DMNORK8 CB CHEBI:66917
DMNORK8 DE Essential thrombocythemia
DM8FSPV ID DM8FSPV
DM8FSPV DN JTZ-951
DM8FSPV HS Phase 3
DM8FSPV PC 50899324
DM8FSPV MW 340.33
DM8FSPV FM C17H16N4O4
DM8FSPV IC InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
DM8FSPV CS C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
DM8FSPV IK FJYRBJKWDXVHHO-UHFFFAOYSA-N
DM8FSPV IU 2-[[7-oxo-5-(2-phenylethyl)-3H-[1,2,4]triazolo[1,5-a]pyridine-8-carbonyl]amino]acetic acid
DM8FSPV CA CAS 1262132-81-9
DM8FSPV DE Anaemia
DM5WCV4 ID DM5WCV4
DM5WCV4 DN JX-594
DM5WCV4 HS Phase 3
DM5WCV4 SN Pexastimogene devacirepvec
DM5WCV4 CP Jennerex Biotherapeutics
DM5WCV4 DE Liver cancer; Colorectal cancer; Hepatocellular carcinoma
DM9J0KD ID DM9J0KD
DM9J0KD DN K-103-IP
DM9J0KD HS Phase 3
DM9J0KD DE Pain
DMCRGY4 ID DMCRGY4
DMCRGY4 DN Karenitecin
DMCRGY4 HS Phase 3
DMCRGY4 SN Karenitecin (TN)
DMCRGY4 CP BioNumerik Pharmaceuticals
DMCRGY4 DT Small molecular drug
DMCRGY4 PC 148202
DMCRGY4 MW 448.6
DMCRGY4 FM C25H28N2O4Si
DMCRGY4 IC InChI=1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1
DMCRGY4 CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O
DMCRGY4 IK POADTFBBIXOWFJ-VWLOTQADSA-N
DMCRGY4 IU (19S)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMCRGY4 CA CAS 203923-89-1
DMCRGY4 DE Lung cancer; Ovarian cancer
DM8VO16 ID DM8VO16
DM8VO16 DN KH-902
DM8VO16 HS Phase 3
DM8VO16 SN Fumintide; KH-902 (intravitreal, AMD/DME), Kanghong Biotechnologies
DM8VO16 CP Chengdu Kanghong Biotechnologies Co Ltd
DM8VO16 DE Diabetic macular edema
DMSDBPG ID DMSDBPG
DMSDBPG DN KN046
DMSDBPG HS Phase 3
DMSDBPG CP Alphamab Oncology
DMSDBPG DT Antibody
DMSDBPG DE Non-small-cell lung cancer
DMP5G1K ID DMP5G1K
DMP5G1K DN KPS-0373
DMP5G1K HS Phase 3
DMP5G1K SN S-0373; TSH release modulator (spinocerebellar ataxia), Kissei; Thyrotropin-releasing hormone derivative (spinocerebellarataxia), Shionogi; Thyrotropin-releasing hormone derivative (Parkinson's disease), Shionogi
DMP5G1K CP Shionogi & Co Ltd
DMP5G1K DE Parkinson disease
DMM2LTC ID DMM2LTC
DMM2LTC DN KSI-301
DMM2LTC HS Phase 3
DMM2LTC CP Kodiak Sciences
DMM2LTC DT Antibody biopolymer conjugate
DMM2LTC DE Diabetic macular edema
DMP3GI2 ID DMP3GI2
DMP3GI2 DN KW-3357
DMP3GI2 HS Phase 3
DMP3GI2 SN Coagulation factor inhibitor (iv, blood clotting disorder), Kyowa; Recombinant antithrombin (iv, blooding clottingdisorder), Kyowa Hakko Kirin
DMP3GI2 CP Kyowa Hakko Kogyo Co Ltd
DMP3GI2 DE Coagulation defect
DMF0NA9 ID DMF0NA9
DMF0NA9 DN KX-01
DMF0NA9 HS Phase 3
DMF0NA9 CP Athenex Buffalo, NY
DMF0NA9 DE Actinic keratosis
DMWTPCA ID DMWTPCA
DMWTPCA DN L-651582
DMWTPCA HS Phase 3
DMWTPCA SN Carboxyamidotriazole (CAI)
DMWTPCA CP National Cancer Institute
DMWTPCA DT Small molecular drug
DMWTPCA PC 108144
DMWTPCA MW 424.7
DMWTPCA FM C17H12Cl3N5O2
DMWTPCA IC InChI=1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)
DMWTPCA CS C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2Cl)CN3C(=C(N=N3)C(=O)N)N)Cl)Cl
DMWTPCA IK WNRZHQBJSXRYJK-UHFFFAOYSA-N
DMWTPCA IU 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]triazole-4-carboxamide
DMWTPCA CA CAS 99519-84-3
DMWTPCA DE Solid tumour/cancer
DMI3YLK ID DMI3YLK
DMI3YLK DN LA-EP2006
DMI3YLK HS Phase 3
DMI3YLK CP Sandoz
DMI3YLK DE Neutropenia
DMA2NYS ID DMA2NYS
DMA2NYS DN Lampalizumab
DMA2NYS HS Phase 3
DMA2NYS CP Genentech
DMA2NYS DT Antibody
DMA2NYS DE Geographic retinal atrophy
DMFJLB6 ID DMFJLB6
DMFJLB6 DN Lanabecestat
DMFJLB6 HS Phase 3
DMFJLB6 SN 1383982-64-6; UNII-X8SPJ492VF; X8SPJ492VF; LY3314814; Lanabecestat [USAN]; Lanabecestat (USAN); SCHEMBL9947930; GTPL7789; SCHEMBL9947926; CHEMBL3261045; SCHEMBL10249890; CHEMBL3989948; CHEMBL3349234; BDBM41542; BDBM41537; MolPort-044-560-403; BDBM136733; EX-A1471; s8193; ZINC95576075; BDBM50012629; US8865911, 20a Isomer 1; CS-7494; Lanabecestat(AZD3293,LY-3314814); HY-100740; LY 3314814; D10946; US8865911, 122; US8865911, 114; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane
DMFJLB6 CP AstraZeneca Wilmington, DE; Eli Lilly Indianapolis, IN
DMFJLB6 PC 67979346
DMFJLB6 MW 412.5
DMFJLB6 FM C26H28N4O
DMFJLB6 IC InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1
DMFJLB6 CS CC#CC1=CC(=CN=C1)C2=CC3=C(CC4([C@]35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
DMFJLB6 IK WKDNQONLGXOZRG-BOPKNSRXSA-N
DMFJLB6 CA CAS 1383982-64-6
DMFJLB6 DE Alzheimer disease
DM4EGPN ID DM4EGPN
DM4EGPN DN Lanperisone
DM4EGPN HS Phase 3
DM4EGPN SN NK-433
DM4EGPN CP Nippon Kayaku Co Ltd
DM4EGPN DT Small molecular drug
DM4EGPN PC 198707
DM4EGPN MW 285.3
DM4EGPN FM C15H18F3NO
DM4EGPN IC InChI=1S/C15H18F3NO/c1-11(10-19-8-2-3-9-19)14(20)12-4-6-13(7-5-12)15(16,17)18/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1
DM4EGPN CS C[C@H](CN1CCCC1)C(=O)C2=CC=C(C=C2)C(F)(F)F
DM4EGPN IK RYZCWZZJFAKYHX-LLVKDONJSA-N
DM4EGPN IU (2R)-2-methyl-3-pyrrolidin-1-yl-1-[4-(trifluoromethyl)phenyl]propan-1-one
DM4EGPN CA CAS 116287-14-0
DM4EGPN DE Musculoskeletal disorder
DMMA0C7 ID DMMA0C7
DMMA0C7 DN Laquinamod
DMMA0C7 HS Phase 3
DMMA0C7 SN Laquinimod sodium; Laquinimod Sodium Salt; 248282-07-7; UNII-4H914M0CSP; Laquinimod sodium [USAN]; TV-5600; 4H914M0CSP; ABR-215062 SODIUM; Laquinimod sodium (USAN); sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate; SAIK-MS compound; ABR 215062 Sodium; SCHEMBL1991182; CHEMBL2103814; DTXSID50179538; QCR-166; JWHPPWBIIQMBQC-UHFFFAOYSA-M; AKOS027326368; TV 5600; FT-0670730; D08938; Sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin- 4-olate; 3-Quinolinecarboxamide, 5-chlo
DMMA0C7 CP Active Biotech; Teva
DMMA0C7 DT Small molecular drug
DMMA0C7 PC 23697158
DMMA0C7 MW 378.8
DMMA0C7 FM C19H16ClN2NaO3
DMMA0C7 IC InChI=1S/C19H17ClN2O3.Na/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24;/h4-11,23H,3H2,1-2H3;/q;+1/p-1
DMMA0C7 CS CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)[O-].[Na+]
DMMA0C7 IK JWHPPWBIIQMBQC-UHFFFAOYSA-M
DMMA0C7 IU sodium;5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate
DMMA0C7 CA CAS 248282-07-7
DMMA0C7 DE Multiple sclerosis
DM3IWS8 ID DM3IWS8
DM3IWS8 DN Laquinimod
DM3IWS8 HS Phase 3
DM3IWS8 SN Laquinimod; 248281-84-7; 5-CHLORO-N-ETHYL-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE; ABR-215062; ABR 215062; 5-Chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid ethyl-phenyl-amide; UNII-908SY76S4G; CIVENTICHEM CV-4057; Laquinimod (ABR-215062); 908SY76S4G; N-Ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide; 5-chloro-n-ethyl-2-hydroxy-1-methyl-4-oxo-n-phenyl-1,4-dihydroquinoline-3-carboxamide; C19H17ClN2O3
DM3IWS8 CP Teva Neuroscience
DM3IWS8 DT Small molecular drug
DM3IWS8 PC 54677946
DM3IWS8 MW 356.8
DM3IWS8 FM C19H17ClN2O3
DM3IWS8 IC InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3
DM3IWS8 CS CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O
DM3IWS8 IK GKWPCEFFIHSJOE-UHFFFAOYSA-N
DM3IWS8 IU 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
DM3IWS8 CA CAS 248281-84-7
DM3IWS8 CB CHEBI:134738
DM3IWS8 DE Lupus; Multiple sclerosis; Huntington disease; Primary progressive multiple sclerosis
DMH2EA1 ID DMH2EA1
DMH2EA1 DN Laromustine
DMH2EA1 HS Phase 3
DMH2EA1 SN Cloretazine; Onrigin; Alkylating agents, Vion; SHP, Vion; Sulfonyl hydrazine prodrugs, Vion; VN-40101M; VNP-40101M; VNP-4090-CE; 90CE
DMH2EA1 CP Vion Pharmaceuticals Inc
DMH2EA1 DT Small molecular drug
DMH2EA1 PC 3081349
DMH2EA1 MW 307.8
DMH2EA1 FM C6H14ClN3O5S2
DMH2EA1 IC InChI=1S/C6H14ClN3O5S2/c1-8-6(11)10(17(3,14)15)9(5-4-7)16(2,12)13/h4-5H2,1-3H3,(H,8,11)
DMH2EA1 CS CNC(=O)N(N(CCCl)S(=O)(=O)C)S(=O)(=O)C
DMH2EA1 IK PVCULFYROUOVGJ-UHFFFAOYSA-N
DMH2EA1 IU 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea
DMH2EA1 CA CAS 173424-77-6
DMH2EA1 DE Solid tumour/cancer
DMAJM12 ID DMAJM12
DMAJM12 DN LATIN T1D
DMAJM12 HS Phase 3
DMAJM12 SN NN9211
DMAJM12 CP Novo Nordisk
DMAJM12 DE Type-1 diabetes
DM09RKB ID DM09RKB
DM09RKB DN LC-150444
DM09RKB HS Phase 3
DM09RKB SN LCD15-0444; Dipeptidyl peptidase IV inhibitors (oral, type 2 diabetes), LG Life Sciences
DM09RKB CP LG Life Sciences Ltd
DM09RKB DE Type-2 diabetes
DMT4K0Z ID DMT4K0Z
DMT4K0Z DN L-citrulline
DMT4K0Z HS Phase 3
DMT4K0Z SN L-citrulline; citrulline; 372-75-8; H-cit-oh; delta-Ureidonorvaline; Sitrulline; N5-Carbamoyl-L-ornithine; L-Cytrulline; L(+)-citrulline; N5-(Aminocarbonyl)ornithine; N(delta)-Carbamylornithine; Citrulline, L-; alpha-Amino-delta-ureidovaleric acid; (S)-2-Amino-5-ureidopentanoic acid; N5-carbamoylornithine; d-ureidonorvaline; Ornithine, N5-(aminocarbonyl)-; L-2-Amino-5-ureidovaleric acid; L-Ornithine, N5-(aminocarbonyl)-; L-(+)-Citrulline; 2-Amino-5-ureidovaleric acid; L-citrullin; (2S)-2-amino-5-(carbamoylamino)pentanoic acid
DMT4K0Z DT Small molecular drug
DMT4K0Z PC 9750
DMT4K0Z MW 175.19
DMT4K0Z FM C6H13N3O3
DMT4K0Z IC InChI=1S/C6H13N3O3/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1
DMT4K0Z CS C(C[C@@H](C(=O)O)N)CNC(=O)N
DMT4K0Z IK RHGKLRLOHDJJDR-BYPYZUCNSA-N
DMT4K0Z IU (2S)-2-amino-5-(carbamoylamino)pentanoic acid
DMT4K0Z CA CAS 372-75-8
DMT4K0Z CB CHEBI:16349
DMT4K0Z DE Acute lung injury
DMFLJHQ ID DMFLJHQ
DMFLJHQ DN LCQ908
DMFLJHQ HS Phase 3
DMFLJHQ SN Pradigastat; LCQ-908; 956136-95-1; UNII-2U23G6VNUZ; LCQ908; 2U23G6VNUZ; LCQ 908; Pradigastat [USAN:INN]; LCQ 908NXA; 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid; 2-{4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)phenyl]cyclohexyl}acetic acid; Pradigastat (USAN); LCQ908-NXA; SCHEMBL180536; GTPL7830; SCHEMBL1289309; CHEMBL2364624; SCHEMBL18286769; SCHEMBL16104874; GXALXAKNHIROPE-UHFFFAOYSA-N; BCP21089; ZINC253387875; AKOS027338695; DB12866; SB16971; CS-1222
DMFLJHQ CP Novartis
DMFLJHQ DT Small molecular drug
DMFLJHQ PC 53387035
DMFLJHQ MW 455.5
DMFLJHQ FM C25H24F3N3O2
DMFLJHQ IC InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)
DMFLJHQ CS C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F
DMFLJHQ IK GXALXAKNHIROPE-UHFFFAOYSA-N
DMFLJHQ IU 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid
DMFLJHQ CA CAS 956136-95-1
DMFLJHQ DE Hepatitis C virus infection; Familial chylomicronemia syndrome; Hypertriglyceridemia
DMQP0X5 ID DMQP0X5
DMQP0X5 DN Lebrikizumab
DMQP0X5 HS Phase 3
DMQP0X5 SN RG3637
DMQP0X5 CP Aerovance
DMQP0X5 DT Monoclonal antibody
DMQP0X5 DE Chronic obstructive pulmonary disease; Severe asthma; Atopic dermatitis; Idiopathic pulmonary fibrosis
DMMX75K ID DMMX75K
DMMX75K DN LEE011
DMMX75K HS Phase 3
DMMX75K SN Ribociclib; LEE011; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013
DMMX75K CP Novartis AG
DMMX75K DT Small molecular drug
DMMX75K PC 44631912
DMMX75K MW 434.5
DMMX75K FM C23H30N8O
DMMX75K IC InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
DMMX75K CS CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5
DMMX75K IK RHXHGRAEPCAFML-UHFFFAOYSA-N
DMMX75K IU 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DMMX75K CA CAS 1211441-98-3
DMMX75K DE Solid tumour/cancer; Breast cancer
DMSCGM8 ID DMSCGM8
DMSCGM8 DN LentiGlobin
DMSCGM8 HS Phase 3
DMSCGM8 SN Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), Genetix; Globin gene therapy (LentiPak, sickle cell/beta-thalassemia), bluebird
DMSCGM8 CP Bluebird bio
DMSCGM8 DE Sickle-cell disorder; Beta thalassemia
DMSRIT4 ID DMSRIT4
DMSRIT4 DN Lenzilumab
DMSRIT4 HS Phase 3
DMSRIT4 SN lenzilumab; GTPL8935; KB003; KB-003
DMSRIT4 TC Antiviral Agents
DMSRIT4 DT Monoclonal antibody
DMSRIT4 DE Coronavirus Disease 2019 (COVID-19)
DMOTCIU ID DMOTCIU
DMOTCIU DN Lerisetron
DMOTCIU HS Phase 3
DMOTCIU SN Lerisetron[inn]; 1-benzyl-2-piperazin-1-ylbenzimidazole
DMOTCIU CP FAES Farma
DMOTCIU DT Small molecular drug
DMOTCIU PC 65997
DMOTCIU MW 292.4
DMOTCIU FM C18H20N4
DMOTCIU IC InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2
DMOTCIU CS C1CN(CCN1)C2=NC3=CC=CC=C3N2CC4=CC=CC=C4
DMOTCIU IK PWWDCRQZITYKDV-UHFFFAOYSA-N
DMOTCIU IU 1-benzyl-2-piperazin-1-ylbenzimidazole
DMOTCIU CA CAS 143257-98-1
DMOTCIU DE Vomiting; Testicular germ cell tumour; Nausea
DMAYC76 ID DMAYC76
DMAYC76 DN Levomequitazine
DMAYC76 HS Phase 3
DMAYC76 SN V-0114; V-0114CP
DMAYC76 CP Pierre Fabre SA
DMAYC76 DT Small molecular drug
DMAYC76 PC 6992284
DMAYC76 MW 322.5
DMAYC76 FM C20H22N2S
DMAYC76 IC InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2/t16-/m0/s1
DMAYC76 CS C1CN2CCC1[C@@H](C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
DMAYC76 IK HOKDBMAJZXIPGC-INIZCTEOSA-N
DMAYC76 IU 10-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine
DMAYC76 CA CAS 88598-74-7
DMAYC76 DE Seasonal allergic rhinitis
DM103O8 ID DM103O8
DM103O8 DN Ligelizumab
DM103O8 HS Phase 3
DM103O8 SN QGE031
DM103O8 CP Novartis
DM103O8 DT Antibody
DM103O8 DE Chronic idiopathic urticaria
DMNM93X ID DMNM93X
DMNM93X DN Linagliptin
DMNM93X HS Phase 3
DMNM93X SN Linagliptin; BI 1356; Ondero; 668270-12-0; Tradjenta; BI-1356; Linagliptin (BI-1356); UNII-3X29ZEJ4R2; BI-1356-BS; CHEMBL237500; 3X29ZEJ4R2; CHEBI:68610; C25H28N8O2; Linagliptin
DMNM93X TC Antiviral Agents
DMNM93X DT Small molecular drug
DMNM93X PC 10096344
DMNM93X MW 472.5
DMNM93X FM C25H28N8O2
DMNM93X IC InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
DMNM93X CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
DMNM93X IK LTXREWYXXSTFRX-QGZVFWFLSA-N
DMNM93X IU 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
DMNM93X CA CAS 668270-12-0
DMNM93X CB CHEBI:68610
DMNM93X DE Coronavirus Disease 2019 (COVID-19)
DM0ZOGX ID DM0ZOGX
DM0ZOGX DN Linopirdine
DM0ZOGX HS Phase 3
DM0ZOGX SN AVIVA; Linopirine; DuP-996
DM0ZOGX CP Bristol-Myers Squibb Pharma Co
DM0ZOGX DT Small molecular drug
DM0ZOGX PC 3932
DM0ZOGX MW 391.5
DM0ZOGX FM C26H21N3O
DM0ZOGX IC InChI=1S/C26H21N3O/c30-25-26(18-20-10-14-27-15-11-20,19-21-12-16-28-17-13-21)23-8-4-5-9-24(23)29(25)22-6-2-1-3-7-22/h1-17H,18-19H2
DM0ZOGX CS C1=CC=C(C=C1)N2C3=CC=CC=C3C(C2=O)(CC4=CC=NC=C4)CC5=CC=NC=C5
DM0ZOGX IK YEJCDKJIEMIWRQ-UHFFFAOYSA-N
DM0ZOGX IU 1-phenyl-3,3-bis(pyridin-4-ylmethyl)indol-2-one
DM0ZOGX CA CAS 105431-72-9
DM0ZOGX CB CHEBI:34823
DM0ZOGX DE Cognitive impairment
DMNF4UH ID DMNF4UH
DMNF4UH DN Liprotamase
DMNF4UH HS Phase 3
DMNF4UH SN LY3031642
DMNF4UH CP Lilly
DMNF4UH DE Cystic fibrosis
DMKZRBP ID DMKZRBP
DMKZRBP DN Litoxetine
DMKZRBP HS Phase 3
DMKZRBP SN Litoxetine; 86811-09-8; 4-(2-Naphthylmethoxy)piperidine; UNII-9980ST005G; CHEMBL471036; 9980ST005G; Litoxetinum; Litoxetina; Litoxetine [INN]; Litoxetinum [INN-Latin]; Litoxetina [INN-Spanish]; AC1L23OW; SCHEMBL119884; ZINC3647; CTK3E8854; DTXSID30235828; BDBM50278564; 4-(naphthalen-2-ylmethoxy)piperidine
DMKZRBP DT Small molecular drug
DMKZRBP PC 65650
DMKZRBP MW 241.33
DMKZRBP FM C16H19NO
DMKZRBP IC InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2
DMKZRBP CS C1CNCCC1OCC2=CC3=CC=CC=C3C=C2
DMKZRBP IK MJJDYOLPMGIWND-UHFFFAOYSA-N
DMKZRBP IU 4-(naphthalen-2-ylmethoxy)piperidine
DMKZRBP CA CAS 86811-09-8
DMKZRBP DE Mood disorder
DMDN4ZP ID DMDN4ZP
DMDN4ZP DN Lixivaptan
DMDN4ZP HS Phase 3
DMDN4ZP SN 168079-32-1; VPA-985; WAY-VPA-985; UNII-8F5X4B082E; VPA985; CHEMBL49429; CRTX-080; VPA 985; 8F5X4B082E; N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide; Lixar; Lixivaptan [USAN:INN]; Lixivaptan (USAN/INN); WAY VPA-985; Lixivaptan (VPA-985); AC1L59LM; WAY-VPA 985; GTPL2238; SCHEMBL1649340; DTXSID00168472; PPHTXRNHTVLQED-UHFFFAOYSA-N; ZINC600399; EX-A1129; BCP09167; BDBM50065115; AKOS022181388; AN-1842; CS-7512; API0009250; NCGC00485402-01; VPA985; BF-Derm1
DMDN4ZP CP Wyeth-Ayerst; Cardiokine
DMDN4ZP DT Small molecular drug
DMDN4ZP PC 172997
DMDN4ZP MW 473.9
DMDN4ZP FM C27H21ClFN3O2
DMDN4ZP IC InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
DMDN4ZP CS CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
DMDN4ZP IK PPHTXRNHTVLQED-UHFFFAOYSA-N
DMDN4ZP IU N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
DMDN4ZP CA CAS 168079-32-1
DMDN4ZP DE Skin infection; Congestive heart failure; Hyponatraemia
DM4OAIU ID DM4OAIU
DM4OAIU DN LMI070
DM4OAIU HS Phase 3
DM4OAIU SN branaplam; Branaplam; 1562338-42-4; NVS-SM1; UNII-P12R69543A; LMI-070; P12R69543A; 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol; Branaplam [INN]; SCHEMBL15475826; LMI070 (NVS-SM1); STWTUEAWRAIWJG-UHFFFAOYSA-N; BCP19909; ZINC146605125; AKOS030526592; CS-5319; HY-19620; Phenol, 5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethyl-4-piperidinyl)oxy)-3-pyridazinyl)-
DM4OAIU CP Novartis Pharmaceuticals East Hanover, NJ
DM4OAIU PC 135565042
DM4OAIU MW 393.5
DM4OAIU FM C22H27N5O2
DM4OAIU IC InChI=1S/C22H27N5O2/c1-21(2)10-16(11-22(3,4)27-21)29-20-8-7-18(25-26-20)17-6-5-14(9-19(17)28)15-12-23-24-13-15/h5-9,12-13,16,27-28H,10-11H2,1-4H3,(H,23,24)
DM4OAIU CS CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C
DM4OAIU IK STWTUEAWRAIWJG-UHFFFAOYSA-N
DM4OAIU IU 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol
DM4OAIU CA CAS 1562338-42-4
DM4OAIU DE Spinal muscular atrophy
DMOFIBM ID DMOFIBM
DMOFIBM DN LMT-X
DMOFIBM HS Phase 3
DMOFIBM SN Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
DMOFIBM CP TauRx Therapeutics Pte Ltd
DMOFIBM DE Acute myeloid leukaemia; Alzheimer disease
DM9EZM0 ID DM9EZM0
DM9EZM0 DN LNP023
DM9EZM0 HS Phase 3
DM9EZM0 SN Iptacopan; LNP-023; UNII-8E05T07Z6W; 8E05T07Z6W; 1644670-37-0; 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid; 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; Iptacopan [INN]; CHEMBL4594448; SCHEMBL16400416; GTPL10710; US9682968, Example-26a; BDBM160475; ZINC223246892; compound 41 [PMID: 32073845]; HY-127105; CS-0093107; 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid; Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-; JGQ
DM9EZM0 CP Novartis
DM9EZM0 DT Small molecular drug
DM9EZM0 PC 90467622
DM9EZM0 MW 422.5
DM9EZM0 FM C25H30N2O4
DM9EZM0 IC InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
DM9EZM0 CS CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC
DM9EZM0 IK RENRQMCACQEWFC-UGKGYDQZSA-N
DM9EZM0 IU 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid
DM9EZM0 CA CAS 1644670-37-0
DM9EZM0 DE IgA nephropathy; Paroxysmal nocturnal haemoglobinuria
DMQNVR8 ID DMQNVR8
DMQNVR8 DN Lopinavir + ritonavir
DMQNVR8 HS Phase 3
DMQNVR8 SN Aluviran + norvir; Kaletra
DMQNVR8 TC Antiviral Agents
DMQNVR8 DT Combination drug
DMQNVR8 PC 11979606
DMQNVR8 MW 1349.7
DMQNVR8 FM C74H96N10O10S2
DMQNVR8 IC InChI=1S/C37H48N6O5S2.C37H48N4O5/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30;1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46);5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t28-,31-,32-,33-;30-,31-,32-,34-/m00/s1
DMQNVR8 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O.CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
DMQNVR8 IK OFFWOVJBSQMVPI-RMLGOCCBSA-N
DMQNVR8 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
DMQNVR8 CA CAS 369372-47-4
DMQNVR8 DE Coronavirus Disease 2019 (COVID-19)
DMX0O9U ID DMX0O9U
DMX0O9U DN Lopinavir + ritonavir + favipiravir
DMX0O9U HS Phase 3
DMX0O9U SN Aluviran + norvir + T-705
DMX0O9U TC Antiviral Agents
DMX0O9U DT Combination drug
DMX0O9U DE Coronavirus Disease 2019 (COVID-19)
DMNY05F ID DMNY05F
DMNY05F DN Lopinavir + ritonavir + oseltamivir
DMNY05F HS Phase 3
DMNY05F SN Aluviran + norvir + tamiflu
DMNY05F TC Antiviral Agents
DMNY05F DT Combination drug
DMNY05F DE Coronavirus Disease 2019 (COVID-19)
DMTL5Q0 ID DMTL5Q0
DMTL5Q0 DN Losartan
DMTL5Q0 HS Phase 3
DMTL5Q0 SN Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
DMTL5Q0 CP Merck & Co
DMTL5Q0 TC Antiviral Agents
DMTL5Q0 DT Small molecular drug
DMTL5Q0 PC 3961
DMTL5Q0 MW 422.9
DMTL5Q0 FM C22H23ClN6O
DMTL5Q0 IC InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
DMTL5Q0 CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
DMTL5Q0 IK PSIFNNKUMBGKDQ-UHFFFAOYSA-N
DMTL5Q0 IU [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DMTL5Q0 CA CAS 114798-26-4
DMTL5Q0 CB CHEBI:6541
DMTL5Q0 DE Discovery agent; Hypertension; Coronavirus Disease 2019 (COVID-19)
DMIL37Z ID DMIL37Z
DMIL37Z DN Losmapimod
DMIL37Z HS Phase 3
DMIL37Z SN 585543-15-3; GSK-AHAB; GW856553; GW856553X; UNII-F2DQF16BXE; F2DQF16BXE; GW-856553; 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; Losmapimod [USAN:INN]; Losmapimod (GW856553X); GSKAHAB; GW 856553X; SB 856553; Losmapimod (USAN/INN); SCHEMBL1070401; GTPL7835; CHEMBL1088752; EX-A486; CHEBI:131167; KKYABQBFGDZVNQ-UHFFFAOYSA-N; MolPort-009-194-138; losmapimod pound> HMS3653G19; BCP09909; AOB87105; ZINC35793138; s7215; BDBM50418610; 2523AH; AKOS015994587
DMIL37Z CP GSK
DMIL37Z DT Small molecular drug
DMIL37Z PC 11552706
DMIL37Z MW 383.5
DMIL37Z FM C22H26FN3O2
DMIL37Z IC InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)
DMIL37Z CS CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C
DMIL37Z IK KKYABQBFGDZVNQ-UHFFFAOYSA-N
DMIL37Z IU 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
DMIL37Z CA CAS 585543-15-3
DMIL37Z CB CHEBI:131167
DMIL37Z DE Acute coronary syndrome
DMWGRQD ID DMWGRQD
DMWGRQD DN LU AE58054
DMWGRQD HS Phase 3
DMWGRQD SN Idalopirdine; Lu AE58054; 467459-31-0; LU-AE58054; UNII-59WCJ0YNWM; LU AE 58054; 59WCJ0YNWM; 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine; 1H-Indole-3-ethanamine,6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; 1H-Indole-3-ethanamine, 6-fluoro-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-; Idalopirdine [USAN:INN]; Idlopirdine; Idalopirdine (USAN/INN); Lu AE58054;Idalopirdine; SCHEMBL762762; Idalopirdine(Lu-AE-58054); GTPL8689; CHEMBL3286580; C20H19F5N2O; EX-A844
DMWGRQD CP Lundbeck
DMWGRQD DT Small molecular drug
DMWGRQD PC 21071390
DMWGRQD MW 398.4
DMWGRQD FM C20H19F5N2O
DMWGRQD IC InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2
DMWGRQD CS C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F
DMWGRQD IK YBAWYTYNMZWMMJ-UHFFFAOYSA-N
DMWGRQD IU 2-(6-fluoro-1H-indol-3-yl)-N-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine
DMWGRQD CA CAS 467459-31-0
DMWGRQD DE Schizophrenia
DMNAYUJ ID DMNAYUJ
DMNAYUJ DN Lu AF35700
DMNAYUJ HS Phase 3
DMNAYUJ CP Lundbeck Deerfield, IL
DMNAYUJ DE Schizophrenia
DMMLXA9 ID DMMLXA9
DMMLXA9 DN LX-4211
DMMLXA9 HS Phase 3
DMMLXA9 SN Sotagliflozin; 1018899-04-1; LX-4211; LX4211; UNII-6B4ZBS263Y; 6B4ZBS263Y; AK170751; (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol; b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-; Sotagliflozin [USAN:INN]; beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-; LX 4211; Tube103; LP 802034
DMMLXA9 CP Lexicon Pharmaceuticals
DMMLXA9 DT Small molecular drug
DMMLXA9 PC 24831714
DMMLXA9 MW 424.9
DMMLXA9 FM C21H25ClO5S
DMMLXA9 IC InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
DMMLXA9 CS CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl
DMMLXA9 IK QKDRXGFQVGOQKS-CRSSMBPESA-N
DMMLXA9 IU (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol
DMMLXA9 CA CAS 1018899-04-1
DMMLXA9 DE Type-2 diabetes; Cardiovascular disease; Type-1 diabetes
DM1BXMY ID DM1BXMY
DM1BXMY DN LY2605541
DM1BXMY HS Phase 3
DM1BXMY SN UNII-6Y83I5F10I; Insulin peglispro [USAN:INN]; INSULIN PEGLISPRO; LY2605541; 6Y83I5F10I; 1200440-65-8; LY 2605541; Polyethylene glycol 20,000 pegylated insulin lispro:(28B-(6-N-((omega-methoxypoly(oxyethylene))carbonyl)-L-lysine),29B-L-proline)human insulin; Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy-, 28B-ester with 28B-(N6-carboxy-L- lysine)-29B-L-prolineinsulin (human)
DM1BXMY CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DM1BXMY DT Small molecular drug
DM1BXMY PC 71301236
DM1BXMY MW 5892
DM1BXMY FM C261H387N65O79S6
DM1BXMY IC InChI=1S/C261H387N65O79S6/c1-30-134(23)208(317-196(343)107-262)255(397)321-207(133(21)22)251(393)290-160(76-83-203(353)354)219(361)285-157(72-79-192(265)339)223(365)312-186-119-409-410-120-187-246(388)309-181(114-328)243(385)297-164(91-126(7)8)226(368)298-170(98-143-54-62-149(333)63-55-143)229(371)286-155(70-77-190(263)337)220(362)293-163(90-125(5)6)224(366)288-159(75-82-202(351)352)222(364)306-177(104-193(266)340)236(378)301-172(100-145-58-66-151(335)67-59-145)232(374)313-185-118-408-407-117-184(216(358)276-110-197(344)281-154(73-80-200(347)348)218(360)284-153(52-43-85-273-260(269)270)214(356)275-111-198(345)282-168(95-140-45-35-32-36-46-140)228(370)300-169(96-141-47-37-33-38-48-141)231(373)302-174(101-146-60-68-152(336)69-61-146)241(383)323-210(137(26)330)256(398)291-161(51-41-42-84-274-261(403)405-88-87-404-29)258(400)326-86-44-53-189(326)249(391)325-212(139(28)332)259(401)402)315-253(395)206(132(19)20)319-238(380)166(93-128(11)12)295-230(372)171(99-144-56-64-150(334)65-57-144)299-225(367)162(89-124(3)4)292-213(355)136(25)280-217(359)158(74-81-201(349)350)289-250(392)204(130(15)16)318-239(381)167(94-129(13)14)296-234(376)176(103-148-109-272-123-279-148)305-242(384)180(113-327)283-199(346)112-277-215(357)183(116-406-411-121-188(314-247(186)389)248(390)324-211(138(27)331)257(399)310-182(115-329)244(386)322-209(135(24)31-2)254(396)316-187)311-227(369)165(92-127(9)10)294-233(375)175(102-147-108-271-122-278-147)304-221(363)156(71-78-191(264)338)287-235(377)179(106-195(268)342)308-252(394)205(131(17)18)320-240(382)173(97-142-49-39-34-40-50-142)303-237(379)178(105-194(267)341)307-245(185)387/h32-40,45-50,54-69,108-109,122-139,153-189,204-212,327-336H,30-31,41-44,51-53,70-107,110-121,262H2,1-29H3,(H2,263,337)(H2,264,338)(H2,265,339)(H2,266,340)(H2,267,341)(H2,268,342)(H,271,278)(H,272,279)(H,274,403)(H,275,356)(H,276,358)(H,277,357)(H,280,359)(H,281,344)(H,282,345)(H,283,346)(H,284,360)(H,285,361)(H,286,371)(H,287,377)(H,288,366)(H,289,392)(H,290,393)(H,291,398)(H,292,355)(H,293,362)(H,294,375)(H,295,372)(H,296,376)(H,297,385)(H,298,368)(H,299,367)(H,300,370)(H,301,378)(H,302,373)(H,303,379)(H,304,363)(H,305,384)(H,306,364)(H,307,387)(H,308,394)(H,309,388)(H,310,399)(H,311,369)(H,312,365)(H,313,374)(H,314,389)(H,315,395)(H,316,396)(H,317,343)(H,318,381)(H,319,380)(H,320,382)(H,321,397)(H,322,386)(H,323,383)(H,324,390)(H,325,391)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,401,402)(H4,269,270,273)/t134-,135-,136-,137+,138+,139+,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,204-,205-,206-,207-,208-,209-,210-,211-,212-/m0/s1
DM1BXMY CS CC[C@H](C)[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC4=CN=CN4)CCC(=O)N)CC(=O)N)C(C)C)CC5=CC=CC=C5)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CC(C)C)CC6=CC=C(C=C6)O)CCC(=O)N)CC(C)C)CCC(=O)O)CC(=O)N)CC7=CC=C(C=C7)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCNC(=O)OCCOC)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)O)C(C)C)CC(C)C)CC2=CC=C(C=C2)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CN=CN2)CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)[C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CN
DM1BXMY IK UFIPGFMPJACHTH-HXDLXPBZSA-N
DM1BXMY IU (4S)-4-[[2-[[(aS,1R,3aS,6R,6aS,9S,12S,13aR,15S,18R,21S,24S,27S,30S,33S,36S,39S,42S,45R,50R,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S,88S,91S,94S,97S)-13a-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-6a,39,97-tris(2-amino-2-oxoethyl)-30,94-bis(3-amino-3-oxopropyl)-3a-benzyl-15-[(2S)-butan-2-yl]-36,68-bis(2-carboxyethyl)-9-[(1R)-1-hydroxyethyl]-12,21,80-tris(hydroxymethyl)-27,42,59-tris[(4-hydroxyphenyl)methyl]-77,91-bis(1H-imidazol-5-ylmethyl)-65-methyl-24,33,56,62,74,88-hexakis(2-methylpropyl)-2a,5a,7,8a,10,13,14a,16,19,22,25,28,31,34,37,40,43,52,55,58,61,64,67,70,73,76,79,82,85,87,90,93,96,99-tetratriacontaoxo-a,53,71-tri(propan-2-yl)-3,4,10a,11a,47,48-hexathia-1a,4a,7a,8,11,14,15a,17,20,23,26,29,32,35,38,41,44,51,54,57,60,63,66,69,72,75,78,81,84,86,89,92,95,98-tetratriacontazatricyclo[43.40.23.76,18]pentadecahectane-50-carbonyl]amino]acetyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-6-(2-methoxyethoxycarbonylamino)-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM1BXMY DE Type-1/2 diabetes
DMEZ0H5 ID DMEZ0H5
DMEZ0H5 DN LY2963016
DMEZ0H5 HS Phase 3
DMEZ0H5 CP Boehringer Ingelheim Pharmaceuticals; Eli Lilly
DMEZ0H5 DE Type-1/2 diabetes
DMWZIRJ ID DMWZIRJ
DMWZIRJ DN LY404039
DMWZIRJ HS Phase 3
DMWZIRJ SN LY 404039; LY-404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid
DMWZIRJ CP Eli Lilly
DMWZIRJ DT Small molecular drug
DMWZIRJ PC 9834591
DMWZIRJ MW 235.22
DMWZIRJ FM C7H9NO6S
DMWZIRJ IC InChI=1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
DMWZIRJ CS C1[C@]([C@@H]2[C@H]([C@@H]2S1(=O)=O)C(=O)O)(C(=O)O)N
DMWZIRJ IK AVDUGNCTZRCAHH-MDASVERJSA-N
DMWZIRJ IU (1R,4S,5S,6S)-4-amino-2,2-dioxo-2lambda6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMWZIRJ CA CAS 635318-11-5
DMWZIRJ CB CHEBI:94640
DMWZIRJ DE Schizophrenia
DM7WORZ ID DM7WORZ
DM7WORZ DN LY-686017
DM7WORZ HS Phase 3
DM7WORZ SN NK1 antagonist (anxiety/alcoholism), Eli Lilly
DM7WORZ CP Eli Lilly & Co
DM7WORZ DT Small molecular drug
DM7WORZ PC 9916461
DM7WORZ MW 587.9
DM7WORZ FM C28H16ClF6N5O
DM7WORZ IC InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
DM7WORZ CS C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl
DM7WORZ IK CAVRKWRKTNINFF-UHFFFAOYSA-N
DM7WORZ IU [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone
DM7WORZ CA CAS 622370-35-8
DM7WORZ DE Alcohol dependence; Atopic dermatitis
DM6LVCQ ID DM6LVCQ
DM6LVCQ DN LY-CoV555
DM6LVCQ HS Phase 3
DM6LVCQ SN LY3819253
DM6LVCQ CP Lilly; AbCellera
DM6LVCQ DT Antibody
DM6LVCQ DE Coronavirus Disease 2019 (COVID-19)
DMGNC6T ID DMGNC6T
DMGNC6T DN M-0011
DMGNC6T HS Phase 3
DMGNC6T SN N-0011; RhLAMAN, Zymenex; Recombinant human alpha-mannosidase (alpha mannosidosis), Zymenex
DMGNC6T CP Zymenex A/S
DMGNC6T DE Alpha-mannosidosis
DM7ZFBA ID DM7ZFBA
DM7ZFBA DN M100907
DM7ZFBA HS Phase 3
DM7ZFBA SN Volinanserin; 139290-65-6; UNII-EW71EE171J; (R)-(2,3-Dimethoxyphenyl)(1-(4-fluorophenethyl)piperidin-4-yl)methanol; CHEMBL74355; EW71EE171J; (R)-(+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUORO-PHENYL)ETHYL]-4-PIPERIDINE METHANOL; M-100907; (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol; Volinanserin [INN]; Serotonin 5-HT2 Receptor Antagonists; VOLINANSERIN
DM7ZFBA DT Small molecular drug
DM7ZFBA PC 5311271
DM7ZFBA MW 373.5
DM7ZFBA FM C22H28FNO3
DM7ZFBA IC InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
DM7ZFBA CS COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DM7ZFBA IK HXTGXYRHXAGCFP-OAQYLSRUSA-N
DM7ZFBA IU (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
DM7ZFBA CA CAS 139290-65-6
DM7ZFBA DE Sleep-wake disorder
DMZ6VD5 ID DMZ6VD5
DMZ6VD5 DN M-518101
DMZ6VD5 HS Phase 3
DMZ6VD5 CP Maruho Co Ltd
DMZ6VD5 DE Psoriasis vulgaris; Plaque psoriasis
DM1PRT6 ID DM1PRT6
DM1PRT6 DN M710
DM1PRT6 HS Phase 3
DM1PRT6 SN 637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)
DM1PRT6 CP Momenta Pharmaceuticals; Mylan
DM1PRT6 DT Small molecular drug
DM1PRT6 PC 71561
DM1PRT6 MW 237.17
DM1PRT6 FM C10H18Cl2N2
DM1PRT6 IC InChI=1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H
DM1PRT6 CS CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl
DM1PRT6 IK FBHKTSXMTASXFJ-UHFFFAOYSA-N
DM1PRT6 IU 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride
DM1PRT6 CA CAS 637-01-4
DM1PRT6 DE Diabetic macular edema
DM8D13S ID DM8D13S
DM8D13S DN MABp1
DM8D13S HS Phase 3
DM8D13S CP Xbiotech Austin, TX
DM8D13S DE Type-2 diabetes; Acne vulgaris; Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Pyoderma gangrenosum; Colorectal cancer; Peripheral vascular disease
DMVXUR0 ID DMVXUR0
DMVXUR0 DN Magrolimab
DMVXUR0 HS Phase 3
DMVXUR0 SN GS-4721
DMVXUR0 CP Gilead Sciences
DMVXUR0 DT Antibody
DMVXUR0 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMJPGUA ID DMJPGUA
DMJPGUA DN Manidipine
DMJPGUA HS Phase 3
DMJPGUA SN manidipine; 89226-50-6; Franidipine; 120092-68-4; Manidipine 6300; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Iperten; Artedil; Manidipine [INN]; Manidipine (Manyper); C35H38N4O6; CHEMBL312176; Manidipine (INN); 2-(4-Diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin
DMJPGUA DT Small molecular drug
DMJPGUA PC 4008
DMJPGUA MW 610.7
DMJPGUA FM C35H38N4O6
DMJPGUA IC InChI=1S/C35H38N4O6/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-16,23,32-33,36H,17-22H2,1-3H3
DMJPGUA CS CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMJPGUA IK ANEBWFXPVPTEET-UHFFFAOYSA-N
DMJPGUA IU 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMJPGUA CA CAS 89226-50-6
DMJPGUA CB CHEBI:135849
DMR23M1 ID DMR23M1
DMR23M1 DN Mapracorat
DMR23M1 HS Phase 3
DMR23M1 SN BOL-303242X; SEGRA, Intendis; SEGRA, Schering AG; ZK-216348; ZK-238587; ZK-245186; Mapracorat (ophthalmic, ocular inflammation); Mapracorat Ophthalmic Suspension, Bausch & Lomb; SEGRA (atopic dermatitis), Bayer; Selective glucocorticoid receptor agonists (SEGRA) Bayer Schering/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA) Schering AG/AstraZeneca; Selective glucocorticoid receptor agonists (SEGRA), Schering AG; Selective glucocorticoid receptor agonists (dermatology), Schering AG; Mapracorat (dermatological, atopic dermatitis), Intendis; SEGRA (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonist (ophthalmic disease), Bausch & Lomb; Selective glucocorticoid receptor agonists (dermatological, eczema), Intendis; Suppressor of pro-inflammatory mediators (eczema), Intendis; BOL-303242-X Ophthalmic Suspension, Bausch & Lomb; Mapracorat (ophthalmic, ocular inflammation), Bausch & Lomb; ZK-245186 (ophthalmic), Bausch & Lomb
DMR23M1 CP Bayer Schering Pharma AG
DMR23M1 DT Small molecular drug
DMR23M1 PC 24795088
DMR23M1 MW 462.5
DMR23M1 FM C25H26F4N2O2
DMR23M1 IC InChI=1S/C25H26F4N2O2/c1-15-7-8-18-20(5-4-6-21(18)31-15)30-14-24(32,25(27,28)29)13-23(2,3)19-12-17(26)11-16-9-10-33-22(16)19/h4-8,11-12,30,32H,9-10,13-14H2,1-3H3/t24-/m1/s1
DMR23M1 CS CC1=NC2=C(C=C1)C(=CC=C2)NC[C@](CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O
DMR23M1 IK VJGFOYBQOIPQFY-XMMPIXPASA-N
DMR23M1 IU (2R)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol
DMR23M1 CA CAS 887375-26-0
DMR23M1 DE Ocular disease
DMJCF1O ID DMJCF1O
DMJCF1O DN Maralixibat
DMJCF1O HS Phase 3
DMJCF1O SN Lopixibat; UNII-UYB6UOF69L; Maralixibat [USAN]; 716313-53-0; UYB6UOF69L; CHEMBL363392; Maralixibat (USAN); Lopixibat cation; CHEMBL17879; 1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium; LUM001 CATION; LUM-001 CATION; SCHEMBL10013954; BDBM50140282; 4-Aza-1-azoniabicyclo(2.2.2)octane, 1-((4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenoxy)methyl)phenyl)methyl)-; D10951; Q27291331; (4R,5R)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1$l^{6}-benzothiepin-4-ol; 1-{4-[4-((4R,5R)-3,3-Dibutyl-7-dimethylamino-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-1lambda*6*-benzo[b]thiepin-5-yl)-phenoxymethyl]-benzyl}-4-aza-1-azonia-bicyclo[2.2.2]octane; chloride
DMJCF1O CP Mirum Pharmaceuticals
DMJCF1O DT Small molecular drug
DMJCF1O PC 9831643
DMJCF1O MW 675
DMJCF1O FM C40H56N3O4S+
DMJCF1O IC InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1
DMJCF1O CS CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC
DMJCF1O IK STPKWKPURVSAJF-LJEWAXOPSA-N
DMJCF1O IU (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol
DMJCF1O CA CAS 716313-53-0
DMJCF1O DE Alagille syndrome; Progressive familial intrahepatic cholestasis
DM3GTAL ID DM3GTAL
DM3GTAL DN Maribavir
DM3GTAL HS Phase 3
DM3GTAL SN 176161-24-3; Benzimidavir; (2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 1263W94; UNII-PTB4X93HE1; PTB4X93HE1; 5,6-Dichloro-2-(isopropylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole; 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine; (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Maribavir [USAN:INN:BAN]; Camvia; C15H19Cl2N3O4; Camvia(TM); Camvia (TN); Bzurea
DM3GTAL DT Small molecular drug
DM3GTAL PC 471161
DM3GTAL MW 376.2
DM3GTAL FM C15H19Cl2N3O4
DM3GTAL IC InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1
DM3GTAL CS CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl
DM3GTAL IK KJFBVJALEQWJBS-XUXIUFHCSA-N
DM3GTAL IU (2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM3GTAL CA CAS 176161-24-3
DM3GTAL DE Cytomegalovirus infection
DM6V34C ID DM6V34C
DM6V34C DN Marimastat
DM6V34C HS Phase 3
DM6V34C SN Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
DM6V34C CP British Biotech plc; Schering-Plough
DM6V34C TC Anticancer Agents
DM6V34C DT Small molecular drug
DM6V34C PC 119031
DM6V34C MW 331.41
DM6V34C FM C15H29N3O5
DM6V34C IC InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
DM6V34C CS CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@H](C(=O)NC)C(C)(C)C
DM6V34C IK OCSMOTCMPXTDND-OUAUKWLOSA-N
DM6V34C IU (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide
DM6V34C CA CAS 154039-60-8
DM6V34C CB CHEBI:50662
DM6V34C DE Lung cancer; Pancreatic cancer
DME9QGW ID DME9QGW
DME9QGW DN Marizomib
DME9QGW HS Phase 3
DME9QGW SN MARIZOMIB; salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1
DME9QGW CP Nereus Pharmaceuticals
DME9QGW DT Small molecular drug
DME9QGW PC 11347535
DME9QGW MW 313.77
DME9QGW FM C15H20ClNO4
DME9QGW IC InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
DME9QGW CS C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl
DME9QGW IK NGWSFRIPKNWYAO-SHTIJGAHSA-N
DME9QGW IU (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
DME9QGW CA CAS 437742-34-2
DME9QGW CB CHEBI:48045
DME9QGW DE Solid tumour/cancer; Malignant glioma; Multiple myeloma; Glioblastoma of brain
DMRSNEU ID DMRSNEU
DMRSNEU DN Masitinib
DMRSNEU HS Phase 3
DMRSNEU SN Masitinib; 790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
DMRSNEU CP AB Science
DMRSNEU DT Small molecular drug
DMRSNEU PC 10074640
DMRSNEU MW 498.6
DMRSNEU FM C28H30N6OS
DMRSNEU IC InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
DMRSNEU CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5
DMRSNEU IK WJEOLQLKVOPQFV-UHFFFAOYSA-N
DMRSNEU IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
DMRSNEU CA CAS 790299-79-5
DMRSNEU CB CHEBI:63450
DMRSNEU DE Amyotrophic lateral sclerosis; Metastatic gastric or gastroesophageal junction cancer; Multiple sclerosis; Gastrointestinal stromal tumour; Ovarian cancer; Pancreatic cancer
DMK9BP2 ID DMK9BP2
DMK9BP2 DN Mavacamten
DMK9BP2 HS Phase 3
DMK9BP2 SN SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461
DMK9BP2 CP MyoKardia South San Francisco, CA Sanofi Bridgewater, NJ
DMK9BP2 PC 117761397
DMK9BP2 MW 273.33
DMK9BP2 FM C15H19N3O2
DMK9BP2 IC InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
DMK9BP2 CS C[C@@H](C1=CC=CC=C1)NC2=CC(=O)N(C(=O)N2)C(C)C
DMK9BP2 IK RLCLASQCAPXVLM-NSHDSACASA-N
DMK9BP2 IU 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione
DMK9BP2 CA CAS 1642288-47-8
DMK9BP2 DE Obstructive hypertrophic cardiomyopathy
DMBPY9Z ID DMBPY9Z
DMBPY9Z DN MBG453
DMBPY9Z HS Phase 3
DMBPY9Z CP Novartis Oncology East Hanover, NJ
DMBPY9Z DE Solid tumour/cancer; Myelodysplastic syndrome
DMVZ57G ID DMVZ57G
DMVZ57G DN MD1003
DMVZ57G HS Phase 3
DMVZ57G CP MedDay Pharmaceuticals Paris, France
DMVZ57G DE Multiple sclerosis
DM5X849 ID DM5X849
DM5X849 DN MEDI4736
DM5X849 HS Phase 3
DM5X849 CP AstraZeneca
DM5X849 DT Monoclonal antibody
DM5X849 DE Solid tumour/cancer
DM4W8RE ID DM4W8RE
DM4W8RE DN Melagatran
DM4W8RE HS Phase 3
DM4W8RE SN Melagatran; 159776-70-2; UNII-2A9QP32MD4; Melagatran [INN]; 2A9QP32MD4; CHEBI:43966; MELAGATRAN (ASTRA-ZENECA); C22H31N5O4; Melagatran (INN); N-((R)-(((2S)-2-((-p-Amidobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine; [((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID; MEL; H-319/68; N-((R)-(((2S)-2-((p-Amidinobenzyl)carbamoyl)-1-azetidinyl)carbonyl)cyclohexylmethyl)glycine
DM4W8RE DT Small molecular drug
DM4W8RE PC 183797
DM4W8RE MW 429.5
DM4W8RE FM C22H31N5O4
DM4W8RE IC InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1
DM4W8RE CS C1CCC(CC1)[C@H](C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O
DM4W8RE IK DKWNMCUOEDMMIN-PKOBYXMFSA-N
DM4W8RE IU 2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid
DM4W8RE CA CAS 159776-70-2
DM4W8RE CB CHEBI:43966
DMQEC6Z ID DMQEC6Z
DMQEC6Z DN Melanoma vaccine
DMQEC6Z HS Phase 3
DMQEC6Z SN NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie
DMQEC6Z CP Institut Curie
DMQEC6Z DT Vaccine
DMQEC6Z DE Melanoma
DM8Z0I3 ID DM8Z0I3
DM8Z0I3 DN MF-101
DM8Z0I3 HS Phase 3
DM8Z0I3 SN DW-700; DW-700); Menopause Formula-101; Estrogen receptor beta agonist (menopausal symptoms), Bionovo; Liquiritigenin (menopausal symptoms), Bionovo
DM8Z0I3 CP Bionovo Inc; Daewon Pharm Co Ltd
DM8Z0I3 DE Hepatitis virus infection
DMRKTCP ID DMRKTCP
DMRKTCP DN MGA012
DMRKTCP HS Phase 3
DMRKTCP SN INCMGA0012; Retifanlimab
DMRKTCP CP MacroGenics
DMRKTCP DT Antibody
DMRKTCP DE Solid tumour/cancer; Metastatic colorectal cancer; Non-small-cell lung cancer; Merkel cell carcinoma; Penile squamous cancer
DMCJRL1 ID DMCJRL1
DMCJRL1 DN MGN-1703
DMCJRL1 HS Phase 3
DMCJRL1 SN TLR-9 agonist (cancer), Mologen
DMCJRL1 CP Mologen Holding AG
DMCJRL1 DE Colorectal cancer; Solid tumour/cancer
DMZHN5B ID DMZHN5B
DMZHN5B DN MIM-D3
DMZHN5B HS Phase 3
DMZHN5B SN TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen
DMZHN5B CP Mimetogen Pharmaceuticals Inc
DMZHN5B DT Small molecular drug
DMZHN5B PC 9808372
DMZHN5B MW 580.5
DMZHN5B FM C24H32N6O11
DMZHN5B IC InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
DMZHN5B CS C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]1C(=O)NCC(=O)O)CCCCN)CCC(=O)O
DMZHN5B IK DVJXNXPFYJIACK-ULQDDVLXSA-N
DMZHN5B IU 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
DMZHN5B CA CAS 263251-78-1
DMZHN5B DE Alzheimer disease
DMCJY35 ID DMCJY35
DMCJY35 DN MIN-101
DMCJY35 HS Phase 3
DMCJY35 SN Roluperidone
DMCJY35 CP Minerva neurosciences
DMCJY35 PC 9799284
DMCJY35 MW 366.4
DMCJY35 FM C22H23FN2O2
DMCJY35 IC InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2
DMCJY35 CS C1CN(CCC1CN2CC3=CC=CC=C3C2=O)CC(=O)C4=CC=C(C=C4)F
DMCJY35 IK RNRYULFRLCBRQS-UHFFFAOYSA-N
DMCJY35 IU 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one
DMCJY35 CA CAS 359625-79-9
DMCJY35 DE Schizophrenia
DM7R3N5 ID DM7R3N5
DM7R3N5 DN Mirikizumab
DM7R3N5 HS Phase 3
DM7R3N5 CP Eli Lilly Indianapolis, IN
DM7R3N5 DE Psoriasis vulgaris
DM5S4LX ID DM5S4LX
DM5S4LX DN Mirvetuximab soravtansine
DM5S4LX HS Phase 3
DM5S4LX SN ZOHXWSHGANNQGO-QRVRWUFNSA-N; DB12489
DM5S4LX CP ImmunoGen Waltham, MA
DM5S4LX PC 91810695
DM5S4LX MW 977.6
DM5S4LX FM C42H61ClN4O14S3
DM5S4LX IC InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1
DM5S4LX CS C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\\C)OC)(NC(=O)O2)O
DM5S4LX IK ZOHXWSHGANNQGO-DSIKUUPMSA-N
DM5S4LX IU 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid
DM5S4LX DE Endometrial cancer; Ovarian cancer
DM3PSUF ID DM3PSUF
DM3PSUF DN MK-3102
DM3PSUF HS Phase 3
DM3PSUF SN Omarigliptin
DM3PSUF CP Merck
DM3PSUF DT Small molecular drug
DM3PSUF PC 46209133
DM3PSUF MW 398.4
DM3PSUF FM C17H20F2N4O3S
DM3PSUF IC InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
DM3PSUF CS CS(=O)(=O)N1C=C2CN(CC2=N1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DM3PSUF IK MKMPWKUAHLTIBJ-ISTRZQFTSA-N
DM3PSUF IU (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine
DM3PSUF CA CAS 1226781-44-7
DM3PSUF CB CHEBI:134735
DM3PSUF DE Type-2 diabetes
DMQBF7O ID DMQBF7O
DMQBF7O DN MK-3222
DMQBF7O HS Phase 3
DMQBF7O CP Merck
DMQBF7O DT Antibody
DMQBF7O DE Psoriasis vulgaris; Hairy cell leukaemia; Plaque psoriasis
DMGNHC2 ID DMGNHC2
DMGNHC2 DN MK-3415A
DMGNHC2 HS Phase 3
DMGNHC2 SN Actoxumab/bezlotoxumab
DMGNHC2 CP Merck
DMGNHC2 DT Antibody
DMGNHC2 DE Malaria; Clostridium infection
DMA25NO ID DMA25NO
DMA25NO DN MK-4214
DMA25NO HS Phase 3
DMA25NO SN INS-19; Recombinant human GCSF (biosimilar), Insmed
DMA25NO CP Insmed Inc
DMA25NO DE Neutropenia
DMLYGH4 ID DMLYGH4
DMLYGH4 DN MK-4827
DMLYGH4 HS Phase 3
DMLYGH4 SN 1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
DMLYGH4 CP Merck
DMLYGH4 DT Small molecular drug
DMLYGH4 PC 24958200
DMLYGH4 MW 320.4
DMLYGH4 FM C19H20N4O
DMLYGH4 IC InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
DMLYGH4 CS C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
DMLYGH4 IK PCHKPVIQAHNQLW-CQSZACIVSA-N
DMLYGH4 IU 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
DMLYGH4 CA CAS 1038915-60-4
DMLYGH4 DE Ewing sarcoma; Ovarian cancer; Breast cancer
DM84LO5 ID DM84LO5
DM84LO5 DN MK-8109
DM84LO5 HS Phase 3
DM84LO5 CP Merck
DM84LO5 DE Ovarian cancer
DMK301H ID DMK301H
DMK301H DN MK-8742
DMK301H HS Phase 3
DMK301H CP Merck
DMK301H DE Hepatitis C virus infection
DMT8IAJ ID DMT8IAJ
DMT8IAJ DN MK-8808
DMT8IAJ HS Phase 3
DMT8IAJ CP Merck
DMT8IAJ DE Rheumatoid arthritis; Follicular lymphoma
DMP36KD ID DMP36KD
DMP36KD DN MLN4924
DMP36KD HS Phase 3
DMP36KD SN Pevonedistat; 905579-51-3; MLN4924; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
DMP36KD CP Takeda
DMP36KD DT Small molecular drug
DMP36KD PC 16720766
DMP36KD MW 443.5
DMP36KD FM C21H25N5O4S
DMP36KD IC InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1
DMP36KD CS C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N
DMP36KD IK MPUQHZXIXSTTDU-QXGSTGNESA-N
DMP36KD IU [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate
DMP36KD CA CAS 905579-51-3
DMP36KD CB CHEBI:95028
DMP36KD DE Advanced malignancy; Myelodysplastic syndrome; Acute myelogenous leukaemia; Nasopharyngeal carcinoma
DMO8PT9 ID DMO8PT9
DMO8PT9 DN MLN8237
DMO8PT9 HS Phase 3
DMO8PT9 SN Alisertib
DMO8PT9 TC Anticancer Agents
DMO8PT9 DT Small molecular drug
DMO8PT9 PC 24771867
DMO8PT9 MW 518.9
DMO8PT9 FM C27H20ClFN4O4
DMO8PT9 IC InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
DMO8PT9 CS COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC
DMO8PT9 IK ZLHFILGSQDJULK-UHFFFAOYSA-N
DMO8PT9 IU 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
DMO8PT9 CA CAS 1028486-01-2
DMO8PT9 CB CHEBI:125628
DMO8PT9 DE Solid tumour/cancer; Small-cell lung cancer
DMFWE9S ID DMFWE9S
DMFWE9S DN Mobocertinib
DMFWE9S HS Phase 3
DMFWE9S SN 1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; TAK788; AP32788; AP-32788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
DMFWE9S CP Takeda
DMFWE9S DT Small molecular drug
DMFWE9S PC 118607832
DMFWE9S MW 585.7
DMFWE9S FM C32H39N7O4
DMFWE9S IC InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)
DMFWE9S CS CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
DMFWE9S IK AZSRSNUQCUDCGG-UHFFFAOYSA-N
DMFWE9S IU propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate
DMFWE9S CA CAS 1847461-43-1
DMFWE9S DE Non-small cell lung cancer
DM2TNJ1 ID DM2TNJ1
DM2TNJ1 DN Molgramostim
DM2TNJ1 HS Phase 3
DM2TNJ1 SN Genfulin; Molgramostim (topical, wound healing); Molgramostim (topical, wound healing), GeneScience; GM-CSF (topical, woundhealing), GeneScience; Granulocyte-macrophage colony stimulating factor (topical, wound healing), GeneScience
DM2TNJ1 CP GeneScience Pharmaceuticals Co Ltd
DM2TNJ1 DE Wound healing; Autoimmune pulmonary alveolar proteinosis
DMF98Q0 ID DMF98Q0
DMF98Q0 DN Momelotinib
DMF98Q0 HS Phase 3
DMF98Q0 SN Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
DMF98Q0 CP Gilead Sciences
DMF98Q0 DT Small molecular drug
DMF98Q0 PC 25062766
DMF98Q0 MW 414.5
DMF98Q0 FM C23H22N6O2
DMF98Q0 IC InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
DMF98Q0 CS C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
DMF98Q0 IK ZVHNDZWQTBEVRY-UHFFFAOYSA-N
DMF98Q0 IU N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
DMF98Q0 CA CAS 1056634-68-4
DMF98Q0 CB CHEBI:91407
DMF98Q0 DE Myelofibrosis; Polycythemia vera; Thrombocythemia
DMQ1FU8 ID DMQ1FU8
DMQ1FU8 DN Montelukast
DMQ1FU8 HS Phase 3
DMQ1FU8 SN Singulair; Montelukast [INN:BAN]; UNII-MHM278SD3E; MK 0476; CHEMBL787; MHM278SD3E; CHEBI:50730; 142522-28-9; Aerokast; Brondilat (TN)
DMQ1FU8 TC Antiviral Agents
DMQ1FU8 DT Small molecular drug
DMQ1FU8 PC 5281040
DMQ1FU8 MW 586.2
DMQ1FU8 FM C35H36ClNO3S
DMQ1FU8 IC InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
DMQ1FU8 CS CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
DMQ1FU8 IK UCHDWCPVSPXUMX-TZIWLTJVSA-N
DMQ1FU8 IU 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
DMQ1FU8 CA CAS 158966-92-8
DMQ1FU8 CB CHEBI:50730
DMQ1FU8 DE Coronavirus Disease 2019 (COVID-19)
DMPVW6H ID DMPVW6H
DMPVW6H DN Morphine-6-glucuronide
DMPVW6H HS Phase 3
DMPVW6H SN Morphine-6-glucuronide; Morphine 6-glucuronide; 20290-10-2; UNII-64Y9KYM60R; Morphine 6-beta-D-glucopyranosiduronide; 64Y9KYM60R; CHEBI:80581; MORPHINE GLUCURONIDE; MORPHINE 6-GLUCURONIDE(MINOR); beta-D-Glucopyranosiduronic acid, (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl; Morphine 6-beta-D-Glucuronide; Glucopyranosiduronic acid, 7,8-didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-alpha-yl-, beta-D-; Morphine glucuronide [INN]; morphine-glucuronide
DMPVW6H TC Analgesics
DMPVW6H DT Small molecular drug
DMPVW6H PC 5360621
DMPVW6H MW 461.5
DMPVW6H FM C23H27NO9
DMPVW6H IC InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-5-13(31-22-17(28)15(26)16(27)19(33-22)21(29)30)20(23)32-18-12(25)4-2-9(14(18)23)8-11(10)24/h2-5,10-11,13,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,13-,15-,16-,17+,19-,20-,22+,23-/m0/s1
DMPVW6H CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O
DMPVW6H IK GNJCUHZOSOYIEC-GAROZEBRSA-N
DMPVW6H IU (2S,3S,4S,5R,6R)-6-[[(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DMPVW6H CA CAS 20290-10-2
DMPVW6H CB CHEBI:80581
DMPVW6H DE Pain
DM15ZIB ID DM15ZIB
DM15ZIB DN Mosunetuzumab
DM15ZIB HS Phase 3
DM15ZIB SN RG7828; RO7030816; BTCT4465A
DM15ZIB DT Antibody
DM15ZIB DE Follicular lymphoma
DMB24H7 ID DMB24H7
DMB24H7 DN Motavizumab
DMB24H7 HS Phase 3
DMB24H7 SN MEDI-524; Motavizumab (USAN/INN)
DMB24H7 CP AstraZeneca
DMB24H7 DT Monoclonal antibody
DMB24H7 DE Respiratory syncytial virus infection
DM8K5Z6 ID DM8K5Z6
DM8K5Z6 DN Motexafin lutetium
DM8K5Z6 HS Phase 3
DM8K5Z6 SN Lutetium texaphyrin; Lu-Tex; Motexafin lutetium < USAN; Optrin (Pharmacyclics); PCI-0123; Antrin (Pharmacyclics, US, US); Lutrin (National Cancer Institute (US), US; Pharmacyclics, , , JP); (PB-7-11-233'2'4)-Bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24
DM8K5Z6 CP Pharmacyclics
DM8K5Z6 DT Small molecular drug
DM8K5Z6 PC 3081907
DM8K5Z6 MW 1184.1
DM8K5Z6 FM C52H74LuN5O15
DM8K5Z6 IC InChI=1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);;1H2/q-1;;;+3;/p-2
DM8K5Z6 CS CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].O.[Lu+3]
DM8K5Z6 IK WIQKYZYFTAEWBF-UHFFFAOYSA-L
DM8K5Z6 IU 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26-tetraza-27-azanidapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6,8(26),9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol;lutetium(3+);diacetate;hydrate
DM8K5Z6 CA CAS 156436-90-7
DM8K5Z6 DE Artery stenosis
DM9K3LM ID DM9K3LM
DM9K3LM DN MPDL-3280A
DM9K3LM HS Phase 3
DM9K3LM CP Genentech
DM9K3LM DT Monoclonal antibody
DM9K3LM DE Melanoma
DMNDCFY ID DMNDCFY
DMNDCFY DN MPL-S
DMNDCFY HS Phase 3
DMNDCFY CP Ribi ImmunoChem Research Inc
DMNDCFY DE Endotoxic shock
DMDV4EP ID DMDV4EP
DMDV4EP DN MRTX849
DMDV4EP HS Phase 3
DMDV4EP SN 2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX-849; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
DMDV4EP CP Mirati Therapeutics
DMDV4EP DT Small molecular drug
DMDV4EP PC 138611145
DMDV4EP MW 604.1
DMDV4EP FM C32H35ClFN7O2
DMDV4EP IC InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
DMDV4EP CS CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
DMDV4EP IK PEMUGDMSUDYLHU-ZEQRLZLVSA-N
DMDV4EP IU 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
DMDV4EP CA CAS 2326521-71-3
DMDV4EP DE Non-small-cell lung cancer
DMUNBMA ID DMUNBMA
DMUNBMA DN MT-1621
DMUNBMA HS Phase 3
DMUNBMA CP Modis Therapeutics
DMUNBMA DT Deoxynucleoside
DMUNBMA DE Thymidine kinase 2 deficiency
DMZPEHY ID DMZPEHY
DMZPEHY DN Multi-epitope peptide melanoma vaccine
DMZPEHY HS Phase 3
DMZPEHY SN Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase); Multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), University of Pittsburgh; MART-1 (51-73) + MART-1(27-35); MART-1(NSC-672643), gp100(NSC-683472), tyrosinase (NSC-699048); MGT (MART-1 (27-35), gp100(209-217, 210M), tyrosinase (368-376, 370D)); (MART-1, gp100, tyrosinase) + (IFNalfa2b + GM-CSF); (MART-1, gp100, tyrosinase) + GM-CSF; (MART-1, gp100, tyrosinase) + IFNalfa2b
DMZPEHY CP University of Pittsburgh
DMZPEHY DT Vaccine
DMZPEHY DE Melanoma
DMG3NFZ ID DMG3NFZ
DMG3NFZ DN Muraglitazar
DMG3NFZ HS Phase 3
DMG3NFZ SN Muraglitazar; 331741-94-7; Pargluva; BMS-298585; UNII-W1MKM70WQI; BMS 298585; W1MKM70WQI; CHEMBL186179; N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine; N-((4-methoxyphenoxy)carbonyl)-N-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine; BMS298585; Muraglitazar [USAN:INN]; CCRIS 9258; AC1L4FVP; Muraglitazar (USAN/INN); DSSTox_CID_31508; DSSTox_RID_97393; DSSTox_GSID_57719; SCHEMBL676469; DTXSID9057719; CTK8E8901; MolPort-006-395-259; IRLWJILLXJGJTD-UHFFFAOYSA-N
DMG3NFZ DT Small molecular drug
DMG3NFZ PC 206044
DMG3NFZ MW 516.5
DMG3NFZ FM C29H28N2O7
DMG3NFZ IC InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
DMG3NFZ CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC
DMG3NFZ IK IRLWJILLXJGJTD-UHFFFAOYSA-N
DMG3NFZ IU 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
DMG3NFZ CA CAS 331741-94-7
DMUQ390 ID DMUQ390
DMUQ390 DN Murepavadin
DMUQ390 HS Phase 3
DMUQ390 SN UNII-0D02GRY87Z; 0D02GRY87Z; 944252-63-5; Murepavadin [INN]; Murepavadin [USAN:INN]; Murepavadin (USAN/INN); CHEMBL3946483; Cyclo(L-alanyl-L-seryl-D-prolyl-L-prolyl-L-threonyl-L-tryptophyl-L-isoleucyl-(2S)-2,4-diaminobutanoyl-L-ornithyl-(2R)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl-L-tryptophyl-(2S)-2,4-diaminobutanoyl-(2S)-2,4-diaminobutanoyl); RO7033877; D10957
DMUQ390 CP Polyphor
DMUQ390 PC 91824766
DMUQ390 MW 1553.8
DMUQ390 FM C73H112N22O16
DMUQ390 IC InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1
DMUQ390 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
DMUQ390 IK RIDRXGOBXZLKHZ-NZUANIILSA-N
DMUQ390 IU (3R,9S,12S,15S,18S,21S,24S,27R,30S,33S,36S,39S,42S,45S)-15,18,24,27,33-pentakis(2-aminoethyl)-30-(3-aminopropyl)-36-[(2S)-butan-2-yl]-42-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-21,39-bis(1H-indol-3-ylmethyl)-12-methyl-1,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazatricyclo[43.3.0.03,7]octatetracontane-2,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecone
DMUQ390 CA CAS 944252-63-5
DMUQ390 DE Ventilator-associated pneumonia
DMS9GE1 ID DMS9GE1
DMS9GE1 DN MyoCell SDF-1
DMS9GE1 HS Phase 3
DMS9GE1 SN Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart
DMS9GE1 CP Bioheart
DMS9GE1 DE Heart failure
DMY60DT ID DMY60DT
DMY60DT DN N8-GP
DMY60DT HS Phase 3
DMY60DT SN NN7088
DMY60DT CP Novo Nordisk
DMY60DT DE Factor VIII deficiency
DMHKJ5I ID DMHKJ5I
DMHKJ5I DN Nabiximols
DMHKJ5I HS Phase 3
DMHKJ5I SN Nabiximols; Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02
DMHKJ5I CP Otsuka America Pharmaceutical
DMHKJ5I DT Small molecular drug
DMHKJ5I PC 44148067
DMHKJ5I MW 628.9
DMHKJ5I FM C42H60O4
DMHKJ5I IC InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1
DMHKJ5I CS CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
DMHKJ5I IK SSNHGLKFJISNTR-FWUPRJFYSA-N
DMHKJ5I IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DMHKJ5I CA CAS 56575-23-6
DMHKJ5I DE Cancer related pain; Muscle spasm
DMDZ6Q3 ID DMDZ6Q3
DMDZ6Q3 DN Napabucasin
DMDZ6Q3 HS Phase 3
DMDZ6Q3 SN 83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
DMDZ6Q3 CP Boston Biomedical Cambridge, MA
DMDZ6Q3 PC 10331844
DMDZ6Q3 MW 240.21
DMDZ6Q3 FM C14H8O4
DMDZ6Q3 IC InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3
DMDZ6Q3 CS CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O
DMDZ6Q3 IK DPHUWDIXHNQOSY-UHFFFAOYSA-N
DMDZ6Q3 IU 2-acetylbenzo[f][1]benzofuran-4,9-dione
DMDZ6Q3 CA CAS 83280-65-3
DMDZ6Q3 DE Pancreatic cancer; Colorectal cancer; Advanced malignancy; Solid tumour/cancer; Gastrointestinal cancer; Haematological malignancy; Hepatocellular carcinoma; Recurring respiratory infection; Recurrent glioblastoma
DMKP45D ID DMKP45D
DMKP45D DN Naproxcinod
DMKP45D HS Phase 3
DMKP45D SN Beprana; Nitronaproxen; AR-P900758XX; AZD-3582; HCT-3012; Nitronaproxen, NicOx; NO-naproxen, AstraZeneca; NO-naproxen, NicOx; NO-NSAID, NicOx/AstraZeneca; Nitric oxide-donating derivative of naproxen (oral, osteoarthritis), NicOx
DMKP45D CP NicOx SA
DMKP45D DT Small molecular drug
DMKP45D PC 9884642
DMKP45D MW 347.4
DMKP45D FM C18H21NO6
DMKP45D IC InChI=1S/C18H21NO6/c1-13(18(20)24-9-3-4-10-25-19(21)22)14-5-6-16-12-17(23-2)8-7-15(16)11-14/h5-8,11-13H,3-4,9-10H2,1-2H3/t13-/m0/s1
DMKP45D CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCO[N+](=O)[O-]
DMKP45D IK AKFJWRDCWYYTIG-ZDUSSCGKSA-N
DMKP45D IU 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DMKP45D CA CAS 163133-43-5
DMKP45D CB CHEBI:76254
DMKP45D DE Inflammation
DMIC56X ID DMIC56X
DMIC56X DN NASVAC
DMIC56X HS Phase 3
DMIC56X SN NASTERAP; HBV vaccine (intranasal), CIGB
DMIC56X CP Center for Genetic Engineering and Biotechnology
DMIC56X DT Vaccine
DMIC56X DE Hepatitis B virus infection
DMRSI1M ID DMRSI1M
DMRSI1M DN NAV5001
DMRSI1M HS Phase 3
DMRSI1M CP Navidea biopharmaceuticals
DMRSI1M DE Dementia
DMVO1C0 ID DMVO1C0
DMVO1C0 DN NBI-98854
DMVO1C0 HS Phase 3
DMVO1C0 SN NBI-98782; Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine; VMAT-2 inhibitor (CNS disease), Neurocrine
DMVO1C0 CP Neurocrine biosciences
DMVO1C0 DT Small molecular drug
DMVO1C0 PC 123836
DMVO1C0 MW 319.4
DMVO1C0 FM C19H29NO3
DMVO1C0 IC InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3
DMVO1C0 CS CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1O)OC)OC
DMVO1C0 IK WEQLWGNDNRARGE-UHFFFAOYSA-N
DMVO1C0 IU 9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
DMVO1C0 CA CAS 3466-75-9
DMVO1C0 DE Movement disorder; Tourette syndrome
DMFD249 ID DMFD249
DMFD249 DN Nebracetam
DMFD249 HS Phase 3
DMFD249 SN Memolog; WEB-1881; WEB-1881-FU
DMFD249 CP Boehringer Ingelheim Corp
DMFD249 DT Small molecular drug
DMFD249 PC 65926
DMFD249 MW 204.27
DMFD249 FM C12H16N2O
DMFD249 IC InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2
DMFD249 CS C1C(CN(C1=O)CC2=CC=CC=C2)CN
DMFD249 IK LCAFGJGYCUMTGS-UHFFFAOYSA-N
DMFD249 IU 4-(aminomethyl)-1-benzylpyrrolidin-2-one
DMFD249 CA CAS 97205-34-0
DMFD249 DE Parkinson disease
DMDBY30 ID DMDBY30
DMDBY30 DN Nelipepimut S
DMDBY30 HS Phase 3
DMDBY30 SN E75
DMDBY30 CP Galena biopharma
DMDBY30 DT Small molecular drug
DMDBY30 PC 9941306
DMDBY30 MW 995.2
DMDBY30 FM C50H78N10O11
DMDBY30 IC InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1
DMDBY30 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N
DMDBY30 IK AHOKKYCUWBLDST-QYULHYBRSA-N
DMDBY30 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMDBY30 CA CAS 160212-35-1
DMDBY30 DE Non-hodgkin lymphoma; Breast cancer; Gastric adenocarcinoma
DMH9EUA ID DMH9EUA
DMH9EUA DN Nemolizumab
DMH9EUA HS Phase 3
DMH9EUA CP Galderma Fort Worth, TX
DMH9EUA DE Atopic dermatitis
DMIPNBG ID DMIPNBG
DMIPNBG DN Nemonaxacin
DMIPNBG HS Phase 3
DMIPNBG CP Warner Chilcott plc
DMIPNBG DE Methicillin-resistant staphylococci infection
DMVP7HI ID DMVP7HI
DMVP7HI DN Nestorone
DMVP7HI HS Phase 3
DMVP7HI SN Nestorone; Nestorone MDTS; Nestorone metered dose transdermal system; Nestorone transdermal spray, Acrux; ST-1435; Nestorone transdermal spray, Population Council/Acrux
DMVP7HI CP Population Council; Population Council Center for Biomedical Research
DMVP7HI DT Small molecular drug
DMVP7HI PC 108059
DMVP7HI MW 370.5
DMVP7HI FM C23H30O4
DMVP7HI IC InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1
DMVP7HI CS CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C
DMVP7HI IK CKFBRGLGTWAVLG-GOMYTPFNSA-N
DMVP7HI IU [(8R,9S,10R,13S,14S,17R)-17-acetyl-13-methyl-16-methylidene-3-oxo-2,6,7,8,9,10,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMVP7HI CA 7759-35-5
DMVP7HI DE Endometriosis
DMTKRY1 ID DMTKRY1
DMTKRY1 DN Netivudine
DMTKRY1 HS Phase 3
DMTKRY1 SN Zonavir; BW-882; BW-882C; 882-C-87; 882C
DMTKRY1 CP Burroughs Wellcome Inc
DMTKRY1 DT Small molecular drug
DMTKRY1 PC 55281
DMTKRY1 MW 282.25
DMTKRY1 FM C12H14N2O6
DMTKRY1 IC InChI=1S/C12H14N2O6/c1-2-3-6-4-14(12(19)13-10(6)18)11-9(17)8(16)7(5-15)20-11/h4,7-9,11,15-17H,5H2,1H3,(H,13,18,19)/t7-,8-,9+,11-/m1/s1
DMTKRY1 CS CC#CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
DMTKRY1 IK QLOCVMVCRJOTTM-SDNRWEOFSA-N
DMTKRY1 IU 1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione
DMTKRY1 CA CAS 84558-93-0
DMTKRY1 DE Virus infection
DMEKAYI ID DMEKAYI
DMEKAYI DN Netupitant
DMEKAYI HS Phase 3
DMEKAYI SN R-1124; NK1 antagonist (emesis), Roche; Ro-67-3189
DMEKAYI CP Helsinn Therapeutics
DMEKAYI DT Small molecular drug
DMEKAYI PC 6451149
DMEKAYI MW 578.6
DMEKAYI FM C30H32F6N4O
DMEKAYI IC InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
DMEKAYI CS CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
DMEKAYI IK WAXQNWCZJDTGBU-UHFFFAOYSA-N
DMEKAYI IU 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
DMEKAYI CA CAS 290297-26-6
DMEKAYI CB CHEBI:85155
DMEKAYI DE Chemotherapy-induced nausea
DME617W ID DME617W
DME617W DN Neucardin
DME617W HS Phase 3
DME617W SN Human neuregulin-1 recombinant peptide fragment (injectable, heart failure/cardiomyopathy), Zensun; RhNRG-1 (injectable, heartfailure/cardiomyopathy), Zensun
DME617W CP Zensun (Shanghai) Sci-Tech Co Ltd
DME617W DE Heart failure; Chronic heart failure
DMYTC4I ID DMYTC4I
DMYTC4I DN NeuVax
DMYTC4I HS Phase 3
DMYTC4I SN NeuVax (TN)
DMYTC4I CP Galena Biopharma
DMYTC4I DT Vaccine
DMYTC4I DE Breast cancer
DMJ2KIE ID DMJ2KIE
DMJ2KIE DN NI-101
DMJ2KIE HS Phase 3
DMJ2KIE SN BART; Ch12F6A; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer! s disease), Neurimmune Therapeutics/Biogen Idec
DMJ2KIE CP Neurimmune Therapeutics AG
DMJ2KIE DT Antibody
DMJ2KIE DE Alzheimer disease
DMFBNA3 ID DMFBNA3
DMFBNA3 DN Nicaraven
DMFBNA3 HS Phase 3
DMFBNA3 SN AVS; Antevan; Antevas
DMFBNA3 CP Chugai Pharmaceutical
DMFBNA3 DT Small molecular drug
DMFBNA3 PC 71234
DMFBNA3 MW 284.31
DMFBNA3 FM C15H16N4O2
DMFBNA3 IC InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
DMFBNA3 CS CC(CNC(=O)C1=CN=CC=C1)NC(=O)C2=CN=CC=C2
DMFBNA3 IK KTXBOOWDLPUROC-UHFFFAOYSA-N
DMFBNA3 IU N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide
DMFBNA3 CA CAS 79455-30-4
DMFBNA3 DE Cerebrovascular disease
DM376WT ID DM376WT
DM376WT DN NKTR 214
DM376WT HS Phase 3
DM376WT CP Nektar Therapeutics San Francisco, CA
DM376WT DE Bladder cancer; Colorectal cancer; Melanoma; Renal cell carcinoma; Solid tumour/cancer; Sarcoma
DM45DS8 ID DM45DS8
DM45DS8 DN NKTR-181
DM45DS8 HS Phase 3
DM45DS8 CP Nektar therapeutics
DM45DS8 PC 73673720
DM45DS8 MW 595.7
DM45DS8 FM C31H49NO10
DM45DS8 IC InChI=1S/C31H49NO10/c1-32-9-8-30-27-23-4-5-24(35-3)28(27)42-29(30)25(6-7-31(30,33)26(32)22-23)41-21-20-40-19-18-39-17-16-38-15-14-37-13-12-36-11-10-34-2/h4-5,25-26,29,33H,6-22H2,1-3H3/t25-,26+,29-,30-,31+/m0/s1
DM45DS8 CS CN1CC[C@]23[C@@H]4[C@H](CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O)OCCOCCOCCOCCOCCOCCOC
DM45DS8 IK RQHILGKAOIGUHU-XPLSERNMSA-N
DM45DS8 IU (4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol
DM45DS8 CA CAS 1211231-76-3
DM45DS8 DE Neuropathic pain; Chronic low back pain; Pain
DMACYW6 ID DMACYW6
DMACYW6 DN NKTR-214
DMACYW6 HS Phase 3
DMACYW6 SN bempegaldesleukin
DMACYW6 CP Nektar Therapeutics
DMACYW6 DT Recombinant protein
DMACYW6 DE Melanoma
DMDJLY9 ID DMDJLY9
DMDJLY9 DN NM-702
DMDJLY9 HS Phase 3
DMDJLY9 SN NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride
DMDJLY9 CP Nissan Chemical America
DMDJLY9 DT Small molecular drug
DMDJLY9 PC 9848253
DMDJLY9 MW 486.2
DMDJLY9 FM C19H19BrCl2N4O2
DMDJLY9 IC InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H
DMDJLY9 CS C1=CC(=CN=C1)CNC2=C(C(=O)NN=C2OCCCC3=CC=C(C=C3)Cl)Br.Cl
DMDJLY9 IK QWGUGDYWUADMGB-UHFFFAOYSA-N
DMDJLY9 IU 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
DMDJLY9 CA CAS 878796-94-2
DMDJLY9 DE Angina pectoris
DMDGK83 ID DMDGK83
DMDGK83 DN NN1841
DMDGK83 HS Phase 3
DMDGK83 SN NovoThirteen (TN)
DMDGK83 CP Novo Nordisk
DMDGK83 DE Hemophilia
DM0QV27 ID DM0QV27
DM0QV27 DN NN5401
DM0QV27 HS Phase 3
DM0QV27 SN Insulin degludec and insulin aspart; Ryzodeg (TN)
DM0QV27 CP Novo Nordisk
DM0QV27 DE Diabetic complication
DM1PI9G ID DM1PI9G
DM1PI9G DN NN8717
DM1PI9G HS Phase 3
DM1PI9G CP Novo Nordisk
DM1PI9G DE Graft-versus-host disease
DMOF0CA ID DMOF0CA
DMOF0CA DN Nolatrexed
DMOF0CA HS Phase 3
DMOF0CA SN Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS
DMOF0CA CP Agouron Pharmaceuticals Inc
DMOF0CA DT Small molecular drug
DMOF0CA PC 135400184
DMOF0CA MW 284.34
DMOF0CA FM C14H12N4OS
DMOF0CA IC InChI=1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19)
DMOF0CA CS CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3
DMOF0CA IK XHWRWCSCBDLOLM-UHFFFAOYSA-N
DMOF0CA IU 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3H-quinazolin-4-one
DMOF0CA CA CAS 147149-76-6
DMOF0CA DE Solid tumour/cancer
DMMC3Y8 ID DMMC3Y8
DMMC3Y8 DN NPC-01
DMMC3Y8 HS Phase 3
DMMC3Y8 SN LEP pill; Low dose estrogen progestin pill (dysmenorrhea), Nobelpharma
DMMC3Y8 CP Nobelpharma Co Ltd
DMMC3Y8 DE Dysmenorrhea
DMCMIJ1 ID DMCMIJ1
DMCMIJ1 DN NT0202
DMCMIJ1 HS Phase 3
DMCMIJ1 SN Amphetamine polistirex
DMCMIJ1 CP Neos therapeutics
DMCMIJ1 DE Attention deficit hyperactivity disorder
DMA16IL ID DMA16IL
DMA16IL DN NU-100
DMA16IL HS Phase 3
DMA16IL SN BaroFeron; Interferon beta-1b (PreEMT, multiple sclerosis), BaroFold; Interferon beta-1b (PreEMT, multiple sclerosis), NuronBiotech
DMA16IL CP Nuron biotech
DMA16IL PC 21987656
DMA16IL MW 378.5
DMA16IL FM C24H30N2O2
DMA16IL IC InChI=1S/C24H30N2O2/c27-23(25-21-7-3-1-4-8-21)19-13-11-18-16-20(14-12-17(18)15-19)24(28)26-22-9-5-2-6-10-22/h11-16,21-22H,1-10H2,(H,25,27)(H,26,28)
DMA16IL CS C1CCC(CC1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=O)NC4CCCCC4
DMA16IL IK MBSRTKPGZKQXQR-UHFFFAOYSA-N
DMA16IL IU 2-N,6-N-dicyclohexylnaphthalene-2,6-dicarboxamide
DMA16IL CA CAS 153250-52-3
DMA16IL DE Multiple sclerosis
DM8JWNA ID DM8JWNA
DM8JWNA DN NVP-LAQ824
DM8JWNA HS Phase 3
DM8JWNA SN Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; Dacinostat; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
DM8JWNA CP Corcept Therapeutics
DM8JWNA DT Small molecular drug
DM8JWNA PC 6445533
DM8JWNA MW 379.5
DM8JWNA FM C22H25N3O3
DM8JWNA IC InChI=1S/C22H25N3O3/c26-14-13-25(12-11-19-15-23-21-4-2-1-3-20(19)21)16-18-7-5-17(6-8-18)9-10-22(27)24-28/h1-10,15,23,26,28H,11-14,16H2,(H,24,27)/b10-9+
DM8JWNA CS C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)/C=C/C(=O)NO
DM8JWNA IK BWDQBBCUWLSASG-MDZDMXLPSA-N
DM8JWNA IU (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
DM8JWNA CA CAS 404951-53-7
DM8JWNA CB CHEBI:94063
DM8JWNA DE leukaemia; Multiple myeloma; Mood disorder
DM3L2GT ID DM3L2GT
DM3L2GT DN O6-Benzylguanine alkylade
DM3L2GT HS Phase 3
DM3L2GT SN KRX-0402; O6-Benzylguanine (BG)
DM3L2GT CP Wiley-Liss; Keryx Biopharmaceuticals
DM3L2GT DE Sarcoma
DMENDP6 ID DMENDP6
DMENDP6 DN OBI-1
DMENDP6 HS Phase 3
DMENDP6 SN Porcine rFVIII, Ipsen/Inspiration; Porcine rFVIII, Octagen/Ipsen; Porcine rFactor VIII, Ipsen/Inspiration; Porcine rFactor VIII, Octagen/Ipsen; Recombinant porcine Factor VIII, Ipsen/Inspiration; Recombinant porcine Factor VIII, Octagen/Ipsen
DMENDP6 CP Baxter international; inspiration biopharmaceuticals
DMENDP6 DE Factor VIII deficiency
DM7KI4E ID DM7KI4E
DM7KI4E DN Oblimersen
DM7KI4E HS Phase 3
DM7KI4E CP Genta Incorp
DM7KI4E PC 118984457
DM7KI4E MW 6058
DM7KI4E FM C172H204N62Na17O91P17S17
DM7KI4E IC InChI=1S/C172H221N62O91P17S17.17Na/c1-69-39-225(169(253)213-149(69)237)117-21-73(236)92(292-117)44-274-326(257,343)320-85-33-129(229-63-191-135-141(181)187-61-189-143(135)229)303-103(85)55-285-332(263,349)314-79-27-122(221-17-9-113(177)201-165(221)249)295-95(79)47-278-330(261,347)312-78-26-121(220-16-8-112(176)200-164(220)248)298-98(78)50-280-338(269,355)322-87-35-131(231-65-193-137-145(231)205-157(183)209-153(137)241)305-105(87)57-287-334(265,351)316-81-29-124(223-19-11-115(179)203-167(223)251)299-99(81)51-281-339(270,356)323-88-36-132(232-66-194-138-146(232)206-158(184)210-154(138)242)307-107(88)59-289-337(268,354)319-84-32-128(228-42-72(4)152(240)216-172(228)256)302-102(84)54-284-341(272,358)325-90-38-134(234-68-196-140-148(234)208-160(186)212-156(140)244)306-106(90)58-288-335(266,352)317-82-30-125(224-20-12-116(180)204-168(224)252)300-100(82)52-282-340(271,357)324-89-37-133(233-67-195-139-147(233)207-159(185)211-155(139)243)308-108(89)60-290-342(273,359)321-86-34-130(230-64-192-136-142(182)188-62-190-144(136)230)304-104(86)56-286-333(264,350)315-80-28-123(222-18-10-114(178)202-166(222)250)296-96(80)48-277-328(259,345)310-76-24-119(218-14-6-110(174)198-162(218)246)294-94(76)46-276-329(260,346)311-77-25-120(219-15-7-111(175)199-163(219)247)297-97(77)49-279-336(267,353)318-83-31-127(227-41-71(3)151(239)215-171(227)255)301-101(83)53-283-331(262,348)313-75-23-118(217-13-5-109(173)197-161(217)245)293-93(75)45-275-327(258,344)309-74-22-126(291-91(74)43-235)226-40-70(2)150(238)214-170(226)254;;;;;;;;;;;;;;;;;/h5-20,39-42,61-68,73-108,117-134,235-236H,21-38,43-60H2,1-4H3,(H,257,343)(H,258,344)(H,259,345)(H,260,346)(H,261,347)(H,262,348)(H,263,349)(H,264,350)(H,265,351)(H,266,352)(H,267,353)(H,268,354)(H,269,355)(H,270,356)(H,271,357)(H,272,358)(H,273,359)(H2,173,197,245)(H2,174,198,246)(H2,175,199,247)(H2,176,200,248)(H2,177,201,249)(H2,178,202,250)(H2,179,203,251)(H2,180,204,252)(H2,181,187,189)(H2,182,188,190)(H,213,237,253)(H,214,238,254)(H,215,239,255)(H,216,240,256)(H3,183,205,209,241)(H3,184,206,210,242)(H3,185,207,211,243)(H3,186,208,212,244);;;;;;;;;;;;;;;;;/q;17*+1/p-17/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,326?,327?,328?,329?,330?,331?,332?,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?;;;;;;;;;;;;;;;;;/m0................./s1
DM7KI4E CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)([O-])O[C@H]3C[C@@H](O[C@@H]3COP(=O)(O[C@H]4C[C@@H](O[C@@H]4COP(=S)([O-])O[C@H]5C[C@@H](O[C@@H]5COP(=S)([O-])O[C@H]6C[C@@H](O[C@@H]6COP(=S)([O-])O[C@H]7C[C@@H](O[C@@H]7COP(=S)([O-])O[C@H]8C[C@@H](O[C@@H]8COP(=S)([O-])O[C@H]9C[C@@H](O[C@@H]9COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1COP(=S)([O-])O[C@H]1C[C@@H](O[C@@H]1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)[S-])N1C=NC2=C(N=CN=C21)N)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM7KI4E IK IBXPAFBDJCXCDW-MHFPCNPESA-A
DM7KI4E IU heptadecasodium;1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfidophosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-oxidophosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM7KI4E CA CAS 190977-41-4
DM7KI4E DE Multiple myeloma; Melanoma
DMEDSVJ ID DMEDSVJ
DMEDSVJ DN Ociperlimab
DMEDSVJ HS Phase 3
DMEDSVJ SN BGB-A1217
DMEDSVJ CP BeiGene
DMEDSVJ DT Antibody
DMEDSVJ DE Cervical cancer; Non-small-cell lung cancer
DM1EO3G ID DM1EO3G
DM1EO3G DN Odanacatib
DM1EO3G HS Phase 3
DM1EO3G SN MK 0822; MK0822; MK-0822A; Odanacatib (USAN)
DM1EO3G CP Merck
DM1EO3G DT Small molecular drug
DM1EO3G PC 10152654
DM1EO3G MW 525.6
DM1EO3G FM C25H27F4N3O3S
DM1EO3G IC InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1
DM1EO3G CS CC(C)(C[C@@H](C(=O)NC1(CC1)C#N)N[C@@H](C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
DM1EO3G IK FWIVDMJALNEADT-SFTDATJTSA-N
DM1EO3G IU (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
DM1EO3G CA CAS 603139-19-1
DM1EO3G DE Osteoporosis
DMYN391 ID DMYN391
DMYN391 DN Odevixibat
DMYN391 HS Phase 3
DMYN391 SN 501692-44-0; UNII-2W150K0UUC; 2W150K0UUC; A4250; AZD8294; 501692-44-0 (free base); Odevixibat (USAN); Odevixibat [USAN]; AR-H064974; A-4250; (S)-2-((R)-2-(2-((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid; SCHEMBL946468; CHEMBL4297588; BDBM77040; GTPL11194; AZD-8294; example 5 [US9694018B1]; WHO 10706; HY-109120; Unk-D-nTyr-Abu-OH (IUPAC condensed name); CS-0078340; D11716; US9694018, 5; (2S)-2-(((2R)-2-((((3,3-Dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)butanoic acid; (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid; Butanoic acid, 2-(((2R)-((((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)(4-hydroxyphenyl)acetyl)amino)-, (2S)-; Butanoic acid, 2-(((2R)-2-((2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)-, (2S)-
DMYN391 CP Albireo Pharma
DMYN391 DT Small molecular drug
DMYN391 PC 10153627
DMYN391 MW 740.9
DMYN391 FM C37H48N4O8S2
DMYN391 IC InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1
DMYN391 CS CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)N[C@H](C3=CC=C(C=C3)O)C(=O)N[C@@H](CC)C(=O)O)SC)C4=CC=CC=C4)CCCC
DMYN391 IK XULSCZPZVQIMFM-IPZQJPLYSA-N
DMYN391 IU (2S)-2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,2,5-benzothiadiazepin-8-yl)oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid
DMYN391 CA CAS 501692-44-0
DMYN391 DE Alagille syndrome
DMBWO5T ID DMBWO5T
DMBWO5T DN ODT-8
DMBWO5T HS Phase 3
DMBWO5T SN H-c(Cys3-Phe6-Phe7-DTrp8-Lys9-Thr10-Phe11-Cys14)-OH; CHEMBL266477; BDBM50136824; (4R,7S,10S,13S,16R,19S,22S,25R)-16-((1H-indol-3-yl)methyl)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-((R)-1-hydroxyethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptaazacyclohexacosane-4-carboxylic acid
DMBWO5T PC 11251755
DMBWO5T MW 1079.3
DMBWO5T FM C54H66N10O10S2
DMBWO5T IC InChI=1S/C54H66N10O10S2/c1-32(65)46-53(72)62-43(27-35-19-9-4-10-20-35)51(70)63-45(54(73)74)31-76-75-30-38(56)47(66)59-41(25-33-15-5-2-6-16-33)49(68)60-42(26-34-17-7-3-8-18-34)50(69)61-44(28-36-29-57-39-22-12-11-21-37(36)39)52(71)58-40(48(67)64-46)23-13-14-24-55/h2-12,15-22,29,32,38,40-46,57,65H,13-14,23-28,30-31,55-56H2,1H3,(H,58,71)(H,59,66)(H,60,68)(H,61,69)(H,62,72)(H,63,70)(H,64,67)(H,73,74)/t32-,38+,40+,41+,42+,43+,44-,45+,46+/m1/s1
DMBWO5T CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)CC6=CC=CC=C6)O
DMBWO5T IK PJRZZHKHLDKTKL-OCZUONHDSA-N
DMBWO5T IU (4R,7S,10S,13S,16R,19S,22S,25R)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxylic acid
DM1FBZ7 ID DM1FBZ7
DM1FBZ7 DN Olodaterol/tiotropium bromide
DM1FBZ7 HS Phase 3
DM1FBZ7 SN 136310-93-5; UNII-XX112XZP0J; XX112XZP0J; (1R,2R,4S,5S,7s)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide; AK-72842; (1R,2R,4S,5S,7S)-7-(2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0
DM1FBZ7 CP Boehringer Ingelheim Pharmaceuticals
DM1FBZ7 DT Small molecular drug
DM1FBZ7 PC 5487426
DM1FBZ7 MW 472.4
DM1FBZ7 FM C19H22BrNO4S2
DM1FBZ7 IC InChI=1S/C19H22NO4S2.BrH/c1-20(2)12-9-11(10-13(20)17-16(12)24-17)23-18(21)19(22,14-5-3-7-25-14)15-6-4-8-26-15;/h3-8,11-13,16-17,22H,9-10H2,1-2H3;1H/q+1;/p-1/t11?,12-,13+,16-,17+;
DM1FBZ7 CS C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.[Br-]
DM1FBZ7 IK DQHNAVOVODVIMG-RGECMCKFSA-M
DM1FBZ7 IU [(1R,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
DM1FBZ7 CA CAS 136310-93-5
DM1FBZ7 CB CHEBI:90959
DM1FBZ7 DE Chronic obstructive pulmonary disease
DM4Z9QI ID DM4Z9QI
DM4Z9QI DN Olokizumab
DM4Z9QI HS Phase 3
DM4Z9QI CP UCB
DM4Z9QI DT Monoclonal antibody
DM4Z9QI DE Rheumatoid arthritis
DM624TW ID DM624TW
DM624TW DN Omecamtiv mecarbil
DM624TW HS Phase 3
DM624TW SN Omecamtiv mecarbil; 873697-71-3; Omecamtiv mecarbil (CK-1827452); CK-1827452; CK1827452; UNII-2M19539ERK; CK 1827452; methyl 4-(2-fluoro-3-(3-(6-Methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate; CHEMBL1800955; AMG-423; 2M19539ERK; Methyl 4-(2-Fluoro-3-{[(6-Methylpyridin-3-Yl)carbamoyl]amino}benzyl)piperazine-1-Carboxylate; Methyl 4-[[2-fluoro-3-[n'-(6-methylpyridin-3-yl)ureido]phenyl]methyl]piperazine-1-carboxylate; Omecamtiv mecarbil [USAN:INN]; omecamtiv mercarbil; MLS006011266; SCHEMBL400544; Omecamtiv Mecarbil;
DM624TW CP Amgen
DM624TW DT Small molecular drug
DM624TW PC 11689883
DM624TW MW 401.4
DM624TW FM C20H24FN5O3
DM624TW IC InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
DM624TW CS CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC
DM624TW IK RFUBTTPMWSKEIW-UHFFFAOYSA-N
DM624TW IU methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-yl)carbamoylamino]phenyl]methyl]piperazine-1-carboxylate
DM624TW CA CAS 873697-71-3
DM624TW DE Heart failure
DMBWY8V ID DMBWY8V
DMBWY8V DN Omega-6-FA
DMBWY8V HS Phase 3
DMBWY8V SN Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398
DMBWY8V PC 56842208
DMBWY8V MW 584.9
DMBWY8V FM C38H64O4
DMBWY8V IC ZCDMRPMKAQLWAO-PZLFCYFRSA-N
DMBWY8V CS CCCCCC=CCC=CCCCCCCCC(=O)O.CCCCCC=CCC=CCC=CCC=CCCCC(=O)O
DMBWY8V IK 1S/C20H32O2.C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22);6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-,13-12-,16-15-;7-6-,10-9-
DMBWY8V IU (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid
DMBWY8V DE Attention deficit hyperactivity disorder
DMK6QBZ ID DMK6QBZ
DMK6QBZ DN OMS721
DMK6QBZ HS Phase 3
DMK6QBZ CP Omeros, Seattle, WA
DMK6QBZ DE Thrombotic microangiopathy; Glomerulonephritis; Lupus; Atypical hemolytic uremic syndrome
DMU86DM ID DMU86DM
DMU86DM DN ONO-1101
DMU86DM HS Phase 3
DMU86DM SN Landiolol; Landiolol [INN]; ONO-1101; Ono 1101; (S-(R*,R*))-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 4-(2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)benzenepropanoate; 133242-30-5; 62NWQ924LH; Benzenepropanoic acid, 4-((2S)-2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)-, ((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester; UNII-62NWQ924LH; [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate
DMU86DM PC 114905
DMU86DM MW 509.6
DMU86DM FM C25H39N3O8
DMU86DM IC WMDSZGFJQKSLLH-RBBKRZOGSA-N
DMU86DM CS CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C
DMU86DM IK 1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22+/m0/s1
DMU86DM IU [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate
DMU86DM CA CAS 133242-30-5
DMU86DM CB CHEBI:135809
DMU86DM DE Atrial fibrillation
DM06KRC ID DM06KRC
DM06KRC DN Oregovomab
DM06KRC HS Phase 3
DM06KRC CP Quest PharmaTech
DM06KRC DT Monoclonal antibody
DM06KRC DE Ovarian cancer; Epithelial ovarian cancer
DMWD3IV ID DMWD3IV
DMWD3IV DN Oseltamivir + hydroxychloroquine
DMWD3IV HS Phase 3
DMWD3IV SN Tamiflu + oxichloroquine
DMWD3IV TC Antiviral Agents
DMWD3IV DT Combination drug
DMWD3IV DE Coronavirus Disease 2019 (COVID-19)
DMHKZLF ID DMHKZLF
DMHKZLF DN OSI-906
DMHKZLF HS Phase 3
DMHKZLF SN Linsitinib; 867160-71-2; OSI-906; Linsitinib(OSI-906); OSI906; OSI 906; OSI-906AA; OSI-906 (Linsitinib); UNII-15A52GPT8T; Kinome_3532; ASP-7487; 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol; 15A52GPT8T; CHEMBL1091644; MMV676605; cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol; C26H23N5O; cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol; Linsitinib [USAN:INN]; OSI906/Linsitinib/; Linsitinib; OSI-906
DMHKZLF DT Small molecular drug
DMHKZLF PC 11640390
DMHKZLF MW 421.5
DMHKZLF FM C26H23N5O
DMHKZLF IC InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)
DMHKZLF CS CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O
DMHKZLF IK PKCDDUHJAFVJJB-UHFFFAOYSA-N
DMHKZLF IU 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
DMHKZLF CA CAS 867160-71-2
DMHKZLF CB CHEBI:91402
DMHKZLF DE Solid tumour/cancer
DM7R145 ID DM7R145
DM7R145 DN Otesaconazole
DM7R145 HS Phase 3
DM7R145 SN Oteseconazole; 1340593-59-0; VT-1161; UNII-VHH774W97N; VHH774W97N; CHEMBL3311228; (R)-2-(2,4-Difluorophenyl)-1,1-Difluoro-3-(1h-Tetrazol-1-Yl)-1-(5-(4-(2,2,2-Trifluoroethoxy)phenyl)pyridin-2-Yl)propan-2-Ol; Oteseconazole [USAN]; Oteseconazole (USAN/INN); SCHEMBL17113021; BDBM50046187; WHO 10138; DB13055; SB17420; HY-17643; CS-0016914; D11785; Q27291837; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-{5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl}propan-2-ol; (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol; 2-Pyridineethanol, alpha-(2,4-difluorophenyl)-beta,beta-difluoro-alpha-(1H-tetrazol-1-ylmethyl)-5-(4-(2,2,2-trifluoroethoxy)phenyl)-, (alphaR)-
DM7R145 CP Mycovia Pharmaceuticals
DM7R145 DT Small molecular drug
DM7R145 PC 77050711
DM7R145 MW 527.4
DM7R145 FM C23H16F7N5O2
DM7R145 IC InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1
DM7R145 CS C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
DM7R145 IK IDUYJRXRDSPPRC-NRFANRHFSA-N
DM7R145 IU (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol
DM7R145 CA CAS 1340593-59-0
DM7R145 DE Onychomycosis; Vulvovaginal Candidiasis
DMLMS6J ID DMLMS6J
DMLMS6J DN OTL-101
DMLMS6J HS Phase 3
DMLMS6J CP Orchard Therapeutics
DMLMS6J DT Gene therapy
DMLMS6J DE Severe combined immunodeficiency
DM3BK2Y ID DM3BK2Y
DM3BK2Y DN OTL-103
DM3BK2Y HS Phase 3
DM3BK2Y CP Orchard Therapeutics
DM3BK2Y DT Gene therapy
DM3BK2Y DE Wiskott-Aldrich syndrome
DM5DRMY ID DM5DRMY
DM5DRMY DN P1101
DM5DRMY HS Phase 3
DM5DRMY SN N-Phenylethylenediamine; 1664-40-0; N1-Phenylethane-1,2-diamine; N-(2-Aminoethyl)aniline; 1,2-Ethanediamine, N-phenyl-; Ethylenediamine, N-phenyl-; N-Phenyl-1,2-ethanediamine; 1,2-Ethanediamine, N1-phenyl-; Benzenamine, N-(2-aminoethyl)-; N'-phenylethane-1,2-diamine; N-phenylethane-1,2-diamine; n1-phenyl-1,2-ethanediamine; MFCD00008162; (2-aminoethyl)phenylamine; N-Phenylethylenediamine, 99%; NSC84247; phenylethylenediamine; EINECS 216-773-4; NSC 84247; 2-phenylaminoethylamine; phenyl ethylene diamine; ACMC-209duf; N -phenylethylenediamine; N-phenyl ethylenediamine; N-phenyl ethylene diamine; N-phenyl-ethylene-diamine; N-(2-aminoethyl)-aniline; N-phenyl ethyl-ene diamine; n2-phenyl-1,2-ethanediamine; N-phenyl-ethane-1,2-diamine; SCHEMBL307775; N-Phenylethylenediamine, 98%; N'-phenyl-ethane-1,2-diamine; N1-phenyl-ethane-1,2-diamine; DTXSID1061861; OCIDXARMXNJACB-UHFFFAOYSA-; Ethylenediamine, N-phenyl- (8CI); STR05027; ZINC1736738; 8473AA; ANW-22213; NSC-84247; SBB004200; STL257388; AKOS005135725; LS10740; MCULE-5870561171; NE53436; AC-25457; AK122216; SY009366; DB-043652; CS-0045385; FT-0629102; ST45237853; EN300-81504; J-010281
DM5DRMY CP PharmaEssentia
DM5DRMY DT Small molecular drug
DM5DRMY PC 74270
DM5DRMY MW 136.19
DM5DRMY FM C8H12N2
DM5DRMY IC InChI=1S/C8H12N2/c9-6-7-10-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
DM5DRMY CS C1=CC=C(C=C1)NCCN
DM5DRMY IK OCIDXARMXNJACB-UHFFFAOYSA-N
DM5DRMY IU N'-phenylethane-1,2-diamine
DM5DRMY CA CAS 1664-40-0
DM5DRMY DE Polycythemia vera
DM7WYXJ ID DM7WYXJ
DM7WYXJ DN P-1101
DM7WYXJ HS Phase 3
DM7WYXJ SN Pegylated interferon alpha (hepatitis B and C virus infection), PharmaEssentia; Pegylated interferon alpha-2b (polycythemia vera), AOP Orphan; PEG-INF-alpha (hepatitis B and C virus infection), PharmaEssentia; PEG-P-IFN-alpha-2b
DM7WYXJ CP Hanall biopharma; medtronic
DM7WYXJ DE Hepatitis B virus infection; Essential thrombocythemia; Myelofibrosis
DM9PVHX ID DM9PVHX
DM9PVHX DN P2B-001
DM9PVHX HS Phase 3
DM9PVHX SN Fixed-dose combination therapy (Parkinsons diease), Pharma Two B
DM9PVHX CP Pharma Two B Ltd
DM9PVHX DE Parkinson disease
DM1T6ZN ID DM1T6ZN
DM1T6ZN DN Pacritinib
DM1T6ZN HS Phase 3
DM1T6ZN SN JAK inhibitor (alone or in combination)s
DM1T6ZN CP Cell Therapeutics
DM1T6ZN DT Small molecular drug
DM1T6ZN PC 46216796
DM1T6ZN MW 472.6
DM1T6ZN FM C28H32N4O3
DM1T6ZN IC InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
DM1T6ZN CS C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2
DM1T6ZN IK HWXVIOGONBBTBY-ONEGZZNKSA-N
DM1T6ZN IU (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
DM1T6ZN CA CAS 937272-79-2
DM1T6ZN DE Myelofibrosis
DMFKOR9 ID DMFKOR9
DMFKOR9 DN Pafuramidine
DMFKOR9 HS Phase 3
DMFKOR9 SN Pafuramidine maleate; DB-289; DB-290; DB-75 prodrug, Immtech; Pafuramidine maleate (oral formulation), Strativa
DMFKOR9 CP Immtech International; University of North Carolina
DMFKOR9 DT Small molecular drug
DMFKOR9 PC 5480200
DMFKOR9 MW 364.4
DMFKOR9 FM C20H20N4O3
DMFKOR9 IC InChI=1S/C20H20N4O3/c1-25-23-19(21)15-7-3-13(4-8-15)17-11-12-18(27-17)14-5-9-16(10-6-14)20(22)24-26-2/h3-12H,1-2H3,(H2,21,23)(H2,22,24)
DMFKOR9 CS CO/N=C(\\N)/C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)/C(=N/OC)/N
DMFKOR9 IK UKOQVLAXCBRRGH-UHFFFAOYSA-N
DMFKOR9 IU N'-methoxy-4-[5-[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]furan-2-yl]benzenecarboximidamide
DMFKOR9 CA CAS 186953-56-0
DMFKOR9 DE Malaria
DMAD2OZ ID DMAD2OZ
DMAD2OZ DN Palovarotene
DMAD2OZ HS Phase 3
DMAD2OZ SN R-667; RG-667; Retinoid receptor agonist, Roche; Ro-3300074; Ro-330074
DMAD2OZ CP Roche
DMAD2OZ DT Small molecular drug
DMAD2OZ PC 10295295
DMAD2OZ MW 414.5
DMAD2OZ FM C27H30N2O2
DMAD2OZ IC InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+
DMAD2OZ CS CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C
DMAD2OZ IK YTFHCXIPDIHOIA-DHZHZOJOSA-N
DMAD2OZ IU 4-[(E)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid
DMAD2OZ CA CAS 410528-02-8
DMAD2OZ DE Emphysema; Fibrodysplasia ossificans progressiva
DM4SKYI ID DM4SKYI
DM4SKYI DN PAMAQUESIDE
DM4SKYI HS Phase 3
DM4SKYI SN CP-148623; Pamaqueside < Prop INN; 11-Ketotigogenyl beta-O-cellobioside
DM4SKYI DT Small molecular drug
DM4SKYI PC 9918516
DM4SKYI MW 754.9
DM4SKYI FM C39H62O14
DM4SKYI IC InChI=1S/C39H62O14/c1-17-7-10-39(48-16-17)18(2)27-24(53-39)12-22-21-6-5-19-11-20(8-9-37(19,3)28(21)23(42)13-38(22,27)4)49-35-33(47)31(45)34(26(15-41)51-35)52-36-32(46)30(44)29(43)25(14-40)50-36/h17-22,24-36,40-41,43-47H,5-16H2,1-4H3/t17-,18+,19+,20+,21+,22+,24+,25-,26-,27+,28-,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-/m1/s1
DM4SKYI CS C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC(=O)[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1
DM4SKYI IK VWMZIGBYZQUQOA-QEEMJVPDSA-N
DM4SKYI IU (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-16-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-11-one
DM4SKYI CA CAS 150332-35-7
DM4SKYI DE Hyperlipidaemia
DMIRYU9 ID DMIRYU9
DMIRYU9 DN Pancopride
DMIRYU9 HS Phase 3
DMIRYU9 SN LAS-30451
DMIRYU9 CP Almirall Prodesfarma SA
DMIRYU9 DT Small molecular drug
DMIRYU9 PC 71342
DMIRYU9 MW 349.9
DMIRYU9 FM C18H24ClN3O2
DMIRYU9 IC InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23)
DMIRYU9 CS C1CC1COC2=CC(=C(C=C2C(=O)NC3CN4CCC3CC4)Cl)N
DMIRYU9 IK DBQMQBCSKXTCIJ-UHFFFAOYSA-N
DMIRYU9 IU 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-(cyclopropylmethoxy)benzamide
DMIRYU9 DE Nausea
DMEW5Z8 ID DMEW5Z8
DMEW5Z8 DN PARABEN
DMEW5Z8 HS Phase 3
DM3H2U4 ID DM3H2U4
DM3H2U4 DN Patrome
DM3H2U4 HS Phase 3
DM3H2U4 CP GlaxoSmithKline
DM3H2U4 DE Parkinson disease
DMHXTAQ ID DMHXTAQ
DMHXTAQ DN Pazufloxacin
DMHXTAQ HS Phase 3
DMHXTAQ SN 127045-41-4; T-3761; UNII-4CZ1R38NDI; 4CZ1R38NDI; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; Pazufloxacin [INN]; SMR000466380; CCRIS 7312; CAS-127045-41-4; T 3761; 127046-18-8; PZFX; Pazufloxacin (JAN/INN); SCHEMBL34460; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; MLS000759513; MLS001424116; CHEMBL240163; DTXSID5046697; CHEBI:94700; HY-B0724B; HMS2051B05; HMS2090H07; BCP12954; LSM-5745; RKL10069; ZINC3779726; Tox21_112531; BDBM50248017; MFCD00865012; AKOS015900451; Tox21_112531_1; AC-3506; CCG-100919; DB11774; GM-1171; KS-5008; NC00169; NCGC00167534-02; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-; AB0012715; D01153; AB00639918-07; AB00639918-09; AB00639918_10; Pazufloxacin, VETRANAL(TM), analytical standard; SR-01000759348; J-005457; Q3898423; SR-01000759348-4; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-
DMHXTAQ DT Small molecular drug
DMHXTAQ PC 65957
DMHXTAQ MW 318.3
DMHXTAQ FM C16H15FN2O4
DMHXTAQ IC InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
DMHXTAQ CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
DMHXTAQ IK XAGMUUZPGZWTRP-ZETCQYMHSA-N
DMHXTAQ IU (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMHXTAQ CA CAS 127045-41-4
DMHXTAQ CB CHEBI:94700
DMHXTAQ DE Conjunctivitis
DMP3G0W ID DMP3G0W
DMP3G0W DN Pazufloxacin
DMP3G0W HS Phase 3
DMP3G0W SN Pazufloxacin; T-3761; Pazufloxacin [INN]; UNII-4CZ1R38NDI; CCRIS 7312; T 3761; 4CZ1R38NDI; C16H15FN2O4; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; SMR000466380; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
DMP3G0W PC 65957
DMP3G0W MW 318.3
DMP3G0W FM C16H15FN2O4
DMP3G0W IC InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
DMP3G0W CS CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
DMP3G0W IK XAGMUUZPGZWTRP-ZETCQYMHSA-N
DMP3G0W IU (2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMP3G0W CA CAS 127045-41-4
DMP3G0W CB CHEBI:94700
DMP3G0W DE Bacterial conjunctivitis
DMJBHO0 ID DMJBHO0
DMJBHO0 DN PC-DAC:Insulin
DMJBHO0 HS Phase 3
DMJBHO0 SN Capsulin; Intesulin; Macrulin; Nodlin; SuliXen; AERx Diabetes Management System; AERx iDMS; Capsulin IR; Capsulin OAD; Capsulin insulin replacement; Insulin tregopil; Ultrafast Insulin program; HIM2; AERx (insulin); AT-1391; AT-2391; Analog-PH20; CADDYS (insulin); CJC-1530; CJC-1531; CJC-1575; CJC-1576; Capsulin oral anti-diabetic; DTY-001; GW-843362; GW-843362M; Hexyl insulin monoconjugate, Nobex; IN-105; Inhaled insulin, Andaris; Insulin-PH20; Intesulin-1; Intesulin-IVE; NB-058; NIN-058; NN-1998; ORMD-0801; Oral insulin, Emisphere; Oral insulin, Nobex; PC-Insulin; Inhaled insulin, QDose/BMS; Inhaled insulin, Quadrant/MicroDose; Insulin (inhaled), Aradigm; Insulin (inhaled), QDose; Insulin (inhaled),Translational Research; Insulin (oral), Biocon; Insulin (oral), Coremed; Insulin (oral), Protein Delivery Inc; Insulin (pulmonary), Translational Research; MicroPor (insulin), Altea
DMJBHO0 CP Lipoxen plc; Aradigm; Translational Research Ltd; Diabetology Ltd; Coremed Inc; Nobex Corp; Altea Therapeutics; ConjuChem Biotechnologies Inc; Bioglan Pharmaceuticals Co; Epic Therapeutics Inc; NOD Pharmaceuticals Inc; Andaris Group Ltd; Emisphere Technologies Inc; halozyme therapeutics
DMJBHO0 DE Type-1 diabetes; Type-2 diabetes
DMMBC5W ID DMMBC5W
DMMBC5W DN PDGF-BB
DMMBC5W HS Phase 3
DMMBC5W SN PDGF-BB (BioChaperone technology, diabetic foot ulcer/venous ulcers/burns)
DMMBC5W CP Adocia SAS
DMMBC5W DE Diabetic foot ulcer
DM53J6B ID DM53J6B
DM53J6B DN PDR001
DM53J6B HS Phase 3
DM53J6B CP Novartis Oncology East Hanover, NJ
DM53J6B DT Antibody
DM53J6B DE Lymphoma; Neuroendocrine cancer; Solid tumour/cancer; Melanoma; Esophageal squamous cell carcinoma
DMBKWAF ID DMBKWAF
DMBKWAF DN Peg-G-CSF
DMBKWAF HS Phase 3
DMBKWAF SN Peg-G-CSF (chemotherapy induced side effects)
DMBKWAF CP Phage Biotechnology Corp
DMBKWAF DE Solid tumour/cancer
DMK6OFY ID DMK6OFY
DMK6OFY DN Peginterferon lambda-1a
DMK6OFY HS Phase 3
DMK6OFY SN BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb
DMK6OFY CP Bristol-myers squibb
DMK6OFY DE Acute myeloid leukaemia
DMESAZK ID DMESAZK
DMESAZK DN Peretinoin
DMESAZK HS Phase 3
DMESAZK SN Polyprenoic acid; E-5166; NIK-333; Peretinoin (oral); Peretinoin (oral), Kowa; Peretinoin (oral formulation, hepatocellular carcinoma), Kowa Pharmaceutical
DMESAZK CP Kowa Pharmaceutical Co Ltd; Eisai Co Ltd
DMESAZK DT Small molecular drug
DMESAZK PC 6437836
DMESAZK MW 302.5
DMESAZK FM C20H30O2
DMESAZK IC InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+
DMESAZK CS CC(=CCC/C(=C/CC/C(=C/C=C/C(=C/C(=O)O)/C)/C)/C)C
DMESAZK IK UUBHZHZSIKRVIV-KCXSXWJSSA-N
DMESAZK IU (2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid
DMESAZK CA CAS 81485-25-8
DMESAZK DE Hepatocellular carcinoma
DMUP5Z0 ID DMUP5Z0
DMUP5Z0 DN PF-03084014
DMUP5Z0 HS Phase 3
DMUP5Z0 SN Nirogacestat; 1290543-63-3; PF-03084014; PF-3084014; UNII-QZ62892OFJ; 865773-15-5; PF 3084014; PF-03084014 (PF-3084014); QZ62892OFJ; Z-3181; PF03084014; Nirogacestat [USAN]; Nirogacestat (USAN/INN); GTPL7746; SCHEMBL13184754; CHEMBL1770916; EX-A855; DTXSID60235679; MolPort-039-193-852; (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide; ZINC38217837; s8018; AKOS030526383; SB16726; DB12005; CS-1689; NCGC00378713-01
DMUP5Z0 CP Pfizer
DMUP5Z0 DT Small molecular drug
DMUP5Z0 PC 46224413
DMUP5Z0 MW 489.6
DMUP5Z0 FM C27H41F2N5O
DMUP5Z0 IC InChI=1S/C27H41F2N5O/c1-7-8-23(32-20-10-9-18-11-19(28)12-22(29)21(18)13-20)25(35)33-24-14-34(17-31-24)27(5,6)16-30-15-26(2,3)4/h11-12,14,17,20,23,30,32H,7-10,13,15-16H2,1-6H3,(H,33,35)/t20-,23-/m0/s1
DMUP5Z0 CS CCC[C@@H](C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)N[C@H]2CCC3=C(C2)C(=CC(=C3)F)F
DMUP5Z0 IK VFCRKLWBYMDAED-REWPJTCUSA-N
DMUP5Z0 IU (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide
DMUP5Z0 CA CAS 1290543-63-3
DMUP5Z0 DE Alzheimer disease; Solid tumour/cancer; Desmoid tumour
DM0TWCY ID DM0TWCY
DM0TWCY DN PF-04950615
DM0TWCY HS Phase 3
DM0TWCY CP Pfizer New York, NY
DM0TWCY DT Antibody
DM0TWCY DE Hypercholesterolaemia
DM8J29L ID DM8J29L
DM8J29L DN PF-04965842
DM8J29L HS Phase 3
DM8J29L PC 78323835
DM8J29L MW 323.42
DM8J29L FM C14H21N5O2S
DM8J29L IC InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)
DM8J29L CS CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3
DM8J29L IK IUEWXNHSKRWHDY-UHFFFAOYSA-N
DM8J29L IU N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
DM8J29L CA CAS 1622902-68-4
DM8J29L DE Lupus; Atopic dermatitis
DM23BUP ID DM23BUP
DM23BUP DN PF-05280014
DM23BUP HS Phase 3
DM23BUP CP Pfizer
DM23BUP DE Breast cancer
DMNZOCK ID DMNZOCK
DMNZOCK DN PF-05280586
DMNZOCK HS Phase 3
DMNZOCK CP Pfizer
DMNZOCK DE Cluster headache; Follicular lymphoma
DM2GF14 ID DM2GF14
DM2GF14 DN PF-06410293
DM2GF14 HS Phase 3
DM2GF14 CP Pfizer
DM2GF14 DT Antibody
DM2GF14 DE Rheumatoid arthritis
DMM4C95 ID DMM4C95
DMM4C95 DN PF-06438179
DMM4C95 HS Phase 3
DMM4C95 CP Pfizer
DMM4C95 DE Rheumatoid arthritis
DMVHZDP ID DMVHZDP
DMVHZDP DN PF-06439535
DMVHZDP HS Phase 3
DMVHZDP CP Pfizer
DMVHZDP DT Antibody
DMVHZDP DE Solid tumour/cancer; Non-small-cell lung cancer
DMW63TQ ID DMW63TQ
DMW63TQ DN PF-06741086
DMW63TQ HS Phase 3
DMW63TQ SN marstacimab
DMW63TQ CP Pfizer
DMW63TQ DT Antibody
DMW63TQ DE Hemophilia
DMWPA4L ID DMWPA4L
DMWPA4L DN PF-07055480
DMWPA4L HS Phase 3
DMWPA4L SN giroctocogene fitelparvovec
DMWPA4L CP Pfizer
DMWPA4L DT Gene therapy
DMWPA4L DE Haemophilia A
DMS1EQ7 ID DMS1EQ7
DMS1EQ7 DN PF-1228305
DMS1EQ7 HS Phase 3
DMS1EQ7 SN Sitaxentan sodium; Sitaxsentan sodium
DMS1EQ7 CP Pfizer
DMS1EQ7 DT Small molecular drug
DMS1EQ7 PC 11477084
DMS1EQ7 MW 476.9
DMS1EQ7 FM C18H14ClN2NaO6S2
DMS1EQ7 IC InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
DMS1EQ7 CS CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+]
DMS1EQ7 IK MDTNUYUCUYPIHE-UHFFFAOYSA-N
DMS1EQ7 IU sodium;(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide
DMS1EQ7 CA CAS 210421-74-2
DMS1EQ7 DE Pulmonary hypertension
DMJ7IKW ID DMJ7IKW
DMJ7IKW DN PF-4494700
DMJ7IKW HS Phase 3
DMJ7IKW SN PF-04494700; TTP-488; TTP-488); Alzheimers therapy, TransTech/Pfizer; Diabetic nephropathy therapy, Transtech/Pfizer; Alzheimer'streatment, TransTech/Pfizer; Alzheimer's therapy (RAGE), Transtech/Pfizer
DMJ7IKW CP Transtech pharma
DMJ7IKW DT Small molecular drug
DMJ7IKW PC 11180124
DMJ7IKW MW 532.1
DMJ7IKW FM C32H38ClN3O2
DMJ7IKW IC InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
DMJ7IKW CS CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC
DMJ7IKW IK KJNNWYBAOPXVJY-UHFFFAOYSA-N
DMJ7IKW IU 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine
DMJ7IKW CA CAS 603148-36-3
DMJ7IKW DE Dementia; Alzheimer disease
DM5DAP3 ID DM5DAP3
DM5DAP3 DN PGF2ALPHA-IE
DM5DAP3 HS Phase 3
DM5DAP3 SN Prostaglandin F2alpha isopropyl ester; (5Z,9alpha,11alpha,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dien-1-oic acid isopropyl ester
DM5DAP3 DT Small molecular drug
DM5DAP3 PC 5283077
DM5DAP3 MW 396.6
DM5DAP3 FM C23H40O5
DM5DAP3 IC InChI=1S/C23H40O5/c1-4-5-8-11-18(24)14-15-20-19(21(25)16-22(20)26)12-9-6-7-10-13-23(27)28-17(2)3/h6,9,14-15,17-22,24-26H,4-5,7-8,10-13,16H2,1-3H3/b9-6-,15-14+/t18-,19+,20+,21-,22+/m0/s1
DM5DAP3 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)OC(C)C)O)O)O
DM5DAP3 IK FPABVZYYTCHNMK-YNRDDPJXSA-N
DM5DAP3 IU propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoate
DM5DAP3 CA CAS 53764-90-2
DM5DAP3 CB CHEBI:165336
DM5DAP3 DE Glaucoma/ocular hypertension
DM8Y12A ID DM8Y12A
DM8Y12A DN PH-80
DM8Y12A HS Phase 3
DM8Y12A SN Vomeropherin (premenstrual syndrome), Pherin; Vomeropherin (premenstrual syndrome), Pherin/ Organon
DM8Y12A CP Pherin Corp
DM8Y12A DE Premenstrual syndrome
DMDC7OH ID DMDC7OH
DMDC7OH DN PH94B NS
DMDC7OH HS Phase 3
DMDC7OH SN Aloradine IN; Aloradine NS
DMDC7OH CP Pherin Pharmaceuticals Los Altos, CA
DMDC7OH DE Social anxiety disorder
DMVEHM4 ID DMVEHM4
DMVEHM4 DN Phentermine+topiramate
DMVEHM4 HS Phase 3
DMVEHM4 SN Qnexa (TN)
DMVEHM4 CP Vivus
DMVEHM4 DT Small molecular drug
DMVEHM4 PC 56842108
DMVEHM4 MW 488.6
DMVEHM4 FM C22H36N2O8S
DMVEHM4 IC InChI=1S/C12H21NO8S.C10H15N/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12;1-10(2,11)8-9-6-4-3-5-7-9/h7-9H,5-6H2,1-4H3,(H2,13,14,15);3-7H,8,11H2,1-2H3/t7-,8-,9?,12+;/m1./s1
DMVEHM4 CS CC1(O[C@@H]2CO[C@@]3(C([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C.CC(C)(CC1=CC=CC=C1)N
DMVEHM4 IK PWDLDBWXTVILPC-QGGVPXFVSA-N
DMVEHM4 IU 2-methyl-1-phenylpropan-2-amine;[(1R,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate
DMVEHM4 CA CAS 960078-81-3
DMVEHM4 DE Obesity
DMGZPX6 ID DMGZPX6
DMGZPX6 DN PI-88
DMGZPX6 HS Phase 3
DMGZPX6 SN CHEMBL603733
DMGZPX6 CP Progen Industries
DMGZPX6 TC Anticancer Agents
DMGZPX6 DT Small molecular drug
DMGZPX6 PC 46233427
DMGZPX6 MW 2516.5
DMGZPX6 FM C30H35Na15O77PS16-3
DMGZPX6 IC InChI=1S/C30H53O77PS16.15Na/c31-108(32,33)82-1-6-14(99-116(55,56)57)20(102-119(64,65)66)25(106-123(76,77)78)29(87-6)94-17-12(97-114(49,50)51)8(3-84-110(37,38)39)89-27(23(17)104-121(70,71)72)92-16-11(96-113(46,47)48)7(2-83-109(34,35)36)88-26(22(16)103-120(67,68)69)93-18-13(98-115(52,53)54)9(4-85-111(40,41)42)90-28(24(18)105-122(73,74)75)95-21-19(101-118(61,62)63)15(100-117(58,59)60)10(5-86-112(43,44)45)91-30(21)107-124(79,80)81;;;;;;;;;;;;;;;/h6-30H,1-5H2,(H2,31,32,33)(H,34,35,36)(H,37,38,39)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81);;;;;;;;;;;;;;;/q;15*+1/p-18/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-;;;;;;;;;;;;;;;/m1.............../s1
DMGZPX6 CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O[C@H]2[C@@H]([C@H](O[C@@H]([C@H]2OS(=O)(=O)[O-])O[C@H]3[C@@H]([C@H](O[C@@H]([C@H]3OS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H](O[C@@H]([C@H]4OS(=O)(=O)[O-])O[C@H]5[C@H]([C@@H]([C@H](O[C@@H]5OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMGZPX6 IK FIYNUMVQYZZZCH-JSZMYKOGSA-A
DMGZPX6 IU pentadecasodium;[(2R,3R,4S,5S,6R)-6-[(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5R,6R)-2-[(2R,3R,4S,5S,6R)-3,5-disulfonatooxy-2-(sulfonatooxymethyl)-6-[(2R,3S,4R,5R,6R)-2,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,4,5-trisulfonatooxyoxan-2-yl]methyl phosphate
DMGZPX6 DE Prostate cancer; Hepatocellular carcinoma
DM7OSHC ID DM7OSHC
DM7OSHC DN Pinaverium bromide
DM7OSHC HS Phase 3
DM7OSHC SN Dicetel; Bromure de pinaverium; Bromuro de pinaverio; Pinaverii bromidum; Pinaverium bromide [INN]; LAT 1717; Bromure de pinaverium [INN-French]; Bromuro de pinaverio [INN-Spanish]; Dicetel (TN); Pinaverii bromidum [INN-Latin]; Pinaverium bromide (INN); Morpholinium, 4-(2-bromo-4,5-dimethoxy)benzyl-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, bromide; 4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium bromide; 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium bromide
DM7OSHC CP Solvay
DM7OSHC DT Small molecular drug
DM7OSHC PC 40703
DM7OSHC MW 591.4
DM7OSHC FM C26H41Br2NO4
DM7OSHC IC InChI=1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1
DM7OSHC CS CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C.[Br-]
DM7OSHC IK IKGXLCMLVINENI-UHFFFAOYSA-M
DM7OSHC IU 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium;bromide
DM7OSHC CA CAS 53251-94-8
DM7OSHC DE Irritable bowel syndrome
DMRG1X3 ID DMRG1X3
DMRG1X3 DN Pirtobrutinib
DMRG1X3 HS Phase 3
DMRG1X3 SN BTK inhibitor 16; 2101700-15-4; Pirtobrutinib [USAN]; UNII-JNA39I7ZVB; JNA39I7ZVB; LOXO-305; SCHEMBL19014257; WHO 11681; HY-131328; LY3527727; CS-0133286; (S)-5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide; 1H-Pyrazole-4-carboxamide, 5-amino-3-(4-(((5-fluoro-2-methoxybenzoyl)amino)methyl)phenyl)-1-((1S)-2,2,2-trifluoro-1-methylethyl)-
DMRG1X3 CP LOXO Oncology
DMRG1X3 DT Small molecular drug
DMRG1X3 PC 129269915
DMRG1X3 MW 479.4
DMRG1X3 FM C22H21F4N5O3
DMRG1X3 IC InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1
DMRG1X3 CS C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N
DMRG1X3 IK FWZAWAUZXYCBKZ-NSHDSACASA-N
DMRG1X3 IU 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
DMRG1X3 CA CAS 2101700-15-4
DMRG1X3 DE Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMQGR45 ID DMQGR45
DMQGR45 DN Pixantrone
DMQGR45 HS Phase 3
DMQGR45 SN Pixuvri (TN)
DMQGR45 CP Cell Therapeutics
DMQGR45 DT Small molecular drug
DMQGR45 PC 134019
DMQGR45 MW 325.4
DMQGR45 FM C17H19N5O2
DMQGR45 IC InChI=1S/C17H19N5O2/c18-4-7-21-12-1-2-13(22-8-5-19)15-14(12)16(23)10-3-6-20-9-11(10)17(15)24/h1-3,6,9,21-22H,4-5,7-8,18-19H2
DMQGR45 CS C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN
DMQGR45 IK PEZPMAYDXJQYRV-UHFFFAOYSA-N
DMQGR45 IU 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione
DMQGR45 CA CAS 144510-96-3
DMQGR45 CB CHEBI:135945
DMQGR45 DE Multiple sclerosis; Follicular lymphoma; Diffuse large B-cell lymphoma; Pediatric cancer
DMCA6BW ID DMCA6BW
DMCA6BW DN Pixykine
DMCA6BW HS Phase 3
DMCA6BW SN Milodistim; Plasmid Immunex yeast 321; PIXY-321
DMCA6BW CP Immunex Corp
DMCA6BW DE Human immunodeficiency virus infection
DM1RWMY ID DM1RWMY
DM1RWMY DN Plasma derived factor VIII PEGylated liposomal
DM1RWMY HS Phase 3
DM1RWMY SN LongAte; NecLip-pdFVIII; Plasma derived factor VIII (PEGylated liposomal (NecLip), hemophilia A), Recoly
DM1RWMY CP Recoly NV
DM1RWMY DE Factor VIII deficiency
DMD7L48 ID DMD7L48
DMD7L48 DN Plinabulin
DMD7L48 HS Phase 3
DMD7L48 SN NPI-2358
DMD7L48 CP Nereus Pharmaceuticals
DMD7L48 DT Small molecular drug
DMD7L48 PC 9949641
DMD7L48 MW 336.4
DMD7L48 FM C19H20N4O2
DMD7L48 IC InChI=1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
DMD7L48 CS CC(C)(C)C1=C(N=CN1)/C=C\\2/C(=O)N/C(=C\\C3=CC=CC=C3)/C(=O)N2
DMD7L48 IK UNRCMCRRFYFGFX-TYPNBTCFSA-N
DMD7L48 IU (3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]piperazine-2,5-dione
DMD7L48 CA CAS 714272-27-2
DMD7L48 DE Non-small-cell lung cancer
DMJ8AUE ID DMJ8AUE
DMJ8AUE DN Plitidepsin
DMJ8AUE HS Phase 3
DMJ8AUE SN Aplidin (TN)
DMJ8AUE CP PharmaMar
DMJ8AUE DT Small molecular drug
DMJ8AUE PC 9812534
DMJ8AUE MW 1110.3
DMJ8AUE FM C57H87N7O15
DMJ8AUE IC InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1
DMJ8AUE CS CC[C@H](C)[C@@H]1[C@H](CC(=O)O[C@H](C(=O)[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
DMJ8AUE IK UUSZLLQJYRSZIS-LXNNNBEUSA-N
DMJ8AUE IU (2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
DMJ8AUE CA CAS 137219-37-5
DMJ8AUE CB CHEBI:90205
DMJ8AUE DE Multiple myeloma; Angioimmunoblastic T-cell Lymphoma
DMV8EXG ID DMV8EXG
DMV8EXG DN PolyHeme
DMV8EXG HS Phase 3
DMV8EXG SN Oxygen-carrying blood substitute, Northfield Laboratories
DMV8EXG CP Northfield Laboratories
DMV8EXG PC 72941846
DMV8EXG MW 347.26
DMV8EXG FM C13H18NO8P
DMV8EXG IC InChI=1S/C8H10NO6P.C5H8O2/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14;6-4-2-1-3-5-7/h2-3,11H,4H2,1H3,(H2,12,13,14);4-5H,1-3H2
DMV8EXG CS CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O.C(CC=O)CC=O
DMV8EXG IK SKKYPUWZZNPUMG-UHFFFAOYSA-N
DMV8EXG IU (4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate;pentanedial
DMV8EXG DE Blood forming organ disorder
DMTD7AB ID DMTD7AB
DMTD7AB DN Pracinostat
DMTD7AB HS Phase 3
DMTD7AB SN Pracinostat; 929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)-
DMTD7AB CP MEI Pharma
DMTD7AB DT Small molecular drug
DMTD7AB PC 49855250
DMTD7AB MW 358.5
DMTD7AB FM C20H30N4O2
DMTD7AB IC InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
DMTD7AB CS CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)/C=C/C(=O)NO
DMTD7AB IK JHDKZFFAIZKUCU-ZRDIBKRKSA-N
DMTD7AB IU (E)-3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide
DMTD7AB CA CAS 929016-96-6
DMTD7AB CB CHEBI:95071
DMTD7AB DE Myelofibrosis; Myelodysplastic syndrome; Acute myeloid leukaemia
DM2ZYX9 ID DM2ZYX9
DM2ZYX9 DN Pradaxa
DM2ZYX9 HS Phase 3
DM2ZYX9 SN Dabigatran etexilate mesylate; 872728-81-9; XETBXHPXHHOLOE-UHFFFAOYSA-N; CP0128; FT-0660872; ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulphonate; 1-methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-amino-methyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide mesylate
DM2ZYX9 CP Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM2ZYX9 PC 11434065
DM2ZYX9 MW 723.8
DM2ZYX9 FM C35H45N7O8S
DM2ZYX9 IC InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)
DM2ZYX9 CS CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\\N.CS(=O)(=O)O
DM2ZYX9 IK XETBXHPXHHOLOE-UHFFFAOYSA-N
DM2ZYX9 IU ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid
DM2ZYX9 CA CAS 872728-81-9
DM2ZYX9 DE Stroke
DMOMDXI ID DMOMDXI
DMOMDXI DN Pratosartan
DMOMDXI HS Phase 3
DMOMDXI SN KD3-671; KT3-671
DMOMDXI CP Kotobuki Pharmaceutical Co Ltd
DMOMDXI DT Small molecular drug
DMOMDXI PC 9802561
DMOMDXI MW 426.5
DMOMDXI FM C25H26N6O
DMOMDXI IC InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)
DMOMDXI CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)CCCC2
DMOMDXI IK KCTFTBCZZUBAKN-UHFFFAOYSA-N
DMOMDXI IU 2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6,7,8-tetrahydrocyclohepta[d]imidazol-4-one
DMOMDXI CA CAS 153804-05-8
DMOMDXI CB CHEBI:32041
DMOMDXI DE Hypertension
DMLSOB7 ID DMLSOB7
DMLSOB7 DN Premarin/Pravachol
DMLSOB7 HS Phase 3
DMLSOB7 SN Estrogen/Eptastatin
DMLSOB7 CP Bristol-Myers Squibb
DMLSOB7 DE Hyperlipidaemia
DMX9YLR ID DMX9YLR
DMX9YLR DN Pridopidine
DMX9YLR HS Phase 3
DMX9YLR SN PRIDOPIDINE; 346688-38-8; 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine; 4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine; ACR-16; UNII-HD4TW8S2VK; ACR16; ACR 16; HD4TW8S2VK; CHEMBL596802; FR310826; Pridopidine [USAN:INN]; Pridopidine (USAN/INN); 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine; SCHEMBL166748; CTK4H2809; DTXSID90188225; ASP 2314; ZINC22063703; BDBM50308028; AKOS015891431; DB11947; NCGC00386586-01; HY-10684; AS-50146; AJ-80925; FR 310826; DB-014417; AX8258340; CS-0002733; FT-0672149; Huntexil; Pridopidine hydrochloride; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co
DMX9YLR CP Teva pharmaceutical
DMX9YLR DT Small molecular drug
DMX9YLR PC 9795739
DMX9YLR MW 281.4
DMX9YLR FM C15H23NO2S
DMX9YLR IC InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3
DMX9YLR CS CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
DMX9YLR IK YGKUEOZJFIXDGI-UHFFFAOYSA-N
DMX9YLR IU 4-(3-methylsulfonylphenyl)-1-propylpiperidine
DMX9YLR CA CAS 346688-38-8
DMX9YLR DE Huntington disease
DMD1FTP ID DMD1FTP
DMD1FTP DN PRO-140
DMD1FTP HS Phase 3
DMD1FTP SN PRO-140 (sc); Humanized monoclonal anibody (subcutaneous, HIV infection), Progenics; PRO-140 (subcutaneous, HIV); CCR5 antagonist (subcutaneous, humanized mAb, HIV infection), Progenics; PRO-140 (subcutaneous, HIV), Progenics Pharmaceuticals
DMD1FTP CP Progenics Pharmaceuticals Inc
DMD1FTP DE Human immunodeficiency virus infection
DM5FZH4 ID DM5FZH4
DM5FZH4 DN ProstaVac
DM5FZH4 HS Phase 3
DM5FZH4 SN Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis); Pox virus vector prostate specific antigen vaccine (benign prostatic hyperplasia/prostatitis), AmVac
DM5FZH4 CP AmVac AG
DM5FZH4 DT Vaccine
DM5FZH4 DE Prostate hyperplasia
DMVU8RW ID DMVU8RW
DMVU8RW DN PRT4445
DMVU8RW HS Phase 3
DMVU8RW CP Portola pharmaceuticals
DMVU8RW DE Bleeding disorder
DMEH641 ID DMEH641
DMEH641 DN PRX-302
DMEH641 HS Phase 3
DMEH641 CP Sophiris
DMEH641 DE Prostate cancer
DMIZJ8M ID DMIZJ8M
DMIZJ8M DN Psoralen
DMIZJ8M HS Phase 3
DMIZJ8M SN Psoralen; 66-97-7; 7H-Furo[3,2-g]chromen-7-one; Ficusin; Furocoumarin; Psoralene; 7H-Furo[3,2-g][1]benzopyran-7-one; Psorline-P; 6,7-Furanocoumarin; furo[3,2-g]chromen-7-one; Furo[3,2-g]coumarin; Furo(4',5',6,7)coumarin; Furo(2',3',7,6)coumarin; Furo(3,2-g)-coumarin; Furo[4',5':6,7]coumarin; Furo[2',3':7,6]coumarin; NSC 404562; UNII-KTZ7ZCN2EX; 7H-Furo(3,2-g)(1)benzopyran-7-one; 7H-Furo[3,2-g]benzopyran-7-one; CCRIS 4343; Furo[2'.3':7.6]coumarin; HSDB 3528; KTZ7ZCN2EX; EINECS 200-639-7; 6-Hydroxy-5-benzofuranacrylic acid beta-lacto
DMIZJ8M DT Small molecular drug
DMIZJ8M PC 6199
DMIZJ8M MW 186.16
DMIZJ8M FM C11H6O3
DMIZJ8M IC InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H
DMIZJ8M CS C1=CC(=O)OC2=CC3=C(C=CO3)C=C21
DMIZJ8M IK ZCCUUQDIBDJBTK-UHFFFAOYSA-N
DMIZJ8M IU furo[3,2-g]chromen-7-one
DMIZJ8M CA CAS 66-97-7
DMIZJ8M CB CHEBI:27616
DMTSN8L ID DMTSN8L
DMTSN8L DN PT005
DMTSN8L HS Phase 3
DMTSN8L SN Perforomist; Atock; Foradil Aerolizer; Foradil Certihaler; YM-08316; Broncoral; Eolus; Oxis Turbuhaler; BD-40A; Eformoterol fumarate; Formoterol Easyhaler; CGP-25827A; AC1OCEVQ; PT-005
DMTSN8L CP Pearl Therapeutics
DMTSN8L DT Small molecular drug
DMTSN8L PC 6917983
DMTSN8L MW 822.9
DMTSN8L FM C42H54N4O13
DMTSN8L IC InChI=1S/2C19H24N2O4.C4H4O4.H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);1H2/b;;2-1+;/t2*13-,19+;;/m11../s1
DMTSN8L CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=CC(=C(C=C2)O)NC=O)O.C(=C/C(=O)O)\\C(=O)O.O
DMTSN8L IK BPXZSHHCUKRDHD-HTLUESNNSA-N
DMTSN8L IU (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate
DMTSN8L DE Chronic obstructive pulmonary disease
DML1KTO ID DML1KTO
DML1KTO DN PT2977
DML1KTO HS Phase 3
DML1KTO SN MK-6482
DML1KTO CP Peloton Therapeutics Dallas, TX
DML1KTO PC 117947097
DML1KTO MW 383.3
DML1KTO FM C17H12F3NO4S
DML1KTO IC InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
DML1KTO CS CS(=O)(=O)C1=C2[C@@H]([C@@H]([C@@H](C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
DML1KTO IK LOMMPXLFBTZENJ-ZACQAIPSSA-N
DML1KTO IU 3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile
DML1KTO CA CAS 1672668-24-4
DML1KTO DE Solid tumour/cancer; Von hippel-lindau disease; Renal cell carcinoma
DMMJ63A ID DMMJ63A
DMMJ63A DN PT-304
DMMJ63A HS Phase 3
DMMJ63A SN 149486-04-4; Thiourea, N-(2-(3-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(3-fluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 3; AC1MHDMA; SCHEMBL6964163; CHEMBL253995; BDBM1896; DTXSID20164299; 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030941; 1-(2-Thiazolyl)-3-[3-fluorophenethyl]thiourea; N-(2-(3-Fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(3-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea
DMMJ63A DT Small molecular drug
DMMJ63A PC 3001163
DMMJ63A MW 281.4
DMMJ63A FM C12H12FN3S2
DMMJ63A IC InChI=1S/C12H12FN3S2/c13-10-3-1-2-9(8-10)4-5-14-11(17)16-12-15-6-7-18-12/h1-3,6-8H,4-5H2,(H2,14,15,16,17)
DMMJ63A CS C1=CC(=CC(=C1)F)CCNC(=S)NC2=NC=CS2
DMMJ63A IK NDHSDDFIIZKISX-UHFFFAOYSA-N
DMMJ63A IU 1-[2-(3-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMMJ63A CA CAS 149486-04-4
DMVDCGZ ID DMVDCGZ
DMVDCGZ DN Pyridoxamine
DMVDCGZ HS Phase 3
DMVDCGZ SN Pyridorin (TN)
DMVDCGZ CP Nephrogenex
DMVDCGZ DT Small molecular drug
DMVDCGZ PC 1052
DMVDCGZ MW 168.19
DMVDCGZ FM C8H12N2O2
DMVDCGZ IC InChI=1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3
DMVDCGZ CS CC1=NC=C(C(=C1O)CN)CO
DMVDCGZ IK NHZMQXZHNVQTQA-UHFFFAOYSA-N
DMVDCGZ IU 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol
DMVDCGZ CA CAS 85-87-0
DMVDCGZ CB CHEBI:16410
DMVDCGZ DE Diabetic nephropathy; Diabetic kidney disease
DMPCFXN ID DMPCFXN
DMPCFXN DN QAW-039
DMPCFXN HS Phase 3
DMPCFXN DE Asthma
DMDU5Y2 ID DMDU5Y2
DMDU5Y2 DN QPI-1002
DMDU5Y2 HS Phase 3
DMDU5Y2 CP Quark Pharmaceuticals
DMDU5Y2 TC siRNA
DMDU5Y2 DT siRNA drug
DMDU5Y2 DE Renal artery disease; Renal transplantation
DMUWXEB ID DMUWXEB
DMUWXEB DN QPI-1007
DMUWXEB HS Phase 3
DMUWXEB SN SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
DMUWXEB CP Quark pharmaceuticals
DMUWXEB DT siRNA drug
DMUWXEB DE Glaucoma/ocular hypertension; Ischemic optic neuropathy; Non-arteritic anterior ischemic optic neuropathy
DMDCQW0 ID DMDCQW0
DMDCQW0 DN Quinotolast
DMDCQW0 HS Phase 3
DMDCQW0 SN Aslock; Quinotalast; FK-021; FR-71021
DMDCQW0 CP Fujisawa Pharmaceutical Co Ltd
DMDCQW0 DT Small molecular drug
DMDCQW0 PC 65871
DMDCQW0 MW 348.32
DMDCQW0 FM C17H12N6O3
DMDCQW0 IC InChI=1S/C17H12N6O3/c24-15(18-17-19-21-22-20-17)12-10-14(26-11-6-2-1-3-7-11)13-8-4-5-9-23(13)16(12)25/h1-10H,(H2,18,19,20,21,22,24)
DMDCQW0 CS C1=CC=C(C=C1)OC2=C3C=CC=CN3C(=O)C(=C2)C(=O)NC4=NNN=N4
DMDCQW0 IK ZUPLNRDTYQWUHP-UHFFFAOYSA-N
DMDCQW0 IU 4-oxo-1-phenoxy-N-(2H-tetrazol-5-yl)quinolizine-3-carboxamide
DMDCQW0 CA CAS 101193-40-2
DMDCQW0 DE Asthma
DMSFX75 ID DMSFX75
DMSFX75 DN QVA-149
DMSFX75 HS Phase 3
DMSFX75 SN Glycopyrrolate mixture with indacaterol; 1262431-94-6; Utibron; Utibron Neohaler; Ultibro Breezhaler; Glycopyrrolate / indacaterol; Indacaterol / glycopyrronium; Indacaterol / glycopyrrolate; QVA149; QVA 149; Glycopyrronium bromide / indacaterol
DMSFX75 CP Sosei; Vectura; Novartis
DMSFX75 DT Small molecular drug
DMSFX75 PC 11564052
DMSFX75 MW 790.8
DMSFX75 FM C43H56BrN3O6
DMSFX75 IC InChI=1S/C24H28N2O3.C19H28NO3.BrH/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q;+1;/p-1/t22-;;/m0../s1
DMSFX75 CS CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DMSFX75 IK GCUZFFAPBPDIFM-IKXQUJFKSA-M
DMSFX75 IU 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one;(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DMSFX75 CA CAS 1262431-94-6
DMSFX75 DE Chronic obstructive pulmonary disease
DM4K9WH ID DM4K9WH
DM4K9WH DN R1678
DM4K9WH HS Phase 3
DM4K9WH SN R-1678; RG-1678
DM4K9WH CP Roche
DM4K9WH DT Small molecular drug
DM4K9WH PC 137905
DM4K9WH MW 342.3
DM4K9WH FM C22H14O4
DM4K9WH IC InChI=1S/C22H14O4/c23-19(15-7-3-1-4-8-15)21(25)17-11-13-18(14-12-17)22(26)20(24)16-9-5-2-6-10-16/h1-14H
DM4K9WH CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C(=O)C(=O)C3=CC=CC=C3
DM4K9WH IK FUEGWHHUYNHBNI-UHFFFAOYSA-N
DM4K9WH IU 1-[4-(2-oxo-2-phenylacetyl)phenyl]-2-phenylethane-1,2-dione
DM4K9WH CA CAS 3363-97-1
DM4K9WH DE Schizophrenia
DM9Z4N5 ID DM9Z4N5
DM9Z4N5 DN RA101495
DM9Z4N5 HS Phase 3
DM9Z4N5 SN Zilucoplan
DM9Z4N5 CP Ra Pharmaceuticals Cambridge, MA
DM9Z4N5 PC 133083018
DM9Z4N5 MW 3562
DM9Z4N5 FM C172H278N24O55
DM9Z4N5 IC InChI=1S/C172H278N24O55/c1-9-10-11-12-13-14-15-16-17-18-19-20-27-44-146(202)182-136(170(226)227)53-56-144(200)177-64-67-229-69-71-231-73-75-233-77-79-235-81-83-237-85-87-239-89-91-241-93-95-243-97-99-245-101-103-247-105-107-249-109-111-251-113-112-250-110-108-248-106-104-246-102-100-244-98-96-242-94-92-240-90-88-238-86-84-236-82-80-234-78-76-232-74-72-230-70-68-228-66-59-145(201)175-60-31-29-41-135(169(224)225)186-165(220)152(126-37-25-22-26-38-126)193-162(217)142-43-34-65-196(142)168(223)140(116-125-47-51-129(199)52-48-125)190-157(212)133(54-57-148(204)205)184-161(216)139(117-127-120-180-154-130(127)39-32-62-178-154)188-159(214)138(115-124-45-49-128(198)50-46-124)189-166(221)153(172(5,6)7)194-163(218)143(119-150(208)209)195(8)167(222)141-118-147(203)176-61-30-28-40-131(181-122(4)197)158(213)192-151(121(2)3)164(219)185-134(55-58-149(206)207)156(211)183-132(42-33-63-179-171(173)174)155(210)187-137(160(215)191-141)114-123-35-23-21-24-36-123/h21,23-24,32,35-36,39,45-52,62,120-121,126,131-143,151-153,198-199H,9-20,22,25-31,33-34,37-38,40-44,53-61,63-119H2,1-8H3,(H,175,201)(H,176,203)(H,177,200)(H,178,180)(H,181,197)(H,182,202)(H,183,211)(H,184,216)(H,185,219)(H,186,220)(H,187,210)(H,188,214)(H,189,221)(H,190,212)(H,191,215)(H,192,213)(H,193,217)(H,194,218)(H,204,205)(H,206,207)(H,208,209)(H,224,225)(H,226,227)(H4,173,174,179)/t131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,151-,152-,153+/m0/s1
DM9Z4N5 CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C1CCCCC1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CNC5=C4C=CC=N5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(=O)O)N(C)C(=O)[C@@H]7CC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O
DM9Z4N5 IK JDXCOXKBIGBZSK-PSNKNOTQSA-N
DM9Z4N5 IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-propan-2-yl-1,4,7,10,13,17-hexazacyclotricosane-14-carbonyl]-methylamino]-3-carboxypropanoyl]amino]-3,3-dimethylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-cyclohexylacetyl]amino]-6-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(4S)-4-carboxy-4-(hexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoic acid
DM9Z4N5 CA CAS 1841136-73-9
DM9Z4N5 DE Paroxysmal nocturnal haemoglobinuria; Myasthenia gravis
DM8RLJ5 ID DM8RLJ5
DM8RLJ5 DN RAD-1901
DM8RLJ5 HS Phase 3
DM8RLJ5 SN ER-306323; ER-308698; SERMs, Eisai/Radius; Selective estrogen receptor modulators, Eisai/Radius
DM8RLJ5 CP Eisai Co Ltd
DM8RLJ5 PC 23642301
DM8RLJ5 MW 458.6
DM8RLJ5 FM C30H38N2O2
DM8RLJ5 IC InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1
DM8RLJ5 CS CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O
DM8RLJ5 IK SIFNOOUKXBRGGB-AREMUKBSSA-N
DM8RLJ5 IU (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
DM8RLJ5 CA CAS 722533-56-4
DM8RLJ5 DE Breast cancer
DMN1ZEU ID DMN1ZEU
DMN1ZEU DN Radiosensitizer gene therapy
DMN1ZEU HS Phase 3
DMN1ZEU SN Radiosensitizer gene therapy (prostate cancer)
DMN1ZEU CP Advantagene
DMN1ZEU DE Pancreatic cancer
DMWA74Y ID DMWA74Y
DMWA74Y DN Radotinib
DMWA74Y HS Phase 3
DMWA74Y SN IY-5511; IY-GV50205; Anticancer, Il-yang
DMWA74Y CP Il-Yang Pharmaceutical Co
DMWA74Y DT Small molecular drug
DMWA74Y PC 16063245
DMWA74Y MW 530.5
DMWA74Y FM C27H21F3N8O
DMWA74Y IC InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
DMWA74Y CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5
DMWA74Y IK DUPWHXBITIZIKZ-UHFFFAOYSA-N
DMWA74Y IU 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
DMWA74Y CA CAS 926037-48-1
DMWA74Y DE leukaemia
DMFSHEM ID DMFSHEM
DMFSHEM DN Ragaglitazar
DMFSHEM HS Phase 3
DMFSHEM SN Ragaglitazar; DRF-2725; (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID; CHEMBL24038; (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid; DRF; 1nyx; DRF2725; AC1L9KVW; 2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; GTPL2664; SCHEMBL4822459; WMUIIGVAWPWQAW-DEOSSOPVSA-N; NN-622; BDBM50109551; DB07675; NNC-61-0029; (-)-DRF-2725; (S)-2-Ethoxy-3-[4-(2-phenoxazin-10-yl-ethoxy)-phenyl]-propionic acid; (2S)-2-ethoxy-3-{4-[2-(phenoxazin-10-yl)ethoxy]phenyl}propanoic acid
DMFSHEM DT Small molecular drug
DMFSHEM PC 447458
DMFSHEM MW 419.5
DMFSHEM FM C25H25NO5
DMFSHEM IC InChI=1S/C25H25NO5/c1-2-29-24(25(27)28)17-18-11-13-19(14-12-18)30-16-15-26-20-7-3-5-9-22(20)31-23-10-6-4-8-21(23)26/h3-14,24H,2,15-17H2,1H3,(H,27,28)/t24-/m0/s1
DMFSHEM CS CCO[C@@H](CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
DMFSHEM IK WMUIIGVAWPWQAW-DEOSSOPVSA-N
DMFSHEM IU (2S)-2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid
DMFSHEM CA CAS 222834-30-2
DMFSHEM DE Type-1 diabetes
DMUNMY0 ID DMUNMY0
DMUNMY0 DN Ralfinamide
DMUNMY0 HS Phase 3
DMUNMY0 SN Ralfinamida; Ralfinamide [INN]; NW 1029; NW-1029; Ralfinamida [INN-Spanish]; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMUNMY0 CP Newron
DMUNMY0 TC Analgesics
DMUNMY0 DT Small molecular drug
DMUNMY0 PC 5745207
DMUNMY0 MW 302.34
DMUNMY0 FM C17H19FN2O2
DMUNMY0 IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMUNMY0 CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F
DMUNMY0 IK BHJIBOFHEFDSAU-LBPRGKRZSA-N
DMUNMY0 IU (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMUNMY0 CA CAS 133865-88-0
DMUNMY0 DE Neuropathic pain
DMD5QRS ID DMD5QRS
DMD5QRS DN Ranirestat
DMD5QRS HS Phase 3
DMD5QRS SN AS-3201
DMD5QRS CP Eisai
DMD5QRS DT Small molecular drug
DMD5QRS PC 153948
DMD5QRS MW 420.2
DMD5QRS FM C17H11BrFN3O4
DMD5QRS IC InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
DMD5QRS CS C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
DMD5QRS IK QCVNMNYRNIMDKV-QGZVFWFLSA-N
DMD5QRS IU (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
DMD5QRS CA CAS 147254-64-6
DMD5QRS DE Diabetic neuropathy
DMVKL3B ID DMVKL3B
DMVKL3B DN Ravulizumab
DMVKL3B HS Phase 3
DMVKL3B SN Ultomiris (TN); Ravulizumab (USAN); Ravulizumab (genetical recombination) (JAN); D11054; 1803171-55-2
DMVKL3B TC Antiviral Agents
DMVKL3B DT Monoclonal antibody
DMVKL3B DE Coronavirus Disease 2019 (COVID-19)
DMPJTZ1 ID DMPJTZ1
DMPJTZ1 DN RBP-7000
DMPJTZ1 HS Phase 3
DMPJTZ1 CP Reckitt benckiser pharmaceutical
DMPJTZ1 DE Non-small-cell lung cancer; Schizophrenia
DMDZW8K ID DMDZW8K
DMDZW8K DN RBT-101
DMDZW8K HS Phase 3
DMDZW8K SN RBT-102; RBT-103; RBT-104; Seasonal/pandemic influenza vaccines (VLPs); Seasonal/pandemic influenza vaccines (VLPs), Redbiotec; Seasonal/pandemic influenza vaccines (virus-like-particles), Redbiotec
DMDZW8K CP Redbiotec AG
DMDZW8K DE Influenza virus infection; Heart failure; Respiratory tract infection
DM2GHCR ID DM2GHCR
DM2GHCR DN Rebamipide
DM2GHCR HS Phase 3
DM2GHCR SN rebamipide; 90098-04-7; Mucosta; Proamipide; 111911-87-6; OPC-12759; Rebamipidum; Pramipide; Rebamipide [INN:JAN]; Rebamipidum [INN-Latin]; Rebamipida [INN-Spanish]; OPC 12759; CCRIS 3585; Rebamipide hydrate; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 139344-42-6; 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid; Mucosta hydrate; NCGC00095161-01; Proamipide hydrate; 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid
DM2GHCR DT Small molecular drug
DM2GHCR PC 5042
DM2GHCR MW 370.8
DM2GHCR FM C19H15ClN2O4
DM2GHCR IC InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
DM2GHCR CS C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl
DM2GHCR IK ALLWOAVDORUJLA-UHFFFAOYSA-N
DM2GHCR IU 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
DM2GHCR CA CAS 90098-04-7
DM2GHCR CB CHEBI:93814
DM2GHCR DE Peptic ulcer
DM8HVNR ID DM8HVNR
DM8HVNR DN Recombinant acidic fibroblast growth factor
DM8HVNR HS Phase 3
DM8HVNR SN AFGF; Rh-aFGF; Recombinant acidic fibroblast growth factor (ulcer/burns); Recombinant acidic fibroblast growth factor (ulcer/burns), SinoBiomed; Recombinant acidic fibroplast growth factor (ulcer/burns), SinoBiomed
DM8HVNR CP SinoBiomed Inc
DM8HVNR DE Skin burns
DMOWQAF ID DMOWQAF
DMOWQAF DN Recombinant human iduronate-2-sulfatase
DMOWQAF HS Phase 3
DMOWQAF SN GC-1111; Recombinant human iduronate-2-sulfatase (Hunter syndrome); Recombinant human iduronate-2-sulfatase (Hunter syndrome), Green Cross
DMOWQAF CP Green Cross Corp
DMOWQAF DE Hunter syndrome
DM7JFDO ID DM7JFDO
DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO HS Phase 3
DM7JFDO SN Willebrand factor/recombinant Factor VIII complex; Recombinant von Willebrand factor/recombinant Factor VIII complex (von Willebrand disease)
DM7JFDO CP Csl behring
DM7JFDO DE Von willebrand disease
DM34GOF ID DM34GOF
DM34GOF DN REL-1017
DM34GOF HS Phase 3
DM34GOF SN Dextromethadone; d-Methadone; S-Methadone; (S)-methadone; (+)-Methadone; S-(+)-Methadone; 6S-Methadone; 5653-80-5; L-(+)-Methadone; (6S)-Methadone; l-Methadone; (S)-(+)-Methadone; UNII-S95RZH8AMH; d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; S95RZH8AMH; (S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone; CHEMBL350719; (S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; 3-14-00-00279 (Beilstein Handbook Reference); Methadone, (+)-; BRN 3213667; (+)-(S)-Methadone; (+)-(6S)-Methadone; SCHEMBL24294; (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one; CHEBI:167308; 3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, (S)-; ZINC1530707; BDBM50223640; DB15198; SB18896; (S)-6-Dimethylamino4,4-diphenylheptan-3-on; Q15634047; (+)-(S)-6-(dimethylamino)-4,4-diphenyl-3-heptanone; 3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)-; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-KRWDZBQOSA-N; UNII-UC6VBE7V1Z component USSIQXCVUWKGNF-QGZVFWFLSA-N; 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (6S)- (9CI); 3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (S)- (8CI)
DM34GOF CP Relmada Therapeutics
DM34GOF DT Small molecular drug
DM34GOF PC 643985
DM34GOF MW 309.4
DM34GOF FM C21H27NO
DM34GOF IC InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m0/s1
DM34GOF CS CCC(=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
DM34GOF IK USSIQXCVUWKGNF-KRWDZBQOSA-N
DM34GOF IU (6S)-6-(dimethylamino)-4,4-diphenylheptan-3-one
DM34GOF CA CAS 5653-80-5
DM34GOF CB CHEBI:167308
DM34GOF DE Neuropathic pain; Major depressive disorder
DMOWINT ID DMOWINT
DMOWINT DN Reloxaliase
DMOWINT HS Phase 3
DMOWINT SN ALLN-177
DMOWINT CP Allena Pharmaceuticals
DMOWINT DT Protein
DMOWINT DE Hyperoxaluria
DM3YXP8 ID DM3YXP8
DM3YXP8 DN Remacemide
DM3YXP8 HS Phase 3
DM3YXP8 SN Remacemida; Remacemidum; Remacemide [INN]; FPL 12924; FPL 12924AA; FPL 14144; FPL 14145; FPL-12944AA; PR 1032-644; PR 934-423; PR1032-646; Remacemida [INN-Spanish]; Remacemidum [INN-Latin]; PR-934-423; Remacemide monohydrochloride, (+-)-isomer; (+)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (+-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; (-)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide; 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide; 2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide
DM3YXP8 CP Astra Zeneca
DM3YXP8 DT Small molecular drug
DM3YXP8 PC 60511
DM3YXP8 MW 268.35
DM3YXP8 FM C17H20N2O
DM3YXP8 IC InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)
DM3YXP8 CS CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN
DM3YXP8 IK YSGASDXSLKIKOD-UHFFFAOYSA-N
DM3YXP8 IU 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide
DM3YXP8 CA CAS 128298-28-2
DM3YXP8 CB CHEBI:91654
DM3YXP8 DE Pain
DM49IGE ID DM49IGE
DM49IGE DN Remdesivir
DM49IGE HS Phase 3
DM49IGE SN L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
DM49IGE CP Gilead Sciences, Foster City, CA
DM49IGE TC Antiviral Agents
DM49IGE DT Small molecular drug
DM49IGE PC 121304016
DM49IGE MW 602.6
DM49IGE FM C27H35N6O8P
DM49IGE IC InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
DM49IGE CS CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
DM49IGE IK RWWYLEGWBNMMLJ-YSOARWBDSA-N
DM49IGE IU 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM49IGE CA CAS 1809249-37-3
DM49IGE CB CHEBI:145994
DM49IGE DE Ebola virus infection; Coronavirus Disease 2019 (COVID-19); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM7HQNX ID DM7HQNX
DM7HQNX DN Renzapride
DM7HQNX HS Phase 3
DM7HQNX SN Renzaprida; Renzapridum; Renzaprida [INN-Spanish]; Renzapridum [INN-Latin]; 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
DM7HQNX CP Alizyme
DM7HQNX DT Small molecular drug
DM7HQNX PC 119574
DM7HQNX MW 323.82
DM7HQNX FM C16H22ClN3O2
DM7HQNX IC InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1
DM7HQNX CS COC1=CC(=C(C=C1C(=O)N[C@@H]2CCN3CCC[C@H]2C3)Cl)N
DM7HQNX IK GZSKEXSLDPEFPT-IINYFYTJSA-N
DM7HQNX IU 4-amino-N-[(4R,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
DM7HQNX CA CAS 112727-80-7
DM7HQNX DE Irritable bowel syndrome
DMVBA7I ID DMVBA7I
DMVBA7I DN Reparixin
DMVBA7I HS Phase 3
DMVBA7I SN reparixin; repertaxin; 266359-83-5; UNII-U604E1NB3K; CHEMBL191413; U604E1NB3K; DF 1681Y; (R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide; Reparixin [USAN:INN]; (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide; (2R)-2-(4-(2-Methylpropyl)phenyl)-N-methylsulfonylpropanamide; 2-(4-isobutylphenyl)propionylmethanesulfonamide; Reparixin (USAN/INN); DSSTox_RID_81678; DSSTox_CID_26509; DSSTox_GSID_46509; ZINC8717; SCHEMBL1884299; GTPL8498; DTXSID6046509; EX-A2461; DF-1681Y; BCP10635; Tox21_112272; BDBM50169045; Repertaxin; Reparixin [INN]; Reparixin (INN/USAN); (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide; RAPARIXIN
DMVBA7I CP Dompe s.p.a.
DMVBA7I DT Small molecular drug
DMVBA7I PC 9838712
DMVBA7I MW 283.39
DMVBA7I FM C14H21NO3S
DMVBA7I IC InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
DMVBA7I CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C
DMVBA7I IK KQDRVXQXKZXMHP-LLVKDONJSA-N
DMVBA7I IU (2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide
DMVBA7I CA CAS 266359-83-5
DMVBA7I DE Graft rejection in heart transplantation; lung transplantation; Ischemia-reperfusion injury; Pancreatic islet transplantation failure
DMDEJX9 ID DMDEJX9
DMDEJX9 DN Reproxalap
DMDEJX9 HS Phase 3
DMDEJX9 SN 2-(3-Amino-6-chloroquinolin-2-yl)propan-2-ol; 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol; Reproxalap [USAN]; UNII-F0GIZ22IJH; F0GIZ22IJH; SCHEMBL12228833; ALD-102; ADX-102; 2-Quinolinemethanol, 3-amino-6-chloro-alpha,alpha-dimethyl-; NS2
DMDEJX9 CP Aldeyra Therapeutics Lexington, MA
DMDEJX9 PC 16088030
DMDEJX9 MW 236.7
DMDEJX9 FM C12H13ClN2O
DMDEJX9 IC InChI=1S/C12H13ClN2O/c1-12(2,16)11-9(14)6-7-5-8(13)3-4-10(7)15-11/h3-6,16H,14H2,1-2H3
DMDEJX9 CS CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O
DMDEJX9 IK GUHFUVLKYSQIOQ-UHFFFAOYSA-N
DMDEJX9 IU 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol
DMDEJX9 CA CAS 916056-79-6
DMDEJX9 DE Sjogren-Larsson syndrome
DMFMWYC ID DMFMWYC
DMFMWYC DN Resatorvid
DMFMWYC HS Phase 3
DMFMWYC SN Resatorvid; TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate
DMFMWYC CP Takeda
DMFMWYC DT Small molecular drug
DMFMWYC PC 11703255
DMFMWYC MW 361.8
DMFMWYC FM C15H17ClFNO4S
DMFMWYC IC InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1
DMFMWYC CS CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=C(C=C(C=C2)F)Cl
DMFMWYC IK LEEIJTHMHDMWLJ-CQSZACIVSA-N
DMFMWYC IU ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate
DMFMWYC CA CAS 243984-11-4
DMFMWYC DE Sepsis
DM3RWXL ID DM3RWXL
DM3RWXL DN Resveratrol
DM3RWXL HS Phase 3
DM3RWXL SN Resveratrol; Resvida; KUC104385N; R 5010; SRT 501; Cis-resveratrol; PREVENTION 8 (RESVERATROL); RM-1812; SRT-501; Trans-resveratrol; CU-01000001503-3; KSC-10-164; Resveratrol-3-sulfate; Trans-3,4',5-trihydroxystilbene; Trans-3,4′,5-Trihydroxystilbene; Trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
DM3RWXL CP Sirtris Pharma
DM3RWXL DT Small molecular drug
DM3RWXL PC 445154
DM3RWXL MW 228.24
DM3RWXL FM C14H12O3
DM3RWXL IC InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
DM3RWXL CS C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
DM3RWXL IK LUKBXSAWLPMMSZ-OWOJBTEDSA-N
DM3RWXL IU 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
DM3RWXL CA CAS 501-36-0
DM3RWXL CB CHEBI:45713
DM3RWXL DE Colorectal cancer; Giant cell arteritis; Rheumatoid arthritis; Systemic sclerosis
DMOYGZF ID DMOYGZF
DMOYGZF DN Retosiban
DMOYGZF HS Phase 3
DMOYGZF SN 820957-38-8; UNII-GIE06H28OX; GSK221149A; GSK-221149A; GIE06H28OX; CHEMBL429736; Retosiban [USAN:INN]; Retosiban (USAN); GSK 221149A; SCHEMBL230301; GTPL8403; DTXSID00231559; PLVGDGRBPMVYPB-FDUHJNRSSA-N; ZINC6718496; BDBM50372608; GSK-221,149-A; SB16762; DB11818; HY-14778; CS-0003555; J3.542.064I; D08986; 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-
DMOYGZF CP GlaxoSmithKline
DMOYGZF DT Small molecular drug
DMOYGZF PC 11340891
DMOYGZF MW 494.6
DMOYGZF FM C27H34N4O5
DMOYGZF IC InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
DMOYGZF CS CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
DMOYGZF IK PLVGDGRBPMVYPB-FDUHJNRSSA-N
DMOYGZF IU (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
DMOYGZF CA CAS 820957-38-8
DMOYGZF DE Preterm labour
DM5E73H ID DM5E73H
DM5E73H DN Revusiran
DM5E73H HS Phase 3
DM5E73H DT siRNA drug
DM5E73H DE Amyloidosis
DMQ4CSX ID DMQ4CSX
DMQ4CSX DN Rezafungin
DMQ4CSX HS Phase 3
DMQ4CSX SN CD-101; CD101; SP-3025; CHEMBL3989945; HY-108009; CS-0027142; J3.555.717B; J3.599.425D; (4R,5R)-N2-[4-(4'-Pentoxy-1,1'-biphenyl-4-yl)benzoyl]-5-[2-(trimethylaminio)ethoxy]-4-hydroxy-cyclo[L-Orn*-[(3R)-3-methyl-L-Ser-]-[(4R)-4-hydroxy-L-Pro-]-2-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-L-Gly-[(3R)-3-methyl-L-Ser-]-[(3S,4S)-3-hydroxy-4-methyl-L-Pro-]-]
DMQ4CSX CP Cidara Therapeutics
DMQ4CSX DT Small molecular drug
DMQ4CSX PC 78318119
DMQ4CSX MW 1226.4
DMQ4CSX FM C63H85N8O17+
DMQ4CSX IC InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1
DMQ4CSX CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O
DMQ4CSX IK LNFCWEXGZIEGJW-TXSVMFMRSA-O
DMQ4CSX IU 2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
DMQ4CSX DE Candidiasis
DMTQJE0 ID DMTQJE0
DMTQJE0 DN RG3638
DMTQJE0 HS Phase 3
DMTQJE0 SN Onartuzumab
DMTQJE0 CP Roche
DMTQJE0 DE Non-small-cell lung cancer; Gastric adenocarcinoma
DMER75Y ID DMER75Y
DMER75Y DN RG6013
DMER75Y HS Phase 3
DMER75Y DT Antibody
DMER75Y DE Haemophilia A
DMJRFYB ID DMJRFYB
DMJRFYB DN RG7201
DMJRFYB HS Phase 3
DMJRFYB CP Roche
DMJRFYB DE Type-2 diabetes
DMF5GZI ID DMF5GZI
DMF5GZI DN RG7388
DMF5GZI HS Phase 3
DMF5GZI SN Idasanutlin; RG7388; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856
DMF5GZI CP Roche
DMF5GZI DT Small molecular drug
DMF5GZI PC 53358942
DMF5GZI MW 616.5
DMF5GZI FM C31H29Cl2F2N3O4
DMF5GZI IC InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1
DMF5GZI CS CC(C)(C)C[C@H]1[C@]([C@H]([C@@H](N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F
DMF5GZI IK TVTXCJFHQKSQQM-LJQIRTBHSA-N
DMF5GZI IU 4-[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid
DMF5GZI CA CAS 1229705-06-9
DMF5GZI DE Haematological malignancy; Solid tumour/cancer; Polycythemia vera; Acute myeloid leukaemia
DMDVAFP ID DMDVAFP
DMDVAFP DN RG7601
DMDVAFP HS Phase 3
DMDVAFP CP Abbott; Roche
DMDVAFP DE Chronic lymphocytic leukaemia
DMGOTK4 ID DMGOTK4
DMGOTK4 DN Rhumab Beta7
DMGOTK4 HS Phase 3
DMGOTK4 CP Roche; Genentech
DMGOTK4 DT Antibody
DMGOTK4 DE Ulcerative colitis
DMLHEU7 ID DMLHEU7
DMLHEU7 DN Ridaforolimus
DMLHEU7 HS Phase 3
DMLHEU7 SN Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus
DMLHEU7 CP Merck
DMLHEU7 DT Small molecular drug
DMLHEU7 PC 11520894
DMLHEU7 MW 990.2
DMLHEU7 FM C53H84NO14P
DMLHEU7 IC InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DMLHEU7 CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC
DMLHEU7 IK BUROJSBIWGDYCN-GAUTUEMISA-N
DMLHEU7 IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-12-[(2R)-1-[(1S,3R,4R)-4-dimethylphosphoryloxy-3-methoxycyclohexyl]propan-2-yl]-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMLHEU7 CA CAS 572924-54-0
DMLHEU7 CB CHEBI:79700
DMLHEU7 DE Sarcoma
DMYXOHV ID DMYXOHV
DMYXOHV DN Rifalazil
DMYXOHV HS Phase 3
DMYXOHV DT Small molecular drug
DMYXOHV PC 135431094
DMYXOHV MW 941.1
DMYXOHV FM C51H64N4O13
DMYXOHV IC InChI=1S/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,58-60,62H,16-19,23H2,1-11H3,(H,53,63)/b13-12+,20-15+,26-14-/t25-,27+,28+,29+,34-,42-,43+,46+,51-/m0/s1
DMYXOHV CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)/C
DMYXOHV IK IXSVOCGZBUJEPI-HTQYORAHSA-N
DMYXOHV IU [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-[4-(2-methylpropyl)piperazin-1-yl]-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate
DMYXOHV CA CAS 129791-92-0
DMYXOHV DE Bacterial infection
DMKTS2M ID DMKTS2M
DMKTS2M DN Rifaximin DR
DMKTS2M HS Phase 3
DMKTS2M CP Salix Pharmaceuticals Raleigh, NC
DMKTS2M DE Crohn disease
DMOSTXF ID DMOSTXF
DMOSTXF DN Rigosertib
DMOSTXF HS Phase 3
DMOSTXF SN Rigosertib; 592542-59-1; UNII-67DOW7F9GL; 67DOW7F9GL; N-[2-Methoxy-5-({[(E)-2-(2,4,6-Trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine; ON-01910.Na; Rigosertib [USAN:INN]; 6FS; Rigosertib (USAN); AC1OCFT5; SCHEMBL498624; Estybon (proposed trade name); SCHEMBL498623; GTPL7833; CHEMBL1241855; ON01910.Na; DTXSID30207984; CHEBI:124939; OWBFCJROIKNMGD-BQYQJAHWSA-N; 1910 Na; ZINC3942646; BCP08296; BDBM50060917; 4006AH; AKOS015966442; DB12146; SB16468; (E)-2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetic a
DMOSTXF CP Onconova Therapeutics
DMOSTXF DT Small molecular drug
DMOSTXF PC 6918736
DMOSTXF MW 451.5
DMOSTXF FM C21H25NO8S
DMOSTXF IC InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
DMOSTXF CS COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
DMOSTXF IK OWBFCJROIKNMGD-BQYQJAHWSA-N
DMOSTXF IU 2-[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]anilino]acetic acid
DMOSTXF CA CAS 592542-59-1
DMOSTXF CB CHEBI:124939
DMOSTXF DE Solid tumour/cancer; Myelodysplastic syndrome
DMGTCI0 ID DMGTCI0
DMGTCI0 DN Rilimogene galvacirepvec
DMGTCI0 HS Phase 3
DMGTCI0 SN Prostvac (TN)
DMGTCI0 CP BM ImmunoTherapeutics
DMGTCI0 DE Prostate cancer
DMP6IMQ ID DMP6IMQ
DMP6IMQ DN Rindopepimut
DMP6IMQ HS Phase 3
DMP6IMQ CP Celldex Therapeutics
DMP6IMQ DE Glioblastoma multiforme; Brain cancer
DMYX7VI ID DMYX7VI
DMYX7VI DN Rintatolimod
DMYX7VI HS Phase 3
DMYX7VI CP Hemispherx Biopharma
DMYX7VI DT siRNA drug
DMYX7VI DE Human immunodeficiency virus infection
DM13V0P ID DM13V0P
DM13V0P DN Rivoceranib
DM13V0P HS Phase 3
DM13V0P CP Elevar Therapeutics
DM13V0P DT Small molecular drug
DM13V0P DE Gastric adenocarcinoma; Solid tumour/cancer; Sarcoma
DMBY31K ID DMBY31K
DMBY31K DN Rivoglitazone
DMBY31K HS Phase 3
DMBY31K SN CS-011; DE-101; Rivoglitazone (ophthalmic); Rivoglitazone (ophthalmic), Santen; CS-011 (ophthalmic), Santen
DMBY31K CP Sankyo Co Ltd
DMBY31K DT Small molecular drug
DMBY31K PC 3055168
DMBY31K MW 397.4
DMBY31K FM C20H19N3O4S
DMBY31K IC InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
DMBY31K CS CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMBY31K IK XMSXOLDPMGMWTH-UHFFFAOYSA-N
DMBY31K IU 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMBY31K CA CAS 185428-18-6
DMBY31K DE Ocular inflammation
DMVQ5X1 ID DMVQ5X1
DMVQ5X1 DN Roclatan
DMVQ5X1 HS Phase 3
DMVQ5X1 SN PG324
DMVQ5X1 CP Aerie pharmaceuticals
DMVQ5X1 PC 118984471
DMVQ5X1 MW 886.1
DMVQ5X1 FM C54H67N3O8
DMVQ5X1 IC InChI=1S/C28H27N3O3.C26H40O5/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24;1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32);3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b;8-3-/t26-;21-,22+,23+,24-,25+/m10/s1
DMVQ5X1 CS CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C.CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
DMVQ5X1 IK QILUCPOIAVKEBG-GCBPXYGZSA-N
DMVQ5X1 IU [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
DMVQ5X1 DE Glaucoma/ocular hypertension
DMSZPR3 ID DMSZPR3
DMSZPR3 DN Rolofylline
DMSZPR3 HS Phase 3
DMSZPR3 SN KW 3902; HMR-4902; KW-3902; MK-7418; Rolofylline (USAN); 1,3-Dipropyl-8-(3-noradamantyl)xanthine; 1,3-Dnax; 8-(3-Noradamantyl)-1,3-dipropylxanthine; 8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione; 8-(Noradamantan-3-yl)-1,3-dipropylxanthine; 8-(hexahydro-2,5-methanopentalen-3a(1h)-yl)-1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione
DMSZPR3 CP Merck
DMSZPR3 DT Small molecular drug
DMSZPR3 PC 64627
DMSZPR3 MW 356.5
DMSZPR3 FM C20H28N4O2
DMSZPR3 IC InChI=1S/C20H28N4O2/c1-3-5-23-16-15(17(25)24(6-4-2)19(23)26)21-18(22-16)20-10-12-7-13(11-20)9-14(20)8-12/h12-14H,3-11H2,1-2H3,(H,21,22)
DMSZPR3 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CC5CC(C3)CC4C5
DMSZPR3 IK PJBFVWGQFLYWCB-UHFFFAOYSA-N
DMSZPR3 IU 1,3-dipropyl-8-(3-tricyclo[3.3.1.03,7]nonanyl)-7H-purine-2,6-dione
DMSZPR3 CA CAS 136199-02-5
DMSZPR3 DE Heart failure
DMPIDXT ID DMPIDXT
DMPIDXT DN Rosiglitazone + metformin
DMPIDXT HS Phase 3
DMPIDXT SN Orantinib; TSU-68; 252916-29-3; SU-6668; SU6668; SU 6668; 210644-62-5; UNII-9RL37ZZ665; Orantinib (TSU-68); NSC 702827; TSU68; CHEMBL274654; 9RL37ZZ665; TSU 68; PDGFR Tyrosine Kinase Inhibitor VI, SU6668; 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid; J-502593; Orantinibum; 3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid; 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; Orantinib [INN]
DMPIDXT CP GSK
DMPIDXT DT Combination drug (small molecular drug)
DMPIDXT PC 5329099
DMPIDXT MW 310.3
DMPIDXT FM C18H18N2O3
DMPIDXT IC InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
DMPIDXT CS CC1=C(NC(=C1CCC(=O)O)C)/C=C\\2/C3=CC=CC=C3NC2=O
DMPIDXT IK NHFDRBXTEDBWCZ-ZROIWOOFSA-N
DMPIDXT IU 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
DMPIDXT CA CAS 210644-62-5
DMPIDXT DE Advanced solid tumour; Diabetic complication
DM18B72 ID DM18B72
DM18B72 DN Rosiglitazone + simvastatin
DM18B72 HS Phase 3
DM18B72 CP GSK
DM18B72 DT Combination drug (small molecular drug)
DM18B72 PC 23644561
DM18B72 MW 241.24
DM18B72 FM C13H11N3O2
DM18B72 IC InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-8H,1H3,(H,16,17)/b11-4-
DM18B72 CS COC1=CC\\2=C(C=C1)NC(=O)/C2=C\\C3C=NC=N3
DM18B72 IK KKGJVFQBVRACGR-WCIBSUBMSA-N
DM18B72 IU (3Z)-3-(4H-imidazol-4-ylmethylidene)-5-methoxy-1H-indol-2-one
DM18B72 DE Type-2 diabetes
DMNGCAD ID DMNGCAD
DMNGCAD DN Rova-T
DMNGCAD HS Phase 3
DMNGCAD SN rovalpituzumab tesirine; Rovalpituzumab Tesirine; Rova-t; Rovalpituzumab-Tesirin; UNII-P256HB60FF; Rovalpituzumab tesirine [INN]; P256HB60FF; Rovalpituzumab tesirine [WHO-DD]; Rovalpituzumab tesirine [USAN:INN]; SC0002; 1613313-09-9
DMNGCAD CP StemcentRx South San Francisco, CA
DMNGCAD PC 131954443
DMNGCAD MW 1617.8
DMNGCAD FM C78H108N10O25S
DMNGCAD IC InChI=1S/C78H108N10O25S/c1-49(2)70(84-68(90)16-21-103-23-25-105-27-29-107-31-33-109-35-36-110-34-32-108-30-28-106-26-24-104-22-17-80-67(89)15-18-85-69(91)43-66(76(85)97)114-48-58(79)77(98)99)72(93)82-52(5)71(92)83-54-13-11-53(12-14-54)47-113-78(100)88-60-42-65(63(102-7)40-57(60)74(95)87-46-51(4)38-61(87)75(88)96)112-20-10-8-9-19-111-64-41-59-56(39-62(64)101-6)73(94)86-45-50(3)37-55(86)44-81-59/h11-14,39-42,44-46,49,52,55,58,61,66,70,75,96H,8-10,15-38,43,47-48,79H2,1-7H3,(H,80,89)(H,82,93)(H,83,92)(H,84,90)(H,98,99)/t52-,55-,58-,61-,66+,70-,75-/m0/s1
DMNGCAD CS CC1=CN2[C@@H](C1)C=NC3=CC(=C(C=C3C2=O)OC)OCCCCCOC4=C(C=C5C(=C4)N([C@H]([C@@H]6CC(=CN6C5=O)C)O)C(=O)OCC7=CC=C(C=C7)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN8C(=O)C[C@H](C8=O)SC[C@@H](C(=O)O)N)OC
DMNGCAD IK NQUUPTGRJYIXSL-YPDXTJLXSA-N
DMNGCAD IU (2R)-3-[(3R)-1-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[4-[[(6S,6aS)-3-[5-[[(6aS)-2-methoxy-8-methyl-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-6-hydroxy-2-methoxy-8-methyl-11-oxo-6a,7-dihydro-6H-pyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl]oxymethyl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid
DMNGCAD CA CAS 1613313-09-9
DMNGCAD DE Small-cell lung cancer; Neuroendocrine cancer
DM9T8OF ID DM9T8OF
DM9T8OF DN RQ-00000004
DM9T8OF HS Phase 3
DM9T8OF SN PF-03716556; RQ-00000774; RQ-4; Acid pump inhibitor (GERD), Pfizer; Acid pump inhibitor (GERD), RaQualia;Acid pump inhibitor (gastroesophageal reflux), Pfizer; Acid pump inhibitor (gastroesophageal reflux), RaQualia
DM9T8OF CP Pfizer Inc
DM9T8OF DE Gastroesophageal reflux disease
DMQM2FH ID DMQM2FH
DMQM2FH DN RRx-001
DMQM2FH HS Phase 3
DMQM2FH SN RRX-001; 925206-65-1; 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHAN-1-ONE; UNII-7RPW6SU9SC; 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone; 7RPW6SU9SC; RRx001; Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-; SCHEMBL2249018; CHEMBL3526802; MolPort-044-559-098; EX-A2006; BCP19228; 1-bromoacetyl-3,3-dinitroazetidine; ZINC34805177; s8405; DB12060; CS-5286; HY-16438; AS-53015
DMQM2FH CP RadioRx
DMQM2FH DT Small molecular drug
DMQM2FH PC 15950826
DMQM2FH MW 268.02
DMQM2FH FM C5H6BrN3O5
DMQM2FH IC InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2
DMQM2FH CS C1C(CN1C(=O)CBr)([N+](=O)[O-])[N+](=O)[O-]
DMQM2FH IK JODKFOVZURLVTG-UHFFFAOYSA-N
DMQM2FH IU 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
DMQM2FH CA CAS 925206-65-1
DMQM2FH DE Lymphoma; Anaplastic glioma; Neuroendocrine cancer; Ovarian epithelial cancer; Solid tumour/cancer; Non-small-cell lung cancer; Small-cell lung cancer
DM62QTW ID DM62QTW
DM62QTW DN RTB101
DM62QTW HS Phase 3
DM62QTW CP ResTORbio
DM62QTW DT Small molecular drug
DM62QTW DE Coronavirus Disease 2019 (COVID-19); Respiratory tract infection
DMDWU1S ID DMDWU1S
DMDWU1S DN Rubitecan
DMDWU1S HS Phase 3
DMDWU1S SN 9-Nitrocamptothecin; 91421-42-0; Orathecin; 9-nitro-20(S)-camptothecin; Camptogen; 9-NC; RFS 2000; RFS-2000; UNII-H19C446XXB; Nitrocamptothecin; H19C446XXB; CHEBI:90225; C20H15N3O6; (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NCGC00167969-01; (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; 9NC; Q-100889; (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; Inhaled Orathecin; L9NC; Rubitecan (inhaled); Aerosolized liposomal 9 nitro-20 (S) camptothecin; Rubitecan (inhaled), SuperGen; 9-Nitro-20(S)-camptothecin; 9-Nitrocamptothecin (9-NC)
DMDWU1S CP SuperGen; Clayton Foundation For Research; MD Anderson Cancer Center
DMDWU1S DT Small molecular drug
DMDWU1S PC 472335
DMDWU1S MW 393.3
DMDWU1S FM C20H15N3O6
DMDWU1S IC InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
DMDWU1S CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O
DMDWU1S IK VHXNKPBCCMUMSW-FQEVSTJZSA-N
DMDWU1S IU (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMDWU1S CA CAS 91421-42-0
DMDWU1S CB CHEBI:90225
DMDWU1S DE Human immunodeficiency virus infection
DMQOCD8 ID DMQOCD8
DMQOCD8 DN RUBOXISTAURIN HYDROCHLORIDE
DMQOCD8 HS Phase 3
DMQOCD8 SN LY-333531.HCl; Ruboxistaurin hydrochloride; 9(S)-(Dimethylaminomethyl)-5,6,7,9,10,11,12,17,18,19,20,21-dodecahydro-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione hydrochloride
DMQOCD8 PC 9870785
DMQOCD8 MW 505
DMQOCD8 FM C28H29ClN4O3
DMQOCD8 IC InChI=1S/C28H28N4O3.ClH/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24;/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34);1H/t18-;/m0./s1
DMQOCD8 CS CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O.Cl
DMQOCD8 IK NYQIEYDJYFVLPO-FERBBOLQSA-N
DMQOCD8 IU (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione;hydrochloride
DMQOCD8 CA CAS 169939-93-9
DMQOCD8 DE Lymphoma
DM25TMP ID DM25TMP
DM25TMP DN Rubraca rucaparib
DM25TMP HS Phase 3
DM25TMP CP Clovis Oncology Boulder, CO
DM25TMP DE Prostate cancer; Ovarian cancer
DM20KYR ID DM20KYR
DM20KYR DN Ruxolitinib
DM20KYR HS Phase 3
DM20KYR SN Ruxolitinib (JAK inhibitor)
DM20KYR CP Incyte
DM20KYR TC Antiviral Agents
DM20KYR DT Small molecular drug
DM20KYR PC 25126798
DM20KYR MW 306.4
DM20KYR FM C17H18N6
DM20KYR IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
DM20KYR CS C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
DM20KYR IK HFNKQEVNSGCOJV-OAHLLOKOSA-N
DM20KYR IU (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DM20KYR CA CAS 941678-49-5
DM20KYR CB CHEBI:66919
DM20KYR DE Essential thrombocythemia; High-risk myelofibrosis; Nasopharyngeal carcinoma; Pancreatic cancer; Coronavirus Disease 2019 (COVID-19)
DMAYTIH ID DMAYTIH
DMAYTIH DN S-06911
DMAYTIH HS Phase 3
DMAYTIH SN Strontium ranelate + vitamin D3 (osteoporosis), Servier; Strontium ranelate + vitamin D3 (fixed-dose combination, osteoporosis), Servier
DMAYTIH CP Servier
DMAYTIH DE Osteoporosis
DMXY34J ID DMXY34J
DMXY34J DN S-110
DMXY34J HS Phase 3
DMXY34J SN DNA demethylating agent (myelodysplastic syndrome), Supergen
DMXY34J CP SuperGen Inc
DMXY34J DE Acute myeloid leukaemia; Chronic myelogenous leukaemia; Solid tumour/cancer
DM408GM ID DM408GM
DM408GM DN S-474474
DM408GM HS Phase 3
DM408GM CP Shionogi
DM408GM DE Metabolic syndrome x
DM7F2VG ID DM7F2VG
DM7F2VG DN SA-237
DM7F2VG HS Phase 3
DM7F2VG SN Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
DM7F2VG CP Chugai Pharmaceutical Co Ltd
DM7F2VG DE Rheumatoid arthritis; Encephalopathy; Neuromyelitis optica
DMGR98T ID DMGR98T
DMGR98T DN SAGE-217
DMGR98T HS Phase 3
DMGR98T SN HARRKNSQXBRBGZ-GVKWWOCJSA-N; SCHEMBL16189866; HY-103040; CS-0023489; 1632051-40-1
DMGR98T CP Sage Therapeutics Cambridge, MA
DMGR98T PC 86294073
DMGR98T MW 409.6
DMGR98T FM C25H35N3O2
DMGR98T IC InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1
DMGR98T CS C[C@]1(CC[C@H]2[C@@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4C(=O)CN5C=C(C=N5)C#N)C)O
DMGR98T IK HARRKNSQXBRBGZ-GVKWWOCJSA-N
DMGR98T IU 1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile
DMGR98T CA CAS 1632051-40-1
DMGR98T DE Essential tremor or related tremors; Major depressive disorder; Parkinson disease; Postpartum depression
DMI1R5S ID DMI1R5S
DMI1R5S DN SAIT101
DMI1R5S HS Phase 3
DMI1R5S CP Archigen Biotech
DMI1R5S DT Antibody
DMI1R5S DE Follicular lymphoma
DMKHLRT ID DMKHLRT
DMKHLRT DN SAND-26
DMKHLRT HS Phase 3
DMKHLRT SN Begedina; CD26-targeting antibody (autoimmunity), ADIENNE
DMKHLRT CP ADIENNE Pharma & Biotech
DMKHLRT DT Antibody
DMKHLRT DE Autoimmune diabetes
DMXAO4J ID DMXAO4J
DMXAO4J DN SAR153191
DMXAO4J HS Phase 3
DMXAO4J CP Sanofi-Aventis
DMXAO4J DE Ankylosing spondylitis
DMHFBOG ID DMHFBOG
DMHFBOG DN SAR231893
DMHFBOG HS Phase 3
DMHFBOG CP Sanofi
DMHFBOG DE Atopic dermatitis; Asthma
DMR0EWV ID DMR0EWV
DMR0EWV DN SAR342434
DMR0EWV HS Phase 3
DMR0EWV DE Diabetic complication; Type-1 diabetes; Type-2 diabetes
DMXGE3O ID DMXGE3O
DMXGE3O DN SAR408701
DMXGE3O HS Phase 3
DMXGE3O CP Sanofi
DMXGE3O DT Antibody drug conjugate
DMXGE3O DE Solid tumour/cancer; Non-small-cell lung cancer
DMDMAE4 ID DMDMAE4
DMDMAE4 DN SAR438584
DMDMAE4 HS Phase 3
DMDMAE4 SN REGN2222
DMDMAE4 DT Antibody
DMDMAE4 DE Respiratory syncytial virus infection
DM8HCFD ID DM8HCFD
DM8HCFD DN Sarilumab
DM8HCFD HS Phase 3
DM8HCFD SN Kevzara
DM8HCFD CP Sanofi/Regeneron
DM8HCFD TC Antiviral Agents
DM8HCFD DT Monoclonal antibody
DM8HCFD SQ Heavy chain: EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light chainDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM8HCFD DE Rheumatoid arthritis; Severely active rheumatoid arthritis; Coronavirus Disease 2019 (COVID-19)
DMUVSG4 ID DMUVSG4
DMUVSG4 DN Sasanlimab
DMUVSG4 HS Phase 3
DMUVSG4 SN PF-06801591
DMUVSG4 CP Pfizer
DMUVSG4 DT Antibody
DMUVSG4 DE Non-muscle invasive bladder cancer
DME5PN3 ID DME5PN3
DME5PN3 DN Satavaptan
DME5PN3 HS Phase 3
DME5PN3 CP Sanofi-Aventis
DME5PN3 DT Small molecular drug
DME5PN3 PC 158348
DME5PN3 MW 643.8
DME5PN3 FM C33H45N3O8S
DME5PN3 IC InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)
DME5PN3 CS CCOC1=CC2=C(C=C1)N(C(=O)C23CCC(CC3)OCCN4CCOCC4)S(=O)(=O)C5=C(C=C(C=C5)C(=O)NC(C)(C)C)OC
DME5PN3 IK QKXJWFOKVQWEDZ-UHFFFAOYSA-N
DME5PN3 IU N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide
DME5PN3 CA CAS 185913-78-4
DME5PN3 DE Acute and chronic heart failure
DMALFKX ID DMALFKX
DMALFKX DN Savolitinib
DMALFKX HS Phase 3
DMALFKX SN 1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri
DMALFKX CP AstraZeneca Wilmington, DE
DMALFKX PC 68289010
DMALFKX MW 345.4
DMALFKX FM C17H15N9
DMALFKX IC InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
DMALFKX CS C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
DMALFKX IK XYDNMOZJKOGZLS-NSHDSACASA-N
DMALFKX IU 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
DMALFKX CA CAS 1313725-88-0
DMALFKX DE Solid tumour/cancer; Renal cell carcinoma
DMAPRWV ID DMAPRWV
DMAPRWV DN SaxaDapa FDC
DMAPRWV HS Phase 3
DMAPRWV CP AstraZeneca
DMAPRWV DE Diabetic complication
DMME6GJ ID DMME6GJ
DMME6GJ DN SB12
DMME6GJ HS Phase 3
DMME6GJ CP Samsung Bioepis
DMME6GJ DT Antibody
DMME6GJ DE Paroxysmal nocturnal haemoglobinuria
DM6L4ZT ID DM6L4ZT
DM6L4ZT DN SB-742457
DM6L4ZT HS Phase 3
DM6L4ZT SN GSK 742457; SB 742457; GSK-742457; 3-(benzenesulfonyl)-8-piperazin-1-yl-quinoline
DM6L4ZT CP GlaxoSmithKline
DM6L4ZT DT Small molecular drug
DM6L4ZT PC 11256720
DM6L4ZT MW 353.4
DM6L4ZT FM C19H19N3O2S
DM6L4ZT IC InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
DM6L4ZT CS C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4
DM6L4ZT IK JJZFWROHYSMCMU-UHFFFAOYSA-N
DM6L4ZT IU 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline
DM6L4ZT CA CAS 607742-69-8
DM6L4ZT DE Alzheimer disease
DM6XNJR ID DM6XNJR
DM6XNJR DN SC-46553
DM6XNJR HS Phase 3
DM6XNJR SN Ginsenoside 20-Glc-Rf; PubChem13034; SC-46553; ZINC238808898; ginsenoside-Rd; 705G938; CHEMBL525935; S597; Ginsenoside Rd
DM6XNJR PC 24721561
DM6XNJR MW 963.2
DM6XNJR FM C48H82O19
DM6XNJR IC FBFMBWCLBGQEBU-RXMALORBSA-N
DM6XNJR CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)O)C
DM6XNJR IK 1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)64-42)22-11-15-46(6)30(22)23(52)16-28-45(5)14-12-29(53)44(3,4)40(45)24(17-47(28,46)7)62-43-39(36(59)33(56)27(20-51)65-43)66-41-37(60)34(57)31(54)25(18-49)63-41/h10,22-43,49-61H,9,11-20H2,1-8H3/t22-,23+,24-,25+,26+,27+,28+,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1
DM6XNJR IU (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM6XNJR DE Cerebral stroke
DMK1IPV ID DMK1IPV
DMK1IPV DN SCY-078
DMK1IPV HS Phase 3
DMK1IPV SN Ibrexafungerp
DMK1IPV CP Scynexis
DMK1IPV DT Small molecular drug
DMK1IPV PC 46871657
DMK1IPV MW 730
DMK1IPV FM C44H67N5O4
DMK1IPV IC InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1
DMK1IPV CS C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C
DMK1IPV IK BODYFEUFKHPRCK-ZCZMVWJSSA-N
DMK1IPV IU (1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid
DMK1IPV CA CAS 1207753-03-4
DMK1IPV DE Fungal infection; Invasive candidiasis
DMAMTGI ID DMAMTGI
DMAMTGI DN SD-101
DMAMTGI HS Phase 3
DMAMTGI SN HCV-ISS; HCV vaccine (ISS), Dynavax/Symphony Dynamo
DMAMTGI CP Scioderm
DMAMTGI DT Oligonucleotide
DMAMTGI DE Hepatitis C virus infection; Melanoma; Skin disease; Squamous cell carcinoma; Squamous head and neck cell carcinom
DM9DEYL ID DM9DEYL
DM9DEYL DN SD-6010
DM9DEYL HS Phase 3
DM9DEYL CP Pfizer New York, NY
DM9DEYL DE Osteoarthritis
DMBD4K3 ID DMBD4K3
DMBD4K3 DN Selinexor
DMBD4K3 HS Phase 3
DMBD4K3 SN Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
DMBD4K3 CP Karyopharm therapeutics
DMBD4K3 DT Small molecular drug
DMBD4K3 PC 71481097
DMBD4K3 MW 443.3
DMBD4K3 FM C17H11F6N7O
DMBD4K3 IC InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-
DMBD4K3 CS C1=CN=C(C=N1)NNC(=O)/C=C\\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMBD4K3 IK DEVSOMFAQLZNKR-RJRFIUFISA-N
DMBD4K3 IU (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
DMBD4K3 CA CAS 1393477-72-9
DMBD4K3 DE Solid tumour/cancer; Diffuse large B-cell lymphoma; Acute myeloid leukaemia; Multiple myeloma; Liposarcoma; Neuroendocrine cancer; Recurrent glioblastoma
DMC7W6R ID DMC7W6R
DMC7W6R DN Selumetinib
DMC7W6R HS Phase 3
DMC7W6R SN Selumetinib; AZD-6244; ARRY142886; AZD6244; ARRY142886; AZD 6244; AZD-6244; 6UH91I579U; ARRY 142886; ARRY-142886; AZD6244 (Selumetinib); AZD6244(Selumetinib); CHEBI:90227; CHEMBL1614701; MEK inhibitors; Selumetinib (AZD6244); UNII-6UH91I579U
DMC7W6R CP AstraZeneca
DMC7W6R DT Small molecular drug
DMC7W6R PC 10127622
DMC7W6R MW 457.7
DMC7W6R FM C17H15BrClFN4O3
DMC7W6R IC InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
DMC7W6R CS CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
DMC7W6R IK CYOHGALHFOKKQC-UHFFFAOYSA-N
DMC7W6R IU 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
DMC7W6R CA CAS 606143-52-6
DMC7W6R CB CHEBI:90227
DMC7W6R DE Non-small-cell lung cancer; Melanoma; Thyroid cancer; Solid tumour/cancer
DML83IW ID DML83IW
DML83IW DN Semagacestat
DML83IW HS Phase 3
DML83IW SN DAPT; AN-37124; AN-44989; LY-374973; LY-411575; LY-424354; LY-450139; LY-4501395; Gamma-secretase inhibitors (Alzheimer's disease), Elan Pharmaceuticals/Eli Lilly
DML83IW CP Eli Lilly & Co
DML83IW DT Small molecular drug
DML83IW PC 9843750
DML83IW MW 361.4
DML83IW FM C19H27N3O4
DML83IW IC InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1
DML83IW CS C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O
DML83IW IK PKXWXXPNHIWQHW-RCBQFDQVSA-N
DML83IW IU (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide
DML83IW CA CAS 425386-60-3
DML83IW CB CHEBI:131158
DML83IW DE Parkinson disease
DMKL9QO ID DMKL9QO
DMKL9QO DN Seocalcitol
DMKL9QO HS Phase 3
DMKL9QO SN Seocalcitol; 134404-52-7; UNII-Q0OZ0D9223; EB-1089; Q0OZ0D9223; EB1089; EB 1089; Seocalcitol [INN:BAN]; CB-1089; (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homovitamin D3 / (22E,24E)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMKL9QO DT Small molecular drug
DMKL9QO PC 5288149
DMKL9QO MW 454.7
DMKL9QO FM C30H46O3
DMKL9QO IC InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1
DMKL9QO CS CCC(CC)(/C=C/C=C/[C@@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)O
DMKL9QO IK LVLLALCJVJNGQQ-SEODYNFXSA-N
DMKL9QO IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMKL9QO CA CAS 134404-52-7
DMKL9QO DE Rickets
DMG2QP4 ID DMG2QP4
DMG2QP4 DN SEP-363856
DMG2QP4 HS Phase 3
DMG2QP4 CP Sunovion
DMG2QP4 PC 89532783
DMG2QP4 MW 183.27
DMG2QP4 FM C9H13NOS
DMG2QP4 IC InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1
DMG2QP4 CS CNC[C@H]1C2=C(CCO1)C=CS2
DMG2QP4 IK ABDDQTDRAHXHOC-QMMMGPOBSA-N
DMG2QP4 IU 1-[(7S)-5,7-dihydro-4H-thieno[2,3-c]pyran-7-yl]-N-methylmethanamine
DMG2QP4 CA CAS 1310426-33-5
DMG2QP4 DE Major depressive disorder; Parkinson disease; Schizophrenia
DM5VH6U ID DM5VH6U
DM5VH6U DN Serlopitant
DM5VH6U HS Phase 3
DM5VH6U SN VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
DM5VH6U CP Menlo Therapeutics Redwood City, CA
DM5VH6U PC 23653789
DM5VH6U MW 555.5
DM5VH6U FM C29H28F7NO2
DM5VH6U IC InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1
DM5VH6U CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
DM5VH6U IK FLNYCRJBCNNHRH-OIYLJQICSA-N
DM5VH6U IU 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one
DM5VH6U CA CAS 860642-69-9
DM5VH6U DE Prurigo nodularis; Psoriasis vulgaris
DMZ61IA ID DMZ61IA
DMZ61IA DN Setipiprant
DMZ61IA HS Phase 3
DMZ61IA SN ACT-129968
DMZ61IA CP Actelion Pharmaceuticals
DMZ61IA DT Small molecular drug
DMZ61IA PC 49843471
DMZ61IA MW 402.4
DMZ61IA FM C24H19FN2O3
DMZ61IA IC InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)
DMZ61IA CS C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54
DMZ61IA IK IHAXLPDVOWLUOS-UHFFFAOYSA-N
DMZ61IA IU 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
DMZ61IA CA CAS 866460-33-5
DMZ61IA DE Asthma
DM1NQDW ID DM1NQDW
DM1NQDW DN SGI110
DM1NQDW HS Phase 3
DM1NQDW CP Astex Pharmaceuticals
DM1NQDW PC 137295284
DM1NQDW MW 581.4
DM1NQDW FM C18H25N9NaO10P
DM1NQDW IC InChI=1S/C18H24N9O10P.Na.H/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30;;/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30);;/q;+1;-1/t7?,8-,9+,10+,11?,12+;;/m0../s1
DM1NQDW CS [H-].C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)OP(=O)(O)OC[C@@H]3C(CC(O3)N4C=NC5=C4N=C(NC5=O)N)O.[Na+]
DM1NQDW IK AYXRQJHOBFJIHP-ZWBDGAAVSA-N
DM1NQDW IU sodium;[(2R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate;hydride
DM1NQDW DE Acute myeloid leukaemia
DM4N1SP ID DM4N1SP
DM4N1SP DN Shigamabs
DM4N1SP HS Phase 3
DM4N1SP SN C-Stx1; C-Stx2; Ca-Stx1; Ca-Stx2; Anti-Shiga toxin monoclonal antibodies, Thallion; Anti-Shiga toxin monoclonals, Sunol;Monoclonal antibodies (HUS), Sunol; Monoclonal antibodies (HUS), Thallion
DM4N1SP CP Bellus Health
DM4N1SP DT Monoclonal antibody
DM4N1SP DE Haemolytic uraemic syndrome; Bacterial infection
DMEWRXA ID DMEWRXA
DMEWRXA DN SHP647
DMEWRXA HS Phase 3
DMEWRXA CP inhibitor, Lexington, MA
DMEWRXA DE Crohn disease; Ulcerative colitis
DMMIWCE ID DMMIWCE
DMMIWCE DN Sifuvirtide
DMMIWCE HS Phase 3
DMMIWCE SN FS-0101; HIV fusion inhibitor (oral), FusoGen; HIV gp41 protein inhibitor (oral), FusoGen; Sifuvirtide (oral, HIV); Sifuvirtide (oral, HIV), FusoGen
DMMIWCE CP FusoGen Pharmaceuticals Inc
DMMIWCE PC 49769437
DMMIWCE MW 4686
DMMIWCE FM C201H307N59O71
DMMIWCE IC InChI=1S/C201H307N59O71/c1-15-93(10)156(257-177(311)124(54-67-151(285)286)235-162(296)109(31-22-70-219-197(209)210)226-168(302)119(49-62-146(275)276)237-184(318)133(81-101-87-225-108-30-21-19-28-105(101)108)254-195(329)160(97(14)264)259-178(312)125(55-68-152(287)288)239-183(317)132(244-161(295)106(202)88-261)80-100-86-224-107-29-20-18-27-104(100)107)191(325)242-123(53-66-150(283)284)173(307)249-135(83-144(208)272)186(320)247-131(79-99-38-42-103(266)43-39-99)189(323)260-159(96(13)263)194(328)241-112(34-25-73-222-200(215)216)163(297)232-117(47-60-142(206)270)176(310)258-158(95(12)17-3)193(327)253-130(78-98-36-40-102(265)41-37-98)182(316)229-113(35-26-74-223-201(217)218)175(309)256-157(94(11)16-2)192(326)252-129(77-92(8)9)179(313)236-121(51-64-148(279)280)171(305)234-122(52-65-149(281)282)174(308)255-138(89-262)190(324)240-115(45-58-140(204)268)167(301)233-118(48-61-145(273)274)170(304)230-114(44-57-139(203)267)166(300)231-116(46-59-141(205)269)172(306)251-136(84-154(291)292)187(321)228-111(33-24-72-221-199(213)214)164(298)248-134(82-143(207)271)185(319)238-120(50-63-147(277)278)169(303)227-110(32-23-71-220-198(211)212)165(299)250-137(85-155(293)294)188(322)246-128(76-91(6)7)181(315)245-127(75-90(4)5)180(314)243-126(196(330)331)56-69-153(289)290/h18-21,27-30,36-43,86-87,90-97,106,109-138,156-160,224-225,261-266H,15-17,22-26,31-35,44-85,88-89,202H2,1-14H3,(H2,203,267)(H2,204,268)(H2,205,269)(H2,206,270)(H2,207,271)(H2,208,272)(H,226,302)(H,227,303)(H,228,321)(H,229,316)(H,230,304)(H,231,300)(H,232,297)(H,233,301)(H,234,305)(H,235,296)(H,236,313)(H,237,318)(H,238,319)(H,239,317)(H,240,324)(H,241,328)(H,242,325)(H,243,314)(H,244,295)(H,245,315)(H,246,322)(H,247,320)(H,248,298)(H,249,307)(H,250,299)(H,251,306)(H,252,326)(H,253,327)(H,254,329)(H,255,308)(H,256,309)(H,257,311)(H,258,310)(H,259,312)(H,260,323)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,330,331)(H4,209,210,219)(H4,211,212,220)(H4,213,214,221)(H4,215,216,222)(H4,217,218,223)/t93-,94-,95-,96+,97+,106-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,156-,157-,158-,159-,160-/m0/s1
DMMIWCE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)N
DMMIWCE IK WIOOVJJJJQAZGJ-ISHQQBGZSA-N
DMMIWCE IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]pentanedioic acid
DMMIWCE DE Human immunodeficiency virus infection
DM4YDAJ ID DM4YDAJ
DM4YDAJ DN Sildenafil
DM4YDAJ HS Phase 3
DM4YDAJ SN sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; BNRNXUUZRGQAQC-UHFFFAOYSA-N; Sildenafil
DM4YDAJ TC Antiviral Agents
DM4YDAJ DT Small molecular drug
DM4YDAJ PC 135398744
DM4YDAJ MW 474.6
DM4YDAJ FM C22H30N6O4S
DM4YDAJ IC InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
DM4YDAJ CS CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
DM4YDAJ IK BNRNXUUZRGQAQC-UHFFFAOYSA-N
DM4YDAJ IU 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DM4YDAJ CA CAS 139755-83-2
DM4YDAJ CB CHEBI:9139
DM4YDAJ DE Coronavirus Disease 2019 (COVID-19)
DMVO7UW ID DMVO7UW
DMVO7UW DN Siltuximab
DMVO7UW HS Phase 3
DMVO7UW SN Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1
DMVO7UW TC Antiviral Agents
DMVO7UW DT Monoclonal antibody
DMVO7UW DE Coronavirus Disease 2019 (COVID-19)
DM18QHT ID DM18QHT
DM18QHT DN Simvastatin acid
DM18QHT HS Phase 3
DM18QHT SN Simvastatin acid; Tenivastatin; UNII-9L6M5TH46B; DIMETHYL-COMPACTIN; 9L6M5TH46B; (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; Tenivastatin [INN]; (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoic acid
DM18QHT PC 64718
DM18QHT MW 436.6
DM18QHT FM C25H40O6
DM18QHT IC InChI=1S/C25H40O6/c1-6-25(4,5)24(30)31-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-18(26)13-19(27)14-22(28)29/h7-8,11,15-16,18-21,23,26-27H,6,9-10,12-14H2,1-5H3,(H,28,29)/t15-,16-,18+,19+,20-,21-,23-/m0/s1
DM18QHT CS CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)C
DM18QHT IK XWLXKKNPFMNSFA-HGQWONQESA-N
DM18QHT IU (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-(2,2-dimethylbutanoyloxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
DM18QHT CA CAS 121009-77-6
DM18QHT DE Chronic obstructive pulmonary disease
DMK8AQP ID DMK8AQP
DMK8AQP DN Sirukumab
DMK8AQP HS Phase 3
DMK8AQP CP GlaxoSmithKline
DMK8AQP DT Monoclonal antibody
DMK8AQP DE Rheumatoid arthritis; Cutaneous lupus erythematosus; Giant cell arteritis; Major depressive disorder
DM6BZCV ID DM6BZCV
DM6BZCV DN Sivelestat
DM6BZCV HS Phase 3
DM6BZCV SN 127373-66-4; UNII-DWI62G0P59; 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid; Elastase Inhibitor IV; C20H22N2O7S; N-(2-(4-(2,2-Dimethylpropionyloxy)phenylsulfonylamino)benzoyl)aminoacetic acid; Sivelestat (ONO-5046); LY544349; CHEMBL76688; LY 544349; DWI62G0P59; Glycine, N-(2-(((4-(2,2-dimethyl-1-oxopropoxy)phenyl)sulfonyl)amino)benzoyl)-; N-(o-(p-Pivaloyloxybenzene)sulfonylaminobenzoyl)glycine
DM6BZCV DT Small molecular drug
DM6BZCV PC 107706
DM6BZCV MW 434.5
DM6BZCV FM C20H22N2O7S
DM6BZCV IC InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24)
DM6BZCV CS CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O
DM6BZCV IK BTGNGJJLZOIYID-UHFFFAOYSA-N
DM6BZCV IU 2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetic acid
DM6BZCV CA CAS 127373-66-4
DM6BZCV CB CHEBI:135704
DM6BZCV DE Anterior uveitis; Pyoderma gangrenosum; Axial spondyloarthritis; Crohn disease; Multiple sclerosis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
DMWOF1E ID DMWOF1E
DMWOF1E DN SKY59
DMWOF1E HS Phase 3
DMWOF1E SN Crovalimab; RO7112689
DMWOF1E CP Roche
DMWOF1E DT Antibody
DMWOF1E DE Haemolytic uraemic syndrome
DMH7W9X ID DMH7W9X
DMH7W9X DN SNDX-275
DMH7W9X HS Phase 3
DMH7W9X SN Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
DMH7W9X CP Bayer Schering
DMH7W9X DT Small molecular drug
DMH7W9X PC 4261
DMH7W9X MW 376.4
DMH7W9X FM C21H20N4O3
DMH7W9X IC InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)
DMH7W9X CS C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3
DMH7W9X IK INVTYAOGFAGBOE-UHFFFAOYSA-N
DMH7W9X IU pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
DMH7W9X CA CAS 209783-80-2
DMH7W9X CB CHEBI:132082
DMH7W9X DE Colorectal cancer; Melanoma; Ovarian cancer; Non-small-cell lung cancer; Breast cancer
DMOQKAD ID DMOQKAD
DMOQKAD DN SNF472
DMOQKAD HS Phase 3
DMOQKAD SN Hexasodium phytate; UNII-ZBX50UG81V; 34367-89-0(Hexasodium phytate); ZBX50UG81V; 34367-89-0; sodium cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen phosphate); Inositol, hexakis(dihydrogen phosphate) hexasodium salt, myo-; Myo-inositol, hexakis(dihydrogen phosphate), hexasodium salt; Q27295268; scyllo-inositol,1,2,3,4,5,6-hexakis(dihydrogenphosphate),hexasodiumsalt; (1R,2R,3S,4S,5S,6S)-cyclohexane-(1,2,3,4,5,6)-hexaylhexakis(hydrogenphosphate),hexasodiumsalt
DMOQKAD CP Sanifit
DMOQKAD DT Small molecular drug
DMOQKAD PC 91667962
DMOQKAD MW 791.93
DMOQKAD FM C6H12Na6O24P6
DMOQKAD IC InChI=1S/C6H18O24P6.6Na/c7-31(8,9)25-1-2(26-32(10,11)12)4(28-34(16,17)18)6(30-36(22,23)24)5(29-35(19,20)21)3(1)27-33(13,14)15;;;;;;/h1-6H,(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24);;;;;;/q;6*+1/p-6
DMOQKAD CS C1(C(C(C(C(C1OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-])OP(=O)(O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMOQKAD IK DHZIAGCFFSRULK-UHFFFAOYSA-H
DMOQKAD IU hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate
DMOQKAD CA CAS 34367-89-0
DMOQKAD DE Calciphylaxis; Calcific uremic arteriolopathy
DMZE2JO ID DMZE2JO
DMZE2JO DN SNS-595
DMZE2JO HS Phase 3
DMZE2JO SN Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DMZE2JO CP Sunesis Pharmaceuticals Inc
DMZE2JO DT Small molecular drug
DMZE2JO PC 9952884
DMZE2JO MW 401.4
DMZE2JO FM C18H19N5O4S
DMZE2JO IC InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
DMZE2JO CS CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O
DMZE2JO IK XZAFZXJXZHRNAQ-STQMWFEESA-N
DMZE2JO IU 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid
DMZE2JO CA CAS 175414-77-4
DMZE2JO DE Ovarian cancer; Acute myeloid leukaemia
DMPBA0D ID DMPBA0D
DMPBA0D DN Sofpironium bromide
DMPBA0D HS Phase 3
DMPBA0D SN BBI-4000; 1628106-94-4; Sofpironium bromide [USAN]; CHEMBL3707223; Sofpironium bromide (JAN/USAN/INN); D10989; Pyrrolidinium, 3-(((2R)-2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy)-1-(2-ethoxy-2-oxoethyl)-1-methyl-, bromide (1:1), (3R)-
DMPBA0D CP Brickell Biotech Boulder, CO
DMPBA0D PC 86301316
DMPBA0D MW 470.4
DMPBA0D FM C22H32BrNO5
DMPBA0D IC InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1
DMPBA0D CS CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
DMPBA0D IK FIAFMTCUJCWADZ-JOFREBOKSA-M
DMPBA0D IU [(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
DMPBA0D CA CAS 1628106-94-4
DMPBA0D DE Primary axillary hyperhidrosis
DM0HIU5 ID DM0HIU5
DM0HIU5 DN Solanezumab
DM0HIU5 HS Phase 3
DM0HIU5 CP Eli Lilly
DM0HIU5 DT Monoclonal antibody
DM0HIU5 DE Alzheimer disease
DM6QZIA ID DM6QZIA
DM6QZIA DN Solithromycin
DM6QZIA HS Phase 3
DM6QZIA SN Solithromycin; CEM-101; OP-1068; OPT-1068; Solithromycin (iv, bacterial pneumonia), Cempra; Solithromycin (malaria), Cempra/Medicines for Malaria Venture; Solithromycin (oral, bacterial pneumonia), Cempra; CEM-101 (iv, bacterial pneumonia), Cempra; CEM-101 (malaria), Cempra/Medicines for Malaria Venture; CEM-101 (oral, bacterial pneumonia), Cempra
DM6QZIA CP Cempra pharmaceuticals
DM6QZIA DT Small molecular drug
DM6QZIA PC 25242512
DM6QZIA MW 845
DM6QZIA FM C43H65FN6O10
DM6QZIA IC InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
DM6QZIA CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=N4)C5=CC(=CC=C5)N)C
DM6QZIA IK IXXFZUPTQVDPPK-ZAWHAJPISA-N
DM6QZIA IU (1S,2R,5S,7R,8R,9R,11R,13R,14R)-15-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DM6QZIA CA 760981-83-7
DM6QZIA DE Bacillus anthracis infection
DMLAYTP ID DMLAYTP
DMLAYTP DN Soluble ferric pyrophosphate
DMLAYTP HS Phase 3
DMLAYTP SN Ferric pyrophosphate; Soluble ferric pyrophosphate (anemia)
DMLAYTP CP Rockwell Medical Inc
DMLAYTP DT Small molecular drug
DMLAYTP PC 24877
DMLAYTP MW 745.21
DMLAYTP FM Fe4O21P6
DMLAYTP IC InChI=1S/4Fe.3H4O7P2/c;;;;3*1-8(2,3)7-9(4,5)6/h;;;;3*(H2,1,2,3)(H2,4,5,6)/q4*+3;;;/p-12
DMLAYTP CS [O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[Fe+3].[Fe+3].[Fe+3].[Fe+3]
DMLAYTP IK CADNYOZXMIKYPR-UHFFFAOYSA-B
DMLAYTP IU iron(3+);phosphonato phosphate
DMLAYTP CA CAS 10058-44-3
DMLAYTP CB CHEBI:132767
DMLAYTP DE Iron-deficiency anemia
DMIG4OX ID DMIG4OX
DMIG4OX DN SOTB07
DMIG4OX HS Phase 3
DMIG4OX DE Asthma
DMLSV74 ID DMLSV74
DMLSV74 DN Sotorasib
DMLSV74 HS Phase 3
DMLSV74 SN AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; AMG510 ; AMG 510; AMG-510; AMG510; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-
DMLSV74 CP Amgen
DMLSV74 DT Small molecular drug
DMLSV74 PC 137278711
DMLSV74 MW 560.6
DMLSV74 FM C30H30F2N6O3
DMLSV74 IC InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1
DMLSV74 CS C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C
DMLSV74 IK NXQKSXLFSAEQCZ-SFHVURJKSA-N
DMLSV74 IU 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
DMLSV74 CA CAS 2252403-56-6
DMLSV74 DE Non-small-cell lung cancer
DMMP51W ID DMMP51W
DMMP51W DN sparsentan
DMMP51W HS Phase 3
DMMP51W SN Sparsentan; RE-021; 254740-64-2; UNII-9242RO5URM; PS433540; PS-433540; CHEMBL539423; 9242RO5URM; BMS-346567; retrophin; Sparsentan [USAN]; compound 7 [PMID 15634011]; PS 33540; Sparsentan (RE-021); Sparsentan(PS433540); SCHEMBL535109; GTPL8448; BCP23969; BDBM50175523; SB16876; DB12548; CS-7947; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); HY-17621; L023324; 4'-((2-butyl-4-oxo-1,3-diazaspiro[44]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide; RE-021
DMMP51W DT Small molecular drug
DMMP51W PC 10257882
DMMP51W MW 592.8
DMMP51W FM C32H40N4O5S
DMMP51W IC InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
DMMP51W CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC
DMMP51W IK WRFHGDPIDHPWIQ-UHFFFAOYSA-N
DMMP51W IU 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
DMMP51W CA CAS 254740-64-2
DMMP51W DE Myocardial infarction; Hypertension; Focal segmental glomerulosclerosis
DM4TOEQ ID DM4TOEQ
DM4TOEQ DN Spartalizumab
DM4TOEQ HS Phase 3
DM4TOEQ CP Novartis
DM4TOEQ DT Monoclonal antibody
DM4TOEQ DE Melanoma
DM7NV1I ID DM7NV1I
DM7NV1I DN SPD-465
DM7NV1I HS Phase 3
DM7NV1I SN Triple-bead MAS, Shire; Triple-bead mixed amphetamine salts (oral, attention deficit hyperactivity disorder ADHD), Shire
DM7NV1I CP Shire plc
DM7NV1I DE Attention deficit hyperactivity disorder
DMVJNFI ID DMVJNFI
DMVJNFI DN Spermidine
DMVJNFI HS Phase 3
DMVJNFI SN Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, > =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0
DMVJNFI DT Small molecular drug
DMVJNFI PC 1102
DMVJNFI MW 145.25
DMVJNFI FM C7H19N3
DMVJNFI IC InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2
DMVJNFI CS C(CCNCCCN)CN
DMVJNFI IK ATHGHQPFGPMSJY-UHFFFAOYSA-N
DMVJNFI IU N'-(3-aminopropyl)butane-1,4-diamine
DMVJNFI CA CAS 124-20-9
DMVJNFI CB CHEBI:16610
DMVJNFI DE Plaque psoriasis; Rheumatoid arthritis
DMACVEI ID DMACVEI
DMACVEI DN SPI-2012
DMACVEI HS Phase 3
DMACVEI CP SPECTRUM pharmaceuticals
DMACVEI DE Breast cancer
DM3PS2E ID DM3PS2E
DM3PS2E DN Squalamine
DM3PS2E HS Phase 3
DM3PS2E SN Squalamine; 148717-90-2; Squalamine [INN]; UNII-F8PO54Z4V7; F8PO54Z4V7; CHEBI:80765; 3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate; (3beta,5alpha,7alpha,24R)-3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate); 3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-; Cholestane-7,24-diol, 3-((3-(4-(aminobutyl)amino)propyl)amio)-, 24-(hydrogen sulfate), (3beta,5alpha,7alpha,24R)-
DM3PS2E CP OHR Pharmaceutical
DM3PS2E DT Small molecular drug
DM3PS2E PC 72495
DM3PS2E MW 628
DM3PS2E FM C34H65N3O5S
DM3PS2E IC InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1
DM3PS2E CS C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCN)C)O)C
DM3PS2E IK UIRKNQLZZXALBI-MSVGPLKSSA-N
DM3PS2E IU [(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
DM3PS2E CA CAS 148717-90-2
DM3PS2E CB CHEBI:80765
DM3PS2E DE Solid tumour/cancer; Diabetic macular edema
DM1ODMR ID DM1ODMR
DM1ODMR DN SR46349B
DM1ODMR HS Phase 3
DM1ODMR SN Eplivanserin fumarate; SR 46349; SR 46349B; SR-46349B; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one
DM1ODMR CP Sanofi-Aventis
DM1ODMR DT Small molecular drug
DM1ODMR PC 135456189
DM1ODMR MW 772.8
DM1ODMR FM C42H46F2N4O8
DM1ODMR IC InChI=1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
DM1ODMR CS CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.CN(CCO/N=C(\\C1=CC=CC=C1F)/C=C/C2=CC=C(C=C2)O)C.C(=C/C(=O)O)\\C(=O)O
DM1ODMR IK RNLKLYQQDLHHBH-ABDBJYMXSA-N
DM1ODMR IU (E)-but-2-enedioic acid;4-[(E,3Z)-3-[2-(dimethylamino)ethoxyimino]-3-(2-fluorophenyl)prop-1-enyl]phenol
DM1ODMR CA CAS 130580-02-8
DM1ODMR DE Schizophrenia; Primary insomnia; Sleep-wake disorder
DMT71EX ID DMT71EX
DMT71EX DN SSR-126517E
DMT71EX HS Phase 3
DMT71EX CP Sanofi-aventis
DMT71EX DE Thrombosis
DMVLKDX ID DMVLKDX
DMVLKDX DN Streptokinase rectal suppository
DMVLKDX HS Phase 3
DMVLKDX SN Proctokinase; Streptokinase rectal suppository (hemorrhoids); Streptokinase rectal suppository (hemorrhoids), CIGB
DMVLKDX CP Center for Genetic Engineering and Biotechnology
DMVLKDX DE Hemorrhoids
DMPOTM4 ID DMPOTM4
DMPOTM4 DN Sulfatinib
DMPOTM4 HS Phase 3
DMPOTM4 SN Anticancer agents, Hutchison; HMPL-012; Kinase inhibitors (cancer), Hutchison; VEGFR-1, 2, 3 and FGFR 1 inhibitor (oral, cancer), Hutchison
DMPOTM4 CP Hutchison Medipharma Enterprises Ltd
DMPOTM4 PC 52920501
DMPOTM4 MW 480.6
DMPOTM4 FM C24H28N6O3S
DMPOTM4 IC InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
DMPOTM4 CS CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C
DMPOTM4 IK TTZSNFLLYPYKIL-UHFFFAOYSA-N
DMPOTM4 IU N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
DMPOTM4 CA CAS 1308672-74-3
DMPOTM4 DE Solid tumour/cancer; Neuroendocrine cancer
DMMD856 ID DMMD856
DMMD856 DN Sulopenem
DMMD856 HS Phase 3
DMMD856 SN CP-70,429; PF-03709270; PF-3,709,270
DMMD856 TC Antiinfective Agents
DMMD856 DT Small molecular drug
DMMD856 PC 9950244
DMMD856 MW 349.5
DMMD856 FM C12H15NO5S3
DMMD856 IC InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1
DMMD856 CS C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O
DMMD856 IK FLSUCZWOEMTFAQ-PRBGKLEPSA-N
DMMD856 IU (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMMD856 CA CAS 120788-07-0
DMMD856 DE Urinary tract infection
DM07653 ID DM07653
DM07653 DN SULTHIAME
DM07653 HS Phase 3
DM07653 SN sultiame; SULTHIAME; Ospolot; sultiam; Sulphenyltame; Sulthiamine; Contravul; Trolone; 61-56-3; Sultiamum; Elisal; Conadil; Riker 594; Bayer A-168; Sultiamum [INN-Latin]; Sultiamo [INN-Spanish]; Sulthiame [USAN]; 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide; UNII-I00Q766CZ2; RP-10284; R-594; EINECS 200-511-0; p-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide, S,S-dioxide; BRN 1222219; Benzenesulfonamide, 4-(tetrahydro-2H-1,2-thiazin-2-yl)-, S,S-dioxide; RP 10284; 4-(1,1-Dioxido-1,2-thiazinan-2-yl)benzenesulfonamide; CHEMBL328560
DM07653 DT Small molecular drug
DM07653 PC 5356
DM07653 MW 290.4
DM07653 FM C10H14N2O4S2
DM07653 IC InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)
DM07653 CS C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N
DM07653 IK HMHVCUVYZFYAJI-UHFFFAOYSA-N
DM07653 IU 4-(1,1-dioxothiazinan-2-yl)benzenesulfonamide
DM07653 CA CAS 61-56-3
DM07653 CB CHEBI:32171
DMYHV17 ID DMYHV17
DMYHV17 DN Sumanirole
DMYHV17 HS Phase 3
DMYHV17 SN PNU 95666; U 95666E; PNU-95666; [2-[(1R)-1-(methylamino)ethyl]phenyl]methanol; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaS)-rel-, 2-naphthalenesulfonate (salt); 2-Naphthalenesulfonic acid, compd with (R*,S*)-alpha-(1-(methylamino)ethyl)benzenemethanol (1:1); 2-Naphthalenesulfonic acid, compd with rel-(alphaS)-alpha-((1R)-1-(methylamino)ethyl)benzenemethanol (1:1)
DMYHV17 CP Pfizer
DMYHV17 DT Small molecular drug
DMYHV17 PC 9818479
DMYHV17 MW 203.24
DMYHV17 FM C11H13N3O
DMYHV17 IC InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1
DMYHV17 CS CN[C@@H]1CC2=C3C(=CC=C2)NC(=O)N3C1
DMYHV17 IK RKZSNTNMEFVBDT-MRVPVSSYSA-N
DMYHV17 IU (10R)-10-(methylamino)-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-2-one
DMYHV17 CA CAS 179386-43-7
DMYHV17 DE Parkinson disease
DMXNZQK ID DMXNZQK
DMXNZQK DN SUN-101
DMXNZQK HS Phase 3
DMXNZQK CP Sunovion
DMXNZQK DE Chronic obstructive pulmonary disease
DMH2FN1 ID DMH2FN1
DMH2FN1 DN Suronacrine maleate
DMH2FN1 HS Phase 3
DMH2FN1 SN HP-128; Suronacrine maleate < Rec INNM; Rac-9-(Benzylamino)-1,2,3,4-tetrahydroacridin-1-ol maleate
DMH2FN1 DT Small molecular drug
DMH2FN1 PC 9953907
DMH2FN1 MW 420.5
DMH2FN1 FM C24H24N2O5
DMH2FN1 IC InChI=1S/C20H20N2O.C4H4O4/c23-18-12-6-11-17-19(18)20(15-9-4-5-10-16(15)22-17)21-13-14-7-2-1-3-8-14;5-3(6)1-2-4(7)8/h1-5,7-10,18,23H,6,11-13H2,(H,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMH2FN1 CS C1CC(C2=C(C3=CC=CC=C3N=C2C1)NCC4=CC=CC=C4)O.C(=C\\C(=O)O)\\C(=O)O
DMH2FN1 IK JRQSVNSUJOFXHC-BTJKTKAUSA-N
DMH2FN1 IU 9-(benzylamino)-1,2,3,4-tetrahydroacridin-1-ol;(Z)-but-2-enedioic acid
DMH2FN1 CA CAS 113108-86-4
DMH2FN1 DE Cognitive impairment
DMY7WH1 ID DMY7WH1
DMY7WH1 DN Sutimlimab
DMY7WH1 HS Phase 3
DMY7WH1 CP Sanofi
DMY7WH1 DT Antibody
DMY7WH1 DE Cold type autoimmune haemolytic anemia
DM3BO8G ID DM3BO8G
DM3BO8G DN SUVN-G3031
DM3BO8G HS Phase 3
DM3BO8G SN LNXDUSQEXVQFGP-UHFFFAOYSA-N; UNII-65V47O9NOP; 65V47O9NOP; SCHEMBL12484542; N-[4-(1-Cyclobutyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; 1394808-82-2
DM3BO8G CP Suven Life Sciences Hyderabad, India
DM3BO8G PC 60151477
DM3BO8G MW 373.5
DM3BO8G FM C21H31N3O3
DM3BO8G IC InChI=1S/C21H31N3O3/c25-21(16-23-12-14-26-15-13-23)22-17-4-6-19(7-5-17)27-20-8-10-24(11-9-20)18-2-1-3-18/h4-7,18,20H,1-3,8-16H2,(H,22,25)
DM3BO8G CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)NC(=O)CN4CCOCC4
DM3BO8G IK LNXDUSQEXVQFGP-UHFFFAOYSA-N
DM3BO8G IU N-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide
DM3BO8G CA CAS 1394808-82-2
DM3BO8G DE Cognitive impairment
DMOVEDH ID DMOVEDH
DMOVEDH DN SYM-004
DMOVEDH HS Phase 3
DMOVEDH SN Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
DMOVEDH CP Symphogen A/S
DMOVEDH DT Antibody
DMOVEDH DE Head and neck cancer; Colorectal cancer; Metastatic colorectal cancer; Recurrent glioblastoma; Non-small-cell lung cancer
DMRUEKC ID DMRUEKC
DMRUEKC DN Synthetic conjugated estrogen
DMRUEKC HS Phase 3
DMRUEKC SN Bijuva; Bithena; DR-2041; SCE-A Vaginal Cream; Synthetic conjugated estrogen (cream, vulvovaginal atrophy); Synthetic conjugated estrogen (cream, vulvovaginal atrophy), Teva
DMRUEKC CP Duramed Pharmaceuticals Inc
DMRUEKC DE Vaginal disease
DMXU4ON ID DMXU4ON
DMXU4ON DN Synthetic hypericin
DMXU4ON HS Phase 3
DMXU4ON SN Hypericin; VIMRxyn; Synthetic hypericin, Nexell
DMXU4ON CP Nexell Therapeutics Inc
DMXU4ON DE Virus infection
DM9L1AC ID DM9L1AC
DM9L1AC DN SYR-472
DM9L1AC HS Phase 3
DM9L1AC SN Trelagliptin succinate; TRELAGLIPTIN SUCCINATE; 1029877-94-8; Trelagliptin (succinate); UNII-4118932Z90; AK198895; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile; 4118932Z90; SYR-472 succinate; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate; SYR 111472 succinate; Trelagliptin succinate [USAN]; SYR111472 SUCCINATE; SYR 472; SYR472; Zafatek (TN); Trelagliptin succinat; SYR472 succinate; syr; Trelagliptin Succinate
DM9L1AC CP Takeda
DM9L1AC DT Small molecular drug
DM9L1AC PC 15983988
DM9L1AC MW 357.4
DM9L1AC FM C18H20FN5O2
DM9L1AC IC InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1
DM9L1AC CS CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCC[C@H](C3)N
DM9L1AC IK IWYJYHUNXVAVAA-OAHLLOKOSA-N
DM9L1AC IU 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
DM9L1AC CA CAS 865759-25-7
DM9L1AC CB CHEBI:134715
DM9L1AC DE Non-insulin dependent diabetes; Metabolic disorder
DMR32KN ID DMR32KN
DMR32KN DN TA-6366
DMR32KN HS Phase 3
DMR32KN SN Hipertene (TN); Imidapril (INN); Imidapril HCl; Imidapril [BAN:INN]; Imidapril [INN:BAN]; Imidaprilum; Imidaprilum [INN-Latin]; Novaloc; Tanatril; imidapril; lmidaprfil; (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid; (S)-3-(N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)-L-alanyl)-1-methyl-2-oxoimidazoline-4-carboxylic acid; 89371-37-9; BW7H1TJS22; C20H27N3O6; CHEMBL317094; MFCD00923828; NCGC00181342-01; UNII-BW7H1TJS22
DMR32KN PC 5464343
DMR32KN MW 405.4
DMR32KN FM C20H27N3O6
DMR32KN IC KLZWOWYOHUKJIG-BPUTZDHNSA-N
DMR32KN CS CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C(CN(C2=O)C)C(=O)O
DMR32KN IK 1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
DMR32KN IU (4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
DMR32KN CA CAS 89371-37-9
DMR32KN CB CHEBI:135654
DMR32KN DE Essential hypertension
DMKSAG1 ID DMKSAG1
DMKSAG1 DN Tabalumab
DMKSAG1 HS Phase 3
DMKSAG1 SN LY2127399
DMKSAG1 CP Lilly
DMKSAG1 DT Monoclonal antibody
DMKSAG1 DE Multiple myeloma
DMW5PHL ID DMW5PHL
DMW5PHL DN Taberminogene vadenovec
DMW5PHL HS Phase 3
DMW5PHL SN Trinam (TN)
DMW5PHL CP Ark Therapeutics
DMW5PHL DE Vascular restinosis
DM1NTVQ ID DM1NTVQ
DM1NTVQ DN Tadekinig alfa
DM1NTVQ HS Phase 3
DM1NTVQ CP AB2 Bio
DM1NTVQ DT Recombinant protein
DM1NTVQ DE XIAP deficiency
DMCF6SX ID DMCF6SX
DMCF6SX DN TAK-491
DMCF6SX HS Phase 3
DMCF6SX SN TAK 491
DMCF6SX CP Takeda
DMCF6SX DT Small molecular drug
DMCF6SX PC 135409642
DMCF6SX MW 568.5
DMCF6SX FM C30H24N4O8
DMCF6SX IC InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
DMCF6SX CS CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C
DMCF6SX IK QJFSABGVXDWMIW-UHFFFAOYSA-N
DMCF6SX IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
DMCF6SX CA CAS 863031-21-4
DMCF6SX CB CHEBI:68845
DMCF6SX DE Hypertension
DM2H8FZ ID DM2H8FZ
DM2H8FZ DN TAK-700
DM2H8FZ HS Phase 3
DM2H8FZ SN Orteronel
DM2H8FZ CP Millennium Pharmaceuticals
DM2H8FZ DT Small molecular drug
DM2H8FZ PC 9883029
DM2H8FZ MW 307.3
DM2H8FZ FM C18H17N3O2
DM2H8FZ IC InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)
DM2H8FZ CS CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O
DM2H8FZ IK OZPFIJIOIVJZMN-UHFFFAOYSA-N
DM2H8FZ IU 6-(7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide
DM2H8FZ CB CHEBI:94965
DM2H8FZ DE Prostate cancer
DMIM5AP ID DMIM5AP
DMIM5AP DN TAK-875
DMIM5AP HS Phase 3
DMIM5AP SN TAK-875; Fasiglifam; 1000413-72-8; TAK875; TAK 875; UNII-GLP1W4JXAH; GLP1W4JXAH; (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid; CHEMBL1829174; [(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid; 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-; J-501277
DMIM5AP CP Takeda Pharmaceuticals U.S.A.
DMIM5AP DT Small molecular drug
DMIM5AP PC 24857286
DMIM5AP MW 524.6
DMIM5AP FM C29H32O7S
DMIM5AP IC InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
DMIM5AP CS CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)[C@@H](CO4)CC(=O)O)C)OCCCS(=O)(=O)C
DMIM5AP IK BZCALJIHZVNMGJ-HSZRJFAPSA-N
DMIM5AP IU 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid
DMIM5AP CA CAS 1000413-72-8
DMIM5AP DE Type-2 diabetes
DM1IZ5D ID DM1IZ5D
DM1IZ5D DN Talabostat
DM1IZ5D HS Phase 3
DM1IZ5D SN Talabostat mesylate; Boroproline compounds, DARA BioSciences; Boroproline compounds, Point Therapeutics; PT-100; Val-boro-Pro
DM1IZ5D CP Point Therapeutics; Tufts University School of Medicine
DM1IZ5D DT Small molecular drug
DM1IZ5D PC 6918572
DM1IZ5D MW 214.07
DM1IZ5D FM C9H19BN2O3
DM1IZ5D IC InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1
DM1IZ5D CS B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O
DM1IZ5D IK FKCMADOPPWWGNZ-YUMQZZPRSA-N
DM1IZ5D IU [(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid
DM1IZ5D CA CAS 149682-77-9
DM1IZ5D DE Constitutional neutropenia; Solid tumour/cancer
DMV7T64 ID DMV7T64
DMV7T64 DN Talactoferrin
DMV7T64 HS Phase 3
DMV7T64 SN Talactoferrin (topical)
DMV7T64 CP Agennix AG
DMV7T64 DE Diabetic foot ulcer
DM3G74J ID DM3G74J
DM3G74J DN Tamibarotene
DM3G74J HS Phase 3
DM3G74J SN Tamibarotene (oral, Alzheimer's disease)
DM3G74J CP Research Foundation Itsuu Laboratory
DM3G74J DT Small molecular drug
DM3G74J PC 108143
DM3G74J MW 351.4
DM3G74J FM C22H25NO3
DM3G74J IC InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DM3G74J CS CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
DM3G74J IK MUTNCGKQJGXKEM-UHFFFAOYSA-N
DM3G74J IU 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
DM3G74J CA CAS 94497-51-5
DM3G74J CB CHEBI:32181
DM3G74J DE Alzheimer disease; T-cell leukaemia
DMJKWMA ID DMJKWMA
DMJKWMA DN Tanezumab
DMJKWMA HS Phase 3
DMJKWMA CP Pfizer New York, NY
DMJKWMA DT Monoclonal antibody
DMJKWMA DE Neuropathic pain; Chronic low back pain; Pain; Osteoarthritis; Cancer related pain
DMWM4D0 ID DMWM4D0
DMWM4D0 DN TAS-120
DMWM4D0 HS Phase 3
DMWM4D0 CP Taiho oncology
DMWM4D0 PC 71621331
DMWM4D0 MW 418.4
DMWM4D0 FM C22H22N6O3
DMWM4D0 IC InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1
DMWM4D0 CS COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC
DMWM4D0 IK KEIPNCCJPRMIAX-HNNXBMFYSA-N
DMWM4D0 IU 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
DMWM4D0 CA CAS 1448169-71-8
DMWM4D0 DE Multiple myeloma; Solid tumour/cancer; Cholangiocarcinoma
DMPYET9 ID DMPYET9
DMPYET9 DN Taspoglutide
DMPYET9 HS Phase 3
DMPYET9 SN BIM-51077; BIM-51079; BIM-51182; Glucagon agonists, Ipsen; ITM-077; R-1583; RG-1583; RO-5073031; Glucagon agonists, Beaufour-Ipsen
DMPYET9 CP Ipsen
DMPYET9 PC 56842233
DMPYET9 MW 3339.7
DMPYET9 FM C152H232N40O45
DMPYET9 IC InChI=1S/C152H232N40O45/c1-20-78(10)119(145(233)168-81(13)125(213)174-105(63-87-66-162-92-39-28-27-38-90(87)92)134(222)176-101(59-75(4)5)135(223)187-117(76(6)7)143(231)173-95(41-30-32-56-154)142(230)192-152(18,19)148(236)184-93(122(157)210)42-33-57-161-150(158)159)189-136(224)103(60-84-34-23-21-24-35-84)177-131(219)99(50-54-115(206)207)172-130(218)94(40-29-31-55-153)170-124(212)80(12)166-123(211)79(11)167-129(217)98(47-51-110(156)199)169-111(200)68-163-127(215)96(48-52-113(202)203)171-132(220)100(58-74(2)3)175-133(221)102(62-86-43-45-89(198)46-44-86)178-139(227)107(70-193)181-141(229)109(72-195)182-144(232)118(77(8)9)188-138(226)106(65-116(208)209)179-140(228)108(71-194)183-147(235)121(83(15)197)190-137(225)104(61-85-36-25-22-26-37-85)180-146(234)120(82(14)196)186-112(201)69-164-128(216)97(49-53-114(204)205)185-149(237)151(16,17)191-126(214)91(155)64-88-67-160-73-165-88/h21-28,34-39,43-46,66-67,73-83,91,93-109,117-121,162,193-198H,20,29-33,40-42,47-65,68-72,153-155H2,1-19H3,(H2,156,199)(H2,157,210)(H,160,165)(H,163,215)(H,164,216)(H,166,211)(H,167,217)(H,168,233)(H,169,200)(H,170,212)(H,171,220)(H,172,218)(H,173,231)(H,174,213)(H,175,221)(H,176,222)(H,177,219)(H,178,227)(H,179,228)(H,180,234)(H,181,229)(H,182,232)(H,183,235)(H,184,236)(H,185,237)(H,186,201)(H,187,223)(H,188,226)(H,189,224)(H,190,225)(H,191,214)(H,192,230)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,119-,120-,121-/m0/s1
DMPYET9 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
DMPYET9 IK WRGVLTAWMNZWGT-VQSPYGJZSA-N
DMPYET9 IU (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DMPYET9 CA CAS 275371-94-3
DMPYET9 DE Type-1 diabetes
DM9GSVQ ID DM9GSVQ
DM9GSVQ DN Tasquinimod
DM9GSVQ HS Phase 3
DM9GSVQ SN TASQ
DM9GSVQ CP Active Biotech
DM9GSVQ DT Small molecular drug
DM9GSVQ PC 54682876
DM9GSVQ MW 406.4
DM9GSVQ FM C20H17F3N2O4
DM9GSVQ IC InChI=1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3
DM9GSVQ CS CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O
DM9GSVQ IK ONDYALNGTUAJDX-UHFFFAOYSA-N
DM9GSVQ IU 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide
DM9GSVQ CA CAS 254964-60-8
DM9GSVQ DE Prostate cancer
DMD6AUX ID DMD6AUX
DMD6AUX DN Tat-NR2B9c
DMD6AUX HS Phase 3
DMD6AUX SN NA-1; NA-1); PSD-95 inhibitor (stroke), NoNO/Arbor Vita; NMDAR NR2 domain-binding protein + HIV-1 Tat protein (Stroke), NoNO/Arbor Vita
DMD6AUX CP Nono inc
DMD6AUX DT Peptide
DMD6AUX PC 44568939
DMD6AUX MW 2518.9
DMD6AUX FM C105H188N42O30
DMD6AUX IC InChI=1S/C105H188N42O30/c1-7-55(6)80(98(175)140-69(34-36-77(154)155)92(169)143-72(50-148)95(172)142-71(48-78(156)157)94(171)146-79(54(4)5)99(176)177)147-97(174)74(52-150)145-96(173)73(51-149)144-93(170)70(46-53(2)3)141-90(167)62(22-10-13-39-108)133-85(162)63(24-15-41-124-101(113)114)135-87(164)65(26-17-43-126-103(117)118)136-88(165)66(27-18-44-127-104(119)120)138-91(168)68(33-35-75(110)152)139-89(166)67(28-19-45-128-105(121)122)137-86(163)64(25-16-42-125-102(115)116)134-84(161)61(21-9-12-38-107)132-83(160)60(20-8-11-37-106)131-82(159)59(23-14-40-123-100(111)112)130-76(153)49-129-81(158)58(109)47-56-29-31-57(151)32-30-56/h29-32,53-55,58-74,79-80,148-151H,7-28,33-52,106-109H2,1-6H3,(H2,110,152)(H,129,158)(H,130,153)(H,131,159)(H,132,160)(H,133,162)(H,134,161)(H,135,164)(H,136,165)(H,137,163)(H,138,168)(H,139,166)(H,140,175)(H,141,167)(H,142,172)(H,143,169)(H,144,170)(H,145,173)(H,146,171)(H,147,174)(H,154,155)(H,156,157)(H,176,177)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/t55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,79-,80-/m0/s1
DMD6AUX CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N
DMD6AUX IK XWQVQFBTSBCKLI-FKXNDIMNSA-N
DMD6AUX IU (4S)-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMD6AUX CA CAS 500992-11-0
DMD6AUX DE Cerebrovascular ischaemia; Stroke
DML6GAN ID DML6GAN
DML6GAN DN Taxol/Paraplatin/Herceptin
DML6GAN HS Phase 3
DML6GAN SN Paclitaxel/carboplatin/trastuzumab
DML6GAN CP Bristol-Myers Squibb
DML6GAN DE Breast cancer
DMGKBZH ID DMGKBZH
DMGKBZH DN TD-1792
DMGKBZH HS Phase 3
DMGKBZH CP Theravance
DMGKBZH DT Small molecular drug
DMGKBZH PC 76960417
DMGKBZH MW 1983.3
DMGKBZH FM C87H95Cl3N16O28S2
DMGKBZH IC InChI=1S/C87H95Cl3N16O28S2/c1-33(2)20-45(94-5)74(117)100-62-66(112)36-11-14-49(43(88)22-36)130-51-24-38-25-52(70(51)134-85-71(69(115)68(114)53(31-107)132-85)133-55-29-87(4,93)72(116)34(3)129-55)131-50-15-12-37(23-44(50)89)67(113)63-81(124)99-59(42-26-40(108)27-48(110)56(42)41-21-35(10-13-47(41)109)57(77(120)101-63)98-78(121)58(38)97-75(118)46(28-54(91)111)96-80(62)123)76(119)95-16-9-19-128-104-61(60-73(90)136-86(92)103-60)79(122)102-64-82(125)106-65(84(126)127)39(32-135-83(64)106)30-105-17-7-6-8-18-105/h6-8,10-15,17-18,21-27,33-34,45-46,53,55,57-59,62-64,66-69,71-72,83,85,94,107,112-116H,9,16,19-20,28-32,93H2,1-5H3,(H15-,91,92,95,96,97,98,99,100,101,102,103,104,108,109,110,111,117,118,119,120,121,122,123,124,126,127)/t34-,45+,46-,53+,55-,57+,58+,59-,62+,63-,64+,66+,67+,68+,69-,71+,72+,83+,85-,87-/m0/s1
DMGKBZH CS C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)NCCCO/N=C(/C1=C(SC(=N1)N)Cl)\\C(=O)N[C@H]1[C@@H]2N(C1=O)C(=C(CS2)C[N+]1=CC=CC=C1)C(=O)[O-])CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMGKBZH IK OGUAFUAJSPORAH-KHCCTVBNSA-N
DMGKBZH IU (6R,7R)-7-[[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[3-[[(1S,2R,18R,19R,22S,25R,28R,40S)-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carbonyl]amino]propoxyimino]acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMGKBZH CA CAS 722454-12-8
DMGKBZH DE Gram-positive bacterial infection; Skin infection
DMVSX6O ID DMVSX6O
DMVSX6O DN Tebipenem
DMVSX6O HS Phase 3
DMVSX6O SN Tebipenem [INN]
DMVSX6O CP Sanofi-Aventis
DMVSX6O DT Small molecular drug
DMVSX6O PC 9800194
DMVSX6O MW 383.5
DMVSX6O FM C16H21N3O4S2
DMVSX6O IC InChI=1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1
DMVSX6O CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O
DMVSX6O IK GXXLUDOKHXEFBQ-YJFSRANCSA-N
DMVSX6O IU (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DMVSX6O CA CAS 161715-21-5
DMVSX6O DE Obesity; Nicotine dependence; Urinary tract infection
DMTCR2O ID DMTCR2O
DMTCR2O DN Tecarfarin
DMTCR2O HS Phase 3
DMTCR2O SN ATI-5923
DMTCR2O CP ARYx Therapeutics
DMTCR2O DT Small molecular drug
DMTCR2O PC 54718618
DMTCR2O MW 460.3
DMTCR2O FM C21H14F6O5
DMTCR2O IC InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
DMTCR2O CS CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
DMTCR2O IK QFLNTQDOVCLQKW-UHFFFAOYSA-N
DMTCR2O IU (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate
DMTCR2O CA CAS 867257-26-9
DMTCR2O DE Cerebrovascular ischaemia; Thrombosis
DMKE187 ID DMKE187
DMKE187 DN Telmisartan
DMKE187 HS Phase 3
DMKE187 SN Telmisartan; 144701-48-4; Micardis; Pritor; BIBR 277; Kinzalmono; BIBR-277; BIBR 277SE; Telmisattan; Targit; Telmisartan [INN]; UNII-U5SYW473RQ; BIBR-277SE; BIBR-277-SE; U5SYW473RQ; CHEMBL1017; CHEBI:9434; Telmisartan
DMKE187 TC Antiviral Agents
DMKE187 DT Small molecular drug
DMKE187 PC 65999
DMKE187 MW 514.6
DMKE187 FM C33H30N4O2
DMKE187 IC InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
DMKE187 CS CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C
DMKE187 IK RMMXLENWKUUMAY-UHFFFAOYSA-N
DMKE187 IU 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
DMKE187 CA CAS 144701-48-4
DMKE187 CB CHEBI:9434
DMKE187 DE Coronavirus Disease 2019 (COVID-19)
DMHQRYE ID DMHQRYE
DMHQRYE DN Tenidap
DMHQRYE HS Phase 3
DMHQRYE DT Small molecular drug
DMHQRYE PC 60712
DMHQRYE MW 320.8
DMHQRYE FM C14H9ClN2O3S
DMHQRYE IC InChI=1S/C14H9ClN2O3S/c15-7-3-4-9-8(6-7)11(13(19)17(9)14(16)20)12(18)10-2-1-5-21-10/h1-6,19H,(H2,16,20)
DMHQRYE CS C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O
DMHQRYE IK IZSFDUMVCVVWKW-UHFFFAOYSA-N
DMHQRYE IU 5-chloro-2-hydroxy-3-(thiophene-2-carbonyl)indole-1-carboxamide
DMHQRYE CA CAS 120210-48-2
DMHQRYE CB CHEBI:35847
DMHQRYE DE Rheumatoid arthritis
DMHOV7D ID DMHOV7D
DMHOV7D DN Tenofovir alafenamide
DMHOV7D HS Phase 3
DMHOV7D SN (S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate; AK109983; EL9943AG5J; GS 7340; GS-7339; GS-7340; GS7340; J4414G3BUK; L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-methylethyl ester; TENOFOVIR ALAFENAMIDE; Tenofovir Alafenamide (GS-7340); Tenofovir Alafenamide [USAN:INN]; UNII-EL9943AG5J; UNII-J4414G3BUK; Vemlidy
DMHOV7D TC Antiviral Agent
DMHOV7D DT Small molecular drug
DMHOV7D PC 9574768
DMHOV7D MW 476.474
DMHOV7D FM C21H29N6O5P
DMHOV7D IC InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
DMHOV7D CS CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OC3=CC=CC=C3
DMHOV7D IK LDEKQSIMHVQZJK-CAQYMETFSA-N
DMHOV7D IU propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate
DMHOV7D CA CAS 379270-37-8
DMHOV7D CB CHEBI:90926
DMHOV7D DE Chronic hepatitis B infection; Human immunodeficiency virus infection
DMZ3P6C ID DMZ3P6C
DMZ3P6C DN Teplizumab
DMZ3P6C HS Phase 3
DMZ3P6C CP MacroGenics
DMZ3P6C DT Antibody
DMZ3P6C DE Type-1 diabetes; Melanoma
DM4MZXE ID DM4MZXE
DM4MZXE DN Terodiline
DM4MZXE HS Phase 3
DM4MZXE SN Bicor; Microl; Mictrol; Micturin; Micturol; Terolin; Terodiline hydrochloride; TD-758
DM4MZXE CP Pharmacia & Upjohn AB
DM4MZXE DT Small molecular drug
DM4MZXE PC 23480
DM4MZXE MW 281.4
DM4MZXE FM C20H27N
DM4MZXE IC InChI=1S/C20H27N/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,16,19,21H,15H2,1-4H3
DM4MZXE CS CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C
DM4MZXE IK UISARWKNNNHPGI-UHFFFAOYSA-N
DM4MZXE IU N-tert-butyl-4,4-diphenylbutan-2-amine
DM4MZXE CA CAS 15793-40-5
DM4MZXE CB CHEBI:135168
DM4MZXE DE Urinary incontinence
DMGRBN5 ID DMGRBN5
DMGRBN5 DN TESAGLITAZAR
DMGRBN5 HS Phase 3
DMGRBN5 SN Tesaglitazar; 251565-85-2; Galida; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AZ 242; AZ-242; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; UNII-6734037O3L; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; BR-44608; 6734037O3L; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
DMGRBN5 DT Small molecular drug
DMGRBN5 PC 208901
DMGRBN5 MW 408.5
DMGRBN5 FM C20H24O7S
DMGRBN5 IC InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
DMGRBN5 CS CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
DMGRBN5 IK CXGTZJYQWSUFET-IBGZPJMESA-N
DMGRBN5 IU (2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
DMGRBN5 CA CAS 251565-85-2
DMGRBN5 DE Type-1 diabetes
DMMTKC6 ID DMMTKC6
DMMTKC6 DN TEV-48125
DMMTKC6 HS Phase 3
DMMTKC6 DT Antibody
DMMTKC6 DE Migraine
DM9R5J6 ID DM9R5J6
DM9R5J6 DN Tezepelumab
DM9R5J6 HS Phase 3
DM9R5J6 CP Amgen; AstraZeneca
DM9R5J6 DT Antibody
DM9R5J6 DE Severe asthma
DMLCXPD ID DMLCXPD
DMLCXPD DN TG-C
DMLCXPD HS Phase 3
DMLCXPD SN 3-Thiaglutaryl-Coa; S-[[(2-Hydroxy-2-oxoethyl)thio]acetyl]coenzyme A; (3R,5S,9R)-1-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-3,5,9-trihydroxy-8,8-dimethyl-10,14,19-trioxo-2,4,6-trioxa-18,21-dithia-11,15-diaza-3,5-diphosphatricosan-23-oic acid 3,5-dioxide; TGC
DMLCXPD DT Small molecular drug
DMLCXPD PC 24768536
DMLCXPD MW 899.7
DMLCXPD FM C25H40N7O19P3S2
DMLCXPD IC InChI=1S/C25H40N7O19P3S2/c1-25(2,20(38)23(39)28-4-3-14(33)27-5-6-56-16(36)9-55-8-15(34)35)10-48-54(45,46)51-53(43,44)47-7-13-19(50-52(40,41)42)18(37)24(49-13)32-12-31-17-21(26)29-11-30-22(17)32/h11-13,18-20,24,37-38H,3-10H2,1-2H3,(H,27,33)(H,28,39)(H,34,35)(H,43,44)(H,45,46)(H2,26,29,30)(H2,40,41,42)/t13-,18-,19-,20+,24-/m1/s1
DMLCXPD CS CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCSC(=O)CSCC(=O)O)O
DMLCXPD IK GKSSRSUPHZUOQO-ITIYDSSPSA-N
DMLCXPD IU 2-[2-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-2-oxoethyl]sulfanylacetic acid
DMLCXPD DE Arthritis
DMPGH7N ID DMPGH7N
DMPGH7N DN ThermoProfen
DMPGH7N HS Phase 3
DMPGH7N CP ZARS Pharma
DMPGH7N DE Pain
DM3PA8H ID DM3PA8H
DM3PA8H DN THVD-201
DM3PA8H HS Phase 3
DM3PA8H SN Tolterodine + pilocarpine (overactive bladder/urinary incontinence), TheraVida
DM3PA8H CP TheraVida Inc
DM3PA8H DE Overactive bladder
DM3DG5C ID DM3DG5C
DM3DG5C DN THX-TS01
DM3DG5C HS Phase 3
DM3DG5C CP Therapix Biosciences Givatayim, Israel
DM3DG5C DE Tourette syndrome
DMMO6P0 ID DMMO6P0
DMMO6P0 DN Tifacogin
DMMO6P0 HS Phase 3
DMMO6P0 SN LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron
DMMO6P0 CP GD Searle & Co; Chiron
DMMO6P0 DT Small molecular drug
DMMO6P0 PC 961320
DMMO6P0 MW 203.31
DMMO6P0 FM C12H13NS
DMMO6P0 IC InChI=1S/C12H13NS/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13H,9-10H2
DMMO6P0 CS C1=CC=C(C=C1)CNCC2=CC=CS2
DMMO6P0 IK GEWKIDGKZRKUFB-UHFFFAOYSA-N
DMMO6P0 IU 1-phenyl-N-(thiophen-2-ylmethyl)methanamine
DMMO6P0 CA CAS 73325-61-8
DMMO6P0 DE Sepsis
DMZBGI8 ID DMZBGI8
DMZBGI8 DN Tilarginine acetate
DMZBGI8 HS Phase 3
DMZBGI8 SN 53308-83-1; L-NMMA acetate; UNII-2FL3530AF2; 2FL3530AF2; DSSTox_RID_81122; DSSTox_CID_25780; DSSTox_GSID_45780; SMR000449329; CAS-53308-83-1; N-omega-Monomethyl-L-arginine monoacetate, 99%
DMZBGI8 CP ArgiNOx
DMZBGI8 DT Small molecular drug
DMZBGI8 PC 135242
DMZBGI8 MW 248.28
DMZBGI8 FM C9H20N4O4
DMZBGI8 IC InChI=1S/C7H16N4O2.C2H4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13;1-2(3)4/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H3,(H,3,4)/t5-;/m0./s1
DMZBGI8 CS CC(=O)O.CN=C(N)NCCC[C@@H](C(=O)O)N
DMZBGI8 IK IKPNWIGTWUZCKM-JEDNCBNOSA-N
DMZBGI8 IU acetic acid;(2S)-2-amino-5-[(N'-methylcarbamimidoyl)amino]pentanoic acid
DMZBGI8 CA CAS 53308-83-1
DMZBGI8 DE Angina pectoris; Myocardial infarction
DMGYK2N ID DMGYK2N
DMGYK2N DN Tilsotolimod
DMGYK2N HS Phase 3
DMGYK2N SN IMO-2125
DMGYK2N CP Idera Pharmaceuticals
DMGYK2N DT Oligonucleotide
DMGYK2N DE Melanoma
DMBFE4K ID DMBFE4K
DMBFE4K DN Tirapazamine
DMBFE4K HS Phase 3
DMBFE4K SN TPZ; Tirazone; SR-259075; SR-4233; SR-4317; SR-4330; SR-4482; Win-59075
DMBFE4K CP Sri international
DMBFE4K DT Small molecular drug
DMBFE4K PC 135413511
DMBFE4K MW 178.15
DMBFE4K FM C7H6N4O2
DMBFE4K IC InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
DMBFE4K CS C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]
DMBFE4K IK ORYDPOVDJJZGHQ-UHFFFAOYSA-N
DMBFE4K IU 1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine
DMBFE4K CA CAS 27314-97-2
DMBFE4K CB CHEBI:78887
DMBFE4K DE Alzheimer disease; Hepatocellular carcinoma
DMQNMAT ID DMQNMAT
DMQNMAT DN Tirzepatide
DMQNMAT HS Phase 3
DMQNMAT CP Eli Lilly
DMQNMAT DE Type 2 diabetes
DM95IPS ID DM95IPS
DM95IPS DN Tivanisiran
DM95IPS HS Phase 3
DM95IPS CP Sylentis
DM95IPS DT Small interfering RNA
DM95IPS DE Dry eye disease
DMNVP8Q ID DMNVP8Q
DMNVP8Q DN Tivantinib
DMNVP8Q HS Phase 3
DMNVP8Q SN Tivantinib; 905854-02-6; ARQ-197; ARQ197; ARQ 197; Tivantinib (ARQ 197); (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; UNII-PJ4H73IL17; PJ4H73IL17; 1000873-98-2; (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione; Tivantinib [USAN:INN]; 1228508-24-4; Tivantinib; ARQ197; ARQ 197, Tivantinib; Tivantinib (ARQ-197); ARQ 197 (Tivantinib); cc-86; SCHEMBL44944; Tivantinib (JAN/USAN/INN); GTPL7948; CHEMBL2103882; CHEBI:91398; QCR-102
DMNVP8Q CP ArQule; Daiichi Sankyo
DMNVP8Q DT Small molecular drug
DMNVP8Q PC 11494412
DMNVP8Q MW 369.4
DMNVP8Q FM C23H19N3O2
DMNVP8Q IC InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
DMNVP8Q CS C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
DMNVP8Q IK UCEQXRCJXIVODC-PMACEKPBSA-N
DMNVP8Q IU (3R,4R)-3-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
DMNVP8Q CA CAS 905854-02-6
DMNVP8Q CB CHEBI:91398
DMNVP8Q DE Solid tumour/cancer; Hepatocellular carcinoma
DMYLT67 ID DMYLT67
DMYLT67 DN TKI258
DMYLT67 HS Phase 3
DMYLT67 SN Dovitinib; 405169-16-6; CHIR-258; TKI-258; Chir 258; 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; CHIR258; Dovitinib (TKI-258, CHIR-258); UNII-I35H55G906; CHEMBL522892; 804551-71-1; I35H55G906; TKI 258; 1027263-12-2; (3Z)-4-Amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]-2(3H)-quinolinone; C21H21FN6O; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
DMYLT67 CP Novartis & Chiron Corp
DMYLT67 TC Anticancer Agents
DMYLT67 DT Small molecular drug
DMYLT67 PC 135611162
DMYLT67 MW 500.5
DMYLT67 FM C24H29FN6O5
DMYLT67 IC InChI=1S/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2
DMYLT67 CS CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N.O
DMYLT67 IK QDPVYZNVVQQULH-UHFFFAOYSA-N
DMYLT67 IU 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;2-hydroxypropanoic acid;hydrate
DMYLT67 CA CAS 915769-50-5
DMYLT67 DE Endometrial cancer; Renal cell carcinoma; Triple negative breast cancer
DMO1234 ID DMO1234
DMO1234 DN TNX-102
DMO1234 HS Phase 3
DMO1234 SN Cyclobenzaprine very low dose
DMO1234 CP TONIX Pharmaceuticals
DMO1234 DT Small molecular drug
DMO1234 PC 22576
DMO1234 MW 311.8
DMO1234 FM C20H22ClN
DMO1234 IC InChI=1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H
DMO1234 CS CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl
DMO1234 IK VXEAYBOGHINOKW-UHFFFAOYSA-N
DMO1234 IU N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)propan-1-amine;hydrochloride
DMO1234 CA CAS 6202-23-9
DMO1234 CB CHEBI:3997
DMO1234 DE Fibromyalgia; Post-traumatic stress disorder
DMYA41S ID DMYA41S
DMYA41S DN TNX-355
DMYA41S HS Phase 3
DMYA41S CP Tanox; Biogen
DMYA41S DE Human immunodeficiency virus infection
DMFDNT0 ID DMFDNT0
DMFDNT0 DN Tocilizumab
DMFDNT0 HS Phase 3
DMFDNT0 SN Actemra; Actemra (TN); Tocilizumab (USAN/INN); Tocilizumab (genetical recombination); Tocilizumab (genetical recombination) (JAN); humanized IgG1 monoclonal antibody
DMFDNT0 CP Roche; Genentech
DMFDNT0 TC Antiviral Agents
DMFDNT0 DT Monoclonal antibody
DMFDNT0 DE Juvenile idiopathic arthritis; Rheumatoid arthritis; Systemic sclerosis; Coronavirus Disease 2019 (COVID-19)
DMATC14 ID DMATC14
DMATC14 DN Tozadenant
DMATC14 HS Phase 3
DMATC14 SN Ro-2; SYN-115; A2a receptor antagonists (Parkinson's disease), Synosia/Roche; Adenosine A2a receptor antagonists (Parkinson's disease), Synosia/Roche
DMATC14 CP Biotie therapies
DMATC14 DT Small molecular drug
DMATC14 PC 11618368
DMATC14 MW 406.5
DMATC14 FM C19H26N4O4S
DMATC14 IC InChI=1S/C19H26N4O4S/c1-19(25)5-7-23(8-6-19)18(24)21-17-20-15-14(26-2)4-3-13(16(15)28-17)22-9-11-27-12-10-22/h3-4,25H,5-12H2,1-2H3,(H,20,21,24)
DMATC14 CS CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O
DMATC14 IK XNBRWUQWSKXMPW-UHFFFAOYSA-N
DMATC14 IU 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide
DMATC14 CA CAS 870070-55-6
DMATC14 DE Parkinson disease
DMLKI2B ID DMLKI2B
DMLKI2B DN Trafermin
DMLKI2B HS Phase 3
DMLKI2B SN Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)
DMLKI2B CP Johnson & Johnson Licensee; Kaken Pharmaceutical
DMLKI2B DE Periodontitis
DM6ENSJ ID DM6ENSJ
DM6ENSJ DN Tralokinumab
DM6ENSJ HS Phase 3
DM6ENSJ SN CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
DM6ENSJ CP Ception Therapeutics
DM6ENSJ DT Monoclonal antibody
DM6ENSJ DE Asthma; Ulcerative colitis; Atopic dermatitis
DM7BSRH ID DM7BSRH
DM7BSRH DN Tramiprosate
DM7BSRH HS Phase 3
DM7BSRH SN Alzhemed; Cerebril; Homotaurine; Vivimind; LU-02659; NC-531; NC-758; Tramiprosate (stroke), Neurochem; Tramiprosate (Alzheimer's disease), Neurochem; 3APS
DM7BSRH CP Neurochem
DM7BSRH DT Small molecular drug
DM7BSRH PC 1646
DM7BSRH MW 139.18
DM7BSRH FM C3H9NO3S
DM7BSRH IC InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)
DM7BSRH CS C(CN)CS(=O)(=O)O
DM7BSRH IK SNKZJIOFVMKAOJ-UHFFFAOYSA-N
DM7BSRH IU 3-aminopropane-1-sulfonic acid
DM7BSRH CA CAS 3687-18-1
DM7BSRH CB CHEBI:1457
DM7BSRH DE Alzheimer disease
DMLB3I4 ID DMLB3I4
DMLB3I4 DN Trastuzumab-DM1
DMLB3I4 HS Phase 3
DMLB3I4 CP Genentech
DMLB3I4 DT Antibody drug conjugate
DMLB3I4 DE Breast cancer
DM1874J ID DM1874J
DM1874J DN TRC105
DM1874J HS Phase 3
DM1874J DT Monoclonal antibody
DM1874J DE Breast cancer; Lung cancer; Ovarian cancer; Macular degeneration; Peritoneal cancer; Fallopian tube cancer; Soft tissue sarcoma; Gestational trophoblastic neoplasia; Hemangiosarcoma; Hepatocellular carcinoma; Renal cell carcinoma; Recurrent glioblastoma; Angiosarcoma
DMOG2X1 ID DMOG2X1
DMOG2X1 DN Trebananib
DMOG2X1 HS Phase 3
DMOG2X1 CP Amgen
DMOG2X1 DT Recombinant protein
DMOG2X1 DE Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer
DMOQ9H1 ID DMOQ9H1
DMOQ9H1 DN Tremelimumab
DMOQ9H1 HS Phase 3
DMOQ9H1 CP AstraZeneca
DMOQ9H1 DT Monoclonal antibody
DMOQ9H1 DE Solid tumour/cancer; Malignant mesothelioma
DMS57DJ ID DMS57DJ
DMS57DJ DN Trimegestone/ethinyl estradiol
DMS57DJ HS Phase 3
DMS57DJ CP Wyeth
DMS57DJ DE Contraception
DMCMDVR ID DMCMDVR
DMCMDVR DN Triptolide
DMCMDVR HS Phase 3
DMCMDVR SN triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315
DMCMDVR DT Small molecular drug
DMCMDVR PC 107985
DMCMDVR MW 360.4
DMCMDVR FM C20H24O6
DMCMDVR IC InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
DMCMDVR CS CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C
DMCMDVR IK DFBIRQPKNDILPW-CIVMWXNOSA-N
DMCMDVR IU (1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
DMCMDVR CA CAS 38748-32-2
DMCMDVR CB CHEBI:9747
DMCMDVR DE Autoimmune diabetes
DMHDNK0 ID DMHDNK0
DMHDNK0 DN TroVax
DMHDNK0 HS Phase 3
DMHDNK0 SN TroVax (TN)
DMHDNK0 CP Oxford BioMedica
DMHDNK0 DT Vaccine
DMHDNK0 DE Prostate cancer
DM0QNF4 ID DM0QNF4
DM0QNF4 DN TRx0237
DM0QNF4 HS Phase 3
DM0QNF4 SN 951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide
DM0QNF4 CP TauRx Therapeutics
DM0QNF4 DT Small molecular drug
DM0QNF4 PC 23651551
DM0QNF4 MW 447.2
DM0QNF4 FM C16H21Br2N3S
DM0QNF4 IC InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H
DM0QNF4 CS CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.Br.Br
DM0QNF4 IK JAUPSVVTGFBHTN-UHFFFAOYSA-N
DM0QNF4 IU 3-N,3-N,7-N,7-N-tetramethyl-10H-phenothiazine-3,7-diamine;dihydrobromide
DM0QNF4 CA CAS 951131-15-0
DM0QNF4 DE Alzheimer disease
DMAFPHB ID DMAFPHB
DMAFPHB DN TRYPTAMINE
DMAFPHB HS Phase 3
DMAFPHB SN tryptamine; 61-54-1; 2-(1H-Indol-3-yl)ethanamine; 3-(2-aminoethyl)indole; 1H-Indole-3-ethanamine; 2-(3-Indolyl)ethylamine; Indol-3-ethylamine; Indole, 3-(2-aminoethyl)-; 2-(Indol-3-yl)ethylamine; 2-(1H-Indol-3-Yl)Ethan-1-Amine; 3-Indoleethylamine; Tryptamin; 2-(1H-indol-3-yl)ethylamine; 2-Indol-3-ylethylamine; 2-(1H-INDOL-3-YL)-ETHYLAMINE; UNII-422ZU9N5TV; (Amino-2 ethyl)-3 indole; (Amino-2 ethyl)-3 indole [French]; Tryptamine, 98%; BRN 0125513; EINECS 200-510-5; CHEMBL6640; 422ZU9N5TV; CHEBI:16765; APJYDQYYACXCRM-UHFFFAOYSA-N
DMAFPHB DT Small molecular drug
DMAFPHB PC 1150
DMAFPHB MW 160.22
DMAFPHB FM C10H12N2
DMAFPHB IC InChI=1S/C10H12N2/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6,11H2
DMAFPHB CS C1=CC=C2C(=C1)C(=CN2)CCN
DMAFPHB IK APJYDQYYACXCRM-UHFFFAOYSA-N
DMAFPHB IU 2-(1H-indol-3-yl)ethanamine
DMAFPHB CA CAS 61-54-1
DMAFPHB CB CHEBI:16765
DMPBJ8W ID DMPBJ8W
DMPBJ8W DN Turoctocog alfa
DMPBJ8W HS Phase 3
DMPBJ8W SN NN7008
DMPBJ8W CP Novo Nordisk
DMPBJ8W DE Haemophilia A
DM71ZL6 ID DM71ZL6
DM71ZL6 DN TZTX-001
DM71ZL6 HS Phase 3
DM71ZL6 SN Teverelix LA; TX 12-001-HR
DM71ZL6 CP Ardana Bioscience
DM71ZL6 DE Endometriosis
DMN72OM ID DMN72OM
DMN72OM DN U300
DMN72OM HS Phase 3
DMN72OM SN Methyl 3,5-dinitrobenzoate; 2702-58-1; Benzoic acid, 3,5-dinitro-, methyl ester; POGCCFLNFPIIGW-UHFFFAOYSA-N; 3,5-dinitro-benzoic acid methyl ester; Methyl 3,5-Dinitrobenzoate,99%; Methyl-3,5-dinitrobenzoate; U300; ACMC-1CR6Q; AC1L5B8W; AC1Q5AI0; KSC494Q3H; SCHEMBL418416; Jsp005266; CHEMBL2252127; CTK3J4833; KS-00000ZZJ; NSC7317; MolPort-001-012-121; Methyl 3,5-dinitrobenzoate, 99%; ALBB-024845; NSC-7317; ZINC1683476; METHYL-3,5-DINITRO BENZOATE; BBL000013; ANW-44565; SBB068882; MFCD00017016; STK386186; 3,5-Dinitrobenzoic acid methyl e
DMN72OM CP Sanofi us
DMN72OM DT Small molecular drug
DMN72OM PC 222067
DMN72OM MW 226.14
DMN72OM FM C8H6N2O6
DMN72OM IC InChI=1S/C8H6N2O6/c1-16-8(11)5-2-6(9(12)13)4-7(3-5)10(14)15/h2-4H,1H3
DMN72OM CS COC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-]
DMN72OM IK POGCCFLNFPIIGW-UHFFFAOYSA-N
DMN72OM IU methyl 3,5-dinitrobenzoate
DMN72OM CA CAS 2702-58-1
DMN72OM DE Type-2 diabetes
DMHTY9W ID DMHTY9W
DMHTY9W DN Ublituximab
DMHTY9W HS Phase 3
DMHTY9W SN TG-1101
DMHTY9W CP TG Therapeutics
DMHTY9W DT Antibody
DMHTY9W DE Chronic lymphocytic leukaemia; Lymphoma; Multiple sclerosis; Nodal marginal zone lymphoma
DMKUOVP ID DMKUOVP
DMKUOVP DN Ublituximab + umbralisib
DMKUOVP HS Phase 3
DMKUOVP CP TG Therapeutics New York, NY
DMKUOVP DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma
DM90AG2 ID DM90AG2
DM90AG2 DN Ularitide
DM90AG2 HS Phase 3
DM90AG2 SN Urodilatin; 115966-23-9; Atriopeptin (95-126); Human urodilatin; Urodilatin human; Ularitide [INN]; Urodilatin ularitide; Anf (95-126); Anp (95-126); ANP 95-126; Atrial natriuretic peptide (95-126); CHEMBL2103920; Urodilatin human, > AKOS030213250; DB05034; CDD 95-126; LS-187531; LS-186876; Thr-Ala-Pro-Arg-Atrial Natriuretic Peptide; atrial natriuretic factor prohormone (95-126)
DM90AG2 CP EKR Therapeutics
DM90AG2 DT Small molecular drug
DM90AG2 PC 16132416
DM90AG2 MW 3505.9
DM90AG2 FM C145H234N52O44S3
DM90AG2 IC InChI=1S/C145H234N52O44S3/c1-11-72(6)112-137(238)171-60-106(208)172-73(7)113(214)177-86(40-41-103(146)205)122(223)190-95(63-198)116(217)170-61-108(210)175-88(51-70(2)3)114(215)169-62-109(211)176-100(133(234)187-92(56-104(147)206)127(228)193-97(65-200)130(231)186-91(54-77-27-16-13-17-28-77)126(227)180-82(31-20-45-163-142(153)154)119(220)189-94(139(240)241)55-78-36-38-79(204)39-37-78)68-243-244-69-101(134(235)185-90(53-76-25-14-12-15-26-76)115(216)168-58-105(207)167-59-107(209)174-80(29-18-43-161-140(149)150)117(218)182-87(42-50-242-10)123(224)188-93(57-110(212)213)128(229)181-85(124(225)196-112)34-23-48-166-145(159)160)195-132(233)99(67-202)194-131(232)98(66-201)192-120(221)83(32-21-46-164-143(155)156)178-118(219)81(30-19-44-162-141(151)152)179-125(226)89(52-71(4)5)184-129(230)96(64-199)191-121(222)84(33-22-47-165-144(157)158)183-135(236)102-35-24-49-197(102)138(239)74(8)173-136(237)111(148)75(9)203/h12-17,25-28,36-39,70-75,80-102,111-112,198-204H,11,18-24,29-35,40-69,148H2,1-10H3,(H2,146,205)(H2,147,206)(H,167,207)(H,168,216)(H,169,215)(H,170,217)(H,171,238)(H,172,208)(H,173,237)(H,174,209)(H,175,210)(H,176,211)(H,177,214)(H,178,219)(H,179,226)(H,180,227)(H,181,229)(H,182,218)(H,183,236)(H,184,230)(H,185,235)(H,186,231)(H,187,234)(H,188,224)(H,189,220)(H,190,223)(H,191,222)(H,192,221)(H,193,228)(H,194,232)(H,195,233)(H,196,225)(H,212,213)(H,240,241)(H4,149,150,161)(H4,151,152,162)(H4,153,154,163)(H4,155,156,164)(H4,157,158,165)(H4,159,160,166)/t72-,73-,74-,75+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,111-,112-/m0/s1
DM90AG2 CS CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C
DM90AG2 IK IUCCYQIEZNQWRS-DWWHXVEHSA-N
DM90AG2 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,49S,52R)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-19-(3-amino-3-oxopropyl)-49-benzyl-28-[(2S)-butan-2-yl]-31,40-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM90AG2 CA CAS 118812-69-4
DM90AG2 DE Heart failure; Acute heart failure
DMIQCFG ID DMIQCFG
DMIQCFG DN Ulinastatin
DMIQCFG HS Phase 3
DMIQCFG SN Urinastatin; Urinary trypsin inhibitor; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-31-6; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor (human urine urinastatin protein moiety); 80449-32-7; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Miraclid; AC1L2Y1N; UTI68; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; AC1Q70L4; AKOS025401879; CS-7119; MR 20 (magnetic p
DMIQCFG DT Small molecular drug
DMIQCFG PC 105102
DMIQCFG MW 220.26
DMIQCFG FM C13H16O3
DMIQCFG IC InChI=1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2
DMIQCFG CS C1CC2(CC=C1)COC(OC2)C3=CC=CO3
DMIQCFG IK ODVKSTFPQDVPJZ-UHFFFAOYSA-N
DMIQCFG IU 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene
DMIQCFG CA CAS 80449-32-7
DMIQCFG DE Premature labour
DM6PMNR ID DM6PMNR
DM6PMNR DN Ulocuplumab
DM6PMNR HS Phase 3
DM6PMNR CP Bristol-myers squibb
DM6PMNR DT Monoclonal antibody
DM6PMNR DE Haematological malignancy; Multiple myeloma
DMCWM03 ID DMCWM03
DMCWM03 DN Unfractionated heparin
DMCWM03 HS Phase 3
DMCWM03 SN Elaprin; UFH (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen); SNAC/heparin capsule (solid oral), Emisphere; SNAD/heparin tablet (solid oral), Emisphere; Unfractionated heparin (solid oral, eligen), Emisphere
DMCWM03 CP Emisphere Technologies Inc
DMCWM03 DE Thrombosis
DM0DIEZ ID DM0DIEZ
DM0DIEZ DN UNI-rhIL-11
DM0DIEZ HS Phase 3
DM0DIEZ SN Recombinant human interleukin 11 (thrombocytopenia), Uni-Bio Science Group; RhIL-11 (thrombocytopenia), Uni-Bio Science Group
DM0DIEZ CP Uni-Bio Science Group Limited
DM0DIEZ DE Thrombocytopenia
DMM2OZH ID DMM2OZH
DMM2OZH DN Ushercell
DMM2OZH HS Phase 3
DMM2OZH SN Cellulose sulfate gel, Polydex
DMM2OZH CP Polydex Pharmaceuticals Ltd
DMM2OZH DT Small molecular drug
DMM2OZH PC 154413
DMM2OZH MW 457.6
DMM2OZH FM C30H35NO3
DMM2OZH IC InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m0/s1
DMM2OZH CS CC1([C@@H]([C@H](C2=C(O1)C=C(C=C2)OC)C3=CC=C(C=C3)OCCN4CCCC4)C5=CC=CC=C5)C
DMM2OZH IK XZEUAXYWNKYKPL-URLMMPGGSA-N
DMM2OZH IU 1-[2-[4-[(3S,4S)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine
DMM2OZH CA CAS 31477-60-8
DMM2OZH DE Bacterial infection
DMD2O0L ID DMD2O0L
DMD2O0L DN UX-001
DMD2O0L HS Phase 3
DMD2O0L CP Ultragenyx Pharmaceutical
DMD2O0L DT Small molecular drug
DMD2O0L PC 656387
DMD2O0L MW 309.27
DMD2O0L FM C11H19NO9
DMD2O0L IC InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6-,7+,8-,9+,11+/m0/s1
DMD2O0L CS CC(=O)N[C@@H]1[C@H](C[C@@](O[C@H]1[C@H]([C@H](CO)O)O)(C(=O)O)O)O
DMD2O0L IK SQVRNKJHWKZAKO-USOVHJGOSA-N
DMD2O0L IU (2R,4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-[(1S,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMD2O0L DE Myopathy; Hereditary inclusion body myositis
DMDCFXJ ID DMDCFXJ
DMDCFXJ DN Vaborbactam
DMDCFXJ HS Phase 3
DMDCFXJ SN RPX-7009; 1360457-46-0; RPX7009; UNII-1C75676F8V; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; CHEMBL3317857; 1C75676F8V; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; Vaborbactam [INN]; RPX 7009; Vaborbactam. RPX7009; Vaborbactam (USAN/INN); Vaborbactam [USAN:INN]; SCHEMBL620289; GTPL10871; Vabomere (vaborbactam + meropenem); EX-A2589; BDBM50089084; MFCD28502176; AKOS032961376; CS-6445; DB12107; SB17184; 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)-; compound 9f [PMID: 25782055]; NCGC00510003-01; HY-19930; 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-; D10998; Q27252228; {(3R,6S)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; 1,2-Oxaborinane-6-acetic acid
DMDCFXJ DT Small molecular drug
DMDCFXJ PC 56649692
DMDCFXJ MW 297.14
DMDCFXJ FM C12H16BNO5S
DMDCFXJ IC InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
DMDCFXJ CS B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
DMDCFXJ IK IOOWNWLVCOUUEX-WPRPVWTQSA-N
DMDCFXJ IU 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid
DMDCFXJ CA CAS 1360457-46-0
DMDCFXJ DE Urinary tract infection
DM9LH10 ID DM9LH10
DM9LH10 DN Vadastuximab talirine
DM9LH10 HS Phase 3
DM9LH10 SN vadastuximab talirine; Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5
DM9LH10 CP Seattle Genetics Bothell, WA
DM9LH10 PC 122706909
DM9LH10 MW 1210.4
DM9LH10 FM C63H71N9O14S
DM9LH10 IC InChI=1S/C63H71N9O14S/c1-35(2)57(69-55(73)11-8-7-9-20-70-56(74)29-54(62(70)79)87-34-47(64)63(80)81)59(76)67-36(3)58(75)68-41-16-12-37(13-17-41)39-23-42-30-65-48-27-52(50(83-5)25-45(48)60(77)71(42)32-39)85-21-10-22-86-53-28-49-46(26-51(53)84-6)61(78)72-33-40(24-43(72)31-66-49)38-14-18-44(82-4)19-15-38/h12-19,25-28,30-33,35-36,42-43,47,54,57H,7-11,20-24,29,34,64H2,1-6H3,(H,67,76)(H,68,75)(H,69,73)(H,80,81)/t36-,42-,43-,47-,54+,57-/m0/s1
DM9LH10 CS C[C@@H](C(=O)NC1=CC=C(C=C1)C2=CN3[C@@H](C2)C=NC4=CC(=C(C=C4C3=O)OC)OCCCOC5=C(C=C6C(=C5)N=C[C@@H]7CC(=CN7C6=O)C8=CC=C(C=C8)OC)OC)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN9C(=O)C[C@H](C9=O)SC[C@@H](C(=O)O)N
DM9LH10 IK BNJNAEJASPUJTO-DUOHOMBCSA-N
DM9LH10 IU (2R)-3-[(3R)-1-[6-[[(2S)-1-[[(2S)-1-[4-[(6aS)-3-[3-[[(6aS)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-6-oxohexyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-2-aminopropanoic acid
DM9LH10 CA CAS 1436390-64-5
DM9LH10 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DM9J5Q4 ID DM9J5Q4
DM9J5Q4 DN VAL-083
DM9J5Q4 HS Phase 3
DM9J5Q4 SN VAL-083; Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6
DM9J5Q4 CP Del Mar Pharmaceuticals
DM9J5Q4 DT Small molecular drug
DM9J5Q4 PC 15942827
DM9J5Q4 MW 146.14
DM9J5Q4 FM C6H10O4
DM9J5Q4 IC InChI=1S/C6H10O4/c7-5(3-1-9-3)6(8)4-2-10-4/h3-8H,1-2H2/t3-,4+,5+,6-
DM9J5Q4 CS C1[C@@H](O1)[C@@H]([C@@H]([C@@H]2CO2)O)O
DM9J5Q4 IK AAFJXZWCNVJTMK-GUCUJZIJSA-N
DM9J5Q4 IU (1S,2R)-1-[(2S)-oxiran-2-yl]-2-[(2R)-oxiran-2-yl]ethane-1,2-diol
DM9J5Q4 CA CAS 23261-20-3
DM9J5Q4 DE Grade IV malignant glioma; Acute myeloid leukaemia; Recurrent glioblastoma; Recurring respiratory infection
DMMKE2H ID DMMKE2H
DMMKE2H DN Valoctocogene roxaparvovec
DMMKE2H HS Phase 3
DMMKE2H SN BMN 270
DMMKE2H CP BioMarin Pharmaceutical
DMMKE2H DT Gene therapy
DMMKE2H DE Haemophilia A
DMQL0KF ID DMQL0KF
DMQL0KF DN Vanadate
DMQL0KF HS Phase 3
DMQL0KF SN Ammonium metavanadate; 7803-55-6; Ammonium vanadate(V); UNII-FL85PX638G; FL85PX638G; Ammonium metavanadate, ACS reagent; Ammoniummetavanadate; Ammonium metavanadate, 99.5%, for analysis; Ammonium metavanadate, 99.996%, (trace metal basis); Ammonium meta-Vanadate; Vanadate (VO31-), ammonium (1:1); AC1LANGP; ammonium vanadiumoylolate; H4NO3V; EC 232-261-3; azanium oxido(dioxo)vanadium; KS-00000WUM; UNTBPXHCXVWYOI-UHFFFAOYSA-O; MolPort-044-723-987; MolPort-003-925-733; MFCD00011430; AKOS030228605; AMMONIUM VANADATE (META), NH4VO3
DMQL0KF DT Small molecular drug
DMQL0KF PC 516859
DMQL0KF MW 116.978
DMQL0KF FM H4NO3V
DMQL0KF IC InChI=1S/H3N.3O.V/h1H3;;;;/q;;;-1;/p+1
DMQL0KF CS [NH4+].[O-][V](=O)=O
DMQL0KF IK UNTBPXHCXVWYOI-UHFFFAOYSA-O
DMQL0KF IU azanium;oxido(dioxo)vanadium
DMQL0KF CA CAS 7803-55-6
DMQL0KF DE Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
DMLIMEA ID DMLIMEA
DMLIMEA DN Varespladib methyl
DMLIMEA HS Phase 3
DMLIMEA SN A-002; LY-333013; S-3013; Varespladib methyl (oral formulation, coronary artery disease); PLA2 inhibitors (inflammation), Lilly/Shionogi; Varespladib (oral formulation, coronary artery disease), Anthera; Varespladib methyl (oral formulation, coronary artery disease), Anthera
DMLIMEA CP Shionogi & Co Ltd
DMLIMEA DT Small molecular drug
DMLIMEA PC 9886917
DMLIMEA MW 394.4
DMLIMEA FM C22H22N2O5
DMLIMEA IC InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)
DMLIMEA CS CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N
DMLIMEA IK VJYDOJXJUCJUHL-UHFFFAOYSA-N
DMLIMEA IU methyl 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetate
DMLIMEA CA CAS 172733-08-3
DMLIMEA DE Rheumatoid arthritis
DMANKTO ID DMANKTO
DMANKTO DN Vatreptacog alfa (activated)
DMANKTO HS Phase 3
DMANKTO SN NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
DMANKTO CP Novo Nordisk A/S
DMANKTO DE Bleeding disorder
DMX04CA ID DMX04CA
DMX04CA DN VB-111
DMX04CA HS Phase 3
DMX04CA CP VBL Therapeutics
DMX04CA DE Glioblastoma multiforme; Malignant glioma; Ovarian cancer; Recurrent glioblastoma
DMXHI89 ID DMXHI89
DMXHI89 DN Velac Gel
DMXHI89 HS Phase 3
DMXHI89 SN Clindamycin/tretinoin
DMXHI89 CP Stiefel Laboratories
DMXHI89 DE Acne vulgaris
DMJBU9V ID DMJBU9V
DMJBU9V DN Velimogene aliplasmid
DMJBU9V HS Phase 3
DMJBU9V SN Allovectin (TN)
DMJBU9V CP Vical
DMJBU9V DE Melanoma
DM6L5ZQ ID DM6L5ZQ
DM6L5ZQ DN Vercirnon
DM6L5ZQ HS Phase 3
DM6L5ZQ SN 1605786
DM6L5ZQ CP GlaxoSmithKline
DM6L5ZQ DT Small molecular drug
DM6L5ZQ PC 10343454
DM6L5ZQ MW 444.9
DM6L5ZQ FM C22H21ClN2O4S
DM6L5ZQ IC InChI=1S/C22H21ClN2O4S/c1-22(2,3)16-4-7-18(8-5-16)30(28,29)24-20-9-6-17(23)14-19(20)21(26)15-10-12-25(27)13-11-15/h4-14,24H,1-3H3
DM6L5ZQ CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)Cl)C(=O)C3=CC=[N+](C=C3)[O-]
DM6L5ZQ IK JRWROCIMSDXGOZ-UHFFFAOYSA-N
DM6L5ZQ IU 4-tert-butyl-N-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]benzenesulfonamide
DM6L5ZQ CA CAS 698394-73-9
DM6L5ZQ DE Crohn disease
DMOQ81Y ID DMOQ81Y
DMOQ81Y DN Vernakalant
DMOQ81Y HS Phase 3
DMOQ81Y SN Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-
DMOQ81Y CP Cardiome Pharma; Merck
DMOQ81Y DT Small molecular drug
DMOQ81Y PC 9930049
DMOQ81Y MW 349.5
DMOQ81Y FM C20H31NO4
DMOQ81Y IC InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1
DMOQ81Y CS COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
DMOQ81Y IK VBHQKCBVWWUUKN-KZNAEPCWSA-N
DMOQ81Y IU (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
DMOQ81Y CA CAS 794466-70-9
DMOQ81Y CB CHEBI:135956
DMOQ81Y DE Atrial fibrillation
DM4CGH5 ID DM4CGH5
DM4CGH5 DN verubecestat
DM4CGH5 HS Phase 3
DM4CGH5 SN example 25 (US8940748)
DM4CGH5 DT Small molecular drug
DM4CGH5 PC 51352361
DM4CGH5 MW 409.4
DM4CGH5 FM C17H17F2N5O3S
DM4CGH5 IC InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1
DM4CGH5 CS C[C@]1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F
DM4CGH5 IK YHYKUSGACIYRML-KRWDZBQOSA-N
DM4CGH5 IU N-[3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxo-6H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DM4CGH5 CA CAS 1286770-55-5
DM4CGH5 DE Alzheimer disease
DMMQ2U9 ID DMMQ2U9
DMMQ2U9 DN VGX-3100
DMMQ2U9 HS Phase 3
DMMQ2U9 CP Inovio Pharmaceuticals
DMMQ2U9 DE Human papillomavirus infection; Cervical Intraepithelial neoplasia; Vulvar squamous intraepithelial lesion; Dysplasia; Vulvar intraepithelial neoplasia
DMCWNZG ID DMCWNZG
DMCWNZG DN Vibegron
DMCWNZG HS Phase 3
DMCWNZG SN Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum
DMCWNZG DT Small molecular drug
DMCWNZG PC 44472635
DMCWNZG MW 444.535
DMCWNZG FM C26H28N4O3
DMCWNZG IC InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
DMCWNZG CS C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O
DMCWNZG IK DJXRIQMCROIRCZ-XOEOCAAJSA-N
DMCWNZG IU (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
DMCWNZG CA CAS 1190389-15-1
DMCWNZG CB ChEBI:142418
DMCWNZG DE Overactive bladder disorder
DMLO0KD ID DMLO0KD
DMLO0KD DN Vicineum
DMLO0KD HS Phase 3
DMLO0KD SN Oportuzumab monatox
DMLO0KD CP Sesen Bio
DMLO0KD DT Recombinant protein
DMLO0KD DE Bladder cancer
DMMTW9K ID DMMTW9K
DMMTW9K DN Vicriviroc
DMMTW9K HS Phase 3
DMMTW9K SN SchD; Sch 417690; PRO 140 & Vicrivirac; SCH-417690; SCH-D; SCH-D690; Sch-D compound; PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine; (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone; 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine
DMMTW9K CP Schering-Plough
DMMTW9K DT Small molecular drug
DMMTW9K PC 3009355
DMMTW9K MW 533.6
DMMTW9K FM C28H38F3N5O2
DMMTW9K IC InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1
DMMTW9K CS C[C@H]1CN(CCN1[C@@H](COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C
DMMTW9K IK CNPVJJQCETWNEU-CYFREDJKSA-N
DMMTW9K IU (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
DMMTW9K CA CAS 306296-47-9
DMMTW9K CB CHEBI:94843
DMMTW9K DE Human immunodeficiency virus infection
DMJFNR9 ID DMJFNR9
DMJFNR9 DN Viramidine
DMJFNR9 HS Phase 3
DMJFNR9 SN Ribamidine; Prodrug of Ribavirin; Ribavirin amidine; Taribavirin hydrochloride; ICN 3142; AVS-000206; AVS-206;ICN-3142; Taribavirin hydrochloride (USAN); Viramidine (TN); 1-.Beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine hydrochloride; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide hydrochloride; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboximidine
DMJFNR9 CP Valeant Pharmaceuticals International
DMJFNR9 DT Small molecular drug
DMJFNR9 PC 451448
DMJFNR9 MW 243.22
DMJFNR9 FM C8H13N5O4
DMJFNR9 IC InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1
DMJFNR9 CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=N)N
DMJFNR9 IK NHKZSTHOYNWEEZ-AFCXAGJDSA-N
DMJFNR9 IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide
DMJFNR9 CA CAS 119567-79-2
DMJFNR9 CB CHEBI:134989
DMJFNR9 DE Hepatitis C virus infection
DMXYM1H ID DMXYM1H
DMXYM1H DN Visilizumab
DMXYM1H HS Phase 3
DMXYM1H SN Nuvion; Visiluzumab; HuM291; SMART anti-CD3 MAb, PDL; SMART anti-CD3 MAb, Protein Design Labs; Anti-CD3 MAb (humanized), PDL
DMXYM1H CP PDL BioPharma Inc; PDL BioPharma
DMXYM1H DT Antibody
DMXYM1H DE Graft-versus-host disease
DMQGV5P ID DMQGV5P
DMQGV5P DN VLB-01
DMQGV5P HS Phase 3
DMQGV5P CP Marco Polo Pharmaceuticals SA
DMQGV5P DE Epilepsy
DMSW80U ID DMSW80U
DMSW80U DN VM-202
DMSW80U HS Phase 3
DMSW80U CP ViroMed
DMSW80U DE Angina pectoris; Amyotrophic lateral sclerosis; Peripheral neuropathy; Diabetic foot ulcer; Peripheral arterial disease
DM4P5UJ ID DM4P5UJ
DM4P5UJ DN VM-501
DM4P5UJ HS Phase 3
DM4P5UJ SN IL-11 agonist (thrombocytopenia, small molecule therapeutic/iv/sc), Viromed
DM4P5UJ CP ViroMed Co Ltd
DM4P5UJ DE Thrombocytopenia
DMOFH1M ID DMOFH1M
DMOFH1M DN Volasertib
DMOFH1M HS Phase 3
DMOFH1M SN Volasertib; 755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947
DMOFH1M CP Boehringer Ingelheim
DMOFH1M DT Small molecular drug
DMOFH1M PC 10461508
DMOFH1M MW 618.8
DMOFH1M FM C34H50N8O3
DMOFH1M IC InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1
DMOFH1M CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
DMOFH1M IK SXNJFOWDRLKDSF-XKHVUIRMSA-N
DMOFH1M IU N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide
DMOFH1M CA CAS 755038-65-4
DMOFH1M DE Acute myeloid leukaemia
DM5T4IS ID DM5T4IS
DM5T4IS DN VP-102
DM5T4IS HS Phase 3
DM5T4IS CP Verrica Pharmaceuticals West Chester, PA
DM5T4IS DE Common wart; Molluscum contagiosum infection
DMWMT5N ID DMWMT5N
DMWMT5N DN VRS-317
DMWMT5N HS Phase 3
DMWMT5N SN HGH-XTEN; Human growth hormone-XTEN; RPEG HGH (injectable, growth deficiency), Versartis; Recombinant PEGylated human growth hormone (injectable, growth deficiency), Versartis
DMWMT5N CP Versartis
DMWMT5N DE Growth hormone deficiency
DMM1Z9G ID DMM1Z9G
DMM1Z9G DN Vutrisiran
DMM1Z9G HS Phase 3
DMM1Z9G SN ALN-TTRsc02
DMM1Z9G CP Alnylam Pharmaceuticals
DMM1Z9G DT Small interfering RNA
DMM1Z9G DE Transthyretin familial amyloid cardiomyopathy
DMJBXO3 ID DMJBXO3
DMJBXO3 DN VX-661
DMJBXO3 HS Phase 3
DMJBXO3 CP Vertex Pharmaceuticals Inc
DMJBXO3 DT Small molecular drug
DMJBXO3 PC 46199646
DMJBXO3 MW 520.5
DMJBXO3 FM C26H27F3N2O6
DMJBXO3 IC InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1
DMJBXO3 CS CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
DMJBXO3 IK MJUVRTYWUMPBTR-MRXNPFEDSA-N
DMJBXO3 IU 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
DMJBXO3 CA CAS 1152311-62-0
DMJBXO3 DE Cystic fibrosis
DMM2JXP ID DMM2JXP
DMM2JXP DN VX-787
DMM2JXP HS Phase 3
DMM2JXP SN Pimodivir
DMM2JXP CP Vertex pharmaceuticals
DMM2JXP DT Small molecular drug
DMM2JXP PC 67286591
DMM2JXP MW 399.4
DMM2JXP FM C20H19F2N5O2
DMM2JXP IC InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1
DMM2JXP CS C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O
DMM2JXP IK JGPXDNKSIXAZEQ-SBBZOCNPSA-N
DMM2JXP IU (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
DMM2JXP CA CAS 1629869-44-8
DMM2JXP DE Influenza A virus infection
DM1JCW8 ID DM1JCW8
DM1JCW8 DN Xaliproden
DM1JCW8 HS Phase 3
DM1JCW8 SN Xaliproden (USAN); 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-(2-(2-Naphthyl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine; 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine; 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine
DM1JCW8 CP Sanofi-Aventis
DM1JCW8 DT Small molecular drug
DM1JCW8 PC 128919
DM1JCW8 MW 381.4
DM1JCW8 FM C24H22F3N
DM1JCW8 IC InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2
DM1JCW8 CS C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
DM1JCW8 IK WJJYZXPHLSLMGE-UHFFFAOYSA-N
DM1JCW8 IU 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
DM1JCW8 CA CAS 135354-02-8
DM1JCW8 CB CHEBI:48520
DM1JCW8 DE Lateral sclerosis; Peripheral sensory neuropathies; Alzheimer disease; Juvenile idiopathic arthritis; Plaque psoriasis
DMK34MZ ID DMK34MZ
DMK34MZ DN Xilonix
DMK34MZ HS Phase 3
DMK34MZ CP Xbiotech
DMK34MZ DE Non-small-cell lung cancer; Influenza virus infection; Colorectal cancer
DMJ6F5C ID DMJ6F5C
DMJ6F5C DN XL019
DMJ6F5C HS Phase 3
DMJ6F5C SN XL019; 945755-56-6; UNII-4L1AM42NVA; (S)-N-(4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide; 4L1AM42NVA; (2S)-N-[4-[2-[[4-(4-Morpholinyl)phenyl]amino]-4-pyrimidinyl]phenyl]-2-pyrrolidinecarboxamide; 945750-13-0; (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide; (2S)-N-[4-(2-{[4-(MORPHOLIN-4-YL)PHENYL]AMINO}PYRIMIDIN-4-YL)PHENYL]PYRROLIDINE-2-CARBOXAMIDE; C25H28N6O2; 2-Pyrrolidinecarboxamide, N-(4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)phe
DMJ6F5C DT Small molecular drug
DMJ6F5C PC 57990869
DMJ6F5C MW 444.5
DMJ6F5C FM C25H28N6O2
DMJ6F5C IC InChI=1S/C25H28N6O2/c32-24(23-2-1-12-26-23)28-19-5-3-18(4-6-19)22-11-13-27-25(30-22)29-20-7-9-21(10-8-20)31-14-16-33-17-15-31/h3-11,13,23,26H,1-2,12,14-17H2,(H,28,32)(H,27,29,30)/t23-/m0/s1
DMJ6F5C CS C1C[C@H](NC1)C(=O)NC2=CC=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5
DMJ6F5C IK ISOCDPQFIXDIMS-QHCPKHFHSA-N
DMJ6F5C IU (2S)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide
DMJ6F5C CA CAS 945755-56-6
DMJ6F5C DE Polycythemia vera; Solid tumour/cancer
DMOKQV7 ID DMOKQV7
DMOKQV7 DN XOMA 052
DMOKQV7 HS Phase 3
DMOKQV7 SN Gevokizumab
DMOKQV7 CP XOMA
DMOKQV7 DT Antibody
DMOKQV7 DE Type-2 diabetes
DMOLR5W ID DMOLR5W
DMOLR5W DN Yttrium (90Y) clivatuzumab tetraxetan
DMOLR5W HS Phase 3
DMOLR5W SN PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
DMOLR5W CP Immunomedics; Garden State Cancer Center; Immunomedics
DMOLR5W DT Antibody
DMOLR5W DE Pancreatic cancer
DMEY1F3 ID DMEY1F3
DMEY1F3 DN Zabofloxacin
DMEY1F3 HS Phase 3
DMEY1F3 SN DW-224a; DW-224aa; PB-101; Zabofloxacin (oral), IASO Pharma/DHP
DMEY1F3 CP Dong Wha Pharmaceutical Co Ltd
DMEY1F3 DT Small molecular drug
DMEY1F3 PC 10388396
DMEY1F3 MW 401.4
DMEY1F3 FM C19H20FN5O4
DMEY1F3 IC InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14+
DMEY1F3 CS CO/N=C/1\\CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F
DMEY1F3 IK ZNPOCLHDJCAZAH-OEAKJJBVSA-N
DMEY1F3 IU 1-cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMEY1F3 DE Pneumonia
DM52QEZ ID DM52QEZ
DM52QEZ DN Zalutumumab
DM52QEZ HS Phase 3
DM52QEZ CP Genmab
DM52QEZ DT Antibody
DM52QEZ SQ Zalutumumab (A chain): QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK > Zalutumumab (B chain)AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
DM52QEZ DE Head and neck cancer
DMKB4ZY ID DMKB4ZY
DMKB4ZY DN Zanolimumab
DMKB4ZY HS Phase 3
DMKB4ZY CP Emergent BioSolutions
DMKB4ZY DT Antibody
DMKB4ZY DE Lymphoma
DM9HUYP ID DM9HUYP
DM9HUYP DN ZANOTERONE
DM9HUYP HS Phase 3
DM9HUYP SN ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-
DM9HUYP DT Small molecular drug
DM9HUYP PC 9844827
DM9HUYP MW 416.6
DM9HUYP FM C23H32N2O3S
DM9HUYP IC InChI=1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1
DM9HUYP CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CC[C@@H]4[C@@]3(CC5=CN(N=C5C4)S(=O)(=O)C)C
DM9HUYP IK MHDDZDPNIDVLNK-ZGIWMXSJSA-N
DM9HUYP IU (1S,2S,10S,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-6-methylsulfonyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol
DM9HUYP CA CAS 107000-34-0
DM9HUYP DE Prostate hyperplasia
DMF30HL ID DMF30HL
DMF30HL DN Zarnestra
DMF30HL HS Phase 3
DMF30HL SN JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
DMF30HL CP Johnson & Johnson
DMF30HL TC Anticancer Agents
DMF30HL DT Small molecular drug
DMF30HL PC 159324
DMF30HL MW 489.4
DMF30HL FM C27H22Cl2N4O
DMF30HL IC InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1
DMF30HL CS CN1C=NC=C1[C@@](C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N
DMF30HL IK PLHJCIYEEKOWNM-HHHXNRCGSA-N
DMF30HL IU 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one
DMF30HL CA CAS 192185-72-1
DMF30HL CB CHEBI:141969
DMF30HL DE Colorectal cancer; Pancreatic cancer; Chronic myelogenous leukaemia; Myelodysplastic syndrome; Human papillomavirus infection; Peripheral T-cell lymphoma; Acute myeloid leukaemia
DMWDEFC ID DMWDEFC
DMWDEFC DN Zatosetron maleate
DMWDEFC HS Phase 3
DMWDEFC SN LY-277359 maleate; Zatosetron maleate < Rec INNM; Endo-5-Chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydrobenzofuran-7-carboxamide maleate
DMWDEFC DT Small molecular drug
DMWDEFC PC 6918153
DMWDEFC MW 464.9
DMWDEFC FM C23H29ClN2O6
DMWDEFC IC InChI=1S/C19H25ClN2O2.C4H4O4/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3;5-3(6)1-2-4(7)8/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13?,14-,15+;
DMWDEFC CS CC1(CC2=C(O1)C(=CC(=C2)Cl)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C.C(=C\\C(=O)O)\\C(=O)O
DMWDEFC IK HAFQATMFFHYNPN-BSLJCGBVSA-N
DMWDEFC IU (Z)-but-2-enedioic acid;5-chloro-2,2-dimethyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-1-benzofuran-7-carboxamide
DMWDEFC CA CAS 123482-23-5
DMWDEFC DE Anxiety disorder
DMP8ESD ID DMP8ESD
DMP8ESD DN Zicronapine
DMP8ESD HS Phase 3
DMP8ESD SN Zicronapine; 170381-16-5; UNII-QZV11V7G6A; QZV11V7G6A; Zicronapine [USAN:INN]; Zicronapine (USAN/INN); SCHEMBL904402; CHEMBL3039528; DTXSID30168849; Lu31-130; AKOS032946690; DB12188; 4-((1R,3S)-6-Chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine; LU-31130; D10329; Piperazine, 4-((1R,3S)-6-chloro-2,3-dihydro-3-phenyl-1H-inden-1-yl)-1,2,2-trimethyl-
DMP8ESD CP Lundbeck
DMP8ESD DT Small molecular drug
DMP8ESD PC 11465618
DMP8ESD MW 354.9
DMP8ESD FM C22H27ClN2
DMP8ESD IC InChI=1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
DMP8ESD CS CC1(CN(CCN1C)[C@@H]2C[C@H](C3=C2C=C(C=C3)Cl)C4=CC=CC=C4)C
DMP8ESD IK BYPMJBXPNZMNQD-PZJWPPBQSA-N
DMP8ESD IU 4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-1,2,2-trimethylpiperazine
DMP8ESD CA CAS 170381-16-5
DMP8ESD DE Schizophrenia
DM09TVB ID DM09TVB
DM09TVB DN Zimura
DM09TVB HS Phase 3
DM09TVB SN ARC-1905
DM09TVB CP Ophthotech Corp
DM09TVB DT Oligonucleotide
DM09TVB DE Macular degeneration
DMFWMKZ ID DMFWMKZ
DMFWMKZ DN ZK-93423
DMFWMKZ HS Phase 3
DMFWMKZ SN ZK 93423; 83910-44-5; ZK93423; ZK 93 423; 6-Benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid ethyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-6-(phenylmethoxy)-, ethyl ester; ALBKMJDFBZVHAK-UHFFFAOYSA-N; PDSP1_001754; AC1L3TNV; AC1Q64YI; CHEMBL10947; GTPL4346; SCHEMBL7117282; CHEMBL1518572; BDBM85039; CHEBI:92593; ZINC5857871; PDSP2_001737; PDSP1_001771; ethyl 6-(benzyloxy)-4-(methoxymethyl)-9h-; BDBM50007553; PDSP2_001754; CAS_121926; NSC_121926
DMFWMKZ DT Small molecular drug
DMFWMKZ PC 121926
DMFWMKZ MW 390.4
DMFWMKZ FM C23H22N2O4
DMFWMKZ IC InChI=1S/C23H22N2O4/c1-3-28-23(26)22-18(14-27-2)21-17-11-16(29-13-15-7-5-4-6-8-15)9-10-19(17)25-20(21)12-24-22/h4-12,25H,3,13-14H2,1-2H3
DMFWMKZ CS CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC(=C3)OCC4=CC=CC=C4
DMFWMKZ IK ALBKMJDFBZVHAK-UHFFFAOYSA-N
DMFWMKZ IU ethyl 4-(methoxymethyl)-6-phenylmethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMFWMKZ CA CAS 83910-44-5
DMFWMKZ CB CHEBI:92593
DMFWMKZ DE Epileptic seizures
DM5ST9Z ID DM5ST9Z
DM5ST9Z DN Zolbetuximab
DM5ST9Z HS Phase 3
DM5ST9Z SN IMAB362
DM5ST9Z CP Astellas Pharma
DM5ST9Z DT Antibody
DM5ST9Z DE Pancreatic cancer; Gastric adenocarcinoma; Esophagogastric junction neoplasm
DM8L7JD ID DM8L7JD
DM8L7JD DN Zoniporide hydrochloride
DM8L7JD HS Phase 3
DM8L7JD SN CP-597396; EMD-392426; Zoniporide hydrochloride < Prop INNM; N''-[5-Cyclopropyl-1-(5-quinolyl)-1H-pyrazol-4-ylcarbonyl]guanidine hydrochloride monohydrate
DM8L7JD DT Small molecular drug
DM8L7JD PC 11962997
DM8L7JD MW 356.8
DM8L7JD FM C17H17ClN6O
DM8L7JD IC InChI=1S/C17H16N6O.ClH/c18-17(19)22-16(24)12-9-21-23(15(12)10-6-7-10)14-5-1-4-13-11(14)3-2-8-20-13;/h1-5,8-10H,6-7H2,(H4,18,19,22,24);1H
DM8L7JD CS C1CC1C2=C(C=NN2C3=CC=CC4=C3C=CC=N4)C(=O)N=C(N)N.Cl
DM8L7JD IK JTEXNYIOROVPIR-UHFFFAOYSA-N
DM8L7JD IU 5-cyclopropyl-N-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide;hydrochloride
DM8L7JD CA CAS 241800-97-5
DM8L7JD DE Angina pectoris
DMMBJYC ID DMMBJYC
DMMBJYC DN ZYH-1
DMMBJYC HS Phase 3
DMMBJYC SN Metabolism disorder treatment, Zydus-Cadila; PPAR alpha/gamma modulator (dyslipdemia), Zydus-Cadila
DMMBJYC CP Zydus-Cadila Group
DMMBJYC DE Lipid metabolism disorder
DM12UX6 ID DM12UX6
DM12UX6 DN 131 I-omburtamab
DM12UX6 HS Phase 2/3
DM12UX6 CP Y-mAbs Therapeutics
DM12UX6 DT Antibody
DM12UX6 DE Neuroblastoma; Brain and central nervous system tumour
DMZ0T24 ID DMZ0T24
DMZ0T24 DN Abagovomab
DMZ0T24 HS Phase 2/3
DMZ0T24 CP Menarini
DMZ0T24 DT Monoclonal antibody
DMZ0T24 DE Ovarian cancer
DMKY9GI ID DMKY9GI
DMKY9GI DN Activated recombinant FVII-albumin fusion protein
DMKY9GI HS Phase 2/3
DMKY9GI SN CSL-689; Activated recombinant FVII-albumin fusion protein (hemophilia); Activated recombinant FVII-albumin fusion protein (hemophilia), CSL Behring; RVIIa-FP (hemophilia), CSL Behring; Recombinant factor VIIa/human albumin fusion protein (hemophilia), CSL Behring
DMKY9GI CP Csl behring
DMKY9GI DE Hemophilia
DM6GTMD ID DM6GTMD
DM6GTMD DN ADX-48621
DM6GTMD HS Phase 2/3
DM6GTMD SN Dipraglurant; 872363-17-2; UNII-CV8JZR21A1; ADX48621; CV8JZR21A1; CHEMBL2346738; 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]-Imidazo[1,2-a]pyridine; Dipraglurant [INN]; ADX-48621; SCHEMBL103033; GTPL6452; C16H12FN3; DTXSID90236230; BCP23706; BDBM50431705; ZINC72266314; 3590AH; 6-Fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine; AKOS030526956; SB16993; DB12733; CS-0690; NCGC00351745-02; HY-14859; DB-076892; FT-0705373; J3.560.334D; W-5761; ADX 48621;ADX48621;ADX-48621
DM6GTMD CP Addex Pharma.
DM6GTMD DT Small molecular drug
DM6GTMD PC 44557636
DM6GTMD MW 265.28
DM6GTMD FM C16H12FN3
DM6GTMD IC InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
DM6GTMD CS C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F
DM6GTMD IK LZXMUJCJAWVHPZ-UHFFFAOYSA-N
DM6GTMD IU 6-fluoro-2-(4-pyridin-2-ylbut-3-ynyl)imidazo[1,2-a]pyridine
DM6GTMD CA CAS 872363-17-2
DM6GTMD DE Mood disorder; Dyskinesia; Parkinson disease
DMMHSLC ID DMMHSLC
DMMHSLC DN Afq056
DMMHSLC HS Phase 2/3
DMMHSLC SN Mavoglurant
DMMHSLC CP Novartis
DMMHSLC DT Small molecular drug
DMMHSLC PC 9926832
DMMHSLC MW 313.4
DMMHSLC FM C19H23NO3
DMMHSLC IC InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
DMMHSLC CS CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
DMMHSLC IK ZFPZEYHRWGMJCV-ZHALLVOQSA-N
DMMHSLC IU methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
DMMHSLC CA CAS 543906-09-8
DMMHSLC DE Fragile X syndrome
DMGC970 ID DMGC970
DMGC970 DN AG-013
DMGC970 HS Phase 2/3
DMGC970 SN ActoBiotic (oral mucositis), ActoGenix; TFF-producing Lactococci lactis (mucositis), ActoGenix/VIB/University of Ghent; Trefoil factor producing micro-organisms (TopAct, oral, mucositis), ActoGenix
DMGC970 CP Flanders Interuniversity Institute for Biotechnology (VIB)
DMGC970 DE Oral mucositis
DMD741P ID DMD741P
DMD741P DN Alagebrium chloride
DMD741P HS Phase 2/3
DMD741P SN PTB; Tetrazolium chloride; ALT-711; ALT-766; N-phenacylthiazolium bromide; Advanced glycosylation end product (AGE)breakers, Alteon; Advanced glycosylation end product (AGE) breakers, Synvista
DMD741P CP Synvista Therapeutics Inc
DMD741P DT Small molecular drug
DMD741P PC 216306
DMD741P MW 267.77
DMD741P FM C13H14ClNOS
DMD741P IC InChI=1S/C13H14NOS.ClH/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12;/h3-7,9H,8H2,1-2H3;1H/q+1;/p-1
DMD741P CS CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C.[Cl-]
DMD741P IK MKOMESMZHZNBIZ-UHFFFAOYSA-M
DMD741P IU 2-(4,5-dimethyl-1,3-thiazol-3-ium-3-yl)-1-phenylethanone;chloride
DMD741P CA CAS 341028-37-3
DMD741P DE Hypotension
DM36HBS ID DM36HBS
DM36HBS DN ALXN1101
DM36HBS HS Phase 2/3
DM36HBS CP Alexion pharmaceuticals
DM36HBS DE Molybdenum cofactor deficiency
DMBFOAZ ID DMBFOAZ
DMBFOAZ DN AMG520
DMBFOAZ HS Phase 2/3
DMBFOAZ SN CNP520
DMBFOAZ CP Amgen Thousand Oaks, CA Novartis East Hanover, NJ
DMBFOAZ DE Alzheimer disease
DMN6F1W ID DMN6F1W
DMN6F1W DN Amiodarone
DMN6F1W HS Phase 2/3
DMN6F1W SN amiodarone; 1951-25-3; Cordarone; Amiodarona; Amiodaronum; Amjodaronum; Amiodaronum [INN-Latin]; Amiodarona [INN-Spanish]; Pacerone; L 3428; L-3428; UNII-N3RQ532IUT; C25H29I2NO3; SKF 33134-A; EINECS 217-772-1; CHEMBL633; BRN 1271711; N3RQ532; Amiodarone
DMN6F1W TC Antiviral Agents
DMN6F1W DT Small molecular drug
DMN6F1W PC 2157
DMN6F1W MW 645.3
DMN6F1W FM C25H29I2NO3
DMN6F1W IC InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
DMN6F1W CS CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMN6F1W IK IYIKLHRQXLHMJQ-UHFFFAOYSA-N
DMN6F1W IU (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
DMN6F1W CA CAS 1951-25-3
DMN6F1W CB CHEBI:2663
DMN6F1W DE Coronavirus Disease 2019 (COVID-19)
DMJRU3A ID DMJRU3A
DMJRU3A DN AMO-02
DMJRU3A HS Phase 2/3
DMJRU3A CP AMO Pharma Berwyn, PA
DMJRU3A DE Myotonic dystrophy
DMDLGRO ID DMDLGRO
DMDLGRO DN Aramchol
DMDLGRO HS Phase 2/3
DMDLGRO SN Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed
DMDLGRO CP Galmed Medical Research Ltd
DMDLGRO DT Small molecular drug
DMDLGRO PC 18738120
DMDLGRO MW 702.1
DMDLGRO FM C44H79NO5
DMDLGRO IC InChI=1S/C44H79NO5/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-40(48)45-34-27-28-43(3)33(29-34)30-38(46)42-36-25-24-35(32(2)23-26-41(49)50)44(36,4)39(47)31-37(42)43/h32-39,42,46-47H,5-31H2,1-4H3,(H,45,48)(H,49,50)/t32-,33+,34+,35-,36+,37+,38-,39+,42+,43+,44-/m1/s1
DMDLGRO CS CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]3[C@@H]2C[C@@H]([C@]4([C@H]3CC[C@@H]4[C@H](C)CCC(=O)O)C)O)O)C
DMDLGRO IK SHKXZIQNFMOPBS-OOMQYRRCSA-N
DMDLGRO IU (4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMDLGRO CA CAS 246529-22-6
DMDLGRO DE Lipid metabolism disorder
DMS8QF9 ID DMS8QF9
DMS8QF9 DN Arimoclomol
DMS8QF9 HS Phase 2/3
DMS8QF9 SN BRX-345
DMS8QF9 CP Biorex Research and Development Co
DMS8QF9 DT Small molecular drug
DMS8QF9 PC 9568077
DMS8QF9 MW 313.78
DMS8QF9 FM C14H20ClN3O3
DMS8QF9 IC InChI=1S/C14H20ClN3O3/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17/h4-5,8-9,13,19H,1-3,6-7,10-11H2/b16-14-/t13-/m1/s1
DMS8QF9 CS C1CCN(CC1)C[C@H](CO/N=C(/C2=C[N+](=CC=C2)[O-])\\Cl)O
DMS8QF9 IK SGEIEGAXKLMUIZ-XUVDNFPMSA-N
DMS8QF9 IU (3Z)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride
DMS8QF9 CA CAS 289893-25-0
DMS8QF9 DE Cerebrovascular ischaemia; Inclusion body myositis
DM15VBJ ID DM15VBJ
DM15VBJ DN Artemisone
DM15VBJ HS Phase 2/3
DM15VBJ SN Artemifone; Artemisone, Medicines For Malaria Venture; MMV-00/1007; Artemisinin derviative, Bayer/WHO/Hong Kong University; Artemisone, Bayer/WHO/Hong Kong University; Semi-synthetic endoperoxide, Bayer/WHO/Hong Kong University
DM15VBJ CP Hong Kong University of Science & Technology
DM15VBJ DT Small molecular drug
DM15VBJ PC 11531457
DM15VBJ MW 401.5
DM15VBJ FM C19H31NO6S
DM15VBJ IC InChI=1S/C19H31NO6S/c1-12-4-5-15-13(2)16(20-8-10-27(21,22)11-9-20)23-17-19(15)14(12)6-7-18(3,24-17)25-26-19/h12-17H,4-11H2,1-3H3/t12-,13-,14+,15+,16-,17-,18-,19-/m1/s1
DM15VBJ CS C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)N5CCS(=O)(=O)CC5)C
DM15VBJ IK FDMUNKXWYMSZIR-NQWKWHCYSA-N
DM15VBJ IU 4-[(1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]-1,4-thiazinane 1,1-dioxide
DM15VBJ CA CAS 255730-18-8
DM15VBJ DE Malaria
DMZGKXW ID DMZGKXW
DMZGKXW DN Atogepant
DMZGKXW HS Phase 2/3
DMZGKXW SN UNII-7CRV8RR151; 7CRV8RR151; AGN-241689; MK-8031; 1374248-81-3; Atogepant [INN]; Atogepant [WHO-DD]; Atogepant [USAN:INN]; SCHEMBL4570348; GTPL9730; CHEMBL3991065; example 4 [US20120122911]; Spiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide, 1',2',5,7-tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxo-, (3'S)-; (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1
DMZGKXW CP Allergan Parsippany, NJ
DMZGKXW PC 72163100
DMZGKXW MW 603.5
DMZGKXW FM C29H23F6N5O3
DMZGKXW IC InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1
DMZGKXW CS C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F
DMZGKXW IK QIVUCLWGARAQIO-OLIXTKCUSA-N
DMZGKXW IU (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
DMZGKXW CA CAS 1374248-81-3
DMZGKXW DE Migraine
DMVB4OS ID DMVB4OS
DMVB4OS DN AVN 211
DMVB4OS HS Phase 2/3
DMVB4OS CP Avineuro Pharmaceuticals
DMVB4OS DE Schizophrenia
DM5YHU2 ID DM5YHU2
DM5YHU2 DN Avoralstat
DM5YHU2 HS Phase 2/3
DM5YHU2 SN TUWMKPVJGGWGNL-UHFFFAOYSA-N; UNII-UX17773O15; UX17773O15; 918407-35-9; Avoralstat [INN]; 3-(2-((4-Carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid; 3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]pyridine-2-carboxylic acid; SCHEMBL17513082; AKOS030629101; DB12120; CS-7551; 2-Pyridinecarboxylic acid, 3-(2-(((4-(aminoiminomethyl)phenyl)amino)carbonyl)-4-ethenyl-5-met
DM5YHU2 CP BioCryst Pharmaceuticals Durham, NC
DM5YHU2 PC 86566678
DM5YHU2 MW 513.5
DM5YHU2 FM C28H27N5O5
DM5YHU2 IC InChI=1S/C28H27N5O5/c1-3-16-12-21(26(34)32-18-8-6-17(7-9-18)25(29)30)20(13-23(16)38-2)19-10-11-22(33-24(19)28(36)37)27(35)31-14-15-4-5-15/h3,6-13,15H,1,4-5,14H2,2H3,(H3,29,30)(H,31,35)(H,32,34)(H,36,37)
DM5YHU2 CS COC1=CC(=C(C=C1C=C)C(=O)NC2=CC=C(C=C2)C(=N)N)C3=C(N=C(C=C3)C(=O)NCC4CC4)C(=O)O
DM5YHU2 IK TUWMKPVJGGWGNL-UHFFFAOYSA-N
DM5YHU2 IU 3-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl]-6-(cyclopropylmethylcarbamoyl)pyridine-2-carboxylic acid
DM5YHU2 CA CAS 918407-35-9
DM5YHU2 DE Hereditary angioedema
DMJQHXD ID DMJQHXD
DMJQHXD DN AZD3293
DMJQHXD HS Phase 2/3
DMJQHXD SN CHEMBL2152914; SCHEMBL9948518; SCHEMBL9948271; SCHEMBL18562845; BDBM50393099
DMJQHXD CP AstraZeneca
DMJQHXD DT Small molecular drug
DMJQHXD PC 57404290
DMJQHXD MW 412.5
DMJQHXD FM C26H28N4O
DMJQHXD IC InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)
DMJQHXD CS CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
DMJQHXD IK WKDNQONLGXOZRG-UHFFFAOYSA-N
DMJQHXD DE Alzheimer disease
DM3827C ID DM3827C
DM3827C DN AZD4547
DM3827C HS Phase 2/3
DM3827C SN AZD4547; 1035270-39-3; AZD-4547; AZD 4547; UNII-2167OG1EKJ; 2167OG1EKJ; CHEBI:63453; KB-74810; N-(5-(3,5-Dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3R,5S)-rel-3,5-dimethylpiperazin-1-yl)benzamide; N-{5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-(cis-3,5-dimethylpiperazin-1-yl)benzamide; rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide; N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide
DM3827C CP AstraZeneca
DM3827C DT Small molecular drug
DM3827C PC 51039095
DM3827C MW 463.6
DM3827C FM C26H33N5O3
DM3827C IC InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
DM3827C CS C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC
DM3827C IK VRQMAABPASPXMW-HDICACEKSA-N
DM3827C IU N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide
DM3827C CA CAS 1035270-39-3
DM3827C CB CHEBI:63453
DM3827C DE Solid tumour/cancer
DMHWE5R ID DMHWE5R
DMHWE5R DN Batabulin
DMHWE5R HS Phase 2/3
DMHWE5R SN T-138067; T-138068; T-67
DMHWE5R CP Tularik Inc
DMHWE5R DT Small molecular drug
DMHWE5R PC 216324
DMHWE5R MW 371.26
DMHWE5R FM C13H7F6NO3S
DMHWE5R IC InChI=1S/C13H7F6NO3S/c1-23-7-3-2-5(4-6(7)14)20-24(21,22)13-11(18)9(16)8(15)10(17)12(13)19/h2-4,20H,1H3
DMHWE5R CS COC1=C(C=C(C=C1)NS(=O)(=O)C2=C(C(=C(C(=C2F)F)F)F)F)F
DMHWE5R IK ROZCIVXTLACYNY-UHFFFAOYSA-N
DMHWE5R IU 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide
DMHWE5R CA CAS 195533-53-0
DMHWE5R DE Solid tumour/cancer
DMKT16N ID DMKT16N
DMKT16N DN Bevacizumab
DMKT16N HS Phase 2/3
DMKT16N SN Bevacizumab (ophthalmic slow-release tissue tablet); Avastin
DMKT16N TC Antiviral Agents
DMKT16N DT Monoclonal antibody
DMKT16N DE Metastatic colorectal cancer; Coronavirus Disease 2019 (COVID-19)
DMUSJ3D ID DMUSJ3D
DMUSJ3D DN BIIB-088
DMUSJ3D HS Phase 2/3
DMUSJ3D SN AGTC 501
DMUSJ3D CP Applied Genetic Technologies
DMUSJ3D DT Gene therapy
DMUSJ3D DE Retinitis pigmentosa
DMYFQJL ID DMYFQJL
DMYFQJL DN BNV-222
DMYFQJL HS Phase 2/3
DMYFQJL SN Diepalrestat choline; UNII-16AHE7410O; 16AHE7410O; CHEMBL4297277; Q27251797; 1665300-21-9; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate, (5Z)-5-((2E)-2-methyl-3-phenyl-2-propen-1-ylidene)-4-oxo-2-thioxo-3-thiazolidineacetate (1:1:1)
DMYFQJL CP BioNevia Pharmaceuticals
DMYFQJL DT Small molecular drug
DMYFQJL PC 117587644
DMYFQJL MW 742
DMYFQJL FM C35H39N3O7S4
DMYFQJL IC InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-;
DMYFQJL CS C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)O.C/C(=C\\C1=CC=CC=C1)/C=C\\2/C(=O)N(C(=S)S2)CC(=O)[O-].C[N+](C)(C)CCO
DMYFQJL IK WKSNHZZSMLFYFI-UROVXFGGSA-M
DMYFQJL IU 2-hydroxyethyl(trimethyl)azanium;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetate;2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DMYFQJL CA CAS 1665300-21-9
DMYFQJL DE Diabetic neuropathy
DMV52CP ID DMV52CP
DMV52CP DN Bucindolol
DMV52CP HS Phase 2/3
DMV52CP SN Bucindolol; 71119-11-4; Bucindolol [INN:BAN]; Bucindololum [INN-Latin]; CHEMBL321582; C22H25N3O2; NCGC00167817-01; 2-(2-Hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile; DSSTox_RID_81872; DSSTox_CID_26744; DSSTox_GSID_46744; Bucindololum; 2-[2-Hydroxy-3-[2-(indol-3-yl)-1,1-dimethylethylamino]propoxy]benzonitrile; Benzonitrile, 2-(2-hydroxy-3-((2-(1H-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-; 2-[2-Hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]benzonitrile
DMV52CP DT Small molecular drug
DMV52CP PC 51045
DMV52CP MW 363.5
DMV52CP FM C22H25N3O2
DMV52CP IC InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
DMV52CP CS CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
DMV52CP IK FBMYKMYQHCBIGU-UHFFFAOYSA-N
DMV52CP IU 2-[2-hydroxy-3-[[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile
DMV52CP CA CAS 71119-11-4
DMV52CP DE Hypertension; Atrial fibrillation
DM31VZT ID DM31VZT
DM31VZT DN CAD-106
DM31VZT HS Phase 2/3
DM31VZT SN Amilomotide; Alzheimers disease vaccine, Cytos/Novartis; Immunodrug vaccines (Alzheimers disease), Cytos/Novartis; Beta amyloid 1-6 peptide/Qbeta virus-like particle conjugate (Alzheimer's disease), Cytos/Novartis
DM31VZT CP Cytos Biotechnology AG
DM31VZT DT Vaccine
DM31VZT DE Alzheimer disease
DMVLXMG ID DMVLXMG
DMVLXMG DN Camostat mesylate
DMVLXMG HS Phase 2/3
DMVLXMG SN Camostat (mesylate); Camostat Methanesulfonate; Camostat methanesulfate; DSSTox_CID_238; DSSTox_GSID_20238; DSSTox_RID_75452; FOY 305; FOY-305; FOY305; Foipan; Foipan (TN); Foipan mesylate; NCGC00167526-01; Q-200778; UNII-451M50A1EQ; camostat mesilate; 451M50A1EQ; C21H26N4O8S; CAS-59721-29-8; CHEMBL85164
DMVLXMG TC Antiviral Agents
DMVLXMG DT Small molecular drug
DMVLXMG PC 5284360
DMVLXMG MW 494.5
DMVLXMG FM C21H26N4O8S
DMVLXMG IC InChI=1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)
DMVLXMG CS CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O
DMVLXMG IK FSEKIHNIDBATFG-UHFFFAOYSA-N
DMVLXMG IU [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate;methanesulfonic acid
DMVLXMG CA CAS 59721-29-8
DMVLXMG CB CHEBI:31347
DMVLXMG DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS); Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMST3FM ID DMST3FM
DMST3FM DN CART-19
DMST3FM HS Phase 2/3
DMST3FM CP Fujian Medical University
DMST3FM DT CAR T Cell Therapy
DMST3FM DE Acute lymphoblastic leukaemia
DM45Z3P ID DM45Z3P
DM45Z3P DN CD123/CLL1 CAR-T Cells
DM45Z3P HS Phase 2/3
DM45Z3P CP Fujian Medical University
DM45Z3P DT CAR T Cell Therapy (Dual specific)
DM45Z3P DE Acute myeloid leukaemia
DM32148 ID DM32148
DM32148 DN CD19 CAR T cells
DM32148 HS Phase 2/3
DM32148 CP Fujian Medical University
DM32148 DT CAR T Cell Therapy
DM32148 DE Acute lymphoblastic leukaemia; B-cell lymphoma
DMFCLT6 ID DMFCLT6
DMFCLT6 DN CE-224535
DMFCLT6 HS Phase 2/3
DMFCLT6 SN CP-23575
DMFCLT6 CP Pfizer Inc
DMFCLT6 DT Small molecular drug
DMFCLT6 PC 11547499
DMFCLT6 MW 480.9
DMFCLT6 FM C22H29ClN4O6
DMFCLT6 IC InChI=1S/C22H29ClN4O6/c1-33-13-16(28)12-26-19(29)11-25-27(21(26)31)15-6-7-18(23)17(10-15)20(30)24-14-22(32)8-4-2-3-5-9-22/h6-7,10-11,16,28,32H,2-5,8-9,12-14H2,1H3,(H,24,30)/t16-/m1/s1
DMFCLT6 CS COC[C@@H](CN1C(=O)C=NN(C1=O)C2=CC(=C(C=C2)Cl)C(=O)NCC3(CCCCCC3)O)O
DMFCLT6 IK FUCKCIVGBCBZNP-MRXNPFEDSA-N
DMFCLT6 IU 2-chloro-N-[(1-hydroxycycloheptyl)methyl]-5-[4-[(2R)-2-hydroxy-3-methoxypropyl]-3,5-dioxo-1,2,4-triazin-2-yl]benzamide
DMFCLT6 CA CAS 724424-43-5
DMFCLT6 DE Arthralgia
DMXCD69 ID DMXCD69
DMXCD69 DN CEP1347
DMXCD69 HS Phase 2/3
DMXCD69 SN AC1L31ZX; SCHEMBL1649555; ZINC103589452; DB05403
DMXCD69 DT Small molecular drug
DMXCD69 PC 9917013
DMXCD69 MW 615.8
DMXCD69 FM C33H33N3O5S2
DMXCD69 IC InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1
DMXCD69 CS CCSCC1=CC2=C(C=C1)N3[C@H]4C[C@@]([C@](O4)(N5C6=C(C=C(C=C6)CSCC)C7=C8CNC(=O)C8=C2C3=C75)C)(C(=O)OC)O
DMXCD69 IK SCMLRESZJCKCTC-KMYQRJGFSA-N
DMXCD69 IU methyl (15S,16R,18R)-10,23-bis(ethylsulfanylmethyl)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboxylate
DMXCD69 CA CAS 156177-65-0
DMXCD69 DE Asthma
DMUOMBZ ID DMUOMBZ
DMUOMBZ DN CLL1 CAR-T Cell
DMUOMBZ HS Phase 2/3
DMUOMBZ CP Fujian Medical University
DMUOMBZ DT CAR T Cell Therapy (Dual specific)
DMUOMBZ DE Acute myeloid leukaemia
DMX9V8K ID DMX9V8K
DMX9V8K DN Contigoside B
DMX9V8K HS Phase 2/3
DMX9V8K SN Isoquercitrin; Isoquercetin; 482-35-9; Hirsutrin; 3-Glucosylquercetin; Glucosyl 3-quercetin; Quercetin 3-glucoside; Quercetol 3-glucoside; Quercetin 3-o-glucopyranoside; Quercetin 3-D-glucoside; Quercetol 3-monoglucoside; Quercetin 3-monoglucoside; Isotrifoliin; Quercetin 3-beta-glucoside; Quercetin 3-O-glucoside; quercetin-3-glucoside; Quercetin 3-beta-O-glucoside; Quercetin-3-O-glucopyranoside; UNII-6HN2PC637T; quercetin-3-O-glucoside; NSC 115918; BRN 0100989; CHEMBL250450; 6HN2PC637T; CHEBI:68352; quercetin 3-O-beta-D-glucopyran
DMX9V8K DT Small molecular drug
DMX9V8K PC 5280804
DMX9V8K MW 464.4
DMX9V8K FM C21H20O12
DMX9V8K IC InChI=1S/C21H20O12/c22-6-13-15(27)17(29)18(30)21(32-13)33-20-16(28)14-11(26)4-8(23)5-12(14)31-19(20)7-1-2-9(24)10(25)3-7/h1-5,13,15,17-18,21-27,29-30H,6H2/t13-,15-,17+,18-,21+/m1/s1
DMX9V8K CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
DMX9V8K IK OVSQVDMCBVZWGM-QSOFNFLRSA-N
DMX9V8K IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMX9V8K CA CAS 482-35-9
DMX9V8K CB CHEBI:68352
DMX9V8K DE Thrombosis
DMJYTUQ ID DMJYTUQ
DMJYTUQ DN CR-845
DMJYTUQ HS Phase 2/3
DMJYTUQ SN Kappa opioid agonist (intravenous, pain), Cara/Ferring; Kappa opioid agonist (oral, pain), Cara/Ferring; Kappa opioid agonist (subcutaneous, pain), Cara/Ferring; CR-845 (iv infusion, pain), Cara/Ferring; CR-845 (oral capsule, pain), Cara/Ferring; CR-845 (subcutaneous, pain), Cara/Ferring; FE-202845 (iv, pain), Cara/Ferring; FE-202845 (oral, pain), Cara/Ferring; FE-202845 (sc, pain), Cara/Ferring
DMJYTUQ CP Cara Therapeutics Inc; cara therapeutics
DMJYTUQ DE Pain; Chronic pain
DMSR7D2 ID DMSR7D2
DMSR7D2 DN CX-516
DMSR7D2 HS Phase 2/3
DMSR7D2 SN Ampalex; BDP 12; CX 516; CX516; BDP-12; SPD-420; Piperidin-1-yl(quinoxalin-6-yl)methanone; 1-(6-Quinoxalinylcarbonyl)piperidine; 1-(6-quinoxalinylcarbonyl)-Piperidine; 1-(quinoxalin-6-ylcarbonyl)piperidine; 6-(piperidin-1-ylcarbonyl)quinoxaline
DMSR7D2 CP Cortex
DMSR7D2 DT Small molecular drug
DMSR7D2 PC 148184
DMSR7D2 MW 241.29
DMSR7D2 FM C14H15N3O
DMSR7D2 IC InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2
DMSR7D2 CS C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2
DMSR7D2 IK ANDGGVOPIJEHOF-UHFFFAOYSA-N
DMSR7D2 IU piperidin-1-yl(quinoxalin-6-yl)methanone
DMSR7D2 CA CAS 154235-83-3
DMSR7D2 CB CHEBI:34605
DMSR7D2 DE Pervasive developmental disorder; Schizophrenia
DML906E ID DML906E
DML906E DN CY-1503
DML906E HS Phase 2/3
DML906E SN Cylexin
DML906E CP Epimmune Inc
DML906E DE Hypertension
DMYVKM5 ID DMYVKM5
DMYVKM5 DN Darbufelone
DMYVKM5 HS Phase 2/3
DMYVKM5 SN PD-136095
DMYVKM5 CP Parke-Davis & Co
DMYVKM5 DT Small molecular drug
DMYVKM5 PC 6444826
DMYVKM5 MW 332.5
DMYVKM5 FM C18H24N2O2S
DMYVKM5 IC InChI=1S/C18H24N2O2S/c1-17(2,3)11-7-10(8-12(14(11)21)18(4,5)6)9-13-15(22)20-16(19)23-13/h7-9,21H,1-6H3,(H2,19,20,22)/b13-9-
DMYVKM5 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N=C(S2)N
DMYVKM5 IK AKTXOQVMWSFEBQ-LCYFTJDESA-N
DMYVKM5 IU (5Z)-2-amino-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazol-4-one
DMYVKM5 CA CAS 139226-28-1
DMYVKM5 DE Asthma
DMZV3SY ID DMZV3SY
DMZV3SY DN Denagliptin
DMZV3SY HS Phase 2/3
DMZV3SY SN GW 823093; GW823093; (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoro-pyrrolidine-2-carbonitrile
DMZV3SY CP Glaxo Smithkline
DMZV3SY DT Small molecular drug
DMZV3SY PC 9887755
DMZV3SY MW 373.4
DMZV3SY FM C20H18F3N3O
DMZV3SY IC InChI=1S/C20H18F3N3O/c21-14-5-1-12(2-6-14)18(13-3-7-15(22)8-4-13)19(25)20(27)26-11-16(23)9-17(26)10-24/h1-8,16-19H,9,11,25H2/t16-,17-,19-/m0/s1
DMZV3SY CS C1[C@@H](CN([C@@H]1C#N)C(=O)[C@H](C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)N)F
DMZV3SY IK URRAHSMDPCMOTH-LNLFQRSKSA-N
DMZV3SY IU (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile
DMZV3SY CA CAS 483369-58-0
DMZV3SY DE Type-2 diabetes
DMVSIN2 ID DMVSIN2
DMVSIN2 DN Emapalumab
DMVSIN2 HS Phase 2/3
DMVSIN2 SN emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501
DMVSIN2 TC Antiviral Agents
DMVSIN2 DT Monoclonal antibody
DMVSIN2 DE Coronavirus Disease 2019 (COVID-19)
DMH8VMP ID DMH8VMP
DMH8VMP DN Emixustat
DMH8VMP HS Phase 2/3
DMH8VMP SN EMIXUSTAT; UNII-02DZ1HBF0M; 1141777-14-1; 02DZ1HBF0M; Emixustat [USAN:INN]; (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol; Incemixustat; ACU 4229; A3V; Emixustat (USAN); SCHEMBL966515; CHEMBL2107821; DTXSID50150665; WJIGGYYSZBWCGC-MRXNPFEDSA-N; ZINC59126886; AKOS032945088; CS-6177; DB12608; HY-19720; D10348; (r)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol; 3-Amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1(R)-ol hydro -chloride
DMH8VMP CP Acucela Seattle, WA
DMH8VMP DT Small molecular drug
DMH8VMP PC 25221720
DMH8VMP MW 263.37
DMH8VMP FM C16H25NO2
DMH8VMP IC InChI=1S/C16H25NO2/c17-10-9-16(18)14-7-4-8-15(11-14)19-12-13-5-2-1-3-6-13/h4,7-8,11,13,16,18H,1-3,5-6,9-10,12,17H2/t16-/m1/s1
DMH8VMP CS C1CCC(CC1)COC2=CC=CC(=C2)[C@@H](CCN)O
DMH8VMP IK WJIGGYYSZBWCGC-MRXNPFEDSA-N
DMH8VMP IU (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol
DMH8VMP CA CAS 1141777-14-1
DMH8VMP DE Age-related macular degeneration; Proliferative diabetic retinopathy
DMOYE70 ID DMOYE70
DMOYE70 DN Fexinidazole
DMOYE70 HS Phase 2/3
DMOYE70 SN Fexinidazole (human African trypanosomiasis); Fexinidazole (African sleeping sickness), Drugs for Neglected Diseases initiative; Fexinidazole (HAT), Drugs for Neglected Diseases initiative; Fexinidazole (human African trypanosomiasis), Drugs for Neglected Diseases initiative
DMOYE70 CP Drugs for Neglected Diseases initiative
DMOYE70 DT Small molecular drug
DMOYE70 PC 68792
DMOYE70 MW 279.32
DMOYE70 FM C12H13N3O3S
DMOYE70 IC InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3
DMOYE70 CS CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-]
DMOYE70 IK MIWWSGDADVMLTG-UHFFFAOYSA-N
DMOYE70 IU 1-methyl-2-[(4-methylsulfanylphenoxy)methyl]-5-nitroimidazole
DMOYE70 CA CAS 59729-37-2
DMOYE70 DE Trypanosomiasis
DMH7CSQ ID DMH7CSQ
DMH7CSQ DN Gavilimomab
DMH7CSQ HS Phase 2/3
DMH7CSQ SN ABX-CBL; CBL-1
DMH7CSQ CP Abgenix Inc
DMH7CSQ DT Antibody
DMH7CSQ DE Graft-versus-host disease
DM0JETC ID DM0JETC
DM0JETC DN Genistein
DM0JETC HS Phase 2/3
DM0JETC SN Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM0JETC CP DSM Nutritional Products
DM0JETC DT Small molecular drug
DM0JETC PC 5280961
DM0JETC MW 270.24
DM0JETC FM C15H10O5
DM0JETC IC InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
DM0JETC CS C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
DM0JETC IK TZBJGXHYKVUXJN-UHFFFAOYSA-N
DM0JETC IU 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM0JETC CA CAS 446-72-0
DM0JETC CB CHEBI:28088
DM0JETC DE Prostate cancer; Menopause symptom
DMW7TZV ID DMW7TZV
DMW7TZV DN GS-6207
DMW7TZV HS Phase 2/3
DMW7TZV SN 2189684-45-3; N-[(1R)-1-[3-[4-Chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
DMW7TZV CP Gilead Sciences
DMW7TZV DT Small molecular drug
DMW7TZV PC 138059678
DMW7TZV MW 958.3
DMW7TZV FM C41H36ClF8N7O5S2
DMW7TZV IC InChI=1S/C41H36ClF8N7O5S2/c1-40(2,63(3,59)60)11-10-22-4-7-24(25-8-9-28(42)33-36(25)56(17-30(45)46)54-39(33)55-64(61,62)23-5-6-23)34(51-22)29(14-19-12-20(43)15-21(44)13-19)52-31(58)18-57-37-32(35(53-57)38(47)48)26-16-27(26)41(37,49)50/h4,7-9,12-13,15,23,26-27,29-30,38H,5-6,14,16-18H2,1-3H3,(H,52,58)(H,54,55)/t26-,27+,29-/m1/s1
DMW7TZV CS CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)F)NS(=O)(=O)C4CC4)[C@@H](CC5=CC(=CC(=C5)F)F)NC(=O)CN6C7=C([C@@H]8C[C@@H]8C7(F)F)C(=N6)C(F)F)S(=O)(=O)C
DMW7TZV IK CPCUUUACFKQOHY-IUAQSZDVSA-N
DMW7TZV IU N-[(1R)-1-[3-[4-chloro-3-(cyclopropylsulfonylamino)-1-(2,2-difluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2R,4S)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
DMW7TZV DE Human immunodeficiency virus infection
DMMTL7V ID DMMTL7V
DMMTL7V DN Hemoglobin raffimer
DMMTL7V HS Phase 2/3
DMMTL7V SN Hemolink; Cross-linked hemoglobin, Hemosol
DMMTL7V CP Ontario Inc
DMMTL7V DE Anemia
DMPLQ1V ID DMPLQ1V
DMPLQ1V DN IFX-1
DMPLQ1V HS Phase 2/3
DMPLQ1V SN IFX-1 mab
DMPLQ1V TC Antiviral Agents
DMPLQ1V DT Monoclonal antibody
DMPLQ1V DE Coronavirus Disease 2019 (COVID-19)
DMONWJ4 ID DMONWJ4
DMONWJ4 DN Imetelstat
DMONWJ4 HS Phase 2/3
DMONWJ4 SN Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448
DMONWJ4 CP Geron
DMONWJ4 DT Small molecular drug
DMONWJ4 PC 71587831
DMONWJ4 MW 4610
DMONWJ4 FM C148H211N68O53P13S13
DMONWJ4 IC InChI=1S/C148H211N68O53P13S13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-97(218)160-34-69(217)38-255-282(242,295)256-51-95-74(25-102(261-95)207-37-68(4)136(221)191-148(207)229)195-274(234,287)249-45-89-78(29-106(264-89)212-61-175-115-124(155)165-56-170-129(115)212)199-277(237,290)252-48-92-81(32-109(267-92)215-64-178-118-132(215)183-143(158)187-139(118)224)202-280(240,293)254-50-94-82(33-110(269-94)216-65-179-119-133(216)184-144(159)188-140(119)225)203-281(241,294)253-49-93-79(30-107(268-93)213-62-176-116-130(213)181-141(156)185-137(116)222)200-278(238,291)246-42-86-72(23-100(260-86)205-35-66(2)134(219)189-146(205)227)193-272(232,285)245-41-85-73(24-101(259-85)206-36-67(3)135(220)190-147(206)228)194-273(233,286)248-44-88-77(28-105(263-88)211-60-174-114-123(154)164-55-169-128(114)211)198-276(236,289)251-47-91-80(31-108(266-91)214-63-177-117-131(214)182-142(157)186-138(117)223)201-279(239,292)250-46-90-76(27-104(265-90)210-59-173-113-122(153)163-54-168-127(113)210)197-275(235,288)244-40-84-71(22-99(258-84)204-20-19-96(150)180-145(204)226)192-271(231,284)247-43-87-75(26-103(262-87)209-58-172-112-121(152)162-53-167-126(112)209)196-270(230,283)243-39-83-70(149)21-98(257-83)208-57-171-111-120(151)161-52-166-125(111)208/h19-20,35-37,52-65,69-95,98-110,217H,5-18,21-34,38-51,149H2,1-4H3,(H,160,218)(H,242,295)(H2,150,180,226)(H2,151,161,166)(H2,152,162,167)(H2,153,163,168)(H2,154,164,169)(H2,155,165,170)(H,189,219,227)(H,190,220,228)(H,191,221,229)(H2,192,231,284)(H2,193,232,285)(H2,194,233,286)(H2,195,234,287)(H2,196,230,283)(H2,197,235,288)(H2,198,236,289)(H2,199,237,290)(H2,200,238,291)(H2,201,239,292)(H2,202,240,293)(H2,203,241,294)(H3,156,181,185,222)(H3,157,182,186,223)(H3,158,183,187,224)(H3,159,184,188,225)/t69?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,270?,271?,272?,273?,274?,275?,276?,277?,278?,279?,280?,281?,282?/m0/s1
DMONWJ4 CS CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OC[C@@H]3[C@H](C[C@@H](O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OC[C@@H]6[C@H](C[C@@H](O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OC[C@@H]9[C@H](C[C@@H](O9)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)NP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)N)S)O
DMONWJ4 IK LVZYXEALRXBLJZ-ISQYCPACSA-N
DMONWJ4 IU N-[3-[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-[[[(2S,3S,5R)-3-amino-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-sulfanylphosphoryl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]amino]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2-hydroxypropyl]hexadecanamide
DMONWJ4 CA CAS 868169-64-6
DMONWJ4 DE Multiple myeloma; Breast cancer; Non-small-cell lung cancer; Essential thrombocythemia; Myelodysplastic syndrome; Myelofibrosis
DMIUA3M ID DMIUA3M
DMIUA3M DN Imprime PGG
DMIUA3M HS Phase 2/3
DMIUA3M SN Imprime PGG (TN)
DMIUA3M CP Biothera
DMIUA3M DE Breast cancer; Colorectal cancer; Head and neck cancer; Melanoma; Non-hodgkin lymphoma
DM5UJ9P ID DM5UJ9P
DM5UJ9P DN IMU-838
DM5UJ9P HS Phase 2/3
DM5UJ9P SN Vidofludimus; 717824-30-1; 4SC-101; SC12267; UNII-8Y1PJ3VG81; SC 12267; CHEMBL197194; 8Y1PJ3VG81; Vidofludimus(4SC-101; SC12267); Vidofludimus [INN]; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; IMU-838; DTXSID50431325; HMS3740I15; AOB87354; BCP14555; ZINC14960644; s7262; AK; Vidofludimus
DM5UJ9P TC Antiviral Agents
DM5UJ9P DT Small molecular drug
DM5UJ9P PC 9820008
DM5UJ9P MW 355.4
DM5UJ9P FM C20H18FNO4
DM5UJ9P IC InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
DM5UJ9P CS COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
DM5UJ9P IK XPRDUGXOWVXZLL-UHFFFAOYSA-N
DM5UJ9P IU 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
DM5UJ9P CA CAS 717824-30-1
DM5UJ9P DE Coronavirus Disease 2019 (COVID-19)
DMC3794 ID DMC3794
DMC3794 DN Indium-111
DMC3794 HS Phase 2/3
DMC3794 SN ABT-806
DMC3794 CP Abbott Laboratories Abbott
DMC3794 DT Antibody
DMC3794 DE Solid tumour/cancer
DMGPJ5U ID DMGPJ5U
DMGPJ5U DN JNJ-54861911
DMGPJ5U HS Phase 2/3
DMGPJ5U CP Janssen research & development
DMGPJ5U PC 68254185
DMGPJ5U MW 367.4
DMGPJ5U FM C18H14FN5OS
DMGPJ5U IC InChI=1S/C18H14FN5OS/c1-18(6-7-26-17(21)24-18)13-8-12(3-4-14(13)19)23-16(25)15-5-2-11(9-20)10-22-15/h2-8,10H,1H3,(H2,21,24)(H,23,25)/t18-/m0/s1
DMGPJ5U CS C[C@]1(C=CSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMGPJ5U IK VLLFGVHGKLDDLW-SFHVURJKSA-N
DMGPJ5U IU N-[3-[(4S)-2-amino-4-methyl-1,3-thiazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMGPJ5U CA CAS 1200493-78-2
DMGPJ5U DE Alzheimer disease
DMBJ4IZ ID DMBJ4IZ
DMBJ4IZ DN LECOZOTAN HYDROCHLORIDE
DMBJ4IZ HS Phase 2/3
DMBJ4IZ SN Lecozotan hydrochloride < USAN; SRA-333; 4-Cyano-N-[2(R)-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-(2-pyridyl)benzamide hydrochloride
DMBJ4IZ DT Small molecular drug
DMBJ4IZ PC 11156648
DMBJ4IZ MW 520
DMBJ4IZ FM C28H30ClN5O3
DMBJ4IZ IC InChI=1S/C28H29N5O3.ClH/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23;/h2-12,21H,13-18,20H2,1H3;1H/t21-;/m1./s1
DMBJ4IZ CS C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5.Cl
DMBJ4IZ IK GXYZREDEYDFJPT-ZMBIFBSDSA-N
DMBJ4IZ IU 4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide;hydrochloride
DMBJ4IZ CA CAS 433282-68-9
DMBJ4IZ DE Cognitive impairment
DMEUGZL ID DMEUGZL
DMEUGZL DN Legumain-cleavable doxorubicin prodrugs
DMEUGZL HS Phase 2/3
DMEUGZL SN Legubicin; LEG-2; LEG-3; Legumain-cleavable doxorubicin prodrugs (cancer); Legumain-cleavabledoxorubicin prodrugs (cancer), Affinity Pharmaceuticals
DMEUGZL CP Scripps Research Institute
DMEUGZL DE Solid tumour/cancer
DM4OYXE ID DM4OYXE
DM4OYXE DN LIAROZOLE
DM4OYXE HS Phase 2/3
DM4OYXE SN Liarozole; Liazal; 115575-11-6; R-75251; LIAROZOLE FUMARATE; Liarozole [INN:BAN]; Liarozolum [INN-Latin]; Liarozol [INN-Spanish]; R 75251; R-61405; R085246; R 61405; R-085246; R 085246; 6-((3-chlorophenyl)(1H-imidazol-1-yl)methyl)-1H-benzo[d]imidazole; UNII-17NYD2210B; CHEMBL389433; UNII-090Y06W08H; 17NYD2210B; 090Y06W08H; Liarozolum; Liarozol; 1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-; NCGC00181034-01; Liarozole, (-)-; Liarozole, (+)-; AC1L1TNN; AC1Q3M3B; SCHEMBL18597; GTPL5210; SCHEMBL15944205; DTXSID9048277
DM4OYXE DT Small molecular drug
DM4OYXE PC 60652
DM4OYXE MW 308.8
DM4OYXE FM C17H13ClN4
DM4OYXE IC InChI=1S/C17H13ClN4/c18-14-3-1-2-12(8-14)17(22-7-6-19-11-22)13-4-5-15-16(9-13)21-10-20-15/h1-11,17H,(H,20,21)
DM4OYXE CS C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4
DM4OYXE IK UGFHIPBXIWJXNA-UHFFFAOYSA-N
DM4OYXE IU 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole
DM4OYXE CA CAS 115575-11-6
DM4OYXE CB CHEBI:135316
DM4OYXE DE Dermatological disease
DMI215P ID DMI215P
DMI215P DN Lopinavir + ritonavir + interferon beta-1b
DMI215P HS Phase 2/3
DMI215P SN Aluviran + norvir + betaseron
DMI215P TC Antiviral Agents
DMI215P DT Combination drug
DMI215P DE Middle East Respiratory Syndrome (MERS)
DMP8HW1 ID DMP8HW1
DMP8HW1 DN LY2157299
DMP8HW1 HS Phase 2/3
DMP8HW1 SN Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
DMP8HW1 CP Eli Lilly
DMP8HW1 DT Small molecular drug
DMP8HW1 PC 10090485
DMP8HW1 MW 369.4
DMP8HW1 FM C22H19N5O
DMP8HW1 IC InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
DMP8HW1 CS CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N
DMP8HW1 IK IVRXNBXKWIJUQB-UHFFFAOYSA-N
DMP8HW1 IU 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
DMP8HW1 CA CAS 700874-72-2
DMP8HW1 CB CHEBI:137064
DMP8HW1 DE Arteriosclerosis; Glioma; Hepatocellular carcinoma; Pancreatic cancer; Solid tumour/cancer; Non-small-cell lung cancer
DMUQWRD ID DMUQWRD
DMUQWRD DN LYS-SAF302
DMUQWRD HS Phase 2/3
DMUQWRD SN SRP-9002
DMUQWRD CP Lysogene; Sarepta Therapeutics
DMUQWRD DT Gene therapy
DMUQWRD DE Mucopolysaccharidosis
DM948AP ID DM948AP
DM948AP DN MAb114
DM948AP HS Phase 2/3
DM948AP CP Ridgeback Biotherapeutics
DM948AP DT Antibody
DM948AP DE Ebola virus infection
DMONYS9 ID DMONYS9
DMONYS9 DN MBX-102
DMONYS9 HS Phase 2/3
DMONYS9 SN Arhalofenate; Mbx-102; MBX 102; 24136-23-0; UNII-1P01UJR9X1; JNJ-39659100; 1P01UJR9X1; CB-102; M-102; Arhalofenate [USAN:INN]; Arhalofenate (USAN/INN); SCHEMBL3302781; CHEMBL2103824; BJBCSGQLZQGGIQ-QGZVFWFLSA-N; ZINC2012859; BDBM50093473; AKOS032945719; DB11811; CS-6812; SB16866; (-)-2-(Acetylamino)ethyl (2R)-(4-chlorophenyl)(3-(trifluoromethyl)phenoxy)acetate; CJ-31172; Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester, (-)-; HY-14831; D09579; UNII-K9TZK4MNO6 component BJBCSGQLZQGGIQ-QGZV
DMONYS9 CP Metabolex
DMONYS9 DT Small molecular drug
DMONYS9 PC 12082259
DMONYS9 MW 415.8
DMONYS9 FM C19H17ClF3NO4
DMONYS9 IC InChI=1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1
DMONYS9 CS CC(=O)NCCOC(=O)[C@@H](C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F
DMONYS9 IK BJBCSGQLZQGGIQ-QGZVFWFLSA-N
DMONYS9 IU 2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate
DMONYS9 CA CAS 24136-23-0
DMONYS9 DE Gout
DMNTCV4 ID DMNTCV4
DMNTCV4 DN MBX-8025
DMNTCV4 HS Phase 2/3
DMNTCV4 SN Ppar; A agonist 2; SCHEMBL4950228; CHEMBL3545019; XJHXZGHPCAKRFK-UHFFFAOYSA-N; HY-100120; CS-0018099; {2-Methyl-4-[5-methyl-2-(4-trifluoromethyl-phenyl)-2H-[1,2,3]triazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid
DMNTCV4 CP Metabolex
DMNTCV4 DT Small molecular drug
DMNTCV4 PC 11236126
DMNTCV4 MW 444.5
DMNTCV4 FM C21H23F3O5S
DMNTCV4 IC InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
DMNTCV4 CS CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C
DMNTCV4 IK JWHYSEDOYMYMNM-QGZVFWFLSA-N
DMNTCV4 IU 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
DMNTCV4 CA CAS 851528-79-5
DMNTCV4 DE Obesity; Familial hypercholesterolemia; Primary biliary cholangitis
DMBIO6E ID DMBIO6E
DMBIO6E DN Meclinertant
DMBIO6E HS Phase 2/3
DMBIO6E SN Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMBIO6E CP Sanofi-aventis
DMBIO6E TC Anticancer Agents
DMBIO6E DT Small molecular drug
DMBIO6E PC 119192
DMBIO6E MW 587.1
DMBIO6E FM C32H31ClN4O5
DMBIO6E IC InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)
DMBIO6E CS COC1=C(C(=CC=C1)OC)C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O
DMBIO6E IK DYLJVOXRWLXDIG-UHFFFAOYSA-N
DMBIO6E IU 2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMBIO6E CA CAS 146362-70-1
DMBIO6E CB CHEBI:125516
DMBIO6E DE Inflammatory bowel disease
DMFE0P1 ID DMFE0P1
DMFE0P1 DN Metformin glycinate
DMFE0P1 HS Phase 2/3
DMFE0P1 SN DMMET-01; Metformin glycinate (diabetes); Type 2 diabetes therapy, Laboratorios Silanes; Metformin glycinate (diabetes), Laboratorios Silanes
DMFE0P1 CP Laboratorios Silanes SA De CV
DMFE0P1 DT Small molecular drug
DMFE0P1 PC 44520175
DMFE0P1 MW 204.23
DMFE0P1 FM C6H16N6O2
DMFE0P1 IC InChI=1S/C4H11N5.C2H5NO2/c1-9(2)4(7)8-3(5)6;3-1-2(4)5/h1-2H3,(H5,5,6,7,8);1,3H2,(H,4,5)
DMFE0P1 CS CN(C)C(=N)N=C(N)N.C(C(=O)O)N
DMFE0P1 IK KOFRCHIVYXPUNL-UHFFFAOYSA-N
DMFE0P1 IU 2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine
DMFE0P1 CA CAS 121369-64-0
DMFE0P1 DE Type-2 diabetes
DM752PU ID DM752PU
DM752PU DN MGCD516
DM752PU HS Phase 2/3
DM752PU SN Sitravatinib
DM752PU CP Mirati therapeutics
DM752PU PC 25212148
DM752PU MW 629.7
DM752PU FM C33H29F2N5O4S
DM752PU IC InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)
DM752PU CS COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DM752PU IK WLAVZAAODLTUSW-UHFFFAOYSA-N
DM752PU IU 1-N'-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DM752PU CA CAS 1123837-84-2
DM752PU DE Non-small-cell lung cancer; Solid tumour/cancer; Breast cancer
DM2YNMI ID DM2YNMI
DM2YNMI DN MK-1654
DM2YNMI HS Phase 2/3
DM2YNMI CP Merck
DM2YNMI DT Antibody
DM2YNMI DE Respiratory syncytial virus infection
DMDQOWT ID DMDQOWT
DMDQOWT DN MOR-208
DMDQOWT HS Phase 2/3
DMDQOWT SN XmAb CD19; XENP-5574; XENP-5603; XmAb-5574; Anti-CD19 humanized mAb (cancer/autoimmune disease), Xencor; Anti-CD19 humanized monoclonal antibody (cancer/autoimmune disease), Xencor
DMDQOWT CP Morphosys
DMDQOWT DT Antibody
DMDQOWT DE Autoimmune diabetes; Diffuse large B-cell lymphoma; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Non-hodgkin lymphoma
DMKMZW2 ID DMKMZW2
DMKMZW2 DN MTC-DOX
DMKMZW2 HS Phase 2/3
DMKMZW2 SN MTC-doxorubicin
DMKMZW2 CP FeRx
DMKMZW2 DE Liver cancer
DM16PWF ID DM16PWF
DM16PWF DN N1-methylnicotinamide
DM16PWF HS Phase 2/3
DM16PWF SN Trigonellinamide; 1-methylnicotinamide; N(1)-Methylnicotinamide; N1-Methylnicotinamide; 3-(Aminocarbonyl)-1-methylpyridinium; 1-Methyl nicotinamide; 3-carbamoyl-1-methylpyridinium; 3106-60-3; Pyridinium, 3-carbamoyl-1-methyl-; UNII-UM47085BXC; N(sup 1)-Methylnicotinamide; 3-carbamoyl-1-methylpyridin-1-ium; BRN 3540351; 1-methylpyridine-3-carboxamide; UM47085BXC; CHEBI:16797; 1-methylpyridin-1-ium-3-carboxamide; CHEMBL1209652; Trigonellamide; Pyridinium, 3-(aminocarbonyl)-1-methyl-; 1-methyl-3-carbamoylpyridinium; 8GC; I-methyl n
DM16PWF DT Small molecular drug
DM16PWF PC 457
DM16PWF MW 137.16
DM16PWF FM C7H9N2O+
DM16PWF IC InChI=1S/C7H8N2O/c1-9-4-2-3-6(5-9)7(8)10/h2-5H,1H3,(H-,8,10)/p+1
DM16PWF CS C[N+]1=CC=CC(=C1)C(=O)N
DM16PWF IK LDHMAVIPBRSVRG-UHFFFAOYSA-O
DM16PWF IU 1-methylpyridin-1-ium-3-carboxamide
DM16PWF CA CAS 3106-60-3
DM16PWF CB CHEBI:16797
DM16PWF DE Hyperlipidemia
DM8D6O2 ID DM8D6O2
DM8D6O2 DN Nafamostat
DM8D6O2 HS Phase 2/3
DM8D6O2 SN FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
DM8D6O2 TC Antiviral Agents
DM8D6O2 DT Small molecular drug
DM8D6O2 PC 4413
DM8D6O2 MW 347.4
DM8D6O2 FM C19H17N5O2
DM8D6O2 IC InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
DM8D6O2 CS C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N
DM8D6O2 IK MQQNFDZXWVTQEH-UHFFFAOYSA-N
DM8D6O2 IU (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
DM8D6O2 CA CAS 81525-10-2
DM8D6O2 CB CHEBI:135466
DM8D6O2 DE Pancreatitis; Sepsis; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS)
DMD5AEB ID DMD5AEB
DMD5AEB DN NAL-GLU
DMD5AEB HS Phase 2/3
DMD5AEB SN [Ac-D2Nal1,D4ClPhe2,D3Pal3,Arg5,DGlu5(anisole adduct),DAla10]-GnRH; Acetyl-D-2-naphthylalanyl-D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L-arginyl-[4-(4-methoxybenzoyl)-D-2-aminobutyryl]-L-leucyl-L-arginyl-L-prolyl-D-alanylamide; N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-arginyl-5-(4-methoxyphenyl)-5-oxo-D-norvalyl-L-leucyl-L-arginyl-L-prolyl-D-alanylamide
DMD5AEB PC 44412112
DMD5AEB MW 343.4
DMD5AEB FM C18H21N3O4
DMD5AEB IC InChI=1S/C18H21N3O4/c19-14(17(23)21-15(18(24)25)7-8-16(20)22)10-11-5-6-12-3-1-2-4-13(12)9-11/h1-6,9,14-15H,7-8,10,19H2,(H2,20,22)(H,21,23)(H,24,25)/t14-,15-/m0/s1
DMD5AEB CS C1=CC=C2C=C(C=CC2=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMD5AEB IK VSZVSSYQFUFEQG-GJZGRUSLSA-N
DMD5AEB IU (2S)-5-amino-2-[[(2S)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-oxopentanoic acid
DMD5AEB DE Prostate cancer
DM901ZW ID DM901ZW
DM901ZW DN Naptumomab estafenatox
DM901ZW HS Phase 2/3
DM901ZW CP Active Biotech
DM901ZW DE Solid tumour/cancer
DM3MJUS ID DM3MJUS
DM3MJUS DN NBTX-001
DM3MJUS HS Phase 2/3
DM3MJUS CP Nobilis Therapeutics Portland, OR
DM3MJUS DE Panic disorder; Post-traumatic stress disorder
DM0798Z ID DM0798Z
DM0798Z DN NLG8189
DM0798Z HS Phase 2/3
DM0798Z SN 1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
DM0798Z CP NewLink Genetics
DM0798Z DT Small molecular drug
DM0798Z PC 405012
DM0798Z MW 218.25
DM0798Z FM C12H14N2O2
DM0798Z IC InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
DM0798Z CS CN1C=C(C2=CC=CC=C21)C[C@H](C(=O)O)N
DM0798Z IK ZADWXFSZEAPBJS-SNVBAGLBSA-N
DM0798Z IU (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid
DM0798Z CA CAS 110117-83-4
DM0798Z DE Acute myeloid leukaemia; Melanoma; Brain cancer; Pancreatic cancer; Prostate cancer
DM4H78P ID DM4H78P
DM4H78P DN NT-501
DM4H78P HS Phase 2/3
DM4H78P SN NTC-201E; CNTF cell implant (ECT), Neurotech; CNTF ophthalmic cell implant (retinitis pigmentosa), Neurotech; Cell implant (ciliary neurotrophic factor), Neurotech; Cell implant (retinitis pigmentosa, ECT), Neurotech
DM4H78P CP Amgen Inc
DM4H78P DE Ocular inflammation; Macular telangiectasia type 2; Retinitis pigmentosa
DMT13UA ID DMT13UA
DMT13UA DN Olokizumab
DMT13UA HS Phase 2/3
DMT13UA SN OLOKIZUMAB; CHEMBL1743050; CDP-6038
DMT13UA TC Antiviral Agents
DMT13UA DT Monoclonal antibody
DMT13UA DE Coronavirus Disease 2019 (COVID-19)
DMTIESG ID DMTIESG
DMTIESG DN Omburtamab
DMTIESG HS Phase 2/3
DMTIESG CP Y-mAbs Therapeutics
DMTIESG DT Antibody
DMTIESG DE Neuroblastoma
DMPDA17 ID DMPDA17
DMPDA17 DN Omburtamab I-131
DMPDA17 HS Phase 2/3
DMPDA17 CP Y-mAbs Therapeutics New York, NY
DMPDA17 DE Small round cell desmoplastic tumour; Neuroblastoma
DMCA2PJ ID DMCA2PJ
DMCA2PJ DN ONO-2506
DMCA2PJ HS Phase 2/3
DMCA2PJ SN (2R)-2-Propyloctanoic acid; Arundic acid; 185517-21-9; (R)-2-PROPYLOCTANOIC ACID; Proglia; Cereact; ONO 2506; R-(-)-Arundic Acid; UNII-F2628ZD0FO; MK-0724; (R)-(-)-2-Propyloctanoic Acid; F2628ZD0FO; NCGC00183861-01; Acide arundique; Acido arzndico; Acidum arundicum; Arundic acid [INN]; Arocyte; Acide arundique [INN-French]; Acidum arundicum [INN-Latin]; Arundic acid (JAN/INN); Acido arzndico [INN-Spanish]; ONO-2506PO; MK 0724; AC1L4LMD; AC1Q5QIF; SCHEMBL4365; DSSTox_RID_83036; DSSTox_CID_28767; DSSTox_GSID_48841; ONO 2506PO; Arocyte; Ono2506; Acido arundico [INN-Spanish]; 2-Propyloctanoic acid; FR149175
DMCA2PJ CP Ono Pharmaceuticals
DMCA2PJ DT Small molecular drug
DMCA2PJ PC 208925
DMCA2PJ MW 186.29
DMCA2PJ FM C11H22O2
DMCA2PJ IC InChI=1S/C11H22O2/c1-3-5-6-7-9-10(8-4-2)11(12)13/h10H,3-9H2,1-2H3,(H,12,13)/t10-/m1/s1
DMCA2PJ CS CCCCCC[C@@H](CCC)C(=O)O
DMCA2PJ IK YCYMCMYLORLIJX-SNVBAGLBSA-N
DMCA2PJ IU (2R)-2-propyloctanoic acid
DMCA2PJ CA CAS 185517-21-9
DMCA2PJ DE Stroke; Type-2 diabetes
DMCTRLN ID DMCTRLN
DMCTRLN DN OT-101
DMCTRLN HS Phase 2/3
DMCTRLN CP Mateon/Oncotelic
DMCTRLN DT Antisense oligonucleotide
DMCTRLN DE Melanoma; Merkel cell carcinoma; Pancreatic cancer; Recurrent glioblastoma; Coronavirus Disease 2019 (COVID-19)
DMURH4X ID DMURH4X
DMURH4X DN Oxypurinol
DMURH4X HS Phase 2/3
DMURH4X SN Oxypurinol (intravenous)
DMURH4X CP Johns Hopkins University
DMURH4X DT Small molecular drug
DMURH4X PC 135398752
DMURH4X MW 152.11
DMURH4X FM C5H4N4O2
DMURH4X IC InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)
DMURH4X CS C1=NNC2=C1C(=O)NC(=O)N2
DMURH4X IK HXNFUBHNUDHIGC-UHFFFAOYSA-N
DMURH4X IU 1,7-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione
DMURH4X CA CAS 2465-59-0
DMURH4X CB CHEBI:28315
DMURH4X DE Heart failure
DM0NZDT ID DM0NZDT
DM0NZDT DN Pactimibe
DM0NZDT HS Phase 2/3
DM0NZDT SN Pactimibe; 189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309
DM0NZDT DT Small molecular drug
DM0NZDT PC 3081927
DM0NZDT MW 416.6
DM0NZDT FM C25H40N2O3
DM0NZDT IC InChI=1S/C25H40N2O3/c1-7-8-9-10-11-12-14-27-15-13-19-17(2)20(16-21(28)29)18(3)22(23(19)27)26-24(30)25(4,5)6/h7-16H2,1-6H3,(H,26,30)(H,28,29)
DM0NZDT CS CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C
DM0NZDT IK TXIIZHHIOHVWJD-UHFFFAOYSA-N
DM0NZDT IU 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid
DM0NZDT CA CAS 189198-30-9
DM0NZDT DE Arteriosclerosis
DMRZ1F2 ID DMRZ1F2
DMRZ1F2 DN Padsevonil
DMRZ1F2 HS Phase 2/3
DMRZ1F2 SN 1294000-61-5; UNII-0R1HN52K0N; UCB0942; UCB1415943-000; (R)-4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)pyrrolidin-2-one; (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one; Padsevonil [INN]; Padsevonil [USAN]; Padsevonil (JAN/USAN); SCHEMBL1672843; CHEMBL4297521; UCB-0942; WHO 10384; DB14977; SB18725; HY-109009; CS-0030507; D11842; Q27237119; (4R)-4-(2-Chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)(1,3,4)thiadiazol-5-yl)methyl)-2-pyrrolidinone; 2-Pyrrolidinone, 4-(2-chloro-2,2-difluoroethyl)-1-((2-(methoxymethyl)-6-(trifluoromethyl)imidazo(2,1-b)-1,3,4-thiadiazol-5-yl)methyl)-, (4R)-
DMRZ1F2 CP UCB
DMRZ1F2 DT Small molecular drug
DMRZ1F2 PC 52911611
DMRZ1F2 MW 432.8
DMRZ1F2 FM C14H14ClF5N4O2S
DMRZ1F2 IC InChI=1S/C14H14ClF5N4O2S/c1-26-6-9-22-24-8(11(14(18,19)20)21-12(24)27-9)5-23-4-7(2-10(23)25)3-13(15,16)17/h7H,2-6H2,1H3/t7-/m1/s1
DMRZ1F2 CS COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl
DMRZ1F2 IK DCXFIOLWWRXEQH-SSDOTTSWSA-N
DMRZ1F2 IU (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one
DMRZ1F2 CA CAS 1294000-61-5
DMRZ1F2 DE Epilepsy
DMHWY2G ID DMHWY2G
DMHWY2G DN Pagoclone
DMHWY2G HS Phase 2/3
DMHWY2G SN IP-456; RP-59037; RP-62955
DMHWY2G CP Rhone-Poulenc SA
DMHWY2G DT Small molecular drug
DMHWY2G PC 131664
DMHWY2G MW 407.9
DMHWY2G FM C23H22ClN3O2
DMHWY2G IC InChI=1S/C23H22ClN3O2/c1-14(2)7-10-16(28)13-19-17-5-3-4-6-18(17)23(29)27(19)21-12-9-15-8-11-20(24)25-22(15)26-21/h3-6,8-9,11-12,14,19H,7,10,13H2,1-2H3
DMHWY2G CS CC(C)CCC(=O)CC1C2=CC=CC=C2C(=O)N1C3=NC4=C(C=C3)C=CC(=N4)Cl
DMHWY2G IK HIUPRQPBWVEQJJ-UHFFFAOYSA-N
DMHWY2G IU 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-3H-isoindol-1-one
DMHWY2G CA CAS 133737-32-3
DMHWY2G DE Anxiety disorder
DMBJ15R ID DMBJ15R
DMBJ15R DN Pexacerfont
DMBJ15R HS Phase 2/3
DMBJ15R SN PEXACERFONT; 459856-18-9; UNII-LF1VBG4ZUK; CRF1 ANTAGONIST; LF1VBG4ZUK; BMS-562086; Pexacerfont [USAN:INN]; BMS 562086; Pexacerfont (USAN/INN); CHEMBL482950; SCHEMBL5235999; BDBM29490; DTXSID60196675; CS-6630; DB12572; HY-12127; D10022; Pyrazolo[1,5-a]-1,3,5-triazine, 13-15; BMS562086;BMS 562086;BMS-562086; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-((1R)-1-methylpropyl)-
DMBJ15R CP Bristol-Myers Squibb
DMBJ15R DT Small molecular drug
DMBJ15R PC 9884366
DMBJ15R MW 340.4
DMBJ15R FM C18H24N6O
DMBJ15R IC InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1
DMBJ15R CS CC[C@@H](C)NC1=NC(=NC2=C(C(=NN21)C)C3=C(N=C(C=C3)OC)C)C
DMBJ15R IK LBWQSAZEYIZZCE-SNVBAGLBSA-N
DMBJ15R IU N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMBJ15R CA CAS 459856-18-9
DMBJ15R DE Anxiety disorder
DMYKNME ID DMYKNME
DMYKNME DN PF-06651600
DMYKNME HS Phase 2/3
DMYKNME SN CBRJPFGIXUFMTM-WDEREUQCSA-N; 1792180-81-4; UNII-2OYE00PC25; 2OYE00PC25; PF06651600; 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; GTPL9559; SCHEMBL16764638; BCP24778; EX-A2613; ZINC526061581; example 5 [WO2015083028]; ACN-040697; compound 11 [PMID: 28139931]; HY-100754; CS-0020243; 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
DMYKNME CP Pfizer New York, NY
DMYKNME PC 118115473
DMYKNME MW 285.34
DMYKNME FM C15H19N5O
DMYKNME IC InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
DMYKNME CS C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
DMYKNME IK CBRJPFGIXUFMTM-WDEREUQCSA-N
DMYKNME IU 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
DMYKNME CA CAS 1792180-81-4
DMYKNME DE Asthma; Crohn disease; Alopecia
DM1QSM3 ID DM1QSM3
DM1QSM3 DN Phenol
DM1QSM3 HS Phase 2/3
DM1QSM3 SN carbolic acid; 108-95-2; Hydroxybenzene; Phenic acid; Oxybenzene; Phenylic acid; Benzenol; Phenyl hydrate; Monophenol; Phenyl hydroxide; Phenylic alcohol; PhOH; Monohydroxybenzene; Phenole; Paoscle; Phenyl alcohol; Phenol alcohol; Izal; Phenol, liquefied; Acide carbolique; Fenolo; Phenosmolin; Fenosmoline; Fenosmolin; Carbolsaure; Fenol; Liquid phenol; Carbolic oil; Phenol, pure; Phenol homopolymer; Phenole [German]; Fenolo [Italian]; Benzene, hydroxy-; Rcra waste number U188; Campho-Phenique Gel; Phenic; Carbolsaure [German]
DM1QSM3 DT Small molecular drug
DM1QSM3 PC 996
DM1QSM3 MW 94.11
DM1QSM3 FM C6H6O
DM1QSM3 IC InChI=1S/C6H6O/c7-6-4-2-1-3-5-6/h1-5,7H
DM1QSM3 CS C1=CC=C(C=C1)O
DM1QSM3 IK ISWSIDIOOBJBQZ-UHFFFAOYSA-N
DM1QSM3 IU phenol
DM1QSM3 CA CAS 108-95-2
DM1QSM3 CB CHEBI:15882
DM1SV8I ID DM1SV8I
DM1SV8I DN PHN-131
DM1SV8I HS Phase 2/3
DM1SV8I SN NALBUPHINE HYDROCHLORIDE; Nalbuphine HCL; Nubain; 23277-43-2; Nalbufina clorhidrato [Spanish]; Nalbuphine hydrochloride [USAN]; En 2234A; UNII-ZU4275277R; EN-2234A; EINECS 245-549-9; ZU4275277R; 17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol hydrochloride; Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, hydrochloride, (5-alpha,6-alpha)-; (5alpha,6alpha)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride; N-Cyclobutylmethyl-14-hydroxydihydronormorphine hydrochloride; Nalbuphine h
DM1SV8I CP PhytoHealth Corp
DM1SV8I DT Small molecular drug
DM1SV8I PC 5360733
DM1SV8I MW 393.9
DM1SV8I FM C21H28ClNO4
DM1SV8I IC InChI=1S/C21H27NO4.ClH/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12;/h4-5,12,15-16,19,23-25H,1-3,6-11H2;1H/t15-,16+,19-,20-,21+;/m0./s1
DM1SV8I CS C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl
DM1SV8I IK YZLZPSJXMWGIFH-BCXQGASESA-N
DM1SV8I IU (4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride
DM1SV8I CA CAS 23277-43-2
DM1SV8I CB CHEBI:7455
DM1SV8I DE Pain
DMPWH30 ID DMPWH30
DMPWH30 DN Pimagedine HCl
DMPWH30 HS Phase 2/3
DMPWH30 CP Synvista Therapeutics
DMPWH30 DT Small molecular drug
DMPWH30 PC 85468708
DMPWH30 MW 110.55
DMPWH30 FM CH7ClN4
DMPWH30 IC InChI=1S/CH6N4.ClH/c2-1(3)5-4;/h4H2,(H4,2,3,5);1H
DMPWH30 CS C(=[NH+]N)(N)N.[Cl-]
DMPWH30 IK UBDZFAGVPPMTIT-UHFFFAOYSA-N
DMPWH30 IU amino(diaminomethylidene)azanium;chloride
DMPWH30 CA CAS 16139-18-7
DMPWH30 DE Diabetic kidney disease
DM0EFQS ID DM0EFQS
DM0EFQS DN Plasminogen
DM0EFQS HS Phase 2/3
DM0EFQS CP Kedrion
DM0EFQS DE Alzheimer disease
DMCGK6X ID DMCGK6X
DMCGK6X DN PRO 140
DMCGK6X HS Phase 2/3
DMCGK6X CP CytoDyn
DMCGK6X DT Antibody
DMCGK6X DE Human immunodeficiency virus-1 infection
DMZI4OV ID DMZI4OV
DMZI4OV DN QLT-091001
DMZI4OV HS Phase 2/3
DMZI4OV SN Crystalets; Davitan A 650; Myvak (VAN); Myvax (VAN); O~15~-acetylretinol; RETINYL ACETATE; RO 1-5275; Retinol acetate; Retinol, acetate; Retinol, acetate, all-trans-; Retinyl acetate, all-trans-; Vitamin A acetate; Vitamin A acetate (VAN); Vitamin A alcohol acetate; Vitamin A ester; Vitamin A1 acetate; all-trans-Retinol acetate; all-trans-Retinyl acetate; all-trans-Retinylacetate; all-trans-Vitamin A acetate; trans-Retinol Acetate; 127-47-9; Acetic acid, retinyl ester; CCRIS 1907; NSC 122045; UNII-3LE3D9D6OY
DMZI4OV PC 638034
DMZI4OV MW 328.5
DMZI4OV FM C22H32O2
DMZI4OV IC QGNJRVVDBSJHIZ-QHLGVNSISA-N
DMZI4OV CS CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOC(=O)C)C)C
DMZI4OV IK 1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9+,18-14+
DMZI4OV IU [(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] acetate
DMZI4OV CA CAS 127-47-9
DMZI4OV CB CHEBI:32095
DMZI4OV DE Barrett esophagus
DMB8UQ3 ID DMB8UQ3
DMB8UQ3 DN Ramatroban
DMB8UQ3 HS Phase 2/3
DMB8UQ3 SN 116649-85-5; Baynas; BAY u3405; Bay u-3405; Bay u 3406; Bay-u-3405; Bay u 3405; BAY-u 3405; UNII-P1ALI72U6C; C21H21FN2O4S; 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid; P1ALI72U6C; 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; CHEMBL361812; (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid; NCGC00167519-01; EN-137774; DSSTox_RID_81819; Baynas (TN); Ramatroban (JAN/INN); [3H]ramatroban
DMB8UQ3 CP Bayer Yakuhin
DMB8UQ3 DT Small molecular drug
DMB8UQ3 PC 123879
DMB8UQ3 MW 416.5
DMB8UQ3 FM C21H21FN2O4S
DMB8UQ3 IC InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
DMB8UQ3 CS C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
DMB8UQ3 IK LDXDSHIEDAPSSA-OAHLLOKOSA-N
DMB8UQ3 IU 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
DMB8UQ3 CA CAS 116649-85-5
DMB8UQ3 CB CHEBI:32087
DMB8UQ3 DE Perennial allergic rhinitis
DM1LFUN ID DM1LFUN
DM1LFUN DN Ravidasvir
DM1LFUN HS Phase 2/3
DM1LFUN SN PPI-668 free base; UNII-AL3G001BI8; AL3G001BI8; 1242087-93-9; Methyl N-[(1S)-1-[[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]-2-naphthalenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamate; Ravidasvir [USAN]; Ravidasvir free base; BL-238630; SCHEMBL7603463; CHEMBL3121849; SCHEMBL12075676; BDBM243443; methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate; SB19743; Carbamic acid, N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-pyrrolidinyl)-1H-benzimidazol-6-yl)-2-naphthalenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-, methyl ester; Methyl N-((1S)-1-(((2S)-2-(5-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3- methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)naphthalen-2-yl)-1H-benzimidazol-2-yl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)carbamate; BI 238630; BI-238630; US9427428, 3; Q27273972; methyl ((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((1S)-1-(((2S)-2-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-benzimidazol-5-yl)-2-naphthyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; methyl((s)-1-((s)-2-(5-(6-(2((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidin-2-yl)-1h-imidazol-4-yl)naphthalen-2-yl)-1h-benzo[d]imidazol-2-yl) pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
DM1LFUN CP Presidio Pharmaceuticals
DM1LFUN DT Small molecular drug
DM1LFUN PC 52918888
DM1LFUN MW 762.9
DM1LFUN FM C42H50N8O6
DM1LFUN IC InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
DM1LFUN CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DM1LFUN IK LCHMHYPWGWYXEL-ZYADHFCISA-N
DM1LFUN IU methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM1LFUN CA CAS 1242087-93-9
DM1LFUN DE Hepatitis C
DML9FD4 ID DML9FD4
DML9FD4 DN Rinfabate
DML9FD4 HS Phase 2/3
DML9FD4 SN RhIGFBP-3; Rinfabate, Insmed; RhIGF-BP3, Insmed; Insulin-like growth factor binding protein-3, Insmed
DML9FD4 CP Insmed Inc
DML9FD4 DE Solid tumour/cancer
DMWZ6DK ID DMWZ6DK
DMWZ6DK DN Roledumab
DMWZ6DK HS Phase 2/3
DMWZ6DK SN DMATRIA; LFB-R593; R-297; R-593; Anti-D human monoclonal antibody, Laboratoire Francais du Fractionnement et des Biotechnologies; R297 antibody (hematological disease), LFB; R297 antibody (hematological disease), Laboratoire Francais du Fractionnement et des Biotechnologies; Anti-RhD antibody (hematological disease), LFB; Anti-rhesus D mAB (hematological disease), LFB
DMWZ6DK CP LFB Biotechnologies
DMWZ6DK DT Antibody
DMWZ6DK DE Anemia
DMNIYSZ ID DMNIYSZ
DMNIYSZ DN RP101
DMNIYSZ HS Phase 2/3
DMNIYSZ SN SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
DMNIYSZ CP RESprotect
DMNIYSZ DT Small molecular drug
DMNIYSZ PC 446727
DMNIYSZ MW 333.13
DMNIYSZ FM C11H13BrN2O5
DMNIYSZ IC InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1
DMNIYSZ CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O
DMNIYSZ IK ODZBBRURCPAEIQ-PIXDULNESA-N
DMNIYSZ IU 5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMNIYSZ CA CAS 69304-47-8
DMNIYSZ DE Pancreatic cancer; Infectious disease
DMOJLCV ID DMOJLCV
DMOJLCV DN SAR164877
DMOJLCV HS Phase 2/3
DMOJLCV CP Sanofi-Aventis
DMOJLCV TC Analgesics
DMOJLCV DE Pain
DMH7IPW ID DMH7IPW
DMH7IPW DN Sarizotan
DMH7IPW HS Phase 2/3
DMH7IPW SN Sarizotan [INN]; EMD 128130; N-((3,4-Dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)-3-pyridinemethanamine; (-)-3-((((R)-2-Chromanylmethyl)amino)methyl)-5-(p-fluorophenyl)pyridine; 1-(3,4-dihydro-2H-chromen-2-yl)-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine
DMH7IPW CP EMD Serono
DMH7IPW DT Small molecular drug
DMH7IPW PC 6918388
DMH7IPW MW 348.4
DMH7IPW FM C22H21FN2O
DMH7IPW IC InChI=1S/C22H21FN2O/c23-20-8-5-17(6-9-20)19-11-16(12-24-14-19)13-25-15-21-10-7-18-3-1-2-4-22(18)26-21/h1-6,8-9,11-12,14,21,25H,7,10,13,15H2/t21-/m1/s1
DMH7IPW CS C1CC2=CC=CC=C2O[C@H]1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F
DMH7IPW IK HKFMQJUJWSFOLY-OAQYLSRUSA-N
DMH7IPW IU 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine
DMH7IPW CA CAS 351862-32-3
DMH7IPW DE Parkinson disease; Rett syndrome
DM31L9K ID DM31L9K
DM31L9K DN Sepofarsen
DM31L9K HS Phase 2/3
DM31L9K SN QR-110
DM31L9K CP ProQR Therapeutics
DM31L9K DT Oligonucleotide
DM31L9K DE Leber congenital amaurosis
DMTV5XC ID DMTV5XC
DMTV5XC DN Sitafloxacin
DMTV5XC HS Phase 2/3
DMTV5XC SN Sitafloxacin; Gracevit; Sitafloxacin Sesquihydrate; UNII-3GJC60U4Q8; Sitafloxacin isomer II; DU-6859a; C19H18ClF2N3O3; 3GJC60U4Q8; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid
DMTV5XC PC 461399
DMTV5XC MW 409.8
DMTV5XC FM C19H18ClF2N3O3
DMTV5XC IC InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
DMTV5XC CS C1CC12CN(CC2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5F)F
DMTV5XC IK PNUZDKCDAWUEGK-CYZMBNFOSA-N
DMTV5XC IU 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid
DMTV5XC CA CAS 127254-12-0
DMTV5XC CB CHEBI:4304
DMTV5XC DE Escherichia Coli Infections
DM30JWZ ID DM30JWZ
DM30JWZ DN SM04554
DM30JWZ HS Phase 2/3
DM30JWZ CP Samumed San Diego,CA
DM30JWZ DT Small molecular drug
DM30JWZ DE Alopecia
DMD9ISG ID DMD9ISG
DMD9ISG DN SM-88
DMD9ISG HS Phase 2/3
DMD9ISG CP Tyme Technologies New York, NY
DMD9ISG PC 3125
DMD9ISG MW 195.21
DMD9ISG FM C10H13NO3
DMD9ISG IC InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)
DMD9ISG CS CC(CC1=CC=C(C=C1)O)(C(=O)O)N
DMD9ISG IK NHTGHBARYWONDQ-UHFFFAOYSA-N
DMD9ISG IU 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
DMD9ISG CA CAS 658-48-0
DMD9ISG DE Prostate cancer; Pancreatic cancer
DM5WQ2U ID DM5WQ2U
DM5WQ2U DN SR-123781A
DM5WQ2U HS Phase 2/3
DM5WQ2U CP Sanofi-aventis
DM5WQ2U PC 145996625
DM5WQ2U MW 4854
DM5WQ2U FM C127H201Na19O134S17
DM5WQ2U IC InChI=1S/C127H220O134S17.19Na/c1-183-32-46-60(235-114-95(203-21)76(192-10)62(48(223-114)34-185-3)237-116-97(205-23)78(194-12)64(50(225-116)36-187-5)239-118-99(207-25)80(196-14)66(52(227-118)38-189-7)241-120-101(209-27)82(198-16)68(55(229-120)41-216-264(138,139)140)244-124-106(258-275(171,172)173)89(254-271(159,160)161)71(57(231-124)43-218-266(144,145)146)246-125-107(259-276(174,175)176)90(255-272(162,163)164)72(58(232-125)44-219-267(147,148)149)247-126-109(261-278(180,181)182)91(256-273(165,166)167)73(252-269(153,154)155)59(234-126)45-220-268(150,151)152)74(190-8)94(202-20)113(222-46)236-61-47(33-184-2)224-115(96(204-22)75(61)191-9)238-63-49(35-186-4)226-117(98(206-24)77(63)193-11)240-65-51(37-188-6)228-119(100(208-26)79(65)195-13)242-67-54(40-215-263(135,136)137)230-121(102(210-28)81(67)197-15)248-86-84(200-18)104(212-30)123(251-92(86)110(128)129)245-70-56(42-217-265(141,142)143)233-127(108(260-277(177,178)179)88(70)253-270(156,157)158)249-87-85(201-19)103(211-29)122(250-93(87)111(130)131)243-69-53(39-214-262(132,133)134)221-112(213-31)105(83(69)199-17)257-274(168,169)170;;;;;;;;;;;;;;;;;;;/h46-109,112-127H,32-45H2,1-31H3,(H,128,129)(H,130,131)(H,132,133,134)(H,135,136,137)(H,138,139,140)(H,141,142,143)(H,144,145,146)(H,147,148,149)(H,150,151,152)(H,153,154,155)(H,156,157,158)(H,159,160,161)(H,162,163,164)(H,165,166,167)(H,168,169,170)(H,171,172,173)(H,174,175,176)(H,177,178,179)(H,180,181,182);;;;;;;;;;;;;;;;;;;/q;19*+1/p-19/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67+,68-,69-,70-,71-,72-,73-,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103+,104-,105+,106-,107-,108-,109-,112+,113-,114+,115+,116+,117-,118+,119+,120-,121-,122-,123-,124+,125-,126-,127-;;;;;;;;;;;;;;;;;;;/m1.................../s1
DM5WQ2U CS COC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC)OC)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3OC)OC)O[C@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@H]5C(=O)[O-])O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]7[C@@H]([C@@H]([C@@H](O[C@H]7C(=O)[O-])O[C@@H]8[C@H](O[C@@H]([C@H]([C@H]8OC)OS(=O)(=O)[O-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])COC)COC)OC)OC)O[C@@H]9[C@@H]([C@H]([C@@H]([C@H](O9)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)OC)OC)OC)OC)OC)OC)OC)OC)OC.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM5WQ2U IK RRHHPXJSGSYSHW-ZURHXDBDSA-A
DM5WQ2U IU nonadecasodium;(2R,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5S,6R)-2-carboxylato-6-[(2R,3R,4S,5S,6S)-4,6-dimethoxy-5-sulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5S,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-5-[(2R,3R,4S,5R,6R)-3,4-disulfonatooxy-6-(sulfonatooxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-disulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-3,4-dimethoxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylate
DM5WQ2U CA CAS 232602-93-6
DM5WQ2U DE Venous thrombosis
DMKGQF0 ID DMKGQF0
DMKGQF0 DN Suvodirsen
DMKGQF0 HS Phase 2/3
DMKGQF0 SN WVE-210201
DMKGQF0 CP Wave Life Sciences
DMKGQF0 DT Antisense oligonucleotide
DMKGQF0 DE Duchenne dystrophy
DMWE3GB ID DMWE3GB
DMWE3GB DN TG-4010
DMWE3GB HS Phase 2/3
DMWE3GB SN MVA-Muc1-IL-2; MVA-TG-9931 (frozen suspension); MUC1/IL-2 antigen therapy (gene transfer system, cancer), Transgene
DMWE3GB CP Transgene
DMWE3GB DE Bipolar disorder; Non-small-cell lung cancer
DMVDTR2 ID DMVDTR2
DMVDTR2 DN Thymoquinone
DMVDTR2 HS Phase 2/3
DMVDTR2 SN 490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
DMVDTR2 DT Small molecular drug
DMVDTR2 PC 10281
DMVDTR2 MW 164.2
DMVDTR2 FM C10H12O2
DMVDTR2 IC InChI=1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3
DMVDTR2 CS CC1=CC(=O)C(=CC1=O)C(C)C
DMVDTR2 IK KEQHJBNSCLWCAE-UHFFFAOYSA-N
DMVDTR2 IU 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione
DMVDTR2 CA CAS 490-91-5
DMVDTR2 CB CHEBI:113532
DMVDTR2 DE Polycystic ovarian syndrome
DM23ARP ID DM23ARP
DM23ARP DN V-710
DM23ARP HS Phase 2/3
DM23ARP SN Vaccine (Staphylococcus aureus), Intercell; Vaccine (Staphylococcus aureus), Merck & Co; Iron surface determinant B-based vaccine (Staphylococcus aureus infection), Merck & Co; IsdB-based vaccine (Staphylococcus aureus infection), Merck & Co
DM23ARP CP Intercell AG
DM23ARP DT Vaccine
DM23ARP DE Staphylococcus infection
DMDG8Q3 ID DMDG8Q3
DMDG8Q3 DN Varlitinib
DMDG8Q3 HS Phase 2/3
DMDG8Q3 SN VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
DMDG8Q3 CP ASLAN Pharmaceuticals
DMDG8Q3 DT Small molecular drug
DMDG8Q3 PC 42642648
DMDG8Q3 MW 466.9
DMDG8Q3 FM C22H19ClN6O2S
DMDG8Q3 IC InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1
DMDG8Q3 CS C[C@@H]1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl
DMDG8Q3 IK UWXSAYUXVSFDBQ-CYBMUJFWSA-N
DMDG8Q3 IU 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine
DMDG8Q3 CA CAS 845272-21-1
DMDG8Q3 DE Breast cancer; Metastatic biliary tract neoplasms
DMTROUI ID DMTROUI
DMTROUI DN Vazegepant
DMTROUI HS Phase 2/3
DMTROUI SN UNII-ODU3ZAZ94J; ODU3ZAZ94J; BHV-3500; BDBM50436107
DMTROUI TC Antiviral Agents
DMTROUI DT Small molecular drug
DMTROUI PC 53472683
DMTROUI MW 638.8
DMTROUI FM C36H46N8O3
DMTROUI IC InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
DMTROUI CS CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
DMTROUI IK JJVAPHYEOZSKJZ-JGCGQSQUSA-N
DMTROUI IU N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide
DMTROUI CA CAS 1337918-83-8
DMTROUI DE Coronavirus Disease 2019 (COVID-19)
DMGKRAJ ID DMGKRAJ
DMGKRAJ DN VB4-845
DMGKRAJ HS Phase 2/3
DMGKRAJ CP Viventia Biotechnologies
DMGKRAJ DT Antibody
DMGKRAJ SQ 9045_H|oportuzumab monatox|||SCFV-KAPPA-HEAVY-TOXIN (V-KAPPA(7-118)+LINKER(119-144)+VH(145-260)+TOX-DOMAIN(281-637))|||||||647||||MW 69566.3|MW 69566.3|: HHHHHHDIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELKRATPSHNSHQVPSAGGPTANSGTSGSEVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSSEFGGAPEFPKPSTPPGSSGLEGGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVRQGTGNDEAGAASADVVSLTCPVAAGECAGPADSGDALLERNYPTGAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPDARGRIRNGALLRVYVPRSSLPGFYRTGLTLAAPEAAGEVERLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPHHHHHHKDEL
DMGKRAJ DE Head and neck cancer
DM0ASTP ID DM0ASTP
DM0ASTP DN Verapamil
DM0ASTP HS Phase 2/3
DM0ASTP SN VERAPAMIL; Iproveratril; 52-53-9; Vasolan; Dilacoran; Isoptin; Falicard; Isoptine; Isoptimo; Finoptin; Calan; Verapamilo; Verapamilum; Verapamilum [INN-Latin]; Lekoptin; Verapamilo [INN-Spanish]; Isotopin; Calcan; Tarka; D-365; Securon; Verelan; Izoptin; Verapamil [USAN:INN:BAN]; CP-16533-1; Covera-HS; Verpamil; CCRIS 6749; Verelan PM; Isoptin SR; C; Verapamil
DM0ASTP TC Antiviral Agents
DM0ASTP DT Small molecular drug
DM0ASTP PC 2520
DM0ASTP MW 454.6
DM0ASTP FM C27H38N2O4
DM0ASTP IC InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
DM0ASTP CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM0ASTP IK SGTNSNPWRIOYBX-UHFFFAOYSA-N
DM0ASTP IU 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM0ASTP CA CAS 52-53-9
DM0ASTP CB CHEBI:77733
DM0ASTP DE Coronavirus Disease 2019 (COVID-19)
DM4WQBO ID DM4WQBO
DM4WQBO DN VM-1500
DM4WQBO HS Phase 2/3
DM4WQBO SN VM-1500 (topical gel formulation, HIV infection)
DM4WQBO CP Viriom Ltd
DM4WQBO DE Human immunodeficiency virus infection
DM5G1NT ID DM5G1NT
DM5G1NT DN VX-210
DM5G1NT HS Phase 2/3
DM5G1NT SN BA-210; VX210
DM5G1NT CP Vertex Pharmaceuticals Boston, MA
DM5G1NT DE Spinal cord injury
DM2U3MX ID DM2U3MX
DM2U3MX DN VX-509
DM2U3MX HS Phase 2/3
DM2U3MX SN Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK
DM2U3MX CP Vertex Pharmaceuticals
DM2U3MX DT Small molecular drug
DM2U3MX PC 59422203
DM2U3MX MW 392.4
DM2U3MX FM C18H19F3N6O
DM2U3MX IC InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
DM2U3MX CS CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3
DM2U3MX IK ASUGUQWIHMTFJL-QGZVFWFLSA-N
DM2U3MX IU (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
DM2U3MX CA CAS 944842-54-0
DM2U3MX DE Rheumatoid arthritis
DMHXJ68 ID DMHXJ68
DMHXJ68 DN WVE-210201
DMHXJ68 HS Phase 2/3
DMHXJ68 CP WaVe Life Sciences Cambridge, MA
DMHXJ68 DE Duchenne dystrophy
DM78DOT ID DM78DOT
DM78DOT DN AllerB
DM78DOT HS Phase 2b
DM78DOT CP Anergis SA
DM78DOT DE Allergy
DMJM9LZ ID DMJM9LZ
DMJM9LZ DN LB80380
DMJM9LZ HS Phase 2b
DMJM9LZ SN LB80380; UNII-S9I9P4J8IU; LB 80380; S9I9P4J8IU; LB-80380; 441785-26-8; PMCDG dipivoxil; AC1O59EP; SCHEMBL4270816; CHEMBL1652128; ANA-380; DTXSID90196062; J3.616.617G; [[1-[(2-aminopurin-9-yl)methyl]cyclopropoxy]methyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate; [({[(2-Aminopurin-9-yl)methyl]cyclopropoxy}methyl)[(2,2-dimethylpropanoyloxy)methoxy]carbonyloxy]methyl 2,2-dimethylpropanoate; 872968-04-2
DMJM9LZ CP LG Life Sciences
DMJM9LZ DT Small molecular drug
DMJM9LZ PC 6480442
DMJM9LZ MW 527.5
DMJM9LZ FM C22H34N5O8P
DMJM9LZ IC InChI=1S/C22H34N5O8P/c1-20(2,3)17(28)31-12-34-36(30,35-13-32-18(29)21(4,5)6)14-33-22(7-8-22)10-27-11-25-15-9-24-19(23)26-16(15)27/h9,11H,7-8,10,12-14H2,1-6H3,(H2,23,24,26)
DMJM9LZ CS CC(C)(C)C(=O)OCOP(=O)(COC1(CC1)CN2C=NC3=CN=C(N=C32)N)OCOC(=O)C(C)(C)C
DMJM9LZ IK JLKJXDOWBVVABZ-UHFFFAOYSA-N
DMJM9LZ IU [[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DMJM9LZ CA CAS 441785-26-8
DMJM9LZ DE Hepatitis B virus infection
DMXB4NL ID DMXB4NL
DMXB4NL DN MEDI4893
DMXB4NL HS Phase 2b
DMXB4NL CP AstraZeneca
DMXB4NL DT Antibody
DMXB4NL DE Hospital-acquired pneumonia; Ventilator-associated pneumonia
DMEARCM ID DMEARCM
DMEARCM DN OrM3
DMEARCM HS Phase 2b
DMEARCM CP Merck Research Laboratories
DMEARCM DE Chronic obstructive pulmonary disease
DMOE582 ID DMOE582
DMOE582 DN TZP-101
DMOE582 HS Phase 2b
DMOE582 SN Ulimorelin; TZP-101; TZP 101; UNII-LGI67MCW2S; 842131-33-3; LGI67MCW2S; CHEMBL1923502; Ulimorelin [USAN:INN]; Ulimorelin (USAN/INN); SCHEMBL804500; TZP101; GTPL3535; CHEMBL1963249; DTXSID00233139; BDBM50359256; DB12128; D09981; (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione; D-Phenylalanine, (2S)-N-((2R)-2-(2-(3-aminopropyl)phenoxy)propyl)-2- cyclopropylglycyl-N-methyl-D-alanyl-4-fluoro-, (3-1)-lactam
DMOE582 CP Tranzyme
DMOE582 DT Small molecular drug
DMOE582 PC 11526696
DMOE582 MW 538.7
DMOE582 FM C30H39FN4O4
DMOE582 IC InChI=1S/C30H39FN4O4/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36)/t19-,20-,25-,27+/m1/s1
DMOE582 CS C[C@@H]1CN[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4
DMOE582 IK WGYPAJVJMXQXTR-ABNZCKJZSA-N
DMOE582 IU (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione
DMOE582 CA CAS 842131-33-3
DMOE582 DE Gastrointestinal disease; Gastroparesis; Ileus
DMUB8WN ID DMUB8WN
DMUB8WN DN Aerovant
DMUB8WN HS Phase 2a
DMUB8WN CP Aerovance
DMUB8WN DE Asthma
DMSC8YW ID DMSC8YW
DMSC8YW DN ANA773
DMSC8YW HS Phase 2a
DMSC8YW CP Anadys Pharmaceuticals
DMSC8YW DE Hepatitis C virus infection
DMJBDL0 ID DMJBDL0
DMJBDL0 DN BIIB104
DMJBDL0 HS Phase 2a
DMJBDL0 CP Biogen
DMJBDL0 DE Cognitive impairment
DM0TH9A ID DM0TH9A
DM0TH9A DN Bimosiamose
DM0TH9A HS Phase 2a
DM0TH9A SN TBC 1269; TBC-1269
DM0TH9A CP Encysive Pharma
DM0TH9A DT Small molecular drug
DM0TH9A PC 9811353
DM0TH9A MW 862.9
DM0TH9A FM C46H54O16
DM0TH9A IC InChI=1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(60-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-30)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1
DM0TH9A CS C1=CC(=CC(=C1)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC=CC(=C5)CC(=O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)CC(=O)O
DM0TH9A IK RYWCQJDEHXJHRI-XJMXIVSISA-N
DM0TH9A IU 2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid
DM0TH9A CA CAS 187269-40-5
DM0TH9A DE Atopic dermatitis; Psoriatic disorder; Chronic obstructive pulmonary disease; Asthma
DMR6LXM ID DMR6LXM
DMR6LXM DN CAP-232
DMR6LXM HS Phase 2a
DMR6LXM SN TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01
DMR6LXM TC Anticancer Agents
DMR6LXM DT Small molecular drug
DMR6LXM PC 6918265
DMR6LXM MW 947.1
DMR6LXM FM C45H58N10O9S2
DMR6LXM IC InChI=1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1
DMR6LXM CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)O
DMR6LXM IK SNAJPQVDGYDQSW-DYCFWDQMSA-N
DMR6LXM IU (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMR6LXM CA CAS 147159-51-1
DMR6LXM DE Pain; Renal cell carcinoma
DMLQ3PO ID DMLQ3PO
DMLQ3PO DN INCB13739
DMLQ3PO HS Phase 2a
DMLQ3PO SN Phenylarsine oxide; phenylarsine oxide; Oxophenylarsine; 637-03-6; Arzene; Phenylarsenoxide; Arsenosobenzene; ARSINE, OXOPHENYL-; Phenyl arsine oxide; Benzene, arsenoso-; arsorosobenzene; Fenylarsinoxid; Caswell No 060; Fenylarsinoxid [Czech]; C6H5AsO; Phenyl arsenoxide; UNII-0HUR2WY345; PAO; EINECS 211-275-3; NSC 42470; EPA Pesticide Chemical Code 007101; BRN 2935227; 0HUR2WY345; CHEBI:75253; MFCD00001990; Phenylarsine oxide, 97%; Phenylarsine Oxide Solution; oxo(phenyl)arsan; Phenylarsinoxyd; oxo(phenyl)arsine; oxo(phenyl)arsane; PhAsO; phenylarsenious
DMLQ3PO CP Incyte
DMLQ3PO DT Small molecular drug
DMLQ3PO PC 11502183
DMLQ3PO MW 398.9
DMLQ3PO FM C19H27ClN2O3S
DMLQ3PO IC InChI=1S/C19H27ClN2O3S/c1-14-17(20)10-5-11-18(14)26(24,25)22-12-6-7-15(13-22)19(23)21-16-8-3-2-4-9-16/h5,10-11,15-16H,2-4,6-9,12-13H2,1H3,(H,21,23)
DMLQ3PO CS CC1=C(C=CC=C1Cl)S(=O)(=O)N2CCCC(C2)C(=O)NC3CCCCC3
DMLQ3PO IK ODRPEKCTTLECBX-UHFFFAOYSA-N
DMLQ3PO IU 1-(3-chloro-2-methylphenyl)sulfonyl-N-cyclohexylpiperidine-3-carboxamide
DMLQ3PO DE Diabetic complication; Type-2 diabetes
DMMWC6F ID DMMWC6F
DMMWC6F DN INCB9471
DMMWC6F HS Phase 2a
DMMWC6F SN INCB-9471; UNII-C5D4W25708; INCB9471; CHEMBL1688243; INCB009471; C5D4W25708; INCB-009471; INCB 9471; INCB0 09471; 869769-98-2; SCHEMBL3676335; ZINC43171152; BDBM50339033; DB12960; 925701-76-4; Piperidine, 1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-((3S)-4-((1R,2R)-2-ethoxy-2,3-dihydro-5-(trifluoromethyl)-1H-inden-1-yl)-3-methyl-1-piperazinyl)-4-methyl-; 5-((4-(4-(2-Ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine
DMMWC6F CP Incyte
DMMWC6F DT Small molecular drug
DMMWC6F PC 49871007
DMMWC6F MW 559.7
DMMWC6F FM C30H40F3N5O2
DMMWC6F IC InChI=1S/C30H40F3N5O2/c1-6-40-25-16-22-15-23(30(31,32)33)7-8-24(22)27(25)38-14-13-37(17-19(38)2)29(5)9-11-36(12-10-29)28(39)26-20(3)34-18-35-21(26)4/h7-8,15,18-19,25,27H,6,9-14,16-17H2,1-5H3/t19-,25+,27+/m0/s1
DMMWC6F CS CCO[C@@H]1CC2=C([C@H]1N3CCN(C[C@@H]3C)C4(CCN(CC4)C(=O)C5=C(N=CN=C5C)C)C)C=CC(=C2)C(F)(F)F
DMMWC6F IK ZMCJFJZOSKEMOM-DNKZPPIMSA-N
DMMWC6F IU (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R,2R)-2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
DMMWC6F CA CAS 869769-98-2
DMMWC6F DE Human immunodeficiency virus infection; Infectious disease
DMYZU6G ID DMYZU6G
DMYZU6G DN MEM-1003
DMYZU6G HS Phase 2a
DMYZU6G SN SCHEMBL1191960; SCHEMBL16332975
DMYZU6G CP Bayer
DMYZU6G DT Small molecular drug
DMYZU6G PC 9802887
DMYZU6G MW 432.9
DMYZU6G FM C22H25ClN2O5
DMYZU6G IC InChI=1S/C22H25ClN2O5/c1-12(2)30-22(27)18-14(4)25-13(3)17(21(26)29-10-9-28-5)19(18)16-8-6-7-15(11-24)20(16)23/h6-8,12,19,25H,9-10H2,1-5H3
DMYZU6G CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC(=C2Cl)C#N)C(=O)OCCOC
DMYZU6G IK GTIKSQYSAKETQA-UHFFFAOYSA-N
DMYZU6G IU 3-O-(2-methoxyethyl) 5-O-propan-2-yl 4-(2-chloro-3-cyanophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMYZU6G DE Dementia; Bipolar disorder
DMGM1IR ID DMGM1IR
DMGM1IR DN RhuDex
DMGM1IR HS Phase 2a
DMGM1IR CP MediGene AG
DMGM1IR DE Rheumatoid arthritis
DMKJDR6 ID DMKJDR6
DMKJDR6 DN VX-702
DMKJDR6 HS Phase 2a
DMKJDR6 SN ST51054128; I14-1965; EC-000.2363; 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide
DMKJDR6 CP Vertex Pharma
DMKJDR6 DT Small molecular drug
DMKJDR6 PC 10341154
DMKJDR6 MW 404.3
DMKJDR6 FM C19H12F4N4O2
DMKJDR6 IC InChI=1S/C19H12F4N4O2/c20-9-4-5-10(14(23)8-9)16-11(18(24)28)6-7-15(26-16)27(19(25)29)17-12(21)2-1-3-13(17)22/h1-8H,(H2,24,28)(H2,25,29)
DMKJDR6 CS C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F
DMKJDR6 IK FYSRKRZDBHOFAY-UHFFFAOYSA-N
DMKJDR6 IU 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide
DMKJDR6 CA CAS 745833-23-2
DMKJDR6 CB CHEBI:94489
DMKJDR6 DE Coronary artery disease; Rheumatoid arthritis; Inflammation
DMAV426 ID DMAV426
DMAV426 DN (S)-oxybutynin
DMAV426 HS Phase 2
DMAV426 CP Sepracor
DMAV426 PC 206530
DMAV426 MW 357.5
DMAV426 FM C22H31NO3
DMAV426 IC InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1
DMAV426 CS CCN(CC)CC#CCOC(=O)[C@](C1CCCCC1)(C2=CC=CC=C2)O
DMAV426 IK XIQVNETUBQGFHX-JOCHJYFZSA-N
DMAV426 IU 4-(diethylamino)but-2-ynyl (2S)-2-cyclohexyl-2-hydroxy-2-phenylacetate
DMAV426 CA CAS 119618-22-3
DMAV426 CB CHEBI:51329
DMAV426 DE Urinary incontinence
DMGDOS2 ID DMGDOS2
DMGDOS2 DN (Z)-endoxifen
DMGDOS2 HS Phase 2
DMGDOS2 SN Endoxifen; Z-Endoxifen; 4-Hydroxy-N-desmethyltamoxifen; (E/Z)-Endoxifen; Endoxifen Z-Isomer; UNII-46AF8680RC; N-Desmethyl-4-hydroxytamoxifen; 110025-28-0; 4-Hydroxy-N-desmethyl-tamoxifen; CHEBI:80555; 46AF8680RC; 4OHNDtam; W-200834; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer); 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer; (Z)-Endoxifen; Endoxifen(E/Z=1:1); 4-hydroxy-N-desmethyl tamoxifen; SCHEMBL10107920; CHEMBL1093458; GTPL10203; EX-A645
DMGDOS2 PC 10090750
DMGDOS2 MW 373.5
DMGDOS2 FM C25H27NO2
DMGDOS2 IC InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
DMGDOS2 CS CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCNC)C3=CC=CC=C3
DMGDOS2 IK MHJBZVSGOZTKRH-IZHYLOQSSA-N
DMGDOS2 IU 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMGDOS2 CA CAS 112093-28-4
DMGDOS2 CB CHEBI:80555
DMGDOS2 DE Breast cancer
DMV86DY ID DMV86DY
DMV86DY DN [131I]-BC8
DMV86DY HS Phase 2
DMV86DY DT Antibody
DMV86DY DE leukaemia
DM4VWXI ID DM4VWXI
DM4VWXI DN [131I]-Metuximab
DM4VWXI HS Phase 2
DM4VWXI CP Elsevier
DM4VWXI DT Antibody
DM4VWXI DE Liver cancer
DMSLMY7 ID DMSLMY7
DMSLMY7 DN 11C-PBR-28
DMSLMY7 HS Phase 2
DMSLMY7 SN Radiolabeled benzodiazepine receptor ligands, NIH; Carbon-11-PBR-101; Carbon-11-PBR-28; Fluorine-18-PBR-06; 11C-PBR-01; 18F-PBR-06
DMSLMY7 CP National Institutes of Health
DMSLMY7 PC 11653141
DMSLMY7 MW 347.4
DMSLMY7 FM C21H20N2O3
DMSLMY7 IC InChI=1S/C21H20N2O3/c1-16(24)23(15-17-8-6-7-11-20(17)25-2)19-14-22-13-12-21(19)26-18-9-4-3-5-10-18/h3-14H,15H2,1-2H3/i2-1
DMSLMY7 CS CC(=O)N(CC1=CC=CC=C1O[11CH3])C2=C(C=CN=C2)OC3=CC=CC=C3
DMSLMY7 IK DHZBNHMEIOBPAE-JVVVGQRLSA-N
DMSLMY7 IU N-[(2-(111C)methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide
DMSLMY7 CA CAS 1005325-43-8
DMSLMY7 DE Brain disease
DMTIED1 ID DMTIED1
DMTIED1 DN 131I-TM-601
DMTIED1 HS Phase 2
DMTIED1 SN Glioma therapy, Transmolecular; Solid tumor imaging, TransMolecular; TM-602; TM-603; TM-803; Toxin-based anticancers, Transmolecular; Iodine-131-TM-601
DMTIED1 CP TransMolecular Inc
DMTIED1 DE Glioma
DM4EP6Y ID DM4EP6Y
DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y HS Phase 2
DM4EP6Y SN GPX-100; (8R,10S)-10-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-1-methoxynaphthacene-5,12-dione hydrochloride; 13-Deoxydoxorubicin hydrochloride
DM4EP6Y CP Access Pharmaceuticals
DM4EP6Y PC 9829418
DM4EP6Y MW 566
DM4EP6Y FM C27H32ClNO10
DM4EP6Y IC InChI=1S/C27H31NO10.ClH/c1-11-22(30)14(28)8-17(37-11)38-16-10-27(35,6-7-29)9-13-19(16)26(34)21-20(24(13)32)23(31)12-4-3-5-15(36-2)18(12)25(21)33;/h3-5,11,14,16-17,22,29-30,32,34-35H,6-10,28H2,1-2H3;1H/t11-,14-,16-,17-,22+,27-;/m0./s1
DM4EP6Y CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(CCO)O)N)O.Cl
DM4EP6Y IK YZSQITAPLDJGKS-RYQLBYGJSA-N
DM4EP6Y IU (7S,9R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
DM4EP6Y CA CAS 65360-29-4
DM4EP6Y DE Solid tumour/cancer
DMNF38S ID DMNF38S
DMNF38S DN 16,16-dimethyl-PGE2
DMNF38S HS Phase 2
DMNF38S SN 16,16-dimethylprostaglandin E2
DMNF38S DT Small molecular drug
DMNF38S PC 5283066
DMNF38S MW 380.5
DMNF38S FM C22H36O5
DMNF38S IC InChI=1S/C22H36O5/c1-4-5-14-22(2,3)20(25)13-12-17-16(18(23)15-19(17)24)10-8-6-7-9-11-21(26)27/h6,8,12-13,16-17,19-20,24-25H,4-5,7,9-11,14-15H2,1-3H3,(H,26,27)/b8-6-,13-12+/t16-,17-,19-,20-/m1/s1
DMNF38S CS CCCCC(C)(C)[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O
DMNF38S IK QAOBBBBDJSWHMU-WMBBNPMCSA-N
DMNF38S IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMNF38S CA CAS 39746-25-3
DMNF38S CB CHEBI:141046
DMNF38S DE Stem cell engraftment
DMT8GVU ID DMT8GVU
DMT8GVU DN 177Lu-DOTATATE
DMT8GVU HS Phase 2
DMT8GVU CP Advanced accelerator applications
DMT8GVU PC 76966897
DMT8GVU MW 1609.5
DMT8GVU FM C65H87LuN14O19S2
DMT8GVU IC InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2
DMT8GVU CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O.[177Lu+3]
DMT8GVU IK MXDPZUIOZWKRAA-PRDSJKGBSA-K
DMT8GVU IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+)
DMT8GVU CA CAS 437608-50-9
DMT8GVU DE Hepatitis C virus infection
DM2TSMD ID DM2TSMD
DM2TSMD DN 177Lu-labelled NeoBOMB1
DM2TSMD HS Phase 2
DM2TSMD CP Novartis/AAA
DM2TSMD DT Radiopharmaceutical therapy agent
DM2TSMD DE Solid tumour/cancer
DM8JVIB ID DM8JVIB
DM8JVIB DN 18F-LMI-1195
DM8JVIB HS Phase 2
DM8JVIB SN Flourine-18-LMI-1195; Fluorine-18-based PET imaging agent (intravenous, heart failure), Lantheus; 18F-based PET imaging agent (intravenous, heart failure), Lantheus
DM8JVIB CP Lantheus medical imaging
DM8JVIB DE Heart failure
DMZWNQF ID DMZWNQF
DMZWNQF DN 2'3'-Dideoxyinosine
DMZWNQF HS Phase 2
DMZWNQF DT Small molecular drug
DMZWNQF PC 16219192
DMBOL4K ID DMBOL4K
DMBOL4K DN 264W94
DMBOL4K HS Phase 2
DMBOL4K SN GW-264
DMBOL4K CP Glaxo Wellcome plc
DMBOL4K DT Small molecular drug
DMBOL4K PC 9823277
DMBOL4K MW 417.6
DMBOL4K FM C23H31NO4S
DMBOL4K IC InChI=1S/C23H31NO4S/c1-5-7-13-23(6-2)16-29(25,26)21-15-20(28-4)19(27-3)14-18(21)22(24-23)17-11-9-8-10-12-17/h8-12,14-15,22,24H,5-7,13,16H2,1-4H3/t22-,23-/m1/s1
DMBOL4K CS CCCC[C@@]1(CS(=O)(=O)C2=CC(=C(C=C2[C@H](N1)C3=CC=CC=C3)OC)OC)CC
DMBOL4K IK CKFWDLFFXXVSBJ-DHIUTWEWSA-N
DMBOL4K IU (3R,5R)-3-butyl-3-ethyl-7,8-dimethoxy-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepine 1,1-dioxide
DMBOL4K CA CAS 178259-25-1
DMBOL4K DE Hyperlipidaemia
DMGBPME ID DMGBPME
DMGBPME DN 2-Methoxyestradiol
DMGBPME HS Phase 2
DMGBPME SN ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
DMGBPME CP EntreMed
DMGBPME DT Small molecular drug
DMGBPME PC 66414
DMGBPME MW 302.4
DMGBPME FM C19H26O3
DMGBPME IC InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
DMGBPME CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O
DMGBPME IK CQOQDQWUFQDJMK-SSTWWWIQSA-N
DMGBPME IU (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMGBPME CA CAS 362-07-2
DMGBPME CB CHEBI:28955
DMGBPME DE Pulmonary arterial hypertension
DMX9MSL ID DMX9MSL
DMX9MSL DN 2X-121
DMX9MSL HS Phase 2
DMX9MSL CP 2X Oncology Cambridge, MA
DMX9MSL DE Breast cancer
DML8M5T ID DML8M5T
DML8M5T DN 3,5-diiodothyropropionic acid
DML8M5T HS Phase 2
DML8M5T SN DITPA)
DML8M5T CP Titan Pharmaceuticals
DML8M5T DT Small molecular drug
DML8M5T PC 160565
DML8M5T MW 510.06
DML8M5T FM C15H12I2O4
DML8M5T IC InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)
DML8M5T CS C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CCC(=O)O)I
DML8M5T IK WONYMNWUJVKVII-UHFFFAOYSA-N
DML8M5T IU 3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
DML8M5T CA CAS 1158-10-7
DML8M5T CB CHEBI:134267
DML8M5T DE Cardiovascular disease; Congestive heart failure
DMTLR6Y ID DMTLR6Y
DMTLR6Y DN 3K3A-APC
DMTLR6Y HS Phase 2
DMTLR6Y CP Zz biotech
DMTLR6Y DE Cerebrovascular ischaemia; Ischemic stroke
DMPFVJB ID DMPFVJB
DMPFVJB DN 5-hydroxymethyl-2-furfural
DMPFVJB HS Phase 2
DMPFVJB SN Aes-103; 5-HMF; 5-hydroxymethylfurfural
DMPFVJB CP Aesrx
DMPFVJB DT Small molecular drug
DMPFVJB PC 237332
DMPFVJB MW 126.11
DMPFVJB FM C6H6O3
DMPFVJB IC InChI=1S/C6H6O3/c7-3-5-1-2-6(4-8)9-5/h1-3,8H,4H2
DMPFVJB CS C1=C(OC(=C1)C=O)CO
DMPFVJB IK NOEGNKMFWQHSLB-UHFFFAOYSA-N
DMPFVJB IU 5-(hydroxymethyl)furan-2-carbaldehyde
DMPFVJB CA 67-47-0
DMPFVJB DE Anemia
DMHBN8X ID DMHBN8X
DMHBN8X DN 60P002
DMHBN8X HS Phase 2
DMHBN8X CP 60 Degrees Pharmaceuticals
DMHBN8X DT Small molecular drug
DMHBN8X DE Dengue
DMOV0AP ID DMOV0AP
DMOV0AP DN 842166X
DMOV0AP HS Phase 2
DMOV0AP SN GW842166X; 666260-75-9; GW 842166X; GW-842166X; UNII-VL1I6P2DZ8; VL1I6P2DZ8; GW842166; GW 842166; CHEMBL225411; 2-((2,4-dichlorophenyl)amino)-N-((tetrahydro-2H-pyran-4-yl)methyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide; TWQYWUXBZHPIIV-UHFFFAOYSA-N; 842166X; MLS006010287; C18H17Cl2F3N4O2; SCHEMBL3015040; DTXSID60216786; MolPort-009-019-316; HMS3656P06; BCP05306; ZINC3947932; BDBM50211843; s2778; 2455AH; AKOS032945128; DB11903; BCP9000755; CS-7768; SB19546; API0013938; GW-842,166X; NCGC00346697-05; NCGC00346697-01; KB-77649; HY-14167
DMOV0AP DT Small molecular drug
DMOV0AP PC 10253143
DMOV0AP MW 449.3
DMOV0AP FM C18H17Cl2F3N4O2
DMOV0AP IC InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27)
DMOV0AP CS C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl
DMOV0AP IK TWQYWUXBZHPIIV-UHFFFAOYSA-N
DMOV0AP IU 2-(2,4-dichloroanilino)-N-(oxan-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide
DMOV0AP CA CAS 666260-75-9
DMOV0AP DE Pain
DML4GU1 ID DML4GU1
DML4GU1 DN 99mTc-MIP-1404
DML4GU1 HS Phase 2
DML4GU1 CP Molecular Insight Pharmaceuticals Inc
DML4GU1 DT ?
DML4GU1 PC 71300957
DML4GU1 MW 1176.3
DML4GU1 FM C40H53ClN10O23Tc
DML4GU1 IC InChI=1S/C37H50N10O20.3CHO.ClH.Tc/c48-26(6-4-22(35(63)64)41-37(67)42-23(36(65)66)5-7-29(51)52)40-21(34(61)62)3-1-2-10-43(13-24-38-8-11-44(24)15-27(49)46(17-30(53)54)18-31(55)56)14-25-39-9-12-45(25)16-28(50)47(19-32(57)58)20-33(59)60;3*1-2;;/h8-9,11-12,21-23H,1-7,10,13-20H2,(H,40,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,41,42,67);3*1H;1H;/q;3*-1;;+4/p-1/t21-,22-,23-;;;;;/m0...../s1/i;;;;;1+1
DML4GU1 CS [CH-]=O.[CH-]=O.[CH-]=O.C1=CN(C(=N1)CN(CCCC[C@@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CC2=NC=CN2CC(=O)N(CC(=O)O)CC(=O)O)CC(=O)N(CC(=O)O)CC(=O)O.[Cl-].[99Tc+4]
DML4GU1 IK XOJYSFPEJAILJZ-LCERUKBVSA-M
DML4GU1 IU (2S)-2-[[(1S)-4-[[(1S)-5-[bis[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]-1-carboxypentyl]amino]-1-carboxy-4-oxobutyl]carbamoylamino]pentanedioic acid;methanone;technetium-99(4+);chloride
DML4GU1 CA CAS 1333117-95-5
DML4GU1 DE Prostate cancer
DMX2LO3 ID DMX2LO3
DMX2LO3 DN 99mTc-RP-128
DMX2LO3 HS Phase 2
DMX2LO3 SN (SP-5-25)-Hydrogen [N,N-dimethylglycyl-kappaN-L-seryl-kappaN-L-cysteinyl-kappaN,kappaS-glycyl-L-threonyl-L-lysyl-L-prolyl-L-prolyl-L-argininato(4-)]oxotechnetate(1-)-99Tc; 186037-48-9
DMX2LO3 DE Diagnostic imaging
DMQXYRG ID DMQXYRG
DMQXYRG DN 9-AMINOCAMPTOTHECIN
DMQXYRG HS Phase 2
DMQXYRG SN IDEC-132; (S)-10-Amino-4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione; 9-Amino-20(S)-camptothecin
DMQXYRG DT Small molecular drug
DMQXYRG PC 72402
DMQXYRG MW 363.4
DMQXYRG FM C20H17N3O4
DMQXYRG IC InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
DMQXYRG CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O
DMQXYRG IK FUXVKZWTXQUGMW-FQEVSTJZSA-N
DMQXYRG IU (19S)-8-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMQXYRG CA CAS 91421-43-1
DMQXYRG CB CHEBI:80755
DMQXYRG DE Acquired immune deficiency syndrome
DM57TY3 ID DM57TY3
DM57TY3 DN 9-ING-41
DM57TY3 HS Phase 2
DM57TY3 SN 1034895-42-5; ND1SOF0DLU; UNII-ND1SOF0DLU; CHEMBL483465; 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione; elraglusib; SCHEMBL3152351; GTPL11412; EX-A4074; BDBM50267716; s9602; SB19735; compound 26 [PMID: 19338355]; HY-113914; CS-0063319; 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)-; 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione; 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione; 4-(5-methyl-5H-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 h-pyrrole-2,5-dione
DM57TY3 CP Actuate Therapeutics
DM57TY3 DT Small molecular drug
DM57TY3 PC 44582816
DM57TY3 MW 404.3
DM57TY3 FM C22H13FN2O5
DM57TY3 IC InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
DM57TY3 CS CN1C=C(C2=CC3=C(C=C21)OCO3)C4=C(C(=O)NC4=O)C5=COC6=C5C=C(C=C6)F
DM57TY3 IK FARXPFGGGGLENU-UHFFFAOYSA-N
DM57TY3 IU 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
DM57TY3 CA CAS 1034895-42-5
DM57TY3 DE Solid tumour/cancer; Myelofibrosis
DM6ZIES ID DM6ZIES
DM6ZIES DN A-6
DM6ZIES HS Phase 2
DM6ZIES SN Angstrom-6; CD44 binding peptide (cancer), Angstrom
DM6ZIES CP Angstrom pharmaceuticals
DM6ZIES DE Macular degeneration
DMHOLB7 ID DMHOLB7
DMHOLB7 DN A-85380
DMHOLB7 HS Phase 2
DMHOLB7 SN A-85380; A 85380; 161416-98-4; CHEMBL59986; (S)-3-(AZETIDIN-2-YLMETHOXY)PYRIDINE; AC1NSJQT; Pyridine, 3-[(2S)-2-azetidinylmethoxy]-; SCHEMBL676026; A-159470; GTPL5460; ZINC3805142; 3-(2(s)-azetidinylmethoxy)pyridine; BDBM50049750; AKOS030230435; NCGC00387223-01; 3-[(2S)-azetidin-2-ylmethoxy]pyridine; 3-[[(2S)-azetidin-2-yl]methoxy]pyridine; 3-((S)-1-Azetidin-2-ylmethoxy)-pyridine; Pyridine, 3-(2-azetidinylmethoxy)-, (S)-
DMHOLB7 DT Small molecular drug
DMHOLB7 PC 5310969
DMHOLB7 MW 164.2
DMHOLB7 FM C9H12N2O
DMHOLB7 IC InChI=1S/C9H12N2O/c1-2-9(6-10-4-1)12-7-8-3-5-11-8/h1-2,4,6,8,11H,3,5,7H2/t8-/m0/s1
DMHOLB7 CS C1CN[C@@H]1COC2=CN=CC=C2
DMHOLB7 IK XKFMBGWHHBCWCD-QMMMGPOBSA-N
DMHOLB7 IU 3-[[(2S)-azetidin-2-yl]methoxy]pyridine
DMHOLB7 CA CAS 161416-98-4
DMOGDCQ ID DMOGDCQ
DMOGDCQ DN Ab-01
DMOGDCQ HS Phase 2
DMOGDCQ SN Ab-02; IL-21 receptor-targeted human monoclonal antibodies (inflammation); Anti-IL-21R mAb (inflammation), Pfizer; IL-21 receptor-targeted human monoclonal antibodies (inflammation), Pfizer
DMOGDCQ CP Pfizer Inc
DMOGDCQ DT Antibody
DMOGDCQ DE Inflammation
DMEW62S ID DMEW62S
DMEW62S DN AB-106
DMEW62S HS Phase 2
DMEW62S SN DS6051b; GTPL11198; AB106
DMEW62S CP AnHeart Therapeutics
DMEW62S DT Small molecular drug
DMEW62S PC 154699459
DMEW62S MW 405.5
DMEW62S FM C23H24FN5O
DMEW62S IC InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)
DMEW62S CS CC(COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)NC(C)C4=CC(=CC=C4)F)N
DMEW62S IK HEVHTYMYEMEBPX-UHFFFAOYSA-N
DMEW62S IU 3-[4-(2-aminopropoxy)phenyl]-N-[1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DMEW62S DE Non-small cell lung cancer
DM48DPS ID DM48DPS
DM48DPS DN AB-729
DM48DPS HS Phase 2
DM48DPS CP Arbutus Biopharma
DM48DPS DT Small interfering RNA
DM48DPS DE Hepatitis B virus infection
DM4ZLTY ID DM4ZLTY
DM4ZLTY DN ABBV-2222
DM4ZLTY HS Phase 2
DM4ZLTY SN QVDYQHXNAQHIKH-YMBRHYMPSA-N; ABBV 2222; 1918143-53-9; BCP25130
DM4ZLTY CP AbbVie
DM4ZLTY PC 121301049
DM4ZLTY MW 559.5
DM4ZLTY FM C28H21F4NO7
DM4ZLTY IC InChI=1S/C28H21F4NO7/c29-26(30)37-17-6-7-18-19(13-21(38-22(18)12-17)14-1-3-15(4-2-14)24(34)35)33-25(36)27(9-10-27)16-5-8-20-23(11-16)40-28(31,32)39-20/h1-8,11-12,19,21,26H,9-10,13H2,(H,33,36)(H,34,35)/t19-,21-/m1/s1
DM4ZLTY CS C1CC1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)N[C@@H]4C[C@@H](OC5=C4C=CC(=C5)OC(F)F)C6=CC=C(C=C6)C(=O)O
DM4ZLTY IK QVDYQHXNAQHIKH-TZIWHRDSSA-N
DM4ZLTY IU 4-[(2R,4R)-4-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid
DM4ZLTY CA CAS 1918143-53-9
DM4ZLTY DE Cystic fibrosis
DMT6H3J ID DMT6H3J
DMT6H3J DN AbGn-168
DMT6H3J HS Phase 2
DMT6H3J SN AbGn-168H; Antibody 168 (autoimmune diseases), Boehringer Ingelheim/AbGenomics; Anti-CD162 mAb (psoriasis), Boehringer/AbGenomics
DMT6H3J CP Abgenomics international
DMT6H3J DT Antibody
DMT6H3J DE Allergy
DMQ6KZM ID DMQ6KZM
DMQ6KZM DN ABI-009
DMQ6KZM HS Phase 2
DMQ6KZM CP Celgene
DMQ6KZM DE Solid tumour/cancer; Malignant perivascular epithelioid cell tumour; Non-muscle invasive bladder cancer; Pulmonary arterial hypertension
DM59OJ2 ID DM59OJ2
DM59OJ2 DN Abicipar pegol
DM59OJ2 HS Phase 2
DM59OJ2 CP Allergan Parsippany, NJ Molecular Partners Zurich, Switzerland
DM59OJ2 DE Diabetic macular edema
DMX1KDM ID DMX1KDM
DMX1KDM DN ABI-H0731
DMX1KDM HS Phase 2
DMX1KDM SN Vebicorvir; UNII-16F6055SMG; 16F6055SMG; 11-Oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide; 2090064-66-5; Vebicorvir [INN]; Vebicorvir [USAN]; SCHEMBL21250344; WHO 11201; Dibenzo(b,F)(1,4)thiazepine-8-carboxamide, 10,11-dihydro-11-oxo-N-((2-(trifluoromethyl)-5-thiazolyl)methyl)-, 5,5-dioxide
DMX1KDM CP Assembly Biosciences
DMX1KDM DT Small molecular drug
DMX1KDM PC 139394142
DMX1KDM MW 467.4
DMX1KDM FM C19H12F3N3O4S2
DMX1KDM IC InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27)
DMX1KDM CS C1=CC=C2C(=C1)C(=O)NC3=C(S2(=O)=O)C=CC(=C3)C(=O)NCC4=CN=C(S4)C(F)(F)F
DMX1KDM IK LBJVBJYMZKEREY-UHFFFAOYSA-N
DMX1KDM IU 6,11,11-trioxo-N-[[2-(trifluoromethyl)-1,3-thiazol-5-yl]methyl]-5H-benzo[b][1,4]benzothiazepine-3-carboxamide
DMX1KDM CA CAS 2090064-66-5
DMX1KDM DE Hepatitis B
DM6X70G ID DM6X70G
DM6X70G DN ABI-H2158
DM6X70G HS Phase 2
DM6X70G CP Assembly Biosciences
DM6X70G DT Small molecular drug
DM6X70G DE Hepatitis B
DMTCXSG ID DMTCXSG
DMTCXSG DN Abituzumab
DMTCXSG HS Phase 2
DMTCXSG CP Emd serono
DMTCXSG DT Antibody
DMTCXSG DE Colorectal cancer
DM23UQ9 ID DM23UQ9
DM23UQ9 DN ABT-122
DM23UQ9 HS Phase 2
DM23UQ9 CP AbbVie
DM23UQ9 DT Monoclonal antibody
DM23UQ9 DE Rheumatoid arthritis; Psoriatic arthritis
DM2OS51 ID DM2OS51
DM2OS51 DN ABT-126
DM2OS51 HS Phase 2
DM2OS51 CP Abbott Laboratories
DM2OS51 PC 24987875
DM2OS51 MW 313.4
DM2OS51 FM C17H19N3OS
DM2OS51 IC InChI=1S/C17H19N3OS/c1-2-4-12(5-3-1)16-18-19-17(22-16)21-15-13-6-11-7-14(15)10-20(8-11)9-13/h1-5,11,13-15H,6-10H2
DM2OS51 CS C1C2CC3CN(C2)CC1C3OC4=NN=C(S4)C5=CC=CC=C5
DM2OS51 IK QZDCYUCETTWCMO-UHFFFAOYSA-N
DM2OS51 IU 2-(1-azatricyclo[3.3.1.13,7]decan-4-yloxy)-5-phenyl-1,3,4-thiadiazole
DM2OS51 CA CAS 1026687-03-5
DM2OS51 DE Schizophrenia; Alzheimer disease
DMN3S1B ID DMN3S1B
DMN3S1B DN ABT-229
DMN3S1B HS Phase 2
DMN3S1B SN Alemcinal; ABT-229; UNII-5DS173ODI4; 5DS173ODI4; ABBOTT-81229.0; 150785-53-8; A-81229; Alemcinal (USAN/INN); CHEMBL300049; ABT229; GTPL1444; BDBM86685; ABT 229; D02801; 8,9-didehydro-N-demethyl-9-deoxo-4', 6, 12-trideoxy-6,9-epoxy-N-ethylerythromycin
DMN3S1B DT Small molecular drug
DMN3S1B PC 9918079
DMN3S1B MW 697.9
DMN3S1B FM C38H67NO10
DMN3S1B IC InChI=1S/C38H67NO10/c1-14-28-23(6)30(40)24(7)32-20(3)17-38(11,49-32)34(48-36-31(41)27(39(12)15-2)16-21(4)45-36)25(8)33(26(9)35(42)46-28)47-29-19-37(10,43-13)18-22(5)44-29/h21-31,33-34,36,40-41H,14-19H2,1-13H3/t21-,22+,23+,24-,25+,26-,27+,28-,29+,30+,31-,33+,34-,36+,37+,38-/m1/s1
DMN3S1B CS CC[C@@H]1[C@@H]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@](C[C@@H](O3)C)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)CC)O)C)C)C)O)C
DMN3S1B IK IWTSXJNGTTXMFK-KTQUSEMZSA-N
DMN3S1B IU (2R,3S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-11-[(2S,3R,4S,6R)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3-hydroxy-9-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMN3S1B CA CAS 150785-53-8
DMN3S1B DE Pain
DM7X54F ID DM7X54F
DM7X54F DN ABT-288
DM7X54F HS Phase 2
DM7X54F SN ABT-288; UNII-5MEI1M3NHH; 5MEI1M3NHH; ABT 288; GNIRITULTPTAQWKNQAVFIVSAN; SCHEMBL2406947; ABT288; GTPL6927; GNIRITULTPTAQW-KNQAVFIVSA-N; 948845-91-8; J3.497.401B; 2-[4'-(3aR,6aR)-(5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl]pyridazin-3(2H)-one; 2-{4'-[(3aR,6aR)-5-Methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1-biphenyl-4-yl}pyridazin-3(2H)-one; 2-[4'-(3aR,6aR)-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)-1,1'-biphenyl-4-yl ]pyridazin-3(2H)-one; (3aR, 6aR)-2-[4'-(5-Methyl-hexahydro-pyrrolo[3,4
DM7X54F CP Abbott Laboratories
DM7X54F DT Small molecular drug
DM7X54F PC 24743471
DM7X54F MW 372.5
DM7X54F FM C23H24N4O
DM7X54F IC InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1
DM7X54F CS CN1C[C@H]2CCN([C@H]2C1)C3=CC=C(C=C3)C4=CC=C(C=C4)N5C(=O)C=CC=N5
DM7X54F IK GNIRITULTPTAQW-KNQAVFIVSA-N
DM7X54F IU 2-[4-[4-[(3aR,6aR)-5-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-1-yl]phenyl]phenyl]pyridazin-3-one
DM7X54F CA CAS 948845-91-8
DM7X54F DE Alzheimer disease
DM6WN2D ID DM6WN2D
DM6WN2D DN ABT-308
DM6WN2D HS Phase 2
DM6WN2D DE Asthma; Eosinophilic esophagitis
DMMZOYN ID DMMZOYN
DMMZOYN DN ABT-348
DMMZOYN HS Phase 2
DMMZOYN SN ILORASERTIB; ABT-348; 1227939-82-3; UNII-6L5D03D975; ABT 348; ABT348; 6L5D03D975; A-968660; Abbott-969660; Ilorasertib [USAN:INN]; Ilorasertib (USAN); Kinome_405; GTPL9914; A-968660.0; SCHEMBL3381224; CHEMBL1980297; DTXSID10153718; WPHKIQPVPYJNAX-UHFFFAOYSA-N; BCP07256; ZINC63298074; BDBM50381716; SB16853; CS-6804; DB11694; KB-74395; HY-16018; US8722890, 1; Z-3287; US8722890, 2; D10423; N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea
DMMZOYN CP Abbott Laboratories Abbott
DMMZOYN DT Small molecular drug
DMMZOYN PC 46207586
DMMZOYN MW 488.5
DMMZOYN FM C25H21FN6O2S
DMMZOYN IC InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)
DMMZOYN CS C1=CC(=CC(=C1)F)NC(=O)NC2=CC=C(C=C2)C3=CSC4=C3C(=NC=C4C5=CN(N=C5)CCO)N
DMMZOYN IK WPHKIQPVPYJNAX-UHFFFAOYSA-N
DMMZOYN IU 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea
DMMZOYN CA CAS 1227939-82-3
DMMZOYN DE Haematological malignancy
DM7XW5Y ID DM7XW5Y
DM7XW5Y DN ABT-384
DM7XW5Y HS Phase 2
DM7XW5Y SN ABT-384; UNII-R5TH77F919; CHEMBL222670; ABT 384; R5TH77F919; SCHEMBL231595; GTPL7357; ABT384; SCHEMBL20457214; BDBM50195291; DB12501; 868623-40-9; 4-{2-methyl-2-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-propionylamino}-adamantane-1-carboxylic acid amide
DM7XW5Y CP Abbott Laboratories
DM7XW5Y DT Small molecular drug
DM7XW5Y PC 11670435
DM7XW5Y MW 493.6
DM7XW5Y FM C25H34F3N5O2
DM7XW5Y IC InChI=1S/C25H34F3N5O2/c1-23(2,33-7-5-32(6-8-33)19-4-3-18(14-30-19)25(26,27)28)22(35)31-20-16-9-15-10-17(20)13-24(11-15,12-16)21(29)34/h3-4,14-17,20H,5-13H2,1-2H3,(H2,29,34)(H,31,35)
DM7XW5Y CS CC(C)(C(=O)NC1C2CC3CC1CC(C3)(C2)C(=O)N)N4CCN(CC4)C5=NC=C(C=C5)C(F)(F)F
DM7XW5Y IK CLHMYBJIOZXCEX-UHFFFAOYSA-N
DM7XW5Y IU 4-[[2-methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
DM7XW5Y CA CAS 868623-40-9
DM7XW5Y DE Alzheimer disease; Hepatitis C virus infection
DMGUTPN ID DMGUTPN
DMGUTPN DN ABT-414
DMGUTPN HS Phase 2
DMGUTPN CP Abbvie
DMGUTPN DT Antibody
DMGUTPN DE Glioblastoma multiforme; Brain cancer; Recurrent glioblastoma
DMNAU1V ID DMNAU1V
DMNAU1V DN ABT-436
DMNAU1V HS Phase 2
DMNAU1V CP Abbott Laboratories
DMNAU1V DE Anxiety disorder
DMFW860 ID DMFW860
DMFW860 DN ABT-450
DMFW860 HS Phase 2
DMFW860 CP Abbott; Enanta
DMFW860 PC 45110509
DMFW860 MW 765.9
DMFW860 FM C40H43N7O7S
DMFW860 IC InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
DMFW860 CS CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
DMFW860 IK UAUIUKWPKRJZJV-QPLHLKROSA-N
DMFW860 IU (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DMFW860 CA CAS 1216941-48-8
DMFW860 DE Hepatitis C virus infection
DMPDVM8 ID DMPDVM8
DMPDVM8 DN ABT-510
DMPDVM8 HS Phase 2
DMPDVM8 SN N-Acetyl-N-methyl-glycyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-argininyl-L-proline N-ethylamide
DMPDVM8 CP Abbott Laboratories
DMPDVM8 DT Small molecular drug
DMPDVM8 PC 6918562
DMPDVM8 MW 994.2
DMPDVM8 FM C46H83N13O11
DMPDVM8 IC InChI=1S/C46H83N13O11/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-/m0/s1
DMPDVM8 CS CCC[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN(C)C(=O)C
DMPDVM8 IK RIWLPSIAFBLILR-WVNGMBSFSA-N
DMPDVM8 IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R,3S)-2-[[(2S)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide
DMPDVM8 CA CAS 251579-55-2
DMPDVM8 DE Solid tumour/cancer
DMEWQ4X ID DMEWQ4X
DMEWQ4X DN ABT-639
DMEWQ4X HS Phase 2
DMEWQ4X SN ABT-639; 1235560-28-7; ABT 639; UNII-0G7D0CQ88I; ABT639; 0G7D0CQ88I; CHEMBL3589557; ABT-639 free base; SCHEMBL400073; GTPL7721; CHEMBL3590674; AGPIHNZOZNKRGT-CYBMUJFWSA-N; MolPort-046-033-584; EX-A1021; BCP17732; BDBM50095309; ZINC113741875; AKOS030526344; SB19105; CS-5515; HY-19721; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide; 4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylcarbonyl]benzenesulfonamide
DMEWQ4X DT Small molecular drug
DMEWQ4X PC 46851313
DMEWQ4X MW 455.9
DMEWQ4X FM C20H20ClF2N3O3S
DMEWQ4X IC InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1
DMEWQ4X CS C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F
DMEWQ4X IK AGPIHNZOZNKRGT-CYBMUJFWSA-N
DMEWQ4X IU 5-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-N-(2-fluorophenyl)benzenesulfonamide
DMEWQ4X CA CAS 1235560-28-7
DMEWQ4X DE Pain
DMLEO2Z ID DMLEO2Z
DMLEO2Z DN ABT-652
DMLEO2Z HS Phase 2
DMLEO2Z CP Abbott Laboratories
DMLEO2Z DE Musculoskeletal pain; Diabetic neuropathy
DMNG35S ID DMNG35S
DMNG35S DN ABT-751
DMNG35S HS Phase 2
DMNG35S SN ABT-751; 141430-65-1; ABT 751; E-7010; ABT751; ABT-751 (E7010); UNII-WDT5V5OB9F; E 7010; WDT5V5OB9F; N-[2-[(4-HYDROXYPHENYL)AMINO]-3-PYRIDYL]-4-METHOXYBENZENESULFONAMIDE; CHEMBL20684; N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide; N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide; Benzenesulfonamide,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy-; N-(2-(4-hydroxyphenylamino)pyridin-3-yl)-4-methoxybenzenesulfonamide
DMNG35S DT Small molecular drug
DMNG35S PC 3035714
DMNG35S MW 371.4
DMNG35S FM C18H17N3O4S
DMNG35S IC InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)
DMNG35S CS COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O
DMNG35S IK URCVCIZFVQDVPM-UHFFFAOYSA-N
DMNG35S IU N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide
DMNG35S CA CAS 141430-65-1
DMNG35S CB CHEBI:95043
DMNG35S DE Solid tumour/cancer
DM6PTIX ID DM6PTIX
DM6PTIX DN ABT-981
DM6PTIX HS Phase 2
DM6PTIX CP AbbVie
DM6PTIX DT Monoclonal antibody
DM6PTIX DE Osteoarthritis
DM9Y1XB ID DM9Y1XB
DM9Y1XB DN ABT-RTA-408
DM9Y1XB HS Phase 2
DM9Y1XB CP Abbvie; reata pharmaceuticals
DM9Y1XB DE Non-small-cell lung cancer
DM91U0R ID DM91U0R
DM91U0R DN ABX-EGF
DM91U0R HS Phase 2
DM91U0R DT Antibody
DMCZFMS ID DMCZFMS
DMCZFMS DN ABX-IL8
DMCZFMS HS Phase 2
DMCZFMS DT Antibody
DMCZFMS DE Melanoma
DMNVFZA ID DMNVFZA
DMNVFZA DN AC-1202
DMNVFZA HS Phase 2
DMNVFZA SN Ketasyn
DMNVFZA CP Accera
DMNVFZA DT Small molecular drug
DMNVFZA PC 10850
DMNVFZA MW 470.7
DMNVFZA FM C27H50O6
DMNVFZA IC InChI=1S/C27H50O6/c1-4-7-10-13-16-19-25(28)31-22-24(33-27(30)21-18-15-12-9-6-3)23-32-26(29)20-17-14-11-8-5-2/h24H,4-23H2,1-3H3
DMNVFZA CS CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC
DMNVFZA IK VLPFTAMPNXLGLX-UHFFFAOYSA-N
DMNVFZA IU 2,3-di(octanoyloxy)propyl octanoate
DMNVFZA CA CAS 538-23-8
DMNVFZA CB CHEBI:76978
DMNVFZA DE Memory loss
DMB0TNL ID DMB0TNL
DMB0TNL DN AC-201
DMB0TNL HS Phase 2
DMB0TNL CP TWi Biotechnology Taipei, Taiwan
DMB0TNL DE Type-2 diabetes
DM3TUBR ID DM3TUBR
DM3TUBR DN Acalabrutinib
DM3TUBR HS Phase 2
DM3TUBR SN Acalabrutinib; 1420477-60-6; ACP-196; Calquence; UNII-I42748ELQW; I42748ELQW; Benzamide; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Acalabrutinib (ACP-196); Calquence (TN); Benzamide, ACP-196; Acalabrutinib; Acalabrutinib(ACP196); GTPL8912; CHEMBL3707348; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; ACP 196; WDENQI; Acalabrutinib
DM3TUBR TC Antiviral Agents
DM3TUBR DT Small molecular drug
DM3TUBR PC 71226662
DM3TUBR MW 465.5
DM3TUBR FM C26H23N7O2
DM3TUBR IC InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
DM3TUBR CS CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
DM3TUBR IK WDENQIQQYWYTPO-IBGZPJMESA-N
DM3TUBR IU 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
DM3TUBR CA CAS 1420477-60-6
DM3TUBR DE Coronavirus Disease 2019 (COVID-19)
DM0FGDO ID DM0FGDO
DM0FGDO DN ACCLAIM
DM0FGDO HS Phase 2
DM0FGDO SN Depon; Excel; Furore; PUMA; Whip; Fenoxaprop ethyl; Fenoxaprop ethyl ester; Fenoxaprop ethyl ester [ANSI]; Tiller Herbicide; HOE 33171; FENOXAPROP-ETHYL; HOE-A 25-01; Ethyl 2-(4-((6-chlorobenzoxazol-2-yl)oxy)phenoxy)propionate; Ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate; Ethyl (D+)-2-(4-(6-chlor-2-benzoxazolyloxy)phenoxy)propanoate [French]; Ethyl 2-(4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy)propanoate; Ethyl 2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate; Ethyl-2-((4-(6-chloro-2-benzoxazolyloxy))-phenoxy)propionate; Ethyl (+-)-2-(4-(6-chloro-2-benzoxazolyloxy)phenoxy)propanoate; Propanoic acid, 2-(4-((6-chloro-2-benzoxazolyl)oxy)phenoxy)-, ethyl ester; (+/-)-2-(4-((6-Chloro-2-benzoxazolyl)oxy)phenoxy)propanoic acid ethyl ester; 2-(4-((6-Chloro-2-benzoxazolylen)oxy)phenoxy)propanoic acid, ethyl ester
DM0FGDO CP Angiogenix
DM0FGDO DT Small molecular drug
DM0FGDO PC 47938
DM0FGDO MW 361.8
DM0FGDO FM C18H16ClNO5
DM0FGDO IC InChI=1S/C18H16ClNO5/c1-3-22-17(21)11(2)23-13-5-7-14(8-6-13)24-18-20-15-9-4-12(19)10-16(15)25-18/h4-11H,3H2,1-2H3
DM0FGDO CS CCOC(=O)C(C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl
DM0FGDO IK PQKBPHSEKWERTG-UHFFFAOYSA-N
DM0FGDO IU ethyl 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoate
DM0FGDO CA CAS 66441-23-4
DM0FGDO CB CHEBI:5008
DM0FGDO DE Coronary artery disease; Angina pectoris
DMZ8PY0 ID DMZ8PY0
DMZ8PY0 DN ACE-031
DMZ8PY0 HS Phase 2
DMZ8PY0 CP Acceleron Pharma
DMZ8PY0 DE Duchenne dystrophy
DMIVUFL ID DMIVUFL
DMIVUFL DN ACH-1625
DMIVUFL HS Phase 2
DMIVUFL SN SOVAPREVIR; 1001667-23-7; UNII-2ND9V3MN6O; ACH-0141625; 2ND9V3MN6O; Sovaprevir [USAN:INN]; Sovaprevir (USAN); Prodrug of ACH-1095; SCHEMBL1462843; CHEMBL2105750; DTXSID00142994; DB12069; SB16836; D10166; 2-Pyrrolidinecarboxamide, N-((1R,2S)-1-(((cyclopropylsulfonyl)amino)carbonyl)-2- ethenylcyclopropyl)-1-((2S)-3,3-dimethyl-1-oxo-2-(2-oxo-2-(1-piperidinyl)ethyl)butyl)-4-
DMIVUFL CP Achillion
DMIVUFL DT Small molecular drug
DMIVUFL PC 53362096
DMIVUFL MW 800
DMIVUFL FM C43H53N5O8S
DMIVUFL IC InChI=1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1
DMIVUFL CS CC(C)(C)[C@H](CC(=O)N1CCCCC1)C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7
DMIVUFL IK MHFMTUBUVQZIRE-WINRQGAFSA-N
DMIVUFL IU (2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide
DMIVUFL CA CAS 1001667-23-7
DMIVUFL DE Hepatitis C virus infection
DM0RPY5 ID DM0RPY5
DM0RPY5 DN ACH-3102
DM0RPY5 HS Phase 2
DM0RPY5 CP Achillion pharmaceuticals
DM0RPY5 PC 71474517
DM0RPY5 MW 1001.3
DM0RPY5 FM C60H72N8O6
DM0RPY5 IC InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1
DM0RPY5 CS CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DM0RPY5 IK LSYBRGMTRKJATA-IVEWBXRVSA-N
DM0RPY5 IU methyl N-[(2S)-1-[(2S,3aS,7aS)-2-[6-[11-[2-[(2S,3aS,7aS)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]-5-tricyclo[8.2.2.24,7]hexadeca-1(12),4,6,10,13,15-hexaenyl]-1H-benzimidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM0RPY5 CA CAS 1415119-52-6
DM0RPY5 DE Hepatitis C virus infection
DMLVCZR ID DMLVCZR
DMLVCZR DN ACH-4471
DMLVCZR HS Phase 2
DMLVCZR SN PIBARDGJJAGJAJ-NQIIRXRSSA-N; UNII-JM8C1SFX0U; JM8C1SFX0U; SCHEMBL17024981; 1903768-17-1; (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
DMLVCZR CP Achillion Pharmaceuticals New Haven, CT
DMLVCZR PC 118323590
DMLVCZR MW 580.4
DMLVCZR FM C26H23BrFN7O3
DMLVCZR IC InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1
DMLVCZR CS CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F
DMLVCZR IK PIBARDGJJAGJAJ-NQIIRXRSSA-N
DMLVCZR IU (2S,4R)-1-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide
DMLVCZR CA CAS 1903768-17-1
DMLVCZR DE Glomerulonephritis; Anaemia
DMPR8E9 ID DMPR8E9
DMPR8E9 DN ACP-001
DMPR8E9 HS Phase 2
DMPR8E9 SN TransCon-PEG Growth Hormone; TransCon-PEG-hGH; Growth hormone (TransCon, subcutaneous sustained-release), Ascendis Pharma
DMPR8E9 CP Ascendis Pharma A/S
DMPR8E9 DE Growth hormone deficiency
DMMG61B ID DMMG61B
DMMG61B DN ACT-GRO-777
DMMG61B HS Phase 2
DMMG61B SN AGRO-100; AS-1411; Anticancer aptamers, Aptamera; GRO-26B; AGRO-100 derivatives, Aptamera; Nucleolin inhibitors (cancer), Aptamera; Nucleolin inhibitors (iv, acute myeloid leukemia), Advanced Cancer Therapeutics
DMMG61B CP Aptamera Inc
DMMG61B DT Aptamer
DMMG61B DE Solid tumour/cancer
DMKBIPR ID DMKBIPR
DMKBIPR DN Actimab-A
DMKBIPR HS Phase 2
DMKBIPR CP Actinium Pharmaceuticals New York, NY
DMKBIPR DE Acute myeloid leukaemia
DM9GRTK ID DM9GRTK
DM9GRTK DN ACYLINE
DM9GRTK HS Phase 2
DM9GRTK SN Acyline; UNII-S3439D3B35; CHEMBL262747; S3439D3B35; BDBM50102456; DB11906; D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-(acetylamino)-L-phenylalanyl-4-(acetylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; Z-3146; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(Ac)]-D-[Aph(Ac)]-Leu-ILys-Pro-DAla-NH2
DM9GRTK PC 16137348
DM9GRTK MW 1533.2
DM9GRTK FM C80H102ClN15O14
DM9GRTK IC InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,70+/m1/s1
DM9GRTK CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9GRTK IK ZWNUQDJANZGVFO-YHSALVGYSA-N
DM9GRTK IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM9GRTK CA CAS 170157-13-8
DM9GRTK DE Prostate cancer
DMLV9GS ID DMLV9GS
DMLV9GS DN AD04
DMLV9GS HS Phase 2
DMLV9GS CP ADial Pharmaceuticals Charlottesville, VA
DMLV9GS DE Alcohol dependence; Opioid dependence
DMMFLXN ID DMMFLXN
DMMFLXN DN AD-452
DMMFLXN HS Phase 2
DMMFLXN SN RS(+)-mefloquine; (+)-erythro-mefloquine
DMMFLXN CP Sosei R&D Ltd
DMMFLXN DE Rheumatoid arthritis
DM8GHIX ID DM8GHIX
DM8GHIX DN ADC-3680
DM8GHIX HS Phase 2
DM8GHIX SN ADC-3680B; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Argenta Discovery; CRTh2 antagonists (oral, allergic asthma/allergic rhinitis/COPD), Pulmagen; Prostaglandin D2 receptor antagonists (oral, COPD/allergic asthma/allergic rhinitis), Argenta Discovery
DM8GHIX CP Argenta Discovery Ltd
DM8GHIX DE Allergic rhinitis
DM821BS ID DM821BS
DM821BS DN Adipiplon
DM821BS HS Phase 2
DM821BS SN GABA modulator (insomnia), Neurogen; NG-2-73
DM821BS CP Neurogen Corporation
DM821BS DT Small molecular drug
DM821BS PC 11198924
DM821BS MW 351.4
DM821BS FM C18H18FN7
DM821BS IC InChI=1S/C18H18FN7/c1-3-5-13-15(22-11-26-17(13)23-12(2)24-26)10-25-9-8-21-18(25)16-14(19)6-4-7-20-16/h4,6-9,11H,3,5,10H2,1-2H3
DM821BS CS CCCC1=C(N=CN2C1=NC(=N2)C)CN3C=CN=C3C4=C(C=CC=N4)F
DM821BS IK UAMAIHOEGLEXSV-UHFFFAOYSA-N
DM821BS IU 7-[[2-(3-fluoropyridin-2-yl)imidazol-1-yl]methyl]-2-methyl-8-propyl-[1,2,4]triazolo[1,5-c]pyrimidine
DM821BS CA CAS 840486-93-3
DM821BS DE Sleep-wake disorder
DMMUPTN ID DMMUPTN
DMMUPTN DN ADL-5747
DMMUPTN HS Phase 2
DMMUPTN CP Pfizer
DMMUPTN DT Small molecular drug
DMMUPTN PC 76967747
DMMUPTN MW 428.9
DMMUPTN FM C24H29ClN2O3
DMMUPTN IC InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)17-9-10-18(21(27)15-17)20-16-24(11-13-25-14-12-24)29-22-8-6-5-7-19(20)22;/h5-10,15-16,25,27H,3-4,11-14H2,1-2H3;1H
DMMUPTN CS CCN(CC)C(=O)C1=CC(=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC=C42)O.Cl
DMMUPTN IK XROFSGVHHSJMMG-UHFFFAOYSA-N
DMMUPTN IU N,N-diethyl-3-hydroxy-4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide;hydrochloride
DMMUPTN CA CAS 1187653-56-0
DMMUPTN DE Pain
DMDQH9A ID DMDQH9A
DMDQH9A DN ADL-5859
DMDQH9A HS Phase 2
DMDQH9A SN PF-04856880
DMDQH9A CP Pfizer
DMDQH9A DT Small molecular drug
DMDQH9A PC 46931003
DMDQH9A MW 428.9
DMDQH9A FM C24H29ClN2O3
DMDQH9A IC InChI=1S/C24H28N2O3.ClH/c1-3-26(4-2)23(28)18-10-8-17(9-11-18)19-16-24(12-14-25-15-13-24)29-21-7-5-6-20(27)22(19)21;/h5-11,16,25,27H,3-4,12-15H2,1-2H3;1H
DMDQH9A CS CCN(CC)C(=O)C1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC(=C42)O.Cl
DMDQH9A IK ZFNLSWREIULTDO-UHFFFAOYSA-N
DMDQH9A IU N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide;hydrochloride
DMDQH9A CA CAS 850173-95-4
DMDQH9A DE Rheumatoid arthritis
DM819CO ID DM819CO
DM819CO DN ADMVA
DM819CO HS Phase 2
DM819CO SN RMVA vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankara vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankaravaccine (HIV-1), Aaron Diamond AIDS Research Center; DNA vaccine (gag, pol, env, tat, nef), ADARC; DNA vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center; HIV-1 vaccine (gag, pol, env, tat, nef), ADARC; HIV-1 vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center
DM819CO CP Aaron Diamond AIDS Research Center
DM819CO DT Vaccine
DM819CO DE Diabetic complication
DMJSWXL ID DMJSWXL
DMJSWXL DN Ad-p53
DMJSWXL HS Phase 2
DMJSWXL SN P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough
DMJSWXL CP Transgene SA
DMJSWXL DE Colorectal cancer; Solid tumour/cancer
DMRYH3M ID DMRYH3M
DMRYH3M DN ADP-A2M4
DMRYH3M HS Phase 2
DMRYH3M CP Adaptimmune
DMRYH3M DE Solid tumour/cancer; Synovial sarcoma
DME384W ID DME384W
DME384W DN AdPEDR
DME384W HS Phase 2
DME384W CP GenVec
DME384W DT Small molecular drug
DME384W PC 11557063
DME384W MW 964.7
DME384W FM C38H41IN14O9
DME384W IC InChI=1S/C20H22N8O5.C18H19IN6O4/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t13-;12-,13+,14-,18+/m00/s1
DME384W CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O.CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DME384W IK BDNQEWFVMDIRTE-VXJTWHGRSA-N
DME384W IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;(2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide
DME384W DE Exudative age-related macular degeneration
DMCNTFW ID DMCNTFW
DMCNTFW DN Ad-RTS-hIL-12
DMCNTFW HS Phase 2
DMCNTFW CP Ziopharm Oncology
DMCNTFW DT Gene therapy
DMCNTFW DE Melanoma; Malignant glioma; Recurrent glioblastoma; Glioblastoma of brain
DMM6B2Y ID DMM6B2Y
DMM6B2Y DN ADU- S100
DMM6B2Y HS Phase 2
DMM6B2Y DT Small molecular drug
DMM6B2Y DE Head and neck cancer
DM8HBUI ID DM8HBUI
DM8HBUI DN ADU-S100
DM8HBUI HS Phase 2
DM8HBUI SN MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885
DM8HBUI CP Aduro Biotech Berkeley, CANovartis Oncology East Hanover, NJ
DM8HBUI PC 135390762
DM8HBUI MW 734.5
DM8HBUI FM C20H22N10Na2O10P2S2
DM8HBUI IC InChI=1S/C20H24N10O10P2S2.2Na/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(32)13-8(38-19)2-36-42(34,44)40-14-11(31)7(1-35-41(33,43)39-13)37-20(14)30-6-28-10-16(22)24-4-26-18(10)30;;/h3-8,11-14,19-20,31-32H,1-2H2,(H,33,43)(H,34,44)(H2,21,23,25)(H2,22,24,26);;/q;2*+1/p-2/t7-,8-,11-,12-,13-,14-,19-,20-,41?,42?;;/m1../s1
DM8HBUI CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)O)OP(=O)(O1)[S-])[O-])O.[Na+].[Na+]
DM8HBUI IK GDWOOOCBNOMMTL-QYUKNOIISA-L
DM8HBUI IU disodium;(1R,6R,8R,9R,10S,15R,17R,18R)-8,17-bis(6-aminopurin-9-yl)-3-oxido-12-oxo-3-sulfanylidene-12-sulfido-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecane-9,18-diol
DM8HBUI CA CAS 1638750-95-4
DM8HBUI DE Solid tumour/cancer; Head and neck cancer
DMGVKHQ ID DMGVKHQ
DMGVKHQ DN ADX10059
DMGVKHQ HS Phase 2
DMGVKHQ CP Addex Pharma.
DMGVKHQ DE Anxiety disorder
DMC8NAO ID DMC8NAO
DMC8NAO DN ADXS-HPV
DMC8NAO HS Phase 2
DMC8NAO CP Advaxis
DMC8NAO DT Vaccine
DMC8NAO DE Cervical Intraepithelial neoplasia; Cervical cancer
DMJVN89 ID DMJVN89
DMJVN89 DN AEB07
DMJVN89 HS Phase 2
DMJVN89 CP Novartis
DMJVN89 DT Small molecular drug
DMJVN89 PC 9963383
DMJVN89 MW 1078.3
DMJVN89 FM C52H71N9O12S2
DMJVN89 IC InChI=1S/C27H36N4O5S.C24H31N5O4.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-3-16-6-8-19(27-23(16)25-2)9-7-17-10-12-29(24(17)33)15-21(30)28-20(13-22(31)32)18-5-4-11-26-14-18;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);4-6,8,11,14,17,20H,3,7,9-10,12-13,15H2,1-2H3,(H,25,27)(H,28,30)(H,31,32);1H3,(H,2,3,4)/t22-;17-,20-;/m10./s1
DMJVN89 CS CCC1=C(N=C(C=C1)CC[C@H]2CCN(C2=O)CC(=O)N[C@@H](CC(=O)O)C3=CN=CC=C3)NC.CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O
DMJVN89 IK XAOWMNBAVQDQSR-WQDYQDSXSA-N
DMJVN89 IU 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;(3S)-3-[[2-[(3S)-3-[2-[5-ethyl-6-(methylamino)pyridin-2-yl]ethyl]-2-oxopyrrolidin-1-yl]acetyl]amino]-3-pyridin-3-ylpropanoic acid;methanesulfonic acid
DMJVN89 DE Transplant rejection
DMQ1GH4 ID DMQ1GH4
DMQ1GH4 DN AEF0117
DMQ1GH4 HS Phase 2
DMQ1GH4 CP Aelis Farma
DMQ1GH4 DT Small molecular drug
DMQ1GH4 DE Marijuana use disorder
DMSBLOU ID DMSBLOU
DMSBLOU DN AEG-33773
DMSBLOU HS Phase 2
DMSBLOU CP Aegera Therapeutics Inc
DMSBLOU DE Diabetic neuropathy
DMI5TXZ ID DMI5TXZ
DMI5TXZ DN AEM-28
DMI5TXZ HS Phase 2
DMI5TXZ SN Apo-E peptide mimetic (acute coronary syndrome), University of Alabama at Birmingham/LipimetiX
DMI5TXZ CP Lipimetix development
DMI5TXZ DE Hyperlipidaemia; Familial hypercholesterolemia
DMNO7BC ID DMNO7BC
DMNO7BC DN AeroLEF
DMNO7BC HS Phase 2
DMNO7BC DE Pain
DMFO2G5 ID DMFO2G5
DMFO2G5 DN Afabicin
DMFO2G5 HS Phase 2
DMFO2G5 SN UNII-DMM8663H2R; DMM8663H2R; 1518800-35-5; Afabicin [INN]; SCHEMBL15479062; SCHEMBL16262317; (6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate; 2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-
DMFO2G5 CP Debiopharm Lausanne, Switzerland
DMFO2G5 PC 72696796
DMFO2G5 MW 485.4
DMFO2G5 FM C23H24N3O7P
DMFO2G5 IC InChI=1S/C23H24N3O7P/c1-15-18-5-3-4-6-19(18)33-20(15)13-25(2)21(27)9-7-16-11-17-8-10-22(28)26(23(17)24-12-16)14-32-34(29,30)31/h3-7,9,11-12H,8,10,13-14H2,1-2H3,(H2,29,30,31)/b9-7+
DMFO2G5 CS CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(N=C3)N(C(=O)CC4)COP(=O)(O)O
DMFO2G5 IK HFYMDQMXVPJNTH-VQHVLOKHSA-N
DMFO2G5 IU [6-[(E)-3-[methyl-[(3-methyl-1-benzofuran-2-yl)methyl]amino]-3-oxoprop-1-enyl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1-yl]methyl dihydrogen phosphate
DMFO2G5 CA CAS 1518800-35-5
DMFO2G5 DE Acute bacterial skin infection
DMFORDT ID DMFORDT
DMFORDT DN Afimoxifene
DMFORDT HS Phase 2
DMFORDT SN 4-Hydroxytamoxifen; Afimoxifene; (Z)-4-Hydroxytamoxifen; Hydroxytamoxifen; 4-Monohydroxytamoxifen; Tamogel; 68047-06-3; trans-4-Hydroxytamoxifen; Ici 79280; 68392-35-8; 65213-48-1; 4-OH-TAM; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; Z-4-hydroxytamoxifen; UNII-95K54647BZ; CHEMBL489; ICI 79,280; TAMOXIFEN, 4-HYDROXY-, (Z)-; BRN 4910749; (E/Z)-4-Hydroxy Tamoxifen; MLS000069742; C26H29NO2; CHEBI:44616; 95K54647BZ; SMR000058939; 4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
DMFORDT CP ASCEND Therapeutics
DMFORDT DT Small molecular drug
DMFORDT PC 449459
DMFORDT MW 387.5
DMFORDT FM C26H29NO2
DMFORDT IC InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
DMFORDT CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
DMFORDT IK TXUZVZSFRXZGTL-QPLCGJKRSA-N
DMFORDT IU 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMFORDT CA CAS 68047-06-3
DMFORDT CB CHEBI:44616
DMFORDT DE Breast cancer; Ductal carcinoma
DMN45IC ID DMN45IC
DMN45IC DN AFM13
DMN45IC HS Phase 2
DMN45IC CP Affimed Therapeutics
DMN45IC DT Antibody
DMN45IC DE Hodgkin lymphoma; Lymphoma; Peripheral T-cell lymphoma; Mycosis fungoides
DMTFE9Y ID DMTFE9Y
DMTFE9Y DN AFN-1252
DMTFE9Y HS Phase 2
DMTFE9Y SN API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium
DMTFE9Y CP Affinium pharmaceuticals
DMTFE9Y DT Small molecular drug
DMTFE9Y PC 10407120
DMTFE9Y MW 375.4
DMTFE9Y FM C22H21N3O3
DMTFE9Y IC InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+
DMTFE9Y CS CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3
DMTFE9Y IK QXTWSUQCXCWEHF-JXMROGBWSA-N
DMTFE9Y IU (E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide
DMTFE9Y CA CAS 620175-39-5
DMTFE9Y DE Staphylococcus infection
DM6AJKC ID DM6AJKC
DM6AJKC DN AFN-1720
DM6AJKC HS Phase 2
DM6AJKC CP Affinium pharmaceuticals
DM6AJKC DE Bacterial infection
DM1FJ2B ID DM1FJ2B
DM1FJ2B DN AFP464
DM1FJ2B HS Phase 2
DM1FJ2B SN UNII-73JNH95XPX; AFP464; 73JNH95XPX; 468719-53-1; AFP 464; AFP-464; Hexanamide, 2,6-diamino-N-(4-(5-amino-6,8-difluoro-7-methyl-4-oxo-4H-1-benzopyran-2-yl)-2-fluorophenyl)-, (2S)-, dimethanesulfonate
DM1FJ2B CP Kirax
DM1FJ2B DT Small molecular drug
DM1FJ2B PC 399587
DM1FJ2B MW 544.5
DM1FJ2B FM C23H27F3N4O6S
DM1FJ2B IC InChI=1S/C22H23F3N4O3.CH4O3S/c1-10-18(24)20(28)17-15(30)9-16(32-21(17)19(10)25)11-5-6-14(12(23)8-11)29-22(31)13(27)4-2-3-7-26;1-5(2,3)4/h5-6,8-9,13H,2-4,7,26-28H2,1H3,(H,29,31);1H3,(H,2,3,4)/t13-;/m0./s1
DM1FJ2B CS CC1=C(C(=C2C(=O)C=C(OC2=C1F)C3=CC(=C(C=C3)NC(=O)[C@H](CCCCN)N)F)N)F.CS(=O)(=O)O
DM1FJ2B IK MJVICFBYAVBBOA-ZOWNYOTGSA-N
DM1FJ2B IU (2S)-2,6-diamino-N-[4-(5-amino-6,8-difluoro-7-methyl-4-oxochromen-2-yl)-2-fluorophenyl]hexanamide;methanesulfonic acid
DM1FJ2B CA CAS 468719-53-1
DM1FJ2B DE Breast cancer
DMD3XMG ID DMD3XMG
DMD3XMG DN AFTVac
DMD3XMG HS Phase 2
DMD3XMG SN Autologous fixed tumor vaccine (AFTVac) therapy; Autologous vaccine (cancer), Cell-Medicine; GM-CSF agonist/IL-2 agonist containing-vaccine; Fixed autologous tumor derivatives + microparticles encapsulating GM-CSF and IL-2, Cell-Medicine
DMD3XMG CP Cell-Medicine Inc
DMD3XMG DT Vaccine
DMD3XMG DE Glioblastoma multiforme
DMA9FKY ID DMA9FKY
DMA9FKY DN AG140699
DMA9FKY HS Phase 2
DMA9FKY CP Pfizer
DMA9FKY TC Anticancer Agents
DMA9FKY DE Melanoma
DMNQ5T2 ID DMNQ5T2
DMNQ5T2 DN AG-858
DMNQ5T2 HS Phase 2
DMNQ5T2 SN Chronic myeloid leukemia therapy, Antigenics; HSP-70 cancer vaccine, Antigenics; HSPPC-70 (cancer); HSPPC-70-C
DMNQ5T2 CP Agenus Inc; Antigenics
DMNQ5T2 DT Vaccine
DMNQ5T2 DE leukaemia
DMPO7UG ID DMPO7UG
DMPO7UG DN AGEN2034
DMPO7UG HS Phase 2
DMPO7UG CP AgenusLexington, MA
DMPO7UG DT Monoclonal antibody
DMPO7UG DE Solid tumour/cancer; Cervical cancer
DMP5Y1A ID DMP5Y1A
DMP5Y1A DN AGN-199981
DMP5Y1A HS Phase 2
DMP5Y1A CP Allergan
DMP5Y1A TC Analgesics
DMP5Y1A DE Neuropathic pain
DM4KOAC ID DM4KOAC
DM4KOAC DN AGN-241751
DM4KOAC HS Phase 2
DM4KOAC CP Allergan
DM4KOAC DT Small molecular drug
DM4KOAC DE Major depressive disorder
DMLQRFO ID DMLQRFO
DMLQRFO DN AGN-2979
DMLQRFO HS Phase 2
DMLQRFO SN BTG-1501; SC-48274; AGN-2979 (free base); 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione; 3-[3-(Dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione monohydrochloride
DMLQRFO DT Small molecular drug
DMLQRFO PC 40914
DMLQRFO MW 332.4
DMLQRFO FM C19H28N2O3
DMLQRFO IC InChI=1S/C19H28N2O3/c1-18(2)13-16(22)20-17(23)19(18,10-7-11-21(3)4)14-8-6-9-15(12-14)24-5/h6,8-9,12H,7,10-11,13H2,1-5H3,(H,20,22,23)
DMLQRFO CS CC1(CC(=O)NC(=O)C1(CCCN(C)C)C2=CC(=CC=C2)OC)C
DMLQRFO IK UJFNSGBGJMRZKS-UHFFFAOYSA-N
DMLQRFO IU 3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione
DMLQRFO CA CAS 53873-21-5
DMLQRFO DE Psychotic disorder
DMMGAUK ID DMMGAUK
DMMGAUK DN AGN-XX/YY
DMMGAUK HS Phase 2
DMMGAUK SN Rezatomidine
DMMGAUK CP ACADIA Pharmaceuticals
DMMGAUK DT Small molecular drug
DMMGAUK PC 11287722
DMMGAUK MW 232.35
DMMGAUK FM C13H16N2S
DMMGAUK IC InChI=1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
DMMGAUK CS CC1=C(C(=CC=C1)[C@H](C)C2=CNC(=S)N2)C
DMMGAUK IK WQXVKEDUCPMRRI-JTQLQIEISA-N
DMMGAUK IU 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydroimidazole-2-thione
DMMGAUK CA CAS 847829-38-3
DMMGAUK DE Fibromyalgia; Diabetic nephropathy
DM2POHA ID DM2POHA
DM2POHA DN AGS-16C3F
DM2POHA HS Phase 2
DM2POHA CP AgensysSanta Monica, CA
DM2POHA DE Renal cell carcinoma
DMMKASG ID DMMKASG
DMMKASG DN AGTC-0106
DMMKASG HS Phase 2
DMMKASG SN Alpha-1 antitrypsin deficiency gene therapy, AGTC; RAAV1-CB-hAAT; Gene therapy (alpha-1 antitrypsin deficiency), Applied Genetic Technologies
DMMKASG CP Agtc; applied genetic technologies
DMMKASG DE Alpha-1 antitrypsin deficiency
DMXJ8Z4 ID DMXJ8Z4
DMXJ8Z4 DN AK104
DMXJ8Z4 HS Phase 2
DMXJ8Z4 CP Akeso Biopharma
DMXJ8Z4 DT Antibody
DMXJ8Z4 DE Cervical cancer; Hepatocellular carcinoma
DMKNRYH ID DMKNRYH
DMKNRYH DN AKB-9778
DMKNRYH HS Phase 2
DMKNRYH CP Aerpio Therapeutics
DMKNRYH PC 46700782
DMKNRYH MW 586.7
DMKNRYH FM C26H26N4O6S3
DMKNRYH IC InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
DMKNRYH CS COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)NS(=O)(=O)O)C3=CSC(=N3)C4=CC=CS4
DMKNRYH IK KWJDHELCGJFUHW-SFTDATJTSA-N
DMKNRYH IU [4-[(2S)-2-[[(2S)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid
DMKNRYH CA CAS 1008510-37-9
DMKNRYH DE Peripheral arterial disease; Diabetic macular edema
DMR8W7Y ID DMR8W7Y
DMR8W7Y DN AKCEA-ANGPTL3-LRX
DMR8W7Y HS Phase 2
DMR8W7Y CP Akcea Therapeutics Cambridge, MA
DMR8W7Y DE Cardiovascular disease
DMCTWIB ID DMCTWIB
DMCTWIB DN AL102
DMCTWIB HS Phase 2
DMCTWIB CP Ayala Pharmaceuticals
DMCTWIB DT Small molecular drug
DMCTWIB DE Desmoid tumour
DM3P91Z ID DM3P91Z
DM3P91Z DN Alacizumab pegol
DM3P91Z HS Phase 2
DM3P91Z SN CDP-791
DM3P91Z CP UCB Celltech
DM3P91Z DT Antibody
DM3P91Z DE Non-small-cell lung cancer
DM2U530 ID DM2U530
DM2U530 DN ALD-401
DM2U530 HS Phase 2
DM2U530 SN ALD-401, Aldagen; ALDH-expressing stem cell therapy (ischemic stroke), Aldagen
DM2U530 CP Cytomedix
DM2U530 DE Cerebrovascular ischaemia
DM6RBYT ID DM6RBYT
DM6RBYT DN ALD-403
DM6RBYT HS Phase 2
DM6RBYT SN MAb (migraine), Alder
DM6RBYT CP Alder biopharmaceuticals
DM6RBYT DE Migraine
DMPWSBL ID DMPWSBL
DMPWSBL DN ALD-518
DMPWSBL HS Phase 2
DMPWSBL DE Rheumatoid arthritis; Psoriatic arthritis
DMUA0XC ID DMUA0XC
DMUA0XC DN ALF-5755
DMUA0XC HS Phase 2
DMUA0XC SN HIP/PAP; Hepatocarcinoma-intestine-pancreas/pancreatic-associated protein
DMUA0XC CP INSERM
DMUA0XC DE Liver failure
DMR2YPF ID DMR2YPF
DMR2YPF DN ALG-1001
DMR2YPF HS Phase 2
DMR2YPF CP Allegro Ophthalmics
DMR2YPF PC 130476723
DMR2YPF MW 637.7
DMR2YPF FM C22H39N9O11S
DMR2YPF IC InChI=1S/C22H39N9O11S/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42)/t11-,12+,13+,14+,17+/m1/s1
DMR2YPF CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O
DMR2YPF IK MYZAXBZLEILEBR-RVFOSREFSA-N
DMR2YPF IU (2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid
DMR2YPF CA CAS 1307293-62-4
DMR2YPF DE Diabetic macular edema
DME3ZYC ID DME3ZYC
DME3ZYC DN ALKS 4230
DME3ZYC HS Phase 2
DME3ZYC CP Alkermes
DME3ZYC DT Protein
DME3ZYC DE Solid tumour/cancer
DMF3QN1 ID DMF3QN1
DMF3QN1 DN ALKS33
DMF3QN1 HS Phase 2
DMF3QN1 SN Samidorphan
DMF3QN1 CP Alkermes
DMF3QN1 DT Small molecular drug
DMF3QN1 PC 11667832
DMF3QN1 MW 370.4
DMF3QN1 FM C21H26N2O4
DMF3QN1 IC InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
DMF3QN1 CS C1CC1CN2CC[C@]34CC(=O)CC[C@]3([C@H]2CC5=C4C(=C(C=C5)C(=O)N)O)O
DMF3QN1 IK RYIDHLJADOKWFM-MAODMQOUSA-N
DMF3QN1 IU (1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dihydroxy-13-oxo-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4-carboxamide
DMF3QN1 CA CAS 852626-89-2
DMF3QN1 DE Alcohol dependence
DMWYMJN ID DMWYMJN
DMWYMJN DN ALN-CC5
DMWYMJN HS Phase 2
DMWYMJN CP Alnylam Pharmaceuticals: Cemdisiran
DMWYMJN DT Antisense oligonucleotide
DMWYMJN DE Haemolytic uraemic syndrome
DMEYNQA ID DMEYNQA
DMEYNQA DN ALN-RSV01
DMEYNQA HS Phase 2
DMEYNQA DT siRNA drug
DMEYNQA DE Respiratory infection; Respiratory syncytial virus infection
DMJPV5X ID DMJPV5X
DMJPV5X DN Alovudine
DMJPV5X HS Phase 2
DMJPV5X SN Alovudine; 25526-93-6; FddT; 3'-DEOXY-3'-FLUOROTHYMIDINE; FddThD; 3'-Fluoro-3'-deoxythymidine; Thymidine, 3'-deoxy-3'-fluoro-; 3'F-TdR; 3'-FddT; Alovudine [USAN:INN]; UNII-PG53R0DWDQ; 3'-Fluorothymidine; 3'-FLT; DRG-0097; PG53R0DWDQ; NSC 140025; BRN 0754299; 3'-Fluorodeoxythymidine; CL 184824; CHEMBL105318; FLT; 1-((2R,4S,5R)-4-fluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; C10H13FN2O4; MIV-310; 1-(3'-Deoxy-3'-fluoro-beta-D-pentofuranosyl)thymine; CL-184824; DSSTox_RID_81738; DSSTox_CID_26579
DMJPV5X DT Small molecular drug
DMJPV5X PC 33039
DMJPV5X MW 244.22
DMJPV5X FM C10H13FN2O4
DMJPV5X IC InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1
DMJPV5X CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)F
DMJPV5X IK UXCAQJAQSWSNPQ-XLPZGREQSA-N
DMJPV5X IU 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJPV5X CA CAS 25526-93-6
DMJPV5X DE Breast cancer
DM5EFXZ ID DM5EFXZ
DM5EFXZ DN Alpha-1 antitrypsin
DM5EFXZ HS Phase 2
DM5EFXZ SN AAT, Transgene; Alpha-1 antitrypsin, Transgene
DM5EFXZ CP Transgene SA
DM5EFXZ DE Bacillus anthracis infection; Coagulation defect
DMLBWT1 ID DMLBWT1
DMLBWT1 DN ALRN-6924
DMLBWT1 HS Phase 2
DMLBWT1 CP Aileron Therapeutics Cambridge, MA
DMLBWT1 DE Acute myeloid leukaemia; Haematological malignancy; Myelodysplastic syndrome; Solid tumour/cancer
DM9KL7P ID DM9KL7P
DM9KL7P DN ALT-801
DM9KL7P HS Phase 2
DM9KL7P SN ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
DM9KL7P CP Altor bioscience
DM9KL7P DE Acute myeloid leukaemia; Bladder cancer; Non-muscle invasive bladder cancer
DMK3U1X ID DMK3U1X
DMK3U1X DN ALT-803
DMK3U1X HS Phase 2
DMK3U1X SN IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
DMK3U1X CP Altor bioscience
DMK3U1X DE Human immunodeficiency virus infection; Solid tumour/cancer; Non-hodgkin lymphoma; Pancreatic cancer; Non-small-cell lung cancer; Bladder cancer; Multiple myeloma; Acute myeloid leukaemia
DMGJ71F ID DMGJ71F
DMGJ71F DN ALT-836
DMGJ71F HS Phase 2
DMGJ71F CP Altor BioScience
DMGJ71F DE Adult respiratory distress syndrome
DMLSK01 ID DMLSK01
DMLSK01 DN Altrakincept
DMLSK01 HS Phase 2
DMLSK01 CP Novartis
DMLSK01 DT Monoclonal antibody
DMLSK01 DE Asthma
DMXSFA0 ID DMXSFA0
DMXSFA0 DN ALV-003
DMXSFA0 HS Phase 2
DMXSFA0 SN Gluten-detoxifying protease (celiac sprue), Alvine Pharmaceuticals; Glutamine-specific cysteine protease (EP-B2) + proline-specific prolyl endopeptidase (PEP) (celiac disease), Alvine
DMXSFA0 CP Alvine Pharmaceuticals Inc
DMXSFA0 DE Coeliac disease
DMO1VHC ID DMO1VHC
DMO1VHC DN ALX-0061
DMO1VHC HS Phase 2
DMO1VHC SN Nanobody therapeutic (autoimmune/inflammatory disease), Ablynx; Anti-IL-6R nanobody therapeutic (autoimmune/inflammatory disease), Ablynx
DMO1VHC CP Ablynx NV
DMO1VHC DT Antibody
DMO1VHC DE Autoimmune diabetes; Rheumatoid arthritis; Systemic lupus erythematosus
DMCAFXM ID DMCAFXM
DMCAFXM DN ALX-101
DMCAFXM HS Phase 2
DMCAFXM SN Rovazolac; UNII-W51K389XIL; W51K389XIL; Rovazolac [INN]; GTPL9625; SCHEMBL15242823; ZUMNJDGBYXHASJ-UHFFFAOYSA-N; example 36 [WO2013130892]; HY-109073; CS-0033536; A-110; ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate; ethyl 2-(5-(3'-(methylsulfonyl)biphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; ethyl 2-(5-(3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate; Ethyl 2-(5-(3'-(methylsulfonyl)-(1,1'-biphenyl)-4-yl)-3-(trifluoromethy
DMCAFXM CP Ralexar Therapeutics Malvern, PA
DMCAFXM PC 89792952
DMCAFXM MW 452.4
DMCAFXM FM C21H19F3N2O4S
DMCAFXM IC InChI=1S/C21H19F3N2O4S/c1-3-30-20(27)13-26-18(12-19(25-26)21(22,23)24)15-9-7-14(8-10-15)16-5-4-6-17(11-16)31(2,28)29/h4-12H,3,13H2,1-2H3
DMCAFXM CS CCOC(=O)CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C
DMCAFXM IK ZUMNJDGBYXHASJ-UHFFFAOYSA-N
DMCAFXM IU ethyl 2-[5-[4-(3-methylsulfonylphenyl)phenyl]-3-(trifluoromethyl)pyrazol-1-yl]acetate
DMCAFXM CA CAS 1454288-88-0
DMCAFXM DE Atopic dermatitis
DMV934L ID DMV934L
DMV934L DN ALX-40-4C
DMV934L HS Phase 2
DMV934L SN AV-9
DMV934L CP NPS Allelix Corp
DMV934L DT Small molecular drug
DMV934L PC 25077385
DMV934L MW 1464.7
DMV934L FM C56H113N37O10
DMV934L IC InChI=1S/C56H113N37O10/c1-29(94)85-31(12-3-21-77-49(60)61)40(96)87-33(14-5-23-79-51(64)65)42(98)89-35(16-7-25-81-53(68)69)44(100)91-37(18-9-27-83-55(72)73)46(102)93-38(19-10-28-84-56(74)75)47(103)92-36(17-8-26-82-54(70)71)45(101)90-34(15-6-24-80-52(66)67)43(99)88-32(13-4-22-78-50(62)63)41(97)86-30(39(57)95)11-2-20-76-48(58)59/h30-38H,2-28H2,1H3,(H2,57,95)(H,85,94)(H,86,97)(H,87,96)(H,88,99)(H,89,98)(H,90,101)(H,91,100)(H,92,103)(H,93,102)(H4,58,59,76)(H4,60,61,77)(H4,62,63,78)(H4,64,65,79)(H4,66,67,80)(H4,68,69,81)(H4,70,71,82)(H4,72,73,83)(H4,74,75,84)/t30-,31-,32-,33-,34-,35-,36-,37-,38-/m1/s1
DMV934L CS CC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N
DMV934L IK LGLVVVCSQBZONM-HCCLCSBVSA-N
DMV934L IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMV934L CA CAS 153127-49-2
DMV934L DE Human immunodeficiency virus infection
DMH5LFR ID DMH5LFR
DMH5LFR DN ALXN6000
DMH5LFR HS Phase 2
DMH5LFR SN Samalizumab
DMH5LFR CP Alexion Pharmaceuticals
DMH5LFR DT Antibody
DMH5LFR DE Chronic lymphocytic leukaemia; Acute myeloid leukaemia; Solid tumour/cancer
DM7ZQAT ID DM7ZQAT
DM7ZQAT DN ALZ-801
DM7ZQAT HS Phase 2
DM7ZQAT CP Alzheon
DM7ZQAT PC 25008296
DM7ZQAT MW 238.31
DM7ZQAT FM C8H18N2O4S
DM7ZQAT IC InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
DM7ZQAT CS CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N
DM7ZQAT IK NRZRFNYKMSAZBI-ZETCQYMHSA-N
DM7ZQAT IU 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid
DM7ZQAT CA CAS 1034190-08-3
DM7ZQAT DE Alzheimer disease
DM9UMSJ ID DM9UMSJ
DM9UMSJ DN AM001
DM9UMSJ HS Phase 2
DM9UMSJ SN MLS000562506; CHEMBL1407569; HMS2222P08; SMR000453693
DM9UMSJ CP AmDerma Pharmaceuticals
DM9UMSJ DT Small molecular drug
DM9UMSJ PC 16745944
DM9UMSJ MW 369.4
DM9UMSJ FM C19H19N3O5
DM9UMSJ IC InChI=1S/C19H19N3O5/c1-2-10-26-14-11-17(27-15(14)12-23)22-9-8-16(21-19(22)25)20-18(24)13-6-4-3-5-7-13/h1,3-9,14-15,17,23H,10-12H2,(H,20,21,24,25)/t14-,15-,17-/m1/s1
DM9UMSJ CS C#CCO[C@@H]1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3
DM9UMSJ IK VUDFTOHJBXWAGS-BFYDXBDKSA-N
DM9UMSJ IU N-[1-[(2R,4R,5R)-5-(hydroxymethyl)-4-prop-2-ynoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
DM9UMSJ DE Actinic keratosis
DMGVQI8 ID DMGVQI8
DMGVQI8 DN AM-001
DMGVQI8 HS Phase 2
DMGVQI8 SN AM-001 (topical); AM-001 (topical), DermAct
DMGVQI8 CP DermAct Pharmaceutical Inc
DMGVQI8 DE Dermatological disease; Actinic keratosis
DMBWNX5 ID DMBWNX5
DMBWNX5 DN AMA-76
DMBWNX5 HS Phase 2
DMBWNX5 CP Amakem
DMBWNX5 DE Glaucoma/ocular hypertension
DMEB3T9 ID DMEB3T9
DMEB3T9 DN Amdoxovir
DMEB3T9 HS Phase 2
DMEB3T9 SN Amdoxovir; DAPD; 145514-04-1; DAPD cpd; UNII-54I81H0M9C; (-)-DAPD; beta-D-2,6-Diaminopurine-dioxolane; 54I81H0M9C; [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol; (2R-cis)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (2R,4R)-4-(2,6-Diamino-9H-purin-9-yl)-1,3-dioxolane-2-methanol; (-)-(2R,4R)-2-Amino-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)adenine; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R,4R)-; 1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)-, (2R-cis)-; Amdoxovir [USAN]
DMEB3T9 DT Small molecular drug
DMEB3T9 PC 124088
DMEB3T9 MW 252.23
DMEB3T9 FM C9H12N6O3
DMEB3T9 IC InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1
DMEB3T9 CS C1[C@@H](O[C@@H](O1)CO)N2C=NC3=C(N=C(N=C32)N)N
DMEB3T9 IK RLAHNGKRJJEIJL-RFZPGFLSSA-N
DMEB3T9 IU [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
DMEB3T9 CA CAS 145514-04-1
DMEB3T9 DE Hepatitis B virus infection
DMIVZ3M ID DMIVZ3M
DMIVZ3M DN AME-133v
DMIVZ3M HS Phase 2
DMIVZ3M SN Ocaratuzumab
DMIVZ3M CP MENTRIK Biotech
DMIVZ3M DT Antibody
DMIVZ3M DE Non-hodgkin lymphoma
DMUMCB9 ID DMUMCB9
DMUMCB9 DN Amelubant
DMUMCB9 HS Phase 2
DMUMCB9 SN Amelubant [INN]; BIIL 283 BS; BIIL 284; Ethyl ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)benzyl)oxy)phenyl)(imino)methyl)carbamate; Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)-, ethyl ester
DMUMCB9 CP Boehringer Ingelheim
DMUMCB9 DT Small molecular drug
DMUMCB9 PC 135564996
DMUMCB9 MW 538.6
DMUMCB9 FM C33H34N2O5
DMUMCB9 IC InChI=1S/C33H34N2O5/c1-4-38-32(37)35-31(34)25-8-16-29(17-9-25)39-21-23-6-5-7-24(20-23)22-40-30-18-12-27(13-19-30)33(2,3)26-10-14-28(36)15-11-26/h5-20,36H,4,21-22H2,1-3H3,(H2,34,35,37)
DMUMCB9 CS CCOC(=O)NC(=N)C1=CC=C(C=C1)OCC2=CC(=CC=C2)COC3=CC=C(C=C3)C(C)(C)C4=CC=C(C=C4)O
DMUMCB9 IK SBVYURPQULDJTI-UHFFFAOYSA-N
DMUMCB9 IU ethyl N-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidoyl]carbamate
DMUMCB9 CA CAS 346735-24-8
DMUMCB9 DE Cystic fibrosis; Pulmonary disease
DMGOFL3 ID DMGOFL3
DMGOFL3 DN AMG 151
DMGOFL3 HS Phase 2
DMGOFL3 CP Amgen
DMGOFL3 DE Type-2 diabetes
DMPQHOR ID DMPQHOR
DMPQHOR DN AMG 208
DMPQHOR HS Phase 2
DMPQHOR SN AMG-208; 1002304-34-8; AMG 208; AMG208; UNII-Y2SR66P7VM; 7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline; Y2SR66P7VM; CHEBI:90626; 7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-Methoxy-4-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; C22H17N5O2; 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline; 7-methoxy-4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methoxy)quinoline; Triazolopyridazine, 4; 3cd8
DMPQHOR CP Amgen Thousand
DMPQHOR DT Small molecular drug
DMPQHOR PC 24864821
DMPQHOR MW 383.4
DMPQHOR FM C22H17N5O2
DMPQHOR IC InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
DMPQHOR CS COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5
DMPQHOR IK HEAIZQNMNCHNFD-UHFFFAOYSA-N
DMPQHOR IU 7-methoxy-4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline
DMPQHOR CA CAS 1002304-34-8
DMPQHOR CB CHEBI:90626
DMPQHOR DE Solid tumour/cancer
DM65PTO ID DM65PTO
DM65PTO DN AMG 232
DM65PTO HS Phase 2
DM65PTO SN KRT-232
DM65PTO CP Amgen
DM65PTO PC 58573469
DM65PTO MW 568.6
DM65PTO FM C28H35Cl2NO5S
DM65PTO IC InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1
DM65PTO CS CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl
DM65PTO IK DRLCSJFKKILATL-YWCVFVGNSA-N
DM65PTO IU 2-[(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2S)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid
DM65PTO CA CAS 1352066-68-2
DM65PTO DE Solid tumour/cancer; Merkel cell carcinoma
DMO72IF ID DMO72IF
DMO72IF DN AMG 301
DMO72IF HS Phase 2
DMO72IF CP Amgen Thousand Oaks, CA Novartis Pharmaceuticals East Hanover, NJ
DMO72IF DE Migraine; Hyperprolactinaemia
DMI3WFG ID DMI3WFG
DMI3WFG DN AMG 334
DMI3WFG HS Phase 2
DMI3WFG CP Amgen
DMI3WFG DE Migraine
DMIOUEY ID DMIOUEY
DMIOUEY DN AMG 337
DMIOUEY HS Phase 2
DMIOUEY PC 44181686
DMIOUEY MW 463.5
DMIOUEY FM C23H22FN7O3
DMIOUEY IC InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
DMIOUEY CS C[C@H](C1=NN=C2N1C=C(C=C2F)C3=CN(N=C3)C)N4C=CC5=C(C4=O)C=C(C=N5)OCCOC
DMIOUEY IK DWHXUGDWKAIASB-CQSZACIVSA-N
DMIOUEY IU 6-[(1R)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one
DMIOUEY CA CAS 1173699-31-4
DMIOUEY DE Solid tumour/cancer; Clear cell sarcoma
DM0DRAZ ID DM0DRAZ
DM0DRAZ DN AMG 479
DM0DRAZ HS Phase 2
DM0DRAZ CP Amgen
DM0DRAZ DE Breast cancer
DME6QH1 ID DME6QH1
DME6QH1 DN AMG 557
DME6QH1 HS Phase 2
DME6QH1 CP Amgen Thousand
DME6QH1 DE Systemic lupus erythematosus; Sjogren syndrome
DMY1XJH ID DMY1XJH
DMY1XJH DN AMG 570
DMY1XJH HS Phase 2
DMY1XJH CP Amgen
DMY1XJH DT Small molecular drug
DMY1XJH DE Systemic lupus erythematosus
DMFXN2T ID DMFXN2T
DMFXN2T DN AMG 745
DMFXN2T HS Phase 2
DMFXN2T CP Amgen
DMFXN2T DE Muscle atrophy
DMWPGB8 ID DMWPGB8
DMWPGB8 DN Amg 747
DMWPGB8 HS Phase 2
DMWPGB8 CP Amgen
DMWPGB8 DE Schizophrenia
DM973N4 ID DM973N4
DM973N4 DN AMG 853
DM973N4 HS Phase 2
DM973N4 SN VIDUPIPRANT; 1169483-24-2; AMG 853; AMG-853; UNII-61OTZ32XNC; 61OTZ32XNC; 2-(4-(4-(tert-butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid; CHEMBL1951575; AMG 853(AMG853;Vidupiprant); Benzeneacetic acid, 5-chloro-4-[2-[[(2-chloro-4-cyclopropylphenyl)sulfonyl]amino]-4-[[(1,1-dimethylethyl)amino]carbonyl]phenoxy]-2-fluoro-; Vidupiprant [USAN:INN]; AMG853;Vidupiprant; Vidupiprant (USAN/INN); AMG853; SCHEMBL4344221; GTPL10169; DTXSID40151606; BCP28132; ZINC43206238
DM973N4 CP Amgen Thousand
DM973N4 DT Small molecular drug
DM973N4 PC 42641863
DM973N4 MW 609.5
DM973N4 FM C28H27Cl2FN2O6S
DM973N4 IC InChI=1S/C28H27Cl2FN2O6S/c1-28(2,3)32-27(36)17-6-8-23(39-24-14-21(31)18(11-19(24)29)13-26(34)35)22(12-17)33-40(37,38)25-9-7-16(10-20(25)30)15-4-5-15/h6-12,14-15,33H,4-5,13H2,1-3H3,(H,32,36)(H,34,35)
DM973N4 CS CC(C)(C)NC(=O)C1=CC(=C(C=C1)OC2=C(C=C(C(=C2)F)CC(=O)O)Cl)NS(=O)(=O)C3=C(C=C(C=C3)C4CC4)Cl
DM973N4 IK PFWVGKROPKKEDW-UHFFFAOYSA-N
DM973N4 IU 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid
DM973N4 CA CAS 1169483-24-2
DM973N4 DE Asthma
DM3H0IX ID DM3H0IX
DM3H0IX DN AMG 890
DM3H0IX HS Phase 2
DM3H0IX SN Olpasiran
DM3H0IX CP Amgen
DM3H0IX DT Small interfering RNA
DM3H0IX DE Cardiac fibrosis
DMODJTX ID DMODJTX
DMODJTX DN AMG-181
DMODJTX HS Phase 2
DMODJTX SN Inflammatory bowel disease therapeutics, Amgen
DMODJTX CP Amgen; astrazeneca
DMODJTX DT Antibody
DMODJTX DE Crohn disease; Ulcerative colitis
DM1T3KQ ID DM1T3KQ
DM1T3KQ DN AMG-714
DM1T3KQ HS Phase 2
DM1T3KQ CP Genmab; Amgen
DM1T3KQ DT Antibody
DM1T3KQ DE Rheumatoid arthritis; Coeliac disease
DMJ4GPR ID DMJ4GPR
DMJ4GPR DN AMP-579
DMJ4GPR HS Phase 2
DMJ4GPR SN RPR-100579; (1S,2R,3S,4R)-4-[7-[1(R)-(3-Chloro-2-thienylmethyl)propylamino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
DMJ4GPR DT Small molecular drug
DMJ4GPR PC 72941762
DMJ4GPR MW 478
DMJ4GPR FM C22H28ClN5O3S
DMJ4GPR IC InChI=1S/C22H28ClN5O3S/c1-3-12(9-17-15(23)6-8-32-17)27-20-13-5-7-28(21(13)26-11-25-20)16-10-14(18(29)19(16)30)22(31)24-4-2/h5-8,11-12,14,16,18-19,29-30H,3-4,9-10H2,1-2H3,(H,24,31)(H,25,26,27)/t12-,14+,16-,18-,19+/m1/s1
DMJ4GPR CS CC[C@H](CC1=C(C=CS1)Cl)NC2=C3C=CN(C3=NC=N2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC
DMJ4GPR IK CKQOOYMMAAPDKH-QODLLSGVSA-N
DMJ4GPR IU (1S,2R,3S,4R)-4-[4-[[(2R)-1-(3-chlorothiophen-2-yl)butan-2-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-N-ethyl-2,3-dihydroxycyclopentane-1-carboxamide
DMJ4GPR CA CAS 213453-89-5
DMJ4GPR DE Hyperlipidaemia
DMGE8FK ID DMGE8FK
DMGE8FK DN AMR-001
DMGE8FK HS Phase 2
DMGE8FK CP Amorcyte; Progenitor Cell Therapy
DMGE8FK DE Heart failure
DMOB01U ID DMOB01U
DMOB01U DN Amsilarotene
DMOB01U HS Phase 2
DMOB01U SN Am-555S; TAC-101; Anticancer retinoic acid receptor antagonist (oral), Taiho
DMOB01U CP Taiho Pharmaceutical Co Ltd
DMOB01U DT Small molecular drug
DMOB01U PC 9800306
DMOB01U MW 385.6
DMOB01U FM C20H27NO3Si2
DMOB01U IC InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24)
DMOB01U CS C[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)O)[Si](C)(C)C
DMOB01U IK VVTNSTLJOVCBDL-UHFFFAOYSA-N
DMOB01U IU 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
DMOB01U CA CAS 125973-56-0
DMOB01U DE Solid tumour/cancer
DMS0GA6 ID DMS0GA6
DMS0GA6 DN AMY-101
DMS0GA6 HS Phase 2
DMS0GA6 SN UNII-4Z4DFR9BX7; 4Z4DFR9BX7; 1427001-89-5 (free base); Compstatin 40; Compstatin analog peptide CP40; CHEMBL4297260; 1427001-89-5; L-Isoleucinamide, D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophyl-N-methylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N2-methyl-, cyclic (3->13)-disulfide; S3,S13-Cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)
DMS0GA6 CP Amyndas
DMS0GA6 DT Peptide
DMS0GA6 PC 131634231
DMS0GA6 MW 1789.1
DMS0GA6 FM C83H117N23O18S2
DMS0GA6 IC InChI=1S/C83H117N23O18S2/c1-11-43(5)68(103-72(114)53(84)30-46-23-25-50(107)26-24-46)80(122)100-61-39-125-126-40-62(82(124)106(10)69(70(86)112)44(6)12-2)101-73(115)55(21-17-29-90-83(87)88)94-76(118)58(33-49-36-89-41-92-49)96-71(113)45(7)93-65(109)38-105(9)81(123)60(31-47-35-91-54-20-15-13-18-51(47)54)99-77(119)59(34-66(110)111)97-74(116)56(27-28-64(85)108)95-75(117)57(98-79(121)67(42(3)4)102-78(61)120)32-48-37-104(8)63-22-16-14-19-52(48)63/h13-16,18-20,22-26,35-37,41-45,53,55-62,67-69,91,107H,11-12,17,21,27-34,38-40,84H2,1-10H3,(H2,85,108)(H2,86,112)(H,89,92)(H,93,109)(H,94,118)(H,95,117)(H,96,113)(H,97,116)(H,98,121)(H,99,119)(H,100,122)(H,101,115)(H,102,120)(H,103,114)(H,110,111)(H4,87,88,90)/t43-,44-,45-,53+,55-,56-,57-,58-,59-,60-,61-,62-,67-,68-,69-/m0/s1
DMS0GA6 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CN(C3=CC=CC=C32)C)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N(C)[C@@H]([C@@H](C)CC)C(=O)N)NC(=O)[C@@H](CC7=CC=C(C=C7)O)N
DMS0GA6 IK MUSGYEMSJUFFHT-UWABRSFTSA-N
DMS0GA6 IU 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMS0GA6 CA CAS 1427001-89-5
DMS0GA6 DE Gingivitis
DMT3S10 ID DMT3S10
DMT3S10 DN AN0128
DMT3S10 HS Phase 2
DMT3S10 SN Bis(3-chloro-4-methyl-phenyl)boranyl 3-hydroxypyridine-2-carboxylate; 2-Pyridinecarboxylic acid, 3-hydroxy-, anhydride with bis(3-chloro-4-methylphenyl)borinic acid; 3-Hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane
DMT3S10 CP Anacor Pharma.
DMT3S10 DT Small molecular drug
DMT3S10 PC 11704019
DMT3S10 MW 400.1
DMT3S10 FM C20H16BCl2NO3
DMT3S10 IC InChI=1S/C20H16BCl2NO3/c1-12-5-7-14(10-16(12)22)21(15-8-6-13(2)17(23)11-15)27-20(26)19-18(25)4-3-9-24-19/h3-11,25H,1-2H3
DMT3S10 CS B(C1=CC(=C(C=C1)C)Cl)(C2=CC(=C(C=C2)C)Cl)OC(=O)C3=C(C=CC=N3)O
DMT3S10 IK ZTLSOLUCMQEGEA-UHFFFAOYSA-N
DMT3S10 IU bis(3-chloro-4-methylphenyl)boranyl 3-hydroxypyridine-2-carboxylate
DMT3S10 CA CAS 872044-70-7
DMT3S10 DE Psoriatic disorder; Atopic dermatitis
DMJ7QP8 ID DMJ7QP8
DMJ7QP8 DN AN-019
DMJ7QP8 HS Phase 2
DMJ7QP8 SN NRC-19; NRC-24; NRC-AN-015; NRC-AN-019; Bcr-Abl inhibitors (CML), Natco
DMJ7QP8 CP Natco Pharma Ltd
DMJ7QP8 DE Chronic myelogenous leukaemia
DM3JNXS ID DM3JNXS
DM3JNXS DN AN-1792
DM3JNXS HS Phase 2
DM3JNXS SN Betabloc; AIP-001
DM3JNXS CP Elan Pharmaceutical Research
DM3JNXS DT Small molecular drug
DM3JNXS PC 15176
DM3JNXS MW 283.83
DM3JNXS FM C16H26ClNO
DM3JNXS IC InChI=1S/C16H25NO.ClH/c1-3-12(2)17-11-16(18)15-9-8-13-6-4-5-7-14(13)10-15;/h8-10,12,16-18H,3-7,11H2,1-2H3;1H
DM3JNXS CS CCC(C)[NH2+]CC(C1=CC2=C(CCCC2)C=C1)O.[Cl-]
DM3JNXS IK KHBXORBAOCQNMC-UHFFFAOYSA-N
DM3JNXS IU butan-2-yl-[2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]azanium;chloride
DM3JNXS CA CAS 1506-12-3
DM3JNXS DE Alzheimer disease
DMDK7CL ID DMDK7CL
DMDK7CL DN AN-2898
DMDK7CL HS Phase 2
DMDK7CL SN PDE4 inhibitor (topical, psoriasis/atopic dermatitis), Anacor
DMDK7CL CP Anacor Pharmaceuticals Inc
DMDK7CL PC 24806574
DMDK7CL MW 276.06
DMDK7CL FM C15H9BN2O3
DMDK7CL IC InChI=1S/C15H9BN2O3/c17-7-10-1-2-13(5-11(10)8-18)21-14-3-4-15-12(6-14)9-20-16(15)19/h1-6,19H,9H2
DMDK7CL CS B1(C2=C(CO1)C=C(C=C2)OC3=CC(=C(C=C3)C#N)C#N)O
DMDK7CL IK UBMGTTRDNUKZMT-UHFFFAOYSA-N
DMDK7CL IU 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzene-1,2-dicarbonitrile
DMDK7CL CA CAS 906673-33-4
DMDK7CL DE Atopic dermatitis
DMG7IEN ID DMG7IEN
DMG7IEN DN Anatibant
DMG7IEN HS Phase 2
DMG7IEN SN Anatibant [INN]; (2S)-N-(3-(4-Carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide
DMG7IEN CP Fournier Pharma
DMG7IEN DT Small molecular drug
DMG7IEN PC 9831652
DMG7IEN MW 711.7
DMG7IEN FM C34H36Cl2N6O5S
DMG7IEN IC InChI=1S/C34H36Cl2N6O5S/c1-20-18-21(2)41-31-24(20)6-3-8-28(31)47-19-25-26(35)13-14-29(30(25)36)48(45,46)42-17-4-7-27(42)34(44)40-16-5-15-39-33(43)23-11-9-22(10-12-23)32(37)38/h3,6,8-14,18,27H,4-5,7,15-17,19H2,1-2H3,(H3,37,38)(H,39,43)(H,40,44)/t27-/m0/s1
DMG7IEN CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)C5=CC=C(C=C5)C(=N)N)Cl)C
DMG7IEN IK XUHBBTKJWIBQMY-MHZLTWQESA-N
DMG7IEN IU (2S)-N-[3-[(4-carbamimidoylbenzoyl)amino]propyl]-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carboxamide
DMG7IEN CA CAS 209733-45-9
DMG7IEN CB CHEBI:138828
DMG7IEN DE Traumatic brain injury
DMTG2O0 ID DMTG2O0
DMTG2O0 DN Anrukinzumab
DMTG2O0 HS Phase 2
DMTG2O0 SN Ab13-2; IMA-638; PF-05230917; Anti-IL-13 antibody (asthma), Wyeth; Anti-IL-13 antibody (ulcerative colitis), Pfizer
DMTG2O0 CP Genentech
DMTG2O0 DT Monoclonal antibody
DMTG2O0 DE Ulcerative colitis; Asthma
DMHVZ27 ID DMHVZ27
DMHVZ27 DN Anti-CD137
DMHVZ27 HS Phase 2
DMHVZ27 SN BMS-663513
DMHVZ27 CP Bristol-Myers Squibb
DMHVZ27 DT Antibody
DMHVZ27 DE Solid tumour/cancer
DMPRIHK ID DMPRIHK
DMPRIHK DN Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
DMPRIHK HS Phase 2
DMPRIHK SN Her2Bi-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute; Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer); Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells (breast cancer), Barbara Ann Karmanos Cancer Institute
DMPRIHK CP Transtarget; barbara ann karmanos cancer institute
DMPRIHK DT Antibody
DMPRIHK DE Breast cancer
DMVQHBK ID DMVQHBK
DMVQHBK DN Anti-GD2 CART
DMVQHBK HS Phase 2
DMVQHBK CP Zhujiang Hospital
DMVQHBK DT CAR T Cell Therapy
DMVQHBK DE Neuroblastoma
DMVRNAO ID DMVRNAO
DMVRNAO DN Anti-IP10
DMVRNAO HS Phase 2
DMVRNAO CP Bristol-myers squibb
DMVRNAO DT Antibody
DMVRNAO DE Ulcerative colitis; Crohn disease
DMJO402 ID DMJO402
DMJO402 DN Anti-LAG3
DMJO402 HS Phase 2
DMJO402 CP Bristol-Myers Squibb Princeton, NJ
DMJO402 DE Gastric adenocarcinoma; Renal cell carcinoma; Non-small-cell lung cancer
DMQ58YH ID DMQ58YH
DMQ58YH DN Anti-LT alpha
DMQ58YH HS Phase 2
DMQ58YH CP Genentech
DMQ58YH DT Antibody
DMQ58YH DE Rheumatoid arthritis
DMQFU1R ID DMQFU1R
DMQFU1R DN Anti-M1 prime
DMQFU1R HS Phase 2
DMQFU1R CP Genentech
DMQFU1R DT Antibody
DMQFU1R DE Asthma
DMJPZDC ID DMJPZDC
DMJPZDC DN Anti-PSCA mab
DMJPZDC HS Phase 2
DMJPZDC CP Agensys
DMJPZDC DT Monoclonal antibody
DMJPZDC DE Pancreatic cancer
DMDKRS3 ID DMDKRS3
DMDKRS3 DN Antistasin
DMDKRS3 HS Phase 2
DMDKRS3 DE Attention deficit hyperactivity disorder
DMRGQVZ ID DMRGQVZ
DMRGQVZ DN Antroquinonol
DMRGQVZ HS Phase 2
DMRGQVZ SN Hocena; Fungal extract (cancer), Golden Biotechnology
DMRGQVZ CP Golden biotechnology
DMRGQVZ PC 24875259
DMRGQVZ MW 390.6
DMRGQVZ FM C24H38O4
DMRGQVZ IC InChI=1S/C24H38O4/c1-16(2)10-8-11-17(3)12-9-13-18(4)14-15-20-19(5)21(25)23(27-6)24(28-7)22(20)26/h10,12,14,19-20,22,26H,8-9,11,13,15H2,1-7H3/b17-12+,18-14+/t19-,20-,22-/m1/s1
DMRGQVZ CS C[C@@H]1[C@H]([C@H](C(=C(C1=O)OC)OC)O)C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMRGQVZ IK LJTSIMVOOOLKOL-FNRDIUJOSA-N
DMRGQVZ IU (4R,5R,6R)-4-hydroxy-2,3-dimethoxy-6-methyl-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]cyclohex-2-en-1-one
DMRGQVZ CA CAS 1010081-09-0
DMRGQVZ CB CHEBI:65415
DMRGQVZ DE Non-small-cell lung cancer; Pancreatic cancer
DMMJOZD ID DMMJOZD
DMMJOZD DN ANW-32821
DMMJOZD HS Phase 2
DMMJOZD SN Cholest-5-en-3-beta-ol; Cholesterol; Cholest-5-en-3-ol (3beta)-; Cholest-5-en-3beta-ol; Cholesterin; Cholesterine; Cholesterol base H; Cholesteryl alcohol; Cholestrin; Cholestrol; Cordulan; Dastar; Dusoline; Dusoran; Dythol; Hydrocerin; Kathro; Lidinit; Lidinite; Nimco cholesterol base H; Provitamin D; Super hartolan; Tegolan; Tegolan (VAN); Wool alcohols B. P.; cholesterol; (-)-Cholesterol; (3beta)-cholest-5-en-3-ol; 3-beta-Hydroxycholest-5-ene; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; 57-88-5; 5:6-Cholesten-3beta-ol; CCRIS 2834; Lanol
DMMJOZD PC 5997
DMMJOZD MW 386.664
DMMJOZD FM C27H46O
DMMJOZD IC HVYWMOMLDIMFJA-DPAQBDIFSA-N
DMMJOZD CS CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C
DMMJOZD IK InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMMJOZD IU (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMMJOZD CA CAS 17528-72-2
DMMJOZD CB ChEBI:15372
DMMJOZD DE Cone rod dystrophy
DMYBQEF ID DMYBQEF
DMYBQEF DN AP26113
DMYBQEF HS Phase 2
DMYBQEF SN 1197958-12-5; ALK-IN-1; UNII-3DGD69C6PV; 3DGD69C6PV; CHEMBL3397300; (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide; 5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine; 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine; AP26113-analog; Tube723; compound 11q [PMID: 27144831]
DMYBQEF DT Small molecular drug
DMYBQEF PC 57390074
DMYBQEF MW 529
DMYBQEF FM C26H34ClN6O2P
DMYBQEF IC InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)
DMYBQEF CS CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC
DMYBQEF IK OVDSPTSBIQCAIN-UHFFFAOYSA-N
DMYBQEF IU 5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine
DMYBQEF CA CAS 1197958-12-5
DMYBQEF DE Solid tumour/cancer
DM3ICYL ID DM3ICYL
DM3ICYL DN AP-301-IH
DM3ICYL HS Phase 2
DM3ICYL SN AP-301; AP-301-IRI; AP-301-PN; AP-301-PN); Peptide TNF alpha analog (pneumonia), Apeptico; Peptide TNF alpha modulator (edema in acute lung injury), Apeptico/Medical College of Georgia; Peptide TNF alpha modulator (ischemia/reperfusion injury), Apeptico
DM3ICYL CP Apeptico Forschung und Entwicklung GmbH
DM3ICYL DE Pneumonia
DMISQOZ ID DMISQOZ
DMISQOZ DN AP-761
DMISQOZ HS Phase 2
DMISQOZ SN BI-671800
DMISQOZ CP Actimis Pharmaceuticals Inc
DMISQOZ DT Small molecular drug
DMISQOZ PC 45270144
DMISQOZ MW 501.5
DMISQOZ FM C25H26F3N5O3
DMISQOZ IC InChI=1S/C25H26F3N5O3/c1-32(2)22-19(14-21(34)35)23(33(3)4)31-20(30-22)13-15-5-11-18(12-6-15)29-24(36)16-7-9-17(10-8-16)25(26,27)28/h5-12H,13-14H2,1-4H3,(H,29,36)(H,34,35)
DMISQOZ CS CN(C)C1=C(C(=NC(=N1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(F)(F)F)N(C)C)CC(=O)O
DMISQOZ IK XEOSTBFUCNZKGS-UHFFFAOYSA-N
DMISQOZ IU 2-[4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid
DMISQOZ CA CAS 1093108-50-9
DMISQOZ DE Asthma
DM1B8IT ID DM1B8IT
DM1B8IT DN Apadoline
DM1B8IT HS Phase 2
DM1B8IT SN ACMC-20mvlw; SCHEMBL7518667; CTK8G8521; 10H-Phenothiazine-2-carboxamide,10-[(1R)-1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-; KXMAIWXPZGQNCR-UHFFFAOYSA-N; L001386; N-propyl-10-[1-(pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide; N-propyl-10-[1-(1-pyrrolidinyl)-2-propyl]-2-phenothiazinecarboxamide
DM1B8IT CP Rhone-Poulenc SA
DM1B8IT DT Small molecular drug
DM1B8IT PC 179334
DM1B8IT MW 395.6
DM1B8IT FM C23H29N3OS
DM1B8IT IC InChI=1S/C23H29N3OS/c1-3-12-24-23(27)18-10-11-22-20(15-18)26(17(2)16-25-13-6-7-14-25)19-8-4-5-9-21(19)28-22/h4-5,8-11,15,17H,3,6-7,12-14,16H2,1-2H3,(H,24,27)/t17-/m1/s1
DM1B8IT CS CCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2[C@H](C)CN4CCCC4
DM1B8IT IK KXMAIWXPZGQNCR-QGZVFWFLSA-N
DM1B8IT IU N-propyl-10-[(2R)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide
DM1B8IT CA CAS 135003-30-4
DM1B8IT DE Pain
DMQMV9F ID DMQMV9F
DMQMV9F DN Apaxifylline
DMQMV9F HS Phase 2
DMQMV9F SN BIIP-20; U-98950; BIIP-20-XX
DMQMV9F CP Boehringer Ingelheim Corp
DMQMV9F DT Small molecular drug
DMQMV9F PC 60949
DMQMV9F MW 318.37
DMQMV9F FM C16H22N4O3
DMQMV9F IC InChI=1S/C16H22N4O3/c1-3-7-19-14-12(15(22)20(8-4-2)16(19)23)17-13(18-14)10-5-6-11(21)9-10/h10H,3-9H2,1-2H3,(H,17,18)/t10-/m0/s1
DMQMV9F CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3CCC(=O)C3
DMQMV9F IK RUHGOZFOVBMWOO-JTQLQIEISA-N
DMQMV9F IU 8-[(1S)-3-oxocyclopentyl]-1,3-dipropyl-7H-purine-2,6-dione
DMQMV9F CA CAS 151581-23-6
DMQMV9F DE Cognitive impairment
DM3VP19 ID DM3VP19
DM3VP19 DN APC-8015F
DM3VP19 HS Phase 2
DM3VP19 SN CD54-postive autologous cell immunotherapy (hormone refractory prostate cancer), Dendreon
DM3VP19 CP Dendreon Corp
DM3VP19 DE Prostate cancer
DMNQ7DV ID DMNQ7DV
DMNQ7DV DN APD-209
DMNQ7DV HS Phase 2
DMNQ7DV SN Undisclosed cachexia therapy (oral fixed-dose combination), Acacia
DMNQ7DV CP Acacia Pharma Ltd
DMNQ7DV PC 49837938
DMNQ7DV MW 1042.3
DMNQ7DV FM C54H95N3O16
DMNQ7DV IC InChI=1S/C54H95N3O16/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-25-28-48(62)56-31-34-68-36-38-70-40-42-71-41-39-69-37-35-67-33-29-49(63)55-30-26-24-27-32-72-54(53(65)66)43-46(60)50(57-45(2)59)52(73-54)51(64)47(61)44-58/h46-47,50-52,58,60-61,64H,3-13,18-44H2,1-2H3,(H,55,63)(H,56,62)(H,57,59)(H,65,66)/t46-,47+,50+,51+,52+,54+/m0/s1
DMNQ7DV CS CCCCCCCCCCCCC#CC#CCCCCCCCCC(=O)NCCOCCOCCOCCOCCOCCC(=O)NCCCCCO[C@@]1(C[C@@H]([C@H]([C@@H](O1)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)O
DMNQ7DV IK VRJMVFQLUBTBKF-HBJHFNNESA-N
DMNQ7DV IU (2R,4S,5R,6R)-5-acetamido-4-hydroxy-2-[5-[3-[2-[2-[2-[2-[2-(pentacosa-10,12-diynoylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]pentoxy]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMNQ7DV CA CAS 1261156-82-4
DMNQ7DV DE Cachexia
DM3XT5V ID DM3XT5V
DM3XT5V DN APD371
DM3XT5V HS Phase 2
DM3XT5V SN Olorinab; UNII-581F7DFA9B; 581F7DFA9B; Olorinab [USAN]; SCHEMBL11995430; 1268881-20-4; (4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide; 1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-; (1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic aci
DM3XT5V CP Arena Pharmaceuticals San Diego, CA
DM3XT5V PC 60164925
DM3XT5V MW 357.4
DM3XT5V FM C18H23N5O3
DM3XT5V IC InChI=1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1
DM3XT5V CS CC(C)(C)[C@@H](CO)NC(=O)C1=NN(C2=C1C[C@H]3[C@@H]2C3)C4=NC=C[N+](=C4)[O-]
DM3XT5V IK ACSQLTBPYZSGBA-GMXVVIOVSA-N
DM3XT5V IU (2S,4S)-N-[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]-9-(4-oxidopyrazin-4-ium-2-yl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxamide
DM3XT5V CA CAS 1268881-20-4
DM3XT5V DE Crohn disease
DM1VITS ID DM1VITS
DM1VITS DN APD-403
DM1VITS HS Phase 2
DM1VITS CP Acacia Pharma Ltd
DM1VITS DE Vomiting
DM9LZ0M ID DM9LZ0M
DM9LZ0M DN APD-515
DM9LZ0M HS Phase 2
DM9LZ0M SN ACA-1515
DM9LZ0M CP Acacia Pharma Ltd
DM9LZ0M DE Xerostomia
DM0FXMZ ID DM0FXMZ
DM0FXMZ DN APG-101
DM0FXMZ HS Phase 2
DM0FXMZ SN CD95 receptor extracellular domain-IgG fused protein (GvHD), Apogenix; CD95 receptor extracellular domain-IgG fused protein (myocardial infarction), Apogenix; CD95 receptor extracellular domain-IgG fused protein (stroke), Apogenix; CD95 receptor extracellular domain-immunoglobulin G fused protein (graft versus hostdisease), Apogenix
DM0FXMZ CP Apogenix GmbH
DM0FXMZ DE Cerebrovascular ischaemia
DMIFA0L ID DMIFA0L
DMIFA0L DN APG-115
DMIFA0L HS Phase 2
DMIFA0L SN 15Qau0SI9J; 15QAU0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-
DMIFA0L CP Ascentage Pharma Rockville, MD
DMIFA0L PC 91972012
DMIFA0L MW 642.6
DMIFA0L FM C34H38Cl2FN3O4
DMIFA0L IC InChI=1S/C34H38Cl2FN3O4/c1-2-40-27(28(41)39-32-16-13-31(14-17-32,15-18-32)30(43)44)25(21-7-6-8-23(36)26(21)37)34(33(40)11-4-3-5-12-33)22-10-9-20(35)19-24(22)38-29(34)42/h6-10,19,25,27H,2-5,11-18H2,1H3,(H,38,42)(H,39,41)(H,43,44)/t25-,27+,31?,32?,34+/m0/s1
DMIFA0L CS CCN1[C@H]([C@@H]([C@]2(C13CCCCC3)C4=C(C=C(C=C4)Cl)NC2=O)C5=C(C(=CC=C5)Cl)F)C(=O)NC67CCC(CC6)(CC7)C(=O)O
DMIFA0L IK YJCZPJQGFSSFOL-MNZPCBJKSA-N
DMIFA0L CA CAS 1818393-16-6
DMIFA0L DE Solid tumour/cancer; Prolymphocytic leukaemia
DM756GE ID DM756GE
DM756GE DN APH-0812
DM756GE HS Phase 2
DM756GE SN Bryostatin-1 + HDAC inhibitor combination (HIV-1 infection), Aphios
DM756GE CP Aphios Corp
DM756GE DE Human immunodeficiency virus-1 infection; Human immunodeficiency virus infection
DMHIS6Z ID DMHIS6Z
DMHIS6Z DN Apilimod
DMHIS6Z HS Phase 2
DMHIS6Z SN Apilimod; STA 5326; STA-5326; GFW2K84S4L; STA5326; Apilimod [INN]; EX-A908
DMHIS6Z TC Antiviral Agents
DMHIS6Z DT Small molecular drug
DMHIS6Z PC 10173277
DMHIS6Z MW 418.5
DMHIS6Z FM C23H26N6O2
DMHIS6Z IC InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
DMHIS6Z CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4
DMHIS6Z IK HSKAZIJJKRAJAV-KOEQRZSOSA-N
DMHIS6Z IU N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMHIS6Z CA CAS 541550-19-0
DMHIS6Z DE Coronavirus Disease 2019 (COVID-19)
DM4N2O0 ID DM4N2O0
DM4N2O0 DN Apilimod dimesylate
DM4N2O0 HS Phase 2
DM4N2O0 CP LAM Therapeutics Guilford, CT
DM4N2O0 PC 11527330
DM4N2O0 MW 610.7
DM4N2O0 FM C25H34N6O8S2
DM4N2O0 IC InChI=1S/C23H26N6O2.2CH4O3S/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20;2*1-5(2,3)4/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28);2*1H3,(H,2,3,4)/b25-17+;;
DM4N2O0 CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4.CS(=O)(=O)O.CS(=O)(=O)O
DM4N2O0 IK GAJWNIKZLYZYSY-OKUPSQOASA-N
DM4N2O0 IU methanesulfonic acid;N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DM4N2O0 CA CAS 870087-36-8
DM4N2O0 DE Non-hodgkin lymphoma
DM7IGO9 ID DM7IGO9
DM7IGO9 DN Apimostinel
DM7IGO9 HS Phase 2
DM7IGO9 SN UNII-TTT1F11FZB; TTT1F11FZB; 1421866-48-9; Apimostinel [USAN]; SCHEMBL14682282; CHEMBL3989872; DB11784; Threonyl-prolyl-2R-(2-benzyl)-prolyl-threonine amide; L-Threoninamide, L-threonyl-L-prolyl-2-(phenylmethyl)-L-prolyl-
DM7IGO9 CP Allergan Parsippany, NJ
DM7IGO9 PC 71249967
DM7IGO9 MW 503.6
DM7IGO9 FM C25H37N5O6
DM7IGO9 IC InChI=1S/C25H37N5O6/c1-15(31)19(26)23(35)29-12-6-10-18(29)22(34)30-13-7-11-25(30,14-17-8-4-3-5-9-17)24(36)28-20(16(2)32)21(27)33/h3-5,8-9,15-16,18-20,31-32H,6-7,10-14,26H2,1-2H3,(H2,27,33)(H,28,36)/t15-,16-,18+,19+,20+,25-/m1/s1
DM7IGO9 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@@]2(CC3=CC=CC=C3)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DM7IGO9 IK DVBUEXCIEIAXPM-PJUQSVSOSA-N
DM7IGO9 IU (2R)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-2-benzylpyrrolidine-2-carboxamide
DM7IGO9 CA CAS 1421866-48-9
DM7IGO9 DE Major depressive disorder
DMP0LST ID DMP0LST
DMP0LST DN APL-101
DMP0LST HS Phase 2
DMP0LST SN Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine
DMP0LST CP Apollomics
DMP0LST DT Small molecular drug
DMP0LST PC 72202701
DMP0LST MW 424.4
DMP0LST FM C20H15F3N8
DMP0LST IC InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3
DMP0LST CS CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F
DMP0LST IK QHXLXUIZUCJRKV-UHFFFAOYSA-N
DMP0LST IU 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
DMP0LST CA CAS 1440964-89-5
DMP0LST DE Non-small cell lung cancer
DMGJ1X2 ID DMGJ1X2
DMGJ1X2 DN Aplindore fumarate
DMGJ1X2 HS Phase 2
DMGJ1X2 SN Aplindore; Aplindore fumarate (USAN); WAY-DAB-452; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one; 8H-1,4-Dioxino(2,3-e)indol-8-one,2,3,7,9-tetrahydro-2-(((phenylmethyl)amino)methyl)-,2(S)-, (2E)-2-butenediotate (1:1)
DMGJ1X2 CP Wyeth
DMGJ1X2 DT Small molecular drug
DMGJ1X2 PC 6440763
DMGJ1X2 MW 426.4
DMGJ1X2 FM C22H22N2O7
DMGJ1X2 IC InChI=1S/C18H18N2O3.C4H4O4/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12;5-3(6)1-2-4(7)8/h1-7,13,19H,8-11H2,(H,20,21);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1
DMGJ1X2 CS C1[C@@H](OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O
DMGJ1X2 IK GELJVTSEGKGLDF-QDSMGTAFSA-N
DMGJ1X2 IU (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one;(E)-but-2-enedioic acid
DMGJ1X2 CA CAS 189681-71-8
DMGJ1X2 DE Schizophrenia
DMGNFBC ID DMGNFBC
DMGNFBC DN APN301
DMGNFBC HS Phase 2
DMGNFBC SN MAb hu14.18 linked with IL-2
DMGNFBC CP Apeiron Biologics
DMGNFBC DT Antibody
DMGNFBC DE Neuroblastoma
DM32YTJ ID DM32YTJ
DM32YTJ DN APN-301
DM32YTJ HS Phase 2
DM32YTJ SN EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
DM32YTJ CP Apeiron biologics
DM32YTJ DE Melanoma; Neuroblastoma
DMEXN7V ID DMEXN7V
DMEXN7V DN APN401
DMEXN7V HS Phase 2
DMEXN7V SN APN-411; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer); Cbl-b modulators (cancer), Apeiron Biologics; E3 ubiquitin ligase casitas B cell lymphoma-b silencing siRNA therapeutics (cancer), Apeiron Biologics; E3 ubiquitin protein ligase Cbl-b silencing siRNA therapeutics (cancer), Apeiron Biologics
DMEXN7V CP Apeiron Biologics
DMEXN7V DT Small interfering RNA
DMEXN7V DE Solid tumour/cancer
DMKVP7E ID DMKVP7E
DMKVP7E DN Apolizumab
DMKVP7E HS Phase 2
DMKVP7E SN Remitogen; Hu 1D10; Hu1D10, PDL; SMART 1D10 MAb, Protein Design Labs; SMART anti-B cell lymphoma
DMKVP7E CP PDL BioPharma
DMKVP7E DT Monoclonal antibody
DMKVP7E DE Solid tumour/cancer
DM6B9HP ID DM6B9HP
DM6B9HP DN Apomine
DM6B9HP HS Phase 2
DM6B9HP SN Apomine; SR-45023A; UNII-JQ95208805; JQ95208805; SR-9223i; SR 45023A; APB-231-A2; SKF 99085; F-99085; 126411-13-0; SCHEMBL1648488; AC1L423G; DB12276; 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol; tetraisopropyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-biphosphonate; Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis-, tetrakis(1-methylethyl); SK&F-99085; 2-(3,5-Di-tert-butyl-4-hydroxyphenyl)ethylidene-1,1-diphosphonic acid tetraisopropyl ester; SR-45023A (Apomine)
DM6B9HP CP Genzyme
DM6B9HP DT Small molecular drug
DM6B9HP PC 176405
DM6B9HP MW 562.7
DM6B9HP FM C28H52O7P2
DM6B9HP IC InChI=1S/C28H52O7P2/c1-18(2)32-36(30,33-19(3)4)25(37(31,34-20(5)6)35-21(7)8)17-22-15-23(27(9,10)11)26(29)24(16-22)28(12,13)14/h15-16,18-21,25,29H,17H2,1-14H3
DM6B9HP CS CC(C)OP(=O)(C(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OC(C)C)OC(C)C)OC(C)C
DM6B9HP IK YLJOVCWVJCDPLN-UHFFFAOYSA-N
DM6B9HP IU 4-[2,2-bis[di(propan-2-yloxy)phosphoryl]ethyl]-2,6-ditert-butylphenol
DM6B9HP CA CAS 126411-13-0
DM6B9HP DE Osteopetrosis
DMNFADH ID DMNFADH
DMNFADH DN APR-246
DMNFADH HS Phase 2
DMNFADH SN Eprenetapopt
DMNFADH CP Aprea Therapeutics
DMNFADH DT Small molecular drug
DMNFADH PC 52918385
DMNFADH MW 199.25
DMNFADH FM C10H17NO3
DMNFADH IC InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3
DMNFADH CS COCC1(C(=O)C2CCN1CC2)CO
DMNFADH IK BGBNULCRKBVAKL-UHFFFAOYSA-N
DMNFADH IU 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one
DMNFADH CA CAS 5291-32-7
DMNFADH DE Solid tumour/cancer; Ovarian cancer; Esophageal cancer; Myelodysplastic syndrome; Bladder cancer; Gastric adenocarcinoma
DM8W4N9 ID DM8W4N9
DM8W4N9 DN Apratastat
DM8W4N9 HS Phase 2
DM8W4N9 SN TMI-005; TMI-05; UNII-C6BZ5263BJ; 287405-51-0; C6BZ5263BJ; CHEMBL206815; TMI 005; Apratastat [USAN:INN]; Apratastat (USAN/INN); MLS006010301; SCHEMBL2834310; GTPL6482; TMI005; Apratastat, > MolPort-021-805-014; BCPP000041; ZINC28571311; BDBM50181008; DB13020; API0013699; compound 5h [PMID: 16426848]; SMR004701369; 4CA-0170; D08859; 3-Thiomorpholinecarboxamide,N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-,(3S)-; TMI-1; Dual TACE/MMP-13 inhibitors (inflammation), Wyeth; Dual TACE/MMP-13 inhibitors (rheumatoid arthritis), Wyeth; Dual TACE/MMP-13 inhibitors, Wyeth-Ayerst
DM8W4N9 CP Wyeth Research
DM8W4N9 DT Small molecular drug
DM8W4N9 PC 11452716
DM8W4N9 MW 414.5
DM8W4N9 FM C17H22N2O6S2
DM8W4N9 IC InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)/t15-/m0/s1
DM8W4N9 CS CC1([C@@H](N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C
DM8W4N9 IK MAVDNGWEBZTACC-HNNXBMFYSA-N
DM8W4N9 IU (3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide
DM8W4N9 CA CAS 287405-51-0
DM8W4N9 DE Rheumatoid arthritis
DMEJICQ ID DMEJICQ
DMEJICQ DN Aprocitentan
DMEJICQ HS Phase 2
DMEJICQ SN ACT-132577; UNII-MZI81HV01P; 1103522-45-7; Despropyl Macitentan; MZI81HV01P; CHEMBL2165326; CHEBI:76609; Macitentan metabolite; ACT 132577; SCHEMBL3646065; ZINC95553608; BDBM50395672; AKOS028114466; CS-2687; HY-15895; BC600808; 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine; N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric diamide
DMEJICQ CP Idorsia Pharmaceuticals Allschwil, Switzerland Janssen Biotech Horsham, PA
DMEJICQ PC 25099191
DMEJICQ MW 546.2
DMEJICQ FM C16H14Br2N6O4S
DMEJICQ IC InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)
DMEJICQ CS C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br
DMEJICQ IK DKULOVKANLVDEA-UHFFFAOYSA-N
DMEJICQ IU 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
DMEJICQ CA CAS 1103522-45-7
DMEJICQ CB CHEBI:76609
DMEJICQ DE Hypertension
DMX2P5G ID DMX2P5G
DMX2P5G DN APX005M
DMX2P5G HS Phase 2
DMX2P5G CP Apexigen San Carlos, CA
DMX2P5G DT Antibody
DMX2P5G DE Solid tumour/cancer; Brain cancer; Chronic lymphocytic leukaemia; Melanoma
DMU6NBO ID DMU6NBO
DMU6NBO DN APX3330
DMU6NBO HS Phase 2
DMU6NBO SN E3330; 136164-66-4; E-3330; E 3330; CHEMBL578390; UNII-11267UI968; 11267UI968; (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid; (E)-2-((4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid; (2E)-3-(5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl))-2-nonyl-2-propenoic acid; SCHEMBL3758716; SCHEMBL3758719; HMS3886N15; APX 3330; EX-A2212; BDBM50303955; s7445; ZINC14252145; CCG-268389; HY-19357; B5875; CS-0015424; E3330, >=98% (HPLC); A14440; (E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dienyl)-2-nonylpropenoic acid; (E)-3-(5,6-Dimethoxy-3-methyl-14-dioxocyclohexa-25-dienyl)-2-nonylpropenoic Acid; Undecanoic acid, 2-((4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene)-, (E)-
DMU6NBO CP Apexian Pharmaceuticals
DMU6NBO DT Small molecular drug
DMU6NBO PC 6439397
DMU6NBO MW 378.5
DMU6NBO FM C21H30O6
DMU6NBO IC InChI=1S/C21H30O6/c1-5-6-7-8-9-10-11-12-15(21(24)25)13-16-14(2)17(22)19(26-3)20(27-4)18(16)23/h13H,5-12H2,1-4H3,(H,24,25)/b15-13+
DMU6NBO CS CCCCCCCCC/C(=C\\C1=C(C(=O)C(=C(C1=O)OC)OC)C)/C(=O)O
DMU6NBO IK AALSSIXXBDPENJ-FYWRMAATSA-N
DMU6NBO IU (2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]undecanoic acid
DMU6NBO CA CAS 136164-66-4
DMU6NBO DE Solid tumour/cancer; Diabetic retinopathy
DM1USXR ID DM1USXR
DM1USXR DN AQ-13
DM1USXR HS Phase 2
DM1USXR SN AQ-13 Dihydrochloride; 169815-40-1; UNII-PKT9732S5K; AQ 13; PKT9732S5K; DTXSID10168761; (N1-(7-Chloroquinolin-4-yl)-3-(N3,N3-diethylamino)propylamine) dihydrochloride; HY-100358; CS-0018673; 1,3-Propanediamine, N'-(7-chloro-4-quinolinyl)-N,N-diethyl-, dihydrochloride
DM1USXR CP Tulane University
DM1USXR DT Small molecular drug
DM1USXR PC 9820475
DM1USXR MW 364.7
DM1USXR FM C16H24Cl3N3
DM1USXR IC InChI=1S/C16H22ClN3.2ClH/c1-3-20(4-2)11-5-9-18-15-8-10-19-16-12-13(17)6-7-14(15)16;;/h6-8,10,12H,3-5,9,11H2,1-2H3,(H,18,19);2*1H
DM1USXR CS CCN(CC)CCCNC1=C2C=CC(=CC2=NC=C1)Cl.Cl.Cl
DM1USXR IK ZNHBPWZRWNFJPN-UHFFFAOYSA-N
DM1USXR IU N-(7-chloroquinolin-4-yl)-N',N'-diethylpropane-1,3-diamine;dihydrochloride
DM1USXR CA CAS 169815-40-1
DM1USXR DE Malaria
DMD2RFO ID DMD2RFO
DMD2RFO DN AQW-051
DMD2RFO HS Phase 2
DMD2RFO SN AQW-051; 669770-29-0; (R)-3-((6-(p-Tolyl)pyridin-3-yl)oxy)quinuclidine; AQW051; NPDLTEZXGWRMLQ-IBGZPJMESA-N; UNII-JQH481R778; SCHEMBL1459285; GTPL7371; SCHEMBL19522679; JQH481R778; ZINC3942685; AKOS030628482; SB17130; AS-35273; (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane
DMD2RFO CP Novartis AG
DMD2RFO DT Small molecular drug
DMD2RFO PC 50914822
DMD2RFO MW 294.4
DMD2RFO FM C19H22N2O
DMD2RFO IC InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
DMD2RFO CS CC1=CC=C(C=C1)C2=NC=C(C=C2)O[C@H]3CN4CCC3CC4
DMD2RFO IK NPDLTEZXGWRMLQ-IBGZPJMESA-N
DMD2RFO IU (3R)-3-[6-(4-methylphenyl)pyridin-3-yl]oxy-1-azabicyclo[2.2.2]octane
DMD2RFO DE Alzheimer disease
DMCH3G5 ID DMCH3G5
DMCH3G5 DN AQX-1125
DMCH3G5 HS Phase 2
DMCH3G5 SN AQX-108; AQX-131; AQX-132; AQX-133; AQX-134; AQX-135; AQX-140; AQX-150; SHIP agonists (cancer/inflammation), Aquinox
DMCH3G5 CP Aquinox Pharmaceuticals Inc
DMCH3G5 DT Small molecular drug
DMCH3G5 PC 76965484
DMCH3G5 MW 321.5
DMCH3G5 FM C20H35NO2
DMCH3G5 IC InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1
DMCH3G5 CS C[C@@]1(CC[C@@H](C[C@@H]1CO)O)[C@H]2CC[C@]3([C@H]([C@@H]2CN)CCC3=C)C
DMCH3G5 IK MDEJTPWQNNMAQF-BVMLLJBZSA-N
DMCH3G5 IU (1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-3,3a,4,5,6,7-hexahydro-2H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol
DMCH3G5 CA CAS 782487-28-9
DMCH3G5 DE Chronic obstructive pulmonary disease
DM93CTQ ID DM93CTQ
DM93CTQ DN AR08
DM93CTQ HS Phase 2
DM93CTQ CP Arbor pharmaceuticals
DM93CTQ DE Attention deficit hyperactivity disorder
DM5TC43 ID DM5TC43
DM5TC43 DN AR-12286
DM5TC43 HS Phase 2
DM5TC43 SN AR-11236; AR-12080; AR-12132; CF-286-03; CF-286-04
DM5TC43 CP Aerie Pharmaceuticals Inc
DM5TC43 PC 66906051
DM5TC43 MW 327.4
DM5TC43 FM C17H17N3O2S
DM5TC43 IC InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)
DM5TC43 CS CN(C)C(C1=CSC=C1)C(=O)NC2=CC3=C(C=C2)C(=O)NC=C3
DM5TC43 IK VDYRZXYYQMMFJW-UHFFFAOYSA-N
DM5TC43 IU 2-(dimethylamino)-N-(1-oxo-2H-isoquinolin-6-yl)-2-thiophen-3-ylacetamide
DM5TC43 CA CAS 1414854-42-4
DM5TC43 DE Glaucoma/ocular hypertension
DM8A71F ID DM8A71F
DM8A71F DN AR-67
DM8A71F HS Phase 2
DM8A71F SN AR-67; Silatecan; 220913-32-6; DB-67; UNII-3YEA04NV6H; 3YEA04NV6H; DB67; AR67; AR 67; (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; NCI60_038363; C26H30N2O5Si; SCHEMBL1266162; CHEMBL412309; GTPL8919; DTXSID00176592; DB 67; BCP19768; 7555AD; NSC708298; ZINC170020689; AKOS030627314; DB12384; NSC-708298; compound 14 [PMID:11052802]; KB-74723; Z3398; Z-3160; 1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9-dihydroxy-, (4S)-
DM8A71F CP Arno Therapeutics
DM8A71F DT Small molecular drug
DM8A71F PC 6712744
DM8A71F MW 478.6
DM8A71F FM C26H30N2O5Si
DM8A71F IC InChI=1S/C26H30N2O5Si/c1-7-26(32)18-11-20-21-16(12-28(20)23(30)17(18)13-33-24(26)31)22(34(5,6)25(2,3)4)15-10-14(29)8-9-19(15)27-21/h8-11,29,32H,7,12-13H2,1-6H3/t26-/m0/s1
DM8A71F CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=C(C=CC(=C5)O)N=C4C3=C2)[Si](C)(C)C(C)(C)C)O
DM8A71F IK XUSKJHCMMWAAHV-SANMLTNESA-N
DM8A71F IU (19S)-10-[tert-butyl(dimethyl)silyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DM8A71F CA CAS 220913-32-6
DM8A71F DE Myelodysplastic syndrome; Glioblastoma multiforme
DMJHA6Q ID DMJHA6Q
DMJHA6Q DN Ar9281
DMJHA6Q HS Phase 2
DMJHA6Q SN 1-(Adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea; UNII-4HA03Q8EZ9; 4HA03Q8EZ9; CHEMBL436774; 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea; 913548-29-5; Ar9281; AR-9281; Apau (enzyme inhibitor); SCHEMBL654229; 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; SCHEMBL18464997; MolPort-023-222-910; HUDQLWBKJOMXSZ-UHFFFAOYSA-N; BDBM100423; BDBM50191854; ZINC36330562; AKOS030231617; J3137087F; US8501783, 1153; 1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea; N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea; N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea
DMJHA6Q CP Ar te Therapeutics
DMJHA6Q DT Small molecular drug
DMJHA6Q PC 12000797
DMJHA6Q MW 319.4
DMJHA6Q FM C18H29N3O2
DMJHA6Q IC InChI=1S/C18H29N3O2/c1-12(22)21-4-2-16(3-5-21)19-17(23)20-18-9-13-6-14(10-18)8-15(7-13)11-18/h13-16H,2-11H2,1H3,(H2,19,20,23)
DMJHA6Q CS CC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMJHA6Q IK HUDQLWBKJOMXSZ-UHFFFAOYSA-N
DMJHA6Q IU 1-(1-acetylpiperidin-4-yl)-3-(1-adamantyl)urea
DMJHA6Q CA CAS 913548-29-5
DMJHA6Q DE Hypertension
DM7PCLY ID DM7PCLY
DM7PCLY DN ARC1779
DM7PCLY HS Phase 2
DM7PCLY CP Archemix
DM7PCLY DT Small molecular drug
DM7PCLY DE Intracranial embolism
DM9LNXS ID DM9LNXS
DM9LNXS DN ARI-3037MO
DM9LNXS HS Phase 2
DM9LNXS CP Arisaph Pharmaceuticals
DM9LNXS DE Dyslipidemia; Cardiovascular disease; Hypertriglyceridemia
DML3PJF ID DML3PJF
DML3PJF DN ARN-810
DML3PJF HS Phase 2
DML3PJF CP Seragon pharmaceuticals
DML3PJF PC 56941241
DML3PJF MW 446.9
DML3PJF FM C26H20ClFN2O2
DML3PJF IC InChI=1S/C26H20ClFN2O2/c1-2-21(22-10-9-20(28)14-23(22)27)26(18-8-11-24-19(13-18)15-29-30-24)17-6-3-16(4-7-17)5-12-25(31)32/h3-15H,2H2,1H3,(H,29,30)(H,31,32)/b12-5+,26-21+
DML3PJF CS CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl
DML3PJF IK BURHGPHDEVGCEZ-KJGLQBJMSA-N
DML3PJF IU (E)-3-[4-[(E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid
DML3PJF CA CAS 1365888-06-7
DML3PJF DE Breast cancer
DM2UP6Z ID DM2UP6Z
DM2UP6Z DN ARO-AAT
DM2UP6Z HS Phase 2
DM2UP6Z CP Arrowhead Pharmaceuticals
DM2UP6Z DT Small interfering RNA
DM2UP6Z DE Alpha-1 antitrypsin deficiency; Alopecia
DM5WK0J ID DM5WK0J
DM5WK0J DN ARQ 092
DM5WK0J HS Phase 2
DM5WK0J SN Miransertib
DM5WK0J CP ArQule; Daiichi
DM5WK0J PC 53262401
DM5WK0J MW 432.5
DM5WK0J FM C27H24N6
DM5WK0J IC InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)
DM5WK0J CS C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N
DM5WK0J IK HNFMVVHMKGFCMB-UHFFFAOYSA-N
DM5WK0J IU 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine
DM5WK0J CA CAS 1313881-70-7
DM5WK0J DE Solid tumour/cancer; Proteus syndrome
DMRG0A3 ID DMRG0A3
DMRG0A3 DN ARQ 531
DMRG0A3 HS Phase 2
DMRG0A3 SN JSFCZQSJQXFJDS-QAPCUYQASA-N; UNII-JTZ51LIXN4; JTZ51LIXN4; 2095393-15-8; ARQ-531; ARQ531; SCHEMBL18770934; SCHEMBL18756744; EX-A2727; BCP29029; HY-112215; CS-0044154; HRA; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol
DMRG0A3 CP ArQule Burlington, MA
DMRG0A3 PC 129045720
DMRG0A3 MW 478.9
DMRG0A3 FM C25H23ClN4O4
DMRG0A3 IC InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5,8-11,14-15,18,31H,6-7,12-13H2,(H2,27,28,29,30)/t15-,18+/m1/s1
DMRG0A3 CS C1C[C@H](OC[C@@H]1NC2=NC=NC3=C2C(=CN3)C(=O)C4=C(C=C(C=C4)OC5=CC=CC=C5)Cl)CO
DMRG0A3 IK JSFCZQSJQXFJDS-QAPCUYQASA-N
DMRG0A3 IU (2-chloro-4-phenoxyphenyl)-[4-[[(3R,6S)-6-(hydroxymethyl)oxan-3-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methanone
DMRG0A3 CA CAS 2095393-15-8
DMRG0A3 DE Hematologic tumour
DMH5CAL ID DMH5CAL
DMH5CAL DN ARQ 761
DMH5CAL HS Phase 2
DMH5CAL CP ArQule
DMH5CAL DE Solid tumour/cancer; Pancreatic cancer
DMYEIOH ID DMYEIOH
DMYEIOH DN ARQ-154
DMYEIOH HS Phase 2
DMYEIOH CP Arcutis Biotherapeutics
DMYEIOH DT Small molecular drug
DMYEIOH DE Plaque psoriasis
DM0VGDC ID DM0VGDC
DM0VGDC DN ARRY-382
DM0VGDC HS Phase 2
DM0VGDC CP Array BioPharma; Celgene
DM0VGDC DE Solid tumour/cancer
DM17469 ID DM17469
DM17469 DN ARRY-502
DM17469 HS Phase 2
DM17469 CP Array BioPharma
DM17469 PC 131633366
DM17469 MW 516.4
DM17469 FM C26H23Cl2NO6
DM17469 IC InChI=1S/C26H23Cl2NO6/c1-33-22-12-17(27)5-2-15(22)8-10-29-25(30)16-3-6-18(7-4-16)35-24-14-23-20(13-21(24)28)19(26(31)32)9-11-34-23/h2-7,12-14,19H,8-11H2,1H3,(H,29,30)(H,31,32)/t19-/m0/s1
DM17469 CS COC1=C(C=CC(=C1)Cl)CCNC(=O)C2=CC=C(C=C2)OC3=C(C=C4[C@H](CCOC4=C3)C(=O)O)Cl
DM17469 IK QIDYUNXQPQEJEC-IBGZPJMESA-N
DM17469 IU (4S)-6-chloro-7-[4-[2-(4-chloro-2-methoxyphenyl)ethylcarbamoyl]phenoxy]-3,4-dihydro-2H-chromene-4-carboxylic acid
DM17469 CA CAS 1202891-16-4
DM17469 DE Allergic asthma
DMTOI7S ID DMTOI7S
DMTOI7S DN ARRY-520
DMTOI7S HS Phase 2
DMTOI7S SN Filanesib; ARRY-520; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; ARRY-520; Filanesib; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04
DMTOI7S CP Array BioPharma.
DMTOI7S TC Anticancer Agents
DMTOI7S DT Small molecular drug
DMTOI7S PC 44224257
DMTOI7S MW 420.5
DMTOI7S FM C20H22F2N4O2S
DMTOI7S IC InChI=1S/C20H22F2N4O2S/c1-25(28-2)19(27)26-20(11-6-12-23,14-7-4-3-5-8-14)29-18(24-26)16-13-15(21)9-10-17(16)22/h3-5,7-10,13H,6,11-12,23H2,1-2H3/t20-/m0/s1
DMTOI7S CS CN(C(=O)N1[C@](SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC
DMTOI7S IK LLXISKGBWFTGEI-FQEVSTJZSA-N
DMTOI7S IU (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide
DMTOI7S CA CAS 885060-09-3
DMTOI7S DE Solid tumour/cancer; Multiple myeloma
DMJ48AB ID DMJ48AB
DMJ48AB DN ARRY-797
DMJ48AB HS Phase 2
DMJ48AB SN CHEMBL1088750; ARRY-797; SCHEMBL222635; ARRY-371797; BDBM50314072
DMJ48AB CP Array BioPharma.
DMJ48AB TC Analgesics
DMJ48AB DT Small molecular drug
DMJ48AB PC 46883775
DMJ48AB MW 416.5
DMJ48AB FM C22H26F2N4O2
DMJ48AB IC InChI=1S/C22H26F2N4O2/c1-14(2)13-28-19-11-17(22(29)25-7-8-27(3)4)21(9-15(19)12-26-28)30-20-6-5-16(23)10-18(20)24/h5-6,9-12,14H,7-8,13H2,1-4H3,(H,25,29)
DMJ48AB CS CC(C)CN1C2=CC(=C(C=C2C=N1)OC3=C(C=C(C=C3)F)F)C(=O)NCCN(C)C
DMJ48AB IK IFGWYHGYNVGVRB-UHFFFAOYSA-N
DMJ48AB IU 5-(2,4-difluorophenoxy)-N-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide
DMJ48AB DE Pain; Osteoarthritis; Dilated cardiomyopathy
DML27AE ID DML27AE
DML27AE DN Arverapamil
DML27AE HS Phase 2
DML27AE SN Arverapamil; (R)-norverapamil; Agi-003; UNII-3J8P56R04P; (R)-(+)-Nor Verapamil Hydrochloride; 123932-43-4; 3J8P56R04P; Rezular; (+)-norverapamil; (R)-desmethylverapamil; (+)-desmethylverapamil; CHEBI:134082; ZINC13492624; AKOS030532539; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, (alphaR)-; UNII-957Z3K3R56 component UPKQNCPKPOLASS-AREMUKBSSA-N
DML27AE CP AGI Therapeutics
DML27AE DT Small molecular drug
DML27AE PC 15593907
DML27AE MW 440.6
DML27AE FM C26H36N2O4
DML27AE IC InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1
DML27AE CS CC(C)[C@@](CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DML27AE IK UPKQNCPKPOLASS-AREMUKBSSA-N
DML27AE IU (2R)-2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-propan-2-ylpentanenitrile
DML27AE CA CAS 123932-43-4
DML27AE CB CHEBI:134082
DML27AE DE Irritable bowel syndrome
DMMX1EJ ID DMMX1EJ
DMMX1EJ DN AS-1402
DMMX1EJ HS Phase 2
DMMX1EJ SN Therex; R-1550; HuHMFG1 derivative, ICRF/Antisoma/Roche; Anti-mucin MAb, ICRF/Antisoma/Roche
DMMX1EJ CP Antisoma
DMMX1EJ DT Antibody
DMMX1EJ DE Breast cancer
DMTUMYX ID DMTUMYX
DMTUMYX DN AS-902330
DMTUMYX HS Phase 2
DMTUMYX SN Sprifermin; Zfgf5; FGF-18, Merck Serono; FGF-18, ZymoGenetics
DMTUMYX CP Emd serono
DMTUMYX DE Arthropathy
DMNVU28 ID DMNVU28
DMNVU28 DN ASB17061
DMNVU28 HS Phase 2
DMNVU28 CP Daiichi Sankyo
DMNVU28 DE Atopic dermatitis
DMMBVCJ ID DMMBVCJ
DMMBVCJ DN ASCJ-9
DMMBVCJ HS Phase 2
DMMBVCJ SN Dimethylcurcumin; ASC-JMX1; ASCJ-9; ASCJ-9 (systemic), AndroScience; ASCJ-9 (topical), AndroScience; Androgen antagonist (alopecia/acne), AndroScience; Androgen receptor degradation enhancers (oral, spinal bulbar muscular atrophy), AndroScience
DMMBVCJ CP AndroScience
DMMBVCJ DE Alopecia; Acne vulgaris
DMDQS4W ID DMDQS4W
DMDQS4W DN ASC-J9
DMDQS4W HS Phase 2
DMDQS4W SN Dimethylcurcumin; 52328-98-0; 917813-54-8; ASCJ-9; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; GO-Y-025; (1E,4E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; Dimethylcurcumin (ASC-J9); 1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one; SCHEMBL3487103; CHC-004; DTXSID10200352; EX-A927; AMY15692; 3454AH; MFCD12912341; MFCD22123809; NSC734923; RSC004738; s6630; AKOS015891371; AKOS025311328; ZINC100007120; CS-0533; DB06133; LS40141; NSC-734923; SB18767; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (1E,4Z,6E)--; 1,4,6-Heptatrien-3-one, 1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-, (Z,E,E)-; AC-31058; DS-14720; HY-15194; ASC-J9,CAS:52328-98-0; W9512; J3.606.945G; A11300; W-5544; GO-Y025; Dimethylcurcumin; ASC J9; GO Y025; 1, 4-dimethoxyphenyl)-1, 6-heptadiene-3,5-dione; (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; 1,7-Bis-(3,4-dimethoxy-phenyl)- 5-hydroxy-hepta-1,4,6-trien-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one; (1E,4Z,6E)-1,7-Bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-hepta-1,4,6-trien-3-one; 115851-85-9
DMDQS4W CP AndroScience
DMDQS4W DT Small molecular drug
DMDQS4W PC 6477182
DMDQS4W MW 396.4
DMDQS4W FM C23H24O6
DMDQS4W IC InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-
DMDQS4W CS COC1=C(C=C(C=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)/O)OC
DMDQS4W IK ZMGUKFHHNQMKJI-CIOHCNBKSA-N
DMDQS4W IU (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
DMDQS4W CA CAS 52328-98-0
DMDQS4W DE Thrombosis; End-stage renal disease
DMZF68E ID DMZF68E
DMZF68E DN Ascrolimus
DMZF68E HS Phase 2
DMZF68E SN A-86281; ABT-281; ZK-248258
DMZF68E CP Abbott Laboratories
DMZF68E PC 9919023
DMZF68E MW 844
DMZF68E FM C44H69N5O11
DMZF68E IC InChI=1S/C44H69N5O11/c1-10-31-18-25(2)17-26(3)19-37(57-8)40-38(58-9)21-28(5)44(55,60-40)41(52)42(53)48-16-12-11-13-33(48)43(54)59-39(29(6)34(50)23-35(31)51)27(4)20-30-14-15-32(36(22-30)56-7)49-24-45-46-47-49/h18,20,24,26,28-34,36-40,50,55H,10-17,19,21-23H2,1-9H3/b25-18+,27-20+/t26-,28+,29+,30-,31+,32-,33-,34-,36+,37-,38-,39+,40+,44+/m0/s1
DMZF68E CS CC[C@@H]1/C=C(/C[C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)/C)O)C)OC)OC)C)\\C
DMZF68E IK HIEKJRVYXXINKH-ADVKXBNGSA-N
DMZF68E IU (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-12-[(E)-1-[(1R,3R,4S)-3-methoxy-4-(tetrazol-1-yl)cyclohexyl]prop-1-en-2-yl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMZF68E CA CAS 148147-65-3
DMZF68E DE Psoriasis vulgaris
DM1CLKO ID DM1CLKO
DM1CLKO DN ASKP-1240
DM1CLKO HS Phase 2
DM1CLKO SN Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kirin/Astellas; Anti-CD40 mAb (organ transplant rejection/autoimmune disease), Kyowa Hakko Kirin/Astellas; 4D11
DM1CLKO CP Astellas pharma us; kyowa hakko kirin pharma
DM1CLKO DT Antibody
DM1CLKO DE Transplant rejection
DM35S2I ID DM35S2I
DM35S2I DN ASM-024
DM35S2I HS Phase 2
DM35S2I CP Asmacure Lt |e
DM35S2I PC 117587641
DM35S2I MW 404.6
DM35S2I FM C22H32N2O3S
DM35S2I IC InChI=1S/C15H25N2.C7H8O3S/c1-3-17(4-2)13-8-11-16(12-14-17)15-9-6-5-7-10-15;1-6-2-4-7(5-3-6)11(8,9)10/h5-7,9-10H,3-4,8,11-14H2,1-2H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1
DM35S2I CS CC[N+]1(CCCN(CC1)C2=CC=CC=C2)CC.CC1=CC=C(C=C1)S(=O)(=O)[O-]
DM35S2I IK PXRYYARWCNIUKT-UHFFFAOYSA-M
DM35S2I IU 1,1-diethyl-4-phenyl-1,4-diazepan-1-ium;4-methylbenzenesulfonate
DM35S2I CA CAS 1609534-90-8
DM35S2I DE Asthma
DMTHR4U ID DMTHR4U
DMTHR4U DN ASM8
DMTHR4U HS Phase 2
DMTHR4U CP Pharmaxis
DMTHR4U DT Antisense drug
DMTHR4U DE Allergic asthma
DM92X7N ID DM92X7N
DM92X7N DN ASN002
DM92X7N HS Phase 2
DM92X7N SN POAZPIKWEFFCBP-UHFFFAOYSA-N; GTPL10000; 2-[1-(4-{[4-(4-hydroxypiperazin-1-yl)phenyl]amino}-5-oxo-5H,6H-pyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl]acetonitrile
DM92X7N CP Asana BioSciences Lawrenceville, NJ
DM92X7N PC 71269142
DM92X7N MW 460.5
DM92X7N FM C24H28N8O2
DM92X7N IC InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29)
DM92X7N CS C1CN(CCC1CC#N)C2=NC3=C(C(=O)NN=C3)C(=N2)NC4=CC=C(C=C4)N5CCC(CC5)O
DM92X7N IK NLFLXLJXEIUQDL-UHFFFAOYSA-N
DM92X7N IU 2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6H-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile
DM92X7N CA CAS 1425381-60-7
DM92X7N DE Eczema; Lymphoma; Solid tumour/cancer
DMWPGLS ID DMWPGLS
DMWPGLS DN ASN100
DMWPGLS HS Phase 2
DMWPGLS CP Arsanis
DMWPGLS DT Monoclonal antibody
DMWPGLS DE Ventilator-associated pneumonia; Hospital-acquired pneumonia
DM6HJ3V ID DM6HJ3V
DM6HJ3V DN ASP0819
DM6HJ3V HS Phase 2
DM6HJ3V CP Astellas Pharma
DM6HJ3V DT Small molecular drug
DM6HJ3V DE Fibromyalgia
DME8XD7 ID DME8XD7
DME8XD7 DN ASP-1707
DME8XD7 HS Phase 2
DME8XD7 CP Astellas Pharma Inc
DME8XD7 DE Endometriosis
DMBADQV ID DMBADQV
DMBADQV DN ASP-3291
DMBADQV HS Phase 2
DMBADQV CP Astellas Pharma Inc
DMBADQV DE Ulcerative colitis
DM4KTN6 ID DM4KTN6
DM4KTN6 DN ASP-3652
DM4KTN6 HS Phase 2
DM4KTN6 SN FK-175; Beta 3 adrenoceptor agonists (overactive bladder), Astellas
DM4KTN6 CP Astellas Pharma Inc
DM4KTN6 DE Overactive bladder
DMZUAH2 ID DMZUAH2
DMZUAH2 DN ASP-4901
DMZUAH2 HS Phase 2
DMZUAH2 CP Astellas Pharma
DMZUAH2 DE Genitourinary disease
DMTF24A ID DMTF24A
DMTF24A DN ASP-7035
DMTF24A HS Phase 2
DMTF24A CP Astellas Pharma Inc
DMTF24A PC 11478371
DMTF24A MW 548.4
DMTF24A FM C25H23F7N2O4
DMTF24A IC InChI=1S/C25H23F7N2O4/c1-14(26)13-38-16-3-4-17(20(11-16)25(30,31)32)23(37)34-8-6-24(28,29)19(12-22(36)33-7-9-35)18-10-15(27)2-5-21(18)34/h2-5,10-12,14,35H,6-9,13H2,1H3,(H,33,36)/b19-12-/t14-/m1/s1
DMTF24A CS C[C@H](COC1=CC(=C(C=C1)C(=O)N2CCC(/C(=C\\C(=O)NCCO)/C3=C2C=CC(=C3)F)(F)F)C(F)(F)F)F
DMTF24A IK VSXSHTIGQAUGMW-VCRXTVNUSA-N
DMTF24A IU (2Z)-N-(2-hydroxyethyl)-2-[4,4,7-trifluoro-1-[4-[(2R)-2-fluoropropoxy]-2-(trifluoromethyl)benzoyl]-2,3-dihydro-1-benzazepin-5-ylidene]acetamide
DMTF24A CA CAS 790694-26-7
DMTF24A DE Nocturia
DMGDF2X ID DMGDF2X
DMGDF2X DN ASP-7147
DMGDF2X HS Phase 2
DMGDF2X CP Astellas Pharma Inc
DMGDF2X DE Irritable bowel syndrome
DM3TN1A ID DM3TN1A
DM3TN1A DN ASP7991
DM3TN1A HS Phase 2
DM3TN1A CP Astellas
DM3TN1A DE Hyperparathyroidism
DMR1MIV ID DMR1MIV
DMR1MIV DN ASP8062
DMR1MIV HS Phase 2
DMR1MIV CP Astellas Northbrook, IL
DMR1MIV DE Fibromyalgia
DMYK1JU ID DMYK1JU
DMYK1JU DN ASP8232
DMYK1JU HS Phase 2
DMYK1JU CP Astellas
DMYK1JU DE Diabetic nephropathy; Diabetic macular edema
DMHLXUY ID DMHLXUY
DMHLXUY DN ASP8273
DMHLXUY HS Phase 2
DMHLXUY CP Astellas pharma us
DMHLXUY PC 71667668
DMHLXUY MW 562.7
DMHLXUY FM C30H42N8O3
DMHLXUY IC InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1
DMHLXUY CS CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
DMHLXUY IK QKDCLUARMDUUKN-XMMPIXPASA-N
DMHLXUY IU 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide
DMHLXUY CA CAS 1448232-80-1
DMHLXUY DE Non-small-cell lung cancer
DMBZQS7 ID DMBZQS7
DMBZQS7 DN ASP-8477
DMBZQS7 HS Phase 2
DMBZQS7 CP Astellas Pharma Inc
DMBZQS7 DE Neuropathic pain
DM2MSGF ID DM2MSGF
DM2MSGF DN ASP9831
DM2MSGF HS Phase 2
DM2MSGF CP Astellas
DM2MSGF DT Small molecular drug
DM2MSGF DE Steatohepatitis; Non-alcoholic steatohepatitis
DMMKW8L ID DMMKW8L
DMMKW8L DN ASTX660
DMMKW8L HS Phase 2
DMMKW8L SN YCXOHEXZVKOGEV-DNRQZRRGSA-N; 1799328-86-1; SCHEMBL16830758; CS-8216; HY-109565; 1-(6-(4-fluorobenzyl)-5-(hydroxymethyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-2-((2R,5R)-5-methyl-2-(((R)-3-methylmorpholino)methyl)piperazin-1-yl)ethan-1-one
DMMKW8L CP Astex Pharmaceuticals Pleasanton, CA
DMMKW8L PC 118169620
DMMKW8L MW 539.7
DMMKW8L FM C30H42FN5O3
DMMKW8L IC InChI=1S/C30H42FN5O3/c1-20-14-35(25(13-32-20)15-34-9-10-39-18-21(34)2)16-28(38)36-19-30(3,4)29-27(36)12-23(26(17-37)33-29)11-22-5-7-24(31)8-6-22/h5-8,12,20-21,25,32,37H,9-11,13-19H2,1-4H3/t20-,21-,25-/m1/s1
DMMKW8L CS C[C@@H]1CN([C@H](CN1)CN2CCOC[C@H]2C)CC(=O)N3CC(C4=C3C=C(C(=N4)CO)CC5=CC=C(C=C5)F)(C)C
DMMKW8L IK YCXOHEXZVKOGEV-DNRQZRRGSA-N
DMMKW8L IU 1-[6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-2H-pyrrolo[3,2-b]pyridin-1-yl]-2-[(2R,5R)-5-methyl-2-[[(3R)-3-methylmorpholin-4-yl]methyl]piperazin-1-yl]ethanone
DMMKW8L CA CAS 1799328-86-1
DMMKW8L DE Solid tumour/cancer; Lymphoma
DMARIQK ID DMARIQK
DMARIQK DN AT-527
DMARIQK HS Phase 2
DMARIQK SN AT527; SCHEMBL18061556; GTPL11295; 2241337-84-6; propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMARIQK CP Atea Pharmaceuticals
DMARIQK DT Small molecular drug
DMARIQK PC 122527270
DMARIQK MW 581.5
DMARIQK FM C24H33FN7O7P
DMARIQK IC InChI=1S/C24H33FN7O7P/c1-13(2)37-21(34)14(3)31-40(35,39-15-9-7-6-8-10-15)36-11-16-18(33)24(4,25)22(38-16)32-12-28-17-19(27-5)29-23(26)30-20(17)32/h6-10,12-14,16,18,22,33H,11H2,1-5H3,(H,31,35)(H3,26,27,29,30)/t14-,16?,18+,22+,24+,40-/m0/s1
DMARIQK CS C[C@@H](C(=O)OC(C)C)N[P@](=O)(OCC1[C@H]([C@@]([C@@H](O1)N2C=NC3=C(N=C(N=C32)N)NC)(C)F)O)OC4=CC=CC=C4
DMARIQK IK OISLSHLAXHALQZ-ZXWZJMKMSA-N
DMARIQK IU propan-2-yl (2S)-2-[[[(3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DMARIQK DE Coronavirus Disease 2019 (COVID-19)
DM35KDA ID DM35KDA
DM35KDA DN Ataciguat
DM35KDA HS Phase 2
DM35KDA SN Ataciguat [INN]; HMR 1766; HMR-1766; 5-Chloro-2-((5-chloro-2-thienyl)sulfonylamino)-N-(4-(morpholin-4-ylsulfonyl)phenyl)benzamide; 5-Chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide; 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM35KDA CP Sanofi-Aventis
DM35KDA TC Analgesics
DM35KDA DT Small molecular drug
DM35KDA PC 213037
DM35KDA MW 576.5
DM35KDA FM C21H19Cl2N3O6S3
DM35KDA IC InChI=1S/C21H19Cl2N3O6S3/c22-14-1-6-18(25-34(28,29)20-8-7-19(23)33-20)17(13-14)21(27)24-15-2-4-16(5-3-15)35(30,31)26-9-11-32-12-10-26/h1-8,13,25H,9-12H2,(H,24,27)
DM35KDA CS C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl
DM35KDA IK PQHLRGARXNPFCF-UHFFFAOYSA-N
DM35KDA IU 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM35KDA CA CAS 254877-67-3
DM35KDA DE Neuropathic pain
DM6ABD9 ID DM6ABD9
DM6ABD9 DN ATHX-105
DM6ABD9 HS Phase 2
DM6ABD9 SN ATH-88651; 5-HT2c receptor agonists (obesity), Athersys Inc
DM6ABD9 CP Athersys
DM6ABD9 DE Obesity
DMWP59B ID DMWP59B
DMWP59B DN ATI-2042
DMWP59B HS Phase 2
DMWP59B SN Budiodarone
DMWP59B CP ARYx Therapeutics
DMWP59B DT Small molecular drug
DMWP59B PC 9833332
DMWP59B MW 703.3
DMWP59B FM C27H31I2NO5
DMWP59B IC InChI=1S/C27H31I2NO5/c1-5-17(4)34-24(31)16-23-25(19-10-8-9-11-22(19)35-23)26(32)18-14-20(28)27(21(29)15-18)33-13-12-30(6-2)7-3/h8-11,14-15,17H,5-7,12-13,16H2,1-4H3/t17-/m0/s1
DMWP59B CS CC[C@H](C)OC(=O)CC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
DMWP59B IK ZXOSVKYCXLTVGS-KRWDZBQOSA-N
DMWP59B IU [(2S)-butan-2-yl] 2-[3-[4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl]-1-benzofuran-2-yl]acetate
DMWP59B CA CAS 335148-45-3
DMWP59B DE Atrial fibrillation
DMT5QYJ ID DMT5QYJ
DMT5QYJ DN ATI-2173
DMT5QYJ HS Phase 2
DMT5QYJ CP Antios Therapeutics
DMT5QYJ DT Small molecular drug
DMT5QYJ DE Hepatitis B
DMTY6OF ID DMTY6OF
DMTY6OF DN ATI-501
DMTY6OF HS Phase 2
DMTY6OF CP Aclaris Therapeutics
DMTY6OF DT Small molecular drug
DMTY6OF DE Alopecia
DM8NODR ID DM8NODR
DM8NODR DN ATI-502
DM8NODR HS Phase 2
DM8NODR SN ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one
DM8NODR CP Aclaris Therapeutics
DM8NODR DT Small molecular drug
DM8NODR PC 46851625
DM8NODR MW 395.4
DM8NODR FM C20H18FN5O3
DM8NODR IC InChI=1S/C20H18FN5O3/c1-10-6-13(8-16(28-3)17(10)21)24-19-22-9-11(2)18(26-19)23-12-4-5-15-14(7-12)25-20(27)29-15/h4-9H,1-3H3,(H,25,27)(H2,22,23,24,26)
DM8NODR CS CC1=CC(=CC(=C1F)OC)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(=O)N4)C
DM8NODR IK OYFMQDVLFYKOPZ-UHFFFAOYSA-N
DM8NODR IU 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one
DM8NODR CA CAS 1236667-40-5
DM8NODR DE Atopic dermatitis; Alopecia
DMK3VYU ID DMK3VYU
DMK3VYU DN ATI-502
DMK3VYU HS Phase 2
DMK3VYU CP Aclaris Therapeutics Wayne, PA
DMK3VYU DE Atopic dermatitis; Vitiligo
DMYAQV2 ID DMYAQV2
DMYAQV2 DN ATL101
DMYAQV2 HS Phase 2
DMYAQV2 CP Atlab pharma; weill medical college
DMYAQV2 DE Influenza virus infection
DMD0I29 ID DMD0I29
DMD0I29 DN ATL-104
DMD0I29 HS Phase 2
DMD0I29 DE Solid tumour/cancer
DM3POT6 ID DM3POT6
DM3POT6 DN ATL1102
DM3POT6 HS Phase 2
DM3POT6 CP ISIS Pharm; Antisense Therapeutics
DM3POT6 DE Multiple sclerosis
DM7I56B ID DM7I56B
DM7I56B DN ATM AVI
DM7I56B HS Phase 2
DM7I56B CP AstraZeneca
DM7I56B DE Bacterial infection
DM4T9RS ID DM4T9RS
DM4T9RS DN ATN-161
DM4T9RS HS Phase 2
DM4T9RS SN PHSCN; PHSCN, University of Michigan; Angiogenesis inhibitors (cancer), Attenuon; Integrin antagonists (cancer), Attenuon; Ac-PHSCN-NH2, University of Michigan
DM4T9RS CP University of Michigan
DM4T9RS DT Small molecular drug
DM4T9RS PC 9960285
DM4T9RS MW 597.6
DM4T9RS FM C23H35N9O8S
DM4T9RS IC InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1
DM4T9RS CS CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N
DM4T9RS IK MMHDBUJXLOFTLC-WOYTXXSLSA-N
DM4T9RS IU (2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]butanediamide
DM4T9RS CA CAS 262438-43-7
DM4T9RS DE Renal cell carcinoma
DMQJ5DV ID DMQJ5DV
DMQJ5DV DN ATN-224
DMQJ5DV HS Phase 2
DMQJ5DV SN Angiogenesis inhibitor, Attenuon; Superoxide dismutase 1 inhibitor, Attenuon
DMQJ5DV CP University of Michigan
DMQJ5DV DT Small molecular drug
DMQJ5DV PC 18442052
DMQJ5DV MW 434.6
DMQJ5DV FM C10H30MoN2O2S4
DMQJ5DV IC InChI=1S/2C5H14NO.Mo.2H2S.2S/c2*1-6(2,3)4-5-7;;;;;/h2*7H,4-5H2,1-3H3;;2*1H2;;/q2*+1;;;;;/p-2
DMQJ5DV CS C[N+](C)(C)CCO.C[N+](C)(C)CCO.[SH-].[SH-].S=[Mo]=S
DMQJ5DV IK FSWNJZRQQVVVJT-UHFFFAOYSA-L
DMQJ5DV IU bis(sulfanylidene)molybdenum;2-hydroxyethyl(trimethyl)azanium;sulfanide
DMQJ5DV CA CAS 649749-10-0
DMQJ5DV DE Solid tumour/cancer
DMUXO3Z ID DMUXO3Z
DMUXO3Z DN AUS-131
DMUXO3Z HS Phase 2
DMUXO3Z SN AUS-131; S-Equol; (-)-(S)-Equol; (-)-Equol; (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol; (3S)-3-(4-hydroxyphenyl)chroman-7-ol; (S)-(-)-4',7-Isoflavandiol; (S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; (S)-3-(4-Hydroxyphenyl)chroman-7-ol; (S)-Equol; 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3S)-; 2T6D2HPX7Q; 4',7-Dihydroxyisoflavan; 4',7-Isoflavandiol; 531-95-3; 7,4'-dihydroxyisoflavan; CCRIS 9222; CHEBI:34741; CHEMBL198877; EINECS 208-522-2; Equol; UNII-2T6D2HPX7Q
DMUXO3Z PC 91469
DMUXO3Z MW 242.27
DMUXO3Z FM C15H14O3
DMUXO3Z IC ADFCQWZHKCXPAJ-GFCCVEGCSA-N
DMUXO3Z IU (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMUXO3Z DE Prostatic hyperplasia
DMZMSQJ ID DMZMSQJ
DMZMSQJ DN AUS-131
DMZMSQJ HS Phase 2
DMZMSQJ CP Ausio Pharmaceuticals
DMZMSQJ PC 91469
DMZMSQJ MW 242.27
DMZMSQJ FM C15H14O3
DMZMSQJ IC InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
DMZMSQJ CS C1[C@H](COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O
DMZMSQJ IK ADFCQWZHKCXPAJ-GFCCVEGCSA-N
DMZMSQJ IU (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
DMZMSQJ CA CAS 531-95-3
DMZMSQJ CB CHEBI:34741
DMZMSQJ DE Hot flushes; Alzheimer disease
DMN7VK1 ID DMN7VK1
DMN7VK1 DN AV-101
DMN7VK1 HS Phase 2
DMN7VK1 SN Anti-epileptic, VistaGen; L-4-chlorokynurenine; NMDA receptor antagonists, University of Maryland/VistaGen; 4-Cl-kynurenine, NIH/VistaGen; 7-Chlorokynurenic acid; 7-Cl-KYN; 7-Cl-KYNA, NIH
DMN7VK1 CP Vistagen therapeutics
DMN7VK1 PC 9859632
DMN7VK1 MW 242.66
DMN7VK1 FM C10H11ClN2O3
DMN7VK1 IC InChI=1S/C10H11ClN2O3/c11-5-1-2-6(7(12)3-5)9(14)4-8(13)10(15)16/h1-3,8H,4,12-13H2,(H,15,16)/t8-/m0/s1
DMN7VK1 CS C1=CC(=C(C=C1Cl)N)C(=O)C[C@@H](C(=O)O)N
DMN7VK1 IK HQLHZNDJQSRKDT-QMMMGPOBSA-N
DMN7VK1 IU (2S)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid
DMN7VK1 CA CAS 153152-32-0
DMN7VK1 DE Neuropathic pain; Major depressive disorder
DMDL9WU ID DMDL9WU
DMDL9WU DN AV-201
DMDL9WU HS Phase 2
DMDL9WU SN AAV (amino acid decarboxylase), Avigen; AAV (tyrosine hydroxylase), Avigen; AAV gene therapy (Parkinsons), Avigen; AAV vector (AADC), Avigen; AAV vector (TH), Avigen; AAV-hAADC-2; Gene therapy (PD), Avigen; Gene therapy (Parkinsons disease), Avigen; Gene therapy (L-aromatic amino acid decarboxylase), Avigen
DMDL9WU CP Avigen Inc
DMDL9WU DE Parkinson disease
DMASRP3 ID DMASRP3
DMASRP3 DN AVA-101
DMASRP3 HS Phase 2
DMASRP3 CP Avalanche biotechnologies
DMASRP3 DE Age-related macular degeneration
DMORJD4 ID DMORJD4
DMORJD4 DN AVB-500
DMORJD4 HS Phase 2
DMORJD4 CP Aravive
DMORJD4 DT Protein
DMORJD4 DE IgA nephropathy
DMLAOHX ID DMLAOHX
DMLAOHX DN Avdoralimab
DMLAOHX HS Phase 2
DMLAOHX SN IPH5401
DMLAOHX TC Antiviral Agents
DMLAOHX DT Monoclonal antibody
DMLAOHX DE Coronavirus Disease 2019 (COVID-19)
DMESMHU ID DMESMHU
DMESMHU DN AVE-0657
DMESMHU HS Phase 2
DMESMHU SN IDDBCP219683
DMESMHU CP Sanofi
DMESMHU DE Cheyne-stokes respiration
DMA42BV ID DMA42BV
DMA42BV DN AVE-2268
DMA42BV HS Phase 2
DMA42BV CP Aventis SA
DMA42BV DE Diabetic complication
DMQGI73 ID DMQGI73
DMQGI73 DN AVI-4557
DMQGI73 HS Phase 2
DMQGI73 CP AVI BioPharma
DMQGI73 DT Antisense drug
DMQGI73 DE Anxiety disorder
DMUOYQR ID DMUOYQR
DMUOYQR DN AVI-5126
DMUOYQR HS Phase 2
DMUOYQR SN Resten-CP; NeuGene (CABG), AVI
DMUOYQR CP AVI BioPharma
DMUOYQR DT Antisense drug
DMUOYQR DE Coronary artery disease
DMJFLBC ID DMJFLBC
DMJFLBC DN AVN 101
DMJFLBC HS Phase 2
DMJFLBC CP Avineuro Pharmaceuticals
DMJFLBC DE Anxiety disorder; Alzheimer disease; Cognitive impairment
DMK2LGM ID DMK2LGM
DMK2LGM DN AVN 322
DMK2LGM HS Phase 2
DMK2LGM CP Avineuro Pharmaceuticals
DMK2LGM DE Alzheimer disease; Cognitive impairment
DMOGFNI ID DMOGFNI
DMOGFNI DN AVN-101
DMOGFNI HS Phase 2
DMOGFNI SN 1061354-48-0; UNII-XML910S5X8; XML910S5X8; 2,8-Dimethyl-5-phenethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride; AVN-101 hydrochloride; AVN-101 HCl; SB18759; 1H-Pyrido(4,3-b)indole, 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-phenylethyl)-, hydrochloride (1:1)
DMOGFNI CP Avineuro
DMOGFNI DT Small molecular drug
DMOGFNI PC 126843189
DMOGFNI MW 340.9
DMOGFNI FM C21H25ClN2
DMOGFNI IC InChI=1S/C21H24N2.ClH/c1-16-8-9-20-18(14-16)19-15-22(2)12-11-21(19)23(20)13-10-17-6-4-3-5-7-17;/h3-9,14H,10-13,15H2,1-2H3;1H
DMOGFNI CS CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4.Cl
DMOGFNI IK RKLJJDFIWWRTEJ-UHFFFAOYSA-N
DMOGFNI IU 2,8-dimethyl-5-(2-phenylethyl)-3,4-dihydro-1H-pyrido[4,3-b]indole;hydrochloride
DMOGFNI CA CAS 1061354-48-0
DMOGFNI DE Cognitive impairment
DMVADGZ ID DMVADGZ
DMVADGZ DN AWD-12-281
DMVADGZ HS Phase 2
DMVADGZ SN GW-842470; AWD-12-343; AWD-12-281 (COPD), elbion/GlaxoSmithKline; AWD-12-281 (allergic rhinitis), elbion/GlaxoSmithKline; AWD-12-281 (asthma), elbion/GlaxoSmithKline; AWD-12-281 (inhaled), elbion/GlaxoSmithKline; AWD-12-281 (intranasal), elbion/GlaxoSmithKline; 842470
DMVADGZ CP ASTA Medica AG
DMVADGZ DT Small molecular drug
DMVADGZ PC 6918428
DMVADGZ MW 458.3
DMVADGZ FM C22H14Cl2FN3O3
DMVADGZ IC InChI=1S/C22H14Cl2FN3O3/c23-17-8-26-9-18(24)20(17)27-22(31)21(30)16-11-28(10-12-1-3-13(25)4-2-12)19-6-5-14(29)7-15(16)19/h1-9,11,29H,10H2,(H,26,27,31)
DMVADGZ CS C1=CC(=CC=C1CN2C=C(C3=C2C=CC(=C3)O)C(=O)C(=O)NC4=C(C=NC=C4Cl)Cl)F
DMVADGZ IK DPHDSIQHVGSITN-UHFFFAOYSA-N
DMVADGZ IU N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide
DMVADGZ CA CAS 257892-33-4
DMVADGZ DE Rhinitis
DMTAEMB ID DMTAEMB
DMTAEMB DN AX-200
DMTAEMB HS Phase 2
DMTAEMB SN Filgrastim (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (stroke, ALS), Sygnis; Granulocyte colony stimulating factor (intravenous, peripheral arterial occlusive disease/spinal cord injury/stroke/Parkinsons disease), Axaron; G-CSF (protein recombinant/iv, stroke/ALS/PAO/PD/SCI), Sygnis
DMTAEMB CP SYGNIS Bioscience GmbH & Co KG
DMTAEMB DE Cardiovascular disease
DMTQ1Y3 ID DMTQ1Y3
DMTQ1Y3 DN AXL-1717
DMTQ1Y3 HS Phase 2
DMTQ1Y3 SN BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum
DMTQ1Y3 CP Axelar AB
DMTQ1Y3 DT Small molecular drug
DMTQ1Y3 PC 72435
DMTQ1Y3 MW 414.4
DMTQ1Y3 FM C22H22O8
DMTQ1Y3 IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1
DMTQ1Y3 CS COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
DMTQ1Y3 IK YJGVMLPVUAXIQN-HAEOHBJNSA-N
DMTQ1Y3 IU (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMTQ1Y3 CA CAS 477-47-4
DMTQ1Y3 CB CHEBI:75251
DMTQ1Y3 DE Solid tumour/cancer
DM4CJNE ID DM4CJNE
DM4CJNE DN AYX-1
DM4CJNE HS Phase 2
DM4CJNE DE Pain
DMHFUJT ID DMHFUJT
DMHFUJT DN AZ-01, PEGylated interferon-beta
DMHFUJT HS Phase 2
DMHFUJT SN PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne; AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis); AZ-01, PEGylated interferon-beta (long-acting, multiple sclerosis), Allozyne
DMHFUJT CP Allozyne Inc
DMHFUJT DE Multiple sclerosis
DM9LKYP ID DM9LKYP
DM9LKYP DN AZ-40140
DM9LKYP HS Phase 2
DM9LKYP CP Asahi Kasei
DM9LKYP DE Type-2 diabetes; Obesity
DMM0N1F ID DMM0N1F
DMM0N1F DN AZD-0865
DMM0N1F HS Phase 2
DMM0N1F SN AR-H044277
DMM0N1F CP AstraZeneca plc
DMM0N1F DT Small molecular drug
DMM0N1F PC 9951066
DMM0N1F MW 366.5
DMM0N1F FM C21H26N4O2
DMM0N1F IC InChI=1S/C21H26N4O2/c1-13-6-5-7-14(2)18(13)11-23-19-10-17(21(27)22-8-9-26)12-25-16(4)15(3)24-20(19)25/h5-7,10,12,23,26H,8-9,11H2,1-4H3,(H,22,27)
DMM0N1F CS CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)NCCO
DMM0N1F IK GHVIMBCFLRTFHI-UHFFFAOYSA-N
DMM0N1F IU 8-[(2,6-dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
DMM0N1F CA CAS 248919-64-4
DMM0N1F DE Gastrointestinal disease
DM7B1AR ID DM7B1AR
DM7B1AR DN AZD-1446
DM7B1AR HS Phase 2
DM7B1AR SN TC-6683; Alpha-4 beta-2 neuronal nicotinic receptor modulator (oral, cognitive disorder), Targacept/AstraZeneca
DM7B1AR CP Targacept Inc
DM7B1AR DT Small molecular drug
DM7B1AR PC 96568204
DM7B1AR MW 240.68
DM7B1AR FM C11H13ClN2O2
DM7B1AR IC InChI=1S/C11H13ClN2O2/c12-10-2-1-9(16-10)11(15)14-5-7-3-13-4-8(7)6-14/h1-2,7-8,13H,3-6H2/t7-,8+
DM7B1AR CS C1[C@@H]2CN(C[C@@H]2CN1)C(=O)C3=CC=C(O3)Cl
DM7B1AR IK GTUIQNHJSXQMKW-OCAPTIKFSA-N
DM7B1AR IU [(3aS,6aR)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl]-(5-chlorofuran-2-yl)methanone
DM7B1AR CA CAS 1025007-04-8
DM7B1AR DE Alzheimer disease
DMLK59M ID DMLK59M
DMLK59M DN AZD1480
DMLK59M HS Phase 2
DMLK59M SN RET inhibitors
DMLK59M CP AstraZeneca
DMLK59M DT Small molecular drug
DMLK59M PC 16659841
DMLK59M MW 348.76
DMLK59M FM C14H14ClFN8
DMLK59M IC InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1
DMLK59M CS CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F
DMLK59M IK PDOQBOJDRPLBQU-QMMMGPOBSA-N
DMLK59M IU 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
DMLK59M CA CAS 935666-88-9
DMLK59M DE Myeloproliferative syndrome
DMUE90I ID DMUE90I
DMUE90I DN AZD1656
DMUE90I HS Phase 2
DMUE90I SN AZD1656; AZD-1656; FJEJHJINOKKDCW-INIZCTEOSA-N; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide; SCHEMBL321593; GTPL7701; UNII-660M185X4D; CHEMBL3219124; AZD 1656; 660M185X4D; 89961-EP2305674A1; 89961-EP2301929A1; 89961-EP2301935A1; 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methylpyrazin-2-yl)benzamide
DMUE90I CP AstraZeneca
DMUE90I DT Small molecular drug
DMUE90I PC 16039797
DMUE90I MW 478.5
DMUE90I FM C24H26N6O5
DMUE90I IC InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
DMUE90I CS CC1=CN=C(C=N1)NC(=O)C2=CC(=CC(=C2)O[C@@H](C)COC)OC3=NC=C(N=C3)C(=O)N4CCC4
DMUE90I IK FJEJHJINOKKDCW-INIZCTEOSA-N
DMUE90I IU 3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide
DMUE90I CA CAS 919783-22-5
DMUE90I DE Diabetic complication
DMX5SG7 ID DMX5SG7
DMX5SG7 DN AZD1772//RDX5791
DMX5SG7 HS Phase 2
DMX5SG7 CP Ardelyx; astrazeneca
DMX5SG7 DE Chronic kidney disease
DMMCL9F ID DMMCL9F
DMMCL9F DN AZD1981
DMMCL9F HS Phase 2
DMMCL9F SN AZD1981; 802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603
DMMCL9F DT Small molecular drug
DMMCL9F PC 11292191
DMMCL9F MW 388.9
DMMCL9F FM C19H17ClN2O3S
DMMCL9F IC InChI=1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)
DMMCL9F CS CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl
DMMCL9F IK JWYIGNODXSRKGP-UHFFFAOYSA-N
DMMCL9F IU 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid
DMMCL9F CA CAS 802904-66-1
DMMCL9F DE Chronic obstructive pulmonary disease
DMOEARH ID DMOEARH
DMOEARH DN Azd2014
DMOEARH HS Phase 2
DMOEARH SN AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)
DMOEARH CP AstraZeneca
DMOEARH DT Small molecular drug
DMOEARH PC 25262792
DMOEARH MW 462.5
DMOEARH FM C25H30N6O3
DMOEARH IC InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1
DMOEARH CS C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOC[C@@H]5C
DMOEARH IK JUSFANSTBFGBAF-IRXDYDNUSA-N
DMOEARH IU 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide
DMOEARH CA CAS 1009298-59-2
DMOEARH DE Solid tumour/cancer
DMGQSVX ID DMGQSVX
DMGQSVX DN AZD-2115
DMGQSVX HS Phase 2
DMGQSVX SN Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca
DMGQSVX CP AstraZeneca
DMGQSVX DE Chronic obstructive pulmonary disease
DM8FZOG ID DM8FZOG
DM8FZOG DN AZD-2327
DM8FZOG HS Phase 2
DM8FZOG SN Opioid receptor delta agonist (anxiety, depression), AstraZeneca
DM8FZOG CP AstraZeneca plc
DM8FZOG DT Small molecular drug
DM8FZOG PC 11525765
DM8FZOG MW 474.6
DM8FZOG FM C29H35FN4O
DM8FZOG IC InChI=1S/C29H35FN4O/c1-3-33(4-2)29(35)24-12-10-23(11-13-24)28(25-6-5-7-27(31)20-25)34-18-16-32(17-19-34)21-22-8-14-26(30)15-9-22/h5-15,20,28H,3-4,16-19,21,31H2,1-2H3/t28-/m1/s1
DM8FZOG CS CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)N)N3CCN(CC3)CC4=CC=C(C=C4)F
DM8FZOG IK XGFLMBBZEPJGHY-MUUNZHRXSA-N
DM8FZOG IU 4-[(R)-(3-aminophenyl)-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-N,N-diethylbenzamide
DM8FZOG CA CAS 875647-81-7
DM8FZOG DE Anxiety disorder
DMF34UY ID DMF34UY
DMF34UY DN AZD-2423
DMF34UY HS Phase 2
DMF34UY SN CCR2b antagonist (pain, COPD), AstraZeneca
DMF34UY CP AstraZeneca plc
DMF34UY DT Small molecular drug
DMF34UY PC 46213922
DMF34UY MW 425.9
DMF34UY FM C20H29ClFN5O2
DMF34UY IC InChI=1S/C20H29ClFN5O2/c1-20(2,3)27-7-6-23-17(13-27)18(28)25-8-10-26(11-9-25)19(29)24-14-4-5-15(21)16(22)12-14/h4-5,12,17,23H,6-11,13H2,1-3H3,(H,24,29)/t17-/m1/s1
DMF34UY CS CC(C)(C)N1CCN[C@H](C1)C(=O)N2CCN(CC2)C(=O)NC3=CC(=C(C=C3)Cl)F
DMF34UY IK SRWQVWAIVQXPJY-QGZVFWFLSA-N
DMF34UY IU 4-[(2R)-4-tert-butylpiperazine-2-carbonyl]-N-(4-chloro-3-fluorophenyl)piperazine-1-carboxamide
DMF34UY CA CAS 1229603-37-5
DMF34UY DE Chronic obstructive pulmonary disease
DMZLGQV ID DMZLGQV
DMZLGQV DN AZD2624
DMZLGQV HS Phase 2
DMZLGQV SN Pavinetant; AZD-2624; MLE4901; 941690-55-7; UNII-3U471ZVC5K; 3U471ZVC5K; AZ124752520; pavinetantum; Pavinetant [USAN]; SCHEMBL3587478; GTPL5775; CHEMBL3545233; CHEBI:140478; QYTBBBAHNIWFOD-NRFANRHFSA-N; BDBM50180193; AKOS032946112; DB11692; CS-7979; 4-Quinolinecarboxamide, 3-((methylsulfonyl)amino)-2-phenyl-N-((1S)-1-phenylpropyl)-; HY-14432; KB-74807; 3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; 3-[(methanesulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMZLGQV CP AstraZeneca
DMZLGQV DT Small molecular drug
DMZLGQV PC 23649245
DMZLGQV MW 459.6
DMZLGQV FM C26H25N3O3S
DMZLGQV IC InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
DMZLGQV CS CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)NS(=O)(=O)C
DMZLGQV IK QYTBBBAHNIWFOD-NRFANRHFSA-N
DMZLGQV IU 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMZLGQV CA CAS 941690-55-7
DMZLGQV CB CHEBI:140478
DMZLGQV DE Schizophrenia; Multiple sclerosis; .
DMYUNXP ID DMYUNXP
DMYUNXP DN AZD2811
DMYUNXP HS Phase 2
DMYUNXP CP AstraZeneca
DMYUNXP DT Small molecular drug
DMYUNXP DE Small-cell lung cancer
DM6AI9N ID DM6AI9N
DM6AI9N DN AZD-2927
DM6AI9N HS Phase 2
DM6AI9N SN AZD2927
DM6AI9N CP AstraZenec, UK
DM6AI9N DT Small molecular drug
DM6AI9N PC 57345449
DM6AI9N MW 308.4
DM6AI9N FM C17H25FN2O2
DM6AI9N IC InChI=1S/C17H25FN2O2/c1-11(2)16(10-20-8-14(21)9-20)19(4)17(22)13-5-6-15(18)12(3)7-13/h5-7,11,14,16,21H,8-10H2,1-4H3/t16-/m1/s1
DM6AI9N CS CC1=C(C=CC(=C1)C(=O)N(C)[C@H](CN2CC(C2)O)C(C)C)F
DM6AI9N IK GAHPWXLXWUVMIV-MRXNPFEDSA-N
DM6AI9N IU 4-fluoro-N-[(2S)-1-(3-hydroxyazetidin-1-yl)-3-methylbutan-2-yl]-N,3-dimethylbenzamide
DM6AI9N DE Atrial fibrillation
DME8Z5M ID DME8Z5M
DME8Z5M DN AZD-3199
DME8Z5M HS Phase 2
DME8Z5M PC 16035068
DME8Z5M MW 578.8
DME8Z5M FM C32H42N4O4S
DME8Z5M IC InChI=1S/C32H42N4O4S/c1-3-35(4-2)20-21-36(19-18-33-17-14-26-12-13-28(37)30-31(26)41-32(39)34-30)29(38)16-23-40-22-15-25-10-7-9-24-8-5-6-11-27(24)25/h5-13,33,37H,3-4,14-23H2,1-2H3,(H,34,39)
DME8Z5M CS CCN(CC)CCN(CCNCCC1=C2C(=C(C=C1)O)NC(=O)S2)C(=O)CCOCCC3=CC=CC4=CC=CC=C43
DME8Z5M IK ZVULMJYRVAVKCP-UHFFFAOYSA-N
DME8Z5M IU N-[2-(diethylamino)ethyl]-N-[2-[2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide
DME8Z5M CA CAS 925243-19-2
DME8Z5M DE Asthma
DMANC59 ID DMANC59
DMANC59 DN AZD-3241
DMANC59 HS Phase 2
DMANC59 SN Parkinson's disease therapeutic, AstraZeneca
DMANC59 CP AstraZeneca plc
DMANC59 PC 11528958
DMANC59 MW 253.32
DMANC59 FM C11H15N3O2S
DMANC59 IC InChI=1S/C11H15N3O2S/c1-7(2)16-6-5-14-8-3-4-12-9(8)10(15)13-11(14)17/h3-4,7,12H,5-6H2,1-2H3,(H,13,15,17)
DMANC59 CS CC(C)OCCN1C2=C(C(=O)NC1=S)NC=C2
DMANC59 IK FVJCUZCRPIMVLB-UHFFFAOYSA-N
DMANC59 IU 1-(2-propan-2-yloxyethyl)-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one
DMANC59 CA CAS 890655-80-8
DMANC59 DE Parkinson disease
DML9M5S ID DML9M5S
DML9M5S DN AZD-4017
DML9M5S HS Phase 2
DML9M5S SN AZD-4017 (oral tablet, ocular hypertension)
DML9M5S CP AstraZeneca plc
DML9M5S DT Small molecular drug
DML9M5S PC 24946280
DML9M5S MW 419.6
DML9M5S FM C22H33N3O3S
DML9M5S IC InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1
DML9M5S CS CCCSC1=C(C=CC(=N1)N2CCC[C@H](C2)CC(=O)O)C(=O)NC3CCCCC3
DML9M5S IK NCDZABJPWMBMIQ-INIZCTEOSA-N
DML9M5S IU 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid
DML9M5S CA CAS 1024033-43-9
DML9M5S DE Ocular hypertension
DM8SVIY ID DM8SVIY
DM8SVIY DN AZD4635
DM8SVIY HS Phase 2
DM8SVIY SN NCWQLHHDGDXIJN-UHFFFAOYSA-N; AZD-4635; 1321514-06-0; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine; SCHEMBL2320714; EX-A1681; AC-30333; HY-101980; CS-0022379; 5-(4-fluorophenyl)-6-(2-chloro-6-methyl-pyridin-4-yl)-1,2,4-triazin-3-amine
DM8SVIY CP AstraZeneca Wilmington, DE
DM8SVIY PC 86676119
DM8SVIY MW 315.73
DM8SVIY FM C15H11ClFN5
DM8SVIY IC InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)
DM8SVIY CS CC1=CC(=CC(=N1)Cl)C2=C(N=C(N=N2)N)C3=CC=C(C=C3)F
DM8SVIY IK NCWQLHHDGDXIJN-UHFFFAOYSA-N
DM8SVIY IU 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine
DM8SVIY CA CAS 1321514-06-0
DM8SVIY DE Solid tumour/cancer; Prostate cancer
DMFVL5J ID DMFVL5J
DMFVL5J DN AZD-4877
DMFVL5J HS Phase 2
DMFVL5J SN Anticancer therapeutic (solid tumors), AstraZeneca
DMFVL5J CP AstraZeneca plc
DMFVL5J DT Small molecular drug
DMFVL5J PC 10368812
DMFVL5J MW 503.7
DMFVL5J FM C28H33N5O2S
DMFVL5J IC InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3
DMFVL5J CS CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=NC3=C(C(=NS3)C)C(=O)N2CC4=CC=CC=C4)C(C)C
DMFVL5J IK SMFXSYMLJDHGIE-UHFFFAOYSA-N
DMFVL5J IU N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide
DMFVL5J CA CAS 1176760-49-8
DMFVL5J DE Acute myeloid leukaemia
DM3JSFK ID DM3JSFK
DM3JSFK DN AZD-5069
DM3JSFK HS Phase 2
DM3JSFK SN CXCR2 inhibitor (COPD), Astrazeneca
DM3JSFK CP AstraZeneca plc
DM3JSFK PC 56645576
DM3JSFK MW 476.5
DM3JSFK FM C18H22F2N4O5S2
DM3JSFK IC InChI=1S/C18H22F2N4O5S2/c1-11(14(26)9-25)29-16-8-15(23-31(27,28)24-6-3-7-24)21-18(22-16)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,25-26H,3,6-7,9-10H2,1H3,(H,21,22,23)/t11-,14+/m1/s1
DM3JSFK CS C[C@H]([C@H](CO)O)OC1=NC(=NC(=C1)NS(=O)(=O)N2CCC2)SCC3=C(C(=CC=C3)F)F
DM3JSFK IK QZECRCLSIGFCIO-RISCZKNCSA-N
DM3JSFK IU N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide
DM3JSFK CA CAS 878385-84-3
DM3JSFK DE Asthma
DMOZ04X ID DMOZ04X
DMOZ04X DN AZD-5213
DMOZ04X HS Phase 2
DMOZ04X CP AstraZeneca plc
DMOZ04X PC 53342708
DMOZ04X MW 327.4
DMOZ04X FM C19H25N3O2
DMOZ04X IC InChI=1S/C19H25N3O2/c20-18(23)14-6-4-13(5-7-14)16-12-17(16)19(24)22-10-8-21(9-11-22)15-2-1-3-15/h4-7,15-17H,1-3,8-12H2,(H2,20,23)/t16-,17+/m1/s1
DMOZ04X CS C1CC(C1)N2CCN(CC2)C(=O)[C@H]3C[C@@H]3C4=CC=C(C=C4)C(=O)N
DMOZ04X IK VCQZCDSEWSFTPO-SJORKVTESA-N
DMOZ04X IU 4-[(1S,2S)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide
DMOZ04X CA CAS 1119807-02-1
DMOZ04X DE Alzheimer disease
DMJ8V3K ID DMJ8V3K
DMJ8V3K DN AZD5312
DMJ8V3K HS Phase 2
DMJ8V3K CP Astrazeneca; isis pharmaceuticals
DMJ8V3K DE Prostate cancer
DM0PFNC ID DM0PFNC
DM0PFNC DN AZD6738
DM0PFNC HS Phase 2
DM0PFNC CP Astrazeneca; eagle pharmaceuticals
DM0PFNC DT Small molecular drug
DM0PFNC PC 54761306
DM0PFNC MW 412.5
DM0PFNC FM C20H24N6O2S
DM0PFNC IC InChI=1S/C20H24N6O2S/c1-13-12-28-10-9-26(13)17-11-16(20(5-6-20)29(2,21)27)24-19(25-17)15-4-8-23-18-14(15)3-7-22-18/h3-4,7-8,11,13,21H,5-6,9-10,12H2,1-2H3,(H,22,23)/t13-,29-/m1/s1
DM0PFNC CS C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)[S@](=N)(=O)C)C4=C5C=CNC5=NC=C4
DM0PFNC IK OHUHVTCQTUDPIJ-JYCIKRDWSA-N
DM0PFNC IU imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane
DM0PFNC DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Small-cell lung cancer
DMIBXK0 ID DMIBXK0
DMIBXK0 DN AZD-7009
DMIBXK0 HS Phase 2
DMIBXK0 SN AR-H065522XX; AZD-7009 (iv formulation, atrial fibrillation conversion)
DMIBXK0 CP AstraZeneca plc
DMIBXK0 DT Small molecular drug
DMIBXK0 PC 72440971
DMIBXK0 MW 496.9
DMIBXK0 FM C22H23ClF2N4O5
DMIBXK0 IC InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31)
DMIBXK0 CS CON=C(C1=CC=C(C=C1)CNC(=O)C2CCN2C(=O)C(C3=CC(=CC(=C3)Cl)OC(F)F)O)N
DMIBXK0 IK XSNMGLZVFNDDPW-UHFFFAOYSA-N
DMIBXK0 IU 1-[2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-(N'-methoxycarbamimidoyl)phenyl]methyl]azetidine-2-carboxamide
DMIBXK0 DE Atrial fibrillation
DMC48SP ID DMC48SP
DMC48SP DN AZD-7268
DMC48SP HS Phase 2
DMC48SP SN Enkephalinergic receptor modulator (oral, depression, anxiety), AstraZeneca
DMC48SP CP AstraZeneca plc
DMC48SP DT Small molecular drug
DMC48SP PC 24772484
DMC48SP MW 498.6
DMC48SP FM C29H30N4O2S
DMC48SP IC InChI=1S/C29H30N4O2S/c1-32(16-17-34)29(35)24-9-7-21(8-10-24)27(26-6-2-4-23-5-3-13-30-28(23)26)22-11-14-33(15-12-22)18-25-19-36-20-31-25/h2-10,13,19-20,34H,11-12,14-18H2,1H3
DMC48SP CS CN(CCO)C(=O)C1=CC=C(C=C1)C(=C2CCN(CC2)CC3=CSC=N3)C4=CC=CC5=C4N=CC=C5
DMC48SP IK ZJKUETLEJYCOBO-UHFFFAOYSA-N
DMC48SP IU N-(2-hydroxyethyl)-N-methyl-4-[quinolin-8-yl-[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl]benzamide
DMC48SP CA CAS 1018988-00-5
DMC48SP DE Anxiety disorder
DMXF26Y ID DMXF26Y
DMXF26Y DN AZD7325
DMXF26Y HS Phase 2
DMXF26Y SN AZD-7325; UNII-KNM216XOUH; KNM216XOUH; CHEMBL1783282; 942437-37-8; AZD7325; KYDURMHFWXCKMW-UHFFFAOYSA-N; SCHEMBL1962584; GTPL7712; AZD 7325; BDBM50418481; SB17497; 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide; 4-Amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide
DMXF26Y CP AstraZeneca
DMXF26Y DT Small molecular drug
DMXF26Y PC 23581869
DMXF26Y MW 354.4
DMXF26Y FM C19H19FN4O2
DMXF26Y IC InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25)
DMXF26Y CS CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC=C3F)OC
DMXF26Y IK KYDURMHFWXCKMW-UHFFFAOYSA-N
DMXF26Y IU 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide
DMXF26Y CA CAS 942437-37-8
DMXF26Y DE Anxiety disorder
DMEW3K9 ID DMEW3K9
DMEW3K9 DN AZD7624
DMEW3K9 HS Phase 2
DMEW3K9 CP Astrazeneca
DMEW3K9 PC 25143624
DMEW3K9 MW 491.6
DMEW3K9 FM C27H30FN5O3
DMEW3K9 IC InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)
DMEW3K9 CS CC1=C(C=C(C=C1F)C(=O)NC2CC2)N3C=CN=C(C3=O)NC4(CC4)C5=CC=CC=C5OCCNC
DMEW3K9 IK NNKPHNTWNILINE-UHFFFAOYSA-N
DMEW3K9 IU N-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide
DMEW3K9 CA CAS 1095004-78-6
DMEW3K9 DE Chronic obstructive pulmonary disease
DMLXFM6 ID DMLXFM6
DMLXFM6 DN AZD-8683
DMLXFM6 HS Phase 2
DMLXFM6 CP AstraZeneca plc
DMLXFM6 DE Chronic obstructive pulmonary disease
DM0M7QW ID DM0M7QW
DM0M7QW DN AZD-8848
DM0M7QW HS Phase 2
DM0M7QW SN AZ-12441970; DSP-3025; SM-324405; TLR7 agonist (allergy), Dainippon/AstraZeneca
DM0M7QW CP Dainippon Sumitomo Pharma Co Ltd
DM0M7QW PC 11592228
DM0M7QW MW 569.7
DM0M7QW FM C29H43N7O5
DM0M7QW IC InChI=1S/C29H43N7O5/c1-3-4-16-41-28-32-26(30)25-27(33-28)36(29(38)31-25)13-7-12-35(11-6-10-34-14-17-40-18-15-34)21-23-9-5-8-22(19-23)20-24(37)39-2/h5,8-9,19H,3-4,6-7,10-18,20-21H2,1-2H3,(H,31,38)(H2,30,32,33)
DM0M7QW CS CCCCOC1=NC(=C2C(=N1)N(C(=O)N2)CCCN(CCCN3CCOCC3)CC4=CC=CC(=C4)CC(=O)OC)N
DM0M7QW IK FEFIBEHSXLKJGI-UHFFFAOYSA-N
DM0M7QW IU methyl 2-[3-[[3-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)propyl-(3-morpholin-4-ylpropyl)amino]methyl]phenyl]acetate
DM0M7QW CA CAS 866269-28-5
DM0M7QW DE Allergic rhinitis
DMFLCW4 ID DMFLCW4
DMFLCW4 DN AZD8931
DMFLCW4 HS Phase 2
DMFLCW4 SN Sapitinib; AZD8931; 848942-61-0; AZD8931 (Sapitinib); AZD-8931; Sapitinib(AZD8931); UNII-3499328002; CHEMBL2408045; 2-(4-((4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-n-methylacetamide; 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-N-methylacetamide; Sapitinib [INN]; 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-((1-(n-methylcarbamoylmethyl)piperidin-4-yl)oxy)quinazoline
DMFLCW4 CP AstraZeneca
DMFLCW4 DT Small molecular drug
DMFLCW4 PC 11488320
DMFLCW4 MW 473.9
DMFLCW4 FM C23H25ClFN5O3
DMFLCW4 IC InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)
DMFLCW4 CS CNC(=O)CN1CCC(CC1)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC
DMFLCW4 IK DFJSJLGUIXFDJP-UHFFFAOYSA-N
DMFLCW4 IU 2-[4-[4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-N-methylacetamide
DMFLCW4 CA CAS 848942-61-0
DMFLCW4 CB CHEBI:132986
DMFLCW4 DE Breast cancer
DMJGYPK ID DMJGYPK
DMJGYPK DN AZD9056
DMJGYPK HS Phase 2
DMJGYPK SN AZD-9056; AZD9056; 345304-65-6; UNII-F13K378W4L; N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide; F13K378W4L; AZD 9056; GTPL7826; SCHEMBL4126642; CHEMBL3545108; HSQAARMBHJCUOK-UHFFFAOYSA-N; MolPort-044-723-510; KS-000000WO; BCP25185; ZINC34356159; AKOS030228502; DB12594; Benzamide, 2-chloro-5-(3-((3-hydroxypropyl)amino)propyl)-N-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-; 2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide
DMJGYPK CP AstraZeneca
DMJGYPK DT Small molecular drug
DMJGYPK PC 10161381
DMJGYPK MW 419
DMJGYPK FM C24H35ClN2O2
DMJGYPK IC InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29)
DMJGYPK CS C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=C(C=CC(=C4)CCCNCCCO)Cl
DMJGYPK IK HSQAARMBHJCUOK-UHFFFAOYSA-N
DMJGYPK IU N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide
DMJGYPK CA CAS 345304-65-6
DMJGYPK DE Chronic obstructive pulmonary disease
DMVKPEZ ID DMVKPEZ
DMVKPEZ DN AZD-9164
DMVKPEZ HS Phase 2
DMVKPEZ SN IDDBCP239717
DMVKPEZ CP AstraZeneca plc
DMVKPEZ PC 44517831
DMVKPEZ MW 465.6
DMVKPEZ FM C29H38FN2O2+
DMVKPEZ IC InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1
DMVKPEZ CS C[C@](C1=CC=CC=C1)(C(=O)O[C@H]2C[N+]3(CCC2CC3)CCC4=CC=C(C=C4)F)N5CCCCC5
DMVKPEZ IK FNYFFCOCVNTJCD-NNMXADRKSA-N
DMVKPEZ IU [(3R)-1-[2-(4-fluorophenyl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2S)-2-phenyl-2-piperidin-1-ylpropanoate
DMVKPEZ CA CAS 1034978-04-5
DMVKPEZ DE Chronic obstructive pulmonary disease
DMB87M3 ID DMB87M3
DMB87M3 DN AZD9668
DMB87M3 HS Phase 2
DMB87M3 SN Alvelestat; 848141-11-7; AZD9668; Alvelestat (AZD9668); AZD 9668; CHEMBL3617964; AZD-9668; KB-105160; Avelestat; 6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide; 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
DMB87M3 CP AstraZeneca
DMB87M3 DT Small molecular drug
DMB87M3 PC 46861623
DMB87M3 MW 545.5
DMB87M3 FM C25H22F3N5O4S
DMB87M3 IC InChI=1S/C25H22F3N5O4S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28/h4-12,14H,13H2,1-3H3,(H,30,34)
DMB87M3 CS CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC3=NC=C(C=C3)S(=O)(=O)C)C4=CC=NN4C
DMB87M3 IK QNQZWEGMKJBHEM-UHFFFAOYSA-N
DMB87M3 IU 6-methyl-5-(2-methylpyrazol-3-yl)-N-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide
DMB87M3 CA CAS 848141-11-7
DMB87M3 DE Chronic obstructive pulmonary disease; Bronchiectasis
DMQOTHP ID DMQOTHP
DMQOTHP DN AZD9833
DMQOTHP HS Phase 2
DMQOTHP SN AZD-9833; UNII-JUP57A8EPZ; JUP57A8EPZ; 2222844-89-3; Camizestrant; Camizestrant [USAN]; SCHEMBL20089710; NSC828717; WHO 11592; NSC-828717; HY-136255; AZ14066724; CS-0121043; 3-Pyridinamine, N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-6,7,8,9-tetrahydro-8-methyl-7-(2,2,2-trifluoroethyl)-3H-pyrazolo(4,3-F)isoquinolin-6-yl)-
DMQOTHP CP AstraZeneca
DMQOTHP DT Small molecular drug
DMQOTHP PC 134453496
DMQOTHP MW 476.5
DMQOTHP FM C24H28F4N6
DMQOTHP IC InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
DMQOTHP CS C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
DMQOTHP IK WDHOIABIERMLGY-CMJOXMDJSA-N
DMQOTHP IU N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
DMQOTHP CA CAS 2222844-89-3
DMQOTHP DE ER-positive breast cancer
DME0JMV ID DME0JMV
DME0JMV DN AZX-100
DME0JMV HS Phase 2
DME0JMV CP AzERx Inc
DME0JMV DE Asthma
DMOMDA4 ID DMOMDA4
DMOMDA4 DN B-701
DMOMDA4 HS Phase 2
DMOMDA4 SN VKRFJPYJBOIVPD-UHFFFAOYSA-N; B 701; NSC 46406; 78218-88-9; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester; AC1L3VIX; AC1Q6T2K; NSC46406; NSC-46406; 3-chloropropyl n,n-bis(2-chloroethyl)-n'-(3-hydroxypropyl)phosphorodiamidate; LS-107974; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amin; 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, 3-chloropropyl ester
DMOMDA4 CP BioClin Therapeutics San Ramon, CA
DMOMDA4 PC 95987
DMOMDA4 MW 355.6
DMOMDA4 FM C10H22Cl3N2O3P
DMOMDA4 IC InChI=1S/C10H22Cl3N2O3P/c11-3-1-10-18-19(17,14-6-2-9-16)15(7-4-12)8-5-13/h16H,1-10H2,(H,14,17)
DMOMDA4 CS C(CNP(=O)(N(CCCl)CCCl)OCCCCl)CO
DMOMDA4 IK VKRFJPYJBOIVPD-UHFFFAOYSA-N
DMOMDA4 IU 3-[[bis(2-chloroethyl)amino-(3-chloropropoxy)phosphoryl]amino]propan-1-ol
DMOMDA4 CA CAS 78218-88-9
DMOMDA4 DE Bladder cancer; Urothelial carcinoma
DM7586F ID DM7586F
DM7586F DN Bafetinib
DM7586F HS Phase 2
DM7586F SN Bafetinib; 859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide
DM7586F CP CytRx
DM7586F DT Small molecular drug
DM7586F PC 11387605
DM7586F MW 576.6
DM7586F FM C30H31F3N8O
DM7586F IC InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1
DM7586F CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CC[C@@H](C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5
DM7586F IK ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
DM7586F IU 4-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-N-[4-methyl-3-[(4-pyrimidin-5-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide
DM7586F CA CAS 859212-16-1
DM7586F DE Bone disease
DM4C7E6 ID DM4C7E6
DM4C7E6 DN BAICALEIN
DM4C7E6 HS Phase 2
DM4C7E6 SN baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761
DM4C7E6 DT Small molecular drug
DM4C7E6 PC 5281605
DM4C7E6 MW 270.24
DM4C7E6 FM C15H10O5
DM4C7E6 IC InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H
DM4C7E6 CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O
DM4C7E6 IK FXNFHKRTJBSTCS-UHFFFAOYSA-N
DM4C7E6 IU 5,6,7-trihydroxy-2-phenylchromen-4-one
DM4C7E6 CA CAS 491-67-8
DM4C7E6 CB CHEBI:2979
DM4C7E6 DE Influenza virus infection
DM3WCL4 ID DM3WCL4
DM3WCL4 DN Baltaleucel-T
DM3WCL4 HS Phase 2
DM3WCL4 CP Cell Medica Houston, TX
DM3WCL4 DE Diffuse large B-cell lymphoma; Hodgkin lymphoma; Lymphoma; Post-transplant lymphoproliferative disorder
DMSZOXQ ID DMSZOXQ
DMSZOXQ DN Baminercept
DMSZOXQ HS Phase 2
DMSZOXQ SN BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec
DMSZOXQ CP Biogen Idec
DMSZOXQ DE Rheumatoid arthritis
DM0TZEP ID DM0TZEP
DM0TZEP DN Bamosiran
DM0TZEP HS Phase 2
DM0TZEP SN SYL040012
DM0TZEP CP Sylentis
DM0TZEP DT Small interfering RNA
DM0TZEP DE Glaucoma/ocular hypertension
DMW03YD ID DMW03YD
DMW03YD DN BAN2401
DMW03YD HS Phase 2
DMW03YD CP BioArtic Neuroscience
DMW03YD DE Alzheimer disease
DMWI0X3 ID DMWI0X3
DMWI0X3 DN Barusiban
DMWI0X3 HS Phase 2
DMWI0X3 SN FE-200440
DMWI0X3 CP Ferring Pharmaceuticals Inc
DMWI0X3 DT Small molecular drug
DMWI0X3 PC 9832431
DMWI0X3 MW 830.1
DMWI0X3 FM C40H63N9O8S
DMWI0X3 IC InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1
DMWI0X3 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSCCC(=O)N[C@@H](C(=O)N1)CC2=CNC3=CC=CC=C32)C(=O)N(C)[C@@H](CCCN)CO)CC(=O)N)[C@H](C)CC
DMWI0X3 IK UGNGRKKDUVKQDF-IHOMMZCZSA-N
DMWI0X3 IU (4S,7S,10S,13S,16R)-N-[(2S)-5-amino-1-hydroxypentan-2-yl]-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-10-[(2R)-butan-2-yl]-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMWI0X3 CA CAS 285571-64-4
DMWI0X3 DE Androgen deficiency
DMQ8J0U ID DMQ8J0U
DMQ8J0U DN Basmisanil
DMQ8J0U HS Phase 2
DMQ8J0U SN 1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha
DMQ8J0U CP Roche
DMQ8J0U PC 57336276
DMQ8J0U MW 445.5
DMQ8J0U FM C21H20FN3O5S
DMQ8J0U IC InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3
DMQ8J0U CS CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4
DMQ8J0U IK VCGRFBXVSFAGGA-UHFFFAOYSA-N
DMQ8J0U IU (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone
DMQ8J0U CA CAS 1159600-41-5
DMQ8J0U DE Alzheimer disease; Cognitive impairment; Complete androgen insensitivity syndrome; Immune dysregulation
DM6CVZ5 ID DM6CVZ5
DM6CVZ5 DN Bavisant
DM6CVZ5 HS Phase 2
DM6CVZ5 SN JNJ-31001074
DM6CVZ5 CP Johnson & Johnson Pharmaceutical Research & Development
DM6CVZ5 DT Small molecular drug
DM6CVZ5 PC 16061509
DM6CVZ5 MW 329.4
DM6CVZ5 FM C19H27N3O2
DM6CVZ5 IC InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2
DM6CVZ5 CS C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4
DM6CVZ5 IK BGBVSGSIXIIREO-UHFFFAOYSA-N
DM6CVZ5 IU (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone
DM6CVZ5 CA CAS 929622-08-2
DM6CVZ5 DE Attention deficit hyperactivity disorder
DM4JGNH ID DM4JGNH
DM4JGNH DN BAY 1067197
DM4JGNH HS Phase 2
DM4JGNH CP Bayer HealthCare Pharmaceuticals
DM4JGNH DE Heart failure
DMHKTGX ID DMHKTGX
DMHKTGX DN BAY 1142524
DMHKTGX HS Phase 2
DMHKTGX SN Fulacimstat; UNII-VIR72PP4ZU; VIR72PP4ZU; BAY1142524; 1488354-15-9; 1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-; 2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-; Fulacimstat [INN]; Fulacimstat; BAY1142524; Fulacimstat(BAY 1142524); CHEMBL4297596; SCHEMBL16701233; EX-A2732; DB15085; BAY-1142524; HY-109059; CS-0032987; (R)-1-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-2,4-dioxo-3-(4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 1-(2,3-Dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxylic acid; 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-((1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid; 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid; 5-Pyrimidinecarboxylic acid, 1-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-
DMHKTGX CP Bayer
DMHKTGX DT Small molecular drug
DMHKTGX PC 91758792
DMHKTGX MW 487.4
DMHKTGX FM C23H16F3N3O6
DMHKTGX IC InChI=1S/C23H16F3N3O6/c1-27-17-7-5-11(9-18(17)35-22(27)34)28-10-14(20(31)32)19(30)29(21(28)33)16-8-6-12-13(16)3-2-4-15(12)23(24,25)26/h2-5,7,9-10,16H,6,8H2,1H3,(H,31,32)/t16-/m1/s1
DMHKTGX CS CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)[C@@H]4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O
DMHKTGX IK JDARDSVOVYVQST-MRXNPFEDSA-N
DMHKTGX IU 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]pyrimidine-5-carboxylic acid
DMHKTGX CA CAS 1488354-15-9
DMHKTGX DE Myocardial infarction
DM8SNEM ID DM8SNEM
DM8SNEM DN BAY 11-42524
DM8SNEM HS Phase 2
DM8SNEM CP Bayer healthcare pharmaceuticals
DM8SNEM DE Heart failure; Left ventricular dysfunction
DM450XS ID DM450XS
DM450XS DN BAY 2253651
DM450XS HS Phase 2
DM450XS CP Bayer
DM450XS DT Small molecular drug
DM450XS DE Obstructive sleep apnea
DMSUB64 ID DMSUB64
DMSUB64 DN BAY 57-1293
DMSUB64 HS Phase 2
DMSUB64 SN Pritelivir; 348086-71-5; BAY-57-1293; UNII-07HQ1TJ4JE; AIC316; BAY57-1293; 07HQ1TJ4JE; Pritelivir (BAY 57-1293); N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide; N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide; Pritelivir [INN]; AIC-316; AIC 316; AC1LANY1; PritelivirBAY-57-1293; SCHEMBL1074614; Pritelivir(BAY 57-1293); DTXSID70188344; EX-A247; MolPort-029-887-140; IVZKZONQVYTCKC-UHFFFAOYSA-N; HMS3653B15; BCP08742
DMSUB64 DT Small molecular drug
DMSUB64 PC 491941
DMSUB64 MW 402.5
DMSUB64 FM C18H18N4O3S2
DMSUB64 IC InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
DMSUB64 CS CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
DMSUB64 IK IVZKZONQVYTCKC-UHFFFAOYSA-N
DMSUB64 IU N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide
DMSUB64 CA CAS 348086-71-5
DMSUB64 DE Herpes simplex virus infection
DMA75FG ID DMA75FG
DMA75FG DN BAY 794980
DMA75FG HS Phase 2
DMA75FG SN BAY-794980; Kogenate FS liposome; Kogenate liposomal; NecLip-rFVIII; PEGLip-formulated exogenous FVIII - Bayer/Zilip-Pharma; PEGLip-FVIII FS - Bayer/Zilip-Pharma; PEGylated octocog alfa sucrose - Bayer/Zilip-Pharma
DMA75FG DE Discovery agent
DMCPUKG ID DMCPUKG
DMCPUKG DN BAY 85-8501
DMCPUKG HS Phase 2
DMCPUKG CP Bayer HealthCare Pharmaceuticals
DMCPUKG PC 66601502
DMCPUKG MW 474.5
DMCPUKG FM C22H17F3N4O3S
DMCPUKG IC InChI=1S/C22H17F3N4O3S/c1-13-18(12-27)20(17-8-7-14(11-26)9-19(17)33(3,31)32)28(2)21(30)29(13)16-6-4-5-15(10-16)22(23,24)25/h4-10,20H,1-3H3/t20-/m1/s1
DMCPUKG CS CC1=C([C@H](N(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C)C3=C(C=C(C=C3)C#N)S(=O)(=O)C)C#N
DMCPUKG IK YAJWYFPMASPAMM-HXUWFJFHSA-N
DMCPUKG IU (4S)-4-(4-cyano-2-methylsulfonylphenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4H-pyrimidine-5-carbonitrile
DMCPUKG CA CAS 1161921-82-9
DMCPUKG DE Bronchiectasis
DMRZLU4 ID DMRZLU4
DMRZLU4 DN BAY 86-5044
DMRZLU4 HS Phase 2
DMRZLU4 SN Lonaprisan; ZK-230211; 211254-73-8; UNII-F5Z5EL4D26; F5Z5EL4D26; AC1OCFKM; ZK-PRA; Lonaprisan [USAN:INN]; Lonaprisan (USAN/INN); SCHEMBL977182; CHEMBL146032; zk230211; BDBM50409115; BAY86-5044; ZK 230211; ZK 232011; D10016; Z-3103; (8S,11R,13S,14S,17S)-11-(4-ACETYLPHENYL)-17-HYDROXY-13-METHYL-17-(PERFLUOROETHYL)-6,7,8,11,12,13,14,15,16,17-DECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-3(2H)-ONE; Lonaprisan
DMRZLU4 CP Bayer HealthCare Pharmaceuticals
DMRZLU4 DT Small molecular drug
DMRZLU4 PC 6918548
DMRZLU4 MW 508.5
DMRZLU4 FM C28H29F5O3
DMRZLU4 IC InChI=1S/C28H29F5O3/c1-15(34)16-3-5-17(6-4-16)22-14-25(2)23(11-12-26(25,36)27(29,30)28(31,32)33)21-9-7-18-13-19(35)8-10-20(18)24(21)22/h3-6,13,21-23,36H,7-12,14H2,1-2H3/t21-,22+,23-,25-,26-/m0/s1
DMRZLU4 CS CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C(C(F)(F)F)(F)F)O)[C@H]4C2=C5CCC(=O)C=C5CC4)C
DMRZLU4 IK VHZPUDNSVGRVMB-RXDLHWJPSA-N
DMRZLU4 IU (8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMRZLU4 CA CAS 211254-73-8
DMRZLU4 DE Breast cancer
DMCSGJ2 ID DMCSGJ2
DMCSGJ2 DN BAY1163877
DMCSGJ2 HS Phase 2
DMCSGJ2 SN Rogaratinib
DMCSGJ2 CP Bayer healthcare pharmaceuticals
DMCSGJ2 PC 71611869
DMCSGJ2 MW 466.6
DMCSGJ2 FM C23H26N6O3S
DMCSGJ2 IC InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)
DMCSGJ2 CS CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N
DMCSGJ2 IK HNLRRJSKGXOYNO-UHFFFAOYSA-N
DMCSGJ2 IU 4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one
DMCSGJ2 CA CAS 1443530-05-9
DMCSGJ2 DE Solid tumour/cancer; Bladder cancer
DM83IYE ID DM83IYE
DM83IYE DN BAY1193397
DM83IYE HS Phase 2
DM83IYE CP Bayer HealthCare Pharmaceuticals Whippany, NJ
DM83IYE DE Peripheral arterial disease
DMYSQMW ID DMYSQMW
DMYSQMW DN BAY-1902607
DMYSQMW HS Phase 2
DMYSQMW CP Bayer
DMYSQMW DE Cough
DMM7Q68 ID DMM7Q68
DMM7Q68 DN BAY-2253651
DMM7Q68 HS Phase 2
DMM7Q68 CP Bayer
DMM7Q68 DE Obstructive sleep apnea
DMVA5NS ID DMVA5NS
DMVA5NS DN BAY-57-9352
DMVA5NS HS Phase 2
DMVA5NS SN Telatinib; Bay 57-9352
DMVA5NS CP Bayer AG
DMVA5NS TC Anticancer Agents
DMVA5NS DT Small molecular drug
DMVA5NS PC 9808844
DMVA5NS MW 409.8
DMVA5NS FM C20H16ClN5O3
DMVA5NS IC InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
DMVA5NS CS CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl
DMVA5NS IK QFCXANHHBCGMAS-UHFFFAOYSA-N
DMVA5NS IU 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide
DMVA5NS CA CAS 332012-40-5
DMVA5NS DE Solid tumour/cancer; Gastric adenocarcinoma
DM7NHLC ID DM7NHLC
DM7NHLC DN BAY-85-3934
DM7NHLC HS Phase 2
DM7NHLC SN Hypoxia-inducible factor prolyl hydroxylase inhibitors (anemia); HIF-PH inhibitors (anemia), Bayer
DM7NHLC CP Bayer HealthCare Pharmaceuticals
DM7NHLC DT Small molecular drug
DM7NHLC PC 69669724
DM7NHLC MW 336.28
DM7NHLC FM C13H13N8NaO2
DM7NHLC IC InChI=1S/C13H14N8O2.Na/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19;/h1-2,7-9,22H,3-6H2;/q;+1/p-1
DM7NHLC CS C1COCCN1C2=NC=NC(=C2)N3C(=C(C=N3)N4C=CN=N4)[O-].[Na+]
DM7NHLC IK VYRQLKYGGSWDNH-UHFFFAOYSA-M
DM7NHLC IU sodium;2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)pyrazol-3-olate
DM7NHLC DE Anemia
DM2XE80 ID DM2XE80
DM2XE80 DN BAY-X-7195
DM2XE80 HS Phase 2
DM2XE80 SN BAY-X-7195; UGWPB2QIT9; UNII-UGWPB2QIT9; BAY X-7195; BAY X 7195; AC1O5X0Q; 143538-27-6; SCHEMBL156423; CHEMBL314115; 4-[(Z,4S)-7-hydroxy-7-oxo-1-[4-(4-phenoxybutoxy)phenyl]hept-2-en-4-yl]sulfanylbenzoic acid
DM2XE80 CP Bayer AG
DM2XE80 DT Small molecular drug
DM2XE80 PC 6442328
DM2XE80 MW 520.6
DM2XE80 FM C30H32O6S
DM2XE80 IC InChI=1S/C30H32O6S/c31-29(32)20-19-27(37-28-17-13-24(14-18-28)30(33)34)10-6-7-23-11-15-26(16-12-23)36-22-5-4-21-35-25-8-2-1-3-9-25/h1-3,6,8-18,27H,4-5,7,19-22H2,(H,31,32)(H,33,34)/b10-6-/t27-/m1/s1
DM2XE80 CS C1=CC=C(C=C1)OCCCCOC2=CC=C(C=C2)C/C=C\\[C@H](CCC(=O)O)SC3=CC=C(C=C3)C(=O)O
DM2XE80 IK MHKAEITVUICXRN-BPGQXAFDSA-N
DM2XE80 IU 4-[(Z,3S)-1-carboxy-6-[4-(4-phenoxybutoxy)phenyl]hex-4-en-3-yl]sulfanylbenzoic acid
DM2XE80 CA CAS 143538-27-6
DM2XE80 DE Asthma
DMLO18H ID DMLO18H
DMLO18H DN BAY-Y-5959
DMLO18H HS Phase 2
DMLO18H CP Bayer AG
DMLO18H PC 9910240
DMLO18H MW 424.5
DMLO18H FM C26H24N4O2
DMLO18H IC InChI=1S/C26H24N4O2/c1-15(2)32-26(31)24-23(21(13-27)16(3)30-25(24)28)19-10-7-11-22-20(19)12-18(14-29-22)17-8-5-4-6-9-17/h4-12,14-15,23,30H,28H2,1-3H3/t23-/m1/s1
DMLO18H CS CC1=C([C@H](C(=C(N1)N)C(=O)OC(C)C)C2=C3C=C(C=NC3=CC=C2)C4=CC=CC=C4)C#N
DMLO18H IK PHJVBZVDUNTGNR-HSZRJFAPSA-N
DMLO18H IU propan-2-yl (4R)-2-amino-5-cyano-6-methyl-4-(3-phenylquinolin-5-yl)-1,4-dihydropyridine-3-carboxylate
DMLO18H CA CAS 146136-94-9
DMLO18H DE Cardiovascular disease
DMB0UF9 ID DMB0UF9
DMB0UF9 DN Bb2121
DMB0UF9 HS Phase 2
DMB0UF9 CP bluebird bioCambridge, MACelgeneSummit, NJ
DMB0UF9 DT CAR T Cell Therapy
DMB0UF9 DE Multiple myeloma
DMR59I4 ID DMR59I4
DMR59I4 DN BBI-5000
DMR59I4 HS Phase 2
DMR59I4 CP Brickell Biotech
DMR59I4 DT Small molecular drug
DMR59I4 DE Alopecia
DMDSNIR ID DMDSNIR
DMDSNIR DN BBI503
DMDSNIR HS Phase 2
DMDSNIR CP Boston Biomedical
DMDSNIR PC 25190990
DMDSNIR MW 539.7
DMDSNIR FM C31H33N5O2S
DMDSNIR IC InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
DMDSNIR CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C
DMDSNIR IK QDWKGEFGLQMDAM-ULJHMMPZSA-N
DMDSNIR IU N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide
DMDSNIR CA CAS 1129403-56-0
DMDSNIR DE Ovarian cancer; Hepatocellular carcinoma; Cholangiocarcinoma; Solid tumour/cancer
DMY1UGV ID DMY1UGV
DMY1UGV DN Bc-3781 intravenous
DMY1UGV HS Phase 2
DMY1UGV SN BC-3781 (intravenous), Nabriva; BC-3781 (oral), Nabriva
DMY1UGV CP Nabriva therapeutics
DMY1UGV DT Small molecular drug
DMY1UGV PC 52918381
DMY1UGV MW 507.7
DMY1UGV FM C28H45NO5S
DMY1UGV IC InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18?,20?,21?,22-,24+,25+,26-,27+,28+/m1/s1
DMY1UGV CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C
DMY1UGV IK KPVIXBKIJXZQJX-IJUBVZAWSA-N
DMY1UGV IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-(4-amino-2-hydroxycyclohexyl)sulfanylacetate
DMY1UGV CA CAS 1061872-97-6
DMY1UGV DE Bacterial infection
DMMKCJ6 ID DMMKCJ6
DMMKCJ6 DN BC-7013
DMMKCJ6 HS Phase 2
DMMKCJ6 SN Pleuromutilin (topical, dermatological infection), Nabriva
DMMKCJ6 CP Nabriva Therapeutics AG
DMMKCJ6 DE Skin infection
DM2BO9W ID DM2BO9W
DM2BO9W DN BCP-13498
DM2BO9W HS Phase 2
DM2BO9W SN Propacetamol; Pro-Dafalgan; Propacetamol (INN); Propacetamol [INN:BAN]; Propacetamol [INN]; Propacetamolum; Propacetamolum [Latin]; Tox21_113811; ZINC55161176; (4-acetamidophenyl) 2-(diethylamino)acetate; 5CHW4JMR82; 66532-85-2; AC1L2ALY; AC1Q6199; AKOS015890722; BCP13498; CHEBI:135089; CHEMBL1851805; DB09288; DSSTox_CID_31589; DSSTox_GSID_57800; DSSTox_RID_97473; DTXSID3057800; EINECS 266-390-1; Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester; N,N-Diethylglycine, ester with 4'-hydroxyacetanilide; SCHEMBL26155; UNII-5CHW4JMR82
DM2BO9W PC 68865
DM2BO9W MW 264.32
DM2BO9W FM C14H20N2O3
DM2BO9W IC QTGAJCQTLIRCFL-UHFFFAOYSA-N
DM2BO9W CS CCN(CC)CC(=O)OC1=CC=C(C=C1)NC(=O)C
DM2BO9W IK 1S/C14H20N2O3/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17/h6-9H,4-5,10H2,1-3H3,(H,15,17)
DM2BO9W IU (4-acetamidophenyl) 2-(diethylamino)acetate
DM2BO9W CA CAS 66532-85-2
DM2BO9W CB CHEBI:135089
DM2BO9W DE Anaesthesia
DMUFY4K ID DMUFY4K
DMUFY4K DN BCT303
DMUFY4K HS Phase 2
DMUFY4K SN Liothyronine sustained release
DMUFY4K CP Intellectual property executives
DMUFY4K DE Hypothyroidism
DMRSG31 ID DMRSG31
DMRSG31 DN BCX-3408
DMRSG31 HS Phase 2
DMRSG31 SN ULODESINE; 548486-59-5; UNII-JNG8L9460Y; JNG8L9460Y; CHEMBL269864; DADMe-immucillin H; Ulodesine [USAN:INN]; Ulodesine (USAN); DADMe-ImmH,7; 1n3i; AC1L9KNW; 7-[[(3R,4R)-3-(hydroxymethyl)-4-oxidanyl-pyrrolidin-1-ium-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one; R-3421; SCHEMBL474735; SCHEMBL16320802; CTK5A2657; BDBM22109; DTXSID00203332; AKOS030554378; DB12353; SB17254; D10431; 4H-Pyrrolo[3,2-d]pyrimidin-4-one,1,5-dihydro-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-pyrrolidinyl]methyl]-; BCX-4208; Ulodesine
DMRSG31 DT Small molecular drug
DMRSG31 PC 135449518
DMRSG31 MW 264.28
DMRSG31 FM C12H16N4O3
DMRSG31 IC InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
DMRSG31 CS C1[C@@H]([C@H](CN1CC2=CNC3=C2N=CNC3=O)O)CO
DMRSG31 IK AFNHHLILYQEHKK-BDAKNGLRSA-N
DMRSG31 IU 7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMRSG31 CA CAS 548486-59-5
DMRSG31 DE Plaque psoriasis; Gout; Autoimmune diabetes
DMKFJXP ID DMKFJXP
DMKFJXP DN BDB001
DMKFJXP HS Phase 2
DMKFJXP CP Birdie Biopharmaceuticals; Seven and Eight Biopharmaceuticals
DMKFJXP DT Antibody
DMKFJXP DE Solid tumour/cancer
DM2Q50G ID DM2Q50G
DM2Q50G DN Belnacasan
DM2Q50G HS Phase 2
DM2Q50G SN Second generation ICE inhibitors, Vertex; VRT-043198; VRT-43198; VX-765; VX-765)
DM2Q50G CP MedKoo Biosciences; vertex pharmaceuticals
DM2Q50G DT Small molecular drug
DM2Q50G PC 11398092
DM2Q50G MW 509
DM2Q50G FM C24H33ClN4O6
DM2Q50G IC InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1
DM2Q50G CS CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl
DM2Q50G IK SJDDOCKBXFJEJB-MOKWFATOSA-N
DM2Q50G IU (2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide
DM2Q50G CA CAS 273404-37-8
DM2Q50G DE Epilepsy
DMWNYIE ID DMWNYIE
DMWNYIE DN Bemarituzumab
DMWNYIE HS Phase 2
DMWNYIE CP Five Prime Therapeutics South San Francisco, CA
DMWNYIE DE Gastric adenocarcinoma
DM0YCPL ID DM0YCPL
DM0YCPL DN Bemcentinib
DM0YCPL HS Phase 2
DM0YCPL SN R428; 1037624-75-1; BGB324; R-428; BGB-324; UNII-0ICW2LX8AS; (S)-1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine; CHEMBL3809489; SYN1131; CS-1046; HY-15150; QC-11751; R 428; W-5845; Bemcentinib [USAN]; R428 (BGB324); Bemcentinib (USAN/INN); BemcentinibR428BGB324); SCHEMBL1639904; GTPL10478; BGB 324; DTXSID70673109; 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine; AMY16774; BCP21180; C30H34N8; EX-A1720; SYN-1131; BDBM50172079; NSC824183; s2841; WHO 10631; ZINC51951669; AKOS032947237; ACN-037541; DB12411; NSC-824183; SB16614; NCGC00386665-07; 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N~3~-[(7S)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; AC-28444; AS-16270; KB-80319; D11438; Q27236818; BGB324; BGB-324; BGB 324; R 428; R-428; Bemcentinib; 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine
DM0YCPL CP Rigel Pharmaceuticals; BerGen BIO
DM0YCPL DT Small molecular drug
DM0YCPL PC 46215462
DM0YCPL MW 506.6
DM0YCPL FM C30H34N8
DM0YCPL IC InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1
DM0YCPL CS C1CCN(C1)[C@H]2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76
DM0YCPL IK KXMZDGSRSGHMMK-VWLOTQADSA-N
DM0YCPL IU 1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine
DM0YCPL CA CAS 1037624-75-1
DM0YCPL DE Non-small-cell lung cancer; Myelodysplastic syndrome; Triple negative breast cancer
DMUL6GY ID DMUL6GY
DMUL6GY DN BEMORADAN
DMUL6GY HS Phase 2
DMUL6GY SN Orf-22867; RWJ-22867; Bemoradan; Rac-7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one; Rac-5-Methyl-6-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-one
DMUL6GY DT Small molecular drug
DMUL6GY PC 5362399
DMUL6GY MW 259.26
DMUL6GY FM C13H13N3O3
DMUL6GY IC InChI=1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)
DMUL6GY CS CC1CC(=O)NN=C1C2=CC3=C(C=C2)NC(=O)CO3
DMUL6GY IK XZPGINPFWXLYNW-UHFFFAOYSA-N
DMUL6GY IU 7-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-4H-1,4-benzoxazin-3-one
DMUL6GY CA CAS 112018-01-6
DMUL6GY DE Heart failure
DMRC0EQ ID DMRC0EQ
DMRC0EQ DN Bertilimumab
DMRC0EQ HS Phase 2
DMRC0EQ SN CAT-213; ICo-008
DMRC0EQ CP Cambridge Antibody Technology
DMRC0EQ DT Monoclonal antibody
DMRC0EQ DE Ocular allergy; Bullous pemphigoid; Psoriasis vulgaris; Ulcerative colitis
DMJ2REU ID DMJ2REU
DMJ2REU DN Berubicin
DMJ2REU HS Phase 2
DMJ2REU SN Berubicin hydrochloride; RTA-744; RTA-769; WP-744; WP-769; Anthracycline derivative topoisomerase II inhibitor (cancer), MD Anderson; Anthracycline derivative topoisomerase II inhibitor (cancer), Reata; Berubicin (intravenous), Reata Pharmaceuticals; Berubicin (oral, cancer); Anthracycline topoisomerase II inhibitor (oral, cancer), MD Anderson Cancer Center; Anthracycline topoisomerase II inhibitor (oral, cancer), Reata Pharmaceuticals; Berubicin (oral, cancer), Reata Pharmaceuticals
DMJ2REU CP MD Anderson Cancer Center
DMJ2REU DT Small molecular drug
DMJ2REU PC 9874592
DMJ2REU MW 633.6
DMJ2REU FM C34H35NO11
DMJ2REU IC InChI=1S/C34H35NO11/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3/t16-,20-,22-,24-,33+,34-/m0/s1
DMJ2REU CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OCC6=CC=CC=C6
DMJ2REU IK FIGNGSHKNAHTSH-JJMFXPFOSA-N
DMJ2REU IU (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-phenylmethoxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMJ2REU CA CAS 677017-23-1
DMJ2REU DE Solid tumour/cancer
DM7583A ID DM7583A
DM7583A DN Beta-caryophyllene
DM7583A HS Phase 2
DM7583A SN BETA-CARYOPHYLLENE; Caryophyllene; (-)-trans-Caryophyllene; 87-44-5; L-Caryophyllene; (-)-beta-caryophyllene; trans-Caryophyllene; (E)-Caryophyllene; (E)-beta-caryophyllene; b-caryophyllene; trans-beta-caryophyllene; Beta-Caryophylene; (-)-Caryophyllene; beta-Caryophyllen; beta-Caryophyllene; CHEBI:10357; (E)-beta-caryophylene; beta-(E)-Caryophyllene; beta-Caryophyllen; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; MFCD00075925; UNII-BHW853AU9H; g-Caryophyllene; (1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene; NSC 11906; E-.beta.-caryophyllene; BHW853AU9H; beta-Caryophyllene, (-); Tincturoid; NSC11906; Caryophyllene B; beta-cariofillene; (1R,4E,9S)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene; beta-caryophillene; Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]-; E-beta-caryophyllene; Caryophyllene, (E); beta-(e)-caryophyllene; beta-trans-caryophyllene; (-)- -caryophyllene; (-)-(E)-Caryophyllene; DSSTox_CID_4739; beta-trans-Caryophyllene; trans-.beta.-Caryophyllene; (-)-I(2)-caryophyllene; DSSTox_RID_77517; DSSTox_GSID_24739; 8-Methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene; CHEMBL445740; DTXSID8024739; HY-N1415; ZINC8234282; Tox21_301497; BDBM50529607; s6058; (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; AKOS024283988; trans-(1R,9S)-8-Methylene-4,11,11-trimethylbicyclo[7.2.0]undec-4-ene; LMPR0103120001; beta-Caryophyllene, >=80%, FCC, FG; CAS-87-44-5; NCGC00142620-01; NCGC00255159-01; ST072181; (-)-trans-Caryophyllene, analytical standard; CS-0016839; V0915; C09629; Q421614; W-109317; UNII-K4H93P747O component NPNUFJAVOOONJE-GFUGXAQUSA-N; (-)-trans-Caryophyllene, >=98.5% (sum of enantiomers, GC); trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1R,4E,9S)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R- (1R*,4E,9S*)]-
DM7583A DT Small molecular drug
DM7583A PC 5281515
DM7583A MW 204.35
DM7583A FM C15H24
DM7583A IC InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1
DM7583A CS C/C/1=C\\CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C
DM7583A IK NPNUFJAVOOONJE-GFUGXAQUSA-N
DM7583A IU (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene
DM7583A CA CAS 87-44-5
DM7583A CB CHEBI:10357
DM7583A DE Pain
DMMI84K ID DMMI84K
DMMI84K DN Beta-lapachone
DMMI84K HS Phase 2
DMMI84K SN ARQ 501; SL 11001; A-lapachone; LAPACHONE, BETA; AK-693/21096016; 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione; 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-B]pyran-5,6-dione
DMMI84K CP Roche
DMMI84K DT Small molecular drug
DMMI84K PC 3885
DMMI84K MW 242.27
DMMI84K FM C15H14O3
DMMI84K IC InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3
DMMI84K CS CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C
DMMI84K IK QZPQTZZNNJUOLS-UHFFFAOYSA-N
DMMI84K IU 2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione
DMMI84K CA CAS 4707-32-8
DMMI84K CB CHEBI:10429
DMMI84K DE Solid tumour/cancer
DML2D8Q ID DML2D8Q
DML2D8Q DN Bevirimat
DML2D8Q HS Phase 2
DML2D8Q SN DSB; Bevirimat dimeglumine; DSB 2NMG; MPC-4326; PA-457; PA-103001-01; PA-103001-04; PA-457 di-NMG; Viral maturation inhibitor (HIV), Myrexis; Viral maturation inhibitor (HIV), Myriad; Viral maturation inhibitor (HIV), Panacos; YK-FH-312; 3-O-(3' 3'-dimethylsuccinyl)-betulinic acid
DML2D8Q CP Panacos
DML2D8Q DT Small molecular drug
DML2D8Q PC 457928
DML2D8Q MW 584.8
DML2D8Q FM C36H56O6
DML2D8Q IC InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1
DML2D8Q CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O
DML2D8Q IK YJEJKUQEXFSVCJ-WRFMNRASSA-N
DML2D8Q IU (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-(3-carboxy-3-methylbutanoyl)oxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DML2D8Q CA CAS 174022-42-5
DML2D8Q CB CHEBI:65484
DML2D8Q DE Human immunodeficiency virus infection
DMKBRDL ID DMKBRDL
DMKBRDL DN BEZ235
DMKBRDL HS Phase 2
DMKBRDL SN BEZ-235; S14-0511; NVP-BEZ-235; NVP-BEZ235, BEZ235; 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
DMKBRDL CP Novartis
DMKBRDL DT Small molecular drug
DMKBRDL PC 11977753
DMKBRDL MW 469.5
DMKBRDL FM C30H23N5O
DMKBRDL IC InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3
DMKBRDL CS CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
DMKBRDL IK JOGKUKXHTYWRGZ-UHFFFAOYSA-N
DMKBRDL IU 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile
DMKBRDL CA CAS 915019-65-7
DMKBRDL CB CHEBI:71952
DMKBRDL DE Solid tumour/cancer
DMVUX1C ID DMVUX1C
DMVUX1C DN BFH-772
DMVUX1C HS Phase 2
DMVUX1C SN NVP-BFH-772
DMVUX1C CP Novartis AG
DMVUX1C PC 24756034
DMVUX1C MW 439.4
DMVUX1C FM C23H16F3N3O3
DMVUX1C IC InChI=1S/C23H16F3N3O3/c24-23(25,26)15-4-2-5-16(10-15)29-22(31)20-6-1-3-14-9-18(7-8-19(14)20)32-21-11-17(12-30)27-13-28-21/h1-11,13,30H,12H2,(H,29,31)
DMVUX1C CS C1=CC(=CC(=C1)NC(=O)C2=CC=CC3=C2C=CC(=C3)OC4=NC=NC(=C4)CO)C(F)(F)F
DMVUX1C IK JNLSTLQFDDAULK-UHFFFAOYSA-N
DMVUX1C IU 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
DMVUX1C CA CAS 890128-81-1
DMVUX1C DE Psoriasis vulgaris
DMRO6XT ID DMRO6XT
DMRO6XT DN BGB-290
DMRO6XT HS Phase 2
DMRO6XT SN Pamiparib
DMRO6XT PC 135565554
DMRO6XT MW 298.31
DMRO6XT FM C16H15FN4O
DMRO6XT IC InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
DMRO6XT CS C[C@]12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F
DMRO6XT IK DENYZIUJOTUUNY-MRXNPFEDSA-N
DMRO6XT IU (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
DMRO6XT CA CAS 1446261-44-4
DMRO6XT DE Recurrent glioblastoma; Solid tumour/cancer; Ovarian cancer
DMQCFSM ID DMQCFSM
DMQCFSM DN BGB-3112
DMQCFSM HS Phase 2
DMQCFSM CP BeiGene Cambridge, MA
DMQCFSM DE Follicular lymphoma
DMDI43Y ID DMDI43Y
DMDI43Y DN BGB-324
DMDI43Y HS Phase 2
DMDI43Y SN BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio
DMDI43Y CP BergenBio AS
DMDI43Y DT siRNA drug
DMDI43Y DE Metastatic malignant neoplasm; Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndrome
DM1X3L0 ID DM1X3L0
DM1X3L0 DN BGB-3245
DM1X3L0 HS Phase 2
DM1X3L0 CP BeiGene
DM1X3L0 DT Small molecular drug
DM1X3L0 DE Solid tumour/cancer
DMS2MQ5 ID DMS2MQ5
DMS2MQ5 DN BGC-20-1531
DMS2MQ5 HS Phase 2
DMS2MQ5 SN AH-22921; EP4 antagonist, BTG; EP4 antagonist, Pharmagene; Migraine therapy, BTG; Migraine therapy, Pharmagene; PGN-1531; EP4 receptor antagonists (migraine), Asterand; R-4 (migraine), Pharmagene
DMS2MQ5 CP Pharmagene plc
DMS2MQ5 DT Small molecular drug
DMS2MQ5 PC 25209437
DMS2MQ5 MW 514.5
DMS2MQ5 FM C26H23N2NaO6S
DMS2MQ5 IC InChI=1S/C26H24N2O6S.Na/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23;/h4-15H,16H2,1-3H3,(H,28,29);/q;+1/p-1
DMS2MQ5 CS CC1=CC=CC=C1S(=O)(=O)[N-]C(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC.[Na+]
DMS2MQ5 IK TVDHMDXPKGMXRT-UHFFFAOYSA-M
DMS2MQ5 IU sodium;[4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methylfuran-2-carbonyl]-(2-methylphenyl)sulfonylazanide
DMS2MQ5 DE Migraine
DMYDM68 ID DMYDM68
DMYDM68 DN BGP-15
DMYDM68 HS Phase 2
DMYDM68 SN 66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, > AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride
DMYDM68 CP N-Gene Research Laboratories
DMYDM68 DT Small molecular drug
DMYDM68 PC 9884807
DMYDM68 MW 351.3
DMYDM68 FM C14H24Cl2N4O2
DMYDM68 IC InChI=1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
DMYDM68 CS C1CCN(CC1)CC(CO/N=C(/C2=CN=CC=C2)\\N)O.Cl.Cl
DMYDM68 IK ISGGVCWFTPTHIX-UHFFFAOYSA-N
DMYDM68 IU N'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride
DMYDM68 CA CAS 66611-37-8
DMYDM68 DE Type-2 diabetes
DMO4MNQ ID DMO4MNQ
DMO4MNQ DN BGS-649
DMO4MNQ HS Phase 2
DMO4MNQ CP Novartis AG
DMO4MNQ DE Endometriosis
DMSROM4 ID DMSROM4
DMSROM4 DN BHQ880
DMSROM4 HS Phase 2
DMSROM4 SN BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis
DMSROM4 CP Novartis
DMSROM4 DT Antibody
DMSROM4 DE Multiple myeloma
DM7ZM1H ID DM7ZM1H
DM7ZM1H DN BHT-3009
DM7ZM1H HS Phase 2
DM7ZM1H CP Bayhill Therapeutics
DM7ZM1H DT Vaccine
DM7ZM1H DE Multiple sclerosis
DM740BS ID DM740BS
DM740BS DN BI 1358894
DM740BS HS Phase 2
DM740BS CP Boehringer Ingelheim
DM740BS DT Small molecular drug
DM740BS DE Depression
DMMSGAT ID DMMSGAT
DMMSGAT DN BI 207127
DMMSGAT HS Phase 2
DMMSGAT SN Deleobuvir; UNII-58BU988K90; 58BU988K90; 863884-77-9; Deleobuvir [USAN:INN]; SCHEMBL900174; SCHEMBL900176; CHEMBL2403318; DTXSID40235516; BMAIGAHXAJEULY-UKTHLTGXSA-N; SB16520; BI-207127; 1221574-24-8; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic; Deleobuvir; (E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid; 2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)-; (E)-3-(2-(1
DMMSGAT CP Boehringer Ingelheim Pharma
DMMSGAT DT Small molecular drug
DMMSGAT PC 56948249
DMMSGAT MW 653.6
DMMSGAT FM C34H33BrN6O3
DMMSGAT IC InChI=1S/C34H33BrN6O3/c1-40-26-17-22(10-11-24(26)29(21-6-3-4-7-21)30(40)31-36-18-23(35)19-37-31)32(44)39-34(14-5-15-34)33-38-25-12-8-20(9-13-28(42)43)16-27(25)41(33)2/h8-13,16-19,21H,3-7,14-15H2,1-2H3,(H,39,44)(H,42,43)/b13-9+
DMMSGAT CS CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7
DMMSGAT IK BMAIGAHXAJEULY-UKTHLTGXSA-N
DMMSGAT IU (E)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid
DMMSGAT CA CAS 863884-77-9
DMMSGAT DE Hepatitis C virus infection
DMJSADP ID DMJSADP
DMJSADP DN BI 2536
DMJSADP HS Phase 2
DMJSADP SN BI2536, BI 2536
DMJSADP CP Boehringer Ingelheim
DMJSADP TC Anticancer Agents
DMJSADP DT Small molecular drug
DMJSADP PC 11364421
DMJSADP MW 521.7
DMJSADP FM C28H39N7O3
DMJSADP IC InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1
DMJSADP CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
DMJSADP IK XQVVPGYIWAGRNI-JOCHJYFZSA-N
DMJSADP IU 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
DMJSADP CA CAS 755038-02-9
DMJSADP DE Acute myeloid leukaemia
DM1NMGJ ID DM1NMGJ
DM1NMGJ DN BI 456906
DM1NMGJ HS Phase 2
DM1NMGJ CP Boehringer Ingelheim; Zealand Pharma
DM1NMGJ DT Small molecular drug
DM1NMGJ DE Type 2 diabetes
DMF86P2 ID DMF86P2
DMF86P2 DN BI 655064
DMF86P2 HS Phase 2
DMF86P2 CP Boehringer ingelheim pharmaceuticals
DMF86P2 DT Antibody
DMF86P2 DE Rheumatoid arthritis; Lupus; Thrombocytopenia
DMJFDS0 ID DMJFDS0
DMJFDS0 DN BI-409306
DMJFDS0 HS Phase 2
DMJFDS0 CP Boehringer Ingelheim Pharmaceuticals
DMJFDS0 PC 135908617
DMJFDS0 MW 311.34
DMJFDS0 FM C16H17N5O2
DMJFDS0 IC InChI=1S/C16H17N5O2/c22-16-13-10-18-21(12-4-7-23-8-5-12)15(13)19-14(20-16)9-11-3-1-2-6-17-11/h1-3,6,10,12H,4-5,7-9H2,(H,19,20,22)
DMJFDS0 CS C1COCCC1N2C3=C(C=N2)C(=O)NC(=N3)CC4=CC=CC=N4
DMJFDS0 IK BZTIJCSHNVZMES-UHFFFAOYSA-N
DMJFDS0 IU 1-(oxan-4-yl)-6-(pyridin-2-ylmethyl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMJFDS0 CA CAS 1189767-28-9
DMJFDS0 DE Psychiatric disorder; Alzheimer disease; Schizophrenia
DMZR9OU ID DMZR9OU
DMZR9OU DN BI-44370
DMZR9OU HS Phase 2
DMZR9OU SN BI-44370; Calcitonin gene-related peptide antagonist (migraine), Boehringer Ingelheim
DMZR9OU CP Boehringer Ingelheim Corp
DMZR9OU DE Migraine
DMSZQHX ID DMSZQHX
DMSZQHX DN BI-505
DMSZQHX HS Phase 2
DMSZQHX CP BioInvent International
DMSZQHX DT Antibody
DMSZQHX DE Multiple myeloma
DM9FZYT ID DM9FZYT
DM9FZYT DN BI-655130
DM9FZYT HS Phase 2
DM9FZYT CP Boehringer Ingelheim Ridgefield, CT
DM9FZYT DE Plaque psoriasis; Palmoplantar pustulosis
DMWH7Z5 ID DMWH7Z5
DMWH7Z5 DN BI-836826
DMWH7Z5 HS Phase 2
DMWH7Z5 CP Boehringer Ingelheim Pharmaceuticals
DMWH7Z5 DT Antibody
DMWH7Z5 DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMUVMY9 ID DMUVMY9
DMUVMY9 DN BI-836858
DMUVMY9 HS Phase 2
DMUVMY9 CP Boehringer Ingelheim Pharmaceuticals
DMUVMY9 DT Antibody
DMUVMY9 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMG3ON2 ID DMG3ON2
DMG3ON2 DN BIA 3-202
DMG3ON2 HS Phase 2
DMG3ON2 SN Nebicapone; 274925-86-9; UNII-NM2KXJ990T; NM2KXJ990T; CHEMBL160038; Ethanone, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-; BIA 3-202; Nebicapone [INN]; 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone; SCHEMBL132167; ZINC8750; 1-(3,4-dihydroxy-5-nitro-phenyl)-2-phenyl-ethanone; CTK8H9559; DTXSID30181912; BIA-3-202; BDBM50108878; AKOS028111881; ACM274925869; FT-0703128
DMG3ON2 DT Small molecular drug
DMG3ON2 PC 9838389
DMG3ON2 MW 273.24
DMG3ON2 FM C14H11NO5
DMG3ON2 IC InChI=1S/C14H11NO5/c16-12(6-9-4-2-1-3-5-9)10-7-11(15(19)20)14(18)13(17)8-10/h1-5,7-8,17-18H,6H2
DMG3ON2 CS C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DMG3ON2 IK MRFOLGFFTUGAEB-UHFFFAOYSA-N
DMG3ON2 IU 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone
DMG3ON2 CA CAS 274925-86-9
DMG3ON2 DE Parkinson disease
DMHYZEK ID DMHYZEK
DMHYZEK DN BIBH 1
DMHYZEK HS Phase 2
DMHYZEK CP Boehringer Ingelheim
DMHYZEK DT Antibody
DMHYZEK DE Solid tumour/cancer
DM9OXEJ ID DM9OXEJ
DM9OXEJ DN BIIB 023
DM9OXEJ HS Phase 2
DM9OXEJ CP Biogen Idec
DM9OXEJ DE Rheumatoid arthritis
DM293JT ID DM293JT
DM293JT DN BIIB 033
DM293JT HS Phase 2
DM293JT DT Antibody
DM293JT DE Multiple sclerosis
DMH7RJ1 ID DMH7RJ1
DMH7RJ1 DN BIIB014
DMH7RJ1 HS Phase 2
DMH7RJ1 SN V2006
DMH7RJ1 CP Biogen Idec
DMH7RJ1 DT Small molecular drug
DMH7RJ1 PC 21874557
DMH7RJ1 MW 321.34
DMH7RJ1 FM C16H15N7O
DMH7RJ1 IC InChI=1S/C16H15N7O/c1-9-7-10(4-5-11(9)17)8-23-15-14(21-22-23)13(19-16(18)20-15)12-3-2-6-24-12/h2-7H,8,17H2,1H3,(H2,18,19,20)
DMH7RJ1 CS CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N
DMH7RJ1 IK HQSBCDPYXDGTCL-UHFFFAOYSA-N
DMH7RJ1 IU 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
DMH7RJ1 CA CAS 442908-10-3
DMH7RJ1 DE Parkinson disease
DMPAJ41 ID DMPAJ41
DMPAJ41 DN BIIB-021
DMPAJ41 HS Phase 2
DMPAJ41 SN CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma
DMPAJ41 CP Conforma Therapeutics Corp
DMPAJ41 DT Small molecular drug
DMPAJ41 PC 16736529
DMPAJ41 MW 318.76
DMPAJ41 FM C14H15ClN6O
DMPAJ41 IC InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4,6H,5H2,1-3H3,(H2,16,19,20)
DMPAJ41 CS CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N
DMPAJ41 IK QULDDKSCVCJTPV-UHFFFAOYSA-N
DMPAJ41 IU 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine
DMPAJ41 CA CAS 848695-25-0
DMPAJ41 CB CHEBI:90687
DMPAJ41 DE Breast cancer
DMZO2SY ID DMZO2SY
DMZO2SY DN BIIB054
DMZO2SY HS Phase 2
DMZO2SY CP Biogen Cambridge, MA
DMZO2SY DE Parkinson disease
DMLV1ET ID DMLV1ET
DMLV1ET DN BIIB074
DMLV1ET HS Phase 2
DMLV1ET SN CNV1014082; BC600719; HY-12796; B5927; (5R)-5-(4-[2-
DMLV1ET CP Biogen
DMLV1ET PC 16046068
DMLV1ET MW 314.4
DMLV1ET FM C18H19FN2O2
DMLV1ET IC InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
DMLV1ET CS C1C[C@H](N[C@H]1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
DMLV1ET IK JESCETIFNOFKEU-SJORKVTESA-N
DMLV1ET IU (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
DMLV1ET CA CAS 934240-30-9
DMLV1ET DE Lumbosacral radiculopathy; Trigeminal neuralgia; Bipolar disorder
DM263RP ID DM263RP
DM263RP DN BIIB092
DM263RP HS Phase 2
DM263RP CP Biogen Cambridge, MA
DM263RP DE Alzheimer disease; Progressive supranuclear palsy
DM2J36F ID DM2J36F
DM2J36F DN BILN-2061
DM2J36F HS Phase 2
DM2J36F SN Ciluprevir; BILN-2061; 300832-84-2; BILN 2061; UNII-75C8DU40T0; CHEMBL297884; 75C8DU40T0; Ciluprevir [USAN:INN]; Ciluprevir (BILN-2061); BILN 2061 ZW; BILN2061; SCHEMBL2524642; BILN-2061-ZW; C40H50N6O8S; (cyclopentoxycarbonylamino)-[[2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy]-dioxo-[ ]carboxylic acid; BDBM50142916; 3548AH; ZINC150339466; AKOS024627485; CS-0339; DB05868; BILN 2061; ; ; BILN 2061ZW; HY-10242; W-5515; F2145-0237
DM2J36F TC Antiviral Agents
DM2J36F DT Small molecular drug
DM2J36F PC 9853710
DM2J36F MW 774.9
DM2J36F FM C40H50N6O8S
DM2J36F IC InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1
DM2J36F CS CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O
DM2J36F IK PJZPDFUUXKKDNB-KNINVFKUSA-N
DM2J36F IU (1S,4R,6S,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
DM2J36F CA CAS 300832-84-2
DM2J36F DE Hepatitis virus infection
DMAG4SX ID DMAG4SX
DMAG4SX DN BILR-355
DMAG4SX HS Phase 2
DMAG4SX SN BILR-355-BS; 11-Ethyl-5-methyl-8-[2-(1-oxidoquinolin-4-yloxy)ethyl]-6,11-dihydro-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
DMAG4SX DE Human immunodeficiency virus infection
DM6EIZG ID DM6EIZG
DM6EIZG DN BIM23A760
DM6EIZG HS Phase 2
DM6EIZG SN Lonapalene; LONAPALENE; RS-43179; 91431-42-4; UNII-WIF31Q54NJ; WIF31Q54NJ; CHEMBL36648; Lonapalenum; Lonapaleno; Lonapalenum [Latin]; Lonapaleno [Spanish]; Lonapalene (USAN); Lonapalene [USAN:INN]; RS 43179; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; AC1L1KN9; SCHEMBL120134; ZINC1630; DTXSID00238563; IFWMVQUGSGWCRP-UHFFFAOYSA-N; HY-U00156; BDBM50004677; CS-7197; ZB000377; D04770; 6-chloro-1,4-diacetoxy-2,3-dimethoxynaphthalene
DM6EIZG CP Ipsen
DM6EIZG DT Small molecular drug
DM6EIZG PC 56237
DM6EIZG MW 338.74
DM6EIZG FM C16H15ClO6
DM6EIZG IC InChI=1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3
DM6EIZG CS CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC
DM6EIZG IK IFWMVQUGSGWCRP-UHFFFAOYSA-N
DM6EIZG IU (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate
DM6EIZG CA CAS 91431-42-4
DM6EIZG DE Acromegaly; Carcinoid syndrome; Psoriasis vulgaris
DMH7Q4E ID DMH7Q4E
DMH7Q4E DN Bimagrumab
DMH7Q4E HS Phase 2
DMH7Q4E CP Novartis
DMH7Q4E DT Antibody
DMH7Q4E DE Type 2 diabetes
DMBRL19 ID DMBRL19
DMBRL19 DN Bimakalim
DMBRL19 HS Phase 2
DMBRL19 SN EMD-52692; SR-44866
DMBRL19 CP Merck KGaA
DMBRL19 DT Small molecular drug
DMBRL19 PC 60674
DMBRL19 MW 278.3
DMBRL19 FM C17H14N2O2
DMBRL19 IC InChI=1S/C17H14N2O2/c1-17(2)10-14(19-8-4-3-5-16(19)20)13-9-12(11-18)6-7-15(13)21-17/h3-10H,1-2H3
DMBRL19 CS CC1(C=C(C2=C(O1)C=CC(=C2)C#N)N3C=CC=CC3=O)C
DMBRL19 IK JTVSKASWNROQQF-UHFFFAOYSA-N
DMBRL19 IU 2,2-dimethyl-4-(2-oxopyridin-1-yl)chromene-6-carbonitrile
DMBRL19 CA CAS 117545-11-6
DMBRL19 DE Angina pectoris
DMB9LRJ ID DMB9LRJ
DMB9LRJ DN Bintrafusp alfa
DMB9LRJ HS Phase 2
DMB9LRJ CP EMD Serono; GlaxoSmithKline
DMB9LRJ DT Recombinant protein
DMB9LRJ DE Non-small cell lung cancer
DM6N05H ID DM6N05H
DM6N05H DN BIO-11006
DM6N05H HS Phase 2
DM6N05H CP BioMarck Pharmaceuticals
DM6N05H DE Chronic obstructive pulmonary disease; Non-small-cell lung cancer
DMPNYXQ ID DMPNYXQ
DMPNYXQ DN BIO-11006
DMPNYXQ HS Phase 2
DMPNYXQ SN UNII-609AWV0US2; 609AWV0US2; DB14886; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid; 901117-03-1
DMPNYXQ CP BioMarck Pharmaceuticals
DMPNYXQ DT Small molecular drug
DMPNYXQ PC 11622197
DMPNYXQ MW 1050.2
DMPNYXQ FM C46H75N13O15
DMPNYXQ IC InChI=1S/C46H75N13O15/c1-24(51-36(64)22-50-28(5)62)39(66)54-31(17-18-35(49)63)41(68)57-33(21-29-13-7-6-8-14-29)43(70)58-34(23-60)44(71)55-30(15-9-11-19-47)42(69)59-37(27(4)61)45(72)53-25(2)38(65)52-26(3)40(67)56-32(46(73)74)16-10-12-20-48/h6-8,13-14,24-27,30-34,37,60-61H,9-12,15-23,47-48H2,1-5H3,(H2,49,63)(H,50,62)(H,51,64)(H,52,65)(H,53,72)(H,54,66)(H,55,71)(H,56,67)(H,57,68)(H,58,70)(H,59,69)(H,73,74)/t24-,25-,26-,27+,30-,31-,32-,33-,34-,37-/m0/s1
DMPNYXQ CS C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)C)O
DMPNYXQ IK KCSNGWMKFYVMKF-HGYIIGRXSA-N
DMPNYXQ IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-acetamidoacetyl)amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]propanoyl]amino]-6-aminohexanoic acid
DMPNYXQ CA CAS 901117-03-1
DMPNYXQ DE Non-small-cell lung cancer
DMKICA3 ID DMKICA3
DMKICA3 DN BIO-1211
DMKICA3 HS Phase 2
DMKICA3 SN BIO-1211; BIO 1211; 187735-94-0; UNII-61G4E2353I; CHEMBL88478; 61G4E2353I; BIO1211; GTPL6589; SCHEMBL1223367; MolPort-023-276-985; ZINC3930111; BDBM50074661; AKOS024457866; L-Proline, N-(2-(4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-; L-Proline, N-((4-((((2-methylphenyl)amino)carbonyl)amino)phenyl)acetyl)-L-leucyl-L-alpha-aspartyl-L-valyl-
DMKICA3 DT Small molecular drug
DMKICA3 PC 9961766
DMKICA3 MW 708.8
DMKICA3 FM C36H48N6O9
DMKICA3 IC InChI=1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1
DMKICA3 CS CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)O
DMKICA3 IK NVVGCQABIHSJSQ-KFZSMJGVSA-N
DMKICA3 IU (2S)-1-[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid
DMKICA3 CA CAS 187735-94-0
DMKICA3 DE Asthma
DM7PT8R ID DM7PT8R
DM7PT8R DN BioE-743
DM7PT8R HS Phase 2
DM7PT8R CP BioElectron Technology Mountain View, CA
DM7PT8R DE Leigh syndrome; Pontocerebellar hypoplasia type 6
DM6PBUM ID DM6PBUM
DM6PBUM DN Birinapant
DM6PBUM HS Phase 2
DM6PBUM SN Birinapant; 1260251-31-7; Birinapant (TL32711); TL-32711; UNII-6O4Z07B57R; TL 32711; 6O4Z07B57R; (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6PBUM CP TetraLogic Pharmaceuticals
DM6PBUM DT Small molecular drug
DM6PBUM PC 49836020
DM6PBUM MW 806.9
DM6PBUM FM C42H56F2N8O6
DM6PBUM IC InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1
DM6PBUM CS CC[C@@H](C(=O)N1C[C@H](C[C@H]1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)C[C@@H]6C[C@@H](CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC)O)O)NC(=O)[C@H](C)NC
DM6PBUM IK PKWRMUKBEYJEIX-DXXQBUJASA-N
DM6PBUM IU (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6PBUM CA CAS 1260251-31-7
DM6PBUM DE Lymphoma; Solid tumour/cancer
DMW76V0 ID DMW76V0
DMW76V0 DN Bisantrene
DMW76V0 HS Phase 2
DMW76V0 SN 39C34M111K; 78186-34-2; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazon); 9,10-Anthracenedicarboxaldehyde, bis((4,5-dihydro-1H-imidazol-2-yl)hydrazone)-; BISANTRENE HYDROCHLORIDE; BRN 0966309; Bisantrene; Bisantrene [INN]; Bisantreno; Bisantreno [INN-Spanish]; Bisantrenum; Bisantrenum [INN-Latin]; CHEMBL25336; CL 216942; N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazono)methyl]-9-anthryl]methyleneamino]-4,5-dihydro-1H-imidazol-2-amine; NSC 337766; UNII-39C34M111K
DMW76V0 DT Small molecular drug
DMW76V0 PC 5351322
DMW76V0 MW 398.474
DMW76V0 FM C22H22N8
DMW76V0 IC InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+
DMW76V0 CS C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5
DMW76V0 IK NJSMWLQOCQIOPE-OCHFTUDZSA-N
DMW76V0 IU N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine
DMW76V0 CA CAS 78186-34-2
DMW76V0 DE Acute myelogenous leukemia
DMVDO93 ID DMVDO93
DMVDO93 DN BL-1020
DMVDO93 HS Phase 2
DMVDO93 SN BL 1020; Perphenazine 4-aminobutyrate; Butanoic acid, 4-amino-, 2-(4-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
DMVDO93 CP BioLineRx
DMVDO93 DT Small molecular drug
DMVDO93 PC 11203271
DMVDO93 MW 489.1
DMVDO93 FM C25H33ClN4O2S
DMVDO93 IC InChI=1S/C25H33ClN4O2S/c26-20-8-9-24-22(19-20)30(21-5-1-2-6-23(21)33-24)12-4-11-28-13-15-29(16-14-28)17-18-32-25(31)7-3-10-27/h1-2,5-6,8-9,19H,3-4,7,10-18,27H2
DMVDO93 CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCOC(=O)CCCN
DMVDO93 IK BABFYCSPNDKXRI-UHFFFAOYSA-N
DMVDO93 IU 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
DMVDO93 CA CAS 751477-01-7
DMVDO93 DE Schizophrenia
DM8R71T ID DM8R71T
DM8R71T DN BL-22
DM8R71T HS Phase 2
DM8R71T SN CAT-3888; GCR-3888; RFB4(dsFv)-PE38; PE38-conjugated anti-CD22 immunotoxin, NCI/Cambridge Antibody Technology/AstraZeneca
DM8R71T CP National Cancer Institute
DM8R71T DT Antibody
DM8R71T DE Acute lymphoblastic leukaemia
DMSBPJI ID DMSBPJI
DMSBPJI DN BL-7040
DMSBPJI HS Phase 2
DMSBPJI SN Monarsen; EN-101; TLR-9 activator (oral, inflammatory bowel disease), BioLineRx; TLR-9 activator (oral, inflammatory bowel disease), Hebrew University of Jerusalem
DMSBPJI CP Yissum Research Development Co
DMSBPJI DT Small molecular drug
DMSBPJI PC 56841946
DMSBPJI MW 6375
DMSBPJI FM C194H253N64O106P19S19
DMSBPJI IC InChI=1S/C194H253N64O106P19S19/c1-78-45-248(189(279)233-165(78)261)137-35-91(108(333-137)58-307-365(285,384)346-84-28-130(326-101(84)51-259)239-19-10-121(195)218-180(239)270)357-375(295,394)321-66-116-98(42-144(341-116)255-74-215-149-162(255)227-177(206)230-171(149)267)360-378(298,397)312-56-106-85(29-131(331-106)240-20-11-122(196)219-181(240)271)347-366(286,385)308-52-102-88(32-134(327-102)243-23-14-125(199)222-184(243)274)350-369(289,388)319-64-114-97(41-143(339-114)254-73-213-147-158(204)209-71-211-160(147)254)359-377(297,396)311-55-105-89(33-135(330-105)244-24-15-126(200)223-185(244)275)351-370(290,389)320-65-115-100(44-146(340-115)257-76-217-151-164(257)229-179(208)232-173(151)269)362-380(300,399)318-63-113-95(39-141(338-113)252-49-82(5)169(265)237-193(252)283)356-374(294,393)316-61-111-93(37-139(336-111)250-47-80(3)167(263)235-191(250)281)354-372(292,391)310-54-104-86(30-132(329-104)241-21-12-123(197)220-182(241)272)348-367(287,386)314-59-109-92(36-138(334-109)249-46-79(2)166(262)234-190(249)280)353-371(291,390)309-53-103-87(31-133(328-103)242-22-13-124(198)221-183(242)273)349-368(288,387)315-60-110-94(38-140(335-110)251-48-81(4)168(264)236-192(251)282)355-373(293,392)317-62-112-96(40-142(337-112)253-50-83(6)170(266)238-194(253)284)358-376(296,395)322-67-117-99(43-145(342-117)256-75-216-150-163(256)228-178(207)231-172(150)268)361-379(299,398)313-57-107-90(34-136(332-107)245-25-16-127(201)224-186(245)276)352-381(301,400)324-69-120-154(157(306-9)176(345-120)258-77-214-148-159(205)210-72-212-161(148)258)364-383(303,402)325-70-119-153(156(305-8)175(344-119)247-27-18-129(203)226-188(247)278)363-382(302,401)323-68-118-152(260)155(304-7)174(343-118)246-26-17-128(202)225-187(246)277/h10-27,45-50,71-77,84-120,130-146,152-157,174-176,259-260H,28-44,51-70H2,1-9H3,(H,285,384)(H,286,385)(H,287,386)(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H2,195,218,270)(H2,196,219,271)(H2,197,220,272)(H2,198,221,273)(H2,199,222,274)(H2,200,223,275)(H2,201,224,276)(H2,202,225,277)(H2,203,226,278)(H2,204,209,211)(H2,205,210,212)(H,233,261,279)(H,234,262,280)(H,235,263,281)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H3,206,227,230,267)(H3,207,228,231,268)(H3,208,229,232,269)
DMSBPJI CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3CO)N4C=CC(=NC4=O)N)OP(=S)(O)OCC5C(CC(O5)N6C=NC7=C6N=C(NC7=O)N)OP(=S)(O)OCC8C(CC(O8)N9C=CC(=NC9=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O
DMSBPJI IK QJYMZHMIZZYHBI-UHFFFAOYSA-N
DMSBPJI IU 1-[4-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMSBPJI DE Inflammatory bowel disease
DMKO0BQ ID DMKO0BQ
DMKO0BQ DN BLD-2660
DMKO0BQ HS Phase 2
DMKO0BQ SN BLD 2660
DMKO0BQ TC Antiviral Agents
DMKO0BQ DT Small molecular drug
DMKO0BQ DE Coronavirus Disease 2019 (COVID-19)
DMYK1DR ID DMYK1DR
DMYK1DR DN BLI-1005
DMYK1DR HS Phase 2
DMYK1DR CP BioLite Taipei, Taiwan
DMYK1DR DE Major depressive disorder
DMG1LVA ID DMG1LVA
DMG1LVA DN BLZ-945
DMG1LVA HS Phase 2
DMG1LVA SN CSF-1R inhibitor (bone cancer); CSF-1R inhibitor (bone cancer), Novartis
DMG1LVA CP Novartis Institutes for BioMedical Research Inc
DMG1LVA DT Small molecular drug
DMG1LVA PC 46184986
DMG1LVA MW 398.5
DMG1LVA FM C20H22N4O3S
DMG1LVA IC InChI=1S/C20H22N4O3S/c1-21-19(26)16-10-13(8-9-22-16)27-12-6-7-15-18(11-12)28-20(24-15)23-14-4-2-3-5-17(14)25/h6-11,14,17,25H,2-5H2,1H3,(H,21,26)(H,23,24)/t14-,17-/m1/s1
DMG1LVA CS CNC(=O)C1=NC=CC(=C1)OC2=CC3=C(C=C2)N=C(S3)N[C@@H]4CCCC[C@H]4O
DMG1LVA IK ADZBMFGQQWPHMJ-RHSMWYFYSA-N
DMG1LVA IU 4-[[2-[[(1R,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide
DMG1LVA CA CAS 953769-46-5
DMG1LVA DE Solid tumour/cancer; Amyotrophic lateral sclerosis
DMQI43G ID DMQI43G
DMQI43G DN BMS 650032
DMQI43G HS Phase 2
DMQI43G SN Asunaprevir; 630420-16-5; BMS-650032; UNII-S9X0KRJ00S; BMS 650032; S9X0KRJ00S; Asunaprevir (BMS-650032); N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4r)-4-[(7-Chloro-4-Methoxyisoquinolin-1-Yl)oxy]-N-{(1r,2s)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-Ethenylcyclopropyl}-L-Prolinamide; Asunaprevir [USAN:INN]; Sunvepra (TN); tert-butyl N-[(1S)-1-[(2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]carbamate; 2R9
DMQI43G CP Bristol-Myers Squibb
DMQI43G DT Small molecular drug
DMQI43G PC 16076883
DMQI43G MW 748.3
DMQI43G FM C35H46ClN5O9S
DMQI43G IC InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
DMQI43G CS CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
DMQI43G IK XRWSZZJLZRKHHD-WVWIJVSJSA-N
DMQI43G IU tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMQI43G CA CAS 630420-16-5
DMQI43G CB CHEBI:134723
DMQI43G DE Hepatitis C virus infection
DMKH4PI ID DMKH4PI
DMKH4PI DN BMS 791325
DMKH4PI HS Phase 2
DMKH4PI SN BMS-791325
DMKH4PI CP Bristol-Myers Squibb
DMKH4PI DT Small molecular drug
DMKH4PI PC 56934415
DMKH4PI MW 659.8
DMKH4PI FM C36H45N5O5S
DMKH4PI IC InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24-,25+,30-,36-/m0/s1
DMKH4PI CS CN1C[C@H]2CC[C@@H](C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8
DMKH4PI IK ZTTKEBYSXUCBSE-QDFUAKMASA-N
DMKH4PI IU (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-[(1S,5R)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl]-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
DMKH4PI CA CAS 958002-33-0
DMKH4PI DE Hepatitis C virus infection
DMDPLEM ID DMDPLEM
DMDPLEM DN BMS-184476
DMDPLEM HS Phase 2
DMDPLEM SN 10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 7-O-(Methylsulfanylmethyl)paclitaxel
DMDPLEM DT Small molecular drug
DMDPLEM PC 6918461
DMDPLEM MW 914
DMDPLEM FM C49H55NO14S
DMDPLEM IC InChI=1S/C49H55NO14S/c1-27-33(62-45(57)38(53)37(30-17-11-8-12-18-30)50-43(55)31-19-13-9-14-20-31)24-49(58)42(63-44(56)32-21-15-10-16-22-32)40-47(6,41(54)39(61-28(2)51)36(27)46(49,4)5)34(60-26-65-7)23-35-48(40,25-59-35)64-29(3)52/h8-22,33-35,37-40,42,53,58H,23-26H2,1-7H3,(H,50,55)/t33-,34-,35+,37-,38+,39+,40-,42-,47+,48-,49+/m0/s1
DMDPLEM CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)OCSC)C)OC(=O)C
DMDPLEM IK UBJAHGAUPNGZFF-XOVTVWCYSA-N
DMDPLEM IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(methylsulfanylmethoxy)-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMDPLEM CA CAS 160237-25-2
DMDPLEM DE Solid tumour/cancer
DML1CK2 ID DML1CK2
DML1CK2 DN BMS-188797
DML1CK2 HS Phase 2
DML1CK2 SN 11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benz[1,2-b]oxet-9-yl ester; 4-O-Deacetyl-4-O-(methoxycarbonyl)paclitaxel
DML1CK2 DT Small molecular drug
DML1CK2 PC 6918494
DML1CK2 MW 869.9
DML1CK2 FM C47H51NO15
DML1CK2 IC InChI=1S/C47H51NO15/c1-25-30(61-42(55)35(51)34(27-16-10-7-11-17-27)48-40(53)28-18-12-8-13-19-28)23-47(57)39(62-41(54)29-20-14-9-15-21-29)37-45(5,38(52)36(60-26(2)49)33(25)44(47,3)4)31(50)22-32-46(37,24-59-32)63-43(56)58-6/h7-21,30-32,34-37,39,50-51,57H,22-24H2,1-6H3,(H,48,53)/t30-,31-,32+,34-,35+,36+,37-,39-,45+,46-,47+/m0/s1
DML1CK2 CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)OC)O)C)OC(=O)C
DML1CK2 IK GMJWGJSDPOAZTP-MIDYMNAOSA-N
DML1CK2 IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DML1CK2 CA CAS 172481-83-3
DML1CK2 DE Solid tumour/cancer
DMJUV6C ID DMJUV6C
DMJUV6C DN BMS-223131
DMJUV6C HS Phase 2
DMJUV6C SN 4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
DMJUV6C PC 9951995
DMJUV6C MW 383.7
DMJUV6C FM C18H13ClF3NO3
DMJUV6C IC InChI=1S/C18H13ClF3NO3/c19-10-2-4-15(25)13(8-10)16-11(5-6-24)17(26)23-14-3-1-9(7-12(14)16)18(20,21)22/h1-4,7-8,24-25H,5-6H2,(H,23,26)
DMJUV6C CS C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O
DMJUV6C IK QESHSZWKJULSAR-UHFFFAOYSA-N
DMJUV6C IU 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-1H-quinolin-2-one
DMJUV6C CA CAS 275375-69-4
DMJUV6C DE Erectile dysfunction
DMQL3VS ID DMQL3VS
DMQL3VS DN BMS-275183
DMQL3VS HS Phase 2
DMQL3VS SN BMS-198246; Oral taxane (cancer), BMS; Oral taxane (cancer), Bristol-Myers Squibb
DMQL3VS CP Bristol-Myers Squibb Co
DMQL3VS DT Small molecular drug
DMQL3VS PC 6918594
DMQL3VS MW 845.9
DMQL3VS FM C43H59NO16
DMQL3VS IC InChI=1S/C43H59NO16/c1-21-24(57-35(50)28(47)31(38(3,4)5)44-36(51)59-39(6,7)8)19-43(53)33(58-34(49)23-16-14-13-15-17-23)30-41(11,32(48)29(56-22(2)45)27(21)40(43,9)10)25(46)18-26-42(30,20-55-26)60-37(52)54-12/h13-17,24-26,28-31,33,46-47,53H,18-20H2,1-12H3,(H,44,51)/t24-,25-,26+,28+,29+,30-,31+,33-,41+,42-,43+/m0/s1
DMQL3VS CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C(C)(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)OC)O)C)OC(=O)C
DMQL3VS IK AHXICHPPXIGCBN-GPWPDEGDSA-N
DMQL3VS IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-12-acetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-4,4-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]oxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMQL3VS CA CAS 355113-98-3
DMQL3VS DE Solid tumour/cancer
DMGYXFP ID DMGYXFP
DMGYXFP DN BMS-582949
DMGYXFP HS Phase 2
DMGYXFP SN BMS-582949; 623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; PS540446; BMS582949 free base; PS 540446
DMGYXFP CP Bristol-Myers Squibb
DMGYXFP DT Small molecular drug
DMGYXFP PC 10409068
DMGYXFP MW 406.5
DMGYXFP FM C22H26N6O2
DMGYXFP IC InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)
DMGYXFP CS CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C
DMGYXFP IK GDTQLZHHDRRBEB-UHFFFAOYSA-N
DMGYXFP IU 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
DMGYXFP CA CAS 623152-17-0
DMGYXFP DE Psoriasis vulgaris; Atherosclerosis
DMDPQV5 ID DMDPQV5
DMDPQV5 DN BMS-599626
DMDPQV5 HS Phase 2
DMDPQV5 SN BMS-599626; 714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703
DMDPQV5 CP Bristol Myers Squibb
DMDPQV5 TC Anticancer Agents
DMDPQV5 DT Small molecular drug
DMDPQV5 PC 10437018
DMDPQV5 MW 530.6
DMDPQV5 FM C27H27FN8O3
DMDPQV5 IC InChI=1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1
DMDPQV5 CS CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F
DMDPQV5 IK LUJZZYWHBDHDQX-QFIPXVFZSA-N
DMDPQV5 IU [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate
DMDPQV5 CA CAS 714971-09-2
DMDPQV5 DE Solid tumour/cancer
DMX302C ID DMX302C
DMX302C DN BMS-690514
DMX302C HS Phase 2
DMX302C SN BMS 690514; BMS690514
DMX302C DT Small molecular drug
DMX302C PC 11349170
DMX302C MW 368.4
DMX302C FM C19H24N6O2
DMX302C IC InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
DMX302C CS COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CC[C@H]([C@@H](C4)O)N
DMX302C IK CSGQVNMSRKWUSH-IAGOWNOFSA-N
DMX302C IU (3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
DMX302C CA CAS 859853-30-8
DMX302C DE Chronic pain
DM51LTG ID DM51LTG
DM51LTG DN BMS-708163
DM51LTG HS Phase 2
DM51LTG SN Avagacestat
DM51LTG CP Bristol-Myers Squibb
DM51LTG DT Small molecular drug
DM51LTG PC 46883536
DM51LTG MW 520.9
DM51LTG FM C20H17ClF4N4O4S
DM51LTG IC InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1
DM51LTG CS C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)[C@H](CCC(F)(F)F)C(=O)N)Cl
DM51LTG IK XEAOPVUAMONVLA-QGZVFWFLSA-N
DM51LTG IU (2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide
DM51LTG CA CAS 1146699-66-2
DM51LTG DE Alzheimer disease
DMTVGY7 ID DMTVGY7
DMTVGY7 DN BMS-770767
DMTVGY7 HS Phase 2
DMTVGY7 CP Bristol-Myers Squibb
DMTVGY7 DE Hypercholesterolaemia
DMKY638 ID DMKY638
DMKY638 DN BMS-813160
DMKY638 HS Phase 2
DMKY638 SN BMS-585059; CCR2/CCR5 chemokine antagonist (immune disorders, cardiovascular disorders), BMS; CCR2/CCR5 dual antagonist (cardiovascular disease), Bristol-Myers Squibb; CCR2/CCR5 dual antagonist (immunology), Bristol-Myers Squibb
DMKY638 CP Bristol-myers squibb
DMKY638 PC 51039119
DMKY638 MW 484.6
DMKY638 FM C25H40N8O2
DMKY638 IC InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5,6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2,3)4)31-33(21)23/h13-14,16-19,30H,8-12H2,1-7H3,(H,28,34)(H,26,27,29)/t16-,17+,18-,19+/m1/s1
DMKY638 CS CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N2CC[C@@H](C2=O)NC3=NC=NC4=CC(=NN43)C(C)(C)C)NC(C)(C)C
DMKY638 IK CMVHFGNTABZQJU-HCXYKTFWSA-N
DMKY638 IU N-[(1R,2S,5R)-5-(tert-butylamino)-2-[(3S)-3-[(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino]-2-oxopyrrolidin-1-yl]cyclohexyl]acetamide
DMKY638 CA CAS 1286279-29-5
DMKY638 DE Diabetic nephropathy; Solid tumour/cancer
DMT8L6P ID DMT8L6P
DMT8L6P DN BMS-817399
DMT8L6P HS Phase 2
DMT8L6P CP Bristol-Myers Squibb
DMT8L6P PC 44537841
DMT8L6P MW 454
DMT8L6P FM C23H36ClN3O4
DMT8L6P IC InChI=1S/C23H36ClN3O4/c1-15(2)18(26-20(29)25-13-22(5,6)30)19(28)27-12-11-23(31,21(3,4)14-27)16-7-9-17(24)10-8-16/h7-10,15,18,30-31H,11-14H2,1-6H3,(H2,25,26,29)/t18-,23+/m1/s1
DMT8L6P CS CC(C)[C@H](C(=O)N1CC[C@@](C(C1)(C)C)(C2=CC=C(C=C2)Cl)O)NC(=O)NCC(C)(C)O
DMT8L6P IK GTDPZONCGOCXOD-JPYJTQIMSA-N
DMT8L6P IU 1-[(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-(2-hydroxy-2-methylpropyl)urea
DMT8L6P CA CAS 1202400-18-7
DMT8L6P DE Rheumatoid arthritis
DMF46PD ID DMF46PD
DMF46PD DN BMS-911543
DMF46PD HS Phase 2
DMF46PD SN BMS-911543; 1271022-90-2; BMS 911543; BMS911543; UNII-7N03P021J8; 7N03P021J8; N,N-Dicyclopropyl-4-[(1,5-Dimethyl-1h-Pyrazol-3-Yl)amino]-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-Carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide; JCINBYQJBYJGDM-UHFFFAOYSA-N
DMF46PD CP Bristol-Myers Squibb
DMF46PD DT Small molecular drug
DMF46PD PC 50922691
DMF46PD MW 432.5
DMF46PD FM C23H28N8O
DMF46PD IC InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)
DMF46PD CS CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6
DMF46PD IK JCINBYQJBYJGDM-UHFFFAOYSA-N
DMF46PD IU N,N-dicyclopropyl-7-[(1,5-dimethylpyrazol-3-yl)amino]-10-ethyl-3-methyl-3,5,8,10-tetrazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,11-pentaene-11-carboxamide
DMF46PD CA CAS 1271022-90-2
DMF46PD DE Myelofibrosis
DMN28WK ID DMN28WK
DMN28WK DN BMS-919373
DMN28WK HS Phase 2
DMN28WK CP Bristol-myers squibb
DMN28WK PC 51030730
DMN28WK MW 468.5
DMN28WK FM C25H20N6O2S
DMN28WK IC InChI=1S/C25H20N6O2S/c26-34(32,33)20-13-18(14-27-16-20)24-30-22-11-6-10-21(17-7-2-1-3-8-17)23(22)25(31-24)29-15-19-9-4-5-12-28-19/h1-14,16H,15H2,(H2,26,32,33)(H,29,30,31)
DMN28WK CS C1=CC=C(C=C1)C2=C3C(=CC=C2)N=C(N=C3NCC4=CC=CC=N4)C5=CC(=CN=C5)S(=O)(=O)N
DMN28WK IK XGKULQQVQWCASY-UHFFFAOYSA-N
DMN28WK IU 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
DMN28WK CA CAS 1272353-82-8
DMN28WK DE Atrial fibrillation
DMUTS1W ID DMUTS1W
DMUTS1W DN BMS-936557
DMUTS1W HS Phase 2
DMUTS1W SN Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex
DMUTS1W CP Medarex Inc
DMUTS1W DT Antibody
DMUTS1W DE Immune System disease
DM7XV4R ID DM7XV4R
DM7XV4R DN BMS-954561
DM7XV4R HS Phase 2
DM7XV4R SN AGN-001; AGN-209323; AGN-2XXXXX; AGN-323; EHT-001; EHT/AGN-0001; EHT/AGN-001; GABA/nicotinic modulator (neuroscience), BMS; Neuropathic pain therapy, ExonHit/Allergan/Bristol-Myers Squibb
DM7XV4R CP Exonhit
DM7XV4R DE Diabetic neuropathy
DMMEAGO ID DMMEAGO
DMMEAGO DN BMS-955176
DMMEAGO HS Phase 2
DMMEAGO CP Bristol-myers squibb
DMMEAGO DE Human immunodeficiency virus-1 infection
DMVJXOH ID DMVJXOH
DMVJXOH DN BMS-986012
DMVJXOH HS Phase 2
DMVJXOH CP Bristol-Myers Squibb
DMVJXOH DT Antibody
DMVJXOH DE Small-cell lung cancer; Solid tumour/cancer
DMHMV6E ID DMHMV6E
DMHMV6E DN BMS-986020
DMHMV6E HS Phase 2
DMHMV6E SN GQBRZBHEPUQRPL-LJQANCHMSA-N; 1257213-50-5; AP-3152 free acid; UNII-38CTP01B4L; 38CTP01B4L; SCHEMBL344742; GTPL9498; EX-A866; MolPort-044-616-249; ZINC113624125; AKOS030631907; CS-5844; AS-35060; HY-100619; FT-0700148; J-690107; Cyclopropanecarboxylic acid, 1-(4'-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1'-biphenyl)-4-yl)-; 1-{4'-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid; 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonyl
DMHMV6E CP Bristol-Myers SquibbPrinceton, NJ
DMHMV6E PC 49792850
DMHMV6E MW 482.5
DMHMV6E FM C29H26N2O5
DMHMV6E IC InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m1/s1
DMHMV6E CS CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
DMHMV6E IK GQBRZBHEPUQRPL-LJQANCHMSA-N
DMHMV6E IU 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
DMHMV6E CA CAS 1257213-50-5
DMHMV6E DE Psoriasis vulgaris; Scleroderma
DMIZKEC ID DMIZKEC
DMIZKEC DN BMS-986036
DMIZKEC HS Phase 2
DMIZKEC CP Bristol-Myers Squibb Princeton, NJ
DMIZKEC DE Type-2 diabetes
DMTKDIP ID DMTKDIP
DMTKDIP DN BMS-986141
DMTKDIP HS Phase 2
DMTKDIP SN UNII-W530IRZ40G; W530IRZ40G; UDM-003183; 1478711-48-6; 4-(4-(((6-Methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)thiazol-2-yl)-N,N-dimethylbenzamide; CHEMBL3716552; SCHEMBL15348940; BDBM176003; DB14942; US9688695, 36; 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide; Benzamide, 4-(4-(((6-methoxy-2-(2-methoxyimidazo(2,1-b)-1,3,4-thiadiazol-6-yl)-4-benzofuranyl)oxy)methyl)-2-thiazolyl)-N,N-dimethyl-
DMTKDIP CP Bristol-Myers Squibb
DMTKDIP DT Small molecular drug
DMTKDIP PC 72188743
DMTKDIP MW 561.6
DMTKDIP FM C27H23N5O5S2
DMTKDIP IC InChI=1S/C27H23N5O5S2/c1-31(2)25(33)16-7-5-15(6-8-16)24-28-17(14-38-24)13-36-21-9-18(34-3)10-22-19(21)11-23(37-22)20-12-32-26(29-20)39-27(30-32)35-4/h5-12,14H,13H2,1-4H3
DMTKDIP CS CN(C)C(=O)C1=CC=C(C=C1)C2=NC(=CS2)COC3=CC(=CC4=C3C=C(O4)C5=CN6C(=N5)SC(=N6)OC)OC
DMTKDIP IK KEEBLYWBELVGPQ-UHFFFAOYSA-N
DMTKDIP IU 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide
DMTKDIP CA CAS 1478711-48-6
DMTKDIP DE Thrombosis
DMZB8AJ ID DMZB8AJ
DMZB8AJ DN BMS-986142
DMZB8AJ HS Phase 2
DMZB8AJ SN Unii-pjx9GH268R; UNII-PJX9GH268R; PJX9GH268R; CHEMBL3900554; 1643368-58-4; GTPL9857; SCHEMBL16319712; BMS986142; BDBM50194720; AKOS032954006; compound 14f [PMID: 27583770]; J3.563.199B; 73T; 6-Fluoro-5-(R)-(3-(S)-(8-Fluoro-1-Methyl-2,4-Dioxo-1,2-Dihydroquinazolin-3(4h)-Yl)-2-Methylphenyl)-2-(S)-(2-Hydroxypropan-2-Yl)-2,3,4,9-Tetrahydro-1h-Carbazole-8-Carboxamide; (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide
DMZB8AJ CP Bristol-Myers SquibbPrinceton, NJ
DMZB8AJ PC 86582336
DMZB8AJ MW 572.6
DMZB8AJ FM C32H30F2N4O4
DMZB8AJ IC InChI=1S/C32H30F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-10,14,16,36,42H,11-13H2,1-4H3,(H2,35,39)/t16-/m0/s1
DMZB8AJ CS CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)C[C@H](CC6)C(C)(C)O)C(=O)N)F
DMZB8AJ IK ZRYMMWAJAFUANM-INIZCTEOSA-N
DMZB8AJ IU (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide
DMZB8AJ CA CAS 1643368-58-4
DMZB8AJ DE Rheumatoid arthritis
DM4QHZS ID DM4QHZS
DM4QHZS DN BMS-986177
DM4QHZS HS Phase 2
DM4QHZS SN Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
DM4QHZS CP Bristol-Myers Squibb
DM4QHZS DT Small molecular drug
DM4QHZS PC 118277544
DM4QHZS MW 626.4
DM4QHZS FM C28H23Cl2F2N9O2
DM4QHZS IC InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1
DM4QHZS CS C[C@@H]1CCC[C@@H](C2=NC=CC(=C2)C3=C(C=NN3C(F)F)NC1=O)N4C=NC(=CC4=O)C5=C(C=CC(=C5)Cl)N6C=C(N=N6)Cl
DM4QHZS IK FSWFYCYPTDLKON-CMJOXMDJSA-N
DM4QHZS IU (9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
DM4QHZS CA CAS 1802425-99-5
DM4QHZS DE Thrombosis; Cerebral ischemia
DM42B0C ID DM42B0C
DM42B0C DN BMS-986253
DM42B0C HS Phase 2
DM42B0C CP Bristol-Myers Squibb
DM42B0C DT Antibody
DM42B0C DE Solid tumour/cancer; Coronavirus Disease 2019 (COVID-19)
DM5OU2W ID DM5OU2W
DM5OU2W DN BMS-986253
DM5OU2W HS Phase 2
DM5OU2W SN Humax-inflam; HuMax-IL8; Humax-IL-8; UNII-N0YWS8X3S9; N0YWS8X3S9; MDX-018; BMS-986253; anti-Il-8 monoclonal antibody humax-IL8; 2231258-73-2
DM5OU2W TC Antiviral Agents
DM5OU2W DT Monoclonal antibody
DM5OU2W DE Coronavirus Disease 2019 (COVID-19)
DMSRVXO ID DMSRVXO
DMSRVXO DN BMS-986263
DMSRVXO HS Phase 2
DMSRVXO SN ND L02 s0201
DMSRVXO CP Bristol-Myers Squibb
DMSRVXO DT Small interfering RNA
DMSRVXO DE Hepatic fibrosis
DMUM2KA ID DMUM2KA
DMUM2KA DN BN82451
DMUM2KA HS Phase 2
DMUM2KA SN UNII-531B661QBY; 335242-75-6; BN-82451; 531B661QBY; 4-(2-(Aminomethyl)-1,3-thiazol-4-yl)-2,6-di(tert-butyl)phenol; Phenol,4-2-(aminomethyl)-4-thiazolyl-2,6-bis(1,1-dimethyl ethyl)-; 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di(tert-butyl)phenol; SCHEMBL197161; HAQOEWGSBVQDHB-UHFFFAOYSA-N; Phenol, 4-(2-(aminomethyl)-4-thiazolyl)-2,6-bis(1,1-dimethylethyl)-; SB17395; KB-59536
DMUM2KA CP Ipsen
DMUM2KA DT Small molecular drug
DMUM2KA PC 72941952
DMUM2KA MW 354.9
DMUM2KA FM C18H27ClN2OS
DMUM2KA IC InChI=1S/C18H26N2OS.ClH/c1-17(2,3)12-7-11(14-10-22-15(9-19)20-14)8-13(16(12)21)18(4,5)6;/h7-8,10,21H,9,19H2,1-6H3;1H
DMUM2KA CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CSC(=N2)CN.Cl
DMUM2KA IK WPWBWGUPSJCKKF-UHFFFAOYSA-N
DMUM2KA IU 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol;hydrochloride
DMUM2KA CA CAS 918656-59-4
DMUM2KA DE Parkinson disease
DMJC8DR ID DMJC8DR
DMJC8DR DN BNC-105
DMJC8DR HS Phase 2
DMJC8DR SN BNC-105P; IL-0035; IL-0049; Combretastatin A4 analogs (cancer), Bionomics; VDAs (cancer), Bionomics; Vascular disruption agents (cancer), Bionomics; Vascular targeting agents (cancer), Bionomics
DMJC8DR CP Iliad Chemicals Pty Ltd
DMJC8DR DT Small molecular drug
DMJC8DR PC 24786555
DMJC8DR MW 372.4
DMJC8DR FM C20H20O7
DMJC8DR IC InChI=1S/C20H20O7/c1-10-16(12-6-7-13(23-2)18(22)19(12)27-10)17(21)11-8-14(24-3)20(26-5)15(9-11)25-4/h6-9,22H,1-5H3
DMJC8DR CS CC1=C(C2=C(O1)C(=C(C=C2)OC)O)C(=O)C3=CC(=C(C(=C3)OC)OC)OC
DMJC8DR IK RADMJHVVIZTENA-UHFFFAOYSA-N
DMJC8DR IU (7-hydroxy-6-methoxy-2-methyl-1-benzofuran-3-yl)-(3,4,5-trimethoxyphenyl)methanone
DMJC8DR CA CAS 945771-74-4
DMJC8DR DE Mesothelioma
DMEGDWA ID DMEGDWA
DMEGDWA DN BNC-210
DMEGDWA HS Phase 2
DMEGDWA SN BNC-10002; GABA-A modulators (oral, anxiety), Bionomics
DMEGDWA CP Bionomics Ltd
DMEGDWA DE Anxiety disorder
DMRWG8B ID DMRWG8B
DMRWG8B DN BNT321
DMRWG8B HS Phase 2
DMRWG8B SN MVT-5873
DMRWG8B CP BioNTech
DMRWG8B DT Antibody
DMRWG8B DE Pancreatic cancer
DM8JQZC ID DM8JQZC
DM8JQZC DN BNZ-1
DM8JQZC HS Phase 2
DM8JQZC CP Bioniz Therapeutics
DM8JQZC DT Peptide
DM8JQZC DE Cutaneous T-cell lymphoma; T-cell leukaemia; Large granular lymphocytic leukemia
DMZ70GE ID DMZ70GE
DMZ70GE DN BOS-228
DMZ70GE HS Phase 2
DMZ70GE CP Boston Pharmaceuticals
DMZ70GE DT Small molecular drug
DMZ70GE DE Bacterial infection
DMKDGI8 ID DMKDGI8
DMKDGI8 DN BP-100-1-01
DMKDGI8 HS Phase 2
DMKDGI8 CP Bio-Path Ogden, Utah
DMKDGI8 DE Myelodysplastic syndrome; Hematologic tumour; Chronic myelogenous leukaemia; Acute myeloid leukaemia; Acute lymphoblastic leukaemia
DMWVPO0 ID DMWVPO0
DMWVPO0 DN BPN14770
DMWVPO0 HS Phase 2
DMWVPO0 SN KRRGWHSEDYQKDQ-UHFFFAOYSA-N; SCHEMBL15659026; 2-(4-((2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acetamide
DMWVPO0 CP Tetra Discovery Partners Grand Rapids, MI
DMWVPO0 PC 90111638
DMWVPO0 MW 405.8
DMWVPO0 FM C21H15ClF3NO2
DMWVPO0 IC InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28)
DMWVPO0 CS C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F
DMWVPO0 IK LTSUMTMGJHPGFX-UHFFFAOYSA-N
DMWVPO0 IU 2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid
DMWVPO0 CA CAS 1606974-33-7
DMWVPO0 DE Alzheimer disease
DMDYZRS ID DMDYZRS
DMDYZRS DN BPS-804
DMDYZRS HS Phase 2
DMDYZRS SN Anti-sclerostin antibody (osteoporosis/hypophophatasia), Novartis
DMDYZRS CP Novartis AG
DMDYZRS DT Antibody
DMDYZRS DE Metabolic bone disease
DM0MO8I ID DM0MO8I
DM0MO8I DN BQ-123
DM0MO8I HS Phase 2
DM0MO8I SN BQ-123; 136553-81-6; BQ123; BQ 123; Cyclo(D-trp-D-asp-pro-D-val-leu); UNII-S2A8YZM151; CHEBI:2965; S2A8YZM151; CHEMBL314691; cyclo[D-Trp-D-Asp-Pro-D-Val-Leu]; cyclo(D-Asp-Pro-D-Val-Leu-D-Trp); cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu); cyclo-[D-Asp-Pro-d-Val-Leu-d-Trp]; cyclo-(D-Asp-Pro-D-Val-Leu-D-Trp); Cyclo(D-trp-D-asp-L-pro-D-val-L-leu); Cyclo[D-trp-D-asp-L-pro-D-val-L-leu]; cyclo[(D)Trp-(D)Asp-Pro-(D)Val-Leu]; cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]; cyclo(D-Asp-L-Pro-D-Val-L-Leu-D-Trp)
DM0MO8I DT Small molecular drug
DM0MO8I PC 443289
DM0MO8I MW 610.7
DM0MO8I FM C31H42N6O7
DM0MO8I IC InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1
DM0MO8I CS CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C(C)C)CC(=O)O)CC3=CNC4=CC=CC=C43
DM0MO8I IK VYCMAAOURFJIHD-PJNXIOHISA-N
DM0MO8I IU 2-[(3R,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM0MO8I CA CAS 136553-81-6
DM0MO8I CB CHEBI:2965
DM0MO8I DE Pulmonary arterial hypertension
DMNFKVW ID DMNFKVW
DMNFKVW DN BR-4628
DMNFKVW HS Phase 2
DMNFKVW CP Bayer HealthCare Pharmaceuticals
DMNFKVW PC 60168629
DMNFKVW MW 381.4
DMNFKVW FM C22H23NO5
DMNFKVW IC InChI=1S/C22H23NO5/c1-6-27-22(26)19-13(4)23-12(3)18(14(5)24)20(19)16-9-7-8-15-17(25)10-11(2)28-21(15)16/h7-10,20,23H,6H2,1-5H3/t20-/m1/s1
DMNFKVW CS CCOC(=O)C1=C(NC(=C([C@H]1C2=CC=CC3=C2OC(=CC3=O)C)C(=O)C)C)C
DMNFKVW IK DXCPBIXBBLLGOZ-HXUWFJFHSA-N
DMNFKVW IU ethyl (4R)-5-acetyl-2,6-dimethyl-4-(2-methyl-4-oxochromen-8-yl)-1,4-dihydropyridine-3-carboxylate
DMNFKVW DE Heart failure
DM3TRF7 ID DM3TRF7
DM3TRF7 DN Brasofensine
DM3TRF7 HS Phase 2
DM3TRF7 SN Brasofensine [INN]
DM3TRF7 CP Lundbeck
DM3TRF7 DT Small molecular drug
DM3TRF7 PC 9554198
DM3TRF7 MW 327.2
DM3TRF7 FM C16H20Cl2N2O
DM3TRF7 IC InChI=1S/C16H20Cl2N2O/c1-20-11-4-6-16(20)13(9-19-21-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,9,11-13,16H,4,6,8H2,1-2H3/b19-9+/t11?,12-,13-,16?/m1/s1
DM3TRF7 CS CN1C2CCC1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)/C=N/OC
DM3TRF7 IK NRLIFEGHTNUYFL-MTKJPOGLSA-N
DM3TRF7 IU (E)-1-[(2R,3S)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-N-methoxymethanimine
DM3TRF7 CA CAS 171655-91-7
DM3TRF7 DE Parkinson disease
DMKGM42 ID DMKGM42
DMKGM42 DN BREQUINAR
DMKGM42 HS Phase 2
DMKGM42 SN Brequinar; 96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum
DMKGM42 DT Small molecular drug
DMKGM42 PC 57030
DMKGM42 MW 375.4
DMKGM42 FM C23H15F2NO2
DMKGM42 IC InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
DMKGM42 CS CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O
DMKGM42 IK PHEZJEYUWHETKO-UHFFFAOYSA-N
DMKGM42 IU 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid
DMKGM42 CA CAS 96187-53-0
DMKGM42 DE Acute myeloid leukaemia; Coronavirus Disease 2019 (COVID-19)
DMXI9BP ID DMXI9BP
DMXI9BP DN Brilacidin
DMXI9BP HS Phase 2
DMXI9BP SN UNII-I1679X069H; 1224095-98-0; I1679X069H; Brilacidin [USAN:INN]; Brilacidin (USAN); SCHEMBL2878543; CHEMBL2219413; DTXSID90153594; AKOS030238222; DB12997; CS-6677; HY-19892; D10414; N,N'-Bis(3-((5-(carbamimidoylamino)pentanoyl)amino)-2-((3R)-pyrrolidin-3-yloxy)-5-(trifluoromethyl)phenyl)pyrimidine-4,6-dicarboxamide; 4,6-Pyrimidinedicarboxamide, N4,N6-bis(3-((5-((aminoiminomethyl)amino)-1-oxopentyl)amino)-2-((3R)-3-pyrrolidinyloxy)-5-(trifluoromethyl)phenyl)-
DMXI9BP CP Cellceutix
DMXI9BP DT Small molecular drug
DMXI9BP PC 25023695
DMXI9BP MW 936.9
DMXI9BP FM C40H50F6N14O6
DMXI9BP IC InChI=1S/C40H50F6N14O6/c41-39(42,43)21-13-25(57-31(61)5-1-3-9-53-37(47)48)33(65-23-7-11-51-18-23)27(15-21)59-35(63)29-17-30(56-20-55-29)36(64)60-28-16-22(40(44,45)46)14-26(34(28)66-24-8-12-52-19-24)58-32(62)6-2-4-10-54-38(49)50/h13-17,20,23-24,51-52H,1-12,18-19H2,(H,57,61)(H,58,62)(H,59,63)(H,60,64)(H4,47,48,53)(H4,49,50,54)/t23-,24-/m1/s1
DMXI9BP CS C1CNC[C@@H]1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4O[C@@H]5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N
DMXI9BP IK QPDYBCZNGUJZDK-DNQXCXABSA-N
DMXI9BP IU 4-N,6-N-bis[3-[5-(diaminomethylideneamino)pentanoylamino]-2-[(3R)-pyrrolidin-3-yl]oxy-5-(trifluoromethyl)phenyl]pyrimidine-4,6-dicarboxamide
DMXI9BP CA CAS 1224095-98-0
DMXI9BP DE Infectious disease; Acute bacterial skin infection
DMLD80M ID DMLD80M
DMLD80M DN Brivoligide
DMLD80M HS Phase 2
DMLD80M SN AYX1
DMLD80M CP Adynxx
DMLD80M DT Oligonucleotide
DMLD80M DE Postoperative pain
DMLFGHX ID DMLFGHX
DMLFGHX DN BRL 35135
DMLFGHX HS Phase 2
DMLFGHX SN Brl35135A; BRL 35135; Methyl 4-(2-(2-hydroxy-2-(3-chlorophenyl)ethylamino)propyl)phenoxyacetate; Brl-35135; 91097-81-3; C20H24ClNO4; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-, methyl ester; AC1Q3M3M; AC1L3U5A; CHEMBL49289; SCHEMBL4611391; CTK5G8940; ZFLBZHXQAMUEFS-UHFFFAOYSA-N; LS-178136; L003499; methyl 4-[2-[(3-chloro-beta-hydroxyphenethyl) amino]propyl]phenoxyacetate; [4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid methyl ester; methyl 2-[4-[2-[[2-(3-chloroph
DMLFGHX DT Small molecular drug
DMLFGHX PC 122186
DMLFGHX MW 377.9
DMLFGHX FM C20H24ClNO4
DMLFGHX IC InChI=1S/C20H24ClNO4/c1-14(22-12-19(23)16-4-3-5-17(21)11-16)10-15-6-8-18(9-7-15)26-13-20(24)25-2/h3-9,11,14,19,22-23H,10,12-13H2,1-2H3
DMLFGHX CS CC(CC1=CC=C(C=C1)OCC(=O)OC)NCC(C2=CC(=CC=C2)Cl)O
DMLFGHX IK ZFLBZHXQAMUEFS-UHFFFAOYSA-N
DMLFGHX IU methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate
DMLFGHX CA CAS 91097-81-3
DMLFGHX DE Diabetic complication
DMUI5PA ID DMUI5PA
DMUI5PA DN Brostallicin
DMUI5PA HS Phase 2
DMUI5PA SN Brostallicin; UNII-RPC6R41K4I; 203258-60-0; RPC6R41K4I; PNU-166196A; Brostallicin [INN]; AC1OCFEA; SCHEMBL3678233; CHEMBL1189025; DTXSID70174222; ZINC3979512; Z-3228; 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide
DMUI5PA CP Cell Therapeutics
DMUI5PA DT Small molecular drug
DMUI5PA PC 6918408
DMUI5PA MW 723.6
DMUI5PA FM C30H35BrN12O5
DMUI5PA IC InChI=1S/C30H35BrN12O5/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35)
DMUI5PA CS CN1C=C(C=C1C(=O)NCCN=C(N)N)NC(=O)C2=CC(=CN2C)NC(=O)C3=CC(=CN3C)NC(=O)C4=CC(=CN4C)NC(=O)C(=C)Br
DMUI5PA IK RXOVOXFAAGIKDQ-UHFFFAOYSA-N
DMUI5PA IU 4-[[4-[[4-[[4-(2-bromoprop-2-enoylamino)-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]-N-[2-(diaminomethylideneamino)ethyl]-1-methylpyrrole-2-carboxamide
DMUI5PA CA CAS 203258-60-0
DMUI5PA DE Breast cancer
DM1ZOCK ID DM1ZOCK
DM1ZOCK DN Bryostatin-1
DM1ZOCK HS Phase 2
DM1ZOCK SN Bryostatin 1; 83314-01-6
DM1ZOCK DT Small molecular drug
DM1ZOCK PC 5280757
DM1ZOCK MW 905
DM1ZOCK FM C47H68O17
DM1ZOCK IC InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1
DM1ZOCK CS CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)/C[C@H]2C[C@@H](OC(=O)C[C@@H](C[C@@H]3C[C@@H](C([C@@](O3)(C[C@@H]4C/C(=C/C(=O)OC)/C[C@@H](O4)/C=C/C([C@@]1(O2)O)(C)C)O)(C)C)OC(=O)C)O)[C@@H](C)O
DM1ZOCK IK MJQUEDHRCUIRLF-TVIXENOKSA-N
DM1ZOCK IU [(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-acetyloxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] (2E,4E)-octa-2,4-dienoate
DM1ZOCK CA CAS 83314-01-6
DM1ZOCK CB CHEBI:88353
DM1ZOCK DE Alzheimer disease
DM2LZIY ID DM2LZIY
DM2LZIY DN BT-061
DM2LZIY HS Phase 2
DM2LZIY CP Biotest
DM2LZIY DT Antibody
DM2LZIY DE Asthma; Psoriasis vulgaris
DMYO185 ID DMYO185
DMYO185 DN BT-062
DMYO185 HS Phase 2
DMYO185 CP Biotest Pharmaceuticals; ImmunoGen
DMYO185 DT Antibody
DMYO185 DE Multiple myeloma
DMDWP0U ID DMDWP0U
DMDWP0U DN BTA-798
DMDWP0U HS Phase 2
DMDWP0U SN Capsid-binding inhibitors, Biota; Capsid-binding (anti-rhinovirus) agents, Biota
DMDWP0U CP Biota pharmaceuticals
DMDWP0U DE Rhinovirus infection
DMS6ZA0 ID DMS6ZA0
DMS6ZA0 DN BTD-001
DMS6ZA0 HS Phase 2
DMS6ZA0 CP Balance Therapeutics San Bruno, CA
DMS6ZA0 DE Narcolepsy
DMY5IX4 ID DMY5IX4
DMY5IX4 DN BTL-TML-001
DMY5IX4 HS Phase 2
DMY5IX4 SN Influenza virus infection, Beech Tree Labs
DMY5IX4 CP Beech Tree Labs Inc
DMY5IX4 DE Influenza virus infection; Herpes simplex labialis
DMA9238 ID DMA9238
DMA9238 DN BTRX-246040
DMA9238 HS Phase 2
DMA9238 CP BlackThorn Therapeutics San Francisco, CA
DMA9238 DE Major depressive disorder
DMWPDUZ ID DMWPDUZ
DMWPDUZ DN BTRX-335140
DMWPDUZ HS Phase 2
DMWPDUZ SN CYM-53093; UNII-XK5ILZ28KI; XK5ILZ28KI; 2244614-14-8; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4 amine; CHEMBL4592045; SCHEMBL20670520; GTPL10452; BTRX335140; BCP32121; CYM53093; BDBM50531908; compound 58 [PMID: 30707578]; HY-124754; CS-0087593; BTRX 335140; BTRX335140; CYM-53093; CYM 53093; CYM53093; 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine; 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine; 4-Piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-N-(tetrahydro-2H-pyran-4-yl)-
DMWPDUZ CP BlackThorn Therapeutics
DMWPDUZ DT Small molecular drug
DMWPDUZ PC 137434175
DMWPDUZ MW 453.6
DMWPDUZ FM C25H32FN5O2
DMWPDUZ IC InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
DMWPDUZ CS CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
DMWPDUZ IK CQOJHAJWCDJEAT-UHFFFAOYSA-N
DMWPDUZ IU 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
DMWPDUZ CA CAS 2244614-14-8
DMWPDUZ DE Major depressive disorder
DMIEPJG ID DMIEPJG
DMIEPJG DN BTT-1023
DMIEPJG HS Phase 2
DMIEPJG SN SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
DMIEPJG CP BioTie Therapies Corp
DMIEPJG DT Antibody
DMIEPJG DE Psoriasis vulgaris
DMZC4V0 ID DMZC4V0
DMZC4V0 DN Buproprion+zonisamide
DMZC4V0 HS Phase 2
DMZC4V0 SN Empatic (TN)
DMZC4V0 CP Orexigen Therapeutics
DMZC4V0 DE Obesity
DMNB4XK ID DMNB4XK
DMNB4XK DN BVD-523
DMNB4XK HS Phase 2
DMNB4XK CP Biomed valley discoveries
DMNB4XK PC 11719003
DMNB4XK MW 433.3
DMNB4XK FM C21H22Cl2N4O2
DMNB4XK IC InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
DMNB4XK CS CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl
DMNB4XK IK KSERXGMCDHOLSS-LJQANCHMSA-N
DMNB4XK IU N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide
DMNB4XK CA CAS 869886-67-9
DMNB4XK DE Solid tumour/cancer; Pancreatic cancer; Melanoma
DM8CWL0 ID DM8CWL0
DM8CWL0 DN BVT.28949
DM8CWL0 HS Phase 2
DM8CWL0 CP Biovitrum
DM8CWL0 DE Glaucoma/ocular hypertension
DMD8GNB ID DMD8GNB
DMD8GNB DN BXT-51072
DMD8GNB HS Phase 2
DMD8GNB SN ALT-2074; SYI-2074
DMD8GNB CP Synvista Therapeutics
DMD8GNB DT Small molecular drug
DMD8GNB PC 130165
DMD8GNB MW 226.19
DMD8GNB FM C10H13NSe
DMD8GNB IC InChI=1S/C10H13NSe/c1-10(2)7-11-12-9-6-4-3-5-8(9)10/h3-6,11H,7H2,1-2H3
DMD8GNB CS CC1(CN[Se]C2=CC=CC=C21)C
DMD8GNB IK FXRYWOJYVGJZLE-UHFFFAOYSA-N
DMD8GNB IU 4,4-dimethyl-2,3-dihydro-1,2-benzoselenazine
DMD8GNB CA CAS 173026-17-0
DMD8GNB DE Cardiovascular disease
DMTRONK ID DMTRONK
DMTRONK DN BZL-101
DMTRONK HS Phase 2
DMTRONK CP Bionovo
DMTRONK DE Breast cancer
DMGE058 ID DMGE058
DMGE058 DN Cabiralizumab
DMGE058 HS Phase 2
DMGE058 CP Bristol-Myers Squibb Princeton, NJFive Prime Therapeutics South San Francisco, CA
DMGE058 DE Solid tumour/cancer; Pancreatic cancer
DMGXCY9 ID DMGXCY9
DMGXCY9 DN Calcium phosphate
DMGXCY9 HS Phase 2
DMGXCY9 SN Bonarka; Calcigenol simple; Calcium orthophosphate; Calcium phosphate; Calcium phosphate (3:2); Calcium phosphate (Ca3(PO4)2); Calcium phosphate tribasic; Calcium tertiary phosphate; Natural whitlockite; Phosphoric acid, calcium salt; Phosphoric acid, calcium salt (2:3); Synthos; TRICALCIUM PHOSPHATE; Tertiary calcium phosphate; Tribasic calcium phosphate; Tricalcium diphosphate; Tricalcium orthophosphate; beta-TCP; beta-Tricalcium phosphate
DMGXCY9 DT Small molecular drug
DMGXCY9 PC 24456
DMGXCY9 MW 310.174
DMGXCY9 FM Ca3O8P2
DMGXCY9 IC InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6
DMGXCY9 CS [O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
DMGXCY9 IK QORWJWZARLRLPR-UHFFFAOYSA-H
DMGXCY9 IU tricalcium;diphosphate
DMGXCY9 CA CAS 7758-87-410103-46-5
DMGXCY9 CB ChEBI:9679
DMGXCY9 DE Osteoporosis
DMDV8MK ID DMDV8MK
DMDV8MK DN CALDARET HYDRATE
DMDV8MK HS Phase 2
DMDV8MK SN MCC-135; Caldaret hydrate; 5-Methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate
DMDV8MK CP Mitsubishi Pharma
DMDV8MK DT Small molecular drug
DMDV8MK PC 9816981
DMDV8MK MW 274.34
DMDV8MK FM C11H18N2O4S
DMDV8MK IC InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2
DMDV8MK CS CC1=CC(=C(C=C1)N2CCNCC2)S(=O)(=O)O.O
DMDV8MK IK ZRQKZWAOIRVBFD-UHFFFAOYSA-N
DMDV8MK IU 5-methyl-2-piperazin-1-ylbenzenesulfonic acid;hydrate
DMDV8MK CA CAS 192509-24-3
DMDV8MK DE Cardiovascular disease
DMAKSMX ID DMAKSMX
DMAKSMX DN Camicinal
DMAKSMX HS Phase 2
DMAKSMX SN 962040
DMAKSMX CP GlaxoSmithKline
DMAKSMX DT Small molecular drug
DMAKSMX PC 15984937
DMAKSMX MW 424.6
DMAKSMX FM C25H33FN4O
DMAKSMX IC InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3/t19-/m0/s1
DMAKSMX CS C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F
DMAKSMX IK RZKDEGZIFSJVNA-IBGZPJMESA-N
DMAKSMX IU 1-[4-(3-fluoroanilino)piperidin-1-yl]-2-[4-[[(3S)-3-methylpiperazin-1-yl]methyl]phenyl]ethanone
DMAKSMX CA CAS 923565-21-3
DMAKSMX DE Delayed gastric emptying; Diabetic gastroparesis
DMQ7UL8 ID DMQ7UL8
DMQ7UL8 DN Camostat
DMQ7UL8 HS Phase 2
DMQ7UL8 SN Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N
DMQ7UL8 DT Small molecular drug
DMQ7UL8 PC 2536
DMQ7UL8 MW 398.4
DMQ7UL8 FM C20H22N4O5
DMQ7UL8 IC InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)
DMQ7UL8 CS CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
DMQ7UL8 IK XASIMHXSUQUHLV-UHFFFAOYSA-N
DMQ7UL8 IU [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate
DMQ7UL8 CA CAS 59721-28-7
DMQ7UL8 CB CHEBI:135632
DMQ7UL8 DE Cystic fibrosis
DMEZLFT ID DMEZLFT
DMEZLFT DN Camsirubicin
DMEZLFT HS Phase 2
DMEZLFT SN UNII-VI79RD8VNN; VI79RD8VNN; 236095-26-4; (8R,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-7,9,10,12-tetrahydrotetracen-5(8H)-one; 5(8H)-Naphthacenone, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,9,10,12-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-, (8R,10S)-
DMEZLFT CP Monopar Therapeutics
DMEZLFT DT Small molecular drug
DMEZLFT PC 135446069
DMEZLFT MW 528.5
DMEZLFT FM C27H32N2O9
DMEZLFT IC InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1
DMEZLFT CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(CCO)O)N)O
DMEZLFT IK GNCWGPLZJLZZPI-KUIJCEFOSA-N
DMEZLFT IU (8R,10S)-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyethyl)-12-imino-1-methoxy-9,10-dihydro-7H-tetracen-5-one
DMEZLFT CA CAS 236095-26-4
DMEZLFT DE Soft tissue sarcoma
DMEYIVW ID DMEYIVW
DMEYIVW DN CAP1-6D
DMEYIVW HS Phase 2
DMEYIVW SN Modified CEA peptide (pancreatic cancer), University of Chicago
DMEYIVW CP University of Chicago
DMEYIVW DT Small molecular drug
DMEYIVW PC 396060
DMEYIVW MW 965.1
DMEYIVW FM C43H68N10O15
DMEYIVW IC InChI=1S/C43H68N10O15/c1-20(2)12-27(49-37(61)26(44)15-24-8-10-25(55)11-9-24)40(64)53-32(19-54)38(62)46-18-34(57)47-23(7)36(60)48-30(17-35(58)59)42(66)50-28(13-21(3)4)39(63)51-29(16-33(45)56)41(65)52-31(43(67)68)14-22(5)6/h8-11,20-23,26-32,54-55H,12-19,44H2,1-7H3,(H2,45,56)(H,46,62)(H,47,57)(H,48,60)(H,49,61)(H,50,66)(H,51,63)(H,52,65)(H,53,64)(H,58,59)(H,67,68)
DMEYIVW CS CC(C)CC(C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)N
DMEYIVW IK SNKUSVNHTCUELQ-UHFFFAOYSA-N
DMEYIVW IU 2-[[4-amino-2-[[2-[[2-[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid
DMEYIVW DE Pancreatic cancer
DMJKLHU ID DMJKLHU
DMJKLHU DN CAP-7.1
DMJKLHU HS Phase 2
DMJKLHU CP CellAct Pharma GmbH
DMJKLHU PC 154701729
DMJKLHU DE Solid tumour/cancer
DMYWO62 ID DMYWO62
DMYWO62 DN Capadenoson
DMYWO62 HS Phase 2
DMYWO62 SN Capadenoson; 544417-40-5; UNII-O519NVW73R; O519NVW73R; CHEMBL3235279; BAY 68-4986; 2-amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-Pyridinedicarbonitrile; C25H18ClN5O2S2; Capadenoson [INN]; 2-amino-6-({(2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)pyridine-3,5-dicarbonitrile; 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile; SCHEMBL174016; Capadenoson;BAY 68-4986
DMYWO62 CP Bayer HealthCare Pharmaceuticals
DMYWO62 DT Small molecular drug
DMYWO62 PC 9936489
DMYWO62 MW 520
DMYWO62 FM C25H18ClN5O2S2
DMYWO62 IC InChI=1S/C25H18ClN5O2S2/c26-17-5-1-16(2-6-17)24-30-18(13-34-24)14-35-25-21(12-28)22(20(11-27)23(29)31-25)15-3-7-19(8-4-15)33-10-9-32/h1-8,13,32H,9-10,14H2,(H2,29,31)
DMYWO62 CS C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO
DMYWO62 IK CITWCLNVRIKQAF-UHFFFAOYSA-N
DMYWO62 IU 2-amino-6-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile
DMYWO62 CA CAS 544417-40-5
DMYWO62 DE Atrial fibrillation
DMY4OMS ID DMY4OMS
DMY4OMS DN Carabersat
DMY4OMS HS Phase 2
DMY4OMS SN SB-204268; SB-204269; SB-258339
DMY4OMS CP SmithKline Beecham plc
DMY4OMS DT Small molecular drug
DMY4OMS PC 193943
DMY4OMS MW 357.4
DMY4OMS FM C20H20FNO4
DMY4OMS IC InChI=1S/C20H20FNO4/c1-11(23)13-6-9-16-15(10-13)17(18(24)20(2,3)26-16)22-19(25)12-4-7-14(21)8-5-12/h4-10,17-18,24H,1-3H3,(H,22,25)/t17-,18+/m0/s1
DMY4OMS CS CC(=O)C1=CC2=C(C=C1)OC([C@@H]([C@H]2NC(=O)C3=CC=C(C=C3)F)O)(C)C
DMY4OMS IK RCLXAPJEFHPYEG-ZWKOTPCHSA-N
DMY4OMS IU N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide
DMY4OMS CA CAS 184653-84-7
DMY4OMS DE Epileptic seizures
DMN5JCX ID DMN5JCX
DMN5JCX DN Carboxyamidotriazole orotate
DMN5JCX HS Phase 2
DMN5JCX CP Tactical Therapeutics
DMN5JCX PC 154732136
DMN5JCX DE Glioblastoma multiforme
DM7ADGX ID DM7ADGX
DM7ADGX DN Carfentanil
DM7ADGX HS Phase 2
DM7ADGX SN CARFENTANIL; Carfentanyl; Carfentanila; Carfentanilum; Wildnil; 59708-52-0; Carfentanil [INN]; Carfentanila [Spanish]; UNII-LA9DTA2L8F; Carfentanilum [INN-Latin]; Carfentanila [INN-Spanish]; Methyl 1-phenylethyl-4-(N-phenylpropionamido)isonipecotate; CHEBI:61084; Methyl 4-(N-propionyl-N-phenylamino)-1-(2-phenylethyl)-4-piperidine-carboxylate; Methyl 4-(N-(1-oxopropyl)-N-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylate; 4-((1-Oxopropyl)phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester
DM7ADGX DT Small molecular drug
DM7ADGX PC 62156
DM7ADGX MW 394.5
DM7ADGX FM C24H30N2O3
DM7ADGX IC InChI=1S/C24H30N2O3/c1-3-22(27)26(21-12-8-5-9-13-21)24(23(28)29-2)15-18-25(19-16-24)17-14-20-10-6-4-7-11-20/h4-13H,3,14-19H2,1-2H3
DM7ADGX CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)C(=O)OC
DM7ADGX IK YDSDEBIZUNNPOB-UHFFFAOYSA-N
DM7ADGX IU methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DM7ADGX CA CAS 59708-52-0
DM7ADGX CB CHEBI:61084
DMAUN15 ID DMAUN15
DMAUN15 DN Carlumab
DMAUN15 HS Phase 2
DMAUN15 SN CCL-2; CNTO-888; Anti-MCP1 monoclonal antibodies, Centocor; CCL2 monoclonal antibody (infusion, cancer), Centocor
DMAUN15 CP Janssen biotech
DMAUN15 DT Antibody
DMAUN15 DE Pulmonary fibrosis
DMN6TKI ID DMN6TKI
DMN6TKI DN Carmoterol
DMN6TKI HS Phase 2
DMN6TKI SN 147568-66-9; 8-Hydroxy-5-((R)-1-hydroxy-2-(((R)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)quinolin-2(1H)-one; UNII-9810NUL4D1; CHEMBL1094785; 9810NUL4D1; 2(1h)-quinolinone, 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-; 8-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]-1,2-dihydroquinolin-2-one; Carmoterol [INN]; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; AC1Q6MT1
DMN6TKI CP Chiesi
DMN6TKI DT Small molecular drug
DMN6TKI PC 63952
DMN6TKI MW 368.4
DMN6TKI FM C21H24N2O4
DMN6TKI IC InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1
DMN6TKI CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O
DMN6TKI IK IHOXNOQMRZISPV-YJYMSZOUSA-N
DMN6TKI IU 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one
DMN6TKI CA CAS 147568-66-9
DMN6TKI DE Chronic obstructive pulmonary disease
DMTBFXW ID DMTBFXW
DMTBFXW DN CART 19
DMTBFXW HS Phase 2
DMTBFXW CP University of Pennsylvania
DMTBFXW DT CAR T Cell Therapy
DMTBFXW DE Acute lymphoblastic leukaemia; Pancreatic cancer
DM28A5D ID DM28A5D
DM28A5D DN CAR-T cells targeting CD19
DM28A5D HS Phase 2
DM28A5D CP The First Affiliated Hospital of Soochow University
DM28A5D DT CAR T Cell Therapy
DM28A5D DE Non-hodgkin lymphoma
DM3RU0A ID DM3RU0A
DM3RU0A DN CAR-T cells targeting CD20
DM3RU0A HS Phase 2
DM3RU0A CP The First Affiliated Hospital of Soochow University
DM3RU0A DT CAR T Cell Therapy
DM3RU0A DE Non-hodgkin lymphoma
DM6XN4C ID DM6XN4C
DM6XN4C DN CAR-T cells targeting CD22
DM6XN4C HS Phase 2
DM6XN4C CP The First Affiliated Hospital of Soochow University
DM6XN4C DT CAR T Cell Therapy
DM6XN4C DE Non-hodgkin lymphoma
DML0KWM ID DML0KWM
DML0KWM DN CAR-T cells targeting CD30
DML0KWM HS Phase 2
DML0KWM CP The First Affiliated Hospital of Soochow University
DML0KWM DT CAR T Cell Therapy
DML0KWM DE Non-hodgkin lymphoma
DMHQKN6 ID DMHQKN6
DMHQKN6 DN CART-19
DMHQKN6 HS Phase 2
DMHQKN6 CP University of Pennsylvania
DMHQKN6 DT CAR T Cell Therapy
DMHQKN6 DE Non-hodgkin lymphoma; B-cell lymphoma; leukaemia; Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Mantle cell lymphoma; Prolymphocytic leukaemia
DMZUV7T ID DMZUV7T
DMZUV7T DN CART-19 cells
DMZUV7T HS Phase 2
DMZUV7T CP University of Pennsylvania
DMZUV7T DT CAR T Cell Therapy
DMZUV7T DE Acute lymphocytic leukaemia; Multiple myeloma
DMQBP7R ID DMQBP7R
DMQBP7R DN CAT 1004
DMQBP7R HS Phase 2
DMQBP7R CP Catabasis Pharmaceuticals
DMQBP7R DE Type-2 diabetes; Duchenne dystrophy
DM2IFYZ ID DM2IFYZ
DM2IFYZ DN CB-10-01
DM2IFYZ HS Phase 2
DM2IFYZ CP Cosmo Pharmaceuticals
DM2IFYZ DT Vaccine
DM2IFYZ DE Melanoma
DM094UH ID DM094UH
DM094UH DN CB-839
DM094UH HS Phase 2
DM094UH PC 71577426
DM094UH MW 571.6
DM094UH FM C26H24F3N7O3S
DM094UH IC InChI=1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)
DM094UH CS C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F
DM094UH IK PRAAPINBUWJLGA-UHFFFAOYSA-N
DM094UH IU N-[6-[4-[5-[(2-pyridin-2-ylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide
DM094UH CA CAS 1439399-58-2
DM094UH DE leukaemia; Breast cancer; Renal cell carcinoma; Solid tumour/cancer
DMK4FRU ID DMK4FRU
DMK4FRU DN CBLB-502
DMK4FRU HS Phase 2
DMK4FRU SN CBLB-501; Mini-flagellin, Cleveland BioLabs; Recombinant flagellin proteins (injury protection), Cleveland BioLabs
DMK4FRU CP Cleveland BioLabs Inc
DMK4FRU DE Acute radiation syndrome
DMSBNTZ ID DMSBNTZ
DMSBNTZ DN CBX-129801
DMSBNTZ HS Phase 2
DMSBNTZ SN Ersatta; C-peptide (depot formulation), Cebix; Long-acting synthetic C-peptide, Cebix; PEGylated C-peptide (diabetic complications), Cebix
DMSBNTZ CP Cebix
DMSBNTZ DE Diabetic complication
DMQ874W ID DMQ874W
DMQ874W DN CC-1088
DMQ874W HS Phase 2
DMQ874W SN CDC801; CC-1088; CHEMBL88153; SCHEMBL185853; CDC-801; DDYUBCCTNHWSQM-UHFFFAOYSA-N; BDBM50216298; HY-U00179; CS-7247; 192819-27-5
DMQ874W DT Small molecular drug
DMQ874W PC 9844338
DMQ874W MW 408.4
DMQ874W FM C23H24N2O5
DMQ874W IC InChI=1S/C23H24N2O5/c1-29-19-11-10-14(12-20(19)30-15-6-2-3-7-15)18(13-21(24)26)25-22(27)16-8-4-5-9-17(16)23(25)28/h4-5,8-12,15,18H,2-3,6-7,13H2,1H3,(H2,24,26)
DMQ874W CS COC1=C(C=C(C=C1)C(CC(=O)N)N2C(=O)C3=CC=CC=C3C2=O)OC4CCCC4
DMQ874W IK DDYUBCCTNHWSQM-UHFFFAOYSA-N
DMQ874W IU 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide
DMQ874W CA CAS 192819-27-5
DMQ874W DE Crohn disease
DMNE7L3 ID DMNE7L3
DMNE7L3 DN CC-220
DMNE7L3 HS Phase 2
DMNE7L3 SN AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266
DMNE7L3 DT Small molecular drug
DMNE7L3 PC 67335295
DMNE7L3 MW 449.5
DMNE7L3 FM C25H27N3O5
DMNE7L3 IC InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
DMNE7L3 CS C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
DMNE7L3 IK IXZOHGPZAQLIBH-NRFANRHFSA-N
DMNE7L3 IU (3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
DMNE7L3 CA CAS 1323403-33-3
DMNE7L3 DE Sarcoidosis; Multiple myeloma; Systemic lupus erythematosus
DMJR9H0 ID DMJR9H0
DMJR9H0 DN CC-292
DMJR9H0 HS Phase 2
DMJR9H0 SN AVL-292; 1202757-89-8; spebrutinib; cc-292; UNII-DRU6NG543J; CC-292 (AVL-292); DRU6NG543J; AVL292; N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide; AK198940; N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide; N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide; Btk inhibitor CC-292; Spebrutinib [USAN:INN]; Spebrutinib (USAN/INN); SCHEMBL626216; GTPL7837; CHEMBL3301625; EX-A255; AVL 292
DMJR9H0 CP Celgene
DMJR9H0 DT Small molecular drug
DMJR9H0 PC 59174488
DMJR9H0 MW 423.4
DMJR9H0 FM C22H22FN5O3
DMJR9H0 IC InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)
DMJR9H0 CS COCCOC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)NC(=O)C=C)F
DMJR9H0 IK KXBDTLQSDKGAEB-UHFFFAOYSA-N
DMJR9H0 IU N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide
DMJR9H0 CA CAS 1202757-89-8
DMJR9H0 DE Chronic lymphocytic leukaemia
DMPMO6G ID DMPMO6G
DMPMO6G DN CC-401
DMPMO6G HS Phase 2
DMPMO6G SN CC-401; 395104-30-0; UNII-NOE38VQA1W; NOE38VQA1W; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole; 3-[3-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOLE; CC 401; C22H24N6O; PubChem22434; SCHEMBL4604749; CHEMBL1614713; CHEBI:91437; DTXSID40192650; MolPort-044-561-531; MolPort-021-804-942; BCPP000298; BCP01960; ZINC38836256; RS0046; HY-13022A; AKOS027251057; AKOS027336636; DB12432; BCP9000495; CS-1955
DMPMO6G TC Anticancer Agents
DMPMO6G DT Small molecular drug
DMPMO6G PC 10430360
DMPMO6G MW 388.5
DMPMO6G FM C22H24N6O
DMPMO6G IC InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)
DMPMO6G CS C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5
DMPMO6G IK XDJCLCLBSGGNKS-UHFFFAOYSA-N
DMPMO6G IU 3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole
DMPMO6G CA CAS 395104-30-0
DMPMO6G CB CHEBI:91437
DMPMO6G DE Solid tumour/cancer
DM0EDHJ ID DM0EDHJ
DM0EDHJ DN CC-90011
DM0EDHJ HS Phase 2
DM0EDHJ SN UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y
DM0EDHJ CP Bristol-Myers Squibb
DM0EDHJ DT Small molecular drug
DM0EDHJ PC 118483201
DM0EDHJ MW 451.5
DM0EDHJ FM C24H23F2N5O2
DM0EDHJ IC InChI=1S/C24H23F2N5O2/c1-30-23(32)21(14-5-6-20(33-2)19(26)11-14)22(15-3-4-16(13-27)18(25)12-15)29-24(30)31-9-7-17(28)8-10-31/h3-6,11-12,17H,7-10,28H2,1-2H3
DM0EDHJ CS CN1C(=O)C(=C(N=C1N2CCC(CC2)N)C3=CC(=C(C=C3)C#N)F)C4=CC(=C(C=C4)OC)F
DM0EDHJ IK NBAIXBAUHIQQGF-UHFFFAOYSA-N
DM0EDHJ IU 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile
DM0EDHJ CA CAS 1821307-10-1
DM0EDHJ DE Lymphoma; Non-hodgkin lymphoma
DMHVEGJ ID DMHVEGJ
DMHVEGJ DN CC-930
DMHVEGJ HS Phase 2
DMHVEGJ SN TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358
DMHVEGJ CP Celgene
DMHVEGJ DT Small molecular drug
DMHVEGJ PC 11597537
DMHVEGJ MW 448.4
DMHVEGJ FM C21H23F3N6O2
DMHVEGJ IC InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
DMHVEGJ CS C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O
DMHVEGJ IK IBGLGMOPHJQDJB-MOKVOYLWSA-N
DMHVEGJ IU 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
DMHVEGJ CA CAS 899805-25-5
DMHVEGJ DE Discoid lupus erythematosus; Idiopathic pulmonary fibrosis
DMJ9XCO ID DMJ9XCO
DMJ9XCO DN CCX-140
DMJ9XCO HS Phase 2
DMJ9XCO SN CCX-140-B; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease), ChemoCentryx; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease/chronic kidney disease), ChemoCentryx
DMJ9XCO CP Chemocentryx
DMJ9XCO PC 25134303
DMJ9XCO MW 495.9
DMJ9XCO FM C20H13ClF3N5O3S
DMJ9XCO IC InChI=1S/C20H13ClF3N5O3S/c1-10-6-15(29-33(31,32)11-2-3-14(21)13(7-11)20(22,23)24)17(26-8-10)18(30)16-12-4-5-25-19(12)28-9-27-16/h2-9,29H,1H3,(H,25,27,28)
DMJ9XCO CS CC1=CC(=C(N=C1)C(=O)C2=C3C=CNC3=NC=N2)NS(=O)(=O)C4=CC(=C(C=C4)Cl)C(F)(F)F
DMJ9XCO IK LUUMLYXKTPBTQR-UHFFFAOYSA-N
DMJ9XCO IU 4-chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide
DMJ9XCO CA CAS 1100318-47-5
DMJ9XCO DE Diabetic nephropathy
DMSHV9C ID DMSHV9C
DMSHV9C DN CCX-354
DMSHV9C HS Phase 2
DMSHV9C SN CCX-354-C; GSK2941266
DMSHV9C CP ChemoCentryx Inc
DMSHV9C PC 135565361
DMSHV9C MW 451.9
DMSHV9C FM C22H22ClN7O2
DMSHV9C IC InChI=1S/C22H22ClN7O2/c1-32-18-13-15(4-5-17(18)23)28-9-11-29(12-10-28)19(31)14-30-22-16(3-2-6-26-22)20(27-30)21-24-7-8-25-21/h2-8,13H,9-12,14H2,1H3,(H,24,25)
DMSHV9C CS COC1=C(C=CC(=C1)N2CCN(CC2)C(=O)CN3C4=C(C=CC=N4)C(=N3)C5=NC=CN5)Cl
DMSHV9C IK ZIMLRKWQDLVPEK-UHFFFAOYSA-N
DMSHV9C IU 1-[4-(4-chloro-3-methoxyphenyl)piperazin-1-yl]-2-[3-(1H-imidazol-2-yl)pyrazolo[3,4-b]pyridin-1-yl]ethanone
DMSHV9C CA CAS 1010073-75-2
DMSHV9C DE Autoimmune diabetes; Rheumatoid arthritis
DMPVAUT ID DMPVAUT
DMPVAUT DN CCX872
DMPVAUT HS Phase 2
DMPVAUT CP Chemocentryx
DMPVAUT DE Diabetic nephropathy; Pancreatic tumour
DMEK580 ID DMEK580
DMEK580 DN CD19 CAR T cells
DMEK580 HS Phase 2
DMEK580 CP Southwest Hospital, China
DMEK580 DT CAR T Cell Therapy
DMEK580 DE B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMQJBUK ID DMQJBUK
DMQJBUK DN CD19-targeting CAR T cells
DMQJBUK HS Phase 2
DMQJBUK CP Uppsala University
DMQJBUK DT CAR T Cell Therapy
DMQJBUK DE B-cell lymphoma; leukaemia
DMQGI8R ID DMQGI8R
DMQGI8R DN CD20 CAR T cells
DMQGI8R HS Phase 2
DMQGI8R CP Southwest Hospital, China
DMQGI8R DT CAR T Cell Therapy
DMQGI8R DE B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMXYLTI ID DMXYLTI
DMXYLTI DN CDP323
DMXYLTI HS Phase 2
DMXYLTI SN Zaurategrast; 455264-31-0; (S)-3-(4-((2,7-Naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoic acid; UNII-06A0IC74I3; 06A0IC74I3; C26H25BrN4O3; Zaurategrast [INN]; SCHEMBL2976322; CTK8C0588; DTXSID90196547; MolPort-023-332-826; KS-00001DY0; ANW-64932; 6274AB; ZINC100041912; AKOS016005046; CS-0322; N-(2-Bromo-3-oxospiro[3.5]non-1-en-1-yl)-4-(2,7-naphthyridin-1-ylamino)-L-phenylalanine; NCGC00378753-01
DMXYLTI CP UCB; Biogen Idec
DMXYLTI DT Small molecular drug
DMXYLTI PC 23394557
DMXYLTI MW 549.5
DMXYLTI FM C28H29BrN4O3
DMXYLTI IC InChI=1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1
DMXYLTI CS CCOC(=O)[C@H](CC1=CC=C(C=C1)NC2=NC=CC3=C2C=NC=C3)NC4=C(C(=O)C45CCCCC5)Br
DMXYLTI IK QCYAXXZCQKMTMO-QFIPXVFZSA-N
DMXYLTI IU ethyl (2S)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate
DMXYLTI CA CAS 455264-30-9
DMXYLTI DE Rheumatoid arthritis; Multiple sclerosis
DM3YB2C ID DM3YB2C
DM3YB2C DN CDP-6038
DM3YB2C HS Phase 2
DM3YB2C DE Rheumatoid arthritis
DM8UQJG ID DM8UQJG
DM8UQJG DN CDX-1307
DM8UQJG HS Phase 2
DM8UQJG SN BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics
DM8UQJG CP Medarex Inc
DM8UQJG DT Vaccine
DM8UQJG DE Bladder cancer
DMCGNJ6 ID DMCGNJ6
DMCGNJ6 DN CDX-1401
DMCGNJ6 HS Phase 2
DMCGNJ6 CP Celldex Therapeutics
DMCGNJ6 DE Solid tumour/cancer; Ovarian cancer
DMKRFCO ID DMKRFCO
DMKRFCO DN CDX-301
DMKRFCO HS Phase 2
DMKRFCO DE Hematopoietic stem cell transplantation; Solid tumour/cancer; Multiple myeloma
DM5GKYD ID DM5GKYD
DM5GKYD DN CDX-3379
DM5GKYD HS Phase 2
DM5GKYD CP Celldex Therapeutics Hampton, NJ
DM5GKYD DE Solid tumour/cancer; Squamous cell carcinoma
DM6Z9BV ID DM6Z9BV
DM6Z9BV DN CeaVac
DM6Z9BV HS Phase 2
DM6Z9BV SN Idiotypic vaccine (CEA), Titan; Monoclonal antibody (cancer), Titan
DM6Z9BV CP Titan Pharmaceuticals
DM6Z9BV DT Vaccine
DM6Z9BV DE Colorectal cancer
DM1S2FZ ID DM1S2FZ
DM1S2FZ DN Cemdisiran
DM1S2FZ HS Phase 2
DM1S2FZ CP Alnylam Pharmaceuticals
DM1S2FZ DT Small interfering RNA
DM1S2FZ DE Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome
DMCT8EY ID DMCT8EY
DMCT8EY DN Cenderitide
DMCT8EY HS Phase 2
DMCT8EY CP Nile Therapeutics
DMCT8EY DE Heart failure; Heart disease
DMU3P1K ID DMU3P1K
DMU3P1K DN Cenerimod
DMU3P1K HS Phase 2
DMU3P1K SN 1262414-04-9; UNII-Y333RS1786; ACT-334441; Y333RS1786; Cenerimod [INN]; Cenerimod [USAN]; SCHEMBL2671193; GTPL9824; MolPort-044-723-844; KS-000006AE; ZINC167253016; AKOS030630068; CS-6364; DB12705; 1,2-Propanediol, 3-(4-(5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl)-2-ethyl-6-methylphenoxy)-, (2S)-; (S)-3-((4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)(1,2,4)oxadiazol-3-yl)-2-ethyl-6-methylphenyl)oxy)propane-1,2-diol; HY-17606; AS-35045; (S)-3-(4-(5-(2-Cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol
DMU3P1K CP Actelion Pharmaceuticals South San Francisco, CA
DMU3P1K PC 49871973
DMU3P1K MW 453.5
DMU3P1K FM C25H31N3O5
DMU3P1K IC InChI=1S/C25H31N3O5/c1-4-16-10-18(9-15(2)23(16)32-14-20(30)13-29)24-27-25(33-28-24)19-11-21(17-7-5-6-8-17)26-22(12-19)31-3/h9-12,17,20,29-30H,4-8,13-14H2,1-3H3/t20-/m0/s1
DMU3P1K CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OC[C@H](CO)O
DMU3P1K IK KJKKMMMRWISKRF-FQEVSTJZSA-N
DMU3P1K IU (2S)-3-[4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]propane-1,2-diol
DMU3P1K CA CAS 1262414-04-9
DMU3P1K DE Systemic lupus erythematosus
DMMN21R ID DMMN21R
DMMN21R DN Cenersen
DMMN21R HS Phase 2
DMMN21R CP Eleos
DMMN21R DT Antisense drug
DMMN21R PC 56841947
DMMN21R MW 6415
DMMN21R FM C195H253N66O106P19S19
DMMN21R IC InChI=1S/C195H253N66O106P19S19/c1-77-43-250(190(282)236-165(77)264)134-32-89(107(336-134)56-317-370(290,389)351-85-28-130(244-20-12-122(198)222-184(244)276)332-103(85)52-313-375(295,394)357-91-34-136(252-45-79(3)167(266)238-192(252)284)340-111(91)60-321-382(302,401)364-99-42-144(260-75-219-150-164(260)231-181(209)235-174(150)273)344-115(99)64-324-378(298,397)360-94-37-139(255-48-82(6)170(269)241-195(255)287)339-110(94)59-320-381(301,400)361-95-38-140(256-71-214-145-157(204)210-69-212-159(145)256)341-112(95)61-322-372(292,391)353-87-30-132(246-22-14-124(200)224-186(246)278)333-104(87)53-314-379(299,398)363-98-41-143(259-74-218-149-163(259)230-180(208)234-173(149)272)345-116(98)65-325-383(303,402)365-96-39-141(257-72-216-147-161(257)228-178(206)232-171(147)270)342-113(96)62-310-368(288,387)349-83-26-128(329-100(83)49-262)242-18-10-120(196)220-182(242)274)355-373(293,392)311-50-101-84(27-129(330-101)243-19-11-121(197)221-183(243)275)350-369(289,388)316-55-106-90(33-135(335-106)251-44-78(2)166(265)237-191(251)283)356-374(294,393)312-51-102-86(29-131(331-102)245-21-13-123(199)223-185(245)277)352-371(291,390)318-57-108-92(35-137(337-108)253-46-80(4)168(267)239-193(253)285)358-376(296,395)319-58-109-93(36-138(338-109)254-47-81(5)169(268)240-194(254)286)359-377(297,396)323-63-114-97(40-142(343-114)258-73-217-148-162(258)229-179(207)233-172(148)271)362-380(300,399)315-54-105-88(31-133(334-105)247-23-15-125(201)225-187(247)279)354-384(304,403)327-67-119-153(156(309-9)177(348-119)261-76-215-146-158(205)211-70-213-160(146)261)367-386(306,405)328-68-118-152(155(308-8)176(347-118)249-25-17-127(203)227-189(249)281)366-385(305,404)326-66-117-151(263)154(307-7)175(346-117)248-24-16-126(202)226-188(248)280/h10-25,43-48,69-76,83-119,128-144,151-156,175-177,262-263H,26-42,49-68H2,1-9H3,(H,288,387)(H,289,388)(H,290,389)(H,291,390)(H,292,391)(H,293,392)(H,294,393)(H,295,394)(H,296,395)(H,297,396)(H,298,397)(H,299,398)(H,300,399)(H,301,400)(H,302,401)(H,303,402)(H,304,403)(H,305,404)(H,306,405)(H2,196,220,274)(H2,197,221,275)(H2,198,222,276)(H2,199,223,277)(H2,200,224,278)(H2,201,225,279)(H2,202,226,280)(H2,203,227,281)(H2,204,210,212)(H2,205,211,213)(H,236,264,282)(H,237,265,283)(H,238,266,284)(H,239,267,285)(H,240,268,286)(H,241,269,287)(H3,206,228,232,270)(H3,207,229,233,271)(H3,208,230,234,272)(H3,209,231,235,273)
DMMN21R CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)OP(=S)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)OC)O
DMMN21R IK UTNSIDJKCKLZLN-UHFFFAOYSA-N
DMMN21R IU 1-[5-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMMN21R DE Acute myeloid leukaemia
DM4V8WF ID DM4V8WF
DM4V8WF DN Cenicriviroc
DM4V8WF HS Phase 2
DM4V8WF SN Cenicriviroc; 497223-25-3; TBR-652; TAK-652; Cenicriviroc mesylate; UNII-15C116UA4Y; TAK652; 15C116UA4Y; TBR652; Cenicriviroc (USAN/INN); SCHEMBL3157768; SCHEMBL3157748; CHEMBL2110727; MolPort-044-723-655; MolPort-044-649-359; EX-A1608; BDBM50422828; AKOS027250788; CS-6148; DB11758; SB16976; HY-14882; AS-35184; D09878; UNII-15C116UA4Y component PNDKCRDVVKJPKG-WHERJAGFSA-N; 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5E)-
DM4V8WF CP Tobira Therapeutics
DM4V8WF DT Small molecular drug
DM4V8WF PC 11285792
DM4V8WF MW 696.9
DM4V8WF FM C41H52N4O4S
DM4V8WF IC InChI=1S/C41H52N4O4S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46)/b34-26+/t50-/m0/s1
DM4V8WF CS CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C
DM4V8WF IK PNDKCRDVVKJPKG-WHERJAGFSA-N
DM4V8WF IU (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide
DM4V8WF CA CAS 497223-25-3
DM4V8WF CB CHEBI:149636
DM4V8WF DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMWUQI9 ID DMWUQI9
DMWUQI9 DN CER-001
DMWUQI9 HS Phase 2
DMWUQI9 CP Cerenis Therapeutics
DMWUQI9 DE Acute coronary syndrome; Cardiovascular disease
DMSABRI ID DMSABRI
DMSABRI DN CERC-301
DMSABRI HS Phase 2
DMSABRI CP Cerecor
DMSABRI PC 11394238
DMSABRI MW 358.4
DMSABRI FM C19H23FN4O2
DMSABRI IC InChI=1S/C19H23FN4O2/c1-14-3-5-15(6-4-14)13-26-19(25)24-10-7-16(17(20)12-24)11-23-18-21-8-2-9-22-18/h2-6,8-9,16-17H,7,10-13H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
DMSABRI CS CC1=CC=C(C=C1)COC(=O)N2CC[C@@H]([C@@H](C2)F)CNC3=NC=CC=N3
DMSABRI IK RECBFDWSXWAXHY-IAGOWNOFSA-N
DMSABRI IU (4-methylphenyl)methyl (3S,4R)-3-fluoro-4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate
DMSABRI CA CAS 808733-05-3
DMSABRI DE Major depressive disorder
DM3SZ7P ID DM3SZ7P
DM3SZ7P DN CERC-801
DM3SZ7P HS Phase 2
DM3SZ7P SN D-(+)-Galactose Anhydrous; D-Galactopyranose; D-Galactopyranoside; D-Galactose; D-Galactose (9CI); D-Glucose-2-13C; Echocon; Echovist; Galactopyranose; Galactopyranoside; Galactose; Galactose, D- (8CI); Galactose, pure; Shu 450; Shu 454; Shu-454; brain sugar; cerebrose; dl-Galactose; 10257-28-0; AC1L1LNU; AC1Q28DZ; AI3-18440; CHEBI:4139; D-Gal; DSSTox_CID_3088; DSSTox_GSID_23088; DSSTox_RID_76869; EINECS 233-595-2; Epitope ID:141794; Gal; MLS001335983; MLS001335984; NCGC00159442-02; SCHEMBL38935; SMR000857326
DM3SZ7P PC 6036
DM3SZ7P MW 180.16
DM3SZ7P FM C6H12O6
DM3SZ7P IC WQZGKKKJIJFFOK-SVZMEOIVSA-N
DM3SZ7P CS C(C1C(C(C(C(O1)O)O)O)O)O
DM3SZ7P IK 1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1
DM3SZ7P IU (3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM3SZ7P CA CAS 10257-28-0
DM3SZ7P CB CHEBI:4139
DM3SZ7P DE Glycosylation disorder
DMSCR2H ID DMSCR2H
DMSCR2H DN Cerdulatinib
DMSCR2H HS Phase 2
DMSCR2H SN PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals
DMSCR2H CP Portola Pharmaceuticals Inc; portola pharmaceuticals
DMSCR2H PC 44595079
DMSCR2H MW 445.5
DMSCR2H FM C20H27N7O3S
DMSCR2H IC InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
DMSCR2H CS CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
DMSCR2H IK BGLPECHZZQDNCD-UHFFFAOYSA-N
DMSCR2H IU 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
DMSCR2H CA CAS 1198300-79-6
DMSCR2H DE Non-hodgkin lymphoma; Atopic dermatitis; B-cell lymphoma; Vitiligo
DMNW5I9 ID DMNW5I9
DMNW5I9 DN CERE-110
DMNW5I9 HS Phase 2
DMNW5I9 CP Ceregene
DMNW5I9 DE Alzheimer disease
DMS01AX ID DMS01AX
DMS01AX DN CERE-120
DMS01AX HS Phase 2
DMS01AX SN Neurturin; NeuroRescue PD; AAV-NTN; AAV2-NRTN; AAV2-Neurturin; NTN gene therapy, Ceregene; Neurological gene therapy, Ceregene; Neurturin gene therapy, Ceregene; Neurturin, Genentech; Parkinsons disease gene therapy, Ceregene; GDNF agonist, StemCells/Genentech; NTN gene-expressing AAV vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme; Neurturin gene-expressing adeno-associated virus vector-based therapy (Parkinson's disease/other neurological diseases), Ceregene/Genzyme
DMS01AX CP Ceregene
DMS01AX DE Parkinson disease
DMAWKSM ID DMAWKSM
DMAWKSM DN CetuGEX
DMAWKSM HS Phase 2
DMAWKSM CP Glycotope GmbH
DMAWKSM DT Antibody
DMAWKSM DE Solid tumour/cancer
DMP56WJ ID DMP56WJ
DMP56WJ DN CF102
DMP56WJ HS Phase 2
DMP56WJ SN 2-Cl-IB-Meca; 163042-96-4; Cl-IB-MECA; Namodenoson; C-Ibza-MU; CF-102; CI-IB-MECA; (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide; UNII-Z07JR07J6C; 2Cl-IB-MECA; 1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE; CHEMBL431733; Z07JR07J6C; CF102; 2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
DMP56WJ CP Can-Fite BioPharm
DMP56WJ DT Small molecular drug
DMP56WJ PC 3035850
DMP56WJ MW 544.7
DMP56WJ FM C18H18ClIN6O4
DMP56WJ IC InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1
DMP56WJ CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
DMP56WJ IK IPSYPUKKXMNCNQ-PFHKOEEOSA-N
DMP56WJ IU (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DMP56WJ CA CAS 163042-96-4
DMP56WJ DE Hepatitis C virus infection; Hepatocellular carcinoma
DM3BN4W ID DM3BN4W
DM3BN4W DN CFI-400945
DM3BN4W HS Phase 2
DM3BN4W SN CFI 400945; CFI400945
DM3BN4W DT Small molecular drug
DM3BN4W PC 58486178
DM3BN4W MW 534.6
DM3BN4W FM C33H34N4O3
DM3BN4W IC InChI=1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1
DM3BN4W CS C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O
DM3BN4W IK DADASRPKWOGKCU-FVTQAUBDSA-N
DM3BN4W IU (2'S,3R)-2'-[3-[(E)-2-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one
DM3BN4W CA CAS 1338806-73-7
DM3BN4W DE Breast cancer
DM1TWIE ID DM1TWIE
DM1TWIE DN CFZ533
DM1TWIE HS Phase 2
DM1TWIE CP Novartis pharmaceuticals
DM1TWIE DE Rheumatoid arthritis; Graves disease; Myasthenia gravis; Sjogren syndrome
DMWY609 ID DMWY609
DMWY609 DN CG201
DMWY609 HS Phase 2
DMWY609 SN Bevonium methyl sulfate; BEVONIUM METILSULFATE; Bevonium methylsulfate; 5205-82-3; Bevonium methylsulphate; Piribenzil methyl sulfate; Bevonii metilsulfas [INN-Latin]; EINECS 226-001-8; CG 201; Metilsulfato de bevonio [INN-Spanish]; Metilsulfate de bevonium [INN-French]; Bevonium metilsulfate [INN]; L-99; 2-(Hydroxymethyl)-1,1-dimethylpiperidinium methyl sulfate benzilate; Piperidinium, 2-(hydroxymethyl)-1,1-dimethyl-, methyl sulfate, benzilate; alpha-Phenylmandelic acid N,N-dimethylpiperidinium-2-methyl ester methylsulfa
DMWY609 CP CG Therapeutics
DMWY609 DT Small molecular drug
DMWY609 PC 31799
DMWY609 MW 465.6
DMWY609 FM C23H31NO7S
DMWY609 IC InChI=1S/C22H28NO3.CH4O4S/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19;1-5-6(2,3)4/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
DMWY609 CS C[N+]1(CCCCC1COC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.COS(=O)(=O)[O-]
DMWY609 IK AXKJGGRSAVLXTE-UHFFFAOYSA-M
DMWY609 IU (1,1-dimethylpiperidin-1-ium-2-yl)methyl 2-hydroxy-2,2-diphenylacetate;methyl sulfate
DMWY609 CA CAS 5205-82-3
DMWY609 CB CHEBI:31283
DMWY609 DE Solid tumour/cancer
DMFAKGR ID DMFAKGR
DMFAKGR DN CG-400549
DMFAKGR HS Phase 2
DMFAKGR SN CG-400329; CG-400462; CG-400587; Bacterial enoyl-ACP reductase inhibitors, CrystalGenomics; FabI inhibitors (antibacterial), CrystalGenomics; FabK inhibitors (bacterial infections, oral), CrystalGenomics
DMFAKGR CP Cg pharmaceuticals
DMFAKGR DT Small molecular drug
DMFAKGR PC 11844916
DMFAKGR MW 340.4
DMFAKGR FM C19H20N2O2S
DMFAKGR IC InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
DMFAKGR CS CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3
DMFAKGR IK YCLREGRRHGLOAK-UHFFFAOYSA-N
DMFAKGR IU 1-[(3-amino-2-methylphenyl)methyl]-4-(2-thiophen-2-ylethoxy)pyridin-2-one
DMFAKGR CA CAS 934628-27-0
DMFAKGR DE Bacterial infection
DM17JSI ID DM17JSI
DM17JSI DN CGC-11047
DM17JSI HS Phase 2
DM17JSI SN UNII-2C4Y86R2AX; 2C4Y86R2AX; (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine; 206991-64-2; CHEMBL3104344; CGC-11047 free base; Pg-11047(free base); AC1O51NW; CHEMBL142464; SCHEMBL2360444; BDBM50445365; 308145-19-9; (Z)-N,N'-Bis[3-(ethylamino)propyl]-2-butene-1,4-diamine; 2-Butene-1,4-diamine, N1,N4-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis[3-(ethylamino)propyl]-, tetrahydrochloride, (2Z)-
DM17JSI CP Progen Pharmaceuticals
DM17JSI DT Small molecular drug
DM17JSI PC 6475492
DM17JSI MW 256.43
DM17JSI FM C14H32N4
DM17JSI IC InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5-
DM17JSI CS CCNCCCNC/C=C\\CNCCCNCC
DM17JSI IK XFWLTFZLLXVKDY-WAYWQWQTSA-N
DM17JSI IU (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM17JSI CA CAS 308145-19-9
DM17JSI DE Prostate cancer
DMYNTQV ID DMYNTQV
DMYNTQV DN CGP-28014
DMYNTQV HS Phase 2
DMYNTQV SN Cgp 28014; 111757-17-6; Methanimidamide, N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropyl-; N-(2-Oxopyridin-6-yl)-N',N'-di-n-propylformamidine; N'-(1,6-Dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide; CGP-28014; N-(2-pyridone-6-yl)-N',N'-di-n-propylformamidine; cgp28014; CHEBI:79969; LS-90457
DMYNTQV CP Novartis AG
DMYNTQV DT Small molecular drug
DMYNTQV PC 159470
DMYNTQV MW 221.3
DMYNTQV FM C12H19N3O
DMYNTQV IC InChI=1S/C12H19N3O/c1-3-8-15(9-4-2)10-13-11-6-5-7-12(16)14-11/h5-7,10H,3-4,8-9H2,1-2H3,(H,14,16)
DMYNTQV CS CCCN(CCC)C=NC1=CC=CC(=O)N1
DMYNTQV IK MEYPAYJYAZKERR-UHFFFAOYSA-N
DMYNTQV IU N'-(6-oxo-1H-pyridin-2-yl)-N,N-dipropylmethanimidamide
DMYNTQV CA CAS 111757-17-6
DMYNTQV DE Major depressive disorder
DMKS7RJ ID DMKS7RJ
DMKS7RJ DN CGS-15873A
DMKS7RJ HS Phase 2
DMKS7RJ SN Rac-trans-7-Hydroxy-4-propyl-1,2,3,4a,5,10b-hexahydro-4H-[1]benzopyrano[3,4-b]pyridine monohydrochloride
DMKS7RJ DT Small molecular drug
DMKS7RJ PC 195284
DMKS7RJ MW 283.79
DMKS7RJ FM C15H22ClNO2
DMKS7RJ IC InChI=1S/C15H21NO2.ClH/c1-2-8-16-9-4-6-11-12-5-3-7-14(17)15(12)18-10-13(11)16;/h3,5,7,11,13,17H,2,4,6,8-10H2,1H3;1H/t11-,13-;/m0./s1
DMKS7RJ CS CCCN1CCC[C@@H]2[C@@H]1COC3=C2C=CC=C3O.Cl
DMKS7RJ IK CEVXGMUELSDOPY-JZKFLRDJSA-N
DMKS7RJ IU (4aR,10bS)-4-propyl-1,2,3,4a,5,10b-hexahydrochromeno[3,4-b]pyridin-7-ol;hydrochloride
DMKS7RJ CA CAS 118929-49-0
DMKS7RJ DE Psychotic disorder
DMLQRYH ID DMLQRYH
DMLQRYH DN CH-4051
DMLQRYH HS Phase 2
DMLQRYH CP Chelsea Therapeutics
DMLQRYH PC 11532464
DMLQRYH MW 449.5
DMLQRYH FM C23H23N5O5
DMLQRYH IC InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)/t18-/m0/s1
DMLQRYH CS C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CC3=C(C=C2)N=C(N=C3N)N)C(=O)O
DMLQRYH IK NAWXUBYGYWOOIX-SFHVURJKSA-N
DMLQRYH IU (2S)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid
DMLQRYH DE Rheumatoid arthritis
DMQ2O8V ID DMQ2O8V
DMQ2O8V DN CHF-3381
DMQ2O8V HS Phase 2
DMQ2O8V SN Indantadol; UNII-Z3867B9SQP; Z3867B9SQP; Indantadol [INN]; CHF 3381; N-(2-Indanyl)glycinamide hydrochloride; 2-(2-indanylamino)acetamide; SCHEMBL399565; ZINC9005; MolPort-015-094-768; MNLULKBKWKTZPE-UHFFFAOYSA-N; AKOS009549166
DMQ2O8V CP Chiesi
DMQ2O8V TC Analgesics
DMQ2O8V DT Small molecular drug
DMQ2O8V PC 10198454
DMQ2O8V MW 226.7
DMQ2O8V FM C11H15ClN2O
DMQ2O8V IC InChI=1S/C11H14N2O.ClH/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10;/h1-4,10,13H,5-7H2,(H2,12,14);1H
DMQ2O8V CS C1C(CC2=CC=CC=C21)NCC(=O)N.Cl
DMQ2O8V IK JPNNIRXUJSPGRM-UHFFFAOYSA-N
DMQ2O8V IU 2-(2,3-dihydro-1H-inden-2-ylamino)acetamide;hydrochloride
DMQ2O8V CA CAS 202914-18-9
DMQ2O8V DE Neuropathic pain
DMTE071 ID DMTE071
DMTE071 DN CHF-5074
DMTE071 HS Phase 2
DMTE071 SN CHF 5074; CHF5074; 749269-83-8; CHF-5074; Itanapraced; UNII-C35RF1MWQZ; GHF-5074; C35RF1MWQZ; CHEMBL196945; 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid; 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid; 1-(3',4'-Dichloro-2-Fluorobiphenyl-4-Yl)cyclopropanecarboxylic Acid; H50; SCHEMBL407631; GTPL7339; DTXSID30225901; AOB5325; LIYLTQQDABRNRX-UHFFFAOYSA-N; ZINC3986651; EX-A1963; BDBM50172482; AKOS026750398; SB16945; CS-5022; NCGC00408905-01; AS-16850; HY-14399; BC600569; FT-0708261
DMTE071 CP Chiesi Pharmaceuticals
DMTE071 DT Small molecular drug
DMTE071 PC 9996409
DMTE071 MW 325.2
DMTE071 FM C16H11Cl2FO2
DMTE071 IC InChI=1S/C16H11Cl2FO2/c17-12-4-1-9(7-13(12)18)11-3-2-10(8-14(11)19)16(5-6-16)15(20)21/h1-4,7-8H,5-6H2,(H,20,21)
DMTE071 CS C1CC1(C2=CC(=C(C=C2)C3=CC(=C(C=C3)Cl)Cl)F)C(=O)O
DMTE071 IK LIYLTQQDABRNRX-UHFFFAOYSA-N
DMTE071 IU 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid
DMTE071 CA CAS 749269-83-8
DMTE071 DE Alzheimer disease; Cognitive impairment
DMALN2M ID DMALN2M
DMALN2M DN Cholyl lysyl fluorescein
DMALN2M HS Phase 2
DMALN2M PC 44470395
DMALN2M FM C51H63N3O11S
DMALN2M IC InChI=1S/C51H63N3O11S/c1-26(36-14-15-37-46-38(25-43(59)51(36,37)3)50(2)18-17-31(57)20-27(50)21-40(46)58)7-16-44(60)54-39(48(63)64)6-4-5-19-52-49(66)53-28-8-11-32(35(22-28)47(61)62)45-33-12-9-29(55)23-41(33)65-42-24-30(56)10-13-34(42)45/h8-13,22-24,26-27,31,36-40,43,46,55,57-59H,4-7,14-21,25H2,1-3H3,(H,54,60)(H,61,62)(H,63,64)(H2,52,53,66)/t26-,27+,31-,36-,37+,38+,39+,40-,43+,46+,50+,51-/m1/s1
DMALN2M CS CC(CCC(=O)NC(CCCCNC(=S)NC1=CC(=C(C=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O)C(=O)O)C5CCC6C5(C(CC7C6C(CC8C7(CCC(C8)O)C)O)O)C
DMALN2M IK ZUJFMZPBQQCXQR-TZCNZRNCSA-N
DMALN2M IU 5-[[(5S)-5-carboxy-5-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]pentyl]carbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid
DMALN2M DE Hepatitis virus infection
DMULZ4W ID DMULZ4W
DMULZ4W DN CHR-2797
DMULZ4W HS Phase 2
DMULZ4W SN Tosedostat; Tosedostat, CHR2797, CHR-2797
DMULZ4W CP Chroma Therape.
DMULZ4W TC Anticancer Agents
DMULZ4W DT Small molecular drug
DMULZ4W PC 15547703
DMULZ4W MW 406.5
DMULZ4W FM C21H30N2O6
DMULZ4W IC InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1
DMULZ4W CS CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2
DMULZ4W IK FWFGIHPGRQZWIW-SQNIBIBYSA-N
DMULZ4W IU cyclopentyl (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-2-phenylacetate
DMULZ4W CA CAS 238750-77-1
DMULZ4W CB CHEBI:95044
DMULZ4W DE Acute myeloid leukaemia; Myelodysplastic syndrome; Inflammation
DMMRKPF ID DMMRKPF
DMMRKPF DN CHS-131
DMMRKPF HS Phase 2
DMMRKPF CP Coherus Biosciences Redwood City, CA
DMMRKPF DE Multiple sclerosis
DMLRTN1 ID DMLRTN1
DMLRTN1 DN CI-1012
DMLRTN1 HS Phase 2
DMLRTN1 SN NCS-675753; PD-161374; HIV replication inhibitor, Parke-Davis/NIAID
DMLRTN1 CP Parke-Davis & Co Ltd
DMLRTN1 DT Small molecular drug
DMLRTN1 PC 72552
DMLRTN1 MW 304.4
DMLRTN1 FM C14H12N2O2S2
DMLRTN1 IC InChI=1S/C14H12N2O2S2/c15-13(17)9-5-1-3-7-11(9)19-20-12-8-4-2-6-10(12)14(16)18/h1-8H,(H2,15,17)(H2,16,18)
DMLRTN1 CS C1=CC=C(C(=C1)C(=O)N)SSC2=CC=CC=C2C(=O)N
DMLRTN1 IK OEEHSSKRJOGQMP-UHFFFAOYSA-N
DMLRTN1 IU 2-[(2-carbamoylphenyl)disulfanyl]benzamide
DMLRTN1 CA CAS 2527-57-3
DMLRTN1 DE Acquired immune deficiency syndrome
DMSI8N3 ID DMSI8N3
DMSI8N3 DN CI-1033
DMSI8N3 HS Phase 2
DMSI8N3 SN Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride
DMSI8N3 CP Pfizer
DMSI8N3 TC Anticancer Agents
DMSI8N3 DT Small molecular drug
DMSI8N3 PC 156414
DMSI8N3 MW 485.9
DMSI8N3 FM C24H25ClFN5O3
DMSI8N3 IC InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
DMSI8N3 CS C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
DMSI8N3 IK OMZCMEYTWSXEPZ-UHFFFAOYSA-N
DMSI8N3 IU N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
DMSI8N3 CA CAS 267243-28-7
DMSI8N3 CB CHEBI:61399
DMSI8N3 DE Lymphoma
DMCFLRH ID DMCFLRH
DMCFLRH DN Cibinetide
DMCFLRH HS Phase 2
DMCFLRH SN UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam
DMCFLRH CP Araim Pharmaceuticals Tarrytown, NY
DMCFLRH PC 91810664
DMCFLRH MW 1257.3
DMCFLRH FM C51H84N16O21
DMCFLRH IC InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
DMCFLRH CS C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
DMCFLRH IK WZTIQQBMSJTRBR-WYKNNRPVSA-N
DMCFLRH IU (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
DMCFLRH CA CAS 1208243-50-8
DMCFLRH DE Depression; Diabetic macular edema; Neuropathic pain; Sarcoidosis; Peripheral neuropathy
DMGTZLW ID DMGTZLW
DMGTZLW DN Cicletanine
DMGTZLW HS Phase 2
DMGTZLW SN Cicletanine; Cycletanide; Tenstaten; 89943-82-8; Justar; BN-1270; Win-90000; cicletanide; BN 1270; Cicletaninum; Cicletanina; Cicletaninum [Latin]; Cicletanina [Spanish]; Cicletanine [USAN:INN:BAN]; Win 90,000; ACMC-20mckj; ACMC-20mcin; AC1Q3NNY; Cicletanine (USAN/INN); (+-)-BN-1270; AC1L1HZ3; SCHEMBL49794; CHEMBL191886; (R)-(-)-CICLETANINE; CHEBI:135078; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (S)-; Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (R)-; CVKNDPRBJVBDSS-UHFFFAOYSA-N
DMGTZLW CP Gilead Sciences
DMGTZLW DT Small molecular drug
DMGTZLW PC 54910
DMGTZLW MW 261.7
DMGTZLW FM C14H12ClNO2
DMGTZLW IC InChI=1S/C14H12ClNO2/c1-8-13(17)12-7-18-14(11(12)6-16-8)9-2-4-10(15)5-3-9/h2-6,14,17H,7H2,1H3
DMGTZLW CS CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl
DMGTZLW IK CVKNDPRBJVBDSS-UHFFFAOYSA-N
DMGTZLW IU 3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
DMGTZLW CA CAS 89943-82-8
DMGTZLW CB CHEBI:135078
DMGTZLW DE Pulmonary arterial hypertension
DMTKSVA ID DMTKSVA
DMTKSVA DN CIMICOXIB
DMTKSVA HS Phase 2
DMTKSVA SN Cimicoxib; 265114-23-6; UNII-W7FHJ107MC; UR-8880; W7FHJ107MC; CHEMBL435381; CHEBI:76127; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide; 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide; Cimicoxib [INN]; 4-(4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl)benzenesulfonamide; AC1Q6UZ8; AC1L4U5V; SCHEMBL3123310; CTK4F8038; DTXSID30181093; KYXDNECMRLFQMZ-UHFFFAOYSA-N; BCP24933; ZINC1494105
DMTKSVA DT Small molecular drug
DMTKSVA PC 213053
DMTKSVA MW 381.8
DMTKSVA FM C16H13ClFN3O3S
DMTKSVA IC InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
DMTKSVA CS COC1=C(C=C(C=C1)C2=C(N=CN2C3=CC=C(C=C3)S(=O)(=O)N)Cl)F
DMTKSVA IK KYXDNECMRLFQMZ-UHFFFAOYSA-N
DMTKSVA IU 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide
DMTKSVA CA CAS 265114-23-6
DMTKSVA CB CHEBI:76127
DMTKSVA DE Pain
DMGEAM6 ID DMGEAM6
DMGEAM6 DN Cinaciguat
DMGEAM6 HS Phase 2
DMGEAM6 SN Cinaciguat; 329773-35-5; BAY 58-2667; BAY582667; UNII-59K0Y58UAD; BAY-58-2667; 59K0Y58UAD; 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid; Cinaciguat [INN:JAN]; cinaciguatum; Z90; Cinaciguat (JAN/INN); SCHEMBL249267; GTPL5168; CHEMBL1236936; QCR-279; Cinaciguat (BAY 58-2667); MolPort-039-139-611; CHEBI:142433; ZINC3934935; BCP07942; 3550AH; AKOS026750293; AN-1845; CS-1169; HY-14181; KB-40005; AB0095741; D07577; W-5794
DMGEAM6 DT Small molecular drug
DMGEAM6 PC 9808022
DMGEAM6 MW 565.7
DMGEAM6 FM C36H39NO5
DMGEAM6 IC InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41)
DMGEAM6 CS C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O
DMGEAM6 IK WPYWMXNXEZFMAK-UHFFFAOYSA-N
DMGEAM6 IU 4-[[4-carboxybutyl-[2-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid
DMGEAM6 CA CAS 329773-35-5
DMGEAM6 CB CHEBI:142433
DMGEAM6 DE Acute decompensated heart failure
DM98RW0 ID DM98RW0
DM98RW0 DN Cirmtuzumab
DM98RW0 HS Phase 2
DM98RW0 SN UC-961
DM98RW0 CP Oncternal Therapeutics San Diego, CA
DM98RW0 DE Mantle cell lymphoma; Chronic lymphocytic leukaemia
DMNRYPF ID DMNRYPF
DMNRYPF DN Cixutumumab
DMNRYPF HS Phase 2
DMNRYPF SN LY3012217
DMNRYPF CP Lilly
DMNRYPF DT Monoclonal antibody
DMNRYPF DE Non-small-cell lung cancer; Liver cancer
DMOFTRE ID DMOFTRE
DMOFTRE DN Cizolirtine
DMOFTRE HS Phase 2
DMOFTRE SN Cizolirtine [INN]; N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine; N,N-dimethyl-2-[(R)-(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
DMOFTRE CP Esteve Laboratories
DMOFTRE TC Analgesics
DMOFTRE DT Small molecular drug
DMOFTRE PC 132412
DMOFTRE MW 259.35
DMOFTRE FM C15H21N3O
DMOFTRE IC InChI=1S/C15H21N3O/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3/h4-10,15H,11-12H2,1-3H3
DMOFTRE CS CN1C(=CC=N1)C(C2=CC=CC=C2)OCCN(C)C
DMOFTRE IK DCMJBKFKXGPPMT-UHFFFAOYSA-N
DMOFTRE IU N,N-dimethyl-2-[(2-methylpyrazol-3-yl)-phenylmethoxy]ethanamine
DMOFTRE CA CAS 142155-43-9
DMOFTRE DE Neuropathic pain
DMTSVJM ID DMTSVJM
DMTSVJM DN CJM112
DMTSVJM HS Phase 2
DMTSVJM CP Novartis Pharmaceuticals East Hanover, NJ
DMTSVJM DE Chronic plaque psoriasis; Multiple myeloma; Plaque psoriasis; Solid tumour/cancer; Acne vulgaris
DM9FHV8 ID DM9FHV8
DM9FHV8 DN CK-2127107
DM9FHV8 HS Phase 2
DM9FHV8 CP Cytokinetics
DM9FHV8 PC 67454400
DM9FHV8 MW 384.4
DM9FHV8 FM C19H18F2N6O
DM9FHV8 IC InChI=1S/C19H18F2N6O/c20-13-6-19(7-13,16-15(21)2-1-4-23-16)11-26-18-24-8-14(9-25-18)27-5-3-12(10-27)17(22)28/h1-5,8-10,13H,6-7,11H2,(H2,22,28)(H,24,25,26)
DM9FHV8 CS C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F
DM9FHV8 IK MQXWPWOCXGARRK-UHFFFAOYSA-N
DM9FHV8 IU 1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide
DM9FHV8 CA CAS 1345410-31-2
DM9FHV8 DE Muscle atrophy; Amyotrophic lateral sclerosis; Spinal muscular atrophy
DMW9F1G ID DMW9F1G
DMW9F1G DN CKD602
DMW9F1G HS Phase 2
DMW9F1G SN Belotecan hydrochloride; 213819-48-8; Belotecan; CKD-602; Belotecan HCl; Camtobell hydrochloride; Belotecan (hydrochloride); CKD 602; UNII-01DZ4127G7; 01DZ4127G7; Belotecan hydrochloride (USAN); Belotecan Hydrochloride [USAN]; CHEMBL2107315; DTXSID60175647; BCP28717; HY-13566A; AKOS027420465; API0009359; CS-6955; (S)-4-ethyl-4-hydroxy-11-(2-(isopropylamino)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; AN-29684; ACM213819488; FT-0662513; D03225; 819C488; J-014022
DMW9F1G DT Small molecular drug
DMW9F1G PC 6456014
DMW9F1G MW 433.5
DMW9F1G FM C25H27N3O4
DMW9F1G IC InChI=1S/C25H27N3O4/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3/t25-/m0/s1
DMW9F1G CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CCNC(C)C)O
DMW9F1G IK LNHWXBUNXOXMRL-VWLOTQADSA-N
DMW9F1G IU (19S)-19-ethyl-19-hydroxy-10-[2-(propan-2-ylamino)ethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMW9F1G CA CAS 256411-32-2
DMW9F1G CB CHEBI:135702
DMW9F1G DE Solid tumour/cancer
DMXH1KC ID DMXH1KC
DMXH1KC DN CL-316,243
DMXH1KC HS Phase 2
DMXH1KC SN UNII-52H8DB0TKX; 52H8DB0TKX; 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid; CL-316243; 5-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-dicarboxylic acid; CL 316243; CL316,243; Cl-316243 Free diacid; AC1NUOLQ; Lopac0_000295; SCHEMBL2345491; GTPL3462; CHEMBL1204876; BDBM25763; ZINC1493298; 183720-02-7; 1,3-Benzodioxole-2,2-dicarboxylic acid, 5-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-; LS-187111
DMXH1KC DT Small molecular drug
DMXH1KC PC 5312115
DMXH1KC MW 465.8
DMXH1KC FM C20H18ClNNa2O7
DMXH1KC IC InChI=1S/C20H20ClNO7.2Na/c1-11(22-10-15(23)13-3-2-4-14(21)9-13)7-12-5-6-16-17(8-12)29-20(28-16,18(24)25)19(26)27;;/h2-6,8-9,11,15,22-23H,7,10H2,1H3,(H,24,25)(H,26,27);;/q;2*+1/p-2/t11-,15+;;/m1../s1
DMXH1KC CS C[C@H](CC1=CC2=C(C=C1)OC(O2)(C(=O)[O-])C(=O)[O-])NC[C@@H](C3=CC(=CC=C3)Cl)O.[Na+].[Na+]
DMXH1KC IK FUZBPOHHSBDTJQ-CFOQQKEYSA-L
DMXH1KC IU disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
DMXH1KC CA CAS 138908-40-4
DMXH1KC DE Obesity
DMSF7WJ ID DMSF7WJ
DMSF7WJ DN CL-329167
DMSF7WJ HS Phase 2
DMSF7WJ SN 2-Butyl-6-(1-methoxy-1-methylethyl)-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]quinazolin-4(3H)-one
DMSF7WJ DT Small molecular drug
DMSF7WJ PC 6918269
DMSF7WJ MW 508.6
DMSF7WJ FM C30H32N6O2
DMSF7WJ IC InChI=1S/C30H32N6O2/c1-5-6-11-27-31-26-17-16-22(30(2,3)38-4)18-25(26)29(37)36(27)19-20-12-14-21(15-13-20)23-9-7-8-10-24(23)28-32-34-35-33-28/h7-10,12-18H,5-6,11,19H2,1-4H3,(H,32,33,34,35)
DMSF7WJ CS CCCCC1=NC2=C(C=C(C=C2)C(C)(C)OC)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMSF7WJ IK XZCUIMYYMKTCBA-UHFFFAOYSA-N
DMSF7WJ IU 2-butyl-6-(2-methoxypropan-2-yl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-4-one
DMSF7WJ DE Hypertension
DM6ZOUV ID DM6ZOUV
DM6ZOUV DN Clazakizumab
DM6ZOUV HS Phase 2
DM6ZOUV SN Clazakizumab; ALD518; CHEMBL2108589; BMS-945429
DM6ZOUV TC Antiviral Agents
DM6ZOUV DT Monoclonal antibody
DM6ZOUV DE Coronavirus Disease 2019 (COVID-19)
DMAIW6C ID DMAIW6C
DMAIW6C DN Clazakizumab
DMAIW6C HS Phase 2
DMAIW6C CP Bristol-myers squibb; alder biopharmaceuticals
DMAIW6C DT Monoclonal antibody
DMAIW6C DE Crohn disease; Rheumatoid arthritis
DMU6R3O ID DMU6R3O
DMU6R3O DN CLG561
DMU6R3O HS Phase 2
DMU6R3O CP Alcon
DMU6R3O DT Antibody
DMU6R3O DE Geographic retinal atrophy
DMH2VS0 ID DMH2VS0
DMH2VS0 DN CLP-1001
DMH2VS0 HS Phase 2
DMH2VS0 SN Cross-linked polyelectrolyte polymer (renal disease), Sorbent Therapeutics
DMH2VS0 CP Sorbent therapeutics
DMH2VS0 DE Chronic heart failure
DMAW4EL ID DMAW4EL
DMAW4EL DN CLR-1404
DMAW4EL HS Phase 2
DMAW4EL SN CLR-1501; CLR-1502
DMAW4EL CP Cellectar LLC
DMAW4EL DE Solid tumour/cancer
DM3Z6IQ ID DM3Z6IQ
DM3Z6IQ DN CLR-3001
DM3Z6IQ HS Phase 2
DM3Z6IQ CP Clera Inc
DM3Z6IQ DE Major depressive disorder
DMQSIY1 ID DMQSIY1
DMQSIY1 DN CLS003
DMQSIY1 HS Phase 2
DMQSIY1 SN Furosemide/digoxin; ICVT; Ionic contra viral therapy
DMQSIY1 CP Cutanea Wayne, PA
DMQSIY1 DE Plantar wart
DM1NCUY ID DM1NCUY
DM1NCUY DN CMI-392
DM1NCUY HS Phase 2
DM1NCUY SN LDP-392; 3-[2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[trans-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzyl]-1-hydroxy-1-methylurea
DM1NCUY CP Millennium Pharmaceuticals
DM1NCUY DT Small molecular drug
DM1NCUY PC 6918268
DM1NCUY MW 633.2
DM1NCUY FM C31H37ClN2O8S
DM1NCUY IC InChI=1S/C31H37ClN2O8S/c1-34(36)31(35)33-18-21-14-19(15-26(37-2)29(21)41-12-13-43-23-8-6-22(32)7-9-23)24-10-11-25(42-24)20-16-27(38-3)30(40-5)28(17-20)39-4/h6-9,14-17,24-25,36H,10-13,18H2,1-5H3,(H,33,35)/t24-,25-/m0/s1
DM1NCUY CS CN(C(=O)NCC1=C(C(=CC(=C1)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC)OCCSC4=CC=C(C=C4)Cl)O
DM1NCUY IK LZVBMKDVEPGGFK-DQEYMECFSA-N
DM1NCUY IU 3-[[2-[2-(4-chlorophenyl)sulfanylethoxy]-3-methoxy-5-[(2S,5S)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]methyl]-1-hydroxy-1-methylurea
DM1NCUY DE Psoriasis vulgaris
DM7GELO ID DM7GELO
DM7GELO DN CMVpp65-A0201
DM7GELO HS Phase 2
DM7GELO SN CMV vaccine (pp65 antigen), City of Hope
DM7GELO CP City of Hope
DM7GELO DT Vaccine
DM7GELO DE Cytomegalovirus infection
DMPSCVY ID DMPSCVY
DMPSCVY DN CMX-2043
DMPSCVY HS Phase 2
DMPSCVY CP Ischemix
DMPSCVY PC 49802864
DMPSCVY MW 406.5
DMPSCVY FM C16H26N2O6S2
DMPSCVY IC InChI=1S/C16H26N2O6S2/c1-10(16(23)24)17-15(22)12(6-7-14(20)21)18-13(19)5-3-2-4-11-8-9-25-26-11/h10-12H,2-9H2,1H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)/t10-,11+,12-/m0/s1
DMPSCVY CS C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1
DMPSCVY IK MQXRTCVZPIHBLD-TUAOUCFPSA-N
DMPSCVY IU (4S)-5-[[(1S)-1-carboxyethyl]amino]-4-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-5-oxopentanoic acid
DMPSCVY CA CAS 910627-26-8
DMPSCVY DE Myocardial reperfusion injury; Cardiac disease
DM0MTP8 ID DM0MTP8
DM0MTP8 DN CN-105
DM0MTP8 HS Phase 2
DM0MTP8 SN 5-Nitroisoquinoline; 607-32-9; Isoquinoline, 5-nitro-; 5-Nitro-isoquinoline; MLS002637661; PYGMPFQCCWBTJQ-UHFFFAOYSA-N; 5-nitroisochinolin; EINECS 210-133-8; 5-nitro isoquinoline; PubChem6272; AI3-61887; Maybridge1_001820; ACMC-1AV1Q; AC1Q1X2S; 5-Nitroisoquinoline, 98%; Oprea1_032003; SCHEMBL1010663; AC1Q201M; AC1L2B31; CHEMBL353253; PYGMPFQCCWBTJQ-UHFFFAOYSA-; KS-00000DJC; CTK2F2846; ZINC93213; HMS546K16; DTXSID00209511; NSC3017; MolPort-001-761-771; HMS3078A13; ACT09900; ALBB-021274; NSC-3017; ANW-33564; SBB066313; MFCD00006905
DM0MTP8 CP AegisCN Raleigh, NC
DM0MTP8 PC 69085
DM0MTP8 MW 174.16
DM0MTP8 FM C9H6N2O2
DM0MTP8 IC InChI=1S/C9H6N2O2/c12-11(13)9-3-1-2-7-6-10-5-4-8(7)9/h1-6H
DM0MTP8 CS C1=CC2=C(C=CN=C2)C(=C1)[N+](=O)[O-]
DM0MTP8 IK PYGMPFQCCWBTJQ-UHFFFAOYSA-N
DM0MTP8 IU 5-nitroisoquinoline
DM0MTP8 CA CAS 607-32-9
DM0MTP8 DE Nontraumatic intracerebral hemorrhage
DM16KJ3 ID DM16KJ3
DM16KJ3 DN CNS-5161
DM16KJ3 HS Phase 2
DM16KJ3 SN CNS5161; 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine; 2-[2-chloro-5-(methylsulfanyl)phenyl]-1-methyl-1-[3-(methylsulfanyl)phenyl]guanidine
DM16KJ3 CP CeNeS
DM16KJ3 TC Analgesics
DM16KJ3 DT Small molecular drug
DM16KJ3 PC 192711
DM16KJ3 MW 351.9
DM16KJ3 FM C16H18ClN3S2
DM16KJ3 IC InChI=1S/C16H18ClN3S2/c1-20(11-5-4-6-12(9-11)21-2)16(18)19-15-10-13(22-3)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)
DM16KJ3 CS CN(C1=CC(=CC=C1)SC)C(=NC2=C(C=CC(=C2)SC)Cl)N
DM16KJ3 IK JHVHEDNLONERHY-UHFFFAOYSA-N
DM16KJ3 IU 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine
DM16KJ3 CA CAS 160754-76-7
DM16KJ3 DE Neuropathic pain
DM2PEU5 ID DM2PEU5
DM2PEU5 DN CNSB-001
DM2PEU5 HS Phase 2
DM2PEU5 SN Flupirtine + opioid (fixed dose, diabetic neuropathic pain), CNSBio; Flupirtine + opioid (fixed dose, diabetic neuropathic pain), Relevare
DM2PEU5 CP Relevare Pharmaceuticals Ltd
DM2PEU5 DE Neuropathic pain
DMOR8SY ID DMOR8SY
DMOR8SY DN CNT0-1959
DMOR8SY HS Phase 2
DMOR8SY CP Janssen biotech
DMOR8SY DT Antibody
DMOR8SY DE Rheumatoid arthritis
DM6RQXB ID DM6RQXB
DM6RQXB DN CNTO-6785
DM6RQXB HS Phase 2
DM6RQXB CP Janssen research & development
DM6RQXB DT Antibody
DM6RQXB DE Rheumatoid arthritis
DMLT7JV ID DMLT7JV
DMLT7JV DN CNV-2197944
DMLT7JV HS Phase 2
DMLT7JV SN GSK-2197944; Cav2.2 channel blocker (chronic pain), GlaxoSmithKline/Convergence Pharmaceuticals
DMLT7JV CP GlaxoSmithKline plc
DMLT7JV PC 44595848
DMLT7JV MW 427.4
DMLT7JV FM C19H20F3N3O3S
DMLT7JV IC InChI=1S/C19H20F3N3O3S/c1-13-12-24(10-11-25(13)18(26)17-4-3-9-23-14(17)2)29(27,28)16-7-5-15(6-8-16)19(20,21)22/h3-9,13H,10-12H2,1-2H3/t13-/m0/s1
DMLT7JV CS C[C@H]1CN(CCN1C(=O)C2=C(N=CC=C2)C)S(=O)(=O)C3=CC=C(C=C3)C(F)(F)F
DMLT7JV IK BLFJGFDZMABYMY-ZDUSSCGKSA-N
DMLT7JV IU (2-methylpyridin-3-yl)-[(2S)-2-methyl-4-[4-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]methanone
DMLT7JV CA CAS 1204535-44-3
DMLT7JV DE Pain
DMH5GQU ID DMH5GQU
DMH5GQU DN CO-101
DMH5GQU HS Phase 2
DMH5GQU SN methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
DMH5GQU CP Clovis Oncology
DMH5GQU DT Small molecular drug
DMH5GQU PC 9828310
DMH5GQU MW 527.6
DMH5GQU FM C27H43F2N3O5
DMH5GQU IC InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1
DMH5GQU CS CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O
DMH5GQU IK HESSNRGIEVBPRB-QDDPNBLJSA-N
DMH5GQU IU [(2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methyl (E)-octadec-9-enoate
DMH5GQU CA CAS 210829-30-4
DMH5GQU DE Pancreatic cancer
DMF4MX9 ID DMF4MX9
DMF4MX9 DN Cobomarsen
DMF4MX9 HS Phase 2
DMF4MX9 SN MRG-106
DMF4MX9 CP miRagen Therapeutics Boulder, CO
DMF4MX9 DE Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Cutaneous T-cell lymphoma
DMDWG36 ID DMDWG36
DMDWG36 DN Codrituzumab
DMDWG36 HS Phase 2
DMDWG36 CP GenentechSouth San Francisco, CA
DMDWG36 DE Hepatic metastasis
DMO0VGH ID DMO0VGH
DMO0VGH DN Coenzyme Q10 analog
DMO0VGH HS Phase 2
DMO0VGH SN Coenzyme Q10 analog (mitochondrial disease); Coenzyme Q10 analog (mitochondrial disease), Edison Pharmaceuticals
DMO0VGH CP Edison Pharmaceuticals Inc
DMO0VGH DE Huntington disease; Leigh syndrome; Mitochondrial respiratory chain disease; Rett syndrome
DMNC76I ID DMNC76I
DMNC76I DN COL-1077
DMNC76I HS Phase 2
DMNC76I CP Columbia Laboratories Inc
DMNC76I DE Pain
DMSGFOY ID DMSGFOY
DMSGFOY DN Coltuximab ravtansine
DMSGFOY HS Phase 2
DMSGFOY CP ImmunoGen Waltham, MA
DMSGFOY DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMI2GSK ID DMI2GSK
DMI2GSK DN Coluracetam
DMI2GSK HS Phase 2
DMI2GSK SN BCI-540; MKC-231; High-affinity choline uptake facilitator (CNS disorders), Mitsubishi; Neurons growth promoting compound (major depressive disorder/anxiety), BrainCells; High-affinity choline uptake facilitator (depression/ anxiety), BrainCells
DMI2GSK CP Mitsubishi Pharma Corp
DMI2GSK DT Small molecular drug
DMI2GSK PC 214346
DMI2GSK MW 341.4
DMI2GSK FM C19H23N3O3
DMI2GSK IC InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23)
DMI2GSK CS CC1=C(OC2=NC3=C(CCCC3)C(=C12)NC(=O)CN4CCCC4=O)C
DMI2GSK IK PSPGQHXMUKWNDI-UHFFFAOYSA-N
DMI2GSK IU N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
DMI2GSK CA CAS 135463-81-9
DMI2GSK DE Alzheimer disease
DMGCTX5 ID DMGCTX5
DMGCTX5 DN Combined PR1/WT1 vaccine
DMGCTX5 HS Phase 2
DMGCTX5 SN Combined PR1/WT1 vaccine (leukemia); Combined PR1/WT1 vaccine (leukemia), NIH; Proteinase 1/Wilms tumor 1 vaccine (leukemia), NIH
DMGCTX5 CP National Institutes of Health
DMGCTX5 DT Vaccine
DMGCTX5 DE Myeloid leukaemia
DM2UOSN ID DM2UOSN
DM2UOSN DN Conatumumab
DM2UOSN HS Phase 2
DM2UOSN CP Amgen; Takeda
DM2UOSN DT Monoclonal antibody
DM2UOSN DE Pain; Colorectal cancer
DMZ0F65 ID DMZ0F65
DMZ0F65 DN Contezolid
DMZ0F65 HS Phase 2
DMZ0F65 SN MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796
DMZ0F65 CP MicuRx Pharmaceuticals Hayward, CA
DMZ0F65 PC 25184541
DMZ0F65 MW 408.3
DMZ0F65 FM C18H15F3N4O4
DMZ0F65 IC InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
DMZ0F65 CS C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F
DMZ0F65 IK SULYVXZZUMRQAX-NSHDSACASA-N
DMZ0F65 IU (5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one
DMZ0F65 CA CAS 1112968-42-9
DMZ0F65 DE MRSA infection; Skin infection
DMMOHUA ID DMMOHUA
DMMOHUA DN Contezolid acefosamil
DMMOHUA HS Phase 2
DMMOHUA SN JANNTEAGZXJITO-BTQNPOSSSA-M; UNII-T79C086548; T79C086548; Contezolid acefosamil [USAN]; CHEMBL3989966; Acetic acid, anhydride with N-(((5R)-3-(4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-2,3,5-trifluorophenyl)-2-oxo-5-oxazolidinyl)methyl)-N-3-isoxazolylphosphoramidic acid, sodium salt (1:1:1); Acetic (5R)-isoxazol-3yl((2-oxo-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-5-yl)methyl)phosphoramidic anhydride, sodium salt (1:1); 1807365-35-0
DMMOHUA CP MicuRx Pharmaceuticals Hayward, CA
DMMOHUA PC 131750213
DMMOHUA MW 552.3
DMMOHUA FM C20H17F3N4NaO8P
DMMOHUA IC InChI=1S/C20H18F3N4O8P.Na/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25;/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32);/q;+1/p-1/t13-;/m1./s1
DMMOHUA CS CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)[O-].[Na+]
DMMOHUA IK JANNTEAGZXJITO-BTQNPOSSSA-M
DMMOHUA IU sodium;acetyloxy-[1,2-oxazol-3-yl-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]amino]phosphinate
DMMOHUA CA CAS 1807365-35-0
DMMOHUA DE Acute bacterial skin infection
DMER82Z ID DMER82Z
DMER82Z DN COR-1
DMER82Z HS Phase 2
DMER82Z CP Corimmun GmbH
DMER82Z DE Heart failure
DMHBOUX ID DMHBOUX
DMHBOUX DN CORT125281
DMHBOUX HS Phase 2
DMHBOUX SN Exicorilant; UNII-GTB859B7K8; GTB859B7K8; Exicorilant [INN]; SCHEMBL16737057; CORT-125281; 1781244-77-6; Methanone, ((4aR,8aS)-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-
DMHBOUX CP Corcept Therapeutics Menlo Park, CA
DMHBOUX PC 118092367
DMHBOUX MW 589.6
DMHBOUX FM C26H23F4N7O3S
DMHBOUX IC InChI=1S/C26H23F4N7O3S/c1-35-32-14-23(34-35)41(39,40)36-9-7-17-11-22-16(13-33-37(22)20-4-2-19(27)3-5-20)12-25(17,15-36)24(38)21-10-18(6-8-31-21)26(28,29)30/h2-6,8,10,13-14,17H,7,9,11-12,15H2,1H3/t17-,25-/m0/s1
DMHBOUX CS CN1N=CC(=N1)S(=O)(=O)N2CC[C@H]3CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
DMHBOUX IK HWJYJKAURRIWJM-GKVSMKOHSA-N
DMHBOUX IU [(4aR,8aS)-1-(4-fluorophenyl)-6-(2-methyltriazol-4-yl)sulfonyl-4,5,7,8,8a,9-hexahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
DMHBOUX CA CAS 1781244-77-6
DMHBOUX DE Prostate cancer
DMVKW0N ID DMVKW0N
DMVKW0N DN Coumate
DMVKW0N HS Phase 2
DMVKW0N DT Small molecular drug
DMVKW0N PC 9859866
DMVKW0N MW 255.25
DMVKW0N FM C10H9NO5S
DMVKW0N IC InChI=1S/C10H9NO5S/c1-6-4-10(12)15-9-5-7(2-3-8(6)9)16-17(11,13)14/h2-5H,1H3,(H2,11,13,14)
DMVKW0N CS CC1=CC(=O)OC2=C1C=CC(=C2)OS(=O)(=O)N
DMVKW0N IK UFGBGFMPBMEVMI-UHFFFAOYSA-N
DMVKW0N IU (4-methyl-2-oxochromen-7-yl) sulfamate
DMVKW0N CA CAS 136167-05-0
DMVKW0N DE Breast cancer
DM2K5VP ID DM2K5VP
DM2K5VP DN Coxsackievirus A21
DM2K5VP HS Phase 2
DM2K5VP SN Cavatak (TN)
DM2K5VP CP Viralytics
DM2K5VP DE Bladder cancer; Lung cancer; Melanoma; Prostate cancer; Glioblastoma multiforme
DM8X5Q1 ID DM8X5Q1
DM8X5Q1 DN CP101
DM8X5Q1 HS Phase 2
DM8X5Q1 CP Finch Therapeutics
DM8X5Q1 DT Small molecular drug
DM8X5Q1 DE Autism spectrum disorder; Clostridium infection
DMIU19E ID DMIU19E
DMIU19E DN CP-101,606
DMIU19E HS Phase 2
DMIU19E SN SCHEMBL5888841; CHEMBL321758; AKOS030627610; CP-101581; (1R,2R)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 1-((1R,2R)-Rel-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol
DMIU19E TC Analgesics
DMIU19E DT Small molecular drug
DMIU19E PC 219101
DMIU19E MW 327.4
DMIU19E FM C20H25NO3
DMIU19E IC InChI=1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1
DMIU19E CS C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O
DMIU19E IK QEMSVZNTSXPFJA-HNAYVOBHSA-N
DMIU19E IU 1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol
DMIU19E CA CAS 134234-12-1
DMIU19E DE Ischemic stroke; Parkinson disease
DMSWLM5 ID DMSWLM5
DMSWLM5 DN CP-122721
DMSWLM5 HS Phase 2
DMSWLM5 SN CP-122721; UNII-R7OYP6N58F; R7OYP6N58F; CHEMBL319118; CHEMBL1917847; DSSTox_CID_27251; DSSTox_RID_82210; DSSTox_GSID_47251; SCHEMBL156646; DTXSID9047251; Tox21_300205; BDBM50067935; ZINC22441997; AKOS030542331; DB05421; NCGC00254228-01; NCGC00247927-01; CAS-145742-28-5; (2S,3S)-N-(2-methoxy-5-(trifluoromethoxy)benzyl)-2-phenylpiperidin-3-amine
DMSWLM5 DT Small molecular drug
DMSWLM5 PC 9821217
DMSWLM5 MW 380.4
DMSWLM5 FM C20H23F3N2O2
DMSWLM5 IC InChI=1S/C20H23F3N2O2/c1-26-18-10-9-16(27-20(21,22)23)12-15(18)13-25-17-8-5-11-24-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,24-25H,5,8,11,13H2,1H3/t17-,19-/m0/s1
DMSWLM5 CS COC1=C(C=C(C=C1)OC(F)(F)F)CN[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMSWLM5 IK ZIWFCOIGUNPHPM-HKUYNNGSSA-N
DMSWLM5 IU (2S,3S)-N-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine
DMSWLM5 CA CAS 145742-28-5
DMSWLM5 DE Major depressive disorder
DMVO5DR ID DMVO5DR
DMVO5DR DN CP-331684
DMVO5DR HS Phase 2
DMVO5DR SN 2-[4-[2-[2(R)-(6-Amino-3-pyridinyl)-2-hydroxyethylamino]ethoxy]phenyl]acetic acid
DMVO5DR DT Small molecular drug
DMVO5DR PC 9840517
DMVO5DR MW 331.4
DMVO5DR FM C17H21N3O4
DMVO5DR IC InChI=1S/C17H21N3O4/c18-16-6-3-13(10-20-16)15(21)11-19-7-8-24-14-4-1-12(2-5-14)9-17(22)23/h1-6,10,15,19,21H,7-9,11H2,(H2,18,20)(H,22,23)/t15-/m0/s1
DMVO5DR CS C1=CC(=CC=C1CC(=O)O)OCCNC[C@@H](C2=CN=C(C=C2)N)O
DMVO5DR IK GZJZZQHTBTUBEL-HNNXBMFYSA-N
DMVO5DR IU 2-[4-[2-[[(2R)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]amino]ethoxy]phenyl]acetic acid
DMVO5DR CA CAS 207922-70-1
DMVO5DR DE Diabetic complication
DMEYMTX ID DMEYMTX
DMEYMTX DN CP-461
DMEYMTX HS Phase 2
DMEYMTX SN CP-461; OSI 461; UNII-68OJX9I7DT; CP 461; 68OJX9I7DT; 1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, monohydrochloride, (1Z)-; 227619-96-7; N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide hydrochloride; AC1O6379; 279238-68-5
DMEYMTX DT Small molecular drug
DMEYMTX PC 6445781
DMEYMTX MW 420.9
DMEYMTX FM C25H22ClFN2O
DMEYMTX IC InChI=1S/C25H21FN2O.ClH/c1-17-22(13-18-9-11-27-12-10-18)21-8-7-20(26)14-24(21)23(17)15-25(29)28-16-19-5-3-2-4-6-19;/h2-14H,15-16H2,1H3,(H,28,29);1H/b22-13-;
DMEYMTX CS CC\\1=C(C2=C(/C1=C\\C3=CC=NC=C3)C=CC(=C2)F)CC(=O)NCC4=CC=CC=C4.Cl
DMEYMTX IK KGXPDNOBLLACKL-BWLGBDCWSA-N
DMEYMTX IU N-benzyl-2-[(3Z)-6-fluoro-2-methyl-3-(pyridin-4-ylmethylidene)inden-1-yl]acetamide;hydrochloride
DMEYMTX CA CAS 227619-96-7
DMEYMTX DE Inflammatory bowel disease
DMZEJLB ID DMZEJLB
DMZEJLB DN CP-533536
DMZEJLB HS Phase 2
DMZEJLB SN Evatanepag; CP-533,536; 2-(3-((((4-(1,1-dimethylethyl)phenyl)methyl)(pyridin-3-ylsulfonyl)amino)methyl)phenoxy)acetic acid; 2-[3-[[pyridin-3-ylsulfonyl-[(4-tert-butylphenyl)methyl]amino]methyl]phenoxy]acetic Acid
DMZEJLB CP Pfizer
DMZEJLB DT Small molecular drug
DMZEJLB PC 9890801
DMZEJLB MW 468.6
DMZEJLB FM C25H28N2O5S
DMZEJLB IC InChI=1S/C25H28N2O5S/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29/h4-15H,16-18H2,1-3H3,(H,28,29)
DMZEJLB CS CC(C)(C)C1=CC=C(C=C1)CN(CC2=CC(=CC=C2)OCC(=O)O)S(=O)(=O)C3=CN=CC=C3
DMZEJLB IK WOHRHWDYFNWPNG-UHFFFAOYSA-N
DMZEJLB IU 2-[3-[[(4-tert-butylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid
DMZEJLB CA CAS 223488-57-1
DMZEJLB DE Osteoporosis
DMX054A ID DMX054A
DMX054A DN CP-547632
DMX054A HS Phase 2
DMX054A SN BFF; CP 547632; CP-547,632; 3-(4-Bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide
DMX054A CP OSI Pharmaceuticals
DMX054A TC Anticancer Agents
DMX054A DT Small molecular drug
DMX054A PC 9811611
DMX054A MW 532.4
DMX054A FM C20H24BrF2N5O3S
DMX054A IC InChI=1S/C20H24BrF2N5O3S/c21-12-9-14(22)13(15(23)10-12)11-31-18-16(17(24)29)19(32-27-18)26-20(30)25-5-1-2-6-28-7-3-4-8-28/h9-10H,1-8,11H2,(H2,24,29)(H2,25,26,30)
DMX054A CS C1CCN(C1)CCCCNC(=O)NC2=C(C(=NS2)OCC3=C(C=C(C=C3F)Br)F)C(=O)N
DMX054A IK HXHAJRMTJXHJJZ-UHFFFAOYSA-N
DMX054A IU 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide
DMX054A CA CAS 252003-65-9
DMX054A DE Solid tumour/cancer; Ovarian cancer; Non-small-cell lung cancer
DMKJFDM ID DMKJFDM
DMKJFDM DN CP-601927
DMKJFDM HS Phase 2
DMKJFDM SN CP-601932; Alpha4beta2 nAchR partial agonists (depression), Pfizer
DMKJFDM CP Pfizer Inc
DMKJFDM DT Small molecular drug
DMKJFDM PC 11498153
DMKJFDM MW 227.22
DMKJFDM FM C12H12F3N
DMKJFDM IC InChI=1S/C12H12F3N/c13-12(14,15)9-1-2-10-7-3-8(6-16-5-7)11(10)4-9/h1-2,4,7-8,16H,3,5-6H2/t7-,8+/m0/s1
DMKJFDM CS C1[C@H]2CNC[C@@H]1C3=C2C=CC(=C3)C(F)(F)F
DMKJFDM IK RNOBTWYQAWEZHH-JGVFFNPUSA-N
DMKJFDM IU (1S,8R)-4-(trifluoromethyl)-10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene
DMKJFDM CA CAS 357425-02-6
DMKJFDM DE Gastrointestinal disease
DMUJ0W7 ID DMUJ0W7
DMUJ0W7 DN CP-724714
DMUJ0W7 HS Phase 2
DMUJ0W7 SN CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide
DMUJ0W7 CP Pfizer
DMUJ0W7 TC Anticancer Agents
DMUJ0W7 DT Small molecular drug
DMUJ0W7 PC 9874913
DMUJ0W7 MW 469.5
DMUJ0W7 FM C27H27N5O3
DMUJ0W7 IC InChI=1S/C27H27N5O3/c1-18-13-21(8-11-25(18)35-22-9-6-19(2)29-15-22)32-27-23-14-20(7-10-24(23)30-17-31-27)5-4-12-28-26(33)16-34-3/h4-11,13-15,17H,12,16H2,1-3H3,(H,28,33)(H,30,31,32)/b5-4+
DMUJ0W7 CS CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)/C=C/CNC(=O)COC)C
DMUJ0W7 IK LLVZBTWPGQVVLW-SNAWJCMRSA-N
DMUJ0W7 IU 2-methoxy-N-[(E)-3-[4-[3-methyl-4-(6-methylpyridin-3-yl)oxyanilino]quinazolin-6-yl]prop-2-enyl]acetamide
DMUJ0W7 CA CAS 845680-17-3
DMUJ0W7 CB CHEBI:91331
DMUJ0W7 DE Lymphoma
DMT3ORQ ID DMT3ORQ
DMT3ORQ DN CP-80794
DMT3ORQ HS Phase 2
DMT3ORQ DT Small molecular drug
DMT3ORQ PC 64922
DMT3ORQ MW 620.8
DMT3ORQ FM C31H48N4O7S
DMT3ORQ IC InChI=1S/C31H48N4O7S/c1-21(2)42-30(39)27(36)24(18-22-10-6-4-7-11-22)32-29(38)26(20-43-3)33-28(37)25(19-23-12-8-5-9-13-23)34-31(40)35-14-16-41-17-15-35/h5,8-9,12-13,21-22,24-27,36H,4,6-7,10-11,14-20H2,1-3H3,(H,32,38)(H,33,37)(H,34,40)/t24-,25-,26-,27+/m0/s1
DMT3ORQ CS CC(C)OC(=O)[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CSC)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)N3CCOCC3)O
DMT3ORQ IK UZQBKCWYZBHBOW-YIPNQBBMSA-N
DMT3ORQ IU propan-2-yl (2R,3S)-4-cyclohexyl-2-hydroxy-3-[[(2R)-3-methylsulfanyl-2-[[(2S)-2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate
DMT3ORQ CA CAS 119625-78-4
DMT3ORQ DE Hypertension
DM6MUCX ID DM6MUCX
DM6MUCX DN CpG-10101
DM6MUCX HS Phase 2
DM6MUCX SN Actilon; Anti-HCV therapy, Coley
DM6MUCX CP Coley Pharmaceutical Group Inc; Coley Pharmaceutical
DM6MUCX DE Hepatitis C virus infection
DMK9NQI ID DMK9NQI
DMK9NQI DN CPP-115
DMK9NQI HS Phase 2
DMK9NQI SN GABA aminotransferase inhibitors (oral), Northwestern University/Catalyst Pharmaceutical Partners; Vigabatrin derivatives (oral, neurological diseases), Northwestern University; Vigabatrin derivatives (oral, drug addiction/epilepsy/neuropathic pain), Catalyst Pharmaceutical Partners
DMK9NQI CP Catalyst pharmaceutical partners
DMK9NQI DT Small molecular drug
DMK9NQI PC 9794014
DMK9NQI MW 177.15
DMK9NQI FM C7H9F2NO2
DMK9NQI IC InChI=1S/C7H9F2NO2/c8-6(9)4-1-3(7(11)12)2-5(4)10/h3,5H,1-2,10H2,(H,11,12)/t3-,5-/m0/s1
DMK9NQI CS C1[C@H](CC(=C(F)F)[C@H]1N)C(=O)O
DMK9NQI IK CBSRETZPFOBWNG-UCORVYFPSA-N
DMK9NQI IU (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid
DMK9NQI CA CAS 640897-20-7
DMK9NQI DE Substance use disorder; Infantile spasm; Tourette syndrome
DMK7DFM ID DMK7DFM
DMK7DFM DN CPX-POM
DMK7DFM HS Phase 2
DMK7DFM CP CicloMed
DMK7DFM DT Small molecular drug
DMK7DFM DE Solid tumour/cancer; Bladder cancer
DMHJEZS ID DMHJEZS
DMHJEZS DN CR-3294
DMHJEZS HS Phase 2
DMHJEZS CP Rottapharm Madaus
DMHJEZS DE Diarrhea
DMNC1AF ID DMNC1AF
DMNC1AF DN CR-665
DMNC1AF HS Phase 2
DMNC1AF SN CR665; UNII-3BX9UG06GG; 3BX9UG06GG; 228546-92-7; CR-665; CR 665; FE 200665; FE-200665; SCHEMBL4451321; DTXSID30177395; jnj-38488502; DB05155; D-Argininamide, D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)-
DMNC1AF CP Ferring Pharmaceuticals Inc
DMNC1AF DT Small molecular drug
DMNC1AF PC 25030387
DMNC1AF MW 671.8
DMNC1AF FM C36H49N9O4
DMNC1AF IC InChI=1S/C36H49N9O4/c1-2-3-15-30(34(48)43-29(16-10-19-41-36(38)39)33(47)42-24-27-17-20-40-21-18-27)44-35(49)31(23-26-13-8-5-9-14-26)45-32(46)28(37)22-25-11-6-4-7-12-25/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H,42,47)(H,43,48)(H,44,49)(H,45,46)(H4,38,39,41)/t28-,29-,30-,31-/m1/s1
DMNC1AF CS CCCC[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC1=CC=NC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)N
DMNC1AF IK DBOGGOVKHSCMNB-OMRVPHBLSA-N
DMNC1AF IU (2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-5-(diaminomethylideneamino)-1-oxo-1-(pyridin-4-ylmethylamino)pentan-2-yl]hexanamide
DMNC1AF CA CAS 228546-92-7
DMNC1AF DE Pain
DMQ47U6 ID DMQ47U6
DMQ47U6 DN CR8020
DMQ47U6 HS Phase 2
DMQ47U6 SN H3N2 and H7N7 influenza monoclonal antibody therapy, Crucell
DMQ47U6 CP Crucell
DMQ47U6 DT Antibody
DMQ47U6 DE Influenza A virus infection; Influenza virus infection
DMO1ZGX ID DMO1ZGX
DMO1ZGX DN CRILVASTATIN
DMO1ZGX HS Phase 2
DMO1ZGX SN Crilvastatin < Rec INN; PMD-387; L-Pyroglutamic acid rac-cis-3,3,5-trimethylcyclohexyl ester; 5-Oxo-L-proline rac-cis-3,3,5-trimethylcyclohexyl ester
DMO1ZGX DT Small molecular drug
DMO1ZGX PC 22845140
DMO1ZGX MW 253.34
DMO1ZGX FM C14H23NO3
DMO1ZGX IC InChI=1S/C14H23NO3/c1-9-6-10(8-14(2,3)7-9)18-13(17)11-4-5-12(16)15-11/h9-11H,4-8H2,1-3H3,(H,15,16)/t9?,10?,11-/m0/s1
DMO1ZGX CS CC1CC(CC(C1)(C)C)OC(=O)[C@@H]2CCC(=O)N2
DMO1ZGX IK FXAAOALUHHXBSO-ILDUYXDCSA-N
DMO1ZGX IU (3,3,5-trimethylcyclohexyl) (2S)-5-oxopyrrolidine-2-carboxylate
DMO1ZGX CA CAS 120551-59-9
DMO1ZGX DE Hyperlipidaemia
DMQUWXY ID DMQUWXY
DMQUWXY DN CRLX101
DMQUWXY HS Phase 2
DMQUWXY CP Cerulean Pharma
DMQUWXY PC 184196
DMQUWXY MW 348.4
DMQUWXY FM C20H16N2O4
DMQUWXY IC InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m1/s1
DMQUWXY CS CC[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
DMQUWXY IK VSJKWCGYPAHWDS-HXUWFJFHSA-N
DMQUWXY IU (19R)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMQUWXY CA CAS 110351-92-3
DMQUWXY DE Solid tumour/cancer; Renal cell carcinoma; Ovarian cancer; Non-small-cell lung cancer
DM85WID ID DM85WID
DM85WID DN Crobenetine
DM85WID HS Phase 2
DM85WID SN CROBENETINE; CROBENETINE); BIII-890-CL; Crobenetine; Crobenetine hydrochloride; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol; (2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol hydrochloride
DM85WID DT Small molecular drug
DM85WID PC 9886143
DM85WID MW 379.5
DM85WID FM C25H33NO2
DM85WID IC InChI=1S/C25H33NO2/c1-18(28-17-19-9-6-5-7-10-19)16-26-14-13-25(4)21-11-8-12-22(27)20(21)15-23(26)24(25,2)3/h5-12,18,23,27H,13-17H2,1-4H3/t18-,23+,25-/m0/s1
DM85WID CS C[C@@H](CN1CC[C@]2(C3=C(C[C@@H]1C2(C)C)C(=CC=C3)O)C)OCC4=CC=CC=C4
DM85WID IK VCCBCXVFGHTDQN-UODBTFMRSA-N
DM85WID IU (1S,9R)-1,13,13-trimethyl-10-[(2S)-2-phenylmethoxypropyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-6-ol
DM85WID CA 221019-25-6
DM85WID DE Pain
DM129T7 ID DM129T7
DM129T7 DN CROMOGLYCATE LISETIL HYDROCHLORIDE
DM129T7 HS Phase 2
DM129T7 SN Diethyl L-lysylcromoglycate dihydrochloride; KY-556; N-556; Cromoglycate lisetil hydrochloride
DM129T7 DT Small molecular drug
DM129T7 PC 196639
DM129T7 MW 652.6
DM129T7 FM C33H36N2O12
DM129T7 IC InChI=1S/C33H36N2O12/c1-3-41-32(39)27-15-21(36)29-23(10-7-12-25(29)46-27)43-17-19(45-31(38)20(35)9-5-6-14-34)18-44-24-11-8-13-26-30(24)22(37)16-28(47-26)33(40)42-4-2/h7-8,10-13,15-16,19-20H,3-6,9,14,17-18,34-35H2,1-2H3/t20-/m0/s1
DM129T7 CS CCOC(=O)C1=CC(=O)C2=C(O1)C=CC=C2OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)OCC)OC(=O)[C@H](CCCCN)N
DM129T7 IK NGJJDHCBOKNREV-FQEVSTJZSA-N
DM129T7 IU ethyl 5-[2-[(2S)-2,6-diaminohexanoyl]oxy-3-(2-ethoxycarbonyl-4-oxochromen-5-yl)oxypropoxy]-4-oxochromene-2-carboxylate
DM129T7 CA CAS 110816-79-0
DM129T7 CB CHEBI:31438
DM129T7 DE Asthma
DMXU5LZ ID DMXU5LZ
DMXU5LZ DN CRS-207
DMXU5LZ HS Phase 2
DMXU5LZ CP Aduro BioTech
DMXU5LZ DT Vaccine
DMXU5LZ DE Pancreatic cancer; Ovarian cancer; Gastric adenocarcinoma; Mesothelioma
DM16IMT ID DM16IMT
DM16IMT DN CRYPTOPHYCIN 52
DM16IMT HS Phase 2
DM16IMT SN LY-355703; [3S-(3alpha,10beta,13E,16beta)]-10-(3-Chloro-4-methoxybenzyl)-16-[2(R*),3(R*)-epoxy-1(R)-methyl-3-phenylpropyl]-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetraone
DM16IMT DT Small molecular drug
DM16IMT PC 9939639
DM16IMT MW 669.2
DM16IMT FM C36H45ClN2O8
DM16IMT IC InChI=1S/C36H45ClN2O8/c1-21(2)17-29-34(42)45-27(22(3)31-32(47-31)24-11-8-7-9-12-24)13-10-14-30(40)39-26(19-23-15-16-28(44-6)25(37)18-23)33(41)38-20-36(4,5)35(43)46-29/h7-12,14-16,18,21-22,26-27,29,31-32H,13,17,19-20H2,1-6H3,(H,38,41)(H,39,40)/b14-10+/t22-,26+,27-,29-,31+,32+/m0/s1
DM16IMT CS C[C@@H]([C@@H]1C/C=C/C(=O)N[C@@H](C(=O)NCC(C(=O)O[C@H](C(=O)O1)CC(C)C)(C)C)CC2=CC(=C(C=C2)OC)Cl)[C@@H]3[C@H](O3)C4=CC=CC=C4
DM16IMT IK LSXOBYNBRKOTIQ-RQUBOUMQSA-N
DM16IMT IU (3S,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
DM16IMT CA CAS 186256-67-7
DM16IMT DE Solid tumour/cancer
DMZCG91 ID DMZCG91
DMZCG91 DN CSL-112
DMZCG91 HS Phase 2
DMZCG91 SN Reconstituted HDL (acute coronary syndrome), CSL
DMZCG91 CP Csl
DMZCG91 DE Arteriosclerosis; Cardiovascular disease
DMQXL1T ID DMQXL1T
DMQXL1T DN CT 327
DMQXL1T HS Phase 2
DMQXL1T CP Creabilis Therapeutics
DMQXL1T DE Psoriasis vulgaris; Plaque psoriasis
DMBRKZ7 ID DMBRKZ7
DMBRKZ7 DN CT1812
DMBRKZ7 HS Phase 2
DMBRKZ7 SN Elayta
DMBRKZ7 CP Cognition Therapeutics Pittsburgh, PA
DMBRKZ7 PC 118278088
DMBRKZ7 MW 431.6
DMBRKZ7 FM C24H33NO4S
DMBRKZ7 IC InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3
DMBRKZ7 CS CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O
DMBRKZ7 IK ISQAPFMBJFZOLG-UHFFFAOYSA-N
DMBRKZ7 IU 4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol
DMBRKZ7 CA CAS 1802632-22-9
DMBRKZ7 DE Alzheimer disease
DMSGYNP ID DMSGYNP
DMSGYNP DN CTK0H-9987
DMSGYNP HS Phase 2
DMSGYNP SN Neoprontosil; Neoprontosil, disodium salt; Neoprontsil; PRONTOCIL; ZINC261161909; ZINC28863804; AZOSULFAMIDE; 132-38-7; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-((4-(aminosulfonyl)phenyl)azo)-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-; 2,7-Naphthalenedisulfonic acid, 6-(acetylamino)-3-[[4-(aminosulfonyl)phenyl]azo]-4-hydroxy-, disodium salt; AABSSN; BDBM50221406; CHEMBL237251; CTK0H9987; DTXSID0074500
DMSGYNP PC 8625
DMSGYNP MW 544.5
DMSGYNP FM C18H16N4O10S3
DMSGYNP IC RALNLQYPLYWQRT-UHFFFAOYSA-N
DMSGYNP CS CC(=O)NC1=C(C=C2C=C(C(=C(C2=C1)O)N=NC3=CC=C(C=C3)S(=O)(=O)N)S(=O)(=O)O)S(=O)(=O)O
DMSGYNP IK 1S/C18H16N4O10S3/c1-9(23)20-14-8-13-10(6-15(14)34(27,28)29)7-16(35(30,31)32)17(18(13)24)22-21-11-2-4-12(5-3-11)33(19,25)26/h2-8,24H,1H3,(H,20,23)(H2,19,25,26)(H,27,28,29)(H,30,31,32)
DMSGYNP IU 6-acetamido-4-hydroxy-3-[(4-sulfamoylphenyl)diazenyl]naphthalene-2,7-disulfonic acid
DMSGYNP DE Trachoma
DMMPC6W ID DMMPC6W
DMMPC6W DN CTL019
DMMPC6W HS Phase 2
DMMPC6W CP Novartis Pharmaceuticals
DMMPC6W DT CAR T Cell Therapy
DMMPC6W DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia
DM3SYOK ID DM3SYOK
DM3SYOK DN CTP-543
DM3SYOK HS Phase 2
DM3SYOK CP Concert Pharmaceuticals Lexington, MA
DM3SYOK DE Asthma
DMBT46Y ID DMBT46Y
DMBT46Y DN CTP-543
DMBT46Y HS Phase 2
DMBT46Y SN Deuruxolitinib; D8-ruxolitinib; UNII-0CA0VSF91Y; Deuruxolitinib (USAN); Deuruxolitinib [USAN]; C-21543; (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1513883-39-0; CTP543; CHEMBL4594381; SCHEMBL19555526; GTPL11410; WHO 11622; D11866; (3R)-3-(2,2,3,3,4,4,5,5-D8)cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1Hpyrazol-1-yl)propanenitrile; H-Pyrazole-1-propanenitrile, beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (betaR)-
DMBT46Y CP Concert Pharmaceuticals
DMBT46Y DT Small molecular drug
DMBT46Y PC 72704611
DMBT46Y MW 314.41
DMBT46Y FM C17H18N6
DMBT46Y IC InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2
DMBT46Y CS [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H]
DMBT46Y IK HFNKQEVNSGCOJV-FBXGHSCESA-N
DMBT46Y IU (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
DMBT46Y CA CAS 1513883-39-0
DMBT46Y DE Alopecia
DMYPXQ2 ID DMYPXQ2
DMYPXQ2 DN CVBT-141H
DMYPXQ2 HS Phase 2
DMYPXQ2 SN CVBT-141A; CVBT-141C; CVBT-141C); Cardio Vascu-Grow; FGF-1-141; Recombinant FGF-1 (coronary heart disease), CardioVascular Therapeutics; Recombinant FGF-1 (peripheral vascular disease), CardioVascular biotherapeutics
DMYPXQ2 CP CardioVascular BioTherapeutics Inc; CardioVascular Biotherapeutics
DMYPXQ2 DE Coronary artery disease; Peripheral arterial disease; Coronary heart disease
DMCN9GX ID DMCN9GX
DMCN9GX DN CVX-045
DMCN9GX HS Phase 2
DMCN9GX SN CVX-22; CovX-045; PF-4856882; TSP-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), CovX; Thrombospondin-1 mimetic (cancer), Pfizer
DMCN9GX CP CovX Pharmaceuticals Inc
DMCN9GX DE Solid tumour/cancer
DMVZT2I ID DMVZT2I
DMVZT2I DN CX-072
DMVZT2I HS Phase 2
DMVZT2I CP CytomX Therapeutics South San Francisco, CA
DMVZT2I DT Antibody
DMVZT2I DE Solid tumour/cancer; Advanced malignancy; Lymphoma; Medulloblastoma
DMS2WB5 ID DMS2WB5
DMS2WB5 DN CX157
DMS2WB5 HS Phase 2
DMS2WB5 SN CX157; O6L62LZJ0Q; CX-157; CX 157; 205187-53-7; UNII-O6L62LZJ0Q; SCHEMBL235650; DTXSID40174517; PDIMOTRDGUQMNY-UHFFFAOYSA-N; HY-100178; CS-0018174; 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide; Phenoxathiin, 3-fluoro-7-(2,2,2-trifluoroethoxy)-, 10,10-dioxide
DMS2WB5 CP CeNeRx Pharma
DMS2WB5 DT Small molecular drug
DMS2WB5 PC 18687754
DMS2WB5 MW 348.27
DMS2WB5 FM C14H8F4O4S
DMS2WB5 IC InChI=1S/C14H8F4O4S/c15-8-1-3-12-10(5-8)22-11-6-9(21-7-14(16,17)18)2-4-13(11)23(12,19)20/h1-6H,7H2
DMS2WB5 CS C1=CC2=C(C=C1OCC(F)(F)F)OC3=C(S2(=O)=O)C=CC(=C3)F
DMS2WB5 IK PDIMOTRDGUQMNY-UHFFFAOYSA-N
DMS2WB5 IU 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
DMS2WB5 CA CAS 205187-53-7
DMS2WB5 DE Mood disorder
DMJD7H4 ID DMJD7H4
DMJD7H4 DN CX-1739
DMJD7H4 HS Phase 2
DMJD7H4 SN CX-1739 (injectable/AMPAKINE, respiratory depression); CX-717 follow-on compound (AMPAKINE), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Biovail Laboratories; CX-1739 (injectable/AMPAKINE, respiratory depression), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Valeant
DMJD7H4 CP Cortex Pharmaceuticals Inc
DMJD7H4 DE Attention deficit hyperactivity disorder
DMA5D6T ID DMA5D6T
DMA5D6T DN CX1789
DMA5D6T HS Phase 2
DMA5D6T CP RespireRx Pharmaceuticals Glen Rock, NJ
DMA5D6T DE Obstructive sleep apnea
DMU62I8 ID DMU62I8
DMU62I8 DN CX2009
DMU62I8 HS Phase 2
DMU62I8 CP CytomX Therapeutics
DMU62I8 DT Probody drug conjugate
DMU62I8 DE Solid tumour/cancer; Neoplasm
DMWE7B9 ID DMWE7B9
DMWE7B9 DN CX-4945
DMWE7B9 HS Phase 2
DMWE7B9 SN 1009820-21-6; Silmitasertib; CX-4945; 5-((3-Chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid; 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid; C6RWP0N0L2; CHEMBL1230165; AK-82006; 5-[(3-Chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-Carboxylic Acid; 5-((3-Chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic acid; C19H12ClN3O2; W-204393
DMWE7B9 CP Cylene Pharmaceuticals
DMWE7B9 DT Small molecular drug
DMWE7B9 PC 24748573
DMWE7B9 MW 349.8
DMWE7B9 FM C19H12ClN3O2
DMWE7B9 IC InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
DMWE7B9 CS C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4
DMWE7B9 IK MUOKSQABCJCOPU-UHFFFAOYSA-N
DMWE7B9 IU 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid
DMWE7B9 CA CAS 1009820-21-6
DMWE7B9 DE Solid tumour/cancer; Cholangiocarcinoma; Coronavirus infection
DMM65W1 ID DMM65W1
DMM65W1 DN CX-717
DMM65W1 HS Phase 2
DMM65W1 SN CX-1763; CX-546; CX-614; CX-727; CX-729; CX-743; CX-815; S-40929; First generation AMPA receptor modulators, Cortex/University of California; First-generation AMPAKINE compounds, University of California/Cortex
DMM65W1 CP University of California
DMM65W1 DT Small molecular drug
DMM65W1 PC 3323368
DMM65W1 MW 233.22
DMM65W1 FM C11H11N3O3
DMM65W1 IC InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2
DMM65W1 CS C1COCCN1C(=O)C2=CC3=NON=C3C=C2
DMM65W1 IK KFRQROSRKSVROW-UHFFFAOYSA-N
DMM65W1 IU 2,1,3-benzoxadiazol-5-yl(morpholin-4-yl)methanone
DMM65W1 CA CAS 211735-82-9
DMM65W1 DE Alzheimer disease; Spinal cord injury
DM3GEHC ID DM3GEHC
DM3GEHC DN CX-8998
DM3GEHC HS Phase 2
DM3GEHC CP Cavion Charlottesville, VA
DM3GEHC DE Epilepsy; Essential tremor or related tremors; Parkinson disease
DMM7Z6K ID DMM7Z6K
DMM7Z6K DN CXA10
DMM7Z6K HS Phase 2
DMM7Z6K CP Complexa
DMM7Z6K DT Small molecular drug
DMM7Z6K DE Pulmonary arterial hypertension; Focal segmental glomerulosclerosis
DM3JFZ2 ID DM3JFZ2
DM3JFZ2 DN CXL
DM3JFZ2 HS Phase 2
DM3JFZ2 SN CYCLOHEXANOL; 108-93-0; Cyclohexyl alcohol; Hexahydrophenol; Hydrophenol; Hydroxycyclohexane; Hexalin; 1-Cyclohexanol; Hydralin; Adronal; Naxol; Adronol; Anol; Cykloheksanol; Cicloesanolo; Phenol, hexahydro-; Cicloesanolo [Italian]; Cykloheksanol [Polish]; Cyclohexanone cyclohexanol mixture; Cyclohexan-1-ol; HSDB 61; NSC 403656; UNII-8E7S519M3P; CCRIS 5896; EINECS 203-630-6; BRN 0906744; AI3-00040; CHEBI:18099; HPXRVTGHNJAIIH-UHFFFAOYSA-N; 8E7S519M3P; MFCD00003855; Cyclohexanol, 98%; CXL; Cyclohexanols; DSSTox_CID_1894; DSSTox_RID_76390
DM3JFZ2 CP AstraZeneca
DM3JFZ2 DT Small molecular drug
DM3JFZ2 PC 7966
DM3JFZ2 MW 100.16
DM3JFZ2 FM C6H12O
DM3JFZ2 IC InChI=1S/C6H12O/c7-6-4-2-1-3-5-6/h6-7H,1-5H2
DM3JFZ2 CS C1CCC(CC1)O
DM3JFZ2 IK HPXRVTGHNJAIIH-UHFFFAOYSA-N
DM3JFZ2 IU cyclohexanol
DM3JFZ2 CA CAS 108-93-0
DM3JFZ2 CB CHEBI:18099
DM3JFZ2 DE Methicillin-resistant staphylococci infection
DMXR8WN ID DMXR8WN
DMXR8WN DN CYCLOPLATAM
DMXR8WN HS Phase 2
DMXR8WN SN Ammine(cyclopentanamine)[(S)-hydroxybutanedioato(2-)-O1,O4]platinum; (S)-(-)-Malatoammine(cyclopentylamine)platinum (II)
DMXR8WN DT Small molecular drug
DMXR8WN PC 3035239
DMXR8WN MW 429.33
DMXR8WN FM C9H18N2O5Pt
DMXR8WN IC InChI=1S/C5H11N.C4H6O5.H3N.Pt/c6-5-3-1-2-4-5;5-2(4(8)9)1-3(6)7;;/h5H,1-4,6H2;2,5H,1H2,(H,6,7)(H,8,9);1H3;/q;;;+2/p-2
DMXR8WN CS C1CCC(C1)N.C(C(C(=O)[O-])O)C(=O)[O-].N.[Pt+2]
DMXR8WN IK OPWOOOGFNULJAQ-UHFFFAOYSA-L
DMXR8WN IU azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+)
DMXR8WN CA CAS 109837-67-4
DMXR8WN DE Solid tumour/cancer
DM0DT45 ID DM0DT45
DM0DT45 DN CYSTEMUSTINE
DM0DT45 HS Phase 2
DM0DT45 SN CMSO2EN2; N-(2-Chloroethyl)-N'-[2-(methylsulfonyl)ethyl]-N-nitrosourea
DM0DT45 DT Small molecular drug
DM0DT45 PC 119545
DM0DT45 MW 257.7
DM0DT45 FM C6H12ClN3O4S
DM0DT45 IC InChI=1S/C6H12ClN3O4S/c1-15(13,14)5-3-8-6(11)10(9-12)4-2-7/h2-5H2,1H3,(H,8,11)
DM0DT45 CS CS(=O)(=O)CCNC(=O)N(CCCl)N=O
DM0DT45 IK IUOVOJHLRFQQNS-UHFFFAOYSA-N
DM0DT45 IU 1-(2-chloroethyl)-3-(2-methylsulfonylethyl)-1-nitrosourea
DM0DT45 CA CAS 79955-36-5
DM0DT45 DE Solid tumour/cancer
DMMWIHC ID DMMWIHC
DMMWIHC DN CYT 99007
DMMWIHC HS Phase 2
DMMWIHC CP Cytheris
DMMWIHC TC Anticancer Agents
DMMWIHC DE Acquired immune deficiency syndrome
DM4LJH8 ID DM4LJH8
DM4LJH8 DN CYT003
DM4LJH8 HS Phase 2
DM4LJH8 DE Asthma
DMIRSWE ID DMIRSWE
DMIRSWE DN CYT-006-AngQb
DMIRSWE HS Phase 2
DMIRSWE SN AngQb; Immunodrug vaccines (hypertension), Cytos
DMIRSWE CP Cytos Biotechnology AG
DMIRSWE DT Vaccine
DMIRSWE DE Hypertension
DMUDMHA ID DMUDMHA
DMUDMHA DN CZEN-002
DMUDMHA HS Phase 2
DMUDMHA SN Bis(N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-L-valinamide) disulfide
DMUDMHA DT Small molecular drug
DMUDMHA PC 16133793
DMUDMHA MW 1664.9
DMUDMHA FM C77H109N21O19S
DMUDMHA IC InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1
DMUDMHA CS CC(C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMUDMHA IK WHNFPRLDDSXQCL-UAZQEYIDSA-N
DMUDMHA IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMUDMHA CA CAS 581-05-5
DMUDMHA DE Fungal infection
DMP6MH9 ID DMP6MH9
DMP6MH9 DN DA-8031
DMP6MH9 HS Phase 2
DMP6MH9 SN Serotonin transporter inhibitor (premature ejaculation), Dong A
DMP6MH9 CP Dong-A Pharmaceutical Co Ltd
DMP6MH9 DE Premature ejaculation
DMACTBM ID DMACTBM
DMACTBM DN DAC-060
DMACTBM HS Phase 2
DMACTBM SN DAC-0060; DAC-60; HDAC inhibitor (topical, skin cancer/actinic keratosis), DAC
DMACTBM CP DAC Srl
DMACTBM DE Keratosis
DM2U45Q ID DM2U45Q
DM2U45Q DN Danegaptide
DM2U45Q HS Phase 2
DM2U45Q SN SCHEMBL2399760; BCP17534; ZP 1609
DM2U45Q CP Pfizer; Zealand Pharma
DM2U45Q DT Small molecular drug
DM2U45Q PC 16656685
DM2U45Q MW 291.3
DM2U45Q FM C14H17N3O4
DM2U45Q IC InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1
DM2U45Q CS C1[C@H](CN([C@@H]1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2
DM2U45Q IK BIZKIHUJGMSVFD-MNOVXSKESA-N
DM2U45Q IU (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
DM2U45Q CA CAS 943134-39-2
DM2U45Q DE Atrial fibrillation
DM20MDU ID DM20MDU
DM20MDU DN Danoprevir
DM20MDU HS Phase 2
DM20MDU SN 850876-88-9; Danoprevir (USAN/INN)
DM20MDU CP InterMune; Genentech
DM20MDU DT Small molecular drug
DM20MDU PC 11285588
DM20MDU MW 731.8
DM20MDU FM C35H46FN5O9S
DM20MDU IC InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1
DM20MDU CS CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\\[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6
DM20MDU IK ZVTDLPBHTSMEJZ-JSZLBQEHSA-N
DM20MDU IU [(1S,4R,6S,7Z,14S,18R)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate
DM20MDU CA CAS 850876-88-9
DM20MDU DE Hepatitis C virus infection
DM7IH48 ID DM7IH48
DM7IH48 DN Dapansutrile
DM7IH48 HS Phase 2
DM7IH48 SN 54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073
DM7IH48 CP Olatec Therapeutics New York, NY
DM7IH48 PC 12714644
DM7IH48 MW 133.17
DM7IH48 FM C4H7NO2S
DM7IH48 IC InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3
DM7IH48 CS CS(=O)(=O)CCC#N
DM7IH48 IK LQFRYKBDZNPJSW-UHFFFAOYSA-N
DM7IH48 IU 3-methylsulfonylpropanenitrile
DM7IH48 CA CAS 54863-37-5
DM7IH48 DE Acute gout flare; Musculoskeletal pain
DMIYFWA ID DMIYFWA
DMIYFWA DN Dapirolizumab pegol
DMIYFWA HS Phase 2
DMIYFWA CP Biogen Cambridge, MAUCBSmyrna, GA
DMIYFWA DE Systemic lupus erythematosus
DMR5J6K ID DMR5J6K
DMR5J6K DN DAPITANT
DMR5J6K HS Phase 2
DMR5J6K SN CHEMBL2103951
DMR5J6K DT Small molecular drug
DMR5J6K PC 132961
DMR5J6K MW 561.7
DMR5J6K FM C37H39NO4
DMR5J6K IC InChI=1S/C37H39NO4/c1-26(29-18-10-12-20-33(29)41-2)35(39)38-24-31-32(25-38)37(40,30-19-11-13-21-34(30)42-3)23-22-36(31,27-14-6-4-7-15-27)28-16-8-5-9-17-28/h4-21,26,31-32,40H,22-25H2,1-3H3/t26-,31-,32+,37+/m0/s1
DMR5J6K CS C[C@@H](C1=CC=CC=C1OC)C(=O)N2C[C@@H]3[C@H](C2)C(CC[C@]3(C4=CC=CC=C4OC)O)(C5=CC=CC=C5)C6=CC=CC=C6
DMR5J6K IK CCIWVEMVBWEMCY-RCFOMQFPSA-N
DMR5J6K IU (2S)-1-[(3aS,4S,7aS)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one
DMR5J6K CA CAS 153438-49-4
DMR5J6K DE Pain
DMCU74R ID DMCU74R
DMCU74R DN Daporinad
DMCU74R HS Phase 2
DMCU74R SN APO-866; FK-866; WK-175
DMCU74R CP Astellas Pharma GmbH
DMCU74R DT Small molecular drug
DMCU74R PC 6914657
DMCU74R MW 391.5
DMCU74R FM C24H29N3O2
DMCU74R IC InChI=1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+
DMCU74R CS C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3
DMCU74R IK KPBNHDGDUADAGP-VAWYXSNFSA-N
DMCU74R IU (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide
DMCU74R CA CAS 658084-64-1
DMCU74R CB CHEBI:94671
DMCU74R DE leukaemia
DM0Y8JP ID DM0Y8JP
DM0Y8JP DN DAS-181
DM0Y8JP HS Phase 2
DM0Y8JP SN Fludase; NEX-DAS-181; Enzyme-based therapy (Tosap, influenza), NexBio
DM0Y8JP CP Nexbio
DM0Y8JP DE Influenza virus infection
DMM3BPL ID DMM3BPL
DMM3BPL DN DAS-431
DMM3BPL HS Phase 2
DMM3BPL CP DrugAbuse Sciences
DMM3BPL DE Dementia
DM7JV4O ID DM7JV4O
DM7JV4O DN DB-041901
DM7JV4O HS Phase 2
DM7JV4O SN Pursennid; Senekot; Senna-lax; Sennaglucosides; Sennosides; Sennoside A&B; Sennoside [JAN]; Sennosides A and B; sennoside; (9,9'-Bianthracene)-2,2'-dicarboxylic acid, 5,5'-bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-; 5,5'-Bis(beta-D-glucopyranosyloxy)-4,4'-dihydroxy(9,9'-bianthrachinon)-2,2'-dicarbonsaeure; 5,5'-Bis(beta-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo(9,9'-bianthracene)-2,2'-dicarboxylic acid; 517-43-1; C42H38O20; EINECS 208-238-9; SENNA
DM7JV4O PC 5199
DM7JV4O MW 862.7
DM7JV4O FM C42H38O20
DM7JV4O IC IPQVTOJGNYVQEO-UHFFFAOYSA-N
DM7JV4O CS C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O
DM7JV4O IK 1S/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)
DM7JV4O IU 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
DM7JV4O CA CAS 517-43-1
DM7JV4O DE Opioid-induced constipation
DMQRCX5 ID DMQRCX5
DMQRCX5 DN DCDS-4501A
DMQRCX5 HS Phase 2
DMQRCX5 CP Genentech
DMQRCX5 DT Antibody
DMQRCX5 DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMCHWX1 ID DMCHWX1
DMCHWX1 DN DCR-PHXC
DMCHWX1 HS Phase 2
DMCHWX1 SN nedosiran
DMCHWX1 CP Dicerna Pharmaceuticals
DMCHWX1 DT Small interfering RNA
DMCHWX1 DE Hyperoxaluria
DM9REBL ID DM9REBL
DM9REBL DN DDP-225
DM9REBL HS Phase 2
DM9REBL SN AA-10021; AA-10025; AA-10026; 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine hydrate hydrochloride
DM9REBL CP Dynogen
DM9REBL DT Small molecular drug
DM9REBL PC 6918194
DM9REBL MW 382.9
DM9REBL FM C17H20ClFN4OS
DM9REBL IC InChI=1S/C17H17FN4S.ClH.H2O/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22;;/h2-5,10,19H,6-9H2,1H3;1H;1H2
DM9REBL CS CC1=CC2=C(N=C(N=C2S1)N3CCNCC3)C4=CC=CC=C4F.O.Cl
DM9REBL IK SAURKKOJWIFYSR-UHFFFAOYSA-N
DM9REBL IU 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrate;hydrochloride
DM9REBL CA CAS 476148-82-0
DM9REBL DE Chronic functional vomiting; Irritable bowel syndrome
DM5XT3G ID DM5XT3G
DM5XT3G DN DE-098
DM5XT3G HS Phase 2
DM5XT3G SN ARG-098; Anti-Fas antibody, Santen; Anti-APO-1 antibody, Santen
DM5XT3G CP Centocor Ortho Biotech Inc
DM5XT3G DT Antibody
DM5XT3G DE Rheumatoid arthritis
DMCQL5I ID DMCQL5I
DMCQL5I DN DE-110
DMCQL5I HS Phase 2
DMCQL5I SN Selective glucocorticoid receptor agonist (allergy), Santen
DMCQL5I CP Santen Pharmaceutical Co Ltd
DMCQL5I DE Xerophthalmia
DMZW50O ID DMZW50O
DMZW50O DN Debio 1347
DMZW50O HS Phase 2
DMZW50O CP Debiopharm
DMZW50O PC 66555680
DMZW50O MW 356.4
DMZW50O FM C20H16N6O
DMZW50O IC InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)
DMZW50O CS CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N
DMZW50O IK BEMNJULZEQTDJY-UHFFFAOYSA-N
DMZW50O IU [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone
DMZW50O CA CAS 1265229-25-1
DMZW50O DE Breast cancer; Solid tumour/cancer
DM1H7UK ID DM1H7UK
DM1H7UK DN Dectrekumab
DM1H7UK HS Phase 2
DM1H7UK SN QAX-576
DM1H7UK DT Antibody
DM1H7UK DE Idiopathic pulmonary fibrosis
DMX4DQH ID DMX4DQH
DMX4DQH DN Delanzomib
DMX4DQH HS Phase 2
DMX4DQH SN ((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-
DMX4DQH CP Cephalon
DMX4DQH DT Small molecular drug
DMX4DQH PC 24800541
DMX4DQH MW 413.3
DMX4DQH FM C21H28BN3O5
DMX4DQH IC InChI=1S/C21H28BN3O5/c1-13(2)12-18(22(29)30)24-21(28)19(14(3)26)25-20(27)17-11-7-10-16(23-17)15-8-5-4-6-9-15/h4-11,13-14,18-19,26,29-30H,12H2,1-3H3,(H,24,28)(H,25,27)/t14-,18+,19+/m1/s1
DMX4DQH CS B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O
DMX4DQH IK SJFBTAPEPRWNKH-CCKFTAQKSA-N
DMX4DQH IU [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
DMX4DQH CA CAS 847499-27-8
DMX4DQH CB CHEBI:141530
DMX4DQH DE Multiple myeloma
DMS2WIN ID DMS2WIN
DMS2WIN DN Delphinidin
DMS2WIN HS Phase 2
DMS2WIN SN IdB-1056; 3,3',4',5,5',7-Hexahydroxy-2-phenylbenzopyrylium chloride; 3,3',4',5,5',7-Hexahydroxyflavylium chloride;3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyrilium chloride
DMS2WIN DT Small molecular drug
DMS2WIN PC 68245
DMS2WIN MW 338.69
DMS2WIN FM C15H11ClO7
DMS2WIN IC InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H
DMS2WIN CS C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-]
DMS2WIN IK FFNDMZIBVDSQFI-UHFFFAOYSA-N
DMS2WIN IU 2-(3,4,5-trihydroxyphenyl)chromenylium-3,5,7-triol;chloride
DMS2WIN CA CAS 8012-95-1
DMS2WIN CB CHEBI:38701
DMS2WIN DE Cardiovascular disease
DM5CB8U ID DM5CB8U
DM5CB8U DN DELTIBANT
DM5CB8U HS Phase 2
DM5CB8U SN CP-0127; Deltibant < Prop INN; SB-238592; Bradycor (Cortech, US); S,S'-(Hexane-1,6-diyl)bis(succinimide-1,3-diyl)bis[D-arginyl-L-arginyl-L-prolyl-(4-hydroxy)-L-prolyl-glycyl-L-phenylalanyl-L-cysteinyl-D-phenylalanyl-L-leucyl-L-arginine]
DM5CB8U PC 70697628
DM5CB8U MW 2805.3
DM5CB8U FM C128H194N40O28S2
DM5CB8U IC InChI=1S/C128H194N40O28S2/c1-71(2)55-85(105(177)155-83(121(193)194)41-25-49-147-127(139)140)157-109(181)89(59-75-33-15-9-16-34-75)159-111(183)91(161-107(179)87(57-73-29-11-7-12-30-73)151-99(171)65-149-113(185)95-61-77(169)67-167(95)117(189)93-43-27-53-163(93)115(187)81(39-23-47-145-125(135)136)153-103(175)79(129)37-21-45-143-123(131)132)69-197-97-63-101(173)165(119(97)191)51-19-5-6-20-52-166-102(174)64-98(120(166)192)198-70-92(112(184)160-90(60-76-35-17-10-18-36-76)110(182)158-86(56-72(3)4)106(178)156-84(122(195)196)42-26-50-148-128(141)142)162-108(180)88(58-74-31-13-8-14-32-74)152-100(172)66-150-114(186)96-62-78(170)68-168(96)118(190)94-44-28-54-164(94)116(188)82(40-24-48-146-126(137)138)154-104(176)80(130)38-22-46-144-124(133)134/h7-18,29-36,71-72,77-98,169-170H,5-6,19-28,37-70,129-130H2,1-4H3,(H,149,185)(H,150,186)(H,151,171)(H,152,172)(H,153,175)(H,154,176)(H,155,177)(H,156,178)(H,157,181)(H,158,182)(H,159,183)(H,160,184)(H,161,179)(H,162,180)(H,193,194)(H,195,196)(H4,131,132,143)(H4,133,134,144)(H4,135,136,145)(H4,137,138,146)(H4,139,140,147)(H4,141,142,148)/t77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97-,98+/m1/s1
DM5CB8U CS CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CS[C@@H]2CC(=O)N(C2=O)CCCCCCN3C(=O)C[C@@H](C3=O)SC[C@@H](C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)CNC(=O)[C@@H]9C[C@H](CN9C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)N)O
DM5CB8U IK JKUYFMHGTOPVMR-WQVVEKGHSA-N
DM5CB8U IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[(3S)-1-[6-[(3R)-3-[(2R)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoic acid
DM5CB8U CA CAS 140661-97-8
DM5CB8U DE Sepsis
DML4PMG ID DML4PMG
DML4PMG DN Dendritic cell vaccine
DML4PMG HS Phase 2
DML4PMG SN Dendritic cell vaccine, University of Bonn; Human telomerase reverse transcriptase (hTERT)-pulsed dendritic cells (cancer), University of Bonn
DML4PMG CP University of Bonn
DML4PMG DT Vaccine
DML4PMG DE Ovarian cancer
DM7GPMB ID DM7GPMB
DM7GPMB DN Depatuxizumab
DM7GPMB HS Phase 2
DM7GPMB CP AbbVieNorth Chicago, IL
DM7GPMB DE Solid tumour/cancer; Glioblastoma of brain
DMH96JW ID DMH96JW
DMH96JW DN Dersalazine
DMH96JW HS Phase 2
DMH96JW SN UR-12715; UR-12746
DMH96JW CP Grupo Uriach
DMH96JW DT Small molecular drug
DMH96JW PC 135484128
DMH96JW MW 600.7
DMH96JW FM C35H32N6O4
DMH96JW IC InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38?
DMH96JW CS CC1=NC2=C(N1CC3CCN(CC3)C(=O)/C=C(/C4=CC=CC=C4)\\C5=CC=C(C=C5)N=NC6=CC(=C(C=C6)O)C(=O)O)C=CN=C2
DMH96JW IK AYEAMZDTWLXZIJ-JEFTWCRZSA-N
DMH96JW IU 2-hydroxy-5-[[4-[(Z)-3-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3-oxo-1-phenylprop-1-enyl]phenyl]diazenyl]benzoic acid
DMH96JW CA CAS 188913-58-8
DMH96JW DE Inflammatory bowel disease
DM63P1W ID DM63P1W
DM63P1W DN Descartes-08
DM63P1W HS Phase 2
DM63P1W CP Cartesian Therapeutics
DM63P1W DT CAR T Cell Therapy
DM63P1W DE Multiple myeloma
DM1UO4S ID DM1UO4S
DM1UO4S DN Descartes-11
DM1UO4S HS Phase 2
DM1UO4S CP Cartesian Therapeutics
DM1UO4S DT CAR T Cell Therapy
DM1UO4S DE Multiple myeloma
DMTY4KN ID DMTY4KN
DMTY4KN DN Dexefaroxan
DMTY4KN HS Phase 2
DMTY4KN SN Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
DMTY4KN CP Pierre Fabre
DMTY4KN DT Small molecular drug
DMTY4KN PC 208820
DMTY4KN MW 216.28
DMTY4KN FM C13H16N2O
DMTY4KN IC InChI=1S/C13H16N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-6H,2,7-9H2,1H3,(H,14,15)/t13-/m1/s1
DMTY4KN CS CC[C@@]1(CC2=CC=CC=C2O1)C3=NCCN3
DMTY4KN IK RATZLMXRALDSJW-CYBMUJFWSA-N
DMTY4KN IU 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole
DMTY4KN CA CAS 143249-88-1
DMTY4KN DE Schizophrenia; Parkinson disease
DM52HUD ID DM52HUD
DM52HUD DN Dexloxiglumide
DM52HUD HS Phase 2
DM52HUD SN Dexloxiglumide; 119817-90-2; (R)-4-(3,4-Dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; UNII-69DY40RH9B; CR-2017; 69DY40RH9B; Dexloxiglumidum; Dexloxiglumida; Dexloxiglumide [INN]; Dexloxiglumidum [INN-Latin]; Dexloxiglumida [INN-Spanish]; PubChem16049; AC1Q3MXI; GTPL889; SCHEMBL366142; CHEMBL550781; AC1L24A8; DTXSID50152604; MolPort-006-170-001; CHEBI:135747; ZINC3801027; KS-000007QQ; AKOS000279054; PB12713; DB04856; CC-26372; AJ-45649; AK129760; AS-35102; KB-210163; AX8123879; CS-0054881; FT-0603098; Q-4119
DM52HUD DT Small molecular drug
DM52HUD PC 65937
DM52HUD MW 461.4
DM52HUD FM C21H30Cl2N2O5
DM52HUD IC InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1
DM52HUD CS CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DM52HUD IK QNQZBKQEIFTHFZ-GOSISDBHSA-N
DM52HUD IU (4R)-4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid
DM52HUD CA CAS 119817-90-2
DM52HUD CB CHEBI:135747
DM52HUD DE Pancreatic malfunction
DM9L15R ID DM9L15R
DM9L15R DN Dextofisopam
DM9L15R HS Phase 2
DM9L15R SN R-Tofisopam; Dextofisopam (USAN/INN); (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DM9L15R CP Vela Pharmaceuticals
DM9L15R DT Small molecular drug
DM9L15R PC 204105
DM9L15R MW 382.5
DM9L15R FM C22H26N2O4
DM9L15R IC InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3/t15-/m0/s1
DM9L15R CS CC[C@H]1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DM9L15R IK RUJBDQSFYCKFAA-HNNXBMFYSA-N
DM9L15R IU (5R)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DM9L15R CA CAS 82059-50-5
DM9L15R DE Irritable bowel syndrome
DMFI5J4 ID DMFI5J4
DMFI5J4 DN Dextromethorphan+quinidine
DMFI5J4 HS Phase 2
DMFI5J4 SN Dextromethorphan hydrobromide monohydrate; 6700-34-1; Dextromethorphan hydrobromide; Methorate; Drixoral Cough; PediaCare 1; Dextromethorphan hydrobromide hydrate; Dextromethorphan (hydrobromide hydrate); Hold; St. Joseph Cough Syrup; Chloraseptic DM; UNII-9D2RTI9KYH; Romilar; Tylenol Cough Liquid; Endotussin-NN Pediatric; Robitussin Cough Calmers; Robitussin Pediatric Cough; 9D2RTI9KYH; Dextromethorphan hydrobromide OROS Tablets; Drixoral Cough & Sore Throat; Robitussin Maximum Strength Cough
DMFI5J4 CP Avanir
DMFI5J4 DT Small molecular drug
DMFI5J4 PC 5462351
DMFI5J4 MW 370.3
DMFI5J4 FM C18H28BrNO2
DMFI5J4 IC InChI=1S/C18H25NO.BrH.H2O/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H;1H2/t15-,17+,18+;;/m1../s1
DMFI5J4 CS CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC.O.Br
DMFI5J4 IK STTADZBLEUMJRG-IKNOHUQMSA-N
DMFI5J4 IU (1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrate;hydrobromide
DMFI5J4 CA CAS 6700-34-1
DMFI5J4 CB CHEBI:4471
DMFI5J4 DE Diabetic neuropathy
DMS9Y1T ID DMS9Y1T
DMS9Y1T DN DG-17
DMS9Y1T HS Phase 2
DMS9Y1T SN DG-35; Nar DG-35 Prodrug; DG-35-VIII
DMS9Y1T CP Narhex Life Sciences Ltd
DMS9Y1T DE Human immunodeficiency virus infection
DMK6FYR ID DMK6FYR
DMK6FYR DN DiabeCell
DMK6FYR HS Phase 2
DMK6FYR SN Porcine pancreatic islet cell therapy (Immupel encapsulated, type 1 diabetes), LCT; Porcine pancreatic islet celltherapy (alginate encapsulated, type 1 diabetes), LCT
DMK6FYR CP Living Cell Technologies Ltd
DMK6FYR DE Insulin-dependent diabetes
DMTJOEL ID DMTJOEL
DMTJOEL DN DIADENOSINE TETRAPHOSPHATE
DMTJOEL HS Phase 2
DMTJOEL SN Ap4A; F-1500 (tetraNa salt); Diadenosine 5',5''-P1,P4-tetraphosphate
DMTJOEL DT Small molecular drug
DMTJOEL PC 21706
DMTJOEL MW 836.4
DMTJOEL FM C20H28N10O19P4
DMTJOEL IC InChI=1S/C20H28N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-50(35,36)47-52(39,40)49-53(41,42)48-51(37,38)44-2-8-12(32)14(34)20(46-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
DMTJOEL CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N
DMTJOEL IK YOAHKNVSNCMZGQ-XPWFQUROSA-N
DMTJOEL IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMTJOEL CA CAS 5542-28-9
DMTJOEL CB CHEBI:17422
DMTJOEL DE Cardiac arrhythmias
DM7AFJ8 ID DM7AFJ8
DM7AFJ8 DN Diannexin
DM7AFJ8 HS Phase 2
DM7AFJ8 CP Altavita Pharmaceuticals; Astellas Pharma
DM7AFJ8 DE Myocardial reperfusion injury
DM20ATW ID DM20ATW
DM20ATW DN Diflomotecan
DM20ATW HS Phase 2
DM20ATW SN BN-80915; R-1536; Diflomotecan; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
DM20ATW DT Small molecular drug
DM20ATW PC 219023
DM20ATW MW 398.4
DM20ATW FM C21H16F2N2O4
DM20ATW IC InChI=1S/C21H16F2N2O4/c1-2-21(28)7-18(26)29-9-12-13(21)5-17-19-11(8-25(17)20(12)27)3-10-4-14(22)15(23)6-16(10)24-19/h3-6,28H,2,7-9H2,1H3/t21-/m1/s1
DM20ATW CS CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O
DM20ATW IK LFQCJSBXBZRMTN-OAQYLSRUSA-N
DM20ATW IU (20R)-20-ethyl-6,7-difluoro-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2(11),3,5,7,9,15(21)-heptaene-14,18-dione
DM20ATW CA CAS 220997-97-7
DM20ATW CB CHEBI:144046
DM20ATW DE Solid tumour/cancer
DMTLB92 ID DMTLB92
DMTLB92 DN DI-Leu16-IL2
DMTLB92 HS Phase 2
DMTLB92 CP Alopexx Oncology
DMTLB92 DT Recombinant protein
DMTLB92 DE B-cell lymphoma; Non-hodgkin lymphoma
DMBYJ92 ID DMBYJ92
DMBYJ92 DN Dilmapimod
DMBYJ92 HS Phase 2
DMBYJ92 SN Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323
DMBYJ92 CP GSK
DMBYJ92 TC Analgesics
DMBYJ92 DT Small molecular drug
DMBYJ92 PC 10297982
DMBYJ92 MW 456.4
DMBYJ92 FM C23H19F3N4O3
DMBYJ92 IC InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
DMBYJ92 CS CC1=C(C=CC(=C1)F)C2=C3C=CC(=O)N(C3=NC(=N2)NC(CO)CO)C4=C(C=CC=C4F)F
DMBYJ92 IK ORVNHOYNEHYKJG-UHFFFAOYSA-N
DMBYJ92 IU 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one
DMBYJ92 CA CAS 444606-18-2
DMBYJ92 DE Acute lung injury
DMCATH2 ID DMCATH2
DMCATH2 DN Dilpacimab
DMCATH2 HS Phase 2
DMCATH2 SN ABT-165
DMCATH2 DT Antibody
DMCATH2 DE Solid tumour/cancer
DM96NHM ID DM96NHM
DM96NHM DN Dimiracetam
DM96NHM HS Phase 2
DM96NHM SN BND-11624; Dimiracetam, Neurotune; NT-11624; NMDA receptor antagonist (oral, neuropathic pain/osteoarthritic pain), Neurotune
DM96NHM CP Brane Discovery Srl
DM96NHM DT Small molecular drug
DM96NHM PC 65955
DM96NHM MW 140.14
DM96NHM FM C6H8N2O2
DM96NHM IC InChI=1S/C6H8N2O2/c9-5-3-8-4(7-5)1-2-6(8)10/h4H,1-3H2,(H,7,9)
DM96NHM CS C1CC(=O)N2C1NC(=O)C2
DM96NHM IK XTXXOHPHLNROBN-UHFFFAOYSA-N
DM96NHM IU 3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione
DM96NHM CA CAS 126100-97-8
DM96NHM DE Neuropathic pain
DM2QBDS ID DM2QBDS
DM2QBDS DN Disitertide
DM2QBDS HS Phase 2
DM2QBDS SN NAFB-001; Disitertide cream (skin disorders), Digna
DM2QBDS CP University of Navarra
DM2QBDS PC 9833838
DM2QBDS MW 1580.8
DM2QBDS FM C68H109N17O22S2
DM2QBDS IC InChI=1S/C68H109N17O22S2/c1-12-32(5)53(85-67(105)54(33(6)13-2)84-64(102)48(30-87)82-56(94)35(8)74-61(99)45(27-51(91)92)79-62(100)43(24-31(3)4)78-63(101)47(29-86)83-65(103)52(71)36(9)88)66(104)80-44(25-37-28-72-39-17-15-14-16-38(37)39)60(98)73-34(7)55(93)75-41(20-22-108-10)58(96)77-42(21-23-109-11)59(97)76-40(18-19-49(69)89)57(95)81-46(68(106)107)26-50(70)90/h14-17,28,31-36,40-48,52-54,72,86-88H,12-13,18-27,29-30,71H2,1-11H3,(H2,69,89)(H2,70,90)(H,73,98)(H,74,99)(H,75,93)(H,76,97)(H,77,96)(H,78,101)(H,79,100)(H,80,104)(H,81,95)(H,82,94)(H,83,103)(H,84,102)(H,85,105)(H,91,92)(H,106,107)/t32-,33-,34-,35-,36+,40-,41-,42-,43-,44-,45-,46-,47-,48-,52-,53-,54-/m0/s1
DM2QBDS CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)N
DM2QBDS IK IUYPEUHIWDMJLM-SWHDLQTQSA-N
DM2QBDS IU (2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DM2QBDS CA CAS 272105-42-7
DM2QBDS DE Macular degeneration
DMYC2LE ID DMYC2LE
DMYC2LE DN Disufenton
DMYC2LE HS Phase 2
DMYC2LE SN 168021-77-0; UNII-797K01YF1M; 797K01YF1M; N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide; SCHEMBL727315; CHEMBL2111090; 2,4-disulfophenyl-N-t-butylnitrone; alpha-(2,4-disulfophenyl)-N-tert-butylnitrone; Q27266726
DMYC2LE CP Oblato
DMYC2LE DT Small molecular drug
DMYC2LE PC 151179
DMYC2LE MW 337.4
DMYC2LE FM C11H15NO7S2
DMYC2LE IC InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)
DMYC2LE CS CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)O)S(=O)(=O)O)[O-]
DMYC2LE IK OVTCHWSLKGENKP-UHFFFAOYSA-N
DMYC2LE IU N-tert-butyl-1-(2,4-disulfophenyl)methanimine oxide
DMYC2LE CA CAS 168021-77-0
DMYC2LE DE Recurrent glioblastoma
DMBMKV8 ID DMBMKV8
DMBMKV8 DN Disulfiram
DMBMKV8 HS Phase 2
DMBMKV8 SN Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
DMBMKV8 CP Odyssey Pharmaceuticals
DMBMKV8 TC Antiviral Agents
DMBMKV8 DT Small molecular drug
DMBMKV8 PC 3117
DMBMKV8 MW 296.5
DMBMKV8 FM C10H20N2S4
DMBMKV8 IC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3
DMBMKV8 CS CCN(CC)C(=S)SSC(=S)N(CC)CC
DMBMKV8 IK AUZONCFQVSMFAP-UHFFFAOYSA-N
DMBMKV8 IU diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
DMBMKV8 CA CAS 97-77-8
DMBMKV8 CB CHEBI:4659
DMBMKV8 DE Alcoholism; Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMOHT5V ID DMOHT5V
DMOHT5V DN DKN-01
DMOHT5V HS Phase 2
DMOHT5V CP Leap Therapeutics
DMOHT5V DT Antibody
DMOHT5V DE Multiple myeloma; Cholangiocarcinoma; Esophageal cancer; Biliary tract cancer; Endometrial cancer; Oesophagogastric junction cancer; Ovarian cancer; Prostate cancer
DMDJUWG ID DMDJUWG
DMDJUWG DN DLX-105
DMDJUWG HS Phase 2
DMDJUWG SN DLX-106; ESBA-105 (intra-articular formulation), ESBATech; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), Delenex; Anti-TNF alpha antibody fragment (intra-articular, osteoarthritis), ESBATech
DMDJUWG CP ESBATech AG
DMDJUWG DT Antibody
DMDJUWG DE Osteoarthritis
DM0157T ID DM0157T
DM0157T DN DM199
DM0157T HS Phase 2
DM0157T CP DiaMedica Therapeutics
DM0157T DT Recombinant?protein
DM0157T DE Autoimmune diabetes; Ischemic stroke; Diabetic nephropathy; Cerebral ischemia
DMMSIG7 ID DMMSIG7
DMMSIG7 DN DM-71
DMMSIG7 HS Phase 2
DMMSIG7 SN Insulin sensitizer (type 2 diabetes), DiaMedica; Bethanechol + n-acetyl cysteine (type 2 diabetes), DiaMedica
DMMSIG7 CP DiaMedica Inc
DMMSIG7 DE Type-2 diabetes
DM1HG3U ID DM1HG3U
DM1HG3U DN DM-99
DM1HG3U HS Phase 2
DM1HG3U CP DiaMedica Inc
DM1HG3U DE Alzheimer disease
DMBC7HZ ID DMBC7HZ
DMBC7HZ DN DM-CHOC-PEN
DMBC7HZ HS Phase 2
DMBC7HZ CP Dekk-Tec
DMBC7HZ PC 16126905
DMBC7HZ MW 724
DMBC7HZ FM C35H48Cl5NO4
DMBC7HZ IC InChI=1S/C35H48Cl5NO4/c1-19(2)8-7-9-20(3)24-12-13-25-23-11-10-21-18-22(14-16-33(21,4)26(23)15-17-34(24,25)5)44-32(42)45-29-27(36)30(35(38,39)40)41-31(43-6)28(29)37/h10,19-20,22-26H,7-9,11-18H2,1-6H3/t20-,22+,23+,24-,25+,26+,33+,34-/m1/s1
DMBC7HZ CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)OC5=C(C(=NC(=C5Cl)OC)C(Cl)(Cl)Cl)Cl)C)C
DMBC7HZ IK ZJUUIXYKTPSIOH-LEZJFEBPSA-N
DMBC7HZ IU [3,5-dichloro-2-methoxy-6-(trichloromethyl)pyridin-4-yl] [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] carbonate
DMBC7HZ CA CAS 942149-56-6
DMBC7HZ DE Brain cancer; Brain metastases
DM725UG ID DM725UG
DM725UG DN DN24-02
DM725UG HS Phase 2
DM725UG SN Lapuleucel-T
DM725UG CP Dendreon
DM725UG DE Urogenital cancer; Colorectal cancer
DMDTVYC ID DMDTVYC
DMDTVYC DN DNCB
DMDTVYC HS Phase 2
DMDTVYC SN 1-Chloro-2,4-dinitrobenzene
DMDTVYC DT Small molecular drug
DMDTVYC PC 6
DMDTVYC MW 202.55
DMDTVYC FM C6H3ClN2O4
DMDTVYC IC InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H
DMDTVYC CS C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl
DMDTVYC IK VYZAHLCBVHPDDF-UHFFFAOYSA-N
DMDTVYC IU 1-chloro-2,4-dinitrobenzene
DMDTVYC CA CAS 97-00-7
DMDTVYC CB CHEBI:34718
DMDTVYC DE Immune System disease
DM89D6C ID DM89D6C
DM89D6C DN DNL758
DM89D6C HS Phase 2
DM89D6C SN SAR443122
DM89D6C CP Denali Therapeutics
DM89D6C DT Small molecular drug
DM89D6C DE Cutaneous lupus erythematosus
DM0QDC9 ID DM0QDC9
DM0QDC9 DN Dolastatin 10
DM0QDC9 HS Phase 2
DM0QDC9 SN Dolastatin 10; Dolastatin-10; Dolostatin 10; UNII-EI946JT51X; CCRIS 7310; CHEBI:67357; NSC 376128; EI946JT51X; L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-
DM0QDC9 PC 9810929
DM0QDC9 MW 785.1
DM0QDC9 FM C42H68N6O6S
DM0QDC9 IC InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1
DM0QDC9 CS CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C
DM0QDC9 IK OFDNQWIFNXBECV-VFSYNPLYSA-N
DM0QDC9 IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DM0QDC9 CA CAS 110417-88-4
DM0QDC9 CB CHEBI:67357
DM0QDC9 DE Leukemia
DMDUV1S ID DMDUV1S
DMDUV1S DN DOLASTATIN-10
DMDUV1S HS Phase 2
DMDUV1S DT Small molecular drug
DMDUV1S PC 9810929
DMDUV1S MW 785.1
DMDUV1S FM C42H68N6O6S
DMDUV1S IC InChI=1S/C42H68N6O6S/c1-13-28(6)37(47(10)42(52)35(26(2)3)45-40(51)36(27(4)5)46(8)9)33(53-11)25-34(49)48-22-17-20-32(48)38(54-12)29(7)39(50)44-31(41-43-21-23-55-41)24-30-18-15-14-16-19-30/h14-16,18-19,21,23,26-29,31-33,35-38H,13,17,20,22,24-25H2,1-12H3,(H,44,50)(H,45,51)/t28-,29+,31-,32-,33+,35-,36-,37-,38+/m0/s1
DMDUV1S CS CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C
DMDUV1S IK OFDNQWIFNXBECV-VFSYNPLYSA-N
DMDUV1S IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DMDUV1S CA CAS 110417-88-4
DMDUV1S CB CHEBI:67357
DMDUV1S DE Solid tumour/cancer
DMCT08V ID DMCT08V
DMCT08V DN Domagrozumab
DMCT08V HS Phase 2
DMCT08V CP Pfizer New York, NY
DMCT08V DE Duchenne dystrophy
DM8VWPH ID DM8VWPH
DM8VWPH DN Doxorubicin-eluting beads
DM8VWPH HS Phase 2
DM8VWPH SN DC Bead (TN)
DM8VWPH CP Bayer HealthCare Pharmaceuticals; Biocompatibles
DM8VWPH DE Liver cancer
DM059CZ ID DM059CZ
DM059CZ DN DPK-060
DM059CZ HS Phase 2
DM059CZ SN DP-9011; DP-9012; DP-9013; DP-9011-DP-9013 series (atopic dermatitis/impetigo), DermaGen
DM059CZ CP DermaGen AB
DM059CZ DE Atopic dermatitis
DMMC3XR ID DMMC3XR
DMMC3XR DN DPV-001
DMMC3XR HS Phase 2
DMMC3XR CP Ubivac
DMMC3XR DE Non-small-cell lung cancer; Prostate cancer
DMGD3XT ID DMGD3XT
DMGD3XT DN DRL-17822
DMGD3XT HS Phase 2
DMGD3XT SN CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's
DMGD3XT CP Dr Reddy's Laboratories Ltd
DMGD3XT PC 58689743
DMGD3XT MW 603.6
DMGD3XT FM C30H31F6N7
DMGD3XT IC InChI=1S/C30H31F6N7/c1-18-4-3-5-22-12-23(27(37-26(18)22)42(14-19-6-7-19)15-20-8-9-20)17-43(28-38-40-41(2)39-28)16-21-10-24(29(31,32)33)13-25(11-21)30(34,35)36/h3-5,10-13,19-20H,6-9,14-17H2,1-2H3
DMGD3XT CS CC1=C2C(=CC=C1)C=C(C(=N2)N(CC3CC3)CC4CC4)CN(CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)C6=NN(N=N6)C
DMGD3XT IK OCNBSSLDAIWTKS-UHFFFAOYSA-N
DMGD3XT IU 3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N,N-bis(cyclopropylmethyl)-8-methylquinolin-2-amine
DMGD3XT CA CAS 898911-09-6
DMGD3XT DE Arteriosclerosis
DM8WU3O ID DM8WU3O
DM8WU3O DN Drug 2862277
DM8WU3O HS Phase 2
DM8WU3O SN 2862277
DM8WU3O DT Antibody
DM8WU3O DE Acute lung injury
DMI69E5 ID DMI69E5
DMI69E5 DN DS-3201b
DMI69E5 HS Phase 2
DMI69E5 SN Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551
DMI69E5 CP Daiichi Sankyo
DMI69E5 DT Small molecular drug
DMI69E5 PC 126481870
DMI69E5 MW 488
DMI69E5 FM C26H34ClN3O4
DMI69E5 IC InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17?,18?,26-/m1/s1
DMI69E5 CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC(=C3C(=C2C)O[C@@](O3)(C)C4CCC(CC4)N(C)C)Cl)C
DMI69E5 IK SSDRNUPMYCFXGM-ZZHSESOFSA-N
DMI69E5 IU (2R)-7-chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide
DMI69E5 CA CAS 1809336-39-7
DMI69E5 DE Acute myeloid leukaemia; Acute lymphoblastic leukaemia; Urothelial carcinoma; Renal cell carcinoma; Small-cell lung cancer; T-cell leukaemia
DMUXIRM ID DMUXIRM
DMUXIRM DN DS-8500
DMUXIRM HS Phase 2
DMUXIRM CP Daiichi Sankyo
DMUXIRM PC 74889211
DMUXIRM MW 153.18
DMUXIRM FM C8H11NO2
DMUXIRM IC InChI=1S/C8H11NO2/c1-3-7-6(4-5-9-7)8(10)11-2/h4-5,9H,3H2,1-2H3
DMUXIRM CS CCC1=C(C=CN1)C(=O)OC
DMUXIRM IK FWZOVQKKSCXOHE-UHFFFAOYSA-N
DMUXIRM IU methyl 2-ethyl-1H-pyrrole-3-carboxylate
DMUXIRM DE Diabetic complication; Type-2 diabetes
DM6UGHA ID DM6UGHA
DM6UGHA DN DSP-6952
DM6UGHA HS Phase 2
DM6UGHA SN Serotonin 4 receptor partial agonist (constipation), Dainippon Sumitomo
DM6UGHA CP Dainippon Sumitomo Pharma Co Ltd
DM6UGHA DE Constipation
DMU2GP4 ID DMU2GP4
DMU2GP4 DN DT-1687
DMU2GP4 HS Phase 2
DMU2GP4 SN DT-1386; MGluR4 PAM (neurological disease/psychiatric disorder), Domain Therapeutics; MGluR4 PAM (neurological disease/psychiatric disorder), Merck Serono
DMU2GP4 CP Domain Therapeutics SA
DMU2GP4 PC 135565465
DMU2GP4 MW 421.5
DMU2GP4 FM C23H23N3O3S
DMU2GP4 IC InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,27H,1-2,6-10H2/b25-19+
DMU2GP4 CS C1COCCN1CCCC2=CC\\3=C(C=C2)OC(=C/C3=N\\O)C4=NC=C5C=CSC5=C4
DMU2GP4 IK ZTEDNASHAWNBKQ-NCELDCMTSA-N
DMU2GP4 IU (NE)-N-[6-(3-morpholin-4-ylpropyl)-2-thieno[3,2-c]pyridin-6-ylchromen-4-ylidene]hydroxylamine
DMU2GP4 CA CAS 1883329-53-0
DMU2GP4 DE Neurological disorder; Parkinson disease
DMV84OK ID DMV84OK
DMV84OK DN DTI-0009
DMV84OK HS Phase 2
DMV84OK SN Selodenosan
DMV84OK CP Aderis Pharmaceuticals
DMV84OK DE Atrial fibrillation
DMX27IT ID DMX27IT
DMX27IT DN DTRM-555
DMX27IT HS Phase 2
DMX27IT CP Zhejiang DTRM Biopharma
DMX27IT DT Small molecular drug
DMX27IT DE Chronic lymphocytic leukaemia
DM1ZJYS ID DM1ZJYS
DM1ZJYS DN Dusigitumab
DM1ZJYS HS Phase 2
DM1ZJYS CP MedImmune Gaithersburg, MD
DM1ZJYS DE Breast cancer
DM7USVA ID DM7USVA
DM7USVA DN Duvelisib
DM7USVA HS Phase 2
DM7USVA SN Duvelisib; 1201438-56-3; IPI-145; INK-1197; UNII-610V23S0JI; IPI 145; 610V23S0JI; INK-1147; Copiktra; IPI-145 (INK1197); Duvelisib [USAN:INN]; IPI145; INK1197; Copiktra (TN); AK145604; Duvelisib (IPI-145, INK1197); Duvel; Duvelisib
DM7USVA TC Antiviral Agents
DM7USVA DT Small molecular drug
DM7USVA PC 50905713
DM7USVA MW 416.9
DM7USVA FM C22H17ClN6O
DM7USVA IC InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
DM7USVA CS C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DM7USVA IK SJVQHLPISAIATJ-ZDUSSCGKSA-N
DM7USVA IU 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one
DM7USVA CA CAS 1201438-56-3
DM7USVA CB CHEBI:131169
DM7USVA DE Coronavirus Disease 2019 (COVID-19)
DMUGBQK ID DMUGBQK
DMUGBQK DN DVC1-0101
DMUGBQK HS Phase 2
DMUGBQK SN Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University
DMUGBQK CP DNAVEC Corp
DMUGBQK DE Arteriosclerosis
DMQKU2F ID DMQKU2F
DMQKU2F DN DWP-05195
DMQKU2F HS Phase 2
DMQKU2F SN DWJ-204; DWP-0519
DMQKU2F CP Daewoong Pharmaceutical Co Ltd
DMQKU2F DE Neuropathic pain
DMBFZET ID DMBFZET
DMBFZET DN DX-890
DMBFZET HS Phase 2
DMBFZET CP Dyax Corp.
DMBFZET PC 56841753
DMBFZET MW 6231
DMBFZET FM C282H412N74O75S6
DMBFZET IC InChI=1S/C282H412N74O75S6/c1-21-150(15)229-273(424)312-154(19)232(383)328-185(117-157-58-30-24-31-59-157)255(406)339-196(123-160-64-36-27-37-65-160)277(428)353-110-52-76-205(353)267(418)324-177(74-50-108-300-282(296)297)246(397)332-189(124-164-129-301-170-67-39-38-66-168(164)170)250(401)310-153(18)231(382)327-184(116-156-56-28-23-29-57-156)253(404)334-193(128-224(380)381)251(402)311-155(20)234(385)347-225(146(7)8)270(421)325-171(68-40-44-102-283)236(387)304-132-215(367)313-173(69-41-45-103-284)242(393)344-202-142-436-435-141-201-262(413)319-176(73-49-107-299-281(294)295)244(395)321-180(95-100-222(376)377)248(399)330-188(121-163-84-90-167(360)91-85-163)257(408)342-198(241(392)307-135-218(370)346-228(149(13)14)278(429)356-113-55-79-208(356)279(430)431)138-432-434-140-200(341-233(384)152(17)309-235(386)169(287)92-98-220(372)373)263(414)333-192(127-212(291)364)259(410)337-194(115-145(5)6)275(426)355-112-54-78-207(355)269(420)351-230(151(16)22-2)274(425)349-227(148(11)12)271(422)326-172(72-48-106-298-280(292)293)237(388)308-136-219(371)352-109-51-75-204(352)266(417)345-203(265(416)350-229)143-437-433-139-199(316-214(366)131-302-213(365)130-303-239(390)183(119-161-80-86-165(358)87-81-161)335-268(419)206-77-53-111-354(206)276(427)195(122-159-62-34-26-35-63-159)338-252(403)182(114-144(3)4)336-272(423)226(147(9)10)348-264(202)415)261(412)320-178(93-97-209(288)361)238(389)305-133-216(368)314-190(125-210(289)362)240(391)306-134-217(369)315-191(126-211(290)363)258(409)318-175(71-43-47-105-286)245(396)329-186(118-158-60-32-25-33-61-158)254(405)331-187(120-162-82-88-166(359)89-83-162)256(407)340-197(137-357)260(411)323-179(94-99-221(374)375)247(398)317-174(70-42-46-104-285)243(394)322-181(249(400)343-201)96-101-223(378)379/h23-39,56-67,80-91,129,144-155,169,171-208,225-230,301,357-360H,21-22,40-55,68-79,92-128,130-143,283-287H2,1-20H3,(H2,288,361)(H2,289,362)(H2,290,363)(H2,291,364)(H,302,365)(H,303,390)(H,304,387)(H,305,389)(H,306,391)(H,307,392)(H,308,388)(H,309,386)(H,310,401)(H,311,402)(H,312,424)(H,313,367)(H,314,368)(H,315,369)(H,316,366)(H,317,398)(H,318,409)(H,319,413)(H,320,412)(H,321,395)(H,322,394)(H,323,411)(H,324,418)(H,325,421)(H,326,422)(H,327,382)(H,328,383)(H,329,396)(H,330,399)(H,331,405)(H,332,397)(H,333,414)(H,334,404)(H,335,419)(H,336,423)(H,337,410)(H,338,403)(H,339,406)(H,340,407)(H,341,384)(H,342,408)(H,343,400)(H,344,393)(H,345,417)(H,346,370)(H,347,385)(H,348,415)(H,349,425)(H,350,416)(H,351,420)(H,372,373)(H,374,375)(H,376,377)(H,378,379)(H,380,381)(H,430,431)(H4,292,293,298)(H4,294,295,299)(H4,296,297,300)/t150-,151-,152-,153-,154-,155-,169-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,225-,226-,227-,228-,229-,230-/m0/s1
DMBFZET CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H]3CSSC[C@H]4C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N4)CC6=CC=C(C=C6)O)CC7=CC=CC=C7)CC(C)C)C(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC3=O)[C@@H](C)CC)C)CC9=CC=CC=C9)CC2=CC=CC=C2)CCCNC(=N)N)CC2=CNC3=CC=CC=C32)C)CC2=CC=CC=C2)CC(=O)O)C)C(C)C)CCCCN)CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N1)CC(C)C)CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)N)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)O)CC1=CC=C(C=C1)O)CCC(=O)O)CCCNC(=N)N)CCC(=O)O)CCCCN)CCC(=O)O)CO)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CCCCN)CC(=O)N)CC(=O)N)CCC(=O)N)CCCNC(=N)N)C(C)C
DMBFZET IK CARVNSROHCBVAO-BUGJESOBSA-N
DMBFZET IU (2S)-1-[(2S)-2-[[2-[[(1R,2aS,4S,8aS,11aS,13S,14aS,16S,17aR,19S,20aS,22S,26aS,28S,29aS,31S,32aS,34R,35aS,38aS,39R,41aS,42S,44aS,45S,47aS,48S,50aS,51R,54S,56aS,57S,59aS,60S,62aS,63S,65aS,66S,69S,72S,75S,81S,87S,90R,99S)-20a,26a,57,72-tetrakis(4-aminobutyl)-34-[[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]propanoyl]amino]-31,75,81-tris(2-amino-2-oxoethyl)-87-(3-amino-3-oxopropyl)-8a,38a,56a,59a,69-pentabenzyl-19,65a-bis[(2S)-butan-2-yl]-13,47a,48-tris(3-carbamimidamidopropyl)-45,54,60-tris(2-carboxyethyl)-35a-(carboxymethyl)-63-(hydroxymethyl)-42,66,99-tris[(4-hydroxyphenyl)methyl]-44a-(1H-indol-3-ylmethyl)-32a,41a,62a-trimethyl-11a,28-bis(2-methylpropyl)-1a,3,7a,9,10a,12,13a,15,16a,18,19a,21,22a,25a,27,28a,30,31a,33,34a,37a,40a,41,43a,44,46a,47,49a,50,53,55a,56,58a,59,61a,62,64a,65,67a,68,71,74,77,80,83,86,89,92,95,98-pentacontaoxo-14a,16,29a-tri(propan-2-yl)-36,37,69a,70a,73a,74a-hexathia-a,2,6a,8,9a,11,12a,14,15a,17,18a,20,21a,24a,26,27a,29,30a,32,33a,36a,39a,40,42a,43,45a,46,48a,49,52,54a,55,57a,58,60a,61,63a,64,66a,67,70,73,76,79,82,85,88,91,94,97-pentacontazaheptacyclo[88.77.4.451,117.04,8.022,26.0102,106.0150,154]pentaheptacontahectane-39-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid
DMBFZET CA CAS 506433-25-6
DMBFZET DE Acute lung injury
DMDYWM8 ID DMDYWM8
DMDYWM8 DN E-10030
DMDYWM8 HS Phase 2
DMDYWM8 SN PDGF-B antagonist (AMD), Eyetech/Archemix; PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), (OSI) Eyetech/Archemix
DMDYWM8 CP Archemix Corp
DMDYWM8 DE Macular degeneration
DMLS269 ID DMLS269
DMLS269 DN E-1224
DMLS269 HS Phase 2
DMLS269 SN BMS-292655; BMS-315801; BMS-379224; Ravuconazole prodrugs, BMS; Ravuconazole back-up compounds, Eisai; Ravuconazole prodrug (fungal infection), Brain Factory; Ravuconazole prodrugs, Bristol-Myers Squibb
DMLS269 CP Bristol-Myers Squibb Co
DMLS269 DT Small molecular drug
DMLS269 PC 57416740
DMLS269 MW 273.14
DMLS269 FM C15H20BNO3
DMLS269 IC InChI=1S/C15H20BNO3/c1-11(18)13-12(7-6-10-17-13)8-9-16-19-14(2,3)15(4,5)20-16/h6-10H,1-5H3/b9-8+
DMLS269 CS B1(OC(C(O1)(C)C)(C)C)/C=C/C2=C(N=CC=C2)C(=O)C
DMLS269 IK DAQLKAUMCVWOCH-CMDGGOBGSA-N
DMLS269 IU 1-[3-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridin-2-yl]ethanone
DMLS269 DE Fungal infection
DMK8SY6 ID DMK8SY6
DMK8SY6 DN E2027
DMK8SY6 HS Phase 2
DMK8SY6 CP Eisai
DMK8SY6 DT Small molecular drug
DMK8SY6 DE Alzheimer disease; Parkinson disease; Lewy body dementia
DMC5PB2 ID DMC5PB2
DMC5PB2 DN E-4716
DMC5PB2 HS Phase 2
DMC5PB2 SN Mapinastine
DMC5PB2 CP Laboratorios Dr Esteve SA
DMC5PB2 DE Respiratory disease
DMQERC6 ID DMQERC6
DMQERC6 DN E5555
DMQERC6 HS Phase 2
DMQERC6 SN Atopaxar
DMQERC6 CP Eisai
DMQERC6 DT Small molecular drug
DMQERC6 PC 10459564
DMQERC6 MW 527.6
DMQERC6 FM C29H38FN3O5
DMQERC6 IC InChI=1S/C29H38FN3O5/c1-7-37-23-15-19-16-33(28(31)24(19)25(30)27(23)38-8-2)17-22(34)18-13-20(29(3,4)5)26(35-6)21(14-18)32-9-11-36-12-10-32/h13-15,31H,7-12,16-17H2,1-6H3
DMQERC6 CS CCOC1=C(C(=C2C(=C1)CN(C2=N)CC(=O)C3=CC(=C(C(=C3)N4CCOCC4)OC)C(C)(C)C)F)OCC
DMQERC6 IK QWKAUGRRIXBIPO-UHFFFAOYSA-N
DMQERC6 IU 1-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)ethanone
DMQERC6 CA CAS 751475-53-3
DMQERC6 DE Acute coronary syndrome
DM1S489 ID DM1S489
DM1S489 DN E6005
DM1S489 HS Phase 2
DM1S489 SN Lotamilast; 947620-48-6; E6005; E-6005; UNII-TO043KKB9C; TO043KKB9C; Methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate; RVT-501; Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate; Lotamilast [USAN]; SCHEMBL369445; CHEMBL3989967; MolPort-046-033-604; BCP25249; EX-A1382; ZINC113676839; AKOS027337123; SB16962; DB12776; CS-7517; (Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate; HY-12740; AS-52366; Benzoic acid, 4-(((3-(6,7
DM1S489 CP Eisai
DM1S489 DT Small molecular drug
DM1S489 PC 24864553
DM1S489 MW 472.5
DM1S489 FM C26H24N4O5
DM1S489 IC InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)
DM1S489 CS CNC1=NC2=CC(=C(C=C2C(=N1)C3=CC(=CC=C3)NC(=O)C4=CC=C(C=C4)C(=O)OC)OC)OC
DM1S489 IK BBTFKAOFCSOZMB-UHFFFAOYSA-N
DM1S489 IU methyl 4-[[3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl]carbamoyl]benzoate
DM1S489 CA CAS 947620-48-6
DM1S489 DE Atopic dermatitis
DMOSL9P ID DMOSL9P
DMOSL9P DN E6201
DMOSL9P HS Phase 2
DMOSL9P SN novel MEK inhibitors
DMOSL9P CP Eisai Ltd.
DMOSL9P DT Small molecular drug
DMOSL9P PC 10172827
DMOSL9P MW 389.4
DMOSL9P FM C21H27NO6
DMOSL9P IC InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1
DMOSL9P CS CCNC1=CC\\2=C(C(=C1)O)C(=O)O[C@H]([C@@H](/C=C\\C(=O)[C@H]([C@H](C/C=C2)O)O)C)C
DMOSL9P IK MWUFVYLAWAXDHQ-HMNLTAHHSA-N
DMOSL9P IU (4S,5R,6Z,9S,10S,12E)-16-(ethylamino)-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione
DMOSL9P CA CAS 603987-35-5
DMOSL9P DE Psoriasis vulgaris
DMUWJI4 ID DMUWJI4
DMUWJI4 DN E-6700
DMUWJI4 HS Phase 2
DMUWJI4 PC 9843006
DMUWJI4 MW 383.4
DMUWJI4 FM C22H25NO5
DMUWJI4 IC InChI=1S/C22H25NO5/c1-14-18(19(24)15(2)21(28-3)20(14)25)12-17(22(26)27)10-6-4-5-8-16-9-7-11-23-13-16/h7,9,11-13H,4-6,8,10H2,1-3H3,(H,26,27)/b17-12+
DMUWJI4 CS CC1=C(C(=O)C(=C(C1=O)OC)C)/C=C(\\CCCCCC2=CN=CC=C2)/C(=O)O
DMUWJI4 IK WWYFKRSBSWBEGV-SFQUDFHCSA-N
DMUWJI4 IU (2E)-2-[(4-methoxy-2,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylidene]-7-pyridin-3-ylheptanoic acid
DMUWJI4 DE Asthma
DMAHGKE ID DMAHGKE
DMAHGKE DN E7016
DMAHGKE HS Phase 2
DMAHGKE SN UNII-M8926C7ILX; E-7016; M8926C7ILX; 902128-92-1; E7016; SCHEMBL1319757; CHEMBL3527000; BDBM97563; GPI 21016; GPI-21016; SB16889; Benzopyrano(4,3,2-de)phthalazin-3(2H)-one, 10-((4-hydroxy-1-piperidinyl)methyl)-; US8470825, 4i; E 7016
DMAHGKE CP Eisai
DMAHGKE DT Small molecular drug
DMAHGKE PC 11660296
DMAHGKE MW 349.4
DMAHGKE FM C20H19N3O3
DMAHGKE IC InChI=1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25)
DMAHGKE CS C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O
DMAHGKE IK HAVFFEMDLROBGI-UHFFFAOYSA-N
DMAHGKE IU 4-[(4-hydroxypiperidin-1-yl)methyl]-8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17)-heptaen-14-one
DMAHGKE CA CAS 902128-92-1
DMAHGKE DE Melanoma
DMZRXTL ID DMZRXTL
DMZRXTL DN E7820
DMZRXTL HS Phase 2
DMZRXTL SN E7820; 289483-69-8; E-7820; E 7820; UNII-TVH5K7949N; TVH5K7949N; 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; NSC-719239; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)-; LWGUASZLXHYWIV-UHFFFAOYSA-N; AC1L52N5; ZINC8704; SCHEMBL1581157; DTXSID20183142; BCP25835; EX-A1818; 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide; NSC719239; AKOS032944953; CS-6075
DMZRXTL CP Eisai
DMZRXTL DT Small molecular drug
DMZRXTL PC 196970
DMZRXTL MW 336.4
DMZRXTL FM C17H12N4O2S
DMZRXTL IC InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
DMZRXTL CS CC1=C2C(=CNC2=C(C=C1)NS(=O)(=O)C3=CC=CC(=C3)C#N)C#N
DMZRXTL IK LWGUASZLXHYWIV-UHFFFAOYSA-N
DMZRXTL IU 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
DMZRXTL CA CAS 289483-69-8
DMZRXTL DE Solid tumour/cancer; Colorectal cancer
DM8K5IF ID DM8K5IF
DM8K5IF DN E7850
DM8K5IF HS Phase 2
DM8K5IF SN Irofulven
DM8K5IF CP Eisai
DM8K5IF DT Small molecular drug
DM8K5IF PC 148189
DM8K5IF MW 246.3
DM8K5IF FM C15H18O3
DM8K5IF IC InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
DM8K5IF CS CC1=C(C2=C(C3(CC3)[C@@](C(=O)C2=C1)(C)O)C)CO
DM8K5IF IK NICJCIQSJJKZAH-AWEZNQCLSA-N
DM8K5IF IU (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
DM8K5IF CA CAS 158440-71-2
DM8K5IF CB CHEBI:135002
DM8K5IF DE Solid tumour/cancer
DM753H8 ID DM753H8
DM753H8 DN EB8018
DM753H8 HS Phase 2
DM753H8 SN Sibofimloc; 1616113-45-1; Antibiotic-202; VRT-1353385; UNII-00OF00QZC4; 1-[2,7-Bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; 1-[2,7-bis({2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl})spiro[fluorene-9,4'-piperidine]-1'-yl]ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone; Sibofimloc [INN]; Sibofimloc [USAN]; Sibofimloc (USAN/INN); CHEMBL4594305; SCHEMBL15836795; EX-A750; Antibiotic-202;VRT-1353385; MFCD28144726; WHO 10950; ZINC209678340; ACN-052475; CS-5487; DA-43714; HY-12820; B5896; D11825; J-690221; 1-(2,7-Bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol-8-yl)spiro(fluorene-9,4'-piperidin)-1'-yl)ethan-1-one; 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4a?piperidine]-1a?yl]ethanone; 8,8'-(1'-Acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-D-glycero-D-manno-oct-7-ynitol); D-Glycero-D-manno-oct-7-ynitol, 8,8'-(1'-acetylspiro(9H-fluorene-9,4'-piperidine)-2,7-diyl)bis(2,6-anhydro-7,8-dideoxy-
DM753H8 CP Enterome Biosciences
DM753H8 DT Small molecular drug
DM753H8 PC 76684239
DM753H8 MW 649.7
DM753H8 FM C35H39NO11
DM753H8 IC InChI=1S/C35H39NO11/c1-18(39)36-12-10-35(11-13-36)23-14-19(4-8-25-29(40)33(44)31(42)27(16-37)46-25)2-6-21(23)22-7-3-20(15-24(22)35)5-9-26-30(41)34(45)32(43)28(17-38)47-26/h2-3,6-7,14-15,25-34,37-38,40-45H,10-13,16-17H2,1H3/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m1/s1
DM753H8 CS CC(=O)N1CCC2(CC1)C3=C(C=CC(=C3)C#C[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=C2C=C(C=C5)C#C[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O
DM753H8 IK SFHMWDMKUYVSQJ-VECBPBMLSA-N
DM753H8 IU 1-[2,7-bis[2-[(2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethynyl]spiro[fluorene-9,4'-piperidine]-1'-yl]ethanone
DM753H8 CA CAS 1616113-45-1
DM753H8 DE Crohn disease
DM0KVJC ID DM0KVJC
DM0KVJC DN EC-145
DM0KVJC HS Phase 2
DM0KVJC SN EC-0255; EC-0260
DM0KVJC CP Endocyte; Merck
DM0KVJC PC 25014653
DM0KVJC MW 1917
DM0KVJC FM C86H109N21O26S2
DM0KVJC IC InChI=1S/C86H109N21O26S2/c1-6-82(129)35-42-36-85(78(127)132-5,64-47(21-26-106(39-42)41-82)46-12-8-9-13-50(46)95-64)49-30-48-57(34-58(49)131-4)105(3)75-84(48)23-27-107-25-11-22-83(7-2,74(84)107)76(125)86(75,130)77(126)103-104-81(128)133-28-29-134-135-40-56(73(123)124)100-70(119)55(33-62(113)114)99-69(118)54(32-61(111)112)98-67(116)51(14-10-24-90-79(87)88)96-68(117)53(31-60(109)110)94-59(108)20-19-52(72(121)122)97-66(115)43-15-17-44(18-16-43)91-37-45-38-92-65-63(93-45)71(120)102-80(89)101-65/h8-9,11-13,15-18,22,30,34,38,42,51-56,74-76,91,95,125,129-130H,6-7,10,14,19-21,23-29,31-33,35-37,39-41H2,1-5H3,(H,94,108)(H,96,117)(H,97,115)(H,98,116)(H,99,118)(H,100,119)(H,103,126)(H,104,128)(H,109,110)(H,111,112)(H,113,114)(H,121,122)(H,123,124)(H4,87,88,90)(H3,89,92,101,102,120)/t42-,51-,52-,53-,54-,55-,56-,74-,75+,76+,82-,83+,84+,85-,86-/m0/s1
DM0KVJC CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NNC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O
DM0KVJC IK KUZYSQSABONDME-QRLOMCMNSA-N
DM0KVJC IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM0KVJC CA CAS 742092-03-1
DM0KVJC DE Solid tumour/cancer
DM1LDIP ID DM1LDIP
DM1LDIP DN Econail
DM1LDIP HS Phase 2
DM1LDIP SN Econazole/SEPA
DM1LDIP CP MacroChem Corporation
DM1LDIP DT Small molecular drug
DM1LDIP PC 68589
DM1LDIP MW 444.7
DM1LDIP FM C18H16Cl3N3O4
DM1LDIP IC InChI=1S/C18H15Cl3N2O.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4)
DM1LDIP CS C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl.[N+](=O)(O)[O-]
DM1LDIP IK DDXORDQKGIZAME-UHFFFAOYSA-N
DM1LDIP IU 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid
DM1LDIP CA CAS 24169-02-6
DM1LDIP DE Fungal infection
DMKAUM9 ID DMKAUM9
DMKAUM9 DN Eculizumab
DMKAUM9 HS Phase 2
DMKAUM9 SN Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion
DMKAUM9 CP Alexion Pharmaceuticals Inc
DMKAUM9 TC Antiviral Agents
DMKAUM9 DT Monoclonal antibody
DMKAUM9 DE Age-related macular degeneration; Coronavirus Disease 2019 (COVID-19)
DMQ08AJ ID DMQ08AJ
DMQ08AJ DN Edotreotide
DMQ08AJ HS Phase 2
DMQ08AJ SN Edotreotide; SMT-487; UNII-U194AS08HZ; 204318-14-9; U194AS08HZ; CHEMBL408350; DOTATOC; DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7); SMT 487; Edotreotide [USAN:INN]; DOTA-TOC acetate; AC1L4KLV; SCHEMBL1649285; SCHEMBL19712197; RZHKDBRREKOZEW-AAXZNHDCSA-N; BDBM50165171; N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DMQ08AJ PC 158782
DMQ08AJ MW 1421.6
DMQ08AJ FM C65H92N14O18S2
DMQ08AJ IC InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1
DMQ08AJ CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O
DMQ08AJ IK RZHKDBRREKOZEW-AAXZNHDCSA-N
DMQ08AJ IU 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
DMQ08AJ CA CAS 204318-14-9
DMQ08AJ DE Acromegaly
DMGJYZ8 ID DMGJYZ8
DMGJYZ8 DN EDP-305
DMGJYZ8 HS Phase 2
DMGJYZ8 DT Small molecular drug
DMGJYZ8 DE Non-alcoholic steatohepatitis; Primary biliary cholangitis
DM5WZ0O ID DM5WZ0O
DM5WZ0O DN EDP-420
DM5WZ0O HS Phase 2
DM5WZ0O SN EP-013420
DM5WZ0O CP Enanta
DM5WZ0O DT Small molecular drug
DM5WZ0O PC 9875927
DM5WZ0O MW 841
DM5WZ0O FM C43H64N6O11
DM5WZ0O IC InChI=1S/C43H64N6O11/c1-12-33-43(9,54)39-26(4)35(46-29(7)50)24(2)19-42(8,56-23-31(22-55-39)47-57-21-30-14-15-34(44-20-30)49-17-13-16-45-49)38(27(5)36(51)28(6)40(53)59-33)60-41-37(52)32(48(10)11)18-25(3)58-41/h13-17,20,24-28,32-33,37-39,41,52,54H,12,18-19,21-23H2,1-11H3/b46-35?,47-31+/t24-,25-,26+,27+,28-,32+,33-,37-,38-,39-,41+,42-,43-/m1/s1
DM5WZ0O CS CC[C@@H]1[C@@]([C@H]2[C@H](C(=NC(=O)C)[C@@H](C[C@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(OC/C(=N/OCC4=CN=C(C=C4)N5C=CC=N5)/CO2)C)C)C)(C)O
DM5WZ0O IK WLGSYOKBEDVHQB-ZIJNRMRWSA-N
DM5WZ0O IU N-[(1R,2R,3R,6R,8R,9R,10R,13E,16S,18R)-9-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-2-hydroxy-2,6,8,10,16,18-hexamethyl-5,7-dioxo-13-[(6-pyrazol-1-ylpyridin-3-yl)methoxyimino]-4,11,15-trioxabicyclo[8.5.4]nonadecan-17-ylidene]acetamide
DM5WZ0O CA CAS 736992-12-4
DM5WZ0O DE Bacterial infection
DM32UOC ID DM32UOC
DM32UOC DN EDP-938
DM32UOC HS Phase 2
DM32UOC CP Enanta Pharmaceuticals
DM32UOC DT Small molecular drug
DM32UOC DE Respiratory syncytial virus infection
DMX4RSD ID DMX4RSD
DMX4RSD DN EFEGATRAN SULFATE HYDRATE
DMX4RSD HS Phase 2
DMX4RSD SN Efegatran sulfate hydrate < Rec INNM; N-Methyl-D-phenylalanyl-L-prolyl-L-arginal sulfate hydrate; N-Methyl-D-phenylalanyl-N-[4-guanidino-1(S)-formylbutyl]-L-prolinamide sulfate hydrate
DMX4RSD DT Small molecular drug
DMX4RSD PC 6918161
DMX4RSD MW 532.6
DMX4RSD FM C21H36N6O8S
DMX4RSD IC InChI=1S/C21H32N6O3.H2O4S.H2O/c1-24-17(13-15-7-3-2-4-8-15)20(30)27-12-6-10-18(27)19(29)26-16(14-28)9-5-11-25-21(22)23;1-5(2,3)4;/h2-4,7-8,14,16-18,24H,5-6,9-13H2,1H3,(H,26,29)(H4,22,23,25);(H2,1,2,3,4);1H2/t16-,17+,18-;;/m0../s1
DMX4RSD CS CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O.O.OS(=O)(=O)O
DMX4RSD IK JJJFZLGPEFEADH-VWRRVXQQSA-N
DMX4RSD IU (2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid;hydrate
DMX4RSD DE Myocardial infarction
DMX6RZG ID DMX6RZG
DMX6RZG DN EFT508
DMX6RZG HS Phase 2
DMX6RZG SN Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
DMX6RZG CP eFFECTOR Therapeutics San Diego, CA
DMX6RZG PC 118598754
DMX6RZG MW 340.4
DMX6RZG FM C17H20N6O2
DMX6RZG IC InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)
DMX6RZG CS CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3
DMX6RZG IK HKTBYUWLRDZAJK-UHFFFAOYSA-N
DMX6RZG IU 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
DMX6RZG CA CAS 1849590-01-7
DMX6RZG DE Solid tumour/cancer; Colorectal cancer; Hepatocellular carcinoma; Lymphoma; Triple negative breast cancer
DMBHP56 ID DMBHP56
DMBHP56 DN Efungumab
DMBHP56 HS Phase 2
DMBHP56 SN Mycograb; Hsp90 mAb; Myc-123C28Y; Hsp90 mAb (cancer), NeuTec; Hsp90 mAb (Candida albicans infection/Cryptococcus neoformans meningitis), NeuTec
DMBHP56 CP University of Manchester
DMBHP56 DT Antibody
DMBHP56 DE Breast cancer
DM6L5TR ID DM6L5TR
DM6L5TR DN EGEN-001
DM6L5TR HS Phase 2
DM6L5TR CP EGEN
DM6L5TR DE Ovarian cancer; Peritoneal cancer; Fallopian tube cancer
DMN1SWB ID DMN1SWB
DMN1SWB DN EGS-21
DMN1SWB HS Phase 2
DMN1SWB SN Glucocerebroside, Enzo; Glucosylceramide, Enzo Biochem
DMN1SWB CP Enzo Biochem Inc
DMN1SWB DT Small molecular drug
DMN1SWB PC 6475228
DMN1SWB MW 812.3
DMN1SWB FM C48H93NO8
DMN1SWB IC InChI=1S/C48H93NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,41-43,45-48,50-51,53-55H,3-34,36,38-40H2,1-2H3,(H,49,52)/b37-35+/t41-,42+,43+,45+,46-,47+,48+/m0/s1
DMN1SWB CS CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O
DMN1SWB IK POQRWMRXUOPCLD-GZXCKHLVSA-N
DMN1SWB IU N-[(E,2S,3R)-3-hydroxy-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide
DMN1SWB CB CHEBI:84744
DMN1SWB DE Crohn disease
DML7WP0 ID DML7WP0
DML7WP0 DN Eldacimibe
DML7WP0 HS Phase 2
DML7WP0 SN ACA-147; WAY-ACA-147
DML7WP0 CP Wyeth
DML7WP0 DT Small molecular drug
DML7WP0 PC 170321
DML7WP0 MW 634.9
DML7WP0 FM C39H58N2O5
DML7WP0 IC InChI=1S/C39H58N2O5/c1-13-14-15-16-21-41(25-27-19-17-26(18-20-27)24-36(2,3)4)33(31-34(43)45-39(11,12)46-35(31)44)40-28-22-29(37(5,6)7)32(42)30(23-28)38(8,9)10/h17-20,22-23,40,42H,13-16,21,24-25H2,1-12H3
DML7WP0 CS CCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=C2C(=O)OC(OC2=O)(C)C)NC3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C
DML7WP0 IK HGLFNRGXRCKGSW-UHFFFAOYSA-N
DML7WP0 IU 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-hexylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione
DML7WP0 CA CAS 141993-70-6
DML7WP0 DE Hyperlipidaemia
DMCSXI4 ID DMCSXI4
DMCSXI4 DN Elezanumab
DMCSXI4 HS Phase 2
DMCSXI4 CP AbbVie
DMCSXI4 DT Antibody
DMCSXI4 DE Multiple sclerosis; Spinal cord injury
DMIOGZM ID DMIOGZM
DMIOGZM DN ELIPRODIL
DMIOGZM HS Phase 2
DMIOGZM SN Eliprodil; 119431-25-3; Eliprodil [INN]; C20H23ClFNO; SL 820715; SL 82-0715; CHEMBL28564; alpha-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol; NCGC00092329-02; 1-Piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-; DSSTox_RID_81089; DSSTox_CID_25744; DSSTox_GSID_45744; 1-(4-Chlorophenyl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanol; (+-)-alpha-(p-Chlorophenyl)-4-(p-fluorobenzyl)-1-piperidineethanol; 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
DMIOGZM DT Small molecular drug
DMIOGZM PC 60703
DMIOGZM MW 347.9
DMIOGZM FM C20H23ClFNO
DMIOGZM IC InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
DMIOGZM CS C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O
DMIOGZM IK GGUSQTSTQSHJAH-UHFFFAOYSA-N
DMIOGZM IU 1-(4-chlorophenyl)-2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethanol
DMIOGZM CA CAS 119431-25-3
DMIOGZM CB CHEBI:91784
DMIOGZM DE Multiple sclerosis
DMB38KH ID DMB38KH
DMB38KH DN Elisidepsin
DMB38KH HS Phase 2
DMB38KH SN Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar
DMB38KH CP PharmaMar SA
DMB38KH PC 9855343
DMB38KH MW 1477.9
DMB38KH FM C75H124N14O16
DMB38KH IC InChI=1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1
DMB38KH CS CC[C@H](C)CCC(=O)N[C@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]2[C@H](OC(=O)[C@@H](NC(=O)/C(=C/C)/NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)[C@@H](C)CC)C(C)C)CC3=CC=CC=C3)C(C)C)C
DMB38KH IK ZNVCPJPCKSJWDH-UCTDCHLSSA-N
DMB38KH IU (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2R)-3-methyl-2-[[(4S)-4-methylhexanoyl]amino]butanoyl]amino]butanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxamide
DMB38KH CB CHEBI:83152
DMB38KH DE Psoriasis vulgaris
DMR50I7 ID DMR50I7
DMR50I7 DN Elsamitrucin
DMR50I7 HS Phase 2
DMR50I7 SN Elsamicin; Elsamitrucina; Elsamitrucine; Elsamitrucinum; Chartreusin analog; Elsamicin A; Antibiotic BBM 2478A; BBM 2478A; BMY 28090; SPI 28090; BBM-2478A; BMS-181171; BMY-28090; BU-2478A; Elsamitrucin [USAN:INN]; Elsamitrucina [INN-Spanish]; Elsamitrucine [INN-French]; Elsamitrucinum [INN-Latin]; E-87/025; 10-O-Elsaminosylelsarosylchartarin; 2-Amino-2,6-dideoxy-3-O-methyl-D-galactose
DMR50I7 CP Spectrum
DMR50I7 DT Small molecular drug
DMR50I7 PC 5362259
DMR50I7 MW 653.6
DMR50I7 FM C33H35NO13
DMR50I7 IC InChI=1S/C33H35NO13/c1-11-9-10-16-19-17(11)29(38)46-25-18-14(24(36)21(20(19)25)30(39)44-16)7-6-8-15(18)45-32-28(33(4,40)27(37)13(3)43-32)47-31-22(34)26(41-5)23(35)12(2)42-31/h6-10,12-13,22-23,26-28,31-32,35-37,40H,34H2,1-5H3/t12-,13-,22-,23+,26-,27+,28+,31-,32+,33+/m1/s1
DMR50I7 CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@H]2[C@@H](O[C@@H]([C@@H]([C@]2(C)O)O)C)OC3=CC=CC4=C3C5=C6C7=C(C=CC(=C7C(=O)O5)C)OC(=O)C6=C4O)N)OC)O
DMR50I7 IK MGQRRMONVLMKJL-KWJIQSIXSA-N
DMR50I7 IU 3-[(2S,3R,4S,5S,6R)-3-[(2R,3R,4R,5S,6R)-3-amino-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-8-hydroxy-15-methyl-11,18-dioxapentacyclo[10.6.2.02,7.09,19.016,20]icosa-1(19),2(7),3,5,8,12(20),13,15-octaene-10,17-dione
DMR50I7 CA CAS 97068-30-9
DMR50I7 DE Solid tumour/cancer
DMB7CPG ID DMB7CPG
DMB7CPG DN Elsiglutide
DMB7CPG HS Phase 2
DMB7CPG SN Tide ZP-1846; ZP-1846; GLP-2 analog (chemotherapy-induced diarrhoea), Zealand Pharma
DMB7CPG CP Zealand Pharma A/S
DMB7CPG DE Diarrhea
DMYOUB6 ID DMYOUB6
DMYOUB6 DN EMA-401
DMYOUB6 HS Phase 2
DMYOUB6 SN Neuropathic pain targeting small molecules (postherpetic neuralgia), Spinifex
DMYOUB6 CP Spinifex pharmaceuticals
DMYOUB6 DT Small molecular drug
DMYOUB6 PC 9937291
DMYOUB6 MW 507.6
DMYOUB6 FM C32H29NO5
DMYOUB6 IC InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
DMYOUB6 CS COC1=C(C2=C(CN([C@@H](C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5
DMYOUB6 IK GHBCIXGRCZIPNQ-MHZLTWQESA-N
DMYOUB6 IU (3S)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMYOUB6 CA CAS 1316755-16-4
DMYOUB6 DE Postherpetic neuralgia; Peripheral neuropathy
DMCLT2F ID DMCLT2F
DMCLT2F DN Emepepimut-S
DMCLT2F HS Phase 2
DMCLT2F CP EMD Serono; Oncothyreon
DMCLT2F DT Vaccine
DMCLT2F DE Non-small-cell lung cancer
DMT4MKF ID DMT4MKF
DMT4MKF DN Emibetuzumab
DMT4MKF HS Phase 2
DMT4MKF CP Eli Lilly Indianapolis, IN
DMT4MKF DE Solid tumour/cancer
DMQH1NV ID DMQH1NV
DMQH1NV DN Emivirine
DMQH1NV HS Phase 2
DMQH1NV SN Emivirine; Coactinon; MKC-442; 149950-60-7; I-EBU; 6-Benzyl-1-(ethoxymethyl)-5-isopropyluracil; 1EtOMe6Bz5i-Pr-U; Emivirine [USAN:INN]; Mkc 442; UNII-X87G8IX72O; 6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYL URACIL; DRG-0302; CHEMBL35033; X87G8IX72O; CHEBI:44143; 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil; 6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione; 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)
DMQH1NV DT Small molecular drug
DMQH1NV PC 65013
DMQH1NV MW 302.37
DMQH1NV FM C17H22N2O3
DMQH1NV IC InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)
DMQH1NV CS CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2
DMQH1NV IK MLILORUFDVLTSP-UHFFFAOYSA-N
DMQH1NV IU 6-benzyl-1-(ethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione
DMQH1NV CA CAS 149950-60-7
DMQH1NV CB CHEBI:44143
DMQH1NV DE Human immunodeficiency virus infection
DMDEL3F ID DMDEL3F
DMDEL3F DN EMZ701
DMDEL3F HS Phase 2
DMDEL3F SN Interferon enhancing therapy
DMDEL3F CP Transition Therapeutics
DMDEL3F DE Hepatitis B virus infection
DMGFZOL ID DMGFZOL
DMGFZOL DN Enadoline
DMGFZOL HS Phase 2
DMGFZOL SN ENADOLINE; 124378-77-4; UNII-KJL283326C; CI-977; 2-(Benzofuran-4-yl)-N-methyl-N-((5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]decan-8-yl)acetamide; CHEMBL318859; KJL283326C; CI 977; 4-Benzofuranacetamide, N-methyl-N-((5R,7S,8S)-7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-; [3H]enadoline; Enadoline [INN]; [3H]-enadoline; C24H32N2O3; 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[45]decan-8-yl]acetamide; [3H]CI977; [3H]CI-977; [3H]-CI977; AC1L1TVT; AC1Q5HUV; DSSTox_CID_27258; DSSTox_RID_82216; Enadoline hydrochloride; PD-129290
DMGFZOL CP Parke-Davis & Co
DMGFZOL DT Small molecular drug
DMGFZOL PC 60768
DMGFZOL MW 396.5
DMGFZOL FM C24H32N2O3
DMGFZOL IC InChI=1S/C24H32N2O3/c1-25(23(27)16-18-6-4-7-22-19(18)9-15-28-22)20-8-11-24(10-5-14-29-24)17-21(20)26-12-2-3-13-26/h4,6-7,9,15,20-21H,2-3,5,8,10-14,16-17H2,1H3/t20-,21-,24-/m0/s1
DMGFZOL CS CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=C5C=COC5=CC=C4
DMGFZOL IK JMBYBVLCYODBJQ-HFMPRLQTSA-N
DMGFZOL IU 2-(1-benzofuran-4-yl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
DMGFZOL CA CAS 124378-77-4
DMGFZOL DE Pain
DMM8Z3Q ID DMM8Z3Q
DMM8Z3Q DN Encequidar
DMM8Z3Q HS Phase 2
DMM8Z3Q SN 849675-66-7; HM-30181-A; HM-30181; HM30181; UNII-K4I4I996O4; K4I4I996O4; 849675-66-7 (free base); HM 30181A; N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; HM30181A; Encequidar [USAN]; HM-30181A; Encequidar (USAN/INN); HM-30181 free base; CHEMBL4594298; SCHEMBL13822558; EX-A3429A; BCP25240; MFCD25976625; WHO 10861; ZINC68014383; CS-6194; DB14070; SB18921; 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide; AS-35283; HY-13646; D11782; Q27281950; 4-oxo-4H-chromen-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide; 4H-1-Benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-; N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide; N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
DMM8Z3Q CP Athenex Oncology
DMM8Z3Q DT Small molecular drug
DMM8Z3Q PC 11399764
DMM8Z3Q MW 688.7
DMM8Z3Q FM C38H36N6O7
DMM8Z3Q IC InChI=1S/C38H36N6O7/c1-47-32-17-24-14-16-43(22-25(24)18-33(32)48-2)15-13-23-9-11-26(12-10-23)44-41-37(40-42-44)28-19-34(49-3)35(50-4)20-29(28)39-38(46)36-21-30(45)27-7-5-6-8-31(27)51-36/h5-12,17-21H,13-16,22H2,1-4H3,(H,39,46)
DMM8Z3Q CS COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)N4N=C(N=N4)C5=CC(=C(C=C5NC(=O)C6=CC(=O)C7=CC=CC=C7O6)OC)OC)OC
DMM8Z3Q IK AHJUHHDDCJQACA-UHFFFAOYSA-N
DMM8Z3Q IU N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
DMM8Z3Q CA CAS 849675-66-7
DMM8Z3Q DE Metastatic breast cancer
DM8NLDI ID DM8NLDI
DM8NLDI DN Endostatin
DM8NLDI HS Phase 2
DM8NLDI CP EntreMed
DM8NLDI PC 187888
DM8NLDI MW 178.19
DM8NLDI FM C9H10N2O2
DM8NLDI IC InChI=1S/C9H10N2O2/c1-11(10-13)7-9(12)8-5-3-2-4-6-8/h2-6H,7H2,1H3
DM8NLDI CS CN(CC(=O)C1=CC=CC=C1)N=O
DM8NLDI IK AAFYOVPTFNNVDN-UHFFFAOYSA-N
DM8NLDI IU N-methyl-N-phenacylnitrous amide
DM8NLDI CA CAS 55984-52-6
DM8NLDI DE Solid tumour/cancer
DMTX8IZ ID DMTX8IZ
DMTX8IZ DN Endoxifen
DMTX8IZ HS Phase 2
DMTX8IZ SN Endoxifen (topical formulation, cancer); Endoxifen (topical formulation, cancer), Jina Pharmaceuticals; Tamoxifen metabolite (topical formulation, cancer), Jina Pharmaceuticals
DMTX8IZ CP Jina Pharmaceuticals Inc
DMTX8IZ DT Small molecular drug
DMTX8IZ PC 10090750
DMTX8IZ MW 373.5
DMTX8IZ FM C25H27NO2
DMTX8IZ IC InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-
DMTX8IZ CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3
DMTX8IZ IK MHJBZVSGOZTKRH-IZHYLOQSSA-N
DMTX8IZ IU 4-[(Z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMTX8IZ CA CAS 112093-28-4
DMTX8IZ CB CHEBI:80555
DMTX8IZ DE Breast cancer
DMMIHSO ID DMMIHSO
DMMIHSO DN ENERGI-F701
DMMIHSO HS Phase 2
DMMIHSO CP Energenesis Biomedical
DMMIHSO DT Small molecular drug
DMMIHSO DE Alopecia
DM96NCR ID DM96NCR
DM96NCR DN Eniluracil
DM96NCR HS Phase 2
DM96NCR SN Eniluracil; 5-ETHYNYLURACIL; 59989-18-3; 5-ethynylpyrimidine-2,4(1H,3H)-dione; Compound 776C; GW776C85; 5-Ethynylpyrimidine-2,4-diol; 776C85; UNII-2E2W0W5XIU; 5-ethynyl-1H-pyrimidine-2,4-dione; 5-Ethynyl-2,4(1H,3H)-pyrimidinedione; 5-Ethynyl-4-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-6-hydroxypyrimidin-2(1H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(3H)-one; 5-Ethynyl-2-hydroxypyrimidin-4(1H)-one; 5-Ethynyl-2,4(1H,3H)pyrimidinedione; 2E2W0W5XIU; 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-; CHEMBL355200; C6H4N2O2; Eniluracil [USAN]
DM96NCR CP Adherex Technologies
DM96NCR DT Small molecular drug
DM96NCR PC 43157
DM96NCR MW 136.11
DM96NCR FM C6H4N2O2
DM96NCR IC InChI=1S/C6H4N2O2/c1-2-4-3-7-6(10)8-5(4)9/h1,3H,(H2,7,8,9,10)
DM96NCR CS C#CC1=CNC(=O)NC1=O
DM96NCR IK JOZGNYDSEBIJDH-UHFFFAOYSA-N
DM96NCR IU 5-ethynyl-1H-pyrimidine-2,4-dione
DM96NCR CA CAS 59989-18-3
DM96NCR DE Hyperlipidaemia
DMJZVPB ID DMJZVPB
DMJZVPB DN ENMD-2076
DMJZVPB HS Phase 2
DMJZVPB SN ENMD-2076; 934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159
DMJZVPB CP Entremed
DMJZVPB DT Small molecular drug
DMJZVPB PC 16041424
DMJZVPB MW 375.5
DMJZVPB FM C21H25N7
DMJZVPB IC InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+
DMJZVPB CS CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C
DMJZVPB IK BLQYVHBZHAISJM-CMDGGOBGSA-N
DMJZVPB IU 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine
DMJZVPB CA CAS 934353-76-1
DMJZVPB DE Acute myeloid leukaemia; Fibrolamellar liver cancer; Hepatocellular carcinoma; Triple negative breast cancer
DMDS20X ID DMDS20X
DMDS20X DN Enoblituzumab
DMDS20X HS Phase 2
DMDS20X CP MacroGenics Rockville, MD
DMDS20X DE Solid tumour/cancer; Prostate cancer
DMLPRZJ ID DMLPRZJ
DMLPRZJ DN Ensaculin hydrochloride
DMLPRZJ HS Phase 2
DMLPRZJ SN Anseculin hydrochloride; Ensaculin hydrochloride; KA-672.HCl; 7-Methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethyl-2H-1-benzopyran-2-one hydrochloride
DMLPRZJ DT Small molecular drug
DMLPRZJ PC 6918282
DMLPRZJ MW 489
DMLPRZJ FM C26H33ClN2O5
DMLPRZJ IC InChI=1S/C26H32N2O5.ClH/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3;/h5-6,8-9,16-17H,7,10-15H2,1-4H3;1H
DMLPRZJ CS CC1=C(C(=O)OC2=CC(=C(C=C12)OCCCN3CCN(CC3)C4=CC=CC=C4OC)OC)C.Cl
DMLPRZJ IK XMONKHCPLIYQCY-UHFFFAOYSA-N
DMLPRZJ IU 7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one;hydrochloride
DMLPRZJ DE Parkinson disease
DM69NF1 ID DM69NF1
DM69NF1 DN EP-101
DM69NF1 HS Phase 2
DM69NF1 SN 106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; EP-101; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409
DM69NF1 CP Elevation Pharmaceuticals
DM69NF1 DT Small molecular drug
DM69NF1 PC 7832
DM69NF1 MW 124.18
DM69NF1 FM C8H12O
DM69NF1 IC InChI=1S/C8H12O/c1-2-6-3-4-7-8(5-6)9-7/h2,6-8H,1,3-5H2
DM69NF1 CS C=CC1CCC2C(C1)O2
DM69NF1 IK SLJFKNONPLNAPF-UHFFFAOYSA-N
DM69NF1 IU 3-ethenyl-7-oxabicyclo[4.1.0]heptane
DM69NF1 CA CAS 106-86-5
DM69NF1 DE Chronic obstructive pulmonary disease; Breast cancer
DMPC4EK ID DMPC4EK
DMPC4EK DN EP-217609
DMPC4EK HS Phase 2
DMPC4EK SN Neutralizable NAPAP analog (thrombosis), Endotis; Neutralizable NAPAP analog (thrombosis), Organon; Fondaparinux analog + thrombin inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Endotis; Neutralizable Factor IIa/Factor X dual inhibitor (thrombosis), Organon
DMPC4EK CP Organon BioSciences
DMPC4EK PC 11686894
DMPC4EK MW 2647.8
DMPC4EK FM C95H151N11O59S8
DMPC4EK IC InChI=1S/C95H151N11O59S8/c1-48-41-57(138-4)49(2)50(3)83(48)167(118,119)105-54(86(111)102-55(87(112)106-32-18-13-19-33-106)42-51-25-27-52(28-26-51)84(96)97)43-64(109)99-30-20-24-63(108)101-53(21-16-17-29-98-62(107)23-15-14-22-61-65-56(47-166-61)103-95(117)104-65)85(110)100-31-34-147-35-36-148-37-38-149-39-40-150-66-58(44-151-168(120,121)122)155-91(78(143-9)69(66)139-5)159-73-71(141-7)80(145-11)93(162-76(73)88(113)114)158-68-60(46-153-170(126,127)128)156-94(82(165-173(135,136)137)75(68)163-171(129,130)131)160-74-72(142-8)79(144-10)92(161-77(74)89(115)116)157-67-59(45-152-169(123,124)125)154-90(146-12)81(70(67)140-6)164-172(132,133)134/h25-28,41,53-56,58-61,65-82,90-94,105H,13-24,29-40,42-47H2,1-12H3,(H3,96,97)(H,98,107)(H,99,109)(H,100,110)(H,101,108)(H,102,111)(H,113,114)(H,115,116)(H2,103,104,117)(H,120,121,122)(H,123,124,125)(H,126,127,128)(H,129,130,131)(H,132,133,134)(H,135,136,137)/t53-,54-,55+,56-,58+,59+,60+,61-,65-,66+,67+,68+,69-,70-,71-,72-,73-,74-,75-,76-,77+,78+,79+,80+,81+,82+,90-,91+,92+,93+,94+/m0/s1
DMPC4EK CS CC1=CC(=C(C(=C1S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)N[C@@H](CCCCNC(=O)CCCC[C@H]2[C@@H]3[C@H](CS2)NC(=O)N3)C(=O)NCCOCCOCCOCCO[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4OC)OC)O[C@H]5[C@@H]([C@H]([C@@H](O[C@@H]5C(=O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]7[C@@H]([C@H]([C@@H](O[C@H]7C(=O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8OC)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)C(=O)N[C@H](CC9=CC=C(C=C9)C(=N)N)C(=O)N1CCCCC1)C)C)OC
DMPC4EK IK QIBHGITUGYXJDF-UDLCEBFESA-N
DMPC4EK IU (2S,3S,4S,5R,6R)-3-[(2R,3R,4S,5R,6R)-5-[2-[2-[2-[2-[[(2S)-6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-2-[4-[[(3S)-4-[[(2R)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]amino]-3-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]-4-oxobutanoyl]amino]butanoylamino]hexanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]-3,4-dimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-6-[(2R,3R,4S,5R,6S)-4,6-dimethoxy-5-sulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxyoxane-2-carboxylic acid
DMPC4EK CA CAS 894494-99-6
DMPC4EK DE Thrombosis
DMZT7EP ID DMZT7EP
DMZT7EP DN EPI 589
DMZT7EP HS Phase 2
DMZT7EP SN (R)-troloxamide quinone; EPI-589
DMZT7EP CP BioElectron Technology Mountain View, CA Sumitomo Dainippon Pharma Osaka, Japan
DMZT7EP DE Amyotrophic lateral sclerosis; Parkinson disease
DMWK26Q ID DMWK26Q
DMWK26Q DN EPX-200
DMWK26Q HS Phase 2
DMWK26Q CP Epygenix Therapeutics Paramus, NJ
DMWK26Q DE Dravet syndrome
DMUXDGZ ID DMUXDGZ
DMUXDGZ DN EPX-300
DMUXDGZ HS Phase 2
DMUXDGZ CP Epygenix Therapeutics Paramus, NJ
DMD4YRG ID DMD4YRG
DMD4YRG DN EQ-917
DMD4YRG HS Phase 2
DMD4YRG CP Equispharm Co Ltd
DMD4YRG DE Solid tumour/cancer
DMCEPUA ID DMCEPUA
DMCEPUA DN ERB-041
DMCEPUA HS Phase 2
DMCEPUA SN 2-(3-Fluoro-4-hydroxyphenyl)-7-vinylbenzoxazol-5-ol
DMCEPUA DT Small molecular drug
DMCEPUA PC 656954
DMCEPUA MW 271.24
DMCEPUA FM C15H10FNO3
DMCEPUA IC InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,18-19H,1H2
DMCEPUA CS C=CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC(=C(C=C3)O)F
DMCEPUA IK MQIMZDXIAHJKQP-UHFFFAOYSA-N
DMCEPUA IU 7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMCEPUA CA CAS 524684-52-4
DMCEPUA DE Inflammatory bowel disease
DMU1XZD ID DMU1XZD
DMU1XZD DN Erteberel
DMU1XZD HS Phase 2
DMU1XZD SN LY-500307; SERBA-1; ER beta agonist (BPH), Lilly; Lead estrogen receptor beta agonists (benign prostatic hyperplasia),Eli Lilly
DMU1XZD CP Eli Lilly & Co
DMU1XZD DT Small molecular drug
DMU1XZD PC 10286159
DMU1XZD MW 282.3
DMU1XZD FM C18H18O3
DMU1XZD IC InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1
DMU1XZD CS C1C[C@H]2[C@@H](C1)C3=C(C=CC(=C3)O)O[C@H]2C4=CC=C(C=C4)O
DMU1XZD IK XIESSJVMWNJCGZ-VKJFTORMSA-N
DMU1XZD IU (3aS,4R,9bR)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
DMU1XZD CA CAS 533884-09-2
DMU1XZD DE Prostate hyperplasia
DM5Z3VP ID DM5Z3VP
DM5Z3VP DN Ertumaxomab
DM5Z3VP HS Phase 2
DM5Z3VP SN Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
DM5Z3VP CP Trion
DM5Z3VP DT Antibody
DM5Z3VP DE Breast cancer
DMYZWDC ID DMYZWDC
DMYZWDC DN ESBA-105
DMYZWDC HS Phase 2
DMYZWDC SN ESBA-105 (ophthalmic liquid formulation); ESBA-105 (ophthalmic liquid formulation), ESBATech; Anti-cytokine single-chain antibody (inflammation), ESBATech
DMYZWDC CP ESBATech AG
DMYZWDC DT Antibody
DMYZWDC DE Ocular disease
DMTB63Q ID DMTB63Q
DMTB63Q DN Estetrol
DMTB63Q HS Phase 2
DMTB63Q SN Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer); Estetrol (oral, contraception/hormone deficiency/osteoporosis/cardiovascular disease/autoimmune disease/breast cancer/prostate cancer), Pantarhei; Estrogen receptor modulator (oral, contraception/hormone deficiency/autoimmune disease/breast cancer/prostate cancer/osteoporosis/cardiovascular disease), Pantarhei
DMTB63Q CP Pantarhei Bioscience BV
DMTB63Q DT Small molecular drug
DMTB63Q PC 27125
DMTB63Q MW 304.4
DMTB63Q FM C18H24O4
DMTB63Q IC InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1
DMTB63Q CS C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O
DMTB63Q IK AJIPIJNNOJSSQC-NYLIRDPKSA-N
DMTB63Q IU (8R,9S,13S,14S,15R,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,15,16,17-tetrol
DMTB63Q CA CAS 15183-37-6
DMTB63Q CB CHEBI:142773
DMTB63Q DE Autoimmune diabetes
DM71BZV ID DM71BZV
DM71BZV DN Etamicastat
DM71BZV HS Phase 2
DM71BZV SN BIA-5453; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), BIAL; Dopamine beta hydroxylase inhibitors (cardiovascular diseases), Portela
DM71BZV CP Portela & Ca SA
DM71BZV DT Small molecular drug
DM71BZV PC 10450387
DM71BZV MW 311.35
DM71BZV FM C14H15F2N3OS
DM71BZV IC InChI=1S/C14H15F2N3OS/c15-9-3-8-4-11(7-20-13(8)12(16)5-9)19-10(1-2-17)6-18-14(19)21/h3,5-6,11H,1-2,4,7,17H2,(H,18,21)/t11-/m1/s1
DM71BZV CS C1[C@H](COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCN
DM71BZV IK CWWWTTYMUOYSQA-LLVKDONJSA-N
DM71BZV IU 4-(2-aminoethyl)-3-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-1H-imidazole-2-thione
DM71BZV CA CAS 760173-05-5
DM71BZV DE Heart failure
DMOCID7 ID DMOCID7
DMOCID7 DN Etazolate
DMOCID7 HS Phase 2
DMOCID7 SN Etazolate hydrochloride; EHT-0202; SQ-20009
DMOCID7 CP Exonhit
DMOCID7 DT Small molecular drug
DMOCID7 PC 3277
DMOCID7 MW 289.33
DMOCID7 FM C14H19N5O2
DMOCID7 IC InChI=1S/C14H19N5O2/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2/h7-8H,5-6H2,1-4H3,(H,15,18)
DMOCID7 CS CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC
DMOCID7 IK OPQRBXUBWHDHPQ-UHFFFAOYSA-N
DMOCID7 IU ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate
DMOCID7 CA CAS 51022-77-6
DMOCID7 CB CHEBI:93135
DMOCID7 DE Neurodegenerative disorder
DM68K39 ID DM68K39
DM68K39 DN ETIPREDNOL DICLOACETATE
DM68K39 HS Phase 2
DM68K39 SN BNP-166; Cronaze (Ivax); Ethinase (Ivax); Etiprednol dicloacetate < USAN; Respicort (Ivax); (11beta,17alpha)-17-(2,2-Dichloroacetoxy)-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic acid ethyl ester
DM68K39 CP Teva Pharmaceutical USA
DM68K39 DT Small molecular drug
DM68K39 PC 9935073
DM68K39 MW 485.4
DM68K39 FM C24H30Cl2O6
DM68K39 IC InChI=1S/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24-/m0/s1
DM68K39 CS CCOC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)C(Cl)Cl
DM68K39 IK QAIOVDNCIZSSSF-RFAJLIJZSA-N
DM68K39 IU ethyl (8S,9S,10R,11S,13S,14S,17R)-17-(2,2-dichloroacetyl)oxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
DM68K39 CA CAS 199331-40-3
DM68K39 CB CHEBI:135783
DM68K39 DE Rhinitis
DMV96BY ID DMV96BY
DMV96BY DN ETS-6218
DMV96BY HS Phase 2
DMV96BY SN Antihistamine+antiviral (fibromyalgia), e-Therapeutics
DMV96BY CP E-Therapeutics Ltd
DMV96BY DE Fibromyalgia
DMZOA2L ID DMZOA2L
DMZOA2L DN ETX-9101
DMZOA2L HS Phase 2
DMZOA2L CP E-Therapeutics Ltd
DMZOA2L DE Asthma
DM1FCDH ID DM1FCDH
DM1FCDH DN EV-077
DM1FCDH HS Phase 2
DM1FCDH SN EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech
DM1FCDH CP Evolva SA
DM1FCDH DE Type-2 diabetes
DMWB94K ID DMWB94K
DMWB94K DN Evenamide
DMWB94K HS Phase 2
DMWB94K SN 1092977-61-1; 2-((3-Butoxyphenethyl)amino)-N,N-dimethylacetamide; UNII-ON5S6N53JS; ON5S6N53JS; MFCD28502433; 2-[(3-Butoxyphenethyl)amino]-N,N-dimethylacetamide; Evenamide [INN]; SCHEMBL3025285; CHEMBL3678076; 2-((2-(3-Butoxyphenyl)ethyl)amino)-N,N-dimethylacetamide; Acetamide, 2-((2-(3-butoxyphenyl)ethyl)amino)-N,N-dimethyl-; BDBM161090; NW-3509; SB18910; AS-48527; HY-17612; SY244487; CS-0014697; Q21098995; 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide; US9051240, 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide
DMWB94K CP Newron Pharmaceuticals
DMWB94K DT Small molecular drug
DMWB94K PC 25105689
DMWB94K MW 278.39
DMWB94K FM C16H26N2O2
DMWB94K IC InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
DMWB94K CS CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C
DMWB94K IK GRHBODILPPXVKN-UHFFFAOYSA-N
DMWB94K IU 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
DMWB94K CA CAS 1092977-61-1
DMWB94K DE Schizophrenia
DM8QXEY ID DM8QXEY
DM8QXEY DN Evt201
DM8QXEY HS Phase 2
DM8QXEY CP Evotec
DM8QXEY DT Small molecular drug
DM8QXEY DE Sleep-wake disorder
DMQGBM1 ID DMQGBM1
DMQGBM1 DN EVT-201
DMQGBM1 HS Phase 2
DMQGBM1 SN IDDBCP221837
DMQGBM1 CP Roche Holding AG
DMQGBM1 PC 9885841
DMQGBM1 MW 372.8
DMQGBM1 FM C17H17ClN6O2
DMQGBM1 IC InChI=1S/C17H17ClN6O2/c1-22(2)8-13-20-16(21-26-13)15-12-7-23(3)17(25)14-10(18)5-4-6-11(14)24(12)9-19-15/h4-6,9H,7-8H2,1-3H3
DMQGBM1 CS CN1CC2=C(N=CN2C3=C(C1=O)C(=CC=C3)Cl)C4=NOC(=N4)CN(C)C
DMQGBM1 IK JCYLWUVDHLVGER-UHFFFAOYSA-N
DMQGBM1 IU 7-chloro-3-[5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl]-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMQGBM1 CA CAS 308239-86-3
DMQGBM1 DE Insomnia
DM73XNG ID DM73XNG
DM73XNG DN EVT302
DM73XNG HS Phase 2
DM73XNG CP Evotec Princeton, NJ
DM73XNG DE Alzheimer disease
DM4FBUH ID DM4FBUH
DM4FBUH DN EXC 001
DM4FBUH HS Phase 2
DM4FBUH CP ISIS Pharm; Excaliard
DM4FBUH DT Antisense drug
DM4FBUH DE Fibrosis
DMC1I56 ID DMC1I56
DMC1I56 DN Exherin
DMC1I56 HS Phase 2
DMC1I56 SN Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541
DMC1I56 CP Adherex Technol.
DMC1I56 TC Anticancer Agents
DMC1I56 DT Small molecular drug
DMC1I56 PC 9916058
DMC1I56 MW 570.7
DMC1I56 FM C22H34N8O6S2
DMC1I56 IC InChI=1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)/t11-,14-,15-,16-,17-/m0/s1
DMC1I56 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C
DMC1I56 IK FQVLRGLGWNWPSS-BXBUPLCLSA-N
DMC1I56 IU (4R,7S,10S,13S,16R)-16-acetamido-13-(1H-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMC1I56 CA CAS 229971-81-7
DMC1I56 DE Solid tumour/cancer
DM5PBLM ID DM5PBLM
DM5PBLM DN EYP001
DM5PBLM HS Phase 2
DM5PBLM SN Vonafexor; 1192171-69-9; UNII-XG6DG6A1UN; XG6DG6A1UN; 4-chloro-5-[4-(2,6-dichlorobenzene-1-; sulfonyl)piperazin-1-yl]-1-benzofuran-2-carboxylic acid; Vonafexor [INN]; SCHEMBL1893285; Vonafexor(PLX007,EYP-001); BCP33693; EX-A4037; EYP001;EYP 001;EYP-001; HY-109197; CS-0119143; 2-Benzofurancarboxylic acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-; 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid
DM5PBLM CP ENYO Pharma
DM5PBLM DT Small molecular drug
DM5PBLM PC 67202717
DM5PBLM MW 489.8
DM5PBLM FM C19H15Cl3N2O5S
DM5PBLM IC InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26)
DM5PBLM CS C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl
DM5PBLM IK XLGQSYUNOIJBNR-UHFFFAOYSA-N
DM5PBLM IU 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid
DM5PBLM CA CAS 1192171-69-9
DM5PBLM DE Non-alcoholic steatohepatitis
DM2L9CO ID DM2L9CO
DM2L9CO DN Ezatiostat
DM2L9CO HS Phase 2
DM2L9CO SN Telintra (TN)
DM2L9CO CP Telik
DM2L9CO DT Small molecular drug
DM2L9CO PC 5310939
DM2L9CO MW 529.6
DM2L9CO FM C27H35N3O6S
DM2L9CO IC InChI=1S/C27H35N3O6S/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32)/t21-,22-,24+/m0/s1
DM2L9CO CS CCOC(=O)[C@H](CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@H](C2=CC=CC=C2)C(=O)OCC)N
DM2L9CO IK GWEJFLVSOGNLSS-WPFOTENUSA-N
DM2L9CO IU ethyl (2S)-2-amino-5-[[(2R)-3-benzylsulfanyl-1-[[(1R)-2-ethoxy-2-oxo-1-phenylethyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoate
DM2L9CO CA CAS 168682-53-9
DM2L9CO DE Myelodysplastic syndrome
DMJ4BKT ID DMJ4BKT
DMJ4BKT DN F-16-IL-2 fusion protein
DMJ4BKT HS Phase 2
DMJ4BKT SN Teleukin; F-16-IL-2; F-16-IL-2 fusion protein (cancer); F-16-IL-2 fusion protein (cancer), Philogen
DMJ4BKT CP Philogen SpA
DMJ4BKT DE Solid tumour/cancer
DMKP3SJ ID DMKP3SJ
DMKP3SJ DN F-351
DMKP3SJ HS Phase 2
DMKP3SJ SN Liver cirrhosis, Gene Networks International; Liver cirrhosis, Shanghai; Liver fibrosis therapy, Shanghai Genomics; Liver fibrosis, Gene Networks International; Liver fibrosis, Shanghai
DMKP3SJ CP GNI Ltd
DMKP3SJ DT Small molecular drug
DMKP3SJ PC 11217901
DMKP3SJ MW 201.22
DMKP3SJ FM C12H11NO2
DMKP3SJ IC InChI=1S/C12H11NO2/c1-9-2-7-12(15)13(8-9)10-3-5-11(14)6-4-10/h2-8,14H,1H3
DMKP3SJ CS CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O
DMKP3SJ IK NETTXQJYJRFTFS-UHFFFAOYSA-N
DMKP3SJ IU 1-(4-hydroxyphenyl)-5-methylpyridin-2-one
DMKP3SJ CA CAS 851518-71-3
DMKP3SJ DE Liver disease
DM6UQNW ID DM6UQNW
DM6UQNW DN F4co vaccine
DM6UQNW HS Phase 2
DM6UQNW SN F4co vaccine (AIDS/HIV infection)
DM6UQNW CP GlaxoSmithKline plc
DM6UQNW DT Vaccine
DM6UQNW DE Human immunodeficiency virus infection
DMDNJ18 ID DMDNJ18
DMDNJ18 DN F-627
DMDNJ18 HS Phase 2
DMDNJ18 SN Recombinant human G-CSF dimer (neutropenia), Generon (Shanghai) Corporation Ltd
DMDNJ18 CP Generon
DMDNJ18 DE Neutropenia
DMBFPO1 ID DMBFPO1
DMBFPO1 DN F-8-IL-10 fusion protein
DMBFPO1 HS Phase 2
DMBFPO1 SN Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen
DMBFPO1 CP Pfizer
DMBFPO1 DE Endometriosis; Inflammatory bowel disease; Rheumatoid arthritis
DM2CUS0 ID DM2CUS0
DM2CUS0 DN F901318
DM2CUS0 HS Phase 2
DM2CUS0 SN Olorofim; F-901318; UNII-T34SH2H9HI; T34SH2H9HI; 1928707-56-5; 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide; CHEMBL4297609; SCHEMBL17767345; BCP25872; BDBM50526857; DB15245; SB19827; F901318; F 901318; Olorofim; HY-104029; CS-0025660; Q27896127; CN1C(=C(C=C1C)C1=CC=CC=C1)C(C(=O)NC1=CC=C(C=C1)N1CCN(CC1)C1=NC=C(C=N1)F)=O; 1H-Pyrrole-2-acetamide, N-(4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)phenyl)-1,5-dimethyl-alpha-oxo-3-phenyl-; 2-(1,5-Dimethyl-3-phenyl-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxo-acetamide
DM2CUS0 CP F2G
DM2CUS0 DT Small molecular drug
DM2CUS0 PC 91885568
DM2CUS0 MW 498.6
DM2CUS0 FM C28H27FN6O2
DM2CUS0 IC InChI=1S/C28H27FN6O2/c1-19-16-24(20-6-4-3-5-7-20)25(33(19)2)26(36)27(37)32-22-8-10-23(11-9-22)34-12-14-35(15-13-34)28-30-17-21(29)18-31-28/h3-11,16-18H,12-15H2,1-2H3,(H,32,37)
DM2CUS0 CS CC1=CC(=C(N1C)C(=O)C(=O)NC2=CC=C(C=C2)N3CCN(CC3)C4=NC=C(C=N4)F)C5=CC=CC=C5
DM2CUS0 IK SUFPWYYDCOKDLL-UHFFFAOYSA-N
DM2CUS0 IU 2-(1,5-dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide
DM2CUS0 CA CAS 1928707-56-5
DM2CUS0 DE Fungal infection
DMXB6KG ID DMXB6KG
DMXB6KG DN FAD-104
DMXB6KG HS Phase 2
DMXB6KG SN ME-2303; (8S,10S)-8-(6-Carboxyhexanoyloxyacetyl)-10-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycinone-14-O-hemipimelate; 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)pimelyladryamycinone
DMXB6KG DT Small molecular drug
DMXB6KG PC 115362
DMXB6KG MW 704.6
DMXB6KG FM C34H37FO15
DMXB6KG IC InChI=1S/C34H37FO15/c1-14-27(40)32(45)26(35)33(49-14)50-18-12-34(46,19(36)13-48-21(39)10-5-3-4-9-20(37)38)11-16-23(18)31(44)25-24(29(16)42)28(41)15-7-6-8-17(47-2)22(15)30(25)43/h6-8,14,18,26-27,32-33,40,42,44-46H,3-5,9-13H2,1-2H3,(H,37,38)/t14-,18-,26+,27+,32-,33-,34-/m0/s1
DMXB6KG CS C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCCCC(=O)O)O)F)O)O
DMXB6KG IK PQMIPLRIRFVQJZ-QBYYVRQOSA-N
DMXB6KG IU 7-[2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethoxy]-7-oxoheptanoic acid
DMXB6KG CA CAS 116521-53-0
DMXB6KG DE Solid tumour/cancer
DM6RKG3 ID DM6RKG3
DM6RKG3 DN Fadolmidine
DM6RKG3 HS Phase 2
DM6RKG3 SN Fadolmidine hydrochloride; MPV-2426
DM6RKG3 CP Orion Corp
DM6RKG3 DT Small molecular drug
DM6RKG3 PC 6433098
DM6RKG3 MW 214.26
DM6RKG3 FM C13H14N2O
DM6RKG3 IC InChI=1S/C13H14N2O/c16-12-4-3-9-1-2-10(13(9)6-12)5-11-7-14-8-15-11/h3-4,6-8,10,16H,1-2,5H2,(H,14,15)
DM6RKG3 CS C1CC2=C(C1CC3=CN=CN3)C=C(C=C2)O
DM6RKG3 IK VTZPAJGVRWKMAG-UHFFFAOYSA-N
DM6RKG3 IU 3-(1H-imidazol-5-ylmethyl)-2,3-dihydro-1H-inden-5-ol
DM6RKG3 CA CAS 189353-31-9
DM6RKG3 DE Pain; Neuropathic pain
DMSFWT7 ID DMSFWT7
DMSFWT7 DN Famitinib
DMSFWT7 HS Phase 2
DMSFWT7 SN Receptor tyrosine kinase inhibitors (cancer); SHR-1020; Receptor tyrosine kinase inhibitors (cancer), Shanghai Hengrui; Tyrosine-kinase inhibitor (oral, cancer), Jiangsu Hengrui; C-Kit/VEGFR2/PDGFR/VEGFR3/Flt1/Flt3 inhibitor (oral, cancer), Jiangsu Hengrui
DMSFWT7 CP Shanghai Hengrui Pharmaceutical Co Ltd; Jiangsu Hengrui Medicine Co Ltd
DMSFWT7 DT Small molecular drug
DMSFWT7 PC 16662431
DMSFWT7 MW 410.5
DMSFWT7 FM C23H27FN4O2
DMSFWT7 IC InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
DMSFWT7 CS CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O)C
DMSFWT7 IK GKEYKDOLBLYGRB-LGMDPLHJSA-N
DMSFWT7 IU 5-[2-(diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one
DMSFWT7 CA CAS 945380-27-8
DMSFWT7 DE Solid tumour/cancer
DM563NC ID DM563NC
DM563NC DN Fasitibant chloride
DM563NC HS Phase 2
DM563NC SN MEN-16132; Bradykinin B2 antagonist (inflammation), Menarini; MEN-11270 analogs, Menarini
DM563NC CP The Menarini Group
DM563NC DT Small molecular drug
DM563NC PC 11535140
DM563NC MW 800.2
DM563NC FM C36H49Cl3N6O6S
DM563NC IC InChI=1S/C36H49Cl2N6O6S.ClH/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5;/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3;1H/q+1;/p-1/t29-;/m0./s1
DM563NC CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@H](CCC[N+](C)(C)C)N)Cl)C.[Cl-]
DM563NC IK ZNHJDJYKDVGQSH-JMAPEOGHSA-M
DM563NC IU [(4S)-4-amino-5-[4-[4-[[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylamino]oxane-4-carbonyl]piperazin-1-yl]-5-oxopentyl]-trimethylazanium;chloride
DM563NC DE Osteoarthritis
DMR3952 ID DMR3952
DMR3952 DN FBS-0701
DMR3952 HS Phase 2
DMR3952 SN Desferrithiocin analog (oral, iron overload), FerroKin Biosciences; Iron chelator (oral, iron overload), FerroKin Biosciences
DMR3952 CP FerroKin BioSciences Inc
DMR3952 DT Small molecular drug
DMR3952 PC 135565672
DMR3952 MW 399.5
DMR3952 FM C18H25NO7S
DMR3952 IC InChI=1S/C18H25NO7S/c1-18(17(21)22)12-27-16(19-18)13-4-3-5-14(15(13)20)26-11-10-25-9-8-24-7-6-23-2/h3-5,20H,6-12H2,1-2H3,(H,21,22)/t18-/m1/s1
DMR3952 CS C[C@@]1(CSC(=N1)C2=C(C(=CC=C2)OCCOCCOCCOC)O)C(=O)O
DMR3952 IK AWHIMFSHNAAMBM-GOSISDBHSA-N
DMR3952 IU (4S)-2-[2-hydroxy-3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]-4-methyl-5H-1,3-thiazole-4-carboxylic acid
DMR3952 CA CAS 945635-15-4
DMR3952 DE Iron overload disease
DM3CVHQ ID DM3CVHQ
DM3CVHQ DN FE-202158
DM3CVHQ HS Phase 2
DM3CVHQ SN V1a agonist (septic shock), Ferring; Vasopressin 1a agonist (septic shock), Ferring
DM3CVHQ CP Ferring Pharmaceuticals Inc
DM3CVHQ PC 53330936
DM3CVHQ MW 1048.3
DM3CVHQ FM C46H73N13O11S2
DM3CVHQ IC InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1
DM3CVHQ CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N
DM3CVHQ IK JCVQBJTWWDYUFQ-MRUTUVJXSA-N
DM3CVHQ IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-1-oxo-5-(propan-2-ylamino)pentan-2-yl]pyrrolidine-2-carboxamide
DM3CVHQ CA CAS 876296-47-8
DM3CVHQ DE Sepsis
DMDGZ1C ID DMDGZ1C
DMDGZ1C DN FE-202767
DMDGZ1C HS Phase 2
DMDGZ1C SN Oxytocin agonists (erectile dysfunction), Ferring
DMDGZ1C CP Ferring Pharmaceuticals Inc
DMDGZ1C PC 102341060
DMDGZ1C MW 1042.2
DMDGZ1C FM C48H68FN11O12S
DMDGZ1C IC InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27?,32-,33-,34-,35-,36-,42-/m0/s1
DMDGZ1C CS CCC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N(CC3=CC=C(C=C3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMDGZ1C IK PVVHQWISMVJHFK-JWKDVPIGSA-N
DMDGZ1C IU (3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-butan-2-yl-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide
DMDGZ1C DE Erectile dysfunction
DMICMXE ID DMICMXE
DMICMXE DN Ferroquine
DMICMXE HS Phase 2
DMICMXE SN Ferroquine; UNII-8D81JS19ET; 8D81JS19ET; SSR97193; Ferroquine [INN]; 185055-67-8
DMICMXE CP Sanofi
DMICMXE DT Small molecular drug
DMICMXE PC 56841801
DMICMXE MW 433.8
DMICMXE FM C23H24ClFeN3
DMICMXE IC InChI=1S/C18H19ClN3.C5H5.Fe/c1-22(2)12-14-5-3-4-13(14)11-21-17-8-9-20-18-10-15(19)6-7-16(17)18;1-2-4-5-3-1;/h4,6-10H,5,11-12H2,1-2H3,(H,20,21);1-3H,4H2;/q2*-1;+2
DMICMXE CS CN(C)CC1=C(C=[C-]C1)CNC2=C3C=CC(=CC3=NC=C2)Cl.C1C=CC=[C-]1.[Fe+2]
DMICMXE IK DLYPREQTTOHKSM-UHFFFAOYSA-N
DMICMXE IU 7-chloro-N-[[2-[(dimethylamino)methyl]cyclopenta-1,4-dien-1-yl]methyl]quinolin-4-amine;cyclopenta-1,3-diene;iron(2+)
DMICMXE CA CAS 185055-67-8
DMICMXE DE Malaria
DMJX2P4 ID DMJX2P4
DMJX2P4 DN Fezakinumab
DMJX2P4 HS Phase 2
DMJX2P4 SN Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
DMJX2P4 CP Wyeth; pfizer
DMJX2P4 DT Antibody
DMJX2P4 DE Psoriasis vulgaris
DM7RYL4 ID DM7RYL4
DM7RYL4 DN FG-2216
DM7RYL4 HS Phase 2
DM7RYL4 PC 6914666
DM7RYL4 MW 280.66
DM7RYL4 FM C12H9ClN2O4
DM7RYL4 IC InChI=1S/C12H9ClN2O4/c13-11-7-4-2-1-3-6(7)10(18)9(15-11)12(19)14-5-8(16)17/h1-4,18H,5H2,(H,14,19)(H,16,17)
DM7RYL4 CS C1=CC=C2C(=C1)C(=C(N=C2Cl)C(=O)NCC(=O)O)O
DM7RYL4 IK OUQVKRKGTAUJQA-UHFFFAOYSA-N
DM7RYL4 IU 2-[(1-chloro-4-hydroxyisoquinoline-3-carbonyl)amino]acetic acid
DM7RYL4 CA CAS 223387-75-5
DM7RYL4 DE Kidney disease
DMXMC8I ID DMXMC8I
DMXMC8I DN FGF-1
DMXMC8I HS Phase 2
DMXMC8I CP CardioVascular BioTherape.
DMXMC8I DE Coronary heart disease
DMCIGRB ID DMCIGRB
DMCIGRB DN Fialuridine
DMCIGRB HS Phase 2
DMCIGRB SN FIAU
DMCIGRB CP Oclassen Pharmaceuticals Inc
DMCIGRB DT Small molecular drug
DMCIGRB PC 50313
DMCIGRB MW 372.09
DMCIGRB FM C9H10FIN2O5
DMCIGRB IC InChI=1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5+,6-,8-/m1/s1
DMCIGRB CS C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I
DMCIGRB IK IPVFGAYTKQKGBM-BYPJNBLXSA-N
DMCIGRB IU 1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DMCIGRB CA CAS 69123-98-4
DMCIGRB DE Hepatitis B virus infection
DMG65WH ID DMG65WH
DMG65WH DN Ficlatuzumab
DMG65WH HS Phase 2
DMG65WH SN AV-299
DMG65WH CP AVEO Pharmaceuticals
DMG65WH DT Monoclonal antibody
DMG65WH DE Non-small-cell lung cancer; Multiple myeloma; Acute myeloid leukaemia; Pancreatic cancer; Squamous cell carcinoma
DMNSYXB ID DMNSYXB
DMNSYXB DN Filibuvir
DMNSYXB HS Phase 2
DMNSYXB SN Filibuvir; 877130-28-4; PF-00868554; UNII-198J479Y2L; 198J479Y2L; (6R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one; (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; Filibuvir [USAN:INN]; 3frz
DMNSYXB CP Pfizer
DMNSYXB DT Small molecular drug
DMNSYXB PC 54708673
DMNSYXB MW 503.6
DMNSYXB FM C29H37N5O3
DMNSYXB IC InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1
DMNSYXB CS CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5
DMNSYXB IK SLVAPEZTBDBAPI-GDLZYMKVSA-N
DMNSYXB IU (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one
DMNSYXB CA CAS 877130-28-4
DMNSYXB DE Hepatitis C virus infection
DMG439E ID DMG439E
DMG439E DN Fipamezole
DMG439E HS Phase 2
DMG439E SN Fipamezole; 150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole
DMG439E DT Small molecular drug
DMG439E PC 213041
DMG439E MW 230.28
DMG439E FM C14H15FN2
DMG439E IC InChI=1S/C14H15FN2/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14/h3-5,8-9H,2,6-7H2,1H3,(H,16,17)
DMG439E CS CCC1(CC2=C(C1)C=C(C=C2)F)C3=CN=CN3
DMG439E IK KXSUAWAUCNFBQJ-UHFFFAOYSA-N
DMG439E IU 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole
DMG439E CA CAS 150586-58-6
DMG439E DE Acute myeloid leukaemia
DMW2QYT ID DMW2QYT
DMW2QYT DN Firategrast
DMW2QYT HS Phase 2
DMW2QYT SN SB 683699; Firategrast (USAN); SB-683699; 2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxy-phenyl]phenyl]propanoic Acid
DMW2QYT CP GSK
DMW2QYT DT Small molecular drug
DMW2QYT PC 9935681
DMW2QYT MW 499.5
DMW2QYT FM C27H27F2NO6
DMW2QYT IC InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1
DMW2QYT CS CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC
DMW2QYT IK YLFZHHDVRSYTKT-NRFANRHFSA-N
DMW2QYT IU (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid
DMW2QYT CA CAS 402567-16-2
DMW2QYT DE Multiple sclerosis
DMJSD5W ID DMJSD5W
DMJSD5W DN FK-070
DMJSD5W HS Phase 2
DMJSD5W SN KDI-792; Kdi 792; FK 070; FK-070; AC1O5X7F; SCHEMBL8657761; JGCFJVFIRFTRKJ-YOLZMAEBSA-N; 130047-30-2; FR-121070; 167678-84-4; (2S,4R)-2-[(Z)-5-carboxy-1-pentenyl]-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)pyrrolidine hydrochloride; 5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3- pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-; 178895-18-6; (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid hydrochloride
DMJSD5W DT Small molecular drug
DMJSD5W PC 6442424
DMJSD5W MW 500.4
DMJSD5W FM C22H27Cl2N3O4S
DMJSD5W IC InChI=1S/C22H26ClN3O4S.ClH/c23-18-8-10-21(11-9-18)31(29,30)25-19-13-20(6-2-1-3-7-22(27)28)26(16-19)15-17-5-4-12-24-14-17;/h2,4-6,8-12,14,19-20,25H,1,3,7,13,15-16H2,(H,27,28);1H/b6-2-;/t19-,20-;/m1./s1
DMJSD5W CS C1[C@H](CN([C@@H]1/C=C\\CCCC(=O)O)CC2=CN=CC=C2)NS(=O)(=O)C3=CC=C(C=C3)Cl.Cl
DMJSD5W IK JGCFJVFIRFTRKJ-YOLZMAEBSA-N
DMJSD5W IU (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid;hydrochloride
DMJSD5W CA CAS 130047-30-2
DMJSD5W DE Angina pectoris
DMEL15U ID DMEL15U
DMEL15U DN FK-143
DMEL15U HS Phase 2
DMEL15U SN FK-143; Fk 143; CHEMBL25083; 163136-03-6; 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; 4-[3-[3-(bis[4-isobutylphenyl)methylamino]benzoyl]indol-1-yl]butyric acid; SCHEMBL3504489; AC1L435G; CTK0H5706; DTXSID80167524; LACIBZRFAYFTOV-UHFFFAOYSA-N; BDBM50057477; 1H-Indole-1-butanoicacid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-; 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
DMEL15U DT Small molecular drug
DMEL15U PC 178077
DMEL15U MW 600.8
DMEL15U FM C40H44N2O3
DMEL15U IC InChI=1S/C40H44N2O3/c1-27(2)23-29-14-18-31(19-15-29)39(32-20-16-30(17-21-32)24-28(3)4)41-34-10-7-9-33(25-34)40(45)36-26-42(22-8-13-38(43)44)37-12-6-5-11-35(36)37/h5-7,9-12,14-21,25-28,39,41H,8,13,22-24H2,1-4H3,(H,43,44)
DMEL15U CS CC(C)CC1=CC=C(C=C1)C(C2=CC=C(C=C2)CC(C)C)NC3=CC=CC(=C3)C(=O)C4=CN(C5=CC=CC=C54)CCCC(=O)O
DMEL15U IK LACIBZRFAYFTOV-UHFFFAOYSA-N
DMEL15U IU 4-[3-[3-[bis[4-(2-methylpropyl)phenyl]methylamino]benzoyl]indol-1-yl]butanoic acid
DMEL15U CA CAS 163136-03-6
DMEL15U DE Prostate disease
DML5AE4 ID DML5AE4
DML5AE4 DN FK-3311
DML5AE4 HS Phase 2
DML5AE4 SN 116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474
DML5AE4 CP Fujisawa Pharmaceutical Co Ltd
DML5AE4 DT Small molecular drug
DML5AE4 PC 164009
DML5AE4 MW 341.3
DML5AE4 FM C15H13F2NO4S
DML5AE4 IC InChI=1S/C15H13F2NO4S/c1-9(19)10-3-5-13(18-23(2,20)21)15(7-10)22-14-6-4-11(16)8-12(14)17/h3-8,18H,1-2H3
DML5AE4 CS CC(=O)C1=CC(=C(C=C1)NS(=O)(=O)C)OC2=C(C=C(C=C2)F)F
DML5AE4 IK DIIYLGZNZGPXRR-UHFFFAOYSA-N
DML5AE4 IU N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide
DML5AE4 CA CAS 116686-15-8
DML5AE4 DE Rheumatoid arthritis
DMKVXYS ID DMKVXYS
DMKVXYS DN FK-409
DMKVXYS HS Phase 2
DMKVXYS SN nor-3; 3-Hexenamide, 4-ethyl-2-(hydroxyimino)-5-nitro-; 92454-83-6; 163180-49-2; ACMC-20eif3; AC1OAT8P; 4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide; CTK3H0114; CTK4D1460
DMKVXYS CP Fujisawa Pharmaceutical Co Ltd
DMKVXYS DT Small molecular drug
DMKVXYS PC 6413529
DMKVXYS MW 215.21
DMKVXYS FM C8H13N3O4
DMKVXYS IC InChI=1S/C8H13N3O4/c1-3-6(5(2)11(14)15)4-7(10-13)8(9)12/h4-5,13H,3H2,1-2H3,(H2,9,12)/b6-4+,10-7-
DMKVXYS CS CC/C(=C\\C(=N\\O)\\C(=O)N)/C(C)[N+](=O)[O-]
DMKVXYS IK MZAGXDHQGXUDDX-JSRXJHBZSA-N
DMKVXYS IU (E,2Z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide
DMKVXYS CA CAS 92454-60-9
DMKVXYS DE Angina pectoris
DMGROQP ID DMGROQP
DMGROQP DN FK-505
DMGROQP HS Phase 2
DMGROQP SN FR-76505; 2-[3-(4-Bromo-2-fluorobenzyl)-7-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl]acetic acid
DMGROQP DT Small molecular drug
DMGROQP PC 3086955
DMGROQP MW 425.2
DMGROQP FM C17H11BrF2N2O4
DMGROQP IC InChI=1S/C17H11BrF2N2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
DMGROQP CS C1=CC2=C(C=C1F)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DMGROQP IK XLOHSVVOWVIPFC-UHFFFAOYSA-N
DMGROQP IU 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-fluoro-2,4-dioxoquinazolin-1-yl]acetic acid
DMGROQP CA CAS 112733-08-1
DMGROQP DE Hyperuricaemia
DMY61TJ ID DMY61TJ
DMY61TJ DN FK-614
DMY61TJ HS Phase 2
DMY61TJ SN ATx08-001; ATx08-001); PPAR gamma agonist (oral, neuropathic pain), Aestus
DMY61TJ CP Fujisawa Pharmaceutical Co Ltd; aestus therapeutics
DMY61TJ DT Small molecular drug
DMY61TJ PC 9869229
DMY61TJ MW 468.4
DMY61TJ FM C21H23Cl2N3O3S
DMY61TJ IC InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
DMY61TJ CS CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=C(C=C(C=C3)Cl)Cl)C
DMY61TJ IK UYGZODVVDUIDDQ-UHFFFAOYSA-N
DMY61TJ IU 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
DMY61TJ CA CAS 193012-35-0
DMY61TJ DE Type-2 diabetes
DMV0MZ3 ID DMV0MZ3
DMV0MZ3 DN FK-962
DMV0MZ3 HS Phase 2
DMV0MZ3 SN FK-960 analog, Fujisawa
DMV0MZ3 CP Fujisawa Pharmaceutical Co Ltd
DMV0MZ3 DT Small molecular drug
DMV0MZ3 PC 56842107
DMV0MZ3 MW 263.31
DMV0MZ3 FM C15H18FNO2
DMV0MZ3 IC InChI=1S/C15H18FNO2/c1-10(18)11-4-8-14(9-5-11)17-15(19)12-2-6-13(16)7-3-12/h2-3,6-7,11,14H,4-5,8-9H2,1H3,(H,17,19)
DMV0MZ3 CS CC(=O)C1CCC(CC1)NC(=O)C2=CC=C(C=C2)F
DMV0MZ3 IK PYMCWQVGVQEZNO-UHFFFAOYSA-N
DMV0MZ3 IU N-(4-acetylcyclohexyl)-4-fluorobenzamide
DMV0MZ3 CA CAS 283167-06-6
DMV0MZ3 DE Alzheimer disease
DM2O7NM ID DM2O7NM
DM2O7NM DN FKB01MD
DM2O7NM HS Phase 2
DM2O7NM CP Fabre-Kramer Pharmaceuticals Houston, TX
DMPXH7N ID DMPXH7N
DMPXH7N DN FKW00GA
DMPXH7N HS Phase 2
DMPXH7N CP Fabre-Kramer Pharmaceuticals Houston, TX
DMPXH7N DE Social phobia
DMKSUOI ID DMKSUOI
DMKSUOI DN Flavopiridol
DMKSUOI HS Phase 2
DMKSUOI SN FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
DMKSUOI CP Sanofi-Aventis
DMKSUOI DT Small molecular drug
DMKSUOI PC 5287969
DMKSUOI MW 401.8
DMKSUOI FM C21H20ClNO5
DMKSUOI IC InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1
DMKSUOI CS CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
DMKSUOI IK BIIVYFLTOXDAOV-YVEFUNNKSA-N
DMKSUOI IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
DMKSUOI CA CAS 146426-40-6
DMKSUOI CB CHEBI:47344
DMKSUOI DE Chronic lymphocytic leukaemia; Acute myeloid leukaemia
DMCN4H6 ID DMCN4H6
DMCN4H6 DN Flezelastine
DMCN4H6 HS Phase 2
DMCN4H6 SN D-18024
DMCN4H6 CP ASTA Medica AG
DMCN4H6 DT Small molecular drug
DMCN4H6 PC 60432
DMCN4H6 MW 455.6
DMCN4H6 FM C29H30FN3O
DMCN4H6 IC InChI=1S/C29H30FN3O/c30-24-14-12-23(13-15-24)21-28-26-10-4-5-11-27(26)29(34)33(31-28)25-9-6-18-32(20-17-25)19-16-22-7-2-1-3-8-22/h1-5,7-8,10-15,25H,6,9,16-21H2
DMCN4H6 CS C1CC(CCN(C1)CCC2=CC=CC=C2)N3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)F
DMCN4H6 IK HQFSNUYUXXPVKL-UHFFFAOYSA-N
DMCN4H6 IU 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one
DMCN4H6 CA CAS 135381-77-0
DMCN4H6 DE Asthma
DMVR6OM ID DMVR6OM
DMVR6OM DN Flotetuzumab
DMVR6OM HS Phase 2
DMVR6OM CP MacroGenics Rockville, MD
DMVR6OM DE Myelodysplastic syndrome; Acute myeloid leukaemia; Acute biphenotypic leukaemia
DMMQ1YU ID DMMQ1YU
DMMQ1YU DN FLUASTERONE
DMMQ1YU HS Phase 2
DMMQ1YU SN HE-2500; 16alpha-Fluoroandrost-5-en-17-one; 8354
DMMQ1YU CP Aeson Therapeutics
DMMQ1YU DT Small molecular drug
DMMQ1YU PC 133967
DMMQ1YU MW 290.4
DMMQ1YU FM C19H27FO
DMMQ1YU IC InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
DMMQ1YU CS C[C@]12CCCCC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)F)C
DMMQ1YU IK VHZXNQKVFDBFIK-NBBHSKLNSA-N
DMMQ1YU IU (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DMMQ1YU CA CAS 112859-71-9
DMMQ1YU DE Arthritis
DME01HT ID DME01HT
DME01HT DN Fluciclatide F-18
DME01HT HS Phase 2
DME01HT CP GE Healthcare; National Cancer Institute
DME01HT DT Small molecular drug
DME01HT PC 139033064
DME01HT MW 1815
DME01HT FM C75H115FN18O27S3
DME01HT IC InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39-/t53-,54-,55-,56-,57-,58-,59-/m0/s1/i76-1
DME01HT CS C1[C@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@@H](CSCC(=O)N[C@H](C(=O)N2)CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO/N=C\\C3=CC=C(C=C3)[18F])C(=O)NCCOCCOCCOCCNC(=O)COCC(=O)N)CC4=CC=CC=C4)CC(=O)O)CCCN=C(N)N
DME01HT IK VXFFXZSNVKXXIB-SOFHUQNMSA-N
DME01HT IU 2-[(1R,4S,10R,13S,16R,19S,25S)-10-[2-[2-[2-[2-[[2-(2-amino-2-oxoethoxy)acetyl]amino]ethoxy]ethoxy]ethoxy]ethylcarbamoyl]-13-benzyl-25-[3-(diaminomethylideneamino)propyl]-4-[4-[[2-[2-[2-[2-[2-[2-[2-[2-[[2-[(Z)-(4-(18F)fluoranylphenyl)methylideneamino]oxyacetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]butyl]-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octazabicyclo[14.11.4]hentriacontan-19-yl]acetic acid
DME01HT DE Solid tumour/cancer
DM0G5O6 ID DM0G5O6
DM0G5O6 DN Flumatinib
DM0G5O6 HS Phase 2
DM0G5O6 SN HH-GV-678
DM0G5O6 CP Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DM0G5O6 DT Small molecular drug
DM0G5O6 PC 46848036
DM0G5O6 MW 562.6
DM0G5O6 FM C29H29F3N8O
DM0G5O6 IC InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
DM0G5O6 CS CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
DM0G5O6 IK BJCJYEYYYGBROF-UHFFFAOYSA-N
DM0G5O6 IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide
DM0G5O6 CA CAS 895519-90-1
DM0G5O6 DE Chronic myelogenous leukaemia
DMCEUOH ID DMCEUOH
DMCEUOH DN Fluoropeptide vaccine
DMCEUOH HS Phase 2
DMCEUOH SN FP-01; Fluoropeptide vaccine (influenza); Fluoropeptide vaccine (influenza), Immune Targeting Systems
DMCEUOH CP Immune Targeting Systems Ltd
DMCEUOH DT Vaccine
DMCEUOH DE Influenza virus infection
DMPBV9D ID DMPBV9D
DMPBV9D DN Flupirtine
DMPBV9D HS Phase 2
DMPBV9D SN Flupirtine; 56995-20-1; Flupirtine [INN:BAN]; Flupirtinum [INN-Latin]; Flupirtino [INN-Spanish]; UNII-MOH3ET196H; C15H17FN4O2; EINECS 260-503-8; MOH3ET196H; JUUFBMODXQKSTD-UHFFFAOYSA-N; ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate; D 9998; flupirtin maleate; ethyl 2-amino-6-(4-fluorobenzylamino)pyridin-3-ylcarbamate; Flupirtinum; Flupirtino; MLS002153180; Carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester; NCGC00015451-03; SMR001230672; Flupirtin; Carbamic acid, [2-ami
DMPBV9D CP Adeona Pharmaceuticals; MI Meda Pharmaceuticals
DMPBV9D DT Small molecular drug
DMPBV9D PC 53276
DMPBV9D MW 304.32
DMPBV9D FM C15H17FN4O2
DMPBV9D IC InChI=1S/C15H17FN4O2/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)
DMPBV9D CS CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N
DMPBV9D IK JUUFBMODXQKSTD-UHFFFAOYSA-N
DMPBV9D IU ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
DMPBV9D CA CAS 56995-20-1
DMPBV9D CB CHEBI:94646
DMPBV9D DE Fibromyalgia; Cancer related pain
DMQX5UA ID DMQX5UA
DMQX5UA DN FLX-787
DMQX5UA HS Phase 2
DMQX5UA CP Flex Pharma, Boston, MA
DMQX5UA DE Amyotrophic lateral sclerosis; Multiple sclerosis; Muscle spasm
DMB9ADM ID DMB9ADM
DMB9ADM DN FolateImmune
DMB9ADM HS Phase 2
DMB9ADM SN Folate-FITC; EC-17; UNII-V7YQ6134AE; V7YQ6134AE; EC17 (Folate-FITC); Folate-fluorescein conjugate; DTXSID40207031; ZMTAPBHUSYTHBY-PMERELPUSA-N; EC 17; DB12559; 910661-23-3; 1159606-35-5
DMB9ADM CP Endocyte Inc
DMB9ADM DT Small molecular drug
DMB9ADM PC 135564966
DMB9ADM MW 872.9
DMB9ADM FM C42H36N10O10S
DMB9ADM IC InChI=1S/C42H36N10O10S/c43-33(55)12-11-30(38(58)59)52(37(57)20-1-3-21(4-2-20)46-18-23-19-47-35-34(48-23)36(56)51-40(44)50-35)14-13-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H2,43,55)(H,58,59)(H2,45,49,63)(H3,44,47,50,51,56)/t30-/m0/s1
DMB9ADM CS C1=CC(=CC=C1C(=O)N(CCNC(=S)NC2=CC3=C(C=C2)C4(C5=C(C=C(C=C5)O)OC6=C4C=CC(=C6)O)OC3=O)[C@@H](CCC(=O)N)C(=O)O)NCC7=CN=C8C(=N7)C(=O)NC(=N8)N
DMB9ADM IK ZMTAPBHUSYTHBY-PMERELPUSA-N
DMB9ADM IU (2S)-5-amino-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]-[2-[(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)carbamothioylamino]ethyl]amino]-5-oxopentanoic acid
DMB9ADM CA CAS 583037-91-6
DMB9ADM DE Renal cell carcinoma; Solid tumour/cancer
DMJNO3D ID DMJNO3D
DMJNO3D DN Follicle stimulating hormone
DMJNO3D HS Phase 2
DMJNO3D SN FSH-GEX; Follicle stimulating hormone (GEX, inferticlity); GT-GP 2.4 GEX; Follicle stimulating hormone (GEX, inferticlity), Glycotope
DMJNO3D CP Glycotope GmbH
DMJNO3D DE Infertility
DMUAXS5 ID DMUAXS5
DMUAXS5 DN FP-1039
DMUAXS5 HS Phase 2
DMUAXS5 SN FPT-039; HGS-1036; Modified growth factor receptor (cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv,cancer), FivePrime Therapeutics; FGFR-1c antagonist (protein fusion/iv, cancer), FivePrime Therapeutics/ Human Genome Sciences
DMUAXS5 CP FivePrime Therapeutics Inc
DMUAXS5 DE Solid tumour/cancer; Endometrial cancer
DMC1F2T ID DMC1F2T
DMC1F2T DN FP-1097
DMC1F2T HS Phase 2
DMC1F2T SN Urinary incontinence therapy, FemmePharma
DMC1F2T CP FemmePharma Inc
DMC1F2T DE Urinary incontinence
DMXOTMP ID DMXOTMP
DMXOTMP DN FPI-01
DMXOTMP HS Phase 2
DMXOTMP SN WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals
DMXOTMP CP Formula pharmaceuticals
DMXOTMP DT Vaccine
DMXOTMP DE Acute myeloid leukaemia
DMEL5SV ID DMEL5SV
DMEL5SV DN FR139317
DMEL5SV HS Phase 2
DMEL5SV SN D-Alanine, N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl-1-methyl-D-tryptophyl-3-(2-pyridinyl)-; FR 139317; 142375-60-8; CHEMBL352396; 2-((1-(Hexahydro-1H-azepinyl)carbonyl)amino-4-methylpentanoyl)-3-(-(1-methyl-1H-indolyl)propionyl)amino-3-(2-pyridyl)propionic acid; D-Alanine, N-(N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-1-methyl-D-tryptophyl)-3-(2-pyridinyl)-; GSK424887
DMEL5SV DT Small molecular drug
DMEL5SV PC 107810
DMEL5SV MW 604.7
DMEL5SV FM C33H44N6O5
DMEL5SV IC InChI=1S/C33H44N6O5/c1-22(2)18-26(37-33(44)39-16-10-4-5-11-17-39)30(40)35-27(19-23-21-38(3)29-14-7-6-13-25(23)29)31(41)36-28(32(42)43)20-24-12-8-9-15-34-24/h6-9,12-15,21-22,26-28H,4-5,10-11,16-20H2,1-3H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43)/t26-,27+,28+/m0/s1
DMEL5SV CS CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@H](CC3=CC=CC=N3)C(=O)O)NC(=O)N4CCCCCC4
DMEL5SV IK LIOKMIQQPDDTNO-UPRLRBBYSA-N
DMEL5SV IU (2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-3-pyridin-2-ylpropanoic acid
DMEL5SV CA CAS 142375-60-8
DMEL5SV DE Anxiety disorder; Depression; Hypertension
DMGO45I ID DMGO45I
DMGO45I DN FR-146687
DMGO45I HS Phase 2
DMGO45I SN FK-687; TF-505; 4-[1-[4-[1(S)-(4-Isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid
DMGO45I DE Prostate disease
DMFZ084 ID DMFZ084
DMFZ084 DN Fresolimumab
DMFZ084 HS Phase 2
DMFZ084 SN GC-1008
DMFZ084 DT Antibody
DMFZ084 DE Brain cancer
DM9ORUW ID DM9ORUW
DM9ORUW DN FRM-0962
DM9ORUW HS Phase 2
DM9ORUW CP Forum pharmaceuticals
DM9ORUW DE Alzheimer disease
DMPQFTA ID DMPQFTA
DMPQFTA DN Fucoxanthin
DMPQFTA HS Phase 2
DMPQFTA SN Fucoxanthin; UNII-06O0TC0VSM; CCRIS 4055; all-trans-Fucoxanthin; BRN 0073179; 06O0TC0VSM; beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one
DMPQFTA PC 5281239
DMPQFTA MW 658.9
DMPQFTA FM C42H58O6
DMPQFTA IC InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
DMPQFTA CS CC(=CC=CC=C(C)C=CC=C(C)C(=O)CC12C(CC(CC1(O2)C)O)(C)C)C=CC=C(C)C=C=C3C(CC(CC3(C)O)OC(=O)C)(C)C
DMPQFTA IK SJWWTRQNNRNTPU-ABBNZJFMSA-N
DMPQFTA IU nan
DMPQFTA CA CAS 3351-86-8
DMPQFTA CB CHEBI:5186
DMPQFTA DE Metabolic syndrome
DMZLBAW ID DMZLBAW
DMZLBAW DN Fucoxanthin
DMZLBAW HS Phase 2
DMZLBAW SN 3351-86-8; UNII-06O0TC0VSM; all-trans-Fucoxanthin; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-beta,beta-carotene; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; CCRIS 4055; BRN 0073179; Fucoxanthol; cis-Fucoxanthin; yl acetate; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-yl acetate; C42H58O6; Beta-sitosterol 45%; SCHEMBL37284; 5-18-04-00673 (Beilstein Handbook Reference); beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; MLS000728353; Fucoxanthin, analytical standard; CHEMBL1575074; SJWWTRQNNRNTPU-ABBNZJFMSA-; Fucoxanthin carotenoid antioxidant; Fucoxanthin, carotenoid antioxidant; HMS2219K22; Fucoxanthin (from Wakame) (Brown Seaweed) (Undaria Pinnatifida); HY-N2302; ZINC8221218; 1772AH; LMPR01070300; MFCD01745140; AKOS037514648; CS-8167; NCGC00247434-01; AS-56344; SMR000453597; C08596; Q96385; 351F868; Fucoxanthin solution, 1 mg/L in ethanol, analytical standard; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaenylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S)-3'-Acetoxy-5alpha,6alpha-epoxy-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6,7,8-tetrahydro-beta,beta-carotene; (3S,3'S,5R,5'R,6S,6'R,8'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,5',6,6',7,8-hexahydro-5,6-epoxy-beta,beta-caroten-3'-
DMZLBAW DT Small molecular drug
DMZLBAW PC 5281239
DMZLBAW MW 658.9
DMZLBAW FM C42H58O6
DMZLBAW IC InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
DMZLBAW CS C/C(=C\\C=C\\C=C(/C)\\C=C\\C=C(/C)\\C(=O)C[C@]12[C@](O1)(C[C@H](CC2(C)C)O)C)/C=C/C=C(\\C)/C=C=C3[C@](C[C@H](CC3(C)C)OC(=O)C)(C)O
DMZLBAW IK SJWWTRQNNRNTPU-ABBNZJFMSA-N
DMZLBAW CA CAS 3351-86-8
DMZLBAW DE Metabolic syndrome x
DMKHNXA ID DMKHNXA
DMKHNXA DN G100
DMKHNXA HS Phase 2
DMKHNXA SN Caffeine, 8-((3-methoxypropyl)amino)-; 8-((3-Methoxypropyl)amino)caffeine; CAFFEINE, 8-((3-METHOXYPROPYL)AMINO)-; BRN 1086127; 95982-26-6; 8-(gamma-Methoxypropyl)-aminocoffein [German]; 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione; 8-[(3-methoxypropyl)amino]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(gamma-Methoxypropyl)-aminocoffein; AC1L1M3J; CTK5H8490; DTXSID70242056; MolPort-002-837-706; CCG-22657; ZINC17172964; AKOS001669223; MCULE-8333260193; LS-48594; EU-0014431; G-100; AO-343/41780992
DMKHNXA CP Immune Design Seattle, WA
DMKHNXA PC 56998
DMKHNXA MW 281.31
DMKHNXA FM C12H19N5O3
DMKHNXA IC InChI=1S/C12H19N5O3/c1-15-8-9(14-11(15)13-6-5-7-20-4)16(2)12(19)17(3)10(8)18/h5-7H2,1-4H3,(H,13,14)
DMKHNXA CS CN1C2=C(N=C1NCCCOC)N(C(=O)N(C2=O)C)C
DMKHNXA IK ZZQHGKMTMAORFI-UHFFFAOYSA-N
DMKHNXA IU 8-(3-methoxypropylamino)-1,3,7-trimethylpurine-2,6-dione
DMKHNXA CA CAS 95982-26-6
DMKHNXA DE Non-hodgkin lymphoma
DMQO2IT ID DMQO2IT
DMQO2IT DN G1T38
DMQO2IT HS Phase 2
DMQO2IT SN YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4
DMQO2IT CP G1 Therapeutics Research Tringle Park, NC
DMQO2IT PC 86269224
DMQO2IT MW 474.6
DMQO2IT FM C26H34N8O
DMQO2IT IC InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)
DMQO2IT CS CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
DMQO2IT IK YPJRHEKCFKOVRT-UHFFFAOYSA-N
DMQO2IT IU 4-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DMQO2IT CA CAS 1628256-23-4
DMQO2IT DE Breast cancer; Non-small-cell lung cancer
DMQR9I8 ID DMQR9I8
DMQR9I8 DN G-202
DMQR9I8 HS Phase 2
DMQR9I8 SN UNII-Q032I35QMX; Q032I35QMX; 1245732-48-2; Mipsagargin [USAN:INN]; Mipsagargin (USAN/INN); CHEMBL3989865; DB11813; D10715
DMQR9I8 CP GenSpera
DMQR9I8 PC 24772106
DMQR9I8 MW 1409.5
DMQR9I8 FM C66H100N6O27
DMQR9I8 IC InChI=1S/C66H100N6O27/c1-8-10-11-17-20-24-51(81)96-55-53-52(37(4)54(55)97-62(91)36(3)9-2)56-66(94,65(7,93)63(92)98-56)44(35-64(53,6)99-38(5)73)95-50(80)23-21-18-15-13-12-14-16-19-22-33-68-48(77)34-39(67)57(82)72-43(61(89)90)27-31-47(76)70-41(59(85)86)25-29-45(74)69-40(58(83)84)26-30-46(75)71-42(60(87)88)28-32-49(78)79/h9,39-44,53-56,93-94H,8,10-35,67H2,1-7H3,(H,68,77)(H,69,74)(H,70,76)(H,71,75)(H,72,82)(H,78,79)(H,83,84)(H,85,86)(H,87,88)(H,89,90)/b36-9-/t39-,40-,41-,42-,43-,44-,53+,54-,55-,56-,64-,65+,66+/m0/s1
DMQR9I8 CS CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)/C(=C\\C)/C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCCCCCCCCCCNC(=O)C[C@@H](C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)N)([C@](C(=O)O3)(C)O)O
DMQR9I8 IK UPYNTAIBQVNPIH-ODMLWHIESA-N
DMQR9I8 IU (2S)-2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[(2S)-4-[[12-[[(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-7-octanoyloxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-4-yl]oxy]-12-oxododecyl]amino]-2-amino-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
DMQR9I8 CA CAS 1245732-48-2
DMQR9I8 DE Solid tumour/cancer; Adenocarcinoma
DMJY2TM ID DMJY2TM
DMJY2TM DN Gabapentin enacarbil
DMJY2TM HS Phase 2
DMJY2TM SN 1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512
DMJY2TM TC Neurology Agents
DMJY2TM DT Small molecular drug
DMJY2TM PC 9883933
DMJY2TM MW 329.39
DMJY2TM FM C16H27NO6
DMJY2TM IC InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)
DMJY2TM CS CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O
DMJY2TM IK TZDUHAJSIBHXDL-UHFFFAOYSA-N
DMJY2TM IU 2-[1-[[1-(2-methylpropanoyloxy)ethoxycarbonylamino]methyl]cyclohexyl]acetic acid
DMJY2TM CA CAS 478296-72-9
DMJY2TM CB CHEBI:68840
DMJY2TM DE Alcohol dependence
DMTXCUS ID DMTXCUS
DMTXCUS DN Galiximab
DMTXCUS HS Phase 2
DMTXCUS CP Biogen Idec
DMTXCUS DT Antibody
DMTXCUS DE Lymphoma
DMXBR27 ID DMXBR27
DMXBR27 DN Gallopamil
DMXBR27 HS Phase 2
DMXBR27 SN 16662-47-8; methoxyverapamil; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; Galopamilo; Galopamilo [INN-Spanish]; Gallopamillum [INN-Latin]; Gallopamil [INN:BAN]; D600; D 600; C28H40N2O5; CHEBI:34772; (+/-)-Methoxyverapamil hydrochloride; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; Methoxyverapamil; GSK 796406
DMXBR27 DT Small molecular drug
DMXBR27 PC 1234
DMXBR27 MW 484.6
DMXBR27 FM C28H40N2O5
DMXBR27 IC InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
DMXBR27 CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC
DMXBR27 IK XQLWNAFCTODIRK-UHFFFAOYSA-N
DMXBR27 IU 5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
DMXBR27 CA CAS 16662-47-8
DMXBR27 CB CHEBI:34772
DMXBR27 DE Hypertension; Asthma
DMAEWS1 ID DMAEWS1
DMAEWS1 DN GAM-501
DMAEWS1 HS Phase 2
DMAEWS1 SN Excellarate; Diabetic ulcer product, Selective Genetics; AdPDGF-B/GAM; Adenoviral gene therapy (PDGF-B), Selective Genetics; PDGF-B adenoviral gene therapy (collagen gel, diabetic foot ulcer), Tissue Repair Company
DMAEWS1 CP Selective Genetics Inc
DMAEWS1 DE Diabetic foot ulcer
DM2IFJQ ID DM2IFJQ
DM2IFJQ DN GBL-310
DM2IFJQ HS Phase 2
DM2IFJQ SN Anti-hyperproliferative (topical, actinic keratosis), Grannus
DM2IFJQ CP Grannus BioSciences Ltd
DM2IFJQ DE Keratosis
DM2VO9T ID DM2VO9T
DM2VO9T DN GBR 830
DM2VO9T HS Phase 2
DM2VO9T CP Glenmark Pharmaceuticals Mumbai, India
DM2VO9T DE Atopic dermatitis
DMYS6MW ID DMYS6MW
DMYS6MW DN GCS-100
DMYS6MW HS Phase 2
DMYS6MW CP La jolla pharmaceutical
DMYS6MW DE Chronic kidney disease
DMY6WUV ID DMY6WUV
DMY6WUV DN GDC-0077
DMY6WUV HS Phase 2
DMY6WUV SN RG6114; SGEUNORSOZVTOL-CABZTGNLSA-N; UNII-L4C1UY2NYH; L4C1UY2NYH; 2060571-02-8; GDC0077; GTPL9636; SCHEMBL18360780; EX-A2685; ZINC669678973; Ro7113755; CS-6459; HY-101562; Propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2S)-; (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide; (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxa
DMY6WUV CP GenentechSouth San Francisco, CA
DMY6WUV PC 124173720
DMY6WUV MW 407.4
DMY6WUV FM C18H19F2N5O4
DMY6WUV IC InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1
DMY6WUV CS C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F
DMY6WUV IK SGEUNORSOZVTOL-CABZTGNLSA-N
DMY6WUV IU (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
DMY6WUV CA CAS 2060571-02-8
DMY6WUV DE Breast cancer; Solid tumour/cancer
DMA9SEY ID DMA9SEY
DMA9SEY DN GDC-0084
DMA9SEY HS Phase 2
DMA9SEY SN GDC-0084/RG7666
DMA9SEY CP Genentech
DMA9SEY PC 57384863
DMA9SEY MW 382.4
DMA9SEY FM C18H22N8O2
DMA9SEY IC InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
DMA9SEY CS CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C
DMA9SEY IK LGWACEZVCMBSKW-UHFFFAOYSA-N
DMA9SEY IU 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine
DMA9SEY CA CAS 1382979-44-3
DMA9SEY DE Glioblastoma of brain
DM1YAK6 ID DM1YAK6
DM1YAK6 DN GDC0941
DM1YAK6 HS Phase 2
DM1YAK6 SN Pictilisib; GDC-0941; 957054-30-7; PICTILISIB; Pictrelisib; GDC 0941; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; UNII-ICY00EMP8P; ICY00EMP8P; Pictilisib (GDC-0941); CHEBI:65326; AK-40872; Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-; GD9; GDC-0941, GDC0941; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
DM1YAK6 CP Genentech
DM1YAK6 DT Small molecular drug
DM1YAK6 PC 17755052
DM1YAK6 MW 513.6
DM1YAK6 FM C23H27N7O3S2
DM1YAK6 IC InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
DM1YAK6 CS CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
DM1YAK6 IK LHNIIDJUOCFXAP-UHFFFAOYSA-N
DM1YAK6 IU 4-[2-(1H-indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine
DM1YAK6 CA CAS 957054-30-7
DM1YAK6 CB CHEBI:65326
DM1YAK6 DE Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer
DMF3MV1 ID DMF3MV1
DMF3MV1 DN GDC-0980/RG7422
DMF3MV1 HS Phase 2
DMF3MV1 SN Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S
DMF3MV1 CP Genentech; Roche
DMF3MV1 DT Small molecular drug
DMF3MV1 PC 25254071
DMF3MV1 MW 498.6
DMF3MV1 FM C23H30N8O3S
DMF3MV1 IC InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1
DMF3MV1 CS CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)[C@H](C)O
DMF3MV1 IK YOVVNQKCSKSHKT-HNNXBMFYSA-N
DMF3MV1 IU (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one
DMF3MV1 CA CAS 1032754-93-0
DMF3MV1 DE Non-hodgkin lymphoma; Solid tumour/cancer
DMMQY0O ID DMMQY0O
DMMQY0O DN GED-0507-34-Levo
DMMQY0O HS Phase 2
DMMQY0O SN GED-0507; GED-0507-34; GED-0507-34E2
DMMQY0O CP Giuliani SpA
DMMQY0O PC 67008033
DMMQY0O MW 195.21
DMMQY0O FM C10H13NO3
DMMQY0O IC InChI=1S/C10H13NO3/c1-14-9(10(12)13)6-7-2-4-8(11)5-3-7/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
DMMQY0O CS CO[C@@H](CC1=CC=C(C=C1)N)C(=O)O
DMMQY0O IK QLJYLJGYIDIJPT-VIFPVBQESA-N
DMMQY0O IU (2S)-3-(4-aminophenyl)-2-methoxypropanoic acid
DMMQY0O CA CAS 921195-93-9
DMMQY0O DE Inflammatory bowel disease
DMJN09S ID DMJN09S
DMJN09S DN GEN-1
DMJN09S HS Phase 2
DMJN09S CP Celsion
DMJN09S DT Gene therapy
DMJN09S DE Ovarian cancer
DMO9WU8 ID DMO9WU8
DMO9WU8 DN Gepirone
DMO9WU8 HS Phase 2
DMO9WU8 SN Gepirone; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepirone ER; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; MJ-13805; Variza; Ariza; Gepironum; AK115965; Gepirona; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; MJ 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q
DMO9WU8 PC 55191
DMO9WU8 MW 359.5
DMO9WU8 FM C19H29N5O2
DMO9WU8 IC InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
DMO9WU8 CS CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
DMO9WU8 IK QOIGKGMMAGJZNZ-UHFFFAOYSA-N
DMO9WU8 IU 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMO9WU8 CA CAS 83928-76-1
DMO9WU8 CB CHEBI:135990
DMO9WU8 DE Cocaine related disorders
DMD3RU8 ID DMD3RU8
DMD3RU8 DN GFT14
DMD3RU8 HS Phase 2
DMD3RU8 CP Genfit
DMD3RU8 DE Hyperlipidaemia
DMTY4PG ID DMTY4PG
DMTY4PG DN GI-4000
DMTY4PG HS Phase 2
DMTY4PG CP GlobeImmune
DMTY4PG DT Vaccine
DMTY4PG DE Colorectal cancer; Pancreatic cancer
DMQ0XZE ID DMQ0XZE
DMQ0XZE DN GI-4000 + gemcitabine
DMQ0XZE HS Phase 2
DMQ0XZE CP GlobeImmune
DMQ0XZE DE Pancreatic cancer
DM72O6F ID DM72O6F
DM72O6F DN GI-6207
DM72O6F HS Phase 2
DM72O6F CP GlobeImmune
DM72O6F DE Thyroid cancer
DMOMS7R ID DMOMS7R
DMOMS7R DN GI-6301
DMOMS7R HS Phase 2
DMOMS7R CP GlobeImmune
DMOMS7R DT Vaccine
DMOMS7R DE Solid tumour/cancer; Advanced cancer; Chordoma
DMSKMET ID DMSKMET
DMSKMET DN Gimatecan
DMSKMET HS Phase 2
DMSKMET SN LBQ-707; ST-1480; ST-1481; Camptothecin analogs, Sigma-Tau; 7-cyano-camptothecin
DMSKMET CP Sigma-Tau Ind Farm Riunite SpA
DMSKMET DT Small molecular drug
DMSKMET PC 9577124
DMSKMET MW 447.5
DMSKMET FM C25H25N3O5
DMSKMET IC InChI=1S/C25H25N3O5/c1-5-25(31)18-10-20-21-16(12-28(20)22(29)17(18)13-32-23(25)30)15(11-26-33-24(2,3)4)14-8-6-7-9-19(14)27-21/h6-11,31H,5,12-13H2,1-4H3/b26-11+/t25-/m0/s1
DMSKMET CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)/C=N/OC(C)(C)C)O
DMSKMET IK UIVFUQKYVFCEKJ-OPTOVBNMSA-N
DMSKMET IU (19S)-19-ethyl-19-hydroxy-10-[(E)-(2-methylpropan-2-yl)oxyiminomethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMSKMET CA CAS 292618-32-7
DMSKMET DE Breast cancer
DMG3O2Z ID DMG3O2Z
DMG3O2Z DN Girentuximab I-124
DMG3O2Z HS Phase 2
DMG3O2Z SN Redectane (TN)
DMG3O2Z CP Wilex
DMG3O2Z DT Monoclonal antibody
DMG3O2Z DE Renal cell carcinoma
DMLFSMX ID DMLFSMX
DMLFSMX DN GK1-399
DMLFSMX HS Phase 2
DMLFSMX SN TTP-399
DMLFSMX CP Forest Laboratories
DMLFSMX DE Diabetic complication; Type-2 diabetes
DMOVB3Y ID DMOVB3Y
DMOVB3Y DN GKT-137831
DMOVB3Y HS Phase 2
DMOVB3Y SN GKT-01; NADPH oxidase inhibitor (oral, renal cancer/ idiopathic pulmonary fibrosis), GenKyoTex
DMOVB3Y CP Genkyotex innovation
DMOVB3Y DT Small molecular drug
DMOVB3Y PC 58496428
DMOVB3Y MW 394.9
DMOVB3Y FM C21H19ClN4O2
DMOVB3Y IC InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3
DMOVB3Y CS CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl
DMOVB3Y IK RGYQPQARIQKJKH-UHFFFAOYSA-N
DMOVB3Y IU 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione
DMOVB3Y CA CAS 1218942-37-0
DMOVB3Y DE Fibrosis
DM17OZM ID DM17OZM
DM17OZM DN GL-0817
DM17OZM HS Phase 2
DM17OZM SN 912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
DM17OZM CP Gliknik
DM17OZM DT Small molecular drug
DM17OZM PC 122706930
DM17OZM MW 5758
DM17OZM FM C261H449N91O56
DM17OZM IC InChI=1S/C261H449N91O56/c1-30-147(26)204(249(406)339-186(124-153-70-38-33-39-71-153)234(391)342-190(131-354)238(395)322-159(75-43-49-99-263)210(367)309-149(28)207(364)341-189(130-353)240(397)344-192(133-356)241(398)343-191(132-355)239(396)335-180(118-137(6)7)230(387)324-175(93-96-195(270)358)223(380)331-178(116-135(2)3)228(385)320-168(84-58-108-298-255(279)280)218(375)313-160(76-44-50-100-264)212(369)312-161(77-45-51-101-265)213(370)314-165(81-55-105-295-252(273)274)216(373)315-167(83-57-107-297-254(277)278)219(376)323-174(92-95-194(269)357)222(379)318-166(82-56-106-296-253(275)276)217(374)316-169(85-59-109-299-256(281)282)220(377)329-177(250(407)408)90-64-114-304-261(291)292)351-248(405)203(146(24)25)348-225(382)171(87-61-111-301-258(285)286)319-215(372)163(79-47-53-103-267)327-245(402)200(143(18)19)347-227(384)173(89-63-113-303-260(289)290)328-246(403)201(144(20)21)349-236(393)182(120-139(10)11)330-206(363)148(27)308-211(368)164(80-54-104-294-251(271)272)325-242(399)193-91-65-115-352(193)196(359)129-306-209(366)187(125-154-127-305-158-74-41-40-72-156(154)158)338-231(388)181(119-138(8)9)334-232(389)184(122-151-66-34-31-35-67-151)336-221(378)170(86-60-110-300-257(283)284)317-214(371)162(78-46-52-102-266)326-244(401)199(142(16)17)346-226(383)172(88-62-112-302-259(287)288)321-229(386)179(117-136(4)5)333-233(390)185(123-152-68-36-32-37-69-152)337-235(392)188(126-155-128-293-134-307-155)340-247(404)202(145(22)23)350-237(394)183(121-140(12)13)332-224(381)176(94-97-197(360)361)311-205(362)150(29)310-243(400)198(141(14)15)345-208(365)157(268)73-42-48-98-262/h31-41,66-72,74,127-128,134-150,157,159-193,198-204,305,353-356H,30,42-65,73,75-126,129-133,262-268H2,1-29H3,(H2,269,357)(H2,270,358)(H,293,307)(H,306,366)(H,308,368)(H,309,367)(H,310,400)(H,311,362)(H,312,369)(H,313,375)(H,314,370)(H,315,373)(H,316,374)(H,317,371)(H,318,379)(H,319,372)(H,320,385)(H,321,386)(H,322,395)(H,323,376)(H,324,387)(H,325,399)(H,326,401)(H,327,402)(H,328,403)(H,329,377)(H,330,363)(H,331,380)(H,332,381)(H,333,390)(H,334,389)(H,335,396)(H,336,378)(H,337,392)(H,338,388)(H,339,406)(H,340,404)(H,341,364)(H,342,391)(H,343,398)(H,344,397)(H,345,365)(H,346,383)(H,347,384)(H,348,382)(H,349,393)(H,350,394)(H,351,405)(H,360,361)(H,407,408)(H4,271,272,294)(H4,273,274,295)(H4,275,276,296)(H4,277,278,297)(H4,279,280,298)(H4,281,282,299)(H4,283,284,300)(H4,285,286,301)(H4,287,288,302)(H4,289,290,303)(H4,291,292,304)/t147-,148-,149-,150-,157-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,198-,199-,200-,201-,202-,203-,204-/m0/s1
DM17OZM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N
DM17OZM IK SSOORFWOBGFTHL-OTEJMHTDSA-N
DM17OZM IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DM17OZM CA CAS 911338-45-9
DM17OZM DE Head and neck cancer; Squamous cell carcinoma; Multiple myeloma; Oral cavity squamous cell carcinoma
DMSVBND ID DMSVBND
DMSVBND DN Glecaprevir
DMSVBND HS Phase 2
DMSVBND SN A-1282576.0; ABT 493; ABT-493; ABT-493(Glecaprevir); CS-8098; D10814; DB13879; EX-A1940; Glecaprevir; Glecaprevir (USAN/INN); Glecaprevir [USAN]; HY-17634; J3.646.120I; K6BUU8J72P; SB19760; SCHEMBL883097; UNII-K6BUU8J72P; glecaprevirum
DMSVBND TC Antiviral Agent
DMSVBND DT Small molecular drug
DMSVBND PC 66828839
DMSVBND MW 838.873
DMSVBND FM C38H46F4N6O9S
DMSVBND IC InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1
DMSVBND CS CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DMSVBND IK CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C
DMSVBND IU (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide
DMSVBND CA CAS 1365970-03-1
DMSVBND DE Chronic hepatitis C infection
DMPHCDL ID DMPHCDL
DMPHCDL DN GLPG-0634
DMPHCDL HS Phase 2
DMPHCDL SN Small molecule, JAK1/JAK2 inhibitor (rheumatoid arthritis), Galapagos/GSK
DMPHCDL CP Abbvie; galapagos
DMPHCDL DT Small molecular drug
DMPHCDL PC 49831257
DMPHCDL MW 425.5
DMPHCDL FM C21H23N5O3S
DMPHCDL IC InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)
DMPHCDL CS C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
DMPHCDL IK RIJLVEAXPNLDTC-UHFFFAOYSA-N
DMPHCDL IU N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
DMPHCDL CA CAS 1206161-97-8
DMPHCDL DE Rheumatoid arthritis; Crohn disease; Cutaneous lupus erythematosus
DMXO4T8 ID DMXO4T8
DMXO4T8 DN GLPG0974
DMXO4T8 HS Phase 2
DMXO4T8 SN compound 99 [PMID 25380412]
DMXO4T8 DT Small molecular drug
DMXO4T8 PC 57520598
DMXO4T8 MW 485
DMXO4T8 FM C25H25ClN2O4S
DMXO4T8 IC InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1
DMXO4T8 CS C[C@@]1(CCN1C(=O)C2=CSC3=CC=CC=C32)C(=O)N(CCCC(=O)O)CC4=CC(=CC=C4)Cl
DMXO4T8 IK MPMKMQHJHDHPBE-RUZDIDTESA-N
DMXO4T8 IU 4-[[(2R)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid
DMXO4T8 CA CAS 1391076-61-1
DMXO4T8 DE Abortion
DMOCRYB ID DMOCRYB
DMOCRYB DN GLPG-1837
DMOCRYB HS Phase 2
DMOCRYB SN GHTGYZMBQPXTCQ-UHFFFAOYSA-N; GLPG1837; 1654725-02-6; SCHEMBL16444982; GLPG 1837; EX-A1819; BCP23611; GLPG-1837(ABBV-974); HY-111099; CS-0034220; N-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-3-carboxamide
DMOCRYB CP Galapagos, AbbVie
DMOCRYB PC 117857370
DMOCRYB MW 348.4
DMOCRYB FM C16H20N4O3S
DMOCRYB IC InChI=1S/C16H20N4O3S/c1-15(2)7-8-10(12(17)21)14(24-11(8)16(3,4)23-15)19-13(22)9-5-6-18-20-9/h5-6H,7H2,1-4H3,(H2,17,21)(H,18,20)(H,19,22)
DMOCRYB CS CC1(CC2=C(C(O1)(C)C)SC(=C2C(=O)N)NC(=O)C3=CC=NN3)C
DMOCRYB IK GHTGYZMBQPXTCQ-UHFFFAOYSA-N
DMOCRYB IU N-(3-carbamoyl-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide
DMOCRYB DE Cystic fibrosis
DMJ85FS ID DMJ85FS
DMJ85FS DN Glutathione-S-S-glutathione
DMJ85FS HS Phase 2
DMJ85FS SN oxiglutatione; glutathione disulfide; GSSG; oxidized glutathione; Glutathione disulphide; L-Glutathione oxidized; Glutathione-ssg; Glutathione, oxidized; Oxigluthione; glutathione oxidized; Glutathone disulfide; Bi(glutathion-S-yl); Oxidized L-glutathione; L-Oxidized glutathione; L(-)-Glutathione; Oxiglutatione [INN]; S,S'-Ethylenebis(glutathione); Oxiglutationum [INN-Latin]; Oxiglutationa [INN-Spanish]; CCRIS 780; OXIDIZED GLUTATHIONE DISULFIDE; Glutathiol; UNII-ULW86O013H
DMJ85FS PC 65359
DMJ85FS MW 612.6
DMJ85FS FM C20H32N6O12S2
DMJ85FS IC InChI=1S/C20H32N6O12S2/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/t9-,10-,11-,12-/m0/s1
DMJ85FS CS C(CC(=O)NC(CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)C(=O)NCC(=O)O)C(C(=O)O)N
DMJ85FS IK YPZRWBKMTBYPTK-BJDJZHNGSA-N
DMJ85FS IU (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMJ85FS CA CAS 27025-41-8
DMJ85FS CB CHEBI:17858
DMJ85FS DE Ovarian cancer
DML6PO5 ID DML6PO5
DML6PO5 DN GM-CSF cancer vaccine
DML6PO5 HS Phase 2
DML6PO5 CP Thomas Jefferson University
DML6PO5 DT Vaccine
DML6PO5 DE Solid tumour/cancer
DMLWKZ7 ID DMLWKZ7
DMLWKZ7 DN GO-203-2c
DMLWKZ7 HS Phase 2
DMLWKZ7 CP Genus Oncology
DMLWKZ7 DE Solid tumour/cancer; Acute myeloid leukaemia
DMKZN3A ID DMKZN3A
DMKZN3A DN Golotimod
DMKZN3A HS Phase 2
DMKZN3A SN 229305-39-9; SCV-07; gamma-D-Glu-L-trp; SCV07; gamma-D-Glutamyl-L-tryptophan; SCV 07; UNII-637C487Y09; 637C487Y09; (R)-2-Amino-5-(((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod [USAN:INN]; (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid; (2R)-2-Amino-5-(((1S)-1-carboxy-2-(1H-indol-3-yl)ethyl)amino)-5-oxopentanoic acid; Golotimod (USAN/INN); GAMMA-D-GLU-TRP-OH; H-D-Glu(L-Trp-OH)-OH; SCHEMBL727944; (gamma-glutamyl-L-tryptophan); CHEMBL2103812; Golotimod (oral); Golotimod (oral), SciClone/Verta; SCV-07 (oral, tuberculosis), SciClone/Verta
DMKZN3A CP Verta Ltd; SciClone Pharmaceuticals
DMKZN3A DT Small molecular drug
DMKZN3A PC 6992140
DMKZN3A MW 333.34
DMKZN3A FM C16H19N3O5
DMKZN3A IC InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13+/m1/s1
DMKZN3A CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)CC[C@H](C(=O)O)N
DMKZN3A IK CATMPQFFVNKDEY-YPMHNXCESA-N
DMKZN3A IU (2R)-2-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid
DMKZN3A CA CAS 229305-39-9
DMKZN3A DE Inflammation; Immune System disease
DMYWA0Z ID DMYWA0Z
DMYWA0Z DN GORALATIDE
DMYWA0Z HS Phase 2
DMYWA0Z SN AcSDKP; Seraspenide; BIM-32001; Goralatide; Acetyl-seryl-aspartyl-lysyl-proline
DMYWA0Z DT Small molecular drug
DMYWA0Z PC 65938
DMYWA0Z MW 487.5
DMYWA0Z FM C20H33N5O9
DMYWA0Z IC InChI=1S/C20H33N5O9/c1-11(27)22-14(10-26)18(31)24-13(9-16(28)29)17(30)23-12(5-2-3-7-21)19(32)25-8-4-6-15(25)20(33)34/h12-15,26H,2-10,21H2,1H3,(H,22,27)(H,23,30)(H,24,31)(H,28,29)(H,33,34)/t12-,13-,14-,15-/m0/s1
DMYWA0Z CS CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O
DMYWA0Z IK HJDRXEQUFWLOGJ-AJNGGQMLSA-N
DMYWA0Z IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid
DMYWA0Z CA CAS 120081-14-3
DMYWA0Z DE Constitutional neutropenia
DMJWE3I ID DMJWE3I
DMJWE3I DN Gossypol
DMJWE3I HS Phase 2
DMJWE3I SN gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate
DMJWE3I DT Small molecular drug
DMJWE3I PC 3503
DMJWE3I MW 518.6
DMJWE3I FM C30H30O8
DMJWE3I IC InChI=1S/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3
DMJWE3I CS CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O
DMJWE3I IK QBKSWRVVCFFDOT-UHFFFAOYSA-N
DMJWE3I IU 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
DMJWE3I CA CAS 20300-26-9
DMJWE3I DE Prostate cancer
DM38ARE ID DM38ARE
DM38ARE DN Gp100:209-217(210M) peptide vaccine
DM38ARE HS Phase 2
DM38ARE SN Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI
DM38ARE CP National Cancer Institute
DM38ARE DT Vaccine
DM38ARE DE Melanoma
DMOHAS2 ID DMOHAS2
DMOHAS2 DN GPC-3298306
DMOHAS2 HS Phase 2
DMOHAS2 SN GPC3 peptide vaccine (hepatocellular carcinoma), Japanese National Cancer Center
DMOHAS2 CP Japanese National Cancer Center
DMOHAS2 DT Vaccine
DMOHAS2 DE Hepatocellular carcinoma
DMOQ7YI ID DMOQ7YI
DMOQ7YI DN GPD-1116
DMOQ7YI HS Phase 2
DMOQ7YI PC 9841417
DMOQ7YI MW 352.4
DMOQ7YI FM C22H16N4O
DMOQ7YI IC InChI=1S/C22H16N4O/c27-22-19-18(14-15-8-3-1-4-9-15)24-25-20(19)17-12-7-13-23-21(17)26(22)16-10-5-2-6-11-16/h1-13H,14H2,(H,24,25)
DMOQ7YI CS C1=CC=C(C=C1)CC2=C3C(=NN2)C4=C(N=CC=C4)N(C3=O)C5=CC=CC=C5
DMOQ7YI IK NOZMPLJNURLIAQ-UHFFFAOYSA-N
DMOQ7YI IU 3-benzyl-5-phenyl-2H-pyrazolo[4,3-c][1,8]naphthyridin-4-one
DMOQ7YI DE Asthma
DM64ZYM ID DM64ZYM
DM64ZYM DN GPI-1485
DM64ZYM HS Phase 2
DM64ZYM SN 186268-78-0; GPI-1485; UNII-0709BVY57W; (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; (2S)-1-(1,2-DIOXO-3,3-DIMETHYLPENTYL)-2-PYRROLIDINECARBOXYLIC ACID; 0709BVY57W; (S)-1-(3,3-Dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid; L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-; GPI 1485; SCHEMBL2006950; CTK6C7007; FOPALECPEUVCTL-QMMMGPOBSA-N; MolPort-023-219-569; ZX-RL003437; 1-(1,2-Dioxo-3,3-dimethylpentyl)-2-pyrrolidine carboxylic acid, 2S; ZINC33979157; 6256AD; AKOS015991368; DB05814; EG-0058
DM64ZYM CP Eisai
DM64ZYM DT Small molecular drug
DM64ZYM PC 9837656
DM64ZYM MW 241.28
DM64ZYM FM C12H19NO4
DM64ZYM IC InChI=1S/C12H19NO4/c1-4-12(2,3)9(14)10(15)13-7-5-6-8(13)11(16)17/h8H,4-7H2,1-3H3,(H,16,17)/t8-/m0/s1
DM64ZYM CS CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)O
DM64ZYM IK FOPALECPEUVCTL-QMMMGPOBSA-N
DM64ZYM IU (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
DM64ZYM CA CAS 186268-78-0
DM64ZYM DE Parkinson disease
DMHNIGB ID DMHNIGB
DMHNIGB DN GPX-150D
DMHNIGB HS Phase 2
DMHNIGB SN CNDO-101; CNDO-101); GPX-150; Doxorubicin analog (cancer), Coronado; 5-imino-13-deoxy-doxorubicin
DMHNIGB CP Gem Pharmaceuticals LLC
DMHNIGB DE Breast cancer; Soft tissue sarcoma
DMMZQ7V ID DMMZQ7V
DMMZQ7V DN Granotapide
DMMZQ7V HS Phase 2
DMMZQ7V SN JTT-130
DMMZQ7V CP Japan Tobacco Inc
DMMZQ7V DT Small molecular drug
DMMZQ7V PC 11607299
DMMZQ7V MW 718.7
DMMZQ7V FM C39H37F3N2O8
DMMZQ7V IC InChI=1S/C39H37F3N2O8/c1-5-50-36(48)38(37(49)51-6-2,27-12-8-7-9-13-27)24-52-33(45)23-25-16-21-32(31(22-25)35(47)44(3)4)43-34(46)30-15-11-10-14-29(30)26-17-19-28(20-18-26)39(40,41)42/h7-22H,5-6,23-24H2,1-4H3,(H,43,46)
DMMZQ7V CS CCOC(=O)C(COC(=O)CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)C(=O)N(C)C)(C4=CC=CC=C4)C(=O)OCC
DMMZQ7V IK FPUQGCOBYOXAED-UHFFFAOYSA-N
DMMZQ7V IU diethyl 2-[[2-[3-(dimethylcarbamoyl)-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]acetyl]oxymethyl]-2-phenylpropanedioate
DMMZQ7V CA CAS 594842-13-4
DMMZQ7V DE Hyperlipidaemia
DMWXJSZ ID DMWXJSZ
DMWXJSZ DN GRC-15300
DMWXJSZ HS Phase 2
DMWXJSZ CP Glenmark Pharmaceuticals Ltd
DMWXJSZ DE Pain
DM9QF65 ID DM9QF65
DM9QF65 DN GR-MD-02
DM9QF65 HS Phase 2
DM9QF65 SN Belapectin
DM9QF65 CP Galectin therapeutics
DM9QF65 DT Protein
DM9QF65 DE Melanoma; Plaque psoriasis; Non-alcoholic steatohepatitis; Hypertension
DMAHOEP ID DMAHOEP
DMAHOEP DN GRNVAC1
DMAHOEP HS Phase 2
DMAHOEP CP Argos Therapeutics
DMAHOEP DT Vaccine
DMAHOEP DE Acute myeloid leukaemia
DMHQV6R ID DMHQV6R
DMHQV6R DN GS-4059
DMHQV6R HS Phase 2
DMHQV6R SN tirabrutinib; Tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno
DMHQV6R CP Gilead Sciences Foster City, CA
DMHQV6R PC 54755438
DMHQV6R MW 454.5
DMHQV6R FM C25H22N6O3
DMHQV6R IC InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)/t18-/m1/s1
DMHQV6R CS CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMHQV6R IK SEJLPXCPMNSRAM-GOSISDBHSA-N
DMHQV6R IU 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one
DMHQV6R CA CAS 1351636-18-4
DMHQV6R DE B-cell lymphoma; Rheumatoid arthritis
DMBDFN7 ID DMBDFN7
DMBDFN7 DN GS-4977
DMBDFN7 HS Phase 2
DMBDFN7 CP Gilead sciences
DMBDFN7 DE Diabetic nephropathy
DMNABMU ID DMNABMU
DMNABMU DN GS-4997
DMNABMU HS Phase 2
DMNABMU PC 71245288
DMNABMU MW 445.5
DMNABMU FM C24H24FN7O
DMNABMU IC InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
DMNABMU CS CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F
DMNABMU IK YIDDLAAKOYYGJG-UHFFFAOYSA-N
DMNABMU IU 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide
DMNABMU CA CAS 1448428-04-3
DMNABMU DE Diabetic nephropathy; Pulmonary arterial hypertension
DMDAHL6 ID DMDAHL6
DMDAHL6 DN GS-5806
DMDAHL6 HS Phase 2
DMDAHL6 CP GILEAD
DMDAHL6 DT Small molecular drug
DMDAHL6 PC 58029842
DMDAHL6 MW 532.1
DMDAHL6 FM C24H30ClN7O3S
DMDAHL6 IC InChI=1S/C24H30ClN7O3S/c1-15-13-32-22(27-23(15)30-10-8-17(26)14-30)12-20(28-32)21-5-3-4-9-31(21)24(33)18-11-16(25)6-7-19(18)29-36(2,34)35/h6-7,11-13,17,21,29H,3-5,8-10,14,26H2,1-2H3/t17-,21-/m0/s1
DMDAHL6 CS CC1=CN2C(=CC(=N2)[C@@H]3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CC[C@@H](C5)N
DMDAHL6 IK GOFXWTVKPWJNGD-UWJYYQICSA-N
DMDAHL6 IU N-[2-[(2S)-2-[5-[(3S)-3-aminopyrrolidin-1-yl]-6-methylpyrazolo[1,5-a]pyrimidin-2-yl]piperidine-1-carbonyl]-4-chlorophenyl]methanesulfonamide
DMDAHL6 CA CAS 1353625-73-6
DMDAHL6 DE Respiratory syncytial virus infection
DMSL3DX ID DMSL3DX
DMSL3DX DN GS-5885
DMSL3DX HS Phase 2
DMSL3DX SN Ledipasvir; 1256388-51-8; GS-5885; UNII-013TE6E4WV; GS5885; GS 5885; WHO 9796; Ledipasvir (GS5885); 013TE6E4WV; CHEBI:85089; methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate; Ledipasvir [USAN:INN]; Ledipasvir (USAN); SCHEMBL2706494; SCHEMBL15116943; CHEMBL2374220; EX-A411; DTXSID90154829; MolPort-039-138-665
DMSL3DX CP Gilead Sciences Inc
DMSL3DX DT Small molecular drug
DMSL3DX PC 67505836
DMSL3DX MW 889
DMSL3DX FM C49H54F2N8O6
DMSL3DX IC InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
DMSL3DX CS CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
DMSL3DX IK VRTWBAAJJOHBQU-KMWAZVGDSA-N
DMSL3DX IU methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DMSL3DX CA CAS 1256388-51-8
DMSL3DX CB CHEBI:85089
DMSL3DX DE Hepatitis C virus infection
DMV7ZU0 ID DMV7ZU0
DMV7ZU0 DN GS-6624
DMV7ZU0 HS Phase 2
DMV7ZU0 CP Gilead Sciences
DMV7ZU0 DT Antibody
DMV7ZU0 DE Colorectal cancer
DMCZH5B ID DMCZH5B
DMCZH5B DN GS-9256
DMCZH5B HS Phase 2
DMCZH5B SN GS-9256; UNII-8V42Y78HRU; 1001094-46-7; GS 9256; 8V42Y78HRU; [[8-chloro-2-[2-(isopropylamino)thiazol-4-yl]-7-methoxy-4-quinolyl]oxy-(cyclopentoxycarbonylamino)-dioxo-[ ]yl]-[(2,6-difluorophenyl)methyl]phosphinic acid; GS9256; SCHEMBL9987287; CHEMBL1956820; DTXSID70142946; DB12876
DMCZH5B CP Gilead
DMCZH5B DT Small molecular drug
DMCZH5B PC 24823649
DMCZH5B MW 957.5
DMCZH5B FM C46H56ClF2N6O8PS
DMCZH5B IC InChI=1S/C46H56ClF2N6O8PS/c1-26(2)50-44-52-36(25-65-44)35-21-39(30-18-19-38(61-3)40(47)41(30)51-35)62-29-20-37-42(56)54-46(64(59,60)24-31-32(48)15-11-16-33(31)49)22-27(46)12-7-5-4-6-8-17-34(43(57)55(37)23-29)53-45(58)63-28-13-9-10-14-28/h11,15-16,18-19,21,25-29,34,37H,4-10,12-14,17,20,22-24H2,1-3H3,(H,50,52)(H,53,58)(H,54,56)(H,59,60)/t27-,29-,34+,37+,46+/m1/s1
DMCZH5B CS CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Cl)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6CCCCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)P(=O)(CC8=C(C=CC=C8F)F)O
DMCZH5B IK RFGUWOCFYCYEDM-ZOMNBDOOSA-N
DMCZH5B IU [(1S,4S,6R,14S,18R)-18-[8-chloro-7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-14-(cyclopentyloxycarbonylamino)-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadecan-4-yl]-[(2,6-difluorophenyl)methyl]phosphinic acid
DMCZH5B CA CAS 1001094-46-7
DMCZH5B DE Hepatitis C virus infection
DMF910Q ID DMF910Q
DMF910Q DN GS-9451
DMF910Q HS Phase 2
DMF910Q SN Vedroprevir; GS-9451; 1098189-15-1; UNII-KGD958X2B9; KGD958X2B9; CHEMBL2013174; Cyclopropanecarboxylic acid, N-[[(1a,3b,5a)-bicyclo[3.1.0]hex-3-yloxy]carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-chloro-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-7-[2-(4-morpholinyl)ethoxy]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethyl-, (1R,2R)-; 1310824-24-8; Vedroprevir [USAN:INN]; GS 9451; GS9451; Vedroprevir (USAN); SCHEMBL10082460; SCHEMBL16241357; BDBM50379653; SB16765; DB12037; D10408
DMF910Q CP GILEAD
DMF910Q DT Small molecular drug
DMF910Q PC 25167947
DMF910Q MW 910.5
DMF910Q FM C45H60ClN7O9S
DMF910Q IC InChI=1S/C45H60ClN7O9S/c1-7-27-21-45(27,41(56)57)51-39(54)33-19-29(22-53(33)40(55)38(44(4,5)6)50-43(58)62-28-17-25-16-26(25)18-28)61-35-20-31(32-23-63-42(49-32)47-24(2)3)48-37-30(35)8-9-34(36(37)46)60-15-12-52-10-13-59-14-11-52/h8-9,20,23-29,33,38H,7,10-19,21-22H2,1-6H3,(H,47,49)(H,50,58)(H,51,54)(H,56,57)/t25-,26+,27-,28?,29-,33+,38-,45-/m1/s1
DMF910Q CS CC[C@@H]1C[C@@]1(C(=O)O)NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](C(C)(C)C)NC(=O)OC3C[C@H]4C[C@H]4C3)OC5=CC(=NC6=C5C=CC(=C6Cl)OCCN7CCOCC7)C8=CSC(=N8)NC(C)C
DMF910Q IK OTXAMWFYPMNDME-OPUYQWCOSA-N
DMF910Q IU (1R,2R)-1-[[(2S,4R)-1-[(2S)-2-[[(1S,5R)-3-bicyclo[3.1.0]hexanyl]oxycarbonylamino]-3,3-dimethylbutanoyl]-4-[8-chloro-7-(2-morpholin-4-ylethoxy)-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxypyrrolidine-2-carbonyl]amino]-2-ethylcyclopropane-1-carboxylic acid
DMF910Q CA CAS 1098189-15-1
DMF910Q DE Chronic HCV-1 infection
DMG5C8D ID DMG5C8D
DMG5C8D DN GS-9620
DMG5C8D HS Phase 2
DMG5C8D SN GS-9620; 1228585-88-3; Vesatolimod; GS9620; UNII-O8M467C50G; GS 9620; CHEMBL2424780; O8M467C50G; 8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one; 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; 4-Amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one; 4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; Vesatolimod [INN]; Vesatolimod [USAN:INN]; Vesatolimod (USAN/INN); SCHEMBL10083191
DMG5C8D CP GILEAD
DMG5C8D DT Small molecular drug
DMG5C8D PC 46241268
DMG5C8D MW 410.5
DMG5C8D FM C22H30N6O2
DMG5C8D IC InChI=1S/C22H30N6O2/c1-2-3-11-30-22-25-20(23)19-21(26-22)28(15-18(29)24-19)14-17-8-6-7-16(12-17)13-27-9-4-5-10-27/h6-8,12H,2-5,9-11,13-15H2,1H3,(H,24,29)(H2,23,25,26)
DMG5C8D CS CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N
DMG5C8D IK VFOKSTCIRGDTBR-UHFFFAOYSA-N
DMG5C8D IU 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one
DMG5C8D CA CAS 1228585-88-3
DMG5C8D DE Hepatitis B virus infection; Human immunodeficiency virus infection
DMYU6P5 ID DMYU6P5
DMYU6P5 DN GS-9857
DMYU6P5 HS Phase 2
DMYU6P5 DT Small molecular drug
DMYU6P5 PC 89921642
DMYU6P5 MW 868.9
DMYU6P5 FM C40H52F4N6O9S
DMYU6P5 IC InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DMYU6P5 CS CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DMYU6P5 IK MZBLZLWXUBZHSL-FZNJKFJKSA-N
DMYU6P5 IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DMYU6P5 CA CAS 1535212-07-7
DMYU6P5 DE Hepatitis C virus infection
DM9Q2B6 ID DM9Q2B6
DM9Q2B6 DN GS-9876
DM9Q2B6 HS Phase 2
DM9Q2B6 SN XCIGZBVOUQVIPI-UHFFFAOYSA-N; lanraplenib; UNII-A6U64OU57E; A6U64OU57E; 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine; 6-(6-Aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine; Lanraplenib [INN]; GTPL9764; SCHEMBL16820581; CHEMBL3986824; example 2 [US9290505]; BDBM212271; GS9876; US9290505, Ex.-2; Ex.-2, US9290505; Imidazo(1,2-a)pyrazin-8-amine, 6-(6-amino-2-pyrazinyl)-N-(4-(4-(3-oxetanyl)-1-piperazinyl)phenyl)-; 6-(6-Aminopyr
DM9Q2B6 CP Gilead Sciences Foster City, CA
DM9Q2B6 PC 118161062
DM9Q2B6 MW 443.5
DM9Q2B6 FM C23H25N9O
DM9Q2B6 IC InChI=1S/C23H25N9O/c24-21-12-25-11-19(28-21)20-13-32-6-5-26-23(32)22(29-20)27-16-1-3-17(4-2-16)30-7-9-31(10-8-30)18-14-33-15-18/h1-6,11-13,18H,7-10,14-15H2,(H2,24,28)(H,27,29)
DM9Q2B6 CS C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N
DM9Q2B6 IK XCIGZBVOUQVIPI-UHFFFAOYSA-N
DM9Q2B6 IU 6-(6-aminopyrazin-2-yl)-N-[4-[4-(oxetan-3-yl)piperazin-1-yl]phenyl]imidazo[1,2-a]pyrazin-8-amine
DM9Q2B6 CA CAS 1800046-95-0
DM9Q2B6 DE Cutaneous lupus erythematosus; Rheumatoid arthritis
DMKWCTR ID DMKWCTR
DMKWCTR DN GS-9973
DMKWCTR HS Phase 2
DMKWCTR SN Entospletinib; 1229208-44-9; GS-9973; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; GS-9973; Entospletinib; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385
DMKWCTR CP Gilead Sciences
DMKWCTR DT Small molecular drug
DMKWCTR PC 59473233
DMKWCTR MW 411.5
DMKWCTR FM C23H21N7O
DMKWCTR IC InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
DMKWCTR CS C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6
DMKWCTR IK XSMSNFMDVXXHGJ-UHFFFAOYSA-N
DMKWCTR IU 6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
DMKWCTR CA CAS 1229208-44-9
DMKWCTR DE B-cell lymphoma; Acute myeloid leukaemia; Haematological malignancy
DMQGPLO ID DMQGPLO
DMQGPLO DN GSK-1070806
DMQGPLO HS Phase 2
DMQGPLO SN Anti-IL-18 monoclonal antibody (intravenous, inflammatory bowel disease), GSK
DMQGPLO CP GlaxoSmithKline
DMQGPLO DT Antibody
DMQGPLO DE Type-2 diabetes
DMDMXKQ ID DMDMXKQ
DMDMXKQ DN GSK1292263
DMDMXKQ HS Phase 2
DMDMXKQ CP GSK
DMDMXKQ DT Small molecular drug
DMDMXKQ PC 24996872
DMDMXKQ MW 456.6
DMDMXKQ FM C23H28N4O4S
DMDMXKQ IC InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3
DMDMXKQ CS CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C
DMDMXKQ IK AYJRTVVIBJSSKN-UHFFFAOYSA-N
DMDMXKQ IU 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole
DMDMXKQ CA CAS 1032823-75-8
DMDMXKQ DE Type-2 diabetes; Gastric adenocarcinoma
DM1EPMF ID DM1EPMF
DM1EPMF DN GSK1322322
DM1EPMF HS Phase 2
DM1EPMF SN GSK-1322322
DM1EPMF CP GlaxoSmithKline
DM1EPMF PC 52918384
DM1EPMF MW 479.5
DM1EPMF FM C22H34FN7O4
DM1EPMF IC InChI=1S/C22H34FN7O4/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26)/t17-,18+/m1/s1
DM1EPMF CS CC1=NC(=C(C(=N1)N2CCN3CCOC[C@@H]3C2)F)NNC(=O)[C@H](CC4CCCC4)CN(C=O)O
DM1EPMF IK SWHNZGMQMGFQGW-MSOLQXFVSA-N
DM1EPMF IU N-[(2R)-3-[2-[6-[(9aS)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-5-fluoro-2-methylpyrimidin-4-yl]hydrazinyl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
DM1EPMF CA CAS 1152107-25-9
DM1EPMF DE Bacterial infection
DMA6RBF ID DMA6RBF
DMA6RBF DN GSK1325756
DMA6RBF HS Phase 2
DMA6RBF SN Danirixin; 954126-98-8; GSK1325756; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea
DMA6RBF CP GlaxoSmithKline
DMA6RBF DT Small molecular drug
DMA6RBF PC 24780598
DMA6RBF MW 441.9
DMA6RBF FM C19H21ClFN3O4S
DMA6RBF IC InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
DMA6RBF CS CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O
DMA6RBF IK NGYNBSHYFOFVLS-LBPRGKRZSA-N
DMA6RBF IU 1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea
DMA6RBF CA CAS 954126-98-8
DMA6RBF DE Chronic obstructive pulmonary disease
DM6HBGN ID DM6HBGN
DM6HBGN DN GSK-1399686
DM6HBGN HS Phase 2
DM6HBGN SN 1399686
DM6HBGN CP GlaxoSmithKline plc
DM6HBGN DE Inflammatory bowel disease
DMZHB37 ID DMZHB37
DMZHB37 DN GSK2110183
DMZHB37 HS Phase 2
DMZHB37 CP GlaxoSmithKline
DMZHB37 DT Small molecular drug
DMZHB37 PC 46843057
DMZHB37 MW 427.3
DMZHB37 FM C18H17Cl2FN4OS
DMZHB37 IC InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1
DMZHB37 CS CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl
DMZHB37 IK AFJRDFWMXUECEW-LBPRGKRZSA-N
DMZHB37 IU N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide
DMZHB37 CA CAS 1047644-62-1
DMZHB37 CB CHEBI:131168
DMZHB37 DE Multiple myeloma; leukaemia; Solid tumour/cancer
DMSHE70 ID DMSHE70
DMSHE70 DN GSK2141795
DMSHE70 HS Phase 2
DMSHE70 SN Uprosertib; 1047634-65-0; GSK2141795; UNII-ZXM835LQ5E; Uprosertib (GSK2141795); GSK2141795C; ZXM835LQ5E; GSK795; GSK-2141795; 2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-;2-Furancarboxamide, N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; Uprosertib [USAN:INN]; Uprosertib (USAN/INN); Uprosertib, GSK2141795; SCHEMBL168584; GTPL7902; CHEMBL3137336; MolPort-044-560-307; AXTAPYRUEKNRBA-JTQLQIEISA-N
DMSHE70 CP GlaxoSmithKline
DMSHE70 DT Small molecular drug
DMSHE70 PC 51042438
DMSHE70 MW 429.2
DMSHE70 FM C18H16Cl2F2N4O2
DMSHE70 IC InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1
DMSHE70 CS CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl
DMSHE70 IK AXTAPYRUEKNRBA-JTQLQIEISA-N
DMSHE70 IU N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide
DMSHE70 CA CAS 1047634-65-0
DMSHE70 DE Lymphoma; Colorectal cancer
DMBWPZJ ID DMBWPZJ
DMBWPZJ DN GSK2245035
DMBWPZJ HS Phase 2
DMBWPZJ SN GSK-2245035
DMBWPZJ CP GlaxoSmithKline
DMBWPZJ DT Small molecular drug
DMBWPZJ PC 44623937
DMBWPZJ MW 390.5
DMBWPZJ FM C20H34N6O2
DMBWPZJ IC InChI=1S/C20H34N6O2/c1-3-10-15(2)28-19-23-17(21)16-18(24-19)26(20(27)22-16)14-9-5-8-13-25-11-6-4-7-12-25/h15H,3-14H2,1-2H3,(H,22,27)(H2,21,23,24)/t15-/m0/s1
DMBWPZJ CS CCC[C@H](C)OC1=NC(=C2C(=N1)N(C(=O)N2)CCCCCN3CCCCC3)N
DMBWPZJ IK LFMPVTVPXHNXOT-HNNXBMFYSA-N
DMBWPZJ IU 6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one
DMBWPZJ CA CAS 1207629-49-9
DMBWPZJ DE Asthma
DMG7YQL ID DMG7YQL
DMG7YQL DN GSK2245840
DMG7YQL HS Phase 2
DMG7YQL SN Gepirone hydrochloride; GEPIRONE HYDROCHLORIDE; Gepirone HCl; UNII-80C9L8EP6V; Gepirone hydrochloride [USAN]; 80C9L8EP6V; 83928-66-9; CHEMBL1204187; Gepirone hydrochloride (USAN); BMY 138951; AC1Q3ELB; AC1L1IK3; SCHEMBL318838; DTXSID30232812; AOB5299; 83928-76-1 (Parent); ORG-33062; SB19633; BMY-13805-1; BMY 13805-1; 3,3-Dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride; D04314; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione hydrochloride; 2,6-Piperidinedione,
DMG7YQL CP GSK
DMG7YQL DT Small molecular drug
DMG7YQL PC 25108829
DMG7YQL MW 516.6
DMG7YQL FM C26H24N6O2S2
DMG7YQL IC InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
DMG7YQL CS CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6
DMG7YQL IK LAMQVIQMVKWXOC-UHFFFAOYSA-N
DMG7YQL IU 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide
DMG7YQL CA CAS 1093403-33-8
DMG7YQL DE Chronic obstructive pulmonary disease
DMLFI7Q ID DMLFI7Q
DMLFI7Q DN GSK-2251052
DMLFI7Q HS Phase 2
DMLFI7Q SN ABX; AN-3365; GSK '052; Boron-based LeuRS inhibitors (Gram-negative bacterial infection), Anacor/GSK; Boron-based leucyl-tRNA synthetase inhibitors (bacterial infection), Anacor/GSK
DMLFI7Q CP Anacor Pharmaceuticals Inc
DMLFI7Q DT Small molecular drug
DMLFI7Q PC 46836890
DMLFI7Q MW 237.06
DMLFI7Q FM C11H16BNO4
DMLFI7Q IC InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2/t10-/m1/s1
DMLFI7Q CS B1(C2=C(C=CC=C2OCCCO)[C@H](O1)CN)O
DMLFI7Q IK FXQIIDINBDJDKL-SNVBAGLBSA-N
DMLFI7Q IU 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol
DMLFI7Q CA CAS 1093643-37-8
DMLFI7Q DE Urinary tract infection
DMIN0SV ID DMIN0SV
DMIN0SV DN GSK2269557
DMIN0SV HS Phase 2
DMIN0SV CP Glaxosmithkline
DMIN0SV PC 49784002
DMIN0SV MW 440.5
DMIN0SV FM C26H28N6O
DMIN0SV IC InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)
DMIN0SV CS CC(C)N1CCN(CC1)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=C6C=CNC6=CC=C5
DMIN0SV IK MCIDWGZGWVSZMK-UHFFFAOYSA-N
DMIN0SV IU 2-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole
DMIN0SV CA CAS 1254036-71-9
DMIN0SV DE Asthma
DM4BTH8 ID DM4BTH8
DM4BTH8 DN GSK2330672
DM4BTH8 HS Phase 2
DM4BTH8 CP GlaxoSmithKline
DM4BTH8 PC 53492727
DM4BTH8 MW 546.7
DM4BTH8 FM C28H38N2O7S
DM4BTH8 IC InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
DM4BTH8 CS CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC
DM4BTH8 IK CZGVOBIGEBDYTP-VSGBNLITSA-N
DM4BTH8 IU 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1lambda6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid
DM4BTH8 CA CAS 1345982-69-5
DM4BTH8 DE Type-2 diabetes; Pruritus
DMB0CXT ID DMB0CXT
DMB0CXT DN GSK2330811
DMB0CXT HS Phase 2
DMB0CXT CP GlaxoSmithKline Research Triangle Park, NC
DMB0CXT DE Systemic sclerosis; Crohn disease
DMXUCG3 ID DMXUCG3
DMXUCG3 DN GSK233705
DMXUCG3 HS Phase 2
DMXUCG3 CP GlaxoSmithKline
DMXUCG3 DE Chronic obstructive pulmonary disease
DMRA3T2 ID DMRA3T2
DMRA3T2 DN GSK2339345
DMRA3T2 HS Phase 2
DMRA3T2 SN GSK-2339345
DMRA3T2 CP GlaxoSmithKline
DMRA3T2 DE Cough
DMBJMZC ID DMBJMZC
DMBJMZC DN GSK239512
DMBJMZC HS Phase 2
DMBJMZC SN 720691-69-0; GSK-239512; 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YL)OXY)PYRIDIN-3-YL)PYRROLIDIN-2-ONE; GSK239512; UNII-4I7U5C459M; CHEMBL3092650; 4I7U5C459M; YFRBKEVUUCQYOW-UHFFFAOYSA-N; SCHEMBL167578; MolPort-035-776-189; ZINC3961802; BDBM50444496; AKOS025291102; SB16754; KS-0000063Q; AS-42474; AK171368; 2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-; J3.497.402K
DMBJMZC CP GSK
DMBJMZC DT Small molecular drug
DMBJMZC PC 9976892
DMBJMZC MW 377.5
DMBJMZC FM C23H27N3O2
DMBJMZC IC InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
DMBJMZC CS C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
DMBJMZC IK YFRBKEVUUCQYOW-UHFFFAOYSA-N
DMBJMZC IU 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
DMBJMZC CA CAS 720691-69-0
DMBJMZC DE Dementia; Alzheimer disease
DMFAU3Z ID DMFAU3Z
DMFAU3Z DN GSK249320
DMFAU3Z HS Phase 2
DMFAU3Z CP GlaxoSmithKline
DMFAU3Z DT Antibody
DMFAU3Z DE Stroke
DMMAIY2 ID DMMAIY2
DMMAIY2 DN GSK-256073
DMMAIY2 HS Phase 2
DMMAIY2 SN GPCR agonists (hyperlipidemia), GSK; GSK-256073-A; HM74A receptor agonists (hyperlipidemia), GSK; G protein-coupled receptor agonists (hyperlipidemia), GSK
DMMAIY2 CP GlaxoSmithKline plc
DMMAIY2 DT Small molecular drug
DMMAIY2 PC 46215799
DMMAIY2 MW 256.69
DMMAIY2 FM C10H13ClN4O2
DMMAIY2 IC InChI=1S/C10H13ClN4O2/c1-2-3-4-5-15-7-6(12-9(11)13-7)8(16)14-10(15)17/h2-5H2,1H3,(H,12,13)(H,14,16,17)
DMMAIY2 CS CCCCCN1C2=C(C(=O)NC1=O)NC(=N2)Cl
DMMAIY2 IK CGAMDQCXAAOFSR-UHFFFAOYSA-N
DMMAIY2 IU 8-chloro-3-pentyl-7H-purine-2,6-dione
DMMAIY2 CA CAS 862892-90-8
DMMAIY2 DE Hyperlipidaemia
DMA2IXQ ID DMA2IXQ
DMA2IXQ DN GSK2586184
DMA2IXQ HS Phase 2
DMA2IXQ SN GSK-2586184
DMA2IXQ CP GlaxoSmithKline
DMA2IXQ PC 44603362
DMA2IXQ MW 389.4
DMA2IXQ FM C22H23N5O2
DMA2IXQ IC InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)
DMA2IXQ CS CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C
DMA2IXQ IK MPYACSQFXVMWNO-UHFFFAOYSA-N
DMA2IXQ IU N-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
DMA2IXQ CA CAS 1206163-45-2
DMA2IXQ DE Arthritis; Systemic lupus erythematosus
DMU5EVR ID DMU5EVR
DMU5EVR DN GSK2586881
DMU5EVR HS Phase 2
DMU5EVR SN GSK-2586881
DMU5EVR CP GlaxoSmithKline
DMU5EVR DE Acute lung injury; Pulmonary arterial hypertension
DM7V96W ID DM7V96W
DM7V96W DN GSK2798745
DM7V96W HS Phase 2
DM7V96W CP GlaxoSmithKline Research Triangle Park, NC
DM7V96W DE Heart failure
DMCIGRW ID DMCIGRW
DMCIGRW DN GSK2838232
DMCIGRW HS Phase 2
DMCIGRW CP GlaxoSmithKline
DMCIGRW DT Small molecular drug
DMCIGRW DE Human immunodeficiency virus-1 infection
DMT5YK7 ID DMT5YK7
DMT5YK7 DN GSK2890457
DMT5YK7 HS Phase 2
DMT5YK7 SN GSK-2890457
DMT5YK7 CP GlaxoSmithKline
DMT5YK7 DE Obesity
DM25YLM ID DM25YLM
DM25YLM DN GSK2981278
DM25YLM HS Phase 2
DM25YLM SN ROR gama modulator 1; 1474110-21-8; UNII-L49V5G013I; L49V5G013I; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide; GTPL9661; SCHEMBL15352875; LZLBRISQTJVZNP-UHFFFAOYSA-N; MolPort-044-561-790; EX-A1179; ZINC142250256; AKOS030526564; CS-5449; GSK-2981278; HY-19770; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide; Benzenesulfonamide, N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-((tetrahydro-2H-pyran-4-yl)
DM25YLM CP GlaxoSmithKline Research Triangle Park, NC
DM25YLM PC 89875987
DM25YLM MW 461.6
DM25YLM FM C25H35NO5S
DM25YLM IC InChI=1S/C25H35NO5S/c1-4-20-5-7-23(8-6-20)26(16-19(2)3)32(28,29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10,15,19,21,27H,4,11-14,16-18H2,1-3H3
DM25YLM CS CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO
DM25YLM IK LZLBRISQTJVZNP-UHFFFAOYSA-N
DM25YLM IU N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide
DM25YLM CA CAS 1474110-21-8
DM25YLM DE Plaque psoriasis
DM7HNFV ID DM7HNFV
DM7HNFV DN GSK2982772
DM7HNFV HS Phase 2
DM7HNFV SN LYPAFUINURXJSG-AWEZNQCLSA-N; 1622848-92-3; UNII-T5W3M0VO9B; T5W3M0VO9B; GSK-2982772; (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide; GTPL9554; SCHEMBL15956219; MolPort-044-830-634; s8484; AKOS030528033; compound 5 [PMID: 28151659]; ACN-041458; CS-6899; GSK 2982772; AS-35128; AC-29894; HY-101760; J3.650.802G; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide; 3-Benzyl-N-[(3s)-5-Methyl-4-Oxo-2,3,4,5-Tetrahydr
DM7HNFV CP GlaxoSmithKline Research Triangle Park, NC
DM7HNFV PC 77108121
DM7HNFV MW 377.4
DM7HNFV FM C20H19N5O3
DM7HNFV IC InChI=1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(23-24-18)11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24)/t14-/m0/s1
DM7HNFV CS CN1C2=CC=CC=C2OC[C@@H](C1=O)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
DM7HNFV IK LYPAFUINURXJSG-AWEZNQCLSA-N
DM7HNFV IU 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
DM7HNFV CA CAS 1622848-92-3
DM7HNFV DE Plaque psoriasis; Psoriasis vulgaris; Rheumatoid arthritis; Ulcerative colitis
DMCDAVK ID DMCDAVK
DMCDAVK DN GSK3036656
DMCDAVK HS Phase 2
DMCDAVK SN GSK656 HCl; GSK656; 2131798-13-3; UNII-P83HS633ZK; P83HS633ZK; CHEMBL4082159; 2131798-13-3 (HCl); GSK-656; GSK-070; BCP29367; EX-A3128; BDBM50241779; GSK-3036656; GSK3036656; GSK070 hydrochloride; HY-107775; CS-0030140; (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride; (S)3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)ol hydrochloride; (S)a?-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)a'ol hydrochloride; Ethanol, 2-(((3S)-3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl)oxy)-, hydrochloride (1:1)
DMCDAVK CP GlaxoSmithKline
DMCDAVK DT Small molecular drug
DMCDAVK PC 134691736
DMCDAVK MW 293.94
DMCDAVK FM C10H14BCl2NO4
DMCDAVK IC InChI=1S/C10H13BClNO4.ClH/c12-6-1-2-7(16-4-3-14)10-9(6)8(5-13)17-11(10)15;/h1-2,8,14-15H,3-5,13H2;1H/t8-;/m1./s1
DMCDAVK CS B1(C2=C(C=CC(=C2[C@H](O1)CN)Cl)OCCO)O.Cl
DMCDAVK IK FUOKBESTQMGROA-DDWIOCJRSA-N
DMCDAVK IU 2-[[(3S)-3-(aminomethyl)-4-chloro-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]ethanol;hydrochloride
DMCDAVK CA CAS 2131798-13-3
DMCDAVK DE Tuberculosis
DMEXKF4 ID DMEXKF4
DMEXKF4 DN GSK3196165
DMEXKF4 HS Phase 2
DMEXKF4 CP GlaxoSmithKline Research Triangle Park, NC
DMEXKF4 DE Rheumatoid arthritis
DMPBK8N ID DMPBK8N
DMPBK8N DN GSK3228836
DMPBK8N HS Phase 2
DMPBK8N SN IONIS-HBVRX; GSK'836
DMPBK8N CP GlaxoSmithKline
DMPBK8N DT Antisense oligonucleotide
DMPBK8N DE Hepatitis B
DMJRD7A ID DMJRD7A
DMJRD7A DN GSK3326595
DMJRD7A HS Phase 2
DMJRD7A SN JLCCNYVTIWRPIZ-NRFANRHFSA-N; 1616392-22-3; 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyrimidine-4-carboxamide; SCHEMBL15825290; MolPort-044-813-754; BDBM178166; AKOS030528008; ZINC220119494; CS-6451; AS-53150; HY-101563; GSK3326595(EPZ015938); US9675614, 208; (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
DMJRD7A CP GlaxoSmithKline Research Triangle Park, NC
DMJRD7A PC 90241742
DMJRD7A MW 452.5
DMJRD7A FM C24H32N6O3
DMJRD7A IC InChI=1S/C24H32N6O3/c1-17(31)30-10-7-20(8-11-30)28-23-12-22(26-16-27-23)24(33)25-13-21(32)15-29-9-6-18-4-2-3-5-19(18)14-29/h2-5,12,16,20-21,32H,6-11,13-15H2,1H3,(H,25,33)(H,26,27,28)/t21-/m0/s1
DMJRD7A CS CC(=O)N1CCC(CC1)NC2=NC=NC(=C2)C(=O)NC[C@@H](CN3CCC4=CC=CC=C4C3)O
DMJRD7A IK JLCCNYVTIWRPIZ-NRFANRHFSA-N
DMJRD7A IU 6-[(1-acetylpiperidin-4-yl)amino]-N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]pyrimidine-4-carboxamide
DMJRD7A CA CAS 1616392-22-3
DMJRD7A DE Non-hodgkin lymphoma; Solid tumour/cancer; Breast cancer
DMO5JS3 ID DMO5JS3
DMO5JS3 DN GSK3389404
DMO5JS3 HS Phase 2
DMO5JS3 SN IONIS-HBV-LRX
DMO5JS3 CP GlaxoSmithKline
DMO5JS3 DT Antisense oligonucleotide
DMO5JS3 DE Hepatitis B
DMMOWT9 ID DMMOWT9
DMMOWT9 DN GSK3640254
DMMOWT9 HS Phase 2
DMMOWT9 SN GSK'254
DMMOWT9 CP ViiV Healthcare
DMMOWT9 DE Human immunodeficiency virus infection
DMV3TO4 ID DMV3TO4
DMV3TO4 DN GSK3810109
DMV3TO4 HS Phase 2
DMV3TO4 CP ViiV Healthcare
DMV3TO4 DT Antibody
DMV3TO4 DE Human immunodeficiency virus-1 infection
DMV6SNU ID DMV6SNU
DMV6SNU DN GSK4069889
DMV6SNU HS Phase 2
DMV6SNU SN TSR-022
DMV6SNU CP AnaptysBio
DMV6SNU DT Antibody
DMV6SNU DE Non-small cell lung cancer
DM3ZL2O ID DM3ZL2O
DM3ZL2O DN GSK-557296
DM3ZL2O HS Phase 2
DM3ZL2O SN Epelsiban; Epelsiban besylate; Premature ejaculation therapeutic (oral), GlaxoSmithKline
DM3ZL2O CP GlaxoSmithKline plc
DM3ZL2O DT Small molecular drug
DM3ZL2O PC 11634973
DM3ZL2O MW 518.6
DM3ZL2O FM C30H38N4O4
DM3ZL2O IC InChI=1S/C30H38N4O4/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35)/t18-,25+,26+,27+/m0/s1
DM3ZL2O CS CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
DM3ZL2O IK UWHCWRQFNKUYCG-QUZACWSFSA-N
DM3ZL2O IU (3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
DM3ZL2O CA CAS 872599-83-2
DM3ZL2O DE Premature ejaculation
DMEVARK ID DMEVARK
DMEVARK DN GSK561679
DMEVARK HS Phase 2
DMEVARK SN VERUCERFONT; 885220-61-1; GSK561679; GSK561679A; UNII-X60608B091; GSK 561679A; NBI-77860; X60608B091; GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine; NBI 77860; Verucerfont [USAN:INN]; GSK 561679; GSK-561679; Verucerfont (USAN/INN); Verucerfont,GSK561679; SCHEMBL205309; CHEMBL1287935; EX-A1718; BDBM50417503; ZINC34661169; SB17107; CS-8099; DB12512; KB-77609; HY-14875; AC-30339; D09695
DMEVARK CP GSK
DMEVARK DT Small molecular drug
DMEVARK PC 11596613
DMEVARK MW 406.5
DMEVARK FM C22H26N6O2
DMEVARK IC InChI=1S/C22H26N6O2/c1-7-18(22-24-15(5)27-30-22)25-19-11-13(3)23-21-20(14(4)26-28(19)21)17-9-8-16(29-6)10-12(17)2/h8-11,18,25H,7H2,1-6H3/t18-/m0/s1
DMEVARK CS CC[C@@H](C1=NC(=NO1)C)NC2=CC(=NC3=C(C(=NN23)C)C4=C(C=C(C=C4)OC)C)C
DMEVARK IK VKHVAUKFLBBZFJ-SFHVURJKSA-N
DMEVARK IU 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine
DMEVARK CA CAS 885220-61-1
DMEVARK DE Major depressive disorder; Alcohol dependence
DMGU05N ID DMGU05N
DMGU05N DN GSK598809
DMGU05N HS Phase 2
DMGU05N CP GSK
DMGU05N PC 24743758
DMGU05N MW 481.5
DMGU05N FM C22H23F4N5OS
DMGU05N IC InChI=1S/C22H23F4N5OS/c1-13-18(32-12-27-13)19-28-29-20(30(19)2)33-7-3-6-31-10-15-9-21(15,11-31)16-5-4-14(8-17(16)23)22(24,25)26/h4-5,8,12,15H,3,6-7,9-11H2,1-2H3
DMGU05N CS CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CC4CC4(C3)C5=C(C=C(C=C5)C(F)(F)F)F
DMGU05N IK ZKRWPAYTJMRKLJ-UHFFFAOYSA-N
DMGU05N IU 5-[5-[3-[1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-4-methyl-1,2,4-triazol-3-yl]-4-methyl-1,3-oxazole
DMGU05N DE Drug abuse
DMTW79H ID DMTW79H
DMTW79H DN GSK683699
DMTW79H HS Phase 2
DMTW79H SN 4-Aminobutanoic acid; 4-aminobutyric acid; GABA; gamma-aminobutyric acid; 1956/12/2; Piperidic acid; Piperidinic acid; Aminalon; Mielogen; Gammalon; Gaballon; butanoic acid, 4-amino-; Mielomade; Gammalone; Gamarex; Gammasol; Gammar; Reanal; Immu-G; gamma-amino-n-butyric acid; gamma-Aminobutanoic acid; Butyric acid, 4-amino-; Gamastan; Gammagee; Gamulin; 4-aminobutyrate; omega-Aminobutyric acid; gamma-Aminobutyric acid; 3-Carboxypropylamine; gamma-Aminobuttersaeure; 4-amino-butanoic acid; gamma-Amino butyric acid; GAMMA-AMINO-BUTANOIC ACID
DMTW79H CP GSK; Tanabe
DMTW79H DT Small molecular drug
DMTW79H PC 119
DMTW79H MW 103.12
DMTW79H FM C4H9NO2
DMTW79H IC InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)
DMTW79H CS C(CC(=O)O)CN
DMTW79H IK BTCSSZJGUNDROE-UHFFFAOYSA-N
DMTW79H IU 4-aminobutanoic acid
DMTW79H CA CAS 56-12-2
DMTW79H CB CHEBI:16865
DMTW79H DE Inflammatory bowel disease
DMPLKAH ID DMPLKAH
DMPLKAH DN GSK-706769
DMPLKAH HS Phase 2
DMPLKAH SN GSK-163929; GSK-929; CCR5 antagonist (HIV), GSK; CCR5 antagonist (HIV), ViiV; CCR5 chemokine antagonists (HIV-1 infection),GlaxoSmithKline
DMPLKAH CP GlaxoSmithKline plc
DMPLKAH DE Human immunodeficiency virus infection
DMIEXUM ID DMIEXUM
DMIEXUM DN GSK768974
DMIEXUM HS Phase 2
DMIEXUM SN PTH analog, GlaxoSmithKline/Unigene; Parathyroid hormone analog (oral, Enteripep), Unigene/GlaxoSmithKline
DMIEXUM CP Unigene Laboratories Inc
DMIEXUM DE Osteoporosis
DMX27Q1 ID DMX27Q1
DMX27Q1 DN GSK933776A
DMX27Q1 HS Phase 2
DMX27Q1 CP GlaxoSmithKline
DMX27Q1 DE Macular degeneration; Alzheimer disease
DM6DKF9 ID DM6DKF9
DM6DKF9 DN GSK961081
DM6DKF9 HS Phase 2
DM6DKF9 SN CHEMBL1683934; SCHEMBL524583; NVEMUJANQDPDSC-DHUJRADRSA-N; BDBM50337878; Biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester; (R)-1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl biphenyl-2-ylcarbamate
DM6DKF9 CP GSK
DM6DKF9 DT Small molecular drug
DM6DKF9 PC 10372836
DM6DKF9 MW 740.2
DM6DKF9 FM C40H42ClN5O7
DM6DKF9 IC InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)/t35-/m0/s1
DM6DKF9 CS COC1=CC(=C(C=C1CNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)Cl)NC(=O)CCN4CCC(CC4)OC(=O)NC5=CC=CC=C5C6=CC=CC=C6
DM6DKF9 IK URWYQGVSPQJGGB-DHUJRADRSA-N
DM6DKF9 IU [1-[3-[2-chloro-4-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-5-methoxyanilino]-3-oxopropyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
DM6DKF9 CA CAS 743461-65-6
DM6DKF9 DE Chronic obstructive pulmonary disease
DM8N3OQ ID DM8N3OQ
DM8N3OQ DN GT-AADC
DM8N3OQ HS Phase 2
DM8N3OQ CP PTC Therapeutics
DM8N3OQ DT Gene therapy
DM8N3OQ DE Aromatic L-amino acid decarboxylase deficiency
DMN6IDO ID DMN6IDO
DMN6IDO DN GTP-010
DMN6IDO HS Phase 2
DMN6IDO CP Gastrotech Pharma
DMN6IDO DE Dyspepsia; Irritable bowel syndrome
DM03NQS ID DM03NQS
DM03NQS DN GTP-200
DM03NQS HS Phase 2
DM03NQS DE Solid tumour/cancer
DMEN5KA ID DMEN5KA
DMEN5KA DN GTS-21
DMEN5KA HS Phase 2
DMEN5KA SN Gts-21; DMXBA; Gts 21; DMXB-Anabaseine; GTS-21 (dihydrochloride); DMXB-A; (E)-3-((2,4-Dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-2,3'-bipyridine dihydrochloride; 2,3'-Bipyridine, 3-((2,4-dimethoxyphenyl)methylene)-3,4,5,6-tetrahydro-, dihydrochloride, (E)-; DMBX-anabaseine; DMBX-A; AC1O5PJQ; SCHEMBL2561893; SCHEMBL12274790; HY-14564A; CS-5486; SB16826; BC654014; AN-16572; GTS-21, > LS-173500; 3-(2,4-Dimethoxybenzylidene)anabaseine dihydrochloride
DMEN5KA DT Small molecular drug
DMEN5KA PC 5310985
DMEN5KA MW 308.4
DMEN5KA FM C19H20N2O2
DMEN5KA IC InChI=1S/C19H20N2O2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16/h3,6-9,11-13H,4-5,10H2,1-2H3/b15-11+
DMEN5KA CS COC1=CC(=C(C=C1)/C=C/2\\CCCN=C2C3=CN=CC=C3)OC
DMEN5KA IK RPYWXZCFYPVCNQ-RVDMUPIBSA-N
DMEN5KA IU 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine
DMEN5KA CA CAS 148372-04-7
DMEN5KA DE Parkinson disease
DMDWYZS ID DMDWYZS
DMDWYZS DN GTx-758
DMDWYZS HS Phase 2
DMDWYZS CP GTx
DMDWYZS PC 46861578
DMDWYZS MW 341.3
DMDWYZS FM C19H13F2NO3
DMDWYZS IC InChI=1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H
DMDWYZS CS C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O
DMDWYZS IK FBCQEUMZZNVQKD-UHFFFAOYSA-N
DMDWYZS IU 3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide
DMDWYZS CA CAS 938067-78-8
DMDWYZS DE Prostate cancer
DMY53PL ID DMY53PL
DMY53PL DN GW 597599
DMY53PL HS Phase 2
DMY53PL SN Vestipitant mesylate < USAN; N-[1(R)-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-2(S)-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide methanesulfonate
DMY53PL CP GlaxoSmithKline
DMY53PL DT Small molecular drug
DMY53PL PC 24969622
DMY53PL MW 587.6
DMY53PL FM C24H28F7N3O4S
DMY53PL IC InChI=1S/C23H24F7N3O.CH4O3S/c1-13-8-18(24)4-5-19(13)20-12-31-6-7-33(20)21(34)32(3)14(2)15-9-16(22(25,26)27)11-17(10-15)23(28,29)30;1-5(2,3)4/h4-5,8-11,14,20,31H,6-7,12H2,1-3H3;1H3,(H,2,3,4)/t14-,20-;/m1./s1
DMY53PL CS CC1=C(C=CC(=C1)F)[C@H]2CNCCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F.CS(=O)(=O)O
DMY53PL IK BHECXGHXWKHZOY-DXPOFMJKSA-N
DMY53PL IU (2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide;methanesulfonic acid
DMY53PL CA CAS 334476-64-1
DMY53PL DE Mood disorder; Major depressive disorder
DMZMCB1 ID DMZMCB1
DMZMCB1 DN GW274150
DMZMCB1 HS Phase 2
DMZMCB1 SN GW274150; GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
DMZMCB1 DT Small molecular drug
DMZMCB1 PC 9797017
DMZMCB1 MW 219.31
DMZMCB1 FM C8H17N3O2S
DMZMCB1 IC InChI=1S/C8H17N3O2S/c1-6(9)11-3-5-14-4-2-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
DMZMCB1 CS CC(=NCCSCC[C@@H](C(=O)O)N)N
DMZMCB1 IK MOLOJNHYNHBPCW-ZETCQYMHSA-N
DMZMCB1 IU (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
DMZMCB1 CA CAS 210354-22-6
DMZMCB1 DE Asthma
DMY3KSU ID DMY3KSU
DMY3KSU DN GW-42004
DMY3KSU HS Phase 2
DMY3KSU SN CB1/CB2 receptor antagonist (oral/capsule, obesity/type 2 diabetes/dyslipidemia), GW Pharmaceuticals
DMY3KSU CP GW Pharmaceuticals plc
DMY3KSU DE Lipid metabolism disorder
DMBX9C0 ID DMBX9C0
DMBX9C0 DN GW-427353
DMBX9C0 HS Phase 2
DMBX9C0 SN UNII-GU14FR8D4A; GU14FR8D4A; GW427353B; Solabegron hydrochloride [USAN]; Solabegron hydrochloride (USAN); GW 427353B; Solabegron Hydrochloride; Solabegron HCl; SCHEMBL565177; CHEMBL2107299; PMXCGBVBIRYFPR-FTBISJDPSA-N; BCP28076; 3'-[(2-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]biphenyl-3-carboxylic acid hydrochloride; D05879; (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-, hydrochloride
DMBX9C0 CP GSK
DMBX9C0 DT Small molecular drug
DMBX9C0 PC 9887812
DMBX9C0 MW 410.9
DMBX9C0 FM C23H23ClN2O3
DMBX9C0 IC InChI=1S/C23H23ClN2O3/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29)/t22-/m0/s1
DMBX9C0 CS C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNC[C@@H](C3=CC(=CC=C3)Cl)O
DMBX9C0 IK LLDXOPKUNJTIRF-QFIPXVFZSA-N
DMBX9C0 IU 3-[3-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethylamino]phenyl]benzoic acid
DMBX9C0 CA CAS 252920-94-8
DMBX9C0 CB CHEBI:141346
DMBX9C0 DE Urinary incontinence
DMH0C8J ID DMH0C8J
DMH0C8J DN GW-813893
DMH0C8J HS Phase 2
DMH0C8J SN Factor Xa inhibitors, GSK; Factor Xa inhibitors, GlaxoSmithKline; 813893
DMH0C8J CP GlaxoSmithKline plc
DMH0C8J PC 9911502
DMH0C8J MW 448
DMH0C8J FM C17H22ClN3O5S2
DMH0C8J IC InChI=1S/C17H22ClN3O5S2/c1-12(16(22)20-7-9-26-10-8-20)21-6-4-14(17(21)23)19-28(24,25)11-5-13-2-3-15(18)27-13/h2-3,5,11-12,14,19H,4,6-10H2,1H3/b11-5+/t12-,14-/m0/s1
DMH0C8J CS C[C@@H](C(=O)N1CCOCC1)N2CC[C@@H](C2=O)NS(=O)(=O)/C=C/C3=CC=C(S3)Cl
DMH0C8J IK ACEFOQMQINFMRW-DYCFVMESSA-N
DMH0C8J IU (E)-2-(5-chlorothiophen-2-yl)-N-[(3S)-1-[(2S)-1-morpholin-4-yl-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide
DMH0C8J CA CAS 478644-12-1
DMH0C8J DE Thrombosis
DM489FT ID DM489FT
DM489FT DN GW-870086-X
DM489FT HS Phase 2
DM489FT SN GW-870086-X (topical, atopic dermatitis), GlaxoSmithKline
DM489FT CP GlaxoSmithKline plc
DM489FT DE Atopic dermatitis
DMQEC9P ID DMQEC9P
DMQEC9P DN GW-870086-X
DMQEC9P HS Phase 2
DMQEC9P SN Glucocorticoid agonist (asthma), GlaxoSmithKline; GW-870086-X (inhaled, asthma), GlaxoSmithKline
DMQEC9P CP GlaxoSmithKline plc
DMQEC9P DE Asthma
DM8XH3S ID DM8XH3S
DM8XH3S DN H-1152
DM8XH3S HS Phase 2
DM8XH3S SN 451462-58-1; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; CHEBI:88220; H-1152P; (S)-H-1152 (hydrochloride); H52; dimethyl fasudil; 4-methyl-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline; 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline; 2gnh; 2gnl; 1q8u; AC1L9LJA; H 1152; SCHEMBL124161; CHEMBL406821; ZINC22706; BDBM14028; BCP16935; 3714AH; AKOS027263830; DB07876; CS-1536; HY-15720; LS-193100; W-5343; 4-methyl-5-[(2S)-2-methyl-1,4-diazepane-1-sulfonyl]isoquinoline
DM8XH3S CP CoTherix
DM8XH3S DT Small molecular drug
DM8XH3S PC 448043
DM8XH3S MW 319.4
DM8XH3S FM C16H21N3O2S
DM8XH3S IC InChI=1S/C16H21N3O2S/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3/t13-/m0/s1
DM8XH3S CS C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=C2C(=CN=C3)C
DM8XH3S IK AWDORCFLUJZUQS-ZDUSSCGKSA-N
DM8XH3S IU 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline
DM8XH3S CA CAS 451462-58-1
DM8XH3S CB CHEBI:88220
DM8XH3S DE Pulmonary arterial hypertension
DMO4I61 ID DMO4I61
DMO4I61 DN H5N1 influenza vaccine
DMO4I61 HS Phase 2
DMO4I61 SN Daronrix; GSK-1119711A; H5N1 influenza vaccine (inactivated whole virus adjuvanted); Avian influenzavaccine (inactivated whole virus adjuvanted), GlaxoSmithKline; H5N1 influenza vaccine (inactivated whole virus adjuvanted), GlaxoSmithKline
DMO4I61 CP GlaxoSmithKline plc
DMO4I61 DT Vaccine
DMO4I61 DE Influenza virus infection
DM74ZKN ID DM74ZKN
DM74ZKN DN HBI-3000
DM74ZKN HS Phase 2
DM74ZKN SN Sulcardine; Multi-ion channel blocker (oral, arrhythmia), SIMM; Multi-ion channel blocker (oral/iv, arrhythmia), HUYA
DM74ZKN CP Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
DM74ZKN DE Heart arrhythmia; Atrial fibrillation
DMSMCXN ID DMSMCXN
DMSMCXN DN HBV vaccine
DMSMCXN HS Phase 2
DMSMCXN SN HBV vaccine (adjuvanted); HBV vaccine (adjuvanted), GlaxoSmithKline Biologicals
DMSMCXN CP GlaxoSmithKline Biologicals
DMSMCXN DT Vaccine
DMSMCXN DE Hepatitis B virus infection
DMX8C6J ID DMX8C6J
DMX8C6J DN HCB1019
DMX8C6J HS Phase 2
DMX8C6J CP OcuNexus Therapeutics
DMX8C6J DT Small molecular drug
DMX8C6J DE Diabetic macular edema
DMRQGMZ ID DMRQGMZ
DMRQGMZ DN HD-003
DMRQGMZ HS Phase 2
DMRQGMZ SN NZ-419; Selective hydroxy radical modulator (chronic kidney disease), Hyundai/ Nippon Zoki
DMRQGMZ CP Nippon Zoki Pharmaceutical Co Ltd
DMRQGMZ DE Kidney disease
DMAX632 ID DMAX632
DMAX632 DN HDV-interferon
DMAX632 HS Phase 2
DMAX632 SN HDV-interferon (sc, HCV infection); HDV-IFN (sc, HCV infection), Hepasome Pharmaceuticals; HDV-interferon (sc, HCV infection), Hepasome Pharmaceuticals
DMAX632 CP Hepasome Pharmaceuticals
DMAX632 DE Hepatitis C virus infection
DMV50R1 ID DMV50R1
DMV50R1 DN HE3235
DMV50R1 HS Phase 2
DMV50R1 SN Apoptone; HE3235; UNII-891O182ZP5; 183387-50-0; HE 3235; 891O182ZP5; SCHEMBL3402872; Pregn-20-yne-3,17-diol, (3alpha,5alpha,17alpha)-; DTXSID70171418; MolPort-044-561-946; ZINC5921098
DMV50R1 CP Harbor Therapeutics
DMV50R1 DT Small molecular drug
DMV50R1 PC 42611099
DMV50R1 MW 316.5
DMV50R1 FM C21H32O2
DMV50R1 IC InChI=1S/C21H32O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14-18,22-23H,5-13H2,2-3H3/t14-,15+,16+,17-,18-,19-,20-,21-/m0/s1
DMV50R1 CS C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C)O
DMV50R1 IK CKAXZOYFIHQCBN-JRRMKBMNSA-N
DMV50R1 IU (3R,5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol
DMV50R1 CA CAS 183387-50-0
DMV50R1 DE Breast cancer
DM9OZU5 ID DM9OZU5
DM9OZU5 DN Heat shock protein vaccine
DM9OZU5 HS Phase 2
DM9OZU5 CP Agenus
DM9OZU5 DT Vaccine
DM9OZU5 DE Meningococcal infection
DM8QGPE ID DM8QGPE
DM8QGPE DN HepaStem
DM8QGPE HS Phase 2
DM8QGPE CP Promethera Biosciences SA/NV
DM8QGPE DE Liver failure
DMX6B95 ID DMX6B95
DMX6B95 DN HER1-VSSP vaccine
DMX6B95 HS Phase 2
DMX6B95 SN HER1-VSSP vaccine (cancer)
DMX6B95 CP The Center of Molecular Immunology
DMX6B95 DT Vaccine
DMX6B95 DE Solid tumour/cancer
DM8TOS0 ID DM8TOS0
DM8TOS0 DN HER-2 Protein AutoVac
DM8TOS0 HS Phase 2
DM8TOS0 CP Pharmexa
DM8TOS0 DE Breast cancer
DMISETH ID DMISETH
DMISETH DN HER2/neu peptide vaccine
DMISETH HS Phase 2
DMISETH SN HER2/neu peptide vaccine (intradermal, breast cancer)
DMISETH CP Fred Hutchinson Cancer Research Center
DMISETH DT Vaccine
DMISETH DE Breast cancer
DMQTREC ID DMQTREC
DMQTREC DN Her2-targeted autologous T-cell therapy
DMQTREC HS Phase 2
DMQTREC SN Her2-targeted autologous T-cell therapy (cancer)
DMQTREC CP Baylor College of Medicine
DMQTREC DE Glioblastoma multiforme
DMI4C90 ID DMI4C90
DMI4C90 DN HF-0220
DMI4C90 HS Phase 2
DMI4C90 SN Cytoprotective steroid (Alzheimer's disease), Newron; Prostaglandin D synthase stimulator (Alzheimer's disease), Newron; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Newron; Cytoprotective steroid (Alzheimer's disease), Hunter-Fleming; Prostaglandin D synthase stimulator (Alzheimer's disease), Hunter-Fleming; Prostaglandin J2 synthesis stimulator (Alzheimer's disease), Hunter-Fleming
DMI4C90 CP Hunter-Fleming Ltd
DMI4C90 PC 9836181
DMI4C90 MW 306.4
DMI4C90 FM C19H30O3
DMI4C90 IC InChI=1S/C19H30O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h11-15,17,20-21H,3-10H2,1-2H3/t11-,12+,13+,14+,15+,17+,18+,19+/m1/s1
DMI4C90 CS C[C@]12CC[C@@H](C[C@@H]1C[C@@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O)O
DMI4C90 IK VFPMCLQMAUVEHD-UCPSWNCLSA-N
DMI4C90 IU (3S,5R,7S,8R,9S,10S,13S,14S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMI4C90 CA CAS 25848-69-5
DMI4C90 DE Alzheimer disease
DMDZE3B ID DMDZE3B
DMDZE3B DN HGT-1111
DMDZE3B HS Phase 2
DMDZE3B SN Metazym; M-0001; Recombinant arylsulfatase A (lysosomal storage disease), Shire; Recombinant arylsulfatase A (lysosomal storage disease), Zymenex; Recombinant arylsulfatase A (metachromatic leukodystrophy), Shire; Lysosomal arylsulfatase A replacement therapy (FGE, metachromatic leukodystrophy), Shire; Lysosomal asa replacement therapy (FGE, metachromatic leukodystrophy), Shire
DMDZE3B CP Zymenex A/S
DMDZE3B DE Metachromatic leukodystrophy
DMHZ4JI ID DMHZ4JI
DMHZ4JI DN HGT-1410
DMHZ4JI HS Phase 2
DMHZ4JI SN Intrathecal sulfamidase replacement therapy (FGE, Sanfilippo syndrome), Shire; Intrathecal heparin n-sulfamidase (FGE, Sanfilippo syndrome), Shire
DMHZ4JI CP Shire Human Genetic Therapies Inc
DMHZ4JI DE Sanfilippo syndrome
DM0LA6E ID DM0LA6E
DM0LA6E DN HGTV43
DM0LA6E HS Phase 2
DM0LA6E CP Enzo Biochem
DM0LA6E TC Antisense
DM0LA6E DT Antisense drug
DM0LA6E DE Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection
DMO10JI ID DMO10JI
DMO10JI DN HibTITER
DMO10JI HS Phase 2
DMO10JI SN Haemophilus vaccine II, Praxis; Conjugate vaccine (Haemophilus influenzae type B/ meningitis), Nuron Biotech
DMO10JI CP Nuron biotech
DMO10JI DT Vaccine
DMO10JI DE Pneumococcal infection
DMLQDBH ID DMLQDBH
DMLQDBH DN HM-5016504
DMLQDBH HS Phase 2
DMLQDBH SN C-Met inhibitor (cancer), Hutchison
DMLQDBH CP Hutchison Medipharma Enterprises Ltd
DMLQDBH DE Solid tumour/cancer
DMZ3BER ID DMZ3BER
DMZ3BER DN HM-78136B
DMZ3BER HS Phase 2
DMZ3BER SN Pan-Her/EGFR inhibitors (cancer), Hanmi
DMZ3BER CP Hanmi Pharmaceutical Co Ltd
DMZ3BER DT Small molecular drug
DMZ3BER PC 25127713
DMZ3BER MW 491.3
DMZ3BER FM C23H21Cl2FN4O3
DMZ3BER IC InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
DMZ3BER CS COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
DMZ3BER IK LPFWVDIFUFFKJU-UHFFFAOYSA-N
DMZ3BER IU 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
DMZ3BER CA CAS 1092364-38-9
DMZ3BER DE Solid tumour/cancer; HER2-positive breast cancer; Non-small-cell lung cancer
DMMQZ3I ID DMMQZ3I
DMMQZ3I DN HMR59
DMMQZ3I HS Phase 2
DMMQZ3I SN AAVCAGsCD59
DMMQZ3I CP Hemera Biosciences
DMMQZ3I DT Gene therapy
DMMQZ3I DE Wet age-related macular degeneration; Dry age-related macular degeneration; Geographic retinal atrophy
DMA6HQJ ID DMA6HQJ
DMA6HQJ DN HO/03/03
DMA6HQJ HS Phase 2
DMA6HQJ SN PKC modulator (topical peptide, DU/VU/PU), HealOr
DMA6HQJ CP HealOr Ltd
DMA6HQJ DE Diabetic foot ulcer
DMNOMV2 ID DMNOMV2
DMNOMV2 DN HP-184
DMNOMV2 HS Phase 2
DMNOMV2 SN Nerispirdine; Nerispirdine hydrochloride; HP 184; N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine; N-(n-Propyl)-3-fluoro-4-pyridinyl-1H-3-methylindol-1-amine hydrochloride; N-(3-Fluoro-4-pyridinyl)-3-methyl-N-propyl-1H-indol-1-amine; 1H-Indol-1-amine, N-(3-fluoro-4-pyridinyl)-3-methyl-N-propyl-, monohydrochloride
DMNOMV2 CP Sanofi-Aventis
DMNOMV2 DT Small molecular drug
DMNOMV2 PC 3081185
DMNOMV2 MW 283.34
DMNOMV2 FM C17H18FN3
DMNOMV2 IC InChI=1S/C17H18FN3/c1-3-10-20(17-8-9-19-11-15(17)18)21-12-13(2)14-6-4-5-7-16(14)21/h4-9,11-12H,3,10H2,1-2H3
DMNOMV2 CS CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C
DMNOMV2 IK BTDHTARYCBHHPJ-UHFFFAOYSA-N
DMNOMV2 IU N-(3-fluoropyridin-4-yl)-3-methyl-N-propylindol-1-amine
DMNOMV2 CA CAS 119229-65-1
DMNOMV2 DE Multiple sclerosis
DMNZ35F ID DMNZ35F
DMNZ35F DN HP-228
DMNZ35F HS Phase 2
DMNZ35F SN HP 228; Ac-Nle-gln-his-D-phe-arg-D-trp-gly-NH2; AC1L2XO7; 109022-88-0; Acetyl-norleucyl-glutaminyl-histidyl-phenylalanyl-arginyl-tryptophyl-glycinamide; L-Norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycinamide; Glycinamide, L-norleucyl-L-glutaminyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-
DMNZ35F CP LION bioscience Inc
DMNZ35F DT Small molecular drug
DMNZ35F PC 9876430
DMNZ35F MW 984.1
DMNZ35F FM C47H65N15O9
DMNZ35F IC InChI=1S/C47H65N15O9/c1-3-4-14-33(57-27(2)63)42(67)59-35(17-18-39(48)64)44(69)62-38(22-30-24-52-26-56-30)46(71)60-36(20-28-11-6-5-7-12-28)45(70)58-34(16-10-19-53-47(50)51)43(68)61-37(41(66)55-25-40(49)65)21-29-23-54-32-15-9-8-13-31(29)32/h5-9,11-13,15,23-24,26,33-38,54H,3-4,10,14,16-22,25H2,1-2H3,(H2,48,64)(H2,49,65)(H,52,56)(H,55,66)(H,57,63)(H,58,70)(H,59,67)(H,60,71)(H,61,68)(H,62,69)(H4,50,51,53)/t33-,34-,35-,36+,37+,38-/m0/s1
DMNZ35F CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N)NC(=O)C
DMNZ35F IK UHKZNDVUBSEJJO-XAYNKGEHSA-N
DMNZ35F IU (2S)-2-[[(2S)-2-acetamidohexanoyl]amino]-N-[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]pentanediamide
DMNZ35F DE Postoperative pain
DM3WSL2 ID DM3WSL2
DM3WSL2 DN HPH-116
DM3WSL2 HS Phase 2
DM3WSL2 SN Azocarbonamide; Azodicarbonamide; ADA, Hubriphar; Azodicarbonamide, H-Phar
DM3WSL2 CP H-Phar Co
DM3WSL2 DE Human immunodeficiency virus infection
DM25PQB ID DM25PQB
DM25PQB DN HPPH
DM25PQB HS Phase 2
DM25PQB SN CHEMBL500853; SCHEMBL12722713; EX-A2655; 14-Ethyl-9-(1-(hexyloxy)ethyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid; HY-13722; 3-Phorbinepropanoic acid, 14-ethyl-9-[1-(hexyloxy)ethyl]-4,8,13,18-tetramethyl-20-oxo-, (3S,4S)-; CS-0007752
DM25PQB PC 148160
DM25PQB MW 636.8
DM25PQB FM C39H48N4O4
DM25PQB IC InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,42,44H,8-16H2,1-7H3,(H,45,46)/t21-,24?,26-/m0/s1
DM25PQB CS CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6C(C(C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C
DM25PQB IK PUUBADHCONCMPA-USOGPTGWSA-N
DM25PQB IU 3-[(21S,22S)-11-ethyl-16-(1-hexoxyethyl)-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
DM25PQB CA CAS 149402-51-7
DM25PQB DE Lung cancer
DM7QUN0 ID DM7QUN0
DM7QUN0 DN HQK-1001
DM7QUN0 HS Phase 2
DM7QUN0 SN Sodium ST-20; Hematological disease therapeutic (oral), HemaQuest
DM7QUN0 CP Hemaquest pharmaceuticals
DM7QUN0 DT Small molecular drug
DM7QUN0 PC 53247304
DM7QUN0 MW 138.14
DM7QUN0 FM C6H11NaO2
DM7QUN0 IC InChI=1S/C6H12O2.Na/c1-4-6(2,3)5(7)8;/h4H2,1-3H3,(H,7,8);/q;+1/p-1
DM7QUN0 CS CCC(C)(C)C(=O)[O-].[Na+]
DM7QUN0 IK OOPXYEYPPHJHSE-UHFFFAOYSA-M
DM7QUN0 IU sodium;2,2-dimethylbutanoate
DM7QUN0 CA CAS 3934-02-9
DM7QUN0 DE Beta thalassemia
DM3WX0K ID DM3WX0K
DM3WX0K DN HQK-1004
DM3WX0K HS Phase 2
DM3WX0K SN Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest
DM3WX0K CP HemaQuest Pharmaceuticals Inc; Vertex Pharmaceuticals Inc
DM3WX0K PC 23622962
DM3WX0K MW 875
DM3WX0K FM C34H74N12O14
DM3WX0K IC InChI=1S/3C6H14N4O2.4C4H8O2/c3*7-4(5(11)12)2-1-3-10-6(8)9;4*1-2-3-4(5)6/h3*4H,1-3,7H2,(H,11,12)(H4,8,9,10);4*2-3H2,1H3,(H,5,6)/t3*4-;;;;/m000..../s1
DM3WX0K CS CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.CCCC(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N.C(C[C@@H](C(=O)O)N)CN=C(N)N
DM3WX0K IK ZVEMACCDKBQNGX-KALODSIISA-N
DM3WX0K IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid
DM3WX0K CA CAS 80407-72-3
DM3WX0K DE Solid tumour/cancer
DMQ30X2 ID DMQ30X2
DMQ30X2 DN HQP1351
DMQ30X2 HS Phase 2
DMQ30X2 SN GZD824; 1257628-77-5; GZD-824; 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; UNII-KV1M7Q3CBP; KV1M7Q3CBP; 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide; CHEMBL2316582; Benzamide, 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-; HQP-1351; olverembatinib; 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide; Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-; HQP1351 free base; HQP-1351 free base; SCHEMBL3424528; GTPL10630; EX-A829; AOB87323; BCP07502; BDBM50425780; ZINC95594040; AKOS026750647; CS-1444; SB16617; compound 10a [PMID: 23301703]; NCGC00351607-06; AK547162; AS-75170; HY-15666; D-824; FT-0700150; A16264; W-6136; J-690110; 4-Methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
DMQ30X2 CP Ascentage Pharma
DMQ30X2 DT Small molecular drug
DMQ30X2 PC 51038269
DMQ30X2 MW 532.6
DMQ30X2 FM C29H27F3N6O
DMQ30X2 IC InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
DMQ30X2 CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CC5=C(NN=C5)N=C4
DMQ30X2 IK TZKBVRDEOITLRB-UHFFFAOYSA-N
DMQ30X2 IU 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
DMQ30X2 CA CAS 1257628-77-5
DMQ30X2 DE Chronic myeloid leukaemia
DML4RCG ID DML4RCG
DML4RCG DN HS-110
DML4RCG HS Phase 2
DML4RCG CP Heat Biologics
DML4RCG DT Vaccine
DML4RCG DE Non-small-cell lung cancer
DM2WP8F ID DM2WP8F
DM2WP8F DN HT-0712
DM2WP8F HS Phase 2
DM2WP8F SN IPL-455903; Small-molecule PDE4 inhibitors (memory disorders), Inflazyme/Helicon
DM2WP8F CP Dart neuroscience
DM2WP8F DT Small molecular drug
DM2WP8F PC 9865375
DM2WP8F MW 393.5
DM2WP8F FM C25H31NO3
DM2WP8F IC InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1
DM2WP8F CS CC1=CC(=CC=C1)C[C@@H]2C[C@H](CNC2=O)C3=CC(=C(C=C3)OC)OC4CCCC4
DM2WP8F IK ABEJDMOBAFLQNJ-NHCUHLMSSA-N
DM2WP8F IU (3S,5S)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3-[(3-methylphenyl)methyl]piperidin-2-one
DM2WP8F CA CAS 617720-02-2
DM2WP8F DE Cognitive impairment
DM2QIN1 ID DM2QIN1
DM2QIN1 DN HT-100
DM2QIN1 HS Phase 2
DM2QIN1 SN Halofunginone
DM2QIN1 CP Halo therapeutics
DM2QIN1 DT Small molecular drug
DM2QIN1 PC 62894
DM2QIN1 MW 414.7
DM2QIN1 FM C16H17BrClN3O3
DM2QIN1 IC InChI=1S/C16H17BrClN3O3/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14/h5-6,8,14-15,19,23H,1-4,7H2
DM2QIN1 CS C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O
DM2QIN1 IK LVASCWIMLIKXLA-UHFFFAOYSA-N
DM2QIN1 IU 7-bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]quinazolin-4-one
DM2QIN1 CA CAS 55837-20-2
DM2QIN1 DE Duchenne dystrophy
DMURXMJ ID DMURXMJ
DMURXMJ DN HTI-101
DMURXMJ HS Phase 2
DMURXMJ CP Hemodynamic Therapeutics
DMURXMJ DE Obesity
DM9MKQ5 ID DM9MKQ5
DM9MKQ5 DN Hu3F8 mAb
DM9MKQ5 HS Phase 2
DM9MKQ5 CP Y-mAbs Therapeutics New York, NY
DM9MKQ5 DE Neuroblastoma; Osteosarcoma
DMKQ3MC ID DMKQ3MC
DMKQ3MC DN Human interferon alpha oral
DMKQ3MC HS Phase 2
DMKQ3MC CP Amarillo biosciences
DMKQ3MC DE Hepatitis C virus infection
DM0NJWG ID DM0NJWG
DM0NJWG DN Human interleukin-2
DM0NJWG HS Phase 2
DM0NJWG SN Pulmoleukin; Human interleukin-2 (inhaled, renal cell carcinoma); Human IL-2 (inhaled, renal cell carcinoma),Immunservice; Human interleukin-2 (inhaled, renal cell carcinoma), Immunservice
DM0NJWG CP Immunservice GmbH
DM0NJWG DE Renal cell carcinoma
DMOPWSX ID DMOPWSX
DMOPWSX DN Ibrolipim
DMOPWSX HS Phase 2
DMOPWSX SN Ibrolipim < Prop INN; NO-1886; OPF-009; 4-[N-(4-Bromo-2-cyanophenyl)carbamoyl]benzylphosphonic acid diethyl ester
DMOPWSX CP TAP Pharmaceuticals
DMOPWSX DT Small molecular drug
DMOPWSX PC 131601
DMOPWSX MW 451.2
DMOPWSX FM C19H20BrN2O4P
DMOPWSX IC InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
DMOPWSX CS CCOP(=O)(CC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)Br)C#N)OCC
DMOPWSX IK KPRTURMJVWXURQ-UHFFFAOYSA-N
DMOPWSX IU N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide
DMOPWSX CA CAS 133208-93-2
DMOPWSX DE Hyperlipidaemia
DM37CX4 ID DM37CX4
DM37CX4 DN IC14
DM37CX4 HS Phase 2
DM37CX4 SN CD14 antibody
DM37CX4 TC Antiviral Agents
DM37CX4 DT Monoclonal antibody
DM37CX4 DE Coronavirus Disease 2019 (COVID-19)
DMUFCQG ID DMUFCQG
DMUFCQG DN IC14
DMUFCQG HS Phase 2
DMUFCQG DT Antibody
DMUFCQG DE Sepsis
DMB1UYV ID DMB1UYV
DMB1UYV DN IC-485
DMB1UYV HS Phase 2
DMB1UYV CP ICOS
DMB1UYV DT Small molecular drug
DMB1UYV PC 23724885
DMB1UYV DE Chronic obstructive pulmonary disease
DMP925B ID DMP925B
DMP925B DN ICA-105665
DMP925B HS Phase 2
DMP925B CP Icagen
DMP925B DE Epilepsy
DMRFY7I ID DMRFY7I
DMRFY7I DN ICA-17043
DMRFY7I HS Phase 2
DMRFY7I SN Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215; Senicapoc
DMRFY7I CP Icagen
DMRFY7I DT Small molecular drug
DMRFY7I PC 216327
DMRFY7I MW 323.3
DMRFY7I FM C20H15F2NO
DMRFY7I IC InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
DMRFY7I CS C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
DMRFY7I IK SCTZUZTYRMOMKT-UHFFFAOYSA-N
DMRFY7I IU 2,2-bis(4-fluorophenyl)-2-phenylacetamide
DMRFY7I CA CAS 289656-45-7
DMRFY7I DE Constitutional neutropenia; Alzheimer disease
DMGHQ37 ID DMGHQ37
DMGHQ37 DN Icaritin
DMGHQ37 HS Phase 2
DMGHQ37 SN Icaritin; 118525-40-9; UNII-UFE666UELY; UFE666UELY; CHEMBL498485; 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; Icartin; Anhydroicaritin; AC1NSXIV; Icaritin(Anhydroicaritin); MLS006010055; BIDD:ER0021; SCHEMBL4223542; Icaritin, > DTXSID00152154; MolPort-020-006-012; TUUXBSASAQJECY-UHFFFAOYSA-N; HY-N0678; ZINC14762797; BDBM50272527; AKOS015896858; CS-3679; DB12672; NCGC00345813-01; AK168251; SMR004701218
DMGHQ37 DT Small molecular drug
DMGHQ37 PC 5318980
DMGHQ37 MW 368.4
DMGHQ37 FM C21H20O6
DMGHQ37 IC InChI=1S/C21H20O6/c1-11(2)4-9-14-15(22)10-16(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(26-3)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
DMGHQ37 CS CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C
DMGHQ37 IK TUUXBSASAQJECY-UHFFFAOYSA-N
DMGHQ37 IU 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DMGHQ37 CA CAS 118525-40-9
DMGHQ37 DE Breast cancer
DMC13BQ ID DMC13BQ
DMC13BQ DN ICO-25
DMC13BQ HS Phase 2
DMC13BQ SN Imuteran; Anti-MUC1 monoclonal antibodies, P Hertzen Moscow Cancer Research Institute; Anti-AG-4 antibodies, P Hertzen Moscow Cancer Research Institute
DMC13BQ CP Russian National Cancer Research Center
DMC13BQ DT Antibody
DMC13BQ DE Breast cancer
DMTXNZK ID DMTXNZK
DMTXNZK DN Icofungipen
DMTXNZK HS Phase 2
DMTXNZK SN PLD-118; 198022-65-0; UNII-I20202Q8M8; BAY-10-8888; I20202Q8M8; Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)-; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylene-cyclopentanecarboxylic acid; PLD118; PLD 118; 156292-16-9; BAY 10-8888; (1r,2s)-2-amino-4-methylidenecyclopentanecarboxylic acid; AC1Q5QVF; AC1L50CI; 2-amino-4-methylenecyclopentane-1-carboxylic acid; SCHEMBL117349; CHEMBL343803; CTK0H0639; DTXSID90173515; RKOUGZGFAYMUIO-RITPCOANSA-N; (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid; Icofungipen [INN]; (1R,2S)-2-Amino-4-methylenecyclopentane-1-carboxylic acid; AHMA
DMTXNZK TC Antifungal Agents
DMTXNZK DT Small molecular drug
DMTXNZK PC 216240
DMTXNZK MW 141.17
DMTXNZK FM C7H11NO2
DMTXNZK IC InChI=1S/C7H11NO2/c1-4-2-5(7(9)10)6(8)3-4/h5-6H,1-3,8H2,(H,9,10)/t5-,6+/m1/s1
DMTXNZK CS C=C1C[C@H]([C@H](C1)N)C(=O)O
DMTXNZK IK RKOUGZGFAYMUIO-RITPCOANSA-N
DMTXNZK IU (1R,2S)-2-amino-4-methylidenecyclopentane-1-carboxylic acid
DMTXNZK CA CAS 198022-65-0
DMTXNZK DE Fungal infection
DM524GR ID DM524GR
DM524GR DN ICP-192
DM524GR HS Phase 2
DM524GR CP InnoCare Pharma
DM524GR DE Bladder cancer
DM7XIAJ ID DM7XIAJ
DM7XIAJ DN ID-93/GLA-SE
DM7XIAJ HS Phase 2
DM7XIAJ CP Infectious disease research institute; aeras global tb vaccine foundation
DM7XIAJ DE Tuberculosis
DMABRXY ID DMABRXY
DMABRXY DN IDM-2101
DMABRXY HS Phase 2
DMABRXY CP Biotech Synergy
DMABRXY DT Vaccine
DMABRXY DE Colorectal cancer
DMSRC5D ID DMSRC5D
DMSRC5D DN IDX899
DMSRC5D HS Phase 2
DMSRC5D SN Fosdevirine; IDX-899; IDX899; GSK2248761; GSK-2248761; 1018450-26-4; UNII-Z4I0C281BJ; Z4I0C281BJ; Fosdevirine [USAN:INN]; GSK2248761A; GSK 2248761A; Fosdevirine (USAN/INN); SCHEMBL1035677; CHEMBL2104968; IDX 899; 1097733-15-7; IDX-12899; GSK 2248761; D09906
DMSRC5D CP GSK
DMSRC5D DT Small molecular drug
DMSRC5D PC 23583058
DMSRC5D MW 413.8
DMSRC5D FM C20H17ClN3O3P
DMSRC5D IC InChI=1S/C20H17ClN3O3P/c1-12-8-13(4-3-7-22)10-15(9-12)28(26,27-2)19-16-11-14(21)5-6-17(16)24-18(19)20(23)25/h3-6,8-11,24H,1-2H3,(H2,23,25)/b4-3+
DMSRC5D CS CC1=CC(=CC(=C1)P(=O)(C2=C(NC3=C2C=C(C=C3)Cl)C(=O)N)OC)/C=C/C#N
DMSRC5D IK CGBYTKOSZYQOPV-ONEGZZNKSA-N
DMSRC5D IU 5-chloro-3-[[3-[(E)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1H-indole-2-carboxamide
DMSRC5D DE Human immunodeficiency virus infection
DMGWNCJ ID DMGWNCJ
DMGWNCJ DN Ifabotuzumab
DMGWNCJ HS Phase 2
DMGWNCJ CP Humanigen Brisbane, CA Olivia Newton-John Cancer Research Institute Heidelberg, Australia
DMGWNCJ DE Acute myeloid leukaemia; Myelodysplastic syndrome; Recurrent glioblastoma
DMZP84Y ID DMZP84Y
DMZP84Y DN Ifetroban sodium
DMZP84Y HS Phase 2
DMZP84Y SN BMS-180291 sodium salt; BMS-180291-02
DMZP84Y CP Bristol-Myers Squibb
DMZP84Y DT Small molecular drug
DMZP84Y PC 23663994
DMZP84Y MW 462.5
DMZP84Y FM C25H31N2NaO5
DMZP84Y IC InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20-,21+,23-;/m0./s1
DMZP84Y CS CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+]
DMZP84Y IK WOHSQDNIXPEQAE-QBKVZTCDSA-M
DMZP84Y IU sodium;3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
DMZP84Y DE Thrombosis
DM4H8EZ ID DM4H8EZ
DM4H8EZ DN IFN-alpha
DM4H8EZ HS Phase 2
DM4H8EZ SN Hanferon; HL-143; IFN-alpha (sc injection, HCV infection); Belerofon (subcutaneous, HCV infection), Nautilus/HanAll; IFN-alpha (sc injection, HCV infection), HanAll; IFN-alpha (subcutaneous, HCV infection), Nautilus/HanAll; Interferon-alpha (subcutaneous, HCV infection), Nautilus/HanAll
DM4H8EZ CP Hanall biopharma
DM4H8EZ DE Hepatitis C virus infection; Hepatocellular carcinoma
DMHI36A ID DMHI36A
DMHI36A DN IFX-1
DMHI36A HS Phase 2
DMHI36A SN XZAPEHKCHWMSPW-MTALQEDYSA-N; Ifx-1; J3.560.481B
DMHI36A CP InflaRx Planegg, Germany
DMHI36A PC 137254326
DMHI36A MW 672.9
DMHI36A FM C43H60O6
DMHI36A IC InChI=1S/C43H60O6/c1-30(17-14-18-31(2)19-21-39-42(9,10)27-37(49-33(4)45)28-43(39,11)48)15-12-13-16-32(3)23-35(46)24-34(29-44)20-22-38-40(5,6)25-36(47)26-41(38,7)8/h12-24,29,36-38,47-48H,25-28H2,1-11H3/b15-12?,16-13?,18-14?,22-20+,30-17?,31-19?,32-23?,34-24-,39-21?/t36?,37-,38?,43-/m1/s1
DMHI36A CS CC(=CC=CC(=CC=C1[C@](C[C@@H](CC1(C)C)OC(=O)C)(C)O)C)C=CC=CC(=CC(=O)/C=C(/C=C/C2C(CC(CC2(C)C)O)(C)C)\\C=O)C
DMHI36A IK XZAPEHKCHWMSPW-MTALQEDYSA-N
DMHI36A IU [(1R,3R)-4-[(15Z,17E)-16-formyl-18-(4-hydroxy-2,2,6,6-tetramethylcyclohexyl)-3,7,12-trimethyl-14-oxooctadeca-2,4,6,8,10,12,15,17-octaenylidene]-3-hydroxy-3,5,5-trimethylcyclohexyl] acetate
DMHI36A DE Hidradenitis suppurativa
DMH97XA ID DMH97XA
DMH97XA DN Igmesine
DMH97XA HS Phase 2
DMH97XA SN Igmesine hydrochloride; JO-1784; UNII-JV6M14TY35; Igmesine Hydrochloride [USAN]; 130152-35-1; Cinnamyl-1-phenyl-1-N-methyl-N-cyclopropylene; JO 1784; CI 1019; CI-1019; JV6M14TY35; (+)-alpha-(E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; (+)-Igmesine hydrochloride; (+)-(E)-N-(Cyclopropylmethyl)-alpha-ethyl-N-methyl-alpha-(3-phenyl-2-propenyl)benzenemethanamine hydrochloride; Igmesine hydrochloride (USAN); (+)-alpha-((E)-Cinnamyl)-N-(cyclopropylmethyl)-alpha-ethyl-N-methylbenzylamine; Alphagen
DMH97XA DT Small molecular drug
DMH97XA PC 6438340
DMH97XA MW 319.5
DMH97XA FM C23H29N
DMH97XA IC InChI=1S/C23H29N/c1-3-23(22-14-8-5-9-15-22,24(2)19-21-16-17-21)18-10-13-20-11-6-4-7-12-20/h4-15,21H,3,16-19H2,1-2H3/b13-10+
DMH97XA CS CCC(C/C=C/C1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3
DMH97XA IK VCZSWYIFCKGTJI-JLHYYAGUSA-N
DMH97XA IU (E)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine
DMH97XA CA CAS 140850-73-3
DMH97XA DE Cystic fibrosis; Chronic obstructive pulmonary disease; Major depressive disorder
DMIHQ5G ID DMIHQ5G
DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G HS Phase 2
DMIHQ5G SN Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte
DMIHQ5G CP Baylor College of Medicine
DMIHQ5G DT Vaccine
DMIHQ5G DE Chronic lymphocytic leukaemia
DM1E4VP ID DM1E4VP
DM1E4VP DN IL-21
DM1E4VP HS Phase 2
DM1E4VP SN BMS-982470
DM1E4VP CP Bristol-Myers Squibb
DM1E4VP DE Colorectal cancer
DMYEGRH ID DMYEGRH
DMYEGRH DN IL-4R
DMYEGRH HS Phase 2
DMDNHRA ID DMDNHRA
DMDNHRA DN Ilodecakin
DMDNHRA HS Phase 2
DMDNHRA SN Prevascar; Ilodecakin, Renovo; Recombinant IL-10 (scarring), Renovo
DMDNHRA CP Renovo Group plc
DMDNHRA DE Sarcoidosis
DMUJ1WV ID DMUJ1WV
DMUJ1WV DN IMCgp100
DMUJ1WV HS Phase 2
DMUJ1WV CP Immunocore
DMUJ1WV DT Monoclonal antibody
DMUJ1WV DE Melanoma; Cutaneous melanoma
DMU1MR9 ID DMU1MR9
DMU1MR9 DN IMD-1041
DMU1MR9 HS Phase 2
DMU1MR9 SN IMD-1041 (oral, COPD/interstitial cystis/type 2 diabetics/chronic inflammatory disease/metabolic syndrome/AD), IMMD
DMU1MR9 CP Institute of Medicinal Molecular Design Inc
DMU1MR9 DE Alzheimer disease
DMMQFG2 ID DMMQFG2
DMMQFG2 DN Imeglimin
DMMQFG2 HS Phase 2
DMMQFG2 SN 775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771
DMMQFG2 CP Merck KGaA
DMMQFG2 DT Small molecular drug
DMMQFG2 PC 24812808
DMMQFG2 MW 155.2
DMMQFG2 FM C6H13N5
DMMQFG2 IC InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
DMMQFG2 CS C[C@@H]1N=C(NC(=N1)N(C)C)N
DMMQFG2 IK GFICWFZTBXUVIG-SCSAIBSYSA-N
DMMQFG2 IU (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine
DMMQFG2 CA CAS 775351-65-0
DMMQFG2 DE Type-2 diabetes; Diabetic complication
DML9AVG ID DML9AVG
DML9AVG DN IMG-7289
DML9AVG HS Phase 2
DML9AVG SN KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide
DML9AVG CP Imago BioSciences San Carlos, CA
DML9AVG PC 122460381
DML9AVG MW 519.6
DML9AVG FM C28H34FN7O2
DML9AVG IC InChI=1S/C28H34FN7O2/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37)/t24-,25-,26+/m0/s1
DML9AVG CS CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5
DML9AVG IK KQKBMHGOHXOHTD-KKUQBAQOSA-N
DML9AVG IU N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide
DML9AVG CA CAS 1990504-34-1
DML9AVG DE Acute myeloid leukaemia; Myelodysplastic syndrome; Myelofibrosis
DMNJ491 ID DMNJ491
DMNJ491 DN IMGN529
DMNJ491 HS Phase 2
DMNJ491 CP ImmunoGen
DMNJ491 DT Antibody
DMNJ491 DE Metastatic non-hodgkin's lymphoma; Non-hodgkin lymphoma
DMIUC3M ID DMIUC3M
DMIUC3M DN IMGN901
DMIUC3M HS Phase 2
DMIUC3M SN Lorvotuzumab mertansine
DMIUC3M CP ImmunoGen
DMIUC3M DE Solid tumour/cancer
DME3POC ID DME3POC
DME3POC DN Imisopasem manganese
DME3POC HS Phase 2
DME3POC SN KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore
DME3POC CP MetaPhore Pharmaceuticals
DME3POC DT Small molecular drug
DME3POC PC 6918487
DME3POC MW 483.4
DME3POC FM C21H35Cl2MnN5
DME3POC IC InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m1.../s1
DME3POC CS C1CC[C@@H]2[C@@H](C1)NCCN[C@@H]3CCCC[C@H]3NCC4=CC=CC(=N4)CN2.Cl[Mn]Cl
DME3POC IK WXEMWBBXVXHEPU-XNPJUPKFSA-L
DME3POC IU dichloromanganese;(4R,9R,14R,19R)-3,10,13,20,26-pentazatetracyclo[20.3.1.04,9.014,19]hexacosa-1(26),22,24-triene
DME3POC DE Pain
DM6IQ3V ID DM6IQ3V
DM6IQ3V DN IMO-2055
DM6IQ3V HS Phase 2
DM6IQ3V CP Idera Pharmaceuticals
DM6IQ3V DE Solid tumour/cancer; Renal cell carcinoma
DMM549D ID DMM549D
DMM549D DN IMO-3100
DMM549D HS Phase 2
DMM549D CP Idera Pharmaceuticals
DMM549D DE Autoimmune diabetes; Psoriasis vulgaris
DMDPNCJ ID DMDPNCJ
DMDPNCJ DN IMO-8400
DMDPNCJ HS Phase 2
DMDPNCJ SN Bazlitoran; Bazlitoran [INN]; Bazlitoran [USAN]; UNII-2U46M95B5M; 2U46M95B5M
DMDPNCJ CP Idera Pharmaceuticals Cambridge, MA
DMDPNCJ SQ CTATCTNNNNTTCTCTNN
DMDPNCJ PC 119058029
DMDPNCJ MW 5801
DMDPNCJ FM C179H233N52O101P17S17
DMDPNCJ IC InChI=1S/C179H233N52O101P17S17/c1-71-41-221(172(252)200-143(71)184)123-32-85(106(303-123)62-293-347(274,364)330-136-109(313-160(140(136)278-10)220-26-19-117(234)199-171(220)251)66-297-349(276,366)332-138-111(315-162(142(138)280-12)231-70-193-134-148(231)203-165(188)206-158(134)245)65-296-346(273,363)328-92-39-130(228-48-78(8)155(242)213-179(228)259)310-105(92)60-289-337(264,354)320-84-31-122(218-24-17-115(183)197-169(218)249)302-98(84)53-285-341(268,358)324-89-36-127(225-45-75(5)152(239)210-176(225)256)308-103(89)58-291-344(271,361)329-93-40-131(229-68-191-132-144(185)189-67-190-146(132)229)311-107(93)61-292-343(270,360)326-86-33-124(222-42-72(2)149(236)207-173(222)253)304-99(86)54-281-333(260,350)316-80-27-119(298-94(80)49-232)215-21-14-112(180)194-166(215)246)321-338(265,355)282-50-95-81(28-118(299-95)214-20-13-79-145(214)201-163(186)204-156(79)243)317-334(261,351)286-55-100-90(37-128(305-100)226-46-76(6)153(240)211-177(226)257)325-342(269,359)290-57-102-88(35-126(307-102)224-44-74(4)151(238)209-175(224)255)323-340(267,357)284-51-96-82(29-120(300-96)216-22-15-113(181)195-167(216)247)318-335(262,352)287-56-101-87(34-125(306-101)223-43-73(3)150(237)208-174(223)254)322-339(266,356)283-52-97-83(30-121(301-97)217-23-16-114(182)196-168(217)248)319-336(263,353)288-59-104-91(38-129(309-104)227-47-77(7)154(241)212-178(227)258)327-345(272,362)295-64-110-137(141(279-11)161(314-110)230-69-192-133-147(230)202-164(187)205-157(133)244)331-348(275,365)294-63-108-135(235)139(277-9)159(312-108)219-25-18-116(233)198-170(219)250/h13-26,41-48,67-70,80-111,118-131,135-142,159-162,232,235H,27-40,49-66H2,1-12H3,(H,260,350)(H,261,351)(H,262,352)(H,263,353)(H,264,354)(H,265,355)(H,266,356)(H,267,357)(H,268,358)(H,269,359)(H,270,360)(H,271,361)(H,272,362)(H,273,363)(H,274,364)(H,275,365)(H,276,366)(H2,180,194,246)(H2,181,195,247)(H2,182,196,248)(H2,183,197,249)(H2,184,200,252)(H2,185,189,190)(H,198,233,250)(H,199,234,251)(H,207,236,253)(H,208,237,254)(H,209,238,255)(H,210,239,256)(H,211,240,257)(H,212,241,258)(H,213,242,259)(H3,186,201,204,243)(H3,187,202,205,244)(H3,188,203,206,245)/t80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,135+,136+,137+,138+,139+,140+,141+,142+,159+,160+,161+,162+,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?,343?,344?,345?,346?,347?,348?,349?/m0/s1
DMDPNCJ CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@@H]5[C@H](O[C@H]([C@@H]5OC)N6C=CC(=O)NC6=O)COP(=S)(O)O[C@@H]7[C@H](O[C@H]([C@@H]7OC)N8C=NC9=C8N=C(NC9=O)N)COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1COP(=O)(O[C@H]1C[C@@H](O[C@@H]1COP(=S)(O)O[C@H]1C[C@@H](O[C@@H]1CO)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)S)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=NC1=O)N)C)N1C=CC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)(O)OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)OC)O
DMDPNCJ IK HDRGJRSISASRAJ-WKPMUQCKSA-N
DMDPNCJ IU 1-[(2R,4S,5R)-5-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-2-[[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMDPNCJ CA CAS 1378549-07-5
DMDPNCJ DE Diffuse large B-cell lymphoma; Rheumatoid arthritis; Waldenstrom macroglobulinemia
DMTN16K ID DMTN16K
DMTN16K DN Implitapide
DMTN16K HS Phase 2
DMTN16K SN Implitapide [INN]; (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
DMTN16K CP MRL international
DMTN16K DT Small molecular drug
DMTN16K PC 5745206
DMTN16K MW 531.7
DMTN16K FM C35H37N3O2
DMTN16K IC InChI=1S/C35H37N3O2/c1-23-19-24(2)36-34-32(23)29-17-8-9-18-31(29)38(34)21-25-11-10-16-28(20-25)33(27-14-6-7-15-27)35(40)37-30(22-39)26-12-4-3-5-13-26/h3-5,8-13,16-20,27,30,33,39H,6-7,14-15,21-22H2,1-2H3,(H,37,40)/t30-,33-/m0/s1
DMTN16K CS CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)[C@H](C5CCCC5)C(=O)N[C@@H](CO)C6=CC=CC=C6)C
DMTN16K IK AMNXBQPRODZJQR-DITALETJSA-N
DMTN16K IU (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
DMTN16K CA CAS 177469-96-4
DMTN16K DE Hyperlipidaemia
DMB1N6P ID DMB1N6P
DMB1N6P DN Impoyz
DMB1N6P HS Phase 2
DMB1N6P SN Clobetasol propionate; CLOBETASOL PROPIONATE; 25122-46-7; Clobetasol 17-propionate; Clobex; Temovate; Dermovate; Embeline; Embeline E; Clobesol; Cormax; Olux; Temovate E; Olux-E; clobetasol 17-propanoate; GR 2/925; C25H32ClFO5; MLS000028708; Clobestasol propionate; Clobetasol propionate [USAN:JAN]; CGP 9555; CCI 4725; EINECS 246-634-3; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; UNII-779619577M; [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12
DMB1N6P CP Promius Pharma Princeton, NJ
DMB1N6P PC 32798
DMB1N6P MW 467
DMB1N6P FM C25H32ClFO5
DMB1N6P IC InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
DMB1N6P CS CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl
DMB1N6P IK CBGUOGMQLZIXBE-XGQKBEPLSA-N
DMB1N6P IU [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
DMB1N6P CA CAS 25122-46-7
DMB1N6P CB CHEBI:31414
DMB1N6P DE Plaque psoriasis
DM15MRZ ID DM15MRZ
DM15MRZ DN IMR-687
DM15MRZ HS Phase 2
DM15MRZ SN Tovinontrine; UNII-W248Y1AKOR; W248Y1AKOR; 2062661-53-2; a]pyrazin-8(7H)-one; CHEMBL4297290; SCHEMBL20358493; BDBM426313; US10513524, Compound (P3; 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-; yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-; 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7himidazo(1,5-a)pyrazin-8-one; Imidazo(1,5-a)pyrazin-8(7H)-one, 6-((3S,4S)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-3-(tetrahydro-2H-pyran-4-yl)-
DM15MRZ CP Imara
DM15MRZ DT Small molecular drug
DM15MRZ PC 124220601
DM15MRZ MW 394.5
DM15MRZ FM C21H26N6O2
DM15MRZ IC InChI=1S/C21H26N6O2/c1-14-10-26(13-19-22-5-2-6-23-19)11-16(14)17-12-27-18(21(28)25-17)9-24-20(27)15-3-7-29-8-4-15/h2,5-6,9,12,14-16H,3-4,7-8,10-11,13H2,1H3,(H,25,28)/t14-,16-/m1/s1
DM15MRZ CS C[C@@H]1CN(C[C@H]1C2=CN3C(=CN=C3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5
DM15MRZ IK GWGNPYYVGANHRJ-GDBMZVCRSA-N
DM15MRZ IU 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-(oxan-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one
DM15MRZ CA CAS 2062661-53-2
DM15MRZ DE Sickle-cell disorder
DMNUXKA ID DMNUXKA
DMNUXKA DN INCAGN01876
DMNUXKA HS Phase 2
DMNUXKA CP Agenis; Incyte
DMNUXKA DT Antibody
DMNUXKA DE Solid tumour/cancer
DMK7OHI ID DMK7OHI
DMK7OHI DN INCAGN01949
DMK7OHI HS Phase 2
DMK7OHI CP Agenis; Incyte
DMK7OHI DT Antibody
DMK7OHI DE Advanced malignancy; Metastatic malignant neoplasm
DMFG8TI ID DMFG8TI
DMFG8TI DN INCB00928
DMFG8TI HS Phase 2
DMFG8TI CP Incyte
DMFG8TI DT Small molecular drug
DMFG8TI DE Multiple myeloma; Myelodysplastic syndrome; Anemia
DMD9RV3 ID DMD9RV3
DMD9RV3 DN INCB039110
DMD9RV3 HS Phase 2
DMD9RV3 SN Examlpe 294 [WO2011112662]
DMD9RV3 DT Small molecular drug
DMD9RV3 PC 53380437
DMD9RV3 MW 553.5
DMD9RV3 FM C26H23F4N9O
DMD9RV3 IC InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)
DMD9RV3 CS C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F
DMD9RV3 IK KTBSXLIQKWEBRB-UHFFFAOYSA-N
DMD9RV3 IU 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
DMD9RV3 CA CAS 1334298-90-6
DMD9RV3 DE Malignant neoplasm; Non-small-cell lung cancer
DMZJP2T ID DMZJP2T
DMZJP2T DN INCB50465
DMZJP2T HS Phase 2
DMZJP2T CP Incyte Wilmington, DE
DMZJP2T DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Marginal zone lymphoma
DMDK0HX ID DMDK0HX
DMDK0HX DN INCB54707
DMDK0HX HS Phase 2
DMDK0HX CP Incyte Wilmington, DE
DMDK0HX DE Hidradenitis suppurativa
DMJN9PU ID DMJN9PU
DMJN9PU DN INCB86550
DMJN9PU HS Phase 2
DMJN9PU CP Incyte
DMJN9PU DT Small molecular drug
DMJN9PU DE Solid tumour/cancer
DM6OFJ8 ID DM6OFJ8
DM6OFJ8 DN Indibulin
DM6OFJ8 HS Phase 2
DM6OFJ8 SN Indibulin; 204205-90-3; 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide; d-24851; UNII-80K4H2RB8P; 80K4H2RB8P; ZIO-301; D 24851; 2-[1-(4-chlorobenzyl)-1h-indol-3-yl]-2-oxo-n-(pyridin-4-yl)acetamide; N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]-glyoxyl Amide; Indibulin [USAN:INN]; 2-{1-[(4-chlorophenyl)methyl]indol-3-yl}-2-oxo-N-(4-pyridyl)acetamide; 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-(4-pyridyl)acetamide; Indibulin (USAN/INN); AC1L1ESK; AC1Q5NS8; MLS006011745; CHEMBL49642
DM6OFJ8 CP ZioPharm
DM6OFJ8 DT Small molecular drug
DM6OFJ8 PC 2929
DM6OFJ8 MW 389.8
DM6OFJ8 FM C22H16ClN3O2
DM6OFJ8 IC InChI=1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28)
DM6OFJ8 CS C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4
DM6OFJ8 IK SOLIIYNRSAWTSQ-UHFFFAOYSA-N
DM6OFJ8 IU 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-pyridin-4-ylacetamide
DM6OFJ8 CA CAS 204205-90-3
DM6OFJ8 DE Advanced sarcoma
DM9SX6Y ID DM9SX6Y
DM9SX6Y DN Indisulam
DM9SX6Y HS Phase 2
DM9SX6Y SN Indisulam; 165668-41-7; E7070; N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; UNII-WJ98J3NM90; E-7070; E 7070; N-(3-Chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide; CHEMBL77517; WJ98J3NM90; N1-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide; 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-; ER-35744; N-(3-Chloro-1H-indol-7-yl)benzene-1,4disulfonamide; Indisulam (IND); indisulam (e7070); Indisulam (USAN/INN); AC1Q6VCX; AC1L50QL; SCHEMBL91389; N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Indisulam [USAN:INN:BAN]
DM9SX6Y DT Small molecular drug
DM9SX6Y PC 216468
DM9SX6Y MW 385.8
DM9SX6Y FM C14H12ClN3O4S2
DM9SX6Y IC InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
DM9SX6Y CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)S(=O)(=O)N)NC=C2Cl
DM9SX6Y IK SETFNECMODOHTO-UHFFFAOYSA-N
DM9SX6Y IU 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide
DM9SX6Y CA CAS 165668-41-7
DM9SX6Y CB CHEBI:145431
DM9SX6Y DE Lymphoma
DMU5SZP ID DMU5SZP
DMU5SZP DN Inecalcitol oral
DMU5SZP HS Phase 2
DMU5SZP SN Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; Inecalcitol; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics; 19-nor-14-epi-23-yne-1,25 dihydroxyvitamin D3
DMU5SZP CP Catholic University of Leuven; Hybrigenics
DMU5SZP DT Small molecular drug
DMU5SZP PC 6915835
DMU5SZP MW 400.6
DMU5SZP FM C26H40O3
DMU5SZP IC InChI=1S/C26H40O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,6-8,11-12,14-17H2,1-4H3/b20-10+/t18-,21-,22-,23-,24-,26-/m1/s1
DMU5SZP CS C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C[C@@H](C3)O)O)C
DMU5SZP IK HHGRMHMXKPQNGF-WNSNRMDMSA-N
DMU5SZP IU (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
DMU5SZP CA CAS 163217-09-2
DMU5SZP DE Prostate cancer; Acute myeloid leukaemia
DMEO9Y7 ID DMEO9Y7
DMEO9Y7 DN INGAP peptide
DMEO9Y7 HS Phase 2
DMEO9Y7 CP Exsulin
DMEO9Y7 DE Type-1/2 diabetes
DMF7J6D ID DMF7J6D
DMF7J6D DN INGN-225
DMF7J6D HS Phase 2
DMF7J6D SN Cancer vaccine (p53), Introgen
DMF7J6D CP Introgen Therapeutics
DMF7J6D DT Vaccine
DMF7J6D DE Head and neck cancer
DM6P91T ID DM6P91T
DM6P91T DN INGN-241
DM6P91T HS Phase 2
DM6P91T SN AD-IL-24, Introgen; AD-mda-7, Introgen; Adenovirus-IL-24, Introgen; Adenovirus-mda-7, Introgen
DM6P91T CP Multivir; Introgen Therapeutics
DM6P91T DE Solid tumour/cancer
DMGO7QT ID DMGO7QT
DMGO7QT DN INK128
DMGO7QT HS Phase 2
DMGO7QT SN 1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)
DMGO7QT CP Intellikine; MMRC
DMGO7QT DT Small molecular drug
DMGO7QT PC 45375953
DMGO7QT MW 309.33
DMGO7QT FM C15H15N7O
DMGO7QT IC InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
DMGO7QT CS CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N
DMGO7QT IK GYLDXIAOMVERTK-UHFFFAOYSA-N
DMGO7QT IU 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
DMGO7QT CA CAS 1224844-38-5
DMGO7QT CB CHEBI:91450
DMGO7QT DE Multiple myeloma; Breast cancer
DMKRGVJ ID DMKRGVJ
DMKRGVJ DN INS-1
DMKRGVJ HS Phase 2
DMKRGVJ SN Diabetes therapeutics, Insmed; Inositol phosphoglycans, Insmed; D-chiro-inositol, Insmed
DMKRGVJ CP Insmed Inc
DMKRGVJ DE Metabolic disorder
DMF93RQ ID DMF93RQ
DMF93RQ DN INS-37217
DMF93RQ HS Phase 2
DMF93RQ SN Denufosol tetrasodium; DCp4U; INS 37217; INS37217; Up4dC; Denufosol tetrasodium (USAN); Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with 2'-deoxycytidine, tetrasodium salt; Tetrasodium [[(3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMF93RQ CP Inspire Pharmaceuticals
DMF93RQ DT Small molecular drug
DMF93RQ PC 10219163
DMF93RQ MW 861.3
DMF93RQ FM C18H23N5Na4O21P4
DMF93RQ IC InChI=1S/C18H27N5O21P4.4Na/c19-11-1-3-22(17(28)20-11)13-5-8(24)9(40-13)6-38-45(30,31)42-47(34,35)44-48(36,37)43-46(32,33)39-7-10-14(26)15(27)16(41-10)23-4-2-12(25)21-18(23)29;;;;/h1-4,8-10,13-16,24,26-27H,5-7H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H2,19,20,28)(H,21,25,29);;;;/q;4*+1/p-4/t8-,9+,10+,13+,14+,15+,16+;;;;/m0..../s1
DMF93RQ CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O.[Na+].[Na+].[Na+].[Na+]
DMF93RQ IK PASYJVRFGUDDEW-WMUGRWSXSA-J
DMF93RQ IU tetrasodium;[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
DMF93RQ CA CAS 318250-11-2
DMF93RQ DE Cystic fibrosis
DMKZUVC ID DMKZUVC
DMKZUVC DN INS-50589
DMKZUVC HS Phase 2
DMKZUVC SN Regrelor; UNII-Q6C8TY6SW1; Q6C8TY6SW1; CHEMBL1162175; INS-50589; 787548-03-2; Regrelor [INN]; GTPL1770; DTXSID80229272; INS 50589; BDBM50371580; [(2S,3aR,4R,6R,6aR)-6-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[4,3-d][1,3]dioxol-4-yl]methyl dihydrogen phosphate
DMKZUVC CP Inspire Pharmaceuticals
DMKZUVC DT Small molecular drug
DMKZUVC PC 11273179
DMKZUVC MW 532.4
DMKZUVC FM C22H25N6O8P
DMKZUVC IC InChI=1S/C22H25N6O8P/c1-2-23-22(29)27-19-16-20(25-11-24-19)28(12-26-16)21-18-17(14(34-21)10-33-37(30,31)32)35-15(36-18)9-8-13-6-4-3-5-7-13/h3-9,11-12,14-15,17-18,21H,2,10H2,1H3,(H2,30,31,32)(H2,23,24,25,27,29)/b9-8+/t14-,15+,17-,18-,21-/m1/s1
DMKZUVC CS CCNC(=O)NC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)COP(=O)(O)O)O[C@@H](O4)/C=C/C5=CC=CC=C5
DMKZUVC IK NXHAXEBZOXCDKD-XIXRRVGJSA-N
DMKZUVC IU [(2S,3aR,4R,6R,6aR)-4-[6-(ethylcarbamoylamino)purin-9-yl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl dihydrogen phosphate
DMKZUVC CA CAS 787548-03-2
DMKZUVC DE Cardiovascular disease
DMNKAFQ ID DMNKAFQ
DMNKAFQ DN Instiladrin
DMNKAFQ HS Phase 2
DMNKAFQ CP Fkd therapies
DMNKAFQ DE Bladder cancer
DMYTKF5 ID DMYTKF5
DMYTKF5 DN Interferon
DMYTKF5 HS Phase 2
DMYTKF5 CP Amarillo biosciences
DMYTKF5 DE Human papillomavirus infection; Hepatitis C virus infection
DMVACTU ID DMVACTU
DMVACTU DN Interferon alpha-2b
DMVACTU HS Phase 2
DMVACTU SN IFN-alpha-XL; IFN-alpha (Medusa), Flamel; Interferon alpha-2b (subcutaneous/controlled release, Medusa); Interferon alpha-2b (subcutaneous/controlled release, Medusa), Flamel
DMVACTU CP Hanall biopharma; medtronic
DMVACTU DE Hepatitis C virus infection
DMQSA7H ID DMQSA7H
DMQSA7H DN Interferon beta 1a
DMQSA7H HS Phase 2
DMQSA7H SN Aerosolised interferon beta 1a; AZD-9412; Inhaled interferon beta 1a; SNG-001
DMQSA7H TC Respiratory Agents
DMQSA7H DE Discovery agent
DM8YF01 ID DM8YF01
DM8YF01 DN Interferon-alpha lozenge
DM8YF01 HS Phase 2
DM8YF01 SN Veldona (TN)
DM8YF01 CP Amarillo Biosciences
DM8YF01 DE Fibromyalgia; Chronic obstructive pulmonary disease; Behcet disease
DMBXEG9 ID DMBXEG9
DMBXEG9 DN Intetumumab
DMBXEG9 HS Phase 2
DMBXEG9 CP Janssen Biotech
DMBXEG9 DT Monoclonal antibody
DMBXEG9 DE Prostate cancer
DMSTJ6Q ID DMSTJ6Q
DMSTJ6Q DN INX-189
DMSTJ6Q HS Phase 2
DMSTJ6Q SN INX-08032; INX-08189; INX-108; Nucleoside polymerase inhibitors (HCV infection), Cardiff University/Rega Institute; Nucleoside polymerase inhibitors (oral, HCV infection), Inhibitex
DMSTJ6Q CP Cardiff University
DMSTJ6Q DT Small molecular drug
DMSTJ6Q PC 46700744
DMSTJ6Q MW 658.6
DMSTJ6Q FM C30H39N6O9P
DMSTJ6Q IC InChI=1S/C30H39N6O9P/c1-17(26(38)42-15-29(2,3)4)35-46(40,45-20-13-9-11-18-10-7-8-12-19(18)20)43-14-21-23(37)30(5,39)27(44-21)36-16-32-22-24(36)33-28(31)34-25(22)41-6/h7-13,16-17,21,23,27,37,39H,14-15H2,1-6H3,(H,35,40)(H2,31,33,34)/t17-,21+,23+,27+,30+,46?/m0/s1
DMSTJ6Q CS C[C@@H](C(=O)OCC(C)(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=NC3=C2N=C(N=C3OC)N)(C)O)O)OC4=CC=CC5=CC=CC=C54
DMSTJ6Q IK YFXGICNMLCGLHJ-RSKRLRQZSA-N
DMSTJ6Q IU 2,2-dimethylpropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
DMSTJ6Q CA CAS 1234490-83-5
DMSTJ6Q DE Hepatitis C virus infection
DMNW0DG ID DMNW0DG
DMNW0DG DN Iodine-131-tositumomab
DMNW0DG HS Phase 2
DMNW0DG DT Antibody
DM5F0QY ID DM5F0QY
DM5F0QY DN IONIS-416858
DM5F0QY HS Phase 2
DM5F0QY SN IONIS-FXI-LRx
DM5F0QY CP Ionis Pharmaceuticals
DM5F0QY DT Antisense oligonucleotide
DM5F0QY DE Thrombosis
DM6PDX2 ID DM6PDX2
DM6PDX2 DN IONIS-C9Rx
DM6PDX2 HS Phase 2
DM6PDX2 SN BIIB078
DM6PDX2 CP Ionis Pharmaceuticals
DM6PDX2 DT Antisense oligonucleotide
DM6PDX2 DE Amyotrophic lateral sclerosis
DM5LM3O ID DM5LM3O
DM5LM3O DN IONIS-DNM2-2.5Rx
DM5LM3O HS Phase 2
DM5LM3O CP Ionis Pharmaceuticals
DM5LM3O DT Antisense oligonucleotide
DM5LM3O DE Centronuclear myopathy
DMJ2763 ID DMJ2763
DMJ2763 DN IONIS-FB-LRx
DMJ2763 HS Phase 2
DMJ2763 CP Ionis Pharmaceuticals
DMJ2763 DT Antisense oligonucleotide
DMJ2763 DE IgA nephropathy
DMWV2N1 ID DMWV2N1
DMWV2N1 DN IONIS-GCCRRX
DMWV2N1 HS Phase 2
DMWV2N1 CP onis Pharmaceuticals Carlsbad, CA
DMWV2N1 DE Type-2 diabetes
DMB4GD9 ID DMB4GD9
DMB4GD9 DN IONIS-GCGR-Rx
DMB4GD9 HS Phase 2
DMB4GD9 CP Ionis Pharmaceuticals
DMB4GD9 DT Antisense oligonucleotide
DMB4GD9 DE Type-2 diabetes; Type 2 diabetes
DMGTJUP ID DMGTJUP
DMGTJUP DN IONIS-PTP1BRX
DMGTJUP HS Phase 2
DMGTJUP CP onis Pharmaceuticals Carlsbad, CA
DMGTJUP DE Type-2 diabetes
DM7VJE1 ID DM7VJE1
DM7VJE1 DN IONIS-TMPRSS6-LRx
DM7VJE1 HS Phase 2
DM7VJE1 CP Ionis Pharmaceuticals
DM7VJE1 DT Antisense oligonucleotide
DM7VJE1 DE Beta thalassemia
DM5TMYC ID DM5TMYC
DM5TMYC DN iOWH032
DM5TMYC HS Phase 2
DM5TMYC SN IOWH-032; CFTR inhibitors (diarrhea), BioFocus
DM5TMYC CP The Institute for OneWorld Health
DM5TMYC PC 135565181
DM5TMYC MW 545.2
DM5TMYC FM C22H15Br2N3O4
DM5TMYC IC InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)
DM5TMYC CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CNC(=O)C3=NC(=NO3)C4=CC(=C(C(=C4)Br)O)Br
DM5TMYC IK DSFNLJXHXBIKDS-UHFFFAOYSA-N
DM5TMYC IU 3-(3,5-dibromo-4-hydroxyphenyl)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide
DM5TMYC CA CAS 1191252-49-9
DM5TMYC DE Diarrhea
DMANRGW ID DMANRGW
DMANRGW DN IP10 C8
DMANRGW HS Phase 2
DMANRGW SN IP10C8
DMANRGW DE Psoriasis vulgaris
DMDUVCZ ID DMDUVCZ
DMDUVCZ DN IPH-2101
DMDUVCZ HS Phase 2
DMDUVCZ CP Innate Pharma
DMDUVCZ DE Multiple myeloma
DMPBR0D ID DMPBR0D
DMPBR0D DN IPH-2102
DMPBR0D HS Phase 2
DMPBR0D CP Innate Pharma SA
DMPBR0D DE Acute myeloid leukaemia
DMQH2SF ID DMQH2SF
DMQH2SF DN IPH4102
DMQH2SF HS Phase 2
DMQH2SF CP Innate Pharma Marseille, France
DMQH2SF DE T-cell lymphoma
DMG5Q7F ID DMG5Q7F
DMG5Q7F DN IPI-549
DMG5Q7F HS Phase 2
DMG5Q7F SN XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
DMG5Q7F CP Infinity Pharmaceuticals Cambridge, MA
DMG5Q7F PC 91933883
DMG5Q7F MW 528.6
DMG5Q7F FM C30H24N8O2
DMG5Q7F IC InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1
DMG5Q7F CS C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N
DMG5Q7F IK XUMALORDVCFWKV-IBGZPJMESA-N
DMG5Q7F IU 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMG5Q7F CA CAS 1693758-51-8
DMG5Q7F DE Adrenocortical carcinoma; Breast cancer; Head and neck cancer; Melanoma; Mesothelioma; Solid tumour/cancer; Bladder cancer
DMW2IF9 ID DMW2IF9
DMW2IF9 DN IR502
DMW2IF9 HS Phase 2
DMW2IF9 SN Zorcell
DMW2IF9 CP Orchestra Therapeutics
DMW2IF9 DE Psoriatic disorder; Plaque psoriasis; Psoriasis vulgaris
DMQ3RWN ID DMQ3RWN
DMQ3RWN DN Iralukast
DMQ3RWN HS Phase 2
DMQ3RWN SN CGP-45715A
DMQ3RWN CP Novartis AG
DMQ3RWN DT Small molecular drug
DMQ3RWN PC 6913104
DMQ3RWN MW 710.8
DMQ3RWN FM C38H37F3O8S
DMQ3RWN IC InChI=1S/C38H37F3O8S/c1-3-11-29-31(18-17-27(23(2)42)36(29)45)48-19-9-7-5-4-6-8-14-34(35(44)24-12-10-13-25(20-24)38(39,40)41)50-26-15-16-28-30(43)22-33(37(46)47)49-32(28)21-26/h4,6,8,10,12-18,20-22,34-35,44-45H,3,5,7,9,11,19H2,1-2H3,(H,46,47)/b6-4-,14-8+/t34-,35+/m0/s1
DMQ3RWN CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCC/C=C\\C=C\\[C@@H]([C@@H](C2=CC(=CC=C2)C(F)(F)F)O)SC3=CC4=C(C=C3)C(=O)C=C(O4)C(=O)O
DMQ3RWN IK IXJCHVMUTFCRBH-SDUHDBOFSA-N
DMQ3RWN IU 7-[(1R,2S,3E,5Z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid
DMQ3RWN CA CAS 151581-24-7
DMQ3RWN DE Asthma
DMI874B ID DMI874B
DMI874B DN Iratumumab
DMI874B HS Phase 2
DMI874B SN MDX-060; Anti-CD30 antibody, Medarex; 5F11
DMI874B CP Medarex
DMI874B DT Antibody
DMI874B DE Lymphoma
DMCAFVN ID DMCAFVN
DMCAFVN DN IRT-102
DMCAFVN HS Phase 2
DMCAFVN CP Tni biotech
DMCAFVN DT Small molecular drug
DMCAFVN PC 42785
DMCAFVN MW 573.7
DMCAFVN FM C27H35N5O7S
DMCAFVN IC InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)
DMCAFVN CS CSCCC(C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N
DMCAFVN IK YFGBQHOOROIVKG-UHFFFAOYSA-N
DMCAFVN IU 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMCAFVN CA CAS 58569-55-4
DMCAFVN DE Pancreatic cancer
DMODLN7 ID DMODLN7
DMODLN7 DN IRX-2
DMODLN7 HS Phase 2
DMODLN7 CP IRX Therapeutics
DMODLN7 DE Head and neck cancer; Acute myeloid leukaemia; Breast cancer; Squamous cell carcinoma; leukaemia
DMHOJ8W ID DMHOJ8W
DMHOJ8W DN Isatoribine
DMHOJ8W HS Phase 2
DMHOJ8W SN 7-Thia-8-oxoguanosine; ANA245; 122970-40-5; UNII-2DNT962H92; ANA-245; 2DNT962H92; Immusine; Isatoribine [USAN:INN]; 7-TOG; Immunosine; Satoribine; N10146; 7-Deaza-7-thia-8-oxoguanosine; AC1L2HO7; SCHEMBL127980; AC1Q6N18; SCHEMBL12592999; CHEMBL2105116; ANA 245; TZYVRXZQAWPIAB-FCLHUMLKSA-N; ZINC8214713; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; DB04860; 5-amino-3-(; A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; BRD-K87535339-001-01-6
DMHOJ8W CP Anadys Pharmaceuticals
DMHOJ8W DT Small molecular drug
DMHOJ8W PC 135409474
DMHOJ8W MW 316.29
DMHOJ8W FM C10H12N4O6S
DMHOJ8W IC InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)/t2-,3-,4-,8-/m1/s1
DMHOJ8W CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)NC(=N3)N)SC2=O)O)O)O
DMHOJ8W IK TZYVRXZQAWPIAB-FCLHUMLKSA-N
DMHOJ8W IU 5-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6H-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione
DMHOJ8W CA CAS 122970-40-5
DMHOJ8W DE Hepatitis C virus infection
DMBZK3P ID DMBZK3P
DMBZK3P DN ISF35
DMBZK3P HS Phase 2
DMBZK3P CP Memgen
DMBZK3P DE Small lymphocytic lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukaemia
DMUPD4G ID DMUPD4G
DMUPD4G DN ISIS 113715
DMUPD4G HS Phase 2
DMUPD4G CP ISIS
DMUPD4G TC Antisense
DMUPD4G DT Antisense drug
DMUPD4G SQ GCTCCTTCCACTGATCCTGC
DMUPD4G DE Type-2 diabetes
DMQ3C05 ID DMQ3C05
DMQ3C05 DN ISIS-APO(a)
DMQ3C05 HS Phase 2
DMQ3C05 DT Antisense drug
DMQ3C05 DE Coronary artery disease
DML84CN ID DML84CN
DML84CN DN ISIS-CRPRx
DML84CN HS Phase 2
DML84CN CP ISIS pharmaceuticals
DML84CN DE Coronary artery disease
DMRN543 ID DMRN543
DMRN543 DN ISIS-EIF4E
DMRN543 HS Phase 2
DMRN543 CP ISIS Pharm
DMRN543 DT Antisense drug
DMRN543 DE Prostate cancer; Non-small-cell lung cancer; Solid tumour/cancer
DMNVZDT ID DMNVZDT
DMNVZDT DN ISIS-FGFR4
DMNVZDT HS Phase 2
DMNVZDT CP ISIS Pharm
DMNVZDT DT Antisense drug
DMNVZDT DE Obesity
DMHETPI ID DMHETPI
DMHETPI DN ISIS-FXI
DMHETPI HS Phase 2
DMHETPI CP ISIS Pharm
DMHETPI DT Antisense drug
DMHETPI DE Coagulation defect
DMICMNU ID DMICMNU
DMICMNU DN ISIS-GCCR
DMICMNU HS Phase 2
DMICMNU CP ISIS Pharm
DMICMNU DT Antisense drug
DMICMNU DE Diabetic complication; Type-2 diabetes
DMHNYWP ID DMHNYWP
DMHNYWP DN ISIS-GCGR
DMHNYWP HS Phase 2
DMHNYWP CP ISIS Pharm
DMHNYWP DT Antisense drug
DMHNYWP DE Diabetic complication; Type-2 diabetes
DM4RXDQ ID DM4RXDQ
DM4RXDQ DN ISIS-HBV
DM4RXDQ HS Phase 2
DM4RXDQ DT Antisense drug
DM4RXDQ DE Hepatitis B virus infection
DMJGVXT ID DMJGVXT
DMJGVXT DN ISIS-PTP1Brx
DMJGVXT HS Phase 2
DMJGVXT CP Isis Pharmaceuticals
DMJGVXT DT Antisense drug
DMJGVXT DE Type-2 diabetes
DM2RS0V ID DM2RS0V
DM2RS0V DN Isofagomine tartrate
DM2RS0V HS Phase 2
DM2RS0V SN Plicera; Afegostat tartrate; AT-2101; HGT-3410; Plicera (TN); NN-42-1007
DM2RS0V CP Amicus Therape.
DM2RS0V DT Small molecular drug
DM2RS0V PC 23581846
DM2RS0V MW 297.26
DM2RS0V FM C10H19NO9
DM2RS0V IC InChI=1S/C6H13NO3.C4H6O6/c8-3-4-1-7-2-5(9)6(4)10;5-1(3(7)8)2(6)4(9)10/h4-10H,1-3H2;1-2,5-6H,(H,7,8)(H,9,10)/t4-,5-,6-;1-,2-/m11/s1
DM2RS0V CS C1[C@@H]([C@H]([C@@H](CN1)O)O)CO.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DM2RS0V IK ULBPPCHRAVUQMC-MUMXBIPUSA-N
DM2RS0V IU (2R,3R)-2,3-dihydroxybutanedioic acid;(3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol
DM2RS0V CA CAS 919364-56-0
DM2RS0V DE Metabolic disorder
DMP2BWX ID DMP2BWX
DMP2BWX DN Ispinesib
DMP2BWX HS Phase 2
DMP2BWX SN SB-715992; Ispinesib (SB-715992 /CK0238273); SB-715992, CK0238273,Ispinesib; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
DMP2BWX CP Cytokinetics
DMP2BWX TC Anticancer Agents
DMP2BWX DT Small molecular drug
DMP2BWX PC 6851740
DMP2BWX MW 517.1
DMP2BWX FM C30H33ClN4O2
DMP2BWX IC InChI=1S/C30H33ClN4O2/c1-20(2)27(34(17-7-16-32)29(36)23-12-10-21(3)11-13-23)28-33-26-18-24(31)14-15-25(26)30(37)35(28)19-22-8-5-4-6-9-22/h4-6,8-15,18,20,27H,7,16-17,19,32H2,1-3H3/t27-/m1/s1
DMP2BWX CS CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=NC3=C(C=CC(=C3)Cl)C(=O)N2CC4=CC=CC=C4)C(C)C
DMP2BWX IK QJZRFPJCWMNVAV-HHHXNRCGSA-N
DMP2BWX IU N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
DMP2BWX CA CAS 336113-53-2
DMP2BWX CB CHEBI:94692
DMP2BWX DE Solid tumour/cancer; Ovarian cancer; Renal cell carcinoma; Head and neck cancer
DMCY9PO ID DMCY9PO
DMCY9PO DN Itarnafloxin
DMCY9PO HS Phase 2
DMCY9PO SN Quarfloxin; CX-3385; CX-3543; Quadruplex DNA oncogene inhibitor (cancer), Cylene; C-Myc/VEGF oncogene inhibitor (cancer), Cylene
DMCY9PO CP Cylene Pharmaceuticals Inc
DMCY9PO DT Small molecular drug
DMCY9PO PC 11635763
DMCY9PO MW 604.7
DMCY9PO FM C35H33FN6O3
DMCY9PO IC InChI=1S/C35H33FN6O3/c1-40-13-4-7-24(40)8-10-39-35(44)26-20-42-29-15-21-5-2-3-6-22(21)16-30(29)45-34-31(42)25(33(26)43)17-27(36)32(34)41-14-9-23(19-41)28-18-37-11-12-38-28/h2-3,5-6,11-12,15-18,20,23-24H,4,7-10,13-14,19H2,1H3,(H,39,44)/t23?,24-/m0/s1
DMCY9PO CS CN1CCC[C@H]1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O
DMCY9PO IK WOQIDNWTQOYDLF-CGAIIQECSA-N
DMCY9PO IU 15-fluoro-N-[2-[(2S)-1-methylpyrrolidin-2-yl]ethyl]-18-oxo-14-(3-pyrazin-2-ylpyrrolidin-1-yl)-12-oxa-1-azapentacyclo[11.7.1.02,11.04,9.017,21]henicosa-2,4,6,8,10,13(21),14,16,19-nonaene-19-carboxamide
DMCY9PO CA CAS 865311-47-3
DMCY9PO DE leukaemia
DMDZWPL ID DMDZWPL
DMDZWPL DN ITCA-638
DMDZWPL HS Phase 2
DMDZWPL SN Omega DUROS, BioMedicines/ ALZA; Omega DUROS, Intarcia/ALZA; Omega IFN (sustained release), BioMedicines/ ALZA; Omega IFN (sustained release, hepatitis C), Intarcia/ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), BioMedicines/ ALZA; Omega interferon (sustained release/subcutaneous/DUROS, hepatitis C), Intarcia/ALZA
DMDZWPL CP Intarcia Therapeutics Inc
DMDZWPL DE Hepatitis C virus infection
DM5UFRO ID DM5UFRO
DM5UFRO DN Itriglumide
DM5UFRO HS Phase 2
DM5UFRO SN CR-2945
DM5UFRO CP Rottapharm Madaus
DM5UFRO DT Small molecular drug
DM5UFRO PC 6604121
DM5UFRO MW 526.7
DM5UFRO FM C33H38N2O4
DM5UFRO IC InChI=1S/C33H38N2O4/c1-22-18-23(2)31(28(19-22)32(39)35-16-14-33(15-17-35)12-5-6-13-33)34-29(36)20-25(21-30(37)38)27-11-7-9-24-8-3-4-10-26(24)27/h3-4,7-11,18-19,25H,5-6,12-17,20-21H2,1-2H3,(H,34,36)(H,37,38)/t25-/m1/s1
DM5UFRO CS CC1=CC(=C(C(=C1)C(=O)N2CCC3(CCCC3)CC2)NC(=O)C[C@H](CC(=O)O)C4=CC=CC5=CC=CC=C54)C
DM5UFRO IK MFOOVZCXWVAWOV-RUZDIDTESA-N
DM5UFRO IU (3R)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid
DM5UFRO CA CAS 201605-51-8
DM5UFRO DE Anxiety disorder
DMCJX79 ID DMCJX79
DMCJX79 DN ITV-1
DMCJX79 HS Phase 2
DMCJX79 CP Immunotech Laboratories
DMCJX79 DT Vaccine
DMCJX79 DE Human immunodeficiency virus infection
DMJV3AX ID DMJV3AX
DMJV3AX DN IVA337
DMJV3AX HS Phase 2
DMJV3AX SN Lanifibranor; 927961-18-0; IVA-337; UNII-28Q8AG0PYL; 28Q8AG0PYL; CHEMBL4091374; CPD1537; 4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic acid; 1H-Indole-2-butanoic acid, 1-(6-benzothiazolylsulfonyl)-5-chloro-; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid; 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid; Lanifbranor; Libfranor; Lanifbranor [INN]; Lanifibranor(IVA-337); SCHEMBL3528615; AMY16813; EX-A1511; BDBM50244350; s8770; DB14801; SB18746; AC-31451; AK689102; BS-17993; HY-104049; CS-0027586; Q27896056; 1-(6-Benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic Acid; 5-Chloro-1-((6-benzothiazolyl)sulfonyl)-1H-indole-2-butanoic acid; 4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid; BJB
DMJV3AX DT Small molecular drug
DMJV3AX PC 68677842
DMJV3AX MW 434.9
DMJV3AX FM C19H15ClN2O4S2
DMJV3AX IC InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24)
DMJV3AX CS C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
DMJV3AX IK OQDQIFQRNZIEEJ-UHFFFAOYSA-N
DMJV3AX IU 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
DMJV3AX CA CAS 927961-18-0
DMJV3AX DE Non-alcoholic steatohepatitis
DM0OYLQ ID DM0OYLQ
DM0OYLQ DN I-vation
DM0OYLQ HS Phase 2
DM0OYLQ SN Triamcinolone implant
DM0OYLQ CP SurModics
DM0OYLQ DE Diabetic retinopathy
DM457XO ID DM457XO
DM457XO DN IW-1701
DM457XO HS Phase 2
DM457XO SN Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
DM457XO CP Cyclerion Therapeutics
DM457XO DT Small molecular drug
DM457XO PC 90445883
DM457XO MW 509.4
DM457XO FM C21H16F5N7O3
DM457XO IC InChI=1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1
DM457XO CS C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NC[C@@](C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F
DM457XO IK YWQFJNWMWZMXRW-HXUWFJFHSA-N
DM457XO IU (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
DM457XO CA CAS 1628732-62-6
DM457XO DE Sickle-cell disorder
DMK2T7J ID DMK2T7J
DMK2T7J DN IW-1973
DMK2T7J HS Phase 2
DMK2T7J SN Praliciguat; UNII-R1S0H458SA; R1S0H458SA; 1628730-49-3; Praliciguat [INN]; GTPL9900; SCHEMBL16082414; IW1973; 1,1,1-trifluoro-3-[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1H-pyrazol-3-yl}pyrimidin-4-yl)amino]-2-(trifluoromethyl)propan-2-ol; 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(((5-fluoro-2-(1-((2-fluorophenyl)methyl)-5-(3-isoxazolyl)-1H-pyrazol-3-yl)-4-pyrimidinyl)amino)methyl)-
DMK2T7J CP Ironwood Pharmaceuticals Cambridge, MA
DMK2T7J PC 86269973
DMK2T7J MW 534.4
DMK2T7J FM C21H14F8N6O2
DMK2T7J IC InChI=1S/C21H14F8N6O2/c22-12-4-2-1-3-11(12)9-35-16(14-5-6-37-34-14)7-15(33-35)18-30-8-13(23)17(32-18)31-10-19(36,20(24,25)26)21(27,28)29/h1-8,36H,9-10H2,(H,30,31,32)
DMK2T7J CS C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(F)(F)F)(C(F)(F)F)O)F)C4=NOC=C4)F
DMK2T7J IK CYSJNTQNMDWAJV-UHFFFAOYSA-N
DMK2T7J IU 1,1,1,3,3,3-hexafluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]propan-2-ol
DMK2T7J CA CAS 1628730-49-3
DMK2T7J CB CHEBI:142431
DMK2T7J DE Heart failure
DMP42W1 ID DMP42W1
DMP42W1 DN IW-6118
DMP42W1 HS Phase 2
DMP42W1 CP Ironwood Pharmaceuticals Inc
DMP42W1 DE Inflammation
DM3WSDR ID DM3WSDR
DM3WSDR DN IXT-m200
DM3WSDR HS Phase 2
DM3WSDR CP InterveXion Therapeutics
DM3WSDR DT Antibody
DM3WSDR DE Methamphetamine use disorder
DM9XKJU ID DM9XKJU
DM9XKJU DN J 591 Lu-177
DM9XKJU HS Phase 2
DM9XKJU CP BZL Biologics
DM9XKJU DE Prostate cancer
DMKU6MW ID DMKU6MW
DMKU6MW DN JB991
DMKU6MW HS Phase 2
DMKU6MW CP Synphora
DMKU6MW DE Sarcoidosis; Skin infection
DM89ASO ID DM89ASO
DM89ASO DN JCAR015
DM89ASO HS Phase 2
DM89ASO CP Juno Therapeutics, Inc.
DM89ASO DT CAR T Cell Therapy
DM89ASO DE B-cell lymphoma; Acute lymphoblastic leukaemia
DMM02VJ ID DMM02VJ
DMM02VJ DN JI-101
DMM02VJ HS Phase 2
DMM02VJ SN JI-101; 900573-88-8; CGI-1842; UNII-980M4N37DH; 980M4N37DH; 1-(1-((2-AMINOPYRIDIN-4-YL)METHYL)-1H-INDOL-4-YL)-3-(5-BROMO-2-METHOXYPHENYL)UREA; SCHEMBL5585996; CHEMBL3545155; MolPort-044-567-620; BCP16892; EX-A2371; JI 101; ZINC38255464; AKOS030526978; SB16904; DB12744; CS-5636; Urea, N-(1-((2-amino-4-pyridinyl)methyl)-1H-indol-4-yl)-N'-(5-bromo-2-methoxyphenyl)-; KB-77988; HY-16265
DMM02VJ CP Jubilant Biosys
DMM02VJ DT Small molecular drug
DMM02VJ PC 11691242
DMM02VJ MW 466.3
DMM02VJ FM C22H20BrN5O2
DMM02VJ IC InChI=1S/C22H20BrN5O2/c1-30-20-6-5-15(23)12-18(20)27-22(29)26-17-3-2-4-19-16(17)8-10-28(19)13-14-7-9-25-21(24)11-14/h2-12H,13H2,1H3,(H2,24,25)(H2,26,27,29)
DMM02VJ CS COC1=C(C=C(C=C1)Br)NC(=O)NC2=C3C=CN(C3=CC=C2)CC4=CC(=NC=C4)N
DMM02VJ IK ZXBFYBLSJMEBEP-UHFFFAOYSA-N
DMM02VJ IU 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea
DMM02VJ CA CAS 900573-88-8
DMM02VJ DE Solid tumour/cancer
DMARQ0H ID DMARQ0H
DMARQ0H DN JKB-122
DMARQ0H HS Phase 2
DMARQ0H SN Opioid receptor modulator (liver disease), Jenken Bioscience
DMARQ0H CP Jenken Biosciences
DMARQ0H DE Hepatitis virus infection
DMJSVRL ID DMJSVRL
DMJSVRL DN JM216
DMJSVRL HS Phase 2
DMJSVRL SN 129580-63-8; JM 216; satraplatin(jm216); Satraplatin (USAN/INN); C081294; YHI-601; C6H13N.C4H6Cl2O4Pt.H3N; Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-; 4023AH; AKOS015914237; BMS-182751; BC679462; FT-0601550; D05807; Bis(acetato-O)amminedichloro(cyclohexanamine)-pt; 580S638; I14-43013; Platinum (lV) cis-dichloro-trans-bis(acetato-O)ammine(cyclohexanamine)
DMJSVRL DT Small molecular drug
DMJSVRL PC 6918220
DMJSVRL MW 502.3
DMJSVRL FM C10H24Cl2N2O4Pt
DMJSVRL IC InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+2/p-2
DMJSVRL CS CC(=O)O.CC(=O)O.C1CCC(CC1)N.N.Cl[Pt]Cl
DMJSVRL IK TWEQNPPRXJRHHM-UHFFFAOYSA-L
DMJSVRL IU acetic acid;azane;cyclohexanamine;dichloroplatinum
DMJSVRL DE Solid tumour/cancer
DMBXWJ5 ID DMBXWJ5
DMBXWJ5 DN JNJ 63723283
DMBXWJ5 HS Phase 2
DMBXWJ5 CP Janssen Research & Development Raritan, NJ
DMBXWJ5 DT Monoclonal antibody
DMBXWJ5 DE Solid tumour/cancer; Multiple myeloma; Prostate cancer; Ulcerative colitis
DMY7Q3I ID DMY7Q3I
DMY7Q3I DN JNJ-10229570
DMY7Q3I HS Phase 2
DMY7Q3I SN JNJ-10229570-AAA; MC5R antagonist (topical, acne), Johnson & Johnson; Melanocortin-5 receptor antagonist (topical, acne), Johnson & Johnson
DMY7Q3I CP Johnson & Johnson
DMY7Q3I PC 10110895
DMY7Q3I MW 389.5
DMY7Q3I FM C22H19N3O2S
DMY7Q3I IC InChI=1S/C22H19N3O2S/c1-26-19-14-8-6-12-17(19)21-24-22(23-16-10-4-3-5-11-16)28-25(21)18-13-7-9-15-20(18)27-2/h3-15H,1-2H3
DMY7Q3I CS COC1=CC=CC=C1C2=NC(=NC3=CC=CC=C3)SN2C4=CC=CC=C4OC
DMY7Q3I IK XTHRTBCPBWJYRO-UHFFFAOYSA-N
DMY7Q3I IU 2,3-bis(2-methoxyphenyl)-N-phenyl-1,2,4-thiadiazol-5-imine
DMY7Q3I CA CAS 524923-88-4
DMY7Q3I DE Acne vulgaris
DM7OTQS ID DM7OTQS
DM7OTQS DN JNJ-10311795
DM7OTQS HS Phase 2
DM7OTQS SN JNJ-10311795; CHEMBL374027; 518062-14-1; SCHEMBL1260969; GTPL6563; BDBM50208224; Phosphonic acid, (2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; Phosphonic acid, P-(2-(3-((methyl(1-(2-naphthalenylcarbonyl)-4-piperidinyl)amino)carbonyl)-2-naphthalenyl)-1-(1-naphthalenyl)-2-oxoethyl)-; [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
DM7OTQS DT Small molecular drug
DM7OTQS PC 10146470
DM7OTQS MW 670.7
DM7OTQS FM C40H35N2O6P
DM7OTQS IC InChI=1S/C40H35N2O6P/c1-41(32-19-21-42(22-20-32)39(44)31-18-17-26-9-2-3-11-28(26)23-31)40(45)36-25-30-13-5-4-12-29(30)24-35(36)37(43)38(49(46,47)48)34-16-8-14-27-10-6-7-15-33(27)34/h2-18,23-25,32,38H,19-22H2,1H3,(H2,46,47,48)
DM7OTQS CS CN(C1CCN(CC1)C(=O)C2=CC3=CC=CC=C3C=C2)C(=O)C4=CC5=CC=CC=C5C=C4C(=O)C(C6=CC=CC7=CC=CC=C76)P(=O)(O)O
DM7OTQS IK XUJQPDQURBZEGJ-UHFFFAOYSA-N
DM7OTQS IU [2-[3-[methyl-[1-(naphthalene-2-carbonyl)piperidin-4-yl]carbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
DM7OTQS CA CAS 518062-14-1
DM7OTQS DE Chronic obstructive pulmonary disease
DMPFG7H ID DMPFG7H
DMPFG7H DN JNJ-16269110
DMPFG7H HS Phase 2
DMPFG7H SN SCHEMBL803531; CHEMBL2103860
DMPFG7H CP Janssen Research & Development
DMPFG7H DT Small molecular drug
DMPFG7H PC 56842069
DMPFG7H MW 572.6
DMPFG7H FM C34H31F3N2O3
DMPFG7H IC InChI=1S/C34H31F3N2O3/c1-42-33(41)31(26-7-3-2-4-8-26)39-21-19-24(20-22-39)23-13-17-28(18-14-23)38-32(40)30-10-6-5-9-29(30)25-11-15-27(16-12-25)34(35,36)37/h2-18,24,31H,19-22H2,1H3,(H,38,40)/t31-/m1/s1
DMPFG7H CS COC(=O)[C@@H](C1=CC=CC=C1)N2CCC(CC2)C3=CC=C(C=C3)NC(=O)C4=CC=CC=C4C5=CC=C(C=C5)C(F)(F)F
DMPFG7H IK WSYALRNYQFNNGP-WJOKGBTCSA-N
DMPFG7H IU methyl (2R)-2-phenyl-2-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]phenyl]piperidin-1-yl]acetate
DMPFG7H CA CAS 403989-79-7
DMPFG7H DE Type-2 diabetes
DM1GRCU ID DM1GRCU
DM1GRCU DN JNJ-17216498
DM1GRCU HS Phase 2
DM1GRCU SN Histamine H3 antagonist (oral, narcolepsy) J&J
DM1GRCU CP Johnson & Johnson
DM1GRCU DE Narcolepsy
DMV1T59 ID DMV1T59
DMV1T59 DN JNJ-18038683
DMV1T59 HS Phase 2
DMV1T59 SN Serotonin 7 antagonist (depression), Johnson & Johnson; 5-HT 7 antagonist (depression), Johnson & Johnson
DMV1T59 CP Johnson & Johnson
DMV1T59 DT Small molecular drug
DMV1T59 PC 11151899
DMV1T59 MW 337.8
DMV1T59 FM C20H20ClN3
DMV1T59 IC InChI=1S/C20H20ClN3/c21-17-8-6-16(7-9-17)20-18-10-12-22-13-11-19(18)24(23-20)14-15-4-2-1-3-5-15/h1-9,22H,10-14H2
DMV1T59 CS C1CNCCC2=C1C(=NN2CC3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMV1T59 IK UKJPMZGILXATGT-UHFFFAOYSA-N
DMV1T59 IU 1-benzyl-3-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[3,4-d]azepine
DMV1T59 CA CAS 851373-91-6
DMV1T59 DE Major depressive disorder
DMKIE9C ID DMKIE9C
DMKIE9C DN JNJ-26481585
DMKIE9C HS Phase 2
DMKIE9C SN 875320-29-9; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; UNII-9BJ85K1J8S; Quisinostat (JNJ-26481585); JNJ26481585; 9BJ85K1J8S; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide
DMKIE9C CP Janssen Research & Development
DMKIE9C DT Small molecular drug
DMKIE9C PC 11538455
DMKIE9C MW 394.5
DMKIE9C FM C21H26N6O2
DMKIE9C IC InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
DMKIE9C CS CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
DMKIE9C IK PAWIYAYFNXQGAP-UHFFFAOYSA-N
DMKIE9C IU N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
DMKIE9C CA CAS 875320-29-9
DMKIE9C CB CHEBI:94771
DMKIE9C DE Advanced stage follicular lymphoma; Solid tumour/cancer
DMQD1GN ID DMQD1GN
DMQD1GN DN JNJ-32729463
DMQD1GN HS Phase 2
DMQD1GN SN Acorafloxacin HCl; Avarofloxacin hydrochloride; Acorafloxacin hydrochloride; UNII-1NWW5SKQ0N; JNJ-32729463-AAC; 1NWW5SKQ0N; Acorafloxacin hydrochloride [USAN]; 1001162-01-1 (HCl); Acorafloxacin hydrochloride (USAN); Avarofloxacin HCl; 1001162-01-1; (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; JNJ-Q2 hydrochloride; SCHEMBL2190495; CHEMBL2364603; DTXSID70142966; JNJ-32729463AAC; Jnj-32729463; 7-((3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride; D10544; Q27252661
DMQD1GN DT Small molecular drug
DMQD1GN PC 67311433
DMQD1GN MW 455.9
DMQD1GN FM C21H24ClF2N3O4
DMQD1GN IC InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24;/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29);1H/b16-11+;
DMQD1GN CS COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl
DMQD1GN IK RDXCNSOGHLLWDV-YFMOEUEHSA-N
DMQD1GN IU 7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
DMQD1GN CA CAS 1001162-01-1
DMQD1GN DE Community-acquired pneumonia
DMV41P5 ID DMV41P5
DMV41P5 DN JNJ-37822681
DMV41P5 HS Phase 2
DMV41P5 SN UNII-GJB2URS7NJ; JNJ-37822681; GJB2URS7NJ; CHEMBL3234237; 935776-74-2; SCHEMBL1022639; MolPort-039-267-898; BDBM50003063; ZINC34951380; DB12579; 3-Pyridazinamine, N-(1-((3,4-difluorophenyl)methyl)-4-piperidinyl)-6-(trifluoromethyl)-; NCGC00386644-01; Z1558691527
DMV41P5 CP Johnson & Johnson Pharmaceutical Research & Development
DMV41P5 DT Small molecular drug
DMV41P5 PC 16058752
DMV41P5 MW 372.34
DMV41P5 FM C17H17F5N4
DMV41P5 IC InChI=1S/C17H17F5N4/c18-13-2-1-11(9-14(13)19)10-26-7-5-12(6-8-26)23-16-4-3-15(24-25-16)17(20,21)22/h1-4,9,12H,5-8,10H2,(H,23,25)
DMV41P5 CS C1CN(CCC1NC2=NN=C(C=C2)C(F)(F)F)CC3=CC(=C(C=C3)F)F
DMV41P5 IK UVUYWJWYRLJHEN-UHFFFAOYSA-N
DMV41P5 IU N-[1-[(3,4-difluorophenyl)methyl]piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine
DMV41P5 CA CAS 935776-74-2
DMV41P5 DE Schizophrenia
DM9UMIO ID DM9UMIO
DM9UMIO DN JNJ-38518168
DM9UMIO HS Phase 2
DM9UMIO CP Janssen research & development
DM9UMIO PC 23650961
DM9UMIO MW 392.5
DM9UMIO FM C23H32N6
DM9UMIO IC InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
DM9UMIO CS CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C
DM9UMIO IK FCRFVPZAXGJLPW-UHFFFAOYSA-N
DM9UMIO IU 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine
DM9UMIO CA CAS 952494-46-1
DM9UMIO DE Rheumatoid arthritis; Plaque psoriasis
DM0WY3H ID DM0WY3H
DM0WY3H DN JNJ-39220675
DM0WY3H HS Phase 2
DM0WY3H SN Histamine H3 receptor antagonist (allergic rhinitis/alcoholism), Johnson & Johnson
DM0WY3H CP Johnson & Johnson Pharmaceutical Research & Development LLC
DM0WY3H DT Small molecular drug
DM0WY3H PC 24771368
DM0WY3H MW 369.4
DM0WY3H FM C21H24FN3O2
DM0WY3H IC InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2
DM0WY3H CS C1CC(C1)N2CCCN(CC2)C(=O)C3=CN=C(C=C3)OC4=CC=C(C=C4)F
DM0WY3H IK IQOWHZHNGJXGHG-UHFFFAOYSA-N
DM0WY3H IU (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(4-fluorophenoxy)pyridin-3-yl]methanone
DM0WY3H CA CAS 959740-39-7
DM0WY3H DE Alcohol dependence
DMUOEKM ID DMUOEKM
DMUOEKM DN JNJ-39393406
DMUOEKM HS Phase 2
DMUOEKM SN JNJ-39393406; UNII-T930SOU82P; T930SOU82P; JNJ 39393406; 953428-73-4; SCHEMBL827762; CHEMBL3545291; DB11867; 1H-1,2,4-Triazole-1-propanamide, 3-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-N,N-dimethyl-5-(4-pyridinyl)-
DMUOEKM CP Janssen Pharmaceutica NV
DMUOEKM DT Small molecular drug
DMUOEKM PC 16755766
DMUOEKM MW 416.4
DMUOEKM FM C19H18F2N6O3
DMUOEKM IC InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)
DMUOEKM CS CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4
DMUOEKM IK IURMHZBQEYNQOH-UHFFFAOYSA-N
DMUOEKM IU 3-[3-[(2,2-difluoro-1,3-benzodioxol-5-yl)amino]-5-pyridin-4-yl-1,2,4-triazol-1-yl]-N,N-dimethylpropanamide
DMUOEKM CA CAS 953428-73-4
DMUOEKM DE Cognitive impairment; Depression; Tobacco dependence
DM219SF ID DM219SF
DM219SF DN JNJ-40346527
DM219SF HS Phase 2
DM219SF CP Janssen Research & Development
DM219SF PC 25230468
DM219SF MW 461.6
DM219SF FM C27H35N5O2
DM219SF IC InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
DM219SF CS CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C
DM219SF IK BNVPFDRNGHMRJS-UHFFFAOYSA-N
DM219SF IU 5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide
DM219SF CA CAS 1142363-52-7
DM219SF DE Hodgkin lymphoma
DM72GZO ID DM72GZO
DM72GZO DN JNJ-42165279
DM72GZO HS Phase 2
DM72GZO CP Janssen research & development
DM72GZO PC 54576693
DM72GZO MW 410.8
DM72GZO FM C18H17ClF2N4O3
DM72GZO IC InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
DM72GZO CS C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl
DM72GZO IK YWGYNGCRVZLMCS-UHFFFAOYSA-N
DM72GZO IU N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
DM72GZO CA CAS 1346528-50-4
DM72GZO DE Anxiety disorder; Social anxiety disorder
DMJ1FXL ID DMJ1FXL
DMJ1FXL DN JNJ-53718678
DMJ1FXL HS Phase 2
DMJ1FXL SN Rilematovir; JNJ-678; UNII-NQ99E8OH3P; NQ99E8OH3P; 1383450-81-4; 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one; 3-[[5-Chloranyl-1-(3-Methylsulfonylpropyl)indol-2-Yl]methyl]-1-[2,2,2-Tris(Fluoranyl)ethyl]imidazo[4,5-C]pyridin-2-One; Rilematovir [INN]; CHEMBL4437054; SCHEMBL17529353; HY-112180; CS-0043622; C(CCN1C(=CC2=CC(=CC=C12)Cl)CN1C2=C(N(C1=O)CC(F)(F)F)C=CN=C2)S(=O)(=O)C; 2H-Imidazo(4,5-C)pyridin-2-one, 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-; 3-((5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)imidazo(4,5-C)pyridin-2-one; 6YA
DMJ1FXL CP Janssen
DMJ1FXL DT Small molecular drug
DMJ1FXL PC 118892432
DMJ1FXL MW 500.9
DMJ1FXL FM C21H20ClF3N4O3S
DMJ1FXL IC InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3
DMJ1FXL CS CS(=O)(=O)CCCN1C2=C(C=C(C=C2)Cl)C=C1CN3C4=C(C=CN=C4)N(C3=O)CC(F)(F)F
DMJ1FXL IK GTQTUABHRCWVLL-UHFFFAOYSA-N
DMJ1FXL IU 3-[[5-chloro-1-(3-methylsulfonylpropyl)indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)imidazo[4,5-c]pyridin-2-one
DMJ1FXL CA CAS 1383450-81-4
DMJ1FXL DE Respiratory syncytial virus infection
DM9RW6H ID DM9RW6H
DM9RW6H DN JNJ-56136379
DM9RW6H HS Phase 2
DM9RW6H SN JNJ-6379
DM9RW6H CP Janssen
DM9RW6H DT Antibody
DM9RW6H DE Hepatitis B
DME2S4D ID DME2S4D
DME2S4D DN JNJ-61393215
DME2S4D HS Phase 2
DME2S4D SN Q66977422
DME2S4D CP Janssen
DME2S4D DT Small molecular drug
DME2S4D PC 139030979
DME2S4D MW 460.4
DME2S4D FM C23H18F4N4O2
DME2S4D IC InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
DME2S4D CS [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
DME2S4D IK HUKWIAXQBOHZIX-USKNZQBOSA-N
DME2S4D IU [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
DME2S4D DE Major depressive disorder
DMVSUH1 ID DMVSUH1
DMVSUH1 DN JNJ-64565111
DMVSUH1 HS Phase 2
DMVSUH1 CP Janssen Research & Development Raritan, NJ
DMVSUH1 DE Type-2 diabetes; Obesity
DM3ICO6 ID DM3ICO6
DM3ICO6 DN JNJ-74494550
DM3ICO6 HS Phase 2
DM3ICO6 SN Cusatuzumab
DM3ICO6 CP Argen Boston; Janssen
DM3ICO6 DT Antibody
DM3ICO6 DE Myelodysplastic syndrome
DMXTKCR ID DMXTKCR
DMXTKCR DN JT02
DMXTKCR HS Phase 2
DMXTKCR CP JYANT Technologies Marietta, GA
DMXTKCR DE Inflammatory bowel disease
DM2LBHN ID DM2LBHN
DM2LBHN DN JTE-051
DM2LBHN HS Phase 2
DM2LBHN DE Allergy; Plaque psoriasis
DM1945H ID DM1945H
DM1945H DN JTT-251
DM1945H HS Phase 2
DM1945H CP Akros pharma
DM1945H DE Type-2 diabetes; Pulmonary arterial hypertension
DMGLVBI ID DMGLVBI
DMGLVBI DN JTT-302
DMGLVBI HS Phase 2
DMGLVBI SN CETP inhibitor (oral, dyslipidemia), Japan Tobacco
DMGLVBI CP Japan Tobacco Inc
DMGLVBI DE Lipid metabolism disorder
DM50M2R ID DM50M2R
DM50M2R DN JTT-654
DM50M2R HS Phase 2
DM50M2R SN 11-beta HSD1 inhibitor (oral, type 2 diabetes), Japan Tobacco; 11-beta hydroxysteroid dehydrogenase (oral, type 2 diabetes), Japan Tobacco
DM50M2R CP Japan Tobacco Inc
DM50M2R DE Type-2 diabetes
DMED5J6 ID DMED5J6
DMED5J6 DN JTT-851
DMED5J6 HS Phase 2
DMED5J6 SN GPCR 40 agonist (type 2 diabetes) Japan Tobacco
DMED5J6 CP Akros pharma
DMED5J6 DE Type-2 diabetes
DMGXTOP ID DMGXTOP
DMGXTOP DN JTX-2011
DMGXTOP HS Phase 2
DMGXTOP CP Jounce Therapeutics Cambridge, MA
DMGXTOP DE Solid tumour/cancer
DMOT0M7 ID DMOT0M7
DMOT0M7 DN JTX-4014
DMOT0M7 HS Phase 2
DMOT0M7 SN Pimivalimab
DMOT0M7 CP Jounce Therapeutics
DMOT0M7 DT Antibody
DMOT0M7 DE Non-small-cell lung cancer
DMZKYNO ID DMZKYNO
DMZKYNO DN Juvidex
DMZKYNO HS Phase 2
DMZKYNO SN Adaprev; Mannose-6-phosphate (scarring), Renovo
DMZKYNO CP Renovo Group plc
DMZKYNO PC 6101690
DMZKYNO MW 260.14
DMZKYNO FM C6H13O9P
DMZKYNO IC InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4-,5-,6-/m1/s1
DMZKYNO CS C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)OP(=O)(O)O
DMZKYNO IK VFRROHXSMXFLSN-KVTDHHQDSA-N
DMZKYNO IU [(2R,3R,4S,5S)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate
DMZKYNO CA CAS 3672-15-9
DMZKYNO CB CHEBI:48042
DMZKYNO DE Sarcoidosis
DMPMU38 ID DMPMU38
DMPMU38 DN JVRS-100
DMPMU38 HS Phase 2
DMPMU38 CP Colby Pharmaceutical
DMPMU38 DT Vaccine
DMPMU38 DE leukaemia
DMD4OK0 ID DMD4OK0
DMD4OK0 DN K-134
DMD4OK0 HS Phase 2
DMD4OK0 SN SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104
DMD4OK0 CP Kowa Pharmaceuticals America
DMD4OK0 DT Small molecular drug
DMD4OK0 PC 9908900
DMD4OK0 MW 399.5
DMD4OK0 FM C22H29N3O4
DMD4OK0 IC InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1
DMD4OK0 CS C1CC[C@H]([C@@H](C1)N(C2CC2)C(=O)NCCCOC3=CC4=C(C=C3)NC(=O)C=C4)O
DMD4OK0 IK ULGNGSQNNMKROG-WOJBJXKFSA-N
DMD4OK0 IU 1-cyclopropyl-1-[(1R,2R)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1H-quinolin-6-yl)oxy]propyl]urea
DMD4OK0 CA CAS 189362-06-9
DMD4OK0 DE Arteriosclerosis
DMZCVD7 ID DMZCVD7
DMZCVD7 DN K-201
DMZCVD7 HS Phase 2
DMZCVD7 SN DKKLXCRMAXNIJF-UHFFFAOYSA-N; UNII-0I621Y6R4Q; K201; 0I621Y6R4Q; 1038410-88-6; K 201; SCHEMBL194018; CHEMBL2440857; DTXSID90146108; K-201, Moberg; Dermatological drug combination (kaprolac, atopic dermatitis), Moberg; Urea + PEG/propylene glycol formulation (atopic dermatitis), Moberg; JTV 519
DMZCVD7 CP Moberg Derma AB
DMZCVD7 DT Small molecular drug
DMZCVD7 PC 9868902
DMZCVD7 MW 461.1
DMZCVD7 FM C25H33ClN2O2S
DMZCVD7 IC InChI=1S/C25H32N2O2S.ClH/c1-29-23-7-8-24-22(18-23)19-27(15-16-30-24)25(28)11-14-26-12-9-21(10-13-26)17-20-5-3-2-4-6-20;/h2-8,18,21H,9-17,19H2,1H3;1H
DMZCVD7 CS COC1=CC2=C(C=C1)SCCN(C2)C(=O)CCN3CCC(CC3)CC4=CC=CC=C4.Cl
DMZCVD7 IK DKKLXCRMAXNIJF-UHFFFAOYSA-N
DMZCVD7 IU 3-(4-benzylpiperidin-1-yl)-1-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)propan-1-one;hydrochloride
DMZCVD7 CA CAS 1038410-88-6
DMZCVD7 DE Atopic dermatitis
DMQVN6P ID DMQVN6P
DMQVN6P DN K-604
DMQVN6P HS Phase 2
DMQVN6P SN BDBM86691
DMQVN6P CP Kowa Pharmaceuticals America
DMQVN6P DT Small molecular drug
DMQVN6P PC 9892288
DMQVN6P MW 502.7
DMQVN6P FM C23H30N6OS3
DMQVN6P IC InChI=1S/C23H30N6OS3/c1-16-14-19(31-2)21(22(24-16)32-3)27-20(30)15-29-10-8-28(9-11-29)12-13-33-23-25-17-6-4-5-7-18(17)26-23/h4-7,14H,8-13,15H2,1-3H3,(H,25,26)(H,27,30)
DMQVN6P CS CC1=CC(=C(C(=N1)SC)NC(=O)CN2CCN(CC2)CCSC3=NC4=CC=CC=C4N3)SC
DMQVN6P IK VGGMTOYKEDKFLN-UHFFFAOYSA-N
DMQVN6P IU 2-[4-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide
DMQVN6P CA CAS 561023-90-3
DMQVN6P DE Arteriosclerosis
DMJLNZQ ID DMJLNZQ
DMJLNZQ DN K-828-AB
DMJLNZQ HS Phase 2
DMJLNZQ SN GABA transaminase inhibitor (oral, dementia), Kowa
DMJLNZQ CP Kowa Co Ltd
DMJLNZQ DE Dementia
DMMSTCF ID DMMSTCF
DMMSTCF DN K-832
DMMSTCF HS Phase 2
DMMSTCF SN 10465-81-3; 1,1'-(Azodicarbonyl)-dipiperidine; AdDP; 1,1-(Azodicarbonyl)dipiperidine; 1,1'-(Azodicarbonyl)dipiperidine; diazene-1,2-diylbis(piperidin-1-ylmethanone); NSC356027; NSC 356027; (NE)-N-(piperidine-1-carbonylimino)piperidine-1-carboxamide; azodicarboxylic acid dipiperidine; (E)-diazene-1,2-diylbis(piperidin-1-ylmethanone); Azodicarboxylic acid dipiperidide; J-503690; SR-4077; (E)-diazene-1,2-diylbis(piperidin-1-yl methanone); SR 4077; PubChem19605; piperidyl (piperidylcarbonyl)diazenyl ketone; AC1Q5JWC; AC1NWBQ9
DMMSTCF CP Kowa
DMMSTCF DT Small molecular drug
DMMSTCF PC 9844960
DMMSTCF MW 418.9
DMMSTCF FM C24H19ClN2OS
DMMSTCF IC InChI=1S/C24H19ClN2OS/c1-29-21-13-9-19(10-14-21)24-22(18-7-11-20(25)12-8-18)15-23(28)27(26-24)16-17-5-3-2-4-6-17/h2-15H,16H2,1H3
DMMSTCF CS CSC1=CC=C(C=C1)C2=NN(C(=O)C=C2C3=CC=C(C=C3)Cl)CC4=CC=CC=C4
DMMSTCF IK HEUAVAATAFEENP-UHFFFAOYSA-N
DMMSTCF IU 2-benzyl-5-(4-chlorophenyl)-6-(4-methylsulfanylphenyl)pyridazin-3-one
DMMSTCF DE Rheumatoid arthritis
DMTMCPZ ID DMTMCPZ
DMTMCPZ DN KB001A
DMTMCPZ HS Phase 2
DMTMCPZ CP Sanofi
DMTMCPZ DT Antibody
DMTMCPZ DE Infectious disease; Cystic fibrosis
DM60G5O ID DM60G5O
DM60G5O DN KB002/003
DM60G5O HS Phase 2
DM60G5O CP KaloBios Pharmaceuticals
DM60G5O DE Rheumatoid arthritis
DM74KIM ID DM74KIM
DM74KIM DN KB-003
DM74KIM HS Phase 2
DM74KIM SN KB-002; Anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios; Anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios
DM74KIM CP Kalobios pharmaceuticals
DM74KIM DT Antibody
DM74KIM DE Severe asthma
DMZ4MCG ID DMZ4MCG
DMZ4MCG DN KB-6806
DMZ4MCG HS Phase 2
DMZ4MCG SN Prucalopride succinate; 179474-85-2; Prucalopride Succinat; Prucalopride (succinate); UNII-4V2G75E1CK; R-108512; BUTANEDIOIC ACID 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-[1-(3-METHOXYPROPYL)-4-PIPERIDINYL]-7-BENZOFURANCARBOXAMIDE; Prucalopride succinate [USAN]; 4V2G75E1CK; R 108512; AK175654; Prucalopride succinate (USAN); resotran; Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1); Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1-
DMZ4MCG CP Kanebo
DMZ4MCG DT Small molecular drug
DMZ4MCG PC 3073291
DMZ4MCG MW 307.82
DMZ4MCG FM C15H22ClN5
DMZ4MCG IC InChI=1S/C15H22ClN5/c1-10(2)21-14-9-12(17)11(16)8-13(14)18-15(21)20-6-4-19(3)5-7-20/h8-10H,4-7,17H2,1-3H3
DMZ4MCG CS CC(C)N1C2=C(C=C(C(=C2)N)Cl)N=C1N3CCN(CC3)C
DMZ4MCG IK QEANRFDFBNUCJR-UHFFFAOYSA-N
DMZ4MCG IU 6-chloro-2-(4-methylpiperazin-1-yl)-3-propan-2-ylbenzimidazol-5-amine
DMZ4MCG CA CAS 148014-93-1
DMZ4MCG DE Chemotherapy-induced nausea
DMEFW3G ID DMEFW3G
DMEFW3G DN KD019
DMEFW3G HS Phase 2
DMEFW3G SN Tesevatinib; XL647; XL-647; 781613-23-8; EXEL-7647; UNII-F6XM2TN5A1; KD-019; XL 647; F6XM2TN5A1; 651031-01-5; 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine; Tesevatinib [USAN:INN]; EXEL 7647; 874286-84-7; KD 019; 1000599-06-3; SCHEMBL721994; SCHEMBL721993; SCHEMBL721992; C24H25Cl2FN4O2; GTPL7944; CHEMBL3544983; EX-A172; QCR-153; MolPort-044-724-458; BCP23438; ZINC38912363; 2809AH; AKOS027255007
DMEFW3G CP Kadmon Pharmaceuticals
DMEFW3G DT Small molecular drug
DMEFW3G PC 10458325
DMEFW3G MW 491.4
DMEFW3G FM C24H25Cl2FN4O2
DMEFW3G IC InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13?,14-,15+
DMEFW3G CS CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC
DMEFW3G IK HVXKQKFEHMGHSL-GOOCMWNKSA-N
DMEFW3G IU 7-[[(3aS,6aR)-2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-yl]methoxy]-N-(3,4-dichloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine
DMEFW3G CA CAS 781613-23-8
DMEFW3G DE Non-small-cell lung cancer; Polycystic kidney disease; Brain metastases; Meningioma metastases; Recurrent glioblastoma
DM548TK ID DM548TK
DM548TK DN KD025
DM548TK HS Phase 2
DM548TK CP Kadmon
DM548TK PC 11950170
DM548TK MW 452.5
DM548TK FM C26H24N6O2
DM548TK IC InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)
DM548TK CS CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5
DM548TK IK GKHIVNAUVKXIIY-UHFFFAOYSA-N
DM548TK IU 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide
DM548TK CA CAS 911417-87-3
DM548TK DE Rheumatoid arthritis; Psoriasis vulgaris; Psoriatic arthritis; Scleroderma; Systemic lupus erythematosus
DME1WV2 ID DME1WV2
DME1WV2 DN KD-7040
DME1WV2 HS Phase 2
DME1WV2 CP Kalypsys Inc
DME1WV2 DE Pain
DMFO6MH ID DMFO6MH
DMFO6MH DN Kevetrin
DMFO6MH HS Phase 2
DMFO6MH CP Cellceutix Corp
DMFO6MH DT Small molecular drug
DMFO6MH PC 437740
DMFO6MH MW 143.21
DMFO6MH FM C5H9N3S
DMFO6MH IC InChI=1S/C5H9N3S/c6-3-1-2-4-9-5(7)8/h1-2,4H2,(H3,7,8)
DMFO6MH CS C(CC#N)CSC(=N)N
DMFO6MH IK PRDJGNVQBVXXEO-UHFFFAOYSA-N
DMFO6MH IU 3-cyanopropyl carbamimidothioate
DMFO6MH CA CAS 500863-50-3
DMFO6MH DE Solid tumour/cancer; Ovarian cancer
DMF6CTI ID DMF6CTI
DMF6CTI DN KHK-6188
DMF6CTI HS Phase 2
DMF6CTI CP Kyowa Hakko Kirin Co Ltd
DMF6CTI DE Neuropathic pain
DM40HOY ID DM40HOY
DM40HOY DN KLH-2109
DM40HOY HS Phase 2
DM40HOY CP Kissei Pharmaceutical Co Ltd
DM40HOY PC 16656889
DM40HOY MW 508.4
DM40HOY FM C22H15F3N2O7S
DM40HOY IC InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
DM40HOY CS COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC
DM40HOY IK BMAAMIIYNNPHAB-UHFFFAOYSA-N
DM40HOY IU 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1H-thieno[3,4-d]pyrimidine-5-carboxylic acid
DM40HOY CA CAS 935283-04-8
DM40HOY DE Endometriosis
DM05TBE ID DM05TBE
DM05TBE DN KLS-0611
DM05TBE HS Phase 2
DM05TBE SN Mucin stimulator (dry eye), Kissei
DM05TBE CP Kissei Pharmaceutical Co Ltd
DM05TBE DE Xerophthalmia
DMNLH9W ID DMNLH9W
DMNLH9W DN KN026
DMNLH9W HS Phase 2
DMNLH9W CP Alphamab Oncology
DMNLH9W DT Antibody
DMNLH9W DE Breast cancer
DMKLMG6 ID DMKLMG6
DMKLMG6 DN KN035
DMKLMG6 HS Phase 2
DMKLMG6 SN Envafolimab
DMKLMG6 CP TRACON Pharmaceuticals
DMKLMG6 DT Antibody
DMKLMG6 DE Advanced malignancy; Solid tumour/cancer; Pleomorphic sarcoma
DMQZ5HF ID DMQZ5HF
DMQZ5HF DN KNI-272
DMQZ5HF HS Phase 2
DMQZ5HF SN NSC651714; NSC-651714; AC1Q5L2H; (4r)-n-tert-butyl-3-[2-hydroxy-3-({n-[(isoquinolin-5-yloxy)acetyl]-s-methyl-l-cysteinyl}amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide; AC1L88B1; KNI 272; 3-(3,4-Dimethoxyphenyl)propionamide; NCI60_018063; 4-Thiazolidinecarboxamide,1-dimethylethyl)-3- [2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3- (methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-,[4R-[3[2S*,3S*(R*)],4R*]]
DMQZ5HF DT Small molecular drug
DMQZ5HF PC 60927
DMQZ5HF MW 667.8
DMQZ5HF FM C33H41N5O6S2
DMQZ5HF IC InChI=1S/C33H41N5O6S2/c1-33(2,3)37-31(42)26-19-46-20-38(26)32(43)29(40)24(15-21-9-6-5-7-10-21)36-30(41)25(18-45-4)35-28(39)17-44-27-12-8-11-22-16-34-14-13-23(22)27/h5-14,16,24-26,29,40H,15,17-20H2,1-4H3,(H,35,39)(H,36,41)(H,37,42)/t24-,25-,26-,29-/m0/s1
DMQZ5HF CS CC(C)(C)NC(=O)[C@@H]1CSCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O
DMQZ5HF IK NJBBLOIWMSYVCQ-VZTVMPNDSA-N
DMQZ5HF IU (4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide
DMQZ5HF CA CAS 147318-81-8
DMQZ5HF CB CHEBI:80006
DMQZ5HF DE Human immunodeficiency virus infection
DMCO8UZ ID DMCO8UZ
DMCO8UZ DN KP-496
DMCO8UZ HS Phase 2
DMCO8UZ DE Asthma
DM4WHOS ID DM4WHOS
DM4WHOS DN KPP203
DM4WHOS HS Phase 2
DM4WHOS CP Novartis PharmaceuticalsEast Hanover, NJ
DM4WHOS DE Subacute cutaneous lupus erythematosus
DMQDLVW ID DMQDLVW
DMQDLVW DN KRP-104
DMQDLVW HS Phase 2
DMQDLVW SN Antigen inhibitor
DMQDLVW CP ActivX Biosciences
DMQDLVW DE Type-2 diabetes
DMOW9X2 ID DMOW9X2
DMOW9X2 DN KRP-203
DMOW9X2 HS Phase 2
DMOW9X2 SN KNF-299; KRP-203-P prodrug, Kyorin
DMOW9X2 CP Kyorin Pharmaceutical Co Ltd
DMOW9X2 DT Small molecular drug
DMOW9X2 PC 11155873
DMOW9X2 MW 480.4
DMOW9X2 FM C24H27Cl2NO3S
DMOW9X2 IC InChI=1S/C24H26ClNO3S.ClH/c25-23-14-22(10-9-19(23)11-12-24(26,16-27)17-28)30-21-8-4-7-20(13-21)29-15-18-5-2-1-3-6-18;/h1-10,13-14,27-28H,11-12,15-17,26H2;1H
DMOW9X2 CS C1=CC=C(C=C1)COC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(CO)N)Cl.Cl
DMOW9X2 IK MYIFLDFUXIHOCJ-UHFFFAOYSA-N
DMOW9X2 IU 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride
DMOW9X2 CA CAS 509088-69-1
DMOW9X2 DE Cutaneous lupus erythematosus
DM08F12 ID DM08F12
DM08F12 DN KT6-971
DM08F12 HS Phase 2
DM08F12 SN Cholesterol absorption inhibitor, Kotobuki
DM08F12 CP Kotobuki Pharmaceutical Co Ltd
DM08F12 DE Hypercholesterolaemia
DMZL48U ID DMZL48U
DMZL48U DN KUR-111
DMZL48U HS Phase 2
DMZL48U SN I-0401; I-040302; TGplPTH1-34; Fibrin-PTH (bone cysts), Kuros; Human parathyroid hormone (PTH) + TISSEEL fibrin sealant + hydroxyapatite/tri-calcium phosphate granules (bone fracture), Kuros/Baxter
DMZL48U CP Kuros Biosurgery AG
DMZL48U DE Bone disease
DM2N0Z3 ID DM2N0Z3
DM2N0Z3 DN KUR-211
DM2N0Z3 HS Phase 2
DM2N0Z3 CP Baxter international; kuros biosurgery
DM2N0Z3 DE Ulcer
DMB4HCY ID DMB4HCY
DMB4HCY DN KUR-212
DMB4HCY HS Phase 2
DMB4HCY SN I-020502; Fibrin-PDGF (wound healing), Baxter/Kuros; Fibrin-recombinant human platelet-derived growth factor (wound healing), Baxter/Kuros
DMB4HCY CP Baxter International Inc
DMB4HCY DE Wound healing
DMK4VOU ID DMK4VOU
DMK4VOU DN KVD001
DMK4VOU HS Phase 2
DMK4VOU CP KalVista Pharmaceuticals Cambridge, MA
DMK4VOU DE Diabetic macular edema
DM5N4OA ID DM5N4OA
DM5N4OA DN KVD824
DM5N4OA HS Phase 2
DM5N4OA CP KalVista Pharmaceuticals
DM5N4OA DE Diabetic macular edema
DMJGL72 ID DMJGL72
DMJGL72 DN KW-2478
DMJGL72 HS Phase 2
DMJGL72 SN KW-2478; 819812-04-9; KW-2478 free base; 2-(2-ethyl-3,5-dihydroxy-6-(3-methoxy-4-(2-morpholinoethoxy)benzoyl)phenyl)-N,N-bis(2-methoxyethyl)acetamide; UNII-QY50S617NM; KW 2478; KW2478; QY50S617NM; 2-ethyl-3,5-dihydroxy-n,n-bis(2-methoxyethyl)-6-(3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl)benzeneacetamide; 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
DMJGL72 CP Kyowa Hakko Kirin
DMJGL72 DT Small molecular drug
DMJGL72 PC 23116322
DMJGL72 MW 574.7
DMJGL72 FM C30H42N2O9
DMJGL72 IC InChI=1S/C30H42N2O9/c1-5-22-23(19-28(35)32(11-13-37-2)12-14-38-3)29(25(34)20-24(22)33)30(36)21-6-7-26(27(18-21)39-4)41-17-10-31-8-15-40-16-9-31/h6-7,18,20,33-34H,5,8-17,19H2,1-4H3
DMJGL72 CS CCC1=C(C(=C(C=C1O)O)C(=O)C2=CC(=C(C=C2)OCCN3CCOCC3)OC)CC(=O)N(CCOC)CCOC
DMJGL72 IK VFUXSYAXEKYYMB-UHFFFAOYSA-N
DMJGL72 IU 2-[2-ethyl-3,5-dihydroxy-6-[3-methoxy-4-(2-morpholin-4-ylethoxy)benzoyl]phenyl]-N,N-bis(2-methoxyethyl)acetamide
DMJGL72 CA CAS 819812-04-9
DMJGL72 DE Solid tumour/cancer
DM15RZO ID DM15RZO
DM15RZO DN KYMRIAH
DM15RZO HS Phase 2
DM15RZO CP Masonic Cancer Center, University of Minnesota
DM15RZO DT CAR T Cell Therapy
DM15RZO DE Acute lymphoblastic leukaemia
DMLHPVW ID DMLHPVW
DMLHPVW DN L1-79
DMLHPVW HS Phase 2
DMLHPVW SN alpha-methylparatyrosine
DMLHPVW CP Yamo Pharmaceuticals
DMLHPVW DE Autism spectrum disorder
DMI2XP1 ID DMI2XP1
DMI2XP1 DN L19-IL-2 fusion protein
DMI2XP1 HS Phase 2
DMI2XP1 SN Darleukin; Immunocytokine fusion protein, Bayer Schering; Immunocytokine fusion protein, Philogen; L19-IL-2 fusion protein, Bayer Schering; L19-IL-2 fusion protein, Philogen
DMI2XP1 CP Philogen SpA
DMI2XP1 DT Antibody
DMI2XP1 DE Lymphoma
DMW6NMP ID DMW6NMP
DMW6NMP DN L19-TNF-alpha
DMW6NMP HS Phase 2
DMW6NMP SN Fibromun
DMW6NMP CP Philogen SpA
DMW6NMP DT Antibody
DMW6NMP DE Colorectal cancer
DMA0DSJ ID DMA0DSJ
DMA0DSJ DN L-694,458
DMA0DSJ HS Phase 2
DMA0DSJ SN DMP 777; 157341-41-8; DMP-777; UNII-3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide; DMP777; CHEMBL310871; L-694458; 3Q0469283P; (S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4methyl-piperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide (3.5% w/w solution); L-694,458; L 694458; SCHEMBL6538142; AC1L433D; CTK4C9348; DTXSID00166251; MolPort-023-332-820; C31H40N4O6; ZINC3936307; KS-00001E6Q; BCP02269
DMA0DSJ DT Small molecular drug
DMA0DSJ PC 177992
DMA0DSJ MW 564.7
DMA0DSJ FM C31H40N4O6
DMA0DSJ IC InChI=1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1
DMA0DSJ CS CCC[C@H](C1=CC2=C(C=C1)OCO2)NC(=O)N3[C@H](C(C3=O)(CC)CC)OC4=CC=C(C=C4)C(=O)N5CCN(CC5)C
DMA0DSJ IK ZSDCIRYNTCVTMF-GIGWZHCTSA-N
DMA0DSJ IU (2S)-N-[(1R)-1-(1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2-[4-(4-methylpiperazine-1-carbonyl)phenoxy]-4-oxoazetidine-1-carboxamide
DMA0DSJ CA CAS 157341-41-8
DMA0DSJ DE Cystic fibrosis
DMB7WT1 ID DMB7WT1
DMB7WT1 DN L-697,661
DMB7WT1 HS Phase 2
DMB7WT1 SN L-697661; L-697,661; 135525-78-9; L 697661; 3-(((4,7-Dichloro-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one; CHEMBL268871; UNII-4660N666EZ; 4660N666EZ; 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone, 3-(((4,7-dichloro-2-benzoxazolyl)methyl)amino)-5-ethyl-6-methyl-; ACMC-20mvsm; SCHEMBL599639; BDBM1317; AC1Q69B2; AC1L22E2; CTK0H5173; DTXSID10159457; AKOS030539285; LS-186956; LS-187602; L697,661; L 697,661
DMB7WT1 DT Small molecular drug
DMB7WT1 PC 65002
DMB7WT1 MW 352.2
DMB7WT1 FM C16H15Cl2N3O2
DMB7WT1 IC InChI=1S/C16H15Cl2N3O2/c1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-6,19H,3,7H2,1-2H3,(H,20,22)
DMB7WT1 CS CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)Cl)Cl)C
DMB7WT1 IK WHFRDXVXYMGAJD-UHFFFAOYSA-N
DMB7WT1 IU 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one
DMB7WT1 CA CAS 135525-78-9
DMB7WT1 DE Human immunodeficiency virus infection
DMTGR25 ID DMTGR25
DMTGR25 DN L-745,870
DMTGR25 HS Phase 2
DMTGR25 SN 158985-00-3; L-745870; UNII-J3OLN3XSX7; J3OLN3XSX7; L-745,870; CHEMBL267014; L 745,870; 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine; 3-(4-[4-Chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine trihydrochloride; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine; 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine; CPMPP-3; Tocris-1002; Lopac-L-131; Biomol-NT_000049; AC1NSK75; L745870; Lopac0_000791; GTPL3303; BPBio1_001299; SCHEMBL1059886; CHEBI:92099
DMTGR25 DT Small molecular drug
DMTGR25 PC 5311200
DMTGR25 MW 326.8
DMTGR25 FM C18H19ClN4
DMTGR25 IC InChI=1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)
DMTGR25 CS C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl
DMTGR25 IK OGJGQVFWEPNYSB-UHFFFAOYSA-N
DMTGR25 IU 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DMTGR25 CA CAS 158985-00-3
DMTGR25 CB CHEBI:92099
DMTGR25 DE Psychotic disorder
DMNO5UE ID DMNO5UE
DMNO5UE DN Labetuzumab I-131
DMNO5UE HS Phase 2
DMNO5UE SN IMMU-111
DMNO5UE CP Immunomedics
DMNO5UE DT Antibody
DMNO5UE DE Colorectal cancer
DM7063I ID DM7063I
DM7063I DN LADIRUBICIN
DM7063I HS Phase 2
DM7063I SN FCE-28729; PNU-159548; Ladirubicin; 3'-(1-Aziridinyl)-3'-deamino-4-demethoxy-4'-O-(methanesulfonyl)daunomycin
DM7063I DT Small molecular drug
DM7063I PC 216232
DM7063I MW 601.6
DM7063I FM C29H31NO11S
DM7063I IC InChI=1S/C29H31NO11S/c1-13-28(41-42(3,37)38)18(30-8-9-30)10-20(39-13)40-19-12-29(36,14(2)31)11-17-21(19)27(35)23-22(26(17)34)24(32)15-6-4-5-7-16(15)25(23)33/h4-7,13,18-20,28,34-36H,8-12H2,1-3H3/t13-,18-,19-,20-,28+,29-/m0/s1
DM7063I CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C
DM7063I IK VMDWTZZCNDEKIO-CBNJBKGYSA-N
DM7063I IU [(2S,3S,4S,6R)-6-[[(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-4-(aziridin-1-yl)-2-methyloxan-3-yl] methanesulfonate
DM7063I CA CAS 171047-47-5
DM7063I DE Breast cancer
DMJSY3Q ID DMJSY3Q
DMJSY3Q DN Ladostigil
DMJSY3Q HS Phase 2
DMJSY3Q SN Ladostigil tartrate; Alzheimer disease therapeutics, Teva; TV-3219; TV-3279; TV-3326
DMJSY3Q CP Hebrew University of Jerusalem
DMJSY3Q DT Small molecular drug
DMJSY3Q PC 208907
DMJSY3Q MW 272.34
DMJSY3Q FM C16H20N2O2
DMJSY3Q IC InChI=1S/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3/t15-/m1/s1
DMJSY3Q CS CCN(C)C(=O)OC1=CC2=C(CC[C@H]2NCC#C)C=C1
DMJSY3Q IK LHXOCOHMBFOVJS-OAHLLOKOSA-N
DMJSY3Q IU [(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate
DMJSY3Q CA CAS 209394-27-4
DMJSY3Q DE Alzheimer disease
DMSIGAB ID DMSIGAB
DMSIGAB DN L-alanosine
DMSIGAB HS Phase 2
DMSIGAB SN SDX-102
DMSIGAB CP Salmedix
DMSIGAB DT Small molecular drug
DMSIGAB PC 135409347
DMSIGAB MW 149.11
DMSIGAB FM C3H7N3O4
DMSIGAB IC InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,9H,1,4H2,(H,7,8)/b6-5-/t2-/m0/s1
DMSIGAB CS C([C@@H](C(=O)O)N)/[N+](=N/O)/[O-]
DMSIGAB IK ZGNLFUXWZJGETL-YUSKDDKASA-N
DMSIGAB IU (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium
DMSIGAB CA CAS 5854-93-3
DMSIGAB DE Brain cancer
DMR0N74 ID DMR0N74
DMR0N74 DN LAM-002
DMR0N74 HS Phase 2
DMR0N74 CP LAM Therapeutics Guilford, CT
DMR0N74 DE B-cell non-hodgkin lymphoma; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia
DM7MBV6 ID DM7MBV6
DM7MBV6 DN Lancovutide
DM7MBV6 HS Phase 2
DM7MBV6 SN Duramycin; Lancovutide; Cystic fibrosis treatment, Molichem; Moli-1901; Moli-901; Duramycin(ophthalmic, dry eye), Lantibio; Lancovutide (ophthalmic, dry eye), Lantibio; Duramycin (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Duramycin (inhaled, cystic fibrosis), Molichem/AOP Orphan; Lancovutide (inhaled, cystic fibrosis), Lantibio/AOP Orphan; Moli-1901 (ophthalmic, dry eye), Lantibio
DM7MBV6 CP Lantibio Inc
DM7MBV6 PC 86289378
DM7MBV6 MW 2013.3
DM7MBV6 FM C89H125N23O25S3
DM7MBV6 IC InChI=1S/C89H125N23O25S3/c1-44(2)67-85(131)107-60-42-138-41-59-80(126)106-61-43-140-46(4)69(87(133)103-56(76(122)108-67)35-49-23-12-7-13-24-49)109-77(123)55(34-48-21-10-6-11-22-48)102-83(129)62-27-18-32-112(62)66(116)39-96-73(119)54(33-47-19-8-5-9-20-47)101-79(125)58(104-81(61)127)37-94-31-17-15-26-53(88(134)135)100-86(132)68(110-78(124)57(36-64(93)114)97-65(115)38-95-84(130)70(111-82(60)128)71(117)89(136)137)45(3)139-40-50(91)72(118)98-51(25-14-16-30-90)74(120)99-52(75(121)105-59)28-29-63(92)113/h5-13,19-24,44-46,50-62,67-71,94,117H,14-18,25-43,90-91H2,1-4H3,(H2,92,113)(H2,93,114)(H,95,130)(H,96,119)(H,97,115)(H,98,118)(H,99,120)(H,100,132)(H,101,125)(H,102,129)(H,103,133)(H,104,127)(H,105,121)(H,106,126)(H,107,131)(H,108,122)(H,109,123)(H,110,124)(H,111,128)(H,134,135)(H,136,137)/t45?,46-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60-,61-,62-,67-,68+,69+,70-,71+/m0/s1
DM7MBV6 CS C[C@H]1[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]3CSC[C@@H]4C(=O)N[C@@H](CS1)C(=O)N[C@@H](CNCCCC[C@H](NC(=O)[C@@H](C(SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)N)CCCCN)N)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC3=O)[C@H](C(=O)O)O)CC(=O)N)C(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N2)CC6=CC=CC=C6)CC7=CC=CC=C7)C(C)C)CC8=CC=CC=C8
DM7MBV6 IK SFWLDKQAUHFCBS-WWXQEMPQSA-N
DM7MBV6 IU (1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-37-(2-amino-2-oxoethyl)-50-(3-amino-3-oxopropyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-41,70-dimethyl-2,5,8,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-octadecaoxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptacontane-65-carboxylic acid
DM7MBV6 DE Chronic obstructive pulmonary disease
DM1VK96 ID DM1VK96
DM1VK96 DN LANEPITANT
DM1VK96 HS Phase 2
DM1VK96 SN LY-303870; LY-302654 (racemate); Lanepitant; N-[1(R)-(1H-Indol-3-ylmethyl)-2-[N-(2-methoxybenzyl)acetamido]ethyl]-2-[4-(1-piperidinyl)piperidin-1-yl]acetamide
DM1VK96 DT Small molecular drug
DM1VK96 PC 3086681
DM1VK96 MW 559.7
DM1VK96 FM C33H45N5O3
DM1VK96 IC InChI=1S/C33H45N5O3/c1-25(39)38(22-26-10-4-7-13-32(26)41-2)23-28(20-27-21-34-31-12-6-5-11-30(27)31)35-33(40)24-36-18-14-29(15-19-36)37-16-8-3-9-17-37/h4-7,10-13,21,28-29,34H,3,8-9,14-20,22-24H2,1-2H3,(H,35,40)/t28-/m1/s1
DM1VK96 CS CC(=O)N(CC1=CC=CC=C1OC)C[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)CN4CCC(CC4)N5CCCCC5
DM1VK96 IK CVXJAPZTZWLRBP-MUUNZHRXSA-N
DM1VK96 IU N-[(2R)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1H-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide
DM1VK96 CA CAS 170566-84-4
DM1VK96 DE Pain
DMPRZX4 ID DMPRZX4
DMPRZX4 DN LAS 100977
DMPRZX4 HS Phase 2
DMPRZX4 SN LABA
DMPRZX4 CP Almirall; Forest Laboratories
DMPRZX4 DT Small molecular drug
DMPRZX4 PC 11962616
DMPRZX4 MW 460.5
DMPRZX4 FM C25H30F2N2O4
DMPRZX4 IC InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
DMPRZX4 CS C1=CC=C(C=C1)C(COCCCCCCNC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O)(F)F
DMPRZX4 IK SFYAXIFVXBKRPK-QFIPXVFZSA-N
DMPRZX4 IU 5-[(1R)-2-[6-(2,2-difluoro-2-phenylethoxy)hexylamino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
DMPRZX4 CA CAS 915133-65-2
DMPRZX4 CB CHEBI:142077
DMPRZX4 DE Chronic obstructive pulmonary disease
DM3WY0B ID DM3WY0B
DM3WY0B DN LAS-41002
DM3WY0B HS Phase 2
DM3WY0B SN Monovo; Corticosteroid receptor modulator (eczema, psoriasis), Almirall
DM3WY0B CP Almirall Prodesfarma SA
DM3WY0B DE Eczema
DMC04SR ID DMC04SR
DMC04SR DN LB-100
DMC04SR HS Phase 2
DMC04SR DT Small molecular drug
DMC04SR PC 3578572
DMC04SR MW 268.31
DMC04SR FM C13H20N2O4
DMC04SR IC InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)
DMC04SR CS CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3
DMC04SR IK JUQMLSGOTNKJKI-UHFFFAOYSA-N
DMC04SR IU 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
DMC04SR DE Solid tumour/cancer; Astrocytoma
DM0OHX3 ID DM0OHX3
DM0OHX3 DN LB-30870
DM0OHX3 HS Phase 2
DM0OHX3 SN N-(Carboxymethyl)-D-diphenylalanyl-L-proline 5-amidinothien-2-ylmethyl amide bis(trifluoroacetate)
DM0OHX3 PC 9871765
DM0OHX3 MW 533.6
DM0OHX3 FM C28H31N5O4S
DM0OHX3 IC InChI=1S/C28H31N5O4S/c29-26(30)22-14-13-20(38-22)16-32-27(36)21-12-7-15-33(21)28(37)25(31-17-23(34)35)24(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-6,8-11,13-14,21,24-25,31H,7,12,15-17H2,(H3,29,30)(H,32,36)(H,34,35)/t21-,25+/m0/s1
DM0OHX3 CS C1C[C@H](N(C1)C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NCC(=O)O)C(=O)NCC4=CC=C(S4)C(=N)N
DM0OHX3 IK BIHPYGVYKSQDLA-SQJMNOBHSA-N
DM0OHX3 IU 2-[[(2R)-1-[(2S)-2-[(5-carbamimidoylthiophen-2-yl)methylcarbamoyl]pyrrolidin-1-yl]-1-oxo-3,3-diphenylpropan-2-yl]amino]acetic acid
DM0OHX3 CA CAS 280780-95-2
DM0OHX3 DE Myocardial infarction
DMQZJNA ID DMQZJNA
DMQZJNA DN LCAR-B38M CAR-T Cell
DMQZJNA HS Phase 2
DMQZJNA CP Nanjing Legend Biotech Co.
DMQZJNA DT CAR T Cell Therapy
DMQZJNA DE Multiple myeloma
DMY4IWC ID DMY4IWC
DMY4IWC DN LCB-2183
DMY4IWC HS Phase 2
DMY4IWC PC 135418284
DMY4IWC MW 206.2
DMY4IWC FM C9H10N4O2
DMY4IWC IC InChI=1S/C9H10N4O2/c1-2-15-5-6-12-8-7(9(14)13-6)10-3-4-11-8/h3-4H,2,5H2,1H3,(H,11,12,13,14)
DMY4IWC CS CCOCC1=NC2=NC=CN=C2C(=O)N1
DMY4IWC IK SFWVULIFVPNTOF-UHFFFAOYSA-N
DMY4IWC IU 2-(ethoxymethyl)-3H-pteridin-4-one
DMY4IWC CA CAS 133914-85-9
DMY4IWC DE Asthma
DMTM4QA ID DMTM4QA
DMTM4QA DN LCL161
DMTM4QA HS Phase 2
DMTM4QA CP Novartis
DMTM4QA PC 24737642
DMTM4QA MW 500.6
DMTM4QA FM C26H33FN4O3S
DMTM4QA IC InChI=1S/C26H33FN4O3S/c1-16(28-2)24(33)30-22(17-7-4-3-5-8-17)26(34)31-14-6-9-21(31)25-29-20(15-35-25)23(32)18-10-12-19(27)13-11-18/h10-13,15-17,21-22,28H,3-9,14H2,1-2H3,(H,30,33)/t16-,21-,22-/m0/s1
DMTM4QA CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC
DMTM4QA IK UFPFGVNKHCLJJO-SSKFGXFMSA-N
DMTM4QA IU (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide
DMTM4QA CA CAS 1005342-46-0
DMTM4QA DE Solid tumour/cancer; Breast cancer; Multiple myeloma; Myelofibrosis
DMM9F25 ID DMM9F25
DMM9F25 DN LDE225
DMM9F25 HS Phase 2
DMM9F25 SN Erismodegib
DMM9F25 CP Novartis Pharmaceuticals
DMM9F25 DT Small molecular drug
DMM9F25 PC 24775005
DMM9F25 MW 485.5
DMM9F25 FM C26H26F3N3O3
DMM9F25 IC InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
DMM9F25 CS C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F
DMM9F25 IK VZZJRYRQSPEMTK-CALCHBBNSA-N
DMM9F25 IU N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide
DMM9F25 CA CAS 956697-53-3
DMM9F25 CB CHEBI:90863
DMM9F25 DE Skin cancer; Medulloblastoma
DMIEZUB ID DMIEZUB
DMIEZUB DN L-DOS47
DMIEZUB HS Phase 2
DMIEZUB CP Helix BioPharma
DMIEZUB DE Lung cancer; Non-small-cell lung cancer; Non-small cell lung cancer
DMS6E9J ID DMS6E9J
DMS6E9J DN Lefitolimod
DMS6E9J HS Phase 2
DMS6E9J SN MGN1703
DMS6E9J CP Mologen
DMS6E9J DE Human immunodeficiency virus-1 infection
DMV2YDK ID DMV2YDK
DMV2YDK DN LEISH-F1
DMV2YDK HS Phase 2
DMV2YDK SN LeIF adjuvant, Corixa; Leish-111f; Leishmanial eukaryotic initiation factor, Corixa; Leishmaniasis vaccine (LeIF), Corixa; Leishmaniasis vaccine, Corixa/ Infectious Disease Research Institute; Vaccine (leishmania), Corixa; LeIF enhanced T-cell vaccine, Corixa, Infectious Disease Research Institute
DMV2YDK CP Infectious Disease Research Institute
DMV2YDK DT Vaccine
DMV2YDK DE Leishmania infection
DMZKBMG ID DMZKBMG
DMZKBMG DN Lenapenem hydrochloride hydrate
DMZKBMG HS Phase 2
DMZKBMG SN BO-2727; L-739428
DMZKBMG CP MSD Japan
DMZKBMG DT Small molecular drug
DMZKBMG PC 443100
DMZKBMG MW 454
DMZKBMG FM C18H32ClN3O6S
DMZKBMG IC InChI=1S/C18H29N3O5S.ClH.H2O/c1-8-14-13(9(2)22)17(24)21(14)15(18(25)26)16(8)27-10-6-11(20-7-10)12(23)4-5-19-3;;/h8-14,19-20,22-23H,4-7H2,1-3H3,(H,25,26);1H;1H2/t8-,9-,10+,11+,12-,13-,14-;;/m1../s1
DMZKBMG CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H](CCNC)O)C(=O)O)[C@@H](C)O.O.Cl
DMZKBMG IK FNSICOGCVDQJPU-HCRFUVGVSA-N
DMZKBMG IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrate;hydrochloride
DMZKBMG CA CAS 149882-71-3
DMZKBMG DE Bacterial infection
DMWAD93 ID DMWAD93
DMWAD93 DN Leniolisib
DMWAD93 HS Phase 2
DMWAD93 SN 1354690-24-6; Leniolisib free base; UNII-L22772Z9CP; (S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-one; L22772Z9CP; 1354690-24-6 (free base); leniolisib(CDZ 173); CDZ173; CDZ-173; 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one; Leniolisib [INN]; Leniolisib (CDZ173); Leniolisib; CDZ173; Leniolisib (USAN/INN); CDZ173-NX; SCHEMBL323054; GTPL9424; CHEMBL3643413; BDBM118299; EX-A2854; MFCD30470232; s8752; ZB1510; CS-7524; DC22326; SB18839; Example 67 [WO2012004299]; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-y; 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one; AS-56217; HY-17635; A16796; D11158; US8653092, 67; Q27282602; 1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-; 9NQ
DMWAD93 CP Novartis
DMWAD93 DT Small molecular drug
DMWAD93 PC 57495353
DMWAD93 MW 450.5
DMWAD93 FM C21H25F3N6O2
DMWAD93 IC InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1
DMWAD93 CS CCC(=O)N1CC[C@@H](C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F
DMWAD93 IK MWKYMZXCGYXLPL-ZDUSSCGKSA-N
DMWAD93 IU 1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one
DMWAD93 CA CAS 1354690-24-6
DMWAD93 DE Sjogren syndrome
DMR1MQW ID DMR1MQW
DMR1MQW DN Lenzilumab
DMR1MQW HS Phase 2
DMR1MQW CP Humanigen Brisbane, CA
DMR1MQW DE Chronic myelogenous leukaemia; Coronavirus Disease 2019 (COVID-19)
DM7W0JE ID DM7W0JE
DM7W0JE DN LEO 124249
DM7W0JE HS Phase 2
DM7W0JE SN delgocitinib; Delgocitinib; UNII-9L0Q8KK220; JTE-052; 9L0Q8KK220; 1263774-59-9; Delgocitinib [USAN]; Delgocitinib (JAN/USAN); JTE052; JTE-052A; GTPL9619; SCHEMBL12547007; LEO 124249A; HY-109053; CS-0031558; D11046; 1,6-Diazaspiro(3.4)octane-1-propanenitrile, 3-methyl-beta-oxo-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-, (3S,4R)-; 3-((3S,4R)-3-methyl-6-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1,6-diazaspiro(3.4)octan-1-yl)-3-oxopropanenitrile
DM7W0JE CP LEO Pharma Madison, NJ
DM7W0JE PC 50914062
DM7W0JE MW 310.35
DM7W0JE FM C16H18N6O
DM7W0JE IC InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
DM7W0JE CS C[C@H]1CN([C@]12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N
DM7W0JE IK LOWWYYZBZNSPDT-ZBEGNZNMSA-N
DM7W0JE IU 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
DM7W0JE CA CAS 1263774-59-9
DM7W0JE DE Asthma; Eczema
DMZ6Y0T ID DMZ6Y0T
DMZ6Y0T DN LEO-32731
DMZ6Y0T HS Phase 2
DMZ6Y0T SN LP0058
DMZ6Y0T CP LEO Pharma A/S
DMZ6Y0T PC 54765967
DMZ6Y0T MW 510.3
DMZ6Y0T FM C19H15Cl2F2NO7S
DMZ6Y0T IC InChI=1S/C19H15Cl2F2NO7S/c20-12-8-24(26)9-13(21)11(12)7-14(25)10-1-2-15(29-18(22)23)17-16(10)30-19(31-17)3-5-32(27,28)6-4-19/h1-2,8-9,18H,3-7H2
DMZ6Y0T CS C1CS(=O)(=O)CCC12OC3=C(C=CC(=C3O2)OC(F)F)C(=O)CC4=C(C=[N+](C=C4Cl)[O-])Cl
DMZ6Y0T IK ZININGNRPUGNSL-UHFFFAOYSA-N
DMZ6Y0T IU 2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-[7-(difluoromethoxy)-1',1'-dioxospiro[1,3-benzodioxole-2,4'-thiane]-4-yl]ethanone
DMZ6Y0T CA CAS 1353546-86-7
DMZ6Y0T DE Psoriasis vulgaris; Plaque psoriasis
DM6DL5K ID DM6DL5K
DM6DL5K DN Leridistim
DM6DL5K HS Phase 2
DM6DL5K SN MPO, Searle; MPO-1; SC-70935; Myelopoietin (1), Searle
DM6DL5K CP GD Searle & Co
DM6DL5K DE Immune System disease
DMMQ6VT ID DMMQ6VT
DMMQ6VT DN Leronlimab
DMMQ6VT HS Phase 2
DMMQ6VT SN PRO 140
DMMQ6VT TC Antiviral Agents
DMMQ6VT DT Monoclonal antibody
DMMQ6VT DE Coronavirus Disease 2019 (COVID-19)
DMSEVBH ID DMSEVBH
DMSEVBH DN Lersivirine
DMSEVBH HS Phase 2
DMSEVBH SN cc-718; Lersivirine (UK-453061)
DMSEVBH CP ViiV Healthcare
DMSEVBH DT Small molecular drug
DMSEVBH PC 16739244
DMSEVBH MW 310.35
DMSEVBH FM C17H18N4O2
DMSEVBH IC InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3
DMSEVBH CS CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N
DMSEVBH IK MCPUZZJBAHRIPO-UHFFFAOYSA-N
DMSEVBH IU 5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile
DMSEVBH CA CAS 473921-12-9
DMSEVBH DE Human immunodeficiency virus infection
DMW50NF ID DMW50NF
DMW50NF DN LE-SN38
DMW50NF HS Phase 2
DMW50NF SN 7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38 lactone; 7-Ethyl-10-hydroxy-camptothecin; SN 38; 10-Hydroxy-7-ethylcamptothecin; 7-Ethyl-10-hydroxycamptothecine; SN38; 7-Ethyl-10-hydroxy-20(S)-camptothecin; UNII-0H43101T0J; Captothecin, 7-ethyl-10-hydroxy-; CHEBI:8988; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 7-Ethyl-10-hydroxy camptothecin; NSC673596; 0H43101T0J; (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; 113015-38-6
DMW50NF CP NeoPharm
DMW50NF DT Small molecular drug
DMW50NF PC 104842
DMW50NF MW 392.4
DMW50NF FM C22H20N2O5
DMW50NF IC InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
DMW50NF CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O
DMW50NF IK FJHBVJOVLFPMQE-QFIPXVFZSA-N
DMW50NF IU (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
DMW50NF CA CAS 86639-52-3
DMW50NF CB CHEBI:8988
DMW50NF DE Solid tumour/cancer; Colorectal cancer
DMIFGLY ID DMIFGLY
DMIFGLY DN Leukemia cancer vaccine
DMIFGLY HS Phase 2
DMIFGLY CP BioSante Pharmaceuticals
DMIFGLY DT Vaccine
DMIFGLY DE Acute myeloid leukaemia
DM5LQEI ID DM5LQEI
DM5LQEI DN Leuvectin
DM5LQEI HS Phase 2
DM5LQEI SN IL-2 gene therapy, Vical; Cytofectin (IL-2), Vical; Gene therapy (interleukin-2), Vical
DM5LQEI CP Vical Inc
DM5LQEI DE Melanoma
DMOS5JZ ID DMOS5JZ
DMOS5JZ DN Lexatumumab
DMOS5JZ HS Phase 2
DMOS5JZ SN HGS-ETR2; TRAIL receptor-2 monoclonal antibodies (cancer), HGS/CAT; TRAIL-R2 mAbs (cancer), Human Genome Sciences/Cambridge Antibody Technology; TNF-related apoptosis-inducing ligand receptor-2 mAbs (cancer), HGS/CAT
DMOS5JZ CP Cambridge Antibody Technology Group plc
DMOS5JZ DT Antibody
DMOS5JZ DE Solid tumour/cancer
DMLEX1D ID DMLEX1D
DMLEX1D DN Lexibulin
DMLEX1D HS Phase 2
DMLEX1D SN Lexibulin; CYT-997; Microtubule inhibitor (oral, solid tumors) Cytopia; VDA anticancer program (iv), Cytopia; Lexibulin (iv infusion, cancer), YM BioSciences; Lexibulin (oral capsule, cancer), YM Biosciences; CYT-997 (iv infusion, cancer), Cytopia; CYT-997 (iv infusion, cancer), YM BioSciences; CYT-997 (oral capsule, cancer), Cytopia; CYT-997 (oral capsule, cancer), YM Biosciences; Vascular disrupting agent/ tubulin inhibitor (iv, cancer), Cytopia; Vascular disrupting agent/tubulin inhibitor (oral, cancer), Cytopia; Vascular targeting agent/ tubulin inhibitor (iv, cancer), Cytopia
DMLEX1D CP Cytopia Ltd; Cytopia
DMLEX1D DE Glioblastoma multiforme
DMZ2YBE ID DMZ2YBE
DMZ2YBE DN Lexipafant
DMZ2YBE HS Phase 2
DMZ2YBE SN LEXIPAFANT; 139133-26-9; UNII-H14917M9YW; BB-882; CHEMBL322832; H14917M9YW; DO6; Lexipafant [USAN:INN:BAN]; BB 882; Lexipafant (USAN/INN); SCHEMBL194598; ZINC1851122; BDBM50048485; N-Methyl-N-((alpha-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)-p-tolyl)sulfonyl)-L-leucine, ethyl ester; D04724; L-Leucine, N-methyl-N-((4-((2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)ethyl)phenyl)sulfonyl)-, ethyl ester; ETHYL4-METHYL-2-[METHYL-[4-[(2-METHYLIMIDAZO[4,5-C]PYRIDIN-1-YL)METHYL]PHENYL]SULFONYLAMINO]PENTANOATE; Benzothiadiazines
DMZ2YBE DT Small molecular drug
DMZ2YBE PC 9804204
DMZ2YBE MW 458.6
DMZ2YBE FM C23H30N4O4S
DMZ2YBE IC InChI=1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1
DMZ2YBE CS CCOC(=O)[C@H](CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C
DMZ2YBE IK AQRXDPFOYJSPMP-QFIPXVFZSA-N
DMZ2YBE IU ethyl (2S)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate
DMZ2YBE CA CAS 139133-26-9
DMZ2YBE DE Hepatovirus infection; Nerve injury
DMCT1RQ ID DMCT1RQ
DMCT1RQ DN LFG-316
DMCT1RQ HS Phase 2
DMCT1RQ CP Novartis AG
DMCT1RQ DT Antibody
DMCT1RQ DE Macular degeneration
DM9T8A2 ID DM9T8A2
DM9T8A2 DN LGD-4665
DM9T8A2 HS Phase 2
DM9T8A2 CP Ligand
DM9T8A2 DE Immune thrombocytopenic purpura
DMPL9KG ID DMPL9KG
DMPL9KG DN LGD-6972
DMPL9KG HS Phase 2
DMPL9KG SN MB-11262
DMPL9KG CP Ligand pharmaceuticals
DMPL9KG PC 44625560
DMPL9KG MW 702.9
DMPL9KG FM C43H46N2O5S
DMPL9KG IC InChI=1S/C43H46N2O5S/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50)/t39-/m1/s1
DMPL9KG CS CC1=CC(=C(C(=C1)C)C2=CC=C(C=C2)NC(=O)[C@H](CC3=CC=C(C=C3)C(=O)NCCS(=O)(=O)O)C4=CC=C(C=C4)C5=CC=C(C=C5)C(C)(C)C)C
DMPL9KG IK HKJMCBYPVCGZFB-LDLOPFEMSA-N
DMPL9KG IU 2-[[4-[(2R)-2-[4-(4-tert-butylphenyl)phenyl]-3-oxo-3-[4-(2,4,6-trimethylphenyl)anilino]propyl]benzoyl]amino]ethanesulfonic acid
DMPL9KG CA CAS 1207989-09-0
DMPL9KG DE Type-2 diabetes; Non-insulin dependent diabetes
DMA0RI9 ID DMA0RI9
DMA0RI9 DN LIDORESTAT
DMA0RI9 HS Phase 2
DMA0RI9 SN Lidorestat; 245116-90-9; IDD-676; UNII-R3734K0M7L; IDD-000676-01; {3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID; CHEMBL363387; R3734K0M7L; 1H-Indole-1-aceticacid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 3-[(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL]INDOLE-N-ACETIC ACID; 3NA; Lidorestat [USAN:INN]; 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 1H-Indole-1-acetic acid, 3-((4,5,7-trifluor
DMA0RI9 DT Small molecular drug
DMA0RI9 PC 157839
DMA0RI9 MW 376.4
DMA0RI9 FM C18H11F3N2O2S
DMA0RI9 IC InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25)
DMA0RI9 CS C1=CC=C2C(=C1)C(=CN2CC(=O)O)CC3=NC4=C(C(=CC(=C4S3)F)F)F
DMA0RI9 IK KYHVTMFADJNSGS-UHFFFAOYSA-N
DMA0RI9 IU 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid
DMA0RI9 CA CAS 245116-90-9
DMA0RI9 DE Diabetic complication
DM32NWD ID DM32NWD
DM32NWD DN LIK-066
DM32NWD HS Phase 2
DM32NWD CP Novartis AG
DM32NWD PC 52913524
DM32NWD MW 416.5
DM32NWD FM C23H28O7
DM32NWD IC InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
DM32NWD CS CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4
DM32NWD IK XFJAMQQAAMJFGB-ZQGJOIPISA-N
DM32NWD IU (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
DM32NWD CA CAS 1291094-73-9
DM32NWD DE Type-2 diabetes; Heart failure
DM9ZHRS ID DM9ZHRS
DM9ZHRS DN LIM-0705
DM9ZHRS HS Phase 2
DM9ZHRS CP Limerick Biopharma
DM9ZHRS PC 20833257
DM9ZHRS MW 382.21
DM9ZHRS FM C15H11O10P
DM9ZHRS IC InChI=1S/C15H11O10P/c16-7-4-9(18)12-11(5-7)24-15(14(20)13(12)19)6-1-2-8(17)10(3-6)25-26(21,22)23/h1-5,16-18,20H,(H2,21,22,23)
DM9ZHRS CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)OP(=O)(O)O)O
DM9ZHRS IK UWJBYNLLMAPJMM-UHFFFAOYSA-N
DM9ZHRS IU [2-hydroxy-5-(3,5,7-trihydroxy-4-oxochromen-2-yl)phenyl] dihydrogen phosphate
DM9ZHRS CA CAS 1111616-69-3
DM9ZHRS DE Insulin-resistant disorder
DMSHGWN ID DMSHGWN
DMSHGWN DN Lintopride
DMSHGWN HS Phase 2
DMSHGWN SN SL-920075
DMSHGWN CP Synthelabo
DMSHGWN DT Small molecular drug
DMSHGWN PC 65900
DMSHGWN MW 310.78
DMSHGWN FM C14H19ClN4O2
DMSHGWN IC InChI=1S/C14H19ClN4O2/c1-3-19-5-4-17-13(19)8-18-14(20)9-6-10(15)11(16)7-12(9)21-2/h6-7H,3-5,8,16H2,1-2H3,(H,18,20)
DMSHGWN CS CCN1CCN=C1CNC(=O)C2=CC(=C(C=C2OC)N)Cl
DMSHGWN IK MJCKISCWHDATBN-UHFFFAOYSA-N
DMSHGWN IU 4-amino-5-chloro-N-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide
DMSHGWN CA CAS 107429-63-0
DMSHGWN DE Nausea
DMWY0V1 ID DMWY0V1
DMWY0V1 DN LIPO-5
DMWY0V1 HS Phase 2
DMWY0V1 SN HIV vaccine (lipoprotein), ANRS/Aventis Pasteur
DMWY0V1 CP Sanofi Pasteur
DMWY0V1 DT Vaccine
DMWY0V1 DE Human immunodeficiency virus infection
DMNGT89 ID DMNGT89
DMNGT89 DN Lirilumab
DMNGT89 HS Phase 2
DMNGT89 CP Bristol-Myers Squibb
DMNGT89 DT Monoclonal antibody
DMNGT89 DE Acute myeloid leukaemia; Solid tumour/cancer; Chronic lymphocytic leukaemia; Myelodysplastic syndrome
DMD4KAU ID DMD4KAU
DMD4KAU DN LIRIMILAST
DMD4KAU HS Phase 2
DMD4KAU SN Lirimilast; Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzofuran-6-ylester
DMD4KAU DT Small molecular drug
DMD4KAU PC 6433118
DMD4KAU MW 443.3
DMD4KAU FM C17H12Cl2N2O6S
DMD4KAU IC InChI=1S/C17H12Cl2N2O6S/c1-28(24,25)27-9-3-5-11-13(7-9)26-16(14(11)21-17(20)23)15(22)10-4-2-8(18)6-12(10)19/h2-7H,1H3,(H3,20,21,23)
DMD4KAU CS CS(=O)(=O)OC1=CC2=C(C=C1)C(=C(O2)C(=O)C3=C(C=C(C=C3)Cl)Cl)NC(=O)N
DMD4KAU IK YPFLFUJKZDAXRA-UHFFFAOYSA-N
DMD4KAU IU [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate
DMD4KAU CA CAS 329306-27-6
DMD4KAU DE Chronic obstructive pulmonary disease
DMVU9X1 ID DMVU9X1
DMVU9X1 DN Lisofylline
DMVU9X1 HS Phase 2
DMVU9X1 SN LISOFYLLINE; (R)-Lisofylline; 100324-81-0; CT-1501R; ProTec; Lisophylline; NSMXQKNUPPXBRG-SECBINFHSA-N; (R)-Lisophylline; 3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; UNII-L1F2Q2X956; 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione; L1F2Q2X956; ProTec (TN); AC1L9UOZ; Lisofylline (USAN/INN); CHEMBL1411; SCHEMBL39131; GTPL9225; DTXSID7058709; CTK8E6838; CT1501R; MolPort-005-943-169; ZINC1887263; LSF; 1836AH; AKOS025394050; SB18959; DB12406; NCGC00186630-01; FT-0670822
DMVU9X1 CP DiaKine Therapeutics
DMVU9X1 DT Small molecular drug
DMVU9X1 PC 501254
DMVU9X1 MW 280.32
DMVU9X1 FM C13H20N4O3
DMVU9X1 IC InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
DMVU9X1 CS C[C@H](CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
DMVU9X1 IK NSMXQKNUPPXBRG-SECBINFHSA-N
DMVU9X1 IU 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
DMVU9X1 CA CAS 100324-81-0
DMVU9X1 CB CHEBI:143527
DMVU9X1 DE Type-1 diabetes
DMZ3OU6 ID DMZ3OU6
DMZ3OU6 DN Lithium
DMZ3OU6 HS Phase 2
DMZ3OU6 SN 7439-93-2; Li; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415] [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414] [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis
DMZ3OU6 DT Small molecular drug
DMZ3OU6 PC 3028194
DMZ3OU6 MW 7
DMZ3OU6 FM Li
DMZ3OU6 IC InChI=1S/Li
DMZ3OU6 CS [Li]
DMZ3OU6 IK WHXSMMKQMYFTQS-UHFFFAOYSA-N
DMZ3OU6 IU lithium
DMZ3OU6 CA CAS 7439-93-2
DMZ3OU6 CB CHEBI:30145
DMZ3OU6 DE Fragile X syndrome
DM3XRUH ID DM3XRUH
DM3XRUH DN LJN452
DM3XRUH HS Phase 2
DM3XRUH SN Tropifexor; 1383816-29-2; UNII-NMZ08KM76Z; NMZ08KM76Z; CPD1549; Tropifexor [INN]; GTPL9725; SCHEMBL19178329; SCHEMBL17848159; LJN-452; EX-A1934; CS-8153; compound 1 [PMID: 29148806]; ACN-053193; AC-30341; 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid; HY-107418; 2-((1R,5S)-3-((5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-4-fluorob
DM3XRUH CP Novartis Pharmaceuticals East Hanover, NJ
DM3XRUH PC 121418176
DM3XRUH MW 603.6
DM3XRUH FM C29H25F4N3O5S
DM3XRUH IC InChI=1S/C29H25F4N3O5S/c30-21-9-15(27(37)38)10-23-25(21)34-28(42-23)36-16-7-8-17(36)12-18(11-16)39-13-20-24(35-41-26(20)14-5-6-14)19-3-1-2-4-22(19)40-29(31,32)33/h1-4,9-10,14,16-18H,5-8,11-13H2,(H,37,38)/t16-,17+,18?
DM3XRUH CS C1C[C@H]2CC(C[C@@H]1N2C3=NC4=C(C=C(C=C4S3)C(=O)O)F)OCC5=C(ON=C5C6=CC=CC=C6OC(F)(F)F)C7CC7
DM3XRUH IK VYLOOGHLKSNNEK-JWTNVVGKSA-N
DM3XRUH IU 2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid
DM3XRUH CA CAS 1383816-29-2
DM3XRUH DE Primary biliary cholangitis
DMVM13R ID DMVM13R
DMVM13R DN LJPC-401
DMVM13R HS Phase 2
DMVM13R CP La Jolla Pharmaceutical
DMVM13R DT Peptide
DMVM13R DE Hemochromatosis; Beta thalassemia
DMCFGP3 ID DMCFGP3
DMCFGP3 DN LKA651
DMCFGP3 HS Phase 2
DMCFGP3 SN 9-Nov
DMCFGP3 CP Novartis
DMCFGP3 DT Antibody
DMCFGP3 DE Diabetic macular edema
DMSJOE3 ID DMSJOE3
DMSJOE3 DN LM-030
DMSJOE3 HS Phase 2
DMSJOE3 CP LifeMax Laboratories Palo Alto, CA
DMSJOE3 DE Congenital ichthyosiform erythroderma
DMW6VA0 ID DMW6VA0
DMW6VA0 DN LM-1507.NA
DMW6VA0 HS Phase 2
DMW6VA0 SN MEN-91507; (E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]vinyl]-2-(1H-tetrazol-5-yl)-4H-benzopyran-4-one sodium salt
DMW6VA0 DE Asthma
DMG7RAV ID DMG7RAV
DMG7RAV DN LMB-2
DMG7RAV HS Phase 2
DMG7RAV SN LMB-2a; AntiTac(Fv)-PE38; Immunotoxin (cancer), National Cancer Institute
DMG7RAV CP National Cancer Institute
DMG7RAV DE Chronic lymphocytic leukaemia
DMQOXNL ID DMQOXNL
DMQOXNL DN LMB763
DMQOXNL HS Phase 2
DMQOXNL SN Nidufexor; 1773489-72-7; LMB-763; UNII-CJ1PL0TE6J; CJ1PL0TE6J; 4-[(N-benzyl-8-chloro-1-methyl-1,4-dihydro[1]benzopyrano[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid; Nidufexor [INN]; CHEMBL4297626; SCHEMBL16702097; GTPL10655; BCP28929; EX-A1854; Nidufexor pound LMB-763 pound(c); BDBM50527021; MFCD31657267; ZINC584641402; compound 1 [PMID: 31940200]; 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid; BS-15605; HY-109096; CS-0039398; Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(cc2)C(O)=O)c2COc3ccc(Cl)cc3-c12; 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid; Benzoic acid, 4-((((8-chloro-1,4-dihydro-1-methyl(1)benzopyrano(4,3-C)pyrazol-3-yl)carbonyl)(phenylmethyl)amino)methyl)-
DMQOXNL CP Novartis
DMQOXNL DT Small molecular drug
DMQOXNL PC 118063735
DMQOXNL MW 487.9
DMQOXNL FM C27H22ClN3O4
DMQOXNL IC InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
DMQOXNL CS CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O
DMQOXNL IK JYTIXGYXBIBOMN-UHFFFAOYSA-N
DMQOXNL IU 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid
DMQOXNL CA CAS 1773489-72-7
DMQOXNL DE Non-alcoholic steatohepatitis; Diabetic nephropathy
DM01SR6 ID DM01SR6
DM01SR6 DN L-NAME
DM01SR6 HS Phase 2
DM01SR6 SN N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate
DM01SR6 CP Registry Operator
DM01SR6 DT Small molecular drug
DM01SR6 PC 39836
DM01SR6 MW 233.23
DM01SR6 FM C7H15N5O4
DM01SR6 IC InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1
DM01SR6 CS COC(=O)[C@H](CCCN=C(N)N[N+](=O)[O-])N
DM01SR6 IK KCWZGJVSDFYRIX-YFKPBYRVSA-N
DM01SR6 IU methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate
DM01SR6 CA CAS 50903-99-6
DM01SR6 CB CHEBI:7549
DM01SR6 DE Hypertension
DMT3KB4 ID DMT3KB4
DMT3KB4 DN Lobeline
DMT3KB4 HS Phase 2
DMT3KB4 SN lobeline; Lobelin; Inflatine; Lobeline [INN]; Lobelinum [INN-Latin]; Lobelina [INN-Spanish]; EINECS 202-012-3; BRN 0091533; AC1LEL62; ZINC56446; Ethanone, 2-(6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl)-1-phenyl-, (2R-(2alpha,6alpha(S*)))-; LS-88107
DMT3KB4 DT Small molecular drug
DMT3KB4 PC 101616
DMT3KB4 MW 337.5
DMT3KB4 FM C22H27NO2
DMT3KB4 IC InChI=1S/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1
DMT3KB4 CS CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMT3KB4 IK MXYUKLILVYORSK-HBMCJLEFSA-N
DMT3KB4 IU 2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone
DMT3KB4 CA CAS 90-69-7
DMT3KB4 CB CHEBI:48723
DMT3KB4 DE Substance use disorder
DMN0VS2 ID DMN0VS2
DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2 HS Phase 2
DMN0VS2 SN Aluviran + norvir + rebetol + betaseron
DMN0VS2 TC Antiviral Agents
DMN0VS2 DT Combination drug
DMN0VS2 DE Coronavirus Disease 2019 (COVID-19)
DM0GZTD ID DM0GZTD
DM0GZTD DN L-ornithine phenylacetate
DM0GZTD HS Phase 2
DM0GZTD SN L-ornthine phenylacetate; OCR-002; UCL-L1V; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy); Nitrogen metabolism modulator (injectable, AHE), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), Ocera; Nitrogen metabolism modulator (injectable, acute hepatic encephalopathy), UCL; Nitrogen metabolism modulator (injectable, hyperammonemia), Ocera; L-ornithine phenylacetate (injectable, AHE), Ocera; L-ornithine phenylacetate (injectable, acute hepatic encephalopathy), Ocera; L-ornithine phenylacetate (injectable, hyperammonemia), Ocera
DM0GZTD CP Ocera therapeutics
DM0GZTD DT Small molecular drug
DM0GZTD PC 44247677
DM0GZTD MW 268.31
DM0GZTD FM C13H20N2O4
DM0GZTD IC InChI=1S/C8H8O2.C5H12N2O2/c9-8(10)6-7-4-2-1-3-5-7;6-3-1-2-4(7)5(8)9/h1-5H,6H2,(H,9,10);4H,1-3,6-7H2,(H,8,9)/t;4-/m.0/s1
DM0GZTD CS C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN
DM0GZTD IK LRSYFEZBIMVWRY-VWMHFEHESA-N
DM0GZTD IU (2S)-2,5-diaminopentanoic acid;2-phenylacetic acid
DM0GZTD CA CAS 952154-79-9
DM0GZTD DE Acute liver failure
DME8O5K ID DME8O5K
DME8O5K DN LOU064
DME8O5K HS Phase 2
DME8O5K CP Novartis Pharmaceuticals East Hanover, NJ
DME8O5K DE Chronic idiopathic urticaria
DMIV9ZE ID DMIV9ZE
DMIV9ZE DN LOXORIBINE
DMIV9ZE HS Phase 2
DMIV9ZE SN AOG; Loxoribine < Rec INN; RWJ-21757; 7-(2-Propenyl)-8-oxo-7,8-dihydroguanosine; 7-Allyl-2-amino-9-beta-D-ribofuranosylpurine-6,8(1H,9H)-dione; 7-Allyl-8-oxo-7,8-dihydroguanosine; 7A8OGua
DMIV9ZE DT Small molecular drug
DMIV9ZE PC 135410906
DMIV9ZE MW 339.3
DMIV9ZE FM C13H17N5O6
DMIV9ZE IC InChI=1S/C13H17N5O6/c1-2-3-17-6-9(15-12(14)16-10(6)22)18(13(17)23)11-8(21)7(20)5(4-19)24-11/h2,5,7-8,11,19-21H,1,3-4H2,(H3,14,15,16,22)/t5-,7-,8-,11-/m1/s1
DMIV9ZE CS C=CCN1C2=C(N=C(NC2=O)N)N(C1=O)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMIV9ZE IK VDCRFBBZFHHYGT-IOSLPCCCSA-N
DMIV9ZE IU 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-1H-purine-6,8-dione
DMIV9ZE CA CAS 121288-39-9
DMIV9ZE DE Immune System disease
DM7BN5W ID DM7BN5W
DM7BN5W DN LPN023
DM7BN5W HS Phase 2
DM7BN5W CP Novartis
DM7BN5W DT Small molecular drug
DM7BN5W DE IgA nephropathy
DMZQBCL ID DMZQBCL
DMZQBCL DN LR3001
DMZQBCL HS Phase 2
DMZQBCL CP Genta
DMZQBCL TC Anticancer Agents
DMZQBCL DT Antisense drug
DMZQBCL DE Myeloid leukaemia
DM0TZPL ID DM0TZPL
DM0TZPL DN LS-71719
DM0TZPL HS Phase 2
DM0TZPL SN Galactooligosaccharide; LS-71719; NOCAS_276547; 4'-Galactooligosaccharide; D-Glucose, O-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-; DTXSID60276547; SCHEMBL12362685
DM0TZPL PC 165512
DM0TZPL MW 504.4
DM0TZPL FM C18H32O16
DM0TZPL IC RXVWSYJTUUKTEA-DSOVBJLESA-N
DM0TZPL CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC(C(CO)O)C(C(C=O)O)O)CO)O)O)O)O
DM0TZPL IK 1S/C18H32O16/c19-1-5(23)9(25)15(6(24)2-20)33-18-14(30)12(28)16(8(4-22)32-18)34-17-13(29)11(27)10(26)7(3-21)31-17/h1,5-18,20-30H,2-4H2/t5-,6+,7+,8+,9+,10-,11-,12+,13+,14+,15+,16-,17-,18-/m0/s1
DM0TZPL IU (2R,3R,4R,5R)-4-[(2S,3R,4R,5R,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanal
DM0TZPL CA CAS 6587-31-1
DM0TZPL DE Anxiety disorder
DME26RS ID DME26RS
DME26RS DN LTB4
DME26RS HS Phase 2
DME26RS SN Leukotriene B4; LEUKOTRIENE B4; 5,12-Dihete; 71160-24-2; 5,12-Hete; UNII-1HGW4DR56D; (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; 1HGW4DR56D; CHEMBL65061; 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; CHEBI:15647; VNYSSYRCGWBHLG-AMOLWHMGSA-N; [5S,12R]-Dihydroxy-[6Z,8E,10E,14Z]-eicosatetraenoic acid; Leukotriene B; 5(S),12(R)-Dihydroxy-6-cis-8-trans-10-trans-14-cis-eicosatetraenoic Acid; (S-(R*,S*-(E,Z,E,Z)))-5,12-Dihydroxy-6,8,10,14-eicosatetraenoic acid; 6,8,10,14-Eicosatetraenoic acid,; Leukotriene B4 agonist (HIV infection), LTB4 Sweden AB; LEUKOTRIENE_B4
DME26RS CP LTB4 Sweden AB
DME26RS DT Small molecular drug
DME26RS PC 5280492
DME26RS MW 336.5
DME26RS FM C20H32O4
DME26RS IC InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19-/m1/s1
DME26RS CS CCCCC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O
DME26RS IK VNYSSYRCGWBHLG-AMOLWHMGSA-N
DME26RS IU (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DME26RS CA CAS 71160-24-2
DME26RS CB CHEBI:15647
DME26RS DE Human immunodeficiency virus infection
DMXEQ0R ID DMXEQ0R
DMXEQ0R DN LTX-109
DMXEQ0R HS Phase 2
DMXEQ0R SN Lytixar
DMXEQ0R CP Lytix Biopharma AS
DMXEQ0R DT Small molecular drug
DMXEQ0R PC 25242323
DMXEQ0R MW 788.1
DMXEQ0R FM C43H69N11O3
DMXEQ0R IC InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
DMXEQ0R CS CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C
DMXEQ0R IK ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
DMXEQ0R IU (2S)-2-amino-5-(diaminomethylideneamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(2-phenylethylamino)pentan-2-yl]amino]-1-oxo-3-(2,5,7-tritert-butyl-1H-indol-3-yl)propan-2-yl]pentanamide
DMXEQ0R CA CAS 1166254-80-3
DMXEQ0R CB CHEBI:77752
DMXEQ0R DE Bacterial infection
DMJOYNZ ID DMJOYNZ
DMJOYNZ DN Lu AF11167
DMJOYNZ HS Phase 2
DMJOYNZ CP Lundbeck
DMJOYNZ DT Small molecular drug
DMJOYNZ DE Schizophrenia
DM2ZUXK ID DM2ZUXK
DM2ZUXK DN Lu-AA34893
DM2ZUXK HS Phase 2
DM2ZUXK CP H Lundbeck A/S
DM2ZUXK DE Anxiety disorder
DM34FWR ID DM34FWR
DM34FWR DN Lu-AA39959
DM34FWR HS Phase 2
DM34FWR CP H Lundbeck A/S
DM34FWR DE Bipolar disorder
DMY2L7V ID DMY2L7V
DMY2L7V DN Lucatumumab
DMY2L7V HS Phase 2
DMY2L7V SN HDC122
DMY2L7V CP Novartis Pharmaceuticals
DMY2L7V DT Monoclonal antibody
DMY2L7V DE Lymphoma
DMCKNBA ID DMCKNBA
DMCKNBA DN Lufironil
DMCKNBA HS Phase 2
DMCKNBA SN Hoe-077
DMCKNBA CP Hoechst AG
DMCKNBA DT Small molecular drug
DMCKNBA PC 60788
DMCKNBA MW 281.31
DMCKNBA FM C13H19N3O4
DMCKNBA IC InChI=1S/C13H19N3O4/c1-19-7-5-15-12(17)10-3-4-14-11(9-10)13(18)16-6-8-20-2/h3-4,9H,5-8H2,1-2H3,(H,15,17)(H,16,18)
DMCKNBA CS COCCNC(=O)C1=CC(=NC=C1)C(=O)NCCOC
DMCKNBA IK JUCNGMPTCXPMNB-UHFFFAOYSA-N
DMCKNBA IU 2-N,4-N-bis(2-methoxyethyl)pyridine-2,4-dicarboxamide
DMCKNBA CA CAS 128075-79-6
DMCKNBA DE Liver cirrhosis
DMGWZ93 ID DMGWZ93
DMGWZ93 DN Lulizumab pegol
DMGWZ93 HS Phase 2
DMGWZ93 CP Bristol-Myers SquibbPrinceton, NJ
DMGWZ93 DE Systemic lupus erythematosus
DMQZXDW ID DMQZXDW
DMQZXDW DN Lum001
DMQZXDW HS Phase 2
DMQZXDW SN SHP625
DMQZXDW CP Lumena pharmaceuticals
DMQZXDW PC 9831642
DMQZXDW MW 710.4
DMQZXDW FM C40H56ClN3O4S
DMQZXDW IC InChI=1S/C40H56N3O4S.ClH/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43;/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3;1H/q+1;/p-1/t38-,39-;/m1./s1
DMQZXDW CS CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-]
DMQZXDW IK POMVPJBWDDJCMP-RUKDTIIFSA-M
DMQZXDW IU (4R,5R)-5-[4-[[4-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol;chloride
DMQZXDW CA CAS 228113-66-4
DMQZXDW DE Primary biliary cirrhosis; Primary biliary cholangitis; Primary sclerosing cholangitis; Progressive familial intrahepatic cholestasis; Structural developmental anomalies of liver
DMCLWDJ ID DMCLWDJ
DMCLWDJ DN Lumacaftor
DMCLWDJ HS Phase 2
DMCLWDJ SN VRT-325; VRT-422; VRT-532; VX-809
DMCLWDJ CP Vertex Pharmaceuticals Inc
DMCLWDJ DT Small molecular drug
DMCLWDJ PC 16678941
DMCLWDJ MW 452.4
DMCLWDJ FM C24H18F2N2O5
DMCLWDJ IC InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
DMCLWDJ CS CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
DMCLWDJ IK UFSKUSARDNFIRC-UHFFFAOYSA-N
DMCLWDJ IU 3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
DMCLWDJ CA CAS 936727-05-8
DMCLWDJ CB CHEBI:90951
DMCLWDJ DE Cystic fibrosis
DMLTI39 ID DMLTI39
DMLTI39 DN Lumiliximab
DMLTI39 HS Phase 2
DMLTI39 SN Gomiliximab; IDEC-152; SI-3401; ST-152; PRIMATIZED anti-CD23 antibody, IDEC
DMLTI39 CP IDEC Pharmaceuticals Corp; Biogen Idec
DMLTI39 DT Antibody
DMLTI39 DE leukaemia
DMLRU9I ID DMLRU9I
DMLRU9I DN Lunacalcipol
DMLRU9I HS Phase 2
DMLRU9I SN CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma
DMLRU9I CP Johns Hopkins University
DMLRU9I DT Small molecular drug
DMLRU9I PC 10672195
DMLRU9I MW 474.7
DMLRU9I FM C28H42O4S
DMLRU9I IC InChI=1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1
DMLRU9I CS C[C@H](C/C=C/S(=O)(=O)C(C)(C)C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMLRU9I IK RFQHCLMGLJGZNV-UXXOMSPDSA-N
DMLRU9I IU (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(E,2R)-5-tert-butylsulfonylpent-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMLRU9I CA CAS 250384-82-8
DMLRU9I DE Psoriasis vulgaris
DMZ2XAP ID DMZ2XAP
DMZ2XAP DN LX-1031
DMZ2XAP HS Phase 2
DMZ2XAP SN LG-103; LP-389924; LP-507518; LP-533401; LP-615819; TPH inhibitor (IBS), Lexicon; Tryptophan 5-hydroxylase inhibitor(IBS), Lexicon
DMZ2XAP CP Lexicon Pharmaceuticals Inc
DMZ2XAP DT Small molecular drug
DMZ2XAP PC 23633604
DMZ2XAP MW 538.5
DMZ2XAP FM C28H25F3N4O4
DMZ2XAP IC InChI=1S/C28H25F3N4O4/c1-38-21-4-2-3-20(14-21)17-9-11-19(12-10-17)25(28(29,30)31)39-24-15-23(34-27(33)35-24)18-7-5-16(6-8-18)13-22(32)26(36)37/h2-12,14-15,22,25H,13,32H2,1H3,(H,36,37)(H2,33,34,35)/t22-,25+/m0/s1
DMZ2XAP CS COC1=CC=CC(=C1)C2=CC=C(C=C2)[C@H](C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N
DMZ2XAP IK XNMUICFMGGQSMZ-WIOPSUGQSA-N
DMZ2XAP IU (2S)-2-amino-3-[4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-[4-(3-methoxyphenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
DMZ2XAP CA CAS 945976-76-1
DMZ2XAP DE Irritable bowel syndrome
DMLA8H3 ID DMLA8H3
DMLA8H3 DN LX2931
DMLA8H3 HS Phase 2
DMLA8H3 CP Lexicon Pharmaceuticals
DMLA8H3 DT Small molecular drug
DMLA8H3 PC 135564845
DMLA8H3 MW 245.23
DMLA8H3 FM C9H15N3O5
DMLA8H3 IC InChI=1S/C9H15N3O5/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13/h2,6-8,13-17H,3H2,1H3,(H,10,11)/b12-4+/t6-,7-,8-/m1/s1
DMLA8H3 CS C/C(=N\\O)/C1=NC=C(N1)[C@H]([C@@H]([C@@H](CO)O)O)O
DMLA8H3 IK AMXVYJYMZLDINS-RSWLNLDNSA-N
DMLA8H3 IU (1R,2S,3R)-1-[2-[(E)-N-hydroxy-C-methylcarbonimidoyl]-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
DMLA8H3 CA CAS 948840-25-3
DMLA8H3 DE Rheumatoid arthritis; Hereditary acantholytic dermatoses
DMLBD5I ID DMLBD5I
DMLBD5I DN LXE408
DMLBD5I HS Phase 2
DMLBD5I SN SCHEMBL16822697; HY-131350; CS-0133456; FC1=C(C=C(C=C1)NC(=O)C1=C(N=C(O1)C)C)C1=NN2C(N=CC(=C2)C2=NC=CC=C2C)=N1; 1799330-15-6; N-(4-Fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
DMLBD5I CP Novartis
DMLBD5I DT Small molecular drug
DMLBD5I PC 118162630
DMLBD5I MW 443.4
DMLBD5I FM C23H18FN7O2
DMLBD5I IC InChI=1S/C23H18FN7O2/c1-12-5-4-8-25-19(12)15-10-26-23-29-21(30-31(23)11-15)17-9-16(6-7-18(17)24)28-22(32)20-13(2)27-14(3)33-20/h4-11H,1-3H3,(H,28,32)
DMLBD5I CS CC1=C(N=CC=C1)C2=CN3C(=NC(=N3)C4=C(C=CC(=C4)NC(=O)C5=C(N=C(O5)C)C)F)N=C2
DMLBD5I IK GNVVPYCWVLCWKV-UHFFFAOYSA-N
DMLBD5I IU N-[4-fluoro-3-[6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide
DMLBD5I DE Visceral leishmaniasis
DM5IX9M ID DM5IX9M
DM5IX9M DN LY-156735
DM5IX9M HS Phase 2
DM5IX9M SN LY 156735; N-[(2r)-2-(6-chloro-5-methoxy-1h-indol-3-yl)propyl]acetamide
DM5IX9M CP Phase 2 Discovery
DM5IX9M DT Small molecular drug
DM5IX9M PC 219018
DM5IX9M MW 280.75
DM5IX9M FM C14H17ClN2O2
DM5IX9M IC InChI=1S/C14H17ClN2O2/c1-8(6-16-9(2)18)11-7-17-13-5-12(15)14(19-3)4-10(11)13/h4-5,7-8,17H,6H2,1-3H3,(H,16,18)/t8-/m0/s1
DM5IX9M CS C[C@@H](CNC(=O)C)C1=CNC2=CC(=C(C=C21)OC)Cl
DM5IX9M IK RKHCTAKUYDTFHE-QMMMGPOBSA-N
DM5IX9M IU N-[(2R)-2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide
DM5IX9M CA CAS 118702-11-7
DM5IX9M DE Anxiety disorder
DMTBFE4 ID DMTBFE4
DMTBFE4 DN LY2090314
DMTBFE4 HS Phase 2
DMTBFE4 SN 603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, >
DMTBFE4 CP Eli Lilly
DMTBFE4 DT Small molecular drug
DMTBFE4 PC 10029385
DMTBFE4 MW 512.5
DMTBFE4 FM C28H25FN6O3
DMTBFE4 IC InChI=1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
DMTBFE4 CS C1CCN(CC1)C(=O)N2CCN3C=C(C4=CC(=CC(=C43)C2)F)C5=C(C(=O)NC5=O)C6=CN=C7N6C=CC=C7
DMTBFE4 IK HRJWTAWVFDCTGO-UHFFFAOYSA-N
DMTBFE4 IU 3-[6-fluoro-10-(piperidine-1-carbonyl)-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-3-yl]-4-imidazo[1,2-a]pyridin-3-ylpyrrole-2,5-dione
DMTBFE4 CA CAS 603288-22-8
DMTBFE4 DE Acute myeloid leukaemia
DMU81BH ID DMU81BH
DMU81BH DN LY-2189102
DMU81BH HS Phase 2
DMU81BH SN Anti-IL-1 beta mAb (cardiovascular disease), Lilly; Anti IL-1 beta antibody (non-insulin dependent diabetes, rheumatoid athritis), Lilly
DMU81BH CP Eli lilly
DMU81BH DT Antibody
DMU81BH DE Cardiovascular disease
DMH3YKJ ID DMH3YKJ
DMH3YKJ DN LY2382770
DMH3YKJ HS Phase 2
DMH3YKJ CP Eli Lilly & Co
DMH3YKJ DT Antibody
DMH3YKJ DE Diabetic nephropathy; Diabetic kidney disease
DMZOIP4 ID DMZOIP4
DMZOIP4 DN LY-2409021
DMZOIP4 HS Phase 2
DMZOIP4 SN Oral glucagon receptor antagonist (type 2 diabetes), Eli Lilly
DMZOIP4 CP Eli Lilly & Co
DMZOIP4 PC 91933867
DMZOIP4 MW 555.6
DMZOIP4 FM C32H36F3NO4
DMZOIP4 IC InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1
DMZOIP4 CS CC1=CC(=CC(=C1C2=CC=C(C=C2)C(C)(C)C)C)O[C@@H](CCC(F)(F)F)C3=CC=C(C=C3)C(=O)NCCC(=O)O
DMZOIP4 IK FASLTMSUPQDLIB-MHZLTWQESA-N
DMZOIP4 IU 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid
DMZOIP4 CA CAS 1488363-78-5
DMZOIP4 DE Type-2 diabetes
DMKYMS2 ID DMKYMS2
DMKYMS2 DN LY-2428757
DMKYMS2 HS Phase 2
DMKYMS2 SN GLP-PEG, Eli Lilly; GLP1-PEG, Eli Lilly
DMKYMS2 CP Eli Lilly & Co
DMKYMS2 DE Type-2 diabetes
DMLTSDC ID DMLTSDC
DMLTSDC DN LY-2456302
DMLTSDC HS Phase 2
DMLTSDC SN Opioid receptor kappa (KOR) antagonist (alcohol dependence), Eli Lilly
DMLTSDC CP Eli Lilly & Co
DMLTSDC DT Small molecular drug
DMLTSDC PC 44129648
DMLTSDC MW 418.5
DMLTSDC FM C26H27FN2O2
DMLTSDC IC InChI=1S/C26H27FN2O2/c1-17-12-18(2)14-21(13-17)24-4-3-11-29(24)16-19-5-8-22(9-6-19)31-25-10-7-20(26(28)30)15-23(25)27/h5-10,12-15,24H,3-4,11,16H2,1-2H3,(H2,28,30)/t24-/m0/s1
DMLTSDC CS CC1=CC(=CC(=C1)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=C(C=C(C=C4)C(=O)N)F)C
DMLTSDC IK ZHPMYDSXGRRERG-DEOSSOPVSA-N
DMLTSDC IU 4-[4-[[(2S)-2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide
DMLTSDC CA CAS 1174130-61-0
DMLTSDC DE Alcohol dependence; Major depressive disorder
DMM5JAN ID DMM5JAN
DMM5JAN DN LY2495655
DMM5JAN HS Phase 2
DMM5JAN CP Eli Lilly
DMM5JAN DE Disuse muscle atrophy
DMCV602 ID DMCV602
DMCV602 DN LY2523355
DMCV602 HS Phase 2
DMCV602 SN Litronesib
DMCV602 CP Lilly
DMCV602 DT Small molecular drug
DMCV602 PC 25167017
DMCV602 MW 511.7
DMCV602 FM C23H37N5O4S2
DMCV602 IC InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1
DMCV602 CS CCNCCS(=O)(=O)NC[C@@]1(N(N=C(S1)NC(=O)C(C)(C)C)C(=O)C(C)(C)C)C2=CC=CC=C2
DMCV602 IK YVAFBXLHPINSIK-QHCPKHFHSA-N
DMCV602 IU N-[(5R)-4-(2,2-dimethylpropanoyl)-5-[[2-(ethylamino)ethylsulfonylamino]methyl]-5-phenyl-1,3,4-thiadiazol-2-yl]-2,2-dimethylpropanamide
DMCV602 CA CAS 910634-41-2
DMCV602 DE Acute myeloid leukaemia
DMTVU2Q ID DMTVU2Q
DMTVU2Q DN LY2541546
DMTVU2Q HS Phase 2
DMTVU2Q CP Eli Lilly
DMTVU2Q DT Antibody
DMTVU2Q DE Osteoporosis
DM81UJW ID DM81UJW
DM81UJW DN LY-2590443
DM81UJW HS Phase 2
DM81UJW CP Eli Lilly & Co
DM81UJW DE Migraine
DMMI0RH ID DMMI0RH
DMMI0RH DN LY-2599506
DMMI0RH HS Phase 2
DMMI0RH SN PSN-010
DMMI0RH CP Prosidion Ltd
DMMI0RH PC 11517248
DMMI0RH MW 415.5
DMMI0RH FM C21H25N3O4S
DMMI0RH IC InChI=1S/C21H25N3O4S/c25-21(24-20-14-22-9-10-23-20)19(13-15-7-11-28-12-8-15)16-1-3-17(4-2-16)29(26,27)18-5-6-18/h1-4,9-10,14-15,18-19H,5-8,11-13H2,(H,23,24,25)/t19-/m1/s1
DMMI0RH CS C1CC1S(=O)(=O)C2=CC=C(C=C2)[C@@H](CC3CCOCC3)C(=O)NC4=NC=CN=C4
DMMI0RH IK DQIITKNITDKAJZ-LJQANCHMSA-N
DMMI0RH IU (2R)-2-(4-cyclopropylsulfonylphenyl)-3-(oxan-4-yl)-N-pyrazin-2-ylpropanamide
DMMI0RH CA CAS 745051-65-4
DMMI0RH DE Diabetic complication
DMCXRZF ID DMCXRZF
DMCXRZF DN LY2603618
DMCXRZF HS Phase 2
DMCXRZF SN LY2603618; Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
DMCXRZF CP Eli Lilly
DMCXRZF DT Small molecular drug
DMCXRZF PC 11955855
DMCXRZF MW 436.3
DMCXRZF FM C18H22BrN5O3
DMCXRZF IC InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
DMCXRZF CS CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OC[C@@H]3CNCCO3
DMCXRZF IK SYYBDNPGDKKJDU-ZDUSSCGKSA-N
DMCXRZF IU 1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
DMCXRZF CA CAS 911222-45-2
DMCXRZF CB CHEBI:124917
DMCXRZF DE Pancreatic cancer
DM4XMF7 ID DM4XMF7
DM4XMF7 DN LY2606368
DM4XMF7 HS Phase 2
DM4XMF7 SN prexasertib; Prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013
DM4XMF7 CP Eli Lilly, Indianapolis, IN
DM4XMF7 PC 46700756
DM4XMF7 MW 365.4
DM4XMF7 FM C18H19N7O2
DM4XMF7 IC InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)
DM4XMF7 CS COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N
DM4XMF7 IK DOTGPNHGTYJDEP-UHFFFAOYSA-N
DM4XMF7 IU 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile
DM4XMF7 CA CAS 1234015-52-1
DM4XMF7 DE Head and neck cancer; Ovarian cancer; Small-cell lung cancer; Squamous cell anal carcinoma; Solid tumour/cancer
DM4EF9Y ID DM4EF9Y
DM4EF9Y DN LY-2608204
DM4EF9Y HS Phase 2
DM4EF9Y SN Glucokinase activator (type 2 diabetes), Eli Lilly
DM4EF9Y CP Eli Lilly & Co
DM4EF9Y DT Small molecular drug
DM4EF9Y PC 46832368
DM4EF9Y MW 559.8
DM4EF9Y FM C28H37N3O3S3
DM4EF9Y IC InChI=1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1
DM4EF9Y CS C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6
DM4EF9Y IK QIIVJLHCZUTGSD-CUBQBAPOSA-N
DM4EF9Y IU (1R,2S)-2-cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide
DM4EF9Y CA CAS 1234703-40-2
DM4EF9Y DE Type-2 diabetes
DMFGNB4 ID DMFGNB4
DMFGNB4 DN LY-2623091
DMFGNB4 HS Phase 2
DMFGNB4 SN Chronic renal disease therapy, Eli Lilly
DMFGNB4 CP Eli Lilly & Co
DMFGNB4 PC 42636651
DMFGNB4 MW 527.6
DMFGNB4 FM C30H30FN5O3
DMFGNB4 IC InChI=1S/C30H30FN5O3/c1-19(17-35-10-12-38-13-11-35)36-27-9-6-20(15-26(27)33-30(36)34-29(32)37)14-25-23-5-3-2-4-21(23)18-39-28-16-22(31)7-8-24(25)28/h2-9,14-16,19H,10-13,17-18H2,1H3,(H3,32,33,34,37)/b25-14+/t19-/m1/s1
DMFGNB4 CS C[C@H](CN1CCOCC1)N2C3=C(C=C(C=C3)/C=C\\4/C5=C(C=C(C=C5)F)OCC6=CC=CC=C64)N=C2NC(=O)N
DMFGNB4 IK YPCLDHGBEKZGEB-RUDKWAFVSA-N
DMFGNB4 IU [5-[(E)-(3-fluoro-6H-benzo[c][1]benzoxepin-11-ylidene)methyl]-1-[(2R)-1-morpholin-4-ylpropan-2-yl]benzimidazol-2-yl]urea
DMFGNB4 CA CAS 1162264-07-4
DMFGNB4 DE Chronic kidney disease
DMTPQUA ID DMTPQUA
DMTPQUA DN LY-2624803
DMTPQUA HS Phase 2
DMTPQUA SN HY-10275; Insomnia therapy, Hypnion; Insomnia therapy, Lilly; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Hypnion; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Lilly
DMTPQUA CP Hypnion
DMTPQUA PC 11567064
DMTPQUA MW 379.5
DMTPQUA FM C22H25N3O3
DMTPQUA IC InChI=1S/C22H25N3O3/c1-22(2,21(26)27)15-24-11-13-25(14-12-24)20-16-7-3-5-9-18(16)28-19-10-6-4-8-17(19)23-20/h3-10H,11-15H2,1-2H3,(H,26,27)
DMTPQUA CS CC(C)(CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=CC=CC=C42)C(=O)O
DMTPQUA IK UEFWDVMEDFCHGW-UHFFFAOYSA-N
DMTPQUA IU 3-(4-benzo[b][1,4]benzoxazepin-6-ylpiperazin-1-yl)-2,2-dimethylpropanoic acid
DMTPQUA CA CAS 879409-35-5
DMTPQUA DE Insomnia
DMZASMP ID DMZASMP
DMZASMP DN LY2784544
DMZASMP HS Phase 2
DMZASMP SN LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine
DMZASMP CP Eli Lilly
DMZASMP DT Small molecular drug
DMZASMP PC 46213929
DMZASMP MW 469.9
DMZASMP FM C23H25ClFN7O
DMZASMP IC InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
DMZASMP CS CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F
DMZASMP IK SQSZANZGUXWJEA-UHFFFAOYSA-N
DMZASMP IU 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine
DMZASMP CA CAS 1229236-86-5
DMZASMP DE Breast cancer; Myeloproliferative neoplasm
DM0KJDY ID DM0KJDY
DM0KJDY DN LY2801653
DM0KJDY HS Phase 2
DM0KJDY SN Merestinib; LY2801653; 1206799-15-6; LY-2801653; UNII-5OGS5K699E; N-(3-fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; 5OGS5K699E; N-(3-Fluoro-4-{[1-Methyl-6-(1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]oxy}phenyl)-1-(4-Fluorophenyl)-6-Methyl-2-Oxo-1,2-Dihydropyridine-3-Carboxamide; C30H22F2N6O3; Merestinib [USAN]; SCHEMBL679002; LY2801653 (Merestinib); GTPL9841; CHEMBL3545307; QCR-139; DTXSID20659635; SYN1222; QHADVLVFMKEIIP-UHFFFAOYSA-N
DM0KJDY CP Lilly
DM0KJDY DT Small molecular drug
DM0KJDY PC 44603533
DM0KJDY MW 552.5
DM0KJDY FM C30H22F2N6O3
DM0KJDY IC InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)
DM0KJDY CS CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F
DM0KJDY IK QHADVLVFMKEIIP-UHFFFAOYSA-N
DM0KJDY IU N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide
DM0KJDY CA CAS 1206799-15-6
DM0KJDY DE Solid tumour/cancer; Biliary tract cancer
DMO8IEZ ID DMO8IEZ
DMO8IEZ DN LY-2828360
DMO8IEZ HS Phase 2
DMO8IEZ CP Eli Lilly & Co
DMO8IEZ DE Pain
DMZ0DMY ID DMZ0DMY
DMZ0DMY DN LY2874455
DMZ0DMY HS Phase 2
DMZ0DMY SN LY2874455; 1254473-64-7; LY-2874455; UNII-E9M363811V; CHEMBL3828009; E9M363811V; AK186860; LY 2874455; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; GKJCVYLDJWTWQU-CXLRFSCWSA-N; SCHEMBL298446; SCHEMBL298445; QCR-90; GTPL8104; DTXSID20154776; MolPort-044-724-281; MolPort-023-219-117; EX-A1340; BCP04756; ZINC73069242; BDBM50189781; 2529AH; s7057; AKOS027251051
DMZ0DMY CP Lilly
DMZ0DMY DT Small molecular drug
DMZ0DMY PC 46944259
DMZ0DMY MW 444.3
DMZ0DMY FM C21H19Cl2N5O2
DMZ0DMY IC InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1
DMZ0DMY CS C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO
DMZ0DMY IK GKJCVYLDJWTWQU-CXLRFSCWSA-N
DMZ0DMY IU 2-[4-[(E)-2-[5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol
DMZ0DMY CA CAS 1254473-64-7
DMZ0DMY DE Solid tumour/cancer
DMQV1OU ID DMQV1OU
DMQV1OU DN LY-2875358
DMQV1OU HS Phase 2
DMQV1OU SN C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly
DMQV1OU CP Eli lilly
DMQV1OU DT Antibody
DMQV1OU DE Solid tumour/cancer
DMV14LM ID DMV14LM
DMV14LM DN LY2886721
DMV14LM HS Phase 2
DMV14LM SN LY2886721; 1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475
DMV14LM CP Lilly
DMV14LM DT Small molecular drug
DMV14LM PC 49837968
DMV14LM MW 390.4
DMV14LM FM C18H16F2N4O2S
DMV14LM IC InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1
DMV14LM CS C1[C@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N
DMV14LM IK NIDRNVHMMDAAIK-YPMLDQLKSA-N
DMV14LM IU N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide
DMV14LM CA CAS 1262036-50-9
DMV14LM DE Alzheimer disease
DMRDEKZ ID DMRDEKZ
DMRDEKZ DN LY2928057
DMRDEKZ HS Phase 2
DMRDEKZ CP Lilly
DMRDEKZ DE Anaemia
DM4N6EK ID DM4N6EK
DM4N6EK DN LY293558
DM4N6EK HS Phase 2
DM4N6EK SN Tezampanel; 154652-83-2; LY-293558; LY293558; Ted-isoquinoline-3-cooh; LY 293558; UNII-GA36S2O9C2; CHEMBL14935; GA36S2O9C2; 150131-78-5; Decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-3-isoquinolinecarboxylic acid; 6-(2-(1H-Tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S,4aR,6R,8aR)-; 3-Isoquinolinecarboxylic acid, decahydro-6-(2-(1H-tetrazol-5-yl)ethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; Tezampanel [INN]
DM4N6EK CP Eli Lilly
DM4N6EK TC Analgesics
DM4N6EK DT Small molecular drug
DM4N6EK PC 127894
DM4N6EK MW 279.34
DM4N6EK FM C13H21N5O2
DM4N6EK IC InChI=1S/C13H21N5O2/c19-13(20)11-6-10-5-8(1-3-9(10)7-14-11)2-4-12-15-17-18-16-12/h8-11,14H,1-7H2,(H,19,20)(H,15,16,17,18)/t8-,9+,10-,11+/m1/s1
DM4N6EK CS C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CCC3=NNN=N3)C(=O)O
DM4N6EK IK ZXFRFPSZAKNPQQ-YTWAJWBKSA-N
DM4N6EK IU (3S,4aR,6R,8aR)-6-[2-(2H-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DM4N6EK CA CAS 154652-83-2
DM4N6EK DE Pain
DMB5L6Q ID DMB5L6Q
DMB5L6Q DN LY-2940094
DMB5L6Q HS Phase 2
DMB5L6Q CP Eli Lilly & Co
DMB5L6Q PC 52914971
DMB5L6Q MW 481
DMB5L6Q FM C22H23ClF2N4O2S
DMB5L6Q IC InChI=1S/C22H23ClF2N4O2S/c1-14-16(11-29(27-14)20-15(12-30)3-2-6-26-20)10-28-7-4-21(5-8-28)19-17(9-18(23)32-19)22(24,25)13-31-21/h2-3,6,9,11,30H,4-5,7-8,10,12-13H2,1H3
DMB5L6Q CS CC1=NN(C=C1CN2CCC3(CC2)C4=C(C=C(S4)Cl)C(CO3)(F)F)C5=C(C=CC=N5)CO
DMB5L6Q IK NKQHBJNRBKHUQR-UHFFFAOYSA-N
DMB5L6Q IU [2-[4-[(2-chloro-4,4-difluorospiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]pyridin-3-yl]methanol
DMB5L6Q CA CAS 1307245-86-8
DMB5L6Q DE Major depressive disorder
DML6XWR ID DML6XWR
DML6XWR DN LY2944876
DML6XWR HS Phase 2
DML6XWR PC 121494121
DML6XWR MW 405.5
DML6XWR FM C16H27N3O7S
DML6XWR IC InChI=1S/C16H27N3O7S/c1-25-7-8-26-6-2-4-18-13(20)3-5-19-14(21)9-12(15(19)22)27-10-11(17)16(23)24/h11-12H,2-10,17H2,1H3,(H,18,20)(H,23,24)/t11-,12?/m0/s1
DML6XWR CS COCCOCCCNC(=O)CCN1C(=O)CC(C1=O)SC[C@@H](C(=O)O)N
DML6XWR IK DLVAZTPQKCTPLB-PXYINDEMSA-N
DML6XWR IU (2R)-2-amino-3-[1-[3-[3-(2-methoxyethoxy)propylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
DML6XWR CA CAS 1492924-65-8
DML6XWR DE Diabetic complication
DMRVEHY ID DMRVEHY
DMRVEHY DN LY3012212
DMRVEHY HS Phase 2
DMRVEHY SN Icrucumab
DMRVEHY CP Lilly
DMRVEHY DE Bladder cancer; Arteriosclerosis
DMFMKQ3 ID DMFMKQ3
DMFMKQ3 DN LY3015014
DMFMKQ3 HS Phase 2
DMFMKQ3 CP Eli lilly
DMFMKQ3 DT Antibody
DMFMKQ3 DE Cardiovascular disease
DMD9KYF ID DMD9KYF
DMD9KYF DN LY3023414
DMD9KYF HS Phase 2
DMD9KYF CP Lilly
DMD9KYF PC 57519748
DMD9KYF MW 406.5
DMD9KYF FM C23H26N4O3
DMD9KYF IC InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1
DMD9KYF CS C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC
DMD9KYF IK ACCFLVVUVBJNGT-AWEZNQCLSA-N
DMD9KYF IU 8-[5-(2-hydroxypropan-2-yl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methylimidazo[4,5-c]quinolin-2-one
DMD9KYF CA CAS 1386874-06-1
DMD9KYF DE Solid tumour/cancer; Prostate cancer
DMDFZK8 ID DMDFZK8
DMDFZK8 DN LY3113593
DMDFZK8 HS Phase 2
DMDFZK8 CP Eli Lilly
DMDFZK8 DT Antibody
DMDFZK8 DE Anaemia
DMAC457 ID DMAC457
DMAC457 DN LY3127804
DMAC457 HS Phase 2
DMAC457 TC Antiviral Agents
DMAC457 DT Monoclonal antibody
DMAC457 DE Coronavirus Disease 2019 (COVID-19)
DM7IFNB ID DM7IFNB
DM7IFNB DN LY3202626
DM7IFNB HS Phase 2
DM7IFNB CP Eli Lilly Indianapolis, IN
DM7IFNB DE Alzheimer disease
DMGMC8H ID DMGMC8H
DMGMC8H DN LY333531
DMGMC8H HS Phase 2
DMGMC8H SN Ruboxistaurin; 169939-94-0; LY-333531; Ruboxistaurin [INN]; LY 333531; UNII-721809WQCP; 721809WQCP; K00587a; 13-((Dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione; CHEMBL432130; (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione; Br-WR99210
DMGMC8H DT Small molecular drug
DMGMC8H PC 153999
DMGMC8H MW 468.5
DMGMC8H FM C28H28N4O3
DMGMC8H IC InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1
DMGMC8H CS CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
DMGMC8H IK ZCBUQCWBWNUWSU-SFHVURJKSA-N
DMGMC8H IU (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
DMGMC8H CA CAS 169939-94-0
DMGMC8H DE Solid tumour/cancer
DM43O9N ID DM43O9N
DM43O9N DN LY-334370
DM43O9N HS Phase 2
DM43O9N SN LY334370; LY-334370; 182563-08-2; UNII-5Q7I1WL2UY; 5Q7I1WL2UY; LY 334370; CHEMBL101690; LY-334,370; 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide; 4-Fluoro-N-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-benzamide; 4-Fluoro-N-(3-(1-methylpiperidin-4-yl)-1H-indol-5-yl)benzamide; AC1NSKBH; GTPL20; GTPL151; SCHEMBL6911508; DTXSID40415518; ZINC1488294; BCP29131; BDBM50130461; NCGC00378776-02; [3H]LY334370; HY-103107; CS-0025021; L000364; 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1h-indol-5-yl]-benzamide
DM43O9N DT Small molecular drug
DM43O9N PC 5311258
DM43O9N MW 351.4
DM43O9N FM C21H22FN3O
DM43O9N IC InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)
DM43O9N CS CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F
DM43O9N IK MDMJLMDBRQXOOI-UHFFFAOYSA-N
DM43O9N IU 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
DM43O9N CA CAS 182563-08-2
DM43O9N DE Migraine
DMD09CT ID DMD09CT
DMD09CT DN LY-362884
DMD09CT HS Phase 2
DMD09CT CP Eli Lilly
DMD09CT PC 9870239
DMD09CT MW 491.5
DMD09CT FM C26H29N5O5
DMD09CT IC InChI=1S/C26H29N5O5/c1-26(2,29-14-18(32)15-35-21-5-3-4-20-23(21)31-25(34)30-20)12-16-6-9-19(10-7-16)36-22-11-8-17(13-28-22)24(27)33/h3-11,13,18,29,32H,12,14-15H2,1-2H3,(H2,27,33)(H2,30,31,34)
DMD09CT CS CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NCC(COC3=CC=CC4=C3NC(=O)N4)O
DMD09CT IK RLYDBONATWKYQX-UHFFFAOYSA-N
DMD09CT IU 6-[4-[2-[[2-hydroxy-3-[(2-oxo-1,3-dihydrobenzimidazol-4-yl)oxy]propyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide
DMD09CT DE Type-2 diabetes; Obesity
DMZCU7I ID DMZCU7I
DMZCU7I DN LY-377604
DMZCU7I HS Phase 2
DMZCU7I SN Ethanolamine analogs, Lilly; Obesity therapeutics, Lilly; Beta-3 adrenoceptor agonists, Lilly
DMZCU7I CP Eli Lilly & Co
DMZCU7I DT Small molecular drug
DMZCU7I PC 9849699
DMZCU7I MW 524.6
DMZCU7I FM C31H32N4O4
DMZCU7I IC InChI=1S/C31H32N4O4/c1-31(2,16-20-10-13-23(14-11-20)39-28-15-12-21(17-33-28)30(32)37)34-18-22(36)19-38-27-9-5-8-26-29(27)24-6-3-4-7-25(24)35-26/h3-15,17,22,34-36H,16,18-19H2,1-2H3,(H2,32,37)/t22-/m0/s1
DMZCU7I CS CC(C)(CC1=CC=C(C=C1)OC2=NC=C(C=C2)C(=O)N)NC[C@@H](COC3=CC=CC4=C3C5=CC=CC=C5N4)O
DMZCU7I IK RBSGUQYXRDKPAE-QFIPXVFZSA-N
DMZCU7I IU 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide
DMZCU7I CA CAS 204592-94-9
DMZCU7I DE Obesity
DM8OG0J ID DM8OG0J
DM8OG0J DN LY-517717
DM8OG0J HS Phase 2
DM8OG0J SN SCHEMBL676862
DM8OG0J CP Eli Lilly
DM8OG0J DT Small molecular drug
DM8OG0J PC 9939865
DM8OG0J MW 459.6
DM8OG0J FM C27H33N5O2
DM8OG0J IC InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1
DM8OG0J CS CN1CCC(CC1)N2CCN(CC2)C(=O)[C@@H](C3=CC=CC=C3)NC(=O)C4=CC5=C(C=C4)C=CN5
DM8OG0J IK VYNKVNDKAOGAAQ-RUZDIDTESA-N
DM8OG0J IU N-[(1R)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1H-indole-6-carboxamide
DM8OG0J CA CAS 313489-71-3
DM8OG0J DE Thrombosis
DMBM2I9 ID DMBM2I9
DMBM2I9 DN LY-518674
DMBM2I9 HS Phase 2
DMBM2I9 SN LY-674; 2-Methyl-2-[4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl]phenoxy]propionic acid
DMBM2I9 CP Eli Lilly
DMBM2I9 DT Small molecular drug
DMBM2I9 PC 135449333
DMBM2I9 MW 409.5
DMBM2I9 FM C23H27N3O4
DMBM2I9 IC InChI=1S/C23H27N3O4/c1-16-7-9-18(10-8-16)15-26-22(29)24-20(25-26)6-4-5-17-11-13-19(14-12-17)30-23(2,3)21(27)28/h7-14H,4-6,15H2,1-3H3,(H,27,28)(H,24,25,29)
DMBM2I9 CS CC1=CC=C(C=C1)CN2C(=O)NC(=N2)CCCC3=CC=C(C=C3)OC(C)(C)C(=O)O
DMBM2I9 IK PNHFDVSKDSLUFH-UHFFFAOYSA-N
DMBM2I9 IU 2-methyl-2-[4-[3-[1-[(4-methylphenyl)methyl]-5-oxo-4H-1,2,4-triazol-3-yl]propyl]phenoxy]propanoic acid
DMBM2I9 CA CAS 425671-29-0
DMBM2I9 DE Diabetic complication
DMMSBW5 ID DMMSBW5
DMMSBW5 DN LY-545694
DMMSBW5 HS Phase 2
DMMSBW5 SN Lead iGluR5 antagonist (pain), Eli Lilly
DMMSBW5 CP Eli Lilly & Co
DMMSBW5 DE Neuropathic pain
DMP05GL ID DMP05GL
DMP05GL DN LYC-30937
DMP05GL HS Phase 2
DMP05GL CP Lycera Ann Arbor, MI
DMP05GL DE Plaque psoriasis; Ulcerative colitis
DMV8WU9 ID DMV8WU9
DMV8WU9 DN LYC-55716
DMV8WU9 HS Phase 2
DMV8WU9 SN Cintirorgon; UNII-LPN433P0EA; LPN433P0EA; 2055536-64-4; Cintirorgon [INN]; cintirorgon (proposed INN); SCHEMBL18302870; GTPL10045; LYC55716; BCP28882; EX-A2635; LYC 55716; CS-7496; compound 32J [WO2016201225A1]; HY-104037; 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
DMV8WU9 CP Lycera Ann Arbor, MI
DMV8WU9 PC 124126348
DMV8WU9 MW 603.5
DMV8WU9 FM C27H23F6NO6S
DMV8WU9 IC InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1
DMV8WU9 CS CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O
DMV8WU9 IK GULSIMHVQYBADX-FQEVSTJZSA-N
DMV8WU9 IU 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
DMV8WU9 CA CAS 2055536-64-4
DMV8WU9 DE Solid tumour/cancer; Non-small-cell lung cancer
DM23Y6K ID DM23Y6K
DM23Y6K DN LYS228
DM23Y6K HS Phase 2
DM23Y6K SN 1810051-96-7 (free acid); 1-((((Z)-1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropane-1-carboxylic acid; SCHEMBL17094584; 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid; l-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid
DM23Y6K DT Small molecular drug
DM23Y6K PC 118380292
DM23Y6K MW 518.5
DM23Y6K FM C16H18N6O10S2
DM23Y6K IC InChI=1S/C16H18N6O10S2/c17-14-18-7(6-33-14)9(20-32-16(1-2-16)13(25)26)11(23)19-10-8(5-21-3-4-31-15(21)27)22(12(10)24)34(28,29)30/h6,8,10H,1-5H2,(H2,17,18)(H,19,23)(H,25,26)(H,28,29,30)/b20-9+/t8-,10+/m1/s1
DM23Y6K CS C1CC1(C(=O)O)O/N=C(\\C2=CSC(=N2)N)/C(=O)N[C@H]3[C@H](N(C3=O)S(=O)(=O)O)CN4CCOC4=O
DM23Y6K IK FWTGYTRQUBRVDW-UWGJAOEXSA-N
DM23Y6K IU 1-[(E)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-[[(3S,4R)-2-oxo-4-[(2-oxo-1,3-oxazolidin-3-yl)methyl]-1-sulfoazetidin-3-yl]amino]ethylidene]amino]oxycyclopropane-1-carboxylic acid
DM23Y6K DE Urinary tract infection
DML0I2Z ID DML0I2Z
DML0I2Z DN M118
DML0I2Z HS Phase 2
DML0I2Z SN Adomiparin
DML0I2Z CP Momenta Pharmaceuticals
DML0I2Z DT Small molecular drug
DML0I2Z PC 21156139
DML0I2Z MW 801.9
DML0I2Z FM C34H42Cl4N8O2Zn
DML0I2Z IC InChI=1S/2C17H20N4O.4ClH.Zn/c2*1-4-21(5-2)11-6-7-14-15(8-11)22-17-10(3)12(18)9-13(19)16(17)20-14;;;;;/h2*6-9H,4-5H2,1-3H3,(H3,18,19);4*1H;/q;;;;;;+2/p-2
DML0I2Z CS CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.CC[N+](=C1C=CC2=NC3=C(C=C(C(=C3OC2=C1)C)N)N)CC.Cl[Zn-2](Cl)(Cl)Cl
DML0I2Z IK JJKNZNYHIUJGIC-UHFFFAOYSA-L
DML0I2Z IU (7,9-diamino-6-methylphenoxazin-3-ylidene)-diethylazanium;tetrachlorozinc(2-)
DML0I2Z DE Acute coronary syndrome
DMZ7YX3 ID DMZ7YX3
DMZ7YX3 DN M-16209
DMZ7YX3 HS Phase 2
DMZ7YX3 SN 1-(3-Bromo-benzo[b]furan-2-ylsulfonyl)imidazolidine-2,4-dione; 1-(3-Bromobenzo[b]furan-2-ylsulfonyl)hydantoin
DMZ7YX3 DT Small molecular drug
DMZ7YX3 PC 164260
DMZ7YX3 MW 359.15
DMZ7YX3 FM C11H7BrN2O5S
DMZ7YX3 IC InChI=1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
DMZ7YX3 CS C1C(=O)NC(=O)N1S(=O)(=O)C2=C(C3=CC=CC=C3O2)Br
DMZ7YX3 IK ZJSUDHQFSBHLDV-UHFFFAOYSA-N
DMZ7YX3 IU 1-[(3-bromo-1-benzofuran-2-yl)sulfonyl]imidazolidine-2,4-dione
DMZ7YX3 CA CAS 128851-36-5
DMZ7YX3 DE Diabetic complication
DMC5MQD ID DMC5MQD
DMC5MQD DN M2951
DMC5MQD HS Phase 2
DMC5MQD SN evobrutinib; Evobrutinib; UNII-ZA45457L1K; ZA45457L1K; 1415823-73-2; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one; 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one; Evobrutinib [INN]; GTPL9752; SCHEMBL14165673; QUIWHXQETADMGN-UHFFFAOYSA-N; MSC2364447C; MSC-2364447C; ZINC205623965; AKOS032954004; CS-6303; MSC 2364447; HY-101215; A250 [WO2012170976]; N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine; 1-(4-((6-Amin
DMC5MQD CP EMD Serono Rockland, MA
DMC5MQD PC 71479709
DMC5MQD MW 429.5
DMC5MQD FM C25H27N5O2
DMC5MQD IC InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
DMC5MQD CS C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
DMC5MQD IK QUIWHXQETADMGN-UHFFFAOYSA-N
DMC5MQD IU 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
DMC5MQD CA CAS 1415823-73-2
DMC5MQD DE Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
DMJCULI ID DMJCULI
DMJCULI DN M7824
DMJCULI HS Phase 2
DMJCULI CP EMD SeronoRockland, MA
DMJCULI DT Antibody
DMJCULI DE Solid tumour/cancer
DMQOBH4 ID DMQOBH4
DMQOBH4 DN mab 1-7F9
DMQOBH4 HS Phase 2
DMQOBH4 CP CeMines
DMQOBH4 DT Antibody
DMQOBH4 DE Multiple myeloma
DMBYDNE ID DMBYDNE
DMBYDNE DN Managlinat dialanetil
DMBYDNE HS Phase 2
DMBYDNE SN CS-917; GP-3034; MB-05032; MB-06322; MB-06633; MB-6322; R-132917; Type 2 diabetes therapeutic, Gensia/Sankyo; Type 2 diabetes therapeutic, SICOR/Sankyo; Diabetes therapeutics, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, Gensia/Sankyo/Daiichi Sankyo; Purine nucleotide analogs, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, SICOR/Sankyo/Daiichi Sankyo
DMBYDNE CP Metabasis Therapeutics Inc
DMBYDNE PC 73014123
DMBYDNE MW 484.6
DMBYDNE FM C21H33N4O5PS
DMBYDNE IC InChI=1S/C21H33N4O5PS/c1-7-28-19(26)13(5)24-31(25-14(6)20(27)29-8-2)17-10-9-15(30-17)18-16(11-12(3)4)32-21(22)23-18/h9-10,12-14,24-25H,7-8,11H2,1-6H3,(H2,22,23)/t13-,14-/m0/s1
DMBYDNE CS CCOC(=O)[C@H](C)NP(C1=CC=C(O1)C2=C(SC(=N2)N)CC(C)C)N[C@@H](C)C(=O)OCC
DMBYDNE IK JGCMEVUWRCNKKE-KBPBESRZSA-N
DMBYDNE IU ethyl (2S)-2-[[[5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphanyl]amino]propanoate
DMBYDNE DE Type-2 diabetes
DMB4A8I ID DMB4A8I
DMB4A8I DN MANOALIDE
DMB4A8I HS Phase 2
DMB4A8I SN manoalide; UNII-E1DK0157K9; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; AC1O5NJS; SCHEMBL20551728; MolPort-020-000-975
DMB4A8I DT Small molecular drug
DMB4A8I PC 6437368
DMB4A8I MW 416.5
DMB4A8I FM C25H36O5
DMB4A8I IC InChI=1S/C25H36O5/c1-16(10-12-20-17(2)8-6-14-25(20,3)4)7-5-9-18-11-13-21(29-23(18)27)19-15-22(26)30-24(19)28/h7,11,15,21,23-24,27-28H,5-6,8-10,12-14H2,1-4H3/b16-7+/t21-,23-,24-/m1/s1
DMB4A8I CS CC1=C(C(CCC1)(C)C)CC/C(=C/CCC2=CC[C@@H](O[C@H]2O)C3=CC(=O)O[C@H]3O)/C
DMB4A8I IK FGJIDQWRRLDGDB-CPIXEKRISA-N
DMB4A8I IU (2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one
DMB4A8I CA CAS 75088-80-1
DMB4A8I CB CHEBI:66666
DMB4A8I DE Arthritis
DMGQ175 ID DMGQ175
DMGQ175 DN Mapatumumab
DMGQ175 HS Phase 2
DMGQ175 CP Human Genome Sciences
DMGQ175 DT Monoclonal antibody
DMGQ175 DE Non-small-cell lung cancer
DMDTI0L ID DMDTI0L
DMDTI0L DN Masilukast
DMDTI0L HS Phase 2
DMDTI0L SN D-3523; MCC-847; ZD-3523
DMDTI0L CP Zeneca Group plc
DMDTI0L DT Small molecular drug
DMDTI0L PC 204056
DMDTI0L MW 615.7
DMDTI0L FM C31H32F3N3O5S
DMDTI0L IC InChI=1S/C31H32F3N3O5S/c1-19(16-31(32,33)34)17-35-29(38)22-11-12-26-25(14-22)24(18-37(26)3)13-21-9-10-23(15-27(21)42-4)30(39)36-43(40,41)28-8-6-5-7-20(28)2/h5-12,14-15,18-19H,13,16-17H2,1-4H3,(H,35,38)(H,36,39)/t19-/m1/s1
DMDTI0L CS CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)C(=O)NC[C@H](C)CC(F)(F)F)C)OC
DMDTI0L IK ULMFXAMQUGLVGA-LJQANCHMSA-N
DMDTI0L IU 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-N-[(2R)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide
DMDTI0L CA CAS 136564-68-6
DMDTI0L DE Asthma
DM2458E ID DM2458E
DM2458E DN Matuzumab
DM2458E HS Phase 2
DM2458E SN EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals
DM2458E CP Merck KgaA; Merck KGaA
DM2458E DT Antibody
DM2458E SQ 3c08_H|Fab72000|Humanized||VH-CH1 (VH(1-115)+CH1(116-213))|||||||223||||MW 24063.8|MW 24063.8|: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS >3c08_L|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-101)+C-KAPPA(102-206))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE >3c09_B|Fab72000|Humanized||L-KAPPA (V-KAPPA(1-106)+C-KAPPA(107-175))|||||||212||||MW 23214.7|MW 23214.7|DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE >3c09_C|Fab72000|Humanized||VH-CH1 (VH(1-121)+CH1(122-191))|||||||223||||MW 24019.8|MW 24019.8|QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYAGRYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
DM2458E DE Gastric adenocarcinoma
DMMVFRC ID DMMVFRC
DMMVFRC DN Mavrilimumab
DMMVFRC HS Phase 2
DMMVFRC CP MedImmune
DMMVFRC DT Antibody
DMMVFRC DE Rheumatoid arthritis
DMWLIPJ ID DMWLIPJ
DMWLIPJ DN MAXY-G34
DMWLIPJ HS Phase 2
DMWLIPJ SN Maxy-G21; MAXY-G-CSF; G-CSF agonist (neutropenia, leukopenia), Maxygen
DMWLIPJ CP Maxygen
DMWLIPJ DE Neutropenia
DMJKHVX ID DMJKHVX
DMJKHVX DN Mazapertine succinate
DMJKHVX HS Phase 2
DMJKHVX SN RWJ-37796
DMJKHVX CP RW Johnson Pharmaceutical Research Institute
DMJKHVX DT Small molecular drug
DMJKHVX PC 60819
DMJKHVX MW 539.7
DMJKHVX FM C30H41N3O6
DMJKHVX IC InChI=1S/C26H35N3O2.C4H6O4/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29;5-3(6)1-2-4(7)8/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3;1-2H2,(H,5,6)(H,7,8)
DMJKHVX CS CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC(=CC=C3)C(=O)N4CCCCC4.C(CC(=O)O)C(=O)O
DMJKHVX IK WAHFGTZTVZRLEY-UHFFFAOYSA-N
DMJKHVX IU butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMJKHVX CA CAS 134208-18-7
DMJKHVX DE Psychotic disorder
DMHU8SJ ID DMHU8SJ
DMHU8SJ DN MB07803
DMHU8SJ HS Phase 2
DMHU8SJ SN MB-07803; 882757-24-6; UNII-GG81XF45C2; MB 07803; GG81XF45C2; SCHEMBL14255484; DTXSID90236932; ACT04837; SB17400; DB05053; HY-16309; CS-0006389; Alanine, N,N'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, diethyl ester; n,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) diethyl ester
DMHU8SJ CP Metabasis Therape
DMHU8SJ DT Small molecular drug
DMHU8SJ PC 24770445
DMHU8SJ MW 556.6
DMHU8SJ FM C24H37N4O7PS
DMHU8SJ IC InChI=1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32)
DMHU8SJ CS CCOC(=O)C(C)(C)NP(=O)(C1=CC=C(O1)C2=C(SC(=N2)N)C(=O)C(C)(C)C)NC(C)(C)C(=O)OCC
DMHU8SJ IK CTKZZUXRWBCFEI-UHFFFAOYSA-N
DMHU8SJ IU ethyl 2-[[[5-[2-amino-5-(2,2-dimethylpropanoyl)-1,3-thiazol-4-yl]furan-2-yl]-[(1-ethoxy-2-methyl-1-oxopropan-2-yl)amino]phosphoryl]amino]-2-methylpropanoate
DMHU8SJ CA CAS 882757-24-6
DMHU8SJ DE Type-2 diabetes
DM6JTSZ ID DM6JTSZ
DM6JTSZ DN MB-07811
DM6JTSZ HS Phase 2
DM6JTSZ SN CHEMBL471897; MB-07811; SCHEMBL3147495; BDBM50242404
DM6JTSZ CP Ligand Pharmaceuticals
DM6JTSZ DT Small molecular drug
DM6JTSZ PC 15942005
DM6JTSZ MW 515
DM6JTSZ FM C28H32ClO5P
DM6JTSZ IC InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1
DM6JTSZ CS CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl
DM6JTSZ IK LGGPZDRLTDGYSQ-JADSYQMUSA-N
DM6JTSZ IU 4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol
DM6JTSZ CA CAS 852948-13-1
DM6JTSZ DE Hyperlipidaemia
DMLPNVS ID DMLPNVS
DMLPNVS DN MB-102
DMLPNVS HS Phase 2
DMLPNVS SN Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0
DMLPNVS CP Mustang Bio New York, NY
DMLPNVS PC 53389120
DMLPNVS MW 372.29
DMLPNVS FM C12H16N6O8
DMLPNVS IC InChI=1S/C12H16N6O8/c13-7-5(9(21)15-3(1-19)11(23)24)17-8(14)6(18-7)10(22)16-4(2-20)12(25)26/h3-4,19-20H,1-2H2,(H2,14,17)(H2,13,18)(H,15,21)(H,16,22)(H,23,24)(H,25,26)/t3-,4-/m1/s1
DMLPNVS CS C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O
DMLPNVS IK XHNJXRDGTITISI-QWWZWVQMSA-N
DMLPNVS IU (2R)-2-[[3,6-diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid
DMLPNVS CA CAS 1313706-17-0
DMLPNVS DE Acute myeloid leukaemia; Acute kidney injury
DM3RBJW ID DM3RBJW
DM3RBJW DN MB-11055
DM3RBJW HS Phase 2
DM3RBJW SN Cryptotanshinone, MD BioAlpha; Cryptotanshinone, Mazence; AMP activated protein kinase stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; AMPK stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence; Lipid metabolism stimulator (liver cirrhosis/steatosis/steatohepatitis), Mazence
DM3RBJW CP Mazence Inc
DM3RBJW DE Fatty liver disease
DMRSN2C ID DMRSN2C
DMRSN2C DN MB-12066
DMRSN2C HS Phase 2
DMRSN2C SN B-lapachone (obesity), Mazence; Beta-lapachone (obesity), Mazence
DMRSN2C CP Mazence Inc
DMRSN2C DE Obesity
DM0AOID ID DM0AOID
DM0AOID DN MB-CART19.1
DM0AOID HS Phase 2
DM0AOID CP Shanghai Children's Medical Center
DM0AOID DT CAR T Cell Therapy
DM0AOID DE Precursor B-lymphoblastic neoplasm
DMJVU7Y ID DMJVU7Y
DMJVU7Y DN MBL-HCV1
DMJVU7Y HS Phase 2
DMJVU7Y SN Anti-HCV antibody, MassBiologics
DMJVU7Y CP Massbiologics
DMJVU7Y DE Hepatitis C virus infection
DMQMTO1 ID DMQMTO1
DMQMTO1 DN MBX-2044
DMQMTO1 HS Phase 2
DMQMTO1 SN MBX-102 analogs, Metabolex
DMQMTO1 CP Metabolex Inc
DMQMTO1 DE Type-2 diabetes
DM0W3R7 ID DM0W3R7
DM0W3R7 DN MCLA-128
DM0W3R7 HS Phase 2
DM0W3R7 CP MerusUtrecht, Netherlands
DM0W3R7 DE Breast cancer
DM0CL4I ID DM0CL4I
DM0CL4I DN MCS-110
DM0CL4I HS Phase 2
DM0CL4I SN Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis
DM0CL4I CP Novartis pharmaceuticals
DM0CL4I DE Bone metastases; Advanced malignancy; Breast cancer; Tenosynovial giant cell tumour; Triple negative breast cancer
DMX4U0B ID DMX4U0B
DMX4U0B DN MCS-18
DMX4U0B HS Phase 2
DMX4U0B SN Helleborus purpurascens-derived anti-inflammatory analgesic (injection, autoimmune disease), DoNatur
DMX4U0B CP DoNatur GmbH
DMX4U0B DE Autoimmune diabetes
DMDR2SZ ID DMDR2SZ
DMDR2SZ DN MCT-125
DMDR2SZ HS Phase 2
DMDR2SZ CP Laxdale Ltd
DMDR2SZ DE Fatigue
DM5DSGJ ID DM5DSGJ
DM5DSGJ DN MD-0727
DM5DSGJ HS Phase 2
DM5DSGJ CP Ironwood Pharmaceuticals
DM5DSGJ PC 11586434
DM5DSGJ MW 193.2
DM5DSGJ FM C10H11NO3
DM5DSGJ IC InChI=1S/C10H11NO3/c1-3-14-10(13)9-6-4-5-8(11-9)7(2)12/h4-6H,3H2,1-2H3
DM5DSGJ CS CCOC(=O)C1=CC=CC(=N1)C(=O)C
DM5DSGJ IK COYXIUHSZNHMAS-UHFFFAOYSA-N
DM5DSGJ IU ethyl 6-acetylpyridine-2-carboxylate
DM5DSGJ CA CAS 114578-70-0
DM5DSGJ DE Hypercholesterolaemia
DM9FXU7 ID DM9FXU7
DM9FXU7 DN MDL-27192
DM9FXU7 HS Phase 2
DM9FXU7 SN 3-(4-Chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5(4H)-one; 5-(4-Chlorophenyl)-4-ethyl-3,4-dihydro-2H-1,2,4-triazol-3-one
DM9FXU7 PC 35793
DM9FXU7 MW 223.66
DM9FXU7 FM C10H10ClN3O
DM9FXU7 IC InChI=1S/C10H10ClN3O/c1-2-14-9(12-13-10(14)15)7-3-5-8(11)6-4-7/h3-6H,2H2,1H3,(H,13,15)
DM9FXU7 CS CCN1C(=NNC1=O)C2=CC=C(C=C2)Cl
DM9FXU7 IK PXINDYJACXPZIN-UHFFFAOYSA-N
DM9FXU7 IU 3-(4-chlorophenyl)-4-ethyl-1H-1,2,4-triazol-5-one
DM9FXU7 CA CAS 31409-32-2
DM9FXU7 DE Epileptic seizures
DMCK8SX ID DMCK8SX
DMCK8SX DN MDX-1097
DMCK8SX HS Phase 2
DMCK8SX SN CKap; MKap; K-1-21; Mab therapy, Immune System therapeutics/Medarex; Monoclonal antibody (multiple myeloma, humanized/murine/chimeric), PacMab/Medarex
DMCK8SX CP Immune System Therapeutics Ltd
DMCK8SX DT Antibody
DMCK8SX DE Haematological malignancy
DM0EZWI ID DM0EZWI
DM0EZWI DN MDX-1100
DM0EZWI HS Phase 2
DM0EZWI CP Medarex
DM0EZWI DT Antibody
DM0EZWI DE Crohn disease
DMKMSC4 ID DMKMSC4
DMKMSC4 DN MDX-1342
DMKMSC4 HS Phase 2
DMKMSC4 SN Anti-CD19 (cancer), MDX/BMS; Anti-CD19 antibody (cancer), Medarex/BMS
DMKMSC4 CP Medarex
DMKMSC4 DT Antibody
DMKMSC4 DE leukaemia
DMO84TL ID DMO84TL
DMO84TL DN ME-3407
DMO84TL HS Phase 2
DMO84TL SN EF-4040; 2-(Butoxycarbonylmethylsulfinyl)thiazolo[5,4-b]pyridine; 2-(Thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetic acid butyl ester
DMO84TL DT Small molecular drug
DMO84TL PC 6918179
DMO84TL MW 298.4
DMO84TL FM C12H14N2O3S2
DMO84TL IC InChI=1S/C12H14N2O3S2/c1-2-3-7-17-10(15)8-19(16)12-14-9-5-4-6-13-11(9)18-12/h4-6H,2-3,7-8H2,1H3
DMO84TL CS CCCCOC(=O)CS(=O)C1=NC2=C(S1)N=CC=C2
DMO84TL IK BUXNKFNNJJTLOS-UHFFFAOYSA-N
DMO84TL IU butyl 2-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfinyl)acetate
DMO84TL DE Duodenal ulcer
DMX9Y7V ID DMX9Y7V
DMX9Y7V DN MEDETOMIDINE
DMX9Y7V HS Phase 2
DMX9Y7V DT Small molecular drug
DMX9Y7V PC 68602
DMX9Y7V MW 200.28
DMX9Y7V FM C13H16N2
DMX9Y7V IC InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)
DMX9Y7V CS CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C
DMX9Y7V IK CUHVIMMYOGQXCV-UHFFFAOYSA-N
DMX9Y7V IU 5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
DMX9Y7V CA CAS 86347-14-0
DMX9Y7V CB CHEBI:48552
DMX9Y7V DE Pain
DMSV60C ID DMSV60C
DMSV60C DN MEDI0382
DMSV60C HS Phase 2
DMSV60C SN Cotadutide; UNII-QL6A9B13HW; QL6A9B13HW; Cotadutide [INN]; Cotadutide [USAN]; MEDI-0382; MEDI 0382 [WHO-DD]; 1686108-82-6; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-(gamma-glupalmitoyl)-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp- Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly; Glycine, L-histidyl-L-seryl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-N6-(N-(1-oxotetradecyl)-L-gamma-glutamyl)-L-lysyl-L-seryl-L-alpha-glutamyl-L-tyrosyl-L-leucyl-L-alpha-aspartyl-L-seryl-L-alpha-glutamyl
DMSV60C CP MedImmune Gaithersburg, MD
DMSV60C PC 134694273
DMSV60C MW 3728
DMSV60C FM C167H252N42O55
DMSV60C IC InChI=1S/C167H252N42O55/c1-13-14-15-16-17-18-19-20-21-22-23-24-31-47-125(219)186-109(165(263)264)53-58-124(218)175-62-35-34-44-102(189-153(251)116(72-131(228)229)201-161(259)122(83-213)206-164(262)137(92(12)215)209-157(255)114(68-94-40-29-26-30-41-94)202-163(261)136(91(11)214)207-127(221)78-181-142(240)105(52-57-123(169)217)190-158(256)119(80-210)203-141(239)100(168)71-97-76-174-84-182-97)146(244)204-120(81-211)159(257)193-108(56-61-130(226)227)148(246)197-112(69-95-48-50-98(216)51-49-95)151(249)195-111(66-86(4)5)150(248)200-118(74-133(232)233)155(253)205-121(82-212)160(258)192-107(55-60-129(224)225)147(245)188-103(45-36-63-176-166(170)171)143(241)184-89(9)139(237)187-104(46-37-64-177-167(172)173)145(243)199-117(73-132(230)231)154(252)198-113(67-93-38-27-25-28-39-93)156(254)208-135(87(6)7)162(260)185-90(10)140(238)194-115(70-96-75-178-101-43-33-32-42-99(96)101)152(250)196-110(65-85(2)3)149(247)191-106(54-59-128(222)223)144(242)183-88(8)138(236)180-77-126(220)179-79-134(234)235/h25-30,32-33,38-43,48-51,75-76,84-92,100,102-122,135-137,178,210-216H,13-24,31,34-37,44-47,52-74,77-83,168H2,1-12H3,(H2,169,217)(H,174,182)(H,175,218)(H,179,220)(H,180,236)(H,181,240)(H,183,242)(H,184,241)(H,185,260)(H,186,219)(H,187,237)(H,188,245)(H,189,251)(H,190,256)(H,191,247)(H,192,258)(H,193,257)(H,194,238)(H,195,249)(H,196,250)(H,197,246)(H,198,252)(H,199,243)(H,200,248)(H,201,259)(H,202,261)(H,203,239)(H,204,244)(H,205,253)(H,206,262)(H,207,221)(H,208,254)(H,209,255)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,263,264)(H4,170,171,176)(H4,172,173,177)/t88-,89-,90-,91+,92+,100-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-/m0/s1
DMSV60C CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)N)C(=O)O
DMSV60C IK YEKUUBPJRPXMBM-PTCFZACGSA-N
DMSV60C IU (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DMSV60C CA CAS 1686108-82-6
DMSV60C DE Type-2 diabetes
DMOXKIC ID DMOXKIC
DMOXKIC DN MEDI3902
DMOXKIC HS Phase 2
DMOXKIC CP AstraZeneca
DMOXKIC DT Antibody
DMOXKIC DE Pseudomonas infection; Ventilator-associated pneumonia
DMDYVN8 ID DMDYVN8
DMDYVN8 DN MEDI-528
DMDYVN8 HS Phase 2
DMDYVN8 CP MedImmune
DMDYVN8 DT Monoclonal antibody
DMDYVN8 DE Asthma
DMPKWR3 ID DMPKWR3
DMPKWR3 DN MEDI-546
DMPKWR3 HS Phase 2
DMPKWR3 CP AstraZeneca
DMPKWR3 DE Ovarian cancer
DMBTVFE ID DMBTVFE
DMBTVFE DN MEDI-551
DMBTVFE HS Phase 2
DMBTVFE CP MedImmune
DMBTVFE DT Antibody
DMBTVFE DE Chronic lymphocytic leukaemia; Encephalopathy; Neuromyelitis optica
DMI9WVM ID DMI9WVM
DMI9WVM DN MEDI-575
DMI9WVM HS Phase 2
DMI9WVM CP MedImmune
DMI9WVM DT Antibody
DMI9WVM DE Glioblastoma multiforme
DMU4CS8 ID DMU4CS8
DMU4CS8 DN MEDI6012
DMU4CS8 HS Phase 2
DMU4CS8 SN RhLCAT; ACP-501
DMU4CS8 DE Acute coronary syndrome; Coronary artery disease
DMGD1YP ID DMGD1YP
DMGD1YP DN MEDI9929
DMGD1YP HS Phase 2
DMGD1YP CP AstraZeneca
DMGD1YP DE Asthma
DM2C1YN ID DM2C1YN
DM2C1YN DN MEGF0444A
DM2C1YN HS Phase 2
DM2C1YN CP Genentech
DM2C1YN DE Non-small-cell lung cancer; Metastatic colorectal cancer
DMHOF7T ID DMHOF7T
DMHOF7T DN MEHD-7945A
DMHOF7T HS Phase 2
DMHOF7T SN RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech
DMHOF7T CP Genentech Inc
DMHOF7T DE Colorectal cancer; Solid tumour/cancer
DMVJ6WS ID DMVJ6WS
DMVJ6WS DN Melogliptin
DMVJ6WS HS Phase 2
DMVJ6WS CP Glenmark pharma
DMVJ6WS PC 11623906
DMVJ6WS MW 320.37
DMVJ6WS FM C15H21FN6O
DMVJ6WS IC InChI=1S/C15H21FN6O/c16-12-4-14(5-17)22(8-12)15(23)6-19-13-2-1-11(3-13)7-21-10-18-9-20-21/h9-14,19H,1-4,6-8H2/t11-,12-,13+,14-/m0/s1
DMVJ6WS CS C1C[C@H](C[C@H]1CN2C=NC=N2)NCC(=O)N3C[C@H](C[C@H]3C#N)F
DMVJ6WS IK JSYGLDMGERSRPC-FQUUOJAGSA-N
DMVJ6WS IU (2S,4S)-4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile
DMVJ6WS CA CAS 868771-57-7
DMVJ6WS DE Type-2 diabetes
DMPNDYU ID DMPNDYU
DMPNDYU DN MEM-3454
DMPNDYU HS Phase 2
DMPNDYU CP Memory Pharmaceuticals
DMPNDYU DT Small molecular drug
DMPNDYU PC 10380472
DMPNDYU MW 306.79
DMPNDYU FM C15H19ClN4O
DMPNDYU IC InChI=1S/C15H18N4O.ClH/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19;/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18);1H/t13-;/m1./s1
DMPNDYU CS C1CN2CCC1[C@@H](C2)NC(=O)C3=NNC4=CC=CC=C43.Cl
DMPNDYU IK CMRLNEYJEPELSM-BTQNPOSSSA-N
DMPNDYU IU N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-1H-indazole-3-carboxamide;hydrochloride
DMPNDYU CA CAS 677305-02-1
DMPNDYU DE Schizophrenia
DMUMCWS ID DMUMCWS
DMUMCWS DN MEMP1972A
DMUMCWS HS Phase 2
DMUMCWS SN RG7449
DMUMCWS CP Genentech
DMUMCWS DE Allergic rhinitis; Asthma
DMIVR9K ID DMIVR9K
DMIVR9K DN MER-3001
DMIVR9K HS Phase 2
DMIVR9K SN Insulin B chain therapeutics (type 1 diabetes), Mercia Pharma/Joslin Diabetes Center
DMIVR9K CP Mercia Pharma Inc
DMIVR9K DE Type-1 diabetes; Type-2 diabetes
DM89QXT ID DM89QXT
DM89QXT DN MET409
DM89QXT HS Phase 2
DM89QXT CP Metacrine
DM89QXT DT Small molecular drug
DM89QXT DE Non-alcoholic steatohepatitis
DMNST69 ID DMNST69
DMNST69 DN Metaiodobenzylguanidine I-131
DMNST69 HS Phase 2
DMNST69 SN Azedra (TN)
DMNST69 CP Molecular Insights Pharmaceuticals
DMNST69 DT Small molecular drug
DMNST69 PC 71184
DMNST69 MW 279.09
DMNST69 FM C8H10IN3
DMNST69 IC InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)/i9+4
DMNST69 CS C1=CC(=CC(=C1)[131I])CN=C(N)N
DMNST69 IK PDWUPXJEEYOOTR-JRGAVVOBSA-N
DMNST69 IU 2-[(3-(131I)iodanylphenyl)methyl]guanidine
DMNST69 CA CAS 77679-27-7
DMNST69 CB CHEBI:135997
DMNST69 DE Neuroblastoma; Neuroendocrine cancer; Pheochromocytoma
DMSZFTP ID DMSZFTP
DMSZFTP DN Met-enkephalin
DMSZFTP HS Phase 2
DMSZFTP SN MET-enkephalin; H-Tyr-Gly-Gly-Phe-Met-OH; 58569-55-4; Tyr-Gly-Gly-Phe-Met-OH; METENKEFALIN; [Met]enkephalin; [5-Methionine]Enkephalin; TYR-GLY-GLY-PHE-MET; Enkephalin M; UNII-9JEZ9OD3AS; (Met5)-enkephalin; Lupex; 9JEZ9OD3AS; CHEMBL13786; CHEBI:6618; ENKEPHALIN, METHIONINE; Opioid growth factor; [Met5]-ENKEPHALIN; [Met5]Enkephalin acetate salt hydrate; Porcine beta-endorphin 1-5; (2S,5S,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-(2-(methylthio)ethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic
DMSZFTP DT Small molecular drug
DMSZFTP PC 443363
DMSZFTP MW 573.7
DMSZFTP FM C27H35N5O7S
DMSZFTP IC InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1
DMSZFTP CS CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMSZFTP IK YFGBQHOOROIVKG-FKBYEOEOSA-N
DMSZFTP IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMSZFTP CA CAS 58569-55-4
DMSZFTP CB CHEBI:6618
DMSZFTP DE Pain
DMS7FRI ID DMS7FRI
DMS7FRI DN Methanesulfonyl fluoride
DMS7FRI HS Phase 2
DMS7FRI SN Fluoride; Methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder)
DMS7FRI CP University of Texas
DMS7FRI DT Small molecular drug
DMS7FRI PC 11207
DMS7FRI MW 98.1
DMS7FRI FM CH3FO2S
DMS7FRI IC InChI=1S/CH3FO2S/c1-5(2,3)4/h1H3
DMS7FRI CS CS(=O)(=O)F
DMS7FRI IK KNWQLFOXPQZGPX-UHFFFAOYSA-N
DMS7FRI IU methanesulfonyl fluoride
DMS7FRI CA CAS 558-25-8
DMS7FRI DE Alzheimer disease
DMHSL87 ID DMHSL87
DMHSL87 DN Methoxyestradiol
DMHSL87 HS Phase 2
DMHSL87 SN SCHEMBL18733359; CHEMBL1473145; HMS3229K11
DMHSL87 DT Small molecular drug
DMHSL87 PC 129631909
DMHSL87 MW 302.4
DMHSL87 FM C19H26O3
DMHSL87 IC InChI=1S/C19H26O3/c1-19-8-7-14-13(15(19)5-6-17(19)21)4-3-11-9-12(20)10-16(22-2)18(11)14/h9-10,13-15,17,20-21H,3-8H2,1-2H3/t13-,14-,15-,17-,19-/m0/s1
DMHSL87 CS C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2O)CCC4=C3C(=CC(=C4)O)OC
DMHSL87 IK PJCUYTOXKIUJSL-SARNLOFESA-N
DMHSL87 IU (8R,9S,13S,14S,17S)-1-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM5GQD7 ID DM5GQD7
DM5GQD7 DN Metoprine
DM5GQD7 HS Phase 2
DM5GQD7 SN METOPRINE; Methodichlorophen; DDMP; 7761-45-7; Metoprine [USAN]; BW-197U; TCMDC-123931; NSC-19494; SK 5265; 5-(3,4-DICHLOROPHENYL)-6-METHYLPYRIMIDINE-2,4-DIAMINE; U 197; NSC7364; U-197; UNII-2L9RKX796Q; Metoprine (USAN); BW 50-197; METOPRINE, METHODICHLOROPHEN; 5-(3,4-Dichlorophenyl)-6-methyl-2,4-pyrimidinediamine; NSC 7364; 2,4-Pyrimidinediamine, 5-(3,4-dichlorophenyl)-6-methyl-; NSC 19494; BW50197; BRN 0223622; 5-(3,4-Dichlorphenyl)-6-methyl-2,4-pyrimidindiamin; 2,4-Diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine; MLS002701892; DDMP; BW 197 U; BW 1970; BW 197U; BW 50197; BW 50,197; 2,4-Diamino-5-(3',4'-dichlorophenyl)-6-methyl pyrimidine; Chloroaniline 1
DM5GQD7 CP Werkheiser
DM5GQD7 DT Small molecular drug
DM5GQD7 PC 24466
DM5GQD7 MW 269.13
DM5GQD7 FM C11H10Cl2N4
DM5GQD7 IC InChI=1S/C11H10Cl2N4/c1-5-9(10(14)17-11(15)16-5)6-2-3-7(12)8(13)4-6/h2-4H,1H3,(H4,14,15,16,17)
DM5GQD7 CS CC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)Cl)Cl
DM5GQD7 IK VQJHOPSWBGJHQS-UHFFFAOYSA-N
DM5GQD7 IU 5-(3,4-dichlorophenyl)-6-methylpyrimidine-2,4-diamine
DM5GQD7 CA CAS 7761-45-7
DM5GQD7 DE Advanced cancer
DMIXT2Y ID DMIXT2Y
DMIXT2Y DN MGAH22
DMIXT2Y HS Phase 2
DMIXT2Y CP MacroGenics
DMIXT2Y DE Solid tumour/cancer
DMPBTVK ID DMPBTVK
DMPBTVK DN MGB-BP-3
DMPBTVK HS Phase 2
DMPBTVK SN 1000277-08-6; MGB-BP3; UNII-532PWU9738; 532PWU9738; J2.725.402K; (E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide; 4-((4-(4-((E)-2-(3-Quinolyl)vinyl)benzoylamino)-1-methyl-1H-pyrrole-2-yl)carbonylamino)-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 4-[[4-[4-[(E)-2-(3-Quinolyl)vinyl]benzoylamino]-1-methyl-1H-pyrrole-2-yl]carbonylamino]-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; CHEMBL236345; SCHEMBL2398755; GTPL10996; HY-U00035; ZINC28864451; CS-6785; DB12892; SB19161; compound 50 [PMID: 17960927]; Q27261055; 1H-Pyrrole-2-carboxamide, 1-methyl-N-(1-methyl-5-(((2-(4-morpholinyl)ethyl)amino)carbonyl)-1H-pyrrol-3-yl)-4-((4-((1E)-2-(3-quinolinyl)ethenyl)benzoyl)amino)-
DMPBTVK CP MGB Biopharma
DMPBTVK DT Small molecular drug
DMPBTVK PC 23730143
DMPBTVK MW 631.7
DMPBTVK FM C36H37N7O4
DMPBTVK IC InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+
DMPBTVK CS CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCN3CCOCC3)C)NC(=O)C4=CC=C(C=C4)/C=C/C5=CC6=CC=CC=C6N=C5
DMPBTVK IK OEKXCVYZBVOWBR-BQYQJAHWSA-N
DMPBTVK IU 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide
DMPBTVK CA CAS 1000277-08-6
DMPBTVK DE Clostridium infection
DM726HX ID DM726HX
DM726HX DN MGCD-0103
DM726HX HS Phase 2
DM726HX SN Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
DM726HX CP MethylGene Inc
DM726HX TC Anticancer Agents
DM726HX DT Small molecular drug
DM726HX PC 9865515
DM726HX MW 396.4
DM726HX FM C23H20N6O
DM726HX IC InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
DM726HX CS C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
DM726HX IK HRNLUBSXIHFDHP-UHFFFAOYSA-N
DM726HX IU N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
DM726HX CA CAS 726169-73-9
DM726HX CB CHEBI:94525
DM726HX DE Solid tumour/cancer; Diffuse large B-cell lymphoma; Melanoma; Non-small-cell lung cancer
DMRPCF2 ID DMRPCF2
DMRPCF2 DN MGCD265
DMRPCF2 HS Phase 2
DMRPCF2 SN MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
DMRPCF2 CP MethylGene
DMRPCF2 DT Small molecular drug
DMRPCF2 PC 24901704
DMRPCF2 MW 517.6
DMRPCF2 FM C26H20FN5O2S2
DMRPCF2 IC InChI=1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
DMRPCF2 CS CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F
DMRPCF2 IK UFICVEHDQUKCEA-UHFFFAOYSA-N
DMRPCF2 IU N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide
DMRPCF2 CA CAS 875337-44-3
DMRPCF2 CB CHEBI:91393
DMRPCF2 DE Non-small-cell lung cancer; Solid tumour/cancer
DMRSK2I ID DMRSK2I
DMRSK2I DN MGCD290
DMRSK2I HS Phase 2
DMRSK2I CP Mirati Therapeutics
DMRSK2I DT Small molecular drug
DMRSK2I DE Vulvovaginal Candidiasis
DMNYPW7 ID DMNYPW7
DMNYPW7 DN MGI-114
DMNYPW7 HS Phase 2
DMNYPW7 SN Irofulven; Irofulven [USAN:INN]; MGI 114; MGI-114; (R)-6'-Hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5H)inden)-7'(6'H)-one; (R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-inden]-7'(6'H)-one; 158440-71-2; 6-(Hydroxymethyl)acylfulvene; 6-Hydroxymethylacylfulvene; 6B799IH05A; Acylfulvene, 6-(hydroxymethyl)-; HMAF; NSC 683863; NSC-683863; Spiro(cyclopropane-1,5'(5H)-inden)-7'(6'H)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (R)-; UNII-6B799IH05A
DMNYPW7 PC 148189
DMNYPW7 MW 246.3
DMNYPW7 FM C15H18O3
DMNYPW7 IC NICJCIQSJJKZAH-AWEZNQCLSA-N
DMNYPW7 CS CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO
DMNYPW7 IK 1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
DMNYPW7 IU (5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
DMNYPW7 CA CAS 158440-71-2
DMNYPW7 CB CHEBI:135002
DMNYPW7 DE Lung cancer
DM1HC9R ID DM1HC9R
DM1HC9R DN MGL-3196
DM1HC9R HS Phase 2
DM1HC9R CP Madrigal pharmaceuticals
DM1HC9R PC 15981237
DM1HC9R MW 435.2
DM1HC9R FM C17H12Cl2N6O4
DM1HC9R IC InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
DM1HC9R CS CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
DM1HC9R IK FDBYIYFVSAHJLY-UHFFFAOYSA-N
DM1HC9R IU 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile
DM1HC9R CA CAS 920509-32-6
DM1HC9R DE Hyperlipidaemia; Familial hypercholesterolemia; Hypercholesterolaemia
DME5CSV ID DME5CSV
DME5CSV DN Mibampator
DME5CSV HS Phase 2
DME5CSV SN LY-450108; LY-451395; AMPA agonists (Alzheimer's Disease), Lilly; AMPA receptor agonist (agitation in Alzheimer's Disease), Eli Lilly
DME5CSV CP Eli Lilly & Co
DME5CSV DT Small molecular drug
DME5CSV PC 9889366
DME5CSV MW 438.6
DME5CSV FM C21H30N2O4S2
DME5CSV IC InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1
DME5CSV CS C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C
DME5CSV IK ULRDYYKSPCRXAJ-KRWDZBQOSA-N
DME5CSV IU N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide
DME5CSV CA CAS 375345-95-2
DME5CSV DE Alzheimer disease
DMGCRKY ID DMGCRKY
DMGCRKY DN Midismase
DMGCRKY HS Phase 2
DMGCRKY SN PC-01; SI-3501; PC-SOD (intravenous), LTT; Lecithin-bound superoxide dismutase (ulcerative colitis), LTT Bio-Pharma
DMGCRKY CP Asahi Glass Co Ltd
DMGCRKY DE Cerebral infarction
DMN45RI ID DMN45RI
DMN45RI DN MIJ821
DMN45RI HS Phase 2
DMN45RI SN CAD 9271
DMN45RI CP Novartis; Cadent Therapeutics
DMN45RI DE Major depressive disorder
DM50Z4U ID DM50Z4U
DM50Z4U DN Milataxel
DM50Z4U HS Phase 2
DM50Z4U SN M-10; MAC-321; Milataxel (oral); TL-00139; TL-139; Milataxel (oral), Taxolog; MAC-321 (injectable), Taxolog/Wyeth; MAC-321 (oral), Taxolog/Wyeth; TL-00139 (injectable), Taxolog/Wyeth; TL-00139 (oral), Taxolog/Wyeth; TL-139 (injectable), Taxolog/Wyeth; TL-139 (oral), Taxolog/Wyeth
DM50Z4U CP Taxolog Inc
DM50Z4U DT Small molecular drug
DM50Z4U PC 6918589
DM50Z4U MW 853.9
DM50Z4U FM C44H55NO16
DM50Z4U IC InChI=1S/C44H55NO16/c1-10-29(47)58-27-19-28-43(21-56-28,60-23(3)46)34-36(59-37(51)24-15-12-11-13-16-24)44(54)20-26(22(2)30(41(44,7)8)32(48)35(50)42(27,34)9)57-38(52)33(49)31(25-17-14-18-55-25)45-39(53)61-40(4,5)6/h11-18,26-28,31-34,36,48-49,54H,10,19-21H2,1-9H3,(H,45,53)/t26-,27-,28+,31-,32+,33+,34-,36-,42+,43-,44+/m0/s1
DM50Z4U CS CCC(=O)O[C@H]1C[C@@H]2[C@@](CO2)([C@@H]3[C@@]1(C(=O)[C@@H](C4=C([C@H](C[C@@]([C@H]3OC(=O)C5=CC=CC=C5)(C4(C)C)O)OC(=O)[C@@H]([C@H](C6=CC=CO6)NC(=O)OC(C)(C)C)O)C)O)C)OC(=O)C
DM50Z4U IK XIVMHSNIQAICTR-UQYHODNASA-N
DM50Z4U IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-15-[(2R,3R)-3-(furan-2-yl)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]oxy-1,12-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-propanoyloxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DM50Z4U CA CAS 352425-37-7
DM50Z4U DE Solid tumour/cancer
DMSLIW6 ID DMSLIW6
DMSLIW6 DN MIN-117
DMSLIW6 HS Phase 2
DMSLIW6 CP Minerva neurosciences
DMSLIW6 PC 74424169
DMSLIW6 MW 538.8
DMSLIW6 FM C25H26Cl3N3O4
DMSLIW6 IC InChI=1S/C25H25Cl2N3O4.ClH/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17;/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3;1H
DMSLIW6 CS CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OCC(CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O.Cl
DMSLIW6 IK HRNDUKHBCUTNAL-UHFFFAOYSA-N
DMSLIW6 IU 1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[[2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-benzofuran-4-yl]oxy]propan-2-ol;hydrochloride
DMSLIW6 DE Major depressive disorder
DMZFW8V ID DMZFW8V
DMZFW8V DN MIN-202
DMZFW8V HS Phase 2
DMZFW8V SN Seltorexant; 1293281-49-8; Seltorexant [USAN]; SCHEMBL1671257; GTPL9308; CHEMBL3597971; JNJ-922; SQOCEMCKYDVLMM-UHFFFAOYSA-N; BDBM118454; Methanone, (5-(4,6-dimethyl-2-pyrimidinyl)hexahydropyrrolo(3,4-C)pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)-; AKOS032954213; US8653263, 107; [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone; ((3aR,6aS)-5-(4,6-dimethylpyrimidin- 2-yl)hexahydropyrrolo(3,4-c)pyrrol-2(1H)-yl)(2
DMZFW8V CP Minerva Neurosciences Waltham, MA
DMZFW8V PC 67116280
DMZFW8V MW 407.4
DMZFW8V FM C21H22FN7O
DMZFW8V IC InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3
DMZFW8V CS CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C
DMZFW8V IK SQOCEMCKYDVLMM-UHFFFAOYSA-N
DMZFW8V IU [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone
DMZFW8V CA CAS 1293281-49-8
DMZFW8V DE Major depressive disorder
DMWJMFZ ID DMWJMFZ
DMWJMFZ DN Miravirsen
DMWJMFZ HS Phase 2
DMWJMFZ SN Miravirsen; Miravirsen [INN]; SPC3649 Parent Acid; UNII-Q083AJW7VS; Q083AJW7VS; 1072874-90-8; RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dC-(2'-O,4'-C-methylene)A-dT-dT-(2'-O,4'-C-methylene)G-(2'-O,4'-C-methylene)m5U-dC-dA-(2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dT-(2'-O,4'-C-methylene)m5C-(2'-O,4'-C-methylene)m5C)
DMWJMFZ CP Santaris Pharma A/S
DMWJMFZ DT Small molecular drug
DMWJMFZ PC 56843415
DMWJMFZ MW 4897
DMWJMFZ FM C151H185N49O83P14S14
DMWJMFZ IC InChI=1S/C151H185N49O83P14S14/c1-60-26-193(140(215)182-119(60)203)87-21-66(74(258-87)34-245-290(225,304)281-110-102-130(199-58-171-94-114(161)165-55-168-117(94)199)268-150(110,44-239-102)50-252-291(226,305)272-65-20-86(187-13-6-79(153)174-134(187)209)256-72(65)33-243-286(221,300)277-105-97-125(262-144(105,37-201)38-234-97)189-15-8-81(155)176-136(189)211)271-285(220,299)241-30-73-67(22-88(257-73)194-27-61(2)120(204)183-141(194)216)273-293(228,307)253-51-151-45-240-103(131(269-151)200-59-172-95-118(200)180-132(162)181-123(95)207)111(151)283-297(232,311)254-52-149-43-238-101(129(267-149)196-29-63(4)122(206)185-143(196)218)109(149)280-289(224,303)244-32-71-64(19-85(255-71)186-12-5-78(152)173-133(186)208)270-284(219,298)242-31-76-69(24-90(260-76)197-56-169-92-112(159)163-53-166-115(92)197)275-294(229,308)249-47-147-41-236-99(127(265-147)191-17-10-83(157)178-138(191)213)107(147)279-288(223,302)247-36-77-70(25-91(261-77)198-57-170-93-113(160)164-54-167-116(93)198)276-295(230,309)250-48-146-40-235-98(126(264-146)190-16-9-82(156)177-137(190)212)106(146)278-287(222,301)246-35-75-68(23-89(259-75)195-28-62(3)121(205)184-142(195)217)274-292(227,306)251-49-148-42-237-100(128(266-148)192-18-11-84(158)179-139(192)214)108(148)282-296(231,310)248-46-145-39-233-96(104(145)202)124(263-145)188-14-7-80(154)175-135(188)210/h5-18,26-29,53-59,64-77,85-91,96-111,124-131,201-202H,19-25,30-52H2,1-4H3,(H,219,298)(H,220,299)(H,221,300)(H,222,301)(H,223,302)(H,224,303)(H,225,304)(H,226,305)(H,227,306)(H,228,307)(H,229,308)(H,230,309)(H,231,310)(H,232,311)(H2,152,173,208)(H2,153,174,209)(H2,154,175,210)(H2,155,176,211)(H2,156,177,212)(H2,157,178,213)(H2,158,179,214)(H2,159,163,166)(H2,160,164,167)(H2,161,165,168)(H,182,203,215)(H,183,204,216)(H,184,205,217)(H,185,206,218)(H3,162,180,181,207)
DMWJMFZ CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3C4C(OC3(CO4)COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6C7C(OC6(CO7)CO)N8C=CC(=NC8=O)N)N9C=CC(=NC9=O)N)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC13COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC4=C(N=CN=C41)N)OP(=S)(O)OCC14COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=NC5=C(N=CN=C51)N)OP(=S)(O)OCC15COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC16COC(C1OP(=S)(O)OCC17COC(C1O)C(O7)N1C=CC(=NC1=O)N)C(O6)N1C=CC(=NC1=O)N)C(O5)N1C=CC(=NC1=O)N)C(O4)N1C=CC(=NC1=O)N)C(O3)N1C=C(C(=O)NC1=O)C)C(O2)N1C=NC2=C1N=C(NC2=O)N
DMWJMFZ IK OSOOBMBDIGGTCP-UHFFFAOYSA-N
DMWJMFZ IU 1-[4-[[3-[[3-(2-amino-6-oxo-1H-purin-9-yl)-7-[[7-[[5-(4-amino-2-oxopyrimidin-1-yl)-3-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-[[3-(4-amino-2-oxopyrimidin-1-yl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-3-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[1-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[3-(4-amino-2-oxopyrimidin-1-yl)-1-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-3-(6-aminopurin-9-yl)-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMWJMFZ CA CAS 1072874-90-8
DMWJMFZ DE Hepatitis C virus infection
DM7K4YR ID DM7K4YR
DM7K4YR DN MIS-416
DM7K4YR HS Phase 2
DM7K4YR SN Microparticle adjuvant (anthrax), Virionyx; Microparticle adjuvant (iv, autoimmune disease/cancer/anthrax), Innate Therapeutics
DM7K4YR CP Innate Therapeutics Ltd
DM7K4YR DE Bacillus anthracis infection; Autoimmune diabetes
DMOJ7QA ID DMOJ7QA
DMOJ7QA DN Mitemcinal fumarate
DMOJ7QA HS Phase 2
DMOJ7QA SN (2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione
DMOJ7QA CP Roche
DMOJ7QA DT Small molecular drug
DMOJ7QA PC 11513721
DMOJ7QA MW 1628
DMOJ7QA FM C84H142N2O28
DMOJ7QA IC InChI=1S/2C40H69NO12.C4H4O4/c2*1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29;5-3(6)1-2-4(7)8/h2*20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-;/m11./s1
DMOJ7QA CS CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.CC[C@@H]1[C@@](C(=O)[C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C(C)C)O)C)C)C)(C)OC.C(=C/C(=O)O)\\C(=O)O
DMOJ7QA IK KQRXEQGYUDDPNW-QXRSSOOUSA-N
DMOJ7QA IU (E)-but-2-enedioic acid;(2S,4R,5R,8R,9S,10S,11R,12R)-5-ethyl-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-4-methoxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-ene-3,7-dione
DMOJ7QA CA CAS 154802-96-7
DMOJ7QA DE Pain
DMIRPSA ID DMIRPSA
DMIRPSA DN Mitoglitazone
DMIRPSA HS Phase 2
DMIRPSA SN MSDC-0160; Mitoglitazone (TN)
DMIRPSA CP Metabolic Solutions Development
DMIRPSA DT Small molecular drug
DMIRPSA PC 10429242
DMIRPSA MW 370.4
DMIRPSA FM C19H18N2O4S
DMIRPSA IC InChI=1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
DMIRPSA CS CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMIRPSA IK IRNJSRAGRIZIHD-UHFFFAOYSA-N
DMIRPSA IU 5-[[4-[2-(5-ethylpyridin-2-yl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMIRPSA CA CAS 146062-49-9
DMIRPSA CB CHEBI:94409
DMIRPSA DE Type-2 diabetes; Alzheimer disease
DMKPZ0Q ID DMKPZ0Q
DMKPZ0Q DN Mitoquinone
DMKPZ0Q HS Phase 2
DMKPZ0Q SN mitoquinone; Mitoquinone cation; 444890-41-9; UNII-47BYS17IY0; 47BYS17IY0; MitoQ; 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium; Mito-Q; Mitoquinone ion; MitoQ; MitoQ10; CHEMBL1229093; SCHEMBL12135674; EX-A926; BCP19134; HY-100116; CS-0018095; A17092; Q27259044; (10-(2,5-Dihydroxy-3,4-dimethoxy-6-methylphenyl)decyl)triphenyl phosphonium
DMKPZ0Q DT Small molecular drug
DMKPZ0Q PC 11388332
DMKPZ0Q MW 583.7
DMKPZ0Q FM C37H44O4P+
DMKPZ0Q IC InChI=1S/C37H44O4P/c1-29-33(35(39)37(41-3)36(40-2)34(29)38)27-19-8-6-4-5-7-9-20-28-42(30-21-13-10-14-22-30,31-23-15-11-16-24-31)32-25-17-12-18-26-32/h10-18,21-26H,4-9,19-20,27-28H2,1-3H3/q+1
DMKPZ0Q CS CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMKPZ0Q IK OIIMUKXVVLRCAF-UHFFFAOYSA-N
DMKPZ0Q IU 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium
DMKPZ0Q CA CAS 444890-41-9
DMKPZ0Q DE Hepatitis C virus infection
DM2NF6X ID DM2NF6X
DM2NF6X DN MIV-210
DM2NF6X HS Phase 2
DM2NF6X CP Medivir; Daewoong
DM2NF6X DT Small molecular drug
DM2NF6X PC 135431817
DM2NF6X MW 269.23
DM2NF6X FM C10H12FN5O3
DM2NF6X IC InChI=1S/C10H12FN5O3/c11-4-1-6(19-5(4)2-17)16-3-13-7-8(16)14-10(12)15-9(7)18/h3-6,17H,1-2H2,(H3,12,14,15,18)/t4-,5+,6+/m0/s1
DM2NF6X CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)CO)F
DM2NF6X IK RTJUXLYUUDBAJN-KVQBGUIXSA-N
DM2NF6X IU 2-amino-9-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM2NF6X CA CAS 92562-88-4
DM2NF6X DE Hepatitis B virus infection
DMWFTRJ ID DMWFTRJ
DMWFTRJ DN MK-0354
DMWFTRJ HS Phase 2
DMWFTRJ SN MK-0354; 851776-28-8; UNII-4U62D8JYIQ; 4U62D8JYIQ; CHEMBL456145; 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole; 1,4,5,6-Tetrahydro-3-(1H-tetrazol-5-yl)cyclopenta[c]pyrazole; 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole; LTQYSJKGRPGMPO-UHFFFAOYSA-N; SCHEMBL1875705; GTPL5784; MolPort-009-683-033; 1,4,5,6-tetrahydro-3-(2H-tetrazol-5-yl)Cyclopentapyrazole; BCP18112; ZINC38312374; BDBM50273099; AKOS030526928; MK 0354; CS-4589
DMWFTRJ DT Small molecular drug
DMWFTRJ PC 11159621
DMWFTRJ MW 176.18
DMWFTRJ FM C7H8N6
DMWFTRJ IC InChI=1S/C7H8N6/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7/h1-3H2,(H,8,9)(H,10,11,12,13)
DMWFTRJ CS C1CC2=C(C1)NN=C2C3=NNN=N3
DMWFTRJ IK LTQYSJKGRPGMPO-UHFFFAOYSA-N
DMWFTRJ IU 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole
DMWFTRJ CA CAS 851776-28-8
DMLTAES ID DMLTAES
DMLTAES DN MK-0752
DMLTAES HS Phase 2
DMLTAES SN MK-0752; 471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635
DMLTAES CP Merck
DMLTAES DT Small molecular drug
DMLTAES PC 9803433
DMLTAES MW 442.9
DMLTAES FM C21H21ClF2O4S
DMLTAES IC InChI=1S/C21H21ClF2O4S/c22-15-2-5-17(6-3-15)29(27,28)21(18-13-16(23)4-7-19(18)24)11-9-14(10-12-21)1-8-20(25)26/h2-7,13-14H,1,8-12H2,(H,25,26)
DMLTAES CS C1CC(CCC1CCC(=O)O)(C2=C(C=CC(=C2)F)F)S(=O)(=O)C3=CC=C(C=C3)Cl
DMLTAES IK XCGJIFAKUZNNOR-UHFFFAOYSA-N
DMLTAES IU 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid
DMLTAES CA CAS 471905-41-6
DMLTAES DE Alzheimer disease
DM2CJB4 ID DM2CJB4
DM2CJB4 DN MK-0773
DM2CJB4 HS Phase 2
DM2CJB4 SN C-8500; MK-773
DM2CJB4 CP Merck & Co Inc
DM2CJB4 DT Small molecular drug
DM2CJB4 PC 11950726
DM2CJB4 MW 479.6
DM2CJB4 FM C27H34FN5O2
DM2CJB4 IC InChI=1S/C27H34FN5O2/c1-26-11-10-17-15(6-9-21-27(17,2)13-19(28)25(35)33(21)3)16(26)7-8-18(26)24(34)30-14-22-31-20-5-4-12-29-23(20)32-22/h4-5,12-13,15-18,21H,6-11,14H2,1-3H3,(H,30,34)(H,29,31,32)/t15-,16-,17-,18+,21+,26-,27+/m0/s1
DM2CJB4 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NCC4=NC5=C(N4)C=CC=N5)CC[C@@H]6[C@@]3(C=C(C(=O)N6C)F)C
DM2CJB4 IK GBEUKTWTUSPHEE-JWJWXJQQSA-N
DM2CJB4 IU (1S,3aS,3bS,5aR,9aS,9bS,11aS)-8-fluoro-N-(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DM2CJB4 CA CAS 606101-58-0
DM2CJB4 DE Osteoporosis
DMRT8K4 ID DMRT8K4
DMRT8K4 DN MK-0812
DMRT8K4 HS Phase 2
DMRT8K4 SN C-6448; MK-812; CCR2 antagonist (rheumatoid arthritis/multiple sclerosis), Merck
DMRT8K4 CP Merck & Co Inc
DMRT8K4 DT Small molecular drug
DMRT8K4 PC 11180808
DMRT8K4 MW 469.5
DMRT8K4 FM C24H34F3N3O3
DMRT8K4 IC InChI=1S/C24H34F3N3O3/c1-15(2)23(7-4-18(11-23)29-20-6-9-33-14-21(20)32-3)22(31)30-8-5-19-16(13-30)10-17(12-28-19)24(25,26)27/h10,12,15,18,20-21,29H,4-9,11,13-14H2,1-3H3/t18-,20+,21-,23+/m1/s1
DMRT8K4 CS CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=C(C3)C=C(C=N4)C(F)(F)F
DMRT8K4 IK MTMDXAIUENDNDL-RJSMDTJLSA-N
DMRT8K4 IU [(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone
DMRT8K4 CA CAS 624733-88-6
DMRT8K4 DE Multiple sclerosis
DM0568C ID DM0568C
DM0568C DN MK-0873
DM0568C HS Phase 2
DM0568C SN MK-0873 (dermatological, psoriasis); MK-0873 (dermatological, psoriasis), Merck & Co
DM0568C CP Merck & Co Inc
DM0568C DT Small molecular drug
DM0568C PC 9919680
DM0568C MW 422.4
DM0568C FM C25H18N4O3
DM0568C IC InChI=1S/C25H18N4O3/c30-23-21-7-2-12-26-24(21)29(16-22(23)25(31)27-19-10-11-19)20-6-1-4-17(14-20)8-9-18-5-3-13-28(32)15-18/h1-7,12-16,19H,10-11H2,(H,27,31)
DM0568C CS C1CC1NC(=O)C2=CN(C3=C(C2=O)C=CC=N3)C4=CC=CC(=C4)C#CC5=C[N+](=CC=C5)[O-]
DM0568C IK JJWKQXNHYDJXKF-UHFFFAOYSA-N
DM0568C IU N-cyclopropyl-1-[3-[2-(1-oxidopyridin-1-ium-3-yl)ethynyl]phenyl]-4-oxo-1,8-naphthyridine-3-carboxamide
DM0568C CA CAS 500355-52-2
DM0568C DE Psoriasis vulgaris
DM8ZTW7 ID DM8ZTW7
DM8ZTW7 DN MK-1029
DM8ZTW7 HS Phase 2
DM8ZTW7 DE Asthma
DMEDITW ID DMEDITW
DMEDITW DN MK-1454
DMEDITW HS Phase 2
DMEDITW CP Merck
DMEDITW DE Lymphoma; Solid tumour/cancer; Squamous head and neck cell carcinom
DM3WDZ5 ID DM3WDZ5
DM3WDZ5 DN MK-1775
DM3WDZ5 HS Phase 2
DM3WDZ5 SN MK-1775; 955365-80-7; Adavosertib; MK1775; MK 1775; UNII-K2T6HJX3I3; AZD 1775; AZD-1775; AZD1775; 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; K2T6HJX3I3; 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one; 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one; AK-99219
DM3WDZ5 CP Merck
DM3WDZ5 DT Small molecular drug
DM3WDZ5 PC 24856436
DM3WDZ5 MW 500.6
DM3WDZ5 FM C27H32N8O2
DM3WDZ5 IC InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
DM3WDZ5 CS CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O
DM3WDZ5 IK BKWJAKQVGHWELA-UHFFFAOYSA-N
DM3WDZ5 IU 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one
DM3WDZ5 CA CAS 955365-80-7
DM3WDZ5 CB CHEBI:91414
DM3WDZ5 DE Ovarian cancer; Solid tumour/cancer
DMVJB09 ID DMVJB09
DMVJB09 DN MK-1903
DMVJB09 HS Phase 2
DMVJB09 SN Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co
DMVJB09 CP Arena Pharmaceuticals Inc
DMVJB09 DT Small molecular drug
DMVJB09 PC 49763030
DMVJB09 MW 164.16
DMVJB09 FM C8H8N2O2
DMVJB09 IC InChI=1S/C8H8N2O2/c11-8(12)7-5-2-3-1-4(3)6(5)9-10-7/h3-4H,1-2H2,(H,9,10)(H,11,12)/t3-,4-/m1/s1
DMVJB09 CS C1[C@H]2[C@@H]1C3=C(C2)C(=NN3)C(=O)O
DMVJB09 IK CUTZNERBKDMLAP-QWWZWVQMSA-N
DMVJB09 IU (2R,4R)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxylic acid
DMVJB09 CA CAS 1268882-43-4
DMVJB09 DE Arteriosclerosis
DMT1OZ6 ID DMT1OZ6
DMT1OZ6 DN MK-2206
DMT1OZ6 HS Phase 2
DMT1OZ6 SN MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
DMT1OZ6 CP Merck
DMT1OZ6 DT Small molecular drug
DMT1OZ6 PC 24964624
DMT1OZ6 MW 407.5
DMT1OZ6 FM C25H21N5O
DMT1OZ6 IC InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
DMT1OZ6 CS C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N
DMT1OZ6 IK ULDXWLCXEDXJGE-UHFFFAOYSA-N
DMT1OZ6 IU 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
DMT1OZ6 CA CAS 1032349-93-1
DMT1OZ6 CB CHEBI:67271
DMT1OZ6 DE Rectal adenocarcinoma; Nasopharyngeal carcinoma
DM1M57I ID DM1M57I
DM1M57I DN MK-2578
DM1M57I HS Phase 2
DM1M57I CP Merck Bioventures
DM1M57I DE Anemia
DM6OLGC ID DM6OLGC
DM6OLGC DN MK-3207
DM6OLGC HS Phase 2
DM6OLGC SN 957116-20-0; MK-3207 Hydrochloride; MK-3207 (Hydrochloride); MK-3207 HCl; MK-3207 HCl salt; 2-((R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl)-N-((R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-Pyrrolo[2,3-b]pyridin]-5-yl)acetamide hydrochloride; MK3207; (8R)-8-(3,5-Difluorophenyl)-10-oxo-n-[(2r)-1,1',2',3-tetrahydro-2'-oxospiro[2h-indene-2,3'-[3h]pyrrolo[2,3-b]pyridin]-5-yl]-6,9-diazaspiro[4.5]decane-9-acetamide hydrochloride; MK 3207 hydrochloride; MK-3207(Hydrochloride); MK3207 HCl
DM6OLGC CP Merck & Co Inc
DM6OLGC DT Small molecular drug
DM6OLGC PC 25019940
DM6OLGC MW 557.6
DM6OLGC FM C31H29F2N5O3
DM6OLGC IC InChI=1S/C31H29F2N5O3/c32-21-10-19(11-22(33)13-21)25-16-35-31(7-1-2-8-31)29(41)38(25)17-26(39)36-23-6-5-18-14-30(15-20(18)12-23)24-4-3-9-34-27(24)37-28(30)40/h3-6,9-13,25,35H,1-2,7-8,14-17H2,(H,36,39)(H,34,37,40)/t25-,30+/m0/s1
DM6OLGC CS C1CCC2(C1)C(=O)N([C@@H](CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(C[C@@]6(C5)C7=C(NC6=O)N=CC=C7)C=C4
DM6OLGC IK AZAANWYREOQRFB-SETSBSEESA-N
DM6OLGC IU 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
DM6OLGC CA CAS 957118-49-9
DM6OLGC DE Migraine
DM347TQ ID DM347TQ
DM347TQ DN MK-3697
DM347TQ HS Phase 2
DM347TQ CP Merck
DM347TQ PC 46190695
DM347TQ MW 447.5
DM347TQ FM C23H21N5O3S
DM347TQ IC InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)
DM347TQ CS CC1=CC(=CN=C1)C2=NC=C(C(=C2)C(=O)NCC3=NC(=C(C=C3)OC)OC)C4=NC=CS4
DM347TQ IK VSOUDUXMPUHJEU-UHFFFAOYSA-N
DM347TQ IU N-[(5,6-dimethoxypyridin-2-yl)methyl]-2-(5-methylpyridin-3-yl)-5-(1,3-thiazol-2-yl)pyridine-4-carboxamide
DM347TQ CA CAS 1224846-01-8
DM347TQ DE Insomnia
DMSPWX6 ID DMSPWX6
DMSPWX6 DN MK-5172
DMSPWX6 HS Phase 2
DMSPWX6 SN UNII-RU4QU6O6X6; 1206524-85-7; RU4QU6O6X6; (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid; 8H-7,10-Methanocyclopropa(18,19)(1,10,3,6)dioxadiazacyclononadecino(11,12-b)quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1aR,5S,8S,10R,22aR)-
DMSPWX6 CP Merck
DMSPWX6 DT Small molecular drug
DMSPWX6 PC 46930991
DMSPWX6 MW 554.6
DMSPWX6 FM C29H38N4O7
DMSPWX6 IC InChI=1S/C29H38N4O7/c1-29(2,3)24-26(34)33-15-18(14-22(33)27(35)36)39-25-20(30-19-11-10-17(38-4)13-21(19)31-25)9-7-5-6-8-16-12-23(16)40-28(37)32-24/h10-11,13,16,18,22-24H,5-9,12,14-15H2,1-4H3,(H,32,37)(H,35,36)/t16-,18-,22+,23-,24-/m1/s1
DMSPWX6 CS CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)O)OC3=NC4=C(C=CC(=C4)OC)N=C3CCCCC[C@@H]5C[C@H]5OC(=O)N1
DMSPWX6 IK IVROMYPOGKZNLP-FDOFPDFBSA-N
DMSPWX6 IU (1R,18R,20R,24S,27S)-24-tert-butyl-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxylic acid
DMSPWX6 CA CAS 1206524-85-7
DMSPWX6 DE Hepatitis C virus infection
DMHTIGU ID DMHTIGU
DMHTIGU DN MK-5442
DMHTIGU HS Phase 2
DMHTIGU CP Merck
DMHTIGU PC 46917559
DMHTIGU MW 514
DMHTIGU FM C29H33ClFNO4
DMHTIGU IC InChI=1S/C29H33ClFNO4/c1-18-13-21(10-11-23(18)28(34)35)25-8-6-5-7-24(25)19(2)36-17-22(33)16-32-29(3,4)15-20-9-12-26(30)27(31)14-20/h5-14,19,22,32-33H,15-17H2,1-4H3,(H,34,35)/t19-,22-/m1/s1
DMHTIGU CS CC1=C(C=CC(=C1)C2=CC=CC=C2[C@@H](C)OC[C@@H](CNC(C)(C)CC3=CC(=C(C=C3)Cl)F)O)C(=O)O
DMHTIGU IK UNFHDRVFEQPUEL-DENIHFKCSA-N
DMHTIGU IU 4-[2-[(1R)-1-[(2R)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid
DMHTIGU CA CAS 787583-71-5
DMHTIGU DE Osteoporosis
DMLMV0O ID DMLMV0O
DMLMV0O DN MK-7655
DMLMV0O HS Phase 2
DMLMV0O SN Relebactam; 1174018-99-5; Relebactam anhydrous; MK-7655; UNII-1OQF7TT3PF; 1OQF7TT3PF; CHEMBL3112741; Sulfuric acid, mono[(1R,2S,5R)-7-oxo-2-[(4-piperidinylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl] ester; Relebactam [INN]; MK7655; MK 7655; (-)-Relebactam anhydrous; BDBM1858; SCHEMBL3721178; EX-A864; SMOBCLHAZXOKDQ-ZJUUUORDSA-N; MolPort-044-723-879; MK-7655A; ZINC43206319; BDBM50447651; AKOS027338697; SB16968; DB12377; CS-5391; Sulfuric acid mono-((2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) est
DMLMV0O CP Merck
DMLMV0O DT Small molecular drug
DMLMV0O PC 44129647
DMLMV0O MW 348.38
DMLMV0O FM C12H20N4O6S
DMLMV0O IC InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1
DMLMV0O CS C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
DMLMV0O IK SMOBCLHAZXOKDQ-ZJUUUORDSA-N
DMLMV0O IU [(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DMLMV0O CA CAS 1174018-99-5
DMLMV0O DE Bacterial infection
DMG6KXB ID DMG6KXB
DMG6KXB DN MK-8245
DMG6KXB HS Phase 2
DMG6KXB SN MK-8245; 1030612-90-8; MK8245; MK 8245; UNII-537E7QE8LX; 537E7QE8LX; CHEMBL1938870; 5-[3-[4-(2-Bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-2H-tetrazole-2-acetic acid; 2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-;2H-Tetrazole-2-acetic acid, 5-[3-[4-(2-bromo-5-fluorophenoxy)-1-piperidinyl]-5-isoxazolyl]-; 2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid; UJEAABFSXKCSGI-UHFFFAOYSA-N; C17H16BrFN6O4; MLS006011144
DMG6KXB DT Small molecular drug
DMG6KXB PC 24988881
DMG6KXB MW 467.2
DMG6KXB FM C17H16BrFN6O4
DMG6KXB IC InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)
DMG6KXB CS C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O
DMG6KXB IK UJEAABFSXKCSGI-UHFFFAOYSA-N
DMG6KXB IU 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid
DMG6KXB CA CAS 1030612-90-8
DMG6KXB DE Type-2 diabetes
DMD6E5W ID DMD6E5W
DMD6E5W DN MK-8342
DMD6E5W HS Phase 2
DMD6E5W CP Merck
DMD6E5W DE Contraception
DMVNAYE ID DMVNAYE
DMVNAYE DN MK-8521
DMVNAYE HS Phase 2
DMVNAYE CP Merck
DMVNAYE DE Type-2 diabetes
DMQHS6B ID DMQHS6B
DMQHS6B DN MK-866
DMQHS6B HS Phase 2
DMQHS6B TC Anticancer Agents
DMQHS6B DE Discovery agent
DMXKOW6 ID DMXKOW6
DMXKOW6 DN MKC-1106-MT
DMXKOW6 HS Phase 2
DMXKOW6 SN Melanoma vaccine (MART-1/tyrosinase), Mannkind
DMXKOW6 CP Colby pharmaceuticals
DMXKOW6 DE Melanoma
DM3I71U ID DM3I71U
DM3I71U DN MKT-077
DM3I71U HS Phase 2
DM3I71U SN FJ-776 (formerly); SDZ-MKT-077; 1-Ethyl-2-[3-ethyl-5-(3-methyl-2,3-dihydrobenzothiazolin-2-ylidene)-4-oxothiazolidin-2-ylidenemethyl]pyridinium chloride
DM3I71U DT Small molecular drug
DM3I71U PC 6444403
DM3I71U MW 432
DM3I71U FM C21H22ClN3OS2
DM3I71U IC InChI=1S/C21H22N3OS2.ClH/c1-4-23-13-9-8-10-15(23)14-18-24(5-2)20(25)19(27-18)21-22(3)16-11-6-7-12-17(16)26-21;/h6-14H,4-5H2,1-3H3;1H/q+1;/p-1/b21-19+;
DM3I71U CS CCN1/C(=C/C2=CC=CC=[N+]2CC)/S/C(=C/3\\N(C4=CC=CC=C4S3)C)/C1=O.[Cl-]
DM3I71U IK VSKYOTRJSLYFHX-UXJRWBAGSA-M
DM3I71U IU (2Z,5E)-3-ethyl-2-[(1-ethylpyridin-1-ium-2-yl)methylidene]-5-(3-methyl-1,3-benzothiazol-2-ylidene)-1,3-thiazolidin-4-one;chloride
DM3I71U CA CAS 147366-41-4
DM3I71U DE Solid tumour/cancer
DMQSO4L ID DMQSO4L
DMQSO4L DN ML-04
DMQSO4L HS Phase 2
DMQSO4L SN BTL-cg; HP-4; ML-04A; Urological therapeutics, Milkhaus; Human chorionic gonadotropin (benign prostate hyperplasia/prostatitis/cancer), Beech Tree Labs
DMQSO4L CP Milkhaus Laboratory Inc
DMQSO4L DE Myelodysplastic syndrome
DMI4E9K ID DMI4E9K
DMI4E9K DN MLN0264
DMI4E9K HS Phase 2
DMI4E9K CP Millenium; The Takeda oncology company
DMI4E9K DE Gastrointestinal cancer
DM24SOL ID DM24SOL
DM24SOL DN MLN1202
DM24SOL HS Phase 2
DM24SOL SN UNNCHYARSNZOPF-UHFFFAOYSA-L; RFI-641; UNII-FR2W015BG1; FR2W015BG1; WAY-154641; CHEMBL425633; SCHEMBL20741446; RF-1461
DM24SOL CP Novartis & Millenium
DM24SOL DT Small molecular drug
DM24SOL PC 16156223
DM24SOL MW 1683.6
DM24SOL FM C58H60N24Na2O22S6
DM24SOL IC InChI=1S/C58H62N24O22S6.2Na/c59-45(83)23-79(24-46(60)84)105(91,92)37-9-1-5-31(17-37)67-53-73-54(68-32-6-2-10-38(18-32)106(93,94)80(25-47(61)85)26-48(62)86)76-57(75-53)71-35-13-15-41(43(21-35)109(99,100)101)42-16-14-36(22-44(42)110(102,103)104)72-58-77-55(69-33-7-3-11-39(19-33)107(95,96)81(27-49(63)87)28-50(64)88)74-56(78-58)70-34-8-4-12-40(20-34)108(97,98)82(29-51(65)89)30-52(66)90;;/h1-22H,23-30H2,(H2,59,83)(H2,60,84)(H2,61,85)(H2,62,86)(H2,63,87)(H2,64,88)(H2,65,89)(H2,66,90)(H,99,100,101)(H,102,103,104)(H3,67,68,71,73,75,76)(H3,69,70,72,74,77,78);;/q;2*+1/p-2
DM24SOL CS C1=CC(=CC(=C1)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC2=NC(=NC(=N2)NC3=CC(=C(C=C3)C4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)N(CC(=O)N)CC(=O)N)NC7=CC(=CC=C7)S(=O)(=O)N(CC(=O)N)CC(=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-])NC8=CC(=CC=C8)S(=O)(=O)N(CC(=O)N)CC(=O)N.[Na+].[Na+]
DM24SOL IK UNNCHYARSNZOPF-UHFFFAOYSA-L
DM24SOL IU disodium;5-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(2-amino-2-oxoethyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]benzenesulfonate
DM24SOL CA CAS 197366-24-8
DM24SOL DE Multiple sclerosis; Metastatic cancer; Respiratory syncytial virus infection
DMBR8NF ID DMBR8NF
DMBR8NF DN MLN2480
DMBR8NF HS Phase 2
DMBR8NF SN VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819
DMBR8NF CP Millennium Pharmaceuticals
DMBR8NF DT Small molecular drug
DMBR8NF PC 25161177
DMBR8NF MW 506.3
DMBR8NF FM C17H12Cl2F3N7O2S
DMBR8NF IC InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1
DMBR8NF CS C[C@H](C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl
DMBR8NF IK VWMJHAFYPMOMGF-ZCFIWIBFSA-N
DMBR8NF IU 2-[(1R)-1-[(6-amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
DMBR8NF CA CAS 1096708-71-2
DMBR8NF DE Solid tumour/cancer; Melanoma
DMJHVZC ID DMJHVZC
DMJHVZC DN MLN-591RL
DMJHVZC HS Phase 2
DMJHVZC SN HuJ591; J591; MLN-5591RL; MLN-591; ATG-J591:RC; Anti-PSMA, Millennium; Lutetium-177-J591; Yttrium-90-J591; Anti-PSMA, Millennium/BZL Biologics; Lutetium-177-MLN-591; Yttrium-90-MLN-591; 111In-J591; 177Lu-J591; 177Lu-MLN-591; 90Y-J591; 90Y-MLN-591
DMJHVZC CP Millennium Pharmaceuticals
DMJHVZC DT Antibody
DMJHVZC DE Prostate cancer
DMXJWNS ID DMXJWNS
DMXJWNS DN MM-093
DMXJWNS HS Phase 2
DMXJWNS SN ABI-001; Recombinant human alpha fetoprotein (autoimmune diseases), Merrimack; RhAFP (autoimmune diseases), Merrimack; Recombinant human alpha-fetoprotein (autoimmune disease), GTC Biotherapeutics
DMXJWNS CP Merrimack Pharmaceuticals
DMXJWNS SQ >Q4QR90|Q4QR90_RAT Alpha-fetoprotein - Rattus norvegicus (Rat).: MKQPATMKWSASISFLLLLNFAEPRVLHTNEFGIESTLDSSQCPTEKNMFNVATIVVAQFVQDATKAEVNKMSSDALAAMKENTGDGCLENQLSVFLDEICHETELFNKYGFSGCCNQSGVERHQCLLARKKTAPDSVPPFHFPETAESCPAYEENRAMSINTFIYDVSKRNPFLYAPTILYLAAQYDKAVPACCKADNMEECFQTKRASMAKELREGSMLNEHVCAVIRKFGSRNLQAVLIIKLSQKFPKANITEIRKLALDVAHIHEQCCHGNAMECLQDGESVMTHICSQQEILSSKTAECCKLPTIELGYCIIHAENGDKPEGLTLNPSEFLGDRNFAQFSSEEKLLFMASFLHEYSRNHPNLPVSVILKTAKSYQEILEKCSQSETPSKCQDNMEEELQKHIQESQALAKQSCDLYQKLGPYYLQNLFLIGYTRKAPQLTSAELIDLTGKMVSIASMCCQLSEEKRSACGEGLADIYIGHLCLRHEANPVNSGINHCCSSSYSNRRLCITSFLRDETYVPPPFSEDKFIFHKDLCQAQGRALQTMKQELLINLVKQKPEMTEEQHAAVTADFSGLLEKCCKDQDQEACFAKEGPKLISKTREALGV
DMXJWNS DE Autoimmune diabetes
DMO7MBS ID DMO7MBS
DMO7MBS DN MM-111
DMO7MBS HS Phase 2
DMO7MBS CP Merrimack
DMO7MBS DT Monoclonal antibody
DMO7MBS DE Gastric adenocarcinoma; Breast cancer
DMDJRU1 ID DMDJRU1
DMDJRU1 DN MM-121
DMDJRU1 HS Phase 2
DMDJRU1 SN SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis
DMDJRU1 CP Merrimack pharmaceuticals; sanofi us
DMDJRU1 DE Breast cancer; Non-small-cell lung cancer
DM2RJ4D ID DM2RJ4D
DM2RJ4D DN MM-141
DM2RJ4D HS Phase 2
DM2RJ4D DE Solid tumour/cancer; Pancreatic cancer
DM6VPIO ID DM6VPIO
DM6VPIO DN MM36
DM6VPIO HS Phase 2
DM6VPIO SN CHEMBL225555
DM6VPIO CP Medimetriks Pharmaceuticals Fairfield, NJ
DM6VPIO DT Small molecular drug
DM6VPIO PC 57855696
DM6VPIO MW 446.4
DM6VPIO FM C23H24F2N2O5
DM6VPIO IC InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)
DM6VPIO CS CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC(=C(C=C3)OC(F)F)OC(C)C
DM6VPIO IK VFBILHPIHUPBPZ-UHFFFAOYSA-N
DM6VPIO IU N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
DM6VPIO CA CAS 937782-05-3
DM6VPIO DE Atopic dermatitis
DMBX2RE ID DMBX2RE
DMBX2RE DN MN-221
DMBX2RE HS Phase 2
DMBX2RE SN Bedoradrine
DMBX2RE CP MediciNova
DMBX2RE DT Small molecular drug
DMBX2RE PC 9963056
DMBX2RE MW 955.1
DMBX2RE FM C48H66N4O14S
DMBX2RE IC InChI=1S/2C24H32N2O5.H2O4S/c2*1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27;1-5(2,3)4/h2*4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3;(H2,1,2,3,4)/t2*20-,23-;/m00./s1
DMBX2RE CS CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.CN(C)C(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=C(C=C3)O)CCO)O)C=C1.OS(=O)(=O)O
DMBX2RE IK VPCOODFYDJWLHD-YMZXMBPUSA-N
DMBX2RE IU 2-[[(7S)-7-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide;sulfuric acid
DMBX2RE CA CAS 194785-31-4
DMBX2RE DE Exacerbation of acute asthma; Aging skin
DMUGN4B ID DMUGN4B
DMUGN4B DN MN-305
DMUGN4B HS Phase 2
DMUGN4B SN Osemozotan hydrochloride; Mkc 242; MCI-242; MKC-242; 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine hydrochloride; 5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
DMUGN4B CP MediciNova
DMUGN4B DT Small molecular drug
DMUGN4B PC 198746
DMUGN4B MW 379.8
DMUGN4B FM C19H22ClNO5
DMUGN4B IC InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1
DMUGN4B CS C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl
DMUGN4B IK GGNCUSDIUUCNKE-RSAXXLAASA-N
DMUGN4B IU 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride
DMUGN4B CA CAS 137275-80-0
DMUGN4B DE Mood disorder
DMQA3MV ID DMQA3MV
DMQA3MV DN MNX-100
DMQA3MV HS Phase 2
DMQA3MV CP MetronomX
DMQA3MV DE Solid tumour/cancer; Medulloblastoma
DMGK1JE ID DMGK1JE
DMGK1JE DN MORAb-004
DMGK1JE HS Phase 2
DMGK1JE CP Eisai
DMGK1JE DE Sarcoma; Melanoma; Colorectal cancer; Merkel cell carcinoma
DMCXNIP ID DMCXNIP
DMCXNIP DN MORAb-009
DMCXNIP HS Phase 2
DMCXNIP SN Amatuximab
DMCXNIP CP Eisai
DMCXNIP DT Antibody
DMCXNIP DE Mesothelioma
DMYCITZ ID DMYCITZ
DMYCITZ DN MP-101
DMYCITZ HS Phase 2
DMYCITZ CP Mediti Pharma
DMYCITZ DE Alzheimer disease
DMELUAK ID DMELUAK
DMELUAK DN MP470
DMELUAK HS Phase 2
DMELUAK SN Amuvatinib; 850879-09-3; MP-470; MP470; MP 470; Amuvatinib (MP-470); HPK56; UNII-SO9S6QZB4R; Amuvatinib(MP470); N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; SO9S6QZB4R; HPK-56; HPK 56; N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-(benzofuro-[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide; Amuvatinib [USAN:INN]; Amuvatinib (MP-470, HPK 56); PubChem22479; Amuvatinib (USAN/INN)
DMELUAK CP SuperGen
DMELUAK TC Anticancer Agents
DMELUAK DT Small molecular drug
DMELUAK PC 11282283
DMELUAK MW 447.5
DMELUAK FM C23H21N5O3S
DMELUAK IC InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)
DMELUAK CS C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6
DMELUAK IK FOFDIMHVKGYHRU-UHFFFAOYSA-N
DMELUAK IU N-(1,3-benzodioxol-5-ylmethyl)-4-([1]benzofuro[3,2-d]pyrimidin-4-yl)piperazine-1-carbothioamide
DMELUAK CA CAS 850879-09-3
DMELUAK CB CHEBI:91389
DMELUAK DE Solid tumour/cancer
DMMRYEK ID DMMRYEK
DMMRYEK DN MPSK3169A
DMMRYEK HS Phase 2
DMMRYEK SN RG7652
DMMRYEK CP Genentech
DMMRYEK DE Metabolic disorder; Cardiovascular disease
DMQR23W ID DMQR23W
DMQR23W DN MRE-0094
DMQR23W HS Phase 2
DMQR23W SN SCHEMBL13010610; MRE 0094
DMQR23W CP Aderis Pharmaceuticals Licensee; King Pharmaceuticals
DMQR23W DT Small molecular drug
DMQR23W PC 9910098
DMQR23W MW 421.8
DMQR23W FM C18H20ClN5O5
DMQR23W IC InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1
DMQR23W CS C1=CC(=CC=C1CCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N)Cl
DMQR23W IK WUCQGGOGHZRELS-LSCFUAHRSA-N
DMQR23W IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(4-chlorophenyl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMQR23W CA CAS 131865-88-8
DMQR23W DE Diabetic foot ulcer
DMJK8L1 ID DMJK8L1
DMJK8L1 DN MRG002
DMJK8L1 HS Phase 2
DMJK8L1 CP Miracogen
DMJK8L1 DT Antibody drug conjugate
DMJK8L1 DE Urothelial carcinoma
DM9M5WV ID DM9M5WV
DM9M5WV DN MRG-201
DM9M5WV HS Phase 2
DM9M5WV CP miRagen Therapeutics Boulder, CO
DM9M5WV DE Scleroderma; Keloid
DMQZWYE ID DMQZWYE
DMQZWYE DN MRX-4
DMQZWYE HS Phase 2
DMQZWYE SN Non-steroidal multifunctional anti-inflammatory drug (MFAID) (nasal spray, allergic rhinitis), Morria
DMQZWYE CP Morria Biopharmaceuticals plc
DMQZWYE PC 91864617
DMQZWYE MW 530.3
DMQZWYE FM C20H18F3N4O8P
DMQZWYE IC InChI=1S/C20H18F3N4O8P/c1-11(28)35-36(31,32)27(16-4-7-33-24-16)10-13-9-26(20(30)34-13)15-8-14(21)19(18(23)17(15)22)25-5-2-12(29)3-6-25/h2,4-5,7-8,13H,3,6,9-10H2,1H3,(H,31,32)/t13-/m1/s1
DMQZWYE CS CC(=O)OP(=O)(N(C[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2F)F)N3CCC(=O)C=C3)F)C4=NOC=C4)O
DMQZWYE IK YCRAGJLWFBGKFE-CYBMUJFWSA-N
DMQZWYE IU acetyloxy-N-(1,2-oxazol-3-yl)-N-[[(5R)-2-oxo-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]phosphonamidic acid
DMQZWYE CA CAS 1807497-11-5
DMQZWYE DE Allergic rhinitis
DMLVQKF ID DMLVQKF
DMLVQKF DN MRX-6
DMLVQKF HS Phase 2
DMLVQKF SN CXCL10 gene inhibitor/phospholipase A2/ MIP 1 ligand inhibitor (contact dermatitis), Morria Biopharmaceuticals; IL 1 beta/IL-6/PGE 2 modulator (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Monocyte chemotactic protein 1/GM-CSF/TNF alpha ligand inhibitor (dermatological emulsion, contact dermatitis), Morria Biopharmaceuticals; Non-steroidal multifunctional anti-inflammatory drug (MFAID) (topical formulation, contact dermatitis), Morria
DMLVQKF CP Morria Biopharmaceuticals plc
DMLVQKF DE Contact dermatitis
DMH1DYU ID DMH1DYU
DMH1DYU DN MSC1936369B
DMH1DYU HS Phase 2
DMH1DYU SN Pimasertib; 1236699-92-5; AS703026; AS-703026; Pimasertib (AS-703026); MSC1936369B; UNII-6ON9RK82AL; AS 703026; (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide; 6ON9RK82AL; N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide; 1204531-26-9; C15H15FIN3O3; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodo-anilino)pyridine-4-carboxamide; N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)pyridine-4-carboxamide; Pimasertib [USAN:INN]
DMH1DYU CP EMD Serono
DMH1DYU DT Small molecular drug
DMH1DYU PC 44187362
DMH1DYU MW 431.2
DMH1DYU FM C15H15FIN3O3
DMH1DYU IC InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1
DMH1DYU CS C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NC[C@@H](CO)O
DMH1DYU IK VIUAUNHCRHHYNE-JTQLQIEISA-N
DMH1DYU IU N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
DMH1DYU CA CAS 1204531-26-9
DMH1DYU CB CHEBI:94793
DMH1DYU DE Colorectal cancer
DMGUI51 ID DMGUI51
DMGUI51 DN MSDC-0602
DMGUI51 HS Phase 2
DMGUI51 SN MSDC-0602; 1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993
DMGUI51 CP Metabolic Solutions Development
DMGUI51 DT Small molecular drug
DMGUI51 PC 25230266
DMGUI51 MW 371.4
DMGUI51 FM C19H17NO5S
DMGUI51 IC InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)
DMGUI51 CS COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMGUI51 IK YAUMOGALQJYOJQ-UHFFFAOYSA-N
DMGUI51 IU 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMGUI51 CA CAS 1133819-87-0
DMGUI51 DE Type-2 diabetes
DMUM370 ID DMUM370
DMUM370 DN MSH-1001
DMUM370 HS Phase 2
DMUM370 SN DNB-001; KR-31378; KR-31378); K+ channel activating compounds, Dongbu/KRICT
DMUM370 CP Danube Pharmaceuticals Inc; Korea Research Institute of Chemical Technology
DMUM370 PC 9823724
DMUM370 MW 425.5
DMUM370 FM C22H27N5O4
DMUM370 IC InChI=1S/C22H27N5O4/c1-22(20(29-2)30-3)19(28)18(16-11-15(24)9-10-17(16)31-22)27-21(26-13-23)25-12-14-7-5-4-6-8-14/h4-11,18-20,28H,12,24H2,1-3H3,(H2,25,26,27)/t18-,19+,22+/m1/s1
DMUM370 CS C[C@]1([C@H]([C@@H](C2=C(O1)C=CC(=C2)N)NC(=NCC3=CC=CC=C3)NC#N)O)C(OC)OC
DMUM370 IK OZHUPJHJQIEDFA-DXIQSLLYSA-N
DMUM370 IU 1-[(2S,3S,4R)-6-amino-2-(dimethoxymethyl)-3-hydroxy-2-methyl-3,4-dihydrochromen-4-yl]-2-benzyl-3-cyanoguanidine
DMUM370 DE Ocular hypertension
DMSE9TH ID DMSE9TH
DMSE9TH DN MT-1303
DMSE9TH HS Phase 2
DMSE9TH CP Mitsubishi Tanabe Pharma Corp
DMSE9TH DT Small molecular drug
DMSE9TH PC 67418070
DMSE9TH MW 413.9
DMSE9TH FM C19H31ClF3NO3
DMSE9TH IC InChI=1S/C19H30F3NO3.ClH/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25;/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3;1H
DMSE9TH CS CCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F.Cl
DMSE9TH IK GEDVJGOVRLHFQG-UHFFFAOYSA-N
DMSE9TH IU 2-amino-2-[2-[4-heptoxy-3-(trifluoromethyl)phenyl]ethyl]propane-1,3-diol;hydrochloride
DMSE9TH CA CAS 942398-84-7
DMSE9TH DE Multiple sclerosis; Crohn disease
DM7I0MT ID DM7I0MT
DM7I0MT DN MT203
DM7I0MT HS Phase 2
DM7I0MT SN Namilumab
DM7I0MT CP National Institute of Allergy and Infectious Diseases (NIAID)
DM7I0MT DT Monoclonal antibody
DM7I0MT DE Plaque psoriasis
DMCNL7Z ID DMCNL7Z
DMCNL7Z DN MT-3724
DMCNL7Z HS Phase 2
DMCNL7Z CP Molecular Templates
DMCNL7Z DT Recombinant?protein
DMCNL7Z DE B-cell chronic lymphocytic leukaemia; B-cell lymphoma; B-cell non-hodgkin lymphoma; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMXSZA4 ID DMXSZA4
DMXSZA4 DN MT-3995
DMXSZA4 HS Phase 2
DMXSZA4 CP Mitsubishi tanabe pharma
DMXSZA4 DE Diabetic nephropathy
DM7VG8L ID DM7VG8L
DM7VG8L DN MTC-896
DM7VG8L HS Phase 2
DM7VG8L SN MC-5 antagonists (dermatological disease), Mimetica
DM7VG8L CP Mimetica Pty Ltd
DM7VG8L DE Seborrhea
DMT0K4F ID DMT0K4F
DMT0K4F DN MTR105
DMT0K4F HS Phase 2
DMT0K4F SN UNII-CTD25O6OBI; CTD25O6OBI; MTR 105; S-Ethylisothiuronium diethyl phosphate; 21704-46-1; Carbamimidothioic acid, ethyl ester, mono(diethyl phospate); Phosphoric acid, diethyl ester, compd. with 2-ethyl-2-thiopseudourea (1:1); Difetur; AC1Q6SNE; AC1L4PKY; CTK4E7529; nitric oxide synthase inhibi-tors; ethyl carbamimidothioate- diethyl hydrogen phosphate(1:1); MTR-105; DTXSID60176093; AKOS030611139; LS-107705; diethyl hydrogen phosphate; Carbamimidothioic acid, ethyl ester, diethyl phosphate (1
DMT0K4F CP Meditor Pharmaceuticals
DMT0K4F DT Small molecular drug
DMT0K4F PC 210823
DMT0K4F MW 258.279
DMT0K4F FM C7H19N2O4PS
DMT0K4F IC InChI=1S/C4H11O4P.C3H8N2S/c1-3-7-9(5,6)8-4-2;1-2-6-3(4)5/h3-4H2,1-2H3,(H,5,6);2H2,1H3,(H3,4,5)
DMT0K4F CS CCOP(=O)(O)OCC.CCSC(=N)N
DMT0K4F IK CSYSULGPHGCBQD-UHFFFAOYSA-N
DMT0K4F IU diethyl hydrogen phosphate;ethyl carbamimidothioate
DMT0K4F CA CAS 21704-46-1
DMT0K4F DE Hypotension
DML7N4B ID DML7N4B
DML7N4B DN MUC1-Poly-ICLC
DML7N4B HS Phase 2
DML7N4B SN Mucin1 peptide vaccine (cancer), University of Pittsburgh
DML7N4B CP University of Pittsburgh
DML7N4B DT Vaccine
DML7N4B DE Colorectal cancer
DMN68ZL ID DMN68ZL
DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL HS Phase 2
DMN68ZL SN Melanoma vaccine, Memorial Sloan-Kettering; Multi-epitope tyrosinase/gp100 vaccine (melanoma); Multi-epitope tyrosinase/gp100 vaccine (melanoma), Memorial Sloan-Kettering
DMN68ZL CP Memorial Sloan-Kettering Cancer Center
DMN68ZL DT Vaccine
DMN68ZL DE Melanoma
DMM6KZR ID DMM6KZR
DMM6KZR DN Mutant ras vaccine
DMM6KZR HS Phase 2
DMM6KZR SN Mutant ras vaccine, NCI; Ras peptide vaccine, NCI; 13 mer ras peptide, NCI
DMM6KZR CP National Cancer Institute
DMM6KZR DT Vaccine
DMM6KZR DE Solid tumour/cancer
DMKDN1C ID DMKDN1C
DMKDN1C DN MVA-85A
DMKDN1C HS Phase 2
DMKDN1C SN AERAS-485; MVA-AG85A; MVA-85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC; MVA-Ag85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC
DMKDN1C CP University of Oxford
DMKDN1C DT Vaccine
DMKDN1C DE Mycobacterium infection
DMDN6FO ID DMDN6FO
DMDN6FO DN MVI-816
DMDN6FO HS Phase 2
DMDN6FO CP Madison vaccines
DMDN6FO DE Prostate cancer
DM25VY8 ID DM25VY8
DM25VY8 DN Mydicar
DM25VY8 HS Phase 2
DM25VY8 SN Mydicar (TN)
DM25VY8 CP Celladon; Targeted Genetics
DM25VY8 DE Heart failure
DMO1XUK ID DMO1XUK
DMO1XUK DN Myeloma cancer vaccine
DMO1XUK HS Phase 2
DMO1XUK CP BioSante Pharmaceuticals
DMO1XUK DT Vaccine
DMO1XUK DE Multiple myeloma
DM9BREJ ID DM9BREJ
DM9BREJ DN MYK-491
DM9BREJ HS Phase 2
DM9BREJ SN Danicamtiv; UNII-7B2CS922HI; 7B2CS922HI; SAR440181; 1970972-74-7; Danicamtiv [INN]; Danicamtiv [USAN]; Danicamtiv (USAN/INN); MYK491; CHEMBL4594304; SCHEMBL17942536; WHO 10942; SAR-440181; HY-109128; CS-0086762; D11824; (R)-4-(1-((3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide; 1-Piperidinecarboxamide, 4-((1R)-1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-3-isoxazolyl-
DM9BREJ CP MyoKardia; Sanofi
DM9BREJ DT Small molecular drug
DM9BREJ PC 122424426
DM9BREJ MW 435.4
DM9BREJ FM C16H20F3N5O4S
DM9BREJ IC InChI=1S/C16H20F3N5O4S/c1-16(19,29(26,27)11-9-23(2)21-13(11)14(17)18)10-3-6-24(7-4-10)15(25)20-12-5-8-28-22-12/h5,8-10,14H,3-4,6-7H2,1-2H3,(H,20,22,25)/t16-/m1/s1
DM9BREJ CS C[C@@](C1CCN(CC1)C(=O)NC2=NOC=C2)(F)S(=O)(=O)C3=CN(N=C3C(F)F)C
DM9BREJ IK NREKKBAMVWQRES-MRXNPFEDSA-N
DM9BREJ IU 4-[(1R)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-N-(1,2-oxazol-3-yl)piperidine-1-carboxamide
DM9BREJ CA CAS 1970972-74-7
DM9BREJ DE Dilated cardiomyopathy
DMQKSGI ID DMQKSGI
DMQKSGI DN Myo-inositol
DMQKSGI HS Phase 2
DMQKSGI SN Scyllo-inositol; inositol; Muco-Inositol; epi-Inositol; i-Inositol; meso-Inositol; Allo-inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; Scyllitol; 643-12-9; D-(+)-chiro-Inositol; cis-Inositol; mesoinositol; Quercinitol; Myoinosite; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Neo-inositol; Meat sugar; 6917-35-7; Phaseomannite; Inositina; Cocositol; D-chiro-Inositol; Inositene; Inosital; Iso-inositol; cyclohexane-1,2,3,4,5,6-hexol; Phaseomannitol; Cyclohexitol; Mesoinosit; Scyllite; Mesoinosite; Inosite
DMQKSGI DT Small molecular drug
DMQKSGI PC 892
DMQKSGI MW 180.16
DMQKSGI FM C6H12O6
DMQKSGI IC InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H
DMQKSGI CS C1(C(C(C(C(C1O)O)O)O)O)O
DMQKSGI IK CDAISMWEOUEBRE-UHFFFAOYSA-N
DMQKSGI IU cyclohexane-1,2,3,4,5,6-hexol
DMQKSGI CA CAS 551-72-4
DMQKSGI CB CHEBI:17268
DMQKSGI DE Alzheimer disease
DMUK6HC ID DMUK6HC
DMUK6HC DN N-5984
DMUK6HC HS Phase 2
DMUK6HC SN N-5984; SCHEMBL364457; XSOXUIXLUNBLJA-RNRVQEDPSA-N; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino)-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid; 6-(2-(R)-((2-(R)-(3-chlorophenyl)-2-hydroxyethyl)amino )-propyl)-2,3-dihydro-1,4-benzodioxin-2-(R)-carboxylic acid
DMUK6HC CP Nisshin Kyorin
DMUK6HC DT Small molecular drug
DMUK6HC PC 9865284
DMUK6HC MW 391.8
DMUK6HC FM C20H22ClNO5
DMUK6HC IC InChI=1S/C20H22ClNO5/c1-12(22-10-16(23)14-3-2-4-15(21)9-14)7-13-5-6-17-18(8-13)26-11-19(27-17)20(24)25/h2-6,8-9,12,16,19,22-23H,7,10-11H2,1H3,(H,24,25)/t12-,16+,19-/m1/s1
DMUK6HC CS C[C@H](CC1=CC2=C(C=C1)O[C@H](CO2)C(=O)O)NC[C@@H](C3=CC(=CC=C3)Cl)O
DMUK6HC IK XSOXUIXLUNBLJA-RNRVQEDPSA-N
DMUK6HC IU (2R)-6-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2,3-dihydro-1,4-benzodioxine-2-carboxylic acid
DMUK6HC DE Type-2 diabetes; Obesity
DMN7EUO ID DMN7EUO
DMN7EUO DN N6022
DMN7EUO HS Phase 2
DMN7EUO SN N6022; 1208315-24-5; N-6022; UNII-80LIU5P95D; 80LIU5P95D; CHEMBL1738699; 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid; 3-{1-(4-Carbamoyl-2-Methylphenyl)-5-[4-(1h-Imidazol-1-Yl)phenyl]-1h-Pyrrol-2-Yl}propanoic Acid; N 6022; YVPGZQLRPAGKLA-UHFFFAOYSA-N; 3-[1-(4-carbamoyl-2-methylphenyl)-5-[4-(1H-imidazol-1-yl)phenyl]-1H-pyrrol-2-yl]propanoic acid; SCHEMBL244480; EX-A343; MolPort-035-789-691; HMS3653J15; BCP09367; s7589; ZINC66156654; BDBM50354475; 2573AH; AKOS030526322; DB12206
DMN7EUO DT Small molecular drug
DMN7EUO PC 44623946
DMN7EUO MW 414.5
DMN7EUO FM C24H22N4O3
DMN7EUO IC InChI=1S/C24H22N4O3/c1-16-14-18(24(25)31)4-9-21(16)28-20(8-11-23(29)30)7-10-22(28)17-2-5-19(6-3-17)27-13-12-26-15-27/h2-7,9-10,12-15H,8,11H2,1H3,(H2,25,31)(H,29,30)
DMN7EUO CS CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O
DMN7EUO IK YVPGZQLRPAGKLA-UHFFFAOYSA-N
DMN7EUO IU 3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid
DMN7EUO CA CAS 1208315-24-5
DMN7EUO DE Asthma
DM7P0WR ID DM7P0WR
DM7P0WR DN NAI-acne
DM7P0WR HS Phase 2
DM7P0WR CP Vicuron Pharmaceuticals Inc
DM7P0WR DE Acne vulgaris
DMSWUNX ID DMSWUNX
DMSWUNX DN Naratuximab emtansine
DMSWUNX HS Phase 2
DMSWUNX SN DEBIO 1562
DMSWUNX CP Debiopharm
DMSWUNX DT Antibody
DMSWUNX DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMD0E8U ID DMD0E8U
DMD0E8U DN Naveglitazar
DMD0E8U HS Phase 2
DMD0E8U SN LY 519818; LY-818; PPAR alpha/gamma co-agonists, Lilly/Ligand
DMD0E8U CP Ligand Pharmaceuticals
DMD0E8U DT Small molecular drug
DMD0E8U PC 9888484
DMD0E8U MW 422.5
DMD0E8U FM C25H26O6
DMD0E8U IC InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1
DMD0E8U CS CO[C@@H](CC1=CC=C(C=C1)OCCCOC2=CC=C(C=C2)OC3=CC=CC=C3)C(=O)O
DMD0E8U IK OKJHGOPITGTTIM-DEOSSOPVSA-N
DMD0E8U IU (2S)-2-methoxy-3-[4-[3-(4-phenoxyphenoxy)propoxy]phenyl]propanoic acid
DMD0E8U CA CAS 476436-68-7
DMD0E8U DE Diabetic complication
DMH9JFZ ID DMH9JFZ
DMH9JFZ DN NBI-5788
DMH9JFZ HS Phase 2
DMH9JFZ SN Tiplimotide; CGP-77116; MSP-771; MSP-771A; APL (multiple sclerosis), Neurocrine/Novartis; Altered peptide ligand (MS), Neurocrine/Novartis
DMH9JFZ CP Neurocrine Biosciences Inc
DMH9JFZ PC 25084501
DMH9JFZ MW 1860.2
DMH9JFZ FM C87H142N24O21
DMH9JFZ IC InChI=1S/C87H142N24O21/c1-15-47(10)67(82(127)105-66(46(8)9)81(126)108-69(51(14)113)84(129)110-35-23-29-60(110)77(122)97-54(28-21-33-94-87(91)92)72(117)107-68(50(13)112)85(130)111-36-24-31-62(111)86(131)132)106-76(121)59(40-63(90)114)99-71(116)49(12)96-73(118)57(38-52-25-17-16-18-26-52)101-74(119)56(37-43(2)3)100-75(120)58(39-53-41-93-42-95-53)102-79(124)64(44(4)5)104-80(125)65(45(6)7)103-78(123)61-30-22-34-109(61)83(128)55(27-19-20-32-88)98-70(115)48(11)89/h16-18,25-26,41-51,54-62,64-69,112-113H,15,19-24,27-40,88-89H2,1-14H3,(H2,90,114)(H,93,95)(H,96,118)(H,97,122)(H,98,115)(H,99,116)(H,100,120)(H,101,119)(H,102,124)(H,103,123)(H,104,125)(H,105,127)(H,106,121)(H,107,117)(H,108,126)(H,131,132)(H4,91,92,94)/t47?,48-,49+,50?,51?,54+,55+,56+,57+,58+,59+,60+,61+,62+,64+,65+,66+,67+,68+,69+/m1/s1
DMH9JFZ CS CCC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N
DMH9JFZ IK NITUEMISTORFON-OOMTWUQISA-N
DMH9JFZ IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid
DMH9JFZ DE Multiple sclerosis
DMT6O2E ID DMT6O2E
DMT6O2E DN NC318
DMT6O2E HS Phase 2
DMT6O2E CP NextCure
DMT6O2E DT Antibody
DMT6O2E DE Non-small cell lung cancer
DMVQKB3 ID DMVQKB3
DMVQKB3 DN NCI-C50000
DMVQKB3 HS Phase 2
DMVQKB3 SN Levomenthol; D-(-)-Menthol; Headache crystals; Hexahydrothymol; I-menthol; Levomentholum; Menthacamphor; Menthol (VAN); Menthol natural; Menthol racemic; Menthomenthol; Peppermint camphor; Racementhol; U.S.P. Menthol; d,l-Menthol; l-(-)-Menthol; l-Menthol; l-Menthol (natural); p-Menthan-3-ol; (+-)-Menthol; (-)-(1R,3R,4S)-Menthol; (-)-Menthyl alcohol; (-)-menthol; (-)-trans-p-Menthan-cis-ol; (1R)-(-)-Menthol; (1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol; (1r,2s,5r)-(-)-menthol; (R)-(-)-Menthol; 1-Menthol; 2216-51-5; 89-78-1
DMVQKB3 PC 16666
DMVQKB3 MW 156.26
DMVQKB3 FM C10H20O
DMVQKB3 IC NOOLISFMXDJSKH-KXUCPTDWSA-N
DMVQKB3 CS CC1CCC(C(C1)O)C(C)C
DMVQKB3 IK 1S/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1
DMVQKB3 IU (1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol
DMVQKB3 CA CAS 89-78-1
DMVQKB3 CB CHEBI:15409
DMVQKB3 DE Pruritus
DM4W28K ID DM4W28K
DM4W28K DN NCX 1022
DM4W28K HS Phase 2
DM4W28K CP NicOx SA
DM4W28K DE Atopic dermatitis
DM2YIZH ID DM2YIZH
DM2YIZH DN NCX-1000
DM2YIZH HS Phase 2
DM2YIZH SN Nitric oxide ursodiol derivative, NicOx/Axcan; UDCA derivative, NicOx/Axcan; Ursodeoxycholic acid derivative, NicOx/Axcan
DM2YIZH CP NicOx SA
DM2YIZH DT Small molecular drug
DM2YIZH PC 129628949
DM2YIZH MW 685.8
DM2YIZH FM C38H55NO10
DM2YIZH IC InChI=1S/C38H55NO10/c1-24(28-10-11-29-36-30(16-18-38(28,29)3)37(2)17-15-27(40)22-26(37)23-31(36)41)7-13-35(43)49-32-12-8-25(21-33(32)46-4)9-14-34(42)47-19-5-6-20-48-39(44)45/h8-9,12,14,21,24,26-31,36,40-41H,5-7,10-11,13,15-20,22-23H2,1-4H3/b14-9+/t24-,26+,27-,28-,29+,30+,31+,36+,37+,38-/m1/s1
DM2YIZH CS C[C@H](CCC(=O)OC1=C(C=C(C=C1)/C=C/C(=O)OCCCCO[N+](=O)[O-])OC)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3[C@H](C[C@H]5[C@@]4(CC[C@H](C5)O)C)O)C
DM2YIZH IK WTAVOESJEWSDJC-OBOLPPCUSA-N
DM2YIZH IU [2-methoxy-4-[(E)-3-(4-nitrooxybutoxy)-3-oxoprop-1-enyl]phenyl] (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
DM2YIZH CA CAS 401519-96-8
DM2YIZH DE Cardiovascular disease
DMOX1CU ID DMOX1CU
DMOX1CU DN NCX-4016
DMOX1CU HS Phase 2
DMOX1CU SN Nitroaspirin; Ncx 4016; NO-ASA; Nitric oxide-releasing aspirin; M-NO-ASA; M-NO-aspirin; [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate; Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester; Benzoic acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl ester; 2-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 2-Acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-(nitrooxymethyl)phenyl ester; 2-Acetoxybenzoic acid 3-nitrooxymethylphenyl ester; 3-((Nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate; 3-(Nitroxymethyl)phenyl 2-acetoxybenzoate
DMOX1CU CP NiCox SA
DMOX1CU TC Analgesics
DMOX1CU DT Small molecular drug
DMOX1CU PC 119032
DMOX1CU MW 331.28
DMOX1CU FM C16H13NO7
DMOX1CU IC InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3
DMOX1CU CS CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-]
DMOX1CU IK IOJUJUOXKXMJNF-UHFFFAOYSA-N
DMOX1CU IU [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate
DMOX1CU CA CAS 175033-36-0
DMOX1CU CB CHEBI:125482
DMOX1CU DE Claudication; Nephropathy; Type-2 diabetes; Inflammation
DM6S83X ID DM6S83X
DM6S83X DN NDDP
DM6S83X HS Phase 2
DM6S83X SN Cis-Bis(2,2-dimethyloctanoato)[trans-1(R),2(R)-diaminocyclohexane]platinum (II)
DM6S83X DT Small molecular drug
DM6S83X PC 56841091
DM6S83X MW 649.8
DM6S83X FM C26H50N2O4Pt
DM6S83X IC InChI=1S/2C10H20O2.C6H12N2.Pt/c2*1-10(2,3)8-6-4-5-7-9(11)12;7-5-3-1-2-4-6(5)8;/h2*4-8H2,1-3H3,(H,11,12);5-8H,1-4H2;/q;;-2;+4/p-2
DM6S83X CS CC(C)(C)CCCCCC(=O)[O-].CC(C)(C)CCCCCC(=O)[O-].C1CCC(C(C1)[NH-])[NH-].[Pt+4]
DM6S83X IK ALPHSAWEOKVWID-UHFFFAOYSA-L
DM6S83X IU (2-azanidylcyclohexyl)azanide;7,7-dimethyloctanoate;platinum(4+)
DM6S83X CA CAS 113427-19-3
DM6S83X DE Solid tumour/cancer
DMVIRN3 ID DMVIRN3
DMVIRN3 DN N-DESMETHYLCLOZAPINE
DMVIRN3 HS Phase 2
DMVIRN3 DT Small molecular drug
DMVIRN3 PC 135409468
DMVIRN3 MW 312.8
DMVIRN3 FM C17H17ClN4
DMVIRN3 IC InChI=1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2
DMVIRN3 CS C1CN(CCN1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
DMVIRN3 IK JNNOSTQEZICQQP-UHFFFAOYSA-N
DMVIRN3 IU 3-chloro-6-piperazin-1-yl-11H-benzo[b][1,4]benzodiazepine
DMVIRN3 CA CAS 6104-71-8
DMVIRN3 CB CHEBI:64050
DMVIRN3 DE Schizoaffective disorder; Schizophrenia
DMUPZFO ID DMUPZFO
DMUPZFO DN Neihulizumab
DMUPZFO HS Phase 2
DMUPZFO CP AbGenomics International Los Altos, CA
DMUPZFO DE Psoriatic arthritis
DMSVWI7 ID DMSVWI7
DMSVWI7 DN Neladenoson bialanate
DMSVWI7 HS Phase 2
DMSVWI7 SN UNII-IV690462VZ; IV690462VZ; 1239309-58-0; Neladenoson dalanate; Neladenoson dalanate [INN]; Neladenoson bialanate [INN]; SCHEMBL7904070; AKOS032946515; DB13138; L-Alanine, L-alanyl-, 2-(4-(2-(((2-(4-chlorophenyl)-4-thiazolyl)methyl)thio)-3,5-dicyano-6-(1-pyrrolidinyl)-4-pyridinyl)phenoxy)ethyl ester; 2-(4-(2-(((2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate
DMSVWI7 CP Bayer HealthCare Pharmaceuticals Whippany, NJ
DMSVWI7 PC 56848985
DMSVWI7 MW 716.3
DMSVWI7 FM C35H34ClN7O4S2
DMSVWI7 IC InChI=1S/C35H34ClN7O4S2/c1-21(39)32(44)40-22(2)35(45)47-16-15-46-27-11-7-23(8-12-27)30-28(17-37)31(43-13-3-4-14-43)42-34(29(30)18-38)49-20-26-19-48-33(41-26)24-5-9-25(36)10-6-24/h5-12,19,21-22H,3-4,13-16,20,39H2,1-2H3,(H,40,44)/t21-,22-/m0/s1
DMSVWI7 CS C[C@@H](C(=O)N[C@@H](C)C(=O)OCCOC1=CC=C(C=C1)C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N5CCCC5)C#N)N
DMSVWI7 IK WESNEIGKOAXSGX-VXKWHMMOSA-N
DMSVWI7 IU 2-[4-[2-[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-3,5-dicyano-6-pyrrolidin-1-ylpyridin-4-yl]phenoxy]ethyl (2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoate
DMSVWI7 CA CAS 1239309-58-0
DMSVWI7 DE Chronic heart failure
DM4LKFO ID DM4LKFO
DM4LKFO DN NELOTANSERIN
DM4LKFO HS Phase 2
DM4LKFO SN NELOTANSERIN; 839713-36-9; UNII-4ZA73QEW2P; 4ZA73QEW2P; CHEMBL598172; APD125; APD-125; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea; 1-[3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL]-3-(2,4-DIFLUOROPHENYL)UREA; N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-N'-(2,4-difluorophenyl)-Urea; Nelotanserin [USAN:INN]; Nelotanserin (USAN/INN); SCHEMBL2345325; APD 125; DTXSID40232868; COSPVUFTLGQDQL-UHFFFAOYSA-N; BCP24992; ZINC38239930; BDBM50324541; AKOS027255058; DB12555
DM4LKFO DT Small molecular drug
DM4LKFO PC 11683556
DM4LKFO MW 437.2
DM4LKFO FM C18H15BrF2N4O2
DM4LKFO IC InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
DM4LKFO CS CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC
DM4LKFO IK COSPVUFTLGQDQL-UHFFFAOYSA-N
DM4LKFO IU 1-[3-(4-bromo-2-methylpyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
DM4LKFO CA CAS 839713-36-9
DM4LKFO DE Sleep-wake disorder; Lewy body dementia
DMNM9DZ ID DMNM9DZ
DMNM9DZ DN Nepicastat oral
DMNM9DZ HS Phase 2
DMNM9DZ SN SYN117
DMNM9DZ CP Biotie Therapies
DMNM9DZ DT Small molecular drug
DMNM9DZ PC 9840545
DMNM9DZ MW 331.8
DMNM9DZ FM C14H16ClF2N3S
DMNM9DZ IC InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1
DMNM9DZ CS C1CC2=C(C[C@H]1N3C(=CNC3=S)CN)C=C(C=C2F)F.Cl
DMNM9DZ IK DIPDUAJWNBEVOY-PPHPATTJSA-N
DMNM9DZ IU 4-(aminomethyl)-3-[(2S)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1H-imidazole-2-thione;hydrochloride
DMNM9DZ CA CAS 170151-24-3
DMNM9DZ DE Post-traumatic stress disorder
DM3ORVD ID DM3ORVD
DM3ORVD DN Neramexane
DM3ORVD HS Phase 2
DM3ORVD SN Neramexane [INN]; Mrz 2579; MRZ 2-579; 1,3,3,5,5-Pentamethylcyclohexanamine; 1,3,3,5,5-pentamethylcyclohexan-1-amine
DM3ORVD CP Merz Pharmaceuticals GmbH
DM3ORVD TC Analgesics
DM3ORVD DT Small molecular drug
DM3ORVD PC 6433106
DM3ORVD MW 169.31
DM3ORVD FM C11H23N
DM3ORVD IC InChI=1S/C11H23N/c1-9(2)6-10(3,4)8-11(5,12)7-9/h6-8,12H2,1-5H3
DM3ORVD CS CC1(CC(CC(C1)(C)N)(C)C)C
DM3ORVD IK OGZQTTHDGQBLBT-UHFFFAOYSA-N
DM3ORVD IU 1,3,3,5,5-pentamethylcyclohexan-1-amine
DM3ORVD CA CAS 219810-59-0
DM3ORVD DE Cancer related pain
DMBJ3GL ID DMBJ3GL
DMBJ3GL DN Nerenone
DMBJ3GL HS Phase 2
DMBJ3GL CP Bayer healthcare pharmaceuticals
DMBJ3GL DE Diabetic nephropathy
DM8H7OA ID DM8H7OA
DM8H7OA DN Netoglitazone
DM8H7OA HS Phase 2
DM8H7OA SN Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
DM8H7OA CP Mitsubishi Pharma
DM8H7OA DT Small molecular drug
DM8H7OA PC 204109
DM8H7OA MW 381.4
DM8H7OA FM C21H16FNO3S
DM8H7OA IC InChI=1S/C21H16FNO3S/c22-18-4-2-1-3-16(18)12-26-17-8-7-14-9-13(5-6-15(14)11-17)10-19-20(24)23-21(25)27-19/h1-9,11,19H,10,12H2,(H,23,24,25)
DM8H7OA CS C1=CC=C(C(=C1)COC2=CC3=C(C=C2)C=C(C=C3)CC4C(=O)NC(=O)S4)F
DM8H7OA IK PKWDZWYVIHVNKS-UHFFFAOYSA-N
DM8H7OA IU 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
DM8H7OA CA CAS 161600-01-7
DM8H7OA DE Non-alcoholic fatty liver disease
DMOZW4C ID DMOZW4C
DMOZW4C DN Neublastin
DMOZW4C HS Phase 2
DMOZW4C CP Biogen Idec
DMOZW4C DE Pain
DMIQDFW ID DMIQDFW
DMIQDFW DN Neu-P11
DMIQDFW HS Phase 2
DMIQDFW SN Piromelatine; UNII-S3UN2146K9; 946846-83-9; S3UN2146K9; NEU-P11; Piromelatine [INN]; NEU-P-11; SCHEMBL8235551; DTXSID90241566; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2-carboxamide; 4H-Pyran-2-carboxamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-; SB19819
DMIQDFW CP Neurim Pharmaceuticals
DMIQDFW DT Small molecular drug
DMIQDFW PC 24815904
DMIQDFW MW 312.32
DMIQDFW FM C17H16N2O4
DMIQDFW IC InChI=1S/C17H16N2O4/c1-22-13-2-3-15-14(9-13)11(10-19-15)4-6-18-17(21)16-8-12(20)5-7-23-16/h2-3,5,7-10,19H,4,6H2,1H3,(H,18,21)
DMIQDFW CS COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3
DMIQDFW IK PNTNBIHOAPJYDB-UHFFFAOYSA-N
DMIQDFW IU N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxopyran-2-carboxamide
DMIQDFW CA CAS 946846-83-9
DMIQDFW DE Insomnia; Alzheimer disease; Dementia
DMINQP1 ID DMINQP1
DMINQP1 DN NEUROPEPTIDE-Y
DMINQP1 HS Phase 2
DMINQP1 SN XKWCTHKJQNUFOQ-HRPSIEBRSA-N; Neuropeptide Y
DMINQP1 DT Small molecular drug
DMINQP1 PC 91928728
DMINQP1 MW 4254
DMINQP1 FM C190H287N55O57
DMINQP1 IC InChI=1S/C190H287N55O57/c1-16-94(9)149(180(296)235-129(81-141(194)255)169(285)227-124(74-93(7)8)172(288)240-150(95(10)17-2)181(297)241-151(100(15)248)182(298)222-116(32-23-67-209-190(203)204)156(272)221-118(57-60-140(193)254)161(277)219-114(30-21-65-207-188(199)200)157(273)224-121(152(196)268)76-102-39-49-108(250)50-40-102)239-173(289)127(79-105-45-55-111(253)56-46-105)230-168(284)128(80-106-86-205-90-211-106)231-159(275)115(31-22-66-208-189(201)202)220-165(281)123(73-92(5)6)225-155(271)97(12)213-174(290)134(88-246)237-167(283)126(78-104-43-53-110(252)54-44-104)229-166(282)125(77-103-41-51-109(251)52-42-103)228-158(274)113(29-20-64-206-187(197)198)217-153(269)96(11)212-163(279)122(72-91(3)4)226-170(286)131(84-147(264)265)233-162(278)119(59-62-145(260)261)218-154(270)98(13)214-177(293)137-34-25-68-242(137)183(299)99(14)215-164(280)130(83-146(262)263)232-160(276)117(58-61-144(258)259)216-143(257)87-210-176(292)136-33-24-70-244(136)186(302)133(82-142(195)256)236-171(287)132(85-148(266)267)234-178(294)139-36-27-71-245(139)185(301)120(28-18-19-63-191)223-175(291)135(89-247)238-179(295)138-35-26-69-243(138)184(300)112(192)75-101-37-47-107(249)48-38-101/h37-56,86,90-100,112-139,149-151,246-253H,16-36,57-85,87-89,191-192H2,1-15H3,(H2,193,254)(H2,194,255)(H2,195,256)(H2,196,268)(H,205,211)(H,210,292)(H,212,279)(H,213,290)(H,214,293)(H,215,280)(H,216,257)(H,217,269)(H,218,270)(H,219,277)(H,220,281)(H,221,272)(H,222,298)(H,223,291)(H,224,273)(H,225,271)(H,226,286)(H,227,285)(H,228,274)(H,229,282)(H,230,284)(H,231,275)(H,232,276)(H,233,278)(H,234,294)(H,235,296)(H,236,287)(H,237,283)(H,238,295)(H,239,289)(H,240,288)(H,241,297)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H4,197,198,206)(H4,199,200,207)(H4,201,202,208)(H4,203,204,209)/t94-,95-,96-,97-,98-,99-,100+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,149-,150-,151-/m0/s1
DMINQP1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]8CCCN8C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]9CCCN9C(=O)[C@H](CC1=CC=C(C=C1)O)N
DMINQP1 IK URPYMXQQVHTUDU-OFGSCBOVSA-N
DMINQP1 IU (4S)-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-[[2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoic acid
DML5S71 ID DML5S71
DML5S71 DN Nexopamil
DML5S71 HS Phase 2
DML5S71 SN LU-49938
DML5S71 CP BASF AG
DML5S71 DT Small molecular drug
DML5S71 PC 65984
DML5S71 MW 404.6
DML5S71 FM C24H40N2O3
DML5S71 IC InChI=1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1
DML5S71 CS CCCCCCN(C)CCC[C@@](C#N)(C1=CC(=C(C(=C1)OC)OC)OC)C(C)C
DML5S71 IK SKDZEFVVFACNLS-DEOSSOPVSA-N
DML5S71 IU (2S)-5-[hexyl(methyl)amino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile
DML5S71 CA CAS 136033-49-3
DML5S71 DE Hypertension
DMJKBAY ID DMJKBAY
DMJKBAY DN NGX-267
DMJKBAY HS Phase 2
DMJKBAY SN 503431-81-0; AF267B; (2S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4,5]DECAN-3-ONE; UNII-8D3PZX7G73; AF 267B; 8D3PZX7G73; (S)-2-Ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one; NGX-267; NGX267; NGX 267; SCHEMBL3651146; CTK1G8674; DTXSID40198399; AF-267B; PHOZOHFUXHPOCK-QMMMGPOBSA-N; ZINC13816318; AKOS025295388; NCGC00162382-01; RT-005412; FT-0668336; (S)-2-Ethyl-8-methyl-1-thia-4,8-diaza-spiro[4.5]decan-3-one; 1-Thia-4,8-diazaspiro(4.5)decan-3-one, 2-ethyl-8-methyl-, (2S)-
DMJKBAY DT Small molecular drug
DMJKBAY PC 10013505
DMJKBAY MW 214.33
DMJKBAY FM C10H18N2OS
DMJKBAY IC InChI=1S/C10H18N2OS/c1-3-8-9(13)11-10(14-8)4-6-12(2)7-5-10/h8H,3-7H2,1-2H3,(H,11,13)/t8-/m0/s1
DMJKBAY CS CC[C@H]1C(=O)NC2(S1)CCN(CC2)C
DMJKBAY IK PHOZOHFUXHPOCK-QMMMGPOBSA-N
DMJKBAY IU (2S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one
DMJKBAY CA CAS 503431-81-0
DMJKBAY DE Schizophrenia
DMDY01J ID DMDY01J
DMDY01J DN NHS-IL2-LT
DMDY01J HS Phase 2
DMDY01J SN Selectikine; EMD-521873; Immunocytokine (solid tumors), Merck Serono
DMDY01J CP Merck Serono SA
DMDY01J DE Solid tumour/cancer
DMRQUH4 ID DMRQUH4
DMRQUH4 DN NI-0801
DMRQUH4 HS Phase 2
DMRQUH4 SN Anti-interferon inducible protein 10, NovImmune
DMRQUH4 CP NovImmune SA
DMRQUH4 DT Antibody
DMRQUH4 DE Autoimmune diabetes
DMKLJMI ID DMKLJMI
DMKLJMI DN NIC-002
DMKLJMI HS Phase 2
DMKLJMI SN NicQb; Nicotine-Qbeta; CYT-002-NicQb; Nicotine vaccine, Cytos/Novartis; Immunodrug (nicotine addiction), Cytos/Novartis
DMKLJMI CP Cytos Biotechnology AG
DMKLJMI DT Vaccine
DMKLJMI DE Nicotine dependence
DMG7XOC ID DMG7XOC
DMG7XOC DN NIC5-15
DMG7XOC HS Phase 2
DMG7XOC SN D-Pinitol; Pinitol; 10284-63-6; 3-O-Methyl-D-chiro-inositol; (+)-Pinitol; D-(+)-Pinitol; Inzitol; Methylinositol; Sennitol; 1-D-4-O-METHYL-MYO-INOSITOL; Pinit; D-ononitol; Ononitol; 1D-4-O-Methyl-myo-inositol; 1D-3-O-methyl-chiro-inositol; D-chiro-Inositol, 3-O-methyl-; 4-O-Methyl-myo-inositol; UNII-TF9HZN9T0M; UNII-A998ME07KR; 5D-5-O-Methyl-chiro-inositol; 6090-97-7; (1r,2s,4s,5s)-6-methoxycyclohexane-1,2,3,4,5-pentol; TF9HZN9T0M; 484-68-4; Matezit; Sennit; CHEMBL493737; A998ME07KR; CHEBI:28548; DSCFFEYYQKSRSV-KLJZZCKASA-N; NSC 43336
DMG7XOC CP Humanetics Minneapolis, MN
DMG7XOC DT Small molecular drug
DMG7XOC PC 164619
DMG7XOC MW 194.18
DMG7XOC FM C7H14O6
DMG7XOC IC InChI=1S/C7H14O6/c1-13-7-5(11)3(9)2(8)4(10)6(7)12/h2-12H,1H3/t2?,3-,4-,5-,6+,7?/m0/s1
DMG7XOC CS COC1[C@@H]([C@H](C([C@@H]([C@@H]1O)O)O)O)O
DMG7XOC IK DSCFFEYYQKSRSV-FEPQRWDDSA-N
DMG7XOC IU (1S,2S,4S,5R)-6-methoxycyclohexane-1,2,3,4,5-pentol
DMG7XOC CA CAS 484-68-4
DMG7XOC CB CHEBI:28548
DMG7XOC DE Alzheimer disease
DM21Z68 ID DM21Z68
DM21Z68 DN Nimacimab
DM21Z68 HS Phase 2
DM21Z68 SN Namacizumab
DM21Z68 CP Bird Rock Bio
DM21Z68 DT Antibody
DM21Z68 DE Diabetic nephropathy
DMPER4A ID DMPER4A
DMPER4A DN NIR178
DMPER4A HS Phase 2
DMPER4A CP Novartis Oncology East Hanover,
DMPER4A DE Non-hodgkin lymphoma; Solid tumour/cancer
DM81SDB ID DM81SDB
DM81SDB DN Niravoline
DM81SDB HS Phase 2
DM81SDB SN AC1L24CB; AC1Q1ZY1; N-methyl-2-(3-nitrophenyl)-N-[(2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide
DM81SDB DT Small molecular drug
DM81SDB PC 9821174
DM81SDB MW 379.5
DM81SDB FM C22H25N3O3
DM81SDB IC InChI=1S/C22H25N3O3/c1-23(21(26)14-16-7-6-9-18(13-16)25(27)28)22-19-10-3-2-8-17(19)15-20(22)24-11-4-5-12-24/h2-3,6-10,13,20,22H,4-5,11-12,14-15H2,1H3/t20-,22-/m0/s1
DM81SDB CS CN([C@@H]1[C@H](CC2=CC=CC=C12)N3CCCC3)C(=O)CC4=CC(=CC=C4)[N+](=O)[O-]
DM81SDB IK ZSDAQBWGAOKTSI-UNMCSNQZSA-N
DM81SDB IU N-methyl-2-(3-nitrophenyl)-N-[(1S,2S)-2-pyrrolidin-1-yl-2,3-dihydro-1H-inden-1-yl]acetamide
DM81SDB CA CAS 130610-93-4
DM81SDB DE Pain
DM8LBYT ID DM8LBYT
DM8LBYT DN NIS793
DM8LBYT HS Phase 2
DM8LBYT CP Novartis Oncology East Hanover,
DM8LBYT DE Solid tumour/cancer; Pancreatic ductal carcinoma
DMQHBSX ID DMQHBSX
DMQHBSX DN NITD609
DMQHBSX HS Phase 2
DMQHBSX SN Cipargamin; 1193314-23-6; NITD-609; NITD 609; UNII-Z7Q4FWA04P; (1'R,3'S)-5,7'-Dichloro-6'-fluoro-3'-methyl-2',3',4',9'-tetrahydrospiro[indoline-3,1'-pyrido[3,4-b]indol]-2-one; Z7Q4FWA04P; CHEMBL1082723; Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one, 5,7'-dichloro-6'-fluoro-2',3',4',9'-tetrahydro-3'-methyl-, (1'R,3'S)-; Cipargamin [INN]; 1252008-89-1; GTPL9721; SCHEMBL1306342; DTXSID70152424; MolPort-039-337-269; ZINC49037032; BDBM50318666; AKOS027253851; SB16518; DB12306; CS-7486; NCGC00263785-01
DMQHBSX DT Small molecular drug
DMQHBSX PC 44469321
DMQHBSX MW 390.2
DMQHBSX FM C19H14Cl2FN3O
DMQHBSX IC InChI=1S/C19H14Cl2FN3O/c1-8-4-11-10-6-14(22)13(21)7-16(10)23-17(11)19(25-8)12-5-9(20)2-3-15(12)24-18(19)26/h2-3,5-8,23,25H,4H2,1H3,(H,24,26)/t8-,19+/m0/s1
DMQHBSX CS C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl
DMQHBSX IK CKLPLPZSUQEDRT-WPCRTTGESA-N
DMQHBSX IU (3R,3'S)-5,7'-dichloro-6'-fluoro-3'-methylspiro[1H-indole-3,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-2-one
DMQHBSX CA CAS 1193314-23-6
DMQHBSX DE Malaria
DMAOUZV ID DMAOUZV
DMAOUZV DN Nivatrotamab
DMAOUZV HS Phase 2
DMAOUZV CP Memorial Sloan Kettering; Y-mAbs Therapeutics
DMAOUZV DT Antibody
DMAOUZV DE Solid tumour/cancer; Small-cell lung cancer
DMUX8JZ ID DMUX8JZ
DMUX8JZ DN Nivocasan
DMUX8JZ HS Phase 2
DMUX8JZ SN GS-9450; LB-84451
DMUX8JZ CP LG Life Sciences Ltd
DMUX8JZ PC 11633038
DMUX8JZ MW 415.4
DMUX8JZ FM C21H22FN3O5
DMUX8JZ IC InChI=1S/C21H22FN3O5/c1-12(2)20(19(27)24-16-9-17(26)29-21(16,28)11-22)10-15(25-30-20)18-14-6-4-3-5-13(14)7-8-23-18/h3-8,12,16,28H,9-11H2,1-2H3,(H,24,27)/t16-,20+,21+/m0/s1
DMUX8JZ CS CC(C)[C@]1(CC(=NO1)C2=NC=CC3=CC=CC=C32)C(=O)N[C@H]4CC(=O)O[C@@]4(CF)O
DMUX8JZ IK VYFGDLGHHBUDTQ-ZLGUVYLKSA-N
DMUX8JZ IU (5R)-N-[(2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxooxolan-3-yl]-3-isoquinolin-1-yl-5-propan-2-yl-4H-1,2-oxazole-5-carboxamide
DMUX8JZ CA CAS 908253-63-4
DMUX8JZ DE Fibrosis
DMTVGMZ ID DMTVGMZ
DMTVGMZ DN NKP 608
DMTVGMZ HS Phase 2
DMTVGMZ SN AV608)
DMTVGMZ CP Novartis; Avera Pharmaceuticals
DMTVGMZ PC 9917079
DMTVGMZ MW 620
DMTVGMZ FM C31H24ClF6N3O2
DMTVGMZ IC InChI=1S/C31H24ClF6N3O2/c32-22-7-5-18(6-8-22)13-24-17-23(40-28(42)26-9-11-39-27-4-2-1-3-25(26)27)10-12-41(24)29(43)19-14-20(30(33,34)35)16-21(15-19)31(36,37)38/h1-9,11,14-16,23-24H,10,12-13,17H2,(H,40,42)/t23-,24+/m0/s1
DMTVGMZ CS C1CN([C@@H](C[C@H]1NC(=O)C2=CC=NC3=CC=CC=C23)CC4=CC=C(C=C4)Cl)C(=O)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
DMTVGMZ IK NXLUTEDAEFXMQR-BJKOFHAPSA-N
DMTVGMZ IU N-[(2R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide
DMTVGMZ CA CAS 177707-12-9
DMTVGMZ DE Mood disorder
DMKD5ZO ID DMKD5ZO
DMKD5ZO DN NN-8226
DMKD5ZO HS Phase 2
DMKD5ZO SN NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk
DMKD5ZO CP ZymoGenetics Inc
DMKD5ZO DT Antibody
DMKD5ZO DE Psoriasis vulgaris
DM3IEHP ID DM3IEHP
DM3IEHP DN NN8555
DM3IEHP HS Phase 2
DM3IEHP CP Novo Nordisk
DM3IEHP DE Rheumatoid arthritis; Crohn disease
DMCFPBE ID DMCFPBE
DMCFPBE DN NN8765
DMCFPBE HS Phase 2
DMCFPBE CP Novo Nordisk
DMCFPBE DE Rheumatoid arthritis
DMDTNOS ID DMDTNOS
DMDTNOS DN NNC-0123-0000-0338
DMDTNOS HS Phase 2
DMDTNOS CP Novo Nordisk A/S
DMDTNOS DE Diabetic complication
DMU3KOH ID DMU3KOH
DMU3KOH DN NNC-0151-0000-0000
DMU3KOH HS Phase 2
DMU3KOH SN Neutrazumab; Anti-C5aR monoclonal antibodies (rheumatoid arthritis/SLE), G2/Novo Nordisk
DMU3KOH CP G2 Therapies Ltd
DMU3KOH DT Antibody
DMU3KOH DE Rheumatoid arthritis
DMPZ97S ID DMPZ97S
DMPZ97S DN NNZ-2566
DMPZ97S HS Phase 2
DMPZ97S SN Glypromate analogs (oral, neuroprotection), Neuren; NNZ-2566 (oral, neurodegeneration/injury); NNZ-2566 (oral, neurodegeneration/injury), Neuren
DMPZ97S CP Neuren pharmaceuticals
DMPZ97S DT Small molecular drug
DMPZ97S PC 11318905
DMPZ97S MW 315.32
DMPZ97S FM C13H21N3O6
DMPZ97S IC InChI=1S/C13H21N3O6/c1-13(5-2-6-16(13)9(17)7-14)12(22)15-8(11(20)21)3-4-10(18)19/h8H,2-7,14H2,1H3,(H,15,22)(H,18,19)(H,20,21)/t8-,13-/m0/s1
DMPZ97S CS C[C@]1(CCCN1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMPZ97S IK BUSXWGRAOZQTEY-SDBXPKJASA-N
DMPZ97S IU (2S)-2-[[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMPZ97S CA CAS 853400-76-7
DMPZ97S DE Fragile X syndrome; Rett syndrome; Traumatic brain injury; Type-1 diabetes
DME8IFQ ID DME8IFQ
DME8IFQ DN Noberastine
DME8IFQ HS Phase 2
DME8IFQ SN Flamizole; R-64947; R-72075
DME8IFQ CP Janssen Pharmaceutica NV
DME8IFQ DT Small molecular drug
DME8IFQ PC 60531
DME8IFQ MW 311.4
DME8IFQ FM C17H21N5O
DME8IFQ IC InChI=1S/C17H21N5O/c1-12-4-5-14(23-12)11-22-16-15(3-2-8-19-16)21-17(22)20-13-6-9-18-10-7-13/h2-5,8,13,18H,6-7,9-11H2,1H3,(H,20,21)
DME8IFQ CS CC1=CC=C(O1)CN2C3=C(C=CC=N3)N=C2NC4CCNCC4
DME8IFQ IK VNIOQSAWKLOGLY-UHFFFAOYSA-N
DME8IFQ IU 3-[(5-methylfuran-2-yl)methyl]-N-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine
DME8IFQ CA CAS 110588-56-2
DME8IFQ DE Asthma
DMEHOI1 ID DMEHOI1
DMEHOI1 DN Novaferon
DMEHOI1 HS Phase 2
DMEHOI1 SN Recombinant interferon-like protein, Genova/Novagenetics/Novagen; Recombinant huIFN-alpha-like protein (cancer, viral infection), Genova/Novagenetics/Novagen
DMEHOI1 CP Novagenetics Inc
DMEHOI1 DE Colorectal cancer
DMHG3UR ID DMHG3UR
DMHG3UR DN NOX-E36
DMHG3UR HS Phase 2
DMHG3UR SN Monocyte chemoattractant protein-1 ligand inhibitor(spiegelmer, diabetic complications), NOXXON; MCP-1 inhibitor (spiegelmer/injectable, diabetic complications/diabetic nephropathy), NOXXON
DMHG3UR CP NOXXON Pharma AG
DMHG3UR DE Diabetic complication
DM5HPZU ID DM5HPZU
DM5HPZU DN NOX-H94
DM5HPZU HS Phase 2
DM5HPZU CP NOXXON Pharma AG; Avant Immunotherapeutics
DM5HPZU DE Anemia
DMP1W9Z ID DMP1W9Z
DMP1W9Z DN NP-01
DMP1W9Z HS Phase 2
DMP1W9Z SN Vanadium (buccal, nanodroplet emulsion (Aonys), type 2 diabetes/metabolic syndrome), Medesis
DMP1W9Z CP Medesis Pharma SA
DMP1W9Z DE Type-2 diabetes
DMLMZ6Q ID DMLMZ6Q
DMLMZ6Q DN NP-2
DMLMZ6Q HS Phase 2
DMLMZ6Q SN NP2 Enkephalin; NPE-1; NPE-2; Enkephalin-expressing gene therapy (HSV carrier, pain), Diamyd; Enkephalin-expressinggene therapy (HSV carrier/NTDDS, pain), Nurel
DMLMZ6Q CP Periphagen holdings
DMLMZ6Q DT Small molecular drug
DMLMZ6Q PC 16130887
DMLMZ6Q MW 3855
DMLMZ6Q FM C161H282N62O36S6
DMLMZ6Q IC InChI=1S/C161H282N62O36S6/c1-20-84(15)120(148(254)206-91(38-25-51-182-153(163)164)125(231)192-70-115(224)197-92(39-26-52-183-154(165)166)132(238)220-121(85(16)21-2)149(255)212-106(67-90-68-181-77-193-90)151(257)223-61-35-48-114(223)145(251)210-103(64-80(7)8)136(242)215-112(76-265)143(249)217-110(74-263)141(247)203-97(44-31-57-188-159(175)176)130(236)207-100(152(258)259)46-33-59-190-161(179)180)221-133(239)98(45-32-58-189-160(177)178)204-140(246)109(73-262)216-137(243)104(66-89-36-23-22-24-37-89)198-116(225)69-191-122(228)86(17)194-126(232)93(40-27-53-184-155(167)168)199-128(234)95(42-29-55-186-157(171)172)201-131(237)99(49-50-117(226)227)205-134(240)102(63-79(5)6)209-144(250)113-47-34-60-222(113)150(256)105(65-81(9)10)211-142(248)111(75-264)214-135(241)101(62-78(3)4)208-123(229)87(18)195-127(233)94(41-28-54-185-156(169)170)200-129(235)96(43-30-56-187-158(173)174)202-139(245)108(72-261)213-124(230)88(19)196-138(244)107(71-260)218-147(253)119(83(13)14)219-146(252)118(162)82(11)12/h22-24,36-37,68,77-88,91-114,118-121,260-265H,20-21,25-35,38-67,69-76,162H2,1-19H3,(H,181,193)(H,191,228)(H,192,231)(H,194,232)(H,195,233)(H,196,244)(H,197,224)(H,198,225)(H,199,234)(H,200,235)(H,201,237)(H,202,245)(H,203,247)(H,204,246)(H,205,240)(H,206,254)(H,207,236)(H,208,229)(H,209,250)(H,210,251)(H,211,248)(H,212,255)(H,213,230)(H,214,241)(H,215,242)(H,216,243)(H,217,249)(H,218,253)(H,219,252)(H,220,238)(H,221,239)(H,226,227)(H,258,259)(H4,163,164,182)(H4,165,166,183)(H4,167,168,184)(H4,169,170,185)(H4,171,172,186)(H4,173,174,187)(H4,175,176,188)(H4,177,178,189)(H4,179,180,190)/t84-,85-,86-,87-,88-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,118-,119-,120-,121-/m0/s1
DMLMZ6Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N
DMLMZ6Q IK AEUKDPKXTPNBNY-XEYRWQBLSA-N
DMLMZ6Q IU (4S)-4-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMLMZ6Q CA CAS 88086-40-2
DMLMZ6Q DE Influenza A virus infection
DME6KAF ID DME6KAF
DME6KAF DN NPC-15199
DME6KAF HS Phase 2
DME6KAF SN 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; F-L-Leu; CHEMBL294989; PPARgamma Activator, Fmoc-Leu; 2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; Fmoc-DL-leucine; N-alpha-Fmoc-L-leucine; NSC334290; ACMC-209iik; AC1L1HVH; n-[(9h-fluoren-9-ylmethoxy)carbonyl]leucin; ACMC-2099ky; AC1Q5SK7; 126727-03-5; 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid; (2S)-2-[(fluoren-9-ylmethoxy)carbonylamino]-4-methylpentanoic acid; GTPL2705; SCHEMBL1002861; CHEBI:91726; CTK8G6077; MolPort-003-700-319; HMS3266H19; SBB056939; IN1334; BDBM50034787; AKOS017268980
DME6KAF CP Scios Inc
DME6KAF DT Small molecular drug
DME6KAF PC 1549133
DME6KAF MW 353.4
DME6KAF FM C21H23NO4
DME6KAF IC InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/t19-/m0/s1
DME6KAF CS CC(C)C[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
DME6KAF IK CBPJQFCAFFNICX-IBGZPJMESA-N
DME6KAF IU (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid
DME6KAF CA CAS 35661-60-0
DME6KAF DE Inflammation
DM9VEAL ID DM9VEAL
DM9VEAL DN NPC-1C
DM9VEAL HS Phase 2
DM9VEAL SN Ensituximab
DM9VEAL CP Neogenix Oncology
DM9VEAL DT Antibody
DM9VEAL DE Colorectal cancer; Pancreatic tumour; Pancreatic cancer
DM3DQXG ID DM3DQXG
DM3DQXG DN NPSP-795
DM3DQXG HS Phase 2
DM3DQXG SN NPSP-790; SB-423557; SB-423557A; SB-423562; SB-423562A
DM3DQXG CP GlaxoSmithKline plc
DM3DQXG PC 9910902
DM3DQXG MW 436.5
DM3DQXG FM C26H32N2O4
DM3DQXG IC InChI=1S/C26H32N2O4/c1-26(2,14-19-11-20-5-3-4-6-21(20)12-19)28-16-23(29)17-32-24-13-18(8-10-25(30)31)7-9-22(24)15-27/h3-7,9,13,19,23,28-29H,8,10-12,14,16-17H2,1-2H3,(H,30,31)/t23-/m1/s1
DM3DQXG CS CC(C)(CC1CC2=CC=CC=C2C1)NC[C@H](COC3=C(C=CC(=C3)CCC(=O)O)C#N)O
DM3DQXG IK NJBFJCJKWWIKRD-HSZRJFAPSA-N
DM3DQXG IU 3-[4-cyano-3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]phenyl]propanoic acid
DM3DQXG CA CAS 351490-27-2
DM3DQXG DE Osteoporosis
DMYXOU2 ID DMYXOU2
DMYXOU2 DN NRX-4204
DMYXOU2 HS Phase 2
DMYXOU2 SN AGN-190205; AGN-191659; AGN-191701; AGN-192326; AGN-192327; AGN-192509; AGN-192599; AGN-192870; AGN-194277; AGN-195393; AGN-4202; ALRT-326; ALRT-4204; LGD-4204; LGD-4326; NRX-194202; RXR ligands, ALRT; RXR ligands, Allergan; Retinoid X receptor agonists, ALRT; Retinoid X receptor agonists, Allergan; VTP-4204; RXR agonists, Allergan/Pfizer; Rexinoid receptor agonist (cancer), NuRx; RXR agonists (cancer/ diabetes), Vitae Pharmaceuticals; RXR agonists, Allergan/Parke-Davis
DMYXOU2 CP Allergan Ligand Retinoid Therapeutics Inc
DMYXOU2 DT Small molecular drug
DMYXOU2 PC 9863342
DMYXOU2 MW 352.5
DMYXOU2 FM C24H32O2
DMYXOU2 IC InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+
DMYXOU2 CS C/C(=C\\C(=O)O)/C=C/C1CC1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DMYXOU2 IK BOOOLEGQBVUTKC-YWRSBGDESA-N
DMYXOU2 IU (2E,4E)-3-methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid
DMYXOU2 DE Diabetic complication
DM9EFH0 ID DM9EFH0
DM9EFH0 DN NS 1209
DM9EFH0 HS Phase 2
DM9EFH0 CP NeuroSearch
DM9EFH0 TC Analgesics
DM9EFH0 DT Small molecular drug
DM9EFH0 PC 135456058
DM9EFH0 MW 516.6
DM9EFH0 FM C24H28N4O7S
DM9EFH0 IC InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)
DM9EFH0 CS CN1CCC2=C(C1)C3=C(C=C2C4=CC=C(C=C4)S(=O)(=O)N(C)C)/C(=N/OC(CCO)C(=O)O)/C(=O)N3
DM9EFH0 IK CFJRSKULEDUDKL-UHFFFAOYSA-N
DM9EFH0 IU 2-[(Z)-[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid
DM9EFH0 CA CAS 245063-59-6
DM9EFH0 DE Neuropathic pain; Epilepsy
DMI5HFU ID DMI5HFU
DMI5HFU DN NS 2359
DMI5HFU HS Phase 2
DMI5HFU SN FPTPUYCHSWIWIB-FUTJPDQTSA-N; SCHEMBL2640060; (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo-[321]octane; GSK372475
DMI5HFU CP GlaxoSmithKline
DMI5HFU DT Small molecular drug
DMI5HFU PC 68470595
DMI5HFU MW 314.2
DMI5HFU FM C16H21Cl2NO
DMI5HFU IC InChI=1S/C16H21Cl2NO/c1-19-11-4-6-16(19)13(9-20-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,11-13,16H,4,6,8-9H2,1-2H3/t11-,12+,13+,16+/m0/s1
DMI5HFU CS CN1[C@H]2CC[C@@H]1[C@@H]([C@H](C2)C3=CC(=C(C=C3)Cl)Cl)COC
DMI5HFU IK PGYDXVBZYKQYCS-VPWBDBDCSA-N
DMI5HFU IU (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
DMI5HFU CA CAS 195875-68-4
DMI5HFU DE Cocaine addiction; Attention deficit hyperactivity disorder; Mood disorder
DMMUR6V ID DMMUR6V
DMMUR6V DN NS-2710
DMMUR6V HS Phase 2
DMMUR6V SN ME-3127
DMMUR6V CP NeuroSearch A/S
DMMUR6V DT Small molecular drug
DMMUR6V PC 9863520
DMMUR6V MW 356.4
DMMUR6V FM C22H20N4O
DMMUR6V IC InChI=1S/C22H20N4O/c1-3-27-25-16(2)17-9-10-22-21(13-17)24-15-26(22)20-8-4-6-18(12-20)19-7-5-11-23-14-19/h4-15H,3H2,1-2H3/b25-16+
DMMUR6V CS CCO/N=C(\\C)/C1=CC2=C(C=C1)N(C=N2)C3=CC=CC(=C3)C4=CN=CC=C4
DMMUR6V IK NHJFEXZXSCFYRX-PCLIKHOPSA-N
DMMUR6V IU (E)-N-ethoxy-1-[1-(3-pyridin-3-ylphenyl)benzimidazol-5-yl]ethanimine
DMMUR6V CA CAS 184220-36-8
DMMUR6V DE Anxiety disorder
DM3H82Q ID DM3H82Q
DM3H82Q DN NS-7
DM3H82Q HS Phase 2
DM3H82Q SN (3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide; DB08305; NS7
DM3H82Q TC Analgesics
DM3H82Q DT Small molecular drug
DM3H82Q PC 9800750
DM3H82Q MW 393.9
DM3H82Q FM C21H29ClFN3O
DM3H82Q IC InChI=1S/C21H28FN3O.ClH/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25;/h8-11,16H,2-7,12-15H2,1H3;1H
DM3H82Q CS CC1=NC(=CC(=N1)OCCCCCN2CCCCC2)C3=CC=C(C=C3)F.Cl
DM3H82Q IK VLYZLIWXMLUPLD-UHFFFAOYSA-N
DM3H82Q IU 4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyrimidine;hydrochloride
DM3H82Q CA CAS 178429-67-9
DM3H82Q DE Nerve injury
DMPJQZG ID DMPJQZG
DMPJQZG DN NSC-645809
DMPJQZG HS Phase 2
DMPJQZG SN XF-02; NSC-645809; C-1311; Imidacrine; Symadex; CHEMBL3545337; XJYNBZQTAZDMHZ-UHFFFAOYSA-N; Imidazoacridone dihydrocheloride hydrate; 138154-55-9; 5-((2-(diethylamino)ethyl)amino)-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one dihydrochloride hydrate
DMPJQZG DT Small molecular drug
DMPJQZG PC 132127
DMPJQZG MW 350.4
DMPJQZG FM C20H22N4O2
DMPJQZG IC InChI=1S/C20H22N4O2/c1-3-23(4-2)10-9-21-15-6-7-16-19-18(15)20(26)14-11-13(25)5-8-17(14)24(19)12-22-16/h5-8,11-12,21,25H,3-4,9-10H2,1-2H3
DMPJQZG CS CCN(CC)CCNC1=C2C3=C(C=C1)N=CN3C4=C(C2=O)C=C(C=C4)O
DMPJQZG IK CUNDRHORZHFPLY-UHFFFAOYSA-N
DMPJQZG IU 10-[2-(diethylamino)ethylamino]-5-hydroxy-1,14-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2(7),3,5,9,11,13(16),14-heptaen-8-one
DMPJQZG CA CAS 138154-39-9
DMPJQZG DE Breast cancer
DMRYLBW ID DMRYLBW
DMRYLBW DN NTO-1151
DMRYLBW HS Phase 2
DMRYLBW CP Nanotherapeutics; national cancer institute
DMRYLBW DE Cervical cancer
DMORNVB ID DMORNVB
DMORNVB DN NU-172
DMORNVB HS Phase 2
DMORNVB CP ARCA biopharma
DMORNVB DE Thrombosis
DMO0C5R ID DMO0C5R
DMO0C5R DN NU300
DMO0C5R HS Phase 2
DMO0C5R CP Nuron biotech
DMO0C5R DE Influenza virus infection
DMOJA5G ID DMOJA5G
DMOJA5G DN Nuplazid
DMOJA5G HS Phase 2
DMOJA5G SN Pimavanserin tartrate; UNII-NA83F1SJSR; 706782-28-7; ACP 103; ACP-103; 706782-28-7 (tartrate); NA83F1SJSR; Pimavanserin tartrate [USAN]; Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; Pimavanserin tartrate (USAN); 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea, ((2R,3R)-2,3-dihydroxysuccinate) (2:1); Nuplazide (TN); pimavanserin hemitartrate; DTXSID50220958; CHEBI:133014; HMS3886L06; HY-14557A; Pimavanserin Dihydroxysuccinate(2:1); AKOS027327334; CCG-270608; CS-7954; 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate; AC-29901; AS-56699; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1); Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1); D08969; Q27284759; bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate; bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate
DMOJA5G CP ACADIA Pharmaceuticals
DMOJA5G DT Small molecular drug
DMOJA5G PC 11672491
DMOJA5G MW 1005.2
DMOJA5G FM C54H74F2N6O10
DMOJA5G IC InChI=1S/2C25H34FN3O2.C4H6O6/c2*1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21;5-1(3(7)8)2(6)4(9)10/h2*4-11,19,23H,12-18H2,1-3H3,(H,27,30);1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
DMOJA5G CS CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMOJA5G IK RGSULKHNAKTFIZ-CEAXSRTFSA-N
DMOJA5G IU (2R,3R)-2,3-dihydroxybutanedioic acid;1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
DMOJA5G CA CAS 706782-28-7
DMOJA5G CB CHEBI:133014
DMOJA5G DE Alzheimer disease
DMTYXQF ID DMTYXQF
DMTYXQF DN NVP-AUY922
DMTYXQF HS Phase 2
DMTYXQF SN Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide
DMTYXQF CP Vernalis; Novartis
DMTYXQF TC Anticancer Agents
DMTYXQF DT Small molecular drug
DMTYXQF PC 135539077
DMTYXQF MW 465.5
DMTYXQF FM C26H31N3O5
DMTYXQF IC InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)
DMTYXQF CS CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C
DMTYXQF IK NDAZATDQFDPQBD-UHFFFAOYSA-N
DMTYXQF IU 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide
DMTYXQF CA CAS 747412-49-3
DMTYXQF CB CHEBI:83656
DMTYXQF DE Multiple myeloma; Solid tumour/cancer
DM2UJ1H ID DM2UJ1H
DM2UJ1H DN NW-3509
DM2UJ1H HS Phase 2
DM2UJ1H SN NW-3381; Sodium channel blockers (epilepsy/pain/mania), Newron
DM2UJ1H CP Newron pharmaceuticals
DM2UJ1H DE Schizophrenia
DMMBAIH ID DMMBAIH
DMMBAIH DN NXN-188
DMMBAIH HS Phase 2
DMMBAIH SN 6634-56-6; 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid; NSC51920; AC1Q5VTF; AC1L6AFP; CTK5C4317; ZINC4721635; NSC-51920; AKOS030583716; KB-274877
DMMBAIH CP Neuraxon
DMMBAIH DT Small molecular drug
DMMBAIH PC 242911
DMMBAIH MW 484.6
DMMBAIH FM C27H36N2O6
DMMBAIH IC InChI=1S/C27H36N2O6/c1-27(7-6-26(32)33,22-2-4-24(30)20(16-22)18-28-8-12-34-13-9-28)23-3-5-25(31)21(17-23)19-29-10-14-35-15-11-29/h2-5,16-17,30-31H,6-15,18-19H2,1H3,(H,32,33)
DMMBAIH CS CC(CCC(=O)O)(C1=CC(=C(C=C1)O)CN2CCOCC2)C3=CC(=C(C=C3)O)CN4CCOCC4
DMMBAIH IK JWNUBAIGCVTLMJ-UHFFFAOYSA-N
DMMBAIH IU 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid
DMMBAIH CA CAS 6634-56-6
DMMBAIH DE Migraine
DMWVBS2 ID DMWVBS2
DMWVBS2 DN NXN-462
DMWVBS2 HS Phase 2
DMWVBS2 SN NNOS inhibitor (chronic headache), Neuraxon; NNOS inhibitor (neuropathic pain), NeurAxon
DMWVBS2 CP Neuraxon
DMWVBS2 DE Headache
DM1P60V ID DM1P60V
DM1P60V DN NYX-2925
DM1P60V HS Phase 2
DM1P60V CP Aptinyx Evanston, IL
DM1P60V DE Peripheral neuropathy; Fibromyalgia
DMX04O8 ID DMX04O8
DMX04O8 DN NYX-2925
DMX04O8 HS Phase 2
DMX04O8 SN 2012536-16-0
DMX04O8 CP Aptinyx
DMX04O8 DT Small molecular drug
DMX04O8 PC 134820579
DMX04O8 MW 297.35
DMX04O8 FM C14H23N3O4
DMX04O8 IC InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m0/s1
DMX04O8 CS C[C@@H]([C@H](C(=O)N)N1C[C@]2(C1=O)CCCN2C(=O)C(C)C)O
DMX04O8 IK NFXPEHLDVKVVKA-RBZYPMLTSA-N
DMX04O8 IU (2R,3S)-3-hydroxy-2-[(4S)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide
DMX04O8 DE Diabetic neuropathy; Fibromyalgia
DMAVM2E ID DMAVM2E
DMAVM2E DN NYX-783
DMAVM2E HS Phase 2
DMAVM2E CP Aptinyx
DMAVM2E DT Small molecular drug
DMAVM2E DE Post-traumatic stress disorder
DMXM34I ID DMXM34I
DMXM34I DN O-304
DMXM34I HS Phase 2
DMXM34I SN 1261289-04-6; O304; 4-chloro-N-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide; SCHEMBL1050337; BCP29039; EX-A1990; MFCD31657425; 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide; BS-14854; HY-112233; CS-0044210; O 304; S0795
DMXM34I CP Betagenon
DMXM34I DT Small molecular drug
DMXM34I PC 50923806
DMXM34I MW 380.2
DMXM34I FM C16H11Cl2N3O2S
DMXM34I IC InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23)
DMXM34I CS C1=CC(=CC=C1CN2C(=O)N=C(S2)NC(=O)C3=CC=C(C=C3)Cl)Cl
DMXM34I IK WEDWLYRQKUTOAX-UHFFFAOYSA-N
DMXM34I IU 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide
DMXM34I DE Type 2 diabetes
DMPF9ZM ID DMPF9ZM
DMPF9ZM DN Obatoclax
DMPF9ZM HS Phase 2
DMPF9ZM SN CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7
DMPF9ZM CP Cephalon
DMPF9ZM DT Small molecular drug
DMPF9ZM PC 11404337
DMPF9ZM MW 317.4
DMPF9ZM FM C20H19N3O
DMPF9ZM IC InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21,23H,1-3H3/b18-17-,19-10-
DMPF9ZM CS CC1=CC(=C(N1)/C=C\\2/C(=C/C(=C/3\\C=C4C=CC=CC4=N3)/N2)OC)C
DMPF9ZM IK CVCLJVVBHYOXDC-IAZSKANUSA-N
DMPF9ZM IU (2Z)-2-[(5Z)-5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole
DMPF9ZM CA CAS 803712-67-6
DMPF9ZM DE Solid tumour/cancer
DMJIBSG ID DMJIBSG
DMJIBSG DN OBE-101
DMJIBSG HS Phase 2
DMJIBSG CP OBEcure
DMJIBSG DE Obesity
DM5D6Y7 ID DM5D6Y7
DM5D6Y7 DN OBI-3424
DM5D6Y7 HS Phase 2
DM5D6Y7 SN UNII-X6SH5T8H76; X6SH5T8H76; CHEMBL4297474; SCHEMBL20870529; 2097713-68-1; 3-(5-((1R)-1-(Bis(aziridin-1-yl(phosphoryloxy)ethyl)-2-nitrophenoxy)-N,N-dimethylbenzamide; Phosphinic acid, P,P-bis(1-aziridinyl)-, (1R)-1-(3-(3-((dimethylamino)carbonyl)phenoxy)-4-nitrophenyl)ethyl ester
DM5D6Y7 CP OBI Pharma
DM5D6Y7 DT Small molecular drug
DM5D6Y7 PC 126961329
DM5D6Y7 MW 460.4
DM5D6Y7 FM C21H25N4O6P
DM5D6Y7 IC InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1
DM5D6Y7 CS C[C@H](C1=CC(=C(C=C1)[N+](=O)[O-])OC2=CC=CC(=C2)C(=O)N(C)C)OP(=O)(N3CC3)N4CC4
DM5D6Y7 IK NWGZZGNICQFUHV-OAHLLOKOSA-N
DM5D6Y7 IU 3-[5-[(1R)-1-[bis(aziridin-1-yl)phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide
DM5D6Y7 CA CAS 2097713-68-1
DM5D6Y7 DE Hepatocellular carcinoma; Prostate cancer; Solid tumour/cancer; Acute lymphoblastic leukaemia
DMVXZC4 ID DMVXZC4
DMVXZC4 DN OBP-601
DMVXZC4 HS Phase 2
DMVXZC4 SN Festinavir; Ed4T; Nucleoside reverse transcriptase inhibitor (HIV infection), Oncolys; Nucleoside reverse transcriptase inhibitor (HIV infection), Yale; 4'-Ed4T; 4'-ethynylstavudine
DMVXZC4 CP Bristol-myers squibb
DMVXZC4 DT Small molecular drug
DMVXZC4 PC 3008897
DMVXZC4 MW 248.23
DMVXZC4 FM C12H12N2O4
DMVXZC4 IC InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
DMVXZC4 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
DMVXZC4 IK OSYWBJSVKUFFSU-SKDRFNHKSA-N
DMVXZC4 IU 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
DMVXZC4 CA CAS 634907-30-5
DMVXZC4 DE Human immunodeficiency virus-1 infection
DM1JBD8 ID DM1JBD8
DM1JBD8 DN OC-000459
DM1JBD8 HS Phase 2
DM1JBD8 SN OC-1768; OC-2125; OC-2184; OC-459; OC-499; ODC-9101; CRTH2 antagonists (asthma/allergy), Oxagen
DM1JBD8 CP Oxagen Ltd
DM1JBD8 DT Small molecular drug
DM1JBD8 PC 11462174
DM1JBD8 MW 348.4
DM1JBD8 FM C21H17FN2O2
DM1JBD8 IC InChI=1S/C21H17FN2O2/c1-13-17(11-16-8-6-14-4-2-3-5-19(14)23-16)18-10-15(22)7-9-20(18)24(13)12-21(25)26/h2-10H,11-12H2,1H3,(H,25,26)
DM1JBD8 CS CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3
DM1JBD8 IK FATGTHLOZSXOBC-UHFFFAOYSA-N
DM1JBD8 IU 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid
DM1JBD8 CA CAS 851723-84-7
DM1JBD8 DE Allergy
DMP6B59 ID DMP6B59
DMP6B59 DN Ocaperidone
DMP6B59 HS Phase 2
DMP6B59 SN Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; Ocaperidona; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
DMP6B59 CP Johnson & Johnson
DMP6B59 DT Small molecular drug
DMP6B59 PC 71351
DMP6B59 MW 420.5
DMP6B59 FM C24H25FN4O2
DMP6B59 IC InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
DMP6B59 CS CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C
DMP6B59 IK ZZQNEJILGNNOEP-UHFFFAOYSA-N
DMP6B59 IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
DMP6B59 CA CAS 129029-23-8
DMP6B59 DE Schizoaffective disorder; Schizophrenia; Idiopathic pulmonary fibrosis; Type-2 diabetes; Diabetic nephropathy; Pancreatic cancer
DM8TDBY ID DM8TDBY
DM8TDBY DN OCFENTANIL
DM8TDBY HS Phase 2
DM8TDBY SN Ocfentanil < Rec INN; A-3217 (hydrochloride); N-(2-Fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide; 1-(2-Phenylethyl)-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine; 2'-Fluoro-2-methoxy-N-(1-phenethyl-4-piperidinyl)acetanilide
DM8TDBY DT Small molecular drug
DM8TDBY PC 60575
DM8TDBY MW 370.5
DM8TDBY FM C22H27FN2O2
DM8TDBY IC InChI=1S/C22H27FN2O2/c1-27-17-22(26)25(21-10-6-5-9-20(21)23)19-12-15-24(16-13-19)14-11-18-7-3-2-4-8-18/h2-10,19H,11-17H2,1H3
DM8TDBY CS COCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3F
DM8TDBY IK NYISTOZKVCMVEL-UHFFFAOYSA-N
DM8TDBY IU N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide
DM8TDBY CA CAS 101343-69-5
DM8TDBY DE Pain
DMT9QI2 ID DMT9QI2
DMT9QI2 DN OCV-101
DMT9QI2 HS Phase 2
DMT9QI2 SN OTS-11101
DMT9QI2 CP OncoTherapy Science Inc
DMT9QI2 DE Pancreatic cancer
DMK0MJP ID DMK0MJP
DMK0MJP DN Odelepran
DMK0MJP HS Phase 2
DMK0MJP SN Odelepran hydrochloride; LY2196044 HCl; LY-2196044; OpRA (alcohol dependence), Eli Lilly; OpRA II (alcoholism), Eli Lilly; Opioid receptor antagonist (alcoholism), Eli Lilly
DMK0MJP CP Eli Lilly & Co
DMK0MJP DT Small molecular drug
DMK0MJP PC 10457387
DMK0MJP MW 373.4
DMK0MJP FM C20H24FN3O3
DMK0MJP IC InChI=1S/C20H24FN3O3/c21-17-11-15(12-23-8-5-14-6-9-26-10-7-14)1-3-18(17)27-19-4-2-16(13-24-19)20(22)25/h1-4,11,13-14,23H,5-10,12H2,(H2,22,25)
DMK0MJP CS C1COCCC1CCNCC2=CC(=C(C=C2)OC3=NC=C(C=C3)C(=O)N)F
DMK0MJP IK QWNDOCKIKKQJNN-UHFFFAOYSA-N
DMK0MJP IU 6-[2-fluoro-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyridine-3-carboxamide
DMK0MJP CA CAS 676501-25-0
DMK0MJP DE Alcohol dependence
DMJL4A7 ID DMJL4A7
DMJL4A7 DN O-desulfated heparin
DMJL4A7 HS Phase 2
DMJL4A7 SN Intravenous
DMJL4A7 CP ParinGenix
DMJL4A7 DE Chronic obstructive pulmonary disease
DMWCBY7 ID DMWCBY7
DMWCBY7 DN Odiparcil
DMWCBY7 HS Phase 2
DMWCBY7 SN SB-424323
DMWCBY7 CP GlaxoSmithKline
DMWCBY7 DT Small molecular drug
DMWCBY7 PC 216385
DMWCBY7 MW 324.4
DMWCBY7 FM C15H16O6S
DMWCBY7 IC InChI=1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1
DMWCBY7 CS CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O
DMWCBY7 IK JRHNIQQUVJOPQC-AQNFWKISSA-N
DMWCBY7 IU 4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one
DMWCBY7 CA CAS 137215-12-4
DMWCBY7 DE Cardiovascular disease
DMVC90W ID DMVC90W
DMVC90W DN Oglemilast
DMVC90W HS Phase 2
DMVC90W SN GRC-3886; Oglemilast (oral, COPD/asthma), Glenmark
DMVC90W CP Glenmark Pharmaceuticals Ltd
DMVC90W DT Small molecular drug
DMVC90W PC 11387409
DMVC90W MW 516.299
DMVC90W FM C20H13Cl2F2N3O5S
DMVC90W IC InChI=1S/C20H13Cl2F2N3O5S/c1-33(29,30)27-9-2-4-14-11(6-9)16-10(3-5-15(18(16)31-14)32-20(23)24)19(28)26-17-12(21)7-25-8-13(17)22/h2-8,20,27H,1H3,(H,25,26,28)
DMVC90W CS CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F
DMVC90W IK OKFDRAHPFKMAJH-UHFFFAOYSA-N
DMVC90W IU N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide
DMVC90W CA CAS 778576-62-8
DMVC90W DE Asthma
DMJTU8D ID DMJTU8D
DMJTU8D DN OGX-427
DMJTU8D HS Phase 2
DMJTU8D CP Isis Pharmaceuticals & OncoGenex
DMJTU8D TC Antisense
DMJTU8D DT Antisense drug
DMJTU8D PC 71710946
DMJTU8D MW 7157
DMJTU8D FM C224H304N79O116P19S19
DMJTU8D IC InChI=1S/C224H304N79O116P19S19/c1-88-46-284(216(318)257-168(88)225)129-34-97(401-420(327,439)363-60-114-102(39-134(386-114)289-52-94(7)187(306)281-222(289)324)406-421(328,440)362-56-110-98(35-130(381-110)285-47-89(2)169(226)258-217(285)319)402-422(329,441)368-63-119-107(44-139(390-119)297-81-252-147-182(297)267-211(237)276-194(147)313)411-430(337,449)372-66-121-108(45-140(392-121)298-82-253-148-183(298)268-212(238)277-195(148)314)412-431(338,450)375-69-123-154(163(357-29-21-349-13)201(396-123)292-54-96(9)189(308)283-224(292)326)414-435(342,454)377-70-124-155(162(356-28-20-348-12)200(395-124)290-51-93(6)173(230)262-221(290)323)415-436(343,455)378-72-126-157(165(359-31-23-351-15)203(398-126)300-84-247-142-175(232)243-76-245-177(142)300)417-433(340,452)374-68-122-152(305)160(354-26-18-346-10)199(394-122)291-53-95(8)188(307)282-223(291)325)111(382-129)57-364-426(333,445)407-103-40-135(293-77-248-143-178(293)263-207(233)272-190(143)309)387-116(103)61-367-423(330,442)403-99-36-131(286-48-90(3)170(227)259-218(286)320)384-113(99)59-366-428(335,447)409-105-42-137(295-79-250-145-180(295)265-209(235)274-192(145)311)391-120(105)65-371-429(336,448)410-106-43-138(296-80-251-146-181(296)266-210(236)275-193(146)312)389-118(106)62-369-424(331,443)404-100-37-132(287-49-91(4)171(228)260-219(287)321)383-112(100)58-365-427(334,446)408-104-41-136(294-78-249-144-179(294)264-208(234)273-191(144)310)388-117(104)64-370-425(332,444)405-101-38-133(288-50-92(5)172(229)261-220(288)322)385-115(101)67-373-432(339,451)416-156-125(397-202(164(156)358-30-22-350-14)299-83-246-141-174(231)242-75-244-176(141)299)71-379-437(344,456)419-159-128(400-206(167(159)361-33-25-353-17)303-87-256-151-186(303)271-215(241)280-198(151)317)74-380-438(345,457)418-158-127(399-205(166(158)360-32-24-352-16)302-86-255-150-185(302)270-214(240)279-197(150)316)73-376-434(341,453)413-153-109(55-304)393-204(161(153)355-27-19-347-11)301-85-254-149-184(301)269-213(239)278-196(149)315/h46-54,75-87,97-140,152-167,199-206,304-305H,18-45,55-74H2,1-17H3,(H,327,439)(H,328,440)(H,329,441)(H,330,442)(H,331,443)(H,332,444)(H,333,445)(H,334,446)(H,335,447)(H,336,448)(H,337,449)(H,338,450)(H,339,451)(H,340,452)(H,341,453)(H,342,454)(H,343,455)(H,344,456)(H,345,457)(H2,225,257,318)(H2,226,258,319)(H2,227,259,320)(H2,228,260,321)(H2,229,261,322)(H2,230,262,323)(H2,231,242,244)(H2,232,243,245)(H,281,306,324)(H,282,307,325)(H,283,308,326)(H3,233,263,272,309)(H3,234,264,273,310)(H3,235,265,274,311)(H3,236,266,275,312)(H3,237,267,276,313)(H3,238,268,277,314)(H3,239,269,278,315)(H3,240,270,279,316)(H3,241,271,280,317)/t97?,98?,99?,100?,101?,102?,103?,104?,105?,106?,107?,108?,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,152?,153?,154?,155?,156?,157?,158?,159?,160?,161?,162?,163?,164?,165?,166?,167?,199-,200-,201-,202-,203-,204-,205-,206-,420?,421?,422?,423?,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?/m1/s1
DMJTU8D CS CC1=CN(C(=O)NC1=O)[C@H]2CC([C@H](O2)COP(=S)(O)OC3C[C@@H](O[C@@H]3COP(=S)(O)OC4C[C@@H](O[C@@H]4COP(=S)(O)OC5C[C@@H](O[C@@H]5COP(=S)(O)OC6C[C@@H](O[C@@H]6COP(=S)(O)OC7C[C@@H](O[C@@H]7COP(=S)(O)OC8C[C@@H](O[C@@H]8COP(=O)(OC9C[C@@H](O[C@@H]9COP(=S)(O)OC1C[C@@H](O[C@@H]1COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1[C@H](O[C@H](C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=NC2=C1N=CNC2=N)OCCOC)OP(=S)(O)OC[C@@H]1C(C([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)O
DMJTU8D IK RMTMMKNSPRRFHW-SVAVBUBPSA-N
DMJTU8D IU 1-[(2R,5R)-5-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-2-[[[(2R,5R)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[(2R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-3-[[(2R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[hydroxy-[[(2R,5R)-3-[hydroxy-[[(2R,5R)-3-hydroxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(6-imino-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy]phosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMJTU8D CA CAS 1002331-21-6
DMJTU8D DE Lung cancer; Prostate cancer; Bladder cancer; Ovarian cancer; Breast cancer
DMNEHY1 ID DMNEHY1
DMNEHY1 DN OI338GT
DMNEHY1 HS Phase 2
DMNEHY1 CP Novo Nordisk
DMNEHY1 DE Type-1/2 diabetes; Type-1 diabetes; Type-2 diabetes
DMVW5KR ID DMVW5KR
DMVW5KR DN Olcegepant
DMVW5KR HS Phase 2
DMVW5KR SN Olcegepant [INN]; BIBN 4096; BIBN 4096 BS; BIBN-4096; BIBN-4096BS; N-((1R)-2-(((1S)-5-Amino-1-((4-(pyridin-4-yl)piperazin-1-yl)carbonyl)pentyl)amino)-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl)-4-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)piperidine-1-carboxamide; N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
DMVW5KR CP Boehringer Ingelheim
DMVW5KR DT Small molecular drug
DMVW5KR PC 6918509
DMVW5KR MW 869.6
DMVW5KR FM C38H47Br2N9O5
DMVW5KR IC InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1
DMVW5KR CS C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)N[C@H](CC4=CC(=C(C(=C4)Br)O)Br)C(=O)N[C@@H](CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6
DMVW5KR IK ITIXDWVDFFXNEG-JHOUSYSJSA-N
DMVW5KR IU N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
DMVW5KR CA CAS 204697-65-4
DMVW5KR DE Migraine
DM0RA8F ID DM0RA8F
DM0RA8F DN Oleoyl-estrone
DM0RA8F HS Phase 2
DM0RA8F SN Anti-obesity hormone-based therapy, Manhattan
DM0RA8F CP Oleoyl-Estrone Developments
DM0RA8F DT Small molecular drug
DM0RA8F PC 6918373
DM0RA8F MW 534.8
DM0RA8F FM C36H54O3
DM0RA8F IC InChI=1S/C36H54O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-35(38)39-29-20-22-30-28(27-29)19-21-32-31(30)25-26-36(2)33(32)23-24-34(36)37/h10-11,20,22,27,31-33H,3-9,12-19,21,23-26H2,1-2H3/b11-10-/t31-,32-,33+,36+/m1/s1
DM0RA8F CS CCCCCCCC/C=C\\CCCCCCCC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4=O)C
DM0RA8F IK IMIPDPVHGGHVNH-YWVHRCQQSA-N
DM0RA8F IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate
DM0RA8F CA CAS 180003-17-2
DM0RA8F DE Obesity; Alzheimer disease; Psychotic disorder
DMXL7HO ID DMXL7HO
DMXL7HO DN OLX10010
DMXL7HO HS Phase 2
DMXL7HO SN OLX 101A
DMXL7HO CP Olix Pharmaceuticals
DMXL7HO DT Small interfering RNA
DMXL7HO DE Hypertrophic scars
DMLMNFX ID DMLMNFX
DMLMNFX DN Omaveloxolone
DMLMNFX HS Phase 2
DMLMNFX SN RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
DMLMNFX CP Reata Pharmaceuticals Irving, TX
DMLMNFX DT Small molecular drug
DMLMNFX PC 71811910
DMLMNFX MW 554.7
DMLMNFX FM C33H44F2N2O3
DMLMNFX IC InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
DMLMNFX CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
DMLMNFX IK RJCWBNBKOKFWNY-IDPLTSGASA-N
DMLMNFX IU N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
DMLMNFX CA CAS 1474034-05-3
DMLMNFX DE Friedreich's ataxia; Melanoma; Psychiatric disorder
DMH9RTV ID DMH9RTV
DMH9RTV DN Omigapil
DMH9RTV HS Phase 2
DMH9RTV SN Omigapil); CGP-3466; CGP-3499B; Neuroprotectant, Novartis; Neuroprotectant, Santhera; Nootropic agent, Novartis; Nootropicagent, Santhera; SNT-317; TCH-346; TCH-346B
DMH9RTV CP Novartis AG
DMH9RTV DT Small molecular drug
DMH9RTV PC 6419718
DMH9RTV MW 275.3
DMH9RTV FM C19H17NO
DMH9RTV IC InChI=1S/C19H17NO/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19/h1,4-11,13H,12,14H2,2H3
DMH9RTV CS CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31
DMH9RTV IK QLMMOGWZCFQAPU-UHFFFAOYSA-N
DMH9RTV IU N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine
DMH9RTV CA CAS 181296-84-4
DMH9RTV CB CHEBI:41778
DMH9RTV DE Lateral sclerosis; Muscular dystrophy
DMWC36Y ID DMWC36Y
DMWC36Y DN OMS405
DMWC36Y HS Phase 2
DMWC36Y CP Omeros
DMWC36Y DE Nicotine dependence; Opioid dependence
DMA4OGL ID DMA4OGL
DMA4OGL DN OMS824
DMA4OGL HS Phase 2
DMA4OGL SN OMS-824
DMA4OGL CP Omeros
DMA4OGL DE Huntington disease
DMT6E5N ID DMT6E5N
DMT6E5N DN Onapristone
DMT6E5N HS Phase 2
DMT6E5N SN Onapristone; 96346-61-1; Onapristone [INN]; ZK-98299; Onapristonum [Latin]; Onapristona [Spanish]; UNII-H6H7G23O3N; ZK 299; CCRIS 6530; ZK 98299; ZK-299; H6H7G23O3N; C29H39NO3; Onapristone (INN); Onapristonum; Onapristona; (8S,11R,13R,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)-
DMT6E5N CP Context Therapeutics
DMT6E5N DT Small molecular drug
DMT6E5N PC 5311505
DMT6E5N MW 449.6
DMT6E5N FM C29H39NO3
DMT6E5N IC InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
DMT6E5N CS C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(CCCO)O)C5=CC=C(C=C5)N(C)C
DMT6E5N IK IEXUMDBQLIVNHZ-YOUGDJEHSA-N
DMT6E5N IU (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMT6E5N CA CAS 96346-61-1
DMT6E5N DE Breast cancer
DMM5SCF ID DMM5SCF
DMM5SCF DN ONC201
DMM5SCF HS Phase 2
DMM5SCF SN Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
DMM5SCF CP Oncoceutics Philadelphia, PA
DMM5SCF PC 73777259
DMM5SCF MW 386.5
DMM5SCF FM C24H26N4O
DMM5SCF IC InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
DMM5SCF CS CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5
DMM5SCF IK VLULRUCCHYVXOH-UHFFFAOYSA-N
DMM5SCF IU 11-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
DMM5SCF CA CAS 1616632-77-9
DMM5SCF DE Glioma; Endometrial cancer; leukaemia; Lymphoma; Multiple myeloma; Neuroendocrine cancer; Recurring respiratory infection; Solid tumour/cancer
DMKIZAL ID DMKIZAL
DMKIZAL DN ONO-1603
DMKIZAL HS Phase 2
DMKIZAL SN N-(4-Chlorobenzyl)-4-[2(S)-formylpyrrolidin-1-yl]-4-oxobutyramide
DMKIZAL DT Small molecular drug
DMKIZAL PC 9797271
DMKIZAL MW 322.78
DMKIZAL FM C16H19ClN2O3
DMKIZAL IC InChI=1S/C16H19ClN2O3/c17-13-5-3-12(4-6-13)10-18-15(21)7-8-16(22)19-9-1-2-14(19)11-20/h3-6,11,14H,1-2,7-10H2,(H,18,21)/t14-/m0/s1
DMKIZAL CS C1C[C@H](N(C1)C(=O)CCC(=O)NCC2=CC=C(C=C2)Cl)C=O
DMKIZAL IK KGDFDVHLEYUZLN-AWEZNQCLSA-N
DMKIZAL IU N-[(4-chlorophenyl)methyl]-4-[(2S)-2-formylpyrrolidin-1-yl]-4-oxobutanamide
DMKIZAL DE Cognitive impairment
DMOT0WR ID DMOT0WR
DMOT0WR DN ONO-2333Ms
DMOT0WR HS Phase 2
DMOT0WR SN Corticotropin-releasing factor-1 antagonist (oral, anxiety/depression), Ono
DMOT0WR CP Ono Pharmaceutical Co Ltd
DMOT0WR PC 9801039
DMOT0WR MW 398.9
DMOT0WR FM C22H27ClN4O
DMOT0WR IC InChI=1S/C22H27ClN4O/c1-5-14(6-2)24-21-17-8-7-9-19(17)25-22-20(13(3)26-27(21)22)16-11-10-15(28-4)12-18(16)23/h10-12,14,24H,5-9H2,1-4H3
DMOT0WR CS CCC(CC)NC1=C2CCCC2=NC3=C(C(=NN31)C)C4=C(C=C(C=C4)OC)Cl
DMOT0WR IK LDIOUQIXNSSOGU-UHFFFAOYSA-N
DMOT0WR IU 10-(2-chloro-4-methoxyphenyl)-11-methyl-N-pentan-3-yl-1,8,12-triazatricyclo[7.3.0.03,7]dodeca-2,7,9,11-tetraen-2-amine
DMOT0WR CA CAS 441060-02-2
DMOT0WR DE Anxiety disorder
DMOGYQ0 ID DMOGYQ0
DMOGYQ0 DN ONO-2952
DMOGYQ0 HS Phase 2
DMOGYQ0 SN Translocator protein 18kDr (TSPO) antagonist (irritable bowel syndrome), Ono Pharmaceutical
DMOGYQ0 CP Ono Pharmaceutical Co Ltd
DMOGYQ0 PC 11524127
DMOGYQ0 MW 398.9
DMOGYQ0 FM C22H20ClFN2O2
DMOGYQ0 IC InChI=1S/C22H20ClFN2O2/c1-12(27)26-11-22(8-9-22)19-18-15(24)4-3-5-16(18)25-20(19)21(26)14-7-6-13(23)10-17(14)28-2/h3-7,10,21,25H,8-9,11H2,1-2H3/t21-/m0/s1
DMOGYQ0 CS CC(=O)N1CC2(CC2)C3=C([C@@H]1C4=C(C=C(C=C4)Cl)OC)NC5=C3C(=CC=C5)F
DMOGYQ0 IK ZBQMTQGDBFZUBG-NRFANRHFSA-N
DMOGYQ0 IU 1-[(1S)-1-(4-chloro-2-methoxyphenyl)-5-fluorospiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,1'-cyclopropane]-2-yl]ethanone
DMOGYQ0 CA CAS 895169-20-7
DMOGYQ0 DE Irritable bowel syndrome
DMQGO74 ID DMQGO74
DMQGO74 DN ONO-3307
DMQGO74 HS Phase 2
DMQGO74 SN 4-Guanidinobenzoic acid 4-sulfamoylphenyl ester methanesulfonate
DMQGO74 DT Small molecular drug
DMQGO74 PC 127139
DMQGO74 MW 334.35
DMQGO74 FM C14H14N4O4S
DMQGO74 IC InChI=1S/C14H14N4O4S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21/h1-8H,(H4,15,16,18)(H2,17,20,21)
DMQGO74 CS C1=CC(=CC=C1C(=O)OC2=CC=C(C=C2)S(=O)(=O)N)N=C(N)N
DMQGO74 IK YFUQTMNUQVFBBS-UHFFFAOYSA-N
DMQGO74 IU (4-sulfamoylphenyl) 4-(diaminomethylideneamino)benzoate
DMQGO74 CA CAS 76472-28-1
DMQGO74 DE Coagulation defect
DMX4MVP ID DMX4MVP
DMX4MVP DN ONO-4053
DMX4MVP HS Phase 2
DMX4MVP SN PGD2 receptor antagonist (allergic rhinitis), Ono Pharmaceutical; Prostaglandin D2 receptor antagonists (allergy/inflammation), Ono Pharmaceutical
DMX4MVP CP Ono Pharmaceutical Co Ltd
DMX4MVP DE Allergic rhinitis
DMLUM3Y ID DMLUM3Y
DMLUM3Y DN ONO-4641
DMLUM3Y HS Phase 2
DMLUM3Y SN Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono
DMLUM3Y CP Emd serono
DMLUM3Y PC 11502996
DMLUM3Y MW 435.6
DMLUM3Y FM C27H33NO4
DMLUM3Y IC InChI=1S/C27H33NO4/c1-4-5-19-6-7-22(26(12-19)31-3)17-32-24-10-11-25-18(2)21(9-8-20(25)13-24)14-28-15-23(16-28)27(29)30/h6-7,10-13,23H,4-5,8-9,14-17H2,1-3H3,(H,29,30)
DMLUM3Y CS CCCC1=CC(=C(C=C1)COC2=CC3=C(C=C2)C(=C(CC3)CN4CC(C4)C(=O)O)C)OC
DMLUM3Y IK QDDQIPUKAXBMBX-UHFFFAOYSA-N
DMLUM3Y IU 1-[[6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid
DMLUM3Y CA CAS 891859-12-4
DMLUM3Y DE Rheumatoid arthritis
DMFX3P1 ID DMFX3P1
DMFX3P1 DN ONO-5129
DMFX3P1 HS Phase 2
DMFX3P1 SN Dual PPAR alpha/gamma agonist (metabolic disorder), Ono
DMFX3P1 CP Ono Pharmaceutical Co Ltd
DMFX3P1 DE Diabetic complication
DMRT28X ID DMRT28X
DMRT28X DN ONO-6126
DMRT28X HS Phase 2
DMRT28X SN 21-Cyanosaframycin-B; NSC 325663; 66082-27-7; C29H30N4O8; 21-cyanosaframycin B; AC1L2P2O; SCHEMBL637953; CHEMBL452709
DMRT28X CP Ono Pharmaceuticals
DMRT28X DT Small molecular drug
DMRT28X PC 9864321
DMRT28X MW 373.4
DMRT28X FM C20H27N3O4
DMRT28X IC InChI=1S/C20H27N3O4/c1-26-17-7-6-15(12-18(17)27-16-4-2-3-5-16)20(14-21)8-10-23(11-9-20)13-19(24)22-25/h6-7,12,16,25H,2-5,8-11,13H2,1H3,(H,22,24)
DMRT28X CS COC1=C(C=C(C=C1)C2(CCN(CC2)CC(=O)NO)C#N)OC3CCCC3
DMRT28X IK VXYDHPDQMSVQCU-UHFFFAOYSA-N
DMRT28X IU 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-N-hydroxyacetamide
DMRT28X CA CAS 401519-28-6
DMRT28X DE Chronic obstructive pulmonary disease
DM5O6GC ID DM5O6GC
DM5O6GC DN ONO-9054
DM5O6GC HS Phase 2
DM5O6GC CP Ono pharmaceutical
DM5O6GC DE Glaucoma/ocular hypertension
DMCUGI8 ID DMCUGI8
DMCUGI8 DN ONO-AE1-437
DMCUGI8 HS Phase 2
DMCUGI8 SN 16-[3-(Methoxymethyl)phenyl]-5-thia-17,18,19,20-tetranorprostaglandin E1
DMCUGI8 DT Small molecular drug
DMCUGI8 PC 9824353
DMCUGI8 MW 436.6
DMCUGI8 FM C23H32O6S
DMCUGI8 IC InChI=1S/C23H32O6S/c1-29-15-17-5-2-4-16(12-17)13-18(24)7-8-19-20(22(26)14-21(19)25)9-11-30-10-3-6-23(27)28/h2,4-5,7-8,12,18-21,24-25H,3,6,9-11,13-15H2,1H3,(H,27,28)/b8-7+/t18-,19-,20-,21-/m1/s1
DMCUGI8 CS COCC1=CC=CC(=C1)C[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCSCCCC(=O)O)O)O
DMCUGI8 IK ORSJUPRAHPZYRL-XHTUOEPPSA-N
DMCUGI8 IU 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoic acid
DMCUGI8 CA CAS 256382-23-7
DMCUGI8 DE Asthma
DMS8Q7A ID DMS8Q7A
DMS8Q7A DN Ontazolast
DMS8Q7A HS Phase 2
DMS8Q7A SN Ontazolast; UNII-8P8TW6B25I; BIRM-270; 147432-77-7; 8P8TW6B25I; N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine; Ontazolast [USAN:INN]; AC1Q4WID; Ontazolast (USAN/INN); SCHEMBL75875; AC1L2G78; CHEMBL2104845; 2-(((S)-2-Cyclohexyl-1-(2-pyridyl)ethyl)amino)-5-methylbenzoxazole; n-[(1s)-2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine; D02847; 32254-EP2311827A1; 32254-EP2301933A1; 32254-EP2281815A1; 32254-EP2305640A2; 2-Benzoxazolamine, N-(2-cyclohexyl-1-(2-pyridinyl)ethyl)-5-methyl-, (S)-
DMS8Q7A CP Boehringer Ingelheim Corp
DMS8Q7A DT Small molecular drug
DMS8Q7A PC 71458
DMS8Q7A MW 335.4
DMS8Q7A FM C21H25N3O
DMS8Q7A IC InChI=1S/C21H25N3O/c1-15-10-11-20-19(13-15)24-21(25-20)23-18(17-9-5-6-12-22-17)14-16-7-3-2-4-8-16/h5-6,9-13,16,18H,2-4,7-8,14H2,1H3,(H,23,24)/t18-/m0/s1
DMS8Q7A CS CC1=CC2=C(C=C1)OC(=N2)N[C@@H](CC3CCCCC3)C4=CC=CC=N4
DMS8Q7A IK RVXKHAITGKBBAC-SFHVURJKSA-N
DMS8Q7A IU N-[(1S)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine
DMS8Q7A CA CAS 147432-77-7
DMS8Q7A DE Asthma
DM0FJIE ID DM0FJIE
DM0FJIE DN Ontuxizumab
DM0FJIE HS Phase 2
DM0FJIE SN Amatuximab
DM0FJIE CP EisaiWoodcliff Lake, NJ MorphotekExton, PA
DM0FJIE DT Antibody
DM0FJIE DE Melanoma; Merkel cell carcinoma; Soft tissue sarcoma; Colorectal cancer
DMB1WF3 ID DMB1WF3
DMB1WF3 DN OPC-14523
DMB1WF3 HS Phase 2
DMB1WF3 SN OPC-14523; UNII-1981OTB4DS; 1981OTB4DS; CHEMBL294144; 145969-30-8; OPC-14523 free base; SCHEMBL5022801; ZINC598353; BDBM50005656; 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-methoxy-3,4-dihydro-2-quinolinone; L001554; 2(1H)-Quinolinone, 1-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-3,4-dihydro-5-methoxy-
DMB1WF3 CP Otsuka Pharmaceutical and Vela Pharmaceuticals; Pharmos and Otsaku
DMB1WF3 DT Small molecular drug
DMB1WF3 PC 9892540
DMB1WF3 MW 413.9
DMB1WF3 FM C23H28ClN3O2
DMB1WF3 IC InChI=1S/C23H28ClN3O2/c1-29-22-8-3-7-21-20(22)9-10-23(28)27(21)12-4-11-25-13-15-26(16-14-25)19-6-2-5-18(24)17-19/h2-3,5-8,17H,4,9-16H2,1H3
DMB1WF3 CS COC1=CC=CC2=C1CCC(=O)N2CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
DMB1WF3 IK TZZGTNZBLPCBIS-UHFFFAOYSA-N
DMB1WF3 IU 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one
DMB1WF3 CA CAS 145969-30-8
DMB1WF3 DE Mood disorder; Bulimia nervosa; Female sexual arousal dysfunction
DMIK2AD ID DMIK2AD
DMIK2AD DN OPC-64005
DMIK2AD HS Phase 2
DMIK2AD CP Otsuka Pharmaceutical
DMIK2AD DE Attention deficit hyperactivity disorder
DML6TAS ID DML6TAS
DML6TAS DN OPI-1002
DML6TAS HS Phase 2
DML6TAS CP Quark Pharm; Pfizer
DML6TAS DT siRNA drug
DML6TAS DE Acute kidney injury
DM1IBRT ID DM1IBRT
DM1IBRT DN OPN-305
DM1IBRT HS Phase 2
DM1IBRT SN OPN-301; TLR-specific mAbs (inflammatory diseases), Opsona; Toll-like receptor specific monoclonal antibodies (inflammatory diseases), Opsona
DM1IBRT CP Opsona therapeutics
DM1IBRT DT Antibody
DM1IBRT DE Myelodysplastic syndrome
DMYG1ZQ ID DMYG1ZQ
DMYG1ZQ DN OPNT001
DMYG1ZQ HS Phase 2
DMYG1ZQ CP Opiant Pharmaceuticals Santa Monica, CA
DMYG1ZQ DE Eating disorder
DM16RIC ID DM16RIC
DM16RIC DN Oprozomib
DM16RIC HS Phase 2
DM16RIC CP Onyx Pharmaceuticals
DM16RIC DT Small molecular drug
DM16RIC PC 25067547
DM16RIC MW 532.6
DM16RIC FM C25H32N4O7S
DM16RIC IC InChI=1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1
DM16RIC CS CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C
DM16RIC IK SWZXEVABPLUDIO-WSZYKNRRSA-N
DM16RIC IU N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
DM16RIC CA CAS 935888-69-0
DM16RIC DE Solid tumour/cancer; Hodgkin lymphoma; Multiple myeloma; Haematological malignancy
DMS4XFI ID DMS4XFI
DMS4XFI DN OPT-302
DMS4XFI HS Phase 2
DMS4XFI CP Opthea
DMS4XFI DE Diabetic macular edema
DMR3P98 ID DMR3P98
DMR3P98 DN ORG 34517/34850
DMR3P98 HS Phase 2
DMR3P98 SN Sardomozide; 4-Aiah; SAM 486A; Cgp 48664; UNII-CEB05S0B9I; SAM486A; 149400-88-4; CEB05S0B9I; 4-amidinoindan-1-one 2'-amidinohydrazone; (E)-2-(4-carbamimidoyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide; Urea azine with 1-oxo-4-indancarboxamidine; Sardomozide chloride; Hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene)-; 4-AMIDINOINDAN-1-ONE-2'-AMIDINOHYDRAZONE; 1443105-76-7; C11H14N6; Cgp 48664A; CHEMBL1202793; Sardomozide [INN]
DMR3P98 CP Organon
DMR3P98 DT Small molecular drug
DMR3P98 PC 9576789
DMR3P98 MW 230.27
DMR3P98 FM C11H14N6
DMR3P98 IC InChI=1S/C11H14N6/c12-10(13)8-3-1-2-7-6(8)4-5-9(7)16-17-11(14)15/h1-3H,4-5H2,(H3,12,13)(H4,14,15,17)/b16-9+
DMR3P98 CS C1C/C(=N\\N=C(N)N)/C2=C1C(=CC=C2)C(=N)N
DMR3P98 IK CYPGNVSXMAUSJY-CXUHLZMHSA-N
DMR3P98 IU (1E)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide
DMR3P98 CA CAS 149400-88-4
DMR3P98 DE Solid tumour/cancer; Mood disorder
DMAWXJT ID DMAWXJT
DMAWXJT DN ORG-13011
DMAWXJT HS Phase 2
DMAWXJT SN FIBOFLAPON; 936350-00-4; UNII-Y1NA96IX3T; Y1NA96IX3T; CHEMBL1922660; Fiboflapon [USAN:INN]; AM803; Fiboflapon (USAN); AM-803; AM 803; SCHEMBL11820; DTXSID20239496; DFQGDHBGRSTTHX-UHFFFAOYSA-N; GSK2190915B; ZINC68247071; BDBM50359080; AKOS030527019; SB16524; CS-3604; Fiboflapon; NCGC00485966-01; HY-15874; 1H-Indole-2-propanoic acid, 3-((1,1-dimethylethyl)thio)-1-((4-(6-ethoxy-3-pyridinyl)phenyl)methyl)-alpha,alpha-Dimethyl-5-((5-methyl-2-pyridinyl)methoxy)-; D10069
DMAWXJT DT Small molecular drug
DMAWXJT PC 9907401
DMAWXJT MW 370.4
DMAWXJT FM C18H25F3N4O
DMAWXJT IC InChI=1S/C18H25F3N4O/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26/h5-6,14H,1-4,7-13H2
DMAWXJT CS C1CC(=O)N(C1)CCCCN2CCN(CC2)C3=NC=CC(=C3)C(F)(F)F
DMAWXJT IK YKJJCYZZWWSBEW-UHFFFAOYSA-N
DMAWXJT IU 1-[4-[4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]butyl]pyrrolidin-2-one
DMAWXJT CA CAS 142494-12-0
DMAWXJT DE Psychotic disorder; Anxiety disorder; Major depressive disorder
DMWN2EC ID DMWN2EC
DMWN2EC DN ORG-25935
DMWN2EC HS Phase 2
DMWN2EC SN Cis-N-(6-Methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-N-methylglycine hydrochloride
DMWN2EC DT Small molecular drug
DMWN2EC PC 11717074
DMWN2EC MW 339.4
DMWN2EC FM C21H25NO3
DMWN2EC IC InChI=1S/C21H25NO3/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24)/t17-,21+/m1/s1
DMWN2EC CS CN(C[C@H]1CCC2=C([C@H]1C3=CC=CC=C3)C=CC(=C2)OC)CC(=O)O
DMWN2EC IK UEBBYLJZCHTLEG-UTKZUKDTSA-N
DMWN2EC IU 2-[[(1R,2S)-6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl]methyl-methylamino]acetic acid
DMWN2EC CA CAS 1147011-84-4
DMWN2EC DE Psychotic disorder
DMDZ4R2 ID DMDZ4R2
DMDZ4R2 DN Org-30029
DMDZ4R2 HS Phase 2
DMDZ4R2 SN Org-30029; Org 30029; 101041-95-6; N'-Hydroxy-5,6-dimethoxybenzo[b]thiophene-2-carboximidamide hydrochloride; DTXSID50143698; AKOS015848621; Benzo(b)thiophene-2-carboximidamide, N-hydroxy-5,6-dimethoxy-, monohydrochloride; (Z)-N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide hydrochloride
DMDZ4R2 CP Organon BioSciences
DMDZ4R2 DT Small molecular drug
DMDZ4R2 PC 9576838
DMDZ4R2 MW 288.75
DMDZ4R2 FM C11H13ClN2O3S
DMDZ4R2 IC InChI=1S/C11H12N2O3S.ClH/c1-15-7-3-6-4-10(11(12)13-14)17-9(6)5-8(7)16-2;/h3-5,14H,1-2H3,(H2,12,13);1H
DMDZ4R2 CS COC1=C(C=C2C(=C1)C=C(S2)/C(=N/O)/N)OC.Cl
DMDZ4R2 IK DVWBMWJOYIFITF-UHFFFAOYSA-N
DMDZ4R2 IU N'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide;hydrochloride
DMDZ4R2 CA CAS 101041-95-6
DMDZ4R2 DE Heart failure
DMIO59F ID DMIO59F
DMIO59F DN ORG-34517
DMIO59F HS Phase 2
DMIO59F SN 11beta-(1,3-Benzodioxol-5-yl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
DMIO59F CP Organon
DMIO59F DT Small molecular drug
DMIO59F PC 9867361
DMIO59F MW 430.5
DMIO59F FM C28H30O4
DMIO59F IC InChI=1S/C28H30O4/c1-3-11-28(30)12-10-23-21-7-4-17-13-19(29)6-8-20(17)26(21)22(15-27(23,28)2)18-5-9-24-25(14-18)32-16-31-24/h5,9,13-14,21-23,30H,4,6-8,10,12,15-16H2,1-2H3/t21-,22+,23-,27-,28-/m0/s1
DMIO59F CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC6=C(C=C5)OCO6)C)O
DMIO59F IK DFELGYQKEOCHOA-BZAFBGKRSA-N
DMIO59F IU (8S,11R,13S,14S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DMIO59F CA CAS 189035-07-2
DMIO59F DE Depression
DM8ARQW ID DM8ARQW
DM8ARQW DN ORM-12741
DM8ARQW HS Phase 2
DM8ARQW SN Alpha 2c adrenoceptor antagonist (neurological diseases), Orion; Alpha 2c adrenoceptor antagonist (psychiatric disorders), Orion
DM8ARQW CP Orion Corp
DM8ARQW DT Small molecular drug
DM8ARQW PC 71301276
DM8ARQW MW 285.4
DM8ARQW FM C18H23NO2
DM8ARQW IC InChI=1S/C18H23NO2/c1-18(12-20-2)9-5-10-19-11-8-14-13-6-3-4-7-15(13)21-16(14)17(18)19/h3-4,6-7,17H,5,8-12H2,1-2H3/t17-,18-/m1/s1
DM8ARQW CS C[C@@]1(CCCN2[C@@H]1C3=C(CC2)C4=CC=CC=C4O3)COC
DM8ARQW IK OCUKPFWNSAAHRP-QZTJIDSGSA-N
DM8ARQW IU (1S,12bS)-1-(methoxymethyl)-1-methyl-2,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine
DM8ARQW CA CAS 610782-82-6
DM8ARQW DE Alzheimer disease
DMRIO6D ID DMRIO6D
DMRIO6D DN ORMD-0901
DMRIO6D HS Phase 2
DMRIO6D SN Exenatide-4 (oral, diabetes), Oramed; GLP1-analog (oral, non-insulin dependent diabetes), Oramed Pharmaceuticals
DMRIO6D CP Oramed Pharmaceuticals Inc
DMRIO6D DE Type-2 diabetes
DM1EK5D ID DM1EK5D
DM1EK5D DN Ortataxel
DM1EK5D HS Phase 2
DM1EK5D SN UNII-8H61Y4E29N; 186348-23-2; 8H61Y4E29N; IDN-5109; IDN 5109; Ortataxel [INN]; Bay-59-8862; SB-T-101131; SB-T 101131; idn5109; SCHEMBL9932772; CHEMBL382300; BAY-59; IND-5109; DB11669; Z-3102; Hexanoic acid, 3-(((1,1-dimethylethoxy)carbonyl)amino)-2-hydroxy-5-methyl-,; Hexanoic acid; IND5109; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate; 13-(N-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate; Genz29155
DM1EK5D CP Spectrum
DM1EK5D DT Small molecular drug
DM1EK5D PC 6918412
DM1EK5D MW 871.9
DM1EK5D FM C44H57NO17
DM1EK5D IC InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1
DM1EK5D CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@]5(C2(C)C)[C@H]([C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)OC(=O)O5)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C
DM1EK5D IK BWKDAMBGCPRVPI-ZQRPHVBESA-N
DM1EK5D IU [(1S,2S,3R,4S,7R,9S,10S,12R,15R,16S)-4,12-diacetyloxy-9-hydroxy-15-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-10,14,20,20-tetramethyl-11,18-dioxo-6,17,19-trioxapentacyclo[11.6.1.01,16.03,10.04,7]icos-13-en-2-yl] benzoate
DM1EK5D CA CAS 186348-23-2
DM1EK5D DE Solid tumour/cancer; Heart transplant rejection
DMSO846 ID DMSO846
DMSO846 DN Orvepitant
DMSO846 HS Phase 2
DMSO846 SN Orvepitant; UNII-IIU6V0W3JD; 579475-18-6; GW823296X; IIU6V0W3JD; GW823296; Orvepitant [USAN:INN]; Orvepitant (USAN/INN); SCHEMBL1421784; CHEMBL2105667; XWNBGDJPEXZSQM-VZOBGQTKSA-N; BDBM50442585; ZINC56898864; AKOS030231272; SB17117; DB12427; NCGC00386593-01; (2R,4S)-N-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methyl-4-((S)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)piperidine-1-c; D09650
DMSO846 CP GSK
DMSO846 DT Small molecular drug
DMSO846 PC 9852175
DMSO846 MW 628.6
DMSO846 FM C31H35F7N4O2
DMSO846 IC InChI=1S/C31H35F7N4O2/c1-18-12-23(32)4-6-26(18)27-16-24(40-10-11-41-25(17-40)5-7-28(41)43)8-9-42(27)29(44)39(3)19(2)20-13-21(30(33,34)35)15-22(14-20)31(36,37)38/h4,6,12-15,19,24-25,27H,5,7-11,16-17H2,1-3H3/t19-,24+,25+,27-/m1/s1
DMSO846 CS CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5[C@H](C4)CCC5=O
DMSO846 IK XWNBGDJPEXZSQM-VZOBGQTKSA-N
DMSO846 IU (2R,4S)-4-[(8aS)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
DMSO846 CA CAS 579475-18-6
DMSO846 DE Anxiety disorder; Depression
DMJX3O8 ID DMJX3O8
DMJX3O8 DN OSI-027
DMJX3O8 HS Phase 2
DMJX3O8 CP OSI
DMJX3O8 DT Small molecular drug
DMJX3O8 PC 135398516
DMJX3O8 MW 406.4
DMJX3O8 FM C21H22N6O3
DMJX3O8 IC InChI=1S/C21H22N6O3/c1-30-15-4-2-3-13-9-14(25-16(13)15)17-18-19(22)23-10-24-27(18)20(26-17)11-5-7-12(8-6-11)21(28)29/h2-4,9-12,25H,5-8H2,1H3,(H,28,29)(H2,22,23,24)
DMJX3O8 CS COC1=CC=CC2=C1NC(=C2)C3=C4C(=NC=NN4C(=N3)C5CCC(CC5)C(=O)O)N
DMJX3O8 IK JROFGZPOBKIAEW-UHFFFAOYSA-N
DMJX3O8 IU 4-[4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid
DMJX3O8 CA CAS 936890-98-1
DMJX3O8 CB CHEBI:91363
DMJX3O8 DE Renal cell carcinoma
DMBVI6E ID DMBVI6E
DMBVI6E DN Ostabolin-C
DMBVI6E HS Phase 2
DMBVI6E CP Zelos Therape.
DMBVI6E DE Osteoporosis
DMHKIOF ID DMHKIOF
DMHKIOF DN OT551
DMHKIOF HS Phase 2
DMHKIOF CP Colby Pharmaceuticals
DMHKIOF DT Small interfering RNA
DMHKIOF DE Age-related macular degeneration
DMTNOXQ ID DMTNOXQ
DMTNOXQ DN OT-551
DMTNOXQ HS Phase 2
DMTNOXQ SN Tempol-H prodrug, Othera
DMTNOXQ CP Othera Pharmaceuticals Inc
DMTNOXQ DT Small molecular drug
DMTNOXQ PC 10131000
DMTNOXQ MW 241.33
DMTNOXQ FM C13H23NO3
DMTNOXQ IC InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3
DMTNOXQ CS CC1(CC(CC(N1O)(C)C)OC(=O)C2CC2)C
DMTNOXQ IK ZWEXEKJLDHNLLA-UHFFFAOYSA-N
DMTNOXQ IU (1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate
DMTNOXQ CA CAS 627085-11-4
DMTNOXQ DE Ocular inflammation
DMFNDBC ID DMFNDBC
DMFNDBC DN Otelixizumab
DMFNDBC HS Phase 2
DMFNDBC CP GSK
DMFNDBC DT Monoclonal antibody
DMFNDBC DE Type-1 diabetes
DM1AQLW ID DM1AQLW
DM1AQLW DN Otilimab
DM1AQLW HS Phase 2
DM1AQLW SN Otilimab [USAN]; UNII-Y8127R3VCH; Y8127R3VCH; MOR103; GSK3196165; 1638332-55-4; human monoclonal antibody
DM1AQLW TC Antiviral Agents
DM1AQLW DT Monoclonal antibody
DM1AQLW DE Coronavirus Disease 2019 (COVID-19)
DMAZIND ID DMAZIND
DMAZIND DN Otlertuzumab
DMAZIND HS Phase 2
DMAZIND CP Aptevo Therapeutics Seattle, WA
DMAZIND DE Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma
DM5Q9RY ID DM5Q9RY
DM5Q9RY DN OX-914
DM5Q9RY HS Phase 2
DM5Q9RY CP Inflazyme Pharmaceuticals
DM5Q9RY DE Asthma
DMBM47Z ID DMBM47Z
DMBM47Z DN Oxazolidinones
DMBM47Z HS Phase 2
DMBM47Z SN 2-Oxazolidone; Oxazolidin-2-one; 2-Oxazolidinone; 497-25-6; 1,3-Oxazolidin-2-one; Oxazolidinone; Oxazolidone; UNII-Z4D49W92PP; EINECS 207-840-9; NSC 35382; BRN 0106251; AI3-38980; CHEBI:1237; Z4D49W92PP; IZXIZTKNFFYFOF-UHFFFAOYSA-N; Carbamic acid, (2-hydroxyethyl)-, gamma-lactone; MFCD00005268; 2-Oxazolidone, 98%; WLN: T5MVOTJ; 51667-26-6; Carbamic acid, .gamma.-lactone; Oxazolidinones; SMR000857362; oxazolodinone; hydroxyoxazoline; 2-oxazolidinon; hydroxy-oxazoline; 2-Oxazolidine; oxazolidine-2-one; PubChem8624; ACMC-209upq; AC1Q6HSI
DMBM47Z DT Small molecular drug
DMBM47Z PC 73949
DMBM47Z MW 87.08
DMBM47Z FM C3H5NO2
DMBM47Z IC InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)
DMBM47Z CS C1COC(=O)N1
DMBM47Z IK IZXIZTKNFFYFOF-UHFFFAOYSA-N
DMBM47Z IU 1,3-oxazolidin-2-one
DMBM47Z CA CAS 497-25-6
DMBM47Z CB CHEBI:1237
DMBM47Z DE Gram-positive bacterial infection
DMSNL51 ID DMSNL51
DMSNL51 DN Oxfendazole
DMSNL51 HS Phase 2
DMSNL51 SN Oxfendazole; Fenbendazole sulfoxide; Synanthic; Systamex; OFDZ; Systemax; Repidose; Oxfendazolum; Oxfendazol; Synanthic (Veterinary); RS-8858; fenbendazole S-oxide; RS 8858; 5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole; Oxfendazol [INN-Spanish]; Oxfendazolum [INN-Latin]; UNII-OMP2H17F9E; HOE 8105; methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate; Oxfendazole [USAN:BAN:INN]; Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate; Oxfendazole (USP/INN)
DMSNL51 PC 40854
DMSNL51 MW 315.3
DMSNL51 FM C15H13N3O3S
DMSNL51 IC InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)
DMSNL51 CS COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3
DMSNL51 IK BEZZFPOZAYTVHN-UHFFFAOYSA-N
DMSNL51 IU methyl N-[6-(benzenesulfinyl)-1H-benzimidazol-2-yl]carbamate
DMSNL51 CA CAS 53716-50-0
DMSNL51 CB CHEBI:35812
DMSNL51 DE Trichuris infection
DMC3PJS ID DMC3PJS
DMC3PJS DN Oxytrex
DMC3PJS HS Phase 2
DMC3PJS DE Pain
DMEGTH1 ID DMEGTH1
DMEGTH1 DN Ozarelix
DMEGTH1 HS Phase 2
DMEGTH1 CP Spectrum
DMEGTH1 PC 25080293
DMEGTH1 MW 1459.1
DMEGTH1 FM C72H96ClN17O14
DMEGTH1 IC InChI=1S/C72H96ClN17O14/c1-5-6-17-52(63(96)85-54(19-12-33-79-71(75)76)70(103)90-34-13-20-59(90)67(100)81-42(2)61(74)94)83-62(95)53(18-9-10-32-80-72(77)104)84-68(101)60(39-45-24-29-51(93)30-25-45)89(4)69(102)58(41-91)88-66(99)57(38-47-14-11-31-78-40-47)87-65(98)56(36-44-22-27-50(73)28-23-44)86-64(97)55(82-43(3)92)37-46-21-26-48-15-7-8-16-49(48)35-46/h7-8,11,14-16,21-31,35,40,42,52-60,91,93H,5-6,9-10,12-13,17-20,32-34,36-39,41H2,1-4H3,(H2,74,94)(H,81,100)(H,82,92)(H,83,95)(H,84,101)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H4,75,76,79)(H3,77,80,104)/t42-,52+,53-,54+,55-,56-,57-,58+,59+,60+/m1/s1
DMEGTH1 CS CCCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DMEGTH1 IK KATZUZNTRINHDT-HALMFYTRSA-N
DMEGTH1 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMEGTH1 CA CAS 295350-45-7
DMEGTH1 DE Prostate disease
DMEYQPN ID DMEYQPN
DMEYQPN DN P-1736
DMEYQPN HS Phase 2
DMEYQPN SN Pyyy; GPR40 modulators (diabetes), Nicholas Piramal; GPR40 modulators (diabetes), Piramal Life Sciences; P-1736-05; GPR40 modulators (diabetes), NPIL Research & Development
DMEYQPN CP Piramal Healthcare Ltd
DMEYQPN DE Diabetic complication
DMMJUHD ID DMMJUHD
DMMJUHD DN P-276
DMMJUHD HS Phase 2
DMMJUHD SN CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development
DMMJUHD CP Piramal Healthcare Ltd
DMMJUHD DT Small molecular drug
DMMJUHD PC 23643976
DMMJUHD MW 401.8
DMMJUHD FM C21H20ClNO5
DMMJUHD IC InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1
DMMJUHD CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
DMMJUHD IK QLUYMIVVAYRECT-OCCSQVGLSA-N
DMMJUHD IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one
DMMJUHD DE Breast cancer
DM9DJL2 ID DM9DJL2
DM9DJL2 DN P276-00
DM9DJL2 HS Phase 2
DM9DJL2 SN CHEMBL2312181; SCHEMBL1180418
DM9DJL2 CP Nicholas Piramal
DM9DJL2 DT Small molecular drug
DM9DJL2 PC 23643975
DM9DJL2 MW 438.3
DM9DJL2 FM C21H21Cl2NO5
DM9DJL2 IC InChI=1S/C21H20ClNO5.ClH/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22;/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3;1H/t12-,14+;/m1./s1
DM9DJL2 CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
DM9DJL2 IK OOVTUOCTLAERQD-OJMBIDBESA-N
DM9DJL2 IU 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride
DM9DJL2 CA CAS 920113-03-7
DM9DJL2 DE Mantle cell lymphoma
DMW1OI6 ID DMW1OI6
DMW1OI6 DN P32/98
DMW1OI6 HS Phase 2
DMW1OI6 SN Isoleucine-thiazolidide; AC1OCFGS; MolPort-044-561-375
DMW1OI6 DT Small molecular drug
DMW1OI6 PC 6918464
DMW1OI6 MW 318.39
DMW1OI6 FM C13H22N2O5S
DMW1OI6 IC InChI=1S/C9H18N2OS.C4H4O4/c1-3-7(2)8(10)9(12)11-4-5-13-6-11;5-3(6)1-2-4(7)8/h7-8H,3-6,10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t7-,8-;/m0./s1
DMW1OI6 CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)N.C(=C/C(=O)O)\\C(=O)O
DMW1OI6 IK ZSOPWZQRZHWYFY-NUXPJIRBSA-N
DMW1OI6 IU (2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(E)-but-2-enedioic acid
DMW1OI6 DE Autism spectrum disorder
DMCBEYH ID DMCBEYH
DMCBEYH DN P54
DMCBEYH HS Phase 2
DMCBEYH DE Solid tumour/cancer
DMG8NLI ID DMG8NLI
DMG8NLI DN P-9808
DMG8NLI HS Phase 2
DMG8NLI SN Porphogen; Porphozym; PBGD, HemeBiotech; PBGD, Zymenex; Recombinant porphobilinogen deaminase, HemeBiotech; Recombinant porphobilinogen deaminase, Zymenex
DMG8NLI CP Zymenex A/S
DMG8NLI DE Porphyria
DM3816P ID DM3816P
DM3816P DN PAC-14028
DM3816P HS Phase 2
DM3816P CP Pacific Pharmaceuticals Co Ltd
DM3816P PC 56649347
DM3816P MW 491.5
DM3816P FM C21H22F5N3O3S
DM3816P IC InChI=1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1
DM3816P CS CCCC1=C(C=CC(=N1)C(F)(F)F)/C=C/C(=O)N[C@H](C)C2=CC(=C(C(=C2)F)NS(=O)(=O)C)F
DM3816P IK UKGJZDSUJSPAJL-YPUOHESYSA-N
DM3816P IU (E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide
DM3816P CA CAS 1005168-10-4
DM3816P DE Atopic dermatitis
DMMIYZ7 ID DMMIYZ7
DMMIYZ7 DN Palifosfamide
DMMIYZ7 HS Phase 2
DMMIYZ7 SN ZIO-201
DMMIYZ7 CP ZIOPHARM Oncology
DMMIYZ7 DT Small molecular drug
DMMIYZ7 PC 100427
DMMIYZ7 MW 221.02
DMMIYZ7 FM C4H11Cl2N2O2P
DMMIYZ7 IC InChI=1S/C4H11Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H3,7,8,9,10)
DMMIYZ7 CS C(CCl)NP(=O)(NCCCl)O
DMMIYZ7 IK BKCJZNIZRWYHBN-UHFFFAOYSA-N
DMMIYZ7 IU bis(2-chloroethylamino)phosphinic acid
DMMIYZ7 CA CAS 31645-39-3
DMMIYZ7 CB CHEBI:80566
DMMIYZ7 DE Soft tissue sarcoma
DMX8ZAQ ID DMX8ZAQ
DMX8ZAQ DN Paliroden
DMX8ZAQ HS Phase 2
DMX8ZAQ SN SR-57667; SR-57667B
DMX8ZAQ CP Sanofi-aventis
DMX8ZAQ DT Small molecular drug
DMX8ZAQ PC 11567682
DMX8ZAQ MW 407.5
DMX8ZAQ FM C26H24F3N
DMX8ZAQ IC InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2
DMX8ZAQ CS C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC=C(C=C3)C4=CC=CC=C4
DMX8ZAQ IK CNEWKIDCGDXBDE-UHFFFAOYSA-N
DMX8ZAQ IU 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
DMX8ZAQ CA CAS 188396-77-2
DMX8ZAQ DE Parkinson disease
DMAZ460 ID DMAZ460
DMAZ460 DN Pankomab-GEX
DMAZ460 HS Phase 2
DMAZ460 SN GT-MAB 2.5 GEX; PankoMab (GlycoExpress, cancer), Glycotope
DMAZ460 CP Glycotope GmbH
DMAZ460 DT Antibody
DMAZ460 DE Solid tumour/cancer
DMV27SP ID DMV27SP
DMV27SP DN Panobacumab
DMV27SP HS Phase 2
DMV27SP SN KBPA-101; Human monoclonal antibody (Pseudomonas aeruginosa), Berna; MAb (Pseudomonas aeruginosa), Berna
DMV27SP CP Aridis Pharmaceuticals
DMV27SP DT Monoclonal antibody
DMV27SP DE Ventilator-associated pneumonia; Hospital-acquired pneumonia; Pseudomonas infection
DMPO4M1 ID DMPO4M1
DMPO4M1 DN Paquinimod
DMPO4M1 HS Phase 2
DMPO4M1 SN ABR-215757; ABR-25757; Project 57-57, Active Biotech
DMPO4M1 CP Active Biotech AB
DMPO4M1 DT Small molecular drug
DMPO4M1 PC 54684617
DMPO4M1 MW 350.4
DMPO4M1 FM C21H22N2O3
DMPO4M1 IC InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
DMPO4M1 CS CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C
DMPO4M1 IK DIKSYHCCYVYKRO-UHFFFAOYSA-N
DMPO4M1 IU N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
DMPO4M1 CA CAS 248282-01-1
DMPO4M1 DE Lupus
DMD275X ID DMD275X
DMD275X DN Pardoprunox
DMD275X HS Phase 2
DMD275X SN Pardoprunox (USAN/INN); 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one; 7-(4-methylpiperazin-1-yl)-3H-benzooxazol-2-one
DMD275X CP Solvay
DMD275X DT Small molecular drug
DMD275X PC 6918525
DMD275X MW 233.27
DMD275X FM C12H15N3O2
DMD275X IC InChI=1S/C12H15N3O2/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9/h2-4H,5-8H2,1H3,(H,13,16)
DMD275X CS CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3
DMD275X IK YVPUUUDAZYFFQT-UHFFFAOYSA-N
DMD275X IU 7-(4-methylpiperazin-1-yl)-3H-1,3-benzoxazol-2-one
DMD275X CA CAS 269718-84-5
DMD275X DE Parkinson disease
DM4N7BT ID DM4N7BT
DM4N7BT DN Paritaprevir
DM4N7BT HS Phase 2
DM4N7BT SN (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; ABT 450; ABT-450; ABT450; CHEMBL3391662; EX-A2278; OU2YM37K86; Paritaprevir; Paritaprevir [USAN:INN]; Paritaprevir(ABT-450); Paritaprevir(Veruprevir ABT-450); SCHEMBL3069964; UNII-OU2YM37K86; Veruprevir; Veruprevir [INN]; Veruprevir anhydrous
DM4N7BT TC Antiviral Agent
DM4N7BT DT Small molecular drug
DM4N7BT PC 45110509
DM4N7BT MW 765.886
DM4N7BT FM C40H43N7O7S
DM4N7BT IC InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1
DM4N7BT CS CC1=NC=C(N=C1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8
DM4N7BT IK UAUIUKWPKRJZJV-QPLHLKROSA-N
DM4N7BT IU (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DM4N7BT CA CAS 1216941-48-8
DM4N7BT DE Hepatitis C virus infection
DMYBIFS ID DMYBIFS
DMYBIFS DN Parsaclisib
DMYBIFS HS Phase 2
DMYBIFS SN INCB050465; Parsaclisib free base; UNII-OS7097575K; 1426698-88-5 (free base); OS7097575K; 1426698-88-5; (4R)-4-{3-[(1S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one; INCB-050465; (4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; Parsaclisib [INN]; Parsaclisib [USAN]; Parsaclisib (USAN/INN); Parsaclisib [USAN:INN]; INCB050465 free base; INCB-050465 free base; CHEMBL4297615; SCHEMBL14736228; BDBM272573; EX-A2638; WHO 10589; DB14867; US10065963, 32c; HY-109068; CS-0033435; D11437; (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one; 2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4R)-
DMYBIFS CP Incyte
DMYBIFS DT Small molecular drug
DMYBIFS PC 86677874
DMYBIFS MW 432.9
DMYBIFS FM C20H22ClFN6O2
DMYBIFS IC InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
DMYBIFS CS CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
DMYBIFS IK ZQPDJCIXJHUERQ-QWRGUYRKSA-N
DMYBIFS IU (4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
DMYBIFS CA CAS 1426698-88-5
DMYBIFS DE Follicular lymphoma
DMCQBFT ID DMCQBFT
DMCQBFT DN Parthenolide
DMCQBFT HS Phase 2
DMCQBFT SN parthenolide; 20554-84-1; (-)-Parthenolide; CHEBI:7939; Parthenolide, Tanacetum parthenium; 4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone; partenolide; C15H20O3; 29552-41-8; Prestwick2_000550; Prestwick3_000550; Epitope ID:115014; SCHEMBL8220; BSPBio_001308; BSPBio_000599; MLS002153872; CHEMBL465158; BPBio1_000659; SCHEMBL13367522; BCBcMAP01_000041; Parthenolide, > MolPort-008-268-168; MolPort-003-959-089; HMS1361B10; HMS3402B10; HMS1989B10; HMS1791B10; HMS1569N21; HMS2096N21
DMCQBFT DT Small molecular drug
DMCQBFT PC 7251185
DMCQBFT MW 248.32
DMCQBFT FM C15H20O3
DMCQBFT IC InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1
DMCQBFT CS C/C/1=C\\CC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C
DMCQBFT IK KTEXNACQROZXEV-PVLRGYAZSA-N
DMCQBFT IU (1S,2R,4R,7E,11S)-4,8-dimethyl-12-methylidene-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-13-one
DMCQBFT CA CAS 20554-84-1
DMCQBFT CB CHEBI:7939
DMU3XJP ID DMU3XJP
DMU3XJP DN Pascolizumab
DMU3XJP HS Phase 2
DMU3XJP SN SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs
DMU3XJP CP Novartis
DMU3XJP DT Monoclonal antibody
DMU3XJP DE Asthma
DM2NJYC ID DM2NJYC
DM2NJYC DN Patidegib
DM2NJYC HS Phase 2
DM2NJYC SN Patidegib hydrochloride; UNII-ZL14FCA5PK; 1169829-40-6; ZL14FCA5PK; IPI-926 Hydrochloride; Saridegib HCl; Patidegib [USAN:INN]; Saridegib [Rescinded USAN]; Saridegib hydrochloride (USAN); CHEMBL2105764; D10325; Methanesulfonamide, N-((2S,3R,3'R,3aS,4'aR,6S,6'aR,6'bS,7aR,12'aS,12'bS)- 2',3',3a,4,4',4'a,5,5',6,6',6'a,6'b,7,7',7a,8',10',12',12'a,12'b-eicosahydro-3,6,11',12'b-tetramethylspiro(furo(3,2-b)pyridine-2(3H),9'(1'H)-naphth(2,1-a)azulen)-3'-yl)-
DM2NJYC CP PellePharm San Francisco, CA
DM2NJYC PC 25027363
DM2NJYC MW 504.8
DM2NJYC FM C29H48N2O3S
DM2NJYC IC InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1
DM2NJYC CS C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@@]6([C@H]5CC4=C(C3)C)C)NS(=O)(=O)C)C)NC1
DM2NJYC IK HZLFFNCLTRVYJG-WWGOJCOQSA-N
DM2NJYC IU N-[(3R,3'R,3'aS,4aR,6'S,6aR,6bS,7'aR,9S,12aS,12bS)-3',6',11,12b-tetramethylspiro[1,2,3,4,4a,5,6,6a,6b,7,8,10,12,12a-tetradecahydronaphtho[2,1-a]azulene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-yl]methanesulfonamide
DM2NJYC CA CAS 1037210-93-7
DM2NJYC DE Basal cell carcinoma; Basal cell nevus syndrome; Chondrosarcoma
DMU0812 ID DMU0812
DMU0812 DN PAZ-320
DMU0812 HS Phase 2
DMU0812 CP Boston Therapeutics
DMU0812 DE Type-2 diabetes
DMVJD2W ID DMVJD2W
DMVJD2W DN Pazopanib + Tyverb/Tykerb
DMVJD2W HS Phase 2
DMVJD2W CP GSK
DMVJD2W DT Combination drug
DMVJD2W PC 10113978; 9941095
DMVJD2W DE Inflammatory breast cancer
DMZCI04 ID DMZCI04
DMZCI04 DN PB-1023
DMZCI04 HS Phase 2
DMZCI04 CP PhaseBio Pharmaceuticals
DMZCI04 DE Type-2 diabetes
DM8MJ3F ID DM8MJ3F
DM8MJ3F DN PB1046
DM8MJ3F HS Phase 2
DM8MJ3F SN Pemziviptadil; PB1046 Vasomera; PB-1120 Vasomera
DM8MJ3F CP Phasebio pharmaceuticals
DM8MJ3F DT Recombinant protein
DM8MJ3F DE Hypertension; Cardiomyopathy; Duchenne dystrophy; Heart failure; Pulmonary arterial hypertension
DM05WIU ID DM05WIU
DM05WIU DN PBI-05204
DM05WIU HS Phase 2
DM05WIU CP Phoenix Biotechnology
DM05WIU PC 11541511
DM05WIU MW 576.7
DM05WIU FM C32H48O9
DM05WIU IC InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
DM05WIU CS C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O
DM05WIU IK JLPDBLFIVFSOCC-XYXFTTADSA-N
DM05WIU IU [(3S,5R,8R,9S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate
DM05WIU CA CAS 465-16-7
DM05WIU CB CHEBI:59030
DM05WIU DE Solid tumour/cancer; Pancreatic cancer
DMPXK27 ID DMPXK27
DMPXK27 DN PBI-4050
DMPXK27 HS Phase 2
DMPXK27 SN setogepram; (3-pentylphenyl)acetic acid; 2-(3-Pentylphenyl)acetic acid; 1002101-19-0; 3-Pentylbenzeneacetic acid; UNII-879OVM0Y1S; Benzeneacetic acid, 3-pentyl-; 879OVM0Y1S; 1002101-19-0 (free acid); Fezagepras; SCHEMBL289216; CHEMBL4297635; GTPL10043; PBI4050; ZINC113492390; DB15447; HY-100775A; AS-59875; CS-0062694; A1-19258; Q27895887
DMPXK27 CP Liminal BioSciences
DMPXK27 DT Small molecular drug
DMPXK27 PC 24749700
DMPXK27 MW 206.28
DMPXK27 FM C13H18O2
DMPXK27 IC InChI=1S/C13H18O2/c1-2-3-4-6-11-7-5-8-12(9-11)10-13(14)15/h5,7-9H,2-4,6,10H2,1H3,(H,14,15)
DMPXK27 CS CCCCCC1=CC(=CC=C1)CC(=O)O
DMPXK27 IK PEGQOIGYZLJMIB-UHFFFAOYSA-N
DMPXK27 IU 2-(3-pentylphenyl)acetic acid
DMPXK27 CA CAS 1002101-19-0
DMPXK27 DE Idiopathic pulmonary fibrosis
DMKWGS1 ID DMKWGS1
DMKWGS1 DN PBT-2
DMKWGS1 HS Phase 2
DMKWGS1 SN AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
DMKWGS1 CP Prana biotechnology
DMKWGS1 DT Small molecular drug
DMKWGS1 PC 10016012
DMKWGS1 MW 271.14
DMKWGS1 FM C12H12Cl2N2O
DMKWGS1 IC InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
DMKWGS1 CS CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl
DMKWGS1 IK YZPOQCQXOSEMAZ-UHFFFAOYSA-N
DMKWGS1 IU 5,7-dichloro-2-[(dimethylamino)methyl]quinolin-8-ol
DMKWGS1 CA CAS 747408-78-2
DMKWGS1 DE Alzheimer disease; Huntington disease
DMYRIHZ ID DMYRIHZ
DMYRIHZ DN PCL-016
DMYRIHZ HS Phase 2
DMYRIHZ CP Novactyl
DMYRIHZ DE Acne vulgaris
DMYFRTB ID DMYFRTB
DMYFRTB DN PCM-075
DMYFRTB HS Phase 2
DMYFRTB SN Onvansertib
DMYFRTB CP TrovaGene San Diego, CA
DMYFRTB PC 49792852
DMYFRTB MW 532.5
DMYFRTB FM C24H27F3N8O3
DMYFRTB IC InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)
DMYFRTB CS CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO
DMYFRTB IK QHLVBNKYJGBCQJ-UHFFFAOYSA-N
DMYFRTB IU 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide
DMYFRTB CA CAS 1034616-18-6
DMYFRTB DE Acute myeloid leukaemia; Solid tumour/cancer; Prostate cancer
DMUHDX3 ID DMUHDX3
DMUHDX3 DN PC-SOD
DMUHDX3 HS Phase 2
DMUHDX3 SN PC-SOD (inhaled)
DMUHDX3 CP LTT Bio-Pharma Co Ltd
DMUHDX3 DE Interstitial lung disease
DM27D4J ID DM27D4J
DM27D4J DN PD-0325901
DM27D4J HS Phase 2
DM27D4J SN PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
DM27D4J CP Pfizer
DM27D4J TC Anticancer Agents
DM27D4J DT Small molecular drug
DM27D4J PC 9826528
DM27D4J MW 482.19
DM27D4J FM C16H14F3IN2O4
DM27D4J IC InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
DM27D4J CS C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O
DM27D4J IK SUDAHWBOROXANE-SECBINFHSA-N
DM27D4J IU N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide
DM27D4J CA CAS 391210-10-9
DM27D4J CB CHEBI:88249
DM27D4J DE Breast cancer
DMXAH4G ID DMXAH4G
DMXAH4G DN PD-143188
DMXAH4G HS Phase 2
DMXAH4G SN PD-147693; PD-149394; PD-155144; PD-163637; PD-163639
DMXAH4G CP Parke-Davis & Co
DMXAH4G DT Small molecular drug
DMXAH4G PC 101650979
DMXAH4G MW 329.5
DMXAH4G FM C24H27N
DMXAH4G IC InChI=1S/C24H27N/c1-3-9-21(10-4-1)23-14-16-25(17-15-23)19-20-8-7-13-24(18-20)22-11-5-2-6-12-22/h1-7,9-14,20,24H,8,15-19H2/t20-,24?/m1/s1
DMXAH4G CS C1CN(CC=C1C2=CC=CC=C2)C[C@@H]3CC=CC(C3)C4=CC=CC=C4
DMXAH4G IK SDOHTVBFDDPWNE-CGHJUBPDSA-N
DMXAH4G IU 4-phenyl-1-[[(1R)-5-phenylcyclohex-3-en-1-yl]methyl]-3,6-dihydro-2H-pyridine
DMXAH4G DE Psychotic disorder
DMWVBTQ ID DMWVBTQ
DMWVBTQ DN PD-145065
DMWVBTQ HS Phase 2
DMWVBTQ SN N-Acetyl-2-D-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)glycyl-L-leucyl-L-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophan
DMWVBTQ DT Small molecular drug
DMWVBTQ PC 123959
DMWVBTQ MW 950.1
DMWVBTQ FM C52H67N7O10
DMWVBTQ IC InChI=1S/C52H67N7O10/c1-8-29(5)44(49(65)57-41(52(68)69)25-34-27-53-38-21-15-14-18-35(34)38)59-50(66)45(30(6)9-2)58-48(64)40(26-42(61)62)55-47(63)39(24-28(3)4)56-51(67)46(54-31(7)60)43-36-19-12-10-16-32(36)22-23-33-17-11-13-20-37(33)43/h10-21,27-30,39-41,43-46,53H,8-9,22-26H2,1-7H3,(H,54,60)(H,55,63)(H,56,67)(H,57,65)(H,58,64)(H,59,66)(H,61,62)(H,68,69)/t29-,30-,39-,40-,41-,44-,45-,46+/m0/s1
DMWVBTQ CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C3C4=CC=CC=C4CCC5=CC=CC=C35)NC(=O)C
DMWVBTQ IK HRAQSWKGRRUBDJ-OMUAVVNCSA-N
DMWVBTQ IU (3S)-3-[[(2S)-2-[[(2R)-2-acetamido-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMWVBTQ CA CAS 153049-49-1
DMWVBTQ DE Hypertension
DMPW28M ID DMPW28M
DMPW28M DN PD-200390
DMPW28M HS Phase 2
DMPW28M SN AC1L4NQF; SCHEMBL9494809; YPPRSIHNTQEZCJ-UHFFFAOYSA-N; 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide; 3-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-[2-(2-pyridyl)ethyl]-N-methylpropanamide; 3-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-methyl-N-[2-(2-pyridinyl)ethyl]propanamide
DMPW28M CP Pfizer
DMPW28M DT Small molecular drug
DMPW28M PC 188931
DMPW28M MW 428.6
DMPW28M FM C25H36N2O2S
DMPW28M IC InChI=1S/C25H36N2O2S/c1-24(2,3)20-16-19(17-21(23(20)29)25(4,5)6)30-15-12-22(28)27(7)14-11-18-10-8-9-13-26-18/h8-10,13,16-17,29H,11-12,14-15H2,1-7H3
DMPW28M CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SCCC(=O)N(C)CCC2=CC=CC=N2
DMPW28M IK YPPRSIHNTQEZCJ-UHFFFAOYSA-N
DMPW28M IU 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide
DMPW28M DE Insomnia
DM6F5EV ID DM6F5EV
DM6F5EV DN PD-360324
DM6F5EV HS Phase 2
DM6F5EV SN PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer
DM6F5EV CP Pfizer
DM6F5EV DE Rheumatoid arthritis
DMGP9VN ID DMGP9VN
DMGP9VN DN PDC-1421
DMGP9VN HS Phase 2
DMGP9VN CP BioLite
DMGP9VN DE Attention deficit hyperactivity disorder
DM6OC53 ID DM6OC53
DM6OC53 DN PDX-101
DM6OC53 HS Phase 2
DM6OC53 SN Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684
DM6OC53 CP National Cancer Institute (NCI)
DM6OC53 TC Anticancer Agents
DM6OC53 DT Small molecular drug
DM6OC53 PC 6918638
DM6OC53 MW 318.3
DM6OC53 FM C15H14N2O4S
DM6OC53 IC InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
DM6OC53 CS C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
DM6OC53 IK NCNRHFGMJRPRSK-MDZDMXLPSA-N
DM6OC53 IU (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
DM6OC53 CA CAS 866323-14-0
DM6OC53 CB CHEBI:61076
DM6OC53 DE Solid tumour/cancer; Haematological malignancy; Peripheral T-cell lymphoma
DMFL96Z ID DMFL96Z
DMFL96Z DN Pegamotecan
DMFL96Z HS Phase 2
DMFL96Z SN Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
DMFL96Z CP Enzon Pharmaceuticals Inc
DMFL96Z DT Small molecular drug
DMFL96Z PC 11297617
DMFL96Z MW 981
DMFL96Z FM C52H48N6O14
DMFL96Z IC InChI=1S/C52H48N6O14/c1-5-51(35-19-39-43-31(17-29-11-7-9-13-37(29)55-43)21-57(39)45(61)33(35)23-69-49(51)65)71-47(63)27(3)53-41(59)25-67-15-16-68-26-42(60)54-28(4)48(64)72-52(6-2)36-20-40-44-32(18-30-12-8-10-14-38(30)56-44)22-58(40)46(62)34(36)24-70-50(52)66/h7-14,17-20,27-28H,5-6,15-16,21-26H2,1-4H3,(H,53,59)(H,54,60)/t27-,28-,51-,52-/m0/s1
DMFL96Z CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@]6(C7=C(COC6=O)C(=O)N8CC9=CC1=CC=CC=C1N=C9C8=C7)CC
DMFL96Z IK DZNNFZGDBUXWMV-ZUWDIFAMSA-N
DMFL96Z IU [(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[2-[2-[2-[[(2S)-1-[[(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxy]-1-oxopropan-2-yl]amino]-2-oxoethoxy]ethoxy]acetyl]amino]propanoate
DMFL96Z CA CAS 581079-18-7
DMFL96Z DE Esophageal cancer
DMPD3X6 ID DMPD3X6
DMPD3X6 DN Pegmusirudin
DMPD3X6 HS Phase 2
DMPD3X6 SN BSF-87981; LU-57291; LU-87981; Polyethylene glycol hirudin, Knoll; SPP-200; PEG-hirudin, Knoll
DMPD3X6 CP Knoll GmbH
DMPD3X6 PC 56841834
DMPD3X6 MW 7266
DMPD3X6 FM C299H462N84O115S6
DMPD3X6 IC InChI=1S/C299H462N84O115S6/c1-27-142(21)234-289(485)361-171(97-134(5)6)244(440)323-120-216(410)335-188(124-385)273(469)337-154(45-34-36-86-317-298(493)497-95-93-495-29-3)240(436)319-114-210(404)332-161(67-80-221(418)419)250(446)338-156(47-38-88-315-296(310)311)248(444)356-180(106-205(305)399)266(462)343-162(61-74-201(301)395)257(453)367-194(130-502-499-127-191-247(443)326-116-209(403)329-157(64-77-218(412)413)241(437)320-117-213(407)333-179(105-204(304)398)265(461)339-155(46-35-37-87-318-299(494)498-96-94-496-30-4)249(445)366-195(279(475)376-234)131-503-500-128-192(276(472)340-159(66-79-220(416)417)243(439)321-119-215(409)336-189(125-386)274(470)359-183(109-208(308)402)272(468)373-231(139(15)16)287(483)371-191)368-261(457)174(100-137(11)12)352-277(473)193-129-501-504-132-196(370-270(466)186(112-229(434)435)363-291(487)238(146(25)390)378-271(467)177(103-150-54-58-153(393)59-55-150)362-286(482)232(140(17)18)375-284(480)230(309)138(13)14)280(476)379-237(145(24)389)290(486)347-167(71-84-225(426)427)256(452)364-187(123-384)246(442)325-115-211(405)331-160(60-73-200(300)394)251(447)357-181(107-206(306)400)267(463)351-173(99-136(9)10)260(456)369-193)278(474)374-233(141(19)20)288(484)380-236(144(23)388)285(481)327-121-212(406)330-158(65-78-219(414)415)242(438)322-122-217(411)372-239(147(26)391)294(490)383-92-42-51-199(383)283(479)348-169(48-39-89-316-297(312)313)292(488)381-90-40-49-197(381)281(477)345-163(62-75-202(302)396)255(451)365-190(126-387)275(471)355-178(104-151-113-314-133-328-151)264(460)358-182(108-207(307)401)268(464)360-184(110-227(430)431)245(441)324-118-214(408)334-185(111-228(432)433)269(465)354-175(101-148-43-32-31-33-44-148)262(458)344-164(68-81-222(420)421)252(448)342-168(72-85-226(428)429)258(454)377-235(143(22)28-2)293(489)382-91-41-50-198(382)282(478)346-166(70-83-224(424)425)253(449)341-165(69-82-223(422)423)254(450)353-176(102-149-52-56-152(392)57-53-149)263(459)350-172(98-135(7)8)259(455)349-170(295(491)492)63-76-203(303)397/h31-33,43-44,52-59,113,133-147,154-199,230-239,384-393H,27-30,34-42,45-51,60-112,114-132,309H2,1-26H3,(H2,300,394)(H2,301,395)(H2,302,396)(H2,303,397)(H2,304,398)(H2,305,399)(H2,306,400)(H2,307,401)(H2,308,402)(H,314,328)(H,317,493)(H,318,494)(H,319,436)(H,320,437)(H,321,439)(H,322,438)(H,323,440)(H,324,441)(H,325,442)(H,326,443)(H,327,481)(H,329,403)(H,330,406)(H,331,405)(H,332,404)(H,333,407)(H,334,408)(H,335,410)(H,336,409)(H,337,469)(H,338,446)(H,339,461)(H,340,472)(H,341,449)(H,342,448)(H,343,462)(H,344,458)(H,345,477)(H,346,478)(H,347,486)(H,348,479)(H,349,455)(H,350,459)(H,351,463)(H,352,473)(H,353,450)(H,354,465)(H,355,471)(H,356,444)(H,357,447)(H,358,460)(H,359,470)(H,360,464)(H,361,485)(H,362,482)(H,363,487)(H,364,452)(H,365,451)(H,366,445)(H,367,453)(H,368,457)(H,369,456)(H,370,466)(H,371,483)(H,372,411)(H,373,468)(H,374,474)(H,375,480)(H,376,475)(H,377,454)(H,378,467)(H,379,476)(H,380,484)(H,412,413)(H,414,415)(H,416,417)(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,428,429)(H,430,431)(H,432,433)(H,434,435)(H,491,492)(H4,310,311,315)(H4,312,313,316)/t142-,143-,144+,145+,146+,147+,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,230-,231-,232-,233-,234-,235-,236-,237-,238-,239-/m0/s1
DMPD3X6 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)C(=O)N1)CCCCNC(=O)OCCOCC)CC(=O)N)CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC7=CN=CN7)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N9CCC[C@H]9C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CCC(=O)O)CCCCNC(=O)OCCOCC)CO)CC(C)C
DMPD3X6 IK MFPRYDMAZLLTGM-IJDGSQHYSA-N
DMPD3X6 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[(1R,6R,9S,12S,15S,18S,24S,27S,33S,36S,39R,44R,47S,53S,56S,59S,67S,73S,76S)-44-[[(2S)-2-[[(4R,7S,10S,13S,19S,22S,25S,28R)-28-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-10-(2-amino-2-oxoethyl)-13-(3-amino-3-oxopropyl)-22-(2-carboxyethyl)-25-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-7-(2-methylpropyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carbonyl]amino]-4-methylpentanoyl]amino]-12,56,73-tris(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-36-[(2S)-butan-2-yl]-15-(3-carbamimidamidopropyl)-18,47,67-tris(2-carboxyethyl)-24,76-bis[4-(2-ethoxyethoxycarbonylamino)butyl]-27,53-bis(hydroxymethyl)-33-(2-methylpropyl)-8,11,14,17,20,23,26,29,32,35,38,45,48,51,54,57,60,62,65,68,71,74,77-tricosaoxo-59-propan-2-yl-3,4,41,42-tetrathia-7,10,13,16,19,22,25,28,31,34,37,46,49,52,55,58,61,63,66,69,72,75,78-tricosazabicyclo[37.22.17]octaheptacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMPD3X6 DE Angina pectoris
DM26YJ1 ID DM26YJ1
DM26YJ1 DN PEGPH20
DM26YJ1 HS Phase 2
DM26YJ1 CP Halozyme Therapeutics San Diego, CA
DM26YJ1 DE Pancreatic cancer; Gallbladder disease; Gastric adenocarcinoma; Non-small-cell lung cancer
DMX9ZM4 ID DMX9ZM4
DMX9ZM4 DN PEG-SN38
DMX9ZM4 HS Phase 2
DMX9ZM4 SN EZN-2208
DMX9ZM4 CP Enzon pharmaceuticals
DMX9ZM4 DT Small molecular drug
DMX9ZM4 PC 59443782
DMX9ZM4 MW 2300.3
DMX9ZM4 FM C118H122N12O37
DMX9ZM4 IC InChI=1S/C118H122N12O37/c1-9-67-71-33-61(131)17-21-87(71)123-103-75(67)45-127-91(103)37-83-79(107(127)143)53-160-111(147)115(83,13-5)164-99(139)41-119-95(135)57-153-27-25-151-49-65(158-31-29-155-59-97(137)121-43-101(141)166-117(15-7)85-39-93-105-77(47-129(93)109(145)81(85)55-162-113(117)149)69(11-3)73-35-63(133)19-23-89(73)125-105)51-157-52-66(159-32-30-156-60-98(138)122-44-102(142)167-118(16-8)86-40-94-106-78(48-130(94)110(146)82(86)56-163-114(118)150)70(12-4)74-36-64(134)20-24-90(74)126-106)50-152-26-28-154-58-96(136)120-42-100(140)165-116(14-6)84-38-92-104-76(46-128(92)108(144)80(84)54-161-112(116)148)68(10-2)72-34-62(132)18-22-88(72)124-104/h17-24,33-40,65-66,131-134H,9-16,25-32,41-60H2,1-8H3,(H,119,135)(H,120,136)(H,121,137)(H,122,138)/t65?,66?,115-,116-,117-,118-/m0/s1
DMX9ZM4 CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)OC(=O)CNC(=O)COCCOCC(COCC(COCCOCC(=O)NCC(=O)O[C@]5(C6=C(COC5=O)C(=O)N7CC8=C(C9=C(C=CC(=C9)O)N=C8C7=C6)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)OCCOCC(=O)NCC(=O)O[C@]3(C4=C(COC3=O)C(=O)N3CC5=C(C6=C(C=CC(=C6)O)N=C5C3=C4)CC)CC)C2=NC2=C1C=C(C=C2)O
DMX9ZM4 IK CXWRXYDTWCBSJF-DPTNTHPESA-N
DMX9ZM4 IU [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[[2-[2-[3-[2,3-bis[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]-2-[2-[2-[[2-[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl]oxy]-2-oxoethyl]amino]-2-oxoethoxy]ethoxy]propoxy]ethoxy]acetyl]amino]acetate
DMX9ZM4 CA CAS 946062-05-1
DMX9ZM4 DE Metastatic colorectal cancer; Breast cancer
DMTDANB ID DMTDANB
DMTDANB DN Pegsunercept
DMTDANB HS Phase 2
DMTDANB SN STNF-R1
DMTDANB CP Amgen
DMTDANB DE Rheumatoid arthritis
DMBPJ9U ID DMBPJ9U
DMBPJ9U DN PEGylated pitrakinra
DMBPJ9U HS Phase 2
DMBPJ9U SN Aeroderm; Dermalast; AER-003; PEGylated pitrakinra (subcutaneous, eczema/allergy), Aerovance; PEGylated AER-001 (subcutaneous, eczema/allergy), Aerovance; PEGylated IL-4 variant (subcutaneous, eczema/allergy), Aerovance
DMBPJ9U CP Aerovance
DMBPJ9U DT Monoclonal antibody
DMBPJ9U DE Allergy; Asthma
DMOMN31 ID DMOMN31
DMOMN31 DN PEITC
DMOMN31 HS Phase 2
DMOMN31 SN Phenethyl-isothiocyanate
DMOMN31 CP New York University
DMOMN31 DT Small molecular drug
DMOMN31 PC 16741
DMOMN31 MW 163.24
DMOMN31 FM C9H9NS
DMOMN31 IC InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2
DMOMN31 CS C1=CC=C(C=C1)CCN=C=S
DMOMN31 IK IZJDOKYDEWTZSO-UHFFFAOYSA-N
DMOMN31 IU 2-isothiocyanatoethylbenzene
DMOMN31 CA CAS 2257-09-2
DMOMN31 CB CHEBI:351346
DMOMN31 DE Prostate cancer
DMIW453 ID DMIW453
DMIW453 DN Pelitinib
DMIW453 HS Phase 2
DMIW453 SN EKB-569; EKI-569; WAY-EKB-569
DMIW453 CP Wyeth
DMIW453 DT Small molecular drug
DMIW453 PC 6445562
DMIW453 MW 467.9
DMIW453 FM C24H23ClFN5O2
DMIW453 IC InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+
DMIW453 CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)F)Cl)C#N)NC(=O)/C=C/CN(C)C
DMIW453 IK WVUNYSQLFKLYNI-AATRIKPKSA-N
DMIW453 IU (E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
DMIW453 CA CAS 257933-82-7
DMIW453 CB CHEBI:38927
DMIW453 DE Lymphoma
DMR6USG ID DMR6USG
DMR6USG DN PELITREXOL
DMR6USG HS Phase 2
DMR6USG SN AG-2037; Pelitrexol < USAN; AG-2032 (racemate); AG-2038 ((6R)-isomer); N-[5-[2-[2-Amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6(S)-yl]ethyl]-4-methylthien-2-ylcarbonyl]-L-glutamic acid
DMR6USG DT Small molecular drug
DMR6USG PC 135431074
DMR6USG MW 463.5
DMR6USG FM C20H25N5O6S
DMR6USG IC InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1
DMR6USG CS CC1=C(SC(=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@H]2CC3=C(NC2)N=C(NC3=O)N
DMR6USG IK QXOPTIPQEVJERB-JQWIXIFHSA-N
DMR6USG IU (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid
DMR6USG CA CAS 446022-33-9
DMR6USG DE Solid tumour/cancer
DMGY5JC ID DMGY5JC
DMGY5JC DN Pentacea
DMGY5JC HS Phase 2
DMGY5JC SN HMN14-734; Bispecific CEA antibody (radiotherapeutic pretargeting), IBC; Anti-CEA/anti-In-DTPA antibody, IBC
DMGY5JC CP IBC Pharmaceuticals Inc
DMGY5JC DT Antibody
DMGY5JC DE Small-cell lung cancer
DMNU48O ID DMNU48O
DMNU48O DN Peptide YY 3-36
DMNU48O HS Phase 2
DMNU48O SN YY 3-36; Peptide YY 3-36 (oral, eligen)
DMNU48O CP Emisphere Technologies Inc
DMNU48O DE Obesity
DMFM6OU ID DMFM6OU
DMFM6OU DN PerioPatch
DMFM6OU HS Phase 2
DMFM6OU CP Izun Pharmaceuticals Corp
DMFM6OU DE Periodontal disease
DMNM4CK ID DMNM4CK
DMNM4CK DN PF-00734200
DMNM4CK HS Phase 2
DMNM4CK SN GOSOGLIPTIN; 869490-23-3; UNII-GI718UO477; PF-00734200; PF-734200; CHEMBL515387; GI718UO477; 2-(4-{(3s,5s)-5-[(3,3-Difluoropyrrolidin-1-Yl)carbonyl]pyrrolidin-3-Yl}piperazin-1-Yl)pyrimidine; 869490-47-1; (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone; (3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone; (3,3-DIFLUOROPYRROLIDIN-1-YL)[(2S,4S)-4-[4-(PYRIMIDIN-2-YL)PIPERAZIN-1-YL]PYRROLIDIN-2-YL]METHANONE; Gosogliptin [USAN:
DMNM4CK DT Small molecular drug
DMNM4CK PC 11516136
DMNM4CK MW 366.4
DMNM4CK FM C17H24F2N6O
DMNM4CK IC InChI=1S/C17H24F2N6O/c18-17(19)2-5-25(12-17)15(26)14-10-13(11-22-14)23-6-8-24(9-7-23)16-20-3-1-4-21-16/h1,3-4,13-14,22H,2,5-12H2/t13-,14-/m0/s1
DMNM4CK CS C1CN(CC1(F)F)C(=O)[C@@H]2C[C@@H](CN2)N3CCN(CC3)C4=NC=CC=N4
DMNM4CK IK QWEWGXUTRTXFRF-KBPBESRZSA-N
DMNM4CK IU (3,3-difluoropyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-ylpiperazin-1-yl)pyrrolidin-2-yl]methanone
DMNM4CK CA CAS 869490-23-3
DMNM4CK DE Type-2 diabetes
DMJPE61 ID DMJPE61
DMJPE61 DN PF-02545920
DMJPE61 HS Phase 2
DMJPE61 SN 1037309-45-7; 2-((4-(1-Methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline succinate; UNII-TJ5KAZ8T5G; TJ5KAZ8T5G; PF-2545920 succinate; SCHEMBL439127; CTK8C0559; DTXSID90647726; ANW-64894; AKOS016005150; KB-80291; Quinoline, 2-((4-(1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-, butanedioate (1:1); AX8234870; TC-153639; Quinoline,2-[[4-[1-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-,succinate salt; 2-[[4-[1-Methyl-4-(4-pyridyl)pyrazol-3-yl]phenoxy]methyl]quinoline
DMJPE61 CP Pfizer
DMJPE61 DT Small molecular drug
DMJPE61 PC 11581936
DMJPE61 MW 392.5
DMJPE61 FM C25H20N4O
DMJPE61 IC InChI=1S/C25H20N4O/c1-29-16-23(18-12-14-26-15-13-18)25(28-29)20-7-10-22(11-8-20)30-17-21-9-6-19-4-2-3-5-24(19)27-21/h2-16H,17H2,1H3
DMJPE61 CS CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5
DMJPE61 IK AZEXWHKOMMASPA-UHFFFAOYSA-N
DMJPE61 IU 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline
DMJPE61 CA CAS 898562-94-2
DMJPE61 DE Schizophrenia; Huntington disease
DMTJWNE ID DMTJWNE
DMTJWNE DN PF-03446962
DMTJWNE HS Phase 2
DMTJWNE CP Pfizer New York, NY
DMTJWNE DE Solid tumour/cancer
DM826SW ID DM826SW
DM826SW DN PF-04236921
DM826SW HS Phase 2
DM826SW CP Pfizer New York, NY
DM826SW DE Systemic lupus erythematosus; Crohn disease
DMPRYU1 ID DMPRYU1
DMPRYU1 DN PF-04457845
DMPRYU1 HS Phase 2
DMPRYU1 SN PF-04457845; 1020315-31-4; UNII-H4C81M8YYW; H4C81M8YYW; CHEMBL1651534; PF 04457845; PF04457845; C23H20F3N5O2; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
DMPRYU1 DT Small molecular drug
DMPRYU1 PC 24771824
DMPRYU1 MW 455.4
DMPRYU1 FM C23H20F3N5O2
DMPRYU1 IC InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)
DMPRYU1 CS C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4
DMPRYU1 IK BATCTBJIJJEPHM-UHFFFAOYSA-N
DMPRYU1 IU N-pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide
DMPRYU1 CA CAS 1020315-31-4
DMPRYU1 DE Liver disease
DMZMUIL ID DMZMUIL
DMZMUIL DN PF-04518600
DMZMUIL HS Phase 2
DMZMUIL CP Pfizer New York, NY
DMZMUIL DE Solid tumour/cancer
DMA9MBR ID DMA9MBR
DMA9MBR DN PF-04523655
DMA9MBR HS Phase 2
DMA9MBR CP Pfizer; Quark Pharmaceuticals
DMA9MBR TC siRNA
DMA9MBR DT siRNA drug
DMA9MBR DE Diabetic macular edema
DMS610L ID DMS610L
DMS610L DN PF-04691502
DMS610L HS Phase 2
DMS610L SN PF-04691502; 1013101-36-4; PF 04691502; UNII-4W39NS61KI; 4W39NS61KI; 2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one; CHEMBL1234354; PF04691502; 2-Amino-8-[trans-4-(2-Hydroxyethoxy)cyclohexyl]-6-(6-Methoxypyridin-3-Yl)-4-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2-Amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
DMS610L CP Pfizer New York, NY
DMS610L DT Small molecular drug
DMS610L PC 25033539
DMS610L MW 425.5
DMS610L FM C22H27N5O4
DMS610L IC InChI=1S/C22H27N5O4/c1-13-17-11-18(14-3-8-19(30-2)24-12-14)21(29)27(20(17)26-22(23)25-13)15-4-6-16(7-5-15)31-10-9-28/h3,8,11-12,15-16,28H,4-7,9-10H2,1-2H3,(H2,23,25,26)
DMS610L CS CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC
DMS610L IK XDLYKKIQACFMJG-UHFFFAOYSA-N
DMS610L IU 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one
DMS610L CA CAS 1013101-36-4
DMS610L DE Endometrial cancer
DMQMF4O ID DMQMF4O
DMQMF4O DN PF-04937319
DMQMF4O HS Phase 2
DMQMF4O CP Pfizer
DMQMF4O PC 46916694
DMQMF4O MW 432.4
DMQMF4O FM C22H20N6O4
DMQMF4O IC InChI=1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)
DMQMF4O CS CC1=CC2=C(O1)C=C(C=C2OC3=CN=C(N=C3)C(=O)N(C)C)C(=O)NC4=NC=C(N=C4)C
DMQMF4O IK MASKQITXHVYVFL-UHFFFAOYSA-N
DMQMF4O IU N,N-dimethyl-5-[[2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl]oxy]pyrimidine-2-carboxamide
DMQMF4O CA CAS 1245603-92-2
DMQMF4O DE Type-2 diabetes
DMRAFBK ID DMRAFBK
DMRAFBK DN PF-04958242
DMRAFBK HS Phase 2
DMRAFBK CP Pfizer
DMRAFBK PC 49853967
DMRAFBK MW 392.5
DMRAFBK FM C18H20N2O4S2
DMRAFBK IC InChI=1S/C18H20N2O4S2/c1-12(2)26(21,22)20-16-10-23-11-17(16)24-14-5-3-13(4-6-14)18-8-7-15(9-19)25-18/h3-8,12,16-17,20H,10-11H2,1-2H3/t16-,17+/m0/s1
DMRAFBK CS CC(C)S(=O)(=O)N[C@H]1COC[C@H]1OC2=CC=C(C=C2)C3=CC=C(S3)C#N
DMRAFBK IK TTYKUKSFWHEBLI-DLBZAZTESA-N
DMRAFBK IU N-[(3S,4S)-4-[4-(5-cyanothiophen-2-yl)phenoxy]oxolan-3-yl]propane-2-sulfonamide
DMRAFBK CA CAS 1258963-59-5
DMRAFBK DE Schizophrenia
DM94NBE ID DM94NBE
DM94NBE DN PF-04991532
DM94NBE HS Phase 2
DM94NBE CP Pfizer
DM94NBE PC 46181428
DM94NBE MW 396.4
DM94NBE FM C18H19F3N4O3
DM94NBE IC InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1
DM94NBE CS C1CCC(C1)C[C@@H](C(=O)NC2=NC=C(C=C2)C(=O)O)N3C=C(N=C3)C(F)(F)F
DM94NBE IK GKMLFBRLRVQVJO-ZDUSSCGKSA-N
DM94NBE IU 6-[[(2S)-3-cyclopentyl-2-[4-(trifluoromethyl)imidazol-1-yl]propanoyl]amino]pyridine-3-carboxylic acid
DM94NBE CA CAS 1215197-37-7
DM94NBE DE Diabetic complication
DMD74BJ ID DMD74BJ
DMD74BJ DN PF-05089771
DMD74BJ HS Phase 2
DMD74BJ SN Nav1.7 blockers (pain), Pfizer; SCN9A blockers (pain), Pfizer/Icagen/Birkbeck; Voltage-gated sodium channel 1.7 blockers (pain), Pfizer
DMD74BJ CP Pfizer
DMD74BJ PC 46840946
DMD74BJ MW 500.4
DMD74BJ FM C18H12Cl2FN5O3S2
DMD74BJ IC InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)
DMD74BJ CS C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
DMD74BJ IK ZYSCOUXLBXGGIM-UHFFFAOYSA-N
DMD74BJ IU 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide
DMD74BJ CA CAS 1235403-62-9
DMD74BJ DE Chronic pain
DMLQ3OK ID DMLQ3OK
DMLQ3OK DN PF-05175157
DMLQ3OK HS Phase 2
DMLQ3OK CP Pfizer
DMLQ3OK PC 52934180
DMLQ3OK MW 405.5
DMLQ3OK FM C23H27N5O2
DMLQ3OK IC InChI=1S/C23H27N5O2/c1-14(2)28-21-17(13-24-28)11-23(12-20(21)29)6-8-27(9-7-23)22(30)16-4-5-18-19(10-16)26-15(3)25-18/h4-5,10,13-14H,6-9,11-12H2,1-3H3,(H,25,26)
DMLQ3OK CS CC1=NC2=C(N1)C=C(C=C2)C(=O)N3CCC4(CC3)CC5=C(C(=O)C4)N(N=C5)C(C)C
DMLQ3OK IK BDXXSFOJPYSYOC-UHFFFAOYSA-N
DMLQ3OK IU 1'-(2-methyl-3H-benzimidazole-5-carbonyl)-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-7-one
DMLQ3OK CA CAS 1301214-47-0
DMLQ3OK DE Type-2 diabetes
DMPVQYR ID DMPVQYR
DMPVQYR DN PF-05212377
DMPVQYR HS Phase 2
DMPVQYR SN SAM-760
DMPVQYR CP Pfizer New York, NY
DMPVQYR DE Alzheimer disease
DMBL3VD ID DMBL3VD
DMBL3VD DN PF-05212384
DMBL3VD HS Phase 2
DMBL3VD SN PKI-587; 1197160-78-3; Gedatolisib; PF-05212384; PKI587; PKI 587; 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; PF 05212384; UNII-96265TNH2R; PF-05212384 (PKI-587); CHEMBL592445; 96265TNH2R; N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea; Gedatolisib (PF-05212384, PKI-587); Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
DMBL3VD CP Pfizer New York, NY
DMBL3VD DT Small molecular drug
DMBL3VD PC 44516953
DMBL3VD MW 615.7
DMBL3VD FM C32H41N9O4
DMBL3VD IC InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)
DMBL3VD CS CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6
DMBL3VD IK DWZAEMINVBZMHQ-UHFFFAOYSA-N
DMBL3VD IU 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
DMBL3VD CA CAS 1197160-78-3
DMBL3VD DE Solid tumour/cancer
DMQLZOF ID DMQLZOF
DMQLZOF DN PF-06252616
DMQLZOF HS Phase 2
DMQLZOF CP Pfizer
DMQLZOF DT Antibody
DMQLZOF DE Muscular dystrophy; Duchenne dystrophy
DMUAOFM ID DMUAOFM
DMUAOFM DN PF-06290510
DMUAOFM HS Phase 2
DMUAOFM CP Pfizer
DMUAOFM DT Vaccine
DMUAOFM DE Staphylococcus infection; Major depressive disorder
DMN94QM ID DMN94QM
DMN94QM DN PF-06291874
DMN94QM HS Phase 2
DMN94QM CP Pfizer
DMN94QM PC 60151939
DMN94QM MW 503.5
DMN94QM FM C26H28F3N3O4
DMN94QM IC InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m0/s1
DMN94QM CS CCC[C@@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC(=C(C(=C2)C)N3C=C(C=N3)C(F)(F)F)C
DMN94QM IK IBDYYOQKQCCSDP-QFIPXVFZSA-N
DMN94QM IU 3-[[4-[(1S)-1-[3,5-dimethyl-4-[4-(trifluoromethyl)pyrazol-1-yl]phenoxy]butyl]benzoyl]amino]propanoic acid
DMN94QM CA CAS 1393124-08-7
DMN94QM DE Type-2 diabetes
DMKM7EW ID DMKM7EW
DMKM7EW DN PF-06463922
DMKM7EW HS Phase 2
DMKM7EW SN SCHEMBL15274056
DMKM7EW CP Pfizer
DMKM7EW DT Small molecular drug
DMKM7EW PC 71731823
DMKM7EW MW 406.4
DMKM7EW FM C21H19FN6O2
DMKM7EW IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DMKM7EW CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DMKM7EW IK IIXWYSCJSQVBQM-LLVKDONJSA-N
DMKM7EW IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DMKM7EW CA CAS 1454846-35-5
DMKM7EW CB CHEBI:143117
DMKM7EW DE Solid tumour/cancer; Non-small-cell lung cancer
DM9S3P7 ID DM9S3P7
DM9S3P7 DN PF-06473871
DM9S3P7 HS Phase 2
DM9S3P7 CP Pfizer
DM9S3P7 DT Antisense oligonucleotide
DM9S3P7 DE Hypertrophic scars
DMMGSFV ID DMMGSFV
DMMGSFV DN PF-06700841
DMMGSFV HS Phase 2
DMMGSFV SN BUWBRTXGQRBBHG-RUXDESIVSA-N; 2140301-96-6; PF-06700841 free base; EX-A2762; 1883299-62-4; ((S)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
DMMGSFV CP Pfizer New York, NY
DMMGSFV PC 118878093
DMMGSFV MW 389.4
DMMGSFV FM C18H21F2N7O
DMMGSFV IC InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1
DMMGSFV CS CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F
DMMGSFV IK BUWBRTXGQRBBHG-MJBXVCDLSA-N
DMMGSFV IU [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
DMMGSFV CA CAS 1883299-62-4
DMMGSFV DE Asthma; Plaque psoriasis; Psoriasis vulgaris
DM8C1H4 ID DM8C1H4
DM8C1H4 DN PF-06823859
DM8C1H4 HS Phase 2
DM8C1H4 CP Pfizer, New York, NY
DM8C1H4 DE Lupus; Rheumatoid arthritis; Dermatomycosis
DM5H8V1 ID DM5H8V1
DM5H8V1 DN PF-06826647
DM5H8V1 HS Phase 2
DM5H8V1 SN Tyk2-IN-8; 2127109-84-4; Tyk2-IN-9; (1r,3r)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Ropsacitinib; Ropsacitinib [USAN]; UNII-HY5SOV7O0Q; HY5SOV7O0Q; CHEMBL4459585; SCHEMBL19253418; SCHEMBL19253420; SCHEMBL19271747; SCHEMBL19276506; BDBM305820; BDBM305821; BCP33615; EX-A4020; US10144738, Example 19; US10144738, Example 20; MFCD32197240; s9676; WHO 11834; HY-126290A; HY-126290; CS-0101462; CS-0114967; (1s,3s)-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile; Cyclobutaneacetonitrile, 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4- yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)-, trans-; trans-3-(Cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutanecarbonitrile; trans-3-Cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)- 1H-pyrazol-1-yl)-cyclobutaneacetonitrile
DM5H8V1 CP Pfizer
DM5H8V1 DT Small molecular drug
DM5H8V1 PC 130339268
DM5H8V1 MW 383.4
DM5H8V1 FM C20H17N9
DM5H8V1 IC InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3
DM5H8V1 CS CN1C=C(C=N1)C2=CN3C(=CC=N3)C(=N2)C4=CN(N=C4)C5(CC(C5)C#N)CC#N
DM5H8V1 IK XPLZTJWZDBFWDE-UHFFFAOYSA-N
DM5H8V1 IU 3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile
DM5H8V1 CA CAS 2127109-84-4
DM5H8V1 DE Plaque psoriasis
DM7EJ8S ID DM7EJ8S
DM7EJ8S DN PF-06882961
DM7EJ8S HS Phase 2
DM7EJ8S SN 2230198-02-2; UNII-DN9IUI24GP; DN9IUI24GP; 2230198-02-2 (free acid); (S)-2-((4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid; 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid; Danuglipron; UK4; Danuglipron [USAN]; CHEMBL4518483; SCHEMBL20266351; BDBM349662; EX-A3607; WHO 11630; US10208019, Example 1A-09; US10208019, Example 4A-01; 2-[[4-[6-[(4-cyano-2-fluoro-phenyl)methoxy]-2-pyridyl]-1-piperidyl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid; AC-31472; PF6882961; Q63141738; 1H-Benzimidazole-6-carboxylic acid, 2-((4-(6-((4-cyano-2-fluorophenyl)methoxy)-2-pyridinyl)-1-piperidinyl)methyl)-1-((2S)-2-oxetanylmethyl)-; 2-{[4-(6-{[(4-cyano-2-fluorophenyl)(methyl-d2)]oxy}pyridin-2-yl)piperidin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F
DM7EJ8S CP Pfizer
DM7EJ8S DT Small molecular drug
DM7EJ8S PC 134611040
DM7EJ8S MW 555.6
DM7EJ8S FM C31H30FN5O4
DM7EJ8S IC InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
DM7EJ8S CS C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
DM7EJ8S IK HYBAKUMPISVZQP-DEOSSOPVSA-N
DM7EJ8S IU 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
DM7EJ8S CA CAS 2230198-02-2
DM7EJ8S DE Type 2 diabetes
DM8T6KQ ID DM8T6KQ
DM8T6KQ DN PF-232798
DM8T6KQ HS Phase 2
DM8T6KQ SN PF-00232798
DM8T6KQ CP Pfizer Inc
DM8T6KQ DT Small molecular drug
DM8T6KQ PC 53316710
DM8T6KQ MW 509.7
DM8T6KQ FM C29H40FN5O2
DM8T6KQ IC InChI=1S/C29H40FN5O2/c1-18(2)29(37)33-12-11-28-27(17-33)31-19(3)35(28)25-15-23-8-9-24(16-25)34(23)13-10-26(32-20(4)36)21-6-5-7-22(30)14-21/h5-7,14,18,23-26H,8-13,15-17H2,1-4H3,(H,32,36)/t23-,24+,25?,26-/m0/s1
DM8T6KQ CS CC1=NC2=C(N1C3C[C@H]4CC[C@@H](C3)N4CC[C@@H](C5=CC(=CC=C5)F)NC(=O)C)CCN(C2)C(=O)C(C)C
DM8T6KQ IK QETUKYDWZIRTEI-HLMSNRGBSA-N
DM8T6KQ IU N-[(1S)-1-(3-fluorophenyl)-3-[(1R,5S)-3-[2-methyl-5-(2-methylpropanoyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridin-1-yl]-8-azabicyclo[3.2.1]octan-8-yl]propyl]acetamide
DM8T6KQ CA CAS 849753-15-7
DM8T6KQ DE Human immunodeficiency virus infection
DMO02LU ID DMO02LU
DMO02LU DN PF-3463275
DMO02LU HS Phase 2
DMO02LU SN PF-03463275
DMO02LU CP Pfizer Inc
DMO02LU PC 44156901
DMO02LU MW 376.9
DMO02LU FM C19H22ClFN4O
DMO02LU IC InChI=1S/C19H22ClFN4O/c1-23-7-13-14(8-23)15(13)9-25(19(26)18-10-24(2)11-22-18)6-12-3-4-17(21)16(20)5-12/h3-5,10-11,13-15H,6-9H2,1-2H3/t13-,14+,15?
DMO02LU CS CN1C[C@@H]2[C@H](C1)C2CN(CC3=CC(=C(C=C3)F)Cl)C(=O)C4=CN(C=N4)C
DMO02LU IK KYLOBHXXQOZRKK-YIONKMFJSA-N
DMO02LU IU N-[(3-chloro-4-fluorophenyl)methyl]-1-methyl-N-[[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide
DMO02LU CA CAS 1173239-39-8
DMO02LU DE Schizophrenia
DMC2FAL ID DMC2FAL
DMC2FAL DN PF-3893787
DMC2FAL HS Phase 2
DMC2FAL SN PF-03893787; PF-3826719
DMC2FAL CP Pfizer Inc
DMC2FAL DT Small molecular drug
DMC2FAL PC 24745335
DMC2FAL MW 262.35
DMC2FAL FM C13H22N6
DMC2FAL IC InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
DMC2FAL CS CN[C@@H]1CCN(C1)C2=NC(=NC(=C2)NCC3CC3)N
DMC2FAL IK ISBHYKVAFKTATD-SNVBAGLBSA-N
DMC2FAL IU 4-N-(cyclopropylmethyl)-6-[(3R)-3-(methylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine
DMC2FAL CA CAS 943057-12-3
DMC2FAL DE Asthma; Atopic dermatitis; Plaque psoriasis
DM3DWKN ID DM3DWKN
DM3DWKN DN PF-4191834
DM3DWKN HS Phase 2
DM3DWKN SN PF-04191834
DM3DWKN CP Pfizer Inc
DM3DWKN DT Small molecular drug
DM3DWKN PC 24986635
DM3DWKN MW 393.5
DM3DWKN FM C22H23N3O2S
DM3DWKN IC InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
DM3DWKN CS CN1C(=CC=N1)C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N
DM3DWKN IK DVNQWYLVSNPCJZ-UHFFFAOYSA-N
DM3DWKN IU 4-[3-[4-(2-methylpyrazol-3-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide
DM3DWKN CA CAS 1029317-21-2
DM3DWKN DE Asthma
DM81D4I ID DM81D4I
DM81D4I DN PF-4447943
DM81D4I HS Phase 2
DM81D4I SN BCP16255
DM81D4I CP Pfizer Inc
DM81D4I DT Small molecular drug
DM81D4I PC 135564558
DM81D4I MW 395.5
DM81D4I FM C20H25N7O2
DM81D4I IC InChI=1S/C20H25N7O2/c1-13-10-26(12-17-21-5-2-6-22-17)11-16(13)18-24-19-15(20(28)25-18)9-23-27(19)14-3-7-29-8-4-14/h2,5-6,9,13-14,16H,3-4,7-8,10-12H2,1H3,(H,24,25,28)/t13-,16-/m1/s1
DM81D4I CS C[C@@H]1CN(C[C@H]1C2=NC3=C(C=NN3C4CCOCC4)C(=O)N2)CC5=NC=CC=N5
DM81D4I IK IWXUVYOOUMLUTQ-CZUORRHYSA-N
DM81D4I IU 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(oxan-4-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one
DM81D4I CA CAS 1082744-20-4
DM81D4I DE Alzheimer disease; Sickle-cell disorder
DML38VU ID DML38VU
DML38VU DN PF-446687
DML38VU HS Phase 2
DML38VU SN PF-00446687; PF-2336652
DML38VU CP Pfizer Inc
DML38VU DE Female sexual arousal dysfunction
DM3YIKR ID DM3YIKR
DM3YIKR DN PF-4523655
DM3YIKR HS Phase 2
DM3YIKR CP Quark Pharm; Pfizer
DM3YIKR DT siRNA drug
DM3YIKR DE Age-related macular degeneration; Diabetic macular degeneration
DM24I0N ID DM24I0N
DM24I0N DN PF-4878691
DM24I0N HS Phase 2
DM24I0N SN PF-04878691; PF-4171455
DM24I0N CP Pfizer Inc
DM24I0N PC 10309114
DM24I0N MW 361.5
DM24I0N FM C17H23N5O2S
DM24I0N IC InChI=1S/C17H23N5O2S/c1-3-14-21-15-16(12-8-4-5-9-13(12)20-17(15)18)22(14)11-7-6-10-19-25(2,23)24/h4-5,8-9,19H,3,6-7,10-11H2,1-2H3,(H2,18,20)
DM24I0N CS CCC1=NC2=C(N1CCCCNS(=O)(=O)C)C3=CC=CC=C3N=C2N
DM24I0N IK YZOQZEXYFLXNKA-UHFFFAOYSA-N
DM24I0N IU N-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
DM24I0N CA CAS 532959-63-0
DM24I0N DE Hepatitis C virus infection; Melanoma
DM3C8GQ ID DM3C8GQ
DM3C8GQ DN PF-489791
DM3C8GQ HS Phase 2
DM3C8GQ SN UNII-2S27T3DSZ3; PF-489791; PF-00489791; 853003-48-2; 2S27T3DSZ3; PF-489,791; ZUHZNKJIJDAJFD-UHFFFAOYSA-N; UK-489,791; SCHEMBL331279; SCHEMBL8042129; GTPL8377; DB11736; SB16722; 1H-Pyrazolo(4,3-d)pyrimidine-3-carboxamide, 1-(2-ethoxyethyl)-5-(ethylmethylamino)-7-((4-methyl-2-pyridinyl)amino)-N-(methylsulfonyl); n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
DM3C8GQ CP Pfizer New York, NY
DM3C8GQ DT Small molecular drug
DM3C8GQ PC 11465695
DM3C8GQ MW 476.6
DM3C8GQ FM C20H28N8O4S
DM3C8GQ IC InChI=1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24)
DM3C8GQ CS CCN(C)C1=NC2=C(C(=N1)NC3=NC=CC(=C3)C)N(N=C2C(=O)NS(=O)(=O)C)CCOCC
DM3C8GQ IK ZUHZNKJIJDAJFD-UHFFFAOYSA-N
DM3C8GQ IU 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-N-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide
DM3C8GQ CA CAS 853003-48-2
DM3C8GQ DE Raynaud disease; Chronic obstructive pulmonary disease
DM0KRLJ ID DM0KRLJ
DM0KRLJ DN PF-885706
DM0KRLJ HS Phase 2
DM0KRLJ SN PF-00885706
DM0KRLJ CP Pfizer Inc
DM0KRLJ DE Gastroesophageal reflux disease
DMF5YEN ID DMF5YEN
DMF5YEN DN PG-102
DMF5YEN HS Phase 2
DMF5YEN SN TNX-100; 5-D12
DMF5YEN CP PanGenetics BV
DMF5YEN DE Autoimmune diabetes
DMJTYO4 ID DMJTYO4
DMJTYO4 DN PGL-2
DMJTYO4 HS Phase 2
DMJTYO4 CP ProSci
DMJTYO4 DE Endometriosis
DMKA705 ID DMKA705
DMKA705 DN PGL-2001
DMKA705 HS Phase 2
DMKA705 SN Steroid sulfatase inhibitor (endometriosis), PregLem
DMKA705 CP Ipsen
DMKA705 PC 6918339
DMKA705 MW 351.5
DMKA705 FM C18H25NO4S
DMKA705 IC InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1
DMKA705 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMKA705 IK YXYXCSOJKUAPJI-ZBRFXRBCSA-N
DMKA705 IU [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate
DMKA705 CA CAS 172377-52-5
DMKA705 DE Endometriosis
DM9JGTQ ID DM9JGTQ
DM9JGTQ DN PH10 nasal spray
DM9JGTQ HS Phase 2
DM9JGTQ CP Pherin Pharmaceuticals Los Altos, CA
DM9JGTQ DE Major depressive disorder
DM71HVW ID DM71HVW
DM71HVW DN PH-794428
DM71HVW HS Phase 2
DM71HVW SN PHA-794428
DM71HVW CP Pfizer
DM71HVW DE Growth hormone deficiency
DMGYBZI ID DMGYBZI
DMGYBZI DN PHA-739358
DMGYBZI HS Phase 2
DMGYBZI SN Danusertib; PHA 739358; Danusertib, PHA-739358; (R)-N-(5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide; 5-Amido-pyrrolopyrazole 9d
DMGYBZI CP Pfizer; Nerviano
DMGYBZI DT Small molecular drug
DMGYBZI PC 11442891
DMGYBZI MW 474.6
DMGYBZI FM C26H30N6O3
DMGYBZI IC InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1
DMGYBZI CS CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=NNC4=C3CN(C4)C(=O)[C@@H](C5=CC=CC=C5)OC
DMGYBZI IK XKFTZKGMDDZMJI-HSZRJFAPSA-N
DMGYBZI IU N-[5-[(2R)-2-methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
DMGYBZI CA CAS 827318-97-8
DMGYBZI CB CHEBI:94490
DMGYBZI DE Prostate cancer
DMS2Q9G ID DMS2Q9G
DMS2Q9G DN PHA848125
DMS2Q9G HS Phase 2
DMS2Q9G SN Milciclib; PHA-848125; 802539-81-7; PHA 848125; Milciclib (PHA-848125); UNII-688000M8S8; PHA848125; MMV676602; 4,5-dihydro-N,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1H-Pyrazolo[4,3-h]quinazoline-3-carboxamide; 688000M8S8; N,1,4,4-tetramethyl-8-(4-(4-methylpiperazin-1-yl)phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide; Milciclib [INN]; N,1,4,4-Tetramethyl-8-{[4-(4-Methylpiperazin-1-Yl)phenyl]amino}-4,5-Dihydro-1h-Pyrazolo[4,3-H]quinazoline-3-Carboxamide
DMS2Q9G CP Nerviano Medical Services
DMS2Q9G DT Small molecular drug
DMS2Q9G PC 16718576
DMS2Q9G MW 460.6
DMS2Q9G FM C25H32N8O
DMS2Q9G IC InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)
DMS2Q9G CS CC1(CC2=CN=C(N=C2C3=C1C(=NN3C)C(=O)NC)NC4=CC=C(C=C4)N5CCN(CC5)C)C
DMS2Q9G IK RXZMYLDMFYNEIM-UHFFFAOYSA-N
DMS2Q9G IU N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
DMS2Q9G CA CAS 802539-81-7
DMS2Q9G DE Thymic cancer
DMRP3CV ID DMRP3CV
DMRP3CV DN Phenylalanine hydroxylase
DMRP3CV HS Phase 2
DMRP3CV SN Oralase; Phenylase; AvPAL-PEG; Phenylalanine hydroxylase, BioMarin; Phenylalanine hydroxylase, IBEX; Poly ethylene glycol-phenylalanine ammonia lyase; Phenylketonuria therapy (enzyme), BioMarin
DMRP3CV CP Biomarin pharmaceutical
DMRP3CV DE Autoimmune diabetes
DMBHPDW ID DMBHPDW
DMBHPDW DN Phenylbutyrate
DMBHPDW HS Phase 2
DMBHPDW SN Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate
DMBHPDW CP Scandinavian
DMBHPDW DT Small molecular drug
DMBHPDW PC 4775
DMBHPDW MW 164.2
DMBHPDW FM C10H12O2
DMBHPDW IC InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)
DMBHPDW CS C1=CC=C(C=C1)CCCC(=O)O
DMBHPDW IK OBKXEAXTFZPCHS-UHFFFAOYSA-N
DMBHPDW IU 4-phenylbutanoic acid
DMBHPDW CA CAS 1821-12-1
DMBHPDW CB CHEBI:41500
DMBHPDW DE Urea cycle disorder
DMJWD62 ID DMJWD62
DMJWD62 DN phorbol 12-myristate 13-acetate
DMJWD62 HS Phase 2
DMJWD62 SN TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate
DMJWD62 DT Small molecular drug
DMJWD62 PC 27924
DMJWD62 MW 616.8
DMJWD62 FM C36H56O8
DMJWD62 IC InChI=1S/C36H56O8/c1-7-8-9-10-11-12-13-14-15-16-17-18-29(39)43-32-24(3)35(42)27(30-33(5,6)36(30,32)44-25(4)38)20-26(22-37)21-34(41)28(35)19-23(2)31(34)40/h19-20,24,27-28,30,32,37,41-42H,7-18,21-22H2,1-6H3/t24-,27+,28-,30-,32-,34-,35-,36-/m1/s1
DMJWD62 CS CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C
DMJWD62 IK PHEDXBVPIONUQT-RGYGYFBISA-N
DMJWD62 IU [(1S,2S,6R,10S,11R,13S,14R,15R)-13-acetyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate
DMJWD62 CA CAS 16561-29-8
DMJWD62 CB CHEBI:37537
DMJWD62 DE Acute myeloid leukaemia; Hodgkin lymphoma
DM4FIWC ID DM4FIWC
DM4FIWC DN PI-88/Taxotere
DM4FIWC HS Phase 2
DM4FIWC SN PI-88/docetaxel
DM4FIWC CP Progen Industries
DM4FIWC DE Solid tumour/cancer
DM3ZEYL ID DM3ZEYL
DM3ZEYL DN Piboserod
DM3ZEYL HS Phase 2
DM3ZEYL SN Piboserod; 152811-62-6; UNII-4UQ3S81B25; SB-207266; SB207256; 4UQ3S81B25; N-((1-butylpiperidin-4-yl)methyl)-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; SB 207266; N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxamide; N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide; Piboserod [INN:BAN]; Serotonin 5-HT4 Receptor Antagonists; SB207266(Piboserod); AC1L42OO; GTPL225; SCHEMBL467339; CHEMBL356359; BDBM85026; DTXSID60165129
DM3ZEYL DT Small molecular drug
DM3ZEYL PC 177336
DM3ZEYL MW 369.5
DM3ZEYL FM C22H31N3O2
DM3ZEYL IC InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26)
DM3ZEYL CS CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42
DM3ZEYL IK KVCSJPATKXABRQ-UHFFFAOYSA-N
DM3ZEYL IU N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide
DM3ZEYL CA CAS 152811-62-6
DM3ZEYL DE Atrial fibrillation
DMYL7VR ID DMYL7VR
DMYL7VR DN Piclamilast
DMYL7VR HS Phase 2
DMYL7VR SN Piclamilast; 144035-83-6; Cpodpmb; RP 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide; UNII-WM58D7C3ZT; RP 73-401; RP-73401; RP-73-401; RPR 73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxybenzamide; WM58D7C3ZT; Benzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridinyl)-4-methoxy-; CHEMBL42126; CHEBI:47619; RRRUXBQSQLKHEL-UHFFFAOYSA-N; RPR-73401; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-p-anisamide; 3-(Cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide; PIL
DMYL7VR DT Small molecular drug
DMYL7VR PC 154575
DMYL7VR MW 381.2
DMYL7VR FM C18H18Cl2N2O3
DMYL7VR IC InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)
DMYL7VR CS COC1=C(C=C(C=C1)C(=O)NC2=C(C=NC=C2Cl)Cl)OC3CCCC3
DMYL7VR IK RRRUXBQSQLKHEL-UHFFFAOYSA-N
DMYL7VR IU 3-cyclopentyloxy-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide
DMYL7VR CA CAS 144035-83-6
DMYL7VR CB CHEBI:47619
DMYL7VR DE Rheumatoid arthritis
DMMO46E ID DMMO46E
DMMO46E DN Pidilizumab
DMMO46E HS Phase 2
DMMO46E SN CT-011
DMMO46E CP CureTech
DMMO46E DT Monoclonal antibody
DMMO46E DE Diffuse large B-cell lymphoma
DMAFZ84 ID DMAFZ84
DMAFZ84 DN PIKAMILONE
DMAFZ84 HS Phase 2
DMAFZ84 SN N-Nicotinoyl-gamma-aminobutyric acid sodium salt; N-(3-Pyridylcarbonyl)-4-aminobutyric acid sodium salt
DMAFZ84 DT Small molecular drug
DMAFZ84 PC 60608
DMAFZ84 MW 208.21
DMAFZ84 FM C10H12N2O3
DMAFZ84 IC InChI=1S/C10H12N2O3/c13-9(14)4-2-6-12-10(15)8-3-1-5-11-7-8/h1,3,5,7H,2,4,6H2,(H,12,15)(H,13,14)
DMAFZ84 CS C1=CC(=CN=C1)C(=O)NCCCC(=O)O
DMAFZ84 IK NAJVRARAUNYNDX-UHFFFAOYSA-N
DMAFZ84 IU 4-(pyridine-3-carbonylamino)butanoic acid
DMAFZ84 CA CAS 34562-97-5
DMAFZ84 DE Anxiety disorder
DM96VWD ID DM96VWD
DM96VWD DN PINOCEMBRIN
DM96VWD HS Phase 2
DM96VWD SN Pinocembrin; 480-39-7; (+)-Pinocembrin; (2S)-pinocembrin; Dihydrochrysin; UNII-8T7C8CH791; NSC 43318; NSC 279005; NSC 661207; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (2S)-; (S)-5,7-dihydroxyflavanone; (S)-5,7-dihydroxy-2-phenylchroman-4-one; CHEMBL399910; CHEBI:28157; (2s)-5,7-dihydroxy-2-phenyl-2,3-dihydro-4h-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-phenyl-4H-1-benzopyran-4-one; 8T7C8CH791; Pinocembrin (6CI); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-phenyl-, (-)-
DM96VWD DT Small molecular drug
DM96VWD PC 68071
DM96VWD MW 256.25
DM96VWD FM C15H12O4
DM96VWD IC InChI=1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1
DM96VWD CS C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3
DM96VWD IK URFCJEUYXNAHFI-ZDUSSCGKSA-N
DM96VWD IU (2S)-5,7-dihydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM96VWD CA CAS 480-39-7
DM96VWD CB CHEBI:28157
DM276N1 ID DM276N1
DM276N1 DN Piritrexim
DM276N1 HS Phase 2
DM276N1 SN Piritrexim; 72732-56-0; Piritrexim [INN]; Piritreximum [Latin]; Piritrexime [French]; 6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine; Piritrexima [Spanish]; BW 301U; UNII-MK2A783ZUT; BW-301U; TCMDC-137235; BRN 5768301; MK2A783ZUT; CHEMBL7492; 2,4-Diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine; 6-(2,5-DIMETHOXY-BENZYL)-5-METHYL-PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINE; 6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
DM276N1 DT Small molecular drug
DM276N1 PC 54369
DM276N1 MW 325.4
DM276N1 FM C17H19N5O2
DM276N1 IC InChI=1S/C17H19N5O2/c1-9-11(6-10-7-12(23-2)4-5-13(10)24-3)8-20-16-14(9)15(18)21-17(19)22-16/h4-5,7-8H,6H2,1-3H3,(H4,18,19,20,21,22)
DM276N1 CS CC1=C2C(=NC(=NC2=NC=C1CC3=C(C=CC(=C3)OC)OC)N)N
DM276N1 IK VJXSSYDSOJBUAV-UHFFFAOYSA-N
DM276N1 IU 6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
DM276N1 CA CAS 72732-56-0
DM276N1 DE Bladder cancer
DMC3T2S ID DMC3T2S
DMC3T2S DN PIRODOMAST
DMC3T2S HS Phase 2
DMC3T2S SN Sch-37224; Pirodomast; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one
DMC3T2S DT Small molecular drug
DMC3T2S PC 54680204
DMC3T2S MW 307.3
DMC3T2S FM C18H17N3O2
DMC3T2S IC InChI=1S/C18H17N3O2/c22-16-14-9-6-10-19-17(14)21(13-7-2-1-3-8-13)18(23)15(16)20-11-4-5-12-20/h1-3,6-10,22H,4-5,11-12H2
DMC3T2S CS C1CCN(C1)C2=C(C3=C(N=CC=C3)N(C2=O)C4=CC=CC=C4)O
DMC3T2S IK ULGABHCZIJXUFO-UHFFFAOYSA-N
DMC3T2S IU 4-hydroxy-1-phenyl-3-pyrrolidin-1-yl-1,8-naphthyridin-2-one
DMC3T2S CA CAS 108310-20-9
DMC3T2S DE Asthma
DMHI6GE ID DMHI6GE
DMHI6GE DN Pirsidomine
DMHI6GE HS Phase 2
DMHI6GE SN C87-3754; CAS-936
DMHI6GE CP Hoechst Marion Roussel Inc
DMHI6GE DT Small molecular drug
DMHI6GE PC 9571076
DMHI6GE MW 330.4
DMHI6GE FM C17H22N4O3
DMHI6GE IC InChI=1S/C17H22N4O3/c1-12-5-4-6-13(2)21(12)20-11-16(24-19-20)18-17(22)14-7-9-15(23-3)10-8-14/h7-13H,4-6H2,1-3H3/t12-,13+
DMHI6GE CS C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=C2)/N=C(/C3=CC=C(C=C3)OC)\\[O-])C
DMHI6GE IK TXPUBJSOHAMNEI-BETUJISGSA-N
DMHI6GE IU (1Z)-N-[3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]oxadiazol-3-ium-5-yl]-4-methoxybenzenecarboximidate
DMHI6GE CA CAS 132722-74-8
DMHI6GE DE Angina pectoris
DMKEV7N ID DMKEV7N
DMKEV7N DN PK1
DMKEV7N HS Phase 2
DMKEV7N SN FCE-28068; N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer linked to Gly-Phe-Leu-Gly-doxorubicin
DMKEV7N DT Small molecular drug
DMKEV7N PC 59235249
DMKEV7N MW 381.3
DMKEV7N FM C17H14Cl2N2O2S
DMKEV7N IC InChI=1S/C17H14Cl2N2O2S/c1-17(10-3-6-12(22)7-4-10)15(23)21(16(24)20(17)2)11-5-8-13(18)14(19)9-11/h3-9,22H,1-2H3/t17-/m1/s1
DMKEV7N CS C[C@]1(C(=O)N(C(=S)N1C)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)O
DMKEV7N IK YPONBLYNQFHCLA-QGZVFWFLSA-N
DMKEV7N IU (5R)-3-(3,4-dichlorophenyl)-5-(4-hydroxyphenyl)-1,5-dimethyl-2-sulfanylideneimidazolidin-4-one
DMKEV7N DE Solid tumour/cancer
DMHUCQS ID DMHUCQS
DMHUCQS DN PL-3994
DMHUCQS HS Phase 2
DMHUCQS PC 121488161
DMHUCQS MW 1875.2
DMHUCQS FM C82H127N27O20S2
DMHUCQS IC InChI=1S/C82H127N27O20S2/c1-6-9-11-15-25-62(112)98-59-41-130-131-42-60(76(126)104-56(34-47-26-28-49(111)29-27-47)79(129)109-39-57(66(83)116)105-77(127)61(109)24-18-32-93-82(88)89)107-74(124)58(40-110)106-78(128)65(44(4)8-3)108-70(120)52(23-17-31-92-81(86)87)100-73(123)55(36-64(114)115)103-69(119)51(21-10-7-2)99-68(118)50(22-16-30-91-80(84)85)97-63(113)38-94-67(117)45(5)96-71(121)53(33-46-19-13-12-14-20-46)101-72(122)54(102-75(59)125)35-48-37-90-43-95-48/h12-14,19-20,26-29,37,43-45,50-61,65,110-111H,6-11,15-18,21-25,30-36,38-42H2,1-5H3,(H2,83,116)(H,90,95)(H,94,117)(H,96,121)(H,97,113)(H,98,112)(H,99,118)(H,100,123)(H,101,122)(H,102,125)(H,103,119)(H,104,126)(H,105,127)(H,106,128)(H,107,124)(H,108,120)(H,114,115)(H4,84,85,91)(H4,86,87,92)(H4,88,89,93)/t44-,45+,50-,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,65-/m0/s1
DMHUCQS CS CCCCCCC(=O)N[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CNC=N2)CC3=CC=CC=C3)C)CCCNC(=N)N)CCCC)CC(=O)O)CCCNC(=N)N)[C@@H](C)CC)CO)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5C[C@@H](NC(=O)[C@@H]5CCCNC(=N)N)C(=O)N
DMHUCQS IK HSHVZRILAMZYHY-WXSGKXQHSA-N
DMHUCQS IU 2-[(4R,7S,10S,13S,16S,19R,22S,28R,31S,34S,37S)-31-benzyl-10-[(2S)-butan-2-yl]-19-butyl-13,22-bis(3-carbamimidamidopropyl)-4-[[(2S)-1-[(2S,5R)-2-(3-carbamimidamidopropyl)-5-carbamoyl-3-oxopiperazin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-37-(heptanoylamino)-7-(hydroxymethyl)-34-(1H-imidazol-4-ylmethyl)-28-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacont-16-yl]acetic acid
DMHUCQS CA CAS 952295-80-6
DMHUCQS DE Hypertension; Congestive heart failure; Asthma
DMYUO6B ID DMYUO6B
DMYUO6B DN PlaMavax
DMYUO6B HS Phase 2
DMYUO6B SN AdCh63-ME-TRAP; MVA-ME-TRAP; ME-TRAP fusion antigen adenoviral vector vaccine (Malaria), Okairos
DMYUO6B CP University of Oxford
DMYUO6B DT Vaccine
DMYUO6B DE Malaria
DMOB1EM ID DMOB1EM
DMOB1EM DN Plasmin
DMOB1EM HS Phase 2
DMOB1EM SN Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke); Plasmin (plasma-derived, peripheral arterial occlusion/ischemic stroke), Talecris Biotherapeutics
DMOB1EM CP Grifols therapeutics
DMOB1EM DE Occlusive disease; Peripheral arterial disease
DMK10ZC ID DMK10ZC
DMK10ZC DN PLECONARIL
DMK10ZC HS Phase 2
DMK10ZC SN Picovir; Pleconaril < Prop INN; SR-263843; SR-63843; VP-63843; Win-63843; 3-[3,5-Dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole
DMK10ZC CP ViroPharma
DMK10ZC DT Small molecular drug
DMK10ZC PC 1684
DMK10ZC MW 381.3
DMK10ZC FM C18H18F3N3O3
DMK10ZC IC InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3
DMK10ZC CS CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F
DMK10ZC IK KQOXLKOJHVFTRN-UHFFFAOYSA-N
DMK10ZC IU 3-[3,5-dimethyl-4-[3-(3-methyl-1,2-oxazol-5-yl)propoxy]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole
DMK10ZC CA CAS 153168-05-9
DMK10ZC DE Virus infection
DM7Y60I ID DM7Y60I
DM7Y60I DN Plevitrexed
DM7Y60I HS Phase 2
DM7Y60I SN ZD 9331; ZD9331; 153537-73-6; Plevitrexed [INN]; ZD-9331; NSC 696259; UNII-L9P2881C3H; CHEMBL126648; (2s)-2-[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}benzoyl)amino]-4-(2h-tetrazol-5-yl)butanoic acid; L9P2881C3H; Plevitrexed (INN); 172521-94-7; (2S)-2-[[4-[(2,7-dimethyl-4-oxo-1H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid; 1H-Tetrazole-5-butanoic acid,
DM7Y60I CP BTG
DM7Y60I DT Small molecular drug
DM7Y60I PC 135430970
DM7Y60I MW 532.5
DM7Y60I FM C26H25FN8O4
DM7Y60I IC InChI=1S/C26H25FN8O4/c1-4-9-35(13-16-11-19-22(10-14(16)2)28-15(3)29-25(19)37)17-5-6-18(20(27)12-17)24(36)30-21(26(38)39)7-8-23-31-33-34-32-23/h1,5-6,10-12,21H,7-9,13H2,2-3H3,(H,30,36)(H,38,39)(H,28,29,37)(H,31,32,33,34)/t21-/m0/s1
DM7Y60I CS CC1=CC2=C(C=C1CN(CC#C)C3=CC(=C(C=C3)C(=O)N[C@@H](CCC4=NNN=N4)C(=O)O)F)C(=O)NC(=N2)C
DM7Y60I IK IEJSCSAMMLUINT-NRFANRHFSA-N
DM7Y60I IU (2S)-2-[[4-[(2,7-dimethyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-2-fluorobenzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid
DM7Y60I CA CAS 153537-73-6
DM7Y60I DE Gastric adenocarcinoma
DMTL39C ID DMTL39C
DMTL39C DN Plevitrexed (R)-isomer
DMTL39C HS Phase 2
DMTL39C SN YW3548
DMTL39C CP BTG
DMTL39C DT Small molecular drug
DMTL39C PC 213022
DMTL39C DE Gastric adenocarcinoma
DMRTD7I ID DMRTD7I
DMRTD7I DN PLX8394
DMRTD7I HS Phase 2
DMRTD7I CP Daiichi sankyo parsippany
DMRTD7I PC 90116675
DMRTD7I MW 542.5
DMRTD7I FM C25H21F3N6O3S
DMRTD7I IC InChI=1S/C25H21F3N6O3S/c26-16-5-6-34(12-16)38(36,37)33-20-4-3-19(27)21(22(20)28)23(35)18-11-32-25-17(18)7-14(8-31-25)15-9-29-24(30-10-15)13-1-2-13/h3-4,7-11,13,16,33H,1-2,5-6,12H2,(H,31,32)/t16-/m1/s1
DMRTD7I CS C1CN(C[C@@H]1F)S(=O)(=O)NC2=C(C(=C(C=C2)F)C(=O)C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)C6CC6)F
DMRTD7I IK YYACLQUDUDXAPA-MRXNPFEDSA-N
DMRTD7I IU (3R)-N-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide
DMRTD7I CA CAS 1393466-87-9
DMRTD7I DE Melanoma; Solid tumour/cancer
DMMKOPX ID DMMKOPX
DMMKOPX DN PM-00104
DMMKOPX HS Phase 2
DMMKOPX SN Zalypsis; PM00104; UNII-C21EZR41AY; C21EZR41AY; PM-00104; 308359-57-1; (6aS,7R,13S,14S,16R)-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-16-[({(2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl}amino)methyl]-6,7,12,13,14,16-hexahydro-6aH-7,13-epimino[1,3]dioxolo[7,8]isoquino[3,2-b][3]benzazocin-5-yl acetate; SCHEMBL7975282; DTXSID0044026; NOCAS_44026; DB12454; CS-1940; HY-16401; 2-Propenamide, N-(((6aS,7R,13S,14S,16R)-5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo
DMMKOPX CP PharmaMar
DMMKOPX DT Small molecular drug
DMMKOPX PC 16061448
DMMKOPX MW 709.7
DMMKOPX FM C37H38F3N3O8
DMMKOPX IC InChI=1S/C37H38F3N3O8/c1-17-11-21-13-25-36(47)43-24(30(42(25)4)28(21)31(46)32(17)48-5)14-23-29(35-34(49-16-50-35)18(2)33(23)51-19(3)44)26(43)15-41-27(45)10-9-20-7-6-8-22(12-20)37(38,39)40/h6-12,24-26,30,36,46-47H,13-16H2,1-5H3,(H,41,45)/b10-9+/t24-,25-,26-,30-,36-/m0/s1
DMMKOPX CS CC1=CC2=C([C@@H]3[C@@H]4CC5=C(C(=C6C(=C5[C@@H](N4[C@H]([C@H](C2)N3C)O)CNC(=O)/C=C/C7=CC(=CC=C7)C(F)(F)F)OCO6)C)OC(=O)C)C(=C1OC)O
DMMKOPX IK VPAHZSUNBOYNQY-DLVGLDQCSA-N
DMMKOPX IU [(1R,2S,13R,15S,16S)-15,22-dihydroxy-21-methoxy-6,20,24-trimethyl-13-[[[(E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl]amino]methyl]-8,10-dioxa-14,24-diazahexacyclo[14.7.1.02,14.04,12.07,11.018,23]tetracosa-4,6,11,18(23),19,21-hexaen-5-yl] acetate
DMMKOPX CA CAS 308359-57-1
DMMKOPX DE Solid tumour/cancer
DMS34YO ID DMS34YO
DMS34YO DN PM184
DMS34YO HS Phase 2
DMS34YO CP PharmaMar Madrid, Spain
DMS34YO DE Colorectal cancer
DM0OVZ2 ID DM0OVZ2
DM0OVZ2 DN PMID27841036-Compound-37
DM0OVZ2 HS Phase 2
DM0OVZ2 SN 2X-121
DM0OVZ2 CP EISAI INC. XU, Weizheng DELAHANTY, Greg WEI, Ling ZHANG, Jie
DM0OVZ2 DT Small molecular drug
DM0OVZ2 PC 135565981
DM0OVZ2 MW 317.3
DM0OVZ2 FM C18H15N5O
DM0OVZ2 IC InChI=1S/C18H15N5O/c24-18-13-6-3-7-14-16(13)17(21-22-18)20-15(19-14)10-23-8-11-4-1-2-5-12(11)9-23/h1-7H,8-10H2,(H,22,24)(H,19,20,21)
DM0OVZ2 CS C1C2=CC=CC=C2CN1CC3=NC4=NNC(=O)C5=C4C(=CC=C5)N3
DM0OVZ2 IK JLFSBHQQXIAQEC-UHFFFAOYSA-N
DM0OVZ2 IU 11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8,11-pentaen-4-one
DM0OVZ2 CA CAS 1140964-99-3
DM0OVZ2 DE Ovarian cancer
DMZUAJ4 ID DMZUAJ4
DMZUAJ4 DN PMX-53
DMZUAJ4 HS Phase 2
DMZUAJ4 SN YOKBGCTZYPOSQM-HPSWDUTRSA-N; PMX53; CHEMBL41547; (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[1630]henicosan-3-yl]-3-phenylpropanamide; PMX 53; AcF-[OP(D-Cha)WR]; Ac-Phe-[Orn-Pro-cha-Trp-Arg]; C5aR-AP; AC1OCFH0; GTPL579; SCHEMBL16492460; SCHEMBL12971688; 219639-75-5; BDBM50111445; AcF-[OP(D-Cha)WR]; N-Acetyl-L-phenylalanyl-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-D-arginine N-52-C-16-lactam
DMZUAJ4 DT Small molecular drug
DMZUAJ4 PC 6918468
DMZUAJ4 MW 896.1
DMZUAJ4 FM C47H65N11O7
DMZUAJ4 IC InChI=1S/C47H65N11O7/c1-29(59)53-37(25-30-13-4-2-5-14-30)42(61)55-36-20-11-22-50-41(60)35(19-10-23-51-47(48)49)54-44(63)39(27-32-28-52-34-18-9-8-17-33(32)34)56-43(62)38(26-31-15-6-3-7-16-31)57-45(64)40-21-12-24-58(40)46(36)65/h2,4-5,8-9,13-14,17-18,28,31,35-40,52H,3,6-7,10-12,15-16,19-27H2,1H3,(H,50,60)(H,53,59)(H,54,63)(H,55,61)(H,56,62)(H,57,64)(H4,48,49,51)/t35-,36-,37-,38+,39-,40-/m0/s1
DMZUAJ4 CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2CCCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]3CCCN3C2=O)CC4CCCCC4)CC5=CNC6=CC=CC=C65)CCCN=C(N)N
DMZUAJ4 IK YOKBGCTZYPOSQM-HPSWDUTRSA-N
DMZUAJ4 IU (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide
DMZUAJ4 DE Atopic dermatitis
DMWT73D ID DMWT73D
DMWT73D DN PMX-60056
DMWT73D HS Phase 2
DMWT73D SN PMX-150; PMX-60054; PMX-60065; PMX-60077; PMX-60079; PMX-60087; PMX-640; PMX-686; PMX-747; PMX-801; Heparin andlow molecular weight heparin (LMWH) reversing agents, PolyMedix
DMWT73D CP PolyMedix Inc
DMWT73D DT Small molecular drug
DMWT73D PC 51349239
DMWT73D MW 1126.3
DMWT73D FM C56H79N13O12
DMWT73D IC InChI=1S/C56H79N13O12/c1-78-45-21-17-33(29-37(45)49(62)70)64-54(75)42(14-6-10-26-58)67-51(72)39-31-35(19-23-47(39)80-3)66-56(77)44(16-8-12-28-60)69-52(73)40-32-36(20-24-48(40)81-4)65-55(76)43(15-7-11-27-59)68-50(71)38-30-34(18-22-46(38)79-2)63-53(74)41(61)13-5-9-25-57/h17-24,29-32,41-44H,5-16,25-28,57-61H2,1-4H3,(H2,62,70)(H,63,74)(H,64,75)(H,65,76)(H,66,77)(H,67,72)(H,68,71)(H,69,73)/t41-,42-,43-,44-/m0/s1
DMWT73D CS COC1=C(C=C(C=C1)NC(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCCN)C(=O)NC2=CC(=C(C=C2)OC)C(=O)N[C@@H](CCCCN)C(=O)NC3=CC(=C(C=C3)OC)C(=O)N[C@@H](CCCCN)C(=O)NC4=CC(=C(C=C4)OC)C(=O)N
DMWT73D IK PWFIFNGOPQUNIT-ITMZJIMRSA-N
DMWT73D IU N-[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-[3-[[(2S)-6-amino-1-(3-carbamoyl-4-methoxyanilino)-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]carbamoyl]-4-methoxyanilino]-1-oxohexan-2-yl]-5-[[(2S)-2,6-diaminohexanoyl]amino]-2-methoxybenzamide
DMWT73D CA CAS 872454-31-4
DMWT73D DE Coagulation defect
DMUVON0 ID DMUVON0
DMUVON0 DN PNT-2258
DMUVON0 HS Phase 2
DMUVON0 CP ProNAi Therapeutics Inc
DMUVON0 DT Antisense drug
DMUVON0 DE Solid tumour/cancer; Diffuse large B-cell lymphoma
DMM8IAQ ID DMM8IAQ
DMM8IAQ DN PNU-142731A
DMM8IAQ HS Phase 2
DMM8IAQ SN 9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indole hydrochloride
DMM8IAQ PC 9846800
DMM8IAQ MW 455
DMM8IAQ FM C24H31ClN6O
DMM8IAQ IC InChI=1S/C24H30N6O.ClH/c31-20(27-11-3-4-12-27)17-30-19-10-2-1-9-18(19)21-22(28-13-5-6-14-28)25-24(26-23(21)30)29-15-7-8-16-29;/h1-2,9-10H,3-8,11-17H2;1H
DMM8IAQ CS C1CCN(C1)C2=NC(=NC3=C2C4=CC=CC=C4N3CC(=O)N5CCCC5)N6CCCC6.Cl
DMM8IAQ IK RLFYAIUQWFELJD-UHFFFAOYSA-N
DMM8IAQ IU 2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)-1-pyrrolidin-1-ylethanone;hydrochloride
DMM8IAQ CA CAS 214212-38-1
DMM8IAQ DE Asthma
DM4OT29 ID DM4OT29
DM4OT29 DN POL-6326
DM4OT29 HS Phase 2
DM4OT29 SN CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor
DM4OT29 CP Polyphor Ltd
DM4OT29 DE Human immunodeficiency virus infection; Breast cancer
DMFCIKN ID DMFCIKN
DMFCIKN DN Polivy
DMFCIKN HS Phase 2
DMFCIKN SN Polatuzumab vedotin-piiq
DMFCIKN CP Roche/Genentech
DMFCIKN DT Antibody
DMFCIKN DE Mantle cell lymphoma
DMUXEBQ ID DMUXEBQ
DMUXEBQ DN Polyamine
DMUXEBQ HS Phase 2
DMUXEBQ DE Subjective cognitive decline
DMXROM7 ID DMXROM7
DMXROM7 DN Polyglutamate camptothecin
DMXROM7 HS Phase 2
DMXROM7 SN CT-2106; PG-interferon; Polyglutamate camptothecin, Cell Therapeutics; Polyglutamate-camptothecin; CPT-Gly-PG; Camptothecin-glycine-polyglutamate; PG-CPT, Cell Therapeutics; PG-camptothecin, CT; Polyglutamate-linked anticancer agents, Cell Therapeutics; PG-G-CSF, Cell Therapeutics
DMXROM7 CP Cell Therapeutics Inc
DMXROM7 DE Solid tumour/cancer
DM2570B ID DM2570B
DM2570B DN Poly-ICLC
DM2570B HS Phase 2
DM2570B CP Oncovir
DM2570B DT Small molecular drug
DM2570B PC 136033680
DM2570B MW 879.6
DM2570B FM C26H43N9O21P2
DM2570B IC InChI=1S/C10H13N4O8P.C9H14N3O8P.C5H12N2O2.C2H4O3/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;6-3-1-2-4-7-5(8)9;3-1-2(4)5/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);7H,1-4,6H2,(H,8,9);3H,1H2,(H,4,5)
DM2570B CS C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O.C(CCNC(=O)O)CN.C(C(=O)O)O
DM2570B IK MRYYMYCQXMFJNE-UHFFFAOYSA-N
DM2570B IU 4-aminobutylcarbamic acid;[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;[3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate;2-hydroxyacetic acid
DM2570B DE Glioblastoma multiforme; Recurrent glioblastoma; Solid tumour/cancer
DM3QDA6 ID DM3QDA6
DM3QDA6 DN Polynoma-1
DM3QDA6 HS Phase 2
DM3QDA6 SN Polyvalent melanoma vaccine, Vaccinoma
DM3QDA6 CP Vaccinoma Inc
DM3QDA6 DT Vaccine
DM3QDA6 DE Melanoma
DMIAZ13 ID DMIAZ13
DMIAZ13 DN Ponezumab
DMIAZ13 HS Phase 2
DMIAZ13 SN Neurological disease and injury therapeutics, Pfizer; PF-04360365; PF-4360365; RI-1014; RI-1219; RI-409; RN-1219
DMIAZ13 CP Rinat Neuroscience Corp
DMIAZ13 DT Antibody
DMIAZ13 DE Alzheimer disease
DM5HMTB ID DM5HMTB
DM5HMTB DN Porphobilinogen
DM5HMTB HS Phase 2
DM5HMTB SN porphobilinogen; 487-90-1; 3-[5-(AMINOMETHYL)-4-(CARBOXYMETHYL)-1H-PYRROL-3-YL]PROPANOIC ACID; UNII-74KHC72QXK; 1H-Pyrrole-3-propanoic acid, 5-(aminomethyl)-4-(carboxymethyl)-; 2-aminomethylpyrrol-3-acetic acid 4-propionic acid; 74KHC72QXK; PBG; CHEBI:17381; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propanoic acid; 5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrole-3-propionic acid; 3-(5-(Aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl)propanoic acid; 5-(aminomethyl)-4-(carboxymethyl)-pyrrole-3-propionic acid
DM5HMTB DT Small molecular drug
DM5HMTB PC 1021
DM5HMTB MW 226.23
DM5HMTB FM C10H14N2O4
DM5HMTB IC InChI=1S/C10H14N2O4/c11-4-8-7(3-10(15)16)6(5-12-8)1-2-9(13)14/h5,12H,1-4,11H2,(H,13,14)(H,15,16)
DM5HMTB CS C1=C(C(=C(N1)CN)CC(=O)O)CCC(=O)O
DM5HMTB IK QSHWIQZFGQKFMA-UHFFFAOYSA-N
DM5HMTB IU 3-[5-(aminomethyl)-4-(carboxymethyl)-1H-pyrrol-3-yl]propanoic acid
DM5HMTB CA CAS 487-90-1
DM5HMTB CB CHEBI:17381
DMH0LM2 ID DMH0LM2
DMH0LM2 DN POT-4
DMH0LM2 HS Phase 2
DMH0LM2 SN AL-78898A; POT-4 EOS Insert; Compstatin complement-inhibiting peptides, Pennsylvania/Potentia; 4(1MeW)7W
DMH0LM2 CP University of Pennsylvania
DMH0LM2 DE Macular degeneration
DMTE8DC ID DMTE8DC
DMTE8DC DN Pozelimab
DMTE8DC HS Phase 2
DMTE8DC SN REGN3918
DMTE8DC CP Regeneron Pharmaceuticals
DMTE8DC DT Antibody
DMTE8DC DE Paroxysmal nocturnal haemoglobinuria
DM4EHVB ID DM4EHVB
DM4EHVB DN PPI-668
DM4EHVB HS Phase 2
DM4EHVB CP Presidio pharmaceuticals
DM4EHVB PC 71665718
DM4EHVB MW 835.8
DM4EHVB FM C42H52Cl2N8O6
DM4EHVB IC InChI=1S/C42H50N8O6.2ClH/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6;;/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54);2*1H/t33-,34-,35-,36-;;/m0../s1
DM4EHVB CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC.Cl.Cl
DM4EHVB IK JYLMWUZJMRNMDA-SPRBZRACSA-N
DM4EHVB IU methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride
DM4EHVB CA CAS 1303533-81-4
DM4EHVB DE Hepatitis C virus infection
DMM6J5Z ID DMM6J5Z
DMM6J5Z DN PQ-912
DMM6J5Z HS Phase 2
DMM6J5Z PC 51030870
DMM6J5Z MW 336.4
DMM6J5Z FM C19H20N4O2
DMM6J5Z IC InChI=1S/C19H20N4O2/c1-2-9-25-15-6-3-13(4-7-15)18-11-20-19(24)23(18)14-5-8-16-17(10-14)22-12-21-16/h3-8,10,12,18H,2,9,11H2,1H3,(H,20,24)(H,21,22)/t18-/m1/s1
DMM6J5Z CS CCCOC1=CC=C(C=C1)[C@H]2CNC(=O)N2C3=CC4=C(C=C3)N=CN4
DMM6J5Z IK XHIKZWOEFZENIX-GOSISDBHSA-N
DMM6J5Z IU (5S)-1-(3H-benzimidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one
DMM6J5Z CA CAS 1276021-65-8
DMM6J5Z DE Dementia
DMMCYZ8 ID DMMCYZ8
DMMCYZ8 DN PQR309
DMMCYZ8 HS Phase 2
DMMCYZ8 SN Bimiralisib; PQR309; 1225037-39-7; PI3K-IN-2; PQR-309; UNII-6Z3QHB00LB; 6Z3QHB00LB; 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; 5-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine; 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine; Bimiralisib [INN]; Bimiralisib [USAN]; PQR309; Bimiralisib; Bimiralisib [WHO-DD]; NCB5; SCHEMBL1309049; GTPL8383; PQR309; Bimiralisib free base; ADGGYDAFIHSYFI-UHFFFAOYSA-N; EX-A2018; BCP15887; PQR-309(PI3K-IN-2)
DMMCYZ8 DT Small molecular drug
DMMCYZ8 PC 58507717
DMMCYZ8 MW 411.4
DMMCYZ8 FM C17H20F3N7O2
DMMCYZ8 IC InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)
DMMCYZ8 CS C1COCCN1C2=NC(=NC(=N2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4
DMMCYZ8 IK ADGGYDAFIHSYFI-UHFFFAOYSA-N
DMMCYZ8 IU 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
DMMCYZ8 CA CAS 1225037-39-7
DMMCYZ8 DE Pain; Squamous head and neck cell carcinom
DM1O0DV ID DM1O0DV
DM1O0DV DN Pradefovir
DM1O0DV HS Phase 2
DM1O0DV SN Remofovir; Pradefovir mesylate; Remofovir mesylate; Hepavir-B; ICN 2001-3; MB-06866; MB-6866; Pradefovir (oral, hepatitis B), Ligand/Chiva
DM1O0DV CP Metabasis Therapeutics Inc
DM1O0DV DT Small molecular drug
DM1O0DV PC 9604654
DM1O0DV MW 423.8
DM1O0DV FM C17H19ClN5O4P
DM1O0DV IC InChI=1S/C17H19ClN5O4P/c18-13-3-1-2-12(8-13)14-4-6-26-28(24,27-14)11-25-7-5-23-10-22-15-16(19)20-9-21-17(15)23/h1-3,8-10,14H,4-7,11H2,(H2,19,20,21)/t14-,28+/m0/s1
DM1O0DV CS C1CO[P@@](=O)(O[C@@H]1C2=CC(=CC=C2)Cl)COCCN3C=NC4=C(N=CN=C43)N
DM1O0DV IK GWNHAOBXDGOXRR-HJFSHJIFSA-N
DM1O0DV IU 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine
DM1O0DV CA CAS 625095-60-5
DM1O0DV DE Hepatitis virus infection
DMIVMR3 ID DMIVMR3
DMIVMR3 DN Prajmaline
DMIVMR3 HS Phase 2
DMIVMR3 SN N(sup 4)-Propylajmalinium; N-Propylajmaline; N-Propylajmalinium; Prajmaline; Prajmalium; Prajmalum; (17R,21-alpha)-17,21-Dihydroxy-4-propylajmalanium; 35080-11-6; 75934UD4GJ; Ajmalanium, 17,21-dihydroxy-4-propyl-, (17R,21-alpha)-; CHEBI:135560; UNII-75934UD4GJ
DMIVMR3 PC 76959818
DMIVMR3 MW 369.5
DMIVMR3 FM C23H33N2O2+
DMIVMR3 IC UAUHEPXILIZYCU-ALHOSYKFSA-N
DMIVMR3 CS CCC[N+]12C3CC(C(C1O)CC)C4C2CC5(C3N(C6=CC=CC=C65)C)C4O
DMIVMR3 IK 1S/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17-,18-,19-,20-,21+,22+,23+,25-/m0/s1
DMIVMR3 IU (1R,9R,10S,12R,13S,14R,15R,16S,17S,18R)-13-ethyl-8-methyl-15-propyl-8-aza-15-azoniahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol
DMIVMR3 CA CAS 35080-11-6
DMIVMR3 CB CHEBI:135560
DMIVMR3 DE Atherosclerosis
DM73UTG ID DM73UTG
DM73UTG DN PRALNACASAN
DM73UTG HS Phase 2
DM73UTG SN Pralnacasan; VX-740; UNII-N986NI319S; 192755-52-5; N986NI319S; HMR3480/VX-740; Pralnacasan [USAN:INN]; HMR 3480; VX 470; Pralnacasan (USAN/INN); AC1L4A1A; SCHEMBL142187; GTPL6467; CHEMBL437526; DTXSID60172873; HMR3480; HMR-3480; BDBM50189360; AKOS030230853; DB04875; D08978; (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide
DM73UTG DT Small molecular drug
DM73UTG PC 153270
DM73UTG MW 523.5
DM73UTG FM C26H29N5O7
DM73UTG IC InChI=1S/C26H29N5O7/c1-2-37-26-18(14-21(33)38-26)29-23(34)19-8-5-13-30-20(32)10-9-17(25(36)31(19)30)28-24(35)22-16-7-4-3-6-15(16)11-12-27-22/h3-4,6-7,11-12,17-19,26H,2,5,8-10,13-14H2,1H3,(H,28,35)(H,29,34)/t17-,18-,19-,26+/m0/s1
DM73UTG CS CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)C4=NC=CC5=CC=CC=C54
DM73UTG IK CXAGHAZMQSCAKJ-WAHHBDPQSA-N
DM73UTG IU (4S,7S)-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1H-pyridazino[1,2-a]diazepine-4-carboxamide
DM73UTG CA CAS 192755-52-5
DM73UTG DE Rheumatoid arthritis
DMBH7XI ID DMBH7XI
DMBH7XI DN Pramiconazole
DMBH7XI HS Phase 2
DMBH7XI SN Azoline; Antifungals, Janssen Research Foundation; R-126638
DMBH7XI CP Barrier Therapeutics
DMBH7XI DT Small molecular drug
DMBH7XI PC 3013050
DMBH7XI MW 659.7
DMBH7XI FM C35H39F2N7O4
DMBH7XI IC InChI=1S/C35H39F2N7O4/c1-25(2)43-17-18-44(34(43)45)29-6-4-27(5-7-29)40-13-15-41(16-14-40)28-8-10-30(11-9-28)46-20-33-47-22-35(48-33,21-42-24-38-23-39-42)31-12-3-26(36)19-32(31)37/h3-12,19,23-25,33H,13-18,20-22H2,1-2H3/t33-,35+/m0/s1
DMBH7XI CS CC(C)N1CCN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5OC[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMBH7XI IK AEKNYBWUEYNWMJ-QWOOXDRHSA-N
DMBH7XI IU 1-[4-[4-[4-[[(2S,4R)-4-(2,4-difluorophenyl)-4-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one
DMBH7XI CA CAS 219923-85-0
DMBH7XI DE Dermatological disease
DMZT8FS ID DMZT8FS
DMZT8FS DN Preverex
DMZT8FS HS Phase 2
DMZT8FS SN Biostent; Phomin; Cytochalasin B; Cytochalasin B containing stent
DMZT8FS CP Poniard Pharmaceuticals Inc
DMZT8FS DT Small molecular drug
DMZT8FS PC 5311281
DMZT8FS MW 479.6
DMZT8FS FM C29H37NO5
DMZT8FS IC InChI=1S/C29H37NO5/c1-18-9-7-13-22(31)15-16-25(32)35-29-23(14-8-10-18)27(33)20(3)19(2)26(29)24(30-28(29)34)17-21-11-5-4-6-12-21/h4-6,8,11-12,14-16,18-19,22-24,26-27,31,33H,3,7,9-10,13,17H2,1-2H3,(H,30,34)/b14-8+,16-15+/t18-,19-,22-,23+,24+,26+,27-,29-/m1/s1
DMZT8FS CS C[C@@H]1CCC[C@H](/C=C/C(=O)O[C@]23[C@@H](/C=C/C1)[C@@H](C(=C)[C@H]([C@H]2[C@@H](NC3=O)CC4=CC=CC=C4)C)O)O
DMZT8FS IK GBOGMAARMMDZGR-TYHYBEHESA-N
DMZT8FS IU (1S,4E,6R,10R,12E,14S,15S,17S,18S,19S)-19-benzyl-6,15-dihydroxy-10,17-dimethyl-16-methylidene-2-oxa-20-azatricyclo[12.7.0.01,18]henicosa-4,12-diene-3,21-dione
DMZT8FS CA CAS 14930-96-2
DMZT8FS CB CHEBI:23527
DMZT8FS DE Artery stenosis
DMK8PTH ID DMK8PTH
DMK8PTH DN PRM-151
DMK8PTH HS Phase 2
DMK8PTH CP Promedior
DMK8PTH DE Macular degeneration; Idiopathic pulmonary fibrosis; Myelofibrosis; Polycythemia vera; Thrombocythemia
DMBZ6CP ID DMBZ6CP
DMBZ6CP DN PRN1008
DMBZ6CP HS Phase 2
DMBZ6CP SN LCFFREMLXLZNHE-GBOLQPHISA-N; SCHEMBL15506003; BDBM143212; US8940744, 31; (R,E)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
DMBZ6CP CP Principia Biopharma South San Francisco, CA
DMBZ6CP PC 73388818
DMBZ6CP MW 665.8
DMBZ6CP FM C36H40FN9O3
DMBZ6CP IC InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/t25-/m1/s1
DMBZ6CP CS CC(C)(/C=C(\\C#N)/C(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N)N6CCN(CC6)C7COC7
DMBZ6CP IK LCFFREMLXLZNHE-GBOLQPHISA-N
DMBZ6CP IU (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
DMBZ6CP CA CAS 1575596-29-0
DMBZ6CP DE Pemphigus vulgaris
DM5ZTE4 ID DM5ZTE4
DM5ZTE4 DN PRO-001
DM5ZTE4 HS Phase 2
DM5ZTE4 SN PRO-001, ProRetina; Proinsulin (recombinant human protein, retinitis pigmentosa), ProRetina
DM5ZTE4 CP ProRetina Therapeutics SL
DM5ZTE4 DE Retinitis pigmentosa
DMFYABR ID DMFYABR
DMFYABR DN PRO-044
DMFYABR HS Phase 2
DMFYABR SN Exon-44 skipping antisense oligonucleotide (Duchenne muscular dystrophy), Prosensa
DMFYABR CP Leiden University Medical Center
DMFYABR DT Antisense drug
DMFYABR DE Duchenne dystrophy
DMMEL6B ID DMMEL6B
DMMEL6B DN PRO22
DMMEL6B HS Phase 2
DMMEL6B CP Realm Therapeutics Malvern, PA
DMMEL6B DE Atopic dermatitis
DMF9RB4 ID DMF9RB4
DMF9RB4 DN Procysteine
DMF9RB4 HS Phase 2
DMF9RB4 SN Procysteine; 19771-63-2; (R)-2-Oxothiazolidine-4-carboxylic acid; (4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid; L-2-Oxothiazolidine-4-carboxylic acid; L-2-Oxothiazolidine-4-carboxylate; 4-Thiazolidinecarboxylic acid, 2-oxo-, (4R)-; CCRIS 7672; Oxothiazolidine carboxylate, L-; UNII-X7063P804E; 2-Oxothiazolidine-4-carboxylate, L-; L-2-Oxo-4-thiazolidinecarboxylic acid; BRN 4179169; (R)-2-Oxo-4-thiazolidinecarboxylic acid; (4R)-2-oxo-4-thiazolidinecarboxylic acid; CHEMBL442218; 4-Thiazolidinecarboxylic acid, 2-oxo-, L-
DMF9RB4 CP Cornell University
DMF9RB4 DT Small molecular drug
DMF9RB4 PC 72390
DMF9RB4 MW 147.15
DMF9RB4 FM C4H5NO3S
DMF9RB4 IC InChI=1S/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1
DMF9RB4 CS C1[C@H](NC(=O)S1)C(=O)O
DMF9RB4 IK BMLMGCPTLHPWPY-REOHCLBHSA-N
DMF9RB4 IU (4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid
DMF9RB4 CA CAS 19771-63-2
DMF9RB4 CB CHEBI:125673
DMF9RB4 DE Amyotrophic lateral sclerosis
DM4MF9V ID DM4MF9V
DM4MF9V DN proglumide
DM4MF9V HS Phase 2
DM4MF9V SN Milid; Nulsa; W-5219
DM4MF9V DT Small molecular drug
DM4MF9V PC 4922
DM4MF9V MW 334.4
DM4MF9V FM C18H26N2O4
DM4MF9V IC InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
DM4MF9V CS CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1
DM4MF9V IK DGMKFQYCZXERLX-UHFFFAOYSA-N
DM4MF9V IU 4-benzamido-5-(dipropylamino)-5-oxopentanoic acid
DM4MF9V CA CAS 6620-60-6
DM4MF9V CB CHEBI:32058
DM4MF9V DE Influenza virus infection
DMZIQ8G ID DMZIQ8G
DMZIQ8G DN Prolarix
DMZIQ8G HS Phase 2
DMZIQ8G SN Prolarix (TN)
DMZIQ8G CP Protherics
DMZIQ8G TC Anticancer Agents
DMZIQ8G DT Small molecular drug
DMZIQ8G PC 403128
DMZIQ8G MW 181.19
DMZIQ8G FM C8H11N3O2
DMZIQ8G IC InChI=1S/C8H11N3O2/c9-7(12)5-11-3-1-2-6(4-11)8(10)13/h1,3-4H,2,5H2,(H2,9,12)(H2,10,13)
DMZIQ8G CS C1C=CN(C=C1C(=O)N)CC(=O)N
DMZIQ8G IK WEJRSYKFMCUCRQ-UHFFFAOYSA-N
DMZIQ8G IU 1-(2-amino-2-oxoethyl)-4H-pyridine-3-carboxamide
DMZIQ8G CA CAS 64881-21-6
DMZIQ8G DE Solid tumour/cancer
DME25TI ID DME25TI
DME25TI DN Prosaptide TX14(A)
DME25TI HS Phase 2
DME25TI SN Prosaptide; TX-14(A)
DME25TI CP Myelos Corp
DME25TI PC 16197909
DME25TI MW 1579.7
DME25TI FM C69H110N16O26
DME25TI IC InChI=1S/C69H110N16O26/c1-13-31(7)53(66(107)80-41(23-29(3)4)61(102)82-46(69(110)111)25-37-15-17-38(88)18-16-37)83-59(100)40(20-22-50(93)94)75-58(99)39(19-21-49(91)92)76-68(109)55(36(12)87)85-57(98)34(10)73-60(101)43(26-47(70)89)78-62(103)44(27-48(71)90)79-63(104)45(28-51(95)96)81-67(108)54(32(8)14-2)84-64(105)42(24-30(5)6)77-56(97)33(9)74-65(106)52(72)35(11)86/h15-18,29-36,39-46,52-55,86-88H,13-14,19-28,72H2,1-12H3,(H2,70,89)(H2,71,90)(H,73,101)(H,74,106)(H,75,99)(H,76,109)(H,77,97)(H,78,103)(H,79,104)(H,80,107)(H,81,108)(H,82,102)(H,83,100)(H,84,105)(H,85,98)(H,91,92)(H,93,94)(H,95,96)(H,110,111)/t31-,32-,33+,34-,35+,36+,39-,40-,41-,42-,43-,44-,45-,46-,52-,53-,54-,55-/m0/s1
DME25TI CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H]([C@@H](C)O)N
DME25TI IK SMUKRAODILXPSW-SRWCCNGVSA-N
DME25TI IU (4S)-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DME25TI DE Neuropathic pain
DMM7F1E ID DMM7F1E
DMM7F1E DN PRUVANSERIN
DMM7F1E HS Phase 2
DMM7F1E SN Pruvanserin; UNII-UL09X1D9EM; 443144-26-1; UL09X1D9EM; CHEMBL1215661; Pruvanserin [USAN:INN]; 7-{4-(2-(4-Fluorophenyl)ethyl)piperazine-1-carbonyl}-1H-indole-3-carbonitrile; 7-[4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl]-1H-indole-3-carbonitrile; AC1O5FMC; Pruvanserin (USAN/INN); SCHEMBL678751; DTXSID40196133; AQRLDDAFYYAIJP-UHFFFAOYSA-N; ZINC56898757; BDBM50324540; LSN2422347; SB16534; EMD 390920; DB13094; EMD-390920; LSN-2422347; NCGC00370956-01; LY2420586; LY-2422347; D06632; L001679
DMM7F1E DT Small molecular drug
DMM7F1E PC 6433122
DMM7F1E MW 376.4
DMM7F1E FM C22H21FN4O
DMM7F1E IC InChI=1S/C22H21FN4O/c23-18-6-4-16(5-7-18)8-9-26-10-12-27(13-11-26)22(28)20-3-1-2-19-17(14-24)15-25-21(19)20/h1-7,15,25H,8-13H2
DMM7F1E CS C1CN(CCN1CCC2=CC=C(C=C2)F)C(=O)C3=CC=CC4=C3NC=C4C#N
DMM7F1E IK AQRLDDAFYYAIJP-UHFFFAOYSA-N
DMM7F1E IU 7-[4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl]-1H-indole-3-carbonitrile
DMM7F1E CA CAS 443144-26-1
DMM7F1E DE Sleep-wake disorder
DMKTP8E ID DMKTP8E
DMKTP8E DN PRX002
DMKTP8E HS Phase 2
DMKTP8E SN Prasinezumab
DMKTP8E CP ProThena; Roche
DMKTP8E DT Antibody
DMKTP8E DE Parkinson disease
DM1JNDV ID DM1JNDV
DM1JNDV DN PRX00933
DM1JNDV HS Phase 2
DM1JNDV CP Proximagen Group plc
DM1JNDV DE Diabetic complication; Obesity
DMR7H2V ID DMR7H2V
DMR7H2V DN PRX-08066
DMR7H2V HS Phase 2
DMR7H2V SN PRX-08066; 866206-54-4; PRX-08066 free base; UNII-82SK298EBU; PRX 08066; CHEMBL513994; 82SK298EBU; 5-((4-(6-chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile; SCHEMBL1604039; DTXSID60235710; IENZFHBNCRQMNP-UHFFFAOYSA-N; BCP14768; BDBM50249180; ZINC40403513; AKOS030526950; QC-5875; CS-0991; SB16508; 5-((4-(6-Chlorothieno(2,3-d)pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile; PRX 08066;PRX08066; NCGC00386238-02; AK548029; HY-15472; Benzonitrile, 5-((4-((6-chlorothieno(2,3-d)pyrimidi
DMR7H2V CP Predix Pharmaceuticals
DMR7H2V DT Small molecular drug
DMR7H2V PC 11502243
DMR7H2V MW 401.9
DMR7H2V FM C19H17ClFN5S
DMR7H2V IC InChI=1S/C19H17ClFN5S/c20-17-8-15-18(23-11-24-19(15)27-17)25-14-3-5-26(6-4-14)10-12-1-2-16(21)13(7-12)9-22/h1-2,7-8,11,14H,3-6,10H2,(H,23,24,25)
DMR7H2V CS C1CN(CCC1NC2=C3C=C(SC3=NC=N2)Cl)CC4=CC(=C(C=C4)F)C#N
DMR7H2V IK IENZFHBNCRQMNP-UHFFFAOYSA-N
DMR7H2V IU 5-[[4-[(6-chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]-2-fluorobenzonitrile
DMR7H2V CA CAS 866206-54-4
DMR7H2V DE Pulmonary arterial hypertension
DMEVXS1 ID DMEVXS1
DMEVXS1 DN PRX-3140
DMEVXS1 HS Phase 2
DMEVXS1 CP Nanotherapeutics
DMEVXS1 DE Post-traumatic stress disorder; Alzheimer disease
DM7YWVT ID DM7YWVT
DM7YWVT DN PRX-321
DM7YWVT HS Phase 2
DM7YWVT SN Silybin B; Milk thistle; 142797-34-0; UNII-853OHH1429; Flavobion; Legalon 70; 853OHH1429; CCRIS 7096; Wild Artichoke; Silybum marianum; Silybin A and B; Milk thistle [NF]; Silymarin + Melatonin; AC1LU7MH; UNII-U946SH95EE; Milk Thistle (Silybum marianum) Extract or Powder; SCHEMBL751461; Silybin B, analytical standard; U946SH95EE; CHEMBL592675; Milk Thistle (Silybum marianum) Extract or Powder [seed]; DTXSID30858697; SEBFKMXJBCUCAI-WAABAYLZSA-N; MolPort-039-139-345; ZINC1530850; BDBM50088491; 2717AH; AKOS015912848
DM7YWVT TC Anticancer Agents
DM7YWVT DT Small molecular drug
DM7YWVT PC 1548994
DM7YWVT MW 482.4
DM7YWVT FM C25H22O10
DM7YWVT IC InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23-,24-,25+/m0/s1
DM7YWVT CS COC1=C(C=CC(=C1)[C@H]2[C@@H](OC3=C(O2)C=C(C=C3)[C@@H]4[C@H](C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
DM7YWVT IK SEBFKMXJBCUCAI-WAABAYLZSA-N
DM7YWVT IU (2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
DM7YWVT CA CAS 65666-07-1
DM7YWVT DE Solid tumour/cancer
DMHZIFJ ID DMHZIFJ
DMHZIFJ DN PS-938285
DMHZIFJ HS Phase 2
DMHZIFJ CP Schering-Plough
DMHZIFJ DE Chronic obstructive pulmonary disease
DMCSN69 ID DMCSN69
DMCSN69 DN PT2385
DMCSN69 HS Phase 2
DMCSN69 SN ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
DMCSN69 CP Peloton Therapeutics Dallas, TX
DMCSN69 PC 91754484
DMCSN69 MW 383.3
DMCSN69 FM C17H12F3NO4S
DMCSN69 IC InChI=1S/C17H12F3NO4S/c1-26(23,24)14-3-2-13(12-7-17(19,20)16(22)15(12)14)25-11-5-9(8-21)4-10(18)6-11/h2-6,16,22H,7H2,1H3/t16-/m0/s1
DMCSN69 CS CS(=O)(=O)C1=C2[C@@H](C(CC2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)(F)F)O
DMCSN69 IK ONBSHRSJOPSEGS-INIZCTEOSA-N
DMCSN69 IU 3-[[(1S)-2,2-difluoro-1-hydroxy-7-methylsulfonyl-1,3-dihydroinden-4-yl]oxy]-5-fluorobenzonitrile
DMCSN69 CA CAS 1672665-49-4
DMCSN69 DE Recurrent glioblastoma; Von hippel-lindau disease; Brain cancer
DMP9TKE ID DMP9TKE
DMP9TKE DN PTC299
DMP9TKE HS Phase 2
DMP9TKE SN 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole; skf-86002; 72873-74-6; Skf 86002; F 86002; F 86002-A(2); UNII-9R6QDF1UO7; 9R6QDF1UO7; CHEMBL313417; 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole; 4-[6-(4-fluorophenyl)-2H,3H-imidazo[2,1-b][1,3]thiazol-5-yl]pyridine; 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo[2,1-b]thiazole; 6-(4-Fluorophenyl)-2,3-dihydro-5-(4-pyridyl)imidazo[2,1-b]thiazole; Imidazo(2,1-b)thiazole,; SK&F 86002
DMP9TKE CP PTC Therape
DMP9TKE TC Anticancer Agents
DMP9TKE DT Small molecular drug
DMP9TKE PC 49787172
DMP9TKE MW 467.3
DMP9TKE FM C25H20Cl2N2O3
DMP9TKE IC InChI=1S/C25H20Cl2N2O3/c1-31-18-7-2-15(3-8-18)24-23-20(21-14-17(27)6-11-22(21)28-23)12-13-29(24)25(30)32-19-9-4-16(26)5-10-19/h2-11,14,24,28H,12-13H2,1H3/t24-/m0/s1
DMP9TKE CS COC1=CC=C(C=C1)[C@H]2C3=C(CCN2C(=O)OC4=CC=C(C=C4)Cl)C5=C(N3)C=CC(=C5)Cl
DMP9TKE IK SRSHBZRURUNOSM-DEOSSOPVSA-N
DMP9TKE IU (4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate
DMP9TKE DE Rheumatoid arthritis; Solid tumour/cancer
DMOYS8A ID DMOYS8A
DMOYS8A DN PTG-300
DMOYS8A HS Phase 2
DMOYS8A SN Rusfertide; Rusfertide [USAN]; UNII-XM71MYX0IQ; XM71MYX0IQ; PTG-300FB; WHO 11456; 1628323-80-7; Isovaleryl-Asp-Thr-His-Phe-Pro-cyclo(Cys-Ile-Lys(palm-gamma-Glu)- Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys)-Lys-NH2
DMOYS8A CP Protagonist Therapeutics
DMOYS8A DT Peptide
DMOYS8A PC 155884410
DMOYS8A MW 2442
DMOYS8A FM C114H181N27O28S2
DMOYS8A IC InChI=1S/C114H181N27O28S2/c1-7-9-10-11-12-13-14-15-16-17-18-19-26-46-90(145)125-79(113(168)169)47-49-89(144)121-53-32-29-42-76-99(154)133-80(58-71-36-22-20-23-37-71)101(156)132-78(48-50-93(148)149)111(166)140-55-34-44-87(140)107(162)130-77(43-33-54-122-114(118)119)100(155)136-84(64-142)104(159)129-75(41-28-31-52-116)98(153)123-63-92(147)127-85(105(160)128-74(97(117)152)40-27-30-51-115)65-170-171-66-86(106(161)138-95(69(5)8-2)109(164)131-76)137-108(163)88-45-35-56-141(88)112(167)83(59-72-38-24-21-25-39-72)135-102(157)81(60-73-62-120-67-124-73)134-110(165)96(70(6)143)139-103(158)82(61-94(150)151)126-91(146)57-68(3)4/h20-25,36-39,62,67-70,74-88,95-96,142-143H,7-19,26-35,40-61,63-66,115-116H2,1-6H3,(H2,117,152)(H,120,124)(H,121,144)(H,123,153)(H,125,145)(H,126,146)(H,127,147)(H,128,160)(H,129,159)(H,130,162)(H,131,164)(H,132,156)(H,133,154)(H,134,165)(H,135,157)(H,136,155)(H,137,163)(H,138,161)(H,139,158)(H,148,149)(H,150,151)(H,168,169)(H4,118,119,122)/t69-,70+,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,95-,96-/m0/s1
DMOYS8A CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)[C@@H](C)CC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCC(=O)O)CC6=CC=CC=C6)C(=O)O
DMOYS8A IK JRVOBXXOZFTSRF-GVIPULMVSA-N
DMOYS8A IU (2S)-5-[4-[(3S,6S,9S,12S,15R,20R,26S,29S,32S,35S)-26-(4-aminobutyl)-6-benzyl-12-[(2S)-butan-2-yl]-32-(3-carbamimidamidopropyl)-3-(2-carboxyethyl)-15-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-3-carboxy-2-(3-methylbutanoylamino)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-20-[[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamoyl]-29-(hydroxymethyl)-2,5,8,11,14,22,25,28,31,34-decaoxo-17,18-dithia-1,4,7,10,13,21,24,27,30,33-decazabicyclo[33.3.0]octatriacontan-9-yl]butylamino]-2-(hexadecanoylamino)-5-oxopentanoic acid
DMOYS8A CA CAS 1628323-80-7
DMOYS8A DE Hemochromatosis; Polycythemia vera
DMV17HK ID DMV17HK
DMV17HK DN PTI-125
DMV17HK HS Phase 2
DMV17HK SN UNII-6NV440YIO0; 6NV440YIO0; PTI-910; Simufilam; Simufilam [USAN]; SCHEMBL12627054; C0105M; WHO 11778; 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)-; 1224591-33-6
DMV17HK CP Pain Therapeutics
DMV17HK DT Small molecular drug
DMV17HK PC 46195331
DMV17HK MW 259.35
DMV17HK FM C15H21N3O
DMV17HK IC InChI=1S/C15H21N3O/c1-17-9-7-15(8-10-17)16-11-14(19)18(15)12-13-5-3-2-4-6-13/h2-6,16H,7-12H2,1H3
DMV17HK CS CN1CCC2(CC1)NCC(=O)N2CC3=CC=CC=C3
DMV17HK IK BSQPTZYKCAULBH-UHFFFAOYSA-N
DMV17HK IU 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one
DMV17HK CA CAS 1224591-33-6
DMV17HK DE Alzheimer disease
DM0ZIT2 ID DM0ZIT2
DM0ZIT2 DN PTX-200
DM0ZIT2 HS Phase 2
DM0ZIT2 SN Plant-derived antiparkinsonian, Phytrix
DM0ZIT2 CP Phytrix AG
DM0ZIT2 DE Parkinson disease; Breast cancer; Acute myeloid leukaemia; Ovarian cancer
DMJIMXH ID DMJIMXH
DMJIMXH DN Puerarin
DMJIMXH HS Phase 2
DMJIMXH SN NPI-031-G; Puerarin (oral formulation, alcoholism); Puerarin (oral formulation, alcoholism), Natural Pharmacia; 5-HT2creceptor antagonists/GABA receptor antagonists (oral formulation, alcoholism), Natural Pharmacia
DMJIMXH CP Natural Pharmacia International Inc
DMJIMXH DT Small molecular drug
DMJIMXH PC 5281807
DMJIMXH MW 416.4
DMJIMXH FM C21H20O9
DMJIMXH IC InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1
DMJIMXH CS C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
DMJIMXH IK HKEAFJYKMMKDOR-VPRICQMDSA-N
DMJIMXH IU 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
DMJIMXH CA CAS 3681-99-0
DMJIMXH CB CHEBI:8633
DMJIMXH DE Alcohol dependence
DMW7L0Y ID DMW7L0Y
DMW7L0Y DN PUL-042
DMW7L0Y HS Phase 2
DMW7L0Y SN ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042
DMW7L0Y TC Antiviral Agents
DMW7L0Y DT Protein/peptide drug
DMW7L0Y DE Coronavirus Disease 2019 (COVID-19)
DMBUSNL ID DMBUSNL
DMBUSNL DN Pumosetrag
DMBUSNL HS Phase 2
DMBUSNL SN DDP-733; MKC-733; N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide; N-((3R)-1-Azabicyclo(2.2.2)oct-3-yl)-7-oxo-4,7-dihydrothieno(3,2-b)pyridine-6-carboxamide; N-(1-azabicyclo[2.2.2]oct-8-yl)-2-oxo-9-thia-5-azabicyclo[4.3.0]nona-3,7,10-triene-3-carboxamide
DMBUSNL CP Dynogen
DMBUSNL DT Small molecular drug
DMBUSNL PC 154104
DMBUSNL MW 303.4
DMBUSNL FM C15H17N3O2S
DMBUSNL IC InChI=1S/C15H17N3O2S/c19-13-10(7-16-11-3-6-21-14(11)13)15(20)17-12-8-18-4-1-9(12)2-5-18/h3,6-7,9,12H,1-2,4-5,8H2,(H,16,19)(H,17,20)/t12-/m0/s1
DMBUSNL CS C1CN2CCC1[C@H](C2)NC(=O)C3=CNC4=C(C3=O)SC=C4
DMBUSNL IK AFUWQWYPPZFWCO-LBPRGKRZSA-N
DMBUSNL IU N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide
DMBUSNL CA CAS 153062-94-3
DMBUSNL DE Gastro-oesophageal reflux; Irritable bowel syndrome
DMVUGF7 ID DMVUGF7
DMVUGF7 DN PUR-0110
DMVUGF7 HS Phase 2
DMVUGF7 SN PCT-233; Purecell complex, inflammation; Thylakoid extract (inflammation), PureCell
DMVUGF7 CP PurGenesis Technologies Inc
DMVUGF7 DE Inflammation
DM6DK9A ID DM6DK9A
DM6DK9A DN PVX-410
DM6DK9A HS Phase 2
DM6DK9A DE Solid tumour/cancer; Multiple myeloma; Triple negative breast cancer
DMLVHAJ ID DMLVHAJ
DMLVHAJ DN PX-12
DMLVHAJ HS Phase 2
DMLVHAJ SN PX12, PX 12, IV-2
DMLVHAJ CP Biomira
DMLVHAJ TC Anticancer Agents
DMLVHAJ DT Small molecular drug
DMLVHAJ PC 219104
DMLVHAJ MW 188.3
DMLVHAJ FM C7H12N2S2
DMLVHAJ IC InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DMLVHAJ CS CCC(C)SSC1=NC=CN1
DMLVHAJ IK BPBPYQWMFCTCNG-UHFFFAOYSA-N
DMLVHAJ IU 2-(butan-2-yldisulfanyl)-1H-imidazole
DMLVHAJ CA CAS 141400-58-0
DMLVHAJ CB CHEBI:94291
DMLVHAJ DE Solid tumour/cancer
DMYISJK ID DMYISJK
DMYISJK DN PX-866
DMYISJK HS Phase 2
DMYISJK SN Sonolisib; PX-866; CHEBI:65345; 502632-66-8; PX866; UNII-987796874T; PX 866; 987796874T; (4S,4aR,5R,6aS,9aR,E)-1-((diallylamino)methylene)-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,7,10-trioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; (1E,4S,4aR,5R,6aS,9aR)-1-{[di(prop-2-en-1-yl)amino]methylidene}-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-2,7,10-trioxo-1,2,4,4a,5,6,6a,7,8,9,9a,10-dodecahydroindeno[4,5-h]isochromen-5-yl acetate; Sonolisib [INN]; GTPL7941; CHEMBL411907
DMYISJK CP Oncothyreon
DMYISJK DT Small molecular drug
DMYISJK PC 9849735
DMYISJK MW 525.6
DMYISJK FM C29H35NO8
DMYISJK IC InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1
DMYISJK CS CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C
DMYISJK IK QIUASFSNWYMDFS-NILGECQDSA-N
DMYISJK IU [(3aR,6E,9S,9aR,10R,11aS)-6-[[bis(prop-2-enyl)amino]methylidene]-5-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-2,3,3a,9,10,11-hexahydroindeno[4,5-h]isochromen-10-yl] acetate
DMYISJK CA CAS 502632-66-8
DMYISJK CB CHEBI:65345
DMYISJK DE Solid tumour/cancer
DMNSRY7 ID DMNSRY7
DMNSRY7 DN PXL-770
DMNSRY7 HS Phase 2
DMNSRY7 CP Poxel SA
DMNSRY7 DT Small molecular drug
DMNSRY7 DE Non-alcoholic fatty liver disease
DMLQK6E ID DMLQK6E
DMLQK6E DN PYM-50028
DMLQK6E HS Phase 2
DMLQK6E SN Cogane; Smilagenin; P-58; P-63
DMLQK6E CP Phytopharm
DMLQK6E DE Neurological disorder
DMSOPAU ID DMSOPAU
DMSOPAU DN Pyrazoloacridine
DMSOPAU HS Phase 2
DMSOPAU SN PD-115934; 2-[3-(Dimethylamino)propyl]-9-methoxy-5-nitro-2,6-dihydropyrazolo[3,4,5-kl]acridine; 9-Methoxy-N,N-dimethyl-5-nitro-2,6-dihydropyrazolo[3,4,5-kl]acridine-2-propanamine
DMSOPAU DT Small molecular drug
DMSOPAU PC 339455
DMSOPAU MW 367.4
DMSOPAU FM C19H21N5O3
DMSOPAU IC InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3
DMSOPAU CS CN(C)CCCN1C2=C3C(=C(C=C2)[N+](=O)[O-])NC4=C(C3=N1)C=C(C=C4)OC
DMSOPAU IK HZCWPKGYTCJSEB-UHFFFAOYSA-N
DMSOPAU IU 3-(4-methoxy-10-nitro-8,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-14-yl)-N,N-dimethylpropan-1-amine
DMSOPAU CA CAS 99009-20-8
DMSOPAU DE Colorectal cancer
DM1794O ID DM1794O
DM1794O DN Pyrethroids
DM1794O HS Phase 2
DM1794O SN resmethrin; 10453-86-8; Benzofuroline; For-syn; Penncapthrin; Resmethrine; Benzyfuroline; Isathrine; Enforcer; Chryson; Synthrin; Pyresthrin; Premgard; Crossfire; Chrysron; Resmethrin [ANSI]; Resbuthrin; Caswell No. 083E; Bioresmethrine; SB Pennick 1382; Penick 1382; Resmetrina [Portuguese]; ARI-B; Resmethrine [ISO-French]; S.B. Penick 1382; d-trans-Resmethrin; 5-Benzylfurfuryl chrysanthemate; NRDC 104; Bioresmethrin (d trans isomer); CCRIS 2501; HSDB 1516; SBP-1382; OMS-1206; EINECS 233-940-7; FMC 17370; ENT 27474; NIA 17370
DM1794O DT Small molecular drug
DM1794O PC 5053
DM1794O MW 338.4
DM1794O FM C22H26O3
DM1794O IC InChI=1S/C22H26O3/c1-15(2)10-19-20(22(19,3)4)21(23)25-14-17-12-18(24-13-17)11-16-8-6-5-7-9-16/h5-10,12-13,19-20H,11,14H2,1-4H3
DM1794O CS CC(=CC1C(C1(C)C)C(=O)OCC2=COC(=C2)CC3=CC=CC=C3)C
DM1794O IK VEMKTZHHVJILDY-UHFFFAOYSA-N
DM1794O IU (5-benzylfuran-3-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate
DM1794O CA CAS 10453-86-8
DM1794O CB CHEBI:8811
DM1794O DE Pest attack
DMU5H3A ID DMU5H3A
DMU5H3A DN PZ-128
DMU5H3A HS Phase 2
DMU5H3A SN UNII-IYT6MP4NS9; IYT6MP4NS9; 371131-16-7; N-((2S,5S,8S,11S,14S,17S,20S)-1,24-diamino-17-(4-aminobutyl)-2-benzyl-11-(3-guanidinopropyl)-14-(hydroxymethyl)-5-isobutyl-8-methyl-1,4,7,10,13,16,19-heptaoxo-3,6,9,12,15,18-hexaazatetracosan-20-yl)palmitamide; Palmitate-kksralf-NH2; PZ128; PZ 128; CHEMBL4297323; DB11839; L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-; Q27280961; N-[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]
DMU5H3A CP Tufts Medical Center
DMU5H3A DT Small molecular drug
DMU5H3A PC 72187679
DMU5H3A MW 1086.5
DMU5H3A FM C55H99N13O9
DMU5H3A IC InChI=1S/C55H99N13O9/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-31-47(70)63-41(28-21-23-32-56)51(74)64-42(29-22-24-33-57)52(75)68-46(37-69)54(77)65-43(30-25-34-61-55(59)60)50(73)62-39(4)49(72)67-45(35-38(2)3)53(76)66-44(48(58)71)36-40-26-18-17-19-27-40/h17-19,26-27,38-39,41-46,69H,5-16,20-25,28-37,56-57H2,1-4H3,(H2,58,71)(H,62,73)(H,63,70)(H,64,74)(H,65,77)(H,66,76)(H,67,72)(H,68,75)(H4,59,60,61)/t39-,41-,42-,43-,44-,45-,46-/m0/s1
DMU5H3A CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N
DMU5H3A IK VZRIKWNVDCTBTF-BKGFHLQYSA-N
DMU5H3A IU N-[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]hexadecanamide
DMU5H3A CA CAS 371131-16-7
DMU5H3A DE Peripheral arterial occlusive disorder
DME71WA ID DME71WA
DME71WA DN Q301
DME71WA HS Phase 2
DME71WA SN Boc-N-Me-Val-OH; 45170-31-8; Boc-N-methyl-L-valine; N-Boc-N-methyl-L-valine; Boc-MeVal-OH; (S)-2-((tert-Butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid; Boc-N-a-methyl-L-valine; L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; MFCD00038760; n-(tert-butoxycarbonyl)-n-methyl-l-valine; N-Boc-N-methylvaline; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid; PubChem12254; Boc-N-Me-L-Val-OH; Boc-Nalpha-methyl-L-valine; Boc-N-; A-Methyl-L-valine; N-Boc-N-Methyl-L-Val-OH; SCHEMBL59435; DTXSID10426676; ZINC2391126; ANW-41482; AKOS015836686; AKOS015905243; AC-8571; AM82390; AT-5684; CS-W008976; AS-15695; BP-21374; AB0017502; Boc-N-Me-Val-OH, >=99.0% (TLC); DB-038153; 170B318; J-300310; N-alpha-t-Butyloxycarbonyl-N-alpha-methyl-L-valine; Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-; (2S)-(tert-Butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (s)-2-(t-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (s)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid; (S)-2-(tert-butoxycarbonyl-methyl-amino)-3-methyl-butyric acid; (2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]-3-methyl butanoic acid; (2S)-2-[[(tert-Butoxy)carbonyl](methyl)amino]-3-methylbutanoic acid; (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoicacid
DME71WA CP Qurient
DME71WA DT Small molecular drug
DME71WA PC 7010608
DME71WA MW 231.29
DME71WA FM C11H21NO4
DME71WA IC InChI=1S/C11H21NO4/c1-7(2)8(9(13)14)12(6)10(15)16-11(3,4)5/h7-8H,1-6H3,(H,13,14)/t8-/m0/s1
DME71WA CS CC(C)[C@@H](C(=O)O)N(C)C(=O)OC(C)(C)C
DME71WA IK XPUAXAVJMJDPDH-QMMMGPOBSA-N
DME71WA IU (2S)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid
DME71WA CA CAS 45170-31-8
DME71WA DE Atopic dermatitis
DMIZYV1 ID DMIZYV1
DMIZYV1 DN QAV-680
DMIZYV1 HS Phase 2
DMIZYV1 CP Novartis AG
DMIZYV1 PC 11508736
DMIZYV1 MW 358.4
DMIZYV1 FM C18H18N2O4S
DMIZYV1 IC InChI=1S/C18H18N2O4S/c1-12-16(10-17(21)22)15-4-3-9-19-18(15)20(12)11-13-5-7-14(8-6-13)25(2,23)24/h3-9H,10-11H2,1-2H3,(H,21,22)
DMIZYV1 CS CC1=C(C2=C(N1CC3=CC=C(C=C3)S(=O)(=O)C)N=CC=C2)CC(=O)O
DMIZYV1 IK YOPFAMROKXHVCQ-UHFFFAOYSA-N
DMIZYV1 IU 2-[2-methyl-1-[(4-methylsulfonylphenyl)methyl]pyrrolo[2,3-b]pyridin-3-yl]acetic acid
DMIZYV1 CA CAS 872365-16-7
DMIZYV1 DE Allergic rhinitis
DMXY0H2 ID DMXY0H2
DMXY0H2 DN QAX-028
DMXY0H2 HS Phase 2
DMXY0H2 SN Bronchodilatory agent (inhaled, COPD), Novartis
DMXY0H2 CP Novartis AG
DMXY0H2 DE Chronic obstructive pulmonary disease
DMUWFI7 ID DMUWFI7
DMUWFI7 DN QAX-576
DMUWFI7 HS Phase 2
DMUWFI7 SN IL-13 modulator (intravenous), Novartis
DMUWFI7 CP Novartis AG
DMUWFI7 DE Allergic rhinitis
DMAFUHK ID DMAFUHK
DMAFUHK DN QGC-001
DMAFUHK HS Phase 2
DMAFUHK SN QGC001
DMAFUHK CP Pfizer
DMAFUHK PC 24851355
DMAFUHK MW 368.5
DMAFUHK FM C8H20N2O6S4
DMAFUHK IC InChI=1S/C8H20N2O6S4/c9-7(1-3-19(11,12)13)5-17-18-6-8(10)2-4-20(14,15)16/h7-8H,1-6,9-10H2,(H,11,12,13)(H,14,15,16)/t7-,8-/m0/s1
DMAFUHK CS C(CS(=O)(=O)O)[C@@H](CSSC[C@H](CCS(=O)(=O)O)N)N
DMAFUHK IK HJPXZXVKLGEMGP-YUMQZZPRSA-N
DMAFUHK IU (3S)-3-amino-4-[[(2S)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid
DMAFUHK CA CAS 648927-86-0
DMAFUHK DE Hypertension
DMKVIWM ID DMKVIWM
DMKVIWM DN QR-333
DMKVIWM HS Phase 2
DMKVIWM CP Quigley Pharma Inc
DMKVIWM DE Diabetic neuropathy
DMIUS5X ID DMIUS5X
DMIUS5X DN R1507
DMIUS5X HS Phase 2
DMIUS5X CP Roche
DMIUS5X PC 5376617
DMIUS5X MW 276.29
DMIUS5X FM C17H12N2O2
DMIUS5X IC InChI=1S/C17H12N2O2/c20-19(21)16-6-3-4-13(12-16)8-10-15-11-9-14-5-1-2-7-17(14)18-15/h1-12H/b10-8+
DMIUS5X CS C1=CC=C2C(=C1)C=CC(=N2)/C=C/C3=CC(=CC=C3)[N+](=O)[O-]
DMIUS5X IK URIXDBULDXTIHZ-CSKARUKUSA-N
DMIUS5X IU 2-[(E)-2-(3-nitrophenyl)ethenyl]quinoline
DMIUS5X CA CAS 7251-91-4
DMIUS5X DE Graves ophthalmopathy
DMP7J0S ID DMP7J0S
DMP7J0S DN R411
DMP7J0S HS Phase 2
DMP7J0S CP Roche
DMP7J0S DT Small molecular drug
DMP7J0S PC 61516
DMP7J0S MW 178.27
DMP7J0S FM C12H18O
DMP7J0S IC InChI=1S/C12H18O/c1-3-12(2,13)10-9-11-7-5-4-6-8-11/h4-8,13H,3,9-10H2,1-2H3
DMP7J0S CS CCC(C)(CCC1=CC=CC=C1)O
DMP7J0S IK AEJRTNBCFUOSEM-UHFFFAOYSA-N
DMP7J0S IU 3-methyl-1-phenylpentan-3-ol
DMP7J0S CA CAS 10415-87-9
DMP7J0S DE Asthma
DM79YAS ID DM79YAS
DM79YAS DN Racotumomab
DM79YAS HS Phase 2
DM79YAS SN P3 MAb, CIM; 1E10 anti-idiotypic MAb, Center of Molecular Immunology
DM79YAS CP The Center of Molecular Immunology
DM79YAS DT Monoclonal antibody
DM79YAS DE Breast cancer
DMOI9EL ID DMOI9EL
DMOI9EL DN Radezolid
DMOI9EL HS Phase 2
DMOI9EL SN Radezolid; Radezolid hydrochloride; RX-103; RX-1741; RX-01-667; Oxazolidinone antibiotic (bacterial infection), Rib-X Pharmaceuticals; Oxazolidinone antibiotic (CAP/uSSSI), Rib-X Pharamceuticals; Radezolid (iv, gram positive bacterial infection), Rib-X Pharmaceuticals; RX-1741 (iv, gram positive bacterial infection), Rib-X Pharmaceuticals; Radezolid (oral, CAP/uSSSI), Rib-X Pharmaceuticals; RX-1741 (oral, CAP/uSSSI), Rib-X Pharmaceuticals
DMOI9EL CP Melinta therapeutics
DMOI9EL DE Pneumonia; Acne vulgaris
DMC56T4 ID DMC56T4
DMC56T4 DN RAF265
DMC56T4 HS Phase 2
DMC56T4 SN RAF265; 927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594
DMC56T4 CP Novartis Pharmaceuticals
DMC56T4 DT Small molecular drug
DMC56T4 PC 11656518
DMC56T4 MW 518.4
DMC56T4 FM C24H16F6N6O
DMC56T4 IC InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)
DMC56T4 CS CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F
DMC56T4 IK YABJJWZLRMPFSI-UHFFFAOYSA-N
DMC56T4 IU 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine
DMC56T4 CA CAS 927880-90-8
DMC56T4 CB CHEBI:91451
DMC56T4 DE Melanoma
DM7G4Y9 ID DM7G4Y9
DM7G4Y9 DN Ralinepag
DM7G4Y9 HS Phase 2
DM7G4Y9 SN UNII-CQY12ZJN6E; CQY12ZJN6E; 1187856-49-0; Ralinepag [USAN:INN]; Ralinepag (USAN/INN); SCHEMBL1118504; SCHEMBL1118506; SCHEMBL12786473; CHEMBL3919269; CHEMBL3301604; AKOS027337124; DB12462; 2-((trans-4-((((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetic acid; Acetic acid, 2-((trans-4-(((((4-chlorophenyl)phenylamino)carbonyl)oxy)methyl)cyclohexyl)methoxy)-; HY-16751; CS-0012350; J3.614.088G; D10725
DM7G4Y9 CP Arena Pharmaceuticals San Diego, CA
DM7G4Y9 PC 44219292
DM7G4Y9 MW 431.9
DM7G4Y9 FM C23H26ClNO5
DM7G4Y9 IC InChI=1S/C23H26ClNO5/c24-19-10-12-21(13-11-19)25(20-4-2-1-3-5-20)23(28)30-15-18-8-6-17(7-9-18)14-29-16-22(26)27/h1-5,10-13,17-18H,6-9,14-16H2,(H,26,27)
DM7G4Y9 CS C1CC(CCC1COCC(=O)O)COC(=O)N(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DM7G4Y9 IK NPDKXVKJRHPDQT-UHFFFAOYSA-N
DM7G4Y9 IU 2-[[4-[[(4-chlorophenyl)-phenylcarbamoyl]oxymethyl]cyclohexyl]methoxy]acetic acid
DM7G4Y9 CA CAS 1187856-49-0
DM7G4Y9 DE Pulmonary hypertension; Pulmonary arterial hypertension
DMBFZSX ID DMBFZSX
DMBFZSX DN RALURIDINE
DMBFZSX HS Phase 2
DMBFZSX SN FCU; FddClUrd; BW-935U83; Raluridine; 5-Chloro-2',3'-dideoxy-3'-fluorouridine
DMBFZSX DT Small molecular drug
DMBFZSX PC 451480
DMBFZSX MW 264.64
DMBFZSX FM C9H10ClFN2O4
DMBFZSX IC InChI=1S/C9H10ClFN2O4/c10-4-2-13(9(16)12-8(4)15)7-1-5(11)6(3-14)17-7/h2,5-7,14H,1,3H2,(H,12,15,16)/t5-,6+,7+/m0/s1
DMBFZSX CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Cl)CO)F
DMBFZSX IK WKVDSZYIGHLONN-RRKCRQDMSA-N
DMBFZSX IU 5-chloro-1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMBFZSX CA CAS 119644-22-3
DMBFZSX DE Human immunodeficiency virus infection
DMP2DNS ID DMP2DNS
DMP2DNS DN Rambazole
DMP2DNS HS Phase 2
DMP2DNS SN Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole pound> SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510
DMP2DNS CP Barrier
DMP2DNS DT Small molecular drug
DMP2DNS PC 9799888
DMP2DNS MW 377.5
DMP2DNS FM C21H23N5S
DMP2DNS IC InChI=1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)
DMP2DNS CS CCC(CC)C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4
DMP2DNS IK SNFYYXUGUBUECJ-UHFFFAOYSA-N
DMP2DNS IU N-[4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl]-1,3-benzothiazol-2-amine
DMP2DNS CA CAS 201410-53-9
DMP2DNS CB CHEBI:102167
DMP2DNS DE Asthma; Psoriasis vulgaris
DMO2TYL ID DMO2TYL
DMO2TYL DN Ramipril
DMO2TYL HS Phase 2
DMO2TYL SN ramipril; 87333-19-5; Tritace; Altace; Carasel; Triatec; Ramace; Delix; Vesdil; Acovil; Cardace; Lostapres; Quark; Hytren; Ramiprilum [Latin]; Hoe-498; Ramiprilum; Pramace; HOE 498; Altace (TN); UNII-L35JN3I7SJ; CHEMBL1168; L35JN3I7SJ; CHEBI:8774; C23H32N2O5; Ramipril
DMO2TYL TC Antiviral Agents
DMO2TYL DT Small molecular drug
DMO2TYL PC 5362129
DMO2TYL MW 416.5
DMO2TYL FM C23H32N2O5
DMO2TYL IC InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
DMO2TYL CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
DMO2TYL IK HDACQVRGBOVJII-JBDAPHQKSA-N
DMO2TYL IU (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
DMO2TYL CA CAS 87333-19-5
DMO2TYL CB CHEBI:8774
DMO2TYL DE Coronavirus Disease 2019 (COVID-19)
DMM15RI ID DMM15RI
DMM15RI DN Ranpirnase
DMM15RI HS Phase 2
DMM15RI CP Tamir Biotechnology
DMM15RI DE Lung cancer
DMK2E0N ID DMK2E0N
DMK2E0N DN RAXOFELAST
DMK2E0N HS Phase 2
DMK2E0N SN IRFI-016; Raxofelast; Rac-2-(5-Acetoxy-4,6,7-trimethyl-2,3-dihydrobenzofuran-2-yl)acetic acid
DMK2E0N DT Small molecular drug
DMK2E0N PC 65961
DMK2E0N MW 278.3
DMK2E0N FM C15H18O5
DMK2E0N IC InChI=1S/C15H18O5/c1-7-8(2)15-12(5-11(20-15)6-13(17)18)9(3)14(7)19-10(4)16/h11H,5-6H2,1-4H3,(H,17,18)
DMK2E0N CS CC1=C(C(=C(C2=C1OC(C2)CC(=O)O)C)OC(=O)C)C
DMK2E0N IK QLWBKUUORSULMI-UHFFFAOYSA-N
DMK2E0N IU 2-(5-acetyloxy-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-2-yl)acetic acid
DMK2E0N CA CAS 128232-14-4
DMK2E0N DE Ischemia
DMIG98L ID DMIG98L
DMIG98L DN RC-3095
DMIG98L HS Phase 2
DMIG98L SN Rc-3095; D-Tpi-Gln-Trp-Ala-Val-Gly-His-Leu-Y(CH2-NH)-Leu-NH2 trifluoroacetate salt; GTPL6183; [D-Tpi6, Leu13 psi(CH2NH)-Leu14]bombesin-(6-14); (D-Tpi6, Leu13psi(CH2-NH)-Leu14)bombesin (6-14)
DMIG98L DT Small molecular drug
DMIG98L PC 11948463
DMIG98L MW 1106.3
DMIG98L FM C56H79N15O9
DMIG98L IC InChI=1S/C56H79N15O9/c1-29(2)18-35(25-61-42(50(58)74)19-30(3)4)66-55(79)45(21-34-24-59-28-64-34)68-48(73)27-63-56(80)49(31(5)6)71-51(75)32(7)65-54(78)44(20-33-23-60-39-14-10-8-12-36(33)39)70-52(76)41(16-17-47(57)72)69-53(77)43-22-38-37-13-9-11-15-40(37)67-46(38)26-62-43/h8-15,23-24,28-32,35,41-45,49,60-62,67H,16-22,25-27H2,1-7H3,(H2,57,72)(H2,58,74)(H,59,64)(H,63,80)(H,65,78)(H,66,79)(H,68,73)(H,69,77)(H,70,76)(H,71,75)/t32-,35-,41-,42-,43+,44-,45-,49-/m0/s1
DMIG98L CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)CN[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]4CC5=C(CN4)NC6=CC=CC=C56
DMIG98L IK IUYCRRDHLJIJBB-QAGBKCHLSA-N
DMIG98L IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methylpentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl]amino]pentanediamide
DMIG98L DE Solid tumour/cancer
DM1TKG4 ID DM1TKG4
DM1TKG4 DN RDEA3170
DM1TKG4 HS Phase 2
DM1TKG4 CP AstraZeneca
DM1TKG4 PC 54767229
DM1TKG4 MW 348.4
DM1TKG4 FM C20H16N2O2S
DM1TKG4 IC InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
DM1TKG4 CS CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
DM1TKG4 IK YYBOLPLTQDKXPM-UHFFFAOYSA-N
DM1TKG4 IU 2-[3-(4-cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid
DM1TKG4 CA CAS 1352792-74-5
DM1TKG4 DE Hyperuricaemia
DMNWYHD ID DMNWYHD
DMNWYHD DN RDEA-684
DMNWYHD HS Phase 2
DMNWYHD CP Ardea Biosciences Inc
DMNWYHD DE Gout
DM4CIKA ID DM4CIKA
DM4CIKA DN RDP58
DM4CIKA HS Phase 2
DM4CIKA SN Delmitide; RDP58; RDP-58; UNII-5759XTJ706; 5759XTJ706; Delmitide [INN]; Allotrap-1258; Allotrap 1258; 287096-87-1; AC1L55WS; AC1Q5JM9; (2r)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-5-guanidino-pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-n-[(1r)-1-[[(1r)-1-[[(1r)-1-[[(1r)-1-[[2-[[(1r)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]pentyl]carbamoyl]-4-guanidino-butyl]hexanamide; RDP 58; RSP-58; SCHEMBL18758870; D-Tyrosinamide, D-arginyl-D-norleucyl-D-norleucyl-D-n
DM4CIKA CP Genzyme
DM4CIKA DT Small molecular drug
DM4CIKA PC 219021
DM4CIKA MW 1228.6
DM4CIKA FM C59H105N17O11
DM4CIKA IC InChI=1S/C59H105N17O11/c1-7-13-22-40(51(81)68-36-48(78)69-47(49(61)79)35-37-29-31-38(77)32-30-37)71-53(83)42(24-15-9-3)73-55(85)44(26-17-11-5)75-57(87)46(28-20-34-67-59(64)65)76-56(86)45(27-18-12-6)74-54(84)43(25-16-10-4)72-52(82)41(23-14-8-2)70-50(80)39(60)21-19-33-66-58(62)63/h29-32,39-47,77H,7-28,33-36,60H2,1-6H3,(H2,61,79)(H,68,81)(H,69,78)(H,70,80)(H,71,83)(H,72,82)(H,73,85)(H,74,84)(H,75,87)(H,76,86)(H4,62,63,66)(H4,64,65,67)/t39-,40-,41-,42-,43-,44-,45-,46-,47-/m1/s1
DM4CIKA CS CCCC[C@H](C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)N[C@H](CCCC)C(=O)NCC(=O)N[C@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)N
DM4CIKA IK SFGFYNXPJMOUHK-PKAFTLKUSA-N
DM4CIKA IU (2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[2-[[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]hexanamide
DM4CIKA CA CAS 287096-87-1
DM4CIKA DE Diarrhea
DM2CJ4O ID DM2CJ4O
DM2CJ4O DN Rebmab-100
DM2CJ4O HS Phase 2
DM2CJ4O CP Genesis Biopharma
DM2CJ4O DT Antibody
DM2CJ4O DE Fallopian tube cancer
DML8N3Y ID DML8N3Y
DML8N3Y DN Recifercept
DML8N3Y HS Phase 2
DML8N3Y SN TA-46
DML8N3Y CP Pfizer
DML8N3Y DT Antibody
DML8N3Y DE Achondroplasia
DMCSR8I ID DMCSR8I
DMCSR8I DN Recoflavone
DMCSR8I HS Phase 2
DMCSR8I SN Recoflavone; DA-6034; Recoflavone (gastritis), Dong-A; DA-6034 (gastritis), Dong-A; Recoflavone (eyedrops, xerophthalmia), Dong-A; DA-6034 (eye drops, xerophthalmia), Dong-A; DA-6034 (ophthalmic, dry eye), Dong-A
DMCSR8I CP Dong-A Pharmaceutical Co Ltd
DMCSR8I DT Small molecular drug
DMCSR8I PC 9952125
DMCSR8I MW 386.4
DMCSR8I FM C20H18O8
DMCSR8I IC InChI=1S/C20H18O8/c1-24-14-5-4-11(6-16(14)25-2)15-9-13(21)20-17(26-3)7-12(8-18(20)28-15)27-10-19(22)23/h4-9H,10H2,1-3H3,(H,22,23)
DMCSR8I CS COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3OC)OCC(=O)O)OC
DMCSR8I IK BCPQOBQIVJZOFL-UHFFFAOYSA-N
DMCSR8I IU 2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid
DMCSR8I CA 203191-10-0
DMCSR8I DE Inflammatory bowel disease
DMURX4B ID DMURX4B
DMURX4B DN Recombinant batroxobin
DMURX4B HS Phase 2
DMURX4B CP SinoBiomed
DMURX4B DE Blood forming organ disorder
DMV0A28 ID DMV0A28
DMV0A28 DN Recombinant RGD-hirudin
DMV0A28 HS Phase 2
DMV0A28 SN Rh-RGD-hirudin; Recombinant RGD-hirudin (injectable, thrombosis); Recombinant RGD-hirudin (injectable, thrombosis),Simcere
DMV0A28 CP Simcere Pharmaceutical Group
DMV0A28 DE Thrombosis
DMSJ3Z5 ID DMSJ3Z5
DMSJ3Z5 DN REGN1979
DMSJ3Z5 HS Phase 2
DMSJ3Z5 CP Regeneron Pharmaceuticals Tarrytown, NY
DMSJ3Z5 DE Solid tumour/cancer; Chronic lymphocytic leukaemia; B-cell non-hodgkin lymphoma
DMTBRPO ID DMTBRPO
DMTBRPO DN REGN910-3
DMTBRPO HS Phase 2
DMTBRPO DT Antibody
DMTBRPO DE Neovascular age-related macular degeneration
DM0KBML ID DM0KBML
DM0KBML DN REGN-COV2
DM0KBML HS Phase 2
DM0KBML CP Regeneron Pharmaceuticals
DM0KBML DT Antibody
DM0KBML DE Coronavirus Disease 2019 (COVID-19)
DM13OVF ID DM13OVF
DM13OVF DN REMD 477
DM13OVF HS Phase 2
DM13OVF SN Volagidemab
DM13OVF CP REMD Biotherapeutics
DM13OVF DT Antibody
DM13OVF DE Type-2 diabetes; Type-1 diabetes; Type 2 diabetes
DMJIB89 ID DMJIB89
DMJIB89 DN Remetinostat
DMJIB89 HS Phase 2
DMJIB89 SN UNII-37NT056AT4; 946150-57-8; Methylparaben suberohydroxamic acid phenyl ester; 37NT056AT4; Remetinostat [USAN]; Remetinostat (USAN/INN); CHEMBL3707219; SCHEMBL12682510; DTXSID20647779; NSC748492; Benzoic acid, 4-((8-(hydroxyamino)-1,8-dioxooctyl)oxy)-, methyl ester; NSC-748492; D10977; methyl 4-[8-(hydroxyamino)-8-oxooctanoyl]oxybenzoate; Methyl 4-{[8-(hydroxyamino)-8-oxooctanoyl]oxy}benzoate; Benzoic acid,8-dioxooctyl]oxy]-, methyl ester (MP-shape)
DMJIB89 CP Medivir Huddinge, Sweden
DMJIB89 PC 24875489
DMJIB89 MW 323.34
DMJIB89 FM C16H21NO6
DMJIB89 IC InChI=1S/C16H21NO6/c1-22-16(20)12-8-10-13(11-9-12)23-15(19)7-5-3-2-4-6-14(18)17-21/h8-11,21H,2-7H2,1H3,(H,17,18)
DMJIB89 CS COC(=O)C1=CC=C(C=C1)OC(=O)CCCCCCC(=O)NO
DMJIB89 IK XDZAHHULFQIBFE-UHFFFAOYSA-N
DMJIB89 IU methyl 4-[8-(hydroxyamino)-8-oxooctanoyl]oxybenzoate
DMJIB89 CA CAS 946150-57-8
DMJIB89 DE Basal cell carcinoma; Cutaneous T-cell lymphoma
DM2USXP ID DM2USXP
DM2USXP DN Remlarsen
DM2USXP HS Phase 2
DM2USXP CP miRagen Therapeutics
DM2USXP DE Keloid
DMZFV3E ID DMZFV3E
DMZFV3E DN Remogli ozin-etabonate
DMZFV3E HS Phase 2
DMZFV3E CP Bhv pharma
DMZFV3E DE Type-2 diabetes
DMW4YK1 ID DMW4YK1
DMW4YK1 DN Remogliflozin etabonate
DMW4YK1 HS Phase 2
DMW4YK1 SN GSK-189075; GSK-189075A; KGT-1681
DMW4YK1 CP GSK
DMW4YK1 DT Small molecular drug
DMW4YK1 PC 9871420
DMW4YK1 MW 522.6
DMW4YK1 FM C26H38N2O9
DMW4YK1 IC InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
DMW4YK1 CS CCOC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
DMW4YK1 IK UAOCLDQAQNNEAX-ABMICEGHSA-N
DMW4YK1 IU ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate
DMW4YK1 CA CAS 442201-24-3
DMW4YK1 DE Type-1/2 diabetes; Type-2 diabetes
DMTGU6K ID DMTGU6K
DMTGU6K DN REN-1654
DMTGU6K HS Phase 2
DMTGU6K SN Antineurodegeneratives, Centaur; CPI-1160; CPI-1189; Parkinsons therapy, Centaur; REN-1189
DMTGU6K CP Centaur Pharmaceuticals Inc
DMTGU6K DT Small molecular drug
DMTGU6K PC 151118
DMTGU6K MW 234.29
DMTGU6K FM C13H18N2O2
DMTGU6K IC InChI=1S/C13H18N2O2/c1-9(16)14-11-7-5-10(6-8-11)12(17)15-13(2,3)4/h5-8H,1-4H3,(H,14,16)(H,15,17)
DMTGU6K CS CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C
DMTGU6K IK DJKNRCWSXSZACF-UHFFFAOYSA-N
DMTGU6K IU 4-acetamido-N-tert-butylbenzamide
DMTGU6K CA CAS 183619-38-7
DMTGU6K DE Cognitive impairment
DMQ73AY ID DMQ73AY
DMQ73AY DN Reovirus
DMQ73AY HS Phase 2
DMQ73AY SN Reolysin (TN)
DMQ73AY CP Oncolytics Biotech
DMQ73AY DE Head and neck cancer
DMT5QSD ID DMT5QSD
DMT5QSD DN Resimmune
DMT5QSD HS Phase 2
DMT5QSD SN A-dmDT390-bisFv immunotoxin
DMT5QSD CP Angimmune
DMT5QSD DE Melanoma; Cutaneous T-cell lymphoma
DMP62L5 ID DMP62L5
DMP62L5 DN Resiniferatoxin
DMP62L5 HS Phase 2
DMP62L5 SN Reciniferatoxin; UNII-A5O6P1UL4I; A5O6P1UL4I; 57444-62-9; RTX; [3H]resiniferatoxin; 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)daphnetoxin 20-(3-hydroxy-5-methoxybenzeneacetate); CHEMBL448382; resinferatoxin; Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2S,3aR,3bS,6aR,9aR,9bR,10R,11aR)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7-oxo-2-(phenylmethyl)-7H-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester; Resiniferatoxin(RTX); CHEMBL17976; RTX
DMP62L5 CP Afferon
DMP62L5 TC Analgesics
DMP62L5 DT Small molecular drug
DMP62L5 PC 5702546
DMP62L5 MW 628.7
DMP62L5 FM C37H40O9
DMP62L5 IC InChI=1S/C37H40O9/c1-21(2)35-17-23(4)37-27(33(35)44-36(45-35,46-37)19-24-9-7-6-8-10-24)14-26(18-34(41)30(37)13-22(3)32(34)40)20-43-31(39)16-25-11-12-28(38)29(15-25)42-5/h6-15,23,27,30,33,38,41H,1,16-20H2,2-5H3/t23-,27+,30-,33-,34-,35-,36-,37-/m1/s1
DMP62L5 CS C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C=C6)O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C
DMP62L5 IK DSDNAKHZNJAGHN-MXTYGGKSSA-N
DMP62L5 IU [(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate
DMP62L5 CA CAS 57444-62-9
DMP62L5 CB CHEBI:8809
DMP62L5 DE Pain; Osteoarthritis; Neuropathic pain; Cancer related pain
DML6XSP ID DML6XSP
DML6XSP DN Resiquimod
DML6XSP HS Phase 2
DML6XSP SN Resiquimod [INN]; R 848; S 28463; R-848; S-28463; VML-600; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol
DML6XSP CP 3M Pharma.
DML6XSP DT Small molecular drug
DML6XSP PC 159603
DML6XSP MW 314.4
DML6XSP FM C17H22N4O2
DML6XSP IC InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
DML6XSP CS CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
DML6XSP IK BXNMTOQRYBFHNZ-UHFFFAOYSA-N
DML6XSP IU 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
DML6XSP CA CAS 144875-48-9
DML6XSP CB CHEBI:36706
DML6XSP DE Herpes simplex virus infection; Actinic keratosis; Cutaneous T-cell lymphoma
DMNE1FR ID DMNE1FR
DMNE1FR DN Resminostat
DMNE1FR HS Phase 2
DMNE1FR SN Resminostat; 864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895
DMNE1FR CP 4SC AG
DMNE1FR DT Small molecular drug
DMNE1FR PC 11609955
DMNE1FR MW 349.4
DMNE1FR FM C16H19N3O4S
DMNE1FR IC InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+
DMNE1FR CS CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO
DMNE1FR IK FECGNJPYVFEKOD-VMPITWQZSA-N
DMNE1FR IU (E)-3-[1-[4-[(dimethylamino)methyl]phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide
DMNE1FR CA CAS 864814-88-0
DMNE1FR DE Hepatocellular carcinoma
DMM4EJI ID DMM4EJI
DMM4EJI DN Resten-NG
DMM4EJI HS Phase 2
DMM4EJI SN Resten-NG (TN)
DMM4EJI CP Cook Pharmica
DMM4EJI DT Antisense drug
DMM4EJI DE Coronary artery disease; Solid tumour/cancer
DMVXZJ4 ID DMVXZJ4
DMVXZJ4 DN RetinoStat
DMVXZJ4 HS Phase 2
DMVXZJ4 SN AngiStat; XiaGen; Cardiovascular disease therapy, Oxford Biomedica; Gene therapy (HRE), Oxford Biomedica; Angiostatin/endostatin gene therapy (LentiVector, AMD), Oxford Biomedica
DMVXZJ4 CP Oxford BioMedica plc
DMVXZJ4 DE Macular degeneration
DMJ37UX ID DMJ37UX
DMJ37UX DN Revacept
DMJ37UX HS Phase 2
DMJ37UX SN Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen
DMJ37UX CP ProCorde GmbH
DMJ37UX DE Arteriosclerosis
DM1FS2W ID DM1FS2W
DM1FS2W DN Revamilast
DM1FS2W HS Phase 2
DM1FS2W SN GRC-4039; PDE 4 inhibitor (inflammation), Glenmark; Phosphodiesterase 4 inhibitor (inflammation), Glenmark; Revamilast (inflammation), Glenmark
DM1FS2W CP Glenmark Pharmaceuticals Ltd
DM1FS2W DT Small molecular drug
DM1FS2W PC 11546664
DM1FS2W MW 440.2
DM1FS2W FM C18H9Cl2F2N3O4
DM1FS2W IC InChI=1S/C18H9Cl2F2N3O4/c19-10-6-25(27)7-11(20)15(10)24-17(26)8-1-2-13(29-18(21)22)16-14(8)9-5-23-4-3-12(9)28-16/h1-7,18,27H
DM1FS2W CS C1=CC(=C2C(=C1C(=O)N=C3C(=CN(C=C3Cl)O)Cl)C4=C(O2)C=CN=C4)OC(F)F
DM1FS2W IK CFRXVFRHMZLQBS-UHFFFAOYSA-N
DM1FS2W IU N-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-6-(difluoromethoxy)-[1]benzofuro[3,2-c]pyridine-9-carboxamide
DM1FS2W CA CAS 893555-90-3
DM1FS2W DE Asthma
DMFIVSR ID DMFIVSR
DMFIVSR DN R-flurbiprofen
DMFIVSR HS Phase 2
DMFIVSR SN Tarenflurbil; (R)-Flurbiprofen; 51543-40-9; Flurizan; R-Flurbiprofen; (R)-2-Flurbiprofen; (R)-2-Flubiprofen; MPC-7869; UNII-501W00OOWA; R-(-)-Flurbiprofen; (2r)-2-(3-Fluoro-4-Phenyl-Phenyl)propanoic Acid; (-)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (R)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid; (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid; CHEMBL190083; 501W00OOWA; CHEBI:38666; E-7869
DMFIVSR DT Small molecular drug
DMFIVSR PC 92337
DMFIVSR MW 244.26
DMFIVSR FM C15H13FO2
DMFIVSR IC InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1
DMFIVSR CS C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
DMFIVSR IK SYTBZMRGLBWNTM-SNVBAGLBSA-N
DMFIVSR IU (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMFIVSR CA CAS 51543-40-9
DMFIVSR CB CHEBI:38666
DMQ8K93 ID DMQ8K93
DMQ8K93 DN RFT-5.dgA
DMQ8K93 HS Phase 2
DMQ8K93 SN IMTOX-25; Anti-CD25 antibody, University of Texas Southwestern Medical Center; Immunotoxin (cancer), University of Texas Southwestern Medical Center/ Cologne University
DMQ8K93 CP University of Texas Southwestern Medical Center
DMQ8K93 DE Human immunodeficiency virus infection
DM2UGT7 ID DM2UGT7
DM2UGT7 DN RG-101
DM2UGT7 HS Phase 2
DM2UGT7 DE Hepatitis C virus infection
DMT1ZX0 ID DMT1ZX0
DMT1ZX0 DN RG1577
DMT1ZX0 HS Phase 2
DMT1ZX0 CP Roche
DMT1ZX0 DE Alzheimer disease
DMT4QRD ID DMT4QRD
DMT4QRD DN RG-4929
DMT4QRD HS Phase 2
DMT4QRD SN R-4929; RO-5093151; 11-beta HSD inhibitor (type 2 diabetes), Roche; 11-beta hydroxysteroid dehydrogenase inhibitor (type 2 diabetes), Roche
DMT4QRD CP F Hoffmann-La Roche Ltd
DMT4QRD DT Small molecular drug
DMT4QRD PC 21846
DMT4QRD MW 398.9
DMT4QRD FM C23H27ClN2O2
DMT4QRD IC InChI=1S/C23H26N2O2.ClH/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18;/h1-10,20H,11-17H2,(H,24,26,27);1H
DMT4QRD CS C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4.Cl
DMT4QRD IK XSOOSXRNMDUWEM-UHFFFAOYSA-N
DMT4QRD IU 3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione;hydrochloride
DMT4QRD CA CAS 5633-14-7
DMT4QRD DE Metabolic disorder
DMEFD0B ID DMEFD0B
DMEFD0B DN RG6100
DMEFD0B HS Phase 2
DMEFD0B CP AC Immune Lausanne, Switzerland Genentech South San Francisco, CA
DMEFD0B DE Alzheimer disease
DMX8JYN ID DMX8JYN
DMX8JYN DN RG-7090
DMX8JYN HS Phase 2
DMX8JYN SN RO-4917523; Antidepressant (oral), Hoffmann-La Roche; MGluR5 antagonist (depression/fragile X syndrome, oral), Roche
DMX8JYN CP F Hoffmann-La Roche Ltd
DMX8JYN DT Small molecular drug
DMX8JYN PC 11438771
DMX8JYN MW 325.8
DMX8JYN FM C18H13ClFN3
DMX8JYN IC InChI=1S/C18H13ClFN3/c1-12-17(8-3-14-9-10-21-18(19)11-14)22-13(2)23(12)16-6-4-15(20)5-7-16/h4-7,9-11H,1-2H3
DMX8JYN CS CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl
DMX8JYN IK UPZWINBEAHDTLA-UHFFFAOYSA-N
DMX8JYN IU 2-chloro-4-[2-[1-(4-fluorophenyl)-2,5-dimethylimidazol-4-yl]ethynyl]pyridine
DMX8JYN CA CAS 802906-73-6
DMX8JYN DE Fragile X syndrome
DM8JMNL ID DM8JMNL
DM8JMNL DN RG7155
DM8JMNL HS Phase 2
DM8JMNL CP Roche
DM8JMNL DE Solid tumour/cancer
DM8J9DC ID DM8J9DC
DM8J9DC DN RG7221
DM8J9DC HS Phase 2
DM8J9DC CP Roche
DM8J9DC DE Colorectal cancer; Metastatic colorectal cancer
DM5RAB9 ID DM5RAB9
DM5RAB9 DN RG-7234
DM5RAB9 HS Phase 2
DM5RAB9 SN R-7234; RO-5027838; 11-beta HSD 2 (type 2 diabetes), Roche; 11-beta hydroxysteroid dehydrogenase inhibitor 2 (type 2 diabetes), Roche
DM5RAB9 CP F Hoffmann-La Roche Ltd
DM5RAB9 DE Type-2 diabetes
DMB4M6O ID DMB4M6O
DMB4M6O DN RG7314
DMB4M6O HS Phase 2
DMB4M6O DE Autism spectrum disorder
DMVXGU0 ID DMVXGU0
DMVXGU0 DN RG7596
DMVXGU0 HS Phase 2
DMVXGU0 CP Genentech
DMVXGU0 DE Haematological malignancy
DMDGPKS ID DMDGPKS
DMDGPKS DN RG7625
DMDGPKS HS Phase 2
DMDGPKS SN Petesicatib; UNII-A26QO95U37; A26QO95U37; RG-7625; RO-5459072; Petesicatib [INN]; SCHEMBL700776; GTPL9855; KXAAIORSMACJSI-AEFFLSMTSA-N; RO5459072; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; 1252637-35-6; (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; (2s,4r)-4-[4-(1-me
DMDGPKS CP RocheBasel, Switzerland
DMDGPKS PC 59543597
DMDGPKS MW 603.5
DMDGPKS FM C25H23F6N5O4S
DMDGPKS IC InChI=1S/C25H23F6N5O4S/c1-35-11-15(10-33-35)14-2-3-19(17(8-14)24(26,27)28)41(39,40)16-9-18(20(37)34-22(13-32)4-5-22)36(12-16)21(38)23(6-7-23)25(29,30)31/h2-3,8,10-11,16,18H,4-7,9,12H2,1H3,(H,34,37)/t16-,18+/m1/s1
DMDGPKS CS CN1C=C(C=N1)C2=CC(=C(C=C2)S(=O)(=O)[C@@H]3C[C@H](N(C3)C(=O)C4(CC4)C(F)(F)F)C(=O)NC5(CC5)C#N)C(F)(F)F
DMDGPKS IK KXAAIORSMACJSI-AEFFLSMTSA-N
DMDGPKS IU (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide
DMDGPKS CA CAS 1252637-35-6
DMDGPKS DE Autoimmune disease; Coeliac disease; Sjogren syndrome
DM6CNFW ID DM6CNFW
DM6CNFW DN RG7686
DM6CNFW HS Phase 2
DM6CNFW CP Roche
DM6CNFW DT Antibody
DM6CNFW DE Hepatocellular carcinoma
DMK5PYS ID DMK5PYS
DMK5PYS DN RG7745
DMK5PYS HS Phase 2
DMK5PYS CP Genentech
DMK5PYS DT Antibody
DMK5PYS DE Infectious disease
DM452RF ID DM452RF
DM452RF DN RG7880
DM452RF HS Phase 2
DM452RF CP Genentech South San Francisco, CA
DM452RF DE Ulcerative colitis; Diabetic foot ulcer
DM2SWI8 ID DM2SWI8
DM2SWI8 DN RG7888
DM2SWI8 HS Phase 2
DM2SWI8 SN MOXR0916
DM2SWI8 DT Antibody
DM2SWI8 DE Solid tumour/cancer; Urothelial carcinoma
DME1YMX ID DME1YMX
DME1YMX DN RG7935
DME1YMX HS Phase 2
DME1YMX DT Antibody
DME1YMX DE Parkinson disease
DMCHZAN ID DMCHZAN
DMCHZAN DN RGH-896
DMCHZAN HS Phase 2
DMCHZAN SN AC1L338E; 1-[2-[[[[[5beta-[(Octadecylaminocarbonyloxy)methyl]tetrahydrofuran]-2beta-yl]methoxy]oxylatophosphinyl]oxy]ethyl]quinolinium; [[[(2R)-5beta-[[(Octadecylcarbamoyl)oxy]methyl]tetrahydrofuran]-2beta-yl]methyl][2-(quinolinium-1-yl)ethyl] phosphate; [(2S,5R)-5-[[hydroxy(2-quinolin-1-ium-1-ylethoxy)phosphoryl]oxymethyl]oxolan-2-yl]methyl N-octadecylcarbamate
DMCHZAN CP Gedeon Richter
DMCHZAN TC Analgesics
DMCHZAN DT Small molecular drug
DMCHZAN PC 10200813
DMCHZAN MW 397.4
DMCHZAN FM C21H20FN3O4
DMCHZAN IC InChI=1S/C21H20FN3O4/c22-15-3-1-13(2-4-15)11-14-7-9-25(10-8-14)20(27)19(26)23-16-5-6-17-18(12-16)29-21(28)24-17/h1-6,12,14H,7-11H2,(H,23,26)(H,24,28)
DMCHZAN CS C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4
DMCHZAN IK GKGRZLGAQZPEHO-UHFFFAOYSA-N
DMCHZAN IU 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide
DMCHZAN CA CAS 496054-87-6
DMCHZAN DE Peripheral neuropathy; Epilepsy
DM4AC2F ID DM4AC2F
DM4AC2F DN RGI-2001
DM4AC2F HS Phase 2
DM4AC2F CP REGiMMUNE
DM4AC2F PC 2826713
DM4AC2F MW 858.3
DM4AC2F FM C50H99NO9
DM4AC2F IC InChI=1S/C50H99NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(54)51-42(41-59-50-49(58)48(57)47(56)44(40-52)60-50)46(55)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-53,55-58H,3-41H2,1-2H3,(H,51,54)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1
DM4AC2F CS CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)[C@@H]([C@@H](CCCCCCCCCCCCCC)O)O
DM4AC2F IK VQFKFAKEUMHBLV-BYSUZVQFSA-N
DM4AC2F IU N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]hexacosanamide
DM4AC2F CA CAS 158021-47-7
DM4AC2F CB CHEBI:466659
DM4AC2F DE Graft-versus-host disease
DMSF10P ID DMSF10P
DMSF10P DN RGN-259
DMSF10P HS Phase 2
DMSF10P CP Regenerx biopharmaceuticals
DMSF10P DE Vaginal infection
DMBSXR9 ID DMBSXR9
DMBSXR9 DN rhACE2
DMBSXR9 HS Phase 2
DMBSXR9 SN recombinant human ACE2; APN01
DMBSXR9 TC Antiviral Agents
DMBSXR9 DT Protein/peptide drug
DMBSXR9 SQ MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPWTLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWNDNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRSRINDAFRLNDNSLEFLGIQPTLGPPNQPPVSIWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNKARSGENPYASIDISKGENNPGFQNTDDVQTSF
DMBSXR9 DE Coronavirus Disease 2019 (COVID-19)
DMN1EFR ID DMN1EFR
DMN1EFR DN RhGDF-5
DMN1EFR HS Phase 2
DMN1EFR SN MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil
DMN1EFR CP Biopharm GmbH
DMN1EFR DE Periodontal disease
DMO9QB8 ID DMO9QB8
DMO9QB8 DN R-IFN-1a
DMO9QB8 HS Phase 2
DMO9QB8 CP Merck-Serono Laboratories
DMO9QB8 DE Hepatitis C virus infection
DM3L51O ID DM3L51O
DM3L51O DN Rilopirox
DM3L51O HS Phase 2
DM3L51O SN Riloprox; Hoe-351
DM3L51O CP Hoechst AG
DM3L51O DT Small molecular drug
DM3L51O PC 71778
DM3L51O MW 357.8
DM3L51O FM C19H16ClNO4
DM3L51O IC InChI=1S/C19H16ClNO4/c1-13-10-15(21(23)19(22)11-13)12-24-16-6-8-18(9-7-16)25-17-4-2-14(20)3-5-17/h2-11,23H,12H2,1H3
DM3L51O CS CC1=CC(=O)N(C(=C1)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)O
DM3L51O IK UDYUIWXQUBNDHC-UHFFFAOYSA-N
DM3L51O IU 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one
DM3L51O CA CAS 104153-37-9
DM3L51O DE Fungal infection
DMSC7TN ID DMSC7TN
DMSC7TN DN Rimacalib
DMSC7TN HS Phase 2
DMSC7TN SN SMP-114
DMSC7TN CP Sumitomo Pharmaceuticals Co Ltd
DMSC7TN DT Small molecular drug
DMSC7TN PC 9800765
DMSC7TN MW 394.4
DMSC7TN FM C22H23FN4O2
DMSC7TN IC InChI=1S/C22H23FN4O2/c1-15(17-7-8-18(19(23)13-17)16-5-3-2-4-6-16)20-14-21(29-26-20)25-22(24)27-9-11-28-12-10-27/h2-8,13-15H,9-12H2,1H3,(H2,24,25)/t15-/m0/s1
DMSC7TN CS C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C3=NOC(=C3)/N=C(\\N)/N4CCOCC4
DMSC7TN IK MYTIJGWONQOOLC-HNNXBMFYSA-N
DMSC7TN IU N'-[3-[(1S)-1-(3-fluoro-4-phenylphenyl)ethyl]-1,2-oxazol-5-yl]morpholine-4-carboximidamide
DMSC7TN CA CAS 215174-50-8
DMSC7TN DE Rheumatoid arthritis
DM2VO97 ID DM2VO97
DM2VO97 DN RK-023
DM2VO97 HS Phase 2
DM2VO97 DE Alopecia
DMVU1R9 ID DMVU1R9
DMVU1R9 DN RM-1929
DMVU1R9 HS Phase 2
DMVU1R9 CP Aspyrian Therapeutics San Diego, CA
DMVU1R9 DE Head and neck cancer
DM20CIM ID DM20CIM
DM20CIM DN RNF43-721
DM20CIM HS Phase 2
DM20CIM SN RNF43-721/Montanide ISA51; Peptide vaccine (subcutaneous, colorectal cancer), Tokyo Women's Medical College
DM20CIM CP Vaccinogen
DM20CIM DE Colorectal cancer
DMDNRU1 ID DMDNRU1
DMDNRU1 DN RNS-60
DMDNRU1 HS Phase 2
DMDNRU1 CP Revalesio Corp
DMDNRU1 DE Asthma; Amyotrophic lateral sclerosis; Multiple sclerosis
DM83QCL ID DM83QCL
DM83QCL DN Ro 31-7453
DM83QCL HS Phase 2
DM83QCL SN Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione
DM83QCL CP Hoffmann La Roche
DM83QCL TC Anticancer Agents
DM83QCL DT Small molecular drug
DM83QCL PC 5327686
DM83QCL MW 400.4
DM83QCL FM C22H16N4O4
DM83QCL IC InChI=1S/C22H16N4O4/c1-24-10-15(13-5-3-4-6-17(13)24)19-20(22(28)23-21(19)27)16-11-25(2)18-9-12(26(29)30)7-8-14(16)18/h3-11H,1-2H3,(H,23,27,28)
DM83QCL CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=C4C=CC(=C5)[N+](=O)[O-])C
DM83QCL IK OVSKGTONMLKNPZ-UHFFFAOYSA-N
DM83QCL IU 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione
DM83QCL CA CAS 125313-92-0
DM83QCL DE Solid tumour/cancer
DMA2UYE ID DMA2UYE
DMA2UYE DN Ro-24-7429
DMA2UYE HS Phase 2
DMA2UYE CP Roche Holding AG
DMA2UYE DT Small molecular drug
DMA2UYE PC 135422895
DMA2UYE MW 272.73
DMA2UYE FM C14H13ClN4
DMA2UYE IC InChI=1S/C14H13ClN4/c1-16-13-8-18-14(12-3-2-6-17-12)10-7-9(15)4-5-11(10)19-13/h2-7,17H,8H2,1H3,(H,16,19)
DMA2UYE CS CN=C1CN=C(C2=C(N1)C=CC(=C2)Cl)C3=CC=CN3
DMA2UYE IK LEAKQIXYSHIHCW-UHFFFAOYSA-N
DMA2UYE IU 7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-1,3-dihydro-1,4-benzodiazepin-2-imine
DMA2UYE CA CAS 139339-45-0
DMA2UYE CB CHEBI:93522
DMA2UYE DE Human immunodeficiency virus infection
DMV319J ID DMV319J
DMV319J DN RO-4905417
DMV319J HS Phase 2
DMV319J CP Roche
DMV319J DT Antibody
DMV319J DE Acute coronary syndrome
DMXA6B3 ID DMXA6B3
DMXA6B3 DN RO-4929097
DMXA6B3 HS Phase 2
DMXA6B3 SN RO4929097; 847925-91-1; Ro 4929097; UNII-KK8645V7LE; KK8645V7LE; RG-4733; N1-[(7S)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide; n1-((7s)-6,7-dihydro-6-oxo-5h-dibenz(b,d)azepin-7-yl)-2,2-dimethyl-n3-(2,2,3,3,3-pentafluoropropyl)propanediamide; OJPLJFIFUQPSJR-INIZCTEOSA-N; cc-19; MLS006011071; SCHEMBL1376366; GTPL7338; CHEBI:86474; DTXSID20233833; C22H20F5N3O3; MolPort-016-633-243; BCPP000088; EX-A1750; ZINC43208642; ABP000966; s1575; AKOS027250816
DMXA6B3 CP Roche
DMXA6B3 DT Small molecular drug
DMXA6B3 PC 49867930
DMXA6B3 MW 469.4
DMXA6B3 FM C22H20F5N3O3
DMXA6B3 IC InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1
DMXA6B3 CS CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C3=CC=CC=C3NC1=O
DMXA6B3 IK OJPLJFIFUQPSJR-INIZCTEOSA-N
DMXA6B3 IU 2,2-dimethyl-N-[(7S)-6-oxo-5,7-dihydrobenzo[d][1]benzazepin-7-yl]-N'-(2,2,3,3,3-pentafluoropropyl)propanediamide
DMXA6B3 CA CAS 847925-91-1
DMXA6B3 CB CHEBI:86474
DMXA6B3 DE Breast cancer
DMNTC7O ID DMNTC7O
DMNTC7O DN RO-4995819
DMNTC7O HS Phase 2
DMNTC7O CP F Hoffmann-La Roche Ltd
DMNTC7O PC 71533696
DMNTC7O MW 447.3
DMNTC7O FM C21H11F6N5
DMNTC7O IC InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)
DMNTC7O CS C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F
DMNTC7O IK DMJHZVARRXJSEG-UHFFFAOYSA-N
DMNTC7O IU 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]pyridin-2-amine
DMNTC7O CA CAS 911115-16-7
DMNTC7O DE Major depressive disorder
DMZJREM ID DMZJREM
DMZJREM DN RO-4998452
DMZJREM HS Phase 2
DMZJREM SN Type 2 diabetes therapeutic (oral), Roche
DMZJREM CP F Hoffmann-La Roche Ltd
DMZJREM DE Type-2 diabetes
DM3U9BY ID DM3U9BY
DM3U9BY DN RO-5126766
DM3U9BY HS Phase 2
DM3U9BY SN VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche
DM3U9BY CP Roche; Verastem Oncology
DM3U9BY DT Small molecular drug
DM3U9BY PC 16719221
DM3U9BY MW 471.5
DM3U9BY FM C21H18FN5O5S
DM3U9BY IC InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)
DM3U9BY CS CC1=C(C(=O)OC2=C1C=CC(=C2)OC3=NC=CC=N3)CC4=C(C(=NC=C4)NS(=O)(=O)NC)F
DM3U9BY IK LMMJFBMMJUMSJS-UHFFFAOYSA-N
DM3U9BY IU 3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one
DM3U9BY CA CAS 946128-88-7
DM3U9BY CB CHEBI:78825
DM3U9BY DE Solid tumour/cancer; Ovarian cancer; Non-small cell lung cancer
DMUB3OY ID DMUB3OY
DMUB3OY DN RO-5323441
DMUB3OY HS Phase 2
DMUB3OY SN Placental growth factor inhibitors (humanized mAb, cancer), BioInvent/Thrombogenics/Roche; 89Zr-RO-5323441
DMUB3OY CP F Hoffmann-La Roche Ltd
DMUB3OY DE Solid tumour/cancer
DMD3WNP ID DMD3WNP
DMD3WNP DN RO5520985
DMD3WNP HS Phase 2
DMD3WNP CP Roche
DMD3WNP DT Monoclonal antibody
DMD3WNP DE Colorectal cancer
DM8A120 ID DM8A120
DM8A120 DN RO7121661
DM8A120 HS Phase 2
DM8A120 SN RG7769
DM8A120 CP Roche
DM8A120 DT Antibody
DM8A120 DE Esophageal squamous cell carcinoma
DMSTH01 ID DMSTH01
DMSTH01 DN Rocilinostat
DMSTH01 HS Phase 2
DMSTH01 SN 1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010
DMSTH01 CP Acetylon pharmaceuticals
DMSTH01 DT Small molecular drug
DMSTH01 PC 53340666
DMSTH01 MW 433.5
DMSTH01 FM C24H27N5O3
DMSTH01 IC InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
DMSTH01 CS C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
DMSTH01 IK QGZYDVAGYRLSKP-UHFFFAOYSA-N
DMSTH01 IU N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide
DMSTH01 CA CAS 1316214-52-4
DMSTH01 CB CHEBI:95073
DMSTH01 DE Autoimmune diabetes; Multiple myeloma
DMYEZ5J ID DMYEZ5J
DMYEZ5J DN Romilkimab
DMYEZ5J HS Phase 2
DMYEZ5J SN SAR156597
DMYEZ5J DT Antibody
DMYEZ5J DE Idiopathic pulmonary fibrosis
DMBJN19 ID DMBJN19
DMBJN19 DN Rontalizumab
DMBJN19 HS Phase 2
DMBJN19 CP Genentech
DMBJN19 DT Antibody
DMBJN19 DE Systemic lupus erythematosus
DMKQXDB ID DMKQXDB
DMKQXDB DN Rostafuroxin
DMKQXDB HS Phase 2
DMKQXDB SN PST-2238; Na+ K+ ATPase (oral, hypertension), Sigma-Tau
DMKQXDB CP Sigma-Tau Ind Farm Riunite SpA
DMKQXDB DT Small molecular drug
DMKQXDB PC 153976
DMKQXDB MW 374.5
DMKQXDB FM C23H34O4
DMKQXDB IC InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1
DMKQXDB CS C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@]4(C5=COC=C5)O)O)C)O
DMKQXDB IK AEAPORIZZWBIEX-DTBDINHYSA-N
DMKQXDB IU (3S,5R,8R,9S,10S,13S,14S,17S)-17-(furan-3-yl)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,14,17-triol
DMKQXDB CA CAS 156722-18-8
DMKQXDB DE Hypertension
DMXB9RS ID DMXB9RS
DMXB9RS DN ROTIGAPTIDE
DMXB9RS HS Phase 2
DMXB9RS SN GAP-486; Rotigaptide < USAN; ZP-123; N-Acetyl-D-tyrosyl-D-prolyl-4(S)-hydroxy-D-prolyl-glycyl-D-alanyl-glycinamide
DMXB9RS DT Small molecular drug
DMXB9RS PC 9938933
DMXB9RS MW 617.7
DMXB9RS FM C28H39N7O9
DMXB9RS IC InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1
DMXB9RS CS C[C@H](C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H]1C[C@@H](CN1C(=O)[C@H]2CCCN2C(=O)[C@@H](CC3=CC=C(C=C3)O)NC(=O)C)O
DMXB9RS IK GFJRASPBQLDRRY-TWTQBQJDSA-N
DMXB9RS IU (2R,4S)-1-[(2R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]-N-[2-[[(2R)-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-4-hydroxypyrrolidine-2-carboxamide
DMXB9RS CA CAS 355151-12-1
DMXB9RS DE Cardiac arrhythmias
DMIZMYQ ID DMIZMYQ
DMIZMYQ DN Roxatidine
DMIZMYQ HS Phase 2
DMIZMYQ SN Desacetyl-tzu-0460; IV9VHT3YUM; ROXATIDINE; Roxatidine (INN); Roxatidine [INN:BAN]; 2-hydroxy-N-(3-(3-(piperidin-1-ylmethyl)phenoxy)propyl)acetamide; 2-hydroxy-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide; 2-hydroxy-n-{3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}acetamide; 78273-80-0; 97900-88-4; Acetamide, 2-hydroxy-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-; C17H26N2O3; N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]hydroxyacetamide; N-{3-[3-(1-Piperidinylmethyl)phenoxy]propyl}hydroxyacetamide; UNII-IV9VHT3YUM
DMIZMYQ PC 91276
DMIZMYQ MW 306.4
DMIZMYQ FM C17H26N2O3
DMIZMYQ IC BCCREUFCSIMJFS-UHFFFAOYSA-N
DMIZMYQ CS C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CO
DMIZMYQ IK 1S/C17H26N2O3/c20-14-17(21)18-8-5-11-22-16-7-4-6-15(12-16)13-19-9-2-1-3-10-19/h4,6-7,12,20H,1-3,5,8-11,13-14H2,(H,18,21)
DMIZMYQ IU 2-hydroxy-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
DMIZMYQ CA CAS 78273-80-0
DMIZMYQ DE Gastro-oesophageal reflux disease
DM15QL9 ID DM15QL9
DM15QL9 DN ROXINDOLE
DM15QL9 HS Phase 2
DM15QL9 SN Roxindole; 112192-04-8; UNII-43227SMS0O; 3-(4-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)butyl)-1H-indol-5-ol; 3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indol-5-ol; CHEMBL431367; CHEBI:48558; 43227SMS0O; NCGC00025216-01; 3-[4-(4-phenyl-3,6-dihydropyridin-1(2H)-yl)butyl]-1H-indol-5-ol; DSSTox_RID_80082; DSSTox_CID_23895; DSSTox_GSID_43895; roxindol; roxindole[inn]; Roxindole [INN]; CAS-112192-04-8; roxindolum; Tocris-1559; AC1Q7AGH; GTPL52; AC1L55YV; SCHEMBL49673; DTXSID5043895; 119742-13-1 (mesylate); ZINC1548439
DM15QL9 DT Small molecular drug
DM15QL9 PC 219050
DM15QL9 MW 346.5
DM15QL9 FM C23H26N2O
DM15QL9 IC InChI=1S/C23H26N2O/c26-21-9-10-23-22(16-21)20(17-24-23)8-4-5-13-25-14-11-19(12-15-25)18-6-2-1-3-7-18/h1-3,6-7,9-11,16-17,24,26H,4-5,8,12-15H2
DM15QL9 CS C1CN(CC=C1C2=CC=CC=C2)CCCCC3=CNC4=C3C=C(C=C4)O
DM15QL9 IK HGEYJZMMUGWEOT-UHFFFAOYSA-N
DM15QL9 IU 3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indol-5-ol
DM15QL9 CA CAS 112192-04-8
DM15QL9 CB CHEBI:48558
DM15QL9 DE Psychotic disorder
DMK0NGB ID DMK0NGB
DMK0NGB DN Rozanolixizumab
DMK0NGB HS Phase 2
DMK0NGB CP UCB Smyrna, GA
DMK0NGB DE Myasthenia gravis
DM4N6PF ID DM4N6PF
DM4N6PF DN RP-49356
DM4N6PF HS Phase 2
DM4N6PF SN Aprikalim; Aprim; Aprikalim); RP-52891
DM4N6PF CP Rhone-Poulenc SA
DM4N6PF DT Small molecular drug
DM4N6PF PC 3034038
DM4N6PF MW 268.4
DM4N6PF FM C12H16N2OS2
DM4N6PF IC InChI=1S/C12H16N2OS2/c1-13-11(16)12(6-2-3-8-17(12)15)10-5-4-7-14-9-10/h4-5,7,9H,2-3,6,8H2,1H3,(H,13,16)/t12-,17?/m1/s1
DM4N6PF CS CNC(=S)[C@@]1(CCCCS1=O)C2=CN=CC=C2
DM4N6PF IK GKEMHVLBZNVZOI-MTATWXBHSA-N
DM4N6PF IU (2R)-N-methyl-1-oxo-2-pyridin-3-ylthiane-2-carbothioamide
DM4N6PF CA CAS 89544-10-5
DM4N6PF DE Hypertension
DMKUE8O ID DMKUE8O
DMKUE8O DN RP5063
DMKUE8O HS Phase 2
DMKUE8O CP Reviva Pharmaceuticals
DMKUE8O DE Schizophrenia; Alzheimer disease; Attention deficit hyperactivity disorder; Bipolar disorder; Major depressive disorder; Parkinson disease
DMYILGK ID DMYILGK
DMYILGK DN RP6530
DMYILGK HS Phase 2
DMYILGK SN tenalisib; HDXDQPRPFRKGKZ-INIZCTEOSA-N; Tenalisib; 1639417-53-0; UNII-2261HH611H; 2261HH611H; Tenalisib [INN]; GTPL9907; SCHEMBL16279460; AKOS027325582; RP-6530; RP 6530; CS-6375; HY-17645; 4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-((1S)-1-(9H-purin-6-ylamino)propyl)-; (S)-2-(1-((7H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one; 3-(3-fluorophenyl)-2-[(1S)-1-[(9H-purin-6-yl)amino]propyl]-4H-chromen-4-one; 3-(3-Fluorophenyl)-2-((1S)-1-((7H-purin-6-yl)amino)propyl)-4H-1-benzopyran-4-one; 1693773-94-2
DMYILGK CP Rhizen PharmaceuticalsLa Chaux-de-Fonds, Switzerland
DMYILGK PC 86291103
DMYILGK MW 415.4
DMYILGK FM C23H18FN5O2
DMYILGK IC InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1
DMYILGK CS CC[C@@H](C1=C(C(=O)C2=CC=CC=C2O1)C3=CC(=CC=C3)F)NC4=NC=NC5=C4NC=N5
DMYILGK IK HDXDQPRPFRKGKZ-INIZCTEOSA-N
DMYILGK IU 3-(3-fluorophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]chromen-4-one
DMYILGK CA CAS 1639417-53-0
DMYILGK DE Cutaneous T-cell lymphoma; Chronic lymphocytic leukaemia
DM4L5VJ ID DM4L5VJ
DM4L5VJ DN R-phenserine
DM4L5VJ HS Phase 2
DM4L5VJ SN Posiphen (TN)
DM4L5VJ CP QR Pharma
DM4L5VJ PC 11249342
DM4L5VJ MW 337.4
DM4L5VJ FM C20H23N3O2
DM4L5VJ IC InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m0/s1
DM4L5VJ CS C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
DM4L5VJ IK PBHFNBQPZCRWQP-AZUAARDMSA-N
DM4L5VJ IU [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate
DM4L5VJ CA CAS 159652-53-6
DM4L5VJ DE Cognitive impairment; Alzheimer disease; Dementia
DMSJU5B ID DMSJU5B
DMSJU5B DN RP-L102
DMSJU5B HS Phase 2
DMSJU5B CP Rocket Pharmaceuticals
DMSJU5B DT Gene therapy
DMSJU5B DE Fanconi's anemia
DMLD4VQ ID DMLD4VQ
DMLD4VQ DN RPL-554
DMLD4VQ HS Phase 2
DMLD4VQ SN RPL-565; VMX-554; VMX-565; PDE 3/PDE 4 inhibitors, Kings College; PDE3/4 inhibitors (respiratory therapeutics), Rhinopharma; PDE3/4 inhibitors (nasal, respiratory disease), Verona Pharma; Trequinsin analogs (respiratory therapeutics), Kings College/Vernalis/Rhinopharma
DMLD4VQ CP King's College London
DMLD4VQ DT Small molecular drug
DMLD4VQ PC 9934746
DMLD4VQ MW 477.6
DMLD4VQ FM C26H31N5O4
DMLD4VQ IC InChI=1S/C26H31N5O4/c1-15-10-16(2)24(17(3)11-15)29-23-14-20-19-13-22(35-5)21(34-4)12-18(19)6-8-30(20)26(33)31(23)9-7-28-25(27)32/h10-14H,6-9H2,1-5H3,(H3,27,28,32)
DMLD4VQ CS CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2CCNC(=O)N)OC)OC)C
DMLD4VQ IK CSOBIBXVIYAXFM-UHFFFAOYSA-N
DMLD4VQ IU 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]ethylurea
DMLD4VQ CA CAS 298680-25-8
DMLD4VQ DE Allergic rhinitis
DM0BFJ5 ID DM0BFJ5
DM0BFJ5 DN RPSGL-Ig
DM0BFJ5 HS Phase 2
DM0BFJ5 CP Thios Pharmaceuticals
DM0BFJ5 DE Delayed graft function
DMBHN4K ID DMBHN4K
DMBHN4K DN RQ-00000005
DMBHN4K HS Phase 2
DMBHN4K SN Capromorelin
DMBHN4K CP RaQualia Pharma
DMBHN4K DT Small molecular drug
DMBHN4K PC 216208
DMBHN4K MW 505.6
DMBHN4K FM C28H35N5O4
DMBHN4K IC InChI=1S/C28H35N5O4/c1-27(2,29)25(35)30-22(18-37-17-21-12-8-5-9-13-21)24(34)33-15-14-23-28(19-33,26(36)32(3)31-23)16-20-10-6-4-7-11-20/h4-13,22H,14-19,29H2,1-3H3,(H,30,35)/t22-,28-/m1/s1
DMBHN4K CS CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3=NN(C(=O)[C@@]3(C2)CC4=CC=CC=C4)C)N
DMBHN4K IK KVLLHLWBPNCVNR-SKCUWOTOSA-N
DMBHN4K IU N-[(2R)-1-[(3aR)-3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-5-yl]-1-oxo-3-phenylmethoxypropan-2-yl]-2-amino-2-methylpropanamide
DMBHN4K CA CAS 193273-66-4
DMBHN4K DE Frailty
DMMYTRU ID DMMYTRU
DMMYTRU DN RQ-00000007 (oral)
DMMYTRU HS Phase 2
DMMYTRU SN CJ-023423; RQ-00000007 (iv); MR-10-A-7
DMMYTRU CP Pfizer Inc; RaQualia Pharma Inc
DMMYTRU DT Small molecular drug
DMMYTRU PC 11677589
DMMYTRU MW 491.6
DMMYTRU FM C26H29N5O3S
DMMYTRU IC InChI=1S/C26H29N5O3S/c1-5-24-29-25-19(4)28-18(3)16-23(25)31(24)21-10-8-20(9-11-21)14-15-27-26(32)30-35(33,34)22-12-6-17(2)7-13-22/h6-13,16H,5,14-15H2,1-4H3,(H2,27,30,32)
DMMYTRU CS CCC1=NC2=C(N1C3=CC=C(C=C3)CCNC(=O)NS(=O)(=O)C4=CC=C(C=C4)C)C=C(N=C2C)C
DMMYTRU IK HZVLFTCYCLXTGV-UHFFFAOYSA-N
DMMYTRU IU 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea
DMMYTRU CA CAS 415903-37-6
DMMYTRU DE Pain
DMSH108 ID DMSH108
DMSH108 DN R-roscovitine
DMSH108 HS Phase 2
DMSH108 SN Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; Roscovitine; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
DMSH108 CP Cyclacel
DMSH108 DT Small molecular drug
DMSH108 PC 160355
DMSH108 MW 354.4
DMSH108 FM C19H26N6O
DMSH108 IC InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
DMSH108 CS CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3
DMSH108 IK BTIHMVBBUGXLCJ-OAHLLOKOSA-N
DMSH108 IU (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol
DMSH108 CA CAS 186692-46-6
DMSH108 CB CHEBI:45307
DMSH108 DE Non-small-cell lung cancer; Solid tumour/cancer; Nasopharyngeal carcinoma
DMGLCVU ID DMGLCVU
DMGLCVU DN R-salbutamol sulphate
DMGLCVU HS Phase 2
DMGLCVU SN ASF-1096
DMGLCVU CP Astion Pharma A/S
DMGLCVU DE Skin infection
DMAJH75 ID DMAJH75
DMAJH75 DN RSV-604
DMAJH75 HS Phase 2
DMAJH75 SN A-60444; A-60445; RSV therapeutics, Arrow; RSV therapeutics, Novartis; Respiratory syncytial virus therapeutics, Novartis; Respiratory syncytial virus therapeutics, Arrow/Virogen; Antivirals (RSV), Arrow/ Virogen
DMAJH75 CP Novavax
DMAJH75 DT Small molecular drug
DMAJH75 PC 5279172
DMAJH75 MW 388.4
DMAJH75 FM C22H17FN4O2
DMAJH75 IC InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1
DMAJH75 CS C1=CC=C(C=C1)C2=N[C@@H](C(=O)NC3=CC=CC=C32)NC(=O)NC4=CC=CC=C4F
DMAJH75 IK MTPVBMVUENFFLL-HXUWFJFHSA-N
DMAJH75 IU 1-(2-fluorophenyl)-3-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea
DMAJH75 CA CAS 676128-63-5
DMAJH75 DE Virus infection
DM3FS1G ID DM3FS1G
DM3FS1G DN RT-001
DM3FS1G HS Phase 2
DM3FS1G SN RT-001, Revance therapeutics; BoNTA protein (topical gel, hyperhidrosis), Revance
DM3FS1G CP Revance Therapeutics Inc
DM3FS1G DT Small molecular drug
DM3FS1G PC 124037379
DM3FS1G MW 310.5
DM3FS1G FM C20H36O2
DM3FS1G IC InChI=1S/C20H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h8-9,11-12H,3-7,10,13-19H2,1-2H3/b9-8-,12-11-/i10D2
DM3FS1G CS [2H]C([2H])(/C=C\\CCCCC)/C=C\\CCCCCCCC(=O)OCC
DM3FS1G IK FMMOOAYVCKXGMF-XMCVDNGOSA-N
DM3FS1G IU ethyl (9Z,12Z)-11,11-dideuteriooctadeca-9,12-dienoate
DM3FS1G CA CAS 1404475-07-5
DM3FS1G DE Acne vulgaris; Friedreich's ataxia
DM8DVC9 ID DM8DVC9
DM8DVC9 DN RT-400
DM8DVC9 HS Phase 2
DM8DVC9 SN JNJ-39588146
DM8DVC9 CP Renova Therapeutics
DM8DVC9 DT Peptide
DM8DVC9 DE Acute decompensated heart failure
DM45NHF ID DM45NHF
DM45NHF DN RTR-003632
DM45NHF HS Phase 2
DM45NHF SN Acetates; Acetic acid,phenyl ester; Phenyl acetate; Acetoxybenzene; Acetyl phenol; Acetylphenol; Fenylester kyseliny octove; IPBVNPXQWQGGJP-UHFFFAOYSA-N; PHENYL ACETATE; Phenol acetate; Phenyl acetate, 97%; Phenyl acetate, 99%; Phenyl ester of acetic acid; phenoxy ethan-1-one; (Acetyloxy)benzene; 122-79-2; 355G9R500Y; AI3-01972; Acetic acid phenyl ester; Acetic acid, phenyl ester; BRN 0636458; CHEBI:8082; EINECS 204-575-0; Fenylester kyseliny octove [Czech]; HSDB 2667; MFCD00008699; NSC 27795; PhOAc; UNII-355G9R500Y; acetic acid phenyl
DM45NHF PC 31229
DM45NHF MW 136.15
DM45NHF FM C8H8O2
DM45NHF IC IPBVNPXQWQGGJP-UHFFFAOYSA-N
DM45NHF CS CC(=O)OC1=CC=CC=C1
DM45NHF IK 1S/C8H8O2/c1-7(9)10-8-5-3-2-4-6-8/h2-6H,1H3
DM45NHF IU phenyl acetate
DM45NHF CA CAS 122-79-2
DM45NHF CB CHEBI:8082
DM45NHF DE Brain cancer
DMVCXZK ID DMVCXZK
DMVCXZK DN Rupintrivir
DMVCXZK HS Phase 2
DMVCXZK SN AG-7088; AG-7185
DMVCXZK CP Pfizer
DMVCXZK DT Small molecular drug
DMVCXZK PC 6440352
DMVCXZK MW 598.7
DMVCXZK FM C31H39FN4O7
DMVCXZK IC InChI=1S/C31H39FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-11,14,18,21-22,24,28H,5,12-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/b11-10+/t21-,22+,24+,28-/m0/s1
DMVCXZK CS CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC2=CC=C(C=C2)F)CC(=O)[C@H](C(C)C)NC(=O)C3=NOC(=C3)C
DMVCXZK IK CAYJBRBGZBCZKO-BHGBQCOSSA-N
DMVCXZK IU ethyl (E,4S)-4-[[(2R,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
DMVCXZK CA CAS 223537-30-2
DMVCXZK DE Virus infection
DMSW5XJ ID DMSW5XJ
DMSW5XJ DN RV521
DMSW5XJ HS Phase 2
DMSW5XJ SN RV521 free base; UNII-KE63TTO7WK; KE63TTO7WK; RV-521; 1903763-82-5 (free base); 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one; 1903763-82-5; Sisunatovir; CHEMBL4297497; SCHEMBL19470916; EX-A4653; RV 521; NCC1=CC2=C(N(C(=N2)CN2C(C3(C4=CC=C(C=C24)F)CC3)=O)CCCC(F)(F)F)C=C1; 1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl]methyl}-6'-fluorospiro[cyclopropane-1,3'-indol]-2'(1'H)-one; Spiro(cyclopropane-1,3'-(3H)indol)-2'(1'H)-one, 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl)methyl)-6'-fluoro-; WVA
DMSW5XJ CP ReViral
DMSW5XJ DT Small molecular drug
DMSW5XJ PC 132016492
DMSW5XJ MW 446.4
DMSW5XJ FM C23H22F4N4O
DMSW5XJ IC InChI=1S/C23H22F4N4O/c24-15-3-4-16-19(11-15)31(21(32)22(16)7-8-22)13-20-29-17-10-14(12-28)2-5-18(17)30(20)9-1-6-23(25,26)27/h2-5,10-11H,1,6-9,12-13,28H2
DMSW5XJ CS C1CC12C3=C(C=C(C=C3)F)N(C2=O)CC4=NC5=C(N4CCCC(F)(F)F)C=CC(=C5)CN
DMSW5XJ IK JOPCJJSYRPUEDS-UHFFFAOYSA-N
DMSW5XJ IU 1'-[[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)benzimidazol-2-yl]methyl]-6'-fluorospiro[cyclopropane-1,3'-indole]-2'-one
DMSW5XJ CA CAS 1903763-82-5
DMSW5XJ DE Respiratory syncytial virus infection
DM652CM ID DM652CM
DM652CM DN RV-568
DM652CM HS Phase 2
DM652CM PC 45109868
DM652CM MW 592.7
DM652CM FM C34H36N6O4
DM652CM IC InChI=1S/C34H36N6O4/c1-22-10-12-24(13-11-22)40-31(19-29(39-40)34(2,3)4)38-33(42)36-27-14-15-28(26-9-7-6-8-25(26)27)44-20-23-16-17-35-30(18-23)37-32(41)21-43-5/h6-19H,20-21H2,1-5H3,(H,35,37,41)(H2,36,38,42)
DM652CM CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCC5=CC(=NC=C5)NC(=O)COC
DM652CM IK RTDCVLCTBQDLBW-UHFFFAOYSA-N
DM652CM IU N-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide
DM652CM CA CAS 1220626-82-3
DM652CM DE Asthma
DM3C9F8 ID DM3C9F8
DM3C9F8 DN RVT-505
DM3C9F8 HS Phase 2
DM3C9F8 CP Dermavant Sciences Phoenix, AZ
DM3C9F8 DE Atopic dermatitis; Psoriasis vulgaris
DMTBAV3 ID DMTBAV3
DMTBAV3 DN RX-0201
DMTBAV3 HS Phase 2
DMTBAV3 CP Rexahn
DMTBAV3 TC Anticancer Agents
DMTBAV3 DE Solid tumour/cancer; Renal cell carcinoma; Pancreatic cancer
DME8ARP ID DME8ARP
DME8ARP DN RX-3117
DME8ARP HS Phase 2
DME8ARP SN Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
DME8ARP CP Rexahn
DME8ARP PC 11242315
DME8ARP MW 257.22
DME8ARP FM C10H12FN3O4
DME8ARP IC InChI=1S/C10H12FN3O4/c11-6-4(3-15)8(16)9(17)7(6)14-2-1-5(12)13-10(14)18/h1-2,7-9,15-17H,3H2,(H2,12,13,18)/t7-,8-,9+/m1/s1
DME8ARP CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H](C(=C2F)CO)O)O
DME8ARP IK QLLGKCJUPWYJON-HLTSFMKQSA-N
DME8ARP IU 4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one
DME8ARP CA CAS 865838-26-2
DME8ARP CB CHEBI:147412
DME8ARP DE Solid tumour/cancer; Bladder cancer; Pancreatic cancer
DMBOZPH ID DMBOZPH
DMBOZPH DN RX-5902
DMBOZPH HS Phase 2
DMBOZPH SN Microtubule-cell cycle inhibitor (oral, cancer), Rexahn; Piperazine G2/M-specific cell cycle and Bcl inhibitors (oral,cancer), Rexahn
DMBOZPH CP Rexahn
DMBOZPH PC 11619093
DMBOZPH MW 441.5
DMBOZPH FM C22H24FN5O4
DMBOZPH IC InChI=1S/C22H24FN5O4/c1-30-16-11-15(12-17(13-16)31-2)27-6-8-28(9-7-27)22(29)26-20-21(32-3)25-18-5-4-14(23)10-19(18)24-20/h4-5,10-13H,6-9H2,1-3H3,(H,24,26,29)
DMBOZPH CS COC1=CC(=CC(=C1)N2CCN(CC2)C(=O)NC3=NC4=C(C=CC(=C4)F)N=C3OC)OC
DMBOZPH IK KAKPGJJRYRYSTP-UHFFFAOYSA-N
DMBOZPH IU 4-(3,5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide
DMBOZPH CA CAS 888478-45-3
DMBOZPH DE Solid tumour/cancer; Triple negative breast cancer
DMXG9ES ID DMXG9ES
DMXG9ES DN RXI-109
DMXG9ES HS Phase 2
DMXG9ES SN A45sd-RxNA
DMXG9ES CP Phio Pharmaceuticals
DMXG9ES DT Small interfering RNA
DMXG9ES DE Fibrosis; Hypertrophic scars
DM4KWEF ID DM4KWEF
DM4KWEF DN S-0509
DM4KWEF HS Phase 2
DM4KWEF SN 3-[3-[N-(2-Benzoylphenyl)-N-(tert-butoxycarbonylmethyl)carbamoylmethyl]ureido]benzoic acid
DM4KWEF PC 9893240
DM4KWEF MW 531.6
DM4KWEF FM C29H29N3O7
DM4KWEF IC InChI=1S/C29H29N3O7/c1-29(2,3)39-25(34)18-32(23-15-8-7-14-22(23)26(35)19-10-5-4-6-11-19)24(33)17-30-28(38)31-21-13-9-12-20(16-21)27(36)37/h4-16H,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)
DM4KWEF CS CC(C)(C)OC(=O)CN(C1=CC=CC=C1C(=O)C2=CC=CC=C2)C(=O)CNC(=O)NC3=CC=CC(=C3)C(=O)O
DM4KWEF IK LROWLFSPDIVWSD-UHFFFAOYSA-N
DM4KWEF IU 3-[[2-(2-benzoyl-N-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]anilino)-2-oxoethyl]carbamoylamino]benzoic acid
DM4KWEF DE Ulcerative colitis
DM9KTSG ID DM9KTSG
DM9KTSG DN S-1360
DM9KTSG HS Phase 2
DM9KTSG SN GW-810781; 810781
DM9KTSG CP Shionogi & Co Ltd
DM9KTSG DT Small molecular drug
DM9KTSG PC 6451047
DM9KTSG MW 313.28
DM9KTSG FM C16H12FN3O3
DM9KTSG IC InChI=1S/C16H12FN3O3/c17-11-3-1-10(2-4-11)7-12-5-6-15(23-12)13(21)8-14(22)16-18-9-19-20-16/h1-6,8-9,22H,7H2,(H,18,19,20)/b14-8-
DM9KTSG CS C1=CC(=CC=C1CC2=CC=C(O2)C(=O)/C=C(/C3=NC=NN3)\\O)F
DM9KTSG IK HFHDGHOGHWXXDT-ZSOIEALJSA-N
DM9KTSG IU (Z)-1-[5-[(4-fluorophenyl)methyl]furan-2-yl]-3-hydroxy-3-(1H-1,2,4-triazol-5-yl)prop-2-en-1-one
DM9KTSG CA CAS 280571-30-4
DM9KTSG DE Human immunodeficiency virus infection
DMKTLSD ID DMKTLSD
DMKTLSD DN S-15535
DMKTLSD HS Phase 2
DMKTLSD SN 4-(Benzodioxan-5-yl)-1-(indan-2-yl)piperazine; S15535; 146998-34-7; S 15535; 1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1h-inden-2-yl)-piperazine; 1-(2,3-dihydro-1H-inden-2-yl)-4-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperazine; Piperazine,1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)-; 1-(2,3-dihydro-1,4-benzodioxin-8-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine; PDSP1_000559; ACMC-20ehn1; [3H]S-15535; GTPL26; GTPL32; AC1L31KI; CHEMBL49247; SCHEMBL1650175; CTK4C5212; BDBM82564; ZINC16050; 1-(1,4-Benzodioxan-5-yl)-4-(indan-2-yl)piperazine
DMKTLSD DT Small molecular drug
DMKTLSD PC 132787
DMKTLSD MW 336.4
DMKTLSD FM C21H24N2O2
DMKTLSD IC InChI=1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2
DMKTLSD CS C1CN(CCN1C2CC3=CC=CC=C3C2)C4=C5C(=CC=C4)OCCO5
DMKTLSD IK QJPPEMXOOWNICQ-UHFFFAOYSA-N
DMKTLSD IU 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine
DMKTLSD CA CAS 146998-34-7
DMKTLSD DE Anxiety disorder
DML2D30 ID DML2D30
DML2D30 DN S-16924
DML2D30 HS Phase 2
DML2D30 SN S-16924; GTPL167; SCHEMBL8109895; s16924; S 16924
DML2D30 CP Servier
DML2D30 DT Small molecular drug
DML2D30 PC 9821498
DML2D30 MW 385.4
DML2D30 FM C22H24FNO4
DML2D30 IC InChI=1S/C22H24FNO4/c23-18-6-4-17(5-7-18)19(25)14-16-8-9-24(15-16)10-11-26-20-2-1-3-21-22(20)28-13-12-27-21/h1-7,16H,8-15H2
DML2D30 CS C1CN(CC1CC(=O)C2=CC=C(C=C2)F)CCOC3=CC=CC4=C3OCCO4
DML2D30 IK DXBFVLGYPFUTEZ-UHFFFAOYSA-N
DML2D30 IU 2-[1-[2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)ethyl]pyrrolidin-3-yl]-1-(4-fluorophenyl)ethanone
DML2D30 DE Anxiety disorder
DMTAX8B ID DMTAX8B
DMTAX8B DN S-2150
DMTAX8B HS Phase 2
DMTAX8B PC 234610
DMTAX8B MW 98.11
DMTAX8B FM C3H6N4
DMTAX8B IC InChI=1S/C3H6N4/c1-2-5-3(4)7-6-2/h1H3,(H3,4,5,6,7)
DMTAX8B CS CC1=NC(=NN1)N
DMTAX8B IK FJRZOOICEHBAED-UHFFFAOYSA-N
DMTAX8B IU 5-methyl-1H-1,2,4-triazol-3-amine
DMTAX8B CA CAS 4923-01-7
DMTAX8B DE Angina pectoris
DM26IH8 ID DM26IH8
DM26IH8 DN S-297995
DM26IH8 HS Phase 2
DM26IH8 SN NALDEMEDINE; UNII-03KSI6WLXH; 03KSI6WLXH; S-297,995; 916072-89-4; Naldemedine [USAN:INN]; Naldemedine (USAN/INN); S 297995; SCHEMBL9880572; GTPL9150; CHEMBL2105755; AKOS032945757; DB11691; Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14- trihydroxy-N-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-; J3.573.009E; D10188
DM26IH8 CP Shionogi
DM26IH8 DT Small molecular drug
DM26IH8 PC 54732242
DM26IH8 MW 570.6
DM26IH8 FM C32H34N4O6
DM26IH8 IC InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1
DM26IH8 CS CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
DM26IH8 IK AXQACEQYCPKDMV-RZAWKFBISA-N
DM26IH8 IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide
DM26IH8 CA CAS 916072-89-4
DM26IH8 DE Opioid dependence
DMU7ZMH ID DMU7ZMH
DMU7ZMH DN S-364735
DMU7ZMH HS Phase 2
DMU7ZMH SN GSK-364735; HIV integrase inhibitors (2), Shionogi/GlaxoSmithKline
DMU7ZMH CP Shionogi
DMU7ZMH DE Human immunodeficiency virus infection
DMD8XOY ID DMD8XOY
DMD8XOY DN S-38093
DMD8XOY HS Phase 2
DMD8XOY SN S-41150; S-38471-1; S-750-1; Histamine H3 antagonists (sleep/cognitive disorders), Servier
DMD8XOY CP Servier
DMD8XOY PC 11380684
DMD8XOY MW 288.4
DMD8XOY FM C17H24N2O2
DMD8XOY IC InChI=1S/C17H24N2O2/c18-17(20)13-5-7-16(8-6-13)21-10-2-9-19-11-14-3-1-4-15(14)12-19/h5-8,14-15H,1-4,9-12H2,(H2,18,20)
DMD8XOY CS C1CC2CN(CC2C1)CCCOC3=CC=C(C=C3)C(=O)N
DMD8XOY IK MRNMYWNBLVJWKG-UHFFFAOYSA-N
DMD8XOY IU 4-[3-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)propoxy]benzamide
DMD8XOY DE Alzheimer disease
DMXDVNZ ID DMXDVNZ
DMXDVNZ DN S-555739
DMXDVNZ HS Phase 2
DMXDVNZ CP Shionogi
DMXDVNZ PC 59232326
DMXDVNZ MW 501.6
DMXDVNZ FM C24H27N3O7S
DMXDVNZ IC InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)
DMXDVNZ CS CC(C)OC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=CC(=C(C=C3)C4=NC=CO4)OCC(=O)O
DMXDVNZ IK ZMZNWNTZRWXTJU-UHFFFAOYSA-N
DMXDVNZ IU 2-[2-(1,3-oxazol-2-yl)-5-[4-(4-propan-2-yloxyphenyl)sulfonylpiperazin-1-yl]phenoxy]acetic acid
DMXDVNZ CA CAS 932372-01-5
DMXDVNZ DE Allergy
DM3GRKY ID DM3GRKY
DM3GRKY DN S-707106
DM3GRKY HS Phase 2
DM3GRKY CP Shionogi
DM3GRKY DE Type-2 diabetes
DMZGNOJ ID DMZGNOJ
DMZGNOJ DN S-777469
DMZGNOJ HS Phase 2
DMZGNOJ CP Shionogi USA Inc
DMZGNOJ PC 57331749
DMZGNOJ MW 414.5
DMZGNOJ FM C23H27FN2O4
DMZGNOJ IC InChI=1S/C23H27FN2O4/c1-3-19-15(2)13-18(20(27)25-23(22(29)30)11-5-4-6-12-23)21(28)26(19)14-16-7-9-17(24)10-8-16/h7-10,13H,3-6,11-12,14H2,1-2H3,(H,25,27)(H,29,30)
DMZGNOJ CS CCC1=C(C=C(C(=O)N1CC2=CC=C(C=C2)F)C(=O)NC3(CCCCC3)C(=O)O)C
DMZGNOJ IK JIYXOJFSPOFZPY-UHFFFAOYSA-N
DMZGNOJ IU 1-[[6-ethyl-1-[(4-fluorophenyl)methyl]-5-methyl-2-oxopyridine-3-carbonyl]amino]cyclohexane-1-carboxylic acid
DMZGNOJ CA CAS 885496-53-7
DMZGNOJ DE Atopic dermatitis
DMRZA6G ID DMRZA6G
DMRZA6G DN S-8921
DMRZA6G HS Phase 2
DMRZA6G SN S-8921; 151165-96-7; S 8921; CHEMBL18380; Methyl-1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate; AC1L4BG3; SCHEMBL1650817; DTXSID70164724; BDBM50085476; Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-2-naphthalenecarboxylate; HY-19298; LS-193177; CS-0015040; methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylpentanoyl)-4-hydroxy-6,7,8-trimethoxynaphthalene-2-carboxylate; 2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7
DMRZA6G CP Shionogi & Co Ltd
DMRZA6G DT Small molecular drug
DMRZA6G PC 153965
DMRZA6G MW 540.6
DMRZA6G FM C30H36O9
DMRZA6G IC InChI=1S/C30H36O9/c1-9-16(10-2)13-19(31)25-26(30(33)39-8)23(17-11-12-20(34-3)21(14-17)35-4)24-18(27(25)32)15-22(36-5)28(37-6)29(24)38-7/h11-12,14-16,32H,9-10,13H2,1-8H3
DMRZA6G CS CCC(CC)CC(=O)C1=C(C2=CC(=C(C(=C2C(=C1C(=O)OC)C3=CC(=C(C=C3)OC)OC)OC)OC)OC)O
DMRZA6G IK QEJQEIIPZKQCNP-UHFFFAOYSA-N
DMRZA6G IU methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylpentanoyl)-4-hydroxy-6,7,8-trimethoxynaphthalene-2-carboxylate
DMRZA6G CA CAS 151165-96-7
DMRZA6G DE Hyperlipidaemia
DMBZO8N ID DMBZO8N
DMBZO8N DN Sabarubicin
DMBZO8N HS Phase 2
DMBZO8N SN BMS-195615; MEN-10755
DMBZO8N CP The Menarini Group
DMBZO8N DT Small molecular drug
DMBZO8N PC 151897
DMBZO8N MW 643.6
DMBZO8N FM C32H37NO13
DMBZO8N IC InChI=1S/C32H37NO13/c1-12-26(37)17(33)7-21(43-12)46-31-13(2)44-22(8-18(31)35)45-19-10-32(42,20(36)11-34)9-16-23(19)30(41)25-24(29(16)40)27(38)14-5-3-4-6-15(14)28(25)39/h3-6,12-13,17-19,21-22,26,31,34-35,37,40-42H,7-11,33H2,1-2H3/t12-,13-,17-,18-,19-,21-,22-,26+,31+,32-/m0/s1
DMBZO8N CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@@H](O[C@H](C[C@@H]2O)O[C@H]3C[C@@](CC4=C3C(=C5C(=C4O)C(=O)C6=CC=CC=C6C5=O)O)(C(=O)CO)O)C)N)O
DMBZO8N IK VQHRZZISQVWPLK-UIRGBLDSSA-N
DMBZO8N IU (7S,9S)-7-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
DMBZO8N CA CAS 211100-13-9
DMBZO8N DE Solid tumour/cancer
DMKDP57 ID DMKDP57
DMKDP57 DN Safotibant
DMKDP57 HS Phase 2
DMKDP57 SN UNII-02HU8HWP7U; 02HU8HWP7U; 633698-99-4; CHEMBL1254771; LF22-0542; LF-22-0542; Safotibant [INN]; Lf 22-0542; SCHEMBL1723565; DTXSID20212769; BDBM50326708; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-methoxy-2,6-dimethylphenyl)sulfonyl)methylamino)ethoxy)-N-methylacetamide; N-((4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl)-2-(2-((4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy)-N-methylacetamide; Acetamide, N-((4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)methyl)-2-(2-(((4-meth
DMKDP57 CP Sanofi
DMKDP57 DT Small molecular drug
DMKDP57 PC 11953367
DMKDP57 MW 502.6
DMKDP57 FM C25H34N4O5S
DMKDP57 IC InChI=1S/C25H34N4O5S/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27)
DMKDP57 CS CC1=CC(=CC(=C1S(=O)(=O)N(C)CCOCC(=O)N(C)CC2=CC=C(C=C2)C3=NCCN3)C)OC
DMKDP57 IK AMTQCENHQIDBHQ-UHFFFAOYSA-N
DMKDP57 IU N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[(4-methoxy-2,6-dimethylphenyl)sulfonyl-methylamino]ethoxy]-N-methylacetamide
DMKDP57 CA CAS 633698-99-4
DMKDP57 DE Diabetic macular edema
DMRFK0B ID DMRFK0B
DMRFK0B DN SAGE-217b
DMRFK0B HS Phase 2
DMRFK0B CP Sage Therapeutics
DMRFK0B DE Major depressive disorder
DM5NC39 ID DM5NC39
DM5NC39 DN SAGE-324
DM5NC39 HS Phase 2
DM5NC39 CP Sage Therapeutics
DM5NC39 DT Small molecular drug
DM5NC39 DE Parkinson disease; Essential tremor or related tremors
DM9RC7D ID DM9RC7D
DM9RC7D DN SAGE-718
DM9RC7D HS Phase 2
DM9RC7D CP Sage Therapeutics
DM9RC7D DT Small molecular drug
DM9RC7D DE Schizophrenia; Parkinson disease
DMRSU4X ID DMRSU4X
DMRSU4X DN Salirasib
DMRSU4X HS Phase 2
DMRSU4X SN 162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
DMRSU4X CP Kadmon
DMRSU4X DT Small molecular drug
DMRSU4X PC 5469318
DMRSU4X MW 358.5
DMRSU4X FM C22H30O2S
DMRSU4X IC InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
DMRSU4X CS CC(=CCC/C(=C/CC/C(=C/CSC1=CC=CC=C1C(=O)O)/C)/C)C
DMRSU4X IK WUILNKCFCLNXOK-CFBAGHHKSA-N
DMRSU4X IU 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid
DMRSU4X CA CAS 162520-00-5
DMRSU4X DE Pancreatic cancer; Non-small-cell lung cancer; Lung cancer
DMQVC3E ID DMQVC3E
DMQVC3E DN Salvianolic acid B
DMQVC3E HS Phase 2
DMQVC3E SN 115939-25-8; 121521-90-2; Salvianolic-acid-B; Lithospermic acid B; MFCD07779133; (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid; (R)-2-(((2R,3R)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid; Danshensuan B; Salcianolic acid B; C36H30O16; PubChem13035; CHEMBL3747259; ZINC49538629; AKOS015920258; AS-56980; S609; 939S258; (R)-2-((2R,3R)-4-((E)-3-((R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-enyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyloxy)-3-(3,4-dihydroxyphenyl)propanoic acid; 1607436-77-0
DMQVC3E DT Small molecular drug
DMQVC3E PC 11629084
DMQVC3E MW 718.6
DMQVC3E FM C36H30O16
DMQVC3E IC InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)/b10-5+/t27-,28-,31-,32+/m1/s1
DMQVC3E CS C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@H]([C@@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O
DMQVC3E IK SNKFFCBZYFGCQN-PDVBOLEISA-N
DMQVC3E IU (2R)-2-[(E)-3-[(2R,3R)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid
DMQVC3E DE Vascular dementia
DM0298B ID DM0298B
DM0298B DN Salvicine
DM0298B HS Phase 2
DM0298B SN Salvicine; 240423-23-8; 8-(3,4-dihydroxy-4-methylpentyl)-3-isopropyl-7-methylnaphthalene-1,2-dione; CHEMBL90715; DTXSID50438718; MolPort-028-744-855; AKOS025401738; ( inverted exclamation markA)Salvicine; QC-1122
DM0298B CP Shanghai Institute of Materia Medica (SIMM)
DM0298B DT Small molecular drug
DM0298B PC 10359290
DM0298B MW 330.4
DM0298B FM C20H26O4
DM0298B IC InChI=1S/C20H26O4/c1-11(2)15-10-13-7-6-12(3)14(17(13)19(23)18(15)22)8-9-16(21)20(4,5)24/h6-7,10-11,16,21,24H,8-9H2,1-5H3
DM0298B CS CC1=C(C2=C(C=C1)C=C(C(=O)C2=O)C(C)C)CCC(C(C)(C)O)O
DM0298B IK NZIUPDOWWMGNCV-UHFFFAOYSA-N
DM0298B IU 8-(3,4-dihydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
DM0298B CA CAS 240423-23-8
DM0298B DE Solid tumour/cancer
DMHVJZ6 ID DMHVJZ6
DMHVJZ6 DN SAM-531
DMHVJZ6 HS Phase 2
DMHVJZ6 SN PF-05212365; PF-5212365; WAY-262531; 5-HT6 receptor antagonist (Alzheimer's disease, schizophrenia), Pfizer
DMHVJZ6 CP Wyeth
DMHVJZ6 DT Small molecular drug
DMHVJZ6 PC 16071605
DMHVJZ6 MW 409.5
DMHVJZ6 FM C22H23N3O3S
DMHVJZ6 IC InChI=1S/C22H23N3O3S/c1-25(2)13-6-14-28-17-11-12-20-19(15-17)22(24-23-20)29(26,27)21-10-5-8-16-7-3-4-9-18(16)21/h3-5,7-12,15H,6,13-14H2,1-2H3,(H,23,24)
DMHVJZ6 CS CN(C)CCCOC1=CC2=C(NN=C2C=C1)S(=O)(=O)C3=CC=CC4=CC=CC=C43
DMHVJZ6 IK NXQGEDVQXVTCDA-UHFFFAOYSA-N
DMHVJZ6 IU N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
DMHVJZ6 CA CAS 925448-93-7
DMHVJZ6 DE Alzheimer disease
DMXTOVE ID DMXTOVE
DMXTOVE DN Sampatrilat
DMXTOVE HS Phase 2
DMXTOVE SN AC1L2YMI; SCHEMBL49065; C26H40N4O9S; UK 81252; LS-172743; (3R)-3-[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]-4-[1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]cyclopentyl]butanoic acid
DMXTOVE DT Small molecular drug
DMXTOVE PC 6324648
DMXTOVE MW 584.7
DMXTOVE FM C26H40N4O9S
DMXTOVE IC InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1
DMXTOVE CS CS(=O)(=O)N[C@@H](CCCCN)C(=O)NC[C@H](CC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)C(=O)O
DMXTOVE IK LPUDGHQMOAHMMF-JBACZVJFSA-N
DMXTOVE IU (2S)-2-[[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid
DMXTOVE CA CAS 129981-36-8
DMXTOVE DE Hypotension
DMP5Z9N ID DMP5Z9N
DMP5Z9N DN SAN-300
DMP5Z9N HS Phase 2
DMP5Z9N CP Santarus
DMP5Z9N DE Rheumatoid arthritis
DMDMQW0 ID DMDMQW0
DMDMQW0 DN SAR-100842
DMDMQW0 HS Phase 2
DMDMQW0 SN LPA1/LPA3 antagonist (renal fibrosis), sanofi-aventis
DMDMQW0 CP Sanofi us
DMDMQW0 PC 44481866
DMDMQW0 MW 445.5
DMDMQW0 FM C27H27NO5
DMDMQW0 IC InChI=1S/C27H27NO5/c1-18-6-5-7-19(14-18)12-13-33-24-15-20(10-11-23(24)32-2)25(29)28-27(26(30)31)16-21-8-3-4-9-22(21)17-27/h3-11,14-15H,12-13,16-17H2,1-2H3,(H,28,29)(H,30,31)
DMDMQW0 CS CC1=CC(=CC=C1)CCOC2=C(C=CC(=C2)C(=O)NC3(CC4=CC=CC=C4C3)C(=O)O)OC
DMDMQW0 IK SOJDTNUCCXWTMG-UHFFFAOYSA-N
DMDMQW0 IU 2-[[4-methoxy-3-[2-(3-methylphenyl)ethoxy]benzoyl]amino]-1,3-dihydroindene-2-carboxylic acid
DMDMQW0 CA CAS 1195941-38-8
DMDMQW0 DE Fibrosis; Systemic sclerosis
DMCLEXM ID DMCLEXM
DMCLEXM DN SAR-110894
DMCLEXM HS Phase 2
DMCLEXM SN SAR-110894D
DMCLEXM CP Sanofi
DMCLEXM DE Alzheimer disease
DMMCA9V ID DMMCA9V
DMMCA9V DN SAR-113945
DMMCA9V HS Phase 2
DMMCA9V SN S-0100229; S-0100658
DMMCA9V CP Sanofi
DMMCA9V DE Osteoarthritis
DMJ34G6 ID DMJ34G6
DMJ34G6 DN SAR-125844
DMJ34G6 HS Phase 2
DMJ34G6 SN Met inhibitor (iv, cancer), sanofi-aventis
DMJ34G6 CP Sanofi
DMJ34G6 PC 25182860
DMJ34G6 MW 550.6
DMJ34G6 FM C25H23FN8O2S2
DMJ34G6 IC InChI=1S/C25H23FN8O2S2/c26-17-3-1-16(2-4-17)19-7-8-22-30-31-25(34(22)32-19)37-18-5-6-20-21(15-18)38-24(28-20)29-23(35)27-9-10-33-11-13-36-14-12-33/h1-8,15H,9-14H2,(H2,27,28,29,35)
DMJ34G6 CS C1COCCN1CCNC(=O)NC2=NC3=C(S2)C=C(C=C3)SC4=NN=C5N4N=C(C=C5)C6=CC=C(C=C6)F
DMJ34G6 IK ODIUNTQOXRXOIV-UHFFFAOYSA-N
DMJ34G6 IU 1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea
DMJ34G6 CA CAS 1116743-46-4
DMJ34G6 DE Solid tumour/cancer
DMUICJD ID DMUICJD
DMUICJD DN SAR-156597
DMUICJD HS Phase 2
DMUICJD SN IL-4/IL-13-targeting bispecific mAb (idiopathic pulmonary fibrosis), sanofi-aventis
DMUICJD CP Sanofi
DMUICJD DT Antibody
DMUICJD DE Pulmonary fibrosis; Idiopathic pulmonary fibrosis; Systemic sclerosis
DMQM7IL ID DMQM7IL
DMQM7IL DN SAR245409
DMQM7IL HS Phase 2
DMQM7IL CP Sanofi; Exelixis
DMQM7IL DT Small molecular drug
DMQM7IL PC 16123056
DMQM7IL MW 270.29
DMQM7IL FM C13H14N6O
DMQM7IL IC InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)
DMQM7IL CS CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N
DMQM7IL IK RGHYDLZMTYDBDT-UHFFFAOYSA-N
DMQM7IL IU 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one
DMQM7IL CA CAS 934493-76-2
DMQM7IL CB CHEBI:124914
DMQM7IL DE Solid tumour/cancer
DMBJU2G ID DMBJU2G
DMBJU2G DN SAR-260093
DMBJU2G HS Phase 2
DMBJU2G CP Pharmaceuticals
DMBJU2G PC 25025505
DMBJU2G MW 448.5
DMBJU2G FM C22H24N8OS
DMBJU2G IC InChI=1S/C22H24N8OS/c1-2-16-11-23-22(24-12-16)29-9-7-17(8-10-29)21-26-18(14-32-21)13-31-20-5-3-19(4-6-20)30-15-25-27-28-30/h3-6,11-12,14-15,17H,2,7-10,13H2,1H3
DMBJU2G CS CCC1=CN=C(N=C1)N2CCC(CC2)C3=NC(=CS3)COC4=CC=C(C=C4)N5C=NN=N5
DMBJU2G IK NFTMKHWBOINJGM-UHFFFAOYSA-N
DMBJU2G IU 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(tetrazol-1-yl)phenoxy]methyl]-1,3-thiazole
DMBJU2G CA CAS 1037792-44-1
DMBJU2G DE Type-2 diabetes
DMEGNHZ ID DMEGNHZ
DMEGNHZ DN SAR279356
DMEGNHZ HS Phase 2
DMEGNHZ SN F598
DMEGNHZ CP Sanofi
DMEGNHZ DE Serious infection
DM63QY0 ID DM63QY0
DM63QY0 DN SAR292833
DM63QY0 HS Phase 2
DM63QY0 CP Sanofi-aventis; Glenmark Pharmaceuticals
DM63QY0 DE Insulin-dependent diabetes; Pain
DMJ9RN8 ID DMJ9RN8
DMJ9RN8 DN SAR-339658
DMJ9RN8 HS Phase 2
DMJ9RN8 SN CHR-1103; GBR-500; TMC-2003; Integrin antibody (inflammation), Chromos; Integrin antibody (inflammation), Targeted Molecules Corp; Integrin antibody (multiple sclerosis), Chromos; Integrin antibody (multiple sclerosis), Glenmark; CD49b antagonist (inflammation/multiple sclerosis), Glenmark
DMJ9RN8 CP Targeted Molecules Corp
DMJ9RN8 DT Antibody
DMJ9RN8 DE Inflammatory bowel disease
DMOSCBF ID DMOSCBF
DMOSCBF DN SAR-3419
DMOSCBF HS Phase 2
DMOSCBF SN HuB4-DM4; DM4-conjugated anti-CD19 monoclonal (cancer), sanofi-aventis/ImmunoGen
DMOSCBF CP ImmunoGen Inc
DMOSCBF DT Antibody
DMOSCBF DE Non-hodgkin lymphoma
DMS1YPZ ID DMS1YPZ
DMS1YPZ DN SAR391786
DMS1YPZ HS Phase 2
DMS1YPZ CP Sanofi
DMS1YPZ DT Antibody
DMS1YPZ DE Muscle atrophy
DMF95KD ID DMF95KD
DMF95KD DN SAR-407899
DMF95KD HS Phase 2
DMF95KD SN ROCK inhibitors, sanofi-aventis; Rho kinase inhibitors, sanofi-aventis
DMF95KD CP Sanofi
DMF95KD PC 15604510
DMF95KD MW 244.29
DMF95KD FM C14H16N2O2
DMF95KD IC InChI=1S/C14H16N2O2/c17-14-13-2-1-12(9-10(13)3-8-16-14)18-11-4-6-15-7-5-11/h1-3,8-9,11,15H,4-7H2,(H,16,17)
DMF95KD CS C1CNCCC1OC2=CC3=C(C=C2)C(=O)NC=C3
DMF95KD IK IPEXHQGMTHOKQV-UHFFFAOYSA-N
DMF95KD IU 6-piperidin-4-yloxy-2H-isoquinolin-1-one
DMF95KD CA CAS 923359-38-0
DMF95KD DE Diabetic nephropathy; Microvascular angina
DM6Q295 ID DM6Q295
DM6Q295 DN SAR566658
DM6Q295 HS Phase 2
DM6Q295 CP Sanofi
DM6Q295 DT Antibody
DM6Q295 DE Solid tumour/cancer
DMT4FI5 ID DMT4FI5
DMT4FI5 DN SAR-566658
DMT4FI5 HS Phase 2
DMT4FI5 SN CA6-targeted DM4 immunotoxin (cancer), sanofi-aventis; DM4-conjugated DS6 MAb (cancer), sanofi-aventis; DM4-conjugated anti-Muc1 monoclonal antibody (cancer), sanofi-aventis
DMT4FI5 CP ImmunoGen Inc
DMT4FI5 DT Antibody
DMT4FI5 DE Solid tumour/cancer; Triple negative breast cancer
DMG9MN2 ID DMG9MN2
DMG9MN2 DN SAR97276
DMG9MN2 HS Phase 2
DMG9MN2 SN Albitiazolium bromide; UNII-3AC0AJ4ILP; 3AC0AJ4ILP; 321915-72-4; SAR 97276; Albitiazolium bromide [INN]; SCHEMBL2017697; CHEMBL520613; DTXSID60185968; 3,3'-(Dodecan-1,12-diyl)bis(5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium) dibromide; AN-28886; 2-[3-[12-[5-(2-hydroxyethyl)-4-methyl-thiazol-3-ium-3-yl]dodecyl]-4-methyl-thiazol-3-ium-5-yl]ethanol dibromide
DMG9MN2 CP Sanofi
DMG9MN2 DT Small molecular drug
DMG9MN2 PC 11377023
DMG9MN2 MW 454.7
DMG9MN2 FM C24H42N2O2S2+2
DMG9MN2 IC InChI=1S/C24H42N2O2S2/c1-21-23(13-17-27)29-19-25(21)15-11-9-7-5-3-4-6-8-10-12-16-26-20-30-24(14-18-28)22(26)2/h19-20,27-28H,3-18H2,1-2H3/q+2
DMG9MN2 CS CC1=C(SC=[N+]1CCCCCCCCCCCC[N+]2=CSC(=C2C)CCO)CCO
DMG9MN2 IK UZPXHZIQHWKNPF-UHFFFAOYSA-N
DMG9MN2 IU 2-[3-[12-[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]dodecyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
DMG9MN2 CA CAS 753439-46-2
DMG9MN2 DE Malaria
DMBLHGP ID DMBLHGP
DMBLHGP DN Saracatinib
DMBLHGP HS Phase 2
DMBLHGP SN H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
DMBLHGP CP AstraZeneca
DMBLHGP TC Anticancer Agents
DMBLHGP DT Small molecular drug
DMBLHGP PC 10302451
DMBLHGP MW 542
DMBLHGP FM C27H32ClN5O5
DMBLHGP IC InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
DMBLHGP CS CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl
DMBLHGP IK OUKYUETWWIPKQR-UHFFFAOYSA-N
DMBLHGP IU N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
DMBLHGP CA CAS 379231-04-6
DMBLHGP DE Solid tumour/cancer; Hematologic tumour; Osteosarcoma
DMUE0AK ID DMUE0AK
DMUE0AK DN Saratin
DMUE0AK HS Phase 2
DMUE0AK CP BioVascular
DMUE0AK DE Inflammation
DM5R89X ID DM5R89X
DM5R89X DN SARIPIDEM
DM5R89X HS Phase 2
DM5R89X SN SL-85.0274; Saripidem; N-[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-ylmethyl]-N-methylbutanamide
DM5R89X DT Small molecular drug
DM5R89X PC 3058746
DM5R89X MW 341.8
DM5R89X FM C19H20ClN3O
DM5R89X IC InChI=1S/C19H20ClN3O/c1-3-6-18(24)22(2)13-16-19(14-8-10-15(20)11-9-14)21-17-7-4-5-12-23(16)17/h4-5,7-12H,3,6,13H2,1-2H3
DM5R89X CS CCCC(=O)N(C)CC1=C(N=C2N1C=CC=C2)C3=CC=C(C=C3)Cl
DM5R89X IK LIFDPEORUVTOCP-UHFFFAOYSA-N
DM5R89X IU N-[[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-N-methylbutanamide
DM5R89X CA CAS 103844-86-6
DM5R89X DE Anxiety disorder
DM1M0PR ID DM1M0PR
DM1M0PR DN Saruplase
DM1M0PR HS Phase 2
DM1M0PR SN Rescupase; CG-4509; PUK, Grunenthal; Pro-urokinase, Grunenthal; Rscu-PA, Grunenthal
DM1M0PR CP Grunenthal GmbH
DM1M0PR DE Thrombosis
DM27KFY ID DM27KFY
DM27KFY DN SB-207266A
DM27KFY HS Phase 2
DM27KFY SN Piboserod hydrochloride; Piboserod HCl; Piboserod (hydrochloride); 178273-87-5; UNII-61Z0VMM0AJ; SB 207266A; 61Z0VMM0AJ; Piboserod hydrochloride [USAN]; SB-207266-A; Piboserod hydrochloride (USAN); N-[(1-Butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide monohydrochloride; SB 207266 hydrochloride; SB-207266A; AC1L42ON; MLS006010278; SCHEMBL2228911; CHEMBL2106927; DTXSID40170453; UABVCZHWRUGYSR-UHFFFAOYSA-N; MolPort-042-665-633; HY-15574A; AKOS030526663; API0004730; SMR004701348; FT-0724495; D05471
DM27KFY DT Small molecular drug
DM27KFY PC 177335
DM27KFY MW 406
DM27KFY FM C22H32ClN3O2
DM27KFY IC InChI=1S/C22H31N3O2.ClH/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25;/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26);1H
DM27KFY CS CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42.Cl
DM27KFY IK UABVCZHWRUGYSR-UHFFFAOYSA-N
DM27KFY IU N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide;hydrochloride
DM27KFY CA CAS 178273-87-5
DM27KFY DE Irritable bowel syndrome
DM8TKG5 ID DM8TKG5
DM8TKG5 DN SB-265610
DM8TKG5 HS Phase 2
DM8TKG5 SN SB 265610; 211096-49-0; CHEMBL38182; UNII-9P785F0579; N-(2-BROMOPHENYL)-N'-(7-CYANO-1H-BENZOTRIAZOL-4-YL)UREA; 9P785F0579; 1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d][1,2,3]triazol-7-yl)urea; sb265610; SCHEMBL1535925; CTK8E9340; DTXSID10175339; MolPort-019-939-274; MolPort-044-561-465; ZINC603064; BCP28242; BDBM50102222; AKOS024457259; NCGC00242491-01; NCGC00242491-02; KB-80496; RT-015648; SB265610, > J-013849; 1-(2-Bromo-phenyl)-3-(7-cyano-3H-benzotriazol-4-yl)-urea; Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-be
DM8TKG5 CP GlaxoSmithKline
DM8TKG5 DT Small molecular drug
DM8TKG5 PC 9841667
DM8TKG5 MW 357.16
DM8TKG5 FM C14H9BrN6O
DM8TKG5 IC InChI=1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)
DM8TKG5 CS C1=CC=C(C(=C1)NC(=O)NC2=CC=C(C3=NNN=C23)C#N)Br
DM8TKG5 IK SEDUMQWZEOMXSO-UHFFFAOYSA-N
DM8TKG5 IU 1-(2-bromophenyl)-3-(7-cyano-2H-benzotriazol-4-yl)urea
DM8TKG5 CA CAS 211096-49-0
DM8TKG5 DE Chronic obstructive pulmonary disease; Asthma
DM4NY58 ID DM4NY58
DM4NY58 DN SB-623
DM4NY58 HS Phase 2
DM4NY58 SN (E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide
DM4NY58 CP GlaxoSmithKline
DM4NY58 TC Anticancer Agents
DM4NY58 DT Small molecular drug
DM4NY58 PC 6918876
DM4NY58 MW 406.5
DM4NY58 FM C24H30N4O2
DM4NY58 IC InChI=1S/C24H30N4O2/c1-3-27(4-2)16-17-28-22-13-10-20(12-15-24(29)26-30)18-21(22)25-23(28)14-11-19-8-6-5-7-9-19/h5-10,12-13,15,18,30H,3-4,11,14,16-17H2,1-2H3,(H,26,29)/b15-12+
DM4NY58 CS CCN(CC)CCN1C2=C(C=C(C=C2)/C=C/C(=O)NO)N=C1CCC3=CC=CC=C3
DM4NY58 IK FFXUDLUXUIJFSS-NTCAYCPXSA-N
DM4NY58 IU (E)-3-[1-[2-(diethylamino)ethyl]-2-(2-phenylethyl)benzimidazol-5-yl]-N-hydroxyprop-2-enamide
DM4NY58 DE Cerebrovascular ischaemia; Ischemic stroke; Stroke; Traumatic brain injury
DMYLBOU ID DMYLBOU
DMYLBOU DN SB-649868
DMYLBOU HS Phase 2
DMYLBOU SN 380899-24-1; UNII-1L1V1K2M4V; SB 649868; 1L1V1K2M4V; SB649868; GTPL4461; N-[[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl]-1-benzofuran-4-carboxamide; SCHEMBL8045969; CHEMBL1272307; DTXSID90191491; EX-A2570; BDBM50417257; AKOS027323765; CS-7584; SB19110; HY-10806; SB-649,868; N-((1-((5-(4-Fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide; 4-Benzofurancarboxamide, N-(((2S)-1-((5-(4-fluorophenyl)-2-m
DMYLBOU CP GlaxoSmithKline
DMYLBOU DT Small molecular drug
DMYLBOU PC 25195495
DMYLBOU MW 477.6
DMYLBOU FM C26H24FN3O3S
DMYLBOU IC InChI=1S/C26H24FN3O3S/c1-16-29-23(24(34-16)17-8-10-18(27)11-9-17)26(32)30-13-3-2-5-19(30)15-28-25(31)21-6-4-7-22-20(21)12-14-33-22/h4,6-12,14,19H,2-3,5,13,15H2,1H3,(H,28,31)/t19-/m0/s1
DMYLBOU CS CC1=NC(=C(S1)C2=CC=C(C=C2)F)C(=O)N3CCCC[C@H]3CNC(=O)C4=C5C=COC5=CC=C4
DMYLBOU IK ZJXIUGNEAIHSBI-IBGZPJMESA-N
DMYLBOU IU N-[[(2S)-1-[5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carbonyl]piperidin-2-yl]methyl]-1-benzofuran-4-carboxamide
DMYLBOU CA CAS 380899-24-1
DMYLBOU DE Insomnia
DMCY785 ID DMCY785
DMCY785 DN SB-656933
DMCY785 HS Phase 2
DMCY785 SN Elubrixin; UNII-MW2AIJ8USP; MW2AIJ8USP; SB-656933-AAF; SB-656933; 688763-64-6; CHEMBL2178579; Elubrixin [USAN:INN]; SB656933; elubirixin; Elubrixin (USAN); SCHEMBL1562280; GTPL8499; DTXSID60218962; BDBM50398333; DB12135; SB 656933; D10332
DMCY785 CP GlaxoSmithKline
DMCY785 DT Small molecular drug
DMCY785 PC 10479502
DMCY785 MW 463.3
DMCY785 FM C17H17Cl2FN4O4S
DMCY785 IC InChI=1S/C17H17Cl2FN4O4S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24/h1-5,21,25H,6-9H2,(H2,22,23,26)
DMCY785 CS C1CN(CCN1)S(=O)(=O)C2=C(C=CC(=C2O)NC(=O)NC3=C(C(=CC=C3)F)Cl)Cl
DMCY785 IK YQYFEGTYCUQBEI-UHFFFAOYSA-N
DMCY785 IU 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea
DMCY785 CA CAS 688763-64-6
DMCY785 DE Chronic obstructive pulmonary disease; Cystic fibrosis
DMRYHWI ID DMRYHWI
DMRYHWI DN SB-705498
DMRYHWI HS Phase 2
DMRYHWI SN SB-705498; 501951-42-4; SB705498; SB 705498; UNII-T74V9O0Y2W; (R)-1-(2-bromophenyl)-3-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)urea; T74V9O0Y2W; 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea; N-(2-Bromophenyl)-N'-[(3R)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl]urea; 1-(2-Bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)-2-pyridyl]pyrrolidin-3-yl]urea; JYILLRHXRVTRSH-GFCCVEGCSA-N; MLS006011113; SCHEMBL1350298; GTPL4311; CHEMBL207433; BMCL163287 Compound 15; BDBM20504
DMRYHWI CP GlaxoSmithKline
DMRYHWI DT Small molecular drug
DMRYHWI PC 9910486
DMRYHWI MW 429.2
DMRYHWI FM C17H16BrF3N4O
DMRYHWI IC InChI=1S/C17H16BrF3N4O/c18-13-3-1-2-4-14(13)24-16(26)23-12-7-8-25(10-12)15-6-5-11(9-22-15)17(19,20)21/h1-6,9,12H,7-8,10H2,(H2,23,24,26)/t12-/m1/s1
DMRYHWI CS C1CN(C[C@@H]1NC(=O)NC2=CC=CC=C2Br)C3=NC=C(C=C3)C(F)(F)F
DMRYHWI IK JYILLRHXRVTRSH-GFCCVEGCSA-N
DMRYHWI IU 1-(2-bromophenyl)-3-[(3R)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea
DMRYHWI CA CAS 501951-42-4
DMRYHWI DE Migraine; Rhinitis
DMRWE5D ID DMRWE5D
DMRWE5D DN SB-728-T
DMRWE5D HS Phase 2
DMRWE5D CP Sangamo BioSciences
DMRWE5D DE Human immunodeficiency virus infection
DM6XJ9S ID DM6XJ9S
DM6XJ9S DN SB-743921
DM6XJ9S HS Phase 2
DM6XJ9S SN N-[1-(3-benzyl-7-chloro-4-oxo-quinazolin-2-yl)propyl]-4-bromo-N-(3-dimethylaminopropyl)benzamide
DM6XJ9S CP GlaxoSmithKline
DM6XJ9S TC Anticancer Agents
DM6XJ9S DT Small molecular drug
DM6XJ9S PC 49867937
DM6XJ9S MW 553.5
DM6XJ9S FM C31H34Cl2N2O3
DM6XJ9S IC InChI=1S/C31H33ClN2O3.ClH/c1-20(2)28(34(17-7-16-33)31(36)23-12-10-21(3)11-13-23)30-26(18-22-8-5-4-6-9-22)29(35)25-15-14-24(32)19-27(25)37-30;/h4-6,8-15,19-20,28H,7,16-18,33H2,1-3H3;1H/t28-;/m1./s1
DM6XJ9S CS CC1=CC=C(C=C1)C(=O)N(CCCN)[C@@H](C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl
DM6XJ9S IK MLMZVWABFOLFGV-LNLSOMNWSA-N
DM6XJ9S IU N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxochromen-2-yl)-2-methylpropyl]-4-methylbenzamide;hydrochloride
DM6XJ9S CA CAS 940929-33-9
DM6XJ9S DE Solid tumour/cancer
DMJRK6D ID DMJRK6D
DMJRK6D DN SB-9200
DMJRK6D HS Phase 2
DMJRK6D SN SB 9200
DMJRK6D CP Spring bank pharmaceuticals
DMJRK6D PC 24737742
DMJRK6D MW 703.6
DMJRK6D FM C25H34N7O13PS
DMJRK6D IC InChI=1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)/t13-,14+,15+,17+,19+,20+,23+,46?/m0/s1
DMJRK6D CS CC(C)OC(=O)OCSP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O[C@@H]4[C@H](O[C@H]([C@@H]4OC)N5C=CC(=O)NC5=O)CO
DMJRK6D IK CJCYTUJOSMYXLE-JDLSZIHUSA-N
DMJRK6D IU [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxyphosphoryl]sulfanylmethyl propan-2-yl carbonate
DMJRK6D CA CAS 942123-43-5
DMJRK6D DE Hepatitis B virus infection
DMG1VXR ID DMG1VXR
DMG1VXR DN SBC-014
DMG1VXR HS Phase 2
DMG1VXR SN AVI-014; Glycosylated recombinant G-CSF (neutropenia), AviGenics; Glycosylated recombinant G-CSF (neutropenia), Synageva
DMG1VXR CP Synageva BioPharma Corp
DMG1VXR DE Neutropenia
DMSUQFJ ID DMSUQFJ
DMSUQFJ DN SBI-087
DMSUQFJ HS Phase 2
DMSUQFJ SN PF-05230895
DMSUQFJ CP Emergent BioSolutions; Pfizer
DMSUQFJ DE Rheumatoid arthritis; Multiple sclerosis
DMGH4Q0 ID DMGH4Q0
DMGH4Q0 DN SC-47085
DMGH4Q0 HS Phase 2
DMGH4Q0 SN Olsalazine; Azodisal; Dipentium; Mirtazanine; Olsalazina; Olsalazina [Spanish]; Olsalazine (INN); Olsalazine [INN:BAN]; Olsalazinum; Olsalazinum [Latin]; Salicylic acid, 5,5'-azodi-; ULS5I8J03O; mordant yellow 5; (E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid); 15722-48-2; 3,3'-Azobis(6-hydroxybenzoic acid); 3,3'-diazene-1,2-diylbis(6-hydroxybenzoic acid); 5,5'-Azobis(salicylic acid); 5,5'-azodisalicylic acid; Benzoic acid, 3,3'-azobis(6-hydroxy-; C.I. Mordant Yellow 5; C14H10N2O6; CHEBI:7770; Rasal; UNII-ULS5I8J03O
DMGH4Q0 PC 22419
DMGH4Q0 MW 302.24
DMGH4Q0 FM C14H10N2O6
DMGH4Q0 IC QQBDLJCYGRGAKP-UHFFFAOYSA-N
DMGH4Q0 CS C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
DMGH4Q0 IK 1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
DMGH4Q0 IU 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
DMGH4Q0 CA CAS 15722-48-2
DMGH4Q0 CB CHEBI:7770
DMGH4Q0 DE Ankylosing spondylitis
DM180VX ID DM180VX
DM180VX DN SC-49483
DM180VX HS Phase 2
DM180VX SN Glycovir; 131262-82-3; UNII-QXJ91425UL; DRG-0193; NSC 670880; Perbutylated-N-butyl-1-deoxynojiromycin; SC 49483; QXJ91425UL; N-Butyl DNJ Prodrug; Butanoic acid, 1-butyl-2-((1-oxobutoxy)methyl)-3,4,5-piperidinetriyl ester, (2R-(2alpha,3beta,4alpha,5beta))-; SC-48334 Prodrug; NSC670880; SC49483; AC1L1TYK; 1,5-(Butylimino)-1-5-dideoxy-D-glucitol tetrabutanoate; AC1Q60AI; SCHEMBL5967912; DTXSID10156986; NSC-670880; DB13106; LS-46130; 1-Butyl-2R,4.alpha.,5.beta.-piperidinetriyl butanoate
DM180VX CP GD Searle & Co
DM180VX DT Small molecular drug
DM180VX PC 60807
DM180VX MW 499.6
DM180VX FM C26H45NO8
DM180VX IC InChI=1S/C26H45NO8/c1-6-11-16-27-17-20(33-22(29)13-8-3)26(35-24(31)15-10-5)25(34-23(30)14-9-4)19(27)18-32-21(28)12-7-2/h19-20,25-26H,6-18H2,1-5H3/t19-,20+,25-,26-/m1/s1
DM180VX CS CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1COC(=O)CCC)OC(=O)CCC)OC(=O)CCC)OC(=O)CCC
DM180VX IK MKGDNVHZSCXBKR-KYVQNOJUSA-N
DM180VX IU [(2R,3R,4R,5S)-3,4,5-tri(butanoyloxy)-1-butylpiperidin-2-yl]methyl butanoate
DM180VX CA CAS 131262-82-3
DM180VX DE Acquired immune deficiency syndrome
DM58HR7 ID DM58HR7
DM58HR7 DN SC-75416
DM58HR7 HS Phase 2
DM58HR7 PC 9858913
DM58HR7 MW 334.72
DM58HR7 FM C15H14ClF3O3
DM58HR7 IC InChI=1S/C15H14ClF3O3/c1-14(2,3)9-6-11-7(5-10(9)16)4-8(13(20)21)12(22-11)15(17,18)19/h4-6,12H,1-3H3,(H,20,21)/t12-/m0/s1
DM58HR7 CS CC(C)(C)C1=C(C=C2C=C([C@H](OC2=C1)C(F)(F)F)C(=O)O)Cl
DM58HR7 IK QGCKNIAMHUUUDI-LBPRGKRZSA-N
DM58HR7 IU (2S)-7-tert-butyl-6-chloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
DM58HR7 CA CAS 215122-74-0
DM58HR7 DE Pain
DMMWCZS ID DMMWCZS
DMMWCZS DN SCH 420814
DMMWCZS HS Phase 2
DMMWCZS SN Preladenant; SCH-420814
DMMWCZS CP Schering-Plough
DMMWCZS DT Small molecular drug
DMMWCZS PC 10117987
DMMWCZS MW 503.6
DMMWCZS FM C25H29N9O3
DMMWCZS IC InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29)
DMMWCZS CS COCCOC1=CC=C(C=C1)N2CCN(CC2)CCN3C4=C(C=N3)C5=NC(=NN5C(=N4)N)C6=CC=CO6
DMMWCZS IK DTYWJKSSUANMHD-UHFFFAOYSA-N
DMMWCZS IU 4-(furan-2-yl)-10-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMMWCZS CA CAS 377727-87-2
DMMWCZS DE Parkinson disease
DMPUAOE ID DMPUAOE
DMPUAOE DN SCH-527123
DMPUAOE HS Phase 2
DMPUAOE SN Navarixin; 473727-83-2; Sch527123; SCH 527123; (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide; MK-7123; CHEMBL216981; (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide; SCHEMBL184744; GTPL8497; KS-00001CQK; CTK8B8735; MolPort-023-331-228; BDBM50200880; MK7123; ANW-61143; ZINC100033051; AKOS016003539; CS-0609; NCGC00390675-01; HY-10198; AX8217127; TC-149888; W-5650; SCH 527123,CAS:473727-83-2; PF-00547659
DMPUAOE CP Pharmacopeia; Schering-Plough
DMPUAOE DT Small molecular drug
DMPUAOE PC 9865554
DMPUAOE MW 397.4
DMPUAOE FM C21H23N3O5
DMPUAOE IC InChI=1S/C21H23N3O5/c1-5-13(15-10-9-11(2)29-15)22-16-17(20(27)19(16)26)23-14-8-6-7-12(18(14)25)21(28)24(3)4/h6-10,13,22-23,25H,5H2,1-4H3/t13-/m1/s1
DMPUAOE CS CC[C@H](C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C
DMPUAOE IK RXIUEIPPLAFSDF-CYBMUJFWSA-N
DMPUAOE IU 2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide
DMPUAOE DE Inflammatory bowel disease; Ulcerative colitis; Chronic obstructive pulmonary disease; Solid tumour/cancer
DMBJY1Z ID DMBJY1Z
DMBJY1Z DN SCH-900271
DMBJY1Z HS Phase 2
DMBJY1Z SN SCH-900271; UNII-G2283XQ6VJ; SCH 900271; G2283XQ6VJ; 915210-50-3; CHEMBL2036958; GTPL8469; SCHEMBL12602910; DTXSID00238609; BDBM50384612; SCH900271; SB17408; DB12433; 2H-Pyrano(2,3-d)pyrimidine-2,4,7(1H,3h)-trione, 5-(3-(1-methylcyclopropyl)propyl)-; 5-(3-(1-Methylcyclopropyl)propyl)-1H-pyrano(2,3-d)pyrimidine-2,4,7(3H)-trione
DMBJY1Z CP Merck
DMBJY1Z DT Small molecular drug
DMBJY1Z PC 56950369
DMBJY1Z MW 276.29
DMBJY1Z FM C14H16N2O4
DMBJY1Z IC InChI=1S/C14H16N2O4/c1-14(5-6-14)4-2-3-8-7-9(17)20-12-10(8)11(18)15-13(19)16-12/h7H,2-6H2,1H3,(H2,15,16,18,19)
DMBJY1Z CS CC1(CC1)CCCC2=CC(=O)OC3=C2C(=O)NC(=O)N3
DMBJY1Z IK ARJKMWXLIHZLQZ-UHFFFAOYSA-N
DMBJY1Z IU 5-[3-(1-methylcyclopropyl)propyl]-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione
DMBJY1Z CA CAS 915210-50-3
DMBJY1Z DE Ischemic stroke
DM67EMK ID DM67EMK
DM67EMK DN SCH-900776
DM67EMK HS Phase 2
DM67EMK SN CHEMBL1643208; MK-8776; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; BCP02883; BDBM50334854; AKOS026750519; MK 8776; NCGC00387868-02; DA-40779; 4CA-1150; BCP0726000317; J3.517.083I; 891494-63-6 pound not SCH900776 pound not SCH-900776; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
DM67EMK CP Merck
DM67EMK DT Small molecular drug
DM67EMK PC 46239015
DM67EMK MW 376.25
DM67EMK FM C15H18BrN7
DM67EMK IC InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3/t9-/m1/s1
DM67EMK CS CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)[C@@H]4CCCNC4
DM67EMK IK GMIZZEXBPRLVIV-SECBINFHSA-N
DM67EMK IU 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3R)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine
DM67EMK CA CAS 891494-63-6
DM67EMK DE Solid tumour/cancer
DMPBKUZ ID DMPBKUZ
DMPBKUZ DN SCH-900978
DMPBKUZ HS Phase 2
DMPBKUZ SN Neurokinin 1 receptor antagonist (emesis), OPKO Health
DMPBKUZ CP OPKO Health Inc
DMPBKUZ PC 11671080
DMPBKUZ MW 539.5
DMPBKUZ FM C25H23F6N5O2
DMPBKUZ IC InChI=1S/C25H23F6N5O2/c1-16(17-9-19(24(26,27)28)11-20(10-17)25(29,30)31)38-14-23(18-5-3-2-4-6-18)8-7-22(12-32,13-33-23)36-15-34-35-21(36)37/h2-6,9-11,15-16,33H,7-8,13-14H2,1H3,(H,35,37)/t16-,22-,23-/m1/s1
DMPBKUZ CS C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@](CN2)(C#N)N3C=NNC3=O)C4=CC=CC=C4
DMPBKUZ IK ACZWFJDLNLZWDP-ZGNKEGEESA-N
DMPBKUZ IU (3S,6S)-6-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-3-(5-oxo-1H-1,2,4-triazol-4-yl)-6-phenylpiperidine-3-carbonitrile
DMPBKUZ CA CAS 873947-10-5
DMPBKUZ DE Cough
DM1C9NQ ID DM1C9NQ
DM1C9NQ DN SCY-635
DM1C9NQ HS Phase 2
DM1C9NQ SN SCY-635; CHEMBL1269597; UNII-WSU5343074; WSU5343074; SCY 635; CID6479267; AC1O57KA; 210759-10-7; BDBM50136473; DB12451; (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-(2-dimethylaminoethylsulfanyl)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM1C9NQ CP SCYNEXIS
DM1C9NQ DT Small molecular drug
DM1C9NQ PC 6479267
DM1C9NQ MW 1321.8
DM1C9NQ FM C66H120N12O13S
DM1C9NQ IC InChI=1S/C66H120N12O13S/c1-27-29-30-42(13)53(79)52-57(83)69-45(28-2)59(85)78(26)65(92-32-31-71(18)19)64(90)75(23)49(36-66(16,17)91)56(82)70-50(40(9)10)62(88)72(20)46(33-37(3)4)55(81)67-43(14)54(80)68-44(15)58(84)73(21)47(34-38(5)6)60(86)74(22)48(35-39(7)8)61(87)76(24)51(41(11)12)63(89)77(52)25/h27,29,37-53,65,79,91H,28,30-36H2,1-26H3,(H,67,81)(H,68,80)(H,69,83)(H,70,82)/b29-27+/t42-,43+,44-,45+,46+,47+,48+,49+,50+,51+,52+,53-,65-/m1/s1
DM1C9NQ CS CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)SCCN(C)C)C
DM1C9NQ IK AQHMBDAHQGYLIU-XNFHFXFQSA-N
DM1C9NQ IU (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM1C9NQ CA CAS 210759-10-7
DM1C9NQ DE Hepatitis C virus infection
DM80HOV ID DM80HOV
DM80HOV DN SDF-1
DM80HOV HS Phase 2
DM80HOV SN JVS-100
DM80HOV CP Juventas Therapeutics
DM80HOV DE Heart failure; Peripheral arterial disease
DMPZ67G ID DMPZ67G
DMPZ67G DN SDZ-281-240
DMPZ67G HS Phase 2
DMPZ67G SN [1R,9S,12S(1'R,3'S),13R,14S,17R,21S,23S,24R,25S,27R]-17-Ethyl-1,14-dihydroxy-12-[2-[3-(hydroxymethyl)cyclopentyl]-1(E)-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22
DMPZ67G DE Pruritus
DM2YIOE ID DM2YIOE
DM2YIOE DN SDZ-MAR-327
DM2YIOE HS Phase 2
DM2YIOE CP Novartis
DM2YIOE DT Small molecular drug
DM2YIOE PC 56603721
DM2YIOE MW 367.5
DM2YIOE FM C23H33N3O
DM2YIOE IC InChI=1S/C23H33N3O/c1-6-23(4,7-2)22(27)25-15-11-18-16-9-8-10-19-21(16)17(14(3)24-19)12-20(18)26(5)13-15/h8-10,15,18,20,24H,6-7,11-13H2,1-5H3,(H,25,27)/t15-,18?,20+/m0/s1
DM2YIOE CS CCC(C)(CC)C(=O)N[C@H]1CC2[C@@H](CC3=C(NC4=CC=CC2=C34)C)N(C1)C
DM2YIOE IK UXRWQKITDPCICD-BEHPGTHXSA-N
DM2YIOE IU N-[(6aR,9S)-5,7-dimethyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-2-ethyl-2-methylbutanamide
DM2YIOE DE Psychotic disorder; Schizophrenia
DMTQ2K0 ID DMTQ2K0
DMTQ2K0 DN SelG1
DMTQ2K0 HS Phase 2
DMTQ2K0 CP Selexys Pharmaceuticals
DMTQ2K0 DT Antibody
DMTQ2K0 DE Vaso-occlusive crisis
DMST4OR ID DMST4OR
DMST4OR DN Selgantolimod
DMST4OR HS Phase 2
DMST4OR SN 2004677-13-6; 4-yl)amino]-2-methylhexan-1-ol; GS-9688; (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-; (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino]-2-methylhexan-1-ol; (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol; Selgantolimod (USAN/INN); CHEMBL4594258; SCHEMBL18109405; GTPL10889; EX-A4247; GS9688; HY-109137; compound (R)-7 [PMID: 32407112]; CS-0086927; D11871; U57
DMST4OR CP Gilead Sciences
DMST4OR DT Small molecular drug
DMST4OR PC 122585078
DMST4OR MW 293.34
DMST4OR FM C14H20FN5O
DMST4OR IC InChI=1S/C14H20FN5O/c1-3-4-5-14(2,8-21)20-12-11-10(18-13(16)19-12)6-9(15)7-17-11/h6-7,21H,3-5,8H2,1-2H3,(H3,16,18,19,20)/t14-/m1/s1
DMST4OR CS CCCC[C@](C)(CO)NC1=NC(=NC2=C1N=CC(=C2)F)N
DMST4OR IK HTCJUBZBSJQWBW-CQSZACIVSA-N
DMST4OR IU (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino]-2-methylhexan-1-ol
DMST4OR DE Hepatitis B
DMDLOBZ ID DMDLOBZ
DMDLOBZ DN Selinexor oral
DMDLOBZ HS Phase 2
DMDLOBZ CP Karyopharm Therapeutics Newton, MA
DMDLOBZ DE Recurrent glioblastoma
DMQM3IX ID DMQM3IX
DMQM3IX DN SELODENOSON
DMQM3IX HS Phase 2
DMQM3IX SN DT-009; DTI-0009; RG-14202; Selodenoson; N6-Cyclopentyl-N5'-ethyladenosine-5'-uronamide
DMQM3IX DT Small molecular drug
DMQM3IX PC 3082555
DMQM3IX MW 376.4
DMQM3IX FM C17H24N6O4
DMQM3IX IC InChI=1S/C17H24N6O4/c1-2-18-16(26)13-11(24)12(25)17(27-13)23-8-21-10-14(19-7-20-15(10)23)22-9-5-3-4-6-9/h7-9,11-13,17,24-25H,2-6H2,1H3,(H,18,26)(H,19,20,22)/t11-,12+,13-,17+/m0/s1
DMQM3IX CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NC4CCCC4)O)O
DMQM3IX IK GWVQGVCXFNYGFP-PFHKOEEOSA-N
DMQM3IX IU (2S,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMQM3IX CA CAS 110299-05-3
DMQM3IX DE Cardiac arrhythmias
DMJH6EL ID DMJH6EL
DMJH6EL DN Selurampanel
DMJH6EL HS Phase 2
DMJH6EL SN BGG-492; BGG-492A; AMPA antagonist (oral, epilepsy), Novartis
DMJH6EL CP Novartis pharmaceuticals
DMJH6EL DT Small molecular drug
DMJH6EL PC 45381907
DMJH6EL MW 377.4
DMJH6EL FM C16H19N5O4S
DMJH6EL IC InChI=1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23)
DMJH6EL CS CC(C)C1=C(C=C2C(=C1)NC(=O)N(C2=O)NS(=O)(=O)C)C3=CC=NN3C
DMJH6EL IK MCECSFFXUPEPDB-UHFFFAOYSA-N
DMJH6EL IU N-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1H-quinazolin-3-yl]methanesulfonamide
DMJH6EL CA CAS 912574-69-7
DMJH6EL DE Epilepsy
DMIJNLG ID DMIJNLG
DMIJNLG DN Semapimod
DMIJNLG HS Phase 2
DMIJNLG SN CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences
DMIJNLG CP Cytokine PharmaSciences Inc
DMIJNLG DT Small molecular drug
DMIJNLG PC 5745214
DMIJNLG MW 744.9
DMIJNLG FM C34H52N18O2
DMIJNLG IC InChI=1S/C34H52N18O2/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52)/b45-19+,46-20+,47-21+,48-22+
DMIJNLG CS C/C(=N\\N=C(N)N)/C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C
DMIJNLG IK PWDYHMBTPGXCSN-VCBMUGGBSA-N
DMIJNLG IU N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide
DMIJNLG CA CAS 352513-83-8
DMIJNLG DE Inflammatory bowel disease; Autoimmune diabetes
DMLDBQ5 ID DMLDBQ5
DMLDBQ5 DN SEN-196
DMLDBQ5 HS Phase 2
DMLDBQ5 SN EX-527; SEN-0014196; SIRT1 inhibitors (Huntingtons disease), Elixir/Siena; Sirtuin-1 inhibitors (oral, Huntington's disease), Elixir/Siena
DMLDBQ5 CP Elixir Pharmaceuticals Inc
DMLDBQ5 DT Small molecular drug
DMLDBQ5 PC 5113032
DMLDBQ5 MW 248.71
DMLDBQ5 FM C13H13ClN2O
DMLDBQ5 IC InChI=1S/C13H13ClN2O/c14-7-4-5-11-10(6-7)8-2-1-3-9(13(15)17)12(8)16-11/h4-6,9,16H,1-3H2,(H2,15,17)
DMLDBQ5 CS C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N
DMLDBQ5 IK FUZYTVDVLBBXDL-UHFFFAOYSA-N
DMLDBQ5 IU 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMLDBQ5 CA CAS 49843-98-3
DMLDBQ5 CB CHEBI:90369
DMLDBQ5 DE Huntington disease
DMOH8LD ID DMOH8LD
DMOH8LD DN Senktide
DMOH8LD HS Phase 2
DMOH8LD SN Senktide; CHEMBL106124; Succinyl-6-asp-8-Me-phe-substance P (6-11); Substance P (6-11), succinyl-asp(6)-Me-phe(8)-; Substance P (6-11), succinyl-aspartyl(6)-methylphenylalanine(8)-; L-Methioninamide, N-(3-carboxy-1-oxopropyl)-L-alpha-aspartyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl-
DMOH8LD DT Small molecular drug
DMOH8LD PC 108147
DMOH8LD MW 842
DMOH8LD FM C40H55N7O11S
DMOH8LD IC InChI=1S/C40H55N7O11S/c1-24(2)19-28(37(55)45-27(36(41)54)17-18-59-4)44-33(49)23-42-39(57)31(21-26-13-9-6-10-14-26)47(3)40(58)30(20-25-11-7-5-8-12-25)46-38(56)29(22-35(52)53)43-32(48)15-16-34(50)51/h5-14,24,27-31H,15-23H2,1-4H3,(H2,41,54)(H,42,57)(H,43,48)(H,44,49)(H,45,55)(H,46,56)(H,50,51)(H,52,53)/t27-,28-,29-,30-,31-/m0/s1
DMOH8LD CS CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
DMOH8LD IK HMHYXLVEFVGOPM-QKUYTOGTSA-N
DMOH8LD IU (3S)-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutanoic acid
DMOH8LD CA CAS 106128-89-6
DMOH8LD DE Ischemic stroke; Epilepsy
DMA12HB ID DMA12HB
DMA12HB DN SEP--4199
DMA12HB HS Phase 2
DMA12HB CP Sunovion Pharmaceuticals
DMA12HB DT Small molecular drug
DMA12HB DE Bipolar disorder
DMD8RU0 ID DMD8RU0
DMD8RU0 DN SEphB4-HSA
DMD8RU0 HS Phase 2
DMD8RU0 CP VasGene Therapeutics
DMD8RU0 DT Recombinant protein
DMD8RU0 DE Solid tumour/cancer; Kaposi sarcoma
DMDW5ZC ID DMDW5ZC
DMDW5ZC DN SER-100
DMDW5ZC HS Phase 2
DMDW5ZC SN ORL1 receptor agonists, Zealand Pharma; ZP-120; ZP-120C
DMDW5ZC CP Zealand Pharma A/S
DMDW5ZC PC 25086585
DMDW5ZC MW 1781.2
DMDW5ZC FM C85H141N27O15
DMDW5ZC IC InChI=1S/C85H141N27O15/c1-52(113)101-61(29-18-46-98-84(94)95)73(117)110-70(49-54-33-37-57(115)38-34-54)82(126)111-69(48-53-31-35-56(114)36-32-53)81(125)109-68(30-19-47-99-85(96)97)80(124)112-71(50-55-51-100-59-21-3-2-20-58(55)59)83(127)108-67(28-10-17-45-92)79(123)107-66(27-9-16-44-91)78(122)106-65(26-8-15-43-90)77(121)105-64(25-7-14-42-89)76(120)104-63(24-6-13-41-88)75(119)103-62(23-5-12-40-87)74(118)102-60(72(93)116)22-4-11-39-86/h2-3,20-21,31-38,51,60-71,100,114-115H,4-19,22-30,39-50,86-92H2,1H3,(H2,93,116)(H,101,113)(H,102,118)(H,103,119)(H,104,120)(H,105,121)(H,106,122)(H,107,123)(H,108,127)(H,109,125)(H,110,117)(H,111,126)(H,112,124)(H4,94,95,98)(H4,96,97,99)/t60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-/m0/s1
DMDW5ZC CS CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N
DMDW5ZC IK GJLXVWOMRRWCIB-MERZOTPQSA-N
DMDW5ZC IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide
DMDW5ZC CA CAS 383123-18-0
DMDW5ZC DE Heart failure
DMYT470 ID DMYT470
DMYT470 DN Seribantumab
DMYT470 HS Phase 2
DMYT470 CP Merrimack Pharmaceuticals Cambridge, MA
DMYT470 DE Colorectal cancer; Head and neck cancer; Non-small-cell lung cancer
DMTNDM2 ID DMTNDM2
DMTNDM2 DN Setrobuvir
DMTNDM2 HS Phase 2
DMTNDM2 CP Anadys Pharmaceuticals
DMTNDM2 DT Small molecular drug
DMTNDM2 PC 135565932
DMTNDM2 MW 560.6
DMTNDM2 FM C25H25FN4O6S2
DMTNDM2 IC InChI=1S/C25H25FN4O6S2/c1-37(33,34)28-17-8-9-18-19(11-17)38(35,36)29-24(27-18)21-23(31)20-14-4-5-15(10-14)22(20)30(25(21)32)12-13-2-6-16(26)7-3-13/h2-3,6-9,11,14-15,20,22,28,31H,4-5,10,12H2,1H3,(H,27,29)/t14-,15+,20+,22-/m0/s1
DMTNDM2 CS CS(=O)(=O)NC1=CC2=C(C=C1)NC(=NS2(=O)=O)C3=C([C@@H]4[C@H]5CC[C@H](C5)[C@@H]4N(C3=O)CC6=CC=C(C=C6)F)O
DMTNDM2 IK DEKOYVOWOVJMPM-RLHIPHHXSA-N
DMTNDM2 IU N-[3-[(1R,2S,7R,8S)-3-[(4-fluorophenyl)methyl]-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-7-yl]methanesulfonamide
DMTNDM2 CA CAS 1071517-39-9
DMTNDM2 DE Hepatitis C virus infection
DM9IMEZ ID DM9IMEZ
DM9IMEZ DN Seviteronel
DM9IMEZ HS Phase 2
DM9IMEZ SN INO-464; 1610537-15-9; CHEMBL3264610; ZINC139920592; AKOS030526607; DB12275; CS-3139; HY-15996; 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)-; UNII-8S5OIN36X4 component ZBRAJOQFSNYJMF-SFHVURJKSA-N
DM9IMEZ CP Innocrin Pharmaceuticals Durham, NC
DM9IMEZ PC 78357816
DM9IMEZ MW 399.3
DM9IMEZ FM C18H17F4N3O3
DM9IMEZ IC InChI=1S/C18H17F4N3O3/c1-9(2)18(26,15-8-23-25-24-15)12-4-3-10-6-13(27-16(19)20)14(28-17(21)22)7-11(10)5-12/h3-9,16-17,26H,1-2H3,(H,23,24,25)/t18-/m0/s1
DM9IMEZ CS CC(C)[C@](C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O
DM9IMEZ IK ZBRAJOQFSNYJMF-SFHVURJKSA-N
DM9IMEZ IU (1S)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol
DM9IMEZ CA CAS 1610537-15-9
DM9IMEZ DE Breast cancer; Prostate cancer
DML10K3 ID DML10K3
DML10K3 DN SF1126
DML10K3 HS Phase 2
DML10K3 SN CC-1126; SF-1126; L-Serine, N2-(1,4-dioxo-4-((4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl)methoxy)butyl)-L-arginylglycyl-L-alpha-aspartyl-, inner salt
DML10K3 CP Semafore Pharma
DML10K3 TC Anticancer Agents
DML10K3 DT Small molecular drug
DML10K3 PC 66577114
DML10K3 MW 852.8
DML10K3 FM C39H48N8O14
DML10K3 IC InChI=1S/C39H48N8O14/c40-39(41)42-13-5-10-26(36(55)43-20-31(51)45-27(18-33(52)53)37(56)46-28(21-48)38(57)58)44-30(50)11-12-34(54)60-22-47(14-16-59-17-15-47)32-19-29(49)25-9-4-8-24(35(25)61-32)23-6-2-1-3-7-23/h1-4,6-9,19,26-28,48H,5,10-18,20-22H2,(H9-,40,41,42,43,44,45,46,50,51,52,53,55,56,57,58)/t26-,27-,28-/m0/s1
DML10K3 CS C1COCC[N+]1(COC(=O)CCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-])C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DML10K3 IK SVNJBEMPMKWDCO-KCHLEUMXSA-N
DML10K3 IU (2S)-2-[[(2S)-3-carboxy-2-[[2-[[(2S)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate
DML10K3 DE Solid tumour/cancer; Head and neck cancer; Hepatocellular carcinoma
DMVIWNK ID DMVIWNK
DMVIWNK DN SFV IL-12 gene therapy
DMVIWNK HS Phase 2
DMVIWNK SN LipoVIL12; SFV IL-12 gene therapy (liposomal); SFV IL-12 gene therapy (liposomal), Regulon
DMVIWNK CP Regulon Inc
DMVIWNK DE Breast cancer
DMAQW9M ID DMAQW9M
DMAQW9M DN SFX-01
DMAQW9M HS Phase 2
DMAQW9M CP Evgen Pharma
DMAQW9M DE Breast cancer; Subarachnoid hemorrhage
DMJ9M5D ID DMJ9M5D
DMJ9M5D DN SGN-30
DMJ9M5D HS Phase 2
DMJ9M5D DT Antibody
DMJ9M5D DE Solid tumour/cancer
DMA4LNE ID DMA4LNE
DMA4LNE DN SGN-LIV1A
DMA4LNE HS Phase 2
DMA4LNE SN Ladiratuzumab Vedotin
DMA4LNE CP Seattle Genetics
DMA4LNE DT Antibody drug conjugate
DMA4LNE DE Small-cell lung cancer; Non-small cell lung cancer
DM5XYFH ID DM5XYFH
DM5XYFH DN SGS742
DM5XYFH HS Phase 2
DM5XYFH SN CGP-36742; CGP36742
DM5XYFH CP Saegis Pharmaceuticals
DM5XYFH DT Small molecular drug
DM5XYFH PC 130021
DM5XYFH MW 179.2
DM5XYFH FM C7H18NO2P
DM5XYFH IC InChI=1S/C7H18NO2P/c1-2-3-6-11(9,10)7-4-5-8/h2-8H2,1H3,(H,9,10)
DM5XYFH CS CCCCP(=O)(CCCN)O
DM5XYFH IK ONNMDRQRSGKZCN-UHFFFAOYSA-N
DM5XYFH IU 3-aminopropyl(butyl)phosphinic acid
DM5XYFH CA CAS 123690-78-8
DM5XYFH DE Schizophrenia
DMLYIPA ID DMLYIPA
DMLYIPA DN SGT-53
DMLYIPA HS Phase 2
DMLYIPA SN P53 gene stimulator (solid tumor), Synergene Therapeutics
DMLYIPA CP Synergene Therapeutics Inc
DMLYIPA DT Gene therapy
DMLYIPA DE Solid tumour/cancer; Pancreatic cancer; Recurrent glioblastoma
DMGIRM1 ID DMGIRM1
DMGIRM1 DN SH-529
DMGIRM1 HS Phase 2
DMGIRM1 SN Glucoprime; GLYC-101; GLYC-101); Iloprost beta-cyclodextrin clathrate; Z-101; ZK-96944; (1-3)-(1-6)-beta-D-glucan,Glycotex
DMGIRM1 CP Bayer Schering Pharma AG; Novogen Ltd
DMGIRM1 DE Peripheral vascular disease
DMIQB13 ID DMIQB13
DMIQB13 DN SHAPE
DMIQB13 HS Phase 2
DMIQB13 DE Lymphoma; Cutaneous T-cell lymphoma
DMT4UC1 ID DMT4UC1
DMT4UC1 DN Sibrotuzumab
DMT4UC1 HS Phase 2
DMT4UC1 DT Antibody
DMT4UC1 DE Metastatic colorectal cancer
DM39RXO ID DM39RXO
DM39RXO DN SiG12D-LODER
DM39RXO HS Phase 2
DM39RXO CP Silenseed
DM39RXO DT Small interfering RNA
DM39RXO DE Pancreatic cancer
DM75RFJ ID DM75RFJ
DM75RFJ DN Siplizumab
DM75RFJ HS Phase 2
DM75RFJ SN Siplizumab (USAN/INN)
DM75RFJ CP Medlmmune; AstraZeneca
DM75RFJ DT Antibody
DM75RFJ DE Psoriasis vulgaris; Lymphoma
DMTXHJ9 ID DMTXHJ9
DMTXHJ9 DN Sirolimus
DMTXHJ9 HS Phase 2
DMTXHJ9 SN Rapammune; Sirolimus; Rapamycin; I2190A; 53123-88-9; (-)-Rapamycin; Wy 090217; SIIA 9268A; Rapamune; I-2190A; AY-22989; RAPA; NSC 226080; I 2190A; AY 22989; Rapamycin (Sirolimus); WY-090217; Antibiotic AY 22989; UNII-W36ZG6FT64; SILA 9268A; CHEBI:9168; CCRIS 9024; W36ZG6FT64; HSDB 7284; C51H79NO13; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Supralimus; Sirolimus
DMTXHJ9 TC Antiviral Agents
DMTXHJ9 DT Small molecular drug
DMTXHJ9 PC 5284616
DMTXHJ9 MW 914.2
DMTXHJ9 FM C51H79NO13
DMTXHJ9 IC InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
DMTXHJ9 CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
DMTXHJ9 IK QFJCIRLUMZQUOT-HPLJOQBZSA-N
DMTXHJ9 IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMTXHJ9 CA CAS 53123-88-9
DMTXHJ9 CB CHEBI:9168
DMTXHJ9 DE Coronavirus Disease 2019 (COVID-19)
DM90DTM ID DM90DTM
DM90DTM DN Sirukumab
DM90DTM HS Phase 2
DM90DTM SN Sirukumab (USAN); Sirukumab (genetical recombination) (JAN); D10080; 1194585-53-9
DM90DTM TC Antiviral Agents
DM90DTM DT Monoclonal antibody
DM90DTM DE Coronavirus Disease 2019 (COVID-19)
DMA9VGW ID DMA9VGW
DMA9VGW DN Sitafloxacin
DMA9VGW HS Phase 2
DMA9VGW SN 127254-12-0; Gracevit; Sitafloxacin Sesquihydrate; DU 6859; 163253-35-8; UNII-3GJC60U4Q8; DU-6859a; Sitafloxacin isomer II; DU 6859A; C19H18ClF2N3O3; 3GJC60U4Q8; CHEBI:4304; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid; Sitafloxacin [INN]; 7-((S)-7-AMINO-5-AZASPIRO[2.4]HEPTAN-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID; STFX; DU-6859; 127254-10-8; Sitafloxacin isomer III (RRS); 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-3-quinolinecarboxylic acid; 7-[(7S)-7-azanyl-5-azaspiro[2.4]heptan-5-yl]-8-chloranyl-6-fluoranyl-1-[(1R,2S)-2-fluoranylcyclopropyl]-4-oxidanylidene-quinoline-3-carboxylic acid; SITAFLOXACIN ISOMER III(RRS); SITAFLOXACINISOMER; SCHEMBL74553; 7-((7S)-Amino-5-azaspiro(2,4)heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2R)-cis-2-fluoro-1-cyclopropyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid; 7-(7-Amino-5-azaspiro(2.4)heptan-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid sesquihydrate; SITAFLOXACINISOMER(RRS); SITAFLOXACINISOMER(RSR); DU6859a; CHEMBL108821; AMSP00027; GTPL11040; HY-B0395; ZINC3795983; AKOS015962212; AC-1388; ACN-048224; AM85541; compound 33 [PMID: 7932562]; YF10030; (-)-7-((7S)-Amino-5-azaspiro(2,4)hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxoq-3-uinolonecarboxylic acid; 3-Quinolinecarboxylic acid, 7-(7-amino-5-azaspiro(2.4)hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, (1R-(1alpha(S*),2alpha))-; 3-Quinolinecarboxylic acid, 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-; 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid; AT-21032; AB01568244_01; 253S358; A805671; A805673; J-519022; (-)-7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluoro-1-cyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 273401-03-9; 3-Quinolinecarboxylic acid, 7-((7S)-7-amino-5-azaspiro(24)hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxo-; 7-((7S)-7-Amino-5-azaspiro[2.4]hept-5-yl)-1-((1S,2S)-2-fluorocyclopropyl)-8-chloro-6-fluoro-4-oxohydroquinoline-3-carboxylic acid; 7-((S)-7-Amino-5-azaspiro[2.4]Heptan-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1 R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydro-3-quinolinecarboxyli c acid; rel-7-((R)-7-Amino-5-azaspiro[2.4]heptan-5-yl)-8-chloro-6-fluoro-1-((1S,2R)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DMA9VGW DT Small molecular drug
DMA9VGW PC 461399
DMA9VGW MW 409.8
DMA9VGW FM C19H18ClF2N3O3
DMA9VGW IC InChI=1S/C19H18ClF2N3O3/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28)/t10-,12+,13+/m0/s1
DMA9VGW CS C1CC12CN(C[C@H]2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)[C@@H]5C[C@@H]5F)F
DMA9VGW IK PNUZDKCDAWUEGK-CYZMBNFOSA-N
DMA9VGW IU 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid
DMA9VGW CA CAS 127254-12-0
DMA9VGW CB CHEBI:4304
DMA9VGW DE Escherichia coli infection
DMY3JWO ID DMY3JWO
DMY3JWO DN Sitamaquine
DMY3JWO HS Phase 2
DMY3JWO SN WR-006026; WR-6026
DMY3JWO CP GlaxoSmithKline; Walter Reed Army Institute of Research
DMY3JWO DT Small molecular drug
DMY3JWO PC 42548
DMY3JWO MW 343.5
DMY3JWO FM C21H33N3O
DMY3JWO IC InChI=1S/C21H33N3O/c1-5-24(6-2)14-10-8-7-9-12-22-20-16-18(25-4)15-19-17(3)11-13-23-21(19)20/h11,13,15-16,22H,5-10,12,14H2,1-4H3
DMY3JWO CS CCN(CC)CCCCCCNC1=CC(=CC2=C(C=CN=C12)C)OC
DMY3JWO IK RVAKDGYPIVSYEU-UHFFFAOYSA-N
DMY3JWO IU N',N'-diethyl-N-(6-methoxy-4-methylquinolin-8-yl)hexane-1,6-diamine
DMY3JWO CA CAS 57695-04-2
DMY3JWO DE Infectious disease
DMNRHMX ID DMNRHMX
DMNRHMX DN SKF-110679
DMNRHMX HS Phase 2
DMNRHMX SN U-75799E
DMNRHMX CP SmithKline Beecham plc
DMNRHMX DT Small molecular drug
DMNRHMX PC 4345065
DMNRHMX MW 873
DMNRHMX FM C46H56N12O6
DMNRHMX IC InChI=1S/C46H56N12O6/c1-27(54-44(62)39(20-29-23-51-35-15-7-5-13-32(29)35)57-43(61)34(48)22-31-25-50-26-53-31)42(60)56-40(21-30-24-52-36-16-8-6-14-33(30)36)46(64)58-38(19-28-11-3-2-4-12-28)45(63)55-37(41(49)59)17-9-10-18-47/h2-8,11-16,23-27,34,37-40,51-52H,9-10,17-22,47-48H2,1H3,(H2,49,59)(H,50,53)(H,54,62)(H,55,63)(H,56,60)(H,57,61)(H,58,64)
DMNRHMX CS CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CC6=CN=CN6)N
DMNRHMX IK WZHKXNSOCOQYQX-UHFFFAOYSA-N
DMNRHMX IU 6-amino-2-[[2-[[2-[2-[[2-[[2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMNRHMX DE Growth hormone deficiency
DMRHD6B ID DMRHD6B
DMRHD6B DN SKL-NP
DMRHD6B HS Phase 2
DMRHD6B DE Pain
DMCDON3 ID DMCDON3
DMCDON3 DN SLV 306
DMCDON3 HS Phase 2
DMCDON3 SN Daglutril; SLV 306; SLV-306; SLV306; UNII-KKV299446X; 182821-27-8; KKV299446X; ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid; Daglutril [INN]; 2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 1H-1-Benzazepine-1-acetic acid, 3-(((1-(2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,S*))-
DMCDON3 CP Solvay Pharma
DMCDON3 DT Small molecular drug
DMCDON3 PC 3038505
DMCDON3 MW 534.6
DMCDON3 FM C31H38N2O6
DMCDON3 IC InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1
DMCDON3 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)CC2(CCCC2)C(=O)N[C@H]3CCC4=CC=CC=C4N(C3=O)CC(=O)O
DMCDON3 IK XMQODGUTLZXUGZ-RPBOFIJWSA-N
DMCDON3 IU 2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DMCDON3 CA CAS 182821-27-8
DMCDON3 DE Acute decompensated heart failure
DM867BJ ID DM867BJ
DM867BJ DN SLV320
DM867BJ HS Phase 2
DM867BJ SN SLV-320; 4-[(4-phenyl-3,5,7-triazabicyclo[4.3.0]nona-2,4,8,10-tetraen-2-yl)amino]cyclohexan-1-ol
DM867BJ CP Solvay
DM867BJ DT Small molecular drug
DM867BJ PC 9953065
DM867BJ MW 308.4
DM867BJ FM C18H20N4O
DM867BJ IC InChI=1S/C18H20N4O/c23-14-8-6-13(7-9-14)20-18-15-10-11-19-17(15)21-16(22-18)12-4-2-1-3-5-12/h1-5,10-11,13-14,23H,6-9H2,(H2,19,20,21,22)
DM867BJ CS C1CC(CCC1NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4)O
DM867BJ IK RBZNJGHIKXAKQE-UHFFFAOYSA-N
DM867BJ IU 4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexan-1-ol
DM867BJ CA CAS 251945-92-3
DM867BJ DE Heart failure
DMXCJKY ID DMXCJKY
DMXCJKY DN SLV-334
DMXCJKY HS Phase 2
DMXCJKY CP Solvay SA
DMXCJKY PC 11215055
DMXCJKY MW 556.6
DMXCJKY FM C33H36N2O6
DMXCJKY IC InChI=1S/C33H36N2O6/c36-29(37)21-35-28-13-4-2-9-24(28)16-17-27(30(35)38)34-32(41)33(18-5-6-19-33)20-25(31(39)40)15-14-23-11-7-10-22-8-1-3-12-26(22)23/h1-4,7-13,25,27H,5-6,14-21H2,(H,34,41)(H,36,37)(H,39,40)/t25-,27+/m1/s1
DMXCJKY CS C1CCC(C1)(C[C@@H](CCC2=CC=CC3=CC=CC=C32)C(=O)O)C(=O)N[C@H]4CCC5=CC=CC=C5N(C4=O)CC(=O)O
DMXCJKY IK LOFDNSDPZTVIIO-VPUSJEBWSA-N
DMXCJKY IU (2R)-2-[[1-[[(3S)-1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]carbamoyl]cyclopentyl]methyl]-4-naphthalen-1-ylbutanoic acid
DMXCJKY CA CAS 182821-33-6
DMXCJKY DE Brain injury
DMM3AI8 ID DMM3AI8
DMM3AI8 DN SLx-4090
DMM3AI8 HS Phase 2
DMM3AI8 SN SLx 4090; SCHEMBL1484252
DMM3AI8 CP Surface
DMM3AI8 DT Small molecular drug
DMM3AI8 PC 53497429
DMM3AI8 MW 546.5
DMM3AI8 FM C31H25F3N2O4
DMM3AI8 IC InChI=1S/C31H25F3N2O4/c1-39-27-9-5-8-26(28(27)20-10-13-23(14-11-20)31(32,33)34)29(37)35-24-15-12-22-19-36(17-16-21(22)18-24)30(38)40-25-6-3-2-4-7-25/h2-15,18H,16-17,19H2,1H3,(H,35,37)
DMM3AI8 CS COC1=CC=CC(=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=CC4=C(CN(CC4)C(=O)OC5=CC=CC=C5)C=C3
DMM3AI8 IK AZUIUVJESCFSLJ-UHFFFAOYSA-N
DMM3AI8 IU phenyl 6-[[3-methoxy-2-[4-(trifluoromethyl)phenyl]benzoyl]amino]-3,4-dihydro-1H-isoquinoline-2-carboxylate
DMM3AI8 CA CAS 913541-47-6
DMM3AI8 DE Hyperlipidaemia; Dyslipidemia; Diabetic complication
DMOLTAD ID DMOLTAD
DMOLTAD DN SM-04690
DMOLTAD HS Phase 2
DMOLTAD CP Samumed
DMOLTAD PC 135565709
DMOLTAD MW 505.5
DMOLTAD FM C29H24FN7O
DMOLTAD IC InChI=1S/C29H24FN7O/c1-16(2)8-26(38)33-21-10-19(12-31-13-21)17-6-7-24-22(11-17)28(37-36-24)29-34-25-15-32-14-23(27(25)35-29)18-4-3-5-20(30)9-18/h3-7,9-16H,8H2,1-2H3,(H,33,38)(H,34,35)(H,36,37)
DMOLTAD CS CC(C)CC(=O)NC1=CN=CC(=C1)C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C=NC=C5C6=CC(=CC=C6)F
DMOLTAD IK AQDWDWAYVBQMAM-UHFFFAOYSA-N
DMOLTAD IU N-[5-[3-[7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl]pyridin-3-yl]-3-methylbutanamide
DMOLTAD CA CAS 1467093-03-3
DMOLTAD DE Osteoarthritis
DMTJOQX ID DMTJOQX
DMTJOQX DN SMP-986
DMTJOQX HS Phase 2
DMTJOQX SN Afacifenacin
DMTJOQX CP Sumitomo Pharmaceuticals Co Ltd
DMTJOQX DT Small molecular drug
DMTJOQX PC 10188853
DMTJOQX MW 481.5
DMTJOQX FM C27H26F3N3O2
DMTJOQX IC InChI=1S/C27H26F3N3O2/c28-27(29,30)35-22-10-6-7-19(17-22)18-32-15-13-21(14-16-32)33-25(20-8-2-1-3-9-20)23-11-4-5-12-24(23)31-26(33)34/h1-12,17,21,25H,13-16,18H2,(H,31,34)
DMTJOQX CS C1CN(CCC1N2C(C3=CC=CC=C3NC2=O)C4=CC=CC=C4)CC5=CC(=CC=C5)OC(F)(F)F
DMTJOQX IK IJUMFEAYOMCXAQ-UHFFFAOYSA-N
DMTJOQX IU 4-phenyl-3-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-1,4-dihydroquinazolin-2-one
DMTJOQX DE Overactive bladder
DMCD6G1 ID DMCD6G1
DMCD6G1 DN SMT-C1100
DMCD6G1 HS Phase 2
DMCD6G1 SN BMN-195; Utrophin modulators (Duchenne muscular dystrophy); VOXC-1100; Utrophin modulators (Duchennemuscular dystrophy), VASTox; Utorphin upregulators (Duchenne muscular dystrophy), VASTox/University of Oxford; Utrophin modulators (Duchenne muscular dystrophy), Summit/BioMarin; Utropine inducer (Duchenne muscular dystrophy), Summit/BioMarin
DMCD6G1 CP Summit Corp plc
DMCD6G1 DT Small molecular drug
DMCD6G1 PC 25109292
DMCD6G1 MW 337.4
DMCD6G1 FM C19H15NO3S
DMCD6G1 IC InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3
DMCD6G1 CS CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3
DMCD6G1 IK KSGCNXAZROJSNW-UHFFFAOYSA-N
DMCD6G1 IU 5-ethylsulfonyl-2-naphthalen-2-yl-1,3-benzoxazole
DMCD6G1 CA CAS 945531-77-1
DMCD6G1 DE Duchenne dystrophy
DMPN314 ID DMPN314
DMPN314 DN SNA-120
DMPN314 HS Phase 2
DMPN314 SN Pegcantratinib; Pegcantratinib [INN]; Pegcantratinib [USAN]; Pegcantratinib [WHO-DD]; UNII-VG44NU1168; VG44NU1168; 1233363-33-1
DMPN314 CP Creabilis Therapeutics Canterbury, United Kingdom
DMPN314 PC 132494168
DMPN314 MW 580.6
DMPN314 FM C32H28N4O7
DMPN314 IC InChI=1S/C32H28N4O7/c1-31-32(29(38)34(30(39)43-32)11-12-41-14-13-40-2)15-22(42-31)35-20-9-5-3-7-17(20)24-25-19(16-33-28(25)37)23-18-8-4-6-10-21(18)36(31)27(23)26(24)35/h3-10,22H,11-16H2,1-2H3,(H,33,37)
DMPN314 CS CC12C3(CC(O1)N4C5=CC=CC=C5C6=C7C(=C8C9=CC=CC=C9N2C8=C64)CNC7=O)C(=O)N(C(=O)O3)CCOCCOC
DMPN314 IK MTDVEOMKVDOULD-UHFFFAOYSA-N
DMPN314 IU 3-[2-(2-methoxyethoxy)ethyl]-15'-methylspiro[1,3-oxazolidine-5,16'-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene]-2,3',4-trione
DMPN314 DE Plaque psoriasis; Pruritus
DMO4EYX ID DMO4EYX
DMO4EYX DN Soblidotin
DMO4EYX HS Phase 2
DMO4EYX SN Auristatin PE; Dolastatin derivative; TZT-1027; YHI-501; ZT-1027
DMO4EYX CP Teikoku Hormone Manufacturing Co Ltd
DMO4EYX DT Small molecular drug
DMO4EYX PC 6918315
DMO4EYX MW 702
DMO4EYX FM C39H67N5O6
DMO4EYX IC InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)/t27-,28+,30-,31+,33-,34-,35-,36+/m0/s1
DMO4EYX CS CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)NCCC2=CC=CC=C2)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C
DMO4EYX IK DZMVCVHATYROOS-ZBFGKEHZSA-N
DMO4EYX IU (2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(2-phenylethylamino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
DMO4EYX CA CAS 149606-27-9
DMO4EYX CB CHEBI:32135
DMO4EYX DE Solid tumour/cancer
DMKNIVG ID DMKNIVG
DMKNIVG DN Sodium butyrate
DMKNIVG HS Phase 2
DMKNIVG SN Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)
DMKNIVG CP Allerderm
DMKNIVG DT Small molecular drug
DMKNIVG PC 5222465
DMKNIVG MW 110.09
DMKNIVG FM C4H7NaO2
DMKNIVG IC InChI=1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1
DMKNIVG CS CCCC(=O)[O-].[Na+]
DMKNIVG IK MFBOGIVSZKQAPD-UHFFFAOYSA-M
DMKNIVG IU sodium;butanoate
DMKNIVG CA CAS 156-54-7
DMKNIVG CB CHEBI:64103
DMKNIVG DE Refractory sickle cell ulcers; Acute myeloid leukaemia
DMH5MVE ID DMH5MVE
DMH5MVE DN Sodium stibogluconate
DMH5MVE HS Phase 2
DMH5MVE SN Lenocta; Sodium stibogluconate (cancer); VQD-001; Sodium stibogluconate (cancer), Greenwich; Sodium stibogluconate (cancer), VioQuest
DMH5MVE CP VioQuest
DMH5MVE DE Solid tumour/cancer
DM157U0 ID DM157U0
DM157U0 DN Sofinicline
DM157U0 HS Phase 2
DM157U0 SN Sofinicline; ABT 894; Sofiniclin; ABT-894; UNII-SQC232V4YY; 799279-80-4; SQC232V4YY; CHEMBL238465; A-422894.0; Sofinicline [USAN:INN]; Sofinicline (USAN); SCHEMBL650488; A 422894.0;Sofiniclin; A 422894.0; MBQYQLWSBRANKQ-IMTBSYHQSA-N; BDBM50224483; ZINC28866069; CS-6792; DB12527; HY-14824; KB-74391; D09382; (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane; (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]-heptane; (1S,5S)-3-(5,6-Dichloro-pyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane; (1S, 5S)-3-(5,6-d
DM157U0 CP Abbott Laboratories; NeuroSearch
DM157U0 DT Small molecular drug
DM157U0 PC 10131048
DM157U0 MW 244.12
DM157U0 FM C10H11Cl2N3
DM157U0 IC InChI=1S/C10H11Cl2N3/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15/h1,3,6,9,13H,2,4-5H2/t6-,9+/m0/s1
DM157U0 CS C1[C@H]2CN(C[C@H]2N1)C3=CC(=C(N=C3)Cl)Cl
DM157U0 IK MBQYQLWSBRANKQ-IMTBSYHQSA-N
DM157U0 IU (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane
DM157U0 CA CAS 799279-80-4
DM157U0 DE Attention deficit hyperactivity disorder
DML2ZWR ID DML2ZWR
DML2ZWR DN Solubilized type 1 native bovine collagen
DML2ZWR HS Phase 2
DML2ZWR SN Solubilized type 1 native bovine collagen (oral, scleroderma); Solubilized type 1 native bovine collagen (oral, scleroderma), arGentis/University of Tennessee
DML2ZWR CP University of Tennessee
DML2ZWR DE Scleroderma
DMKCBSM ID DMKCBSM
DMKCBSM DN SOM3355
DMKCBSM HS Phase 2
DMKCBSM CP SOM Biotech Cambridge, MA
DMKCBSM DE Tardive dyskinesia; Huntington disease
DMTVS3A ID DMTVS3A
DMTVS3A DN Somatoprim
DMTVS3A HS Phase 2
DMTVS3A SN SCHEMBL10652839
DMTVS3A CP DeveloGen
DMTVS3A DT Small molecular drug
DMTVS3A PC 9919857
DMTVS3A MW 1123.3
DMTVS3A FM C60H74N12O10
DMTVS3A IC InChI=1S/C60H74N12O10/c1-37(73)54-59(81)70-50(31-39-18-6-3-7-19-39)60(82)72(36-51(62)74)29-15-26-52(75)63-28-14-25-53(76)66-47(30-38-16-4-2-5-17-38)56(78)68-49(33-41-35-65-45-23-11-9-21-43(41)45)58(80)69-48(32-40-34-64-44-22-10-8-20-42(40)44)57(79)67-46(55(77)71-54)24-12-13-27-61/h2-11,16-23,34-35,37,46-50,54,64-65,73H,12-15,24-33,36,61H2,1H3,(H2,62,74)(H,63,75)(H,66,76)(H,67,79)(H,68,78)(H,69,80)(H,70,81)(H,71,77)/t37-,46+,47+,48-,49+,50+,54+/m1/s1
DMTVS3A CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N(CCCC(=O)NCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC(=O)N)CC7=CC=CC=C7)O
DMTVS3A IK ABFNTRQPWNXUHA-VEVJRHMJSA-N
DMTVS3A IU 2-[(3S,6S,9S,12R,15S,18S)-9-(4-aminobutyl)-3,18-dibenzyl-6-[(1R)-1-hydroxyethyl]-12,15-bis(1H-indol-3-ylmethyl)-2,5,8,11,14,17,20,25-octaoxo-1,4,7,10,13,16,19,24-octazacyclooctacos-1-yl]acetamide
DMTVS3A CA CAS 252845-37-7
DMTVS3A DE Acromegaly
DMK3RL8 ID DMK3RL8
DMK3RL8 DN Somatropin intranasal rhGH
DMK3RL8 HS Phase 2
DMK3RL8 SN ALTU-238; CP-024; HGH-191; Somatropin (intranasal); Human growth hormone (crystalline), Altus/Genentech; RhGH (oral, eligen), Novartis; Somatropin (crystalline), Altus/Genentech; Somatropin (sustained release, subcutaneous), Althea; Humatrope (oral, CADDYS), Lilly/Emisphere; Recombinant human growth hormone (oral, CADDYS), Lilly/Emisphere; RhGH (oral, CADDYS), Lilly/Emisphere; RhGH (oral, eligen), Emisphere/Novartis; Somatropin (nasal spray, CriticalSorb, growth hormone deficiency), Critical Pharmaceuticals; Somatropin (oral, CADDYS), Lilly/Emisphere; Somatropin (sustained release, subcutaneous), Altus/Genentech; Human growth hormone, (sustained release, subcutaneous), Altus/Genentech
DMK3RL8 CP Nastech Pharmaceutical; Emisphere Technologies Inc; Critical Pharmaceuticals Ltd; Altus Pharmaceuticals Inc
DMK3RL8 DE Growth hormone deficiency
DME53YS ID DME53YS
DME53YS DN Sotrastaurin acetate
DME53YS HS Phase 2
DME53YS SN Sotrastaurin acetate; UNII-R1SIA15KZ1; 908351-31-5; R1SIA15KZ1; Sotrastaurin acetate [USAN]; AEB 071; Sotrastaurin acetate (USAN); SCHEMBL3846239; CHEMBL2105655; KB-74525; D09718; 3-(1H-Indol-3-yl)-4-(2-(4-methylpiperazin-1-yl)quinazolin-4-yl)-1H-pyrrole-2,5-dione acetate; 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-, acetate
DME53YS CP Novartis
DME53YS DT Small molecular drug
DME53YS PC 24779745
DME53YS MW 498.5
DME53YS FM C27H26N6O4
DME53YS IC InChI=1S/C25H22N6O2.C2H4O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18;1-2(3)4/h2-9,14,26H,10-13H2,1H3,(H,29,32,33);1H3,(H,3,4)
DME53YS CS CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65
DME53YS IK RVEUYBMXVVDLFO-UHFFFAOYSA-N
DME53YS IU acetic acid;3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione
DME53YS CA CAS 908351-31-5
DME53YS DE Renal transplantation
DM2UKJV ID DM2UKJV
DM2UKJV DN SP-333
DM2UKJV HS Phase 2
DM2UKJV SN Guanylate cyclase-C receptor agonist (peptide, UC), Synergy Pharmaceuticals; Guanylate cyclase-C receptor analog (peptide, UC), Synergy Pharmaceuticals
DM2UKJV CP Synergy Pharmaceuticals Inc
DM2UKJV DE Ulcerative colitis
DM9OPK3 ID DM9OPK3
DM9OPK3 DN SPD-556
DM9OPK3 HS Phase 2
DM9OPK3 SN M-0002
DM9OPK3 CP Movetis
DM9OPK3 DT Small molecular drug
DM9OPK3 PC 73030
DM9OPK3 MW 382.4
DM9OPK3 FM C21H18O5S
DM9OPK3 IC InChI=1S/C21H18O5S/c1-13-11-15(22)7-9-17(13)21(18-10-8-16(23)12-14(18)2)19-5-3-4-6-20(19)27(24,25)26-21/h3-12,22-23H,1-2H3
DM9OPK3 CS CC1=C(C=CC(=C1)O)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=C(C=C(C=C4)O)C
DM9OPK3 IK OLQIKGSZDTXODA-UHFFFAOYSA-N
DM9OPK3 IU 4-[3-(4-hydroxy-2-methylphenyl)-1,1-dioxo-2,1lambda6-benzoxathiol-3-yl]-3-methylphenol
DM9OPK3 CA CAS 2303-01-7
DM9OPK3 DE Heart failure
DMJH2AC ID DMJH2AC
DMJH2AC DN SPD-557
DMJH2AC HS Phase 2
DMJH2AC SN M-0003; Gastroprokinetic compound (gastroparesis), Janssen; Gastroprokinetic compound (gastroparesis), Movetis
DMJH2AC CP Janssen Pharmaceutica NV
DMJH2AC PC 9823762
DMJH2AC MW 425.9
DMJH2AC FM C21H32ClN3O4
DMJH2AC IC InChI=1S/C21H32ClN3O4/c1-21(2)10-15-18(23)16(22)9-14(19(15)29-21)20(27)24-11-13-5-7-25(12-17(13)26)6-4-8-28-3/h9,13,17,26H,4-8,10-12,23H2,1-3H3,(H,24,27)/t13-,17+/m0/s1
DMJH2AC CS CC1(CC2=C(O1)C(=CC(=C2N)Cl)C(=O)NC[C@@H]3CCN(C[C@H]3O)CCCOC)C
DMJH2AC IK FOUUNSGQVBGYQM-SUMWQHHRSA-N
DMJH2AC IU 4-amino-5-chloro-N-[[(3S,4S)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl]methyl]-2,2-dimethyl-3H-1-benzofuran-7-carboxamide
DMJH2AC CA CAS 219984-49-3
DMJH2AC DE Diabetic gastroparesis
DMKJ9LU ID DMKJ9LU
DMKJ9LU DN SPD602
DMKJ9LU HS Phase 2
DMKJ9LU CP Shire
DMKJ9LU DE Anemia
DM26AHR ID DM26AHR
DM26AHR DN SPI-1005
DM26AHR HS Phase 2
DM26AHR SN Ebselen [INN]; Ebselene; Ebselene [French]; Ebseleno; Ebseleno [Spanish]; Ebselenum; Ebselenum [Latin]; Harmokisane; PZ 51; PZ-51; PZ51; RP 60931; SPI-1005; SPI-3005; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-Phenyl-1,2-benzisoselenazolin-3-one; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; DR 3305; DR-3305; E 3520
DM26AHR TC Antiviral Agents
DM26AHR DT Small molecular drug
DM26AHR PC 3194
DM26AHR MW 274.19
DM26AHR FM C13H9NOSe
DM26AHR IC InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DM26AHR CS C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DM26AHR IK DYEFUKCXAQOFHX-UHFFFAOYSA-N
DM26AHR IU 2-phenyl-1,2-benzoselenazol-3-one
DM26AHR CA CAS 60940-34-3
DM26AHR CB CHEBI:77543
DM26AHR DE Reperfusion injury and stroke; Coronavirus Disease 2019 (COVID-19)
DMNPRMC ID DMNPRMC
DMNPRMC DN SPI-1620
DMNPRMC HS Phase 2
DMNPRMC SN 142569-99-1; SPI-1620; Suc[Glu9,Ala11,15]ET-110-21; GTPL3886; IRL1620; IRL2620; AKOS024456459
DMNPRMC CP Spectrum
DMNPRMC DT Small molecular drug
DMNPRMC PC 16133819
DMNPRMC MW 1820.9
DMNPRMC FM C86H117N17O27
DMNPRMC IC InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
DMNPRMC CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
DMNPRMC IK DXPHNGAMYPPTBJ-TZMIJSMNSA-N
DMNPRMC IU (4S)-4-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-(3-carboxypropanoylamino)propanoyl]amino]butanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMNPRMC CA CAS 142569-99-1
DMNPRMC DE Solid tumour/cancer
DMHC2AW ID DMHC2AW
DMHC2AW DN SPI-205
DMHC2AW HS Phase 2
DMHC2AW CP SPECTRUM pharmaceuticals
DMHC2AW DE Parkinson disease
DM7NJWY ID DM7NJWY
DM7NJWY DN Spiroglumide
DM7NJWY HS Phase 2
DM7NJWY SN UNII-EZS5V8UN4Y; 137795-35-8; EZS5V8UN4Y; CHEMBL283820; CR-2194; (4R)-5-(8-azaspiro[45]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid; (R)-gamma-(3,5-Dichlorobenzamido)-delta-oxo-8-azaspiro(45)decane-8-valeric acid; Spiroglumide [INN]; AC1Q3LYL; AC1L24DH; SCHEMBL7920324; CTK0H9697; DTXSID60160311; FJCZHMXAGBYXHJ-QGZVFWFLSA-N; BDBM50048772; (R)-5-(8-Aza-spiro[45]dec-8-yl)-4-(3,5-dichloro-benzoylamino)-5-oxo-pentanoic acid; Radaxafine HCl
DM7NJWY DT Small molecular drug
DM7NJWY PC 65987
DM7NJWY MW 441.3
DM7NJWY FM C21H26Cl2N2O4
DM7NJWY IC InChI=1S/C21H26Cl2N2O4/c22-15-11-14(12-16(23)13-15)19(28)24-17(3-4-18(26)27)20(29)25-9-7-21(8-10-25)5-1-2-6-21/h11-13,17H,1-10H2,(H,24,28)(H,26,27)/t17-/m1/s1
DM7NJWY CS C1CCC2(C1)CCN(CC2)C(=O)[C@@H](CCC(=O)O)NC(=O)C3=CC(=CC(=C3)Cl)Cl
DM7NJWY IK FJCZHMXAGBYXHJ-QGZVFWFLSA-N
DM7NJWY IU (4R)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid
DM7NJWY CA CAS 137795-35-8
DM7NJWY DE Neuropathic pain; Stomach disease
DMRXCUQ ID DMRXCUQ
DMRXCUQ DN SPL-108
DMRXCUQ HS Phase 2
DMRXCUQ CP Splash Pharmaceuticals
DMRXCUQ DT Peptide
DMRXCUQ DE Ovarian epithelial cancer; Ovarian cancer
DMZIC4Q ID DMZIC4Q
DMZIC4Q DN SPN-812
DMZIC4Q HS Phase 2
DMZIC4Q CP Supernus Pharmaceuticals
DMZIC4Q DE Attention deficit hyperactivity disorder
DMOVQP8 ID DMOVQP8
DMOVQP8 DN SPP-600
DMOVQP8 HS Phase 2
DMOVQP8 SN SPP-630; SPP-635
DMOVQP8 CP Speedel Pharma
DMOVQP8 DE Hypertension
DMFAO5G ID DMFAO5G
DMFAO5G DN S-PRAnt
DMFAO5G HS Phase 2
DMFAO5G SN S-PRAnt (symptoms of uterine fibroids)
DMFAO5G CP Bayer AG
DMFAO5G DE Uterine fibroids
DMWK9BX ID DMWK9BX
DMWK9BX DN SQ-109
DMWK9BX HS Phase 2
DMWK9BX SN SQ-37; SQ-59; Antibiotics (tuberculosis), Sequella; Second-generation EMB, Sequella; Second-generation ethambutol, Sequella
DMWK9BX CP Sequella
DMWK9BX DT Small molecular drug
DMWK9BX PC 5274428
DMWK9BX MW 330.5
DMWK9BX FM C22H38N2
DMWK9BX IC InChI=1S/C22H38N2/c1-16(2)5-4-6-17(3)7-8-23-9-10-24-22-20-12-18-11-19(14-20)15-21(22)13-18/h5,7,18-24H,4,6,8-15H2,1-3H3/b17-7+
DMWK9BX CS CC(=CCC/C(=C/CNCCNC1C2CC3CC(C2)CC1C3)/C)C
DMWK9BX IK JFIBVDBTCDTBRH-REZTVBANSA-N
DMWK9BX IU N'-(2-adamantyl)-N-[(2E)-3,7-dimethylocta-2,6-dienyl]ethane-1,2-diamine
DMWK9BX CA CAS 502487-67-4
DMWK9BX DE Bacterial infection; Tuberculosis
DMRFO34 ID DMRFO34
DMRFO34 DN SR 16234
DMRFO34 HS Phase 2
DMRFO34 SN 229634-98-4; TS 108; TAS-108; SR 16234; SR16234; UNII-9B29N23K7E; 9B29N23K7E; SCHEMBL2836841; DTXSID30177512; C33H47NO3.C6H8O7; (7alpha)-21-(4-((Diethylamino)methyl)-2-methoxyphenoxy)-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol 2-hydroxy-1,2,3-propanetricarboxylate; Y1847; 354808-47-2; (7R,8S,9S,13R,14S,17R)-17-(2-(4-((Diethylamino)methyl)-2-methoxyphenoxy)ethyl)-7,13-dimethyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-ol 2-hydroxypropane-1,2,3-tricarboxylate
DMRFO34 CP SRI International
DMRFO34 DT Small molecular drug
DMRFO34 PC 9874874
DMRFO34 MW 697.9
DMRFO34 FM C39H55NO10
DMRFO34 IC InChI=1S/C33H47NO3.C6H8O7/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4;7-3(8)1-6(13,5(11)12)2-4(9)10/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22-,25-,28-,29+,32-,33-;/m1./s1
DMRFO34 CS CCN(CC)CC1=CC(=C(C=C1)OCC[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3[C@@H](CC5=C4C=CC(=C5)O)C)C)OC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMRFO34 IK VOHOCSJONOJOSD-SCIDSJFVSA-N
DMRFO34 IU (7R,8S,9S,13R,14S,17R)-17-[2-[4-(diethylaminomethyl)-2-methoxyphenoxy]ethyl]-7,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-ol;2-hydroxypropane-1,2,3-tricarboxylic acid
DMRFO34 CA CAS 229634-98-4
DMRFO34 DE Breast cancer
DMNAECP ID DMNAECP
DMNAECP DN SR-147778
DMNAECP HS Phase 2
DMNAECP SN Surinabant; SR-147778; UNII-SF8R9VCB0X; 288104-79-0; SR147778; SR 147778; SF8R9VCB0X; CHEMBL189676; Surinabant [INN]; DSSTox_CID_27357; DSSTox_RID_82293; DSSTox_GSID_47357; SCHEMBL675894; GTPL9233; DTXSID2047357; CHEBI:125484; ZINC1549068; Tox21_300239; BDBM50171290; DB13070; NCGC00254070-01; NCGC00247959-01; 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide; LS-193786; FT-0766481; CAS-288104-79-0; BRD-K09557221-001-01-6
DMNAECP DT Small molecular drug
DMNAECP PC 9849616
DMNAECP MW 522.299
DMNAECP FM C23H23BrCl2N4O
DMNAECP IC InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31)
DMNAECP CS CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br
DMNAECP IK HMXDWDSNPRNUKI-UHFFFAOYSA-N
DMNAECP IU 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMNAECP CA CAS 288104-79-0
DMNAECP CB CHEBI:125484
DMNAECP DE Obesity
DMFDA4Y ID DMFDA4Y
DMFDA4Y DN SR-2640
DMFDA4Y HS Phase 2
DMFDA4Y SN SR 2640; SR-2640; SR 2640 Hydrochloride; 105350-26-3; CHEMBL18132; SR2640; Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]-; QMPB; Benzoic acid, 2-((3-(2-quinolinylmethoxy)phenyl)amino)-; SR-01000076219; Tocris-1804; Lopac-S-7690; AC1L2TN9; Lopac0_001079; 2-(3-(2-Quinolylmethoxy)phenylamino)benzoic acid; MLS002153402; cid_128355; GTPL3329; SCHEMBL9119607; CTK8F0698; CHEBI:104023; HMS3263G20; HMS2236C03; ZINC596951; HMS3373N15; Tox21_501079; BDBM50006798; AKOS030239522; LP01079; CCG-205156; NCGC00015965-02; NCGC00015965-04
DMFDA4Y DT Small molecular drug
DMFDA4Y PC 128355
DMFDA4Y MW 370.4
DMFDA4Y FM C23H18N2O3
DMFDA4Y IC InChI=1S/C23H18N2O3/c26-23(27)20-9-2-4-11-22(20)24-17-7-5-8-19(14-17)28-15-18-13-12-16-6-1-3-10-21(16)25-18/h1-14,24H,15H2,(H,26,27)
DMFDA4Y CS C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)NC4=CC=CC=C4C(=O)O
DMFDA4Y IK LMPZHLXYBWGGNT-UHFFFAOYSA-N
DMFDA4Y IU 2-[3-(quinolin-2-ylmethoxy)anilino]benzoic acid
DMFDA4Y CA CAS 105350-26-3
DMFDA4Y CB CHEBI:104023
DMFDA4Y DE Asthma
DMQSN7B ID DMQSN7B
DMQSN7B DN SR-31747
DMQSN7B HS Phase 2
DMQSN7B SN SR-317417A
DMQSN7B CP Sanofi-aventis; Sanofi-Synthelabo
DMQSN7B DT Small molecular drug
DMQSN7B PC 6439330
DMQSN7B MW 396.4
DMQSN7B FM C23H35Cl2N
DMQSN7B IC InChI=1S/C23H34ClN.ClH/c1-2-25(21-13-7-4-8-14-21)17-9-10-19-15-16-22(23(24)18-19)20-11-5-3-6-12-20;/h9-10,15-16,18,20-21H,2-8,11-14,17H2,1H3;1H/b10-9-;
DMQSN7B CS CCN(C/C=C\\C1=CC(=C(C=C1)C2CCCCC2)Cl)C3CCCCC3.Cl
DMQSN7B IK HKHPCMBPASXYGP-KVVVOXFISA-N
DMQSN7B IU N-[(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]-N-ethylcyclohexanamine;hydrochloride
DMQSN7B CA CAS 132173-07-0
DMQSN7B DE Rheumatoid arthritis
DMTOCIV ID DMTOCIV
DMTOCIV DN SR-43845
DMTOCIV HS Phase 2
DMTOCIV SN N-[3-(3-Pyridyl)propionyl]-L-phenylalanyl-L-histidyl-cyclostatinyl-L-isoleucyl-1,1-di(hydroxymethyl)ethylamide; N-[3-(3-Pyridyl)propionyl]-L-phenylalanyl-L-histidyl-(3S,4S)-4-amino-3-hydroxy-5-cyclohexylpentanoyl-L-isoleucyl-1,1-di(hydroxymethyl)ethylamide; [S-(R*,R*)]-5-Cyclohexyl-2,4,5-trideoxy-N-[1-[[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]carbonyl]-2-methylbutyl]-4-[[N-[N-[1-oxo-3-(3-pyridinyl)propyl]-L-phenylalanyl]-L-histidyl]amino-L-threo
DMTOCIV DT Small molecular drug
DMTOCIV PC 163918
DMTOCIV MW 833
DMTOCIV FM C44H64N8O8
DMTOCIV IC InChI=1S/C44H64N8O8/c1-4-29(2)40(43(60)52-44(3,26-53)27-54)51-39(57)23-37(55)34(20-30-12-7-5-8-13-30)49-42(59)36(22-33-25-46-28-47-33)50-41(58)35(21-31-14-9-6-10-15-31)48-38(56)18-17-32-16-11-19-45-24-32/h6,9-11,14-16,19,24-25,28-30,34-37,40,53-55H,4-5,7-8,12-13,17-18,20-23,26-27H2,1-3H3,(H,46,47)(H,48,56)(H,49,59)(H,50,58)(H,51,57)(H,52,60)
DMTOCIV CS CCC(C)C(C(=O)NC(C)(CO)CO)NC(=O)CC(C(CC1CCCCC1)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC3=CC=CC=C3)NC(=O)CCC4=CN=CC=C4)O
DMTOCIV IK NZGWKVVFXREROW-UHFFFAOYSA-N
DMTOCIV IU 2-[[5-cyclohexyl-3-hydroxy-4-[[3-(1H-imidazol-5-yl)-2-[[3-phenyl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]propanoyl]amino]pentanoyl]amino]-N-(1,3-dihydroxy-2-methylpropan-2-yl)-3-methylpentanamide
DMTOCIV CA CAS 114037-60-4
DMTOCIV DE Glaucoma/ocular hypertension
DMW6UA3 ID DMW6UA3
DMW6UA3 DN SR-46559A
DMW6UA3 HS Phase 2
DMW6UA3 SN 6-[2-(Diethylamino)-2-methylpropylamino]-3-phenyl-4-propylpyridazine sesquifumarate
DMW6UA3 DT Small molecular drug
DMW6UA3 PC 57348184
DMW6UA3 MW 1029.2
DMW6UA3 FM C54H76N8O12
DMW6UA3 IC InChI=1S/2C21H32N4.3C4H4O4/c2*1-6-12-18-15-19(22-16-21(4,5)25(7-2)8-3)23-24-20(18)17-13-10-9-11-14-17;3*5-3(6)1-2-4(7)8/h2*9-11,13-15H,6-8,12,16H2,1-5H3,(H,22,23);3*1-2H,(H,5,6)(H,7,8)
DMW6UA3 CS CCCC1=CC(=NN=C1C2=CC=CC=C2)NCC(C)(C)N(CC)CC.CCCC1=CC(=NN=C1C2=CC=CC=C2)NCC(C)(C)N(CC)CC.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
DMW6UA3 IK AEOGOPZZLSQJKM-UHFFFAOYSA-N
DMW6UA3 IU but-2-enedioic acid;2-N,2-N-diethyl-2-methyl-1-N-(6-phenyl-5-propylpyridazin-3-yl)propane-1,2-diamine
DMW6UA3 CA CAS 137733-33-6
DMW6UA3 DE Cognitive impairment
DM5GAC4 ID DM5GAC4
DM5GAC4 DN SRD-441
DM5GAC4 HS Phase 2
DM5GAC4 SN Aureostat; ST-441; STP-01a; Protease inhibitor (atopic dermatitis), Surface Therapeutics
DM5GAC4 CP Surface Therapeutics Ltd
DM5GAC4 DE Atopic dermatitis
DMYAXNM ID DMYAXNM
DMYAXNM DN SRK-015
DMYAXNM HS Phase 2
DMYAXNM SN Apitegromab
DMYAXNM CP Scholar Rock
DMYAXNM DT Antibody
DMYAXNM DE Spinal muscular atrophy
DMR09IH ID DMR09IH
DMR09IH DN SRP-9001
DMR09IH HS Phase 2
DMR09IH CP Sarepta Therapeutics
DMR09IH DT Gene therapy
DMR09IH DE Duchenne dystrophy
DMKOTUJ ID DMKOTUJ
DMKOTUJ DN SRX246
DMKOTUJ HS Phase 2
DMKOTUJ CP Azevan Pharmaceuticals
DMKOTUJ DT Small molecular drug
DMKOTUJ DE Fear-related disorder; Anxiety disorder; Intermittent explosive disorder; Huntington disease; Post-traumatic stress disorder
DMMU41F ID DMMU41F
DMMU41F DN SRX-246
DMMU41F HS Phase 2
DMMU41F SN AVN-518; SRX-246-HCI; Vasopressin V1a antagonist (capsule/oral, stress-related affective illness/anxiety), Azevan Pharmaceutoicals
DMMU41F CP Azevan Pharmaceuticals Inc
DMMU41F DT Small molecular drug
DMMU41F PC 44428550
DMMU41F MW 703.9
DMMU41F FM C42H49N5O5
DMMU41F IC InChI=1S/C42H49N5O5/c1-30(32-16-8-3-9-17-32)43-40(49)36(28-38(48)45-26-22-34(23-27-45)44-24-12-5-13-25-44)46-35(21-20-31-14-6-2-7-15-31)39(41(46)50)47-37(29-52-42(47)51)33-18-10-4-11-19-33/h2-4,6-11,14-21,30,34-37,39H,5,12-13,22-29H2,1H3,(H,43,49)/b21-20+/t30-,35-,36-,37-,39+/m1/s1
DMMU41F CS C[C@H](C1=CC=CC=C1)NC(=O)[C@@H](CC(=O)N2CCC(CC2)N3CCCCC3)N4[C@@H]([C@@H](C4=O)N5[C@H](COC5=O)C6=CC=CC=C6)/C=C/C7=CC=CC=C7
DMMU41F IK FJUKOXWSIGULLE-JVOQCOEYSA-N
DMMU41F IU (2R)-4-oxo-2-[(3S,4R)-2-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-4-[(E)-2-phenylethenyl]azetidin-1-yl]-N-[(1R)-1-phenylethyl]-4-(4-piperidin-1-ylpiperidin-1-yl)butanamide
DMMU41F CA CAS 512784-93-9
DMMU41F DE Anxiety disorder; Post-traumatic stress disorder
DMGJEB8 ID DMGJEB8
DMGJEB8 DN SSR125543
DMGJEB8 HS Phase 2
DMGJEB8 SN SSR 125543; 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine
DMGJEB8 CP Sanofi-Aventis
DMGJEB8 DT Small molecular drug
DMGJEB8 PC 5282340
DMGJEB8 MW 483
DMGJEB8 FM C27H28ClFN2OS
DMGJEB8 IC InChI=1S/C27H28ClFN2OS/c1-6-11-31(24(13-19-8-9-19)20-10-7-16(2)23(29)14-20)27-30-26(18(4)33-27)21-12-17(3)25(32-5)15-22(21)28/h1,7,10,12,14-15,19,24H,8-9,11,13H2,2-5H3/t24-/m0/s1
DMGJEB8 CS CC1=C(C=C(C=C1)[C@H](CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F
DMGJEB8 IK IEAKXXNRGSLYTQ-DEOSSOPVSA-N
DMGJEB8 IU 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine
DMGJEB8 CA CAS 752253-39-7
DMGJEB8 CB CHEBI:34969
DMGJEB8 DE Anxiety disorder; Congenital adrenal hyperplasia
DMCMD93 ID DMCMD93
DMCMD93 DN SSR149415
DMCMD93 HS Phase 2
DMCMD93 SN Nelivaptan; SSR 149415; 439687-69-1; UNII-3TY57MQ4OA; SR-149415; SSR-149415; 3TY57MQ4OA; CHEMBL582857; Nelivaptan [INN]; DSSTox_CID_27358; DSSTox_RID_82294; DSSTox_GSID_47358; GTPL2202; DTXSID7047358; SCHEMBL14517029; MolPort-042-665-640; Tox21_300240; BDBM50299343; ZINC42833251; DB12643; SSR-149,415; NCGC00254222-01; NCGC00247960-01; CAS-439687-69-1; (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide; Nelivaptan; 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide
DMCMD93 CP Sanofi-Aventis
DMCMD93 DT Small molecular drug
DMCMD93 PC 9895468
DMCMD93 MW 630.1
DMCMD93 FM C30H32ClN3O8S
DMCMD93 IC InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1
DMCMD93 CS CN(C)C(=O)[C@@H]1C[C@H](CN1[C@]2(C3=C(C=CC(=C3)Cl)N(C2=O)S(=O)(=O)C4=C(C=C(C=C4)OC)OC)C5=CC=CC=C5OC)O
DMCMD93 IK NJXZWIIMWNEOGJ-WEWKHQNJSA-N
DMCMD93 IU (2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide
DMCMD93 CA CAS 439687-69-1
DMCMD93 DE Anxiety disorder; Major depressive disorder
DMA0QZH ID DMA0QZH
DMA0QZH DN SSR-180575
DMA0QZH HS Phase 2
DMA0QZH SN 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide
DMA0QZH DT Small molecular drug
DMA0QZH PC 9930560
DMA0QZH MW 394.9
DMA0QZH FM C21H19ClN4O2
DMA0QZH IC InChI=1S/C21H19ClN4O2/c1-24(2)18(27)12-16-19-15-10-9-13(22)11-17(15)25(3)20(19)21(28)26(23-16)14-7-5-4-6-8-14/h4-11H,12H2,1-3H3
DMA0QZH CS CN1C2=C(C=CC(=C2)Cl)C3=C1C(=O)N(N=C3CC(=O)N(C)C)C4=CC=CC=C4
DMA0QZH IK HJSQVJOROCIILI-UHFFFAOYSA-N
DMA0QZH IU 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide
DMA0QZH CA CAS 220448-02-2
DMA0QZH DE Rheumatoid arthritis
DMVZ01T ID DMVZ01T
DMVZ01T DN SSR240600
DMVZ01T HS Phase 2
DMVZ01T SN Burapitant; SSR-240600; SCHEMBL1281822; CHEMBL3544947; BDBM86055; SSR-240600C; AN-27922; L001672
DMVZ01T DT Small molecular drug
DMVZ01T PC 9917944
DMVZ01T MW 682.5
DMVZ01T FM C31H35Cl2F6N3O3
DMVZ01T IC InChI=1S/C31H35Cl2F6N3O3/c1-28(2,27(40)44)20-5-8-41(9-6-20)10-7-29(21-3-4-24(32)25(33)17-21)18-42(11-12-45-29)26(43)15-19-13-22(30(34,35)36)16-23(14-19)31(37,38)39/h3-4,13-14,16-17,20H,5-12,15,18H2,1-2H3,(H2,40,44)
DMVZ01T CS CC(C)(C1CCN(CC1)CCC2(CN(CCO2)C(=O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=CC(=C(C=C4)Cl)Cl)C(=O)N
DMVZ01T IK ZLNYUCXXSDDIFU-UHFFFAOYSA-N
DMVZ01T IU 2-[1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]piperidin-4-yl]-2-methylpropanamide
DMVZ01T DE Urinary incontinence
DMFNZPY ID DMFNZPY
DMFNZPY DN SSR-240612
DMFNZPY HS Phase 2
DMFNZPY SN N2-[3(R)-(1,3-Benzodioxol-5-yl)-3-(6-methoxynaphthalen-2-ylsulfonamido)propionyl]-4-[2(R),6(S)-dimethylpiperidin-1-ylmethyl]-N1-isopropyl-N1-methyl-D-phenylalaninamide hydrochloride
DMFNZPY DT Small molecular drug
DMFNZPY PC 44235958
DMFNZPY MW 793.4
DMFNZPY FM C42H53ClN4O7S
DMFNZPY IC InChI=1S/C42H52N4O7S.ClH/c1-27(2)45(5)42(48)38(20-30-10-12-31(13-11-30)25-46-28(3)8-7-9-29(46)4)43-41(47)24-37(34-16-19-39-40(23-34)53-26-52-39)44-54(49,50)36-18-15-32-21-35(51-6)17-14-33(32)22-36;/h10-19,21-23,27-29,37-38,44H,7-9,20,24-26H2,1-6H3,(H,43,47);1H/t28-,29+,37-,38-;/m1./s1
DMFNZPY CS C[C@@H]1CCC[C@@H](N1CC2=CC=C(C=C2)C[C@H](C(=O)N(C)C(C)C)NC(=O)C[C@H](C3=CC4=C(C=C3)OCO4)NS(=O)(=O)C5=CC6=C(C=C5)C=C(C=C6)OC)C.Cl
DMFNZPY IK GLHHFOSVBQQNAW-GDYXXZBVSA-N
DMFNZPY IU (2R)-2-[[(3R)-3-(1,3-benzodioxol-5-yl)-3-[(6-methoxynaphthalen-2-yl)sulfonylamino]propanoyl]amino]-3-[4-[[(2S,6R)-2,6-dimethylpiperidin-1-yl]methyl]phenyl]-N-methyl-N-propan-2-ylpropanamide;hydrochloride
DMFNZPY CA CAS 464930-42-5
DMFNZPY DE Rheumatoid arthritis
DMGTB2Q ID DMGTB2Q
DMGTB2Q DN SSR411298
DMGTB2Q HS Phase 2
DMGTB2Q CP Sanofi-Aventis
DMGTB2Q DE Major depressive disorder
DMRGTZ2 ID DMRGTZ2
DMRGTZ2 DN SSTarbaclofen
DMRGTZ2 HS Phase 2
DMRGTZ2 CP Seaside Therapeutics; Roche
DMRGTZ2 DE Fragile X syndrome; Autism spectrum disorder
DMH4C3M ID DMH4C3M
DMH4C3M DN STA-5326
DMH4C3M HS Phase 2
DMH4C3M SN Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMH4C3M CP Synta Pharma
DMH4C3M DT Small molecular drug
DMH4C3M PC 10173277
DMH4C3M MW 418.5
DMH4C3M FM C23H26N6O2
DMH4C3M IC InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
DMH4C3M CS CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4
DMH4C3M IK HSKAZIJJKRAJAV-KOEQRZSOSA-N
DMH4C3M IU N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
DMH4C3M CA CAS 541550-19-0
DMH4C3M DE Rheumatoid arthritis; Crohn disease
DMEG4TC ID DMEG4TC
DMEG4TC DN Stannsoporfin
DMEG4TC HS Phase 2
DMEG4TC SN SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)
DMEG4TC CP InfaCare Pharma.
DMEG4TC DT Small molecular drug
DMEG4TC PC 23725028
DMEG4TC MW 754.3
DMEG4TC FM C34H36Cl2N4O4Sn
DMEG4TC IC InChI=1S/C34H38N4O4.2ClH.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;;/h13-16H,7-12H2,1-6H3,(H4,35,36,37,38,39,40,41,42);2*1H;/q;;;+4/p-4
DMEG4TC CS [H+].[H+].CCC1=C(C2=NC1=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=NC(=C2)C(=C5C)CC)[N-]4)C)CCC(=O)[O-])CCC(=O)[O-])C)C.[Cl-].[Cl-].[Sn+4]
DMEG4TC IK LLDZJTIZVZFNCM-UHFFFAOYSA-J
DMEG4TC IU 3-[18-(2-carboxylatoethyl)-8,13-diethyl-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;hydron;tin(4+);dichloride
DMEG4TC DE Neonatal hyperbilirubinemia
DMJ1DIB ID DMJ1DIB
DMJ1DIB DN S-tenatoprazole
DMJ1DIB HS Phase 2
DMJ1DIB SN Benatoprazole; Protop; Tenatoprazole; Ulsacare; STU-199; STU-Na; TU-199; S-tenatoprazole-Na
DMJ1DIB CP Mitsubishi-Tokyo Pharmaceuticals Inc
DMJ1DIB DE Peptic ulcer
DMKVBL8 ID DMKVBL8
DMKVBL8 DN Stenoparib
DMKVBL8 HS Phase 2
DMKVBL8 CP Allarity Therapeutics
DMKVBL8 DT Small molecular drug
DMKVBL8 DE Ovarian cancer
DMR9COG ID DMR9COG
DMR9COG DN STX-100
DMR9COG HS Phase 2
DMR9COG CP Biogen Idec
DMR9COG DE Idiopathic pulmonary fibrosis
DMLNKX7 ID DMLNKX7
DMLNKX7 DN STX-107
DMLNKX7 HS Phase 2
DMLNKX7 SN 2-Methyl-4-(pyridin-3-ylethynyl)thiazole; MTEP; mGluR5 Antagonist, MTEP; 329205-68-7; 2-methyl-4-(pyridin-3-ylethynyl)thiazole; CHEMBL292065; 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine; 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; 3-(2-(2-methylthiazol-4-yl)ethynyl)pyridine; 3-[2-(2-Methylthiazol-4-yl)ethynyl]pyridine; 3-(2-Methyl-thiazol-4-ylethynyl)-pyridine; SCHEMBL187254; GTPL3336; CTK1B8867; DTXSID30430775; ZINC1489321; IN1238; BDBM50122758; FCH3417361; API0006876; ACN-027361; KB-274670
DMLNKX7 CP Merck Research Laboratories
DMLNKX7 DT Small molecular drug
DMLNKX7 PC 16662948
DMLNKX7 MW 319.4
DMLNKX7 FM C18H10FN3S
DMLNKX7 IC InChI=1S/C18H10FN3S/c1-12-22-17(11-23-12)4-2-13-3-5-18(21-10-13)15-6-14(9-20)7-16(19)8-15/h3,5-8,10-11H,1H3
DMLNKX7 CS CC1=NC(=CS1)C#CC2=CN=C(C=C2)C3=CC(=CC(=C3)C#N)F
DMLNKX7 IK SYOSUEIMOYEGKU-UHFFFAOYSA-N
DMLNKX7 IU 3-fluoro-5-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-2-yl]benzonitrile
DMLNKX7 CA CAS 935685-90-8
DMLNKX7 DE Autism spectrum disorder
DMJK5CT ID DMJK5CT
DMJK5CT DN STX-140
DMJK5CT HS Phase 2
DMJK5CT SN (9beta,13alpha,14beta,17alpha)-2-Methoxyestra-1,3,5(10)-Triene-3,17-Diyl Disulfamate; STX140; CHEMBL218382; 2-MeOE2bisMATE; 2-methoxyestradiol-3,17-O,O-bis-sulfamate; STX 140; 2-MeOEbisMATE; 2gd8; 2-methoxyestradiol 3,17-O,O-bis-sulfamate; 2-MbM; 2-methoxyestradiol-3,17-O,O-bis(sulfamate); SCHEMBL446846; BDBM50200936; DB08416; (9beta,17beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diyl disulfamate; Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, disulfamate, (17beta)-; 401600-86-0; Angiomates; Estrone sulphatase inhibitors, Ipsen; STX-213; STX-641; Steroid sulfatase inhibitors, Sterix Ltd; 2-MeOE2-bis MATE; 2-MeSEMATE; 2-ethyl-estradiol bis-sulfamate; 2-methoxyestradiol, Sterix; 2-methoxyestradiol-bis-sulfamate; 2-methoxyestradiol-bis-sulfamate, Sterix
DMJK5CT CP EntreMed
DMJK5CT DT Small molecular drug
DMJK5CT PC 9804302
DMJK5CT MW 460.6
DMJK5CT FM C19H28N2O7S2
DMJK5CT IC InChI=1S/C19H28N2O7S2/c1-19-8-7-12-13(15(19)5-6-18(19)28-30(21,24)25)4-3-11-9-17(27-29(20,22)23)16(26-2)10-14(11)12/h9-10,12-13,15,18H,3-8H2,1-2H3,(H2,20,22,23)(H2,21,24,25)/t12-,13+,15-,18-,19-/m0/s1
DMJK5CT CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=CC(=C(C=C34)OC)OS(=O)(=O)N
DMJK5CT IK AQSNIXKAKUZPSI-SSTWWWIQSA-N
DMJK5CT IU [(8R,9S,13S,14S,17S)-2-methoxy-13-methyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMJK5CT CA CAS 401600-86-0
DMJK5CT DE Osteoporosis
DMO9LBE ID DMO9LBE
DMO9LBE DN SUN N4057
DMO9LBE HS Phase 2
DMO9LBE SN Piclozotan; UNII-FQE44HS7AH; FQE44HS7AH; CHEMBL345237; 182415-09-4; SUN N4057; Piclozotan [INN]; 3-Chloro-4-(4-(4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5(4H)-one; SCHEMBL562627; URMTUEWUIGOJBW-UHFFFAOYSA-N; SUN N-4057; BDBM50097342; DB12361; L001621; 3-Chloro-4-[4-(3'',6''-dihydro-2''H-[2,4'']bipyridinyl-1''-yl)-butyl]-4H-benzo[f][1,4]oxazepin-5-one; 3-chloro-4,5-dihydro-4-(4-(4-(2-pyridyl)-1,2,5,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5-one
DMO9LBE DT Small molecular drug
DMO9LBE PC 9801640
DMO9LBE MW 409.9
DMO9LBE FM C23H24ClN3O2
DMO9LBE IC InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2
DMO9LBE CS C1CN(CC=C1C2=CC=CC=N2)CCCCN3C(=COC4=CC=CC=C4C3=O)Cl
DMO9LBE IK URMTUEWUIGOJBW-UHFFFAOYSA-N
DMO9LBE IU 3-chloro-4-[4-(4-pyridin-2-yl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1,4-benzoxazepin-5-one
DMO9LBE CA CAS 182415-09-4
DMO9LBE DE Coronary artery disease
DMPK34E ID DMPK34E
DMPK34E DN Sun13834
DMPK34E HS Phase 2
DMPK34E SN Trifluperidol; Trisedil; Triperidol; Psychoperidol; Flumoperone; Psicoperidol; Trisedyl; Psicoperidol-R; McN-JR-2498; 749-13-3; Trifluperidolo; Trifluperidolo [DCIT]; R-2498; Trifluperidolo [Italian]; Trifluperidolum [INN-Latin]; NSC 170978; UNII-R8869Q7R8I; Trifluperidol [USAN:INN:BAN]; P 459; BRN 1556208; CHEMBL15023; 1-Butanone, 1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-; GPMXUUPHFNMNDH-UHFFFAOYSA-N; R8869Q7R8I; NSC170978; Triperidol (TN)
DMPK34E CP Wyeth
DMPK34E DT Small molecular drug
DMPK34E PC 5567
DMPK34E MW 409.4
DMPK34E FM C22H23F4NO2
DMPK34E IC InChI=1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2
DMPK34E CS C1CN(CCC1(C2=CC(=CC=C2)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F
DMPK34E IK GPMXUUPHFNMNDH-UHFFFAOYSA-N
DMPK34E IU 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
DMPK34E CA CAS 749-13-3
DMPK34E CB CHEBI:135662
DMPK34E DE Gram-positive bacterial infection
DMSWPA6 ID DMSWPA6
DMSWPA6 DN Superoxide dismutase
DMSWPA6 HS Phase 2
DMSWPA6 SN Orgotein; HSOD, Yeda; Manganese SOD, Boehringer Ingelheim; NK-341; Orgotein, Yeda; SOD, Yeda; Superoxide dismutase, Boehringer Ingelheim; Superoxide dismutase, Nippon; Superoxide dismutase, Yeda; HSOD, Bio-Technology General; Orgotein, Bio-Technology General; SOD, Bio-Technology General; Superoxide dismutase, Bio-Technology
DMSWPA6 CP Weizmann Institute of Science; Nippon Kayaku Co Ltd; Boehringer Ingelheim Corp
DMSWPA6 DE Myocardial infarction
DMAIGTE ID DMAIGTE
DMAIGTE DN SurVaxM
DMAIGTE HS Phase 2
DMAIGTE CP MimiVax Rochester, NY
DMAIGTE DE Multiple myeloma; Glioblastoma of brain
DM2KQ71 ID DM2KQ71
DM2KQ71 DN Sutezolid
DM2KQ71 HS Phase 2
DM2KQ71 SN PF-02341272; PF-2341272; PNU-100480; PNU-101244; PNU-101603; U-100480; U-101244; U-101603; U-94901
DM2KQ71 CP Sequella
DM2KQ71 DT Small molecular drug
DM2KQ71 PC 465951
DM2KQ71 MW 353.4
DM2KQ71 FM C16H20FN3O3S
DM2KQ71 IC InChI=1S/C16H20FN3O3S/c1-11(21)18-9-13-10-20(16(22)23-13)12-2-3-15(14(17)8-12)19-4-6-24-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
DM2KQ71 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCSCC3)F
DM2KQ71 IK FNDDDNOJWPQCBZ-ZDUSSCGKSA-N
DM2KQ71 IU N-[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DM2KQ71 CA CAS 168828-58-8
DM2KQ71 DE Tuberculosis
DMQD753 ID DMQD753
DMQD753 DN SUVN-502
DMQD753 HS Phase 2
DMQD753 SN SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven
DMQD753 CP Suven Life Sciences
DMQD753 DT Small molecular drug
DMQD753 PC 10073773
DMQD753 MW 478.4
DMQD753 FM C21H24BrN3O3S
DMQD753 IC InChI=1S/C21H24BrN3O3S/c1-23-9-11-24(12-10-23)14-16-15-25(20-8-7-17(28-2)13-18(16)20)29(26,27)21-6-4-3-5-19(21)22/h3-8,13,15H,9-12,14H2,1-2H3
DMQD753 CS CN1CCN(CC1)CC2=CN(C3=C2C=C(C=C3)OC)S(=O)(=O)C4=CC=CC=C4Br
DMQD753 IK GWCYPEHWIZXYFZ-UHFFFAOYSA-N
DMQD753 IU 1-(2-bromophenyl)sulfonyl-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]indole
DMQD753 CA CAS 701205-60-9
DMQD753 DE Neurological disorder; Alzheimer disease
DMZV27P ID DMZV27P
DMZV27P DN SXC-2023
DMZV27P HS Phase 2
DMZV27P CP Promentis Pharmaceuticals
DMZV27P DT Small molecular drug
DMZV27P DE Trichotillomania
DMXLE71 ID DMXLE71
DMXLE71 DN SYL-040012
DMXLE71 HS Phase 2
DMXLE71 SN SYL-0012; Beta 2 adrenoceptor-targeting siRNA (ocular hypertension), Sylentis
DMXLE71 CP Sylentis Sau
DMXLE71 DT siRNA drug
DMXLE71 DE Ocular hypertension
DMDF7XB ID DMDF7XB
DMDF7XB DN SYN120
DMDF7XB HS Phase 2
DMDF7XB SN Landipirdine; 1000308-25-7; UNII-J0NX985GDI; J0NX985GDI; CHEMBL1082508; RO5025181; RO5025181-000; N-(((1R)-6-(3-fluorobenzenesulfonyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)urea; Landipirdine [USAN]; Landipirdine (USAN/INN); SCHEMBL315956; SYN-120; BDBM50416003; SB18761; D11157; Q27896229; R05025181; R0-5025181; R0-5025181-000; R05025181-000; (R)-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea; [(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea; Urea, N-(((1R)-6-((3-fluorophenyl)sulfonyl)-1,2,3,4-tetrahydro-1-naphthalenyl)methyl)-
DMDF7XB CP Acorda Therapeutics
DMDF7XB DT Small molecular drug
DMDF7XB PC 46220503
DMDF7XB MW 362.4
DMDF7XB FM C18H19FN2O3S
DMDF7XB IC InChI=1S/C18H19FN2O3S/c19-14-5-2-6-15(10-14)25(23,24)16-7-8-17-12(9-16)3-1-4-13(17)11-21-18(20)22/h2,5-10,13H,1,3-4,11H2,(H3,20,21,22)/t13-/m0/s1
DMDF7XB CS C1C[C@H](C2=C(C1)C=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)F)CNC(=O)N
DMDF7XB IK MTTHRRVVGMPYQG-ZDUSSCGKSA-N
DMDF7XB IU [(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea
DMDF7XB CA CAS 1000308-25-7
DMDF7XB DE Parkinson disease
DMPW0UL ID DMPW0UL
DMPW0UL DN SYN-120
DMPW0UL HS Phase 2
DMPW0UL CP Biotie Therapies
DMPW0UL DE Alzheimer disease; Parkinson disease
DMF9Z2T ID DMF9Z2T
DMF9Z2T DN T-2007
DMF9Z2T HS Phase 2
DMF9Z2T SN DPB sodium; Diphenylbarbituric sodium; Diphenylbarbituric acid (epilepsy), Taro; 5,5-diphenylbarbituric sodium
DMF9Z2T CP Taro Pharmaceutical Industries Ltd
DMF9Z2T DE Epilepsy
DM06GDC ID DM06GDC
DM06GDC DN T2c-001
DM06GDC HS Phase 2
DM06GDC SN T2c-001-AMI; T2c-001-CHD; T2c-001-DCM; T2c-001-SW; Autologous bone marrow-derived endothelial progenitor cell therapy, Goethe University/t2cure; Autologous endothelial progenitor cells (myocardial infarction), Goethe University/t2cure; Endothelial progenitor cell therapy (ischemia), Goethe University/t2cure
DM06GDC CP Johann Wolfgang Goethe-Universitat Frankfurt am Main
DM06GDC DE Congestive heart failure
DM5C70M ID DM5C70M
DM5C70M DN T-607
DM5C70M HS Phase 2
DM5C70M SN T-607; AC1LA5AL; 2-[(Ethyl)disulfanyl]-2-methylthioacetamide; 2-(ethyldisulfanyl)-2-methylsulfanylacetamide; 2-(ethyldisulfanyl)-2-methylsulfanyl-acetamide; 92504-EP2298748A2; 92504-EP2295416A2
DM5C70M CP Tularik Inc
DM5C70M DT Small molecular drug
DM5C70M PC 462014
DM5C70M MW 197.3
DM5C70M FM C5H11NOS3
DM5C70M IC InChI=1S/C5H11NOS3/c1-3-9-10-5(8-2)4(6)7/h5H,3H2,1-2H3,(H2,6,7)
DM5C70M CS CCSSC(C(=O)N)SC
DM5C70M IK OKTRVIBXCNRKHI-UHFFFAOYSA-N
DM5C70M IU 2-(ethyldisulfanyl)-2-methylsulfanylacetamide
DM5C70M DE Solid tumour/cancer
DMD72F4 ID DMD72F4
DMD72F4 DN T-817MA
DMD72F4 HS Phase 2
DMD72F4 SN Edonerpic maleate; T-817MA; UNII-0LB9F7I5P3; 0LB9F7I5P3; 519187-97-4; T-817; T-817 maleate; SCHEMBL48064; RLUCYBFCLXANSO-BTJKTKAUSA-N; HY-17631A; DC10762; CS-8069; J2.179.155E; 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol maleate; 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate; 1-(3-(2-(Benzo(b)thiophene-5-yl)ethoxy)propyl)azetidine-3-ol maleate; 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol maleate; 3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-, (2Z)-2-butenedioate (1:
DMD72F4 CP Toyama Chemical
DMD72F4 DT Small molecular drug
DMD72F4 PC 11338749
DMD72F4 MW 407.5
DMD72F4 FM C20H25NO6S
DMD72F4 IC InChI=1S/C16H21NO2S.C4H4O4/c18-15-11-17(12-15)6-1-7-19-8-4-13-2-3-16-14(10-13)5-9-20-16;5-3(6)1-2-4(7)8/h2-3,5,9-10,15,18H,1,4,6-8,11-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMD72F4 CS C1C(CN1CCCOCCC2=CC3=C(C=C2)SC=C3)O.C(=C\\C(=O)O)\\C(=O)O
DMD72F4 IK RLUCYBFCLXANSO-BTJKTKAUSA-N
DMD72F4 IU 1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol;(Z)-but-2-enedioic acid
DMD72F4 CA CAS 519187-97-4
DMD72F4 DE Alzheimer disease
DM4JFMZ ID DM4JFMZ
DM4JFMZ DN T-82
DM4JFMZ HS Phase 2
DM4JFMZ SN 2-[2-(1-Benzylpiperidin-4-yl)ethyl]-9-methoxy-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-one hemifumarate
DM4JFMZ DT Small molecular drug
DM4JFMZ PC 193285
DM4JFMZ MW 598.2
DM4JFMZ FM C31H36ClN3O5S
DM4JFMZ IC InChI=1S/C31H36ClN3O5S/c1-37-26-19-22(20-27(38-2)30(26)39-3)31(36)40-18-17-34-15-13-33(14-16-34)11-6-12-35-24-7-4-5-8-28(24)41-29-21-23(32)9-10-25(29)35/h4-5,7-10,19-21H,6,11-18H2,1-3H3
DM4JFMZ CS COC1=CC(=CC(=C1OC)OC)C(=O)OCCN2CCN(CC2)CCCN3C4=C(C=C(C=C4)Cl)SC5=CC=CC=C53
DM4JFMZ IK KZAJTVRKNKAXAG-UHFFFAOYSA-N
DM4JFMZ IU 2-[4-[3-(3-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 3,4,5-trimethoxybenzoate
DM4JFMZ CA CAS 38455-99-1
DM4JFMZ DE Cognitive impairment
DMMWPSQ ID DMMWPSQ
DMMWPSQ DN TA-2005
DMMWPSQ HS Phase 2
DMMWPSQ SN Carmoterol hydrochloride; CHF 4226.01; 8-Hydroxy-5-((1R)-1-hydroxy-2-(N-(1R)-2-(p-methoxyphenyl)isopropylamino)ethyl)carbostyril HCl; 8-Hydroxy-5-(1-hydroxy-2-(N-(2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)carbostyril hydrochloride; 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one hydrochloride; 8-hydroxy-5-[(1r)-1-hydroxy-2-{[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]quinolin-2(1h)-one hydrochloride(1:1)
DMMWPSQ CP Chiesi
DMMWPSQ DT Small molecular drug
DMMWPSQ PC 63951
DMMWPSQ MW 404.9
DMMWPSQ FM C21H25ClN2O4
DMMWPSQ IC InChI=1S/C21H24N2O4.ClH/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21;/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26);1H/t13-,19+;/m1./s1
DMMWPSQ CS C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O.Cl
DMMWPSQ IK SYCWERNQGSKYAG-QVRIGTRMSA-N
DMMWPSQ IU 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one;hydrochloride
DMMWPSQ CA CAS 100429-08-1
DMMWPSQ DE Chronic obstructive pulmonary disease
DMZ7I51 ID DMZ7I51
DMZ7I51 DN TA-270
DMZ7I51 HS Phase 2
DMZ7I51 CP DIC Corporation
DMZ7I51 PC 54710630
DMZ7I51 MW 524.6
DMZ7I51 FM C29H36N2O7
DMZ7I51 IC InChI=1S/C29H36N2O7/c1-5-6-7-8-9-10-15-38-28-26(33)21-13-12-20(18-22(21)31(2)29(28)35)30-25(32)14-11-19-16-23(36-3)27(34)24(17-19)37-4/h11-14,16-18,33-34H,5-10,15H2,1-4H3,(H,30,32)/b14-11+
DMZ7I51 CS CCCCCCCCOC1=C(C2=C(C=C(C=C2)NC(=O)/C=C/C3=CC(=C(C(=C3)OC)O)OC)N(C1=O)C)O
DMZ7I51 IK SZNJINHODJLULD-SDNWHVSQSA-N
DMZ7I51 IU (E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-N-(4-hydroxy-1-methyl-3-octoxy-2-oxoquinolin-7-yl)prop-2-enamide
DMZ7I51 DE Asthma
DMZTAJL ID DMZTAJL
DMZTAJL DN TA-7906
DMZTAJL HS Phase 2
DMZTAJL SN T-2585; PDE4 inhibitor (skin disease), Maruho; PDE4 inhibitors (inflammation), Tanabe Seiyaku; T-2585.HCl
DMZTAJL CP Tanabe Seiyaku Co Ltd
DMZTAJL DE Atopic dermatitis
DMAZHT0 ID DMAZHT0
DMAZHT0 DN TA-8995
DMAZHT0 HS Phase 2
DMAZHT0 SN Obicetrapib; UNII-8O74K609HN; 8O74K609HN; 866399-87-3; Obicetrapib [INN]; CHEMBL3785197; SCHEMBL17002081; AMG-899; DEZ-001; Obicetrapib (AMG-899 TA-8995); AKOS032954130; HY-18778; 4-((2-(((3,5-Bis(trifluoromethyl)phenyl)methyl)((2R,4S)-1- (ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4- tetrahydroquinolin-4-yl)amino)pyrimidin-5-yl)oxy)butanoic acid; 1(2H)-Quinolinecarboxylic acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl)(5-(3-carboxypropoxy)-2-pyrimidinyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-,
DMAZHT0 CP Mitsubishi Tanabe Pharma Corp
DMAZHT0 PC 11498596
DMAZHT0 MW 722.6
DMAZHT0 FM C32H31F9N4O5
DMAZHT0 IC InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1
DMAZHT0 CS CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
DMAZHT0 IK NRWORBQAOQVYBJ-GJZUVCINSA-N
DMAZHT0 IU 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2R,4S)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic acid
DMAZHT0 CA CAS 866399-87-3
DMAZHT0 DE Hyperlipidaemia; Cardiovascular disease
DMNL9HO ID DMNL9HO
DMNL9HO DN Tabimorelin
DMNL9HO HS Phase 2
DMNL9HO SN NN-703; NNC-26-0703; Tabimorelin; N-[5-Amino-5-methyl-2(E)-hexenoyl]-N-methyl-3-(2-naphthyl)-D-alanyl-N-methyl-D-phenylalanine methylamide
DMNL9HO DT Small molecular drug
DMNL9HO PC 9810101
DMNL9HO MW 528.7
DMNL9HO FM C32H40N4O3
DMNL9HO IC InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
DMNL9HO CS CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)[C@H](CC3=CC=CC=C3)C(=O)NC)N
DMNL9HO IK WURGZWOTGMLDJP-ZCYANPAGSA-N
DMNL9HO IU (E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(2R)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
DMNL9HO CA CAS 193079-69-5
DMNL9HO DE Growth hormone deficiency
DMP1873 ID DMP1873
DMP1873 DN TAK-063
DMP1873 HS Phase 2
DMP1873 CP Takeda
DMP1873 PC 46848915
DMP1873 MW 428.4
DMP1873 FM C23H17FN6O2
DMP1873 IC InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3
DMP1873 CS COC1=CN(N=C(C1=O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F
DMP1873 IK KVHRYLNQDWXAGI-UHFFFAOYSA-N
DMP1873 IU 1-(2-fluoro-4-pyrazol-1-ylphenyl)-5-methoxy-3-(2-phenylpyrazol-3-yl)pyridazin-4-one
DMP1873 CA CAS 1238697-26-1
DMP1873 DE Schizophrenia
DMHPEFS ID DMHPEFS
DMHPEFS DN TAK-128
DMHPEFS HS Phase 2
DMHPEFS SN Y-128
DMHPEFS CP Mitsubishi Pharma Corp
DMHPEFS DE Diabetic neuropathy
DM81UAZ ID DM81UAZ
DM81UAZ DN TAK-272
DM81UAZ HS Phase 2
DM81UAZ CP Takeda
DM81UAZ DT Small molecular drug
DM81UAZ PC 56591871
DM81UAZ MW 536.1
DM81UAZ FM C27H42ClN5O4
DM81UAZ IC InChI=1S/C27H41N5O4.ClH/c1-20(2)19-32(22-16-21(17-28-18-22)26(33)30-11-14-36-15-12-30)27(34)25-29-23-8-4-5-9-24(23)31(25)10-6-7-13-35-3;/h4-5,8-9,20-22,28H,6-7,10-19H2,1-3H3;1H/t21-,22+;/m1./s1
DM81UAZ CS CC(C)CN([C@H]1C[C@H](CNC1)C(=O)N2CCOCC2)C(=O)C3=NC4=CC=CC=C4N3CCCCOC.Cl
DM81UAZ IK PUXOYQIZZIWCHH-NSLUPJTDSA-N
DM81UAZ IU 1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholine-4-carbonyl)piperidin-3-yl]benzimidazole-2-carboxamide;hydrochloride
DM81UAZ CA CAS 1202269-24-6
DM81UAZ DE Type-2 diabetes
DMEYKRN ID DMEYKRN
DMEYKRN DN TAK-379
DMEYKRN HS Phase 2
DMEYKRN SN Insulin sensitizer (oral, diabetes mellitus), Takeda
DMEYKRN CP Takeda Pharmaceutical Co Ltd
DMEYKRN DE Type-2 diabetes
DMD51RN ID DMD51RN
DMD51RN DN TAK-448
DMD51RN HS Phase 2
DMD51RN CP Takeda
DMD51RN PC 46700761
DMD51RN MW 1225.4
DMD51RN FM C58H80N16O14
DMD51RN IC InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1
DMD51RN CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=NC)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](CC5=CC=C(C=C5)O)NC(=O)C)O)O
DMD51RN IK MWXWMWSUUYXMRA-GRKBUMBKSA-N
DMD51RN IU (2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
DMD51RN CA CAS 1234319-68-6
DMD51RN DE Prostate cancer
DMNB4P1 ID DMNB4P1
DMNB4P1 DN TAK-653
DMNB4P1 HS Phase 2
DMNB4P1 CP Takeda
DMNB4P1 PC 56655833
DMNB4P1 MW 373.5
DMNB4P1 FM C19H23N3O3S
DMNB4P1 IC InChI=1S/C19H23N3O3S/c1-14-13-22-11-12-26(23,24)21-19(22)18(20-14)15-7-9-17(10-8-15)25-16-5-3-2-4-6-16/h7-10,13,16H,2-6,11-12H2,1H3
DMNB4P1 CS CC1=CN2CCS(=O)(=O)N=C2C(=N1)C3=CC=C(C=C3)OC4CCCCC4
DMNB4P1 IK PXJBHEHFVQVDDS-UHFFFAOYSA-N
DMNB4P1 IU 9-(4-cyclohexyloxyphenyl)-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide
DMNB4P1 CA CAS 1358751-06-0
DMNB4P1 DE Depression
DMJH3U0 ID DMJH3U0
DMJH3U0 DN TAK-659
DMJH3U0 HS Phase 2
DMJH3U0 CP Millennium pharmaceuticals
DMJH3U0 PC 53252276
DMJH3U0 MW 344.4
DMJH3U0 FM C17H21FN6O
DMJH3U0 IC InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1
DMJH3U0 CS CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)N[C@@H]4CCCC[C@@H]4N
DMJH3U0 IK MJHOMTRKVMKCNE-NWDGAFQWSA-N
DMJH3U0 IU 6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-4-(1-methylpyrazol-4-yl)-1,2-dihydropyrrolo[3,4-c]pyridin-3-one
DMJH3U0 CA CAS 1312691-33-0
DMJH3U0 DE Haematological malignancy; Diffuse large B-cell lymphoma
DMZKPI8 ID DMZKPI8
DMZKPI8 DN TAK-715
DMZKPI8 HS Phase 2
DMZKPI8 SN P38 MAP kinase inhibitor (rheumatoid arthritis), Takeda
DMZKPI8 CP Takeda Pharmaceutical Co Ltd
DMZKPI8 DT Small molecular drug
DMZKPI8 PC 9952773
DMZKPI8 MW 399.5
DMZKPI8 FM C24H21N3OS
DMZKPI8 IC InChI=1S/C24H21N3OS/c1-3-21-27-22(18-11-7-8-16(2)14-18)23(29-21)19-12-13-25-20(15-19)26-24(28)17-9-5-4-6-10-17/h4-15H,3H2,1-2H3,(H,25,26,28)
DMZKPI8 CS CCC1=NC(=C(S1)C2=CC(=NC=C2)NC(=O)C3=CC=CC=C3)C4=CC=CC(=C4)C
DMZKPI8 IK HEKAIDKUDLCBRU-UHFFFAOYSA-N
DMZKPI8 IU N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]pyridin-2-yl]benzamide
DMZKPI8 CA CAS 303162-79-0
DMZKPI8 CB CHEBI:91360
DMZKPI8 DE Rheumatoid arthritis
DMWPSJR ID DMWPSJR
DMWPSJR DN TAK-831
DMWPSJR HS Phase 2
DMWPSJR CP Takeda Deerfield, IL
DMWPSJR DE Friedreich's ataxia; Schizophrenia
DMZEU6M ID DMZEU6M
DMZEU6M DN TAK-831
DMZEU6M HS Phase 2
DMZEU6M SN Luvadaxistat; 3(2H)-one; UNII-76IC00YRVR; 76IC00YRVR; CHEMBL2338801; 1425511-32-5; 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-; 4-Hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one; 4-Hydroxy-6-(2-(4-(trifluoromethyl)phenyl)ethyl)pyridazin-3(2H)-one; Luvadaxistat [USAN]; SCHEMBL14719667; BDBM50431085; WHO 11254; ZINC95592350; 3(2H)-Pyridazinone, 4-hydroxy-6-(2-(4-(trifluoromethyl)phenyl)ethyl)-; 6-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione
DMZEU6M CP Takeda
DMZEU6M DT Small molecular drug
DMZEU6M PC 71270546
DMZEU6M MW 284.23
DMZEU6M FM C13H11F3N2O2
DMZEU6M IC InChI=1S/C13H11F3N2O2/c14-13(15,16)9-4-1-8(2-5-9)3-6-10-7-11(19)12(20)18-17-10/h1-2,4-5,7H,3,6H2,(H,17,19)(H,18,20)
DMZEU6M CS C1=CC(=CC=C1CCC2=CC(=O)C(=O)NN2)C(F)(F)F
DMZEU6M IK QBQMUMMSYHUDFM-UHFFFAOYSA-N
DMZEU6M IU 6-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione
DMZEU6M CA CAS 1425511-32-5
DMZEU6M DE Friedreich's ataxia
DMBQD9H ID DMBQD9H
DMBQD9H DN TAK-906
DMBQD9H HS Phase 2
DMBQD9H SN Trazpiroben; UNII-FH87H57Q4Y; FH87H57Q4Y; triazaspiro[4.5]decan-3-yl]methyl}benzoic acid; 1352993-39-5; 3-{[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-; Trazpiroben [INN]; Trazpiroben [USAN]; SCHEMBL318454; WHO 11123; (3-((1-Cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8 triazaspiro(4.5) decan-3-yl)methyl)benzoic acid; 3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid; Benzoic acid, 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro(4.5)dec-3-yl)methyl)-
DMBQD9H CP Takeda
DMBQD9H DT Small molecular drug
DMBQD9H PC 54768846
DMBQD9H MW 517.7
DMBQD9H FM C31H39N3O4
DMBQD9H IC InChI=1S/C31H39N3O4/c35-28(25-10-3-1-4-11-25)15-8-18-32-19-16-31(17-20-32)30(38)33(23-34(31)27-13-5-2-6-14-27)22-24-9-7-12-26(21-24)29(36)37/h1,3-4,7,9-12,21,27H,2,5-6,8,13-20,22-23H2,(H,36,37)
DMBQD9H CS C1CCC(CC1)N2CN(C(=O)C23CCN(CC3)CCCC(=O)C4=CC=CC=C4)CC5=CC(=CC=C5)C(=O)O
DMBQD9H IK BDXJYAAYLZTLEK-UHFFFAOYSA-N
DMBQD9H IU 3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid
DMBQD9H CA CAS 1352993-39-5
DMBQD9H DE Diabetic gastroparesis
DMOZAMN ID DMOZAMN
DMOZAMN DN TAK-935
DMOZAMN HS Phase 2
DMOZAMN PC 73437845
DMOZAMN MW 373.4
DMOZAMN FM C23H23N3O2
DMOZAMN IC InChI=1S/C23H23N3O2/c27-22(20-7-4-12-25-21(20)19-8-13-24-14-9-19)26-15-10-23(28,11-16-26)17-18-5-2-1-3-6-18/h1-9,12-14,28H,10-11,15-17H2
DMOZAMN CS C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
DMOZAMN IK XKUZMIUSBMCVPP-UHFFFAOYSA-N
DMOZAMN IU (4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone
DMOZAMN CA CAS 1429505-03-2
DMOZAMN DE Glutamate excitotoxity; Dravet syndrome; LennoxGastaut syndrome; Tuberous sclerosis
DMARVFG ID DMARVFG
DMARVFG DN Talacotuzumab
DMARVFG HS Phase 2
DMARVFG SN JNJ 473; JNJ 56022473; TAL
DMARVFG CP Janssen Research & Development Raritan, NJ
DMARVFG DE Acute myeloid leukaemia
DMJOM5L ID DMJOM5L
DMJOM5L DN Talampanel
DMJOM5L HS Phase 2
DMJOM5L SN Ampanel; Kinampa; GYKI 53773; LY 300164; GYKI-53773; IDR-53773; LY-300164; Talampanel (INN); (8R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-(-)-1-(4-Aminophenyl)-3-acetyl-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine; (R)-7-Acetyl-5-(p-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo(4,5-h)(2,3)benzodiazepine; (R)-7-acetyl-5-(p-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine
DMJOM5L CP Teva Pharmaceutical Industries
DMJOM5L DT Small molecular drug
DMJOM5L PC 164509
DMJOM5L MW 337.4
DMJOM5L FM C19H19N3O3
DMJOM5L IC InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1
DMJOM5L CS C[C@@H]1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3
DMJOM5L IK JACAAXNEHGBPOQ-LLVKDONJSA-N
DMJOM5L IU 1-[(8R)-5-(4-aminophenyl)-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone
DMJOM5L CA CAS 161832-65-1
DMJOM5L CB CHEBI:34992
DMJOM5L DE Parkinson disease
DMQKZDT ID DMQKZDT
DMQKZDT DN Talnetant
DMQKZDT HS Phase 2
DMQKZDT SN Talnetant [INN]; SB 223412; SB-223412; N-((S)-alpha-Ethylbenzyl)-3-hydroxy-2-phenylcinchoninamide;N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide; 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
DMQKZDT CP GlaxoSmithKline
DMQKZDT DT Small molecular drug
DMQKZDT PC 5311424
DMQKZDT MW 382.5
DMQKZDT FM C25H22N2O2
DMQKZDT IC InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)/t20-/m0/s1
DMQKZDT CS CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)O
DMQKZDT IK BIAVGWDGIJKWRM-FQEVSTJZSA-N
DMQKZDT IU 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DMQKZDT CA CAS 174636-32-9
DMQKZDT DE Schizoaffective disorder; Schizophrenia; Irritable bowel syndrome
DMNLQHK ID DMNLQHK
DMNLQHK DN Tanespimycin
DMNLQHK HS Phase 2
DMNLQHK SN CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374
DMNLQHK CP Bristol-Myers Squibb; Infinity Pharmaceuticals
DMNLQHK TC Anticancer Agents
DMNLQHK DT Small molecular drug
DMNLQHK PC 6505803
DMNLQHK MW 585.7
DMNLQHK FM C31H43N3O8
DMNLQHK IC InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
DMNLQHK CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)/C)OC)OC(=O)N)\\C)C)O)OC
DMNLQHK IK AYUNIORJHRXIBJ-TXHRRWQRSA-N
DMNLQHK IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMNLQHK CA CAS 75747-14-7
DMNLQHK CB CHEBI:64153
DMNLQHK DE Multiple myeloma; Breast cancer
DM1TSHL ID DM1TSHL
DM1TSHL DN Taprenepag
DM1TSHL HS Phase 2
DM1TSHL SN Taprenepag isopropyl; CP-544326; PF-04217329; PF-4217329
DM1TSHL CP Pfizer Inc
DM1TSHL DT Small molecular drug
DM1TSHL PC 18376177
DM1TSHL MW 478.5
DM1TSHL FM C24H22N4O5S
DM1TSHL IC InChI=1S/C24H22N4O5S/c29-24(30)18-33-22-5-1-4-20(14-22)17-27(34(31,32)23-6-2-11-25-15-23)16-19-7-9-21(10-8-19)28-13-3-12-26-28/h1-15H,16-18H2,(H,29,30)
DM1TSHL CS C1=CC(=CC(=C1)OCC(=O)O)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4
DM1TSHL IK MFFBXYNKZHTCEY-UHFFFAOYSA-N
DM1TSHL IU 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetic acid
DM1TSHL CA CAS 752187-80-7
DM1TSHL DE Glaucoma/ocular hypertension
DMDB4EJ ID DMDB4EJ
DMDB4EJ DN Tarafenacin
DMDB4EJ HS Phase 2
DMDB4EJ SN SVT-40776; Muscarinic M3 receptor antagonist (overactive bladder), SALVAT
DMDB4EJ CP Laboratorios SALVAT SA
DMDB4EJ DT Small molecular drug
DMDB4EJ PC 25147683
DMDB4EJ MW 408.4
DMDB4EJ FM C21H20F4N2O2
DMDB4EJ IC InChI=1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2/t19-/m0/s1
DMDB4EJ CS C1CN2CCC1[C@H](C2)OC(=O)N(CC3=CC(=C(C(=C3)F)F)F)C4=CC(=CC=C4)F
DMDB4EJ IK UXZDMXYRRQJIBJ-IBGZPJMESA-N
DMDB4EJ IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]carbamate
DMDB4EJ CA CAS 385367-47-5
DMDB4EJ DE Overactive bladder
DM95FR3 ID DM95FR3
DM95FR3 DN Tarextumab
DM95FR3 HS Phase 2
DM95FR3 CP Oncomed pharmaceuticals
DM95FR3 DT Monoclonal antibody
DM95FR3 DE Pancreatic cancer; Small-cell lung cancer
DMA7ISF ID DMA7ISF
DMA7ISF DN Tarloxotinib
DMA7ISF HS Phase 2
DMA7ISF SN Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0
DMA7ISF CP Rain Therapeutics
DMA7ISF DT Small molecular drug
DMA7ISF PC 51038316
DMA7ISF MW 601.9
DMA7ISF FM C24H24BrClN9O3+
DMA7ISF IC InChI=1S/C24H23BrClN9O3/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36)/p+1/b5-4+
DMA7ISF CS CN1C=NC(=C1C[N+](C)(C)C/C=C/C(=O)NC2=NC=C3C(=C2)C(=NC=N3)NC4=CC(=C(C=C4)Cl)Br)[N+](=O)[O-]
DMA7ISF IK MUJMYVFVAWFUJL-SNAWJCMRSA-O
DMA7ISF IU [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium
DMA7ISF CA CAS 1636938-13-0
DMA7ISF DE Non-small-cell lung cancer
DML97KB ID DML97KB
DML97KB DN TAS-106
DML97KB HS Phase 2
DML97KB CP Taiho Pharma U.S.A.
DML97KB DT Small molecular drug
DML97KB PC 176885
DML97KB MW 267.24
DML97KB FM C11H13N3O5
DML97KB IC InChI=1S/C11H13N3O5/c1-2-11(18)6(5-15)19-9(8(11)16)14-4-3-7(12)13-10(14)17/h1,3-4,6,8-9,15-16,18H,5H2,(H2,12,13,17)/t6-,8+,9-,11-/m1/s1
DML97KB CS C#C[C@]1([C@H](O[C@H]([C@@H]1O)N2C=CC(=NC2=O)N)CO)O
DML97KB IK JFIWEPHGRUDAJN-DYUFWOLASA-N
DML97KB IU 4-amino-1-[(2R,3R,4S,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DML97KB CA CAS 180300-43-0
DML97KB DE Head and neck cancer
DM3D52L ID DM3D52L
DM3D52L DN TAS-114
DM3D52L HS Phase 2
DM3D52L PC 53630253
DM3D52L MW 451.5
DM3D52L FM C21H29N3O6S
DM3D52L IC InChI=1S/C21H29N3O6S/c1-16(17-6-4-9-19(14-17)30-18-7-2-3-8-18)23-31(27,28)13-5-12-29-15-24-11-10-20(25)22-21(24)26/h4,6,9-11,14,16,18,23H,2-3,5,7-8,12-13,15H2,1H3,(H,22,25,26)/t16-/m1/s1
DM3D52L CS C[C@H](C1=CC(=CC=C1)OC2CCCC2)NS(=O)(=O)CCCOCN3C=CC(=O)NC3=O
DM3D52L IK AMCGLRWKUQPNKD-MRXNPFEDSA-N
DM3D52L IU N-[(1R)-1-(3-cyclopentyloxyphenyl)ethyl]-3-[(2,4-dioxopyrimidin-1-yl)methoxy]propane-1-sulfonamide
DM3D52L DE Solid tumour/cancer; Non-small-cell lung cancer
DM9QFW2 ID DM9QFW2
DM9QFW2 DN Tau-binding PET tracer
DM9QFW2 HS Phase 2
DM9QFW2 SN T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens
DM9QFW2 CP Siemens Medical Solutions Molecular Imaging
DM9QFW2 DT Small molecular drug
DM9QFW2 PC 71059746
DM9QFW2 MW 263.27
DM9QFW2 FM C16H10FN3
DM9QFW2 IC InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H
DM9QFW2 CS C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4
DM9QFW2 IK GETAAWDSFUCLBS-UHFFFAOYSA-N
DM9QFW2 IU 7-(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole
DM9QFW2 CA CAS 1415379-56-4
DM9QFW2 DE Alzheimer disease
DMZX0VF ID DMZX0VF
DMZX0VF DN Tavokinogene telseplasmid
DMZX0VF HS Phase 2
DMZX0VF SN TAVO
DMZX0VF CP OncoSec Medical
DMZX0VF DT Gene therapy
DMZX0VF DE Melanoma; Triple negative breast cancer
DM4I6XK ID DM4I6XK
DM4I6XK DN TB-402
DM4I6XK HS Phase 2
DM4I6XK SN Anti-FVIII MAb 2E9; MAb-LE2E9; TGX-LE2E9
DM4I6XK CP ThromboGenics
DM4I6XK DT Antibody
DM4I6XK DE Atrial fibrillation; Venous thromboembolism
DMDPBMH ID DMDPBMH
DMDPBMH DN TB-403
DMDPBMH HS Phase 2
DMDPBMH CP BioInvent International Lund, Sweden Oncurious Leuven, Belgium
DMDPBMH DE Glioblastoma of brain
DMZTOJ6 ID DMZTOJ6
DMZTOJ6 DN TBA-7371
DMZTOJ6 HS Phase 2
DMZTOJ6 SN 1494675-86-3; DprE1-IN-1; AZ7371; N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide; UNII-R3T98GBE3C; AZ-7371; R3T98GBE3C; CHEMBL3109802; 1H-Pyrrolo(3,2-b)pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-((6-methoxy-5-methyl-4-pyrimidinyl)methyl)-6-methyl-; 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-4-pyrimidinyl)methyl]-6-methyl-; ZA7371; AZ-7371DprE1-IN-1; AZ7371;DprE1-IN-1; SCHEMBL16395186; EX-A777; BCP16818; BDBM50019654; MFCD29477419; ZINC103248024; CS-5414; ZA-7371; HY-19750; FT-0700212; J-690193; N-(2-Hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6- methyl-1H-pyrrolo(3,2-b)pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-pyrimidin-4-yl)methyl]-6-methyl-pyrrolo[3,2-b]pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide
DMZTOJ6 CP TB Alliance
DMZTOJ6 DT Small molecular drug
DMZTOJ6 PC 72792692
DMZTOJ6 MW 355.4
DMZTOJ6 FM C18H21N5O3
DMZTOJ6 IC InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
DMZTOJ6 CS CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
DMZTOJ6 IK VDRYGTNDKXIPSK-UHFFFAOYSA-N
DMZTOJ6 IU N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide
DMZTOJ6 CA CAS 1494675-86-3
DMZTOJ6 DE Tuberculosis
DMZCA0K ID DMZCA0K
DMZCA0K DN TBC-3711
DMZCA0K HS Phase 2
DMZCA0K SN N-(2-Acetyl-4,6-dimethylphenyl)-3-[N-(3,4-dimethylisoxazol-5-yl)sulfamoyl]thiophene-2-carboxamide
DMZCA0K CP Encysive Pharmaceuticals
DMZCA0K DT Small molecular drug
DMZCA0K PC 9911482
DMZCA0K MW 447.5
DMZCA0K FM C20H21N3O5S2
DMZCA0K IC InChI=1S/C20H21N3O5S2/c1-10-8-11(2)17(15(9-10)14(5)24)21-19(25)18-16(6-7-29-18)30(26,27)23-20-12(3)13(4)22-28-20/h6-9,23H,1-5H3,(H,21,25)
DMZCA0K CS CC1=CC(=C(C(=C1)C(=O)C)NC(=O)C2=C(C=CS2)S(=O)(=O)NC3=C(C(=NO3)C)C)C
DMZCA0K IK IAYNHDZSSDUYHY-UHFFFAOYSA-N
DMZCA0K IU N-(2-acetyl-4,6-dimethylphenyl)-3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxamide
DMZCA0K CA CAS 349453-49-2
DMZCA0K DE Hypotension
DMM5BVG ID DMM5BVG
DMM5BVG DN TBR-760
DMM5BVG HS Phase 2
DMM5BVG SN CHEMBL4594435; BIM-23A760
DMM5BVG CP Tiburio Therapeutics
DMM5BVG DT Small molecular drug
DMM5BVG PC 139593389
DMM5BVG DE Pituitary adenoma
DM8AM60 ID DM8AM60
DM8AM60 DN TC-5214
DM8AM60 HS Phase 2
DM8AM60 SN Dexmecamylamine; DEXMECAMYLAMINE; UNII-5Y1141YI4U; 107538-05-6; 5Y1141YI4U; TC 5214; (1R,2S,4S)-N,2,3,3-Tetramethylbicyclo(2.2.1)heptan-2-amine; Dexmecamylamine [USAN:INN]; Dexmecamylamine (USAN); CHEMBL2103881; BDBM50045047; ZINC43763856; DB11807; D10111; UNII-6EE945D3OK component IMYZQPCYWPFTAG-NGZCFLSTSA-N; Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl-, (1R,2S,4S)-
DM8AM60 CP Atacama Therapeutics Wellesley, MA
DM8AM60 PC 12358971
DM8AM60 MW 203.75
DM8AM60 FM C11H22ClN
DM8AM60 IC InChI=1S/C11H21N.ClH/c1-10(2)8-5-6-9(7-8)11(10,3)12-4;/h8-9,12H,5-7H2,1-4H3;1H/t8-,9+,11-;/m0./s1
DM8AM60 CS C[C@@]1([C@@H]2CC[C@@H](C2)C1(C)C)NC.Cl
DM8AM60 IK PKVZBNCYEICAQP-GSTSRXQZSA-N
DM8AM60 IU (1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine;hydrochloride
DM8AM60 CA CAS 107596-30-5
DM8AM60 DE Palmar hyperhidrosis
DMWPI2U ID DMWPI2U
DMWPI2U DN TC-6499-12
DMWPI2U HS Phase 2
DMWPI2U SN TC-6499; Alpha 4 beta 2 neuronal nicotinic modulator (pain/IBS), Targacept
DMWPI2U CP Targacept Inc
DMWPI2U DE Irritable bowel syndrome
DMNFP21 ID DMNFP21
DMNFP21 DN TC-6987
DMNFP21 HS Phase 2
DMNFP21 PC 44511587
DMNFP21 MW 357.4
DMNFP21 FM C20H21F2N3O
DMNFP21 IC InChI=1S/C20H21F2N3O/c21-16-9-15(10-17(22)11-16)20(26)24-19-14-3-6-25(7-4-14)18(19)8-13-2-1-5-23-12-13/h1-2,5,9-12,14,18-19H,3-4,6-8H2,(H,24,26)/t18-,19+/m0/s1
DMNFP21 CS C1CN2CCC1[C@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC(=CC(=C4)F)F
DMNFP21 IK UAKZGMMGIMKFMV-RBUKOAKNSA-N
DMNFP21 IU 3,5-difluoro-N-[(2S,3R)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]benzamide
DMNFP21 CA CAS 1196701-27-5
DMNFP21 DE Asthma
DM9PVNJ ID DM9PVNJ
DM9PVNJ DN TCN-032
DM9PVNJ HS Phase 2
DM9PVNJ CP Theraclone Sciences
DM9PVNJ DT Antibody
DM9PVNJ DE Influenza virus infection
DMJ3KPO ID DMJ3KPO
DMJ3KPO DN TD-101
DMJ3KPO HS Phase 2
DMJ3KPO CP Transderm
DMJ3KPO DT siRNA drug
DMJ3KPO DE Pachyonychia; Flavivirus infection
DMTJMK5 ID DMTJMK5
DMTJMK5 DN TD-1211
DMTJMK5 HS Phase 2
DMTJMK5 SN Axelopran; UNII-85U7ROB149; TD-1211; 85U7ROB149; 949904-48-7; Axelopran [USAN:INN]; TD 1211; SCHEMBL1773803; SCHEMBL1773801; CHEMBL3137313; AKOS027337117; SB16947; DB12013; Benzamide, 3-((3-endo)-8-(2-((cyclohexylmethyl)((2S)-2,3-dihydroxy-1-oxopropyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)-
DMTJMK5 CP Theravance
DMTJMK5 DT Small molecular drug
DMTJMK5 PC 67156338
DMTJMK5 MW 457.6
DMTJMK5 FM C26H39N3O4
DMTJMK5 IC InChI=1S/C26H39N3O4/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32)/t21?,22-,23+,24-/m0/s1
DMTJMK5 CS C1CCC(CC1)CN(CCN2[C@@H]3CC[C@H]2CC(C3)C4=CC(=CC=C4)C(=O)N)C(=O)[C@H](CO)O
DMTJMK5 IK ATLYLVPZNWDJBW-NHYNNZIHSA-N
DMTJMK5 IU 3-[(1S,5R)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide
DMTJMK5 CA CAS 949904-48-7
DMTJMK5 DE Opioid-induced constipation
DM6SANW ID DM6SANW
DM6SANW DN TD-5108
DM6SANW HS Phase 2
DM6SANW SN Velusetrag; TD-5108; UNII-J4VNV64ARB; J4VNV64ARB; Velusetrag [USAN:INN]; SCHEMBL2917361; GTPL8425; CHEMBL2087337; Serotonin 5-HT4 Receptor Agonists; BDBM50391069; ZINC15821733; TD 5108; DB12702; compound 15 [PMID 22959244]; N-((1R,3R,5S)-8-((2R)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8-azabicyclo(3.2.1)oct-3-yl)-1-(1-methylethyl)-2-oxo-1,2-dihydroquinoline-3-carboxamide; 3-Quinolinecarboxamide, 1,2-dihydro-N-((3-endo)-8-((2R)-2-hydroxy-3-(methyl(methylsulfonyl)amino)propyl)-8-azabicyclo(3.2.1)oct-3-yl)-1-(1-meth
DM6SANW DT Small molecular drug
DM6SANW PC 11842633
DM6SANW MW 504.6
DM6SANW FM C25H36N4O5S
DM6SANW IC InChI=1S/C25H36N4O5S/c1-16(2)29-23-8-6-5-7-17(23)11-22(25(29)32)24(31)26-18-12-19-9-10-20(13-18)28(19)15-21(30)14-27(3)35(4,33)34/h5-8,11,16,18-21,30H,9-10,12-15H2,1-4H3,(H,26,31)/t18?,19-,20+,21-/m0/s1
DM6SANW CS CC(C)N1C2=CC=CC=C2C=C(C1=O)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C[C@H](CN(C)S(=O)(=O)C)O
DM6SANW IK HXLOHDZQBKCUCR-VTHDOGFWSA-N
DM6SANW IU N-[(1S,5R)-8-[(2R)-2-hydroxy-3-[methyl(methylsulfonyl)amino]propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-propan-2-ylquinoline-3-carboxamide
DM6SANW CA CAS 866933-46-2
DM6SANW DE Gastroparesis
DM3C9NV ID DM3C9NV
DM3C9NV DN TD-8954
DM3C9NV HS Phase 2
DM3C9NV SN TD-8954; UNII-35F0Y2W16Q; CHEMBL2402904; 35F0Y2W16Q; 916075-84-8; compound 18 [PMID 23756062]; SCHEMBL390795; GTPL8426; BDBM50436989; SB17471; DB12725; 1-Piperidinecarboxylic acid, 4-((4-((((2-(1-methylethyl)-1H-benzimidazol-7-yl)carbonyl)amino)methyl)-1-piperidinyl)methyl)-, methyl ester; methyl 4-[[4-[[(2-propan-2-yl1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate
DM3C9NV CP Theravance
DM3C9NV DT Small molecular drug
DM3C9NV PC 11961293
DM3C9NV MW 455.6
DM3C9NV FM C25H37N5O3
DM3C9NV IC InChI=1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)
DM3C9NV CS CC(C)C1=NC2=C(C=CC=C2N1)C(=O)NCC3CCN(CC3)CC4CCN(CC4)C(=O)OC
DM3C9NV IK MZOITCJKGUIQEI-UHFFFAOYSA-N
DM3C9NV IU methyl 4-[[4-[[(2-propan-2-yl-1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate
DM3C9NV CA CAS 916075-84-8
DM3C9NV DE Alzheimer disease; Gastrointestinal disease
DMQD5NA ID DMQD5NA
DMQD5NA DN TD-9855
DMQD5NA HS Phase 2
DMQD5NA PC 46189893
DMQD5NA MW 321.3
DMQD5NA FM C18H18F3NO
DMQD5NA IC InChI=1S/C18H18F3NO/c19-14-9-16(20)18(17(21)10-14)23-11-13-3-1-2-4-15(13)12-5-7-22-8-6-12/h1-4,9-10,12,22H,5-8,11H2
DMQD5NA CS C1CNCCC1C2=CC=CC=C2COC3=C(C=C(C=C3F)F)F
DMQD5NA IK TZIALEBTHQWNAO-UHFFFAOYSA-N
DMQD5NA IU 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine
DMQD5NA CA CAS 1227056-84-9
DMQD5NA DE Pain; Orthostatic hypotension
DM6YI5T ID DM6YI5T
DM6YI5T DN Tegobuvir
DM6YI5T HS Phase 2
DM6YI5T SN Tegobuvir; 1000787-75-6; UNII-5NOK5X389M; 5-((6-(2,4-bis(Trifluoromethyl)phenyl)pyridazin-3-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; 5NOK5X389M; GS-9190; GS-333126; W-204340; 5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-;5H-Imidazo[4,5-c]pyridine, 5-[[6-[2,4-bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-; Tegobuvir [USAN:INN]; GS 9190; Tegobuvir (USAN/INN); GS 333126; SCHEMBL496778; CHEMBL1957287; DTXSID80142917
DM6YI5T CP Gilead
DM6YI5T DT Small molecular drug
DM6YI5T PC 23649154
DM6YI5T MW 517.4
DM6YI5T FM C25H14F7N5
DM6YI5T IC InChI=1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2
DM6YI5T CS C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F
DM6YI5T IK XBEQSQDCBSKCHJ-UHFFFAOYSA-N
DM6YI5T IU 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine
DM6YI5T CA CAS 1000787-75-6
DM6YI5T DE Hepatitis C virus infection
DM9AWSO ID DM9AWSO
DM9AWSO DN Telapristone
DM9AWSO HS Phase 2
DM9AWSO SN Telapristone acetate; Proellex; 198414-31-2; UNII-1K9EYK92PQ; CDB-4124; 1K9EYK92PQ; Telapristone acetate [USAN]; Telapristone acetate (USAN); CCRIS 9331; CDB 4124; SCHEMBL374762; CHEMBL2105694; DTXSID60173587; RU-44675; 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione; D09972; 19-Norpregna-4,9-diene-3,20-dione, 17-(acetyloxy)-11-(4-(dimethylamino)phenyl)-21-methoxy-, (11beta)-; A-Acetoxy-21-methoxy-11
DM9AWSO CP Repros Therapeutics
DM9AWSO DT Small molecular drug
DM9AWSO PC 20761503
DM9AWSO MW 463.6
DM9AWSO FM C29H37NO4
DM9AWSO IC InChI=1S/C29H37NO4/c1-28-16-24(18-5-8-20(9-6-18)30(2)3)27-22-12-10-21(31)15-19(22)7-11-23(27)25(28)13-14-29(28,33)26(32)17-34-4/h5-6,8-9,15,23-25,33H,7,10-14,16-17H2,1-4H3/t23-,24+,25-,28-,29-/m0/s1
DM9AWSO CS C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(C(=O)COC)O)C5=CC=C(C=C5)N(C)C
DM9AWSO IK BHERMCLNVOVDPU-DQFOBABISA-N
DM9AWSO IU (8S,11R,13S,14S,17R)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(2-methoxyacetyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DM9AWSO CA CAS 198414-30-1
DM9AWSO DE Endometriosis
DMFT5D6 ID DMFT5D6
DMFT5D6 DN Telcagepant
DMFT5D6 HS Phase 2
DMFT5D6 SN MK 0974; MK0974; N7R; MK-0974; Telcagepant (USAN); N-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
DMFT5D6 CP Merck
DMFT5D6 DT Small molecular drug
DMFT5D6 PC 11319053
DMFT5D6 MW 566.5
DMFT5D6 FM C26H27F5N6O3
DMFT5D6 IC InChI=1S/C26H27F5N6O3/c27-18-4-1-3-17(21(18)28)15-6-7-19(23(38)36(13-15)14-26(29,30)31)33-24(39)35-11-8-16(9-12-35)37-20-5-2-10-32-22(20)34-25(37)40/h1-5,10,15-16,19H,6-9,11-14H2,(H,33,39)(H,32,34,40)/t15-,19-/m1/s1
DMFT5D6 CS C1C[C@H](C(=O)N(C[C@@H]1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(NC4=O)N=CC=C5
DMFT5D6 IK CGDZXLJGHVKVIE-DNVCBOLYSA-N
DMFT5D6 IU N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
DMFT5D6 CA CAS 781649-09-0
DMFT5D6 DE Cluster headache; Migraine
DM8UCNK ID DM8UCNK
DM8UCNK DN Telisotuzumab vedotin
DM8UCNK HS Phase 2
DM8UCNK SN ABBV-399
DM8UCNK CP AbbVie
DM8UCNK DT Antibody
DM8UCNK DE Non-small-cell lung cancer
DMUQH78 ID DMUQH78
DMUQH78 DN Tempol
DMUQH78 HS Phase 2
DMUQH78 SN MTS-01; Tempol (hypertension); Tempol (hypertension), Cary; Tempol (gel formulation, hair loss), Mitos
DMUQH78 CP Georgetown University; Mitos Pharmaceuticals Inc
DMUQH78 DT Small molecular drug
DMUQH78 PC 137994
DMUQH78 MW 172.24
DMUQH78 FM C9H18NO2
DMUQH78 IC InChI=1S/C9H18NO2/c1-8(2)5-7(11)6-9(3,4)10(8)12/h7,11H,5-6H2,1-4H3
DMUQH78 CS CC1(CC(CC(N1[O])(C)C)O)C
DMUQH78 IK UZFMOKQJFYMBGY-UHFFFAOYSA-N
DMUQH78 CA CAS 2226-96-2
DMUQH78 DE Spinal cord injury
DMVS61L ID DMVS61L
DMVS61L DN Tepoxalin
DMVS61L HS Phase 2
DMVS61L SN TEPOXALIN; 103475-41-8; Orf-20485; ORF 20485; Tepoxaline; Tepoxalina; Tepoxalinum [Latin]; Tepoxaline [French]; Tepoxalina [Spanish]; RWJ 20485; Tepoxalin [USAN:INN]; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; UNII-TZ4OX61974; C20H20ClN3O3; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-; CHEMBL316040; CHEBI:76277; TZ4OX61974; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; RWJ-20485; SIL-4R
DMVS61L DT Small molecular drug
DMVS61L PC 59757
DMVS61L MW 385.8
DMVS61L FM C20H20ClN3O3
DMVS61L IC InChI=1S/C20H20ClN3O3/c1-23(26)20(25)12-7-16-13-19(14-3-5-15(21)6-4-14)24(22-16)17-8-10-18(27-2)11-9-17/h3-6,8-11,13,26H,7,12H2,1-2H3
DMVS61L CS CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O
DMVS61L IK XYKWNRUXCOIMFZ-UHFFFAOYSA-N
DMVS61L IU 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-N-hydroxy-N-methylpropanamide
DMVS61L CA CAS 103475-41-8
DMVS61L CB CHEBI:76277
DMVS61L DE Asthma
DMC3P45 ID DMC3P45
DMC3P45 DN Terameprocol
DMC3P45 HS Phase 2
DMC3P45 SN EM-1421; Terameprocol (INN/USAN); Meso-Tetra-O-methylnordihydroguaiaretic acid; Meso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol; Meso-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene
DMC3P45 CP Erimos
DMC3P45 DT Small molecular drug
DMC3P45 PC 476861
DMC3P45 MW 358.5
DMC3P45 FM C22H30O4
DMC3P45 IC InChI=1S/C22H30O4/c1-15(11-17-7-9-19(23-3)21(13-17)25-5)16(2)12-18-8-10-20(24-4)22(14-18)26-6/h7-10,13-16H,11-12H2,1-6H3/t15-,16+
DMC3P45 CS C[C@H](CC1=CC(=C(C=C1)OC)OC)[C@@H](C)CC2=CC(=C(C=C2)OC)OC
DMC3P45 IK ORQFDHFZSMXRLM-IYBDPMFKSA-N
DMC3P45 IU 4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene
DMC3P45 CA CAS 24150-24-1
DMC3P45 DE Solid tumour/cancer
DMZNFPG ID DMZNFPG
DMZNFPG DN Terguride
DMZNFPG HS Phase 2
DMZNFPG SN terguride; Dironyl; 37686-84-3; trans-Dihydrolisuride; (+)-Terguride; (5R,8S,10R)-Terguride; S(+)-Terguride; UNII-21OJT43Q88; TDHL; Transdihydrolisuride; (+)-(5R,8S,10R)-Terguride; CHEMBL73151; MLS000069833; Terguride [INN]; 21OJT43Q88; Terguridum [Latin]; Tergurida [Spanish]; SMR000058934; 9,10-alpha-Dihydrolisuride; 1,1-diethyl-3-(6-methyl-8alpha-ergolinyl)urea; Terguridum; Tergurida; Tergurid; EINECS 253-624-2; BRN 0766582; ZK 31224; trans-Dihydro Lisuride; 6-Methyl-8alpha-(diethylcarbamoylamino)ergoline
DMZNFPG CP ErgoNex Pharma; Pfizer
DMZNFPG DT Small molecular drug
DMZNFPG PC 443951
DMZNFPG MW 340.5
DMZNFPG FM C20H28N4O
DMZNFPG IC InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)/t14-,16+,18+/m0/s1
DMZNFPG CS CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
DMZNFPG IK JOAHPSVPXZTVEP-YXJHDRRASA-N
DMZNFPG IU 3-[(6aR,9S,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMZNFPG CA CAS 37686-84-3
DMZNFPG CB CHEBI:32193
DMZNFPG DE Pulmonary arterial hypertension
DMR4YEG ID DMR4YEG
DMR4YEG DN Tesidolumab
DMR4YEG HS Phase 2
DMR4YEG SN LFG316
DMR4YEG CP Novartis
DMR4YEG DT Antibody
DMR4YEG DE Age-related macular degeneration
DM1KGS7 ID DM1KGS7
DM1KGS7 DN Tesofensine
DM1KGS7 HS Phase 2
DM1KGS7 SN NS-2330
DM1KGS7 CP NeuroSearch A/S
DM1KGS7 DT Small molecular drug
DM1KGS7 PC 11370864
DM1KGS7 MW 328.3
DM1KGS7 FM C17H23Cl2NO
DM1KGS7 IC InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1
DM1KGS7 CS CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl
DM1KGS7 IK VCVWXKKWDOJNIT-ZOMKSWQUSA-N
DM1KGS7 IU (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
DM1KGS7 CA CAS 195875-84-4
DM1KGS7 DE Pain
DMMK6IT ID DMMK6IT
DMMK6IT DN Testogen TDS
DMMK6IT HS Phase 2
DMMK6IT SN OriTex; OriTex); TDS-testosterone; Testosterone (oral, testosterone deficiency), Clarus; Testosterone (transdermal, TDS), TransDermal Technologies
DMMK6IT CP TransDermal Technologies Inc; Clarus Therapeutics Inc
DMMK6IT DE Hypogonadism
DMR5GSB ID DMR5GSB
DMR5GSB DN Tetrahydrouridine
DMR5GSB HS Phase 2
DMR5GSB SN 3,4,5,6-Tetrahydrouridine; NSC-112907; NSC 112907; CHEMBL2311128; 18771-50-1; U 23284; NSC-112907-D; BRN 0752319; 2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-; NSC112907; AC1L1H1G; SCHEMBL587704; 3,4,5, 6-Tetrahydrouridine; 2(1H)-Pyrimidinone, tetrahydro-4-hydroxy-1-.beta.-D-ribofuranosyl-; UCKYOOZPSJFJIZ-XVKVHKPRSA-N; MolPort-044-561-340; BDBM50421666; AKOS032953792; DB12484; LS-7719; CS-7633; HY-15345; 3,4,5,6-Tetrahydrouridine (> 80% by HPLC); J-012078
DMR5GSB CP BioVision
DMR5GSB DT Small molecular drug
DMR5GSB PC 29243
DMR5GSB MW 248.23
DMR5GSB FM C9H16N2O6
DMR5GSB IC InChI=1S/C9H16N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4-8,12-15H,1-3H2,(H,10,16)/t4-,5?,6-,7-,8-/m1/s1
DMR5GSB CS C1CN(C(=O)NC1O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMR5GSB IK UCKYOOZPSJFJIZ-XVKVHKPRSA-N
DMR5GSB IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one
DMR5GSB CA CAS 18771-50-1
DMR5GSB DE Solid tumour/cancer
DMGNK67 ID DMGNK67
DMGNK67 DN TETRAPLATIN TETRANITRATE
DMGNK67 HS Phase 2
DMGNK67 SN BBR-3464; Tetraplatin tetranitrate; Hexaamminedichlorobis[mu-(1,6-hexanediamine-kappaN:kappaN')]triplatinum(4+) tetranitrate
DMGNK67 DE Solid tumour/cancer
DM2LBC3 ID DM2LBC3
DM2LBC3 DN TEW-7197
DM2LBC3 HS Phase 2
DM2LBC3 SN Vactosertib
DM2LBC3 CP Medpacto
DM2LBC3 PC 54766013
DM2LBC3 MW 399.4
DM2LBC3 FM C22H18FN7
DM2LBC3 IC InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)
DM2LBC3 CS CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4
DM2LBC3 IK FJCDSQATIJKQKA-UHFFFAOYSA-N
DM2LBC3 IU 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline
DM2LBC3 CA CAS 1352608-82-2
DM2LBC3 DE Solid tumour/cancer; Myelodysplastic syndrome; Myeloproliferative neoplasm; Urothelial carcinoma
DMF61ML ID DMF61ML
DMF61ML DN TF0023
DMF61ML HS Phase 2
DMF61ML CP Techfields Pharma Dover, DE
DMF61ML DE Heart attack; Ischemic stroke; Type-2 diabetes
DM2ZLWH ID DM2ZLWH
DM2ZLWH DN TG-0054
DM2ZLWH HS Phase 2
DM2ZLWH SN CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology
DM2ZLWH CP TaiGen Biotechnology Co Ltd
DM2ZLWH PC 44479007
DM2ZLWH MW 566.7
DM2ZLWH FM C27H51N8O3P
DM2ZLWH IC InChI=1S/C27H51N8O3P/c28-25-19-26(35-15-13-34(14-16-35)17-18-39(36,37)38)33-27(32-25)31-21-23-9-7-22(8-10-23)20-29-11-4-12-30-24-5-2-1-3-6-24/h19,22-24,29-30H,1-18,20-21H2,(H2,36,37,38)(H3,28,31,32,33)
DM2ZLWH CS C1CCC(CC1)NCCCNCC2CCC(CC2)CNC3=NC(=CC(=N3)N4CCN(CC4)CCP(=O)(O)O)N
DM2ZLWH IK QLVSJMZJSABWRX-UHFFFAOYSA-N
DM2ZLWH IU 2-[4-[6-amino-2-[[4-[[3-(cyclohexylamino)propylamino]methyl]cyclohexyl]methylamino]pyrimidin-4-yl]piperazin-1-yl]ethylphosphonic acid
DM2ZLWH CA CAS 1191448-17-5
DM2ZLWH DE Macular degeneration
DMPH1AG ID DMPH1AG
DMPH1AG DN TG100801
DMPH1AG HS Phase 2
DMPH1AG SN 867331-82-6; TG 100801; TG100801; UNII-1VZO7A0J9S; TG-100801; 1VZO7A0J9S; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; 4-Chloro-3-(5-methyl-3-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-amino)benzo[e][1,2,4]triazin-7-yl)phenyl benzoate; C33H30ClN5O3; CHEMBL403989; SCHEMBL12198196; KS-00001CQP; BDBM97971; DTXSID20235791; MolPort-027-835-464; BCP02570; 3641AC; ABP000364; ZINC29136020; AKOS016008711; CS-0785; DB05075; NCGC00378840-01; KB-81090; HY-10186; TG100-801; W-5618
DMPH1AG CP TargeGen
DMPH1AG DT Small molecular drug
DMPH1AG PC 11973736
DMPH1AG MW 580.1
DMPH1AG FM C33H30ClN5O3
DMPH1AG IC InChI=1S/C33H30ClN5O3/c1-22-19-24(28-21-27(13-14-29(28)34)42-32(40)23-7-3-2-4-8-23)20-30-31(22)36-33(38-37-30)35-25-9-11-26(12-10-25)41-18-17-39-15-5-6-16-39/h2-4,7-14,19-21H,5-6,15-18H2,1H3,(H,35,36,38)
DMPH1AG CS CC1=CC(=CC2=C1N=C(N=N2)NC3=CC=C(C=C3)OCCN4CCCC4)C5=C(C=CC(=C5)OC(=O)C6=CC=CC=C6)Cl
DMPH1AG IK JMGXJHWTVBGOKG-UHFFFAOYSA-N
DMPH1AG IU [4-chloro-3-[5-methyl-3-[4-(2-pyrrolidin-1-ylethoxy)anilino]-1,2,4-benzotriazin-7-yl]phenyl] benzoate
DMPH1AG CA CAS 867331-82-6
DMPH1AG DE Macular degeneration
DMZ571Y ID DMZ571Y
DMZ571Y DN TG-2349
DMZ571Y HS Phase 2
DMZ571Y SN HCV NS3-4A protease inhibitor, TaiGen Biotechnology
DMZ571Y CP Taigen biotechnology
DMZ571Y PC 51037069
DMZ571Y MW 897
DMZ571Y FM C47H56N6O10S
DMZ571Y IC InChI=1S/C47H56N6O10S/c1-28(2)60-32-21-19-29(20-22-32)40-49-38-34-16-11-12-18-37(34)63-39(38)42(50-40)61-33-25-36-41(54)51-47(44(56)52-64(58,59)46(3)23-24-46)26-30(47)13-7-5-4-6-8-17-35(43(55)53(36)27-33)48-45(57)62-31-14-9-10-15-31/h7,11-13,16,18-22,28,30-31,33,35-36H,4-6,8-10,14-15,17,23-27H2,1-3H3,(H,48,57)(H,51,54)(H,52,56)/b13-7-/t30-,33-,35+,36+,47-/m1/s1
DMZ571Y CS CC(C)OC1=CC=C(C=C1)C2=NC3=C(C(=N2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)NS(=O)(=O)C8(CC8)C)OC9=CC=CC=C93
DMZ571Y IK GZRNOYTVBWWFLJ-NTPALUMKSA-N
DMZ571Y IU cyclopentyl N-[(1S,4R,6S,7Z,14S,18R)-4-[(1-methylcyclopropyl)sulfonylcarbamoyl]-2,15-dioxo-18-[[2-(4-propan-2-yloxyphenyl)-[1]benzofuro[3,2-d]pyrimidin-4-yl]oxy]-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-14-yl]carbamate
DMZ571Y CA CAS 1435923-88-8
DMZ571Y DE Hepatitis C virus infection
DMJ2FTU ID DMJ2FTU
DMJ2FTU DN TGBA01AD
DMJ2FTU HS Phase 2
DMJ2FTU SN ARABINOFURANOSYLURACIL; Spongouridin; 1-pentofuranosylpyrimidine-2,4(1H,3H)-dione; Uracil arabinoside; 3083-77-0; 1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; Uridine-5-d; AK-47314; AC1L1AWE; ACMC-209m8u; 1-.beta.-D-Ribofuranosyl-2,4(1H,3H)-pyrimidinedione; NCIOpen2_003486; Oprea1_327785; MLS006011814; CHEMBL68846; SCHEMBL2056758; ARONIS003790; AC1Q69D3; KS-00003WPG; CTK8J4890
DMJ2FTU CP Fabre-Kramer
DMJ2FTU DT Small molecular drug
DMJ2FTU PC 1177
DMJ2FTU MW 244.2
DMJ2FTU FM C9H12N2O6
DMJ2FTU IC InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)
DMJ2FTU CS C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
DMJ2FTU IK DRTQHJPVMGBUCF-UHFFFAOYSA-N
DMJ2FTU IU 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMJ2FTU CA CAS 40436-51-9
DMJ2FTU CB CHEBI:143353
DMJ2FTU DE Mood disorder
DMNXJ5B ID DMNXJ5B
DMNXJ5B DN TGFK08AA
DMNXJ5B HS Phase 2
DMNXJ5B CP Fabre Kramer Pharmaceuticals Inc
DMNXJ5B DE Generalized anxiety disorder
DMGWE4H ID DMGWE4H
DMGWE4H DN TGFK09SD
DMGWE4H HS Phase 2
DMGWE4H CP Fabre Kramer Pharmaceuticals Inc
DMGWE4H DE Hypoactive sexual desire dysfunction
DMQ6ANE ID DMQ6ANE
DMQ6ANE DN TGOF02N
DMQ6ANE HS Phase 2
DMQ6ANE CP Fabre-Kramer Pharmaceuticals
DMQ6ANE DE Schizophrenia
DMI57ZA ID DMI57ZA
DMI57ZA DN TGWOOAA
DMI57ZA HS Phase 2
DMI57ZA CP Fabre-Kramer Pharmaceuticals
DMI57ZA DE Social phobia; Generalized anxiety disorder
DMFU0JY ID DMFU0JY
DMFU0JY DN TH-302
DMFU0JY HS Phase 2
DMFU0JY SN TH-302; evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; TH-302; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
DMFU0JY CP Threshold Pharmaceuticals
DMFU0JY DT Small molecular drug
DMFU0JY PC 11984561
DMFU0JY MW 449.04
DMFU0JY FM C9H16Br2N5O4P
DMFU0JY IC InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
DMFU0JY CS CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr
DMFU0JY IK UGJWRPJDTDGERK-UHFFFAOYSA-N
DMFU0JY IU 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine
DMFU0JY CA CAS 918633-87-1
DMFU0JY DE Soft tissue sarcoma; Melanoma; Prostate cancer; Squamous cell carcinoma; Pancreatic cancer
DMW8X05 ID DMW8X05
DMW8X05 DN THR-149
DMW8X05 HS Phase 2
DMW8X05 CP Oxurion
DMW8X05 DT Small molecular drug
DMW8X05 DE Diabetic macular edema
DMBO021 ID DMBO021
DMBO021 DN THR-18
DMBO021 HS Phase 2
DMBO021 CP Thrombotech Technologies Ltd
DMBO021 PC 86291591
DMBO021 MW 2390.8
DMBO021 FM C105H167F3N28O28S2
DMBO021 IC InChI=1S/C103H166N28O26S2.C2HF3O2/c1-15-56(9)81(129-98(155)82(57(10)16-2)128-88(145)66(37-39-77(136)137)117-86(143)65(36-38-76(134)135)119-93(150)74-30-23-45-130(74)99(156)58(11)114-84(141)67(40-47-158-13)118-85(142)64(115-59(12)132)28-21-43-112-102(107)108)97(154)120-68(41-48-159-14)87(144)124-73(52-78(138)139)91(148)121-69(29-22-44-113-103(109)110)100(157)131-46-24-31-75(131)94(151)125-71(50-60-25-18-17-19-26-60)90(147)122-70(49-53(3)4)89(146)123-72(51-61-32-34-62(133)35-33-61)92(149)126-80(55(7)8)96(153)127-79(54(5)6)95(152)116-63(83(104)140)27-20-42-111-101(105)106;3-2(4,5)1(6)7/h17-19,25-26,32-35,53-58,63-75,79-82,133H,15-16,20-24,27-31,36-52H2,1-14H3,(H2,104,140)(H,114,141)(H,115,132)(H,116,152)(H,117,143)(H,118,142)(H,119,150)(H,120,154)(H,121,148)(H,122,147)(H,123,146)(H,124,144)(H,125,151)(H,126,149)(H,127,153)(H,128,145)(H,129,155)(H,134,135)(H,136,137)(H,138,139)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113);(H,6,7)/t56-,57-,58-,63-,64-,65-,66-,67-,68-,69-,70-,71?,72-,73-,74-,75-,79?,80-,81-,82-;/m0./s1
DMBO021 CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NC(CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](C(C)C)C(=O)NC(C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C.C(=O)(C(F)(F)F)O
DMBO021 IK UNDAPMUKULIMSY-HGKXDEPLSA-N
DMBO021 IU (4S)-4-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid;2,2,2-trifluoroacetic acid
DMBO021 CA CAS 1383452-03-6
DMBO021 DE Asthma
DMAVQR1 ID DMAVQR1
DMAVQR1 DN THR-184
DMAVQR1 HS Phase 2
DMAVQR1 CP Oxurion
DMAVQR1 DT Small molecular drug
DMAVQR1 DE Renal fibrosis
DM1BYNF ID DM1BYNF
DM1BYNF DN THRX-198321
DM1BYNF HS Phase 2
DM1BYNF SN Beta 2 adrenoreceptor agonist/muscarinic receptor antagonist (asthma), Theravance
DM1BYNF CP GlaxoSmithKline; Theravance
DM1BYNF DE Chronic obstructive pulmonary disease
DM4BLJM ID DM4BLJM
DM4BLJM DN Thymoctonan
DM4BLJM HS Phase 2
DM4BLJM SN FCE-25388; Thymic humoral factor gamma-2; Thymus humoral factor gamma-2; THF-gamma-2
DM4BLJM CP Weizmann Institute of Science
DM4BLJM DT Small molecular drug
DM4BLJM PC 9897695
DM4BLJM MW 918
DM4BLJM FM C43H67N9O13
DM4BLJM IC InChI=1S/C43H67N9O13/c1-24(2)19-27(45)37(58)47-29(15-16-35(54)55)40(61)50-31(22-36(56)57)38(59)46-23-34(53)52-18-10-14-33(52)42(63)48-28(13-8-9-17-44)39(60)49-30(21-26-11-6-5-7-12-26)41(62)51-32(43(64)65)20-25(3)4/h5-7,11-12,24-25,27-33H,8-10,13-23,44-45H2,1-4H3,(H,46,59)(H,47,58)(H,48,63)(H,49,60)(H,50,61)(H,51,62)(H,54,55)(H,56,57)(H,64,65)/t27-,28-,29-,30-,31-,32-,33-/m0/s1
DM4BLJM CS CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)N
DM4BLJM IK NYJVPTKMDYSZDU-MRNVWEPHSA-N
DM4BLJM IU (2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM4BLJM CA CAS 107489-37-2
DM4BLJM DE Immune System disease
DME4LA1 ID DME4LA1
DME4LA1 DN Tideglusib
DME4LA1 HS Phase 2
DME4LA1 SN NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
DME4LA1 DT Small molecular drug
DME4LA1 PC 11313622
DME4LA1 MW 334.4
DME4LA1 FM C19H14N2O2S
DME4LA1 IC InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
DME4LA1 CS C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43
DME4LA1 IK PMJIHLSCWIDGMD-UHFFFAOYSA-N
DME4LA1 IU 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
DME4LA1 CA CAS 865854-05-3
DME4LA1 CB CHEBI:147398
DME4LA1 DE Osteosarcoma
DM5XRMA ID DM5XRMA
DM5XRMA DN Tipapkinogene sovacivec
DM5XRMA HS Phase 2
DM5XRMA CP Transgene
DM5XRMA DE Cervical Intraepithelial neoplasia
DMS9BDQ ID DMS9BDQ
DMS9BDQ DN Tipelukast
DMS9BDQ HS Phase 2
DMS9BDQ SN Asthma therapy, MediciNova; KCA-757; MN-001
DMS9BDQ CP Kyorin Pharmaceutical Co Ltd
DMS9BDQ DT Small molecular drug
DMS9BDQ PC 9893228
DMS9BDQ MW 530.7
DMS9BDQ FM C29H38O7S
DMS9BDQ IC InChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)
DMS9BDQ CS CCCC1=C(C=CC(=C1OCCCC(=O)O)C(=O)C)OCCCSC2=C(C(=C(C=C2)C(=O)C)O)CCC
DMS9BDQ IK KPWYNAGOBXLMSE-UHFFFAOYSA-N
DMS9BDQ IU 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenyl)sulfanylpropoxy]-2-propylphenoxy]butanoic acid
DMS9BDQ CA CAS 125961-82-2
DMS9BDQ DE Asthma; Idiopathic pulmonary fibrosis
DM1SB94 ID DM1SB94
DM1SB94 DN Tiprelestat
DM1SB94 HS Phase 2
DM1SB94 SN Elafin; Recombinant leukocyte elastase/proteinase-3 inhibitor (iv, inflammation), Proteo Biotech
DM1SB94 CP Proteo Biotech AG
DM1SB94 PC 44201346
DM1SB94 MW 5999
DM1SB94 FM C254H416N72O75S10
DM1SB94 IC InChI=1S/C254H416N72O75S10/c1-28-129(17)195-239(387)288-142(60-38-43-85-258)208(356)283-141(59-37-42-84-257)210(358)306-168-120-407-406-119-167-228(376)294-152(99-123(5)6)215(363)284-140(58-36-41-83-256)209(357)296-158(106-191(347)348)221(369)317-200(137(25)331)244(392)299-157(105-190(345)346)218(366)308-169(248(396)321-91-49-65-172(321)231(379)274-110-186(339)310-195)121-410-408-117-165(227(375)295-155(102-138-55-33-32-34-56-138)220(368)313-194(128(15)16)251(399)325-95-53-68-175(325)232(380)292-151(252(400)401)73-77-180(262)333)302-203(351)135(23)276-207(355)147(80-97-402-26)278-183(336)107-272-206(354)163-115-404-405-116-164(225(373)277-134(22)202(350)282-148(81-98-403-27)214(362)293-153(100-124(7)8)216(364)300-159(104-182(264)335)247(395)326-96-54-71-178(326)250(398)324-94-52-67-174(324)233(381)297-156(103-181(263)334)217(365)285-143(211(359)305-167)62-45-87-269-253(265)266)304-212(360)144(63-46-88-270-254(267)268)289-240(388)196(130(18)29-2)314-219(367)154(101-125(9)10)298-241(389)197(131(19)30-3)316-242(390)198(132(20)31-4)315-236(384)177-70-51-93-323(177)249(397)170(122-411-409-118-166(307-229(168)377)226(374)286-145(74-78-188(341)342)205(353)271-108-184(337)279-160(112-327)222(370)303-163)309-223(371)161(113-328)280-185(338)109-273-230(378)171-64-48-90-320(171)245(393)149(61-39-44-86-259)291-243(391)199(136(24)330)318-224(372)162(114-329)301-238(386)193(127(13)14)311-234(382)173-66-47-89-319(173)187(340)111-275-204(352)139(57-35-40-82-255)287-237(385)192(126(11)12)312-235(383)176-69-50-92-322(176)246(394)150(75-79-189(343)344)290-213(361)146(72-76-179(261)332)281-201(349)133(21)260/h32-34,55-56,123-137,139-178,192-200,327-331H,28-31,35-54,57-122,255-260H2,1-27H3,(H2,261,332)(H2,262,333)(H2,263,334)(H2,264,335)(H,271,353)(H,272,354)(H,273,378)(H,274,379)(H,275,352)(H,276,355)(H,277,373)(H,278,336)(H,279,337)(H,280,338)(H,281,349)(H,282,350)(H,283,356)(H,284,363)(H,285,365)(H,286,374)(H,287,385)(H,288,387)(H,289,388)(H,290,361)(H,291,391)(H,292,380)(H,293,362)(H,294,376)(H,295,375)(H,296,357)(H,297,381)(H,298,389)(H,299,392)(H,300,364)(H,301,386)(H,302,351)(H,303,370)(H,304,360)(H,305,359)(H,306,358)(H,307,377)(H,308,366)(H,309,371)(H,310,339)(H,311,382)(H,312,383)(H,313,368)(H,314,367)(H,315,384)(H,316,390)(H,317,369)(H,318,372)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,400,401)(H4,265,266,269)(H4,267,268,270)/t129-,130-,131-,132-,133-,134-,135-,136+,137+,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,192-,193-,194-,195-,196-,197-,198-,199-,200-/m0/s1
DM1SB94 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCNC(=N)N)CC(=O)N)CC(=O)N)CC(C)C)CCSC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]7CCCN7C(=O)[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N4)CO)CCC(=O)O)NC2=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H]8CCCN8C(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]9CCCN9C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)[C@@H](C)CC)[C@@H](C)CC)CC(C)C)[C@@H](C)CC)CCCNC(=N)N)CCSC)C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)O)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N1)CC(=O)O)[C@@H](C)O)CC(=O)O)CCCCN)CC(C)C)CCCCN)CCCCN
DM1SB94 IK MDCUNMLZLNGCQA-HWOAGHQOSA-N
DM1SB94 IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(1R,4S,4aS,7S,7aS,10S,10aS,13aR,16S,20aS,22S,23aS,25S,26aS,28S,29aS,31S,32aS,34R,37S,40S,43S,46S,49S,52S,58R,63R,66S,72S,75R,81S,84S,87R,92R,98S)-58-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-7a,10a,23a-tris(4-aminobutyl)-7,22-bis(2-amino-2-oxoethyl)-4a,40,46,49-tetrakis[(2S)-butan-2-yl]-4,37-bis(3-carbamimidamidopropyl)-66-(2-carboxyethyl)-26a,32a-bis(carboxymethyl)-29a-[(1R)-1-hydroxyethyl]-72-(hydroxymethyl)-31,84-dimethyl-20a,25,43-tris(2-methylpropyl)-28,81-bis(2-methylsulfanylethyl)-2a,3,5a,6,8a,9,11a,15,18a,21,21a,24,24a,27,27a,30,30a,33,33a,35a,36,39,42,45,48,51,57,64,67,70,73,76,79,82,85,93,99-heptatriacontaoxo-15a,16a,38a,39a,60,61,89,90-octathia-a,2,3a,5,6a,8,9a,12a,14,19a,20,22a,23,25a,26,28a,29,31a,32,34a,35,36a,38,41,44,47,50,56,65,68,71,74,77,80,83,86,94-heptatriacontazaoctacyclo[90.25.17.434,75.263,113.010,14.016,20.052,56.094,98]tetracontahectane-87-carbonyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-5-amino-5-oxopentanoic acid
DM1SB94 CA CAS 820211-82-3
DM1SB94 DE Myocardial infarction
DMT8SMO ID DMT8SMO
DMT8SMO DN TKA-731
DMT8SMO HS Phase 2
DMT8SMO DE Pain
DMGWP8L ID DMGWP8L
DMGWP8L DN TLC-388
DMGWP8L HS Phase 2
DMGWP8L CP TLC Biopharmaceuticals
DMGWP8L PC 46871946
DMGWP8L MW 850.7
DMGWP8L FM C39H30N8O15
DMGWP8L IC InChI=1S/C39H30N8O15/c1-5-39(26-13-30-34-18(14-43(30)36(49)25(26)16-60-38(39)51)8-21-24(15-42(3)4)31(48)7-6-27(21)40-34)61-37(50)17(2)62-41-35-22-9-19(44(52)53)11-28(46(56)57)32(22)33-23(35)10-20(45(54)55)12-29(33)47(58)59/h6-13,17,48H,5,14-16H2,1-4H3/t17?,39-/m0/s1
DMGWP8L CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)OC(=O)C(C)ON=C6C7=C(C(=CC(=C7)[N+](=O)[O-])[N+](=O)[O-])C8=C6C=C(C=C8[N+](=O)[O-])[N+](=O)[O-]
DMGWP8L IK JCCCLGDYMMTBPM-HXDHBHDHSA-N
DMGWP8L IU [(19S)-8-[(dimethylamino)methyl]-19-ethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[(2,4,5,7-tetranitrofluoren-9-ylidene)amino]oxypropanoate
DMGWP8L CA CAS 1432468-79-5
DMGWP8L DE Solid tumour/cancer
DMVXLQ7 ID DMVXLQ7
DMVXLQ7 DN TLN-4601
DMVXLQ7 HS Phase 2
DMVXLQ7 SN Diazepinomicin; TLN-4601; BU-4664L; 733035-26-2; UNII-YPH994Y0RF; ECO-4601; YPH994Y0RF; 11H-Dibenzo(b,E)(1,4)diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy-10-((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl)-; TLN 4601; ECO 4601; CHEMBL550961; DTXSID40223539; SALVHVNECODMJP-GNUCVDFRSA-N; ZINC3938687; ECO-04601; DB12420; KB-81170
DMVXLQ7 DT Small molecular drug
DMVXLQ7 PC 9868980
DMVXLQ7 MW 462.6
DMVXLQ7 FM C28H34N2O4
DMVXLQ7 IC InChI=1S/C28H34N2O4/c1-18(2)8-5-9-19(3)10-6-11-20(4)14-15-30-23-16-21(31)17-25(33)27(23)29-26-22(28(30)34)12-7-13-24(26)32/h7-8,10,12-14,16-17,29,31-33H,5-6,9,11,15H2,1-4H3/b19-10+,20-14+
DMVXLQ7 CS CC(=CCC/C(=C/CC/C(=C/CN1C2=C(C(=CC(=C2)O)O)NC3=C(C1=O)C=CC=C3O)/C)/C)C
DMVXLQ7 IK SALVHVNECODMJP-GNUCVDFRSA-N
DMVXLQ7 IU 1,3,10-trihydroxy-5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-11H-benzo[b][1,4]benzodiazepin-6-one
DMVXLQ7 CA CAS 733035-26-2
DMVXLQ7 CB CHEBI:156321
DMVXLQ7 DE Solid tumour/cancer
DMKV5UM ID DMKV5UM
DMKV5UM DN TM-601
DMKV5UM HS Phase 2
DMKV5UM CP TransMolecular Inc
DMKV5UM PC 86278273
DMKV5UM MW 3996
DMKV5UM FM C158H249N53O47S11
DMKV5UM IC InChI=1S/C158H249N53O47S11/c1-77(2)55-96-138(241)205-105(144(247)186-86(125(165)228)28-18-47-173-156(166)167)70-264-262-68-103-131(234)177-63-115(217)176-64-116(218)183-87(25-12-15-44-159)128(231)178-65-117(219)184-88(29-19-48-174-157(168)169)129(232)179-66-118(220)185-89(26-13-16-45-160)133(236)202-107-72-267-269-75-110-149(252)195-98(56-81-23-10-9-11-24-81)143(246)208-124(80(5)213)154(257)209-123(79(4)212)153(256)199-102(61-122(226)227)141(244)196-99(58-83-62-172-76-181-83)139(242)189-92(37-39-113(163)215)136(239)190-94(42-53-260-7)132(235)182-78(3)126(229)187-91(30-20-49-175-158(170)171)134(237)188-90(27-14-17-46-161)135(238)203-108(73-266-265-71-106(146(249)193-96)204-137(240)93(38-40-114(164)216)191-151(254)111-31-21-50-210(111)119(221)67-180-130(233)97(194-147(107)250)57-82-33-35-84(214)36-34-82)148(251)198-100(59-120(222)223)140(243)197-101(60-121(224)225)142(245)206-109(150(253)201-103)74-268-263-69-104(200-127(230)85(162)41-52-259-6)145(248)192-95(43-54-261-8)155(258)211-51-22-32-112(211)152(255)207-110/h9-11,23-24,33-36,62,76-80,85-112,123-124,212-214H,12-22,25-32,37-61,63-75,159-162H2,1-8H3,(H2,163,215)(H2,164,216)(H2,165,228)(H,172,181)(H,176,217)(H,177,234)(H,178,231)(H,179,232)(H,180,233)(H,182,235)(H,183,218)(H,184,219)(H,185,220)(H,186,247)(H,187,229)(H,188,237)(H,189,242)(H,190,239)(H,191,254)(H,192,248)(H,193,249)(H,194,250)(H,195,252)(H,196,244)(H,197,243)(H,198,251)(H,199,256)(H,200,230)(H,201,253)(H,202,236)(H,203,238)(H,204,240)(H,205,241)(H,206,245)(H,207,255)(H,208,246)(H,209,257)(H,222,223)(H,224,225)(H,226,227)(H4,166,167,173)(H4,168,169,174)(H4,170,171,175)/t78-,79+,80+,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,123-,124-/m0/s1
DMKV5UM CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]4C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCSC)CCC(=O)N)CC5=CNC=N5)CC(=O)O)[C@@H](C)O)[C@@H](C)O)CC6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@@H](NC(=O)[C@H](CSSC[C@@H](C(=O)N4)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC(=O)O)CC(=O)O)NC(=O)[C@H](CCSC)N)CCSC)C(=O)N[C@H](C(=O)NCC(=O)N8CCC[C@H]8C(=O)N[C@H](C(=O)N3)CCC(=O)N)CC9=CC=C(C=C9)O)CCCCN)CCCNC(=N)N)CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)CC(C)C)CCCCN)CCCNC(=N)N
DMKV5UM IK QPAKKWCQMHUHNI-GQIQPHNSSA-N
DMKV5UM IU 2-[(1R,4R,5aR,8aS,9R,12S,17aS,18S,20aS,21R,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54R,59R,62S,65S,74S,77R,80S,86S,92S)-51,80,92-tris(4-aminobutyl)-5a-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-9-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-39,62-bis(3-amino-3-oxopropyl)-24-benzyl-48,86-bis(3-carbamimidamidopropyl)-20a,33-bis(carboxymethyl)-27,30-bis[(1R)-1-hydroxyethyl]-74-[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-45-methyl-8a-(2-methylpropyl)-12,42-bis(2-methylsulfanylethyl)-a,3,7a,10,10a,13,15a,18a,19,21a,22,25,28,31,34,37,40,43,46,49,52,61,64,70,73,76,79,82,85,88,91,94,97-tritriacontaoxo-2a,3a,6,7,12a,13a,56,57-octathia-2,6a,9a,11,14,16a,19a,20,22a,23,26,29,32,35,38,41,44,47,50,53,60,63,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[57.41.10.84,54.421,77.014,18.065,69]docosahectan-17a-yl]acetic acid
DMKV5UM CA CAS 163515-35-3
DMKV5UM DE Solid tumour/cancer
DMW145U ID DMW145U
DMW145U DN TMC-310911
DMW145U HS Phase 2
DMW145U CP Janssen research & development
DMW145U PC 53361968
DMW145U MW 756
DMW145U FM C38H53N5O7S2
DMW145U IC InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1
DMW145U CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7
DMW145U IK JQUNFHFWXCXPRK-AMMMHQJVSA-N
DMW145U IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
DMW145U CA CAS 1000287-05-7
DMW145U DE Human immunodeficiency virus infection
DME8PFQ ID DME8PFQ
DME8PFQ DN TMX-049
DME8PFQ HS Phase 2
DME8PFQ CP Teijin Pharma
DME8PFQ DE Diabetic nephropathy
DMH4BFD ID DMH4BFD
DMH4BFD DN TN-871
DMH4BFD HS Phase 2
DMH4BFD SN 1-[6-Butyl-5H-indeno[5,6-d]-1,3-dioxol-5-yl]-4-methylpiperazine dihydrochloride; 2-n-Butyl-5,6-methylenedioxy-1-(4-methylpiperazinyl)indene dihydrochloride
DMH4BFD DE Cognitive impairment
DM3AIF7 ID DM3AIF7
DM3AIF7 DN TNF alpha kinoid
DM3AIF7 HS Phase 2
DM3AIF7 SN TNFa Kinoid; Debio-0512; TNF-K; TNF-kinoid; Anti-TNF alpha vaccine, Neovacs
DM3AIF7 CP Neovacs SA
DM3AIF7 DT Vaccine
DM3AIF7 DE Autoimmune diabetes
DM8DZKI ID DM8DZKI
DM8DZKI DN TNP-2092
DM8DZKI HS Phase 2
DM8DZKI SN UNII-W2P7EF7O6O; W2P7EF7O6O; CBR-2092; CHEMBL4594404; 3-((E)-((4-((1-((3R)-1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl)cyclopropyl)methylamino)-1-piperidinyl)imino)methyl)rifamycin; Rifamycin, 3-((E)-((4-((1-((3R)-1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizin-8-yl)-3-pyrrolidinyl)cyclopropyl)methylamino)-1-piperidinyl)imino)methyl)-
DM8DZKI CP TenNor Therapeutics
DM8DZKI DT Small molecular drug
DM8DZKI PC 145722022
DM8DZKI MW 1205.4
DM8DZKI FM C65H81FN6O15
DM8DZKI IC InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(39-15-16-39)27-43(63(82)83)62(81)72(51)30-45(52)66/h12-14,20,26-28,30-31,33,35-36,39-41,46,53-54,58,74-78H,15-19,21-25,29H2,1-11H3,(H,68,80)(H,82,83)/b13-12+,26-20+,32-14-,67-28+/t31-,33-,35+,36-,40+,46-,53-,54+,58+,64-/m0/s1
DM8DZKI CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCC(CC5)N(C)C6(CC6)[C@@H]7CCN(C7)C8=C(C9=C(C=C(C(=O)N9C=C8F)C(=O)O)C1CC1)C)/C
DM8DZKI IK OPZFMLLAJBIKAN-YSBZUPOXSA-N
DM8DZKI IU 8-[(3R)-3-[1-[[1-[(E)-[(7S,9E,11S,12S,13S,14S,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-26-yl]methylideneamino]piperidin-4-yl]-methylamino]cyclopropyl]pyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid
DM8DZKI CA CAS 922717-97-3
DM8DZKI DE Joint infection; Skin and skin-structure infection
DMAJ6YL ID DMAJ6YL
DMAJ6YL DN TNX-1300
DMAJ6YL HS Phase 2
DMAJ6YL SN RBP-8000
DMAJ6YL CP Tonix Pharmaceuticals
DMAJ6YL DT Recombinant protein
DMAJ6YL DE Cocaine addiction
DMBIJZ6 ID DMBIJZ6
DMBIJZ6 DN Tocopherol
DMBIJZ6 HS Phase 2
DMBIJZ6 SN Methyltocols; tocoferol; tocoferoles; tocophrol; Tocopherols
DMBIJZ6 PC 14985
DMBIJZ6 IU (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
DMBIJZ6 DE Phenylketonuria
DMLCUAS ID DMLCUAS
DMLCUAS DN TOFIMILAST
DMLCUAS HS Phase 2
DMLCUAS SN CP-325366; Tofimilast < Prop INN; 9-Cyclopentyl-7-ethyl-3-(2-thienyl)-5,6-dihydro-9H-pyrazolo[3,4-c][1,2,4]triazolo[4,3-a]pyridine
DMLCUAS DT Small molecular drug
DMLCUAS PC 9896267
DMLCUAS MW 339.5
DMLCUAS FM C18H21N5S
DMLCUAS IC InChI=1S/C18H21N5S/c1-2-14-13-9-10-22-17(15-8-5-11-24-15)19-20-18(22)16(13)23(21-14)12-6-3-4-7-12/h5,8,11-12H,2-4,6-7,9-10H2,1H3
DMLCUAS CS CCC1=NN(C2=C1CCN3C2=NN=C3C4=CC=CS4)C5CCCC5
DMLCUAS IK DHCOPPHTVOXDKU-UHFFFAOYSA-N
DMLCUAS IU 12-cyclopentyl-10-ethyl-5-thiophen-2-yl-3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,10-tetraene
DMLCUAS CA CAS 185954-27-2
DMLCUAS DE Chronic obstructive pulmonary disease
DMTGNWU ID DMTGNWU
DMTGNWU DN Tofisopam
DMTGNWU HS Phase 2
DMTGNWU SN tofisopam; 22345-47-7; Grandaxin; Seriel; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; Egyt 341; Tofisopamum; 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-; tofizopam; NCGC00165912-02; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine; benzodiazepine; EGYT 341; Grandaxin; Nodeprine; Seriel; Tofisopamum [INN-Latin]; 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; Tofisopam [INN:DCF:JAN]; EINECS 244-922-3; CCRIS 8738; Emandaxin (TN); DSSTox_CID_3681; Tofisopam (JP17/INN); DSSTox_RID_77145; DSSTox_GSID_23681; SCHEMBL43522; Tofisopam (patented in japan); CHEMBL404216; SCHEMBL8086894; DTXSID3023681; CHEBI:32241; BCP09600; Tox21_112269; MFCD00823171; Tofisopam, >=98% (HPLC), solid; AKOS025401672; DB08811; QC-1212; NCGC00165912-01; NCGC00165912-03; AC-24288; LS-14948; CAS-22345-47-7; DB-045872; FT-0638212; X6663; D01254; 345T477; Q945537; Q-201839; BRD-A69095630-001-01-1; 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine; (1Z,3Z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine
DMTGNWU DT Small molecular drug
DMTGNWU PC 5502
DMTGNWU MW 382.5
DMTGNWU FM C22H26N2O4
DMTGNWU IC InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3
DMTGNWU CS CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DMTGNWU IK RUJBDQSFYCKFAA-UHFFFAOYSA-N
DMTGNWU IU 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DMTGNWU CA CAS 22345-47-7
DMTGNWU CB CHEBI:32241
DMTGNWU DE Irritable bowel syndrome; Hyperuricaemia
DMVJWPR ID DMVJWPR
DMVJWPR DN TOK-001
DMVJWPR HS Phase 2
DMVJWPR SN Galeterone; 851983-85-2; Galaterone; VN/124-1; UNII-WA33E149SW; TOK 001; VN/124; WA33E149SW; (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Galeterone [USAN:INN]; Galeterone (USAN); TOK-001(Galeterone); SCHEMBL939234; GTPL8638; 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol; CHEMBL2105738; Galeterone, >
DMVJWPR CP Tokai Pharmaceuticals
DMVJWPR DT Small molecular drug
DMVJWPR PC 11188409
DMVJWPR MW 388.5
DMVJWPR FM C26H32N2O
DMVJWPR IC InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1
DMVJWPR CS C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O
DMVJWPR IK PAFKTGFSEFKSQG-PAASFTFBSA-N
DMVJWPR IU (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMVJWPR CA CAS 851983-85-2
DMVJWPR DE Prostate cancer
DMW17KS ID DMW17KS
DMW17KS DN TOL-3021
DMW17KS HS Phase 2
DMW17KS CP Tolerion
DMW17KS DE leukaemia
DMORFZD ID DMORFZD
DMORFZD DN Tolamba
DMORFZD HS Phase 2
DMORFZD SN AIC, Dynavax; AIC, UCB Pharma; AIC-0003; Allergy therapeutic, Dynavax; Amb a 1 ISS conjugate, Dynavax; Ragweed allergy vaccine, Dynavax; Ragweed allergy vaccine, UCB Pharma; ISS-1018 (allergy), Dynavax
DMORFZD CP Dynavax Technologies
DMORFZD DT Vaccine
DMORFZD DE Allergic rhinitis
DMT4OPL ID DMT4OPL
DMT4OPL DN Tonabersat
DMT4OPL HS Phase 2
DMT4OPL SN SB-220453; USL-260; 5-HT1d agonist (migraine), Minster; 5-HT1d agonist (migraine), SB
DMT4OPL CP Upsher-smith laboratories
DMT4OPL DT Small molecular drug
DMT4OPL PC 6918324
DMT4OPL MW 391.8
DMT4OPL FM C20H19ClFNO4
DMT4OPL IC InChI=1S/C20H19ClFNO4/c1-10(24)11-5-7-16-13(8-11)17(18(25)20(2,3)27-16)23-19(26)12-4-6-15(22)14(21)9-12/h4-9,17-18,25H,1-3H3,(H,23,26)/t17-,18-/m0/s1
DMT4OPL CS CC(=O)C1=CC2=C(C=C1)OC([C@H]([C@H]2NC(=O)C3=CC(=C(C=C3)F)Cl)O)(C)C
DMT4OPL IK XLIIRNOPGJTBJD-ROUUACIJSA-N
DMT4OPL IU N-[(3S,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-chloro-4-fluorobenzamide
DMT4OPL CA CAS 175013-84-0
DMT4OPL DE Epilepsy
DMBH316 ID DMBH316
DMBH316 DN Tonapofylline
DMBH316 HS Phase 2
DMBH316 SN Bg 9928; 340021-17-2; BG-9928; UNII-83VNU4U44T; BG9928; CHEMBL386974; CHEMBL414157; 83VNU4U44T; 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[222]octanyl]propanoic acid; bicyclo[222]octane-1-propanoic acid, 4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)-; 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[222]oct-1-yl]-propionic acid; Bicyclo(222)octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; Tonapofylline [USAN:INN]
DMBH316 DT Small molecular drug
DMBH316 PC 216466
DMBH316 MW 416.5
DMBH316 FM C22H32N4O4
DMBH316 IC InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)
DMBH316 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CCC(CC3)(CC4)CCC(=O)O
DMBH316 IK ZWTVVWUOTJRXKM-UHFFFAOYSA-N
DMBH316 IU 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid
DMBH316 CA CAS 340021-17-2
DMBH316 DE Acute and chronic heart failure
DMA04DE ID DMA04DE
DMA04DE DN Topiroxostat
DMA04DE HS Phase 2
DMA04DE SN FYX-051; Xanthine oxidoreductase inhibitor (oral, gout), Fuji Yakuhin
DMA04DE CP Fuji Yakuhin Kogyo Co Ltd
DMA04DE DT Small molecular drug
DMA04DE PC 5288320
DMA04DE MW 248.24
DMA04DE FM C13H8N6
DMA04DE IC InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
DMA04DE CS C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
DMA04DE IK UBVZQGOVTLIHLH-UHFFFAOYSA-N
DMA04DE IU 4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
DMA04DE CA CAS 577778-58-6
DMA04DE DE Gout
DM2HDTM ID DM2HDTM
DM2HDTM DN Tosagestin
DM2HDTM HS Phase 2
DM2HDTM SN Org-30659; Org-30659/estradiol
DM2HDTM CP Organon BioSciences
DM2HDTM DT Small molecular drug
DM2HDTM PC 159355
DM2HDTM MW 308.4
DM2HDTM FM C21H24O2
DM2HDTM IC InChI=1S/C21H24O2/c1-4-21(23)10-9-18-17-7-5-14-11-15(22)6-8-16(14)19(17)13(2)12-20(18,21)3/h1,9-11,16-19,23H,2,5-8,12H2,3H3/t16-,17-,18-,19+,20-,21-/m0/s1
DM2HDTM CS C[C@]12CC(=C)[C@H]3[C@H]([C@@H]1C=C[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
DM2HDTM IK YJSTYQGZKJHXLN-OLGWUGKESA-N
DM2HDTM IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-11-methylidene-2,6,7,8,9,10,12,14-octahydro-1H-cyclopenta[a]phenanthren-3-one
DM2HDTM CA CAS 110072-15-6
DM2HDTM DE Contraception
DMAWLVB ID DMAWLVB
DMAWLVB DN TPI ASM8
DMAWLVB HS Phase 2
DMAWLVB CP Topigen Pharmaceuticals
DMAWLVB TC Antisense
DMAWLVB DT Antisense drug
DMAWLVB DE Asthma
DMSA2LZ ID DMSA2LZ
DMSA2LZ DN TPI-1020
DMSA2LZ HS Phase 2
DMSA2LZ SN Nitrobudesonide; NCX-1020; NO-budesonide; Budesonide-21-nitrooxymethylbenzoate
DMSA2LZ CP NicOx SA
DMSA2LZ DE Chronic obstructive pulmonary disease
DMC5TV6 ID DMC5TV6
DMC5TV6 DN TPI-287
DMC5TV6 HS Phase 2
DMC5TV6 SN 849213-15-6; (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate; TPI 287; SCHEMBL10000720; DTXSID50233967; Q27273546
DMC5TV6 CP Cortice Biosciences
DMC5TV6 DT Small molecular drug
DMC5TV6 PC 11564168
DMC5TV6 MW 870
DMC5TV6 FM C46H63NO15
DMC5TV6 IC InChI=1S/C46H63NO15/c1-13-32-58-30-20-31-45(22-55-31,61-26(6)49)36-38(60-39(51)27-17-15-14-16-18-27)46(54)21-29(57-40(52)34(50)28(19-23(2)3)47-41(53)62-42(7,8)9)24(4)33(43(46,10)11)35(56-25(5)48)37(59-32)44(30,36)12/h13-18,23,28-32,34-38,50,54H,1,19-22H2,2-12H3,(H,47,53)/t28-,29-,30-,31+,32?,34+,35-,36-,37-,38-,44+,45-,46+/m0/s1
DMC5TV6 CS CC1=C2[C@@H]([C@H]3[C@@]4([C@H](C[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO5)OC(=O)C)OC(O3)C=C)C)OC(=O)C
DMC5TV6 IK FDTAUJJRHBRHIJ-FDJAAIFISA-N
DMC5TV6 IU [(1R,2S,5R,7S,11R,12S,15S,17S,18S,19S)-2,12-diacetyloxy-9-ethenyl-17-hydroxy-15-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-14,19,20,20-tetramethyl-4,8,10-trioxapentacyclo[9.7.1.113,17.02,5.07,19]icos-13-en-18-yl] benzoate
DMC5TV6 CA CAS 849213-15-6
DMC5TV6 DE Progressive supranuclear palsy; Alzheimer disease; Glioblastoma multiforme; Breast cancer
DM4R23C ID DM4R23C
DM4R23C DN TPM-1/Morphine
DM4R23C HS Phase 2
DM4R23C CP Phosphagenics
DM4R23C DE Pain
DMYP7TO ID DMYP7TO
DMYP7TO DN Trametinib + 2141795
DMYP7TO HS Phase 2
DMYP7TO CP GlaxoSmithKline
DMYP7TO DT Combination drug
DMYP7TO PC 11707110; 2141795
DMYP7TO DE Solid tumour/cancer
DMU1LXS ID DMU1LXS
DMU1LXS DN Trastuzumab Emtansine
DMU1LXS HS Phase 2
DMU1LXS CP GenentechSouth San Francisco, CA
DMU1LXS DT Antibody drug conjugate
DMU1LXS DE Breast cancer; HER2-positive breast cancer
DM1ZQEN ID DM1ZQEN
DM1ZQEN DN TRAXOPRODIL MESYLATE
DM1ZQEN HS Phase 2
DM1ZQEN SN (S,S)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
DM1ZQEN DT Small molecular drug
DM1ZQEN PC 9802399
DM1ZQEN MW 423.5
DM1ZQEN FM C21H29NO6S
DM1ZQEN IC InChI=1S/C20H25NO3.CH4O3S/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17;1-5(2,3)4/h2-10,15,19,22-24H,11-14H2,1H3;1H3,(H,2,3,4)/t15-,19+;/m0./s1
DM1ZQEN CS C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O.CS(=O)(=O)O
DM1ZQEN IK OZBWUANKVIMZIA-WRRDZZDISA-N
DM1ZQEN IU 1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol;methanesulfonic acid
DM1ZQEN CA CAS 188591-67-5
DM1ZQEN DE Neurological disorder
DM7XZY5 ID DM7XZY5
DM7XZY5 DN Triapine
DM7XZY5 HS Phase 2
DM7XZY5 SN Triapine; 236392-56-6; 143621-35-6; 3-Apct; Pan 811; 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP; UNII-U4XIL4091C; NSC 663249; 200933-27-3; OCX 191; 2-((3-Aminopyridin-2-yl)methylene)hydrazinecarbothioamide; C7H9N5S; PAN-811; U4XIL4091C; 3-aminopyridine-2-carbaldehyde-thiosemicarbazone; [(E)-(3-amino-2-pyridyl)methyleneamino]thiourea; 3-Aminopyridine-2-carboxaldehyde- thiosemicarbazone; Hydrazinecarbothioamide, 2-((3-amino-2-pyridinyl)methylene)-; (E)-2-((3-aminopyridin-2-yl)methylene)hydrazinecarbothioamide
DM7XZY5 DT Small molecular drug
DM7XZY5 PC 9571836
DM7XZY5 MW 195.25
DM7XZY5 FM C7H9N5S
DM7XZY5 IC InChI=1S/C7H9N5S/c8-5-2-1-3-10-6(5)4-11-12-7(9)13/h1-4H,8H2,(H3,9,12,13)/b11-4+
DM7XZY5 CS C1=CC(=C(N=C1)/C=N/NC(=S)N)N
DM7XZY5 IK XMYKNCNAZKMVQN-NYYWCZLTSA-N
DM7XZY5 IU [(E)-(3-aminopyridin-2-yl)methylideneamino]thiourea
DM7XZY5 CA CAS 143621-35-6
DM7XZY5 DE Nerve injury
DMWU41P ID DMWU41P
DMWU41P DN TRIDMAC
DMWU41P HS Phase 2
DMWU41P SN 65-23-6; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-; 2-Picoline-4,5-dimethanol, 3-hydroxy-
DMWU41P CP Targacept
DMWU41P DT Small molecular drug
DMWU41P DE Mood disorder
DM13G5R ID DM13G5R
DM13G5R DN TRK-170
DM13G5R HS Phase 2
DM13G5R CP Toray Industries Inc
DM13G5R DE Inflammatory bowel disease
DM64NYP ID DM64NYP
DM64NYP DN TRN-157
DM64NYP HS Phase 2
DM64NYP SN LAMA antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals; Long acting muscarinic M3 antagonist (inhalant, COPD/asthma), Theron Pharmaceuticals
DM64NYP CP Theron pharmaceuticals
DM64NYP DE Chronic obstructive pulmonary disease
DMMQYF6 ID DMMQYF6
DMMQYF6 DN TRO-19622
DMMQYF6 HS Phase 2
DMMQYF6 SN Olesoxime; UNII-I2QN18P645; TRO 19622; NSC 21311; 22033-87-0; Cholest-4-en-3-one oxime; I2QN18P645; TRO-19622; Olesoxime, Z-; cholest-4-en-3-one, oxime; Olesoxime [USAN:INN]; SCHEMBL1010552; C27H45NO; QNTASHOAVRSLMD-FCARAQADSA-; MolPort-023-276-596; 3948AH; AKOS005145744; ZINC100657483; API0009039; 66514-00-9; 033T870; UNII-A6778U5IFY component QNTASHOAVRSLMD-FCARAQADSA-N
DMMQYF6 CP Trophos
DMMQYF6 DT Small molecular drug
DMMQYF6 PC 9930827
DMMQYF6 MW 399.7
DMMQYF6 FM C27H45NO
DMMQYF6 IC InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3/b28-21+/t19-,22+,23-,24+,25+,26+,27-/m1/s1
DMMQYF6 CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C/C(=N/O)/CC[C@]34C)C
DMMQYF6 IK QNTASHOAVRSLMD-SIWSWZRQSA-N
DMMQYF6 IU (NE)-N-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ylidene]hydroxylamine
DMMQYF6 CA CAS 66538-08-7
DMMQYF6 DE Peripheral neuropathy
DMR8Y4F ID DMR8Y4F
DMR8Y4F DN Troplasminogen alfa
DMR8Y4F HS Phase 2
DMR8Y4F SN TAPgen; BB-10153; Thrombin activatable plasminogen, British Biotech; Thrombin activatable plasminogen, Vernalis
DMR8Y4F CP Vernalis
DMR8Y4F DE Myocardial infarction
DMAZ2L6 ID DMAZ2L6
DMAZ2L6 DN TROXACITABINE
DMAZ2L6 HS Phase 2
DMAZ2L6 SN Troxatyl; BCH-4556; SPD-758; Troxacitabine < Prop INN; Beta-L-OddC; (-)-beta-L-Dioxolanecytidine
DMAZ2L6 CP Shire Pharmaceuticals
DMAZ2L6 DT Small molecular drug
DMAZ2L6 PC 454194
DMAZ2L6 MW 213.19
DMAZ2L6 FM C8H11N3O4
DMAZ2L6 IC InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1
DMAZ2L6 CS C1[C@H](O[C@H](O1)CO)N2C=CC(=NC2=O)N
DMAZ2L6 IK RXRGZNYSEHTMHC-BQBZGAKWSA-N
DMAZ2L6 IU 4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one
DMAZ2L6 CA CAS 145918-75-8
DMAZ2L6 CB CHEBI:134886
DMAZ2L6 DE Solid tumour/cancer
DMHEWT7 ID DMHEWT7
DMHEWT7 DN TRU-015
DMHEWT7 HS Phase 2
DMHEWT7 SN CytoxB20G; XXX_CytoxB20G; CD20 antagonist, Trubion; PF-5212374
DMHEWT7 CP Trubion Pharmaceuticals Inc; Trubion
DMHEWT7 DE Lymphoma
DMVX6H0 ID DMVX6H0
DMVX6H0 DN TRV027
DMVX6H0 HS Phase 2
DMVX6H0 CP Forest laboratories; trevena
DMVX6H0 PC 3082475
DMVX6H0 MW 926.1
DMVX6H0 FM C43H67N13O10
DMVX6H0 IC InChI=1S/C43H67N13O10/c1-7-24(4)35(40(63)53-31(19-27-20-47-22-49-27)41(64)56-17-9-11-32(56)38(61)50-25(5)42(65)66)55-37(60)30(18-26-12-14-28(57)15-13-26)52-39(62)34(23(2)3)54-36(59)29(51-33(58)21-46-6)10-8-16-48-43(44)45/h12-15,20,22-25,29-32,34-35,46,57H,7-11,16-19,21H2,1-6H3,(H,47,49)(H,50,61)(H,51,58)(H,52,62)(H,53,63)(H,54,59)(H,55,60)(H,65,66)(H4,44,45,48)/t24-,25+,29-,30-,31-,32-,34-,35-/m0/s1
DMVX6H0 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMVX6H0 IK XIEWFECSPPTVQN-KMIMAYJXSA-N
DMVX6H0 IU (2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMVX6H0 CA CAS 1234510-46-3
DMVX6H0 DE Heart failure
DMMNXIW ID DMMNXIW
DMMNXIW DN TS-022
DMMNXIW HS Phase 2
DMMNXIW SN Prostaglandin derivative (topical, dermatitis), Taisho
DMMNXIW CP Taisho Pharmaceutical Co Ltd
DMMNXIW PC 16049813
DMMNXIW MW 421
DMMNXIW FM C20H33ClO5S
DMMNXIW IC InChI=1S/C20H31ClO4S.H2O/c21-17-12-19(23)16(9-10-18(22)14-6-2-1-3-7-14)15(17)8-4-5-11-26-13-20(24)25;/h14-19,22-23H,1-8,11-13H2,(H,24,25);1H2/t15-,16-,17-,18-,19-;/m1./s1
DMMNXIW CS C1CCC(CC1)[C@@H](C#C[C@H]2[C@@H](C[C@H]([C@@H]2CCCCSCC(=O)O)Cl)O)O.O
DMMNXIW IK HBBRGHQOBDRHIE-HICYURJWSA-N
DMMNXIW IU 2-[4-[(1R,2S,3R,5R)-5-chloro-2-[(3S)-3-cyclohexyl-3-hydroxyprop-1-ynyl]-3-hydroxycyclopentyl]butylsulfanyl]acetic acid;hydrate
DMMNXIW DE Atopic dermatitis
DMZE6Y9 ID DMZE6Y9
DMZE6Y9 DN TT-100
DMZE6Y9 HS Phase 2
DMZE6Y9 SN TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct
DMZE6Y9 CP TriAct Therapeutics
DMZE6Y9 DE Non-small-cell lung cancer
DMSIXG4 ID DMSIXG4
DMSIXG4 DN TT-173
DMSIXG4 HS Phase 2
DMSIXG4 CP Thrombotargets
DMSIXG4 DE Bleeding disorder
DMCDMFP ID DMCDMFP
DMCDMFP DN TT-223
DMCDMFP HS Phase 2
DMCDMFP SN E1-INT; GLP1-INT; Islet cell neogenesis therapy, Transition Therapeutics; Islet neogenesis therapy, Transition; Diabetes therapy, Waratah/MGH; EGF-INT, Transition Therapeutics; Glucagon-like peptide + gastrin analog, Transition; INT (diabetes), Waratah/MGH; Epidermal growth factor analog + TT-223 (diabetes), Transition; Islet neogenesis therapy (GLP-1, gastrin), Transition; Glucagon-like peptide + TT-223, (diabetes) Transition
DMCDMFP CP Waratah Pharmaceuticals Inc
DMCDMFP DE Type-1 diabetes
DMRQ0SA ID DMRQ0SA
DMRQ0SA DN TT-401
DMRQ0SA HS Phase 2
DMRQ0SA CP Transition Therapeutics
DMRQ0SA DE Type-2 diabetes
DM6TAFE ID DM6TAFE
DM6TAFE DN TTAC-0001
DM6TAFE HS Phase 2
DM6TAFE SN VEGFR-2 antibody (cancer), PharmAbcine
DM6TAFE CP PharmAbcine
DM6TAFE DT Antibody
DM6TAFE DE Recurrent glioblastoma
DMBNU1W ID DMBNU1W
DMBNU1W DN TTP-054
DMBNU1W HS Phase 2
DMBNU1W SN Glucagon-like peptide 1 receptor modulator (oral, type 2 diabetes) TransTech Pharma
DMBNU1W CP TransTech Pharma Inc
DMBNU1W DE Type-2 diabetes
DMZ6RG2 ID DMZ6RG2
DMZ6RG2 DN TTP273
DMZ6RG2 HS Phase 2
DMZ6RG2 CP vTv Therapeutics High Point, NC
DMZ6RG2 DE Type-2 diabetes
DMBKQSZ ID DMBKQSZ
DMBKQSZ DN TTP399
DMBKQSZ HS Phase 2
DMBKQSZ CP vTv Therapeutics
DMBKQSZ DT Small interfering RNA
DMBKQSZ DE Type-1 diabetes; Type 2 diabetes
DMMNTOW ID DMMNTOW
DMMNTOW DN TTP435
DMMNTOW HS Phase 2
DMMNTOW DE Obesity
DMR37X8 ID DMR37X8
DMR37X8 DN TTP-448
DMR37X8 HS Phase 2
DMR37X8 CP TransTech Pharma
DMR37X8 DE Alzheimer disease
DMCQARM ID DMCQARM
DMCQARM DN TTP889
DMCQARM HS Phase 2
DMCQARM SN VP-14637; VP 14637; 235106-62-4; (E)-2,2'-((4-hydroxyphenyl)methylene)bis(4-((E)-(5-methyl-1H-tetrazol-1-ylimino)methyl)phenol); MDT-637; AC1O5AXS; CHEMBL3393516; SCHEMBL20741449; SCHEMBL16743389; CHEMBL3393661; (4E)-2-[(4-hydroxyphenyl)-[(3E)-3-[[(5-methyltetrazol-1-yl)amino]methylidene]-6-oxocyclohexa-1,4-dien-1-yl]methyl]-4-[[(5-methyltetrazol-1-yl)amino]methylidene]cyclohexa-2,5-dien-1-one; DB12195; ACM235106624; J-015135
DMCQARM CP TransTech Pharma
DMCQARM DT Small molecular drug
DMCQARM PC 135484065
DMCQARM MW 510.5
DMCQARM FM C25H22N10O3
DMCQARM IC InChI=1S/C25H22N10O3/c1-15-28-30-32-34(15)26-13-17-3-9-23(37)21(11-17)25(19-5-7-20(36)8-6-19)22-12-18(4-10-24(22)38)14-27-35-16(2)29-31-33-35/h3-14,25,36-38H,1-2H3/b26-13+,27-14+
DMCQARM CS CC1=NN=NN1/N=C/C2=CC(=C(C=C2)O)C(C3=C(C=CC(=C3)/C=N/N4N=NN=C4C)O)C5=CC=C(C=C5)O
DMCQARM IK BLUJRJMLDHEMRX-BMNRKXRESA-N
DMCQARM IU 2-[[2-hydroxy-5-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenol
DMCQARM CA CAS 235106-62-4
DMCQARM DE Blood forming organ disorder; Respiratory syncytial virus infection
DMW7PFS ID DMW7PFS
DMW7PFS DN Turosteride
DMW7PFS HS Phase 2
DMW7PFS SN FCE-26073
DMW7PFS CP Pharmacia & Upjohn AB
DMW7PFS DT Small molecular drug
DMW7PFS PC 65986
DMW7PFS MW 459.7
DMW7PFS FM C27H45N3O3
DMW7PFS IC InChI=1S/C27H45N3O3/c1-16(2)28-25(33)30(17(3)4)24(32)21-10-9-19-18-8-11-22-27(6,15-13-23(31)29(22)7)20(18)12-14-26(19,21)5/h16-22H,8-15H2,1-7H3,(H,28,33)/t18-,19-,20-,21+,22+,26-,27+/m0/s1
DMW7PFS CS CC(C)NC(=O)N(C(C)C)C(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)N4C)C)C
DMW7PFS IK WMPQMBUXZHMEFZ-YJPJVVPASA-N
DMW7PFS IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-6,9a,11a-trimethyl-7-oxo-N-propan-2-yl-N-(propan-2-ylcarbamoyl)-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DMW7PFS CA CAS 137099-09-3
DMW7PFS DE Prostate disease
DM28M6I ID DM28M6I
DM28M6I DN TV-1102
DM28M6I HS Phase 2
DM28M6I CP Teva Pharmaceutical & Antisense Therapeutics
DM28M6I TC Antisense
DM28M6I DT Antisense drug
DM28M6I DE Multiple sclerosis
DM19GUH ID DM19GUH
DM19GUH DN TVB-2640
DM19GUH HS Phase 2
DM19GUH CP 3-v biosciences
DM19GUH DE Advanced solid tumour; Astrocytoma; Colon cancer
DMP30SA ID DMP30SA
DMP30SA DN TVB-2640
DMP30SA HS Phase 2
DMP30SA SN FASN-IN-2; 1399177-37-7; 4-(1-(4-Cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3- yl)benzoyl)piperidin-4-yl)benzonitrile; US8871790, 480; CHEMBL3661754; SCHEMBL12488853; BDBM137084; BCP30428; EX-A3643; s9714; ZINC150188638; HY-112829; CS-0066310; TVB2640; TVB 2640;FASN-IN-2; US8871790, 152; 4-(1-(4-Cyclobutyl-2-methyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4H-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile; 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
DMP30SA CP 3-V Biosciences
DMP30SA DT Small molecular drug
DMP30SA PC 66548316
DMP30SA MW 439.6
DMP30SA FM C27H29N5O
DMP30SA IC InChI=1S/C27H29N5O/c1-17-14-24(22-4-3-5-22)25(26-29-18(2)30-31-26)15-23(17)27(33)32-12-10-21(11-13-32)20-8-6-19(16-28)7-9-20/h6-9,14-15,21-22H,3-5,10-13H2,1-2H3,(H,29,30,31)
DMP30SA CS CC1=CC(=C(C=C1C(=O)N2CCC(CC2)C3=CC=C(C=C3)C#N)C4=NNC(=N4)C)C5CCC5
DMP30SA IK BBGOSBDSLYHMRA-UHFFFAOYSA-N
DMP30SA IU 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1H-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
DMP30SA DE Non-alcoholic fatty liver disease
DMGYSZ0 ID DMGYSZ0
DMGYSZ0 DN TVI-Kidney-1
DMGYSZ0 HS Phase 2
DMGYSZ0 CP TVAX Biomedical
DMGYSZ0 DT Vaccine
DMGYSZ0 DE Renal cell carcinoma
DMKJIDU ID DMKJIDU
DMKJIDU DN TZI-41078
DMKJIDU HS Phase 2
DMKJIDU SN 3,5-Di-tert-butyl-4-hydroxybenzophenone oxime
DMKJIDU DE Arthritis
DM4NXWE ID DM4NXWE
DM4NXWE DN UB-311
DM4NXWE HS Phase 2
DM4NXWE CP United Biomedical
DM4NXWE DE Alzheimer disease
DMXLAPF ID DMXLAPF
DMXLAPF DN UCB-11056
DMXLAPF HS Phase 2
DMXLAPF SN 127390-77-6; Ucb-11056; Ucb 11056; 2-(4-morpholino-6-propyl-1,3,5-triazin-2-yl)aminoethanol; UNII-MU6BC50P47; MU6BC50P47; 2-((4-Morpholino-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; 2-((4-(4-Morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)ethanol; Ethanol,2-[[4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl]amino]-; Ethanol, 2-((4-(4-morpholinyl)-6-propyl-1,3,5-triazin-2-yl)amino)-; NERMEVBNTXXDNG-UHFFFAOYSA-N; ACMC-20msf9; AC1L2Y9Y; SCHEMBL3365592; CTK4B5589; DTXSID60155545; ZINC3803539
DMXLAPF CP UCB Pharma SA
DMXLAPF DT Small molecular drug
DMXLAPF PC 130928
DMXLAPF MW 267.33
DMXLAPF FM C12H21N5O2
DMXLAPF IC InChI=1S/C12H21N5O2/c1-2-3-10-14-11(13-4-7-18)16-12(15-10)17-5-8-19-9-6-17/h18H,2-9H2,1H3,(H,13,14,15,16)
DMXLAPF CS CCCC1=NC(=NC(=N1)N2CCOCC2)NCCO
DMXLAPF IK NERMEVBNTXXDNG-UHFFFAOYSA-N
DMXLAPF IU 2-[(4-morpholin-4-yl-6-propyl-1,3,5-triazin-2-yl)amino]ethanol
DMXLAPF CA CAS 127390-77-6
DMXLAPF DE Cognitive impairment
DM5Z34K ID DM5Z34K
DM5Z34K DN UCB-35440
DM5Z34K HS Phase 2
DM5Z34K SN 5-[4-(N-Carbamoyl-N-hydroxyamino)-1-butynyl]-2-[2-[4-[1(R)-(4-chlorophenyl)-1-phenylmethyl]piperazin-1-yl]ethoxy]benzamide
DM5Z34K PC 9894415
DM5Z34K MW 576.1
DM5Z34K FM C31H34ClN5O4
DM5Z34K IC InChI=1S/C31H34ClN5O4/c32-26-12-10-25(11-13-26)29(24-7-2-1-3-8-24)36-18-16-35(17-19-36)20-21-41-28-14-9-23(22-27(28)30(33)38)6-4-5-15-37(40)31(34)39/h1-3,7-14,22,29,40H,5,15-21H2,(H2,33,38)(H2,34,39)/t29-/m1/s1
DM5Z34K CS C1CN(CCN1CCOC2=C(C=C(C=C2)C#CCCN(C(=O)N)O)C(=O)N)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
DM5Z34K IK KHVLZYHEWIBDOU-GDLZYMKVSA-N
DM5Z34K IU 5-[4-[carbamoyl(hydroxy)amino]but-1-ynyl]-2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]benzamide
DM5Z34K CA CAS 299460-62-1
DM5Z34K DE Rhinitis
DMUNJZB ID DMUNJZB
DMUNJZB DN UCN-01
DMUNJZB HS Phase 2
DMUNJZB SN UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)
DMUNJZB CP Keryx BioPharma.
DMUNJZB TC Anticancer Agents
DMUNJZB DT Small molecular drug
DMUNJZB PC 72271
DMUNJZB MW 482.5
DMUNJZB FM C28H26N4O4
DMUNJZB IC InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
DMUNJZB CS C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC
DMUNJZB IK PBCZSGKMGDDXIJ-HQCWYSJUSA-N
DMUNJZB IU (2S,3R,4R,6R,18R)-18-hydroxy-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
DMUNJZB CA CAS 112953-11-4
DMUNJZB DE Non-small-cell lung cancer
DMIERPK ID DMIERPK
DMIERPK DN UE-2343
DMIERPK HS Phase 2
DMIERPK CP Actinogen Medical Sydney, Australia
DMIERPK DE Alzheimer disease
DMWDJ15 ID DMWDJ15
DMWDJ15 DN UFT/leucovorin calcium
DMWDJ15 HS Phase 2
DMWDJ15 CP Taiho Pharmaceutical
DMWDJ15 DE Colorectal cancer
DM2O4MI ID DM2O4MI
DM2O4MI DN UK-432097
DM2O4MI HS Phase 2
DM2O4MI SN Adenosine A2a agonist (asthma), Pfizer
DM2O4MI CP Pfizer Inc
DM2O4MI DT Small molecular drug
DM2O4MI PC 9833519
DM2O4MI MW 777.9
DM2O4MI FM C40H47N11O6
DM2O4MI IC InChI=1S/C40H47N11O6/c1-2-41-37(54)33-31(52)32(53)39(57-33)51-24-46-30-34(45-23-28(25-11-5-3-6-12-25)26-13-7-4-8-14-26)48-35(49-36(30)51)38(55)43-19-20-44-40(56)47-27-16-21-50(22-17-27)29-15-9-10-18-42-29/h3-15,18,24,27-28,31-33,39,52-53H,2,16-17,19-23H2,1H3,(H,41,54)(H,43,55)(H2,44,47,56)(H,45,48,49)/t31-,32+,33-,39+/m0/s1
DM2O4MI CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C(=O)NCCNC(=O)NC4CCN(CC4)C5=CC=CC=N5)NCC(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DM2O4MI IK ZOTHAEBAWXWVID-HXEFRTELSA-N
DM2O4MI IU 6-(2,2-diphenylethylamino)-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]-N-[2-[(1-pyridin-2-ylpiperidin-4-yl)carbamoylamino]ethyl]purine-2-carboxamide
DM2O4MI CA CAS 380221-63-6
DM2O4MI DE Chronic obstructive pulmonary disease
DM8LBUK ID DM8LBUK
DM8LBUK DN UNI-PH (1-34)
DM8LBUK HS Phase 2
DM8LBUK SN Recombinant parathyroid hormone 1-34 (osteoporosis), Uni-Bio Science Group; RhPTH 1-34 (osteoporosis), Uni-Bio Science Group
DM8LBUK CP Uni-Bio Science Group Limited
DM8LBUK DE Osteoporosis
DMOMI97 ID DMOMI97
DMOMI97 DN UNI-rE-4
DMOMI97 HS Phase 2
DMOMI97 SN RE-4 (type 2 diabetes), Uni-Bio Science Group; Recombinant exendin-4 (type 2 diabetes), Uni-Bio Science Group
DMOMI97 CP Uni-Bio Science Group Limited
DMOMI97 DE Type-2 diabetes
DMFZULI ID DMFZULI
DMFZULI DN Upamostat
DMFZULI HS Phase 2
DMFZULI SN WX-671
DMFZULI CP Wilex
DMFZULI DT Small molecular drug
DMFZULI PC 9830667
DMFZULI MW 629.8
DMFZULI FM C32H47N5O6S
DMFZULI IC InChI=1S/C32H47N5O6S/c1-8-43-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34-40)35-44(41,42)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35,40H,8,12-15,17H2,1-7H3,(H2,33,34)/t28-/m0/s1
DMFZULI CS CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC(=CC=C2)/C(=N/O)/N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
DMFZULI IK HUASEDVYRABWCV-NDEPHWFRSA-N
DMFZULI IU ethyl 4-[(2S)-3-[3-[(Z)-N'-hydroxycarbamimidoyl]phenyl]-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate
DMFZULI DE Breast cancer
DME6X27 ID DME6X27
DME6X27 DN UR-63325
DME6X27 HS Phase 2
DME6X27 SN DP-1; Histamine H4 antagonist (allergic rhinitis, asthma), Palau
DME6X27 CP Palau Pharma SA
DME6X27 PC 42603186
DME6X27 MW 259.31
DME6X27 FM C13H17N5O
DME6X27 IC InChI=1S/C13H17N5O/c1-15-7-5-18(6-7)12-11-10(16-13(14)17-12)8-3-2-4-9(8)19-11/h7,15H,2-6H2,1H3,(H2,14,16,17)
DME6X27 CS CNC1CN(C1)C2=NC(=NC3=C2OC4=C3CCC4)N
DME6X27 IK WUSKTVHULHXVSO-UHFFFAOYSA-N
DME6X27 IU 9-[3-(methylamino)azetidin-1-yl]-7-oxa-10,12-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraen-11-amine
DME6X27 DE Allergic rhinitis
DMY89BN ID DMY89BN
DMY89BN DN URC102
DMY89BN HS Phase 2
DMY89BN DE Gout
DM6RTVG ID DM6RTVG
DM6RTVG DN Urelumab
DM6RTVG HS Phase 2
DM6RTVG CP Bristol-Myers Squibb Princeton, NJ
DM6RTVG DE Solid tumour/cancer; B-cell non-hodgkin lymphoma; Melanoma
DM0YO4Q ID DM0YO4Q
DM0YO4Q DN Urocortin 2
DM0YO4Q HS Phase 2
DM0YO4Q SN Urocortin 2; Urocortin II; Urocortin-2; 351999-18-3
DM0YO4Q CP Neurocrine Biosci
DM0YO4Q PC 56843276
DM0YO4Q MW 4450
DM0YO4Q FM C194H339N63O54S
DM0YO4Q IC InChI=1S/C194H339N63O54S/c1-38-96(25)142(199)181(303)250-144(94(21)22)184(306)243-126(76-92(17)18)176(298)247-130(83-258)179(301)241-124(74-90(13)14)174(296)242-129(79-141(271)272)178(300)251-145(95(23)24)189(311)257-69-47-53-132(257)180(302)254-146(97(26)39-2)183(305)218-82-137(265)227-120(70-86(5)6)171(293)239-122(72-88(9)10)172(294)237-117(56-61-135(197)263)168(290)253-148(99(28)41-4)186(308)245-125(75-91(15)16)175(297)240-123(73-89(11)12)173(295)238-119(58-63-140(269)270)165(287)235-115(54-59-133(195)261)161(283)223-103(32)155(277)230-111(49-43-65-213-191(203)204)160(282)222-102(31)154(276)229-110(48-42-64-212-190(201)202)159(281)221-100(29)152(274)220-101(30)153(275)231-112(50-44-66-214-192(205)206)163(285)236-118(57-62-139(267)268)164(286)234-116(55-60-134(196)262)162(284)224-106(35)158(280)255-150(108(37)260)188(310)256-149(107(36)259)187(309)246-128(78-136(198)264)170(292)226-105(34)157(279)233-114(52-46-68-216-194(209)210)167(289)252-147(98(27)40-3)185(307)244-121(71-87(7)8)169(291)225-104(33)156(278)232-113(51-45-67-215-193(207)208)166(288)249-143(93(19)20)182(304)217-81-138(266)228-127(77-109-80-211-85-219-109)177(299)248-131(84-312)151(200)273/h80,85-108,110-132,142-150,258-260,312H,38-79,81-84,199H2,1-37H3,(H2,195,261)(H2,196,262)(H2,197,263)(H2,198,264)(H2,200,273)(H,211,219)(H,217,304)(H,218,305)(H,220,274)(H,221,281)(H,222,282)(H,223,283)(H,224,284)(H,225,291)(H,226,292)(H,227,265)(H,228,266)(H,229,276)(H,230,277)(H,231,275)(H,232,278)(H,233,279)(H,234,286)(H,235,287)(H,236,285)(H,237,294)(H,238,295)(H,239,293)(H,240,297)(H,241,301)(H,242,296)(H,243,306)(H,244,307)(H,245,308)(H,246,309)(H,247,298)(H,248,299)(H,249,288)(H,250,303)(H,251,300)(H,252,289)(H,253,290)(H,254,302)(H,255,280)(H,256,310)(H,267,268)(H,269,270)(H,271,272)(H4,201,202,212)(H4,203,204,213)(H4,205,206,214)(H4,207,208,215)(H4,209,210,216)/t96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107+,108+,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,142-,143-,144-,145-,146-,147-,148-,149-,150-/m0/s1
DM0YO4Q CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)N)N
DM0YO4Q IK ZEBBPGHOLWPSGI-KPLDDXDLSA-N
DM0YO4Q IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid
DM0YO4Q CA CAS 351999-18-3
DM0YO4Q DE Congestive heart failure
DM4SOAW ID DM4SOAW
DM4SOAW DN URSOLIC ACID
DM4SOAW HS Phase 2
DM4SOAW SN Ursolic acid; Prunol; Malol; Urson; 77-52-1; 3beta-Hydroxyurs-12-en-28-oic acid; (3beta)-3-Hydroxyurs-12-en-28-oic acid; 3beta-Hydroxy-12-ursen-28-ic acid; UNII-P3M2575F3F; CHEBI:9908; CCRIS 7123; EINECS 201-034-0; CHEMBL169; Merotaine; AI3-03109; NSC4060; P3M2575F3F; NSC-4060; Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-; HNMR; .beta.-Ursolic acid; NSC 4060; NSC 167406
DM4SOAW DT Small molecular drug
DM4SOAW PC 64945
DM4SOAW MW 456.7
DM4SOAW FM C30H48O3
DM4SOAW IC InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
DM4SOAW CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM4SOAW IK WCGUUGGRBIKTOS-GPOJBZKASA-N
DM4SOAW IU (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM4SOAW CA CAS 77-52-1
DM4SOAW CB CHEBI:9908
DM4SOAW DE Metabolic syndrome x
DMDPFTB ID DMDPFTB
DMDPFTB DN V-101
DMDPFTB HS Phase 2
DMDPFTB SN TETRASUL; Tetradisul; Animert; 2227-13-6; Animert V-10; Animert V-10K; Animert V-101; Philips-duphar V-101; Caswell No. 213; Tetrasul [BSI:ISO]; UNII-BEO7JP5U0R; ENT 27,115; 2,4,4',5-Tetrachlorodiphenyl sulfide; 2,4,5,4'-Tetrachlorodiphenyl sulfide; 2,4,4',5-Tetrachlorodiphenyl sulphide; V-101; V 101; p-Chlorophenyl 2,4,5-trichlorophenyl sulfide; 4-Chlorophenyl 2,4,5-trichlorophenyl sulfide; Sulfide, p-chlorophenyl 2,4,5-trichlorophenyl; EINECS 218-761-4; BEO7JP5U0R; 3,4,6,4'-Tetrachlor-diphenylsulfid; EPA Pesticide Chemical Code
DMDPFTB CP Vicept Therapeutics Inc
DMDPFTB DT Small molecular drug
DMDPFTB PC 16685
DMDPFTB MW 324
DMDPFTB FM C12H6Cl4S
DMDPFTB IC InChI=1S/C12H6Cl4S/c13-7-1-3-8(4-2-7)17-12-6-10(15)9(14)5-11(12)16/h1-6H
DMDPFTB CS C1=CC(=CC=C1SC2=CC(=C(C=C2Cl)Cl)Cl)Cl
DMDPFTB IK QUWSDLYBOVGOCW-UHFFFAOYSA-N
DMDPFTB IU 1,2,4-trichloro-5-(4-chlorophenyl)sulfanylbenzene
DMDPFTB CA CAS 2227-13-6
DMDPFTB CB CHEBI:82162
DMDPFTB DE Erythema
DM1ODP6 ID DM1ODP6
DM1ODP6 DN VA-106483
DM1ODP6 HS Phase 2
DM1ODP6 SN Fedovapagon; UNII-VX2GBO4I0V; 347887-36-9; VX2GBO4I0V; VA-106483; CHEMBL518043; Fedovapagon [INN]; SCHEMBL2547119; DTXSID40188331; MolPort-042-665-819; BDBM50246575; ZINC38471398; DB11734; NCGC00386702-01; 1,2-Pyrrolidinedicarboxamide, N2,N2-dimethyl-N1-((2-methyl-4-((2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)methyl)-, (2S)-; (2S)-N2,N2-dimethyl-N1-((2-Methyl-4-(2,3,4,5-tetrahydro-1H-1-benzazepine-1-carbonyl)phenyl)methyl)pyrrolidine-1,2-dicarboxamide
DM1ODP6 DT Small molecular drug
DM1ODP6 PC 10298385
DM1ODP6 MW 462.6
DM1ODP6 FM C27H34N4O3
DM1ODP6 IC InChI=1S/C27H34N4O3/c1-19-17-21(25(32)30-15-7-6-10-20-9-4-5-11-23(20)30)13-14-22(19)18-28-27(34)31-16-8-12-24(31)26(33)29(2)3/h4-5,9,11,13-14,17,24H,6-8,10,12,15-16,18H2,1-3H3,(H,28,34)/t24-/m0/s1
DM1ODP6 CS CC1=C(C=CC(=C1)C(=O)N2CCCCC3=CC=CC=C32)CNC(=O)N4CCC[C@H]4C(=O)N(C)C
DM1ODP6 IK RUOLFWZIFNQQGH-DEOSSOPVSA-N
DM1ODP6 IU (2S)-2-N,2-N-dimethyl-1-N-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]pyrrolidine-1,2-dicarboxamide
DM1ODP6 CA CAS 347887-36-9
DM1ODP6 DE Nocturia
DMAYWXD ID DMAYWXD
DMAYWXD DN VA-111913
DMAYWXD HS Phase 2
DMAYWXD SN VA-111913 TS; VA-913; VT-913; V1a antagonists (dysmenorrhea), Vantia; Vasopressin 1a antagonists (dysmenorrhea), Vantia/Ferring
DMAYWXD CP Ferring Pharmaceuticals Inc
DMAYWXD DT Small molecular drug
DMAYWXD PC 135564707
DMAYWXD MW 453.9
DMAYWXD FM C23H21ClFN5O2
DMAYWXD IC InChI=1S/C23H21ClFN5O2/c1-29-21-16(11-27-29)12-30(20-7-6-17(24)9-19(20)28-21)23(32)14-4-5-15(18(25)8-14)10-26-22(31)13-2-3-13/h4-9,11,13,28H,2-3,10,12H2,1H3,(H,26,31)
DMAYWXD CS CN1C2=C(CN(C3=C(N2)C=C(C=C3)Cl)C(=O)C4=CC(=C(C=C4)CNC(=O)C5CC5)F)C=N1
DMAYWXD IK VOEZSPDOPDPGSY-UHFFFAOYSA-N
DMAYWXD IU N-[[4-(8-chloro-1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)-2-fluorophenyl]methyl]cyclopropanecarboxamide
DMAYWXD CA CAS 877856-17-2
DMAYWXD DE Dysmenorrhea
DM9GZW6 ID DM9GZW6
DM9GZW6 DN Vabicaserin
DM9GZW6 HS Phase 2
DM9GZW6 SN Vabicaserin hydrochloride; PF-05208769; PF-5208769; SCA-136; WY-16629
DM9GZW6 CP Wyeth
DM9GZW6 DT Small molecular drug
DM9GZW6 PC 11521822
DM9GZW6 MW 228.33
DM9GZW6 FM C15H20N2
DM9GZW6 IC InChI=1S/C15H20N2/c1-3-11-9-16-7-8-17-10-12-4-2-5-13(12)14(6-1)15(11)17/h1,3,6,12-13,16H,2,4-5,7-10H2/t12-,13-/m0/s1
DM9GZW6 CS C1C[C@H]2CN3CCNCC4=C3C(=CC=C4)[C@H]2C1
DM9GZW6 IK NPTIPEQJIDTVKR-STQMWFEESA-N
DM9GZW6 IU (12R,16S)-7,10-diazatetracyclo[8.6.1.05,17.012,16]heptadeca-1,3,5(17)-triene
DM9GZW6 CA CAS 887258-95-9
DM9GZW6 DE Psychotic disorder
DMDAKZW ID DMDAKZW
DMDAKZW DN Vacc-4x
DMDAKZW HS Phase 2
DMDAKZW CP Bionor Pharma
DMDAKZW DT Vaccine
DMDAKZW DE Human immunodeficiency virus-1 infection
DMK7CYX ID DMK7CYX
DMK7CYX DN Vadimezan
DMK7CYX HS Phase 2
DMK7CYX SN DMXAA; AS-1404; ASA-404; R-1564; 5,6-MeXAA; 5,6-dimethylxanthenone-4-acetic acid
DMK7CYX CP Antisoma; University of Auckland
DMK7CYX DT Small molecular drug
DMK7CYX PC 123964
DMK7CYX MW 282.29
DMK7CYX FM C17H14O4
DMK7CYX IC InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)
DMK7CYX CS CC1=C(C2=C(C=C1)C(=O)C3=CC=CC(=C3O2)CC(=O)O)C
DMK7CYX IK XGOYIMQSIKSOBS-UHFFFAOYSA-N
DMK7CYX IU 2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid
DMK7CYX CA CAS 117570-53-3
DMK7CYX CB CHEBI:75934
DMK7CYX DE Solid tumour/cancer
DMIKH67 ID DMIKH67
DMIKH67 DN Valetizumab
DMIKH67 HS Phase 2
DMIKH67 DT Antibody
DMIKH67 DE Multiple sclerosis
DMAEB9O ID DMAEB9O
DMAEB9O DN Valomaciclovir stearate
DMAEB9O HS Phase 2
DMAEB9O SN Omaciclovir; Valomaciclovir; A 174606.0; A 182091.0; ABT-091; ABT-606; Anti-VZV drug; EPB-348; MIV-606; RP-606; A-174606.6; ABT-182091.0; 2HM-HBG
DMAEB9O CP Medivir AB
DMAEB9O DT Small molecular drug
DMAEB9O PC 135399823
DMAEB9O MW 618.9
DMAEB9O FM C33H58N6O5
DMAEB9O IC InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1
DMAEB9O CS CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CCOC(=O)[C@H](C(C)C)N)CN1C=NC2=C1N=C(NC2=O)N
DMAEB9O IK ACBSZTQIFTYFGH-IAPPQJPRSA-N
DMAEB9O IU [(2R)-4-[(2S)-2-amino-3-methylbutanoyl]oxy-2-[(2-amino-6-oxo-1H-purin-9-yl)methyl]butyl] octadecanoate
DMAEB9O CA CAS 195156-77-5
DMAEB9O DE Varicella zoster virus infection
DMFWZ2U ID DMFWZ2U
DMFWZ2U DN Valopicitabine dihydrochloride
DMFWZ2U HS Phase 2
DMFWZ2U SN Valopicitabine; NM-106; NM-107; NM-283; NMC-283; Hepatitis C therapeutics, Novartis/Idenix; 2'-C-methylcytidine
DMFWZ2U CP Idenix Pharmaceuticals Inc
DMFWZ2U DT Small molecular drug
DMFWZ2U PC 11293303
DMFWZ2U MW 429.3
DMFWZ2U FM C15H26Cl2N4O6
DMFWZ2U IC InChI=1S/C15H24N4O6.2ClH/c1-7(2)10(17)12(21)25-11-8(6-20)24-13(15(11,3)23)19-5-4-9(16)18-14(19)22;;/h4-5,7-8,10-11,13,20,23H,6,17H2,1-3H3,(H2,16,18,22);2*1H/t8-,10+,11-,13-,15-;;/m1../s1
DMFWZ2U CS CC(C)[C@@H](C(=O)O[C@@H]1[C@H](O[C@H]([C@]1(C)O)N2C=CC(=NC2=O)N)CO)N.Cl.Cl
DMFWZ2U IK XENHXZMAOSTXGD-DSMKLBDQSA-N
DMFWZ2U IU [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-2-(hydroxymethyl)-4-methyloxolan-3-yl] (2S)-2-amino-3-methylbutanoate;dihydrochloride
DMFWZ2U CA CAS 640725-71-9
DMFWZ2U DE Virus infection
DMCF5E0 ID DMCF5E0
DMCF5E0 DN Vaniprevir
DMCF5E0 HS Phase 2
DMCF5E0 SN Vaniprevir; UNII-CV3X74AO1H; MK-7009; MK7009; 923590-37-8; CV3X74AO1H; Vaniprevir [USAN:INN]; vanihep; 3su6; SCHEMBL3264200; BDBM103836; BCP09841; ZINC95627836; AKOS030527003; SB16734; DB11929; CS-0340; NCGC00485973-01; HY-10243; Cyclopropanecarboxamide, N-(((6-(2-carboxy-2,3-dihydro-1H-isoindol-4-yl)-2,2-dimethylhexyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethyl-, (1-2)-lactone, (1R,2R)-
DMCF5E0 CP Merck
DMCF5E0 DT Small molecular drug
DMCF5E0 PC 24765256
DMCF5E0 MW 757.9
DMCF5E0 FM C38H55N5O9S
DMCF5E0 IC InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1
DMCF5E0 CS CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
DMCF5E0 IK KUQWGLQLLVFLSM-ONAXAZCASA-N
DMCF5E0 IU (1R,21S,24S)-21-tert-butyl-N-[(1R,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-ethylcyclopropyl]-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6(11),7,9-triene-24-carboxamide
DMCF5E0 CA CAS 923590-37-8
DMCF5E0 DE Hepatitis C virus infection
DMNFVKC ID DMNFVKC
DMNFVKC DN Vapitadine
DMNFVKC HS Phase 2
DMNFVKC SN Hivenyl; Vapitadine dihydrochloride; R-129160; Vapitadine (oral), Barrier Therapeutics
DMNFVKC CP Barrier Therapeutics Inc
DMNFVKC DT Small molecular drug
DMNFVKC PC 9842252
DMNFVKC MW 296.37
DMNFVKC FM C17H20N4O
DMNFVKC IC InChI=1S/C17H20N4O/c18-15(22)14-11-20-16-17(6-8-19-9-7-17)13-4-2-1-3-12(13)5-10-21(14)16/h1-4,11,19H,5-10H2,(H2,18,22)
DMNFVKC CS C1CN2C(=CN=C2C3(CCNCC3)C4=CC=CC=C41)C(=O)N
DMNFVKC IK VQWGYPVNVICKFC-UHFFFAOYSA-N
DMNFVKC IU spiro[5,6-dihydroimidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide
DMNFVKC CA CAS 793655-64-8
DMNFVKC DE Allergic skin disorder
DMQSC5O ID DMQSC5O
DMQSC5O DN Varlilumab
DMQSC5O HS Phase 2
DMQSC5O CP Celldex Therapeutics Hampton, NJ
DMQSC5O DE Colorectal cancer; Head and neck cancer; Ovarian cancer; Recurrent glioblastoma; Renal cell carcinoma
DMKU93J ID DMKU93J
DMKU93J DN VAS-203
DMKU93J HS Phase 2
DMKU93J SN NOS inhibitor, Vasopharm; Nitric oxide synthase inhibitor, Vasopharm
DMKU93J CP Vasopharm GmbH
DMKU93J DE Brain injury
DMRJ5LP ID DMRJ5LP
DMRJ5LP DN Vasoactive intestinal peptide
DMRJ5LP HS Phase 2
DMRJ5LP SN CCRIS 7231; Vasoactive intestinal polypeptide; Vasointestinal Peptide; Vasoactive intestinal peptide, synthetic porcine; SCHEMBL3041046; GTPL1152; VIP (Vasoactive Intestinal Peptide); LS-174653; VIP
DMRJ5LP CP Mondo Biotech
DMRJ5LP DT Small molecular drug
DMRJ5LP PC 53314964
DMRJ5LP MW 3326.8
DMRJ5LP FM C147H237N43O43S
DMRJ5LP IC InChI=1S/C147H237N43O43S/c1-18-75(12)115(142(229)180-96(56-72(6)7)131(218)183-104(145(232)233)63-110(155)200)188-139(226)106(68-192)185-134(221)101(62-109(154)199)177-130(217)95(55-71(4)5)174-132(219)97(58-81-37-41-84(195)42-38-81)175-125(212)88(33-23-26-49-149)167-123(210)89(34-24-27-50-150)171-140(227)113(73(8)9)186-118(205)76(13)164-121(208)93(47-53-234-17)170-127(214)92(45-46-107(152)197)169-122(209)87(32-22-25-48-148)166-124(211)90(35-28-51-161-146(156)157)168-129(216)94(54-70(2)3)173-126(213)91(36-29-52-162-147(158)159)172-143(230)116(78(15)193)189-136(223)98(59-82-39-43-85(196)44-40-82)176-133(220)100(61-108(153)198)178-135(222)103(65-112(203)204)182-144(231)117(79(16)194)190-137(224)99(57-80-30-20-19-21-31-80)181-141(228)114(74(10)11)187-119(206)77(14)165-128(215)102(64-111(201)202)179-138(225)105(67-191)184-120(207)86(151)60-83-66-160-69-163-83/h19-21,30-31,37-44,66,69-79,86-106,113-117,191-196H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,197)(H2,153,198)(H2,154,199)(H2,155,200)(H,160,163)(H,164,208)(H,165,215)(H,166,211)(H,167,210)(H,168,216)(H,169,209)(H,170,214)(H,171,227)(H,172,230)(H,173,213)(H,174,219)(H,175,212)(H,176,220)(H,177,217)(H,178,222)(H,179,225)(H,180,229)(H,181,228)(H,182,231)(H,183,218)(H,184,207)(H,185,221)(H,186,205)(H,187,206)(H,188,226)(H,189,223)(H,190,224)(H,201,202)(H,203,204)(H,232,233)(H4,156,157,161)(H4,158,159,162)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-/m0/s1
DMRJ5LP CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N
DMRJ5LP IK VBUWHHLIZKOSMS-RIWXPGAOSA-N
DMRJ5LP IU (2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid
DMRJ5LP CA CAS 37221-79-7
DMRJ5LP DE Pulmonary arterial hypertension; Chronic obstructive pulmonary disease
DMY0UEQ ID DMY0UEQ
DMY0UEQ DN VATALANIB
DMY0UEQ HS Phase 2
DMY0UEQ SN Vatalanib; 212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919
DMY0UEQ DT Small molecular drug
DMY0UEQ PC 151194
DMY0UEQ MW 346.8
DMY0UEQ FM C20H15ClN4
DMY0UEQ IC InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
DMY0UEQ CS C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4
DMY0UEQ IK YCOYDOIWSSHVCK-UHFFFAOYSA-N
DMY0UEQ IU N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
DMY0UEQ CA CAS 212141-54-3
DMY0UEQ CB CHEBI:90620
DMY0UEQ DE Solid tumour/cancer
DM3V7QO ID DM3V7QO
DM3V7QO DN Vatelizumab
DM3V7QO HS Phase 2
DM3V7QO CP Pharmaceuticals
DM3V7QO DT Antibody
DM3V7QO DE Multiple sclerosis
DML2CPW ID DML2CPW
DML2CPW DN VAY736
DML2CPW HS Phase 2
DML2CPW CP MorphoSys; Novartis Pharmaceuticals
DML2CPW DT Antibody
DML2CPW DE Sjogren syndrome; Pemphigus vulgaris; Rheumatoid arthritis
DM0YWQ4 ID DM0YWQ4
DM0YWQ4 DN VB 1953
DM0YWQ4 HS Phase 2
DM0YWQ4 CP Vyome Therapeutics
DM0YWQ4 DE Acne vulgaris
DM047HI ID DM047HI
DM047HI DN VBP15
DM047HI HS Phase 2
DM047HI SN vamorolone; Vamorolone; 13209-41-1; UNII-8XP29XMB43; VBP-15; 8XP29XMB43; CHEMBL2348780; 17,21-Dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione; A-Methyl-9,11-dehydro Prednisolone; (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one; Vamorolone [USAN]; VBP-15 free alcohol; VBP 15; EINECS 236-177-8; AC1MHYKY; Vamorolone (USAN/INN); SCHEMBL143459; GTPL9247; A)-17,21-dihydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione; ZINC33650317
DM047HI CP ReveraGen BioPharma Rockville, MD
DM047HI PC 3035000
DM047HI MW 356.5
DM047HI FM C22H28O4
DM047HI IC InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1
DM047HI CS C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C
DM047HI IK ZYTXTXAMMDTYDQ-DGEXFFLYSA-N
DM047HI IU (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one
DM047HI CA CAS 13209-41-1
DM047HI DE Duchenne dystrophy; Inflammatory bowel disease; Multiple sclerosis; Rheumatoid arthritis
DMAJ85O ID DMAJ85O
DMAJ85O DN VDA-1102
DMAJ85O HS Phase 2
DMAJ85O CP Vidac Pharma Jerusalem, Israel
DMAJ85O DE Actinic keratosis
DME6I03 ID DME6I03
DME6I03 DN VDA-1102
DME6I03 HS Phase 2
DME6I03 SN SB18685; 941277-00-5
DME6I03 CP Vidac Pharma
DME6I03 DT Small molecular drug
DME6I03 PC 135905444
DME6I03 DE Actinic keratosis
DM5BL4C ID DM5BL4C
DM5BL4C DN Veltuzumab
DM5BL4C HS Phase 2
DM5BL4C CP Takeda
DM5BL4C DT Monoclonal antibody
DM5BL4C DE Systemic lupus erythematosus; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Solid tumour/cancer; Thrombocytopenia
DMLPEZS ID DMLPEZS
DMLPEZS DN Venglustat
DMLPEZS HS Phase 2
DMLPEZS SN Ibiglustat; 1401090-53-6; UNII-BLP1XA3FZA; BLP1XA3FZA; (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate; Ibiglustat [INN]; SCHEMBL12615329; YFHRCLAKZBDRHN-MRXNPFEDSA-N; Ibiglustat(Genz-682452 pound(c); GZ-452; SAR402671; ZINC202143443; AKOS027337125; CS-6512; Carbamic acid, N-(1-(2-(4-fluorophenyl)-4-thiazolyl)-1-methylethyl)-, (3S)-1-azabicyclo(2.2.2)oct-3-yl ester; (3S)-1-Azabicyclo(2.2.2)octan-3-yl N-(2-(2-(4-fluorophenyl)-1,3-thiazol-4-yl)propan-2-yl)carbamate; GZ4026
DMLPEZS CP Genzyme, Cambridge, MA
DMLPEZS PC 60199242
DMLPEZS MW 389.5
DMLPEZS FM C20H24FN3O2S
DMLPEZS IC InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1
DMLPEZS CS CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)O[C@@H]3CN4CCC3CC4
DMLPEZS IK YFHRCLAKZBDRHN-MRXNPFEDSA-N
DMLPEZS IU [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate
DMLPEZS CA CAS 1401090-53-6
DMLPEZS DE Fabry disease; Gaucher disease; Parkinson disease
DMFLZPC ID DMFLZPC
DMFLZPC DN VER 50589
DMFLZPC HS Phase 2
DMFLZPC TC Anticancer Agents
DMFLZPC DT Small molecular drug
DMFLZPC PC 135446210
DMFLZPC MW 388.8
DMFLZPC FM C19H17ClN2O5
DMFLZPC IC InChI=1S/C19H17ClN2O5/c1-3-21-19(25)17-16(10-4-6-11(26-2)7-5-10)18(27-22-17)12-8-13(20)15(24)9-14(12)23/h4-9,23-24H,3H2,1-2H3,(H,21,25)
DMFLZPC CS CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)OC)C3=CC(=C(C=C3O)O)Cl
DMFLZPC IK JXPCDMPJCKNLBY-UHFFFAOYSA-N
DMFLZPC IU 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-1,2-oxazole-3-carboxamide
DMFLZPC DE Breast cancer
DM104SP ID DM104SP
DM104SP DN Vericigiuat
DM104SP HS Phase 2
DM104SP CP Bayer healthcare pharmaceutical
DM104SP DE Heart failure
DMBQC3L ID DMBQC3L
DMBQC3L DN Verubulin
DMBQC3L HS Phase 2
DMBQC3L SN Azixa; Verubulin hydrochloride; EP-128495; MPC-6827; Apoptosis inducer (cancer), Myriad; Caspase inducer (cancer), Myriad; Cell cycle arrest inducer (cancer), Myriad; Tubulin inhibitor (cancer), Myriad
DMBQC3L CP Maxim Pharmaceuticals Inc
DMBQC3L DT Small molecular drug
DMBQC3L PC 11414799
DMBQC3L MW 279.34
DMBQC3L FM C17H17N3O
DMBQC3L IC InChI=1S/C17H17N3O/c1-12-18-16-7-5-4-6-15(16)17(19-12)20(2)13-8-10-14(21-3)11-9-13/h4-11H,1-3H3
DMBQC3L CS CC1=NC2=CC=CC=C2C(=N1)N(C)C3=CC=C(C=C3)OC
DMBQC3L IK SNHCRNMVYDHVDT-UHFFFAOYSA-N
DMBQC3L IU N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine
DMBQC3L CA CAS 827031-83-4
DMBQC3L DE Solid tumour/cancer; Brain metastases; Glioblastoma multiforme; Recurrent glioblastoma
DM0POWG ID DM0POWG
DM0POWG DN Vidofludimus
DM0POWG HS Phase 2
DM0POWG SN Vidofludimus; 717824-30-1; 4SC-101; UNII-8Y1PJ3VG81; SC12267; Vidofludimus(4SC-101; SC12267); CHEMBL197194; 8Y1PJ3VG81; 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic Acid; 2-{[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid; 2-[[2-fluoranyl-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid; Vidofludimus [INN]; SC 12267; SCHEMBL247888; GTPL9860; KS-00000TTT; BDBM16111; EX-A546; DTXSID50431325; MolPort-039-193-851; BCP14555; AOB87354; s7262; ZINC14960644
DM0POWG CP 4SC AG
DM0POWG DT Small molecular drug
DM0POWG PC 9820008
DM0POWG MW 355.4
DM0POWG FM C20H18FNO4
DM0POWG IC InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
DM0POWG CS COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F
DM0POWG IK XPRDUGXOWVXZLL-UHFFFAOYSA-N
DM0POWG IU 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
DM0POWG CA CAS 717824-30-1
DM0POWG DE Inflammatory bowel disease; Rheumatoid arthritis
DME7VZD ID DME7VZD
DME7VZD DN Vilaprisan
DME7VZD HS Phase 2
DME7VZD SN Vilaprisan; UNII-IN59K53GI9; BAY1002670; IN59K53GI9; 1262108-14-4; Vilaprisan [INN]; BAY 1002670; Vilaprisan [USAN:INN]; Vilaprisan (USAN/INN); SCHEMBL2121854; CHEMBL3989936; BCP24069; DB11971; 20,20,21,21,21-Pentafluoro-17-hydroxy-11beta-(4-(methanesulfonyl)phenyl)-19-nor-17alpha-pregna-4,9-dien-3-one; 19-Norpregna-4,9-dien-3-one, 20,20,21,21,21-pentafluoro-17-hydroxy-11-(4-(methylsulfonyl)phenyl)-, (11beta,17alpha)-
DME7VZD DT Small molecular drug
DME7VZD PC 50915138
DME7VZD MW 544.6
DME7VZD FM C27H29F5O4S
DME7VZD IC InChI=1S/C27H29F5O4S/c1-24-14-21(15-3-7-18(8-4-15)37(2,35)36)23-19-10-6-17(33)13-16(19)5-9-20(23)22(24)11-12-25(24,34)26(28,29)27(30,31)32/h3-4,7-8,13,20-22,34H,5-6,9-12,14H2,1-2H3/t20-,21+,22-,24-,25-/m0/s1
DME7VZD CS C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(C(C(F)(F)F)(F)F)O)C5=CC=C(C=C5)S(=O)(=O)C
DME7VZD IK JUFWQQVHQFDUOD-ANRPBIDPSA-N
DME7VZD IU (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DME7VZD CA CAS 1262108-14-4
DME7VZD DE Endometriosis
DM2X0SP ID DM2X0SP
DM2X0SP DN VIR-2218
DM2X0SP HS Phase 2
DM2X0SP SN ALN-HBV02
DM2X0SP CP Alnylam Pharmaceuticals; Vir Biotechnology
DM2X0SP DT Small interfering RNA
DM2X0SP DE Hepatitis B virus infection
DMEXMV5 ID DMEXMV5
DMEXMV5 DN Virexxa
DMEXMV5 HS Phase 2
DMEXMV5 CP Pharmsynthez ZAO
DMEXMV5 DE Endometrial cancer
DM1G6ME ID DM1G6ME
DM1G6ME DN VIS410
DM1G6ME HS Phase 2
DM1G6ME CP Visterra
DM1G6ME DT Antibody
DM1G6ME DE Influenza A virus infection
DMY5NUR ID DMY5NUR
DMY5NUR DN VK-2809
DMY5NUR HS Phase 2
DMY5NUR CP Viking Therapeutics San Diego, CA
DMY5NUR DE Hypercholesterolaemia
DMLT94F ID DMLT94F
DMLT94F DN VLS-101
DMLT94F HS Phase 2
DMLT94F CP VelosBio
DMLT94F DT Antibody drug conjugate
DMLT94F DE Solid tumour/cancer
DM4O17U ID DM4O17U
DM4O17U DN VLTS-589
DM4O17U HS Phase 2
DM4O17U SN Deltavasc; Del-1 gene therapy, Valentis; Gene therapy (Del-1, PINC), Valentis
DM4O17U CP Valentis
DM4O17U DE Peripheral vascular disease
DM9KNJT ID DM9KNJT
DM9KNJT DN Vobarilizumab
DM9KNJT HS Phase 2
DM9KNJT SN ALX-0061
DM9KNJT CP Ablynx
DM9KNJT DT Antibody
DM9KNJT DE Rheumatoid arthritis; Systemic lupus erythematosus
DMQMYP5 ID DMQMYP5
DMQMYP5 DN VOFOPITANT HYDROCHLORIDE
DMQMYP5 HS Phase 2
DMQMYP5 SN GR-205171A; Vofopitant hydrochloride < Prop INNM; GR-205171 (free base); (2S,3S)-N-[2-Methoxy-5-[5-(trifluoromethyl)-1-tetrazolyl]benzyl]-N-(2-phenylpiperidin-3-yl)amine dihydrochloride
DMQMYP5 DT Small molecular drug
DMQMYP5 PC 6918330
DMQMYP5 MW 505.4
DMQMYP5 FM C21H25Cl2F3N6O
DMQMYP5 IC InChI=1S/C21H23F3N6O.2ClH/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14;;/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3;2*1H/t17-,19-;;/m0../s1
DMQMYP5 CS COC1=C(C=C(C=C1)N2C(=NN=N2)C(F)(F)F)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4.Cl.Cl
DMQMYP5 IK YVNRXILPJNISEM-FFUVTKDNSA-N
DMQMYP5 IU (2S,3S)-N-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine;dihydrochloride
DMQMYP5 CA CAS 168266-51-1
DMQMYP5 DE Vomiting
DMNQG24 ID DMNQG24
DMNQG24 DN Volociximab
DMNQG24 HS Phase 2
DMNQG24 CP Abbott Laboratories
DMNQG24 DT Antibody
DMNQG24 DE Non-small-cell lung cancer
DMIM1U9 ID DMIM1U9
DMIM1U9 DN Vorolanib
DMIM1U9 HS Phase 2
DMIM1U9 SN UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
DMIM1U9 CP Xcovery
DMIM1U9 DT Small molecular drug
DMIM1U9 PC 59215954
DMIM1U9 MW 439.5
DMIM1U9 FM C23H26FN5O3
DMIM1U9 IC InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1
DMIM1U9 CS CC1=C(NC(=C1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O
DMIM1U9 IK KMIOJWCYOHBUJS-HAKPAVFJSA-N
DMIM1U9 IU N-[(3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMIM1U9 CA CAS 1013920-15-4
DMIM1U9 DE Non-small cell lung cancer
DMW4LTI ID DMW4LTI
DMW4LTI DN Votucalis
DMW4LTI HS Phase 2
DMW4LTI SN EV-131; REV-131; Tick-derived compounds, Evolutec; Votucalis (intranasal), Evolutec; Votucalis (ophthalmic), Evolutec; Votucalis (respiratory disease), Evolutec; REV-131 (intranasal), Evolutec; REV-131 (ophthalmic), Evolutec; REV-131 (respiratory disease), Evolutec
DMW4LTI CP Evolutec Group plc; Evolutec
DMW4LTI DE Allergic rhinitis
DMUQZT4 ID DMUQZT4
DMUQZT4 DN VPI-2690B
DMUQZT4 HS Phase 2
DMUQZT4 CP Vascular Pharmaceuticals Research Triangle Park, NC
DMUQZT4 DE Diabetic nephropathy
DMHET8R ID DMHET8R
DMHET8R DN VRC-HIVDNA016-00-VP
DMHET8R HS Phase 2
DMHET8R CP Vaccine Research Center (NIAID)
DMHET8R DT Vaccine
DMHET8R DE Human immunodeficiency virus infection
DMGBLI3 ID DMGBLI3
DMGBLI3 DN VS-6063
DMGBLI3 HS Phase 2
DMGBLI3 SN Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu
DMGBLI3 CP Verastem
DMGBLI3 DT Small molecular drug
DMGBLI3 PC 25117126
DMGBLI3 MW 510.5
DMGBLI3 FM C20H21F3N8O3S
DMGBLI3 IC InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)
DMGBLI3 CS CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F
DMGBLI3 IK FWLMVFUGMHIOAA-UHFFFAOYSA-N
DMGBLI3 IU N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
DMGBLI3 CA CAS 1073154-85-4
DMGBLI3 DE Solid tumour/cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer
DMY9ZGN ID DMY9ZGN
DMY9ZGN DN VT-111a
DMY9ZGN HS Phase 2
DMY9ZGN CP Viron therapeutics
DMY9ZGN DE Acute coronary syndrome
DMCGK9H ID DMCGK9H
DMCGK9H DN VT-1129
DMCGK9H HS Phase 2
DMCGK9H SN Metalloenzyme inhibitors (fungal infection); VT-1161; VT-1235; Metalloenzyme inhibitors (fungal infection), Viamet
DMCGK9H CP Viamet pharmaceuticals
DMCGK9H PC 91886002
DMCGK9H MW 513.4
DMCGK9H FM C22H14F7N5O2
DMCGK9H IC InChI=1S/C22H14F7N5O2/c23-15-4-7-17(18(24)9-15)20(35,11-34-12-31-32-33-34)21(25,26)19-8-3-14(10-30-19)13-1-5-16(6-2-13)36-22(27,28)29/h1-10,12,35H,11H2/t20-/m0/s1
DMCGK9H CS C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OC(F)(F)F
DMCGK9H IK NCEHACHJIXJSPD-FQEVSTJZSA-N
DMCGK9H IU (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(trifluoromethoxy)phenyl]pyridin-2-yl]propan-2-ol
DMCGK9H CA CAS 1340593-70-5
DMCGK9H DE Onchocerciasis; Cryptococcal meningitis infection; Onychomycosis
DMNY3J0 ID DMNY3J0
DMNY3J0 DN VTB-38543
DMNY3J0 HS Phase 2
DMNY3J0 CP Allergan Parsippany, NJ
DMNY3J0 DE Atopic dermatitis
DMCA8G1 ID DMCA8G1
DMCA8G1 DN VTP-43742
DMCA8G1 HS Phase 2
DMCA8G1 CP Vitae PharmaceuticalsFort Washington, PA
DMCA8G1 PC 118282339
DMCA8G1 MW 552.7
DMCA8G1 FM C27H35F3N4O3S
DMCA8G1 IC InChI=1S/C27H35F3N4O3S/c1-4-38(36,37)23-10-9-22(31-14-23)13-33-26(35)19-11-20-16-34(25(17(2)3)24(20)32-12-19)15-18-5-7-21(8-6-18)27(28,29)30/h9-12,14,17-18,21,25H,4-8,13,15-16H2,1-3H3,(H,33,35)/t18?,21?,25-/m1/s1
DMCA8G1 CS CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C([C@H](N(C3)CC4CCC(CC4)C(F)(F)F)C(C)C)N=C2
DMCA8G1 IK XUYMIRYNRKXKOR-JBWFSBJDSA-N
DMCA8G1 IU (7R)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-7-propan-2-yl-6-[[4-(trifluoromethyl)cyclohexyl]methyl]-5,7-dihydropyrrolo[3,4-b]pyridine-3-carboxamide
DMCA8G1 DE Autoimmune disease; Psoriasis vulgaris
DMN6J18 ID DMN6J18
DMN6J18 DN Vupanorsen
DMN6J18 HS Phase 2
DMN6J18 SN IONIS-ANGPTL3-LRx; AKCEA-ANGPTL3-LRx
DMN6J18 CP Akcea Therapeutics; Ionis Pharmaceuticals
DMN6J18 DT Antisense oligonucleotide
DMN6J18 DE Hypertriglyceridemia; Non-alcoholic fatty liver disease; Type 2 diabetes
DM6BKG2 ID DM6BKG2
DM6BKG2 DN VVP-808
DM6BKG2 HS Phase 2
DM6BKG2 SN Insulin sensitizer (type 2 diabetes), Verva Pharmaceuticals
DM6BKG2 CP Verva Pharmaceuticals Ltd
DM6BKG2 DE Type-2 diabetes
DMDKWA3 ID DMDKWA3
DMDKWA3 DN Vx-001
DMDKWA3 HS Phase 2
DMDKWA3 SN HTERT572Y peptide vaccine (cancer), Vaxon; HLA-A2 monopeptide vaccine (cancer), Vaxon; TERT572 + TERT572Y peptide (cancer), Vaxon
DMDKWA3 CP Vaxon Biotech SA
DMDKWA3 DT Vaccine
DMDKWA3 DE Breast cancer
DMZ3FE8 ID DMZ3FE8
DMZ3FE8 DN VX-135
DMZ3FE8 HS Phase 2
DMZ3FE8 CP Vertex pharmaceuticals
DMZ3FE8 DE Hepatitis C virus infection
DMLWM4G ID DMLWM4G
DMLWM4G DN VX-15
DMLWM4G HS Phase 2
DMLWM4G SN VX-15/2503; Plexin B1 antagonist (autoimmune disease/cancer), Vaccinex; Anti-CD100 MAb (autoimmune disease/cancer), Vaccinex;Anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex
DMLWM4G CP Vaccinex Inc
DMLWM4G DT Antibody
DMLWM4G DE Multiple sclerosis; Huntington disease; Non-small-cell lung cancer
DMGDB21 ID DMGDB21
DMGDB21 DN VX-150
DMGDB21 HS Phase 2
DMGDB21 CP Vertex Pharmaceuticals Boston, MA
DMGDB21 DE Neuropathic pain
DMO3U4W ID DMO3U4W
DMO3U4W DN VX-222
DMO3U4W HS Phase 2
DMO3U4W SN VX-222; Lomibuvir; 1026785-59-0; 1026785-55-6; VX 222; VX-222 (VCH-222, Lomibuvir); UNII-37L2LF4A2D; VCH222; VCH-222; VX222; 37L2LF4A2D; Lomibuvir (VX-222, VCH-222); 2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(trans-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-;2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(trans-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-
DMO3U4W CP Vertex
DMO3U4W DT Small molecular drug
DMO3U4W PC 24798764
DMO3U4W MW 445.6
DMO3U4W FM C25H35NO4S
DMO3U4W IC InChI=1S/C25H35NO4S/c1-16-5-7-17(8-6-16)23(28)26(18-9-11-19(27)12-10-18)21-15-20(13-14-25(2,3)4)31-22(21)24(29)30/h15-19,27H,5-12H2,1-4H3,(H,29,30)
DMO3U4W CS CC1CCC(CC1)C(=O)N(C2CCC(CC2)O)C3=C(SC(=C3)C#CC(C)(C)C)C(=O)O
DMO3U4W IK WPMJNLCLKAKMLA-UHFFFAOYSA-N
DMO3U4W IU 5-(3,3-dimethylbut-1-ynyl)-3-[(4-hydroxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylic acid
DMO3U4W CA CAS 1026785-55-6
DMO3U4W CB CHEBI:94757
DMO3U4W DE Hepatitis C virus infection
DMSTHG1 ID DMSTHG1
DMSTHG1 DN VX-371
DMSTHG1 HS Phase 2
DMSTHG1 CP Vertex
DMSTHG1 DE Cystic fibrosis; Primary ciliary dyskinesia
DM93YKJ ID DM93YKJ
DM93YKJ DN VX-680
DM93YKJ HS Phase 2
DM93YKJ SN Tozasertib; MK 0457; VX 680; VX6; L-001281814; MK-045; MK-0457; Tozasertib (USAN); VX-68; MK-0457, Tozasertib, VX680, VX-680; N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide; Cyclopropane carboxylic acid{4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2-ylsulphanyl]-phenyl}-amide; Cyclopropanecarboxylic Acid {4-[4-(4-Methyl-Piperazin-1-Yl)-6-(5-Methyl-2h-Pyrazol-3-Ylamino)-Pyrimidin-2-Ylsulfanyl]-Phenyl}-Amide
DM93YKJ CP Vertex; Merck
DM93YKJ TC Anticancer Agents
DM93YKJ DT Small molecular drug
DM93YKJ PC 5494449
DM93YKJ MW 464.6
DM93YKJ FM C23H28N8OS
DM93YKJ IC InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)
DM93YKJ CS CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C
DM93YKJ IK GCIKSSRWRFVXBI-UHFFFAOYSA-N
DM93YKJ IU N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
DM93YKJ CA CAS 639089-54-6
DM93YKJ CB CHEBI:91336
DM93YKJ DE Solid tumour/cancer
DMJAEG6 ID DMJAEG6
DMJAEG6 DN VX-745
DMJAEG6 HS Phase 2
DMJAEG6 SN 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido[1,6-b]pyridazin-6-one; 209410-46-8; Neflamapimod; VX 745; VX745; VRT-031745; UNII-TYL52QM320; TYL52QM320; CHEBI:90528; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one; 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one; Neflamapimod (USAN); Neflamapimod [USAN]; AK-44905; C19H9Cl2F2N3OS; 5-(2,6-Dichlorophenyl)-2-[(2,4-Difluorophenyl)sulfanyl]-6h-Pyrimido[1,6-B]pyridazin-6-One; VX745, VX-745; 5-(2,6-Dichlorophenyl)-2-((2,4-difluorophenyl)thio)-6H-pyrimido(1,6-b)pyridazin-6-one; Vertex 745 (VX745)
DMJAEG6 CP Vertex Pharma
DMJAEG6 DT Small molecular drug
DMJAEG6 PC 3038525
DMJAEG6 MW 436.3
DMJAEG6 FM C19H9Cl2F2N3OS
DMJAEG6 IC InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H
DMJAEG6 CS C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
DMJAEG6 IK VEPKQEUBKLEPRA-UHFFFAOYSA-N
DMJAEG6 IU 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenyl)sulfanylpyrimido[1,6-b]pyridazin-6-one
DMJAEG6 CA CAS 209410-46-8
DMJAEG6 CB CHEBI:90528
DMJAEG6 DE Rheumatoid arthritis; Alzheimer disease
DMJUSM8 ID DMJUSM8
DMJUSM8 DN VX-759
DMJUSM8 HS Phase 2
DMJUSM8 SN CHEMBL352911; 3-{isopropyl[(Trans-4-Methylcyclohexyl)carbonyl]amino}-5-Phenylthiophene-2-Carboxylic Acid; 3-[Isopropyl-(4-methyl-cyclohexanecarbonyl)-amino]-5-phenyl-thiophene-2-carboxylic acid; VX-759; 3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-5-phenyl-thiophene-2-carboxylic acid; VX759; NN3; VX 759; thiophene scaffold, 21; AC1L9XFB; NNI-2; 478025-29-5; SCHEMBL102322; CHEMBL561360; SCHEMBL1666872; SCHEMBL14376078; SCHEMBL13249635; BDBM35554; BDBM50139678; DB08279
DMJUSM8 CP Vertex
DMJUSM8 DT Small molecular drug
DMJUSM8 PC 503536
DMJUSM8 MW 385.5
DMJUSM8 FM C22H27NO3S
DMJUSM8 IC InChI=1S/C22H27NO3S/c1-14(2)23(21(24)17-11-9-15(3)10-12-17)18-13-19(27-20(18)22(25)26)16-7-5-4-6-8-16/h4-8,13-15,17H,9-12H2,1-3H3,(H,25,26)
DMJUSM8 CS CC1CCC(CC1)C(=O)N(C2=C(SC(=C2)C3=CC=CC=C3)C(=O)O)C(C)C
DMJUSM8 IK RZXQBIKGWSLVEK-UHFFFAOYSA-N
DMJUSM8 IU 3-[(4-methylcyclohexanecarbonyl)-propan-2-ylamino]-5-phenylthiophene-2-carboxylic acid
DMJUSM8 CA CAS 478025-29-5
DMJUSM8 DE Hepatitis C virus infection
DME321B ID DME321B
DME321B DN VX-944
DME321B HS Phase 2
DME321B SN AVN-944; AVN944; 297730-17-7; AVN 944; UNII-I3NPL1V48Q; I3NPL1V48Q; 501345-02-4; VX 944; SCHEMBL19784823; CHEMBL3349001; DTXSID80183921; EX-A778; AOB5557; ZINC3963015; AKOS027340045; CS-3427; NCGC00345803-01; NCGC00345803-05; HY-13560; AS-16899; SC-82478; (R)-1-cyanobutan-2-yl ((S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethyl)carbamate; Carbamic acid, ((1S)-1-(3-((((3-methoxy-4-(5- oxazolyl)phenyl)amino)carbonyl)amino)phenyl)ethyl)-, (1R)-1-(cyanomethyl)propyl ester; (2R)-1-cyanobutan-2-yl N-[(1S)-1-[3-({[3-metho
DME321B CP Avalon Pharmaceuticals
DME321B DT Small molecular drug
DME321B PC 9918559
DME321B MW 477.5
DME321B FM C25H27N5O5
DME321B IC InChI=1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1
DME321B CS CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C3=CN=CO3)OC
DME321B IK GYCPCOJTCINIFZ-OXJNMPFZSA-N
DME321B IU [(2R)-1-cyanobutan-2-yl] N-[(1S)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate
DME321B CA CAS 297730-17-7
DME321B DE Solid tumour/cancer
DMPSBTL ID DMPSBTL
DMPSBTL DN VY-AADC
DMPSBTL HS Phase 2
DMPSBTL CP Voyager Therapeutics
DMPSBTL DT Gene therapy
DMPSBTL DE Parkinson disease
DMH6XJG ID DMH6XJG
DMH6XJG DN WCK-2349
DMH6XJG HS Phase 2
DMH6XJG SN WCK-177 prodrug (MRSA infection), Wockhardt
DMH6XJG CP Wockhardt
DMH6XJG PC 16734914
DMH6XJG MW 431.5
DMH6XJG FM C22H26FN3O5
DMH6XJG IC InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
DMH6XJG CS C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
DMH6XJG IK OUXXDXXQNWKOIF-RYUDHWBXSA-N
DMH6XJG IU (12S)-8-[4-[(2S)-2-aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
DMH6XJG CA CAS 706809-20-3
DMH6XJG DE MRSA infection
DMVQARP ID DMVQARP
DMVQARP DN WCK-771
DMVQARP HS Phase 2
DMVQARP SN WCK-771A
DMVQARP CP Wockhardt Ltd
DMVQARP DT Small molecular drug
DMVQARP PC 9850037
DMVQARP MW 534.6
DMVQARP FM C25H35FN6O6
DMVQARP IC InChI=1S/C19H21FN2O4.C6H14N4O2/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21;7-4(5(11)12)2-1-3-10-6(8)9/h8-11,23H,2-7H2,1H3,(H,25,26);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t10-;4-/m00/s1
DMVQARP CS C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O.C(C[C@@H](C(=O)O)N)CN=C(N)N
DMVQARP IK WIFOPRFVQIVWTB-YBVIJTQESA-N
DMVQARP IU (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(12S)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
DMVQARP CA CAS 306748-89-0
DMVQARP DE Bacterial infection
DMZ67Q0 ID DMZ67Q0
DMZ67Q0 DN WT1 peptide vaccine
DMZ67Q0 HS Phase 2
DMZ67Q0 SN WT1 peptide vaccine (cancer); WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin; Cancer vaccine (Wilms tumor gene 1 + KLH + GM-CSF advuvants), Humboldt University of Berlin
DMZ67Q0 CP Charity Medical School of the Humboldt University of Berlin
DMZ67Q0 DT Vaccine
DMZ67Q0 DE leukaemia
DMNFZYE ID DMNFZYE
DMNFZYE DN WT1-targeted autologous dendritic cell vaccine
DMNFZYE HS Phase 2
DMNFZYE SN WT1-targeted autologous dendritic cell vaccine (cancer)
DMNFZYE CP University of Antwerp; Argos Therapeutics Durham; NC Geron; Dendreon Seattle; WA; ImmunoCellular Therapeutics
DMNFZYE DT Vaccine
DMNFZYE DE Acute myeloid leukaemia
DMFVNSB ID DMFVNSB
DMFVNSB DN WY-50295-tromethamine
DMFVNSB HS Phase 2
DMFVNSB SN WY-50295T; Wy-49232
DMFVNSB CP Wyeth-Ayerst Pharmaceuticals Inc
DMFVNSB DT Small molecular drug
DMFVNSB PC 10435196
DMFVNSB MW 478.5
DMFVNSB FM C27H30N2O6
DMFVNSB IC InChI=1S/C23H19NO3.C4H11NO3/c1-15(23(25)26)17-6-7-19-13-21(11-9-18(19)12-17)27-14-20-10-8-16-4-2-3-5-22(16)24-20;5-4(1-6,2-7)3-8/h2-13,15H,14H2,1H3,(H,25,26);6-8H,1-3,5H2/t15-;/m0./s1
DMFVNSB CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O.C(C(CO)(CO)N)O
DMFVNSB IK FKKBZYRUPFNJJC-RSAXXLAASA-N
DMFVNSB IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;(2S)-2-[6-(quinolin-2-ylmethoxy)naphthalen-2-yl]propanoic acid
DMFVNSB CA CAS 133899-56-6
DMFVNSB DE Asthma
DMW1NKO ID DMW1NKO
DMW1NKO DN X-82
DMW1NKO HS Phase 2
DMW1NKO CP Tyrogenex West Palm Beach
DMW1NKO DE Macular degeneration; Solid tumour/cancer; Age-related macular degeneration
DMXG5WU ID DMXG5WU
DMXG5WU DN Xanomeline tartrate
DMXG5WU HS Phase 2
DMXG5WU SN Memcor; Xanomeline tartrate [USAN]; LY 246708 tartrate; Xanomeline tartrate (USAN); Pyridine, 3-(4-(hexyloxy0-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1); 3-(4-(Hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine L-(+)-tartrate (1:1); 3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMXG5WU CP Sauerberg
DMXG5WU DT Small molecular drug
DMXG5WU PC 71456
DMXG5WU MW 431.5
DMXG5WU FM C18H29N3O7S
DMXG5WU IC InChI=1S/C14H23N3OS.C4H6O6/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12;5-1(3(7)8)2(6)4(9)10/h8H,3-7,9-11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DMXG5WU CS CCCCCCOC1=NSN=C1C2=CCCN(C2)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMXG5WU IK SJSVWTMVMBGIHQ-LREBCSMRSA-N
DMXG5WU IU (2R,3R)-2,3-dihydroxybutanedioic acid;3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMXG5WU CA CAS 152854-19-8
DMXG5WU DE Parkinson disease
DM0NFMS ID DM0NFMS
DM0NFMS DN XEN-2174
DM0NFMS HS Phase 2
DM0NFMS CP Xenome
DM0NFMS DE Cancer related pain
DMR69CG ID DMR69CG
DMR69CG DN XEN-402
DMR69CG HS Phase 2
DMR69CG CP Xenon Pharmaceuticals Inc
DMR69CG DT Small molecular drug
DMR69CG PC 49836093
DMR69CG MW 429.3
DMR69CG FM C22H14F3NO5
DMR69CG IC InChI=1S/C22H14F3NO5/c23-22(24,25)19-6-5-12(31-19)9-26-15-4-2-1-3-13(15)21(20(26)27)10-28-16-8-18-17(7-14(16)21)29-11-30-18/h1-8H,9-11H2/t21-/m0/s1
DMR69CG CS C1[C@]2(C3=CC=CC=C3N(C2=O)CC4=CC=C(O4)C(F)(F)F)C5=CC6=C(C=C5O1)OCO6
DMR69CG IK NEBUOXBYNAHKFV-NRFANRHFSA-N
DMR69CG IU (7S)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]spiro[6H-furo[2,3-f][1,3]benzodioxole-7,3'-indole]-2'-one
DMR69CG CA CAS 1259933-16-8
DMR69CG DE Osteoarthritis; Vasodilatation of extremities; Pain
DMG7PDY ID DMG7PDY
DMG7PDY DN XEN-D0501
DMG7PDY HS Phase 2
DMG7PDY SN XEN-D501; Ion channel modulator 1 (overactive bladder), Xention; TRPV1 antagonist (overactive bladder), Xention;VR1 antagonist (overactive bladder), Xention; Vanilloid receptor-1 antagonist (overactive bladder), Xention; Ion channel modulator (overactive bladder), Xention/Scion/Bristol-Myers Squibb
DMG7PDY CP Bristol-Myers Squibb Co
DMG7PDY DE Overactive bladder
DM4ZIDH ID DM4ZIDH
DM4ZIDH DN Xentuzumab
DM4ZIDH HS Phase 2
DM4ZIDH CP Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM4ZIDH DE Prostate cancer; Breast cancer
DMML7BE ID DMML7BE
DMML7BE DN Xl147
DMML7BE HS Phase 2
DMML7BE SN N-[3-(2,1,3-Benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; 956958-53-5; XL147 analogue; PI3K inhibitor X; XL 147; Pilaralisib analogue; N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide; N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide; CHEBI:71957; C21H16N6O2S2; N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide; Benzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-; 1033110-57-4; PubChem22457; XL-147 derivative 2; cc-43; AC1Q2LO8; AC1LZ6F0; SAR245408 + MSC1936369B
DMML7BE CP Exelixis
DMML7BE TC Anticancer Agents
DMML7BE DT Small molecular drug
DMML7BE PC 1893730
DMML7BE MW 448.5
DMML7BE FM C21H16N6O2S2
DMML7BE IC InChI=1S/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)
DMML7BE CS CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4
DMML7BE IK MQMKRQLTIWPEDM-UHFFFAOYSA-N
DMML7BE IU N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide
DMML7BE CA CAS 1033110-57-4
DMML7BE CB CHEBI:71957
DMML7BE DE Solid tumour/cancer
DMMHX9K ID DMMHX9K
DMMHX9K DN XL-820
DMMHX9K HS Phase 2
DMMHX9K SN EXEL-9820
DMMHX9K CP Exelixis
DMMHX9K DE Solid tumour/cancer
DMHJTR2 ID DMHJTR2
DMHJTR2 DN XL880
DMHJTR2 HS Phase 2
DMHJTR2 SN GSK 089; GSK 1363089; GSK1363089; XL 880; GSK1363089, GSK089, foretinib, EXEL-2880, XL880; 88Z; MET inhibitors
DMHJTR2 CP Exelixis; GlaxoSmithKline
DMHJTR2 TC Anticancer Agents
DMHJTR2 DT Small molecular drug
DMHJTR2 PC 42642645
DMHJTR2 MW 632.7
DMHJTR2 FM C34H34F2N4O6
DMHJTR2 IC InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
DMHJTR2 CS COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DMHJTR2 IK CXQHYVUVSFXTMY-UHFFFAOYSA-N
DMHJTR2 IU 1-N'-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMHJTR2 CA CAS 849217-64-7
DMHJTR2 CB CHEBI:91418
DMHJTR2 DE Squamous head and neck cell carcinom; Renal cell carcinoma; Gastric adenocarcinoma; Solid tumour/cancer; Breast cancer
DMVB8EO ID DMVB8EO
DMVB8EO DN XLCART001
DMVB8EO HS Phase 2
DMVB8EO CP The First Affiliated Hospital with Nanjing Medical University
DMVB8EO DT CAR T Cell Therapy
DMVB8EO DE B-cell lymphoma
DMLIPY1 ID DMLIPY1
DMLIPY1 DN Xmab 5871
DMLIPY1 HS Phase 2
DMLIPY1 SN XmAb 5871 (TN)
DMLIPY1 CP Amgen; Xencor
DMLIPY1 DE Rheumatoid arthritis; Autoimmune diabetes; IgG4 related disease; Systemic lupus erythematosus
DMWEB07 ID DMWEB07
DMWEB07 DN XOMA-629
DMWEB07 HS Phase 2
DMWEB07 SN Acne therapy, XOMA; BPI peptides, XOMA; XMP-629; XMP.629; BPI peptide (acne, Staphylococcus infection, impetigo), Xoma; Bactericidal permeability increasing protein (acne, Staphylococcus infection, impetigo), XOMA
DMWEB07 CP XOMA Ltd
DMWEB07 DE Acne vulgaris
DM8N3ZQ ID DM8N3ZQ
DM8N3ZQ DN XP-21279
DM8N3ZQ HS Phase 2
DM8N3ZQ SN Levodopa transported prodrug (Parkinson's disease), XenoPort; L-dopa transported prodrug (Parkinson's disease), XenoPort
DM8N3ZQ CP Xenoport
DM8N3ZQ DE Parkinson disease
DMELUYN ID DMELUYN
DMELUYN DN XP-23829
DMELUYN HS Phase 2
DMELUYN SN Methylhydrogenfumarate prodrug (multiple sclerosis), XenoPort
DMELUYN CP Xenoport
DMELUYN PC 46179632
DMELUYN MW 243.26
DMELUYN FM C11H17NO5
DMELUYN IC InChI=1S/C11H17NO5/c1-4-12(5-2)9(13)8-17-11(15)7-6-10(14)16-3/h6-7H,4-5,8H2,1-3H3/b7-6+
DMELUYN CS CCN(CC)C(=O)COC(=O)/C=C/C(=O)OC
DMELUYN IK AKUGRXRLHCCENI-VOTSOKGWSA-N
DMELUYN IU 4-O-[2-(diethylamino)-2-oxoethyl] 1-O-methyl (E)-but-2-enedioate
DMELUYN CA CAS 1208229-58-6
DMELUYN DE Multiple sclerosis; Plaque psoriasis
DMOKUA5 ID DMOKUA5
DMOKUA5 DN XR-5000
DMOKUA5 HS Phase 2
DMOKUA5 SN DACA; SN-22995
DMOKUA5 CP Xenova
DMOKUA5 DE Colorectal cancer
DMPI6N0 ID DMPI6N0
DMPI6N0 DN XZK-monascus
DMPI6N0 HS Phase 2
DMPI6N0 CP Beijing peking university wbl biotech
DMPI6N0 DE Hyperlipidaemia
DM54MAJ ID DM54MAJ
DM54MAJ DN YF-476
DM54MAJ HS Phase 2
DM54MAJ SN Sograzepide; FE-999008; Gastrin inhibitor, Ferring; YM-476
DM54MAJ CP Ferring Pharmaceuticals Inc
DM54MAJ DT Small molecular drug
DM54MAJ PC 9870520
DM54MAJ MW 498.6
DM54MAJ FM C28H30N6O3
DM54MAJ IC InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)/t25-/m0/s1
DM54MAJ CS CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC=CC(=C3)NC)C4=CC=CC=N4
DM54MAJ IK YDZYKNJZCVIKPP-VWLOTQADSA-N
DM54MAJ IU 1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea
DM54MAJ CA CAS 155488-25-8
DM54MAJ DE Stomach ulcer
DMCHFB0 ID DMCHFB0
DMCHFB0 DN YH-4808
DMCHFB0 HS Phase 2
DMCHFB0 SN Second generation acid pump antagonist, Yuhan
DMCHFB0 CP Yuhan Corp
DMCHFB0 DE Duodenal ulcer
DM740LV ID DM740LV
DM740LV DN YKP-GI
DM740LV HS Phase 2
DM740LV SN SKL-IBS; YKP-10811; 5-HT 4 receptor partial agonist (irritable bowel syndrome/constipation), SK Life science
DM740LV CP SK Life Science
DM740LV DT Small molecular drug
DM740LV PC 45275554
DM740LV MW 493
DM740LV FM C24H30ClFN4O4
DM740LV IC InChI=1S/C24H30ClFN4O4/c1-33-22-13-20(27)19(25)12-18(22)23(31)29-14-15-6-9-30(10-7-15)11-8-21(34-24(28)32)16-2-4-17(26)5-3-16/h2-5,12-13,15,21H,6-11,14,27H2,1H3,(H2,28,32)(H,29,31)/t21-/m0/s1
DM740LV CS COC1=CC(=C(C=C1C(=O)NCC2CCN(CC2)CC[C@@H](C3=CC=C(C=C3)F)OC(=O)N)Cl)N
DM740LV IK KGMMSPVVHZGPHL-NRFANRHFSA-N
DM740LV IU [(1S)-3-[4-[[(4-amino-5-chloro-2-methoxybenzoyl)amino]methyl]piperidin-1-yl]-1-(4-fluorophenyl)propyl] carbamate
DM740LV CA CAS 1221416-43-8
DM740LV DE Constipation
DM5Q1W4 ID DM5Q1W4
DM5Q1W4 DN Ym155
DM5Q1W4 HS Phase 2
DM5Q1W4 SN Sepantronium
DM5Q1W4 CP Astellas Pharma
DM5Q1W4 DT Small molecular drug
DM5Q1W4 PC 11178236
DM5Q1W4 MW 443.3
DM5Q1W4 FM C20H19BrN4O3
DM5Q1W4 IC InChI=1S/C20H19N4O3.BrH/c1-13-23(9-10-27-2)17-18(24(13)12-14-11-21-7-8-22-14)20(26)16-6-4-3-5-15(16)19(17)25;/h3-8,11H,9-10,12H2,1-2H3;1H/q+1;/p-1
DM5Q1W4 CS CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]
DM5Q1W4 IK QBIYUDDJPRGKNJ-UHFFFAOYSA-M
DM5Q1W4 IU 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione;bromide
DM5Q1W4 CA CAS 781661-94-7
DM5Q1W4 CB CHEBI:139608
DM5Q1W4 DE Non-hodgkin lymphoma; Breast cancer
DMAZNVX ID DMAZNVX
DMAZNVX DN YM-264
DMAZNVX HS Phase 2
DMAZNVX SN YM 264; 131888-54-5; 1-(3-Methyl-3-phenylbutyl)-4-(2-(3-pyridyl)thiazolidin-4-ylcarbonyl)piperazine fumarate; 1-(3-methyl-3-phenylbutyl]-4-[2-(3-pyridyl)thiazolidin-4-ylcarbonyl]piperazine fumarate; AC1O5RFQ; SCHEMBL9819914; SCHEMBL9819910; LBPPBLYOJCIZRW-WLHGVMLRSA-N; BCP20243; HY-101833; CS-0021927
DMAZNVX CP Yamanouchi Pharmaceutical Co Ltd
DMAZNVX DT Small molecular drug
DMAZNVX PC 6439322
DMAZNVX MW 540.7
DMAZNVX FM C28H36N4O5S
DMAZNVX IC InChI=1S/C24H32N4OS.C4H4O4/c1-24(2,20-8-4-3-5-9-20)10-12-27-13-15-28(16-14-27)23(29)21-18-30-22(26-21)19-7-6-11-25-17-19;5-3(6)1-2-4(7)8/h3-9,11,17,21-22,26H,10,12-16,18H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMAZNVX CS CC(C)(CCN1CCN(CC1)C(=O)C2CSC(N2)C3=CN=CC=C3)C4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O
DMAZNVX IK LBPPBLYOJCIZRW-WLHGVMLRSA-N
DMAZNVX IU (E)-but-2-enedioic acid;[4-(3-methyl-3-phenylbutyl)piperazin-1-yl]-(2-pyridin-3-yl-1,3-thiazolidin-4-yl)methanone
DMAZNVX CA CAS 131888-54-5
DMAZNVX DE Sepsis
DMS7609 ID DMS7609
DMS7609 DN YM-358
DMS7609 HS Phase 2
DMS7609 SN 2,7-Diethyl-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-5H-pyrazolo[1,5-b][1,2,4]triazole potassium salt monohydrate
DMS7609 DT Small molecular drug
DMS7609 PC 9801006
DMS7609 MW 398.5
DMS7609 FM C22H22N8
DMS7609 IC InChI=1S/C22H22N8/c1-3-16-14-29(30-22(16)23-20(4-2)26-30)13-15-9-11-17(12-10-15)18-7-5-6-8-19(18)21-24-27-28-25-21/h5-12,14H,3-4,13H2,1-2H3,(H,24,25,27,28)
DMS7609 CS CCC1=CN(N2C1=NC(=N2)CC)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMS7609 IK LASWNZRBIPFGHP-UHFFFAOYSA-N
DMS7609 IU 2,7-diethyl-5-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrazolo[1,5-b][1,2,4]triazole
DMS7609 DE Hypertension
DMKJF6H ID DMKJF6H
DMKJF6H DN YM-430
DMKJF6H HS Phase 2
DMKJF6H SN YM-15430-1; YM-15430-2; YM-15430-3; YM-15430-4
DMKJF6H CP Yamanouchi Pharmaceutical Co Ltd
DMKJF6H PC 9850612
DMKJF6H MW 553.6
DMKJF6H FM C29H35N3O8
DMKJF6H IC InChI=1S/C29H35N3O8/c1-19-25(28(34)38-3)27(21-10-9-11-22(16-21)32(36)37)26(20(2)31-19)29(35)39-15-8-7-14-30-17-23(33)18-40-24-12-5-4-6-13-24/h4-6,9-13,16,23,27,30-31,33H,7-8,14-15,17-18H2,1-3H3/t23-,27-/m0/s1
DMKJF6H CS CC1=C([C@@H](C(=C(N1)C)C(=O)OCCCCNC[C@@H](COC2=CC=CC=C2)O)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMKJF6H IK HBXMSJLNXYLVTA-HOFKKMOUSA-N
DMKJF6H IU 5-O-[4-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]butyl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMKJF6H DE Hypertension
DMRZBPI ID DMRZBPI
DMRZBPI DN YM-543
DMRZBPI HS Phase 2
DMRZBPI SN ASP-543; SGLT-2 inhibitor (oral, diabetes), Astellas/Kotobuki
DMRZBPI CP Kotobuki Pharmaceutical Co Ltd
DMRZBPI PC 11998655
DMRZBPI MW 499.6
DMRZBPI FM C28H37NO7
DMRZBPI IC InChI=1S/C23H24O6.C5H14NO/c24-12-19-20(26)21(27)22(28)23(29-19)17-11-13(6-7-18(17)25)8-14-9-15-4-2-1-3-5-16(15)10-14;1-6(2,3)4-5-7/h1-7,9-11,19-28H,8,12H2;7H,4-5H2,1-3H3/q;+1/p-1/t19-,20-,21+,22-,23+;/m1./s1
DMRZBPI CS C[N+](C)(C)CCO.C1=CC=C2C=C(C=C2C=C1)CC3=CC(=C(C=C3)[O-])[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMRZBPI IK UKOOBSDARBTSHN-NGOMLPPMSA-M
DMRZBPI IU 4-(azulen-2-ylmethyl)-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenolate;2-hydroxyethyl(trimethyl)azanium
DMRZBPI CA CAS 1610007-47-0
DMRZBPI DE Type-2 diabetes
DMUPJWH ID DMUPJWH
DMUPJWH DN YM-598
DMUPJWH HS Phase 2
DMUPJWH CP Astellas
DMUPJWH PC 12093171
DMUPJWH MW 529.6
DMUPJWH FM C24H20KN5O5S
DMUPJWH IC InChI=1S/C24H20N5O5S.K/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22;/h3-16H,1-2H3;/q-1;+1/b16-13+;
DMUPJWH CS COC1=CC=CC=C1OC2=C(N=C(N=C2OC)C3=NC=CC=N3)[N-]S(=O)(=O)/C=C/C4=CC=CC=C4.[K+]
DMUPJWH IK WOPWEXSDEXIRNG-ZUQRMPMESA-N
DMUPJWH IU potassium;[6-methoxy-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-[(E)-2-phenylethenyl]sulfonylazanide
DMUPJWH CA CAS 342005-82-7
DMUPJWH DE Prostate cancer
DMU79X2 ID DMU79X2
DMU79X2 DN Ym-758
DMU79X2 HS Phase 2
DMU79X2 SN YM 758 Phosphate; (R)-(-)-N-[2-[3-[(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]piperidino]ethyl]-4-fluorobenzamide monophosphate; YM 758; N-[2-[(3R)-3-[(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl]-1-piperidinyl]ethyl]-4-fluorobenzamide Phosphate
DMU79X2 DT Small molecular drug
DMU79X2 PC 9894205
DMU79X2 MW 469.5
DMU79X2 FM C26H32FN3O4
DMU79X2 IC InChI=1S/C26H32FN3O4/c1-33-23-14-19-9-12-30(17-21(19)15-24(23)34-2)26(32)20-4-3-11-29(16-20)13-10-28-25(31)18-5-7-22(27)8-6-18/h5-8,14-15,20H,3-4,9-13,16-17H2,1-2H3,(H,28,31)/t20-/m1/s1
DMU79X2 CS COC1=C(C=C2CN(CCC2=C1)C(=O)[C@@H]3CCCN(C3)CCNC(=O)C4=CC=C(C=C4)F)OC
DMU79X2 IK MWLKUSHZNSYRKK-HXUWFJFHSA-N
DMU79X2 IU N-[2-[(3R)-3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)piperidin-1-yl]ethyl]-4-fluorobenzamide
DMU79X2 CA CAS 312752-85-5
DMU79X2 DE Angina pectoris
DM7KR4C ID DM7KR4C
DM7KR4C DN YM-934
DM7KR4C HS Phase 2
DM7KR4C SN YM-934; YM 934; UNII-Z0E489238B; 136544-11-1; 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide; Z0E489238B; 2H-1,4-Benzoxazine, 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridinyl)-, N-oxide; CHEMBL93539; SCHEMBL4260665; AC1L305E; DTXSID90159834; GOTJEXSHEQBBSV-UHFFFAOYSA-N; LS-41736
DM7KR4C DT Small molecular drug
DM7KR4C PC 131974
DM7KR4C MW 301.3
DM7KR4C FM C15H15N3O4
DM7KR4C IC InChI=1S/C15H15N3O4/c1-15(2)10-16(14-5-3-4-8-17(14)19)12-9-11(18(20)21)6-7-13(12)22-15/h3-9H,10H2,1-2H3
DM7KR4C CS CC1(CN(C2=C(O1)C=CC(=C2)[N+](=O)[O-])C3=CC=CC=[N+]3[O-])C
DM7KR4C IK GOTJEXSHEQBBSV-UHFFFAOYSA-N
DM7KR4C IU 2,2-dimethyl-6-nitro-4-(1-oxidopyridin-1-ium-2-yl)-3H-1,4-benzoxazine
DM7KR4C CA CAS 136544-11-1
DM7KR4C DE Angina pectoris
DM0K8U7 ID DM0K8U7
DM0K8U7 DN YSIL6
DM0K8U7 HS Phase 2
DM0K8U7 CP Y's Therapeutics
DM0K8U7 DE Crohn disease
DM3YVKQ ID DM3YVKQ
DM3YVKQ DN YT-146
DM3YVKQ HS Phase 2
DM3YVKQ SN Adenosine A2 agonists, Yamasa
DM3YVKQ CP Yamasa Shoyu Co Ltd
DM3YVKQ DT Small molecular drug
DM3YVKQ PC 146207
DM3YVKQ MW 375.4
DM3YVKQ FM C18H25N5O4
DM3YVKQ IC InChI=1S/C18H25N5O4/c1-2-3-4-5-6-7-8-12-21-16(19)13-17(22-12)23(10-20-13)18-15(26)14(25)11(9-24)27-18/h10-11,14-15,18,24-26H,2-6,9H2,1H3,(H2,19,21,22)/t11-,14-,15-,18-/m1/s1
DM3YVKQ CS CCCCCCC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DM3YVKQ IK NVGGIHKSKVAPEY-XKLVTHTNSA-N
DM3YVKQ IU (2R,3R,4S,5R)-2-(6-amino-2-oct-1-ynylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM3YVKQ CA CAS 90596-75-1
DM3YVKQ DE Hypertension
DM2M80G ID DM2M80G
DM2M80G DN Z 360
DM2M80G HS Phase 2
DM2M80G SN Z-360
DM2M80G TC Anticancer Agents
DM2M80G DT Small molecular drug
DM2M80G PC 9872609
DM2M80G MW 520.6
DM2M80G FM C29H36N4O5
DM2M80G IC InChI=1S/C29H36N4O5/c1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37/h7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)/t22-/m1/s1
DM2M80G CS CC(C)(C)C(=O)CN1C2=CC=CC=C2N(C[C@H](C1=O)NC(=O)NC3=CC=CC(=C3)C(=O)O)C4CCCCC4
DM2M80G IK VIJCCFFEBCOOIE-JOCHJYFZSA-N
DM2M80G IU 3-[[(3R)-1-cyclohexyl-5-(3,3-dimethyl-2-oxobutyl)-4-oxo-2,3-dihydro-1,5-benzodiazepin-3-yl]carbamoylamino]benzoic acid
DM2M80G CA CAS 209219-38-5
DM2M80G DE Discovery agent
DMUT9OE ID DMUT9OE
DMUT9OE DN Zadaxin/lamivudine
DMUT9OE HS Phase 2
DMUT9OE CP SciClone Pharmaceuticals
DMUT9OE DE Hepatitis B virus infection
DMJN3BA ID DMJN3BA
DMJN3BA DN Zalospirone
DMJN3BA HS Phase 2
DMJN3BA SN Zalospirone hydrochloride; Wy-47846
DMJN3BA CP Wyeth
DMJN3BA DT Small molecular drug
DMJN3BA PC 163925
DMJN3BA MW 419.5
DMJN3BA FM C24H29N5O2
DMJN3BA IC InChI=1S/C24H29N5O2/c30-22-20-18-6-7-19(17-5-4-16(17)18)21(20)23(31)29(22)11-2-1-10-27-12-14-28(15-13-27)24-25-8-3-9-26-24/h3-9,16-21H,1-2,10-15H2/t16-,17+,18-,19+,20-,21+
DMJN3BA CS C1CN(CCN1CCCCN2C(=O)[C@@H]3[C@@H]4C=C[C@H]([C@@H]3C2=O)[C@@H]5[C@H]4C=C5)C6=NC=CC=N6
DMJN3BA IK AERLHOTUXIJQFV-RCPZPFRWSA-N
DMJN3BA IU (1S,2S,6R,7R,8R,11S)-4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-diene-3,5-dione
DMJN3BA CA CAS 114298-18-9
DMJN3BA DE Anxiety disorder
DMTYD8Q ID DMTYD8Q
DMTYD8Q DN ZD2079
DMTYD8Q HS Phase 2
DMTYD8Q SN Talibegron hydrochloride; ZD 2079; 178600-17-4; Talibegron HCl; ICID2079; UNII-N251Q608VU; ZD-2079; Talibegron hydrochloride [USAN]; ZD2079; SCH 417849; N251Q608VU; NCGC00092315-01; 4-[2-[[(2R)-2-HYDROXY-2-PHENYLETHYL]AMINO]ETHOXY]-BENZENEACETIC ACID HYDROCHLORIDE; DSSTox_RID_83233; DSSTox_CID_28968; DSSTox_GSID_49042; Talibegron hydrochloride (USAN); Benzeneacetic acid, 4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethoxy)-, hydrochloride; CAS-178600-17-4; Talibegron hydrochloride; ZD 2079 hydrochloride; AC1L4KMI; C18H21NO4.HCl
DMTYD8Q DT Small molecular drug
DMTYD8Q PC 158793
DMTYD8Q MW 351.8
DMTYD8Q FM C18H22ClNO4
DMTYD8Q IC InChI=1S/C18H21NO4.ClH/c20-17(15-4-2-1-3-5-15)13-19-10-11-23-16-8-6-14(7-9-16)12-18(21)22;/h1-9,17,19-20H,10-13H2,(H,21,22);1H/t17-;/m0./s1
DMTYD8Q CS C1=CC=C(C=C1)[C@H](CNCCOC2=CC=C(C=C2)CC(=O)O)O.Cl
DMTYD8Q IK KCEFVYIWOQSJCH-LMOVPXPDSA-N
DMTYD8Q IU 2-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid;hydrochloride
DMTYD8Q CA CAS 178600-17-4
DMTYD8Q DE Diabetic complication
DMH85M0 ID DMH85M0
DMH85M0 DN ZD-6126
DMH85M0 HS Phase 2
DMH85M0 SN 219923-05-4; ZD6126; ZD-6126; UNII-GBO3S6M9W7; GBO3S6M9W7; N-Acetylcochinol-O-phosphate; AZD-6126; N-Acetylcolchicinol dihydrogenphosphate; ZD 6126; SCHEMBL1285000; CHEMBL257662; ANG 453; AZD6126, ANG453; ZINC3993833; AZD 6126; BCP9000366; DB11872; BCP0726000110; ZM 445526; Acetamide, N-((5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo(a,c)cyclohepten-5-yl)-
DMH85M0 CP Angiogene Pharmaceuticals Ltd; Angiogene
DMH85M0 DT Small molecular drug
DMH85M0 PC 9896434
DMH85M0 MW 437.4
DMH85M0 FM C20H24NO8P
DMH85M0 IC InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1
DMH85M0 CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC
DMH85M0 IK UGBMEXLBFDAOGL-INIZCTEOSA-N
DMH85M0 IU [(8S)-8-acetamido-13,14,15-trimethoxy-5-tricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaenyl] dihydrogen phosphate
DMH85M0 CA CAS 219923-05-4
DMH85M0 DE Solid tumour/cancer
DMPE2B9 ID DMPE2B9
DMPE2B9 DN ZD-7288
DMPE2B9 HS Phase 2
DMPE2B9 SN N-ethyl-1,2-dimethyl-6-methylimino-N-phenylpyrimidin-4-amine; AC1L3XOD; SCHEMBL9380740; GTPL2359; ZINC100058922; N-Ethyl-1,6-dihydro-1,2-dimethyl-6-(methylimino)-N-phenyl-4-pyrimidinamine; AKOS027381051; ZINC255004003
DMPE2B9 CP Zeneca Group plc
DMPE2B9 DT Small molecular drug
DMPE2B9 PC 9796088
DMPE2B9 MW 292.81
DMPE2B9 FM C15H21ClN4
DMPE2B9 IC InChI=1S/C15H20N4.ClH/c1-5-19(13-9-7-6-8-10-13)15-11-14(16-3)18(4)12(2)17-15;/h6-11H,5H2,1-4H3;1H
DMPE2B9 CS CCN(C1=CC=CC=C1)C2=CC(=[N+](C(=N2)C)C)NC.[Cl-]
DMPE2B9 IK DUWKUHWHTPRMAP-UHFFFAOYSA-N
DMPE2B9 IU 4-N-ethyl-6-N,1,2-trimethyl-4-N-phenylpyrimidin-1-ium-4,6-diamine;chloride
DMPE2B9 CA CAS 133059-99-1
DMPE2B9 DE Angina pectoris
DM6VQTF ID DM6VQTF
DM6VQTF DN ZEN-3694
DM6VQTF HS Phase 2
DM6VQTF CP Zenith Epigenetics
DM6VQTF DT Small molecular drug
DM6VQTF DE Prostate cancer
DM9KB7A ID DM9KB7A
DM9KB7A DN ZGN-1061
DM9KB7A HS Phase 2
DM9KB7A SN Aclimostat; UNII-X150A3JK8R; X150A3JK8R; 2082752-83-6; (3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3- methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl 3-[2-(morpholin-4-yl)ethyl]azetidine-1-carboxylate; Aclimostat [INN]; CHEMBL4297651; SCHEMBL18497467; BDBM148432; US9682965, 1; (3R,4S,5S,6R)-5-Methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(2.5)octan-6-yl 3-(2-(morpholin-4-yl)ethyl)azetidine-1-carboxylate; (3R,4S,5S,6R)5Methoxy4((2R,3R)2methyl3(3methylbut2en1yl)oxiran2yl)1oxaspiro(2.5)octan6yl 3(2(morpholin4yl)ethyl)azetidine1carboxylate; 1-Azetidinecarboxylic acid, 3-(2-(4-morpholinyl)ethyl)-, (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester
DM9KB7A CP Zafgen
DM9KB7A DT Small molecular drug
DM9KB7A PC 126573394
DM9KB7A MW 478.6
DM9KB7A FM C26H42N2O6
DM9KB7A IC InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1
DM9KB7A CS CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)N4CC(C4)CCN5CCOCC5)OC)C
DM9KB7A IK QJWJPMLDQYEPPW-AUKZVGPFSA-N
DM9KB7A IU [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] 3-(2-morpholin-4-ylethyl)azetidine-1-carboxylate
DM9KB7A CA CAS 2082752-83-6
DM9KB7A DE Type 2 diabetes
DMJ94L0 ID DMJ94L0
DMJ94L0 DN ZK-91587
DMJ94L0 HS Phase 2
DMJ94L0 SN SH-D515; 15beta, 16beta-Methylenemexrenone
DMJ94L0 DT Small molecular drug
DMJ94L0 PC 122017
DMJ94L0 MW 412.5
DMJ94L0 FM C25H32O5
DMJ94L0 IC InChI=1S/C25H32O5/c1-23-7-4-14(26)10-13(23)11-16(22(28)29-3)20-17(23)5-8-24(2)21(20)15-12-18(15)25(24)9-6-19(27)30-25/h10,15-18,20-21H,4-9,11-12H2,1-3H3/t15-,16-,17+,18+,20-,21+,23+,24+,25+/m1/s1
DMJ94L0 CS C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@@H]2CC[C@]4([C@H]3[C@@H]5C[C@@H]5[C@@]46CCC(=O)O6)C)C(=O)OC
DMJ94L0 IK YDIQJONNFLVNGD-FPMRONRSSA-N
DMJ94L0 IU methyl (1'R,2S,2'S,3'S,5'S,7'S,10'S,11'R,18'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carboxylate
DMJ94L0 CA CAS 84542-26-7
DMJ94L0 DE Cardiovascular disease
DM4MSLY ID DM4MSLY
DM4MSLY DN ZN-c3
DM4MSLY HS Phase 2
DM4MSLY CP Zentalis Pharmaceuticals
DM4MSLY DT Small molecular drug
DM4MSLY DE Uterine serous carcinoma
DMG7YI9 ID DMG7YI9
DMG7YI9 DN ZYH7
DMG7YI9 HS Phase 2
DMG7YI9 CP Zydus Cadila
DMG7YI9 DT Small molecular drug
DMG7YI9 DE Lipid metabolism disorder; Dyslipidemia
DMTXBUV ID DMTXBUV
DMTXBUV DN BT1718
DMTXBUV HS Phase 1/2a
DMTXBUV CP Bicycle Therapeutics
DMTXBUV DT Bicycle toxin conjugate
DMTXBUV DE Solid tumour/cancer
DM824EG ID DM824EG
DM824EG DN COVA322
DM824EG HS Phase 1/2a
DM824EG CP Covagen/Johnson & Johnson
DM824EG DT Monoclonal antibody
DM824EG DE Psoriasis vulgaris
DMJ1NG4 ID DMJ1NG4
DMJ1NG4 DN Dalazatide
DMJ1NG4 HS Phase 1b/2a
DMJ1NG4 SN Dalazatide [INN]; UNII-6U0259J807; 1081110-69-1; o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide; 6U0259J807
DMJ1NG4 CP KV1.3 Therapeutics
DMJ1NG4 PC 86278334
DMJ1NG4 MW 4442
DMJ1NG4 FM C184H296N57O55PS7
DMJ1NG4 IC InChI=1S/C184H296N57O55PS7/c1-14-94(5)139-172(283)223-124(79-138(254)255)162(273)238-144(100(11)249)176(287)236-140(95(6)15-2)178(289)240-68-33-46-135(240)171(282)217-112(41-24-28-61-187)152(263)224-125(82-242)163(274)212-116(45-32-66-204-182(197)198)153(264)229-134-91-304-303-89-132-168(279)214-114(43-30-64-202-180(193)194)148(259)210-113(42-25-29-62-188)156(267)237-143(99(10)248)175(286)232-130(147(258)206-81-137(253)234-141(97(8)246)174(285)227-129(145(192)256)86-299-301-90-133(169(280)235-139)231-166(277)128(85-245)233-179(290)184(58-34-67-205-183(199)200,295-71-70-294-69-63-189)241(101(12)250)177(288)109(190)74-104-49-53-108(54-50-104)296-297(291,292)293)87-300-302-88-131(228-154(265)117(55-56-136(191)252)215-158(269)120(75-102-35-18-16-19-36-102)218-146(257)96(7)208-173(284)142(98(9)247)239-170(134)281)167(278)213-111(40-23-27-60-186)150(261)222-123(78-106-80-201-92-207-106)161(272)226-126(83-243)164(275)216-118(57-72-298-13)155(266)209-110(39-22-26-59-185)149(260)220-122(77-105-47-51-107(251)52-48-105)159(270)211-115(44-31-65-203-181(195)196)151(262)219-119(73-93(3)4)157(268)225-127(84-244)165(276)221-121(160(271)230-132)76-103-37-20-17-21-38-103/h16-21,35-38,47-54,80,92-100,109-135,139-144,242-249,251H,14-15,22-34,39-46,55-79,81-91,185-190H2,1-13H3,(H2,191,252)(H2,192,256)(H,201,207)(H,206,258)(H,208,284)(H,209,266)(H,210,259)(H,211,270)(H,212,274)(H,213,278)(H,214,279)(H,215,269)(H,216,275)(H,217,282)(H,218,257)(H,219,262)(H,220,260)(H,221,276)(H,222,261)(H,223,283)(H,224,263)(H,225,268)(H,226,272)(H,227,285)(H,228,265)(H,229,264)(H,230,271)(H,231,277)(H,232,286)(H,233,290)(H,234,253)(H,235,280)(H,236,287)(H,237,267)(H,238,273)(H,239,281)(H,254,255)(H4,193,194,202)(H4,195,196,203)(H4,197,198,204)(H4,199,200,205)(H2,291,292,293)/t94-,95-,96-,97+,98+,99+,100+,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130?,131-,132-,133-,134-,135-,139-,140-,141-,142-,143-,144-,184+/m0/s1
DMJ1NG4 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]3CSSC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC5=CC=CC=C5)CO)CC(C)C)CCCNC(=N)N)CC6=CC=C(C=C6)O)CCCCN)CCSC)CO)CC7=CNC=N7)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC3=O)[C@@H](C)O)C)CC8=CC=CC=C8)CCC(=O)N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@](CCCNC(=N)N)(N(C(=O)C)C(=O)[C@H](CC9=CC=C(C=C9)OP(=O)(O)O)N)OCCOCCN)C(=O)N)[C@@H](C)O)[C@@H](C)O)CCCCN)CCCNC(=N)N)CCCNC(=N)N)CO)CCCCN)[C@@H](C)CC)[C@@H](C)O)CC(=O)O
DMJ1NG4 IK GORAHSAIYZMTHZ-LBFSFEBVSA-N
DMJ1NG4 IU 2-[(1R,2aS,4S,7S,10S,13S,19S,22S,25S,28S,31R,36R,39S,48S,51S,54S,57R,60S,63S,66S,69S,72S,75S,78S,81S,84S,87S,90R,93S,96S,99S)-31-[[(2S)-2-[[(2R)-2-[acetyl-[(2S)-2-amino-3-(4-phosphonooxyphenyl)propanoyl]amino]-2-[2-(2-aminoethoxy)ethoxy]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-10,51,75,87-tetrakis(4-aminobutyl)-93-(3-amino-3-oxopropyl)-60,96-dibenzyl-19,28-bis[(2S)-butan-2-yl]-4,54,69-tris(3-carbamimidamidopropyl)-36-carbamoyl-2a,22,39,48-tetrakis[(1R)-1-hydroxyethyl]-7,63,81-tris(hydroxymethyl)-72-[(4-hydroxyphenyl)methyl]-84-(1H-imidazol-4-ylmethyl)-99-methyl-66-(2-methylpropyl)-78-(2-methylsulfanylethyl)-1a,3,4a,6,9,12,18,21,24,27,30,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98-dotriacontaoxo-6a,7a,10a,11a,33,34-hexathia-a,2,3a,5,8,11,17,20,23,26,29,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82,85,88,91,94,97-dotriacontazatetracyclo[55.47.4.445,90.013,17]dodecahectan-25-yl]acetic acid
DMJ1NG4 CA CAS 1081110-69-1
DMJ1NG4 DE Plaque psoriasis; Inclusion body myositis; Psoriasis vulgaris
DMV401D ID DMV401D
DMV401D DN Debio-0824
DMV401D HS Phase 1b/2a
DMV401D SN Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One
DMV401D CP Kineta
DMV401D DE Psoriatic arthritis; Psoriasis vulgaris
DMT17XU ID DMT17XU
DMT17XU DN 131I-radretumab
DMT17XU HS Phase 1/2
DMT17XU SN L-19; L-19-IgG1; L-19-SIP; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Bayer Schering/Philogen; Single chain Fv antibody fragment-based radioimmunotherapeutics, ETH Zurich/Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; L-19 based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Bayer Schering/Philogen; ScFv-based radioimmunotherapeutics (cancer), ETH Zurich/Schering/Philogen; 125I-L-19; 125I-L-19-IgG1; 125I-L-19-SIP
DMT17XU CP ETH Zurich
DMT17XU DT Antibody
DMT17XU DE Non-small-cell lung cancer
DMVZ9XL ID DMVZ9XL
DMVZ9XL DN 177Lu-labelled DOTA-JR11
DMVZ9XL HS Phase 1/2
DMVZ9XL CP Ipsen
DMVZ9XL DT Radiopharmaceutical therapy agent
DMVZ9XL DE Neuroendocrine cancer
DMWPD7N ID DMWPD7N
DMWPD7N DN 177Lu-labelled PSMA-R2
DMWPD7N HS Phase 1/2
DMWPD7N CP Novartis/AAA
DMWPD7N DT Radiopharmaceutical therapy agent
DMWPD7N DE Prostate cancer
DM6JLNT ID DM6JLNT
DM6JLNT DN 177-Lu-NeoB
DM6JLNT HS Phase 1/2
DM6JLNT CP Advanced Accelerator Applications
DM6JLNT DT Small molecular drug
DM6JLNT DE Solid tumour/cancer
DMF4AOE ID DMF4AOE
DMF4AOE DN 177-Lu-PSMA-R2
DMF4AOE HS Phase 1/2
DMF4AOE CP Advanced Accelerator Applications
DMF4AOE DT Small molecular drug
DMF4AOE DE Prostate cancer
DMCLKA4 ID DMCLKA4
DMCLKA4 DN 2-hydroxyoleic acid
DMCLKA4 HS Phase 1/2
DMCLKA4 SN 2R-hydroxy-oleic acid; 2R-hydroxy-9Z-octadecenoic acid; R-Hydroxy-olsaure; (R)-2-Hydroxyoleic acid; SCHEMBL378127; ZINC14210872; LMFA02000056; UNII-OSV3KVO1BT component JBSOOFITVPOOSY-DOOKAGJSSA-N
DMCLKA4 CP Bridge BioResearch International Ltd
DMCLKA4 DT Small molecular drug
DMCLKA4 PC 9796304
DMCLKA4 MW 298.5
DMCLKA4 FM C18H34O3
DMCLKA4 IC InChI=1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,17,19H,2-8,11-16H2,1H3,(H,20,21)/b10-9-
DMCLKA4 CS CCCCCCCC/C=C\\CCCCCCC(C(=O)O)O
DMCLKA4 IK JBSOOFITVPOOSY-KTKRTIGZSA-N
DMCLKA4 IU (Z)-2-hydroxyoctadec-9-enoic acid
DMCLKA4 CA CAS 56472-29-8
DMCLKA4 CB CHEBI:143096
DMCLKA4 DE Hypertension
DMYPQT4 ID DMYPQT4
DMYPQT4 DN 4SCAR19 and 4SCAR123
DMYPQT4 HS Phase 1/2
DMYPQT4 CP Shenzhen Geno-Immune Medical Institute
DMYPQT4 DT CAR T Cell Therapy (Dual specific)
DMYPQT4 DE B-cell lymphoma
DMFVTSG ID DMFVTSG
DMFVTSG DN 4SCAR19 and 4SCAR20
DMFVTSG HS Phase 1/2
DMFVTSG CP Shenzhen Geno-Immune Medical Institute
DMFVTSG DT CAR T Cell Therapy (Dual specific)
DMFVTSG DE B-cell lymphoma
DM8CMUW ID DM8CMUW
DM8CMUW DN 4SCAR19 and 4SCAR22
DM8CMUW HS Phase 1/2
DM8CMUW CP Shenzhen Geno-Immune Medical Institute
DM8CMUW DT CAR T Cell Therapy (Dual specific)
DM8CMUW DE B-cell lymphoma
DMUYFS1 ID DMUYFS1
DMUYFS1 DN 4SCAR19 and 4SCAR30
DMUYFS1 HS Phase 1/2
DMUYFS1 CP Shenzhen Geno-Immune Medical Institute
DMUYFS1 DT CAR T Cell Therapy (Dual specific)
DMUYFS1 DE B-cell lymphoma
DMZKFU7 ID DMZKFU7
DMZKFU7 DN 4SCAR19 and 4SCAR38
DMZKFU7 HS Phase 1/2
DMZKFU7 CP Shenzhen Geno-Immune Medical Institute
DMZKFU7 DT CAR T Cell Therapy (Dual specific)
DMZKFU7 DE B-cell lymphoma
DMKC8F9 ID DMKC8F9
DMKC8F9 DN 4SCAR19 and 4SCAR70
DMKC8F9 HS Phase 1/2
DMKC8F9 CP Shenzhen Geno-Immune Medical Institute
DMKC8F9 DT CAR T Cell Therapy (Dual specific)
DMKC8F9 DE B-cell lymphoma
DMIY1ZB ID DMIY1ZB
DMIY1ZB DN 4SCAR19 cells
DMIY1ZB HS Phase 1/2
DMIY1ZB CP Shenzhen Geno-Immune Medical Institute
DMIY1ZB DT CAR T Cell Therapy
DMIY1ZB DE B-cell lymphoma
DMI8TW3 ID DMI8TW3
DMI8TW3 DN 4SCAR19/22 T cells
DMI8TW3 HS Phase 1/2
DMI8TW3 CP Zhujiang Hospital
DMI8TW3 DT CAR T Cell Therapy (Dual specific)
DMI8TW3 DE B-cell lymphoma; leukaemia
DMEGSU5 ID DMEGSU5
DMEGSU5 DN 4SCAR-GD2
DMEGSU5 HS Phase 1/2
DMEGSU5 CP Shenzhen Geno-Immune Medical Institute
DMEGSU5 DT CAR T Cell Therapy
DMEGSU5 DE Tumour
DMM8J5W ID DMM8J5W
DMM8J5W DN 4SCAR-PSMA
DMM8J5W HS Phase 1/2
DMM8J5W CP Shenzhen Geno-Immune Medical Institute
DMM8J5W DT CAR T Cell Therapy
DMM8J5W DE Bladder cancer
DM129VT ID DM129VT
DM129VT DN 514G3
DM129VT HS Phase 1/2
DM129VT CP XBiotech
DM129VT DT Antibody
DM129VT DE Staphylococcus infection
DMFAMNH ID DMFAMNH
DMFAMNH DN 99mTc-rBitistatin
DMFAMNH HS Phase 1/2
DMFAMNH CP Temple University
DMFAMNH DE Embolism
DMGTOIX ID DMGTOIX
DMGTOIX DN A166
DMGTOIX HS Phase 1/2
DMGTOIX CP KLUS Pharma
DMGTOIX DT Antibody drug conjugate
DMGTOIX DE Solid tumour/cancer
DMAPUZY ID DMAPUZY
DMAPUZY DN AAV1-FS344
DMAPUZY HS Phase 1/2
DMAPUZY CP Milo biotechnology
DMAPUZY DE Macular degeneration; Duchenne dystrophy; Inclusion body myositis
DMI27RF ID DMI27RF
DMI27RF DN AAV-AQP1
DMI27RF HS Phase 1/2
DMI27RF CP MeiraGTx
DMI27RF DT Gene therapy
DMI27RF DE Xerostomia
DMNZJAE ID DMNZJAE
DMNZJAE DN AAV-CNGA3
DMNZJAE HS Phase 1/2
DMNZJAE CP Janssen; MeiraGTx
DMNZJAE DT Gene therapy
DMNZJAE DE Achromatopsia
DM0CJAN ID DM0CJAN
DM0CJAN DN AAV-CNGB3
DM0CJAN HS Phase 1/2
DM0CJAN CP MeiraGTx
DM0CJAN DT Gene therapy
DM0CJAN DE Achromatopsia
DMAH6UJ ID DMAH6UJ
DMAH6UJ DN AAV-RPE65
DMAH6UJ HS Phase 1/2
DMAH6UJ CP MeiraGTx
DMAH6UJ DT Gene therapy
DMAH6UJ DE Leber congenital amaurosis
DM7TF49 ID DM7TF49
DM7TF49 DN AAV-RPGR
DM7TF49 HS Phase 1/2
DM7TF49 CP MeiraGTx
DM7TF49 DT Gene therapy
DM7TF49 DE Retinitis pigmentosa
DMDOXMN ID DMDOXMN
DMDOXMN DN AB928
DMDOXMN HS Phase 1/2
DMDOXMN CP Arcus Biosciences Hayward, CA
DMDOXMN PC 135242184
DMDOXMN MW 426.5
DMDOXMN FM C23H22N8O
DMDOXMN IC InChI=1S/C23H22N8O/c1-14-15(11-24)6-4-8-17(14)18-10-19(28-22(25)27-18)20-13-31(30-29-20)12-16-7-5-9-21(26-16)23(2,3)32/h4-10,13,32H,12H2,1-3H3,(H2,25,27,28)
DMDOXMN CS CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N
DMDOXMN IK BUXIAWLTBSXYSW-UHFFFAOYSA-N
DMDOXMN IU 3-[2-amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile
DMDOXMN CA CAS 2239273-34-6
DMDOXMN DE Solid tumour/cancer; Metastatic colorectal cancer
DMUBLC3 ID DMUBLC3
DMUBLC3 DN ABO-101
DMUBLC3 HS Phase 1/2
DMUBLC3 CP Abeona Therapeutics
DMUBLC3 DT Gene therapy
DMUBLC3 DE Mucopolysaccharidosis
DMFJB35 ID DMFJB35
DMFJB35 DN ABO-102
DMFJB35 HS Phase 1/2
DMFJB35 CP Abeona Therapeutics
DMFJB35 DT Gene therapy
DMFJB35 DE Mucopolysaccharidosis
DM31NJU ID DM31NJU
DM31NJU DN ABY-025
DM31NJU HS Phase 1/2
DM31NJU CP Affibody Holding AB
DM31NJU DE Bladder cancer
DMIRGTZ ID DMIRGTZ
DMIRGTZ DN ACHM-CNGA3
DMIRGTZ HS Phase 1/2
DMIRGTZ CP Applied Genetic Technologies
DMIRGTZ DT Gene therapy
DMIRGTZ DE Achromatopsia
DMC4ZQD ID DMC4ZQD
DMC4ZQD DN ACHM-CNGB3
DMC4ZQD HS Phase 1/2
DMC4ZQD CP Applied Genetic Technologies
DMC4ZQD DT Gene therapy
DMC4ZQD DE Achromatopsia
DM5YDSU ID DM5YDSU
DM5YDSU DN ACI-24
DM5YDSU HS Phase 1/2
DM5YDSU SN Beta amyloid vaccine (liposomal/SupraAntigen, Alzheimer's disease/Down syndrome), AC Immune
DM5YDSU CP AC Immune SA
DM5YDSU DT Vaccine
DM5YDSU DE Alzheimer disease
DM7IWTF ID DM7IWTF
DM7IWTF DN ACP-319
DM7IWTF HS Phase 1/2
DM7IWTF CP Acerta pharma
DM7IWTF DE Chronic lymphocytic leukaemia
DMEU86T ID DMEU86T
DMEU86T DN ACT017
DMEU86T HS Phase 1/2
DMEU86T CP Acticor Biotech
DMEU86T DT Small molecular drug
DMEU86T DE Cerebral ischemia
DM4L28K ID DM4L28K
DM4L28K DN Ad35-GRIN
DM4L28K HS Phase 1/2
DM4L28K SN Adenovirus serotype 35 vector-delivered gag/rt/int/nef vaccine (HIV infection), International AIDS Vaccine Initiative
DM4L28K CP International AIDS Vaccine Initiative
DM4L28K DT Vaccine
DM4L28K DE Human immunodeficiency virus infection
DMEGPSW ID DMEGPSW
DMEGPSW DN AdCh63 AMA1
DMEGPSW HS Phase 1/2
DMEGPSW SN MVA AMA1; Recombinant adenovirus-poxvirus prime-boost malaria vaccine, Oxford University/MRC/Wellcome
DMEGPSW CP University of Oxford
DMEGPSW DT Vaccine
DMEGPSW DE Malaria
DMBGXH5 ID DMBGXH5
DMBGXH5 DN AdCh63-MSP1
DMBGXH5 HS Phase 1/2
DMBGXH5 SN MVA-MSP1; MSP1 prime-boost vaccine (Plasmodium infection); MSP1 prime-boost vaccine (Plasmodium infection), University of Oxford
DMBGXH5 CP University of Oxford
DMBGXH5 DT Vaccine
DMBGXH5 DE Malaria
DMYOMSC ID DMYOMSC
DMYOMSC DN Aderbasib
DMYOMSC HS Phase 1/2
DMYOMSC SN INCB-007839; INCB-7839; Sheddase inhibitors (anticancer), Incyte; ADAM inhibitors (oral, cancer), Incyte
DMYOMSC CP Incyte Corp
DMYOMSC DT Small molecular drug
DMYOMSC PC 16070111
DMYOMSC MW 416.5
DMYOMSC FM C21H28N4O5
DMYOMSC IC InChI=1S/C21H28N4O5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29H,7-14H2,1H3,(H,22,26)/t16-,17-/m0/s1
DMYOMSC CS COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO
DMYOMSC IK DJXMSZSZEIKLQZ-IRXDYDNUSA-N
DMYOMSC IU methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate
DMYOMSC CA CAS 791828-58-5
DMYOMSC DE Breast cancer
DM87H0S ID DM87H0S
DM87H0S DN ADG106
DM87H0S HS Phase 1/2
DM87H0S CP Adagene
DM87H0S DT Antibody
DM87H0S DE Non-hodgkin lymphoma; Solid tumour/cancer
DMB19IO ID DMB19IO
DMB19IO DN Ad-IL-12 DNA therapeutic
DMB19IO HS Phase 1/2
DMB19IO SN INXN-2001
DMB19IO CP ZIOPHARM Oncology
DMB19IO DE Melanoma; Recurrent glioblastoma
DMOPVET ID DMOPVET
DMOPVET DN ADXS-PSA
DMOPVET HS Phase 1/2
DMOPVET SN Advaxis PSA; Lovaxin P; Lm CLLO CPSA; ADXS31-142; PSA/Listeria vector (cancer), Advaxis; Prostate specific antigen/Listeria vector (cancer), Advaxis
DMOPVET CP Advaxis Inc
DMOPVET DT Antibody
DMOPVET DE Prostate cancer
DMEOS5K ID DMEOS5K
DMEOS5K DN AEE-788
DMEOS5K HS Phase 1/2
DMEOS5K SN AEE; AEE 788; AEE788; GNF-Pf-5343; AEE-788, NVP-AEE 788, AEE788
DMEOS5K CP Novartis AG
DMEOS5K TC Anticancer Agents
DMEOS5K DT Small molecular drug
DMEOS5K PC 10297043
DMEOS5K MW 440.6
DMEOS5K FM C27H32N6
DMEOS5K IC InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)/t20-/m1/s1
DMEOS5K CS CCN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N3)N=CN=C4N[C@H](C)C5=CC=CC=C5
DMEOS5K IK OONFNUWBHFSNBT-HXUWFJFHSA-N
DMEOS5K IU 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
DMEOS5K CA CAS 497839-62-0
DMEOS5K DE Solid tumour/cancer
DM2HRYD ID DM2HRYD
DM2HRYD DN AEG35156
DM2HRYD HS Phase 1/2
DM2HRYD CP Aegera Therapeutics
DM2HRYD TC siRNA
DM2HRYD DT siRNA drug
DM2HRYD DE Solid tumour/cancer
DMMNIBY ID DMMNIBY
DMMNIBY DN Aflunov
DMMNIBY HS Phase 1/2
DMMNIBY SN Aflunov (TN)
DMMNIBY CP Novartis Vaccines & Diagnostics
DMMNIBY DT Vaccine
DMMNIBY DE Influenza A virus H5N1 infection
DMFTZX0 ID DMFTZX0
DMFTZX0 DN AFM24
DMFTZX0 HS Phase 1/2
DMFTZX0 CP Affimed Therapeutics
DMFTZX0 DT Antibody
DMFTZX0 DE Solid tumour/cancer
DMRET3H ID DMRET3H
DMRET3H DN AG-013958
DMRET3H HS Phase 1/2
DMRET3H SN AG-13958
DMRET3H CP Pfizer Inc
DMRET3H PC 9934283
DMRET3H MW 467.5
DMRET3H FM C26H22FN7O
DMRET3H IC InChI=1S/C26H22FN7O/c1-16-13-25(34(2)33-16)26(35)30-24-15-19(7-10-21(24)27)29-18-6-9-20-22(31-32-23(20)14-18)11-8-17-5-3-4-12-28-17/h3-15,29H,1-2H3,(H,30,35)(H,31,32)/b11-8+
DMRET3H CS CC1=NN(C(=C1)C(=O)NC2=C(C=CC(=C2)NC3=CC4=C(C=C3)C(=NN4)/C=C/C5=CC=CC=N5)F)C
DMRET3H IK JXSVVZKPEDIRTN-DHZHZOJOSA-N
DMRET3H IU N-[2-fluoro-5-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]amino]phenyl]-2,5-dimethylpyrazole-3-carboxamide
DMRET3H CA CAS 319460-94-1
DMRET3H DE Age-related macular degeneration
DMEN2L7 ID DMEN2L7
DMEN2L7 DN AG019
DMEN2L7 HS Phase 1/2
DMEN2L7 CP Intrexon T1D Partners; ActoBio Therapeutics
DMEN2L7 DT Gene therapy
DMEN2L7 DE Type-1 diabetes
DMAP5B4 ID DMAP5B4
DMAP5B4 DN AGEN1884
DMAP5B4 HS Phase 1/2
DMAP5B4 CP Agenus Lexington, MA
DMAP5B4 DE Solid tumour/cancer; Cervical cancer
DMHZUF8 ID DMHZUF8
DMHZUF8 DN AGN-208397
DMHZUF8 HS Phase 1/2
DMHZUF8 CP Allergan Inc
DMHZUF8 DE Retina venous occlusion
DMTS51C ID DMTS51C
DMTS51C DN AGTC-501
DMTS51C HS Phase 1/2
DMTS51C CP Applied Genetic Technologies
DMTS51C DT Gene therapy
DMTS51C DE Retinitis pigmentosa
DMJVGIH ID DMJVGIH
DMJVGIH DN AIGIV
DMJVGIH HS Phase 1/2
DMJVGIH SN Anthrax immune globulin therapy (intravenous); Anthrax immune globulin therapy (intravenous), Emergent
DMJVGIH CP Adma biologics; emergent biosolutions
DMJVGIH DE Diabetic neuropathy
DML0GIU ID DML0GIU
DML0GIU DN AIV001
DML0GIU HS Phase 1/2
DML0GIU CP AiViva BioPharma
DML0GIU DT Small molecular drug
DML0GIU DE Basal cell carcinoma
DMNXLOT ID DMNXLOT
DMNXLOT DN ALAMIFOVIR
DMNXLOT HS Phase 1/2
DMNXLOT SN LY-582563; MCC-478; Alamifovir; 2-[2-Amino-6-(4-methoxyphenylsulfanyl)-9H-purin-9-yl]ethoxymethylphosphonic acid bis(2,2,2-trifluoroethyl) diester
DMNXLOT CP Eli Lilly
DMNXLOT DT Small molecular drug
DMNXLOT PC 491022
DMNXLOT MW 575.4
DMNXLOT FM C19H20F6N5O5PS
DMNXLOT IC InChI=1S/C19H20F6N5O5PS/c1-32-12-2-4-13(5-3-12)37-16-14-15(28-17(26)29-16)30(10-27-14)6-7-33-11-36(31,34-8-18(20,21)22)35-9-19(23,24)25/h2-5,10H,6-9,11H2,1H3,(H2,26,28,29)
DMNXLOT CS COC1=CC=C(C=C1)SC2=NC(=NC3=C2N=CN3CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)N
DMNXLOT IK VDBGPMJFHCJMOL-UHFFFAOYSA-N
DMNXLOT IU 9-[2-[bis(2,2,2-trifluoroethoxy)phosphorylmethoxy]ethyl]-6-(4-methoxyphenyl)sulfanylpurin-2-amine
DMNXLOT CA CAS 193681-12-8
DMNXLOT DE Virus infection
DMGQX0U ID DMGQX0U
DMGQX0U DN ALX148
DMGQX0U HS Phase 1/2
DMGQX0U CP ALX Oncology
DMGQX0U DT Protein
DMGQX0U DE Non-hodgkin lymphoma; Solid tumour/cancer; Myelodysplastic syndrome
DMEF4L5 ID DMEF4L5
DMEF4L5 DN AMG888/U3-1287
DMEF4L5 HS Phase 1/2
DMEF4L5 CP Amgen
DMEF4L5 DE Non-small-cell lung cancer
DM7RNKM ID DM7RNKM
DM7RNKM DN AMT-060
DM7RNKM HS Phase 1/2
DM7RNKM SN AAV gene therapy (hemophilia B), Amsterdam Molecular Therapeutics/St Jude
DM7RNKM CP Amsterdam Molecular Therapeutics BV
DM7RNKM DE Factor IX deficiency
DMR9H6B ID DMR9H6B
DMR9H6B DN AMXI 5001
DMR9H6B HS Phase 1/2
DMR9H6B CP AtlasMedx
DMR9H6B DT Small molecular drug
DMR9H6B DE Solid tumour/cancer
DMDHJNV ID DMDHJNV
DMDHJNV DN Annamycin
DMDHJNV HS Phase 1/2
DMDHJNV SN 92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903
DMDHJNV CP Moleculin Biotech
DMDHJNV DT Small molecular drug
DMDHJNV PC 115212
DMDHJNV MW 640.4
DMDHJNV FM C26H25IO11
DMDHJNV IC InChI=1S/C26H25IO11/c1-9-19(30)24(35)18(27)25(37-9)38-13-7-26(36,14(29)8-28)6-12-15(13)23(34)17-16(22(12)33)20(31)10-4-2-3-5-11(10)21(17)32/h2-5,9,13,18-19,24-25,28,30,33-36H,6-8H2,1H3/t9-,13-,18+,19-,24-,25-,26-/m0/s1
DMDHJNV CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)CO)O)I)O)O
DMDHJNV IK CIDNKDMVSINJCG-GKXONYSUSA-N
DMDHJNV IU (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
DMDHJNV CA CAS 92689-49-1
DMDHJNV DE Acute myeloid leukaemia
DM4D3YF ID DM4D3YF
DM4D3YF DN Anti-BCMA CAR-T cells
DM4D3YF HS Phase 1/2
DM4D3YF CP Shenzhen BinDeBio Ltd.
DM4D3YF DT CAR T Cell Therapy
DM4D3YF DE Multiple myeloma
DMZ18IO ID DMZ18IO
DMZ18IO DN Anti-BCMA-CAR-transduced T cells
DMZ18IO HS Phase 1/2
DMZ18IO CP Southwest Hospital, China
DMZ18IO DT CAR T Cell Therapy
DMZ18IO DE leukaemia; Lymphoma; Multiple myeloma
DMFV6TY ID DMFV6TY
DMFV6TY DN Anti-CD123-CAR-transduced T cells
DMFV6TY HS Phase 1/2
DMFV6TY CP Southwest Hospital, China
DMFV6TY DT CAR T Cell Therapy
DMFV6TY DE leukaemia
DMLFB25 ID DMLFB25
DMLFB25 DN Anti-CD19 and Anti-CD20 CAR-T Cells
DMLFB25 HS Phase 1/2
DMLFB25 CP Shanghai Longyao Biotechnology Inc., Ltd.
DMLFB25 DT CAR T Cell Therapy (Dual specific)
DMLFB25 DE B-cell lymphoma
DMS326R ID DMS326R
DMS326R DN Anti-CD19 CAR T cells
DMS326R HS Phase 1/2
DMS326R CP Peking University
DMS326R DT CAR T Cell Therapy
DMS326R DE B-cell lymphoma
DMHSLVJ ID DMHSLVJ
DMHSLVJ DN Anti-CD19 CAR transduced T cells
DMHSLVJ HS Phase 1/2
DMHSLVJ CP Second Affiliated Hospital of Guangzhou Medical University
DMHSLVJ DT CAR T Cell Therapy
DMHSLVJ DE Acute lymphocytic leukaemia; Chronic lymphocytic leukaemia; Lymphoma
DM04HNB ID DM04HNB
DM04HNB DN Anti-CD19 CAR-T
DM04HNB HS Phase 1/2
DM04HNB CP The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
DM04HNB DT CAR T Cell Therapy
DM04HNB DE Haematopoietic/lymphoid cancer
DM1EH9D ID DM1EH9D
DM1EH9D DN Anti-CD19 CAR-T cells
DM1EH9D HS Phase 1/2
DM1EH9D CP Shenzhen BinDeBio Ltd.
DM1EH9D DT CAR T Cell Therapy
DM1EH9D DE leukaemia; Lymphoma
DM92CUG ID DM92CUG
DM92CUG DN Anti-CD19 CAR-T cells
DM92CUG HS Phase 1/2
DM92CUG CP Wuhan Sian Medical Technology Co., Ltd
DM92CUG DT CAR T Cell Therapy
DM92CUG DE Acute lymphoblastic leukaemia; B-cell lymphoma
DMDRYZK ID DMDRYZK
DMDRYZK DN Anti-CD19 CAR-T cells
DMDRYZK HS Phase 1/2
DMDRYZK CP PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DMDRYZK DT CAR T Cell Therapy
DMDRYZK DE Acute lymphocytic leukaemia; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
DMSFEOC ID DMSFEOC
DMSFEOC DN Anti-CD19 CAR-T cells
DMSFEOC HS Phase 1/2
DMSFEOC CP Kai Lin Xu; Jun Nian Zheng
DMSFEOC DT CAR T Cell Therapy
DMSFEOC DE B-cell chronic lymphocytic leukaemia
DMMUSHR ID DMMUSHR
DMMUSHR DN Anti-CD19/22-CAR vector-transduced T cells
DMMUSHR HS Phase 1/2
DMMUSHR CP Chinese PLA General Hospital
DMMUSHR DT CAR T Cell Therapy (Dual specific)
DMMUSHR DE Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Prolymphocytic leukaemia
DM1WB8H ID DM1WB8H
DM1WB8H DN Anti-CD19-CAR PBL
DM1WB8H HS Phase 1/2
DM1WB8H CP National Cancer Institute (NCI)
DM1WB8H DT CAR T Cell Therapy
DM1WB8H DE Mantle cell lymphoma; Primary mediastinal B-cell lymphoma; Diffuse large B-cell lymphoma
DMQXU4C ID DMQXU4C
DMQXU4C DN Anti-CD19-CAR vector-transduced T cells
DMQXU4C HS Phase 1/2
DMQXU4C CP Chinese PLA General Hospital
DMQXU4C DT CAR T Cell Therapy
DMQXU4C DE Mantle cell lymphoma; B-cell non-hodgkin lymphoma; Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Prolymphocytic leukaemia
DMNTP23 ID DMNTP23
DMNTP23 DN Anti-CD19-CAR-T cells
DMNTP23 HS Phase 1/2
DMNTP23 CP Shanghai GeneChem Co., Ltd.
DMNTP23 DT CAR T Cell Therapy
DMNTP23 DE leukaemia
DM4WEZL ID DM4WEZL
DM4WEZL DN Anti-CD20 CAR-T cells
DM4WEZL HS Phase 1/2
DM4WEZL CP Southwest Hospital, China
DM4WEZL DT CAR T Cell Therapy (Dual specific)
DM4WEZL DE Diffuse large B-cell lymphoma
DMCDUJY ID DMCDUJY
DMCDUJY DN Anti-CD20-CAR vector-transduced autologous T cells
DMCDUJY HS Phase 1/2
DMCDUJY CP Chinese PLA General Hospital
DMCDUJY DT CAR T Cell Therapy
DMCDUJY DE Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Haematopoietic/lymphoid cancer; Mantle cell lymphoma; Prolymphocytic leukaemia
DMXMK30 ID DMXMK30
DMXMK30 DN Anti-CD20-CAR-transduced T cells
DMXMK30 HS Phase 1/2
DMXMK30 CP Southwest Hospital, China
DMXMK30 DT CAR T Cell Therapy
DMXMK30 DE leukaemia; Lymphoma
DMY6U8R ID DMY6U8R
DMY6U8R DN Anti-CD22 CAR-T cells
DMY6U8R HS Phase 1/2
DMY6U8R CP Shenzhen BinDeBio Ltd.
DMY6U8R DT CAR T Cell Therapy
DMY6U8R DE leukaemia; Lymphoma
DMTO9VF ID DMTO9VF
DMTO9VF DN Anti-CD22-CAR-transduced T cells
DMTO9VF HS Phase 1/2
DMTO9VF CP Affiliated Hospital to Academy of Military Medical Sciences
DMTO9VF DT CAR T Cell Therapy
DMTO9VF DE leukaemia; Lymphoma
DM8139V ID DM8139V
DM8139V DN Anti-CD30 CAR T cells
DM8139V HS Phase 1/2
DM8139V CP Peking University
DM8139V DT CAR T Cell Therapy
DM8139V DE Lymphoma
DMTZSPJ ID DMTZSPJ
DMTZSPJ DN Anti-CD30-CAR-transduced T cells
DMTZSPJ HS Phase 1/2
DMTZSPJ CP Southwest Hospital, China
DMTZSPJ DT CAR T Cell Therapy
DMTZSPJ DE leukaemia; Lymphoma
DM9NPF6 ID DM9NPF6
DM9NPF6 DN Anti-CD33 CAR-T cells
DM9NPF6 HS Phase 1/2
DM9NPF6 CP Shenzhen BinDeBio Ltd.
DM9NPF6 DT CAR T Cell Therapy
DM9NPF6 DE Myeloid leukaemia
DMTVXBY ID DMTVXBY
DMTVXBY DN Anti-CD38 CAR-T cells
DMTVXBY HS Phase 1/2
DMTVXBY CP Shenzhen BinDeBio Ltd.
DMTVXBY DT CAR T Cell Therapy
DMTVXBY DE Multiple myeloma
DMV5H0S ID DMV5H0S
DMV5H0S DN Anti-C-met CAR-T cells
DMV5H0S HS Phase 1/2
DMV5H0S CP Shenzhen BinDeBio Ltd.
DMV5H0S DT CAR T Cell Therapy
DMV5H0S DE Colorectal cancer; Hepatocellular carcinoma; Ovarian cancer; Renal cell carcinoma
DMYKZB3 ID DMYKZB3
DMYKZB3 DN Anti-DR5 cells
DMYKZB3 HS Phase 1/2
DMYKZB3 CP Shenzhen BinDeBio Ltd.
DMYKZB3 DT CAR T Cell Therapy
DMYKZB3 DE Hepatocellular carcinoma
DM8EAGV ID DM8EAGV
DM8EAGV DN Anti-EGFR V III CAR-T cells
DM8EAGV HS Phase 1/2
DM8EAGV CP Shenzhen BinDeBio Ltd.
DM8EAGV DT CAR T Cell Therapy
DM8EAGV DE Glioma; Hepatocellular carcinoma; Lung cancer
DMDKTYU ID DMDKTYU
DMDKTYU DN Anti-EGFRvIII CAR transduced PBL
DMDKTYU HS Phase 1/2
DMDKTYU CP National Cancer Institute (NCI)
DMDKTYU DT CAR T Cell Therapy
DMDKTYU DE Brain cancer; Malignant glioma; Recurrent glioblastoma
DM8ENKS ID DM8ENKS
DM8ENKS DN Anti-Factor D
DM8ENKS HS Phase 1/2
DM8ENKS CP Genentech
DM8ENKS DT Antibody
DM8ENKS DE Age-related macular degeneration
DMQD6B9 ID DMQD6B9
DMQD6B9 DN Anti-HER2 CAR-T
DMQD6B9 HS Phase 1/2
DMQD6B9 CP Zhi Yang
DMQD6B9 DT CAR T Cell Therapy
DMQD6B9 DE Colorectal cancer; Gastric adenocarcinoma; Glioma; Lung cancer; Ovarian cancer; Pancreatic cancer
DMQZJ3B ID DMQZJ3B
DMQZJ3B DN Anti-HIV ribozyme therapy
DMQZJ3B HS Phase 1/2
DMQZJ3B SN OZ1; RRZ2; HIV ribozyme gene therapy, Gene Shears; Gene therapy (HIV), Gene Shears; Anti-HIV ribozyme therapy, Johnson & Johnson; Anti-HIV-1 gene transfer product, Johnson & Johnson
DMQZJ3B CP Gene Shears Pty Ltd
DMQZJ3B DE Human immunodeficiency virus infection
DMXI03L ID DMXI03L
DMXI03L DN Anti-mesothelin CAR transduced PBL
DMXI03L HS Phase 1/2
DMXI03L CP National Cancer Institute (NCI)
DMXI03L DT CAR T Cell Therapy
DMXI03L DE Cervical cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer
DM4NMBW ID DM4NMBW
DM4NMBW DN Anti-Mesothelin CAR-T cells
DM4NMBW HS Phase 1/2
DM4NMBW CP Shenzhen BinDeBio Ltd.
DM4NMBW DT CAR T Cell Therapy
DM4NMBW DE Gastric adenocarcinoma; Mesothelioma; Pancreatic cancer
DM0C1IX ID DM0C1IX
DM0C1IX DN Anti-MUC1 CAR T Cells
DM0C1IX HS Phase 1/2
DM0C1IX CP PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DM0C1IX DT CAR T Cell Therapy
DM0C1IX DE Breast cancer; Hepatocellular carcinoma; Pancreatic cancer
DMDHKN1 ID DMDHKN1
DMDHKN1 DN Anti-MUC1 CAR T Cells
DMDHKN1 HS Phase 1/2
DMDHKN1 CP The First Affiliated Hospital of Guangdong Pharmaceutical University
DMDHKN1 DT CAR T Cell Therapy
DMDHKN1 DE Lung cancer; Non-small-cell lung cancer
DMTQIB2 ID DMTQIB2
DMTQIB2 DN Anti-MUC1 CAR-T cells
DMTQIB2 HS Phase 1/2
DMTQIB2 CP PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DMTQIB2 DT CAR T Cell Therapy
DMTQIB2 DE Colorectal cancer; Gastric adenocarcinoma; Malignant glioma
DMXYOTP ID DMXYOTP
DMXYOTP DN Anti-MUC1 CAR-T cells
DMXYOTP HS Phase 1/2
DMXYOTP CP The First Affiliated Hospital of Guangdong Pharmaceutical University
DMXYOTP DT CAR T Cell Therapy
DMXYOTP DE Esophageal cancer
DM26VCZ ID DM26VCZ
DM26VCZ DN Anti-NY-ESO-1 CAR-T cells
DM26VCZ HS Phase 1/2
DM26VCZ CP Shenzhen BinDeBio Ltd.
DM26VCZ DT CAR T Cell Therapy
DM26VCZ DE Esophageal cancer; Lung cancer; Multiple myeloma; Synovial sarcoma
DM2910G ID DM2910G
DM2910G DN Anti-VEGFR2 CD8 cell therapy
DM2910G HS Phase 1/2
DM2910G SN Anti-VEGFR2 CD8 cell therapy (cancer)
DM2910G CP Pervasis Therapeutics
DM2910G DE Solid tumour/cancer
DMXU98C ID DMXU98C
DMXU98C DN AO-176
DMXU98C HS Phase 1/2
DMXU98C CP Arch Oncology
DMXU98C DT Antibody
DMXU98C DE Solid tumour/cancer
DMBGA35 ID DMBGA35
DMBGA35 DN AP-1030
DMBGA35 HS Phase 1/2
DMBGA35 SN AP-1102; AP-1130; MS-05; Combined MC1/MC4 receptor agonists, Action Pharma; Melanocortin-1/-4 receptor agonists, ActionPharma; Melanocortin-1/melanocortin-4 receptor agonists, Action Pharma
DMBGA35 CP Action Pharma A/S
DMBGA35 DE Metabolic disorder
DM2LU8M ID DM2LU8M
DM2LU8M DN AP1903
DM2LU8M HS Phase 1/2
DM2LU8M SN Rimiducid; AP1903; 195514-63-7; UNII-H564L1W5J2; AP 1903; AP-1903; H564L1W5J2; Rimiducid [INN]; Rimiducid [USAN:INN]; CHEMBL269259; SCHEMBL10111062; DTXSID80173226; EX-A1711; AKOS030238859; CS-3162; KB-74710; HY-16046; Z-3163; 2-Piperidinecarboxylic acid, 1-(1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) ester, (2S-(1(R*),2R*(S*(S*(1(R*),2R*)))))-
DM2LU8M CP Bellicum Pharmaceuticals
DM2LU8M PC 16135625
DM2LU8M MW 1411.6
DM2LU8M FM C78H98N4O20
DM2LU8M IC InChI=1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)/t57-,58-,59-,60-,61+,62+/m0/s1
DM2LU8M CS CC[C@@H](C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)[C@@H](CCC6=CC(=C(C=C6)OC)OC)OC(=O)[C@@H]7CCCCN7C(=O)[C@@H](CC)C8=CC(=C(C(=C8)OC)OC)OC
DM2LU8M IK GQLCLPLEEOUJQC-ZTQDTCGGSA-N
DM2LU8M IU [(1R)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate
DM2LU8M CA CAS 195514-63-7
DM2LU8M DE Transplant rejection
DMJLMEF ID DMJLMEF
DMJLMEF DN AP-30663
DMJLMEF HS Phase 1/2
DMJLMEF CP Acesion Pharma
DMJLMEF DE Atrial fibrillation
DM71I53 ID DM71I53
DM71I53 DN APC-100
DM71I53 HS Phase 1/2
DM71I53 CP Adamis Pharmaceuticals
DM71I53 PC 99479
DM71I53 MW 220.31
DM71I53 FM C14H20O2
DM71I53 IC InChI=1S/C14H20O2/c1-8-9(2)13-11(10(3)12(8)15)6-7-14(4,5)16-13/h15H,6-7H2,1-5H3
DM71I53 CS CC1=C(C2=C(CCC(O2)(C)C)C(=C1O)C)C
DM71I53 IK SEBPXHSZHLFWRL-UHFFFAOYSA-N
DM71I53 IU 2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-ol
DM71I53 CA CAS 950-99-2
DM71I53 DE Prostate cancer
DM8O3R9 ID DM8O3R9
DM8O3R9 DN APG-1252
DM8O3R9 HS Phase 1/2
DM8O3R9 CP Ascentage Pharma
DM8O3R9 DT Small molecular drug
DM8O3R9 DE Small-cell lung cancer; Solid tumour/cancer
DMPWBM2 ID DMPWBM2
DMPWBM2 DN APG-2575
DMPWBM2 HS Phase 1/2
DMPWBM2 SN Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-
DMPWBM2 CP Ascentage Pharma
DMPWBM2 DT Small molecular drug
DMPWBM2 PC 137355972
DMPWBM2 MW 882.4
DMPWBM2 FM C45H48ClN7O8S
DMPWBM2 IC InChI=1S/C45H48ClN7O8S/c46-33-4-2-30(3-5-33)39-25-45(12-1-13-45)14-10-32(39)28-51-16-18-52(19-17-51)34-6-8-38(42(23-34)61-35-22-31-11-15-47-43(31)49-26-35)44(54)50-62(57,58)37-7-9-40(41(24-37)53(55)56)48-27-36-29-59-20-21-60-36/h2-9,11,15,22-24,26,36,48H,1,10,12-14,16-21,25,27-29H2,(H,47,49)(H,50,54)/t36-/m0/s1
DMPWBM2 CS C1CC2(C1)CCC(=C(C2)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NC[C@H]7COCCO7)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9
DMPWBM2 IK FNBXDBIYRAPDPI-BHVANESWSA-N
DMPWBM2 IU 4-[4-[[8-(4-chlorophenyl)spiro[3.5]non-7-en-7-yl]methyl]piperazin-1-yl]-N-[4-[[(2S)-1,4-dioxan-2-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
DMPWBM2 CA CAS 2180923-05-9
DMPWBM2 DE Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMV7Q6X ID DMV7Q6X
DMV7Q6X DN APN-201
DMV7Q6X HS Phase 1/2
DMV7Q6X SN Lipoxysan; Liposomal SOD (wound healing), Polymun; Liposomal SOD (Peyronie's disease), Polymun; RhSOD (liposomal, dermatitis), Apeiron; Liposomal superoxide dismutase (recombinant, encapsulated, topical), Polymun
DMV7Q6X CP Polymun Scientific Immunobiologische Forschung GmbH
DMV7Q6X DE Dermatitis
DM76S3X ID DM76S3X
DM76S3X DN ARO-HBV
DM76S3X HS Phase 1/2
DM76S3X SN JNJ-3989
DM76S3X CP Arrowhead Pharmaceuticals
DM76S3X DT Small interfering RNA
DM76S3X DE Hepatitis B
DMI17NX ID DMI17NX
DMI17NX DN ART621
DMI17NX HS Phase 1/2
DMI17NX CP Arana Therapeutics
DMI17NX DE Psoriasis vulgaris; Rheumatoid arthritis
DMYCID5 ID DMYCID5
DMYCID5 DN ARV-110
DMYCID5 HS Phase 1/2
DMYCID5 CP Arvinas
DMYCID5 DT Small molecular drug
DMYCID5 DE Prostate cancer
DM276Y8 ID DM276Y8
DM276Y8 DN ARV-471
DM276Y8 HS Phase 1/2
DM276Y8 CP Arvinas
DM276Y8 DT Small molecular drug
DM276Y8 DE Breast cancer
DMVNCSK ID DMVNCSK
DMVNCSK DN ASC-101
DMVNCSK HS Phase 1/2
DMVNCSK SN Engraftin; Recombinant enzyme (bone marrow transplant), America Stem Cell
DMVNCSK CP America stem cell
DMVNCSK DE Haematological malignancy
DM8V0UL ID DM8V0UL
DM8V0UL DN ASP-9521
DM8V0UL HS Phase 1/2
DM8V0UL CP Astellas Pharma Inc
DM8V0UL PC 25210792
DM8V0UL MW 330.4
DM8V0UL FM C19H26N2O3
DM8V0UL IC InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3
DM8V0UL CS CC(C)(CC1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)OC)O
DM8V0UL IK OXSCPDKUZWPWFR-UHFFFAOYSA-N
DM8V0UL IU [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone
DM8V0UL DE Prostate cancer
DMVZXIA ID DMVZXIA
DMVZXIA DN ASTX029
DMVZXIA HS Phase 1/2
DMVZXIA CP Astex Pharmaceuticals
DMVZXIA DT Small molecular drug
DMVZXIA DE Solid tumour/cancer
DM9EM5G ID DM9EM5G
DM9EM5G DN ASTX295
DM9EM5G HS Phase 1/2
DM9EM5G CP Astex Pharmaceuticals
DM9EM5G DT Small molecular drug
DM9EM5G DE Solid tumour/cancer
DMSOQ6E ID DMSOQ6E
DMSOQ6E DN AT-342
DMSOQ6E HS Phase 1/2
DMSOQ6E CP Audentes Therapeutics
DMSOQ6E DT Gene therapy
DMSOQ6E DE Crigler-Najjar syndrome
DM7O89Q ID DM7O89Q
DM7O89Q DN AT-777
DM7O89Q HS Phase 1/2
DM7O89Q CP Atea Pharmaceuticals
DM7O89Q DT Small molecular drug
DM7O89Q DE Hepatitis C
DMB5X7Z ID DMB5X7Z
DMB5X7Z DN ATG002
DMB5X7Z HS Phase 1/2
DMB5X7Z CP CoMentis
DMB5X7Z DE Diabetic foot ulcer
DM84YEC ID DM84YEC
DM84YEC DN Atiprimod
DM84YEC HS Phase 1/2
DM84YEC SN Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine
DM84YEC CP Callisto Pharm.
DM84YEC DT Small molecular drug
DM84YEC PC 129869
DM84YEC MW 336.6
DM84YEC FM C22H44N2
DM84YEC IC InChI=1S/C22H44N2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20H2,1-4H3
DM84YEC CS CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC
DM84YEC IK SERHTTSLBVGRBY-UHFFFAOYSA-N
DM84YEC IU 3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-N,N-diethylpropan-1-amine
DM84YEC CA CAS 123018-47-3
DM84YEC DE Multiple myeloma
DM75QY9 ID DM75QY9
DM75QY9 DN ATL-313
DM75QY9 HS Phase 1/2
DM75QY9 SN DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data
DM75QY9 CP University of Virginia
DM75QY9 DT Small molecular drug
DM75QY9 PC 11627443
DM75QY9 MW 499.5
DM75QY9 FM C23H29N7O6
DM75QY9 IC InChI=1S/C23H29N7O6/c1-35-23(34)29-9-7-12(8-10-29)3-2-4-14-27-19(24)15-20(28-14)30(11-25-15)22-17(32)16(31)18(36-22)21(33)26-13-5-6-13/h11-13,16-18,22,31-32H,3,5-10H2,1H3,(H,26,33)(H2,24,27,28)/t16-,17+,18-,22+/m0/s1
DM75QY9 CS COC(=O)N1CCC(CC1)CC#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)C(=O)NC5CC5)O)O)N
DM75QY9 IK SQJXTUJMBYVDBB-RQXXJAGISA-N
DM75QY9 IU methyl 4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(cyclopropylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]prop-2-ynyl]piperidine-1-carboxylate
DM75QY9 CA CAS 844873-47-8
DM75QY9 DE Arteriosclerosis
DMLAKPI ID DMLAKPI
DMLAKPI DN AU101
DMLAKPI HS Phase 1/2
DMLAKPI CP Aurora BioPharma Cambridge, MA
DMLAKPI DE Osteosarcoma; Recurrent glioblastoma; Recurring respiratory infection; Sarcoma
DMPAZ3U ID DMPAZ3U
DMPAZ3U DN AU105
DMPAZ3U HS Phase 1/2
DMPAZ3U CP Aurora BioPharma Cambridge, MA
DMPAZ3U DE Recurrent glioblastoma
DMG9OAV ID DMG9OAV
DMG9OAV DN AUTO1
DMG9OAV HS Phase 1/2
DMG9OAV CP Autolus Therapeutics
DMG9OAV DT CAR T Cell Therapy
DMG9OAV DE Acute lymphoblastic leukaemia
DM0PWX2 ID DM0PWX2
DM0PWX2 DN AUTO2
DM0PWX2 HS Phase 1/2
DM0PWX2 CP Autolus Limited
DM0PWX2 DT CAR T Cell Therapy (Dual specific)
DM0PWX2 DE Multiple myeloma
DMC5NSO ID DMC5NSO
DMC5NSO DN AUTO3
DMC5NSO HS Phase 1/2
DMC5NSO CP Autolus Limited
DMC5NSO DT CAR T Cell Therapy (Dual specific)
DMC5NSO DE Acute lymphoblastic leukaemia; Diffuse large B-cell lymphoma
DM2YTGQ ID DM2YTGQ
DM2YTGQ DN Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
DM2YTGQ HS Phase 1/2
DM2YTGQ CP Fred Hutchinson Cancer Research Center
DM2YTGQ DT CAR T Cell Therapy
DM2YTGQ DE Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle cell lymphoma; Non-hodgkin lymphoma
DMLOGI4 ID DMLOGI4
DMLOGI4 DN Autologous CD19-targeting CAR T cells
DMLOGI4 HS Phase 1/2
DMLOGI4 CP Hebei Senlang Biotechnology Inc., Ltd.
DMLOGI4 DT CAR T Cell Therapy
DMLOGI4 DE leukaemia
DMRS58M ID DMRS58M
DMRS58M DN Avrina
DMRS58M HS Phase 1/2
DMRS58M SN NF-KB Decoy
DMRS58M CP Anesiva
DMRS58M DE Skin infection
DMC1XHK ID DMC1XHK
DMC1XHK DN AVR-RD-01
DMC1XHK HS Phase 1/2
DMC1XHK CP AVROBIO
DMC1XHK DT Gene therapy
DMC1XHK DE Fabry disease
DMOPVIQ ID DMOPVIQ
DMOPVIQ DN AVX701
DMOPVIQ HS Phase 1/2
DMOPVIQ SN Cea cancer immunotherapy
DMOPVIQ CP Alphavax
DMOPVIQ DE Colorectal cancer; Rectosigmoid junction cancer
DM7O29W ID DM7O29W
DM7O29W DN AVX901
DM7O29W HS Phase 1/2
DM7O29W SN HER2 cancer immunotherapy
DM7O29W CP Alphavax
DM7O29W DE Breast cancer
DMWLZI6 ID DMWLZI6
DMWLZI6 DN AZD0466
DMWLZI6 HS Phase 1/2
DMWLZI6 CP AstraZeneca
DMWLZI6 DT Small molecular drug
DMWLZI6 DE Hematologic tumour
DMT2FAP ID DMT2FAP
DMT2FAP DN AZD-2836
DMT2FAP HS Phase 1/2
DMT2FAP SN A-00060058; A-00060617; A-48504; A-48756; A-48773; A-831; HCV NS5A inhibitors, Arrow Therapeutics; Hepatitis C virus therapeutics (NS5A inhibitors), Arrow
DMT2FAP CP AstraZeneca
DMT2FAP DE Hepatitis C virus infection
DMD9Y5T ID DMD9Y5T
DMD9Y5T DN AZD7648
DMD9Y5T HS Phase 1/2
DMD9Y5T SN AZD-7648; 2230820-11-6; UNII-97A09L5JCK; 97A09L5JCK; 7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one; 7-Methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one; 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one; CHEMBL4439259; SCHEMBL20299477; GTPL10601; US10407446, Example 3; BDBM413450; BCP30676; EX-A2988; AZD 7648;AZD7648; MFCD32062688; NSC817043; s8843; ZB1555; NSC-817043; SB23233; compound 16 [PMID: 31851518]; AC-31586; BS-16016; HY-111783; CS-0091859; CN1C(=O)N(C2CCOCC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12; 7-Methyl-2-((7-methyl(1,2,4)triazolo(1,5- a)pyridin-6-yl)amino)-9-(tetrahydro-2H-pyran- 4-yl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one, 7,9-dihydro-7-methyl-2-((7- methyl(1,2,4)triazolo(1,5-a)pyridin-6- yl)amino)-9-(tetrahydro-2H-pyran-4-yl)-
DMD9Y5T CP AstraZeneca
DMD9Y5T DT Small molecular drug
DMD9Y5T PC 135151360
DMD9Y5T MW 380.4
DMD9Y5T FM C18H20N8O2
DMD9Y5T IC InChI=1S/C18H20N8O2/c1-11-7-15-20-10-21-25(15)9-13(11)22-17-19-8-14-16(23-17)26(18(27)24(14)2)12-3-5-28-6-4-12/h7-10,12H,3-6H2,1-2H3,(H,19,22,23)
DMD9Y5T CS CC1=CC2=NC=NN2C=C1NC3=NC=C4C(=N3)N(C(=O)N4C)C5CCOCC5
DMD9Y5T IK XISVSTPEXYIKJL-UHFFFAOYSA-N
DMD9Y5T IU 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one
DMD9Y5T CA CAS 2230820-11-6
DMD9Y5T DE Solid tumour/cancer
DMPFGL8 ID DMPFGL8
DMPFGL8 DN BAL-101553
DMPFGL8 HS Phase 1/2
DMPFGL8 CP Basilea Pharmaceutica International Ltd
DMPFGL8 DT Small molecular drug
DMPFGL8 PC 45259014
DMPFGL8 MW 515.6
DMPFGL8 FM C26H29N9O3
DMPFGL8 IC InChI=1S/C26H29N9O3/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37)/t19-/m0/s1
DMPFGL8 CS C1=CC=C2C(=C1)N=C(N2CC(=O)C3=CC=C(C=C3)NC(=O)[C@H](CCCCN)N)C4=NON=C4NCCC#N
DMPFGL8 IK NIPZLALJRAHABJ-IBGZPJMESA-N
DMPFGL8 IU (2S)-2,6-diamino-N-[4-[2-[2-[4-(2-cyanoethylamino)-1,2,5-oxadiazol-3-yl]benzimidazol-1-yl]acetyl]phenyl]hexanamide
DMPFGL8 CA CAS 1263384-43-5
DMPFGL8 DE Solid tumour/cancer; Recurrent glioblastoma
DMFA4CK ID DMFA4CK
DMFA4CK DN BAY 1902607
DMFA4CK HS Phase 1/2
DMFA4CK CP Bayer
DMFA4CK DT Small molecular drug
DMFA4CK DE Cough
DMH70A9 ID DMH70A9
DMH70A9 DN BCMA CAR T cells
DMH70A9 HS Phase 1/2
DMH70A9 CP Shenzhen Geno-Immune Medical Institute
DMH70A9 DT CAR T Cell Therapy
DMH70A9 DE Multiple myeloma
DM1DHPO ID DM1DHPO
DM1DHPO DN BCMA CAR-T
DM1DHPO HS Phase 1/2
DM1DHPO CP Henan Cancer Hospital
DM1DHPO DT CAR T Cell Therapy
DM1DHPO DE Multiple myeloma
DMZK7IT ID DMZK7IT
DMZK7IT DN BCT-100
DMZK7IT HS Phase 1/2
DMZK7IT SN RhArg-peg; Pegylated recombinant human arginase (cancer), BCT
DMZK7IT CP Bio-Cancer Treatment International Ltd
DMZK7IT DE Solid tumour/cancer
DMJ5MPG ID DMJ5MPG
DMJ5MPG DN BDC-1001
DMJ5MPG HS Phase 1/2
DMJ5MPG CP Bolt Biotherapeutics
DMJ5MPG DT Antibody drug conjugate
DMJ5MPG DE Solid tumour/cancer
DMODTX5 ID DMODTX5
DMODTX5 DN BDTX-189
DMODTX5 HS Phase 1/2
DMODTX5 SN 2414572-47-5; EX-A4379
DMODTX5 CP Black Diamond Therapeutics
DMODTX5 DT Small molecular drug
DMODTX5 PC 154824631
DMODTX5 MW 561
DMODTX5 FM C29H29ClN6O4
DMODTX5 IC InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)
DMODTX5 CS C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)OCCN5CCOCC5
DMODTX5 IK HIBPKFXWOPYJPZ-UHFFFAOYSA-N
DMODTX5 IU N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide
DMODTX5 DE Solid tumour/cancer
DMXVRI0 ID DMXVRI0
DMXVRI0 DN Beclanorsen
DMXVRI0 HS Phase 1/2
DMXVRI0 SN SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
DMXVRI0 CP Santaris Pharma A/S
DMXVRI0 DT Antisense drug
DMXVRI0 DE leukaemia
DMVYTG7 ID DMVYTG7
DMVYTG7 DN BGB-283
DMVYTG7 HS Phase 1/2
DMVYTG7 SN Lifirafenib
DMVYTG7 DT Small molecular drug
DMVYTG7 PC 89670174
DMVYTG7 MW 478.4
DMVYTG7 FM C25H17F3N4O3
DMVYTG7 IC InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1
DMVYTG7 CS C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F
DMVYTG7 IK NGFFVZQXSRKHBM-FKBYEOEOSA-N
DMVYTG7 IU 5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DMVYTG7 CA CAS 1446090-79-4
DMVYTG7 DE Solid tumour/cancer
DM5VG6S ID DM5VG6S
DM5VG6S DN BGB-A333
DM5VG6S HS Phase 1/2
DM5VG6S CP BeiGene
DM5VG6S DT Antibody
DM5VG6S DE Solid tumour/cancer
DMI42Q0 ID DMI42Q0
DMI42Q0 DN BGB-A425
DMI42Q0 HS Phase 1/2
DMI42Q0 CP BeiGene
DMI42Q0 DT Antibody
DMI42Q0 DE Solid tumour/cancer; Non-small cell lung cancer
DMXKDUL ID DMXKDUL
DMXKDUL DN BGT226
DMXKDUL HS Phase 1/2
DMXKDUL SN BGT-226 free base; 915020-55-2; UNII-ZXE7F2GMJJ; BGT226 free base; ZXE7F2GMJJ; BGT-226; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-trifluoromethylphenyl]-1,3-dihydroimidazo[4,5-c]quinolin-2-one; CHEBI:71967; BGT 226; NVPBGT226; 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one; NPV-BGT226; SCHEMBL146939
DMXKDUL CP Novartis
DMXKDUL DT Small molecular drug
DMXKDUL PC 11978790
DMXKDUL MW 534.5
DMXKDUL FM C28H25F3N6O2
DMXKDUL IC InChI=1S/C28H25F3N6O2/c1-35-24-16-33-22-6-3-17(18-4-8-25(39-2)34-15-18)13-20(22)26(24)37(27(35)38)19-5-7-23(21(14-19)28(29,30)31)36-11-9-32-10-12-36/h3-8,13-16,32H,9-12H2,1-2H3
DMXKDUL CS CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC
DMXKDUL IK BMMXYEBLEBULND-UHFFFAOYSA-N
DMXKDUL IU 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one
DMXKDUL CA CAS 915020-55-2
DMXKDUL CB CHEBI:71967
DMXKDUL DE Solid tumour/cancer
DMTOMWB ID DMTOMWB
DMTOMWB DN BI 1206
DMTOMWB HS Phase 1/2
DMTOMWB CP BioInvent
DMTOMWB DT Antibody
DMTOMWB DE Chronic lymphocytic leukaemia; B-cell lymphoma; leukaemia
DMR8EPF ID DMR8EPF
DMR8EPF DN BIIB-087
DMR8EPF HS Phase 1/2
DMR8EPF SN rAAV2tYF-CB-hRS1
DMR8EPF CP Applied Genetic Technologies
DMR8EPF DT Gene therapy
DMR8EPF DE X-linked retinoschisis
DMV1EA9 ID DMV1EA9
DMV1EA9 DN BIL010t
DMV1EA9 HS Phase 1/2
DMV1EA9 CP Biosceptre
DMV1EA9 DE Solid tumour/cancer; Alzheimer disease
DMZEA9X ID DMZEA9X
DMZEA9X DN BIW-8962
DMZEA9X HS Phase 1/2
DMZEA9X CP Kyowa Hakko Kirin Pharma
DMZEA9X DT Antibody
DMZEA9X DE Multiple myeloma
DMFKA4G ID DMFKA4G
DMFKA4G DN BLZ-100
DMFKA4G HS Phase 1/2
DMFKA4G SN Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6
DMFKA4G CP Blaze Bioscience
DMFKA4G PC 121488172
DMFKA4G MW 4766
DMFKA4G FM C203H296N58O52S12
DMFKA4G IC InChI=1S/C203H296N58O52S12/c1-107(2)85-130-178(291)253-139(185(298)240-129(196(309)310)50-36-76-223-201(215)216)100-319-317-98-137-171(284)225-93-154(268)224-94-155(269)231-120(46-32-72-219-197(207)208)168(281)226-95-156(270)232-121(47-33-73-220-198(209)210)169(282)227-96-157(271)233-122(45-27-28-71-218-153(267)55-22-17-29-77-258-145-64-58-113-41-23-25-43-117(113)162(145)202(6,7)149(258)53-20-14-13-15-21-54-150-203(8,9)163-118-44-26-24-42-114(118)59-65-146(163)259(150)78-30-31-84-325(311,312)313)173(286)250-141-102-322-324-105-144-189(302)243-132(86-111-39-18-16-19-40-111)183(296)256-165(110(5)263)194(307)257-164(109(4)262)193(306)247-136(91-161(277)278)181(294)244-133(88-115-92-217-106-229-115)179(292)236-125(62-66-151(205)265)176(289)237-127(69-82-315-11)172(285)230-108(3)166(279)234-123(48-34-74-221-199(211)212)174(287)235-124(49-35-75-222-200(213)214)175(288)251-142(103-321-320-101-140(186(299)241-130)252-177(290)126(63-67-152(206)266)238-191(304)147-51-37-79-260(147)158(272)97-228-170(283)131(242-187(141)300)87-112-56-60-116(264)61-57-112)188(301)246-134(89-159(273)274)180(293)245-135(90-160(275)276)182(295)254-143(190(303)249-137)104-323-318-99-138(248-167(280)119(204)68-81-314-10)184(297)239-128(70-83-316-12)195(308)261-80-38-52-148(261)192(305)255-144/h13-16,18-21,23-26,39-44,53-54,56-61,64-65,92,106-110,119-144,147-148,164-165,262-263H,17,22,27-38,45-52,55,62-63,66-91,93-105,204H2,1-12H3,(H64-,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,264,265,266,267,268,269,270,271,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,309,310,311,312,313)/t108-,109+,110+,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,147-,148-,164-,165-/m0/s1
DMFKA4G CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]4C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCSC)CCC(=O)N)CC5=CNC=N5)CC(=O)O)[C@@H](C)O)[C@@H](C)O)CC6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@@H](NC(=O)[C@H](CSSC[C@@H](C(=O)N4)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC(=O)O)CC(=O)O)NC(=O)[C@H](CCSC)N)CCSC)C(=O)N[C@H](C(=O)NCC(=O)N8CCC[C@H]8C(=O)N[C@H](C(=O)N3)CCC(=O)N)CC9=CC=C(C=C9)O)CCCCNC(=O)CCCCCN\\1C2=C(C3=CC=CC=C3C=C2)C(/C1=C/C=C/C=C/C=C/C1=[N+](C2=C(C1(C)C)C1=CC=CC=C1C=C2)CCCCS(=O)(=O)[O-])(C)C)CCCNC(=N)N)CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)CC(C)C)CCCNC(=N)N)CCCNC(=N)N
DMFKA4G IK LWXYOERUKGQNKQ-IQDTYCCDSA-N
DMFKA4G IU 4-[2-[(1E,3E,5E,7Z)-7-[3-[6-[4-[(1R,4R,5aR,8aS,9R,12S,17aS,18S,20aS,21R,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54R,59R,62S,65S,74S,77R,80S,86S,92S)-9-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-39,62-bis(3-amino-3-oxopropyl)-24-benzyl-5a-[[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl]-48,51,86,92-tetrakis(3-carbamimidamidopropyl)-17a,20a,33-tris(carboxymethyl)-27,30-bis[(1R)-1-hydroxyethyl]-74-[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-45-methyl-8a-(2-methylpropyl)-12,42-bis(2-methylsulfanylethyl)-a,3,7a,10,10a,13,15a,18a,19,21a,22,25,28,31,34,37,40,43,46,49,52,61,64,70,73,76,79,82,85,88,91,94,97-tritriacontaoxo-2a,3a,6,7,12a,13a,56,57-octathia-2,6a,9a,11,14,16a,19a,20,22a,23,26,29,32,35,38,41,44,47,50,53,60,63,69,72,75,78,81,84,87,90,93,96,99-tritriacontazahexacyclo[57.41.10.84,54.421,77.014,18.065,69]docosahectan-80-yl]butylamino]-6-oxohexyl]-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]butane-1-sulfonate
DMFKA4G CA CAS 1673565-40-6
DMFKA4G DE Glioma; Malignant primary brain tumour
DMDQO0S ID DMDQO0S
DMDQO0S DN BMS-753493
DMDQO0S HS Phase 1/2
DMDQO0S SN Epofolate; Epothilone folate conjugate; BMS-493; BMS-748285 folate conjugate, Bristol-Myers Squibb; Targeted epothilone-folate conjugate (Endocyte technology, cancer), BMS; Targeted epothilone-folate conjugate (Endocyte technology, cancer), Bristol-Myers Squibb
DMDQO0S CP Bristol-Myers Squibb Co
DMDQO0S DT Small molecular drug
DMDQO0S PC 135566069
DMDQO0S MW 1569.7
DMDQO0S FM C67H92N16O22S3
DMDQO0S IC InChI=1S/C67H92N16O22S3/c1-32-9-7-11-45-46(26-47(33(2)23-38-30-106-35(4)74-38)105-52(90)27-48(84)67(5,6)55(92)34(3)54(32)91)83(45)19-20-103-66(102)104-21-22-107-108-31-44(63(100)101)80-60(96)43(25-51(88)89)79-58(94)40(10-8-18-71-64(68)69)77-59(95)42(24-50(86)87)76-49(85)17-16-41(62(98)99)78-57(93)36-12-14-37(15-13-36)72-28-39-29-73-56-53(75-39)61(97)82-65(70)81-56/h12-15,23,29-30,32,34,40-48,54,72,84,91H,7-11,16-22,24-28,31H2,1-6H3,(H,76,85)(H,77,95)(H,78,93)(H,79,94)(H,80,96)(H,86,87)(H,88,89)(H,98,99)(H,100,101)(H4,68,69,71)(H3,70,73,81,82,97)/b33-23+/t32-,34+,40-,41-,42-,43-,44-,45+,46-,47-,48-,54-,83?/m0/s1
DMDQO0S CS C[C@H]1CCC[C@@H]2[C@@H](N2CCOC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C3=CC=C(C=C3)NCC4=CN=C5C(=N4)C(=O)NC(=N5)N)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C6=CSC(=N6)C)/C
DMDQO0S IK TURJYGRXEJIBGT-OCOMGVANSA-N
DMDQO0S IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[2-[(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-5,9-dioxo-4-oxa-17-azabicyclo[14.1.0]heptadecan-17-yl]ethoxycarbonyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDQO0S CA CAS 958646-17-8
DMDQO0S DE Solid tumour/cancer
DMGM7QD ID DMGM7QD
DMGM7QD DN BMS-777607
DMGM7QD HS Phase 1/2
DMGM7QD SN BMS-777607; 1025720-94-8; BMS 777607; 1196681-44-3; BMS777607; ASLAN-002; UNII-A3MMS6HDO1; N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; A3MMS6HDO1; N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-((2-amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
DMGM7QD DT Small molecular drug
DMGM7QD PC 24794418
DMGM7QD MW 512.9
DMGM7QD FM C25H19ClF2N4O4
DMGM7QD IC InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)
DMGM7QD CS CCOC1=C(C(=O)N(C=C1)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C(=NC=C4)N)Cl)F
DMGM7QD IK VNBRGSXVFBYQNN-UHFFFAOYSA-N
DMGM7QD IU N-[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide
DMGM7QD CA CAS 1025720-94-8
DMGM7QD CB CHEBI:91409
DM5HUY8 ID DM5HUY8
DM5HUY8 DN BMS-863233
DM5HUY8 HS Phase 1/2
DM5HUY8 CP Bristol Myers Squibb
DM5HUY8 DT Small molecular drug
DM5HUY8 PC 135564632
DM5HUY8 MW 289.71
DM5HUY8 FM C14H12ClN3O2
DM5HUY8 IC InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m0/s1
DM5HUY8 CS C1C[C@H](NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl
DM5HUY8 IK JJWLXRKVUJDJKG-VIFPVBQESA-N
DM5HUY8 IU 8-chloro-2-[(2S)-pyrrolidin-2-yl]-3H-[1]benzofuro[3,2-d]pyrimidin-4-one
DM5HUY8 CA CAS 1169558-38-6
DM5HUY8 DE Haematological malignancy
DMDCHM7 ID DMDCHM7
DMDCHM7 DN BMS-986016
DMDCHM7 HS Phase 1/2
DMDCHM7 CP Bristol-Myers Squibb
DMDCHM7 DE Solid tumour/cancer; Hematologic tumour
DM6LDI4 ID DM6LDI4
DM6LDI4 DN BMS-986158
DM6LDI4 HS Phase 1/2
DM6LDI4 SN KGERZPVQIRYWRK-GDLZYMKVSA-N; 1800340-40-2; UNII-X8BW0MQ5PI; X8BW0MQ5PI; SCHEMBL16861831; EX-A2678; CS-7497; HY-101567; (S)-2-(3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-5H-pyrido[3,2-b]indol-7-yl)propan-2-ol
DM6LDI4 CP Bristol-Myers Squibb Princeton, NJ
DM6LDI4 PC 118196485
DM6LDI4 MW 495.6
DM6LDI4 FM C30H33N5O2
DM6LDI4 IC InChI=1S/C30H33N5O2/c1-19-28(34(4)33-32-19)22-16-26-27(31-18-22)24-11-10-23(30(2,3)36)17-25(24)35(26)29(20-8-6-5-7-9-20)21-12-14-37-15-13-21/h5-11,16-18,21,29,36H,12-15H2,1-4H3/t29-/m1/s1
DM6LDI4 CS CC1=C(N(N=N1)C)C2=CC3=C(C4=C(N3[C@@H](C5CCOCC5)C6=CC=CC=C6)C=C(C=C4)C(C)(C)O)N=C2
DM6LDI4 IK KGERZPVQIRYWRK-GDLZYMKVSA-N
DM6LDI4 IU 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol
DM6LDI4 CA CAS 1800340-40-2
DM6LDI4 DE Solid tumour/cancer
DMM10J4 ID DMM10J4
DMM10J4 DN BMS-986288
DMM10J4 HS Phase 1/2
DMM10J4 CP Bristol-Myers Squibb
DMM10J4 DT Probody
DMM10J4 DE Solid tumour/cancer
DMTEY1L ID DMTEY1L
DMTEY1L DN BMS-986315
DMTEY1L HS Phase 1/2
DMTEY1L CP Bristol-Myers Squibb
DMTEY1L DT Antibody
DMTEY1L DE Solid tumour/cancer
DMA9MP5 ID DMA9MP5
DMA9MP5 DN BN-2629
DMA9MP5 HS Phase 1/2
DMA9MP5 SN SG-2000; SJG-136; SP-2001
DMA9MP5 CP Spirogen Ltd
DMA9MP5 PC 393111
DMA9MP5 MW 556.6
DMA9MP5 FM C31H32N4O6
DMA9MP5 IC InChI=1S/C31H32N4O6/c1-18-8-20-14-32-24-12-28(26(38-3)10-22(24)30(36)34(20)16-18)40-6-5-7-41-29-13-25-23(11-27(29)39-4)31(37)35-17-19(2)9-21(35)15-33-25/h10-15,20-21H,1-2,5-9,16-17H2,3-4H3/t20-,21-/m0/s1
DMA9MP5 CS COC1=C(C=C2C(=C1)C(=O)N3CC(=C)C[C@H]3C=N2)OCCCOC4=C(C=C5C(=C4)N=C[C@@H]6CC(=C)CN6C5=O)OC
DMA9MP5 IK RWZVMMQNDHPRQD-SFTDATJTSA-N
DMA9MP5 IU (6aS)-3-[3-[[(6aS)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-8-methylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one
DMA9MP5 CA CAS 232931-57-6
DMA9MP5 DE Solid tumour/cancer
DMGF2PU ID DMGF2PU
DMGF2PU DN BNT411
DMGF2PU HS Phase 1/2
DMGF2PU CP BioNTech
DMGF2PU DT Small molecular drug
DMGF2PU DE Small-cell lung cancer
DMIMA4V ID DMIMA4V
DMIMA4V DN BPX-501
DMIMA4V HS Phase 1/2
DMIMA4V CP Bellicum pharmaceuticals
DMIMA4V DE Osteoporosis; Immunodeficiency; Hematopoietic stem cell transplantation; Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Solid tumour/cancer
DMV9QGW ID DMV9QGW
DMV9QGW DN BPX-601
DMV9QGW HS Phase 1/2
DMV9QGW CP Bellicum Pharmaceuticals
DMV9QGW DT CAR T Cell Therapy
DMV9QGW DE Gastric adenocarcinoma; Pancreatic cancer; Prostate cancer
DMCEGP2 ID DMCEGP2
DMCEGP2 DN BrevaRex
DMCEGP2 HS Phase 1/2
DMCEGP2 SN BrevaRex MAb; monoclonal antibody
DMCEGP2 CP Tapimmune; mabvax therapeutics
DMCEGP2 DT Monoclonal antibody
DMCEGP2 DE Pancreatic cancer
DMQKXSW ID DMQKXSW
DMQKXSW DN BRN-3122594
DMQKXSW HS Phase 1/2
DMQKXSW SN FLUOCORTOLONE; Flucortolone; Fluocortolon; Fluocortolona [INN-Spanish]; Fluocortolone [USAN:INN:BAN]; Fluocortolonum [INN-Latin]; Fluorcortolone; Fluorocortolone; SH 742; Ultralan oral; 152-97-6; 6-alpha-Fluoro-16-alpha-methyl-1-dehydrocorticosterone; 6-alpha-Fluoro-16-alpha-methylpregna-1,4-diene-11-beta,21-diol-3,20-dione; 65VXC1MH0J; 6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; BRN 3122594; EINECS 205-811-5; UNII-65VXC1MH0J
DMQKXSW PC 9053
DMQKXSW MW 376.5
DMQKXSW FM C22H29FO4
DMQKXSW IC GAKMQHDJQHZUTJ-ULHLPKEOSA-N
DMQKXSW CS CC1CC2C3CC(C4=CC(=O)C=CC4(C3C(CC2(C1C(=O)CO)C)O)C)F
DMQKXSW IK 1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1
DMQKXSW IU (6S,8S,9S,10R,11S,13S,14S,16R,17S)-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMQKXSW CA CAS 152-97-6
DMQKXSW CB CHEBI:135581
DMQKXSW DE Haemorrhoid
DMYBKMV ID DMYBKMV
DMYBKMV DN BT5528
DMYBKMV HS Phase 1/2
DMYBKMV CP Bicycle Therapeutics
DMYBKMV DT Bicycle?toxin conjugate
DMYBKMV DE Solid tumour/cancer
DM1FJW6 ID DM1FJW6
DM1FJW6 DN BT8009
DM1FJW6 HS Phase 1/2
DM1FJW6 CP Bicycle Therapeutics
DM1FJW6 DT Bicycle?toxin conjugate
DM1FJW6 DE Solid tumour/cancer
DMEWXFK ID DMEWXFK
DMEWXFK DN C 82
DMEWXFK HS Phase 1/2
DMEWXFK SN N-(4-Chlorophenyl)-2H-triazol-4-amine; SCHEMBL15831502; C82
DMEWXFK CP PRISM Pharma Yokohama, Japan
DMEWXFK PC 75202656
DMEWXFK MW 194.62
DMEWXFK FM C8H7ClN4
DMEWXFK IC InChI=1S/C8H7ClN4/c9-6-1-3-7(4-2-6)11-8-5-10-13-12-8/h1-5H,(H2,10,11,12,13)
DMEWXFK CS C1=CC(=CC=C1NC2=NNN=C2)Cl
DMEWXFK IK IUTZKZLVPUPHDA-UHFFFAOYSA-N
DMEWXFK IU N-(4-chlorophenyl)-2H-triazol-4-amine
DMEWXFK DE Scleroderma
DMPJLS4 ID DMPJLS4
DMPJLS4 DN CAD-1883
DMPJLS4 HS Phase 1/2
DMPJLS4 CP Cadent Therapeutics
DMPJLS4 DE Ataxic disorder
DMUZIRY ID DMUZIRY
DMUZIRY DN Cal-1
DMUZIRY HS Phase 1/2
DMUZIRY SN Cal-1-transduced hematopoietic
DMUZIRY CP Calimmune
DMUZIRY DE Human immunodeficiency virus-1 infection
DM6ZXWY ID DM6ZXWY
DM6ZXWY DN CAR.CD30 cells
DM6ZXWY HS Phase 1/2
DM6ZXWY CP UNC Lineberger Comprehensive Cancer Center
DM6ZXWY DT CAR T Cell Therapy
DM6ZXWY DE Immune System disease; Immunoproliferative disorder; Lymphatic disease; Lymphoma; Neoplasm
DMOI5PB ID DMOI5PB
DMOI5PB DN CARCIK-CD19
DMOI5PB HS Phase 1/2
DMOI5PB CP Fondazione Matilde Tettamanti Menotti De Marchi Onlus
DMOI5PB DT CAR T Cell Therapy
DMOI5PB DE Acute lymphocytic leukaemia
DMENIQ7 ID DMENIQ7
DMENIQ7 DN CAR-T cells targeting BCMA
DMENIQ7 HS Phase 1/2
DMENIQ7 CP Hebei Senlang Biotechnology Inc., Ltd.
DMENIQ7 DT CAR T Cell Therapy
DMENIQ7 DE leukaemia; Lymphoma; Multiple myeloma
DMIM9TZ ID DMIM9TZ
DMIM9TZ DN CAR-T cells targeting CD19
DMIM9TZ HS Phase 1/2
DMIM9TZ CP Hebei Senlang Biotechnology Inc., Ltd.
DMIM9TZ DT CAR T Cell Therapy
DMIM9TZ DE leukaemia; Lymphoma; Multiple myeloma
DMJVENR ID DMJVENR
DMJVENR DN CAR-T cells targeting CD2
DMJVENR HS Phase 1/2
DMJVENR CP Shenzhen Geno-Immune Medical Institute
DMJVENR DT CAR T Cell Therapy
DMJVENR DE Cervical cancer
DMVFHL9 ID DMVFHL9
DMVFHL9 DN CAR-T cells targeting CD22
DMVFHL9 HS Phase 1/2
DMVFHL9 CP Hebei Senlang Biotechnology Inc., Ltd.
DMVFHL9 DT CAR T Cell Therapy
DMVFHL9 DE leukaemia; Lymphoma; Multiple myeloma
DMZHJV8 ID DMZHJV8
DMZHJV8 DN CAR-T cells targeting CD30
DMZHJV8 HS Phase 1/2
DMZHJV8 CP Hebei Senlang Biotechnology Inc., Ltd.
DMZHJV8 DT CAR T Cell Therapy
DMZHJV8 DE leukaemia; Lymphoma; Multiple myeloma
DM6VCPX ID DM6VCPX
DM6VCPX DN CAR-T cells targeting CEA
DM6VCPX HS Phase 1/2
DM6VCPX CP Shanghai GeneChem Co., Ltd.
DM6VCPX DT CAR T Cell Therapy
DM6VCPX DE Colorectal cancer
DMCPM92 ID DMCPM92
DMCPM92 DN CAR-T cells targeting CLL1
DMCPM92 HS Phase 1/2
DMCPM92 CP Hebei Senlang Biotechnology Inc., Ltd.
DMCPM92 DT CAR T Cell Therapy
DMCPM92 DE leukaemia; Lymphoma; Multiple myeloma
DMREQCF ID DMREQCF
DMREQCF DN CAR-T Cells targeting EpCAM
DMREQCF HS Phase 1/2
DMREQCF CP First Affiliated Hospital of Chengdu Medical College
DMREQCF DT CAR T Cell Therapy
DMREQCF DE Colon cancer; Esophageal cancer; Gastric adenocarcinoma; Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer
DMN3C2I ID DMN3C2I
DMN3C2I DN CAR-T cells targeting EphA2
DMN3C2I HS Phase 1/2
DMN3C2I CP Fuda Cancer Hospital, Guangzhou
DMN3C2I DT CAR T Cell Therapy
DMN3C2I DE Malignant glioma
DMFCPG0 ID DMFCPG0
DMFCPG0 DN CAR-T cells targeting GD2
DMFCPG0 HS Phase 1/2
DMFCPG0 CP Fuda Cancer Hospital, Guangzhou
DMFCPG0 DT CAR T Cell Therapy
DMFCPG0 DE Glioma
DMT89K2 ID DMT89K2
DMT89K2 DN CAR-T cells targeting GD2
DMT89K2 HS Phase 1/2
DMT89K2 CP Shenzhen Geno-Immune Medical Institute
DMT89K2 DT CAR T Cell Therapy
DMT89K2 DE Glioblastoma multiforme; Lung cancer
DMDSKR2 ID DMDSKR2
DMDSKR2 DN CAR-T cells targeting Glypican-3 (GPC3)
DMDSKR2 HS Phase 1/2
DMDSKR2 CP Fuda Cancer Hospital, Guangzhou
DMDSKR2 DT CAR T Cell Therapy
DMDSKR2 DE Hepatocellular carcinoma
DM6H1MQ ID DM6H1MQ
DM6H1MQ DN CAR-T cells targeting GPC3
DM6H1MQ HS Phase 1/2
DM6H1MQ CP Shanghai GeneChem Co., Ltd.
DM6H1MQ DT CAR T Cell Therapy
DM6H1MQ DE Hepatocellular carcinoma
DM1W7LV ID DM1W7LV
DM1W7LV DN CAR-T cells targeting MAGE-A1
DM1W7LV HS Phase 1/2
DM1W7LV CP Shenzhen Geno-Immune Medical Institute
DM1W7LV DT CAR T Cell Therapy
DM1W7LV DE Lung cancer
DMUBEX4 ID DMUBEX4
DMUBEX4 DN CAR-T cells targeting MAGE-A4
DMUBEX4 HS Phase 1/2
DMUBEX4 CP Shenzhen Geno-Immune Medical Institute
DMUBEX4 DT CAR T Cell Therapy
DMUBEX4 DE Lung cancer
DMMAQJ7 ID DMMAQJ7
DMMAQJ7 DN CAR-T cells targeting Mesothelin
DMMAQJ7 HS Phase 1/2
DMMAQJ7 CP Shenzhen Geno-Immune Medical Institute
DMMAQJ7 DT CAR T Cell Therapy
DMMAQJ7 DE Cervical cancer; Lung cancer
DMPK35H ID DMPK35H
DMPK35H DN CAR-T cells targeting mesothelin
DMPK35H HS Phase 1/2
DMPK35H CP Shanghai GeneChem Co., Ltd.
DMPK35H DT CAR T Cell Therapy
DMPK35H DE Pancreatic cancer
DM5FKU1 ID DM5FKU1
DM5FKU1 DN CAR-T cells targeting Muc1
DM5FKU1 HS Phase 1/2
DM5FKU1 CP Shenzhen Geno-Immune Medical Institute
DM5FKU1 DT CAR T Cell Therapy
DM5FKU1 DE Cervical cancer
DMBPN4K ID DMBPN4K
DMBPN4K DN CAR-T cells targeting MucI
DMBPN4K HS Phase 1/2
DMBPN4K CP Shenzhen Geno-Immune Medical Institute
DMBPN4K DT CAR T Cell Therapy
DMBPN4K DE Glioblastoma multiforme; Lung cancer
DMW340V ID DMW340V
DMW340V DN CAR-T cells targeting PSMA
DMW340V HS Phase 1/2
DMW340V CP Shenzhen Geno-Immune Medical Institute
DMW340V DT CAR T Cell Therapy
DMW340V DE Cervical cancer
DM0MCTJ ID DM0MCTJ
DM0MCTJ DN CART-123 cells
DM0MCTJ HS Phase 1/2
DM0MCTJ CP The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DM0MCTJ DT CAR T Cell Therapy
DM0MCTJ DE Acute myeloid leukaemia
DMB4HEW ID DMB4HEW
DMB4HEW DN CART-138 cells
DMB4HEW HS Phase 1/2
DMB4HEW CP The First Affiliated Hospital of Soochow University
DMB4HEW DT CAR T Cell Therapy
DMB4HEW DE Multiple myeloma
DMUS79V ID DMUS79V
DMUS79V DN CART-138 cells
DMUS79V HS Phase 1/2
DMUS79V CP Chinese PLA General Hospital
DMUS79V DT CAR T Cell Therapy
DMUS79V DE Multiple myeloma
DMWYT4K ID DMWYT4K
DMWYT4K DN CART-19 cells
DMWYT4K HS Phase 1/2
DMWYT4K CP The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DMWYT4K DT CAR T Cell Therapy
DMWYT4K DE Acute lymphoblastic leukaemia
DMX0R1E ID DMX0R1E
DMX0R1E DN CART-19/22
DMX0R1E HS Phase 1/2
DMX0R1E CP Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
DMX0R1E DT CAR T Cell Therapy (Dual specific)
DMX0R1E DE leukaemia
DMVW1GY ID DMVW1GY
DMVW1GY DN CART-19/BCMA
DMVW1GY HS Phase 1/2
DMVW1GY CP The First Affiliated Hospital of Soochow University
DMVW1GY DT CAR T Cell Therapy (Dual specific)
DMVW1GY DE Multiple myeloma
DMKGU5F ID DMKGU5F
DMKGU5F DN CART20
DMKGU5F HS Phase 1/2
DMKGU5F CP Beijing Biohealthcare Biotechnology Co.,Ltd
DMKGU5F DT CAR T Cell Therapy
DMKGU5F DE B-cell lymphoma
DMLE8T9 ID DMLE8T9
DMLE8T9 DN CART30
DMLE8T9 HS Phase 1/2
DMLE8T9 CP Chinese PLA General Hospital
DMLE8T9 DT CAR T Cell Therapy
DMLE8T9 DE Non-hodgkin lymphoma; Hodgkin lymphoma
DM81JIT ID DM81JIT
DM81JIT DN CART33 cells
DM81JIT HS Phase 1/2
DM81JIT CP Chinese PLA General Hospital
DM81JIT DT CAR T Cell Therapy
DM81JIT DE Myeloid leukaemia
DMWOYNT ID DMWOYNT
DMWOYNT DN CART-BCMA cells
DMWOYNT HS Phase 1/2
DMWOYNT CP The First Affiliated Hospital of Soochow University
DMWOYNT DT CAR T Cell Therapy
DMWOYNT DE Multiple myeloma
DM3I267 ID DM3I267
DM3I267 DN CART-EGFR
DM3I267 HS Phase 1/2
DM3I267 CP Chinese PLA General Hospital
DM3I267 DT CAR T Cell Therapy
DM3I267 DE Solid tumour/cancer
DMMTDK1 ID DMMTDK1
DMMTDK1 DN CART-HER-2
DMMTDK1 HS Phase 1/2
DMMTDK1 CP Chinese PLA General Hospital
DMMTDK1 DT CAR T Cell Therapy
DMMTDK1 DE Solid tumour/cancer
DMKCJ75 ID DMKCJ75
DMKCJ75 DN CBL0102
DMKCJ75 HS Phase 1/2
DMKCJ75 CP Cleveland biolabs
DMKCJ75 DE Hepatocellular carcinoma
DMCWVPU ID DMCWVPU
DMCWVPU DN CBP-501
DMCWVPU HS Phase 1/2
DMCWVPU SN UNII-XH2662798I; 565434-85-7; XH2662798I; Cdc25C phosphatase (211-221); CBP501; CBP 501; SCHEMBL17101340; Z-3278; D-Arginine, 4-benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D- arginyl-D-arginyl-D-glutaminyl-D-arginyl-
DMCWVPU CP CanBas
DMCWVPU DT Small molecular drug
DMCWVPU PC 16156006
DMCWVPU MW 1929.1
DMCWVPU FM C86H122F5N29O17
DMCWVPU IC InChI=1S/C86H122F5N29O17/c87-64-49(65(88)67(90)68(91)66(64)89)39-60(118-80(135)62(42-122)120-77(132)59(38-47-40-109-51-19-8-7-18-48(47)51)117-79(134)61(41-121)119-70(125)50(92)36-44-25-27-46(28-26-44)69(124)45-16-5-2-6-17-45)78(133)116-58(37-43-14-3-1-4-15-43)76(131)113-54(22-11-33-106-84(98)99)72(127)110-52(20-9-31-104-82(94)95)71(126)111-53(21-10-32-105-83(96)97)73(128)114-56(29-30-63(93)123)75(130)112-55(23-12-34-107-85(100)101)74(129)115-57(81(136)137)24-13-35-108-86(102)103/h2,5-8,16-19,25-28,40,43,50,52-62,109,121-122H,1,3-4,9-15,20-24,29-39,41-42,92H2,(H2,93,123)(H,110,127)(H,111,126)(H,112,130)(H,113,131)(H,114,128)(H,115,129)(H,116,133)(H,117,134)(H,118,135)(H,119,125)(H,120,132)(H,136,137)(H4,94,95,104)(H4,96,97,105)(H4,98,99,106)(H4,100,101,107)(H4,102,103,108)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m1/s1
DMCWVPU CS C1CCC(CC1)C[C@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H](CC2=C(C(=C(C(=C2F)F)F)F)F)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)N
DMCWVPU IK DEZJGRPRBZSAKI-KMGSDFBDSA-N
DMCWVPU IU (2R)-2-[[(2R)-2-[[(2R)-5-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-(4-benzoylphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(2,3,4,5,6-pentafluorophenyl)propanoyl]amino]-3-cyclohexylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoic acid
DMCWVPU CA CAS 565434-85-7
DMCWVPU DE Mesothelioma; Solid tumour/cancer
DMMQYL9 ID DMMQYL9
DMMQYL9 DN CC-223
DMMQYL9 HS Phase 1/2
DMMQYL9 SN GW 791343 HYDROCHLORIDE; GW791343 trihydrochloride; 309712-55-8; 1019779-04-4; GW791343 HCl; GW791343 (trihydrochloride); GW791343; GW-791343; 2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride; GW791343 (HCL); GW-791343 hydrochloride; C20H27Cl3F2N4O; GW 791343 Trihydrochloride; C20H24F2N4O.3ClH; CTK8F0044; EX-A438; GW 791343 HCl; WSBRAHWNJBXXJM-UHFFFAOYSA-N; MolPort-023-219-209; BCP23425; AKOS024457596; CS-1030; BCP9000749; API0008007; HY-15470; BCP0726000290; RT-017402; KB-272661
DMMQYL9 CP Celgene
DMMQYL9 DT Small molecular drug
DMMQYL9 PC 58298316
DMMQYL9 MW 397.5
DMMQYL9 FM C21H27N5O3
DMMQYL9 IC InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24)
DMMQYL9 CS CC(C)(C1=NC=C(C=C1)C2=CN=C3C(=N2)N(C(=O)CN3)C4CCC(CC4)OC)O
DMMQYL9 IK UFKLYTOEMRFKAD-UHFFFAOYSA-N
DMMQYL9 IU 3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]-5-(4-methoxycyclohexyl)-7,8-dihydropyrazino[2,3-b]pyrazin-6-one
DMMQYL9 CA CAS 1228013-30-6
DMMQYL9 DE Solid tumour/cancer
DM9UZM1 ID DM9UZM1
DM9UZM1 DN CCS1477
DM9UZM1 HS Phase 1/2
DM9UZM1 SN CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
DM9UZM1 CP CellCentric
DM9UZM1 DT Small molecular drug
DM9UZM1 PC 134457551
DM9UZM1 MW 534.6
DM9UZM1 FM C30H32F2N4O3
DM9UZM1 IC InChI=1S/C30H32F2N4O3/c1-17-29(18(2)39-34-17)19-7-14-26-25(15-19)33-30(36(26)20-8-11-22(38-3)12-9-20)27-5-4-6-28(37)35(27)21-10-13-23(31)24(32)16-21/h7,10,13-16,20,22,27H,4-6,8-9,11-12H2,1-3H3/t20?,22?,27-/m0/s1
DM9UZM1 CS CC1=C(C(=NO1)C)C2=CC3=C(C=C2)N(C(=N3)[C@@H]4CCCC(=O)N4C5=CC(=C(C=C5)F)F)C6CCC(CC6)OC
DM9UZM1 IK SKDNDJWEBPQKCS-RIQBOWGZSA-N
DM9UZM1 IU (6S)-1-(3,4-difluorophenyl)-6-[5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methoxycyclohexyl)benzimidazol-2-yl]piperidin-2-one
DM9UZM1 DE Solid tumour/cancer
DM2B1V0 ID DM2B1V0
DM2B1V0 DN CCT301-38 (targeting ROR2)
DM2B1V0 HS Phase 1/2
DM2B1V0 CP Shanghai Sinobioway Sunterra Biotech
DM2B1V0 DT CAR T Cell Therapy
DM2B1V0 DE Renal cell carcinoma
DM0F9CD ID DM0F9CD
DM0F9CD DN CCT301-59 (targeting ROR2)
DM0F9CD HS Phase 1/2
DM0F9CD CP Shanghai Sinobioway Sunterra Biotech
DM0F9CD DT CAR T Cell Therapy
DM0F9CD DE Renal cell carcinoma
DMHOWU5 ID DMHOWU5
DMHOWU5 DN CD123-specific gene-engineered T cells
DMHOWU5 HS Phase 1/2
DMHOWU5 CP Shenzhen Geno-Immune Medical Institute
DMHOWU5 DT CAR T Cell Therapy
DMHOWU5 DE Acute myeloid leukaemia
DMHMC19 ID DMHMC19
DMHMC19 DN CD137 CAR-T Cell
DMHMC19 HS Phase 1/2
DMHMC19 CP Wuhan Sian Medical Technology Co., Ltd
DMHMC19 DT CAR T Cell Therapy
DMHMC19 DE Acute lymphoblastic leukaemia; B-cell lymphoma
DMCSGNU ID DMCSGNU
DMCSGNU DN CD138 CAR T cells
DMCSGNU HS Phase 1/2
DMCSGNU CP Shenzhen Geno-Immune Medical Institute
DMCSGNU DT CAR T Cell Therapy
DMCSGNU DE Multiple myeloma
DMRJ3ND ID DMRJ3ND
DMRJ3ND DN CD19 and CD20 CAR-T Cells
DMRJ3ND HS Phase 1/2
DMRJ3ND CP Chinese PLA General Hospital
DMRJ3ND DT CAR T Cell Therapy (Dual specific)
DMRJ3ND DE B-cell lymphoma; leukaemia
DM581CS ID DM581CS
DM581CS DN CD19 and CD22 CAR-T Cells
DM581CS HS Phase 1/2
DM581CS CP Ruijin Hospital
DM581CS DT CAR T Cell Therapy (Dual specific)
DM581CS DE Lymphoma
DMQB7SZ ID DMQB7SZ
DMQB7SZ DN CD19 and CD22 CAR-T Cells
DMQB7SZ HS Phase 1/2
DMQB7SZ CP Chinese PLA General Hospital
DMQB7SZ DT CAR T Cell Therapy (Dual specific)
DMQB7SZ DE B-cell lymphoma; leukaemia
DMQJ6YL ID DMQJ6YL
DMQJ6YL DN CD19 CAR Gene Transduced T Lymphocytes
DMQJ6YL HS Phase 1/2
DMQJ6YL CP Jichi Medical University
DMQJ6YL DT CAR T Cell Therapy
DMQJ6YL DE Non-hodgkin lymphoma
DMMHLJQ ID DMMHLJQ
DMMHLJQ DN CD19 CAR T cells
DMMHLJQ HS Phase 1/2
DMMHLJQ CP Sheba Medical Center
DMMHLJQ DT CAR T Cell Therapy
DMMHLJQ DE Acute lymphoblastic leukaemia; B-cell non-hodgkin lymphoma
DMUARWH ID DMUARWH
DMUARWH DN CD19 CAR T Cells
DMUARWH HS Phase 1/2
DMUARWH CP Fred Hutchinson Cancer Research Center
DMUARWH DT CAR T Cell Therapy
DMUARWH DE Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Large cell lymphoma; Mantle cell lymphoma
DM69A1W ID DM69A1W
DM69A1W DN CD19 CART
DM69A1W HS Phase 1/2
DM69A1W CP Shanghai Bioray Laboratory Inc.
DM69A1W DT CAR T Cell Therapy
DM69A1W DE Acute lymphoblastic leukaemia
DMU348C ID DMU348C
DMU348C DN CD19 CART
DMU348C HS Phase 1/2
DMU348C CP Shenzhen Second People's Hospital
DMU348C DT CAR T Cell Therapy
DMU348C DE B-cell lymphoma
DMECGKO ID DMECGKO
DMECGKO DN CD19 CAR-T Cells
DMECGKO HS Phase 1/2
DMECGKO CP Henan Cancer Hospital
DMECGKO DT CAR T Cell Therapy
DMECGKO DE Acute lymphoblastic leukaemia
DM8KESD ID DM8KESD
DM8KESD DN CD19 CAR-T lymphocytes
DM8KESD HS Phase 1/2
DM8KESD CP Federal Research Institute of Pediatric Hematology, Oncology and Immunology
DM8KESD DT CAR T Cell Therapy
DM8KESD DE Acute lymphoblastic leukaemia
DMGDK9C ID DMGDK9C
DMGDK9C DN CD19 specific CAR T cells
DMGDK9C HS Phase 1/2
DMGDK9C CP Seattle Children's Hospital
DMGDK9C DT CAR T Cell Therapy
DMGDK9C DE Acute leukaemia
DM8RXFB ID DM8RXFB
DM8RXFB DN CD19 targeted chimeric antigen receptor T cells
DM8RXFB HS Phase 1/2
DM8RXFB CP Zhejiang University
DM8RXFB DT CAR T Cell Therapy
DM8RXFB DE B-cell lymphoma
DM79GPF ID DM79GPF
DM79GPF DN CD19.CAR T Cells
DM79GPF HS Phase 1/2
DM79GPF CP University Hospital Heidelberg
DM79GPF DT CAR T Cell Therapy
DM79GPF DE Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle cell lymphoma
DMNZ7F2 ID DMNZ7F2
DMNZ7F2 DN CD19.CAR-T cells
DMNZ7F2 HS Phase 1/2
DMNZ7F2 CP Xinqiao Hospital of Chongqing
DMNZ7F2 DT CAR T Cell Therapy
DMNZ7F2 DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
DMQE7TW ID DMQE7TW
DMQE7TW DN CD19-CAR T cell
DMQE7TW HS Phase 1/2
DMQE7TW CP Bambino Gesù Hospital and Research Institute
DMQE7TW DT CAR T Cell Therapy
DMQE7TW DE Acute lymphoblastic leukaemia; Non-hodgkin lymphoma
DMKQRUJ ID DMKQRUJ
DMKQRUJ DN CD19-directed CAR-T cells
DMKQRUJ HS Phase 1/2
DMKQRUJ CP Shanghai Tongji Hospital, Tongji University School of Medicine
DMKQRUJ DT CAR T Cell Therapy
DMKQRUJ DE leukaemia; Lymphoma
DMI2OVA ID DMI2OVA
DMI2OVA DN CD19-targeting CAR T Cells
DMI2OVA HS Phase 1/2
DMI2OVA CP Fuda Cancer Hospital, Guangzhou
DMI2OVA DT CAR T Cell Therapy
DMI2OVA DE B-cell lymphoma
DM4MBUI ID DM4MBUI
DM4MBUI DN CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
DM4MBUI HS Phase 1/2
DM4MBUI CP Xuzhou Medical University
DM4MBUI DT CAR T Cell Therapy (Dual specific)
DM4MBUI DE Haematopoietic/lymphoid cancer
DMHPZ8G ID DMHPZ8G
DMHPZ8G DN CD20-Specific CAR T Cells
DMHPZ8G HS Phase 1/2
DMHPZ8G CP Fred Hutchinson Cancer Research Center
DMHPZ8G DT CAR T Cell Therapy
DMHPZ8G DE Chronic lymphocytic leukaemia; Follicular lymphoma; Large cell lymphoma; Lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma
DM40NEB ID DM40NEB
DM40NEB DN CD22 CAR-T
DM40NEB HS Phase 1/2
DM40NEB CP Kai Lin Xu; Jun Nian Zheng
DM40NEB DT CAR T Cell Therapy
DM40NEB DE B-cell lymphoma
DM61MBG ID DM61MBG
DM61MBG DN CD22-Targeted CAR-T cells
DM61MBG HS Phase 1/2
DM61MBG CP Southwest Hospital, China
DM61MBG DT CAR T Cell Therapy
DM61MBG DE leukaemia; Lymphoma
DMM35D2 ID DMM35D2
DMM35D2 DN CD33-specific gene-engineered T cells
DMM35D2 HS Phase 1/2
DMM35D2 CP Shenzhen Geno-Immune Medical Institute
DMM35D2 DT CAR T Cell Therapy
DMM35D2 DE Acute myeloid leukaemia
DMFZS8A ID DMFZS8A
DMFZS8A DN CD38 and BCMA CAR-T Cells
DMFZS8A HS Phase 1/2
DMFZS8A CP Chinese PLA General Hospital
DMFZS8A DT CAR T Cell Therapy (Dual specific)
DMFZS8A DE Multiple myeloma
DMPS3I6 ID DMPS3I6
DMPS3I6 DN CD38 CAR T cells
DMPS3I6 HS Phase 1/2
DMPS3I6 CP Shenzhen Geno-Immune Medical Institute
DMPS3I6 DT CAR T Cell Therapy
DMPS3I6 DE Multiple myeloma
DM0USBX ID DM0USBX
DM0USBX DN CD38 CAR-T Cell
DM0USBX HS Phase 1/2
DM0USBX CP Chinese PLA General Hospital
DM0USBX DT CAR T Cell Therapy
DM0USBX DE Acute lymphoblastic leukaemia
DMCH98G ID DMCH98G
DMCH98G DN CD38-specific gene-engineered T cells
DMCH98G HS Phase 1/2
DMCH98G CP Shenzhen Geno-Immune Medical Institute
DMCH98G DT CAR T Cell Therapy
DMCH98G DE Acute myeloid leukaemia
DMS5OL0 ID DMS5OL0
DMS5OL0 DN CD56 CAR T cells
DMS5OL0 HS Phase 1/2
DMS5OL0 CP Shenzhen Geno-Immune Medical Institute
DMS5OL0 DT CAR T Cell Therapy
DMS5OL0 DE Multiple myeloma
DM35XCT ID DM35XCT
DM35XCT DN CD56-specific gene-engineered T cells
DM35XCT HS Phase 1/2
DM35XCT CP Shenzhen Geno-Immune Medical Institute
DM35XCT DT CAR T Cell Therapy
DM35XCT DE Acute myeloid leukaemia
DMD1V7I ID DMD1V7I
DMD1V7I DN Celgosivir
DMD1V7I HS Phase 1/2
DMD1V7I SN BuCast; MDL 28574; B-CAST; MBI-3253; MDL 28,574; MDL 28,574A; MDL-28574; MX-3253; VIR-222; Butanoic acid, (1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyl ester; [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate; (1S,6S,7S,8R,8aR)-Octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate;6-O-Butanoylcastanospermine
DMD1V7I CP Migenix
DMD1V7I DT Small molecular drug
DMD1V7I PC 60734
DMD1V7I MW 259.3
DMD1V7I FM C12H21NO5
DMD1V7I IC InChI=1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3/t7-,8-,10+,11+,12+/m0/s1
DMD1V7I CS CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O
DMD1V7I IK HTJGLYIJVSDQAE-VWNXEWBOSA-N
DMD1V7I IU [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
DMD1V7I CA CAS 121104-96-9
DMD1V7I DE Dengue fever
DMAO04B ID DMAO04B
DMAO04B DN CEP-32496
DMAO04B HS Phase 1/2
DMAO04B SN AB-024; B-RAF kinase inhibitors (melanoma), Ambit/Cephalon
DMAO04B CP Teva pharmaceutical
DMAO04B DT Small molecular drug
DMAO04B PC 56846693
DMAO04B MW 517.5
DMAO04B FM C24H22F3N5O5
DMAO04B IC InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)
DMAO04B CS CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F
DMAO04B IK DKNUPRMJNUQNHR-UHFFFAOYSA-N
DMAO04B IU 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea
DMAO04B CA CAS 1188910-76-0
DMAO04B DE Solid tumour/cancer
DMY8NUF ID DMY8NUF
DMY8NUF DN CEP-9722
DMY8NUF HS Phase 1/2
DMY8NUF CP Cephalon
DMY8NUF PC 24780387
DMY8NUF MW 418.5
DMY8NUF FM C24H26N4O3
DMY8NUF IC InChI=1S/C24H26N4O3/c1-26-9-11-27(12-10-26)13-28-23(29)18-14-5-3-6-15(14)22-20(21(18)24(28)30)19-16(25-22)7-4-8-17(19)31-2/h4,7-8,25H,3,5-6,9-13H2,1-2H3
DMY8NUF CS CN1CCN(CC1)CN2C(=O)C3=C(C2=O)C4=C(C5=C3CCC5)NC6=C4C(=CC=C6)OC
DMY8NUF IK CTLOSZHDGZLOQE-UHFFFAOYSA-N
DMY8NUF IU 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione
DMY8NUF CA CAS 916574-83-9
DMY8NUF DE Non-small-cell lung cancer; Cerebrovascular ischaemia
DMCR7EF ID DMCR7EF
DMCR7EF DN CEQ-508
DMCR7EF HS Phase 1/2
DMCR7EF SN CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina
DMCR7EF CP Cequent Pharmaceuticals Inc
DMCR7EF DT siRNA drug
DMCR7EF DE Familial adenomatous polyposis
DMUW6KP ID DMUW6KP
DMUW6KP DN CERC-803
DMUW6KP HS Phase 1/2
DMUW6KP SN Fucopyranose, L- (7CI); Fucose; L-Fucose; L-Galactopyranose, 6-deoxy-; L-fucopyranose; L-galactomethylose; fucopyranose; (-)-L-Fucose; (3S,4R,5S,6S)-6-Methyltetrahydro-2H-pyran-2,3,4,5-tetraol; 6-Deoxy-Galactopyranose; 6-Deoxy-Galactopyranoside; 6-Deoxy-Galactose; 6-Deoxy-L-Galactopyranose; 6-Deoxy-L-Galactopyranoside; 6-Deoxy-L-Galactose; 6-Deoxy-L-beta-galactose; 6-Desoxygalactose; 6-methyltetrahydropyran-2,3,4,5-tetraol; 6696-41-9; 87-96-7; CHEBI:2181; CHEMBL469449; Epitope ID:152214; Fuc; L-Fuc; SCHEMBL63943; bmse000036
DMUW6KP PC 17106
DMUW6KP MW 164.16
DMUW6KP FM C6H12O5
DMUW6KP IC SHZGCJCMOBCMKK-DHVFOXMCSA-N
DMUW6KP CS CC1C(C(C(C(O1)O)O)O)O
DMUW6KP IK 1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1
DMUW6KP IU (3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol
DMUW6KP CA CAS 87-96-7
DMUW6KP CB CHEBI:2181
DMUW6KP DE Glycosylation disorder
DMD3XMW ID DMD3XMW
DMD3XMW DN Cethrin
DMD3XMW HS Phase 1/2
DMD3XMW SN Quinacrine, Dihydrochloride
DMD3XMW CP Alseres Pharmaceuticals Purchased rights for Cethrin from BioAxone Therapeutic
DMD3XMW DT Small molecular drug
DMD3XMW PC 16760629
DMD3XMW MW 472.9
DMD3XMW FM C23H32Cl3N3O
DMD3XMW IC InChI=1S/C23H30ClN3O.2ClH/c1-5-27(6-2)11-7-8-16(3)25-22-14-18(24)15-23-20(22)13-17-12-19(28-4)9-10-21(17)26-23;;/h9-10,12-16,25H,5-8,11H2,1-4H3;2*1H
DMD3XMW CS CCN(CC)CCCC(C)NC1=CC(=CC2=C1C=C3C=C(C=CC3=N2)OC)Cl.Cl.Cl
DMD3XMW IK QKAZHUGLNKCCGY-UHFFFAOYSA-N
DMD3XMW IU 4-N-(3-chloro-7-methoxyacridin-1-yl)-1-N,1-N-diethylpentane-1,4-diamine;dihydrochloride
DMD3XMW DE Spinal cord injury
DMJBQ96 ID DMJBQ96
DMJBQ96 DN Cetrelimab
DMJBQ96 HS Phase 1/2
DMJBQ96 SN JNJ-63723283
DMJBQ96 CP Janssen
DMJBQ96 DT Antibody
DMJBQ96 DE Solid tumour/cancer
DM2BXDU ID DM2BXDU
DM2BXDU DN CFG920
DM2BXDU HS Phase 1/2
DM2BXDU CP Novartis pharmaceuticals
DM2BXDU PC 49871869
DM2BXDU MW 288.73
DM2BXDU FM C14H13ClN4O
DM2BXDU IC InChI=1S/C14H13ClN4O/c1-10-2-4-16-9-12(10)19-7-6-18(14(19)20)11-3-5-17-13(15)8-11/h2-5,8-9H,6-7H2,1H3
DM2BXDU CS CC1=C(C=NC=C1)N2CCN(C2=O)C3=CC(=NC=C3)Cl
DM2BXDU IK ZVIFCOOHWGNPHJ-UHFFFAOYSA-N
DM2BXDU IU 1-(2-chloropyridin-4-yl)-3-(4-methylpyridin-3-yl)imidazolidin-2-one
DM2BXDU CA CAS 1260006-20-9
DM2BXDU DE Prostate cancer
DMB5KRA ID DMB5KRA
DMB5KRA DN CFI-402411
DMB5KRA HS Phase 1/2
DMB5KRA CP Treadwell Therapeutics
DMB5KRA DT Small molecular drug
DMB5KRA DE Solid tumour/cancer
DMPYW28 ID DMPYW28
DMPYW28 DN CG-806
DMPYW28 HS Phase 1/2
DMPYW28 SN 1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; CG-806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)-
DMPYW28 CP Aptose Biosciences
DMPYW28 DT Small molecular drug
DMPYW28 PC 66981446
DMPYW28 MW 509.5
DMPYW28 FM C26H19F4N5O2
DMPYW28 IC InChI=1S/C26H19F4N5O2/c1-13-11-31-23(33-13)19-8-7-17(20-12-32-24(36)22(19)20)18-6-5-16(10-21(18)27)35-25(37)34-15-4-2-3-14(9-15)26(28,29)30/h2-11H,12H2,1H3,(H,31,33)(H,32,36)(H2,34,35,37)
DMPYW28 CS CC1=CN=C(N1)C2=C3C(=C(C=C2)C4=C(C=C(C=C4)NC(=O)NC5=CC=CC(=C5)C(F)(F)F)F)CNC3=O
DMPYW28 IK BOLRZWTVMUHQQU-UHFFFAOYSA-N
DMPYW28 IU 1-[3-fluoro-4-[7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea
DMPYW28 CA CAS 1370466-81-1
DMPYW28 DE Acute myeloid leukaemia
DMHNFXR ID DMHNFXR
DMHNFXR DN Chimeric Antigen Receptor Modified T cells Targeting CD19
DMHNFXR HS Phase 1/2
DMHNFXR CP Southwest Hospital, China
DMHNFXR DT CAR T Cell Therapy
DMHNFXR DE leukaemia; Lymphoma
DMIXPNG ID DMIXPNG
DMIXPNG DN CHR-3996
DMIXPNG HS Phase 1/2
DMIXPNG SN CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
DMIXPNG CP Chroma Therapeutics Ltd
DMIXPNG DT Small molecular drug
DMIXPNG PC 49857317
DMIXPNG MW 394.4
DMIXPNG FM C20H19FN6O2
DMIXPNG IC InChI=1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18?
DMIXPNG CS C1[C@@H]2[C@@H](C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO
DMIXPNG IK QRGHOAATPOLDPF-BYICEURKSA-N
DMIXPNG IU 2-[(1S,5R)-6-[(6-fluoroquinolin-2-yl)methylamino]-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide
DMIXPNG CA CAS 1256448-47-1
DMIXPNG DE Solid tumour/cancer; Lymphoma
DM90BUD ID DM90BUD
DM90BUD DN ChronSeal
DM90BUD HS Phase 1/2
DM90BUD SN Antibiotic-free recombinant HGF, Linkoping; Recombinant HGF, Kringle/ChronTech; Recombinant HGF, Kringle/Tripep
DM90BUD CP Linkoping University
DM90BUD DE Fibrosis
DMRSI1O ID DMRSI1O
DMRSI1O DN ChronVac-C hepatitis C DNA vaccine
DMRSI1O HS Phase 1/2
DMRSI1O SN ChronVac-C (TN)
DMRSI1O CP Inovio Pharmaceuticals; ChronTech Pharma
DMRSI1O DT Vaccine
DMRSI1O DE Hepatitis C virus infection
DMTV4L7 ID DMTV4L7
DMTV4L7 DN CHS-828
DMTV4L7 HS Phase 1/2
DMTV4L7 SN Cancer therapeutics, LEO Pharma; GMX-1778
DMTV4L7 CP LEO Pharma A/S
DMTV4L7 DT Small molecular drug
DMTV4L7 PC 148198
DMTV4L7 MW 371.9
DMTV4L7 FM C19H22ClN5O
DMTV4L7 IC InChI=1S/C19H22ClN5O/c20-16-5-7-18(8-6-16)26-14-4-2-1-3-11-23-19(24-15-21)25-17-9-12-22-13-10-17/h5-10,12-13H,1-4,11,14H2,(H2,22,23,24,25)
DMTV4L7 CS C1=CC(=CC=C1OCCCCCCN=C(NC#N)NC2=CC=NC=C2)Cl
DMTV4L7 IK BOIPLTNGIAPDBY-UHFFFAOYSA-N
DMTV4L7 IU 2-[6-(4-chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine
DMTV4L7 CA CAS 200484-11-3
DMTV4L7 CB CHEBI:95016
DMTV4L7 DE Solid tumour/cancer
DMMVWSY ID DMMVWSY
DMMVWSY DN CK-101
DMMVWSY HS Phase 1/2
DMMVWSY SN IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena
DMMVWSY CP Checkpoint Therapeutics New York, NY
DMMVWSY PC 117909640
DMMVWSY MW 530.6
DMMVWSY FM C29H28F2N6O2
DMMVWSY IC InChI=1S/C29H28F2N6O2/c1-2-25(39)33-21-7-3-5-19(17-21)22-8-4-6-20-18-32-29(35-28(20)22)34-23-9-10-24(27(31)26(23)30)37-13-11-36(12-14-37)15-16-38/h2-10,17-18,38H,1,11-16H2,(H,33,39)(H,32,34,35)
DMMVWSY CS C=CC(=O)NC1=CC=CC(=C1)C2=CC=CC3=CN=C(N=C32)NC4=C(C(=C(C=C4)N5CCN(CC5)CCO)F)F
DMMVWSY IK IDRGFNPZDVBSSE-UHFFFAOYSA-N
DMMVWSY IU N-[3-[2-[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]quinazolin-8-yl]phenyl]prop-2-enamide
DMMVWSY CA CAS 1660963-42-7
DMMVWSY DE Non-small-cell lung cancer
DML8US9 ID DML8US9
DML8US9 DN CLIC-1901
DML8US9 HS Phase 1/2
DML8US9 CP Ottawa Hospital Research Institute
DML8US9 DT CAR T Cell Therapy
DML8US9 DE Acute lymphoblastic leukaemia; Non-hodgkin lymphoma
DMCT917 ID DMCT917
DMCT917 DN CLL1-specific gene-engineered T cells
DMCT917 HS Phase 1/2
DMCT917 CP Shenzhen Geno-Immune Medical Institute
DMCT917 DT CAR T Cell Therapy
DMCT917 DE Acute myeloid leukaemia
DM2FSM5 ID DM2FSM5
DM2FSM5 DN CLR-1401
DM2FSM5 HS Phase 1/2
DM2FSM5 SN COLD (cancer), Novelos; 18-(p-iodophenyl)octadecyl phosphocholine
DM2FSM5 CP Cellectar LLC
DM2FSM5 PC 11377191
DM2FSM5 MW 637.6
DM2FSM5 FM C29H53INO4P
DM2FSM5 IC InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3
DM2FSM5 CS C[N+](C)(C)CCOP(=O)([O-])OCCCCCCCCCCCCCCCCCCC1=CC=C(C=C1)I
DM2FSM5 IK ZOAIEFWMQLYMTF-UHFFFAOYSA-N
DM2FSM5 IU 18-(4-iodophenyl)octadecyl 2-(trimethylazaniumyl)ethyl phosphate
DM2FSM5 CA CAS 208986-26-9
DM2FSM5 DE Solid tumour/cancer
DM64FY7 ID DM64FY7
DM64FY7 DN CLR457
DM64FY7 HS Phase 1/2
DM64FY7 CP Novartis pharmaceuticals
DM64FY7 DE Advanced solid tumour
DMWZOD7 ID DMWZOD7
DMWZOD7 DN CNVN-202
DMWZOD7 HS Phase 1/2
DMWZOD7 CP MD Anderson Cancer Center
DMWZOD7 DE Non-small-cell lung cancer
DM1ZGUX ID DM1ZGUX
DM1ZGUX DN CPHPC
DM1ZGUX HS Phase 1/2
DM1ZGUX SN Amyloid beta inhibitor; SAP binding inhibitor, Roche; Serum amyloid P binding inhibitor, Roche; Ro-63-8695
DM1ZGUX CP F Hoffmann-La Roche Ltd
DM1ZGUX DT Small molecular drug
DM1ZGUX PC 125516
DM1ZGUX MW 340.37
DM1ZGUX FM C16H24N2O6
DM1ZGUX IC InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1
DM1ZGUX CS C1C[C@@H](N(C1)C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)O)C(=O)O
DM1ZGUX IK HZLAWYIBLZNRFZ-VXGBXAGGSA-N
DM1ZGUX IU (2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid
DM1ZGUX CA CAS 224624-80-0
DM1ZGUX DE Parkinson disease
DMJEXLI ID DMJEXLI
DMJEXLI DN CPI-0209
DMJEXLI HS Phase 1/2
DMJEXLI DT Small molecular drug
DMJEXLI DE Solid tumour/cancer
DM3XWJ8 ID DM3XWJ8
DM3XWJ8 DN CPI-1205
DM3XWJ8 HS Phase 1/2
DM3XWJ8 SN HPODOLXTMDHLLC-QGZVFWFLSA-N; 1621862-70-1; UNII-455J2479FY; CPI1205; CPI 1205; 455J2479FY; (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide; GTPL9115; SCHEMBL17329268; MolPort-044-560-382; KS-000006BA; EX-A1068; s8353; AKOS030628484; ZINC220982768; CS-7648; compound 13 [PMID: 27739677]; HY-100021; J3.556.402K; N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-
DM3XWJ8 CP Constellation Pharmaceuticals Cambridge, MA
DM3XWJ8 PC 78320408
DM3XWJ8 MW 518.6
DM3XWJ8 FM C27H33F3N4O3
DM3XWJ8 IC InChI=1S/C27H33F3N4O3/c1-16-13-23(37-4)21(25(35)32-16)14-31-26(36)24-18(3)34(22-8-6-5-7-20(22)24)17(2)19-9-11-33(12-10-19)15-27(28,29)30/h5-8,13,17,19H,9-12,14-15H2,1-4H3,(H,31,36)(H,32,35)/t17-/m1/s1
DM3XWJ8 CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)[C@H](C)C4CCN(CC4)CC(F)(F)F)C)OC
DM3XWJ8 IK HPODOLXTMDHLLC-QGZVFWFLSA-N
DM3XWJ8 IU N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[(1R)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide
DM3XWJ8 CA CAS 1621862-70-1
DM3XWJ8 DE B-cell lymphoma; Prostate cancer
DM6078F ID DM6078F
DM6078F DN CT84.66
DM6078F HS Phase 1/2
DM6078F SN T84.66; Anti-CEA IgG1 radioimmunotherapeutic, City of Hope; Anti-carcinoembryonic antigen IgG1 radioimmunotherapeutic, City ofHope
DM6078F CP City of Hope
DM6078F DE Breast cancer
DM95XR8 ID DM95XR8
DM95XR8 DN CTCE-9908
DM95XR8 HS Phase 1/2
DM95XR8 SN Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019
DM95XR8 CP Chemokine Therapeutics Corp; Chemokine Therapeutics
DM95XR8 PC 16186350
DM95XR8 MW 1927.3
DM95XR8 FM C86H147N27O23
DM95XR8 IC InChI=1S/C86H147N27O23/c1-45(2)35-58(104-81(133)64(43-116)110-83(135)68(47(5)6)112-66(120)39-99-71(123)53(89)17-9-12-30-87)75(127)108-62(41-114)79(131)106-60(37-49-22-26-51(118)27-23-49)77(129)102-56(20-15-33-97-85(92)93)73(125)96-32-14-11-19-55(70(91)122)101-74(126)57(21-16-34-98-86(94)95)103-78(130)61(38-50-24-28-52(119)29-25-50)107-80(132)63(42-115)109-76(128)59(36-46(3)4)105-82(134)65(44-117)111-84(136)69(48(7)8)113-67(121)40-100-72(124)54(90)18-10-13-31-88/h22-29,45-48,53-65,68-69,114-119H,9-21,30-44,87-90H2,1-8H3,(H2,91,122)(H,96,125)(H,99,123)(H,100,124)(H,101,126)(H,102,129)(H,103,130)(H,104,133)(H,105,134)(H,106,131)(H,107,132)(H,108,127)(H,109,128)(H,110,135)(H,111,136)(H,112,120)(H,113,121)(H4,92,93,97)(H4,94,95,98)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,68-,69-/m0/s1
DM95XR8 CS CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@@H](C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCCCN)N
DM95XR8 IK VUYRSKROGTWHDC-HZGLMRDYSA-N
DM95XR8 IU (2S)-2,6-diamino-N-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(5S)-6-amino-5-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2,6-diaminohexanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-6-oxohexyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]hexanamide
DM95XR8 CA CAS 1030384-98-5
DM95XR8 DE Sarcoma
DM90XQC ID DM90XQC
DM90XQC DN CTX001
DM90XQC HS Phase 1/2
DM90XQC CP CRISPR Therapeutics; Vertex Pharmaceuticals
DM90XQC DT Gene therapy
DM90XQC DE Sickle-cell disorder; Beta thalassemia
DMJ7LP0 ID DMJ7LP0
DMJ7LP0 DN CTX110
DMJ7LP0 HS Phase 1/2
DMJ7LP0 CP CRISPR Therapeutics
DMJ7LP0 DT Gene therapy
DMJ7LP0 DE Non-hodgkin lymphoma
DMHIQDC ID DMHIQDC
DMHIQDC DN CUDC-907
DMHIQDC HS Phase 1/2
DMHIQDC SN CUDC-907; 1339928-25-4; Fimepinostat; CUDC 907; UNII-3S9RX35S5X; CUDC907; 3S9RX35S5X; CHEMBL3622533; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; Fimepinostat [USAN]; PI3K/HDAC Inhibitor centn; MLS006010994; SCHEMBL1284705; GTPL8952; KS-00000TDO; EX-A742; AOB6775; DTXSID90712307; MolPort-023-293-550; JOWXJLIFIIOYMS-UHFFFAOYSA-N; HMS3656H04; BCP06870; s2759; BDBM50188961; 2341AH; ZINC73488511; ABP001045; AKOS026750340; SB16569; CUDC-907 (PI3K/HDAC Inhibi
DMHIQDC CP Curis
DMHIQDC DT Small molecular drug
DMHIQDC PC 54575456
DMHIQDC MW 508.6
DMHIQDC FM C23H24N8O4S
DMHIQDC IC InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
DMHIQDC CS CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO
DMHIQDC IK JOWXJLIFIIOYMS-UHFFFAOYSA-N
DMHIQDC IU N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide
DMHIQDC CA CAS 1339928-25-4
DMHIQDC DE Diffuse large B-cell lymphoma; Neuroblastoma; Solid tumour/cancer; Acute myelogenous leukaemia
DMCPZYT ID DMCPZYT
DMCPZYT DN CV-9201
DMCPZYT HS Phase 1/2
DMCPZYT SN CV-9201-1; CV-9201-2; CV-9201-3; CV-9201-4; CV-9201-5; RNA-based vaccine (NY-ESO-1, MAGE-C1/CT7, MAGE-C2/CT10, NSCLC), CureVac
DMCPZYT CP CureVac GmbH
DMCPZYT DT Vaccine
DMCPZYT DE Non-small-cell lung cancer
DM03LWZ ID DM03LWZ
DM03LWZ DN CVX-060
DM03LWZ HS Phase 1/2
DM03LWZ CP CovX
DM03LWZ DT Antibody
DM03LWZ DE Solid tumour/cancer
DMBUYIK ID DMBUYIK
DMBUYIK DN CWP232291
DMBUYIK HS Phase 1/2
DMBUYIK CP JW Pharmaceutical
DMBUYIK DT Small molecular drug
DMBUYIK DE Multiple myeloma; Acute myeloid leukaemia
DMUGMFN ID DMUGMFN
DMUGMFN DN CXB-909
DMUGMFN HS Phase 1/2
DMUGMFN CP Krenitsky Pharmaceuticals Inc
DMUGMFN DE Neurodegenerative disorder
DME6NMJ ID DME6NMJ
DME6NMJ DN CYT-0851
DME6NMJ HS Phase 1/2
DME6NMJ CP Cyteir Therapeutics
DME6NMJ DT Small molecular drug
DME6NMJ DE Solid tumour/cancer; B-cell lymphoma
DMJPSIL ID DMJPSIL
DMJPSIL DN Dapivirine
DMJPSIL HS Phase 1/2
DMJPSIL SN Dapivirinum; R 147681; R147681; TMC 120; TMC120; GEL-002; R-147681; TMC-120; TMC120-R147681; TMC-120/R-147681; 4-((4-((2,4,6-Trimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; 4-({4-[(2,4,6-Trimethylphenyl)amino]pyrimidin-2-yl}amino)benzenecarbonitrile; 4-[4-(2,4,6-TRIMETHYL-PHENYLAMINO)-PYRIMIDIN-2-YLAMINO]-BENZONITRILE; 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
DMJPSIL CP International Partnership for Microbicides, Inc.
DMJPSIL DT Small molecular drug
DMJPSIL PC 214347
DMJPSIL MW 329.4
DMJPSIL FM C20H19N5
DMJPSIL IC InChI=1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25)
DMJPSIL CS CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C
DMJPSIL IK ILAYIAGXTHKHNT-UHFFFAOYSA-N
DMJPSIL IU 4-[[4-(2,4,6-trimethylanilino)pyrimidin-2-yl]amino]benzonitrile
DMJPSIL CA CAS 244767-67-7
DMJPSIL DE Human immunodeficiency virus infection
DMJKFNU ID DMJKFNU
DMJKFNU DN DCC-2036
DMJKFNU HS Phase 1/2
DMJKFNU SN REBASTINIB; DCC-2036; 1020172-07-9; DCC-2036 (Rebastinib); DCC 2036; CHEBI:62166; UNII-75017Q6I97; Rebastinib(DCC-2036); 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; DCC2036; DP-1919; 4-[4-({[3-Tert-Butyl-1-(Quinolin-6-Yl)-1h-Pyrazol-5-Yl]carbamoyl}amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide; 75017Q6I97; 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(
DMJKFNU CP Deciphera Pharmaceuticals
DMJKFNU DT Small molecular drug
DMJKFNU PC 25066467
DMJKFNU MW 553.6
DMJKFNU FM C30H28FN7O3
DMJKFNU IC InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
DMJKFNU CS CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
DMJKFNU IK WVXNSAVVKYZVOE-UHFFFAOYSA-N
DMJKFNU IU 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMJKFNU CA CAS 1020172-07-9
DMJKFNU CB CHEBI:62166
DMJKFNU DE Acute lymphoblastic leukaemia; Breast cancer; Chronic myeloid leukaemia
DMHW289 ID DMHW289
DMHW289 DN DCC-3014
DMHW289 HS Phase 1/2
DMHW289 SN Vimseltinib; UNII-PX9FTM69BF; PX9FTM69BF; DCC3014; 1628606-05-2; 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one; 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one; Vimseltinib [INN]; SCHEMBL16047448; GTPL11190; EX-A4700; NSC828316; NSC-828316; example 10 [WO2014145025A2]; HY-136256; CS-0121044; 3-Methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3H)-pyrimidinone; 4(3H)-Pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-
DMHW289 CP Deciphera Pharmaceuticals
DMHW289 DT Small molecular drug
DMHW289 PC 86267612
DMHW289 MW 431.5
DMHW289 FM C23H25N7O2
DMHW289 IC InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
DMHW289 CS CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
DMHW289 IK TVGAHWWPABTBCX-UHFFFAOYSA-N
DMHW289 IU 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
DMHW289 CA CAS 1628606-05-2
DMHW289 DE Solid tumour/cancer
DMWE205 ID DMWE205
DMWE205 DN DCR-MYC
DMWE205 HS Phase 1/2
DMWE205 CP Dicerna pharmaceuticals
DMWE205 DT siRNA drug
DMWE205 DE Hepatocellular carcinoma
DM0I5LM ID DM0I5LM
DM0I5LM DN DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells
DM0I5LM HS Phase 1/2
DM0I5LM SN BLT-HIV; Lentiviral vector delivered DNA-directed RNAi therapeutic (HIV infection), Benitec; RHIV7-shl-TAR-CCR5RZ; T-cell therapy (HIV infection), Benitec; Lentiviral vector delivered DNA-directed RNAi therapeutic (HIV-associated lymphoma), Benitec; DdRNAi therapy (rHIV7-shl-TAR-CCR5RZ, T-cells, HIV), Benitec; DdRNAi therapy (rHIV7-shl-TAR-CCR5RZ, stem cells, HIV/lymphoma), Benitec
DM0I5LM CP Benitec Ltd
DM0I5LM DT RNAi therapeutics
DM0I5LM DE Human immunodeficiency virus infection
DMCMT4V ID DMCMT4V
DMCMT4V DN Dexamethasone palmitate
DMCMT4V HS Phase 1/2
DMCMT4V SN Cortiject; Dexamethasone palmitate, Novagali; NOVA-22026; NOVA-22032; NOVA-63035; Corticosteroid therapy (ophthalmic emulsion, Novasorb), Novagali; Retinopathy therapy (ophthalmic emulsion, Novasorb), Novagali
DMCMT4V CP Santen
DMCMT4V DT Small molecular drug
DMCMT4V PC 63044
DMCMT4V MW 630.9
DMCMT4V FM C38H59FO6
DMCMT4V IC InChI=1S/C38H59FO6/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-34(43)45-26-33(42)38(44)27(2)23-31-30-20-19-28-24-29(40)21-22-35(28,3)37(30,39)32(41)25-36(31,38)4/h21-22,24,27,30-32,41,44H,5-20,23,25-26H2,1-4H3/t27-,30+,31+,32+,35+,36+,37+,38+/m1/s1
DMCMT4V CS CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)O
DMCMT4V IK WDPYZTKOEFDTCU-WDJQFAPHSA-N
DMCMT4V IU [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hexadecanoate
DMCMT4V CA CAS 14899-36-6
DMCMT4V CB CHEBI:31471
DMCMT4V DE Choroidal neovascularization
DMACPQO ID DMACPQO
DMACPQO DN Dihydrexidine
DMACPQO HS Phase 1/2
DMACPQO SN DIHYDREXIDINE; (+)-Dihydrexidine; UNII-Q3PJ4B4D0X; Q3PJ4B4D0X; CHEMBL25856; Dihydrexidine hydrochloride; (6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol; (6aR,12bS)-5,6,6a,7,8,12b-Hexahydrobenzo(a)phenanthridine-10,11-diol; Rel-Dihydrexidine; Dihydrexidine, (+)-; Lopac-D-5814; Biomol-NT_000033; AC1O7G2G; Lopac0_000380; 5,6,6a,7,8,12b-Hexahydro-benzo[a]phenanthridine-10,11-diol; BPBio1_001227; SCHEMBL4614575; CHEBI:124993; DAR-0100; IP-202; BDBM50010686; ZINC25758512; CCG-204474; NCGC00024845-04
DMACPQO DT Small molecular drug
DMACPQO PC 5311070
DMACPQO MW 267.32
DMACPQO FM C17H17NO2
DMACPQO IC InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m0/s1
DMACPQO CS C1CC2=CC(=C(C=C2[C@H]3[C@H]1NCC4=CC=CC=C34)O)O
DMACPQO IK BGOQGUHWXBGXJW-YOEHRIQHSA-N
DMACPQO IU (6aS,12bR)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol
DMACPQO CA CAS 123039-93-0
DMACPQO DE Psychotic disorder
DM71BFM ID DM71BFM
DM71BFM DN DNA-Ad
DM71BFM HS Phase 1/2
DM71BFM SN DNA-prime/adenovirus (Ad5)-boost CSP-and AMA1-encoding malaria vaccine (Biojector2000, intramuscular), US NavalMedical Research Center (NMRC)/Bioject/Vical/GenVec
DM71BFM CP US Naval Medical Research Center
DM71BFM DT Vaccine
DM71BFM DE Malaria
DMK4VY9 ID DMK4VY9
DMK4VY9 DN DS-7300
DMK4VY9 HS Phase 1/2
DMK4VY9 SN O-(3,5-dichlorophenyl)hydroxylamine; 99907-90-1; 3,5-Dichlorophenoxyamine; Hydroxylamine, O-(3,5-dichlorophenyl)-; SCHEMBL4210449; DTXSID00471352; MFCD09029771; ZINC21987339; AKOS006290319; AK141702
DMK4VY9 CP Daiichi Sankyo
DMK4VY9 DT Antibody drug conjugate
DMK4VY9 DE Solid tumour/cancer
DM7WK6N ID DM7WK6N
DM7WK6N DN DSP-0509
DM7WK6N HS Phase 1/2
DM7WK6N CP Sumitomo Dainippon Pharma
DM7WK6N DT Small molecular drug
DM7WK6N DE Solid tumour/cancer
DM8K0PR ID DM8K0PR
DM8K0PR DN DSP-107
DM8K0PR HS Phase 1/2
DM8K0PR CP KAHR Medical
DM8K0PR DT Recombinant?protein
DM8K0PR DE Solid tumour/cancer
DMRXQCL ID DMRXQCL
DMRXQCL DN DT388IL-3
DMRXQCL HS Phase 1/2
DMRXQCL CP Wake Forest University
DMRXQCL DE Acute myeloid leukaemia
DM8M71U ID DM8M71U
DM8M71U DN DTX301
DM8M71U HS Phase 1/2
DM8M71U CP Ultragenyx Pharmaceutical
DM8M71U DT Gene therapy
DM8M71U DE Ornithine transcarbamylase deficiency
DM72DU3 ID DM72DU3
DM72DU3 DN DZD9008
DM72DU3 HS Phase 1/2
DM72DU3 CP Dizal Pharmaceuticals
DM72DU3 DT Small molecular drug
DM72DU3 DE Non-small cell lung cancer
DMH2NKD ID DMH2NKD
DMH2NKD DN EB-101
DMH2NKD HS Phase 1/2
DMH2NKD SN Beta amyloid vaccine (Alzheimer's disease), Atlas Pharmaceuticals
DMH2NKD CP Atlas Pharmaceuticals Inc
DMH2NKD DT Vaccine
DMH2NKD DE Alzheimer disease; Dystrophic epidermolysis bullosa
DMI71FN ID DMI71FN
DMI71FN DN EDO-S101
DMI71FN HS Phase 1/2
DMI71FN SN Tinostamustine; Minomustine; 1236199-60-2; UNII-29DKI2H2NY; 29DKI2H2NY; Tinostamustine [USAN]; SCHEMBL7915449; CHEMBL3989941; EDO-S-101; EDO-S 101; MolPort-046-033-566; EX-A1322; ZINC68244536; AKOS030526024; CS-6484; HY-101780; EDO-S101,1236199-60-2, EDO-S101,EDO S101,EDOS101; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-
DMI71FN CP Mundipharma Cambridge, United Kingdom
DMI71FN PC 46836227
DMI71FN MW 415.4
DMI71FN FM C19H28Cl2N4O2
DMI71FN IC InChI=1S/C19H28Cl2N4O2/c1-24-17-9-8-15(25(12-10-20)13-11-21)14-16(17)22-18(24)6-4-2-3-5-7-19(26)23-27/h8-9,14,27H,2-7,10-13H2,1H3,(H,23,26)
DMI71FN CS CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO
DMI71FN IK GISXTRIGVCKQBX-UHFFFAOYSA-N
DMI71FN IU 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide
DMI71FN CA CAS 1236199-60-2
DMI71FN DE Solid tumour/cancer; Haematological malignancy
DMHRCQI ID DMHRCQI
DMHRCQI DN eFT226
DMHRCQI HS Phase 1/2
DMHRCQI SN Zotatifin; EFT226; UNII-2EWN8Z05CN; 2EWN8Z05CN; 2098191-53-6; EFT-226; Zotatifin [INN]; 4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile; 4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl)benzonitrile; Zotatifin [USAN]; Zotatifin (USAN/INN); CHEMBL4303782; SCHEMBL18864788; EX-A4623; NSC818001; NSC828584; WHO 10998; NSC-818001; NSC-828584; HY-112163; CS-0043584; D11837; Benzonitrile, 4-((5aR,6S,7S,8R,8aS)-7-((dimethylamino)methyl)-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)-
DMHRCQI CP eFFECTOR Therapeutics
DMHRCQI DT Small molecular drug
DMHRCQI PC 129138801
DMHRCQI MW 487.5
DMHRCQI FM C28H29N3O5
DMHRCQI IC InChI=1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1
DMHRCQI CS CN(C)C[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5
DMHRCQI IK QYCXWOACFWMQFO-WZWZCULESA-N
DMHRCQI IU 4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile
DMHRCQI CA CAS 2098191-53-6
DMHRCQI DE Solid tumour/cancer
DMF7EX8 ID DMF7EX8
DMF7EX8 DN EGFR antisense DNA
DMF7EX8 HS Phase 1/2
DMF7EX8 SN Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh
DMF7EX8 CP University of Pittsburgh
DMF7EX8 DT Antisense drug
DMF7EX8 DE Head and neck cancer
DMDWCOF ID DMDWCOF
DMDWCOF DN EGFR CART
DMDWCOF HS Phase 1/2
DMDWCOF CP Shenzhen Second People's Hospital
DMDWCOF DT CAR T Cell Therapy
DMDWCOF DE Colorectal cancer
DMC284G ID DMC284G
DMC284G DN EGFRvIII CAR
DMC284G HS Phase 1/2
DMC284G CP Kite pharma santa monica; national cancer institute
DMC284G DE Glioblastoma multiforme
DM5FCO4 ID DM5FCO4
DM5FCO4 DN Elpamotide
DM5FCO4 HS Phase 1/2
DM5FCO4 SN OTS-102; VEGFR2-169; Epitope peptide vaccine (pancreatic cancer), Wakayama University; VEGFR2-epitope peptide, Wakayama
DM5FCO4 CP OncoTherapy Science Inc
DM5FCO4 DT Vaccine
DM5FCO4 DE Biliary cancer
DM7CLEZ ID DM7CLEZ
DM7CLEZ DN Eltanexor oral
DM7CLEZ HS Phase 1/2
DM7CLEZ SN KPT-8602; Eltanexor; UNII-Q59IQJ9NTK; Q59IQJ9NTK; 1642300-52-4; Eltanexor [INN]; Eltanexor [WHO-DD]; SCHEMBL16324809; MolPort-044-830-659; s8397; AKOS032945053; CS-5947; HY-100423; (E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide; 5-Pyrimidineacetamide, alpha-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)methylene)-, (alphaE)-; (2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide
DM7CLEZ CP Karyopharm Therapeutics Newton, MA
DM7CLEZ PC 86345880
DM7CLEZ MW 428.29
DM7CLEZ FM C17H10F6N6O
DM7CLEZ IC InChI=1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)/b13-6+
DM7CLEZ CS C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C2=NN(C=N2)/C=C(\\C3=CN=CN=C3)/C(=O)N
DM7CLEZ IK JFBAVWVBLRIWHM-AWNIVKPZSA-N
DM7CLEZ IU (E)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-2-pyrimidin-5-ylprop-2-enamide
DM7CLEZ CA CAS 1642300-52-4
DM7CLEZ DE Colorectal cancer; Myelodysplastic syndrome; Prostate cancer
DMCAUKW ID DMCAUKW
DMCAUKW DN EMB-01
DMCAUKW HS Phase 1/2
DMCAUKW CP EpimAb Biotherapeutics
DMCAUKW DT Antibody
DMCAUKW DE Neoplasm; Non-small cell lung cancer
DMMD10S ID DMMD10S
DMMD10S DN EMD 55900
DMMD10S HS Phase 1/2
DMMD10S SN 27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R*,S*)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468
DMMD10S DT Antibody
DMMD10S DE Glioma
DMIOUFK ID DMIOUFK
DMIOUFK DN Emfilermin
DMIOUFK HS Phase 1/2
DMIOUFK SN AM-424; Leukemia inhibitory factor, AMRAD; RhLIF, AMRAD; RhLIF, Serono; Recombinant LIF protein, AMRAD/Serono; R-LIF, AMRAD/Serono
DMIOUFK CP Zenyth Therapeutics Ltd
DMIOUFK DE Infertility
DM1PQJO ID DM1PQJO
DM1PQJO DN Enapotamab vedotin
DM1PQJO HS Phase 1/2
DM1PQJO CP GenMab
DM1PQJO DT Antibody
DM1PQJO DE Solid tumour/cancer
DMN0EMP ID DMN0EMP
DMN0EMP DN Epicatechin
DMN0EMP HS Phase 1/2
DMN0EMP SN (-)-Epicatechin; Epicatechin; 490-46-0; L-Epicatechin; (-)-Epicatechol; l-Acacatechin; (2R,3R)-2-(3,4-Dihydroxyphenyl)chroman-3,5,7-triol; Epicatechol; l-Epicatechol; (-)epicatechin; (2R,3R)-(-)-Epicatechin; UNII-34PHS7TU43; epi-Catechin; epi-Catechol; CCRIS 7097; EINECS 207-710-1; NSC 81161; Epicatechol, (-)-; CHEBI:90; 34PHS7TU43; PFTAWBLQPZVEMU-UKRRQHHQSA-N; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; (-)-(2R:3R)-5,7,3',4'-Tetrahydroxyflavan-3-ol; AK105372; C15H14O6
DMN0EMP DT Small molecular drug
DMN0EMP PC 72276
DMN0EMP MW 290.27
DMN0EMP FM C15H14O6
DMN0EMP IC InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1
DMN0EMP CS C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O
DMN0EMP IK PFTAWBLQPZVEMU-UKRRQHHQSA-N
DMN0EMP IU (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
DMN0EMP CA CAS 17334-50-8
DMN0EMP CB CHEBI:90
DMN0EMP DE Duchenne dystrophy; Friedreich's ataxia
DMWSGZU ID DMWSGZU
DMWSGZU DN Epithalon
DMWSGZU HS Phase 1/2
DMWSGZU SN Epitalon; BDM-E; Epitalon (Russian Academy of Medical Sciences); Retinal disease therapeutic, Biodiem; L-Alanyl-L-glutamyl-L-aspartyl-glycine
DMWSGZU CP BioDiem Ltd
DMWSGZU DT Small molecular drug
DMWSGZU PC 219042
DMWSGZU MW 390.35
DMWSGZU FM C14H22N4O9
DMWSGZU IC InChI=1S/C14H22N4O9/c1-6(15)12(25)17-7(2-3-9(19)20)14(27)18-8(4-10(21)22)13(26)16-5-11(23)24/h6-8H,2-5,15H2,1H3,(H,16,26)(H,17,25)(H,18,27)(H,19,20)(H,21,22)(H,23,24)/t6-,7-,8-/m0/s1
DMWSGZU CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N
DMWSGZU IK HGHOBRRUMWJWCU-FXQIFTODSA-N
DMWSGZU IU (4S)-4-[[(2S)-2-aminopropanoyl]amino]-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMWSGZU CA CAS 64082-79-7
DMWSGZU DE Ocular inflammation
DMTY96S ID DMTY96S
DMTY96S DN Eptacog beta
DMTY96S HS Phase 1/2
DMTY96S CP Hema Biologics
DMTY96S DT Small molecular drug
DMTY96S DE Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Mantle cell lymphoma
DMN2FS3 ID DMN2FS3
DMN2FS3 DN EPZ-5676
DMN2FS3 HS Phase 1/2
DMN2FS3 SN pinometostat; EPZ-5676; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine
DMN2FS3 CP Epizyme
DMN2FS3 DT Small molecular drug
DMN2FS3 PC 57345410
DMN2FS3 MW 562.7
DMN2FS3 FM C30H42N8O3
DMN2FS3 IC InChI=1S/C30H42N8O3/c1-16(2)37(13-22-25(39)26(40)29(41-22)38-15-34-24-27(31)32-14-33-28(24)38)19-10-17(11-19)6-9-23-35-20-8-7-18(30(3,4)5)12-21(20)36-23/h7-8,12,14-17,19,22,25-26,29,39-40H,6,9-11,13H2,1-5H3,(H,35,36)(H2,31,32,33)/t17?,19?,22-,25-,26-,29-/m1/s1
DMN2FS3 CS CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C
DMN2FS3 IK LXFOLMYKSYSZQS-XKHGBIBOSA-N
DMN2FS3 IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[[3-[2-(6-tert-butyl-1H-benzimidazol-2-yl)ethyl]cyclobutyl]-propan-2-ylamino]methyl]oxolane-3,4-diol
DMN2FS3 CA CAS 1380288-87-8
DMN2FS3 CB CHEBI:124919
DMN2FS3 DE Acute lymphoblastic leukaemia; Acute lymphocytic leukaemia; Acute myeloid leukaemia
DMNZ6VA ID DMNZ6VA
DMNZ6VA DN Erythropoietin-transfected autologous cell therapy
DMNZ6VA HS Phase 1/2
DMNZ6VA SN Epodure; Erythropoietin-transfected autologous cell therapy (Biopump); Erythropoietin-transfected autologous cell therapy (Biopump), Medgenics
DMNZ6VA CP Medgenics
DMNZ6VA DE Anemia
DMUNM4D ID DMUNM4D
DMUNM4D DN ESR0114
DMUNM4D HS Phase 1/2
DMUNM4D CP Escalier Biosciences Encinitas, CA
DMUNM4D DE Plaque psoriasis
DMIREUZ ID DMIREUZ
DMIREUZ DN Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy
DMIREUZ HS Phase 1/2
DMIREUZ SN Adenosine deaminase-transduced hematopoietic stem cell therapy; Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy (ADA-SCID)
DMIREUZ CP San Raffaele Telethon Institute for Gene Therapy
DMIREUZ DE Immunodeficiency
DM64PM7 ID DM64PM7
DM64PM7 DN EXO-230
DM64PM7 HS Phase 1/2
DM64PM7 SN GLY-230
DM64PM7 CP Glycadia Inc
DM64PM7 DE Diabetic neuropathy
DML6EVJ ID DML6EVJ
DML6EVJ DN F-14512
DML6EVJ HS Phase 1/2
DML6EVJ SN Polyamine-epipodophyllotoxin conjugate (cancer), Pierre Fabre
DML6EVJ CP Pierre Fabre SA
DML6EVJ DT Small molecular drug
DML6EVJ PC 25229664
DML6EVJ MW 641.8
DML6EVJ FM C33H47N5O8
DML6EVJ IC InChI=1S/C33H47N5O8/c1-42-26-13-20(14-27(43-2)32(26)40)29-21-15-24-25(46-19-45-24)16-22(21)31(23-18-44-33(41)30(23)29)38-28(39)17-37-12-6-11-36-9-4-3-8-35-10-5-7-34/h13-16,23,29-31,35-37,40H,3-12,17-19,34H2,1-2H3,(H,38,39)/t23-,29+,30-,31+/m0/s1
DML6EVJ CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)NC(=O)CNCCCNCCCCNCCCN
DML6EVJ IK NUZMJDHDPVKFJN-TYDXHICZSA-N
DML6EVJ IU N-[(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl]-2-[3-[4-(3-aminopropylamino)butylamino]propylamino]acetamide
DML6EVJ CA CAS 866874-63-7
DML6EVJ DE Solid tumour/cancer
DM49BX1 ID DM49BX1
DM49BX1 DN F-16-131I
DM49BX1 HS Phase 1/2
DM49BX1 SN Tenarad; Radiolabeled scFv antibody F-16 (solid tumor/hematological malignancy), Philogen
DM49BX1 CP Philogen SpA
DM49BX1 DT Antibody
DM49BX1 DE Haematological malignancy
DMQSF5C ID DMQSF5C
DMQSF5C DN FBT-A05
DMQSF5C HS Phase 1/2
DMQSF5C SN Lymphomun; Bi-20; TPBs-05; Anti-CD20 bivalent monoclonal antibody (hematological cancer), Fresenius Biotech; Trifunctional antibody therapy (blood malignancy), Fresenius/Trion; Anti-CD20 bivalent monoclonal antibody (B-cell lymphoma, Triomab), Trion/Fresenius
DMQSF5C CP TRION Pharma GmbH
DMQSF5C DT Antibody
DMQSF5C DE Chronic lymphocytic leukaemia
DMQ8VUW ID DMQ8VUW
DMQ8VUW DN FCN-437
DMQ8VUW HS Phase 1/2
DMQ8VUW CP Fochon Pharmaceuticals
DMQ8VUW DE Breast cancer
DMRHOFB ID DMRHOFB
DMRHOFB DN Ferritarg P
DMRHOFB HS Phase 1/2
DMRHOFB SN Ferritarg; Ferrotarg P; Hodgkins disease therapy (polyclonal antibody), MAT Biopharma; Y90 anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; Yttrium-90 anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; Yttrium-90 anti-ferritin polyclonal antibody (refractory Hodgkin! s disease), MAT Biopharma; 90Y-labelled anti-ferritin polyclonal antibody (Hodgkins disease), MAT Biopharma; 90Y-labelled polyclonal IgG (Hodgkins disease), MAT Biopharma; 90Y-labelled polyclonal immunoglobulin G (Hogkinsdisease), MAT biopharma
DMRHOFB CP MAT Biopharma
DMRHOFB DT Antibody
DMRHOFB DE Lymphoma
DM1XIMU ID DM1XIMU
DM1XIMU DN FF-10101
DM1XIMU HS Phase 1/2
DM1XIMU SN 1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-
DM1XIMU CP FUJIFILM Pharmaceuticals
DM1XIMU DT Small molecular drug
DM1XIMU PC 90052320
DM1XIMU MW 530.7
DM1XIMU FM C29H38N8O2
DM1XIMU IC InChI=1S/C29H38N8O2/c1-6-17-31-27-24(21-33-29(35-27)34-25-15-13-23(20-30)14-16-25)11-8-7-9-18-32-28(39)22(2)37(5)26(38)12-10-19-36(3)4/h10,12-16,21-22H,6-7,9,17-19H2,1-5H3,(H,32,39)(H2,31,33,34,35)/b12-10+/t22-/m0/s1
DM1XIMU CS CCCNC1=NC(=NC=C1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C)NC2=CC=C(C=C2)C#N
DM1XIMU IK HJFSVYUFOXAVAA-YUAYGMJFSA-N
DM1XIMU IU (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide
DM1XIMU CA CAS 1472797-69-5
DM1XIMU DE Acute myeloid leukaemia
DM0HSJK ID DM0HSJK
DM0HSJK DN FF-10501-01
DM0HSJK HS Phase 1/2
DM0HSJK CP FUJIFILM Pharmaceuticals U.S.A. Cambridge, MA
DM0HSJK DE Acute myeloid leukaemia; Chronic myelogenous leukaemia; Myelodysplastic syndrome; Haematological malignancy
DM72JE4 ID DM72JE4
DM72JE4 DN FF-10502
DM72JE4 HS Phase 1/2
DM72JE4 SN UNII-R5B1HX1HUY; R5B1HX1HUY; 184302-49-6; 4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one; 4'-Thio-fac; SCHEMBL1986004; 4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one; 2'beta-Fluoro-4'-O-thia-2'-deoxycytidine; 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)cytosine
DM72JE4 CP FUJIFILM Pharmaceuticals
DM72JE4 DT Small molecular drug
DM72JE4 PC 9903330
DM72JE4 MW 261.279
DM72JE4 FM C9H12FN3O3S
DM72JE4 IC InChI=1S/C9H12FN3O3S/c10-6-7(15)4(3-14)17-8(6)13-2-1-5(11)12-9(13)16/h1-2,4,6-8,14-15H,3H2,(H2,11,12,16)/t4-,6+,7-,8-/m1/s1
DM72JE4 CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](S2)CO)O)F
DM72JE4 IK NIDPJRZOVFIBQB-PXBUCIJWSA-N
DM72JE4 IU 4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one
DM72JE4 CA CAS 184302-49-6
DM72JE4 DE Solid tumour/cancer
DMWEJ0C ID DMWEJ0C
DMWEJ0C DN FGF401
DMWEJ0C HS Phase 1/2
DMWEJ0C SN Roblitinib; 1708971-55-4; FGF-401; UNII-M64JF6WMSA; M64JF6WMSA; N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide; N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide; Roblitinib [INN]; NVP-FGF401; GTPL9768; FGF 401 [WHO-DD]; CHEMBL3908979; SCHEMBL16668840; BHKDKKZMPODMIQ-UHFFFAOYSA-N; MolPort-044-756-212; BDBM209325; EX-A1341
DMWEJ0C CP Novartis Oncology East Hanover, NJ
DMWEJ0C PC 118036971
DMWEJ0C MW 506.6
DMWEJ0C FM C25H30N8O4
DMWEJ0C IC InChI=1S/C25H30N8O4/c1-31-7-8-32(23(35)15-31)14-18-10-17-4-3-6-33(24(17)29-21(18)16-34)25(36)30-22-11-20(27-5-9-37-2)19(12-26)13-28-22/h10-11,13,16H,3-9,14-15H2,1-2H3,(H2,27,28,30,36)
DMWEJ0C CS CN1CCN(C(=O)C1)CC2=C(N=C3C(=C2)CCCN3C(=O)NC4=NC=C(C(=C4)NCCOC)C#N)C=O
DMWEJ0C IK BHKDKKZMPODMIQ-UHFFFAOYSA-N
DMWEJ0C IU N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide
DMWEJ0C CA CAS 1708971-55-4
DMWEJ0C DE Hepatocellular carcinoma; Solid tumour/cancer
DMI7S39 ID DMI7S39
DMI7S39 DN FLX475
DMI7S39 HS Phase 1/2
DMI7S39 CP FLX BioSouth San Francisco, CA
DMI7S39 DT Small molecular drug
DMI7S39 DE Solid tumour/cancer
DME2W4T ID DME2W4T
DME2W4T DN Forodesine
DME2W4T HS Phase 1/2
DME2W4T SN Immucillin H; Fodosine; Immucillin-H; 209799-67-7; BCX-1777; 1,4-dideoxy-4-aza-1-(s)-(9-deazahypoxanthin-9-yl)-d-ribitol; UNII-426X066ELK; CHEMBL218291; CHEBI:43362; 426X066ELK; (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol; IMH; 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; (2R,3R,4S,5S)-2-(hydroxymethyl)-5-(4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidine-3,4-diol; Fodosine (TN)
DME2W4T CP BioCryst Pharma.
DME2W4T TC Anticancer Agents
DME2W4T DT Small molecular drug
DME2W4T PC 135409409
DME2W4T MW 266.25
DME2W4T FM C11H14N4O4
DME2W4T IC InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1
DME2W4T CS C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
DME2W4T IK IWKXDMQDITUYRK-KUBHLMPHSA-N
DME2W4T IU 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DME2W4T CA CAS 209799-67-7
DME2W4T CB CHEBI:43362
DME2W4T DE B-cell acute lymphoblastic leukaemia; Cutaneous T-cell lymphoma
DM3ZN6Y ID DM3ZN6Y
DM3ZN6Y DN FPA-008
DM3ZN6Y HS Phase 1/2
DM3ZN6Y CP Five prime therapeutics
DM3ZN6Y DE Autoimmune diabetes; Pigmented villonodular synovitis; Tenosynovial giant cell tumour
DMXV6YP ID DMXV6YP
DMXV6YP DN Fus-1 tumor suppressor gene therapy
DMXV6YP HS Phase 1/2
DMXV6YP SN Fus-1 tumor suppres; INGN-401; P53 bystander effector, Introgen; DOTAP:chol-TUSC2; FUS1-DOTAP:cholesterol; Fus-1 tumor suppressor gene therapy - nanoparticle formulation (cancer); Fus-1 tumor suppressor gene therapy-nanoparticle formulation (cancer), MD Anderson
DMXV6YP CP Genprex
DMXV6YP DE Non-small-cell lung cancer
DMG48WN ID DMG48WN
DMG48WN DN G0-203-2c
DMG48WN HS Phase 1/2
DMG48WN CP Genus 0ncology
DMG48WN DE Acute myeloid leukaemia; Pancreatic cancer
DMTV42K ID DMTV42K
DMTV42K DN G1
DMTV42K HS Phase 1/2
DMTV42K SN CHEMBL569766; 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone; 1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone; SR-01000506928; AC1NT1SF; GTPL1014; SCHEMBL12700948; cid_5322399; cid_3136849; MolPort-003-004-976; ML051; HMS3650I22; ZINC4172149; BDBM50303803; STK330808; AKOS015969580; HY-107216; CS-0027669; UNM000011063001; UNM000000675701; SR-01000506928-1; SR-01000506928-3; 925419-53-0
DMTV42K DT Small molecular drug
DMTV42K PC 5322399
DMTV42K MW 412.3
DMTV42K FM C21H18BrNO3
DMTV42K IC InChI=1S/C21H18BrNO3/c1-11(24)12-5-6-18-15(7-12)13-3-2-4-14(13)21(23-18)16-8-19-20(9-17(16)22)26-10-25-19/h2-3,5-9,13-14,21,23H,4,10H2,1H3/t13-,14+,21-/m1/s1
DMTV42K CS CC(=O)C1=CC2=C(C=C1)N[C@H]([C@@H]3[C@H]2C=CC3)C4=CC5=C(C=C4Br)OCO5
DMTV42K IK VHSVKVWHYFBIFJ-HKZYLEAXSA-N
DMTV42K IU 1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]ethanone
DMTV42K CA CAS 881639-98-1
DMTV42K CB CHEBI:156296
DMTV42K DE Lymphoma; Solid tumour/cancer
DM32AKH ID DM32AKH
DM32AKH DN G-207 virus construct
DM32AKH HS Phase 1/2
DM32AKH SN HrR3; G-207; G-47; G-47delta; G-207 virus construct, Catherex; G-207 virus construct, MediGene; HSV mutants (glioma), NCI; Oncolytic herpes simplex virus (glioma), Catherex/MediGene
DM32AKH CP MediGene Inc
DM32AKH DE Glioma
DMQU4EI ID DMQU4EI
DMQU4EI DN Galnobax
DMQU4EI HS Phase 1/2
DMQU4EI CP NovaLead Pharma Shrewsbury, MA
DMQU4EI DE Diabetic foot ulcer
DMN7QBE ID DMN7QBE
DMN7QBE DN GANTACURIUM CHLORIDE
DMN7QBE HS Phase 1/2
DMN7QBE SN AV-430A; GW-0430; GW-280430A; Gantacurium chloride; (Z)-2-Chlorofumaric acid 1-[3-[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium-2-yl]propyl] 4-[3-[6,7-dimethoxy-2(R)-methyl-1(S)-(3,4,5-trimethoxyphenyl)-1,2,3
DMN7QBE CP Avera Pharmaceuticals
DMN7QBE PC 10772467
DMN7QBE MW 1064.5
DMN7QBE FM C53H69Cl3N2O14
DMN7QBE IC InChI=1S/C53H69ClN2O14.2ClH/c1-55(19-15-34-26-41(59-3)43(61-5)30-37(34)40(55)23-33-24-45(63-7)51(67-11)46(25-33)64-8)17-13-22-70-53(58)39(54)32-49(57)69-21-14-18-56(2)20-16-35-27-42(60-4)44(62-6)31-38(35)50(56)36-28-47(65-9)52(68-12)48(29-36)66-10;;/h24-32,40,50H,13-23H2,1-12H3;2*1H/q+2;;/p-2/b39-32-;;/t40-,50+,55-,56+;;/m1../s1
DMN7QBE CS C[N@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)/C(=C/C(=O)OCCC[N@+]4(CCC5=CC(=C(C=C5[C@@H]4C6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C)/Cl.[Cl-].[Cl-]
DMN7QBE IK SDIFKXLSGXCGEN-WJUBNSBASA-L
DMN7QBE IU 4-O-[3-[(1S,2R)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] 1-O-[3-[(1R,2S)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (Z)-2-chlorobut-2-enedioate;dichloride
DMN7QBE CA CAS 213998-46-0
DMN7QBE DE Anaesthesia
DMCT9NG ID DMCT9NG
DMCT9NG DN GB1275
DMCT9NG HS Phase 1/2
DMCT9NG CP Gossamer Bio
DMCT9NG DE Pancreatic cancer
DM5VF04 ID DM5VF04
DM5VF04 DN GD2-CART01
DM5VF04 HS Phase 1/2
DM5VF04 CP Bambino Gesù Hospital and Research Institute
DM5VF04 DT CAR T Cell Therapy
DM5VF04 DE Neuroblastoma
DM8J0MK ID DM8J0MK
DM8J0MK DN GEA-6414
DM8J0MK HS Phase 1/2
DM8J0MK SN Tolfenamic acid; Acide tolfenamique; Acido tolfenamico; Acidum tolfenamicum; Bifenac; Clotam; GEA 6414; Tolfedine; tolfenamic acid; 13710-19-5; 2-(3-Chloro-2-methylanilino)benzoic acid; 2-[(3-Chloro-2-methylphenyl)amino]benzoic Acid; 3G943U18KM; Anthranilic acid, N-(3-chloro-o-tolyl)-; Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]-; CAS-13710-19-5; CHEBI:32243; N-(2-Methyl-3-chlorophenyl)anthranilic acid; N-(3-Chloro-2-methylphenyl)anthranilic acid; N-(3-Chloro-o-tolyl)-anthranilic acid; NCGC00016705-05; UNII-3G943U18KM
DM8J0MK PC 610479
DM8J0MK MW 261.7
DM8J0MK FM C14H12ClNO2
DM8J0MK IC YEZNLOUZAIOMLT-UHFFFAOYSA-N
DM8J0MK CS CC1=C(C=CC=C1Cl)NC2=CC=CC=C2C(=O)O
DM8J0MK IK 1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)
DM8J0MK IU 2-(3-chloro-2-methylanilino)benzoic acid
DM8J0MK CA CAS 13710-19-5
DM8J0MK CB CHEBI:32243
DM8J0MK DE Parkinsonism
DMD8RLY ID DMD8RLY
DMD8RLY DN GEN3009
DMD8RLY HS Phase 1/2
DMD8RLY CP AbbVie; Genmab
DMD8RLY DT Antibody
DMD8RLY DE B-cell non-hodgkin lymphoma
DMZABYH ID DMZABYH
DMZABYH DN GEN3013
DMZABYH HS Phase 1/2
DMZABYH DT Antibody
DMZABYH DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
DMY1CP9 ID DMY1CP9
DMY1CP9 DN GLG-801
DMY1CP9 HS Phase 1/2
DMY1CP9 CP GLG Pharma Jupiter, FL
DMY1CP9 DE Chronic lymphocytic leukaemia
DM7DWLY ID DM7DWLY
DM7DWLY DN GLR2007
DM7DWLY HS Phase 1/2
DM7DWLY CP Gan & Lee Pharmaceuticals
DM7DWLY DE Non-small-cell lung cancer; Glioblastoma of brain
DMGN679 ID DMGN679
DMGN679 DN GPC3-CART cells
DMGN679 HS Phase 1/2
DMGN679 CP Shanghai GeneChem Co., Ltd.
DMGN679 DT CAR T Cell Therapy
DMGN679 DE Hepatocellular carcinoma
DM1GE67 ID DM1GE67
DM1GE67 DN GS-4224
DM1GE67 HS Phase 1/2
DM1GE67 SN Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632
DM1GE67 CP Gilead Sciences
DM1GE67 DT Small molecular drug
DM1GE67 PC 12439252
DM1GE67 MW 138.12
DM1GE67 FM C6H6N2O2
DM1GE67 IC InChI=1S/C6H6N2O2/c1-10-6(9)5-2-3-7-8-4-5/h2-4H,1H3
DM1GE67 CS COC(=O)C1=CN=NC=C1
DM1GE67 IK IJFLWNYKGMQQOW-UHFFFAOYSA-N
DM1GE67 IU methyl pyridazine-4-carboxylate
DM1GE67 CA CAS 34231-77-1
DM1GE67 DE Solid tumour/cancer
DMTJQ8S ID DMTJQ8S
DMTJQ8S DN GS-9219
DMTJQ8S HS Phase 1/2
DMTJQ8S SN PMEG prodrug (cancer), Gilead
DMTJQ8S CP Gilead Sciences Inc
DMTJQ8S DT Small molecular drug
DMTJQ8S PC 16047979
DMTJQ8S MW 526.5
DMTJQ8S FM C21H35N8O6P
DMTJQ8S IC InChI=1S/C21H35N8O6P/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26)/t13-,14-/m0/s1
DMTJQ8S CS CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(N=C(N=C21)N)NC3CC3)N[C@@H](C)C(=O)OCC
DMTJQ8S IK ANSPEDQTHURSFQ-KBPBESRZSA-N
DMTJQ8S IU ethyl (2S)-2-[[2-[2-amino-6-(cyclopropylamino)purin-9-yl]ethoxymethyl-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphoryl]amino]propanoate
DMTJQ8S CA CAS 859209-74-8
DMTJQ8S DE Solid tumour/cancer
DM059OH ID DM059OH
DM059OH DN GSK3145095
DM059OH HS Phase 1/2
DM059OH SN 1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK-3145095; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)
DM059OH CP GlaxoSmithKline
DM059OH DT Small molecular drug
DM059OH PC 118557502
DM059OH MW 397.4
DM059OH FM C20H17F2N5O2
DM059OH IC InChI=1S/C20H17F2N5O2/c21-13-9-12-6-7-15(19(28)25-17(12)14(22)10-13)23-20(29)18-24-16(26-27-18)8-11-4-2-1-3-5-11/h1-5,9-10,15H,6-8H2,(H,23,29)(H,25,28)(H,24,26,27)/t15-/m0/s1
DM059OH CS C1CC2=C(C(=CC(=C2)F)F)NC(=O)[C@H]1NC(=O)C3=NNC(=N3)CC4=CC=CC=C4
DM059OH IK ATQAGKAMBISZQM-HNNXBMFYSA-N
DM059OH IU 5-benzyl-N-[(3S)-7,9-difluoro-2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide
DM059OH CA CAS 1622849-43-7
DM059OH DE Pancreatic cancer
DMK2RIB ID DMK2RIB
DMK2RIB DN GTB-3550
DMK2RIB HS Phase 1/2
DMK2RIB SN OXS-3550
DMK2RIB CP GT Biopharma
DMK2RIB DT Recombinant protein
DMK2RIB DE Myelodysplastic syndrome; Systemic mastocytosis; Acute myelogenous leukaemia; Mast cell leukaemia
DM0S24D ID DM0S24D
DM0S24D DN GTU-TB vaccine
DM0S24D HS Phase 1/2
DM0S24D SN DNA vaccine (Mycobacterium tuberculosis infection), FIT Biotech
DM0S24D CP VaxOnco; National Institute of Allergy and Infectious Diseases; National Institutes of Health
DM0S24D DT Vaccine
DM0S24D DE Mycobacterium infection
DMIFCY2 ID DMIFCY2
DMIFCY2 DN H3B-6545
DMIFCY2 HS Phase 1/2
DMIFCY2 SN JPFTZIJTXCHJNE-HMOQVRKWSA-N; SCHEMBL18261010; HY-112596; CS-0047714; (2e)-N,N-dimethyl-4-{[2-({5-[(1z)-4,4,4-trifluoro-1-(3-fluoro-1h-indazol-5-yl)-2-phenylbut-1-en-1-yl]pyridin-2-yl}oxy)ethyl]amino}but-2-enamide
DMIFCY2 CP EisaiWoodcliff Lake, NJH3 Biomedicine Cambridge, MA
DMIFCY2 PC 124091040
DMIFCY2 MW 567.6
DMIFCY2 FM C30H29F4N5O2
DMIFCY2 IC InChI=1S/C30H29F4N5O2/c1-39(2)27(40)9-6-14-35-15-16-41-26-13-11-22(19-36-26)28(21-10-12-25-23(17-21)29(31)38-37-25)24(18-30(32,33)34)20-7-4-3-5-8-20/h3-13,17,19,35H,14-16,18H2,1-2H3,(H,37,38)/b9-6+,28-24-
DMIFCY2 CS CN(C)C(=O)/C=C/CNCCOC1=NC=C(C=C1)/C(=C(/CC(F)(F)F)\\C2=CC=CC=C2)/C3=CC4=C(NN=C4C=C3)F
DMIFCY2 IK JPFTZIJTXCHJNE-HMOQVRKWSA-N
DMIFCY2 IU (E)-N,N-dimethyl-4-[2-[5-[(Z)-4,4,4-trifluoro-1-(3-fluoro-2H-indazol-5-yl)-2-phenylbut-1-enyl]pyridin-2-yl]oxyethylamino]but-2-enamide
DMIFCY2 DE Breast cancer
DMQWI7V ID DMQWI7V
DMQWI7V DN Hematopoietic stem cell gene therapy
DMQWI7V HS Phase 1/2
DMQWI7V SN Hematopoietic stem cell gene therapy (Wiskott-Aldrich syndrome)
DMQWI7V CP Advantagene
DMQWI7V DE Wiskott-Aldrich syndrome
DM1U6VX ID DM1U6VX
DM1U6VX DN HER-2-targeting CAR T Cells
DM1U6VX HS Phase 1/2
DM1U6VX CP Fuda Cancer Hospital, Guangzhou
DM1U6VX DT CAR T Cell Therapy
DM1U6VX DE Breast cancer
DM0C5MV ID DM0C5MV
DM0C5MV DN HH2710
DM0C5MV HS Phase 1/2
DM0C5MV CP HaiHe Biopharma
DM0C5MV DE Solid tumour/cancer
DMJDVCW ID DMJDVCW
DMJDVCW DN HL-085
DMJDVCW HS Phase 1/2
DMJDVCW CP Kechow Pharma
DMJDVCW DE Melanoma
DMDFG1O ID DMDFG1O
DMDFG1O DN HLF 1-11
DMDFG1O HS Phase 1/2
DMDFG1O SN Antimicrobial peptides, AM-Pharma; HLF(1-11); Antimicrobial peptides (bacterial infections), AM-Pharma; Antimicrobial peptides (fungal infections), AM-Pharma; HLF 1-11, AM-Pharma; Human lactoferrin 1-11, AM-Pharma; Human lactoferrin peptides (antibacterial), AM-Pharma
DMDFG1O CP Pharming Group NV
DMDFG1O DT Peptide
DMDFG1O DE Bacterial infection; Bacteremia; Candidemia
DMV1SDA ID DMV1SDA
DMV1SDA DN HM43239
DMV1SDA HS Phase 1/2
DMV1SDA CP Hanmi Pharmaceutical
DMV1SDA DT Small molecular drug
DMV1SDA DE Acute myeloid leukaemia
DM1ZHML ID DM1ZHML
DM1ZHML DN HPN328
DM1ZHML HS Phase 1/2
DM1ZHML CP Harpoon Therapeutics
DM1ZHML DE Small-cell lung cancer
DM86OJ0 ID DM86OJ0
DM86OJ0 DN HPN536
DM86OJ0 HS Phase 1/2
DM86OJ0 CP Harpoon Therapeutics
DM86OJ0 DE Solid tumour/cancer
DMEY1AP ID DMEY1AP
DMEY1AP DN HSDB-3165
DMEY1AP HS Phase 1/2
DMEY1AP SN D-Gluconic acid potassium salt; Potassium gluconate; D-Gluconic acid, potassium salt; Gluconic acid potassium salt; Gluconic acid, monopotassium salt; Gluconsan; Gluconsan K; Kalium Gluconate; Kalium-beta; Kaon elixir; Katorin; Monopotassium D-gluconate; Potalium; Potasoral; Potassium D-gluconate; Potassuril; Sirokal; 12H3K5QKN9; 299-27-4; D-Gluconic acid, monopotassium salt; EINECS 206-074-2; HSDB 3165; K-Iao; KOK; Kaon; MFCD00064211; UNII-12H3K5QKN9; potassium (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
DMEY1AP PC 16760467
DMEY1AP MW 234.25
DMEY1AP FM C6H11KO7
DMEY1AP IC HLCFGWHYROZGBI-JJKGCWMISA-M
DMEY1AP CS C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[K+]
DMEY1AP IK 1S/C6H12O7.K/c7-1-2(8)3(9)4(10)5(11)6(12)13;/h2-5,7-11H,1H2,(H,12,13);/q;+1/p-1/t2-,3-,4+,5-;/m1./s1
DMEY1AP IU potassium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
DMEY1AP CA CAS 299-27-4
DMEY1AP CB CHEBI:32032
DMEY1AP DE Essential hypertension
DM7C1AJ ID DM7C1AJ
DM7C1AJ DN HT-2157
DM7C1AJ HS Phase 1/2
DM7C1AJ SN HT-2157; 303149-14-6; SNAP 37889; UNII-WW4KZW83BX; WW4KZW83BX; HT 2157; CHEMBL210288; SNAP-37889; 1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1h-indol-2-one; 1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one; 1-Phenyl-3-((3-(trifluoromethyl)phenyl)imino)-1H-indol-2-one; SNAP37889; AC1LSUW9; UNII-J4DRJ9BFS1; UNII-EH5R4IAX6Q; J4DRJ9BFS1; EH5R4IAX6Q; Bionet1_002696; SCHEMBL916990; SCHEMBL8273294; GTPL6126; HMS576C18; MolPort-002-854-320; BDBM50187923; ZINC100301780; AKOS005078094; SNAP-37889, (E)-; CS-6094; HT-2157(SNAP37889)
DM7C1AJ CP Dart NeuroScience
DM7C1AJ DT Small molecular drug
DM7C1AJ PC 1471834
DM7C1AJ MW 366.3
DM7C1AJ FM C21H13F3N2O
DM7C1AJ IC InChI=1S/C21H13F3N2O/c22-21(23,24)14-7-6-8-15(13-14)25-19-17-11-4-5-12-18(17)26(20(19)27)16-9-2-1-3-10-16/h1-13H
DM7C1AJ CS C1=CC=C(C=C1)N2C3=CC=CC=C3C(=NC4=CC=CC(=C4)C(F)(F)F)C2=O
DM7C1AJ IK TXCGMRVPXUBHAL-UHFFFAOYSA-N
DM7C1AJ IU 1-phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
DM7C1AJ CA CAS 303149-14-6
DM7C1AJ DE Cognitive impairment
DMNHE43 ID DMNHE43
DMNHE43 DN HTU-PA
DMNHE43 HS Phase 1/2
DMNHE43 SN Human tissue urokinase type plasminogen activator, Global Biotech
DMNHE43 CP Global Biotech Inc
DMNHE43 DE Cerebrovascular ischaemia
DMIU1HY ID DMIU1HY
DMIU1HY DN HuM-195-Ac-225
DMIU1HY HS Phase 1/2
DMIU1HY SN HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab
DMIU1HY CP PDL BioPharma Inc
DMIU1HY DE Acute myeloid leukaemia; Acute myelogenous leukaemia
DMOVF6E ID DMOVF6E
DMOVF6E DN Humanized CD19 CAR-T cells
DMOVF6E HS Phase 1/2
DMOVF6E CP Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
DMOVF6E DT CAR T Cell Therapy
DMOVF6E DE Acute lymphoblastic leukaemia
DM7U458 ID DM7U458
DM7U458 DN IDX-184
DM7U458 HS Phase 1/2
DM7U458 SN B-102; B-184; B-299; IDX-102; Next-generation nucleotide polymerase inhibitors (HCV infection), Idenix; Next-generation nucleotide polymerase inhibitors (hepatitis C virus infection), Idenix; 2'-methyl guanosine prodrug (hepatitis C virus infection), Idenix
DM7U458 CP Idenix Pharmaceuticals Inc
DM7U458 DT Small molecular drug
DM7U458 PC 135565589
DM7U458 MW 626.6
DM7U458 FM C25H35N6O9PS
DM7U458 IC InChI=1S/C25H35N6O9PS/c1-24(2,13-32)22(35)42-10-9-38-41(37,28-11-15-7-5-4-6-8-15)39-12-16-18(33)25(3,36)21(40-16)31-14-27-17-19(31)29-23(26)30-20(17)34/h4-8,14,16,18,21,32-33,36H,9-13H2,1-3H3,(H,28,37)(H3,26,29,30,34)/t16-,18-,21-,25-,41?/m1/s1
DM7U458 CS C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(NCC4=CC=CC=C4)OCCSC(=O)C(C)(C)CO)O)O
DM7U458 IK FGHMGRXAHIXTBM-TWFJNEQDSA-N
DM7U458 IU S-[2-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate
DM7U458 CA CAS 1036915-08-8
DM7U458 DE Hepatitis C virus infection
DMLEVFW ID DMLEVFW
DMLEVFW DN IFN alpha kinoid
DMLEVFW HS Phase 1/2
DMLEVFW SN Antiferon; IFNa kinoid; IFN-K; Inactivated IFN alpha + keyhole limpet hemocyanin (SLE/HIV), Neovacs; Anti-interferonalpha (HIV/SLE), Neovacs/sanofi pasteur
DMLEVFW CP Neovacs SA
DMLEVFW DE Human immunodeficiency virus infection
DM1CG47 ID DM1CG47
DM1CG47 DN IL-2 XL
DM1CG47 HS Phase 1/2
DM1CG47 SN IL-2 XL (controlled release, Medusa); IL-2 XL (controlled release, Medusa), Flamel; Interleukin-2 (long-acting, Medusa), Flamel
DM1CG47 CP Flamel Technologies SA
DM1CG47 DE Renal cell carcinoma
DMJ9CY4 ID DMJ9CY4
DMJ9CY4 DN IL-2/gene-modified lymphocytes
DMJ9CY4 HS Phase 1/2
DMJ9CY4 CP National Cancer Institute
DMJ9CY4 DE Ovarian cancer
DMKV5D6 ID DMKV5D6
DMKV5D6 DN IM19 CAR-T
DMKV5D6 HS Phase 1/2
DMKV5D6 CP Beijing Immunochina Medical Science & Technology Co., Ltd.
DMKV5D6 DT CAR T Cell Therapy
DMKV5D6 DE leukaemia
DMHQ2U8 ID DMHQ2U8
DMHQ2U8 DN IMC-F106C
DMHQ2U8 HS Phase 1/2
DMHQ2U8 CP Immunocore
DMHQ2U8 DT Recombinant protein
DMHQ2U8 DE Solid tumour/cancer
DM09JOZ ID DM09JOZ
DM09JOZ DN ImMucin
DM09JOZ HS Phase 1/2
DM09JOZ SN MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical
DM09JOZ CP Hadassah Medical Organization
DM09JOZ DT Vaccine
DM09JOZ DE Multiple myeloma
DM18ZLW ID DM18ZLW
DM18ZLW DN IMP-321
DM18ZLW HS Phase 1/2
DM18ZLW SN Soluble CD223 (cancer), Immutep; Soluble LAG-3 (cancer), Immutep
DM18ZLW CP Immutep SA
DM18ZLW PC 72941955
DM18ZLW MW 1259.4
DM18ZLW FM C56H78N18O14S
DM18ZLW IC InChI=1S/C56H78N18O14S/c57-23-3-1-6-41(70-55(88)43(27-34-7-13-39(75)14-8-34)72-52(85)35-9-11-36(12-10-35)68-56(89)73-59)53(86)71-42(15-20-50(82)83)54(87)69-40(51(58)84)5-2-4-26-74(48(80)30-64-46(78)18-16-44(76)62-24-21-37-28-60-32-66-37)49(81)31-65-47(79)19-17-45(77)63-25-22-38-29-61-33-67-38/h7-14,28-29,32-33,40-43,75H,1-6,15-27,30-31,57,59H2,(H2,58,84)(H,60,66)(H,61,67)(H,62,76)(H,63,77)(H,64,78)(H,65,79)(H,69,87)(H,70,88)(H,71,86)(H,72,85)(H,82,83)(H2,68,73,89)/t40-,41-,42-,43-/m1/s1
DM18ZLW CS C1=CC(=CC=C1C[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC2=CN=CN2)C(=O)CNC(=O)CCC(=O)NCCC3=CN=CN3)C(=O)N)NC(=O)C4=CC=C(C=C4)NC(=S)NN)O
DM18ZLW IK ONKCBKDTKZIWHZ-MRWFHJSOSA-N
DM18ZLW IU (4R)-4-[[(2R)-6-amino-2-[[(2R)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2R)-1-amino-6-[bis[2-[[4-[2-(1H-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM18ZLW CA CAS 928150-91-8
DM18ZLW DE Allergy
DM43ICH ID DM43ICH
DM43ICH DN IMSA101
DM43ICH HS Phase 1/2
DM43ICH CP ImmuneSensor Therapeutics
DM43ICH DT Small molecular drug
DM43ICH DE Solid tumour/cancer
DMNHZS4 ID DMNHZS4
DMNHZS4 DN IMX-110
DMNHZS4 HS Phase 1/2
DMNHZS4 CP Immix Biopharma Los Angeles, CA
DMNHZS4 DE Solid tumour/cancer
DM8XN4A ID DM8XN4A
DM8XN4A DN INCAGN1876
DM8XN4A HS Phase 1/2
DM8XN4A CP Agenus Lexington, MA Incyte Wilmington, DE
DM8XN4A DE Solid tumour/cancer
DM7OE3X ID DM7OE3X
DM7OE3X DN INCAGN1949
DM7OE3X HS Phase 1/2
DM7OE3X CP Agenus Lexington, MA Incyte Wilmington, DE
DM7OE3X DE Solid tumour/cancer
DM8124R ID DM8124R
DM8124R DN INCB01158
DM8124R HS Phase 1/2
DM8124R SN CB-1158
DM8124R CP Calithera Biosciences; Incyte
DM8124R DE Solid tumour/cancer
DM7TZL0 ID DM7TZL0
DM7TZL0 DN INCB054329
DM7TZL0 HS Phase 1/2
DM7TZL0 SN 1628607-64-6; (S)-6-(3,5-dimethylisoxazol-4-yl)-3-(pyridin-2-yl)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylen-2(1H)-one; Q50825078; SCHEMBL16038298; INCB54329; US9624241, Example 14; BDBM318469; INCB-54329; EX-A3126; INCB-054329; NSC816024; s8753; NSC-816024; HY-112504; CS-0046160; INCB054329 pound INCB-054329,INCB-54329 pound(c); CC1=NOC(C)=C1C1=CC=C2C3=C1OC[C@H](C=1N=CC=CC=1)N3C(=O)N2; (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one
DM7TZL0 CP Incyte
DM7TZL0 DT Small molecular drug
DM7TZL0 PC 90410660
DM7TZL0 MW 348.4
DM7TZL0 FM C19H16N4O3
DM7TZL0 IC InChI=1S/C19H16N4O3/c1-10-16(11(2)26-22-10)12-6-7-14-17-18(12)25-9-15(23(17)19(24)21-14)13-5-3-4-8-20-13/h3-8,15H,9H2,1-2H3,(H,21,24)/t15-/m1/s1
DM7TZL0 CS CC1=C(C(=NO1)C)C2=C3C4=C(C=C2)NC(=O)N4[C@H](CO3)C5=CC=CC=N5
DM7TZL0 IK XYLPKCDRAAYATL-OAHLLOKOSA-N
DM7TZL0 IU (11S)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-11-pyridin-2-yl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-2-one
DM7TZL0 DE Solid tumour/cancer; Refractory hematologic malignancy
DMG65CV ID DMG65CV
DMG65CV DN INCB057643
DMG65CV HS Phase 1/2
DMG65CV SN INCB-057643; 1820889-23-3; UNII-87TZD0JEBS; 87TZD0JEBS; 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one; 2,2,4-Trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo(2,3-C)pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo(b)(1,4)oxazin-3(4H)-one; CHEMBL4594412; SCHEMBL17200525; US9957268, Example 75; BDBM391587; BCP29506; EX-A1908; NSC807398; s8714; NSC-807398; BS-16298; HY-111485; AK00799038; CS-0042192; INCB057643; INCB 057643; CC1(OC2=C(N(C1=O)C)C=C(C=C2C=2C1=C(C(N(C2)C)=O)NC=C1)S(=O)(=O)C)C; 2,2,4-trimethyl-8-(6-methyl-7- oxo-6,7-dihydro-1H- pyrrolo[2,3-c]pyridin-4-yl)-6- (methylsulfonyl)-2H-1,4- benzoxazin-3(4H)-one; 2H-1,4-Benzoxazin-3(4H)-one, 8-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)-2,2,4-trimethyl-6-(methylsulfonyl)-
DMG65CV CP Incyte
DMG65CV DT Small molecular drug
DMG65CV PC 118467751
DMG65CV MW 415.5
DMG65CV FM C20H21N3O5S
DMG65CV IC InChI=1S/C20H21N3O5S/c1-20(2)19(25)23(4)15-9-11(29(5,26)27)8-13(17(15)28-20)14-10-22(3)18(24)16-12(14)6-7-21-16/h6-10,21H,1-5H3
DMG65CV CS CC1(C(=O)N(C2=CC(=CC(=C2O1)C3=CN(C(=O)C4=C3C=CN4)C)S(=O)(=O)C)C)C
DMG65CV IK VZSAMEOETVNDQH-UHFFFAOYSA-N
DMG65CV IU 2,2,4-trimethyl-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-methylsulfonyl-1,4-benzoxazin-3-one
DMG65CV CA CAS 1820889-23-3
DMG65CV DE Solid tumour/cancer
DMED9QV ID DMED9QV
DMED9QV DN INCB40093
DMED9QV HS Phase 1/2
DMED9QV SN Dezapelisib; 1262440-25-4; UNII-2K59L7G59M; CHEMBL2216863; INCB040093; 2K59L7G59M; Dezapelisib (USAN); Dezapelisib [USAN]; (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; SCHEMBL975754; GTPL9728; INCB40093; RSIWALKZYXPAGW-NSHDSACASA-N; INCB 40093; BDBM50004547; SB18837; example 15 [WO2011008487]; compound 67 [PMID: 22924688]; D10924; 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one; 6-(3-fluorophenyl)-3-methyl-7-((1S)-1-(9
DMED9QV CP Incyte
DMED9QV DT Small molecular drug
DMED9QV PC 58111426
DMED9QV MW 421.5
DMED9QV FM C20H16FN7OS
DMED9QV IC InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1
DMED9QV CS CC1=CSC2=NC(=C(C(=O)N12)C3=CC(=CC=C3)F)[C@H](C)NC4=NC=NC5=C4NC=N5
DMED9QV IK RSIWALKZYXPAGW-NSHDSACASA-N
DMED9QV IU 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(7H-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one
DMED9QV CA CAS 1262440-25-4
DMED9QV DE Lymphoma
DMKMSP2 ID DMKMSP2
DMKMSP2 DN INCB53914
DMKMSP2 HS Phase 1/2
DMKMSP2 CP Incyte Wilmington, DE
DMKMSP2 DE Advanced malignancy
DMBGU7V ID DMBGU7V
DMBGU7V DN INCB57643
DMBGU7V HS Phase 1/2
DMBGU7V CP Incyte Wilmington, DE
DMBGU7V DE Advanced malignancy
DMRLV7G ID DMRLV7G
DMRLV7G DN INCB59872
DMRLV7G HS Phase 1/2
DMRLV7G CP IncyteWilmington, DE
DMRLV7G DE Acute myeloid leukaemia; Small-cell lung cancer
DMQO5UF ID DMQO5UF
DMQO5UF DN INCB62079
DMQO5UF HS Phase 1/2
DMQO5UF CP Incyte Wilmington, DE
DMQO5UF DE Liver cancer
DMKNA94 ID DMKNA94
DMKNA94 DN INO-8875
DMKNA94 HS Phase 1/2
DMKNA94 SN PJ-875; Adenosine A1 agonist (atrial fibrillation), Inotek; Adenosine A1 agonist (glaucoma), Inotek
DMKNA94 CP Inotek pharmaceuticals
DMKNA94 PC 11610599
DMKNA94 MW 380.36
DMKNA94 FM C15H20N6O6
DMKNA94 IC InChI=1S/C15H20N6O6/c22-11-9(5-26-21(24)25)27-15(12(11)23)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,22-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
DMKNA94 CS C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO[N+](=O)[O-])O)O
DMKNA94 IK AQLVRTWKJDTWQQ-SDBHATRESA-N
DMKNA94 IU [(2R,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl nitrate
DMKNA94 CA CAS 871108-05-3
DMKNA94 DE Glaucoma/ocular hypertension
DMMZSIB ID DMMZSIB
DMMZSIB DN Interferon alpha 5
DMMZSIB HS Phase 1/2
DMMZSIB SN Interferon alpha 5 (infection)
DMMZSIB CP Biotecnol SA
DMMZSIB DE Infectious disease
DM9PJZT ID DM9PJZT
DM9PJZT DN Ipamorelin
DM9PJZT HS Phase 1/2
DM9PJZT SN Ipamorelin [INN]; SCHEMBL18428173; DTXSID80168955; CI-304; 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide; 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide.; (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4H-imidazol-4-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide; 2-methylalanyl-L-histidyl-3-naphthalen-2-yl-D-alanyl-D-phenylalanyl-L-lysinamide, 2-Methylalanyl-L-histidyl-3-(2-naph
DM9PJZT CP Sapphire therapeutics
DM9PJZT DT Small molecular drug
DM9PJZT PC 9831659
DM9PJZT MW 711.9
DM9PJZT FM C38H49N9O5
DM9PJZT IC InChI=1S/C38H49N9O5/c1-38(2,41)37(52)47-32(21-28-22-42-23-43-28)36(51)46-31(20-25-15-16-26-12-6-7-13-27(26)18-25)35(50)45-30(19-24-10-4-3-5-11-24)34(49)44-29(33(40)48)14-8-9-17-39/h3-7,10-13,15-16,18,22-23,29-32H,8-9,14,17,19-21,39,41H2,1-2H3,(H2,40,48)(H,42,43)(H,44,49)(H,45,50)(H,46,51)(H,47,52)/t29-,30+,31+,32-/m0/s1
DM9PJZT CS CC(C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N
DM9PJZT IK NEHWBYHLYZGBNO-BVEPWEIPSA-N
DM9PJZT IU (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DM9PJZT CA CAS 170851-70-4
DM9PJZT DE Postoperative ileus
DM8E3N6 ID DM8E3N6
DM8E3N6 DN IPP-204106
DM8E3N6 HS Phase 1/2
DM8E3N6 SN NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique
DM8E3N6 CP Centre National de la Recherche Scientifique (CNRS)
DM8E3N6 DE Solid tumour/cancer
DMQ5EYJ ID DMQ5EYJ
DMQ5EYJ DN ISA-P53-01
DMQ5EYJ HS Phase 1/2
DMQ5EYJ SN P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals
DMQ5EYJ CP ISA Pharmaceuticals BV
DMQ5EYJ DT Vaccine
DMQ5EYJ DE Colorectal cancer
DM1WD8F ID DM1WD8F
DM1WD8F DN ISB 1302
DM1WD8F HS Phase 1/2
DM1WD8F CP Ichnos Sciences
DM1WD8F DT Antibody
DM1WD8F DE HER2-positive breast cancer
DMG107N ID DMG107N
DMG107N DN ISB 1342
DMG107N HS Phase 1/2
DMG107N SN GBR1342
DMG107N CP Ichnos Sciences
DMG107N DT Antibody
DMG107N DE Multiple myeloma
DMH32LC ID DMH32LC
DMH32LC DN ISIS-DMPK
DMH32LC HS Phase 1/2
DMH32LC DT Antisense drug
DMH32LC DE Myotonic dystrophy
DMDTNFB ID DMDTNFB
DMDTNFB DN ISIS-STAT3
DMDTNFB HS Phase 1/2
DMDTNFB CP ISIS Pharm
DMDTNFB DT Antisense drug
DMDTNFB DE Solid tumour/cancer
DMA41DO ID DMA41DO
DMA41DO DN Isunakinra
DMA41DO HS Phase 1/2
DMA41DO SN EBI-005
DMA41DO CP Buzzard Pharmaceuticals
DMA41DO DT Recombinant protein
DMA41DO DE Solid tumour/cancer
DM08TH3 ID DM08TH3
DM08TH3 DN ITI-214
DM08TH3 HS Phase 1/2
DM08TH3 CP Intra-Cellular; Takeda
DM08TH3 PC 42639643
DM08TH3 MW 507.6
DM08TH3 FM C29H26FN7O
DM08TH3 IC InChI=1S/C29H26FN7O/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21/h2-4,6-9,12-16,22-23,31H,5,10-11,17H2,1H3/t22-,23+/m1/s1
DM08TH3 CS CN1C(=O)C2=C(N(N=C2N3C1=N[C@H]4[C@@H]3CCC4)CC5=CC=C(C=C5)C6=NC(=CC=C6)F)NC7=CC=CC=C7
DM08TH3 IK BBIPVJCGIASXJB-PKTZIBPZSA-N
DM08TH3 IU (11R,15S)-5-anilino-4-[[4-(6-fluoropyridin-2-yl)phenyl]methyl]-8-methyl-1,3,4,8,10-pentazatetracyclo[7.6.0.02,6.011,15]pentadeca-2,5,9-trien-7-one
DM08TH3 CA CAS 1160521-50-5
DM08TH3 DE Schizophrenia; Complete androgen insensitivity syndrome; Immune dysregulation; Parkinson disease
DM3KXMG ID DM3KXMG
DM3KXMG DN IZONSTERIDE
DM3KXMG HS Phase 1/2
DM3KXMG SN Izonsteride < Prop INN; LY-320236; (4aR,10bR)-8-(4-Ethylbenzothiazol-2-ylsulfanyl)-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one
DM3KXMG DT Small molecular drug
DM3KXMG PC 172988
DM3KXMG MW 422.6
DM3KXMG FM C24H26N2OS2
DM3KXMG IC InChI=1S/C24H26N2OS2/c1-4-15-6-5-7-19-22(15)25-23(29-19)28-17-9-10-18-16(14-17)8-11-20-24(18,2)13-12-21(27)26(20)3/h5-7,9-10,14,20H,4,8,11-13H2,1-3H3/t20-,24-/m1/s1
DM3KXMG CS CCC1=C2C(=CC=C1)SC(=N2)SC3=CC4=C(C=C3)[C@]5(CCC(=O)N([C@@H]5CC4)C)C
DM3KXMG IK VMGWGDPZHXPFTC-HYBUGGRVSA-N
DM3KXMG IU (4aR,10bR)-8-[(4-ethyl-1,3-benzothiazol-2-yl)sulfanyl]-4,10b-dimethyl-2,4a,5,6-tetrahydro-1H-benzo[f]quinolin-3-one
DM3KXMG CA CAS 176975-26-1
DM3KXMG DE Hirsutism
DMNMV0D ID DMNMV0D
DMNMV0D DN JAB-3312
DMNMV0D HS Phase 1/2
DMNMV0D CP AbbVie; Jacobio Pharmaceuticals
DMNMV0D DT Small molecular drug
DMNMV0D DE Solid tumour/cancer
DMTMVEW ID DMTMVEW
DMTMVEW DN JCAR014
DMTMVEW HS Phase 1/2
DMTMVEW CP Fred Hutchinson Cancer Research Center
DMTMVEW DT CAR T Cell Therapy
DMTMVEW DE B-cell lymphoma; Mediastinal large B-cell lymphoma; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma; B-cell non-hodgkin lymphoma
DMJV2IF ID DMJV2IF
DMJV2IF DN JCAR017
DMJV2IF HS Phase 1/2
DMJV2IF CP Juno Therapeutics, Inc.
DMJV2IF DT CAR T Cell Therapy
DMJV2IF DE Mantle cell lymphoma; Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Multiple myeloma; Follicular lymphoma; Primary mediastinal B-cell lymphoma; leukaemia; B-cell non-hodgkin lymphoma
DM8P7FC ID DM8P7FC
DM8P7FC DN JCARH125
DM8P7FC HS Phase 1/2
DM8P7FC CP Juno Therapeutics, Inc.
DM8P7FC DT CAR T Cell Therapy
DM8P7FC DE Multiple myeloma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle cell lymphoma; Non-hodgkin lymphoma
DMD9X6U ID DMD9X6U
DMD9X6U DN JNJ-68284528
DMD9X6U HS Phase 1/2
DMD9X6U CP Janssen Research & Development, LLC
DMD9X6U DT CAR T Cell Therapy
DMD9X6U DE Multiple myeloma
DMGEZVF ID DMGEZVF
DMGEZVF DN JS016
DMGEZVF HS Phase 1/2
DMGEZVF SN LY-CoV016
DMGEZVF CP Lilly; Junshi Biosciences
DMGEZVF DT Antibody
DMGEZVF DE Coronavirus Disease 2019 (COVID-19)
DMELJDI ID DMELJDI
DMELJDI DN KAI-9803
DMELJDI HS Phase 1/2
DMELJDI SN DELCASERTIB; UNII-5G7N7E908H; 5G7N7E908H; KAI-9803; BMS-875944; Delcasertib [USAN:INN]; 949100-39-4; HY-106262; CS-0025460; L-Arginine, L-cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L- glutaminyl-L-arginyl-L-arginyl-, (1->1')-disulfide with L-cysteinyl-L-seryl-L-phenylalanyl-L- asparaginyl-L-seryl-L-tyrosyl-L-alpha-glutamyl-L-leucylglycyl-L-seryl-L-leucine; L-Cysteinyl-L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L- arginyl-L-arginyl-L-arginine (1->1')-d
DMELJDI CP KAI Pharma.
DMELJDI DT Small molecular drug
DMELJDI PC 56843747
DMELJDI MW 2880.3
DMELJDI FM C120H199N45O34S2
DMELJDI IC InChI=1S/C120H199N45O34S2/c1-61(2)48-80(96(179)145-55-92(174)148-86(56-166)110(193)163-85(114(198)199)49-62(3)4)159-106(189)78(37-39-93(175)176)156-107(190)83(52-65-30-34-67(170)35-31-65)161-112(195)88(58-168)165-109(192)84(53-90(126)172)162-108(191)82(50-63-18-6-5-7-19-63)160-111(194)87(57-167)164-95(178)69(124)60-201-200-59-68(123)94(177)158-81(51-64-28-32-66(169)33-29-64)97(180)146-54-91(173)147-70(22-12-42-139-115(127)128)98(181)149-71(20-8-10-40-121)99(182)150-72(21-9-11-41-122)100(183)151-73(23-13-43-140-116(129)130)101(184)152-75(25-15-45-142-118(133)134)103(186)155-77(36-38-89(125)171)105(188)154-74(24-14-44-141-117(131)132)102(185)153-76(26-16-46-143-119(135)136)104(187)157-79(113(196)197)27-17-47-144-120(137)138/h5-7,18-19,28-35,61-62,68-88,166-170H,8-17,20-27,36-60,121-124H2,1-4H3,(H2,125,171)(H2,126,172)(H,145,179)(H,146,180)(H,147,173)(H,148,174)(H,149,181)(H,150,182)(H,151,183)(H,152,184)(H,153,185)(H,154,188)(H,155,186)(H,156,190)(H,157,187)(H,158,177)(H,159,189)(H,160,194)(H,161,195)(H,162,191)(H,163,193)(H,164,178)(H,165,192)(H,175,176)(H,196,197)(H,198,199)(H4,127,128,139)(H4,129,130,140)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)(H4,137,138,144)/t68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-/m0/s1
DMELJDI CS CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)N)N
DMELJDI IK XPXZTVWPRKJTAA-PJKOMPQUSA-N
DMELJDI IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid
DMELJDI CA CAS 949100-39-4
DMELJDI DE Acute myocardial infarction
DM5U3IF ID DM5U3IF
DM5U3IF DN KB-004
DM5U3IF HS Phase 1/2
DM5U3IF SN Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios
DM5U3IF CP KaloBios Pharmaceuticals Inc
DM5U3IF DT Antibody
DM5U3IF DE Haematological malignancy
DMI9FXE ID DMI9FXE
DMI9FXE DN KBP-5074
DMI9FXE HS Phase 1/2
DMI9FXE CP KBP Biosciences Princeton, NJ
DMI9FXE PC 137796979
DMI9FXE MW 504
DMI9FXE FM C28H30ClN5O2
DMI9FXE IC InChI=1S/C28H30ClN5O2/c29-23-15-19(6-5-18(23)16-30)34-27(17-3-1-2-4-17)22-8-9-24-21(26(22)32-34)7-10-25(31-24)28(36)33-13-11-20(35)12-14-33/h5-7,10,15,17,20,22,27,35H,1-4,8-9,11-14H2/t22-,27+/m1/s1
DMI9FXE CS C1CCC(C1)[C@H]2[C@@H]3CCC4=C(C3=NN2C5=CC(=C(C=C5)C#N)Cl)C=CC(=N4)C(=O)N6CCC(CC6)O
DMI9FXE IK UXHQLGLGLZKHTC-AMGIVPHBSA-N
DMI9FXE IU 4-[(3S,3aS)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile
DMI9FXE DE Hypertension
DMZ416B ID DMZ416B
DMZ416B DN KD020
DMZ416B HS Phase 1/2
DMZ416B CP Kadmon pharmaceuticals
DMZ416B DE Kidney disease
DM0NZYC ID DM0NZYC
DM0NZYC DN KO-539
DM0NZYC HS Phase 1/2
DM0NZYC SN UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6
DM0NZYC CP Kura Oncology
DM0NZYC DT Small molecular drug
DM0NZYC PC 138497449
DM0NZYC MW 717.9
DM0NZYC FM C33H42F3N9O2S2
DM0NZYC IC InChI=1S/C33H42F3N9O2S2/c1-21(43-11-13-44(14-12-43)49(4,46)47)19-45-25(18-37)15-27-22(2)23(5-6-29(27)45)20-42-9-7-24(8-10-42)39-30-28-16-26(17-33(34,35)36)48-31(28)41-32(38-3)40-30/h5-6,15-16,21,24H,7-14,17,19-20H2,1-4H3,(H2,38,39,40,41)/t21-/m0/s1
DM0NZYC CS CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F
DM0NZYC IK BGGALFIXXQOTPY-NRFANRHFSA-N
DM0NZYC IU 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
DM0NZYC CA CAS 2134675-36-6
DM0NZYC DE Acute myeloid leukaemia
DML29RF ID DML29RF
DML29RF DN KP-100
DML29RF HS Phase 1/2
DML29RF CP Kinetek Pharmaceuticals Inc
DML29RF DE Type-1 diabetes
DMA5B1S ID DMA5B1S
DMA5B1S DN KRN-330
DMA5B1S HS Phase 1/2
DMA5B1S CP Kyowa Hakko Kirin Pharma
DMA5B1S DT Antibody
DMA5B1S DE Colorectal cancer
DME8JW1 ID DME8JW1
DME8JW1 DN KTE-C19 CAR
DME8JW1 HS Phase 1/2
DME8JW1 CP Kite pharma santa monica; national cancer institute
DME8JW1 DE Diffuse large B-cell lymphoma
DMXJ683 ID DMXJ683
DMXJ683 DN KY1044
DMXJ683 HS Phase 1/2
DMXJ683 CP Kymab
DMXJ683 DT Antibody
DMXJ683 DE Solid tumour/cancer
DMBEQ08 ID DMBEQ08
DMBEQ08 DN L-377202
DMBEQ08 HS Phase 1/2
DMBEQ08 SN N-[N-(4-Carboxybutyryl)-4(R)-hydroxy-L-prolyl-L-alanyl-L-seryl-L-cyclohexylglycyl-L-glutaminyl-L-seryl-L-leucyl]doxorubicin
DMBEQ08 DT Small molecular drug
DMBEQ08 PC 56842144
DMBEQ08 MW 1396.4
DMBEQ08 FM C65H89N9O25
DMBEQ08 IC InChI=1S/C65H89N9O25/c1-28(2)19-37(60(91)69-36-21-47(98-30(4)53(36)84)99-42-23-65(96,43(79)27-77)22-34-49(42)57(88)51-50(55(34)86)54(85)33-13-9-14-41(97-5)48(33)56(51)87)70-61(92)38(25-75)72-59(90)35(17-18-44(66)80)68-64(95)52(31-11-7-6-8-12-31)73-62(93)39(26-76)71-58(89)29(3)67-63(94)40-20-32(78)24-74(40)45(81)15-10-16-46(82)83/h9,13-14,28-32,35-40,42,47,52-53,75-78,84,86,88,96H,6-8,10-12,15-27H2,1-5H3,(H2,66,80)(H,67,94)(H,68,95)(H,69,91)(H,70,92)(H,71,89)(H,72,90)(H,73,93)(H,82,83)/t29-,30-,32?,35-,36-,37-,38-,39-,40-,42-,47-,52-,53+,65-/m0/s1
DMBEQ08 CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C6CCCCC6)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H]7CC(CN7C(=O)CCCC(=O)O)O)O
DMBEQ08 IK CZXGBIFEWYVYJY-ATFCTERFSA-N
DMBEQ08 IU 5-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-2-[[(2S)-5-amino-1-[[(2S)-3-hydroxy-1-[[(2S)-1-[[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-cyclohexyl-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-4-hydroxypyrrolidin-1-yl]-5-oxopentanoic acid
DMBEQ08 DE Solid tumour/cancer
DMFHV9L ID DMFHV9L
DMFHV9L DN Leber's congenital amaurosis gene therapy
DMFHV9L HS Phase 1/2
DMFHV9L SN LCA gene therapy, Applied Genetic Technologies; Leber's congenital amaurosis gene therapy, Applied Genetic Technologies; RAAV2-CB-hRPE65
DMFHV9L CP Applied Genetic Technologies Corp
DMFHV9L DE Visual disturbance; Leber congenital amaurosis
DMQN9ME ID DMQN9ME
DMQN9ME DN LGH-447
DMQN9ME HS Phase 1/2
DMQN9ME CP Novartis
DMQN9ME PC 44814409
DMQN9ME MW 440.5
DMQN9ME FM C24H23F3N4O
DMQN9ME IC InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
DMQN9ME CS C[C@H]1C[C@H](C[C@H](C1)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DMQN9ME IK VRQXRVAKPDCRCI-ZNMIVQPWSA-N
DMQN9ME IU N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DMQN9ME CA CAS 1210608-43-7
DMQN9ME DE Multiple myeloma
DMENF5K ID DMENF5K
DMENF5K DN Liatermin
DMENF5K HS Phase 1/2
DMENF5K SN RGDNF; GDNF, Amgen; Glial derived neurotrophic factor, Amgen/Medtronic
DMENF5K CP Amgen Inc
DMENF5K DE Lateral sclerosis
DMEMRW0 ID DMEMRW0
DMEMRW0 DN Lipoteichoic acid
DMEMRW0 HS Phase 1/2
DMEMRW0 SN Oncomycin; Lipoteichoic acid (cancer); Lipoteichoic acid (cancer), Lunamed; TLR-2 modulator (subcutaneous, solid tumor), LUNAMeD; Toll like receptor-2 modulator (subcutaneous, solid tumor), LUNAMeD
DMEMRW0 CP Lunamed Operations AG
DMEMRW0 PC 137349712
DMEMRW0 MW 775
DMEMRW0 FM C39H70N2O13
DMEMRW0 IC InChI=1S/C39H70N2O13/c1-5-7-9-11-12-13-14-15-16-17-18-20-22-31(45)52-28(24-49-30(44)21-19-10-8-6-2)25-50-39-36(48)37(34(46)29(23-42)53-39)54-38-33(41-27(4)43)35(47)32(40)26(3)51-38/h14-15,26,28-29,32-39,42,46-48H,5-13,16-25,40H2,1-4H3,(H,41,43)/b15-14+/t26-,28-,29-,32+,33-,34-,35+,36-,37+,38+,39+/m1/s1
DMEMRW0 CS CCCCCCC/C=C/CCCCCC(=O)O[C@@H](CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)C)N)O)NC(=O)C)O)COC(=O)CCCCCC
DMEMRW0 IK PANDRCFROUDETH-YLSOAJEOSA-N
DMEMRW0 IU [(2S)-1-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3-acetamido-5-amino-4-hydroxy-6-methyloxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-heptanoyloxypropan-2-yl] (E)-pentadec-7-enoate
DMEMRW0 CA CAS 56411-57-5
DMEMRW0 DE Solid tumour/cancer
DMGTB5N ID DMGTB5N
DMGTB5N DN LJM716
DMGTB5N HS Phase 1/2
DMGTB5N CP Novartis pharmaceuticals
DMGTB5N DT Antibody
DMGTB5N DE Breast cancer
DM095HQ ID DM095HQ
DM095HQ DN LM11A-31
DM095HQ HS Phase 1/2
DM095HQ SN N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide
DM095HQ CP PharmatrophiX Menlo Park, CA
DM095HQ DT Small molecular drug
DM095HQ PC 18604758
DM095HQ MW 243.35
DM095HQ FM C12H25N3O2
DM095HQ IC InChI=1S/C12H25N3O2/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15/h10-11H,3-9,13H2,1-2H3,(H,14,16)/t10-,11-/m0/s1
DM095HQ CS CC[C@H](C)[C@@H](C(=O)NCCN1CCOCC1)N
DM095HQ IK YNMUTYLWSRFTPX-QWRGUYRKSA-N
DM095HQ IU (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide
DM095HQ CA CAS 1243259-19-9
DM095HQ DE Alzheimer disease
DMCJ10K ID DMCJ10K
DMCJ10K DN LM11A-31
DMCJ10K HS Phase 1/2
DMCJ10K DE Alzheimer disease
DMW3QGJ ID DMW3QGJ
DMW3QGJ DN LM-94
DMW3QGJ HS Phase 1/2
DMW3QGJ SN Bilcolic; Bilicante; Hymecromone; Cantabilin; Cantabiline; Cholestil; Cholonerton; Coumarin 4; Crodimon; Cumarote-C; Eurogale; Himecromona; Hymecromon; Hymecromonum; Imecromone; Imecromone [DCIT]; Medilla; Mendiaxon; Omega 127; Pilot 447; Resocyanine; beta-Methylumbelliferone; 2H-1-Benzopyran-2-one, 7-hydroxy-4-methyl-; 4-MU; 4-Methyl-7-hydroxycoumarin; 4-Methylumbelliferon; 4-methylumbelliferone; 7-HYDROXY-4-METHYLCOUMARIN; 7-Hydroxy-4-methyl-2-oxo-2H-1-benzopyran; 7-Hydroxy-4-methyl-2H-chromen-2-one; 90-33-5; LM 94; NSC 19026; NSC 9408
DMW3QGJ PC 5280567
DMW3QGJ MW 176.17
DMW3QGJ FM C10H8O3
DMW3QGJ IC HSHNITRMYYLLCV-UHFFFAOYSA-N
DMW3QGJ CS CC1=CC(=O)OC2=C1C=CC(=C2)O
DMW3QGJ IK 1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3
DMW3QGJ IU 7-hydroxy-4-methylchromen-2-one
DMW3QGJ CA CAS 90-33-5
DMW3QGJ CB CHEBI:17224
DMW3QGJ DE Cholangitis
DMYGNDI ID DMYGNDI
DMYGNDI DN LMP1-CAR-T cells
DMYGNDI HS Phase 1/2
DMYGNDI CP The Second Hospital of Nanjing Medical University
DMYGNDI DT CAR T Cell Therapy
DMYGNDI DE Nasopharyngeal carcinoma
DMZNIAG ID DMZNIAG
DMZNIAG DN LS-172108
DMZNIAG HS Phase 1/2
DMZNIAG SN Tirilazad; Tirilazad (INN); LS-172108; PNU 74006F; RBKASMJPSJDQKY-RBFSKHHSSA-N; SCHEMBL483318; Tirilazad [INN:BAN]; Tirilazadum; Tirilazadum [INN-Latin]; U 74006; YD064E883I; ZINC43133316; tirilazad of tirilazad; 110101-66-1; 21-[4-(2,6-Di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methylpregna-1,4,9(11)-triene-3,20-dione; AC1L2XOZ; C38H52N6O2; CHEBI:135853; CHEMBL1630578; D08606; DB13050; Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)erazinyl)-16-methyl-, (16alpha)-; S048; UNII-YD064E883I
DMZNIAG PC 104903
DMZNIAG MW 624.9
DMZNIAG FM C38H52N6O2
DMZNIAG IC RBKASMJPSJDQKY-RBFSKHHSSA-N
DMZNIAG CS CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C
DMZNIAG IK 1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1
DMZNIAG IU (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
DMZNIAG CA CAS 110101-66-1
DMZNIAG CB CHEBI:135853
DMZNIAG DE Cerebral stroke
DM5N04G ID DM5N04G
DM5N04G DN LT-1951
DM5N04G HS Phase 1/2
DM5N04G SN Nona-arginine; Nona-l-arginine; UNII-PK7O6W0U44; 143413-47-2; PK7O6W0U44; (Arg)9; LT-1951; (Arg)9 peptide; H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH; DB12648; L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-
DM5N04G CP Lumen Therapeutics
DM5N04G PC 25077438
DM5N04G MW 1423.7
DM5N04G FM C54H110N36O10
DM5N04G IC InChI=1S/C54H110N36O10/c55-28(10-1-19-74-46(56)57)37(91)83-29(11-2-20-75-47(58)59)38(92)84-30(12-3-21-76-48(60)61)39(93)85-31(13-4-22-77-49(62)63)40(94)86-32(14-5-23-78-50(64)65)41(95)87-33(15-6-24-79-51(66)67)42(96)88-34(16-7-25-80-52(68)69)43(97)89-35(17-8-26-81-53(70)71)44(98)90-36(45(99)100)18-9-27-82-54(72)73/h28-36H,1-27,55H2,(H,83,91)(H,84,92)(H,85,93)(H,86,94)(H,87,95)(H,88,96)(H,89,97)(H,90,98)(H,99,100)(H4,56,57,74)(H4,58,59,75)(H4,60,61,76)(H4,62,63,77)(H4,64,65,78)(H4,66,67,79)(H4,68,69,80)(H4,70,71,81)(H4,72,73,82)/t28-,29-,30-,31-,32-,33-,34-,35-,36-/m0/s1
DM5N04G CS C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)CN=C(N)N
DM5N04G IK XUNKPNYCNUKOAU-VXJRNSOOSA-N
DM5N04G IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM5N04G CA CAS 143413-47-2
DM5N04G DE Coronary artery disease
DM2LYIN ID DM2LYIN
DM2LYIN DN LX-7101
DM2LYIN HS Phase 1/2
DM2LYIN CP Lexicon Pharmaceuticals Inc
DM2LYIN PC 56962369
DM2LYIN MW 451.5
DM2LYIN FM C23H29N7O3
DM2LYIN IC InChI=1S/C23H29N7O3/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27)
DM2LYIN CS CC1=CNC2=C1C(=NC=N2)N3CCC(CC3)(CN)C(=O)NC4=CC(=CC=C4)OC(=O)N(C)C
DM2LYIN IK PWPNYABQEOGNNC-UHFFFAOYSA-N
DM2LYIN IU [3-[[4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] N,N-dimethylcarbamate
DM2LYIN CA CAS 1192189-69-7
DM2LYIN DE Glaucoma/ocular hypertension
DM65MEL ID DM65MEL
DM65MEL DN LXS196
DM65MEL HS Phase 1/2
DM65MEL SN XXJXHXJWQSCNPX-UHFFFAOYSA-N; 1874276-76-2; LXS-196; NVP-LXS196; SCHEMBL17506262; CHEMBL3982723; LXS 196; BDBM251460; EX-A2690; BCP20781; ZINC584641445; CS-7529; HY-101569; US9452998, 9; 3-amino-N-(3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl)-6-(3-(trifluoromethyl)pyridin-2-yl)pyrazine-2-carboxamide
DM65MEL CP Novartis Oncology East Hanover, NJ
DM65MEL PC 118873253
DM65MEL MW 472.5
DM65MEL FM C22H23F3N8O
DM65MEL IC InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)
DM65MEL CS CC1(CCN(CC1)C2=C(N=CC=C2)NC(=O)C3=NC(=CN=C3N)C4=C(C=CC=N4)C(F)(F)F)N
DM65MEL IK XXJXHXJWQSCNPX-UHFFFAOYSA-N
DM65MEL IU 3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
DM65MEL CA CAS 1874276-76-2
DM65MEL DE Melanoma; Solid tumour/cancer
DMHXTNW ID DMHXTNW
DMHXTNW DN LY-2228820
DMHXTNW HS Phase 1/2
DMHXTNW SN Ralimetinib; 862505-00-8; LY-2228820 free base; UNII-73I34XW4HD; 73I34XW4HD; 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-Imidazo[4,5-b]pyridin-2-amine; C24H29FN6; Ralimetinib [USAN:INN]; LY2228820 free base; Ralimetinib (USAN/INN); GTPL7959; SCHEMBL3989306; SCHEMBL13826263; CHEMBL2364626; DTXSID00235456; MolPort-009-679-493; XPPBBJCBDOEXDN-UHFFFAOYSA-N; BCPP000180; BCP02033; ZINC34630490; ABP000309; 2526AH; ABP000548; AKOS027282678; SB16635; BCP9000871; DB11787; NCGC00346537-05; LY-2180895; LY-2211877; LY-2228820 mesylate; LY-2231377; LY-2322600; LY-479754; LY-22288202MsOH; P38 MAP kinase inhibitors (inflammation, cancer), Lilly
DMHXTNW CP Lilly
DMHXTNW DT Small molecular drug
DMHXTNW PC 11539025
DMHXTNW MW 420.5
DMHXTNW FM C24H29FN6
DMHXTNW IC InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)
DMHXTNW CS CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N
DMHXTNW IK XPPBBJCBDOEXDN-UHFFFAOYSA-N
DMHXTNW IU 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine
DMHXTNW CA CAS 862505-00-8
DMHXTNW DE Solid tumour/cancer
DMADEHZ ID DMADEHZ
DMADEHZ DN LY2880070
DMADEHZ HS Phase 1/2
DMADEHZ SN 1375637-35-6; SCHEMBL15124196; BCP32047; EX-A3339; ZINC199531075; LY 2880070 pound>>LY-2880070; (R)-[5-(2-Methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy) -pyrazin-2-yl]-amine; (R)-[5-(2-methoxy-6-methyl-pyridin-3-yl)-2H-pyrazol-3-yl]-[6-(piperidin-3-yloxy)-pyrazin-2-yl]-amine; N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine
DMADEHZ CP Esperas Pharma
DMADEHZ DT Small molecular drug
DMADEHZ PC 56968075
DMADEHZ MW 381.4
DMADEHZ FM C19H23N7O2
DMADEHZ IC InChI=1S/C19H23N7O2/c1-12-5-6-14(19(22-12)27-2)15-8-16(26-25-15)23-17-10-21-11-18(24-17)28-13-4-3-7-20-9-13/h5-6,8,10-11,13,20H,3-4,7,9H2,1-2H3,(H2,23,24,25,26)/t13-/m1/s1
DMADEHZ CS CC1=NC(=C(C=C1)C2=CC(=NN2)NC3=CN=CC(=N3)O[C@@H]4CCCNC4)OC
DMADEHZ IK LAEFIEWPUJMANC-CYBMUJFWSA-N
DMADEHZ IU N-[5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl]-6-[(3R)-piperidin-3-yl]oxypyrazin-2-amine
DMADEHZ DE Solid tumour/cancer
DMTJWIQ ID DMTJWIQ
DMTJWIQ DN LY2940680
DMTJWIQ HS Phase 1/2
DMTJWIQ SN LY2940680; 1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]
DMTJWIQ CP Lilly
DMTJWIQ DT Small molecular drug
DMTJWIQ PC 49848070
DMTJWIQ MW 512.5
DMTJWIQ FM C26H24F4N6O
DMTJWIQ IC InChI=1S/C26H24F4N6O/c1-34(25(37)20-8-7-16(27)15-21(20)26(28,29)30)17-10-13-36(14-11-17)24-19-6-4-3-5-18(19)23(32-33-24)22-9-12-31-35(22)2/h3-9,12,15,17H,10-11,13-14H2,1-2H3
DMTJWIQ CS CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F
DMTJWIQ IK SZBGQDXLNMELTB-UHFFFAOYSA-N
DMTJWIQ IU 4-fluoro-N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide
DMTJWIQ CA CAS 1258861-20-9
DMTJWIQ DE Solid tumour/cancer; Ovarian cancer
DM7T1CR ID DM7T1CR
DM7T1CR DN LY3016859
DM7T1CR HS Phase 1/2
DM7T1CR SN TGF-alpha.epiregulin mAb
DM7T1CR CP Eli lilly
DM7T1CR DE Chronic kidney disease
DMC5SAW ID DMC5SAW
DMC5SAW DN LY3039478
DMC5SAW HS Phase 1/2
DMC5SAW SN LY3039478; Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-
DMC5SAW CP Eli Lilly
DMC5SAW DT Small molecular drug
DMC5SAW PC 71236992
DMC5SAW MW 464.4
DMC5SAW FM C22H23F3N4O4
DMC5SAW IC InChI=1S/C22H23F3N4O4/c1-13(27-17(31)8-9-22(23,24)25)20(32)28-18-15-6-3-2-5-14(15)16-7-4-10-26-19(16)29(11-12-30)21(18)33/h2-7,10,13,18,30H,8-9,11-12H2,1H3,(H,27,31)(H,28,32)/t13-,18-/m0/s1
DMC5SAW CS C[C@@H](C(=O)N[C@H]1C2=CC=CC=C2C3=C(N=CC=C3)N(C1=O)CCO)NC(=O)CCC(F)(F)F
DMC5SAW IK YCBAQKQAINQRFW-UGSOOPFHSA-N
DMC5SAW IU 4,4,4-trifluoro-N-[(2S)-1-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide
DMC5SAW CA CAS 1421438-81-4
DMC5SAW DE Lymphoma; T-cell acute lymphoblastic leukaemia; Solid tumour/cancer
DM8RJTB ID DM8RJTB
DM8RJTB DN LY3295668
DM8RJTB HS Phase 1/2
DM8RJTB SN 1919888-06-4; (2R,4R)-1-(3-Chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid; AK-01; LY-3295668; (2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-({3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}methyl)-2-methylpiperidine-4-carboxylic acid; UNII-1WX8O5XV4R; 1WX8O5XV4R; SCHEMBL17747406; NSC816863; NSC-816863; Aurora A kinase inhibitor LY3295668; HY-114258; CS-0080775; LY3295668 (AK-01); A16869; (2R,4R)-1-[(3-Chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridyl]methyl]-2-methyl-piperidine-4-carboxylic acid; 1-((3-Chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2R,4R)-,4-piperidinecarboxylic acid; 4-Piperidinecarboxylic acid, 1-((3-chloro-2-fluorophenyl)methyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyridinyl)methyl)-2-methyl-, (2R,4R)-; EG7
DM8RJTB CP Eli Lilly
DM8RJTB DT Small molecular drug
DM8RJTB PC 121333423
DM8RJTB MW 489.9
DM8RJTB FM C24H26ClF2N5O2
DM8RJTB IC InChI=1S/C24H26ClF2N5O2/c1-14-10-21(31-30-14)29-20-7-6-18(26)19(28-20)12-24(23(33)34)8-9-32(15(2)11-24)13-16-4-3-5-17(25)22(16)27/h3-7,10,15H,8-9,11-13H2,1-2H3,(H,33,34)(H2,28,29,30,31)/t15-,24-/m1/s1
DM8RJTB CS C[C@@H]1C[C@](CCN1CC2=C(C(=CC=C2)Cl)F)(CC3=C(C=CC(=N3)NC4=NNC(=C4)C)F)C(=O)O
DM8RJTB IK YQQZZYYQTCPEAS-OYLFLEFRSA-N
DM8RJTB IU (2R,4R)-1-[(3-chloro-2-fluorophenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl]methyl]-2-methylpiperidine-4-carboxylic acid
DM8RJTB CA CAS 1919888-06-4
DM8RJTB DE Solid tumour/cancer
DMA1CSR ID DMA1CSR
DMA1CSR DN LY3499446
DMA1CSR HS Phase 1/2
DMA1CSR DT Small molecular drug
DMA1CSR DE Solid tumour/cancer
DMK2L38 ID DMK2L38
DMK2L38 DN M3814
DMK2L38 HS Phase 1/2
DMK2L38 SN MOWXJLUYGFNTAL-DEOSSOPVSA-N; M-3814; 1637542-33-6; M-3814(nedisertib); nedisertib (proposed INN); UNII-GN429E725A; GTPL9766; SCHEMBL16235559; GN429E725A; MSC2490484A; EX-A1679; example 136 [WO2014183850]; HY-101570; CS-0021723; (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol
DMK2L38 CP EMD Serono Rockland, MA
DMK2L38 PC 86292849
DMK2L38 MW 481.9
DMK2L38 FM C24H21ClFN5O3
DMK2L38 IC InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3/t24-/m0/s1
DMK2L38 CS COC1=NN=C(C=C1)[C@H](C2=C(C=C(C(=C2)C3=NC=NC4=C3C=CC(=C4)N5CCOCC5)F)Cl)O
DMK2L38 IK MOWXJLUYGFNTAL-DEOSSOPVSA-N
DMK2L38 IU (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol
DMK2L38 CA CAS 1637542-33-6
DMK2L38 DE Solid tumour/cancer; Locally advanced rectal cancer
DMIRG15 ID DMIRG15
DMIRG15 DN MaC46/M87o
DMIRG15 HS Phase 1/2
DMIRG15 SN HIV-1 infection gene therapy, Georg-Speyer-Haus
DMIRG15 CP Takara bio
DMIRG15 DE Human immunodeficiency virus-1 infection
DM6H3YS ID DM6H3YS
DM6H3YS DN MAGE-A10 TCR
DM6H3YS HS Phase 1/2
DM6H3YS CP Adaptimmune Philadelphia, PA
DM6H3YS DE Bladder cancer; Head and neck cancer; Melanoma; Merkel cell carcinoma
DMFK5IX ID DMFK5IX
DMFK5IX DN MAK683
DMFK5IX HS Phase 1/2
DMFK5IX SN XLIBABIFOBYHSV-UHFFFAOYSA-N; EED inhibitor-1; 1951408-58-4; MAK-683; N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine; SCHEMBL17841485; EX-A1723; BCP29116; ACN-053195; CS-8054; AC-30344; HY-103663
DMFK5IX CP Novartis Oncology East Hanover, NJ
DMFK5IX PC 121412508
DMFK5IX MW 376.4
DMFK5IX FM C20H17FN6O
DMFK5IX IC InChI=1S/C20H17FN6O/c1-12-13(3-2-7-22-12)16-10-24-20(27-11-25-26-19(16)27)23-9-15-14-6-8-28-18(14)5-4-17(15)21/h2-5,7,10-11H,6,8-9H2,1H3,(H,23,24)
DMFK5IX CS CC1=C(C=CC=N1)C2=CN=C(N3C2=NN=C3)NCC4=C(C=CC5=C4CCO5)F
DMFK5IX IK XLIBABIFOBYHSV-UHFFFAOYSA-N
DMFK5IX IU N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine
DMFK5IX CA CAS 1951408-58-4
DMFK5IX DE Diffuse large B-cell lymphoma
DMBZ68C ID DMBZ68C
DMBZ68C DN MALP-2S
DMBZ68C HS Phase 1/2
DMBZ68C CP MBiotec GmbH
DMBZ68C DE Pancreatic cancer
DMH0ROP ID DMH0ROP
DMH0ROP DN Maltose
DMH0ROP HS Phase 1/2
DMH0ROP SN beta-maltose; Maltobiose; Maltose, pure; Advanctose 100; 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranose; Cextromaltose; Maltodiose; Finetose; Sunmalt; Malt sugar; Finetose F; Sunmalt S; UNII-R4B6462NGR; D-Glucose, 4-O-alpha-D-glucopyranosyl-; AI3-09089; EINECS 200-716-5; BRN 0093798; 4-O-alpha-D-Glucopyranosyl-D-glucose; R4B6462NGR; 4-(alpha-D-Glucosido)-D-glucose; CHEBI:18147; beta-D-Cellobiose; GUBGYTABKSRVRQ-QUYVBRFLSA-N; beta-D-glucopyranose, 4-O-alpha-D-glucopyranosyl-
DMH0ROP DT Small molecular drug
DMH0ROP PC 6255
DMH0ROP MW 342.3
DMH0ROP FM C12H22O11
DMH0ROP IC InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9-,10-,11-,12-/m1/s1
DMH0ROP CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
DMH0ROP IK GUBGYTABKSRVRQ-QUYVBRFLSA-N
DMH0ROP IU (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMH0ROP CA CAS 133-99-3
DMH0ROP CB CHEBI:18147
DMXU7P6 ID DMXU7P6
DMXU7P6 DN MB-CART20.1
DMXU7P6 HS Phase 1/2
DMXU7P6 CP Miltenyi Biotec GmbH
DMXU7P6 DT CAR T Cell Therapy
DMXU7P6 DE Non-hodgkin lymphoma
DMS19IH ID DMS19IH
DMS19IH DN MBO7133
DMS19IH HS Phase 1/2
DMS19IH CP Metabasis Therapeutics Inc
DMS19IH DE Liver cancer
DMTCADJ ID DMTCADJ
DMTCADJ DN McN3377
DMTCADJ HS Phase 1/2
DMTCADJ SN Fenobamum; Fenobam (TN); Fenobamum [INN-Latin]; McN-3377; NPL-2009; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea; N-(3-Chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea; 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4H-imidazol-2-yl)urea
DMTCADJ CP McNeil Laboratories
DMTCADJ TC Psychiatric
DMTCADJ DT Small molecular drug
DMTCADJ PC 162834
DMTCADJ DE Fragile X syndrome
DM6JN19 ID DM6JN19
DM6JN19 DN ME-344
DM6JN19 HS Phase 1/2
DM6JN19 SN NV-128; NV-344; MTOR inhibitor (cancer), Novogen; MTOR inhibitors (cancer), Marshall Edwards
DM6JN19 CP Mei pharma
DM6JN19 DT Small molecular drug
DM6JN19 PC 68026984
DM6JN19 MW 348.4
DM6JN19 FM C22H20O4
DM6JN19 IC InChI=1S/C22H20O4/c1-13-20(25)11-10-18-21(15-4-8-17(24)9-5-15)19(12-26-22(13)18)14-2-6-16(23)7-3-14/h2-11,19,21,23-25H,12H2,1H3/t19-,21-/m0/s1
DM6JN19 CS CC1=C(C=CC2=C1OC[C@H]([C@H]2C3=CC=C(C=C3)O)C4=CC=C(C=C4)O)O
DM6JN19 IK QVCAATSEPLQVBX-FPOVZHCZSA-N
DM6JN19 IU (3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol
DM6JN19 CA CAS 1374524-68-1
DM6JN19 DE Solid tumour/cancer; Breast cancer
DMMB5CV ID DMMB5CV
DMMB5CV DN Medusa IL-2
DMMB5CV HS Phase 1/2
DMMB5CV CP Flamel Technol
DMMB5CV TC Anticancer Agents
DMMB5CV DE Solid tumour/cancer
DMJVFK7 ID DMJVFK7
DMJVFK7 DN Meplazumab
DMJVFK7 HS Phase 1/2
DMJVFK7 SN Mepolizumab
DMJVFK7 TC Antiviral Agents
DMJVFK7 DT Monoclonal antibody
DMJVFK7 DE Coronavirus Disease 2019 (COVID-19)
DMENFD6 ID DMENFD6
DMENFD6 DN Metelimumab
DMENFD6 HS Phase 1/2
DMENFD6 SN CAT-192; SL15A-IgG4; Anti-TGF beta 1 antibodies, Genzyme General/Cambridge Antibody Technologies
DMENFD6 CP Cambridge Antibody Technology Group plc; MedImmune
DMENFD6 DT Antibody
DMENFD6 DE Scleroderma
DME6PB0 ID DME6PB0
DME6PB0 DN MG7-CART
DME6PB0 HS Phase 1/2
DME6PB0 CP Xijing Hospital
DME6PB0 DT CAR T Cell Therapy
DME6PB0 DE Acute myeloid leukaemia
DM1KZW0 ID DM1KZW0
DM1KZW0 DN MGC018
DM1KZW0 HS Phase 1/2
DM1KZW0 CP MacroGenics
DM1KZW0 DT Antibody drug conjugate
DM1KZW0 DE Solid tumour/cancer
DMAHWLR ID DMAHWLR
DMAHWLR DN MGD007
DMAHWLR HS Phase 1/2
DMAHWLR CP MacroGenics
DMAHWLR DT Monoclonal antibody
DMAHWLR DE Metastatic colorectal cancer; Colorectal cancer
DMCVMUL ID DMCVMUL
DMCVMUL DN MGD013
DMCVMUL HS Phase 1/2
DMCVMUL CP MacroGenics Rockville, MD
DMCVMUL DT Antibody
DMCVMUL DE Solid tumour/cancer; Hematologic tumour; Hepatocellular carcinoma
DM4H7UY ID DM4H7UY
DM4H7UY DN Milatuzumab
DM4H7UY HS Phase 1/2
DM4H7UY CP Immunomedics
DM4H7UY DT Antibody
DM4H7UY DE Chronic lymphocytic leukaemia; Systemic lupus erythematosus
DM25QKC ID DM25QKC
DM25QKC DN MK-1308
DM25QKC HS Phase 1/2
DM25QKC SN Quavonlimab
DM25QKC CP Merck
DM25QKC DT Antibody
DM25QKC DE Solid tumour/cancer
DM21WBH ID DM21WBH
DM21WBH DN MK-2461
DM21WBH HS Phase 1/2
DM21WBH SN MK 2461
DM21WBH DT Small molecular drug
DM21WBH PC 44137946
DM21WBH MW 495.6
DM21WBH FM C24H25N5O5S
DM21WBH IC InChI=1S/C24H25N5O5S/c1-28-13-18(12-26-28)17-9-22-23(25-11-17)6-4-16-3-5-19(10-21(16)24(22)30)27-35(31,32)29(2)14-20-15-33-7-8-34-20/h3-6,9-13,20,27H,7-8,14-15H2,1-2H3/t20-/m1/s1
DM21WBH CS CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)NS(=O)(=O)N(C)C[C@@H]5COCCO5)N=C2
DM21WBH IK JGEBLDKNWBUGRZ-HXUWFJFHSA-N
DM21WBH IU 14-[[[(2R)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
DM21WBH CA CAS 917879-39-1
DM21WBH DE Alzheimer disease
DMCVBQD ID DMCVBQD
DMCVBQD DN MLN1117
DMCVBQD HS Phase 1/2
DMCVBQD CP Takeda
DMCVBQD PC 70798655
DMCVBQD MW 363.4
DMCVBQD FM C19H17N5O3
DMCVBQD IC InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)
DMCVBQD CS C1COCCN1C(=O)C2=CN=C3N2C=C(C=C3)C4=CC5=C(C=C4)OC(=N5)N
DMCVBQD IK BLGWHBSBBJNKJO-UHFFFAOYSA-N
DMCVBQD IU [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone
DMCVBQD CA CAS 1268454-23-4
DMCVBQD DE Solid tumour/cancer
DMGC96P ID DMGC96P
DMGC96P DN MLN-2704
DMGC96P HS Phase 1/2
DMGC96P SN MLN-5591DM1; MLN-591DM1; ATG-J591: DM1
DMGC96P CP Millennium Pharmaceuticals
DMGC96P DT Antibody
DMGC96P DE Prostate cancer
DMG7XHE ID DMG7XHE
DMG7XHE DN Monalizumab
DMG7XHE HS Phase 1/2
DMG7XHE SN IPH2201
DMG7XHE CP AstraZeneca; Innate Pharma
DMG7XHE DT Antibody
DMG7XHE DE Chronic lymphocytic leukaemia; Solid tumour/cancer; Head and neck cancer
DMXVIQN ID DMXVIQN
DMXVIQN DN MOR-103
DMXVIQN HS Phase 1/2
DMXVIQN SN MOR-04357; Antibody (inflammation), MorphoSys; GM-CSF antibody (rheumatoid arthritis), MorphoSys; MOR-103 (rheumatoid arthritis), MorphoSys; GM-CSF antibody (iv infusion, inflammation), MorphoSys/Galapagos
DMXVIQN CP Glaxosmithkline
DMXVIQN DT Antibody
DMXVIQN DE Multiple sclerosis
DMR8AHJ ID DMR8AHJ
DMR8AHJ DN MOR-202
DMR8AHJ HS Phase 1/2
DMR8AHJ SN Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys
DMR8AHJ CP Celgene summit; nj morphosys
DMR8AHJ DT Antibody
DMR8AHJ DE Multiple myeloma
DMR3VCY ID DMR3VCY
DMR3VCY DN MP0250
DMR3VCY HS Phase 1/2
DMR3VCY CP Molecular Partners Zurich, Switzerland
DMR3VCY DE Non-small-cell lung cancer
DME7PBN ID DME7PBN
DME7PBN DN mRNA-3704
DME7PBN HS Phase 1/2
DME7PBN CP Moderna Therapeutics
DME7PBN DT mRNA therapy
DME7PBN DE Methylmalonic acidemia
DM35YFC ID DM35YFC
DM35YFC DN MS-1819
DM35YFC HS Phase 1/2
DM35YFC SN Recombinant lipase (exocrine pancreatic insufficiency), Laboratoires Mayoly Spindler
DM35YFC CP Laboratoires Mayoly Spindler
DM35YFC PC 3613823
DM35YFC MW 277.4
DM35YFC FM C16H23NOS
DM35YFC IC InChI=1S/C16H23NOS/c1-16(2,3)14-6-4-13(5-7-14)12-18-17-15-8-10-19-11-9-15/h4-7H,8-12H2,1-3H3
DM35YFC CS CC(C)(C)C1=CC=C(C=C1)CON=C2CCSCC2
DM35YFC IK QKZIKPBOHKELOB-UHFFFAOYSA-N
DM35YFC IU N-[(4-tert-butylphenyl)methoxy]thian-4-imine
DM35YFC DE Exocrine pancreatic insufficiency
DMIS75V ID DMIS75V
DMIS75V DN MTL-CEPBA
DMIS75V HS Phase 1/2
DMIS75V CP MiNA Therapeutics
DMIS75V DT Small activating RNA
DMIS75V DE Hepatocellular carcinoma
DMFUDHM ID DMFUDHM
DMFUDHM DN MUC-1 CART cell immunotherapy
DMFUDHM HS Phase 1/2
DMFUDHM CP Second Affiliated Hospital, School of Medicine, Zhejiang University
DMFUDHM DT CAR T Cell Therapy
DMFUDHM DE Intrahepatic cholangiocarcinoma
DMPNR0J ID DMPNR0J
DMPNR0J DN Muc1-specific gene-engineered T cells
DMPNR0J HS Phase 1/2
DMPNR0J CP Shenzhen Geno-Immune Medical Institute
DMPNR0J DT CAR T Cell Therapy
DMPNR0J DE Acute myeloid leukaemia
DMU6MJ1 ID DMU6MJ1
DMU6MJ1 DN NAHE-001
DMU6MJ1 HS Phase 1/2
DMU6MJ1 SN Interferon alpha 5 modulator (HCV infection), Digna Biotech
DMU6MJ1 CP Digna Biotech SL
DMU6MJ1 DE Hepatitis C virus infection
DM5O4GR ID DM5O4GR
DM5O4GR DN NB1011
DM5O4GR HS Phase 1/2
DM5O4GR SN Thymectacin; BVDU prodrug; NB1011; UNII-2ZRZ4TSW3F; 2ZRZ4TSW3F; 5-(2-Bromovinyl)-2'-deoxy-5'-uridyl-phenyl-alanylphosphoramidate, trans-; (E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl phenyl L-methoxyalaninylphosphoramidate; L-Alanine, N-(5-((1E)-2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl)-, methyl ester; E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(L-methylalaninyl)-phenylphosphoramidate; 232925-18-7; Brivudine phosphoramidate; AC1O5U63; SCHEMBL13904642; DTXSID00177862; NB-1011; NB 1011; DB05116; LS-181955; J3.616.614B; methyl (2S)-2
DM5O4GR DT Small molecular drug
DM5O4GR PC 6440764
DM5O4GR MW 574.3
DM5O4GR FM C21H25BrN3O9P
DM5O4GR IC InChI=1S/C21H25BrN3O9P/c1-13(20(28)31-2)24-35(30,34-15-6-4-3-5-7-15)32-12-17-16(26)10-18(33-17)25-11-14(8-9-22)19(27)23-21(25)29/h3-9,11,13,16-18,26H,10,12H2,1-2H3,(H,24,30)(H,23,27,29)/b9-8+/t13-,16-,17+,18+,35?/m0/s1
DM5O4GR CS C[C@@H](C(=O)OC)NP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)/C=C/Br)O)OC3=CC=CC=C3
DM5O4GR IK CFBLUORPOFELCE-BACVZHSASA-N
DM5O4GR IU methyl (2S)-2-[[[(2R,3S,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
DM5O4GR CA CAS 232925-18-7
DM5O4GR DE Breast cancer
DMTAODR ID DMTAODR
DMTAODR DN NBE-002
DMTAODR HS Phase 1/2
DMTAODR CP NBE-Therapeutics
DMTAODR DT Antibody drug conjugate
DMTAODR DE Solid tumour/cancer
DMZSIV1 ID DMZSIV1
DMZSIV1 DN NC410
DMZSIV1 HS Phase 1/2
DMZSIV1 CP NextCure
DMZSIV1 DT Recombinant protein
DMZSIV1 DE Solid tumour/cancer
DMCDQX0 ID DMCDQX0
DMCDQX0 DN ND-0801
DMCDQX0 HS Phase 1/2
DMCDQX0 CP NeuroDerm Ltd
DMCDQX0 DE Attention deficit hyperactivity disorder
DMPMF6L ID DMPMF6L
DMPMF6L DN Nepadutant
DMPMF6L HS Phase 1/2
DMPMF6L SN MEN 11420; LS-55819; AC1MJ6M2; SCHEMBL1649325; GTPL2123; Cyclo(N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparginyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl), cyclic(2-5)-peptide; (2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid; Nepadutant [INN]; MEN-11,420; Cyclo(Asn(2-deoxy-2-AcNH-beta-D-Glc)-Asp-Trp-Phe-Dap-Leu)cyclo(2beta,5beta); Cyclo(N-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-asparaginyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-2,3-diaminopropionyl-L-leucyl),cyclic(2-5)-peptide
DMPMF6L CP Menarini
DMPMF6L DT Small molecular drug
DMPMF6L PC 3086682
DMPMF6L MW 965
DMPMF6L FM C45H60N10O14
DMPMF6L IC InChI=1S/C45H60N10O14/c1-21(2)13-31(45(67)68)53-43(66)32-19-48-34(58)17-30(50-39(62)26(46)16-35(59)55-44-36(49-22(3)57)38(61)37(60)33(20-56)69-44)42(65)52-29(15-24-18-47-27-12-8-7-11-25(24)27)41(64)51-28(40(63)54-32)14-23-9-5-4-6-10-23/h4-12,18,21,26,28-33,36-38,44,47,56,60-61H,13-17,19-20,46H2,1-3H3,(H,48,58)(H,49,57)(H,50,62)(H,51,64)(H,52,65)(H,53,66)(H,54,63)(H,55,59)(H,67,68)/t26-,28-,29-,30-,31-,32-,33+,36+,37+,38+,44+/m0/s1
DMPMF6L CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(=O)N[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)NC(=O)C)N
DMPMF6L IK NPSVXOVMLVOMDD-SXRVEDALSA-N
DMPMF6L IU (2S)-2-[[(3S,6S,9S,12S)-12-[[(2S)-4-[[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoyl]amino]-6-benzyl-9-(1H-indol-3-ylmethyl)-5,8,11,14-tetraoxo-1,4,7,10-tetrazacyclotetradecane-3-carbonyl]amino]-4-methylpentanoic acid
DMPMF6L DE Postoperative ileus; Infantile colics
DMXKOUC ID DMXKOUC
DMXKOUC DN Neu-120
DMXKOUC HS Phase 1/2
DMXKOUC SN Neu-108; NMDA receptor modulators (Parkinson's Disease), Neurim
DMXKOUC CP Neurim Pharmaceuticals
DMXKOUC DE Parkinson disease
DMEOLVP ID DMEOLVP
DMEOLVP DN NI-0401
DMEOLVP HS Phase 1/2
DMEOLVP SN Anti-CD3 antibody, NovImmune/Merck Serono
DMEOLVP CP NovImmune
DMEOLVP DT Antibody
DMEOLVP DE Autoimmune diabetes
DMMOA2X ID DMMOA2X
DMMOA2X DN Nikkomycin Z
DMMOA2X HS Phase 1/2
DMMOA2X SN SP-920704
DMMOA2X CP Bayer AG
DMMOA2X DT Small molecular drug
DMMOA2X PC 456557
DMMOA2X MW 495.4
DMMOA2X FM C20H25N5O10
DMMOA2X IC InChI=1S/C20H25N5O10/c1-7(13(28)9-3-2-8(26)6-22-9)11(21)17(31)24-12(19(32)33)16-14(29)15(30)18(35-16)25-5-4-10(27)23-20(25)34/h2-7,11-16,18,26,28-30H,21H2,1H3,(H,24,31)(H,32,33)(H,23,27,34)/t7-,11-,12-,13-,14-,15+,16+,18+/m0/s1
DMMOA2X CS C[C@H]([C@@H](C1=NC=C(C=C1)O)O)[C@@H](C(=O)N[C@@H]([C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)C(=O)O)N
DMMOA2X IK WWJFFVUVFNBJTN-VHDFTHOZSA-N
DMMOA2X IU (2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid
DMMOA2X CA CAS 59456-70-1
DMMOA2X CB CHEBI:623918
DMMOA2X DE Candidiasis
DM7SMNJ ID DM7SMNJ
DM7SMNJ DN NKTR-255
DM7SMNJ HS Phase 1/2
DM7SMNJ CP Nektar Therapeutics
DM7SMNJ DE Colorectal cancer; Head and neck cancer
DMYR8LF ID DMYR8LF
DMYR8LF DN NKTR-262
DMYR8LF HS Phase 1/2
DMYR8LF CP Nektar Therapeutics
DMYR8LF DE Solid tumour/cancer; Melanoma
DMDNJP5 ID DMDNJP5
DMDNJP5 DN NM21-1480
DMDNJP5 HS Phase 1/2
DMDNJP5 CP Numab Therapeutics
DMDNJP5 DT Antibody
DMDNJP5 DE Advanced solid tumour; Non-small cell lung cancer
DMDASRW ID DMDASRW
DMDASRW DN Norleucine
DMDASRW HS Phase 1/2
DMDASRW SN L-Norleucine; 327-57-1; H-Nle-OH; NORLEUCINE; (S)-2-Aminohexanoic acid; Glycoleucine; Caprine; L-(+)-Norleucine; L-2-Aminohexanoic acid; 2-Aminocaproic acid; L-2-Aminohexanoate; L-Aminohexanoate; alpha-Aminocaproic acid; (2S)-2-aminohexanoic acid; (S)-(+)-2-Aminohexanoic acid; Norleucine (VAN); L-Aminohexanoic acid; Hexanoic acid, 2-amino-, (S)-; 2S-amino-hexanoic acid; (S)-2-Aminocaproic acid; (S)-Norleucine; NSC 10378; L(+)-Norleucine; UNII-832C8OV84S; EINECS 206-321-4; BRN 1721750; NLE; CHEBI:18347; LRQKBLKVPFOOQJ-YFKPBYRVSA-N
DMDASRW DT Small molecular drug
DMDASRW PC 21236
DMDASRW MW 131.17
DMDASRW FM C6H13NO2
DMDASRW IC InChI=1S/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
DMDASRW CS CCCC[C@@H](C(=O)O)N
DMDASRW IK LRQKBLKVPFOOQJ-YFKPBYRVSA-N
DMDASRW IU (2S)-2-aminohexanoic acid
DMDASRW CA CAS 327-57-1
DMDASRW CB CHEBI:18347
DM78KMT ID DM78KMT
DM78KMT DN NPB-001-056
DM78KMT HS Phase 1/2
DM78KMT SN KM-80; NPB-001-05; Bcr-abl kinase inhibitor (oral, cancer), Piramal Life Sciences; Bcr-abl kinase inhibitor(oral, cancer), NPIL Research & Development
DM78KMT CP Piramal Healthcare Ltd
DM78KMT DE Chronic myelogenous leukaemia
DMU9BCD ID DMU9BCD
DMU9BCD DN NS-018
DMU9BCD HS Phase 1/2
DMU9BCD SN NS-018; ilginatinib; 1239358-86-1; UNII-56R994WX4L; 56R994WX4L; GTPL7839; SCHEMBL14954406; UQTPDWDAYHAZNT-AWEZNQCLSA-N; NS018; ZINC68245917; HY-19631A; AKOS030526348; DB12784; CS-5358; SB16921; 2,6-Pyridinediamine, N2-((1S)-1-(4-fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-; (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2yl)pyridine-2,6-diamine; (S)-N-(1-(4-Fluorophenyl)ethyl)-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine
DMU9BCD CP Nippon Shinyaku
DMU9BCD DT Small molecular drug
DMU9BCD PC 46866319
DMU9BCD MW 389.4
DMU9BCD FM C21H20FN7
DMU9BCD IC InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)/t14-/m0/s1
DMU9BCD CS C[C@@H](C1=CC=C(C=C1)F)NC2=CC(=CC(=N2)NC3=NC=CN=C3)C4=CN(N=C4)C
DMU9BCD IK UQTPDWDAYHAZNT-AWEZNQCLSA-N
DMU9BCD IU 6-N-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methylpyrazol-4-yl)-2-N-pyrazin-2-ylpyridine-2,6-diamine
DMU9BCD CA CAS 1239358-86-1
DMU9BCD DE Myelofibrosis
DMOYS1N ID DMOYS1N
DMOYS1N DN NT219
DMOYS1N HS Phase 1/2
DMOYS1N SN UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-
DMOYS1N CP Purple Biotech
DMOYS1N DT Small molecular drug
DMOYS1N PC 135914977
DMOYS1N MW 412.3
DMOYS1N FM C16H14BrNO5S
DMOYS1N IC InChI=1S/C16H14BrNO5S/c17-14-9(1-3-10(19)16(14)23)2-4-13(24)18-7-8-5-11(20)15(22)12(21)6-8/h1-6,19-23H,7H2,(H,18,24)/b4-2+
DMOYS1N CS C1=CC(=C(C(=C1/C=C/C(=S)NCC2=CC(=C(C(=C2)O)O)O)Br)O)O
DMOYS1N IK XDDQKKXXQHUUHJ-DUXPYHPUSA-N
DMOYS1N IU (E)-3-(2-bromo-3,4-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]prop-2-enethioamide
DMOYS1N CA CAS 1198078-60-2
DMOYS1N DE Solid tumour/cancer
DMBQRGV ID DMBQRGV
DMBQRGV DN NT-501 CNTF
DMBQRGV HS Phase 1/2
DMBQRGV CP Neurotech usa
DMBQRGV DE Ovarian cancer
DMS0L6J ID DMS0L6J
DMS0L6J DN NY-ESO-TCR
DMS0L6J HS Phase 1/2
DMS0L6J CP Adaptimmune Philadelphia, PA GlaxoSmithKline Philadelphia, PA
DMS0L6J DE Melanoma; Multiple myeloma; Myxoid round cell liposarcoma; Ovarian cancer; Synovial sarcoma
DMD2L1U ID DMD2L1U
DMD2L1U DN OBI-888
DMD2L1U HS Phase 1/2
DMD2L1U CP OBI Pharma
DMD2L1U DT Antibody
DMD2L1U DE Solid tumour/cancer
DMPB9OD ID DMPB9OD
DMPB9OD DN OBI-999
DMPB9OD HS Phase 1/2
DMPB9OD CP OBI Pharma
DMPB9OD DT Antibody drug conjugate
DMPB9OD DE Solid tumour/cancer
DM9MF08 ID DM9MF08
DM9MF08 DN OBP-301
DM9MF08 HS Phase 1/2
DM9MF08 CP Oncolys Biopharma
DM9MF08 DE Liver cancer; Head and neck cancer; Breast cancer
DMOKVJD ID DMOKVJD
DMOKVJD DN ODM-207
DMOKVJD HS Phase 1/2
DMOKVJD SN BET-IN-4; 1801503-93-4; ODM207; SCHEMBL16896828; NSC818620; NSC-818620; HY-111916; CS-0093944; COC1=C(C=C2C=C(C)C(=O)N(CC3=NC=CC=C3)C2=C1)C1=C(C)ON=C1C; 6-(3,5-Dimethylisoxazol-4-yl)-7-methoxy-3-methyl-1-(pyridin-2-ylmethyl)quinolin-2(1H)-one
DMOKVJD CP Orion
DMOKVJD DT Small molecular drug
DMOKVJD PC 118224658
DMOKVJD MW 375.4
DMOKVJD FM C22H21N3O3
DMOKVJD IC InChI=1S/C22H21N3O3/c1-13-9-16-10-18(21-14(2)24-28-15(21)3)20(27-4)11-19(16)25(22(13)26)12-17-7-5-6-8-23-17/h5-11H,12H2,1-4H3
DMOKVJD CS CC1=CC2=CC(=C(C=C2N(C1=O)CC3=CC=CC=N3)OC)C4=C(ON=C4C)C
DMOKVJD IK YVGWSVHZXWFLIT-UHFFFAOYSA-N
DMOKVJD IU 6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-methoxy-3-methyl-1-(pyridin-2-ylmethyl)quinolin-2-one
DMOKVJD DE Solid tumour/cancer
DMPLBDF ID DMPLBDF
DMPLBDF DN Omburtamab I-124
DMPLBDF HS Phase 1/2
DMPLBDF CP Y-mAbs Therapeutics New York, NY
DMPLBDF DE Glioma
DM2DHJS ID DM2DHJS
DM2DHJS DN ONC1-13B
DM2DHJS HS Phase 1/2
DM2DHJS CP Allachem
DM2DHJS PC 77461273
DM2DHJS MW 492.4
DM2DHJS FM C22H16F4N4O3S
DM2DHJS IC InChI=1S/C22H16F4N4O3S/c1-28-18(31)15-5-4-14(9-17(15)23)30-20(34)29(19(32)21(30)6-7-33-11-21)13-3-2-12(10-27)16(8-13)22(24,25)26/h2-5,8-9H,6-7,11H2,1H3,(H,28,31)/t21-/m1/s1
DM2DHJS CS CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)[C@]23CCOC3)C4=CC(=C(C=C4)C#N)C(F)(F)F)F
DM2DHJS IK QKKPJFTYJCXESR-OAQYLSRUSA-N
DM2DHJS IU 4-[(5R)-3-[4-cyano-3-(trifluoromethyl)phenyl]-4-oxo-2-sulfanylidene-7-oxa-1,3-diazaspiro[4.4]nonan-1-yl]-2-fluoro-N-methylbenzamide
DM2DHJS DE Prostate cancer
DMV6GX7 ID DMV6GX7
DMV6GX7 DN ONO-7475
DMV6GX7 HS Phase 1/2
DMV6GX7 SN 1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO-7475; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide
DMV6GX7 CP Ono Pharmaceutical
DMV6GX7 DT Small molecular drug
DMV6GX7 PC 90645873
DMV6GX7 MW 562.6
DMV6GX7 FM C32H26N4O6
DMV6GX7 IC InChI=1S/C32H26N4O6/c1-40-28-16-21-24(17-29(28)41-2)33-14-13-27(21)42-20-11-12-30(34-18-20)35-31(38)23-15-22-25(9-6-10-26(22)37)36(32(23)39)19-7-4-3-5-8-19/h3-5,7-8,11-18H,6,9-10H2,1-2H3,(H,34,35,38)
DMV6GX7 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CN=C(C=C3)NC(=O)C4=CC5=C(CCCC5=O)N(C4=O)C6=CC=CC=C6
DMV6GX7 IK WHMMKPWGWNYYFE-UHFFFAOYSA-N
DMV6GX7 IU N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide
DMV6GX7 CA CAS 1646839-59-9
DMV6GX7 DE Myelodysplastic syndrome; Acute leukaemia
DMXLPYE ID DMXLPYE
DMXLPYE DN ONO-7579
DMXLPYE HS Phase 1/2
DMXLPYE CP Ono Pharmaceutical Osaka, Japan
DMXLPYE DE Solid tumour/cancer
DMGIN7J ID DMGIN7J
DMGIN7J DN Onyvax-105
DMGIN7J HS Phase 1/2
DMGIN7J SN Antibody therapy (colerectal cancer), CRC/Onyvax; Vaccine (colorectal cancer), CRC/ImClone; Vaccine (colorectal cancer), CRC/Onyvax
DMGIN7J CP Cancer Research Campaign; VaxOnco
DMGIN7J DT Vaccine
DMGIN7J DE Colorectal cancer; Prostate cancer
DMIU26T ID DMIU26T
DMIU26T DN OP-1250
DMIU26T HS Phase 1/2
DMIU26T CP Olema Pharmaceuticals; Otsuka America Pharmaceutical
DMIU26T DT Small interfering RNA
DMIU26T DE Breast cancer
DMELJIV ID DMELJIV
DMELJIV DN OPA-6566
DMELJIV HS Phase 1/2
DMELJIV CP Acucela; otsuka pharmaceutical
DMELJIV DE Glaucoma/ocular hypertension
DM6VGO3 ID DM6VGO3
DM6VGO3 DN OPB-31121
DM6VGO3 HS Phase 1/2
DM6VGO3 CP Otsuka America Pharmaceutical
DM6VGO3 DE Hepatocellular carcinoma
DMZB6LO ID DMZB6LO
DMZB6LO DN OPC-167832
DMZB6LO HS Phase 1/2
DMZB6LO SN 1883747-71-4; 5-(((3R,4R)-1-(4-Chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl)methoxy)-8-fluoro-3,4-dihydroquinolin-2(1H)-one; UNII-1PQN78P4S3; 1PQN78P4S3; SCHEMBL17543112
DMZB6LO CP Otsuka America Pharmaceutical
DMZB6LO DT Small molecular drug
DMZB6LO PC 118904282
DMZB6LO MW 456.8
DMZB6LO FM C21H20ClF3N2O4
DMZB6LO IC InChI=1S/C21H20ClF3N2O4/c22-11-7-14(24)20(15(25)8-11)27-6-5-21(30,17(28)9-27)10-31-16-3-2-13(23)19-12(16)1-4-18(29)26-19/h2-3,7-8,17,28,30H,1,4-6,9-10H2,(H,26,29)/t17-,21-/m1/s1
DMZB6LO CS C1CC(=O)NC2=C(C=CC(=C21)OC[C@@]3(CCN(C[C@H]3O)C4=C(C=C(C=C4F)Cl)F)O)F
DMZB6LO IK XZISSTDXPBUCJA-DYESRHJHSA-N
DMZB6LO IU 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy]-8-fluoro-3,4-dihydro-1H-quinolin-2-one
DMZB6LO CA CAS 1883747-71-4
DMZB6LO DE Tuberculosis
DM471ZH ID DM471ZH
DM471ZH DN ORE-1001
DM471ZH HS Phase 1/2
DM471ZH SN MLN-4760; UNII-4LD0ZHV25K; 4LD0ZHV25K; CHEMBL429844; MLN 4760; 305335-31-3; (S,S)-2-{1-CARBOXY-2-[3-(3,5-DICHLORO-BENZYL)-3H-IMIDAZOL-4-YL]-ETHYLAMINO}-4-METHYL-PENTANOIC ACID; XX5; N-[(1s)-1-carboxy-3-methylbutyl]-3-(3,5-dichlorobenzyl)-l-histidine; (2S)-2-[[(2S)-3-[3-[(3,5-dichlorophenyl)methyl]imidazol-4-yl]-1-hydroxy-1-oxopropan-2-yl]amino]-4-methylpentanoic acid; AC1L9LSK; GTPL7866; SCHEMBL1691048; BDBM21489; DTXSID70184609; ZINC1549629; DB12271; HY-19414; CS-0015513
DM471ZH CP Millennium Pharmaceuticals Inc
DM471ZH DT Small molecular drug
DM471ZH PC 448281
DM471ZH MW 428.3
DM471ZH FM C19H23Cl2N3O4
DM471ZH IC InChI=1S/C19H23Cl2N3O4/c1-11(2)3-16(18(25)26)23-17(19(27)28)7-15-8-22-10-24(15)9-12-4-13(20)6-14(21)5-12/h4-6,8,10-11,16-17,23H,3,7,9H2,1-2H3,(H,25,26)(H,27,28)/t16-,17-/m0/s1
DM471ZH CS CC(C)C[C@@H](C(=O)O)N[C@@H](CC1=CN=CN1CC2=CC(=CC(=C2)Cl)Cl)C(=O)O
DM471ZH IK NTCCRGGIJNDEAB-IRXDYDNUSA-N
DM471ZH IU (2S)-2-[[(1S)-1-carboxy-2-[3-[(3,5-dichlorophenyl)methyl]imidazol-4-yl]ethyl]amino]-4-methylpentanoic acid
DM471ZH CA CAS 305335-31-3
DM471ZH CB CHEBI:166834
DM471ZH DE Type-2 diabetes; Diabetic complication
DM27RXS ID DM27RXS
DM27RXS DN ORIN1001
DM27RXS HS Phase 1/2
DM27RXS CP Orinove
DM27RXS DT Small interfering RNA
DM27RXS DE Metastatic breast cancer
DMWCJ1F ID DMWCJ1F
DMWCJ1F DN OT-58
DMWCJ1F HS Phase 1/2
DMWCJ1F CP Orphan Technologies
DMWCJ1F DT Recombinant protein
DMWCJ1F DE Homocystinuria
DMYGK1D ID DMYGK1D
DMYGK1D DN OTL-300
DMYGK1D HS Phase 1/2
DMYGK1D CP Orchard Therapeutics
DMYGK1D DT Gene therapy
DMYGK1D DE Beta thalassemia
DMN0ZQ5 ID DMN0ZQ5
DMN0ZQ5 DN OTSGC-A24
DMN0ZQ5 HS Phase 1/2
DMN0ZQ5 SN Peptide vaccine (gastric cancer), OncoTherapy
DMN0ZQ5 CP OncoTherapy Science Inc
DMN0ZQ5 DT Vaccine
DMN0ZQ5 DE Colorectal cancer
DMI8RG1 ID DMI8RG1
DMI8RG1 DN OTX-015
DMI8RG1 HS Phase 1/2
DMI8RG1 SN MK 8628
DMI8RG1 CP Constellation pharmaceuticals
DMI8RG1 DT Small molecular drug
DMI8RG1 PC 9936746
DMI8RG1 MW 492
DMI8RG1 FM C25H22ClN5O2S
DMI8RG1 IC InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1
DMI8RG1 CS CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C
DMI8RG1 IK GNMUEVRJHCWKTO-FQEVSTJZSA-N
DMI8RG1 IU 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-(4-hydroxyphenyl)acetamide
DMI8RG1 CA CAS 202590-98-5
DMI8RG1 DE Myelodysplastic syndrome; Solid tumour/cancer; Acute myeloid leukaemia
DMXF9DM ID DMXF9DM
DMXF9DM DN OXB-102
DMXF9DM HS Phase 1/2
DMXF9DM SN AXO-Lenti-PD
DMXF9DM CP Oxford BioMedica; Axovant Sciences
DMXF9DM DT Gene therapy
DMXF9DM DE Parkinson disease
DMTH75R ID DMTH75R
DMTH75R DN OXY-111A
DMTH75R HS Phase 1/2
DMTH75R SN OXYRENS; Myo-inositol trispyrophosphate; Oxyren (oxygen release enhancer) haemoglobin-oxygen affinity allosteric modulators (Cardiovascular disease/cancer), NormOxys
DMTH75R CP NormOxys Inc
DMTH75R DE Cardiovascular disease
DM6V5OB ID DM6V5OB
DM6V5OB DN P-552-02
DM6V5OB HS Phase 1/2
DM6V5OB SN CF-552; KM-003; P-552; Sodium channel blocker (oral, dry mouth/ Sjogren's syndrome), Parion Sciences
DM6V5OB CP Parion Sciences Inc
DM6V5OB DT Small molecular drug
DM6V5OB PC 10310524
DM6V5OB MW 451.9
DM6V5OB FM C19H26ClN7O4
DM6V5OB IC InChI=1S/C19H26ClN7O4/c20-15-17(22)26-16(21)14(25-15)18(30)27-19(23)24-8-2-1-3-11-4-6-13(7-5-11)31-10-12(29)9-28/h4-7,12,28-29H,1-3,8-10H2,(H4,21,22,26)(H3,23,24,27,30)
DM6V5OB CS C1=CC(=CC=C1CCCCN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N)OCC(CO)O
DM6V5OB IK NTRKMGDUWYBLMS-UHFFFAOYSA-N
DM6V5OB IU 3,5-diamino-6-chloro-N-[N'-[4-[4-(2,3-dihydroxypropoxy)phenyl]butyl]carbamimidoyl]pyrazine-2-carboxamide
DM6V5OB CA CAS 587879-32-1
DM6V5OB DE Cystic fibrosis
DMLSYJQ ID DMLSYJQ
DMLSYJQ DN PA-799
DMLSYJQ HS Phase 1/2
DMLSYJQ SN MEN1611; CH-5033855; CH-5061565; CH-5089788; CH-5108135; CH-5111436; CH-5138134
DMLSYJQ CP Chugai Pharmaceutical Co Ltd
DMLSYJQ DT Small molecular drug
DMLSYJQ PC 49784945
DMLSYJQ MW 377.4
DMLSYJQ FM C15H19N7O3S
DMLSYJQ IC InChI=1S/C15H19N7O3S/c1-26(23,24)22-3-2-11-12(10-8-17-14(16)18-9-10)19-15(20-13(11)22)21-4-6-25-7-5-21/h8-9H,2-7H2,1H3,(H2,16,17,18)
DMLSYJQ CS CS(=O)(=O)N1CCC2=C(N=C(N=C21)N3CCOCC3)C4=CN=C(N=C4)N
DMLSYJQ IK JEGHXKRHKHPBJD-UHFFFAOYSA-N
DMLSYJQ IU 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine
DMLSYJQ CA CAS 1007207-67-1
DMLSYJQ DE Solid tumour/cancer; Colorectal cancer
DMZKFJO ID DMZKFJO
DMZKFJO DN PAT-SC1
DMZKFJO HS Phase 1/2
DMZKFJO SN SC-1; Adjuvant therapy (gastric cancer), University of Wurzburg; SC-1 (gastric cancer), CAT; SC-1 (gastric cancer), Debiopharm; SC-1 (gastric cancer), Patrys; SC-1 (stomach cancer), OncoMab
DMZKFJO CP Universitat Wurzburg
DMZKFJO DT Antibody
DMZKFJO DE Gastric adenocarcinoma
DMJC2RU ID DMJC2RU
DMJC2RU DN PBCAR0191
DMJC2RU HS Phase 1/2
DMJC2RU CP Precision BioSciences, Inc.
DMJC2RU DT CAR T Cell Therapy
DMJC2RU DE Acute lymphoblastic leukaemia; Non-hodgkin lymphoma
DM7NKWQ ID DM7NKWQ
DM7NKWQ DN PBCAR20A
DM7NKWQ HS Phase 1/2
DM7NKWQ CP Precision Biosciences
DM7NKWQ DT CAR T Cell Therapy
DM7NKWQ DE Non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMSGM2L ID DMSGM2L
DMSGM2L DN PBCAR269A
DMSGM2L HS Phase 1/2
DMSGM2L CP Precision Biosciences
DMSGM2L DT CAR T Cell Therapy
DMSGM2L DE Multiple myeloma
DMGFPQ0 ID DMGFPQ0
DMGFPQ0 DN PBF509
DMGFPQ0 HS Phase 1/2
DMGFPQ0 SN 5-Bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine; 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine; SCHEMBL2546228; CHEMBL3694769; ATFXVNUWQOXRRU-UHFFFAOYSA-N; BDBM128295; ZINC72317391; AKOS030527812; DS-19509; US8796284, 1; 1337962-47-6
DMGFPQ0 CP Novartis OncologyEast Hanover, NJ Palobiofarma Barcelona, Spain
DMGFPQ0 PC 53466958
DMGFPQ0 MW 306.12
DMGFPQ0 FM C10H8BrN7
DMGFPQ0 IC InChI=1S/C10H8BrN7/c11-7-8(12)15-10(18-6-2-4-14-18)16-9(7)17-5-1-3-13-17/h1-6H,(H2,12,15,16)
DMGFPQ0 CS C1=CN(N=C1)C2=NC(=NC(=C2Br)N)N3C=CC=N3
DMGFPQ0 IK ATFXVNUWQOXRRU-UHFFFAOYSA-N
DMGFPQ0 IU 5-bromo-2,6-di(pyrazol-1-yl)pyrimidin-4-amine
DMGFPQ0 CA CAS 1337962-47-6
DMGFPQ0 DE Non-small-cell lung cancer
DMSJ54W ID DMSJ54W
DMSJ54W DN PC14586
DMSJ54W HS Phase 1/2
DMSJ54W CP PMV Pharmaceuticals
DMSJ54W DT Small interfering RNA
DMSJ54W DE Solid tumour/cancer
DM9DR13 ID DM9DR13
DM9DR13 DN PCAR-019
DM9DR13 HS Phase 1/2
DM9DR13 CP PersonGen BioTherapeutics (Suzhou) Co., Ltd.
DM9DR13 DT CAR T Cell Therapy
DM9DR13 DE Acute lymphocytic leukaemia; B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
DM1D6BT ID DM1D6BT
DM1D6BT DN PEGylated hyaluronidase (human recombinant)
DM1D6BT HS Phase 1/2
DM1D6BT SN PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme
DM1D6BT CP Halozyme Therapeutics San Diego; CA
DM1D6BT DE Pancreatic cancer
DMMAUOK ID DMMAUOK
DMMAUOK DN PEN-221
DMMAUOK HS Phase 1/2
DMMAUOK CP Tarveda Therapeutics Watertown, MA
DMMAUOK PC 118634103
DMMAUOK MW 1786.6
DMMAUOK FM C83H109ClN14O20S4
DMMAUOK IC InChI=1S/C83H109ClN14O20S4/c1-44-18-17-24-65(115-9)83(113)39-64(116-81(112)96-83)45(2)71-82(5,118-71)66(38-68(102)98(7)62-35-50(32-44)36-63(114-8)69(62)84)117-80(111)46(3)97(6)67(101)29-31-119-120-41-59(72(87)103)92-78(109)61-43-122-121-42-60(93-73(104)54(86)33-48-19-11-10-12-20-48)77(108)90-57(34-49-25-27-52(100)28-26-49)75(106)91-58(37-51-40-88-55-22-14-13-21-53(51)55)76(107)89-56(23-15-16-30-85)74(105)95-70(47(4)99)79(110)94-61/h10-14,17-22,24-28,35-36,40,45-47,54,56-61,64-66,70-71,88,99-100,113H,15-16,23,29-34,37-39,41-43,85-86H2,1-9H3,(H2,87,103)(H,89,107)(H,90,108)(H,91,106)(H,92,109)(H,93,104)(H,94,110)(H,95,105)(H,96,112)/b24-17+,44-18+/t45-,46+,47-,54-,56+,57+,58-,59+,60+,61+,64+,65-,66+,70+,71+,82+,83+/m1/s1
DMMAUOK CS C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCSSC[C@@H](C(=O)N)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)CCCCN)CC6=CNC7=CC=CC=C76)CC8=CC=C(C=C8)O)NC(=O)[C@@H](CC9=CC=CC=C9)N)C)\\C)OC)(NC(=O)O2)O
DMMAUOK IK JVPMJFUBODFGNB-UFDFPQQFSA-N
DMMAUOK IU [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[3-[[(2R)-3-amino-2-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-oxopropyl]disulfanyl]propanoyl-methylamino]propanoate
DMMAUOK CA CAS 1853254-97-3
DMMAUOK DE Neuroendocrine cancer; Small-cell lung cancer
DMLPTOF ID DMLPTOF
DMLPTOF DN PEN-866
DMLPTOF HS Phase 1/2
DMLPTOF CP Tarveda Therapeutics Watertown, MA
DMLPTOF PC 135564925
DMLPTOF MW 880
DMLPTOF FM C49H49N7O9
DMLPTOF IC InChI=1S/C49H49N7O9/c1-5-31-33-20-30(8-9-38(33)50-43-35(31)24-55-40(43)22-37-36(45(55)59)25-64-46(60)49(37,63)6-2)65-48(62)54-16-12-27(13-17-54)11-15-53-18-14-28-19-29(7-10-39(28)53)56-44(51-52-47(56)61)34-21-32(26(3)4)41(57)23-42(34)58/h7-10,14,18-23,26-27,57-58,63H,5-6,11-13,15-17,24-25H2,1-4H3,(H,52,61)/t49-/m0/s1
DMLPTOF CS CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)CCN7C=CC8=C7C=CC(=C8)N9C(=NNC9=O)C1=CC(=C(C=C1O)O)C(C)C
DMLPTOF IK QTPZAEAYDWMVJO-GGCSAXROSA-N
DMLPTOF IU [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-[2-[5-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-oxo-1H-1,2,4-triazol-4-yl]indol-1-yl]ethyl]piperidine-1-carboxylate
DMLPTOF CA CAS 1472614-83-7
DMLPTOF DE Solid tumour/cancer
DMM9L1R ID DMM9L1R
DMM9L1R DN PEP-223/CoVaccine HT
DMM9L1R HS Phase 1/2
DMM9L1R SN Prostate cancer vaccine, Pepscan/Novartis; Prostate cancer vaccine, Pepscan/PowderJect; Prostate cancer vaccine(anti-GnRH, TDK), Pepscan
DMM9L1R CP Pepscan Systems BV
DMM9L1R DT Vaccine
DMM9L1R DE Prostate cancer
DM03GDJ ID DM03GDJ
DM03GDJ DN Pepinemab
DM03GDJ HS Phase 1/2
DM03GDJ SN VX15/2503
DM03GDJ CP Vaccinex
DM03GDJ DT Antibody
DM03GDJ DE Squamous head and neck cell carcinom
DMBUJVX ID DMBUJVX
DMBUJVX DN Phenoxodiol
DMBUJVX HS Phase 1/2
DMBUJVX SN Dehydroequol; Idronoxil; Haginin E; NV 06; NV-06; Idronoxil (USAN/INN); 2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl); 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol; 3-(4-Hydroxyphenyl)-2H-chromen-7-ol; 7-hydroxy-3-hydroxyphenyl-1H-benzopyran
DMBUJVX CP Marshall Edwards
DMBUJVX TC Anticancer Agents
DMBUJVX DT Small molecular drug
DMBUJVX PC 219100
DMBUJVX MW 240.25
DMBUJVX FM C15H12O3
DMBUJVX IC InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-8,16-17H,9H2
DMBUJVX CS C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O
DMBUJVX IK ZZUBHVMHNVYXRR-UHFFFAOYSA-N
DMBUJVX IU 3-(4-hydroxyphenyl)-2H-chromen-7-ol
DMBUJVX CA CAS 81267-65-4
DMBUJVX DE Ovarian cancer
DMYEAB1 ID DMYEAB1
DMYEAB1 DN PIPERINE
DMYEAB1 HS Phase 1/2
DMYEAB1 SN piperine; 94-62-2; 1-Piperoylpiperidine; Piperin; Bioperine; Piperoylpiperidine; (E,E)-1-piperoylpiperidine; N-[(E,E)-Piperoyl]piperidine; Piperidine, 1-piperoyl-, (E,E)-; UNII-U71XL721QK; FEMA No. 2909; CCRIS 5572; Piperine (aliphatic); 1-Piperoylpiperidine, (E,E)-; 7780-20-3; C17H19NO3; EINECS 202-348-0; NSC 21727; 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoyl]piperidine; N-(E,E)-piperoyl-piperidine; CHEMBL43185; U71XL721QK; CHEBI:28821; MXXWOMGUGJBKIW-YPCIICBESA-N; NSC21727; piperidine, 1-[(2E,4E)-5-(1,3-benzodioxol-5-yl)
DMYEAB1 DT Small molecular drug
DMYEAB1 PC 638024
DMYEAB1 MW 285.34
DMYEAB1 FM C17H19NO3
DMYEAB1 IC InChI=1S/C17H19NO3/c19-17(18-10-4-1-5-11-18)7-3-2-6-14-8-9-15-16(12-14)21-13-20-15/h2-3,6-9,12H,1,4-5,10-11,13H2/b6-2+,7-3+
DMYEAB1 CS C1CCN(CC1)C(=O)/C=C/C=C/C2=CC3=C(C=C2)OCO3
DMYEAB1 IK MXXWOMGUGJBKIW-YPCIICBESA-N
DMYEAB1 IU (2E,4E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpenta-2,4-dien-1-one
DMYEAB1 CA CAS 94-62-2
DMYEAB1 CB CHEBI:28821
DMYEAB1 DE Vitiligo
DMX168L ID DMX168L
DMX168L DN PLX2853
DMX168L HS Phase 1/2
DMX168L CP Plexxikon
DMX168L DT Small molecular drug
DMX168L DE Acute myeloid leukaemia; Solid tumour/cancer
DM5DZEL ID DM5DZEL
DM5DZEL DN PLX9486
DM5DZEL HS Phase 1/2
DM5DZEL SN CGT9486
DM5DZEL CP Plexxikon
DM5DZEL DT Small molecular drug
DM5DZEL DE Solid tumour/cancer; Gastrointestinal stromal tumour
DMQOW0H ID DMQOW0H
DMQOW0H DN PP-1420
DMQOW0H HS Phase 1/2
DMQOW0H SN Pancreatic polypeptide analog (sc, obesity), Imperial College London
DMQOW0H CP Imperial College London
DMQOW0H DE Obesity
DM0HTEF ID DM0HTEF
DM0HTEF DN PRI-724
DM0HTEF HS Phase 1/2
DM0HTEF CP PRISM BioLab
DM0HTEF PC 71509318
DM0HTEF MW 658.6
DM0HTEF FM C33H35N6O7P
DM0HTEF IC InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
DM0HTEF CS C[C@H]1[C@H]2N([C@H](C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C
DM0HTEF IK VHOZWHQPEJGPCC-AZXNYEMZSA-N
DM0HTEF IU [4-[[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate
DM0HTEF CA CAS 1422253-38-0
DM0HTEF DE Acute myeloid leukaemia
DM8J5H1 ID DM8J5H1
DM8J5H1 DN PRLX93936
DM8J5H1 HS Phase 1/2
DM8J5H1 CP Prolexys Pharmaceuticals
DM8J5H1 DE Solid tumour/cancer
DMJ42E6 ID DMJ42E6
DMJ42E6 DN ProSavin
DMJ42E6 HS Phase 1/2
DMJ42E6 SN Dopamine synthesis pathway gene therapy (Parkinson's disease), Oxford BioMedica
DMJ42E6 CP Oxford BioMedica plc
DMJ42E6 DE Parkinson disease
DMOUW65 ID DMOUW65
DMOUW65 DN PRX-102
DMOUW65 HS Phase 1/2
DMOUW65 SN Galactosidase enzyme replacement therapy (Fabry disease), Protalix
DMOUW65 CP Protalix biotherapeutics
DMOUW65 PC 121488171
DMOUW65 MW 560.6
DMOUW65 FM C24H44N6O9
DMOUW65 IC InChI=1S/C24H44N6O9/c25-17(23(35)36)5-1-3-11-27-19(31)7-9-21(33)29-13-15-39-16-14-30-22(34)10-8-20(32)28-12-4-2-6-18(26)24(37)38/h17-18H,1-16,25-26H2,(H,27,31)(H,28,32)(H,29,33)(H,30,34)(H,35,36)(H,37,38)/t17-,18-/m0/s1
DMOUW65 CS C(CCNC(=O)CCC(=O)NCCOCCNC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N)C[C@@H](C(=O)O)N
DMOUW65 IK CQPWQUAJPPFCDP-ROUUACIJSA-N
DMOUW65 IU (2S)-2-amino-6-[[4-[2-[2-[[4-[[(5S)-5-amino-5-carboxypentyl]amino]-4-oxobutanoyl]amino]ethoxy]ethylamino]-4-oxobutanoyl]amino]hexanoic acid
DMOUW65 CA CAS 1644392-61-9
DMOUW65 DE Fabry disease
DM2CDLS ID DM2CDLS
DM2CDLS DN QLT-091568
DM2CDLS HS Phase 1/2
DM2CDLS SN OT-730; Beta adrenoceptor antagonist prodrug (glaucoma/ocular hypertension), Othera
DM2CDLS CP Othera Pharmaceuticals Inc
DM2CDLS PC 11554979
DM2CDLS MW 492.6
DM2CDLS FM C25H36N2O8
DM2CDLS IC InChI=1S/C25H36N2O8/c1-15-9-19(28)20(29)10-18(15)22(31)34-13-17(35-23(32)25(4)6-7-25)11-27-24(2,3)14-26-21(30)16-5-8-33-12-16/h9-10,16-17,27-29H,5-8,11-14H2,1-4H3,(H,26,30)/t16?,17-/m0/s1
DM2CDLS CS CC1=CC(=C(C=C1C(=O)OC[C@H](CNC(C)(C)CNC(=O)C2CCOC2)OC(=O)C3(CC3)C)O)O
DM2CDLS IK ANXXSWNMHQHOQC-DJNXLDHESA-N
DM2CDLS IU [(2S)-2-(1-methylcyclopropanecarbonyl)oxy-3-[[2-methyl-1-(oxolane-3-carbonylamino)propan-2-yl]amino]propyl] 4,5-dihydroxy-2-methylbenzoate
DM2CDLS CA CAS 870809-51-1
DM2CDLS DE Glaucoma/ocular hypertension
DMZD7OA ID DMZD7OA
DMZD7OA DN Quaratusugene ozeplasmid
DMZD7OA HS Phase 1/2
DMZD7OA SN GPX-001; CNVN 202
DMZD7OA CP Genprex
DMZD7OA DT Gene therapy
DMZD7OA DE Non-small-cell lung cancer
DM614BA ID DM614BA
DM614BA DN Re-188-P-2045
DM614BA HS Phase 1/2
DM614BA SN Neotide; RE-P2045; Rhenium 188-P-2045; Rhenium-188-labeled peptide (lung cancer), Antisoma; Rhenium-188-labeled peptide (lung cancer), Bryan Oncor/ Antisoma
DM614BA CP Diatide Inc
DM614BA DE Lung cancer
DMY3TAD ID DMY3TAD
DMY3TAD DN Recombinant factor VIIa PEGylated liposomal
DMY3TAD HS Phase 1/2
DMY3TAD SN Recombinant factor VIIa; Recombinant factor VIIa (PEGylated liposomal (NecLip), Hemophilia A) Recoly
DMY3TAD CP Recoly NV
DMY3TAD DE Factor VII deficiency
DM7LOSK ID DM7LOSK
DM7LOSK DN REGN4018
DM7LOSK HS Phase 1/2
DM7LOSK DT Antibody
DM7LOSK DE Ovarian cancer
DMAGX0Q ID DMAGX0Q
DMAGX0Q DN REGN5458
DMAGX0Q HS Phase 1/2
DMAGX0Q DT Antibody
DMAGX0Q DE Multiple myeloma
DMRE0LU ID DMRE0LU
DMRE0LU DN REGN5459
DMRE0LU HS Phase 1/2
DMRE0LU CP Regeneron Pharmaceuticals; Sanofi
DMRE0LU DT Antibody
DMRE0LU DE Multiple myeloma
DM0Y6WU ID DM0Y6WU
DM0Y6WU DN REGN5678
DM0Y6WU HS Phase 1/2
DM0Y6WU CP Regeneron Pharmaceuticals
DM0Y6WU DT Antibody
DM0Y6WU DE Prostate cancer
DM5MFHO ID DM5MFHO
DM5MFHO DN REIC gene therapy
DM5MFHO HS Phase 1/2
DM5MFHO CP Momotaro-Gene
DM5MFHO DE Prostate cancer
DMDO6J1 ID DMDO6J1
DMDO6J1 DN Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
DMDO6J1 HS Phase 1/2
DMDO6J1 CP Xinqiao Hospital of Chongqing
DMDO6J1 DT CAR T Cell Therapy
DMDO6J1 DE Hepatocellular carcinoma
DMAGE91 ID DMAGE91
DMAGE91 DN RG7800
DMAGE91 HS Phase 1/2
DMAGE91 PC 89741565
DMAGE91 MW 416.5
DMAGE91 FM C24H28N6O
DMAGE91 IC InChI=1S/C24H28N6O/c1-5-19-22-11-21(27-30(22)13-16(3)25-19)20-12-23(31)29-14-18(10-15(2)24(29)26-20)17-6-8-28(4)9-7-17/h10-14,17H,5-9H2,1-4H3
DMAGE91 CS CCC1=NC(=CN2C1=CC(=N2)C3=CC(=O)N4C=C(C=C(C4=N3)C)C5CCN(CC5)C)C
DMAGE91 IK GYFRQCMDLBNZSF-UHFFFAOYSA-N
DMAGE91 IU 2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)pyrido[1,2-a]pyrimidin-4-one
DMAGE91 DE Spinal muscular atrophy
DM5AIKR ID DM5AIKR
DM5AIKR DN RGX-104
DM5AIKR HS Phase 1/2
DM5AIKR SN Rgx-104 hydrochloride; RGX-104 hydrochloride; 610318-03-1; UNII-D32013XLTX; SCHEMBL3975944; D32013XLTX; LCMIYQOJZLRHTO-GJFSDDNBSA-N; (r)-2-(3-{3-[[2chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid hydrochloride salt
DM5AIKR CP Rgenix New York, NY
DM5AIKR PC 68861574
DM5AIKR MW 632.5
DM5AIKR FM C34H34Cl2F3NO3
DM5AIKR IC InChI=1S/C34H33ClF3NO3.ClH/c1-24(18-19-42-29-16-8-10-25(20-29)21-32(40)41)39(22-28-15-9-17-31(33(28)35)34(36,37)38)23-30(26-11-4-2-5-12-26)27-13-6-3-7-14-27;/h2-17,20,24,30H,18-19,21-23H2,1H3,(H,40,41);1H/t24-;/m1./s1
DM5AIKR CS C[C@H](CCOC1=CC=CC(=C1)CC(=O)O)N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4.Cl
DM5AIKR IK LCMIYQOJZLRHTO-GJFSDDNBSA-N
DM5AIKR IU 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid;hydrochloride
DM5AIKR CA CAS 610318-03-1
DM5AIKR DE Lymphoma; Solid tumour/cancer; Non-small-cell lung cancer
DMU3PD7 ID DMU3PD7
DMU3PD7 DN RGX-121
DMU3PD7 HS Phase 1/2
DMU3PD7 CP REGENXBIO
DMU3PD7 DT Gene therapy
DMU3PD7 DE Mucopolysaccharidosis
DMSDZ8U ID DMSDZ8U
DMSDZ8U DN Rintatolimod
DMSDZ8U HS Phase 1/2
DMSDZ8U SN Ampligen
DMSDZ8U TC Antiviral Agents
DMSDZ8U DT Protein/peptide drug
DMSDZ8U DE Coronavirus Disease 2019 (COVID-19)
DM9FNC8 ID DM9FNC8
DM9FNC8 DN RP-3500
DM9FNC8 HS Phase 1/2
DM9FNC8 CP Repare Therapeutics
DM9FNC8 DT Small molecular drug
DM9FNC8 DE Solid tumour/cancer
DMKVMWO ID DMKVMWO
DMKVMWO DN RP-L201
DMKVMWO HS Phase 1/2
DMKVMWO CP Rocket Pharmaceuticals
DMKVMWO DT Gene therapy
DMKVMWO DE Leukocyte adhesion deficiency type 1
DMXYHC7 ID DMXYHC7
DMXYHC7 DN RU-101
DMXYHC7 HS Phase 1/2
DMXYHC7 SN RU-10; Recombinant human serum albumin (ocular, dry eye), R-Tech Ueno
DMXYHC7 CP R-tech ueno
DMXYHC7 DE Xerophthalmia
DM1LO8K ID DM1LO8K
DM1LO8K DN RVX-208
DM1LO8K HS Phase 1/2
DM1LO8K CP Resverlogix
DM1LO8K DT Small molecular drug
DM1LO8K PC 24871506
DM1LO8K DE Alzheimer disease
DMCBQTF ID DMCBQTF
DMCBQTF DN S-3304
DMCBQTF HS Phase 1/2
DMCBQTF SN BPHA; BPHA, Shionogi; MMP inhibitors, Shionogi; Matrix metalloproteinase inhibitor, Shionogi
DMCBQTF CP Shionogi & Co Ltd
DMCBQTF DT Small molecular drug
DMCBQTF PC 10718956
DMCBQTF MW 464.6
DMCBQTF FM C24H20N2O4S2
DMCBQTF IC InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)/t22-/m1/s1
DMCBQTF CS CC1=CC=C(C=C1)C#CC2=CC=C(S2)S(=O)(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O
DMCBQTF IK YWCLDDLVLSQGSZ-JOCHJYFZSA-N
DMCBQTF IU (2R)-3-(1H-indol-3-yl)-2-[[5-[2-(4-methylphenyl)ethynyl]thiophen-2-yl]sulfonylamino]propanoic acid
DMCBQTF CA CAS 203640-27-1
DMCBQTF DE Solid tumour/cancer
DMVKQT8 ID DMVKQT8
DMVKQT8 DN SALACINOL
DMVKQT8 HS Phase 1/2
DMVKQT8 SN SALACINOL; 200399-47-9; CHEMBL239249; CHEMBL1208974; AC1O52U7; BDBM50180585; BDBM50330955; FT-0674499; 1,4-dideoxy-1,4-{(S)-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]episulfoniumylidene}-D-arabinitol; 1,4-Dideoxy-1,4-[(S)-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]episulfoniumylidene]-D-arabinitol Inner Salt; [(2S,3S)-4-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-1,3-dihydroxybutan-2-yl] sulfate
DMVKQT8 DT Small molecular drug
DMVKQT8 PC 6451151
DMVKQT8 MW 334.4
DMVKQT8 FM C9H18O9S2
DMVKQT8 IC InChI=1S/C9H18O9S2/c10-1-7(18-20(15,16)17)5(12)3-19-4-6(13)9(14)8(19)2-11/h5-14H,1-4H2/t5-,6-,7+,8-,9+,19?/m1/s1
DMVKQT8 CS C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H](CO)OS(=O)(=O)[O-])O)CO)O)O
DMVKQT8 IK SOWRVDSZMRPKRG-XESHOGEWSA-N
DMVKQT8 IU [(2S,3S)-4-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-1,3-dihydroxybutan-2-yl] sulfate
DMVKQT8 CA CAS 200399-47-9
DMPXOGD ID DMPXOGD
DMPXOGD DN SAR-161271
DMPXOGD HS Phase 1/2
DMPXOGD CP Sanofi
DMPXOGD DE Type-1 diabetes
DM6M8O4 ID DM6M8O4
DM6M8O4 DN SAR440234
DM6M8O4 HS Phase 1/2
DM6M8O4 CP Sanofi
DM6M8O4 DT Antibody
DM6M8O4 DE Acute myeloid leukaemia; leukaemia
DMD20YH ID DMD20YH
DMD20YH DN SAR-650984
DMD20YH HS Phase 1/2
DMD20YH SN Anti-CD38 monoclonal antibody (leukemia), ImmunoGen/sanofi-aventis
DMD20YH CP ImmunoGen Inc
DMD20YH DT Antibody
DMD20YH DE Haematological malignancy
DMA8Z4N ID DMA8Z4N
DMA8Z4N DN SB-318
DMA8Z4N HS Phase 1/2
DMA8Z4N CP Sangamo Therapeutics
DMA8Z4N DT Gene therapy
DMA8Z4N DE Mucopolysaccharidosis
DM98YFK ID DM98YFK
DM98YFK DN SB-913
DM98YFK HS Phase 1/2
DM98YFK CP Sangamo Therapeutics
DM98YFK DT Gene therapy
DM98YFK DE Mucopolysaccharidosis
DMUP52Y ID DMUP52Y
DMUP52Y DN SB-FIX
DMUP52Y HS Phase 1/2
DMUP52Y CP Sangamo Therapeutics
DMUP52Y DT Gene therapy
DMUP52Y DE Haemophilia B
DMS1NMO ID DMS1NMO
DMS1NMO DN SCRI-huCAR19v1
DMS1NMO HS Phase 1/2
DMS1NMO CP Seattle Children's Hospital
DMS1NMO DT CAR T Cell Therapy
DMS1NMO DE leukaemia; Lymphoma
DMBFUOI ID DMBFUOI
DMBFUOI DN SECTA belomycin
DMBFUOI HS Phase 1/2
DMBFUOI CP Inovio
DMBFUOI DE Solid tumour/cancer
DMD37Q5 ID DMD37Q5
DMD37Q5 DN SEL24
DMD37Q5 HS Phase 1/2
DMD37Q5 SN MEN1703
DMD37Q5 CP Menarini
DMD37Q5 DT Small molecular drug
DMD37Q5 DE Acute myeloid leukaemia
DMH064K ID DMH064K
DMH064K DN SEL-24
DMH064K HS Phase 1/2
DMH064K SN Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita
DMH064K CP Selvita Life Sciences Solutions
DMH064K DE Solid tumour/cancer; Acute myeloid leukaemia
DM4NK3J ID DM4NK3J
DM4NK3J DN SF0166
DM4NK3J HS Phase 1/2
DM4NK3J CP SciFluor Life Sciences Cambridge, MA
DM4NK3J DE Diabetic macular edema
DMRC7PI ID DMRC7PI
DMRC7PI DN SGN-CD33A
DMRC7PI HS Phase 1/2
DMRC7PI CP Seattle genetics
DMRC7PI DT Antibody
DMRC7PI DE Acute myeloid leukaemia
DMADNY3 ID DMADNY3
DMADNY3 DN SHR-1314
DMADNY3 HS Phase 1/2
DMADNY3 CP Jiangsu HengRui Medicine Shanghai, China
DMADNY3 DE Plaque psoriasis
DMMUCH0 ID DMMUCH0
DMMUCH0 DN SHR2554
DMMUCH0 HS Phase 1/2
DMMUCH0 CP Jiangsu Hengrui
DMMUCH0 DT Small molecular drug
DMMUCH0 DE Haematopoietic/lymphoid cancer; Prostate cancer
DMZTQD8 ID DMZTQD8
DMZTQD8 DN Sirna-027
DMZTQD8 HS Phase 1/2
DMZTQD8 CP Sirna Therapeutics
DMZTQD8 DT siRNA drug
DMZTQD8 DE Neovascular age-related macular degeneration; Exudative age-related macular degeneration
DMSOX57 ID DMSOX57
DMSOX57 DN SJCAR19
DMSOX57 HS Phase 1/2
DMSOX57 CP St. Jude Children's Research Hospital
DMSOX57 DT CAR T Cell Therapy
DMSOX57 DE Acute lymphoblastic leukaemia
DMSTEFK ID DMSTEFK
DMSTEFK DN SKB264
DMSTEFK HS Phase 1/2
DMSTEFK CP KLUS Pharma
DMSTEFK DT Antibody drug conjugate
DMSTEFK DE Solid tumour/cancer
DMOCHVE ID DMOCHVE
DMOCHVE DN SL-401
DMOCHVE HS Phase 1/2
DMOCHVE CP Stemline Therapeutics
DMOCHVE DE Blastic plasmacytoid dendritic cell neoplasm; Acute myeloid leukaemia; Multiple myeloma; Myeloproliferative neoplasm
DMEJT5Z ID DMEJT5Z
DMEJT5Z DN SN-32793
DMEJT5Z HS Phase 1/2
DMEJT5Z SN PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha
DMEJT5Z CP University of Auckland
DMEJT5Z DE Non-small-cell lung cancer
DMCGX9Y ID DMCGX9Y
DMCGX9Y DN SNDX-5613
DMCGX9Y HS Phase 1/2
DMCGX9Y SN 2169919-21-3; SNDX5613; SCHEMBL19693219; SCHEMBL19693428; EX-A4343; NSC825775; NSC-825775; HY-136175; CS-0120274
DMCGX9Y CP Syndax Pharmaceuticals
DMCGX9Y DT Small molecular drug
DMCGX9Y PC 132212657
DMCGX9Y MW 630.8
DMCGX9Y FM C32H47FN6O4S
DMCGX9Y IC InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3
DMCGX9Y CS CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC
DMCGX9Y IK FRVSRBKUQZKTOW-UHFFFAOYSA-N
DMCGX9Y IU N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide
DMCGX9Y DE T lymphoblastic leukaemia
DMNV8SY ID DMNV8SY
DMNV8SY DN SNN-0029
DMNV8SY HS Phase 1/2
DMNV8SY SN VEGF (intracerebroventricular, amyotrophic lateral sclerosis), NeuroNova/VIB/Genentech
DMNV8SY CP Flanders Interuniversity Institute for Biotechnology (VIB)
DMNV8SY DE Lateral sclerosis
DM2X3BR ID DM2X3BR
DM2X3BR DN SNN-0031
DM2X3BR HS Phase 1/2
DM2X3BR SN Platelet derived growth factor (parkinson's disease), NeuroNova; PDGF-BB (parkinson's disease), NeuroNova
DM2X3BR CP NeuroNova AB
DM2X3BR DE Brain injury
DMIU0VP ID DMIU0VP
DMIU0VP DN SNX-5422
DMIU0VP HS Phase 1/2
DMIU0VP SN 908115-27-5; PF-04929113; SNX-5422; SNX 5422; SNX5422; UNII-BF52J69Q8T; PF 04929113; PF-04929113 (SNX-5422); BF52J69Q8T; PF04929113; PF-4929113; cc-40; MLS006011083; SCHEMBL1220791; SCHEMBL1220790; CHEMBL1195136; SCHEMBL15604989; DTXSID50238270; C25H30F3N5O4; MolPort-023-293-502; BCPP000065; HMS3656B09; EX-A2343; BCP02427; s2656; ZINC95616595; ABP000737; ZINC100071931; ZINC252517142; AKOS027276395; SB16643; DB06070; API0008143; RL05706; SNX-5422 /; CS-0272; NCGC00346640-01; NCGC00386184-02; Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrah
DMIU0VP CP Serenex
DMIU0VP DT Small molecular drug
DMIU0VP PC 44195571
DMIU0VP MW 521.5
DMIU0VP FM C25H30F3N5O4
DMIU0VP IC InChI=1S/C25H30F3N5O4/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36)
DMIU0VP CS CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)OC(=O)CN)C(F)(F)F)C
DMIU0VP IK AVDSOVJPJZVBTC-UHFFFAOYSA-N
DMIU0VP IU [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]anilino]cyclohexyl] 2-aminoacetate
DMIU0VP CA CAS 908115-27-5
DMIU0VP DE Haematological malignancy; Chronic lymphocytic leukaemia; Neuroendocrine cancer; Non-small-cell lung cancer
DMXNTR7 ID DMXNTR7
DMXNTR7 DN SOBI003
DMXNTR7 HS Phase 1/2
DMXNTR7 CP Swedish Orphan Biovitrum
DMXNTR7 DT Recombinant protein
DMXNTR7 DE Sanfilippo syndrome
DMST6A3 ID DMST6A3
DMST6A3 DN Sodium pyruvate
DMST6A3 HS Phase 1/2
DMST6A3 SN SODIUM PYRUVATE; 113-24-6; Pyruvic acid sodium salt; sodium 2-oxopropanoate; Pyruvic acid, sodium salt; Propanoic acid, 2-oxo-, sodium salt; Sodium alpha-ketopropionate; 2-Oxopropanoic acid sodium salt; UNII-POD38AIF08; POD38AIF08; CHEBI:50144; Natriumpyruvat; alpha-Ketopropionic acid sodium salt; MFCD00002586; Propanoic acid, 2-oxo-, sodium salt (1:1); S-6005; Pyruvic acid, sodium salt, 99+%; Pyruvate Sodium; Natrum pyruvicum; CHEMBL181886; sodiumpyruvate; Guna-flam; Guna-hypertension; EINECS 204-024-4; pyruvic acid na-salt; N-115; Sodium pyruvate (inhaled); Reactive oxygen species antagonist (inhaled), EmphyCorp; Sodium pyruvate (inhaled), EmphyCorp; PYRUVATE SODIUM
DMST6A3 CP EmphyCorp Inc
DMST6A3 DT Small molecular drug
DMST6A3 PC 23662274
DMST6A3 MW 110.04
DMST6A3 FM C3H3NaO3
DMST6A3 IC InChI=1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1
DMST6A3 CS CC(=O)C(=O)[O-].[Na+]
DMST6A3 IK DAEPDZWVDSPTHF-UHFFFAOYSA-M
DMST6A3 IU sodium;2-oxopropanoate
DMST6A3 CA CAS 113-24-6
DMST6A3 CB CHEBI:50144
DMST6A3 DE Asthma
DM3GO0J ID DM3GO0J
DM3GO0J DN Sodium taurocholate
DM3GO0J HS Phase 1/2
DM3GO0J SN Sodium taurocholate (rectal gel, diabetes/ obesity)
DM3GO0J CP Satiogen Pharmaceuticals Inc
DM3GO0J DT Small molecular drug
DM3GO0J PC 23666345
DM3GO0J MW 537.7
DM3GO0J FM C26H44NNaO7S
DM3GO0J IC InChI=1S/C26H45NO7S.Na/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29;/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34);/q;+1/p-1/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-;/m1./s1
DM3GO0J CS C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C.[Na+]
DM3GO0J IK JAJWGJBVLPIOOH-IZYKLYLVSA-M
DM3GO0J IU sodium;2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate
DM3GO0J CA CAS 145-42-6
DM3GO0J CB CHEBI:36276
DM3GO0J DE Type-2 diabetes
DMEVGI9 ID DMEVGI9
DMEVGI9 DN SPK-7001
DMEVGI9 HS Phase 1/2
DMEVGI9 CP Spark Therapeutics
DMEVGI9 DT Gene therapy
DMEVGI9 DE Choroidal dystrophy
DM8K7CN ID DM8K7CN
DM8K7CN DN SPK-8011
DM8K7CN HS Phase 1/2
DM8K7CN CP Spark Therapeutics
DM8K7CN DT Gene therapy
DM8K7CN DE Haemophilia A
DMCP8F3 ID DMCP8F3
DMCP8F3 DN SPK-8016
DMCP8F3 HS Phase 1/2
DMCP8F3 CP Spark Therapeutics
DMCP8F3 DT Gene therapy
DMCP8F3 DE Haemophilia A
DMJDV0K ID DMJDV0K
DMJDV0K DN SPR720
DMJDV0K HS Phase 1/2
DMJDV0K SN UNII-1NL76YUU6E; 1NL76YUU6E; CHEMBL2221212; VXC-486 phosphate; SCHEMBL10323399; BDBM50112815; ZINC95566061; HY-135655A; CS-0127906; 1384984-31-9; 2-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2R)-oxolan-2-yl]-3H-benzimidazol-5-yl]pyrimidin-2-yl]propan-2-yl dihydrogen phosphate; N-Ethyl-N'-(6-fluoro-5-(2-(1-methyl-1-(phosphonooxy)ethyl)-5-pyrimidinyl)-7-((2R)-tetrahydro-2-furanyl)-1H-benzimidazol-2-yl)urea; Urea, N-ethyl-N'-(6-fluoro-5-(2-(1-methyl-1-(phosphonooxy)ethyl)-5-pyrimidinyl)-7-((2R)-tetrahydro-2-furanyl)-1H-benzimidazol-2-yl)-
DMJDV0K CP Spero Therapeutics
DMJDV0K DT Small molecular drug
DMJDV0K PC 68108988
DMJDV0K MW 508.4
DMJDV0K FM C21H26FN6O6P
DMJDV0K IC InChI=1S/C21H26FN6O6P/c1-4-23-20(29)28-19-26-13-8-12(16(22)15(17(13)27-19)14-6-5-7-33-14)11-9-24-18(25-10-11)21(2,3)34-35(30,31)32/h8-10,14H,4-7H2,1-3H3,(H2,30,31,32)(H3,23,26,27,28,29)/t14-/m1/s1
DMJDV0K CS CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)OP(=O)(O)O
DMJDV0K IK COTQDURISRILOR-CQSZACIVSA-N
DMJDV0K IU 2-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2R)-oxolan-2-yl]-3H-benzimidazol-5-yl]pyrimidin-2-yl]propan-2-yl dihydrogen phosphate
DMJDV0K CA CAS 1384984-31-9
DMJDV0K DE Mycobacterium infection
DMG8JLC ID DMG8JLC
DMG8JLC DN SRP-9003
DMG8JLC HS Phase 1/2
DMG8JLC SN MYO-101
DMG8JLC CP Sarepta Therapeutics
DMG8JLC DT Gene therapy
DMG8JLC DE Limb girdle muscular dystrophy
DMK095Z ID DMK095Z
DMK095Z DN SRP-9004
DMK095Z HS Phase 1/2
DMK095Z CP Sarepta Therapeutics
DMK095Z DT Gene therapy
DMK095Z DE Limb girdle muscular dystrophy
DMBCIXL ID DMBCIXL
DMBCIXL DN Stamulumab
DMBCIXL HS Phase 1/2
DMBCIXL SN MYO-028; MYO-029; RK-35; GDF-8 program, Wyeth BioPharma/Genetics Institute; Anti-myostatin antibody, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Wyeth BioPharma/Cambridge Antibody Technology
DMBCIXL CP Wyeth
DMBCIXL DT Antibody
DMBCIXL DE Duchenne dystrophy
DMX3CNS ID DMX3CNS
DMX3CNS DN Stargen
DMX3CNS HS Phase 1/2
DMX3CNS SN Juvenile degenerative retinal disease therapy, Oxford BioMedica; ABCR gene therapy (Stargardt disease, LentiVector), Oxford BioMedica
DMX3CNS CP Oxford BioMedica plc
DMX3CNS DE Retinitis pigmentosa
DMZM6I2 ID DMZM6I2
DMZM6I2 DN Sym013
DMZM6I2 HS Phase 1/2
DMZM6I2 CP Symphogen Somerville, NJ
DMZM6I2 DE Epithelial ovarian cancer; Solid tumour/cancer
DM9B7Z5 ID DM9B7Z5
DM9B7Z5 DN Sym015
DM9B7Z5 HS Phase 1/2
DM9B7Z5 CP Symphogen Somerville, NJ
DM9B7Z5 DE Solid tumour/cancer
DMB2NP8 ID DMB2NP8
DMB2NP8 DN T-1249
DMB2NP8 HS Phase 1/2
DMB2NP8 SN Tifuvirtide; Peptide T1249; UNII-M6W86MD258; M6W86MD258; 251562-00-2; Tifuvirtide [INN]; T 1249; DB05413; 111997-EP2298761A1; 111997-EP2272516A2
DMB2NP8 DT Small molecular drug
DMB2NP8 PC 16130644
DMB2NP8 MW 5037
DMB2NP8 FM C235H341N57O67
DMB2NP8 IC InChI=1S/C235H341N57O67/c1-20-120(13)194(290-218(342)155(69-83-184(246)303)258-198(322)122(15)254-201(325)149(63-77-178(240)297)263-211(335)157(71-85-187(307)308)270-221(345)166(97-117(7)8)280-222(346)164(95-115(3)4)277-199(323)124(17)256-235(359)196(125(18)294)292-234(358)195(121(14)21-2)291-217(341)148(58-38-42-94-239)261-205(329)150(64-78-179(241)298)265-212(336)158(72-86-188(309)310)272-227(351)172(104-131-111-251-142-52-32-27-47-137(131)142)284-215(339)159(73-87-189(311)312)267-208(332)153(67-81-182(244)301)269-226(350)170(257-126(19)295)102-129-109-249-140-50-30-25-45-135(129)140)233(357)275-154(68-82-183(245)302)209(333)264-151(65-79-180(242)299)207(331)266-156(70-84-186(305)306)210(334)260-146(56-36-40-92-237)204(328)287-175(107-185(247)304)230(354)274-161(75-89-191(315)316)214(338)282-169(101-128-59-61-134(296)62-60-128)225(349)271-160(74-88-190(313)314)213(337)279-165(96-116(5)6)220(344)268-152(66-80-181(243)300)206(330)259-145(55-35-39-91-236)202(326)278-167(98-118(9)10)224(348)288-176(108-193(319)320)231(355)262-147(57-37-41-93-238)203(327)283-171(103-130-110-250-141-51-31-26-46-136(130)141)219(343)255-123(16)200(324)289-177(114-293)232(356)281-168(99-119(11)12)223(347)286-173(105-132-112-252-143-53-33-28-48-138(132)143)228(352)273-162(76-90-192(317)318)216(340)285-174(106-133-113-253-144-54-34-29-49-139(133)144)229(353)276-163(197(248)321)100-127-43-23-22-24-44-127/h22-34,43-54,59-62,109-113,115-125,145-177,194-196,249-253,293-294,296H,20-21,35-42,55-58,63-108,114,236-239H2,1-19H3,(H2,240,297)(H2,241,298)(H2,242,299)(H2,243,300)(H2,244,301)(H2,245,302)(H2,246,303)(H2,247,304)(H2,248,321)(H,254,325)(H,255,343)(H,256,359)(H,257,295)(H,258,322)(H,259,330)(H,260,334)(H,261,329)(H,262,355)(H,263,335)(H,264,333)(H,265,336)(H,266,331)(H,267,332)(H,268,344)(H,269,350)(H,270,345)(H,271,349)(H,272,351)(H,273,352)(H,274,354)(H,275,357)(H,276,353)(H,277,323)(H,278,326)(H,279,337)(H,280,346)(H,281,356)(H,282,338)(H,283,327)(H,284,339)(H,285,340)(H,286,347)(H,287,328)(H,288,348)(H,289,324)(H,290,342)(H,291,341)(H,292,358)(H,305,306)(H,307,308)(H,309,310)(H,311,312)(H,313,314)(H,315,316)(H,317,318)(H,319,320)/t120-,121-,122-,123-,124-,125+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,194-,195-,196-/m0/s1
DMB2NP8 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC9=CNC1=CC=CC=C19)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C
DMB2NP8 IK ZFEAMMNVDPDEGE-LGRGJMMZSA-N
DMB2NP8 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-aminohexanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DMB2NP8 CA CAS 251562-00-2
DMB2NP8 DE Human immunodeficiency virus infection
DMWIH59 ID DMWIH59
DMWIH59 DN T2c-003
DMWIH59 HS Phase 1/2
DMWIH59 SN Bone marrow-derived progenitor cells therapy (intra-arterial infusion, diabetic neuropathy), t2cure
DMWIH59 CP Johann Wolfgang Goethe-Universitat Frankfurt am Main
DMWIH59 DE Diabetic neuropathy
DM1FY97 ID DM1FY97
DM1FY97 DN T3D-959
DM1FY97 HS Phase 1/2
DM1FY97 CP T3d therapeutics
DM1FY97 DE Alzheimer disease
DMCFSZ5 ID DMCFSZ5
DMCFSZ5 DN TAI-GPC3-CART cells
DMCFSZ5 HS Phase 1/2
DMCFSZ5 CP Shanghai GeneChem Co., Ltd.
DMCFSZ5 DT CAR T Cell Therapy
DMCFSZ5 DE Hepatocellular carcinoma
DMJSQXT ID DMJSQXT
DMJSQXT DN TAK-007
DMJSQXT HS Phase 1/2
DMJSQXT CP Takeda
DMJSQXT DT CAR-NK Cell therapy
DMJSQXT DE Hematologic tumour
DM1AB4L ID DM1AB4L
DM1AB4L DN Talotrexin
DM1AB4L HS Phase 1/2
DM1AB4L SN Talvesta; Talotrexin ammonium; PT-523; PT-633; 10-deaza-PT-523
DM1AB4L CP Hana Biosciences; Dana-Farber Cancer Institute Inc
DM1AB4L DT Small molecular drug
DM1AB4L PC 130731
DM1AB4L MW 573.6
DM1AB4L FM C27H27N9O6
DM1AB4L IC InChI=1S/C27H27N9O6/c28-21-20-22(36-27(29)35-21)32-13-16(33-20)12-31-15-9-7-14(8-10-15)23(37)34-19(26(41)42)6-3-11-30-24(38)17-4-1-2-5-18(17)25(39)40/h1-2,4-5,7-10,13,19,31H,3,6,11-12H2,(H,30,38)(H,34,37)(H,39,40)(H,41,42)(H4,28,29,32,35,36)/t19-/m0/s1
DM1AB4L CS C1=CC=C(C(=C1)C(=O)NCCC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=CN=C4C(=N3)C(=NC(=N4)N)N)C(=O)O
DM1AB4L IK NYQPLPNEESYGNO-IBGZPJMESA-N
DM1AB4L IU 2-[[(4S)-4-carboxy-4-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]butyl]carbamoyl]benzoic acid
DM1AB4L CA CAS 113857-87-7
DM1AB4L DE Solid tumour/cancer
DM13AH8 ID DM13AH8
DM13AH8 DN TAS-0728
DM13AH8 HS Phase 1/2
DM13AH8 CP Taiho Oncology
DM13AH8 DT Small molecular drug
DM13AH8 DE Solid tumour/cancer
DM2LZ8F ID DM2LZ8F
DM2LZ8F DN Taurocholic acid
DM2LZ8F HS Phase 1/2
DM2LZ8F SN Taurocholic acid; TAUROCHOLIC ACID; Taurocholate; Cholyltaurine; Cholaic acid; N-Choloyltaurine; Cholic acid taurine conjugate; 81-24-3; Taurine, N-choloyl-; Acidum cholatauricum; Taurine Cholate; UNII-5E090O0G3Z; HSDB 832; C26H45NO7S; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid 24-taurine; NSC25505; EINECS 201-336-2; NSC 25505; Ethanesulfonic acid, 2-(((3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxy-24-oxocholan-24-yl)amino)-; 2-((3-alpha,7-alpha,12-alpha-Trihydroxy-24-oxo-5-be ta-cholan-24-yl)amino)ethanesulfonic acid; [3H]taurocholic acid
DM2LZ8F DT Small molecular drug
DM2LZ8F PC 6675
DM2LZ8F MW 515.7
DM2LZ8F FM C26H45NO7S
DM2LZ8F IC InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-/m1/s1
DM2LZ8F CS C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM2LZ8F IK WBWWGRHZICKQGZ-HZAMXZRMSA-N
DM2LZ8F IU 2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
DM2LZ8F CA CAS 81-24-3
DM2LZ8F CB CHEBI:28865
DM2LZ8F DE Type-2 diabetes
DM5NICF ID DM5NICF
DM5NICF DN TBI-1501
DM5NICF HS Phase 1/2
DM5NICF CP Takara Bio Inc.
DM5NICF DT CAR T Cell Therapy
DM5NICF DE Acute lymphoblastic leukaemia
DMR65X7 ID DMR65X7
DMR65X7 DN TC-110
DMR65X7 HS Phase 1/2
DMR65X7 CP TCR2 Therapeutics
DMR65X7 DT TCR-T cell therapy
DMR65X7 DE Non-hodgkin lymphoma; Acute lymphoblastic leukaemia
DM9S5I1 ID DM9S5I1
DM9S5I1 DN TC-210
DM9S5I1 HS Phase 1/2
DM9S5I1 CP TCR2 Therapeutics
DM9S5I1 DT TCR-T cell therapy
DM9S5I1 DE Ovarian cancer; Cholangiocarcinoma; Peritoneal mesothelioma; Non-small cell lung cancer
DMZFIGQ ID DMZFIGQ
DMZFIGQ DN TG02
DMZFIGQ HS Phase 1/2
DMZFIGQ SN SB1317; 937270-47-8; TG02; TG-02; TG02 (Double bond Z/E); UNII-40D08182TT; CHEMBL1944698; 40D08182TT; SB-1317; 1204918-72-8; C23H24N4O; Tube011; SB-1317 free base; TG02 (Double bond E); TG02 [WHO-DD]; SCHEMBL823947; SCHEMBL2298965; GTPL9095; SCHEMBL17595943; EX-A239; MolPort-039-139-793; AOB87361; BCP07033; ZINC68251500; BDBM50363196; 4029AH; AKOS030527020; AKOS032950000; SB1317(TG-02); SB14606; CS-0884; compound 26h [PMID: 22148278]; KB-80503; HY-15166; W-5884
DMZFIGQ DT Small molecular drug
DMZFIGQ PC 16739650
DMZFIGQ MW 372.5
DMZFIGQ FM C23H24N4O
DMZFIGQ IC InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+
DMZFIGQ CS CN1C/C=C/CCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1
DMZFIGQ IK VXBAJLGYBMTJCY-NSCUHMNNSA-N
DMZFIGQ IU (16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene
DMZFIGQ CA CAS 1204918-72-8
DMZFIGQ DE Solid tumour/cancer; Anaplastic astrocytoma; Recurrent glioblastoma
DMON4IL ID DMON4IL
DMON4IL DN TG100-115
DMON4IL HS Phase 1/2
DMON4IL SN TG-100115; TG-100-115; TG100115, TG100-115; 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol; 3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol; 3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol
DMON4IL CP TargeGen
DMON4IL DT Small molecular drug
DMON4IL PC 10427712
DMON4IL MW 346.3
DMON4IL FM C18H14N6O2
DMON4IL IC InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)
DMON4IL CS C1=CC(=CC(=C1)O)C2=NC3=C(N=C(N=C3N=C2C4=CC(=CC=C4)O)N)N
DMON4IL IK UJIAQDJKSXQLIT-UHFFFAOYSA-N
DMON4IL IU 3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol
DMON4IL CA CAS 677297-51-7
DMON4IL CB CHEBI:94691
DMON4IL DE Myocardial infarction; Angioedema
DMNKLZM ID DMNKLZM
DMNKLZM DN TgAAG76
DMNKLZM HS Phase 1/2
DMNKLZM SN RAAV 2/2.hRPE65p.hRPE65; AAV RPE65 gene therapy (RPE65-mediated blindness), Targeted Genetics/University of London/Moorfields
DMNKLZM CP University of London
DMNKLZM DE Blindness
DMDJLX7 ID DMDJLX7
DMDJLX7 DN Timcodar dimesilate
DMDJLX7 HS Phase 1/2
DMDJLX7 SN Timcodar dimesilate < Prop INNM; VX-853; N1-Benzyl-4-chloro-N2-methyl-N2-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-N1-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]-L-phenylalaninamide dimethanesulfonate
DMDJLX7 CP Vertex Pharmaceuticals
DMDJLX7 DT Small molecular drug
DMDJLX7 PC 9811663
DMDJLX7 MW 941.5
DMDJLX7 FM C45H53ClN4O12S2
DMDJLX7 IC InChI=1S/C43H45ClN4O6.2CH4O3S/c1-47(43(51)40(49)34-27-38(52-2)41(54-4)39(28-34)53-3)37(26-32-10-14-35(44)15-11-32)42(50)48(29-33-8-6-5-7-9-33)36(16-12-30-18-22-45-23-19-30)17-13-31-20-24-46-25-21-31;2*1-5(2,3)4/h5-11,14-15,18-25,27-28,36-37H,12-13,16-17,26,29H2,1-4H3;2*1H3,(H,2,3,4)/t37-;;/m0../s1
DMDJLX7 CS CN([C@@H](CC1=CC=C(C=C1)Cl)C(=O)N(CC2=CC=CC=C2)C(CCC3=CC=NC=C3)CCC4=CC=NC=C4)C(=O)C(=O)C5=CC(=C(C(=C5)OC)OC)OC.CS(=O)(=O)O.CS(=O)(=O)O
DMDJLX7 IK LXIAWDJOQUWVQS-SHRURHRBSA-N
DMDJLX7 IU (2S)-N-benzyl-3-(4-chlorophenyl)-N-(1,5-dipyridin-4-ylpentan-3-yl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]propanamide;methanesulfonic acid
DMDJLX7 CA CAS 183313-30-6
DMDJLX7 DE Solid tumour/cancer
DM0VXIM ID DM0VXIM
DM0VXIM DN TJ003234
DM0VXIM HS Phase 1/2
DM0VXIM SN TJ003234 mab
DM0VXIM TC Antiviral Agents
DM0VXIM DT Monoclonal antibody
DM0VXIM DE Coronavirus Disease 2019 (COVID-19)
DMLROMP ID DMLROMP
DMLROMP DN TKM-PLK1
DMLROMP HS Phase 1/2
DMLROMP CP Tekmira Pharmaceuticals
DMLROMP DT siRNA drug
DMLROMP DE Solid tumour/cancer
DM6AXV9 ID DM6AXV9
DM6AXV9 DN TOL-101
DM6AXV9 HS Phase 1/2
DM6AXV9 SN MAb (transplant rejection), Tolera Therapeutics; Monoclonal antibody (transplant rejection), Tolera Therapeutics; Anti-TCR alpha/beta antibody (transplant rejection/type 1 diabetes/multiple sclerosis), Tolera
DM6AXV9 CP Tolera Therapeutics Inc
DM6AXV9 DT Antibody
DM6AXV9 DE Multiple sclerosis
DMHTG8P ID DMHTG8P
DMHTG8P DN TP-0903
DMHTG8P HS Phase 1/2
DMHTG8P SN YUAALFPUEOYPNX-UHFFFAOYSA-N; 1341200-45-0; TP0903; UNII-14D65TV20J; CHEMBL2022968; compound 13; 14D65TV20J; TP 0903; 2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide; GTPL8863; SCHEMBL12813478; EX-A609; MolPort-039-193-844; ZINC84617535; BDBM50382425; AKOS026750306; CS-4281; DA-45909; HY-12963; S7846; FT-0700169; B5940; J-690134; 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-N,N-dimethylbenzene-1-sulfonamide
DMHTG8P CP Tolero Pharmaceuticals Lehi, UT
DMHTG8P PC 56839178
DMHTG8P MW 516.1
DMHTG8P FM C24H30ClN7O2S
DMHTG8P IC InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)
DMHTG8P CS CN1CCN(CC1)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)N(C)C)Cl
DMHTG8P IK YUAALFPUEOYPNX-UHFFFAOYSA-N
DMHTG8P IU 2-[[5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]pyrimidin-4-yl]amino]-N,N-dimethylbenzenesulfonamide
DMHTG8P CA CAS 1341200-45-0
DMHTG8P DE Solid tumour/cancer; Chronic lymphocytic leukaemia
DM9FB2T ID DM9FB2T
DM9FB2T DN TPX-0005
DM9FB2T HS Phase 1/2
DM9FB2T SN FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778
DM9FB2T CP TP Therapeutics San Diego, CA
DM9FB2T PC 135565923
DM9FB2T MW 355.4
DM9FB2T FM C18H18FN5O2
DM9FB2T IC InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1
DM9FB2T CS C[C@H]1CNC(=O)C2=C3N=C(C=CN3N=C2)N[C@@H](C4=C(O1)C=CC(=C4)F)C
DM9FB2T IK FIKPXCOQUIZNHB-WDEREUQCSA-N
DM9FB2T IU (3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
DM9FB2T CA CAS 1802220-02-5
DM9FB2T DE Solid tumour/cancer
DMIVE67 ID DMIVE67
DMIVE67 DN TPX-0046
DMIVE67 HS Phase 1/2
DMIVE67 CP Turning Point Therapeutics
DMIVE67 DT Small interfering RNA
DMIVE67 DE Solid tumour/cancer
DM8D2LC ID DM8D2LC
DM8D2LC DN Tractinostat
DM8D2LC HS Phase 1/2
DM8D2LC CP Viracta Therapeutics Cardiff, CA
DM8D2LC DE Lymphoma; Solid tumour/cancer
DM1ZK4W ID DM1ZK4W
DM1ZK4W DN TRBC1
DM1ZK4W HS Phase 1/2
DM1ZK4W CP Autolus Limited
DM1ZK4W DT CAR T Cell Therapy
DM1ZK4W DE Anaplastic large cell lymphoma; Angioimmunoblastic T-cell Lymphoma; Non-hodgkin lymphoma; Peripheral T-cell lymphoma
DMXI8CD ID DMXI8CD
DMXI8CD DN TRC-253
DMXI8CD HS Phase 1/2
DMXI8CD SN OUEHJEYKNYQVRC-UHFFFAOYSA-N; TRC253; SCHEMBL19128768; EX-A1808; 2110426-27-0; 5-(8-oxo-5-(6-(piperidin-4-yloxy)pyridin-3-yl)-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile
DMXI8CD CP Janssen Research & Development Raritan, NJTRACON PharmaceuticalsSan Diego, CA
DMXI8CD PC 130229812
DMXI8CD MW 502.5
DMXI8CD FM C23H21F3N6O2S
DMXI8CD IC InChI=1S/C23H21F3N6O2S/c24-23(25,26)17-10-15(13-29-18(17)11-27)31-20(33)22(6-1-7-22)32(21(31)35)14-2-3-19(30-12-14)34-16-4-8-28-9-5-16/h2-3,10,12-13,16,28H,1,4-9H2
DMXI8CD CS C1CC2(C1)C(=O)N(C(=S)N2C3=CN=C(C=C3)OC4CCNCC4)C5=CC(=C(N=C5)C#N)C(F)(F)F
DMXI8CD IK OUEHJEYKNYQVRC-UHFFFAOYSA-N
DMXI8CD IU 5-[8-oxo-5-(6-piperidin-4-yloxypyridin-3-yl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile
DMXI8CD DE Prostate cancer
DML54PD ID DML54PD
DML54PD DN TriCAR-T-CD19
DML54PD HS Phase 1/2
DML54PD CP Timmune Biotech Inc.
DML54PD DT CAR T Cell Therapy
DML54PD DE Non-hodgkin lymphoma
DM8IC5H ID DM8IC5H
DM8IC5H DN Triciribine
DM8IC5H HS Phase 1/2
DM8IC5H SN NSC154020; Akt Inhibitor V, Triciribine; MLS002702033; Akt/PKB Signaling Inhibitor-2; NSC-154020; TCN; Akt inhibitor V; AC1Q7CGY; AC1L6DVE; tricyclic nucleoside (TCN); SCHEMBL61269; GTPL5920; CHEMBL1892348; CHEBI:91697; HMS3268N05; HMS3654C06; HMS3229A09; HSCI1_000386; CCG-206732; 5-methyl-1-pentofuranosyl-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine; SMR001565606; SC-89664; NCI60_001091; Akt/protein kinase B signaling inhibitor-2; BRD-A42649439-001-01-0; BRD-A42649439-001-02-8; 1,5,6,8-Pentaazaacennaphthylen-3-amine, 1,5-dih
DM8IC5H DT Small molecular drug
DM8IC5H PC 65399
DM8IC5H MW 320.3
DM8IC5H FM C13H16N6O4
DM8IC5H IC InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)/t6-,8-,9-,13-/m1/s1
DM8IC5H CS CN1C2=NC=NC3=C2C(=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)C(=N1)N
DM8IC5H IK HOGVTUZUJGHKPL-HTVVRFAVSA-N
DM8IC5H IU (2R,3R,4S,5R)-2-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM8IC5H CA CAS 35943-35-2
DM8IC5H CB CHEBI:65310
DM8IC5H DE Solid tumour/cancer
DMBN1XS ID DMBN1XS
DMBN1XS DN Triciribine prodrug
DMBN1XS HS Phase 1/2
DMBN1XS SN TSR-826; Triciribine prodrug (oral, cancer); Triciribine prodrug (oral, cancer), TSRL
DMBN1XS CP Cahaba pharmaceuticals
DMBN1XS DE Solid tumour/cancer
DM9IQ4A ID DM9IQ4A
DM9IQ4A DN TRU-016
DM9IQ4A HS Phase 1/2
DM9IQ4A CP Emergent BioSolutions
DM9IQ4A DE Chronic lymphocytic leukaemia
DMQS5DY ID DMQS5DY
DMQS5DY DN TRX-518
DMQS5DY HS Phase 1/2
DMQS5DY SN GITR monoclonal antibody (cancer/viral infection), TolerRx; Glucocorticoid-induced TNF receptor monoclonal antibody (viral infection/cancer), TolerRx; GITR mAb (IgG/iv, cancer/viral infection), TolerRx
DMQS5DY CP Gitr
DMQS5DY DT Antibody
DMQS5DY DE Melanoma; Solid tumour/cancer
DMFOR9Y ID DMFOR9Y
DMFOR9Y DN TSR-011
DMFOR9Y HS Phase 1/2
DMFOR9Y CP Tesaro
DMFOR9Y PC 57345941
DMFOR9Y MW 577.7
DMFOR9Y FM C33H44FN5O3
DMFOR9Y IC InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)
DMFOR9Y CS CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F
DMFOR9Y IK WSTUJEXAPHIEIM-UHFFFAOYSA-N
DMFOR9Y IU 4-fluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide
DMFOR9Y CA CAS 1357920-84-3
DMFOR9Y DE Non-small-cell lung cancer
DMH9RGV ID DMH9RGV
DMH9RGV DN TTP-814
DMH9RGV HS Phase 1/2
DMH9RGV SN PTP-1B inhibitors (oral, type 2 diabetes), TransTech Pharma
DMH9RGV CP TransTech Pharma Inc
DMH9RGV DE Diabetic complication
DMRJK26 ID DMRJK26
DMRJK26 DN UCART019
DMRJK26 HS Phase 1/2
DMRJK26 CP Chinese PLA General Hospital
DMRJK26 DT CAR T Cell Therapy
DMRJK26 DE B-cell lymphoma; leukaemia
DMI0H3B ID DMI0H3B
DMI0H3B DN UshStat
DMI0H3B HS Phase 1/2
DMI0H3B SN Myosin 7A gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica; Myosin VIIA gene therapy (Usher syndrome 1B, LentiVector), Oxford BioMedica
DMI0H3B CP Sanofi us
DMI0H3B DE Deafness; Retinitis pigmentosa
DM6HPEC ID DM6HPEC
DM6HPEC DN USL311
DM6HPEC HS Phase 1/2
DM6HPEC SN Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; USL-311; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7
DM6HPEC CP Upsher-Smith Maple Grove, MN
DM6HPEC PC 56961879
DM6HPEC MW 422.6
DM6HPEC FM C24H34N6O
DM6HPEC IC InChI=1S/C24H34N6O/c1-19(2)28-15-9-21(10-16-28)29-13-4-14-30(18-17-29)23-6-3-5-22(27-23)24(31)26-20-7-11-25-12-8-20/h3,5-8,11-12,19,21H,4,9-10,13-18H2,1-2H3,(H,25,26,31)
DM6HPEC CS CC(C)N1CCC(CC1)N2CCCN(CC2)C3=CC=CC(=N3)C(=O)NC4=CC=NC=C4
DM6HPEC IK XNUNVQKARNSSEO-UHFFFAOYSA-N
DM6HPEC IU 6-[4-(1-propan-2-ylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-pyridin-4-ylpyridine-2-carboxamide
DM6HPEC CA CAS 1373268-67-7
DM6HPEC DE Recurring respiratory infection; Solid tumour/cancer
DMPWHU6 ID DMPWHU6
DMPWHU6 DN V81444
DMPWHU6 HS Phase 1/2
DMPWHU6 CP Vernalis
DMPWHU6 PC 44537963
DMPWHU6 MW 407.4
DMPWHU6 FM C20H21N7O3
DMPWHU6 IC InChI=1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)/t15-/m0/s1
DMPWHU6 CS CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)CO[C@H]5CCOC5
DMPWHU6 IK KURQKNMKCGYWRJ-HNNXBMFYSA-N
DMPWHU6 IU 7-(5-methylfuran-2-yl)-3-[[6-[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine
DMPWHU6 CA CAS 1202402-40-1
DMPWHU6 DE Parkinson disease; Advanced cancer
DM8A5E0 ID DM8A5E0
DM8A5E0 DN Vecabrutinib
DM8A5E0 HS Phase 1/2
DM8A5E0 SN UNII-PQ7O0OB5GU; PQ7O0OB5GU; Vecabrutinib [INN]; BIIB-062; SCHEMBL16765727; BSK-4841; FP-182; 1510829-06-7
DM8A5E0 CP Sunesis Pharmaceuticals South San Francisco, CA
DM8A5E0 PC 72547837
DM8A5E0 MW 529.9
DM8A5E0 FM C22H24ClF4N7O2
DM8A5E0 IC InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1
DM8A5E0 CS C1C[C@H](C(=O)N(C1)[C@H]2CN(CC[C@@H]2C(=O)N)C3=NC=NC(=C3F)N)NC4=CC(=CC(=C4)C(F)(F)F)Cl
DM8A5E0 IK QLRRJMOBVVGXEJ-XHSDSOJGSA-N
DM8A5E0 IU (3R,4S)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-[(3R)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxopiperidin-1-yl]piperidine-4-carboxamide
DM8A5E0 CA CAS 1510829-06-7
DM8A5E0 DE B-cell lymphoma
DMAN21O ID DMAN21O
DMAN21O DN VG-101
DMAN21O HS Phase 1/2
DMAN21O SN Seala; VG-101 analogs, Bionovo; Estrogen receptor beta selective agonists (topical intravaginal gel, vaginal dryness), Bionovo; VG-101 (topical intravaginal gel, vaginal dryness), Bionovo
DMAN21O CP Bionovo Inc
DMAN21O DE Menopause symptom
DMAMIU4 ID DMAMIU4
DMAMIU4 DN VIR-201
DMAMIU4 HS Phase 1/2
DMAMIU4 CP Virax Holdings Ltd
DMAMIU4 DE Human immunodeficiency virus infection
DMN62MP ID DMN62MP
DMN62MP DN WASP gene therapy
DMN62MP HS Phase 1/2
DMN62MP SN WASP gene therapy (Wiskott-Aldrich syndrome, lentiviral vector)
DMN62MP CP Genethon
DMN62MP DE Wiskott-Aldrich syndrome
DMUGHWR ID DMUGHWR
DMUGHWR DN WP-1066
DMUGHWR HS Phase 1/2
DMUGHWR SN WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; WP-1066; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312
DMUGHWR CP MD Anderson Cancer Center
DMUGHWR DT Small molecular drug
DMUGHWR PC 11210478
DMUGHWR MW 356.2
DMUGHWR FM C17H14BrN3O
DMUGHWR IC InChI=1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1
DMUGHWR CS C[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C2=NC(=CC=C2)Br)/C#N
DMUGHWR IK VFUAJMPDXIRPKO-LQELWAHVSA-N
DMUGHWR IU (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide
DMUGHWR CA CAS 857064-38-1
DMUGHWR DE Solid tumour/cancer; Brain cancer; Recurrent glioblastoma
DM3FIMD ID DM3FIMD
DM3FIMD DN WT-4869
DM3FIMD HS Phase 1/2
DM3FIMD CP Chugai Pharmaceutical Co Ltd
DM3FIMD DE leukaemia
DMRABOS ID DMRABOS
DMRABOS DN WX-554
DMRABOS HS Phase 1/2
DMRABOS CP UCB SA
DMRABOS DE Solid tumour/cancer
DMZ9VCF ID DMZ9VCF
DMZ9VCF DN X-396
DMZ9VCF HS Phase 1/2
DMZ9VCF SN ALK inhibitors (cancer); X-276; X-353; X-376; ALK inhibitors (cancer), Xcovery; Anaplastic lymphoma kinase inhibitors (cancer), Xcovery
DMZ9VCF CP Xcovery
DMZ9VCF DT Small molecular drug
DMZ9VCF PC 56960447
DMZ9VCF MW 547.4
DMZ9VCF FM C25H25Cl2FN6O3
DMZ9VCF IC InChI=1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1
DMZ9VCF CS C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=CC(=NN=C2N)C(=O)NC3=CC=C(C=C3)C(=O)N4CCN(CC4)C
DMZ9VCF IK ONPGOSVDVDPBCY-CQSZACIVSA-N
DMZ9VCF IU 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide
DMZ9VCF CA CAS 1365267-27-1
DMZ9VCF DE Advanced solid tumour
DMU6TG7 ID DMU6TG7
DMU6TG7 DN XMT-1592
DMU6TG7 HS Phase 1/2
DMU6TG7 CP Mersana Therapeutics
DMU6TG7 DT Antibody drug conjugate
DMU6TG7 DE Non-small-cell lung cancer; Ovarian cancer
DM148HX ID DM148HX
DM148HX DN XToll
DM148HX HS Phase 1/2
DM148HX SN Heat shock protein 10 (autoimmune diseases/inflammation), CBio; Hsp10 (autoimmune diseases/inflammation), CBio; Recombinant Cpn10 (autoimmune diseases/inflammation), CBio; Recombinant chaperonin 10 (autoimmune diseases/inflammation), CBio
DM148HX CP University of Queensland
DM148HX DE Autoimmune diabetes
DMXSEHF ID DMXSEHF
DMXSEHF DN Y-39983
DMXSEHF HS Phase 1/2
DMXSEHF SN RKI-983; SNJ-1656; ROCK inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis; Rho-associated protein kinase inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis
DMXSEHF CP Mitsubishi Pharma Corp
DMXSEHF DT Small molecular drug
DMXSEHF PC 9810884
DMXSEHF MW 280.32
DMXSEHF FM C16H16N4O
DMXSEHF IC InChI=1S/C16H16N4O/c1-10(17)11-2-4-12(5-3-11)16(21)20-14-7-9-19-15-13(14)6-8-18-15/h2-10H,17H2,1H3,(H2,18,19,20,21)/t10-/m1/s1
DMXSEHF CS C[C@H](C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2)N
DMXSEHF IK JTVBXQAYBIJXRP-SNVBAGLBSA-N
DMXSEHF IU 4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide
DMXSEHF CA CAS 199433-58-4
DMXSEHF CB CHEBI:91412
DMXSEHF DE Glaucoma/ocular hypertension
DMIA9JD ID DMIA9JD
DMIA9JD DN YSCMA
DMIA9JD HS Phase 1/2
DMIA9JD SN YS-110; Anti-CD26 humanized antibody (cancer), Y's Therapeutics/Kissei Pharmaceutical
DMIA9JD CP Y's Therapeutics Co Ltd
DMIA9JD DT Antibody
DMIA9JD DE Haematological malignancy
DMMQGPE ID DMMQGPE
DMMQGPE DN Zenocutuzomab
DMMQGPE HS Phase 1/2
DMMQGPE SN MCLA-128; PB4188
DMMQGPE CP Merus
DMMQGPE DT Antibody
DMMQGPE DE Solid tumour/cancer
DMDJSOH ID DMDJSOH
DMDJSOH DN ZK-001
DMDJSOH HS Phase 1/2
DMDJSOH SN Anfibatide; Declotana; Antithrombosis agent (injectable, angina), Lee's Pharmaceutical Holdings; Thrombolysin (injectable, angina), Lee's Pharmaceutical Holdings
DMDJSOH CP Lee's Pharmaceutical Holdings (Hong Kong) Ltd
DMDJSOH DE Thrombosis
DMVG4OC ID DMVG4OC
DMVG4OC DN ZN-c5
DMVG4OC HS Phase 1/2
DMVG4OC CP Zentalis Pharmaceuticals
DMVG4OC DT Small molecular drug
DMVG4OC DE Breast cancer
DMLV4U1 ID DMLV4U1
DMLV4U1 DN ZN-e4
DMLV4U1 HS Phase 1/2
DMLV4U1 CP Zentalis Pharmaceuticals
DMLV4U1 DT Small molecular drug
DMLV4U1 DE Non-small-cell lung cancer
DMPZE2G ID DMPZE2G
DMPZE2G DN ZPL521
DMPZE2G HS Phase 1/2
DMPZE2G CP Novartis Pharmaceuticals East Hanover, NJ
DMPZE2G DE Atopic dermatitis
DM459Q7 ID DM459Q7
DM459Q7 DN BMS-833923
DM459Q7 HS Phase 1b
DM459Q7 SN BMS-833923; 1059734-66-5; BMS 833923; XL139; XL 139; BMS833923; UNII-41J7ZJ239R; N-(2-Methyl-5-((methylamino)methyl)phenyl)-4-((4-phenylquinazolin-2-yl)amino)benzamide; 41J7ZJ239R; XL-139; C30H27N5O; N-(2-methyl-5-((methylamino)methyl)phenyl)-4-(4-phenylquinazolin-2-ylamino)benzamide; Benzamide, N-[2-methyl-5-[(methylamino)methyl]phenyl]-4-[(4-phenyl-2-quinazolinyl)amino]-; BMS-833923 free base anhydrous; XL139 mesylate; SCHEMBL4138073; GTPL8202; CHEMBL3545403; EX-A789; MolPort-035-395-837; HMS3653O09; BCP07837; AOB87352
DM459Q7 CP Exelixis; Bristol-Myers Squibb
DM459Q7 DT Small molecular drug
DM459Q7 PC 57662985
DM459Q7 MW 473.6
DM459Q7 FM C30H27N5O
DM459Q7 IC InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)
DM459Q7 CS CC1=C(C=C(C=C1)CNC)NC(=O)C2=CC=C(C=C2)NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5
DM459Q7 IK KLRRGBHZCJLIEL-UHFFFAOYSA-N
DM459Q7 IU N-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide
DM459Q7 CA CAS 1059734-66-5
DM459Q7 DE Solid tumour/cancer
DMNCOE1 ID DMNCOE1
DMNCOE1 DN FRM-6308
DMNCOE1 HS Phase 1b
DMNCOE1 CP Forum pharmaceuticals
DMNCOE1 DE Schizophrenia
DMVWYOU ID DMVWYOU
DMVWYOU DN GGF
DMVWYOU HS Phase 1b
DMVWYOU CP Acorda Therapeutics
DMVWYOU DE Congestive heart failure
DMQGH76 ID DMQGH76
DMQGH76 DN S-222611
DMQGH76 HS Phase 1b
DMQGH76 CP Shionogi
DMQGH76 DE Malignant solid tumour
DMG74BY ID DMG74BY
DMG74BY DN (-)-3PPP, Maryland
DMG74BY HS Phase 1
DMG74BY DE Schizophrenia
DM1CZSJ ID DM1CZSJ
DM1CZSJ DN (+)-JQ1
DM1CZSJ HS Phase 1
DM1CZSJ SN 1268524-70-4; (+)-JQ-1; JQ1 compound; (+)-JQ1; JQ-1; UNII-1MRH0IMX0W; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-JQ1; 1MRH0IMX0W; JQ1; CHEMBL1957266; AK109409; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3
DM1CZSJ DT Small molecular drug
DM1CZSJ PC 46907787
DM1CZSJ MW 457
DM1CZSJ FM C23H25ClN4O2S
DM1CZSJ IC InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1
DM1CZSJ CS CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C
DM1CZSJ IK DNVXATUJJDPFDM-KRWDZBQOSA-N
DM1CZSJ IU tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
DM1CZSJ CA CAS 1268524-70-4
DM1CZSJ CB CHEBI:95080
DM1CZSJ DE Testicular cancer
DMBOXA1 ID DMBOXA1
DMBOXA1 DN [3H]fenobam
DMBOXA1 HS Phase 1
DMBOXA1 SN 57653-26-6; 3-(3-chlorophenyl)-1-(1-methyl-4-oxo-5H-imidazol-2-yl)urea; SMR001456387; MLS006011708; ZINC1436; GTPL1434; GTPL1433; 1-(3-chlorophenyl)-3-(1-methyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)urea; CTK8F9740; CTK5B9436; DWPQODZAOSWNHB-UHFFFAOYSA-N; LP00842; NCGC00092384-04; FT-0630701
DMBOXA1 DT Small molecular drug
DMBOXA1 PC 135497698
DMBOXA1 MW 266.68
DMBOXA1 FM C11H11ClN4O2
DMBOXA1 IC InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
DMBOXA1 CS CN1CC(=O)NC1=NC(=O)NC2=CC(=CC=C2)Cl
DMBOXA1 IK DWPQODZAOSWNHB-UHFFFAOYSA-N
DMBOXA1 IU 1-(3-chlorophenyl)-3-(1-methyl-4-oxoimidazolidin-2-ylidene)urea
DMBOXA1 CA CAS 57653-26-6
DMBOXA1 DE Allodynia
DMSCV02 ID DMSCV02
DMSCV02 DN [N-methyl-3H(3)]AZ-10419369
DMSCV02 HS Phase 1
DMSCV02 SN AR-A2; AZ-01134; AZ-10419369; AZ-12320927; AZ-12333053; AZ-12426308; AZ-12426792; AZD-8129; M-519351; M-549715; M-555601; AR-A-000002; AR-A2 analogs, AstraZeneca
DMSCV02 CP AstraZeneca
DMSCV02 DT Small molecular drug
DMSCV02 PC 25067576
DMSCV02 MW 468.6
DMSCV02 FM C26H30N4O4
DMSCV02 IC InChI=1S/C26H30N4O4/c1-18-3-8-21(30-11-9-28(2)10-12-30)25-24(18)22(31)17-23(34-25)26(32)27-19-4-6-20(7-5-19)29-13-15-33-16-14-29/h3-8,17H,9-16H2,1-2H3,(H,27,32)/i2T3
DMSCV02 CS [3H]C([3H])([3H])N1CCN(CC1)C2=C3C(=C(C=C2)C)C(=O)C=C(O3)C(=O)NC4=CC=C(C=C4)N5CCOCC5
DMSCV02 IK JKPWOPNZKYPRPZ-BHTRQJOGSA-N
DMSCV02 IU 5-methyl-N-(4-morpholin-4-ylphenyl)-4-oxo-8-[4-(tritritiomethyl)piperazin-1-yl]chromene-2-carboxamide
DMSCV02 DE Mood disorder
DMSMRC1 ID DMSMRC1
DMSMRC1 DN 1069C
DMSMRC1 HS Phase 1
DMSMRC1 SN CHEMBL418565; 1069C85; 1069C; AC1OCF0R; SCHEMBL8965590; UMSHZWFCVXIDEO-UHFFFAOYSA-N; BDBM50280140; Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo[1,2-b]pyridazine-2-yl]carbamate; Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo[1,2-b]pyridazin-2yl]carbamate; [6-(3,4,5-Trimethoxy-benzyloxy)-imidazo[1,2-b]pyridazin-2-yl]-carbamic acid methyl ester; methyl N-[6-[(3,4,5-trimethoxyphenyl)methoxy]imidazo[1,2-b]pyridazin-2-yl]carbamate
DMSMRC1 DT Small molecular drug
DMSMRC1 PC 6918099
DMSMRC1 MW 388.4
DMSMRC1 FM C18H20N4O6
DMSMRC1 IC InChI=1S/C18H20N4O6/c1-24-12-7-11(8-13(25-2)17(12)26-3)10-28-16-6-5-15-19-14(9-22(15)21-16)20-18(23)27-4/h5-9H,10H2,1-4H3,(H,20,23)
DMSMRC1 CS COC1=CC(=CC(=C1OC)OC)COC2=NN3C=C(N=C3C=C2)NC(=O)OC
DMSMRC1 IK UMSHZWFCVXIDEO-UHFFFAOYSA-N
DMSMRC1 IU methyl N-[6-[(3,4,5-trimethoxyphenyl)methoxy]imidazo[1,2-b]pyridazin-2-yl]carbamate
DMSMRC1 DE Solid tumour/cancer
DM5IPHE ID DM5IPHE
DM5IPHE DN 1192U90
DM5IPHE HS Phase 1
DM5IPHE SN LS-25359; 2-Amino-N-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide; 2-Amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl] benzamide; 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide
DM5IPHE CP GlaxoSmithKline
DM5IPHE DT Small molecular drug
DM5IPHE PC 127912
DM5IPHE MW 409.5
DM5IPHE FM C22H27N5OS
DM5IPHE IC InChI=1S/C22H27N5OS/c23-19-9-3-1-7-17(19)22(28)24-11-5-6-12-26-13-15-27(16-14-26)21-18-8-2-4-10-20(18)29-25-21/h1-4,7-10H,5-6,11-16,23H2,(H,24,28)
DM5IPHE CS C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2N)C3=NSC4=CC=CC=C43
DM5IPHE IK GMDXHLCLNHCEIC-UHFFFAOYSA-N
DM5IPHE IU 2-amino-N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzamide
DM5IPHE CA CAS 155289-31-9
DM5IPHE DE Psychotic disorder; Schizophrenia
DMICUPT ID DMICUPT
DMICUPT DN 11C-6-Me-BTA-1
DMICUPT HS Phase 1
DMICUPT SN Carbon-11-6-Me-BTA-1; 11C-BTA-1
DMICUPT CP University of Pittsburgh
DMICUPT DE Alzheimer disease
DMYVDXW ID DMYVDXW
DMYVDXW DN 11C-AZD-2184
DMYVDXW HS Phase 1
DMYVDXW SN AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184
DMYVDXW CP AstraZeneca plc
DMYVDXW DE Alzheimer disease
DMQ0RXA ID DMQ0RXA
DMQ0RXA DN 11C-GSK-215083
DMQ0RXA HS Phase 1
DMQ0RXA SN 11C-5-HT 6 receptor antagonist (neurodegenerative disease), GlaxoSmithKline; 11C-GSK-215083 PET maging agent (neurodegenerative disease), GlaxoSmithKline
DMQ0RXA CP GlaxoSmithKline plc
DMQ0RXA DE Neurodegenerative disorder
DMCFPX8 ID DMCFPX8
DMCFPX8 DN 123-Iodine-labeled MFE-23
DMCFPX8 HS Phase 1
DMCFPX8 SN CEA antibody program (cancer/imaging); MFE-23-albumin fusion protein; CEA antibody program (cancer/imaging), Cancer Research Technology/UCL/Novozymes Delta; Albumin-linked anti-CEA single chain antibody fragment (cancer), UCL/CRT/Novozymes; Anti-CEA scFv-albumin fusion (cancer), UCL/CRT/Novozymes; 123-Iodine-labeledMFE-23; 125-I-labeled MFE-23-his; 125-Iodine-labeled MFE-23; 99mTc-labeled MFE-23
DMCFPX8 CP University College London
DMCFPX8 DT Antibody
DMCFPX8 DE Solid tumour/cancer
DM5ZC0E ID DM5ZC0E
DM5ZC0E DN 124I-8H9
DM5ZC0E HS Phase 1
DM5ZC0E CP MRI Interventions
DM5ZC0E DT Antibody
DM5ZC0E DE Glioblastoma multiforme
DMD751X ID DMD751X
DMD751X DN 1614235 + 2330672
DMD751X HS Phase 1
DMD751X SN AC1LUPX5
DMD751X CP GlaxoSmithKline
DMD751X DT Combination drug (small molecular drug)
DMD751X PC 1614235
DMD751X MW 342.5
DMD751X FM C21H28NO3+
DMD751X IC InChI=1S/C21H27NO3/c1-4-22(5-2)17(3)16-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,24H,4-5,16H2,1-3H3/p+1/t17-/m1/s1
DMD751X CS CC[NH+](CC)[C@H](C)COC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O
DMD751X IK DULUETYTNBOZNG-QGZVFWFLSA-O
DMD751X IU diethyl-[(2R)-1-(2-hydroxy-2,2-diphenylacetyl)oxypropan-2-yl]azanium
DMD751X DE Type-2 diabetes
DMFG1YA ID DMFG1YA
DMFG1YA DN 177Lu-AMBA
DMFG1YA HS Phase 1
DMFG1YA SN Ga67-AMBA; Ga68-AMBA; Galenium67-AMBA; Galenium68-AMBA; In111-AMBA; Indium-111-AMBA; Lutetium-111-AMBA; Gastrin releasing peptide receptor agonist (radiotherapeutic, cancer), Bracco; GRP-R agonist (radiotherapeutic, cancer), Bracco; 111In-AMBA; 177Lu-AMBA (cancer), Marillion Pharmaceuticals; 177Lu-DOTA-G-4-aminobenzoyl-QWAVGHLM-NH2; 67Ga-AMBA; 68Ga-AMBA
DMFG1YA CP Bracco SpA
DMFG1YA DE Breast cancer
DMM2V74 ID DMM2V74
DMM2V74 DN 177Lu-labelled CTT-1403
DMM2V74 HS Phase 1
DMM2V74 CP Cancer Targeted Technologies
DMM2V74 DT Radiopharmaceutical therapy agent
DMM2V74 DE Prostate cancer
DMZ5YMX ID DMZ5YMX
DMZ5YMX DN 18F-FEDAA-1106
DMZ5YMX HS Phase 1
DMZ5YMX SN ZK-6032924; FEDAA-1106-[18F]; Fluorine-18-FEDAA-1106; 18F-labeled PET imaging agent (Alzheimer's disease), Bayer; 18F-labeled PET imaging agent (multiple sclerosis), Bayer
DMZ5YMX CP Taisho Pharmaceutical Co Ltd
DMZ5YMX DE Alzheimer disease
DMGE3DY ID DMGE3DY
DMGE3DY DN 18-MC
DMGE3DY HS Phase 1
DMGE3DY CP Savant HWP San Carlos, CA
DMGE3DY DE Substance use disorder
DMJ1SQY ID DMJ1SQY
DMJ1SQY DN 19-28z T CELLS
DMJ1SQY HS Phase 1
DMJ1SQY CP Memorial Sloan Kettering Cancer Center
DMJ1SQY DT CAR T Cell Therapy
DMJ1SQY DE Non-hodgkin lymphoma
DMQ8NTZ ID DMQ8NTZ
DMQ8NTZ DN 192C86
DMQ8NTZ HS Phase 1
DMQ8NTZ SN BW-192C86
DMQ8NTZ CP Burroughs Wellcome Inc
DMQ8NTZ DT Small molecular drug
DMQ8NTZ PC 9576901
DMQ8NTZ MW 411.6
DMQ8NTZ FM C20H33N3O4S
DMQ8NTZ IC InChI=1S/C20H33N3O4S/c1-2-22-16-11-15(28-10-6-9-19(25)26)12-17(16)23(20(22)27)21-13-18(24)14-7-4-3-5-8-14/h13-18,24H,2-12H2,1H3,(H,25,26)/b21-13+
DMQ8NTZ CS CCN1C2CC(CC2N(C1=O)/N=C/C(C3CCCCC3)O)SCCCC(=O)O
DMQ8NTZ IK YDMMNNOYPGHBEY-FYJGNVAPSA-N
DMQ8NTZ IU 4-[[3-[(E)-(2-cyclohexyl-2-hydroxyethylidene)amino]-1-ethyl-2-oxo-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]imidazol-5-yl]sulfanyl]butanoic acid
DMQ8NTZ CA CAS 139147-26-5
DMQ8NTZ DE Thrombosis
DMN9MPX ID DMN9MPX
DMN9MPX DN 212Pb-labelled DOTAMTATE
DMN9MPX HS Phase 1
DMN9MPX CP OranoMed/Radiomedix
DMN9MPX DT Radiopharmaceutical therapy agent
DMN9MPX DE Neuroendocrine cancer
DM2SQBF ID DM2SQBF
DM2SQBF DN 225Ac-labelled aCD33
DM2SQBF HS Phase 1
DM2SQBF CP Actinium Pharmaceuticals
DM2SQBF DT Radiopharmaceutical therapy agent
DM2SQBF DE Acute myeloid leukaemia
DM3E2IY ID DM3E2IY
DM3E2IY DN 225Ac-labelled aCD38
DM3E2IY HS Phase 1
DM3E2IY CP Actinium Pharmaceuticals
DM3E2IY DT Radiopharmaceutical therapy agent
DM3E2IY DE Multiple myeloma
DM1ZY6M ID DM1ZY6M
DM1ZY6M DN 227Th-labelled MSLN-TTC
DM1ZY6M HS Phase 1
DM1ZY6M SN BAY2287411
DM1ZY6M CP Bayer
DM1ZY6M DT Radiopharmaceutical therapy agent
DM1ZY6M DE Epithelioid mesothelioma
DM7L45S ID DM7L45S
DM7L45S DN 227Th-labelled PSMA-TTC
DM7L45S HS Phase 1
DM7L45S SN BAY2315497
DM7L45S CP Bayer
DM7L45S DT Radiopharmaceutical therapy agent
DM7L45S DE Prostate cancer
DMDFA3E ID DMDFA3E
DMDFA3E DN 349U85.HCL
DMDFA3E HS Phase 1
DMDFA3E SN 6-Piperidinoquinolin-2(1H)-one hydrochloride
DMDFA3E DT Small molecular drug
DMDFA3E PC 164016
DMDFA3E MW 264.75
DMDFA3E FM C14H17ClN2O
DMDFA3E IC InChI=1S/C14H16N2O.ClH/c17-14-7-4-11-10-12(5-6-13(11)15-14)16-8-2-1-3-9-16;/h4-7,10H,1-3,8-9H2,(H,15,17);1H
DMDFA3E CS C1CCN(CC1)C2=CC3=C(C=C2)NC(=O)C=C3.Cl
DMDFA3E IK KYTREJMWHJPVSI-UHFFFAOYSA-N
DMDFA3E IU 6-piperidin-1-yl-1H-quinolin-2-one;hydrochloride
DMDFA3E CA CAS 116942-30-4
DMDFA3E DE Cardiovascular disease
DM4Z1CH ID DM4Z1CH
DM4Z1CH DN 4-aminosalicylate sodium
DM4Z1CH HS Phase 1
DM4Z1CH SN AGI-022; Salicylate prodrug (oralcontrolled release, ulcerative colitis), AGI Therapeutics; 4-ASA-Na; 4-ASA-Na (oral, controlled release), AGI Therapeutics
DM4Z1CH CP Athpharma Ltd
DM4Z1CH DT Small molecular drug
DM4Z1CH PC 2724368
DM4Z1CH MW 175.12
DM4Z1CH FM C7H6NNaO3
DM4Z1CH IC InChI=1S/C7H7NO3.Na/c8-4-1-2-5(7(10)11)6(9)3-4;/h1-3,9H,8H2,(H,10,11);/q;+1/p-1
DM4Z1CH CS C1=CC(=C(C=C1N)O)C(=O)[O-].[Na+]
DM4Z1CH IK FVVDKUPCWXUVNP-UHFFFAOYSA-M
DM4Z1CH IU sodium;4-amino-2-hydroxybenzoate
DM4Z1CH CA 133-10-8
DM4Z1CH DE Inflammatory bowel disease
DM8XMPT ID DM8XMPT
DM8XMPT DN 4SC-203
DM8XMPT HS Phase 1
DM8XMPT CP 4SC AG
DM8XMPT PC 44467821
DM8XMPT MW 642.8
DM8XMPT FM C33H38N8O4S
DM8XMPT IC InChI=1S/C33H38N8O4S/c1-21-6-9-27(43-3)26(16-21)37-32(42)39-33-38-24-8-7-22(17-30(24)46-33)36-31-23-18-28(44-4)29(19-25(23)34-20-35-31)45-15-5-10-41-13-11-40(2)12-14-41/h6-9,16-20H,5,10-15H2,1-4H3,(H,34,35,36)(H2,37,38,39,42)
DM8XMPT CS CC1=CC(=C(C=C1)OC)NC(=O)NC2=NC3=C(S2)C=C(C=C3)NC4=NC=NC5=CC(=C(C=C54)OC)OCCCN6CCN(CC6)C
DM8XMPT IK MAFACRSJGNJHCF-UHFFFAOYSA-N
DM8XMPT IU 1-(2-methoxy-5-methylphenyl)-3-[6-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl]amino]-1,3-benzothiazol-2-yl]urea
DM8XMPT CA CAS 895533-09-2
DM8XMPT DE Solid tumour/cancer
DMG75P3 ID DMG75P3
DMG75P3 DN 4SC-205
DMG75P3 HS Phase 1
DMG75P3 CP 4SC AG
DMG75P3 DE Lymphoma
DM5RLM4 ID DM5RLM4
DM5RLM4 DN 4SCAR19 cells
DM5RLM4 HS Phase 1
DM5RLM4 CP The First People's Hospital of Yunnan
DM5RLM4 DT CAR T Cell Therapy
DM5RLM4 DE Acute lymphoblastic leukaemia
DM0351T ID DM0351T
DM0351T DN 5-FP
DM0351T HS Phase 1
DM0351T SN 5-Fluoro-2(1H)-pyrimidinone
DM0351T DT Small molecular drug
DM0351T PC 101498
DM0351T MW 114.08
DM0351T FM C4H3FN2O
DM0351T IC InChI=1S/C4H3FN2O/c5-3-1-6-4(8)7-2-3/h1-2H,(H,6,7,8)
DM0351T CS C1=C(C=NC(=O)N1)F
DM0351T IK HPABFFGQPLJKBP-UHFFFAOYSA-N
DM0351T IU 5-fluoro-1H-pyrimidin-2-one
DM0351T CA CAS 2022-78-8
DM0351T CB CHEBI:125539
DM0351T DE Solid tumour/cancer
DMOIE05 ID DMOIE05
DMOIE05 DN 609A
DMOIE05 HS Phase 1
DMOIE05 CP 3SBio
DMOIE05 DT Antibody
DMOIE05 DE Solid tumour/cancer
DMQ789Z ID DMQ789Z
DMQ789Z DN 8H9
DMQ789Z HS Phase 1
DMQ789Z CP Memorial Sloan-Kettering Cancer Center
DMQ789Z DT Antibody
DMQ789Z DE Solid tumour/cancer; Brain cancer
DMJR6TC ID DMJR6TC
DMJR6TC DN 90Y-cG250
DMJR6TC HS Phase 1
DMJR6TC SN Radiolabeled G250 derived mAb (cancer), Wilex/Ludwig Institute; 90Y-DOTA-cG250
DMJR6TC CP Wilex AG
DMJR6TC DT Antibody
DMJR6TC DE Solid tumour/cancer
DMJB6E2 ID DMJB6E2
DMJB6E2 DN 99mTc-MIP-1405
DMJB6E2 HS Phase 1
DMJB6E2 CP Molecular Insight Pharmaceuticals
DMJB6E2 DE Prostate cancer
DMYKPXJ ID DMYKPXJ
DMYKPXJ DN 9cUAB-30
DMYKPXJ HS Phase 1
DMYKPXJ SN UAB-112; UAB-20; UAB-30; UAB-75; UAB-76; UAB-8; Retinoic acid analogs (cancer), University of Alabama; (9Z)-UAB-30
DMYKPXJ CP University of Alabama at Birmingham
DMYKPXJ DE Solid tumour/cancer
DMGJ7A4 ID DMGJ7A4
DMGJ7A4 DN A/Anhui/05
DMGJ7A4 HS Phase 1
DMGJ7A4 SN Inactivated H5N1 avian influenza vaccine, NIAID
DMGJ7A4 CP Glaxosmithkline; novavax; vaxart
DMGJ7A4 DT Vaccine
DMGJ7A4 DE Influenza virus infection
DMRWTFG ID DMRWTFG
DMRWTFG DN A-337
DMRWTFG HS Phase 1
DMRWTFG DT Antibody
DMRWTFG DE Non-small-cell lung cancer
DM25CBW ID DM25CBW
DM25CBW DN A-348441
DM25CBW HS Phase 1
DM25CBW SN A-348441; CHEMBL219684; SCHEMBL699533; BDBM50195155; KB-3305
DM25CBW DT Small molecular drug
DM25CBW PC 9854142
DM25CBW MW 850.2
DM25CBW FM C54H75NO7
DM25CBW IC InChI=1S/C54H75NO7/c1-7-22-54(61)24-21-43-40-15-11-34-27-37(56)14-16-39(34)49(40)41(31-52(43,54)4)33-9-12-36(13-10-33)55(6)25-26-62-38-20-23-51(3)35(28-38)29-46(57)50-44-18-17-42(32(2)8-19-48(59)60)53(44,5)47(58)30-45(50)51/h9-10,12-13,27,32,35,38,40-47,50,57-58,61H,8,11,14-21,23-26,28-31H2,1-6H3,(H,59,60)/t32-,35+,38+,40+,41-,42-,43+,44+,45+,46-,47+,50+,51+,52+,53-,54+/m1/s1
DM25CBW CS CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)CCO[C@H]6CC[C@]7([C@@H](C6)C[C@H]([C@@H]8[C@@H]7C[C@@H]([C@]9([C@H]8CC[C@@H]9[C@H](C)CCC(=O)O)C)O)O)C)C)O
DM25CBW IK LEUWECPXLBIBOF-NZWIZOFBSA-N
DM25CBW IU (4R)-4-[(3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-[2-[4-[(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl]-N-methylanilino]ethoxy]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM25CBW DE Type-2 diabetes
DMX0JLI ID DMX0JLI
DMX0JLI DN A-837093
DMX0JLI HS Phase 1
DMX0JLI SN 3,4-dihydro-naphthalen-1-olate
DMX0JLI CP Abbott
DMX0JLI DT Small molecular drug
DMX0JLI PC 135436761
DMX0JLI MW 517.6
DMX0JLI FM C24H27N3O6S2
DMX0JLI IC InChI=1S/C24H27N3O6S2/c1-14(2)11-12-24(3)17-8-6-5-7-16(17)21(28)20(22(24)29)23-25-18-10-9-15(26-34(4,30)31)13-19(18)35(32,33)27-23/h5-10,13-14,26,28H,11-12H2,1-4H3,(H,25,27)/t24-/m1/s1
DMX0JLI CS CC(C)CC[C@@]1(C2=CC=CC=C2C(=C(C1=O)C3=NS(=O)(=O)C4=C(N3)C=CC(=C4)NS(=O)(=O)C)O)C
DMX0JLI IK ZTRJLSWOQIDJIS-XMMPIXPASA-N
DMX0JLI IU N-[3-[(4R)-1-hydroxy-4-methyl-4-(3-methylbutyl)-3-oxonaphthalen-2-yl]-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-7-yl]methanesulfonamide
DMX0JLI CA CAS 847442-84-6
DMX0JLI DE Hepatitis C virus infection
DM92RQT ID DM92RQT
DM92RQT DN AAB-003/PF-05236812
DM92RQT HS Phase 1
DM92RQT CP Janssen Alzheimer Immunotherapy; Pfizer
DM92RQT DE Alzheimer disease
DMG4RK0 ID DMG4RK0
DMG4RK0 DN AAD-2004
DMG4RK0 HS Phase 1
DMG4RK0 SN AAD-2004; 927685-43-6; UNII-11VWK61J69; 11VWK61J69; 2-Hydroxy-5-((4-(trifluoromethyl)phenethyl)amino)benzoic acid; Benzoic acid, 2-hydroxy-5-((2-(4-(trifluoromethyl)phenyl)ethyl)amino)-; Benzoic acid, 2-hydroxy-5-[[2-[4-(trifluoromethyl)phenyl]ethyl]amino]-; UTMVACIBQLDZLP-UHFFFAOYSA-N; SCHEMBL608498; ZINC34885635; AKOS027338686; SB16954; AS-35180; 2-HYDROXY-5-(2-(4-TRIFLUOROMETHYL-PHENYL)-ETHYLAMINO)-BENZOIC ACID
DMG4RK0 CP GNT Pharma Co Ltd
DMG4RK0 DT Small molecular drug
DMG4RK0 PC 16042343
DMG4RK0 MW 325.28
DMG4RK0 FM C16H14F3NO3
DMG4RK0 IC InChI=1S/C16H14F3NO3/c17-16(18,19)11-3-1-10(2-4-11)7-8-20-12-5-6-14(21)13(9-12)15(22)23/h1-6,9,20-21H,7-8H2,(H,22,23)
DMG4RK0 CS C1=CC(=CC=C1CCNC2=CC(=C(C=C2)O)C(=O)O)C(F)(F)F
DMG4RK0 IK UTMVACIBQLDZLP-UHFFFAOYSA-N
DMG4RK0 IU 2-hydroxy-5-[2-[4-(trifluoromethyl)phenyl]ethylamino]benzoic acid
DMG4RK0 CA CAS 927685-43-6
DMG4RK0 DE Alzheimer disease
DMIX5HF ID DMIX5HF
DMIX5HF DN AAV2/8-LSPhGAA
DMIX5HF HS Phase 1
DMIX5HF SN ACTUS 101
DMIX5HF CP Actus Therapeutics
DMIX5HF DT Gene therapy
DMIX5HF DE Pompe disease
DMIDEKB ID DMIDEKB
DMIDEKB DN AAV2-hFIX16
DMIDEKB HS Phase 1
DMIDEKB SN AAV-F.IX, University of Pennsylvania; AAV-factor IX gene therapy (hemophilia B), University of Pennsylvania
DMIDEKB CP University of Pennsylvania
DMIDEKB DE Factor IX deficiency
DMBG9HI ID DMBG9HI
DMBG9HI DN AB023
DMBG9HI HS Phase 1
DMBG9HI CP Aronora
DMBG9HI DT Antibody
DMBG9HI DE End-stage renal disease
DMGONUE ID DMGONUE
DMGONUE DN AB680
DMGONUE HS Phase 1
DMGONUE SN AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH
DMGONUE CP Arcus Biosciences
DMGONUE DT Small molecular drug
DMGONUE PC 130205852
DMGONUE MW 580.8
DMGONUE FM C20H24ClFN4O9P2
DMGONUE IC InChI=1S/C20H24ClFN4O9P2/c1-10(11-4-2-3-5-13(11)22)24-14-6-16(21)25-19-12(14)7-23-26(19)20-18(28)17(27)15(35-20)8-34-37(32,33)9-36(29,30)31/h2-7,10,15,17-18,20,27-28H,8-9H2,1H3,(H,24,25)(H,32,33)(H2,29,30,31)/t10-,15+,17+,18+,20+/m0/s1
DMGONUE CS C[C@@H](C1=CC=CC=C1F)NC2=CC(=NC3=C2C=NN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(CP(=O)(O)O)O)O)O)Cl
DMGONUE IK MFYLCAMJNGIULC-KCVUFLITSA-N
DMGONUE IU [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMGONUE CA CAS 2105904-82-1
DMGONUE DE Pancreatic cancer
DMYFB10 ID DMYFB10
DMYFB10 DN Abaperidone
DMYFB10 HS Phase 1
DMYFB10 SN FI-8602
DMYFB10 CP Ferrer Internacional SA
DMYFB10 DT Small molecular drug
DMYFB10 PC 3037308
DMYFB10 MW 452.5
DMYFB10 FM C25H25FN2O5
DMYFB10 IC InChI=1S/C25H25FN2O5/c26-18-2-4-20-23(12-18)33-27-24(20)16-6-9-28(10-7-16)8-1-11-31-19-3-5-21-22(13-19)32-15-17(14-29)25(21)30/h2-5,12-13,15-16,29H,1,6-11,14H2
DMYFB10 CS C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCCOC4=CC5=C(C=C4)C(=O)C(=CO5)CO
DMYFB10 IK ICAXEUYZCLRXKY-UHFFFAOYSA-N
DMYFB10 IU 7-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one
DMYFB10 CA CAS 183849-43-6
DMYFB10 DE Schizophrenia
DMIQXDJ ID DMIQXDJ
DMIQXDJ DN ABBV-151
DMIQXDJ HS Phase 1
DMIQXDJ CP AbbVie
DMIQXDJ DT Antibody
DMIQXDJ DE Solid tumour/cancer
DM71Q69 ID DM71Q69
DM71Q69 DN ABBV-184
DM71Q69 HS Phase 1
DM71Q69 CP AbbVie
DM71Q69 DT TCR-T cell therapy
DM71Q69 DE Non-small-cell lung cancer; Acute myeloid leukaemia
DMUCF9L ID DMUCF9L
DMUCF9L DN ABBV-2451
DMUCF9L HS Phase 1
DMUCF9L CP AbbVie
DMUCF9L DE Cystic fibrosis
DMCZI8L ID DMCZI8L
DMCZI8L DN ABBV-257
DMCZI8L HS Phase 1
DMCZI8L CP AbbVieNorth Chicago, IL
DMCZI8L DE Rheumatoid arthritis
DMU6K37 ID DMU6K37
DMU6K37 DN ABBV-2737
DMU6K37 HS Phase 1
DMU6K37 CP AbbVie
DMU6K37 DE Cystic fibrosis
DMB01L5 ID DMB01L5
DMB01L5 DN ABBV-3067
DMB01L5 HS Phase 1
DMB01L5 CP AbbVie
DMB01L5 DE Cystic fibrosis
DM49O6Y ID DM49O6Y
DM49O6Y DN ABBV-323
DM49O6Y HS Phase 1
DM49O6Y CP AbbVieNorth Chicago, IL
DM49O6Y DE Crohn disease
DMQGPRE ID DMQGPRE
DMQGPRE DN ABBV-399
DMQGPRE HS Phase 1
DMQGPRE CP Abbvie
DMQGPRE DE Solid tumour/cancer
DMPD0KL ID DMPD0KL
DMPD0KL DN ABBV-428
DMPD0KL HS Phase 1
DMPD0KL CP AbbVieNorth Chicago, IL
DMPD0KL DE Solid tumour/cancer
DM87SM9 ID DM87SM9
DM87SM9 DN ABBV-467
DM87SM9 HS Phase 1
DM87SM9 CP AbbVie
DM87SM9 DT Small molecular drug
DM87SM9 DE Multiple myeloma
DM90EO3 ID DM90EO3
DM90EO3 DN ABBV-621
DM90EO3 HS Phase 1
DM90EO3 CP AbbVie
DM90EO3 DT Small molecular drug
DM90EO3 DE Haematological malignancy; Solid tumour/cancer; Hematologic tumour
DMTEA9C ID DMTEA9C
DMTEA9C DN ABBV-744
DMTEA9C HS Phase 1
DMTEA9C SN OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318
DMTEA9C CP AbbVieNorth Chicago, IL
DMTEA9C PC 132010322
DMTEA9C MW 491.6
DMTEA9C FM C28H30FN3O4
DMTEA9C IC InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)
DMTEA9C CS CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C
DMTEA9C IK OEDSFMUSNZDJFD-UHFFFAOYSA-N
DMTEA9C IU N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
DMTEA9C CA CAS 2138861-99-9
DMTEA9C DE Prostate cancer; Acute myeloid leukaemia
DMZM0T8 ID DMZM0T8
DMZM0T8 DN ABBV-838
DMZM0T8 HS Phase 1
DMZM0T8 CP AbbVieNorth Chicago, IL
DMZM0T8 DE Multiple myeloma
DMPXDL6 ID DMPXDL6
DMPXDL6 DN ABBV-CLS-579
DMPXDL6 HS Phase 1
DMPXDL6 CP AbbVie; Calico Life Sciences
DMPXDL6 DT Antibody
DMPXDL6 DE Solid tumour/cancer
DMUSOM9 ID DMUSOM9
DMUSOM9 DN ABBV-CX-2029
DMUSOM9 HS Phase 1
DMUSOM9 CP AbbVie; CytomX Therapeutics
DMUSOM9 DT Antibody drug conjugate
DMUSOM9 DE Hematologic tumour
DM1KD7U ID DM1KD7U
DM1KD7U DN ABI-011
DM1KD7U HS Phase 1
DM1KD7U CP Celgene
DM1KD7U DE Solid tumour/cancer; Lymphoma
DM4TN6W ID DM4TN6W
DM4TN6W DN ABI-H3733
DM4TN6W HS Phase 1
DM4TN6W CP Assembly Biosciences
DM4TN6W DT Small molecular drug
DM4TN6W DE Hepatitis B
DMS1HR3 ID DMS1HR3
DMS1HR3 DN ABM-1310
DMS1HR3 HS Phase 1
DMS1HR3 CP ABM Therapeutics
DMS1HR3 DT Small molecular drug
DMS1HR3 DE Solid tumour/cancer
DMA4WEO ID DMA4WEO
DMA4WEO DN ABSK021
DMA4WEO HS Phase 1
DMA4WEO CP Abbisko Therapeutics
DMA4WEO DT Small molecular drug
DMA4WEO DE Solid tumour/cancer
DMG4H9Y ID DMG4H9Y
DMG4H9Y DN ABT-072
DMG4H9Y HS Phase 1
DMG4H9Y CP Abbott
DMG4H9Y PC 57775240
DMG4H9Y MW 469.6
DMG4H9Y FM C24H27N3O5S
DMG4H9Y IC InChI=1S/C24H27N3O5S/c1-24(2,3)20-15-19(27-13-12-21(28)25-23(27)29)14-17(22(20)32-4)9-6-16-7-10-18(11-8-16)26-33(5,30)31/h6-15,26H,1-5H3,(H,25,28,29)/b9-6+
DMG4H9Y CS CC(C)(C)C1=CC(=CC(=C1OC)/C=C/C2=CC=C(C=C2)NS(=O)(=O)C)N3C=CC(=O)NC3=O
DMG4H9Y IK XMZSTQYSBYEENY-RMKNXTFCSA-N
DMG4H9Y IU N-[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide
DMG4H9Y CA CAS 1132936-00-5
DMG4H9Y DE Hepatitis C virus infection
DMJFWPR ID DMJFWPR
DMJFWPR DN ABT-102
DMJFWPR HS Phase 1
DMJFWPR SN 3-(1H-indazol-4-yl)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)urea
DMJFWPR CP Abbott
DMJFWPR TC Analgesics
DMJFWPR DT Small molecular drug
DMJFWPR PC 11256560
DMJFWPR MW 348.4
DMJFWPR FM C21H24N4O
DMJFWPR IC InChI=1S/C21H24N4O/c1-21(2,3)14-8-9-15-13(11-14)7-10-18(15)24-20(26)23-17-5-4-6-19-16(17)12-22-25-19/h4-6,8-9,11-12,18H,7,10H2,1-3H3,(H,22,25)(H2,23,24,26)/t18-/m1/s1
DMJFWPR CS CC(C)(C)C1=CC2=C(C=C1)[C@@H](CC2)NC(=O)NC3=CC=CC4=C3C=NN4
DMJFWPR IK TYOYXJNGINZFET-GOSISDBHSA-N
DMJFWPR IU 1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-(1H-indazol-4-yl)urea
DMJFWPR CA CAS 808756-71-0
DMJFWPR DE Chronic pain
DM1F50I ID DM1F50I
DM1F50I DN ABT-110
DM1F50I HS Phase 1
DM1F50I SN Hu-alphaD11; PG-110; Humanized anti-NGF antibody (pain), Lay Line Genomics; Humanized anti-NGF antibody (pain), PanGenetics; Humanized anti-nerve growth factor antibody (pain), Lay Line Genomics; Humanized anti-nerve growth factor antibody (pain), PanGenetics
DM1F50I CP Abbvie
DM1F50I DE Chronic pain
DMQ3O1U ID DMQ3O1U
DMQ3O1U DN ABT-165
DMQ3O1U HS Phase 1
DMQ3O1U CP AbbVieNorth Chicago, IL
DMQ3O1U DE Solid tumour/cancer
DMR7OGL ID DMR7OGL
DMR7OGL DN ABT-239
DMR7OGL HS Phase 1
DMR7OGL SN 4-[2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl]benzonitrile
DMR7OGL CP Abbott
DMR7OGL DT Small molecular drug
DMR7OGL PC 9818903
DMR7OGL MW 330.4
DMR7OGL FM C22H22N2O
DMR7OGL IC InChI=1S/C22H22N2O/c1-16-3-2-11-24(16)12-10-21-14-20-13-19(8-9-22(20)25-21)18-6-4-17(15-23)5-7-18/h4-9,13-14,16H,2-3,10-12H2,1H3/t16-/m1/s1
DMR7OGL CS C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C4=CC=C(C=C4)C#N
DMR7OGL IK KFHYZKCRXNRKRC-MRXNPFEDSA-N
DMR7OGL IU 4-[2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]-1-benzofuran-5-yl]benzonitrile
DMR7OGL CA CAS 460746-46-7
DMR7OGL DE Cognitive impairment
DM7TOWX ID DM7TOWX
DM7TOWX DN ABT-333
DM7TOWX HS Phase 1
DM7TOWX SN Dasabuvir; 1132935-63-7; ABT-333; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; ABT333; UNII-DE54EQW8T1; ABT 333; Dasabuvir (ABT-333); DE54EQW8T1; CHEBI:85182; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; C26H27N3O5S; Dasabuvir [INN]; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; Dasabuvir [USAN:INN]; Dasabuvir (USA
DM7TOWX CP Abbott
DM7TOWX DT Small molecular drug
DM7TOWX PC 56640146
DM7TOWX MW 493.6
DM7TOWX FM C26H27N3O5S
DM7TOWX IC InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
DM7TOWX CS CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O
DM7TOWX IK NBRBXGKOEOGLOI-UHFFFAOYSA-N
DM7TOWX IU N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
DM7TOWX CA CAS 1132935-63-7
DM7TOWX CB CHEBI:85182
DM7TOWX DE Hepatitis C virus infection
DMWN7D3 ID DMWN7D3
DMWN7D3 DN ABT-354
DMWN7D3 HS Phase 1
DMWN7D3 CP Abbvie
DMWN7D3 DE Alzheimer disease
DM4KPV0 ID DM4KPV0
DM4KPV0 DN ABT-413
DM4KPV0 HS Phase 1
DM4KPV0 DT Antibody
DM4KPV0 DE Solid tumour/cancer
DMVLPRT ID DMVLPRT
DMVLPRT DN ABT-700
DMVLPRT HS Phase 1
DMVLPRT CP Abbott Laboratories Abbott
DMVLPRT DE Advanced solid tumour
DMFH3JM ID DMFH3JM
DMFH3JM DN ABT-767
DMFH3JM HS Phase 1
DMFH3JM CP Abbott Laboratories Abbott
DMFH3JM DE Solid tumour/cancer
DMB9N4J ID DMB9N4J
DMB9N4J DN ABT-957
DMB9N4J HS Phase 1
DMB9N4J CP Abbott Laboratories
DMB9N4J DE Alzheimer disease
DM9SYVJ ID DM9SYVJ
DM9SYVJ DN ABX-1431
DM9SYVJ HS Phase 1
DM9SYVJ SN SQZJGTOZFRNWCX-UHFFFAOYSA-N; CHEMBL3945728; SCHEMBL15100632; BDBM180052; US9133148, 9aq
DM9SYVJ CP Abide Therapeutics San Diego, CA
DM9SYVJ PC 71657619
DM9SYVJ MW 507.4
DM9SYVJ FM C20H22F9N3O2
DM9SYVJ IC InChI=1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2
DM9SYVJ CS C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CN3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F
DM9SYVJ IK SQZJGTOZFRNWCX-UHFFFAOYSA-N
DM9SYVJ IU 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate
DM9SYVJ CA CAS 1446817-84-0
DM9SYVJ DE Neuropathic pain; Tourette syndrome
DMS3915 ID DMS3915
DMS3915 DN AC 165198
DMS3915 HS Phase 1
DMS3915 CP Amylin Pharmaceuticals; Biocon
DMS3915 DE Diabetic complication
DMB5A63 ID DMB5A63
DMB5A63 DN AC0058TA
DMB5A63 HS Phase 1
DMB5A63 CP ACEA Biosciences San Diego, CA
DMB5A63 DE Autoimmune disease
DM36WTQ ID DM36WTQ
DM36WTQ DN AC-262271
DM36WTQ HS Phase 1
DM36WTQ SN IOP lowering (glaucoma), Allergan; Muscarinic M1 agonists (pain, glaucoma), ACADIA/Allergan
DM36WTQ CP Acadia pharmaceuticals
DM36WTQ DE Glaucoma/ocular hypertension
DMPS6U9 ID DMPS6U9
DMPS6U9 DN AC430
DMPS6U9 HS Phase 1
DMPS6U9 SN 152-97-6; SCHEMBL11862489; ZINC21981448; AKOS025402073
DMPS6U9 CP Ambit Biosciences
DMPS6U9 DT Small molecular drug
DMPS6U9 PC 46892373
DMPS6U9 MW 349.4
DMPS6U9 FM C19H16FN5O
DMPS6U9 IC InChI=1S/C19H16FN5O/c1-11-10-16(25-24-11)22-18-14-4-2-3-5-15(14)21-19(23-18)17(26)12-6-8-13(20)9-7-12/h2-10,17,26H,1H3,(H2,21,22,23,24,25)
DMPS6U9 CS CC1=CC(=NN1)NC2=NC(=NC3=CC=CC=C32)C(C4=CC=C(C=C4)F)O
DMPS6U9 IK DCRWIATZWHLIPN-UHFFFAOYSA-N
DMPS6U9 IU (4-fluorophenyl)-[4-[(5-methyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]methanol
DMPS6U9 CA CAS 1241914-87-3
DMPS6U9 DE leukaemia
DMJ36YH ID DMJ36YH
DMJ36YH DN ACE-011
DMJ36YH HS Phase 1
DMJ36YH SN 116496-76-5; 4-Acetamido-3-ethoxynitrobenzene; N-(2-ethoxy-4-nitrophenyl)acetamide; Acetamide,N-(2-ethoxy-4-nitrophenyl)-; 2'-ETHOXY-4'-NITROACETANILIDE; CDS1_004703; AC1MEGDI; ACMC-20c3rb; CBMicro_030367; 2-Ethoxy-4-nitroacetanilide; Oprea1_342150; DivK1c_005743; ACE011; SCHEMBL2204761; KS-00002AMW; CTK4A9819; DTXSID60387001; XZWVZJDHIDYKPB-UHFFFAOYSA-N; MolPort-000-279-575; ZX-AT005552; ZINC5061120; OR9529; AKOS001044796; PS-6223; VZ36467; MCULE-3006561606; AB07920; AS02565; KB-71958; CC-31292; AJ-53053; Acetamide, N-(2-ethoxy-4-nitrop
DMJ36YH DT Small molecular drug
DMJ36YH PC 2877953
DMJ36YH MW 224.21
DMJ36YH FM C10H12N2O4
DMJ36YH IC InChI=1S/C10H12N2O4/c1-3-16-10-6-8(12(14)15)4-5-9(10)11-7(2)13/h4-6H,3H2,1-2H3,(H,11,13)
DMJ36YH CS CCOC1=C(C=CC(=C1)[N+](=O)[O-])NC(=O)C
DMJ36YH IK XZWVZJDHIDYKPB-UHFFFAOYSA-N
DMJ36YH IU N-(2-ethoxy-4-nitrophenyl)acetamide
DMJ36YH CA CAS 116496-76-5
DMJ36YH DE Anemia
DMUBYFM ID DMUBYFM
DMUBYFM DN ACE-041
DMUBYFM HS Phase 1
DMUBYFM SN N-(5-bromo-2-methylpyridin-4-yl)acetamide; 1244949-22-1; ACE041; DTXSID10670359; 4605AA; ZINC38540942; AKOS016011880; FCH1349294; AJ-96556; EN001564; KB-258244; AX8247344; Acetamide, N-(5-bromo-2-methyl-4-pyridinyl)-
DMUBYFM CP Acceleron Pharma
DMUBYFM DT Small molecular drug
DMUBYFM PC 45480413
DMUBYFM MW 229.07
DMUBYFM FM C8H9BrN2O
DMUBYFM IC InChI=1S/C8H9BrN2O/c1-5-3-8(11-6(2)12)7(9)4-10-5/h3-4H,1-2H3,(H,10,11,12)
DMUBYFM CS CC1=CC(=C(C=N1)Br)NC(=O)C
DMUBYFM IK OMGSODSTISOTIL-UHFFFAOYSA-N
DMUBYFM IU N-(5-bromo-2-methylpyridin-4-yl)acetamide
DMUBYFM CA CAS 1244949-22-1
DMUBYFM DE Age-related macular degeneration
DM19UTO ID DM19UTO
DM19UTO DN Acebilustat
DM19UTO HS Phase 1
DM19UTO SN UNII-J64RI4D29U; J64RI4D29U; 943764-99-6; Acebilustat [INN]; Acebilustat(ZK322); Acebilustat [WHO-DD]; SCHEMBL3036353; MolPort-046-033-585; EX-A1277; EP-501; AKOS030632028; CS-5999; HY-17625; Benzoic acid, 4-(((1S,4S)-5-((4-(4-(2-oxazolyl)phenoxy)phenyl)methyl)-2,5-diazabicyclo(2.2.1)hept-2-yl)methyl)-
DM19UTO CP Celtaxsys Atlanta, GA
DM19UTO PC 68488178
DM19UTO MW 481.5
DM19UTO FM C29H27N3O4
DM19UTO IC InChI=1S/C29H27N3O4/c33-29(34)23-5-1-20(2-6-23)16-31-18-25-15-24(31)19-32(25)17-21-3-9-26(10-4-21)36-27-11-7-22(8-12-27)28-30-13-14-35-28/h1-14,24-25H,15-19H2,(H,33,34)/t24-,25-/m0/s1
DM19UTO CS C1[C@H]2CN([C@@H]1CN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C5=NC=CO5)CC6=CC=C(C=C6)C(=O)O
DM19UTO IK GERJIEKMNDGSCS-DQEYMECFSA-N
DM19UTO IU 4-[[(1S,4S)-5-[[4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]benzoic acid
DM19UTO CA CAS 943764-99-6
DM19UTO DE Chronic blistering skin disorder
DMW6X0O ID DMW6X0O
DMW6X0O DN ACH-2684
DMW6X0O HS Phase 1
DMW6X0O SN Deldeprevir; ACH-2684; UNII-5ZT4SBY0BD; 5ZT4SBY0BD; ACH-0142684; Neceprevir [USAN]; Deldeprevir [USAN:INN]; CHEMBL3040582; SCHEMBL13291708; UDMJANYPQWEDFT-ZAWFUYGJSA-N; Cyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide, N- (cyclopropylsulfonyl)-6-(2-(3,3-difluoro-1-piperidinyl)-2-oxoethyl)- 1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-((7-methoxy-8-methyl-2-(4-(1- methylethyl)-2-thiazolyl)-4-quinolinyl)oxy)-5,16-dioxo-, (2R,6R,12Z,13aS,14aR,16aS)-
DMW6X0O CP Achillion pharmaceuticals
DMW6X0O DT Small molecular drug
DMW6X0O PC 56935739
DMW6X0O MW 911.1
DMW6X0O FM C45H56F2N6O8S2
DMW6X0O IC InChI=1S/C45H56F2N6O8S2/c1-26(2)34-24-62-41(49-34)33-21-37(32-15-16-36(60-4)27(3)39(32)48-33)61-30-20-35-40(55)50-45(43(57)51-63(58,59)31-13-14-31)22-29(45)12-9-7-5-6-8-11-28(42(56)53(35)23-30)19-38(54)52-18-10-17-44(46,47)25-52/h9,12,15-16,21,24,26,28-31,35H,5-8,10-11,13-14,17-20,22-23,25H2,1-4H3,(H,50,55)(H,51,57)/b12-9-/t28-,29-,30-,35+,45-/m1/s1
DMW6X0O CS CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@H]4C(=O)N[C@@]5(C[C@H]5/C=C\\CCCCC[C@@H](C(=O)N4C3)CC(=O)N6CCCC(C6)(F)F)C(=O)NS(=O)(=O)C7CC7)C8=NC(=CS8)C(C)C)OC
DMW6X0O IK UDMJANYPQWEDFT-ZAWFUYGJSA-N
DMW6X0O IU (1S,4R,6S,7Z,14R,18R)-N-cyclopropylsulfonyl-14-[2-(3,3-difluoropiperidin-1-yl)-2-oxoethyl]-18-[7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide
DMW6X0O CA CAS 1229626-28-1
DMW6X0O DE Hepatitis C virus infection
DM5SJO9 ID DM5SJO9
DM5SJO9 DN ACHN-975
DM5SJO9 HS Phase 1
DM5SJO9 CP Achaogen
DM5SJO9 PC 71466517
DM5SJO9 MW 369.4
DM5SJO9 FM C20H23N3O4
DM5SJO9 IC InChI=1S/C20H23N3O4/c1-20(2,21)17(19(26)23-27)22-18(25)14-9-7-13(8-10-14)5-3-4-6-15-11-16(15)12-24/h7-10,15-17,24,27H,11-12,21H2,1-2H3,(H,22,25)(H,23,26)/t15-,16+,17-/m1/s1
DM5SJO9 CS CC(C)([C@@H](C(=O)NO)NC(=O)C1=CC=C(C=C1)C#CC#C[C@@H]2C[C@H]2CO)N
DM5SJO9 IK GOCUUDXEOKIQRU-IXDOHACOSA-N
DM5SJO9 IU N-[(2S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-[4-[(1R,2R)-2-(hydroxymethyl)cyclopropyl]buta-1,3-diynyl]benzamide
DM5SJO9 CA CAS 1410809-36-7
DM5SJO9 DE Pseudomonas infection
DMKVE8X ID DMKVE8X
DMKVE8X DN Acriflavine
DMKVE8X HS Phase 1
DMKVE8X SN Acriflavine; Xanthacridinum; Euflavine; Pantonsiletten; Flavinetten; Assiflavine; Choliflavin; Bialflavina; Vetaflavin; Buroflavin; Tolivalin; Isravin; Diacrid; Zoriflavin; Trachosept; Gonacin; Flavisept; Flavioform; Bovoflavin; Mediflavin; Bioacridin; Angiflan; Tripla-etilo; Glyco-flavine; Acriflavine neutral; Acriflavine [NF]; Caswell No. 008; Euflavin; Flavacridinum hydrochloricum; Trypaflavine Neutral; CCRIS 5617; UNII-1T3A50395T; EPA Pesticide Chemical Code 000501; Acridinium, 3,6-diamino-10-methyl-, chloride, mixt. with 3,6-acridined
DMKVE8X DT Small molecular drug
DMKVE8X PC 443101
DMKVE8X MW 469
DMKVE8X FM C27H25ClN6
DMKVE8X IC InChI=1S/C14H13N3.C13H11N3.ClH/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17;14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10;/h2-8H,1H3,(H3,15,16);1-7H,14-15H2;1H
DMKVE8X CS C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.[Cl-]
DMKVE8X IK PEJLNXHANOHNSU-UHFFFAOYSA-N
DMKVE8X IU acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride
DMKVE8X CA CAS 8048-52-0
DMKVE8X DE Human immunodeficiency virus infection
DMOZ3AT ID DMOZ3AT
DMOZ3AT DN ACT-178882
DMOZ3AT HS Phase 1
DMOZ3AT SN MK-1597
DMOZ3AT CP Actelion Ltd
DMOZ3AT PC 12001785
DMOZ3AT MW 647
DMOZ3AT FM C33H38Cl3N3O4
DMOZ3AT IC InChI=1S/C33H38Cl3N3O4/c1-21-15-29(35)32(30(36)16-21)43-14-13-42-31-8-4-23(18-38-31)26-9-11-37-19-27(26)33(40)39(25-5-6-25)20-24-17-22(10-12-41-2)3-7-28(24)34/h3-4,7-8,15-18,25-27,37H,5-6,9-14,19-20H2,1-2H3/t26-,27+/m1/s1
DMOZ3AT CS CC1=CC(=C(C(=C1)Cl)OCCOC2=NC=C(C=C2)[C@H]3CCNC[C@@H]3C(=O)N(CC4=C(C=CC(=C4)CCOC)Cl)C5CC5)Cl
DMOZ3AT IK PGSRKJVMAOWDEC-SXOMAYOGSA-N
DMOZ3AT IU (3R,4S)-N-[[2-chloro-5-(2-methoxyethyl)phenyl]methyl]-N-cyclopropyl-4-[6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]pyridin-3-yl]piperidine-3-carboxamide
DMOZ3AT CA CAS 1007392-69-9
DMOZ3AT DE Cardiovascular disease
DM5KMYQ ID DM5KMYQ
DM5KMYQ DN Actimab-M
DM5KMYQ HS Phase 1
DM5KMYQ SN Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1
DM5KMYQ CP Actinium Pharmaceuticals New York, NY
DM5KMYQ PC 167045
DM5KMYQ MW 225.023
DM5KMYQ FM Ac
DM5KMYQ IC InChI=1S/Ac/i1-2
DM5KMYQ CS [225Ac]
DM5KMYQ IK QQINRWTZWGJFDB-YPZZEJLDSA-N
DM5KMYQ IU actinium-225
DM5KMYQ CA CAS 14265-85-1
DM5KMYQ DE Multiple myeloma
DMRDY0G ID DMRDY0G
DMRDY0G DN ACV-1
DMRDY0G HS Phase 1
DMRDY0G CP Metabolic Pharmaceuticals
DMRDY0G TC Analgesics
DMRDY0G PC 90488812
DMRDY0G MW 1807
DMRDY0G FM C71H103N23O25S4
DMRDY0G IC InChI=1S/C71H103N23O25S4/c1-3-32(2)55-68(117)89-44(56(74)105)27-120-122-30-47-65(114)88-43(26-95)62(111)87-42(23-54(103)104)70(119)94-18-6-8-48(94)66(115)81-36(7-4-16-78-71(75)76)57(106)90-46(29-123-121-28-45(63(112)91-47)80-51(98)24-72)64(113)84-39(21-50(73)97)60(109)83-38(19-33-10-12-35(96)13-11-33)59(108)85-40(22-53(101)102)61(110)86-41(20-34-25-77-31-79-34)69(118)93-17-5-9-49(93)67(116)82-37(58(107)92-55)14-15-52(99)100/h10-13,25,31-32,36-49,55,95-96H,3-9,14-24,26-30,72H2,1-2H3,(H2,73,97)(H2,74,105)(H,77,79)(H,80,98)(H,81,115)(H,82,116)(H,83,109)(H,84,113)(H,85,108)(H,86,110)(H,87,111)(H,88,114)(H,89,117)(H,90,106)(H,91,112)(H,92,107)(H,99,100)(H,101,102)(H,103,104)(H4,75,76,78)/t32-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,55-/m0/s1
DMRDY0G CS CC[C@H](C)[C@H]1C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2)NC(=O)CN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N1)CCC(=O)O)CC5=CNC=N5)CC(=O)O)CC6=CC=C(C=C6)O)CC(=O)N)CCCNC(=N)N)CC(=O)O)CO)C(=O)N
DMRDY0G IK KJQOYUHYAZGPIZ-PIJHVLQJSA-N
DMRDY0G IU 3-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-30-(2-amino-2-oxoethyl)-9-[(2S)-butan-2-yl]-36-(3-carbamimidamidopropyl)-6-carbamoyl-24,45-bis(carboxymethyl)-48-(hydroxymethyl)-27-[(4-hydroxyphenyl)methyl]-21-(1H-imidazol-4-ylmethyl)-8,11,14,20,23,26,29,32,35,38,44,47,50,52-tetradecaoxo-3,4,55,56-tetrathia-7,10,13,19,22,25,28,31,34,37,43,46,49,51-tetradecazatetracyclo[31.17.7.015,19.039,43]heptapentacontan-12-yl]propanoic acid
DMRDY0G CA CAS 467428-30-4
DMRDY0G DE Neuropathic pain
DM8VQ1S ID DM8VQ1S
DM8VQ1S DN AD-337
DM8VQ1S HS Phase 1
DM8VQ1S CP Arakis
DM8VQ1S DE Chemotherapy-induced nausea; Myalgia; Fibromyalgia
DMG82ZA ID DMG82ZA
DMG82ZA DN Ad35-GRIN/ENV
DMG82ZA HS Phase 1
DMG82ZA SN Ad35 vector-delivered gag/rt/int/nef + Ad35 vector-delivered env combination vaccine (HIV infection), International AIDS Vaccine Initiative
DMG82ZA CP International AIDS Vaccine Initiative
DMG82ZA DT Vaccine
DMG82ZA DE Human immunodeficiency virus infection
DMFTGHX ID DMFTGHX
DMFTGHX DN Ad5CMV-NIS
DMFTGHX HS Phase 1
DMFTGHX SN Sodium iodide symporter adenoviral gene therapy (prostate cancer); Sodium iodide symporter adenoviral gene therapy (prostate cancer), Mayo Clinic
DMFTGHX CP Mayo Foundation
DMFTGHX DE Prostate cancer
DMMBQV3 ID DMMBQV3
DMMBQV3 DN Ad5-ENVA-48
DMMBQV3 HS Phase 1
DMMBQV3 SN Ad26-ENVA-01; Ad5-HVR48-ENVA-01; HIV vaccine (ad35 vector), IAVI/Crucell; Recombinant envelope adenovirus 5 vaccine (HIV infection), Crucell/Harvard Medical School; Adenovirus vector vaccine (HIV infection), IAVI/Crucell/BIDMC/Harvard; HIV vaccine (rAd26 vector), IAVI/Crucell/Beth Israel Deaconess Medical Center/Harvard; HIV vaccine (AdVac, PER.C6), Crucell/IAVI/BIDMC/Harvard
DMMBQV3 CP Crucell NV
DMMBQV3 DT Vaccine
DMMBQV3 DE Human immunodeficiency virus-1 infection
DM2UMGE ID DM2UMGE
DM2UMGE DN Ad5-TRAIL
DM2UMGE HS Phase 1
DM2UMGE SN Ad5-TRAIL adenoviral gene therapy (prostate cancer), University of Iowa
DM2UMGE CP University of Iowa
DM2UMGE DE Prostate cancer
DM16QSG ID DM16QSG
DM16QSG DN Adaphostin
DM16QSG HS Phase 1
DM16QSG SN NSC-680410; NSC-726814; 241127-58-2
DM16QSG CP Mayo Foundation
DM16QSG DT Small molecular drug
DM16QSG PC 387042
DM16QSG MW 393.5
DM16QSG FM C24H27NO4
DM16QSG IC InChI=1S/C24H27NO4/c26-21-5-6-22(27)19(10-21)14-25-20-3-1-18(2-4-20)23(28)29-24-11-15-7-16(12-24)9-17(8-15)13-24/h1-6,10,15-17,25-27H,7-9,11-14H2
DM16QSG CS C1C2CC3CC1CC(C2)(C3)OC(=O)C4=CC=C(C=C4)NCC5=C(C=CC(=C5)O)O
DM16QSG IK YJZSUCFGHXQWDM-UHFFFAOYSA-N
DM16QSG IU 1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate
DM16QSG CA CAS 241127-58-2
DM16QSG DE Chronic myelogenous leukaemia
DM59EUY ID DM59EUY
DM59EUY DN ADCI
DM59EUY HS Phase 1
DM59EUY SN SBG-017
DM59EUY CP National Institutes of Health
DM59EUY DT Small molecular drug
DM59EUY PC 130099
DM59EUY MW 250.29
DM59EUY FM C16H14N2O
DM59EUY IC InChI=1S/C16H14N2O/c17-15(19)16-12-7-3-1-5-10(12)9-14(18-16)11-6-2-4-8-13(11)16/h1-8,14,18H,9H2,(H2,17,19)
DM59EUY CS C1C2C3=CC=CC=C3C(N2)(C4=CC=CC=C41)C(=O)N
DM59EUY IK IFLVGRRVGPXYON-UHFFFAOYSA-N
DM59EUY IU 16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene-1-carboxamide
DM59EUY CA CAS 124070-15-1
DM59EUY DE Epileptic seizures
DMEXT97 ID DMEXT97
DMEXT97 DN ADG116
DMEXT97 HS Phase 1
DMEXT97 CP Adagene
DMEXT97 DT Antibody
DMEXT97 DE Solid tumour/cancer
DMM45P9 ID DMM45P9
DMM45P9 DN Ad-IFN-alpha
DMM45P9 HS Phase 1
DMM45P9 SN Ad-IFN-alpha (cancer); Ad-IFN-alpha (cancer), MD Anderson Cancer Center/NCI; Adenoviral-mediated IFN-alpha (gene therapy, cancer), MD Anderson Cancer Center/NCI
DMM45P9 CP MD Anderson Cancer Center
DMM45P9 DE Bladder cancer
DMQVEZB ID DMQVEZB
DMQVEZB DN Adjustable basal insulin
DMQVEZB HS Phase 1
DMQVEZB SN Adjustable basal insulin (diabetes); BIOD-Adjustable Basal; BIOD-Basal; Adjustable basal insulin (diabetes), Biodel
DMQVEZB CP Biodel
DMQVEZB DE Diabetic complication
DM9GLHO ID DM9GLHO
DM9GLHO DN Ad-OC-hsvTK/valacyclovir
DM9GLHO HS Phase 1
DM9GLHO SN Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute
DM9GLHO CP Winship Cancer Institute
DM9GLHO DE Prostate cancer
DMS6DPF ID DMS6DPF
DMS6DPF DN ADPT01
DMS6DPF HS Phase 1
DMS6DPF CP Novartis
DMS6DPF DT Antibody
DMS6DPF DE Breast cancer
DM6NUCA ID DM6NUCA
DM6NUCA DN ADR-851
DM6NUCA HS Phase 1
DM6NUCA SN Adr 851; 123805-17-4; UNII-303JW6Z3QJ; 303JW6Z3QJ; Adr-851; PCBGZTCWZUGEJX-QRPNPIFTSA-N; AC1L2WPB; SCHEMBL8785455; DTXSID00154097; 4-Amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzofuran-7-carboxamide hcl; KB-289941; 4-amino-5-chloro-N-[[(2S)-pyrrolidin-2-yl]methyl]-2,3-dihydro-1-benzofuran-7-carboxamide hydrochloride; 7-Benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-, monohydrochloride, (S)-; (S)-4-amino-5-chloro-N-(2-pyrrolidinylmethyl)-2,3-dihydrobenzo[b]furan-7-carboxamide hydro
DM6NUCA CP Adria Laboratories Inc
DM6NUCA DT Small molecular drug
DM6NUCA PC 130053
DM6NUCA MW 332.2
DM6NUCA FM C14H19Cl2N3O2
DM6NUCA IC InChI=1S/C14H18ClN3O2.ClH/c15-11-6-10(13-9(12(11)16)3-5-20-13)14(19)18-7-8-2-1-4-17-8;/h6,8,17H,1-5,7,16H2,(H,18,19);1H/t8-;/m0./s1
DM6NUCA CS C1C[C@H](NC1)CNC(=O)C2=CC(=C(C3=C2OCC3)N)Cl.Cl
DM6NUCA IK PCBGZTCWZUGEJX-QRPNPIFTSA-N
DM6NUCA IU 4-amino-5-chloro-N-[[(2S)-pyrrolidin-2-yl]methyl]-2,3-dihydro-1-benzofuran-7-carboxamide;hydrochloride
DM6NUCA CA CAS 123805-17-4
DM6NUCA DE Nausea and vomiting
DMYHIAR ID DMYHIAR
DMYHIAR DN AdRTVP-1
DMYHIAR HS Phase 1
DMYHIAR SN AdRTVP-1, Baylor College of Medicine; Gene therapy (RTVP-1); Gene therapy (RTVP-1), Baylor College of Medicine; Related to Testes-Specific Vespid and Pathogenesis Protein-1 adenoviral gene therapy, BCM
DMYHIAR CP Baylor College of Medicine
DMYHIAR DE Prostate cancer
DMHIPF5 ID DMHIPF5
DMHIPF5 DN ADV-1002401
DMHIPF5 HS Phase 1
DMHIPF5 SN GKM-001; Hypoglycemic agent (diabetes), Advinus
DMHIPF5 CP Advinus Therapeutics
DMHIPF5 DE Type-2 diabetes
DMH8Z9W ID DMH8Z9W
DMH8Z9W DN ADVAX
DMH8Z9W HS Phase 1
DMH8Z9W CP Aaron Diamond AIDS Research Center; International AIDS Vaccine Initiative Ichor Medical Systems
DMH8Z9W DE Human immunodeficiency virus infection
DMBUOX4 ID DMBUOX4
DMBUOX4 DN ADX71149
DMBUOX4 HS Phase 1
DMBUOX4 CP Addex Pharmaceuticals; Johnson & Johnson Pharmaceutical
DMBUOX4 PC 25195461
DMBUOX4 MW 344.9
DMBUOX4 FM C20H25ClN2O
DMBUOX4 IC InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
DMBUOX4 CS CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
DMBUOX4 IK HYOGJHCDLQSAHX-UHFFFAOYSA-N
DMBUOX4 IU 1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)pyridin-2-one
DMBUOX4 CA CAS 1127498-03-6
DMBUOX4 DE Anxiety disorder; Epilepsy; Psychiatric disorder
DM7X2HK ID DM7X2HK
DM7X2HK DN AE-08
DM7X2HK HS Phase 1
DM7X2HK CP Antigen express
DM7X2HK DT Vaccine
DM7X2HK DE Melanoma
DMQRKXP ID DMQRKXP
DMQRKXP DN AEA-35p
DMQRKXP HS Phase 1
DMQRKXP SN Peptide vaccines (H1N1 influenza virus infection), Antigen Express
DMQRKXP CP Antigen Express Inc
DMQRKXP DT Vaccine
DMQRKXP DE Influenza virus infection
DM8I4G0 ID DM8I4G0
DM8I4G0 DN AEB701
DM8I4G0 HS Phase 1
DM8I4G0 DE Melanoma
DMQF982 ID DMQF982
DMQF982 DN AEW-541
DMQF982 HS Phase 1
DMQF982 SN AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-
DMQF982 CP Novartis AG
DMQF982 TC Anticancer Agents
DMQF982 DT Small molecular drug
DMQF982 PC 11476171
DMQF982 MW 439.6
DMQF982 FM C27H29N5O
DMQF982 IC InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)
DMQF982 CS C1CN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6
DMQF982 IK AECDBHGVIIRMOI-UHFFFAOYSA-N
DMQF982 IU 7-[3-(azetidin-1-ylmethyl)cyclobutyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DMQF982 CA CAS 475488-34-7
DMQF982 DE Multiple myeloma
DM8LG2I ID DM8LG2I
DM8LG2I DN AF-130
DM8LG2I HS Phase 1
DM8LG2I CP Merck Kenilworth, NJ
DM8LG2I DE Hypertension
DMNF3GW ID DMNF3GW
DMNF3GW DN Afeletecan
DMNF3GW HS Phase 1
DMNF3GW SN Afeletecan hydrochloride; Camptothecin glycoconjugate, Bayer; Topoisomerase I inhibitors, Bayer
DMNF3GW CP Bayer AG
DMNF3GW DT Small molecular drug
DMNF3GW PC 9941008
DMNF3GW MW 896
DMNF3GW FM C45H49N7O11S
DMNF3GW IC InChI=1S/C45H49N7O11S/c1-6-45(30-17-33-35-25(15-24-9-7-8-10-31(24)49-35)19-52(33)40(56)29(30)20-60-43(45)58)63-41(57)34(22(2)3)51-39(55)32(16-27-18-46-21-47-27)50-44(64)48-26-11-13-28(14-12-26)62-42-37(54)38(59-5)36(53)23(4)61-42/h7-15,17-18,21-23,32,34,36-38,42,53-54H,6,16,19-20H2,1-5H3,(H,46,47)(H,51,55)(H2,48,50,64)/t23-,32-,34-,36+,37-,38+,42+,45-/m0/s1
DMNF3GW CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)[C@H](C(C)C)NC(=O)[C@H](CC6=CN=CN6)NC(=S)NC7=CC=C(C=C7)O[C@@H]8[C@H]([C@@H]([C@@H]([C@@H](O8)C)O)OC)O
DMNF3GW IK SLOJCSGNHWIKIG-JNYZSSQASA-N
DMNF3GW IU [(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] (2S)-2-[[(2S)-2-[[4-[(2R,3S,4R,5R,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxyphenyl]carbamothioylamino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoate
DMNF3GW CA CAS 215604-75-4
DMNF3GW DE Breast cancer
DM0I8RZ ID DM0I8RZ
DM0I8RZ DN Affitope AD-01
DM0I8RZ HS Phase 1
DM0I8RZ SN AD-01; Amyloid beta 40-42 peptide vaccine (sc, Alzheimer's), AFFiRiS
DM0I8RZ CP Affiris GmbH
DM0I8RZ DT Vaccine
DM0I8RZ DE Alzheimer disease
DMIFJZD ID DMIFJZD
DMIFJZD DN AFM11
DMIFJZD HS Phase 1
DMIFJZD CP Affimed Therapeutics
DMIFJZD DT Antibody
DMIFJZD DE Non-hodgkin lymphoma; B-cell non-hodgkin lymphoma; leukaemia
DMSX24U ID DMSX24U
DMSX24U DN AFO-18
DMSX24U HS Phase 1
DMSX24U SN Peptide vaccine (CAF-01 adjuvanted, HIV-1 infection), Statens Serum Institut
DMSX24U CP Statens Serum Institut
DMSX24U DT Vaccine
DMSX24U DE Human immunodeficiency virus-1 infection
DMHBUMZ ID DMHBUMZ
DMHBUMZ DN AFP TCR
DMHBUMZ HS Phase 1
DMHBUMZ CP Adaptimmune Philadelphia, PA
DMHBUMZ DE Hepatocellular carcinoma
DMY4WVK ID DMY4WVK
DMY4WVK DN AG-024322
DMY4WVK HS Phase 1
DMY4WVK SN AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine
DMY4WVK CP Pfizer
DMY4WVK DT Small molecular drug
DMY4WVK PC 135413565
DMY4WVK MW 418.4
DMY4WVK FM C23H20F2N6
DMY4WVK IC InChI=1S/C23H20F2N6/c1-3-26-9-14-10-27-11-17(12(14)2)13-4-5-19-16(6-13)21(31-30-19)23-28-20-8-15(24)7-18(25)22(20)29-23/h4-8,10-11,26H,3,9H2,1-2H3,(H,28,29)(H,30,31)
DMY4WVK CS CCNCC1=CN=CC(=C1C)C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C=C(C=C5F)F
DMY4WVK IK MEKASOQEXYKAKM-UHFFFAOYSA-N
DMY4WVK IU N-[[5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine
DMY4WVK CA CAS 837364-57-5
DMY4WVK DE Solid tumour/cancer
DMFU58V ID DMFU58V
DMFU58V DN AG2034
DMFU58V HS Phase 1
DMFU58V DT Small molecular drug
DMFU58V PC 135465775
DMFU58V MW 467.5
DMFU58V FM C18H21N5O6S2
DMFU58V IC InChI=1S/C18H21N5O6S2/c19-18-22-14-13(16(27)23-18)31-9(7-20-14)2-1-8-3-5-11(30-8)15(26)21-10(17(28)29)4-6-12(24)25/h3,5,9-10H,1-2,4,6-7H2,(H,21,26)(H,24,25)(H,28,29)(H4,19,20,22,23,27)/t9-,10-/m0/s1
DMFU58V CS C1[C@@H](SC2=C(N1)N=C(NC2=O)N)CCC3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMFU58V IK HHKAOUMVRGSKLS-UWVGGRQHSA-N
DMFU58V IU (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-3,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
DMFU58V CA CAS 177575-17-6
DMFU58V DE Solid tumour/cancer
DMYTJG7 ID DMYTJG7
DMYTJG7 DN AG-270
DMYTJG7 HS Phase 1
DMYTJG7 SN REOUTEBTFSILJY-UHFFFAOYSA-N; AG 270; 3(2H)-Pyridazinone, 6-(m-methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-, hydrochloride; 6-(m-Methoxyphenyl)-4-methyl-2-(2-morpholinoethyl)-3(2H)-pyridazinone hydrochloride; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate [French]; 13299-99-5; AC1L496O; DTXSID20157888; Morpholinoethyl-2 methyl-4 (m-methoxyphenyl)-6 pyridazone-3 chlorhydrate; LS-130006; 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one hydrochloride
DMYTJG7 CP Agios Pharmaceuticals Cambridge, MA
DMYTJG7 PC 202785
DMYTJG7 MW 365.9
DMYTJG7 FM C18H24ClN3O3
DMYTJG7 IC InChI=1S/C18H23N3O3.ClH/c1-14-12-17(15-4-3-5-16(13-15)23-2)19-21(18(14)22)7-6-20-8-10-24-11-9-20;/h3-5,12-13H,6-11H2,1-2H3;1H
DMYTJG7 CS CC1=CC(=NN(C1=O)CCN2CCOCC2)C3=CC(=CC=C3)OC.Cl
DMYTJG7 IK REOUTEBTFSILJY-UHFFFAOYSA-N
DMYTJG7 IU 6-(3-methoxyphenyl)-4-methyl-2-(2-morpholin-4-ylethyl)pyridazin-3-one;hydrochloride
DMYTJG7 CA CAS 13299-99-5
DMYTJG7 DE Lymphoma; Solid tumour/cancer
DMZTMEJ ID DMZTMEJ
DMZTMEJ DN AG-270
DMZTMEJ HS Phase 1
DMZTMEJ CP Agios Pharmaceuticals
DMZTMEJ DT Small molecular drug
DMZTMEJ DE Lymphoma; Solid tumour/cancer
DM7PLMJ ID DM7PLMJ
DM7PLMJ DN AG-707
DM7PLMJ HS Phase 1
DM7PLMJ CP Agenus
DM7PLMJ DE Herpes simplex virus infection
DMV6JFK ID DMV6JFK
DMV6JFK DN AGEN1181
DMV6JFK HS Phase 1
DMV6JFK CP Agenus
DMV6JFK DT Antibody
DMV6JFK DE Solid tumour/cancer
DMAXVZ1 ID DMAXVZ1
DMAXVZ1 DN AGEN2373
DMAXVZ1 HS Phase 1
DMAXVZ1 CP Agenus; Gilead Sciences
DMAXVZ1 DT Antibody
DMAXVZ1 DE Solid tumour/cancer
DMVMIBY ID DMVMIBY
DMVMIBY DN AGG-523
DMVMIBY HS Phase 1
DMVMIBY SN PF-5212371, WAY-266523
DMVMIBY CP Pfizer
DMVMIBY PC 16048422
DMVMIBY MW 476.5
DMVMIBY FM C28H29FN2O4
DMVMIBY IC InChI=1S/C28H29FN2O4/c1-28(2,18-19-8-14-23(29)15-9-19)31-27(35)24(16-17-25(32)33)30-26(34)22-12-10-21(11-13-22)20-6-4-3-5-7-20/h3-15,24H,16-18H2,1-2H3,(H,30,34)(H,31,35)(H,32,33)/t24-/m0/s1
DMVMIBY CS CC(C)(CC1=CC=C(C=C1)F)NC(=O)[C@H](CCC(=O)O)NC(=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMVMIBY IK JWQMTWCFNZSLNR-DEOSSOPVSA-N
DMVMIBY IU (4S)-5-[[1-(4-fluorophenyl)-2-methylpropan-2-yl]amino]-5-oxo-4-[(4-phenylbenzoyl)amino]pentanoic acid
DMVMIBY CA CAS 920289-29-8
DMVMIBY DE Osteoarthritis
DMVHPOX ID DMVHPOX
DMVHPOX DN AGN-242266
DMVHPOX HS Phase 1
DMVHPOX CP AbbVie
DMVHPOX DT Small molecular drug
DMVHPOX DE Non-alcoholic steatohepatitis
DMU21JF ID DMU21JF
DMU21JF DN AGS-009
DMU21JF HS Phase 1
DMU21JF DT Antibody
DMU21JF DE Systemic lupus erythematosus
DMDUIO4 ID DMDUIO4
DMDUIO4 DN AGS-348
DMDUIO4 HS Phase 1
DMDUIO4 CP Agios pharmaceuticals
DMDUIO4 DE Hereditary angioedema
DML79KE ID DML79KE
DML79KE DN AGT-182
DML79KE HS Phase 1
DML79KE SN HIRMAb-IDUS; Iduronidase/human insulin receptor-targeting chimeric mAb fusion protein (imucopolysaccharidosis type II), ArmaGen
DML79KE CP ArmaGen Technologies Inc
DML79KE DT Antibody
DML79KE DE Hunter syndrome
DMHMT49 ID DMHMT49
DMHMT49 DN AI3-23606
DMHMT49 HS Phase 1
DMHMT49 SN AMOT0097; FUBFWTUFPGFHOJ-UHFFFAOYSA-N; Furan, 2-nitro-; Furan, nitro-; LS-70264; Nitrofuran; Nitrofuran (VAN); Q-103253; Q27116311; TC-155289; TRA0000166; ZINC1689931; 17EZI4D981; 2-NITROFURAN; 2-Nitrofuran, 97%; 2-Nitrofurane; 27194-24-7; 5-17-01-00296 (Beilstein Handbook Reference); 5-Nitrofuran; 609-39-2; 9109AB; AI3-23606; AKOS015900364; AM20100483; ANW-66544; BCP23236; BRN 0112523; C-51401; C14414; CHEBI:34890; CTK1A5052; DB-002205; FCH1116845; FT-0632538; H118; NSC 59983; NSC-59983; NSC59983; SCHEMBL30623; UNII-17EZI4D981
DMHMT49 PC 11865
DMHMT49 MW 113.07
DMHMT49 FM C4H3NO3
DMHMT49 IC FUBFWTUFPGFHOJ-UHFFFAOYSA-N
DMHMT49 CS C1=COC(=C1)[N+](=O)[O-]
DMHMT49 IK 1S/C4H3NO3/c6-5(7)4-2-1-3-8-4/h1-3H
DMHMT49 IU 2-nitrofuran
DMHMT49 CA CAS 609-39-2
DMHMT49 CB CHEBI:34890
DMHMT49 DE Trypanosomiasis
DMDA1UB ID DMDA1UB
DMDA1UB DN AI-850
DMDA1UB HS Phase 1
DMDA1UB CP Acusphere
DMDA1UB DE Solid tumour/cancer
DMSPBOW ID DMSPBOW
DMSPBOW DN AIC100
DMSPBOW HS Phase 1
DMSPBOW CP AffyImmune Therapeutics
DMSPBOW DT CAR T Cell Therapy
DMSPBOW DE Thyroid cancer
DMNHBMC ID DMNHBMC
DMNHBMC DN AIC-292
DMNHBMC HS Phase 1
DMNHBMC CP AiCuris GmbH & Co KG
DMNHBMC PC 44230181
DMNHBMC MW 437.2
DMNHBMC FM C19H12Cl2F2N4O2
DMNHBMC IC InChI=1S/C19H12Cl2F2N4O2/c20-11-3-10(4-12(22)5-11)17-7-16(19(29)26-8-18(28)24-9-26)25-27(17)13-1-2-15(23)14(21)6-13/h1-7H,8-9H2,(H,24,28)
DMNHBMC CS C1C(=O)NCN1C(=O)C2=NN(C(=C2)C3=CC(=CC(=C3)Cl)F)C4=CC(=C(C=C4)F)Cl
DMNHBMC IK JPOJKNJIKXMZRB-UHFFFAOYSA-N
DMNHBMC IU 1-[1-(3-chloro-4-fluorophenyl)-5-(3-chloro-5-fluorophenyl)pyrazole-3-carbonyl]imidazolidin-4-one
DMNHBMC CA CAS 1187917-12-9
DMNHBMC DE Human immunodeficiency virus infection
DMW9ZFS ID DMW9ZFS
DMW9ZFS DN AIKO-150
DMW9ZFS HS Phase 1
DMW9ZFS SN 6beta-Naltrexol; beta-Naltrexol; 6beta-Hydroxynaltrexone; 6alpha-Hydroxynaltrexone; 49625-89-0; 6alpha-Naltrexol; UNII-J0W963M37T; CHEMBL140278; J0W963M37T; naltrexol; Naltrexone-6-beta-ol; alpha-Naltrexol; 6beta-Naltrexone; 6alpha-Naltrexone; 6-alpha-naltrexol; N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine; SCHEMBL679700; DTXSID80197942; JLVNEHKORQFVQJ-PYIJOLGTSA-N; ZINC6092289; BDBM50001709; NCGC00165851-01; FT-0672600; Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol
DMW9ZFS CP Aiko Biotechnology Inc
DMW9ZFS DT Small molecular drug
DMW9ZFS PC 5486554
DMW9ZFS MW 343.4
DMW9ZFS FM C20H25NO4
DMW9ZFS IC InChI=1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1
DMW9ZFS CS C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1O)OC5=C(C=C4)O)O
DMW9ZFS IK JLVNEHKORQFVQJ-PYIJOLGTSA-N
DMW9ZFS IU (4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMW9ZFS CA CAS 49625-89-0
DMW9ZFS DE Opioid dependence
DMHCBI0 ID DMHCBI0
DMHCBI0 DN AIP-303
DMHCBI0 HS Phase 1
DMHCBI0 CP Advanced Innovative Partners
DMHCBI0 DT Radiopharmaceutical therapy agent
DMHCBI0 DE Breast cancer
DM6PN4H ID DM6PN4H
DM6PN4H DN AjvW2
DM6PN4H HS Phase 1
DM6PN4H SN 2,6-Piperazinedione, 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-, rel-; Icrf 193; ICRF-193; 21416-88-6; BRN 3981691; 2,6-Piperazinedione, 4,4'-(1,2-dimethylethylene)di-, meso-; 2,6-Piperazinedione, 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-, (R*,S*)-; AC1L3O6B; meso-2,3-Bis(3,5-dioxopiperazine-1-yl)butane; KBioSS_000487; BSPBio_001147; KBioGR_000487; SCHEMBL438498; CHEMBL264684; KBio3_000893; KBio3_000894; KBio2_003055; CHEBI:93771; KBio2_000487; KBio2_005623; HMS1990I09; HMS1792I09; Bio2_000884; HMS3403I09; Bio2_000404; HMS1362I09; ICRF
DM6PN4H DT Antibody
DM6PN4H DE Thrombosis
DM4FOX0 ID DM4FOX0
DM4FOX0 DN AK107
DM4FOX0 HS Phase 1
DM4FOX0 SN 2,5-Bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole; 2,5-bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole; AK.107; AC1LARBL; CTK5J5532; 2,5-bis[4-(1H-imidazol-2-yl)phenyl]oxazole; 2,5-Bis(4-imidazol-2-ylphenyl)-1,3-oxazole
DM4FOX0 CP Akeso Biopharma Guangdong, China Merck Kenilworth, NJ
DM4FOX0 PC 473613
DM4FOX0 MW 353.4
DM4FOX0 FM C21H15N5O
DM4FOX0 IC InChI=1S/C21H15N5O/c1-3-15(19-22-9-10-23-19)4-2-14(1)18-13-26-21(27-18)17-7-5-16(6-8-17)20-24-11-12-25-20/h1-13H,(H,22,23)(H,24,25)
DM4FOX0 CS C1=CC(=CC=C1C2=CN=C(O2)C3=CC=C(C=C3)C4=NC=CN4)C5=NC=CN5
DM4FOX0 IK POIOBVFAFSUWGR-UHFFFAOYSA-N
DM4FOX0 IU 2,5-bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole
DM4FOX0 DE Solid tumour/cancer
DM9JU8L ID DM9JU8L
DM9JU8L DN AKP-501
DM9JU8L HS Phase 1
DM9JU8L SN JR-041; Recombinant FSH (female infertility), JCR Pharamceuticals/ASKA Pharmaceutical; Recombinant follicle stimulating hormone (female infertility), JCR Pharamceuticals/ASKA Pharmaceutical
DM9JU8L CP JCR Pharmaceuticals Co Ltd
DM9JU8L DE Female infertility
DMHD615 ID DMHD615
DMHD615 DN ALB-109564(a)
DMHD615 HS Phase 1
DMHD615 SN ALB-109564; Vinca alkaloid analogs (cancer), Albany Molecular Research
DMHD615 CP Bessor-brightwaters pharma
DMHD615 PC 46209467
DMHD615 MW 930
DMHD615 FM C47H62Cl2N4O9S
DMHD615 IC InChI=1S/C47H60N4O9S.2ClH/c1-9-43(55)23-28-24-46(41(53)58-6,37-30(14-18-50(25-28)26-43)31-20-29(61-8)12-13-34(31)48-37)33-21-32-35(22-36(33)57-5)49(4)39-45(32)16-19-51-17-11-15-44(10-2,38(45)51)40(60-27(3)52)47(39,56)42(54)59-7;;/h11-13,15,20-22,28,38-40,48,55-56H,9-10,14,16-19,23-26H2,1-8H3;2*1H/t28-,38-,39+,40+,43-,44+,45+,46-,47-;;/m0../s1
DMHD615 CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=C(N3)C=CC(=C4)SC)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.Cl.Cl
DMHD615 IK MTABGSVEFKMZFG-USKOTZBXSA-N
DMHD615 IU methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-7-methylsulfanyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;dihydrochloride
DMHD615 CA CAS 1300114-12-8
DMHD615 DE Solid tumour/cancer
DMYTIP4 ID DMYTIP4
DMYTIP4 DN Aleplasinin
DMYTIP4 HS Phase 1
DMYTIP4 SN PAZ-417; PAI inhibitors (Alzheimers disease), Wyeth; Plasminogen activator inhibitor inhibitors (Alzheimers disease),Wyeth
DMYTIP4 CP Wyeth
DMYTIP4 DT Small molecular drug
DMYTIP4 PC 10224267
DMYTIP4 MW 425.5
DMYTIP4 FM C28H27NO3
DMYTIP4 IC InChI=1S/C28H27NO3/c1-18-6-5-7-20(14-18)21-10-13-25-23(15-21)24(26(30)27(31)32)17-29(25)16-19-8-11-22(12-9-19)28(2,3)4/h5-15,17H,16H2,1-4H3,(H,31,32)
DMYTIP4 CS CC1=CC(=CC=C1)C2=CC3=C(C=C2)N(C=C3C(=O)C(=O)O)CC4=CC=C(C=C4)C(C)(C)C
DMYTIP4 IK HSXLMAFNWCSZGP-UHFFFAOYSA-N
DMYTIP4 IU 2-[1-[(4-tert-butylphenyl)methyl]-5-(3-methylphenyl)indol-3-yl]-2-oxoacetic acid
DMYTIP4 CA CAS 481629-87-2
DMYTIP4 DE Alzheimer disease
DMXMK5S ID DMXMK5S
DMXMK5S DN Alfa-interferon
DMXMK5S HS Phase 1
DMXMK5S CP National Cancer Institute (NCI)
DMXMK5S DE Endometriosis
DMGIAND ID DMGIAND
DMGIAND DN ALLO-501
DMGIAND HS Phase 1
DMGIAND CP Allogene Therapeutics
DMGIAND DT CAR T Cell Therapy
DMGIAND DE Non-hodgkin lymphoma
DMHE3MD ID DMHE3MD
DMHE3MD DN ALLO-715
DMHE3MD HS Phase 1
DMHE3MD CP Allogene Therapeutics
DMHE3MD DT CAR T Cell Therapy
DMHE3MD DE Multiple myeloma
DMCYV26 ID DMCYV26
DMCYV26 DN Allogeneic CART-19
DMCYV26 HS Phase 1
DMCYV26 CP The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DMCYV26 DT CAR T Cell Therapy
DMCYV26 DE leukaemia
DM4RHM5 ID DM4RHM5
DM4RHM5 DN Allogeneic CART-33
DM4RHM5 HS Phase 1
DM4RHM5 CP The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
DM4RHM5 DT CAR T Cell Therapy
DM4RHM5 DE Myeloid leukaemia
DMCSEUY ID DMCSEUY
DMCSEUY DN ALN-TTR01
DMCSEUY HS Phase 1
DMCSEUY DT Antisense oligonucleotide
DMCSEUY DE Amyloidosis; Transthyretin familial amyloid cardiomyopathy
DM89DHO ID DM89DHO
DM89DHO DN ALN-VSP
DM89DHO HS Phase 1
DM89DHO CP Alnylam Pharmaceuticals
DM89DHO DT RNAi therapeutics
DM89DHO DE Liver cancer
DMGFVYL ID DMGFVYL
DMGFVYL DN ALO-1567
DMGFVYL HS Phase 1
DMGFVYL SN AL01567; 2-Fluorospiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione
DMGFVYL DT Small molecular drug
DMGFVYL PC 119155
DMGFVYL MW 268.24
DMGFVYL FM C15H9FN2O2
DMGFVYL IC InChI=1S/C15H9FN2O2/c16-8-5-6-10-9-3-1-2-4-11(9)15(12(10)7-8)13(19)17-14(20)18-15/h1-7H,(H2,17,18,19,20)
DMGFVYL CS C1=CC=C2C(=C1)C3=C(C24C(=O)NC(=O)N4)C=C(C=C3)F
DMGFVYL IK JRGBXEJDIMXJAP-UHFFFAOYSA-N
DMGFVYL IU 2-fluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione
DMGFVYL CA CAS 97677-19-5
DMGFVYL DE Glaucoma/ocular hypertension
DMIEKTF ID DMIEKTF
DMIEKTF DN Alofanib
DMIEKTF HS Phase 1
DMIEKTF SN 1612888-66-0; 3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid; RPT-835(alofanib); UNII-LQX7RFK8MZ; RPT-835; RPT835; LQX7RFK8MZ; ES000835; Alofanib [INN]; Alofanib(RPT835); Syn007154; CHEMBL4594436; SCHEMBL18660613; AMY16650; BCP31905; EX-A2731; MFCD30533418; NSC790182; s8754; Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-; NSC-790182; SB19665; AC-31695; AK668992; AS-56846; HY-17601; CS-0014684; RPT835; RPT-835; RPT 835; Q27283135; 3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
DMIEKTF DT Small molecular drug
DMIEKTF PC 86280646
DMIEKTF MW 413.4
DMIEKTF FM C19H15N3O6S
DMIEKTF IC InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)
DMIEKTF CS CC1=CC(=C(C=C1C2=CN=CC=C2)NS(=O)(=O)C3=CC=CC(=C3)C(=O)O)[N+](=O)[O-]
DMIEKTF IK QUQGQIASFYWKAB-UHFFFAOYSA-N
DMIEKTF IU 3-[(4-methyl-2-nitro-5-pyridin-3-ylphenyl)sulfamoyl]benzoic acid
DMIEKTF CA CAS 1612888-66-0
DMIEKTF DE Gastric adenocarcinoma
DMP9VXQ ID DMP9VXQ
DMP9VXQ DN ALPHA-FMH
DMP9VXQ HS Phase 1
DMP9VXQ SN Alpha-(Fluoromethyl)histidine
DMP9VXQ DT Small molecular drug
DMP9VXQ PC 107653
DMP9VXQ MW 187.17
DMP9VXQ FM C7H10FN3O2
DMP9VXQ IC InChI=1S/C7H10FN3O2/c8-3-7(9,6(12)13)1-5-2-10-4-11-5/h2,4H,1,3,9H2,(H,10,11)(H,12,13)
DMP9VXQ CS C1=C(NC=N1)CC(CF)(C(=O)O)N
DMP9VXQ IK AJFGLTPLWPTALJ-UHFFFAOYSA-N
DMP9VXQ IU 2-amino-2-(fluoromethyl)-3-(1H-imidazol-5-yl)propanoic acid
DMP9VXQ CA CAS 70050-43-0
DMP9VXQ DE Pruritus
DMBVM1Q ID DMBVM1Q
DMBVM1Q DN AlphaMedix
DMBVM1Q HS Phase 1
DMBVM1Q CP Orano Med; RadioMedix
DMBVM1Q DT Peptide
DMBVM1Q DE Neuroendocrine cancer
DMTD4EF ID DMTD4EF
DMTD4EF DN ALPN-202
DMTD4EF HS Phase 1
DMTD4EF CP Alpine Immune Sciences
DMTD4EF DT Protein
DMTD4EF DE Solid tumour/cancer
DMUJCBT ID DMUJCBT
DMUJCBT DN Altiratinib
DMUJCBT HS Phase 1
DMUJCBT CP Deciphera pharmaceuticals
DMUJCBT PC 54576299
DMUJCBT MW 510.5
DMUJCBT FM C26H21F3N4O4
DMUJCBT IC InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)
DMUJCBT CS C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F
DMUJCBT IK GNNDEPIMDAZHRQ-UHFFFAOYSA-N
DMUJCBT IU 1-N'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMUJCBT CA CAS 1345847-93-9
DMUJCBT DE Solid tumour/cancer
DM6KU93 ID DM6KU93
DM6KU93 DN Alvespimycin hydrochloride
DM6KU93 HS Phase 1
DM6KU93 SN Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG
DM6KU93 CP Bristol-Myers Squibb; Kosan Biosci.
DM6KU93 TC Anticancer Agents
DM6KU93 DT Small molecular drug
DM6KU93 PC 9852573
DM6KU93 MW 653.2
DM6KU93 FM C32H49ClN4O8
DM6KU93 IC InChI=1S/C32H48N4O8.ClH/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8;/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40);1H/b11-9-,19-10+,21-16+;/t18-,20+,25+,26+,28-,30+;/m1./s1
DM6KU93 CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\\C)C)O)OC.Cl
DM6KU93 IK DFSYBWLNYPEFJK-IHLRWNDRSA-N
DM6KU93 IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[2-(dimethylamino)ethylamino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate;hydrochloride
DM6KU93 CA CAS 467214-21-7
DM6KU93 DE Refractory hematologic malignancy; Ovarian cancer
DMBGI74 ID DMBGI74
DMBGI74 DN ALX-0141
DMBGI74 HS Phase 1
DMBGI74 SN Nanobody therapeutic (bone disease), Ablynx; Nanobody therapeutic (osteoporosis), Ablynx
DMBGI74 CP Ablynx NV
DMBGI74 DE Osteoporosis
DMIRYM8 ID DMIRYM8
DMIRYM8 DN ALX-0651
DMIRYM8 HS Phase 1
DMIRYM8 SN Anti-CXCR4 nanobodies (cancer), Ablynx
DMIRYM8 CP Bristol-myers squibb
DMIRYM8 DE Haematological malignancy
DMJ8ACF ID DMJ8ACF
DMJ8ACF DN ALX-0761
DMJ8ACF HS Phase 1
DMJ8ACF CP Ablynx
DMJ8ACF DT Monoclonal antibody
DMJ8ACF DE Psoriasis vulgaris
DMLJWPN ID DMLJWPN
DMLJWPN DN Alx-5407
DMLJWPN HS Phase 1
DMLJWPN SN 2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid
DMLJWPN CP NPS Pharmaceuticals
DMLJWPN DT Small molecular drug
DMLJWPN PC 6604909
DMLJWPN MW 393.4
DMLJWPN FM C24H24FNO3
DMLJWPN IC InChI=1S/C24H24FNO3/c1-26(17-24(27)28)16-15-23(20-7-11-21(25)12-8-20)29-22-13-9-19(10-14-22)18-5-3-2-4-6-18/h2-14,23H,15-17H2,1H3,(H,27,28)/t23-/m1/s1
DMLJWPN CS CN(CC[C@H](C1=CC=C(C=C1)F)OC2=CC=C(C=C2)C3=CC=CC=C3)CC(=O)O
DMLJWPN IK FDORQEIHOKEJNX-HSZRJFAPSA-N
DMLJWPN IU 2-[[(3R)-3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid
DMLJWPN CB CHEBI:92943
DMLJWPN DE Schizophrenia
DMVXRYC ID DMVXRYC
DMVXRYC DN AM-211
DMVXRYC HS Phase 1
DMVXRYC SN AM-211; UNII-SZB129M7SZ; 1175526-27-8; SZB129M7SZ; CHEMBL2181753; AM211; [1,1'-Biphenyl]-3-acetic acid, 2'-[[ethyl[[(phenylmethyl)amino]carbonyl]amino]methyl]-6-methoxy-4'-(trifluoromethyl)-; SCHEMBL138450; DTXSID80151807; OPXIRFWNLBDKQB-UHFFFAOYSA-N; BDBM50397640; SB17010; HY-13213; CS-0003178; [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid
DMVXRYC CP Amira Pharmaceuticals Inc
DMVXRYC DT Small molecular drug
DMVXRYC PC 44158492
DMVXRYC MW 500.5
DMVXRYC FM C27H27F3N2O4
DMVXRYC IC InChI=1S/C27H27F3N2O4/c1-3-32(26(35)31-16-18-7-5-4-6-8-18)17-20-15-21(27(28,29)30)10-11-22(20)23-13-19(14-25(33)34)9-12-24(23)36-2/h4-13,15H,3,14,16-17H2,1-2H3,(H,31,35)(H,33,34)
DMVXRYC CS CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)O)OC)C(=O)NCC3=CC=CC=C3
DMVXRYC IK OPXIRFWNLBDKQB-UHFFFAOYSA-N
DMVXRYC IU 2-[3-[2-[[benzylcarbamoyl(ethyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetic acid
DMVXRYC CA CAS 1175526-27-8
DMVXRYC DE Asthma
DM7Z8NP ID DM7Z8NP
DM7Z8NP DN AM-461
DM7Z8NP HS Phase 1
DM7Z8NP CP Amira Pharmaceuticals Inc
DM7Z8NP PC 44600763
DM7Z8NP MW 459.6
DM7Z8NP FM C25H33NO5S
DM7Z8NP IC InChI=1S/C25H33NO5S/c1-24(2,3)23(29)26-18-9-11-19(17(14-18)15-32-25(4,5)6)31-21-12-16(13-22(27)28)8-10-20(21)30-7/h8-12,14H,13,15H2,1-7H3,(H,26,29)(H,27,28)
DM7Z8NP CS CC(C)(C)C(=O)NC1=CC(=C(C=C1)OC2=C(C=CC(=C2)CC(=O)O)OC)CSC(C)(C)C
DM7Z8NP IK SDHFXINHZHARIB-UHFFFAOYSA-N
DM7Z8NP IU 2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxyphenyl]acetic acid
DM7Z8NP CA CAS 1203503-64-3
DM7Z8NP DE Respiratory disease
DM7CD8Z ID DM7CD8Z
DM7CD8Z DN AMAP-102
DM7CD8Z HS Phase 1
DM7CD8Z SN 5-HT antagonist (rheumatism), AnaMar
DM7CD8Z CP AnaMar Medical AB
DM7CD8Z DE Arthritis
DMFELMQ ID DMFELMQ
DMFELMQ DN AMEP
DMFELMQ HS Phase 1
DMFELMQ SN (Aminomethyl)phosphonic acid; 1066-51-9; AMINOMETHYLPHOSPHONIC ACID; Aminomethanephosphonic acid; AMeP; 1-Aminomethylphosphonic acid; 1-Aminomethylphosphonate; Amino methane phosphoric acid; Caswell No. 037C; Phosphaglycine; (1-Aminomethyl)phosphonic acid; Phosphonic acid, aminomethyl-; UNII-90825O5C1U; Phosphonic acid, (aminomethyl)-; Aminomethylphosphonic acid (AMPA); NSC 30076; EPA Pesticide Chemical Code 207800; CHEBI:28812; MGRVRXRGTBOSHW-UHFFFAOYSA-N; (Aminomethyl)phosphonic acid, 99%; MFCD00008105; GEO-00169; 90825O5C1U
DMFELMQ CP BioAlliance Pharma SA
DMFELMQ DT Small molecular drug
DMFELMQ PC 14017
DMFELMQ MW 111.04
DMFELMQ FM CH6NO3P
DMFELMQ IC InChI=1S/CH6NO3P/c2-1-6(3,4)5/h1-2H2,(H2,3,4,5)
DMFELMQ CS C(N)P(=O)(O)O
DMFELMQ IK MGRVRXRGTBOSHW-UHFFFAOYSA-N
DMFELMQ IU aminomethylphosphonic acid
DMFELMQ CA CAS 1066-51-9
DMFELMQ CB CHEBI:28812
DMFELMQ DE Melanoma
DMKF1O2 ID DMKF1O2
DMKF1O2 DN AMG 119
DMKF1O2 HS Phase 1
DMKF1O2 CP Amgen
DMKF1O2 DT CAR T Cell Therapy
DMKF1O2 DE Small-cell lung cancer
DMM0HNF ID DMM0HNF
DMM0HNF DN AMG 160
DMM0HNF HS Phase 1
DMM0HNF DT Antibody
DMM0HNF DE Non-small cell lung cancer
DMUETI2 ID DMUETI2
DMUETI2 DN AMG 167
DMUETI2 HS Phase 1
DMUETI2 CP Amgen Thousand
DMUETI2 DE Osteoporosis
DMS72GN ID DMS72GN
DMS72GN DN AMG 172
DMS72GN HS Phase 1
DMS72GN CP Amgen
DMS72GN DE Renal cell carcinoma
DM0Q7NO ID DM0Q7NO
DM0Q7NO DN AMG 176
DM0Q7NO HS Phase 1
DM0Q7NO SN JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-
DM0Q7NO CP AmgenThousand Oaks, CA
DM0Q7NO PC 118910268
DM0Q7NO MW 613.2
DM0Q7NO FM C33H41ClN2O5S
DM0Q7NO IC InChI=1S/C33H41ClN2O5S/c1-21-6-4-8-30(40-3)27-12-9-25(27)18-36-19-33(15-5-7-23-16-26(34)11-13-28(23)33)20-41-31-14-10-24(17-29(31)36)32(37)35-42(38,39)22(21)2/h4,8,10-11,13-14,16-17,21-22,25,27,30H,5-7,9,12,15,18-20H2,1-3H3,(H,35,37)/b8-4+/t21-,22+,25-,27+,30-,33-/m0/s1
DM0Q7NO CS C[C@H]1C/C=C/[C@@H]([C@@H]2CC[C@H]2CN3C[C@@]4(CCCC5=C4C=CC(=C5)Cl)COC6=C3C=C(C=C6)C(=O)NS(=O)(=O)[C@@H]1C)OC
DM0Q7NO IK JQNINBDKGLWYMU-GEAQBIRJSA-N
DM0Q7NO IU (3'R,4S,6'R,7'S,8'E,11'S,12'R)-7-chloro-7'-methoxy-11',12'-dimethyl-13',13'-dioxospiro[2,3-dihydro-1H-naphthalene-4,22'-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-15'-one
DM0Q7NO CA CAS 1883727-34-1
DM0Q7NO DE Multiple myeloma; Acute myeloid leukaemia
DMWG2K6 ID DMWG2K6
DMWG2K6 DN AMG 199
DMWG2K6 HS Phase 1
DMWG2K6 CP Amgen
DMWG2K6 DT Antibody
DMWG2K6 DE Gastric adenocarcinoma; Esophagogastric junction neoplasm
DMA1I04 ID DMA1I04
DMA1I04 DN AMG 211
DMA1I04 HS Phase 1
DMA1I04 CP AmgenThousand Oaks, CA MedImmune Gaithersburg, MD
DMA1I04 DE Solid tumour/cancer
DMLQJ5P ID DMLQJ5P
DMLQJ5P DN AMG 228
DMLQJ5P HS Phase 1
DMLQJ5P CP Amgen
DMLQJ5P DT Antibody
DMLQJ5P DE Solid tumour/cancer
DMXYCZV ID DMXYCZV
DMXYCZV DN AMG 256
DMXYCZV HS Phase 1
DMXYCZV CP Amgen
DMXYCZV DT Protein
DMXYCZV DE Solid tumour/cancer
DM92YWD ID DM92YWD
DM92YWD DN AMG 282
DM92YWD HS Phase 1
DM92YWD DT Antibody
DM92YWD DE Asthma
DM9P0NA ID DM9P0NA
DM9P0NA DN AMG 319
DM9P0NA HS Phase 1
DM9P0NA CP Amgen Thousand
DM9P0NA PC 68947304
DM9P0NA MW 385.4
DM9P0NA FM C21H16FN7
DM9P0NA IC InChI=1S/C21H16FN7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12H,1H3,(H2,24,25,26,27,28)/t12-/m0/s1
DM9P0NA CS C[C@@H](C1=C(N=C2C=C(C=CC2=C1)F)C3=CC=CC=N3)NC4=NC=NC5=C4NC=N5
DM9P0NA IK KWRYMZHCQIOOEB-LBPRGKRZSA-N
DM9P0NA IU N-[(1S)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7H-purin-6-amine
DM9P0NA CA CAS 1608125-21-8
DM9P0NA DE Myeloid leukaemia; Hematologic tumour
DMC3G2E ID DMC3G2E
DMC3G2E DN AMG 330
DMC3G2E HS Phase 1
DMC3G2E CP Amgen
DMC3G2E DT Antibody
DMC3G2E DE Acute myeloid leukaemia
DM7CNTG ID DM7CNTG
DM7CNTG DN AMG 397
DM7CNTG HS Phase 1
DM7CNTG SN UNII-BO0V7196L2; BO0V7196L2; Murizatoclax; Murizatoclax [USAN]; SCHEMBL21040009; WHO 11281; (13S,31R,32R,4R,5E,8S,9R)-6'-Chloro-4-methoxy-8,9-dimethyl-4-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-3',4'-dihydro-12H,14H,2'Hspiro(10lambda6-thia-11-aza-1(5,7)-(1,5)benzoxazepina-3(1,2)-cyclobutanacyclododecaphan-5-ene-13,1'-naphthalene)-10,10,12-trione; 2245848-05-7; Spiro(5,7-etheno-1H,11H-cyclobut(i)(1,4)oxazepino(3,4-f)(1,2,7)thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen)-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-16-(((9aR)-octahydro-2H-pyrido(1,2-a)pyrazin-2-yl)methyl)-, 10,10-dioxide, (1'S,11R,12S,14E,16R,16aR,18aR)-
DM7CNTG CP Amgen
DM7CNTG DT Small molecular drug
DM7CNTG PC 138669688
DM7CNTG MW 765.4
DM7CNTG FM C42H57ClN4O5S
DM7CNTG IC InChI=1S/C42H57ClN4O5S/c1-29-8-6-18-42(51-3,27-45-20-21-46-19-5-4-10-35(46)25-45)37-14-11-33(37)24-47-26-41(17-7-9-31-22-34(43)13-15-36(31)41)28-52-39-16-12-32(23-38(39)47)40(48)44-53(49,50)30(29)2/h6,12-13,15-16,18,22-23,29-30,33,35,37H,4-5,7-11,14,17,19-21,24-28H2,1-3H3,(H,44,48)/b18-6+/t29-,30+,33-,35+,37+,41-,42-/m0/s1
DM7CNTG CS C[C@H]1C/C=C/[C@@]([C@@H]2CC[C@H]2CN3C[C@@]4(CCCC5=C4C=CC(=C5)Cl)COC6=C3C=C(C=C6)C(=O)NS(=O)(=O)[C@@H]1C)(CN7CCN8CCCC[C@@H]8C7)OC
DM7CNTG IK BJTFTQIBRVBSBH-VCQPVEJUSA-N
DM7CNTG IU (3'R,4S,6'R,7'R,8'E,11'S,12'R)-7'-[[(9aR)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methyl]-7-chloro-7'-methoxy-11',12'-dimethyl-13',13'-dioxospiro[2,3-dihydro-1H-naphthalene-4,22'-20-oxa-13lambda6-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene]-15'-one
DM7CNTG CA CAS 2245848-05-7
DM7CNTG DE Refractory hematologic malignancy
DMVQX5K ID DMVQX5K
DMVQX5K DN AMG 404
DMVQX5K HS Phase 1
DMVQX5K CP Amgen
DMVQX5K DT Antibody
DMVQX5K DE Solid tumour/cancer
DMYFZLA ID DMYFZLA
DMYFZLA DN AMG 420
DMYFZLA HS Phase 1
DMYFZLA CP Amgen
DMYFZLA DT Antibody
DMYFZLA DE Multiple myeloma
DMLAP8F ID DMLAP8F
DMLAP8F DN AMG 424
DMLAP8F HS Phase 1
DMLAP8F CP Amgen
DMLAP8F DT Antibody
DMLAP8F DE Multiple myeloma
DMI7JO6 ID DMI7JO6
DMI7JO6 DN AMG 427
DMI7JO6 HS Phase 1
DMI7JO6 CP Amgen
DMI7JO6 DT Antibody
DMI7JO6 DE Acute myeloid leukaemia
DMG64PE ID DMG64PE
DMG64PE DN AMG 506
DMG64PE HS Phase 1
DMG64PE DT Protein
DMG64PE DE Solid tumour/cancer
DM2POGY ID DM2POGY
DM2POGY DN AMG 509
DM2POGY HS Phase 1
DM2POGY CP Amgen
DM2POGY DT Antibody
DM2POGY DE Prostate cancer
DMNEFQ6 ID DMNEFQ6
DMNEFQ6 DN AMG 529
DMNEFQ6 HS Phase 1
DMNEFQ6 CP Amgen Thousand Oaks, CA
DMNEFQ6 DE Cardiovascular disease
DMQ0N5Z ID DMQ0N5Z
DMQ0N5Z DN AMG 562
DMQ0N5Z HS Phase 1
DMQ0N5Z CP Amgen
DMQ0N5Z DT Antibody
DMQ0N5Z DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
DMRMC7U ID DMRMC7U
DMRMC7U DN AMG 579
DMRMC7U HS Phase 1
DMRMC7U CP Amgen
DMRMC7U PC 59351313
DMRMC7U MW 441.5
DMRMC7U FM C25H23N5O3
DMRMC7U IC InChI=1S/C25H23N5O3/c1-16(31)30-14-10-17(11-15-30)22-25(27-13-12-26-22)33-19-8-6-18(7-9-19)23(32)24-28-20-4-2-3-5-21(20)29-24/h2-9,12-13,17H,10-11,14-15H2,1H3,(H,28,29)
DMRMC7U CS CC(=O)N1CCC(CC1)C2=NC=CN=C2OC3=CC=C(C=C3)C(=O)C4=NC5=CC=CC=C5N4
DMRMC7U IK ZNPDAYJZIRPRFQ-UHFFFAOYSA-N
DMRMC7U IU 1-[4-[3-[4-(1H-benzimidazole-2-carbonyl)phenoxy]pyrazin-2-yl]piperidin-1-yl]ethanone
DMRMC7U CA CAS 1227067-61-9
DMRMC7U DE Schizophrenia
DMJFKW3 ID DMJFKW3
DMJFKW3 DN AMG 595
DMJFKW3 HS Phase 1
DMJFKW3 CP Amgen
DMJFKW3 DE Glioblastoma multiforme
DM4G1SP ID DM4G1SP
DM4G1SP DN AMG 596
DM4G1SP HS Phase 1
DM4G1SP CP Amgen
DM4G1SP DT Antibody
DM4G1SP DE Recurrent glioblastoma; Glioblastoma multiforme
DMA3B9T ID DMA3B9T
DMA3B9T DN AMG 673
DMA3B9T HS Phase 1
DMA3B9T CP Amgen
DMA3B9T DT Antibody
DMA3B9T DE Acute myeloid leukaemia
DM6IT3M ID DM6IT3M
DM6IT3M DN AMG 701
DM6IT3M HS Phase 1
DM6IT3M CP Amgen
DM6IT3M DT Antibody
DM6IT3M DE Multiple myeloma
DMLYP2N ID DMLYP2N
DMLYP2N DN AMG 757
DMLYP2N HS Phase 1
DMLYP2N CP Amgen
DMLYP2N DT Antibody
DMLYP2N DE Small-cell lung cancer; Neuroendocrine cancer
DMTGZN8 ID DMTGZN8
DMTGZN8 DN AMG 780
DMTGZN8 HS Phase 1
DMTGZN8 DE Solid tumour/cancer
DMEIMBP ID DMEIMBP
DMEIMBP DN AMG 811
DMEIMBP HS Phase 1
DMEIMBP CP Amgen
DMEIMBP DE Systemic lupus erythematosus; Discoid lupus erythematosus
DMB6Q19 ID DMB6Q19
DMB6Q19 DN AMG 820
DMB6Q19 HS Phase 1
DMB6Q19 CP Amgen Thousand
DMB6Q19 DE Solid tumour/cancer
DM1FJ9C ID DM1FJ9C
DM1FJ9C DN AMG 876
DM1FJ9C HS Phase 1
DM1FJ9C CP Amgen
DM1FJ9C DE Type-2 diabetes
DMASGXJ ID DMASGXJ
DMASGXJ DN AMG 900
DMASGXJ HS Phase 1
DMASGXJ SN AMG-900; AMG 900; 945595-80-2; AMG900; UNII-9R2G075611; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; 9R2G075611; N-(4-((3-(2-aminopyrimidin-4-yl)pyridin-2-yl)oxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine; N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen- 2-yl)phthalazin-1-amine; IVUGFMLRJOCGAS-UHFFFAOYSA-N
DMASGXJ CP Amgen Thousand
DMASGXJ DT Small molecular drug
DMASGXJ PC 24856041
DMASGXJ MW 503.6
DMASGXJ FM C28H21N7OS
DMASGXJ IC InChI=1S/C28H21N7OS/c1-17-15-24(37-16-17)25-20-5-2-3-6-21(20)26(35-34-25)32-18-8-10-19(11-9-18)36-27-22(7-4-13-30-27)23-12-14-31-28(29)33-23/h2-16H,1H3,(H,32,35)(H2,29,31,33)
DMASGXJ CS CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N
DMASGXJ IK IVUGFMLRJOCGAS-UHFFFAOYSA-N
DMASGXJ IU N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine
DMASGXJ CA CAS 945595-80-2
DMASGXJ DE Solid tumour/cancer
DMCG7XL ID DMCG7XL
DMCG7XL DN AMG 910
DMCG7XL HS Phase 1
DMCG7XL CP Amgen
DMCG7XL DT Antibody
DMCG7XL DE Gastric adenocarcinoma; Esophagogastric junction neoplasm
DMZQ2DK ID DMZQ2DK
DMZQ2DK DN AMG 986
DMZQ2DK HS Phase 1
DMZQ2DK SN DOMQFIFVDIAOOT-ROUUACIJSA-N; UNII-4B8REJ8ZGY; 4B8REJ8ZGY; Azelaprag; Azelaprag [INN]; azelaprag (proposed INN); AMG986; SCHEMBL18247065; GTPL10061; AMG-986; 2049980-18-7; example 263 [WO2016187308A1]; (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide; 2-Pyrimidineethanesulfonamide, N-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl)-alpha,beta,5-trimethyl-, (alphaS,betaR)-
DMZQ2DK CP Amgen Thousand Oaks, CA
DMZQ2DK PC 122702529
DMZQ2DK MW 523.6
DMZQ2DK FM C25H29N7O4S
DMZQ2DK IC InChI=1S/C25H29N7O4S/c1-15-10-19(14-26-11-15)24-29-30-25(32(24)22-20(35-5)8-7-9-21(22)36-6)31-37(33,34)18(4)17(3)23-27-12-16(2)13-28-23/h7-14,17-18H,1-6H3,(H,30,31)/t17-,18-/m0/s1
DMZQ2DK CS CC1=CC(=CN=C1)C2=NN=C(N2C3=C(C=CC=C3OC)OC)NS(=O)(=O)[C@@H](C)[C@H](C)C4=NC=C(C=N4)C
DMZQ2DK IK DOMQFIFVDIAOOT-ROUUACIJSA-N
DMZQ2DK IU (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide
DMZQ2DK CA CAS 2049980-18-7
DMZQ2DK DE Heart failure
DMEHOVF ID DMEHOVF
DMEHOVF DN AMG-139
DMEHOVF HS Phase 1
DMEHOVF SN Anti-inflammatory agent (psoriasis, IBD), Amgen
DMEHOVF CP Amgen; astrazeneca
DMEHOVF DT Antibody
DMEHOVF DE Crohn disease
DMSHK23 ID DMSHK23
DMSHK23 DN AMG-191
DMSHK23 HS Phase 1
DMSHK23 CP Amgen Inc
DMSHK23 DE Inflammation
DMJQDUC ID DMJQDUC
DMJQDUC DN Aminoguanidine
DMJQDUC HS Phase 1
DMJQDUC SN aminoguanidine; Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284
DMJQDUC DT Small molecular drug
DMJQDUC PC 2146
DMJQDUC MW 74.09
DMJQDUC FM CH6N4
DMJQDUC IC InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)
DMJQDUC CS C(=NN)(N)N
DMJQDUC IK HAMNKKUPIHEESI-UHFFFAOYSA-N
DMJQDUC IU 2-aminoguanidine
DMJQDUC CA CAS 79-17-4
DMJQDUC CB CHEBI:40618
DMJQDUC DE Rheumatoid arthritis; Insulin-resistant disorder; Diabetic retinopathy
DMH9M62 ID DMH9M62
DMH9M62 DN AMP-224
DMH9M62 HS Phase 1
DMH9M62 CP Amplimmune Gaithersburg, MD
DMH9M62 DT Monoclonal antibody
DMH9M62 DE Solid tumour/cancer; Colorectal cancer
DMT27PA ID DMT27PA
DMT27PA DN AMV564
DMT27PA HS Phase 1
DMT27PA CP Amphivena Therapeutics South San Francisco, CA
DMT27PA DE Acute myeloid leukaemia
DMR35U4 ID DMR35U4
DMR35U4 DN AMXT1501
DMR35U4 HS Phase 1
DMR35U4 SN (S)-N-(5-Amino-6-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-6-oxohexyl)palmitamide; 441022-64-6; CHEMBL474784; SCHEMBL10033849; N-(N6-Palmitoyl-L-lysyl)-4,9-diazadodecane-1,12-diamine
DMR35U4 CP Aminex Therapeutics
DMR35U4 DT Small molecular drug
DMR35U4 PC 9916009
DMR35U4 MW 568.9
DMR35U4 FM C32H68N6O2
DMR35U4 IC InChI=1S/C32H68N6O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-22-31(39)37-28-16-15-21-30(34)32(40)38-29-20-27-36-25-18-17-24-35-26-19-23-33/h30,35-36H,2-29,33-34H2,1H3,(H,37,39)(H,38,40)/t30-/m0/s1
DMR35U4 CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)NCCCNCCCCNCCCN)N
DMR35U4 IK USNCWPSRPOWEBG-PMERELPUSA-N
DMR35U4 IU N-[(5S)-5-amino-6-[3-[4-(3-aminopropylamino)butylamino]propylamino]-6-oxohexyl]hexadecanamide
DMR35U4 DE Solid tumour/cancer
DM8B2WQ ID DM8B2WQ
DM8B2WQ DN AN-2718
DM8B2WQ HS Phase 1
DM8B2WQ SN Boron-based leucyl-tRNA synthetase inhibitor (topical, fungal infections), Anacor
DM8B2WQ CP Anacor pharmaceuticals
DM8B2WQ PC 11845944
DM8B2WQ MW 168.39
DM8B2WQ FM C7H6BClO2
DM8B2WQ IC InChI=1S/C7H6BClO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
DM8B2WQ CS B1(C2=C(CO1)C=C(C=C2)Cl)O
DM8B2WQ IK HMAFTPZYFJFEHK-UHFFFAOYSA-N
DM8B2WQ IU 5-chloro-1-hydroxy-3H-2,1-benzoxaborole
DM8B2WQ CA CAS 174672-06-1
DM8B2WQ DE Fungal infection
DM67OU4 ID DM67OU4
DM67OU4 DN ANAVEX 2-73
DM67OU4 HS Phase 1
DM67OU4 CP Anavex
DM67OU4 PC 46932299
DM67OU4 MW 317.9
DM67OU4 FM C19H24ClNO
DM67OU4 IC InChI=1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H
DM67OU4 CS CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3.Cl
DM67OU4 IK FEQOLYDPQKHFTD-UHFFFAOYSA-N
DM67OU4 IU 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;hydrochloride
DM67OU4 CA CAS 195615-84-0
DM67OU4 DE Alzheimer disease; Infantile spasm; Parkinson disease; Rett syndrome; Cognitive impairment
DM39QWN ID DM39QWN
DM39QWN DN ANS-6637
DM39QWN HS Phase 1
DM39QWN CP Amygdala Neurosciences Palo Alto, CA
DM39QWN DE Substance use disorder
DM3OFZC ID DM3OFZC
DM3OFZC DN Anti-BCMA CAR T cells
DM3OFZC HS Phase 1
DM3OFZC CP Allife Medical Science and Technology Co., Ltd.
DM3OFZC DT CAR T Cell Therapy
DM3OFZC DE Multiple myeloma
DMNFO2B ID DMNFO2B
DMNFO2B DN Anti-BCMA CAR T cells
DMNFO2B HS Phase 1
DMNFO2B CP National Cancer Institute (NCI)
DMNFO2B DT CAR T Cell Therapy
DMNFO2B DE Multiple myeloma
DMUKNDO ID DMUKNDO
DMUKNDO DN Anti-BCMA CART Cells
DMUKNDO HS Phase 1
DMUKNDO CP Shenzhen Second People's Hospital
DMUKNDO DT CAR T Cell Therapy
DMUKNDO DE Multiple myeloma
DM2TFUD ID DM2TFUD
DM2TFUD DN Anti-BCMA CAR-T cells
DM2TFUD HS Phase 1
DM2TFUD CP The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
DM2TFUD DT CAR T Cell Therapy
DM2TFUD DE Multiple myeloma
DMK25QD ID DMK25QD
DMK25QD DN Anti-BCMA CAR-T cells
DMK25QD HS Phase 1
DMK25QD CP Hebei Senlang Biotechnology Inc., Ltd.
DMK25QD DT CAR T Cell Therapy
DMK25QD DE leukaemia; Lymphoma
DMYIZFW ID DMYIZFW
DMYIZFW DN Anti-CD123 CAR-T cells
DMYIZFW HS Phase 1
DMYIZFW CP Hebei Senlang Biotechnology Inc., Ltd.
DMYIZFW DT CAR T Cell Therapy
DMYIZFW DE leukaemia; Lymphoma
DM82OS7 ID DM82OS7
DM82OS7 DN Anti-CD123 CAR-T treatment
DM82OS7 HS Phase 1
DM82OS7 CP Second Affiliated Hospital of Xi'an Jiaotong University
DM82OS7 DT CAR T Cell Therapy
DMGUM90 ID DMGUM90
DMGUM90 DN Anti-CD133-CAR vector-transduced T cells
DMGUM90 HS Phase 1
DMGUM90 CP Chinese PLA General Hospital
DMGUM90 DT CAR T Cell Therapy
DMGUM90 DE Brain cancer; Colorectal cancer; Liver cancer; Ovarian cancer; Pancreatic cancer
DMCABUR ID DMCABUR
DMCABUR DN Anti-CD19 anti-CD20 Bispecific CAR-T
DMCABUR HS Phase 1
DMCABUR CP Beijing Doing Biomedical Co., Ltd.
DMCABUR DT CAR T Cell Therapy (Dual specific)
DMCABUR DE leukaemia; Lymphoma
DMH789J ID DMH789J
DMH789J DN AntiCD19 CART
DMH789J HS Phase 1
DMH789J CP Case Comprehensive Cancer Center
DMH789J DT CAR T Cell Therapy
DMH789J DE Non-hodgkin lymphoma
DM9W1BS ID DM9W1BS
DM9W1BS DN Anti-CD19 CAR-T
DM9W1BS HS Phase 1
DM9W1BS CP First Affiliated Hospital of Wenzhou Medical University
DM9W1BS DT CAR T Cell Therapy
DM9W1BS DE Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Haematopoietic/lymphoid cancer
DMW549Y ID DMW549Y
DMW549Y DN Anti-CD19 CART Cells
DMW549Y HS Phase 1
DMW549Y CP Shenzhen Second People's Hospital
DMW549Y DT CAR T Cell Therapy
DMW549Y DE Multiple myeloma
DMUQ3C1 ID DMUQ3C1
DMUQ3C1 DN Anti-CD19 CAR-T cells
DMUQ3C1 HS Phase 1
DMUQ3C1 CP Hebei Senlang Biotechnology Inc., Ltd.
DMUQ3C1 DT CAR T Cell Therapy
DMUQ3C1 DE leukaemia; Lymphoma
DMUVYC5 ID DMUVYC5
DMUVYC5 DN Anti-CD19 EBV CTL therapy
DMUVYC5 HS Phase 1
DMUVYC5 CP Atara Biotherapeutics
DMUVYC5 DT CAR T Cell Therapy
DMUVYC5 DE Acute lymphoblastic leukaemia
DMF93T2 ID DMF93T2
DMF93T2 DN Anti-CD19/BCMA CAR-T cells
DMF93T2 HS Phase 1
DMF93T2 CP Peng Liu
DMF93T2 DT CAR T Cell Therapy (Dual specific)
DMF93T2 DE Multiple myeloma
DMWKYSM ID DMWKYSM
DMWKYSM DN Anti-CD19-CAR
DMWKYSM HS Phase 1
DMWKYSM CP National Cancer Institute (NCI)
DMWKYSM DT CAR T Cell Therapy
DMWKYSM DE Acute lymphoblastic leukaemia; B-cell lymphoma; Large cell lymphoma; leukaemia; Non-hodgkin lymphoma
DMMRANJ ID DMMRANJ
DMMRANJ DN Anti-CD19-CAR T
DMMRANJ HS Phase 1
DMMRANJ CP Beijing Doing Biomedical Co., Ltd.
DMMRANJ DT CAR T Cell Therapy
DMMRANJ DE leukaemia; Lymphoma
DMYQFCN ID DMYQFCN
DMYQFCN DN Anti-CD19-CAR T cells
DMYQFCN HS Phase 1
DMYQFCN CP National Cancer Institute (NCI)
DMYQFCN DT CAR T Cell Therapy
DMYQFCN DE B-cell lymphoma; Non-hodgkin lymphoma
DMUFRDK ID DMUFRDK
DMUFRDK DN Anti-CD22
DMUFRDK HS Phase 1
DMUFRDK CP Seattle Genetics; Genentech
DMUFRDK DT Antibody
DMUFRDK DE Haematological malignancy
DMKL92E ID DMKL92E
DMKL92E DN Anti-CD22 CAR-T cells
DMKL92E HS Phase 1
DMKL92E CP Hebei Senlang Biotechnology Inc., Ltd.
DMKL92E DT CAR T Cell Therapy
DMKL92E DE leukaemia; Lymphoma
DMTK78L ID DMTK78L
DMTK78L DN Anti-CD30 CAR-T cells
DMTK78L HS Phase 1
DMTK78L CP Hebei Senlang Biotechnology Inc., Ltd.
DMTK78L DT CAR T Cell Therapy
DMTK78L DE leukaemia; Lymphoma
DM2IEB7 ID DM2IEB7
DM2IEB7 DN Anti-CD30-CAR T cells
DM2IEB7 HS Phase 1
DM2IEB7 CP National Cancer Institute (NCI)
DM2IEB7 DT CAR T Cell Therapy
DM2IEB7 DE Hodgkin lymphoma; Large cell lymphoma; Lymphoma
DMVSPZM ID DMVSPZM
DMVSPZM DN Anti-CD38 CAR-T cells
DMVSPZM HS Phase 1
DMVSPZM CP Sorrento Therapeutics, Inc.
DMVSPZM DT CAR T Cell Therapy
DMVSPZM DE Multiple myeloma
DMZ2D0G ID DMZ2D0G
DMZ2D0G DN Anti-CD45 mabs
DMZ2D0G HS Phase 1
DMZ2D0G SN AHCD45 therapy, Baylor College; YTH-24; YTH-24/54; YTH-25.4; YTH-54.12; Anti-CD45 mAbs (stem cell transplantation/cancer); Anti-CD45 mAbs (stem cell transplantation/cancer), Baylor College
DMZ2D0G CP Baylor College of Medicine
DMZ2D0G DT Antibody
DMZ2D0G DE Lymphoma
DMMFL2P ID DMMFL2P
DMMFL2P DN Anti-CD7 CAR-T cells
DMMFL2P HS Phase 1
DMMFL2P CP Hebei Senlang Biotechnology Inc., Ltd.
DMMFL2P DT CAR T Cell Therapy
DMMFL2P DE leukaemia; Lymphoma
DMA7L3O ID DMA7L3O
DMA7L3O DN Anti-CEA CAR-T cells
DMA7L3O HS Phase 1
DMA7L3O CP Roger Williams Medical Center
DMA7L3O DT CAR T Cell Therapy
DMA7L3O DE Acute myeloid leukaemia
DMDZR0V ID DMDZR0V
DMDZR0V DN Anti-CEA CAR-T cells
DMDZR0V HS Phase 1
DMDZR0V CP Sorrento Therapeutics, Inc.
DMDZR0V DT CAR T Cell Therapy
DMDZR0V DE Colorectal cancer; Gastric adenocarcinoma; Pancreatic cancer; Peritoneal metastasis
DMJA3H1 ID DMJA3H1
DMJA3H1 DN Anti-CEA-CAR T
DMJA3H1 HS Phase 1
DMJA3H1 CP Southwest Hospital, China
DMJA3H1 DT CAR T Cell Therapy
DMJA3H1 DE Colorectal cancer; Gastric adenocarcinoma; Lung cancer; Pancreatic cancer
DM0ZDJ5 ID DM0ZDJ5
DM0ZDJ5 DN Anti-EGFL7
DM0ZDJ5 HS Phase 1
DM0ZDJ5 CP Genentech
DM0ZDJ5 DT Antibody
DM0ZDJ5 DE Non-small-cell lung cancer
DMIVUX1 ID DMIVUX1
DMIVUX1 DN Anti-EGFR CAR T
DMIVUX1 HS Phase 1
DMIVUX1 CP RenJi Hospital
DMIVUX1 DT CAR T Cell Therapy
DMIVUX1 DE Glioma
DM73920 ID DM73920
DM73920 DN Anti-EGFRvIII CAR T cells
DM73920 HS Phase 1
DM73920 CP Beijing Sanbo Brain Hospital
DM73920 DT CAR T Cell Therapy
DM73920 DE Glioblastoma multiforme
DM6QENU ID DM6QENU
DM6QENU DN Anti-FGFR3
DM6QENU HS Phase 1
DM6QENU CP Genentech
DM6QENU DT Antibody
DM6QENU DE Multiple myeloma
DMBVUFL ID DMBVUFL
DMBVUFL DN Anti-GD2 T-cells (1RG-CART)
DMBVUFL HS Phase 1
DMBVUFL CP Cancer Research UK
DMBVUFL DT CAR T Cell Therapy
DMBVUFL DE Neuroblastoma
DMCNFZG ID DMCNFZG
DMCNFZG DN Anti-GD2-CAR engineered T cells
DMCNFZG HS Phase 1
DMCNFZG CP National Cancer Institute (NCI)
DMCNFZG DT CAR T Cell Therapy
DMCNFZG DE Neuroblastoma; Osteosarcoma; Sarcoma
DMUMWFK ID DMUMWFK
DMUMWFK DN Anti-GPC3 CAR T
DMUMWFK HS Phase 1
DMUMWFK CP RenJi Hospital
DMUMWFK DT CAR T Cell Therapy
DMUMWFK DE Hepatocellular carcinoma
DMK4GIS ID DMK4GIS
DMK4GIS DN Anti-hCD70 CAR transduced PBL
DMK4GIS HS Phase 1
DMK4GIS CP National Cancer Institute (NCI)
DMK4GIS DT CAR T Cell Therapy
DMK4GIS DE Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
DMDMNJ6 ID DMDMNJ6
DMDMNJ6 DN Anti-HER3/EGFR DAF
DMDMNJ6 HS Phase 1
DMDMNJ6 CP Genentech
DMDMNJ6 DE Metastatic epithelial tumour
DMY2MO4 ID DMY2MO4
DMY2MO4 DN Anti-meso-CAR T cells
DMY2MO4 HS Phase 1
DMY2MO4 CP Chinese PLA General Hospital
DMY2MO4 DT CAR T Cell Therapy
DMY2MO4 DE Mesothelin Positive tumour
DM5UQA9 ID DM5UQA9
DM5UQA9 DN Anti-meso-CAR vector transduced T cells
DM5UQA9 HS Phase 1
DM5UQA9 CP Chinese PLA General Hospital
DM5UQA9 DT CAR T Cell Therapy
DM5UQA9 DE Endometrial cancer; Malignant mesothelioma; Ovarian cancer; Pancreatic cancer; Triple negative breast cancer
DM5BIM1 ID DM5BIM1
DM5BIM1 DN Anti-mesothelin CAR T Cells
DM5BIM1 HS Phase 1
DM5BIM1 CP China Meitan General Hospital
DM5BIM1 DT CAR T Cell Therapy
DM5BIM1 DE Tumour
DMUKFCG ID DMUKFCG
DMUKFCG DN Anti-Mesothelin CAR-T cells
DMUKFCG HS Phase 1
DMUKFCG CP Chinese PLA General Hospital
DMUKFCG DT CAR T Cell Therapy
DMUKFCG DE Solid tumour/cancer
DMQ5ZND ID DMQ5ZND
DMQ5ZND DN Anti-MUC1 mab
DMQ5ZND HS Phase 1
DMQ5ZND CP Quest PharmaTech
DMQ5ZND DT Monoclonal antibody
DMQ5ZND DE Pancreatic cancer
DMRWI7E ID DMRWI7E
DMRWI7E DN Anti-N3pG-Abeta antibody
DMRWI7E HS Phase 1
DMRWI7E DT Antibody
DMRWI7E DE Alzheimer disease
DMFZ52G ID DMFZ52G
DMFZ52G DN Anti-OX40 mab
DMFZ52G HS Phase 1
DMFZ52G CP AgonOx
DMFZ52G DT Monoclonal antibody
DMFZ52G DE Prostate cancer
DM0UL47 ID DM0UL47
DM0UL47 DN Anti-PD-L1
DM0UL47 HS Phase 1
DM0UL47 SN BMS-936559
DM0UL47 CP Bristol-Myers Squibb
DM0UL47 DT Antibody
DM0UL47 DE Solid tumour/cancer; Human immunodeficiency virus-1 infection
DMWIJL1 ID DMWIJL1
DMWIJL1 DN Anti-PD-L1 CSR T cells
DMWIJL1 HS Phase 1
DMWIJL1 CP Beijing Sanbo Brain Hospital
DMWIJL1 DT CAR T Cell Therapy
DMWIJL1 DE Glioblastoma multiforme
DMAESIY ID DMAESIY
DMAESIY DN ANX005
DMAESIY HS Phase 1
DMAESIY CP Annexon Biosciences South San Francisco, CA
DMAESIY DE Neurodegenerative disorder
DM7XES6 ID DM7XES6
DM7XES6 DN ANX-042
DM7XES6 HS Phase 1
DM7XES6 SN BNP sliced variant (heart failure), Anexon; B-type natriuretic peptide spliced variant (heart failure), Anexon
DM7XES6 CP Teva Pharmaceuticals USA
DM7XES6 DE Chronic heart failure
DMGDARN ID DMGDARN
DMGDARN DN AP32788
DMGDARN HS Phase 1
DMGDARN CP Takeda Oncology Cambridge, MA
DMGDARN DE Non-small-cell lung cancer
DM36FOG ID DM36FOG
DM36FOG DN APD-597
DM36FOG HS Phase 1
DM36FOG SN JNJ-38431055
DM36FOG CP Arena Pharmaceuticals Inc
DM36FOG DT Small molecular drug
DM36FOG PC 11691484
DM36FOG MW 479.6
DM36FOG FM C21H29N5O6S
DM36FOG IC InChI=1S/C21H29N5O6S/c1-13(2)31-21(27)26-10-8-15(9-11-26)32-20-18(30-4)19(22-12-23-20)25-16-6-7-17(24-14(16)3)33(5,28)29/h6-7,12-13,15H,8-11H2,1-5H3,(H,22,23,25)
DM36FOG CS CC1=C(C=CC(=N1)S(=O)(=O)C)NC2=C(C(=NC=N2)OC3CCN(CC3)C(=O)OC(C)C)OC
DM36FOG IK WPDCHTSXOPUOII-UHFFFAOYSA-N
DM36FOG IU propan-2-yl 4-[5-methoxy-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate
DM36FOG CA CAS 897732-93-3
DM36FOG DE Type-2 diabetes
DMRGF9Q ID DMRGF9Q
DMRGF9Q DN APD-916
DMRGF9Q HS Phase 1
DMRGF9Q SN Histamine H3 antagonists (sleep disorder), Arena; Biphenyl derivatives/aryl ethers/anilines (sleep disorder), Arena
DMRGF9Q CP Arena Pharmaceuticals Inc
DMRGF9Q DE Sleep-wake disorder
DMLEKUY ID DMLEKUY
DMLEKUY DN APG-1387
DMLEKUY HS Phase 1
DMLEKUY SN AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706
DMLEKUY CP Ascentage Pharma Rockville, MD
DMLEKUY PC 73336238
DMLEKUY MW 1157.4
DMLEKUY FM C60H72N10O10S2
DMLEKUY IC InChI=1S/C60H72N10O10S2/c1-39(61-3)55(71)63-49-37-67(34-32-45-28-30-51(69(45)59(49)75)57(73)65-53(41-18-9-5-10-19-41)42-20-11-6-12-21-42)81(77,78)47-26-17-27-48(36-47)82(79,80)68-35-33-46-29-31-52(70(46)60(76)50(38-68)64-56(72)40(2)62-4)58(74)66-54(43-22-13-7-14-23-43)44-24-15-8-16-25-44/h5-27,36,39-40,45-46,49-54,61-62H,28-35,37-38H2,1-4H3,(H,63,71)(H,64,72)(H,65,73)(H,66,74)/t39-,40-,45+,46+,49-,50-,51-,52-/m0/s1
DMLEKUY CS C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)S(=O)(=O)C5=CC(=CC=C5)S(=O)(=O)N6CC[C@H]7CC[C@H](N7C(=O)[C@H](C6)NC(=O)[C@H](C)NC)C(=O)NC(C8=CC=CC=C8)C9=CC=CC=C9)NC
DMLEKUY IK AKLBERUGKZNEJY-RTEPGWBGSA-N
DMLEKUY IU (5S,8S,10aR)-3-[3-[[(5S,8S,10aR)-8-(benzhydrylcarbamoyl)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-3-yl]sulfonyl]phenyl]sulfonyl-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
DMLEKUY CA CAS 1570231-89-8
DMLEKUY DE Haematological malignancy; Solid tumour/cancer; Nasopharyngeal carcinoma
DM6P93J ID DM6P93J
DM6P93J DN API-023
DM6P93J HS Phase 1
DM6P93J SN AGN-201904; Proton pump inhibitor prodrug, Alevium; Proton pump inhibitor prodrug, Allergan; AGN-201904-Z; Omeprazole prodrug (GERD), Alevium
DM6P93J CP Allergan Inc
DM6P93J DE Gastroesophageal reflux disease
DM4WAC2 ID DM4WAC2
DM4WAC2 DN APL-501
DM4WAC2 HS Phase 1
DM4WAC2 CP Apollomics
DM4WAC2 DT Antibody
DM4WAC2 DE Solid tumour/cancer
DMPJBCR ID DMPJBCR
DMPJBCR DN APO-010
DMPJBCR HS Phase 1
DMPJBCR SN MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget
DMPJBCR CP Apoxis SA
DMPJBCR DE Multiple myeloma
DMU8QD2 ID DMU8QD2
DMU8QD2 DN Apramycin
DMU8QD2 HS Phase 1
DMU8QD2 SN AC1O533Z; XZNUGFQTQHRASN-PHTOHMOASA-N
DMU8QD2 DT Small molecular drug
DMU8QD2 PC 3081545
DMU8QD2 MW 539.6
DMU8QD2 FM C21H41N5O11
DMU8QD2 IC InChI=1S/C21H41N5O11/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31/h5-21,26-32H,2-4,22-25H2,1H3/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-/m1/s1
DMU8QD2 CS CN[C@H]1[C@H]([C@@H]2[C@H](C[C@H]([C@H](O2)O[C@@H]3[C@H](C[C@H]([C@@H]([C@H]3O)O)N)N)N)O[C@@H]1O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)N)O)O)O
DMU8QD2 IK XZNUGFQTQHRASN-XQENGBIVSA-N
DMU8QD2 IU (2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol
DMU8QD2 CA CAS 37321-09-8
DMU8QD2 CB CHEBI:2790
DMU8QD2 DE Gram-negative bacterial infection
DMXIKYR ID DMXIKYR
DMXIKYR DN APTO-253
DMXIKYR HS Phase 1
DMXIKYR CP Aptose biosciences
DMXIKYR PC 11960271
DMXIKYR MW 367.4
DMXIKYR FM C22H14FN5
DMXIKYR IC InChI=1S/C22H14FN5/c1-11-17(15-10-12(23)6-7-16(15)26-11)22-27-20-13-4-2-8-24-18(13)19-14(21(20)28-22)5-3-9-25-19/h2-10,26H,1H3,(H,27,28)
DMXIKYR CS CC1=C(C2=C(N1)C=CC(=C2)F)C3=NC4=C5C=CC=NC5=C6C(=C4N3)C=CC=N6
DMXIKYR IK NIRXBXIPHUTNNI-UHFFFAOYSA-N
DMXIKYR IU 2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10]phenanthroline
DMXIKYR CA CAS 916151-99-0
DMXIKYR DE Solid tumour/cancer
DMXDMH5 ID DMXDMH5
DMXDMH5 DN APVO414
DMXDMH5 HS Phase 1
DMXDMH5 SN MOR209/ES414
DMXDMH5 CP Aptevo Therapeutics Seattle, WAMorphoSysPlanegg, Germany
DMXDMH5 DE Prostate cancer
DMUAMZY ID DMUAMZY
DMUAMZY DN APVO436
DMUAMZY HS Phase 1
DMUAMZY CP Aptevo
DMUAMZY DT Antibody
DMUAMZY DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMXIMQT ID DMXIMQT
DMXIMQT DN APX-3330
DMXIMQT HS Phase 1
DMXIMQT SN AR-03; E-3330; APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics; APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics; E-3330 analogs (cancer/retinopathy), ApeX Therapeutics
DMXIMQT CP ApeX Therapeutics
DMXIMQT DE Ocular cancer; Solid tumour/cancer
DM4RK6P ID DM4RK6P
DM4RK6P DN AR-12
DM4RK6P HS Phase 1
DM4RK6P SN 2-Amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide; OSU-03012; 742112-33-0; OSU 03012; OSU03012; PDK1 inhibitor AR-12; OSU-03012 (AR-12); UNII-EX3O2Q61UV; 2-amino-N-(4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide; AR 12; EX3O2Q61UV; CHEMBL1650595; 2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide; 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]acetamide; PubChem22592; MLS006010170; SCHEMBL570472; GTPL8005; C26H19F3N4O; EX-A253; DTXSID50225206; CHEBI:131196; MolPort-009-019-120
DM4RK6P DT Small molecular drug
DM4RK6P PC 10027278
DM4RK6P MW 460.4
DM4RK6P FM C26H19F3N4O
DM4RK6P IC InChI=1S/C26H19F3N4O/c27-26(28,29)24-14-23(33(32-24)20-10-8-19(9-11-20)31-25(34)15-30)18-7-12-22-17(13-18)6-5-16-3-1-2-4-21(16)22/h1-14H,15,30H2,(H,31,34)
DM4RK6P CS C1=CC=C2C(=C1)C=CC3=C2C=CC(=C3)C4=CC(=NN4C5=CC=C(C=C5)NC(=O)CN)C(F)(F)F
DM4RK6P IK YULUCECVQOCQFQ-UHFFFAOYSA-N
DM4RK6P IU 2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide
DM4RK6P CA CAS 742112-33-0
DM4RK6P CB CHEBI:131196
DM4RK6P DE Lymphoma
DMY0DPM ID DMY0DPM
DMY0DPM DN ARC-1905
DMY0DPM HS Phase 1
DMY0DPM SN Aptamer C5 inhibitors (age-related macular degeneration), Archemix/Ophthotech
DMY0DPM CP Archemix Corp
DMY0DPM DT Aptamer
DMY0DPM DE Macular degeneration
DMFJZK3 ID DMFJZK3
DMFJZK3 DN Arecoline
DMFJZK3 HS Phase 1
DMFJZK3 SN arecoline; Arecholine; Arecaline; 63-75-2; Methylarecaiden; Methylarecaidin; Arecolin; Arekolin; Arecoline base; Arecaidine methyl ester; Arecholin; methyl 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate; 3-Pyridinecarboxylic acid, 1,2,5,6-tetrahydro-1-methyl-, methyl ester; Methyl N-methyltetrahydronicotinate; C8H13NO2; N-Methyltetrahydronicotinic acid, methyl ester; Methyl 1,2,5,6-tetrahydro-1-methylnicotinate; UNII-4ALN5933BH; NSC 56321; Methyl N-methyl-1,2,5,6-tetrahydronicotinate; CCRIS 7688
DMFJZK3 DT Small molecular drug
DMFJZK3 PC 2230
DMFJZK3 MW 155.19
DMFJZK3 FM C8H13NO2
DMFJZK3 IC InChI=1S/C8H13NO2/c1-9-5-3-4-7(6-9)8(10)11-2/h4H,3,5-6H2,1-2H3
DMFJZK3 CS CN1CCC=C(C1)C(=O)OC
DMFJZK3 IK HJJPJSXJAXAIPN-UHFFFAOYSA-N
DMFJZK3 IU methyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate
DMFJZK3 CA CAS 63-75-2
DMFJZK3 CB CHEBI:2814
DMFJZK3 DE Parkinson disease
DMPLHBI ID DMPLHBI
DMPLHBI DN ARI-0001 cells
DMPLHBI HS Phase 1
DMPLHBI CP Sara V. Latorre
DMPLHBI DT CAR T Cell Therapy
DMPLHBI DE leukaemia; Lymphoma
DMN4D3A ID DMN4D3A
DMN4D3A DN ARI-2243
DMN4D3A HS Phase 1
DMN4D3A CP Arisaph Pharmaceuticals
DMN4D3A DE Type-2 diabetes
DMY5IM2 ID DMY5IM2
DMY5IM2 DN ARL-67085
DMY5IM2 HS Phase 1
DMY5IM2 SN AR-C 67085XX; AR-C67085MX; AR-C67775XX; FPL-67085; FPL-67085MX; SPL-67085
DMY5IM2 CP Fisons plc
DMY5IM2 DT Small molecular drug
DMY5IM2 PC 5310954
DMY5IM2 MW 648.2
DMY5IM2 FM C14H22Cl2N5O12P3S
DMY5IM2 IC InChI=1S/C14H22Cl2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1
DMY5IM2 CS CCCSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)N
DMY5IM2 IK ZLIAJZQKKBOFJR-WOUKDFQISA-N
DMY5IM2 IU [[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid
DMY5IM2 DE Thrombosis
DMQUFNY ID DMQUFNY
DMQUFNY DN ARM210
DMQUFNY HS Phase 1
DMQUFNY SN Arm-210; UNII-1033GN605L; 1033GN605L; Rycal dmd; SCHEMBL15326996; ARM-210; JIGDAUOKKYKRKO-UHFFFAOYSA-N; s48168; S-48168; 4-((7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl)benzoic acid; Benzoic acid, 4-((2,3-dihydro-7-methoxy-1,4-benzothiazepin-4(5H)-yl)methyl)-; 4-((7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methyl)benzoic acid; 1467605-57-7
DMQUFNY CP ARMGO Pharma Tarrytown, NY
DMQUFNY PC 71761628
DMQUFNY MW 329.4
DMQUFNY FM C18H19NO3S
DMQUFNY IC InChI=1S/C18H19NO3S/c1-22-16-6-7-17-15(10-16)12-19(8-9-23-17)11-13-2-4-14(5-3-13)18(20)21/h2-7,10H,8-9,11-12H2,1H3,(H,20,21)
DMQUFNY CS COC1=CC2=C(C=C1)SCCN(C2)CC3=CC=C(C=C3)C(=O)O
DMQUFNY IK JIGDAUOKKYKRKO-UHFFFAOYSA-N
DMQUFNY IU 4-[(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)methyl]benzoic acid
DMQUFNY CA CAS 1467605-57-7
DMQUFNY DE Duchenne dystrophy
DM4D85V ID DM4D85V
DM4D85V DN ARN-6039
DM4D85V HS Phase 1
DM4D85V SN BOS172767
DM4D85V CP Arrien Pharmaceuticals Salt Lake City, UT Boston Pharmaceuticals Cambridge, MA
DM4D85V DE Multiple sclerosis; Psoriasis vulgaris
DM5R7VI ID DM5R7VI
DM5R7VI DN ARN-6039
DM5R7VI HS Phase 1
DM5R7VI SN 6-methoxy-5-morpholino-2-((3-(trifluoromethyl)pyridin-2-yl)methyl)-2,3-dihydro-1H-inden-1-one; 1675206-11-7; SCHEMBL16552820; COc1cc2C(=O)C(Cc3ncccc3C(F)(F)F)Cc2cc1N1CCOCC1
DM5R7VI CP Arrien Pharmaceuticals; Boston Pharmaceuticals
DM5R7VI DT Small molecular drug
DM5R7VI PC 117940165
DM5R7VI MW 406.4
DM5R7VI FM C21H21F3N2O3
DM5R7VI IC InChI=1S/C21H21F3N2O3/c1-28-19-12-15-13(11-18(19)26-5-7-29-8-6-26)9-14(20(15)27)10-17-16(21(22,23)24)3-2-4-25-17/h2-4,11-12,14H,5-10H2,1H3
DM5R7VI CS COC1=C(C=C2CC(C(=O)C2=C1)CC3=C(C=CC=N3)C(F)(F)F)N4CCOCC4
DM5R7VI IK CQSDLVKTQRLMJB-UHFFFAOYSA-N
DM5R7VI IU 6-methoxy-5-morpholin-4-yl-2-[[3-(trifluoromethyl)pyridin-2-yl]methyl]-2,3-dihydroinden-1-one
DM5R7VI DE Multiple sclerosis
DMV5PEK ID DMV5PEK
DMV5PEK DN ARO-HIF2
DMV5PEK HS Phase 1
DMV5PEK CP Arrowhead Pharmaceuticals
DMV5PEK DT Antisense oligonucleotide
DMV5PEK DE Renal cell carcinoma
DMCRLQZ ID DMCRLQZ
DMCRLQZ DN ARQ 621
DMCRLQZ HS Phase 1
DMCRLQZ SN ARQ 621; 1095253-39-6; ARQ-621; UNII-UU55190C8S; ARQ621; UU55190C8S; (R)-N-(3-AMINOPROPYL)-3-CHLORO-N-(1-(7-CHLORO-4-OXO-3-(PHENYLAMINO)-3,4-DIHYDROQUINAZOLIN-2-YL)BUT-3-YN-1-YL)-2-FLUOROBENZAMIDE; Benzamide, N-(3-aminopropyl)-3-chloro-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylamino)-2-quinazolinyl]-3-butyn-1-yl]-2-fluoro-; SCHEMBL361201; C28H24Cl2FN5O2; DTXSID80148974; EX-A857; UPJSUQWHUVLLNW-XMMPIXPASA-N; MolPort-035-789-699; BCP28395; 2122AH; ZINC68203755; s7355; AKOS032945139; SB19448; NCGC00386362-01; KB-74734
DMCRLQZ CP ArQule
DMCRLQZ DT Small molecular drug
DMCRLQZ PC 25110841
DMCRLQZ MW 552.4
DMCRLQZ FM C28H24Cl2FN5O2
DMCRLQZ IC InChI=1S/C28H24Cl2FN5O2/c1-2-8-24(35(16-7-15-32)27(37)21-11-6-12-22(30)25(21)31)26-33-23-17-18(29)13-14-20(23)28(38)36(26)34-19-9-4-3-5-10-19/h1,3-6,9-14,17,24,34H,7-8,15-16,32H2/t24-/m1/s1
DMCRLQZ CS C#CC[C@H](C1=NC2=C(C=CC(=C2)Cl)C(=O)N1NC3=CC=CC=C3)N(CCCN)C(=O)C4=C(C(=CC=C4)Cl)F
DMCRLQZ IK UPJSUQWHUVLLNW-XMMPIXPASA-N
DMCRLQZ IU N-(3-aminopropyl)-N-[(1R)-1-(3-anilino-7-chloro-4-oxoquinazolin-2-yl)but-3-ynyl]-3-chloro-2-fluorobenzamide
DMCRLQZ CA CAS 1095253-39-6
DMCRLQZ DE Haematological malignancy
DMP9ZT1 ID DMP9ZT1
DMP9ZT1 DN ARQ 736
DMP9ZT1 HS Phase 1
DMP9ZT1 CP ArQule
DMP9ZT1 PC 46869123
DMP9ZT1 MW 674.5
DMP9ZT1 FM C25H25N8Na2O8PS
DMP9ZT1 IC InChI=1S/C25H27N8O8PS.2Na/c1-31-11-8-21(30-31)43(37,38)32-10-3-5-18(15-32)27-24-26-9-7-20(28-24)23-22(29-25-33(23)12-13-39-25)17-4-2-6-19(14-17)40-16-41-42(34,35)36;;/h2,4,6-9,11-14,18H,3,5,10,15-16H2,1H3,(H,26,27,28)(H2,34,35,36);;/q;2*+1/p-2/t18-;;/m1../s1
DMP9ZT1 CS CN1C=CC(=N1)S(=O)(=O)N2CCC[C@H](C2)NC3=NC=CC(=N3)C4=C(N=C5N4C=CO5)C6=CC(=CC=C6)OCOP(=O)([O-])[O-].[Na+].[Na+]
DMP9ZT1 IK HXINDCTZKGGRDE-JPKZNVRTSA-L
DMP9ZT1 IU disodium;[3-[5-[2-[[(3R)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate
DMP9ZT1 CA CAS 1228237-57-7
DMP9ZT1 DE Solid tumour/cancer
DM7MWX0 ID DM7MWX0
DM7MWX0 DN ARQ 751
DM7MWX0 HS Phase 1
DM7MWX0 CP ArQule Burlington, MA
DM7MWX0 DE Solid tumour/cancer
DM1FTEC ID DM1FTEC
DM1FTEC DN ARQ-171
DM1FTEC HS Phase 1
DM1FTEC SN ARQ-550RP; ARQ-580; E2F modulators (anticancer); E2F modulators (anticancer), ArQule; 550 series (E2F modulators), Arqule; 550 series (anticancer), Arqule; 550 series, Arqule
DM1FTEC CP ArQule
DM1FTEC DE Solid tumour/cancer
DMBQWVR ID DMBQWVR
DMBQWVR DN ARQ-751
DMBQWVR HS Phase 1
DMBQWVR CP Merck
DMBQWVR DT Small molecular drug
DMBQWVR DE Solid tumour/cancer
DMMPTCK ID DMMPTCK
DMMPTCK DN ARRY-300
DMMPTCK HS Phase 1
DMMPTCK CP Array BioPharma; Novartis Pharmaceuticals
DMMPTCK DE Solid tumour/cancer
DMCNV0M ID DMCNV0M
DMCNV0M DN ARRY-380
DMCNV0M HS Phase 1
DMCNV0M SN 937265-83-3; ARRY-380 Analog; ARRY-380 (analog ); UNII-H32S1659ED; HER2-Inhibitor-1; H32S1659ED; 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine; HER2 Inhibitor 1; SCHEMBL10169911; C29H27N7O4S; DTXSID00239555; MolPort-023-293-540; HMS3656B04; BDBM185146; EX-A1261; AOB87708; BCP02833; ZINC73096245; 2227AH; s2752; AKOS026750520; CS-0484; SB16599; BCP9000319; NCGC00346672-01; NCGC00346672-06
DMCNV0M CP Array BioPharma
DMCNV0M DT Small molecular drug
DMCNV0M PC 42598643
DMCNV0M MW 569.6
DMCNV0M FM C29H27N7O4S
DMCNV0M IC InChI=1S/C29H27N7O4S/c1-19-13-21(4-7-26(19)39-22-9-11-36-28(15-22)32-18-34-36)35-29-24-14-20(3-6-25(24)31-17-33-29)27-8-5-23(40-27)16-30-10-12-41(2,37)38/h3-9,11,13-15,17-18,30H,10,12,16H2,1-2H3,(H,31,33,35)
DMCNV0M CS CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)C4=CC=C(O4)CNCCS(=O)(=O)C)OC5=CC6=NC=NN6C=C5
DMCNV0M IK QVMNYGOVNWWFKF-UHFFFAOYSA-N
DMCNV0M IU 6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazolin-4-amine
DMCNV0M CA CAS 937265-83-3
DMCNV0M DE Solid tumour/cancer
DM4CZ2Y ID DM4CZ2Y
DM4CZ2Y DN ARX-424
DM4CZ2Y HS Phase 1
DM4CZ2Y SN Long-acting interferon beta (multiple sclerosis), Merck Serono/ Ambrx
DM4CZ2Y CP Ambrx
DM4CZ2Y DE Multiple sclerosis
DMM9ORD ID DMM9ORD
DMM9ORD DN ASG-15ME
DMM9ORD HS Phase 1
DMM9ORD CP Agensys; seattle genetics
DMM9ORD DT Antibody
DMM9ORD DE Bladder cancer; Urothelial carcinoma
DM0Z3JS ID DM0Z3JS
DM0Z3JS DN ASG-22ME
DM0Z3JS HS Phase 1
DM0Z3JS CP Seattle Genetics; Agensys
DM0Z3JS DT Antibody
DM0Z3JS DE Solid tumour/cancer
DMD0BMN ID DMD0BMN
DMD0BMN DN ASG-5ME
DMD0BMN HS Phase 1
DMD0BMN CP Seattle Genetics; Agensys
DMD0BMN DT Antibody
DMD0BMN DE Prostate cancer; Pancreatic cancer
DMJCX6D ID DMJCX6D
DMJCX6D DN ASN003
DMJCX6D HS Phase 1
DMJCX6D CP Asana BioSciences Lawrenceville, NJ
DMJCX6D DE Solid tumour/cancer
DMYHEUA ID DMYHEUA
DMYHEUA DN ASN007
DMYHEUA HS Phase 1
DMYHEUA CP Asana BioSciences Lawrenceville, NJ
DMYHEUA DE Solid tumour/cancer
DM8DBT6 ID DM8DBT6
DM8DBT6 DN ASP-0777
DM8DBT6 HS Phase 1
DM8DBT6 CP Astellas Pharma Inc
DM8DBT6 DE Alzheimer disease
DMC80LV ID DMC80LV
DMC80LV DN ASP1948
DMC80LV HS Phase 1
DMC80LV SN PTZ-329
DMC80LV CP Astellas Pharma; Potenza Therapeutics
DMC80LV DT Antibody
DMC80LV DE Solid tumour/cancer
DMX4PWV ID DMX4PWV
DMX4PWV DN ASP1951
DMX4PWV HS Phase 1
DMX4PWV SN PTZ-522
DMX4PWV CP Astellas Pharma; Potenza Therapeutics
DMX4PWV DT Antibody
DMX4PWV DE Solid tumour/cancer
DMW72NJ ID DMW72NJ
DMW72NJ DN ASP3026
DMW72NJ HS Phase 1
DMW72NJ SN ASP3026; 1097917-15-1; ASP-3026; ASP 3026; N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine; UNII-HP4L6MXF10; HP4L6MXF10; 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine; MGGBYMDAPCCKCT-UHFFFAOYSA-N; MLS006011176; GTPL7740; SCHEMBL2827739; CHEMBL3545360; C29H40N8O3S; QCR-144; EX-A140; DTXSID90149038; AOB6601; MolPort-028-720-342; BCP06436; 2229AH; ZINC68120928; s8054
DMW72NJ CP Astellas Pharma
DMW72NJ DT Small molecular drug
DMW72NJ PC 25134326
DMW72NJ MW 580.7
DMW72NJ FM C29H40N8O3S
DMW72NJ IC InChI=1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34)
DMW72NJ CS CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC
DMW72NJ IK MGGBYMDAPCCKCT-UHFFFAOYSA-N
DMW72NJ IU 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine
DMW72NJ CA CAS 1097917-15-1
DMW72NJ DE Diffuse large B-cell lymphoma
DM1RD0T ID DM1RD0T
DM1RD0T DN ASP-4058
DM1RD0T HS Phase 1
DM1RD0T CP Astellas Pharma Inc
DM1RD0T PC 16755143
DM1RD0T MW 442.3
DM1RD0T FM C19H12F6N4O2
DM1RD0T IC InChI=1S/C19H12F6N4O2/c1-9(18(20,21)22)30-15-5-3-11(6-12(15)19(23,24)25)17-28-16(29-31-17)10-2-4-13-14(7-10)27-8-26-13/h2-9H,1H3,(H,26,27)/t9-/m0/s1
DM1RD0T CS C[C@@H](C(F)(F)F)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC4=C(C=C3)N=CN4)C(F)(F)F
DM1RD0T IK NJNXCJPSMWKXHO-VIFPVBQESA-N
DM1RD0T IU 3-(3H-benzimidazol-5-yl)-5-[3-(trifluoromethyl)-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxyphenyl]-1,2,4-oxadiazole
DM1RD0T CA CAS 952565-91-2
DM1RD0T DE Multiple sclerosis
DMA71OL ID DMA71OL
DMA71OL DN ASP8374
DMA71OL HS Phase 1
DMA71OL SN PTZ-201
DMA71OL CP Astellas Northbrook, IL Potenza Therapeutics Cambridge, MA
DMA71OL DE Solid tumour/cancer
DMCDMPW ID DMCDMPW
DMCDMPW DN ASP9801
DMCDMPW HS Phase 1
DMCDMPW CP Astellas Pharma
DMCDMPW DT Oncolytic virus therapy
DMCDMPW DE Solid tumour/cancer
DMCN7WI ID DMCN7WI
DMCN7WI DN AST-005
DMCN7WI HS Phase 1
DMCN7WI CP Exicure Skokie, IL Purdue Pharma Stamford, CT
DMCN7WI DE Psoriasis vulgaris
DM7C68W ID DM7C68W
DM7C68W DN AST-008
DM7C68W HS Phase 1
DM7C68W CP Exicure Skokie, IL
DM7C68W DE Solid tumour/cancer
DMD83WO ID DMD83WO
DMD83WO DN AST-1306
DMD83WO HS Phase 1
DMD83WO SN Allitinib; Allitinib tosylate
DMD83WO CP Allist Pharmaceutical Inc
DMD83WO DT Small molecular drug
DMD83WO PC 24739943
DMD83WO MW 448.9
DMD83WO FM C24H18ClFN4O2
DMD83WO IC InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)
DMD83WO CS C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl
DMD83WO IK MVZGYPSXNDCANY-UHFFFAOYSA-N
DMD83WO IU N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide
DMD83WO CA CAS 897383-62-9
DMD83WO CB CHEBI:91467
DMD83WO DE Solid tumour/cancer
DMD2BIT ID DMD2BIT
DMD2BIT DN AT001/r84
DMD2BIT HS Phase 1
DMD2BIT CP Affitech
DMD2BIT DT Antibody
DMD2BIT DE Solid tumour/cancer
DMYIPKJ ID DMYIPKJ
DMYIPKJ DN AT13148
DMYIPKJ HS Phase 1
DMYIPKJ CP Astex pharmaceuticals
DMYIPKJ PC 24905401
DMYIPKJ MW 313.8
DMYIPKJ FM C17H16ClN3O
DMYIPKJ IC InChI=1S/C17H16ClN3O/c18-16-7-5-15(6-8-16)17(22,11-19)14-3-1-12(2-4-14)13-9-20-21-10-13/h1-10,22H,11,19H2,(H,20,21)/t17-/m0/s1
DMYIPKJ CS C1=CC(=CC=C1C2=CNN=C2)[C@@](CN)(C3=CC=C(C=C3)Cl)O
DMYIPKJ IK IIRWNGPLJQXWFJ-KRWDZBQOSA-N
DMYIPKJ IU (1S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol
DMYIPKJ CA CAS 1056901-62-2
DMYIPKJ DE Solid tumour/cancer
DM2B9E0 ID DM2B9E0
DM2B9E0 DN AT13387
DM2B9E0 HS Phase 1
DM2B9E0 SN AT-13387
DM2B9E0 CP Astex Therape.
DM2B9E0 TC Anticancer Agents
DM2B9E0 DT Small molecular drug
DM2B9E0 PC 11955716
DM2B9E0 MW 409.5
DM2B9E0 FM C24H31N3O3
DM2B9E0 IC InChI=1S/C24H31N3O3/c1-16(2)20-11-21(23(29)12-22(20)28)24(30)27-14-18-5-4-17(10-19(18)15-27)13-26-8-6-25(3)7-9-26/h4-5,10-12,16,28-29H,6-9,13-15H2,1-3H3
DM2B9E0 CS CC(C)C1=CC(=C(C=C1O)O)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C
DM2B9E0 IK IFRGXKKQHBVPCQ-UHFFFAOYSA-N
DM2B9E0 IU (2,4-dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
DM2B9E0 CA CAS 912999-49-6
DM2B9E0 CB CHEBI:140592
DM2B9E0 DE Melanoma
DMCE08M ID DMCE08M
DMCE08M DN AT7519
DMCE08M HS Phase 1
DMCE08M SN LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide
DMCE08M CP Astex Therape.
DMCE08M TC Anticancer Agents
DMCE08M DT Small molecular drug
DMCE08M PC 11338033
DMCE08M MW 382.2
DMCE08M FM C16H17Cl2N5O2
DMCE08M IC InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)
DMCE08M CS C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl
DMCE08M IK OVPNQJVDAFNBDN-UHFFFAOYSA-N
DMCE08M IU 4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide
DMCE08M CA CAS 844442-38-2
DMCE08M CB CHEBI:91326
DMCE08M DE Solid tumour/cancer
DMHYO38 ID DMHYO38
DMHYO38 DN AT-787
DMHYO38 HS Phase 1
DMHYO38 CP Atea Pharmaceuticals
DMHYO38 DT Small molecular drug
DMHYO38 DE Hepatitis C
DM6O0TM ID DM6O0TM
DM6O0TM DN ATA2271
DM6O0TM HS Phase 1
DM6O0TM CP Atara Biotherapeutics
DM6O0TM DT CAR T Cell Therapy
DM6O0TM DE Mesothelioma
DMIMH8L ID DMIMH8L
DMIMH8L DN ATD transdermal gel
DMIMH8L HS Phase 1
DMIMH8L CP Antares
DMIMH8L DE Contraception
DM96JTX ID DM96JTX
DM96JTX DN ATEVIRDINE
DM96JTX HS Phase 1
DM96JTX SN Atevirdine; 136816-75-6; Atevirdine mesylate; UNII-N24015WC6D; CHEMBL280527; N24015WC6D; U-87201E; 1-[(5-Methoxyindol-2-yl)carbonyl]-4-[3-(ethylamino)-2-pyridyl]piperazine; [4-[3-(ethylamino)-2-pyridyl]piperazin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone; Atevirdine [INN]; Piperazine, 1-(3-(ethylamino)-2-pyridinyl)-4-((5-methoxy-1H-indol-2-yl)carbonyl)-; Piperazine, 1-[3-(ethylamino)-2-pyridinyl]-4-[(5-methoxy-1H-indol-2-yl)carbonyl]-; AC1Q5KK9; AC1L1U1S; SCHEMBL356038; bis(heteroaryl)piperazine analog; BDBM1437
DM96JTX DT Small molecular drug
DM96JTX PC 60848
DM96JTX MW 379.5
DM96JTX FM C21H25N5O2
DM96JTX IC InChI=1S/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3
DM96JTX CS CCNC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)OC
DM96JTX IK UCPOMLWZWRTIAA-UHFFFAOYSA-N
DM96JTX IU [4-[3-(ethylamino)pyridin-2-yl]piperazin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone
DM96JTX CA CAS 136816-75-6
DM96JTX DE Human immunodeficiency virus infection
DMWGKHZ ID DMWGKHZ
DMWGKHZ DN ATF-936
DMWGKHZ HS Phase 1
DMWGKHZ CP Novartis AG
DMWGKHZ PC 44201334
DMWGKHZ MW 482.6
DMWGKHZ FM C30H30N2O4
DMWGKHZ IC InChI=1S/C30H30N2O4/c1-6-16-36-24-13-14-26-25(18-24)29(23-11-9-22(10-12-23)20(3)4)31-30(33)32(26)19-21-8-15-27(34-5)28(17-21)35-7-2/h1,8-15,17-18,20H,7,16,19H2,2-5H3
DMWGKHZ CS CCOC1=C(C=CC(=C1)CN2C3=C(C=C(C=C3)OCC#C)C(=NC2=O)C4=CC=C(C=C4)C(C)C)OC
DMWGKHZ IK IIBRYYCFSIBSFT-UHFFFAOYSA-N
DMWGKHZ IU 1-[(3-ethoxy-4-methoxyphenyl)methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one
DMWGKHZ CA CAS 717103-89-4
DMWGKHZ DE Osteoporosis
DMT5Z84 ID DMT5Z84
DMT5Z84 DN ATI-0917
DMT5Z84 HS Phase 1
DMT5Z84 SN FB-636
DMT5Z84 CP The Procter & Gamble Co
DMT5Z84 DE Human immunodeficiency virus infection
DMBKO2W ID DMBKO2W
DMBKO2W DN ATI-355
DMBKO2W HS Phase 1
DMBKO2W SN Atinumab; Anti-Nogo-A mAbs, Novartis; Anti-Nogo-A monoclonal antibodies, Novartis; 11C7; 7B12
DMBKO2W CP Novartis AG
DMBKO2W DT Antibody
DMBKO2W DE Nerve injury
DM6GKMU ID DM6GKMU
DM6GKMU DN ATI-9242
DM6GKMU HS Phase 1
DM6GKMU SN Antipsychotic agent (oral, psychiatric disorders), ARYx Therapeutics; Antipsychotic agent (oral, schizophrenia), ARYx Therapeutics
DM6GKMU CP ARYx Therapeutics Inc
DM6GKMU DE Schizophrenia
DMR93S5 ID DMR93S5
DMR93S5 DN ATL1103
DMR93S5 HS Phase 1
DMR93S5 CP ISIS Pharm; Antisense Therapeutics
DMR93S5 DT Antisense drug
DMR93S5 DE Acromegaly
DMZI4UX ID DMZI4UX
DMZI4UX DN ATLCAR.CD30 cells
DMZI4UX HS Phase 1
DMZI4UX CP UNC Lineberger Comprehensive Cancer Center
DMZI4UX DT CAR T Cell Therapy
DMZI4UX DE Immune System disease; Immunoproliferative disorder; Lymphatic disease; Lymphoma; Neoplasm
DM3IPSX ID DM3IPSX
DM3IPSX DN ATLCAR.CD30.CCR4 cells
DM3IPSX HS Phase 1
DM3IPSX CP UNC Lineberger Comprehensive Cancer Center
DM3IPSX DT CAR T Cell Therapy (Dual specific)
DM3IPSX DE Immune System disease; Immunoproliferative disorder; Lymphatic disease; Lymphoma; Neoplasm
DMU67HD ID DMU67HD
DMU67HD DN ATR-01
DMU67HD HS Phase 1
DMU67HD CP Millendo Therapeutics Ann Arbor, MI
DMU67HD DE Adrenocortical carcinoma
DMUMVXK ID DMUMVXK
DMUMVXK DN ATR-101
DMUMVXK HS Phase 1
DMUMVXK CP Atterocor
DMUMVXK DT Small molecular drug
DMUMVXK PC 131678
DMUMVXK MW 458.1
DMUMVXK FM C27H40ClN3O
DMUMVXK IC InChI=1S/C27H39N3O.ClH/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6;/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31);1H
DMUMVXK CS CC(C)C1=C(C(=CC=C1)C(C)C)NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C.Cl
DMUMVXK IK SDOOGTHIDFZUNM-UHFFFAOYSA-N
DMUMVXK IU 1-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]-3-[2,6-di(propan-2-yl)phenyl]urea;hydrochloride
DMUMVXK CA CAS 133825-81-7
DMUMVXK DE Malignant adrenal gland cancer; Arteriosclerosis
DMBCATZ ID DMBCATZ
DMBCATZ DN ATR-107
DMBCATZ HS Phase 1
DMBCATZ SN PF-05230900
DMBCATZ CP Wyeth
DMBCATZ DT Antibody
DMBCATZ DE Crohn disease
DMTG9EV ID DMTG9EV
DMTG9EV DN ATRC-101
DMTG9EV HS Phase 1
DMTG9EV CP Atreca
DMTG9EV DT Antibody
DMTG9EV DE Solid tumour/cancer
DML4SIE ID DML4SIE
DML4SIE DN Atu-027
DML4SIE HS Phase 1
DML4SIE SN PI3K expression inhibitors (AtuPLEX, cancer), Atugen; Phosphoinositide 3 kinase expression inhibitors (AtuPLEX, cancer), Atugen
DML4SIE CP Silence Therapeutics AG
DML4SIE DE Solid tumour/cancer
DMKNMAE ID DMKNMAE
DMKNMAE DN Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
DMKNMAE HS Phase 1
DMKNMAE CP Fred Hutchinson Cancer Research Center
DMKNMAE DT CAR T Cell Therapy
DMKNMAE DE Plasma cell myeloma
DMQA1VT ID DMQA1VT
DMQA1VT DN Autologous cell based gene therapy
DMQA1VT HS Phase 1
DMQA1VT SN Autologous cell based gene therapy (pulmonary hypertension)
DMQA1VT CP University of Toronto
DMQA1VT DE Pulmonary hypertension
DMJW4TP ID DMJW4TP
DMJW4TP DN Autologous ET1402L1-CART cells
DMJW4TP HS Phase 1
DMJW4TP CP Aeon Therapeutics (Shanghai) Co., Ltd.
DMJW4TP DT CAR T Cell Therapy
DMJW4TP DE Hepatocellular carcinoma; Liver cancer; Metastatic liver cancer
DMARYFK ID DMARYFK
DMARYFK DN Autologous melanoma cell vaccine
DMARYFK HS Phase 1
DMARYFK SN Autologous melanoma cell vaccine (neoplasm)
DMARYFK CP Dana-Farber Cancer Institute Inc
DMARYFK DE Solid tumour/cancer
DMZ763A ID DMZ763A
DMZ763A DN Autologous T Cells Expressing MET scFv CAR
DMZ763A HS Phase 1
DMZ763A CP University of Pennsylvania
DMZ763A DT CAR T Cell Therapy
DMZ763A DE Melanoma; Breast cancer
DMTLU37 ID DMTLU37
DMTLU37 DN Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
DMTLU37 HS Phase 1
DMTLU37 CP University of Pennsylvania
DMTLU37 DT CAR T Cell Therapy
DMTLU37 DE Pancreatic cancer
DMOAET3 ID DMOAET3
DMOAET3 DN Autologous T-cell therapy
DMOAET3 HS Phase 1
DMOAET3 SN Anti-PSMA designer T cells, Roger Williams; Gene therapy (chimeric anti-PSMA antibody-TCR), Roger Williams; Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer); Autologous T-cell therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center; Retrovirus-based ex vivo gene therapy (anti-PSMA-CD3, prostate cancer), Roger Williams Medical Center
DMOAET3 CP Roger Williams Medical Center
DMOAET3 DT Antibody
DMOAET3 DE Prostate cancer
DMZLCTD ID DMZLCTD
DMZLCTD DN AV-203
DMZLCTD HS Phase 1
DMZLCTD SN ErbB3-targeted antibodies (cancer), AVEO/Biogen Idec
DMZLCTD CP Aveo oncology
DMZLCTD DT Antibody
DMZLCTD DE Solid tumour/cancer
DME630T ID DME630T
DME630T DN AV4025
DME630T HS Phase 1
DME630T CP Allachem
DME630T DE Hepatitis C virus infection
DMVL87N ID DMVL87N
DMVL87N DN AV-965
DMVL87N HS Phase 1
DMVL87N CP Avera Pharmaceuticals Inc
DMVL87N DE Alzheimer disease
DMKCRMD ID DMKCRMD
DMKCRMD DN AVB-S6-500
DMKCRMD HS Phase 1
DMKCRMD CP Aravive Biologics Houston, TX
DMKCRMD DE Acute myeloid leukaemia; Solid tumour/cancer
DMSR91U ID DMSR91U
DMSR91U DN AVE0118
DMSR91U HS Phase 1
DMSR91U SN UNII-Q1B712V03A; AVE-0118; CHEMBL1671897; Q1B712V03A; 498577-53-0; CHDSRMIDIQABTP-UHFFFAOYSA-N; SCHEMBL498292; ZINC3986746; BDBM50417943; SB17438; NCGC00386732-01; (1,1'-Biphenyl)-2-carboxamide, 2'-((((4-methoxyphenyl)acetyl)amino)methyl)-N-(2-(3-pyridinyl)ethyl)-; 2'-((2-(4-Methoxyphenyl)acetylamino)methyl)biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)amide; (1,1'-Biphenyl)-2-carboxamide, 2'-(((2-(4-methoxyphenyl)acetyl)amino)methyl)-N-(2-(3-pyridinyl)ethyl)-
DMSR91U CP Sanofi-Aventis
DMSR91U DT Small molecular drug
DMSR91U PC 9811357
DMSR91U MW 479.6
DMSR91U FM C30H29N3O3
DMSR91U IC InChI=1S/C30H29N3O3/c1-36-25-14-12-22(13-15-25)19-29(34)33-21-24-8-2-3-9-26(24)27-10-4-5-11-28(27)30(35)32-18-16-23-7-6-17-31-20-23/h2-15,17,20H,16,18-19,21H2,1H3,(H,32,35)(H,33,34)
DMSR91U CS COC1=CC=C(C=C1)CC(=O)NCC2=CC=CC=C2C3=CC=CC=C3C(=O)NCCC4=CN=CC=C4
DMSR91U IK CHDSRMIDIQABTP-UHFFFAOYSA-N
DMSR91U IU 2-[2-[[[2-(4-methoxyphenyl)acetyl]amino]methyl]phenyl]-N-(2-pyridin-3-ylethyl)benzamide
DMSR91U CA CAS 498577-53-0
DMSR91U DE Obstructive sleep apnea
DM56VG2 ID DM56VG2
DM56VG2 DN AVE0897
DM56VG2 HS Phase 1
DM56VG2 CP Sanofi-Aventis
DM56VG2 DE Type-2 diabetes
DMJY35M ID DMJY35M
DMJY35M DN AVE1701
DMJY35M HS Phase 1
DMJY35M CP Sanofi-Aventis
DMJY35M DE Rheumatoid arthritis
DMZNTHJ ID DMZNTHJ
DMZNTHJ DN AVE-8112
DMZNTHJ HS Phase 1
DMZNTHJ SN AVE8112
DMZNTHJ CP The michael j. fox foundation for parkinson's research; sanofi us
DMZNTHJ DE Parkinson disease
DMVUW8A ID DMVUW8A
DMVUW8A DN AVI-6002
DMVUW8A HS Phase 1
DMVUW8A SN NeuGene Plus (Ebola virus), AVI; Neugene (Ebola virus), AVI BioPharma; Polymerase cofactor VP35 modulator (Ebola virus infection,TSO), AVI BioPharma; Viral membrane associated protein VP24 modulator (Ebola virus infection, TSO), AVI BioPharma; AVI-4537 + AVI-4538 + AVI-4539 (Ebola virus infection), AVI BioPharma
DMVUW8A CP AVI BioPharma Inc
DMVUW8A DE Ebola virus infection
DMIJSDO ID DMIJSDO
DMIJSDO DN AVI-6003
DMIJSDO HS Phase 1
DMIJSDO SN NeuGene Plus; NeuGene (Marburg virus, TSO), AVI BioPharma
DMIJSDO CP Genphar
DMIJSDO DE Marburg virus infection
DMVD327 ID DMVD327
DMVD327 DN AVI-7288
DMVD327 HS Phase 1
DMVD327 CP Sarepta therapeutics
DMVD327 DT Antisense drug
DMVD327 DE Marburg virus infection
DMLI9U6 ID DMLI9U6
DMLI9U6 DN AVI-7537
DMLI9U6 HS Phase 1
DMLI9U6 CP Sarepta therapeutics
DMLI9U6 DT Antisense drug
DMLI9U6 DE Ebola virus infection
DMZ39T6 ID DMZ39T6
DMZ39T6 DN AVID200
DMZ39T6 HS Phase 1
DMZ39T6 CP Bristol-Myers Squibb
DMZ39T6 DT Small molecular drug
DMZ39T6 DE Solid tumour/cancer
DMGAKR9 ID DMGAKR9
DMGAKR9 DN AVL-3288
DMGAKR9 HS Phase 1
DMGAKR9 CP Anvyl pharmaceuticals
DMGAKR9 PC 16005981
DMGAKR9 MW 388.2
DMGAKR9 FM C19H15Cl2N3O2
DMGAKR9 IC InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,22H,1H3,(H,23,25)/b17-11-
DMGAKR9 CS CC1=NOC(=C1)/C(=C/NC2=CC=C(C=C2)Cl)/C(=O)NC3=CC=C(C=C3)Cl
DMGAKR9 IK VMAKIACTLSBBIY-BOPFTXTBSA-N
DMGAKR9 IU (Z)-3-(4-chloroanilino)-N-(4-chlorophenyl)-2-(3-methyl-1,2-oxazol-5-yl)prop-2-enamide
DMGAKR9 CA CAS 917837-54-8
DMGAKR9 DE Cognitive impairment; Complete androgen insensitivity syndrome; Immune dysregulation
DMNIVFJ ID DMNIVFJ
DMNIVFJ DN AVN-322
DMNIVFJ HS Phase 1
DMNIVFJ SN 1194574-68-9; N,7-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[3,4-e]pyrimidin-2-amine hydrochloride; SB17475
DMNIVFJ CP Avineuro
DMNIVFJ DT Small molecular drug
DMNIVFJ PC 135905417
DMNIVFJ MW 393.9
DMNIVFJ FM C17H20ClN5O2S
DMNIVFJ IC InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H
DMNIVFJ CS CNC1=NN2C3=C(CN(CC3)C)C=NC2=C1S(=O)(=O)C4=CC=CC=C4.Cl
DMNIVFJ IK HLQZXWFRTGIZIJ-UHFFFAOYSA-N
DMNIVFJ IU 5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
DMNIVFJ DE Alzheimer disease
DM8CYJ1 ID DM8CYJ1
DM8CYJ1 DN AVP-13358
DM8CYJ1 HS Phase 1
DM8CYJ1 SN IgE inhibitors, AVANIR; Allergy/asthma therapeutic, AVANIR
DM8CYJ1 CP AVANIR Pharmaceuticals Inc
DM8CYJ1 DT Small molecular drug
DM8CYJ1 PC 9805635
DM8CYJ1 MW 491.6
DM8CYJ1 FM C30H29N5O2
DM8CYJ1 IC InChI=1S/C30H29N5O2/c36-28(35-26-3-1-2-10-31-26)22-6-9-24-25(14-22)34-27(33-24)21-4-7-23(8-5-21)32-29(37)30-15-18-11-19(16-30)13-20(12-18)17-30/h1-10,14,18-20H,11-13,15-17H2,(H,32,37)(H,33,34)(H,31,35,36)
DM8CYJ1 CS C1C2CC3CC1CC(C2)(C3)C(=O)NC4=CC=C(C=C4)C5=NC6=C(N5)C=C(C=C6)C(=O)NC7=CC=CC=N7
DM8CYJ1 IK LUPHOOKVGNVAFT-UHFFFAOYSA-N
DM8CYJ1 IU 2-[4-(adamantane-1-carbonylamino)phenyl]-N-pyridin-2-yl-3H-benzimidazole-5-carboxamide
DM8CYJ1 CA CAS 459805-03-9
DM8CYJ1 DE Rhinitis
DMMWEH6 ID DMMWEH6
DMMWEH6 DN AVP-21D9
DMMWEH6 HS Phase 1
DMMWEH6 SN Thravixa; AVP-1C6; AVP-22G12; AVP-8C1; Anthrax antibody, AVANIR; Anthrax toxin Mab, Xenerex; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), AVANIR; Protective antigen-targeting human monoclonal antibodies (intravenous, anthrax), Emergent
DMMWEH6 CP Emergent biosolutions
DMMWEH6 DT Antibody
DMMWEH6 DE Bacillus anthracis infection
DMAKD0I ID DMAKD0I
DMAKD0I DN AVX-470
DMAKD0I HS Phase 1
DMAKD0I SN Anti-TNF antibody (oral, IBD), Avaxia Biologics
DMAKD0I CP Avaxia Biologics Inc
DMAKD0I DT Antibody
DMAKD0I DE Inflammatory bowel disease; Ulcerative colitis
DMRQ32K ID DMRQ32K
DMRQ32K DN AX-024
DMRQ32K HS Phase 1
DMRQ32K SN VMMKGVRPILDZML-UHFFFAOYSA-N; SCHEMBL903258; AKOS030622922; CS-8052; HY-107390; 1370544-73-2
DMRQ32K CP Artax Biopharma Cambridge, MA
DMRQ32K PC 56949412
DMRQ32K MW 339.4
DMRQ32K FM C21H22FNO2
DMRQ32K IC InChI=1S/C21H22FNO2/c1-24-18-8-9-20-19(12-18)21(15-4-6-17(22)7-5-15)16(14-25-20)13-23-10-2-3-11-23/h4-9,12H,2-3,10-11,13-14H2,1H3
DMRQ32K CS COC1=CC2=C(C=C1)OCC(=C2C3=CC=C(C=C3)F)CN4CCCC4
DMRQ32K IK VMMKGVRPILDZML-UHFFFAOYSA-N
DMRQ32K IU 1-[[4-(4-fluorophenyl)-6-methoxy-2H-chromen-3-yl]methyl]pyrrolidine
DMRQ32K DE Multiple sclerosis
DMFBMU7 ID DMFBMU7
DMFBMU7 DN Axatilamab
DMFBMU7 HS Phase 1
DMFBMU7 SN SNDX-6352
DMFBMU7 CP Syndax Pharmaceuticals
DMFBMU7 DT Antibody
DMFBMU7 DE Solid tumour/cancer
DM6L5IP ID DM6L5IP
DM6L5IP DN Axitirome
DM6L5IP HS Phase 1
DM6L5IP SN CGP-26214; CGS-25845; CGS-26214
DM6L5IP CP Novartis AG
DM6L5IP DT Small molecular drug
DM6L5IP PC 166559
DM6L5IP MW 453.5
DM6L5IP FM C25H24FNO6
DM6L5IP IC InChI=1S/C25H24FNO6/c1-4-32-25(31)24(30)27-18-11-14(2)23(15(3)12-18)33-19-9-10-21(28)20(13-19)22(29)16-5-7-17(26)8-6-16/h5-13,22,28-29H,4H2,1-3H3,(H,27,30)
DM6L5IP CS CCOC(=O)C(=O)NC1=CC(=C(C(=C1)C)OC2=CC(=C(C=C2)O)C(C3=CC=C(C=C3)F)O)C
DM6L5IP IK FUBBWDWIGBTUPQ-UHFFFAOYSA-N
DM6L5IP IU ethyl 2-[4-[3-[(4-fluorophenyl)-hydroxymethyl]-4-hydroxyphenoxy]-3,5-dimethylanilino]-2-oxoacetate
DM6L5IP CA CAS 156740-57-7
DM6L5IP DE Hyperlipidaemia
DM7ZU3B ID DM7ZU3B
DM7ZU3B DN AXT-914
DM7ZU3B HS Phase 1
DM7ZU3B CP Novartis AG
DM7ZU3B DE Osteoporosis
DMWCJEU ID DMWCJEU
DMWCJEU DN AZD0156
DMWCJEU HS Phase 1
DMWCJEU SN AOTRIQLYUAFVSC-UHFFFAOYSA-N; 1821428-35-6; AZD-0156; UNII-P5T0XWC07Z; P5T0XWC07Z; GTPL9942; CHEMBL3960662; SCHEMBL17246146; AZD 0156 [WHO-DD]; MolPort-044-560-374; BDBM245474; BCP18990; EX-A1321; s8375; ZINC498035578; AKOS030629510; CS-5889; SB19769; AZD0156 (AZD-0156); AS-35329; compound 64 [PMID: 29683659]; HY-100016; US9428503, 1; 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one; 8-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[
DMWCJEU CP AstraZeneca Wilmington, DE
DMWCJEU PC 118502708
DMWCJEU MW 461.6
DMWCJEU FM C26H31N5O3
DMWCJEU IC InChI=1S/C26H31N5O3/c1-29(2)11-4-12-34-24-8-6-19(16-28-24)18-5-7-22-21(15-18)25-23(17-27-22)30(3)26(32)31(25)20-9-13-33-14-10-20/h5-8,15-17,20H,4,9-14H2,1-3H3
DMWCJEU CS CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4CCOCC4)C5=CN=C(C=C5)OCCCN(C)C
DMWCJEU IK AOTRIQLYUAFVSC-UHFFFAOYSA-N
DMWCJEU IU 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one
DMWCJEU CA CAS 1821428-35-6
DMWCJEU DE Solid tumour/cancer
DMHBEKM ID DMHBEKM
DMHBEKM DN AZD0284
DMHBEKM HS Phase 1
DMHBEKM CP AstraZeneca Wilmington, DE
DMHBEKM DE Plaque psoriasis
DMMW72C ID DMMW72C
DMMW72C DN AZD-1152-HQPA
DMMW72C HS Phase 1
DMMW72C SN Barasertib
DMMW72C DT Small molecular drug
DMMW72C PC 16007391
DMMW72C MW 507.6
DMMW72C FM C26H30FN7O3
DMMW72C IC InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)
DMMW72C CS CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
DMMW72C IK QYZOGCMHVIGURT-UHFFFAOYSA-N
DMMW72C IU 2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide
DMMW72C CA CAS 722544-51-6
DMMW72C CB CHEBI:91367
DMMW72C DE Solid tumour/cancer
DMBEA6V ID DMBEA6V
DMBEA6V DN AZD1208
DMBEA6V HS Phase 1
DMBEA6V SN AZD1208; 1204144-28-4; AZD-1208; UNII-S98NFM1378; (R,Z)-5-((2-(3-aminopiperidin-1-yl)-[1,1'-biphenyl]-3-yl)methylene)thiazolidine-2,4-dione; CHEMBL2048872; S98NFM1378; AZD 1208; AK174910; GTPL7698; (5Z)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione; (5Z)-5-({2-[(3R)-3-Aminopiperidin-1-yl]-3-phenylphenyl}methylidene)-1,3-thiazolidine-2,4-dione; SCHEMBL1580644; MolPort-035-395-904; EX-A1804; AOB87151; s7104; 2236AH; ZINC84670255; BDBM50387298; AKOS025404917; CS-1668; QC-11435; HY-15604
DMBEA6V CP AstraZeneca
DMBEA6V DT Small molecular drug
DMBEA6V PC 58423153
DMBEA6V MW 379.5
DMBEA6V FM C21H21N3O2S
DMBEA6V IC InChI=1S/C21H21N3O2S/c22-16-9-5-11-24(13-16)19-15(12-18-20(25)23-21(26)27-18)8-4-10-17(19)14-6-2-1-3-7-14/h1-4,6-8,10,12,16H,5,9,11,13,22H2,(H,23,25,26)/b18-12-/t16-/m1/s1
DMBEA6V CS C1C[C@H](CN(C1)C2=C(C=CC=C2C3=CC=CC=C3)/C=C\\4/C(=O)NC(=O)S4)N
DMBEA6V IK MCUJKPPARUPFJM-UWCCDQBKSA-N
DMBEA6V IU (5Z)-5-[[2-[(3R)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione
DMBEA6V CA CAS 1204144-28-4
DMBEA6V DE Solid tumour/cancer
DMYBX4N ID DMYBX4N
DMYBX4N DN AZD1390
DMYBX4N HS Phase 1
DMYBX4N SN VQSZIPCGAGVRRP-UHFFFAOYSA-N; SCHEMBL18631972; AZD-1390; EX-A2670; CS-8217; 2089288-03-7; HY-109566
DMYBX4N CP AstraZeneca Wilmington, DE
DMYBX4N PC 126689157
DMYBX4N MW 477.6
DMYBX4N FM C27H32FN5O2
DMYBX4N IC InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3
DMYBX4N CS CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C
DMYBX4N IK VQSZIPCGAGVRRP-UHFFFAOYSA-N
DMYBX4N IU 7-fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one
DMYBX4N CA CAS 2089288-03-7
DMYBX4N DE Recurrent glioblastoma
DM6UOXF ID DM6UOXF
DM6UOXF DN AZD1419
DM6UOXF HS Phase 1
DM6UOXF DE Asthma
DMQ1OX4 ID DMQ1OX4
DMQ1OX4 DN AZD1979
DMQ1OX4 HS Phase 1
DMQ1OX4 PC 49801838
DMQ1OX4 MW 462.5
DMQ1OX4 FM C25H26N4O5
DMQ1OX4 IC InChI=1S/C25H26N4O5/c1-31-19-8-4-18(5-9-19)22-26-27-23(34-22)24(30)29-11-21(12-29)33-20-6-2-17(3-7-20)10-28-13-25(14-28)15-32-16-25/h2-9,21H,10-16H2,1H3
DMQ1OX4 CS COC1=CC=C(C=C1)C2=NN=C(O2)C(=O)N3CC(C3)OC4=CC=C(C=C4)CN5CC6(C5)COC6
DMQ1OX4 IK BKKPIQPFRAPEAY-UHFFFAOYSA-N
DMQ1OX4 IU [5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-[3-[4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy]azetidin-1-yl]methanone
DMQ1OX4 CA CAS 1254035-84-1
DMQ1OX4 CB CHEBI:139154
DMQ1OX4 DE Obesity
DMZQEDY ID DMZQEDY
DMZQEDY DN AZD-2551
DMZQEDY HS Phase 1
DMZQEDY CP AstraZeneca plc
DMZQEDY DE Chronic obstructive pulmonary disease
DMXFYN0 ID DMXFYN0
DMXFYN0 DN AZD-3043
DMXFYN0 HS Phase 1
DMXFYN0 SN TD-4756; THRX-918661
DMXFYN0 CP Theravance Inc
DMXFYN0 DT Small molecular drug
DMXFYN0 PC 10286834
DMXFYN0 MW 351.4
DMXFYN0 FM C19H29NO5
DMXFYN0 IC InChI=1S/C19H29NO5/c1-5-11-24-19(22)13-15-9-10-16(17(12-15)23-8-4)25-14-18(21)20(6-2)7-3/h9-10,12H,5-8,11,13-14H2,1-4H3
DMXFYN0 CS CCCOC(=O)CC1=CC(=C(C=C1)OCC(=O)N(CC)CC)OCC
DMXFYN0 IK QPUVKSKJCNGSGT-UHFFFAOYSA-N
DMXFYN0 IU propyl 2-[4-[2-(diethylamino)-2-oxoethoxy]-3-ethoxyphenyl]acetate
DMXFYN0 CA CAS 579494-66-9
DMXFYN0 DE Anaesthesia
DMICW7D ID DMICW7D
DMICW7D DN AZD-3161
DMICW7D HS Phase 1
DMICW7D CP AstraZeneca plc
DMICW7D PC 56945146
DMICW7D MW 474.4
DMICW7D FM C23H21F3N4O4
DMICW7D IC InChI=1S/C23H21F3N4O4/c1-32-21-10-28-19(9-29-21)17-3-2-4-20-18(17)7-16(12-34-20)30-22(31)14-5-6-15(27-8-14)11-33-13-23(24,25)26/h2-6,8-10,16H,7,11-13H2,1H3,(H,30,31)/t16-/m0/s1
DMICW7D CS COC1=NC=C(N=C1)C2=C3C[C@@H](COC3=CC=C2)NC(=O)C4=CN=C(C=C4)COCC(F)(F)F
DMICW7D IK LRHQXIQLHVPUNA-INIZCTEOSA-N
DMICW7D IU N-[(3S)-5-(5-methoxypyrazin-2-yl)-3,4-dihydro-2H-chromen-3-yl]-6-(2,2,2-trifluoroethoxymethyl)pyridine-3-carboxamide
DMICW7D CA CAS 1369501-46-1
DMICW7D DE Peripheral neuropathy
DMC1BXV ID DMC1BXV
DMC1BXV DN AZD-3514
DMC1BXV HS Phase 1
DMC1BXV CP AstraZeneca plc
DMC1BXV PC 46893585
DMC1BXV MW 519.6
DMC1BXV FM C25H32F3N7O2
DMC1BXV IC InChI=1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3
DMC1BXV CS CC(=O)N1CCN(CC1)CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5C(F)(F)F)CC4
DMC1BXV IK JMEYDSHPKCSIJC-UHFFFAOYSA-N
DMC1BXV IU 1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone
DMC1BXV CA CAS 1240299-33-5
DMC1BXV DE Prostate cancer
DM72FOD ID DM72FOD
DM72FOD DN Azd-3839
DM72FOD HS Phase 1
DM72FOD SN GTPL6931; 4b05; (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-[3-(pyrimidin-5-yl)phenyl]-2,3-dihydro-1H-isoindol-1-amine; 32D
DM72FOD CP AstraZeneca plc
DM72FOD DT Small molecular drug
DM72FOD PC 46202416
DM72FOD MW 431.4
DM72FOD FM C24H16F3N5
DM72FOD IC InChI=1S/C24H16F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22H,(H2,28,32)/t24-/m0/s1
DM72FOD CS C1=CC(=CC(=C1)[C@@]2(C3=C(C(=CC=C3)F)C(=N2)N)C4=CC(=NC=C4)C(F)F)C5=CN=CN=C5
DM72FOD IK MRXBCEQZNKUUIP-DEOSSOPVSA-N
DM72FOD IU (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine
DM72FOD CA CAS 1227163-84-9
DM72FOD DE Alzheimer disease
DMOYPTK ID DMOYPTK
DMOYPTK DN AZD4573
DMOYPTK HS Phase 1
DMOYPTK SN AVIWDYSJSPOOAR-LSDHHAIUSA-N; 2057509-72-3; SCHEMBL18338402; HY-112088; CS-0043316; AZD-4573,AZD4573,AZD 4573; (1S,3R)-3-Acetamido-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexanecarboxamide
DMOYPTK CP AstraZeneca Wilmington, DE
DMOYPTK PC 124155204
DMOYPTK MW 429.9
DMOYPTK FM C22H28ClN5O2
DMOYPTK IC InChI=1S/C22H28ClN5O2/c1-13(29)26-15-6-4-5-14(7-15)21(30)27-20-8-16(18(23)11-24-20)17-10-25-28-12-22(2,3)9-19(17)28/h8,10-11,14-15H,4-7,9,12H2,1-3H3,(H,26,29)(H,24,27,30)/t14-,15+/m0/s1
DMOYPTK CS CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)NC2=NC=C(C(=C2)C3=C4CC(CN4N=C3)(C)C)Cl
DMOYPTK IK AVIWDYSJSPOOAR-LSDHHAIUSA-N
DMOYPTK IU (1S,3R)-3-acetamido-N-[5-chloro-4-(5,5-dimethyl-4,6-dihydropyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl]cyclohexane-1-carboxamide
DMOYPTK CA CAS 2057509-72-3
DMOYPTK DE Haematological malignancy
DM36EY7 ID DM36EY7
DM36EY7 DN AZD4721
DM36EY7 HS Phase 1
DM36EY7 CP Astrazeneca
DM36EY7 DE Chronic obstructive pulmonary disease
DMVWMUK ID DMVWMUK
DMVWMUK DN AZD4785
DMVWMUK HS Phase 1
DMVWMUK SN IONIS-KRAS-2.5RX
DMVWMUK CP AstraZeneca Wilmington, DEIonis Pharmaceuticals Carlsbad, CA
DMVWMUK DE Solid tumour/cancer
DMRP3N8 ID DMRP3N8
DMRP3N8 DN AZD4831
DMRP3N8 HS Phase 1
DMRP3N8 CP AstraZeneca Wilmington, DE
DMRP3N8 DE Heart failure
DMQEO4V ID DMQEO4V
DMQEO4V DN AZD-5122
DMQEO4V HS Phase 1
DMQEO4V CP AstraZeneca plc
DMQEO4V DE Chronic obstructive pulmonary disease
DMW4GM2 ID DMW4GM2
DMW4GM2 DN AZD5153
DMW4GM2 HS Phase 1
DMW4GM2 SN RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe
DMW4GM2 CP AstraZeneca Wilmington, DE
DMW4GM2 PC 118693659
DMW4GM2 MW 479.6
DMW4GM2 FM C25H33N7O3
DMW4GM2 IC InChI=1S/C25H33N7O3/c1-18-24(33)29(2)14-15-30(18)16-17-35-21-6-4-19(5-7-21)20-10-12-31(13-11-20)23-9-8-22-26-27-25(34-3)32(22)28-23/h4-9,18,20H,10-17H2,1-3H3/t18-/m1/s1
DMW4GM2 CS C[C@@H]1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C
DMW4GM2 IK RSMYFSPOTCDHHJ-GOSISDBHSA-N
DMW4GM2 IU (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one
DMW4GM2 CA CAS 1869912-39-9
DMW4GM2 DE Solid tumour/cancer
DMBQ2TF ID DMBQ2TF
DMBQ2TF DN AZD-5438
DMBQ2TF HS Phase 1
DMBQ2TF SN 602306-29-6; AZD5438; AZD-5438; AZD 5438; 4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine; CHEMBL488436; UNII-276Z913G29; MMV676604; 4-[2-METHYL-1-ISOPROPYL-1H-IMIDAZOL-5-YL]-N-[4-(METHYLSULFONYL)PHENYL]-2-PYRIMIDINAMINE; 2-Pyrimidinamine,4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-; 276Z913G29; 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine
DMBQ2TF DT Small molecular drug
DMBQ2TF PC 16747683
DMBQ2TF MW 371.5
DMBQ2TF FM C18H21N5O2S
DMBQ2TF IC InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)
DMBQ2TF CS CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(C=C3)S(=O)(=O)C
DMBQ2TF IK WJRRGYBTGDJBFX-UHFFFAOYSA-N
DMBQ2TF IU 4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine
DMBQ2TF CA CAS 602306-29-6
DMBQ2TF CB CHEBI:91419
DMBQ2TF DE Solid tumour/cancer
DMV6DF3 ID DMV6DF3
DMV6DF3 DN AZD5658
DMV6DF3 HS Phase 1
DMV6DF3 CP AstraZeneca
DMV6DF3 DE Diabetic complication; Obesity
DM7QGHO ID DM7QGHO
DM7QGHO DN AZD5991
DM7QGHO HS Phase 1
DM7QGHO SN KBQCEQAXHPIRTF-UHFFFAOYSA-N; AZD-5991 (Racemate); 2143061-81-6; UNII-E3T5XXY9HX; E3T5XXY9HX; SCHEMBL19472011; EX-A2673; HY-101533A; CS-0077938; E4W
DM7QGHO CP AstraZeneca Wilmington, DE
DM7QGHO PC 131634760
DM7QGHO MW 672.3
DM7QGHO FM C35H34ClN5O3S2
DM7QGHO IC InChI=1S/C35H34ClN5O3S2/c1-20-31-29(38-40(20)3)19-45-17-22-15-23(41(4)37-22)18-46-24-14-21-8-5-6-9-25(21)30(16-24)44-13-7-10-26-27-11-12-28(36)32(31)33(27)39(2)34(26)35(42)43/h5-6,8-9,11-12,14-16H,7,10,13,17-19H2,1-4H3,(H,42,43)
DM7QGHO CS CC1=C2C(=NN1C)CSCC3=NN(C(=C3)CSC4=CC5=CC=CC=C5C(=C4)OCCCC6=C(N(C7=C6C=CC(=C27)Cl)C)C(=O)O)C
DM7QGHO IK KBQCEQAXHPIRTF-UHFFFAOYSA-N
DM7QGHO IU 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(36),4(38),6,11,14,16,18,20,23,29(37),30,32,34-tridecaene-23-carboxylic acid
DM7QGHO CA CAS 2143061-82-7
DM7QGHO DE Haematological malignancy
DM0WCR4 ID DM0WCR4
DM0WCR4 DN AZD-6088
DM0WCR4 HS Phase 1
DM0WCR4 SN SCHEMBL648624; ZXKUTOMRBVXFKV-OALUTQOASA-N; propan-2-yl 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahydro-3H-benzoimidazol-1-yl]-1-piperidyl]-4-methyl-piperidine-1-carboxylate
DM0WCR4 CP AstraZeneca plc
DM0WCR4 DT Small molecular drug
DM0WCR4 PC 25221108
DM0WCR4 MW 392.5
DM0WCR4 FM C21H36N4O3
DM0WCR4 IC InChI=1S/C21H36N4O3/c1-3-28-20(27)23-14-10-21(2,11-15-23)24-12-8-16(9-13-24)25-18-7-5-4-6-17(18)22-19(25)26/h16-18H,3-15H2,1-2H3,(H,22,26)/t17-,18-/m0/s1
DM0WCR4 CS CCOC(=O)N1CCC(CC1)(C)N2CCC(CC2)N3[C@H]4CCCC[C@@H]4NC3=O
DM0WCR4 IK IVJDEIANCSDDAO-ROUUACIJSA-N
DM0WCR4 IU ethyl 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahydro-3H-benzimidazol-1-yl]piperidin-1-yl]-4-methylpiperidine-1-carboxylate
DM0WCR4 DE Neuropathic pain
DMW4VQF ID DMW4VQF
DMW4VQF DN AZD6423
DMW4VQF HS Phase 1
DMW4VQF CP Astrazeneca
DMW4VQF DE Suicidal ideation
DM84WXZ ID DM84WXZ
DM84WXZ DN AZD-7295
DM84WXZ HS Phase 1
DM84WXZ SN A-689; HCV NS5a polymerase inhibitor, Arrow; HCV NS5a polymerase inhibitor, AstraZeneca
DM84WXZ CP Arrow Therapeutics Ltd
DM84WXZ DT Small molecular drug
DM84WXZ PC 57339445
DM84WXZ MW 644.7
DM84WXZ FM C32H35F3N4O5S
DM84WXZ IC InChI=1S/C32H35F3N4O5S/c1-2-19-45(42,43)39-17-15-38(16-18-39)21-22-3-11-26(12-4-22)36-30(40)24-7-5-23(6-8-24)28-20-27(37-31(41)25-9-10-25)13-14-29(28)44-32(33,34)35/h3-8,11-14,20,25H,2,9-10,15-19,21H2,1H3,(H,36,40)(H,37,41)
DM84WXZ CS CCCS(=O)(=O)N1CCN(CC1)CC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C4=C(C=CC(=C4)NC(=O)C5CC5)OC(F)(F)F
DM84WXZ IK MAQDQJWCSSCURR-UHFFFAOYSA-N
DM84WXZ IU 4-[5-(cyclopropanecarbonylamino)-2-(trifluoromethoxy)phenyl]-N-[4-[(4-propylsulfonylpiperazin-1-yl)methyl]phenyl]benzamide
DM84WXZ CA CAS 929890-64-2
DM84WXZ DE Hepatitis C virus infection
DMS9I6A ID DMS9I6A
DMS9I6A DN AZD7687
DMS9I6A HS Phase 1
DMS9I6A SN AZD7687; 1166827-44-6; CHEMBL2178944; CHEMBL2178953; AZD-7687; AZD 7687; UNII-6QTJ9P2NYT; 6QTJ9P2NYT; SCHEMBL2252415; SCHEMBL5532381; SCHEMBL2252417; GTPL7827; SCHEMBL2255196; DTXSID60655297; YXFNPRHZMOGREC-SHTZXODSSA-N; 3466AH; ZINC43206395; BDBM50399684; BDBM50399710; AZD 7687;AZD-7687; ZINC101581684; AKOS030526281; CS-1026; NCGC00378858-01; HY-15497; KB-144428; W-5990; {4-[4-(6-Carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid; {trans-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid
DMS9I6A CP AstraZeneca
DMS9I6A DT Small molecular drug
DMS9I6A PC 42636350
DMS9I6A MW 367.4
DMS9I6A FM C21H25N3O3
DMS9I6A IC InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)
DMS9I6A CS CC1=C(N=C(C(=N1)C)C(=O)N)C2=CC=C(C=C2)C3CCC(CC3)CC(=O)O
DMS9I6A IK YXFNPRHZMOGREC-UHFFFAOYSA-N
DMS9I6A IU 2-[4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid
DMS9I6A CA CAS 1166827-44-6
DMS9I6A DE Diabetic complication; Obesity
DM1FW0C ID DM1FW0C
DM1FW0C DN AZD7762
DM1FW0C HS Phase 1
DM1FW0C SN AZD7762; 860352-01-8; AZD-7762; (S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide; AZD 7762; UNII-5D822Y3L1H; 3-(Carbamoylamino)-5-(3-Fluorophenyl)-N-[(3s)-Piperidin-3-Yl]thiophene-2-Carboxamide; CHEMBL2041933; 5D822Y3L1H; J-502468; 5-(3-Fluorophenyl)-N-[(3s)-3-Piperidyl]-3-Ureido-Thiophene-2-Carboxamide; IAYGCINLNONXHY-LBPRGKRZSA-N; YDJ; AZD7762 hydrochloride; 5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide; SCHEMBL1127614; GTPL7713; AOB1915; QCR-261; CHEBI:131156
DM1FW0C CP AstraZeneca
DM1FW0C DT Small molecular drug
DM1FW0C PC 11152667
DM1FW0C MW 362.4
DM1FW0C FM C17H19FN4O2S
DM1FW0C IC InChI=1S/C17H19FN4O2S/c18-11-4-1-3-10(7-11)14-8-13(22-17(19)24)15(25-14)16(23)21-12-5-2-6-20-9-12/h1,3-4,7-8,12,20H,2,5-6,9H2,(H,21,23)(H3,19,22,24)/t12-/m0/s1
DM1FW0C CS C1C[C@@H](CNC1)NC(=O)C2=C(C=C(S2)C3=CC(=CC=C3)F)NC(=O)N
DM1FW0C IK IAYGCINLNONXHY-LBPRGKRZSA-N
DM1FW0C IU 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide
DM1FW0C CA CAS 860352-01-8
DM1FW0C CB CHEBI:131156
DM1FW0C DE Solid tumour/cancer
DM8DMI0 ID DM8DMI0
DM8DMI0 DN AZD-8165
DM8DMI0 HS Phase 1
DM8DMI0 SN AZ-12971554; Thombin inhibitor prodrug (oral), AstraZeneca
DM8DMI0 CP AstraZeneca plc
DM8DMI0 DT Small molecular drug
DM8DMI0 PC 44548240
DM8DMI0 MW 513.9
DM8DMI0 FM C23H21ClFN7O4
DM8DMI0 IC InChI=1S/C23H21ClFN7O4/c1-2-20(33)36-21(14-3-6-17(25)7-4-14)23(35)32-19(9-10-28-32)22(34)26-12-15-11-16(24)5-8-18(15)31-13-27-29-30-31/h3-8,10-11,13,19,21H,2,9,12H2,1H3,(H,26,34)/t19-,21+/m0/s1
DM8DMI0 CS CCC(=O)O[C@H](C1=CC=C(C=C1)F)C(=O)N2[C@@H](CC=N2)C(=O)NCC3=C(C=CC(=C3)Cl)N4C=NN=N4
DM8DMI0 IK YUHNXUAATAMVKD-PZJWPPBQSA-N
DM8DMI0 IU [(1R)-2-[(3S)-3-[[5-chloro-2-(tetrazol-1-yl)phenyl]methylcarbamoyl]-3,4-dihydropyrazol-2-yl]-1-(4-fluorophenyl)-2-oxoethyl] propanoate
DM8DMI0 CA CAS 1201686-72-7
DM8DMI0 DE Thrombosis
DMWYF1H ID DMWYF1H
DMWYF1H DN AZD8186
DMWYF1H HS Phase 1
DMWYF1H SN AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA; CHEMBL3408248; AZD 8186; 8-[(1R)-1-(3,5-difluoroanilino)ethyl]-N,N-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide; SCHEMBL1636956; GTPL8527; MolPort-039-137-739; EX-A1649; BDBM50070322; s7694; AKOS025404922; ZINC116734639; CS-4975; ACN-037528; SB16709; KS-0000063L; AK174916; AC-29024; HY-12330; KB-334360; B5950; AZD8186; 1627494-13-6; AZD-8186; AIQ4OWD0RA; UNII-AIQ4OWD0RA;
DMWYF1H CP Astrazeneca
DMWYF1H DT Small molecular drug
DMWYF1H PC 52913813
DMWYF1H MW 457.5
DMWYF1H FM C24H25F2N3O4
DMWYF1H IC InChI=1S/C24H25F2N3O4/c1-14(27-18-11-16(25)10-17(26)12-18)19-8-15(24(31)28(2)3)9-20-21(30)13-22(33-23(19)20)29-4-6-32-7-5-29/h8-14,27H,4-7H2,1-3H3/t14-/m1/s1
DMWYF1H CS C[C@H](C1=CC(=CC2=C1OC(=CC2=O)N3CCOCC3)C(=O)N(C)C)NC4=CC(=CC(=C4)F)F
DMWYF1H IK LMJFJIDLEAWOQJ-CQSZACIVSA-N
DMWYF1H IU 8-[(1R)-1-(3,5-difluoroanilino)ethyl]-N,N-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide
DMWYF1H CA CAS 1627494-13-6
DMWYF1H DE Solid tumour/cancer
DMTD57A ID DMTD57A
DMTD57A DN AZD8329
DMTD57A HS Phase 1
DMTD57A SN AZD-8329; AZD 8329; UNII-5B38CV1212; 1048668-70-7; CHEMBL2177609; 5B38CV1212; 4-[4-(2-Adamantylcarbamoyl)-5-Tert-Butyl-Pyrazol-1-Yl]benzoic Acid; AZD8329; XWBXJBSVYVJAMZ-UHFFFAOYSA-N; SCHEMBL617351; GTPL7715; BDBM50399335; 4-(4-(Adamant-2-ylcarbamoyl)-5-tert-butylpyrazol-1-yl)benzoic acid; Benzoic acid, 4-(5-(1,1-dimethylethyl)-4-((tricyclo(3.3.1.13,7)dec-2-ylamino)carbonyl)-1H-pyrazol-1-yl)-; 4-[4-(2-adamantylcarbamoyl)-5-tertbutyl-pyrazol-1-yl]benzoic acid; 4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic ac
DMTD57A CP AstraZeneca
DMTD57A DT Small molecular drug
DMTD57A PC 25006684
DMTD57A MW 421.5
DMTD57A FM C25H31N3O3
DMTD57A IC InChI=1S/C25H31N3O3/c1-25(2,3)22-20(13-26-28(22)19-6-4-16(5-7-19)24(30)31)23(29)27-21-17-9-14-8-15(11-17)12-18(21)10-14/h4-7,13-15,17-18,21H,8-12H2,1-3H3,(H,27,29)(H,30,31)
DMTD57A CS CC(C)(C)C1=C(C=NN1C2=CC=C(C=C2)C(=O)O)C(=O)NC3C4CC5CC(C4)CC3C5
DMTD57A IK XWBXJBSVYVJAMZ-UHFFFAOYSA-N
DMTD57A IU 4-[4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl]benzoic acid
DMTD57A CA CAS 1048668-70-7
DMTD57A DE Obesity; Diabetic complication
DM9X20P ID DM9X20P
DM9X20P DN AZD-8418
DM9X20P HS Phase 1
DM9X20P CP AstraZeneca plc
DM9X20P PC 44556193
DM9X20P MW 373.8
DM9X20P FM C19H20ClN3O3
DM9X20P IC InChI=1S/C19H20ClN3O3/c1-10(11-4-5-11)23-9-13-6-12(7-14(20)17(13)19(23)25)16-8-15(21-26-16)18(24)22(2)3/h6-8,10-11H,4-5,9H2,1-3H3/t10-/m0/s1
DM9X20P CS C[C@@H](C1CC1)N2CC3=C(C2=O)C(=CC(=C3)C4=CC(=NO4)C(=O)N(C)C)Cl
DM9X20P IK MCPBSUCAISQZQK-JTQLQIEISA-N
DM9X20P IU 5-[7-chloro-2-[(1S)-1-cyclopropylethyl]-1-oxo-3H-isoindol-5-yl]-N,N-dimethyl-1,2-oxazole-3-carboxamide
DM9X20P CA CAS 1198309-73-7
DM9X20P DE Schizophrenia
DM3EWUX ID DM3EWUX
DM3EWUX DN AZD8701
DM3EWUX HS Phase 1
DM3EWUX SN ION736
DM3EWUX CP AstraZeneca; Ionis Pharmaceuticals
DM3EWUX DT Antisense oligonucleotide
DM3EWUX DE Solid tumour/cancer
DMPMDTH ID DMPMDTH
DMPMDTH DN Azd9496
DMPMDTH HS Phase 1
DMPMDTH SN DFBDRVGWBHBJNR-BBNFHIFMSA-N; 1639042-08-2; UNII-DA9P7LN909; DA9P7LN909; CHEMBL3623004; AZD-9496; (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid; SCHEMBL16266273; SCHEMBL16266275; MolPort-044-560-384; EX-A1326; s8372; BDBM50125052; ZINC219669733; AKOS030526632; AC-29011; HY-12870; Selective estrogen
DMPMDTH CP AstraZeneca Wilmington, DE
DMPMDTH PC 86287635
DMPMDTH MW 442.5
DMPMDTH FM C25H25F3N2O2
DMPMDTH IC InChI=1S/C25H25F3N2O2/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2,3)28)22-18(26)11-15(12-19(22)27)8-9-21(31)32/h4-9,11-12,14,24,29H,10,13H2,1-3H3,(H,31,32)/b9-8+/t14-,24-/m1/s1
DMPMDTH CS C[C@@H]1CC2=C([C@H](N1CC(C)(C)F)C3=C(C=C(C=C3F)/C=C/C(=O)O)F)NC4=CC=CC=C24
DMPMDTH IK DFBDRVGWBHBJNR-BBNFHIFMSA-N
DMPMDTH IU (E)-3-[3,5-difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid
DMPMDTH CA CAS 1639042-08-2
DMPMDTH DE Breast cancer
DMAXHC0 ID DMAXHC0
DMAXHC0 DN AZD9567
DMAXHC0 HS Phase 1
DMAXHC0 SN ZQFNDBISEYQVRR-LOSJGSFVSA-N; AZD-9567; GTPL9812; SCHEMBL17643955; AZD 9567; example 1 [WO2016046260A1]; compound 15 [PMID: 29424542]; B9W; 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide; 2,2-bis(fluoranyl)-~{N}-[(1~{R},2~{S})-3-methyl-1-[1-(1-methyl-6-oxidanylidene-pyridin-3-yl)indazol-5-yl]oxy-1-phenyl-butan-2-yl]propanamide
DMAXHC0 CP AstraZeneca Wilmington, DE
DMAXHC0 PC 121248172
DMAXHC0 MW 494.5
DMAXHC0 FM C27H28F2N4O3
DMAXHC0 IC InChI=1S/C27H28F2N4O3/c1-17(2)24(31-26(35)27(3,28)29)25(18-8-6-5-7-9-18)36-21-11-12-22-19(14-21)15-30-33(22)20-10-13-23(34)32(4)16-20/h5-17,24-25H,1-4H3,(H,31,35)/t24-,25+/m0/s1
DMAXHC0 CS CC(C)[C@@H]([C@@H](C1=CC=CC=C1)OC2=CC3=C(C=C2)N(N=C3)C4=CN(C(=O)C=C4)C)NC(=O)C(C)(F)F
DMAXHC0 IK ZQFNDBISEYQVRR-LOSJGSFVSA-N
DMAXHC0 IU 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide
DMAXHC0 CA CAS 1893415-00-3
DMAXHC0 DE Rheumatoid arthritis
DMWYHXG ID DMWYHXG
DMWYHXG DN AZD-9819
DMWYHXG HS Phase 1
DMWYHXG SN Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca
DMWYHXG CP AstraZeneca plc
DMWYHXG PC 24890141
DMWYHXG MW 492.5
DMWYHXG FM C25H19F3N6O2
DMWYHXG IC InChI=1S/C25H19F3N6O2/c1-3-30-23(35)22-24(36)33(19-6-4-5-17(13-19)25(26,27)28)15(2)21(32-22)20-11-12-31-34(20)18-9-7-16(14-29)8-10-18/h4-13H,3H2,1-2H3,(H,30,35)
DMWYHXG CS CCNC(=O)C1=NC(=C(N(C1=O)C2=CC=CC(=C2)C(F)(F)F)C)C3=CC=NN3C4=CC=C(C=C4)C#N
DMWYHXG IK ZRJDPTREGVHMGQ-UHFFFAOYSA-N
DMWYHXG IU 6-[2-(4-cyanophenyl)pyrazol-3-yl]-N-ethyl-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide
DMWYHXG CA CAS 956907-23-6
DMWYHXG DE Chronic obstructive pulmonary disease
DM0LKHV ID DM0LKHV
DM0LKHV DN B7-2/GM-CSF
DM0LKHV HS Phase 1
DM0LKHV CP NuVax Therapeutics
DM0LKHV DT Small molecular drug
DM0LKHV PC 9862248
DM0LKHV MW 328.4
DM0LKHV FM C20H24O4
DM0LKHV IC InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)
DM0LKHV CS CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O
DM0LKHV IK QNAZTOHXCZPOSA-UHFFFAOYSA-N
DM0LKHV IU 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
DM0LKHV CA CAS 211110-63-3
DM0LKHV CB CHEBI:79988
DM0LKHV DE Dementia; Schizophrenia; Dyslipidemia; Solid tumour/cancer
DM5KU30 ID DM5KU30
DM5KU30 DN BAL-30072
DM5KU30 HS Phase 1
DM5KU30 SN UNII-LY97ZJM4QX; BAL30072; LY97ZJM4QX; CHEMBL1256967; BAL-30072; 941285-15-0; BAL 30072; SCHEMBL13318507; BDBM50327179; 4-Thiazoleacetamide, 2-amino-alpha-(((1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy)imino)-N-((3S)-2,2-dimethyl-4-oxo-1-(Sulfooxy)-3-azetidinyl)-, (alphaz)-; (S)-3-(2-(2-aminothiazol-4-yl)-2-((1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)methoxyimino)acetamido)-2,2-dimethyl-4-oxoazetidin-1-yl hydrogen sulfate
DM5KU30 CP Basilea Pharmaceutica International Ltd
DM5KU30 DT Small molecular drug
DM5KU30 PC 135905457
DM5KU30 MW 518.5
DM5KU30 FM C16H18N6O10S2
DM5KU30 IC InChI=1S/C16H18N6O10S2/c1-16(2)12(14(26)22(16)32-34(28,29)30)19-13(25)11(8-6-33-15(17)18-8)20-31-5-7-3-9(23)10(24)4-21(7)27/h3-4,6,12,24,27H,5H2,1-2H3,(H2,17,18)(H,19,25)(H,28,29,30)/b20-11+/t12-/m1/s1
DM5KU30 CS CC1([C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)/C(=N/OCC2=CC(=O)C(=CN2O)O)/C3=CSC(=N3)N)C
DM5KU30 IK KLFSEZJCLYBFKQ-ZICWZVMQSA-N
DM5KU30 IU [(3S)-3-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate
DM5KU30 DE Bacterial infection
DMAJPOX ID DMAJPOX
DMAJPOX DN Balapiravir
DMAJPOX HS Phase 1
DMAJPOX SN Balapiravir hydrochloride; HCV NS5B polymerase inhibitor, Roche; RO4588161-001; RNA polymerase inhibitor (HCV infection), Roche; RNA polymerase inhibitor (hepatitis C infection), Roche; R-1479 prodrug (HCV infection), Roche
DMAJPOX CP Roche
DMAJPOX DT Small molecular drug
DMAJPOX PC 11691726
DMAJPOX MW 494.5
DMAJPOX FM C21H30N6O8
DMAJPOX IC InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1
DMAJPOX CS CC(C)C(=O)OC[C@@]1([C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)OC(=O)C(C)C)OC(=O)C(C)C)N=[N+]=[N-]
DMAJPOX IK VKXWOLCNTHXCLF-DXEZIKHYSA-N
DMAJPOX IU [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
DMAJPOX CA CAS 690270-29-2
DMAJPOX DE Hepatitis C virus infection
DM3415L ID DM3415L
DM3415L DN BAX-499
DM3415L HS Phase 1
DM3415L SN ARC-19499; Tissue factor pathway inhibitor (hemophilia A/hemophilia B), Archemix
DM3415L CP Archemix Corp
DM3415L DE Factor IX deficiency
DMLRGX1 ID DMLRGX1
DMLRGX1 DN BAY 1082439
DMLRGX1 HS Phase 1
DMLRGX1 CP Bayer HealthCare Pharmaceuticals
DMLRGX1 DT Small molecular drug
DMLRGX1 PC 136336430
DMLRGX1 MW 494.5
DMLRGX1 FM C25H30N6O5
DMLRGX1 IC InChI=1S/C25H30N6O5/c1-16-18(4-3-7-26-16)24(33)29-25-28-21-19(23-27-8-9-31(23)25)5-6-20(22(21)34-2)36-15-17(32)14-30-10-12-35-13-11-30/h3-7,17,27,32H,8-15H2,1-2H3/t17-/m0/s1
DMLRGX1 CS CC1=C(C=CC=N1)C(=O)N=C2N=C3C(=C4N2CCN4)C=CC(=C3OC)OC[C@H](CN5CCOCC5)O
DMLRGX1 IK QJTLLKKDFGPDPF-KRWDZBQOSA-N
DMLRGX1 IU N-[8-[(2S)-2-hydroxy-3-morpholin-4-ylpropoxy]-7-methoxy-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]-2-methylpyridine-3-carboxamide
DMLRGX1 DE Solid tumour/cancer
DMYPU8V ID DMYPU8V
DMYPU8V DN BAY 1238097
DMYPU8V HS Phase 1
DMYPU8V CP Bayer
DMYPU8V DT Small molecular drug
DMYPU8V DE Neoplasm
DMF9ALP ID DMF9ALP
DMF9ALP DN BAY 1817080
DMF9ALP HS Phase 1
DMF9ALP SN Eliapixant
DMF9ALP CP Bayer
DMF9ALP DT Small molecular drug
DMF9ALP DE Endometriosis; Cough
DMQIKZG ID DMQIKZG
DMQIKZG DN BAY 1834942
DMQIKZG HS Phase 1
DMQIKZG SN Tinurilimab
DMQIKZG CP Bayer
DMQIKZG DT Antibody
DMQIKZG DE Solid tumour/cancer
DMNVPI1 ID DMNVPI1
DMNVPI1 DN BAY 1905254
DMNVPI1 HS Phase 1
DMNVPI1 CP Bayer
DMNVPI1 DT Antibody
DMNVPI1 DE Solid tumour/cancer
DMD9N12 ID DMD9N12
DMD9N12 DN BAY 2416964
DMD9N12 HS Phase 1
DMD9N12 SN 2242464-44-2; BAY2416964; SCHEMBL20471217; BCP33103; EX-A4271; MFCD32693912; NSC825713; s8995; NSC-825713; BAY-2416964; HY-135829; CS-0114330; BAY-2416964;BAY2416964; ClC1=CC=C(C=C1)C=1C=C(C(N(N=1)C=1C=NN(C=1)C)=O)C(=O)N[C@H](CO)C; (S)-6-(4-Chlorophenyl)-N-(1-hydroxypropan-2-yl)-2-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide
DMD9N12 CP Bayer
DMD9N12 DT Small molecular drug
DMD9N12 PC 135303769
DMD9N12 MW 387.8
DMD9N12 FM C18H18ClN5O3
DMD9N12 IC InChI=1S/C18H18ClN5O3/c1-11(10-25)21-17(26)15-7-16(12-3-5-13(19)6-4-12)22-24(18(15)27)14-8-20-23(2)9-14/h3-9,11,25H,10H2,1-2H3,(H,21,26)/t11-/m0/s1
DMD9N12 CS C[C@@H](CO)NC(=O)C1=CC(=NN(C1=O)C2=CN(N=C2)C)C3=CC=C(C=C3)Cl
DMD9N12 IK YAGSZKAJPHGVOV-NSHDSACASA-N
DMD9N12 IU 6-(4-chlorophenyl)-N-[(2S)-1-hydroxypropan-2-yl]-2-(1-methylpyrazol-4-yl)-3-oxopyridazine-4-carboxamide
DMD9N12 DE Solid tumour/cancer
DM98EP5 ID DM98EP5
DM98EP5 DN BAY 2701439
DM98EP5 HS Phase 1
DM98EP5 SN HER2-TTC
DM98EP5 CP Bayer
DM98EP5 DT Antibody
DM98EP5 DE Solid tumour/cancer
DM14XQN ID DM14XQN
DM14XQN DN BAY 79-4620
DM14XQN HS Phase 1
DM14XQN CP Bayer HealthCare Pharmaceuticals
DM14XQN DT Antibody
DM14XQN DE Solid tumour/cancer
DM31RQS ID DM31RQS
DM31RQS DN BAY 86-8050
DM31RQS HS Phase 1
DM31RQS CP Bayer HealthCare Pharmaceuticals
DM31RQS DE Heart failure
DMCQEL6 ID DMCQEL6
DMCQEL6 DN BAY 94-9343
DMCQEL6 HS Phase 1
DMCQEL6 CP Bayer HealthCare Pharmaceuticals
DMCQEL6 DE Solid tumour/cancer
DM8U3Q2 ID DM8U3Q2
DM8U3Q2 DN BAY-1075553
DM8U3Q2 HS Phase 1
DM8U3Q2 CP Bayer AG
DM8U3Q2 DE Prostate cancer
DMTB4R8 ID DMTB4R8
DMTB4R8 DN BAY1125976
DMTB4R8 HS Phase 1
DMTB4R8 CP Bayer healthcare pharmaceuticals
DMTB4R8 PC 70817911
DMTB4R8 MW 383.4
DMTB4R8 FM C23H21N5O
DMTB4R8 IC InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)
DMTB4R8 CS C1CC(C1)(C2=CC=C(C=C2)C3=C(N4C(=N3)C=CC(=N4)C(=O)N)C5=CC=CC=C5)N
DMTB4R8 IK JBGYKRAZYDNCNV-UHFFFAOYSA-N
DMTB4R8 IU 2-[4-(1-aminocyclobutyl)phenyl]-3-phenylimidazo[1,2-b]pyridazine-6-carboxamide
DMTB4R8 CA CAS 1402608-02-9
DMTB4R8 DE Solid tumour/cancer
DMVPAZ7 ID DMVPAZ7
DMVPAZ7 DN BAY1143572
DMVPAZ7 HS Phase 1
DMVPAZ7 CP Bayer healthcare pharmaceuticals
DMVPAZ7 DE Solid tumour/cancer
DMUK6YM ID DMUK6YM
DMUK6YM DN BAY1161909
DMUK6YM HS Phase 1
DMUK6YM CP Bayer healthcare pharmaceuticals
DMUK6YM PC 71599640
DMUK6YM MW 559.6
DMUK6YM FM C29H26FN5O4S
DMUK6YM IC InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1
DMUK6YM CS C[C@H](C1=CC=C(C=C1)F)C(=O)NC2=CC=C(C=C2)C3=CN4C(=NC(=N4)NC5=C(C=C(C=C5)S(=O)(=O)C)OC)C=C3
DMUK6YM IK NRJKIOCCERLIDG-GOSISDBHSA-N
DMUK6YM IU (2R)-2-(4-fluorophenyl)-N-[4-[2-(2-methoxy-4-methylsulfonylanilino)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl]propanamide
DMUK6YM CA CAS 1443763-60-7
DMUK6YM DE Solid tumour/cancer
DM7L91K ID DM7L91K
DM7L91K DN BAY1179470
DM7L91K HS Phase 1
DM7L91K CP Bayer healthcare pharmaceuticals
DM7L91K DE Solid tumour/cancer
DMCJNRL ID DMCJNRL
DMCJNRL DN BAY1251152
DMCJNRL HS Phase 1
DMCJNRL SN YZCUMZWULWOUMD-UHFFFAOYSA-N; SCHEMBL15720569; (rac)-5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine; 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine
DMCJNRL CP Bayer Pharmaceuticals Whippany, NJ
DMCJNRL PC 74767009
DMCJNRL MW 404.4
DMCJNRL FM C19H18F2N4O2S
DMCJNRL IC InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)
DMCJNRL CS COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)CS(=N)(=O)C
DMCJNRL IK YZCUMZWULWOUMD-UHFFFAOYSA-N
DMCJNRL IU 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
DMCJNRL CA CAS 1610358-59-2
DMCJNRL DE Haematological malignancy
DMPNBJ1 ID DMPNBJ1
DMPNBJ1 DN BAY1436032
DMPNBJ1 HS Phase 1
DMPNBJ1 SN RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid
DMPNBJ1 CP Bayer Pharmaceuticals Whippany, NJ
DMPNBJ1 PC 118310260
DMPNBJ1 MW 489.5
DMPNBJ1 FM C26H30F3N3O3
DMPNBJ1 IC InChI=1S/C26H30F3N3O3/c1-16-12-19(15-25(2,3)14-16)32-22-10-4-17(5-11-23(33)34)13-21(22)31-24(32)30-18-6-8-20(9-7-18)35-26(27,28)29/h4,6-10,13,16,19H,5,11-12,14-15H2,1-3H3,(H,30,31)(H,33,34)/t16-,19+/m0/s1
DMPNBJ1 CS C[C@H]1C[C@H](CC(C1)(C)C)N2C3=C(C=C(C=C3)CCC(=O)O)N=C2NC4=CC=C(C=C4)OC(F)(F)F
DMPNBJ1 IK RNMAUIMMNAHKQR-QFBILLFUSA-N
DMPNBJ1 IU 3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid
DMPNBJ1 DE Acute myeloid leukaemia; Solid tumour/cancer
DMNL5G7 ID DMNL5G7
DMNL5G7 DN BAY-1817080
DMNL5G7 HS Phase 1
DMNL5G7 CP Bayer
DMNL5G7 DE Endometriosis
DM8V62T ID DM8V62T
DM8V62T DN BAY1834845
DM8V62T HS Phase 1
DM8V62T CP Bayer Pharmaceuticals Whippany, NJ
DM8V62T DE Psoriasis vulgaris
DML781M ID DML781M
DML781M DN BAY1895344
DML781M HS Phase 1
DML781M SN YBXRSCXGRPSTMW-CYBMUJFWSA-N; BAY-1895344; 1876467-74-1; BAY 1895344; (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine; UNII-7N13IK9LNH; 7N13IK9LNH; SCHEMBL17501318; MolPort-044-756-215; EX-A1662; AKOS032953592; ACN-051236; AC-30337; AK688481; (R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine
DML781M CP Bayer Pharmaceuticals Whippany, NJ
DML781M PC 118869362
DML781M MW 375.4
DML781M FM C20H21N7O
DML781M IC InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1
DML781M CS C[C@@H]1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C
DML781M IK YBXRSCXGRPSTMW-CYBMUJFWSA-N
DML781M IU (3R)-3-methyl-4-[4-(2-methylpyrazol-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine
DML781M CA CAS 1876467-74-1
DML781M DE Lymphoma; Solid tumour/cancer
DMRL6W5 ID DMRL6W5
DMRL6W5 DN BAY2402234
DMRL6W5 HS Phase 1
DMRL6W5 SN KNVJMHHAXCPZHF-JTQLQIEISA-N; BAY-2402234; SCHEMBL20108031; HY-112645; CS-0058850
DMRL6W5 CP Bayer Pharmaceuticals Whippany, NJ
DMRL6W5 PC 134470179
DMRL6W5 MW 520.799
DMRL6W5 FM C21H18ClF5N4O4
DMRL6W5 IC InChI=1S/C21H18ClF5N4O4/c1-3-30-17(9-32)29-31(20(30)34)15-8-16(35-10(2)21(25,26)27)11(7-14(15)24)19(33)28-18-12(22)5-4-6-13(18)23/h4-8,10,32H,3,9H2,1-2H3,(H,28,33)/t10-/m0/s1
DMRL6W5 CS CCN1C(=NN(C1=O)C2=C(C=C(C(=C2)O[C@@H](C)C(F)(F)F)C(=O)NC3=C(C=CC=C3Cl)F)F)CO
DMRL6W5 IK KNVJMHHAXCPZHF-JTQLQIEISA-N
DMRL6W5 IU N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide
DMRL6W5 CA CAS 2225819-06-5
DMRL6W5 DE Myeloid leukaemia
DMXIDWE ID DMXIDWE
DMXIDWE DN BAY-60-5521
DMXIDWE HS Phase 1
DMXIDWE SN CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer
DMXIDWE CP Bayer AG
DMXIDWE PC 11691871
DMXIDWE MW 503.6
DMXIDWE FM C30H37F4NO
DMXIDWE IC InChI=1S/C30H37F4NO/c1-29(2)16-22-25(23(36)17-29)24(18-8-4-3-5-9-18)26(28(35-22)20-10-6-7-11-20)27(31)19-12-14-21(15-13-19)30(32,33)34/h12-15,18,20,23,27,36H,3-11,16-17H2,1-2H3/t23-,27-/m0/s1
DMXIDWE CS CC1(C[C@@H](C2=C(C1)N=C(C(=C2C3CCCCC3)[C@H](C4=CC=C(C=C4)C(F)(F)F)F)C5CCCC5)O)C
DMXIDWE IK BHKIPHICFOJGLD-HOFKKMOUSA-N
DMXIDWE IU (5S)-4-cyclohexyl-2-cyclopentyl-3-[(S)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-7,7-dimethyl-6,8-dihydro-5H-quinolin-5-ol
DMXIDWE CA CAS 893409-49-9
DMXIDWE DE Arteriosclerosis
DMOUVE7 ID DMOUVE7
DMOUVE7 DN BAY-85-8102
DMOUVE7 HS Phase 1
DMOUVE7 SN Benzodiazepine receptor agonist (brain disease imaging), University of Sydney; DPA-714-[18F]; F-18 DPA-714; Fluorine-18-DPA-714; Translocator protein-specific ligand (brain disease imaging), University of Sydney; 18F-DPA-714
DMOUVE7 CP University of Sydney
DMOUVE7 DE Brain disease
DM195JA ID DM195JA
DM195JA DN BAY-86-7548
DM195JA HS Phase 1
DM195JA SN Bombesin-68Ga-labeled tracer (PET/CT cancer imaging), Bayer
DM195JA CP Bayer AG
DM195JA DE Solid tumour/cancer
DMSBWAQ ID DMSBWAQ
DMSBWAQ DN Bb21217
DMSBWAQ HS Phase 1
DMSBWAQ CP bluebird bio
DMSBWAQ DT CAR T Cell Therapy
DMSBWAQ DE Multiple myeloma
DMTG9WM ID DMTG9WM
DMTG9WM DN BBI-6000
DMTG9WM HS Phase 1
DMTG9WM CP Brickell Biotech Boulder, CO
DMTG9WM DE Psoriasis vulgaris
DM572ZL ID DM572ZL
DM572ZL DN BBP-398
DM572ZL HS Phase 1
DM572ZL CP NaVire Pharma
DM572ZL DT Small molecular drug
DM572ZL DE Solid tumour/cancer
DMGFABM ID DMGFABM
DMGFABM DN BC-3205
DMGFABM HS Phase 1
DMGFABM SN BC-3205 (oral); BC-3205 (oral), Nabriva; Pleuromutilin (oral, respiratory infection), Nabriva
DMGFABM CP Nabriva Therapeutics AG
DMGFABM DT Small molecular drug
DMGFABM PC 44205184
DMGFABM MW 576.8
DMGFABM FM C32H52N2O5S
DMGFABM IC InChI=1S/C32H52N2O5S/c1-8-30(6)16-24(31(7)20(4)11-13-32(21(5)28(30)37)14-12-23(35)27(31)32)39-25(36)18-40-22-10-9-15-34(17-22)29(38)26(33)19(2)3/h8,19-22,24,26-28,37H,1,9-18,33H2,2-7H3/t20-,21+,22?,24-,26-,27+,28+,30-,31+,32+/m1/s1
DMGFABM CS C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CSC4CCCN(C4)C(=O)[C@@H](C(C)C)N)C
DMGFABM IK AFYOQRIZFPJUAR-UBTCORFISA-N
DMGFABM IU [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[1-[(2R)-2-amino-3-methylbutanoyl]piperidin-3-yl]sulfanylacetate
DMGFABM DE Respiratory tract infection
DMM0VBU ID DMM0VBU
DMM0VBU DN BCA101
DMM0VBU HS Phase 1
DMM0VBU CP Bicara Therapeutics
DMM0VBU DT Antibody
DMM0VBU DE Solid tumour/cancer
DMZYCWT ID DMZYCWT
DMZYCWT DN BCI-632
DMZYCWT HS Phase 1
DMZYCWT SN LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,
DMZYCWT CP BrainCells
DMZYCWT DT Small molecular drug
DMZYCWT PC 9886034
DMZYCWT MW 378.2
DMZYCWT FM C15H14Cl2FNO5
DMZYCWT IC InChI=1S/C15H14Cl2FNO5/c16-8-2-1-6(3-9(8)17)5-24-10-4-7-11(14(7,18)12(20)21)15(10,19)13(22)23/h1-3,7,10-11H,4-5,19H2,(H,20,21)(H,22,23)/t7-,10-,11+,14-,15+/m1/s1
DMZYCWT CS C1[C@@H]2[C@@H]([C@]2(C(=O)O)F)[C@@]([C@@H]1OCC3=CC(=C(C=C3)Cl)Cl)(C(=O)O)N
DMZYCWT IK LFAGGDAZZKUVKO-JAGWWQSPSA-N
DMZYCWT IU (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMZYCWT CA CAS 569686-87-9
DMZYCWT DE Major depressive disorder; Alzheimer disease
DMRXDN3 ID DMRXDN3
DMRXDN3 DN BCI-838
DMRXDN3 HS Phase 1
DMRXDN3 CP BrainCells
DMRXDN3 DE Major depressive disorder; Alzheimer disease
DMQ76B4 ID DMQ76B4
DMQ76B4 DN BCL11a shRNA
DMQ76B4 HS Phase 1
DMQ76B4 CP Boston Children's Hospital; bluebird bio
DMQ76B4 DT Short hairpin RNA
DMQ76B4 DE Sickle-cell disorder
DMZ51EX ID DMZ51EX
DMZ51EX DN BCL201
DMZ51EX HS Phase 1
DMZ51EX CP Novartis Oncology East Hanover, NJ
DMZ51EX DE Follicular lymphoma; Mantle cell lymphoma
DMJ37LH ID DMJ37LH
DMJ37LH DN BCMA CART
DMJ37LH HS Phase 1
DMJ37LH CP University of Pennsylvania
DMJ37LH DT CAR T Cell Therapy
DMJ37LH DE Multiple myeloma
DM2V4EO ID DM2V4EO
DM2V4EO DN BCMA CART and huCART19
DM2V4EO HS Phase 1
DM2V4EO CP University of Pennsylvania
DM2V4EO DT CAR T Cell Therapy (Dual specific)
DM2V4EO DE Multiple myeloma
DMJ4W5V ID DMJ4W5V
DMJ4W5V DN BCMA CAR-T Cells
DMJ4W5V HS Phase 1
DMJ4W5V CP The Pregene (ShenZhen) Biotechnology Company, Ltd.
DMJ4W5V DT CAR T Cell Therapy
DMJ4W5V DE Multiple myeloma
DMZDLHV ID DMZDLHV
DMZDLHV DN BCMA nanobody CAR-T cells
DMZDLHV HS Phase 1
DMZDLHV CP Henan Cancer Hospital
DMZDLHV DT CAR T Cell Therapy
DMZDLHV DE Multiple myeloma
DMZ13WQ ID DMZ13WQ
DMZ13WQ DN BCMA-CD19 cCAR
DMZ13WQ HS Phase 1
DMZ13WQ CP iCell Gene Therapeutics
DMZ13WQ DT CAR T Cell Therapy
DMZ13WQ DE Multiple myeloma
DMEPHMR ID DMEPHMR
DMEPHMR DN BCMA-CS1 cCAR
DMEPHMR HS Phase 1
DMEPHMR CP iCell Gene Therapeutics
DMEPHMR DT CAR T Cell Therapy
DMEPHMR DE Multiple myeloma
DMW0ZDF ID DMW0ZDF
DMW0ZDF DN BCMA-specific CAR-expressing T Lymphocytes
DMW0ZDF HS Phase 1
DMW0ZDF CP Fred Hutchinson Cancer Research Center
DMW0ZDF DT CAR T Cell Therapy
DMW0ZDF DE Plasma cell myeloma
DMGAP53 ID DMGAP53
DMGAP53 DN BDD-10103
DMGAP53 HS Phase 1
DMGAP53 CP Berolina Innovative Research and Development Services Pharma AG
DMGAP53 DE Pain
DMUR49N ID DMUR49N
DMUR49N DN Begacestat
DMUR49N HS Phase 1
DMUR49N SN GSI-953; PF-05212362; PF-5212362; WAY-201953; WAY-210953
DMUR49N CP Wyeth
DMUR49N DT Small molecular drug
DMUR49N PC 11269353
DMUR49N MW 391.7
DMUR49N FM C9H8ClF6NO3S2
DMUR49N IC InChI=1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2/t4-/m1/s1
DMUR49N CS C1=C(SC(=C1)Cl)S(=O)(=O)N[C@H](CO)C(C(F)(F)F)C(F)(F)F
DMUR49N IK PSXOKXJMVRSARX-SCSAIBSYSA-N
DMUR49N IU 5-chloro-N-[(2S)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide
DMUR49N CA CAS 769169-27-9
DMUR49N DE Alzheimer disease
DM9R0VA ID DM9R0VA
DM9R0VA DN Belerofon
DM9R0VA HS Phase 1
DM9R0VA SN IFNa
DM9R0VA CP Nautilus Biotech
DM9R0VA DE Hepatitis C virus infection
DM0ZNAR ID DM0ZNAR
DM0ZNAR DN Belvarafenib
DM0ZNAR HS Phase 1
DM0ZNAR SN 1446113-23-0; UNII-31M3WLJ3KG; 31M3WLJ3KG; 4-Amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide; CHEMBL3977543; SCHEMBL15066408; BDBM185591; BCP31233; EX-A3061; s8853; HM95573; BS-15746; HY-109080; CS-0039257; Belvarafenib(GDC5573, HM95573, RG6185); US9156852, 116; 4-Amino-N-(1-(3-chloro-2-fluorophenylamino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide; V1Y
DM0ZNAR CP Hanmi Pharmaceutical
DM0ZNAR DT Small molecular drug
DM0ZNAR PC 89655386
DM0ZNAR MW 478.9
DM0ZNAR FM C23H16ClFN6OS
DM0ZNAR IC InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
DM0ZNAR CS CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N
DM0ZNAR IK KVCQTKNUUQOELD-UHFFFAOYSA-N
DM0ZNAR IU 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
DM0ZNAR CA CAS 1446113-23-0
DM0ZNAR DE Solid tumour/cancer
DMN7J43 ID DMN7J43
DMN7J43 DN Benzo(a)pyrene
DMN7J43 HS Phase 1
DMN7J43 SN benzo[a]pyrene; 3,4-Benzopyrene; benzo[pqr]tetraphene; BENZO(A)PYRENE; 3,4-Benzpyrene; Benzpyrene; benzo[def]chrysene; 6,7-Benzopyrene; Benz[a]pyrene; 3,4-BP; 3,4-Benz[a]pyrene; 3,4-Benzopirene; 3,4-Benzpyren; Benzo[d,e,f]chrysene; Benz(a)pyrene; (B(a)P); B(a)P; BP; 3,4 Benzpyrene; RCRA waste number U022; Benzo(d,e,f)chrysene; 3,4-Benz(a)pyrene; NSC 21914; 3,4-Benzo(a)pyrene; B[a]p; 3,4-Benzpyren [German]; CCRIS 76; Benzo[A]-Pyrene; Benzo(def)chrysene; 3,4-benzylpyrene; 3,4-Benzopirene [Italian]
DMN7J43 PC 2336
DMN7J43 MW 252.3
DMN7J43 FM C20H12
DMN7J43 IC InChI=1S/C20H12/c1-2-7-17-15(4-1)12-16-9-8-13-5-3-6-14-10-11-18(17)20(16)19(13)14/h1-12H
DMN7J43 CS C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3
DMN7J43 IK FMMWHPNWAFZXNH-UHFFFAOYSA-N
DMN7J43 IU benzo[a]pyrene
DMN7J43 CA CAS 50-32-8
DMN7J43 CB CHEBI:29865
DMN7J43 DE Environmental exposure
DMMW4HV ID DMMW4HV
DMMW4HV DN Benzoylphenylurea
DMMW4HV HS Phase 1
DMMW4HV SN benzoylphenylurea; SCHEMBL83109
DMMW4HV PC 19851629
DMMW4HV MW 240.26
DMMW4HV FM C14H12N2O2
DMMW4HV IC InChI=1S/C14H12N2O2/c15-14(18)16(12-9-5-2-6-10-12)13(17)11-7-3-1-4-8-11/h1-10H,(H2,15,18)
DMMW4HV CS C1=CC=C(C=C1)C(=O)N(C2=CC=CC=C2)C(=O)N
DMMW4HV IK XYFMGGWVGACNEC-UHFFFAOYSA-N
DMMW4HV IU N-carbamoyl-N-phenylbenzamide
DMMW4HV DE Solid tumours
DMBUI2A ID DMBUI2A
DMBUI2A DN BETULINIC ACID
DMBUI2A HS Phase 1
DMBUI2A SN betulinic acid; 472-15-1; Mairin; Betulic acid; NSC 113090; CCRIS 6748; 3-Hydroxylup-20(29)-en-28-oic acid; UNII-4G6A18707N; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; EINECS 207-448-8; NSC677578; als-357; NSC 677578; CHEMBL269277; CHEBI:3087; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; 4G6A18707N; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; AK-72848; Lupatic Acid; SMR000445624
DMBUI2A DT Small molecular drug
DMBUI2A PC 64971
DMBUI2A MW 456.7
DMBUI2A FM C30H48O3
DMBUI2A IC InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
DMBUI2A CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C(=O)O
DMBUI2A IK QGJZLNKBHJESQX-FZFNOLFKSA-N
DMBUI2A IU (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DMBUI2A CA CAS 472-15-1
DMBUI2A CB CHEBI:3087
DMBUI2A DE Melanoma
DM7RPSG ID DM7RPSG
DM7RPSG DN BF-1
DM7RPSG HS Phase 1
DM7RPSG SN BF-1; 518980-66-0; Piperidine, 4-(6-ethoxy-1-methoxy-9H-thioxanthen-9-ylidene)-1-methyl-; SCHEMBL4475418; GTPL8424; CTK1E4820; DTXSID70437783; SB18757; L022232
DM7RPSG CP Biofrontera
DM7RPSG DT Small molecular drug
DM7RPSG PC 10287037
DM7RPSG MW 367.5
DM7RPSG FM C22H25NO2S
DM7RPSG IC InChI=1S/C22H25NO2S/c1-4-25-16-8-9-17-20(14-16)26-19-7-5-6-18(24-3)22(19)21(17)15-10-12-23(2)13-11-15/h5-9,14H,4,10-13H2,1-3H3
DM7RPSG CS CCOC1=CC2=C(C=C1)C(=C3CCN(CC3)C)C4=C(C=CC=C4S2)OC
DM7RPSG IK ANZVBVKYXOGOQC-UHFFFAOYSA-N
DM7RPSG IU 4-(6-ethoxy-1-methoxythioxanthen-9-ylidene)-1-methylpiperidine
DM7RPSG CA CAS 518980-66-0
DM7RPSG DE Cluster headache; Migraine
DMHELFU ID DMHELFU
DMHELFU DN BF-389
DMHELFU HS Phase 1
DMHELFU SN Biofor 389; BF-389; UNII-MGJ3XBS5KD; MGJ3XBS5KD; BF 389; 127245-22-1; 4-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-methyl-5,6-dihydro-2H-1,2-oxazin-3(4H)-one; Dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2-oxazin-3(4H)-one; 2H-1,2-Oxazin-3(4H)-one, dihydro-4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-2-methyl-; 2H-1,2-Oxazin-3(4H)-one, 4-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)dihydro-2-methyl-; Biofor-389; AC1O5RBB; SCHEMBL8291651; LS-100029
DMHELFU CP Biofor Inc
DMHELFU DT Small molecular drug
DMHELFU PC 6439259
DMHELFU MW 331.4
DMHELFU FM C20H29NO3
DMHELFU IC InChI=1S/C20H29NO3/c1-19(2,3)15-11-13(12-16(17(15)22)20(4,5)6)10-14-8-9-24-21(7)18(14)23/h10-12,22H,8-9H2,1-7H3/b14-10+
DMHELFU CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C/2\\CCON(C2=O)C
DMHELFU IK BWRYNNCGEDOTRW-GXDHUFHOSA-N
DMHELFU IU (4E)-4-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-2-methyloxazinan-3-one
DMHELFU CA CAS 127245-22-1
DMHELFU DE Rheumatoid arthritis
DM84LXE ID DM84LXE
DM84LXE DN BGB-10188
DM84LXE HS Phase 1
DM84LXE DT Small molecular drug
DM84LXE DE Solid tumour/cancer; B-cell lymphoma
DM7QTIC ID DM7QTIC
DM7QTIC DN BGB-11417
DM7QTIC HS Phase 1
DM7QTIC CP BeiGene
DM7QTIC DT Small molecular drug
DM7QTIC DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMUP6M5 ID DMUP6M5
DMUP6M5 DN BGB-15025
DMUP6M5 HS Phase 1
DMUP6M5 CP BeiGene
DMUP6M5 DT Small molecular drug
DMUP6M5 DE Solid tumour/cancer
DMIF9DZ ID DMIF9DZ
DMIF9DZ DN BGB-3113
DMIF9DZ HS Phase 1
DMIF9DZ CP BeiGene Cambridge, MA
DMIF9DZ DE B-cell lymphoma
DMQMEDH ID DMQMEDH
DMQMEDH DN BGB-A445
DMQMEDH HS Phase 1
DMQMEDH CP BeiGene
DMQMEDH DT Antibody
DMQMEDH DE Solid tumour/cancer
DMED4AJ ID DMED4AJ
DMED4AJ DN BGC-20-1259
DMED4AJ HS Phase 1
DMED4AJ SN RS-1259
DMED4AJ CP Sankyo Co Ltd
DMED4AJ DT Small molecular drug
DMED4AJ PC 6918634
DMED4AJ MW 862.9
DMED4AJ FM C42H50N6O14
DMED4AJ IC InChI=1S/2C19H23N3O5.C4H4O4/c2*1-20-18(12-13-26-16-10-6-15(7-11-16)22(24)25)14-4-8-17(9-5-14)27-19(23)21(2)3;5-3(6)1-2-4(7)8/h2*4-11,18,20H,12-13H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*18-;/m00./s1
DMED4AJ CS CN[C@@H](CCOC1=CC=C(C=C1)[N+](=O)[O-])C2=CC=C(C=C2)OC(=O)N(C)C.CN[C@@H](CCOC1=CC=C(C=C1)[N+](=O)[O-])C2=CC=C(C=C2)OC(=O)N(C)C.C(=C/C(=O)O)\\C(=O)O
DMED4AJ IK JOSUCKKYZJUIPW-SOBORHNCSA-N
DMED4AJ IU (E)-but-2-enedioic acid;[4-[(1S)-1-(methylamino)-3-(4-nitrophenoxy)propyl]phenyl] N,N-dimethylcarbamate
DMED4AJ DE Parkinson disease
DMM2EZW ID DMM2EZW
DMM2EZW DN BHV-5000
DMM2EZW HS Phase 1
DMM2EZW CP Biohaven Pharmaceuticals New Haven, CT
DMM2EZW DE Rett syndrome
DMUJ1EL ID DMUJ1EL
DMUJ1EL DN BI 113823
DMUJ1EL HS Phase 1
DMUJ1EL CP Boehringer Ingelheim Pharmaceuticals
DMUJ1EL DE Osteoarthritis
DMGMFXJ ID DMGMFXJ
DMGMFXJ DN BI 1701963
DMGMFXJ HS Phase 1
DMGMFXJ CP Boehringer Ingelheim
DMGMFXJ DT Small molecular drug
DMGMFXJ DE Solid tumour/cancer
DMFJGUL ID DMFJGUL
DMFJGUL DN BI 3011441
DMFJGUL HS Phase 1
DMFJGUL CP Boehringer Ingelheim
DMFJGUL DT Small molecular drug
DMFJGUL DE Solid tumour/cancer
DMWHZFS ID DMWHZFS
DMWHZFS DN BI 754091
DMWHZFS HS Phase 1
DMWHZFS CP Boehringer Ingelheim
DMWHZFS DT Antibody
DMWHZFS DE Neoplasm
DMZMAOW ID DMZMAOW
DMZMAOW DN BI 765063
DMZMAOW HS Phase 1
DMZMAOW SN OSE-172
DMZMAOW CP Boehringer Ingelheim; OSE Immunotherapeutics
DMZMAOW DT Antibody
DMZMAOW DE Solid tumour/cancer
DMRI6YT ID DMRI6YT
DMRI6YT DN BI 836880
DMRI6YT HS Phase 1
DMRI6YT CP Boehringer Ingelheim
DMRI6YT DT Antibody
DMRI6YT DE Neoplasm; Wet age-related macular degeneration
DMMQ12N ID DMMQ12N
DMMQ12N DN BI 860585
DMMQ12N HS Phase 1
DMMQ12N CP Boehringer ingelheim pharmaceuticals
DMMQ12N DE Solid tumour/cancer
DM7W5N2 ID DM7W5N2
DM7W5N2 DN BI 894999
DM7W5N2 HS Phase 1
DM7W5N2 CP Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DM7W5N2 PC 90647162
DM7W5N2 MW 429.5
DM7W5N2 FM C25H27N5O2
DM7W5N2 IC InChI=1S/C25H27N5O2/c1-16-13-21(28-29(3)25(16)31)24-27-22-15-26-20(19-9-11-32-12-10-19)14-23(22)30(24)17(2)18-7-5-4-6-8-18/h4-8,13-15,17,19H,9-12H2,1-3H3/t17-/m0/s1
DM7W5N2 CS CC1=CC(=NN(C1=O)C)C2=NC3=CN=C(C=C3N2[C@@H](C)C4=CC=CC=C4)C5CCOCC5
DM7W5N2 IK QNFGQQDKBYVNAS-KRWDZBQOSA-N
DM7W5N2 IU 2,4-dimethyl-6-[6-(oxan-4-yl)-1-[(1S)-1-phenylethyl]imidazo[4,5-c]pyridin-2-yl]pyridazin-3-one
DM7W5N2 CA CAS 1660117-38-3
DM7W5N2 DE Solid tumour/cancer
DMEPJ7C ID DMEPJ7C
DMEPJ7C DN BI 905677
DMEPJ7C HS Phase 1
DMEPJ7C CP Boehringer Ingelheim
DMEPJ7C DT Antibody
DMEPJ7C DE Solid tumour/cancer
DMXO3PV ID DMXO3PV
DMXO3PV DN BI 905681
DMXO3PV HS Phase 1
DMXO3PV CP Boehringer Ingelheim
DMXO3PV DT Antibody
DMXO3PV DE Solid tumour/cancer
DME9NYV ID DME9NYV
DME9NYV DN BI 905711
DME9NYV HS Phase 1
DME9NYV CP Boehringer Ingelheim
DME9NYV DT Antibody
DME9NYV DE Solid tumour/cancer
DM2Z4YQ ID DM2Z4YQ
DM2Z4YQ DN BI 907828
DM2Z4YQ HS Phase 1
DM2Z4YQ CP Boehringer Ingelheim
DM2Z4YQ DT Small molecular drug
DM2Z4YQ DE Solid tumour/cancer
DMKQHE5 ID DMKQHE5
DMKQHE5 DN BI-11634
DMKQHE5 HS Phase 1
DMKQHE5 CP Boehringer Ingelheim Corp
DMKQHE5 PC 117587663
DMKQHE5 MW 464.9
DMKQHE5 FM C22H22ClN4NaO4
DMKQHE5 IC InChI=1S/C22H23ClN4O4.Na/c1-13-9-14(3-6-19(13)27-7-8-31-12-20(27)28)22(29)26-18(11-30-2)21-24-16-5-4-15(23)10-17(16)25-21;/h3-6,9-10,18H,7-8,11-12H2,1-2H3,(H2,24,25,26,29);/q;+1/p-1/t18-;/m0./s1
DMKQHE5 CS CC1=C(C=CC(=C1)C(=O)[N-][C@@H](COC)C2=NC3=C(N2)C=C(C=C3)Cl)N4CCOCC4=O.[Na+]
DMKQHE5 IK OJSUHLVJVGHFKW-FERBBOLQSA-M
DMKQHE5 IU sodium;[(1R)-1-(6-chloro-1H-benzimidazol-2-yl)-2-methoxyethyl]-[3-methyl-4-(3-oxomorpholin-4-yl)benzoyl]azanide
DMKQHE5 CA CAS 1622159-00-5
DMKQHE5 DE Thrombosis
DMLJOAF ID DMLJOAF
DMLJOAF DN BI-135585
DMLJOAF HS Phase 1
DMLJOAF CP Boehringer Ingelheim Pharmaceuticals
DMLJOAF PC 44476893
DMLJOAF MW 460.6
DMLJOAF FM C28H32N2O4
DMLJOAF IC InChI=1S/C28H32N2O4/c1-20(21-10-12-22(13-11-21)23-14-16-29(4)25(31)18-23)30-17-15-28(34-26(30)32,19-27(2,3)33)24-8-6-5-7-9-24/h5-14,16,18,20,33H,15,17,19H2,1-4H3/t20-,28-/m0/s1
DMLJOAF CS C[C@@H](C1=CC=C(C=C1)C2=CC(=O)N(C=C2)C)N3CC[C@](OC3=O)(CC(C)(C)O)C4=CC=CC=C4
DMLJOAF IK TXNPQZGSVXLGGP-MMTVBGGISA-N
DMLJOAF IU (6S)-6-(2-hydroxy-2-methylpropyl)-3-[(1S)-1-[4-(1-methyl-2-oxopyridin-4-yl)phenyl]ethyl]-6-phenyl-1,3-oxazinan-2-one
DMLJOAF CA CAS 1114561-85-1
DMLJOAF DE Type-2 diabetes
DM2KVM0 ID DM2KVM0
DM2KVM0 DN BI-44847
DM2KVM0 HS Phase 1
DM2KVM0 CP Ajinomoto Co Inc
DM2KVM0 PC 10181733
DM2KVM0 MW 440.5
DM2KVM0 FM C21H29FN2O7
DM2KVM0 IC InChI=1S/C21H29FN2O7/c1-10(2)24-11(3)14(7-12-5-6-13(29-4)8-15(12)22)20(23-24)31-21-19(28)18(27)17(26)16(9-25)30-21/h5-6,8,10,16-19,21,25-28H,7,9H2,1-4H3/t16-,17-,18+,19-,21+/m1/s1
DM2KVM0 CS CC1=C(C(=NN1C(C)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=C(C=C(C=C3)OC)F
DM2KVM0 IK AOBLNYCSGWSIPG-YRIDSSQKSA-N
DM2KVM0 IU (2S,3R,4S,5S,6R)-2-[4-[(2-fluoro-4-methoxyphenyl)methyl]-5-methyl-1-propan-2-ylpyrazol-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM2KVM0 CA CAS 421592-30-5
DM2KVM0 DE Type-2 diabetes
DM3JOIX ID DM3JOIX
DM3JOIX DN BI-754091
DM3JOIX HS Phase 1
DM3JOIX CP Boehringer Ingelheim
DM3JOIX DT Monoclonal antibody
DM3JOIX DE Solid tumour/cancer; Advanced malignancy
DMNUY32 ID DMNUY32
DMNUY32 DN BI-811283
DMNUY32 HS Phase 1
DMNUY32 CP Boehringer Ingelheim Pharmaceuticals
DMNUY32 DE Acute myeloid leukaemia
DMOJZUE ID DMOJZUE
DMOJZUE DN BI-831266
DMOJZUE HS Phase 1
DMOJZUE CP Boehringer Ingelheim Pharmaceuticals
DMOJZUE DE Solid tumour/cancer
DM4T916 ID DM4T916
DM4T916 DN BI-836845
DM4T916 HS Phase 1
DM4T916 CP Boehringer Ingelheim Pharmaceuticals
DM4T916 DE Solid tumour/cancer
DMGFH7T ID DMGFH7T
DMGFH7T DN BI-836880
DMGFH7T HS Phase 1
DMGFH7T CP Boehringer Ingelheim Pharmaceuticals Ridgefield, CT
DMGFH7T DE Solid tumour/cancer
DMY4B6J ID DMY4B6J
DMY4B6J DN BI-847325
DMY4B6J HS Phase 1
DMY4B6J CP Boehringer Ingelheim Pharmaceuticals
DMY4B6J PC 135567102
DMY4B6J MW 464.6
DMY4B6J FM C29H28N4O2
DMY4B6J IC InChI=1S/C29H28N4O2/c1-4-30-26(34)17-13-20-12-16-24-25(18-20)32-29(35)27(24)28(22-8-6-5-7-9-22)31-23-14-10-21(11-15-23)19-33(2)3/h5-12,14-16,18,32,35H,4,19H2,1-3H3,(H,30,34)
DMY4B6J CS CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4
DMY4B6J IK OCUQMWSIGPQEMX-UHFFFAOYSA-N
DMY4B6J IU 3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide
DMY4B6J DE Solid tumour/cancer
DMNOSYW ID DMNOSYW
DMNOSYW DN BI-853520
DMNOSYW HS Phase 1
DMNOSYW CP Boehringer Ingelheim Pharmaceuticals
DMNOSYW DE Solid tumour/cancer
DMP70FI ID DMP70FI
DMP70FI DN BIBT986
DMP70FI HS Phase 1
DMP70FI SN Tanogitran; UNII-X5QRR6Z56Q; X5QRR6Z56Q; CHEMBL1270156; Tanogitran [INN]; BIBT986; 637328-69-9; SCHEMBL2471738; MAOALPSHCIBFJZ-RUZDIDTESA-N; ZINC64527030; BDBM50328705; J3.538.630K; (R)-2-(4-Amidinophenylaminomethyl)-1-methyl-5-[l -(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl]-benzimidazole; (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl) -ethyl]-benzimidazole
DMP70FI CP Boehringer Ingelheim Pharmaceuticals
DMP70FI DT Small molecular drug
DMP70FI PC 9826322
DMP70FI MW 477.6
DMP70FI FM C25H31N7O3
DMP70FI IC InChI=1S/C25H31N7O3/c1-25(29-15-22(33)34,24(35)32-11-3-4-12-32)17-7-10-20-19(13-17)30-21(31(20)2)14-28-18-8-5-16(6-9-18)23(26)27/h5-10,13,28-29H,3-4,11-12,14-15H2,1-2H3,(H3,26,27)(H,33,34)/t25-/m1/s1
DMP70FI CS C[C@@](C1=CC2=C(C=C1)N(C(=N2)CNC3=CC=C(C=C3)C(=N)N)C)(C(=O)N4CCCC4)NCC(=O)O
DMP70FI IK MAOALPSHCIBFJZ-RUZDIDTESA-N
DMP70FI IU 2-[[(2R)-2-[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazol-5-yl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]amino]acetic acid
DMP70FI CA CAS 637328-69-9
DMP70FI DE Thrombosis
DMUBMN5 ID DMUBMN5
DMUBMN5 DN BIBV 308
DMUBMN5 HS Phase 1
DMUBMN5 SN Terbogrel; UNII-5Z4KWQ5OGN; 149979-74-8; 5Z4KWQ5OGN; CHEMBL281398; Terbogrel [USAN:INN]; BIBV 308 SE; Terbogrel (USAN/INN); AC1O6AAX; SCHEMBL42848; BIBV-308-SE; SCHEMBL15413063; ZINC11726169; BDBM50075624; DB12204; CS-6743; (5E)-6-(m-(3-tert-Butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid; 6-(3-(((Cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid; HY-19189; D06077; L001474; 6-{3-[1-(tert-butylamino)-2-cyano-(E)-1-iminomethylamino]phenyl}-6-(3-pyridyl)-(E)-5-hexenoic acid
DMUBMN5 CP Boehringer Ingelheim
DMUBMN5 DT Small molecular drug
DMUBMN5 PC 6449876
DMUBMN5 MW 405.5
DMUBMN5 FM C23H27N5O2
DMUBMN5 IC InChI=1S/C23H27N5O2/c1-23(2,3)28-22(26-16-24)27-19-10-6-8-17(14-19)20(11-4-5-12-21(29)30)18-9-7-13-25-15-18/h6-11,13-15H,4-5,12H2,1-3H3,(H,29,30)(H2,26,27,28)/b20-11+
DMUBMN5 CS CC(C)(C)N=C(NC#N)NC1=CC=CC(=C1)/C(=C\\CCCC(=O)O)/C2=CN=CC=C2
DMUBMN5 IK XUTLOCQNGLJNSA-RGVLZGJSSA-N
DMUBMN5 IU (E)-6-[3-[(N'-tert-butyl-N-cyanocarbamimidoyl)amino]phenyl]-6-pyridin-3-ylhex-5-enoic acid
DMUBMN5 CA CAS 149979-74-8
DMUBMN5 DE Peripheral vascular disease
DM79XGM ID DM79XGM
DM79XGM DN BIBX-1382
DM79XGM HS Phase 1
DM79XGM SN Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; BIBX-1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047
DM79XGM CP Boehringer Ingelheim Corp
DM79XGM DT Small molecular drug
DM79XGM PC 6918508
DM79XGM MW 387.8
DM79XGM FM C18H19ClFN7
DM79XGM IC InChI=1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24)
DM79XGM CS CN1CCC(CC1)NC2=NC=C3C(=N2)C(=NC=N3)NC4=CC(=C(C=C4)F)Cl
DM79XGM IK FTFRZXFNZVCRSK-UHFFFAOYSA-N
DM79XGM IU 4-N-(3-chloro-4-fluorophenyl)-6-N-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-4,6-diamine
DM79XGM CA CAS 196612-93-8
DM79XGM CB CHEBI:93243
DM79XGM DE Chronic lymphocytic leukaemia
DM5AW7J ID DM5AW7J
DM5AW7J DN BIIB 015
DM5AW7J HS Phase 1
DM5AW7J CP Biogen Idec
DM5AW7J DT Antibody
DM5AW7J DE Solid tumour/cancer
DMZ1V0E ID DMZ1V0E
DMZ1V0E DN BIIB 022
DMZ1V0E HS Phase 1
DMZ1V0E CP Biogen Idec
DMZ1V0E DE Non-small-cell lung cancer; Hepatocellular carcinoma
DMTRF71 ID DMTRF71
DMTRF71 DN BIIB 028
DMTRF71 HS Phase 1
DMTRF71 CP Biogen Idec
DMTRF71 DE Solid tumour/cancer
DMVS87W ID DMVS87W
DMVS87W DN BIIB068
DMVS87W HS Phase 1
DMVS87W CP Biogen Cambridge, MA
DMVS87W DE Systemic lupus erythematosus
DMUC6EP ID DMUC6EP
DMUC6EP DN BIIB095
DMUC6EP HS Phase 1
DMUC6EP CP Biogen
DMUC6EP DE Pain
DM9UZD7 ID DM9UZD7
DM9UZD7 DN Bile acid
DM9UZD7 HS Phase 1
DM9UZD7 SN Bile Salts; Bile acid; Bile salt; CHEBI:22868
DM9UZD7 PC 439520
DM9UZD7 MW 408.6
DM9UZD7 FM C24H40O5
DM9UZD7 IC BHQCQFFYRZLCQQ-UMZBRFQRSA-N
DM9UZD7 CS CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C
DM9UZD7 IK 1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13?,14-,15+,16?,17?,18?,19+,20-,22?,23?,24?/m0/s1
DM9UZD7 IU 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DM9UZD7 CB CHEBI:22868
DM9UZD7 DE Inflammatory bowel disease
DMBTSZD ID DMBTSZD
DMBTSZD DN BIMU-1
DMBTSZD HS Phase 1
DMBTSZD SN BIMU-8
DMBTSZD CP Boehringer Ingelheim Corp
DMBTSZD DT Small molecular drug
DMBTSZD PC 9929033
DMBTSZD MW 328.4
DMBTSZD FM C18H24N4O2
DMBTSZD IC InChI=1S/C18H24N4O2/c1-3-21-15-6-4-5-7-16(15)22(18(21)24)17(23)19-12-10-13-8-9-14(11-12)20(13)2/h4-7,12-14H,3,8-11H2,1-2H3,(H,19,23)/t12?,13-,14?/m0/s1
DMBTSZD CS CCN1C2=CC=CC=C2N(C1=O)C(=O)NC3C[C@@H]4CCC(C3)N4C
DMBTSZD IK MZRKHUUDDHJVHS-MOKVOYLWSA-N
DMBTSZD IU 3-ethyl-N-[(5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxobenzimidazole-1-carboxamide
DMBTSZD DE Cognitive impairment
DMQ9KZW ID DMQ9KZW
DMQ9KZW DN Biomed 101
DMQ9KZW HS Phase 1
DMQ9KZW SN BioMed 101; SC-41930; SC 41930; 120072-59-5; CHEMBL14823; CGS 24115; 7-(3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-3,4-dihydro-8-propyl-; 2H-1-Benzopyran-2-carboxylicacid, 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-; 7-(3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy)-8-propylchroman-2-carboxylic acid; SC-41390
DMQ9KZW CP Intarcia Therape.
DMQ9KZW TC Anticancer Agents
DMQ9KZW DT Small molecular drug
DMQ9KZW PC 114999
DMQ9KZW MW 484.6
DMQ9KZW FM C28H36O7
DMQ9KZW IC InChI=1S/C28H36O7/c1-5-8-21-23(13-10-19-11-14-25(28(30)31)35-26(19)21)33-16-7-17-34-24-15-12-20(18(3)29)27(32-4)22(24)9-6-2/h10,12-13,15,25H,5-9,11,14,16-17H2,1-4H3,(H,30,31)
DMQ9KZW CS CCCC1=C(C=CC2=C1OC(CC2)C(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)C)OC)CCC
DMQ9KZW IK ZVVCSBSDFGYRCB-UHFFFAOYSA-N
DMQ9KZW IU 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2H-chromene-2-carboxylic acid
DMQ9KZW CA CAS 120072-59-5
DMQ9KZW DE Renal cell carcinoma; Inflammatory bowel disease; Kidney cancer
DMS4P6K ID DMS4P6K
DMS4P6K DN Biostrophin
DMS4P6K HS Phase 1
DMS4P6K SN Duchenne muscular dystrophy therapy, Asklepios; Adeno-associated virus gene therapy (dystrophin), AskBio; Adeno-associated virus gene therapy (dystrophin), Asklepios
DMS4P6K CP Asklepios biopharmaceuticals
DMS4P6K DE Duchenne dystrophy
DMGAR9Y ID DMGAR9Y
DMGAR9Y DN BIT225
DMGAR9Y HS Phase 1
DMGAR9Y SN BIT-225; BIT225; 917909-71-8; SCHEMBL3109704; CHEMBL1242296; WVROWPPEIMRGAB-UHFFFAOYSA-N; ZINC43151503; 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-; SB16851; 5-(1-methyl-1H-pyrazol-4-yl)-2-naphthoylguanidine
DMGAR9Y CP Biotron
DMGAR9Y DT Small molecular drug
DMGAR9Y PC 12004418
DMGAR9Y MW 293.32
DMGAR9Y FM C16H15N5O
DMGAR9Y IC InChI=1S/C16H15N5O/c1-21-9-12(8-19-21)13-4-2-3-10-7-11(5-6-14(10)13)15(22)20-16(17)18/h2-9H,1H3,(H4,17,18,20,22)
DMGAR9Y CS CN1C=C(C=N1)C2=CC=CC3=C2C=CC(=C3)C(=O)N=C(N)N
DMGAR9Y IK WVROWPPEIMRGAB-UHFFFAOYSA-N
DMGAR9Y IU N-(diaminomethylidene)-5-(1-methylpyrazol-4-yl)naphthalene-2-carboxamide
DMGAR9Y CA CAS 917909-71-8
DMGAR9Y DE Hepatitis C virus infection
DM61JH5 ID DM61JH5
DM61JH5 DN BIWA 4
DM61JH5 HS Phase 1
DM61JH5 CP Boehringer Ingelheim
DM61JH5 DT Antibody
DM61JH5 DE Solid tumour/cancer
DMX9ER7 ID DMX9ER7
DMX9ER7 DN BIZELESIN
DMX9ER7 HS Phase 1
DMX9ER7 SN Bizelesin < Rec INN; U-77779; (S,S)-1,3-Bis[2-[1-(Chloromethyl)-5-hydroxy-8-methyl-1,2,3,6-tetrahydrobenzo[1,2-b:4,3-b']dipyrrol-3-ylcarbonyl]-1H-indol-5-yl]urea
DMX9ER7 DT Small molecular drug
DMX9ER7 PC 60794
DMX9ER7 MW 815.7
DMX9ER7 FM C43H36Cl2N8O5
DMX9ER7 IC InChI=1S/C43H36Cl2N8O5/c1-19-15-46-39-33(54)11-31-37(35(19)39)23(13-44)17-52(31)41(56)29-9-21-7-25(3-5-27(21)50-29)48-43(58)49-26-4-6-28-22(8-26)10-30(51-28)42(57)53-18-24(14-45)38-32(53)12-34(55)40-36(38)20(2)16-47-40/h3-12,15-16,23-24,46-47,50-51,54-55H,13-14,17-18H2,1-2H3,(H2,48,49,58)/t23-,24-/m1/s1
DMX9ER7 CS CC1=CNC2=C(C=C3C(=C12)[C@@H](CN3C(=O)C4=CC5=C(N4)C=CC(=C5)NC(=O)NC6=CC7=C(C=C6)NC(=C7)C(=O)N8C[C@H](C9=C1C(=CNC1=C(C=C98)O)C)CCl)CCl)O
DMX9ER7 IK FONKWHRXTPJODV-DNQXCXABSA-N
DMX9ER7 IU 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea
DMX9ER7 CA CAS 129655-21-6
DMX9ER7 DE Skin disease
DMAYSFK ID DMAYSFK
DMAYSFK DN BL-1021
DMAYSFK HS Phase 1
DMAYSFK SN UNII-7Q35V52Q2Z; BL-1021; BL-1021 free; 7Q35V52Q2Z; Butanamide, 4-amino-N-[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-N-methyl-, hydrochloride (1:1);Butanamide, 4-amino-N-[3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)propyl]-N-methyl-, hydrochloride (1:1); 1002331-76-1; CHEMBL490932; Butanamide, 4-amino-N-(3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)propyl)-N-methyl-, hydrochloride (1:1)
DMAYSFK CP Tel Aviv University
DMAYSFK DT Small molecular drug
DMAYSFK PC 24898306
DMAYSFK MW 384.9
DMAYSFK FM C23H29ClN2O
DMAYSFK IC InChI=1S/C23H28N2O.ClH/c1-25(23(26)13-6-16-24)17-7-12-22-20-10-4-2-8-18(20)14-15-19-9-3-5-11-21(19)22;/h2-5,8-12H,6-7,13-17,24H2,1H3;1H
DMAYSFK CS CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)C(=O)CCCN.Cl
DMAYSFK IK DEKZAWRGNGHZKY-UHFFFAOYSA-N
DMAYSFK IU 4-amino-N-methyl-N-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propyl]butanamide;hydrochloride
DMAYSFK CA CAS 1002331-76-1
DMAYSFK DE Pain
DM27J3D ID DM27J3D
DM27J3D DN BLU-554
DM27J3D HS Phase 1
DM27J3D SN MGZKYOAQVGSSGC-DLBZAZTESA-N; 1707289-21-1; N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide; BLU554; SCHEMBL16668287; EX-A841; MolPort-044-727-735; s8503; AKOS030632994; CS-5986; ACN-037513; AC-29871; HY-100492; N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide
DM27J3D CP Blueprint Medicines Cambridge, MA
DM27J3D PC 91885617
DM27J3D MW 503.4
DM27J3D FM C24H24Cl2N4O4
DM27J3D IC InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1
DM27J3D CS COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)N[C@@H]4COCC[C@@H]4NC(=O)C=C)Cl)OC
DM27J3D IK MGZKYOAQVGSSGC-DLBZAZTESA-N
DM27J3D IU N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino]oxan-4-yl]prop-2-enamide
DM27J3D CA CAS 1707289-21-1
DM27J3D DE Hepatocellular carcinoma
DMYHNV3 ID DMYHNV3
DMYHNV3 DN BLY719
DMYHNV3 HS Phase 1
DMYHNV3 CP Novartis pharmaceuticals
DMYHNV3 DE Solid tumour/cancer
DMIRX3Z ID DMIRX3Z
DMIRX3Z DN BM-212
DMIRX3Z HS Phase 1
DMIRX3Z SN BM-212; BM212; UNII-U9HSU4GZWL; 146204-42-4; U9HSU4GZWL; 1-{[1,5-Bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl}-4-methylpiperazine; 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine; BM 212; AC1L9VRH; CHEMBL321077; SCHEMBL1452627; BCP24821; ZINC22445591; AKOS032944899; CS-5953; Piperazine, 1-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methyl-; HY-100725
DMIRX3Z DT Small molecular drug
DMIRX3Z PC 456926
DMIRX3Z MW 414.4
DMIRX3Z FM C23H25Cl2N3
DMIRX3Z IC InChI=1S/C23H25Cl2N3/c1-17-19(16-27-13-11-26(2)12-14-27)15-23(18-3-5-20(24)6-4-18)28(17)22-9-7-21(25)8-10-22/h3-10,15H,11-14,16H2,1-2H3
DMIRX3Z CS CC1=C(C=C(N1C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C
DMIRX3Z IK YWZIODCWLMCMMW-UHFFFAOYSA-N
DMIRX3Z IU 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine
DMIRX3Z CA CAS 146204-42-4
DMIRX3Z DE Asthma
DM43RV5 ID DM43RV5
DM43RV5 DN BM-ca
DM43RV5 HS Phase 1
DM43RV5 SN Anti-CD20 antibodies (lymphoma), BioMedics
DM43RV5 CP BioMedics Japan Inc
DM43RV5 DT Antibody
DM43RV5 DE Non-hodgkin lymphoma
DMJNFI2 ID DMJNFI2
DMJNFI2 DN BMEC-1217B
DMJNFI2 HS Phase 1
DMJNFI2 SN TCM-B; Cytokine regulator (asthma), Medigreen; 1217B; 1217B-AR
DMJNFI2 CP Industrial Technology Research Institute
DMJNFI2 DE Allergic rhinitis
DMTZ3A6 ID DMTZ3A6
DMTZ3A6 DN BMS-196085
DMTZ3A6 HS Phase 1
DMTZ3A6 SN BMS-196085; UNII-FM0D5L3W03; FM0D5L3W03; CHEMBL322862; 170686-10-9; SCHEMBL7042488; BDBM50106829; Methanesulfonamide, N-(5-((1R)-2-(((1R)-1-(4-(difluoromethoxy)phenyl)-2-phenylethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-; Methanesulfonamide, N-(5-(2-((1-(4-(difluoromethoxy)phenyl)-2-phenylethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-, (R-(R*,R*))-; N-(5-{(R)-2-[(R)-1-(4-Difluoromethoxy-phenyl)-2-phenyl-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide
DMTZ3A6 DT Small molecular drug
DMTZ3A6 PC 9870286
DMTZ3A6 MW 492.5
DMTZ3A6 FM C24H26F2N2O5S
DMTZ3A6 IC InChI=1S/C24H26F2N2O5S/c1-34(31,32)28-21-14-18(9-12-22(21)29)23(30)15-27-20(13-16-5-3-2-4-6-16)17-7-10-19(11-8-17)33-24(25)26/h2-12,14,20,23-24,27-30H,13,15H2,1H3/t20-,23+/m1/s1
DMTZ3A6 CS CS(=O)(=O)NC1=C(C=CC(=C1)[C@H](CN[C@H](CC2=CC=CC=C2)C3=CC=C(C=C3)OC(F)F)O)O
DMTZ3A6 IK XWLVOJZVWRCRMD-OFNKIYASSA-N
DMTZ3A6 IU N-[5-[(1R)-2-[[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide
DMTZ3A6 CA CAS 170686-10-9
DMTZ3A6 DE Diabetic complication
DM5M48F ID DM5M48F
DM5M48F DN BMS214662
DM5M48F HS Phase 1
DM5M48F SN BMV; BMS 214662; BMS-214662; (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile; (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile; 3-BENZYL-1-(1H-IMIDAZOL-4-YLMETHYL)-4-(THIEN-2-YLSULFONYL)-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE-7-CARBONITRILE; 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
DM5M48F CP Bristol-Myers Squibb
DM5M48F TC Anticancer Agents
DM5M48F DT Small molecular drug
DM5M48F PC 448545
DM5M48F MW 489.6
DM5M48F FM C25H23N5O2S2
DM5M48F IC InChI=1S/C25H23N5O2S2/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22/h1-11,14,18,23H,12,15-17H2,(H,27,28)/t23-/m1/s1
DM5M48F CS C1[C@H](N(CC2=C(N1CC3=CN=CN3)C=CC(=C2)C#N)S(=O)(=O)C4=CC=CS4)CC5=CC=CC=C5
DM5M48F IK OLCWFLWEHWLBTO-HSZRJFAPSA-N
DM5M48F IU (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile
DM5M48F CA CAS 195987-41-8
DM5M48F DE Non-small-cell lung cancer
DMGDJQR ID DMGDJQR
DMGDJQR DN BMS-394136
DMGDJQR HS Phase 1
DMGDJQR CP Bristol-Myers Squibb
DMGDJQR DE Arrhythmia
DMPK32V ID DMPK32V
DMPK32V DN BMS-754807
DMPK32V HS Phase 1
DMPK32V SN BMS-754807; 1001350-96-4; BMS 754807; BMS754807; UNII-W9E3353E8J; CHEMBL575448; CHEBI:88339; W9E3353E8J; 1-{4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}-N-(6-fluoropyridin-3-yl)-2-methyl-L-prolinamide; W-204348; J-501009; 2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-;2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridin
DMPK32V DT Small molecular drug
DMPK32V PC 24785538
DMPK32V MW 461.5
DMPK32V FM C23H24FN9O
DMPK32V IC InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1
DMPK32V CS C[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F
DMPK32V IK LQVXSNNAFNGRAH-QHCPKHFHSA-N
DMPK32V IU (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide
DMPK32V CA CAS 1001350-96-4
DMPK32V CB CHEBI:88339
DMKR8S1 ID DMKR8S1
DMKR8S1 DN BMS-779788
DMKR8S1 HS Phase 1
DMKR8S1 CP Bristol-Myers Squibb; Exelixis
DMKR8S1 PC 59251511
DMKR8S1 MW 509.1
DMKR8S1 FM C28H29ClN2O3S
DMKR8S1 IC InChI=1S/C28H29ClN2O3S/c1-27(2,23-11-6-7-12-24(23)29)26-30-25(28(3,4)32)18-31(26)21-15-13-19(14-16-21)20-9-8-10-22(17-20)35(5,33)34/h6-18,32H,1-5H3
DMKR8S1 CS CC(C)(C1=CC=CC=C1Cl)C2=NC(=CN2C3=CC=C(C=C3)C4=CC(=CC=C4)S(=O)(=O)C)C(C)(C)O
DMKR8S1 IK JLPURTXCSILYLW-UHFFFAOYSA-N
DMKR8S1 IU 2-[2-[2-(2-chlorophenyl)propan-2-yl]-1-[4-(3-methylsulfonylphenyl)phenyl]imidazol-4-yl]propan-2-ol
DMKR8S1 DE Arteriosclerosis
DM2WMJ7 ID DM2WMJ7
DM2WMJ7 DN BMS-816336
DM2WMJ7 HS Phase 1
DM2WMJ7 SN 11B-HSD-1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), BMS; 11B-HSD-1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), Bristol-Myers Squibb; 11beta-hydroxysteroid dehydrogenase-type 1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), BMS; 11beta-hydroxysteroid dehydrogenase-type 1 inhibitors (non-insulin dependent diabetes/obesity/metabolic syndrome), Bristol-Myers Squibb
DM2WMJ7 CP Bristol-Myers Squibb Co
DM2WMJ7 PC 59336911
DM2WMJ7 MW 341.4
DM2WMJ7 FM C21H27NO3
DM2WMJ7 IC InChI=1S/C21H27NO3/c23-18-11-22(12-18)19(24)10-21(15-4-2-1-3-5-15)16-6-13-7-17(21)9-14(8-16)20(13)25/h1-5,13-14,16-18,20,23,25H,6-12H2
DM2WMJ7 CS C1C2CC3CC(C2O)CC1C3(CC(=O)N4CC(C4)O)C5=CC=CC=C5
DM2WMJ7 IK OAAZMUGLOXGVNH-UHFFFAOYSA-N
DM2WMJ7 IU 1-(3-hydroxyazetidin-1-yl)-2-(6-hydroxy-2-phenyl-2-adamantyl)ethanone
DM2WMJ7 DE Lipid metabolism disorder
DMCX0H7 ID DMCX0H7
DMCX0H7 DN BMS-820132
DMCX0H7 HS Phase 1
DMCX0H7 CP Bristol-Myers Squibb Co
DMCX0H7 DE Type-2 diabetes
DMPQ5XC ID DMPQ5XC
DMPQ5XC DN BMS-824383
DMPQ5XC HS Phase 1
DMPQ5XC CP Bristol-Myers Squibb
DMPQ5XC DE Hepatitis C virus infection
DMCW71N ID DMCW71N
DMCW71N DN BMS-830216
DMCW71N HS Phase 1
DMCW71N CP Bristol-Myers Squibb
DMCW71N PC 44539266
DMCW71N MW 548.9
DMCW71N FM C24H22ClN2O7PS
DMCW71N IC InChI=1S/C24H22ClN2O7PS/c1-32-20-10-17(8-9-19(20)33-12-21(14-2-3-14)34-35(29,30)31)27-13-26-18-11-22(36-23(18)24(27)28)15-4-6-16(25)7-5-15/h4-11,13-14,21H,2-3,12H2,1H3,(H2,29,30,31)/t21-/m0/s1
DMCW71N CS COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OC[C@@H](C5CC5)OP(=O)(O)O
DMCW71N IK YDTUJCNTIMWHPJ-NRFANRHFSA-N
DMCW71N IU [(1R)-2-[4-[6-(4-chlorophenyl)-4-oxothieno[3,2-d]pyrimidin-3-yl]-2-methoxyphenoxy]-1-cyclopropylethyl] dihydrogen phosphate
DMCW71N CA CAS 1197420-06-6
DMCW71N DE Obesity
DMZS1D2 ID DMZS1D2
DMZS1D2 DN BMS-852927
DMZS1D2 HS Phase 1
DMZS1D2 CP Bristol-myers squibb
DMZS1D2 PC 49787490
DMZS1D2 MW 609.5
DMZS1D2 FM C29H28Cl2F2N2O4S
DMZS1D2 IC InChI=1S/C29H28Cl2F2N2O4S/c1-28(2,26-19(30)7-6-8-20(26)31)27-34-25(29(3,4)37)14-35(27)23-10-9-16(11-22(23)33)17-12-21(32)18(15-36)24(13-17)40(5,38)39/h6-14,36-37H,15H2,1-5H3
DMZS1D2 CS CC(C)(C1=CN(C(=N1)C(C)(C)C2=C(C=CC=C2Cl)Cl)C3=C(C=C(C=C3)C4=CC(=C(C(=C4)S(=O)(=O)C)CO)F)F)O
DMZS1D2 IK HNAJDMYOTDNOBK-UHFFFAOYSA-N
DMZS1D2 IU 2-[2-[2-(2,6-dichlorophenyl)propan-2-yl]-1-[2-fluoro-4-[3-fluoro-4-(hydroxymethyl)-5-methylsulfonylphenyl]phenyl]imidazol-4-yl]propan-2-ol
DMZS1D2 DE Arteriosclerosis
DM7JW0B ID DM7JW0B
DM7JW0B DN BMS-903452
DM7JW0B HS Phase 1
DM7JW0B CP Bristol-Myers Squibb Co
DM7JW0B PC 53477157
DM7JW0B MW 513.4
DM7JW0B FM C21H19Cl2FN4O4S
DM7JW0B IC InChI=1S/C21H19Cl2FN4O4S/c1-33(30,31)15-2-3-18(17(24)8-15)28-12-16(23)19(9-20(28)29)32-14-4-6-27(7-5-14)21-25-10-13(22)11-26-21/h2-3,8-12,14H,4-7H2,1H3
DM7JW0B CS CS(=O)(=O)C1=CC(=C(C=C1)N2C=C(C(=CC2=O)OC3CCN(CC3)C4=NC=C(C=N4)Cl)Cl)F
DM7JW0B IK OGIAVRWXUPYGGC-UHFFFAOYSA-N
DM7JW0B IU 5-chloro-4-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]oxy-1-(2-fluoro-4-methylsulfonylphenyl)pyridin-2-one
DM7JW0B CA CAS 1339944-47-6
DM7JW0B DE Type-2 diabetes
DM3K8VM ID DM3K8VM
DM3K8VM DN BMS-908662
DM3K8VM HS Phase 1
DM3K8VM SN BMS-908662; XL281; BMS 908662; BMS-908662 free base; 870603-16-0; GTPL7968; SCHEMBL10049428; SCHEMBL20299316; CHEMBL3545027; EXEL-2819; Carbamic acid, (5-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydro; BMS908662; XL-281; XL 281; DB12854; Carbamic acid, N-(6-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)-, methyl ester; Methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)carbamate, (+/-)-; Methyl (5-(2-(5-chloro-2-methyl
DM3K8VM CP Exelixis; Bristol-Myers Squibb
DM3K8VM DT Small molecular drug
DM3K8VM PC 56931136
DM3K8VM MW 462.9
DM3K8VM FM C24H19ClN4O4
DM3K8VM IC InChI=1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)
DM3K8VM CS CC1=C(C=C(C=C1)Cl)N2C(=O)C3=CC=CC=C3C2(C4=CC5=C(C=C4)N=C(N5)NC(=O)OC)O
DM3K8VM IK MMNNTJYFHUDSKL-UHFFFAOYSA-N
DM3K8VM IU methyl N-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1H-benzimidazol-2-yl]carbamate
DM3K8VM CA CAS 870603-16-0
DM3K8VM DE Solid tumour/cancer
DMG3J6C ID DMG3J6C
DMG3J6C DN BMS-933043
DMG3J6C HS Phase 1
DMG3J6C CP Bristol-Myers Squibb
DMG3J6C PC 59286554
DMG3J6C MW 325.37
DMG3J6C FM C16H19N7O
DMG3J6C IC InChI=1S/C16H19N7O/c1-4-22-5-2-12(1)16(9-22)8-18-15(24-16)21-13-7-14(20-10-19-13)23-6-3-17-11-23/h3,6-7,10-12H,1-2,4-5,8-9H2,(H,18,19,20,21)/t16-/m0/s1
DMG3J6C CS C1CN2CCC1[C@@]3(C2)CN=C(O3)NC4=CC(=NC=N4)N5C=CN=C5
DMG3J6C IK RLXBHTUZCPORKT-INIZCTEOSA-N
DMG3J6C IU (3R)-N-(6-imidazol-1-ylpyrimidin-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,5'-4H-1,3-oxazole]-2'-amine
DMG3J6C DE Psychiatric disorder
DMYIBFM ID DMYIBFM
DMYIBFM DN BMS-936561
DMYIBFM HS Phase 1
DMYIBFM CP Bristol-Myers Squibb
DMYIBFM DE Haematological malignancy
DMS4H1J ID DMS4H1J
DMS4H1J DN BMS-936564
DMS4H1J HS Phase 1
DMS4H1J CP Bristol-Myers Squibb
DMS4H1J DE B-cell chronic lymphocytic leukaemia; Acute myeloid leukaemia
DMZ4WMT ID DMZ4WMT
DMZ4WMT DN BMS-986104
DMZ4WMT HS Phase 1
DMZ4WMT SN Unii-KJ9D084FO4; UNII-KJ9D084FO4; KJ9D084FO4; 1622180-31-7; CHEMBL3806158; SCHEMBL15953811; BPMMYKAHRIEVDH-VOQZNFBZSA-N; J3.582.853B; ((1R,3 S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; ((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; Cyclopentanemethanol, 1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)-, (1R,3S)-
DMZ4WMT CP Bristol-Myers SquibbPrinceton, NJ
DMZ4WMT PC 77050638
DMZ4WMT MW 329.5
DMZ4WMT FM C22H35NO
DMZ4WMT IC InChI=1S/C22H35NO/c1-2-3-4-5-6-17-7-8-19-14-20(10-9-18(19)13-17)21-11-12-22(23,15-21)16-24/h9-10,14,17,21,24H,2-8,11-13,15-16,23H2,1H3/t17-,21+,22-/m1/s1
DMZ4WMT CS CCCCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@H]3CC[C@@](C3)(CO)N
DMZ4WMT IK BPMMYKAHRIEVDH-VOQZNFBZSA-N
DMZ4WMT IU [(1R,3S)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methanol
DMZ4WMT CA CAS 1622180-31-7
DMZ4WMT DE Rheumatoid arthritis
DMYLFQR ID DMYLFQR
DMYLFQR DN BMS-986120
DMYLFQR HS Phase 1
DMYLFQR SN 1478712-37-6; UNII-WDT28B7071; WDT28B7071; 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine; 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine; 4-(4-(((6-Methoxy-2-(2-methoxyimidazo(2,1-b)(1,3,4)thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine; CHEMBL3716726; SCHEMBL15348871; GTPL10269; BDBM176061; EX-A3977; BMS986120; HY-19837; CS-0016978; US9688695, 94; 2-methoxy-6-[6-methoxy-4-[[5-methyl-2-(4-morpholinyl)-4-thiazolyl]methoxy]-2-benzofuranyl]-imidazo[2,1-b]-1,3,4-thiadiazole; Imidazo(2,1-b)-1,3,4-thiadiazole, 2-methoxy-6-(6-methoxy-4-((5-methyl-2-(4-morpholinyl)-4-thiazolyl)methoxy)-2-benzofuranyl)
DMYLFQR CP Bristol-Myers Squibb
DMYLFQR DT Small molecular drug
DMYLFQR PC 72190270
DMYLFQR MW 513.6
DMYLFQR FM C23H23N5O5S2
DMYLFQR IC InChI=1S/C23H23N5O5S2/c1-13-17(25-21(34-13)27-4-6-31-7-5-27)12-32-18-8-14(29-2)9-19-15(18)10-20(33-19)16-11-28-22(24-16)35-23(26-28)30-3/h8-11H,4-7,12H2,1-3H3
DMYLFQR CS CC1=C(N=C(S1)N2CCOCC2)COC3=CC(=CC4=C3C=C(O4)C5=CN6C(=N5)SC(=N6)OC)OC
DMYLFQR IK MINMDCMSHDBHKG-UHFFFAOYSA-N
DMYLFQR IU 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine
DMYLFQR CA CAS 1478712-37-6
DMYLFQR DE Thrombosis
DMXU5FK ID DMXU5FK
DMXU5FK DN BMS-986189
DMXU5FK HS Phase 1
DMXU5FK CP Bristol-Myers Squibb
DMXU5FK DT Small molecule immunotherapy
DMHTEZ8 ID DMHTEZ8
DMHTEZ8 DN BMS-986249
DMHTEZ8 HS Phase 1
DMHTEZ8 CP Bristol-Myers Squibb
DMHTEZ8 DT Antibody
DMHTEZ8 DE Solid tumour/cancer
DMTMUWJ ID DMTMUWJ
DMTMUWJ DN BMS-986299
DMTMUWJ HS Phase 1
DMTMUWJ CP Bristol-Myers Squibb
DMTMUWJ DT Small molecular drug
DMTMUWJ DE Solid tumour/cancer
DMM3DBU ID DMM3DBU
DMM3DBU DN BMS-986301
DMM3DBU HS Phase 1
DMM3DBU CP Bristol-Myers Squibb
DMM3DBU DT Small molecular drug
DMM3DBU DE Solid tumour/cancer
DMB6FMH ID DMB6FMH
DMB6FMH DN BMTP-11
DMB6FMH HS Phase 1
DMB6FMH SN IL-11Ralpha targeted proapoptotic peptide (prostate cancer), MD Anderson Cancer Center; IL-11Ralpha targeted proapoptotic peptide (prostate cancer), Mercator
DMB6FMH CP MD Anderson Cancer Center
DMB6FMH DE Prostate cancer
DMW8VEH ID DMW8VEH
DMW8VEH DN BMY-43748
DMW8VEH HS Phase 1
DMW8VEH SN 7-[3(S)-Aminopyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-5-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylicacid
DMW8VEH DT Small molecular drug
DMW8VEH PC 488361
DMW8VEH MW 418.4
DMW8VEH FM C20H17F3N4O3
DMW8VEH IC InChI=1S/C20H17F3N4O3/c1-9-15-17(28)12(20(29)30)8-27(14-3-2-10(21)6-13(14)22)18(15)25-19(16(9)23)26-5-4-11(24)7-26/h2-3,6,8,11H,4-5,7,24H2,1H3,(H,29,30)/t11-/m0/s1
DMW8VEH CS CC1=C2C(=O)C(=CN(C2=NC(=C1F)N3CC[C@@H](C3)N)C4=C(C=C(C=C4)F)F)C(=O)O
DMW8VEH IK SKYPQEVVXGJKIJ-NSHDSACASA-N
DMW8VEH IU 7-[(3S)-3-aminopyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-5-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMW8VEH DE Bacterial infection
DMSBM6A ID DMSBM6A
DMSBM6A DN BNC-101
DMSBM6A HS Phase 1
DMSBM6A CP Bionomics
DMSBM6A DT Antibody
DMSBM6A DE Metastatic colorectal cancer
DMI4UY3 ID DMI4UY3
DMI4UY3 DN BNC375
DMI4UY3 HS Phase 1
DMI4UY3 CP Merck Kenilworth, NJ Bionomics Thebarton, Australia
DMI4UY3 PC 118160666
DMI4UY3 MW 394.9
DMI4UY3 FM C19H23ClN2O3S
DMI4UY3 IC InChI=1S/C19H23ClN2O3S/c1-19(2)15(11-22-16-10-13(20)6-9-17(16)25-3)18(19)12-4-7-14(8-5-12)26(21,23)24/h4-10,15,18,22H,11H2,1-3H3,(H2,21,23,24)/t15-,18-/m1/s1
DMI4UY3 CS CC1([C@@H]([C@H]1C2=CC=C(C=C2)S(=O)(=O)N)CNC3=C(C=CC(=C3)Cl)OC)C
DMI4UY3 IK LWWDCTBUJUEFDE-CRAIPNDOSA-N
DMI4UY3 IU 4-[(1R,3R)-3-[(5-chloro-2-methoxyanilino)methyl]-2,2-dimethylcyclopropyl]benzenesulfonamide
DMI4UY3 DE Cognitive impairment
DMU790L ID DMU790L
DMU790L DN BOS172722
DMU790L HS Phase 1
DMU790L SN SGWLRDAOCLITOM-UHFFFAOYSA-N; SCHEMBL15515080; CHEMBL3924132; BDBM241338; US9409907, 182
DMU790L CP Boston Pharmaceuticals Cambridge, MA
DMU790L PC 73386890
DMU790L MW 446.5
DMU790L FM C24H30N8O
DMU790L IC InChI=1S/C24H30N8O/c1-7-33-19-11-16(22-31-27-14-32(22)6)8-9-18(19)29-23-25-12-17-10-15(2)28-21(20(17)30-23)26-13-24(3,4)5/h8-12,14H,7,13H2,1-6H3,(H,26,28)(H,25,29,30)
DMU790L CS CCOC1=C(C=CC(=C1)C2=NN=CN2C)NC3=NC=C4C=C(N=C(C4=N3)NCC(C)(C)C)C
DMU790L IK SGWLRDAOCLITOM-UHFFFAOYSA-N
DMU790L IU 8-N-(2,2-dimethylpropyl)-2-N-[2-ethoxy-4-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-methylpyrido[3,4-d]pyrimidine-2,8-diamine
DMU790L CA CAS 1578245-44-9
DMU790L DE Solid tumour/cancer
DM9L0D8 ID DM9L0D8
DM9L0D8 DN BOS172738
DM9L0D8 HS Phase 1
DM9L0D8 SN UNII-EW27AA6XBH; EW27AA6XBH; Zeteletinib hemiadipate; BOS172738 hemiadipate; DS5010; BOS-172738; 2375837-06-0; Hexanedioic acid, compd. with 6-(6,7-dimethoxy-3-quinolinyl)-N-(3-(2,2,2-trifluoro-1,1-dimethylethyl)-5-isoxazolyl)-3-pyridineacetamide (1:2)
DM9L0D8 CP Boston Pharmaceuticals
DM9L0D8 DT Small molecular drug
DM9L0D8 PC 155801569
DM9L0D8 MW 1147.1
DM9L0D8 FM C56H56F6N8O12
DM9L0D8 IC InChI=1S/2C25H23F3N4O4.C6H10O4/c2*1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16;7-5(8)3-1-2-4-6(9)10/h2*5-6,8-13H,7H2,1-4H3,(H,31,33);1-4H2,(H,7,8)(H,9,10)
DM9L0D8 CS CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F.CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F.C(CCC(=O)O)CC(=O)O
DM9L0D8 IK KIKHVJAFGVCFGH-UHFFFAOYSA-N
DM9L0D8 IU 2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide;hexanedioic acid
DM9L0D8 CA CAS 2375837-06-0
DM9L0D8 DE Solid tumour/cancer
DMI826O ID DMI826O
DMI826O DN BP1002
DMI826O HS Phase 1
DMI826O CP Bio-Path Holdings
DMI826O DT Antisense oligonucleotide
DMI826O DE Haematopoietic/lymphoid cancer
DMNY0U5 ID DMNY0U5
DMNY0U5 DN BPI-9016 M
DMNY0U5 HS Phase 1
DMNY0U5 CP Betta Pharmaceutical
DMNY0U5 DT Small molecular drug
DMNY0U5 DE Solid tumour/cancer
DM51MSD ID DM51MSD
DM51MSD DN BPX-101
DM51MSD HS Phase 1
DM51MSD CP Bellicum Pharmaceuticals
DM51MSD DT Vaccine
DM51MSD DE Prostate cancer
DMYERSD ID DMYERSD
DMYERSD DN BPX-701
DMYERSD HS Phase 1
DMYERSD CP Bellicum Pharmaceuticals Houston, TX
DMYERSD DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMOQ2GB ID DMOQ2GB
DMOQ2GB DN BR6819
DMOQ2GB HS Phase 1
DMOQ2GB CP Bayer HealthCare Pharmaceuticals Whippany, NJ
DMOQ2GB DE Heart failure
DM4R6UV ID DM4R6UV
DM4R6UV DN Bradykinin
DM4R6UV HS Phase 1
DM4R6UV SN BRADYKININ; Kallidin I; 58-82-2; L-Bradykinin; Synthetic bradykinin; Bradykinin (synthetic); Callidin I; UNII-S8TIM42R2W; Kallidin 9; BRS 640; PRS 640; S8TIM42R2W; CHEBI:3165; CHEMBL406291; Bradykinin, Lysyl; BK; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; EINECS 200-398-8; L-arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-arginine
DM4R6UV DT Small molecular drug
DM4R6UV PC 439201
DM4R6UV MW 1060.2
DM4R6UV FM C50H73N15O11
DM4R6UV IC InChI=1S/C50H73N15O11/c51-32(16-7-21-56-49(52)53)45(72)65-25-11-20-39(65)47(74)64-24-9-18-37(64)43(70)58-28-40(67)59-34(26-30-12-3-1-4-13-30)41(68)62-36(29-66)46(73)63-23-10-19-38(63)44(71)61-35(27-31-14-5-2-6-15-31)42(69)60-33(48(75)76)17-8-22-57-50(54)55/h1-6,12-15,32-39,66H,7-11,16-29,51H2,(H,58,70)(H,59,67)(H,60,69)(H,61,71)(H,62,68)(H,75,76)(H4,52,53,56)(H4,54,55,57)/t32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
DM4R6UV CS C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DM4R6UV IK QXZGBUJJYSLZLT-FDISYFBBSA-N
DM4R6UV IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM4R6UV CA CAS 58-82-2
DM4R6UV CB CHEBI:3165
DMK7BND ID DMK7BND
DMK7BND DN Briciclib
DMK7BND HS Phase 1
DMK7BND SN Briciclib; 865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); Briciclib; ON 014185; SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro
DMK7BND CP Onconova therapeutics
DMK7BND DT Small molecular drug
DMK7BND PC 11248490
DMK7BND MW 474.4
DMK7BND FM C19H23O10PS
DMK7BND IC InChI=1S/C19H23O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H2,20,21,22)/b8-7+
DMK7BND CS COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)OP(=O)(O)O
DMK7BND IK LXENKEWVEVKKGV-BQYQJAHWSA-N
DMK7BND IU [2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenyl] dihydrogen phosphate
DMK7BND CA CAS 865783-99-9
DMK7BND DE Solid tumour/cancer
DM1V9YG ID DM1V9YG
DM1V9YG DN BRL-52656
DM1V9YG HS Phase 1
DM1V9YG SN CHEMBL433508; BRL-52656; SCHEMBL7641140; BRL-52656A; BDBM50007164; 1-(2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethanone; 1-((S)-2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethanone; (S)-1-(2-Pyrrolidin-1-ylmethyl-piperidin-1-yl)-2-(4-trifluoromethyl-phenyl)-ethanone(BRL 52656)
DM1V9YG CP SmithKline Beecham plc
DM1V9YG DT Small molecular drug
DM1V9YG PC 9865223
DM1V9YG MW 354.4
DM1V9YG FM C19H25F3N2O
DM1V9YG IC InChI=1S/C19H25F3N2O/c20-19(21,22)16-8-6-15(7-9-16)13-18(25)24-12-2-1-5-17(24)14-23-10-3-4-11-23/h6-9,17H,1-5,10-14H2/t17-/m0/s1
DM1V9YG CS C1CCN([C@@H](C1)CN2CCCC2)C(=O)CC3=CC=C(C=C3)C(F)(F)F
DM1V9YG IK RFTWMVGLYKJUCZ-KRWDZBQOSA-N
DM1V9YG IU 1-[(2S)-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone
DM1V9YG DE Pain
DMTDWIE ID DMTDWIE
DMTDWIE DN BRX-005
DMTDWIE HS Phase 1
DMTDWIE SN Arimoclomol maleate; BRX-220; Bimoclomol derivatives, Biorex
DMTDWIE CP Biorex Research and Development Co
DMTDWIE DT Small molecular drug
DMTDWIE PC 6421776
DMTDWIE MW 260.329
DMTDWIE FM C14H20N4O
DMTDWIE IC InChI=1S/C14H20N4O/c1-2-7-18(8-3-1)10-13-11-19-17-14(16-13)12-5-4-6-15-9-12/h4-6,9,13H,1-3,7-8,10-11H2,(H,16,17)
DMTDWIE CS C1CCN(CC1)CC2CONC(=N2)C3=CN=CC=C3
DMTDWIE IK QWVRTSZDKPRPDF-UHFFFAOYSA-N
DMTDWIE IU 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2H-1,2,4-oxadiazine
DMTDWIE CA CAS 276690-58-5
DMTDWIE DE Amyotrophic lateral sclerosis; Diabetic foot ulcer
DMS4H30 ID DMS4H30
DMS4H30 DN BT-063
DMS4H30 HS Phase 1
DMS4H30 SN Lupus monocloncal antibody, Biotest; SLE therapeutic antibody, Biotest
DMS4H30 CP Biotest AG
DMS4H30 DT Antibody
DMS4H30 DE Autoimmune diabetes
DMC8XHQ ID DMC8XHQ
DMC8XHQ DN BTX-A51
DMC8XHQ HS Phase 1
DMC8XHQ CP BioTheryX
DMC8XHQ DT Small molecular drug
DMC8XHQ DE Non-hodgkin lymphoma; Advanced solid tumour
DMJ56MS ID DMJ56MS
DMJ56MS DN BUTYLATEDHYDROXYTOLUENE
DMJ56MS HS Phase 1
DMJ56MS SN 2,6-Di-tert-butyl-4-methylphenol; 128-37-0; Butylated hydroxytoluene; Butylhydroxytoluene; 2,6-Di-tert-butyl-p-cresol; 2,6-Di-t-butyl-4-methylphenol; Ionol; DBPC; Stavox; Dibunol; BHT; Ionol CP; Topanol; Impruvol; Vianol; Dalpac; Ionole; Deenax; Antioxidant KB; 3,5-Di-tert-butyl-4-hydroxytoluene; Sumilizer BHT; Antioxidant 4K; Topanol O; Topanol OC; Vanlube PC; Vanlube PCX; Sustane BHT; Tenamene 3; Antioxidant DBPC; Antioxidant 29; Antioxidant 30; Tenox BHT; Nonox TBC; Chemanox 11; Ionol 1; Agidol; Catalin CAO-3; Advastab 401; Ionol (antioxidan
DMJ56MS DT Small molecular drug
DMJ56MS PC 31404
DMJ56MS MW 220.35
DMJ56MS FM C15H24O
DMJ56MS IC InChI=1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3
DMJ56MS CS CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C
DMJ56MS IK NLZUEZXRPGMBCV-UHFFFAOYSA-N
DMJ56MS IU 2,6-ditert-butyl-4-methylphenol
DMJ56MS CA CAS 128-37-0
DMJ56MS CB CHEBI:34247
DM43GPX ID DM43GPX
DM43GPX DN BVI-007
DM43GPX HS Phase 1
DM43GPX CP BioVascular
DM43GPX DE Thrombotic stroke; Myocardial infarction
DMEP321 ID DMEP321
DMEP321 DN BVT-74316
DMEP321 HS Phase 1
DMEP321 SN BVT-5182; BVT-5182C; 5-HT6 antagonists (obesity), Biovitrum; 5-HT6 antagonists (obesity), Proximagen
DMEP321 CP Swedish Orphan Biovitrum AB
DMEP321 DT Small molecular drug
DMEP321 PC 16092139
DMEP321 MW 416.5
DMEP321 FM C21H24N2O5S
DMEP321 IC InChI=1S/C21H24N2O5S/c1-14-3-4-19(26-2)18(11-14)23-29(24,25)17-12-15-7-10-27-21(15)20(13-17)28-16-5-8-22-9-6-16/h3-4,7,10-13,16,22-23H,5-6,8-9H2,1-2H3
DMEP321 CS CC1=CC(=C(C=C1)OC)NS(=O)(=O)C2=CC(=C3C(=C2)C=CO3)OC4CCNCC4
DMEP321 IK UPQJYTNALAIZCC-UHFFFAOYSA-N
DMEP321 IU N-(2-methoxy-5-methylphenyl)-7-piperidin-4-yloxy-1-benzofuran-5-sulfonamide
DMEP321 CA CAS 917095-86-4
DMEP321 DE Obesity
DMY9L4C ID DMY9L4C
DMY9L4C DN BXCL702
DMY9L4C HS Phase 1
DMY9L4C CP BioXcel Therapeutics Branford, CT
DMY9L4C DE Haematological malignancy
DMH6B9J ID DMH6B9J
DMH6B9J DN BZ-55
DMH6B9J HS Phase 1
DMH6B9J SN Alentin; Aminophenurobutane; Bucarban; Bucrol; Bukarban; Burcol; Butisulfina; Carbutamid; Carbutamide; Carbutamide [INN:BAN]; Diabetin; Diabetoplex; Diaboral; Diabutan; Emedan; Glucidoral; Glucofren; Glybutamide; Inbuton; Invenol; N'-(Butylcarbamoyl)sulfanilamide; N-Butyl-N'-sulfanilylurea; N-Butylsulfanilylurea; N-Sulfanilyl-N'-butylurea; Nadisan; Nadizan; Norboral; Oranil; Oranyl; Orasulin; Sulfonamide carbutamide; Urea, 1-butyl-3-sulfanilyl-; 1-BUTYL-3-SULFANILYLUREA; 339-43-5; 4-amino-N-[(butylamino)carbonyl]benzenesulfonamide; BZ 55
DMH6B9J PC 9564
DMH6B9J MW 271.34
DMH6B9J FM C11H17N3O3S
DMH6B9J IC VDTNNGKXZGSZIP-UHFFFAOYSA-N
DMH6B9J CS CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)N
DMH6B9J IK 1S/C11H17N3O3S/c1-2-3-8-13-11(15)14-18(16,17)10-6-4-9(12)5-7-10/h4-7H,2-3,8,12H2,1H3,(H2,13,14,15)
DMH6B9J IU 1-(4-aminophenyl)sulfonyl-3-butylurea
DMH6B9J CA CAS 339-43-5
DMH6B9J CB CHEBI:135118
DMH6B9J DE Diabetes mellitus
DMOV2ZD ID DMOV2ZD
DMOV2ZD DN C188-9
DMOV2ZD HS Phase 1
DMOV2ZD SN QDCJDYWGYVPBDO-UHFFFAOYSA-N; UNII-KZ3DLD11RQ; KZ3DLD11RQ; AC1LQFBK; MLS006011646; SCHEMBL16394007; CHEMBL3392776; MolPort-000-644-242; N-(1B; ZINC1154831; AKOS001673470; MCULE-7568979350; NCGC00262829-02; SMR004703404; EU-0081697; AB00117290-01; C-188-9; N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide; N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide; Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-; 432001-19-9
DMOV2ZD CP StemMed Houston, TX
DMOV2ZD PC 1324494
DMOV2ZD MW 471.5
DMOV2ZD FM C27H21NO5S
DMOV2ZD IC InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3
DMOV2ZD CS COC1=CC=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C4=C(C=CC5=CC=CC=C54)O
DMOV2ZD IK QDCJDYWGYVPBDO-UHFFFAOYSA-N
DMOV2ZD IU N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide
DMOV2ZD CA CAS 432001-19-9
DMOV2ZD DE Solid tumour/cancer
DMOFT1V ID DMOFT1V
DMOFT1V DN C-2507
DMOFT1V HS Phase 1
DMOFT1V SN L-0008708100; L-870810; L-870812; L-900564; HIV integrase inhibitors, Merck & Co; Integric acid, Merck & Co
DMOFT1V CP Merck & Co Inc
DMOFT1V DT Small molecular drug
DMOFT1V PC 56973024
DMOFT1V MW 502.5
DMOFT1V FM C11H20F6N2O7S3
DMOFT1V IC InChI=1S/C9H19NO3S.C2HF6NO4S2/c11-14(12,13)9-5-4-8-10-6-2-1-3-7-10;3-1(4,5)14(10,11)9-15(12,13)2(6,7)8/h1-9H2,(H,11,12,13);9H
DMOFT1V CS C1CCN(CC1)CCCCS(=O)(=O)O.C(F)(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F
DMOFT1V IK IMVWFEMFPIUJGS-UHFFFAOYSA-N
DMOFT1V IU 4-piperidin-1-ylbutane-1-sulfonic acid;1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide
DMOFT1V DE Human immunodeficiency virus infection
DMR0S8U ID DMR0S8U
DMR0S8U DN C326
DMR0S8U HS Phase 1
DMR0S8U CP Avidia
DMR0S8U DE Crohn disease
DMSO3JA ID DMSO3JA
DMSO3JA DN C7R-GD2.CART cells
DMSO3JA HS Phase 1
DMSO3JA CP Baylor College of Medicine
DMSO3JA DT CAR T Cell Therapy
DMSO3JA DE Neuroblastoma
DMPQ1TM ID DMPQ1TM
DMPQ1TM DN CA-011
DMPQ1TM HS Phase 1
DMPQ1TM SN 2-Amino-4-(p-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-1,3-thiazol-2-amine; 2104/9/8; 2-Amino-4-(4-nitrophenyl)thiazole; 4-(4-Nitrophenyl)-2-thiazolamine; 2-Thiazolamine, 4-(4-nitrophenyl)-; 4-(4-nitrophenyl)thiazol-2-amine; THIAZOLE, 2-AMINO-4-(p-NITROPHENYL)-; 4-(4-Nitrophenyl)thiazol-2-ylamine; 2-amino-4-(4'-nitrophenyl)-1,3-thiazole; RIKJWJIWXCUKQV-UHFFFAOYSA-N; BRN 0200321; 4-(4-Nitro-phenyl)-thiazol-2-ylamine; AI3-62320; 4-(4-nitrophenyl)-1,3-thiazole-2-ylamine; DSSTox_CID_65; AC1L27WX; Cambridge id 5156331; DSSTox_RID_
DMPQ1TM CP Concentric Analgesics Los Altos, CA
DMPQ1TM PC 16420
DMPQ1TM MW 221.24
DMPQ1TM FM C9H7N3O2S
DMPQ1TM IC InChI=1S/C9H7N3O2S/c10-9-11-8(5-15-9)6-1-3-7(4-2-6)12(13)14/h1-5H,(H2,10,11)
DMPQ1TM CS C1=CC(=CC=C1C2=CSC(=N2)N)[N+](=O)[O-]
DMPQ1TM IK RIKJWJIWXCUKQV-UHFFFAOYSA-N
DMPQ1TM IU 4-(4-nitrophenyl)-1,3-thiazol-2-amine
DMPQ1TM CA CAS 2104-09-8
DMPQ1TM DE Chronic pain
DMYDNQ2 ID DMYDNQ2
DMYDNQ2 DN CA102N
DMYDNQ2 HS Phase 1
DMYDNQ2 CP Holy Stone Healthcare
DMYDNQ2 DT Small molecular drug
DMYDNQ2 DE Solid tumour/cancer
DMOUHR4 ID DMOUHR4
DMOUHR4 DN CA-170
DMOUHR4 HS Phase 1
DMOUHR4 SN 3-Aminopyrrolidine dihydrochloride; 103831-11-4; pyrrolidin-3-amine dihydrochloride; 3-Pyrrolidinamine, dihydrochloride; 3-Aminopyrrolidine 2HCl; 3-Aminopyrrolidine diHCl; SCHEMBL555933; ACMC-2099s1; ACMC-2099s3; ACMC-20989g; 3-pyrrolidinamine dihydrochloride; CTK0H7226; DTXSID00583661; MolPort-002-343-989; NJPNCMOUEXEGBL-UHFFFAOYSA-N; 3-Amino-pyrrolidine dihydrochloride; KS-00000JI6; ACT01710; ANW-14978; SBB003982; ( -3-Aminopyrrolidine dihydrochloride; AKOS015844825; VP60158; AM85320; VP60228; TRA0055207; TRA0000843; TRA0097
DMOUHR4 CP Curis Lexington, MA
DMOUHR4 DT Small molecule immunotherapy
DMOUHR4 PC 16212596
DMOUHR4 MW 159.05
DMOUHR4 FM C4H12Cl2N2
DMOUHR4 IC InChI=1S/C4H10N2.2ClH/c5-4-1-2-6-3-4;;/h4,6H,1-3,5H2;2*1H
DMOUHR4 CS C1CNCC1N.Cl.Cl
DMOUHR4 IK NJPNCMOUEXEGBL-UHFFFAOYSA-N
DMOUHR4 IU pyrrolidin-3-amine;dihydrochloride
DMOUHR4 CA CAS 103831-11-4
DMOUHR4 DE Lymphoma; Solid tumour/cancer
DMQ2OP0 ID DMQ2OP0
DMQ2OP0 DN CA-170
DMQ2OP0 HS Phase 1
DMQ2OP0 CP Curis
DMQ2OP0 DT Small molecular drug
DMQ2OP0 DE Lymphoma; Solid tumour/cancer
DMWV8C6 ID DMWV8C6
DMWV8C6 DN CA-4948
DMWV8C6 HS Phase 1
DMWV8C6 SN RWIMETUXCNDSLE-UHFFFAOYSA-N; SCHEMBL16896371; GTPL10152; CA4948; AU4948; AU-4948; example 1 [WO2015104688A1]; HY-109585; CS-0032273; 6'-Amino-N-[2-(morpholin-4-yl)-[1,3]oxazolo[4,5-b]pyridin-6-yl]-[2,3'-bipyridine]-6-carboxamide; 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide
DMWV8C6 CP Curis Lexington, MA
DMWV8C6 PC 118224238
DMWV8C6 MW 417.4
DMWV8C6 FM C21H19N7O3
DMWV8C6 IC InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29)
DMWV8C6 CS C1COCCN1C2=NC3=C(O2)C=C(C=N3)NC(=O)C4=CC=CC(=N4)C5=CN=C(C=C5)N
DMWV8C6 IK RWIMETUXCNDSLE-UHFFFAOYSA-N
DMWV8C6 IU 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide
DMWV8C6 DE Lymphoma
DMA1QUC ID DMA1QUC
DMA1QUC DN CAD-1833
DMA1QUC HS Phase 1
DMA1QUC CP Cadent Therapeutics Cambridge, MA
DMA1QUC DE Essential tremor or related tremors; Spinocerebellar ataxia
DMQ7WJI ID DMQ7WJI
DMQ7WJI DN CAF-01
DMQ7WJI HS Phase 1
DMQ7WJI SN TDB; Liposomal adjuvant, Statens Serum Institut; Alpha,alpha'-trehalose 6,6'-dibehenate
DMQ7WJI CP Statens Serum Institut
DMQ7WJI DE Vaccination
DMT4Z5B ID DMT4Z5B
DMT4Z5B DN CALAA-01
DMT4Z5B HS Phase 1
DMT4Z5B SN Ribonucleotide reductase M2 subunit (RRM2)-targeted siRNA agent (RONDEL, intravenous, cancer), Calando
DMT4Z5B CP Calando pharmaceuticals
DMT4Z5B DE Solid tumour/cancer
DMQTUH8 ID DMQTUH8
DMQTUH8 DN Calanolide A
DMQTUH8 HS Phase 1
DMQTUH8 SN NSC-675451; NSC-664737 (racemate); (+)-(10R,11S,12S)-12-Hydroxy-6,6,10,11-tetramethyl-4-propyl-6,10,11,12-tetrahydro-2H-benzo[1,2-b:3,4-b':5,6-b'']tripyran-2-one; (+)-Calanolide A
DMQTUH8 CP Sarawak MediChem Pharmaceuticals
DMQTUH8 DT Small molecular drug
DMQTUH8 PC 64972
DMQTUH8 MW 370.4
DMQTUH8 FM C22H26O5
DMQTUH8 IC InChI=1S/C22H26O5/c1-6-7-13-10-15(23)26-21-16(13)20-14(8-9-22(4,5)27-20)19-17(21)18(24)11(2)12(3)25-19/h8-12,18,24H,6-7H2,1-5H3/t11-,12-,18+/m1/s1
DMQTUH8 CS CCCC1=CC(=O)OC2=C1C3=C(C=CC(O3)(C)C)C4=C2[C@H]([C@@H]([C@H](O4)C)C)O
DMQTUH8 IK NIDRYBLTWYFCFV-FMTVUPSXSA-N
DMQTUH8 IU (16R,17S,18S)-18-hydroxy-10,10,16,17-tetramethyl-6-propyl-3,9,15-trioxatetracyclo[12.4.0.02,7.08,13]octadeca-1(14),2(7),5,8(13),11-pentaen-4-one
DMQTUH8 CA CAS 142632-32-4
DMQTUH8 CB CHEBI:65552
DMQTUH8 DE Mycobacterium infection
DM1FLXD ID DM1FLXD
DM1FLXD DN CAN04
DM1FLXD HS Phase 1
DM1FLXD CP Cantargia
DM1FLXD DT Antibody
DM1FLXD DE Non-small-cell lung cancer
DM9ERH1 ID DM9ERH1
DM9ERH1 DN Capravirine
DM9ERH1 HS Phase 1
DM9ERH1 SN AG-1549; S-1153; NNRTI (HIV infection), Pfizer
DM9ERH1 CP Shionogi & Co Ltd
DM9ERH1 DT Small molecular drug
DM9ERH1 PC 1783
DM9ERH1 MW 451.4
DM9ERH1 FM C20H20Cl2N4O2S
DM9ERH1 IC InChI=1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
DM9ERH1 CS CC(C)C1=C(N(C(=N1)COC(=O)N)CC2=CC=NC=C2)SC3=CC(=CC(=C3)Cl)Cl
DM9ERH1 IK YQXCVAGCMNFUMQ-UHFFFAOYSA-N
DM9ERH1 IU [5-(3,5-dichlorophenyl)sulfanyl-4-propan-2-yl-1-(pyridin-4-ylmethyl)imidazol-2-yl]methyl carbamate
DM9ERH1 CA CAS 178979-85-6
DM9ERH1 DE Human immunodeficiency virus infection
DM8NLPI ID DM8NLPI
DM8NLPI DN CAR CD30 T cells
DM8NLPI HS Phase 1
DM8NLPI CP UNC Lineberger Comprehensive Cancer Center
DM8NLPI DT CAR T Cell Therapy
DM8NLPI DE Non-hodgkin lymphoma; Hodgkin lymphoma
DMA9M81 ID DMA9M81
DMA9M81 DN CAR138 T Cells
DMA9M81 HS Phase 1
DMA9M81 CP UNC Lineberger Comprehensive Cancer Center
DMA9M81 DT CAR T Cell Therapy
DMA9M81 DE Immune System disease; Multiple myeloma
DMXD4TC ID DMXD4TC
DMXD4TC DN CAR19 T cells carrying cytoplasmic activated PD-1
DMXD4TC HS Phase 1
DMXD4TC CP Henan Cancer Hospital
DMXD4TC DT CAR T Cell Therapy
DMXD4TC DE Non-hodgkin lymphoma
DM4CXE2 ID DM4CXE2
DM4CXE2 DN CAR-20/19-T Cells
DM4CXE2 HS Phase 1
DM4CXE2 CP Medical College of Wisconsin
DM4CXE2 DT CAR T Cell Therapy (Dual specific)
DM4CXE2 DE B-cell non-hodgkin lymphoma; Chronic lymphocytic leukaemia; Pancreatic cancer
DM4SNK8 ID DM4SNK8
DM4SNK8 DN CARD-024
DM4SNK8 HS Phase 1
DM4SNK8 SN 1-alpha-hydroxyvitamin D5 (cardiovascular diseases), Cardiavent; 1a(OH)VitD5 (cardiovascular diseases), Cardiavent
DM4SNK8 CP Cardiavent Inc
DM4SNK8 PC 10025615
DM4SNK8 MW 428.7
DM4SNK8 FM C29H48O2
DM4SNK8 IC InChI=1S/C29H48O2/c1-7-22(19(2)3)11-10-20(4)26-14-15-27-23(9-8-16-29(26,27)6)12-13-24-17-25(30)18-28(31)21(24)5/h12-13,19-20,22,25-28,30-31H,5,7-11,14-18H2,1-4,6H3/b23-12+,24-13-/t20-,22-,25-,26-,27+,28+,29-/m1/s1
DM4SNK8 CS CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)C(C)C
DM4SNK8 IK NWFOBODUYTUMNC-VPSCEVSQSA-N
DM4SNK8 IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM4SNK8 CA CAS 187935-17-7
DM4SNK8 DE Cardiovascular disease
DM5WKU1 ID DM5WKU1
DM5WKU1 DN Cardiotrophin-1
DM5WKU1 HS Phase 1
DM5WKU1 SN Cardiotrophin-1 (acute liver failure/obesity/interferon stimulator)
DM5WKU1 CP Digna Biotech SL
DM5WKU1 DE Acute liver failure
DMQH2DK ID DMQH2DK
DMQH2DK DN CAR-GPC3 T Cells
DMQH2DK HS Phase 1
DMQH2DK CP Carsgen Therapeutics, Ltd.
DMQH2DK DT CAR T Cell Therapy
DMQH2DK DE Lung squamous cell carcinoma
DMU6ZMX ID DMU6ZMX
DMU6ZMX DN Carmoxirole
DMU6ZMX HS Phase 1
DMU6ZMX SN Carmoxirole hydrochloride; EMD-45609
DMU6ZMX CP Merck KGaA
DMU6ZMX DT Small molecular drug
DMU6ZMX PC 57364
DMU6ZMX MW 374.5
DMU6ZMX FM C24H26N2O2
DMU6ZMX IC InChI=1S/C24H26N2O2/c27-24(28)20-9-10-23-22(16-20)21(17-25-23)8-4-5-13-26-14-11-19(12-15-26)18-6-2-1-3-7-18/h1-3,6-7,9-11,16-17,25H,4-5,8,12-15H2,(H,27,28)
DMU6ZMX CS C1CN(CC=C1C2=CC=CC=C2)CCCCC3=CNC4=C3C=C(C=C4)C(=O)O
DMU6ZMX IK AFSOIHMEOKEZJF-UHFFFAOYSA-N
DMU6ZMX IU 3-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1H-indole-5-carboxylic acid
DMU6ZMX CA CAS 98323-83-2
DMU6ZMX CB CHEBI:64200
DMU6ZMX DE Hypertension
DMC7Y5F ID DMC7Y5F
DMC7Y5F DN CAR-T cells recognizing EpCAM
DMC7Y5F HS Phase 1
DMC7Y5F CP Sichuan University
DMC7Y5F DT CAR T Cell Therapy
DMC7Y5F DE Melanoma; Breast cancer
DMTZADW ID DMTZADW
DMTZADW DN CAR-T cells targeting BCMA
DMTZADW HS Phase 1
DMTZADW CP Second Affiliated Hospital of Xi'an Jiaotong University
DMTZADW DT CAR T Cell Therapy
DMTZADW DE Multiple myeloma
DM3AHNX ID DM3AHNX
DM3AHNX DN CAR-T Cells targeting CD19
DM3AHNX HS Phase 1
DM3AHNX CP Seattle Children's Hospital
DM3AHNX DT CAR T Cell Therapy
DM3AHNX DE Acute lymphoblastic leukaemia
DMJK1R0 ID DMJK1R0
DMJK1R0 DN CAR-T cells targeting CD19
DMJK1R0 HS Phase 1
DMJK1R0 CP Sinobioway Cell Therapy Co., Ltd.
DMJK1R0 DT CAR T Cell Therapy
DMJK1R0 DE Lymphoma
DM6Z7AD ID DM6Z7AD
DM6Z7AD DN CAR-T cells targeting CD80/86
DM6Z7AD HS Phase 1
DM6Z7AD CP Second Affiliated Hospital of Guangzhou Medical University
DM6Z7AD DT CAR T Cell Therapy
DM6Z7AD DE Solid tumour/cancer
DMX4ZDY ID DMX4ZDY
DMX4ZDY DN CAR-T Cells targeting CEA
DMX4ZDY HS Phase 1
DMX4ZDY CP First Affiliated Hospital of Harbin Medical University
DMX4ZDY DT CAR T Cell Therapy
DMX4ZDY DE Pancreatic cancer
DMRSG04 ID DMRSG04
DMRSG04 DN CAR-T cells targeting EGFRviii
DMRSG04 HS Phase 1
DMRSG04 CP Shenzhen Geno-Immune Medical Institute
DMRSG04 DT CAR T Cell Therapy
DMRSG04 DE Glioblastoma multiforme
DMWAMNT ID DMWAMNT
DMWAMNT DN CAR-T Cells targeting EGFRvIII
DMWAMNT HS Phase 1
DMWAMNT CP First Affiliated Hospital of Harbin Medical University
DMWAMNT DT CAR T Cell Therapy
DMWAMNT DE Pancreatic cancer
DMQ2Y1J ID DMQ2Y1J
DMQ2Y1J DN CAR-T cells targeting EpCAM
DMQ2Y1J HS Phase 1
DMQ2Y1J CP Jian-Kun Hu
DMQ2Y1J DT CAR T Cell Therapy
DMQ2Y1J DE Metastatic cancer; Gastric adenocarcinoma
DMLI5VG ID DMLI5VG
DMLI5VG DN CAR-T cells targeting HER2
DMLI5VG HS Phase 1
DMLI5VG CP Second Affiliated Hospital of Guangzhou Medical University
DMLI5VG DT CAR T Cell Therapy
DMLI5VG DE Solid tumour/cancer
DMYCMNR ID DMYCMNR
DMYCMNR DN CAR-T Cells targeting HER2
DMYCMNR HS Phase 1
DMYCMNR CP First Affiliated Hospital of Harbin Medical University
DMYCMNR DT CAR T Cell Therapy
DMYCMNR DE Pancreatic cancer
DMGI58S ID DMGI58S
DMGI58S DN CAR-T cells targeting Lewis-Y
DMGI58S HS Phase 1
DMGI58S CP Second Affiliated Hospital of Guangzhou Medical University
DMGI58S DT CAR T Cell Therapy
DMGI58S DE Solid tumour/cancer
DM6DULC ID DM6DULC
DM6DULC DN CAR-T Cells targeting Mesothelin
DM6DULC HS Phase 1
DM6DULC CP First Affiliated Hospital of Harbin Medical University
DM6DULC DT CAR T Cell Therapy
DM6DULC DE Pancreatic cancer
DMTZXSO ID DMTZXSO
DMTZXSO DN CAR-T cells targeting Mesothelin
DMTZXSO HS Phase 1
DMTZXSO CP Second Affiliated Hospital of Guangzhou Medical University
DMTZXSO DT CAR T Cell Therapy
DMTZXSO DE Solid tumour/cancer
DM6GRNC ID DM6GRNC
DM6GRNC DN CAR-T cells targeting MUC1
DM6GRNC HS Phase 1
DM6GRNC CP Second Affiliated Hospital of Guangzhou Medical University
DM6GRNC DT CAR T Cell Therapy
DM6GRNC DE Solid tumour/cancer
DMNH1Y5 ID DMNH1Y5
DMNH1Y5 DN CAR-T Cells targeting MUCI
DMNH1Y5 HS Phase 1
DMNH1Y5 CP First Affiliated Hospital of Harbin Medical University
DMNH1Y5 DT CAR T Cell Therapy
DMNH1Y5 DE Pancreatic cancer
DMU4G9J ID DMU4G9J
DMU4G9J DN CAR-T cells targeting PSCA
DMU4G9J HS Phase 1
DMU4G9J CP Second Affiliated Hospital of Guangzhou Medical University
DMU4G9J DT CAR T Cell Therapy
DMU4G9J DE Solid tumour/cancer
DMWIXLC ID DMWIXLC
DMWIXLC DN CAR-T Cells targeting PSCA
DMWIXLC HS Phase 1
DMWIXLC CP First Affiliated Hospital of Harbin Medical University
DMWIXLC DT CAR T Cell Therapy
DMWIXLC DE Pancreatic cancer
DMQ4UJ6 ID DMQ4UJ6
DMQ4UJ6 DN CART-10 cells
DMQ4UJ6 HS Phase 1
DMQ4UJ6 CP Zhujiang Hospital
DMQ4UJ6 DT CAR T Cell Therapy
DMQ4UJ6 DE Acute lymphoblastic leukaemia
DMAKZTW ID DMAKZTW
DMAKZTW DN CART-117 cells
DMAKZTW HS Phase 1
DMAKZTW CP Zhujiang Hospital
DMAKZTW DT CAR T Cell Therapy
DMAKZTW DE Myelodysplastic syndrome; Acute myeloid leukaemia
DMD0XWR ID DMD0XWR
DMD0XWR DN CART123 cells
DMD0XWR HS Phase 1
DMD0XWR CP University of Pennsylvania
DMD0XWR DT CAR T Cell Therapy
DMD0XWR DE Acute myeloid leukaemia
DMEN6YF ID DMEN6YF
DMEN6YF DN CART-123 cells
DMEN6YF HS Phase 1
DMEN6YF CP Zhujiang Hospital
DMEN6YF DT CAR T Cell Therapy
DMEN6YF DE Myelodysplastic syndrome; Acute myeloid leukaemia
DM1R8P4 ID DM1R8P4
DM1R8P4 DN CART-19
DM1R8P4 HS Phase 1
DM1R8P4 CP Henan Cancer Hospital
DM1R8P4 DT CAR T Cell Therapy
DM1R8P4 DE B-cell lymphoma
DM8R2ZX ID DM8R2ZX
DM8R2ZX DN CART-19
DM8R2ZX HS Phase 1
DM8R2ZX CP Beijing Sanwater Biological Technology Co., Ltd.
DM8R2ZX DT CAR T Cell Therapy
DM8R2ZX DE Acute lymphoblastic leukaemia
DMY218P ID DMY218P
DMY218P DN CART-19 autologous T-cells
DMY218P HS Phase 1
DMY218P CP University of Pennsylvania
DMY218P DT CAR T Cell Therapy
DMY218P DE Lymphoma
DMM95XS ID DMM95XS
DMM95XS DN CART19 cell
DMM95XS HS Phase 1
DMM95XS CP Shenzhen Second People's Hospital
DMM95XS DT CAR T Cell Therapy
DMM95XS DE B-cell prolymphocytic leukaemia
DMHWVY1 ID DMHWVY1
DMHWVY1 DN CART-19 cells
DMHWVY1 HS Phase 1
DMHWVY1 CP Zhujiang Hospital
DMHWVY1 DT CAR T Cell Therapy
DMHWVY1 DE Acute lymphoblastic leukaemia
DMKW27X ID DMKW27X
DMKW27X DN CART-19 cells
DMKW27X HS Phase 1
DMKW27X CP Henan Cancer Hospital
DMKW27X DT CAR T Cell Therapy
DMKW27X DE Acute lymphoblastic leukaemia
DMTCB8I ID DMTCB8I
DMTCB8I DN CART-19 T cells
DMTCB8I HS Phase 1
DMTCB8I CP University of Pennsylvania
DMTCB8I DT CAR T Cell Therapy
DMTCB8I DE Multiple myeloma
DMR0Z65 ID DMR0Z65
DMR0Z65 DN CART-20 cells
DMR0Z65 HS Phase 1
DMR0Z65 CP Zhujiang Hospital
DMR0Z65 DT CAR T Cell Therapy
DMR0Z65 DE Acute lymphoblastic leukaemia
DM6X82R ID DM6X82R
DM6X82R DN CART22 cells
DM6X82R HS Phase 1
DM6X82R CP University of Pennsylvania
DM6X82R DT CAR T Cell Therapy
DM6X82R DE Acute lymphoblastic leukaemia
DMLGJKE ID DMLGJKE
DMLGJKE DN CART-22 cells
DMLGJKE HS Phase 1
DMLGJKE CP Zhujiang Hospital
DMLGJKE DT CAR T Cell Therapy
DMLGJKE DE Acute lymphoblastic leukaemia
DMY3NWK ID DMY3NWK
DMY3NWK DN CART22 cells expressing anti-CD22 scFv TCRz:41BB
DMY3NWK HS Phase 1
DMY3NWK CP University of Pennsylvania
DMY3NWK DT CAR T Cell Therapy
DMY3NWK DE Acute lymphoblastic leukaemia
DM4XT15 ID DM4XT15
DM4XT15 DN CART22-65s cells
DM4XT15 HS Phase 1
DM4XT15 CP University of Pennsylvania
DM4XT15 DT CAR T Cell Therapy
DM4XT15 DE Acute lymphoblastic leukaemia
DMOJ1AH ID DMOJ1AH
DMOJ1AH DN CART22-65s cells and huCART19 Cells
DMOJ1AH HS Phase 1
DMOJ1AH CP University of Pennsylvania
DMOJ1AH DT CAR T Cell Therapy (Dual specific)
DMOJ1AH DE Acute lymphoblastic leukaemia
DMBHCSL ID DMBHCSL
DMBHCSL DN CART-33 cells
DMBHCSL HS Phase 1
DMBHCSL CP Zhujiang Hospital
DMBHCSL DT CAR T Cell Therapy
DMBHCSL DE Myelodysplastic syndrome; Acute myeloid leukaemia
DMRNIB9 ID DMRNIB9
DMRNIB9 DN CART-34 cells
DMRNIB9 HS Phase 1
DMRNIB9 CP Zhujiang Hospital
DMRNIB9 DT CAR T Cell Therapy
DMRNIB9 DE Myelodysplastic syndrome; Acute myeloid leukaemia
DMKN8XD ID DMKN8XD
DMKN8XD DN CART-38 cells
DMKN8XD HS Phase 1
DMKN8XD CP Zhujiang Hospital
DMKN8XD DT CAR T Cell Therapy
DMKN8XD DE Myelodysplastic syndrome; Acute myeloid leukaemia
DMQTOBF ID DMQTOBF
DMQTOBF DN CART-56 cells
DMQTOBF HS Phase 1
DMQTOBF CP Zhujiang Hospital
DMQTOBF DT CAR T Cell Therapy
DMQTOBF DE Myelodysplastic syndrome; Acute myeloid leukaemia
DMVK3M2 ID DMVK3M2
DMVK3M2 DN CART-BCMA
DMVK3M2 HS Phase 1
DMVK3M2 CP University of Pennsylvania
DMVK3M2 DT CAR T Cell Therapy
DMVK3M2 DE Multiple myeloma
DM4OWJ8 ID DM4OWJ8
DM4OWJ8 DN CART-ddBCMA
DM4OWJ8 HS Phase 1
DM4OWJ8 CP Arcellx
DM4OWJ8 DT CAR T Cell Therapy
DM4OWJ8 DE Multiple myeloma
DMGPR1C ID DMGPR1C
DMGPR1C DN CART-EGFRvIII T cells
DMGPR1C HS Phase 1
DMGPR1C CP University of Pennsylvania
DMGPR1C DT CAR T Cell Therapy
DMGPR1C DE Glioma; Recurrent glioblastoma
DM90QPK ID DM90QPK
DM90QPK DN CART-meso cells
DM90QPK HS Phase 1
DM90QPK CP University of Pennsylvania
DM90QPK DT CAR T Cell Therapy
DM90QPK DE Pancreatic cancer
DMV84ZR ID DMV84ZR
DMV84ZR DN CARTmeso/19
DMV84ZR HS Phase 1
DMV84ZR CP First Affiliated Hospital of Wenzhou Medical University
DMV84ZR DT CAR T Cell Therapy (Dual specific)
DMV84ZR DE Pancreatic cancer
DMZ4I03 ID DMZ4I03
DMZ4I03 DN CART-meso-19 T cells
DMZ4I03 HS Phase 1
DMZ4I03 CP University of Pennsylvania
DMZ4I03 DT CAR T Cell Therapy (Dual specific)
DMZ4I03 DE Pancreatic cancer
DMOJEXG ID DMOJEXG
DMOJEXG DN CART-Muc1 cells
DMOJEXG HS Phase 1
DMOJEXG CP Zhujiang Hospital
DMOJEXG DT CAR T Cell Therapy
DMOJEXG DE Myelodysplastic syndrome; Acute myeloid leukaemia
DM39LPN ID DM39LPN
DM39LPN DN CarVAC
DM39LPN HS Phase 1
DM39LPN CP iCell Gene Therapeutics
DM39LPN DT CAR T Cell Therapy
DM39LPN DE B-cell lymphoma
DMO53AD ID DMO53AD
DMO53AD DN Cavrotolimod
DMO53AD HS Phase 1
DMO53AD CP Exicure
DMO53AD DT Small molecular drug
DMO53AD DE Solid tumour/cancer
DM12GN7 ID DM12GN7
DM12GN7 DN CB-5083
DM12GN7 HS Phase 1
DM12GN7 CP Cleave biosciences
DM12GN7 PC 73051434
DM12GN7 MW 413.5
DM12GN7 FM C24H23N5O2
DM12GN7 IC InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)
DM12GN7 CS CC1=CC2=C(C=CC=C2N1C3=NC4=C(COCC4)C(=N3)NCC5=CC=CC=C5)C(=O)N
DM12GN7 IK RDALZZCKQFLGJP-UHFFFAOYSA-N
DM12GN7 IU 1-[4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl]-2-methylindole-4-carboxamide
DM12GN7 CA CAS 1542705-92-9
DM12GN7 DE Multiple myeloma; Solid tumour/cancer
DMOXDIY ID DMOXDIY
DMOXDIY DN CB-5339
DMOXDIY HS Phase 1
DMOXDIY CP Cleave Therapeutics
DMOXDIY DT Small molecular drug
DMOXDIY DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMXQGKL ID DMXQGKL
DMXQGKL DN CB-813
DMXQGKL HS Phase 1
DMXQGKL SN CB-813d; Recombinant human factor VIIa (Alterase, hemophilia), Catalyst Biosciences; RhFVIIa (Alterase, hemophilia), Catalyst Biosciences; Recombinant human factor VIIa (Alterase, hemophilia), Catalyst Biosciences/Wyeth Pharmaceuticals
DMXQGKL CP Catalyst biosciences; pfizer
DMXQGKL DT Small molecular drug
DMXQGKL PC 208688
DMXQGKL MW 349.9
DMXQGKL FM C20H28ClNO2
DMXQGKL IC InChI=1S/C20H28ClNO2/c21-19-15-16(9-10-18(19)17-6-2-1-3-7-17)5-4-8-20(23)22-11-13-24-14-12-22/h9-10,15,17H,1-8,11-14H2
DMXQGKL CS C1CCC(CC1)C2=C(C=C(C=C2)CCCC(=O)N3CCOCC3)Cl
DMXQGKL IK GCECPNQPPJYYOR-UHFFFAOYSA-N
DMXQGKL IU 4-(3-chloro-4-cyclohexylphenyl)-1-morpholin-4-ylbutan-1-one
DMXQGKL CA CAS 32808-74-5
DMXQGKL DE Hemophilia
DMORN60 ID DMORN60
DMORN60 DN CBL0137
DMORN60 HS Phase 1
DMORN60 CP Cleveland biolabs
DMORN60 PC 44519124
DMORN60 MW 336.4
DMORN60 FM C21H24N2O2
DMORN60 IC InChI=1S/C21H24N2O2/c1-13(2)22-9-10-23-20-7-5-16(14(3)24)11-18(20)19-12-17(15(4)25)6-8-21(19)23/h5-8,11-13,22H,9-10H2,1-4H3
DMORN60 CS CC(C)NCCN1C2=C(C=C(C=C2)C(=O)C)C3=C1C=CC(=C3)C(=O)C
DMORN60 IK JKCSODVERGVDLT-UHFFFAOYSA-N
DMORN60 IU 1-[6-acetyl-9-[2-(propan-2-ylamino)ethyl]carbazol-3-yl]ethanone
DMORN60 CA CAS 1197996-80-7
DMORN60 CB CHEBI:138650
DMORN60 DE Advanced solid tumour
DMOTLN4 ID DMOTLN4
DMOTLN4 DN CBT-101
DMOTLN4 HS Phase 1
DMOTLN4 SN L-Asparaginyl-L-leucyl-glycyl-L-valyl-L-[S-(acetamidomethyl)]cysteinamide hydrochloride
DMOTLN4 DE Glaucoma/ocular hypertension; Solid tumour/cancer
DMW1OKT ID DMW1OKT
DMW1OKT DN CBT-501
DMW1OKT HS Phase 1
DMW1OKT CP CBT Pharmaceuticals Santa Clara, CA
DMW1OKT DE Solid tumour/cancer
DM0SRAN ID DM0SRAN
DM0SRAN DN CC-122
DM0SRAN HS Phase 1
DM0SRAN SN cc-122; 1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
DM0SRAN CP Celgene
DM0SRAN DT Small molecular drug
DM0SRAN PC 24967599
DM0SRAN MW 286.29
DM0SRAN FM C14H14N4O3
DM0SRAN IC InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
DM0SRAN CS CC1=NC2=CC=CC(=C2C(=O)N1C3CCC(=O)NC3=O)N
DM0SRAN IK RSNPAKAFCAAMBH-UHFFFAOYSA-N
DM0SRAN IU 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione
DM0SRAN CA CAS 1015474-32-4
DM0SRAN DE Solid tumour/cancer; Recurrent glioblastoma; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Hepatocellular carcinoma; Lymphoma; Multiple myeloma
DMAYHT4 ID DMAYHT4
DMAYHT4 DN CC-31244
DMAYHT4 HS Phase 1
DMAYHT4 CP Cocrystal Pharma
DMAYHT4 DT Small molecular drug
DMAYHT4 DE Hepatitis C virus infection
DMILHMC ID DMILHMC
DMILHMC DN CC8464
DMILHMC HS Phase 1
DMILHMC SN ASP1807
DMILHMC CP Astellas Northbrook, IL Chromocell North Brunswick, NJ
DMILHMC DE Neuropathic pain; Pain
DMXUT3Z ID DMXUT3Z
DMXUT3Z DN CC-8490
DMXUT3Z HS Phase 1
DMXUT3Z CP Celgene
DMXUT3Z DE Brain cancer
DMK0QDO ID DMK0QDO
DMK0QDO DN CC-90002
DMK0QDO HS Phase 1
DMK0QDO DT Antibody
DMK0QDO DE Acute myeloid leukaemia; Myelodysplastic syndrome; Non-hodgkin lymphoma; Solid tumour/cancer; leukaemia
DMHJLB6 ID DMHJLB6
DMHJLB6 DN CC-90006
DMHJLB6 HS Phase 1
DMHJLB6 CP AnaptysBio San Diego, CA Celgene Summit, NJ
DMHJLB6 DT Antibody
DMHJLB6 DE Psoriasis vulgaris
DMKH3Z9 ID DMKH3Z9
DMKH3Z9 DN CC-90010
DMKH3Z9 HS Phase 1
DMKH3Z9 CP CelgeneSummit, NJ
DMKH3Z9 DE Non-hodgkin lymphoma; Solid tumour/cancer
DMO0AJE ID DMO0AJE
DMO0AJE DN CC-90010
DMO0AJE HS Phase 1
DMO0AJE SN UNII-K424WH3WU0; K424WH3WU0; 1706738-98-8; Trotabresib; Trotabresib [USAN]; SCHEMBL16650974; BDBM285044; EX-A4706; US10023592, Example 89; QC5487; WHO 11839; Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O; 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one; 1(2H)-Isoquinolinone, 4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl)-2-methyl-; 4-(2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl)-2-methylisoquinolin-1(2H)-one; 4-[2-(cyclopropylmethoxy)- 5-methylsulfonylphenyl]-2- methylisoquinolin-1-one
DMO0AJE CP Bristol-Myers Squibb
DMO0AJE DT Small molecular drug
DMO0AJE PC 118021883
DMO0AJE MW 383.5
DMO0AJE FM C21H21NO4S
DMO0AJE IC InChI=1S/C21H21NO4S/c1-22-12-19(16-5-3-4-6-17(16)21(22)23)18-11-15(27(2,24)25)9-10-20(18)26-13-14-7-8-14/h3-6,9-12,14H,7-8,13H2,1-2H3
DMO0AJE CS CN1C=C(C2=CC=CC=C2C1=O)C3=C(C=CC(=C3)S(=O)(=O)C)OCC4CC4
DMO0AJE IK UWZAJPITKGWMFJ-UHFFFAOYSA-N
DMO0AJE IU 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one
DMO0AJE CA CAS 1706738-98-8
DMO0AJE DE Glioblastoma of brain; Astrocytoma
DM1GV6O ID DM1GV6O
DM1GV6O DN CC-90011
DM1GV6O HS Phase 1
DM1GV6O CP CelgeneSummit, NJ
DM1GV6O DE Non-hodgkin lymphoma; Solid tumour/cancer
DM1M4B8 ID DM1M4B8
DM1M4B8 DN CC-93269
DM1M4B8 HS Phase 1
DM1M4B8 SN BCMA TCE
DM1M4B8 CP Bristol-Myers Squibb
DM1M4B8 DT Antibody
DM1M4B8 DE Multiple myeloma
DM4581B ID DM4581B
DM4581B DN CC-94676
DM4581B HS Phase 1
DM4581B CP Bristol-Myers Squibb
DM4581B DE Prostate cancer; Invasive prostate cancer
DM7E1W0 ID DM7E1W0
DM7E1W0 DN CC-95251
DM7E1W0 HS Phase 1
DM7E1W0 CP Bristol-Myers Squibb
DM7E1W0 DT Antibody
DM7E1W0 DE Solid tumour/cancer
DMJCIGN ID DMJCIGN
DMJCIGN DN CC-95775
DMJCIGN HS Phase 1
DMJCIGN CP Bristol-Myers Squibb
DMJCIGN DT Small molecular drug
DMJCIGN DE Non-hodgkin lymphoma
DMLONJG ID DMLONJG
DMLONJG DN CC-97540
DMLONJG HS Phase 1
DMLONJG CP Bristol-Myers Squibb
DMLONJG DT CAR T Cell Therapy
DMLONJG DE Non-hodgkin lymphoma
DM69YM1 ID DM69YM1
DM69YM1 DN CC-98633
DM69YM1 HS Phase 1
DM69YM1 CP Bristol-Myers Squibb
DM69YM1 DT CAR T Cell Therapy
DM69YM1 DE Multiple myeloma
DM1UEBR ID DM1UEBR
DM1UEBR DN CC-99712
DM1UEBR HS Phase 1
DM1UEBR CP Bristol-Myers Squibb
DM1UEBR DT Antibody drug conjugate
DM1UEBR DE Multiple myeloma
DM86CZJ ID DM86CZJ
DM86CZJ DN C-CAR011
DM86CZJ HS Phase 1
DM86CZJ CP Cellular Biomedicine Group Ltd.
DM86CZJ DT CAR T Cell Therapy
DM86CZJ DE Non-hodgkin lymphoma
DMT35N2 ID DMT35N2
DMT35N2 DN C-CAR088
DMT35N2 HS Phase 1
DMT35N2 CP Hebei Yanda Ludaopei Hospital
DMT35N2 DT CAR T Cell Therapy
DMT35N2 DE Multiple myeloma
DMCFMHR ID DMCFMHR
DMCFMHR DN CCR5 mab
DMCFMHR HS Phase 1
DMCFMHR CP Progenics Pharmaceuticals
DMCFMHR DT Antibody
DMCFMHR DE Human immunodeficiency virus infection
DMPTYE6 ID DMPTYE6
DMPTYE6 DN CCW702
DMPTYE6 HS Phase 1
DMPTYE6 CP AbbVie
DMPTYE6 DT Antibody
DMPTYE6 DE Prostate cancer
DMCWVS7 ID DMCWVS7
DMCWVS7 DN CCX-025
DMCWVS7 HS Phase 1
DMCWVS7 SN CCX-807; CCR9 chemokine receptor-targeting therapeutic (gastrointestinal diseases), ChemoCentryx
DMCWVS7 CP ChemoCentryx Inc
DMCWVS7 DE Crohn disease
DMO7TES ID DMO7TES
DMO7TES DN CCX507
DMO7TES HS Phase 1
DMO7TES CP ChemoCentryxMountain View, CA
DMO7TES DE Ulcerative colitis
DM0XDYT ID DM0XDYT
DM0XDYT DN CD10-CART
DM0XDYT HS Phase 1
DM0XDYT CP Zhujiang Hospital
DM0XDYT DT CAR T Cell Therapy (Dual specific)
DM0XDYT DE leukaemia
DMDFY1R ID DMDFY1R
DMDFY1R DN CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
DMDFY1R HS Phase 1
DMDFY1R CP Affiliated Hospital to Academy of Military Medical Sciences
DMDFY1R DT CAR T Cell Therapy
DMDFY1R DE Acute myeloid leukaemia
DMUJF9T ID DMUJF9T
DMUJF9T DN CD123-CD33 Ccar
DMUJF9T HS Phase 1
DMUJF9T CP iCell Gene Therapeutics
DMUJF9T DT CAR T Cell Therapy
DMUJF9T DE Acute myeloid leukaemia; Myelodysplastic syndrome
DM2AHXW ID DM2AHXW
DM2AHXW DN CD171 specific CAR T cells expressing EGFRt
DM2AHXW HS Phase 1
DM2AHXW CP Seattle Children's Hospital
DM2AHXW DT CAR T Cell Therapy
DM2AHXW DE Ganglioneuroblastoma; Neuroblastoma
DM4PWNU ID DM4PWNU
DM4PWNU DN CD19 CAR T
DM4PWNU HS Phase 1
DM4PWNU CP Shanghai Tong Ren Hospital
DM4PWNU DT CAR T Cell Therapy
DM4PWNU DE Acute lymphoblastic leukaemia; B-cell lymphoma
DMB8RI6 ID DMB8RI6
DMB8RI6 DN CD19 CAR T cells
DMB8RI6 HS Phase 1
DMB8RI6 CP Institute of Hematology & Blood Diseases Hospital
DMB8RI6 DT CAR T Cell Therapy
DMB8RI6 DE Acute lymphoblastic leukaemia; B-cell non-hodgkin lymphoma
DMCUBFR ID DMCUBFR
DMCUBFR DN CD19 CAR T Cells
DMCUBFR HS Phase 1
DMCUBFR CP Baylor College of Medicine
DMCUBFR DT CAR T Cell Therapy
DMCUBFR DE Acute lymphocytic leukaemia; Chronic lymphocytic leukaemia; Non-hodgkin lymphoma
DMJCT6Q ID DMJCT6Q
DMJCT6Q DN CD19 CAR T-cells
DMJCT6Q HS Phase 1
DMJCT6Q CP University College, London
DMJCT6Q DT CAR T Cell Therapy
DMJCT6Q DE Acute lymphoblastic leukaemia; Recurrent adult burkitt lymphoma
DMYFWQT ID DMYFWQT
DMYFWQT DN CD19 CAR T-cells
DMYFWQT HS Phase 1
DMYFWQT CP Third Military Medical University
DMYFWQT DT CAR T Cell Therapy
DMYFWQT DE Non-hodgkin lymphoma
DM6GNDP ID DM6GNDP
DM6GNDP DN CD19 CAR-T cells
DM6GNDP HS Phase 1
DM6GNDP CP Tianjin Mycure Medical Technology Co., Ltd
DM6GNDP DT CAR T Cell Therapy
DM6GNDP DE Acute lymphoblastic leukaemia
DMNDACU ID DMNDACU
DMNDACU DN CD19 CAR-T cells
DMNDACU HS Phase 1
DMNDACU CP Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
DMNDACU DT CAR T Cell Therapy
DMNDACU DE Acute lymphoblastic leukaemia
DM49RAT ID DM49RAT
DM49RAT DN CD19 Redirected Autologous T Cells
DM49RAT HS Phase 1
DM49RAT CP Shanghai GeneChem Co., Ltd.
DM49RAT DT CAR T Cell Therapy
DM49RAT DE Systemic lupus erythematosus
DMMO2EJ ID DMMO2EJ
DMMO2EJ DN CD19.CAR-aNKT cells
DMMO2EJ HS Phase 1
DMMO2EJ CP Baylor College of Medicine
DMMO2EJ DT CAR T Cell Therapy
DMMO2EJ DE B-cell small lymphocytic lymphoma; Chronic lymphocytic leukaemia; Myeloid leukaemia; Non-hodgkin lymphoma
DMVONF0 ID DMVONF0
DMVONF0 DN CD19/CD22 CAR T cells
DMVONF0 HS Phase 1
DMVONF0 CP Crystal Mackall, MD
DMVONF0 DT CAR T Cell Therapy (Dual specific)
DMVONF0 DE Acute lymphoblastic leukaemia
DMKA2FL ID DMKA2FL
DMKA2FL DN CD19/CD22 CAR T-Cells
DMKA2FL HS Phase 1
DMKA2FL CP National Cancer Institute (NCI)
DMKA2FL DT CAR T Cell Therapy (Dual specific)
DMKA2FL DE Acute lymphocytic leukaemia; B-cell lymphoma; B-cell prolymphocytic leukaemia; leukaemia; Non-hodgkin lymphoma
DMPADR1 ID DMPADR1
DMPADR1 DN CD19/CD22 Chimeric Antigen Receptor T Cells
DMPADR1 HS Phase 1
DMPADR1 CP Crystal Mackall, MD
DMPADR1 DT CAR T Cell Therapy (Dual specific)
DMPADR1 DE Acute lymphoblastic leukaemia; B-cell lymphoma; Mediastinal large B-cell lymphoma
DMGUQ8V ID DMGUQ8V
DMGUQ8V DN CD19+ CAR T Cells
DMGUQ8V HS Phase 1
DMGUQ8V CP M.D. Anderson Cancer Center
DMGUQ8V DT CAR T Cell Therapy
DMGUQ8V DE leukaemia; Lymphoma
DMUR1MN ID DMUR1MN
DMUR1MN DN CD19-CAR and CD28-CAR T Cells
DMUR1MN HS Phase 1
DMUR1MN CP City of Hope Medical Center
DMUR1MN DT CAR T Cell Therapy (Dual specific)
DMUR1MN DE Acute lymphoblastic leukaemia
DMJIW5Z ID DMJIW5Z
DMJIW5Z DN CD19-CAR-T Cells
DMJIW5Z HS Phase 1
DMJIW5Z CP Bioceltech Therapeutics, Ltd.
DMJIW5Z DT CAR T Cell Therapy
DMJIW5Z DE Acute lymphoblastic leukaemia
DML07UZ ID DML07UZ
DML07UZ DN CD19-CAR-T2 Cells
DML07UZ HS Phase 1
DML07UZ CP Guangdong General Hospital
DML07UZ DT CAR T Cell Therapy
DML07UZ DE Acute lymphoblastic leukaemia
DM3LRAF ID DM3LRAF
DM3LRAF DN CD19CAT-41BBZ CAR T-cells
DM3LRAF HS Phase 1
DM3LRAF CP University College, London
DM3LRAF DT CAR T Cell Therapy
DM3LRAF DE Acute lymphoblastic leukaemia
DM2OEQ9 ID DM2OEQ9
DM2OEQ9 DN CD19-directed CAR-T cells
DM2OEQ9 HS Phase 1
DM2OEQ9 CP Peking Union Medical College Hospital
DM2OEQ9 DT CAR T Cell Therapy
DM2OEQ9 DE Non-hodgkin lymphoma
DMETGAQ ID DMETGAQ
DMETGAQ DN CD19-directed CAR-T cells
DMETGAQ HS Phase 1
DMETGAQ CP Chinese PLA General Hospital
DMETGAQ DT CAR T Cell Therapy
DMETGAQ DE leukaemia
DMCZ3A2 ID DMCZ3A2
DMCZ3A2 DN CD19-targeted CART cells
DMCZ3A2 HS Phase 1
DMCZ3A2 CP jiuwei cui
DMCZ3A2 DT CAR T Cell Therapy
DMCZ3A2 DE leukaemia
DMT7YOU ID DMT7YOU
DMT7YOU DN CD19t-haNK
DMT7YOU HS Phase 1
DMT7YOU CP NantKwest
DMT7YOU DT CAR-NK Cell therapy
DMT7YOU DE Diffuse large B-cell lymphoma
DMOHACZ ID DMOHACZ
DMOHACZ DN CD19-TriCAR-T
DMOHACZ HS Phase 1
DMOHACZ CP Timmune Biotech Inc.
DMOHACZ DT CAR T Cell Therapy
DMOHACZ DE Non-hodgkin lymphoma
DMGXS8L ID DMGXS8L
DMGXS8L DN CD20Bi aATC
DMGXS8L HS Phase 1
DMGXS8L SN CD20Bi activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; CD20Bi-armed ATC (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute; Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma); Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos Cancer Institute
DMGXS8L CP Barbara Ann Karmanos Cancer Institute
DMGXS8L DE Non-hodgkin lymphoma
DMSJBUZ ID DMSJBUZ
DMSJBUZ DN CD20-CART
DMSJBUZ HS Phase 1
DMSJBUZ CP Zhujiang Hospital
DMSJBUZ DT CAR T Cell Therapy (Dual specific)
DMSJBUZ DE leukaemia
DM37OJN ID DM37OJN
DM37OJN DN CD20-CAR-T Cells
DM37OJN HS Phase 1
DM37OJN CP Xin Wang
DM37OJN DT CAR T Cell Therapy
DM37OJN DE B-cell lymphoma
DMUYTW3 ID DMUYTW3
DMUYTW3 DN CD20-CD19 cCAR
DMUYTW3 HS Phase 1
DMUYTW3 CP iCell Gene Therapeutics
DMUYTW3 DT CAR T Cell Therapy
DMUYTW3 DE B-cell lymphoma
DMHMPK1 ID DMHMPK1
DMHMPK1 DN CD22-CART
DMHMPK1 HS Phase 1
DMHMPK1 CP Zhujiang Hospital
DMHMPK1 DT CAR T Cell Therapy (Dual specific)
DMHMPK1 DE leukaemia
DMP5V83 ID DMP5V83
DMP5V83 DN CD22-specific CAR T-cells also expressing an EGFRt
DMP5V83 HS Phase 1
DMP5V83 CP Seattle Children's Hospital
DMP5V83 DT CAR T Cell Therapy
DMP5V83 DE leukaemia
DMFGQXB ID DMFGQXB
DMFGQXB DN CD28 and CD137 CAR-T Cells
DMFGQXB HS Phase 1
DMFGQXB CP Affiliated Hospital to Academy of Military Medical Sciences
DMFGQXB DT CAR T Cell Therapy (Dual specific)
DMFGQXB DE Acute lymphoblastic leukaemia
DM4VCJA ID DM4VCJA
DM4VCJA DN CD30 CAR T Cells
DM4VCJA HS Phase 1
DM4VCJA CP Baylor College of Medicine
DM4VCJA DT CAR T Cell Therapy
DM4VCJA DE Non-hodgkin lymphoma; Hodgkin lymphoma
DMYD31U ID DMYD31U
DMYD31U DN CD33-CAR-T Cell
DMYD31U HS Phase 1
DMYD31U CP M.D. Anderson Cancer Center
DMYD31U DT CAR T Cell Therapy
DMYD31U DE Haematopoietic/lymphoid cancer; Acute myeloid leukaemia
DMNX0V7 ID DMNX0V7
DMNX0V7 DN CD38 CAR-T
DMNX0V7 HS Phase 1
DMNX0V7 CP Celularity; Sorrento Therapeutics
DMNX0V7 DT CAR T Cell Therapy
DMNX0V7 DE Multiple myeloma
DM09SW6 ID DM09SW6
DM09SW6 DN CD4CAR
DM09SW6 HS Phase 1
DM09SW6 CP iCell Gene Therapeutics
DM09SW6 DT CAR T Cell Therapy
DM09SW6 DE T-cell leukaemia
DMHTNLJ ID DMHTNLJ
DMHTNLJ DN CD7.CAR/28zeta CAR T cells
DMHTNLJ HS Phase 1
DMHTNLJ CP Baylor College of Medicine
DMHTNLJ DT CAR T Cell Therapy
DMHTNLJ DE B-cell acute lymphoblastic leukaemia; Cutaneous T-cell lymphoma; Non-hodgkin lymphoma
DM8DWOL ID DM8DWOL
DM8DWOL DN CDNA vaccine
DM8DWOL HS Phase 1
DM8DWOL SN CDNA vaccine (prostate cancer)
DM8DWOL CP Colby Pharmaceuticals
DM8DWOL DE Prostate cancer
DMN8I5Q ID DMN8I5Q
DMN8I5Q DN CDP-7657
DMN8I5Q HS Phase 1
DMN8I5Q CP Biogen Idec
DMN8I5Q DT Antibody
DMN8I5Q DE Systemic lupus erythematosus
DM049IX ID DM049IX
DM049IX DN CDRI-97/78
DM049IX HS Phase 1
DM049IX SN Antimalarial compound, CDRI/IPCA labs
DM049IX CP Central Drug Research Institute
DM049IX PC 9870599
DM049IX MW 500.6
DM049IX FM C28H36O8
DM049IX IC InChI=1S/C28H36O8/c1-17(24-15-33-28(36-35-24)21-11-18-10-19(13-21)14-22(28)12-18)20-4-6-23(7-5-20)34-27(2,3)16-32-26(31)9-8-25(29)30/h4-7,18-19,21-22,24H,1,8-16H2,2-3H3,(H,29,30)
DM049IX CS CC(C)(COC(=O)CCC(=O)O)OC1=CC=C(C=C1)C(=C)C2COC3(C4CC5CC(C4)CC3C5)OO2
DM049IX IK LKAAAECAYCDCQW-UHFFFAOYSA-N
DM049IX IU 4-[2-methyl-2-[4-(1-spiro[1,2,4-trioxane-3,2'-adamantane]-6-ylethenyl)phenoxy]propoxy]-4-oxobutanoic acid
DM049IX DE Malaria
DMKUXB5 ID DMKUXB5
DMKUXB5 DN CDT-fenofibrate
DMKUXB5 HS Phase 1
DMKUXB5 CP SCOLR Pharma
DMKUXB5 DE Hyperlipidaemia
DMPVUGE ID DMPVUGE
DMPVUGE DN CDX-1127
DMPVUGE HS Phase 1
DMPVUGE CP Celldex Therapeutics
DMPVUGE DE Solid tumour/cancer; leukaemia; Lymphoma
DMS20X6 ID DMS20X6
DMS20X6 DN CDX-1135
DMS20X6 HS Phase 1
DMS20X6 SN SCR1; BRL-55730; Soluble complement receptor type 1, AVANT; Soluble complement receptor type 1, Celldex; YM-203; TP-10, AVANT Immunotherapeutics; TP-10, Celldex
DMS20X6 CP Celldex therapeutics
DMS20X6 DE Macular degeneration
DMUGN0J ID DMUGN0J
DMUGN0J DN CDX-1140
DMUGN0J HS Phase 1
DMUGN0J CP Celldex Therapeutics
DMUGN0J DT Antibody
DMUGN0J DE Solid tumour/cancer; Melanoma
DMVDIWO ID DMVDIWO
DMVDIWO DN CDX-527
DMVDIWO HS Phase 1
DMVDIWO CP Celldex Therapeutics
DMVDIWO DT Antibody
DMVDIWO DE Solid tumour/cancer
DM45BHM ID DM45BHM
DM45BHM DN CEA CAR-T
DM45BHM HS Phase 1
DM45BHM CP Sorrento Therapeutics
DM45BHM DT CAR T Cell Therapy
DM45BHM DE Ascites; Peritoneal metastasis
DMYDTJ6 ID DMYDTJ6
DMYDTJ6 DN CEP-11981
DMYDTJ6 HS Phase 1
DMYDTJ6 SN CEP-11981; UNII-J8AY0Z4CBP; 856691-93-5; J8AY0Z4CBP; CHEMBL2010872; BOL-303213X; compound 11b [PMID 22148921]; GTPL8189; SCHEMBL2439310; DTXSID80234942; CEP11981; BDBM50379186; CEP 11981; 4H-Indazolo(5,4-a)pyrrolo(3,4-C)carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-; Z-3152
DMYDTJ6 CP Cephalon
DMYDTJ6 DT Small molecular drug
DMYDTJ6 PC 11751922
DMYDTJ6 MW 477.6
DMYDTJ6 FM C28H27N7O
DMYDTJ6 IC InChI=1S/C28H27N7O/c1-15(2)13-35-22-8-5-16(32-28-29-9-4-10-30-28)11-18(22)24-19-12-31-27(36)25(19)23-17(26(24)35)6-7-21-20(23)14-34(3)33-21/h4-5,8-11,14-15H,6-7,12-13H2,1-3H3,(H,31,36)(H,29,30,32)
DMYDTJ6 CS CC(C)CN1C2=C(C=C(C=C2)NC3=NC=CC=N3)C4=C1C5=C(C6=CN(N=C6CC5)C)C7=C4CNC7=O
DMYDTJ6 IK AEULIVPVIDOLIN-UHFFFAOYSA-N
DMYDTJ6 IU 19-methyl-3-(2-methylpropyl)-7-(pyrimidin-2-ylamino)-3,13,19,20-tetrazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17,20-octaen-14-one
DMYDTJ6 CA CAS 856691-93-5
DMYDTJ6 DE Solid tumour/cancer
DMYXQBF ID DMYXQBF
DMYXQBF DN CEP-37251
DMYXQBF HS Phase 1
DMYXQBF SN ART-010; EGX-010; OVP (bone loss), Peptech; Osteoprotegerin variant protein (bone loss), Arana; Osteoprotegerin variant protein (bone loss), EvoGenix; Osteoprotegerin variant protein (bone loss), Peptech
DMYXQBF CP EvoGenix Pty Ltd
DMYXQBF DE Bone metastases
DMV632P ID DMV632P
DMV632P DN CEP-37440
DMV632P HS Phase 1
DMV632P SN Dual ALK/FAK inhibitor (cancer), Cephalon; Dual anaplastic lymphoma kinase/focal adhesion kinase inhibitor (cancer),Cephalon
DMV632P CP Teva pharmaceutical
DMV632P DT Small molecular drug
DMV632P PC 71721648
DMV632P MW 580.1
DMV632P FM C30H38ClN7O3
DMV632P IC InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1
DMV632P CS CNC(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C4=C(C[C@H](CCC4)N5CCN(CC5)CCO)C=C3)OC
DMV632P IK BCSHRERPHLTPEE-NRFANRHFSA-N
DMV632P IU 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methylbenzamide
DMV632P CA CAS 1391712-60-9
DMV632P DE Solid tumour/cancer
DMLBKZV ID DMLBKZV
DMLBKZV DN CER-002
DMLBKZV HS Phase 1
DMLBKZV CP Cerenis Therapeutics
DMLBKZV DE Dyslipidemia
DMGAW0H ID DMGAW0H
DMGAW0H DN CER-522
DMGAW0H HS Phase 1
DMGAW0H SN ApoA-I peptide HDL mimetic (aortic valve stenosis), Cerenis/Montreal Heart Institute
DMGAW0H CP Montreal Heart Institute
DMGAW0H DE Aortic valve stenosis
DMH701Q ID DMH701Q
DMH701Q DN CFI-402257
DMH701Q HS Phase 1
DMH701Q SN 1610759-22-2; CHEMBL4442392; CHEMBL4469414; SCHEMBL16729234; SCHEMBL17182976; SCHEMBL17190272; SCHEMBL22046104; SCHEMBL22875551; BCP31204; EX-A2577; BDBM50512456; BDBM50533120; NSC800888; ZINC669678971; CS-6527; NSC-800888; SB19839; AK685452; HY-101340; CFI 402257; CFI402257; J3.619.525H; 1610677-37-6; N-cyclopropyl-4-(7-((((1r,3r)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide; N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
DMH701Q CP Treadwell Therapeutics
DMH701Q DT Small molecular drug
DMH701Q PC 118086034
DMH701Q MW 498.6
DMH701Q FM C28H30N6O3
DMH701Q IC InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35)
DMH701Q CS CC1=C(C=CC(=C1)C2=C3N=C(C=C(N3N=C2)NCC4CC(C4)(C)O)OC5=CN=CC=C5)C(=O)NC6CC6
DMH701Q IK PMQUGSPFUBGJCZ-UHFFFAOYSA-N
DMH701Q IU N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
DMH701Q DE Solid tumour/cancer
DM3U2VY ID DM3U2VY
DM3U2VY DN CG-200745
DM3U2VY HS Phase 1
DM3U2VY SN CG-0006; CG-005; HDAC inhibitors (cancer, oral/intravenous), CrystalGenomics; Histone deacetylase inhibitors (cancer, oral/intravenous), CrystalGenomics
DM3U2VY CP CrystalGenomics Inc
DM3U2VY PC 16117309
DM3U2VY MW 427.5
DM3U2VY FM C24H33N3O4
DM3U2VY IC InChI=1S/C24H33N3O4/c1-27(2)17-9-16-25-24(29)20(11-4-3-5-15-23(28)26-30)18-31-22-14-8-12-19-10-6-7-13-21(19)22/h6-8,10-14,30H,3-5,9,15-18H2,1-2H3,(H,25,29)(H,26,28)/b20-11+
DM3U2VY CS CN(C)CCCNC(=O)/C(=C/CCCCC(=O)NO)/COC1=CC=CC2=CC=CC=C21
DM3U2VY IK AUGCSOFQTDKPSO-RGVLZGJSSA-N
DM3U2VY IU (E)-N-[3-(dimethylamino)propyl]-N'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide
DM3U2VY CA CAS 936221-33-9
DM3U2VY DE Solid tumour/cancer
DMTCLM3 ID DMTCLM3
DMTCLM3 DN CGM097
DMTCLM3 HS Phase 1
DMTCLM3 CP Novartis pharmaceuticals
DMTCLM3 PC 53240420
DMTCLM3 MW 659.3
DMTCLM3 FM C38H47ClN4O4
DMTCLM3 IC InChI=1S/C38H47ClN4O4/c1-25(2)47-35-22-33-28(20-34(35)46-5)21-36(44)43(38(33)27-8-10-29(39)11-9-27)32-16-14-30(15-17-32)41(4)23-26-6-12-31(13-7-26)42-19-18-40(3)37(45)24-42/h8-11,14-17,20,22,25-26,31,38H,6-7,12-13,18-19,21,23-24H2,1-5H3/t26?,31?,38-/m0/s1
DMTCLM3 CS CC(C)OC1=C(C=C2CC(=O)N([C@H](C2=C1)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)N(C)CC5CCC(CC5)N6CCN(C(=O)C6)C)OC
DMTCLM3 IK CLRSLRWKONPSRQ-CPOWQTMSSA-N
DMTCLM3 IU (1S)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one
DMTCLM3 DE Solid tumour/cancer
DMAY8I4 ID DMAY8I4
DMAY8I4 DN CGTG-102
DMAY8I4 HS Phase 1
DMAY8I4 SN Ad5/3-D24-GMCSF; Adenovirus-based gene therapy (breast cancer, injectable formulation), Oncos
DMAY8I4 CP Oncos Therapeutics Ltd
DMAY8I4 DE Solid tumour/cancer
DMSDNU1 ID DMSDNU1
DMSDNU1 DN CHF 5407
DMSDNU1 HS Phase 1
DMSDNU1 CP Chiesi
DMSDNU1 DE Chronic obstructive pulmonary disease
DMTE18G ID DMTE18G
DMTE18G DN CHF-4227
DMTE18G HS Phase 1
DMTE18G SN CHF-3316; CHF-4056; SERMs, Chiesi; Selective estrogen receptor modulators, Chiesi; CHF-3316.01
DMTE18G CP Chiesi Farmaceutici SpA
DMTE18G DT Small molecular drug
DMTE18G PC 9912639
DMTE18G MW 471.6
DMTE18G FM C30H33NO4
DMTE18G IC InChI=1S/C30H33NO4/c1-33-25-12-7-23(8-13-25)29-21-35-30-20-24(32)9-14-27(30)28(29)19-22-5-10-26(11-6-22)34-18-17-31-15-3-2-4-16-31/h5-14,20,32H,2-4,15-19,21H2,1H3
DMTE18G CS COC1=CC=C(C=C1)C2=C(C3=C(C=C(C=C3)O)OC2)CC4=CC=C(C=C4)OCCN5CCCCC5
DMTE18G IK ZUDXUNPSRMREOJ-UHFFFAOYSA-N
DMTE18G IU 3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2H-chromen-7-ol
DMTE18G CA CAS 444643-64-5
DMTE18G DE Osteoporosis
DMSOB5D ID DMSOB5D
DMSOB5D DN Chi Lob 7/4
DMSOB5D HS Phase 1
DMSOB5D SN Anti-CD40 MAb (chimeric, cancer), Cancer Research UK
DMSOB5D CP Cancer Research UK
DMSOB5D DE B-cell lymphoma
DM3L52Q ID DM3L52Q
DM3L52Q DN Chlorcyclizine
DM3L52Q HS Phase 1
DM3L52Q SN 1-(4-Chlorobenzhydryl)-4-methylpiperazine; Alergicide; Chlorcycline; Chlorcyclizine [INN:BAN]; Chlorcyclizinum; Chlorcyclizinum [INN-Latin]; Chlorocycline; Chlorocyclizine; Clorciclizina; Clorciclizina [DCIT]; Clorciclizinio [INN-Spanish]; Compound 47-282; Di-Paralene; Di-paralen; Diparalene; HSDB 3217; Histachlorazene; Histantin; Histantine; N-Methyl-N'-(4-chlorobenzhydryl)piperazine; NSC 25246; Perazyl; Piparalene; Trihistan; chlorcyclizine
DM3L52Q TC Antihistamines
DM3L52Q DT Small molecular drug
DM3L52Q PC 2710
DM3L52Q MW 300.83
DM3L52Q FM C18H21ClN2
DM3L52Q IC InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3
DM3L52Q CS CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DM3L52Q IK WFNAKBGANONZEQ-UHFFFAOYSA-N
DM3L52Q IU 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine
DM3L52Q CA CAS 82-93-9
DM3L52Q CB CHEBI:94402
DM3L52Q DE Hepatitis C virus infection
DMJLZ8T ID DMJLZ8T
DMJLZ8T DN CHT-25
DMJLZ8T HS Phase 1
DMJLZ8T CP University College London
DMJLZ8T DE Hodgkin lymphoma
DM2OB6S ID DM2OB6S
DM2OB6S DN CI-8993
DM2OB6S HS Phase 1
DM2OB6S CP Curis
DM2OB6S DT Antibody
DM2OB6S DE Solid tumour/cancer
DM6SCUK ID DM6SCUK
DM6SCUK DN CI-959
DM6SCUK HS Phase 1
DM6SCUK SN CI-959; UNII-1A8130P4IY; CI 959; CI 159; 104795-68-8; 1A8130P4IY; Benzo(b)thiophene-2-carboxamide, 5-methoxy-3-(1-methylethoxy)-N-1H-tetrazol-5-yl-, monosodium salt; DSSTox_RID_82225; DSSTox_CID_27268; DSSTox_GSID_47268; DTXSID8047268; CHEMBL3183386; Tox21_300435; NCGC00254320-01; LS-41129
DM6SCUK DT Small molecular drug
DM6SCUK PC 13961743
DM6SCUK MW 355.35
DM6SCUK FM C14H14N5NaO3S
DM6SCUK IC InChI=1S/C14H15N5O3S.Na/c1-7(2)22-11-9-6-8(21-3)4-5-10(9)23-12(11)13(20)15-14-16-18-19-17-14;/h4-7H,1-3H3,(H2,15,16,17,18,19,20);/q;+1/p-1
DM6SCUK CS CC(C)OC1=C(SC2=C1C=C(C=C2)OC)C(=O)NC3=NN=N[N-]3.[Na+]
DM6SCUK IK UCLODRCAPZIYOW-UHFFFAOYSA-M
DM6SCUK IU sodium;5-methoxy-3-propan-2-yloxy-N-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)-1-benzothiophene-2-carboxamide
DM6SCUK CA CAS 104795-68-8
DM6SCUK DE Asthma
DM8T2KA ID DM8T2KA
DM8T2KA DN CI-966
DM8T2KA HS Phase 1
DM8T2KA SN 1-[2-[Bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid hydrochloride
DM8T2KA DT Small molecular drug
DM8T2KA PC 198693
DM8T2KA MW 473.4
DM8T2KA FM C23H21F6NO3
DM8T2KA IC InChI=1S/C23H21F6NO3/c24-22(25,26)18-7-3-15(4-8-18)20(16-5-9-19(10-6-16)23(27,28)29)33-13-12-30-11-1-2-17(14-30)21(31)32/h2-10,20H,1,11-14H2,(H,31,32)
DM8T2KA CS C1CN(CC(=C1)C(=O)O)CCOC(C2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F
DM8T2KA IK CMHQDSBIBSKHFP-UHFFFAOYSA-N
DM8T2KA IU 1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
DM8T2KA CA CAS 110283-79-9
DM8T2KA CB CHEBI:93185
DM8T2KA DE Convulsion
DMB2MKU ID DMB2MKU
DMB2MKU DN CIGB-128
DMB2MKU HS Phase 1
DMB2MKU SN HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB
DMB2MKU CP Center for Genetic Engineering and Biotechnology
DMB2MKU DE Basal cell carcinoma
DMJFPK6 ID DMJFPK6
DMJFPK6 DN CIGB-228
DMJFPK6 HS Phase 1
DMJFPK6 SN Therapeutic peptide subunit vaccine (E7 antigen, HPV), CIGB
DMJFPK6 CP Center for Genetic Engineering and Biotechnology
DMJFPK6 DT Vaccine
DMJFPK6 DE Human papillomavirus infection
DM8XM72 ID DM8XM72
DM8XM72 DN CIGB-500
DM8XM72 HS Phase 1
DM8XM72 SN Cytoprotectant (GHRP-6, ischemia-reperfusion damage), CIGB
DM8XM72 CP Center for Genetic Engineering and Biotechnology
DM8XM72 DE Cerebrovascular ischaemia
DMSGRA7 ID DMSGRA7
DMSGRA7 DN CIGB-M3
DMSGRA7 HS Phase 1
DMSGRA7 SN 131I-labeled anti-CEA diabody (cancer), CIGB
DMSGRA7 CP Center for Genetic Engineering and Biotechnology
DMSGRA7 DT Antibody
DMSGRA7 DE Colorectal cancer
DM7EAG8 ID DM7EAG8
DM7EAG8 DN Cilobradine
DM7EAG8 HS Phase 1
DM7EAG8 SN Cilobradine; UNII-5O1LL04GJ3; 5O1LL04GJ3; 147541-45-5; Cilobradine [INN]; DK-AH269; SCHEMBL628133; GTPL2355; CHEMBL1436376; ZINC13829377; NCGC00165786-01
DM7EAG8 CP Boehringer Ingelheim Corp
DM7EAG8 DT Small molecular drug
DM7EAG8 PC 9869877
DM7EAG8 MW 482.6
DM7EAG8 FM C28H38N2O5
DM7EAG8 IC InChI=1S/C28H38N2O5/c1-32-24-8-7-20(14-25(24)33-2)9-12-29-11-5-6-21(18-29)19-30-13-10-22-15-26(34-3)27(35-4)16-23(22)17-28(30)31/h7-8,14-16,21H,5-6,9-13,17-19H2,1-4H3/t21-/m0/s1
DM7EAG8 CS COC1=C(C=C(C=C1)CCN2CCC[C@@H](C2)CN3CCC4=CC(=C(C=C4CC3=O)OC)OC)OC
DM7EAG8 IK OBUFMJDDZTXJPY-NRFANRHFSA-N
DM7EAG8 IU 3-[[(3S)-1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM7EAG8 CA CAS 147541-45-5
DM7EAG8 DE Cardiac arrhythmias
DMJLNEF ID DMJLNEF
DMJLNEF DN Cipatinib
DMJLNEF HS Phase 1
DMJLNEF SN HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui
DMJLNEF CP Jiangsu Hengrui Medicine Co Ltd
DMJLNEF DE Solid tumour/cancer
DMQLODU ID DMQLODU
DMQLODU DN Citarinostat
DMQLODU HS Phase 1
DMQLODU SN ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942
DMQLODU CP Celgene Summit, NJ
DMQLODU PC 53340426
DMQLODU MW 467.9
DMQLODU FM C24H26ClN5O3
DMQLODU IC InChI=1S/C24H26ClN5O3/c25-20-12-7-8-13-21(20)30(19-10-4-3-5-11-19)24-27-16-18(17-28-24)23(32)26-15-9-2-1-6-14-22(31)29-33/h3-5,7-8,10-13,16-17,33H,1-2,6,9,14-15H2,(H,26,32)(H,29,31)
DMQLODU CS C1=CC=C(C=C1)N(C2=CC=CC=C2Cl)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
DMQLODU IK VLIUIBXPEDFJRF-UHFFFAOYSA-N
DMQLODU IU 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
DMQLODU CA CAS 1316215-12-9
DMQLODU DE Multiple myeloma
DMRJF2Q ID DMRJF2Q
DMRJF2Q DN Citatuzumab bogatox
DMRJF2Q HS Phase 1
DMRJF2Q SN VB6-845; Antibody therapeutic (ovary tumor), Viventia; Ovary cancer therapeutic (antibody), Viventia; Anti-EpCAM-bouganin conjugate (anticancer), Viventia
DMRJF2Q CP Viventia Biotech Inc
DMRJF2Q DT Antibody
DMRJF2Q DE Solid tumour/cancer
DMRQX9H ID DMRQX9H
DMRQX9H DN CJ-12255
DMRQX9H HS Phase 1
DMRQX9H PC 22882070
DMRQX9H MW 498.7
DMRQX9H FM C32H38N2O3
DMRQX9H IC InChI=1S/C32H38N2O3/c1-21(2)24-14-15-28(37-3)25(18-24)19-33-30-26-16-17-34(20-27(26)32(35)36)31(30)29(22-10-6-4-7-11-22)23-12-8-5-9-13-23/h4-15,18,21,26-27,29-31,33H,16-17,19-20H2,1-3H3,(H,35,36)/t26-,27-,30-,31-/m0/s1
DMRQX9H CS CC(C)C1=CC(=C(C=C1)OC)CN[C@H]2[C@H]3CCN([C@H]2C(C4=CC=CC=C4)C5=CC=CC=C5)C[C@@H]3C(=O)O
DMRQX9H IK UGYNIDYASJFWTR-FXZOGHEHSA-N
DMRQX9H IU (3R,4S,5S,6S)-6-benzhydryl-5-[(2-methoxy-5-propan-2-ylphenyl)methylamino]-1-azabicyclo[2.2.2]octane-3-carboxylic acid
DMRQX9H CA CAS 146725-78-2
DMRQX9H DE Eczema
DMGSEB0 ID DMGSEB0
DMGSEB0 DN CKD-516
DMGSEB0 HS Phase 1
DMGSEB0 SN S-516; Tubulin polymerization inhibitor (iv, solid cancer), Chong Kun Dang
DMGSEB0 CP Chong Kun Dang Pharmaceutical Corp
DMGSEB0 DT Small molecular drug
DMGSEB0 PC 46929961
DMGSEB0 MW 573.1
DMGSEB0 FM C26H29ClN6O5S
DMGSEB0 IC InChI=1S/C26H28N6O5S.ClH/c1-14(2)22(27)25(34)31-26-30-18(11-38-26)15-6-7-17(19(8-15)32-13-28-12-29-32)23(33)16-9-20(35-3)24(37-5)21(10-16)36-4;/h6-14,22H,27H2,1-5H3,(H,30,31,34);1H/t22-;/m0./s1
DMGSEB0 CS CC(C)[C@@H](C(=O)NC1=NC(=CS1)C2=CC(=C(C=C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)N4C=NC=N4)N.Cl
DMGSEB0 IK FIAUXCMEQTWLQZ-FTBISJDPSA-N
DMGSEB0 IU (2S)-2-amino-3-methyl-N-[4-[3-(1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol-2-yl]butanamide;hydrochloride
DMGSEB0 CA CAS 1240321-53-2
DMGSEB0 DE Solid tumour/cancer
DMJX6SM ID DMJX6SM
DMJX6SM DN CKD-712
DMJX6SM HS Phase 1
DMJX6SM CP Chong Kun Dang Pharmaceutical Corp
DMJX6SM DE Solid tumour/cancer
DM4UAPD ID DM4UAPD
DM4UAPD DN Clemizole
DM4UAPD HS Phase 1
DM4UAPD SN Clemizole; 442-52-4; Histacur; Clemizol; Histakool; Lergopenin; Clemizolum; Depocural; 1-(p-Chlorobenzyl)-2-pyrrolidylmethylenebenzimidazole; 1-(4-Chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzo[d]imidazole; NSC 46261; UNII-T97CB3796L; CHEBI:52140; CJXAEXPPLWQRFR-UHFFFAOYSA-N; T97CB3796L; 1-[(4-chlorophenyl)methyl]-2-(pyrrolidin-1-ylmethyl)benzimidazole; 1H-Benzimidazole, 1-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-; 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole
DM4UAPD CP Eiger BioPharmaceuticals
DM4UAPD DT Small molecular drug
DM4UAPD PC 2782
DM4UAPD MW 325.8
DM4UAPD FM C19H20ClN3
DM4UAPD IC InChI=1S/C19H20ClN3/c20-16-9-7-15(8-10-16)13-23-18-6-2-1-5-17(18)21-19(23)14-22-11-3-4-12-22/h1-2,5-10H,3-4,11-14H2
DM4UAPD CS C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl
DM4UAPD IK CJXAEXPPLWQRFR-UHFFFAOYSA-N
DM4UAPD IU 1-[(4-chlorophenyl)methyl]-2-(pyrrolidin-1-ylmethyl)benzimidazole
DM4UAPD CA CAS 442-52-4
DM4UAPD CB CHEBI:52140
DM4UAPD DE Hepatitis C virus infection
DM5EM04 ID DM5EM04
DM5EM04 DN CLL1-CD33 cCART cell therapy
DM5EM04 HS Phase 1
DM5EM04 CP iCell Gene Therapeutics
DM5EM04 DT CAR T Cell Therapy
DM5EM04 DE Acute myeloid leukaemia
DM05R4C ID DM05R4C
DM05R4C DN CLN-081
DM05R4C HS Phase 1
DM05R4C CP Cullinan Oncology; Taiho Pharmaceutical
DM05R4C DT Small molecular drug
DM05R4C DE Non-small-cell lung cancer
DM2QBMI ID DM2QBMI
DM2QBMI DN CLP-1004
DM2QBMI HS Phase 1
DM2QBMI CP Sorbent therapeutics
DM2QBMI DE Hypertension
DM674MP ID DM674MP
DM674MP DN CLT030
DM674MP HS Phase 1
DM674MP CP Cellerant Therapeutics
DM674MP DT Antibody drug conjugate
DM674MP DE Acute myeloid leukaemia
DMJQG25 ID DMJQG25
DMJQG25 DN CLX-0921
DMJQG25 HS Phase 1
DMJQG25 SN CLX-090502; CLX-090503; CLX-090717; CLX-092402
DMJQG25 CP Calyx Therapeutics Inc; Calyx Therapeutics
DMJQG25 PC 9958278
DMJQG25 MW 519.6
DMJQG25 FM C28H25NO7S
DMJQG25 IC InChI=1S/C28H25NO7S/c1-33-22-12-18(13-23(16-22)34-2)14-24(27(31)35-3)19-6-10-21(11-7-19)36-20-8-4-17(5-9-20)15-25-26(30)29-28(32)37-25/h4-14,16,25H,15H2,1-3H3,(H,29,30,32)/b24-14+
DMJQG25 CS COC1=CC(=CC(=C1)/C=C(\\C2=CC=C(C=C2)OC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)/C(=O)OC)OC
DMJQG25 IK IVAQJHSXBVHUQT-ZVHZXABRSA-N
DMJQG25 IU methyl (E)-3-(3,5-dimethoxyphenyl)-2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]prop-2-enoate
DMJQG25 CA CAS 606932-81-4
DMJQG25 DE Type-2 diabetes
DMMC6YR ID DMMC6YR
DMMC6YR DN CM2489
DMMC6YR HS Phase 1
DMMC6YR CP CalciMedica
DMMC6YR DE Psoriasis vulgaris
DMSJVX3 ID DMSJVX3
DMSJVX3 DN CM3.1-AC100
DMSJVX3 HS Phase 1
DMSJVX3 SN CM-3, CellMed/AstraZeneca; GLP-1 analog (diabetes), CellMed/AstraZeneca
DMSJVX3 CP CellMed AG
DMSJVX3 DE Diabetic complication
DMY5V4U ID DMY5V4U
DMY5V4U DN CM-CS1 T-cell
DMY5V4U HS Phase 1
DMY5V4U CP Celyad (formerly named Cardio3 BioSciences)
DMY5V4U DT CAR T Cell Therapy
DMY5V4U DE Multiple myeloma; Myelodysplastic syndrome; Acute myeloid leukaemia
DMHBNKP ID DMHBNKP
DMHBNKP DN C-Met/PD-L1 CAR-T Cell
DMHBNKP HS Phase 1
DMHBNKP CP The Second Hospital of Nanjing Medical University
DMHBNKP DT CAR T Cell Therapy (Dual specific)
DMHBNKP DE Hepatocellular carcinoma
DMGMI8P ID DMGMI8P
DMGMI8P DN CMP-001
DMGMI8P HS Phase 1
DMGMI8P SN vidutolimod
DMGMI8P CP Checkmate Pharmaceuticals
DMGMI8P DE Melanoma; Non-small-cell lung cancer
DM6NG3C ID DM6NG3C
DM6NG3C DN CMV glycoprotein B subunit vaccine
DM6NG3C HS Phase 1
DM6NG3C SN CMV gB subunit vaccine, GlaxoSmithKline; CMV glycoprotein B subunit vaccine, GlaxoSmithKline; Cytomegalovirus glycoprotein B subunit vaccine, GlaxoSmithKline; GSK-1492903-A
DM6NG3C CP Glaxosmithkline
DM6NG3C DT Vaccine
DM6NG3C DE Cytomegalovirus infection
DMMF0J3 ID DMMF0J3
DMMF0J3 DN CMX-157
DMMF0J3 HS Phase 1
DMMF0J3 SN Hexadecyloxypropyl tenofovir
DMMF0J3 CP Chimerix
DMMF0J3 DT Small molecular drug
DMMF0J3 PC 23628250
DMMF0J3 MW 569.7
DMMF0J3 FM C28H52N5O5P
DMMF0J3 IC InChI=1S/C28H52N5O5P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-36-19-17-20-38-39(34,35)24-37-25(2)21-33-23-32-26-27(29)30-22-31-28(26)33/h22-23,25H,3-21,24H2,1-2H3,(H,34,35)(H2,29,30,31)/t25-/m1/s1
DMMF0J3 CS CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@H](C)CN1C=NC2=C(N=CN=C21)N)O
DMMF0J3 IK SCTJKHUUZLXJIP-RUZDIDTESA-N
DMMF0J3 IU [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
DMMF0J3 CA CAS 911208-73-6
DMMF0J3 DE Human immunodeficiency virus infection
DM8L36X ID DM8L36X
DM8L36X DN CNTO-3649
DM8L36X HS Phase 1
DM8L36X CP Centocor Ortho Biotech Inc
DM8L36X DE Type-2 diabetes
DMF8WAT ID DMF8WAT
DMF8WAT DN CNTO-5825
DMF8WAT HS Phase 1
DMF8WAT CP Janssen Biotech
DMF8WAT DT Antibody
DMF8WAT DE Allergic asthma
DMUBP0V ID DMUBP0V
DMUBP0V DN CNTO888
DMUBP0V HS Phase 1
DMUBP0V DT Antibody
DMUBP0V DE Solid tumour/cancer
DMJPEVA ID DMJPEVA
DMJPEVA DN CNTX-0290
DMJPEVA HS Phase 1
DMJPEVA CP Centrexion Therapeutics Boston, MA
DMJPEVA DE Chronic pain
DMCOJM7 ID DMCOJM7
DMCOJM7 DN CNTX-6970
DMCOJM7 HS Phase 1
DMCOJM7 CP Centrexion Therapeutics Boston, MA
DMCOJM7 DE Inflammatory pain
DMMEFO0 ID DMMEFO0
DMMEFO0 DN COH29
DMMEFO0 HS Phase 1
DMMEFO0 SN Coh-29; COH-29; UNII-07802BU06S; 07802BU06S; 1190932-38-7; Rnr inhibitor COH29; SCHEMBL10036527; MolPort-044-567-552; AKOS032944935; CS-6153; HY-19931; N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide; Benzamide, N-(4-(3,4-dihydroxyphenyl)-5-phenyl-2-thiazolyl)-3,4-dihydroxy-
DMMEFO0 CP Novonco Therapeutics Los Angeles, CA
DMMEFO0 PC 44253415
DMMEFO0 MW 420.4
DMMEFO0 FM C22H16N2O5S
DMMEFO0 IC InChI=1S/C22H16N2O5S/c25-15-8-6-13(10-17(15)27)19-20(12-4-2-1-3-5-12)30-22(23-19)24-21(29)14-7-9-16(26)18(28)11-14/h1-11,25-28H,(H,23,24,29)
DMMEFO0 CS C1=CC=C(C=C1)C2=C(N=C(S2)NC(=O)C3=CC(=C(C=C3)O)O)C4=CC(=C(C=C4)O)O
DMMEFO0 IK LGGDLPSXAGQFSG-UHFFFAOYSA-N
DMMEFO0 IU N-[4-(3,4-dihydroxyphenyl)-5-phenyl-1,3-thiazol-2-yl]-3,4-dihydroxybenzamide
DMMEFO0 CA CAS 1190932-38-7
DMMEFO0 DE Solid tumour/cancer
DMXQOHV ID DMXQOHV
DMXQOHV DN COM701
DMXQOHV HS Phase 1
DMXQOHV CP Compugen
DMXQOHV DT Antibody
DMXQOHV DE Solid tumour/cancer
DMR6T8L ID DMR6T8L
DMR6T8L DN COM902
DMR6T8L HS Phase 1
DMR6T8L CP Compugen
DMR6T8L DT Antibody
DMR6T8L DE Solid tumour/cancer
DMTLP1N ID DMTLP1N
DMTLP1N DN Combinectin
DMTLP1N HS Phase 1
DMTLP1N SN GSK3732394
DMTLP1N CP ViiV Healthcare
DMTLP1N DE Human immunodeficiency virus infection
DMA7PWX ID DMA7PWX
DMA7PWX DN Combotox
DMA7PWX HS Phase 1
DMA7PWX SN IMTOX 22; Anti CD22/N97A; Anti CD22/ricin; Anti CD19 + anti CD22/N97A; Ricin-conjugated anti-CD22 and anti-CD19; IgG-RFB4-dgA and IgG-HD37-dgA
DMA7PWX CP University of Texas Southwestern Medical Center
DMA7PWX DE leukaemia
DMULBZM ID DMULBZM
DMULBZM DN Cosibelimab
DMULBZM HS Phase 1
DMULBZM SN CK-301/TG-1501
DMULBZM CP Checkpoint Therapeutics
DMULBZM DT Antibody
DMULBZM DE Non-small cell lung cancer
DM6K3JQ ID DM6K3JQ
DM6K3JQ DN COTI-2
DM6K3JQ HS Phase 1
DM6K3JQ SN Coti-2; UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
DM6K3JQ CP Cotinga Pharmaceuticals London, Canada
DM6K3JQ PC 91810660
DM6K3JQ MW 366.5
DM6K3JQ FM C19H22N6S
DM6K3JQ IC InChI=1S/C19H22N6S/c26-19(23-22-16-7-3-5-15-6-4-10-21-18(15)16)25-13-11-24(12-14-25)17-8-1-2-9-20-17/h1-2,4,6,8-10H,3,5,7,11-14H2,(H,23,26)/b22-16+
DM6K3JQ CS C1CC2=C(/C(=N/NC(=S)N3CCN(CC3)C4=CC=CC=N4)/C1)N=CC=C2
DM6K3JQ IK UTDAKQMBNSHJJB-CJLVFECKSA-N
DM6K3JQ IU N-[(E)-6,7-dihydro-5H-quinolin-8-ylideneamino]-4-pyridin-2-ylpiperazine-1-carbothioamide
DM6K3JQ CA CAS 1039455-84-9
DM6K3JQ DE Cervical cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cavity cancer
DM32TFO ID DM32TFO
DM32TFO DN CP-870,893
DM32TFO HS Phase 1
DM32TFO CP Roche
DM32TFO DT Small molecular drug
DM32TFO DE Solid tumour/cancer
DM3J1T9 ID DM3J1T9
DM3J1T9 DN CPC-212
DM3J1T9 HS Phase 1
DM3J1T9 CP Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC
DM3J1T9 DE Alzheimer disease
DMDQG4Y ID DMDQG4Y
DMDQG4Y DN CPC-250
DMDQG4Y HS Phase 1
DMDQG4Y CP Allergan Parsippany, NJ Chase Pharmaceuticals Washington, DC
DMDQG4Y DE Alzheimer disease
DMVDYTG ID DMVDYTG
DMVDYTG DN CPG 52364
DMVDYTG HS Phase 1
DMVDYTG SN SCHEMBL5049937
DMVDYTG CP Coley Pharma.
DMVDYTG DT Small molecular drug
DMVDYTG PC 11774935
DMVDYTG MW 436.5
DMVDYTG FM C24H32N6O2
DMVDYTG IC InChI=1S/C24H32N6O2/c1-28(2)11-10-25-23-19-16-21(31-3)22(32-4)17-20(19)26-24(27-23)30-14-12-29(13-15-30)18-8-6-5-7-9-18/h5-9,16-17H,10-15H2,1-4H3,(H,25,26,27)
DMVDYTG CS CN(C)CCNC1=NC(=NC2=CC(=C(C=C21)OC)OC)N3CCN(CC3)C4=CC=CC=C4
DMVDYTG IK NRDOWTUUBQCUMC-UHFFFAOYSA-N
DMVDYTG IU N-[6,7-dimethoxy-2-(4-phenylpiperazin-1-yl)quinazolin-4-yl]-N',N'-dimethylethane-1,2-diamine
DMVDYTG DE Systemic lupus erythematosus
DMJSFTX ID DMJSFTX
DMJSFTX DN CPI-006
DMJSFTX HS Phase 1
DMJSFTX CP Corvus Pharmaceuticals
DMJSFTX DT Antibody
DMJSFTX DE Advanced cancer; Solid tumour/cancer
DMMBQ20 ID DMMBQ20
DMMBQ20 DN CPI-818
DMMBQ20 HS Phase 1
DMMBQ20 CP Corvus Pharmaceuticals
DMMBQ20 DT Small molecular drug
DMMBQ20 DE T-cell lymphoma
DMFMGZR ID DMFMGZR
DMFMGZR DN CPL207-280CA
DMFMGZR HS Phase 1
DMFMGZR DT Small molecular drug
DMFMGZR DE Type 2 diabetes
DMQCHU3 ID DMQCHU3
DMQCHU3 DN CPP -15
DMQCHU3 HS Phase 1
DMQCHU3 SN CPP-15
DMQCHU3 CP Catalyst pharmaceutical partners
DMQCHU3 DE Infantile spasm
DMKWSFI ID DMKWSFI
DMKWSFI DN CR-002
DMKWSFI HS Phase 1
DMKWSFI SN CR-002 liquid API; Alpha 1 proteinase inhibitor (inhaled solution), CSL Behring; CR-002, CSL Behring
DMKWSFI CP CSL Behring
DMKWSFI DE Cystic fibrosis
DMT7L30 ID DMT7L30
DMT7L30 DN CR-3465
DMT7L30 HS Phase 1
DMT7L30 DE Allergy
DMHDSYF ID DMHDSYF
DMHDSYF DN CRX-675
DMHDSYF HS Phase 1
DMHDSYF SN RC-529
DMHDSYF CP GlaxoSmithKline
DMHDSYF DE Hepatitis virus infection
DMG0SPO ID DMG0SPO
DMG0SPO DN CS-0777
DMG0SPO HS Phase 1
DMG0SPO SN CS-0777; UNII-KCH74QG79A; KCH74QG79A; 827344-05-8; CS 0777; SCHEMBL1454408; CHEMBL1951587; YXEQXPNSBUIRDZ-OAQYLSRUSA-N; ZINC59872504; 1192731-63-7; 1-Butanone, 1-(5-((3R)-3-amino-4-hydroxy-3-methylbutyl)-1-methyl-1H-pyrrol-2-yl)-4-(4-methylphenyl)-
DMG0SPO CP Daiichi Sankyo
DMG0SPO DT Small molecular drug
DMG0SPO PC 11371290
DMG0SPO MW 342.5
DMG0SPO FM C21H30N2O2
DMG0SPO IC InChI=1S/C21H30N2O2/c1-16-7-9-17(10-8-16)5-4-6-20(25)19-12-11-18(23(19)3)13-14-21(2,22)15-24/h7-12,24H,4-6,13-15,22H2,1-3H3/t21-/m1/s1
DMG0SPO CS CC1=CC=C(C=C1)CCCC(=O)C2=CC=C(N2C)CC[C@](C)(CO)N
DMG0SPO IK YXEQXPNSBUIRDZ-OAQYLSRUSA-N
DMG0SPO IU 1-[5-[(3R)-3-amino-4-hydroxy-3-methylbutyl]-1-methylpyrrol-2-yl]-4-(4-methylphenyl)butan-1-one
DMG0SPO CA CAS 827344-05-8
DMG0SPO DE Multiple sclerosis
DMU8OCN ID DMU8OCN
DMU8OCN DN CS1-CAR T Therapy
DMU8OCN HS Phase 1
DMU8OCN CP City of Hope Medical Center
DMU8OCN DT CAR T Cell Therapy
DMU8OCN DE Plasma cell myeloma
DMRH740 ID DMRH740
DMRH740 DN CS-8080
DMRH740 HS Phase 1
DMRH740 SN Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc
DMRH740 CP Daiichi Sankyo Inc
DMRH740 PC 16212738
DMRH740 MW 959.9
DMRH740 FM C61H99ClN2O4
DMRH740 IC InChI=1S/C61H99N2.ClHO4/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-44-52-62-56-48-42-40-46-54(56)60(3,4)58(62)50-38-37-39-51-59-61(5,6)55-47-41-43-49-57(55)63(59)53-45-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-2;2-1(3,4)5/h37-43,46-51H,7-36,44-45,52-53H2,1-6H3;(H,2,3,4,5)/q+1;/p-1
DMRH740 CS CCCCCCCCCCCCCCCCCCN\\1C2=CC=CC=C2C(/C1=C\\C=C\\C=C\\C3=[N+](C4=CC=CC=C4C3(C)C)CCCCCCCCCCCCCCCCCC)(C)C.[O-]Cl(=O)(=O)=O
DMRH740 IK ZQSBJPAQPRVNHU-UHFFFAOYSA-M
DMRH740 IU (2E)-2-[(2E,4E)-5-(3,3-dimethyl-1-octadecylindol-1-ium-2-yl)penta-2,4-dienylidene]-3,3-dimethyl-1-octadecylindole;perchlorate
DMRH740 CA CAS 127274-91-3
DMRH740 CB CHEBI:52027
DMRH740 DE Arteriosclerosis
DMO97RV ID DMO97RV
DMO97RV DN CSL-362
DMO97RV HS Phase 1
DMO97RV SN CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3
DMO97RV CP Csl; janssen research & development
DMO97RV DT Antibody
DMO97RV DE Acute myeloid leukaemia
DM7I39W ID DM7I39W
DM7I39W DN CSL-362-AML
DM7I39W HS Phase 1
DM7I39W CP Janssen Biotech
DM7I39W DT Antibody
DM7I39W DE leukaemia
DMI7XMU ID DMI7XMU
DMI7XMU DN CT 868
DMI7XMU HS Phase 1
DMI7XMU CP Carmot Therapeutics
DMI7XMU DT Small molecular drug
DMI7XMU DE Type 2 diabetes
DMBCJW6 ID DMBCJW6
DMBCJW6 DN CT053
DMBCJW6 HS Phase 1
DMBCJW6 CP CARsgen Therapeutics
DMBCJW6 DT CAR T Cell Therapy
DMBCJW6 DE Multiple myeloma
DMW16VR ID DMW16VR
DMW16VR DN CT-200
DMW16VR HS Phase 1
DMW16VR CP Celleron Therapeutics
DMW16VR DE Solid tumour/cancer
DMHBK6L ID DMHBK6L
DMHBK6L DN CTAP-201
DMHBK6L HS Phase 1
DMHBK6L SN Vitamin D analogs, Cytochroma; Vitamin D analogs (iv, hyperparathyroidism), Cytochroma
DMHBK6L CP Cytochroma Inc
DMHBK6L DE Hyperparathyroidism
DM2HES0 ID DM2HES0
DM2HES0 DN CTCE-0214
DM2HES0 HS Phase 1
DM2HES0 SN CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics
DM2HES0 CP Chemokine Therapeutics
DM2HES0 DE Constitutional neutropenia
DMIKX01 ID DMIKX01
DMIKX01 DN CTP-298
DMIKX01 HS Phase 1
DMIKX01 SN C-10276; CTP-518; Deuterated atazanavir isotopologs (HIV infection), CoNCERT/GSK
DMIKX01 CP CoNCERT Pharmaceuticals Inc
DMIKX01 DE Human immunodeficiency virus infection
DM68I93 ID DM68I93
DM68I93 DN CTS-21166
DM68I93 HS Phase 1
DM68I93 CP CoMentis
DM68I93 DE Alzheimer disease
DMAV86R ID DMAV86R
DMAV86R DN CTT1403
DMAV86R HS Phase 1
DMAV86R CP Cancer Targeted Technology
DMAV86R DT Small molecular drug
DMAV86R DE Prostate cancer
DMHK9WR ID DMHK9WR
DMHK9WR DN CTX-101
DMHK9WR HS Phase 1
DMHK9WR CP CRISPR Therapeutics
DMHK9WR DT CAR T Cell Therapy
DMHK9WR DE Non-hodgkin lymphoma; B-cell lymphoma
DMWS40H ID DMWS40H
DMWS40H DN CTX120
DMWS40H HS Phase 1
DMWS40H CP CRISPR Therapeutics
DMWS40H DT CAR T Cell Therapy
DMWS40H DE Multiple myeloma
DM926CH ID DM926CH
DM926CH DN CTX130
DM926CH HS Phase 1
DM926CH CP CRISPR Therapeutics
DM926CH DT CAR T Cell Therapy
DM926CH DE T-cell lymphoma
DMMPKN3 ID DMMPKN3
DMMPKN3 DN CTX-471
DMMPKN3 HS Phase 1
DMMPKN3 CP Compass Therapeutics
DMMPKN3 DT Antibody
DMMPKN3 DE Solid tumour/cancer
DM9ZOMD ID DM9ZOMD
DM9ZOMD DN CUDC-101
DM9ZOMD HS Phase 1
DM9ZOMD SN CUDC-101; 1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149
DM9ZOMD CP Curis
DM9ZOMD DT Small molecular drug
DM9ZOMD PC 24756910
DM9ZOMD MW 434.5
DM9ZOMD FM C24H26N4O4
DM9ZOMD IC InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)
DM9ZOMD CS COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO
DM9ZOMD IK PLIVFNIUGLLCEK-UHFFFAOYSA-N
DM9ZOMD IU 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide
DM9ZOMD CA CAS 1012054-59-9
DM9ZOMD DE Solid tumour/cancer
DMYD37G ID DMYD37G
DMYD37G DN CV8102
DMYD37G HS Phase 1
DMYD37G CP CureVac
DMYD37G DE Melanoma; Squamous cell carcinoma
DMTSIYZ ID DMTSIYZ
DMTSIYZ DN CVN058
DMTSIYZ HS Phase 1
DMTSIYZ CP Cerevance
DMTSIYZ DT Small molecular drug
DMTSIYZ DE Schizophrenia
DMY84TW ID DMY84TW
DMY84TW DN CVT-6883
DMY84TW HS Phase 1
DMY84TW SN CVT-6883; 752222-83-6; GS-6201; UNII-67CKV7X08G; CHEMBL260933; 67CKV7X08G; CVT 6883; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione; 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione; Kinome_3621; SCHEMBL238694; GTPL5615; CVT6883; AOB4675; MolPort-035-765-814; CTV-6883; ZINC29055563; BDBM50236738; AKOS024458311; API0004749; 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione
DMY84TW DT Small molecular drug
DMY84TW PC 11270783
DMY84TW MW 446.4
DMY84TW FM C21H21F3N6O2
DMY84TW IC InChI=1S/C21H21F3N6O2/c1-3-8-30-19(31)16-18(29(4-2)20(30)32)27-17(26-16)14-10-25-28(12-14)11-13-6-5-7-15(9-13)21(22,23)24/h5-7,9-10,12H,3-4,8,11H2,1-2H3,(H,26,27)
DMY84TW CS CCCN1C(=O)C2=C(N=C(N2)C3=CN(N=C3)CC4=CC(=CC=C4)C(F)(F)F)N(C1=O)CC
DMY84TW IK KOYXXLLNCXWUNF-UHFFFAOYSA-N
DMY84TW IU 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7H-purine-2,6-dione
DMY84TW CA CAS 752222-83-6
DMY84TW DE Asthma
DMO23R0 ID DMO23R0
DMO23R0 DN CVX 096
DMO23R0 HS Phase 1
DMO23R0 SN PF-04856883
DMO23R0 CP Pfizer
DMO23R0 DE Type-2 diabetes
DMV74JC ID DMV74JC
DMV74JC DN CVX-241
DMV74JC HS Phase 1
DMV74JC CP Pfizer
DMV74JC DE Solid tumour/cancer
DMRD2B0 ID DMRD2B0
DMRD2B0 DN CXD-101
DMRD2B0 HS Phase 1
DMRD2B0 CP AstraZeneca plc
DMRD2B0 PC 16225380
DMRD2B0 MW 403.5
DMRD2B0 FM C24H29N5O
DMRD2B0 IC InChI=1S/C24H29N5O/c1-17-21(15-28(2)27-17)16-29-13-11-19(12-14-29)18-7-9-20(10-8-18)24(30)26-23-6-4-3-5-22(23)25/h3-10,15,19H,11-14,16,25H2,1-2H3,(H,26,30)
DMRD2B0 CS CC1=NN(C=C1CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N)C
DMRD2B0 IK JHDZMASHNBKTPS-UHFFFAOYSA-N
DMRD2B0 IU N-(2-aminophenyl)-4-[1-[(1,3-dimethylpyrazol-4-yl)methyl]piperidin-4-yl]benzamide
DMRD2B0 CA CAS 934828-12-3
DMRD2B0 DE Solid tumour/cancer
DM4GJ50 ID DM4GJ50
DM4GJ50 DN CXR-1002
DM4GJ50 HS Phase 1
DM4GJ50 CP CXR Biosciences Ltd
DM4GJ50 DE Solid tumour/cancer
DMSM42V ID DMSM42V
DMSM42V DN CYAD-101
DMSM42V HS Phase 1
DMSM42V CP Celyad (formerly named Cardio3 BioSciences)
DMSM42V DT CAR T Cell Therapy
DMSM42V DE Colorectal cancer
DM9ODT6 ID DM9ODT6
DM9ODT6 DN CYC065
DM9ODT6 HS Phase 1
DM9ODT6 SN DLPIYBKBHMZCJI-WBVHZDCISA-N; 1070790-89-4; CYC-065; UNII-YET2XNU791; YET2XNU791; SCHEMBL13300946; CHEMBL3655762; BDBM106950; CS-7615; HY-101212; US8592581, 1; 2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-
DM9ODT6 CP Cyclacel Pharmaceuticals Berkeley Heights, NJ
DM9ODT6 PC 24983461
DM9ODT6 MW 397.5
DM9ODT6 FM C21H31N7O
DM9ODT6 IC InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1
DM9ODT6 CS CC[C@@H]([C@@H](C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C
DM9ODT6 IK DLPIYBKBHMZCJI-WBVHZDCISA-N
DM9ODT6 IU (2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol
DM9ODT6 CA CAS 1070790-89-4
DM9ODT6 DE Lymphoma; Solid tumour/cancer
DMUMHXT ID DMUMHXT
DMUMHXT DN CYC116
DMUMHXT HS Phase 1
DMUMHXT SN 693228-63-6; CYC-116; CYC116; CHEMBL482967; Kinome_636; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2uue; CYC 116; GPSZYOIFQZPWEJ-UHFFFAOYSA-N; 2c5t; AC1O4WKE; MLS006011244; SCHEMBL2074998; SYN1034; EX-A753; CYC-116/CYC116; MolPort-009-679-476; HMS3244O12; HMS3244P11; BCPP000273
DMUMHXT CP Cyclacel Limited
DMUMHXT TC Anticancer Agents
DMUMHXT DT Small molecular drug
DMUMHXT PC 6420138
DMUMHXT MW 368.5
DMUMHXT FM C18H20N6OS
DMUMHXT IC InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
DMUMHXT CS CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4
DMUMHXT IK GPSZYOIFQZPWEJ-UHFFFAOYSA-N
DMUMHXT IU 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
DMUMHXT DE Solid tumour/cancer
DMC6PKJ ID DMC6PKJ
DMC6PKJ DN CYC140
DMC6PKJ HS Phase 1
DMC6PKJ SN Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)-
DMC6PKJ CP Cyclacel Pharmaceuticals
DMC6PKJ DT Small molecular drug
DMC6PKJ PC 57336523
DMC6PKJ MW 679.8
DMC6PKJ FM C36H53N7O6
DMC6PKJ IC InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30-/m0/s1
DMC6PKJ CS CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5
DMC6PKJ IK BBAWEDCPNXPBQM-YQYHUCGXSA-N
DMC6PKJ IU (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide
DMC6PKJ DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMI6EUB ID DMI6EUB
DMI6EUB DN Cyclolignan picropodophyllin
DMI6EUB HS Phase 1
DMI6EUB SN PPP; IGF-1R inhibitor (cancer), Karolinska
DMI6EUB CP Karolinska Institute
DMI6EUB DE Colorectal cancer
DMAWVTX ID DMAWVTX
DMAWVTX DN Cyclopentenylcytosine
DMAWVTX HS Phase 1
DMAWVTX SN cyclopentenyl cytosine; 90597-22-1; NSC-375575; CPE-C; UNII-69MO0NDN8K; NSC 375575; NSC375575; BRN 4258358; 69MO0NDN8K; CHEMBL63647; 1-((1R,2S,3R)-4-Hydroxymethyl-2,3-dihydroxy-4-cyclopenten-1-yl)cytosine; 4-amino-1-[(1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one; 4-amino-1-[(1r,4r,5s)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2(1h)-one; CPE-cytosine; 2(1H)-Pyrimidinone, 4-amino-1-((1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl)-
DMAWVTX DT Small molecular drug
DMAWVTX PC 72828
DMAWVTX MW 239.23
DMAWVTX FM C10H13N3O4
DMAWVTX IC InChI=1S/C10H13N3O4/c11-7-1-2-13(10(17)12-7)6-3-5(4-14)8(15)9(6)16/h1-3,6,8-9,14-16H,4H2,(H2,11,12,17)/t6-,8-,9+/m1/s1
DMAWVTX CS C1=CN(C(=O)N=C1N)[C@@H]2C=C([C@H]([C@H]2O)O)CO
DMAWVTX IK DUJGMZAICVPCBJ-VDAHYXPESA-N
DMAWVTX IU 4-amino-1-[(1R,4R,5S)-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one
DMAWVTX CA CAS 90597-22-1
DMAWVTX DE Solid tumour/cancer
DMNICD4 ID DMNICD4
DMNICD4 DN CYT-013-IL1bQb
DMNICD4 HS Phase 1
DMNICD4 SN Immunodrug vaccines (IL-1 beta) (rheumatoid arthritis), Cytos
DMNICD4 CP Cytos Biotechnology AG
DMNICD4 DT Vaccine
DMNICD4 DE Inflammation
DMTV09A ID DMTV09A
DMTV09A DN Cyt-1010
DMTV09A HS Phase 1
DMTV09A CP Tulane University
DMTV09A PC 44129692
DMTV09A MW 624.7
DMTV09A FM C35H40N6O5
DMTV09A IC InChI=1S/C35H40N6O5/c36-27(18-23-13-15-25(42)16-14-23)32(43)39-29-12-6-7-17-37-33(44)30(19-22-8-2-1-3-9-22)40-35(46)31(41-34(29)45)20-24-21-38-28-11-5-4-10-26(24)28/h1-5,8-11,13-16,21,27,29-31,38,42H,6-7,12,17-20,36H2,(H,37,44)(H,39,43)(H,40,46)(H,41,45)/t27-,29+,30-,31-/m0/s1
DMTV09A CS C1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5
DMTV09A IK CFVGCGXJRNVTFP-LYXINOJLSA-N
DMTV09A IU (2S)-2-amino-N-[(3S,6S,9R)-3-benzyl-6-(1H-indol-3-ylmethyl)-2,5,8-trioxo-1,4,7-triazacyclotridec-9-yl]-3-(4-hydroxyphenyl)propanamide
DMTV09A DE Pain
DMJ83Z7 ID DMJ83Z7
DMJ83Z7 DN CYT-609
DMJ83Z7 HS Phase 1
DMJ83Z7 SN Aurimune
DMJ83Z7 CP CytImmune sciences INC
DMJ83Z7 DE Solid tumour/cancer
DMAY6X2 ID DMAY6X2
DMAY6X2 DN CZ-48
DMAY6X2 HS Phase 1
DMAY6X2 SN Camptothecin-20-O-propionate; UNII-4S145C552U; CZ-48; 194414-69-2; 4S145C552U; SF 6A; CZ48; Camptothecin-20(S)-O-propionate; CZ 48; SCHEMBL1618775; CHEMBL124162; DTXSID30173074; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-(1-oxopropoxy)-, (S)-
DMAY6X2 DT Small molecular drug
DMAY6X2 PC 9887472
DMAY6X2 MW 404.4
DMAY6X2 FM C23H20N2O5
DMAY6X2 IC InChI=1S/C23H20N2O5/c1-3-19(26)30-23(4-2)16-10-18-20-14(9-13-7-5-6-8-17(13)24-20)11-25(18)21(27)15(16)12-29-22(23)28/h5-10H,3-4,11-12H2,1-2H3/t23-/m0/s1
DMAY6X2 CS CCC(=O)O[C@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)CC
DMAY6X2 IK YCNIQYLWIPCLNY-QHCPKHFHSA-N
DMAY6X2 IU [(19S)-19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl] propanoate
DMAY6X2 CA CAS 194414-69-2
DMAY6X2 DE Solid tumour/cancer; Lymphoma
DMGA1DS ID DMGA1DS
DMGA1DS DN D-0502
DMGA1DS HS Phase 1
DMGA1DS CP InventisBio
DMGA1DS DT Small molecular drug
DMGA1DS DE Breast cancer
DMTP9ER ID DMTP9ER
DMTP9ER DN D-20133
DMTP9ER HS Phase 1
DMTP9ER SN OMPEP; octadecyl-(2-(N-methylpiperidino)ethyl)phosphate; 146764-26-3; D 20133; 1-(2-((Hydroxy(octadecyloxy)phosphinyl)oxy)ethyl)-1-methylpiperidinium inner salt; Piperidinium, 1-(2-((hydroxy(octadecyloxy)phosphinyl)oxy)ethyl)-1-methyl-, inner salt; SCHEMBL2293548; AC1L31K0; DTXSID90163471; LS-116681; 2-(1-methylpiperidin-1-ium-1-yl)ethyl octadecyl phosphate
DMTP9ER CP ASTA Medica AG
DMTP9ER DT Small molecular drug
DMTP9ER PC 132778
DMTP9ER MW 476.7
DMTP9ER FM C26H55NO4P+
DMTP9ER IC InChI=1S/C26H54NO4P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-25-30-32(28,29)31-26-24-27(2)22-19-18-20-23-27/h3-26H2,1-2H3/p+1
DMTP9ER CS CCCCCCCCCCCCCCCCCCOP(=O)(O)OCC[N+]1(CCCCC1)C
DMTP9ER IK CUQJLYFFQBHUGW-UHFFFAOYSA-O
DMTP9ER IU 2-(1-methylpiperidin-1-ium-1-yl)ethyl octadecyl hydrogen phosphate
DMTP9ER DE Solid tumour/cancer
DMIMK84 ID DMIMK84
DMIMK84 DN D2C7
DMIMK84 HS Phase 1
DMIMK84 CP Istari Oncology
DMIMK84 DT Antibody
DMIMK84 DE Glioblastoma of brain
DM7V2OM ID DM7V2OM
DM7V2OM DN D-3263
DM7V2OM HS Phase 1
DM7V2OM SN TDBTU; 125700-69-8; N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate; O-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; MFCD00077730; AK170015; o-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-n,n,n',n'-tetramethyluroniumtetrafluoroborate; 1,1,3,3-tetramethyl-2-(4-oxobenzo[d][1,2,3]triazin-3(4h)-yl)uronium tetrafluoroborate; TDBTU; N,N,N',N'-Tetramethyl-O-(3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl)uronium tetrafluoroborate
DM7V2OM CP Dendreon
DM7V2OM DT Small molecular drug
DM7V2OM PC 44137358
DM7V2OM MW 373.5
DM7V2OM FM C21H31N3O3
DM7V2OM IC InChI=1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3/t14-,16+,17-/m1/s1
DM7V2OM CS C[C@@H]1CC[C@H]([C@@H](C1)C(=O)N2C3=C(C=C(C=C3)OC)N(C2=O)CCN)C(C)C
DM7V2OM IK ZGTYTFYRCIRWBL-HYVNUMGLSA-N
DM7V2OM IU 3-(2-aminoethyl)-5-methoxy-1-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexanecarbonyl]benzimidazol-2-one
DM7V2OM CA CAS 947257-66-1
DM7V2OM DE Solid tumour/cancer
DM4OTWL ID DM4OTWL
DM4OTWL DN DA-1229
DM4OTWL HS Phase 1
DM4OTWL SN DPP-IV inhibitor (tablet, type II diabetes), Dong-A
DM4OTWL CP Dong-A Pharmaceutical Co Ltd
DM4OTWL DT Small molecular drug
DM4OTWL PC 25022354
DM4OTWL MW 401.4
DM4OTWL FM C19H26F3N3O3
DM4OTWL IC InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
DM4OTWL CS CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](CC2=CC(=C(C=C2F)F)F)N
DM4OTWL IK LCDDAGSJHKEABN-MLGOLLRUSA-N
DM4OTWL IU (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one
DM4OTWL CA CAS 1222102-29-5
DM4OTWL DE Type-2 diabetes
DMPJA64 ID DMPJA64
DMPJA64 DN DA-1241
DMPJA64 HS Phase 1
DMPJA64 CP Dong-A ST
DMPJA64 DT Small molecular drug
DMPJA64 DE Type 2 diabetes
DM4JG0B ID DM4JG0B
DM4JG0B DN DA-3607
DM4JG0B HS Phase 1
DM4JG0B SN Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A
DM4JG0B CP Dong-A Pharmaceutical Co Ltd
DM4JG0B DE Brain cancer
DMKPAOD ID DMKPAOD
DMKPAOD DN DA-6886
DMKPAOD HS Phase 1
DMKPAOD SN 5-HT4 agonist (IBS-c), Dong-A
DMKPAOD CP Dong-A Pharmaceutical Co Ltd
DMKPAOD PC 54575171
DMKPAOD MW 406.9
DMKPAOD FM C19H27ClN6O2
DMKPAOD IC InChI=1S/C19H27ClN6O2/c1-28-18-12-17(21)16(20)11-15(18)19(27)22-13-14-3-8-25(9-4-14)6-2-7-26-10-5-23-24-26/h5,10-12,14H,2-4,6-9,13,21H2,1H3,(H,22,27)
DMKPAOD CS COC1=CC(=C(C=C1C(=O)NCC2CCN(CC2)CCCN3C=CN=N3)Cl)N
DMKPAOD IK AULLTYAISZREAX-UHFFFAOYSA-N
DMKPAOD IU 4-amino-5-chloro-2-methoxy-N-[[1-[3-(triazol-1-yl)propyl]piperidin-4-yl]methyl]benzamide
DMKPAOD CA CAS 1342815-16-0
DMKPAOD DE Irritable bowel syndrome
DMBRN2G ID DMBRN2G
DMBRN2G DN DA-697b
DMBRN2G HS Phase 1
DMBRN2G SN DZ-697b; Oral anticoagulants, Daiichi
DMBRN2G CP Daiichi Seiyaku Co Ltd
DMBRN2G DE Thrombosis
DM9KS1A ID DM9KS1A
DM9KS1A DN DA-727
DM9KS1A HS Phase 1
DM9KS1A CP Kotobuki Pharmaceutical Co Ltd
DM9KS1A DE Hypertension
DMQR4HA ID DMQR4HA
DMQR4HA DN DABIS MALEATE
DMQR4HA HS Phase 1
DMQR4HA SN E-83-041; 1,4-Bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane dimaleate
DMQR4HA DT Small molecular drug
DMQR4HA PC 54599345
DMQR4HA MW 340.2
DMQR4HA FM C13H21Cl2N2O4+
DMQR4HA IC InChI=1S/C9H18Cl2N2.C4H4O4/c10-1-3-12-5-7-13(9-12,4-2-11)8-6-12;5-3(6)1-2-4(7)8/h1-9H2;1-2H,(H,5,6)(H,7,8)/q+2;/p-1/b;2-1-
DMQR4HA CS C1C[N+]2(CC[N+]1(C2)CCCl)CCCl.C(=C\\C(=O)[O-])\\C(=O)O
DMQR4HA IK HKVBKOPISPWMSR-BTJKTKAUSA-M
DMQR4HA IU 1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane;(Z)-4-hydroxy-4-oxobut-2-enoate
DMQR4HA CA CAS 73387-70-9
DMQR4HA DE Solid tumour/cancer
DM5TB76 ID DM5TB76
DM5TB76 DN DACRA 089
DM5TB76 HS Phase 1
DM5TB76 SN KBP-089
DM5TB76 CP Eli Lilly
DM5TB76 DT Peptide
DM5TB76 DE Type 2 diabetes
DMWT5RS ID DMWT5RS
DMWT5RS DN Daniquidone
DMWT5RS HS Phase 1
DMWT5RS SN Batracylin
DMWT5RS CP National Cancer Institute
DMWT5RS DT Small molecular drug
DMWT5RS PC 71750
DMWT5RS MW 249.27
DMWT5RS FM C15H11N3O
DMWT5RS IC InChI=1S/C15H11N3O/c16-10-5-6-13-9(7-10)8-18-14(17-13)11-3-1-2-4-12(11)15(18)19/h1-7H,8,16H2
DMWT5RS CS C1C2=C(C=CC(=C2)N)N=C3N1C(=O)C4=CC=CC=C43
DMWT5RS IK SRIOCKJKFXAKHK-UHFFFAOYSA-N
DMWT5RS IU 8-amino-10H-isoindolo[1,2-b]quinazolin-12-one
DMWT5RS CA CAS 67199-66-0
DMWT5RS DE Lymphoma
DM4A3U7 ID DM4A3U7
DM4A3U7 DN DAVLB-HYDRAZIDE
DM4A3U7 HS Phase 1
DM4A3U7 SN Desacetylvinblastine-3-carboxyhydrazide
DM4A3U7 DT Small molecular drug
DM4A3U7 PC 6918076
DM4A3U7 MW 768.9
DM4A3U7 FM C43H56N6O7
DM4A3U7 IC InChI=1S/C43H56N6O7/c1-6-39(53)21-25-22-42(38(52)56-5,33-27(13-17-48(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)55-4)47(3)35-41(28)15-18-49-16-10-14-40(7-2,34(41)49)36(50)43(35,54)37(51)46-44/h8-12,14,19-20,25,34-36,45,50,53-54H,6-7,13,15-18,21-24,44H2,1-5H3,(H,46,51)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
DM4A3U7 CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NN)O)O)CC)OC)C(=O)OC)O
DM4A3U7 IK PPRGGNQLPSVURC-KOTLKJBCSA-N
DM4A3U7 IU methyl (13S,15S,17S)-17-ethyl-13-[(1R,9R,10S,11R,12R,19R)-12-ethyl-10-(hydrazinecarbonyl)-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
DM4A3U7 DE Solid tumour/cancer
DM1K248 ID DM1K248
DM1K248 DN DB-053072
DM1K248 HS Phase 1
DM1K248 SN Methylglyoxylate; Pyruvate; Natriumpyruvat; Propanoic acid, 2-oxo-, ion(1-); Pyruvate ion; pyruvate; 10110-EP2277876A1; 10110-EP2292614A1; 10110-EP2295413A1; 10110-EP2295432A1; 10110-EP2295550A2; 10110-EP2298312A1; 10110-EP2308874A1; 10110-EP2311830A1; 10110-EP2316835A1; 2-Oxopropanoate; 2-oxidanylidenepropanoate; 2-oxo-Propanoic acid; 2-oxopropanoic acid, ion(1-); 2hzl; 57-60-3; BDBM50159792; CHEBI:15361; CHEMBL181886; CTK1H3219; DB-007695; DB-053072; DTXSID50205604; FT-0731491; HO43T60JMG; LCTONWCANYUPML-UHFFFAOYSA-M; UNII-HO43T60JMG
DM1K248 PC 107735
DM1K248 MW 87.05
DM1K248 FM C3H3O3-
DM1K248 IC LCTONWCANYUPML-UHFFFAOYSA-M
DM1K248 CS CC(=O)C(=O)[O-]
DM1K248 IK 1S/C3H4O3/c1-2(4)3(5)6/h1H3,(H,5,6)/p-1
DM1K248 IU 2-oxopropanoate
DM1K248 CA CAS 57-60-3
DM1K248 CB CHEBI:15361
DM1K248 DE Prostate cancer
DM6K47B ID DM6K47B
DM6K47B DN DC/I540/KLH vaccine
DM6K47B HS Phase 1
DM6K47B SN HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber
DM6K47B CP Dana-Farber Cancer Institute Inc
DM6K47B DT Vaccine
DM6K47B DE Brain cancer
DMLVG9D ID DMLVG9D
DMLVG9D DN DCC-3014
DMLVG9D HS Phase 1
DMLVG9D CP Deciphera Pharmaceuticals Waltham, MA
DMLVG9D DE Haematological malignancy; Solid tumour/cancer
DMQ8ACY ID DMQ8ACY
DMQ8ACY DN DCCCyB
DMQ8ACY HS Phase 1
DMQ8ACY SN DCCCyB; CHEMBL2146721; 916159-99-4; Benzamide,2,4-dichloro-N-[[1-(cyclopropylmethyl)-4-[(cyclopropylmethyl)sulfonyl]cyclohexyl]methyl]-; SCHEMBL678963; ZINC34807040; BDBM50391757; KB-74916; J3.560.315H
DMQ8ACY CP Merck
DMQ8ACY DT Small molecular drug
DMQ8ACY PC 15951941
DMQ8ACY MW 458.4
DMQ8ACY FM C22H29Cl2NO3S
DMQ8ACY IC InChI=1S/C22H29Cl2NO3S/c23-17-5-6-19(20(24)11-17)21(26)25-14-22(12-15-1-2-15)9-7-18(8-10-22)29(27,28)13-16-3-4-16/h5-6,11,15-16,18H,1-4,7-10,12-14H2,(H,25,26)
DMQ8ACY CS C1CC1CC2(CCC(CC2)S(=O)(=O)CC3CC3)CNC(=O)C4=C(C=C(C=C4)Cl)Cl
DMQ8ACY IK PSIMLOLEQCVVJV-UHFFFAOYSA-N
DMQ8ACY IU 2,4-dichloro-N-[[1-(cyclopropylmethyl)-4-(cyclopropylmethylsulfonyl)cyclohexyl]methyl]benzamide
DMQ8ACY DE Schizophrenia
DMQIEFB ID DMQIEFB
DMQIEFB DN Debio 0827
DMQIEFB HS Phase 1
DMQIEFB CP Debiopharm
DMQIEFB PC 16123252
DMQIEFB MW 518.7
DMQIEFB FM C22H34N2O6S3
DMQIEFB IC InChI=1S/C22H34N2O6S3/c1-4-28-22(27)30-16(2)29-20(25)13-24-21(26)18(12-17-8-6-5-7-9-17)14-32-33-15-19(23)10-11-31-3/h5-9,16,18-19H,4,10-15,23H2,1-3H3,(H,24,26)
DMQIEFB CS CCOC(=O)OC(C)OC(=O)CNC(=O)C(CC1=CC=CC=C1)CSSCC(CCSC)N
DMQIEFB IK BJCNUZJDFWFVBY-UHFFFAOYSA-N
DMQIEFB IU 1-ethoxycarbonyloxyethyl 2-[[2-[[(2-amino-4-methylsulfanylbutyl)disulfanyl]methyl]-3-phenylpropanoyl]amino]acetate
DMQIEFB DE Chronic pain
DMWP3G1 ID DMWP3G1
DMWP3G1 DN Debio 0932
DMWP3G1 HS Phase 1
DMWP3G1 CP Debiopharm
DMWP3G1 PC 44156921
DMWP3G1 MW 442.6
DMWP3G1 FM C22H30N6O2S
DMWP3G1 IC InChI=1S/C22H30N6O2S/c1-22(2,3)12-24-8-9-28-14-6-7-25-20(23)19(14)26-21(28)31-18-11-17-16(29-13-30-17)10-15(18)27(4)5/h6-7,10-11,24H,8-9,12-13H2,1-5H3,(H2,23,25)
DMWP3G1 CS CC(C)(C)CNCCN1C2=C(C(=NC=C2)N)N=C1SC3=CC4=C(C=C3N(C)C)OCO4
DMWP3G1 IK RVJIQAYFTOPTKK-UHFFFAOYSA-N
DMWP3G1 IU 2-[[6-(dimethylamino)-1,3-benzodioxol-5-yl]sulfanyl]-1-[2-(2,2-dimethylpropylamino)ethyl]imidazo[4,5-c]pyridin-4-amine
DMWP3G1 CA CAS 1061318-81-7
DMWP3G1 DE Solid tumour/cancer
DMPXLMB ID DMPXLMB
DMPXLMB DN Demobesin
DMPXLMB HS Phase 1
DMPXLMB SN Bombesin antagonist (prostate/breast/NSCL), Biomedica lifesciences; 99mTc-Demobesin-6
DMPXLMB CP Biomedica Life Sciences SA
DMPXLMB DE Breast cancer
DMTULGS ID DMTULGS
DMTULGS DN Demogastrin
DMTULGS HS Phase 1
DMTULGS SN Technetium-99m-Demogastrin 2; Cholecystokinin-2 receptor/gastrin-R binding radiolabeled minigastrinanalogue (medullary thyroid cancer), Biomedica Life Science; 99mTc-Demogastrin 2; 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
DMTULGS CP Biomedica Life Sciences SA
DMTULGS DE Thyroid cancer
DMURVPF ID DMURVPF
DMURVPF DN Dendritic cell vaccine
DMURVPF HS Phase 1
DMURVPF SN Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute
DMURVPF CP National Cancer Institute
DMURVPF DT Vaccine
DMURVPF DE Head and neck cancer
DMTR7EH ID DMTR7EH
DMTR7EH DN Desoxypeganine
DMTR7EH HS Phase 1
DMTR7EH SN Alcoholism therapy, HF Arzneimittelforschung; Desoxypeganine, HF Arzneimittelforschung
DMTR7EH CP HF Arzneimittelforschung GmbH & Co KG
DMTR7EH DT Small molecular drug
DMTR7EH PC 442894
DMTR7EH MW 172.23
DMTR7EH FM C11H12N2
DMTR7EH IC InChI=1S/C11H12N2/c1-2-5-10-9(4-1)8-13-7-3-6-11(13)12-10/h1-2,4-5H,3,6-8H2
DMTR7EH CS C1CC2=NC3=CC=CC=C3CN2C1
DMTR7EH IK WUFQLZTXIWKION-UHFFFAOYSA-N
DMTR7EH IU 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline
DMTR7EH CA CAS 495-59-0
DMTR7EH CB CHEBI:4428
DMTR7EH DE Alcohol dependence
DMAE9I0 ID DMAE9I0
DMAE9I0 DN Dexpirronium
DMAE9I0 HS Phase 1
DMAE9I0 SN Anticholinergic compound (COPD), Meda
DMAE9I0 CP Meda AB
DMAE9I0 DE Chronic obstructive pulmonary disease
DMI8QNB ID DMI8QNB
DMI8QNB DN DFP 13318
DMI8QNB HS Phase 1
DMI8QNB CP Delta-Fly Pharma Tokushima, Japan
DMI8QNB DE Solid tumour/cancer
DMY6QFH ID DMY6QFH
DMY6QFH DN DFP-11207
DMY6QFH HS Phase 1
DMY6QFH CP Delta-fly pharma
DMY6QFH PC 52919121
DMY6QFH MW 713
DMY6QFH FM C32H26ClFN4O12
DMY6QFH IC InChI=1S/C32H26ClFN4O12/c1-4-26(39)48-24-11-19(12-25(36-24)49-27(40)5-2)31(44)47-22-13-23(35-14-20(22)33)50-30(43)18-9-7-8-17(10-18)28(41)38-29(42)21(34)15-37(32(38)45)16-46-6-3/h7-15H,4-6,16H2,1-3H3
DMY6QFH CS CCC(=O)OC1=CC(=CC(=N1)OC(=O)CC)C(=O)OC2=CC(=NC=C2Cl)OC(=O)C3=CC=CC(=C3)C(=O)N4C(=O)C(=CN(C4=O)COCC)F
DMY6QFH IK WUQYJRNEHOAADL-UHFFFAOYSA-N
DMY6QFH IU [5-chloro-2-[3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoyl]oxypyridin-4-yl] 2,6-di(propanoyloxy)pyridine-4-carboxylate
DMY6QFH CA CAS 1296177-16-6
DMY6QFH DE Solid tumour/cancer
DMGO4XJ ID DMGO4XJ
DMGO4XJ DN DFP-14927
DMGO4XJ HS Phase 1
DMGO4XJ CP Delta-Fly Pharma
DMGO4XJ DT Small molecular drug
DMGO4XJ DE Solid tumour/cancer
DM6OJI1 ID DM6OJI1
DM6OJI1 DN DIAPLASININ
DM6OJI1 HS Phase 1
DM6OJI1 SN Diaplasinin < USAN; PAI-749; 1-Benzyl-3-pentyl-2-[6-(1H-tetrazol-5-ylmethoxy)naphthalen-2-yl]-1H-indole
DM6OJI1 DT Small molecular drug
DM6OJI1 PC 6450820
DM6OJI1 MW 501.6
DM6OJI1 FM C32H31N5O
DM6OJI1 IC InChI=1S/C32H31N5O/c1-2-3-5-13-29-28-12-8-9-14-30(28)37(21-23-10-6-4-7-11-23)32(29)26-16-15-25-20-27(18-17-24(25)19-26)38-22-31-33-35-36-34-31/h4,6-12,14-20H,2-3,5,13,21-22H2,1H3,(H,33,34,35,36)
DM6OJI1 CS CCCCCC1=C(N(C2=CC=CC=C21)CC3=CC=CC=C3)C4=CC5=C(C=C4)C=C(C=C5)OCC6=NNN=N6
DM6OJI1 IK BDPXZFKVHDEPIQ-UHFFFAOYSA-N
DM6OJI1 IU 1-benzyl-3-pentyl-2-[6-(2H-tetrazol-5-ylmethoxy)naphthalen-2-yl]indole
DM6OJI1 CA CAS 481631-45-2
DM6OJI1 DE Thrombosis
DMPWOH9 ID DMPWOH9
DMPWOH9 DN DKY709
DMPWOH9 HS Phase 1
DMPWOH9 CP Novartis
DMPWOH9 DT Small molecular drug
DMPWOH9 DE Solid tumour/cancer
DMM8GZT ID DMM8GZT
DMM8GZT DN DL-017
DMM8GZT HS Phase 1
DMM8GZT SN 3-[4-(2-Methoxyphenyl)piperazin-1-ylmethyl]-5-(methylsulfanyl)-2,3-dihydroimidazo[1,2-c]quinazoline
DMM8GZT PC 9931976
DMM8GZT MW 421.6
DMM8GZT FM C23H27N5OS
DMM8GZT IC InChI=1S/C23H27N5OS/c1-29-21-10-6-5-9-20(21)27-13-11-26(12-14-27)16-17-15-24-22-18-7-3-4-8-19(18)25-23(30-2)28(17)22/h3-10,17H,11-16H2,1-2H3
DMM8GZT CS COC1=CC=CC=C1N2CCN(CC2)CC3CN=C4N3C(=NC5=CC=CC=C54)SC
DMM8GZT IK DVYBIZHLZSDANU-UHFFFAOYSA-N
DMM8GZT IU 3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-5-methylsulfanyl-2,3-dihydroimidazo[1,2-c]quinazoline
DMM8GZT DE Hypertension
DMCT4BA ID DMCT4BA
DMCT4BA DN DMUC-5754A
DMCT4BA HS Phase 1
DMCT4BA CP Genentech
DMCT4BA DT Antibody
DMCT4BA DE Ovarian cancer; Peritoneal cancer; Fallopian tube cancer
DMQFX8R ID DMQFX8R
DMQFX8R DN DN1406131
DMQFX8R HS Phase 1
DMQFX8R CP Jiangxi Qingfeng Pharmaceutical
DMQFX8R DT Small molecular drug
DMQFX8R DE Solid tumour/cancer
DM0JT9C ID DM0JT9C
DM0JT9C DN DN1508052
DM0JT9C HS Phase 1
DM0JT9C CP Shanghai De Novo Pharmatech
DM0JT9C DT Small molecular drug
DM0JT9C DE Solid tumour/cancer
DMOSCQ9 ID DMOSCQ9
DMOSCQ9 DN DNL104
DMOSCQ9 HS Phase 1
DMOSCQ9 CP Denali Therapeutics
DMOSCQ9 DT Small molecular drug
DMOSCQ9 DE Alzheimer disease
DMZT89C ID DMZT89C
DMZT89C DN DNL151
DMZT89C HS Phase 1
DMZT89C CP Denali Therapeutics South San Francisco, CA
DMZT89C DE Parkinson disease
DMFEORD ID DMFEORD
DMFEORD DN DNL201
DMFEORD HS Phase 1
DMFEORD CP Denali Therapeutics South San Francisco, CA
DMFEORD DE Parkinson disease
DMNSC0O ID DMNSC0O
DMNSC0O DN DNL747
DMNSC0O HS Phase 1
DMNSC0O CP Denali Therapeutics
DMNSC0O DT Small molecular drug
DMNSC0O DE Alzheimer disease; Amyotrophic lateral sclerosis
DMZS350 ID DMZS350
DMZS350 DN Donor-derived CD19/22 bispecific CAR-T cells
DMZS350 HS Phase 1
DMZS350 CP Chinese PLA General Hospital
DMZS350 DT CAR T Cell Therapy (Dual specific)
DMZS350 DE leukaemia
DMXZ6A0 ID DMXZ6A0
DMXZ6A0 DN DP-4088
DMXZ6A0 HS Phase 1
DMXZ6A0 SN DPOC-4088; Anticoagulant thrombin inhibitor (oral), Merck & Co; Anticoagulant thrombin inhibitor (oral, deep vein thrombosis), Diakron/ Orchid
DMXZ6A0 CP Merck & Co Inc
DMXZ6A0 PC 9955534
DMXZ6A0 MW 452.8
DMXZ6A0 FM C19H16ClF3N6O2
DMXZ6A0 IC InChI=1S/C19H16ClF3N6O2/c20-15-9-27-17(28-11-19(22,23)14-5-1-2-6-25-14)18(31)29(15)10-16(30)26-8-13-12(21)4-3-7-24-13/h1-7,9H,8,10-11H2,(H,26,30)(H,27,28)
DMXZ6A0 CS C1=CC=NC(=C1)C(CNC2=NC=C(N(C2=O)CC(=O)NCC3=C(C=CC=N3)F)Cl)(F)F
DMXZ6A0 IK AATHXZYXWMKUFC-UHFFFAOYSA-N
DMXZ6A0 IU 2-[6-chloro-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-oxopyrazin-1-yl]-N-[(3-fluoropyridin-2-yl)methyl]acetamide
DMXZ6A0 CA CAS 312904-62-4
DMXZ6A0 DE Coagulation defect
DM4ZDOE ID DM4ZDOE
DM4ZDOE DN DpC
DM4ZDOE HS Phase 1
DM4ZDOE CP Oncochel Therapeutics
DM4ZDOE DT Small molecular drug
DM4ZDOE DE Solid tumour/cancer
DMJY9TW ID DMJY9TW
DMJY9TW DN DRF-1042
DMJY9TW HS Phase 1
DMJY9TW SN 4(S)-Ethyl-4-hydroxy-12-(2-hydroxyethoxy)-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[2,1-b]quinoline-3,14-dione
DMJY9TW DT Small molecular drug
DMJY9TW PC 23631031
DMJY9TW MW 408.4
DMJY9TW FM C22H20N2O6
DMJY9TW IC InChI=1S/C22H20N2O6/c1-2-22(28)15-10-17-18-13(9-12-5-3-4-6-16(12)23-18)20(29-8-7-25)24(17)19(26)14(15)11-30-21(22)27/h3-6,9-10,20,25,28H,2,7-8,11H2,1H3/t20?,22-/m0/s1
DMJY9TW CS CC[C@@]1(C2=C(COC1=O)C(=O)N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)O
DMJY9TW IK XAKLYHGHEFMDAP-IAXKEJLGSA-N
DMJY9TW IU (19S)-19-ethyl-19-hydroxy-12-(2-hydroxyethoxy)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMJY9TW CA CAS 200619-13-2
DMJY9TW DE Solid tumour/cancer
DM0DJPE ID DM0DJPE
DM0DJPE DN Drug 2838232
DM0DJPE HS Phase 1
DM0DJPE SN 2838232
DM0DJPE DE Human immunodeficiency virus infection
DMM57CS ID DMM57CS
DMM57CS DN Drug 2849330
DMM57CS HS Phase 1
DMM57CS SN 2849330
DMM57CS DT Antibody
DMM57CS DE Solid tumour/cancer
DMNFEC6 ID DMNFEC6
DMNFEC6 DN Drug 2878175
DMNFEC6 HS Phase 1
DMNFEC6 SN 2878175
DMNFEC6 DE Hepatitis virus infection
DMWXQC9 ID DMWXQC9
DMWXQC9 DN Drug 2881078
DMWXQC9 HS Phase 1
DMWXQC9 SN 2881078
DMWXQC9 DE Heart failure
DMXCN37 ID DMXCN37
DMXCN37 DN DS-1040
DMXCN37 HS Phase 1
DMXCN37 PC 260178
DMXCN37 MW 265.69
DMXCN37 FM C13H12ClNO3
DMXCN37 IC InChI=1S/C13H12ClNO3/c1-18-7-6-15-11-10(14)12(16)8-4-2-3-5-9(8)13(11)17/h2-5,15H,6-7H2,1H3
DMXCN37 CS COCCNC1=C(C(=O)C2=CC=CC=C2C1=O)Cl
DMXCN37 IK IAPJSKHYZZLKBU-UHFFFAOYSA-N
DMXCN37 IU 2-chloro-3-(2-methoxyethylamino)naphthalene-1,4-dione
DMXCN37 CA CAS 22272-22-6
DMXCN37 DE Ischemic stroke
DMPR3A6 ID DMPR3A6
DMPR3A6 DN DS-1055
DMPR3A6 HS Phase 1
DMPR3A6 CP Daiichi Sankyo
DMPR3A6 DT Antibody
DMPR3A6 DE Solid tumour/cancer
DM42KZW ID DM42KZW
DM42KZW DN DS-1093
DM42KZW HS Phase 1
DM42KZW PC 2723758
DM42KZW MW 130.15
DM42KZW FM C5H10N2O2
DM42KZW IC InChI=1S/C5H10N2O2/c8-5(9)4-3-6-1-2-7-4/h4,6-7H,1-3H2,(H,8,9)
DM42KZW CS C1CNC(CN1)C(=O)O
DM42KZW IK JSSXHAMIXJGYCS-UHFFFAOYSA-N
DM42KZW IU piperazine-2-carboxylic acid
DM42KZW CA CAS 2762-32-5
DM42KZW DE Anemia
DM029TQ ID DM029TQ
DM029TQ DN DS-1150b
DM029TQ HS Phase 1
DM029TQ CP Daiichi sankyo
DM029TQ DE Type-2 diabetes
DMXST9F ID DMXST9F
DMXST9F DN DS-1205
DMXST9F HS Phase 1
DMXST9F CP Daiichi Sankyo Parsippany, NJ
DMXST9F DE Non-small-cell lung cancer
DMNDGPT ID DMNDGPT
DMNDGPT DN DS-2969
DMNDGPT HS Phase 1
DMNDGPT CP Daiichi Sankyo
DMNDGPT DT Small molecular drug
DMNDGPT DE Clostridium infection
DMA2B5Y ID DMA2B5Y
DMA2B5Y DN DS-3032
DMA2B5Y HS Phase 1
DMA2B5Y CP Daiichi sankyo
DMA2B5Y DE Solid tumour/cancer; Haematological malignancy
DMG7I5J ID DMG7I5J
DMG7I5J DN DS-3078
DMG7I5J HS Phase 1
DMG7I5J CP Daiichi Sankyo
DMG7I5J DE Lymphoma; Solid tumour/cancer
DMRLPFG ID DMRLPFG
DMRLPFG DN DS-3201
DMRLPFG HS Phase 1
DMRLPFG SN QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione
DMRLPFG CP Daiichi Sankyo Basking Ridge, NJ
DMRLPFG PC 22627096
DMRLPFG MW 255.27
DMRLPFG FM C14H13N3O2
DMRLPFG IC InChI=1S/C14H13N3O2/c1-9-15-8-10(16-9)6-7-17-13(18)11-4-2-3-5-12(11)14(17)19/h2-5,8H,6-7H2,1H3,(H,15,16)
DMRLPFG CS CC1=NC=C(N1)CCN2C(=O)C3=CC=CC=C3C2=O
DMRLPFG IK QTGYNKYZRZATJB-UHFFFAOYSA-N
DMRLPFG IU 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]isoindole-1,3-dione
DMRLPFG DE Acute lymphoblastic leukaemia; Acute myeloid leukaemia
DM6WN9X ID DM6WN9X
DM6WN9X DN DS-3801
DM6WN9X HS Phase 1
DM6WN9X PC 69388802
DM6WN9X MW 280.16
DM6WN9X FM C10H18BrNO3
DM6WN9X IC InChI=1S/C10H18BrNO3/c1-10(2,3)15-9(13)12-4-5-14-8(6-11)7-12/h8H,4-7H2,1-3H3/t8-/m1/s1
DM6WN9X CS CC(C)(C)OC(=O)N1CCO[C@@H](C1)CBr
DM6WN9X IK RLXCSEPIBOWMOJ-MRVPVSSYSA-N
DM6WN9X IU tert-butyl (2S)-2-(bromomethyl)morpholine-4-carboxylate
DM6WN9X CA CAS 919286-71-8
DM6WN9X DE Constipation
DM0RD4F ID DM0RD4F
DM0RD4F DN DS-6051
DM0RD4F HS Phase 1
DM0RD4F DE Solid tumour/cancer
DMTKZ1Q ID DMTKZ1Q
DMTKZ1Q DN DS-6157
DMTKZ1Q HS Phase 1
DMTKZ1Q CP Daiichi Sankyo
DMTKZ1Q DT Antibody drug conjugate
DMTKZ1Q DE Gastrointestinal stromal tumour
DM7C4U9 ID DM7C4U9
DM7C4U9 DN DS-7309
DM7C4U9 HS Phase 1
DM7C4U9 CP Daiichi Sankyo
DM7C4U9 PC 22278920
DM7C4U9 MW 217.31
DM7C4U9 FM C14H19NO
DM7C4U9 IC InChI=1S/C14H19NO/c1-11-8-15(9-12(2)14(11)16)10-13-6-4-3-5-7-13/h3-7,11-12H,8-10H2,1-2H3
DM7C4U9 CS CC1CN(CC(C1=O)C)CC2=CC=CC=C2
DM7C4U9 IK KUUYMZATYJQLLZ-UHFFFAOYSA-N
DM7C4U9 IU 1-benzyl-3,5-dimethylpiperidin-4-one
DM7C4U9 CA CAS 836-21-5
DM7C4U9 DE Diabetic complication
DMCFJM3 ID DMCFJM3
DMCFJM3 DN DS-7423
DMCFJM3 HS Phase 1
DMCFJM3 CP Daiichi Sankyo
DMCFJM3 DE Solid tumour/cancer
DMJPUDW ID DMJPUDW
DMJPUDW DN DS-8273
DMJPUDW HS Phase 1
DMJPUDW CP Daiichi Sankyo
DMJPUDW DT Antibody
DMJPUDW DE Solid tumour/cancer; Colorectal cancer
DM31VNC ID DM31VNC
DM31VNC DN DS-8895
DM31VNC HS Phase 1
DM31VNC DT Antibody
DM31VNC DE Solid tumour/cancer
DM4ZCY0 ID DM4ZCY0
DM4ZCY0 DN DSP-0337
DM4ZCY0 HS Phase 1
DM4ZCY0 CP Sumitomo Dainippon Pharma
DM4ZCY0 DT Small molecular drug
DM4ZCY0 DE Solid tumour/cancer
DMY95MZ ID DMY95MZ
DMY95MZ DN DSP-0565
DMY95MZ HS Phase 1
DMY95MZ CP Sunovion pharmaceuticals
DMY95MZ PC 46189864
DMY95MZ MW 229.25
DMY95MZ FM C14H12FNO
DMY95MZ IC InChI=1S/C14H12FNO/c15-13-8-4-3-7-12(13)11-6-2-1-5-10(11)9-14(16)17/h1-8H,9H2,(H2,16,17)
DMY95MZ CS C1=CC=C(C(=C1)CC(=O)N)C2=CC=CC=C2F
DMY95MZ IK MWAPNZXZUGCADE-UHFFFAOYSA-N
DMY95MZ IU 2-[2-(2-fluorophenyl)phenyl]acetamide
DMY95MZ DE Epilepsy
DMJDP0E ID DMJDP0E
DMJDP0E DN DSP-1053
DMJDP0E HS Phase 1
DMJDP0E CP Sunovion Pharmaceuticals
DMJDP0E PC 44182694
DMJDP0E MW 502.4
DMJDP0E FM C26H32BrNO4
DMJDP0E IC InChI=1S/C26H32BrNO4/c1-30-14-15-32-26-18-21(2-4-23(26)27)16-20-7-11-28(12-8-20)10-6-19-3-5-25-22(17-19)24(29)9-13-31-25/h2-5,17-18,20H,6-16H2,1H3
DMJDP0E CS COCCOC1=C(C=CC(=C1)CC2CCN(CC2)CCC3=CC4=C(C=C3)OCCC4=O)Br
DMJDP0E IK ZSVLGHSNQJYODD-UHFFFAOYSA-N
DMJDP0E IU 6-[2-[4-[[4-bromo-3-(2-methoxyethoxy)phenyl]methyl]piperidin-1-yl]ethyl]-2,3-dihydrochromen-4-one
DMJDP0E DE Major depressive disorder
DM4WSHG ID DM4WSHG
DM4WSHG DN DSP-1200
DM4WSHG HS Phase 1
DM4WSHG CP Sunovion Pharmaceuticals Marlborough, MA
DM4WSHG DE Depression
DM0WTMD ID DM0WTMD
DM0WTMD DN DSP-2230
DM0WTMD HS Phase 1
DM0WTMD CP Sumitomo Dainippon Pharma
DM0WTMD PC 129080919
DM0WTMD MW 419.4
DM0WTMD FM C20H20F3N5O2
DM0WTMD IC InChI=1S/C20H20F3N5O2/c1-10(19(24)29)25-9-16-26-15-5-6-17(27-20(15)28(16)11-3-2-4-11)30-12-7-13(21)18(23)14(22)8-12/h5-8,10-11,25H,2-4,9H2,1H3,(H2,24,29)/t10-/m0/s1
DM0WTMD CS C[C@@H](C(=O)N)NCC1=NC2=C(N1C3CCC3)N=C(C=C2)OC4=CC(=C(C(=C4)F)F)F
DM0WTMD IK HHXCJIMPEJSJTG-JTQLQIEISA-N
DM0WTMD IU (2S)-2-[[3-cyclobutyl-5-(3,4,5-trifluorophenoxy)imidazo[4,5-b]pyridin-2-yl]methylamino]propanamide
DM0WTMD DE Neuropathic pain
DMYHU24 ID DMYHU24
DMYHU24 DN DSP-3905
DMYHU24 HS Phase 1
DMYHU24 CP Sumitomo Dainippon Pharma
DMYHU24 DE Neuropathic pain
DMM86OH ID DMM86OH
DMM86OH DN DSP-6745
DMM86OH HS Phase 1
DMM86OH CP Sunovion Pharmaceuticals Marlborough, MA
DMM86OH DE Parkinson disease
DM2PYE0 ID DM2PYE0
DM2PYE0 DN DSP-8658
DM2PYE0 HS Phase 1
DM2PYE0 CP Sunovion Pharmaceuticals
DM2PYE0 DE Type-2 diabetes; Alzheimer disease
DM69ZBU ID DM69ZBU
DM69ZBU DN DST-2970
DM69ZBU HS Phase 1
DM69ZBU CP DisperSol Technologies
DM69ZBU DT Small molecular drug
DM69ZBU DE Prostate cancer
DMYFOJQ ID DMYFOJQ
DMYFOJQ DN DT-200
DMYFOJQ HS Phase 1
DMYFOJQ CP Akashi Therapeutics Cambridge, MA
DMYFOJQ DE Duchenne dystrophy
DM5AGKV ID DM5AGKV
DM5AGKV DN DTRMWXHS-12
DM5AGKV HS Phase 1
DM5AGKV SN DTRM-12
DM5AGKV CP Zhejiang DTRM Biopharma
DM5AGKV DT Small molecular drug
DM5AGKV DE B-cell lymphoma; Chronic lymphocytic leukaemia
DM1FX09 ID DM1FX09
DM1FX09 DN DT-TX-30
DM1FX09 HS Phase 1
DM1FX09 SN DT-TX-30-SE
DM1FX09 CP Boehringer Ingelheim Corp
DM1FX09 DE Angina pectoris
DM8WBNF ID DM8WBNF
DM8WBNF DN DTX401
DM8WBNF HS Phase 1
DM8WBNF CP Ultragenyx Pharmaceutical
DM8WBNF DT Gene therapy
DM8WBNF DE Pompe disease
DM3P0H1 ID DM3P0H1
DM3P0H1 DN Duvortuxizumab
DM3P0H1 HS Phase 1
DM3P0H1 CP Janssen Research & Development Raritan, NJ
DM3P0H1 DE B-cell lymphoma
DMDSVRP ID DMDSVRP
DMDSVRP DN DV-1179
DMDSVRP HS Phase 1
DMDSVRP CP Dynavax Technologies
DMDSVRP DE Systemic lupus erythematosus; Autoimmune disease
DMJ0Y86 ID DMJ0Y86
DMJ0Y86 DN DV281
DMJ0Y86 HS Phase 1
DMJ0Y86 CP Dynavax Berkeley, CA
DMJ0Y86 DE Non-small-cell lung cancer
DMQKDJZ ID DMQKDJZ
DMQKDJZ DN DWJ-208
DMQKDJZ HS Phase 1
DMQKDJZ CP Daewoong Pharmaceutical Co Ltd
DMQKDJZ DE Pain; Cancer related pain; Neuropathic pain
DM4XZY9 ID DM4XZY9
DM4XZY9 DN DWP-09031
DM4XZY9 HS Phase 1
DM4XZY9 SN DWJ-301
DM4XZY9 CP Daewoong Pharmaceutical Co Ltd
DM4XZY9 DE Alzheimer disease
DMS1NC8 ID DMS1NC8
DMS1NC8 DN DZ-2640
DMS1NC8 HS Phase 1
DMS1NC8 SN (1R,5S,6S)-2-[6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-6(S)-ylsulfanyl]-6-[1(R)-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester
DMS1NC8 PC 101700650
DMS1NC8 MW 463.5
DMS1NC8 FM C22H29N3O6S
DMS1NC8 IC InChI=1S/C22H29N3O6S/c1-11-16-15(12(2)26)19(27)25(16)17(20(28)30-10-31-21(29)22(3,4)5)18(11)32-13-8-14-23-6-7-24(14)9-13/h6-7,11-13,15-16,26H,8-10H2,1-5H3/t11-,12-,13+,15-,16+/m1/s1
DMS1NC8 CS C[C@@H]1[C@H]2[C@H](C(=O)N2C(=C1S[C@H]3CC4=NC=CN4C3)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O
DMS1NC8 IK SVIXKYNOOFZUFA-QUEVPRLRSA-N
DMS1NC8 IU 2,2-dimethylpropanoyloxymethyl (4R,5R,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMS1NC8 DE Bacterial infection
DMEQY4Z ID DMEQY4Z
DMEQY4Z DN DZD1516
DMEQY4Z HS Phase 1
DMEQY4Z CP Dizal Pharmaceuticals
DMEQY4Z DT Small molecular drug
DMEQY4Z DE HER2-positive breast cancer
DM3LOF1 ID DM3LOF1
DM3LOF1 DN E 7974
DM3LOF1 HS Phase 1
DM3LOF1 SN 26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872
DM3LOF1 CP Eisai Co. Ltd.
DM3LOF1 DT Small molecular drug
DM3LOF1 PC 10127315
DM3LOF1 MW 437.6
DM3LOF1 FM C24H43N3O4
DM3LOF1 IC InChI=1S/C24H43N3O4/c1-15(2)19(14-17(5)23(30)31)26(9)22(29)20(24(6,7)8)25-21(28)18-12-10-11-13-27(18)16(3)4/h14-16,18-20H,10-13H2,1-9H3,(H,25,28)(H,30,31)/b17-14+/t18-,19-,20-/m1/s1
DM3LOF1 CS CC(C)[C@@H](/C=C(\\C)/C(=O)O)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H]1CCCCN1C(C)C
DM3LOF1 IK FWYMMXUDTATKLG-PGLMLKKXSA-N
DM3LOF1 IU (E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
DM3LOF1 CA CAS 610787-07-0
DM3LOF1 DE Ovarian cancer
DMNEVKA ID DMNEVKA
DMNEVKA DN E2012
DMNEVKA HS Phase 1
DMNEVKA SN 870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N
DMNEVKA CP Eisai
DMNEVKA DT Small molecular drug
DMNEVKA PC 11560787
DMNEVKA MW 419.5
DMNEVKA FM C25H26FN3O2
DMNEVKA IC InChI=1S/C25H26FN3O2/c1-17-15-28(16-27-17)23-11-6-19(14-24(23)31-3)13-21-5-4-12-29(25(21)30)18(2)20-7-9-22(26)10-8-20/h6-11,13-16,18H,4-5,12H2,1-3H3/b21-13+/t18-/m0/s1
DMNEVKA CS CC1=CN(C=N1)C2=C(C=C(C=C2)/C=C/3\\CCCN(C3=O)[C@@H](C)C4=CC=C(C=C4)F)OC
DMNEVKA IK PUOAETJYKQITMO-LANLRWRYSA-N
DMNEVKA IU (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one
DMNEVKA CA CAS 870843-42-8
DMNEVKA DE Alzheimer disease
DMQDKYV ID DMQDKYV
DMQDKYV DN E-2212
DMQDKYV HS Phase 1
DMQDKYV CP Eisai Co Ltd
DMQDKYV PC 46854987
DMQDKYV MW 480.5
DMQDKYV FM C25H23F3N6O
DMQDKYV IC InChI=1S/C25H23F3N6O/c1-16-14-33(15-29-16)21-11-9-17(30-24(21)35-2)10-12-22-31-23-19(7-5-13-34(23)32-22)18-6-3-4-8-20(18)25(26,27)28/h3-4,6,8-12,14-15,19H,5,7,13H2,1-2H3/b12-10+/t19-/m0/s1
DMQDKYV CS CC1=CN(C=N1)C2=C(N=C(C=C2)/C=C/C3=NN4CCC[C@H](C4=N3)C5=CC=CC=C5C(F)(F)F)OC
DMQDKYV IK SSGLBUGNISHUAO-RDELFYGPSA-N
DMQDKYV IU (8S)-2-[(E)-2-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]ethenyl]-8-[2-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine
DMQDKYV CA CAS 1123193-82-7
DMQDKYV DE Alzheimer disease
DM4BD5U ID DM4BD5U
DM4BD5U DN E2730
DM4BD5U HS Phase 1
DM4BD5U CP Eisai Woodcliff Lake, NJ
DM4BD5U DE Epilepsy
DMFVT43 ID DMFVT43
DMFVT43 DN E7046
DMFVT43 HS Phase 1
DMFVT43 SN MKLKAQMPKHNQPR-NSHDSACASA-N; UNII-YWY620GU8I; 1369489-71-3; E-7046; YWY620GU8I; ER-886046; SCHEMBL881212; CHEMBL3670685; MolPort-044-561-624; BDBM119448; EX-A1726; ZINC114766778; CS-7559; Benzoic acid, 4-((1S)-1-(((3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazol-4-yl)carbonyl)amino)ethyl)-; AC-30338; HY-103088; US8686018, 107; (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid; 4-[(1S)-1-[[3-(difluoromethyl)-1-methyl-5-[3-(trifluoromet
DMFVT43 CP Adlai Nortye Hangzhou, China
DMFVT43 PC 56944705
DMFVT43 MW 483.4
DMFVT43 FM C22H18F5N3O4
DMFVT43 IC InChI=1S/C22H18F5N3O4/c1-11(12-6-8-13(9-7-12)21(32)33)28-19(31)16-17(18(23)24)29-30(2)20(16)34-15-5-3-4-14(10-15)22(25,26)27/h3-11,18H,1-2H3,(H,28,31)(H,32,33)/t11-/m0/s1
DMFVT43 CS C[C@@H](C1=CC=C(C=C1)C(=O)O)NC(=O)C2=C(N(N=C2C(F)F)C)OC3=CC=CC(=C3)C(F)(F)F
DMFVT43 IK MKLKAQMPKHNQPR-NSHDSACASA-N
DMFVT43 IU 4-[(1S)-1-[[3-(difluoromethyl)-1-methyl-5-[3-(trifluoromethyl)phenoxy]pyrazole-4-carbonyl]amino]ethyl]benzoic acid
DMFVT43 CA CAS 1369489-71-3
DMFVT43 DE Rectal adenocarcinoma
DMDOCNW ID DMDOCNW
DMDOCNW DN E-7050
DMDOCNW HS Phase 1
DMDOCNW SN C-Met and VEGF-2 tyrosine kinase inhibitor (oral, cancer), Eisai
DMDOCNW CP Eisai Co Ltd
DMDOCNW DT Small molecular drug
DMDOCNW PC 16118392
DMDOCNW MW 633.7
DMDOCNW FM C33H37F2N7O4
DMDOCNW IC InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)
DMDOCNW CS CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
DMDOCNW IK UQRCJCNVNUFYDX-UHFFFAOYSA-N
DMDOCNW IU 1-N'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
DMDOCNW CA CAS 928037-13-2
DMDOCNW DE Head and neck cancer
DM8TU5R ID DM8TU5R
DM8TU5R DN E7766
DM8TU5R HS Phase 1
DM8TU5R CP Eisai
DM8TU5R DT Small molecular drug
DM8TU5R DE Solid tumour/cancer
DM8RD4T ID DM8RD4T
DM8RD4T DN EC0489
DM8RD4T HS Phase 1
DM8RD4T SN EC-0489
DM8RD4T CP Endocyte
DM8RD4T DT Small molecular drug
DM8RD4T PC 25229525
DM8RD4T MW 2550.7
DM8RD4T FM C111H156N22O43S2
DM8RD4T IC InChI=1S/C111H156N22O43S2/c1-6-107(172)39-52-40-110(104(170)175-5,89-57(29-33-132(46-52)51-107)56-11-8-9-12-60(56)120-89)59-37-58-68(38-75(59)174-4)131(3)101-109(58)31-34-133-32-10-30-108(7-2,100(109)133)102(168)111(101,173)103(169)129-130-106(171)176-35-36-177-178-50-67(99(166)167)126-96(162)63(19-25-78(145)116-45-71(139)85(153)88(156)74(142)49-136)122-95(161)65(22-28-81(149)150)124-93(159)62(18-24-77(144)115-44-70(138)84(152)87(155)73(141)48-135)121-94(160)64(21-27-80(147)148)123-92(158)61(17-23-76(143)114-43-69(137)83(151)86(154)72(140)47-134)119-79(146)26-20-66(98(164)165)125-91(157)53-13-15-54(16-14-53)113-41-55-42-117-90-82(118-55)97(163)128-105(112)127-90/h8-16,30,37-38,42,52,61-67,69-74,83-88,100-102,113,120,134-142,151-156,168,172-173H,6-7,17-29,31-36,39-41,43-51H2,1-5H3,(H,114,143)(H,115,144)(H,116,145)(H,119,146)(H,121,160)(H,122,161)(H,123,158)(H,124,159)(H,125,157)(H,126,162)(H,129,169)(H,130,171)(H,147,148)(H,149,150)(H,164,165)(H,166,167)(H3,112,117,127,128,163)/t52-,61-,62-,63-,64-,65-,66-,67-,69-,70-,71-,72+,73+,74+,83+,84+,85+,86+,87+,88+,100-,101+,102+,107-,108+,109+,110-,111-/m0/s1
DM8RD4T CS CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)NNC(=O)OCCSSC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O
DM8RD4T IK PHCAWPRQWLBYTH-HCDHKMFTSA-N
DM8RD4T IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1,5-dioxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1,5-dioxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]amino]-1,5-dioxo-5-[[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino]pentan-2-yl]amino]-5-oxopentanoic acid
DM8RD4T DE Solid tumour/cancer
DMXW07J ID DMXW07J
DMXW07J DN EDP-239
DMXW07J HS Phase 1
DMXW07J SN NS5a HCV inhibitors, Enanta
DMXW07J CP Enanta pharmaceuticals; novartis pharmaceuticals
DMXW07J DE Hepatitis C virus infection
DMWTVM1 ID DMWTVM1
DMWTVM1 DN EDP-322
DMWTVM1 HS Phase 1
DMWTVM1 SN EP-16322; Antibacterial (oral, Gram-positive infections), Enanta; EDP-MRSA-1 (oral), Enanta
DMWTVM1 CP Enanta Pharmaceuticals Inc
DMWTVM1 DE Bacterial infection
DM8KRA3 ID DM8KRA3
DM8KRA3 DN EDP-514
DM8KRA3 HS Phase 1
DM8KRA3 CP Enanta Pharmaceuticals
DM8KRA3 DT Small molecular drug
DM8KRA3 DE Chronic HBV infection
DM3AD65 ID DM3AD65
DM3AD65 DN EGFR806-specific CAR T cell
DM3AD65 HS Phase 1
DM3AD65 CP Seattle Children's Hospital
DM3AD65 DT CAR T Cell Therapy
DM3AD65 DE Atypical teratoid/rhabdoid tumour; Choroid plexus carcinoma; Ependymoma; Germ cell tumour; Glioma; Medulloblastoma; Pineoblastoma; Gastric adenocarcinoma
DMZN35T ID DMZN35T
DMZN35T DN EGFRt/19-28z/4-1BBL CAR T cells
DMZN35T HS Phase 1
DMZN35T CP Memorial Sloan Kettering Cancer Center
DMZN35T DT CAR T Cell Therapy
DMZN35T DE Chronic lymphocytic leukaemia
DM6XWV4 ID DM6XWV4
DM6XWV4 DN EGFRvIII CAR T cells
DM6XWV4 HS Phase 1
DM6XWV4 CP Gary Archer Ph.D.
DM6XWV4 DT CAR T Cell Therapy
DM6XWV4 DE Glioblastoma multiforme; Recurrent glioblastoma
DMA46RN ID DMA46RN
DMA46RN DN EGFRvIII-CARs
DMA46RN HS Phase 1
DMA46RN CP Gary Archer Ph.D.
DMA46RN DT CAR T Cell Therapy
DMA46RN DE Recurrent glioblastoma
DMDPGCS ID DMDPGCS
DMDPGCS DN EGT-0001474
DMDPGCS HS Phase 1
DMDPGCS CP Theracos
DMDPGCS PC 75059718
DMDPGCS MW 695.2
DMDPGCS FM C34H47ClN2O11
DMDPGCS IC InChI=1S/C24H29ClO7.2C5H9NO2/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18;2*7-5(8)4-2-1-3-6-4/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2;2*4,6H,1-3H2,(H,7,8)
DMDPGCS CS C1CC(NC1)C(=O)O.C1CC(NC1)C(=O)O.C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
DMDPGCS IK DAQOCDWUCJBXEI-UHFFFAOYSA-N
DMDPGCS IU 2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;pyrrolidine-2-carboxylic acid
DMDPGCS DE Type-2 diabetes
DMXAUB7 ID DMXAUB7
DMXAUB7 DN EI1071
DMXAUB7 HS Phase 1
DMXAUB7 CP Elixiron Immunotherapeutics
DMXAUB7 DT Small molecular drug
DMXAUB7 DE Solid tumour/cancer
DMA4BRV ID DMA4BRV
DMA4BRV DN Elinogrel
DMA4BRV HS Phase 1
DMA4BRV SN Elinogrel; 936500-94-6; UNII-915Y8E749J; 915Y8E749J; 5-CHLORO-N-[[[4-[6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL]PHENYL]AMINO]CARBONYL]-2-THIOPHENESULFONAMIDE; PRT-060128; Elinogrel [USAN:INN]; PRT 060128; Elinogrel (USAN/INN); SCHEMBL160663; CHEMBL2103828; MolPort-035-941-202; ZINC43153259; BDBM50397204; AKOS025142086; NCGC00387478-01; AN-26210; FT-0724857; D09607; 500C946; 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea
DMA4BRV CP Novartis Pharmaceuticals; Portola Pharmaceuticals
DMA4BRV DT Small molecular drug
DMA4BRV PC 16066663
DMA4BRV MW 523.9
DMA4BRV FM C20H15ClFN5O5S2
DMA4BRV IC InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)
DMA4BRV CS CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)(=O)C4=CC=C(S4)Cl)F
DMA4BRV IK LGSDFTPAICUONK-UHFFFAOYSA-N
DMA4BRV IU 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea
DMA4BRV CA CAS 936500-94-6
DMA4BRV DE Myocardial infarction
DMM9S51 ID DMM9S51
DMM9S51 DN ELND-002
DMM9S51 HS Phase 1
DMM9S51 SN ELND-002 (oral, multiple sclerosis); Alpha-4 integrin antagonists (oral, autoimmune diseases), Elan; Alpha-4 integrin antagonists (oral, multiple sclerosis), Elan; ELND-002 (oral, multiple sclerosis), Elan
DMM9S51 CP Elan Corp plc
DMM9S51 DE Autoimmune diabetes
DMLQYVD ID DMLQYVD
DMLQYVD DN ELND-004
DMLQYVD HS Phase 1
DMLQYVD CP Elan Corp plc
DMLQYVD DE Autoimmune diabetes
DMQPI4V ID DMQPI4V
DMQPI4V DN ELOMOTECAN HYDROCHLORIDE
DMQPI4V HS Phase 1
DMQPI4V SN BN-80927; R-1559; Elomotecan hydrochloride; (+)-9-Chloro-5(R)-ethyl-5-hydroxy-10-methyl-12-(4-methylpiperidin-1-ylmethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione hydrochloride
DMQPI4V DT Small molecular drug
DMQPI4V PC 216300
DMQPI4V MW 558.5
DMQPI4V FM C29H33Cl2N3O4
DMQPI4V IC InChI=1S/C29H32ClN3O4.ClH/c1-4-29(36)12-26(34)37-15-21-22(29)10-25-27-20(14-33(25)28(21)35)19(13-32-7-5-16(2)6-8-32)18-9-17(3)23(30)11-24(18)31-27;/h9-11,16,36H,4-8,12-15H2,1-3H3;1H/t29-;/m1./s1
DMQPI4V CS CC[C@]1(CC(=O)OCC2=C1C=C3C4=NC5=C(C=C(C(=C5)Cl)C)C(=C4CN3C2=O)CN6CCC(CC6)C)O.Cl
DMQPI4V IK OLYFGLXPXPABOP-XXIQNXCHSA-N
DMQPI4V IU (20R)-6-chloro-20-ethyl-20-hydroxy-7-methyl-10-[(4-methylpiperidin-1-yl)methyl]-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4(9),5,7,10,15(21)-heptaene-14,18-dione;hydrochloride
DMQPI4V CA CAS 220997-99-9
DMQPI4V DE Solid tumour/cancer
DMIV04R ID DMIV04R
DMIV04R DN Elpetrigine
DMIV04R HS Phase 1
DMIV04R SN ELPETRIGINE; 212778-82-0; JZP-4; 3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine; UNII-1X64S9H3ZS; 1X64S9H3ZS; 2,6-DIAMINO-3-(2,3,5-TRICHLOROPHENYL)PYRAZINE; 2,6-DIAMINO-3-(2,3,5-TRICHLOROPHENYL)-PYRAZINE; JZP4; Elpetrigine [USAN:INN]; Elpetrigine (USAN/INN); CHEMBL29919; SCHEMBL978547; ZINC9967; CTK0J9586; NNXUYJFHOVCRSM-UHFFFAOYSA-N; AKOS015966238; AN-29755; ACM212778820; D09609; 778D820; 2,6-Diamino-3-(2,3,5-trichlorophenyl) pyrazine; 2,6-Pyrazinediamine, 3-(2,3,5-trichlorophenyl)-; 2,6-Diamino-3- (2,3,5-trichlorophenyl) pyrazin
DMIV04R CP Jazz Pharmaceuticals
DMIV04R DT Small molecular drug
DMIV04R PC 9926001
DMIV04R MW 289.5
DMIV04R FM C10H7Cl3N4
DMIV04R IC InChI=1S/C10H7Cl3N4/c11-4-1-5(8(13)6(12)2-4)9-10(15)17-7(14)3-16-9/h1-3H,(H4,14,15,17)
DMIV04R CS C1=C(C=C(C(=C1C2=NC=C(N=C2N)N)Cl)Cl)Cl
DMIV04R IK NNXUYJFHOVCRSM-UHFFFAOYSA-N
DMIV04R IU 3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine
DMIV04R CA CAS 212778-82-0
DMIV04R DE Bipolar disorder
DM4W7Z0 ID DM4W7Z0
DM4W7Z0 DN Emactuzumab
DM4W7Z0 HS Phase 1
DM4W7Z0 CP GenentechSouth San Francisco, CA
DM4W7Z0 DE Solid tumour/cancer
DM6AMKZ ID DM6AMKZ
DM6AMKZ DN Embeconazole
DM6AMKZ HS Phase 1
DM6AMKZ SN CS-758; R-120758; Triazole derivative (oral, fungal infection), Daiichi Sankyo
DM6AMKZ CP Sankyo Co Ltd
DM6AMKZ DT Small molecular drug
DM6AMKZ PC 6475890
DM6AMKZ MW 542.6
DM6AMKZ FM C27H25F3N4O3S
DM6AMKZ IC InChI=1S/C27H25F3N4O3S/c1-18(27(35,15-34-17-32-16-33-34)23-9-8-21(28)11-25(23)30)38-22-13-36-26(37-14-22)5-3-2-4-20-7-6-19(12-31)10-24(20)29/h2-11,16-18,22,26,35H,13-15H2,1H3/b4-2+,5-3+/t18-,22?,26?,27-/m1/s1
DM6AMKZ CS C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)SC3COC(OC3)/C=C/C=C/C4=C(C=C(C=C4)C#N)F
DM6AMKZ IK XSRKBFUVSRRJDX-ILLAMVBCSA-N
DM6AMKZ IU 4-[(1E,3E)-4-[5-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]sulfanyl-1,3-dioxan-2-yl]buta-1,3-dienyl]-3-fluorobenzonitrile
DM6AMKZ CA CAS 329744-44-7
DM6AMKZ DE Fungal infection
DM38JZU ID DM38JZU
DM38JZU DN EMD-1204831
DM38JZU HS Phase 1
DM38JZU CP Merck KGaA
DM38JZU PC 25134692
DM38JZU MW 473.5
DM38JZU FM C25H27N7O3
DM38JZU IC InChI=1S/C25H27N7O3/c1-30-18-21(14-28-30)23-5-6-24(33)32(29-23)17-19-3-2-4-20(13-19)25-26-15-22(16-27-25)35-12-9-31-7-10-34-11-8-31/h2-6,13-16,18H,7-12,17H2,1H3
DM38JZU CS CN1C=C(C=N1)C2=NN(C(=O)C=C2)CC3=CC(=CC=C3)C4=NC=C(C=N4)OCCN5CCOCC5
DM38JZU IK CIUKPBWULKEZMF-UHFFFAOYSA-N
DM38JZU IU 6-(1-methylpyrazol-4-yl)-2-[[3-[5-(2-morpholin-4-ylethoxy)pyrimidin-2-yl]phenyl]methyl]pyridazin-3-one
DM38JZU CA CAS 1100598-15-9
DM38JZU DE Solid tumour/cancer
DMQ6YAZ ID DMQ6YAZ
DMQ6YAZ DN EMD-534085
DMQ6YAZ HS Phase 1
DMQ6YAZ SN EMD-534085; 858668-07-2; EMD534085; EMD 534085; UNII-AL67QX8036; CHEMBL1077204; AL67QX8036; 1-(2-(Dimethylamino)ethyl)-3-(((2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano(3,2-C)quinolin-2-yl)methyl)urea; 1-[2-(dimethylamino)ethyl]-3-{[(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl}urea
DMQ6YAZ DT Small molecular drug
DMQ6YAZ PC 23634407
DMQ6YAZ MW 476.5
DMQ6YAZ FM C25H31F3N4O2
DMQ6YAZ IC InChI=1S/C25H31F3N4O2/c1-32(2)13-12-29-24(33)30-15-18-9-10-19-22(16-6-4-3-5-7-16)31-21-11-8-17(25(26,27)28)14-20(21)23(19)34-18/h3-8,11,14,18-19,22-23,31H,9-10,12-13,15H2,1-2H3,(H2,29,30,33)/t18-,19+,22+,23+/m1/s1
DMQ6YAZ CS CN(C)CCNC(=O)NC[C@H]1CC[C@H]2[C@@H](NC3=C([C@H]2O1)C=C(C=C3)C(F)(F)F)C4=CC=CC=C4
DMQ6YAZ IK MARIUIDCPUZLKZ-FUKQBSRTSA-N
DMQ6YAZ IU 1-[[(2R,4aS,5R,10bS)-5-phenyl-9-(trifluoromethyl)-3,4,4a,5,6,10b-hexahydro-2H-pyrano[3,2-c]quinolin-2-yl]methyl]-3-[2-(dimethylamino)ethyl]urea
DMQ6YAZ CA CAS 858668-07-2
DMQ6YAZ DE Haematological malignancy
DMBIPQL ID DMBIPQL
DMBIPQL DN Enavatuzumab
DMBIPQL HS Phase 1
DMBIPQL CP Abbott Laboratories
DMBIPQL DT Antibody
DMBIPQL DE Solid tumour/cancer
DMKPBVX ID DMKPBVX
DMKPBVX DN Englitazone sodium
DMKPBVX HS Phase 1
DMKPBVX SN Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt
DMKPBVX DT Small molecular drug
DMKPBVX PC 13728795
DMKPBVX MW 375.4
DMKPBVX FM C20H18NNaO3S
DMKPBVX IC InChI=1S/C20H19NO3S.Na/c22-19-18(25-20(23)21-19)12-14-6-9-17-15(10-14)7-8-16(24-17)11-13-4-2-1-3-5-13;/h1-6,9-10,16,18H,7-8,11-12H2,(H,21,22,23);/q;+1/p-1/t16-,18?;/m1./s1
DMKPBVX CS C1CC2=C(C=CC(=C2)CC3C(=O)[N-]C(=O)S3)O[C@H]1CC4=CC=CC=C4.[Na+]
DMKPBVX IK JQWYNJRCVYGLMO-GPPXSFHXSA-M
DMKPBVX IU sodium;5-[[(2R)-2-benzyl-3,4-dihydro-2H-chromen-6-yl]methyl]-1,3-thiazolidin-3-ide-2,4-dione
DMKPBVX CA CAS 109229-57-4
DMKPBVX DE Type-2 diabetes
DMGLHYU ID DMGLHYU
DMGLHYU DN Enkastim-ev
DMGLHYU HS Phase 1
DMGLHYU SN Hsp 70 peptide-activated human natural killer cell therapy (cancer), multimmune GmbH
DMGLHYU CP Multimmune GmbH
DMGLHYU DE Solid tumour/cancer
DM9BJ3G ID DM9BJ3G
DM9BJ3G DN ENMD-1198
DM9BJ3G HS Phase 1
DM9BJ3G SN EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed
DM9BJ3G CP EntreMed
DM9BJ3G DT Small molecular drug
DM9BJ3G PC 11483754
DM9BJ3G MW 311.4
DM9BJ3G FM C20H25NO2
DM9BJ3G IC InChI=1S/C20H25NO2/c1-20-8-3-4-17(20)14-6-5-12-10-16(19(21)22)18(23-2)11-15(12)13(14)7-9-20/h3,8,10-11,13-14,17H,4-7,9H2,1-2H3,(H2,21,22)/t13-,14+,17-,20-/m0/s1
DM9BJ3G CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=CC(=C(C=C34)OC)C(=O)N
DM9BJ3G IK YQJWOUQGXATDAE-ACNBBOPNSA-N
DM9BJ3G IU (8S,9S,13R,14S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carboxamide
DM9BJ3G CA CAS 864668-87-1
DM9BJ3G DE Solid tumour/cancer
DMMJXAR ID DMMJXAR
DMMJXAR DN Entolimod
DMMJXAR HS Phase 1
DMMJXAR CP Cleveland BioLabs Buffalo, NY
DMMJXAR DE Solid tumour/cancer; Colorectal cancer; Radiation syndrome
DMQ6GUY ID DMQ6GUY
DMQ6GUY DN EOS100850
DMQ6GUY HS Phase 1
DMQ6GUY SN UNII-HQ700V0X06; HQ700V0X06; Inupadenant; Inupadenant [INN]; Inupadenant [USAN]; SCHEMBL20521605; WHO 11380; UNII-L9RDR3F7GU component QYCCLUSYHJXDEX-RWYGWLOXSA-N; 2246607-08-7; Thiazolo(5,4-E)(1,2,4)triazolo(1,5-C)pyrimidin-2(3H)-one, 5-amino-3-(2-(4-(2,4-difluoro-5-(2-((S)-methylsulfinyl)ethoxy)phenyl)-1-piperazinyl)ethyl)-8-(2-furanyl)-; Thiazolo(5,4-E)(1,2,4)triazolo(1,5-C)pyrimidin-2(3H)-one, 5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)-1-piperazinyl)ethyl)-8-(2-furanyl)-, (+)-
DMQ6GUY CP iTeos Therapeutics
DMQ6GUY DT Small molecular drug
DMQ6GUY PC 135346794
DMQ6GUY MW 604.7
DMQ6GUY FM C25H26F2N8O4S2
DMQ6GUY IC InChI=1S/C25H26F2N8O4S2/c1-41(37)12-11-39-19-14-17(15(26)13-16(19)27)33-7-4-32(5-8-33)6-9-34-22-20(40-25(34)36)23-29-21(18-3-2-10-38-18)31-35(23)24(28)30-22/h2-3,10,13-14H,4-9,11-12H2,1H3,(H2,28,30)/t41-/m0/s1
DMQ6GUY CS C[S@](=O)CCOC1=C(C=C(C(=C1)N2CCN(CC2)CCN3C4=C(C5=NC(=NN5C(=N4)N)C6=CC=CO6)SC3=O)F)F
DMQ6GUY IK QYCCLUSYHJXDEX-RWYGWLOXSA-N
DMQ6GUY IU 7-amino-10-[2-[4-[2,4-difluoro-5-[2-[(S)-methylsulfinyl]ethoxy]phenyl]piperazin-1-yl]ethyl]-4-(furan-2-yl)-12-thia-3,5,6,8,10-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7-tetraen-11-one
DMQ6GUY CA CAS 2246607-08-7
DMQ6GUY DE Solid tumour/cancer
DMKR3GD ID DMKR3GD
DMKR3GD DN EP-42675
DMKR3GD HS Phase 1
DMKR3GD SN NAPAP analogs, Organon; Factor IIa/Factor X dual inhibitors (thrombosis), Endotis; Factor IIa/Factor X dual inhibitors (thrombosis), Organon; NAPAP-PS conjugate (thrombosis), Endotis; NAPAP-PS conjugate (thrombosis), Organon
DMKR3GD CP Organon BioSciences
DMKR3GD PC 124220520
DMKR3GD MW 2477.2
DMKR3GD FM C79H125N7Na8O56S7
DMKR3GD IC InChI=1S/C79H125N7O56S7.8Na/c1-39-33-46(115-4)40(2)41(3)69(39)143(95,96)85-44(71(89)84-45(72(90)86-24-14-13-15-25-86)34-42-18-20-43(21-19-42)70(80)81)35-51(88)82-22-16-17-50(87)83-23-26-124-27-28-125-29-30-126-31-32-127-52-47(36-128-144(97,98)99)132-76(64(120-9)55(52)116-5)136-59-57(118-7)66(122-11)78(139-62(59)73(91)92)135-54-49(38-130-146(103,104)105)133-79(68(142-149(112,113)114)61(54)140-147(106,107)108)137-60-58(119-8)65(121-10)77(138-63(60)74(93)94)134-53-48(37-129-145(100,101)102)131-75(123-12)67(56(53)117-6)141-148(109,110)111;;;;;;;;/h18-21,33,44-45,47-49,52-68,75-79,85H,13-17,22-32,34-38H2,1-12H3,(H3,80,81)(H,82,88)(H,83,87)(H,84,89)(H,91,92)(H,93,94)(H,97,98,99)(H,100,101,102)(H,103,104,105)(H,106,107,108)(H,109,110,111)(H,112,113,114);;;;;;;;/t44-,45+,47+,48+,49+,52+,53+,54+,55-,56-,57-,58-,59-,60-,61-,62-,63+,64+,65+,66+,67+,68+,75-,76+,77+,78+,79+;;;;;;;;/m0......../s1
DMKR3GD CS CC1=CC(=C(C(=C1S(=O)(=O)N[C@@H](CC(=O)NCCCC(=O)NCCOCCOCCOCCO[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2OC)OC)O[C@H]3[C@@H]([C@H]([C@@H](O[C@@H]3C(=O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]5[C@@H]([C@H]([C@@H](O[C@H]5C(=O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6OC)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)C(=O)N[C@H](CC7=CC=C(C=C7)C(=N)N)C(=O)N8CCCCC8)C)C)OC.[Na].[Na].[Na].[Na].[Na].[Na].[Na].[Na]
DMKR3GD IK QYMUZBCRFQFXJQ-KIDSDGJESA-N
DMKR3GD CA CAS 343776-67-0
DMKR3GD DE Thrombosis
DM49RI7 ID DM49RI7
DM49RI7 DN EP-51216
DM49RI7 HS Phase 1
DM49RI7 SN (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide
DM49RI7 CP Euro-peptides SA
DM49RI7 DT Small molecular drug
DM49RI7 PC 6918424
DM49RI7 MW 831
DM49RI7 FM C46H58N10O5
DM49RI7 IC InChI=1S/C46H58N10O5/c1-26-32(29-13-4-7-16-35(29)50-26)23-39(53-42(57)20-12-22-48)44(59)55-41(25-34-28(3)52-37-18-9-6-15-31(34)37)46(61)56-40(45(60)54-38(43(49)58)19-10-11-21-47)24-33-27(2)51-36-17-8-5-14-30(33)36/h4-9,13-18,38-41,50-52H,10-12,19-25,47-48H2,1-3H3,(H2,49,58)(H,53,57)(H,54,60)(H,55,59)(H,56,61)/t38-,39+,40-,41+/m0/s1
DM49RI7 CS CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N[C@H](CC3=C(NC4=CC=CC=C43)C)C(=O)N[C@@H](CC5=C(NC6=CC=CC=C65)C)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)CCCN
DM49RI7 IK DFXFDNPRHWLXON-AANMMBORSA-N
DM49RI7 IU (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-(4-aminobutanoylamino)-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]hexanamide
DM49RI7 DE Eating disorder
DMW739O ID DMW739O
DMW739O DN EP-51389
DMW739O HS Phase 1
DMW739O CP Euro-peptides SA
DMW739O PC 9827407
DMW739O MW 502.6
DMW739O FM C28H34N6O3
DMW739O IC InChI=1S/C28H34N6O3/c1-15-19(17-9-5-7-11-21(17)31-15)13-23(25(29)35)33-26(36)24(34-27(37)28(3,4)30)14-20-16(2)32-22-12-8-6-10-18(20)22/h5-12,23-24,31-32H,13-14,30H2,1-4H3,(H2,29,35)(H,33,36)(H,34,37)/t23-,24-/m1/s1
DMW739O CS CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N)NC(=O)[C@@H](CC3=C(NC4=CC=CC=C43)C)NC(=O)C(C)(C)N
DMW739O IK RVAXPKJGCHKWJV-DNQXCXABSA-N
DMW739O IU 2-amino-N-[(2R)-1-[[(2R)-1-amino-3-(2-methyl-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(2-methyl-1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
DMW739O DE Eating disorder
DMV0MHI ID DMV0MHI
DMV0MHI DN EP-7041
DMV0MHI HS Phase 1
DMV0MHI SN QPVLDUCHRPJGCJ-QBIMZIAESA-N; SCHEMBL16998942
DMV0MHI CP eXIthera Pharmaceuticals Westborough, MA
DMV0MHI PC 91827409
DMV0MHI MW 402.5
DMV0MHI FM C21H30N4O4
DMV0MHI IC InChI=1S/C21H30N4O4/c1-13(15-7-5-3-2-4-6-8-15)24-21(29)25-18(20(27)28)16(19(25)26)11-14-9-10-23-17(22)12-14/h9-10,12-13,15-16,18H,2-8,11H2,1H3,(H2,22,23)(H,24,29)(H,27,28)/t13-,16-,18+/m1/s1
DMV0MHI CS C[C@H](C1CCCCCCC1)NC(=O)N2[C@@H]([C@H](C2=O)CC3=CC(=NC=C3)N)C(=O)O
DMV0MHI IK QPVLDUCHRPJGCJ-QBIMZIAESA-N
DMV0MHI IU (2S,3R)-3-[(2-aminopyridin-4-yl)methyl]-1-[[(1R)-1-cyclooctylethyl]carbamoyl]-4-oxoazetidine-2-carboxylic acid
DMV0MHI DE Thrombosis
DMUFN29 ID DMUFN29
DMUFN29 DN EPI-7386
DMUFN29 HS Phase 1
DMUFN29 CP ESSA Pharma
DMUFN29 DT Small molecular drug
DMUFN29 DE Prostate cancer
DMAQYRL ID DMAQYRL
DMAQYRL DN Eptacog alfa
DMAQYRL HS Phase 1
DMAQYRL SN Alfa; Eptacog alfa (GlycoPEGylation, intravenous, hemophilia), Novo Nordisk; Eptacog alfa (GlycoPEGylation, subcutaneous, hemophilia), Novo Nordisk
DMAQYRL CP Neose Technologies Inc
DMAQYRL SQ DB00036 sequence: ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP
DMAQYRL DE Hemophilia
DMXI9P4 ID DMXI9P4
DMXI9P4 DN EPX-100
DMXI9P4 HS Phase 1
DMXI9P4 CP Epygenix Therapeutics Paramus, NJ
DMXI9P4 DE Dravet syndrome
DMKMR2X ID DMKMR2X
DMKMR2X DN ERB-257
DMKMR2X HS Phase 1
DMKMR2X CP Wyeth
DMKMR2X DE Sepsis
DM9YNTO ID DM9YNTO
DM9YNTO DN ERY974
DM9YNTO HS Phase 1
DM9YNTO CP Chugai Pharma USA Berkeley Heights, NJ
DM9YNTO DE Solid tumour/cancer
DMY0HU6 ID DMY0HU6
DMY0HU6 DN ETC-1922159
DMY0HU6 HS Phase 1
DMY0HU6 SN Etc-159; ETC-159; UNII-5L854240DQ; 1638250-96-0; CHEMBL3633802; 5L854240DQ; SCHEMBL17626176; MolPort-044-728-903; KS-00000TT9; BDBM50133866; ZINC175660737; AKOS030526630; CS-5162; 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide; HY-18988; 2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide
DMY0HU6 CP Biomedical Sciences Institute SingaporeD3 (Drug Product and Development) Singapore
DMY0HU6 PC 86280523
DMY0HU6 MW 391.4
DMY0HU6 FM C19H17N7O3
DMY0HU6 IC InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27)
DMY0HU6 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4
DMY0HU6 IK QTRXIFVSTWXRJJ-UHFFFAOYSA-N
DMY0HU6 IU 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide
DMY0HU6 CA CAS 1638250-96-0
DMY0HU6 DE Solid tumour/cancer
DMS436I ID DMS436I
DMS436I DN ETX201
DMS436I HS Phase 1
DMS436I CP ETX Pharma, Maryland
DMS436I DE Crohn disease
DMY9ZAS ID DMY9ZAS
DMY9ZAS DN EUK-189
DMY9ZAS HS Phase 1
DMY9ZAS SN EUK-189 (topical formulation, radiation burns); EUK-189 (topical formulation, radiation burns), Minerva/Proteome; EUK-189 (topicalformulation, radiation burns), Minerva/Tyrian
DMY9ZAS CP Eukarion Inc
DMY9ZAS DT Small molecular drug
DMY9ZAS PC 146157762
DMY9ZAS MW 469.4
DMY9ZAS FM C22H26MnN2O6-2
DMY9ZAS IC InChI=1S/C20H24N2O4.C2H4O2.Mn/c1-3-25-17-9-5-7-15(19(17)23)13-21-11-12-22-14-16-8-6-10-18(20(16)24)26-4-2;1-2(3)4;/h5-10,13-14,23-24H,3-4,11-12H2,1-2H3;1H3,(H,3,4);/p-2
DMY9ZAS CS CCOC1=CC=CC(=C1[O-])C=NCCN=CC2=C(C(=CC=C2)OCC)[O-].CC(=O)O.[Mn]
DMY9ZAS IK SZYIPDLZPMRUNA-UHFFFAOYSA-L
DMY9ZAS IU acetic acid;2-ethoxy-6-[2-[(3-ethoxy-2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;manganese
DMY9ZAS DE Skin burns
DMOG8IE ID DMOG8IE
DMOG8IE DN EVT 401
DMOG8IE HS Phase 1
DMOG8IE CP Evotec
DMOG8IE DE Rheumatoid arthritis
DMAKWQD ID DMAKWQD
DMAKWQD DN EVT100
DMAKWQD HS Phase 1
DMAKWQD CP EvotecHamburg, GermanyJanssen Research & Development Raritan, NJ
DMAKWQD DE Major depressive disorder
DM3VC6T ID DM3VC6T
DM3VC6T DN EW-A-401
DM3VC6T HS Phase 1
DM3VC6T CP Sangamo BioSciences
DM3VC6T DE Peripheral vascular disease
DM2NBC7 ID DM2NBC7
DM2NBC7 DN EZN-2968
DM2NBC7 HS Phase 1
DM2NBC7 CP Santaris Pharma A/S
DM2NBC7 DE Solid tumour/cancer
DMXFY18 ID DMXFY18
DMXFY18 DN EZN-3042
DMXFY18 HS Phase 1
DMXFY18 CP Santaris Pharma A/S
DMXFY18 DE Solid tumour/cancer
DMNPS59 ID DMNPS59
DMNPS59 DN EZN-4176
DMNPS59 HS Phase 1
DMNPS59 CP Santaris Pharma A/S
DMNPS59 DT Antisense drug
DMNPS59 DE Prostate cancer
DMAH12E ID DMAH12E
DMAH12E DN F-15845
DMAH12E HS Phase 1
DMAH12E SN UNII-3VKL9K971D; 3VKL9K971D; F-15845; (-)-F-15845; 2H-1,5-Benzoxathiepin-3-amine, 3,4-dihydro-N-((2S)-3-((2-methoxyphenyl)thio)-2-methylpropyl)-, hydrobromide, (3R)-; 3-(R)-(3-(2-Methoxyphenylthio-2-(S)-methylpropyl)amino)-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate; (-)-(3R)-N-((2S)-3-((2-Methoxyphenyl)sulfanyl)-2-methylpropyl)-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine hydrobromide
DMAH12E CP Pierre Fabre SA
DMAH12E DT Small molecular drug
DMAH12E PC 72941926
DMAH12E MW 456.5
DMAH12E FM C20H26BrNO2S2
DMAH12E IC InChI=1S/C20H25NO2S2.BrH/c1-15(13-24-19-9-5-3-7-17(19)22-2)11-21-16-12-23-18-8-4-6-10-20(18)25-14-16;/h3-10,15-16,21H,11-14H2,1-2H3;1H/t15-,16+;/m0./s1
DMAH12E CS C[C@@H](CN[C@@H]1COC2=CC=CC=C2SC1)CSC3=CC=CC=C3OC.Br
DMAH12E IK CUWFVJMNULNBTG-IDVLALEDSA-N
DMAH12E IU (3R)-N-[(2S)-3-(2-methoxyphenyl)sulfanyl-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine;hydrobromide
DMAH12E CA CAS 866760-23-8
DMAH12E DE Angina pectoris
DML4JXZ ID DML4JXZ
DML4JXZ DN F-7TG
DML4JXZ HS Phase 1
DML4JXZ SN Recombinant human factor VIIa (hemophilia), GTC/LFB; RhFVIIa (hemophilia), GTC/LFB
DML4JXZ CP Catalyst biosciences; pfizer
DML4JXZ DE Hemophilia
DM71HLX ID DM71HLX
DM71HLX DN FAZ053
DM71HLX HS Phase 1
DM71HLX CP Novartis Pharmaceuticals East Hanover, NJ
DM71HLX DT Monoclonal antibody
DM71HLX DE Solid tumour/cancer; Advanced cancer
DM13YK0 ID DM13YK0
DM13YK0 DN Ferroportin mab
DM13YK0 HS Phase 1
DM13YK0 CP Eli Lilly
DM13YK0 DT Antibody
DM13YK0 DE Anemia
DMS1O56 ID DMS1O56
DMS1O56 DN FF-10101-01
DMS1O56 HS Phase 1
DMS1O56 CP FUJIFILM Pharmaceuticals U.S.A. Cambridge, MA
DMS1O56 DE Acute myeloid leukaemia
DMX5290 ID DMX5290
DMX5290 DN FF-10502-01
DMX5290 HS Phase 1
DMX5290 CP FUJIFILM Pharmaceuticals U.S.A Valhalla, NJ
DMX5290 DE Lymphoma; Solid tumour/cancer
DM2GHIP ID DM2GHIP
DM2GHIP DN FFC-14A
DM2GHIP HS Phase 1
DM2GHIP SN KP 1019; KP-692; HInd(RuInd2CI4), University of Vienna; KP-1019 (anhydrous); Ruthenium(III) complex, Faustus Forschung
DM2GHIP CP Faustus Forschungs Cie Translational Cancer Research GmbH
DM2GHIP DE Solid tumour/cancer
DM8U2IE ID DM8U2IE
DM8U2IE DN FGI-101-1A6
DM8U2IE HS Phase 1
DM8U2IE SN FGI-101; Anti-tumor susceptibility gene protein 101 mAb (viral infection), Functional Genetics; Anti-TSG101 monoclonal antibody (viral infection/prostate cancer), Functional Genetics
DM8U2IE CP Functional genetics
DM8U2IE DT Antibody
DM8U2IE DE Influenza virus infection
DMY61GX ID DMY61GX
DMY61GX DN FGLL
DMY61GX HS Phase 1
DMY61GX SN NCAM mimetics (Alzheimer's disease), Enkam
DMY61GX CP ENKAM Pharmaceuticals A/S
DMY61GX DE Alzheimer disease
DMLH2Q6 ID DMLH2Q6
DMLH2Q6 DN Figopitant
DMLH2Q6 HS Phase 1
DMLH2Q6 SN BIIF-1149; BIIF-1149CL; NK1 antagonists, Boehringer Ingelheim
DMLH2Q6 CP Boehringer Ingelheim Corp
DMLH2Q6 DT Small molecular drug
DMLH2Q6 PC 9914857
DMLH2Q6 MW 527.5
DMLH2Q6 FM C27H31F6N3O
DMLH2Q6 IC InChI=1S/C27H31F6N3O/c1-34(10-9-20-15-22(26(28,29)30)17-23(16-20)27(31,32)33)25(37)24(21-5-3-2-4-6-21)36-13-11-35(12-14-36)18-19-7-8-19/h2-6,15-17,19,24H,7-14,18H2,1H3/t24-/m0/s1
DMLH2Q6 CS CN(CCC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C(=O)[C@H](C2=CC=CC=C2)N3CCN(CC3)CC4CC4
DMLH2Q6 IK HUTHJVYJUPXHDF-DEOSSOPVSA-N
DMLH2Q6 IU (2S)-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(cyclopropylmethyl)piperazin-1-yl]-N-methyl-2-phenylacetamide
DMLH2Q6 CA CAS 502422-74-4
DMLH2Q6 DE Diabetic complication
DM2SALJ ID DM2SALJ
DM2SALJ DN Flanvotumab
DM2SALJ HS Phase 1
DM2SALJ SN IMC-20D7S; Gp75 monoclonal antibodies (melanoma), ImClone; Gp75 mAb (melanoma), ImClone/Eli Lilly; GP75/TRP1 mAbs (melanoma), ImClone/Eli Lilly
DM2SALJ CP Eli lilly
DM2SALJ DT Antibody
DM2SALJ DE Melanoma
DM7BMD6 ID DM7BMD6
DM7BMD6 DN FN-1501
DM7BMD6 HS Phase 1
DM7BMD6 SN 1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide
DM7BMD6 CP Fosun Pharmaceutical
DM7BMD6 DT Small molecular drug
DM7BMD6 PC 72195175
DM7BMD6 MW 431.5
DM7BMD6 FM C22H25N9O
DM7BMD6 IC InChI=1S/C22H25N9O/c1-30-8-10-31(11-9-30)13-15-2-4-16(5-3-15)27-22(32)19-18(12-26-29-19)28-21-17-6-7-23-20(17)24-14-25-21/h2-7,12,14H,8-11,13H2,1H3,(H,26,29)(H,27,32)(H2,23,24,25,28)
DM7BMD6 CS CN1CCN(CC1)CC2=CC=C(C=C2)NC(=O)C3=C(C=NN3)NC4=NC=NC5=C4C=CN5
DM7BMD6 IK VXLAKHWYGRKCGI-UHFFFAOYSA-N
DM7BMD6 IU N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide
DM7BMD6 CA CAS 1429515-59-2
DM7BMD6 DE Solid tumour/cancer
DMKX174 ID DMKX174
DMKX174 DN FOR46
DMKX174 HS Phase 1
DMKX174 CP Fortis Therapeutics
DMKX174 DT Antibody drug conjugate
DMKX174 DE Multiple myeloma
DMH1NXO ID DMH1NXO
DMH1NXO DN FP-025
DMH1NXO HS Phase 1
DMH1NXO DE Asthma
DMV9FTH ID DMV9FTH
DMV9FTH DN FP-045
DMV9FTH HS Phase 1
DMV9FTH CP Foresee Pharmaceuticals Newark, DE
DMV9FTH DE Cardiovascular disease
DM8BG0M ID DM8BG0M
DM8BG0M DN FP-253-GDEPT
DM8BG0M HS Phase 1
DM8BG0M SN FP-253; PNP-GDEPT; GDEPT (prostate cancer), Mayne; GDEPT (fludarabine phosphate, prostate cancer), CSIRO; Gene-directed enzyme prodrug therapy (prostate cancer), Mayne; OAdV gene therapy (PNP/ fludarabine phosphate), Mayne; Ovine adenovirus gene therapy (purine nucleoside phosphorylase/fludarabine phosphate), Mayne; OAdV GDEPT (E coli PNP/fludarabine phosphate, prostate cancer), Broadvector; Ovine atadenovirus GDEPT (purine nucleoside phosphorylase/fludarabine phosphate, prostate cancer), Biotech Equity Partners
DM8BG0M CP Pnp therapeutics
DM8BG0M DE Prostate cancer
DM1EBRK ID DM1EBRK
DM1EBRK DN FPA144
DM1EBRK HS Phase 1
DM1EBRK CP Five Prime Therapeutics South San Francisco, ca
DM1EBRK DE Bladder cancer; Gastric adenocarcinoma
DMI9A1Z ID DMI9A1Z
DMI9A1Z DN FPI-1434
DMI9A1Z HS Phase 1
DMI9A1Z CP Fusion Pharmaceuticals
DMI9A1Z DT Radiopharmaceutical therapy
DMI9A1Z DE Solid tumour/cancer
DMUI8F3 ID DMUI8F3
DMUI8F3 DN Friulimicin
DMUI8F3 HS Phase 1
DMUI8F3 SN Friulimicin B; Friulimicin (antibacterial), Combinature; Friulimicin (antibiotic), Combinature; Friulimicin (iv, bacterial infection), Combinature; Friulimicin (iv, bacterial infection), Merlion; Friulimicin (topical, bacterial infection), Merlion
DMUI8F3 CP MerLion Pharmaceuticals Pte Ltd; Combinature Biopharm AG
DMUI8F3 PC 56842195
DMUI8F3 MW 1303.5
DMUI8F3 FM C59H94N14O19
DMUI8F3 IC InChI=1S/C59H94N14O19/c1-30(2)19-14-12-10-8-9-11-13-15-22-41(75)65-35(25-40(61)74)52(84)71-49-34(7)64-53(85)39-21-18-24-73(39)57(89)46(31(3)4)69-56(88)48(33(6)60)68-43(77)29-63-50(82)36(26-44(78)79)66-42(76)28-62-51(83)37(27-45(80)81)67-55(87)47(32(5)59(91)92)70-54(86)38-20-16-17-23-72(38)58(49)90/h13,15,30-39,46-49H,8-12,14,16-29,60H2,1-7H3,(H2,61,74)(H,62,83)(H,63,82)(H,64,85)(H,65,75)(H,66,76)(H,67,87)(H,68,77)(H,69,88)(H,70,86)(H,71,84)(H,78,79)(H,80,81)(H,91,92)/b15-13-/t32-,33+,34-,35-,36-,37-,38+,39-,46-,47-,48+,49-/m0/s1
DMUI8F3 CS C[C@H]1[C@@H](C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N1)C(C)C)[C@@H](C)N)CC(=O)O)CC(=O)O)[C@H](C)C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)C/C=C\\CCCCCCCC(C)C
DMUI8F3 IK HVYFVLAUKMGKHL-USKUEUQVSA-N
DMUI8F3 IU (2S)-2-[(3S,4S,7S,13S,16R,22S,28S,31S,34R)-16-[(1R)-1-aminoethyl]-3-[[(2S)-4-amino-2-[[(Z)-12-methyltridec-3-enoyl]amino]-4-oxobutanoyl]amino]-22,28-bis(carboxymethyl)-4-methyl-2,6,12,15,18,21,24,27,30,33-decaoxo-13-propan-2-yl-1,5,11,14,17,20,23,26,29,32-decazatricyclo[32.4.0.07,11]octatriacontan-31-yl]propanoic acid
DMUI8F3 CA 239802-15-4
DMUI8F3 DE Bacterial infection
DM0QH9K ID DM0QH9K
DM0QH9K DN FS118
DM0QH9K HS Phase 1
DM0QH9K CP F-star Biotechnology Cambridge, United Kingdom
DM0QH9K DT Antibody
DM0QH9K DE Advanced malignancy; Advanced cancer
DMPENAL ID DMPENAL
DMPENAL DN FSI-189
DMPENAL HS Phase 1
DMPENAL CP Gilead Sciences
DMPENAL DT Antibody
DMPENAL DE Non-hodgkin lymphoma
DMZOAT3 ID DMZOAT3
DMZOAT3 DN FT-1101
DMZOAT3 HS Phase 1
DMZOAT3 CP FORMA Therapeutics Watertown, MA
DMZOAT3 DE Haematological malignancy
DMCK3OI ID DMCK3OI
DMCK3OI DN FT-7051
DMCK3OI HS Phase 1
DMCK3OI CP FORMA Therapeutics
DMCK3OI DE Prostate cancer
DMGJNTQ ID DMGJNTQ
DMGJNTQ DN FT-819
DMGJNTQ HS Phase 1
DMGJNTQ CP Fate Therapeutics
DMGJNTQ DT CAR T Cell Therapy
DMGJNTQ DE Chronic lymphocytic leukaemia
DML028U ID DML028U
DML028U DN G1T28-1
DML028U HS Phase 1
DML028U DE Solid tumour/cancer
DMRGP72 ID DMRGP72
DMRGP72 DN G1T-48
DMRGP72 HS Phase 1
DMRGP72 CP G1 Therapeutics
DMRGP72 DE Breast cancer
DM3H6YC ID DM3H6YC
DM3H6YC DN G-619
DM3H6YC HS Phase 1
DM3H6YC SN 4-Methoxy-N3-(3-picolyl)-1,3-benzenedicarboxamide; 4-Methoxy-N3-(3-pyridylmethyl)-1,3-benzenedicarboxamide
DM3H6YC DT Small molecular drug
DM3H6YC PC 130587
DM3H6YC MW 285.3
DM3H6YC FM C15H15N3O3
DM3H6YC IC InChI=1S/C15H15N3O3/c1-21-13-5-4-11(14(16)19)7-12(13)15(20)18-9-10-3-2-6-17-8-10/h2-8H,9H2,1H3,(H2,16,19)(H,18,20)
DM3H6YC CS COC1=C(C=C(C=C1)C(=O)N)C(=O)NCC2=CN=CC=C2
DM3H6YC IK QWZWECXMQXZQOG-UHFFFAOYSA-N
DM3H6YC IU 4-methoxy-3-N-(pyridin-3-ylmethyl)benzene-1,3-dicarboxamide
DM3H6YC CA CAS 108828-56-4
DM3H6YC DE Thrombosis
DMJLIQ2 ID DMJLIQ2
DMJLIQ2 DN GALAMUSTINE HYDROCHLORIDE
DMJLIQ2 HS Phase 1
DMJLIQ2 SN C6-GLM; C6-GalM; C6-Galactose mustard; G-6-M; Galamustine hydrochloride; 6-[Bis(2-chloroethyl)amino]-6-deoxy-D-galactopyranose hydrochloride
DMJLIQ2 DT Small molecular drug
DMJLIQ2 PC 135696
DMJLIQ2 MW 340.6
DMJLIQ2 FM C10H20Cl3NO5
DMJLIQ2 IC InChI=1S/C10H19Cl2NO5.ClH/c11-1-3-13(4-2-12)5-6-7(14)8(15)9(16)10(17)18-6;/h6-10,14-17H,1-5H2;1H/t6-,7+,8+,9-,10?;/m1./s1
DMJLIQ2 CS C(CCl)N(CCCl)C[C@@H]1[C@@H]([C@@H]([C@H](C(O1)O)O)O)O.Cl
DMJLIQ2 IK YPEQSOJVCFFDKJ-IBUKJIQJSA-N
DMJLIQ2 IU (3R,4S,5R,6R)-6-[bis(2-chloroethyl)aminomethyl]oxane-2,3,4,5-tetrol;hydrochloride
DMJLIQ2 CA CAS 107811-63-2
DMJLIQ2 DE Solid tumour/cancer
DMG9C4I ID DMG9C4I
DMG9C4I DN Galidesivir
DMG9C4I HS Phase 1
DMG9C4I SN 1EL1K52SH1; BCX 4430; BCX 4430 HCl; BCX4430; CS-3778; Galidesivir (hydrochloride); HY-18649; Immucillin-A; SB16943; SCHEMBL4838048; UNII-1EL1K52SH1
DMG9C4I TC Antiviral Agents
DMG9C4I DT Small molecular drug
DMG9C4I PC 10445549
DMG9C4I MW 265.27
DMG9C4I FM C11H15N5O3
DMG9C4I IC InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1
DMG9C4I CS C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
DMG9C4I IK AMFDITJFBUXZQN-KUBHLMPHSA-N
DMG9C4I IU (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
DMG9C4I CA CAS 249503-25-1
DMG9C4I DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMIXMQE ID DMIXMQE
DMIXMQE DN GAP T cells
DMIXMQE HS Phase 1
DMIXMQE CP Baylor College of Medicine
DMIXMQE DT CAR T Cell Therapy
DMIXMQE DE Solid tumour/cancer
DM52O7W ID DM52O7W
DM52O7W DN GBR1302
DM52O7W HS Phase 1
DM52O7W CP Glenmark Pharmaceuticals
DM52O7W DT Antibody
DM52O7W DE Solid tumour/cancer
DMQBEYV ID DMQBEYV
DMQBEYV DN GC021109
DMQBEYV HS Phase 1
DMQBEYV CP GliaCure Boston, MA
DMQBEYV DE Alzheimer disease
DM6R4DO ID DM6R4DO
DM6R4DO DN GC-1008
DM6R4DO HS Phase 1
DM6R4DO SN TGF-beta; TGF-Beta; Tgfbeta; TGF beta; Milk growth factor; Transforming Growth Factor beta; Platelet Transforming Growth Factor; Bone-Derived Transforming Growth Factor; TGF-beta; D016212000; 122304-04-5
DM6R4DO CP Genzyme
DM6R4DO DT Small molecular drug
DM6R4DO PC 56842206
DM6R4DO MW 4760
DM6R4DO FM C211H345N61O62S
DM6R4DO IC InChI=1S/C211H345N61O62S/c1-32-107(20)161(265-170(297)112(25)233-167(294)109(22)237-195(322)159(105(16)17)263-189(316)136(86-101(8)9)251-171(298)122(212)73-82-335-31)198(325)248-129(63-68-149(213)280)180(307)260-144(96-273)191(318)234-108(21)166(293)231-94-152(283)239-133(83-98(2)3)188(315)267-162(114(27)275)199(326)249-132(67-72-157(291)292)181(308)266-163(115(28)276)200(327)254-135(85-100(6)7)183(310)253-140(92-150(214)281)186(313)242-124(52-40-75-227-208(218)219)175(302)244-128(64-69-154(285)286)172(299)232-95-153(284)262-158(104(14)15)196(323)256-139(91-120-59-61-121(279)62-60-120)190(317)268-165(117(30)278)202(329)264-160(106(18)19)197(324)255-137(89-118-47-35-33-36-48-118)182(309)238-113(26)203(330)270-79-44-57-147(270)194(321)269-164(116(29)277)201(328)257-141(93-151(215)282)187(314)246-130(65-70-155(287)288)174(301)236-110(23)168(295)250-138(90-119-49-37-34-38-50-119)185(312)241-123(51-39-74-226-207(216)217)173(300)235-111(24)169(296)258-142(87-102(10)11)204(331)272-81-46-58-148(272)205(332)271-80-45-56-146(271)193(320)247-127(55-43-78-230-211(224)225)176(303)245-131(66-71-156(289)290)179(306)240-126(54-42-77-229-210(222)223)178(305)261-145(97-274)192(319)243-125(53-41-76-228-209(220)221)177(304)252-134(84-99(4)5)184(311)259-143(206(333)334)88-103(12)13/h33-38,47-50,59-62,98-117,122-148,158-165,273-279H,32,39-46,51-58,63-97,212H2,1-31H3,(H2,213,280)(H2,214,281)(H2,215,282)(H,231,293)(H,232,299)(H,233,294)(H,234,318)(H,235,300)(H,236,301)(H,237,322)(H,238,309)(H,239,283)(H,240,306)(H,241,312)(H,242,313)(H,243,319)(H,244,302)(H,245,303)(H,246,314)(H,247,320)(H,248,325)(H,249,326)(H,250,295)(H,251,298)(H,252,304)(H,253,310)(H,254,327)(H,255,324)(H,256,323)(H,257,328)(H,258,296)(H,259,311)(H,260,307)(H,261,305)(H,262,284)(H,263,316)(H,264,329)(H,265,297)(H,266,308)(H,267,315)(H,268,317)(H,269,321)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,333,334)(H4,216,217,226)(H4,218,219,227)(H4,220,221,228)(H4,222,223,229)(H4,224,225,230)/t107-,108-,109-,110-,111-,112-,113-,114+,115+,116+,117+,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,158-,159-,160-,161-,162-,163-,164-,165-/m0/s1
DM6R4DO CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)N
DM6R4DO IK ZRKFYGHZFMAOKI-QMGMOQQFSA-N
DM6R4DO IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid
DM6R4DO CA CAS 122304-04-5
DM6R4DO DE Pleural disease; Idiopathic pulmonary fibrosis
DMK96CE ID DMK96CE
DMK96CE DN GC-1113
DMK96CE HS Phase 1
DMK96CE DE Anemia
DMJ7WRI ID DMJ7WRI
DMJ7WRI DN GCC-1290K
DMJ7WRI HS Phase 1
DMJ7WRI SN GC-1290K; GC-2101; GCC-1290A; GCC-1290K (salt formulation, oral), Green Cross; Dopamine modulators (Parkinson's disease, oral), Kangwon University/Green Cross; (+)-3-hydroxymorphinan; 3-HM; 3-HM prodrugs (Parkinson's disease), Green Cross; 3-hydroxymorphinan prodrugs (Parkinson's disease), Green Cross
DMJ7WRI CP Kangwon University Pharmaceutical College
DMJ7WRI DE Parkinson disease
DMHMZC7 ID DMHMZC7
DMHMZC7 DN GCC-4401
DMHMZC7 HS Phase 1
DMHMZC7 CP Green cross
DMHMZC7 DE Thrombosis
DM9TD2N ID DM9TD2N
DM9TD2N DN GD2 T cells
DM9TD2N HS Phase 1
DM9TD2N CP Baylor College of Medicine
DM9TD2N DT CAR T Cell Therapy
DM9TD2N DE Neuroblastoma; Osteosarcoma
DMSE19U ID DMSE19U
DMSE19U DN GDC0134
DMSE19U HS Phase 1
DMSE19U SN RG6000
DMSE19U CP DLK-1 protein inhibitor
DMSE19U DE Amyotrophic lateral sclerosis
DM1B3UM ID DM1B3UM
DM1B3UM DN GDC-0152
DM1B3UM HS Phase 1
DM1B3UM SN GDC 0152; GDC0152
DM1B3UM DT Small molecular drug
DM1B3UM PC 46940575
DM1B3UM MW 498.6
DM1B3UM FM C25H34N6O3S
DM1B3UM IC InChI=1S/C25H34N6O3S/c1-16(26-2)22(32)27-21(18-12-7-4-8-13-18)25(34)31-15-9-14-19(31)23(33)28-24-20(29-30-35-24)17-10-5-3-6-11-17/h3,5-6,10-11,16,18-19,21,26H,4,7-9,12-15H2,1-2H3,(H,27,32)(H,28,33)/t16-,19-,21-/m0/s1
DM1B3UM CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=C(N=NS3)C4=CC=CC=C4)NC
DM1B3UM IK WZRFLSDVFPIXOV-LRQRDZAKSA-N
DM1B3UM IU (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-(4-phenylthiadiazol-5-yl)pyrrolidine-2-carboxamide
DM1B3UM CA CAS 873652-48-3
DM1B3UM DE Obesity; Solid tumour/cancer
DMUNFEP ID DMUNFEP
DMUNFEP DN GDC0310
DMUNFEP HS Phase 1
DMUNFEP SN RG6029; FCTMRPTVPHVTTN-UHFFFAOYSA-N; SCHEMBL16770884; BDBM71258; BCP25347; US9694002, 346; 1788066-71-6
DMUNFEP CP Genentech South San Francisco, CA Xenon Pharmaceuticals Burnaby, Canada
DMUNFEP PC 118120526
DMUNFEP MW 599
DMUNFEP FM C25H25ClF6N2O4S
DMUNFEP IC InChI=1S/C25H25ClF6N2O4S/c1-39(36,37)33-23(35)18-10-17(14-2-3-14)21(11-20(18)27)38-13-24(29)4-6-34(7-5-24)12-15-8-16(25(30,31)32)9-19(26)22(15)28/h8-11,14H,2-7,12-13H2,1H3,(H,33,35)
DMUNFEP CS CS(=O)(=O)NC(=O)C1=C(C=C(C(=C1)C2CC2)OCC3(CCN(CC3)CC4=C(C(=CC(=C4)C(F)(F)F)Cl)F)F)F
DMUNFEP IK FCTMRPTVPHVTTN-UHFFFAOYSA-N
DMUNFEP IU 4-[[1-[[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-fluoropiperidin-4-yl]methoxy]-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide
DMUNFEP DE Chronic pain
DM3Z2JB ID DM3Z2JB
DM3Z2JB DN GDC-0349
DM3Z2JB HS Phase 1
DM3Z2JB SN MTORC1/2 inhibitors
DM3Z2JB CP Genentech
DM3Z2JB DT Small molecular drug
DM3Z2JB PC 59239165
DM3Z2JB MW 452.5
DM3Z2JB FM C24H32N6O3
DM3Z2JB IC InChI=1S/C24H32N6O3/c1-3-25-24(31)26-18-6-4-17(5-7-18)22-27-21-12-29(19-14-33-15-19)9-8-20(21)23(28-22)30-10-11-32-13-16(30)2/h4-7,16,19H,3,8-15H2,1-2H3,(H2,25,26,31)/t16-/m0/s1
DM3Z2JB CS CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4COC4)C(=N2)N5CCOC[C@@H]5C
DM3Z2JB IK RGJOJUGRHPQXGF-INIZCTEOSA-N
DM3Z2JB IU 1-ethyl-3-[4-[4-[(3S)-3-methylmorpholin-4-yl]-7-(oxetan-3-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea
DM3Z2JB CA CAS 1207360-89-1
DM3Z2JB DE Non-hodgkin lymphoma
DMDZ26X ID DMDZ26X
DMDZ26X DN GDC-0425
DMDZ26X HS Phase 1
DMDZ26X CP Genentech
DMDZ26X PC 58266779
DMDZ26X MW 321.4
DMDZ26X FM C18H19N5O
DMDZ26X IC InChI=1S/C18H19N5O/c1-2-23-8-5-12(6-9-23)24-17-14(10-19)21-11-15-16(17)13-4-3-7-20-18(13)22-15/h3-4,7,11-12H,2,5-6,8-9H2,1H3,(H,20,22)
DMDZ26X CS CCN1CCC(CC1)OC2=C3C4=C(NC3=CN=C2C#N)N=CC=C4
DMDZ26X IK XEZLBMHDUXSICI-UHFFFAOYSA-N
DMDZ26X IU 3-(1-ethylpiperidin-4-yl)oxy-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2,4,6,10,12-hexaene-4-carbonitrile
DMDZ26X CA CAS 1627539-18-7
DMDZ26X DE Lymphoma
DMDY08K ID DMDY08K
DMDY08K DN GDC-0623
DMDY08K HS Phase 1
DMDY08K SN 1168091-68-6; GDC 0623; UNII-HW67545I4Q; RG 7421; GDC0623; HW67545I4Q; G-868; Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-; 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE; RFWVETIZUQEJEF-UHFFFAOYSA-N; GTPL9909; SCHEMBL1615104; CHEMBL3330650; MolPort-039-193-834; BCP28689; AOB87143; EX-A2060; s7553; ZINC43206499; BDBM50025226; AKOS027253679; DB11982; SB16957; CS-2281; BC600628; HY-15610; KB-144448; FT-0769207; Z-3311
DMDY08K CP Genentech
DMDY08K DT Small molecular drug
DMDY08K PC 42642654
DMDY08K MW 456.21
DMDY08K FM C16H14FIN4O3
DMDY08K IC InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)
DMDY08K CS C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO
DMDY08K IK RFWVETIZUQEJEF-UHFFFAOYSA-N
DMDY08K IU 5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide
DMDY08K CA CAS 1168091-68-6
DMDY08K DE Solid tumour/cancer
DMFC2OY ID DMFC2OY
DMFC2OY DN GDC-0994
DMFC2OY HS Phase 1
DMFC2OY CP Genentech
DMFC2OY PC 71727581
DMFC2OY MW 440.9
DMFC2OY FM C21H18ClFN6O2
DMFC2OY IC InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1
DMFC2OY CS CN1C(=CC=N1)NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)[C@H](CO)C4=CC(=C(C=C4)Cl)F
DMFC2OY IK RZUOCXOYPYGSKL-GOSISDBHSA-N
DMFC2OY IU 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one
DMFC2OY CA CAS 1453848-26-4
DMFC2OY DE Solid tumour/cancer
DMJA27W ID DMJA27W
DMJA27W DN GDC-5573
DMJA27W HS Phase 1
DMJA27W SN RG6185
DMJA27W CP GenentechSouth San Francisco, CA
DMJA27W DE Solid tumour/cancer
DMMF6UB ID DMMF6UB
DMMF6UB DN GE-1170A
DMMF6UB HS Phase 1
DMMF6UB SN Elongation factor Tu inhibitors (bacterial infection); LDI-028; LDK-733; Elongation factor Tu inhibitors (bacterial infection), Novartis
DMMF6UB CP Novartis Institutes for BioMedical Research Inc
DMMF6UB DE Bacterial infection
DMJK7V0 ID DMJK7V0
DMJK7V0 DN Ge2270a
DMJK7V0 HS Phase 1
DMJK7V0 SN GE 2770; GE-2270; 134861-34-0; SCHEMBL12519961; CHEBI:29584; LS-187584; LS-186934
DMJK7V0 DT Small molecular drug
DMJK7V0 PC 16129640
DMJK7V0 MW 1290.5
DMJK7V0 FM C56H55N15O10S6
DMJK7V0 IC InChI=1S/C56H55N15O10S6/c1-24(2)39-55-70-42(36(87-55)19-80-5)47(77)59-17-38(73)67-43(44(74)26-10-7-6-8-11-26)54-66-34(23-85-54)52-63-31(20-83-52)41-27(50-64-32(21-82-50)46(76)61-29(16-37(72)58-4)53-69-40(25(3)86-53)48(78)68-39)13-14-28(60-41)51-65-33(22-84-51)49-62-30(18-81-49)56(79)71-15-9-12-35(71)45(57)75/h6-8,10-11,13-14,20-24,29-30,35,39,43-44,74H,9,12,15-19H2,1-5H3,(H2,57,75)(H,58,72)(H,59,77)(H,61,76)(H,67,73)(H,68,78)
DMJK7V0 CS CC1=C2C(=O)NC(C3=NC(=C(S3)COC)C(=O)NCC(=O)NC(C4=NC(=CS4)C5=NC(=CS5)C6=C(C=CC(=N6)C7=NC(=CS7)C8=NC(CO8)C(=O)N9CCCC9C(=O)N)C3=NC(=CS3)C(=O)NC(C(=N2)S1)CC(=O)NC)C(C1=CC=CC=C1)O)C(C)C
DMJK7V0 IK JMDULECOHIXMNX-UHFFFAOYSA-N
DMJK7V0 IU 1-[2-[2-[35-[hydroxy(phenyl)methyl]-28-(methoxymethyl)-21-methyl-18-[2-(methylamino)-2-oxoethyl]-16,23,30,33-tetraoxo-25-propan-2-yl-3,13,20,27,37-pentathia-7,17,24,31,34,39,40,41,42,43-decazaheptacyclo[34.2.1.12,5.112,15.119,22.126,29.06,11]tritetraconta-1(38),2(43),4,6(11),7,9,12(42),14,19(41),21,26(40),28,36(39)-tridecaen-8-yl]-1,3-thiazol-4-yl]-4,5-dihydro-1,3-oxazole-4-carbonyl]pyrrolidine-2-carboxamide
DMJK7V0 CB CHEBI:29584
DMJK7V0 DE Bacterial infection
DMDMKVL ID DMDMKVL
DMDMKVL DN GEM333
DMDMKVL HS Phase 1
DMDMKVL CP Gemoab
DMDMKVL DT Antibody
DMDMKVL DE Acute myeloid leukaemia
DM3GSPR ID DM3GSPR
DM3GSPR DN GEM3PSCA
DM3GSPR HS Phase 1
DM3GSPR CP Gemoab
DM3GSPR DT Antibody
DM3GSPR DE Non-small cell lung cancer
DMV8IWJ ID DMV8IWJ
DMV8IWJ DN GEN1029
DMV8IWJ HS Phase 1
DMV8IWJ CP GenMab
DMV8IWJ DT Antibody
DMV8IWJ DE Solid tumour/cancer
DMNP6T3 ID DMNP6T3
DMNP6T3 DN GEN1042
DMNP6T3 HS Phase 1
DMNP6T3 CP GenMab
DMNP6T3 DT Antibody
DMNP6T3 DE Solid tumour/cancer
DMQ9317 ID DMQ9317
DMQ9317 DN GEN1044
DMQ9317 HS Phase 1
DMQ9317 CP AbbVie
DMQ9317 DT Antibody
DMQ9317 DE Solid tumour/cancer
DMEWRNZ ID DMEWRNZ
DMEWRNZ DN GEN1046
DMEWRNZ HS Phase 1
DMEWRNZ CP GenMab
DMEWRNZ DT Antibody
DMEWRNZ DE Solid tumour/cancer
DMWR93D ID DMWR93D
DMWR93D DN Genaconazole
DMWR93D HS Phase 1
DMWR93D SN SM-8668; SM-8668 analogs; SM-9164; Sch-39304; Sch-42426; Sch-42427
DMWR93D CP Sumitomo Pharmaceuticals Co Ltd
DMWR93D DT Small molecular drug
DMWR93D PC 452261
DMWR93D MW 331.34
DMWR93D FM C13H15F2N3O3S
DMWR93D IC InChI=1S/C13H15F2N3O3S/c1-9(22(2,20)21)13(19,6-18-8-16-7-17-18)11-4-3-10(14)5-12(11)15/h3-5,7-9,19H,6H2,1-2H3/t9-,13-/m1/s1
DMWR93D CS C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C
DMWR93D IK HFGZFHCWKKQGIS-NOZJJQNGSA-N
DMWR93D IU (2R,3R)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2-ol
DMWR93D CA CAS 120924-80-3
DMWR93D DE Fungal infection
DMJP83V ID DMJP83V
DMJP83V DN Gene therapy, IFN-b
DMJP83V HS Phase 1
DMJP83V SN Gene therapy (IFN-b)
DMJP83V CP Nagoya University
DMJP83V DE Glioblastoma multiforme
DMTGN0U ID DMTGN0U
DMTGN0U DN Genz 644282
DMTGN0U HS Phase 1
DMTGN0U SN GENZ-644282; Genz 644282; genz644282; UNII-717I541I2R; 717I541I2R; 2,3-dimethoxy-12-(2-(methylamino)ethyl)-[1,3]dioxolo[4',5':4,5]benzo[1,2-h]benzo[c][1,6]naphthyridin-13(12H)-one; SCHEMBL241696; CHEMBL191958; EX-A481; AOB87160; BCP20983; ZINC6718458; SAR402674; AKOS030526835; CS-1525; SAR 402674; SAR-402674; HY-16228; Benzo(C)(1,3)benzodioxolo(5,6-H)(1,6)naphthyridin-13(12H)-one, 2,3-dimethoxy-12-(2-(methylamino)ethyl)-; BC600645; DA-42192; GENZ-644282/GENZ644282; FT-0700324; A3434; W-6112; A13206
DMTGN0U PC 10294813
DMTGN0U MW 407.4
DMTGN0U FM C22H21N3O5
DMTGN0U IC InChI=1S/C22H21N3O5/c1-23-4-5-25-21-14-8-19-20(30-11-29-19)9-16(14)24-10-15(21)12-6-17(27-2)18(28-3)7-13(12)22(25)26/h6-10,23H,4-5,11H2,1-3H3
DMTGN0U CS CNCCN1C2=C(C=NC3=CC4=C(C=C32)OCO4)C5=CC(=C(C=C5C1=O)OC)OC
DMTGN0U IK BAORCAMWLWRZQG-UHFFFAOYSA-N
DMTGN0U IU 16,17-dimethoxy-21-[2-(methylamino)ethyl]-5,7-dioxa-11,21-diazapentacyclo[11.8.0.02,10.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-one
DMTGN0U CA CAS 529488-28-6
DMTGN0U DE Solid tumours
DMIXABW ID DMIXABW
DMIXABW DN Genz-644282
DMIXABW HS Phase 1
DMIXABW SN Genz-644283; Anticancer compound (cancer), Genzyme
DMIXABW CP Genzyme Corp
DMIXABW DT Small molecular drug
DMIXABW PC 10294813
DMIXABW MW 407.4
DMIXABW FM C22H21N3O5
DMIXABW IC InChI=1S/C22H21N3O5/c1-23-4-5-25-21-14-8-19-20(30-11-29-19)9-16(14)24-10-15(21)12-6-17(27-2)18(28-3)7-13(12)22(25)26/h6-10,23H,4-5,11H2,1-3H3
DMIXABW CS CNCCN1C2=C(C=NC3=CC4=C(C=C32)OCO4)C5=CC(=C(C=C5C1=O)OC)OC
DMIXABW IK BAORCAMWLWRZQG-UHFFFAOYSA-N
DMIXABW IU 16,17-dimethoxy-21-[2-(methylamino)ethyl]-5,7-dioxa-11,21-diazapentacyclo[11.8.0.02,10.04,8.014,19]henicosa-1(13),2,4(8),9,11,14,16,18-octaen-20-one
DMIXABW CA CAS 529488-28-6
DMIXABW DE Solid tumour/cancer
DMA9UX2 ID DMA9UX2
DMA9UX2 DN Gerilimzumab
DMA9UX2 HS Phase 1
DMA9UX2 CP Bird Rock Bio, La Jolla, CA
DMA9UX2 DE Rheumatoid arthritis
DMDMPKC ID DMDMPKC
DMDMPKC DN GGF-2
DMDMPKC HS Phase 1
DMDMPKC SN Glial growth factor 2, Cambridge Neuroscience; RhGGF2, Cambridge Neuroscience; GGF-2, CeNeS; GGF-2 (cardiac failure/neurodegenerative disorders); GGF-2 (cardiac failure/neurodegenerative disorders), Acorda
DMDMPKC CP Acorda therapeutics
DMDMPKC DE Heart failure
DM8U23L ID DM8U23L
DM8U23L DN GGTI-2418
DM8U23L HS Phase 1
DM8U23L CP Kirax
DM8U23L PC 11539477
DM8U23L MW 441.5
DM8U23L FM C23H31N5O4
DM8U23L IC InChI=1S/C23H31N5O4/c1-15(2)11-18(22(30)31)26-23(32)28-10-9-27(13-19-16(3)24-14-25-19)21(29)20(28)12-17-7-5-4-6-8-17/h4-8,14-15,18,20H,9-13H2,1-3H3,(H,24,25)(H,26,32)(H,30,31)/t18-,20-/m0/s1
DM8U23L CS CC1=C(N=CN1)CN2CCN([C@H](C2=O)CC3=CC=CC=C3)C(=O)N[C@@H](CC(C)C)C(=O)O
DM8U23L IK COLCNDRDBCLVOC-ICSRJNTNSA-N
DM8U23L IU (2S)-2-[[(2S)-2-benzyl-4-[(5-methyl-1H-imidazol-4-yl)methyl]-3-oxopiperazine-1-carbonyl]amino]-4-methylpentanoic acid
DM8U23L CA CAS 501010-06-6
DM8U23L DE Solid tumour/cancer
DMKY1L4 ID DMKY1L4
DMKY1L4 DN Glucose-6-phosphate
DMKY1L4 HS Phase 1
DMKY1L4 SN Robison ester; Glucose 6-phosphate; 6-O-phosphono-D-glucopyranose; D-glucopyranose 6-phosphate; D-glucopyranose, 6-(dihydrogen phosphate); Glucose 6-(dihydrogen phosphate); 299-31-0; {[(2R,3S,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}phosphonic acid; D-glucose-6P; Glc6P; D-glucose-6-P; a-D-glucose 6- phosphate; AC1L1LI0; SCHEMBL48379; CHEBI:4170; GTPL4647; AC1Q28E3; D-Glucopyranose 6-phosphoric acid
DMKY1L4 DT Small molecular drug
DMKY1L4 PC 5958
DMKY1L4 MW 260.14
DMKY1L4 FM C6H13O9P
DMKY1L4 IC InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6?/m1/s1
DMKY1L4 CS C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)OP(=O)(O)O
DMKY1L4 IK NBSCHQHZLSJFNQ-GASJEMHNSA-N
DMKY1L4 IU [(2R,3S,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DMKY1L4 CA CAS 299-31-0
DMKY1L4 CB CHEBI:4170
DM1PK0T ID DM1PK0T
DM1PK0T DN GLYCAR T cells
DM1PK0T HS Phase 1
DM1PK0T CP Baylor College of Medicine
DM1PK0T DT CAR T Cell Therapy
DM1PK0T DE Hepatocellular carcinoma
DMCKZUT ID DMCKZUT
DMCKZUT DN GlyT1 PET radiotracers
DMCKZUT HS Phase 1
DMCKZUT SN GlyT1 PET radiotracers (schizophrenia); Glycine transporter 1 positron emission tomography radiotracers, Merck; [11C]-CMPyPB; Fluorine-18-CFpyPB; [18F]-MK-6577; GlyT1 PET radiotracers (schizophrenia), Merck & Co; 18F-CFpyPB
DMCKZUT CP Merck & Co Inc
DMCKZUT DE Schizophrenia
DML1KSA ID DML1KSA
DML1KSA DN GMI-1359
DML1KSA HS Phase 1
DML1KSA CP GlycoMimetics
DML1KSA DT Small molecular drug
DML1KSA DE Solid tumour/cancer; Breast cancer
DMIFSN2 ID DMIFSN2
DMIFSN2 DN GMX1777
DMIFSN2 HS Phase 1
DMIFSN2 SN Teglarinad chloride; GMX1777; UNII-D6V5QYX9MZ; 432037-57-5; D6V5QYX9MZ; EB1627; 1-[[[[2-[2-[2-[2-Methoxyethoxy]ethoxy]ethoxy]ethoxy]carbonyl]oxy]methyl]-4-[N'-cyano-N''-[6-[4-chlorophenoxy]hexyl]guanidino]pyridinium chloride; Teglarinad chloride [USAN:INN]; GMX 1777; GMX-1777 chloride; CHEMBL190412; SCHEMBL2672343; CTK1D4865; Teglarinad chloride (USAN/INN); EB-1627; D09678
DMIFSN2 CP Gemin X
DMIFSN2 TC Anticancer Agents
DMIFSN2 DT Small molecular drug
DMIFSN2 PC 9961434
DMIFSN2 MW 672.6
DMIFSN2 FM C30H43Cl2N5O8
DMIFSN2 IC InChI=1S/C30H42ClN5O8.ClH/c1-38-16-17-39-18-19-40-20-21-41-22-23-43-30(37)44-25-36-13-10-27(11-14-36)35-29(34-24-32)33-12-4-2-3-5-15-42-28-8-6-26(31)7-9-28;/h6-11,13-14H,2-5,12,15-23,25H2,1H3,(H,33,34);1H
DMIFSN2 CS COCCOCCOCCOCCOC(=O)OC[N+]1=CC=C(C=C1)NC(=NCCCCCCOC2=CC=C(C=C2)Cl)NC#N.[Cl-]
DMIFSN2 IK DAHMXVAETAAQOZ-UHFFFAOYSA-N
DMIFSN2 IU [4-[[N'-[6-(4-chlorophenoxy)hexyl]-N-cyanocarbamimidoyl]amino]pyridin-1-ium-1-yl]methyl 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl carbonate;chloride
DMIFSN2 CA CAS 432037-57-5
DMIFSN2 DE Solid tumour/cancer
DMD6H8B ID DMD6H8B
DMD6H8B DN GMZ-2
DMD6H8B HS Phase 1
DMD6H8B SN Adjuvanted PfGLURP + PfMSP3 vaccine (malaria), AMANET; GLURP-MSP3 bivalent vaccine (malaria), EMVI; Malaria vaccine (PfGLURP + PfMSP3 + aluminium hydroxide adjuvant), EMVI
DMD6H8B CP African Malaria Network Trust
DMD6H8B DT Vaccine
DMD6H8B DE Malaria
DMURO94 ID DMURO94
DMURO94 DN GNE Lipoplex
DMURO94 HS Phase 1
DMURO94 SN GNE Lipoplex (intramuscular, HIBM-2)
DMURO94 CP Gradalis
DMURO94 DE Myopathy
DMYWDT4 ID DMYWDT4
DMYWDT4 DN GNKG-168
DMYWDT4 HS Phase 1
DMYWDT4 CP SBI Biotech
DMYWDT4 DE Chronic lymphocytic leukaemia
DMKMU2S ID DMKMU2S
DMKMU2S DN GNX102
DMKMU2S HS Phase 1
DMKMU2S CP GlycoNex
DMKMU2S DT Antibody
DMKMU2S DE Solid tumour/cancer
DM035LO ID DM035LO
DM035LO DN GP-3269
DM035LO HS Phase 1
DM035LO SN GP-1-3269
DM035LO CP Metabasis Therapeutics Inc
DM035LO DE Convulsion
DM9JV80 ID DM9JV80
DM9JV80 DN Gp41 HIV-1 vaccine
DM9JV80 HS Phase 1
DM9JV80 SN FIV inhibitors, Mymetics; MYM-V101; N-36E; S-291; Anti-retrovirals, Mymetics; Gp41 HIV-1 vaccine (virosomes); Gp41-derived peptides, Mymetics; HIV-1 therapeutics, Mymetics; Gp41 HIV-1 vaccine (virosomes), Mymetics
DM9JV80 CP Mymetics
DM9JV80 DE Human immunodeficiency virus infection
DM2MILF ID DM2MILF
DM2MILF DN GPA-TriMAR-T cells
DM2MILF HS Phase 1
DM2MILF CP Timmune Biotech Inc.
DM2MILF DT CAR T Cell Therapy
DM2MILF DE Melanoma
DMVWHS1 ID DMVWHS1
DMVWHS1 DN GPC3 targeting CAR-T cells
DMVWHS1 HS Phase 1
DMVWHS1 CP Second Affiliated Hospital of Guangzhou Medical University
DMVWHS1 DT CAR T Cell Therapy
DMVWHS1 DE Hepatocellular carcinoma; Lung squamous cell carcinoma
DM0ZQ48 ID DM0ZQ48
DM0ZQ48 DN GPI-16072
DM0ZQ48 HS Phase 1
DM0ZQ48 CP MGI Pharma
DM0ZQ48 TC Analgesics
DM0ZQ48 DT Small molecular drug
DM0ZQ48 PC 56603712
DM0ZQ48 MW 226.12
DM0ZQ48 FM C6H11O7P
DM0ZQ48 IC InChI=1S/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(12)13-11/h4,11-12H,1-3H2,(H,7,8)(H,9,10)
DM0ZQ48 CS C(CC(=O)O)C(CP(O)OO)C(=O)O
DM0ZQ48 IK HKANXFJUBKMWSW-UHFFFAOYSA-N
DM0ZQ48 IU 2-[[hydroperoxy(hydroxy)phosphanyl]methyl]pentanedioic acid
DM0ZQ48 DE Neuropathic pain
DM8MGSH ID DM8MGSH
DM8MGSH DN GPRC5D CAR-T cell therapy
DM8MGSH HS Phase 1
DM8MGSH CP Bristol-Myers Squibb; Eureka Therapeutics
DM8MGSH DT CAR T Cell Therapy
DM8MGSH DE Multiple myeloma
DMFA2XQ ID DMFA2XQ
DMFA2XQ DN GQ1001
DMFA2XQ HS Phase 1
DMFA2XQ CP GeneQuantum Healthcare
DMFA2XQ DT Antibody drug conjugate
DMFA2XQ DE Solid tumour/cancer
DMZ0D3V ID DMZ0D3V
DMZ0D3V DN GRC-6211
DMZ0D3V HS Phase 1
DMZ0D3V SN Oxolinic acid; oxolinic acid; 14698-29-4; Nidantin; Prodoxol; Prodoxal; Emyrenil; Dioxacin; Gramurin; Oxolinic; Oksaren; Ossian; Uroxol; Utibid; Urotrate; Uritrate; Pietil; Oxoboi; Ultibid; Starner; Acido oxolinico; Uro-alvar; Acide oxolinique; Acidum oxolinicum; Cistopax; Tiurasin; Orthurine; Acido ossolico; 5-Ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; NSC-110364; Urinox; Acido ossolico [DCIT]; 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid; GRC-6127; TRPV1 antagonists (asthma), Glenmark/Lilly; TRPV1 antagonists (incontinence), Glenmark/Lilly; TRPV1 antagonists (pain), Glenmark/Lilly; Transient receptor potential vanilloid sub-family 1 (pain), Glenmark/ Lilly; Vanilloid receptor VR1 antagonists (incontinence/pain/asthma), Glenmark/Lilly
DMZ0D3V CP Glenmark Pharmaceuticals Ltd
DMZ0D3V DT Small molecular drug
DMZ0D3V PC 138393987
DMZ0D3V MW 377.4
DMZ0D3V FM C22H20FN3O2
DMZ0D3V IC InChI=1S/C22H20FN3O2/c23-15-5-6-20-17(11-15)19(12-22(28-20)8-2-9-22)26-21(27)25-18-4-1-3-14-13-24-10-7-16(14)18/h1,3-7,10-11,13,19H,2,8-9,12H2,(H2,25,26,27)/t19-/m1/s1
DMZ0D3V CS C1CC2(C1)C[C@H](C3=C(O2)C=CC(=C3)F)NC(=O)NC4=CC=CC5=C4C=CN=C5
DMZ0D3V IK JADKHWDNSKIILG-LJQANCHMSA-N
DMZ0D3V IU 1-[(4R)-6-fluorospiro[3,4-dihydrochromene-2,1'-cyclobutane]-4-yl]-3-isoquinolin-5-ylurea
DMZ0D3V DE Asthma
DMGF71W ID DMGF71W
DMGF71W DN GRN163
DMGF71W HS Phase 1
DMGF71W CP Geron Corp
DMGF71W DT Small molecular drug
DMGF71W PC 56603713
DMGF71W MW 534.9
DMGF71W FM C15H26B3N3O8P2S2-2
DMGF71W IC InChI=1S/C15H28B3N3O8P2S2/c16-13-1-7(19)11(28-13)5-25-31(24,33)21-9-3-15(18)29-12(9)6-26-30(23,32)20-8-2-14(17)27-10(8)4-22/h7-15,22H,1-6,19H2,(H2,20,23,32)(H2,21,24,33)/p-2
DMGF71W CS [B]C1CC(C(O1)COP(=S)(NC2CC(OC2COP(=S)(NC3CC(OC3CO)[B])[O-])[B])[O-])N
DMGF71W IK HHVGDFKKILAWTA-UHFFFAOYSA-L
DMGF71W DE Multiple myeloma
DMI319T ID DMI319T
DMI319T DN GS 9667
DMI319T HS Phase 1
DMI319T SN GS-9667; CVT-3619; UNII-6E68796C40; 618380-90-8; 6E68796C40; IZRXENCTXNMAMI-DIJFLQFKSA-N; CVT 3619; GTPL5593; SCHEMBL1150300; CHEMBL3545011; DTXSID40210823; EX-A2686; BDBM50149592; GS9667
DMI319T CP Gilead Sciences
DMI319T DT Small molecular drug
DMI319T PC 11561692
DMI319T MW 461.5
DMI319T FM C21H24FN5O4S
DMI319T IC InChI=1S/C21H24FN5O4S/c22-11-4-1-2-7-15(11)32-8-14-17(29)18(30)21(31-14)27-10-25-16-19(23-9-24-20(16)27)26-12-5-3-6-13(12)28/h1-2,4,7,9-10,12-14,17-18,21,28-30H,3,5-6,8H2,(H,23,24,26)/t12-,13-,14-,17-,18-,21-/m1/s1
DMI319T CS C1C[C@H]([C@@H](C1)O)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CSC5=CC=CC=C5F)O)O
DMI319T IK IZRXENCTXNMAMI-DIJFLQFKSA-N
DMI319T IU (2S,3S,4R,5R)-2-[(2-fluorophenyl)sulfanylmethyl]-5-[6-[[(1R,2R)-2-hydroxycyclopentyl]amino]purin-9-yl]oxolane-3,4-diol
DMI319T CA CAS 618380-90-8
DMI319T DE Hypertriglyceridemia
DMS25DL ID DMS25DL
DMS25DL DN GS-1423
DMS25DL HS Phase 1
DMS25DL SN AGEN 1423
DMS25DL CP Agenus; Gilead Sciences
DMS25DL DT Antibody
DMS25DL DE Solid tumour/cancer
DMZVFOQ ID DMZVFOQ
DMZVFOQ DN GS-5829
DMZVFOQ HS Phase 1
DMZVFOQ CP Gilead Sciences Foster City, CA
DMZVFOQ DE Solid tumour/cancer
DMRDNPC ID DMRDNPC
DMRDNPC DN GS-6620
DMRDNPC HS Phase 1
DMRDNPC SN GS-441326; NS5B polymerase inhibitor (HCV infection), Gilead Sciences
DMRDNPC CP Gilead Sciences Inc
DMRDNPC DT Small molecular drug
DMRDNPC PC 58059494
DMRDNPC MW 644.6
DMRDNPC FM C29H37N6O9P
DMRDNPC IC InChI=1S/C29H37N6O9P/c1-17(2)26(36)42-24-22(43-29(15-30,28(24,6)38)23-13-12-21-25(31)32-16-33-35(21)23)14-40-45(39,44-20-10-8-7-9-11-20)34-19(5)27(37)41-18(3)4/h7-13,16-19,22,24,38H,14H2,1-6H3,(H,34,39)(H2,31,32,33)/t19-,22+,24+,28+,29-,45?/m0/s1
DMRDNPC CS C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)(C)O)OC(=O)C(C)C)OC4=CC=CC=C4
DMRDNPC IK YAAQYJCOIFNMKX-CVANIGNKSA-N
DMRDNPC IU [(2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
DMRDNPC CA CAS 1350735-70-4
DMRDNPC DE Hepatitis C virus infection
DMXG3T1 ID DMXG3T1
DMXG3T1 DN GS-6637
DMXG3T1 HS Phase 1
DMXG3T1 PC 3862902
DMXG3T1 MW 125.96
DMXG3T1 FM C6H11BO2
DMXG3T1 IC InChI=1S/C6H11BO2/c8-7(9)6-4-2-1-3-5-6/h4,8-9H,1-3,5H2
DMXG3T1 CS B(C1=CCCCC1)(O)O
DMXG3T1 IK XZWQKJXJNKYMAP-UHFFFAOYSA-N
DMXG3T1 IU cyclohexen-1-ylboronic acid
DMXG3T1 CA CAS 89490-05-1
DMXG3T1 DE Substance use disorder
DMNX3US ID DMNX3US
DMNX3US DN GS-9820
DMNX3US HS Phase 1
DMNX3US CP Gilead Sciences
DMNX3US PC 11618268
DMNX3US MW 401.4
DMNX3US FM C21H16FN7O
DMNX3US IC InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1
DMNX3US CS C[C@@H](C1=NC2=C(C=C(C=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
DMNX3US IK DOCINCLJNAXZQF-LBPRGKRZSA-N
DMNX3US IU 6-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)ethyl]quinazolin-4-one
DMNX3US CA CAS 870281-34-8
DMNX3US DE Lymphoma; Chronic lymphocytic leukaemia
DMMF5IE ID DMMF5IE
DMMF5IE DN GS-9883
DMMF5IE HS Phase 1
DMMF5IE SN Bictegravir; Bictegravir (USAN/INN); Bictegravir [INN]; Bictegravir [USAN:INN]; SB18851; SOLUWJRYJLAZCX-LYOVBCGYSA-N; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 1611493-60-7; 8GB79LOJ07; BCP25703; BDBM330048; CHEMBL3989866; DB11799; GS 9883; GS-9883; GS-9883-01; SCHEMBL15914278; UNII-8GB79LOJ07
DMMF5IE PC 90311989
DMMF5IE MW 449.4
DMMF5IE FM C21H18F3N3O5
DMMF5IE IC SOLUWJRYJLAZCX-LYOVBCGYSA-N
DMMF5IE CS C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
DMMF5IE IK 1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1
DMMF5IE IU (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
DMMF5IE CA CAS 1611493-60-7
DMMF5IE DE Human immunodeficiency virus infection
DMGHN98 ID DMGHN98
DMGHN98 DN GS-9901
DMGHN98 HS Phase 1
DMGHN98 PC 86763204
DMGHN98 MW 477.9
DMGHN98 FM C22H17ClFN9O
DMGHN98 IC InChI=1S/C22H17ClFN9O/c23-13-5-6-14(24)17-15(13)21(34)33(11-2-1-7-28-9-11)20(30-17)16(10-3-4-10)29-19-12(8-25)18(26)31-22(27)32-19/h1-2,5-7,9-10,16H,3-4H2,(H5,26,27,29,31,32)/t16-/m0/s1
DMGHN98 CS C1CC1[C@@H](C2=NC3=C(C=CC(=C3C(=O)N2C4=CN=CC=C4)Cl)F)NC5=NC(=NC(=C5C#N)N)N
DMGHN98 IK XDSXYMOZKDUASY-INIZCTEOSA-N
DMGHN98 IU 2,4-diamino-6-[[(S)-(5-chloro-8-fluoro-4-oxo-3-pyridin-3-ylquinazolin-2-yl)-cyclopropylmethyl]amino]pyrimidine-5-carbonitrile
DMGHN98 CA CAS 1640247-87-5
DMGHN98 DE Haematological malignancy
DMSR5HD ID DMSR5HD
DMSR5HD DN GSI-136
DMSR5HD HS Phase 1
DMSR5HD SN WAY-179642; WAY-208983; WAY-GSI-A; WAY-GSI-B; Gamma-secretase inhibitors (oral, Alzheimer's disease), Wyeth
DMSR5HD CP Wyeth
DMSR5HD DT Small molecular drug
DMSR5HD PC 11358855
DMSR5HD MW 311.9
DMSR5HD FM C11H18ClNO3S2
DMSR5HD IC InChI=1S/C11H18ClNO3S2/c1-3-8(4-2)9(7-14)13-18(15,16)11-6-5-10(12)17-11/h5-6,8-9,13-14H,3-4,7H2,1-2H3/t9-/m1/s1
DMSR5HD CS CCC(CC)[C@@H](CO)NS(=O)(=O)C1=CC=C(S1)Cl
DMSR5HD IK PYZFRRVBPNGCBX-SECBINFHSA-N
DMSR5HD IU 5-chloro-N-[(2S)-3-ethyl-1-hydroxypentan-2-yl]thiophene-2-sulfonamide
DMSR5HD CA CAS 443989-01-3
DMSR5HD DE Alzheimer disease
DMO87YS ID DMO87YS
DMO87YS DN GSK065
DMO87YS HS Phase 1
DMO87YS SN CHEMBL4091152; (R)-3-(5-Chloro-6-(1-(pyridin-2-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid; 3-[5-Chloranyl-6-[(1~{r})-1-Pyridin-2-Ylethoxy]-1,2-Benzoxazol-3-Yl]propanoic Acid; 1953156-61-0; 8R5; SCHEMBL17844622; GTPL10358; BDBM50266003; GSK3335065; inhibitor C1 [PMID: 28604669]; ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)O[C@H](C)C1=NC=CC=C1
DMO87YS CP GlaxoSmithKline
DMO87YS DT Small molecular drug
DMO87YS PC 121415134
DMO87YS MW 346.8
DMO87YS FM C17H15ClN2O4
DMO87YS IC InChI=1S/C17H15ClN2O4/c1-10(13-4-2-3-7-19-13)23-16-9-15-11(8-12(16)18)14(20-24-15)5-6-17(21)22/h2-4,7-10H,5-6H2,1H3,(H,21,22)/t10-/m1/s1
DMO87YS CS C[C@H](C1=CC=CC=N1)OC2=C(C=C3C(=C2)ON=C3CCC(=O)O)Cl
DMO87YS IK WPAHVUADNLXSOM-SNVBAGLBSA-N
DMO87YS IU 3-[5-chloro-6-[(1R)-1-pyridin-2-ylethoxy]-1,2-benzoxazol-3-yl]propanoic acid
DMO87YS DE Pancreatitis
DMXRPT6 ID DMXRPT6
DMXRPT6 DN GSK1070916
DMXRPT6 HS Phase 1
DMXRPT6 SN GSK-1070916
DMXRPT6 CP GlaxoSmith-Kline
DMXRPT6 DT Small molecular drug
DMXRPT6 PC 46885626
DMXRPT6 MW 507.6
DMXRPT6 FM C30H33N7O
DMXRPT6 IC InChI=1S/C30H33N7O/c1-6-37-19-26(28(34-37)21-10-12-23(13-11-21)32-30(38)36(4)5)24-14-15-31-29-25(24)17-27(33-29)22-9-7-8-20(16-22)18-35(2)3/h7-17,19H,6,18H2,1-5H3,(H,31,33)(H,32,38)
DMXRPT6 CS CCN1C=C(C(=N1)C2=CC=C(C=C2)NC(=O)N(C)C)C3=C4C=C(NC4=NC=C3)C5=CC=CC(=C5)CN(C)C
DMXRPT6 IK QTBWCSQGBMPECM-UHFFFAOYSA-N
DMXRPT6 IU 3-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethylpyrazol-3-yl]phenyl]-1,1-dimethylurea
DMXRPT6 CA CAS 942918-07-2
DMXRPT6 CB CHEBI:91362
DMXRPT6 DE Advanced solid tumour
DMCJUI9 ID DMCJUI9
DMCJUI9 DN GSK1070916A
DMCJUI9 HS Phase 1
DMCJUI9 CP GlaxoSmithKline
DMCJUI9 DE Solid tumour/cancer
DMK3S9J ID DMK3S9J
DMK3S9J DN GSK1144814
DMK3S9J HS Phase 1
DMK3S9J CP GSK
DMK3S9J DE Schizophrenia; Alcohol dependence
DMNYGB8 ID DMNYGB8
DMNYGB8 DN GSK-1322888
DMNYGB8 HS Phase 1
DMNYGB8 SN 1322888
DMNYGB8 CP GlaxoSmithKline plc
DMNYGB8 DE Gastroparesis
DMZC9XU ID DMZC9XU
DMZC9XU DN GSK-1360707
DMZC9XU HS Phase 1
DMZC9XU SN Monoamine reuptake inhibitors (depression), GlaxoSmithKline; Serotonin/dopamine/norepinephrine reuptake inhibitors (depression), GlaxoSmithKline
DMZC9XU CP GlaxoSmithKline plc
DMZC9XU PC 24802841
DMZC9XU MW 286.2
DMZC9XU FM C14H17Cl2NO
DMZC9XU IC InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m0/s1
DMZC9XU CS COC[C@@]12C[C@@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl
DMZC9XU IK ICXJGCSEMJXNQF-KBPBESRZSA-N
DMZC9XU IU (1S,6R)-6-(3,4-dichlorophenyl)-1-(methoxymethyl)-3-azabicyclo[4.1.0]heptane
DMZC9XU CA CAS 1013098-04-8
DMZC9XU DE Major depressive disorder
DMEJMTR ID DMEJMTR
DMEJMTR DN GSK1440115
DMEJMTR HS Phase 1
DMEJMTR SN UNII-GCT6G5G3C7; GCT6G5G3C7; GSK 1440115; SCHEMBL2957737; 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid; (1,1'-Biphenyl)-4-carboxylic acid, 4'-((1R)-1-((2-(6,7-dichloro-2,3-dihydro-3-oxo-4H-1,4-benzoxazin-4-yl)acetyl)methylamino)-2-(4-morpholinyl)ethyl)-
DMEJMTR CP GlaxoSmithKline
DMEJMTR DT Small molecular drug
DMEJMTR PC 24760693
DMEJMTR MW 598.5
DMEJMTR FM C30H29Cl2N3O6
DMEJMTR IC InChI=1S/C30H29Cl2N3O6/c1-33(28(36)17-35-25-14-23(31)24(32)15-27(25)41-18-29(35)37)26(16-34-10-12-40-13-11-34)21-6-2-19(3-7-21)20-4-8-22(9-5-20)30(38)39/h2-9,14-15,26H,10-13,16-18H2,1H3,(H,38,39)/t26-/m0/s1
DMEJMTR CS CN([C@@H](CN1CCOCC1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)O)C(=O)CN4C(=O)COC5=CC(=C(C=C54)Cl)Cl
DMEJMTR IK YNBJTYUXPHTSFF-SANMLTNESA-N
DMEJMTR IU 4-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-morpholin-4-ylethyl]phenyl]benzoic acid
DMEJMTR CA CAS 1003878-16-7
DMEJMTR DE Asthma
DMWDQOV ID DMWDQOV
DMWDQOV DN GSK1482160
DMWDQOV HS Phase 1
DMWDQOV CP GSK
DMWDQOV TC Analgesics
DMWDQOV PC 45273136
DMWDQOV MW 334.72
DMWDQOV FM C14H14ClF3N2O2
DMWDQOV IC InChI=1S/C14H14ClF3N2O2/c1-20-10(5-6-11(20)21)13(22)19-7-8-3-2-4-9(12(8)15)14(16,17)18/h2-4,10H,5-7H2,1H3,(H,19,22)
DMWDQOV CS CN1C(CCC1=O)C(=O)NCC2=C(C(=CC=C2)C(F)(F)F)Cl
DMWDQOV IK BJEMSIVBBUBXMZ-UHFFFAOYSA-N
DMWDQOV IU N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-5-oxopyrrolidine-2-carboxamide
DMWDQOV DE Pain
DM2L7TH ID DM2L7TH
DM2L7TH DN GSK1521498
DM2L7TH HS Phase 1
DM2L7TH SN GSK-1521498; GSK-1521498B
DM2L7TH CP GlaxoSmithKline
DM2L7TH DT Small molecular drug
DM2L7TH PC 24737629
DM2L7TH MW 402.4
DM2L7TH FM C24H20F2N4
DM2L7TH IC InChI=1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)
DM2L7TH CS C1C(CC2=CC=CC=C21)NCC3=C(C=C(C=C3F)C4=CC(=CC=C4)C5=NC=NN5)F
DM2L7TH IK WIEDUMBCZQRGSY-UHFFFAOYSA-N
DM2L7TH IU N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine
DM2L7TH CA CAS 1007573-18-3
DM2L7TH DE Obesity
DM7I1AQ ID DM7I1AQ
DM7I1AQ DN GSK1614235
DM7I1AQ HS Phase 1
DM7I1AQ CP GSK
DM7I1AQ DE Type-2 diabetes
DMC6QE4 ID DMC6QE4
DMC6QE4 DN GSK1795091
DMC6QE4 HS Phase 1
DMC6QE4 CP GlaxoSmithKline Research Triangle Park, NC
DMC6QE4 DE Solid tumour/cancer
DMA41JD ID DMA41JD
DMA41JD DN GSK-1827771
DMA41JD HS Phase 1
DMA41JD SN IL-1 antagonist (antibody, rheumatoid arthritis), GSK
DMA41JD CP GlaxoSmithKline plc
DMA41JD DT Antibody
DMA41JD DE Rheumatoid arthritis
DMC14KV ID DMC14KV
DMC14KV DN GSK1995057
DMC14KV HS Phase 1
DMC14KV CP Quark Pharmaceuticals
DMC14KV DT Antibody
DMC14KV DE Adult respiratory distress syndrome
DMRU4YV ID DMRU4YV
DMRU4YV DN GSK-2018682
DMRU4YV HS Phase 1
DMRU4YV SN PPI-4621; PPI-4667; PPI-4939; PPI-4955; PPI-4667-P; PPI-5955-P; S1P1 receptor agonists (immune disorder), GlaxoSmithKline
DMRU4YV CP Praecis Pharmaceuticals Inc
DMRU4YV PC 24988201
DMRU4YV MW 440.9
DMRU4YV FM C22H21ClN4O4
DMRU4YV IC InChI=1S/C22H21ClN4O4/c1-13(2)30-22-17(23)11-14(12-24-22)21-25-20(26-31-21)16-5-3-6-18-15(16)8-10-27(18)9-4-7-19(28)29/h3,5-6,8,10-13H,4,7,9H2,1-2H3,(H,28,29)
DMRU4YV CS CC(C)OC1=C(C=C(C=N1)C2=NC(=NO2)C3=C4C=CN(C4=CC=C3)CCCC(=O)O)Cl
DMRU4YV IK NFIGDBFIDKDNIG-UHFFFAOYSA-N
DMRU4YV IU 4-[4-[5-(5-chloro-6-propan-2-yloxypyridin-3-yl)-1,2,4-oxadiazol-3-yl]indol-1-yl]butanoic acid
DMRU4YV CA CAS 1034688-30-6
DMRU4YV DE Immune System disease
DMM7ZXR ID DMM7ZXR
DMM7ZXR DN GSK2126458
DMM7ZXR HS Phase 1
DMM7ZXR SN 1086062-66-9; Omipalisib; GSK-2126458; GSK 2126458; UNII-1X8F5A3NA0; 2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide; 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide; 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide; 1X8F5A3NA0; Omipalisib (GSK2126458, GSK458); C25H17F2N5O3S; Omipalisib [USAN:INN]
DMM7ZXR CP GlaxoSmithKline
DMM7ZXR DT Small molecular drug
DMM7ZXR PC 25167777
DMM7ZXR MW 505.5
DMM7ZXR FM C25H17F2N5O3S
DMM7ZXR IC InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
DMM7ZXR CS COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F
DMM7ZXR IK CGBJSGAELGCMKE-UHFFFAOYSA-N
DMM7ZXR IU 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide
DMM7ZXR CA CAS 1086062-66-9
DMM7ZXR CB CHEBI:95093
DMM7ZXR DE Lymphoma
DMRXW9P ID DMRXW9P
DMRXW9P DN GSK-2130579A
DMRXW9P HS Phase 1
DMRXW9P SN Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline
DMRXW9P CP Glaxosmithkline
DMRXW9P DT Vaccine
DMRXW9P DE Acute myeloid leukaemia
DMUNVXR ID DMUNVXR
DMUNVXR DN GSK-2239633
DMUNVXR HS Phase 1
DMUNVXR CP GlaxoSmithKline plc
DMUNVXR PC 46861584
DMUNVXR MW 549.1
DMUNVXR FM C24H25ClN4O5S2
DMUNVXR IC InChI=1S/C24H25ClN4O5S2/c1-24(2,31)23(30)26-13-15-6-4-7-16(12-15)14-29-17-8-5-9-18(34-3)21(17)22(27-29)28-36(32,33)20-11-10-19(25)35-20/h4-12,31H,13-14H2,1-3H3,(H,26,30)(H,27,28)
DMUNVXR CS CC(C)(C(=O)NCC1=CC(=CC=C1)CN2C3=C(C(=CC=C3)OC)C(=N2)NS(=O)(=O)C4=CC=C(S4)Cl)O
DMUNVXR IK YTEVTHHGQMUPHC-UHFFFAOYSA-N
DMUNVXR IU N-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methyl]-2-hydroxy-2-methylpropanamide
DMUNVXR CA CAS 1240516-71-5
DMUNVXR DE Asthma
DM5VS7B ID DM5VS7B
DM5VS7B DN GSK-2241658A
DM5VS7B HS Phase 1
DM5VS7B SN NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A
DM5VS7B CP GlaxoSmithKline plc
DM5VS7B DT Vaccine
DM5VS7B DE Melanoma
DMR24MI ID DMR24MI
DMR24MI DN GSK-2256098
DMR24MI HS Phase 1
DMR24MI SN Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline
DMR24MI CP GlaxoSmithKline
DMR24MI DT Small molecular drug
DMR24MI PC 46214930
DMR24MI MW 414.9
DMR24MI FM C20H23ClN6O2
DMR24MI IC InChI=1S/C20H23ClN6O2/c1-12(2)27-19(9-13(3)25-27)24-18-10-17(15(21)11-22-18)23-16-8-6-5-7-14(16)20(28)26-29-4/h5-12H,1-4H3,(H,26,28)(H2,22,23,24)
DMR24MI CS CC1=NN(C(=C1)NC2=NC=C(C(=C2)NC3=CC=CC=C3C(=O)NOC)Cl)C(C)C
DMR24MI IK BVAHPPKGOOJSPU-UHFFFAOYSA-N
DMR24MI IU 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-N-methoxybenzamide
DMR24MI CA CAS 1224887-10-8
DMR24MI DE Solid tumour/cancer; Pulmonary arterial hypertension
DM7FN12 ID DM7FN12
DM7FN12 DN GSK2256294
DM7FN12 HS Phase 1
DM7FN12 SN GSK-2256294
DM7FN12 CP GlaxoSmithKline
DM7FN12 PC 59448236
DM7FN12 MW 447.5
DM7FN12 FM C21H24F3N7O
DM7FN12 IC InChI=1S/C21H24F3N7O/c1-12-28-19(26-2)31-20(29-12)30-16-5-3-4-14(9-16)18(32)27-11-15-7-6-13(10-25)8-17(15)21(22,23)24/h6-8,14,16H,3-5,9,11H2,1-2H3,(H,27,32)(H2,26,28,29,30,31)/t14-,16+/m1/s1
DM7FN12 CS CC1=NC(=NC(=N1)N[C@H]2CCC[C@H](C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)NC
DM7FN12 IK LQHDJQIMETZMPH-ZBFHGGJFSA-N
DM7FN12 IU (1R,3S)-N-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]cyclohexane-1-carboxamide
DM7FN12 CA CAS 1142090-23-0
DM7FN12 DE Chronic obstructive pulmonary disease
DMOWTRL ID DMOWTRL
DMOWTRL DN GSK-2315698
DMOWTRL HS Phase 1
DMOWTRL SN GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline
DMOWTRL CP GlaxoSmithKline plc
DMOWTRL DT Antibody
DMOWTRL DE Amyloidosis
DMZ5A6D ID DMZ5A6D
DMZ5A6D DN GSK2398852
DMZ5A6D HS Phase 1
DMZ5A6D SN 2398852
DMZ5A6D DT Antibody
DMZ5A6D DE Amyloidosis
DMIVHDN ID DMIVHDN
DMIVHDN DN GSK2618960
DMIVHDN HS Phase 1
DMIVHDN CP Glaxosmithkline
DMIVHDN DE Multiple sclerosis; Sjogren syndrome
DMCBGLW ID DMCBGLW
DMCBGLW DN GSK2636771
DMCBGLW HS Phase 1
DMCBGLW SN GSK2636771; 1372540-25-4; GSK-2636771; 2-methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid; UNII-DW94IAT0LS; DW94IAT0LS; GSK 2636771; 2-Methyl-1-((2-methyl-3-(trifluoromethyl)phenyl)methyl)-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid; 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid; lic acid; XTKLTGBKIDQGQL-UHFFFAOYSA-N
DMCBGLW CP GlaxoSmithKline
DMCBGLW DT Small molecular drug
DMCBGLW PC 56949517
DMCBGLW MW 433.4
DMCBGLW FM C22H22F3N3O3
DMCBGLW IC InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)
DMCBGLW CS CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C(C=C(C=C32)N4CCOCC4)C(=O)O)C
DMCBGLW IK XTKLTGBKIDQGQL-UHFFFAOYSA-N
DMCBGLW IU 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid
DMCBGLW CA CAS 1372540-25-4
DMCBGLW DE Solid tumour/cancer; Prostate cancer
DMQOM5V ID DMQOM5V
DMQOM5V DN GSK2646264
DMQOM5V HS Phase 1
DMQOM5V SN CQLSAYKHANAIMX-UHFFFAOYSA-N; GTPL10108; compound 44 [PMID: 30249354]; 7-{2-methoxy-6-[(4-methylpyridin-2-yl)methoxy]phenyl}-2,3,4,5,5a,9a-hexahydro-1H-3-benzazepine
DMQOM5V CP GlaxoSmithKline Research Triangle Park, NC
DMQOM5V PC 60194098
DMQOM5V MW 374.5
DMQOM5V FM C24H26N2O2
DMQOM5V IC InChI=1S/C24H26N2O2/c1-17-8-13-26-21(14-17)16-28-23-5-3-4-22(27-2)24(23)20-7-6-18-9-11-25-12-10-19(18)15-20/h3-8,13-15,25H,9-12,16H2,1-2H3
DMQOM5V CS CC1=CC(=NC=C1)COC2=CC=CC(=C2C3=CC4=C(CCNCC4)C=C3)OC
DMQOM5V IK KYANYGKXMNYFBX-UHFFFAOYSA-N
DMQOM5V IU 7-[2-methoxy-6-[(4-methylpyridin-2-yl)methoxy]phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine
DMQOM5V CA CAS 1398695-47-0
DMQOM5V DE Cutaneous lupus erythematosus; Urticaria
DM3KARJ ID DM3KARJ
DM3KARJ DN GSK2647544
DM3KARJ HS Phase 1
DM3KARJ SN GSK-2647544
DM3KARJ CP GlaxoSmithKline
DM3KARJ DE Alzheimer disease
DMAK89L ID DMAK89L
DMAK89L DN GSK2661380
DMAK89L HS Phase 1
DMAK89L SN GSK-2661380
DMAK89L CP GlaxoSmithKline
DMAK89L DT Antibody
DMAK89L DE Solid tumour/cancer
DMSGNVK ID DMSGNVK
DMSGNVK DN GSK2793660
DMSGNVK HS Phase 1
DMSGNVK SN 2793660
DMSGNVK CP Glaxosmithkline
DMSGNVK DE Bronchiectasis
DMJDVW4 ID DMJDVW4
DMJDVW4 DN GSK2816126
DMJDVW4 HS Phase 1
DMJDVW4 SN GSK 126; GSK-126
DMJDVW4 CP Glaxosmithkline
DMJDVW4 DT Small molecular drug
DMJDVW4 PC 68210102
DMJDVW4 MW 526.7
DMJDVW4 FM C31H38N6O2
DMJDVW4 IC InChI=1S/C31H38N6O2/c1-6-22(5)37-18-20(3)29-25(30(38)34-17-26-19(2)13-21(4)35-31(26)39)14-24(15-27(29)37)23-7-8-28(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,22,32H,6,9-12,17H2,1-5H3,(H,34,38)(H,35,39)/t22-/m0/s1
DMJDVW4 CS CC[C@H](C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C
DMJDVW4 IK FKSFKBQGSFSOSM-QFIPXVFZSA-N
DMJDVW4 IU 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
DMJDVW4 CA CAS 1346574-57-9
DMJDVW4 CB CHEBI:124921
DMJDVW4 DE Solid tumour/cancer
DMU1X8K ID DMU1X8K
DMU1X8K DN GSK2820151
DMU1X8K HS Phase 1
DMU1X8K CP GlaxoSmithKline
DMU1X8K DT Small molecular drug
DMU1X8K DE Solid tumour/cancer
DMC47M9 ID DMC47M9
DMC47M9 DN GSK2831781
DMC47M9 HS Phase 1
DMC47M9 CP GlaxoSmithKline Research Triangle Park, NC
DMC47M9 DE Autoimmune disease; Plaque psoriasis
DM6KE4G ID DM6KE4G
DM6KE4G DN GSK2849330
DM6KE4G HS Phase 1
DM6KE4G CP Glaxosmithkline
DM6KE4G DT Antibody
DM6KE4G DE Solid tumour/cancer
DMT3V2W ID DMT3V2W
DMT3V2W DN GSK2879552
DMT3V2W HS Phase 1
DMT3V2W CP Glaxosmithkline
DMT3V2W PC 66571643
DMT3V2W MW 364.5
DMT3V2W FM C23H28N2O2
DMT3V2W IC InChI=1S/C23H28N2O2/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19/h1-9,17,21-22,24H,10-16H2,(H,26,27)/t21-,22+/m0/s1
DMT3V2W CS C1CN(CCC1CN[C@@H]2C[C@H]2C3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)O
DMT3V2W IK LRULVYSBRWUVGR-FCHUYYIVSA-N
DMT3V2W IU 4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]methyl]benzoic acid
DMT3V2W CA CAS 1401966-69-5
DMT3V2W DE Small-cell lung cancer
DM4ZK6G ID DM4ZK6G
DM4ZK6G DN GSK3050002
DM4ZK6G HS Phase 1
DM4ZK6G CP GlaxoSmithKline Research Triangle Park, NC
DM4ZK6G DE Psoriatic arthritis
DMCKNJX ID DMCKNJX
DMCKNJX DN GSK3052230
DMCKNJX HS Phase 1
DMCKNJX CP Glaxosmithkline
DMCKNJX DE Solid tumour/cancer
DM70DYV ID DM70DYV
DM70DYV DN GSK311739
DM70DYV HS Phase 1
DM70DYV CP Glaxosmithkline
DM70DYV DE Rhinovirus infection
DMQZSXD ID DMQZSXD
DMQZSXD DN GSK3117391
DMQZSXD HS Phase 1
DMQZSXD CP Glaxosmithkline
DMQZSXD DT Small molecular drug
DMQZSXD PC 53630042
DMQZSXD MW 403.5
DMQZSXD FM C22H33N3O4
DMQZSXD IC InChI=1S/C22H33N3O4/c26-20(25-28)13-12-18-11-10-16(14-23-18)15-24-21(17-6-2-1-3-7-17)22(27)29-19-8-4-5-9-19/h10-11,14,17,19,21,24,28H,1-9,12-13,15H2,(H,25,26)/t21-/m0/s1
DMQZSXD CS C1CCC(CC1)[C@@H](C(=O)OC2CCCC2)NCC3=CN=C(C=C3)CCC(=O)NO
DMQZSXD IK AFDPFLDWOXXHQM-NRFANRHFSA-N
DMQZSXD IU cyclopentyl (2S)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetate
DMQZSXD CA CAS 1018673-42-1
DMQZSXD DE Rheumatoid arthritis
DM2KCIP ID DM2KCIP
DM2KCIP DN GSK3179106
DM2KCIP HS Phase 1
DM2KCIP SN RET Kinase inhibitor 1; SCHEMBL16055027; CHEMBL3355009; IDXKJSSOUXWLDB-UHFFFAOYSA-N; CS-7799; HY-100459; 1627856-64-7; 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
DM2KCIP CP GlaxoSmithKline Research Triangle Park, NC
DM2KCIP PC 78427026
DM2KCIP MW 467.4
DM2KCIP FM C22H21F4N3O4
DM2KCIP IC InChI=1S/C22H21F4N3O4/c1-4-32-16-9-19(30)27-11-14(16)12-5-6-13(15(23)7-12)8-20(31)28-18-10-17(33-29-18)21(2,3)22(24,25)26/h5-7,9-11H,4,8H2,1-3H3,(H,27,30)(H,28,29,31)
DM2KCIP CS CCOC1=CC(=O)NC=C1C2=CC(=C(C=C2)CC(=O)NC3=NOC(=C3)C(C)(C)C(F)(F)F)F
DM2KCIP IK IDXKJSSOUXWLDB-UHFFFAOYSA-N
DM2KCIP IU 2-[4-(4-ethoxy-6-oxo-1H-pyridin-3-yl)-2-fluorophenyl]-N-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]acetamide
DM2KCIP CA CAS 1627856-64-7
DM2KCIP DE Inflammatory bowel disease
DMJAVN7 ID DMJAVN7
DMJAVN7 DN GSK3186899
DMJAVN7 HS Phase 1
DMJAVN7 SN CHEMBL4563818; 1972617-87-0; 3,3,3-Trifluoro-N-(trans-4-((3-((S)-2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide; SCHEMBL17948393; SCHEMBL20878264; SCHEMBL20878281; BDBM50517287; TQ0152; DDD-853651; SB18814; HY-112622; CS-0058580; 3,3,3-trifluoro-N-((1S,4r)-4-((3-((S)-2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide
DMJAVN7 CP GlaxoSmithKline
DMJAVN7 DT Small molecular drug
DMJAVN7 PC 122429808
DMJAVN7 MW 491.5
DMJAVN7 FM C19H28F3N7O3S
DMJAVN7 IC InChI=1S/C19H28F3N7O3S/c1-12-11-29(7-8-32-12)17-15-10-23-18(25-16(15)26-27-17)24-13-2-4-14(5-3-13)28-33(30,31)9-6-19(20,21)22/h10,12-14,28H,2-9,11H2,1H3,(H2,23,24,25,26,27)/t12-,13?,14?/m0/s1
DMJAVN7 CS C[C@H]1CN(CCO1)C2=NNC3=NC(=NC=C32)NC4CCC(CC4)NS(=O)(=O)CCC(F)(F)F
DMJAVN7 IK RQWCISVRFNZHMJ-HSBZDZAISA-N
DMJAVN7 IU 3,3,3-trifluoro-N-[4-[[3-[(2S)-2-methylmorpholin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]cyclohexyl]propane-1-sulfonamide
DMJAVN7 DE Leishmaniasis
DMVEGND ID DMVEGND
DMVEGND DN GSK3368715
DMVEGND HS Phase 1
DMVEGND SN 1629013-22-4; N~1~-({5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N~1~,N~2~-dimethylethane-1,2-diamine; EPZ019997; SCHEMBL16121956; EX-A4367; NSC823806; EPZ-019997; NSC-823806; GSK-3368715; HY-128717; CS-0099584; KZS; N1-((3-(4,4-Bis(ethoxymethyl)cyclohexyl)-1H-pyrazol-4-yl)methyl)-N1,N2-dimethylethane-1,2-diamine
DMVEGND CP GlaxoSmithKline
DMVEGND DT Small molecular drug
DMVEGND PC 90462880
DMVEGND MW 366.5
DMVEGND FM C20H38N4O2
DMVEGND IC InChI=1S/C20H38N4O2/c1-5-25-15-20(16-26-6-2)9-7-17(8-10-20)19-18(13-22-23-19)14-24(4)12-11-21-3/h13,17,21H,5-12,14-16H2,1-4H3,(H,22,23)
DMVEGND CS CCOCC1(CCC(CC1)C2=C(C=NN2)CN(C)CCNC)COCC
DMVEGND IK SPEGERVLTUWZPA-UHFFFAOYSA-N
DMVEGND IU N'-[[5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N,N'-dimethylethane-1,2-diamine
DMVEGND DE Solid tumour/cancer
DMIEAMU ID DMIEAMU
DMIEAMU DN GSK-356278
DMIEAMU HS Phase 1
DMIEAMU SN PDE4 inhibitor (oral, depression/anxiety), GlaxoSmithKline
DMIEAMU CP Glaxosmithkline
DMIEAMU DT Small molecular drug
DMIEAMU PC 10252640
DMIEAMU MW 439.5
DMIEAMU FM C21H25N7O2S
DMIEAMU IC InChI=1S/C21H25N7O2S/c1-4-28-20-15(11-23-28)19(25-14-5-7-29-8-6-14)16(10-22-20)21-27-26-18(30-21)9-17-12(2)24-13(3)31-17/h10-11,14H,4-9H2,1-3H3,(H,22,25)
DMIEAMU CS CCN1C2=NC=C(C(=C2C=N1)NC3CCOCC3)C4=NN=C(O4)CC5=C(N=C(S5)C)C
DMIEAMU IK AWDJJMXJUOHGLC-UHFFFAOYSA-N
DMIEAMU IU 5-[5-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine
DMIEAMU CA CAS 720704-34-7
DMIEAMU DE Huntington disease
DMRYNJD ID DMRYNJD
DMRYNJD DN GSK3745417
DMRYNJD HS Phase 1
DMRYNJD CP GlaxoSmithKline
DMRYNJD DE Solid tumour/cancer
DM1UQ4Y ID DM1UQ4Y
DM1UQ4Y DN GSK3845097
DM1UQ4Y HS Phase 1
DM1UQ4Y CP GlaxoSmithKline
DM1UQ4Y DT TCR-T cell therapy
DM1UQ4Y DE Solid tumour/cancer
DMN4I7P ID DMN4I7P
DMN4I7P DN GSK3901961
DMN4I7P HS Phase 1
DMN4I7P CP GlaxoSmithKline
DMN4I7P DT TCR-T cell therapy
DMN4I7P DE Solid tumour/cancer
DMI3FU6 ID DMI3FU6
DMI3FU6 DN GSK4074386
DMI3FU6 HS Phase 1
DMI3FU6 SN TSR-033
DMI3FU6 CP AnaptysBio; GlaxoSmithKline
DMI3FU6 DT Antibody
DMI3FU6 DE Solid tumour/cancer
DM0P729 ID DM0P729
DM0P729 DN GSK461364
DM0P729 HS Phase 1
DM0P729 SN GSK461364; 929095-18-1; GSK-461364; 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide; GSK 461364; UNII-8QO27TK6Q4; GSK-461364A; (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide; 8QO27TK6Q4; CHEMBL1908394; GSK461364A; ZHJGWYRLJUCMRT-QGZVFWFLSA-N; SCHEMBL310080; GTPL5684; C27H28F3N5O2S; CTK8B7590; CHEBI:91333; DTXSID60239197; MolPort-016-633-304; BCP01720; GSK 461364A
DM0P729 CP GlaxoSmithKline
DM0P729 TC Anticancer Agents
DM0P729 DT Small molecular drug
DM0P729 PC 15983966
DM0P729 MW 543.6
DM0P729 FM C27H28F3N5O2S
DM0P729 IC InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1
DM0P729 CS C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)CN5CCN(CC5)C)C(=O)N
DM0P729 IK ZHJGWYRLJUCMRT-QGZVFWFLSA-N
DM0P729 IU 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide
DM0P729 CA CAS 929095-18-1
DM0P729 CB CHEBI:91333
DM0P729 DE Non-hodgkin lymphoma; Solid tumour/cancer
DMPAWBN ID DMPAWBN
DMPAWBN DN GSK525762
DMPAWBN HS Phase 1
DMPAWBN SN GSK-525762
DMPAWBN CP GlaxoSmithKline
DMPAWBN DT Small molecular drug
DMPAWBN PC 46943432
DMPAWBN MW 423.9
DMPAWBN FM C22H22ClN5O2
DMPAWBN IC InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1
DMPAWBN CS CCNC(=O)C[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C
DMPAWBN IK AAAQFGUYHFJNHI-SFHVURJKSA-N
DMPAWBN IU 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide
DMPAWBN CA CAS 1260907-17-2
DMPAWBN CB CHEBI:95082
DMPAWBN DE Solid tumour/cancer; Haematological malignancy
DM5E9LX ID DM5E9LX
DM5E9LX DN GSK586529
DM5E9LX HS Phase 1
DM5E9LX CP GSK
DM5E9LX DE Anxiety disorder; Depression
DMWI0AL ID DMWI0AL
DMWI0AL DN GSK6097608
DMWI0AL HS Phase 1
DMWI0AL CP GlaxoSmithKline
DMWI0AL DT Antibody
DMWI0AL DE Solid tumour/cancer
DMJPXZ4 ID DMJPXZ4
DMJPXZ4 DN GSK618334
DMJPXZ4 HS Phase 1
DMJPXZ4 SN Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride
DMJPXZ4 CP GSK
DMJPXZ4 DT Small molecular drug
DMJPXZ4 PC 107969
DMJPXZ4 MW 343.9
DMJPXZ4 FM C19H34ClNO2
DMJPXZ4 IC InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
DMJPXZ4 CS CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
DMJPXZ4 IK SWZTYAVBMYWFGS-UHFFFAOYSA-N
DMJPXZ4 IU 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
DMJPXZ4 CA CAS 162359-56-0
DMJPXZ4 CB CHEBI:63112
DMJPXZ4 DE Drug abuse; Nasopharyngeal carcinoma
DM7CIN4 ID DM7CIN4
DM7CIN4 DN GSK-625433
DM7CIN4 HS Phase 1
DM7CIN4 SN NS5B HCV polymerase inhibitors, GlaxoSmithKline; SB-711845; SB-750330; 625433
DM7CIN4 CP GlaxoSmithKline plc
DM7CIN4 DT Small molecular drug
DM7CIN4 PC 11569786
DM7CIN4 MW 512.6
DM7CIN4 FM C26H32N4O5S
DM7CIN4 IC InChI=1S/C26H32N4O5S/c1-25(2,3)19-8-7-17(13-20(19)35-5)23(31)30-21(22-27-10-12-36-22)18(15-34-4)14-26(30,24(32)33)16-29-11-6-9-28-29/h6-13,18,21H,14-16H2,1-5H3,(H,32,33)/t18-,21-,26-/m1/s1
DM7CIN4 CS CC(C)(C)C1=C(C=C(C=C1)C(=O)N2[C@H]([C@H](C[C@@]2(CN3C=CC=N3)C(=O)O)COC)C4=NC=CS4)OC
DM7CIN4 IK HLQXYDHLDZTWDW-KAWPREARSA-N
DM7CIN4 IU (2R,4S,5R)-1-(4-tert-butyl-3-methoxybenzoyl)-4-(methoxymethyl)-2-(pyrazol-1-ylmethyl)-5-(1,3-thiazol-2-yl)pyrrolidine-2-carboxylic acid
DM7CIN4 CA CAS 885264-71-1
DM7CIN4 DE Hepatitis C virus infection
DMRBVHE ID DMRBVHE
DMRBVHE DN GSK690693
DMRBVHE HS Phase 1
DMRBVHE SN 937174-76-0; GSK690693; GSK-690693; GSK 690693; UNII-GWH480321B; (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol; CHEBI:90677; GWH480321B; 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol; 4-{2-(4-Amino-1,2,5-Oxadiazol-3-Yl)-1-Ethyl-7-[(3s)-Piperidin-3-Ylmethoxy]-1h-Imidazo[4,5-C]pyridin-4-Yl}-2-Methylbut-3-Yn-2-Ol; J-502225; C21H27N7O3
DMRBVHE TC Anticancer Agents
DMRBVHE DT Small molecular drug
DMRBVHE PC 16725726
DMRBVHE MW 425.5
DMRBVHE FM C21H27N7O3
DMRBVHE IC InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1
DMRBVHE CS CCN1C2=C(C(=NC=C2OC[C@H]3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N
DMRBVHE IK KGPGFQWBCSZGEL-ZDUSSCGKSA-N
DMRBVHE IU 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol
DMRBVHE CA CAS 937174-76-0
DMRBVHE CB CHEBI:90677
DMRBVHE DE Haematological malignancy
DM4LR0Y ID DM4LR0Y
DM4LR0Y DN GSK-958108
DM4LR0Y HS Phase 1
DM4LR0Y CP GlaxoSmithKline plc
DM4LR0Y DE Premature ejaculation
DMX2J57 ID DMX2J57
DMX2J57 DN GT103
DMX2J57 HS Phase 1
DMX2J57 CP Grid Therapeutics
DMX2J57 DT Antibody
DMX2J57 DE Non-small-cell lung cancer
DM20HS7 ID DM20HS7
DM20HS7 DN GTP-004
DM20HS7 HS Phase 1
DM20HS7 CP GT Biopharma Washington, DC
DM20HS7 DE Myasthenia gravis
DM4T5LH ID DM4T5LH
DM4T5LH DN Guanosine
DM4T5LH HS Phase 1
DM4T5LH DT Small molecular drug
DM4T5LH PC 135398635
DM4T5LH MW 283.24
DM4T5LH FM C10H13N5O5
DM4T5LH IC InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1
DM4T5LH CS C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N=C(NC2=O)N
DM4T5LH IK NYHBQMYGNKIUIF-UUOKFMHZSA-N
DM4T5LH IU 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM4T5LH CA CAS 118-00-3
DM4T5LH CB CHEBI:16750
DMM1RB6 ID DMM1RB6
DMM1RB6 DN GW-328267
DMM1RB6 HS Phase 1
DMM1RB6 SN UNII-DJF621DE4F; DJF621DE4F; GW-328267; CHEMBL186113; GW328267; (S)-2-[[6-Amino-9-[4-(2-ethyl-2H-tetrazole-5-yl)-4-de(hydroxymethyl)-1-deoxy-beta-D-ribofuranose-1-yl]-9H-purine-2-yl]amino]-3-phenyl-1-propanol; (S)-2-((6-Amino-9-(4-(2-ethyl-2H-tetrazole-5-yl)-4-de(hydroxymethyl)-1-deoxy-beta-D-ribofuranose-1-yl)-9H-purine-2-yl)amino)-3-phenyl-1-propanol; SCHEMBL1979140; BDBM50150766; J2.047.755E
DMM1RB6 DT Small molecular drug
DMM1RB6 PC 9869857
DMM1RB6 MW 482.5
DMM1RB6 FM C21H26N10O4
DMM1RB6 IC InChI=1S/C21H26N10O4/c1-2-31-28-18(27-29-31)16-14(33)15(34)20(35-16)30-10-23-13-17(22)25-21(26-19(13)30)24-12(9-32)8-11-6-4-3-5-7-11/h3-7,10,12,14-16,20,32-34H,2,8-9H2,1H3,(H3,22,24,25,26)/t12-,14-,15+,16-,20+/m0/s1
DMM1RB6 CS CCN1N=C(N=N1)[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=C(N=C43)N[C@@H](CC5=CC=CC=C5)CO)N)O)O
DMM1RB6 IK FLBKPDIBGNWXMT-NIQZGXKPSA-N
DMM1RB6 IU (2R,3R,4S,5R)-2-[6-amino-2-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]purin-9-yl]-5-(2-ethyltetrazol-5-yl)oxolane-3,4-diol
DMM1RB6 CA CAS 210237-78-8
DMM1RB6 DE Allergic rhinitis
DMOE5SZ ID DMOE5SZ
DMOE5SZ DN GW-409544
DMOE5SZ HS Phase 1
DMOE5SZ SN GW-409544X; GW-544; GW-6471; Lipid regulators, Ligand/Glaxo
DMOE5SZ CP Ligand Pharmaceuticals Inc
DMOE5SZ DT Small molecular drug
DMOE5SZ PC 446642
DMOE5SZ MW 510.6
DMOE5SZ FM C31H30N2O5
DMOE5SZ IC InChI=1S/C31H30N2O5/c1-21(19-29(34)24-9-5-3-6-10-24)32-28(31(35)36)20-23-13-15-26(16-14-23)37-18-17-27-22(2)38-30(33-27)25-11-7-4-8-12-25/h3-16,19,28,32H,17-18,20H2,1-2H3,(H,35,36)/b21-19-/t28-/m0/s1
DMOE5SZ CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)N/C(=C\\C(=O)C4=CC=CC=C4)/C
DMOE5SZ IK GGUVRMBIEPYOKL-WMVCGJOFSA-N
DMOE5SZ IU (2S)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-[[(Z)-4-oxo-4-phenylbut-2-en-2-yl]amino]propanoic acid
DMOE5SZ CA CAS 258345-41-4
DMOE5SZ CB CHEBI:79990
DMOE5SZ DE Hyperlipidaemia
DMBDW93 ID DMBDW93
DMBDW93 DN GW-695634
DMBDW93 HS Phase 1
DMBDW93 SN GW-5634; GW-5634 Na salt; GW-5634 sodium salt; GW-678248; GW-8248; GW-8635; Non-nucleoside reverse transcriptase inhibitor (hiv infection), GlaxoSmithKline; 678248; 695634
DMBDW93 CP GlaxoSmithKline plc
DMBDW93 PC 9916697
DMBDW93 MW 574.4
DMBDW93 FM C26H21Cl2N3O6S
DMBDW93 IC InChI=1S/C26H21Cl2N3O6S/c1-3-24(32)31-38(35,36)20-5-6-22(15(2)8-20)30-25(33)14-37-23-7-4-18(27)12-21(23)26(34)17-9-16(13-29)10-19(28)11-17/h4-12H,3,14H2,1-2H3,(H,30,33)(H,31,32)
DMBDW93 CS CCC(=O)NS(=O)(=O)C1=CC(=C(C=C1)NC(=O)COC2=C(C=C(C=C2)Cl)C(=O)C3=CC(=CC(=C3)C#N)Cl)C
DMBDW93 IK GAQZNFUDILDDDI-UHFFFAOYSA-N
DMBDW93 IU N-[4-[[2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]acetyl]amino]-3-methylphenyl]sulfonylpropanamide
DMBDW93 DE Human immunodeficiency virus infection
DMQ46DN ID DMQ46DN
DMQ46DN DN GW-796406
DMQ46DN HS Phase 1
DMQ46DN SN N-[3-Methyl-2(S)-(sulfanylmethyl)butyryl]-4-(1H-pyrazol-1-yl)-L-phenylalanine; 796406
DMQ46DN DE Hypotension
DMGO6M1 ID DMGO6M1
DMGO6M1 DN GZ402666
DMGO6M1 HS Phase 1
DMGO6M1 DE Pompe disease; Type 2 glycogen storage disease
DME6VX4 ID DME6VX4
DME6VX4 DN GZ402668
DME6VX4 HS Phase 1
DME6VX4 DT Antibody
DME6VX4 DE Multiple sclerosis
DMTWNLY ID DMTWNLY
DMTWNLY DN GZ402674
DMTWNLY HS Phase 1
DMTWNLY CP Sanofi
DMTWNLY DE Solid tumour/cancer
DMRCHOU ID DMRCHOU
DMRCHOU DN H-103
DMRCHOU HS Phase 1
DMRCHOU SN Oncolytic adenovirus (metastasis), Shanghai Sunway Biotech
DMRCHOU CP Shanghai Sunway Biotech Co Ltd
DMRCHOU DE Metastatic malignant neoplasm
DMAYTRK ID DMAYTRK
DMAYTRK DN H3B-6527
DMAYTRK HS Phase 1
DMAYTRK SN MBWRLLRCTIYXDW-UHFFFAOYSA-N; 1702259-66-2; UNII-4HTE364XIK; 4HTE364XIK; N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide; Eisai/H3 Biomedicine; CHEMBL3939295; SCHEMBL16659467; BDBM249396; EX-A1510; BCP17555; ZINC521836463; AKOS032960479; H3B6527; CS-5830; ACN-037543; AK684091; AC-29878; HY-100491; US9434697, 108; N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acryla
DMAYTRK CP EisaiWoodcliff Lake, NJH3 Biomedicine Cambridge, MA
DMAYTRK PC 118029202
DMAYTRK MW 629.5
DMAYTRK FM C29H34Cl2N8O4
DMAYTRK IC InChI=1S/C29H34Cl2N8O4/c1-6-25(40)35-20-14-18(39-12-10-38(7-2)11-13-39)8-9-19(20)34-23-16-24(33-17-32-23)37(3)29(41)36-28-26(30)21(42-4)15-22(43-5)27(28)31/h6,8-9,14-17H,1,7,10-13H2,2-5H3,(H,35,40)(H,36,41)(H,32,33,34)
DMAYTRK CS CCN1CCN(CC1)C2=CC(=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl)NC(=O)C=C
DMAYTRK IK MBWRLLRCTIYXDW-UHFFFAOYSA-N
DMAYTRK IU N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide
DMAYTRK CA CAS 1702259-66-2
DMAYTRK DE Hepatocellular carcinoma
DMMVXGR ID DMMVXGR
DMMVXGR DN H3B-8800
DMMVXGR HS Phase 1
DMMVXGR SN (2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017
DMMVXGR CP H3 Biomedicine
DMMVXGR DT Small molecular drug
DMMVXGR PC 92135969
DMMVXGR MW 555.7
DMMVXGR FM C31H45N3O6
DMMVXGR IC InChI=1S/C31H45N3O6/c1-22(26-11-6-7-16-32-26)9-8-10-23(2)29-24(3)12-13-27(39-30(37)34-19-17-33(5)18-20-34)31(4,38)15-14-25(35)21-28(36)40-29/h6-13,16,22,24-25,27,29,35,38H,14-15,17-21H2,1-5H3/b9-8+,13-12+,23-10+/t22-,24+,25-,27+,29-,31-/m1/s1
DMMVXGR CS C[C@H]1/C=C/[C@@H]([C@](CC[C@H](CC(=O)O[C@@H]1/C(=C/C=C/[C@@H](C)C2=CC=CC=N2)/C)O)(C)O)OC(=O)N3CCN(CC3)C
DMMVXGR IK YOIQWBAHJZGRFW-WVRLKXNASA-N
DMMVXGR IU [(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-pyridin-2-ylhepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl] 4-methylpiperazine-1-carboxylate
DMMVXGR CA CAS 1825302-42-8
DMMVXGR DE Myelodysplastic syndrome; Chronic myelomonocytic leukaemia; Acute myeloid leukaemia
DMHI8RS ID DMHI8RS
DMHI8RS DN HCBE-11
DMHI8RS HS Phase 1
DMHI8RS CP Biogen Inc
DMHI8RS DT Antibody
DMHI8RS DE Solid tumour/cancer
DMVRTCW ID DMVRTCW
DMVRTCW DN HDM201
DMVRTCW HS Phase 1
DMVRTCW CP Novartis pharmaceuticals
DMVRTCW PC 71678098
DMVRTCW MW 555.4
DMVRTCW FM C26H24Cl2N6O4
DMVRTCW IC InChI=1S/C26H24Cl2N6O4/c1-13(2)33-21-19(30-22(33)17-11-29-26(38-5)31-23(17)37-4)25(36)34(18-10-16(28)12-32(3)24(18)35)20(21)14-6-8-15(27)9-7-14/h6-13,20H,1-5H3/t20-/m0/s1
DMVRTCW CS CC(C)N1C2=C(C(=O)N([C@H]2C3=CC=C(C=C3)Cl)C4=CC(=CN(C4=O)C)Cl)N=C1C5=CN=C(N=C5OC)OC
DMVRTCW IK AGBSXNCBIWWLHD-FQEVSTJZSA-N
DMVRTCW IU (4S)-5-(5-chloro-1-methyl-2-oxopyridin-3-yl)-4-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4H-pyrrolo[3,4-d]imidazol-6-one
DMVRTCW CA CAS 1448867-41-1
DMVRTCW DE Haematological malignancy; Liposarcoma; Solid tumour/cancer
DMM7VOB ID DMM7VOB
DMM7VOB DN Hepapoietin
DMM7VOB HS Phase 1
DMM7VOB SN APS-1010; Hepapoietin, SnowBrand; Hepapoietin (liver/kidney disease); Hepapoietin (liver/kidney disease), Atlas Pharmaceuticals
DMM7VOB CP SnowBrand Pharmaceuticals Inc
DMM7VOB DE Liver disease
DMBFYSR ID DMBFYSR
DMBFYSR DN Hepcidin mab
DMBFYSR HS Phase 1
DMBFYSR CP Eli Lilly
DMBFYSR DT Antibody
DMBFYSR DE Anemia
DMXETUQ ID DMXETUQ
DMXETUQ DN HER-2/HER-1 vaccine
DMXETUQ HS Phase 1
DMXETUQ SN HER-2/HER-1 vaccine (solid tumors)
DMXETUQ CP Ohio State University
DMXETUQ DT Vaccine
DMXETUQ DE Solid tumour/cancer
DMZXDBN ID DMZXDBN
DMZXDBN DN HER2-CAR T Cells
DMZXDBN HS Phase 1
DMZXDBN CP City of Hope Medical Center
DMZXDBN DT CAR T Cell Therapy
DMZXDBN DE Malignant neoplasm; Metastatic malignant neoplasm
DMJ52F9 ID DMJ52F9
DMJ52F9 DN HER2p63-71 peptide vaccine
DMJ52F9 HS Phase 1
DMJ52F9 SN Cancer vaccine, Mie University; HER2p63-71 peptide vaccine, Mie University; HER2p780-788 peptide vaccine, Mie University
DMJ52F9 CP Mie University School of Medicine
DMJ52F9 DT Vaccine
DMJ52F9 DE Solid tumour/cancer
DMJKBWO ID DMJKBWO
DMJKBWO DN HER2-specific CAR T cell
DMJKBWO HS Phase 1
DMJKBWO CP Seattle Children's Hospital
DMJKBWO DT CAR T Cell Therapy
DMJKBWO DE Atypical teratoid/rhabdoid tumour; Choroid plexus carcinoma; Ependymoma; Germ cell tumour; Glioma; Medulloblastoma; Pineoblastoma; Gastric adenocarcinoma
DM7UJ6E ID DM7UJ6E
DM7UJ6E DN HER2-specific T cells
DM7UJ6E HS Phase 1
DM7UJ6E CP Baylor College of Medicine
DM7UJ6E DT CAR T Cell Therapy
DM7UJ6E DE Recurrent glioblastoma
DMDZQ23 ID DMDZQ23
DMDZQ23 DN HF-0299
DMDZQ23 HS Phase 1
DMDZQ23 CP St Marianna University School of Medicine
DMDZQ23 DE Pain
DMS9WXG ID DMS9WXG
DMS9WXG DN HGS-1029
DMS9WXG HS Phase 1
DMS9WXG SN AEG-40056; AEG-40057; AEG-40706; AEG-40730; AEG-40826; XIAP antagonists (anticancer), Aegera; Inhibitor of apoptosis (IAP) protein antagonists (cancer), Aegera/HGS; XIAP antagonists (small molecule, cancer), Aegera/HGS; Inhibitory apoptosis protein (IAP) antagonists (apoptosis stimulators, cancer), Aegera/HGS
DMS9WXG CP Aegera Therapeutics Inc
DMS9WXG DE Haematological malignancy; Solid tumour/cancer
DMQIE58 ID DMQIE58
DMQIE58 DN HH2853
DMQIE58 HS Phase 1
DMQIE58 CP HaiHe Biopharma
DMQIE58 DT Small molecular drug
DMQIE58 DE Non-hodgkin lymphoma; Solid tumour/cancer
DMRQ4L6 ID DMRQ4L6
DMRQ4L6 DN HHCYH33
DMRQ4L6 HS Phase 1
DMRQ4L6 SN CYH33; UNII-RCA38L4HB5; RCA38L4HB5; 1494684-28-4; Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate; CYH 33; CYH-33; SCHEMBL16622890; BDBM330295; HY-123938; CS-0087546; US9724352, I-33; Carbamic acid, N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)-, methyl ester; Methyl N-(5-(6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)pyrrolo(2,1-F)(1,2,4)triazin-2-yl)-4-(trifluoromethyl)-2-pyridinyl)carbamate; methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate
DMRQ4L6 CP HaiHe Biopharma
DMRQ4L6 DT Small molecular drug
DMRQ4L6 PC 72550012
DMRQ4L6 MW 598.6
DMRQ4L6 FM C24H29F3N8O5S
DMRQ4L6 IC InChI=1S/C24H29F3N8O5S/c1-39-23(36)29-20-12-18(24(25,26)27)17(13-28-20)21-30-22(33-7-9-40-10-8-33)19-11-16(15-35(19)31-21)14-32-3-5-34(6-4-32)41(2,37)38/h11-13,15H,3-10,14H2,1-2H3,(H,28,29,36)
DMRQ4L6 CS COC(=O)NC1=NC=C(C(=C1)C(F)(F)F)C2=NN3C=C(C=C3C(=N2)N4CCOCC4)CN5CCN(CC5)S(=O)(=O)C
DMRQ4L6 IK KTLQDDGRBDLKMN-UHFFFAOYSA-N
DMRQ4L6 IU methyl N-[5-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylpyrrolo[2,1-f][1,2,4]triazin-2-yl]-4-(trifluoromethyl)pyridin-2-yl]carbamate
DMRQ4L6 CA CAS 1494684-28-4
DMRQ4L6 DE Breast cancer
DM45MR0 ID DM45MR0
DM45MR0 DN HIP-2B
DM45MR0 HS Phase 1
DM45MR0 CP CureDM
DM45MR0 DE Type-1/2 diabetes; Type-2 diabetes
DMT3HKZ ID DMT3HKZ
DMT3HKZ DN HL-018
DMT3HKZ HS Phase 1
DMT3HKZ CP HanAll Biopharma Co Ltd
DMT3HKZ DE Diabetic complication
DME4D7H ID DME4D7H
DME4D7H DN HM71224
DME4D7H HS Phase 1
DME4D7H SN Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
DME4D7H CP Hanmi Pharmaceutical
DME4D7H DT Small molecular drug
DME4D7H PC 56644522
DME4D7H MW 470.5
DME4D7H FM C26H26N6O3
DME4D7H IC InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
DME4D7H CS CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)OC=C4
DME4D7H IK LZMJNVRJMFMYQS-UHFFFAOYSA-N
DME4D7H IU N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
DME4D7H CA CAS 1353552-97-2
DME4D7H DE Rheumatoid arthritis
DMXZ1A8 ID DMXZ1A8
DMXZ1A8 DN HMPL-523
DMXZ1A8 HS Phase 1
DMXZ1A8 CP Hutchison MediPharma
DMXZ1A8 DT Small molecular drug
DMXZ1A8 DE Non-hodgkin lymphoma
DMEGN5I ID DMEGN5I
DMEGN5I DN HMPL-689
DMEGN5I HS Phase 1
DMEGN5I CP Hutchison MediPharma
DMEGN5I DT Small molecular drug
DMEGN5I DE Lymphoma
DM695QT ID DM695QT
DM695QT DN HMR-1031
DM695QT HS Phase 1
DM695QT SN MDL-819767; 3(S)-[2(S)-[4,4-Dimethyl-3-[4-[3-(2-methylphenyl)ureido]benzyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoylamino]-3-phenylpropionic acid
DM695QT PC 9809368
DM695QT MW 627.7
DM695QT FM C35H41N5O6
DM695QT IC InChI=1S/C35H41N5O6/c1-22(2)19-29(31(43)37-28(20-30(41)42)25-12-7-6-8-13-25)40-32(44)35(4,5)39(34(40)46)21-24-15-17-26(18-16-24)36-33(45)38-27-14-10-9-11-23(27)3/h6-18,22,28-29H,19-21H2,1-5H3,(H,37,43)(H,41,42)(H2,36,38,45)/t28-,29-/m0/s1
DM695QT CS CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CN3C(=O)N(C(=O)C3(C)C)[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C4=CC=CC=C4
DM695QT IK OPZVCXYTOHAOHN-VMPREFPWSA-N
DM695QT IU (3S)-3-[[(2S)-2-[4,4-dimethyl-3-[[4-[(2-methylphenyl)carbamoylamino]phenyl]methyl]-2,5-dioxoimidazolidin-1-yl]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
DM695QT CA CAS 479203-71-9
DM695QT DE Arthritis
DMRYM03 ID DMRYM03
DMRYM03 DN HMS5552
DMRYM03 HS Phase 1
DMRYM03 SN Dorzagliatin; UNII-X59W6980E8; X59W6980E8; 1191995-00-2; Sinogliatin; RO5305552; Dorzagliatin [INN]; Dorzagliatin [USAN:INN]; SCHEMBL1079619; HMUMWSORCUWQJO-QAPCUYQASA-N; HMS-5552; AKOS030527745; RO-5305552; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5; (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((R; (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide; (2S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1
DMRYM03 CP Hua Medicine Shanghai, China
DMRYM03 PC 57920094
DMRYM03 MW 462.9
DMRYM03 FM C22H27ClN4O5
DMRYM03 IC InChI=1S/C22H27ClN4O5/c1-14(2)9-18(22(31)24-20-7-8-26(25-20)11-15(29)13-28)27-12-16(10-21(27)30)32-19-6-4-3-5-17(19)23/h3-8,10,14-15,18,28-29H,9,11-13H2,1-2H3,(H,24,25,31)/t15-,18+/m1/s1
DMRYM03 CS CC(C)C[C@@H](C(=O)NC1=NN(C=C1)C[C@H](CO)O)N2CC(=CC2=O)OC3=CC=CC=C3Cl
DMRYM03 IK HMUMWSORCUWQJO-QAPCUYQASA-N
DMRYM03 IU (2S)-2-[3-(2-chlorophenoxy)-5-oxo-2H-pyrrol-1-yl]-N-[1-[(2R)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide
DMRYM03 CA CAS 1191995-00-2
DMRYM03 DE Type-2 diabetes
DMI0KQW ID DMI0KQW
DMI0KQW DN HPN217
DMI0KQW HS Phase 1
DMI0KQW CP AbbVie
DMI0KQW DE Multiple myeloma
DMLZDVR ID DMLZDVR
DMLZDVR DN HPN424
DMLZDVR HS Phase 1
DMLZDVR CP Harpoon Therapeutics
DMLZDVR DE Prostate cancer
DMUEZ7V ID DMUEZ7V
DMUEZ7V DN HPP404
DMUEZ7V HS Phase 1
DMUEZ7V CP TransTech Pharma Inc
DMUEZ7V DE Allergic rhinitis
DM5VSZR ID DM5VSZR
DM5VSZR DN HPP-607
DM5VSZR HS Phase 1
DM5VSZR CP TransTech Pharma Inc
DM5VSZR DE Solid tumour/cancer
DMSLDHG ID DMSLDHG
DMSLDHG DN HPP-854
DMSLDHG HS Phase 1
DMSLDHG CP High Point Pharmaceuticals
DMSLDHG DE Alzheimer disease
DMZXG7Q ID DMZXG7Q
DMZXG7Q DN HPP971
DMZXG7Q HS Phase 1
DMZXG7Q SN ANT 401
DMZXG7Q CP vTv Therapeutics
DMZXG7Q DT Small molecular drug
DMZXG7Q DE Non-alcoholic steatohepatitis
DMJG4WR ID DMJG4WR
DMJG4WR DN HSDB-674
DMJG4WR HS Phase 1
DMJG4WR SN Alcool butylique secondaire; Butan-2-ol; Butanol secondaire; Butanol secondaire [French]; Butanol-2; Butyl alcohol, sec-; Butylene hydrate; Ethyl methyl carbinol; Ethylmethyl carbinol; Methyl ethyl carbinol; Methylethyl carbinol; Methylethylcarbinol; R-(-)-2-Butanol; SEC-BUTYL ALCOHOL; n-Butan-2-ol; s-Butanol; s-Butyl alcohol; sec-Butanol; sec-C4H9OH; 1-Methyl propanol; 1-Methyl-1-propanol; 1-Methylpropyl alcohol; 2-Butanol; 2-Butanol (natural); 2-Butyl alcohol; 2-Hydroxybutane; 78-92-2; CCS 301; Caswell No. 119C; NSC 25499
DMJG4WR PC 6568
DMJG4WR MW 74.12
DMJG4WR FM C4H10O
DMJG4WR IC BTANRVKWQNVYAZ-UHFFFAOYSA-N
DMJG4WR CS CCC(C)O
DMJG4WR IK 1S/C4H10O/c1-3-4(2)5/h4-5H,3H2,1-2H3
DMJG4WR IU butan-2-ol
DMJG4WR CA CAS 78-92-2
DMJG4WR CB CHEBI:35687
DMJG4WR DE Rheumatoid arthritis
DML6HP3 ID DML6HP3
DML6HP3 DN HSP-990
DML6HP3 HS Phase 1
DML6HP3 SN NVP-HSP990; 934343-74-5; HSP-990; UNII-E0WBA7B62L; HSP990 (NVP-HSP990); E0WBA7B62L; HSP990; NVP-HSP990(HSP990); SCHEMBL1351184; CHEMBL3360305; (7r)-2-Amino-7-[4-Fluoro-2-(6-Methoxypyridin-2-Yl)phenyl]-4-Methyl-7,8-Dihydropyrido[4,3-D]pyrimidin-5(6h)-One; NVP-HSP-990; HSP990 (NVP-HSP); NVP-HSP990,HSP990; DTXSID50239429; MolPort-023-219-119; 4u93; HSP990, NVP-HSP990; EX-A1560; AOB87737; NVP-HSP990 (HSP990); ZINC60329723; 2608AH; s7097; BDBM50031735; AKOS025404948; CS-3941; SB16642; BCP9001013
DML6HP3 CP Novartis AG
DML6HP3 DT Small molecular drug
DML6HP3 PC 46216556
DML6HP3 MW 379.4
DML6HP3 FM C20H18FN5O2
DML6HP3 IC InChI=1S/C20H18FN5O2/c1-10-18-16(26-20(22)23-10)9-15(25-19(18)27)12-7-6-11(21)8-13(12)14-4-3-5-17(24-14)28-2/h3-8,15H,9H2,1-2H3,(H,25,27)(H2,22,23,26)/t15-/m1/s1
DML6HP3 CS CC1=C2C(=NC(=N1)N)C[C@@H](NC2=O)C3=C(C=C(C=C3)F)C4=NC(=CC=C4)OC
DML6HP3 IK WSMQUUGTQYPVPD-OAHLLOKOSA-N
DML6HP3 IU (7R)-2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
DML6HP3 CA CAS 934343-74-5
DML6HP3 DE Solid tumour/cancer
DMI4TEC ID DMI4TEC
DMI4TEC DN HTI-1090
DMI4TEC HS Phase 1
DMI4TEC SN SHR9146
DMI4TEC CP Atridia; Hengrui Therapeutics
DMI4TEC DT Small molecular drug
DMI4TEC DE Solid tumour/cancer
DMB3LQU ID DMB3LQU
DMB3LQU DN HuA33
DMB3LQU HS Phase 1
DMB3LQU SN CDP-833; A33-radionuclides, American Cyanamid; A33-radionuclides, Celltech; HuA33, Ludwig Institute for Cancer Research/Life Science Pharmaceuticals
DMB3LQU CP UCB Celltech
DMB3LQU DT Antibody
DMB3LQU DE Colorectal cancer
DM9VB4I ID DM9VB4I
DM9VB4I DN Hu-CART meso cells
DM9VB4I HS Phase 1
DM9VB4I CP University of Pennsylvania
DM9VB4I DT CAR T Cell Therapy
DM9VB4I DE Fallopian tube cancer; Lung cancer; Ovarian cancer; Peritoneal mesothelioma; Pleural mesothelioma
DMNAR29 ID DMNAR29
DMNAR29 DN HuCART19
DMNAR29 HS Phase 1
DMNAR29 CP University of Pennsylvania
DMNAR29 DT CAR T Cell Therapy
DMNAR29 DE leukaemia; Lymphoma
DM4F8AU ID DM4F8AU
DM4F8AU DN HuCART-meso cells
DM4F8AU HS Phase 1
DM4F8AU CP University of Pennsylvania
DM4F8AU DT CAR T Cell Therapy
DM4F8AU DE Lymphatic disease; Pancreatic cancer; Pediatric cancer
DMDZBTY ID DMDZBTY
DMDZBTY DN HuM195/rGel
DMDZBTY HS Phase 1
DMDZBTY SN HuM195/rGel, MD Anderson; Conjugated anti-CD33 antibodies (cancer), MD Anderson; HuM195-gelonin immunotoxin (leukemia), Targa Therapeutics; HuM195/rGel (leukemia), Targa Therapeutics; Anti-CD33 immunotoxin (leukemia), Memorial Sloan-Kettering; HuM195-gelonin immunotoxin, Memorial Sloan-Kettering/MD Anderson; HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome); HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics; HuM195/rGel (intravenous infusion, acute myelogenous leukemia/chronic myelogenous leukemia/meylodisplastic syndrome), Targa Therapeutics
DMDZBTY CP Targa therapeutics
DMDZBTY DT Antibody
DMDZBTY DE leukaemia
DM0W275 ID DM0W275
DM0W275 DN Human CD19 targeted T Cells
DM0W275 HS Phase 1
DM0W275 CP Hrain Biotechnology Co., Ltd.
DM0W275 DT CAR T Cell Therapy
DM0W275 DE Follicular lymphoma; Diffuse large B-cell lymphoma
DMVGBA1 ID DMVGBA1
DMVGBA1 DN HuMNC2-CAR44 T cells
DMVGBA1 HS Phase 1
DMVGBA1 CP Minerva Biotechnologies
DMVGBA1 DT CAR T Cell Therapy
DMVGBA1 DE Breast cancer
DMFRM15 ID DMFRM15
DMFRM15 DN HX-100
DMFRM15 HS Phase 1
DMFRM15 CP Hydra Biosciences Cambridge, MA
DMFRM15 DE Diabetic neuropathy
DMRE6UT ID DMRE6UT
DMRE6UT DN IBC-VS01
DMRE6UT HS Phase 1
DMRE6UT CP Orban Biotech
DMRE6UT DE Type-1 diabetes
DMXUJ1P ID DMXUJ1P
DMXUJ1P DN IBI188
DMXUJ1P HS Phase 1
DMXUJ1P CP Innovent Biologics
DMXUJ1P DT Antibody
DMXUJ1P DE Myelodysplastic syndrome
DMYBHIR ID DMYBHIR
DMYBHIR DN IBI-20089
DMYBHIR HS Phase 1
DMYBHIR CP Icon Bioscience Sunnyvale, CA
DMYBHIR DE Diabetic macular edema
DMB83V4 ID DMB83V4
DMB83V4 DN IBI318
DMB83V4 HS Phase 1
DMB83V4 CP Innovent Biologics
DMB83V4 DT Antibody
DMB83V4 DE Non-small cell lung cancer
DMHS29U ID DMHS29U
DMHS29U DN Iboctadekin
DMHS29U HS Phase 1
DMHS29U CP GlaxoSmithKline
DMHS29U DE Ovarian cancer; Non-hodgkin lymphoma
DMW1ZAM ID DMW1ZAM
DMW1ZAM DN Iboctadekin + Doxil
DMW1ZAM HS Phase 1
DMW1ZAM CP GSK
DMW1ZAM DT Combination drug
DMW1ZAM PC 5478883; 31703
DMW1ZAM DE Ovarian cancer
DMZCBMS ID DMZCBMS
DMZCBMS DN Iboctadekin + Rituximab
DMZCBMS HS Phase 1
DMZCBMS SN Pepstatin A; 26305-03-3; Pepstatine; Ahpatinin C; UNII-V6Y2T27Q1U; MLS002222329; Iva-Val-Val-Sta-Ala-Sta-OH; V6Y2T27Q1U; CHEMBL296588; 39324-30-6; FAXGPCHRFPCXOO-LXTPJMTPSA-N; C34H63N5O9; NCGC00161670-06; Pepstatin (nonspecific); DSSTox_RID_81334; DSSTox_CID_26095; DSSTox_GSID_46095; CCRIS 3603; Pepstatina; Pepstatinum; Pepstatin (VAN); Ia Quinidine
DMZCBMS CP GSK
DMZCBMS DT Combination drug (Antibody)
DMZCBMS DE Follicular lymphoma; Non-hodgkin lymphoma; Atrial fibrillation
DMMPFZO ID DMMPFZO
DMMPFZO DN IC9.GD2.CAR.IL-15 T-cells
DMMPFZO HS Phase 1
DMMPFZO CP UNC Lineberger Comprehensive Cancer Center
DMMPFZO DT CAR T Cell Therapy
DMMPFZO DE Neuroblastoma
DMP1ZF8 ID DMP1ZF8
DMP1ZF8 DN IC9-CAR19 cells
DMP1ZF8 HS Phase 1
DMP1ZF8 CP UNC Lineberger Comprehensive Cancer Center
DMP1ZF8 DT CAR T Cell Therapy
DMP1ZF8 DE Acute lymphoblastic leukaemia; Immune System disease; Immunoproliferative disorder
DMNCBIU ID DMNCBIU
DMNCBIU DN IC9-CAR19 T cells
DMNCBIU HS Phase 1
DMNCBIU CP UNC Lineberger Comprehensive Cancer Center
DMNCBIU DT CAR T Cell Therapy
DMNCBIU DE B-cell lymphoma; Immune System disease; Immunoproliferative disorder; Lymphoma
DMRYHWA ID DMRYHWA
DMRYHWA DN IC9-GD2-CD28-OX40
DMRYHWA HS Phase 1
DMRYHWA CP Baylor College of Medicine
DMRYHWA DT CAR T Cell Therapy
DMRYHWA DE Neuroblastoma
DMHG4Q9 ID DMHG4Q9
DMHG4Q9 DN ICAR19 CAR-T cells
DMHG4Q9 HS Phase 1
DMHG4Q9 CP Immune Cell, Inc.
DMHG4Q9 DT CAR T Cell Therapy
DMHG4Q9 DE B-cell lymphoma; leukaemia
DM3YZCV ID DM3YZCV
DM3YZCV DN ICAR30 T cells
DM3YZCV HS Phase 1
DM3YZCV CP Immune Cell, Inc.
DM3YZCV DT CAR T Cell Therapy
DM3YZCV DE Anaplastic large cell lymphoma; Hodgkin lymphoma
DMY6V5T ID DMY6V5T
DMY6V5T DN ICasp9M28z T cell
DMY6V5T HS Phase 1
DMY6V5T CP Memorial Sloan Kettering Cancer Center
DMY6V5T DT CAR T Cell Therapy
DMY6V5T DE Lung cancer; Malignant pleural effusion; Mesothelioma; Metastatic malignant neoplasm
DM79W8K ID DM79W8K
DM79W8K DN ICo-007
DM79W8K HS Phase 1
DM79W8K CP ISIS Pharm; iCo Therapeutics
DM79W8K TC Antisense
DM79W8K DT Antisense drug
DM79W8K DE Diabetic retinopathy; Diabetic macular edema
DM64LVS ID DM64LVS
DM64LVS DN ICT-121
DM64LVS HS Phase 1
DM64LVS CP Immunocellular therapeutics
DM64LVS DT Vaccine
DM64LVS DE Solid tumour/cancer; Recurrent glioblastoma
DMNWPMO ID DMNWPMO
DMNWPMO DN IDH305
DMNWPMO HS Phase 1
DMNWPMO SN DCGDPJCUIKLTDU-SUNYJGFJSA-N; IDH-305; 1628805-46-8; UNII-A791KH7YZW; A791KH7YZW; CHEMBL3947537; SCHEMBL16045032; BDBM247859; CS-8084; HY-104036; US9434719, 466; (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one; C81
DMNWPMO CP Novartis Oncology East Hanover, NJ
DMNWPMO PC 90415637
DMNWPMO MW 490.5
DMNWPMO FM C23H22F4N6O2
DMNWPMO IC InChI=1S/C23H22F4N6O2/c1-12-8-17(30-10-16(12)15-4-6-28-19(9-15)23(25,26)27)14(3)31-21-29-7-5-20(32-21)33-18(13(2)24)11-35-22(33)34/h4-10,13-14,18H,11H2,1-3H3,(H,29,31,32)/t13-,14-,18+/m0/s1
DMNWPMO CS CC1=CC(=NC=C1C2=CC(=NC=C2)C(F)(F)F)[C@H](C)NC3=NC=CC(=N3)N4[C@H](COC4=O)[C@H](C)F
DMNWPMO IK DCGDPJCUIKLTDU-SUNYJGFJSA-N
DMNWPMO IU (4R)-4-[(1S)-1-fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-5-[2-(trifluoromethyl)pyridin-4-yl]pyridin-2-yl]ethyl]amino]pyrimidin-4-yl]-1,3-oxazolidin-2-one
DMNWPMO CA CAS 1628805-46-8
DMNWPMO DE Advanced malignancy
DM1RNT7 ID DM1RNT7
DM1RNT7 DN IDR-1018
DM1RNT7 HS Phase 1
DM1RNT7 SN IMX-003 series; Innate defense regulators (bacterial infection), Inimex
DM1RNT7 CP Inimex Pharmaceuticals Inc
DM1RNT7 DE Bacterial infection
DMYG3PZ ID DMYG3PZ
DMYG3PZ DN IDX-189
DMYG3PZ HS Phase 1
DMYG3PZ CP Idenix
DMYG3PZ DE Hepatitis C virus infection
DMMPINS ID DMMPINS
DMMPINS DN IGM-2323
DMMPINS HS Phase 1
DMMPINS CP IGM Biosciences
DMMPINS DT Antibody
DMMPINS DE Non-hodgkin lymphoma
DMFJXDZ ID DMFJXDZ
DMFJXDZ DN IGM-8444
DMFJXDZ HS Phase 1
DMFJXDZ CP IGM Biosciences
DMFJXDZ DT Antibody
DMFJXDZ DE Solid tumour/cancer; Hematologic tumour
DM1MY26 ID DM1MY26
DM1MY26 DN IGN523
DM1MY26 HS Phase 1
DM1MY26 CP Igenica
DM1MY26 DT Antibody
DM1MY26 DE Acute myeloid leukaemia
DMDU54Y ID DMDU54Y
DMDU54Y DN IK-175
DMDU54Y HS Phase 1
DMDU54Y CP Ikena Oncology
DMDU54Y DT Small molecular drug
DMDU54Y DE Urothelial carcinoma
DMQ01MP ID DMQ01MP
DMQ01MP DN ILV-095
DMQ01MP HS Phase 1
DMQ01MP SN PF-05212368, WAY-264095
DMQ01MP CP Wyeth; pfizer
DMQ01MP DT Antibody
DMQ01MP DE Psoriasis vulgaris
DM4MY9C ID DM4MY9C
DM4MY9C DN IM156
DM4MY9C HS Phase 1
DM4MY9C CP ImmunoMetHouston, TX
DM4MY9C DE Solid tumour/cancer
DM43X0Q ID DM43X0Q
DM43X0Q DN IM19
DM43X0Q HS Phase 1
DM43X0Q CP Beijing Immunochina Medical Science & Technology Co., Ltd.
DM43X0Q DT CAR T Cell Therapy
DM43X0Q DE Haematological malignancy; Non-hodgkin lymphoma
DMTNYIB ID DMTNYIB
DMTNYIB DN IM21 CART
DMTNYIB HS Phase 1
DMTNYIB CP Peking Union Medical College Hospital
DMTNYIB DT CAR T Cell Therapy
DMTNYIB DE Multiple myeloma
DML5O7T ID DML5O7T
DML5O7T DN IM23
DML5O7T HS Phase 1
DML5O7T CP Beijing Immunochina Medical Science & Technology Co., Ltd.
DML5O7T DT CAR T Cell Therapy
DML5O7T DE Acute myeloid leukaemia
DMD9U5Q ID DMD9U5Q
DMD9U5Q DN IMA 203
DMD9U5Q HS Phase 1
DMD9U5Q CP Immatics
DMD9U5Q DT Cell therapy
DMD9U5Q DE Solid tumour/cancer; Hematologic tumour
DMWSI04 ID DMWSI04
DMWSI04 DN IMC-002
DMWSI04 HS Phase 1
DMWSI04 CP ImmuneOncia Therapeutics
DMWSI04 DT Antibody
DMWSI04 DE Lymphoma; Solid tumour/cancer
DMXI5ON ID DMXI5ON
DMXI5ON DN IMC-3C5
DMXI5ON HS Phase 1
DMXI5ON DE Solid tumour/cancer
DMUYN26 ID DMUYN26
DMUYN26 DN IMC-CS4
DMUYN26 HS Phase 1
DMUYN26 DE Solid tumour/cancer
DMCZQNJ ID DMCZQNJ
DMCZQNJ DN IMC-EB10
DMCZQNJ HS Phase 1
DMCZQNJ SN Anti-Flt-3 Mab
DMCZQNJ CP Eli Lilly
DMCZQNJ DT Antibody
DMCZQNJ DE Acute myeloid leukaemia
DMOFSLE ID DMOFSLE
DMOFSLE DN IMD-0354
DMOFSLE HS Phase 1
DMOFSLE SN IMD-2560; IMD-2560); I-kappaB kinase beta inhibitor (dermatological, atopic dermatitis/acne), Institute of Medicinal MolecularDesign; I-kappaB kinase beta inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD; IKK-beta inhibitor (dermatological, atopic dermatitis/acne), IMMD; IL-6 release inhibitor (oral, rheumatoid arthritis/osteoporosis), IMMD
DMOFSLE CP Institute of Medicinal Molecular Design Inc
DMOFSLE DT Small molecular drug
DMOFSLE PC 5081913
DMOFSLE MW 383.67
DMOFSLE FM C15H8ClF6NO2
DMOFSLE IC InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)
DMOFSLE CS C1=CC(=C(C=C1Cl)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)O
DMOFSLE IK CHILCFMQWMQVAL-UHFFFAOYSA-N
DMOFSLE IU N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide
DMOFSLE CA CAS 978-62-1
DMOFSLE CB CHEBI:93310
DMOFSLE DE Acne vulgaris
DMUVLC4 ID DMUVLC4
DMUVLC4 DN IMGC936
DMUVLC4 HS Phase 1
DMUVLC4 CP ImmunoGen; MacroGenics
DMUVLC4 DT Antibody drug conjugate
DMUVLC4 DE Solid tumour/cancer
DMT9MHE ID DMT9MHE
DMT9MHE DN IMGN289
DMT9MHE HS Phase 1
DMT9MHE CP Immunogen
DMT9MHE DE Solid tumour/cancer
DMSYB83 ID DMSYB83
DMSYB83 DN IMGN-388
DMSYB83 HS Phase 1
DMSYB83 SN Intetumumab-DM4; CNTO-95-DM4; Integrin-targeting antibody (TAP), Centocor; Integrin-targeting antibody (TAP), ImmunoGen
DMSYB83 CP Centocor Ortho Biotech Inc
DMSYB83 DT Antibody
DMSYB83 DE Solid tumour/cancer
DMR8OG2 ID DMR8OG2
DMR8OG2 DN IMGN-853
DMR8OG2 HS Phase 1
DMR8OG2 SN HuFR107-SPDB-DM4; FOLR1-targeting DM4 conjugates (cancer), Immunogen
DMR8OG2 CP Immunogen
DMR8OG2 DE Solid tumour/cancer
DMTFUM4 ID DMTFUM4
DMTFUM4 DN IMMU-114
DMTFUM4 HS Phase 1
DMTFUM4 SN HLA-DR mAb (cancer), Immunomedics
DMTFUM4 CP Immunomedics
DMTFUM4 DT Antibody
DMTFUM4 DE leukaemia; Haematological malignancy
DMEHWPC ID DMEHWPC
DMEHWPC DN IMO-9200
DMEHWPC HS Phase 1
DMEHWPC CP Idera Pharmaceuticals Cambridge, MA
DMEHWPC DE Autoimmune disease
DMXSMF9 ID DMXSMF9
DMXSMF9 DN IMP-701
DMXSMF9 HS Phase 1
DMXSMF9 SN Anti-membrane bound LAG-3 monoclonal antibody (cancer, infectious disease), Immutep
DMXSMF9 CP Immutep SA
DMXSMF9 DT Antibody
DMXSMF9 DE Solid tumour/cancer
DMPXOVA ID DMPXOVA
DMPXOVA DN IN10018
DMPXOVA HS Phase 1
DMPXOVA CP InxMed
DMPXOVA DT Small molecular drug
DMPXOVA DE Metastatic melanoma
DMCQTLG ID DMCQTLG
DMCQTLG DN INB03
DMCQTLG HS Phase 1
DMCQTLG CP INmune Bio
DMCQTLG DT Protein
DMCQTLG DE Solid tumour/cancer
DM2FH10 ID DM2FH10
DM2FH10 DN INBRX-105
DM2FH10 HS Phase 1
DM2FH10 CP Inhibrx
DM2FH10 DT Antibody
DM2FH10 DE Solid tumour/cancer
DMUNSPI ID DMUNSPI
DMUNSPI DN INBRX-109
DMUNSPI HS Phase 1
DMUNSPI CP Inhibrx
DMUNSPI DT Antibody drug conjugate
DMUNSPI DE Solid tumour/cancer
DMDSZNC ID DMDSZNC
DMDSZNC DN INCAGN2385
DMDSZNC HS Phase 1
DMDSZNC CP Agenis; Incyte
DMDSZNC DT Antibody
DMDSZNC DE Melanoma
DM5SO1T ID DM5SO1T
DM5SO1T DN INCAGN2390
DM5SO1T HS Phase 1
DM5SO1T CP Agenis; Incyte
DM5SO1T DT Antibody
DM5SO1T DE Solid tumour/cancer
DMW7CLY ID DMW7CLY
DMW7CLY DN INCB15050
DMW7CLY HS Phase 1
DMW7CLY CP Incyte
DMW7CLY DE Human immunodeficiency virus infection
DMFOXGB ID DMFOXGB
DMFOXGB DN INCB81776
DMFOXGB HS Phase 1
DMFOXGB SN INCB081776
DMFOXGB CP Incyte
DMFOXGB DT Small molecular drug
DMFOXGB DE Solid tumour/cancer
DM5WCBM ID DM5WCBM
DM5WCBM DN ING-1
DM5WCBM HS Phase 1
DM5WCBM DT Antibody
DM5WCBM DE Solid tumour/cancer
DM601GL ID DM601GL
DM601GL DN INNO-105
DM601GL HS Phase 1
DM601GL SN Opioid growth factor (cancer), Innovive/Penn State; (MEt5)-enkephalin (cancer), Innovive/Penn State
DM601GL CP Pennsylvania State University
DM601GL DE Solid tumour/cancer
DMG6S8U ID DMG6S8U
DMG6S8U DN INNO-305
DMG6S8U HS Phase 1
DMG6S8U CP CytRx
DMG6S8U DE Lung cancer; Acute myeloid leukaemia
DM90P1K ID DM90P1K
DM90P1K DN INO-3401
DM90P1K HS Phase 1
DM90P1K SN DNA vaccine (intradermal Cellectra electroporation, H5N1 influenza), Inovio
DM90P1K CP Inovio pharmaceuticals
DM90P1K DT Vaccine
DM90P1K DE Influenza A virus H5N1 infection
DMP6I9T ID DMP6I9T
DMP6I9T DN INO-3510
DMP6I9T HS Phase 1
DMP6I9T CP Inovio Pharmaceuticals
DMP6I9T DT Vaccine
DMP6I9T DE Influenza A virus H1N1/H5N1 infection
DMA46DO ID DMA46DO
DMA46DO DN INS-117548
DMA46DO HS Phase 1
DMA46DO SN ROCKI/ROCKII inhibitor (ophthalmic solution, ocular hypertension/glaucoma), Wisconsin Alumni Research Foundation (WARF)/Inspire
DMA46DO CP University of Wisconsin-Madison
DMA46DO DE Glaucoma/ocular hypertension
DMMR7CH ID DMMR7CH
DMMR7CH DN Insulin oral sublingual
DMMR7CH HS Phase 1
DMMR7CH CP Biodel
DMMR7CH DE Type-1 diabetes
DM93QP2 ID DM93QP2
DM93QP2 DN Insulin transdermal
DM93QP2 HS Phase 1
DM93QP2 CP Transdermal Global
DM93QP2 DE Type-1/2 diabetes
DMXPLMN ID DMXPLMN
DMXPLMN DN INTOPLICINE
DMXPLMN HS Phase 1
DMXPLMN SN RP-60475; Intoplicine; 11-[3-(Dimethylamino)propylamino]-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-3-ol
DMXPLMN DT Small molecular drug
DMXPLMN PC 65954
DMXPLMN MW 348.4
DMXPLMN FM C21H24N4O
DMXPLMN IC InChI=1S/C21H24N4O/c1-13-12-23-21(22-9-4-10-25(2)3)19-18-16-7-6-15(26)11-14(16)5-8-17(18)24-20(13)19/h5-8,11-12,24,26H,4,9-10H2,1-3H3,(H,22,23)
DMXPLMN CS CC1=CN=C(C2=C1NC3=C2C4=C(C=C3)C=C(C=C4)O)NCCCN(C)C
DMXPLMN IK QROONAIPJKQFMC-UHFFFAOYSA-N
DMXPLMN IU 16-[3-(dimethylamino)propylamino]-13-methyl-11,15-diazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2(7),3,5,8,12(17),13,15-octaen-5-ol
DMXPLMN CA CAS 125974-72-3
DMXPLMN CB CHEBI:135474
DMXPLMN DE Solid tumour/cancer
DMU03WD ID DMU03WD
DMU03WD DN IO-202
DMU03WD HS Phase 1
DMU03WD CP Immune-Onc Therapeutics
DMU03WD DT Antibody
DMU03WD DE Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
DMNBPKS ID DMNBPKS
DMNBPKS DN Iofolastat I-124
DMNBPKS HS Phase 1
DMNBPKS SN Trofex (TN)
DMNBPKS CP Molecular Insight Pharmaceuticals
DMNBPKS DT Small molecular drug
DMNBPKS PC 25194767
DMNBPKS MW 531.3
DMNBPKS FM C19H26IN3O7
DMNBPKS IC InChI=1S/C19H26IN3O7/c20-13-6-4-12(5-7-13)11-21-10-2-1-3-14(17(26)27)22-19(30)23-15(18(28)29)8-9-16(24)25/h4-7,14-15,21H,1-3,8-11H2,(H,24,25)(H,26,27)(H,28,29)(H2,22,23,30)/t14-,15-/m0/s1/i20-4
DMNBPKS CS C1=CC(=CC=C1CNCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)[123I]
DMNBPKS IK OXUUJYOSVPMNKP-ZANJDRPYSA-N
DMNBPKS IU (2S)-2-[[(1S)-1-carboxy-5-[(4-(123I)iodanylphenyl)methylamino]pentyl]carbamoylamino]pentanedioic acid
DMNBPKS CA CAS 949575-24-0
DMNBPKS DE Prostate cancer
DMY0QL7 ID DMY0QL7
DMY0QL7 DN Iomab-ACT
DMY0QL7 HS Phase 1
DMY0QL7 CP Actinium Pharmaceuticals
DMY0QL7 DT Antibody
DMY0QL7 DE Diffuse large B-cell lymphoma; B-cell acute lymphoblastic leukaemia
DMD7LHM ID DMD7LHM
DMD7LHM DN ION 224
DMD7LHM HS Phase 1
DMD7LHM SN IONIS-DGAT2-Rx
DMD7LHM CP Ionis Pharmaceuticals
DMD7LHM DT Antisense oligonucleotide
DMD7LHM DE Non-alcoholic steatohepatitis
DMGN96R ID DMGN96R
DMGN96R DN Ipafricept
DMGN96R HS Phase 1
DMGN96R CP Bayer healthcare pharmaceuticals; oncomed pharmaceuticals
DMGN96R DE Ovarian cancer
DMFEI6T ID DMFEI6T
DMFEI6T DN IPH5201
DMFEI6T HS Phase 1
DMFEI6T CP AstraZeneca
DMFEI6T DT Antibody
DMFEI6T DE Solid tumour/cancer
DMEIM5G ID DMEIM5G
DMEIM5G DN IPI-940
DMEIM5G HS Phase 1
DMEIM5G CP Infinity Pharmaceuticals Inc
DMEIM5G DE Pain
DMPKH6Y ID DMPKH6Y
DMPKH6Y DN IPL 550,260
DMPKH6Y HS Phase 1
DMPKH6Y CP Inflazyme Pharmaceuticals
DMPKH6Y DE Inflammation
DMHW1LI ID DMHW1LI
DMHW1LI DN Iptakalim
DMHW1LI HS Phase 1
DMHW1LI SN 2,3-Dimethyl-N-isopropyl-2-butanamine hydrochloride
DMHW1LI DT Small molecular drug
DMHW1LI PC 10057607
DMHW1LI MW 143.27
DMHW1LI FM C9H21N
DMHW1LI IC InChI=1S/C9H21N/c1-7(2)9(5,6)10-8(3)4/h7-8,10H,1-6H3
DMHW1LI CS CC(C)C(C)(C)NC(C)C
DMHW1LI IK RGWFHCMKBAMWDX-UHFFFAOYSA-N
DMHW1LI IU 2,3-dimethyl-N-propan-2-ylbutan-2-amine
DMHW1LI CA 642407-44-1
DMHW1LI DE Hypertension
DMET0H4 ID DMET0H4
DMET0H4 DN IQB-9302
DMET0H4 HS Phase 1
DMET0H4 PC 9927200
DMET0H4 MW 286.4
DMET0H4 FM C18H26N2O
DMET0H4 IC InChI=1S/C18H26N2O/c1-13-6-5-7-14(2)17(13)19-18(21)16-8-3-4-11-20(16)12-15-9-10-15/h5-7,15-16H,3-4,8-12H2,1-2H3,(H,19,21)
DMET0H4 CS CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2CC3CC3
DMET0H4 IK DNUYDQISHIJMLD-UHFFFAOYSA-N
DMET0H4 IU 1-(cyclopropylmethyl)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
DMET0H4 CA CAS 166181-63-1
DMET0H4 DE Pain
DMHP71R ID DMHP71R
DMHP71R DN IQ-DAA
DMHP71R HS Phase 1
DMHP71R SN Anti-anthrax toxin mAb, IQ; Human monoclonal antibodies (anthrax), IQ; IQN-protective antigen (human mAb), IQ corporation; MAb-based immunotherapy (anthrax), IQ; IQNLF + IQNPA (human mAbs, Bacillus anthracis infection), IQ Therapeutics
DMHP71R CP IQ Therapeutics BV
DMHP71R DE Bacillus anthracis infection
DMR3E4L ID DMR3E4L
DMR3E4L DN Irdabisant
DMR3E4L HS Phase 1
DMR3E4L SN CEP-26401
DMR3E4L CP Cephalon
DMR3E4L DT Small molecular drug
DMR3E4L PC 25070031
DMR3E4L MW 313.4
DMR3E4L FM C18H23N3O2
DMR3E4L IC InChI=1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1
DMR3E4L CS C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3
DMR3E4L IK XUKROCVZGZNGSI-CQSZACIVSA-N
DMR3E4L IU 3-[4-[3-[(2R)-2-methylpyrrolidin-1-yl]propoxy]phenyl]-1H-pyridazin-6-one
DMR3E4L CA CAS 1005402-19-6
DMR3E4L DE Cognitive impairment
DM5YUOM ID DM5YUOM
DM5YUOM DN Irofulven/Taxotere
DM5YUOM HS Phase 1
DM5YUOM SN MGI 114/docetaxel
DM5YUOM CP MGI Pharma
DM5YUOM DE Solid tumour/cancer
DM9SCME ID DM9SCME
DM9SCME DN IRX4204
DM9SCME HS Phase 1
DM9SCME SN 220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid
DM9SCME CP Io Therapeutics
DM9SCME DT Small molecular drug
DM9SCME PC 9863341
DM9SCME MW 352.5
DM9SCME FM C24H32O2
DM9SCME IC InChI=1S/C24H32O2/c1-16(13-21(25)26)7-8-18-15-24(18,6)17-9-10-19-20(14-17)23(4,5)12-11-22(19,2)3/h7-10,13-14,18H,11-12,15H2,1-6H3,(H,25,26)/b8-7+,16-13+/t18-,24-/m1/s1
DM9SCME CS C/C(=C\\C(=O)O)/C=C/[C@@H]1C[C@]1(C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DM9SCME IK BOOOLEGQBVUTKC-NVQSDHBMSA-N
DM9SCME IU (2E,4E)-3-methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid
DM9SCME CA CAS 220619-73-8
DM9SCME DE Prostate cancer; Breast cancer; Pancreatic cancer; Non-small-cell lung cancer
DMCED9U ID DMCED9U
DMCED9U DN IRX-5183
DMCED9U HS Phase 1
DMCED9U SN AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics
DMCED9U CP Vitae Pharmaceuticals
DMCED9U PC 9867758
DMCED9U MW 437.9
DMCED9U FM C22H22ClF2NO4
DMCED9U IC InChI=1S/C22H22ClF2NO4/c1-21(2)5-6-22(3,4)16-12(21)9-11(18(27)17(16)23)19(28)26-10-7-13(24)15(20(29)30)14(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)
DMCED9U CS CC1(CCC(C2=C1C=C(C(=C2Cl)O)C(=O)NC3=CC(=C(C(=C3)F)C(=O)O)F)(C)C)C
DMCED9U IK PNAWUIKCVQSLFG-UHFFFAOYSA-N
DMCED9U IU 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid
DMCED9U CA CAS 367273-07-2
DMCED9U DE Solid tumour/cancer
DMKO7EA ID DMKO7EA
DMKO7EA DN ISF-402
DMKO7EA HS Phase 1
DMKO7EA SN Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Pallane; Urinary tetrapeptide (diabetes), Monash University/International Diabetes Institute/Dia-B Tech Ltd
DMKO7EA CP Dia-B Tech
DMKO7EA DE Type-2 diabetes
DMEJ4B7 ID DMEJ4B7
DMEJ4B7 DN ISIS 325568
DMEJ4B7 HS Phase 1
DMEJ4B7 SN BDBM231666; N-(2-(1H-indol-3-yl)ethyl)-3-(3-thiazol-2-ylureido)benzenesulfonamide (1b)
DMEJ4B7 CP Licensed to Ortho-McNeil, Inc.
DMEJ4B7 TC Antisense
DMEJ4B7 DT Antisense drug
DMEJ4B7 DE Type-2 diabetes
DM9Y51T ID DM9Y51T
DM9Y51T DN ISIS-ANGPTL3
DM9Y51T HS Phase 1
DM9Y51T DT Antisense drug
DM9Y51T DE Hyperlipidaemia
DMX3FN4 ID DMX3FN4
DMX3FN4 DN ISIS-APOCIII
DMX3FN4 HS Phase 1
DMX3FN4 CP ISIS Pharm
DMX3FN4 DT Antisense drug
DMX3FN4 DE Metabolic syndrome x; Atherosclerosis; Hyperlipemia; Inflammation
DM8P3N5 ID DM8P3N5
DM8P3N5 DN ISIS-AR
DM8P3N5 HS Phase 1
DM8P3N5 DT Antisense drug
DM8P3N5 DE Prostate cancer
DMQDUG4 ID DMQDUG4
DMQDUG4 DN ISIS-CRP
DMQDUG4 HS Phase 1
DMQDUG4 SN 1-(Tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; 172889-27-9; pp2; PP 2; 1-(tert-butyl)-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; AG 1879; 1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; PP2; 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; AG-1879; CHEMBL406845; CHEBI:78331; AK-60369; 1-tert-butyl-3-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-amine; 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H16ClN5; 1qpe; 4few; PBBRWFOVCUAONR-UHFFFAOYSA-N; AG1879; PP 2 (AG 1879)
DMQDUG4 CP ISIS Pharm
DMQDUG4 DT Antisense drug
DMQDUG4 DE Inflammation; Cardiovascular disease
DMDKAIC ID DMDKAIC
DMDKAIC DN ISIS-SGLT2
DMDKAIC HS Phase 1
DMDKAIC CP ISIS Pharm
DMDKAIC DT Antisense drug
DMDKAIC DE Type-2 diabetes
DMV1BTP ID DMV1BTP
DMV1BTP DN ISIS-SOD1
DMV1BTP HS Phase 1
DMV1BTP CP ISIS Pharm
DMV1BTP DT Antisense drug
DMV1BTP DE Motor neurone disease; Amyotrophic lateral sclerosis
DMDB7KU ID DMDB7KU
DMDB7KU DN ISO-1
DMDB7KU HS Phase 1
DMDB7KU SN 478336-92-4; MIF Antagonist, ISO-1; methyl 2-(3-(4-hydroxyphenyl)-4,5-dihydroisoxazol-5-yl)acetate; CHEMBL210858; IN1228; 5-Isoxazoleacetic acid, 4,5-dihydro-3-(4-hydroxyphenyl)-, methyl ester; Macrophage Migration Inhibitory Factor Antagonist, ISO-1; (S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid, methyl ester; 4,5-DIHYDRO-3-(4-HYDROXYPHENYL)-5-ISOXAZOLEACETIC ACID, METHYL ESTER; AC1O1KG2; SCHEMBL668287; GTPL9984; CTK8E8677; MolPort-027-836-626; BCP15471; EX-A2475; BDBM50186426; 6540AB
DMDB7KU DT Small molecular drug
DMDB7KU PC 4633677
DMDB7KU MW 235.24
DMDB7KU FM C12H13NO4
DMDB7KU IC InChI=1S/C12H13NO4/c1-16-12(15)7-10-6-11(13-17-10)8-2-4-9(14)5-3-8/h2-5,10,14H,6-7H2,1H3
DMDB7KU CS COC(=O)CC1CC(=NO1)C2=CC=C(C=C2)O
DMDB7KU IK AIXMJTYHQHQJLU-UHFFFAOYSA-N
DMDB7KU IU methyl 2-[3-(4-hydroxyphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetate
DMDB7KU CA CAS 478336-92-4
DMBQ8CA ID DMBQ8CA
DMBQ8CA DN ISO-901
DMBQ8CA HS Phase 1
DMBQ8CA SN FOLITIXORIN; Modufolin; Tetrahydromethylenefolate; 3432-99-3; 5,10-Methylene-tetrahydrofolate; 5,10-Methylenetetrahydrofolic acid; 5,10-methylenetetrahydrofolate; CH2H4folate; CHEBI:20502; L-Glutamic acid,N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-; MTHF; N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic acid; N-{4-[3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid
DMBQ8CA PC 135400185
DMBQ8CA MW 457.4
DMBQ8CA FM C20H23N7O6
DMBQ8CA IC QYNUQALWYRSVHF-ABLWVSNPSA-N
DMBQ8CA CS C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)NC(CCC(=O)O)C(=O)O
DMBQ8CA IK 1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12?,13-/m0/s1
DMBQ8CA IU (2S)-2-[[4-(3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid
DMBQ8CA CA CAS 3432-99-3
DMBQ8CA CB CHEBI:9139
DMBQ8CA DE Rheumatoid arthritis
DMR17YI ID DMR17YI
DMR17YI DN Isoquine
DMR17YI HS Phase 1
DMR17YI SN ISOQUINE; CHEMBL147587; NINDS_000687; Spectrum_000046; Spectrum4_000147; Spectrum2_000768; Spectrum5_000808; Spectrum3_000299; AC1L1D2I; KBioSS_000426; BSPBio_001838; KBioGR_000594; DivK1c_000687; SPBio_000816; SCHEMBL5836418; KBio2_000426; KBio1_000687; KBio3_001338; KBio2_002994; CTK6E7963; KBio2_005562; ZINC36378506; BDBM50134931; IDI1_000687; NCGC00178968-01; SBI-0051280.P003; AB00053418_02; 5-(7-chloroquinolin-4-ylamino)-2-diethylaminomethylphenol; 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DMR17YI DT Small molecular drug
DMR17YI PC 2166
DMR17YI MW 355.9
DMR17YI FM C20H22ClN3O
DMR17YI IC InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-5-7-16(12-20(14)25)23-18-9-10-22-19-11-15(21)6-8-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
DMR17YI CS CCN(CC)CC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DMR17YI IK QGFYFOHMBDMGBZ-UHFFFAOYSA-N
DMR17YI IU 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
DMR17YI DE Malaria
DMBPV9W ID DMBPV9W
DMBPV9W DN IT-139
DMBPV9W HS Phase 1
DMBPV9W CP Intezyne
DMBPV9W DE Solid tumour/cancer
DMAYD7O ID DMAYD7O
DMAYD7O DN IT-141
DMAYD7O HS Phase 1
DMAYD7O CP IntezyneTampa, FL
DMAYD7O DE Solid tumour/cancer
DMY1DFK ID DMY1DFK
DMY1DFK DN ITASETRON
DMY1DFK HS Phase 1
DMY1DFK SN DAU6215CL; DAU-6215; Itasetron < Rec INN; U-98079A; N-(endo-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide; 2-Oxo-N-(1alphaH,5alphaH-tropan-3alpha-yl)-1-benzimidazoline-1-carboxamide
DMY1DFK DT Small molecular drug
DMY1DFK PC 6918106
DMY1DFK MW 300.36
DMY1DFK FM C16H20N4O2
DMY1DFK IC InChI=1S/C16H20N4O2/c1-19-11-6-7-12(19)9-10(8-11)17-15(21)20-14-5-3-2-4-13(14)18-16(20)22/h2-5,10-12H,6-9H2,1H3,(H,17,21)(H,18,22)/t10?,11-,12+
DMY1DFK CS CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)N3C4=CC=CC=C4NC3=O
DMY1DFK IK RWXRJSRJIITQAK-YOGCLGLASA-N
DMY1DFK IU N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3H-benzimidazole-1-carboxamide
DMY1DFK CA CAS 123258-84-4
DMY1DFK CB CHEBI:140079
DMY1DFK DE Nausea
DM702MU ID DM702MU
DM702MU DN ITX-5061
DM702MU HS Phase 1
DM702MU SN ITX5061; UNII-J4RA8K2Q2A; J4RA8K2Q2A; ITX-5061; 1252679-52-9; ITX 5061; CHEMBL3402567; HY-19900; CS-0016951; 1-Naphthaleneacetamide, N-(5-(1,1-dimethylethyl)-2-methoxy-3- ((methylsulfonyl)amino)phenyl)-4-(2-(4-morpholinyl)ethoxy)-alpha-oxo-, hydrochloride (1:1)
DM702MU CP Itherx
DM702MU DT Small molecular drug
DM702MU PC 56843466
DM702MU MW 620.2
DM702MU FM C30H38ClN3O7S
DM702MU IC InChI=1S/C30H37N3O7S.ClH/c1-30(2,3)20-18-24(28(38-4)25(19-20)32-41(5,36)37)31-29(35)27(34)23-10-11-26(22-9-7-6-8-21(22)23)40-17-14-33-12-15-39-16-13-33;/h6-11,18-19,32H,12-17H2,1-5H3,(H,31,35);1H
DM702MU CS CC(C)(C)C1=CC(=C(C(=C1)NS(=O)(=O)C)OC)NC(=O)C(=O)C2=CC=C(C3=CC=CC=C32)OCCN4CCOCC4.Cl
DM702MU IK ICIJBYYMEBOTQP-UHFFFAOYSA-N
DM702MU IU N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride
DM702MU CA CAS 1252679-52-9
DM702MU DE Human immunodeficiency virus-1 infection
DMSGEU6 ID DMSGEU6
DMSGEU6 DN JAB-3068
DMSGEU6 HS Phase 1
DMSGEU6 SN SHP2-IN-6; SCHEMBL19704279; JAB3068; NSC827676; NSC-827676; HY-131132; CS-0129188; 2169223-48-5
DMSGEU6 CP AbbVie; Jacobio Pharmaceuticals
DMSGEU6 DT Small molecular drug
DMSGEU6 PC 132222602
DMSGEU6 MW 476.5
DMSGEU6 FM C22H26F2N6O2S
DMSGEU6 IC InChI=1S/C22H26F2N6O2S/c1-13(31)30-11-22(23,24)18-14(30)3-2-4-15(18)33-20-19(26)28-17(9-27-20)29-7-5-21(6-8-29)12-32-10-16(21)25/h2-4,9,16H,5-8,10-12,25H2,1H3,(H2,26,28)/t16-/m1/s1
DMSGEU6 CS CC(=O)N1CC(C2=C1C=CC=C2SC3=NC=C(N=C3N)N4CCC5(CC4)COC[C@H]5N)(F)F
DMSGEU6 IK HGYTYZKWKUXRKA-MRXNPFEDSA-N
DMSGEU6 IU 1-[4-[3-amino-5-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl]sulfanyl-3,3-difluoro-2H-indol-1-yl]ethanone
DMSGEU6 DE Solid tumour/cancer
DM7XAV1 ID DM7XAV1
DM7XAV1 DN JBH492
DM7XAV1 HS Phase 1
DM7XAV1 CP Novartis
DM7XAV1 DT Antibody drug conjugate
DM7XAV1 DE Chronic lymphocytic leukaemia; Non-hodgkin lymphoma
DMR3SO5 ID DMR3SO5
DMR3SO5 DN JCAR018
DMR3SO5 HS Phase 1
DMR3SO5 CP Juno Therapeutics Seattle, WA
DMR3SO5 DE Acute lymphoblastic leukaemia; Non-hodgkin lymphoma
DM1T8KN ID DM1T8KN
DM1T8KN DN JCAR020
DM1T8KN HS Phase 1
DM1T8KN CP Juno Therapeutics Seattle, WA
DM1T8KN DE Ovarian cancer
DM324RM ID DM324RM
DM324RM DN JCAR023
DM324RM HS Phase 1
DM324RM CP Juno Therapeutics Seattle, WA
DM324RM DE Neuroblastoma
DMYR3IE ID DMYR3IE
DMYR3IE DN JES-9501
DMYR3IE HS Phase 1
DMYR3IE SN DHED; Dehydroevodiamine; Dehydroevodiamine hydrochloride
DMYR3IE CP Seoul University
DMYR3IE DE Alzheimer disease
DMMI4XR ID DMMI4XR
DMMI4XR DN JNJ-17305600
DMMI4XR HS Phase 1
DMMI4XR CP Johnson & Johnson Pharmaceutical Research & Development
DMMI4XR DE Schizophrenia
DMSQ3AZ ID DMSQ3AZ
DMSQ3AZ DN JNJ-26483327
DMSQ3AZ HS Phase 1
DMSQ3AZ SN MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson
DMSQ3AZ CP Johnson & Johnson
DMSQ3AZ DE Solid tumour/cancer
DMNSJ3C ID DMNSJ3C
DMNSJ3C DN JNJ-26854165
DMNSJ3C HS Phase 1
DMNSJ3C SN Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474
DMNSJ3C CP Johnson & Johnson Pharmaceutical
DMNSJ3C DT Small molecular drug
DMNSJ3C PC 11609586
DMNSJ3C MW 328.4
DMNSJ3C FM C21H20N4
DMNSJ3C IC InChI=1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)
DMNSJ3C CS C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
DMNSJ3C IK CEGSUKYESLWKJP-UHFFFAOYSA-N
DMNSJ3C IU 1-N-[2-(1H-indol-3-yl)ethyl]-4-N-pyridin-4-ylbenzene-1,4-diamine
DMNSJ3C CA CAS 881202-45-5
DMNSJ3C DE Prostate cancer; Non-small-cell lung cancer; Solid tumour/cancer
DM49VWQ ID DM49VWQ
DM49VWQ DN JNJ-3534
DM49VWQ HS Phase 1
DM49VWQ CP Janssen Research & Development Raritan, NJ
DM49VWQ DE Psoriasis vulgaris
DMDIPW8 ID DMDIPW8
DMDIPW8 DN JNJ-38877605
DMDIPW8 HS Phase 1
DMDIPW8 SN C-met inhibitor, Ortho Biotech Oncology Research & Development; C-met inhibitor (solid tumors), ORD/J&J PRD
DMDIPW8 CP Johnson & Johnson Pharmaceutical Research & Development LLC
DMDIPW8 DT Small molecular drug
DMDIPW8 PC 46911863
DMDIPW8 MW 377.3
DMDIPW8 FM C19H13F2N7
DMDIPW8 IC InChI=1S/C19H13F2N7/c1-27-11-13(10-23-27)16-6-7-17-24-25-18(28(17)26-16)19(20,21)14-4-5-15-12(9-14)3-2-8-22-15/h2-11H,1H3
DMDIPW8 CS CN1C=C(C=N1)C2=NN3C(=NN=C3C(C4=CC5=C(C=C4)N=CC=C5)(F)F)C=C2
DMDIPW8 IK JRWCBEOAFGHNNU-UHFFFAOYSA-N
DMDIPW8 IU 6-[difluoro-[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline
DMDIPW8 CA CAS 943540-75-8
DMDIPW8 CB CHEBI:91417
DMDIPW8 DE Solid tumour/cancer
DM45SGE ID DM45SGE
DM45SGE DN JNJ-39439335
DM45SGE HS Phase 1
DM45SGE SN Mavatrep; 956274-94-5; JNJ-39439335; UNII-F197218T99; F197218T99; Mavatrep [USAN:INN]; Mavatrep (USAN); JNJ 39439335; SCHEMBL1796599; SCHEMBL1797450; CHEMBL2364618; Mavatrep(JNJ-39439335); Mavatrep; JNJ-39439335; DTXSID90241905; BCP23936; EX-A2266; ZINC43175494; BDBM50086717; AKOS030527038; DB12875; CS-4591; SB17026; trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol; BC600772; HY-16935; B5930; J3.561.747G; D10370
DM45SGE CP Johnson & Johnson Pharmaceutical Research & Development
DM45SGE DT Small molecular drug
DM45SGE PC 17751090
DM45SGE MW 422.4
DM45SGE FM C25H21F3N2O
DM45SGE IC InChI=1S/C25H21F3N2O/c1-24(2,31)20-6-4-3-5-19(20)17-10-13-21-22(15-17)30-23(29-21)14-9-16-7-11-18(12-8-16)25(26,27)28/h3-15,31H,1-2H3,(H,29,30)/b14-9+
DM45SGE CS CC(C)(C1=CC=CC=C1C2=CC3=C(C=C2)N=C(N3)/C=C/C4=CC=C(C=C4)C(F)(F)F)O
DM45SGE IK ORDHXXHTBUZRCN-NTEUORMPSA-N
DM45SGE IU 2-[2-[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-3H-benzimidazol-5-yl]phenyl]propan-2-ol
DM45SGE CA CAS 956274-94-5
DM45SGE DE Musculoskeletal pain
DMOL9JR ID DMOL9JR
DMOL9JR DN JNJ-42491293
DMOL9JR HS Phase 1
DMOL9JR SN MGlu2 receptor PET ligand (psychiatric disease); MGlu2 receptor PET ligand (psychiatric disease), Johnson & Johnson
DMOL9JR CP Johnson & Johnson Pharmaceutical Research & Development LLC
DMOL9JR DE Psychiatric disorder
DMQ5ZVK ID DMQ5ZVK
DMQ5ZVK DN JNJ-54175446
DMQ5ZVK HS Phase 1
DMQ5ZVK SN CWFVVQFVGMFTBD-SECBINFHSA-N; UNII-32524GLF40; 32524GLF40; 1627902-21-9; SCHEMBL16036477; BDBM254266; AKOS032947046; AS-35269; J3.655.327H; US9464084, 158; (R)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone; (r)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-1,4,6,7-tetrahydro-5h-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone; Methanone, (2-chloro-3-(trifluoromethyl)phenyl)((4R)-1-(5-fluoro-2-py
DMQ5ZVK CP Janssen Research & Development Raritan, NJ
DMQ5ZVK PC 90409366
DMQ5ZVK MW 440.8
DMQ5ZVK FM C18H13ClF4N6O
DMQ5ZVK IC InChI=1S/C18H13ClF4N6O/c1-9-15-13(29(27-26-15)17-24-7-10(20)8-25-17)5-6-28(9)16(30)11-3-2-4-12(14(11)19)18(21,22)23/h2-4,7-9H,5-6H2,1H3/t9-/m1/s1
DMQ5ZVK CS C[C@@H]1C2=C(CCN1C(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl)N(N=N2)C4=NC=C(C=N4)F
DMQ5ZVK IK CWFVVQFVGMFTBD-SECBINFHSA-N
DMQ5ZVK IU [2-chloro-3-(trifluoromethyl)phenyl]-[(4R)-1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]methanone
DMQ5ZVK CA CAS 1627902-21-9
DMQ5ZVK DE Major depressive disorder
DMBV3P8 ID DMBV3P8
DMBV3P8 DN JNJ-54728518
DMBV3P8 HS Phase 1
DMBV3P8 CP Janssen Research & Development Raritan, NJ
DMBV3P8 DE Type-2 diabetes
DM0QZJX ID DM0QZJX
DM0QZJX DN JNJ-55308942
DM0QZJX HS Phase 1
DM0QZJX CP Johnson & Johnson
DM0QZJX DE Anhedonia; Mood disorder; Neuroinflammation
DMSPQDM ID DMSPQDM
DMSPQDM DN JNJ-61610588
DMSPQDM HS Phase 1
DMSPQDM CP Janssen Research & Development Raritan, NJ
DMSPQDM DE Solid tumour/cancer
DM5SZAK ID DM5SZAK
DM5SZAK DN JNJ-63709178
DM5SZAK HS Phase 1
DM5SZAK CP Janssen
DM5SZAK DT Antibody
DM5SZAK DE Acute myeloid leukaemia
DMJFK6X ID DMJFK6X
DMJFK6X DN JNJ-63898081
DMJFK6X HS Phase 1
DMJFK6X CP Janssen
DMJFK6X DT Antibody
DMJFK6X DE Solid tumour/cancer
DMLYAGD ID DMLYAGD
DMLYAGD DN JNJ-64264681
DMLYAGD HS Phase 1
DMLYAGD CP Janssen
DMLYAGD DE Non-hodgkin lymphoma; Chronic lymphocytic leukaemia
DMYJCUP ID DMYJCUP
DMYJCUP DN JNJ-64417184
DMYJCUP HS Phase 1
DMYJCUP CP Janssen
DMYJCUP DE Respiratory syncytial virus infection
DMDBW2N ID DMDBW2N
DMDBW2N DN JNJ-64619178
DMDBW2N HS Phase 1
DMDBW2N SN 2086772-26-9; UNII-N8VKI8FPW0; N8VKI8FPW0; JNJ64619178; CHEMBL4249337; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol; Onametostat; (1S,2R,3S,5R)-3-(2-(2-Amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclopentane-1,2-diol; entane-1,2-diol; Onametostat [INN]; SCHEMBL18572106; EX-A2791; BDBM50462572; NSC808507; NSC-808507; JNJ45031882; HY-101564; CS-0021720; S8624; A16861; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop; (1~{S},2~{R},3~{S},5~{R})-3-[2-(2-azanyl-3-bromanyl-quinolin-7-yl)ethyl]-5-(4-azanylpyrrolo[2,3-d]pyrimidin-7-yl)cyclop entane-1,2-diol; 1,2-Cyclopentanediol, 3-(2-(2-amino-3-bromo-7-quinolinyl)ethyl)-5-(4-amino-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, (1S,2R,3S,5R)-; K8N
DMDBW2N CP Janssen
DMDBW2N DT Small molecular drug
DMDBW2N PC 126637809
DMDBW2N MW 483.4
DMDBW2N FM C22H23BrN6O2
DMDBW2N IC InChI=1S/C22H23BrN6O2/c23-15-8-12-3-1-11(7-16(12)28-21(15)25)2-4-13-9-17(19(31)18(13)30)29-6-5-14-20(24)26-10-27-22(14)29/h1,3,5-8,10,13,17-19,30-31H,2,4,9H2,(H2,25,28)(H2,24,26,27)/t13-,17+,18+,19-/m0/s1
DMDBW2N CS C1[C@@H]([C@H]([C@H]([C@@H]1N2C=CC3=C(N=CN=C32)N)O)O)CCC4=CC5=NC(=C(C=C5C=C4)Br)N
DMDBW2N IK DBSMLQTUDJVICQ-CJODITQLSA-N
DMDBW2N IU (1S,2R,3S,5R)-3-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
DMDBW2N CA CAS 2086772-26-9
DMDBW2N DE Myelodysplastic syndrome; Solid tumour/cancer
DMQOHRA ID DMQOHRA
DMQOHRA DN JNJ-67571244
DMQOHRA HS Phase 1
DMQOHRA CP Janssen
DMQOHRA DT Antibody
DMQOHRA DE Acute myeloid leukaemia; Myelodysplastic syndrome
DM6URNJ ID DM6URNJ
DM6URNJ DN JNJ-67856633
DM6URNJ HS Phase 1
DM6URNJ CP Janssen
DM6URNJ DE Non-hodgkin lymphoma; Chronic lymphocytic leukaemia
DM6VR13 ID DM6VR13
DM6VR13 DN JNJ-69086420
DM6VR13 HS Phase 1
DM6VR13 CP Janssen
DM6VR13 DT Antibody
DM6VR13 DE Prostate cancer
DMY7CW1 ID DMY7CW1
DMY7CW1 DN JNJ-74699157
DMY7CW1 HS Phase 1
DMY7CW1 CP Janssen
DMY7CW1 DE Solid tumour/cancer
DMFMWLQ ID DMFMWLQ
DMFMWLQ DN JS004
DMFMWLQ HS Phase 1
DMFMWLQ SN TAB004
DMFMWLQ CP Junshi Biosciences
DMFMWLQ DT Antibody
DMFMWLQ DE Solid tumour/cancer
DMVJWBS ID DMVJWBS
DMVJWBS DN JSI-1187
DMVJWBS HS Phase 1
DMVJWBS CP JS InnoPharm
DMVJWBS DT Small molecular drug
DMVJWBS DE Solid tumour/cancer
DM4QIOH ID DM4QIOH
DM4QIOH DN JSM 6427
DM4QIOH HS Phase 1
DM4QIOH CP Jerini AG
DM4QIOH DE Macular degeneration
DM01JU8 ID DM01JU8
DM01JU8 DN JTE-451
DM01JU8 HS Phase 1
DM01JU8 CP Akros Pharma Princeton, NJ
DM01JU8 DE Plaque psoriasis
DMHMDC0 ID DMHMDC0
DMHMDC0 DN JWCAR029
DMHMDC0 HS Phase 1
DMHMDC0 CP Peking University
DMHMDC0 DT CAR T Cell Therapy
DMHMDC0 DE Non-hodgkin lymphoma
DMW5J9B ID DMW5J9B
DMW5J9B DN JX-929
DMW5J9B HS Phase 1
DMW5J9B CP Jennerex Biotherapeutics
DMW5J9B DE Solid tumour/cancer
DMFKEVO ID DMFKEVO
DMFKEVO DN KA2237
DMFKEVO HS Phase 1
DMFKEVO CP Karus Therapeutics Oxfordshire, United Kingdom
DMFKEVO DE B-cell lymphoma
DMW0H9Y ID DMW0H9Y
DMW0H9Y DN KA2507
DMW0H9Y HS Phase 1
DMW0H9Y CP Karus Therapeutics Oxfordshire, United Kingdom
DMW0H9Y DE Solid tumour/cancer
DMXYN1H ID DMXYN1H
DMXYN1H DN KAR5585
DMXYN1H HS Phase 1
DMXYN1H SN Rodatristat; Rodatristat [USAN]; UNII-507FY6OL37; SCHEMBL16573975; TZSZZENYCISATO-WIOPSUGQSA-N; 507FY6OL37; Ethyl (3S)-8-(2-amino-6-((1R)-1-(5-chloro(1,1'-biphenyl)-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro(4.5)decane-3-carboxylate; (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate; 2,8-Diazaspiro(4.5)decane-3-carboxylic acid, 8-(2-amino-6-((1R)-1-(5-chloro(1,1'-biphenyl)-2-yl)-2,2,2-trifluoroethoxy)-4
DMXYN1H CP Karos Pharmaceuticals New Haven, CT
DMXYN1H PC 92045025
DMXYN1H MW 590
DMXYN1H FM C29H31ClF3N5O3
DMXYN1H IC InChI=1S/C29H31ClF3N5O3/c1-2-40-26(39)22-16-28(17-35-22)10-12-38(13-11-28)23-15-24(37-27(34)36-23)41-25(29(31,32)33)20-9-8-19(30)14-21(20)18-6-4-3-5-7-18/h3-9,14-15,22,25,35H,2,10-13,16-17H2,1H3,(H2,34,36,37)/t22-,25+/m0/s1
DMXYN1H CS CCOC(=O)[C@@H]1CC2(CCN(CC2)C3=CC(=NC(=N3)N)O[C@H](C4=C(C=C(C=C4)Cl)C5=CC=CC=C5)C(F)(F)F)CN1
DMXYN1H IK TZSZZENYCISATO-WIOPSUGQSA-N
DMXYN1H IU ethyl (3S)-8-[2-amino-6-[(1R)-1-(4-chloro-2-phenylphenyl)-2,2,2-trifluoroethoxy]pyrimidin-4-yl]-2,8-diazaspiro[4.5]decane-3-carboxylate
DMXYN1H CA CAS 1673571-51-1
DMXYN1H DE Pulmonary arterial hypertension
DMTYNRB ID DMTYNRB
DMTYNRB DN KD033
DMTYNRB HS Phase 1
DMTYNRB CP Kadmon
DMTYNRB DT Recombinant protein
DMTYNRB DE Solid tumour/cancer
DMNFDYE ID DMNFDYE
DMNFDYE DN KD3010
DMNFDYE HS Phase 1
DMNFDYE CP Kalypsys
DMNFDYE DE Obesity; Metabolic disorder
DMZK7N8 ID DMZK7N8
DMZK7N8 DN Keratinocyte growth factor
DMZK7N8 HS Phase 1
DMZK7N8 SN RHu-KGF
DMZK7N8 CP Amgen
DMZK7N8 DE Solid tumour/cancer
DMQ6DLZ ID DMQ6DLZ
DMQ6DLZ DN KF-17837
DMQ6DLZ HS Phase 1
DMQ6DLZ SN CHEMBL27508; (E)-8-(3,4-Dimethoxystyryl)-7-methyl-1,3-dipropylxanthine; 141807-96-7; 1H-Purine-2,6-dione, 3,7-dihydro-8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-dipropyl-7-methyl-, (E)-; UQGGPCQNHJCOPS-PKNBQFBNSA-N; 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-7-methyl-1,3-dipropylpurine-2,6-dione; AC1O68AZ; SCHEMBL537086; SCHEMBL537085; SCHEMBL9364001; 8-[2-(3,4-Dimethoxy-phenyl)-vinyl]-7-methyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; BDBM50006710; KF-17387; LS-126824; L006852
DMQ6DLZ DT Small molecular drug
DMQ6DLZ PC 6448585
DMQ6DLZ MW 412.5
DMQ6DLZ FM C22H28N4O4
DMQ6DLZ IC InChI=1S/C22H28N4O4/c1-6-12-25-20-19(21(27)26(13-7-2)22(25)28)24(3)18(23-20)11-9-15-8-10-16(29-4)17(14-15)30-5/h8-11,14H,6-7,12-13H2,1-5H3/b11-9+
DMQ6DLZ CS CCCN1C2=C(C(=O)N(C1=O)CCC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C
DMQ6DLZ IK UQGGPCQNHJCOPS-PKNBQFBNSA-N
DMQ6DLZ IU 8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-7-methyl-1,3-dipropylpurine-2,6-dione
DMQ6DLZ CA CAS 141807-96-7
DMQ6DLZ DE Parkinson disease
DMR14VE ID DMR14VE
DMR14VE DN KH-901
DMR14VE HS Phase 1
DMR14VE SN Comfeagen; GM-CSF gene-carrying recombinant adenovirus vaccine (solid tumor), Kanghong Biotechnologies
DMR14VE CP Chengdu Kanghong Biotechnologies Co Ltd
DMR14VE DT Vaccine
DMR14VE DE Solid tumour/cancer
DMLSUQ8 ID DMLSUQ8
DMLSUQ8 DN KHK2455
DMLSUQ8 HS Phase 1
DMLSUQ8 CP Kyowa Kirin Princeton, NJ
DMLSUQ8 DE Solid tumour/cancer
DMR7EF6 ID DMR7EF6
DMR7EF6 DN KHK-2866
DMR7EF6 HS Phase 1
DMR7EF6 CP Kyowa Hakko Kirin Pharma
DMR7EF6 DT Antibody
DMR7EF6 DE Ovarian cancer
DMIAVBL ID DMIAVBL
DMIAVBL DN Ki23819
DMIAVBL HS Phase 1
DMIAVBL DE Solid tumour/cancer
DMUB3H9 ID DMUB3H9
DMUB3H9 DN KITE-439
DMUB3H9 HS Phase 1
DMUB3H9 CP Gilead Sciences; Kite Pharma
DMUB3H9 DT TCR-T cell therapy
DMUB3H9 DE Cervical cancer; Solid tumour/cancer
DMXR6HI ID DMXR6HI
DMXR6HI DN KITE-585
DMXR6HI HS Phase 1
DMXR6HI CP Kite, A Gilead Company
DMXR6HI DT CAR T Cell Therapy
DMXR6HI DE Multiple myeloma
DMBSI6Y ID DMBSI6Y
DMBSI6Y DN KITE-718
DMBSI6Y HS Phase 1
DMBSI6Y CP Kite Pharma
DMBSI6Y DT TCR-T cell therapy
DMBSI6Y DE Solid tumour/cancer
DME8DUV ID DME8DUV
DME8DUV DN KM-023
DME8DUV HS Phase 1
DME8DUV CP Kainos Medicine Inc
DME8DUV DE Human immunodeficiency virus infection
DMRAWGC ID DMRAWGC
DMRAWGC DN KM-819
DMRAWGC HS Phase 1
DMRAWGC CP Kainos Medicine
DMRAWGC DE Parkinson disease
DM1D2O0 ID DM1D2O0
DM1D2O0 DN KML-001
DM1D2O0 HS Phase 1
DM1D2O0 CP Komipharm International Co Ltd
DM1D2O0 PC 60356606
DM1D2O0 MW 334.75
DM1D2O0 FM C16H15ClN2O4
DM1D2O0 IC InChI=1S/C16H15ClN2O4/c1-11(12-2-4-13(17)5-3-12)18-16(20)10-23-15-8-6-14(7-9-15)19(21)22/h2-9,11H,10H2,1H3,(H,18,20)
DM1D2O0 CS CC(C1=CC=C(C=C1)Cl)NC(=O)COC2=CC=C(C=C2)[N+](=O)[O-]
DM1D2O0 IK FIOKOSHFWPOUGX-UHFFFAOYSA-N
DM1D2O0 IU N-[1-(4-chlorophenyl)ethyl]-2-(4-nitrophenoxy)acetamide
DM1D2O0 DE Solid tumour/cancer
DMZMSBI ID DMZMSBI
DMZMSBI DN KO-947
DMZMSBI HS Phase 1
DMZMSBI SN ODIUJYZERXVGEI-UHFFFAOYSA-N; KO947; 1695533-89-1; GTPL9976; SCHEMBL16619993; EX-A1980; BCP25116; HY-112181; CS-0043627; 6-benzyl-3-pyridin-4-yl-2,5-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one; 6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[4,3-g]quinazolin-7-one; KO947,1695533-89-1,1,5,6,8-Tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one,KO947,KO-947,KO 947
DMZMSBI CP Kura Oncology San Diego, CA
DMZMSBI PC 136653617
DMZMSBI MW 355.4
DMZMSBI FM C21H17N5O
DMZMSBI IC InChI=1S/C21H17N5O/c27-21-23-18-11-19-17(20(25-24-19)15-6-8-22-9-7-15)10-16(18)13-26(21)12-14-4-2-1-3-5-14/h1-11H,12-13H2,(H,23,27)(H,24,25)
DMZMSBI CS C1C2=CC3=C(C=C2NC(=O)N1CC4=CC=CC=C4)NN=C3C5=CC=NC=C5
DMZMSBI IK ODIUJYZERXVGEI-UHFFFAOYSA-N
DMZMSBI IU 6-benzyl-3-pyridin-4-yl-5,8-dihydro-1H-pyrazolo[4,3-g]quinazolin-7-one
DMZMSBI DE Solid tumour/cancer
DM4953W ID DM4953W
DM4953W DN KOS-2187
DM4953W HS Phase 1
DM4953W CP Kosan Biosci.
DM4953W DT Small molecular drug
DM4953W PC 56603679
DM4953W MW 812
DM4953W FM C43H73NO13
DM4953W IC InChI=1S/C43H73NO13/c1-22(2)44(12)30-19-24(4)53-40(33(30)46)57-37-26(6)34(55-31-21-42(10,52-13)36(48)28(8)54-31)27(7)39(49)56-38(29-17-15-14-16-18-29)43(11,51)35(47)25(5)32(45)23(3)20-41(37,9)50/h14-18,22-28,30-38,40,45-48,50-51H,19-21H2,1-13H3/t23-,24?,25+,26+,27-,28?,30?,31?,32+,33?,34+,35-,36?,37-,38-,40?,41-,42?,43+/m1/s1
DM4953W CS C[C@@H]1C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O[C@@H]([C@@]([C@@H]([C@H]([C@H]1O)C)O)(C)O)C2=CC=CC=C2)C)OC3CC(C(C(O3)C)O)(C)OC)C)OC4C(C(CC(O4)C)N(C)C(C)C)O)(C)O
DM4953W IK BCKWPVFDVOGCTM-AFGVNUEFSA-N
DM4953W IU (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-7,10,12,13-tetrahydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-6-[3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-14-phenyl-oxacyclotetradecan-2-one
DM4953W DE Gastroesophageal reflux disease; Gastrointestinal disease
DMSKI8W ID DMSKI8W
DMSKI8W DN KPG-121
DMSKI8W HS Phase 1
DMSKI8W CP Kangpu Biopharmaceuticals
DMSKI8W DT Small molecular drug
DMSKI8W DE Prostate cancer
DM1O2X6 ID DM1O2X6
DM1O2X6 DN KPG-818
DM1O2X6 HS Phase 1
DM1O2X6 CP Kangpu Biopharmaceuticals
DM1O2X6 DT Small molecular drug
DM1O2X6 DE Systemic lupus erythematosus
DMYBHER ID DMYBHER
DMYBHER DN KPL-716
DMYBHER HS Phase 1
DMYBHER CP Kiniksa Pharmaceuticals Lexington, MA
DMYBHER DE Atopic dermatitis; Nodular prurigo
DM9JXMD ID DM9JXMD
DM9JXMD DN KPT-9274
DM9JXMD HS Phase 1
DM9JXMD SN Pak4-IN-1; PAK4-IN-1; 1643913-93-2; UNII-9T56TV18X7; 9T56TV18X7; SCHEMBL16345416; SCHEMBL16348032; KPT9274; EX-A563; BCP10637; KPT 9274;KPT9274; ZINC253387914; AKOS030526635; CS-5146; SB19836; PAK4-IN-1 pound KPT9274 pound(c); NCGC00484085-01; HY-12793; J-690230; 2-Propenamide, 3-(6-amino-3-pyridinyl)-N-((5-(4-((4,4-difluoro-1-piperidinyl)carbonyl)phenyl)-7-(4-fluorophenyl)-2-benzofuranyl)methyl)-, (2E)-; 4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide; (E)-3-(6-aminopyridin-3-
DM9JXMD CP Karyopharm Therapeutics Newton, MA
DM9JXMD PC 117779453
DM9JXMD MW 610.6
DM9JXMD FM C35H29F3N4O3
DM9JXMD IC InChI=1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)/b12-2+
DM9JXMD CS C1CN(CCC1(F)F)C(=O)C2=CC=C(C=C2)C3=CC(=C4C(=C3)C=C(O4)CNC(=O)/C=C/C5=CN=C(C=C5)N)C6=CC=C(C=C6)F
DM9JXMD IK MRFOPLWJZULAQD-SWGQDTFXSA-N
DM9JXMD IU (E)-3-(6-aminopyridin-3-yl)-N-[[5-[4-(4,4-difluoropiperidine-1-carbonyl)phenyl]-7-(4-fluorophenyl)-1-benzofuran-2-yl]methyl]prop-2-enamide
DM9JXMD CA CAS 1643913-93-2
DM9JXMD DE Non-hodgkin lymphoma; Solid tumour/cancer
DMK0BTN ID DMK0BTN
DMK0BTN DN KQ-791
DMK0BTN HS Phase 1
DMK0BTN CP Kaneq Bioscience Montreal, Canada
DMK0BTN DE Type-2 diabetes
DMODGJU ID DMODGJU
DMODGJU DN KRN633
DMODGJU HS Phase 1
DMODGJU SN KRN-633; VEGF Receptor Tyrosine Kinase Inhibitor III, KRN633; KRN633, KRN-633, KRN 633; N-(2-Chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N′-propylurea
DMODGJU CP Kirin
DMODGJU TC Anticancer Agents
DMODGJU DT Small molecular drug
DMODGJU PC 9549295
DMODGJU MW 416.9
DMODGJU FM C20H21ClN4O4
DMODGJU IC InChI=1S/C20H21ClN4O4/c1-4-7-22-20(26)25-15-6-5-12(8-14(15)21)29-19-13-9-17(27-2)18(28-3)10-16(13)23-11-24-19/h5-6,8-11H,4,7H2,1-3H3,(H2,22,25,26)
DMODGJU CS CCCNC(=O)NC1=C(C=C(C=C1)OC2=NC=NC3=CC(=C(C=C32)OC)OC)Cl
DMODGJU IK VPBYZLCHOKSGRX-UHFFFAOYSA-N
DMODGJU IU 1-[2-chloro-4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-propylurea
DMODGJU CA CAS 286370-15-8
DMODGJU DE Solid tumour/cancer; Glioma
DM8FQPX ID DM8FQPX
DM8FQPX DN KTN3379
DM8FQPX HS Phase 1
DM8FQPX CP Kolltan pharmaceuticals
DM8FQPX DT Antibody
DM8FQPX DE Solid tumour/cancer
DMTFWLE ID DMTFWLE
DMTFWLE DN KUC-7483
DMTFWLE HS Phase 1
DMTFWLE SN Ritobegron ethyl ester; KUC-7322; Beta 3 adrenoceptor agonists (urinary incontinence), Kissei; N-phenylglycine derivatives, Kissei; 4-hydroxynorephedrine derivative (urinary incontinence), Kissei
DMTFWLE CP Kissei Pharmaceutical Co Ltd
DMTFWLE PC 9820882
DMTFWLE MW 373.4
DMTFWLE FM C21H27NO5
DMTFWLE IC InChI=1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
DMTFWLE CS CC1=CC(=C(C=C1OCC(=O)O)C)CCN[C@@H](C)[C@@H](C2=CC=C(C=C2)O)O
DMTFWLE IK VMMYRRFPMAGXNP-BTYIYWSLSA-N
DMTFWLE IU 2-[4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid
DMTFWLE CA CAS 255734-04-4
DMTFWLE DE Overactive bladder
DMKFVX5 ID DMKFVX5
DMKFVX5 DN KUL-7211
DMKFVX5 HS Phase 1
DMKFVX5 CP Kissei Pharmaceutical Co Ltd
DMKFVX5 PC 9798256
DMKFVX5 MW 345.4
DMKFVX5 FM C19H23NO5
DMKFVX5 IC InChI=1S/C19H23NO5/c1-13(19(24)15-4-6-16(21)7-5-15)20-11-10-14-2-8-17(9-3-14)25-12-18(22)23/h2-9,13,19-21,24H,10-12H2,1H3,(H,22,23)/t13-,19-/m0/s1
DMKFVX5 CS C[C@@H]([C@@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)OCC(=O)O
DMKFVX5 IK KKXPBQQLKHBRDA-DJJJIMSYSA-N
DMKFVX5 IU 2-[4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenoxy]acetic acid
DMKFVX5 DE Neurogenic bladder dysfunction
DMKMN5R ID DMKMN5R
DMKMN5R DN KUR-501
DMKMN5R HS Phase 1
DMKMN5R SN CMD-501
DMKMN5R CP Kuur Therapeutics
DMKMN5R DT CAR-NKT Cell therapy
DMKMN5R DE Neuroblastoma
DMS9LVC ID DMS9LVC
DMS9LVC DN KUR-502
DMS9LVC HS Phase 1
DMS9LVC CP Kuur Therapeutics
DMS9LVC DT CAR T Cell Therapy
DMS9LVC DE B-cell lymphoma
DMFO7RP ID DMFO7RP
DMFO7RP DN KW-2449
DMFO7RP HS Phase 1
DMFO7RP SN Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo
DMFO7RP CP Kyowa Hakko Kogyo Co Ltd
DMFO7RP DT Small molecular drug
DMFO7RP PC 11427553
DMFO7RP MW 332.4
DMFO7RP FM C20H20N4O
DMFO7RP IC InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)/b10-7+
DMFO7RP CS C1CN(CCN1)C(=O)C2=CC=C(C=C2)/C=C/C3=NNC4=CC=CC=C43
DMFO7RP IK YYLKKYCXAOBSRM-JXMROGBWSA-N
DMFO7RP IU [4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone
DMFO7RP CA CAS 841258-76-2
DMFO7RP CB CHEBI:91441
DMFO7RP DE Acute myeloid leukaemia
DMALK7F ID DMALK7F
DMALK7F DN KW-5092
DMALK7F HS Phase 1
DMALK7F SN Propanedinitrile, (1-(2-(((5-(1-piperidinylmethyl)-2-furanyl)methyl)amino)ethyl)-2-imidazolidinylidene)-, (E)-2-butenedioate (1:1); Propanedinitrile, (1-(2-(((5-(1-piperidinylmethyl)-2-furanyl)methyl)amino)etyhyl)-2-imidazolidinylidene)-, (E)-2-butenedioate (1:1); 135017-85-5; C19H26N6O.C4H4O4; AC1O5RKQ; LS-120041; (1-(2-(((5-(piperidinomethyl)-2-furanyl)methyl)amino)ethyl)-2-imidazolidinylidene)propanedinitrile fumarate
DMALK7F DT Small molecular drug
DMALK7F PC 6439389
DMALK7F MW 470.5
DMALK7F FM C23H30N6O5
DMALK7F IC InChI=1S/C19H26N6O.C4H4O4/c20-12-16(13-21)19-23-7-11-25(19)10-6-22-14-17-4-5-18(26-17)15-24-8-2-1-3-9-24;5-3(6)1-2-4(7)8/h4-5,22-23H,1-3,6-11,14-15H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMALK7F CS C1CCN(CC1)CC2=CC=C(O2)CNCCN3CCNC3=C(C#N)C#N.C(=C/C(=O)O)\\C(=O)O
DMALK7F IK ULJCVCIVEVXIKD-WLHGVMLRSA-N
DMALK7F IU (E)-but-2-enedioic acid;2-[1-[2-[[5-(piperidin-1-ylmethyl)furan-2-yl]methylamino]ethyl]imidazolidin-2-ylidene]propanedinitrile
DMALK7F CA CAS 135017-85-5
DMALK7F DE Pain
DML4H05 ID DML4H05
DML4H05 DN KX2-361
DML4H05 HS Phase 1
DML4H05 SN KX-02
DML4H05 CP Kinex pharmaceuticals
DML4H05 PC 11545920
DML4H05 MW 405.5
DML4H05 FM C24H24FN3O2
DML4H05 IC InChI=1S/C24H24FN3O2/c25-21-3-1-2-18(14-21)16-27-24(29)15-22-7-4-20(17-26-22)19-5-8-23(9-6-19)28-10-12-30-13-11-28/h1-9,14,17H,10-13,15-16H2,(H,27,29)
DML4H05 CS C1COCCN1C2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC(=CC=C4)F
DML4H05 IK CMKKPJNMYLOUCE-UHFFFAOYSA-N
DML4H05 IU N-[(3-fluorophenyl)methyl]-2-[5-(4-morpholin-4-ylphenyl)pyridin-2-yl]acetamide
DML4H05 CA CAS 897016-26-1
DML4H05 DE Brain cancer; Glioblastoma multiforme
DMWSC5L ID DMWSC5L
DMWSC5L DN L-778123
DMWSC5L HS Phase 1
DMWSC5L SN 183499-57-2; L-778123; UNII-31ZXM8ZKQ3; 4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE; 31ZXM8ZKQ3; CHEMBL279433; 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile; L-778123 free base; 4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile; 4-[(5-{[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl}imidazol-1-yl)methyl]benzonitrile; SCHEMBL1683541; AC1L50Q0; CTK7C7787; 1s63; 1s64; BDBM50097071; ZINC53070632
DMWSC5L DT Small molecular drug
DMWSC5L PC 216454
DMWSC5L MW 405.9
DMWSC5L FM C22H20ClN5O
DMWSC5L IC InChI=1S/C22H20ClN5O/c23-19-2-1-3-20(10-19)28-9-8-26(15-22(28)29)14-21-12-25-16-27(21)13-18-6-4-17(11-24)5-7-18/h1-7,10,12,16H,8-9,13-15H2
DMWSC5L CS C1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)C#N)C4=CC(=CC=C4)Cl
DMWSC5L IK JNUGFGAVPBYSHF-UHFFFAOYSA-N
DMWSC5L IU 4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile
DMWSC5L CA CAS 183499-57-2
DMWSC5L DE Lymphoma
DMXKO1L ID DMXKO1L
DMXKO1L DN L-796568
DMXKO1L HS Phase 1
DMXKO1L SN UNII-P50A5YTO0O; L-796568; P50A5YTO0O; CHEMBL111201; AC1MI4YO; L-796568 free base; SCHEMBL1276546; BDBM50092645; N-{4-[2-((R)-2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-4-[3-(4-trifluoromethyl-phenyl)-thiazol-2-yl]-benzenesulfonamide; (R)-N-(4-(2-((2-Hydroxy-2-(pyridin-3-yl)ethyl)amino)ethyl)phenyl)-4-(4-(4-trifluoromethylphenyl)thiazol-2-yl)benzenesulfonamide; (1R)-1-(3-Pyridyl)-2-[4-[[4-[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]phenyl]sulfonylamino]phenethylamino]ethanol
DMXKO1L DT Small molecular drug
DMXKO1L PC 3038500
DMXKO1L MW 624.7
DMXKO1L FM C31H27F3N4O3S2
DMXKO1L IC InChI=1S/C31H27F3N4O3S2/c32-31(33,34)25-9-5-22(6-10-25)28-20-42-30(37-28)23-7-13-27(14-8-23)43(40,41)38-26-11-3-21(4-12-26)15-17-36-19-29(39)24-2-1-16-35-18-24/h1-14,16,18,20,29,36,38-39H,15,17,19H2/t29-/m0/s1
DMXKO1L CS C1=CC(=CN=C1)[C@H](CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)C4=NC(=CS4)C5=CC=C(C=C5)C(F)(F)F)O
DMXKO1L IK MSOUIIHPMJCUNI-LJAQVGFWSA-N
DMXKO1L IU N-[4-[2-[[(2R)-2-hydroxy-2-pyridin-3-ylethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]benzenesulfonamide
DMXKO1L CA CAS 211031-01-5
DMXKO1L DE Obesity
DM8ANIM ID DM8ANIM
DM8ANIM DN Lactermin
DM8ANIM HS Phase 1
DM8ANIM SN PV-701, GroPep
DM8ANIM CP Novozymes GroPep Limited
DM8ANIM DE Oral mucositis
DMO4GPK ID DMO4GPK
DMO4GPK DN Lactose
DMO4GPK HS Phase 1
DMO4GPK SN Aletobiose; D-(+)-Lactose; D-Lactose; Fast-flo; Fast-flo Lactose; Galactinum; Lactin; Lactobiose; Lactose; Lactose [JAN]; Lactose anhydrous; Lactosum anhydricum; Milk sugar; Pharmatose 450M; Saccharum lactin; beta-D-Lactose; beta-Lactose; (+)-Lactose; .beta.-Lactose; 4-(beta-D-Galactosido)-D-glucose; 4-O-beta-D-Galactopyranosyl-D-glucose; 4-O-beta-D-Galactopyranosyl-beta-D-glucopyranose; 5965-66-2; D-Glucose, 4-O-beta-D-galactopyranosyl; EINECS 227-751-9; UNII-13Q3A43E0S; beta-D-Glucopyranose, 4-O-beta-D-galactopyranosyl-
DMO4GPK PC 6134
DMO4GPK MW 342.3
DMO4GPK FM C12H22O11
DMO4GPK IC GUBGYTABKSRVRQ-DCSYEGIMSA-N
DMO4GPK CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DMO4GPK IK 1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
DMO4GPK IU (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMO4GPK CA CAS 5965-66-2
DMO4GPK CB CHEBI:36218
DMO4GPK DE Lactose intolerance
DMC0VJF ID DMC0VJF
DMC0VJF DN Laevo-Bambuterol
DMC0VJF HS Phase 1
DMC0VJF SN R-Bambuterol; R-bambuterol hydrochloride
DMC0VJF CP Dongguan Kaifa Biomedicine Inc
DMC0VJF DE Asthma
DM7JNHU ID DM7JNHU
DM7JNHU DN LAM-001
DM7JNHU HS Phase 1
DM7JNHU CP LAM Therapeutics Guilford, CT
DM7JNHU DE Lymphangioleiomyomatosis
DMQHWMJ ID DMQHWMJ
DMQHWMJ DN LAM-003
DMQHWMJ HS Phase 1
DMQHWMJ CP AI Therapeutics
DMQHWMJ DE Acute myeloid leukaemia; Non-hodgkin lymphoma
DM1C4UM ID DM1C4UM
DM1C4UM DN LAMB3-transduced autologous epidermal stem cells
DM1C4UM HS Phase 1
DM1C4UM SN LAMB3-transduced autologous epidermal stem cells (retroviral vector, junctionalepidermolysis bullosa), University of Modena and Reggio Emilia/Holostem; LAMB3-transduced autologous epidermal stem cells (ZFN-mediated transduction, epidermolysis bullosa), University of Modena and Reggio Amilia/San Raffaele-Telethon Institute for Gene Therapy/Sangamo
DM1C4UM CP University of Modena; Reggio Emilia
DM1C4UM DE Epidermolysis bullosa
DMV80DP ID DMV80DP
DMV80DP DN LAS-186323
DMV80DP HS Phase 1
DMV80DP SN DHODH inhibitor (autoimmune disease), Alimirall; DHODH inhibitor (rheumatoid arthritis/multiple sclerosis), Almirall
DMV80DP CP Almirall Prodesfarma SA
DMV80DP DE Multiple sclerosis
DM4YA0D ID DM4YA0D
DM4YA0D DN LBR-101
DM4YA0D HS Phase 1
DM4YA0D CP Labrys biologics
DM4YA0D DT Antibody
DM4YA0D DE Migraine
DMJEACT ID DMJEACT
DMJEACT DN LC-1
DMJEACT HS Phase 1
DMJEACT SN Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix
DMJEACT CP Leuchemix Inc
DMJEACT DE Acute myeloid leukaemia
DMHT3CB ID DMHT3CB
DMHT3CB DN LC-350189
DMHT3CB HS Phase 1
DMHT3CB DE Gout
DMEY2LK ID DMEY2LK
DMEY2LK DN LCAR-B4822M CAR-T Cell
DMEY2LK HS Phase 1
DMEY2LK CP Second Affiliated Hospital of Xi'an Jiaotong University
DMEY2LK DT CAR T Cell Therapy
DMEY2LK DE Multiple myeloma
DM9LYXQ ID DM9LYXQ
DM9LYXQ DN Leflunomide
DM9LYXQ HS Phase 1
DM9LYXQ SN leflunomide; 75706-12-6; Arava; lefunamide; Leflunomidum; Leflunomida; HWA 486; Leflunomidum [INN-Latin]; HWA-486; Leflunomida [INN-Spanish]; SU 101 (pharmaceutical); SU101; Arava (TN); UNII-G162GK9U4W; S; Leflunomide
DM9LYXQ TC Antiviral Agents
DM9LYXQ DT Small molecular drug
DM9LYXQ PC 3899
DM9LYXQ MW 270.21
DM9LYXQ FM C12H9F3N2O2
DM9LYXQ IC InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
DM9LYXQ CS CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
DM9LYXQ IK VHOGYURTWQBHIL-UHFFFAOYSA-N
DM9LYXQ IU 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
DM9LYXQ CA CAS 75706-12-6
DM9LYXQ CB CHEBI:6402
DM9LYXQ DE Coronavirus Disease 2019 (COVID-19)
DMKZVLH ID DMKZVLH
DMKZVLH DN Lefradafiban
DMKZVLH HS Phase 1
DMKZVLH SN BIBU-104; BIBU-104XX; BIBV-104
DMKZVLH CP Boehringer Ingelheim Corp
DMKZVLH DT Small molecular drug
DMKZVLH PC 9576916
DMKZVLH MW 439.5
DMKZVLH FM C23H25N3O6
DMKZVLH IC InChI=1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1
DMKZVLH CS COC(=O)C[C@@H]1C[C@H](NC1=O)COC2=CC=C(C=C2)C3=CC=C(C=C3)/C(=N/C(=O)OC)/N
DMKZVLH IK PGCFXITVMNNKON-ROUUACIJSA-N
DMKZVLH IU methyl 2-[(3S,5S)-5-[[4-[4-[(Z)-N'-methoxycarbonylcarbamimidoyl]phenyl]phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetate
DMKZVLH CA CAS 149503-79-7
DMKZVLH CB CHEBI:60634
DMKZVLH DE Angina pectoris
DM5INZP ID DM5INZP
DM5INZP DN LEQ-506
DM5INZP HS Phase 1
DM5INZP PC 45100669
DM5INZP MW 432.6
DM5INZP FM C25H32N6O
DM5INZP IC InChI=1S/C25H32N6O/c1-17-16-30(11-12-31(17)23-15-26-22(14-27-23)25(4,5)32)24-19(3)18(2)21(28-29-24)13-20-9-7-6-8-10-20/h6-10,14-15,17,32H,11-13,16H2,1-5H3/t17-/m1/s1
DM5INZP CS C[C@@H]1CN(CCN1C2=NC=C(N=C2)C(C)(C)O)C3=NN=C(C(=C3C)C)CC4=CC=CC=C4
DM5INZP IK POERAARDVFVDLO-QGZVFWFLSA-N
DM5INZP IU 2-[5-[(2R)-4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl]pyrazin-2-yl]propan-2-ol
DM5INZP CA CAS 1204975-42-7
DM5INZP DE Solid tumour/cancer
DMNHPOT ID DMNHPOT
DMNHPOT DN LErafAON
DMNHPOT HS Phase 1
DMNHPOT SN RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm
DMNHPOT CP NeoPharm
DMNHPOT DT Antisense drug
DMNHPOT DE Solid tumour/cancer
DM2B0TJ ID DM2B0TJ
DM2B0TJ DN Leukocyte interleukin
DM2B0TJ HS Phase 1
DM2B0TJ SN Multikine (TN)
DM2B0TJ CP CEL-SCI
DM2B0TJ DE Human immunodeficiency virus infection; Head and neck cancer
DMI4O92 ID DMI4O92
DMI4O92 DN LFA-102
DMI4O92 HS Phase 1
DMI4O92 CP Novartis AG
DMI4O92 DT Antibody
DMI4O92 DE Solid tumour/cancer
DMAG6BV ID DMAG6BV
DMAG6BV DN LGK974
DMAG6BV HS Phase 1
DMAG6BV SN 1243244-14-5; LGK974; LGK-974; 2-(2',3-Dimethyl-[2,4'-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide; WNT-974; LGK 974; UNII-U27F40013Q; CHEBI:78030; CHEMBL3188386; U27F40013Q; AK165831; 2-(2',3-dimethyl-2,4'-bipyridin-5-yl)-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide; MLS006011002; SCHEMBL1723611; KS-00000SUI; MolPort-029-945-290; HMS3653G11; BCP08495; EX-A1402; ZINC95930187; STL556617; BDBM50133870; BBL102809; 2140AH; s7143; AKOS025211913; SB19314; CS-2807; DB12561; NCGC00347950-07; NCGC00347950-01; OR302651; QC-11701
DMAG6BV DT Small molecular drug
DMAG6BV PC 46926973
DMAG6BV MW 396.4
DMAG6BV FM C23H20N6O
DMAG6BV IC InChI=1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)
DMAG6BV CS CC1=CC(=CN=C1C2=CC(=NC=C2)C)CC(=O)NC3=NC=C(C=C3)C4=NC=CN=C4
DMAG6BV IK XXYGTCZJJLTAGH-UHFFFAOYSA-N
DMAG6BV IU 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-(5-pyrazin-2-ylpyridin-2-yl)acetamide
DMAG6BV CA CAS 1243244-14-5
DMAG6BV CB CHEBI:78030
DMAG6BV DE Solid tumour/cancer
DMYK52O ID DMYK52O
DMYK52O DN LHC165
DMYK52O HS Phase 1
DMYK52O SN LHC-165; 1258595-14-0; 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid; UNII-RD02U4QLM1; RD02U4QLM1; SCHEMBL174281; US9597326, Compound 20; BDBM301804; NSC819211; s8838; NSC-819211; HY-111786; CS-0091872; 3-(5-amino-2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenethyl)benzo[f][1,7]naphthyridin-8-yl)propanoic acid; Benzo(F)(1,7)naphthyridine-8-propanoic acid, 5-amino-2-(2-(4-(2-(3,3-difluoro-3-phosphonopropoxy)ethoxy)-2-methylphenyl)ethyl)-
DMYK52O CP Novartis
DMYK52O DT Small molecular drug
DMYK52O PC 49838259
DMYK52O MW 603.5
DMYK52O FM C29H32F2N3O7P
DMYK52O IC InChI=1S/C29H32F2N3O7P/c1-18-14-22(41-13-12-40-11-10-29(30,31)42(37,38)39)7-6-21(18)5-2-20-15-24-23-8-3-19(4-9-26(35)36)16-25(23)34-28(32)27(24)33-17-20/h3,6-8,14-17H,2,4-5,9-13H2,1H3,(H2,32,34)(H,35,36)(H2,37,38,39)
DMYK52O CS CC1=C(C=CC(=C1)OCCOCCC(F)(F)P(=O)(O)O)CCC2=CC3=C4C=CC(=CC4=NC(=C3N=C2)N)CCC(=O)O
DMYK52O IK SDLWKRZBLTZSEL-UHFFFAOYSA-N
DMYK52O IU 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid
DMYK52O CA CAS 1258595-14-0
DMYK52O DE Solid tumour/cancer
DMFNSHM ID DMFNSHM
DMFNSHM DN LHF-535
DMFNSHM HS Phase 1
DMFNSHM SN BET7FM8SQG; UNII-BET7FM8SQG; 1450929-77-7; (Z)-2-(4-(2-(1-(4-Isopropoxyphenyl)-1H-benzo[d]imidazol-5-yl)vinyl)phenyl)propan-2-ol; CHEMBL4537239; SCHEMBL15201523; HY-112762; CS-0063343; 2-[4-[(Z)-2-[1-(4-propan-2-yloxyphenyl)benzimidazol-5-yl]ethenyl]phenyl]propan-2-ol; Benzenemethanol, alpha,alpha-dimethyl-4-((1Z)-2-(1-(4-(1-methylethoxy)phenyl)-1H-benzimidazol-5-yl)ethenyl)-
DMFNSHM CP Kineta
DMFNSHM DT Small molecular drug
DMFNSHM PC 71711529
DMFNSHM MW 412.5
DMFNSHM FM C27H28N2O2
DMFNSHM IC InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-
DMFNSHM CS CC(C)OC1=CC=C(C=C1)N2C=NC3=C2C=CC(=C3)/C=C\\C4=CC=C(C=C4)C(C)(C)O
DMFNSHM IK DBNZTRPIBJSUIX-WAYWQWQTSA-N
DMFNSHM IU 2-[4-[(Z)-2-[1-(4-propan-2-yloxyphenyl)benzimidazol-5-yl]ethenyl]phenyl]propan-2-ol
DMFNSHM CA CAS 1450929-77-7
DMFNSHM DE Lassa fever
DMJRALD ID DMJRALD
DMJRALD DN LIPO-4
DMJRALD HS Phase 1
DMJRALD SN HIV vaccine (four peptide), INRS
DMJRALD CP INRS-Institut Armand-Frappier
DMJRALD DT Vaccine
DMJRALD DE Human immunodeficiency virus infection
DMESZQU ID DMESZQU
DMESZQU DN Litenimod
DMESZQU HS Phase 1
DMESZQU SN Li-28; CpG oligonucleotide immunomodulator (cancer), Oligovax
DMESZQU CP Oligovax SAS
DMESZQU PC 56841944
DMESZQU MW 8370
DMESZQU FM C256H322N95O129P25S25
DMESZQU IC InChI=1S/C256H322N95O129P25S25/c1-101-44-330(248(371)317-227(101)354)166-18-110(353)137(431-166)54-405-481(380,506)468-123-31-179(339-88-292-192-205(261)274-79-283-214(192)339)444-150(123)67-418-483(382,508)457-112-20-167(326-14-10-162(257)305-244(326)367)432-138(112)55-407-487(386,512)461-116-24-172(332-46-103(3)229(356)319-250(332)373)440-146(116)63-415-499(398,524)477-132-40-188(348-97-301-201-223(348)309-240(270)313-236(201)363)452-158(132)75-426-484(383,509)460-115-23-170(329-17-13-165(260)308-247(329)370)435-141(115)58-410-496(395,521)471-127-35-183(343-92-296-196-209(265)278-83-287-218(196)343)451-157(127)74-425-505(404,530)480-135-43-191(351-100-304-204-226(351)312-243(273)316-239(204)366)455-161(135)78-429-493(392,518)467-122-30-178(338-52-109(9)235(362)325-256(338)379)439-145(122)62-414-498(397,523)473-129-37-185(345-94-298-198-211(267)280-85-289-220(198)345)446-152(129)69-420-491(390,516)465-120-28-176(336-50-107(7)233(360)323-254(336)377)437-143(120)60-412-489(388,514)463-118-26-174(334-48-105(5)231(358)321-252(334)375)442-148(118)65-417-500(399,525)478-133-41-189(349-98-302-202-224(349)310-241(271)314-237(202)364)453-159(133)76-427-485(384,510)458-113-21-168(327-15-11-163(258)306-245(327)368)433-139(113)56-408-494(393,519)469-125-33-181(341-90-294-194-207(263)276-81-285-216(194)341)448-154(125)71-423-503(402,528)475-130-38-186(346-95-299-199-212(268)281-86-290-221(199)346)447-153(130)70-421-492(391,517)466-121-29-177(337-51-108(8)234(361)324-255(337)378)438-144(121)61-413-497(396,522)472-128-36-184(344-93-297-197-210(266)279-84-288-219(197)344)445-151(128)68-419-490(389,515)464-119-27-175(335-49-106(6)232(359)322-253(335)376)436-142(119)59-411-488(387,513)462-117-25-173(333-47-104(4)230(357)320-251(333)374)441-147(117)64-416-501(400,526)479-134-42-190(350-99-303-203-225(350)311-242(272)315-238(203)365)454-160(134)77-428-486(385,511)459-114-22-169(328-16-12-164(259)307-246(328)369)434-140(114)57-409-495(394,520)470-126-34-182(342-91-295-195-208(264)277-82-286-217(195)342)449-155(126)72-424-504(403,529)476-131-39-187(347-96-300-200-213(269)282-87-291-222(200)347)450-156(131)73-422-502(401,527)474-124-32-180(340-89-293-193-206(262)275-80-284-215(193)340)443-149(124)66-406-482(381,507)456-111-19-171(430-136(111)53-352)331-45-102(2)228(355)318-249(331)372/h10-17,44-52,79-100,110-161,166-191,352-353H,18-43,53-78H2,1-9H3,(H,380,506)(H,381,507)(H,382,508)(H,383,509)(H,384,510)(H,385,511)(H,386,512)(H,387,513)(H,388,514)(H,389,515)(H,390,516)(H,391,517)(H,392,518)(H,393,519)(H,394,520)(H,395,521)(H,396,522)(H,397,523)(H,398,524)(H,399,525)(H,400,526)(H,401,527)(H,402,528)(H,403,529)(H,404,530)(H2,257,305,367)(H2,258,306,368)(H2,259,307,369)(H2,260,308,370)(H2,261,274,283)(H2,262,275,284)(H2,263,276,285)(H2,264,277,286)(H2,265,278,287)(H2,266,279,288)(H2,267,280,289)(H2,268,281,290)(H2,269,282,291)(H,317,354,371)(H,318,355,372)(H,319,356,373)(H,320,357,374)(H,321,358,375)(H,322,359,376)(H,323,360,377)(H,324,361,378)(H,325,362,379)(H3,270,309,313,363)(H3,271,310,314,364)(H3,272,311,315,365)(H3,273,312,316,366)
DMESZQU CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)O
DMESZQU IK CJZRVARTODENJN-UHFFFAOYSA-N
DMESZQU IU 1-[5-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[[5-(6-aminopurin-9-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMESZQU DE Glioblastoma multiforme
DMR7LKC ID DMR7LKC
DMR7LKC DN LM-CD45
DMR7LKC HS Phase 1
DMR7LKC SN Anti-CD45, Baxter; Anti-CD45, Cantab
DMR7LKC CP Cantab Biopharmaceuticals Ltd
DMR7LKC DT Antibody
DMR7LKC DE Transplant rejection
DMU901D ID DMU901D
DMU901D DN L-MDAM
DMU901D HS Phase 1
DMU901D SN L-MDAM; 176857-41-3; UNII-W9CXL7O6LL; W9CXL7O6LL; GAMMA-METHYLENE-10-DEAZAAMINOPTERIN; MDAM; SCHEMBL1065136; ZINC1542008; KB-78169; Z-3290; L-Glutamic acid, N-(4-(2-(2,4-diamino-6-pteridinyl)ethyl)benzoyl)-4-methylene-; (2S)-2-[4-[2-(2,4-Diamino-6-pteridinyl)ethyl]benzoylamino]-4-methyleneglutaric acid
DMU901D CP BioNumerik Pharmaceuticals
DMU901D DT Small molecular drug
DMU901D PC 9803852
DMU901D MW 451.4
DMU901D FM C21H21N7O5
DMU901D IC InChI=1S/C21H21N7O5/c1-10(19(30)31)8-14(20(32)33)26-18(29)12-5-2-11(3-6-12)4-7-13-9-24-17-15(25-13)16(22)27-21(23)28-17/h2-3,5-6,9,14H,1,4,7-8H2,(H,26,29)(H,30,31)(H,32,33)(H4,22,23,24,27,28)/t14-/m0/s1
DMU901D CS C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)O
DMU901D IK QCLDSHDOWCMFBV-AWEZNQCLSA-N
DMU901D IU (2S)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid
DMU901D CA CAS 176857-41-3
DMU901D DE Solid tumour/cancer
DMZU2G1 ID DMZU2G1
DMZU2G1 DN LMP-1/LMP-2 CTLs
DMZU2G1 HS Phase 1
DMZU2G1 SN Ad5f35LMPd1-2; LMP-1/LMP-2 CTLs, Baylor College of Medicine/NCI; LMP-1/LMP-2 specific cytotoxic T-lymphocytes (gene therapy,nasopharyngeal cancer/lymphoma), Baylor College of Medicine/NCI
DMZU2G1 CP Baylor College of Medicine
DMZU2G1 DE Lymphoma
DM4FW2E ID DM4FW2E
DM4FW2E DN LMP400
DM4FW2E HS Phase 1
DM4FW2E SN INDOTECAN; 915303-09-2; UNII-BTA69L5M8D; NSC-724998; BTA69L5M8D; 2,3-dimethoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; LMP-400; NSC724998; Indotecan(LMP400); Indotecan (LMP400); CHEMBL216462; SCHEMBL7712572; DTXSID90238613; BCP34018; EX-A3020; Indotecan hydrochloride (LMP-400); ZB1545; SB16793; HY-18351; CS-0007476; LMP400; LMP-400; LMP 400; Q27274872; 3-[(Morpholine)-1-propyl]-5,3-dimethoxy-8,9-meth ylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
DM4FW2E CP LMP400
DM4FW2E DT Small molecular drug
DM4FW2E PC 11533060
DM4FW2E MW 478.5
DM4FW2E FM C26H26N2O7
DM4FW2E IC InChI=1S/C26H26N2O7/c1-31-19-10-15-18(13-20(19)32-2)26(30)28(5-3-4-27-6-8-33-9-7-27)24-16-11-21-22(35-14-34-21)12-17(16)25(29)23(15)24/h10-13H,3-9,14H2,1-2H3
DM4FW2E CS COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6CCOCC6)OC
DM4FW2E IK FMFIFGLHVOZDEL-UHFFFAOYSA-N
DM4FW2E IU 15,16-dimethoxy-20-(3-morpholin-4-ylpropyl)-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione
DM4FW2E CA CAS 915303-09-2
DM4FW2E DE Lymphoma; Neoplasm
DMUCQYW ID DMUCQYW
DMUCQYW DN LMP744
DMUCQYW HS Phase 1
DMUCQYW SN LMP-744; 308246-52-8; MJ-III-65; LMP744 free base; UNII-29BY7HQV0T; NSC-706744; 29BY7HQV0T; NCI60_037977; CHEMBL126159; 308246-52-8 (free base); 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; AC1L9FIC; SCHEMBL4162998; DTXSID30327954; BCP34017; EX-A3021; BDBM50237809; HY-U00248; NSC706743; CS-7432; NSC-706743; Q27894415; 20-[3-(2-Hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-; 5H-[1,6]indeno[1,2-c]isoquinoline- 5,12(6H)-dione,6-[3-[(2-hydroxyethyl)amino]propyl]-2,3-dimethoxy-; 6-[3-(2-Hydroxyethyl)aminopropyl]-5,11-diketo-2,3-dimethoxy-8,9-(methylenedioxy)- 11H-indeno[1,2-c]isoquinoline
DMUCQYW CP Gibson Oncology
DMUCQYW DT Small molecular drug
DMUCQYW PC 397888
DMUCQYW MW 452.5
DMUCQYW FM C24H24N2O7
DMUCQYW IC InChI=1S/C24H24N2O7/c1-30-17-8-13-16(11-18(17)31-2)24(29)26(6-3-4-25-5-7-27)22-14-9-19-20(33-12-32-19)10-15(14)23(28)21(13)22/h8-11,25,27H,3-7,12H2,1-2H3
DMUCQYW CS COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCNCCO)OC
DMUCQYW IK QCSDJDQOJBQTDV-UHFFFAOYSA-N
DMUCQYW IU 20-[3-(2-hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione
DMUCQYW CA CAS 308246-52-8
DMUCQYW DE Solid tumour/cancer
DM9OA35 ID DM9OA35
DM9OA35 DN Long-acting erythropoietin conjugate
DM9OA35 HS Phase 1
DM9OA35 SN HM-10760; HM-10760A; LAPS-EPO; Long-acting erythropoietin conjugate (LAPS, anemia); Long-acting erythropoietin conjugate (LAPS, anemia), Hanmi
DM9OA35 CP Hanmi pharmaceutical
DM9OA35 DE Anemia
DMCKE90 ID DMCKE90
DMCKE90 DN Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules
DMCKE90 HS Phase 1
DMCKE90 SN Aluviran + norvir + interferon apha + traditional Chinese Medicines granules
DMCKE90 TC Antiviral Agents
DMCKE90 DT Combination drug
DMCKE90 DE Coronavirus Disease 2019 (COVID-19)
DMDLTCU ID DMDLTCU
DMDLTCU DN Lotilibcin
DMDLTCU HS Phase 1
DMDLTCU SN Lotilibcin; JA-002; JA-003; WAP-8294A2; Acne therapy (dermatological formulation), Janus; Lotilibcin (injectable), aRigen; MRSA infection therapy (gel), Janus; S aureus infection therapy (gel), Janus; Lotilibcin (cream, acne), Janus; Lotilibcin (dermatological cream, acne), aRigen; Lotilibcin (gel, Staphycoccus infection), aRigen; Lotilibcin (gel, skin infections), Janus; WAP-8294A2 (injectable), aRigen; WAP-8294A2 (cream, acne), Janus; WAP-8294A2 (dermatological cream, acne), aRigen; WAP-8294A2 (gel, MRSA), aRigen; WAP-8294A2 (gel, skin infections), Janus
DMDLTCU CP Wakamoto Pharmaceutical Co Ltd
DMDLTCU PC 16184172
DMDLTCU MW 1562.8
DMDLTCU FM C73H111N17O21
DMDLTCU IC InChI=1S/C73H111N17O21/c1-38(2)17-14-20-43-32-56(94)80-53(37-92)69(106)88-59(61(98)62(77)99)71(108)87-52(36-91)63(100)79-35-57(95)89(7)54(30-41-18-10-9-11-19-41)70(107)86-49(29-39(3)4)66(103)81-46(23-15-27-74)64(101)82-47(25-26-58(96)97)65(102)85-51(33-55(76)93)68(105)84-50(31-42-34-78-45-22-13-12-21-44(42)45)67(104)83-48(24-16-28-75)72(109)90(8)60(40(5)6)73(110)111-43/h9-13,18-19,21-22,34,38-40,43,46-54,59-61,78,91-92,98H,14-17,20,23-33,35-37,74-75H2,1-8H3,(H2,76,93)(H2,77,99)(H,79,100)(H,80,94)(H,81,103)(H,82,101)(H,83,104)(H,84,105)(H,85,102)(H,86,107)(H,87,108)(H,88,106)(H,96,97)/t43-,46-,47+,48-,49+,50-,51-,52+,53+,54-,59-,60+,61-/m1/s1
DMDLTCU CS CC(C)CCC[C@@H]1CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)O1)C(C)C)C)CCCN)CC2=CNC3=CC=CC=C32)CC(=O)N)CCC(=O)O)CCCN)CC(C)C)CC4=CC=CC=C4)C)CO)[C@H](C(=O)N)O)CO
DMDLTCU IK LEKBQPKGXGFBAN-MMXTXZKOSA-N
DMDLTCU IU 3-[(3S,6R,9R,12R,15S,18R,21S,24R,30S,33R,36S,40R)-33-[(1R)-2-amino-1-hydroxy-2-oxoethyl]-12-(2-amino-2-oxoethyl)-6,18-bis(3-aminopropyl)-24-benzyl-30,36-bis(hydroxymethyl)-9-(1H-indol-3-ylmethyl)-4,25-dimethyl-40-(4-methylpentyl)-21-(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-3-propan-2-yl-1-oxa-4,7,10,13,16,19,22,25,28,31,34,37-dodecazacyclotetracont-15-yl]propanoic acid
DMDLTCU CA 169148-84-9
DMDLTCU DE Bacterial infection
DMDXFBJ ID DMDXFBJ
DMDXFBJ DN LOXO-195
DMDXFBJ HS Phase 1
DMDXFBJ SN OEBIHOVSAMBXIB-SJKOYZFVSA-N; LOXO195; UNII-0J45910S3X; 2097002-61-2; 0J45910S3X; LOXO-195 (S racemic); LOXO 195; SCHEMBL18823882; EX-A1873; HY-101977; CS-0022378; Cas registry number 2097002-61-2 ~1~1 C20 H21 F N6 O 10H-5,7-ethenopyrazolo(3,4-d)pyrido(2,3-k)pyrrolo(2,1-m)(1,3,7)triazacyclotridecin-10-one, 17-fluoro-1,2,3,11,12,13,14,18b-octahydro-12-methyl-, (12R,18bR)-; 12H-15,17-Ethenopyrazolo[3,4-d]pyrido[2,3-k]pyrrolo[2,1-m][1,3,7]triazacyclotridecin-12-one, 5-fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-, (3aR,10R)-; (13E,14E,22R,6R
DMDXFBJ CP Bayer Pharmaceuticals Whippany, NJ; Loxo Oncology Stamford, CT
DMDXFBJ PC 129103609
DMDXFBJ MW 380.4
DMDXFBJ FM C20H21FN6O
DMDXFBJ IC InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1
DMDXFBJ CS C[C@@H]1CCC2=C(C=C(C=N2)F)[C@H]3CCCN3C4=NC5=C(C=NN5C=C4)C(=O)N1
DMDXFBJ IK OEBIHOVSAMBXIB-SJKOYZFVSA-N
DMDXFBJ IU (6R,15R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7(12),8,10,18(25),19,22-heptaen-17-one
DMDXFBJ CA CAS 2097002-61-2
DMDXFBJ DE Solid tumour/cancer
DMYIXQZ ID DMYIXQZ
DMYIXQZ DN LP-108
DMYIXQZ HS Phase 1
DMYIXQZ CP Newave Pharmaceuticals
DMYIXQZ DE Acute myeloid leukaemia; Myelodysplastic syndrome; Chronic myelomonocytic leukaemia
DM8VBQJ ID DM8VBQJ
DM8VBQJ DN LS-69767
DM8VBQJ HS Phase 1
DM8VBQJ SN Dietade Dietary Foods; Fructooligosaccharides; Fructose, furanose form; Frutooligosaccharides; SCHEMBL3966; beta-D-Arabino-hexulose; beta-D-Fructose; beta-D-fructofuranose; beta-Fruit sugar; beta-Levulose; (2,1-beta-D-Fructosyl)n; (2->1)-beta-D-fructan; (2R,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol; .beta.-D-Fructofuranose; 2x7x; 470-23-5; B986VTP17J; CAS-57-48-7; CHEBI:28645; DSSTox_CID_3081; DSSTox_GSID_23081; DSSTox_RID_76866; UNII-B986VTP17J; beta-D-fructofuranose (closed ring structure)
DM8VBQJ PC 439709
DM8VBQJ MW 180.16
DM8VBQJ FM C6H12O6
DM8VBQJ IC RFSUNEUAIZKAJO-ARQDHWQXSA-N
DM8VBQJ CS C(C1C(C(C(O1)(CO)O)O)O)O
DM8VBQJ IK 1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m1/s1
DM8VBQJ IU (2R,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol
DM8VBQJ CA CAS 53188-23-1
DM8VBQJ CB CHEBI:28645
DM8VBQJ DE Chronic myelogenous leukaemia
DM94E6W ID DM94E6W
DM94E6W DN LTT462
DM94E6W HS Phase 1
DM94E6W CP Novartis Oncology East Hanover, NJ
DM94E6W DE Solid tumour/cancer
DMQ0K95 ID DMQ0K95
DMQ0K95 DN Lu-02-750
DMQ0K95 HS Phase 1
DMQ0K95 SN Dopamine receptor agonist (Parkinson's disease), H Lundbeck
DMQ0K95 CP Axon Biochemicals BV
DMQ0K95 DE Parkinson disease
DMP9UO0 ID DMP9UO0
DMP9UO0 DN Lu-AE04621
DMP9UO0 HS Phase 1
DMP9UO0 CP H Lundbeck A/S
DMP9UO0 DE Parkinson disease
DMQI970 ID DMQI970
DMQI970 DN Lumoxiti
DMQI970 HS Phase 1
DMQI970 SN Moxetumumab pasudotox-tdfk
DMQI970 CP Innate Pharma
DMQI970 DT Antibody
DMQI970 DE Hairy cell leukaemia
DMPQE2S ID DMPQE2S
DMPQE2S DN LVGN6051
DMPQE2S HS Phase 1
DMPQE2S CP Lyvgen Biopharma
DMPQE2S DT Antibody
DMPQE2S DE Solid tumour/cancer
DM8ZS7T ID DM8ZS7T
DM8ZS7T DN LX2761
DM8ZS7T HS Phase 1
DM8ZS7T SN 1610954-97-6; LX-2761; N-(1-((2-(Dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-butanamide; CHEMBL4074614; SCHEMBL15741132; BDBM176714; EX-A2828; ACN-053194; AC-31562; HY-101122; CS-0020883; N-[2-(dimethylamino)ethyl]-2-methyl-2-[4-[4-[[2-methyl-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]phenyl]methyl]phenyl]butanoylamino]propanamide; US9688710, 136 N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide
DM8ZS7T CP Lexicon Pharmaceuticals
DM8ZS7T DT Small molecular drug
DM8ZS7T PC 76070894
DM8ZS7T MW 601.8
DM8ZS7T FM C32H47N3O6S
DM8ZS7T IC InChI=1S/C32H47N3O6S/c1-20-10-15-23(29-27(38)26(37)28(39)30(41-29)42-6)19-24(20)18-22-13-11-21(12-14-22)8-7-9-25(36)34-32(2,3)31(40)33-16-17-35(4)5/h10-15,19,26-30,37-39H,7-9,16-18H2,1-6H3,(H,33,40)(H,34,36)/t26-,27-,28+,29+,30-/m1/s1
DM8ZS7T CS CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)SC)O)O)O)CC3=CC=C(C=C3)CCCC(=O)NC(C)(C)C(=O)NCCN(C)C
DM8ZS7T IK BNPZTRDIESRGTC-IXYVTWBDSA-N
DM8ZS7T IU N-[2-(dimethylamino)ethyl]-2-methyl-2-[4-[4-[[2-methyl-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]phenyl]methyl]phenyl]butanoylamino]propanamide
DM8ZS7T DE Type 2 diabetes
DMO548K ID DMO548K
DMO548K DN LX9211
DMO548K HS Phase 1
DMO548K CP Lexicon Pharmaceuticals The Woodlands, TX
DMO548K DE Neuropathic pain
DMQE9PS ID DMQE9PS
DMQE9PS DN LXH254
DMQE9PS HS Phase 1
DMQE9PS SN UEPXBTCUIIGYCY-UHFFFAOYSA-N; SCHEMBL16094629; BDBM88120; HY-112089; CS-0043317; US9694016, 1156; 1800398-38-2; N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide
DMQE9PS CP Novartis Oncology East Hanover, NJ
DMQE9PS PC 90456533
DMQE9PS MW 502.5
DMQE9PS FM C25H25F3N4O4
DMQE9PS IC InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)
DMQE9PS CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=NC=C2)C(F)(F)F)C3=CC(=NC(=C3)OCCO)N4CCOCC4
DMQE9PS IK UEPXBTCUIIGYCY-UHFFFAOYSA-N
DMQE9PS IU N-[3-[2-(2-hydroxyethoxy)-6-morpholin-4-ylpyridin-4-yl]-4-methylphenyl]-2-(trifluoromethyl)pyridine-4-carboxamide
DMQE9PS CA CAS 1800398-38-2
DMQE9PS DE Non-small-cell lung cancer
DM3OP41 ID DM3OP41
DM3OP41 DN LXR 623
DM3OP41 HS Phase 1
DM3OP41 SN LXR-623
DM3OP41 DT Small molecular drug
DM3OP41 PC 16734800
DM3OP41 MW 422.8
DM3OP41 FM C21H12ClF5N2
DM3OP41 IC InChI=1S/C21H12ClF5N2/c22-18-10-15(24)9-6-13(18)11-29-20(12-4-7-14(23)8-5-12)16-2-1-3-17(19(16)28-29)21(25,26)27/h1-10H,11H2
DM3OP41 CS C1=CC2=C(N(N=C2C(=C1)C(F)(F)F)CC3=C(C=C(C=C3)F)Cl)C4=CC=C(C=C4)F
DM3OP41 IK KYWWJENKIMRJBI-UHFFFAOYSA-N
DM3OP41 IU 2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)indazole
DM3OP41 CA CAS 875787-07-8
DM3OP41 DE Arteriosclerosis
DMCBV20 ID DMCBV20
DMCBV20 DN LY-2334737
DMCBV20 HS Phase 1
DMCBV20 SN Gem prodrug (cancer), Eli Lilly; Gemcitabine prodrug (cancer), Lilly
DMCBV20 CP Eli Lilly & Co
DMCBV20 DT Small molecular drug
DMCBV20 PC 11646777
DMCBV20 MW 389.4
DMCBV20 FM C17H25F2N3O5
DMCBV20 IC InChI=1S/C17H25F2N3O5/c1-3-5-10(6-4-2)14(25)20-12-7-8-22(16(26)21-12)15-17(18,19)13(24)11(9-23)27-15/h7-8,10-11,13,15,23-24H,3-6,9H2,1-2H3,(H,20,21,25,26)/t11-,13-,15-/m1/s1
DMCBV20 CS CCCC(CCC)C(=O)NC1=NC(=O)N(C=C1)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
DMCBV20 IK MEOYFIHNRBNEPI-UXIGCNINSA-N
DMCBV20 IU N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-propylpentanamide
DMCBV20 CA CAS 892128-60-8
DMCBV20 DE Solid tumour/cancer
DML8M3B ID DML8M3B
DML8M3B DN LY-2584702
DML8M3B HS Phase 1
DML8M3B SN LY-S6K1; LY-S6K1 HCl; LY-S6K1 tosylate; P70 S6 kinase inhibitor (cancer), Eli Lilly
DML8M3B CP Eli Lilly & Co
DML8M3B DT Small molecular drug
DML8M3B PC 25118925
DML8M3B MW 445.4
DML8M3B FM C21H19F4N7
DML8M3B IC InChI=1S/C21H19F4N7/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30)
DML8M3B CS CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(C=C5)F)C(F)(F)F
DML8M3B IK FYXRSVDHGLUMHB-UHFFFAOYSA-N
DML8M3B IU 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methylimidazol-2-yl]piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine
DML8M3B CA CAS 1082949-67-4
DML8M3B DE Solid tumour/cancer
DM289Z4 ID DM289Z4
DM289Z4 DN LY2624587
DM289Z4 HS Phase 1
DM289Z4 CP Eli Lilly & Co
DM289Z4 DT Antibody
DM289Z4 DE Solid tumour/cancer; Metastatic cancer
DM93AJW ID DM93AJW
DM93AJW DN LY2780301
DM93AJW HS Phase 1
DM93AJW SN P70 S6 Kinase and AKT Dual Inhibitor
DM93AJW CP Lilly
DM93AJW DE Solid tumour/cancer
DM9NYHT ID DM9NYHT
DM9NYHT DN LY2787106
DM9NYHT HS Phase 1
DM9NYHT DT Antibody
DM9NYHT DE Anemia
DM8LGWR ID DM8LGWR
DM8LGWR DN LY-2811376
DM8LGWR HS Phase 1
DM8LGWR SN LY2811376; 1194044-20-6; (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; LY-2811376; LY 2811376; UNII-UR18YJ97SJ; UR18YJ97SJ; CHEMBL2333941; (4s)-4-[2,4-Difluoro-5-(Pyrimidin-5-Yl)phenyl]-4-Methyl-5,6-Dihydro-4h-1,3-Thiazin-2-Amine; (4S)-4-[2,4-Difluoro-5-(5-pyrimidinyl)phenyl]-5,6-dihydro-4-methyl-4H-1,3-thiazin-2-amine; J-501480; MJQMRGWYPNIERM-HNNXBMFYSA-N; 4H-1,3-Thiazin-2-amine, 4-(2,4-difluoro-5-(5-pyrimidinyl)phenyl)-5,6-dihydro-4-methyl-, (4S)-; 4H-1,3-Thiazin-2-amine,
DM8LGWR CP Eli Lilly & Co
DM8LGWR DT Small molecular drug
DM8LGWR PC 44251605
DM8LGWR MW 320.4
DM8LGWR FM C15H14F2N4S
DM8LGWR IC InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1
DM8LGWR CS C[C@]1(CCSC(=N1)N)C2=C(C=C(C(=C2)C3=CN=CN=C3)F)F
DM8LGWR IK MJQMRGWYPNIERM-HNNXBMFYSA-N
DM8LGWR IU (4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine
DM8LGWR CA CAS 1194044-20-6
DM8LGWR DE Alzheimer disease
DM5EXJV ID DM5EXJV
DM5EXJV DN LY-2881835
DM5EXJV HS Phase 1
DM5EXJV CP Eli Lilly & Co
DM5EXJV DT Small molecular drug
DM5EXJV PC 51049992
DM5EXJV MW 491.6
DM5EXJV FM C33H33NO3
DM5EXJV IC InChI=1S/C33H33NO3/c1-2-5-29(22-32(35)36)27-12-14-30(15-13-27)37-24-26-10-8-25(9-11-26)23-34-20-18-33(19-21-34)17-16-28-6-3-4-7-31(28)33/h3-4,6-17,29H,18-24H2,1H3,(H,35,36)/t29-/m0/s1
DM5EXJV CS CC#C[C@@H](CC(=O)O)C1=CC=C(C=C1)OCC2=CC=C(C=C2)CN3CCC4(CC3)C=CC5=CC=CC=C45
DM5EXJV IK FHRWHNJJQGSCQC-LJAQVGFWSA-N
DM5EXJV IU (3S)-3-[4-[[4-(spiro[indene-1,4'-piperidine]-1'-ylmethyl)phenyl]methoxy]phenyl]hex-4-ynoic acid
DM5EXJV CA CAS 1292290-38-0
DM5EXJV DE Type-2 diabetes
DMGLTE2 ID DMGLTE2
DMGLTE2 DN LY2922470
DMGLTE2 HS Phase 1
DMGLTE2 SN 1423018-12-5; CHEMBL3955132; (S)-3-(4-((5-((8-Methoxy-3,4-dihydroquinolin-1(2H)-yl)methyl)thiophen-2-yl)methoxy)phenyl)hex-4-ynoic acid; LY-2922470; SCHEMBL14695980; BCP24962; BDBM50204012; HY-19835; CS-0016977; (3S)-3-[4-[[5-[(8-methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]thiophen-2-yl]methoxy]phenyl]hex-4-ynoic acid
DMGLTE2 DT Small molecular drug
DMGLTE2 PC 71257551
DMGLTE2 MW 475.6
DMGLTE2 FM C28H29NO4S
DMGLTE2 IC InChI=1S/C28H29NO4S/c1-3-6-22(17-27(30)31)20-10-12-23(13-11-20)33-19-25-15-14-24(34-25)18-29-16-5-8-21-7-4-9-26(32-2)28(21)29/h4,7,9-15,22H,5,8,16-19H2,1-2H3,(H,30,31)/t22-/m0/s1
DMGLTE2 CS CC#C[C@@H](CC(=O)O)C1=CC=C(C=C1)OCC2=CC=C(S2)CN3CCCC4=C3C(=CC=C4)OC
DMGLTE2 IK VJVDLRVFJTVWEO-QFIPXVFZSA-N
DMGLTE2 IU (3S)-3-[4-[[5-[(8-methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]thiophen-2-yl]methoxy]phenyl]hex-4-ynoic acid
DMGLTE2 CA CAS 1423018-12-5
DMGLTE2 DE Type 2 diabetes
DMY1AFS ID DMY1AFS
DMY1AFS DN LY294002
DMY1AFS HS Phase 1
DMY1AFS SN 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 154447-36-6; LY 294002; LY-294002; 2-morpholino-8-phenyl-4H-chromen-4-one; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; UNII-31M2U1DVID; LY-294,002; 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one; 31M2U1DVID; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; CHEMBL98350; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; CHEBI:65329; 2-morpholino-8-phenyl-chromen-4-one; AK162301; 2-(morpholin-4-yl)-8-phenylchromen-4-one; LY2; 15447-36-6; IN1266; IN1268; Lys 294002; BMK1-D5; H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-(9CI); 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholin-4-yl-8-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-(9CI); 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One
DMY1AFS CP Genentech
DMY1AFS DT Small molecular drug
DMY1AFS PC 3973
DMY1AFS MW 307.3
DMY1AFS FM C19H17NO3
DMY1AFS IC InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
DMY1AFS CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DMY1AFS IK CZQHHVNHHHRRDU-UHFFFAOYSA-N
DMY1AFS IU 2-morpholin-4-yl-8-phenylchromen-4-one
DMY1AFS CA CAS 154447-36-6
DMY1AFS CB CHEBI:65329
DMY1AFS DE Neuroblastoma
DM16IX2 ID DM16IX2
DM16IX2 DN LY-2979165
DM16IX2 HS Phase 1
DM16IX2 SN Bipolar disorder therapy, Eli Lilly
DM16IX2 CP Eli Lilly & Co
DM16IX2 DT Small molecular drug
DM16IX2 PC 53246986
DM16IX2 MW 355.37
DM16IX2 FM C13H17N5O5S
DM16IX2 IC InChI=1S/C13H17N5O5S/c1-4(14)9(19)17-13(11(22)23)2-5(24-12-15-3-16-18-12)6-7(8(6)13)10(20)21/h3-8H,2,14H2,1H3,(H,17,19)(H,20,21)(H,22,23)(H,15,16,18)/t4-,5+,6-,7-,8-,13-/m0/s1
DM16IX2 CS C[C@@H](C(=O)N[C@]1(C[C@H]([C@@H]2[C@H]1[C@H]2C(=O)O)SC3=NC=NN3)C(=O)O)N
DM16IX2 IK BBGHHIUQOKQCBW-LDZWZCGGSA-N
DM16IX2 IU (1R,2S,4R,5R,6R)-2-[[(2S)-2-aminopropanoyl]amino]-4-(1H-1,2,4-triazol-5-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DM16IX2 CA CAS 1311385-35-9
DM16IX2 DE Bipolar disorder
DM6PFCN ID DM6PFCN
DM6PFCN DN LY3009120
DM6PFCN HS Phase 1
DM6PFCN CP Lilly
DM6PFCN PC 71721540
DM6PFCN MW 424.5
DM6PFCN FM C23H29FN6O
DM6PFCN IC InChI=1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)
DM6PFCN CS CC1=CC(=C(C=C1C2=C(N=C3C(=C2)C=NC(=N3)NC)C)NC(=O)NCCC(C)(C)C)F
DM6PFCN IK HHCBMISMPSAZBF-UHFFFAOYSA-N
DM6PFCN IU 1-(3,3-dimethylbutyl)-3-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea
DM6PFCN CA CAS 1454682-72-4
DM6PFCN DE Solid tumour/cancer
DMJPCHK ID DMJPCHK
DMJPCHK DN LY309887
DMJPCHK HS Phase 1
DMJPCHK DT Small molecular drug
DMJPCHK PC 135430850
DMJPCHK MW 449.5
DMJPCHK FM C19H23N5O6S
DMJPCHK IC InChI=1S/C19H23N5O6S/c20-19-23-15-11(16(27)24-19)7-9(8-21-15)1-2-10-3-5-13(31-10)17(28)22-12(18(29)30)4-6-14(25)26/h3,5,9,12H,1-2,4,6-8H2,(H,22,28)(H,25,26)(H,29,30)(H4,20,21,23,24,27)/t9-,12+/m1/s1
DMJPCHK CS C1[C@H](CNC2=C1C(=O)NC(=N2)N)CCC3=CC=C(S3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMJPCHK IK GQCXGHHHNACOGE-SKDRFNHKSA-N
DMJPCHK IU (2S)-2-[[5-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
DMJPCHK CA CAS 127228-54-0
DMJPCHK DE Solid tumour/cancer
DM5OP86 ID DM5OP86
DM5OP86 DN LY3127804
DM5OP86 HS Phase 1
DM5OP86 CP Eli Lilly Indianapolis, IN
DM5OP86 DE Solid tumour/cancer
DM9RTXM ID DM9RTXM
DM9RTXM DN LY3164530
DM9RTXM HS Phase 1
DM9RTXM CP Eli Lilly
DM9RTXM DT Monoclonal antibody
DM9RTXM DE Advanced cancer; Solid tumour/cancer
DMQP6VB ID DMQP6VB
DMQP6VB DN LY3200882
DMQP6VB HS Phase 1
DMQP6VB SN PNPFMWIDAKQFPY-UHFFFAOYSA-N; 1898283-02-7; LY-3200882; 2-{4-[(4-{[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy}pyridin-2-yl)amino]pyridin-2-yl}propan-2-ol; 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol; SCHEMBL17645407; EX-A1680; BCP20882; HY-103021; CS-0023129
DMQP6VB CP Eli Lilly Indianapolis, IN
DMQP6VB PC 121249291
DMQP6VB MW 435.5
DMQP6VB FM C24H29N5O3
DMQP6VB IC InChI=1S/C24H29N5O3/c1-24(2,30)21-13-17(5-9-25-21)27-22-14-19(6-10-26-22)32-20-15-29(18-3-4-18)28-23(20)16-7-11-31-12-8-16/h5-6,9-10,13-16,18,30H,3-4,7-8,11-12H2,1-2H3,(H,25,26,27)
DMQP6VB CS CC(C)(C1=NC=CC(=C1)NC2=NC=CC(=C2)OC3=CN(N=C3C4CCOCC4)C5CC5)O
DMQP6VB IK PNPFMWIDAKQFPY-UHFFFAOYSA-N
DMQP6VB IU 2-[4-[[4-[1-cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]oxypyridin-2-yl]amino]pyridin-2-yl]propan-2-ol
DMQP6VB CA CAS 1898283-02-7
DMQP6VB DE Solid tumour/cancer
DMFDAY7 ID DMFDAY7
DMFDAY7 DN LY3214996
DMFDAY7 HS Phase 1
DMFDAY7 SN JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one
DMFDAY7 CP Eli Lilly Indianapolis, IN
DMFDAY7 PC 121408882
DMFDAY7 MW 453.6
DMFDAY7 FM C22H27N7O2S
DMFDAY7 IC InChI=1S/C22H27N7O2S/c1-22(2)19-15(20(30)29(22)9-8-28-10-12-31-13-11-28)14-17(32-19)16-4-6-23-21(25-16)26-18-5-7-24-27(18)3/h4-7,14H,8-13H2,1-3H3,(H,23,25,26)
DMFDAY7 CS CC1(C2=C(C=C(S2)C3=NC(=NC=C3)NC4=CC=NN4C)C(=O)N1CCN5CCOCC5)C
DMFDAY7 IK JNPRPMBJODOFEC-UHFFFAOYSA-N
DMFDAY7 IU 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one
DMFDAY7 CA CAS 1951483-29-6
DMFDAY7 DE Solid tumour/cancer
DMOV2ML ID DMOV2ML
DMOV2ML DN LY3300054
DMOV2ML HS Phase 1
DMOV2ML CP Eli Lilly Indianapolis, IN
DMOV2ML DT Monoclonal antibody
DMOV2ML DE Solid tumour/cancer; Advanced malignancy
DMG6HLE ID DMG6HLE
DMG6HLE DN LY3303560
DMG6HLE HS Phase 1
DMG6HLE CP Eli Lilly Indianapolis, IN
DMG6HLE DE Alzheimer disease
DMD51GC ID DMD51GC
DMD51GC DN LY3321367
DMD51GC HS Phase 1
DMD51GC CP Eli Lilly Indianapolis, IN
DMD51GC DE Solid tumour/cancer
DMONZ1L ID DMONZ1L
DMONZ1L DN LY3381916
DMONZ1L HS Phase 1
DMONZ1L CP Eli Lilly Indianapolis, IN
DMONZ1L DE Solid tumour/cancer
DMB51K2 ID DMB51K2
DMB51K2 DN LY3405105
DMB51K2 HS Phase 1
DMB51K2 SN SCHEMBL20971700; GTPL11356; (3S)-1-[(2E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl 4-{[5-methyl-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}piperidine-1-carboxylate
DMB51K2 CP Eli Lilly
DMB51K2 DT Small molecular drug
DMB51K2 PC 138608760
DMB51K2 MW 497.6
DMB51K2 FM C26H39N7O3
DMB51K2 IC InChI=1S/C26H39N7O3/c1-18(2)22-16-27-33-23(15-19(3)28-25(22)33)29-20-8-12-31(13-9-20)26(35)36-21-10-14-32(17-21)24(34)7-6-11-30(4)5/h6-7,15-16,18,20-21,29H,8-14,17H2,1-5H3/b7-6+/t21-/m0/s1
DMB51K2 CS CC1=NC2=C(C=NN2C(=C1)NC3CCN(CC3)C(=O)O[C@H]4CCN(C4)C(=O)/C=C/CN(C)C)C(C)C
DMB51K2 IK GRDAHPJRLCTJNA-BXKJMJEDSA-N
DMB51K2 IU [(3S)-1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(5-methyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate
DMB51K2 DE Solid tumour/cancer
DMFU0H5 ID DMFU0H5
DMFU0H5 DN LY3410738
DMFU0H5 HS Phase 1
DMFU0H5 CP Eli Lilly
DMFU0H5 DT Small molecular drug
DMFU0H5 DE Solid tumour/cancer
DM5QO1A ID DM5QO1A
DM5QO1A DN LY3415244
DM5QO1A HS Phase 1
DM5QO1A CP Eli Lilly
DM5QO1A DT Antibody
DM5QO1A DE Solid tumour/cancer
DMZLIWX ID DMZLIWX
DMZLIWX DN LY3475070
DMZLIWX HS Phase 1
DMZLIWX CP Eli Lilly
DMZLIWX DE Solid tumour/cancer
DMY8W3S ID DMY8W3S
DMY8W3S DN LY3484356
DMY8W3S HS Phase 1
DMY8W3S CP Eli Lilly
DMY8W3S DE Breast cancer
DMLXGAI ID DMLXGAI
DMLXGAI DN LYS-6KAKT1
DMLXGAI HS Phase 1
DMLXGAI CP Eli Lilly & Co
DMLXGAI DE Solid tumour/cancer
DMHDCSL ID DMHDCSL
DMHDCSL DN LZM009
DMHDCSL HS Phase 1
DMHDCSL CP Livzon Pharmaceutical Zhuhai City, China
DMHDCSL DT Monoclonal antibody
DMHDCSL DE Solid tumour/cancer; Advanced malignancy
DMK7UNL ID DMK7UNL
DMK7UNL DN M-0004
DMK7UNL HS Phase 1
DMK7UNL SN Gastroprokinetic compound (pediatric reflux), Janssen; Gastroprokinetic compound (pediatric reflux), Movetis
DMK7UNL CP Janssen Pharmaceutica NV
DMK7UNL DE Gastroesophageal reflux disease
DME6UNO ID DME6UNO
DME6UNO DN M012
DME6UNO HS Phase 1
DME6UNO SN Benzal chloride; 98-87-3; (DICHLOROMETHYL)BENZENE; alpha,alpha-Dichlorotoluene; Benzylidene chloride; Benzene, (dichloromethyl)-; Benzyl dichloride; Dichloromethylbenzene; Benzylene chloride; Chlorobenzal; Dichlorophenylmethane; DICHLOROTOLUENE; Chlorure de benzylidene; Benzene, dichloromethyl-; RCRA waste number U017; NSC 7915; Benzylidene dichloride; UNII-222447TR16; 29797-40-8; alpha,alpha-Dichlorotoluene; CHEBI:82273; Toluene, .alpha.,.alpha.-dichloro-; 222447TR16; DSSTox_CID_5014; DSSTox_RID_77628; DSSTox_GSID_25014; CAS-98-87-3; CCRIS 959; Toluene, alpha,alpha-dichloro-; Cloruro de bencilideno; Chlorure de benzylidene [French]; Cloruro de bencilideno [Spanish]; HSDB 5322; EINECS 202-709-2; UN1886; RCRA waste no. U017; benzalchlorid; BRN 1099407; AI3-28597; chlorobenzyl chloride; EINECS 249-854-8; Benzal chloride???; WLN: GYGR; 1-(dichloromethyl)benzene; alpha-alpha-Dichlorotoluene; EC 202-709-2; EC 249-854-8; SCHEMBL28353; 4-05-00-00817 (Beilstein Handbook Reference); alpha,alpha-Dichlortoluene; CHEMBL1412576; DTXSID6025014; Cl[C](Cl)C1=CC=CC=C1; NSC7915; alpha,alpha-Dichlorotoluene, 95%; ALPHA,ALPHA-DICHLORO-TOLUENE; NSC-7915; ZINC1586312; Tox21_201313; Tox21_300171; MFCD00000829; AKOS015902605; FS-4304; MCULE-5551252494; Toluene, alpha,alpha-dichloro- (8CI); UN 1886; NCGC00091362-01; NCGC00091362-02; NCGC00091362-03; NCGC00254144-01; NCGC00258865-01; Benzylidene chloride [UN1886] [Poison]; FT-0694812; C19165; Q419420; alpha,alpha-Dichlorotoluene, PESTANAL(R), analytical standard
DME6UNO CP Merganser Biotech
DME6UNO DT Small molecular drug
DME6UNO PC 7411
DME6UNO MW 161.03
DME6UNO FM C7H6Cl2
DME6UNO IC InChI=1S/C7H6Cl2/c8-7(9)6-4-2-1-3-5-6/h1-5,7H
DME6UNO CS C1=CC=C(C=C1)C(Cl)Cl
DME6UNO IK CAHQGWAXKLQREW-UHFFFAOYSA-N
DME6UNO IU dichloromethylbenzene
DME6UNO CA CAS 98-87-3
DME6UNO CB CHEBI:82273
DME6UNO DE Myelodysplastic syndrome; Polycythemia vera; Thalassemia
DMP8QY2 ID DMP8QY2
DMP8QY2 DN M1774
DMP8QY2 HS Phase 1
DMP8QY2 SN 674783-97-2; 9-Mesityl-10-methylacridinium Perchlorate; 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate; MFCD09038536; Acridinium, 10-methyl-9-(2,4,6-trimethylphenyl)-, perchlorate; ACMC-209nz7; 9-Mesityl-10-methyl-10-acridinium Perchlorate; [Acr-Mes]+(ClO4)-; SCHEMBL10009695; 10-Methyl-9-(2,4,6-trimethylphenyl)acridinium Perchlorate; DTXSID60580419; ANW-35345; AKOS015843774; SY076797; 9-mesityl-10-methyl-acridinium perchlorate; CS-0103389; 9-Mesityl-10-methylacridin-10-ium perchlorate; 9-Mesityl-10-methylacridinium perchlorate, 95%; 9-Mesityl-10-methylacridinium perchlorate, AldrichCPR; 10-METHYL-9-(2,4,6-TRIMETHYLPHENYL)ACRIDIN-10-IUM PERCHLORATE
DMP8QY2 CP EMD Serono
DMP8QY2 DT Small molecular drug
DMP8QY2 PC 15953479
DMP8QY2 MW 411.9
DMP8QY2 FM C23H22ClNO4
DMP8QY2 IC InChI=1S/C23H22N.ClHO4/c1-15-13-16(2)22(17(3)14-15)23-18-9-5-7-11-20(18)24(4)21-12-8-6-10-19(21)23;2-1(3,4)5/h5-14H,1-4H3;(H,2,3,4,5)/q+1;/p-1
DMP8QY2 CS CC1=CC(=C(C(=C1)C)C2=C3C=CC=CC3=[N+](C4=CC=CC=C42)C)C.[O-]Cl(=O)(=O)=O
DMP8QY2 IK LFMBERYWDLWXNO-UHFFFAOYSA-M
DMP8QY2 IU 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate
DMP8QY2 CA CAS 674783-97-2
DMP8QY2 DE Solid tumour/cancer
DM3PVBJ ID DM3PVBJ
DM3PVBJ DN M2698
DM3PVBJ HS Phase 1
DM3PVBJ SN HXAUJHZZPCBFPN-QGZVFWFLSA-N; 1379545-95-5; SCHEMBL15262358; EX-A1187; AKOS030627134; M2698(MSC-2363318A)
DM3PVBJ CP EMD Serono Rockland, MA
DM3PVBJ PC 89808643
DM3PVBJ MW 449.9
DM3PVBJ FM C21H19ClF3N5O
DM3PVBJ IC InChI=1S/C21H19ClF3N5O/c22-16-6-5-12(9-15(16)21(23,24)25)17(10-30-7-2-8-30)29-20-14-4-1-3-13(19(26)31)18(14)27-11-28-20/h1,3-6,9,11,17H,2,7-8,10H2,(H2,26,31)(H,27,28,29)/t17-/m1/s1
DM3PVBJ CS C1CN(C1)C[C@H](C2=CC(=C(C=C2)Cl)C(F)(F)F)NC3=NC=NC4=C3C=CC=C4C(=O)N
DM3PVBJ IK HXAUJHZZPCBFPN-QGZVFWFLSA-N
DM3PVBJ IU 4-[[(1S)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]quinazoline-8-carboxamide
DM3PVBJ CA CAS 1379545-95-5
DM3PVBJ DE Solid tumour/cancer
DM6PI5B ID DM6PI5B
DM6PI5B DN M3258
DM6PI5B HS Phase 1
DM6PI5B SN LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid
DM6PI5B CP EMD Serono
DM6PI5B DT Small molecular drug
DM6PI5B PC 138319683
DM6PI5B MW 329.2
DM6PI5B FM C17H20BNO5
DM6PI5B IC InChI=1S/C17H20BNO5/c20-17(13-8-11-5-6-15(13)24-11)19-16(18(21)22)7-10-9-23-14-4-2-1-3-12(10)14/h1-4,9,11,13,15-16,21-22H,5-8H2,(H,19,20)/t11-,13-,15+,16+/m1/s1
DM6PI5B CS B([C@H](CC1=COC2=CC=CC=C21)NC(=O)[C@@H]3C[C@H]4CC[C@@H]3O4)(O)O
DM6PI5B IK RFQDLTYXNINJON-OYNZBZHQSA-N
DM6PI5B IU [(1R)-2-(1-benzofuran-3-yl)-1-[[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carbonyl]amino]ethyl]boronic acid
DM6PI5B DE Multiple myeloma
DMG98QO ID DMG98QO
DMG98QO DN M3541
DMG98QO HS Phase 1
DMG98QO SN Aminomalonic acid; 1068-84-4; Aminomalonate; 2-Aminomalonic acid; 2-Aminopropanedioic Acid; alpha-Aminomalonic acid; Propanedioic acid, amino-; aminopropanedioic acid; Propanedioic acid,2-amino-; CHEBI:17475; C00872; Q-102736; Malonic acid, amino-; Aminomalonicacid; Aminopropanedioate; amino-Propanedioate; amino-Malonic acid; a-aminomalonic acid; NSC 352096; amino-Propanedioic acid; AC1L2PBO; .alpha.-Aminomalonic acid; AC1Q5S2H; Propanedioic acid, 2-amino-; SCHEMBL209221; Malonic acid, amino- (8CI); Jsp000609; CHEMBL1232731; KS-00000K
DMG98QO CP EMD Serono Rockland, MA
DMG98QO PC 100714
DMG98QO MW 119.08
DMG98QO FM C3H5NO4
DMG98QO IC InChI=1S/C3H5NO4/c4-1(2(5)6)3(7)8/h1H,4H2,(H,5,6)(H,7,8)
DMG98QO CS C(C(=O)O)(C(=O)O)N
DMG98QO IK JINBYESILADKFW-UHFFFAOYSA-N
DMG98QO IU 2-aminopropanedioic acid
DMG98QO CA CAS 1068-84-4
DMG98QO CB CHEBI:17475
DMG98QO DE Solid tumour/cancer
DMQBO3V ID DMQBO3V
DMQBO3V DN M4344
DMQBO3V HS Phase 1
DMQBO3V SN VX-803; Butanehydrazide; Butyrohydrazide; Butyric acid hydrazide; 3538-65-6; butanehydrazide; Butanohydrazide; Butyrylhydrazine; Butanoic acid, hydrazide; n-Butyric acid hydrazide; butyric hydrazide; butanoic acid hydrazide; FCCCRBDJBTVFSJ-UHFFFAOYSA-N; butyryl hydrazine; Butanohydrazide #; EINECS 222-579-0; N-butanoyl-hydrazine; butryic acid hydrazide; ACMC-1AEKP; AC1L2SBF; AC1Q5PVE; SCHEMBL924945; Mr-I-33; ARONIS010643; SCHEMBL11029887; CTK3J2024; DTXSID70188869; MolPort-000-152-665; BDBM233138; NSC41957; NSC24021; KS-000041YT; ALBB-002745; ZINC1608800; NSC-240
DMQBO3V CP EMD Serono Rockland, MA; Vertex Pharmaceuticals Boston, MA
DMQBO3V PC 86720912
DMQBO3V MW 541.6
DMQBO3V FM C25H29F2N9O3
DMQBO3V IC InChI=1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)
DMQBO3V CS C1CN(CCC1C(=O)N2CCN(CC2)C3COC3)C4=C(C=NC=C4NC(=O)C5=C6N=CC(=CN6N=C5N)F)F
DMQBO3V IK QAYHKBLKSXWOEO-UHFFFAOYSA-N
DMQBO3V IU 2-amino-6-fluoro-N-[5-fluoro-4-[4-[4-(oxetan-3-yl)piperazine-1-carbonyl]piperidin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMQBO3V DE Solid tumour/cancer
DM6J085 ID DM6J085
DM6J085 DN M6223
DM6J085 HS Phase 1
DM6J085 CP EMD Serono
DM6J085 DT Antibody
DM6J085 DE Solid tumour/cancer
DMDK4MG ID DMDK4MG
DMDK4MG DN M7583
DMDK4MG HS Phase 1
DMDK4MG SN ZAXMFSSGOARPBM-UHFFFAOYSA-N; 51123-09-2; 5-amino-n-ethyl-2-methyl-n-phenylbenzenesulfonamide; 5-Amino-N-ethyl-2-methyl-N-phenylbenzenesulphonamide; 4-AMINO TOLUENE-2-(N-ETHYL) SULFONANILIDE; 5-AMINO-N-ETHYL-O-TOLUENESULFONANILIDE; Q-200530; AMINO-4-METHYL-BENZENE-3-(N-ETHYL)-SULFANILIDE; 5-amino-N-ethyl-2-methyl-N-phenylbenzene-1-sulfonamide; NSC84161; EINECS 256-998-5; NSC 84161; AC1Q2YPH; AC1L3WX0; AC1Q6V7C; AC1Q2YP6; SCHEMBL9072675; 4-Aminotoluol-2-sulfethylanilid; Benzenesulfonamide, 3-amino-N-ethyl-6-methyl-N-phenyl-; CTK4J3696; MolPort-001-759-851
DMDK4MG CP EMD Serono Rockland, MA
DMDK4MG PC 96649
DMDK4MG MW 290.4
DMDK4MG FM C15H18N2O2S
DMDK4MG IC InChI=1S/C15H18N2O2S/c1-3-17(14-7-5-4-6-8-14)20(18,19)15-11-13(16)10-9-12(15)2/h4-11H,3,16H2,1-2H3
DMDK4MG CS CCN(C1=CC=CC=C1)S(=O)(=O)C2=C(C=CC(=C2)N)C
DMDK4MG IK ZAXMFSSGOARPBM-UHFFFAOYSA-N
DMDK4MG IU 5-amino-N-ethyl-2-methyl-N-phenylbenzenesulfonamide
DMDK4MG CA CAS 51123-09-2
DMDK4MG DE Haematological malignancy
DM132EG ID DM132EG
DM132EG DN M802
DM132EG HS Phase 1
DM132EG DT Antibody
DM132EG DE Solid tumour/cancer
DMZ9NVP ID DMZ9NVP
DMZ9NVP DN M8891
DMZ9NVP HS Phase 1
DMZ9NVP CP EMD Serono Rockland, MA
DMZ9NVP DE Solid tumour/cancer
DMZUM67 ID DMZUM67
DMZUM67 DN M9241
DMZUM67 HS Phase 1
DMZUM67 SN NHS-IL12
DMZUM67 CP EMD Serono
DMZUM67 DE Pancreatic cancer
DM59TI2 ID DM59TI2
DM59TI2 DN M9831
DM59TI2 HS Phase 1
DM59TI2 SN 2-Methyl-1,3-benzothiazole-5-carboxylic acid; 24851-69-2; 2-Methylbenzo[d]thiazole-5-carboxylic acid; 2-Methyl-benzothiazole-5-carboxylic acid; 2-methyl-1,3-benzothiazole-5-carboxylic acid; 5-Benzothiazolecarboxylic acid, 2-methyl-; 2-methylbenzothiazole-5-carboxylic acid; SMR000015267; MLS000030206; AC1LDLFR; AC1Q2PD7; SCHEMBL1105986; cid_649953; CHEMBL1480093; CTK0J4554; KS-00000IVD; BDBM87603; DTXSID50349491; MolPort-002-499-021; TVUFPZOJUJGDDD-UHFFFAOYSA-N; HMS2396B08; ZINC873707; ZX-CM001754; ZX-AL001070; ANW-56675; AKOS000320290; FCH1781098; CS-W019372; MCULE-8154234969; FS
DM59TI2 CP EMD Serono Rockland, MA
DM59TI2 PC 649953
DM59TI2 MW 193.22
DM59TI2 FM C9H7NO2S
DM59TI2 IC InChI=1S/C9H7NO2S/c1-5-10-7-4-6(9(11)12)2-3-8(7)13-5/h2-4H,1H3,(H,11,12)
DM59TI2 CS CC1=NC2=C(S1)C=CC(=C2)C(=O)O
DM59TI2 IK TVUFPZOJUJGDDD-UHFFFAOYSA-N
DM59TI2 IU 2-methyl-1,3-benzothiazole-5-carboxylic acid
DM59TI2 CA CAS 24851-69-2
DM59TI2 DE Solid tumour/cancer
DM0HKU7 ID DM0HKU7
DM0HKU7 DN Macozinone
DM0HKU7 HS Phase 1
DM0HKU7 SN PBTZ169; 1377239-83-2; PBTZ-169; 2-(4-(cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one; UNII-A3M1353L40; A3M1353L40; 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one; 4H-1,3-Benzothiazin-4-one, 2-(4-(cyclohexylmethyl)-1-piperazinyl)-8-nitro-6-(trifluoromethyl)-; 4H-1,3-Benzothiazin-4-one, 2-[4-(cyclohexylmethyl)-1-piperazinyl]-8-nitro-6-(trifluoromethyl)-; Macozinone [INN]; SCHEMBL6128230; CHEMBL3330226; BTZ-169; PBTZ 169;PBTZ-169; BCP18094; EX-A1013; PBTZ-169;PBTZ 169;Macozinone; BDBM50515570; MFCD28902203; s6549; AKOS030526001; ZINC141433347; CS-5777; DB14821; SB19755; YH65042; BS-15317; HY-12903; DS-015880; 2-(4-(Cyclohexylmethyl)piperazin-1-yl)-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one
DM0HKU7 DT Small molecular drug
DM0HKU7 PC 57331386
DM0HKU7 MW 456.5
DM0HKU7 FM C20H23F3N4O3S
DM0HKU7 IC InChI=1S/C20H23F3N4O3S/c21-20(22,23)14-10-15-17(16(11-14)27(29)30)31-19(24-18(15)28)26-8-6-25(7-9-26)12-13-4-2-1-3-5-13/h10-11,13H,1-9,12H2
DM0HKU7 CS C1CCC(CC1)CN2CCN(CC2)C3=NC(=O)C4=C(S3)C(=CC(=C4)C(F)(F)F)[N+](=O)[O-]
DM0HKU7 IK BJDZBXGJNBMCAV-UHFFFAOYSA-N
DM0HKU7 IU 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one
DM0HKU7 CA CAS 1377239-83-2
DM0HKU7 DE Mycobacterium infection
DM9F15C ID DM9F15C
DM9F15C DN MAU868
DM9F15C HS Phase 1
DM9F15C CP Amplyx Pharmaceuticals
DM9F15C DT Antibody
DM9F15C DE Epstein barr virus infection
DMMP7XG ID DMMP7XG
DMMP7XG DN MAXY-4
DMMP7XG HS Phase 1
DMMP7XG SN CTLA4-Ig proteins (rheumatoid arthritis), Maxygen
DMMP7XG CP Maxygen Inc
DMMP7XG DE Autoimmune diabetes
DMSZ8HT ID DMSZ8HT
DMSZ8HT DN MazF gene therapy
DMSZ8HT HS Phase 1
DMSZ8HT SN MazF gene therapy (HIV)
DMSZ8HT CP Takara bio
DMSZ8HT DE Human immunodeficiency virus-1 infection
DMLA1QD ID DMLA1QD
DMLA1QD DN MB-101
DMLA1QD HS Phase 1
DMLA1QD CP Mustang Bio New York, NY
DMLA1QD DE Recurrent glioblastoma
DMS0P5O ID DMS0P5O
DMS0P5O DN MB-103
DMS0P5O HS Phase 1
DMS0P5O CP Mustang Bio
DMS0P5O DT CAR T Cell Therapy
DMS0P5O DE Glioblastoma multiforme
DMRP4BM ID DMRP4BM
DMRP4BM DN MB-104
DMRP4BM HS Phase 1
DMRP4BM CP Mustang Bio
DMRP4BM DT CAR T Cell Therapy
DMRP4BM DE Multiple myeloma
DMVGTP6 ID DMVGTP6
DMVGTP6 DN MB-105
DMVGTP6 HS Phase 1
DMVGTP6 CP Mustang Bio
DMVGTP6 DT CAR T Cell Therapy
DMVGTP6 DE Prostate cancer
DMPE0KD ID DMPE0KD
DMPE0KD DN MB-110
DMPE0KD HS Phase 1
DMPE0KD SN DBPR-110; UNII-78GIB3SHQQ; 78GIB3SHQQ; 1310694-75-7; CHEMBL4468585; DBPR110; DBPR 110; SCHEMBL12547715; BDBM50522267; SB18773; Cyclopropanecarboxamide, N,N'-((1,1'-biphenyl)-4,4'-diylbis(5,2-thiazolediyl-(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethanediyl)))bis-; Q27266669; N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenyl-acetyl]pyrrolidin-2-yl]thiazol-5-yl]phenyl]phenyl]thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenyl-ethyl]cyclopropanecarboxamide; N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]phenyl]phenyl]-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
DMPE0KD CP Microbio
DMPE0KD DT Small molecular drug
DMPE0KD PC 53247390
DMPE0KD MW 861.1
DMPE0KD FM C50H48N6O4S2
DMPE0KD IC InChI=1S/C50H48N6O4S2/c57-45(37-23-24-37)53-43(35-9-3-1-4-10-35)49(59)55-27-7-13-39(55)47-51-29-41(61-47)33-19-15-31(16-20-33)32-17-21-34(22-18-32)42-30-52-48(62-42)40-14-8-28-56(40)50(60)44(36-11-5-2-6-12-36)54-46(58)38-25-26-38/h1-6,9-12,15-22,29-30,37-40,43-44H,7-8,13-14,23-28H2,(H,53,57)(H,54,58)/t39-,40-,43+,44+/m0/s1
DMPE0KD CS C1C[C@H](N(C1)C(=O)[C@@H](C2=CC=CC=C2)NC(=O)C3CC3)C4=NC=C(S4)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CN=C(S7)[C@@H]8CCCN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)C1CC1
DMPE0KD IK FZCLQOXUWMCXCV-XCIZVNRNSA-N
DMPE0KD IU N-[(1R)-2-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2R)-2-(cyclopropanecarbonylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1,3-thiazol-5-yl]phenyl]phenyl]-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]cyclopropanecarboxamide
DMPE0KD CA CAS 1310694-75-7
DMPE0KD DE Hepatitis C virus infection
DM85AXS ID DM85AXS
DM85AXS DN MBS301
DM85AXS HS Phase 1
DM85AXS CP Beijing Mabworks Biotech
DM85AXS DT Antibody
DM85AXS DE Solid tumour/cancer
DMTXIZ1 ID DMTXIZ1
DMTXIZ1 DN MBX-700
DMTXIZ1 HS Phase 1
DMTXIZ1 CP Microbiotix
DMTXIZ1 DE Hepatitis C virus infection
DMFIS4D ID DMFIS4D
DMFIS4D DN MCD-386
DMFIS4D HS Phase 1
DMFIS4D SN CDD-0102; CDD-0262; CDD-0264; CDD-102; MCD-386 Forte; MCD-386 Transderm; MCD-386CR; MCD-386 Forte/Transderm; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), Cognitive Pharmaceuticals; Tetrahydropyrimidine muscarinic M1 agonists (Alzeimer's disease), University of Toledo; Tetrahydropyrimidine muscarinicM1 agonists (Alzheimer's disease), Mithridion; MCD-386 (oral controlled release, CNS disorders), Mithridion; MCD-386 (high dose transdermal, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (high dose, Alzheimer's disease/schizophrenia), Mithridion; MCD-386 (transdermal, Alzheimer's disease/schizophrenia), Mithridion
DMFIS4D CP Mithridion Inc; University of Toledo
DMFIS4D DE Alzheimer disease
DM8CGUV ID DM8CGUV
DM8CGUV DN MCLA-145
DM8CGUV HS Phase 1
DM8CGUV CP Merus
DM8CGUV DT Antibody
DM8CGUV DE Lymphoma; Solid tumour/cancer
DMF0O3X ID DMF0O3X
DMF0O3X DN MCLA-158
DMF0O3X HS Phase 1
DMF0O3X CP Merus
DMF0O3X DT Antibody
DMF0O3X DE Solid tumour/cancer
DMW9YOJ ID DMW9YOJ
DMW9YOJ DN MCP-201
DMW9YOJ HS Phase 1
DMW9YOJ CP Mt Cook Pharma
DMW9YOJ DE Pain
DM65B7G ID DM65B7G
DM65B7G DN MCP-202
DM65B7G HS Phase 1
DM65B7G SN Delta receptor agonist (overactive bladder, oral), Mt Cook Pharma
DM65B7G CP Mt Cook Pharma
DM65B7G DE Overactive bladder
DMAESQI ID DMAESQI
DMAESQI DN MCY-M11
DMAESQI HS Phase 1
DMAESQI CP MaxCyte
DMAESQI DT CAR-PBMC Cell therapy
DMAESQI DE Ovarian cancer; Peritoneal cancer; Fallopian tube cancer; Peritoneal mesothelioma
DM1DISM ID DM1DISM
DM1DISM DN MDAM (y-methylene-10-deazaaminopterin)
DM1DISM HS Phase 1
DM1DISM CP BioNumerik Pharmaceuticals
DM1DISM DE Solid tumour/cancer
DMAQ24G ID DMAQ24G
DMAQ24G DN MDCO-216
DMAQ24G HS Phase 1
DMAQ24G CP The Medicines Company
DMAQ24G DE Arteriosclerosis; Acute coronary syndrome
DMC60S8 ID DMC60S8
DMC60S8 DN MDL-27531
DMC60S8 HS Phase 1
DMC60S8 SN 4-Methyl-5-(methylsulfonyl)-3-phenyl-1,2,4-triazole
DMC60S8 DT Small molecular drug
DMC60S8 PC 164013
DMC60S8 MW 237.28
DMC60S8 FM C10H11N3O2S
DMC60S8 IC InChI=1S/C10H11N3O2S/c1-13-9(8-6-4-3-5-7-8)11-12-10(13)16(2,14)15/h3-7H,1-2H3
DMC60S8 CS CN1C(=NN=C1S(=O)(=O)C)C2=CC=CC=C2
DMC60S8 IK DPGDRICHXKQXEN-UHFFFAOYSA-N
DMC60S8 IU 4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole
DMC60S8 CA CAS 116850-44-3
DMC60S8 DE Epilepsy
DML5FX2 ID DML5FX2
DML5FX2 DN MDX-018
DML5FX2 HS Phase 1
DML5FX2 SN HuMax-IL8; HuMax-Inflam; Anti-inflammatory antibody, Medarex/Genmab; Anti-inflammatory therapeutic, Genmab/Medarex
DML5FX2 CP Genmab A/S
DML5FX2 DE Autoimmune diabetes; Solid tumour/cancer
DM0RIQF ID DM0RIQF
DM0RIQF DN MDX-1203
DM0RIQF HS Phase 1
DM0RIQF SN Alkylating agent-antibody conjugate (cancer), Medarex
DM0RIQF CP Medarex Inc
DM0RIQF DT Antibody
DM0RIQF DE Solid tumour/cancer
DM3402P ID DM3402P
DM3402P DN MDX-1411
DM3402P HS Phase 1
DM3402P CP Medarex Inc
DM3402P DT Antibody
DM3402P DE Solid tumour/cancer
DMEMQ5J ID DMEMQ5J
DMEMQ5J DN ME-1071
DMEMQ5J HS Phase 1
DMEMQ5J SN CP-3242; MBL inhibitor (intravenous, bacterial infection), Meiji Seika Kaisha; Metallo-beta-lactamase inhibitor (intravenous, bacterial infection), Meiji Seika Kaisha
DMEMQ5J CP Meiji Seika Kaisha Ltd
DMEMQ5J PC 16064853
DMEMQ5J MW 216.14
DMEMQ5J FM C8H10Na2O4
DMEMQ5J IC InChI=1S/C8H12O4.2Na/c1-3-5(7(9)10)6(4-2)8(11)12;;/h3-4H2,1-2H3,(H,9,10)(H,11,12);;/q;2*+1/p-2/b6-5-;;
DMEMQ5J CS CC/C(=C(\\CC)/C(=O)[O-])/C(=O)[O-].[Na+].[Na+]
DMEMQ5J IK GLJFFZOATODZQQ-XNOMRPDFSA-L
DMEMQ5J IU disodium;(Z)-2,3-diethylbut-2-enedioate
DMEMQ5J DE Bacterial infection
DM39PSZ ID DM39PSZ
DM39PSZ DN ME1100
DM39PSZ HS Phase 1
DM39PSZ SN Arbekacin inhalation
DM39PSZ CP Meiji seika pharma
DM39PSZ DE Bacterial pneumonia
DMFNYQ9 ID DMFNYQ9
DMFNYQ9 DN ME-401
DMFNYQ9 HS Phase 1
DMFNYQ9 CP MEI Pharma San Diego,CA
DMFNYQ9 DE Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Lymphoma
DMYVBU6 ID DMYVBU6
DMYVBU6 DN MEDI0562
DMYVBU6 HS Phase 1
DMYVBU6 CP MedImmune Gaithersburg, MD
DMYVBU6 DE Solid tumour/cancer
DMPLFBV ID DMPLFBV
DMPLFBV DN MEDI0680
DMPLFBV HS Phase 1
DMPLFBV CP Medimmune
DMPLFBV DT Monoclonal antibody
DMPLFBV DE Solid tumour/cancer
DMD9OVI ID DMD9OVI
DMD9OVI DN MEDI1191
DMD9OVI HS Phase 1
DMD9OVI CP AstraZeneca; Moderna Therapeutics
DMD9OVI DT mRNA therapy
DMD9OVI DE Solid tumour/cancer
DMQDBSU ID DMQDBSU
DMQDBSU DN MEDI1341
DMQDBSU HS Phase 1
DMQDBSU CP MedImmune Gaithersburg, MD
DMQDBSU DE Parkinson disease
DMX0DUH ID DMX0DUH
DMX0DUH DN MEDI2228
DMX0DUH HS Phase 1
DMX0DUH CP AstraZeneca
DMX0DUH DT Antibody drug conjugate
DMX0DUH DE Multiple myeloma
DMCMYPX ID DMCMYPX
DMCMYPX DN MEDI-2338
DMCMYPX HS Phase 1
DMCMYPX CP MedImmune
DMCMYPX DE Chronic obstructive pulmonary disease
DM0H5JD ID DM0H5JD
DM0H5JD DN MEDI3617
DM0H5JD HS Phase 1
DM0H5JD CP Astrazeneca; medimmune
DM0H5JD DT Antibody
DM0H5JD DE Solid tumour/cancer; Ovarian cancer
DMBI4EN ID DMBI4EN
DMBI4EN DN MEDI4212
DMBI4EN HS Phase 1
DMBI4EN CP AstraZeneca
DMBI4EN DE Asthma
DMNI60O ID DMNI60O
DMNI60O DN MEDI4276
DMNI60O HS Phase 1
DMNI60O CP MedImmune Gaithersburg, MD
DMNI60O DE Solid tumour/cancer
DME7BMT ID DME7BMT
DME7BMT DN MEDI4920
DME7BMT HS Phase 1
DME7BMT DE Sjogren syndrome; Rheumatoid arthritis
DM3IJQ5 ID DM3IJQ5
DM3IJQ5 DN MEDI5117
DM3IJQ5 HS Phase 1
DM3IJQ5 CP AstraZeneca
DM3IJQ5 DE Rheumatoid arthritis
DM3WP70 ID DM3WP70
DM3WP70 DN MEDI-547
DM3WP70 HS Phase 1
DM3WP70 SN MedImmune, MedImmune/AstraZeneca
DM3WP70 CP AstraZeneca
DM3WP70 DT Antibody
DM3WP70 DE Solid tumour/cancer
DM6ADMG ID DM6ADMG
DM6ADMG DN MEDI-557
DM6ADMG HS Phase 1
DM6ADMG CP AstraZeneca
DM6ADMG DT Antibody
DM6ADMG DE Respiratory syncytial virus infection
DMFWPLQ ID DMFWPLQ
DMFWPLQ DN MEDI-565
DMFWPLQ HS Phase 1
DMFWPLQ CP MedImmune
DMFWPLQ DT Monoclonal antibody
DMFWPLQ DE Gastrointestinal cancer
DMCJFLS ID DMCJFLS
DMCJFLS DN MEDI-570
DMCJFLS HS Phase 1
DMCJFLS CP AstraZeneca; MedImmune
DMCJFLS DE Systemic lupus erythematosus
DMNL8MO ID DMNL8MO
DMNL8MO DN MEDI-573
DMNL8MO HS Phase 1
DMNL8MO CP MedImmune
DMNL8MO DE Solid tumour/cancer
DMJ1E24 ID DMJ1E24
DMJ1E24 DN MEDI5752
DMJ1E24 HS Phase 1
DMJ1E24 CP AstraZeneca
DMJ1E24 DT Antibody
DMJ1E24 DE Solid tumour/cancer; Non-small cell lung cancer
DMPW21Z ID DMPW21Z
DMPW21Z DN MEDI-578
DMPW21Z HS Phase 1
DMPW21Z DE Pain
DM1YSMD ID DM1YSMD
DM1YSMD DN MEDI6383
DM1YSMD HS Phase 1
DM1YSMD DT Antibody
DM1YSMD DE Solid tumour/cancer
DM8BXDI ID DM8BXDI
DM8BXDI DN MEDI7814
DM8BXDI HS Phase 1
DM8BXDI CP AstraZeneca
DM8BXDI DE Chronic obstructive pulmonary disease
DM0J7UR ID DM0J7UR
DM0J7UR DN MEDI9197
DM0J7UR HS Phase 1
DM0J7UR SN RRTPWQXEERTRRK-UHFFFAOYSA-N; UNII-16598XQ2BT; 16598XQ2BT; 1359993-59-1; N-(4-((4-Amino-2-butyl-1H-imidazo(4,5-C)quinolin-1-yl)oxy)butyl)octadecanamide; N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide; SCHEMBL671176; MEDI-9197; AKOS032946368; Octadecanamide, N-(4-((4-amino-2-butyl-1H-imidazo(4,5-C)quinolin-1-yl)oxy)butyl)-
DM0J7UR CP MedImmune Gaithersburg, MD
DM0J7UR PC 56833311
DM0J7UR MW 593.9
DM0J7UR FM C36H59N5O2
DM0J7UR IC InChI=1S/C36H59N5O2/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-18-19-27-33(42)38-28-22-23-29-43-41-32(26-6-4-2)40-34-35(41)30-24-20-21-25-31(30)39-36(34)37/h20-21,24-25H,3-19,22-23,26-29H2,1-2H3,(H2,37,39)(H,38,42)
DM0J7UR CS CCCCCCCCCCCCCCCCCC(=O)NCCCCON1C(=NC2=C1C3=CC=CC=C3N=C2N)CCCC
DM0J7UR IK RRTPWQXEERTRRK-UHFFFAOYSA-N
DM0J7UR IU N-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide
DM0J7UR CA CAS 1359993-59-1
DM0J7UR DE Solid tumour/cancer
DM1ALHT ID DM1ALHT
DM1ALHT DN MEDl-551
DM1ALHT HS Phase 1
DM1ALHT CP Astrazeneca; medimmune
DM1ALHT DT Antibody
DM1ALHT DE Scleroderma
DMA1KQV ID DMA1KQV
DMA1KQV DN MEM-1414
DMA1KQV HS Phase 1
DMA1KQV SN R-1533; PDE 4 inhibitor (Alzheimer's), Memory; PDE 4 inhibitor (Alzheimer's), Memory/Roche
DMA1KQV CP Memory Pharmaceuticals Corp
DMA1KQV DE Mood disorder
DME18UM ID DME18UM
DME18UM DN MER-102
DME18UM HS Phase 1
DME18UM CP Merrion Pharmaceuticals
DME18UM DE Thrombosis
DMQSJ9T ID DMQSJ9T
DMQSJ9T DN Meso-CART
DMQSJ9T HS Phase 1
DMQSJ9T CP Shanghai GeneChem Co., Ltd.
DMQSJ9T DT CAR T Cell Therapy
DMQSJ9T DE Pancreatic cancer
DMHXA79 ID DMHXA79
DMHXA79 DN Mesothelin-targeted T cells
DMHXA79 HS Phase 1
DMHXA79 CP Memorial Sloan Kettering Cancer Center
DMHXA79 DT CAR T Cell Therapy
DMHXA79 DE Breast cancer
DMTQ4PN ID DMTQ4PN
DMTQ4PN DN Metastat
DMTQ4PN HS Phase 1
DMTQ4PN DT Small molecular drug
DMTQ4PN PC 54678924
DMTQ4PN MW 371.3
DMTQ4PN FM C19H17NO7
DMTQ4PN IC InChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21,23,25,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1
DMTQ4PN CS C1[C@@H]2CC3=C(C(=CC=C3)O)C(=C2C(=O)[C@]4([C@@H]1CC(=O)C(=C4O)C(=O)N)O)O
DMTQ4PN IK NBRQRXRBIHVLGI-OWXODZSWSA-N
DMTQ4PN IU (4aS,5aR,12aR)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
DMTQ4PN CA CAS 15866-90-7
DMTQ4PN DE Acne vulgaris
DMQE4IX ID DMQE4IX
DMQE4IX DN MG-1102
DMQE4IX HS Phase 1
DMQE4IX DE Solid tumour/cancer
DM2PVLH ID DM2PVLH
DM2PVLH DN MGA271
DM2PVLH HS Phase 1
DM2PVLH CP MacroGenics
DM2PVLH DE Metastatic cancer
DMQB4VN ID DMQB4VN
DMQB4VN DN MGD006
DMQB4VN HS Phase 1
DMQB4VN CP MacroGenics
DMQB4VN DT Monoclonal antibody
DMQB4VN DE Acute myeloid lymphoma; Acute lymphoblastic leukaemia
DME4B8I ID DME4B8I
DME4B8I DN MGD009
DME4B8I HS Phase 1
DME4B8I CP MacroGenics Rockville, MD
DME4B8I DE Solid tumour/cancer
DMA368V ID DMA368V
DMA368V DN MGD010
DMA368V HS Phase 1
DMA368V CP MacroGenicsRockville, MDTakeda Pharmaceuticals
DMA368V DE Autoimmune disease
DMZN5QX ID DMZN5QX
DMZN5QX DN MGD014
DMZN5QX HS Phase 1
DMZN5QX CP MacroGenics
DMZN5QX DT Antibody
DMZN5QX DE Human immunodeficiency virus-1 infection
DM2BYWI ID DM2BYWI
DM2BYWI DN MGD019
DM2BYWI HS Phase 1
DM2BYWI CP MacroGenics
DM2BYWI DT Antibody
DM2BYWI DE Solid tumour/cancer
DMTS5VF ID DMTS5VF
DMTS5VF DN MGN-1706
DMTS5VF HS Phase 1
DMTS5VF DE Solid tumour/cancer
DMU9VDS ID DMU9VDS
DMU9VDS DN Mibefradil
DMU9VDS HS Phase 1
DMU9VDS SN Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
DMU9VDS CP Tau therapeutics; cavion
DMU9VDS DT Small molecular drug
DMU9VDS PC 60663
DMU9VDS MW 495.6
DMU9VDS FM C29H38FN3O3
DMU9VDS IC InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
DMU9VDS CS CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
DMU9VDS IK HBNPJJILLOYFJU-VMPREFPWSA-N
DMU9VDS IU [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
DMU9VDS CA CAS 116644-53-2
DMU9VDS CB CHEBI:6920
DMU9VDS DE Ovarian cancer; Glioblastoma multiforme
DMTUVCG ID DMTUVCG
DMTUVCG DN MIK665
DMTUVCG HS Phase 1
DMTUVCG SN 1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; MIK665; S-64315; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5
DMTUVCG CP Novartis; Servier
DMTUVCG DT Small molecular drug
DMTUVCG PC 118157243
DMTUVCG MW 875.4
DMTUVCG FM C47H44ClFN6O6S
DMTUVCG IC InChI=1S/C47H44ClFN6O6S/c1-29-34(16-17-38(42(29)48)59-25-24-55-22-20-54(2)21-23-55)40-41-45(51-28-52-46(41)62-43(40)30-12-14-32(49)15-13-30)61-39(47(56)57)26-31-8-4-6-10-36(31)60-27-33-18-19-50-44(53-33)35-9-5-7-11-37(35)58-3/h4-19,28,39H,20-27H2,1-3H3,(H,56,57)/t39-/m1/s1
DMTUVCG CS CC1=C(C=CC(=C1Cl)OCCN2CCN(CC2)C)C3=C(SC4=NC=NC(=C34)O[C@H](CC5=CC=CC=C5OCC6=NC(=NC=C6)C7=CC=CC=C7OC)C(=O)O)C8=CC=C(C=C8)F
DMTUVCG IK PKYIMGFMRFVOMB-LDLOPFEMSA-N
DMTUVCG IU (2R)-2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid
DMTUVCG DE Acute myeloid leukaemia
DMDER9S ID DMDER9S
DMDER9S DN Minnelide
DMDER9S HS Phase 1
DMDER9S SN UNII-1CIV2UMO40; 1CIV2UMO40; 14-O-Phosphonooxymethyltriptolide disodium salt; CHEMBL3740500; Triptolide O-Methyl Phosphate Disodium Salt; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-C)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-((phosphonooxy)methoxy)-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-; 1254702-87-8
DMDER9S CP Minneamrita Therapeutics Tampa, FL
DMDER9S PC 46203139
DMDER9S MW 514.4
DMDER9S FM C21H25Na2O10P
DMDER9S IC InChI=1S/C21H27O10P.2Na/c1-9(2)19-14(30-19)15-21(31-15)18(3)5-4-10-11(7-26-16(10)22)12(18)6-13-20(21,29-13)17(19)27-8-28-32(23,24)25;;/h9,12-15,17H,4-8H2,1-3H3,(H2,23,24,25);;/q;2*+1/p-2/t12-,13-,14-,15-,17+,18-,19-,20+,21+;;/m0../s1
DMDER9S CS CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2OCOP(=O)([O-])[O-])O7)COC6=O)C.[Na+].[Na+]
DMDER9S IK ZHBJMVNZRZUQEP-KIKMAQITSA-L
DMDER9S IU disodium;[(1S,2S,4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl]oxymethyl phosphate
DMDER9S CA CAS 1254702-87-8
DMDER9S DE Solid tumour/cancer
DM5VEN9 ID DM5VEN9
DM5VEN9 DN Minnelide 001
DM5VEN9 HS Phase 1
DM5VEN9 CP Minneamrita therapeutics
DM5VEN9 DE Gastrointestinal cancer; Gastric adenocarcinoma
DMCPF90 ID DMCPF90
DMCPF90 DN Mivebresib
DMCPF90 HS Phase 1
DMCPF90 SN ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815
DMCPF90 CP AbbVieNorth Chicago, IL
DMCPF90 PC 71600087
DMCPF90 MW 459.5
DMCPF90 FM C22H19F2N3O4S
DMCPF90 IC InChI=1S/C22H19F2N3O4S/c1-3-32(29,30)26-14-5-7-19(31-20-6-4-13(23)10-18(20)24)16(11-14)17-12-27(2)22(28)21-15(17)8-9-25-21/h4-12,25-26H,3H2,1-2H3
DMCPF90 CS CCS(=O)(=O)NC1=CC(=C(C=C1)OC2=C(C=C(C=C2)F)F)C3=CN(C(=O)C4=C3C=CN4)C
DMCPF90 IK RDONXGFGWSSFMY-UHFFFAOYSA-N
DMCPF90 IU N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide
DMCPF90 CA CAS 1445993-26-9
DMCPF90 DE Acute myeloid leukaemia; Multiple myeloma; Solid tumour/cancer
DMFLP21 ID DMFLP21
DMFLP21 DN MK 8719
DMFLP21 HS Phase 1
DMFLP21 CP Alectos Therapeutics Vancouver, Canada Merck Whitehouse Station, NJ
DMFLP21 DE Progressive supranuclear palsy
DM2TAUR ID DM2TAUR
DM2TAUR DN MK-0731
DM2TAUR HS Phase 1
DM2TAUR SN C-4251; MK-731
DM2TAUR CP Merck & Co Inc
DM2TAUR DT Small molecular drug
DM2TAUR PC 11655511
DM2TAUR MW 459.5
DM2TAUR FM C25H28F3N3O2
DM2TAUR IC InChI=1S/C25H28F3N3O2/c1-29-11-10-23(22(28)15-29)30(2)24(33)31-14-17(20-12-19(26)8-9-21(20)27)13-25(31,16-32)18-6-4-3-5-7-18/h3-9,12-13,22-23,32H,10-11,14-16H2,1-2H3/t22-,23+,25-/m1/s1
DM2TAUR CS CN1CC[C@@H]([C@@H](C1)F)N(C)C(=O)N2CC(=C[C@@]2(CO)C3=CC=CC=C3)C4=C(C=CC(=C4)F)F
DM2TAUR IK MYBGWENAVMIGMM-GIFXNVAJSA-N
DM2TAUR IU (5S)-3-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-5-(hydroxymethyl)-N-methyl-5-phenyl-2H-pyrrole-1-carboxamide
DM2TAUR CA CAS 845256-65-7
DM2TAUR DE Solid tumour/cancer
DMHS79I ID DMHS79I
DMHS79I DN MK-1092
DMHS79I HS Phase 1
DMHS79I CP Merck
DMHS79I DE Type-1 diabetes
DME1ZAH ID DME1ZAH
DME1ZAH DN MK-1496
DME1ZAH HS Phase 1
DME1ZAH CP Merck
DME1ZAH PC 67313626
DME1ZAH MW 236.35
DME1ZAH FM C14H24N2O
DME1ZAH IC InChI=1S/C14H24N2O/c1-10(15)11-5-7-12(8-6-11)13(17)9-16-14(2,3)4/h5-8,10,13,16-17H,9,15H2,1-4H3/t10-,13+/m0/s1
DME1ZAH CS C[C@@H](C1=CC=C(C=C1)[C@@H](CNC(C)(C)C)O)N
DME1ZAH IK KUHBBYPXWKYKKR-GXFFZTMASA-N
DME1ZAH IU (1S)-1-[4-[(1S)-1-aminoethyl]phenyl]-2-(tert-butylamino)ethanol
DME1ZAH CA CAS 1037254-47-9
DME1ZAH DE Solid tumour/cancer
DMKNH8B ID DMKNH8B
DMKNH8B DN MK-2118
DMKNH8B HS Phase 1
DMKNH8B CP Merck
DMKNH8B DT Small molecular drug
DMKNH8B DE Lymphoma; Solid tumour/cancer
DMUHOJP ID DMUHOJP
DMUHOJP DN MK-2637
DMUHOJP HS Phase 1
DMUHOJP CP Merck
DMUHOJP DE Schizophrenia
DM5EFPS ID DM5EFPS
DM5EFPS DN MK-3134
DM5EFPS HS Phase 1
DM5EFPS CP Merck
DM5EFPS PC 11973780
DM5EFPS MW 457.5
DM5EFPS FM C25H26F3N3O2
DM5EFPS IC InChI=1S/C25H26F3N3O2/c1-16-29-22-7-3-6-21(25(26,27)28)23(22)24(32)31(16)18-8-10-19(11-9-18)33-20-12-14-30(15-13-20)17-4-2-5-17/h3,6-11,17,20H,2,4-5,12-15H2,1H3
DM5EFPS CS CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5)C(F)(F)F
DM5EFPS IK ZWUFGBNOUKQGBR-UHFFFAOYSA-N
DM5EFPS IU 3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-methyl-5-(trifluoromethyl)quinazolin-4-one
DM5EFPS CA CAS 862310-66-5
DM5EFPS DE Dementia
DMG0Q27 ID DMG0Q27
DMG0Q27 DN MK-3281
DMG0Q27 HS Phase 1
DMG0Q27 SN MK-3281; UNII-3593C180JO; CHEMBL1233524; 3593C180JO; (7r)-14-Cyclohexyl-7-{[2-(Dimethylamino)ethyl](Methyl)amino}-7,8-Dihydro-6h-Indolo[1,2-E][1,5]benzoxazocine-11-Carboxylic Acid; MK3281; cyclohexyl-[2-dimethylaminoethyl(methyl)amino][ ]carboxylic acid; SCHEMBL3073622; BDBM50335314; 1187645-92-6
DMG0Q27 CP Merck
DMG0Q27 DT Small molecular drug
DMG0Q27 PC 49800096
DMG0Q27 MW 475.6
DMG0Q27 FM C29H37N3O3
DMG0Q27 IC InChI=1S/C29H37N3O3/c1-30(2)15-16-31(3)22-18-32-25-17-21(29(33)34)13-14-23(25)27(20-9-5-4-6-10-20)28(32)24-11-7-8-12-26(24)35-19-22/h7-8,11-14,17,20,22H,4-6,9-10,15-16,18-19H2,1-3H3,(H,33,34)/t22-/m1/s1
DMG0Q27 CS CN(C)CCN(C)[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)C(=C2C4=CC=CC=C4OC1)C5CCCCC5
DMG0Q27 IK YQUCBFIQSJVCOR-JOCHJYFZSA-N
DMG0Q27 IU (10R)-19-cyclohexyl-10-[2-(dimethylamino)ethyl-methylamino]-8-oxa-12-azatetracyclo[10.7.0.02,7.013,18]nonadeca-1(19),2,4,6,13(18),14,16-heptaene-15-carboxylic acid
DMG0Q27 CA CAS 886041-60-7
DMG0Q27 DE Hepatitis C virus infection
DMW2O5D ID DMW2O5D
DMW2O5D DN MK-3328
DMW2O5D HS Phase 1
DMW2O5D SN UNII-4I12ES557C; MK-3328 F-18; 4I12ES557C; 1201324-21-1; (18F)MK-3328; [18F]MK-3328; CHEMBL2203396; SCHEMBL12268073
DMW2O5D CP Merck
DMW2O5D DT Small molecular drug
DMW2O5D PC 44555286
DMW2O5D MW 268.25
DMW2O5D FM C14H9FN4O
DMW2O5D IC InChI=1S/C14H9FN4O/c1-19-5-4-8-6-9(7-16-12(8)19)13-17-10-2-3-11(15)18-14(10)20-13/h2-7H,1H3
DMW2O5D CS CN1C=CC2=CC(=CN=C21)C3=NC4=C(O3)N=C(C=C4)F
DMW2O5D IK WYQHKOHCTMNFAU-UHFFFAOYSA-N
DMW2O5D IU 5-fluoro-2-(1-methylpyrrolo[2,3-b]pyridin-5-yl)-[1,3]oxazolo[5,4-b]pyridine
DMW2O5D CA CAS 1201323-97-8
DMW2O5D DE Alzheimer disease
DML5V76 ID DML5V76
DML5V76 DN MK-4166
DML5V76 HS Phase 1
DML5V76 CP Merck
DML5V76 DT Antibody
DML5V76 DE Solid tumour/cancer
DMCA1NX ID DMCA1NX
DMCA1NX DN MK-4280
DMCA1NX HS Phase 1
DMCA1NX CP Merck
DMCA1NX DT Antibody
DMCA1NX DE Solid tumour/cancer; Neoplasm
DMN40DU ID DMN40DU
DMN40DU DN MK-4621
DMN40DU HS Phase 1
DMN40DU CP Merck
DMN40DU DE Solid tumour/cancer
DMCT37W ID DMCT37W
DMCT37W DN MK-4830
DMCT37W HS Phase 1
DMCT37W CP Merck
DMCT37W DT Antibody
DMCT37W DE Solid tumour/cancer
DMFGYKS ID DMFGYKS
DMFGYKS DN MK-5108
DMFGYKS HS Phase 1
DMFGYKS SN 1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689
DMFGYKS DT Small molecular drug
DMFGYKS PC 24748204
DMFGYKS MW 461.9
DMFGYKS FM C22H21ClFN3O3S
DMFGYKS IC InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)
DMFGYKS CS C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O
DMFGYKS IK LCVIRAZGMYMNNT-UHFFFAOYSA-N
DMFGYKS IU 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid
DMFGYKS CA CAS 1010085-13-8
DMFGYKS CB CHEBI:125340
DMFGYKS DE Solid tumour/cancer
DMSA27Z ID DMSA27Z
DMSA27Z DN MK-6186
DMSA27Z HS Phase 1
DMSA27Z SN MK-6186; UNII-K3978U665M; 1034474-19-5; K3978U665M; MK 6186; SCHEMBL2878768; CHEMBL1939499; FZBAOOQVQXATRL-UHFFFAOYSA-N; ZINC73240561; DB12999; DA-16093; 3-(1-((1H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-5-chloro-1H-indazol-4-yloxy)-5-chlorobenzonitrile; FT-0726721; 3-((1-((2H-pyrazolo[3,4-b]pyridin-3-yl)methyl)-5-chloro-1H-indazol-4-yl)oxy)-5-chlorobenzonitrile; 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4- b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile
DMSA27Z CP Merck & Co Inc
DMSA27Z DT Small molecular drug
DMSA27Z PC 24988948
DMSA27Z MW 435.3
DMSA27Z FM C21H12Cl2N6O
DMSA27Z IC InChI=1S/C21H12Cl2N6O/c22-13-6-12(9-24)7-14(8-13)30-20-16-10-26-29(19(16)4-3-17(20)23)11-18-15-2-1-5-25-21(15)28-27-18/h1-8,10H,11H2,(H,25,27,28)
DMSA27Z CS C1=CC2=C(NN=C2N=C1)CN3C4=C(C=N3)C(=C(C=C4)Cl)OC5=CC(=CC(=C5)C#N)Cl
DMSA27Z IK FZBAOOQVQXATRL-UHFFFAOYSA-N
DMSA27Z IU 3-chloro-5-[5-chloro-1-(2H-pyrazolo[3,4-b]pyridin-3-ylmethyl)indazol-4-yl]oxybenzonitrile
DMSA27Z CA CAS 1034474-19-5
DMSA27Z DE Human immunodeficiency virus infection
DMZUA5C ID DMZUA5C
DMZUA5C DN MK-6302
DMZUA5C HS Phase 1
DMZUA5C SN INS-20; Pegylated GCSF, Insmed/Merck
DMZUA5C CP Insmed Inc
DMZUA5C DE Neutropenia
DMV8BI4 ID DMV8BI4
DMV8BI4 DN MK-6325
DMV8BI4 HS Phase 1
DMV8BI4 CP Merck
DMV8BI4 DT Small molecular drug
DMV8BI4 PC 121596640
DMV8BI4 MW 821
DMV8BI4 FM C42H56N6O9S
DMV8BI4 IC InChI=1S/C42H56N6O9S/c1-41(20-21-41)58(53,54)47-39(51)42-24-27(42)14-8-4-3-5-9-16-32-38(50)48-25-29(23-34(48)36(49)46-42)56-37-31(43-30-19-18-28(55-2)22-33(30)44-37)15-10-6-7-12-26-13-11-17-35(26)57-40(52)45-32/h8,14,18-19,22,26-27,29,32,34-35H,3-7,9-13,15-17,20-21,23-25H2,1-2H3,(H,45,52)(H,46,49)(H,47,51)/b14-8+/t26-,27-,29-,32+,34+,35-,42-/m1/s1
DMV8BI4 CS CC1(CC1)S(=O)(=O)NC(=O)[C@@]23C[C@H]2/C=C/CCCCC[C@H]4C(=O)N5C[C@@H](C[C@H]5C(=O)N3)OC6=NC7=C(C=CC(=C7)OC)N=C6CCCCC[C@@H]8CCC[C@H]8OC(=O)N4
DMV8BI4 IK BLFKRFGLQFYXDF-WAZRELCSSA-N
DMV8BI4 IU (3R,20R,24R,28S,34E,36S,38R,41S)-9-methoxy-N-(1-methylcyclopropyl)sulfonyl-26,40,42-trioxo-4,25-dioxa-1,6,13,27,39-pentazaheptacyclo[26.13.1.13,41.05,14.07,12.020,24.036,38]tritetraconta-5,7(12),8,10,13,34-hexaene-38-carboxamide
DMV8BI4 CA CAS 1263814-52-3
DMV8BI4 DE Hepatitis C virus infection
DMBSXZ1 ID DMBSXZ1
DMBSXZ1 DN MK-7162
DMBSXZ1 HS Phase 1
DMBSXZ1 CP Merck
DMBSXZ1 DE Solid tumour/cancer
DMLQOF1 ID DMLQOF1
DMLQOF1 DN MK-7246
DMLQOF1 HS Phase 1
DMLQOF1 SN IDDBCP261213; IDDBCP271467
DMLQOF1 CP Merck & Co Inc
DMLQOF1 DT Small molecular drug
DMLQOF1 PC 45268455
DMLQOF1 MW 416.5
DMLQOF1 FM C21H21FN2O4S
DMLQOF1 IC InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-21(25)26)17-4-2-3-5-19(17)24(20)13-15/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)/t15-/m1/s1
DMLQOF1 CS CN([C@@H]1CCC2=C(C3=CC=CC=C3N2C1)CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F
DMLQOF1 IK JTCAGRAKUAAYDY-OAHLLOKOSA-N
DMLQOF1 IU 2-[(7R)-7-[(4-fluorophenyl)sulfonyl-methylamino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]acetic acid
DMLQOF1 CA CAS 1218918-62-7
DMLQOF1 DE Respiratory disease
DMJ2Q6H ID DMJ2Q6H
DMJ2Q6H DN MK-7288
DMJ2Q6H HS Phase 1
DMJ2Q6H CP Merck
DMJ2Q6H DE Excessive daytime sleepiness
DMA1EDN ID DMA1EDN
DMA1EDN DN MK-8033
DMA1EDN HS Phase 1
DMA1EDN SN MK-8033; 1001917-37-8; UNII-350H6PBQ5Q; 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide; 350H6PBQ5Q; CHEMBL2323775; MK8033; 1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide; 1-[2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridin-9-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide
DMA1EDN CP Merck
DMA1EDN DT Small molecular drug
DMA1EDN PC 45142457
DMA1EDN MW 471.5
DMA1EDN FM C25H21N5O3S
DMA1EDN IC InChI=1S/C25H21N5O3S/c1-30-15-20(13-28-30)19-11-23-24(27-12-19)8-7-18-6-5-17(10-22(18)25(23)31)16-34(32,33)29-14-21-4-2-3-9-26-21/h2-13,15,29H,14,16H2,1H3
DMA1EDN CS CN1C=C(C=N1)C2=CC3=C(C=CC4=C(C3=O)C=C(C=C4)CS(=O)(=O)NCC5=CC=CC=N5)N=C2
DMA1EDN IK VMJFTOSOFDEKTM-UHFFFAOYSA-N
DMA1EDN IU 1-[5-(1-methylpyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-14-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide
DMA1EDN CA CAS 1001917-37-8
DMA1EDN DE Solid tumour/cancer
DMLCTI5 ID DMLCTI5
DMLCTI5 DN MK-8353
DMLCTI5 HS Phase 1
DMLCTI5 SN KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide
DMLCTI5 CP Merck Kenilworth, NJ
DMLCTI5 PC 58282870
DMLCTI5 MW 691.8
DMLCTI5 FM C37H41N9O3S
DMLCTI5 IC InChI=1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1
DMLCTI5 CS CC(C)OC1=NC=C(C=C1)C2=NNC3=C2C=C(C=C3)NC(=O)[C@@]4(CCN(C4)CC(=O)N5CCC(=CC5)C6=CC=C(C=C6)C7=NN(C=N7)C)SC
DMLCTI5 IK KPQQGHGDBBJGFA-QNGWXLTQSA-N
DMLCTI5 IU (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide
DMLCTI5 DE Solid tumour/cancer
DMHTWBL ID DMHTWBL
DMHTWBL DN MK-8504
DMHTWBL HS Phase 1
DMHTWBL CP Merck
DMHTWBL DT Small molecular drug
DMHTWBL DE Human immunodeficiency virus-1 infection
DMQHPME ID DMQHPME
DMQHPME DN MK-8583
DMQHPME HS Phase 1
DMQHPME CP Merck
DMQHPME DT Small molecular drug
DMQHPME DE Human immunodeficiency virus-1 infection
DMETIBD ID DMETIBD
DMETIBD DN MK-8719
DMETIBD HS Phase 1
DMETIBD SN 1382799-40-7; (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano[3,2-d]thiazole-6,7-diol; (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazole-6,7-diol; SCHEMBL9956073; CHEMBL4111094; GTPL10508; BDBM205424; MK8719; s8890; compound 42 [PMID: 31487175]; US9243020, 19; Q66885447; (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-ethylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol; (3AR,5S,6S,7R,7aR,E)-5-(difluoromethyl)-2-(ethylimino)hexahydro-5H-pyrano[3,2-d]thiazole-6,7-diol
DMETIBD CP Alectos
DMETIBD DT Small molecular drug
DMETIBD PC 136416849
DMETIBD MW 268.28
DMETIBD FM C9H14F2N2O3S
DMETIBD IC InChI=1S/C9H14F2N2O3S/c1-2-12-9-13-3-4(14)5(15)6(7(10)11)16-8(3)17-9/h3-8,14-15H,2H2,1H3,(H,12,13)/t3-,4-,5+,6+,8-/m1/s1
DMETIBD CS CCN=C1N[C@@H]2[C@H]([C@@H]([C@H](O[C@@H]2S1)C(F)F)O)O
DMETIBD IK UDQTXCHQKHIQMH-KYGLGHNPSA-N
DMETIBD IU (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-ethylimino-1,3a,5,6,7,7a-hexahydropyrano[3,2-d][1,3]thiazole-6,7-diol
DMETIBD DE Progressive supranuclear palsy
DMAS1RB ID DMAS1RB
DMAS1RB DN MK-8776
DMAS1RB HS Phase 1
DMAS1RB SN MK-8776 Racemate; MK-8776 S-isomer; SCH900776 (Racemate); CHEMBL1643208; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine; 891495-88-8; SCH900776 S-isomer; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; 6-BROMO-3-(1-METHYLPYRAZOL-4-YL)-5-[(3R)-PIPERIDIN-3-YL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE; BCP02883; BDBM50334854; NSC764659; AKOS026750519; MK 8776; NSC-764659; NCGC00387868-02; DA-40779; BCP0726000317; FT-0700501; FT-0771683; J3.517.083I; Q27086899; SCH 900776 (CAS:891494-64-7); 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine
DMAS1RB DT Small molecular drug
DMAS1RB PC 16224745
DMAS1RB MW 376.25
DMAS1RB FM C15H18BrN7
DMAS1RB IC InChI=1S/C15H18BrN7/c1-22-8-10(6-19-22)11-7-20-23-14(17)12(16)13(21-15(11)23)9-3-2-4-18-5-9/h6-9,18H,2-5,17H2,1H3
DMAS1RB CS CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4
DMAS1RB IK GMIZZEXBPRLVIV-UHFFFAOYSA-N
DMAS1RB IU 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine
DMAS1RB CB CHEBI:131165
DMAS1RB DE Hodgkin lymphoma
DMDB3OK ID DMDB3OK
DMDB3OK DN MLN-3126
DMDB3OK HS Phase 1
DMDB3OK SN CCR9 antagonist (oral, Crohn's disease), Millennium
DMDB3OK CP Millennium Pharmaceuticals Inc
DMDB3OK DE Sjogren syndrome
DMCVO2Y ID DMCVO2Y
DMCVO2Y DN MLN-576
DMCVO2Y HS Phase 1
DMCVO2Y SN XR-11576
DMCVO2Y CP Xenova Group plc
DMCVO2Y DE Acute lymphoblastic leukaemia
DMWK951 ID DMWK951
DMWK951 DN MLN7243
DMWK951 HS Phase 1
DMWK951 CP Millennium pharmaceuticals
DMWK951 DE Solid tumour/cancer
DMUANF3 ID DMUANF3
DMUANF3 DN MLN8054
DMUANF3 HS Phase 1
DMUANF3 SN ZZL; MLN-8054
DMUANF3 CP Millenium; Takeda
DMUANF3 TC Anticancer Agents
DMUANF3 DT Small molecular drug
DMUANF3 PC 11712649
DMUANF3 MW 476.9
DMUANF3 FM C25H15ClF2N4O2
DMUANF3 IC InChI=1S/C25H15ClF2N4O2/c26-15-6-9-17-18(10-15)23(21-19(27)2-1-3-20(21)28)29-11-14-12-30-25(32-22(14)17)31-16-7-4-13(5-8-16)24(33)34/h1-10,12H,11H2,(H,33,34)(H,30,31,32)
DMUANF3 CS C1C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)C(=N1)C4=C(C=CC=C4F)F)NC5=CC=C(C=C5)C(=O)O
DMUANF3 IK HHFBDROWDBDFBR-UHFFFAOYSA-N
DMUANF3 IU 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid
DMUANF3 CA CAS 869363-13-3
DMUANF3 CB CHEBI:91366
DMUANF3 DE Solid tumour/cancer
DMXQHZC ID DMXQHZC
DMXQHZC DN MM-151
DMXQHZC HS Phase 1
DMXQHZC CP Merrimack Pharmaceuticals
DMXQHZC DE Solid tumour/cancer
DMYSJTR ID DMYSJTR
DMYSJTR DN MM-302
DMYSJTR HS Phase 1
DMYSJTR CP Merrimack Pharmaceuticals
DMYSJTR DE Breast cancer
DMIMVEX ID DMIMVEX
DMIMVEX DN MMI-0100
DMIMVEX HS Phase 1
DMIMVEX SN Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix
DMIMVEX CP Moerae Matrix Inc
DMIMVEX DE Fibrosis; Airway inflammation
DMAQJHO ID DMAQJHO
DMAQJHO DN Monohydroxyethylrutoside
DMAQJHO HS Phase 1
DMAQJHO SN Frederine; MonoHER; VUF-5434; Mono-7-hydroxyethylrutoside
DMAQJHO CP Universiteit Maastricht
DMAQJHO DE Cardiovascular disease
DMM7TBO ID DMM7TBO
DMM7TBO DN MORAb-022
DMM7TBO HS Phase 1
DMM7TBO SN Antibody (inflammation/autoimmune disease), Morphotek
DMM7TBO CP Eisai
DMM7TBO DT Antibody
DMM7TBO DE Autoimmune diabetes; Rheumatoid arthritis
DMTUKW9 ID DMTUKW9
DMTUKW9 DN MORAb-066
DMTUKW9 HS Phase 1
DMTUKW9 SN Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek
DMTUKW9 CP Eisai
DMTUKW9 DT Antibody
DMTUKW9 DE Pancreatic cancer; Solid tumour/cancer
DMJOMD4 ID DMJOMD4
DMJOMD4 DN MP-0112
DMJOMD4 HS Phase 1
DMJOMD4 SN DARPin (age related macular degeneration), Molecular Partners/Allergan; VEGF-A specific DARPin, Molecular Partners/Allergan
DMJOMD4 CP Molecular Partners AG
DMJOMD4 PC 10464700
DMJOMD4 MW 168.15
DMJOMD4 FM C7H8N2O3
DMJOMD4 IC InChI=1S/C7H8N2O3/c1-12-6-4-2-3-5(8)7(6)9(10)11/h2-4H,8H2,1H3
DMJOMD4 CS COC1=CC=CC(=C1[N+](=O)[O-])N
DMJOMD4 IK RITQAMSEQYWFML-UHFFFAOYSA-N
DMJOMD4 IU 3-methoxy-2-nitroaniline
DMJOMD4 CA CAS 16554-47-5
DMJOMD4 DE Macular degeneration
DMQRNTG ID DMQRNTG
DMQRNTG DN MP-124
DMQRNTG HS Phase 1
DMQRNTG CP Mitsubishi Tanabe Pharma
DMQRNTG DE Ischemic stroke; Stroke
DM5VXWO ID DM5VXWO
DM5VXWO DN MP-157
DM5VXWO HS Phase 1
DM5VXWO CP Mitsubishi Tanabe Pharma Corp
DM5VXWO DE Hypertension
DME7JFM ID DME7JFM
DME7JFM DN MR1-1
DME7JFM HS Phase 1
DME7JFM SN MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX
DME7JFM CP IVAX Corp
DME7JFM DE Brain cancer
DMVNLGW ID DMVNLGW
DMVNLGW DN MR-1817
DMVNLGW HS Phase 1
DMVNLGW CP Mochida Pharmaceutical Co Ltd
DMVNLGW DE Pain
DMUVGMS ID DMUVGMS
DMUVGMS DN MRG-110
DMUVGMS HS Phase 1
DMUVGMS CP miRagen Therapeutics
DMUVGMS DT Oligonucleotide
DMUVGMS DE Heart failure
DMFTAWU ID DMFTAWU
DMFTAWU DN mRNA-2416
DMFTAWU HS Phase 1
DMFTAWU SN mRNA-OX40L
DMFTAWU CP Moderna Therapeutics
DMFTAWU DT mRNA therapy
DMFTAWU DE Lymphoma; Solid tumour/cancer; Ovarian cancer
DMUKBI2 ID DMUKBI2
DMUKBI2 DN mRNA-2752
DMUKBI2 HS Phase 1
DMUKBI2 SN mRNA-OX40L/IL-23/IL-36 gamma
DMUKBI2 CP Moderna Therapeutics
DMUKBI2 DT mRNA therapy
DMUKBI2 DE Solid tumour/cancer
DMM5N8P ID DMM5N8P
DMM5N8P DN MRX-2843
DMM5N8P HS Phase 1
DMM5N8P SN 1429882-07-4; UNC-2371A; UNII-2MT30EHI63; 2MT30EHI63; CHEMBL3326007; (1r,4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; UNC2371A; SCHEMBL14854108; SCHEMBL17175579; BDBM350861; BCP30180; BDBM50055490; MFCD28502224; ZINC299829706; CS-8117; SB17283; AS-35252; HY-101549; US9795606, B20; A16958; UNC2371;UNC-2371;UNC 2371;MRX 2843 ;MRX2843; Cyclohexanol, 4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-, trans-; trans-(1R,4R)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; trans-4-(2-((2-Cyclopropylethyl)amino)-5-(4-((4-methyl-1-piperazinyl)methyl)phenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)cyclohexanol
DMM5N8P CP Meryx
DMM5N8P DT Small molecular drug
DMM5N8P PC 89495685
DMM5N8P MW 488.7
DMM5N8P FM C29H40N6O
DMM5N8P IC InChI=1S/C29H40N6O/c1-33-14-16-34(17-15-33)19-22-4-6-23(7-5-22)27-20-35(24-8-10-25(36)11-9-24)28-26(27)18-31-29(32-28)30-13-12-21-2-3-21/h4-7,18,20-21,24-25,36H,2-3,8-17,19H2,1H3,(H,30,31,32)
DMM5N8P CS CN1CCN(CC1)CC2=CC=C(C=C2)C3=CN(C4=NC(=NC=C34)NCCC5CC5)C6CCC(CC6)O
DMM5N8P IK LBEJYFVJIPQSNX-UHFFFAOYSA-N
DMM5N8P IU 4-[2-(2-cyclopropylethylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol
DMM5N8P CA CAS 89495685
DMM5N8P DE Solid tumour/cancer
DMWKDOQ ID DMWKDOQ
DMWKDOQ DN MRX34
DMWKDOQ HS Phase 1
DMWKDOQ CP Mirna therapeutics
DMWKDOQ DE Liver cancer
DM7ER9J ID DM7ER9J
DM7ER9J DN MS-553
DM7ER9J HS Phase 1
DM7ER9J CP MingSight Pharmaceuticals
DM7ER9J DE Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DMH8VXE ID DMH8VXE
DMH8VXE DN MSB2311
DMH8VXE HS Phase 1
DMH8VXE CP MabSpace Biosciences Suzhou, China
DMH8VXE DT Monoclonal antibody
DMH8VXE DE Solid tumour/cancer; Advanced malignancy
DM6XTZL ID DM6XTZL
DM6XTZL DN MSC-1
DM6XTZL HS Phase 1
DM6XTZL CP AstraZeneca
DM6XTZL DT Antibody
DM6XTZL DE Solid tumour/cancer
DM6XC8H ID DM6XC8H
DM6XC8H DN MSC110
DM6XC8H HS Phase 1
DM6XC8H SN Lacnotuzumab
DM6XC8H CP Novartis
DM6XC8H DT Antibody
DM6XC8H DE Pigmented villonodular synovitis
DMEP7HO ID DMEP7HO
DMEP7HO DN MSH-372
DMEP7HO HS Phase 1
DMEP7HO SN MIV-150; MIV-150)
DMEP7HO CP Medivir AB
DMEP7HO DT Small molecular drug
DMEP7HO PC 468179
DMEP7HO MW 368.4
DMEP7HO FM C19H17FN4O3
DMEP7HO IC InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m0/s1
DMEP7HO CS CCC(=O)C1=C(C(=C(C=C1)F)[C@H]2C[C@H]2NC(=O)NC3=NC=C(C=C3)C#N)O
DMEP7HO IK NKPHEWJJTGPRSL-GXTWGEPZSA-N
DMEP7HO IU 1-(5-cyanopyridin-2-yl)-3-[(1R,2R)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
DMEP7HO DE Human immunodeficiency virus infection
DM1N9YS ID DM1N9YS
DM1N9YS DN MSX-122
DM1N9YS HS Phase 1
DM1N9YS CP Metastatix
DM1N9YS TC Anticancer Agents
DM1N9YS DT Small molecular drug
DM1N9YS PC 11687907
DM1N9YS MW 292.34
DM1N9YS FM C16H16N6
DM1N9YS IC InChI=1S/C16H16N6/c1-7-17-15(18-8-1)21-11-13-3-5-14(6-4-13)12-22-16-19-9-2-10-20-16/h1-10H,11-12H2,(H,17,18,21)(H,19,20,22)
DM1N9YS CS C1=CN=C(N=C1)NCC2=CC=C(C=C2)CNC3=NC=CC=N3
DM1N9YS IK PXZXYRKDDXKDTK-UHFFFAOYSA-N
DM1N9YS IU N-[[4-[(pyrimidin-2-ylamino)methyl]phenyl]methyl]pyrimidin-2-amine
DM1N9YS CA CAS 897657-95-3
DM1N9YS DE Solid tumour/cancer
DMPCUN5 ID DMPCUN5
DMPCUN5 DN MT-110
DMPCUN5 HS Phase 1
DMPCUN5 SN MuS110; Bispecific EpCAM/CD3 antibody (cancer), Micromet
DMPCUN5 CP Micromet AG
DMPCUN5 DT Antibody
DMPCUN5 DE Solid tumour/cancer
DMT0EBU ID DMT0EBU
DMT0EBU DN MT-112
DMT0EBU HS Phase 1
DMT0EBU SN BiTE antibody (solid tumor), Micromet/Bayer
DMT0EBU CP Amgenl; bayer healthcare pharmaceuticals
DMT0EBU DT Antibody
DMT0EBU DE Solid tumour/cancer
DM5SN0A ID DM5SN0A
DM5SN0A DN MT-5111
DM5SN0A HS Phase 1
DM5SN0A CP Molecular Templates
DM5SN0A DT Recombinant?protein
DM5SN0A DE Solid tumour/cancer
DMG4QDT ID DMG4QDT
DMG4QDT DN MUC-1 dendritic cancer vaccine
DMG4QDT HS Phase 1
DMG4QDT CP Microvax
DMG4QDT DT Vaccine
DMG4QDT DE Solid tumour/cancer
DMAGCHE ID DMAGCHE
DMAGCHE DN Multi-envelope HIV vaccine
DMAGCHE HS Phase 1
DMAGCHE SN PolyEnv1; AIDS vaccine, St Jude; HIV vaccine, St Jude; Multi-envelope AIDS vaccine, St Jude; Multi-envelope HIV vaccine, St Jude; Vaccine (HIV), St Jude
DMAGCHE CP St Jude Children's Research Hospital
DMAGCHE DT Vaccine
DMAGCHE DE Human immunodeficiency virus infection
DM3JUXW ID DM3JUXW
DM3JUXW DN MVA HER-2 AutoVac
DM3JUXW HS Phase 1
DM3JUXW SN MVA-BN HER-2 AutoVac; MVA-BN-HER2; PX-103.2; MVA-BN Breast (cancer vaccine), Bavarian Nordic; MVA-BN breast cancer vaccine, BN ImmunoTherapeutics/ Pharmexa; MVA-BN/Her-2/Neu
DM3JUXW CP Pharmexa A/S
DM3JUXW DT Vaccine
DM3JUXW DE Breast cancer
DMFMW5C ID DMFMW5C
DMFMW5C DN MVA-BN Breast
DMFMW5C HS Phase 1
DMFMW5C SN MVA-BN-pRo (TN)
DMFMW5C CP BN ImmunoTherapeutics
DMFMW5C DE Prostate cancer
DM1FUAR ID DM1FUAR
DM1FUAR DN MV-CEA
DM1FUAR HS Phase 1
DM1FUAR SN Measles virus derivative producing cea; Carcinoembryonic antigen-expressing measles virus (cancer), NCI; Mv-cea (ovarian and peritoneal cavity cancer), NCI
DM1FUAR CP National Cancer Institute
DM1FUAR DE Glioblastoma multiforme
DMEJ4C1 ID DMEJ4C1
DMEJ4C1 DN MVT-5873
DMEJ4C1 HS Phase 1
DMEJ4C1 CP MabVax Therapeutics San Diego, CA
DMEJ4C1 DE Colorectal cancer; Pancreatic cancer; Prostate cancer; Solid tumour/cancer
DM5O4X9 ID DM5O4X9
DM5O4X9 DN Mycophenolic acid glucuronide
DM5O4X9 HS Phase 1
DM5O4X9 SN MPAG; Mycophenolic acid glucosiduronate; mycophenolic acid glucuronide; UNII-54TS5J9T0K; 54TS5J9T0K; AC1O5XMV; BYFGTSAYQQIUCN-HGIHDBQLSA-N; Mycophenolic Acid ; A-D-Glucuronide; ZINC13550000; (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[[5-[(E)-6-hydroxy-3-methyl-6-oxohex-2-enyl]-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-4-yl]oxy]oxane-2-carboxylic acid; 5-[(2E)-5-Carboxy-3-methyl-2-penten-1-yl]-1,3-dihydro-6-methoxy-7-methyl-3-oxo-4-isobenzofuranyl
DM5O4X9 PC 6442661
DM5O4X9 MW 496.5
DM5O4X9 FM C23H28O12
DM5O4X9 IC InChI=1S/C23H28O12/c1-9(5-7-13(24)25)4-6-11-18(32-3)10(2)12-8-33-22(31)14(12)19(11)34-23-17(28)15(26)16(27)20(35-23)21(29)30/h4,15-17,20,23,26-28H,5-8H2,1-3H3,(H,24,25)(H,29,30)/b9-4+/t15-,16-,17+,20-,23+/m0/s1
DM5O4X9 CS CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)OC3C(C(C(C(O3)C(=O)O)O)O)O
DM5O4X9 IK BYFGTSAYQQIUCN-HGIHDBQLSA-N
DM5O4X9 IU (2S,3S,4S,5R,6S)-6-[[5-[(E)-5-carboxy-3-methylpent-2-enyl]-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-4-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DM5O4X9 CA CAS 31528-44-6
DM5O4X9 DE Lung transplantation
DMHO6XP ID DMHO6XP
DMHO6XP DN MyoDys
DMHO6XP HS Phase 1
DMHO6XP SN PTG11025; TG-5001; Gene therapy (DMD), Transgene; Gene therapy (Duchenne muscular dystrophy), Transgene; Gene therapy (DMD/ BMD), Transgene; Gene therapy (Duchenne muscular dystrophy/ Becker muscular dystrophy), Transgene
DMHO6XP CP Transgene SA
DMHO6XP DE Duchenne dystrophy
DM4ZN8M ID DM4ZN8M
DM4ZN8M DN N-803
DM4ZN8M HS Phase 1
DM4ZN8M SN Anktiva; ALT-803
DM4ZN8M CP ImmunityBio
DM4ZN8M DT Recombinant protein
DM4ZN8M DE Human immunodeficiency virus infection
DM3PC0J ID DM3PC0J
DM3PC0J DN N-8295
DM3PC0J HS Phase 1
DM3PC0J SN Universal flu vaccine; M2e-ISS; NP-ISS; ISS vaccine (influenza), Dynavax; M2e/NP-ISS; Influenza vaccine (immunostimulatory sequence-based), Dynavax; Influenza vaccine (ND-ISS-based), Dynavax
DM3PC0J CP Dynavax Technologies Corp
DM3PC0J DT Vaccine
DM3PC0J DE Influenza virus infection
DM3IT6R ID DM3IT6R
DM3IT6R DN N9-GP
DM3IT6R HS Phase 1
DM3IT6R SN NN7999
DM3IT6R CP Novo Nordisk
DM3IT6R DE Factor IX deficiency
DM3E20L ID DM3E20L
DM3E20L DN Nagrestipen
DM3E20L HS Phase 1
DM3E20L SN EMIP; BB-10010; ECI-301; Macrophage inflammatory protein 1a, British Biotech; Stem cell protector, British Biotech; MIP-1a, British Biotech; MIP-1 alpha derivatives (cancer), Effector
DM3E20L CP Vernalis plc
DM3E20L DE Bone marrow transplantation
DMMKZYV ID DMMKZYV
DMMKZYV DN Namitecan
DMMKZYV HS Phase 1
DMMKZYV SN ST-1968; ST-1976; ST-2649; ST-2724; ST-3280; ST-3833; ST-4167; ST-4215; ST-5548; Peptide-camptothecin conjugates (cancer); Topoisomerase I inhibiting camptothecin analog (cancer), Sigma-Tau; Topoisomerase I inhibitor (cancer), Sigma-Tau; Peptide-camptothecin conjugates (cancer), Sigma-Tau
DMMKZYV CP Sigma-Tau Ind Farm Riunite SpA
DMMKZYV DT Small molecular drug
DMMKZYV PC 10950142
DMMKZYV MW 434.4
DMMKZYV FM C23H22N4O5
DMMKZYV IC InChI=1S/C23H22N4O5/c1-2-23(30)17-9-19-20-15(11-27(19)21(28)16(17)12-31-22(23)29)14(10-25-32-8-7-24)13-5-3-4-6-18(13)26-20/h3-6,9-10,30H,2,7-8,11-12,24H2,1H3/b25-10+/t23-/m0/s1
DMMKZYV CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)/C=N/OCCN)O
DMMKZYV IK IBTISPLPBBHVSU-UVOOVGFISA-N
DMMKZYV IU (19S)-10-[(E)-2-aminoethoxyiminomethyl]-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
DMMKZYV CA CAS 372105-27-6
DMMKZYV DE Solid tumour/cancer
DMHAZLM ID DMHAZLM
DMHAZLM DN Naringenin
DMHAZLM HS Phase 1
DMHAZLM SN naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 4',5,7-Trihydroxyflavanone; Naringenine; (+/-)-Naringenin; naringetol; 480-41-1; salipurpol; (-)-Naringenin; NARIGENIN; Salipurol; 5,7,4'-Trihydroxyflavanone; 93602-28-9; (S)-Naringenin; BE-14348A; NSC 34875; ( inverted exclamation markA)-Naringenin; CHEMBL32571; MLS000738094; MLS000028739; CHEBI:50202; Flavanone, 4',5,7-trihydroxy-; FTVWIRXFELQLPI-UHFFFAOYSA-N; NSC34875; NSC11855; MFCD00006844; SMR000059039; AK122638; NSC 11855; 4',7-Trihydroxyflavanone
DMHAZLM DT Small molecular drug
DMHAZLM PC 932
DMHAZLM MW 272.25
DMHAZLM FM C15H12O5
DMHAZLM IC InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2
DMHAZLM CS C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O
DMHAZLM IK FTVWIRXFELQLPI-UHFFFAOYSA-N
DMHAZLM IU 5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMHAZLM CA CAS 67604-48-2
DMHAZLM CB CHEBI:50202
DMZ2G69 ID DMZ2G69
DMZ2G69 DN Navicixizumab
DMZ2G69 HS Phase 1
DMZ2G69 CP OncoMed Pharmaceuticals Redwood City, CA
DMZ2G69 DE Colorectal cancer; Fallopian tube cancer; Metastatic colorectal cancer; Ovarian cancer; Peritoneal cavity cancer
DMG0SWE ID DMG0SWE
DMG0SWE DN NBF-006
DMG0SWE HS Phase 1
DMG0SWE CP Nitto Biopharma
DMG0SWE DT Small interfering RNA
DMG0SWE DE Colorectal cancer; Non-small-cell lung cancer; Pancreatic cancer
DM5BQK3 ID DM5BQK3
DM5BQK3 DN NBI-34041
DM5BQK3 HS Phase 1
DM5BQK3 CP Neurocrine Biosciences; GlaxoSmithKline
DM5BQK3 DT Small molecular drug
DM5BQK3 PC 9888194
DM5BQK3 MW 417.4
DM5BQK3 FM C22H26Cl2N4
DM5BQK3 IC InChI=1S/C22H26Cl2N4/c1-4-6-16(7-5-2)27-10-11-28-22-19(27)12-14(3)25-21(22)20(26-28)17-9-8-15(23)13-18(17)24/h8-9,12-13,16H,4-7,10-11H2,1-3H3
DM5BQK3 CS CCCC(CCC)N1CCN2C3=C1C=C(N=C3C(=N2)C4=C(C=C(C=C4)Cl)Cl)C
DM5BQK3 IK AKLMUGFDGONMAA-UHFFFAOYSA-N
DM5BQK3 IU 3-(2,4-dichlorophenyl)-9-heptan-4-yl-6-methyl-1,2,5,9-tetrazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene
DM5BQK3 CA CAS 268545-87-5
DM5BQK3 DE Eating disorder
DM5OWXA ID DM5OWXA
DM5OWXA DN NBM-BMX
DM5OWXA HS Phase 1
DM5OWXA CP NatureWise Biotech & Medicals
DM5OWXA DT Small molecular drug
DM5OWXA DE Solid tumour/cancer
DMPHZI5 ID DMPHZI5
DMPHZI5 DN NBQX
DMPHZI5 HS Phase 1
DMPHZI5 SN nbqx; 118876-58-7; FG 9202; 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline; 6-Nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione; CHEMBL222519; CHEBI:31073; SBB066176; 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide; 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxobenzo(f)quinoxaline-8-sulfonamide; 6-Nitro-7-sulphamoylbenzo[f]quinoxaline-2,3-dione; 6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline
DMPHZI5 DT Small molecular drug
DMPHZI5 PC 3272524
DMPHZI5 MW 336.28
DMPHZI5 FM C12H8N4O6S
DMPHZI5 IC InChI=1S/C12H8N4O6S/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22)
DMPHZI5 CS C1=CC2=C3C(=CC(=C2C(=C1)S(=O)(=O)N)[N+](=O)[O-])NC(=O)C(=O)N3
DMPHZI5 IK UQNAFPHGVPVTAL-UHFFFAOYSA-N
DMPHZI5 IU 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide
DMPHZI5 CA CAS 118876-58-7
DMPHZI5 CB CHEBI:31073
DMPHZI5 DE Neurological disorder
DMF3MN1 ID DMF3MN1
DMF3MN1 DN NBXT-001+Nobilis inhalation device
DMF3MN1 HS Phase 1
DMF3MN1 CP Nobilis Therapeutics Portland, OR
DMF3MN1 DE Alzheimer disease
DMM2SNG ID DMM2SNG
DMM2SNG DN NC-4016
DMM2SNG HS Phase 1
DMM2SNG CP Nanocarrier
DMM2SNG DE Solid tumour/cancer
DMUSPW5 ID DMUSPW5
DMUSPW5 DN NCO-48
DMUSPW5 HS Phase 1
DMUSPW5 CP Nucorion Pharmaceuticals
DMUSPW5 DT Small molecular drug
DMUSPW5 DE Hepatitis B virus infection
DMKJRQS ID DMKJRQS
DMKJRQS DN NCX-1015
DMKJRQS HS Phase 1
DMKJRQS SN Nitroprednisolone; NCX-1004; NCX-1016; NO-prednisolone
DMKJRQS CP NicOx SA
DMKJRQS PC 101123241
DMKJRQS MW 540.6
DMKJRQS FM C29H34NO9+
DMKJRQS IC InChI=1S/C29H34NO9/c1-27-11-9-20(31)13-19(27)7-8-21-22-10-12-29(35,28(22,2)14-23(32)25(21)27)24(33)16-38-26(34)18-5-3-17(4-6-18)15-39-30(36)37/h3-6,9,11,13,21-23,25,32,35H,7-8,10,12,14-16H2,1-2H3,(H,36,37)/q+1/t21-,22-,23-,25+,27-,28-,29-/m0/s1
DMKJRQS CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)C4=CC=C(C=C4)CO[N+](=O)O)O)CCC5=CC(=O)C=C[C@]35C)O
DMKJRQS IK HSVTZTOFRYKVEA-KGWLDMEJSA-N
DMKJRQS IU [4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylphenyl]methoxy-hydroxy-oxoazanium
DMKJRQS DE Rheumatoid arthritis
DMM7RC5 ID DMM7RC5
DMM7RC5 DN NCX-6560
DMM7RC5 HS Phase 1
DMM7RC5 SN NCX 6560
DMM7RC5 CP NicOx
DMM7RC5 PC 11239321
DMM7RC5 MW 675.7
DMM7RC5 FM C37H42FN3O8
DMM7RC5 IC InChI=1S/C37H42FN3O8/c1-25(2)35-34(37(45)39-29-13-7-4-8-14-29)33(26-11-5-3-6-12-26)36(27-15-17-28(38)18-16-27)40(35)20-19-30(42)23-31(43)24-32(44)48-21-9-10-22-49-41(46)47/h3-8,11-18,25,30-31,42-43H,9-10,19-24H2,1-2H3,(H,39,45)/t30-,31-/m1/s1
DMM7RC5 CS CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)OCCCCO[N+](=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMM7RC5 IK QBBIDMMGINYIJJ-FIRIVFDPSA-N
DMM7RC5 IU 4-nitrooxybutyl (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
DMM7RC5 DE Cardiovascular disease
DMVQAEK ID DMVQAEK
DMVQAEK DN ND-1.1
DMVQAEK HS Phase 1
DMVQAEK SN Avian influenza vaccine, West Coast Biologicals; Ad-HA-dsRNA; H5N1 avian influenza vaccine (oral, adenoviral vector,dsRNA adjuvant), Vaxart
DMVQAEK CP Glaxosmithkline; novavax; vaxart
DMVQAEK DT Vaccine
DMVQAEK DE Influenza virus infection
DMUBTC6 ID DMUBTC6
DMUBTC6 DN ND7001
DMUBTC6 HS Phase 1
DMUBTC6 CP Neuro3d
DMUBTC6 DE Mood disorder
DM830EN ID DM830EN
DM830EN DN NEO-201
DM830EN HS Phase 1
DM830EN CP Precision Biologics
DM830EN DT Antibody
DM830EN DE Solid tumour/cancer
DMXTYWJ ID DMXTYWJ
DMXTYWJ DN Neovastat
DMXTYWJ HS Phase 1
DMXTYWJ CP Ferrer; Hospira; LG Life Sciences; AEterna Zentaris
DMXTYWJ TC Anticancer Agents
DMXTYWJ DE Renal cell carcinoma; Non-small-cell lung cancer
DM59ZDN ID DM59ZDN
DM59ZDN DN Nesvacumab
DM59ZDN HS Phase 1
DM59ZDN SN REGN910; SAR307746
DM59ZDN DT Antibody
DM59ZDN DE Solid tumour/cancer
DMNJTLC ID DMNJTLC
DMNJTLC DN Neu-2000
DMNJTLC HS Phase 1
DMNJTLC SN NMDA antagonists , GNT Pharma; NMDA antagonists, Neurotech; Neu-2000KL
DMNJTLC CP Gnt pharma
DMNJTLC PC 9951955
DMNJTLC MW 383.22
DMNJTLC FM C15H8F7NO3
DMNJTLC IC InChI=1S/C15H8F7NO3/c16-10-7(11(17)13(19)9(12(10)18)15(20,21)22)4-23-5-1-2-8(24)6(3-5)14(25)26/h1-3,23-24H,4H2,(H,25,26)
DMNJTLC CS C1=CC(=C(C=C1NCC2=C(C(=C(C(=C2F)F)C(F)(F)F)F)F)C(=O)O)O
DMNJTLC IK HABROHXUHNHQMY-UHFFFAOYSA-N
DMNJTLC IU 2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid
DMNJTLC CA CAS 640290-67-1
DMNJTLC DE Cardiac arrest
DMQK5ET ID DMQK5ET
DMQK5ET DN NG-350A
DMQK5ET HS Phase 1
DMQK5ET CP PsiOxus Therapeutics
DMQK5ET DT Gene therapy
DMQK5ET DE Solid tumour/cancer
DMITVHM ID DMITVHM
DMITVHM DN NG-641
DMITVHM HS Phase 1
DMITVHM CP PsiOxus Therapeutics
DMITVHM DT Gene therapy
DMITVHM DE Solid tumour/cancer
DMM1Y8F ID DMM1Y8F
DMM1Y8F DN NGD 94-1
DMM1Y8F HS Phase 1
DMM1Y8F SN 2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; Ngd 94-1; 178928-68-2; UNII-DO9M06BFRJ; Ngd-94-1; DO9M06BFRJ; CHEMBL103772; 179333-18-7; 2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; 2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-pyrimidine; 2-[4-[(2-phenyl-3H-imidazol-4-yl)methyl]piperazin-1-yl]pyrimidine; [3H]NGD941; [3H]-NGD941; [3H]NGD 94-1; AC1L4NQX; ngd94-1; 2-{4-[(2-phenyl-1h-imidazol-4-yl)methyl]piperazin-1-yl}pyrimidine; 2-Phenyl-4(5)-((4-(2-pyrimidinyl)-piperazin-1-yl)methyl)imidazole dimaleate; AC1Q4X5G; GTPL979; SCHEMBL6901339; Ngd-94-1; Diphenylbutylpiperidines pimozide
DMM1Y8F CP Schering-Plough
DMM1Y8F DT Small molecular drug
DMM1Y8F PC 188942
DMM1Y8F MW 320.4
DMM1Y8F FM C18H20N6
DMM1Y8F IC InChI=1S/C18H20N6/c1-2-5-15(6-3-1)17-21-13-16(22-17)14-23-9-11-24(12-10-23)18-19-7-4-8-20-18/h1-8,13H,9-12,14H2,(H,21,22)
DMM1Y8F CS C1CN(CCN1CC2=CN=C(N2)C3=CC=CC=C3)C4=NC=CC=N4
DMM1Y8F IK OTVQCHUIPJYASM-UHFFFAOYSA-N
DMM1Y8F IU 2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine
DMM1Y8F CA CAS 178928-68-2
DMM1Y8F DE Schizophrenia
DMF21XQ ID DMF21XQ
DMF21XQ DN NGM120
DMF21XQ HS Phase 1
DMF21XQ CP NGM Biopharmaceuticals
DMF21XQ DT Antibody
DMF21XQ DE Solid tumour/cancer
DMYNSRH ID DMYNSRH
DMYNSRH DN NGM313
DMYNSRH HS Phase 1
DMYNSRH CP NGM Biopharmaceuticals South San Francisco, CA
DMYNSRH DE Type-2 diabetes
DMTVQH2 ID DMTVQH2
DMTVQH2 DN NGP 555
DMTVQH2 HS Phase 1
DMTVQH2 SN WDEKUGNKKOGFOA-UHFFFAOYSA-N; NGP555; 1304630-27-0; UNII-1XA7T7L527; CHEMBL2151100; SCHEMBL16198584; NGP-455; 1XA7T7L527; HY-108714; CS-0030521; 2-Thiazolamine, N-(5-ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-; N-(5-Ethyl-2,4-dimethylphenyl)-4-(3-fluoro-4-(4-methylimidazol-1-yl)phenyl)-1,3-thiazol-2-amine
DMTVQH2 CP NeuroGenetic Pharmaceuticals Rancho Santa Fe, CA
DMTVQH2 PC 46853593
DMTVQH2 MW 406.5
DMTVQH2 FM C23H23FN4S
DMTVQH2 IC InChI=1S/C23H23FN4S/c1-5-17-10-20(15(3)8-14(17)2)26-23-27-21(12-29-23)18-6-7-22(19(24)9-18)28-11-16(4)25-13-28/h6-13H,5H2,1-4H3,(H,26,27)
DMTVQH2 CS CCC1=CC(=C(C=C1C)C)NC2=NC(=CS2)C3=CC(=C(C=C3)N4C=C(N=C4)C)F
DMTVQH2 IK WDEKUGNKKOGFOA-UHFFFAOYSA-N
DMTVQH2 IU N-(5-ethyl-2,4-dimethylphenyl)-4-[3-fluoro-4-(4-methylimidazol-1-yl)phenyl]-1,3-thiazol-2-amine
DMTVQH2 CA CAS 1304630-27-0
DMTVQH2 DE Alzheimer disease
DMU6CQ7 ID DMU6CQ7
DMU6CQ7 DN NHS-IL 12
DMU6CQ7 HS Phase 1
DMU6CQ7 SN NHS-IL12
DMU6CQ7 CP Emd serono; national cancer institute
DMU6CQ7 DE Solid tumour/cancer
DM31FOP ID DM31FOP
DM31FOP DN NI-0101
DM31FOP HS Phase 1
DM31FOP SN TLR4 monoclonal antibody therapy (autoimmune and inflammatory diseases), Novimmune
DM31FOP CP NovImmune SA
DM31FOP DT Antibody
DM31FOP DE Autoimmune diabetes
DM32VKQ ID DM32VKQ
DM32VKQ DN NI-0701
DM32VKQ HS Phase 1
DM32VKQ SN Alpha-RANTES; RANTES ligand inhibitor (iv, autoimmune/inflammatory disease), NovImmune
DM32VKQ CP NovImmune SA
DM32VKQ DE Autoimmune diabetes
DM8J3WE ID DM8J3WE
DM8J3WE DN Nibentan
DM8J3WE HS Phase 1
DM8J3WE SN HE-11; Rac-N-[5-(Diethylamino)-1-phenylpentyl]-4-nitrobenzamide hydrochloride
DM8J3WE DT Small molecular drug
DM8J3WE PC 177905
DM8J3WE MW 419.9
DM8J3WE FM C22H30ClN3O3
DM8J3WE IC InChI=1S/C22H29N3O3.ClH/c1-3-24(4-2)17-9-8-12-21(18-10-6-5-7-11-18)23-22(26)19-13-15-20(16-14-19)25(27)28;/h5-7,10-11,13-16,21H,3-4,8-9,12,17H2,1-2H3,(H,23,26);1H
DM8J3WE CS CCN(CC)CCCCC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)[N+](=O)[O-].Cl
DM8J3WE IK CHCBAYRWJULIDW-UHFFFAOYSA-N
DM8J3WE IU N-[5-(diethylamino)-1-phenylpentyl]-4-nitrobenzamide;hydrochloride
DM8J3WE CA CAS 157832-56-9
DM8J3WE DE Cardiac arrhythmias
DMJBYSE ID DMJBYSE
DMJBYSE DN Nicotinamide riboside
DMJBYSE HS Phase 1
DMJBYSE SN nicotinamide riboside; nicotinamide ribose; nicotinamide-beta-riboside; nicotinamide ribonucleoside; N-ribosylnicotinamide; 1341-23-7; ribosylnicotinamide; 1-(beta-D-Ribofuranosyl)nicotinamide; UNII-0I8H2M0L7N; 0I8H2M0L7N; CHEBI:15927; 3-Carbamoyl-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium; SRT647; SRT-647; SRT 647; N-ribosyl-nicotinamide; AC1L98BO; beta-nicotinamide D-riboside; SCHEMBL938611; N-Ribosyl-Nicotinamide New; Pyridinium, 3-(aminocarbonyl)-1-beta-D-ribofuranosyl-; CHEMBL43849
DMJBYSE CP ChromaDex Irvine, CA
DMJBYSE PC 439924
DMJBYSE MW 255.25
DMJBYSE FM C11H15N2O5+
DMJBYSE IC InChI=1S/C11H14N2O5/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18-11/h1-4,7-9,11,14-16H,5H2,(H-,12,17)/p+1/t7-,8-,9-,11-/m1/s1
DMJBYSE CS C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DMJBYSE IK JLEBZPBDRKPWTD-TURQNECASA-O
DMJBYSE IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
DMJBYSE CA CAS 1341-23-7
DMJBYSE CB CHEBI:15927
DMJBYSE DE Mitochondrial myopathy
DM0PYEQ ID DM0PYEQ
DM0PYEQ DN NIP-004
DM0PYEQ HS Phase 1
DM0PYEQ SN Blood clotting modulator, Nissan; NIP-022; ONO-7746; ONO-7746); Peptidomimetic thrombopoietin agonist (thrombocytopenia), Nissan Chemical; Peptidomimetic thrombopoietin agonist (thrombocytopenia), Nissan Chemical/Ono
DM0PYEQ CP Nissan Chemical Industries Ltd
DM0PYEQ PC 87416054
DM0PYEQ MW 455.3
DM0PYEQ FM C18H12Cl2N2O4S2
DM0PYEQ IC InChI=1S/C18H12Cl2N2O4S2/c1-8(21-22-17(24)13-4-5-14(28-13)18(25)26)10-7-27-16(15(10)23)9-2-3-11(19)12(20)6-9/h2-7,23H,1H3,(H,22,24)(H,25,26)/b21-8-
DM0PYEQ CS C/C(=N/NC(=O)C1=CC=C(S1)C(=O)O)/C2=CSC(=C2O)C3=CC(=C(C=C3)Cl)Cl
DM0PYEQ IK JYODIYJKYDDIDN-WNFQYIGGSA-N
DM0PYEQ IU 5-[[(Z)-1-[5-(3,4-dichlorophenyl)-4-hydroxythiophen-3-yl]ethylideneamino]carbamoyl]thiophene-2-carboxylic acid
DM0PYEQ DE Thrombocytopenia
DM4I02O ID DM4I02O
DM4I02O DN NJA-730
DM4I02O HS Phase 1
DM4I02O CP NapaJen Pharma
DM4I02O DT Antisense oligonucleotide
DM4I02O DE Graft-versus-host disease
DMSENTW ID DMSENTW
DMSENTW DN NJH395
DMSENTW HS Phase 1
DMSENTW CP Novartis
DMSENTW DT Antibody drug conjugate
DMSENTW DE HER2-positive metastatic breast cancer
DMGSDPL ID DMGSDPL
DMGSDPL DN NK-314
DMGSDPL HS Phase 1
DMGSDPL SN Topoisomerase modulator, Nippon Kayaku
DMGSDPL CP Nippon Kayaku Co Ltd
DMGSDPL DE Solid tumour/cancer
DM5AWK1 ID DM5AWK1
DM5AWK1 DN NKP-1339
DM5AWK1 HS Phase 1
DM5AWK1 SN 197723-00-5; KP-1339; EX-A1916; BCP26252; Z-3126; 1H-indazole; tetrachlororuthenium(1-) sodium salt
DM5AWK1 CP Niiki Pharma
DM5AWK1 DT Small molecular drug
DM5AWK1 PC 25134754
DM5AWK1 MW 502.1
DM5AWK1 FM C14H12Cl4N4NaRu
DM5AWK1 IC InChI=1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+3/p-4
DM5AWK1 CS C1=CC=C2C(=C1)C=NN2.C1=CC=C2C(=C1)C=NN2.[Na+].Cl[Ru-](Cl)(Cl)Cl
DM5AWK1 IK WVVOCRYXBTVDRN-UHFFFAOYSA-J
DM5AWK1 IU sodium;1H-indazole;tetrachlororuthenium(1-)
DM5AWK1 DE Solid tumour/cancer
DMDLJM1 ID DMDLJM1
DMDLJM1 DN NKR-2 CAR-T Cells
DMDLJM1 HS Phase 1
DMDLJM1 CP Celyad (formerly named Cardio3 BioSciences)
DMDLJM1 DT CAR T Cell Therapy
DMDLJM1 DE Myelodysplastic syndrome; Acute myeloid leukaemia
DMR5ATX ID DMR5ATX
DMR5ATX DN NKR-2 cells
DMR5ATX HS Phase 1
DMR5ATX CP Celyad (formerly named Cardio3 BioSciences)
DMR5ATX DT CAR T Cell Therapy
DMR5ATX DE Acute myeloid leukaemia
DMI7ZK3 ID DMI7ZK3
DMI7ZK3 DN NKTT-120
DMI7ZK3 HS Phase 1
DMI7ZK3 SN INKT mAb; Natural killer T cell antibody (asthma/COPD/Dermatitis); NKT cell antibody (asthma/COPD/Dermatitis), NKT; Natural killer T cell antibody (asthma/COPD/Dermatitis), NKT Therapeutics
DMI7ZK3 CP Nkt therapeutics
DMI7ZK3 DT Antibody
DMI7ZK3 DE Sickle-cell disorder
DMP9J5V ID DMP9J5V
DMP9J5V DN NLG802
DMP9J5V HS Phase 1
DMP9J5V CP NewLink Genetics Ames, IA
DMP9J5V DE Solid tumour/cancer
DMYPWHD ID DMYPWHD
DMYPWHD DN NLG919
DMYPWHD HS Phase 1
DMYPWHD SN NLG919; 1402836-58-1; 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol; NLG 919; CHEMBL3629569; AK166956; 1-Cyclohexyl-2-(5H-imidazo-[5,1-a]isoindol-5-yl)ethanol; alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol; 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol; YTRRAUACYORZLX-UHFFFAOYSA-N; GTPL9019; SCHEMBL13280897; GDC0919; EX-A574; DTXSID20735206; MolPort-035-395-785; HMS3653M05; AOB87373; GDC 0919; NLG919(GDC-0919); 2588AH; RG6078; BDBM50126144; s7111; AKOS025287054; CS-3512; SB16495; ACN-028914; KS-0000062W
DMYPWHD CP Newlink genetics
DMYPWHD DT Small molecular drug
DMYPWHD PC 66558287
DMYPWHD MW 282.4
DMYPWHD FM C18H22N2O
DMYPWHD IC InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2
DMYPWHD CS C1CCC(CC1)C(CC2C3=CC=CC=C3C4=CN=CN24)O
DMYPWHD IK YTRRAUACYORZLX-UHFFFAOYSA-N
DMYPWHD IU 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol
DMYPWHD CA CAS 1402836-58-1
DMYPWHD DE Solid tumour/cancer
DMPJMB7 ID DMPJMB7
DMPJMB7 DN NLX-101
DMPJMB7 HS Phase 1
DMPJMB7 SN F-15599; F 15599; F-15,599; F15599
DMPJMB7 DT Small molecular drug
DMPJMB7 PC 11741361
DMPJMB7 MW 394.8
DMPJMB7 FM C19H21ClF2N4O
DMPJMB7 IC InChI=1S/C19H21ClF2N4O/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14/h2-3,8-10,23H,4-7,11-12H2,1H3
DMPJMB7 CS CC1=CN=C(N=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=C(C=C3)F)Cl)F
DMPJMB7 IK WAAXKNFGOFTGLP-UHFFFAOYSA-N
DMPJMB7 IU (3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-methylpyrimidin-2-yl)methylamino]methyl]piperidin-1-yl]methanone
DMPJMB7 CA CAS 635323-95-4
DMPJMB7 DE Rett syndrome
DM5INE7 ID DM5INE7
DM5INE7 DN NM-3
DM5INE7 HS Phase 1
DM5INE7 SN NM-3; 181427-78-1; isocoumarin NM-3; NM 3 (isocoumarin); NM 3; NM-3 (isocoumarin); AC1NUU2Q; SCHEMBL3191297; CTK4D7870; 2-(8-Hydroxy-6-methoxy-1-oxo-1H-isochromen-3-yl)propionic acid; 8-Hydroxy-6-methoxy-alpha-methyl-1-oxo-1H-2-benzopyran-3-acetic acid; AKOS030619018; DB12818; FT-0717128; 2-(8-hydroxy-6-methoxy-1-oxoisochromen-3-yl)propanoic acid; 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid; 2-(8-hydroxy-6-methoxy-1-oxo-1H-isochromen-3-yl)propanoic acid; 1H-2-Benzopyran-3-aceticacid, 8-hydroxy-6-methox
DM5INE7 CP Genzyme
DM5INE7 DT Small molecular drug
DM5INE7 PC 5493470
DM5INE7 MW 264.23
DM5INE7 FM C13H12O6
DM5INE7 IC InChI=1S/C13H12O6/c1-6(12(15)16)10-4-7-3-8(18-2)5-9(14)11(7)13(17)19-10/h3-6,14H,1-2H3,(H,15,16)
DM5INE7 CS CC(C1=CC2=CC(=CC(=C2C(=O)O1)O)OC)C(=O)O
DM5INE7 IK BPZCXUROMKDLGX-UHFFFAOYSA-N
DM5INE7 IU 2-(8-hydroxy-6-methoxy-1-oxoisochromen-3-yl)propanoic acid
DM5INE7 CA CAS 181427-78-1
DM5INE7 DE Solid tumour/cancer
DM2XIRW ID DM2XIRW
DM2XIRW DN NMS-03305293
DM2XIRW HS Phase 1
DM2XIRW SN NMS-P293
DM2XIRW CP Nerviano Medical Sciences
DM2XIRW DT Small molecular drug
DM2XIRW DE Solid tumour/cancer
DMDGCHR ID DMDGCHR
DMDGCHR DN NN-1218
DMDGCHR HS Phase 1
DMDGCHR CP Novo Nordisk A/S
DMDGCHR DE Diabetic complication; Type-1 diabetes; Type-2 diabetes
DMRJEXM ID DMRJEXM
DMRJEXM DN NN-414
DMRJEXM HS Phase 1
DMRJEXM SN NNC-55-0414
DMRJEXM CP Novo Nordisk A/S
DMRJEXM DT Small molecular drug
DMRJEXM PC 135410911
DMRJEXM MW 291.8
DMRJEXM FM C9H10ClN3O2S2
DMRJEXM IC InChI=1S/C9H10ClN3O2S2/c1-9(2-3-9)12-8-11-5-4-6(10)16-7(5)17(14,15)13-8/h4H,2-3H2,1H3,(H2,11,12,13)
DMRJEXM CS CC1(CC1)N=C2NC3=C(SC(=C3)Cl)S(=O)(=O)N2
DMRJEXM IK KYSFUHHFTIGRJN-UHFFFAOYSA-N
DMRJEXM IU 6-chloro-N-(1-methylcyclopropyl)-1,1-dioxo-4H-thieno[3,2-e][1,2,4]thiadiazin-3-imine
DMRJEXM CA CAS 279215-43-9
DMRJEXM DE Type-1 diabetes
DMHVIZC ID DMHVIZC
DMHVIZC DN NN-7415
DMHVIZC HS Phase 1
DMHVIZC SN NNC-0172-0000-2021
DMHVIZC CP Novo Nordisk A/S
DMHVIZC DE Factor IX deficiency
DMYXDB9 ID DMYXDB9
DMYXDB9 DN NN-8828
DMYXDB9 HS Phase 1
DMYXDB9 SN NNC-114-0005; NNC-0114-0000-0005; Anti-IL-21 (inflammation), Novo Nordisk; MIL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), Novo Nordisk; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics
DMYXDB9 CP ZymoGenetics Inc
DMYXDB9 DT Antibody
DMYXDB9 DE Autoimmune diabetes
DM1RBT8 ID DM1RBT8
DM1RBT8 DN NN-9926
DM1RBT8 HS Phase 1
DM1RBT8 SN NNC-0113-0987
DM1RBT8 CP Novo Nordisk A/S
DM1RBT8 DE Type-2 diabetes
DMUPA7C ID DMUPA7C
DMUPA7C DN NOCICEPTIN
DMUPA7C HS Phase 1
DMUPA7C SN Nociceptin; Orphanin FQ; Nociceptin/orphanin FQ; 170713-75-4; Orphanin FQ (rat); Orphanin FQ (swine); Orphanin FQ (human); Nociceptin (1-17); UNII-7AYI9N34FF; Orphanin FQ (pig); 7AYI9N34FF; CHEBI:80266; Human nociceptin; L-Glutamine, L-phenylalanylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-alanyl-L-asparaginyl-; Nociceptin (human); Nociceptin(1-17)-OH; FGGFTGARKSARKLANQ; Orphaninfq(swine)(9ci); GTPL1681; CHEMBL396460; BDBM50004178; AKOS024458690; nociceptin/orphanin FQ
DMUPA7C PC 16131448
DMUPA7C MW 1809
DMUPA7C FM C79H129N27O22
DMUPA7C IC InChI=1S/C79H129N27O22/c1-41(2)33-54(72(122)95-44(5)66(116)103-56(36-59(84)110)73(123)102-53(77(127)128)27-28-58(83)109)104-70(120)49(23-13-15-29-80)100-69(119)52(26-18-32-90-79(87)88)99-65(115)43(4)96-75(125)57(40-107)105-71(121)50(24-14-16-30-81)101-68(118)51(25-17-31-89-78(85)86)98-64(114)42(3)94-61(112)39-93-76(126)63(45(6)108)106-74(124)55(35-47-21-11-8-12-22-47)97-62(113)38-91-60(111)37-92-67(117)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,107-108H,13-18,23-40,80-82H2,1-6H3,(H2,83,109)(H2,84,110)(H,91,111)(H,92,117)(H,93,126)(H,94,112)(H,95,122)(H,96,125)(H,97,113)(H,98,114)(H,99,115)(H,100,119)(H,101,118)(H,102,123)(H,103,116)(H,104,120)(H,105,121)(H,106,124)(H,127,128)(H4,85,86,89)(H4,87,88,90)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
DMUPA7C CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMUPA7C IK PULGYDLMFSFVBL-SMFNREODSA-N
DMUPA7C IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMUPA7C CA CAS 170713-75-4
DMUPA7C CB CHEBI:80266
DMUPA7C DE Headache
DM2ILSJ ID DM2ILSJ
DM2ILSJ DN Norbuprenorphine
DM2ILSJ HS Phase 1
DM2ILSJ SN Norbuprenorphine; N-Desalkylbuprenorphine; Des(cyclopropylmethyl)buprenorphine; UNII-7E53B4O073; 7E53B4O073; 6,14-Ethenomorphinan-7-methanol, alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-; AC1L3GBB; SCHEMBL14408877; CHEMBL1743323; YOYLLRBMGQRFTN-IOMBULRVSA-N; ZINC6031944; LS-67705; 6,14-ethenomorphinan-3-ol, 4,5-epoxy-18,19-dihydro-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-methoxy-, (5alpha,6beta,14beta,18R)-
DM2ILSJ PC 114976
DM2ILSJ MW 413.5
DM2ILSJ FM C25H35NO4
DM2ILSJ IC InChI=1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1
DM2ILSJ CS CC(C)(C)C(C)(C1CC23CCC1(C4C25CCNC3CC6=C5C(=C(C=C6)O)O4)OC)O
DM2ILSJ IK YOYLLRBMGQRFTN-IOMBULRVSA-N
DM2ILSJ IU (1S,2S,6R,14R,15R,16R)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DM2ILSJ CA CAS 78715-23-8
DM2ILSJ DE Human immunodeficiency virus infection
DME2QUZ ID DME2QUZ
DME2QUZ DN NOV1501
DME2QUZ HS Phase 1
DME2QUZ SN ABL001; TR009
DME2QUZ CP ABL Bio
DME2QUZ DT Antibody
DME2QUZ DE Solid tumour/cancer
DMMYRHV ID DMMYRHV
DMMYRHV DN NOX-700
DMMYRHV HS Phase 1
DMMYRHV CP Medinox
DMMYRHV DE Type-2 diabetes
DMMKN4Q ID DMMKN4Q
DMMKN4Q DN NOX-A12
DMMKN4Q HS Phase 1
DMMKN4Q SN Ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON; SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON; CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation), Noxxon
DMMKN4Q CP NOXXON Pharma AG
DMMKN4Q DE Macular degeneration
DMHARE7 ID DMHARE7
DMHARE7 DN NP-500
DMHARE7 HS Phase 1
DMHARE7 CP Napo Pharmaceuticals
DMHARE7 DE Type-2 diabetes; Metabolic syndrome x
DMZ72BD ID DMZ72BD
DMZ72BD DN NP-G2-044
DMZ72BD HS Phase 1
DMZ72BD SN 1ER2O3UZ4W; UNII-1ER2O3UZ4W; SCHEMBL17038863; 3-Furancarboxamide, 2-methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-; 2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide; 1807454-59-6
DMZ72BD CP Novita Pharmaceuticals New York, NY
DMZ72BD PC 91844684
DMZ72BD MW 399.4
DMZ72BD FM C21H16F3N3O2
DMZ72BD IC InChI=1S/C21H16F3N3O2/c1-13-16(10-11-29-13)20(28)25-19-17-4-2-3-5-18(17)27(26-19)12-14-6-8-15(9-7-14)21(22,23)24/h2-11H,12H2,1H3,(H,25,26,28)
DMZ72BD CS CC1=C(C=CO1)C(=O)NC2=NN(C3=CC=CC=C32)CC4=CC=C(C=C4)C(F)(F)F
DMZ72BD IK XLLRLAABUFOJPC-UHFFFAOYSA-N
DMZ72BD IU 2-methyl-N-[1-[[4-(trifluoromethyl)phenyl]methyl]indazol-3-yl]furan-3-carboxamide
DMZ72BD CA CAS 1807454-59-6
DMZ72BD DE Solid tumour/cancer
DMFDBV5 ID DMFDBV5
DMFDBV5 DN NPT200-11
DMFDBV5 HS Phase 1
DMFDBV5 CP Neuropore Therapies
DMFDBV5 DT Small molecular drug
DMFDBV5 DE Multiple system atrophy; Parkinson disease
DMX8LY4 ID DMX8LY4
DMX8LY4 DN NS-8
DMX8LY4 HS Phase 1
DMX8LY4 SN NS-8; 186033-14-7; 2-amino-3-cyano-4-methyl-5-(2-fluorophenyl)pyrrole; 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile; KVDWOQGDMAEJLM-UHFFFAOYSA-N; CHEMBL42661; SCHEMBL4624842; ZINC21886; MolPort-005-943-258; AKOS027201108; EN300-254366; 2-amino-3-cyano-4-methyl-5-(2fluorophenyl)pyrrole; Z2306534448
DMX8LY4 CP Nippon Shinyaku Co Ltd
DMX8LY4 DT Small molecular drug
DMX8LY4 PC 10176749
DMX8LY4 MW 215.23
DMX8LY4 FM C12H10FN3
DMX8LY4 IC InChI=1S/C12H10FN3/c1-7-9(6-14)12(15)16-11(7)8-4-2-3-5-10(8)13/h2-5,16H,15H2,1H3
DMX8LY4 CS CC1=C(NC(=C1C#N)N)C2=CC=CC=C2F
DMX8LY4 IK KVDWOQGDMAEJLM-UHFFFAOYSA-N
DMX8LY4 IU 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile
DMX8LY4 DE Urinary incontinence
DMRAX19 ID DMRAX19
DMRAX19 DN NSC-14983
DMRAX19 HS Phase 1
DMRAX19 SN Aspartic acid, N-carbamoyl-; Carbamoylaspartic acid; Carbamyl-L-aspartic acid; Carbamylaspartic acid; L-N-Carbamoylaspartic acid; L-Ureidosuccinate; L-Ureidosuccinic acid; N-(aminocarbonyl)-L-aspartic acid; N-Carbamoyl-L-aspartic acid; N-Carbamoyl-S-aspartic acid; N-Carbamoylaspartic acid; N-carbamoyl-L-aspartate; R2521024DK; Succinic acid, ureido-; Ureidosuccinate; carbamyl-aspartate; 13184-27-5; 2-Ureidobutanedioic acid; EINECS 236-134-3; L-Aspartic acid, N-(aminocarbonyl)-; NSC 14983; UNII-R2521024DK
DMRAX19 PC 93072
DMRAX19 MW 176.13
DMRAX19 FM C5H8N2O5
DMRAX19 IC HLKXYZVTANABHZ-REOHCLBHSA-N
DMRAX19 CS C(C(C(=O)O)NC(=O)N)C(=O)O
DMRAX19 IK 1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)/t2-/m0/s1
DMRAX19 IU (2S)-2-(carbamoylamino)butanedioic acid
DMRAX19 CA CAS 13184-27-5
DMRAX19 CB CHEBI:15859
DMRAX19 DE Dyslipidaemia
DM6093Y ID DM6093Y
DM6093Y DN NSC-172130
DM6093Y HS Phase 1
DM6093Y SN Depresym; Dosulepin HCl; Dothiepin HCl; Dothiepin hydrochloride; Prothiaden hydrochloride; Prothiadene; Prothiadene hydrochloride; Prothiadiene; Xerenal; (3E)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride; 25627-36-5; 3H0042311V; 897-15-4; CHEBI:36805; Dibenzo(b,e)thiepin-delta(sup 11(6H),gamma)-propylamine, N,N-dimethyl-, hydrochloride, (E)-; EINECS 212-978-8; Idom; N,N-Dimethyldibenzo(b,e)thiepin-delta(sup 11(6H),gamma)-propylamine hydrochloride; NSC 172130; NSC172130; UNII-3H0042311V
DM6093Y PC 9884029
DM6093Y MW 331.9
DM6093Y FM C19H22ClNS
DM6093Y IC XUPZAARQDNSRJB-SJDTYFKWSA-N
DM6093Y CS CN(C)CCC=C1C2=CC=CC=C2CSC3=CC=CC=C31.Cl
DM6093Y IK 1S/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H/b17-11+;
DM6093Y IU (3E)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine;hydrochloride
DM6093Y CA CAS 897-15-4
DM6093Y CB CHEBI:36805
DM6093Y DE Depression
DM96RD5 ID DM96RD5
DM96RD5 DN NSC-38348
DM96RD5 HS Phase 1
DM96RD5 SN Camphophyline; Corafil; Diaethylaminoaethyl-theophyllin; Dietamiphylline; Diethylaminoethyl theophylline; Diethylaminoethyltheophylline; Etamifilina [INN-Spanish]; Etamifillina [DCIT]; Etaminophylline; Etamiphyllin; Etamiphyllin [INN]; Etamiphylline; Etamiphylline [INN-French]; Etamiphyllinum [INN-Latin]; Milliphylline; Millophyline; Millophylline; Parephyllin; Queryl; R-3588; Solufilina; Soluphyline; 7-(2-(Diethylamino)ethyl)theophylline; 7-(Diethylaminoethyl)theophylline; NSC 38348; UNII-221A91BQ2S
DM96RD5 PC 28329
DM96RD5 MW 279.34
DM96RD5 FM C13H21N5O2
DM96RD5 IC AWKLBIOQCIORSB-UHFFFAOYSA-N
DM96RD5 CS CCN(CC)CCN1C=NC2=C1C(=O)N(C(=O)N2C)C
DM96RD5 IK 1S/C13H21N5O2/c1-5-17(6-2)7-8-18-9-14-11-10(18)12(19)16(4)13(20)15(11)3/h9H,5-8H2,1-4H3
DM96RD5 IU 7-[2-(diethylamino)ethyl]-1,3-dimethylpurine-2,6-dione
DM96RD5 CA CAS 314-35-2
DM96RD5 CB CHEBI:135157
DM96RD5 DE Asthma
DMTYGWV ID DMTYGWV
DMTYGWV DN NSC-639829
DMTYGWV HS Phase 1
DMTYGWV SN N-[4-(5-Bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea
DMTYGWV DT Small molecular drug
DMTYGWV PC 368697
DMTYGWV MW 470.3
DMTYGWV FM C21H20BrN5O3
DMTYGWV IC InChI=1S/C21H20BrN5O3/c1-13-10-15(8-9-18(13)30-21-23-11-14(22)12-24-21)25-20(29)26-19(28)16-6-4-5-7-17(16)27(2)3/h4-12H,1-3H3,(H2,25,26,28,29)
DMTYGWV CS CC1=C(C=CC(=C1)NC(=O)NC(=O)C2=CC=CC=C2N(C)C)OC3=NC=C(C=N3)Br
DMTYGWV IK JNGQUJZDVFZPEN-UHFFFAOYSA-N
DMTYGWV IU N-[[4-(5-bromopyrimidin-2-yl)oxy-3-methylphenyl]carbamoyl]-2-(dimethylamino)benzamide
DMTYGWV CA CAS 134742-19-1
DMTYGWV DE Solid tumour/cancer
DM5QHID ID DM5QHID
DM5QHID DN NSD-788
DM5QHID HS Phase 1
DM5QHID SN GABA-A receptor modulator (anxiety/depression), NeuroSearch
DM5QHID CP NeuroSearch A/S
DM5QHID DE Anxiety disorder
DM1ITDN ID DM1ITDN
DM1ITDN DN NsG-0202
DM1ITDN HS Phase 1
DM1ITDN SN ECB-AD; ECT-AD; ECT-NGF; ECT (Alzheimers Disease), NsGene; Encapsulated cell technology (Alzheimers Disease), NsGene; Encapsulated ARPE-19 cells (Alzheimers disease), NsGene
DM1ITDN CP NsGene A/S
DM1ITDN DE Alzheimer disease
DMSWJ6D ID DMSWJ6D
DMSWJ6D DN NU-206
DMSWJ6D HS Phase 1
DMSWJ6D SN HRSpo-1; Secreted proteins (IBD), ARCA; Secreted proteins (mucositis), ARCA; Secreted proteins (GI and bone diseases),Kyowa Hakko Kirin/ARCA; Secreted proteins (IBD), Kirin/ARCA; Secreted proteins (inflammatory bowel disease), ARCA/Kirin; Secreted proteins (mucositis), Kirin/ARCA; Human R-Spondin-1 (GI and bone diseases), ARCA; Low-density lipoprotein receptor related protein 6 (IBD), Kirin/ARCA
DMSWJ6D CP Kirin Brewery Co Ltd
DMSWJ6D DE Gastrointestinal disease
DMQ0F5P ID DMQ0F5P
DMQ0F5P DN NUC-3373
DMQ0F5P HS Phase 1
DMQ0F5P SN Fosifloxuridine nafalbenamide; 1332837-31-6; CHEMBL2181367; EX-A4413; DB14859; J3.616.613D; UNII-4YO6QT3SZ9 component BIOWRMNRHMERIO-XWVUVRNUSA-N; L-Alanine, N-(-2'-deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, phenylmethyl ester
DMQ0F5P CP NuCana
DMQ0F5P DT Small molecular drug
DMQ0F5P PC 53373585
DMQ0F5P MW 613.5
DMQ0F5P FM C29H29FN3O9P
DMQ0F5P IC InChI=1S/C29H29FN3O9P/c1-18(28(36)39-16-19-8-3-2-4-9-19)32-43(38,42-24-13-7-11-20-10-5-6-12-21(20)24)40-17-25-23(34)14-26(41-25)33-15-22(30)27(35)31-29(33)37/h2-13,15,18,23,25-26,34H,14,16-17H2,1H3,(H,32,38)(H,31,35,37)/t18-,23-,25+,26+,43?/m0/s1
DMQ0F5P CS C[C@@H](C(=O)OCC1=CC=CC=C1)NP(=O)(OC[C@@H]2[C@H](C[C@@H](O2)N3C=C(C(=O)NC3=O)F)O)OC4=CC=CC5=CC=CC=C54
DMQ0F5P IK BIOWRMNRHMERIO-ZVAHOJSLSA-N
DMQ0F5P IU benzyl (2S)-2-[[[(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
DMQ0F5P CA CAS 1332837-31-6
DMQ0F5P DE Solid tumour/cancer
DMNF09S ID DMNF09S
DMNF09S DN NV-04
DMNF09S HS Phase 1
DMNF09S SN Phenolic hormone (cardiovascular), Novogen; Trans-NV-04
DMNF09S CP Novogen
DMNF09S DE Cardiovascular disease
DMLKS7W ID DMLKS7W
DMLKS7W DN NV-5138
DMLKS7W HS Phase 1
DMLKS7W SN UNII-06CA9QMG6Z; 4-(difluoromethyl)-L-leucine; 2095886-80-7; SCHEMBL18762589; ZINC585143195; HY-114384; N[C@H](C(=O)O)CC(C(F)F)(C)C; CS-0084893; ((S)-2-Amino-5,5-difluoro-4,4-dimethylpentanoic acid; Pentanoic acid, 2-amino-5,5-difluoro-4,4-dimethyl-, (2S)-; K94
DMLKS7W CP Navitor Pharmaceuticals
DMLKS7W DT Small molecular drug
DMLKS7W PC 129050791
DMLKS7W MW 181.18
DMLKS7W FM C7H13F2NO2
DMLKS7W IC InChI=1S/C7H13F2NO2/c1-7(2,6(8)9)3-4(10)5(11)12/h4,6H,3,10H2,1-2H3,(H,11,12)/t4-/m0/s1
DMLKS7W CS CC(C)(C[C@@H](C(=O)O)N)C(F)F
DMLKS7W IK HRFIMCJTDKEPPV-BYPYZUCNSA-N
DMLKS7W IU (2S)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid
DMLKS7W CA CAS 2095886-80-7
DMLKS7W DE Major depressive disorder
DM0UOA9 ID DM0UOA9
DM0UOA9 DN NV-52
DM0UOA9 HS Phase 1
DM0UOA9 CP Novogen
DM0UOA9 DE Inflammatory bowel disease
DM0EKUQ ID DM0EKUQ
DM0EKUQ DN NY-ESO-1 vaccine
DM0EKUQ HS Phase 1
DM0EKUQ SN Cancer vaccine (peptides), Ludwig Institute; NY-ESO-1b; NY-ESO-1 OLP-4; NY-ESO-1 peptide immunotherapy, Ludwig Institute; NY-ESO-1 vaccine (peptides); NY-ESO-1 DP4 peptide (157-170); NY-ESO-1 vaccine (peptides), Ludwig Institute
DM0EKUQ CP Ludwig Institute for Cancer Research
DM0EKUQ DT Vaccine
DM0EKUQ DE Solid tumour/cancer
DMWN2FP ID DMWN2FP
DMWN2FP DN NZV930
DMWN2FP HS Phase 1
DMWN2FP SN SRF 373
DMWN2FP CP Surface oncology
DMWN2FP DT Antibody
DMWN2FP DE Solid tumour/cancer
DMPLV9G ID DMPLV9G
DMPLV9G DN OBP-801
DMPLV9G HS Phase 1
DMPLV9G CP Astellas Pharma Inc
DMPLV9G PC 11178958
DMPLV9G MW 473.6
DMPLV9G FM C20H31N3O6S2
DMPLV9G IC InChI=1S/C20H31N3O6S2/c1-11(2)18-15(24)9-17(26)29-13-6-4-5-7-30-31-10-14(20(28)23-18)22-19(27)12(3)21-16(25)8-13/h4,6,11-15,18,24H,5,7-10H2,1-3H3,(H,21,25)(H,22,27)(H,23,28)/b6-4+/t12-,13-,14-,15+,18-/m1/s1
DMPLV9G CS C[C@@H]1C(=O)N[C@@H]2CSSCC/C=C/[C@H](CC(=O)N1)OC(=O)C[C@@H]([C@H](NC2=O)C(C)C)O
DMPLV9G IK XFLBOEMFLGLWFF-HDXRNPEWSA-N
DMPLV9G IU (1S,5S,6R,9S,15E,20R)-5-hydroxy-20-methyl-6-propan-2-yl-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetrone
DMPLV9G CA CAS 328548-11-4
DMPLV9G DE Solid tumour/cancer
DMW4JRY ID DMW4JRY
DMW4JRY DN OBT076
DMW4JRY HS Phase 1
DMW4JRY SN MEN1309
DMW4JRY CP Oxford BioTherapeutics
DMW4JRY DT Antibody drug conjugate
DMW4JRY DE Breast cancer
DMOSRFZ ID DMOSRFZ
DMOSRFZ DN OC-10X
DMOSRFZ HS Phase 1
DMOSRFZ SN AMD therapy, OcuCure
DMOSRFZ CP Ocucure therapeutics
DMOSRFZ PC 4793207
DMOSRFZ MW 300.4
DMOSRFZ FM C20H16N2O
DMOSRFZ IC InChI=1S/C20H16N2O/c23-20-17-8-4-5-9-18(17)21-19(22-20)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,19,21H,(H,22,23)
DMOSRFZ CS C1=CC=C(C=C1)C2=CC=C(C=C2)C3NC4=CC=CC=C4C(=O)N3
DMOSRFZ IK XRUAOBKXCFNPCK-UHFFFAOYSA-N
DMOSRFZ IU 2-(4-phenylphenyl)-2,3-dihydro-1H-quinazolin-4-one
DMOSRFZ DE Macular degeneration; Proliferative diabetic retinopathy
DMZK1GW ID DMZK1GW
DMZK1GW DN OG987SC
DMZK1GW HS Phase 1
DMZK1GW SN NN9927
DMZK1GW CP Novo Nordisk
DMZK1GW DE Type-2 diabetes
DMH0D5M ID DMH0D5M
DMH0D5M DN OI287GT
DMH0D5M HS Phase 1
DMH0D5M SN NN1956
DMH0D5M CP Novo Nordisk
DMH0D5M DE Type-1/2 diabetes
DMERDMV ID DMERDMV
DMERDMV DN OI362GT
DMERDMV HS Phase 1
DMERDMV SN NN1954
DMERDMV CP Novo Nordisk
DMERDMV DE Type-1/2 diabetes
DMSJWTE ID DMSJWTE
DMSJWTE DN OKI 179
DMSJWTE HS Phase 1
DMSJWTE CP OnKure Therapeutics
DMSJWTE DT Small molecular drug
DMSJWTE DE Solid tumour/cancer
DMLVNWO ID DMLVNWO
DMLVNWO DN Oleclumab
DMLVNWO HS Phase 1
DMLVNWO CP MedImmune Gaithersburg, MD
DMLVNWO DE Solid tumour/cancer
DM2THBX ID DM2THBX
DM2THBX DN OM-174
DM2THBX HS Phase 1
DM2THBX SN UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate
DM2THBX CP OM Pharma
DM2THBX PC 9833422
DM2THBX MW 1135.3
DM2THBX FM C52H100N2O20P2
DM2THBX IC InChI=1S/C52H100N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-38(56)34-42(57)53-45-48(61)47(60)41(72-52(45)74-76(66,67)68)37-69-51-46(49(62)50(40(36-55)71-51)73-75(63,64)65)54-43(58)35-39(32-29-26-23-20-17-14-11-8-5-2)70-44(59)33-30-27-24-21-18-15-12-9-6-3/h38-41,45-52,55-56,60-62H,4-37H2,1-3H3,(H,53,57)(H,54,58)(H2,63,64,65)(H2,66,67,68)/t38-,39-,40-,41-,45-,46-,47-,48-,49-,50-,51-,52-/m1/s1
DM2THBX CS CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OP(=O)(O)O)O)NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O)O)O
DM2THBX IK GOWLTLODGKPXMN-MWJFIXGVSA-N
DM2THBX IU [(3R)-1-[[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3,4-dihydroxy-5-[[(3R)-3-hydroxytetradecanoyl]amino]-6-phosphonooxyoxan-2-yl]methoxy]-4-hydroxy-6-(hydroxymethyl)-5-phosphonooxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] dodecanoate
DM2THBX CA CAS 171092-39-0
DM2THBX DE Solid tumour/cancer
DMWHZEG ID DMWHZEG
DMWHZEG DN OMN-54
DMWHZEG HS Phase 1
DMWHZEG CP Omnitura therapeutics
DMWHZEG DE Solid tumour/cancer
DMTFU8Q ID DMTFU8Q
DMTFU8Q DN OMP-131R10
DMTFU8Q HS Phase 1
DMTFU8Q CP OncoMed
DMTFU8Q DT Antibody
DMTFU8Q DE Solid tumour/cancer
DMWK679 ID DMWK679
DMWK679 DN OMP-18R5
DMWK679 HS Phase 1
DMWK679 SN Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals
DMWK679 CP Oncomed pharmaceuticals; Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
DMWK679 DE Solid tumour/cancer
DMX1D0S ID DMX1D0S
DMX1D0S DN OMP-21M18
DMX1D0S HS Phase 1
DMX1D0S CP GlaxoSmithKline
DMX1D0S DE Solid tumour/cancer
DMGWC86 ID DMGWC86
DMGWC86 DN OMP-52M51
DMGWC86 HS Phase 1
DMGWC86 CP Glaxosmithkline; oncomed pharmaceuticals
DMGWC86 DT Antibody
DMGWC86 DE Solid tumour/cancer
DMO0JP1 ID DMO0JP1
DMO0JP1 DN OMS527
DMO0JP1 HS Phase 1
DMO0JP1 CP Omeros
DMO0JP1 DT Small interfering RNA
DMO0JP1 DE Substance use disorder
DMWYEDX ID DMWYEDX
DMWYEDX DN ON-01210.Na
DMWYEDX HS Phase 1
DMWYEDX SN Ex-RAD; Tyrosine kinase inhibitor (radiation protection), Onconova; ON-01210.Na (oral, radiation sickness); ON-01210.Na (oral, radiation sickness), Onconova; ON-01210.Na (sc, radiation sickness), Onconova Therapeutics
DMWYEDX CP Onconova Therapeutics Inc
DMWYEDX DT Small molecular drug
DMWYEDX PC 23668369
DMWYEDX MW 358.8
DMWYEDX FM C16H12ClNaO4S
DMWYEDX IC InChI=1S/C16H13ClO4S.Na/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19;/h1-10H,11H2,(H,18,19);/q;+1/p-1/b10-9+;
DMWYEDX CS C1=CC(=CC=C1CS(=O)(=O)/C=C/C2=CC=C(C=C2)C(=O)[O-])Cl.[Na+]
DMWYEDX IK PRFBWBYKWZVQJF-RRABGKBLSA-M
DMWYEDX IU sodium;4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoate
DMWYEDX CA CAS 922139-31-9
DMWYEDX DE Radiation syndrome; Acute radiation syndrome
DM5VY23 ID DM5VY23
DM5VY23 DN ONC206
DM5VY23 HS Phase 1
DM5VY23 SN UNII-OW6LM47PNK; OW6LM47PNK; 1638178-87-6; 7-benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; SCHEMBL20464679; ONC-206; NSC783746; s6853; NSC-783746; HY-135147; CS-0109614; 4-((2,4-Difluorophenyl)methyl)-2,4,6,7,8,9-hexahydro-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-E)pyrimidin-5(1H)-one; 7-Benzyl-4-(2,4-difluorobenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one
DM5VY23 CP Oncoceutics
DM5VY23 DT Small molecular drug
DM5VY23 PC 135297777
DM5VY23 MW 408.4
DM5VY23 FM C23H22F2N4O
DM5VY23 IC InChI=1S/C23H22F2N4O/c24-18-7-6-17(20(25)12-18)14-29-22(30)19-15-27(13-16-4-2-1-3-5-16)10-8-21(19)28-11-9-26-23(28)29/h1-7,12H,8-11,13-15H2
DM5VY23 CS C1CN(CC2=C1N3CCN=C3N(C2=O)CC4=C(C=C(C=C4)F)F)CC5=CC=CC=C5
DM5VY23 IK ITMGVSSHWMTJRR-UHFFFAOYSA-N
DM5VY23 IU 11-benzyl-7-[(2,4-difluorophenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
DM5VY23 CA CAS 1638178-87-6
DM5VY23 DE Brain and central nervous system tumour
DM8B40M ID DM8B40M
DM8B40M DN ONC-392
DM8B40M HS Phase 1
DM8B40M CP OncoImmune
DM8B40M DT Antibody
DM8B40M DE Non-small-cell lung cancer; Solid tumour/cancer
DMC29LV ID DMC29LV
DMC29LV DN ONO-4059
DMC29LV HS Phase 1
DMC29LV CP ONO Pharmaceutical
DMC29LV DE B-cell lymphoma
DMO4SD2 ID DMO4SD2
DMO4SD2 DN ONO-4232
DMO4SD2 HS Phase 1
DMO4SD2 CP Ono pharma usa
DMO4SD2 DE Acute heart failure
DME63VK ID DME63VK
DME63VK DN ONO-4578
DME63VK HS Phase 1
DME63VK SN BMS-986310
DME63VK CP Ono Pharmaceutical; Bristol-Myers Squibb
DME63VK DE Solid tumour/cancer
DMGBKCJ ID DMGBKCJ
DMGBKCJ DN ONO-7475
DMGBKCJ HS Phase 1
DMGBKCJ CP Ono Pharmaceutical Osaka, Japan
DMGBKCJ DE Acute myeloid leukaemia
DMUZFVH ID DMUZFVH
DMUZFVH DN ONT-10
DMUZFVH HS Phase 1
DMUZFVH CP Oncothyreon
DMUZFVH DT Vaccine
DMUZFVH DE Solid tumour/cancer
DMBVZND ID DMBVZND
DMBVZND DN ONYX-015
DMBVZND HS Phase 1
DMBVZND SN Dl1520; E1B-deleted adenovirus (cancer), ONYX
DMBVZND CP Onyx Pharmaceuticals Inc
DMBVZND DE Head and neck cancer
DMECVP9 ID DMECVP9
DMECVP9 DN OP-0595
DMECVP9 HS Phase 1
DMECVP9 SN Nacubactam; 1452458-86-4; RG6080; RG-6080; UNII-832O37V7MZ; RO7079901; 832O37V7MZ; FPI-1459; 1452458-86-4 (free acid); RO-7079901; (1R,2S,5R)-2-((2-aminoethoxy)carbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; Nacubactam [INN]; Nacubactam (USAN); Nacubactam [USAN:INN]; CHEMBL3989959; SCHEMBL15206610; SCHEMBL17975933; GTPL10833; MFCD28986228; OP0595; ZINC207610051; DB15353; SB17180; AS-35134; HY-109008; CS-0030506; D11329; Q27269383; (1R,2S,5R)-2-((2-Aminoethoxy)carbamoyl)-7-oxo- 1,6-diazabicyclo(3.2.1)octan-6-yl hydrogen sulfate; (2S,5R)-2-(2-Aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate; (2S,5R)-N-(2-Aminoethoxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide; [(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester; Sulfuric acid, mono((1R,2S,5R)-2-(((2-aminoethoxy)amino)carbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester, (-)-
DMECVP9 CP Meiji Seika Pharma
DMECVP9 DT Small molecular drug
DMECVP9 PC 73386748
DMECVP9 MW 324.31
DMECVP9 FM C9H16N4O7S
DMECVP9 IC InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
DMECVP9 CS C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN
DMECVP9 IK RSBPYSTVZQAADE-RQJHMYQMSA-N
DMECVP9 IU [(2S,5R)-2-(2-aminoethoxycarbamoyl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
DMECVP9 CA CAS 1452458-86-4
DMECVP9 DE Bacterial infection
DM7YFW5 ID DM7YFW5
DM7YFW5 DN OPB-111077
DM7YFW5 HS Phase 1
DM7YFW5 CP Rockville
DM7YFW5 DT Small interfering RNA
DM7YFW5 DE Hepatocellular carcinoma; Haematological malignancy; Solid tumour/cancer
DM760FA ID DM760FA
DM760FA DN OPB-51602
DM760FA HS Phase 1
DM760FA CP Otsuka America Pharmaceutical
DM760FA DE Solid tumour/cancer
DMZWFKQ ID DMZWFKQ
DMZWFKQ DN OPC-14117
DMZWFKQ HS Phase 1
DMZWFKQ SN N-(7-Hydroxy-2,2,4,6-trimethylindan-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide; 7-Hydroxy-1-[2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamido]-2,2,4,6-tetramethylindan
DMZWFKQ DT Small molecular drug
DMZWFKQ PC 59739
DMZWFKQ MW 437.6
DMZWFKQ FM C26H35N3O3
DMZWFKQ IC InChI=1S/C26H35N3O3/c1-17-13-18(2)24(31)23-21(17)15-26(3,4)25(23)27-22(30)16-28-9-11-29(12-10-28)19-7-6-8-20(14-19)32-5/h6-8,13-14,25,31H,9-12,15-16H2,1-5H3,(H,27,30)
DMZWFKQ CS CC1=CC(=C(C2=C1CC(C2NC(=O)CN3CCN(CC3)C4=CC(=CC=C4)OC)(C)C)O)C
DMZWFKQ IK LYAUICDWKQJAGX-UHFFFAOYSA-N
DMZWFKQ IU N-(7-hydroxy-2,2,4,6-tetramethyl-1,3-dihydroinden-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide
DMZWFKQ CA CAS 103233-65-4
DMZWFKQ DE Neurological disorder
DMLUYAJ ID DMLUYAJ
DMLUYAJ DN OPK-0018
DMLUYAJ HS Phase 1
DMLUYAJ CP OPKO Health
DMLUYAJ DE Asthma
DM3HOUX ID DM3HOUX
DM3HOUX DN OPL-CCL2-LPM
DM3HOUX HS Phase 1
DM3HOUX SN CCR2 targeting agent (arthritis/nephritis/cardiovascular/pulmonaryl/CNS); Leukocyte population modulator (arthritis/nephritis/cardiovascular/pulmonary/CNS), Osprey
DM3HOUX CP Osprey Pharmaceuticals Ltd
DM3HOUX DE Arthritis
DMH6SNO ID DMH6SNO
DMH6SNO DN OP-R003
DMH6SNO HS Phase 1
DMH6SNO SN VX-30; OP-R003-1; Elsilimomab derivative (hematological disease), OPi/Vaccinex; IL-6 antibodies (hematological disease), EUSA; IL6 antibodies (hematological disease), OPi/Vaccinex; OP-R003 (hematological cancer), GSK; OP-R003 (inflammation), GSK; Anti-IL-6 human MAb (hematological cancer), GSK; Anti-IL-6 human MAb(inflammation), GSK
DMH6SNO CP Vaccinex Inc
DMH6SNO DE Haematological malignancy
DMBG534 ID DMBG534
DMBG534 DN Org-25435
DMBG534 HS Phase 1
DMBG534 SN Org 25435; CHEMBL325728
DMBG534 CP Organon BioSciences
DMBG534 DT Small molecular drug
DMBG534 PC 9885653
DMBG534 MW 369.5
DMBG534 FM C19H31NO6
DMBG534 IC InChI=1S/C19H31NO6/c1-7-15(20(8-10-22-3)9-11-23-4)19(21)26-18-16(24-5)12-14(2)13-17(18)25-6/h12-13,15H,7-11H2,1-6H3/t15-/m1/s1
DMBG534 CS CC[C@H](C(=O)OC1=C(C=C(C=C1OC)C)OC)N(CCOC)CCOC
DMBG534 IK GKRFHHRXDUACIN-OAHLLOKOSA-N
DMBG534 IU (2,6-dimethoxy-4-methylphenyl) (2R)-2-[bis(2-methoxyethyl)amino]butanoate
DMBG534 CA CAS 256456-73-2
DMBG534 DE Epilepsy
DME0WX2 ID DME0WX2
DME0WX2 DN Org-43902
DME0WX2 HS Phase 1
DME0WX2 SN LH-ago1; ORG-41247; ORG-42619; ORG-43311; SC-20565; Luteinizing hormone receptor (LHR) agonist, NV Organon; Oral LH agonist, Schering-Plough; Low molecular weight luteinizing hormone (LMW LH) receptor agonist, Merck & Co; Luteinizing hormone agonist (oral), Merck & Co; Luteinizing hormone agonist (oral), Schering-Plough
DME0WX2 CP Organon BioSciences
DME0WX2 DE Infertility
DMR12S0 ID DMR12S0
DMR12S0 DN ORIC-101
DMR12S0 HS Phase 1
DMR12S0 SN VNLTWJIWEYPBIF-SXJSTINISA-N; 2222344-98-9
DMR12S0 CP ORIC Pharmaceuticals South San Francisco, CA
DMR12S0 PC 134415769
DMR12S0 MW 501.7
DMR12S0 FM C34H47NO2
DMR12S0 IC InChI=1S/C34H47NO2/c1-22(2)35(7)25-11-8-23(9-12-25)29-21-33(6)30(16-17-34(33,37)19-18-32(3,4)5)28-14-10-24-20-26(36)13-15-27(24)31(28)29/h8-9,11-12,20,22,27-31,37H,10,13-17,21H2,1-7H3/t27-,28-,29+,30-,31+,33-,34+/m0/s1
DMR12S0 CS CC(C)N(C)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C#CC(C)(C)C)O)[C@H]4[C@H]2[C@H]5CCC(=O)C=C5CC4)C
DMR12S0 IK VNLTWJIWEYPBIF-KMSLUKAPSA-N
DMR12S0 IU (8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-13-methyl-11-[4-[methyl(propan-2-yl)amino]phenyl]-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DMR12S0 DE Solid tumour/cancer
DMS8NM5 ID DMS8NM5
DMS8NM5 DN OS2966
DMS8NM5 HS Phase 1
DMS8NM5 CP OncoSynergy
DMS8NM5 DT Antibody
DMS8NM5 DE Glioblastoma of brain
DMF2CZ9 ID DMF2CZ9
DMF2CZ9 DN OSI-930
DMF2CZ9 HS Phase 1
DMF2CZ9 SN OSI 930; OSI930; OSI-930 is a multi-targeted tyrosine kinase inhibitor; 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
DMF2CZ9 CP OSI Pharmaceuticals
DMF2CZ9 TC Anticancer Agents
DMF2CZ9 DT Small molecular drug
DMF2CZ9 PC 9868037
DMF2CZ9 MW 443.4
DMF2CZ9 FM C22H16F3N3O2S
DMF2CZ9 IC InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)
DMF2CZ9 CS C1=CC=C2C(=C1)C(=CC=N2)CNC3=C(SC=C3)C(=O)NC4=CC=C(C=C4)OC(F)(F)F
DMF2CZ9 IK FGTCROZDHDSNIO-UHFFFAOYSA-N
DMF2CZ9 IU 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide
DMF2CZ9 CA CAS 728033-96-3
DMF2CZ9 CB CHEBI:91433
DMF2CZ9 DE Solid tumour/cancer
DMI24RF ID DMI24RF
DMI24RF DN OT-82
DMI24RF HS Phase 1
DMI24RF SN 1800487-55-1; N-(3-(1H-pyrazol-4-yl)propyl)-3-((4-fluorophenyl)ethynyl)-4-(pyridin-4-yl)benzamide; OT82; SCHEMBL16869651; NSC826040; NSC-826040; HY-136241; CS-0120951
DMI24RF CP OncoTartis
DMI24RF DT Small molecular drug
DMI24RF PC 118203189
DMI24RF MW 424.5
DMI24RF FM C26H21FN4O
DMI24RF IC InChI=1S/C26H21FN4O/c27-24-8-4-19(5-9-24)3-6-22-16-23(7-10-25(22)21-11-14-28-15-12-21)26(32)29-13-1-2-20-17-30-31-18-20/h4-5,7-12,14-18H,1-2,13H2,(H,29,32)(H,30,31)
DMI24RF CS C1=CC(=CC=C1C#CC2=C(C=CC(=C2)C(=O)NCCCC3=CNN=C3)C4=CC=NC=C4)F
DMI24RF IK CEPAXRIKSUXHHB-UHFFFAOYSA-N
DMI24RF IU 3-[2-(4-fluorophenyl)ethynyl]-N-[3-(1H-pyrazol-4-yl)propyl]-4-pyridin-4-ylbenzamide
DMI24RF DE Lymphoma
DMWIEC1 ID DMWIEC1
DMWIEC1 DN OTSA-101-DTPA-90Y
DMWIEC1 HS Phase 1
DMWIEC1 CP University of Tokyo/Centre Leon-Berard
DMWIEC1 DT Antibody
DMWIEC1 DE Synovial sarcoma
DMF5KNO ID DMF5KNO
DMF5KNO DN OTSSP167
DMF5KNO HS Phase 1
DMF5KNO SN OTSSP 167; OTSSP-167; AMX10201
DMF5KNO DT Small molecular drug
DMF5KNO PC 135398499
DMF5KNO MW 487.4
DMF5KNO FM C25H28Cl2N4O2
DMF5KNO IC InChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29)
DMF5KNO CS CC(=O)C1=CN=C2C=CC(=NC2=C1NC3CCC(CC3)CN(C)C)C4=CC(=C(C(=C4)Cl)O)Cl
DMF5KNO IK DKZYXHCYPUVGAF-UHFFFAOYSA-N
DMF5KNO IU 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone
DMF5KNO CA CAS 1431697-89-0
DMF5KNO CB CHEBI:95088
DMF5KNO DE Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Myelodysplastic syndrome; Myeloproliferative neoplasm
DMN4LMT ID DMN4LMT
DMN4LMT DN Oxeglitazar
DMN4LMT HS Phase 1
DMN4LMT SN EMD-336340; EML-16156; EML-4156; LM-4156
DMN4LMT CP Merck Sante SA
DMN4LMT DT Small molecular drug
DMN4LMT PC 6445229
DMN4LMT MW 314.4
DMN4LMT FM C19H22O4
DMN4LMT IC InChI=1S/C19H22O4/c1-13(9-18(20)21)5-6-14-11-19(2,3)12-23-17-8-7-15(22-4)10-16(14)17/h5-11H,12H2,1-4H3,(H,20,21)/b6-5+,13-9+
DMN4LMT CS C/C(=C\\C(=O)O)/C=C/C1=CC(COC2=C1C=C(C=C2)OC)(C)C
DMN4LMT IK FVGXANXBVWECQE-BYWGDBCOSA-N
DMN4LMT IU (2E,4E)-5-(7-methoxy-3,3-dimethyl-2H-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid
DMN4LMT CA CAS 280585-34-4
DMN4LMT DE Gout
DMXZOI0 ID DMXZOI0
DMXZOI0 DN P11187
DMXZOI0 HS Phase 1
DMXZOI0 CP Piramal enterprises
DMXZOI0 DE Type-2 diabetes
DMXHKYJ ID DMXHKYJ
DMXHKYJ DN P1446A-05
DMXHKYJ HS Phase 1
DMXHKYJ CP Nicholas Piramal
DMXHKYJ PC 67409219
DMXHKYJ MW 469.8
DMXHKYJ FM C22H19ClF3NO5
DMXHKYJ IC InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1
DMXHKYJ CS CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=C(C=C(C=C4)C(F)(F)F)Cl)O)O
DMXHKYJ IK MRPGRAKIAJJGMM-OCCSQVGLSA-N
DMXHKYJ IU 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one
DMXHKYJ CA CAS 1000023-04-0
DMXHKYJ DE Solid tumour/cancer
DMJ3PNS ID DMJ3PNS
DMJ3PNS DN P-2745
DMJ3PNS HS Phase 1
DMJ3PNS CP Piramal Life Sciences Ltd
DMJ3PNS DE Chronic myelogenous leukaemia
DMIYQEM ID DMIYQEM
DMIYQEM DN P-7170
DMIYQEM HS Phase 1
DMIYQEM CP Piramal Life Sciences Ltd
DMIYQEM DE Solid tumour/cancer
DMNZQU5 ID DMNZQU5
DMNZQU5 DN P-7435
DMNZQU5 HS Phase 1
DMNZQU5 SN DGAT1 inhibitors (diabetes/metabolic disorder), Piramal Life Sciences
DMNZQU5 CP Piramal enterprises
DMNZQU5 DE Diabetic complication
DMYQUIP ID DMYQUIP
DMYQUIP DN PAC1
DMYQUIP HS Phase 1
DMYQUIP SN PAC-1
DMYQUIP DT Small molecular drug
DMYQUIP PC 135421197
DMYQUIP MW 392.5
DMYQUIP FM C23H28N4O2
DMYQUIP IC InChI=1S/C23H28N4O2/c1-2-7-20-10-6-11-21(23(20)29)16-24-25-22(28)18-27-14-12-26(13-15-27)17-19-8-4-3-5-9-19/h2-6,8-11,16,29H,1,7,12-15,17-18H2,(H,25,28)/b24-16+
DMYQUIP CS C=CCC1=C(C(=CC=C1)/C=N/NC(=O)CN2CCN(CC2)CC3=CC=CC=C3)O
DMYQUIP IK YQNRVGJCPCNMKT-LFVJCYFKSA-N
DMYQUIP IU 2-(4-benzylpiperazin-1-yl)-N-[(E)-(2-hydroxy-3-prop-2-enylphenyl)methylideneamino]acetamide
DMYQUIP CA CAS 315183-21-2
DMYQUIP DE Anaplastic astrocytoma; Recurrent glioblastoma
DMX9AK6 ID DMX9AK6
DMX9AK6 DN PACAP38
DMX9AK6 HS Phase 1
DMX9AK6 SN H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-OH
DMX9AK6 DE Nerve injury
DMXQ4NO ID DMXQ4NO
DMXQ4NO DN Palomid-529
DMXQ4NO HS Phase 1
DMXQ4NO SN Palomid 529; 914913-88-5; P529; Palomid 529 (P529); 8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one; SG 00529; SG-00529; P-529; 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one; UNII-XV9409EWG4; 6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-; 8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one; Palomid529; 6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-; 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one; RES-529; XV9409EWG4; Palomid 529,P529; cc-513; MLS006011187; Palomid 529 - P529; SCHEMBL290034; C22H26Cl2N2O8; CHEMBL2141712; EX-A254; QCR-215; SYN5215; BCPP000131; HMS3655L14; HMS3673G05; AMY22735; BCP02474; ABP000907; MFCD18633224; NSC775306; NSC801008; s2238; 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one; AKOS024463339; ACN-030389; BCP9001049; CCG-268719; CS-0258; DB12812; NSC-775306; NSC-801008; Palomid 529 (P529) /P529; SB16564; SG00529; 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one; NCGC00263125-01; NCGC00263125-10; AC-31523; AK160239; AS-16573; HY-14581; SMR004702956; AB0008147; SW219676-1; Y0291; W-5766; J-519339; Q27294013
DMXQ4NO DT Small molecular drug
DMXQ4NO PC 11998575
DMXQ4NO MW 406.4
DMXQ4NO FM C24H22O6
DMXQ4NO IC InChI=1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3
DMXQ4NO CS CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O
DMXQ4NO IK YEAHTLOYHVWAKW-UHFFFAOYSA-N
DMXQ4NO IU 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one
DMXQ4NO CA CAS 914913-88-5
DMXQ4NO DE Macular degeneration
DMY9LG1 ID DMY9LG1
DMY9LG1 DN PAN-90806
DMY9LG1 HS Phase 1
DMY9LG1 CP OSI Pharmaceuticals Inc
DMY9LG1 DE Solid tumour/cancer; Diabetic retinopathy
DMZSD3T ID DMZSD3T
DMZSD3T DN Patient-derived CD19- and CD22 specific CAR
DMZSD3T HS Phase 1
DMZSD3T CP Seattle Children's Hospital
DMZSD3T DT CAR T Cell Therapy (Dual specific)
DMZSD3T DE leukaemia; Lymphoma
DMFSMCB ID DMFSMCB
DMFSMCB DN Patritumab
DMFSMCB HS Phase 1
DMFSMCB CP Daiichi sankyo
DMFSMCB DT Antibody
DMFSMCB DE Non-small-cell lung cancer
DMDC9TB ID DMDC9TB
DMDC9TB DN P-BCMA-101 CAR-T cells
DMDC9TB HS Phase 1
DMDC9TB CP Poseida Therapeutics, Inc.
DMDC9TB DT CAR T Cell Therapy
DMDC9TB DE Multiple myeloma
DMOPGXM ID DMOPGXM
DMOPGXM DN PBF-1129
DMOPGXM HS Phase 1
DMOPGXM CP Palobiofarma Barcelona, Spain
DMOPGXM DE Non-small-cell lung cancer
DMBSQH9 ID DMBSQH9
DMBSQH9 DN PBF-999
DMBSQH9 HS Phase 1
DMBSQH9 SN CHEMBL3942498; SCHEMBL15905362; BDBM247392; SB18883; US9447095, 42; 5-bromo-4-N-prop-2-ynyl-2-(1,2,4-triazol-1-yl)pyrimidine-4,6-diamine; 1620909-95-6
DMBSQH9 CP Palobiofarma
DMBSQH9 DT Small molecular drug
DMBSQH9 PC 77107498
DMBSQH9 MW 294.11
DMBSQH9 FM C9H8BrN7
DMBSQH9 IC InChI=1S/C9H8BrN7/c1-2-3-13-8-6(10)7(11)15-9(16-8)17-5-12-4-14-17/h1,4-5H,3H2,(H3,11,13,15,16)
DMBSQH9 CS C#CCNC1=NC(=NC(=C1Br)N)N2C=NC=N2
DMBSQH9 IK OQCWNHHZPYJHQR-UHFFFAOYSA-N
DMBSQH9 IU 5-bromo-4-N-prop-2-ynyl-2-(1,2,4-triazol-1-yl)pyrimidine-4,6-diamine
DMBSQH9 DE Solid tumour/cancer; Huntington disease
DM0O2N4 ID DM0O2N4
DM0O2N4 DN pbi-shRNA EWS-FLI-Type 1
DM0O2N4 HS Phase 1
DM0O2N4 CP Gradalis
DM0O2N4 DT Short hairpin RNA
DM0O2N4 DE Ewing sarcoma
DM529QO ID DM529QO
DM529QO DN pbi-shRNA STMN1
DM529QO HS Phase 1
DM529QO CP Gradalis
DM529QO DT Short hairpin RNA
DM529QO DE Breast cancer; Solid tumour/cancer
DMMR4E7 ID DMMR4E7
DMMR4E7 DN PBSVax
DMMR4E7 HS Phase 1
DMMR4E7 CP Profectus biosciences
DMMR4E7 DE Human immunodeficiency virus infection
DM23K45 ID DM23K45
DM23K45 DN Pc4
DM23K45 HS Phase 1
DM23K45 SN Pc4; Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC
DM23K45 CP Case Western Reserve University
DM23K45 DE Psoriasis vulgaris
DMNHSI8 ID DMNHSI8
DMNHSI8 DN PCO371
DMNHSI8 HS Phase 1
DMNHSI8 SN Pco-371; UNII-TE53TU0WSQ; TE53TU0WSQ; PCO-371; 1613373-33-3; SCHEMBL17104864; CHEMBL3976807; US9428505, Compound 7; BDBM64562; PC-0371; J3.591.565F; 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-
DMNHSI8 CP Chugai Pharma USA Berkeley Heights, NJ
DMNHSI8 PC 76283707
DMNHSI8 MW 635.7
DMNHSI8 FM C29H32F3N5O6S
DMNHSI8 IC InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44(41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)
DMNHSI8 CS CC1=CC(=CC(=C1CCS(=O)(=O)N2CCC3(CC2)C(=O)NC(=N3)C4=CC=C(C=C4)OC(F)(F)F)C)N5C(=O)NC(=O)C5(C)C
DMNHSI8 IK LDZJFVOUPUFOHX-UHFFFAOYSA-N
DMNHSI8 IU 1-[3,5-dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethylimidazolidine-2,4-dione
DMNHSI8 CA CAS 1613373-33-3
DMNHSI8 DE Hypoparathyroidism
DMH86KO ID DMH86KO
DMH86KO DN PCSK9 Adnectin
DMH86KO HS Phase 1
DMH86KO SN PCSK9 Adnectin (cardiovascular); Adnectin program (cardiovascular disease), Adnexus/BMS; PCSK9 Adnectin (cardiovascular), Bristol-Myers Squibb
DMH86KO CP Bristol-myers squibb
DMH86KO DE Cardiovascular disease
DM74YO8 ID DM74YO8
DM74YO8 DN PDC-41
DM74YO8 HS Phase 1
DM74YO8 SN THG-113; THG-113.31; PDC-31 (iv, premature labor); PGF2 alpha antagonist (primary dysmenorrhea/topical), PDC Biotech; Prostaglandin F2 alpha antagonist (primary dysmenorrhea/topical), PDC Biotech; PDC-31 (iv, premature labor), PDC; PGF2 alpha antagonist (injectable, premature labor/dysmenorrhea), PDC Biotech; Prostaglandin F2 alpha antagonist (injectable, premature labor/dysmenorrhea), PDC Biotech
DM74YO8 CP Theratechnologies Inc
DM74YO8 DE Dysmenorrhea
DMLJHM2 ID DMLJHM2
DMLJHM2 DN PD-L1 t-haNK
DMLJHM2 HS Phase 1
DMLJHM2 CP ImmunityBio; NantKwest
DMLJHM2 DT CAR T Cell Therapy
DMLJHM2 DE Solid tumour/cancer
DM4CY2G ID DM4CY2G
DM4CY2G DN PEDF gene therapy
DM4CY2G HS Phase 1
DM4CY2G SN AdPEDF; AdGVPEDF.11D; PEDF gene therapy (ophthalmic); PEDF gene therapy (ophthalmic), GenVec; Pigment epithelium-derived factor gene therapy, GenVec
DM4CY2G CP GenVec Inc
DM4CY2G DE Macular degeneration
DMB5JWX ID DMB5JWX
DMB5JWX DN Pegadricase
DMB5JWX HS Phase 1
DMB5JWX CP 3SBio
DMB5JWX PC 86278331
DMB5JWX MW 304.34
DMB5JWX FM C13H24N2O6
DMB5JWX IC InChI=1S/C13H24N2O6/c1-20-8-9-21-12(17)6-5-11(16)15-7-3-2-4-10(14)13(18)19/h10H,2-9,14H2,1H3,(H,15,16)(H,18,19)/t10-/m0/s1
DMB5JWX CS COCCOC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N
DMB5JWX IK PNFORBBPPMQASU-JTQLQIEISA-N
DMB5JWX IU (2S)-2-amino-6-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]hexanoic acid
DMB5JWX CA CAS 1040753-26-1
DMB5JWX DE Gout
DMW7VGZ ID DMW7VGZ
DMW7VGZ DN PegCNTF
DMW7VGZ HS Phase 1
DMW7VGZ SN Piperidine, 1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-; Sch-37370; 117796-52-8; Sch 37370; UNII-GA60WRR45J; N-Acetyldesloratadine; GA60WRR45J; CHEMBL10971; RESPATADINE; ethanone, 1-[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]-; AC1L1TPN; AC1Q5KQ9; SCHEMBL3071641; GTPL1853; DTXSID10151911; FLTBEMVEAFMWDD-UHFFFAOYSA-N; ZINC596712; BDBM50007473; 1-Acetyl-4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cycloheptal(1,2-b)pyridin-11-ylidine)piperidine; SCH-37370
DMW7VGZ CP Nektar/Regeneron
DMW7VGZ DT Small molecular drug
DMW7VGZ PC 60680
DMW7VGZ MW 352.9
DMW7VGZ FM C21H21ClN2O
DMW7VGZ IC InChI=1S/C21H21ClN2O/c1-14(25)24-11-8-15(9-12-24)20-19-7-6-18(22)13-17(19)5-4-16-3-2-10-23-21(16)20/h2-3,6-7,10,13H,4-5,8-9,11-12H2,1H3
DMW7VGZ CS CC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
DMW7VGZ IK FLTBEMVEAFMWDD-UHFFFAOYSA-N
DMW7VGZ IU 1-[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]ethanone
DMW7VGZ CA CAS 117796-52-8
DMW7VGZ DE Obesity
DM0E37K ID DM0E37K
DM0E37K DN Pegdinetanib
DM0E37K HS Phase 1
DM0E37K SN BMS-844203
DM0E37K CP Bristol-Myers Squibb
DM0E37K PC 86278317
DM0E37K MW 694.8
DM0E37K FM C27H46N6O13S
DM0E37K IC InChI=1S/C27H46N6O13S/c1-42-12-8-31-26(40)45-15-18(16-46-27(41)32-9-13-43-2)44-11-3-4-21(34)29-6-7-30-22(35)5-10-33-23(36)14-20(24(33)37)47-17-19(28)25(38)39/h18-20H,3-17,28H2,1-2H3,(H,29,34)(H,30,35)(H,31,40)(H,32,41)(H,38,39)/t19-,20?/m0/s1
DM0E37K CS COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(C1=O)SC[C@@H](C(=O)O)N
DM0E37K IK PQEJXGNZBLONLG-XJDOXCRVSA-N
DM0E37K IU (2R)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
DM0E37K CA CAS 906450-24-6
DM0E37K DE Non-small-cell lung cancer
DMQ4Z1P ID DMQ4Z1P
DMQ4Z1P DN Peginterferon beta
DMQ4Z1P HS Phase 1
DMQ4Z1P SN AZ-01; AZ-60; Jak2 inhibitors (myeloproliferative disorders); Jak2 inhibitors (myeloproliferative disorders), AstraZeneca
DMQ4Z1P CP Allozyne
DMQ4Z1P DE Multiple sclerosis
DMMEPKR ID DMMEPKR
DMMEPKR DN PEG-Interferon lambda (IL-29)
DMMEPKR HS Phase 1
DMMEPKR CP ZymoGenetics
DMMEPKR DE Virus infection
DMHV58T ID DMHV58T
DMHV58T DN Peldesine
DMHV58T HS Phase 1
DMHV58T DT Small molecular drug
DMHV58T PC 135413525
DMHV58T MW 241.25
DMHV58T FM C12H11N5O
DMHV58T IC InChI=1S/C12H11N5O/c13-12-16-9-8(4-7-2-1-3-14-5-7)6-15-10(9)11(18)17-12/h1-3,5-6,15H,4H2,(H3,13,16,17,18)
DMHV58T CS C1=CC(=CN=C1)CC2=CNC3=C2N=C(NC3=O)N
DMHV58T IK DOHVAKFYAHLCJP-UHFFFAOYSA-N
DMHV58T IU 2-amino-7-(pyridin-3-ylmethyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMHV58T CA CAS 133432-71-0
DMTEG6B ID DMTEG6B
DMTEG6B DN PENCLOMEDINE
DMTEG6B HS Phase 1
DMTEG6B SN Penclomidine; CRC-88-04; 3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine
DMTEG6B DT Small molecular drug
DMTEG6B PC 60203
DMTEG6B MW 325.4
DMTEG6B FM C8H6Cl5NO2
DMTEG6B IC InChI=1S/C8H6Cl5NO2/c1-15-5-3(9)6(8(11,12)13)14-7(16-2)4(5)10/h1-2H3
DMTEG6B CS COC1=C(C(=NC(=C1Cl)OC)C(Cl)(Cl)Cl)Cl
DMTEG6B IK DZVPGIORVGSQMC-UHFFFAOYSA-N
DMTEG6B IU 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine
DMTEG6B CA CAS 108030-77-9
DMTEG6B DE Solid tumour/cancer
DM0BNLC ID DM0BNLC
DM0BNLC DN PENNVAX-6
DM0BNLC HS Phase 1
DM0BNLC CP Inovio pharmaceuticals; national institute of allergy and infectious diseases
DM0BNLC DE Human immunodeficiency virus infection
DMUTISK ID DMUTISK
DMUTISK DN Pennvax-B
DMUTISK HS Phase 1
DMUTISK SN Pennvax-B (TN)
DMUTISK CP Inovio Pharmaceuticals
DMUTISK DT Vaccine
DMUTISK DE Human immunodeficiency virus infection
DM7YX8G ID DM7YX8G
DM7YX8G DN Pennvax-G
DM7YX8G HS Phase 1
DM7YX8G SN Pennvax-G (TN)
DM7YX8G CP Inovio Pharmaceuticals
DM7YX8G DT Vaccine
DM7YX8G DE Human immunodeficiency virus infection
DMVYRH2 ID DMVYRH2
DMVYRH2 DN Perifosine
DMVYRH2 HS Phase 1
DMVYRH2 SN D 21266; NKA17; D-21266; KRX-0401; KRX-0401, NSC 639966; Octadecyl-(1,1-dimethyl-4-piperidylio)phosphate; Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt; Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt; (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate; 4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt
DMVYRH2 CP AEterna Zentaris
DMVYRH2 TC Anticancer Agents
DMVYRH2 DT Small molecular drug
DMVYRH2 PC 148177
DMVYRH2 MW 461.7
DMVYRH2 FM C25H52NO4P
DMVYRH2 IC InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3
DMVYRH2 CS CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C
DMVYRH2 IK SZFPYBIJACMNJV-UHFFFAOYSA-N
DMVYRH2 IU (1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate
DMVYRH2 CA CAS 157716-52-4
DMVYRH2 CB CHEBI:67272
DMVYRH2 DE Solid tumour/cancer
DM5PUO0 ID DM5PUO0
DM5PUO0 DN PF-00337210
DM5PUO0 HS Phase 1
DM5PUO0 SN PF-00337210; N,2-Dimethyl-6-{[7-(2-Morpholin-4-Ylethoxy)quinolin-4-Yl]oxy}-1-Benzofuran-3-Carboxamide; SCHEMBL899025; LGXVKMDGSIWEHL-UHFFFAOYSA-N; ZINC34783303; PF-337210; N,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide
DM5PUO0 CP Pfizer New York, NY
DM5PUO0 DT Small molecular drug
DM5PUO0 PC 11236560
DM5PUO0 MW 461.5
DM5PUO0 FM C26H27N3O5
DM5PUO0 IC InChI=1S/C26H27N3O5/c1-17-25(26(30)27-2)21-6-4-19(16-24(21)33-17)34-23-7-8-28-22-15-18(3-5-20(22)23)32-14-11-29-9-12-31-13-10-29/h3-8,15-16H,9-14H2,1-2H3,(H,27,30)
DM5PUO0 CS CC1=C(C2=C(O1)C=C(C=C2)OC3=C4C=CC(=CC4=NC=C3)OCCN5CCOCC5)C(=O)NC
DM5PUO0 IK LGXVKMDGSIWEHL-UHFFFAOYSA-N
DM5PUO0 IU N,2-dimethyl-6-[7-(2-morpholin-4-ylethoxy)quinolin-4-yl]oxy-1-benzofuran-3-carboxamide
DM5PUO0 CA CAS 854514-88-8
DM5PUO0 DE Solid tumour/cancer
DM93LMS ID DM93LMS
DM93LMS DN PF-01247324
DM93LMS HS Phase 1
DM93LMS SN Nav1.8 blockers (pain); Nav1.8 blockers (pain), Pfizer; Voltage-gated sodium channel 1.8 blockers (pain), Pfizer
DM93LMS CP Pfizer Inc
DM93LMS DT Small molecular drug
DM93LMS PC 11659955
DM93LMS MW 330.6
DM93LMS FM C13H10Cl3N3O
DM93LMS IC InChI=1S/C13H10Cl3N3O/c1-18-13(20)10-3-2-7(12(17)19-10)8-4-6(14)5-9(15)11(8)16/h2-5H,1H3,(H2,17,19)(H,18,20)
DM93LMS CS CNC(=O)C1=NC(=C(C=C1)C2=C(C(=CC(=C2)Cl)Cl)Cl)N
DM93LMS IK HPIUHDCRVYDAEJ-UHFFFAOYSA-N
DM93LMS IU 6-amino-N-methyl-5-(2,3,5-trichlorophenyl)pyridine-2-carboxamide
DM93LMS CA CAS 875051-72-2
DM93LMS DE Pain
DMLGD0V ID DMLGD0V
DMLGD0V DN PF-04776548
DMLGD0V HS Phase 1
DMLGD0V SN PF-04776548 (oral, HIV infection)
DMLGD0V CP Pfizer Inc
DMLGD0V DE Human immunodeficiency virus infection
DMDSCQG ID DMDSCQG
DMDSCQG DN PF-04840082
DMDSCQG HS Phase 1
DMDSCQG CP Pfizer New York, NY
DMDSCQG DE Osteoporosis
DMZ8QRI ID DMZ8QRI
DMZ8QRI DN PF-04995274
DMZ8QRI HS Phase 1
DMZ8QRI SN UNII-XI179PG9LV; PF 04995274; XI179PG9LV; 1331782-27-4; CHEMBL2152922; (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF04995274; compound 2d [PMID: 22974325]; SCHEMBL619629; GTPL9059; WLLOFQROROXOMO-GOSISDBHSA-N; ZINC95577747; BDBM50398598; DB12675; NCGC00386746-01; PF-04995274, > 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol
DMZ8QRI CP Pfizer Inc
DMZ8QRI DT Small molecular drug
DMZ8QRI PC 53354764
DMZ8QRI MW 432.5
DMZ8QRI FM C23H32N2O6
DMZ8QRI IC InChI=1S/C23H32N2O6/c26-23(7-12-27-13-8-23)16-25-9-4-17(5-10-25)14-29-22-21-19(30-18-6-11-28-15-18)2-1-3-20(21)31-24-22/h1-3,17-18,26H,4-16H2/t18-/m1/s1
DMZ8QRI CS C1COC[C@@H]1OC2=CC=CC3=C2C(=NO3)OCC4CCN(CC4)CC5(CCOCC5)O
DMZ8QRI IK WLLOFQROROXOMO-GOSISDBHSA-N
DMZ8QRI IU 4-[[4-[[4-[(3R)-oxolan-3-yl]oxy-1,2-benzoxazol-3-yl]oxymethyl]piperidin-1-yl]methyl]oxan-4-ol
DMZ8QRI CA CAS 1331782-27-4
DMZ8QRI DE Alzheimer disease
DMAEK3L ID DMAEK3L
DMAEK3L DN PF-05082566
DMAEK3L HS Phase 1
DMAEK3L CP Pfizer
DMAEK3L DE Non-hodgkin lymphoma; Solid tumour/cancer
DM4QPT0 ID DM4QPT0
DM4QPT0 DN PF-05105679
DM4QPT0 HS Phase 1
DM4QPT0 CP Pfizer Inc
DM4QPT0 PC 60195662
DM4QPT0 MW 428.5
DM4QPT0 FM C26H21FN2O3
DM4QPT0 IC InChI=1S/C26H21FN2O3/c1-17(19-9-11-23(27)12-10-19)29(16-18-5-4-7-21(13-18)26(31)32)25(30)22-14-20-6-2-3-8-24(20)28-15-22/h2-15,17H,16H2,1H3,(H,31,32)/t17-/m1/s1
DM4QPT0 CS C[C@H](C1=CC=C(C=C1)F)N(CC2=CC(=CC=C2)C(=O)O)C(=O)C3=CC4=CC=CC=C4N=C3
DM4QPT0 IK BXNMZRPTQFVRFA-QGZVFWFLSA-N
DM4QPT0 IU 3-[[[(1R)-1-(4-fluorophenyl)ethyl]-(quinoline-3-carbonyl)amino]methyl]benzoic acid
DM4QPT0 CA CAS 1398583-31-7
DM4QPT0 DE Pain
DMUF6W9 ID DMUF6W9
DMUF6W9 DN PF-05186462
DMUF6W9 HS Phase 1
DMUF6W9 CP Pfizer Inc
DMUF6W9 DE Pain
DM7B2JC ID DM7B2JC
DM7B2JC DN PF-05190457
DM7B2JC HS Phase 1
DM7B2JC CP Pfizer Inc
DM7B2JC PC 58438464
DM7B2JC MW 512.7
DM7B2JC FM C29H32N6OS
DM7B2JC IC InChI=1S/C29H32N6OS/c1-19-11-25(31-18-30-19)22-3-5-24-21(12-22)4-6-26(24)35-16-29(17-35)7-9-33(10-8-29)27(36)13-23-15-34-14-20(2)37-28(34)32-23/h3,5,11-12,14-15,18,26H,4,6-10,13,16-17H2,1-2H3/t26-/m1/s1
DM7B2JC CS CC1=CC(=NC=N1)C2=CC3=C(C=C2)[C@@H](CC3)N4CC5(C4)CCN(CC5)C(=O)CC6=CN7C=C(SC7=N6)C
DM7B2JC IK ZIUDADZJCKGWKR-AREMUKBSSA-N
DM7B2JC IU 2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-[2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone
DM7B2JC CA CAS 1334782-79-4
DM7B2JC DE Type-2 diabetes
DM7OC9K ID DM7OC9K
DM7OC9K DN PF-05230905
DM7OC9K HS Phase 1
DM7OC9K SN ATN-192
DM7OC9K CP Pfizer New York, NY
DM7OC9K DE Rheumatoid arthritis
DM7GSZL ID DM7GSZL
DM7GSZL DN PF-05230907
DM7GSZL HS Phase 1
DM7GSZL DE Nontraumatic intracerebral hemorrhage
DMQYBSH ID DMQYBSH
DMQYBSH DN PF-05231023
DMQYBSH HS Phase 1
DMQYBSH CP Pfizer
DMQYBSH DT Antibody
DMQYBSH DE Type-2 diabetes
DM2NTBL ID DM2NTBL
DM2NTBL DN PF-05241328
DM2NTBL HS Phase 1
DM2NTBL CP Pfizer Inc
DM2NTBL PC 68109743
DM2NTBL MW 436.9
DM2NTBL FM C19H21ClN4O4S
DM2NTBL IC InChI=1S/C19H21ClN4O4S/c1-11(2)10-28-19-16(20)8-14(9-21-19)24-17-6-5-13(7-15(17)12(3)22-24)18(25)23-29(4,26)27/h5-9,11H,10H2,1-4H3,(H,23,25)
DM2NTBL CS CC1=NN(C2=C1C=C(C=C2)C(=O)NS(=O)(=O)C)C3=CC(=C(N=C3)OCC(C)C)Cl
DM2NTBL IK RVTSXVZXEGFIPW-UHFFFAOYSA-N
DM2NTBL IU 1-[5-chloro-6-(2-methylpropoxy)pyridin-3-yl]-3-methyl-N-methylsulfonylindazole-5-carboxamide
DM2NTBL CA CAS 1387633-03-5
DM2NTBL DE Pain
DM5KBDY ID DM5KBDY
DM5KBDY DN PF-06263507
DM5KBDY HS Phase 1
DM5KBDY CP Pfizer
DM5KBDY DT Antibody
DM5KBDY DE Solid tumour/cancer
DMASKX9 ID DMASKX9
DMASKX9 DN PF-06342674
DMASKX9 HS Phase 1
DMASKX9 CP Pfizer
DMASKX9 DE Type-1 diabetes; Type-2 diabetes
DMGB32Z ID DMGB32Z
DMGB32Z DN PF-06427878
DMGB32Z HS Phase 1
DMGB32Z DE Hyperlipidaemia; Cardiovascular disease
DM9UZTO ID DM9UZTO
DM9UZTO DN PF-06444752
DM9UZTO HS Phase 1
DM9UZTO DE Asthma
DMNLK5Y ID DMNLK5Y
DMNLK5Y DN PF-06647020
DMNLK5Y HS Phase 1
DMNLK5Y CP PfizerNew York, NY StemcentrxSouth San Francisco, CA
DMNLK5Y DE Solid tumour/cancer
DM056JD ID DM056JD
DM056JD DN PF-06648671
DM056JD HS Phase 1
DM056JD SN 1587727-31-8; 2-[(1S)-1-[(2S,5R)-5-[4-Chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)-2H-pyrido[1,2-a]pyrazine-1,6-dione; CHEMBL3951810; SCHEMBL15611304; BDBM193081; HY-120789; CS-0079177; US9193726, 69; Q29213634; 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione
DM056JD CP Pfizer
DM056JD DT Small molecular drug
DM056JD PC 73441910
DM056JD MW 538.9
DM056JD FM C25H23ClF4N4O3
DM056JD IC InChI=1S/C25H23ClF4N4O3/c1-13-11-32(12-31-13)19-3-4-20-24(36)33(7-8-34(20)23(19)35)14(2)21-5-6-22(37-21)15-9-18(27)17(26)10-16(15)25(28,29)30/h3-4,9-12,14,21-22H,5-8H2,1-2H3/t14-,21-,22+/m0/s1
DM056JD CS CC1=CN(C=N1)C2=CC=C3C(=O)N(CCN3C2=O)[C@@H](C)[C@@H]4CC[C@@H](O4)C5=CC(=C(C=C5C(F)(F)F)Cl)F
DM056JD IK AKCDDYGYIGPEKL-JQOQJDEVSA-N
DM056JD IU 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]oxolan-2-yl]ethyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione
DM056JD DE Alzheimer disease
DMGUKRN ID DMGUKRN
DMGUKRN DN PF-06648671
DMGUKRN HS Phase 1
DMGUKRN CP Pfizer New York, NY
DMGUKRN DE Alzheimer disease
DMK19V6 ID DMK19V6
DMK19V6 DN PF-06671008
DMK19V6 HS Phase 1
DMK19V6 CP PfizerNew York, NY
DMK19V6 DE Solid tumour/cancer
DM2ZJ1C ID DM2ZJ1C
DM2ZJ1C DN PF-06747143
DM2ZJ1C HS Phase 1
DM2ZJ1C CP PfizerNew York, NY
DM2ZJ1C DE Acute myeloid leukaemia
DMQUNRW ID DMQUNRW
DMQUNRW DN PF-06763809
DMQUNRW HS Phase 1
DMQUNRW CP Pfizer New York, NY
DMQUNRW DE Plaque psoriasis
DMDE9I6 ID DMDE9I6
DMDE9I6 DN PF-06801591
DMDE9I6 HS Phase 1
DMDE9I6 CP Pfizer New York, NY
DMDE9I6 DT Antibody
DMDE9I6 DE Solid tumour/cancer; Advanced malignancy; Non-hodgkin lymphoma
DMSJOTL ID DMSJOTL
DMSJOTL DN PF-06817024
DMSJOTL HS Phase 1
DMSJOTL CP Pfizer New York, NY
DMSJOTL DE Atopic dermatitis
DML3WT6 ID DML3WT6
DML3WT6 DN PF-06821497
DML3WT6 HS Phase 1
DML3WT6 SN UNII-S4L4MM20B6; S4L4MM20B6; CHEMBL4080228; PF06821497; 1844849-10-0; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one; SCHEMBL17330426; GTPL10516; BDBM50246967; NSC800019; DB14799; HY-101571A; NSC-800019; compound 23a [PMID: 29211475]; CS-0092626; Q29209799; 1(2H)-Isoquinolinone, 5,8-dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-; 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one; CJD
DML3WT6 CP Pfizer
DML3WT6 DT Small molecular drug
DML3WT6 PC 118572065
DML3WT6 MW 467.3
DML3WT6 FM C22H24Cl2N2O5
DML3WT6 IC InChI=1S/C22H24Cl2N2O5/c1-11-6-17(29-2)15(21(27)25-11)8-26-5-4-13-16(23)7-14(19(24)18(13)22(26)28)20(30-3)12-9-31-10-12/h6-7,12,20H,4-5,8-10H2,1-3H3,(H,25,27)/t20-/m1/s1
DML3WT6 CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)[C@@H](C4COC4)OC)Cl)OC
DML3WT6 IK RXCVUHMIWHRLDF-HXUWFJFHSA-N
DML3WT6 IU 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1-one
DML3WT6 CA CAS 1844849-10-0
DML3WT6 DE Small-cell lung cancer; Follicular lymphoma; Prostate cancer; Diffuse large B-cell lymphoma
DMRGVT9 ID DMRGVT9
DMRGVT9 DN PF-06826647
DMRGVT9 HS Phase 1
DMRGVT9 CP Pfizer New York, NY
DMRGVT9 DE Plaque psoriasis
DMOX6EJ ID DMOX6EJ
DMOX6EJ DN PF-06840003
DMOX6EJ HS Phase 1
DMOX6EJ SN 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione; 198474-05-4; PF06840003; 2,5-Pyrrolidinedione, 3-(5-fluoro-1H-indol-3-yl)-; 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione; SCHEMBL5463464; GTPL9565; CTK0A0183; DTXSID00630149; MXKLDYKORJEOPR-UHFFFAOYSA-N; KS-000008MY; EX-A1186; EOS200271; AKOS027252536; CS-6186; AS-51973; HY-101111; 3-(5-Fluoro-1H-indol-3-yl)-pyrrolidine-2,5-dione
DMOX6EJ CP iTeos Therapeutics Gosselies, Belgium Pfizer New York, NY
DMOX6EJ PC 23063810
DMOX6EJ MW 232.21
DMOX6EJ FM C12H9FN2O2
DMOX6EJ IC InChI=1S/C12H9FN2O2/c13-6-1-2-10-7(3-6)9(5-14-10)8-4-11(16)15-12(8)17/h1-3,5,8,14H,4H2,(H,15,16,17)
DMOX6EJ CS C1C(C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F
DMOX6EJ IK MXKLDYKORJEOPR-UHFFFAOYSA-N
DMOX6EJ IU 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione
DMOX6EJ CA CAS 198474-05-4
DMOX6EJ DE Glioma
DMRZHV6 ID DMRZHV6
DMRZHV6 DN PF-06873600
DMRZHV6 HS Phase 1
DMRZHV6 SN QIEKHLDZKRQLLN-FOIQADDNSA-N; SCHEMBL19857421; HY-114177; CS-0078633
DMRZHV6 CP Pfizer New York, NY
DMRZHV6 PC 134247638
DMRZHV6 MW 471.5
DMRZHV6 FM C20H27F2N5O4S
DMRZHV6 IC InChI=1S/C20H27F2N5O4S/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25)/t15-,20-/m1/s1
DMRZHV6 CS C[C@]1(CCC[C@H]1N2C3=NC(=NC=C3C=C(C2=O)C(F)F)NC4CCN(CC4)S(=O)(=O)C)O
DMRZHV6 IK QIEKHLDZKRQLLN-FOIQADDNSA-N
DMRZHV6 IU 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one
DMRZHV6 CA CAS 2185857-97-8
DMRZHV6 DE Breast cancer
DM7BOFR ID DM7BOFR
DM7BOFR DN PF-06939999
DM7BOFR HS Phase 1
DM7BOFR CP Pfizer
DM7BOFR DE Solid tumour/cancer
DMYP9WR ID DMYP9WR
DMYP9WR DN PF-06940434
DMYP9WR HS Phase 1
DMYP9WR CP Pfizer
DMYP9WR DE Solid tumour/cancer
DMDQJEZ ID DMDQJEZ
DMDQJEZ DN PF-06952229
DMDQJEZ HS Phase 1
DMDQJEZ SN SCHEMBL16879380; BDBM280355; US10030004, Compound 22; NSC826119; NSC-826119; HY-136244; CS-0120989; PF06952229; ClC=1C=CC(=C(C1)C1=NC=C(C(=C1)NC1=CC=NC=C1C(=O)NC(CO)CO)C(C)C)F; 1801333-55-0; Synthesis of 4-[[2-(5-chloro-2-fluoro-phenyl)-5-isopropyl-4-pyridyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]pyridine-3-carboxamide
DMDQJEZ CP Pfizer
DMDQJEZ DT Small molecular drug
DMDQJEZ PC 118211239
DMDQJEZ MW 458.9
DMDQJEZ FM C23H24ClFN4O3
DMDQJEZ IC InChI=1S/C23H24ClFN4O3/c1-13(2)17-10-27-21(16-7-14(24)3-4-19(16)25)8-22(17)29-20-5-6-26-9-18(20)23(32)28-15(11-30)12-31/h3-10,13,15,30-31H,11-12H2,1-2H3,(H,28,32)(H,26,27,29)
DMDQJEZ CS CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC(CO)CO)C3=C(C=CC(=C3)Cl)F
DMDQJEZ IK IPBLCOKXDQHSQW-UHFFFAOYSA-N
DMDQJEZ IU 4-[[2-(5-chloro-2-fluorophenyl)-5-propan-2-ylpyridin-4-yl]amino]-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide
DMDQJEZ DE Solid tumour/cancer
DME3BJL ID DME3BJL
DME3BJL DN PF-07062119
DME3BJL HS Phase 1
DME3BJL CP Pfizer
DME3BJL DT Antibody
DME3BJL DE Solid tumour/cancer
DMMJZ2E ID DMMJZ2E
DMMJZ2E DN PF-07104091
DMMJZ2E HS Phase 1
DMMJZ2E CP Pfizer
DMMJZ2E DT Small molecular drug
DMMJZ2E DE Triple negative breast cancer; Small-cell lung cancer; Non-small cell lung cancer
DMPKO84 ID DMPKO84
DMPKO84 DN PF-07220060
DMPKO84 HS Phase 1
DMPKO84 CP Pfizer
DMPKO84 DE Prostate cancer; Liposarcoma
DMSMNRQ ID DMSMNRQ
DMSMNRQ DN PF-07265807
DMSMNRQ HS Phase 1
DMSMNRQ SN PF-5807; ARRY-067
DMSMNRQ CP Pfizer
DMSMNRQ DT Small molecular drug
DMSMNRQ DE Solid tumour/cancer
DMCOUHT ID DMCOUHT
DMCOUHT DN PF-2413873
DMCOUHT HS Phase 1
DMCOUHT SN PF-02413873
DMCOUHT CP Pfizer Inc
DMCOUHT DT Small molecular drug
DMCOUHT PC 16662425
DMCOUHT MW 359.4
DMCOUHT FM C18H21N3O3S
DMCOUHT IC InChI=1S/C18H21N3O3S/c1-11-7-15(8-12(2)16(11)9-19)24-18-13(3)21(10-25(4,22)23)20-17(18)14-5-6-14/h7-8,14H,5-6,10H2,1-4H3
DMCOUHT CS CC1=CC(=CC(=C1C#N)C)OC2=C(N(N=C2C3CC3)CS(=O)(=O)C)C
DMCOUHT IK QSFGZNVRVZHUGV-UHFFFAOYSA-N
DMCOUHT IU 4-[3-cyclopropyl-5-methyl-1-(methylsulfonylmethyl)pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile
DMCOUHT CA CAS 936345-35-6
DMCOUHT DE Endometriosis
DMG2IE5 ID DMG2IE5
DMG2IE5 DN PF-3732010
DMG2IE5 HS Phase 1
DMG2IE5 SN P-cadherin MAb, PF-03072010, PF-03732010
DMG2IE5 CP Pfizer
DMG2IE5 DT Antibody
DMG2IE5 DE Solid tumour/cancer
DM36PKZ ID DM36PKZ
DM36PKZ DN PF-3758309
DM36PKZ HS Phase 1
DM36PKZ SN PF-309
DM36PKZ CP Pfizer
DM36PKZ DT Small molecular drug
DM36PKZ PC 25227462
DM36PKZ MW 490.6
DM36PKZ FM C25H30N8OS
DM36PKZ IC InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1
DM36PKZ CS CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)N[C@H](CN(C)C)C5=CC=CC=C5)SC=C2
DM36PKZ IK AYCPARAPKDAOEN-LJQANCHMSA-N
DM36PKZ IU N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methylthieno[3,2-d]pyrimidin-4-yl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide
DM36PKZ CA CAS 898044-15-0
DM36PKZ CB CHEBI:93751
DM36PKZ DE Solid tumour/cancer
DML0OCD ID DML0OCD
DML0OCD DN PF-3864086
DML0OCD HS Phase 1
DML0OCD CP Pfizer Inc
DML0OCD DE Pain
DMU2A6D ID DMU2A6D
DMU2A6D DN PF-4217903
DMU2A6D HS Phase 1
DMU2A6D SN 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N; PF-04217903
DMU2A6D CP Pfizer
DMU2A6D DT Small molecular drug
DMU2A6D PC 17754438
DMU2A6D MW 372.4
DMU2A6D FM C19H16N8O
DMU2A6D IC InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2
DMU2A6D CS C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=C1
DMU2A6D IK PDMUGYOXRHVNMO-UHFFFAOYSA-N
DMU2A6D IU 2-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyrazin-5-yl]pyrazol-1-yl]ethanol
DMU2A6D CA CAS 956905-27-4
DMU2A6D CB CHEBI:91425
DMU2A6D DE Solid tumour/cancer
DMMETU8 ID DMMETU8
DMMETU8 DN PF-4418948
DMMETU8 HS Phase 1
DMMETU8 SN PF-04418948; Prostaglandin E2 EP2 subtype antagonist (endometriosis), Pfizer
DMMETU8 CP Pfizer Inc
DMMETU8 DT Small molecular drug
DMMETU8 PC 25114442
DMMETU8 MW 409.4
DMMETU8 FM C23H20FNO5
DMMETU8 IC InChI=1S/C23H20FNO5/c1-29-19-8-4-17-11-20(9-5-16(17)10-19)30-14-23(22(27)28)12-25(13-23)21(26)15-2-6-18(24)7-3-15/h2-11H,12-14H2,1H3,(H,27,28)
DMMETU8 CS COC1=CC2=C(C=C1)C=C(C=C2)OCC3(CN(C3)C(=O)C4=CC=C(C=C4)F)C(=O)O
DMMETU8 IK LWJGMYMNSNVCEM-UHFFFAOYSA-N
DMMETU8 IU 1-(4-fluorobenzoyl)-3-[(6-methoxynaphthalen-2-yl)oxymethyl]azetidine-3-carboxylic acid
DMMETU8 CA CAS 1078166-57-0
DMMETU8 DE Endometriosis
DM3427C ID DM3427C
DM3427C DN PF-4427429
DM3427C HS Phase 1
DM3427C SN PF-04427429; RI-307; Anti-CGRP antibodies (migraine), Pfizer
DM3427C CP Labrys biologics
DM3427C DE Migraine
DMYR7XP ID DMYR7XP
DMYR7XP DN PF-4455242
DMYR7XP HS Phase 1
DMYR7XP SN PF-04455242
DMYR7XP CP Pfizer Inc
DMYR7XP DT Small molecular drug
DMYR7XP PC 53465410
DMYR7XP MW 409
DMYR7XP FM C21H29ClN2O2S
DMYR7XP IC InChI=1S/C21H28N2O2S.ClH/c1-17(2)15-22-16-18-9-11-19(12-10-18)20-7-3-4-8-21(20)26(24,25)23-13-5-6-14-23;/h3-4,7-12,17,22H,5-6,13-16H2,1-2H3;1H
DMYR7XP CS CC(C)CNCC1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)N3CCCC3.Cl
DMYR7XP IK WRNZYMZEVIVCFL-UHFFFAOYSA-N
DMYR7XP IU 2-methyl-N-[[4-(2-pyrrolidin-1-ylsulfonylphenyl)phenyl]methyl]propan-1-amine;hydrochloride
DMYR7XP CA CAS 1322001-35-3
DMYR7XP DE Bipolar disorder
DMKOE84 ID DMKOE84
DMKOE84 DN PF-4603629
DMKOE84 HS Phase 1
DMKOE84 SN BRX-1177; PF-04603629; Exendin-4 transferrin fusion protein (diabetes), Pfizer/BioRexis
DMKOE84 CP Biorexis Pharmaceutical Corp
DMKOE84 DE Type-2 diabetes
DMSLE03 ID DMSLE03
DMSLE03 DN PF-562271
DMSLE03 HS Phase 1
DMSLE03 SN PF-00562271
DMSLE03 CP Pfizer
DMSLE03 DT Small molecular drug
DMSLE03 PC 11713159
DMSLE03 MW 507.5
DMSLE03 FM C21H20F3N7O3S
DMSLE03 IC InChI=1S/C21H20F3N7O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30)
DMSLE03 CS CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C
DMSLE03 IK MZDKLVOWGIOKTN-UHFFFAOYSA-N
DMSLE03 IU N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide
DMSLE03 CA CAS 717907-75-0
DMSLE03 CB CHEBI:91370
DMSLE03 DE Solid tumour/cancer
DMGLEM1 ID DMGLEM1
DMGLEM1 DN PF9601N
DMGLEM1 HS Phase 1
DMGLEM1 SN PF9601N; 133845-63-3; CHEMBL45069; FA-3; SYN5118; AOB1749; BDBM50087800; ZINC29405716; NCGC00370705-03; AS-16482
DMGLEM1 CP Pfizer
DMGLEM1 DT Small molecular drug
DMGLEM1 PC 9947954
DMGLEM1 MW 290.4
DMGLEM1 FM C19H18N2O
DMGLEM1 IC InChI=1S/C19H18N2O/c1-2-10-20-13-17-11-16-12-18(8-9-19(16)21-17)22-14-15-6-4-3-5-7-15/h1,3-9,11-12,20-21H,10,13-14H2
DMGLEM1 CS C#CCNCC1=CC2=C(N1)C=CC(=C2)OCC3=CC=CC=C3
DMGLEM1 IK YFPNAYXYKXAKJC-UHFFFAOYSA-N
DMGLEM1 IU N-[(5-phenylmethoxy-1H-indol-2-yl)methyl]prop-2-yn-1-amine
DMGLEM1 DE Parkinson disease
DMLDZX1 ID DMLDZX1
DMLDZX1 DN PfAMA-1
DMLDZX1 HS Phase 1
DMLDZX1 SN PfAMA-1-FVO[25-545]; Apical membrane antigen 1 vaccine (Plasmodium infection), African Malaria Network Trust/European Malaria Vaccine Initiative/Biomedical Primate Research Centre; AMA-1 vaccine (malaria), AMANET/EMVI/BPRC
DMLDZX1 CP Biomedical Primate Research Centre
DMLDZX1 DT Vaccine
DMLDZX1 DE Malaria
DM6ER9L ID DM6ER9L
DM6ER9L DN Pfizer 10
DM6ER9L HS Phase 1
DM6ER9L CP Pfizer
DM6ER9L DE Female sexual arousal dysfunction
DMME5P8 ID DMME5P8
DMME5P8 DN Pfizer 4
DMME5P8 HS Phase 1
DMME5P8 CP Pfizer
DMME5P8 DE Female sexual arousal dysfunction
DMIR21F ID DMIR21F
DMIR21F DN PFK-158
DMIR21F HS Phase 1
DMIR21F CP Advanced cancer therapeutics
DMIR21F PC 71730058
DMIR21F MW 328.3
DMIR21F FM C18H11F3N2O
DMIR21F IC InChI=1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H/b6-5+
DMIR21F CS C1=CC(=CC2=C1C=CC(=N2)/C=C/C(=O)C3=CC=NC=C3)C(F)(F)F
DMIR21F IK IAJOMYABKVAZCN-AATRIKPKSA-N
DMIR21F IU (E)-1-pyridin-4-yl-3-[7-(trifluoromethyl)quinolin-2-yl]prop-2-en-1-one
DMIR21F CA CAS 1462249-75-7
DMIR21F DE Solid tumour/cancer
DM68D3O ID DM68D3O
DM68D3O DN PG-545
DM68D3O HS Phase 1
DM68D3O SN PG-457; PG-500; PG-501; PG-502; PG-503; PG-504; PG-505; PG-506; PG-507; PG-508; PG-509; PG-510; PG-511; PG-512; PG-513; PG-514;PG-536; PG-546; PG-547; PG-554; PG-562; PG-500 series (heparan sulfate mimetics), Progen
DM68D3O CP Progen Pharmaceuticals Ltd
DM68D3O DT ?
DM68D3O PC 57412324
DM68D3O MW 2363.8
DM68D3O FM C51H75Na13O60S13
DM68D3O IC InChI=1S/C51H88O60S13.13Na/c1-22(2)7-6-8-23(3)27-11-12-28-26-10-9-24-17-25(13-15-50(24,4)29(26)14-16-51(27,28)5)95-46-42(108-121(79,80)81)38(104-117(67,68)69)34(30(96-46)18-91-112(52,53)54)100-47-43(109-122(82,83)84)39(105-118(70,71)72)35(31(97-47)19-92-113(55,56)57)101-48-44(110-123(85,86)87)40(106-119(73,74)75)36(32(98-48)20-93-114(58,59)60)102-49-45(111-124(88,89)90)41(107-120(76,77)78)37(103-116(64,65)66)33(99-49)21-94-115(61,62)63;;;;;;;;;;;;;/h22-49H,6-21H2,1-5H3,(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H,88,89,90);;;;;;;;;;;;;/q;13*+1/p-13/t23-,24+,25+,26+,27-,28+,29+,30-,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47-,48-,49-,50+,51-;;;;;;;;;;;;;/m1............./s1
DM68D3O CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COS(=O)(=O)[O-])O[C@@H]7[C@@H]([C@H]([C@@H]([C@H](O7)COS(=O)(=O)[O-])O[C@@H]8[C@@H]([C@H]([C@@H]([C@H](O8)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])C)C.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM68D3O IK PHIUHBOJEMIHQZ-YAPWIAIGSA-A
DM68D3O IU tridecasodium;[(2R,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[[(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate
DM68D3O CA CAS 1144492-69-2
DM68D3O DE Ocular disease
DM2Y4FG ID DM2Y4FG
DM2Y4FG DN PHA-793887
DM2Y4FG HS Phase 1
DM2Y4FG SN Cyclin-dependent kinase inhibitor (cancer), Nerviano
DM2Y4FG CP Nerviano Medical Sciences Srl
DM2Y4FG DT Small molecular drug
DM2Y4FG PC 46191454
DM2Y4FG MW 361.5
DM2Y4FG FM C19H31N5O2
DM2Y4FG IC InChI=1S/C19H31N5O2/c1-12(2)10-15(25)20-17-14-11-24(19(3,4)16(14)21-22-17)18(26)13-6-8-23(5)9-7-13/h12-13H,6-11H2,1-5H3,(H2,20,21,22,25)
DM2Y4FG CS CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C
DM2Y4FG IK HUXYBQXJVXOMKX-UHFFFAOYSA-N
DM2Y4FG IU N-[6,6-dimethyl-5-(1-methylpiperidine-4-carbonyl)-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide
DM2Y4FG CA CAS 718630-59-2
DM2Y4FG CB CHEBI:91371
DM2Y4FG DE Solid tumour/cancer
DMUANF9 ID DMUANF9
DMUANF9 DN PHE-377
DMUANF9 HS Phase 1
DMUANF9 SN V 377; 2-(Diisopropylamino)-2',6'-acetoxylidide, hydrochloride; 2',6'-ACETOXYLIDIDE, 2-(DIISOPROPYLAMINO)-, HYDROCHLORIDE; AC1Q1RXG; AC1L1G06; LS-13907; 77966-84-8; [2-(2,6-dimethylanilino)-2-oxoethyl]-di(propan-2-yl)azanium chloride; [2-[(2,6-dimethylphenyl)amino]-2-oxoethyl]-di(propan-2-yl)azanium chloride
DMUANF9 CP PharmEste SRL
DMUANF9 DT Small molecular drug
DMUANF9 PC 53956
DMUANF9 MW 298.8
DMUANF9 FM C16H27ClN2O
DMUANF9 IC InChI=1S/C16H26N2O.ClH/c1-11(2)18(12(3)4)10-15(19)17-16-13(5)8-7-9-14(16)6;/h7-9,11-12H,10H2,1-6H3,(H,17,19);1H
DMUANF9 CS CC1=C(C(=CC=C1)C)NC(=O)C[NH+](C(C)C)C(C)C.[Cl-]
DMUANF9 IK OJTPHJHZGWBMET-UHFFFAOYSA-N
DMUANF9 IU [2-(2,6-dimethylanilino)-2-oxoethyl]-di(propan-2-yl)azanium;chloride
DMUANF9 CA CAS 77966-84-8
DMUANF9 DE Pain
DMBZ2QT ID DMBZ2QT
DMBZ2QT DN PHE885
DMBZ2QT HS Phase 1
DMBZ2QT CP Novartis
DMBZ2QT DT CAR T Cell Therapy
DMBZ2QT DE Multiple myeloma
DMERJ6V ID DMERJ6V
DMERJ6V DN PHX-1766
DMERJ6V HS Phase 1
DMERJ6V SN HCV protease inhibitors, Phenomix; Hepatitis c virus protease inhibitors, Phenomix; PHX-1176
DMERJ6V CP Phenomix Corp
DMERJ6V DE Hepatitis C virus infection
DMU26OE ID DMU26OE
DMU26OE DN PIM447
DMU26OE HS Phase 1
DMU26OE SN VRQXRVAKPDCRCI-ZNMIVQPWSA-N; PIM-447; 1210608-43-7; PIM447 (LGH447); N-{4-[(1r,3s,5s)-3-Amino-5-Methylcyclohexyl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide; N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide; UNII-9TG5O4V25H; SCHEMBL3215332; GTPL9790; 9TG5O4V25H; CHEMBL3651966; PIM 447 [WHO-DD]; BDBM106870; ZINC116907270; AKOS032945086; CS-5929; compound 8 [PMID: 26505898]; HY-19322; J3.552.648J; US8592455, 70; 5H7; 2-Pyr
DMU26OE CP Novartis Oncology East Hanover, NJ
DMU26OE PC 44814409
DMU26OE MW 440.5
DMU26OE FM C24H23F3N4O
DMU26OE IC InChI=1S/C24H23F3N4O/c1-13-9-14(11-15(28)10-13)16-7-8-29-12-21(16)31-24(32)20-6-5-19(27)23(30-20)22-17(25)3-2-4-18(22)26/h2-8,12-15H,9-11,28H2,1H3,(H,31,32)/t13-,14+,15-/m0/s1
DMU26OE CS C[C@H]1C[C@H](C[C@H](C1)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DMU26OE IK VRQXRVAKPDCRCI-ZNMIVQPWSA-N
DMU26OE IU N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DMU26OE CA CAS 1210608-43-7
DMU26OE DE Myelofibrosis
DMF3IBC ID DMF3IBC
DMF3IBC DN Plasma derived human butyrylcholinesterase
DMF3IBC HS Phase 1
DMF3IBC SN Plasma derived human butyrylcholinesterase (im, drug induced neurotoxicity); HuBChE (im, drug induced neurotoxicity), Dynport; Bioscavenger (im, drug induced neurotoxicity), Dynport/Baxter; Plasma derived human butyrylcholinesterase (im, drug induced neurotoxicity), Dynport/Baxter
DMF3IBC CP DynPort Vaccine Company LLC
DMF3IBC DE Neurotoxicity
DMBK9AM ID DMBK9AM
DMBK9AM DN PLX-4720
DMBK9AM HS Phase 1
DMBK9AM SN PLX 4720; PLX4720 (BRAF inhibitor)
DMBK9AM DT Small molecular drug
DMBK9AM PC 24180719
DMBK9AM MW 413.8
DMBK9AM FM C17H14ClF2N3O3S
DMBK9AM IC InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)
DMBK9AM CS CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F
DMBK9AM IK YZDJQTHVDDOVHR-UHFFFAOYSA-N
DMBK9AM IU N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide
DMBK9AM CA CAS 918505-84-7
DMBK9AM CB CHEBI:90295
DMBK9AM DE Cutaneous melanoma
DMXLHVW ID DMXLHVW
DMXLHVW DN PLX51107
DMXLHVW HS Phase 1
DMXLHVW SN AMSUHYUVOVCWTP-INIZCTEOSA-N; SCHEMBL16085681; HY-111422; CS-0040568; 4-[6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl]benzoic acid
DMXLHVW CP Plexxikon Berkeley, CA
DMXLHVW PC 90448953
DMXLHVW MW 438.5
DMXLHVW FM C26H22N4O3
DMXLHVW IC InChI=1S/C26H22N4O3/c1-15-24(17(3)33-29-15)20-12-23-25(28-13-20)21(18-7-9-19(10-8-18)26(31)32)14-30(23)16(2)22-6-4-5-11-27-22/h4-14,16H,1-3H3,(H,31,32)/t16-/m0/s1
DMXLHVW CS CC1=C(C(=NO1)C)C2=CC3=C(C(=CN3[C@@H](C)C4=CC=CC=N4)C5=CC=C(C=C5)C(=O)O)N=C2
DMXLHVW IK AMSUHYUVOVCWTP-INIZCTEOSA-N
DMXLHVW IU 4-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[(1S)-1-pyridin-2-ylethyl]pyrrolo[3,2-b]pyridin-3-yl]benzoic acid
DMXLHVW CA CAS 1627929-55-8
DMXLHVW DE Haematological malignancy; Solid tumour/cancer
DMK4PWM ID DMK4PWM
DMK4PWM DN PLX-5622
DMK4PWM HS Phase 1
DMK4PWM CP Plexxikon Inc
DMK4PWM DE Autoimmune diabetes
DMED2WN ID DMED2WN
DMED2WN DN PLX73086
DMED2WN HS Phase 1
DMED2WN CP Plexxikon Berkeley, CA
DMED2WN DE Solid tumour/cancer
DM0IVGU ID DM0IVGU
DM0IVGU DN PLX7486
DM0IVGU HS Phase 1
DM0IVGU CP Daiichi sankyo
DM0IVGU DE Pancreatic cancer; Solid tumour/cancer
DMIS8BV ID DMIS8BV
DMIS8BV DN PMD-026
DMIS8BV HS Phase 1
DMIS8BV CP Phoenix Molecular Designs
DMIS8BV DT Small molecular drug
DMIS8BV DE Triple negative breast cancer; Metastatic breast cancer
DMY9XWB ID DMY9XWB
DMY9XWB DN PMI-005
DMY9XWB HS Phase 1
DMY9XWB CP Louisiana State University
DMY9XWB DE Osteoarthritis
DMQ82SH ID DMQ82SH
DMQ82SH DN PMZ-2123
DMQ82SH HS Phase 1
DMQ82SH CP Pharmazz Willowbrook, IL
DMQ82SH DE Cerebral oedema in diabetic ketoacidosis
DM9B68S ID DM9B68S
DM9B68S DN POL-6014
DM9B68S HS Phase 1
DM9B68S SN Serine protease inhibitors (inhaled, PEM, asthma/COPD), Polyphor
DM9B68S CP Polyphor Ltd
DM9B68S DE Chronic obstructive pulmonary disease; Cystic fibrosis
DMTOLI5 ID DMTOLI5
DMTOLI5 DN Pomaglumetad
DMTOLI5 HS Phase 1
DMTOLI5 CP Eli Lilly
DMTOLI5 DE Schizophrenia
DMCU54M ID DMCU54M
DMCU54M DN Posiphen R-phenserine
DMCU54M HS Phase 1
DMCU54M CP Qr pharma
DMCU54M DE Alzheimer disease
DM2D7Z0 ID DM2D7Z0
DM2D7Z0 DN PPC-5650
DM2D7Z0 HS Phase 1
DM2D7Z0 CP Antalium Inc
DM2D7Z0 DE Pain
DMSAQBC ID DMSAQBC
DMSAQBC DN PPI-2458
DMSAQBC HS Phase 1
DMSAQBC SN Metapro; 6-O-[N-[1(R)-Carbamoyl-2-methylpropyl]carbamoyl]fumagillol
DMSAQBC CP Praecis Pharmaceuticals
DMSAQBC DT Small molecular drug
DMSAQBC PC 6918653
DMSAQBC MW 424.5
DMSAQBC FM C22H36N2O6
DMSAQBC IC InChI=1S/C22H36N2O6/c1-12(2)7-8-15-21(5,30-15)18-17(27-6)14(9-10-22(18)11-28-22)29-20(26)24-16(13(3)4)19(23)25/h7,13-18H,8-11H2,1-6H3,(H2,23,25)(H,24,26)/t14-,15-,16-,17-,18-,21+,22+/m1/s1
DMSAQBC CS CC(C)[C@H](C(=O)N)NC(=O)O[C@@H]1CC[C@]2(CO2)[C@H]([C@@H]1OC)[C@@]3([C@H](O3)CC=C(C)C)C
DMSAQBC IK QBDVVYNLLXGUGN-XGTBZJOHSA-N
DMSAQBC IU [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-[(2R)-1-amino-3-methyl-1-oxobutan-2-yl]carbamate
DMSAQBC CA CAS 431077-35-9
DMSAQBC DE Autoimmune diabetes
DMEOJUN ID DMEOJUN
DMEOJUN DN PPI-383
DMEOJUN HS Phase 1
DMEOJUN CP Presidio pharmaceuticals
DMEOJUN DE Hepatitis C virus infection
DMTOXLG ID DMTOXLG
DMTOXLG DN PPI-461
DMTOXLG HS Phase 1
DMTOXLG CP Presidio
DMTOXLG DE Hepatitis C virus infection
DMOYUPM ID DMOYUPM
DMOYUPM DN PPL-100
DMOYUPM HS Phase 1
DMOYUPM SN HIV protease inhibitors, Ambrilia; HIV protease inhibitors, Pharmacor; HIV protease inhibitors, Procyon; HIV protease inhibitors, TaiMed; MK-8122; P-1946; PL-337; HIV protease inhibitors, Merck & Co
DMOYUPM CP Pharmacor Inc
DMOYUPM DT Small molecular drug
DMOYUPM PC 513956
DMOYUPM MW 624.8
DMOYUPM FM C33H44N4O6S
DMOYUPM IC InChI=1S/C33H44N4O6S/c1-24(2)22-37(44(41,42)29-19-17-27(34)18-20-29)28(23-38)16-10-11-21-35-32(39)31(36-33(40)43-3)30(25-12-6-4-7-13-25)26-14-8-5-9-15-26/h4-9,12-15,17-20,24,28,30-31,38H,10-11,16,21-23,34H2,1-3H3,(H,35,39)(H,36,40)/t28-,31-/m0/s1
DMOYUPM CS CC(C)CN([C@@H](CCCCNC(=O)[C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC(=O)OC)CO)S(=O)(=O)C3=CC=C(C=C3)N
DMOYUPM IK QAHLFXYLXBBCPS-IZEXYCQBSA-N
DMOYUPM IU methyl N-[(2S)-1-[[(5S)-5-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-6-hydroxyhexyl]amino]-1-oxo-3,3-diphenylpropan-2-yl]carbamate
DMOYUPM CA CAS 612547-11-2
DMOYUPM DE Human immunodeficiency virus infection
DMY2GDQ ID DMY2GDQ
DMY2GDQ DN P-PSMA-101
DMY2GDQ HS Phase 1
DMY2GDQ CP Poseida Therapeutics
DMY2GDQ DT CAR T Cell Therapy
DMY2GDQ DE Prostate cancer
DMHIS3M ID DMHIS3M
DMHIS3M DN PRAX-330
DMHIS3M HS Phase 1
DMHIS3M CP Praxis Precision Medicines Cambridge, MA
DMHIS3M DE Epilepsy
DMCUE71 ID DMCUE71
DMCUE71 DN PRGN-3005
DMCUE71 HS Phase 1
DMCUE71 CP Precigen
DMCUE71 DT CAR T Cell Therapy
DMCUE71 DE Refractory hematologic malignancy
DMR7BAO ID DMR7BAO
DMR7BAO DN PRN1371
DMR7BAO HS Phase 1
DMR7BAO SN PUIXMSRTTHLNKI-UHFFFAOYSA-N; 1802929-43-6; PRN-1371; UNII-S3OPE9IA3Q; S3OPE9IA3Q; 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one; GTPL9788; US9567334, Example 6; SCHEMBL16993012; BDBM286984; BCP20493; s8578; AKOS032954157; CS-7485; compound 34 [PMID: 28665128]; HY-101768; J3.662.238E; 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one
DMR7BAO CP Principia Biopharma South San Francisco, CA
DMR7BAO PC 118295624
DMR7BAO MW 561.5
DMR7BAO FM C26H30Cl2N6O4
DMR7BAO IC InChI=1S/C26H30Cl2N6O4/c1-5-20(35)33-11-9-32(10-12-33)7-6-8-34-24-16(15-30-26(29-2)31-24)13-17(25(34)36)21-22(27)18(37-3)14-19(38-4)23(21)28/h5,13-15H,1,6-12H2,2-4H3,(H,29,30,31)
DMR7BAO CS CNC1=NC=C2C=C(C(=O)N(C2=N1)CCCN3CCN(CC3)C(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl
DMR7BAO IK PUIXMSRTTHLNKI-UHFFFAOYSA-N
DMR7BAO IU 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one
DMR7BAO CA CAS 1802929-43-6
DMR7BAO DE Solid tumour/cancer
DMQNS51 ID DMQNS51
DMQNS51 DN PRN2246
DMQNS51 HS Phase 1
DMQNS51 SN SAR442168
DMQNS51 CP Principia Biopharma South San Francisco, CA Sanofi Bridgewater, NJ
DMQNS51 DE Multiple sclerosis
DMLKF3H ID DMLKF3H
DMLKF3H DN Prolanta
DMLKF3H HS Phase 1
DMLKF3H CP Oncolix Houston, TX
DMLKF3H DE Fallopian tube cancer; Ovarian cancer; Peritoneal cavity cancer
DME1Y9W ID DME1Y9W
DME1Y9W DN Protexia
DME1Y9W HS Phase 1
DME1Y9W SN RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene
DME1Y9W CP Nexia Biotechnologies Inc
DME1Y9W DE Alzheimer disease
DMBL7CW ID DMBL7CW
DMBL7CW DN PRT-062607
DMBL7CW HS Phase 1
DMBL7CW SN P-14276; P-505-15; Syk tyrosine kinase inhibitors (oral, cancers/inflammatory diseases/thrombosis), Portola
DMBL7CW CP Portola Pharmaceuticals Inc
DMBL7CW DT Small molecular drug
DMBL7CW PC 44462758
DMBL7CW MW 393.4
DMBL7CW FM C19H23N9O
DMBL7CW IC InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1
DMBL7CW CS C1CC[C@H]([C@H](C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N
DMBL7CW IK TXGKRVFSSHPBAJ-JKSUJKDBSA-N
DMBL7CW IU 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide
DMBL7CW CA CAS 1370261-96-3
DMBL7CW DE Chronic lymphocytic leukaemia
DMIKE0O ID DMIKE0O
DMIKE0O DN PRT1419
DMIKE0O HS Phase 1
DMIKE0O CP Prelude Therapeutics
DMIKE0O DT Small molecular drug
DMIKE0O DE Melanoma
DMHNZ3U ID DMHNZ3U
DMHNZ3U DN PRT543
DMHNZ3U HS Phase 1
DMHNZ3U CP Prelude Therapeutics
DMHNZ3U DT Small molecular drug
DMHNZ3U DE Solid tumour/cancer; Hematologic tumour
DMP5CLY ID DMP5CLY
DMP5CLY DN PRT6207
DMP5CLY HS Phase 1
DMP5CLY DE Solid tumour/cancer
DMW3MCX ID DMW3MCX
DMW3MCX DN PRT811
DMW3MCX HS Phase 1
DMW3MCX CP Prelude Therapeutics
DMW3MCX DT Small molecular drug
DMW3MCX DE Glioma
DM5KI6X ID DM5KI6X
DM5KI6X DN PRX003
DM5KI6X HS Phase 1
DM5KI6X CP Prothena Biosciences South San Francisco, CA
DM5KI6X DE Psoriasis vulgaris
DM5TLAP ID DM5TLAP
DM5TLAP DN PRX-07034
DM5TLAP HS Phase 1
DM5TLAP SN 5-HT 6 antagonists (obesity/cognitive impairment), EPIX; 5-HT 6 antagonists (obesity/cognitive impairment), Predix
DM5TLAP CP Epix Pharmaceutical
DM5TLAP DT Small molecular drug
DM5TLAP PC 23653584
DM5TLAP MW 490.4
DM5TLAP FM C21H29Cl2N3O4S
DM5TLAP IC InChI=1S/C21H28ClN3O4S.ClH/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27;/h5-6,11-14,23-24H,7-10H2,1-4H3;1H
DM5TLAP CS CC(C1=C(C(=CC(=C1)Cl)OC)OC)NC2=C(C=CC(=C2)N3CCNCC3)S(=O)(=O)C.Cl
DM5TLAP IK PILCQJJJAFRKHO-UHFFFAOYSA-N
DM5TLAP IU N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline;hydrochloride
DM5TLAP CA CAS 903580-39-2
DM5TLAP DE Obesity
DMWT8RI ID DMWT8RI
DMWT8RI DN PRX-105
DMWT8RI HS Phase 1
DMWT8RI SN Acetylcholinesterase (poison intoxication, ProCellEx), Protalix/Hebrew University of Jerusalem; Acetylcholinesterase (poison intoxication, plant cell-expression), Protalix/Hebrew University of Jerusalem
DMWT8RI CP Hebrew University of Jerusalem
DMWT8RI DE Poison intoxication
DM2594H ID DM2594H
DM2594H DN PS-178990
DM2594H HS Phase 1
DM2594H SN SARMs (muscle wasting disease), BMS; SARMs (muscle wasting disease), Ligand; SARMs (muscle wasting disease), Pharmacopeia; Selective androgen receptor modulators (muscle wasting disease), BMS; Selective androgen receptor modulators (muscle wasting disease), Ligand; Selective androgen receptor modulators (muscle wasting disease), Pharmacopeia
DM2594H CP Bristol-Myers Squibb Co
DM2594H DE Muscle atrophy
DM75FWO ID DM75FWO
DM75FWO DN PSI-697
DM75FWO HS Phase 1
DM75FWO SN PSI-697; UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic
DM75FWO CP Pfizer
DM75FWO DT Small molecular drug
DM75FWO PC 12004316
DM75FWO MW 367.8
DM75FWO FM C21H18ClNO3
DM75FWO IC InChI=1S/C21H18ClNO3/c22-14-8-5-12(6-9-14)11-17-20(24)18(21(25)26)16-10-7-13-3-1-2-4-15(13)19(16)23-17/h5-10,24H,1-4,11H2,(H,25,26)
DM75FWO CS C1CCC2=C(C1)C=CC3=C(C(=C(N=C23)CC4=CC=C(C=C4)Cl)O)C(=O)O
DM75FWO IK DIEPFYNZGUUVHD-UHFFFAOYSA-N
DM75FWO IU 2-[(4-chlorophenyl)methyl]-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid
DM75FWO CA CAS 851546-61-7
DM75FWO DE Thrombosis; Atherosclerosis
DM5ZR4Q ID DM5ZR4Q
DM5ZR4Q DN PSI-938
DM5ZR4Q HS Phase 1
DM5ZR4Q SN PSI-352938; PSI-938; UNII-3Z30JH9QX1; 3Z30JH9QX1; PSI938; PSI 938; 1231747-17-3; 1199809-32-9; SCHEMBL2679397; CHEMBL2160007; CS-6672; HY-15231; Guanosine, 2'-deoxy-6-O-ethyl-2'-fluoro-2'-methyl-, cyclic 3',5'-(1-methylethyl (R)-phosphate), (2'R)-; 9-[(4aR,6R,7R,7aR)-7-Fluoro-2-isopropoxy-7-methyl-2-oxo-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxy-purin-2-amine
DM5ZR4Q CP Pharmasset
DM5ZR4Q DT Small molecular drug
DM5ZR4Q PC 46863668
DM5ZR4Q MW 431.36
DM5ZR4Q FM C16H23FN5O6P
DM5ZR4Q IC InChI=1S/C16H23FN5O6P/c1-5-24-13-10-12(20-15(18)21-13)22(7-19-10)14-16(4,17)11-9(26-14)6-25-29(23,28-11)27-8(2)3/h7-9,11,14H,5-6H2,1-4H3,(H2,18,20,21)/t9-,11-,14-,16-,29?/m1/s1
DM5ZR4Q CS CCOC1=NC(=NC2=C1N=CN2[C@H]3[C@]([C@H]4[C@H](O3)COP(=O)(O4)OC(C)C)(C)F)N
DM5ZR4Q IK PVRFQJIRERYGTQ-UYISCHNFSA-N
DM5ZR4Q IU 9-[(4aR,6R,7R,7aR)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine
DM5ZR4Q CA CAS 1231747-17-3
DM5ZR4Q DE Hepatitis C virus infection
DM8Y1M9 ID DM8Y1M9
DM8Y1M9 DN PSMA CAR-T cell therapy
DM8Y1M9 HS Phase 1
DM8Y1M9 CP Tmunity
DM8Y1M9 DT CAR T Cell Therapy
DM8Y1M9 DE Prostate cancer
DMRHQTU ID DMRHQTU
DMRHQTU DN PSMA subunit vaccine
DMRHQTU HS Phase 1
DMRHQTU SN Recombinant soluble PSMA vaccine; RsPSMA vaccine; PSMA subunit vaccine (prostate cancer); PSMA recombinant soluble protein vaccine, CYTOGEN/Progenics; PSMA rs protein vaccine, CYTOGEN/Progenics; PSMA protein vaccine (prostate cancer), Progenics/CYTOGEN; PSMA purified protein vaccine (prostate cancer), Progenics/CYTOGEN; PSMA subunit vaccine (prostate cancer), Progenics/CYTOGEN; PSMA-based therapeutics, CYTOGEN/Progenics
DMRHQTU CP Alphavax
DMRHQTU DT Vaccine
DMRHQTU DE Prostate cancer
DMOYX6W ID DMOYX6W
DMOYX6W DN PSMA-targeted tubulysin B conjugates
DMOYX6W HS Phase 1
DMOYX6W SN DUPA-TubH III; DUPA-tubulysin III; EC-1069; PSMA-targeted tubulysin B conjugates (prostate cancer); PSMA-targeted tubulysin B conjugates (prostate cancer), Endocyte/Purdue University
DMOYX6W CP Endocyte
DMOYX6W DE Prostate cancer
DM03O8T ID DM03O8T
DM03O8T DN PSMA-VRP
DM03O8T HS Phase 1
DM03O8T SN Alphavirus vector vaccine (prostate cancer), Progenics/Cytogen; PSMA antigen vaccine (prostate cancer), PSMA Co LLC/AlphaVax;PSMA viral vector vaccine (prostate cancer), PSMA Co LLC/AlphaVax; PSMA viral vector vaccine (prostate cancer), Progenics/CYTOGEN; PSMA antigen vaccine (prostate cancer), CYTOGEN/Progenics/AlphaVax
DM03O8T CP Alphavax
DM03O8T DT Vaccine
DM03O8T DE Prostate cancer
DMB6M1P ID DMB6M1P
DMB6M1P DN PT-112
DMB6M1P HS Phase 1
DMB6M1P SN 167683-61-6; Thiourea, N-(5-bromo-2-pyridinyl)-N'-(2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl)-; 1-(5-bromopyridin-2-yl)-3-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]thiourea; N-(2-(2-Chloro-3-ethoxy-6-fluorophenethyl))-N'-(2-(5-bromopyridyl))thiourea; PETT deriv. 9; N-[2-(2-Chloro-3-ethoxy-6-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]-; PT-112; AC1MHDLZ; SCHEMBL6906082; CHEMBL398891; BDBM2859; LY300046HCl Analog 10; DTXSID70168348
DMB6M1P DT Small molecular drug
DMB6M1P PC 3001152
DMB6M1P MW 432.7
DMB6M1P FM C16H16BrClFN3OS
DMB6M1P IC InChI=1S/C16H16BrClFN3OS/c1-2-23-13-5-4-12(19)11(15(13)18)7-8-20-16(24)22-14-6-3-10(17)9-21-14/h3-6,9H,2,7-8H2,1H3,(H2,20,21,22,24)
DMB6M1P CS CCOC1=C(C(=C(C=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br)Cl
DMB6M1P IK DTHZUSMREBJMBT-UHFFFAOYSA-N
DMB6M1P IU 1-(5-bromopyridin-2-yl)-3-[2-(2-chloro-3-ethoxy-6-fluorophenyl)ethyl]thiourea
DMB6M1P CA CAS 167683-61-6
DMB6M1P DE Solid tumour/cancer
DMWBA1S ID DMWBA1S
DMWBA1S DN PT-302
DMWBA1S HS Phase 1
DMWBA1S SN 149485-77-8; Thiourea, N-(2-(4-fluorophenyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(4-fluorophenyl)ethyl]-N'-2-thiazolyl-; PETT Analog 4; AC1MHDMB; CHEMBL253996; BDBM1897; DTXSID00164292; 1-[2-(4-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; AKOS030030877; 1-(2-Thiazolyl)-3-[4-fluorophenethyl]thiourea; N-(2-(4-Fluorophenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(4-fluorophenyl)ethyl]-3-thiazol-2-yl-thiourea
DMWBA1S DT Small molecular drug
DMWBA1S PC 3001164
DMWBA1S MW 281.4
DMWBA1S FM C12H12FN3S2
DMWBA1S IC InChI=1S/C12H12FN3S2/c13-10-3-1-9(2-4-10)5-6-14-11(17)16-12-15-7-8-18-12/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
DMWBA1S CS C1=CC(=CC=C1CCNC(=S)NC2=NC=CS2)F
DMWBA1S IK WGSDLRNUZBUXDV-UHFFFAOYSA-N
DMWBA1S IU 1-[2-(4-fluorophenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMWBA1S CA CAS 149485-77-8
DMQNRGE ID DMQNRGE
DMQNRGE DN PTG-100
DMQNRGE HS Phase 1
DMQNRGE CP Protagonist Therapeutics Milpitas, CA
DMQNRGE DE Ulcerative colitis
DMRQ5YT ID DMRQ5YT
DMRQ5YT DN PTH(7-34) liposomal cream
DMRQ5YT HS Phase 1
DMRQ5YT SN PTH(7-34); PTH(7-34) liposomal cream (Novasome); PTH(7-34) liposomal cream (Novasome), IGI
DMRQ5YT CP IGI Inc
DMRQ5YT DT Small molecular drug
DMRQ5YT PC 16131009
DMRQ5YT MW 3481
DMRQ5YT FM C156H243N47O40S2
DMRQ5YT IC InChI=1S/C156H243N47O40S2/c1-80(2)57-106(189-148(237)114(67-120(162)207)196-146(235)112(65-90-72-169-78-176-90)195-139(228)103(48-55-244-13)179-129(218)93(160)61-86-31-17-15-18-32-86)130(219)174-74-121(208)178-95(37-23-26-50-157)131(220)194-111(64-89-71-168-77-175-89)145(234)192-109(60-83(7)8)143(232)200-118(76-205)152(241)201-117(75-204)151(240)186-104(49-56-245-14)138(227)184-101(43-46-122(209)210)135(224)182-99(41-30-54-172-156(166)167)140(229)202-126(84(9)10)153(242)187-102(44-47-123(211)212)137(226)193-110(63-88-70-173-94-36-22-21-35-92(88)94)144(233)191-108(59-82(5)6)141(230)183-98(40-29-53-171-155(164)165)133(222)180-96(38-24-27-51-158)132(221)181-97(39-25-28-52-159)134(223)190-107(58-81(3)4)142(231)185-100(42-45-119(161)206)136(225)197-116(69-125(215)216)150(239)203-127(85(11)12)154(243)199-113(66-91-73-170-79-177-91)147(236)198-115(68-124(213)214)149(238)188-105(128(163)217)62-87-33-19-16-20-34-87/h15-22,31-36,70-73,77-85,93,95-118,126-127,173,204-205H,23-30,37-69,74-76,157-160H2,1-14H3,(H2,161,206)(H2,162,207)(H2,163,217)(H,168,175)(H,169,176)(H,170,177)(H,174,219)(H,178,208)(H,179,218)(H,180,222)(H,181,221)(H,182,224)(H,183,230)(H,184,227)(H,185,231)(H,186,240)(H,187,242)(H,188,238)(H,189,237)(H,190,223)(H,191,233)(H,192,234)(H,193,226)(H,194,220)(H,195,228)(H,196,235)(H,197,225)(H,198,236)(H,199,243)(H,200,232)(H,201,241)(H,202,229)(H,203,239)(H,209,210)(H,211,212)(H,213,214)(H,215,216)(H4,164,165,171)(H4,166,167,172)/t93-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-/m0/s1
DMRQ5YT CS CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC7=CC=CC=C7)N
DMRQ5YT IK YKGRXSLQYRREKO-DFOPOJAZSA-N
DMRQ5YT IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoic acid
DMRQ5YT CA CAS 101380-54-5
DMRQ5YT DE Alopecia
DMV5X8M ID DMV5X8M
DMV5X8M DN PTI-125
DMV5X8M HS Phase 1
DMV5X8M CP Pain Therapeutics Austin, TX
DMV5X8M DE Alzheimer disease
DMNO91Q ID DMNO91Q
DMNO91Q DN PTI-202
DMNO91Q HS Phase 1
DMNO91Q CP Pain therapeutics
DMNO91Q DE Pain
DM0A6N9 ID DM0A6N9
DM0A6N9 DN PTI-80
DM0A6N9 HS Phase 1
DM0A6N9 CP Proteotech
DM0A6N9 DE Alzheimer disease
DMAWO5I ID DMAWO5I
DMAWO5I DN PTX-100
DMAWO5I HS Phase 1
DMAWO5I CP Prescient Therapeutics South Melbourne, Australia
DMAWO5I DE Solid tumour/cancer
DM38F50 ID DM38F50
DM38F50 DN PTX-35
DM38F50 HS Phase 1
DM38F50 CP Pelican Therapeutics
DM38F50 DT Antibody
DM38F50 DE Solid tumour/cancer
DMJO0BP ID DMJO0BP
DMJO0BP DN PU3
DMJO0BP HS Phase 1
DMJO0BP SN PU3; 9-BUTYL-8-(3,4,5-TRIMETHOXYBENZYL)-9H-PURIN-6-AMINE; 352519-21-2; CHEMBL113690; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine; 1uym; 1uy6; Purine-Based Inhibitor 1; AC1L9MK5; PU-3; SCHEMBL2604975; BDBM15374; CTK1B7081; DTXSID40332291; ZINC3832013; AKOS030562182; DB02754; KB-275186; 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]-
DMJO0BP TC Anticancer Agents
DMJO0BP DT Small molecular drug
DMJO0BP PC 448965
DMJO0BP MW 371.4
DMJO0BP FM C19H25N5O3
DMJO0BP IC InChI=1S/C19H25N5O3/c1-5-6-7-24-15(23-16-18(20)21-11-22-19(16)24)10-12-8-13(25-2)17(27-4)14(9-12)26-3/h8-9,11H,5-7,10H2,1-4H3,(H2,20,21,22)
DMJO0BP CS CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC(=C(C(=C3)OC)OC)OC
DMJO0BP IK TUOSCZDRWRYPRS-UHFFFAOYSA-N
DMJO0BP IU 9-butyl-8-[(3,4,5-trimethoxyphenyl)methyl]purin-6-amine
DMJO0BP CA CAS 352519-21-2
DMJO0BP DE Solid tumour/cancer
DMKSU35 ID DMKSU35
DMKSU35 DN PU-AD
DMKSU35 HS Phase 1
DMKSU35 CP Samus Therapeutics Topsfield, MA
DMKSU35 DE Alzheimer disease; Encephalopathy
DMIYHAW ID DMIYHAW
DMIYHAW DN PU-H71
DMIYHAW HS Phase 1
DMIYHAW SN PU-H71; 873436-91-0; PU H71; PU-H 71; UNII-06IVK87M04; CHEMBL200102; 06IVK87M04; 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-n-(1-methylethyl)-9h-purine-9-propanamine; NSC 750424; 8-[(6-Iodo-1,3-Benzodioxol-5-Yl)thio]-9-[3-(Isopropylamino)propyl]-9h-Purin-6-Amine; 8-(6-Iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine; 8-((6-Iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine; H71; PUH-71; 2fwz; PU-H-71
DMIYHAW DT Small molecular drug
DMIYHAW PC 9549213
DMIYHAW MW 512.4
DMIYHAW FM C18H21IN6O2S
DMIYHAW IC InChI=1S/C18H21IN6O2S/c1-10(2)21-4-3-5-25-17-15(16(20)22-8-23-17)24-18(25)28-14-7-13-12(6-11(14)19)26-9-27-13/h6-8,10,21H,3-5,9H2,1-2H3,(H2,20,22,23)
DMIYHAW CS CC(C)NCCCN1C2=NC=NC(=C2N=C1SC3=C(C=C4C(=C3)OCO4)I)N
DMIYHAW IK SUPVGFZUWFMATN-UHFFFAOYSA-N
DMIYHAW IU 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6-amine
DMIYHAW CA CAS 873436-91-0
DMIYHAW DE Solid tumour/cancer; Breast cancer; Myelofibrosis
DMX5LB7 ID DMX5LB7
DMX5LB7 DN PUR0200
DMX5LB7 HS Phase 1
DMX5LB7 CP Pulmatrix
DMX5LB7 DE Chronic obstructive pulmonary disease
DMJY15D ID DMJY15D
DMJY15D DN PWT-33597
DMJY15D HS Phase 1
DMJY15D SN PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics
DMJY15D CP Pathway Therapeutics Ltd
DMJY15D PC 46917355
DMJY15D MW 588.6
DMJY15D FM C26H30F2N8O4S
DMJY15D IC InChI=1S/C26H30F2N8O4S/c1-34(2)13-16-41(37,38)33-18-9-7-17(8-10-18)23-30-25(35-11-14-40-15-12-35)32-26(31-23)36-19-5-4-6-20(39-3)21(19)29-24(36)22(27)28/h4-10,22,33H,11-16H2,1-3H3
DMJY15D CS CN(C)CCS(=O)(=O)NC1=CC=C(C=C1)C2=NC(=NC(=N2)N3CCOCC3)N4C5=C(C(=CC=C5)OC)N=C4C(F)F
DMJY15D IK GDCJHDUWWAKBIW-UHFFFAOYSA-N
DMJY15D IU N-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide
DMJY15D CA CAS 1246203-32-6
DMJY15D DE Solid tumour/cancer
DMWU682 ID DMWU682
DMWU682 DN PX-102
DMWU682 HS Phase 1
DMWU682 SN Px-102; PX20606 trans-isomer; UNII-378SU5NO8S; 378SU5NO8S; CHEMBL3822773; 1268244-85-4 (trans-isomer); 4-((1S,2S)-2-(2-CHLORO-4-((5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)ISOXAZOL-4-YL)METHOXY)PHENYL)CYCLOPROPYL)BENZOIC ACID; Px-104; 2020096-17-5; 1268244-85-4; PX 20606; SCHEMBL17087854; 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid; BDBM50185707; ZINC115372389; DB15416; 4-(2-(2-Chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid; AC-30349; PX-20606; PX-102(PX-20606); UNII-6TU6SUZ3BY component XBUXXJUEBFDQHD-NHCUHLMSSA-N; Benzoic acid, 4-((1R,2R)-2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)-, rel-(-)-; Benzoic acid, 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)-
DMWU682 DT Small molecular drug
DMWU682 PC 118374999
DMWU682 MW 554.8
DMWU682 FM C29H22Cl3NO4
DMWU682 IC InChI=1S/C29H22Cl3NO4/c30-23-2-1-3-24(31)26(23)27-22(28(37-33-27)16-6-7-16)14-36-18-10-11-19(25(32)12-18)21-13-20(21)15-4-8-17(9-5-15)29(34)35/h1-5,8-12,16,20-21H,6-7,13-14H2,(H,34,35)/t20-,21-/m1/s1
DMWU682 CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)[C@H]5C[C@@H]5C6=CC=C(C=C6)C(=O)O)Cl
DMWU682 IK XBUXXJUEBFDQHD-NHCUHLMSSA-N
DMWU682 IU 4-[(1S,2S)-2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]benzoic acid
DMWU682 CA CAS 1268244-85-4
DMWU682 DE Hepatic fibrosis
DM4AU8K ID DM4AU8K
DM4AU8K DN PX-478
DM4AU8K HS Phase 1
DM4AU8K SN PX-478; 685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di
DM4AU8K TC Anticancer Agents
DM4AU8K DT Small molecular drug
DM4AU8K PC 11234794
DM4AU8K MW 394.1
DM4AU8K FM C13H20Cl4N2O3
DM4AU8K IC InChI=1S/C13H18Cl2N2O3.2ClH/c14-5-7-17(20,8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19;;/h1-4,12H,5-9,16H2,(H,18,19);2*1H/t12-;;/m0../s1
DM4AU8K CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)[N+](CCCl)(CCCl)[O-].Cl.Cl
DM4AU8K IK GIGCDIVNDFQKRA-LTCKWSDVSA-N
DM4AU8K IU 4-[(2S)-2-amino-2-carboxyethyl]-N,N-bis(2-chloroethyl)benzeneamine oxide;dihydrochloride
DM4AU8K CA CAS 685898-44-6
DM4AU8K DE Solid tumour/cancer
DMVQJOS ID DMVQJOS
DMVQJOS DN PXS-25
DMVQJOS HS Phase 1
DMVQJOS CP Pharmaxis Ltd
DMVQJOS DE Fibrosis
DMW7K39 ID DMW7K39
DMW7K39 DN Pyrotinib
DMW7K39 HS Phase 1
DMW7K39 SN UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho
DMW7K39 CP Hengrui Therapeutics Princeton, NJ
DMW7K39 PC 51039030
DMW7K39 MW 583.1
DMW7K39 FM C32H31ClN6O3
DMW7K39 IC InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1
DMW7K39 CS CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/[C@H]5CCCN5C
DMW7K39 IK SADXACCFNXBCFY-IYNHSRRRSA-N
DMW7K39 IU (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide
DMW7K39 CA CAS 1269662-73-8
DMW7K39 DE Solid tumour/cancer
DMRGWDB ID DMRGWDB
DMRGWDB DN PZ01 CAR-T cells
DMRGWDB HS Phase 1
DMRGWDB CP Pinze Lifetechnology Co. Ltd.
DMRGWDB DT CAR T Cell Therapy
DMRGWDB DE Acute lymphoblastic leukaemia; B-cell lymphoma
DMP3QSA ID DMP3QSA
DMP3QSA DN Quinazoline derivative 9
DMP3QSA HS Phase 1
DMP3QSA SN PMID26161698-Compound-47
DMP3QSA CP SENEX BIOTECHNOLOGY INC
DMP3QSA DT Small molecular drug
DMP3QSA PC 71661259
DMP3QSA MW 450.5
DMP3QSA FM C27H26N6O
DMP3QSA IC InChI=1S/C27H26N6O/c1-32-10-12-33(13-11-32)27(34)23-6-5-21-14-19(2-4-22(21)16-23)8-9-29-26-24-15-20(17-28)3-7-25(24)30-18-31-26/h2-7,14-16,18H,8-13H2,1H3,(H,29,30,31)
DMP3QSA CS CN1CCN(CC1)C(=O)C2=CC3=C(C=C2)C=C(C=C3)CCNC4=NC=NC5=C4C=C(C=C5)C#N
DMP3QSA IK VNADJTWHOAMTLY-UHFFFAOYSA-N
DMP3QSA IU 4-[2-[6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl]ethylamino]quinazoline-6-carbonitrile
DMP3QSA CA CAS 1449228-40-3
DMP3QSA DE Breast cancer
DM64U1Y ID DM64U1Y
DM64U1Y DN R-1663
DM64U1Y HS Phase 1
DM64U1Y CP Roche Holding AG
DM64U1Y DE Coagulation defect
DMSKHIC ID DMSKHIC
DMSKHIC DN R4996
DMSKHIC HS Phase 1
DMSKHIC CP Roche
DMSKHIC PC 738660
DMSKHIC MW 208.64
DMSKHIC FM C11H9ClO2
DMSKHIC IC InChI=1S/C11H9ClO2/c12-9-3-1-8(2-4-9)11-6-5-10(7-13)14-11/h1-6,13H,7H2
DMSKHIC CS C1=CC(=CC=C1C2=CC=C(O2)CO)Cl
DMSKHIC IK PMHZVTQIEAIJBK-UHFFFAOYSA-N
DMSKHIC IU [5-(4-chlorophenyl)furan-2-yl]methanol
DMSKHIC CA CAS 33342-29-9
DMSKHIC DE Neurological disorder
DM5XCRQ ID DM5XCRQ
DM5XCRQ DN R552
DM5XCRQ HS Phase 1
DM5XCRQ SN 2-(Methylthio)thiazole; 5053-24-7; 2-Methylthiothiazole; 2-methylthio thiazole; 2-Methylthio-1,3-thiazole; Thiazole, 2-(methylthio)-; 2-methylsulfanyl-1,3-thiazole; 2-(methylsulfanyl)-1,3-thiazole; MFCD00858981; ACMC-209knn; 2-(methylthio) thiazole; 2-methylsulfanyl-thiazole; 2-(Methylmercapto)thiazole; 2-Methylthiothiazole, 97%; C4H5NS2; SCHEMBL496215; DTXSID60375024; ZINC2570798; ANW-31041; AKOS006223218; GS-6827; FT-0658231; M1712; A828155; Q-100565
DM5XCRQ CP Rigel
DM5XCRQ DT Small molecular drug
DM5XCRQ PC 2760100
DM5XCRQ MW 131.2
DM5XCRQ FM C4H5NS2
DM5XCRQ IC InChI=1S/C4H5NS2/c1-6-4-5-2-3-7-4/h2-3H,1H3
DM5XCRQ CS CSC1=NC=CS1
DM5XCRQ IK VQNOAXZUEKPSJC-UHFFFAOYSA-N
DM5XCRQ IU 2-methylsulfanyl-1,3-thiazole
DM5XCRQ CA CAS 5053-24-7
DM5XCRQ DE Nervous system paraneoplastic or autoimmune disorders
DMVA186 ID DMVA186
DMVA186 DN R7334
DMVA186 HS Phase 1
DMVA186 SN R 7334; 2-Nitro-6,7,8,9-tetrahydronaphtho(1,2-b)furan; 2-nitro-6,7,8,9-tetrahydrobenzo[g][1]benzofuran; 6,7,8,9-Tetrahydro-2-nitronaphtho(1,2-b)furan
DMVA186 CP Roche
DMVA186 DT Antibody
DMVA186 DE Macular degeneration
DME0CJ9 ID DME0CJ9
DME0CJ9 DN R763
DME0CJ9 HS Phase 1
DME0CJ9 TC Anticancer Agents
DME0CJ9 DT Small molecular drug
DME0CJ9 PC 11569967
DME0CJ9 MW 451.5
DME0CJ9 FM C24H30FN7O
DME0CJ9 IC InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1
DME0CJ9 CS CC1=C(C=CC(=C1)NC2=NC=C(C(=N2)N[C@@H]3[C@@H]4C[C@H]([C@@H]3C(=O)N)C=C4)F)N5CCN(CC5)C
DME0CJ9 IK KSOVGRCOLZZTPF-QMKUDKLTSA-N
DME0CJ9 IU (1S,2S,3R,4R)-3-[[5-fluoro-2-[3-methyl-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
DME0CJ9 CA CAS 871357-89-0
DME0CJ9 DE Haematological malignancy
DM1N8PZ ID DM1N8PZ
DM1N8PZ DN rAAV1.tMCK.human-alpha-sarcoglycan
DM1N8PZ HS Phase 1
DM1N8PZ SN alpha-sarcoglycan adenoviral gene therapy
DM1N8PZ DE Discovery agent
DMNVDI2 ID DMNVDI2
DMNVDI2 DN RAD-140
DMNVDI2 HS Phase 1
DMNVDI2 SN RAD-35010; Selective androgen receptor modulators (oral, sarcopenia/osteoporosis), Radius Health
DMNVDI2 CP Radius Health Inc
DMNVDI2 DT Small molecular drug
DMNVDI2 PC 44200882
DMNVDI2 MW 393.8
DMNVDI2 FM C20H16ClN5O2
DMNVDI2 IC InChI=1S/C20H16ClN5O2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27H,1-2H3/t12-,18+/m0/s1
DMNVDI2 CS CC1=C(C=CC(=C1Cl)C#N)N[C@@H](C2=NN=C(O2)C3=CC=C(C=C3)C#N)[C@H](C)O
DMNVDI2 IK XMBUPPIEVAFYHO-KPZWWZAWSA-N
DMNVDI2 IU 2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile
DMNVDI2 CA CAS 1182367-47-0
DMNVDI2 DE Osteoporosis; Breast cancer
DMIEJ0W ID DMIEJ0W
DMIEJ0W DN Radiolabelled-huA33
DMIEJ0W HS Phase 1
DMIEJ0W SN Radiolabelled-huA33 (colorectal cancer); Radiolabelled-huA33 (colorectal cancer), Ludwig; 124I-huA33; 125I-huA33
DMIEJ0W CP Ludwig Institute for Cancer Research
DMIEJ0W DT Antibody
DMIEJ0W DE Colorectal cancer
DM4VTX6 ID DM4VTX6
DM4VTX6 DN RASV-Sp
DM4VTX6 HS Phase 1
DM4VTX6 SN Recombinant attenuated Salmonella Typhi vaccine vectors expressing the Streptococcus pneumoniae surface protein (PspA) alpha-helical domain fused to B-lactamase (oral, Streptococcus pneumoniae infection), Arizona State University
DM4VTX6 CP Arizona State University
DM4VTX6 DT Vaccine
DM4VTX6 DE Streptococcus infection
DMAP6CS ID DMAP6CS
DMAP6CS DN RBN-2397
DMAP6CS HS Phase 1
DMAP6CS SN 2381037-82-5; Atamparib; Atamparib [INN]; UNII-B1MW2ME77A; B1MW2ME77A; SCHEMBL21521281; RBN2397; BCP33764; EX-A4038; RBN2397;RBN 2397; NSC825956; s8993; NSC-825956; HY-136174; CS-0120272; 3(2H)-Pyridazinone, 5-(((1S)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)-; 5-(((2S)-1-(3-Oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2H)-one
DMAP6CS CP Ribon Therapeutics
DMAP6CS DT Small molecular drug
DMAP6CS PC 146047148
DMAP6CS MW 523.4
DMAP6CS FM C20H23F6N7O3
DMAP6CS IC InChI=1S/C20H23F6N7O3/c1-12(30-14-10-29-31-17(35)16(14)20(24,25)26)11-36-7-2-15(34)32-3-5-33(6-4-32)18-27-8-13(9-28-18)19(21,22)23/h8-10,12H,2-7,11H2,1H3,(H2,30,31,35)/t12-/m0/s1
DMAP6CS CS C[C@@H](COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
DMAP6CS IK UQZCQKXJAXKZQH-LBPRGKRZSA-N
DMAP6CS IU 4-[[(2S)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1H-pyridazin-6-one
DMAP6CS CA CAS 2381037-82-5
DMAP6CS DE Solid tumour/cancer
DM25GIA ID DM25GIA
DM25GIA DN REC-01
DM25GIA HS Phase 1
DM25GIA CP Recardio San Francisco, CA
DM25GIA DE Acute myocardial infarction
DMHT5XV ID DMHT5XV
DMHT5XV DN REC-02
DMHT5XV HS Phase 1
DMHT5XV CP Recardio San Francisco, CA
DMHT5XV DE Congestive heart failure
DMK9Y71 ID DMK9Y71
DMK9Y71 DN Recombinant human Erbb3 fragment therapeutic tumor vaccine
DMK9Y71 HS Phase 1
DMK9Y71 SN Fragment therapeutic tumor vaccine; Recombinant human Erbb3 fragment therapeutic tumor vaccine (injectable, Erbb2-overexpressing cancer)
DMK9Y71 CP Zensun (Shanghai) Sci-Tech Co Ltd
DMK9Y71 DT Vaccine
DMK9Y71 DE Solid tumour/cancer
DMYBELW ID DMYBELW
DMYBELW DN REGN1193
DMYBELW HS Phase 1
DMYBELW CP Regeneron Pharmaceuticals; Sanofi
DMYBELW DT Antibody
DMYBELW DE Type-2 diabetes
DME3VU8 ID DME3VU8
DME3VU8 DN REGN1400
DME3VU8 HS Phase 1
DME3VU8 DT Antibody
DME3VU8 DE Solid tumour/cancer
DM0E3ZG ID DM0E3ZG
DM0E3ZG DN REGN3048
DM0E3ZG HS Phase 1
DM0E3ZG DT Antibody
DM0E3ZG DE Coronavirus infection
DM7LIV2 ID DM7LIV2
DM7LIV2 DN REGN3051
DM7LIV2 HS Phase 1
DM7LIV2 CP Regeneron Pharmaceuticals; Sanofi
DM7LIV2 DT Antibody
DM7LIV2 DE Coronavirus infection
DMWJ0IH ID DMWJ0IH
DMWJ0IH DN REGN-421
DMWJ0IH HS Phase 1
DMWJ0IH SN Dll4 antibody; Dll4-Fc; Delta-like ligand 4 antibody (VelociSuite), Regeneron, sanofi-aventis
DMWJ0IH CP Regeneron pharmaceuticals; sanofi us
DMWJ0IH DT Antibody
DMWJ0IH DE Solid tumour/cancer
DM3720L ID DM3720L
DM3720L DN REGN5093
DM3720L HS Phase 1
DM3720L CP Regeneron Pharmaceuticals
DM3720L DT Antibody
DM3720L DE Non-small-cell lung cancer
DM0ZMNI ID DM0ZMNI
DM0ZMNI DN REGN6569
DM0ZMNI HS Phase 1
DM0ZMNI CP Regeneron Pharmaceuticals
DM0ZMNI DT Antibody
DM0ZMNI DE Squamous head and neck cell carcinom
DMHR7D4 ID DMHR7D4
DMHR7D4 DN REGN-910
DMHR7D4 HS Phase 1
DMHR7D4 SN SAR-3077646; Anti-angiopoietin-2 antibody (cancer), Regeneron/sanofi-aventis
DMHR7D4 CP Regeneron Pharmaceuticals Inc
DMHR7D4 DT Antibody
DMHR7D4 DE Solid tumour/cancer
DMZJH23 ID DMZJH23
DMZJH23 DN REP8839
DMZJH23 HS Phase 1
DMZJH23 SN REP-8839; SB-682150; 2-[3-[4-Bromo-5-(1-fluorovinyl)-3-methylthien-2-ylmethylamino]propylamino]quinolin-4(1H)-one
DMZJH23 CP Replidyne
DMZJH23 DT Small molecular drug
DMZJH23 PC 9868368
DMZJH23 MW 450.4
DMZJH23 FM C20H21BrFN3OS
DMZJH23 IC InChI=1S/C20H21BrFN3OS/c1-12-17(27-20(13(2)22)19(12)21)11-23-8-5-9-24-18-10-16(26)14-6-3-4-7-15(14)25-18/h3-4,6-7,10,23H,2,5,8-9,11H2,1H3,(H2,24,25,26)
DMZJH23 CS CC1=C(SC(=C1Br)C(=C)F)CNCCCNC2=CC(=O)C3=CC=CC=C3N2
DMZJH23 IK BGJMKHPWCFXMOW-UHFFFAOYSA-N
DMZJH23 IU 2-[3-[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methylamino]propylamino]-1H-quinolin-4-one
DMZJH23 CA CAS 757942-43-1
DMZJH23 DE Bacterial infection
DMZ8WAQ ID DMZ8WAQ
DMZ8WAQ DN Retroviral vector-transduced autologous T cells to express CD22-specific CARs
DMZ8WAQ HS Phase 1
DMZ8WAQ CP Xinqiao Hospital of Chongqing
DMZ8WAQ DT CAR T Cell Therapy
DMZ8WAQ DE Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma
DMLHIMO ID DMLHIMO
DMLHIMO DN REV-576
DMLHIMO HS Phase 1
DMLHIMO SN Complement C5a inhibitor (inflammatory disorders/reperfusion injury), Evolutec
DMLHIMO CP Evolutec Group plc
DMLHIMO DE Autoimmune diabetes
DM7B650 ID DM7B650
DM7B650 DN RG-2833
DM7B650 HS Phase 1
DM7B650 SN RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen
DM7B650 CP Repligen
DM7B650 DT Small molecular drug
DM7B650 PC 56654642
DM7B650 MW 339.4
DM7B650 FM C20H25N3O2
DM7B650 IC InChI=1S/C20H25N3O2/c1-15-10-12-16(13-11-15)20(25)22-14-6-2-3-9-19(24)23-18-8-5-4-7-17(18)21/h4-5,7-8,10-13H,2-3,6,9,14,21H2,1H3,(H,22,25)(H,23,24)
DM7B650 CS CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N
DM7B650 IK VOPDXHFYDJAYNS-UHFFFAOYSA-N
DM7B650 IU N-[6-(2-aminoanilino)-6-oxohexyl]-4-methylbenzamide
DM7B650 CA CAS 1215493-56-3
DM7B650 DE Friedreich's ataxia
DM8GC65 ID DM8GC65
DM8GC65 DN RG3039
DM8GC65 HS Phase 1
DM8GC65 CP Repligen
DM8GC65 PC 53258905
DM8GC65 MW 432.3
DM8GC65 FM C21H23Cl2N5O
DM8GC65 IC InChI=1S/C21H23Cl2N5O/c22-15-3-1-4-16(23)14(15)11-28-9-7-13(8-10-28)12-29-18-6-2-5-17-19(18)20(24)27-21(25)26-17/h1-6,13H,7-12H2,(H4,24,25,26,27)
DM8GC65 CS C1CN(CCC1COC2=CC=CC3=C2C(=NC(=N3)N)N)CC4=C(C=CC=C4Cl)Cl
DM8GC65 IK MNLHFGXIUJNDAF-UHFFFAOYSA-N
DM8GC65 IU 5-[[1-[(2,6-dichlorophenyl)methyl]piperidin-4-yl]methoxy]quinazoline-2,4-diamine
DM8GC65 CA CAS 1005504-62-0
DM8GC65 DE Spinal muscular atrophy
DM45HT6 ID DM45HT6
DM45HT6 DN RG6062
DM45HT6 HS Phase 1
DM45HT6 SN Glofitamab
DM45HT6 CP Roche/Genentech
DM45HT6 DT Antibody
DM45HT6 DE Follicular lymphoma
DMO9BGI ID DMO9BGI
DMO9BGI DN RG6076
DMO9BGI HS Phase 1
DMO9BGI CP Roche/Genentech
DMO9BGI DT Recombinant protein
DMO9BGI DE Hematologic tumour
DM9QNMB ID DM9QNMB
DM9QNMB DN RG6084
DM9QNMB HS Phase 1
DM9QNMB CP Roche
DM9QNMB DT Antisense oligonucleotide
DM9QNMB DE Hepatitis B virus infection
DM6TLPD ID DM6TLPD
DM6TLPD DN RG6115
DM6TLPD HS Phase 1
DM6TLPD SN RO7119929
DM6TLPD CP Roche/Genentech
DM6TLPD DE Hepatocellular carcinoma
DMX8YO1 ID DMX8YO1
DMX8YO1 DN RG6125
DMX8YO1 HS Phase 1
DMX8YO1 CP RocheBasel, Switzerland
DMX8YO1 DE Rheumatoid arthritis
DMJFM3O ID DMJFM3O
DMJFM3O DN RG6139
DMJFM3O HS Phase 1
DMJFM3O CP Roche/Genentech
DMJFM3O DT Antibody
DMJFM3O DE Solid tumour/cancer
DMIHC4R ID DMIHC4R
DMIHC4R DN RG6146
DMIHC4R HS Phase 1
DMIHC4R CP Roche/Genentech South San Francisco, CA
DMIHC4R DE Haematological malignancy; Solid tumour/cancer
DMSM0IJ ID DMSM0IJ
DMSM0IJ DN RG6279
DMSM0IJ HS Phase 1
DMSM0IJ SN RO7284755
DMSM0IJ CP Roche/Genentech
DMSM0IJ DT Recombinant protein
DMSM0IJ DE Solid tumour/cancer
DMBRYZ7 ID DMBRYZ7
DMBRYZ7 DN RG6292
DMBRYZ7 HS Phase 1
DMBRYZ7 SN CD25 mAb
DMBRYZ7 CP Roche/Genentech
DMBRYZ7 DT Antibody
DMBRYZ7 DE Solid tumour/cancer
DMEFUSJ ID DMEFUSJ
DMEFUSJ DN RG6296
DMEFUSJ HS Phase 1
DMEFUSJ SN AFM-26
DMEFUSJ CP Affimed Therapeutics; Roche/Genentech
DMEFUSJ DT Antibody
DMEFUSJ DE Multiple myeloma
DMSX5NJ ID DMSX5NJ
DMSX5NJ DN RG6330
DMSX5NJ HS Phase 1
DMSX5NJ SN GDC-6036
DMSX5NJ CP Roche/Genentech
DMSX5NJ DE Solid tumour/cancer
DMOWYKS ID DMOWYKS
DMOWYKS DN RG6346
DMOWYKS HS Phase 1
DMOWYKS CP Dicerna Pharmaceuticals; Roche
DMOWYKS DT Small interfering RNA
DMOWYKS DE Hepatitis B virus infection
DMMWS3O ID DMMWS3O
DMMWS3O DN RG-7010
DMMWS3O HS Phase 1
DMMWS3O SN R-7010; PEGylated IGF1 (amyotrophic lateral sclerosis), Roche
DMMWS3O CP F Hoffmann-La Roche Ltd
DMMWS3O DE Motor neurone disease
DM2IDQ9 ID DM2IDQ9
DM2IDQ9 DN RG-7103
DM2IDQ9 HS Phase 1
DM2IDQ9 SN R-7103; RO-5024118; VPAC2 agonist (COPD), Roche
DM2IDQ9 CP F Hoffmann-La Roche Ltd
DM2IDQ9 PC 90871060
DM2IDQ9 MW 3576.1
DM2IDQ9 FM C161H260N46O46
DM2IDQ9 IC InChI=1S/C161H260N46O46/c1-18-19-38-99(136(230)180-85(10)132(226)179-86(11)133(227)183-100(40-24-30-59-163)137(231)187-103-44-28-34-63-174-123(218)74-117(200-152(246)116(73-122(169)217)199-148(242)110(67-83(6)7)194-149(243)111(196-141(103)235)69-93-46-50-96(213)51-47-93)153(247)195-109(66-82(4)5)147(241)188-102(42-26-32-61-165)138(232)184-98(39-23-29-58-162)135(229)177-77-124(219)176-78-125(220)204-128(88(13)209)131(170)225)185-143(237)106(54-56-120(167)215)190-139(233)101(41-25-31-60-164)186-140(234)105(45-35-64-175-160(171)172)189-146(240)108(65-81(2)3)193-142(236)104(43-27-33-62-166)191-157(251)129(89(14)210)205-154(248)112(70-94-48-52-97(214)53-49-94)197-151(245)115(72-121(168)216)198-144(238)107(55-57-126(221)222)192-158(252)130(90(15)211)206-155(249)113(68-92-36-21-20-22-37-92)203-159(253)161(17,84(8)9)207-134(228)87(12)181-145(239)118(75-127(223)224)201-156(250)119(79-208)202-150(244)114(182-91(16)212)71-95-76-173-80-178-95/h20-22,36-37,46-53,76,80-90,98-119,128-130,208-211,213-214H,18-19,23-35,38-45,54-75,77-79,162-166H2,1-17H3,(H2,167,215)(H2,168,216)(H2,169,217)(H2,170,225)(H,173,178)(H,174,218)(H,176,219)(H,177,229)(H,179,226)(H,180,230)(H,181,239)(H,182,212)(H,183,227)(H,184,232)(H,185,237)(H,186,234)(H,187,231)(H,188,241)(H,189,240)(H,190,233)(H,191,251)(H,192,252)(H,193,236)(H,194,243)(H,195,247)(H,196,235)(H,197,245)(H,198,238)(H,199,242)(H,200,246)(H,201,250)(H,202,244)(H,203,253)(H,204,220)(H,205,248)(H,206,249)(H,207,228)(H,221,222)(H,223,224)(H4,171,172,175)/t85-,86-,87-,88?,89?,90?,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,128-,129-,130-,161-/m0/s1
DM2IDQ9 CS CCCC[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCCCNC(=O)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=C(C=C2)O)CC(C)C)CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)O)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@](C)(C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CN=CN5)NC(=O)C
DM2IDQ9 IK AXQOGBKHHSARHC-CEPMLMOKSA-N
DM2IDQ9 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-2,3-dimethylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,5S,8S,11S,19S)-11-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[2-[[2-[[(2S)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]-8-(2-amino-2-oxoethyl)-2-[(4-hydroxyphenyl)methyl]-5-(2-methylpropyl)-3,6,9,13,20-pentaoxo-1,4,7,10,14-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid
DM2IDQ9 CA CAS 1001080-55-2
DM2IDQ9 DE Chronic obstructive pulmonary disease
DM6XVCO ID DM6XVCO
DM6XVCO DN RG7116
DM6XVCO HS Phase 1
DM6XVCO CP Roche
DM6XVCO DE Solid tumour/cancer
DMTWSM2 ID DMTWSM2
DMTWSM2 DN RG7129
DMTWSM2 HS Phase 1
DMTWSM2 CP Roche
DMTWSM2 PC 53241828
DMTWSM2 MW 389.3
DMTWSM2 FM C18H14F3N5O2
DMTWSM2 IC InChI=1S/C18H14F3N5O2/c1-17(18(20,21)9-28-16(23)26-17)12-6-11(3-4-13(12)19)25-15(27)14-5-2-10(7-22)8-24-14/h2-6,8H,9H2,1H3,(H2,23,26)(H,25,27)/t17-/m1/s1
DMTWSM2 CS C[C@]1(C(COC(=N1)N)(F)F)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMTWSM2 IK DVMUZHLUMHPCGZ-QGZVFWFLSA-N
DMTWSM2 IU N-[3-[(4R)-2-amino-5,5-difluoro-4-methyl-6H-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMTWSM2 CA CAS 1310347-50-2
DMTWSM2 DE Alzheimer disease
DMYX4NP ID DMYX4NP
DMYX4NP DN RG7203
DMYX4NP HS Phase 1
DMYX4NP CP Roche
DMYX4NP DE Schizophrenia
DMGFAVQ ID DMGFAVQ
DMGFAVQ DN RG7304
DMGFAVQ HS Phase 1
DMGFAVQ CP Chugai; Roche
DMGFAVQ PC 74890577
DMGFAVQ MW 228.25
DMGFAVQ FM C12H12N4O
DMGFAVQ IC InChI=1S/C12H12N4O/c1-16(11-7-12(17)15-13-9-11)14-8-10-5-3-2-4-6-10/h2-9H,1H3,(H,15,17)/b14-8-
DMGFAVQ CS CN(C1=CC(=O)NN=C1)/N=C\\C2=CC=CC=C2
DMGFAVQ IK CTGDOGPKSFBVDA-ZSOIEALJSA-N
DMGFAVQ IU 4-[[(Z)-benzylideneamino]-methylamino]-1H-pyridazin-6-one
DMGFAVQ DE Solid tumour/cancer
DMIW5NG ID DMIW5NG
DMIW5NG DN RG7342
DMIW5NG HS Phase 1
DMIW5NG DE Schizophrenia
DMOE5NQ ID DMOE5NQ
DMOE5NQ DN RG7347
DMOE5NQ HS Phase 1
DMOE5NQ CP Genentech; Roche
DMOE5NQ DE Solid tumour/cancer
DMFDKS7 ID DMFDKS7
DMFDKS7 DN RG-7348
DMFDKS7 HS Phase 1
DMFDKS7 SN MB-11362; Nucleosides (HepDirect, HCV infection), Roche/Metabasis
DMFDKS7 CP Roche Holding AG
DMFDKS7 DE Hepatitis C virus infection
DMFGR98 ID DMFGR98
DMFGR98 DN RG-7351
DMFGR98 HS Phase 1
DMFGR98 SN TAAR1 part agonist (depression), Roche; Trace amine-associated receptor 1 part agonist (depression), Roche
DMFGR98 CP Roche Holding AG
DMFGR98 DE Major depressive disorder
DM1NHEA ID DM1NHEA
DM1NHEA DN RG7450
DM1NHEA HS Phase 1
DM1NHEA SN Anti-STEAP1, DSTP3086S
DM1NHEA CP Seattle Genetics; Roche
DM1NHEA DE Prostate cancer
DM5OTGR ID DM5OTGR
DM5OTGR DN RG7461
DM5OTGR HS Phase 1
DM5OTGR CP Roche/Genentech South San Francisco, CA
DM5OTGR DE Solid tumour/cancer
DMK6P9J ID DMK6P9J
DMK6P9J DN RG7741
DMK6P9J HS Phase 1
DMK6P9J SN GDC-0575
DMK6P9J CP Roche
DMK6P9J DE Lymphoma; Solid tumour/cancer
DMXBS6U ID DMXBS6U
DMXBS6U DN RG7775
DMXBS6U HS Phase 1
DMXBS6U CP Genentech
DMXBS6U DE Acute myeloid leukaemia
DMACLIH ID DMACLIH
DMACLIH DN RG7813
DMACLIH HS Phase 1
DMACLIH SN Cergutuzumab amunaleukin
DMACLIH CP GenentechSouth San Francisco, CA
DMACLIH DE Solid tumour/cancer
DMD16JK ID DMD16JK
DMD16JK DN RG-7816
DMD16JK HS Phase 1
DMD16JK CP Roche
DMD16JK DE Autism spectrum disorder
DMRGHKN ID DMRGHKN
DMRGHKN DN RG7827
DMRGHKN HS Phase 1
DMRGHKN CP Roche/Genentech
DMRGHKN DT Recombinant protein
DMRGHKN DE Solid tumour/cancer
DMCUBZO ID DMCUBZO
DMCUBZO DN RG7828
DMCUBZO HS Phase 1
DMCUBZO CP GenentechSouth San Francisco, CA
DMCUBZO DE Haematological malignancy
DMGLXQ9 ID DMGLXQ9
DMGLXQ9 DN RG7854
DMGLXQ9 HS Phase 1
DMGLXQ9 CP Roche
DMGLXQ9 DT Small molecular drug
DMGLXQ9 DE Hepatitis B virus infection
DM2E5Z7 ID DM2E5Z7
DM2E5Z7 DN RG7882
DM2E5Z7 HS Phase 1
DM2E5Z7 CP Genentech
DM2E5Z7 DT Antibody
DM2E5Z7 DE Ovarian cancer; Pancreatic cancer
DM1R4MQ ID DM1R4MQ
DM1R4MQ DN RG7893
DM1R4MQ HS Phase 1
DM1R4MQ DE Pain
DMKVIS5 ID DMKVIS5
DMKVIS5 DN RG7907
DMKVIS5 HS Phase 1
DMKVIS5 SN CPAM
DMKVIS5 CP Roche
DMKVIS5 DT Small molecular drug
DMKVIS5 PC 139202885
DMKVIS5 MW 352.15
DMKVIS5 FM C15H11BrFNO3
DMKVIS5 IC InChI=1S/C15H11BrFNO3/c16-11-8-10(17)3-4-12(11)18-15(21)6-2-9-1-5-13(19)14(20)7-9/h1-8,19-20H,(H,18,21)/b6-2+
DMKVIS5 CS C1=CC(=C(C=C1/C=C/C(=O)NC2=C(C=C(C=C2)F)Br)O)O
DMKVIS5 IK XOHNWHLPLQQICZ-QHHAFSJGSA-N
DMKVIS5 IU (E)-N-(2-bromo-4-fluorophenyl)-3-(3,4-dihydroxyphenyl)prop-2-enamide
DMKVIS5 DE Hepatitis B
DMEGOQP ID DMEGOQP
DMEGOQP DN RGB-286638
DMEGOQP HS Phase 1
DMEGOQP SN GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech
DMEGOQP CP GPC Biotech AG
DMEGOQP DT Small molecular drug
DMEGOQP PC 11285001
DMEGOQP MW 618.6
DMEGOQP FM C29H37Cl2N7O4
DMEGOQP IC InChI=1S/C29H35N7O4.2ClH/c1-39-16-13-34-9-11-35(12-10-34)19-20-5-7-21(8-6-20)26-25-27(32-31-26)22-3-2-4-23(24(22)28(25)37)30-29(38)33-36-14-17-40-18-15-36;;/h2-8H,9-19H2,1H3,(H,31,32)(H2,30,33,38);2*1H
DMEGOQP CS COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6.Cl.Cl
DMEGOQP IK WJVMGQMXUBAAPL-UHFFFAOYSA-N
DMEGOQP IU 1-[3-[4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-4-oxo-1H-indeno[1,2-c]pyrazol-5-yl]-3-morpholin-4-ylurea;dihydrochloride
DMEGOQP CA CAS 784210-87-3
DMEGOQP DE Haematological malignancy
DMVJMF1 ID DMVJMF1
DMVJMF1 DN RGD-891
DMVJMF1 HS Phase 1
DMVJMF1 SN Klerval; RPR-109039; N-Ethyl-N-[4-(4-piperidyl)butyryl]-glycyl-L-aspartyl-L-(3-cyclohexyl)alaninamide
DMVJMF1 PC 9806811
DMVJMF1 MW 523.7
DMVJMF1 FM C26H45N5O6
DMVJMF1 IC InChI=1S/C26H45N5O6/c1-2-31(23(33)10-6-9-18-11-13-28-14-12-18)17-22(32)29-21(16-24(34)35)26(37)30-20(25(27)36)15-19-7-4-3-5-8-19/h18-21,28H,2-17H2,1H3,(H2,27,36)(H,29,32)(H,30,37)(H,34,35)/t20-,21-/m0/s1
DMVJMF1 CS CCN(CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N)C(=O)CCCC2CCNCC2
DMVJMF1 IK PWINFPFVCZSLBF-SFTDATJTSA-N
DMVJMF1 IU (3S)-4-[[(2S)-1-amino-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-[[2-[ethyl(4-piperidin-4-ylbutanoyl)amino]acetyl]amino]-4-oxobutanoic acid
DMVJMF1 CA CAS 169512-56-5
DMVJMF1 DE Angina pectoris; Thrombosis
DMQAIU1 ID DMQAIU1
DMQAIU1 DN RGLS4326
DMQAIU1 HS Phase 1
DMQAIU1 SN UNII-UCH3QQH1C0; UCH3QQH1C0; RGLS-4326; 2229964-07-0
DMQAIU1 CP Regulus Therapeutics
DMQAIU1 DT Oligonucleotide
DMQAIU1 PC 154824286
DMQAIU1 MW 3082.4
DMQAIU1 FM C95H115F3N32O51P8S8
DMQAIU1 IC InChI=1S/C95H115F3N32O51P8S8/c1-32-92(22-131)65(61(162-32)83(170-92)128-29-110-50-69(102)106-27-108-71(50)128)179-189(150,197)160-25-95-35(4)164-63(84(173-95)130-31-112-52-73(130)119-86(104)121-75(52)137)67(95)180-186(147,194)157-21-40-56(58(151-5)79(168-40)124-13-8-42(100)114-88(124)139)177-185(146,193)155-19-38-55(48(98)78(167-38)127-28-109-49-68(101)105-26-107-70(49)127)176-183(144,191)154-17-36-53(46(96)76(165-36)122-12-7-41(99)113-87(122)138)174-182(143,190)153-18-37-54(47(97)77(166-37)123-14-9-43(132)115-89(123)140)175-184(145,192)156-20-39-57(59(152-6)80(169-39)125-15-10-44(133)116-90(125)141)178-187(148,195)159-24-94-34(3)163-62(82(172-94)126-16-11-45(134)117-91(126)142)66(94)181-188(149,196)158-23-93-33(2)161-60(64(93)135)81(171-93)129-30-111-51-72(129)118-85(103)120-74(51)136/h7-16,26-40,46-48,53-67,76-84,131,135H,17-25H2,1-6H3,(H,143,190)(H,144,191)(H,145,192)(H,146,193)(H,147,194)(H,148,195)(H,149,196)(H,150,197)(H2,99,113,138)(H2,100,114,139)(H2,101,105,107)(H2,102,106,108)(H,115,132,140)(H,116,133,141)(H,117,134,142)(H3,103,118,120,136)(H3,104,119,121,137)/t32-,33-,34-,35-,36+,37+,38+,39+,40+,46+,47+,48+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64-,65-,66-,67-,76+,77+,78+,79+,80+,81+,82+,83+,84+,92-,93-,94-,95-,182?,183?,184?,185?,186?,187?,188?,189?/m0/s1
DMQAIU1 CS C[C@H]1[C@]2([C@H]([C@@H](O1)[C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=S)(O)OC[C@]56[C@@H](O[C@H]([C@@H]5OP(=O)(OC[C@@H]7[C@H]([C@H]([C@@H](O7)N8C=CC(=NC8=O)N)OC)OP(=S)(O)OC[C@@H]9[C@H]([C@H]([C@@H](O9)N1C=NC2=C(N=CN=C21)N)F)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=NC1=O)N)F)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)F)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=CC(=O)NC1=O)OC)OP(=S)(O)OC[C@]12[C@@H](O[C@H]([C@@H]1OP(=S)(O)OC[C@]13[C@@H](O[C@H]([C@@H]1O)[C@@H](O3)N1C=NC3=C1N=C(NC3=O)N)C)[C@@H](O2)N1C=CC(=O)NC1=O)C)S)[C@@H](O6)N1C=NC2=C1N=C(NC2=O)N)C)CO
DMQAIU1 IK WAVSYQSKUSIMAY-IOHKGNKKSA-N
DMQAIU1 IU 1-[(1S,3R,4R,6S,7S)-1-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(2R,3R,4R,5R)-2-[[[(1S,3R,4R,6S,7S)-3-(2-amino-6-oxo-1H-purin-9-yl)-1-[[[(1S,3R,4R,6S,7S)-3-(6-aminopurin-9-yl)-1-(hydroxymethyl)-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-7-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(6-aminopurin-9-yl)-4-fluorooxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluorooxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-fluorooxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-7-[[(1R,3R,4R,6S,7S)-3-(2-amino-6-oxo-1H-purin-9-yl)-7-hydroxy-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-1-yl]methoxy-hydroxyphosphinothioyl]oxy-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-3-yl]pyrimidine-2,4-dione
DMQAIU1 CA CAS 2229964-07-0
DMQAIU1 DE Autosomal dominant polycystic kidney disease
DMU87HW ID DMU87HW
DMU87HW DN RGX-111
DMU87HW HS Phase 1
DMU87HW CP REGENXBIO
DMU87HW DT Gene therapy
DMU87HW DE Mucopolysaccharidosis
DM8VGRX ID DM8VGRX
DM8VGRX DN RGX-202
DM8VGRX HS Phase 1
DM8VGRX CP Rgenix
DM8VGRX DT Small molecular drug
DM8VGRX DE Gastrointestinal cancer
DMDM85L ID DMDM85L
DMDM85L DN RH 1
DMDM85L HS Phase 1
DMDM85L SN RH-1
DMDM85L TC Anticancer Agents
DMDM85L DT Small molecular drug
DMDM85L PC 394347
DMDM85L MW 234.25
DMDM85L FM C12H14N2O3
DMDM85L IC InChI=1S/C12H14N2O3/c1-7-9(13-2-3-13)12(17)8(6-15)10(11(7)16)14-4-5-14/h15H,2-6H2,1H3
DMDM85L CS CC1=C(C(=O)C(=C(C1=O)N2CC2)CO)N3CC3
DMDM85L IK JKDLOGLNPDVUCX-UHFFFAOYSA-N
DMDM85L IU 2,5-bis(aziridin-1-yl)-3-(hydroxymethyl)-6-methylcyclohexa-2,5-diene-1,4-dione
DMDM85L CA CAS 221635-42-3
DMDM85L DE Discovery agent
DM1HUA3 ID DM1HUA3
DM1HUA3 DN RHIgM12B7
DM1HUA3 HS Phase 1
DM1HUA3 SN SHIgM12; B7-DC-crosslinking recombinant human monoclonal antibody (cancer), Mayo Clinic
DM1HUA3 CP Mayo Foundation
DM1HUA3 DT Antibody
DM1HUA3 DE Solid tumour/cancer
DM2A1DP ID DM2A1DP
DM2A1DP DN Ribavirin
DM2A1DP HS Phase 1
DM2A1DP SN ribavirin; 36791-04-5; Tribavirin; Rebetol; Virazole; Ribavirine; Copegus; Vilona; Ribamide; Ribasphere; Ribamidil; Viramid; Ribamidyl; Ribavirinum; Ribavirina; Rebetron; Varazid; RTCA; Ribavirin Capsules; Ribavirinum [INN-Latin]; Ribavirine [INN-French]; Ribavirina [INN-Spanish]; ICN-1229; Rebretron; Virazid; Ribav; 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide; DRG-0028; 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; UNII-49717AWG6K; Ribavirin (Copegus); Copegus; Cotronak; RBV; RTC; Ravanex; Ribacine; Ribovirin; Viramide; Virazide; R 9644; SCH 18908; C-Virin; Copegus (TN); Drug: Ribavirin; KS-1104; R-964; RG-964; Rebetol (TN); Ribasphere (TN); Ribavirin [USAN:INN]; Vilona (TN); Virazole (Ribavirin) Inhalation Solution; Virazole (TN); AA-504/07617051; Ro 20-9963/000; Ro-20-9963; Ribavirin (JAN/USP/INN); 1-beta-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide; 1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide; RBI034 (2-5A antisense compound) + Ribavirin
DM2A1DP CP Hoffmann-La Roche pharmaceutical company
DM2A1DP TC Antiviral Agents
DM2A1DP DT Small molecular drug
DM2A1DP PC 37542
DM2A1DP MW 244.2
DM2A1DP FM C8H12N4O5
DM2A1DP IC InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
DM2A1DP CS C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
DM2A1DP IK IWUCXVSUMQZMFG-AFCXAGJDSA-N
DM2A1DP IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
DM2A1DP CA CAS 36791-04-5
DM2A1DP CB CHEBI:63580
DM2A1DP DE Hepatitis C virus infection; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMB9861 ID DMB9861
DMB9861 DN Rilapladib
DMB9861 HS Phase 1
DMB9861 CP GSK
DMB9861 DT Small molecular drug
DMB9861 PC 9918381
DMB9861 MW 735.8
DMB9861 FM C40H38F5N3O3S
DMB9861 IC InChI=1S/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3
DMB9861 CS COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F
DMB9861 IK NNBGCSGCRSCFEA-UHFFFAOYSA-N
DMB9861 IU 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DMB9861 CA CAS 412950-08-4
DMB9861 DE Cardiovascular disease; Arteriosclerosis
DMUT4YZ ID DMUT4YZ
DMUT4YZ DN RLY-1971
DMUT4YZ HS Phase 1
DMUT4YZ CP Relay Therapeutics
DMUT4YZ DT Small molecular drug
DMUT4YZ DE Solid tumour/cancer
DM3O52N ID DM3O52N
DM3O52N DN RLY-4008
DM3O52N HS Phase 1
DM3O52N CP Relay Therapeutics
DM3O52N DT Small molecular drug
DM3O52N DE Solid tumour/cancer
DMQ65YW ID DMQ65YW
DMQ65YW DN RO-09-4889
DMQ65YW HS Phase 1
DMQ65YW SN Ro-0094889; 2',3'-Di-O-acetyl-5'-deoxy-5-vinylcytidine
DMQ65YW DE Solid tumour/cancer
DM95F8B ID DM95F8B
DM95F8B DN RO-14
DM95F8B HS Phase 1
DM95F8B SN Very low molecular weight heparin (venous thromboembolism), Rovi
DM95F8B CP Laboratorios Farmaceuticos Rovi SA
DM95F8B DE Phlebothrombosis
DM9PQ2N ID DM9PQ2N
DM9PQ2N DN RO-23-7553
DM9PQ2N HS Phase 1
DM9PQ2N SN BXL-353; ILX-23-7553; (1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19),16-tetraen-23-yne-1,3,25-triol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrocholecalciferol; 1alpha,25-Dihydroxy-16,17,23,23,24,24-hexadehydrovitamin D3
DM9PQ2N DT Small molecular drug
DM9PQ2N PC 6438384
DM9PQ2N MW 410.6
DM9PQ2N FM C27H38O3
DM9PQ2N IC InChI=1S/C27H38O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-12,18,22,24-25,28-30H,2,7-9,13,15-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,24+,25+,27-/m1/s1
DM9PQ2N CS C[C@H](CC#CC(C)(C)O)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DM9PQ2N IK JKFZMIQMKFWJAY-RQJQXFIZSA-N
DM9PQ2N IU (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM9PQ2N CA CAS 118694-43-2
DM9PQ2N DE Prostate disease
DML4C3Q ID DML4C3Q
DML4C3Q DN RO-5212054
DML4C3Q HS Phase 1
DML4C3Q SN PLX-3603
DML4C3Q CP Hoffmann-La Roche AG
DML4C3Q DE Solid tumour/cancer
DMVXQ5W ID DMVXQ5W
DMVXQ5W DN RO-5458640
DMVXQ5W HS Phase 1
DMVXQ5W SN Anti-TWEAK humanized monoclonal antibody (iv, cancer), Hoffmann-La Roche
DMVXQ5W CP Scantibodies Laboratory; biogen Idec
DMVXQ5W DE Solid tumour/cancer
DM7H6XI ID DM7H6XI
DM7H6XI DN RO6870810
DM7H6XI HS Phase 1
DM7H6XI SN JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-
DM7H6XI CP Roche
DM7H6XI DT Small molecular drug
DM7H6XI PC 54670351
DM7H6XI MW 540.1
DM7H6XI FM C27H34ClN7OS
DM7H6XI IC InChI=1S/C27H34ClN7OS/c1-17-18(2)37-27-24(17)25(20-6-8-21(28)9-7-20)30-22(26-32-31-19(3)35(26)27)16-23(36)29-10-5-11-34-14-12-33(4)13-15-34/h6-9,22H,5,10-16H2,1-4H3,(H,29,36)/t22-/m0/s1
DM7H6XI CS CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NCCCN4CCN(CC4)C)C5=CC=C(C=C5)Cl)C
DM7H6XI IK PKQXLRYFPSZKDU-QFIPXVFZSA-N
DM7H6XI IU 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]acetamide
DM7H6XI CA CAS 1349719-98-7
DM7H6XI DE Multiple myeloma
DMDRBNJ ID DMDRBNJ
DMDRBNJ DN ROCICLOVIR
DMDRBNJ HS Phase 1
DMDRBNJ SN Hoe-602; Rociclovir; 2-Amino-9-[1,3-bis(isopropoxy)-2-propyloxymethyl]purine; 6-Deoxy-9-(1-isopropoxymethyl-2-isopropoxyethoxymethyl)guanine
DMDRBNJ DT Small molecular drug
DMDRBNJ PC 65905
DMDRBNJ MW 323.39
DMDRBNJ FM C15H25N5O3
DMDRBNJ IC InChI=1S/C15H25N5O3/c1-10(2)21-6-12(7-22-11(3)4)23-9-20-8-18-13-5-17-15(16)19-14(13)20/h5,8,10-12H,6-7,9H2,1-4H3,(H2,16,17,19)
DMDRBNJ CS CC(C)OCC(COC(C)C)OCN1C=NC2=CN=C(N=C21)N
DMDRBNJ IK FBHWXSOQXQBXER-UHFFFAOYSA-N
DMDRBNJ IU 9-[1,3-di(propan-2-yloxy)propan-2-yloxymethyl]purin-2-amine
DMDRBNJ CA CAS 108436-80-2
DMDRBNJ DE Virus infection
DM82KWY ID DM82KWY
DM82KWY DN Ronomilast
DM82KWY HS Phase 1
DM82KWY SN ELB-353; PDE4 inhibitor, BioTie; PDE4 inhibitor, elbion; AWD-12-353
DM82KWY CP Elbion AG
DM82KWY DT Small molecular drug
DM82KWY PC 9803446
DM82KWY MW 443.3
DM82KWY FM C21H13Cl2FN4O2
DM82KWY IC InChI=1S/C21H13Cl2FN4O2/c22-16-8-25-9-17(23)18(16)27-21(30)19(29)15-11-28(20-14(15)2-1-7-26-20)10-12-3-5-13(24)6-4-12/h1-9,11H,10H2,(H,25,27,30)
DM82KWY CS C1=CC2=C(N=C1)N(C=C2C(=O)C(=O)NC3=C(C=NC=C3Cl)Cl)CC4=CC=C(C=C4)F
DM82KWY IK JERXUPDBWDWFCF-UHFFFAOYSA-N
DM82KWY IU N-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-oxoacetamide
DM82KWY CA CAS 418794-42-0
DM82KWY DE Chronic obstructive pulmonary disease
DM5EUIY ID DM5EUIY
DM5EUIY DN ROR1 CAR-specific Autologous T-Lymphocytes
DM5EUIY HS Phase 1
DM5EUIY CP Fred Hutchinson Cancer Research Center
DM5EUIY DT CAR T Cell Therapy
DM5EUIY DE Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Mantle cell lymphoma
DMIAK9P ID DMIAK9P
DMIAK9P DN ROR1R-CAR-T Cell
DMIAK9P HS Phase 1
DMIAK9P CP M.D. Anderson Cancer Center
DMIAK9P DT CAR T Cell Therapy
DMIAK9P DE leukaemia
DM9O3RY ID DM9O3RY
DM9O3RY DN Rosmantuzumab
DM9O3RY HS Phase 1
DM9O3RY CP OncoMed Pharmaceuticals Redwood City, CA
DM9O3RY DE Colorectal cancer; Solid tumour/cancer
DME9UTO ID DME9UTO
DME9UTO DN RP4010
DME9UTO HS Phase 1
DME9UTO CP Rhizen PharmaceuticalsLa Chaux-de-Fonds, Switzerland
DME9UTO DE Non-hodgkin lymphoma
DMHZ24N ID DMHZ24N
DMHZ24N DN RP-A501
DMHZ24N HS Phase 1
DMHZ24N CP Rocket Pharmaceuticals
DMHZ24N DT Gene therapy
DMHZ24N DE Type 2 glycogen storage disease
DMXKFOQ ID DMXKFOQ
DMXKFOQ DN RPI-78M
DMXKFOQ HS Phase 1
DMXKFOQ SN Antiviral agent, Receptogen; RPI-78M; Receptin (injectable), ReceptoPharm; Receptin (oral), ReceptoPharm; RPI-78M (injectable), ReceptoPharm; RPI-78M (oral), ReceptoPharm
DMXKFOQ CP ReceptoPharm Inc; ReceptoPharm
DMXKFOQ DE Multiple sclerosis; Rheumatoid arthritis
DM5OXPZ ID DM5OXPZ
DM5OXPZ DN RPI-MN
DM5OXPZ HS Phase 1
DM5OXPZ SN Pepteron (oral, HIV), ReceptoPharm; RPI-MN (oral, HIV); RPI-MN (oral, HIV), ReceptoPharm
DM5OXPZ CP ReceptoPharm Inc
DM5OXPZ DE Human immunodeficiency virus infection; Amyotrophic lateral sclerosis
DMA6JME ID DMA6JME
DMA6JME DN RTA 901
DMA6JME HS Phase 1
DMA6JME CP Reata Pharmaceuticals
DMA6JME DT Small molecular drug
DMA6JME DE Diabetic neuropathy
DM7C062 ID DM7C062
DM7C062 DN RTA-901
DM7C062 HS Phase 1
DM7C062 CP Reata Pharmaceuticals Irving, TX
DM7C062 DE Diabetic neuropathy
DMY8D5O ID DMY8D5O
DMY8D5O DN RTI-336
DMY8D5O HS Phase 1
DMY8D5O SN CHEMBL432878; RTI-336; 3-(4-Chloro-phenyl)-8-methyl-2-(3-p-tolyl-isoxazol-5-yl)-8-aza-bicyclo[3.2.1]octane
DMY8D5O CP Research Triangle Institute
DMY8D5O DT Small molecular drug
DMY8D5O PC 11524766
DMY8D5O MW 429.4
DMY8D5O FM C24H26Cl2N2O
DMY8D5O IC InChI=1S/C24H25ClN2O.ClH/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2;/h3-10,14,19-20,22,24H,11-13H2,1-2H3;1H/t19-,20+,22+,24-;/m0./s1
DMY8D5O CS CC1=CC=C(C=C1)C2=NOC(=C2)[C@@H]3[C@H]4CC[C@H](N4C)C[C@@H]3C5=CC=C(C=C5)Cl.Cl
DMY8D5O IK IZMZEMAKFSYLMD-SXBQIKTFSA-N
DMY8D5O IU 5-[(1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl]-3-(4-methylphenyl)-1,2-oxazole;hydrochloride
DMY8D5O CA CAS 204069-50-1
DMY8D5O DE Cocaine addiction
DM1B4CQ ID DM1B4CQ
DM1B4CQ DN RTL-1000
DM1B4CQ HS Phase 1
DM1B4CQ SN VG-1000; VGI-303; Recombinant t-cell ligand (multiple sclerosis), Artielle
DM1B4CQ CP Artielle immunotherapeutics
DM1B4CQ DE Multiple sclerosis
DMYRPC8 ID DMYRPC8
DMYRPC8 DN RVSVIN HIV-1 gag vaccine
DMYRPC8 HS Phase 1
DMYRPC8 SN RVSVIN HIV-1 gag vaccine, Profectus Biosciences; RVSV vector-based HIV-1 vaccine, Profectus BioSciences; Recombinant VSV vector-based HIV-1 vaccine, Profectus BioSciences; Recombinant vesicular stomatitis virus vector-based HIV-1 vaccine, Profectus BioSciences
DMYRPC8 CP Wyeth Pharmaceuticals
DMYRPC8 DT Vaccine
DMYRPC8 DE Human immunodeficiency virus infection
DM0YCG3 ID DM0YCG3
DM0YCG3 DN RVT-103+RVT-104
DM0YCG3 HS Phase 1
DM0YCG3 CP Axovant Sciences New York, NY
DM0YCG3 DE Alzheimer disease
DMJVCS1 ID DMJVCS1
DMJVCS1 DN RWJ-671818
DMJVCS1 HS Phase 1
DMJVCS1 SN RWJ-671818; CHEMBL1083499; N-[2-(Carbamimidamidooxy)ethyl]-2-{3-[(2,2-Difluoro-2-Phenylethyl)amino]-6-Methyl-2-Oxopyrazin-1(2h)-Yl}acetamide; SCHEMBL3243104; BDBM50312651; NLI
DMJVCS1 DT Small molecular drug
DMJVCS1 PC 9866964
DMJVCS1 MW 423.4
DMJVCS1 FM C18H23F2N7O3
DMJVCS1 IC InChI=1S/C18H23F2N7O3/c1-12-9-24-15(25-11-18(19,20)13-5-3-2-4-6-13)16(29)27(12)10-14(28)23-7-8-30-26-17(21)22/h2-6,9H,7-8,10-11H2,1H3,(H,23,28)(H,24,25)(H4,21,22,26)
DMJVCS1 CS CC1=CN=C(C(=O)N1CC(=O)NCCON=C(N)N)NCC(C2=CC=CC=C2)(F)F
DMJVCS1 IK IDCKXHIGLKQWMM-UHFFFAOYSA-N
DMJVCS1 IU N-[2-(diaminomethylideneamino)oxyethyl]-2-[3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxopyrazin-1-yl]acetamide
DMJVCS1 DE Thrombosis
DM6YAGE ID DM6YAGE
DM6YAGE DN RWJ-67657
DM6YAGE HS Phase 1
DM6YAGE SN 215303-72-3; RWJ-67657; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol
DM6YAGE TC Analgesics
DM6YAGE DT Small molecular drug
DM6YAGE PC 3008319
DM6YAGE MW 425.5
DM6YAGE FM C27H24FN3O
DM6YAGE IC InChI=1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2
DM6YAGE CS C1=CC=C(C=C1)CCCN2C(=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F)C#CCCO
DM6YAGE IK QSUSKMBNZQHHPA-UHFFFAOYSA-N
DM6YAGE IU 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol
DM6YAGE CA CAS 215303-72-3
DM6YAGE DE Arthritis
DM4O07Q ID DM4O07Q
DM4O07Q DN RWJ-68023
DM4O07Q HS Phase 1
DM4O07Q SN Motilin receptor antagonists, RW Johnson
DM4O07Q CP RW Johnson Pharmaceutical Research Institute
DM4O07Q PC 9809991
DM4O07Q MW 672
DM4O07Q FM C34H37Cl3N4O4
DM4O07Q IC InChI=1S/C34H37Cl3N4O4/c35-34(36,37)31(42)39-33(23-26-8-3-1-4-9-26)15-14-27(24-33)25-41(32(43)38-28-10-5-2-6-11-28)29-12-7-13-30(22-29)45-21-18-40-16-19-44-20-17-40/h1-13,22,24H,14-21,23,25H2,(H,38,43)(H,39,42)/t33-/m1/s1
DM4O07Q CS C1C[C@](C=C1CN(C2=CC(=CC=C2)OCCN3CCOCC3)C(=O)NC4=CC=CC=C4)(CC5=CC=CC=C5)NC(=O)C(Cl)(Cl)Cl
DM4O07Q IK DPBURRXPRULCQN-MGBGTMOVSA-N
DM4O07Q IU N-[(1R)-1-benzyl-3-[[3-(2-morpholin-4-ylethoxy)-N-(phenylcarbamoyl)anilino]methyl]cyclopent-2-en-1-yl]-2,2,2-trichloroacetamide
DM4O07Q DE Irritable bowel syndrome
DM4XETK ID DM4XETK
DM4XETK DN RX108
DM4XETK HS Phase 1
DM4XETK CP NeuPharma
DM4XETK DT Small molecular drug
DM4XETK DE Solid tumour/cancer
DM6NVTR ID DM6NVTR
DM6NVTR DN RXDX-106
DM6NVTR HS Phase 1
DM6NVTR SN CEP-40783; 1437321-24-8; CEP40783; UNII-1969ZJE05Q; 1969ZJE05Q; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide; RXDX-106 (CEP-40783); SCHEMBL16089863; BCP25839; EX-A2540; MFCD28502441; NSC797770; s8570; AKOS032960472; ZINC205893112; CCG-270157; CS-6371; NSC-797770; SB18930; AC-31425; AS-35141; HY-100946; N-(4-((6,7-Dimethoxy-4-quinolinyl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-5-pyrimidinecarboxamide
DM6NVTR CP Ignyta
DM6NVTR DT Small molecular drug
DM6NVTR PC 71576419
DM6NVTR MW 588.6
DM6NVTR FM C31H26F2N4O6
DM6NVTR IC InChI=1S/C31H26F2N4O6/c1-17(2)36-16-22(30(39)37(31(36)40)20-8-5-18(32)6-9-20)29(38)35-19-7-10-26(23(33)13-19)43-25-11-12-34-24-15-28(42-4)27(41-3)14-21(24)25/h5-17H,1-4H3,(H,35,38)
DM6NVTR CS CC(C)N1C=C(C(=O)N(C1=O)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C5C=C(C(=CC5=NC=C4)OC)OC)F
DM6NVTR IK FKCWHHYUMFGOPY-UHFFFAOYSA-N
DM6NVTR IU N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide
DM6NVTR CA CAS 1437321-24-8
DM6NVTR DE Solid tumour/cancer
DMYR1K8 ID DMYR1K8
DMYR1K8 DN S-17092-1
DMYR1K8 HS Phase 1
DMYR1K8 SN NXSXRIHXEQSYEZ-KNJMJIDISA-N; S 17092; CHEMBL1086968; 176797-26-5; S-17092; s17092; SCHEMBL194654; GTPL6565; DTXSID70433003; ZINC3825778; BDBM50316818; NCGC00485216-01; S 17092, > ((2S,3aS,7aS)-1-((1R,2R)-2-phenylcyclopropanecarbonyl)octahydro-1H-indol-2-yl)(thiazolidin-3-yl)methanone; (2S,3aS,7aS)-1-(((R,R)-2-Phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1H-indole; [(2S,3aS,7aS)-Octahydro-1-[[(1R,2R)-2-phenylcyclopropyl]carbonyl]-1H-indol-2-yl]-3-thiazolidinyl--methanone; S-17092 (undefined isomer); (2S,3aS,7aS)-1-[(1R,2R)-2-Phenylcyclopropylcarbonyl]-2-(thiazolidin-3-ylcarbonyl)perhydroindole
DMYR1K8 DT Small molecular drug
DMYR1K8 PC 9929984
DMYR1K8 MW 384.5
DMYR1K8 FM C22H28N2O2S
DMYR1K8 IC InChI=1S/C22H28N2O2S/c25-21(18-13-17(18)15-6-2-1-3-7-15)24-19-9-5-4-8-16(19)12-20(24)22(26)23-10-11-27-14-23/h1-3,6-7,16-20H,4-5,8-14H2/t16-,17-,18+,19-,20-/m0/s1
DMYR1K8 CS C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H]3C[C@H]3C4=CC=CC=C4)C(=O)N5CCSC5
DMYR1K8 IK NXSXRIHXEQSYEZ-KNJMJIDISA-N
DMYR1K8 IU [(2S,3aS,7aS)-2-(1,3-thiazolidine-3-carbonyl)-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-[(1R,2R)-2-phenylcyclopropyl]methanone
DMYR1K8 CA CAS 176797-26-5
DMYR1K8 DE Non-small-cell lung cancer; Cognitive impairment
DMDQRWT ID DMDQRWT
DMDQRWT DN S-265744 LAP
DMDQRWT HS Phase 1
DMDQRWT CP Shionogi & GlaxoSmithKline
DMDQRWT DE Human immunodeficiency virus infection
DM6XZRL ID DM6XZRL
DM6XZRL DN SA-5845
DM6XZRL HS Phase 1
DM6XZRL SN Carbon-11 labeled sigma opioid receptor ligands, Santen; FE-SA-4503; FE-SA-5845; Carbon-11-SA-4503; Carbon-11-SA-5845; 11C-SA-4503; 11C-SA-5845
DM6XZRL CP Santen Pharmaceutical Co Ltd
DM6XZRL DE Central nervous system disease; Psychotic disorder
DMBGUDR ID DMBGUDR
DMBGUDR DN Safingol
DMBGUDR HS Phase 1
DMBGUDR SN Kynac; Kynacyte; SPC-100270; Safingol < Rec INN; L-threo-Dihydrosphingosine; SPC-100271 (HCl); (2S,3S)-2-Aminooctadecane-1,3-diol
DMBGUDR DT Small molecular drug
DMBGUDR PC 3058739
DMBGUDR MW 301.5
DMBGUDR FM C18H39NO2
DMBGUDR IC InChI=1S/C18H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h17-18,20-21H,2-16,19H2,1H3/t17-,18-/m0/s1
DMBGUDR CS CCCCCCCCCCCCCCC[C@@H]([C@H](CO)N)O
DMBGUDR IK OTKJDMGTUTTYMP-ROUUACIJSA-N
DMBGUDR IU (2S,3S)-2-aminooctadecane-1,3-diol
DMBGUDR CA CAS 15639-50-6
DMBGUDR DE Psoriasis vulgaris
DM1UIQP ID DM1UIQP
DM1UIQP DN SAFIRONIL
DM1UIQP HS Phase 1
DM1UIQP SN Hoe-277; Safironil; N,N'-Bis(3-methoxypropyl)pyridine-2,4-dicarboxamide
DM1UIQP DT Small molecular drug
DM1UIQP PC 65973
DM1UIQP MW 309.36
DM1UIQP FM C15H23N3O4
DM1UIQP IC InChI=1S/C15H23N3O4/c1-21-9-3-6-17-14(19)12-5-8-16-13(11-12)15(20)18-7-4-10-22-2/h5,8,11H,3-4,6-7,9-10H2,1-2H3,(H,17,19)(H,18,20)
DM1UIQP CS COCCCNC(=O)C1=CC(=NC=C1)C(=O)NCCCOC
DM1UIQP IK HLSXICGBWKECLM-UHFFFAOYSA-N
DM1UIQP IU 2-N,4-N-bis(3-methoxypropyl)pyridine-2,4-dicarboxamide
DM1UIQP CA CAS 134377-69-8
DM1UIQP DE Transplant rejection
DMJ3HQY ID DMJ3HQY
DMJ3HQY DN Salvinorin A
DMJ3HQY HS Phase 1
DMJ3HQY SN Salvinorin A; Salvinorin; Divinorin A; 83729-01-5; UNII-T56W91NG6J; CHEMBL445332; T56W91NG6J; CHEBI:67900; 2H-Naphtho(2,1-c)pyran-7-carboxylic acid, 9-(acetyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2S-(2alpha,4aalpha,6abeta,7beta,9beta,10aalpha,10bbeta))-; (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(3-furanyl)dodechydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester; (-)-Salvinorin A; herbal ecstasy; Mexican mint; salvinorin-A; Salvonorin A; Diviner's S
DMJ3HQY DT Small molecular drug
DMJ3HQY PC 128563
DMJ3HQY MW 432.5
DMJ3HQY FM C23H28O8
DMJ3HQY IC InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DMJ3HQY CS CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMJ3HQY IK OBSYBRPAKCASQB-AGQYDFLVSA-N
DMJ3HQY IU methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMJ3HQY CA CAS 83729-01-5
DMJ3HQY CB CHEBI:67900
DMJ3HQY DE Cerebral vasospasm
DMDHQYA ID DMDHQYA
DMDHQYA DN SAM-6
DMDHQYA HS Phase 1
DMDHQYA CP Pack of Parker; OncoMab GmbH
DMDHQYA DT Antibody
DMDHQYA DE Melanoma
DMWU71N ID DMWU71N
DMWU71N DN SAN-134
DMWU71N HS Phase 1
DMWU71N SN GLP-2 (osteoporosis), SANOS; Glucagon-like peptide-2 (osteoporosis), SANOS
DMWU71N CP SANOS Bioscience A/S
DMWU71N DE Osteoporosis
DMQ9ZY0 ID DMQ9ZY0
DMQ9ZY0 DN SAR-104772
DMQ9ZY0 HS Phase 1
DMQ9ZY0 SN TAFIa inhibitor (stroke), sanofi-aventis; SAR-104772 (oral, stroke), sanofi-aventis
DMQ9ZY0 CP Sanofi
DMQ9ZY0 DE Cerebrovascular ischaemia
DMRIH0S ID DMRIH0S
DMRIH0S DN SAR113244
DMRIH0S HS Phase 1
DMRIH0S SN LPA-1/LPA-3
DMRIH0S CP Sanofi
DMRIH0S DE Systemic lupus erythematosus
DMZ1XR5 ID DMZ1XR5
DMZ1XR5 DN SAR-114137
DMZ1XR5 HS Phase 1
DMZ1XR5 CP Sanofi
DMZ1XR5 PC 9828551
DMZ1XR5 MW 534.6
DMZ1XR5 FM C25H34N4O7S
DMZ1XR5 IC InChI=1S/C25H34N4O7S/c1-4-20(22(31)23-27-25(36-28-23)18-8-6-5-7-9-18)26-24(32)19(16-37(33,34)15-17(2)3)14-21(30)29-10-12-35-13-11-29/h5-9,17,19-20H,4,10-16H2,1-3H3,(H,26,32)/t19?,20-/m0/s1
DMZ1XR5 CS CC[C@@H](C(=O)C1=NOC(=N1)C2=CC=CC=C2)NC(=O)C(CC(=O)N3CCOCC3)CS(=O)(=O)CC(C)C
DMZ1XR5 IK IUMMRYVGHFJSRD-ANYOKISRSA-N
DMZ1XR5 IU 2-(2-methylpropylsulfonylmethyl)-4-morpholin-4-yl-4-oxo-N-[(2S)-1-oxo-1-(5-phenyl-1,2,4-oxadiazol-3-yl)butan-2-yl]butanamide
DMZ1XR5 CA CAS 537706-31-3
DMZ1XR5 DE Pain
DMD2VRY ID DMD2VRY
DMD2VRY DN SAR-115740
DMD2VRY HS Phase 1
DMD2VRY DE Pain
DMKHM7O ID DMKHM7O
DMKHM7O DN SAR-126119
DMKHM7O HS Phase 1
DMKHM7O SN SAR-104772 (intravenous, stroke), sanofi-aventis
DMKHM7O CP Sanofi
DMKHM7O DE Cerebrovascular ischaemia
DMQ98MW ID DMQ98MW
DMQ98MW DN SAR164653
DMQ98MW HS Phase 1
DMQ98MW CP Sanofi
DMQ98MW DE Diabetic complication
DMO8QY1 ID DMO8QY1
DMO8QY1 DN SAR-21609
DMO8QY1 HS Phase 1
DMO8QY1 SN TLR9 agonist (asthma/viral respiratory tract infection), sanofi-aventis
DMO8QY1 CP Coley Pharmaceutical Group Inc
DMO8QY1 DE Asthma
DMTFAGU ID DMTFAGU
DMTFAGU DN SAR228810
DMTFAGU HS Phase 1
DMTFAGU CP Sanofi
DMTFAGU DT Antibody
DMTFAGU DE Alzheimer disease
DMUAJZD ID DMUAJZD
DMUAJZD DN SAR247799
DMUAJZD HS Phase 1
DMUAJZD CP Sanofi Bridgewater, NJ
DMUAJZD DE Cardiovascular disease
DM15PG9 ID DM15PG9
DM15PG9 DN SAR351034
DM15PG9 HS Phase 1
DM15PG9 CP Sanofi-Aventis
DM15PG9 DE Dyslipidemia; Type-2 diabetes
DMA6O9R ID DMA6O9R
DMA6O9R DN SAR-389644
DMA6O9R HS Phase 1
DMA6O9R SN SAR-389644C; Prostaglandin D2 antagonist (asthma/allergic rhinitis), sanofi-aventis
DMA6O9R CP Sanofi
DMA6O9R DE Allergic rhinitis
DMC1AZP ID DMC1AZP
DMC1AZP DN SAR-405838
DMC1AZP HS Phase 1
DMC1AZP SN AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis
DMC1AZP CP Ascenta Therapeutics; Sanofi US
DMC1AZP DT Small molecular drug
DMC1AZP PC 53476877
DMC1AZP MW 562.5
DMC1AZP FM C29H34Cl2FN3O3
DMC1AZP IC InChI=1S/C29H34Cl2FN3O3/c1-28(2,3)14-22-29(19-12-7-15(30)13-21(19)34-27(29)38)23(18-5-4-6-20(31)24(18)32)25(35-22)26(37)33-16-8-10-17(36)11-9-16/h4-7,12-13,16-17,22-23,25,35-36H,8-11,14H2,1-3H3,(H,33,37)(H,34,38)/t16?,17?,22-,23-,25+,29+/m0/s1
DMC1AZP CS CC(C)(C)C[C@H]1[C@@]2([C@H]([C@@H](N1)C(=O)NC3CCC(CC3)O)C4=C(C(=CC=C4)Cl)F)C5=C(C=C(C=C5)Cl)NC2=O
DMC1AZP IK IDKAKZRYYDCJDU-AEPXTFJPSA-N
DMC1AZP IU (2'R,3R,3'S,5'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-5'-(2,2-dimethylpropyl)-N-(4-hydroxycyclohexyl)-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide
DMC1AZP CA CAS 1303607-60-4
DMC1AZP DE Solid tumour/cancer
DM53IPE ID DM53IPE
DM53IPE DN SAR425899
DM53IPE HS Phase 1
DM53IPE DE Diabetic complication; Type-2 diabetes
DM7QO05 ID DM7QO05
DM7QO05 DN SAR438335
DM7QO05 HS Phase 1
DM7QO05 CP Sanofi US Bridgewater, NJ
DM7QO05 DE Type-2 diabetes
DM5UXAB ID DM5UXAB
DM5UXAB DN SAR442085
DM5UXAB HS Phase 1
DM5UXAB CP Sanofi
DM5UXAB DT Antibody
DM5UXAB DE Plasma cell myeloma
DMXD5QP ID DMXD5QP
DMXD5QP DN SAR442257
DMXD5QP HS Phase 1
DMXD5QP CP Sanofi
DMXD5QP DT Antibody
DMXD5QP DE Malignant neoplasm
DMTAOPC ID DMTAOPC
DMTAOPC DN SAR442720
DMTAOPC HS Phase 1
DMTAOPC SN RMC-4630
DMTAOPC CP Revolution Medicines
DMTAOPC DT Small molecular drug
DMTAOPC DE Solid tumour/cancer
DM6UN42 ID DM6UN42
DM6UN42 DN SAR444245
DM6UN42 HS Phase 1
DM6UN42 SN THOR-707
DM6UN42 CP Sanofi
DM6UN42 DT Recombinant protein
DM6UN42 DE Solid tumour/cancer
DMZ9YWG ID DMZ9YWG
DMZ9YWG DN SB 11285
DMZ9YWG HS Phase 1
DMZ9YWG CP F-star Therapeutics
DMZ9YWG DE Melanoma; Head-neck squamous cell carcinoma
DMXTKYR ID DMXTKYR
DMXTKYR DN SB-1578
DMXTKYR HS Phase 1
DMXTKYR CP S*BIO Pte Ltd
DMXTKYR PC 16750271
DMXTKYR MW 462.5
DMXTKYR FM C26H30N4O4
DMXTKYR IC InChI=1S/C26H30N4O4/c1-2-12-30(11-1)13-16-33-24-7-5-21-17-20(24)18-31-14-3-4-15-32-19-22-6-8-25(34-22)23-9-10-27-26(28-21)29-23/h3-10,17H,1-2,11-16,18-19H2,(H,27,28,29)/b4-3+
DMXTKYR CS C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=C(O4)C5=NC(=NC=C5)NC(=C3)C=C2
DMXTKYR IK NNXDIGHYPZHXTR-ONEGZZNKSA-N
DMXTKYR IU (9E)-15-(2-pyrrolidin-1-ylethoxy)-7,12,26-trioxa-19,21,24-triazatetracyclo[18.3.1.12,5.114,18]hexacosa-1(24),2,4,9,14,16,18(25),20,22-nonaene
DMXTKYR CA CAS 937273-04-6
DMXTKYR DE Solid tumour/cancer
DMLPB0X ID DMLPB0X
DMLPB0X DN SB-436811
DMLPB0X HS Phase 1
DMLPB0X SN SB-436811; CHEMBL366221; 346729-66-6; Benzamide,3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-3-pyrrolidinyl]-; SCHEMBL6949936; GTPL2164; ZINC3964101; BDBM50240963; KB-74923; 3,4-Dichloro-N-{(S)-1-[4-(3-dimethylamino-propoxy)-benzyl]-pyrrolidin-3-yl}-benzamide; (S)-3,4-dichloro-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)benzamide; (S)-N-(1-(4-(3-(dimethylamino)propoxy)benzyl)pyrrolidin-3-yl)-3,4-dichlorobenzamide
DMLPB0X DT Small molecular drug
DMLPB0X PC 9846574
DMLPB0X MW 450.4
DMLPB0X FM C23H29Cl2N3O2
DMLPB0X IC InChI=1S/C23H29Cl2N3O2/c1-27(2)11-3-13-30-20-7-4-17(5-8-20)15-28-12-10-19(16-28)26-23(29)18-6-9-21(24)22(25)14-18/h4-9,14,19H,3,10-13,15-16H2,1-2H3,(H,26,29)/t19-/m0/s1
DMLPB0X CS CN(C)CCCOC1=CC=C(C=C1)CN2CC[C@@H](C2)NC(=O)C3=CC(=C(C=C3)Cl)Cl
DMLPB0X IK AMSSIFVGNFEEFU-IBGZPJMESA-N
DMLPB0X IU 3,4-dichloro-N-[(3S)-1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]pyrrolidin-3-yl]benzamide
DMLPB0X DE Asthma
DMSZIP5 ID DMSZIP5
DMSZIP5 DN SB-639
DMSZIP5 HS Phase 1
DMSZIP5 SN SB-639; CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide
DMSZIP5 CP GlaxoSmithKline
DMSZIP5 TC Anticancer Agents
DMSZIP5 DT Small molecular drug
DMSZIP5 PC 6918877
DMSZIP5 MW 404.5
DMSZIP5 FM C24H28N4O2
DMSZIP5 IC InChI=1S/C24H28N4O2/c29-24(26-30)13-10-20-8-11-22-21(18-20)25-23(12-9-19-6-2-1-3-7-19)28(22)17-16-27-14-4-5-15-27/h1-3,6-8,10-11,13,18,30H,4-5,9,12,14-17H2,(H,26,29)/b13-10+
DMSZIP5 CS C1CCN(C1)CCN2C3=C(C=C(C=C3)/C=C/C(=O)NO)N=C2CCC4=CC=CC=C4
DMSZIP5 IK RCDIZKAYZBEALO-JLHYYAGUSA-N
DMSZIP5 IU (E)-N-hydroxy-3-[2-(2-phenylethyl)-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide
DMSZIP5 DE Solid tumour/cancer
DMXU2GS ID DMXU2GS
DMXU2GS DN SBS-1000
DMXU2GS HS Phase 1
DMXU2GS SN PrInsulin; Diabetes therapy, SemBioSys; Human insulin (safflower), SemBioSys; Plant-derived insulin (diabetes), SemBioSys; Safflower seed-derived human insulin (diabetes), SemBioSys
DMXU2GS CP SemBioSys Genetics Inc
DMXU2GS DE Diabetic complication
DMHBD3T ID DMHBD3T
DMHBD3T DN SBT6050
DMHBD3T HS Phase 1
DMHBD3T CP Silverback Therapeutics
DMHBD3T DT Antibody drug conjugate
DMHBD3T DE Solid tumour/cancer
DM7GSLB ID DM7GSLB
DM7GSLB DN SC-20713
DM7GSLB HS Phase 1
DM7GSLB SN Etynodiol; Aethynodiolum; CHEBI:50785; CHEMBL1201406; DB13866; DTXSID1023025; EINECS 214-971-5; Ethinodiol; Etinodiol; Etinodiol [INN-Spanish]; Etinodiolo; Etinodiolo [DCIT]; Etynodiol (INN); Etynodiol [INN:BAN]; Etynodiolum; Etynodiolum [INN-Latin]; HSDB 7897; LS-97401; (3-beta,17-alpha)-19-Norpregn-4-en-20-yne-3,17-diol; (3beta,17alpha)-19-Norpregn-4-en-20-yne-3,17-diol; (3beta,17beta)-17-ethynylestr-4-ene-3,17-diol; 1231-93-2; 17-alpha-Ethynyl-19-norandrost-4-ene-3-beta,17-beta-diol; 17alpha-Ethynyl-19-norandrost-4-ene-3beta,17beta-diol; 17alpha-Ethynyl-estra-4-ene-3beta,17beta-diol; 17alpha-ethynylestr-4-ene-3beta,17beta-diol; 19-Nor-17-alpha-pregn-4-en-20-yne-3-beta,17-diol; 3beta-hydroxynorethisterone; 9E01C36A9S; SCHEMBL140933; UNII-9E01C36A9S; ZINC30691629; ethynodiol; ZINC000030691629
DM7GSLB PC 14309340
DM7GSLB MW 300.4
DM7GSLB FM C20H28O2
DM7GSLB IC JYILPERKVHXLNF-UHFFFAOYSA-N
DM7GSLB CS CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(CCC34)O
DM7GSLB IK 1S/C20H28O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,14-18,21-22H,4-11H2,2H3
DM7GSLB IU 17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
DM7GSLB CA CAS 1231-93-2
DM7GSLB DE Contraception
DMQ2K1V ID DMQ2K1V
DMQ2K1V DN SCH-442416
DMQ2K1V HS Phase 1
DMQ2K1V SN 316173-57-6; SCH 442416; SCH-442416; UNII-ZMC4G1W59S; 2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; SCH442416; ZMC4G1W59S; CHEMBL136689; SCH-442,416; 2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; SCHEMBL981184; GTPL3283; CTK8B9468; CHEBI:92814; DTXSID70443263; MolPort-023-276-442; ZINC602847; HMS3269G07; BCP01942; MFCD08703126; BDBM50094037; ANW-62570; AKOS016003924; SCH442,416; NCGC00159575-01; AJ-23684; AC-27414
DMQ2K1V DT Small molecular drug
DMQ2K1V PC 10668061
DMQ2K1V MW 389.4
DMQ2K1V FM C20H19N7O2
DMQ2K1V IC InChI=1S/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)
DMQ2K1V CS COC1=CC=C(C=C1)CCCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
DMQ2K1V IK AEULVFLPCJOBCE-UHFFFAOYSA-N
DMQ2K1V IU 4-(furan-2-yl)-10-[3-(4-methoxyphenyl)propyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMQ2K1V CA CAS 316173-57-6
DMQ2K1V CB CHEBI:92814
DMDP6UF ID DMDP6UF
DMDP6UF DN SCH-721015
DMDP6UF HS Phase 1
DMDP6UF SN RAd-IFN, Merck & Co; RAd-IFN, Schering-Plough; Ad.hIFN-alpha2b, Merck & Co; Recombinant adenovirus vector expressing hybrid-interferon (bladder neoplasm), Merck & Co
DMDP6UF CP Fkd therapies
DMDP6UF DE Mesothelioma
DM7A6R5 ID DM7A6R5
DM7A6R5 DN SCH-900117
DM7A6R5 HS Phase 1
DM7A6R5 CP Merck
DM7A6R5 DE Rheumatoid arthritis
DMRD1IW ID DMRD1IW
DMRD1IW DN SCO-088
DMRD1IW HS Phase 1
DMRD1IW SN Vodobatinib; UNII-N8Q12KU2SW; N8Q12KU2SW; Vodobatinib (USAN); Vodobatinib [USAN]; K0706; 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide; 1388803-90-4; SUNK706; SCO088; SUN-K706; CHEMBL4130229; SCHEMBL15363815; GTPL11191; WHO 11506; D11786; 4-Methyl-3-quinolin-3-ylethynylbenzoic acid N'-(2-chloro-6-methylbenzoyl) hydrazide
DMRD1IW CP Sun Pharma Advanced Research Company
DMRD1IW DT Small molecular drug
DMRD1IW PC 89884852
DMRD1IW MW 453.9
DMRD1IW FM C27H20ClN3O2
DMRD1IW IC InChI=1S/C27H20ClN3O2/c1-17-10-12-22(26(32)30-31-27(33)25-18(2)6-5-8-23(25)28)15-20(17)13-11-19-14-21-7-3-4-9-24(21)29-16-19/h3-10,12,14-16H,1-2H3,(H,30,32)(H,31,33)
DMRD1IW CS CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3
DMRD1IW IK ZQOBVMHBVWNVBG-UHFFFAOYSA-N
DMRD1IW IU 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide
DMRD1IW CA CAS 1388803-90-4
DMRD1IW DE Chronic myeloid leukaemia
DMB1MZS ID DMB1MZS
DMB1MZS DN SCO-120
DMB1MZS HS Phase 1
DMB1MZS CP Sun Pharma Advanced Research Company
DMB1MZS DE Breast cancer
DMU0Q6L ID DMU0Q6L
DMU0Q6L DN SDX-7320
DMU0Q6L HS Phase 1
DMU0Q6L CP SynDevRx Cambridge, MA
DMU0Q6L DT Polymer drug conjugate
DMU0Q6L DE Solid tumour/cancer
DMU9ZGN ID DMU9ZGN
DMU9ZGN DN SDZ-GPI-562
DMU9ZGN HS Phase 1
DMU9ZGN SN GPI-562
DMU9ZGN CP Sandoz AG
DMU9ZGN DE Thrombosis
DM8SINB ID DM8SINB
DM8SINB DN SDZ-LAV-694
DM8SINB HS Phase 1
DM8SINB SN LAV-694; 6-[2-(2,5-Dimethoxyphenyl)ethyl]-4-ethylquinazoline
DM8SINB DE Actinic keratosis
DML6QJN ID DML6QJN
DML6QJN DN SDZ-MKS-492
DML6QJN HS Phase 1
DML6QJN SN MKS-492
DML6QJN CP Novartis AG
DML6QJN DT Small molecular drug
DML6QJN PC 163931
DML6QJN MW 433.5
DML6QJN FM C20H27N5O6
DML6QJN IC InChI=1S/C20H27N5O6/c1-23-17-16(18(27)24(2)20(23)28)25(8-9-29-3)19(22-17)21-13(11-26)12-6-7-14(30-4)15(10-12)31-5/h6-7,10,13,26H,8-9,11H2,1-5H3,(H,21,22)/t13-/m0/s1
DML6QJN CS CN1C2=C(C(=O)N(C1=O)C)N(C(=N2)N[C@@H](CO)C3=CC(=C(C=C3)OC)OC)CCOC
DML6QJN IK VZLFAVFWNOZVFM-ZDUSSCGKSA-N
DML6QJN IU 8-[[(1R)-1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
DML6QJN CA CAS 114606-56-3
DML6QJN DE Asthma
DMX94YF ID DMX94YF
DMX94YF DN SEA-CD70
DMX94YF HS Phase 1
DMX94YF CP Seagen
DMX94YF DT Antibody
DMX94YF DE Acute myeloid leukaemia; Myelodysplastic syndrome
DM7GUH3 ID DM7GUH3
DM7GUH3 DN SEA-TGT
DM7GUH3 HS Phase 1
DM7GUH3 CP Seagen
DM7GUH3 DT Antibody
DM7GUH3 DE Solid tumour/cancer
DMCP7SD ID DMCP7SD
DMCP7SD DN Seclidemstat
DMCP7SD HS Phase 1
DMCP7SD SN UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide
DMCP7SD CP Salarius Pharmaceuticals
DMCP7SD DT Small molecular drug
DMCP7SD PC 135565033
DMCP7SD MW 450.9
DMCP7SD FM C20H23ClN4O4S
DMCP7SD IC InChI=1S/C20H23ClN4O4S/c1-14(18-13-16(21)6-7-19(18)26)22-23-20(27)15-4-3-5-17(12-15)30(28,29)25-10-8-24(2)9-11-25/h3-7,12-13,26H,8-11H2,1-2H3,(H,23,27)/b22-14+
DMCP7SD CS C/C(=N\\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCN(CC2)C)/C3=C(C=CC(=C3)Cl)O
DMCP7SD IK MVSQDUZRRVBYLA-HYARGMPZSA-N
DMCP7SD IU N-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-(4-methylpiperazin-1-yl)sulfonylbenzamide
DMCP7SD CA CAS 1423715-37-0
DMCP7SD DE Ewing sarcoma
DMHCUZV ID DMHCUZV
DMHCUZV DN SEL120
DMHCUZV HS Phase 1
DMHCUZV SN SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride
DMHCUZV CP Ryvu Therapeutics
DMHCUZV DT Small molecular drug
DMHCUZV PC 73776232
DMHCUZV MW 450.6
DMHCUZV FM C15H19Br2ClN4
DMHCUZV IC InChI=1S/C15H18Br2N4.ClH/c1-9-11(16)12(17)10-3-2-6-21-14(10)13(9)19-15(21)20-7-4-18-5-8-20;/h18H,2-8H2,1H3;1H
DMHCUZV CS CC1=C2C3=C(CCCN3C(=N2)N4CCNCC4)C(=C1Br)Br.Cl
DMHCUZV IK GQXLWUCQESKBSC-UHFFFAOYSA-N
DMHCUZV IU 6,7-dibromo-5-methyl-2-piperazin-1-yl-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene;hydrochloride
DMHCUZV CA CAS 1609452-30-3
DMHCUZV DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMF89ZT ID DMF89ZT
DMF89ZT DN SEP-228432
DMF89ZT HS Phase 1
DMF89ZT CP Sunovion Pharmaceuticals
DMF89ZT DE Neuropathic pain; Depression
DMTZ983 ID DMTZ983
DMTZ983 DN SER-101
DMTZ983 HS Phase 1
DMTZ983 SN RO-1160367
DMTZ983 CP Roche Holding AG
DMTZ983 DE Congestive heart failure
DMD2GKF ID DMD2GKF
DMD2GKF DN SFLT-01
DMD2GKF HS Phase 1
DMD2GKF SN AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme
DMD2GKF CP Applied Genetic Technologies Corp
DMD2GKF DE Macular degeneration
DMDAHEL ID DMDAHEL
DMDAHEL DN SGM-1019
DMDAHEL HS Phase 1
DMDAHEL CP Second Genome South San Francisco, CA
DMDAHEL DE Inflammatory bowel disease
DMVBQ2L ID DMVBQ2L
DMVBQ2L DN SGN LIV1A
DMVBQ2L HS Phase 1
DMVBQ2L CP Seattle genetics
DMVBQ2L DT Antibody
DMVBQ2L DE Breast cancer
DMXA7W9 ID DMXA7W9
DMXA7W9 DN SGN-70
DMXA7W9 HS Phase 1
DMXA7W9 CP Seattle Genetics
DMXA7W9 DT Antibody
DMXA7W9 DE Autoimmune diabetes
DMATJL9 ID DMATJL9
DMATJL9 DN SGN-B6A
DMATJL9 HS Phase 1
DMATJL9 CP Seagen
DMATJL9 DT Antibody drug conjugate
DMATJL9 DE Solid tumour/cancer
DMSVD2R ID DMSVD2R
DMSVD2R DN SGN-CD228A
DMSVD2R HS Phase 1
DMSVD2R CP Seagen
DMSVD2R DT Antibody drug conjugate
DMSVD2R DE Solid tumour/cancer
DMKW10G ID DMKW10G
DMKW10G DN SGN-CD30C
DMKW10G HS Phase 1
DMKW10G CP Seagen
DMKW10G DT Antibody drug conjugate
DMKW10G DE Lymphoma
DMMJ1PO ID DMMJ1PO
DMMJ1PO DN SGN-CD70A
DMMJ1PO HS Phase 1
DMMJ1PO CP Seattle genetics
DMMJ1PO DT Antibody
DMMJ1PO DE Non-hodgkin lymphoma
DM3RSMF ID DM3RSMF
DM3RSMF DN Sgx523
DM3RSMF HS Phase 1
DM3RSMF SN SGX-523; SGX523, SGX-523
DM3RSMF CP SGX Pharma; Eli Lilly
DM3RSMF TC Anticancer Agents
DM3RSMF DT Small molecular drug
DM3RSMF PC 24779724
DM3RSMF MW 359.4
DM3RSMF FM C18H13N7S
DM3RSMF IC InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3
DM3RSMF CS CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2
DM3RSMF IK BCZUAADEACICHN-UHFFFAOYSA-N
DM3RSMF IU 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline
DM3RSMF CA CAS 1022150-57-7
DM3RSMF CB CHEBI:90624
DM3RSMF DE Solid tumour/cancer
DMO0CA8 ID DMO0CA8
DMO0CA8 DN SHP616
DMO0CA8 HS Phase 1
DMO0CA8 CP ShireLexington, MA
DMO0CA8 DE Neuromyelitis optica
DMGFTAI ID DMGFTAI
DMGFTAI DN SHR0534
DMGFTAI HS Phase 1
DMGFTAI CP Jiangsu Hengrui
DMGFTAI DE Type 2 diabetes
DMDSFEB ID DMDSFEB
DMDSFEB DN SI-B001
DMDSFEB HS Phase 1
DMDSFEB CP Baili pharm
DMDSFEB DT Antibody
DMDSFEB DE Metastatic epithelial tumour
DMJW5R0 ID DMJW5R0
DMJW5R0 DN SI-B003
DMJW5R0 HS Phase 1
DMJW5R0 CP SystImmune
DMJW5R0 DT Antibody
DMJW5R0 DE Solid tumour/cancer
DMFK7UR ID DMFK7UR
DMFK7UR DN Simotaxel
DMFK7UR HS Phase 1
DMFK7UR SN MST-997; TL-909
DMFK7UR CP Taxolog Inc
DMFK7UR DT Small molecular drug
DMFK7UR PC 11286005
DMFK7UR MW 896
DMFK7UR FM C46H57NO15S
DMFK7UR IC InChI=1S/C46H57NO15S/c1-23(2)58-42(55)47-33(29-18-13-19-63-29)34(50)41(54)59-28-21-46(56)38(61-40(53)27-14-9-8-10-15-27)36-44(7,30(49)20-31-45(36,22-57-31)62-25(4)48)37(51)35(32(24(28)3)43(46,5)6)60-39(52)26-16-11-12-17-26/h8-10,13-15,18-19,23,26,28,30-31,33-36,38,49-50,56H,11-12,16-17,20-22H2,1-7H3,(H,47,55)/t28-,30-,31+,33-,34+,35+,36-,38-,44+,45-,46+/m0/s1
DMFK7UR CS CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CS5)NC(=O)OC(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)OC(=O)C7CCCC7
DMFK7UR IK SLGIWUWTSWJBQE-VLCCYYTCSA-N
DMFK7UR IU [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-12-(cyclopentanecarbonyloxy)-1,9-dihydroxy-15-[(2R,3R)-2-hydroxy-3-(propan-2-yloxycarbonylamino)-3-thiophen-2-ylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
DMFK7UR CA CAS 791635-59-1
DMFK7UR DE Solid tumour/cancer
DMG7XKP ID DMG7XKP
DMG7XKP DN SKF-105494
DMG7XKP HS Phase 1
DMG7XKP CP SmithKline Beecham plc
DMG7XKP PC 9963434
DMG7XKP MW 1102.3
DMG7XKP FM C54H83N15O10
DMG7XKP IC InChI=1S/C54H83N15O10/c1-4-79-35-21-19-34(20-22-35)29-39-48(75)67-40(28-33-14-7-5-8-15-33)50(77)69-44(32(2)3)51(78)68-41(30-42(55)70)49(76)66-37(16-11-25-54(31-43(71)63-39)23-9-6-10-24-54)47(74)65-38(18-13-27-62-53(59)60)46(73)64-36(45(56)72)17-12-26-61-52(57)58/h5,7-8,14-15,19-22,32,36-41,44H,4,6,9-13,16-18,23-31H2,1-3H3,(H2,55,70)(H2,56,72)(H,63,71)(H,64,73)(H,65,74)(H,66,76)(H,67,75)(H,68,78)(H,69,77)(H4,57,58,61)(H4,59,60,62)/t36-,37+,38+,39-,40+,41+,44+/m1/s1
DMG7XKP CS CCOC1=CC=C(C=C1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCC3(CCCCC3)CC(=O)N2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N)CC(=O)N)C(C)C)CC4=CC=CC=C4
DMG7XKP IK PZEDOGNXHJQAKP-CQRSLYTBSA-N
DMG7XKP IU (10R,13S,16S,19S,22S)-N-[(2S)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-19-(2-amino-2-oxoethyl)-13-benzyl-10-[(4-ethoxyphenyl)methyl]-8,11,14,17,20-pentaoxo-16-propan-2-yl-9,12,15,18,21-pentazaspiro[5.19]pentacosane-22-carboxamide
DMG7XKP CA CAS 114923-99-8
DMG7XKP DE Diuretic vasodilator
DMUN7EQ ID DMUN7EQ
DMUN7EQ DN SKF-105809
DMUN7EQ HS Phase 1
DMUN7EQ SN SKF-105561
DMUN7EQ CP SmithKline Beecham plc
DMUN7EQ DT Small molecular drug
DMUN7EQ PC 129725
DMUN7EQ MW 323.4
DMUN7EQ FM C18H17N3OS
DMUN7EQ IC InChI=1S/C18H17N3OS/c1-23(22)15-6-4-13(5-7-15)17-18(14-8-10-19-11-9-14)21-12-2-3-16(21)20-17/h4-11H,2-3,12H2,1H3
DMUN7EQ CS CS(=O)C1=CC=C(C=C1)C2=C(N3CCCC3=N2)C4=CC=NC=C4
DMUN7EQ IK KSEJZTWORQXILM-UHFFFAOYSA-N
DMUN7EQ IU 2-(4-methylsulfinylphenyl)-3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
DMUN7EQ CA CAS 122454-69-7
DMUN7EQ DE Pain
DM4I92Z ID DM4I92Z
DM4I92Z DN SKI-G-801
DM4I92Z HS Phase 1
DM4I92Z CP Genosco
DM4I92Z DT Small molecular drug
DM4I92Z DE Acute myeloid leukaemia
DMTSKXR ID DMTSKXR
DMTSKXR DN SKI-O-703
DMTSKXR HS Phase 1
DMTSKXR CP OscotecChonan, South Korea
DMTSKXR DE Rheumatoid arthritis
DMW64UZ ID DMW64UZ
DMW64UZ DN SKL-10406
DMW64UZ HS Phase 1
DMW64UZ CP SK Life Science
DMW64UZ DE Major depressive disorder
DM8YNI6 ID DM8YNI6
DM8YNI6 DN SKL-PSY
DM8YNI6 HS Phase 1
DM8YNI6 SN 5-HT 1a receptor modulator (psychiatric disorder), SK Life Science; 5-HT 1a receptor modulator (schizophrenia/depression), SK Life science
DM8YNI6 CP SK Life Science
DM8YNI6 DE Bipolar disorder
DMN3D72 ID DMN3D72
DMN3D72 DN SL-172154
DMN3D72 HS Phase 1
DMN3D72 CP Shattuck Labs
DMN3D72 DT Recombinant protein
DMN3D72 DE Ovarian cancer
DMIVGYK ID DMIVGYK
DMIVGYK DN SL-801
DMIVGYK HS Phase 1
DMIVGYK SN CMASLSTVVOYJQY-UHFFFAOYSA-N; 1076235-04-5; SCHEMBL1592515; S-03747; 1H-Pyrrole-2,5-dione, 1-[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]-3-[(3,3-dimethylbutoxy)methyl]-4-methyl-
DMIVGYK CP Stemline Therapeutics New York, NY
DMIVGYK PC 25103750
DMIVGYK MW 419.8
DMIVGYK FM C18H21ClF3N3O3
DMIVGYK IC InChI=1S/C18H21ClF3N3O3/c1-10-11(9-28-8-7-17(2,3)4)16(27)25(15(10)26)24-13-6-5-12(14(19)23-13)18(20,21)22/h5-6H,7-9H2,1-4H3,(H,23,24)
DMIVGYK CS CC1=C(C(=O)N(C1=O)NC2=NC(=C(C=C2)C(F)(F)F)Cl)COCCC(C)(C)C
DMIVGYK IK CMASLSTVVOYJQY-UHFFFAOYSA-N
DMIVGYK IU 1-[[6-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-3-(3,3-dimethylbutoxymethyl)-4-methylpyrrole-2,5-dione
DMIVGYK CA CAS 1076235-04-5
DMIVGYK DE Solid tumour/cancer
DMVUL1H ID DMVUL1H
DMVUL1H DN Sleeping Beauty CAR-TCR
DMVUL1H HS Phase 1
DMVUL1H CP Ziopharm Oncology
DMVUL1H DT CAR T Cell Therapy
DMVUL1H DE leukaemia
DMIAOU6 ID DMIAOU6
DMIAOU6 DN SLN124
DMIAOU6 HS Phase 1
DMIAOU6 CP Silence Therapeutics
DMIAOU6 DT Small interfering RNA
DMIAOU6 DE Beta thalassemia
DM7WKTM ID DM7WKTM
DM7WKTM DN SLV-338
DM7WKTM HS Phase 1
DM7WKTM CP Solvay SA
DM7WKTM DE Cardiovascular disease
DM491NI ID DM491NI
DM491NI DN SM04755
DM491NI HS Phase 1
DM491NI CP Samumed
DM491NI DE Liver cancer; Plaque psoriasis
DM4KLNA ID DM4KLNA
DM4KLNA DN SM08502
DM4KLNA HS Phase 1
DM4KLNA CP Samumed San Diego, CA
DM4KLNA DE Solid tumour/cancer
DM73YG5 ID DM73YG5
DM73YG5 DN SM09419
DM73YG5 HS Phase 1
DM73YG5 CP Biosplice
DM73YG5 DT Small molecular drug
DM73YG5 DE Hematologic tumour
DM8L1GJ ID DM8L1GJ
DM8L1GJ DN SNA-125
DM8L1GJ HS Phase 1
DM8L1GJ CP Sienna Biopharmaceuticals Westlake Village, CA
DM8L1GJ DE Atopic dermatitis; Pruritus; Psoriasis vulgaris
DM8ZROW ID DM8ZROW
DM8ZROW DN SNDX-6352
DM8ZROW HS Phase 1
DM8ZROW CP Syndax Pharmaceuticals Waltham, MA
DM8ZROW DE Solid tumour/cancer
DMEITAS ID DMEITAS
DMEITAS DN SNS-032
DMEITAS HS Phase 1
DMEITAS SN BMS-387032; BMS-387072; BMS-387032, SNS-032; N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide L-tartaric acid salt (2:1); N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
DMEITAS CP Sunesis; Bristol Myers Squibb
DMEITAS TC Anticancer Agents
DMEITAS DT Small molecular drug
DMEITAS PC 3025986
DMEITAS MW 380.5
DMEITAS FM C17H24N4O2S2
DMEITAS IC InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
DMEITAS CS CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3
DMEITAS IK OUSFTKFNBAZUKL-UHFFFAOYSA-N
DMEITAS IU N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
DMEITAS CA CAS 345627-80-7
DMEITAS CB CHEBI:91399
DMEITAS DE Solid tumour/cancer
DMAC5F2 ID DMAC5F2
DMAC5F2 DN SNS-314
DMAC5F2 HS Phase 1
DMAC5F2 SN SN-314
DMAC5F2 CP Sunesis Pharma
DMAC5F2 TC Anticancer Agents
DMAC5F2 DT Small molecular drug
DMAC5F2 PC 24995524
DMAC5F2 MW 430.9
DMAC5F2 FM C18H15ClN6OS2
DMAC5F2 IC InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26)
DMAC5F2 CS C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4
DMAC5F2 IK FAYAUAZLLLJJGH-UHFFFAOYSA-N
DMAC5F2 IU 1-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl]urea
DMAC5F2 CA CAS 1057249-41-8
DMAC5F2 CB CHEBI:94720
DMAC5F2 DE Solid tumour/cancer
DMCGPU8 ID DMCGPU8
DMCGPU8 DN SNX281
DMCGPU8 HS Phase 1
DMCGPU8 CP Silicon Therapeutics
DMCGPU8 DT Small molecular drug
DMCGPU8 DE Lymphoma; Solid tumour/cancer
DMB3WJF ID DMB3WJF
DMB3WJF DN Solulin
DMB3WJF HS Phase 1
DMB3WJF SN PN-02; Recombinant thrombomodulin, PAION
DMB3WJF CP Bayer Schering Pharma AG
DMB3WJF DE Thrombosis
DMB3YZJ ID DMB3YZJ
DMB3YZJ DN Sonepcizumab
DMB3YZJ HS Phase 1
DMB3YZJ CP Lpath
DMB3YZJ DT Antibody
DMB3YZJ DE Macular degeneration
DMBKL6O ID DMBKL6O
DMBKL6O DN SOR-C13
DMBKL6O HS Phase 1
DMBKL6O CP Soricimed biopharma
DMBKL6O PC 121596688
DMBKL6O MW 1565.8
DMBKL6O FM C72H116N20O19
DMBKL6O IC InChI=1S/C72H116N20O19/c1-39(2)31-48(84-63(102)49(33-42-17-8-7-9-18-42)85-60(99)46(24-25-56(94)95)81-59(98)44(75)19-10-12-26-73)62(101)88-52(34-43-36-78-38-80-43)70(109)92-30-16-23-55(92)67(106)89-53(37-93)65(104)82-45(20-11-13-27-74)61(100)90-58(41(5)6)68(107)86-50(35-57(96)97)64(103)87-51(32-40(3)4)69(108)91-29-15-22-54(91)66(105)83-47(71(110)111)21-14-28-79-72(76)77/h7-9,17-18,36,38-41,44-55,58,93H,10-16,19-35,37,73-75H2,1-6H3,(H,78,80)(H,81,98)(H,82,104)(H,83,105)(H,84,102)(H,85,99)(H,86,107)(H,87,103)(H,88,101)(H,89,106)(H,90,100)(H,94,95)(H,96,97)(H,110,111)(H4,76,77,79)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1
DMBKL6O CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N
DMBKL6O IK LGANPTNILMNMES-TVNHODDRSA-N
DMBKL6O IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
DMBKL6O CA CAS 1187852-48-7
DMBKL6O DE Ovarian cancer; Solid tumour/cancer; Alzheimer disease
DMAD6HS ID DMAD6HS
DMAD6HS DN SPC4955
DMAD6HS HS Phase 1
DMAD6HS CP Santaris Pharma A/S
DMAD6HS DE High blood cholesterol level
DMUPQ70 ID DMUPQ70
DMUPQ70 DN SPC5001
DMUPQ70 HS Phase 1
DMUPQ70 CP Santaris Pharma A/S
DMUPQ70 DE Hyperlipidaemia
DMO1FTI ID DMO1FTI
DMO1FTI DN Sphingosine
DMO1FTI HS Phase 1
DMO1FTI SN sphingosine; D-erythro-Sphingosine; 123-78-4; 4-Sphingenine; D-Sphingosine; Sphing-4-enine; cerebroside; trans-D-erythro-2-Amino-4-octadecene-1,3-diol; Sphingenine; (4E)-Sphingenine; 4-trans-Sphingenine; (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol; Sphingoid; D-erythro-Sphingosine (synthetic); UNII-NGZ37HRE42; D-erythro-C18-Sphingosine; (E)-2-Amino-4-octadecan-1,3-diol; (2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol; trans-4-Sphingenine; CCRIS 6899; NGZ37HRE42; (2S,3R)-2-aminooctadec-4-ene-1,3-diol
DMO1FTI DT Small molecular drug
DMO1FTI PC 5280335
DMO1FTI MW 299.5
DMO1FTI FM C18H37NO2
DMO1FTI IC InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1
DMO1FTI CS CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)N)O
DMO1FTI IK WWUZIQQURGPMPG-KRWOKUGFSA-N
DMO1FTI IU (E,2S,3R)-2-aminooctadec-4-ene-1,3-diol
DMO1FTI CA CAS 123-78-4
DMO1FTI CB CHEBI:16393
DMJCQKA ID DMJCQKA
DMJCQKA DN Sphingosine-1-Phosphate
DMJCQKA HS Phase 1
DMJCQKA SN Sphingosine 1-phosphate; sphingosine-1-phosphate; 26993-30-6; D-erythro-Sphingosine-1-phosphate; C18-Sphingosine 1-phosphate; Sphing-4-enine 1-phosphate; S1P; CHEBI:37550; D-erythro-sphingosine 1-phosphate; UNII-YVE187NJ1U; Sphingosine 1-phosphic acid; (2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate; Sphing-4-enine-1-phosphate; YVE187NJ1U; CHEMBL225155; DUYSYHSSBDVJSM-KRWOKUGFSA-N; 4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-; (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol 1-(Dihydroge
DMJCQKA DT Small molecular drug
DMJCQKA PC 5283560
DMJCQKA MW 379.5
DMJCQKA FM C18H38NO5P
DMJCQKA IC InChI=1S/C18H38NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h14-15,17-18,20H,2-13,16,19H2,1H3,(H2,21,22,23)/b15-14+/t17-,18+/m0/s1
DMJCQKA CS CCCCCCCCCCCCC/C=C/[C@H]([C@H](COP(=O)(O)O)N)O
DMJCQKA IK DUYSYHSSBDVJSM-KRWOKUGFSA-N
DMJCQKA IU [(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enyl] dihydrogen phosphate
DMJCQKA CA CAS 26993-30-6
DMJCQKA CB CHEBI:37550
DMJCQKA DE Acne vulgaris
DM5IPUS ID DM5IPUS
DM5IPUS DN SPI-014
DM5IPUS HS Phase 1
DM5IPUS SN SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals
DM5IPUS CP Satori Pharmaceuticals Inc
DM5IPUS PC 46221695
DM5IPUS MW 369.82
DM5IPUS FM CLa2O5
DM5IPUS IC InChI=1S/CH2O3.2La.2O/c2-1(3)4;;;;/h(H2,2,3,4);;;;/q;2*+3;2*-2/p-2
DM5IPUS CS C(=O)([O-])[O-].[O-2].[O-2].[La+3].[La+3]
DM5IPUS IK VMVUIGXLELJYAZ-UHFFFAOYSA-L
DM5IPUS IU lanthanum(3+);oxygen(2-);carbonate
DM5IPUS CA CAS 1347739-77-8
DM5IPUS DE Hypophosphatasia; Alzheimer disease
DM8O2AQ ID DM8O2AQ
DM8O2AQ DN SPN-803
DM8O2AQ HS Phase 1
DM8O2AQ CP Supernus Pharmaceuticals Inc
DM8O2AQ DT Antisense drug
DM8O2AQ DE Parkinson disease
DMO5760 ID DMO5760
DMO5760 DN SR13668
DMO5760 HS Phase 1
DMO5760 DT Small molecular drug
DMO5760 PC 9845566
DMO5760 MW 430.5
DMO5760 FM C25H22N2O5
DMO5760 IC InChI=1S/C25H22N2O5/c1-4-31-24(28)13-6-8-19-15(10-13)17-12-18-16-11-14(25(29)32-5-2)7-9-20(16)27-22(18)23(30-3)21(17)26-19/h6-12,26-27H,4-5H2,1-3H3
DMO5760 CS CCOC(=O)C1=CC2=C(C=C1)NC3=C(C4=C(C=C23)C5=C(N4)C=CC(=C5)C(=O)OCC)OC
DMO5760 IK BMTPVPNVQOYGAP-UHFFFAOYSA-N
DMO5760 IU diethyl 6-methoxy-5,7-dihydroindolo[2,3-b]carbazole-2,10-dicarboxylate
DMO5760 CA CAS 637774-61-9
DMO5760 DE Solid tumour/cancer
DMYRPBI ID DMYRPBI
DMYRPBI DN SR-4554
DMYRPBI HS Phase 1
DMYRPBI SN CRC-94/17; N-(3,3,3-Trifluoro-2-hydroxypropyl)-2-(2-nitro-1-imidazolyl)acetamide
DMYRPBI DT Small molecular drug
DMYRPBI PC 9882197
DMYRPBI MW 282.18
DMYRPBI FM C8H9F3N4O4
DMYRPBI IC InChI=1S/C8H9F3N4O4/c9-8(10,11)5(16)3-13-6(17)4-14-2-1-12-7(14)15(18)19/h1-2,5,16H,3-4H2,(H,13,17)
DMYRPBI CS C1=CN(C(=N1)[N+](=O)[O-])CC(=O)NCC(C(F)(F)F)O
DMYRPBI IK BTLNRJMECFTISR-UHFFFAOYSA-N
DMYRPBI IU 2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoro-2-hydroxypropyl)acetamide
DMYRPBI CA CAS 167648-73-9
DMYRPBI DE Diagnostic imaging
DMQMO4N ID DMQMO4N
DMQMO4N DN SRF388
DMQMO4N HS Phase 1
DMQMO4N CP Surface oncology
DMQMO4N DT Antibody
DMQMO4N DE Solid tumour/cancer; Liver cancer
DMTK1BV ID DMTK1BV
DMTK1BV DN SRF617
DMTK1BV HS Phase 1
DMTK1BV CP Surface oncology
DMTK1BV DT Antibody
DMTK1BV DE Solid tumour/cancer
DM0EWMT ID DM0EWMT
DM0EWMT DN SRK-181
DM0EWMT HS Phase 1
DM0EWMT CP Scholar Rock
DM0EWMT DT Antibody
DM0EWMT DE Solid tumour/cancer
DM7DAKX ID DM7DAKX
DM7DAKX DN SRT2379
DM7DAKX HS Phase 1
DM7DAKX CP Sirtris
DM7DAKX DE Type-2 diabetes
DMRAXFH ID DMRAXFH
DMRAXFH DN SRT3025
DMRAXFH HS Phase 1
DMRAXFH CP Sirtris
DMRAXFH PC 46245047
DMRAXFH MW 569.7
DMRAXFH FM C31H31N5O2S2
DMRAXFH IC InChI=1S/C31H31N5O2S2/c1-38-17-9-14-26-27(35-29(39-26)22-10-3-2-4-11-22)28(37)33-24-13-6-5-12-23(24)30-34-25-18-21(19-32-31(25)40-30)20-36-15-7-8-16-36/h2-6,10-13,18-19H,7-9,14-17,20H2,1H3,(H,33,37)
DMRAXFH CS COCCCC1=C(N=C(S1)C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C4=NC5=C(S4)N=CC(=C5)CN6CCCC6
DMRAXFH IK MRRXPMZNBRXCPZ-UHFFFAOYSA-N
DMRAXFH IU 5-(3-methoxypropyl)-2-phenyl-N-[2-[6-(pyrrolidin-1-ylmethyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]-1,3-thiazole-4-carboxamide
DMRAXFH DE Type-2 diabetes
DMO1N8A ID DMO1N8A
DMO1N8A DN SRX-251
DMO1N8A HS Phase 1
DMO1N8A SN AVN-246; SRX-108; SRX-31; SRX-74; Vasopressin V1a antagonist (Raynauds disease/dysmenorrhea), Azevan Pharmaceuticals; Vasopressin V1a antagonist (psychiatric disorders/dysmenorrhea), Azevan
DMO1N8A CP Azevan Pharmaceuticals Inc
DMO1N8A PC 11686429
DMO1N8A MW 771.9
DMO1N8A FM C43H48F3N5O5
DMO1N8A IC InChI=1S/C43H48F3N5O5/c1-47(28-31-14-11-17-33(26-31)43(44,45)46)40(53)36(27-38(52)49-24-20-34(21-25-49)48-22-9-4-10-23-48)50-35(19-18-30-12-5-2-6-13-30)39(41(50)54)51-37(29-56-42(51)55)32-15-7-3-8-16-32/h2-3,5-8,11-19,26,34-37,39H,4,9-10,20-25,27-29H2,1H3/b19-18+/t35-,36-,37-,39+/m1/s1
DMO1N8A CS CN(CC1=CC(=CC=C1)C(F)(F)F)C(=O)[C@@H](CC(=O)N2CCC(CC2)N3CCCCC3)N4[C@@H]([C@@H](C4=O)N5[C@H](COC5=O)C6=CC=CC=C6)/C=C/C7=CC=CC=C7
DMO1N8A IK GOQPVIZMGXUXOL-GRLAPFOSSA-N
DMO1N8A IU (2R)-N-methyl-4-oxo-2-[(3S,4R)-2-oxo-3-[(4S)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-4-[(E)-2-phenylethenyl]azetidin-1-yl]-4-(4-piperidin-1-ylpiperidin-1-yl)-N-[[3-(trifluoromethyl)phenyl]methyl]butanamide
DMO1N8A DE Dysmenorrhea
DMSUFW6 ID DMSUFW6
DMSUFW6 DN SSR-125047
DMSUFW6 HS Phase 1
DMSUFW6 SN Tolrestat; TOLRESTAT; 82964-04-3; Alredase; Lorestat; Tolrestatin; Tolrestatum; Tolrestatum [Latin]; AY-27773; 2-(6-Methoxy-N-methyl-5-(trifluoromethyl)naphthalene-1-carbothioamido)acetic acid; UNII-0T93LG5NMK; AY 27773; AY-27,773; CHEMBL436; 0T93LG5NMK; CHEBI:48549; LUBHDINQXIHVLS-UHFFFAOYSA-N; N-{[6-methoxy-5-(trifluoromethyl)naphthalen-1-yl]carbonothioyl}-N-methylglycine; NCGC00183862-01; N-(6-Methoxythio-5-(trifluoromethyl)-1-naphthoyl)sarcosine; N-{[6-methoxy-5-(trifluoromethyl)-1-naphthyl]carbonothioyl}-N-methylglycine
DMSUFW6 CP Sanofi-Aventis
DMSUFW6 DT Small molecular drug
DMSUFW6 PC 53359
DMSUFW6 MW 357.3
DMSUFW6 FM C16H14F3NO3S
DMSUFW6 IC InChI=1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)
DMSUFW6 CS CN(CC(=O)O)C(=S)C1=CC=CC2=C1C=CC(=C2C(F)(F)F)OC
DMSUFW6 IK LUBHDINQXIHVLS-UHFFFAOYSA-N
DMSUFW6 IU 2-[[6-methoxy-5-(trifluoromethyl)naphthalene-1-carbothioyl]-methylamino]acetic acid
DMSUFW6 CA CAS 82964-04-3
DMSUFW6 CB CHEBI:48549
DMSUFW6 DE Schizophrenia; Diabetic cataract
DMG6NI8 ID DMG6NI8
DMG6NI8 DN SSR-125329A
DMG6NI8 HS Phase 1
DMG6NI8 SN SR-125329; N-[3-[4-(2-Adamantyl)-3,5-dichlorophenyl]-2(Z)-propenyl]-N-cyclohexyl-N-ethylamine
DMG6NI8 DE Immune System disease
DMOJA7N ID DMOJA7N
DMOJA7N DN SSR-128428
DMOJA7N HS Phase 1
DMOJA7N CP Sanofi-Synthelabo
DMOJA7N DE Thrombosis
DMXQF1T ID DMXQF1T
DMXQF1T DN SSR-181507
DMXQF1T HS Phase 1
DMXQF1T SN UNII-H276H25KW0; H276H25KW0; SSR-181507; 8-Azabicyclo(3.2.1)octane-3-methanamine, 8-benzoyl-N-(((2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-, (3-exo)-
DMXQF1T CP Sanofi-Aventis
DMXQF1T DT Small molecular drug
DMXQF1T PC 56603722
DMXQF1T MW 426.9
DMXQF1T FM C24H27ClN2O3
DMXQF1T IC InChI=1S/C24H27ClN2O3/c25-18-6-9-22-23(12-18)30-21(15-29-22)14-26-13-16-10-19-7-8-20(11-16)27(19)24(28)17-4-2-1-3-5-17/h1-6,9,12,16,19-21,26H,7-8,10-11,13-15H2/t16?,19-,20+,21-/m0/s1
DMXQF1T CS C1C[C@H]2CC(C[C@@H]1N2C(=O)C3=CC=CC=C3)CNC[C@H]4COC5=C(O4)C=C(C=C5)Cl
DMXQF1T IK VDQJQKSTXHXBME-DTHFOOOUSA-N
DMXQF1T IU [(1S,5R)-3-[[[(3S)-6-chloro-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]methyl]-8-azabicyclo[3.2.1]octan-8-yl]-phenylmethanone
DMXQF1T CA CAS 737743-26-9
DMXQF1T DE Schizophrenia
DMX6V1L ID DMX6V1L
DMX6V1L DN ST-1141
DMX6V1L HS Phase 1
DMX6V1L SN Ghrelin agonist (oral, opioid-induced bowel dysfunction), Helsinn
DMX6V1L CP Sapphire Therapeutics Inc
DMX6V1L DE Functional bowel disorder
DMGPIV0 ID DMGPIV0
DMGPIV0 DN STA-5312
DMGPIV0 HS Phase 1
DMGPIV0 SN 2-[3-(4-Cyanobenzyl)indolizin-1-yl]-N-(3-methylisothiazol-5-yl)-2-oxoacetamide
DMGPIV0 DT Small molecular drug
DMGPIV0 PC 9843935
DMGPIV0 MW 400.5
DMGPIV0 FM C22H16N4O2S
DMGPIV0 IC InChI=1S/C22H16N4O2S/c1-14-10-20(29-25-14)24-22(28)21(27)18-12-17(26-9-3-2-4-19(18)26)11-15-5-7-16(13-23)8-6-15/h2-10,12H,11H2,1H3,(H,24,28)
DMGPIV0 CS CC1=NSC(=C1)NC(=O)C(=O)C2=C3C=CC=CN3C(=C2)CC4=CC=C(C=C4)C#N
DMGPIV0 IK IZZYUABKZYIINT-UHFFFAOYSA-N
DMGPIV0 IU 2-[3-[(4-cyanophenyl)methyl]indolizin-1-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
DMGPIV0 CA CAS 501948-05-6
DMGPIV0 DE Solid tumour/cancer
DMDF29A ID DMDF29A
DMDF29A DN STM 434
DMDF29A HS Phase 1
DMDF29A CP Atara Biotherapeutics South San Francisco, CA
DMDF29A DE Ovarian cancer
DMXCJP8 ID DMXCJP8
DMXCJP8 DN STP1002
DMXCJP8 HS Phase 1
DMXCJP8 CP ST Pharm
DMXCJP8 DT Small molecular drug
DMXCJP8 DE Solid tumour/cancer
DMC5HXI ID DMC5HXI
DMC5HXI DN STRO-002
DMC5HXI HS Phase 1
DMC5HXI CP Sutro Biopharma
DMC5HXI DT Antibody drug conjugate
DMC5HXI DE Ovarian cancer
DMJAPRK ID DMJAPRK
DMJAPRK DN STX 64
DMJAPRK HS Phase 1
DMJAPRK SN BN-83495; STX-64; (6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-3-yl) sulfamate; 6-OXO-8,9,10,11-TETRAHYDRO-7H-CYCLOHEPTA[C][1]BENZOPYRAN-3-O-SULFAMATE; 667-Coumate
DMJAPRK CP Amgen
DMJAPRK TC Anticancer Agents
DMJAPRK DT Small molecular drug
DMJAPRK PC 5287541
DMJAPRK MW 309.34
DMJAPRK FM C14H15NO5S
DMJAPRK IC InChI=1S/C14H15NO5S/c15-21(17,18)20-9-6-7-11-10-4-2-1-3-5-12(10)14(16)19-13(11)8-9/h6-8H,1-5H2,(H2,15,17,18)
DMJAPRK CS C1CCC2=C(CC1)C(=O)OC3=C2C=CC(=C3)OS(=O)(=O)N
DMJAPRK IK DSLPMJSGSBLWRE-UHFFFAOYSA-N
DMJAPRK IU (6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-3-yl) sulfamate
DMJAPRK CA CAS 288628-05-7
DMJAPRK DE Prostate cancer
DMMAS3K ID DMMAS3K
DMMAS3K DN SULFAMIDE
DMMAS3K HS Phase 1
DMMAS3K SN Sulfuric diamide; 7803-58-9; Sulfamamide; Sulfuryl amide; Sulfuryl diamide; Sulfonyl diamide; sulfamoylamine; sulphamide; Sulphuric diamide; UNII-VS7TZW634V; Imidosulfamic acid; H4N2O2S; H2NSO2NH2; VS7TZW634V; CHEMBL355001; CHEBI:29368; NVBFHJWHLNUMCV-UHFFFAOYSA-N; MFCD00011606; Sulfamide, 98+%; Imidosulfamic acid (VAN); aminosulfonamide; NSC 252; diamidodioxidosulfur; EINECS 232-262-9; Sulfamide, 99%; AI3-30237; NH2SO2NH2; AC1Q55HN; KSC377O7F; NSC252; AC1L332P; DTXSID5064885; CTK2H7772; BDBM26995; NSC-252; MolPort-000-146-081
DMMAS3K DT Small molecular drug
DMMAS3K PC 82267
DMMAS3K MW 96.11
DMMAS3K FM H4N2O2S
DMMAS3K IC InChI=1S/H4N2O2S/c1-5(2,3)4/h(H4,1,2,3,4)
DMMAS3K CS NS(=O)(=O)N
DMMAS3K IK NVBFHJWHLNUMCV-UHFFFAOYSA-N
DMMAS3K IU sulfamide
DMMAS3K CA CAS 7803-58-9
DMMAS3K CB CHEBI:29368
DMIF8RY ID DMIF8RY
DMIF8RY DN SUN-K0706
DMIF8RY HS Phase 1
DMIF8RY CP Sun Pharma Advanced Research Mumbai, India
DMIF8RY DE Chronic lymphocytic leukaemia; Parkinson disease
DMDOSL0 ID DMDOSL0
DMDOSL0 DN SUN-N8075
DMDOSL0 HS Phase 1
DMDOSL0 SN SUN-8075; SUN-N5030; Sodium/calcium ion exchange inhibitor (acute ischemic stroke), Asubio Pharma; Sodium/calcium ion exchange inhibitor (acute ischemic stroke), Daiichi Sankyo
DMDOSL0 CP Daiichi Suntory Biomedical Research Co Ltd
DMDOSL0 DE Cerebral infarction
DMTOUY9 ID DMTOUY9
DMTOUY9 DN Suramin
DMTOUY9 HS Phase 1
DMTOUY9 SN Antrypol; Belganyl; Farma; Fourneau; Germanin; Moranyl; Naganil; Naganin; Naganine; Naganol; Naphuride; SVR; Suramine; SURAMIN SODIUM; Sodium suramin; Suramine sodium; Farma 939; Naganol 6 Na; Germanin (TN); SGCTO-001
DMTOUY9 CP Bayer Pharmaceuticals Corporation
DMTOUY9 TC Antinematodal Agents
DMTOUY9 DT Small molecular drug
DMTOUY9 PC 5361
DMTOUY9 MW 1297.3
DMTOUY9 FM C51H40N6O23S6
DMTOUY9 IC InChI=1S/C51H40N6O23S6/c1-25-9-11-29(49(60)54-37-13-15-41(83(69,70)71)35-21-33(81(63,64)65)23-43(45(35)37)85(75,76)77)19-39(25)56-47(58)27-5-3-7-31(17-27)52-51(62)53-32-8-4-6-28(18-32)48(59)57-40-20-30(12-10-26(40)2)50(61)55-38-14-16-42(84(72,73)74)36-22-34(82(66,67)68)24-44(46(36)38)86(78,79)80/h3-24H,1-2H3,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
DMTOUY9 CS CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C
DMTOUY9 IK FIAFUQMPZJWCLV-UHFFFAOYSA-N
DMTOUY9 IU 8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
DMTOUY9 CA CAS 145-63-1
DMTOUY9 CB CHEBI:45906
DMTOUY9 DE African trypanosomiasis
DMZP671 ID DMZP671
DMZP671 DN SUVN 911
DMZP671 HS Phase 1
DMZP671 CP Suven Life Sciences
DMZP671 DT Small molecular drug
DMZP671 DE Major depressive disorder
DMLPBVF ID DMLPBVF
DMLPBVF DN SUVN-911
DMLPBVF HS Phase 1
DMLPBVF SN Alpha 4 beta 2 nicotinic acetylcholine receptor (nAChR) antagonist (depression), Suven
DMLPBVF CP Suven Life Sciences Ltd
DMLPBVF DE Major depressive disorder
DM6ZOD2 ID DM6ZOD2
DM6ZOD2 DN SUVN-D4010
DM6ZOD2 HS Phase 1
DM6ZOD2 SN DWTFBJGTRBMHPG-UHFFFAOYSA-N; UNII-GNQ25KYD72; GNQ25KYD72; 1428862-32-1; SCHEMBL14810657; 1-isopropyl-3-{5-[1-(3-methoxy propyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole; 1-isopropyl-3-{5-[1-(3-methoxy propyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole
DM6ZOD2 CP Suven Life Sciences Hyderabad, India
DM6ZOD2 PC 71508291
DM6ZOD2 MW 383.5
DM6ZOD2 FM C21H29N5O2
DM6ZOD2 IC InChI=1S/C21H29N5O2/c1-15(2)26-18-8-5-4-7-17(18)19(24-26)21-23-22-20(28-21)16-9-12-25(13-10-16)11-6-14-27-3/h4-5,7-8,15-16H,6,9-14H2,1-3H3
DM6ZOD2 CS CC(C)N1C2=CC=CC=C2C(=N1)C3=NN=C(O3)C4CCN(CC4)CCCOC
DM6ZOD2 IK DWTFBJGTRBMHPG-UHFFFAOYSA-N
DM6ZOD2 IU 2-[1-(3-methoxypropyl)piperidin-4-yl]-5-(1-propan-2-ylindazol-3-yl)-1,3,4-oxadiazole
DM6ZOD2 CA CAS 1428862-32-1
DM6ZOD2 DE Alzheimer disease
DMHMG6X ID DMHMG6X
DMHMG6X DN SX-682
DMHMG6X HS Phase 1
DMHMG6X SN 1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SX682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-
DMHMG6X CP Syntrix Biosystems
DMHMG6X DT Small molecular drug
DMHMG6X PC 90467234
DMHMG6X MW 467.2
DMHMG6X FM C19H14BF4N3O4S
DMHMG6X IC InChI=1S/C19H14BF4N3O4S/c21-13-1-3-14(4-2-13)27-17(28)12-8-25-18(26-9-12)32-10-11-7-15(31-19(22,23)24)5-6-16(11)20(29)30/h1-9,29-30H,10H2,(H,27,28)
DMHMG6X CS B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O
DMHMG6X IK SDUDZBCEHIZMFZ-UHFFFAOYSA-N
DMHMG6X IU [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
DMHMG6X CA CAS 1648843-04-2
DMHMG6X DE Melanoma; Myelodysplastic syndrome
DMK48PM ID DMK48PM
DMK48PM DN SY-1365
DMK48PM HS Phase 1
DMK48PM SN QYQWRTVXDYKLRC-BLLGGJCASA-N; SCHEMBL17150548
DMK48PM CP Syros Pharmaceuticals Cambridge, MA
DMK48PM PC 118426108
DMK48PM MW 587.1
DMK48PM FM C31H35ClN8O2
DMK48PM IC InChI=1S/C31H35ClN8O2/c1-31(39-29(42)26-13-12-21(17-33-26)36-27(41)11-7-15-40(2)3)14-6-8-20(16-31)37-30-35-19-24(32)28(38-30)23-18-34-25-10-5-4-9-22(23)25/h4-5,7,9-13,17-20,34H,6,8,14-16H2,1-3H3,(H,36,41)(H,39,42)(H,35,37,38)/b11-7+/t20-,31+/m1/s1
DMK48PM CS C[C@@]1(CCC[C@H](C1)NC2=NC=C(C(=N2)C3=CNC4=CC=CC=C43)Cl)NC(=O)C5=NC=C(C=C5)NC(=O)/C=C/CN(C)C
DMK48PM IK SCJNYBYSTCRPAO-LXBQGUBHSA-N
DMK48PM IU N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-1-methylcyclohexyl]-5-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridine-2-carboxamide
DMK48PM CA CAS 1816989-16-8
DMK48PM DE Solid tumour/cancer
DMH8UF0 ID DMH8UF0
DMH8UF0 DN SY-1425
DMH8UF0 HS Phase 1
DMH8UF0 CP Syros Pharmaceuticals Cambridge, MA
DMH8UF0 DE Acute myeloid leukaemia; Myelodysplastic syndrome
DMNW3LH ID DMNW3LH
DMNW3LH DN SY-5609
DMNW3LH HS Phase 1
DMNW3LH CP Syros Pharmaceuticals
DMNW3LH DT Small molecular drug
DMNW3LH DE Solid tumour/cancer
DMVXLS5 ID DMVXLS5
DMVXLS5 DN Sym021
DMVXLS5 HS Phase 1
DMVXLS5 CP Symphogen Somerville, NJ
DMVXLS5 DT Monoclonal antibody
DMVXLS5 DE Solid tumour/cancer; Advanced malignancy; Lymphoma; Non-hodgkin lymphoma
DMCK2YR ID DMCK2YR
DMCK2YR DN Sym022
DMCK2YR HS Phase 1
DMCK2YR CP Symphogen
DMCK2YR DT Antibody
DMCK2YR DE Lymphoma; Solid tumour/cancer
DMV3L62 ID DMV3L62
DMV3L62 DN Sym023
DMV3L62 HS Phase 1
DMV3L62 CP Symphogen
DMV3L62 DT Antibody
DMV3L62 DE Lymphoma; Solid tumour/cancer
DM0EZ69 ID DM0EZ69
DM0EZ69 DN SYN004
DM0EZ69 HS Phase 1
DM0EZ69 CP Synermore Biologics Taipei, Taiwan
DM0EZ69 DE Solid tumour/cancer
DMX05W8 ID DMX05W8
DMX05W8 DN SYN-1001
DMX05W8 HS Phase 1
DMX05W8 CP Synta Pharma
DMX05W8 DE Pain
DM4UVTO ID DM4UVTO
DM4UVTO DN SYN125
DM4UVTO HS Phase 1
DM4UVTO CP Symphogen
DM4UVTO DT Antibody
DM4UVTO DE Solid tumour/cancer; Uterine serous carcinoma
DMZJNHM ID DMZJNHM
DMZJNHM DN SYNB1891
DMZJNHM HS Phase 1
DMZJNHM CP Symphogen
DMZJNHM DE Lymphoma; Neoplasm
DM83E5B ID DM83E5B
DM83E5B DN Synthetic neutrophil inhibitor peptide
DM83E5B HS Phase 1
DM83E5B SN SNIP; Nalpha-Acetyl-L-arginyl-L-glutamyl-glycyl-L-seryl-L-tyrosyl-L-phenylalanyl-L-phenylalanyl-glycyl-L-aspartyl-L-asparaginyl-L-alaninamide
DM83E5B DT Small molecular drug
DM83E5B PC 71482
DM83E5B MW 324.68
DM83E5B FM C9H10ClN2O5PS
DM83E5B IC InChI=1S/C9H10ClN2O5PS/c1-15-18(14,16-2)19-5-12-8-7(17-9(12)13)3-6(10)4-11-8/h3-4H,5H2,1-2H3
DM83E5B CS COP(=O)(OC)SCN1C2=C(C=C(C=N2)Cl)OC1=O
DM83E5B IK VNKBTWQZTQIWDV-UHFFFAOYSA-N
DM83E5B IU 6-chloro-3-(dimethoxyphosphorylsulfanylmethyl)-[1,3]oxazolo[4,5-b]pyridin-2-one
DM83E5B CA CAS 35575-96-3
DM83E5B CB CHEBI:38578
DM83E5B DE Rhinitis
DMH76KD ID DMH76KD
DMH76KD DN Syntropin
DMH76KD HS Phase 1
DMH76KD SN Human growth hormone (subcutaneous, dwarfism), Phage Biotechnology
DMH76KD CP Phage Biotechnology Corp
DMH76KD DE Dwarfism
DMD23AX ID DMD23AX
DMD23AX DN Systebryl
DMD23AX HS Phase 1
DMD23AX SN PTI-19; PTI-51; Systemic AA amyloidosis therapy, ProteoTech
DMD23AX CP ProteoTech Inc
DMD23AX PC 10038269
DMD23AX MW 261.23
DMD23AX FM C13H11NO5
DMD23AX IC InChI=1S/C13H11NO5/c15-9-3-1-7(5-11(9)17)13(19)14-8-2-4-10(16)12(18)6-8/h1-6,15-18H,(H,14,19)
DMD23AX CS C1=CC(=C(C=C1C(=O)NC2=CC(=C(C=C2)O)O)O)O
DMD23AX IK XIKSEDLKDYKPTO-UHFFFAOYSA-N
DMD23AX IU N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide
DMD23AX CA CAS 633700-15-9
DMD23AX DE Amyloidosis
DMNE9Z0 ID DMNE9Z0
DMNE9Z0 DN T-0128
DMNE9Z0 HS Phase 1
DMNE9Z0 SN M salt; MEN-4901; Glycylglycyl-N-[3-[(4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yloxy]propyl]glycinamide compound with dextran carboxymethyl ether sodiu
DMNE9Z0 DT Small molecular drug
DMNE9Z0 PC 129631910
DMNE9Z0 MW 1716.3
DMNE9Z0 FM C87H170N6O26
DMNE9Z0 IC InChI=1S/C20H36O16.C11H11N.C7H15NO2.C7H12O3.C6H6O.C5H13N.C4H8N2O2.6C4H10.C3H7NO.H2O/c1-3-6-9(21)12(24)15(27)18(33-6)31-4-7-10(22)13(25)16(28)19(34-7)32-5-8-11(23)14(26)17(30-2)20(35-8)36-29;1-2-9-7-8-12-11-6-4-3-5-10(9)11;1-3-7(9)8-5-4-6-10-2;1-2-7(9)4-3-5-10-6(7)8;7-6-4-2-1-3-5-6;1-3-4-5-6-2;1-3(7)6-2-4(5)8;6*1-3-4-2;1-3(5)4-2;/h6-29H,3-5H2,1-2H3;3-8H,2H2,1H3;3-6H2,1-2H3,(H,8,9);9H,2-5H2,1H3;1-4H,5H2;6H,3-5H2,1-2H3;2H2,1H3,(H2,5,8)(H,6,7);6*3-4H2,1-2H3;1-2H3,(H,4,5);1H2/t6-,7?,8-,9-,10-,11-,12+,13+,14+,15-,16-,17-,18+,19+,20-;;;7-;;;;;;;;;;;/m1..0.........../s1
DMNE9Z0 CS CCCC.CCCC.CCCC.CCCC.CCCC.CCCC.CCCCNC.CC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OCC2[C@H]([C@@H]([C@H]([C@H](O2)OC[C@@H]3[C@H]([C@@H]([C@H]([C@H](O3)OO)OC)O)O)O)O)O)O)O)O.CCC1=CC=NC2=CC=CC=C12.CCC(=O)NCCCOC.CC[C@@]1(CCCOC1=O)O.CC(=O)NC.CC(=O)NCC(=O)N.C1C=CC=CC1=O.O
DMNE9Z0 IK HYSLQFLGTWXGPE-JCQKILSGSA-N
DMNE9Z0 IU 2-acetamidoacetamide;butane;cyclohexa-2,4-dien-1-one;(2R,3S,4S,5R,6S)-2-ethyl-6-[[(3S,4S,5R,6S)-6-[[(2R,3S,4S,5R,6R)-6-hydroperoxy-3,4-dihydroxy-5-methoxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]oxane-3,4,5-triol;(3S)-3-ethyl-3-hydroxyoxan-2-one;4-ethylquinoline;N-(3-methoxypropyl)propanamide;N-methylacetamide;N-methylbutan-1-amine;hydrate
DMNE9Z0 DE Solid tumour/cancer
DMV8IQW ID DMV8IQW
DMV8IQW DN Tafluposide
DMV8IQW HS Phase 1
DMV8IQW SN F-11782
DMV8IQW CP Pierre Fabre SA
DMV8IQW PC 9877073
DMV8IQW MW 1116.7
DMV8IQW FM C45H35F10O20P
DMV8IQW IC InChI=1S/C45H35F10O20P/c1-13-64-9-22-39(70-13)42(72-23(56)10-65-40-33(52)29(48)27(46)30(49)34(40)53)43(73-24(57)11-66-41-35(54)31(50)28(47)32(51)36(41)55)45(71-22)74-37-16-7-19-18(68-12-69-19)6-15(16)25(26-17(37)8-67-44(26)58)14-4-20(62-2)38(21(5-14)63-3)75-76(59,60)61/h4-7,13,17,22,25-26,37,39,42-43,45H,8-12H2,1-3H3,(H2,59,60,61)/t13-,17+,22-,25-,26+,37-,39-,42+,43-,45+/m1/s1
DMV8IQW CS C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OP(=O)(O)O)OC)OC(=O)COC8=C(C(=C(C(=C8F)F)F)F)F)OC(=O)COC9=C(C(=C(C(=C9F)F)F)F)F
DMV8IQW IK RTJVUHUGTUDWRK-CSLCKUBZSA-N
DMV8IQW IU [(2R,4aR,6R,7R,8S,8aR)-6-[[(5S,5aR,8aR,9R)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-8-yl] 2-(2,3,4,5,6-pentafluorophenoxy)acetate
DMV8IQW CA CAS 179067-42-6
DMV8IQW DE Solid tumour/cancer
DM6OKH4 ID DM6OKH4
DM6OKH4 DN TAK-020
DM6OKH4 HS Phase 1
DM6OKH4 CP Takeda Pharmaceuticals Deerfield, IL
DM6OKH4 DE Rheumatoid arthritis
DM0ZQ7J ID DM0ZQ7J
DM0ZQ7J DN TAK-041
DM0ZQ7J HS Phase 1
DM0ZQ7J CP Takeda Deerfield, IL
DM0ZQ7J DE XY disorder of sex development due to androgen resistance
DMX9EA0 ID DMX9EA0
DMX9EA0 DN TAK-058
DMX9EA0 HS Phase 1
DMX9EA0 DE Schizophrenia; XY disorder of sex development due to androgen resistance
DMKUT08 ID DMKUT08
DMKUT08 DN TAK-071
DMKUT08 HS Phase 1
DMKUT08 SN WFSARWQASFQZMG-FGZHOGPDSA-N; 1820812-16-5
DMKUT08 CP Takeda Pharmaceuticals Deerfield, IL
DMKUT08 PC 92042879
DMKUT08 MW 421.5
DMKUT08 FM C24H24FN3O3
DMKUT08 IC InChI=1S/C24H24FN3O3/c1-15-17(11-16-3-5-18(6-4-16)28-9-2-8-26-28)12-19-20(23(15)25)13-27(24(19)30)21-14-31-10-7-22(21)29/h2-6,8-9,12,21-22,29H,7,10-11,13-14H2,1H3/t21-,22-/m0/s1
DMKUT08 CS CC1=C(C2=C(C=C1CC3=CC=C(C=C3)N4C=CC=N4)C(=O)N(C2)[C@H]5COCC[C@@H]5O)F
DMKUT08 IK WFSARWQASFQZMG-VXKWHMMOSA-N
DMKUT08 IU 4-fluoro-2-[(3S,4S)-4-hydroxyoxan-3-yl]-5-methyl-6-[(4-pyrazol-1-ylphenyl)methyl]-3H-isoindol-1-one
DMKUT08 CA CAS 1820812-16-5
DMKUT08 DE Alzheimer disease
DMD79TX ID DMD79TX
DMD79TX DN TAK-102
DMD79TX HS Phase 1
DMD79TX CP Takeda
DMD79TX DT CAR T Cell Therapy
DMD79TX DE Solid tumour/cancer
DMTXE19 ID DMTXE19
DMTXE19 DN TAK-114
DMTXE19 HS Phase 1
DMTXE19 DE Ulcerative colitis
DMYG704 ID DMYG704
DMYG704 DN TAK-137
DMYG704 HS Phase 1
DMYG704 PC 56649286
DMYG704 MW 352.4
DMYG704 FM C19H16N2O3S
DMYG704 IC InChI=1S/C19H16N2O3S/c22-25(23)14-13-21-12-4-7-18(19(21)20-25)15-8-10-17(11-9-15)24-16-5-2-1-3-6-16/h1-12H,13-14H2
DMYG704 CS C1CS(=O)(=O)N=C2N1C=CC=C2C3=CC=C(C=C3)OC4=CC=CC=C4
DMYG704 IK VKKLOYOLCCDGLD-UHFFFAOYSA-N
DMYG704 IU 9-(4-phenoxyphenyl)-3,4-dihydropyrido[2,1-c][1,2,4]thiadiazine 2,2-dioxide
DMYG704 CA CAS 1358749-55-9
DMYG704 DE Psychiatric disorder
DMRINBJ ID DMRINBJ
DMRINBJ DN TAK-169
DMRINBJ HS Phase 1
DMRINBJ CP Molecular Templates
DMRINBJ DT Recombinant protein
DMRINBJ DE Multiple myeloma
DMVYEFZ ID DMVYEFZ
DMVYEFZ DN TAK-202
DMVYEFZ HS Phase 1
DMVYEFZ CP Takeda Oncology Deerfield, IL
DMVYEFZ DE Melanoma; Solid tumour/cancer
DMW10HM ID DMW10HM
DMW10HM DN Tak-220
DMW10HM HS Phase 1
DMW10HM SN AIDS228341; TAK220; TBR220; TBR-220; 1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
DMW10HM CP Takeda
DMW10HM DT Small molecular drug
DMW10HM PC 5275766
DMW10HM MW 553.1
DMW10HM FM C31H41ClN4O3
DMW10HM IC InChI=1S/C31H41ClN4O3/c1-22-4-9-28(21-29(22)32)36(31(39)27-12-18-35(19-13-27)23(2)37)15-3-14-34-16-10-25(11-17-34)20-24-5-7-26(8-6-24)30(33)38/h4-9,21,25,27H,3,10-20H2,1-2H3,(H2,33,38)
DMW10HM CS CC1=C(C=C(C=C1)N(CCCN2CCC(CC2)CC3=CC=C(C=C3)C(=O)N)C(=O)C4CCN(CC4)C(=O)C)Cl
DMW10HM IK ASSJTMUEFHUKMJ-UHFFFAOYSA-N
DMW10HM IU 1-acetyl-N-[3-[4-[(4-carbamoylphenyl)methyl]piperidin-1-yl]propyl]-N-(3-chloro-4-methylphenyl)piperidine-4-carboxamide
DMW10HM CA CAS 333994-00-6
DMW10HM DE Human immunodeficiency virus-1 infection
DM4GKV2 ID DM4GKV2
DM4GKV2 DN TAK-243
DM4GKV2 HS Phase 1
DM4GKV2 SN Tak-243; V9GGV0YCDI; UNII-V9GGV0YCDI; Uae inhibitor MLN7243; SCHEMBL15191794; KJDAGXLMHXUAGV-DGWLBADLSA-N; Sulfamic acid, ((1R,2R,3S,4R)-2,3-dihydroxy-4-((2-(3-((trifluoromethyl)thio)phenyl)pyrazolo(1,5-a)pyrimidin-7-yl)amino)cyclopentyl)methyl ester; ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio)phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate; ((1R,2R,3S,4R)-2,3-Dihydroxy-4-((2-(3-(trifluoromethylsulfanyl)phenyl)pyrazolo(1,5-a)pyrimidin-7-yl)amino)cyclopentyl)methyl sulfamate
DM4GKV2 CP Takeda Oncology Deerfield, IL
DM4GKV2 PC 71715374
DM4GKV2 MW 519.5
DM4GKV2 FM C19H20F3N5O5S2
DM4GKV2 IC InChI=1S/C19H20F3N5O5S2/c20-19(21,22)33-12-3-1-2-10(6-12)13-8-16-24-5-4-15(27(16)26-13)25-14-7-11(17(28)18(14)29)9-32-34(23,30)31/h1-6,8,11,14,17-18,25,28-29H,7,9H2,(H2,23,30,31)/t11-,14-,17-,18+/m1/s1
DM4GKV2 CS C1[C@@H]([C@H]([C@H]([C@@H]1NC2=CC=NC3=CC(=NN23)C4=CC(=CC=C4)SC(F)(F)F)O)O)COS(=O)(=O)N
DM4GKV2 IK KJDAGXLMHXUAGV-DGWLBADLSA-N
DM4GKV2 IU [(1R,2R,3S,4R)-2,3-dihydroxy-4-[[2-[3-(trifluoromethylsulfanyl)phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl sulfamate
DM4GKV2 CA CAS 1450833-55-2
DM4GKV2 DE Solid tumour/cancer
DM1AKNI ID DM1AKNI
DM1AKNI DN TAK-252
DM1AKNI HS Phase 1
DM1AKNI SN SL-279252
DM1AKNI CP Takeda
DM1AKNI DT Recombinant protein
DM1AKNI DE Solid tumour/cancer
DM6KOBZ ID DM6KOBZ
DM6KOBZ DN TAK-285
DM6KOBZ HS Phase 1
DM6KOBZ SN TAK-285; 871026-44-7; TAK 285; TAK285; UNII-70CCB438L6; N-(2-(4-(3-CHLORO-4-(3-(TRIFLUOROMETHYL)PHENOXY)PHENYLAMINO)-5H-PYRROLO[3,2-D]PYRIMIDIN-5-YL)ETHYL)-3-HYDROXY-3-METHYLBUTANAMIDE; CHEMBL1614725; 70CCB438L6; N-{2-[4-({3-Chloro-4-[3-(Trifluoromethyl)phenoxy]phenyl}amino)-5h-Pyrrolo[3,2-D]pyrimidin-5-Yl]ethyl}-3-Hydroxy-3-Methylbutanamide; n-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5h-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide; C26H25ClF3N5O3
DM6KOBZ DT Small molecular drug
DM6KOBZ PC 11620908
DM6KOBZ MW 548
DM6KOBZ FM C26H25ClF3N5O3
DM6KOBZ IC InChI=1S/C26H25ClF3N5O3/c1-25(2,37)14-22(36)31-9-11-35-10-8-20-23(35)24(33-15-32-20)34-17-6-7-21(19(27)13-17)38-18-5-3-4-16(12-18)26(28,29)30/h3-8,10,12-13,15,37H,9,11,14H2,1-2H3,(H,31,36)(H,32,33,34)
DM6KOBZ CS CC(C)(CC(=O)NCCN1C=CC2=C1C(=NC=N2)NC3=CC(=C(C=C3)OC4=CC=CC(=C4)C(F)(F)F)Cl)O
DM6KOBZ IK ZYQXEVJIFYIBHZ-UHFFFAOYSA-N
DM6KOBZ IU N-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide
DM6KOBZ CA CAS 871026-44-7
DM6KOBZ DE Solid tumour/cancer
DMMWNQP ID DMMWNQP
DMMWNQP DN TAK-329
DMMWNQP HS Phase 1
DMMWNQP CP Takeda Pharmaceuticals U.S.A.
DMMWNQP DE Diabetic complication
DM7DFBL ID DM7DFBL
DM7DFBL DN TAK-441
DM7DFBL HS Phase 1
DM7DFBL SN TAK-441; 1186231-83-3; CHEMBL2205230; TAK 441; SCHEMBL1061476; GTPL8200; BCP20946; ZINC43207688; BDBM50401323; LM2094; SB18887; KB-80790; Z-3185; 6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide
DM7DFBL CP Millennium Pharmaceuticals
DM7DFBL DT Small molecular drug
DM7DFBL PC 44187367
DM7DFBL MW 576.6
DM7DFBL FM C28H31F3N4O6
DM7DFBL IC InChI=1S/C28H31F3N4O6/c1-3-19-13-20-23(27(40)35(19)14-21(37)17-7-5-4-6-8-17)25(41-16-28(29,30)31)24(33(20)2)26(39)32-18-9-11-34(12-10-18)22(38)15-36/h4-8,13,18,36H,3,9-12,14-16H2,1-2H3,(H,32,39)
DM7DFBL CS CCC1=CC2=C(C(=C(N2C)C(=O)NC3CCN(CC3)C(=O)CO)OCC(F)(F)F)C(=O)N1CC(=O)C4=CC=CC=C4
DM7DFBL IK ZADWXQMNNVICKB-UHFFFAOYSA-N
DM7DFBL IU 6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide
DM7DFBL CA CAS 1186231-83-3
DM7DFBL DE Solid tumour/cancer
DMUXAP1 ID DMUXAP1
DMUXAP1 DN TAK-573
DMUXAP1 HS Phase 1
DMUXAP1 CP Takeda
DMUXAP1 DT Recombinant protein
DMUXAP1 DE Refractory multiple myeloma; Multiple myeloma
DMNFZOT ID DMNFZOT
DMNFZOT DN TAK-593
DMNFZOT HS Phase 1
DMNFZOT SN TAK-593; 1005780-62-0; UNII-H3I42X8XX7; H3I42X8XX7; CHEMBL2180604; 1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-;1H-Pyrazole-5-carboxamide, N-[5-[[2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl]oxy]-2-methylphenyl]-1,3-dimethyl-; TAK 593; SCHEMBL2515478; DZFZXPPHBWCXPQ-UHFFFAOYSA-N; ZINC95579919; BDBM50399537; AKOS030526192; CS-2403; DB13093; NCGC00485933-01; 1H-Pyrazole-5-carboxamide, N-(5-((2-((cyclopropylcarbonyl)amino)imidazo
DMNFZOT DT Small molecular drug
DMNFZOT PC 24767976
DMNFZOT MW 445.5
DMNFZOT FM C23H23N7O3
DMNFZOT IC InChI=1S/C23H23N7O3/c1-13-4-7-16(11-17(13)24-23(32)18-10-14(2)27-29(18)3)33-21-9-8-20-25-19(12-30(20)28-21)26-22(31)15-5-6-15/h4,7-12,15H,5-6H2,1-3H3,(H,24,32)(H,26,31)
DMNFZOT CS CC1=C(C=C(C=C1)OC2=NN3C=C(N=C3C=C2)NC(=O)C4CC4)NC(=O)C5=CC(=NN5C)C
DMNFZOT IK DZFZXPPHBWCXPQ-UHFFFAOYSA-N
DMNFZOT IU N-[5-[2-(cyclopropanecarbonylamino)imidazo[1,2-b]pyridazin-6-yl]oxy-2-methylphenyl]-2,5-dimethylpyrazole-3-carboxamide
DMNFZOT CA CAS 1005780-62-0
DMNFZOT DE Solid tumour/cancer
DMQ8YKR ID DMQ8YKR
DMQ8YKR DN TAK-648
DMQ8YKR HS Phase 1
DMQ8YKR CP Takeda
DMQ8YKR DE Type 2 diabetes
DMCKF5J ID DMCKF5J
DMCKF5J DN TAK-676
DMCKF5J HS Phase 1
DMCKF5J CP Takeda
DMCKF5J DE Solid tumour/cancer
DML3M0O ID DML3M0O
DML3M0O DN TAK-701
DML3M0O HS Phase 1
DML3M0O SN SCHEMBL131582
DML3M0O CP Takeda
DML3M0O DT Small molecular drug
DML3M0O PC 16760691
DML3M0O MW 380.5
DML3M0O FM C18H16N6S2
DML3M0O IC InChI=1S/C18H16N6S2/c1-24-16(18(23)26-15-9-5-3-7-13(15)21)11(10-19)17(22)25-14-8-4-2-6-12(14)20/h2-9H,20-23H2/b17-11+,18-16-
DML3M0O CS [C-]#[N+]/C(=C(/N)\\SC1=CC=CC=C1N)/C(=C(\\N)/SC2=CC=CC=C2N)/C#N
DML3M0O IK OSXOBXXOVNWNOP-UNEKJRSWSA-N
DML3M0O IU (Z,2Z)-4-amino-2-[amino-(2-aminophenyl)sulfanylmethylidene]-4-(2-aminophenyl)sulfanyl-3-isocyanobut-3-enenitrile
DML3M0O DE Advanced malignancy
DMC4RNA ID DMC4RNA
DMC4RNA DN TAK-733
DMC4RNA HS Phase 1
DMC4RNA SN TAK-733; 1035555-63-5; TAK733; TAK 733; UNII-5J61HSP0QJ; (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione; 5J61HSP0QJ; CHEMBL1615025; 3-[(2r)-2,3-Dihydroxypropyl]-6-Fluoro-5-[(2-Fluoro-4-Iodophenyl)amino]-8-Methylpyrido[2,3-D]pyrimidine-4,7(3h,8h)-Dione; MLS006011054; SCHEMBL1528606; GTPL9911; DTXSID20648089; MolPort-023-293-497; RCLQNICOARASSR-SECBINFHSA-N; example 18 [US8470837]; AOB87182; EX-A2164; BCP06625
DMC4RNA CP Millennium Pharmaceuticals
DMC4RNA DT Small molecular drug
DMC4RNA PC 24963252
DMC4RNA MW 504.23
DMC4RNA FM C17H15F2IN4O4
DMC4RNA IC InChI=1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1
DMC4RNA CS CN1C2=C(C(=C(C1=O)F)NC3=C(C=C(C=C3)I)F)C(=O)N(C=N2)C[C@H](CO)O
DMC4RNA IK RCLQNICOARASSR-SECBINFHSA-N
DMC4RNA IU 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione
DMC4RNA CA CAS 1035555-63-5
DMC4RNA DE Solid tumour/cancer
DMW43DL ID DMW43DL
DMW43DL DN TAK-828
DMW43DL HS Phase 1
DMW43DL SN ICMFYVOUDGRBLG-NJMNTPMDSA-N; TAK828F; GTPL9867; TAK-828F; SCHEMBL17390967; SCHEMBL17390969; SCHEMBL17391123; ICMFYVOUDGRBLG-VFHHBZAHSA-N; ICMFYVOUDGRBLG-XVNUGVHUSA-N; compound 10 [PMID: 29510038]; E3V; {cis-3-[(5R)-5-[(7-fluoro-1,1-dimethyl-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridine-6(5H)-carbonyl]cyclobutyl}acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7,8-dihydro-1,6-naphthyridin-6 (5H)-yl)carbonyl)cyclobutyl)acetic acid; (cis-3-(((5R)-5-((7-fluoro-1,1-dimethyl-2
DMW43DL CP Takeda Pharmaceuticals Deerfield, IL
DMW43DL PC 118622692
DMW43DL MW 509.6
DMW43DL FM C28H32FN3O5
DMW43DL IC InChI=1S/C28H32FN3O5/c1-28(2)8-6-16-13-18(14-20(29)24(16)28)30-26(35)25-19-4-5-22(37-3)31-21(19)7-9-32(25)27(36)17-10-15(11-17)12-23(33)34/h4-5,13-15,17,25H,6-12H2,1-3H3,(H,30,35)(H,33,34)/t15?,17?,25-/m1/s1
DMW43DL CS CC1(CCC2=C1C(=CC(=C2)NC(=O)[C@H]3C4=C(CCN3C(=O)C5CC(C5)CC(=O)O)N=C(C=C4)OC)F)C
DMW43DL IK ICMFYVOUDGRBLG-NJMNTPMDSA-N
DMW43DL IU 2-[3-[(5R)-5-[(7-fluoro-1,1-dimethyl-2,3-dihydroinden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl]cyclobutyl]acetic acid
DMW43DL DE Crohn disease
DM5KDGI ID DM5KDGI
DM5KDGI DN TAK-901
DM5KDGI HS Phase 1
DM5KDGI SN TAK-901; 934541-31-8; TAK901; TAK 901; UNII-DM9UIR23R7; 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; DM9UIR23R7; 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide; C28H32N4O3S; 5-[3-(ethanesulfonyl)phenyl]-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; cc-11; MLS006010174
DM5KDGI CP Takeda
DM5KDGI DT Small molecular drug
DM5KDGI PC 16124208
DM5KDGI MW 504.6
DM5KDGI FM C28H32N4O3S
DM5KDGI IC InChI=1S/C28H32N4O3S/c1-5-36(34,35)21-8-6-7-19(14-21)23-15-22(28(33)30-20-9-11-32(4)12-10-20)18(3)26-25(23)24-13-17(2)16-29-27(24)31-26/h6-8,13-16,20H,5,9-12H2,1-4H3,(H,29,31)(H,30,33)
DM5KDGI CS CCS(=O)(=O)C1=CC=CC(=C1)C2=CC(=C(C3=C2C4=C(N3)N=CC(=C4)C)C)C(=O)NC5CCN(CC5)C
DM5KDGI IK WKDACQVEJIVHMZ-UHFFFAOYSA-N
DM5KDGI IU 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide
DM5KDGI CA CAS 934541-31-8
DM5KDGI DE Haematological malignancy
DM1ALY9 ID DM1ALY9
DM1ALY9 DN TAK-931
DM1ALY9 HS Phase 1
DM1ALY9 SN XGVXKJKTISMIOW-ZDUSSCGKSA-N; UNII-LST350G3XU; LST350G3XU; 1330782-76-7; SCHEMBL19410618; SCHEMBL12459022; EX-A2702; HY-100888; CS-0020550; Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-; 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 (3H)-one
DM1ALY9 CP Takeda Oncology Deerfield, IL
DM1ALY9 PC 135564531
DM1ALY9 MW 341.4
DM1ALY9 FM C17H19N5OS
DM1ALY9 IC InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1
DM1ALY9 CS CC1=C(C=NN1)C2=CC3=C(S2)C(=O)NC(=N3)[C@@H]4CC5CCN4CC5
DM1ALY9 IK XGVXKJKTISMIOW-ZDUSSCGKSA-N
DM1ALY9 IU 2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one
DM1ALY9 CA CAS 1330782-76-7
DM1ALY9 DE Solid tumour/cancer
DMN4OGH ID DMN4OGH
DMN4OGH DN TAK-960
DMN4OGH HS Phase 1
DMN4OGH SN TAK-960; 1137868-52-0; TAK960; TAK 960; CHEMBL2392545; AK172385; benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-; 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide
DMN4OGH CP Millennium Pharmaceuticals
DMN4OGH DT Small molecular drug
DMN4OGH PC 53357478
DMN4OGH MW 561.6
DMN4OGH FM C27H34F3N7O3
DMN4OGH IC InChI=1S/C27H34F3N7O3/c1-35-10-8-16(9-11-35)32-24(38)18-12-22(40-3)20(13-19(18)28)33-26-31-14-21-23(34-26)37(17-6-4-5-7-17)15-27(29,30)25(39)36(21)2/h12-14,16-17H,4-11,15H2,1-3H3,(H,32,38)(H,31,33,34)
DMN4OGH CS CN1CCC(CC1)NC(=O)C2=CC(=C(C=C2F)NC3=NC=C4C(=N3)N(CC(C(=O)N4C)(F)F)C5CCCC5)OC
DMN4OGH IK GWRSATNRNFYMDI-UHFFFAOYSA-N
DMN4OGH IU 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-N-(1-methylpiperidin-4-yl)benzamide
DMN4OGH DE Solid tumour/cancer
DMSQZEP ID DMSQZEP
DMSQZEP DN TAR-200
DMSQZEP HS Phase 1
DMSQZEP CP TARIS Biomedical Lexington, MA
DMSQZEP DE Bladder cancer
DM5WDKY ID DM5WDKY
DM5WDKY DN TAS-103
DM5WDKY HS Phase 1
DM5WDKY DT Small molecular drug
DM5WDKY PC 135413533
DM5WDKY MW 333.4
DM5WDKY FM C20H19N3O2
DM5WDKY IC InChI=1S/C20H19N3O2/c1-23(2)10-9-21-20-18-17(13-5-3-4-6-14(13)19(18)25)15-8-7-12(24)11-16(15)22-20/h3-8,11,24H,9-10H2,1-2H3,(H,21,22)
DM5WDKY CS CN(C)CCNC1=NC2=C(C=CC(=C2)O)C3=C1C(=O)C4=CC=CC=C43
DM5WDKY IK ROWSTIYZUWEOMM-UHFFFAOYSA-N
DM5WDKY IU 6-[2-(dimethylamino)ethylamino]-3-hydroxyindeno[2,1-c]quinolin-7-one
DM5WDKY CA CAS 174634-08-3
DM5WDKY DE Solid tumour/cancer
DMRX530 ID DMRX530
DMRX530 DN TAS-116
DMRX530 HS Phase 1
DMRX530 SN Tas-116; 1260533-36-5; UNII-PLO044MUDZ; PLO044MUDZ; SCHEMBL2694525; CHEMBL3661115; BDBM126083; ZINC169703510; KB-334563; US8779142, 102; Benzamide, 3-ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)-; 3-ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide; 3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide
DMRX530 CP Taiho Oncology Princeton, NJ
DMRX530 PC 67501411
DMRX530 MW 454.5
DMRX530 FM C25H26N8O
DMRX530 IC InChI=1S/C25H26N8O/c1-5-16-10-17(24(26)34)6-7-20(16)33-25-22(23(30-33)15(2)3)21(8-9-27-25)32-13-19(28-14-32)18-11-29-31(4)12-18/h6-15H,5H2,1-4H3,(H2,26,34)
DMRX530 CS CCC1=C(C=CC(=C1)C(=O)N)N2C3=NC=CC(=C3C(=N2)C(C)C)N4C=C(N=C4)C5=CN(N=C5)C
DMRX530 IK NVVPMZUGELHVMH-UHFFFAOYSA-N
DMRX530 IU 3-ethyl-4-[4-[4-(1-methylpyrazol-4-yl)imidazol-1-yl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-1-yl]benzamide
DMRX530 CA CAS 1260533-36-5
DMRX530 DE Solid tumour/cancer
DMJXBVP ID DMJXBVP
DMJXBVP DN TAS-119
DMJXBVP HS Phase 1
DMJXBVP CP Taiho oncology
DMJXBVP DE Solid tumour/cancer
DMHIA7Y ID DMHIA7Y
DMHIA7Y DN TAS-1440
DMHIA7Y HS Phase 1
DMHIA7Y CP Taiho Oncology; Astex Pharmaceuticals
DMHIA7Y DT Small molecular drug
DMHIA7Y DE Acute myeloid leukaemia
DMFG6ML ID DMFG6ML
DMFG6ML DN TAS3681
DMFG6ML HS Phase 1
DMFG6ML CP Taiho Oncology Princeton, NJ
DMFG6ML DE Prostate cancer
DMKW4AJ ID DMKW4AJ
DMKW4AJ DN Tasidotin hydrochloride
DMKW4AJ HS Phase 1
DMKW4AJ SN Tasidotin HCl; BSF 223651; ILX 651; LU 223651; Tasidotin hydrochloride (USAN)
DMKW4AJ CP Genzyme
DMKW4AJ DT Small molecular drug
DMKW4AJ PC 11479259
DMKW4AJ MW 643.3
DMKW4AJ FM C32H59ClN6O5
DMKW4AJ IC InChI=1S/C32H58N6O5.ClH/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9;/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39);1H/t22-,23-,24-,25-,26-;/m0./s1
DMKW4AJ CS CC(C)[C@@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NC(C)(C)C)NC(=O)[C@H](C(C)C)N(C)C.Cl
DMKW4AJ IK OOKIODJYZSVHDO-QMYFOHRPSA-N
DMKW4AJ IU (2S)-N-tert-butyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride
DMKW4AJ CA CAS 623174-20-9
DMKW4AJ DE Solid tumour/cancer
DM9CDPO ID DM9CDPO
DM9CDPO DN TBC-M4
DM9CDPO HS Phase 1
DM9CDPO SN MVA-based HIV subtype C vaccine, IAVI; Modified vaccinia Ankara-based HIV subtype C vaccine, International AIDS Vaccine Initiative
DM9CDPO CP National Institute of Cholera and Enteric Diseases
DM9CDPO DT Vaccine
DM9CDPO DE Human immunodeficiency virus infection
DM4W92J ID DM4W92J
DM4W92J DN TC-2216
DM4W92J HS Phase 1
DM4W92J SN NNR Therapeutics; TC-5685; Nicotinic ACh modulators (schizophrenia), Targacept; Alpha-4 beta-2 neuronal nicotinic receptor (schizophrenia, depression), Targacept; Oral alpha-4/beta-2 neuronal nicotinic receptor stimulator (shizophrenia/depression), Targacept
DM4W92J CP Targacept
DM4W92J DT Small molecular drug
DM4W92J PC 10176607
DM4W92J MW 203.28
DM4W92J FM C12H17N3
DM4W92J IC InChI=1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2
DM4W92J CS C1CC2(CCN(C2)C3=CN=CC=C3)NC1
DM4W92J IK NXIPMBQVNTWEEX-UHFFFAOYSA-N
DM4W92J IU 7-pyridin-3-yl-1,7-diazaspiro[4.4]nonane
DM4W92J CA CAS 646055-67-6
DM4W92J DE Mood disorder
DMJEBK8 ID DMJEBK8
DMJEBK8 DN TCD-717
DMJEBK8 HS Phase 1
DMJEBK8 SN Choline kinase alpha inhibitor (iv, solid tumors), TCD Pharma
DMJEBK8 CP TCD Pharma
DMJEBK8 PC 11239949
DMJEBK8 MW 717.7
DMJEBK8 FM C46H38Cl2N4+2
DMJEBK8 IC InChI=1S/C46H38Cl2N4/c1-49(39-23-19-37(47)20-24-39)43-27-29-51(45-9-5-3-7-41(43)45)31-33-11-15-35(16-12-33)36-17-13-34(14-18-36)32-52-30-28-44(42-8-4-6-10-46(42)52)50(2)40-25-21-38(48)22-26-40/h3-30H,31-32H2,1-2H3/q+2
DMJEBK8 CS CN(C1=CC=C(C=C1)Cl)C2=CC=[N+](C3=CC=CC=C32)CC4=CC=C(C=C4)C5=CC=C(C=C5)C[N+]6=CC=C(C7=CC=CC=C76)N(C)C8=CC=C(C=C8)Cl
DMJEBK8 IK QGYGTMZEJNOHNU-UHFFFAOYSA-N
DMJEBK8 IU 1-[[4-[4-[[4-(4-chloro-N-methylanilino)quinolin-1-ium-1-yl]methyl]phenyl]phenyl]methyl]-N-(4-chlorophenyl)-N-methylquinolin-1-ium-4-amine
DMJEBK8 CA CAS 850993-73-6
DMJEBK8 DE Solid tumour/cancer
DMV0AH8 ID DMV0AH8
DMV0AH8 DN TCN-P
DMV0AH8 HS Phase 1
DMV0AH8 SN TRICIRIBINE PHOSPHATE; 61966-08-3; TCN-P; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594
DMV0AH8 CP Cahaba Pharmaceuticals
DMV0AH8 DT Small molecular drug
DMV0AH8 PC 43860
DMV0AH8 MW 400.28
DMV0AH8 FM C13H17N6O7P
DMV0AH8 IC InChI=1S/C13H17N6O7P/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(21)8(20)6(26-13)3-25-27(22,23)24/h2,4,6,8-9,13,20-21H,3H2,1H3,(H2,14,17)(H2,22,23,24)/t6-,8-,9-,13-/m1/s1
DMV0AH8 CS CN1C2=NC=NC3=C2C(=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)C(=N1)N
DMV0AH8 IK URLYINUFLXOMHP-HTVVRFAVSA-N
DMV0AH8 IU [(2R,3S,4R,5R)-5-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMV0AH8 CA CAS 61966-08-3
DMV0AH8 DE Acute myeloid leukaemia
DMO8L6T ID DMO8L6T
DMO8L6T DN TD-0714
DMO8L6T HS Phase 1
DMO8L6T CP Theravance Biopharma South San Francisco, CA
DMO8L6T DE Heart failure
DMJG7AY ID DMJG7AY
DMJG7AY DN TD-1473
DMJG7AY HS Phase 1
DMJG7AY CP Theravance Biopharma South San Francisco, CA
DMJG7AY DE Ulcerative colitis
DM58J7E ID DM58J7E
DM58J7E DN Tedalinab
DM58J7E HS Phase 1
DM58J7E SN Tedalinab; UNII-5R7X34Y6Q1; 916591-01-0; CHEMBL3234681; 5R7X34Y6Q1; Tedalinab [INN]; SCHEMBL1431320; ZINC72266313; GRC-10693; BDBM50005917; (4S,7R)-N-tert-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1H-4,7-methanoindazole-3-carboxamide; KB-80825; 4,7-Methano-1H-indazole-3-carboxamide, 1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-, (4S,7R)-
DM58J7E CP Glenmark Pharmaceuticals Ltd
DM58J7E DT Small molecular drug
DM58J7E PC 67029278
DM58J7E MW 345.4
DM58J7E FM C19H21F2N3O
DM58J7E IC InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
DM58J7E CS CC(C)(C)NC(=O)C1=NN(C2=C1[C@H]3CC[C@@H]2C3)C4=C(C=C(C=C4)F)F
DM58J7E IK NTPZXHMTJGOMCJ-WDEREUQCSA-N
DM58J7E IU (1R,7S)-N-tert-butyl-3-(2,4-difluorophenyl)-3,4-diazatricyclo[5.2.1.02,6]deca-2(6),4-diene-5-carboxamide
DM58J7E CA CAS 916591-01-0
DM58J7E DE Pain
DMV5LGJ ID DMV5LGJ
DMV5LGJ DN Tedatioxetine
DMV5LGJ HS Phase 1
DMV5LGJ SN TEDATIOXETINE; 508233-95-2; UNII-5H681S8O3S; Lu AA24530; 5H681S8O3S; Tedatioxetine [USAN:INN]; Tedatioxetine (USAN); 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine; SCHEMBL547653; Lu-AA24530; CHEMBL2104986; Lu-AA-24530; ZINC34003654; DB12641; SB16713; D10170; Piperidine, 4-(2-((4-methylphenyl)thio)phenyl)-
DMV5LGJ CP Lundbeck; Takeda Pharmaceuticals
DMV5LGJ DT Small molecular drug
DMV5LGJ PC 9878913
DMV5LGJ MW 283.4
DMV5LGJ FM C18H21NS
DMV5LGJ IC InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
DMV5LGJ CS CC1=CC=C(C=C1)SC2=CC=CC=C2C3CCNCC3
DMV5LGJ IK CVASBKDYSQKLSO-UHFFFAOYSA-N
DMV5LGJ IU 4-[2-(4-methylphenyl)sulfanylphenyl]piperidine
DMV5LGJ CA CAS 508233-95-2
DMV5LGJ DE Major depressive disorder; Generalized anxiety disorder
DMZG9U0 ID DMZG9U0
DMZG9U0 DN TeloB-Vax
DMZG9U0 HS Phase 1
DMZG9U0 CP Adamis Pharmaceuticals
DMZG9U0 DE Prostate cancer
DM7Q4EX ID DM7Q4EX
DM7Q4EX DN Temanogrel
DM7Q4EX HS Phase 1
DM7Q4EX SN Temanogrel hydrochloride; APD-791; 5-HT 2a inverse agonist (arterial thrombosis), Arena Pharmaceutical
DM7Q4EX CP Arena Pharmaceuticals; Arena Pharmaceuticals Inc
DM7Q4EX DT Small molecular drug
DM7Q4EX PC 11604525
DM7Q4EX MW 436.5
DM7Q4EX FM C24H28N4O4
DM7Q4EX IC InChI=1S/C24H28N4O4/c1-27-22(8-9-25-27)21-17-19(26-24(29)18-4-3-5-20(16-18)30-2)6-7-23(21)32-15-12-28-10-13-31-14-11-28/h3-9,16-17H,10-15H2,1-2H3,(H,26,29)
DM7Q4EX CS CN1C(=CC=N1)C2=C(C=CC(=C2)NC(=O)C3=CC(=CC=C3)OC)OCCN4CCOCC4
DM7Q4EX IK ZEOQUKRCASTCFR-UHFFFAOYSA-N
DM7Q4EX IU 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-ylethoxy)phenyl]benzamide
DM7Q4EX CA CAS 887936-68-7
DM7Q4EX DE Cardiovascular disease
DM4UOY5 ID DM4UOY5
DM4UOY5 DN TEN010
DM4UOY5 HS Phase 1
DM4UOY5 CP Tensha Therapeutics
DM4UOY5 DE Advanced solid tumour; Solid tumour/cancer
DMGJCDR ID DMGJCDR
DMGJCDR DN Teneligliptin
DMGJCDR HS Phase 1
DMGJCDR SN Teneligliptin; 760937-92-6; UNII-28ZHI4CF9C; Teneligliptin [INN]; 28ZHI4CF9C; Teneligliptin hydrobromide; CHEMBL2147777; MP-513; Teneligliptin (INN); [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone; C22H30N6OS; {(2s,4s)-4-[4-(3-Methyl-1-Phenyl-1h-Pyrazol-5-Yl)piperazin-1-Yl]pyrrolidin-2-Yl}(1,3-Thiazolidin-3-Yl)methanone; 906093-29-6; Teneli; SCHEMBL161778; GTPL9906; WGRQANOPCQRCME-PMACEKPBSA-N; CHEBI:136042; MolPort-039-139-824; MP513; ZINC36520254; BDBM50391565
DMGJCDR CP Mitsubishi Pharma America
DMGJCDR DT Small molecular drug
DMGJCDR PC 11949652
DMGJCDR MW 426.6
DMGJCDR FM C22H30N6OS
DMGJCDR IC InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
DMGJCDR CS CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5
DMGJCDR IK WGRQANOPCQRCME-PMACEKPBSA-N
DMGJCDR IU [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
DMGJCDR CA CAS 760937-92-6
DMGJCDR CB CHEBI:136042
DMGJCDR DE Type-2 diabetes
DMC84Y9 ID DMC84Y9
DMC84Y9 DN Tepoditamab
DMC84Y9 HS Phase 1
DMC84Y9 SN MCLA-117
DMC84Y9 DT Antibody
DMC84Y9 DE Acute myelogenous leukaemia
DM3DUHL ID DM3DUHL
DM3DUHL DN TESTOSTERONE BUCICLATE
DM3DUHL HS Phase 1
DM3DUHL SN CDB-1781; Testosterone buciclate; Testosterone trans-4-n-butylcyclohexylcarboxylate; [17beta(trans)]-(4-Butylcyclohexylcarbonyloxy)androst-4-en-3-one; 20 Aet-1
DM3DUHL DT Small molecular drug
DM3DUHL PC 114819
DM3DUHL MW 454.7
DM3DUHL FM C30H46O3
DM3DUHL IC InChI=1S/C30H46O3/c1-4-5-6-20-7-9-21(10-8-20)28(32)33-27-14-13-25-24-12-11-22-19-23(31)15-17-29(22,2)26(24)16-18-30(25,27)3/h19-21,24-27H,4-18H2,1-3H3/t20?,21?,24-,25-,26-,27-,29-,30-/m0/s1
DM3DUHL CS CCCCC1CCC(CC1)C(=O)O[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C
DM3DUHL IK ODZDZTOROXGJAV-IRWJKHRASA-N
DM3DUHL IU [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate
DM3DUHL CA CAS 105165-22-8
DM3DUHL DE Contraception
DMAOJBX ID DMAOJBX
DMAOJBX DN Tetrandrine
DMAOJBX HS Phase 1
DMAOJBX SN Tetrandrine, Millenia Hope; Tetrandrine, West Virginia University; Tranex-18
DMAOJBX CP West Virginia University
DMAOJBX DT Small molecular drug
DMAOJBX PC 73078
DMAOJBX MW 622.7
DMAOJBX FM C38H42N2O6
DMAOJBX IC InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30-/m0/s1
DMAOJBX CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC
DMAOJBX IK WVTKBKWTSCPRNU-KYJUHHDHSA-N
DMAOJBX IU (1S,14S)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
DMAOJBX CA CAS 518-34-3
DMAOJBX CB CHEBI:49
DMAOJBX DE Colorectal cancer; Sarcoma
DMNDHKL ID DMNDHKL
DMNDHKL DN TG-1701
DMNDHKL HS Phase 1
DMNDHKL CP TG Therapeutics
DMNDHKL DT Small molecular drug
DMNDHKL DE Non-hodgkin lymphoma; Chronic lymphocytic leukaemia
DM3K4FY ID DM3K4FY
DM3K4FY DN TG-1801
DM3K4FY HS Phase 1
DM3K4FY SN NI-1701
DM3K4FY CP TG Therapeutics
DM3K4FY DT Antibody
DM3K4FY DE B-cell lymphoma
DMWBQ2Z ID DMWBQ2Z
DMWBQ2Z DN TGF-BR2 mab
DMWBQ2Z HS Phase 1
DMWBQ2Z CP Lilly
DMWBQ2Z DT Antibody
DMWBQ2Z DE Solid tumour/cancer
DMC1HRA ID DMC1HRA
DMC1HRA DN Thiarabine
DMC1HRA HS Phase 1
DMC1HRA SN THIARABINE; 26599-17-7; UNII-YCO2764D5Z; YCO2764D5Z; Thio-Cytarabine; 4'-Thioaracytidine; 4'-Thio-ara-C; T-araC; OSI 7836; 4'-Thio-1- beta-D-arabinofuranosylcytosine; cytidine, 4'-thio-arabino-; AC1L524F; SCHEMBL1955046; CHEMBL1631221; 4-Amino-1-(4-thio-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone; ZINC17378676; 2(1H)-Pyrimidinone, 4-amino-1-(4-thio-beta-D-arabinofuranosyl)-; SB18955; KB-81109; HY-16496; LS-193593; CS-0006364
DMC1HRA CP Access Pharmaceuticals
DMC1HRA DT Small molecular drug
DMC1HRA PC 168566
DMC1HRA MW 259.279
DMC1HRA FM C9H13N3O4S
DMC1HRA IC InChI=1S/C9H13N3O4S/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
DMC1HRA CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](S2)CO)O)O
DMC1HRA IK GAKJJSAXUFZQTL-CCXZUQQUSA-N
DMC1HRA IU 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]pyrimidin-2-one
DMC1HRA CA CAS 26599-17-7
DMC1HRA DE Solid tumour/cancer
DMOLFAU ID DMOLFAU
DMOLFAU DN Thiopilocarpine
DMOLFAU HS Phase 1
DMOLFAU SN ENS-163; SDZ ENA-163; SDZ-ENS-163
DMOLFAU CP Novartis AG
DMOLFAU DT Small molecular drug
DMOLFAU PC 189508
DMOLFAU MW 322.32
DMOLFAU FM C11H19N2O5PS
DMOLFAU IC InChI=1S/C11H16N2OS.H3O4P/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2;1-5(2,3)4/h5,7-8,10H,3-4,6H2,1-2H3;(H3,1,2,3,4)/t8-,10-;/m0./s1
DMOLFAU CS CC[C@H]1[C@H](CSC1=O)CC2=CN=CN2C.OP(=O)(O)O
DMOLFAU IK PSRPKRDUWXFVQS-GNAZCLTHSA-N
DMOLFAU IU (3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]thiolan-2-one;phosphoric acid
DMOLFAU CA CAS 117707-51-4
DMOLFAU DE Cognitive impairment
DMHRY8A ID DMHRY8A
DMHRY8A DN THR-687
DMHRY8A HS Phase 1
DMHRY8A CP Oxurion
DMHRY8A DT Small molecular drug
DMHRY8A DE Diabetic macular edema; Diabetic retinopathy
DMO8SGD ID DMO8SGD
DMO8SGD DN Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy
DMO8SGD HS Phase 1
DMO8SGD SN Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama
DMO8SGD CP University of Alabama at Birmingham
DMO8SGD DE Solid tumour/cancer
DMSVO92 ID DMSVO92
DMSVO92 DN Tigapotide
DMSVO92 HS Phase 1
DMSVO92 CP Kotinos Pharmaceuticals
DMSVO92 SQ PCK3145 (PSP-94 [31-45]) Sequence: PGDSTRKCMDLKGNK
DMSVO92 PC 16155604
DMSVO92 MW 2039.1
DMSVO92 FM C82H119N21O34S3
DMSVO92 IC InChI=1S/C82H119N21O34S3/c1-35(104)64(100-69(123)48(17-20-58(84)112)90-73(127)52(93-68(122)46(83)16-21-60(114)115)25-43-28-86-47-11-9-8-10-45(43)47)79(133)96-54(27-63(120)121)75(129)95-53(26-59(85)113)74(128)97-55(29-138-32-87-39(5)108)76(130)92-49(18-22-61(116)117)70(124)101-65(36(2)105)80(134)99-57(31-140-34-89-41(7)110)78(132)102-66(37(3)106)81(135)98-56(30-139-33-88-40(6)109)77(131)94-51(24-42-12-14-44(111)15-13-42)72(126)91-50(19-23-62(118)119)71(125)103-67(38(4)107)82(136)137/h8-15,28,35-38,46,48-57,64-67,86,104-107,111H,16-27,29-34,83H2,1-7H3,(H2,84,112)(H2,85,113)(H,87,108)(H,88,109)(H,89,110)(H,90,127)(H,91,126)(H,92,130)(H,93,122)(H,94,131)(H,95,129)(H,96,133)(H,97,128)(H,98,135)(H,99,134)(H,100,123)(H,101,124)(H,102,132)(H,103,125)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,136,137)/t35-,36-,37-,38-,46+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,64+,65+,66+,67+/m1/s1
DMSVO92 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSCNC(=O)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)O)N)O
DMSVO92 IK ZRXXHPDJLAQCPC-SFJRRRFZSA-N
DMSVO92 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S)-1-[[(2S,3R)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S,3R)-1-[[(2R)-3-(acetamidomethylsulfanyl)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-amino-1,4-dioxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-amino-1,5-dioxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-amino-5-oxopentanoic acid
DMSVO92 CA CAS 414903-37-0
DMSVO92 DE Prostate cancer
DMM3U2Q ID DMM3U2Q
DMM3U2Q DN TJ4309
DMM3U2Q HS Phase 1
DMM3U2Q SN TJ00439
DMM3U2Q CP I-MAB Biopharma; TRACON Pharmaceuticals
DMM3U2Q DT Antibody
DMM3U2Q DE Solid tumour/cancer
DMLUOVS ID DMLUOVS
DMLUOVS DN TJC4
DMLUOVS HS Phase 1
DMLUOVS SN TJ011133
DMLUOVS CP I-MAB Biopharma
DMLUOVS DT Antibody
DMLUOVS DE Lymphoma; Solid tumour/cancer
DMTGLOY ID DMTGLOY
DMTGLOY DN TK216
DMTGLOY HS Phase 1
DMTGLOY CP Oncternal Therapeutics San Diego, CA
DMTGLOY DE Ewing sarcoma
DMCFGD4 ID DMCFGD4
DMCFGD4 DN TM38837
DMCFGD4 HS Phase 1
DMCFGD4 SN TM-38837; compound 8; CHEMBL3341897; 1253641-65-4; TM38837; GTPL8705; SCHEMBL16127787; BCP24151; BDBM50044129; AKOS030525391; 1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-yl-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]pyrazole-3-carboxamide; 1-(2,4-Dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-1H-pyrazole-3-carboxamide
DMCFGD4 CP 7TM Pharma A/S
DMCFGD4 DT Small molecular drug
DMCFGD4 PC 49779607
DMCFGD4 MW 617.5
DMCFGD4 FM C30H25Cl2F3N4OS
DMCFGD4 IC InChI=1S/C30H25Cl2F3N4OS/c1-2-23-27(29(40)37-38-16-4-3-5-17-38)36-39(25-14-11-21(31)18-24(25)32)28(23)26-15-13-22(41-26)12-8-19-6-9-20(10-7-19)30(33,34)35/h6-7,9-11,13-15,18H,2-5,16-17H2,1H3,(H,37,40)
DMCFGD4 CS CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(S4)C#CC5=CC=C(C=C5)C(F)(F)F
DMCFGD4 IK VQOCBFYUDSBDCZ-UHFFFAOYSA-N
DMCFGD4 IU 1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-yl-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]pyrazole-3-carboxamide
DMCFGD4 DE Metabolic disorder; Obesity
DMH3E5C ID DMH3E5C
DMH3E5C DN TMB-365
DMH3E5C HS Phase 1
DMH3E5C CP TaiMed Biologics
DMH3E5C DT Antibody
DMH3E5C DE Human immunodeficiency virus-1 infection
DMYEALO ID DMYEALO
DMYEALO DN TMC-647055
DMYEALO HS Phase 1
DMYEALO SN TMC647055; 1204416-97-6; TMC-647055; UNII-11BD024G7J; TMC 647055; 11BD024G7J; 113-cyclohexyl-13-methoxy-5,11-dimethyl-17H-8-oxa-4-thia-3,5,11-triaza-1(10,6)-benzo[3,4]azepino[1,2-a]indolacyclododecaphane-2,12-dione 4,4-dioxide; TMC647055 Choline; SCHEMBL1239667; CHEMBL2043025; DTXSID90152860; BDBM243456; EX-A1252; AOB87185; BCP06459; ZINC84726167; AKOS030627003; SB16907; DB11822; NCGC00482982-02; DA-47229; BC600546; 2,19-Methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclodocosine-8,18(9H,15H)-dione, 27-cycl
DMYEALO CP Janssen research & development
DMYEALO DT Small molecular drug
DMYEALO PC 44556044
DMYEALO MW 606.7
DMYEALO FM C32H38N4O6S
DMYEALO IC InChI=1S/C32H38N4O6S/c1-34-13-15-42-16-14-35(2)43(39,40)33-31(37)22-9-11-27-28(19-22)36-20-24(32(34)38)17-23-18-25(41-3)10-12-26(23)30(36)29(27)21-7-5-4-6-8-21/h9-12,17-19,21H,4-8,13-16,20H2,1-3H3,(H,33,37)
DMYEALO CS CN1CCOCCN(S(=O)(=O)NC(=O)C2=CC3=C(C=C2)C(=C4N3CC(=CC5=C4C=CC(=C5)OC)C1=O)C6CCCCC6)C
DMYEALO IK UOBYJVFBFSLCTQ-UHFFFAOYSA-N
DMYEALO IU 28-cyclohexyl-22-methoxy-10,16-dimethyl-9,9-dioxo-13-oxa-9lambda6-thia-1,8,10,16-tetrazapentacyclo[16.8.1.12,6.13,26.020,25]nonacosa-2,4,6(29),18,20(25),21,23,26(28)-octaene-7,17-dione
DMYEALO CA CAS 1204416-97-6
DMYEALO DE Hepatitis C virus infection
DMAOV7M ID DMAOV7M
DMAOV7M DN TMC649128
DMAOV7M HS Phase 1
DMAOV7M CP Medivir; Tibotec
DMAOV7M PC 24769037
DMAOV7M MW 422.4
DMAOV7M FM C18H26N6O6
DMAOV7M IC InChI=1S/C18H26N6O6/c1-9(2)15(25)28-8-18(22-23-20)13(29-16(26)10(3)4)11(5)14(30-18)24-7-6-12(19)21-17(24)27/h6-7,9-11,13-14H,8H2,1-5H3,(H2,19,21,27)/t11-,13-,14+,18+/m0/s1
DMAOV7M CS C[C@H]1[C@@H]([C@](O[C@H]1N2C=CC(=NC2=O)N)(COC(=O)C(C)C)N=[N+]=[N-])OC(=O)C(C)C
DMAOV7M IK XJBILYMRFVHPJB-XJQUKVTJSA-N
DMAOV7M IU [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
DMAOV7M CA CAS 1019639-33-8
DMAOV7M DE Hepatitis C virus infection
DMAI0SH ID DMAI0SH
DMAI0SH DN TNB-383B
DMAI0SH HS Phase 1
DMAI0SH CP AbbVie
DMAI0SH DT Antibody
DMAI0SH DE Multiple myeloma
DMSRICG ID DMSRICG
DMSRICG DN TNB-486
DMSRICG HS Phase 1
DMSRICG CP Teneobio
DMSRICG DT Antibody
DMSRICG DE B-cell lymphoma
DMHD6PA ID DMHD6PA
DMHD6PA DN TnMUC-1 CAR-T cell therapy
DMHD6PA HS Phase 1
DMHD6PA CP Tmunity
DMHD6PA DT CAR T Cell Therapy
DMHD6PA DE Solid tumour/cancer
DMZ60X4 ID DMZ60X4
DMZ60X4 DN TNO155
DMZ60X4 HS Phase 1
DMZ60X4 CP Novartis Oncology East Hanover, NJ
DMZ60X4 DE Solid tumour/cancer
DMSKF29 ID DMSKF29
DMSKF29 DN TNT009
DMSKF29 HS Phase 1
DMSKF29 CP South San Francisco, CA
DMSKF29 DE Bullous pemphigoid; Cold type autoimmune haemolytic anemia
DMD0NA1 ID DMD0NA1
DMD0NA1 DN TP 6076
DMD0NA1 HS Phase 1
DMD0NA1 CP Tetraphase Pharmaceuticals
DMD0NA1 DT Small molecular drug
DMD0NA1 DE Multidrug resistant infection
DMJVZBC ID DMJVZBC
DMJVZBC DN TP-0184
DMJVZBC HS Phase 1
DMJVZBC SN Itacnosertib; UNII-22Z53X5LHF; 22Z53X5LHF; 1628870-27-8; methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine; N4-([2,2'-bipyridin]-3-yl)-N2-[3-methoxy-4-(4-; 2-N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-pyridin-2-ylpyridin-3-yl)pyrimidine-2,4-diamine; Itacnosertib [INN]; SCHEMBL16129103; GTPL10632; TP0184; example 11 [WO2014151871A9]; 2,4-Pyrimidinediamine, N4-(2,2'-bipyridin)-3-yl-N2-(3-methoxy-4-(4-methyl-1-piperazinyl)phenyl)-; N2-(3-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)-N4-(2-(pyridin-2-yl)pyridin-3-yl)pyrimidine-2,4-diamine
DMJVZBC CP Sumitomo Dainippon Pharma
DMJVZBC DT Small molecular drug
DMJVZBC PC 86290265
DMJVZBC MW 468.6
DMJVZBC FM C26H28N8O
DMJVZBC IC InChI=1S/C26H28N8O/c1-33-14-16-34(17-15-33)22-9-8-19(18-23(22)35-2)30-26-29-13-10-24(32-26)31-21-7-5-12-28-25(21)20-6-3-4-11-27-20/h3-13,18H,14-17H2,1-2H3,(H2,29,30,31,32)
DMJVZBC CS CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4=C(N=CC=C4)C5=CC=CC=N5)OC
DMJVZBC IK XSQKEVGTZSBVBR-UHFFFAOYSA-N
DMJVZBC IU 2-N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-pyridin-2-ylpyridin-3-yl)pyrimidine-2,4-diamine
DMJVZBC CA CAS 1628870-27-8
DMJVZBC DE Solid tumour/cancer
DM3Z07E ID DM3Z07E
DM3Z07E DN TP-1287
DM3Z07E HS Phase 1
DM3Z07E SN UNII-7MPP85IIJ3; 7MPP85IIJ3; CHEMBL4594423; SCHEMBL18251861; 2044686-42-0; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methyl-4-piperidinyl)-7-(phosphonooxy)-
DM3Z07E CP Sumitomo Dainippon Pharma
DM3Z07E DT Small molecular drug
DM3Z07E PC 124083048
DM3Z07E MW 481.8
DM3Z07E FM C21H21ClNO8P
DM3Z07E IC InChI=1S/C21H21ClNO8P/c1-23-7-6-12(16(26)10-23)19-18(31-32(27,28)29)9-15(25)20-14(24)8-17(30-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,16,25-26H,6-7,10H2,1H3,(H2,27,28,29)/t12-,16+/m0/s1
DM3Z07E CS CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)OP(=O)(O)O
DM3Z07E IK YRNFLVUMZIRYKY-BLLLJJGKSA-N
DM3Z07E IU [2-(2-chlorophenyl)-5-hydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4-oxochromen-7-yl] dihydrogen phosphate
DM3Z07E CA CAS 2044686-42-0
DM3Z07E DE Solid tumour/cancer
DMBTL2M ID DMBTL2M
DMBTL2M DN TP-1454
DMBTL2M HS Phase 1
DMBTL2M CP Sumitomo Dainippon Pharma
DMBTL2M DE Solid tumour/cancer
DM3PJSE ID DM3PJSE
DM3PJSE DN TP-271
DM3PJSE HS Phase 1
DM3PJSE SN UNII-Y6IUM7395Q; Y6IUM7395Q; 1207284-17-0; (S)-N-((5aR,6aS,7S,10aS)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-((5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-[(5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-1-methylpyrrolidine-2-carboxamide; CHEMBL2057236; SCHEMBL13397803; GTPL11013; TP271; DB15040
DM3PJSE CP Tetraphase Pharmaceuticals
DM3PJSE DT Small molecular drug
DM3PJSE PC 54726193
DM3PJSE MW 558.6
DM3PJSE FM C27H31FN4O8
DM3PJSE IC InChI=1S/C27H31FN4O8/c1-31(2)19-12-8-10-7-11-13(28)9-14(30-26(39)15-5-4-6-32(15)3)20(33)17(11)21(34)16(10)23(36)27(12,40)24(37)18(22(19)35)25(29)38/h9-10,12,15,19,33-34,37,40H,4-8H2,1-3H3,(H2,29,38)(H,30,39)/t10-,12-,15-,19-,27-/m0/s1
DM3PJSE CS CN1CCC[C@H]1C(=O)NC2=CC(=C3C[C@H]4C[C@H]5[C@@H](C(=O)C(=C([C@]5(C(=O)C4=C(C3=C2O)O)O)O)C(=O)N)N(C)C)F
DM3PJSE IK VIWUYPVRNWIKLS-HMFHYXQTSA-N
DM3PJSE IU (2S)-N-[(5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-1-methylpyrrolidine-2-carboxamide
DM3PJSE CA CAS 1207284-17-0
DM3PJSE DE Respiratory tract infection; Pneumonia
DMBQ6XY ID DMBQ6XY
DMBQ6XY DN TP-3654
DMBQ6XY HS Phase 1
DMBQ6XY SN 1361951-15-6; TP3654; UNII-EOB0N7BOY4; EOB0N7BOY4; SGI-9481; 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; SCHEMBL102560; CHEMBL3975308; SCHEMBL19986953; SCHEMBL20794171; SCHEMBL22421478; BDBM242374; BCP30070; EX-A1828; NSC805149; AKOS032960444; CS-6293; NSC-805149; SB17245; TP3654; TP 3654; BS-15262; HY-101126; AK00792306; S6774; US9416132, 8-31; 2-(4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; 4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol
DMBQ6XY CP Sumitomo Dainippon Pharma
DMBQ6XY DT Small molecular drug
DMBQ6XY PC 66598080
DMBQ6XY MW 418.5
DMBQ6XY FM C22H25F3N4O
DMBQ6XY IC InChI=1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)
DMBQ6XY CS CC(C)(C1CCC(CC1)NC2=NN3C(=NC=C3C4=CC(=CC=C4)C(F)(F)F)C=C2)O
DMBQ6XY IK XRNVABDYQLHODA-UHFFFAOYSA-N
DMBQ6XY IU 2-[4-[[3-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexyl]propan-2-ol
DMBQ6XY CA CAS 1361951-15-6
DMBQ6XY DE Solid tumour/cancer
DM5RIT8 ID DM5RIT8
DM5RIT8 DN TP-6076
DM5RIT8 HS Phase 1
DM5RIT8 CP Tetraphase Pharmaceuticals
DM5RIT8 DT Small interfering RNA
DM5RIT8 DE Enterobacteriaceae infection; Multidrug resistant infection
DMG4U32 ID DMG4U32
DMG4U32 DN TPST-1120
DMG4U32 HS Phase 1
DMG4U32 CP Tempest Therapeutics
DMG4U32 DE Solid tumour/cancer
DM3GSB2 ID DM3GSB2
DM3GSB2 DN TPST-1495
DM3GSB2 HS Phase 1
DM3GSB2 CP Tempest Therapeutics
DM3GSB2 DE Solid tumour/cancer
DMC2IJN ID DMC2IJN
DMC2IJN DN TPX-0022
DMC2IJN HS Phase 1
DMC2IJN SN CSF1R-IN-2; SCHEMBL20694441; TPX0022; NSC820832; NSC-820832; HY-111787; CS-0091874; 2271119-26-5
DMC2IJN CP Turning Point Therapeutics
DMC2IJN DT Small molecular drug
DMC2IJN PC 137455315
DMC2IJN MW 409.4
DMC2IJN FM C20H20FN7O2
DMC2IJN IC InChI=1S/C20H20FN7O2/c1-3-27-10-13-12(8-22)14(21)4-5-15(13)30-11(2)9-24-20(29)17-18(23)26-28-7-6-16(27)25-19(17)28/h4-7,11H,3,9-10H2,1-2H3,(H2,23,26)(H,24,29)/t11-/m0/s1
DMC2IJN CS CCN1CC2=C(C=CC(=C2C#N)F)O[C@H](CNC(=O)C3=C4N=C1C=CN4N=C3N)C
DMC2IJN IK UUDPUQDMSHQSKH-NSHDSACASA-N
DMC2IJN IU (11S)-16-amino-2-ethyl-6-fluoro-11-methyl-14-oxo-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaene-5-carbonitrile
DMC2IJN DE Solid tumour/cancer
DMGC2AT ID DMGC2AT
DMGC2AT DN TR1801-ADC
DMGC2AT HS Phase 1
DMGC2AT CP Tanabe Research Laboratories
DMGC2AT DT Antibody drug conjugate
DMGC2AT DE Solid tumour/cancer
DMMRDUN ID DMMRDUN
DMMRDUN DN TrasGEX
DMMRDUN HS Phase 1
DMMRDUN CP Glycotope GmbH
DMMRDUN DT Antibody
DMMRDUN DE Solid tumour/cancer
DM1DIVY ID DM1DIVY
DM1DIVY DN TRemelimumab + MEDI0562
DM1DIVY HS Phase 1
DM1DIVY CP MedImmune Gaithersburg, MD
DM1DIVY DE Solid tumour/cancer
DMQ7UN6 ID DMQ7UN6
DMQ7UN6 DN Trodusquemine
DMQ7UN6 HS Phase 1
DMQ7UN6 SN Produlestan; Trodulamine; Aminosterol 1436; MSI-1436; Aminosterols (obesity, type 2 diabetes), Genaera
DMQ7UN6 CP Genaera
DMQ7UN6 DT Small molecular drug
DMQ7UN6 PC 9917968
DMQ7UN6 MW 685.1
DMQ7UN6 FM C37H72N4O5S
DMQ7UN6 IC InChI=1S/C37H72N4O5S/c1-26(2)34(46-47(43,44)45)13-10-27(3)30-11-12-31-35-32(15-17-37(30,31)5)36(4)16-14-29(24-28(36)25-33(35)42)41-23-9-22-40-20-7-6-19-39-21-8-18-38/h26-35,39-42H,6-25,38H2,1-5H3,(H,43,44,45)/t27-,28-,29+,30-,31+,32+,33-,34-,35+,36+,37-/m1/s1
DMQ7UN6 CS C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCNCCCN)C)O)C
DMQ7UN6 IK WUJVPODXELZABP-FWJXURDUSA-N
DMQ7UN6 IU [(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-[4-(3-aminopropylamino)butylamino]propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate
DMQ7UN6 CA CAS 186139-09-3
DMQ7UN6 DE Obesity; Breast cancer
DMDSF0Q ID DMDSF0Q
DMDSF0Q DN TROVIRDINE HYDROCHLORIDE
DMDSF0Q HS Phase 1
DMDSF0Q SN TROVIRDINE HYDROCHLORIDE; 148311-89-1; UNII-70714531RJ; 70714531RJ; AC1NS2PN; CHEMBL543611; SCHEMBL2231102; KB-81362; 1-(5-bromopyridin-2-yl)-3-(2-pyridin-2-ylethyl)thiourea hydrochloride
DMDSF0Q DT Small molecular drug
DMDSF0Q PC 5327620
DMDSF0Q MW 373.7
DMDSF0Q FM C13H14BrClN4S
DMDSF0Q IC InChI=1S/C13H13BrN4S.ClH/c14-10-4-5-12(17-9-10)18-13(19)16-8-6-11-3-1-2-7-15-11;/h1-5,7,9H,6,8H2,(H2,16,17,18,19);1H
DMDSF0Q CS C1=CC=NC(=C1)CCNC(=S)NC2=NC=C(C=C2)Br.Cl
DMDSF0Q IK IUQKLSJRANLIKE-UHFFFAOYSA-N
DMDSF0Q IU 1-(5-bromopyridin-2-yl)-3-(2-pyridin-2-ylethyl)thiourea;hydrochloride
DMDSF0Q CA CAS 148311-89-1
DMDSF0Q DE Human immunodeficiency virus infection
DMSLQW2 ID DMSLQW2
DMSLQW2 DN TRPH-222
DMSLQW2 HS Phase 1
DMSLQW2 CP Triphase Accelerator
DMSLQW2 DT Antibody drug conjugate
DMSLQW2 DE Non-hodgkin lymphoma; B-cell lymphoma
DM2WZ86 ID DM2WZ86
DM2WZ86 DN TRV250
DM2WZ86 HS Phase 1
DM2WZ86 CP Trevena Chesterbrook, PA
DM2WZ86 DE Migraine
DMHD8CF ID DMHD8CF
DMHD8CF DN TRV734
DMHD8CF HS Phase 1
DMHD8CF CP Trevena Chesterbrook, PA
DMHD8CF DE Chronic pain
DM9IDUH ID DM9IDUH
DM9IDUH DN TRX518
DM9IDUH HS Phase 1
DM9IDUH CP Leap Therapeutics
DM9IDUH DT Antibody
DM9IDUH DE Solid tumour/cancer
DMVGN42 ID DMVGN42
DMVGN42 DN TRX-818
DMVGN42 HS Phase 1
DMVGN42 SN CVM-1118; ZRPWVAHVWBPHID-UHFFFAOYSA-L; TRX-818 sodium; TRX818; EX-A580; MolPort-044-567-575; CVM-1118(CVM1118); B5932; J-690105; (2'S,3R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-N-((1r,4R)-4-hydroxycyclohexyl)-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrroli dine]-5'-carboxamide
DMVGN42 CP TaiRx Taipei, Taiwan
DMVGN42 PC 124080980
DMVGN42 MW 393.21
DMVGN42 FM C16H11FNNa2O5P
DMVGN42 IC InChI=1S/C16H13FNO5P.2Na/c1-23-14-6-5-11-15(16(14)24(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9;;/h2-8H,1H3,(H,18,19)(H2,20,21,22);;/q;2*+1/p-2
DMVGN42 CS COC1=C(C2=C(C=C1)NC(=CC2=O)C3=CC(=CC=C3)F)P(=O)([O-])[O-].[Na+].[Na+]
DMVGN42 IK ZRPWVAHVWBPHID-UHFFFAOYSA-L
DMVGN42 IU disodium;2-(3-fluorophenyl)-6-methoxy-5-phosphonato-1H-quinolin-4-one
DMVGN42 DE Solid tumour/cancer
DMNTVUK ID DMNTVUK
DMNTVUK DN TS01
DMNTVUK HS Phase 1
DMNTVUK DE Stroke
DM56PFL ID DM56PFL
DM56PFL DN TSR-042
DM56PFL HS Phase 1
DM56PFL CP TESARO Waltham, MA
DM56PFL DT Monoclonal antibody
DM56PFL DE Solid tumour/cancer; Advanced malignancy; Metastatic cancer
DMZ9EMO ID DMZ9EMO
DMZ9EMO DN TST001
DMZ9EMO HS Phase 1
DMZ9EMO CP Transcenta
DMZ9EMO DT Antibody
DMZ9EMO DE Solid tumour/cancer
DMT5AEF ID DMT5AEF
DMT5AEF DN TST-10088
DMT5AEF HS Phase 1
DMT5AEF CP Cangene Winnipeg, Canada
DMT5AEF DE Solid tumour/cancer
DMLDSX8 ID DMLDSX8
DMLDSX8 DN TT-30
DMLDSX8 HS Phase 1
DMLDSX8 SN CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Alexion; CR2/factor H modulator (fusion protein, autoimmune/inflammatory disease), Taligen
DMLDSX8 CP Taligen Therapeutics Inc
DMLDSX8 DE Autoimmune diabetes
DM4QV8Y ID DM4QV8Y
DM4QV8Y DN TT-301
DM4QV8Y HS Phase 1
DM4QV8Y SN Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics
DM4QV8Y CP Northwestern University
DM4QV8Y PC 54576073
DM4QV8Y MW 395.5
DM4QV8Y FM C23H21N7
DM4QV8Y IC InChI=1S/C23H21N7/c1-2-5-19(6-3-1)21-17-20(18-7-11-24-12-8-18)22(28-27-21)29-13-15-30(16-14-29)23-25-9-4-10-26-23/h1-12,17H,13-16H2
DM4QV8Y CS C1CN(CCN1C2=NN=C(C=C2C3=CC=NC=C3)C4=CC=CC=C4)C5=NC=CC=N5
DM4QV8Y IK ZPJGUEPHFXPAQF-UHFFFAOYSA-N
DM4QV8Y IU 6-phenyl-4-pyridin-4-yl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine
DM4QV8Y CA CAS 886208-76-0
DM4QV8Y DE Alzheimer disease
DM7CHZ2 ID DM7CHZ2
DM7CHZ2 DN TTC-352
DM7CHZ2 HS Phase 1
DM7CHZ2 CP TTC Oncology Edina, MN
DM7CHZ2 DE Breast cancer
DM7E6V2 ID DM7E6V2
DM7E6V2 DN TTC-352
DM7E6V2 HS Phase 1
DM7E6V2 SN Sherpa TTC-352; UNII-65ILH3Y0MI; 65ILH3Y0MI; CHEMBL3763743; 1607819-68-0; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophene-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)-benzo[b]thiophene-6-ol; SCHEMBL15658409; BDBM50145856; J3.603.123I; 2-(4-Hydroxyphenoxy)-3-(4-fluorophenyl)benzo[b]thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol; 3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo(b)thiophene-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol; 3-(4-fluorophenyl)-2-(4-hydroxyphenoxyl)benzo[b]thiophen-6-ol; Selective human estrogen-receptor alpha partial agonist TTC-352; Benzo(b)thiophene-6-ol, 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-; V9J
DM7E6V2 CP TTC Oncology
DM7E6V2 DT Small molecular drug
DM7E6V2 PC 74222430
DM7E6V2 MW 352.4
DM7E6V2 FM C20H13FO3S
DM7E6V2 IC InChI=1S/C20H13FO3S/c21-13-3-1-12(2-4-13)19-17-10-7-15(23)11-18(17)25-20(19)24-16-8-5-14(22)6-9-16/h1-11,22-23H
DM7E6V2 CS C1=CC(=CC=C1C2=C(SC3=C2C=CC(=C3)O)OC4=CC=C(C=C4)O)F
DM7E6V2 IK UDBMVVLTKJMPCJ-UHFFFAOYSA-N
DM7E6V2 IU 3-(4-fluorophenyl)-2-(4-hydroxyphenoxy)-1-benzothiophen-6-ol
DM7E6V2 CA CAS 1607819-68-0
DM7E6V2 DE Metastatic melanoma
DMDNPAV ID DMDNPAV
DMDNPAV DN TTI-621
DMDNPAV HS Phase 1
DMDNPAV CP Trillium Therapeutics Mississauga, Canada
DMDNPAV DT Recombinant protein
DMDNPAV DE Melanoma; Merkel cell carcinoma; Mycosis fungoides; Squamous cell carcinoma; Haematological malignancy; Solid tumour/cancer
DMOCQ4K ID DMOCQ4K
DMOCQ4K DN TTI-622
DMOCQ4K HS Phase 1
DMOCQ4K CP Trillium Therapeutics
DMOCQ4K DT Recombinant protein
DMOCQ4K DE Lymphoma; Myeloma
DMCG01R ID DMCG01R
DMCG01R DN TTP-4000
DMCG01R HS Phase 1
DMCG01R SN Extracellular RAGE domain (diabetic nephropathy), TransTech; Extracellular RAGE domain (Alzheimer's disease), TransTech
DMCG01R CP Transtech pharma
DMCG01R DE Alzheimer disease
DMYFUOP ID DMYFUOP
DMYFUOP DN TTP-547
DMYFUOP HS Phase 1
DMYFUOP SN Glucokinase activator (diabetes), TransTech Pharma
DMYFUOP CP TransTech Pharma Inc
DMYFUOP DE Diabetic complication
DM8H2AG ID DM8H2AG
DM8H2AG DN TTX-030
DM8H2AG HS Phase 1
DM8H2AG CP AbbVie
DM8H2AG DT Antibody
DM8H2AG DE Lymphoma; Solid tumour/cancer
DM6GKYF ID DM6GKYF
DM6GKYF DN TTX-080
DM6GKYF HS Phase 1
DM6GKYF CP Tizona Therapeutics
DM6GKYF DT Antibody
DM6GKYF DE Solid tumour/cancer
DM36ONA ID DM36ONA
DM36ONA DN Turofexorate isopropyl
DM36ONA HS Phase 1
DM36ONA SN 629664-81-9; Turofexorate isopropyl; WAY-362450; XL335; isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR-450; Turofexorate Isopropyl (XL335); UNII-S6KDM312I5; WAY 362450; S6KDM312I5; WAY362450; XL-335; 3-(3,4-difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethyl-Azepino[4,5-b]indole-5-carboxylic acid 1-methylethyl ester; 1-methylethyl 3-[(3,4-difluorophenyl)carbonyl]-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR 450; Turofexorate isopropyl [USAN:I
DM36ONA CP Pfizer New York, NY
DM36ONA DT Small molecular drug
DM36ONA PC 10026128
DM36ONA MW 438.5
DM36ONA FM C25H24F2N2O3
DM36ONA IC InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
DM36ONA CS CC(C)OC(=O)C1=CN(CC(C2=C1NC3=CC=CC=C32)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DM36ONA IK INASOKQDNHHMRE-UHFFFAOYSA-N
DM36ONA IU propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-2,6-dihydroazepino[4,5-b]indole-5-carboxylate
DM36ONA CA CAS 629664-81-9
DM36ONA DE Hyperlipidaemia
DMZIK8R ID DMZIK8R
DMZIK8R DN TXA709
DMZIK8R HS Phase 1
DMZIK8R CP TAXIS Pharmaceuticals
DMZIK8R DT Small interfering RNA
DMZIK8R DE MRSA infection
DMWOE62 ID DMWOE62
DMWOE62 DN U3-1565
DMWOE62 HS Phase 1
DMWOE62 CP Amgen Thousand; Daiichi
DMWOE62 DE Solid tumour/cancer
DM5XMHB ID DM5XMHB
DM5XMHB DN UC-781
DM5XMHB HS Phase 1
DM5XMHB SN Thiocarboxanilide; UC-040; UC-10; UC-82; Oxathiin carboxanilide analogs, Biosyn/CONRAD; UC analogs, Biosyn/CONRAD; Oxathiin carboxanilide analogs, Uniroyal/NCI/Southern Research Institute; UC analogs, Uniroyal/NCI/Southern Research Institute
DM5XMHB CP Biosyn
DM5XMHB DT Small molecular drug
DM5XMHB PC 3000926
DM5XMHB MW 335.8
DM5XMHB FM C17H18ClNO2S
DM5XMHB IC InChI=1S/C17H18ClNO2S/c1-11(2)6-8-21-16-10-13(4-5-15(16)18)19-17(22)14-7-9-20-12(14)3/h4-7,9-10H,8H2,1-3H3,(H,19,22)
DM5XMHB CS CC1=C(C=CO1)C(=S)NC2=CC(=C(C=C2)Cl)OCC=C(C)C
DM5XMHB IK YZHIXLCGPOTQNB-UHFFFAOYSA-N
DM5XMHB IU N-[4-chloro-3-(3-methylbut-2-enoxy)phenyl]-2-methylfuran-3-carbothioamide
DM5XMHB CA CAS 178870-32-1
DM5XMHB DE Human immunodeficiency virus infection
DMG7FLI ID DMG7FLI
DMG7FLI DN UCART123
DMG7FLI HS Phase 1
DMG7FLI CP Cellectis S.A.
DMG7FLI DT CAR T Cell Therapy
DMG7FLI DE Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
DMARHU4 ID DMARHU4
DMARHU4 DN UCART-22
DMARHU4 HS Phase 1
DMARHU4 CP Cellectis
DMARHU4 DT CAR T Cell Therapy
DMARHU4 DE B-cell acute lymphoblastic leukaemia
DM2Y4D7 ID DM2Y4D7
DM2Y4D7 DN UCARTCS1
DM2Y4D7 HS Phase 1
DM2Y4D7 CP Cellectis
DM2Y4D7 DT CAR T Cell Therapy
DM2Y4D7 DE Multiple myeloma
DMSCXB7 ID DMSCXB7
DMSCXB7 DN UK-240455
DMSCXB7 HS Phase 1
DMSCXB7 SN UK-212189 (racemate); (aR)-N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-(2-hydroxyethyl)methanesulfonamide
DMSCXB7 DT Small molecular drug
DMSCXB7 PC 9842188
DMSCXB7 MW 368.2
DMSCXB7 FM C11H11Cl2N3O5S
DMSCXB7 IC InChI=1S/C11H11Cl2N3O5S/c1-22(20,21)16(2-3-17)9-7(13)5(12)4-6-8(9)15-11(19)10(18)14-6/h4,17H,2-3H2,1H3,(H,14,18)(H,15,19)
DMSCXB7 CS CS(=O)(=O)N(CCO)C1=C2C(=CC(=C1Cl)Cl)NC(=O)C(=O)N2
DMSCXB7 IK BGJHUMNCODFLCH-UHFFFAOYSA-N
DMSCXB7 IU N-(6,7-dichloro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)-N-(2-hydroxyethyl)methanesulfonamide
DMSCXB7 CA CAS 178908-09-3
DMSCXB7 DE Nerve injury
DMI8795 ID DMI8795
DMI8795 DN UK-371800
DMI8795 HS Phase 1
DMI8795 DT Small molecular drug
DMI8795 PC 135430955
DMI8795 MW 519.6
DMI8795 FM C23H33N7O5S
DMI8795 IC InChI=1S/C23H33N7O5S/c1-6-18-19-20(27-28(18)4)22(31)26-21(25-19)17-12-16(13-24-23(17)35-15(3)14-34-5)36(32,33)30-10-8-29(7-2)9-11-30/h12-13,15H,6-11,14H2,1-5H3,(H,25,26,31)/t15-/m1/s1
DMI8795 CS CCC1=C2C(=NN1C)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)O[C@H](C)COC
DMI8795 IK WKISNFXGTYNPOO-OAHLLOKOSA-N
DMI8795 IU 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2R)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-methyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DMI8795 DE Erectile dysfunction
DMFYKDX ID DMFYKDX
DMFYKDX DN UK-396082
DMFYKDX HS Phase 1
DMFYKDX SN UK-396082; UNII-2Q5861SUIG; UK-396,082; UK 396082; 2Q5861SUIG; CHEMBL398110; 400044-47-5; (2s)-5-Amino-2-[(1-Propyl-1h-Imidazol-4-Yl)methyl]pentanoic Acid; SCHEMBL3841442; GTPL8657; DTXSID70193074; BDBM50226610; DB12099; compound 21 [PMID: 17990866]; (2S)-5-amino-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid; (S)-5-amino-2-((1-propyl-1H-imidazol-4-yl)methyl)pentanoic acid; (S)-2-(1-Propyl-1H-imidazole-4-ylmethyl)-5-aminopentanoic acid; 1H-Imidazole-4-propanoic acid, alpha-(3-aminopropyl)-1-propyl-, (alphaS)-
DMFYKDX DT Small molecular drug
DMFYKDX PC 11241908
DMFYKDX MW 239.31
DMFYKDX FM C12H21N3O2
DMFYKDX IC InChI=1S/C12H21N3O2/c1-2-6-15-8-11(14-9-15)7-10(12(16)17)4-3-5-13/h8-10H,2-7,13H2,1H3,(H,16,17)/t10-/m0/s1
DMFYKDX CS CCCN1C=C(N=C1)C[C@H](CCCN)C(=O)O
DMFYKDX IK OTDGPKRCQXSTPV-JTQLQIEISA-N
DMFYKDX IU (2S)-5-amino-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid
DMFYKDX CA CAS 400044-47-5
DMFYKDX DE Thrombosis
DMO8Z1D ID DMO8Z1D
DMO8Z1D DN UK-66914
DMO8Z1D HS Phase 1
DMO8Z1D SN UK-66914; 113049-11-9; Methanesulfonamide, N-[4-[1-hydroxy-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]phenyl]-; Methanesulfonamide, N-(4-(1-hydroxy-2-(4-(4-pyridinyl)-1-piperazinyl)ethyl)phenyl)-; UK66914; UK 66914; UK-66,914; AC1MIZ8F; SCHEMBL6375438
DMO8Z1D CP Pfizer Ltd
DMO8Z1D DT Small molecular drug
DMO8Z1D PC 3082653
DMO8Z1D MW 376.5
DMO8Z1D FM C18H24N4O3S
DMO8Z1D IC InChI=1S/C18H24N4O3S/c1-26(24,25)20-16-4-2-15(3-5-16)18(23)14-21-10-12-22(13-11-21)17-6-8-19-9-7-17/h2-9,18,20,23H,10-14H2,1H3
DMO8Z1D CS CS(=O)(=O)NC1=CC=C(C=C1)C(CN2CCN(CC2)C3=CC=NC=C3)O
DMO8Z1D IK MXVFGNOLZDAKQJ-UHFFFAOYSA-N
DMO8Z1D IU N-[4-[1-hydroxy-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]phenyl]methanesulfonamide
DMO8Z1D CA CAS 113049-11-9
DMO8Z1D DE Cardiac arrhythmias
DMHG7DZ ID DMHG7DZ
DMHG7DZ DN UltraCD40L
DMHG7DZ HS Phase 1
DMHG7DZ SN SP-D-CD40L; 4-trimer SP-D-CD40L (anticancer, adjuvant), Multimeric Biotherapeutics
DMHG7DZ CP Biogen Idec
DMHG7DZ DE Systemic lupus erythematosus
DMTLNGV ID DMTLNGV
DMTLNGV DN Umespirone
DMTLNGV HS Phase 1
DMTLNGV SN KC-7218; KC-9172
DMTLNGV CP Solvay SA
DMTLNGV DT Small molecular drug
DMTLNGV PC 65902
DMTLNGV MW 512.6
DMTLNGV FM C28H40N4O5
DMTLNGV IC InChI=1S/C28H40N4O5/c1-5-6-14-31-24(33)22-26(35)32(27(36)23(25(31)34)28(22,2)3)15-10-9-13-29-16-18-30(19-17-29)20-11-7-8-12-21(20)37-4/h7-8,11-12,22-23H,5-6,9-10,13-19H2,1-4H3
DMTLNGV CS CCCCN1C(=O)C2C(=O)N(C(=O)C(C1=O)C2(C)C)CCCCN3CCN(CC3)C4=CC=CC=C4OC
DMTLNGV IK BXNRTMZZILHVNJ-UHFFFAOYSA-N
DMTLNGV IU 3-butyl-7-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone
DMTLNGV CA CAS 107736-98-1
DMTLNGV DE Anxiety disorder
DMI5UEB ID DMI5UEB
DMI5UEB DN Unacylated ghrelin
DMI5UEB HS Phase 1
DMI5UEB SN AZP-01; Diabetes therapeutic peptide, Theratechnologies; TH-0332; Un-octanoylated ghrelin; Unacylated ghrelin (diabetes); Ghrelin inhibitor peptides (diabetes), Theratechnologies; UAG (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Theratechnologies; Un-octanoylated ghrelin (diabetes), Alize Pharma; Unacylated ghrelin (diabetes), Alize Pharma/Eli Lilly
DMI5UEB CP Theratechnologies Inc
DMI5UEB DE Type-1 diabetes
DMR38M4 ID DMR38M4
DMR38M4 DN UNBS-1450
DMR38M4 HS Phase 1
DMR38M4 SN UNBS-1244; Na+ K+ ATPase inhibitor, (intravenous, cancer), Unibioscreen; 2''-oxovoruscharin
DMR38M4 CP Unibioscreen SA
DMR38M4 DT Small molecular drug
DMR38M4 PC 154731948
DMR38M4 DE Solid tumour/cancer
DMIKV9W ID DMIKV9W
DMIKV9W DN Utomilumab
DMIKV9W HS Phase 1
DMIKV9W SN PF-05082566
DMIKV9W CP Pfizer
DMIKV9W DT Antibody
DMIKV9W DE Solid tumour/cancer
DMJSX9N ID DMJSX9N
DMJSX9N DN V-24343
DMJSX9N HS Phase 1
DMJSX9N SN CB1 antagonists, Vernalis; Cannabinoid CB1 receptor antagonists, Vernalis
DMJSX9N CP Vernalis
DMJSX9N DE Type-2 diabetes
DMYAIUB ID DMYAIUB
DMYAIUB DN Valortim
DMYAIUB HS Phase 1
DMYAIUB SN Anthrax antibody, Medarex; MDX-1303; Anthrax antibody, Medarex/PharmAthene; Anti-B anthracis, Bristol Myers Squibb/PharmAthene; Anti-B anthracis PA (anthrax), Medarex/BMS/PharmAthene
DMYAIUB CP Pharmathene
DMYAIUB DT Antibody
DMYAIUB DE Bacterial infection
DM3ZW6A ID DM3ZW6A
DM3ZW6A DN VAN-10-4-eluting stent
DM3ZW6A HS Phase 1
DM3ZW6A SN INC-105-eluting stent, Inncardio/University of Strathclyde; VAN-10-4-eluting stent, University of Strathclyde; Marigold compound (drug-eluting stent, restenosis), Inncardio/University of Strathclyde
DM3ZW6A CP University of Strathclyde
DM3ZW6A DE Artery stenosis
DMULRYC ID DMULRYC
DMULRYC DN VBY- 036
DMULRYC HS Phase 1
DMULRYC SN VBY-036
DMULRYC CP Virobay
DMULRYC DE Neuropathic pain
DMTKPH4 ID DMTKPH4
DMTKPH4 DN VBY- 891
DMTKPH4 HS Phase 1
DMTKPH4 SN VBY-891
DMTKPH4 CP Virobay Inc
DMTKPH4 DE Autoimmune diabetes
DM4YIWK ID DM4YIWK
DM4YIWK DN VBY-129
DM4YIWK HS Phase 1
DM4YIWK SN Cathepsin S inhibitor (oral, psoriasis), Virobay
DM4YIWK CP Virobay Inc
DM4YIWK DE Autoimmune diabetes; Crohn disease; Neuropathic pain
DMU263R ID DMU263R
DMU263R DN VBY-376
DMU263R HS Phase 1
DMU263R SN Protease inhibitor (hepatitis C virus infection), Virobay
DMU263R CP Virobay Inc
DMU263R DE Hepatitis C virus infection
DMMKUOZ ID DMMKUOZ
DMMKUOZ DN VCH-286
DMMKUOZ HS Phase 1
DMMKUOZ CP ViroChem Pharma Inc
DMMKUOZ PC 124582705
DMMKUOZ MW 600.8
DMMKUOZ FM C34H50F2N4O3
DMMKUOZ IC InChI=1S/C34H50F2N4O3/c1-24(2)40-32(42)38(22-25-13-18-43-19-14-25)23-33(40)20-28-8-9-29(21-33)39(28)17-12-30(26-6-4-3-5-7-26)37-31(41)27-10-15-34(35,36)16-11-27/h3-7,24-25,27-30H,8-23H2,1-2H3,(H,37,41)/t28-,29+,30-,33?/m0/s1
DMMKUOZ CS CC(C)N1C(=O)N(CC12C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)CC6CCOCC6
DMMKUOZ IK YZGXEGUSPLSQOJ-VUQZBIHUSA-N
DMMKUOZ IU 4,4-difluoro-N-[(1S)-3-[(1S,5R)-1'-(oxan-4-ylmethyl)-2'-oxo-3'-propan-2-ylspiro[8-azabicyclo[3.2.1]octane-3,4'-imidazolidine]-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
DMMKUOZ DE Human immunodeficiency virus infection
DMS9EKG ID DMS9EKG
DMS9EKG DN VCL-1M01
DMS9EKG HS Phase 1
DMS9EKG SN VCL-IM01; EPT (plasmid DNA), Vical; IL-2/EP; MedPulser, cancer (plasmid DNA), Vical; Plasmid DNA (transdermal, EPT), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma); IL-2 gene therapy (pVCL-1102 plasmid DNA vector, melanoma), Vical; IL-2 gene therapy (plasmid, transdermal, melanoma), Vical
DMS9EKG CP Vical Inc
DMS9EKG DE Melanoma
DMDSC63 ID DMDSC63
DMDSC63 DN VEL-0230
DMDSC63 HS Phase 1
DMDSC63 SN NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar
DMDSC63 CP Nippon Chemiphar Co Ltd
DMDSC63 DT Small molecular drug
DMDSC63 PC 25102841
DMDSC63 MW 309.33
DMDSC63 FM C14H24NNaO5
DMDSC63 IC InChI=1S/C14H25NO5.Na/c1-8(2)5-10(7-19-6-9(3)4)15-13(16)11-12(20-11)14(17)18;/h8-12H,5-7H2,1-4H3,(H,15,16)(H,17,18);/q;+1/p-1/t10-,11-,12-;/m0./s1
DMDSC63 CS CC(C)C[C@@H](COCC(C)C)NC(=O)[C@@H]1[C@H](O1)C(=O)[O-].[Na+]
DMDSC63 IK SGAKODIXAHVUKL-LFELFHSZSA-M
DMDSC63 IU sodium;(2S,3S)-3-[[(2S)-4-methyl-1-(2-methylpropoxy)pentan-2-yl]carbamoyl]oxirane-2-carboxylate
DMDSC63 CA CAS 221144-20-3
DMDSC63 DE Rheumatoid arthritis
DM9OEK1 ID DM9OEK1
DM9OEK1 DN Velpatasvir
DM9OEK1 HS Phase 1
DM9OEK1 SN GS 5816; GS-5816; GS5816; KCU0C7RS7Z; UNII-KCU0C7RS7Z; Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
DM9OEK1 TC Antiviral Agent
DM9OEK1 DT Small molecular drug
DM9OEK1 PC 67683363
DM9OEK1 MW 883.019
DM9OEK1 FM C49H54N8O8
DM9OEK1 IC InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
DM9OEK1 CS CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
DM9OEK1 IK FHCUMDQMBHQXKK-CDIODLITSA-N
DM9OEK1 IU methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
DM9OEK1 CA CAS 1377049-84-7
DM9OEK1 CB CHEBI:133009
DM9OEK1 DE Hepatitis C virus infection
DM9GC4R ID DM9GC4R
DM9GC4R DN VGX-100
DM9GC4R HS Phase 1
DM9GC4R CP Circadian Technologies
DM9GC4R DE Solid tumour/cancer
DMM1N5C ID DMM1N5C
DMM1N5C DN VGX-1027
DMM1N5C HS Phase 1
DMM1N5C SN VGX-1027; 6501-72-0; GIT 27; git-27; 2-(3-phenyl-4,5-dihydroisoxazol-5-yl)acetic acid; 4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID; 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic Acid; GIT27; SCHEMBL1404343; CHEMBL1320667; CTK5C2027; VGX-127; EX-A366; DTXSID50445023; AOB1858; MUFJHYRCIHHATF-UHFFFAOYSA-N; MolPort-022-917-316; HMS3653J11; BCP09284; VGX 1027; VGX-1027(GIT 27); MFCD08696167; s7515; 2792AH; GIT-27 (VGX-1027); AKOS022538967; AKOS000282755; CS-2737; NCGC00186000-02; NCGC00186000-01; AK175225; HY-15507; AB0279943; KB-272590
DMM1N5C CP Inovio Pharmaceuticals
DMM1N5C DT Small molecular drug
DMM1N5C PC 10798271
DMM1N5C MW 205.21
DMM1N5C FM C11H11NO3
DMM1N5C IC InChI=1S/C11H11NO3/c13-11(14)7-9-6-10(12-15-9)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,13,14)
DMM1N5C CS C1C(ON=C1C2=CC=CC=C2)CC(=O)O
DMM1N5C IK MUFJHYRCIHHATF-UHFFFAOYSA-N
DMM1N5C IU 2-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid
DMM1N5C CA CAS 6501-72-0
DMM1N5C DE Rheumatoid arthritis
DMGMEH7 ID DMGMEH7
DMGMEH7 DN VGX-3400
DMGMEH7 HS Phase 1
DMGMEH7 CP Inovio Pharmaceuticals
DMGMEH7 DT Vaccine
DMGMEH7 DE Influenza A virus H5N1 infection
DMDFC2Y ID DMDFC2Y
DMDFC2Y DN VIC-1911
DMDFC2Y HS Phase 1
DMDFC2Y SN TAS 119
DMDFC2Y CP VITRAC Therapeutics
DMDFC2Y DE Solid tumour/cancer
DM6LQIU ID DM6LQIU
DM6LQIU DN VIR-2482
DM6LQIU HS Phase 1
DM6LQIU CP Vir Biotechnology
DM6LQIU DT Antibody
DM6LQIU DE Influenza A virus infection
DMB3I04 ID DMB3I04
DMB3I04 DN VM-206
DMB3I04 HS Phase 1
DMB3I04 CP ViroMed Co Ltd
DMB3I04 DT Vaccine
DMB3I04 DE Solid tumour/cancer
DM4AXPT ID DM4AXPT
DM4AXPT DN VMD-928
DM4AXPT HS Phase 1
DM4AXPT CP VM Oncology
DM4AXPT DT Small molecular drug
DM4AXPT DE Lymphoma; Solid tumour/cancer
DMNZ6XH ID DMNZ6XH
DMNZ6XH DN VNRX-5133
DMNZ6XH HS Phase 1
DMNZ6XH SN Taniborbactam; UNII-8IGQ156Z07; 8IGQ156Z07; 1613267-49-4; (3R)-3-[[2-[4-(2-aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid; (3~{R})-3-[2-[4-(2-azanylethylamino)cyclohexyl]ethanoylamino]-2-oxidanyl-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid; Taniborbactam [INN]; Taniborbactam [USAN]; Taniborbactam (USAN/INN); VNRX5133; CHEMBL4463697; CHEMBL4584705; CHEMBL4594290; SCHEMBL15778142; SCHEMBL15778144; SCHEMBL15779391; GTPL10774; WHO 10817; HY-109124; CS-0078360; D11718; (3R)-3-(((trans-4-((2-Aminoethyl)amino)cyclohexyl)acetyl)amino)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid; (R)-3-(2-((1S,4R)-rel-4-((2-Aminoethyl)amino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid; (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid; 2H-1,2-Benzoxaborin-8-carboxylic acid, 3-((2-(trans-4-((2-aminoethyl)amino)cyclohexyl)acetyl)amino)-3,4-dihydro-2-hydroxy-, (3R)-
DMNZ6XH CP VenatoRx Pharmaceuticals
DMNZ6XH DT Small molecular drug
DMNZ6XH PC 76902493
DMNZ6XH MW 389.3
DMNZ6XH FM C19H28BN3O5
DMNZ6XH IC InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
DMNZ6XH CS B1([C@H](CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O
DMNZ6XH IK PFZUWUXKQPRWAL-PXCJXSSVSA-N
DMNZ6XH IU (3R)-3-[[2-[4-(2-aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
DMNZ6XH CA CAS 1613267-49-4
DMNZ6XH DE Bacterial infection
DMDG30Q ID DMDG30Q
DMDG30Q DN VOB560
DMDG30Q HS Phase 1
DMDG30Q SN S 65487
DMDG30Q CP Novartis
DMDG30Q DT Small molecular drug
DMDG30Q DE Multiple myeloma; Acute myeloid leukaemia; Non-hodgkin lymphoma
DM215XO ID DM215XO
DM215XO DN Voxilaprevir
DM215XO HS Phase 1
DM215XO SN 0570F37359; DB12026; GS-9857; J3.665.048F; SCHEMBL15412621; UNII-0570F37359; Voxilaprevir; Voxilaprevir (USAN/INN); Voxilaprevir [USAN:INN]
DM215XO TC Antiviral Agent
DM215XO DT Small molecular drug
DM215XO PC 89921642
DM215XO MW 868.943
DM215XO FM C40H52F4N6O9S
DM215XO IC InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1
DM215XO CS CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C
DM215XO IK MZBLZLWXUBZHSL-FZNJKFJKSA-N
DM215XO IU (1R,18R,20R,24S,27S,28S)-24-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
DM215XO CA CAS 1535212-07-7
DM215XO DE Hepatitis C virus infection
DM0S9OT ID DM0S9OT
DM0S9OT DN VRC07-523LS
DM0S9OT HS Phase 1
DM0S9OT CP TaiMed Biologics
DM0S9OT DT Antibody
DM0S9OT DE Human immunodeficiency virus-1 infection
DMN9JCD ID DMN9JCD
DMN9JCD DN VS-4718
DMN9JCD HS Phase 1
DMN9JCD SN PND-1186
DMN9JCD CP Verastem
DMN9JCD PC 25073775
DMN9JCD MW 501.5
DMN9JCD FM C25H26F3N5O3
DMN9JCD IC InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32)
DMN9JCD CS CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC
DMN9JCD IK IGUBBWJDMLCRIK-UHFFFAOYSA-N
DMN9JCD IU 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-N-methylbenzamide
DMN9JCD CA CAS 1061353-68-1
DMN9JCD DE Solid tumour/cancer
DMMO3G5 ID DMMO3G5
DMMO3G5 DN VS-5584
DMMO3G5 HS Phase 1
DMMO3G5 SN 5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; 1246560-33-7; VS-5584 (SB2343); UNII-W71J4X250V; SB-2343; SB2343; CHEMBL3393066; W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; C17H22N8O; QYBGBLQCOOISAR-UHFFFAOYSA-N; SCHEMBL539098; GTPL8382; EX-A288; DTXSID10677328; MolPort-035-757-944; HMS3652B16; BCP08247; 2797AH; ZINC95644685; s7016; VS5584; BDBM50059635; AKOS024465057; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; SB16877
DMMO3G5 CP Verastem
DMMO3G5 DT Small molecular drug
DMMO3G5 PC 46912230
DMMO3G5 MW 354.4
DMMO3G5 FM C17H22N8O
DMMO3G5 IC InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)
DMMO3G5 CS CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N
DMMO3G5 IK QYBGBLQCOOISAR-UHFFFAOYSA-N
DMMO3G5 IU 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine
DMMO3G5 CA CAS 1246560-33-7
DMMO3G5 DE Solid tumour/cancer; Malignant mesothelioma
DMQEOD6 ID DMQEOD6
DMQEOD6 DN VTP-27999
DMQEOD6 HS Phase 1
DMQEOD6 SN VTP-27999; C26H41ClN4O5; 6076AC; CS-0311; HY-50768; W-5512; 142C510; Carbamic acid, N-[2-[(R)-(3-chlorophenyl)[(3R)-1-[[[(2S)-2-(methylamino)-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl]amino]carbonyl]-3-piperidinyl]methoxy]ethyl]-, methyl ester
DMQEOD6 CP Vitae Pharmaceuticals
DMQEOD6 DT Small molecular drug
DMQEOD6 PC 16126898
DMQEOD6 MW 525.1
DMQEOD6 FM C26H41ClN4O5
DMQEOD6 IC InChI=1S/C26H41ClN4O5/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32)/t19-,21-,23+,24+/m1/s1
DMQEOD6 CS CN[C@@H](C[C@H]1CCCOC1)CNC(=O)N2CCC[C@H](C2)[C@H](C3=CC(=CC=C3)Cl)OCCNC(=O)OC
DMQEOD6 IK NXWASIVXQMMPLM-ZXMXYHOLSA-N
DMQEOD6 IU methyl N-[2-[(R)-(3-chlorophenyl)-[(3R)-1-[[(2S)-2-(methylamino)-3-[(3R)-oxan-3-yl]propyl]carbamoyl]piperidin-3-yl]methoxy]ethyl]carbamate
DMQEOD6 CA CAS 942142-51-0
DMQEOD6 DE Hypertension
DM9W0B6 ID DM9W0B6
DM9W0B6 DN VTR-297
DM9W0B6 HS Phase 1
DM9W0B6 CP Vanda Pharmaceuticals Washington, DC
DM9W0B6 DT Small molecular drug
DM9W0B6 DE Hematologic tumour
DM4ZIRK ID DM4ZIRK
DM4ZIRK DN VTX-1463
DM4ZIRK HS Phase 1
DM4ZIRK SN TLR-8 agonist (allergic rhinitis), VentiRx
DM4ZIRK CP VentiRx Pharmaceuticals Inc
DM4ZIRK DE Allergic rhinitis
DMC8J0G ID DMC8J0G
DMC8J0G DN VX-128
DMC8J0G HS Phase 1
DMC8J0G CP Vertex Pharmaceuticals Boston, MA
DMC8J0G DE Pain
DM8UTPJ ID DM8UTPJ
DM8UTPJ DN VX-500
DM8UTPJ HS Phase 1
DM8UTPJ CP Vertex
DM8UTPJ DE Hepatitis C virus infection
DMAJ2T4 ID DMAJ2T4
DMAJ2T4 DN VX-916
DMAJ2T4 HS Phase 1
DMAJ2T4 CP Vertex
DMAJ2T4 DE Hepatitis C virus infection
DMR9PCT ID DMR9PCT
DMR9PCT DN VX-970
DMR9PCT HS Phase 1
DMR9PCT SN VE 822
DMR9PCT CP Vertex pharmaceuticals
DMR9PCT PC 59472121
DMR9PCT MW 463.6
DMR9PCT FM C24H25N5O3S
DMR9PCT IC InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)
DMR9PCT CS CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N
DMR9PCT IK JZCWLJDSIRUGIN-UHFFFAOYSA-N
DMR9PCT IU 3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine
DMR9PCT CA CAS 1232416-25-9
DMR9PCT CB CHEBI:131166
DMR9PCT DE Solid tumour/cancer
DMC9N7D ID DMC9N7D
DMC9N7D DN VYR 006
DMC9N7D HS Phase 1
DMC9N7D CP Vyera Pharmaceuticals
DMC9N7D DT Small molecular drug
DMC9N7D DE Toxoplasmosis
DMJ2R69 ID DMJ2R69
DMJ2R69 DN W-198
DMJ2R69 HS Phase 1
DMJ2R69 SN 5-Bromotetrandrine
DMJ2R69 CP Chengdu Kanghong Pharmaceutical Group Co Ltd
DMJ2R69 DT Small molecular drug
DMJ2R69 PC 9831563
DMJ2R69 MW 701.6
DMJ2R69 FM C38H41BrN2O6
DMJ2R69 IC InChI=1S/C38H41BrN2O6/c1-40-15-13-24-20-31(43-4)33-21-27(24)28(40)17-22-7-10-25(11-8-22)46-32-19-23(9-12-30(32)42-3)18-29-34-26(14-16-41(29)2)35(39)37(44-5)38(45-6)36(34)47-33/h7-12,19-21,28-29H,13-18H2,1-6H3/t28-,29-/m0/s1
DMJ2R69 CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(CCN6C)C(=C(C(=C7O3)OC)OC)Br)OC)OC
DMJ2R69 IK ANJMFZGRGHQXMA-VMPREFPWSA-N
DMJ2R69 IU (1S,14S)-19-bromo-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18(33),19,21,24,26,31-dodecaene
DMJ2R69 DE Solid tumour/cancer
DMJQHTN ID DMJQHTN
DMJQHTN DN WCK-1152
DMJQHTN HS Phase 1
DMJQHTN SN Antibacterial fluoroquinolones, Wockhardt; WCK-1153; WCK-1457; WCK-783; WCK-919; WCK-993A
DMJQHTN CP Wockhardt Ltd
DMJQHTN PC 11619057
DMJQHTN MW 403.4
DMJQHTN FM C21H26FN3O4
DMJQHTN IC InChI=1S/C21H26FN3O4/c1-21(2)10-24(7-6-15(21)23)17-14(22)8-12-16(19(17)29-3)25(11-4-5-11)9-13(18(12)26)20(27)28/h8-9,11,15H,4-7,10,23H2,1-3H3,(H,27,28)/t15-/m0/s1
DMJQHTN CS CC1(CN(CC[C@@H]1N)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F)C
DMJQHTN IK PMBHAWNZPPNADR-HNNXBMFYSA-N
DMJQHTN IU 7-[(4S)-4-amino-3,3-dimethylpiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMJQHTN DE Respiratory tract inflammation
DM57FHW ID DM57FHW
DM57FHW DN WF-11605
DM57FHW HS Phase 1
DM57FHW SN 9-Acetoxy-2-(1,2-dimethylpropyl)-8-(hexopyranosyloxy)-2,4a,7,7,10a,12a-hexamethyl-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydrochrysene-1-carboxylic acid
DM57FHW DT Small molecular drug
DM57FHW PC 3081238
DM57FHW MW 692.9
DM57FHW FM C38H60O11
DM57FHW IC InChI=1S/C38H60O11/c1-18(2)19(3)38(10)26(41)16-37(9)22-11-12-25-34(5,6)31(49-33-29(44)28(43)27(42)24(17-39)48-33)23(47-20(4)40)15-35(25,7)21(22)13-14-36(37,8)30(38)32(45)46/h18-19,23-25,27-31,33,39,42-44H,11-17H2,1-10H3,(H,45,46)/t19?,23-,24-,25+,27-,28+,29-,30-,31+,33+,35-,36+,37-,38+/m1/s1
DM57FHW CS CC(C)C(C)[C@@]1([C@@H]([C@@]2(CCC3=C([C@]2(CC1=O)C)CC[C@@H]4[C@@]3(C[C@H]([C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)OC(=O)C)C)C)C(=O)O)C
DM57FHW IK FBAPXRMZLULGNA-LEAUMUBASA-N
DM57FHW IU (1R,2R,4aS,6aR,8R,9R,10aS,12aS)-9-acetyloxy-2,4a,7,7,10a,12a-hexamethyl-2-(3-methylbutan-2-yl)-3-oxo-8-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4,5,6,6a,8,9,10,11,12-decahydrochrysene-1-carboxylic acid
DM57FHW CA CAS 127475-47-2
DM57FHW DE Bacterial infection
DM8RNSB ID DM8RNSB
DM8RNSB DN WP1220
DM8RNSB HS Phase 1
DM8RNSB SN mol4239; MOL-4239; PTN9LJL6PY; UNII-PTN9LJL6PY; WP-1220; 2,4-Pentadienamide, 5-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E,4E)-; 1204306-34-2; SCHEMBL862248; SCHEMBL1316581; CHEMBL4594434; (2E,4E)-5-(6-Bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-2,4-pentadienamide; (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide
DM8RNSB CP Moleculin Biotech
DM8RNSB DT Small molecular drug
DM8RNSB PC 44554865
DM8RNSB MW 382.3
DM8RNSB FM C19H16BrN3O
DM8RNSB IC InChI=1S/C19H16BrN3O/c1-14(15-7-3-2-4-8-15)22-19(24)16(13-21)9-5-10-17-11-6-12-18(20)23-17/h2-12,14H,1H3,(H,22,24)/b10-5+,16-9+/t14-/m0/s1
DM8RNSB CS C[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C=C/C2=NC(=CC=C2)Br)/C#N
DM8RNSB IK IVAUEQVCSQZMGV-QIUCFAMLSA-N
DM8RNSB IU (2E,4E)-5-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]penta-2,4-dienamide
DM8RNSB CA CAS 1204306-34-2
DM8RNSB DE Cutaneous T-cell lymphoma
DM9PNR6 ID DM9PNR6
DM9PNR6 DN WST-057
DM9PNR6 HS Phase 1
DM9PNR6 CP WinSanTor San Diego, CA
DM9PNR6 DE Peripheral neuropathy
DM7MS10 ID DM7MS10
DM7MS10 DN WVT078
DM7MS10 HS Phase 1
DM7MS10 CP Novartis
DM7MS10 DT Antibody
DM7MS10 DE Multiple myeloma
DMFBOQ7 ID DMFBOQ7
DMFBOQ7 DN Xanthine
DMFBOQ7 HS Phase 1
DMFBOQ7 SN xanthine; 69-89-6; 2,6-Dihydroxypurine; Xanthin; 2,6-dioxopurine; Pseudoxanthine; Isoxanthine; 1H-Purine-2,6(3H,7H)-dione; Xanthic oxide; 1H-Purine-2,6-diol; 9H-Purine-2,6-diol; Purine-2,6-diol; 3,7-Dihydro-1H-purine-2,6-dione; 2,6(1,3)-Purinedion; 1H-Purine-2,6-dione, 3,7-dihydro-; 3,7-dihydropurine-2,6-dione; USAF CB-17; XAN; Purine-2(3H),6(1H)-dione; 2,6-Dioxo-1,2,3,6-tetrahydropurine; 3,9-dihydro-1H-purine-2,6-dione; 9H-Purine-2,6-(1H,3H)-dione; 1H-Purine-2,6-dione, 3,9-dihydro-; Purine-2,6-(1H,3H)-dione; 9H-xanthine
DMFBOQ7 CP Schering-Plough
DMFBOQ7 DT Small molecular drug
DMFBOQ7 PC 1188
DMFBOQ7 MW 152.11
DMFBOQ7 FM C5H4N4O2
DMFBOQ7 IC InChI=1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11)
DMFBOQ7 CS C1=NC2=C(N1)C(=O)NC(=O)N2
DMFBOQ7 IK LRFVTYWOQMYALW-UHFFFAOYSA-N
DMFBOQ7 IU 3,7-dihydropurine-2,6-dione
DMFBOQ7 CA CAS 69-89-6
DMFBOQ7 CB CHEBI:17712
DMFBOQ7 DE Apnea
DM1UIOA ID DM1UIOA
DM1UIOA DN XB-947
DM1UIOA HS Phase 1
DM1UIOA SN XR-469R; (+)-2(R)-[4-(7-Chloroquinoxalin-2-yloxy)phenoxy]propionic acid sodium salt; (R)-(+)-XK-469
DM1UIOA DT Small molecular drug
DM1UIOA PC 157156
DM1UIOA MW 358.8
DM1UIOA FM C18H15ClN2O4
DM1UIOA IC InChI=1S/C18H15ClN2O4/c1-11(18(22)23-2)24-13-4-6-14(7-5-13)25-17-10-20-15-8-3-12(19)9-16(15)21-17/h3-11H,1-2H3
DM1UIOA CS CC(C(=O)OC)OC1=CC=C(C=C1)OC2=CN=C3C=CC(=CC3=N2)Cl
DM1UIOA IK NPUWJNOFOGQLSR-UHFFFAOYSA-N
DM1UIOA IU methyl 2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoate
DM1UIOA CA CAS 78104-71-9
DM1UIOA DE Solid tumour/cancer
DMNKV3O ID DMNKV3O
DMNKV3O DN XEN007
DMNKV3O HS Phase 1
DMNKV3O CP Xenon
DMNKV3O DE Migraine
DMJVL57 ID DMJVL57
DMJVL57 DN XEN1101
DMJVL57 HS Phase 1
DMJVL57 CP Xenon
DMJVL57 DE Epilepsy
DMRP9YF ID DMRP9YF
DMRP9YF DN XEN901
DMRP9YF HS Phase 1
DMRP9YF CP Xenon
DMRP9YF DE Epilepsy
DMU0V45 ID DMU0V45
DMU0V45 DN XEN-D0101
DMU0V45 HS Phase 1
DMU0V45 SN XEN-D101; Potassium channel Kv1.5 modulator (atrial fibillation), Xention
DMU0V45 CP BioFocus DPI
DMU0V45 DE Atrial fibrillation
DMR0U4V ID DMR0U4V
DMR0U4V DN XEN-D0103
DMR0U4V HS Phase 1
DMR0U4V SN KCNA voltage-gated potassium channel-5 inhibitor (atrial fibrillation), Xention
DMR0U4V CP Xention Ltd
DMR0U4V DE Atrial fibrillation
DMVYO41 ID DMVYO41
DMVYO41 DN XK-469
DMVYO41 HS Phase 1
DMVYO41 SN Rac-2-[4-(7-Chloroquinoxalin-2-yloxy)phenoxy]propionic acid sodium salt
DMVYO41 DT Small molecular drug
DMVYO41 PC 23675947
DMVYO41 MW 366.7
DMVYO41 FM C17H12ClN2NaO4
DMVYO41 IC InChI=1S/C17H13ClN2O4.Na/c1-10(17(21)22)23-12-3-5-13(6-4-12)24-16-9-19-14-7-2-11(18)8-15(14)20-16;/h2-10H,1H3,(H,21,22);/q;+1/p-1
DMVYO41 CS CC(C(=O)[O-])OC1=CC=C(C=C1)OC2=CN=C3C=CC(=CC3=N2)Cl.[Na+]
DMVYO41 IK OJENKXNXJPNEPU-UHFFFAOYSA-M
DMVYO41 IU sodium;2-[4-(7-chloroquinoxalin-2-yl)oxyphenoxy]propanoate
DMVYO41 CA CAS 157434-99-6
DMVYO41 DE Solid tumour/cancer
DMYSQHT ID DMYSQHT
DMYSQHT DN XL-041
DMYSQHT HS Phase 1
DMYSQHT SN XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb
DMYSQHT CP Exelixis; X-Ceptor Therapeutics Inc
DMYSQHT DE Arteriosclerosis
DM3LRAC ID DM3LRAC
DM3LRAC DN XL092
DM3LRAC HS Phase 1
DM3LRAC SN SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2
DM3LRAC CP Exelixis
DM3LRAC DT Small molecular drug
DM3LRAC PC 139350422
DM3LRAC MW 528.5
DM3LRAC FM C29H25FN4O5
DM3LRAC IC InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)
DM3LRAC CS CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F
DM3LRAC IK JSPCKALGNNVYOO-UHFFFAOYSA-N
DM3LRAC IU 1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
DM3LRAC DE Solid tumour/cancer
DME0F5W ID DME0F5W
DME0F5W DN XL418
DME0F5W HS Phase 1
DME0F5W CP Exelixis
DME0F5W TC Anticancer Agents
DME0F5W PC 56963011
DME0F5W MW 609.5
DME0F5W FM C26H32BrF3N8O
DME0F5W IC InChI=1S/C26H32BrF3N8O/c1-17-19(31-6-9-36-7-2-3-8-36)14-18(21(39)4-5-26(28,29)30)15-20(17)37-10-12-38(13-11-37)25-22-23(27)34-35-24(22)32-16-33-25/h14-16,31H,2-13H2,1H3,(H,32,33,34,35)
DME0F5W CS CC1=C(C=C(C=C1N2CCN(CC2)C3=NC=NC4=NNC(=C43)Br)C(=O)CCC(F)(F)F)NCCN5CCCC5
DME0F5W IK IKBSEBRGSVFUHM-UHFFFAOYSA-N
DME0F5W IU 1-[3-[4-(3-bromo-2H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-ylethylamino)phenyl]-4,4,4-trifluorobutan-1-one
DME0F5W CA CAS 871343-09-8
DME0F5W DE Solid tumour/cancer
DMY93SW ID DMY93SW
DMY93SW DN XL550
DMY93SW HS Phase 1
DMY93SW CP Exelixis; Daiichi-Sankyo
DMY93SW DE Type-2 diabetes
DM89NML ID DM89NML
DM89NML DN XL652/XL014
DM89NML HS Phase 1
DM89NML CP Exelixis; Bristol-Myers Squibb
DM89NML DE Metabolic disorder; Cardiovascular disease
DMYS13R ID DMYS13R
DMYS13R DN XL999
DMYS13R HS Phase 1
DMYS13R CP Exelixis
DMYS13R TC Anticancer Agents
DMYS13R PC 10433653
DMYS13R MW 445.5
DMYS13R FM C26H28FN5O
DMYS13R IC InChI=1S/C26H28FN5O/c1-3-32-11-9-19(10-12-32)30-20-7-8-22-21(14-20)24(26(33)31-22)23(25-28-15-16(2)29-25)17-5-4-6-18(27)13-17/h4-8,13-15,19,30H,3,9-12H2,1-2H3,(H,28,29)(H,31,33)/b24-23-
DMYS13R CS CCN1CCC(CC1)NC2=CC\\3=C(C=C2)NC(=O)/C3=C(/C4=CC(=CC=C4)F)\\C5=NC=C(N5)C
DMYS13R IK DMQYDVBIPXAAJA-VHXPQNKSSA-N
DMYS13R IU (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1H-imidazol-2-yl)methylidene]-1H-indol-2-one
DMYS13R CA CAS 705946-27-6
DMYS13R DE Advanced malignancy
DMXTOCE ID DMXTOCE
DMXTOCE DN XmAb13676
DMXTOCE HS Phase 1
DMXTOCE CP XencorMonrovia, CA
DMXTOCE DE B-cell lymphoma; Non-hodgkin lymphoma
DMJIH83 ID DMJIH83
DMJIH83 DN XmAb20717
DMJIH83 HS Phase 1
DMJIH83 SN XmAb717
DMJIH83 CP Xencor
DMJIH83 DT Antibody
DMJIH83 DE Solid tumour/cancer; Advanced malignancy; Melanoma; Breast cancer
DMQB3HD ID DMQB3HD
DMQB3HD DN XmAb22841
DMQB3HD HS Phase 1
DMQB3HD SN XmAb841
DMQB3HD CP Xencor
DMQB3HD DT Antibody
DMQB3HD DE Solid tumour/cancer
DMK9XUQ ID DMK9XUQ
DMK9XUQ DN XmAb23104
DMK9XUQ HS Phase 1
DMK9XUQ SN XmAb104
DMK9XUQ CP Xencor
DMK9XUQ DT Antibody
DMK9XUQ DE Solid tumour/cancer
DM6V0KY ID DM6V0KY
DM6V0KY DN Xmab-2513
DM6V0KY HS Phase 1
DM6V0KY SN XENP-0367; XENP-0522; XmAb antibodies (infusion, cancer), Xencor; Anti-CD30 humanized mAb (infusion, cancer), Xencor
DM6V0KY CP Xencor
DM6V0KY DT Antibody
DM6V0KY DE Lymphoma
DME7IVL ID DME7IVL
DME7IVL DN Xmab-7195
DME7IVL HS Phase 1
DME7IVL SN IgE inhibitor (asthma/allergy), Xencor
DME7IVL CP Xencor Inc
DME7IVL DE Asthma
DM4MDCH ID DM4MDCH
DM4MDCH DN XMT-1001
DM4MDCH HS Phase 1
DM4MDCH CP Mersana Therapeutics
DM4MDCH DE Solid tumour/cancer
DMK0AW6 ID DMK0AW6
DMK0AW6 DN XOMA-3AB
DMK0AW6 HS Phase 1
DMK0AW6 SN Botulism therapy, XOMA; Botulinum type A neurotoxin mAbs (botulism), XOMA; Anti-type A botulinum neurotoxin monoclonal antibodies (botulism), XOMA/NIAID
DMK0AW6 CP Xoma; national institute of allergy and infectious diseases
DMK0AW6 DT Antibody
DMK0AW6 DE Clostridium infection
DMO9KZE ID DMO9KZE
DMO9KZE DN XR-5944
DMO9KZE HS Phase 1
DMO9KZE SN MLN-944; XR-11576 analogs; XR-5000 analogs; XR-5942
DMO9KZE CP Xenova Group plc
DMO9KZE DT Small molecular drug
DMO9KZE PC 439035
DMO9KZE MW 586.7
DMO9KZE FM C34H34N8O2
DMO9KZE IC InChI=1S/C34H34N8O2/c1-21-7-3-11-25-29(21)41-31-23(9-5-13-27(31)39-25)33(43)37-19-17-35-15-16-36-18-20-38-34(44)24-10-6-14-28-32(24)42-30-22(2)8-4-12-26(30)40-28/h3-14,35-36H,15-20H2,1-2H3,(H,37,43)(H,38,44)
DMO9KZE CS CC1=C2C(=CC=C1)N=C3C=CC=C(C3=N2)C(=O)NCCNCCNCCNC(=O)C4=CC=CC5=NC6=CC=CC(=C6N=C54)C
DMO9KZE IK SFOADSRLCHRTKT-UHFFFAOYSA-N
DMO9KZE IU 9-methyl-N-[2-[2-[2-[(9-methylphenazine-1-carbonyl)amino]ethylamino]ethylamino]ethyl]phenazine-1-carboxamide
DMO9KZE CA CAS 343247-32-5
DMO9KZE DE Gastric adenocarcinoma
DML3K9N ID DML3K9N
DML3K9N DN XTL-6865
DML3K9N HS Phase 1
DML3K9N CP XTL Biopharmaceuticals
DML3K9N DE Hepatitis C virus infection
DMKHVNE ID DMKHVNE
DMKHVNE DN YKP-1358
DMKHVNE HS Phase 1
DMKHVNE CP SK Pharmaceuticals
DMKHVNE DE Schizoaffective disorder; Schizophrenia
DMW2HS8 ID DMW2HS8
DMW2HS8 DN YM-116
DMW2HS8 HS Phase 1
DMW2HS8 CP Yamanouchi Pharmaceutical Co Ltd
DMW2HS8 PC 9795793
DMW2HS8 MW 247.29
DMW2HS8 FM C16H13N3
DMW2HS8 IC InChI=1S/C16H13N3/c1-2-4-15-13(3-1)14-6-5-11(8-16(14)19-15)7-12-9-17-10-18-12/h1-6,8-10,19H,7H2,(H,17,18)
DMW2HS8 CS C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)CC4=CN=CN4
DMW2HS8 IK SHWQRVBJVFBWGP-UHFFFAOYSA-N
DMW2HS8 IU 2-(1H-imidazol-5-ylmethyl)-9H-carbazole
DMW2HS8 DE Solid tumour/cancer
DMNLY9R ID DMNLY9R
DMNLY9R DN YM-16151-4
DMNLY9R HS Phase 1
DMNLY9R SN YM-151; YM-16151-1; (-)-YM-16151-1
DMNLY9R CP Yamanouchi Pharmaceutical Co Ltd
DMNLY9R DT Small molecular drug
DMNLY9R PC 128387
DMNLY9R MW 583.6
DMNLY9R FM C30H37N3O9
DMNLY9R IC InChI=1S/C30H37N3O9/c1-19-26(29(35)39-3)28(27(20(2)32-19)30(36)40-4)24-16-21(33(37)38)12-13-25(24)41-15-9-8-14-31-17-22(34)18-42-23-10-6-5-7-11-23/h5-7,10-13,16,22,28,31-32,34H,8-9,14-15,17-18H2,1-4H3
DMNLY9R CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=C(C=CC(=C2)[N+](=O)[O-])OCCCCNCC(COC3=CC=CC=C3)O)C(=O)OC
DMNLY9R IK GQJFGCIETONRNJ-UHFFFAOYSA-N
DMNLY9R IU dimethyl 4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-nitrophenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMNLY9R CA CAS 103434-30-6
DMNLY9R DE Hypertension
DMS31YW ID DMS31YW
DMS31YW DN YM-57158
DMS31YW HS Phase 1
DMS31YW SN YM-158; 3-(4-tert-Butylthiazol-2-ylmethoxy)-N-[5-[3-(4-chlorophenylsulfonyl)propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]benzamide monosodium salt monohydrate
DMS31YW DT Small molecular drug
DMS31YW PC 5312140
DMS31YW MW 721.2
DMS31YW FM C32H34ClN6NaO6S2
DMS31YW IC InChI=1S/C32H33ClN6O5S2.Na.H2O/c1-32(2,3)28-20-45-30(35-28)19-43-24-8-4-7-22(17-24)31(40)34-26-16-21(9-14-27(26)44-18-29-36-38-39-37-29)6-5-15-46(41,42)25-12-10-23(33)11-13-25;;/h4,7-14,16-17,20H,5-6,15,18-19H2,1-3H3,(H2,34,36,37,38,39,40);;1H2/q;+1;/p-1
DMS31YW CS CC(C)(C)C1=CSC(=N1)COC2=CC=CC(=C2)C(=O)[N-]C3=C(C=CC(=C3)CCCS(=O)(=O)C4=CC=C(C=C4)Cl)OCC5=NNN=N5.O.[Na+]
DMS31YW IK XHOMMMSIYBSJNL-UHFFFAOYSA-M
DMS31YW IU sodium;[3-[(4-tert-butyl-1,3-thiazol-2-yl)methoxy]benzoyl]-[5-[3-(4-chlorophenyl)sulfonylpropyl]-2-(2H-tetrazol-5-ylmethoxy)phenyl]azanide;hydrate
DMS31YW DE Allergic rhinitis
DMCM0K6 ID DMCM0K6
DMCM0K6 DN YPEG-Somatropin
DMCM0K6 HS Phase 1
DMCM0K6 SN YPEG-Somatropin (growth hormone deficiency)
DMCM0K6 CP Xiamen Amoytop Biotech Co Ltd
DMCM0K6 DE Growth hormone deficiency
DM5BMIO ID DM5BMIO
DM5BMIO DN YTB323
DM5BMIO HS Phase 1
DM5BMIO CP Novartis
DM5BMIO DT CAR T Cell Therapy
DM5BMIO DE Diffuse large B-cell lymphoma; Chronic lymphocytic leukaemia; Small lymphocytic lymphoma
DM1H75D ID DM1H75D
DM1H75D DN Z-100
DM1H75D HS Phase 1
DM1H75D SN Ancer; SSM; Specific Substance of Maruyama; Ancer 20
DM1H75D CP Zeria Pharmaceutical Co Ltd
DM1H75D DE Human immunodeficiency virus infection
DMZQP7N ID DMZQP7N
DMZQP7N DN ZD7114
DMZQP7N HS Phase 1
DMZQP7N SN Zeneca ZD7114; ZD7114; ZD 7114; ICI D7114; UNII-EF5S87KTK2; EF5S87KTK2; (S)-4-(2-Hydroxy-3-phenoxypropylaminoethoxy)-N-(2-methoxyethyl)phenoxyacetamide; Acetamide, 2-(4-(2-((2-hydroxy-3-phenoxypropyl)amino)ethoxy)phenoxy)-N-(2-methoxyethyl)-, (S)-; C22H30N2O6; 129689-30-1; AC1L3TKA; SCHEMBL304881; CHEMBL1788312; ICI-D-7114; ZINC3793213; LS-9736; API0009229; 2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide; NCGC00163153-01; AJ-45629
DMZQP7N DT Small molecular drug
DMZQP7N PC 121877
DMZQP7N MW 418.5
DMZQP7N FM C22H30N2O6
DMZQP7N IC InChI=1S/C22H30N2O6/c1-27-13-12-24-22(26)17-30-21-9-7-20(8-10-21)28-14-11-23-15-18(25)16-29-19-5-3-2-4-6-19/h2-10,18,23,25H,11-17H2,1H3,(H,24,26)/t18-/m0/s1
DMZQP7N CS COCCNC(=O)COC1=CC=C(C=C1)OCCNC[C@@H](COC2=CC=CC=C2)O
DMZQP7N IK RVMBDLSFFNKKLG-SFHVURJKSA-N
DMZQP7N IU 2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide
DMZQP7N CA CAS 129689-30-1
DMZQP7N DE Diabetic complication
DM3KYO4 ID DM3KYO4
DM3KYO4 DN ZD-9379
DM3KYO4 HS Phase 1
DM3KYO4 CP AstraZeneca plc
DM3KYO4 PC 9843028
DM3KYO4 MW 383.8
DM3KYO4 FM C19H14ClN3O4
DM3KYO4 IC InChI=1S/C19H14ClN3O4/c1-9-7-11(27-2)4-6-14(9)23-19(26)15-16(18(25)22-23)21-13-8-10(20)3-5-12(13)17(15)24/h3-8H,1-2H3,(H,21,24)(H,22,25)
DM3KYO4 CS CC1=C(C=CC(=C1)OC)N2C(=O)C3=C(C(=O)N2)NC4=C(C3=O)C=CC(=C4)Cl
DM3KYO4 IK PSTDMIAVUUYOOQ-UHFFFAOYSA-N
DM3KYO4 IU 7-chloro-2-(4-methoxy-2-methylphenyl)-3,5-dihydropyridazino[4,5-b]quinoline-1,4,10-trione
DM3KYO4 DE Cerebrovascular ischaemia
DM2S04R ID DM2S04R
DM2S04R DN Zemab
DM2S04R HS Phase 1
DM2S04R CP Novartis AG
DM2S04R DT Antibody
DM2S04R DE Solid tumour/cancer
DM72GZV ID DM72GZV
DM72GZV DN ZEN003694
DM72GZV HS Phase 1
DM72GZV CP Zenith Epigenetics
DM72GZV DT Small molecular drug
DM72GZV DE Prostate cancer
DM2LHPU ID DM2LHPU
DM2LHPU DN ZK-200775
DM2LHPU HS Phase 1
DM2LHPU SN Fanapanel; MPQX; 161605-73-8; ZK 200775; ZK200775; Fanapanel [INN]; UNII-E3AP71EM0O; ZK-200775; E3AP71EM0O; NCGC00159553-01; [7-morpholin-4-yl-2,3-dioxo-6-(trifluoromethyl)-4H-quinoxalin-1-yl]methylphosphonic acid; DSSTox_RID_81332; DSSTox_CID_26093; DSSTox_GSID_46093; ((3,4-Dihydro-7-morpholino-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl)methyl)phosphonic acid; {[7-Morpholin-4-Yl-2,3-Dioxo-6-(Trifluoromethyl)-3,4-Dihydroquinoxalin-1(2h)-Yl]methyl}phosphonic Acid; CAS-161605-73-8; C14H15F3N3O6P; ZK1; AC1L4LOG; AC1Q6RR4
DM2LHPU DT Small molecular drug
DM2LHPU PC 208953
DM2LHPU MW 409.25
DM2LHPU FM C14H15F3N3O6P
DM2LHPU IC InChI=1S/C14H15F3N3O6P/c15-14(16,17)8-5-9-11(6-10(8)19-1-3-26-4-2-19)20(7-27(23,24)25)13(22)12(21)18-9/h5-6H,1-4,7H2,(H,18,21)(H2,23,24,25)
DM2LHPU CS C1COCCN1C2=CC3=C(C=C2C(F)(F)F)NC(=O)C(=O)N3CP(=O)(O)O
DM2LHPU IK WZMQMKNCWDCCMT-UHFFFAOYSA-N
DM2LHPU IU [7-morpholin-4-yl-2,3-dioxo-6-(trifluoromethyl)-4H-quinoxalin-1-yl]methylphosphonic acid
DM2LHPU CA CAS 161605-73-8
DM2LHPU DE Coronary artery disease
DMTNUA4 ID DMTNUA4
DMTNUA4 DN ZL-1201
DMTNUA4 HS Phase 1
DMTNUA4 CP ZAI Lab
DMTNUA4 DT Antibody
DMTNUA4 DE Solid tumour/cancer
DMX6AJ8 ID DMX6AJ8
DMX6AJ8 DN ZM-H1505R
DMX6AJ8 HS Phase 1
DMX6AJ8 CP Shanghai Zhimeng Biopharma
DMX6AJ8 DT Small molecular drug
DMX6AJ8 DE Hepatitis B
DMGTL8Z ID DMGTL8Z
DMGTL8Z DN ZP-1848
DMGTL8Z HS Phase 1
DMGTL8Z SN Glucagon-like peptide-2 analog (inflammatory bowel disease/ Crohn's disease), Zealand
DMGTL8Z CP Zealand Pharma A/S
DMGTL8Z DE Inflammatory bowel disease
DMRVDUM ID DMRVDUM
DMRVDUM DN ZP2929
DMRVDUM HS Phase 1
DMRVDUM CP Zealand Pharma A/S
DMRVDUM DE Diabetic complication; Obesity; Type-1 diabetes
DMVIMQX ID DMVIMQX
DMVIMQX DN ZSTK474
DMVIMQX HS Phase 1
DMVIMQX SN ZSTK474; 475110-96-4; ZSTK-474; 4,4'-(6-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazine-2,4-diyl)dimorpholine; ZSTK 474; TCMDC-137004; UNII-K0068GK39A; CHEMBL586702; CHEBI:90545; K0068GK39A; 2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine; 2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-bis(morpholino)-1,3,5-triazine; AK-40326; 2-(Difluoromethyl)-1-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)-1h-Benzimidazole; C19H21F2N7O2; 2wxl; PubChem22461; SCHEMBL373282; QCR-72; GTPL7965; CTK8B6247; SYN1099
DMVIMQX TC Anticancer Agents
DMVIMQX DT Small molecular drug
DMVIMQX PC 11647372
DMVIMQX MW 417.4
DMVIMQX FM C19H21F2N7O2
DMVIMQX IC InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
DMVIMQX CS C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5
DMVIMQX IK HGVNLRPZOWWDKD-UHFFFAOYSA-N
DMVIMQX IU 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine
DMVIMQX CA CAS 475110-96-4
DMVIMQX CB CHEBI:90545
DMVIMQX DE Solid tumour/cancer
DMO2WYX ID DMO2WYX
DMO2WYX DN ZT-1
DMO2WYX HS Phase 1
DMO2WYX SN (5R,9R)-5-(5-Chloro-2-hydroxy-3-methoxybenzylideneamino)-11-ethylidene-7-methyl-1,2,5,6,9,10-hexahydro-5,9-methanocycloocta[b]pyridin-2-one; 180694-97-7
DMO2WYX DT Small molecular drug
DMO2WYX PC 135543744
DMO2WYX MW 410.9
DMO2WYX FM C23H23ClN2O3
DMO2WYX IC InChI=1S/C23H23ClN2O3/c1-4-17-14-7-13(2)11-23(17,18-5-6-21(27)26-19(18)9-14)25-12-15-8-16(24)10-20(29-3)22(15)28/h4-8,10,12,14,28H,9,11H2,1-3H3,(H,26,27)/b17-4+,25-12?/t14-,23+/m0/s1
DMO2WYX CS C/C=C/1\\[C@@H]2CC3=C([C@]1(CC(=C2)C)N=CC4=C(C(=CC(=C4)Cl)OC)O)C=CC(=O)N3
DMO2WYX IK UYRWZANUXPUEPQ-OWNLDCJBSA-N
DMO2WYX IU (1R,9R,13E)-1-[(5-chloro-2-hydroxy-3-methoxyphenyl)methylideneamino]-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMO2WYX CA CAS 180694-97-7
DMO2WYX DE Parkinson disease
DMAU8L9 ID DMAU8L9
DMAU8L9 DN ZW49
DMAU8L9 HS Phase 1
DMAU8L9 CP Zymeworks
DMAU8L9 DT Antibody drug conjugate
DMAU8L9 DE Solid tumour/cancer
DMSLPTO ID DMSLPTO
DMSLPTO DN ZY01
DMSLPTO HS Phase 1
DMSLPTO CP Zydus Cadila Group
DMSLPTO DE Diabetic complication; Obesity
DM796RI ID DM796RI
DM796RI DN ZYAN1
DM796RI HS Phase 1
DM796RI SN Desidustat; 1616690-16-4; UNII-Y962PQA4KS; Y962PQA4KS; 1,2-dihydroquinoline-3-carbonyl]glycine; N-[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-; 2-(1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetic acid; ZYAN1 compound; Desidustat [INN]; SCHEMBL15846922; BCP29692; EX-A2999; s9699; ZB1514; CS-8034; BS-16050; HY-103227; A16921; 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid; Glycine, N-((1-(cyclopropylmethoxy)-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl)carbonyl)-; N-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine
DM796RI CP Zydus Cadila
DM796RI DT Small molecular drug
DM796RI PC 75593290
DM796RI MW 332.31
DM796RI FM C16H16N2O6
DM796RI IC InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)
DM796RI CS C1CC1CON2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O
DM796RI IK IKRKQQLJYBAPQT-UHFFFAOYSA-N
DM796RI IU 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid
DM796RI CA CAS 1616690-16-4
DM796RI DE Anaemia
DMU2D0B ID DMU2D0B
DMU2D0B DN ZYDPLA 1
DMU2D0B HS Phase 1
DMU2D0B CP Cadila Healthcare Gujarat, India
DMU2D0B DE Type-2 diabetes
DM4IG16 ID DM4IG16
DM4IG16 DN ZYGK-1
DM4IG16 HS Phase 1
DM4IG16 SN Glucokinase activator (oral, diabetes), Zydus-Cadila
DM4IG16 CP Zydus-Cadila Group
DM4IG16 DE Diabetic complication
DMZ6042 ID DMZ6042
DMZ6042 DN ZYOG1
DMZ6042 HS Phase 1
DMZ6042 CP Zydus Cadila Group
DMZ6042 DE Diabetic complication
DM1XOZK ID DM1XOZK
DM1XOZK DN ZYT-1
DM1XOZK HS Phase 1
DM1XOZK SN Lipid lowering molecule (dyslipidemia), Zydus-Cadila
DM1XOZK CP Zydus-Cadila Group
DM1XOZK DE Lipid metabolism disorder
DMX1ZQV ID DMX1ZQV
DMX1ZQV DN (S)-DRF-1042
DMX1ZQV HS Clinical trial
DMX1ZQV SN 5(S)-(2'-hydroxyethoxy)-20(S)-camptothecin; 5(S)-(2'-hydroxyethoxy)-20(S)-CPT
DMX1ZQV DT Small molecular drug
DMX1ZQV PC 91623363
DMX1ZQV MW 408.4
DMX1ZQV FM C22H20N2O6
DMX1ZQV IC InChI=1S/C22H20N2O6/c1-2-22(28)11-13-10-16-17-14(9-12-5-3-4-6-15(12)23-17)20(29-8-7-25)24(16)19(26)18(13)30-21(22)27/h3-6,9-10,20,25,28H,2,7-8,11H2,1H3/t20-,22-/m0/s1
DMX1ZQV CS CC[C@@]1(CC2=C(C(=O)N3[C@H](C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)OC1=O)O
DMX1ZQV IK UPAYPYZHFCRCMO-UNMCSNQZSA-N
DMX1ZQV IU (12S,18S)-18-ethyl-18-hydroxy-12-(2-hydroxyethoxy)-16-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,17-dione
DMX1ZQV DE Bladder cancer
DMN2I3P ID DMN2I3P
DMN2I3P DN alpha-ketothiazole analogue 36
DMN2I3P HS Clinical trial
DMN2I3P SN alpha-ketothiazole analogue 36; GTPL6549; CHEMBL273653; BDBM12976; (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide
DMN2I3P DT Small molecular drug
DMN2I3P PC 16098914
DMN2I3P MW 723.7
DMN2I3P FM C29H43BrN10O5S
DMN2I3P IC InChI=1S/C29H43BrN10O5S/c1-16(2)22(25(43)38-20(6-4-12-35-27(31)32)23(41)26-34-14-15-46-26)40-24(42)21(7-5-13-36-28(33)44)39-29(45)37-17(3)18-8-10-19(30)11-9-18/h8-11,14-17,20-22H,4-7,12-13H2,1-3H3,(H,38,43)(H,40,42)(H4,31,32,35)(H3,33,36,44)(H2,37,39,45)/t17-,20+,21+,22+/m1/s1
DMN2I3P CS C[C@H](C1=CC=C(C=C1)Br)NC(=O)N[C@@H](CCCNC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)C2=NC=CS2
DMN2I3P IK BGBJLVHKOHYLME-MNAPGUCWSA-N
DMN2I3P IU (2S)-2-[[(1R)-1-(4-bromophenyl)ethyl]carbamoylamino]-5-(carbamoylamino)-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pentanamide
DMN2I3P DE Alzheimer disease
DM6NVPT ID DM6NVPT
DM6NVPT DN Anti-CD19 Chimeric Antigen Receptor T Cells
DM6NVPT HS Clinical trial
DM6NVPT CP National Taiwan University Hospital
DM6NVPT DT CAR T Cell Therapy
DM6NVPT DE leukaemia
DM3M9OY ID DM3M9OY
DM3M9OY DN Anti-CD19/20-CAR vector-transduced T cells
DM3M9OY HS Clinical trial
DM3M9OY CP Chinese PLA General Hospital
DM3M9OY DT CAR T Cell Therapy (Dual specific)
DM3M9OY DE Acute lymphoblastic leukaemia; B-cell chronic lymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Prolymphocytic leukaemia
DMGPTFL ID DMGPTFL
DMGPTFL DN AZ-4217
DMGPTFL HS Clinical trial
DMGPTFL SN AZ4217; AZ 4217
DMGPTFL DT Small molecular drug
DMGPTFL PC 57406537
DMGPTFL MW 476.5
DMGPTFL FM C30H25FN4O
DMGPTFL IC InChI=1S/C30H25FN4O/c1-4-8-20-14-22(17-33-16-20)21-9-6-10-23(15-21)30(24-13-19(3)29(36)35(5-2)18-24)25-11-7-12-26(31)27(25)28(32)34-30/h6-7,9-18H,5H2,1-3H3,(H2,32,34)/t30-/m0/s1
DMGPTFL CS CCN1C=C(C=C(C1=O)C)[C@]2(C3=C(C(=CC=C3)F)C(=N2)N)C4=CC=CC(=C4)C5=CN=CC(=C5)C#CC
DMGPTFL IK TUGLMYZSOPKJOA-PMERELPUSA-N
DMGPTFL IU 5-[(1R)-3-amino-4-fluoro-1-[3-(5-prop-1-ynylpyridin-3-yl)phenyl]isoindol-1-yl]-1-ethyl-3-methylpyridin-2-one
DMGPTFL DE Rheumatoid arthritis
DMCEPKM ID DMCEPKM
DMCEPKM DN BCMA-CART
DMCEPKM HS Clinical trial
DMCEPKM CP Shanghai Bioray Laboratory Inc.
DMCEPKM DT CAR T Cell Therapy
DMCEPKM DE Multiple myeloma
DMWXGRQ ID DMWXGRQ
DMWXGRQ DN BCMA-UCART
DMWXGRQ HS Clinical trial
DMWXGRQ CP Shanghai Bioray Laboratory Inc.
DMWXGRQ DT CAR T Cell Therapy
DMWXGRQ DE Multiple myeloma
DM531SA ID DM531SA
DM531SA DN bimatoprost (free acid form)
DM531SA HS Clinical trial
DM531SA SN 17-phenyl-omega-trinor-PGF2alpha
DM531SA DT Small molecular drug
DM531SA PC 5283081
DM531SA MW 388.5
DM531SA FM C23H32O5
DM531SA IC InChI=1S/C23H32O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-22,24-26H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,21-,22+/m0/s1
DM531SA CS C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](CCC2=CC=CC=C2)O)C/C=C\\CCCC(=O)O)O
DM531SA IK YFHHIZGZVLHBQZ-KDACTHKWSA-N
DM531SA IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enoic acid
DM531SA CA CAS 38344-08-0
DM531SA CB CHEBI:73773
DM531SA DE Alzheimer disease
DMN2EI1 ID DMN2EI1
DMN2EI1 DN bis-triazole derivative 10
DMN2EI1 HS Clinical trial
DMN2EI1 SN CHEMBL2016873; bis-triazole derivative 10; GTPL6537; SCHEMBL15308834
DMN2EI1 DT Small molecular drug
DMN2EI1 PC 56599309
DMN2EI1 MW 681.8
DMN2EI1 FM C33H35N11O4S
DMN2EI1 IC InChI=1S/C33H35N11O4S/c34-31(35)26-11-9-22(10-12-26)16-36-32(45)29-14-27-19-43(41-38-27)17-24-7-4-8-25(13-24)18-44-20-28(39-42-44)15-30(33(46)37-29)40-49(47,48)21-23-5-2-1-3-6-23/h1-13,19-20,29-30,40H,14-18,21H2,(H3,34,35)(H,36,45)(H,37,46)/t29-,30+/m0/s1
DMN2EI1 CS C1[C@H](C(=O)N[C@@H](CC2=CN(CC3=CC=CC(=C3)CN4C=C1N=N4)N=N2)C(=O)NCC5=CC=C(C=C5)C(=N)N)NS(=O)(=O)CC6=CC=CC=C6
DMN2EI1 IK BKSCOHJNKDJECO-XZWHSSHBSA-N
DMN2EI1 IU (8S,11R)-11-(benzylsulfonylamino)-N-[(4-carbamimidoylphenyl)methyl]-10-oxo-3,4,5,9,14,15,16-heptazatetracyclo[16.3.1.13,6.113,16]tetracosa-1(21),4,6(24),13(23),14,18(22),19-heptaene-8-carboxamide
DMN2EI1 DE Otitis media
DMLF2UY ID DMLF2UY
DMLF2UY DN CAR-BCMA T cell
DMLF2UY HS Clinical trial
DMLF2UY CP Kang YU
DMLF2UY DT CAR T Cell Therapy
DMLF2UY DE Multiple myeloma
DMXU2D1 ID DMXU2D1
DMXU2D1 DN CAR-CD19 T cell
DMXU2D1 HS Clinical trial
DMXU2D1 CP Kang YU
DMXU2D1 DT CAR T Cell Therapy
DMXU2D1 DE B-cell lymphoma; leukaemia
DM6ZHTV ID DM6ZHTV
DM6ZHTV DN CAR-CLD18 T cell
DM6ZHTV HS Clinical trial
DM6ZHTV CP Kang YU
DM6ZHTV DT CAR T Cell Therapy
DM6ZHTV DE Adenocarcinoma; Pancreatic cancer
DMBDT3V ID DMBDT3V
DMBDT3V DN CAR-GPC3 T cell
DMBDT3V HS Clinical trial
DMBDT3V CP Kang YU
DMBDT3V DT CAR T Cell Therapy
DMBDT3V DE Hepatocellular carcinoma
DM0RX5E ID DM0RX5E
DM0RX5E DN CAR-GPC3 T cells
DM0RX5E HS Clinical trial
DM0RX5E CP RenJi Hospital
DM0RX5E DT CAR T Cell Therapy
DM0RX5E DE Hepatocellular carcinoma
DMGW10M ID DMGW10M
DMGW10M DN CAR-T cells targeting BCMA
DMGW10M HS Clinical trial
DMGW10M CP Zhujiang Hospital
DMGW10M DT CAR T Cell Therapy
DMGW10M DE Multiple myeloma
DMHBQYU ID DMHBQYU
DMHBQYU DN CAR-T cells targeting CD138
DMHBQYU HS Clinical trial
DMHBQYU CP Zhujiang Hospital
DMHBQYU DT CAR T Cell Therapy
DMHBQYU DE Multiple myeloma
DMH5C37 ID DMH5C37
DMH5C37 DN CAR-T cells targeting CD38
DMH5C37 HS Clinical trial
DMH5C37 CP Zhujiang Hospital
DMH5C37 DT CAR T Cell Therapy
DMH5C37 DE Multiple myeloma; Acute myeloid leukaemia
DMAK1ME ID DMAK1ME
DMAK1ME DN CAR-T cells targeting CD56
DMAK1ME HS Clinical trial
DMAK1ME CP Zhujiang Hospital
DMAK1ME DT CAR T Cell Therapy
DMAK1ME DE Multiple myeloma; Acute myeloid leukaemia
DMUEQ6C ID DMUEQ6C
DMUEQ6C DN CART-meso cells
DMUEQ6C HS Clinical trial
DMUEQ6C CP Shenzhen BinDeBio Ltd.
DMUEQ6C DT CAR T Cell Therapy
DMUEQ6C DE Pancreatic cancer
DM2V6R7 ID DM2V6R7
DM2V6R7 DN CD19-CAR T Cells
DM2V6R7 HS Clinical trial
DM2V6R7 CP First Affiliated Hospital of Harbin Medical University
DM2V6R7 DT CAR T Cell Therapy
DM2V6R7 DE Acute lymphoblastic leukaemia
DMF936G ID DMF936G
DMF936G DN CD19CART
DMF936G HS Clinical trial
DMF936G CP Innovative Cellular Therapeutics Co., Ltd.
DMF936G DT CAR T Cell Therapy
DMF936G DE B-cell lymphoma; leukaemia
DMLPAFG ID DMLPAFG
DMLPAFG DN CD19-targeted CAR-T cells
DMLPAFG HS Clinical trial
DMLPAFG CP Qingdao Central Hospital
DMLPAFG DT CAR T Cell Therapy
DMLPAFG DE leukaemia
DMS87UT ID DMS87UT
DMS87UT DN CD19-targeted CAR-T cells
DMS87UT HS Clinical trial
DMS87UT CP Sinobioway Cell Therapy Co., Ltd.
DMS87UT DT CAR T Cell Therapy
DMS87UT DE leukaemia; Lymphoma
DM8VTF2 ID DM8VTF2
DM8VTF2 DN CD19-UCART
DM8VTF2 HS Clinical trial
DM8VTF2 CP Shanghai Bioray Laboratory Inc.
DM8VTF2 DT CAR T Cell Therapy
DM8VTF2 DE Acute lymphoblastic leukaemia; Non-hodgkin lymphoma
DMXM19W ID DMXM19W
DMXM19W DN dequalinium
DMXM19W HS Clinical trial
DMXM19W SN dequalinium; Dequadin; 6707-58-0; UNII-E7QC7V26B8; Dequavagyn; Decamine; Labosept; Sorot; GNF-Pf-5483; E7QC7V26B8; CHEBI:41872; Polycidine; Dequavet; Dekadin; Rumilet; Dekamin; Sentril; Sanoral; Oralgol; Ivazil; Dequadin chloride; Dequalin chloride; C30H40N4; DEQ; 1,1'-decane-1,10-diylbis(4-amino-2-methylquinolinium); Solvidont; Quinolinium, 1,1'-(1,10-decanediyl)bis(4-amino-2-methyl-; 1-[10-(4-amino-2-methylquinolyl)decyl]-2-methyl-4-quinolylamine; CHEMBL121663
DMXM19W DT Small molecular drug
DMXM19W PC 2993
DMXM19W MW 456.7
DMXM19W FM C30H40N4+2
DMXM19W IC InChI=1S/C30H38N4/c1-23-21-27(31)25-15-9-11-17-29(25)33(23)19-13-7-5-3-4-6-8-14-20-34-24(2)22-28(32)26-16-10-12-18-30(26)34/h9-12,15-18,21-22,31-32H,3-8,13-14,19-20H2,1-2H3/p+2
DMXM19W CS CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C
DMXM19W IK PCSWXVJAIHCTMO-UHFFFAOYSA-P
DMXM19W IU 1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine
DMXM19W CA CAS 6707-58-0
DMXM19W CB CHEBI:41872
DMXM19W DE Myelopathy
DMV6RMB ID DMV6RMB
DMV6RMB DN EPCAM-targeted CAR-T cells
DMV6RMB HS Clinical trial
DMV6RMB CP Sinobioway Cell Therapy Co., Ltd.
DMV6RMB DT CAR T Cell Therapy
DMV6RMB DE Liver cancer; Gastric adenocarcinoma
DM2N653 ID DM2N653
DM2N653 DN example 98 (WO2011020806)
DM2N653 HS Clinical trial
DM2N653 SN GTPL6540; SCHEMBL1173236; example 98 [WO2011020806]
DM2N653 DT Small molecular drug
DM2N653 PC 50991498
DM2N653 MW 376.8
DM2N653 FM C18H18ClFN4O2
DM2N653 IC InChI=1S/C18H18ClFN4O2/c1-10-5-11(19)7-22-16(10)17(25)23-12-3-4-14(20)13(6-12)18(2)9-26-8-15(21)24-18/h3-7H,8-9H2,1-2H3,(H2,21,24)(H,23,25)/t18-/m0/s1
DM2N653 CS CC1=CC(=CN=C1C(=O)NC2=CC(=C(C=C2)F)[C@@]3(COCC(=N3)N)C)Cl
DM2N653 IK RAFVKOLBEOKYJW-SFHVURJKSA-N
DM2N653 IU N-[3-[(3R)-5-amino-3-methyl-2,6-dihydro-1,4-oxazin-3-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide
DM2N653 DE Focal segmental glomerulosclerosis
DM87BTM ID DM87BTM
DM87BTM DN GD2-targeted CAR-T cells
DM87BTM HS Clinical trial
DM87BTM CP Sinobioway Cell Therapy Co., Ltd.
DM87BTM DT CAR T Cell Therapy
DM87BTM DE Neuroblastoma
DM7W6YN ID DM7W6YN
DM7W6YN DN GR148672X
DM7W6YN HS Clinical trial
DM7W6YN DT Small molecular drug
DM7W6YN PC 135457124
DM7W6YN MW 340.3
DM7W6YN FM C15H11F3N2O2S
DM7W6YN IC InChI=1S/C15H11F3N2O2S/c1-9-4-2-5-10(8-9)19-20-12(14(22)15(16,17)18)13(21)11-6-3-7-23-11/h2-8,21H,1H3
DM7W6YN CS CC1=CC(=CC=C1)N=NC(=C(C2=CC=CS2)O)C(=O)C(F)(F)F
DM7W6YN IK OETQEFUTOKYBSL-UHFFFAOYSA-N
DM7W6YN IU 1,1,1-trifluoro-4-hydroxy-3-[(3-methylphenyl)diazenyl]-4-thiophen-2-ylbut-3-en-2-one
DM7W6YN CA CAS 263890-70-6
DM7W6YN DE Acute lymphoblastic leukaemia
DMCV5ND ID DMCV5ND
DMCV5ND DN GSK-264220A
DMCV5ND HS Clinical trial
DMCV5ND SN GSK 264220A; 685506-42-7; CHEMBL513349; 3-[2-methyl-5-(piperidine-1-sulfonyl)furan-3-yl]-1-phenylurea; GSK-264220A; AC1MDFFU; AC1Q2G0T; MLS000850100; GTPL6697; SCHEMBL15798229; CTK8F0072; DTXSID30384608; MolPort-001-806-822; HMS2799K10; HMS3648O15; ZINC4324633; 1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea; BDBM50254290; AKOS024457788; MCULE-4804513903; CCG-242835; NCGC00344077-02; SMR000456118; RT-013120; SR-01000774442; SR-01000774442-2; N-[2-methyl-5-(piperidinosulfonyl)-3-furyl]-N'-phenylurea
DMCV5ND DT Small molecular drug
DMCV5ND PC 2810413
DMCV5ND MW 363.4
DMCV5ND FM C17H21N3O4S
DMCV5ND IC InChI=1S/C17H21N3O4S/c1-13-15(19-17(21)18-14-8-4-2-5-9-14)12-16(24-13)25(22,23)20-10-6-3-7-11-20/h2,4-5,8-9,12H,3,6-7,10-11H2,1H3,(H2,18,19,21)
DMCV5ND CS CC1=C(C=C(O1)S(=O)(=O)N2CCCCC2)NC(=O)NC3=CC=CC=C3
DMCV5ND IK LVOVQRPAMXCXTM-UHFFFAOYSA-N
DMCV5ND IU 1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea
DMCV5ND CA CAS 685506-42-7
DMCV5ND DE Coagulation defect
DM5I2HL ID DM5I2HL
DM5I2HL DN GSK269962A
DM5I2HL HS Clinical trial
DM5I2HL SN GSK-269962A; GSK269962; GSK 269962; GSK-269962; aminofurazanyl-azabenzimidazole 6n
DM5I2HL DT Small molecular drug
DM5I2HL PC 16095342
DM5I2HL MW 570.6
DM5I2HL FM C29H30N8O5
DM5I2HL IC InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38)
DM5I2HL CS CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6
DM5I2HL IK YOVNFNXUCOWYSG-UHFFFAOYSA-N
DM5I2HL IU N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide
DM5I2HL CA CAS 925213-63-4
DM5I2HL DE Inflammation
DM21Y8J ID DM21Y8J
DM21Y8J DN isatin sulfonamide 34
DM21Y8J HS Clinical trial
DM21Y8J SN CHEMBL439753; Isatin Sulfonamide 34; JMC522188 Compound 2; Pyrrolidine Isatin Analogue 2; GTPL6515; SCHEMBL2264739; BDBM10323; PKOUAUWPBMZQCH-FQEVSTJZSA-N; isatin sulfonamide 34 [PMID: 11384246]; (S)-1-Benzyl-5-{1-[2-(phenoxymethyl)pyrrolidinyl]sulfonyl}isatin; (s)-1-benzyl-5-[1-[2-(phenoxymethyl)pyrrolidinyl]sulfonyl]-isatin; 5-[(2S)-2-(phenoxymethyl)pyrrolidin-1-yl]sulfonyl-1-(phenylmethyl)indole-2,3-dione; (S)-1-benzyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione
DM21Y8J DT Small molecular drug
DM21Y8J PC 9847835
DM21Y8J MW 476.5
DM21Y8J FM C26H24N2O5S
DM21Y8J IC InChI=1S/C26H24N2O5S/c29-25-23-16-22(13-14-24(23)27(26(25)30)17-19-8-3-1-4-9-19)34(31,32)28-15-7-10-20(28)18-33-21-11-5-2-6-12-21/h1-6,8-9,11-14,16,20H,7,10,15,17-18H2/t20-/m0/s1
DM21Y8J CS C1C[C@H](N(C1)S(=O)(=O)C2=CC3=C(C=C2)N(C(=O)C3=O)CC4=CC=CC=C4)COC5=CC=CC=C5
DM21Y8J IK PKOUAUWPBMZQCH-FQEVSTJZSA-N
DM21Y8J IU 1-benzyl-5-[(2S)-2-(phenoxymethyl)pyrrolidin-1-yl]sulfonylindole-2,3-dione
DM21Y8J DE Cystic fibrosis
DMDU6GN ID DMDU6GN
DMDU6GN DN JNJ-479655
DMDU6GN HS Clinical trial
DMDU6GN SN 1428327-31-4; N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide; JNJ-47965567; JNJ 47965567; N-{[4-(4-Phenylpiperazin-1-Yl)oxan-4-Yl]methyl}-2-(Phenylsulfanyl)pyridine-3-Carboxamide; P2X Antagonist III; antagonist JNJ47965567; GTPL7538; CHEMBL2338352; MolPort-035-941-198; ZINC95590396; AKOS025142079; JNJ47965567; NCGC00387264-01; J-115; JNJ-47965567, > Z2235332565; N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide
DMDU6GN DT Small molecular drug
DMDU6GN PC 66553218
DMDU6GN MW 488.6
DMDU6GN FM C28H32N4O2S
DMDU6GN IC InChI=1S/C28H32N4O2S/c33-26(25-12-7-15-29-27(25)35-24-10-5-2-6-11-24)30-22-28(13-20-34-21-14-28)32-18-16-31(17-19-32)23-8-3-1-4-9-23/h1-12,15H,13-14,16-22H2,(H,30,33)
DMDU6GN CS C1COCCC1(CNC(=O)C2=C(N=CC=C2)SC3=CC=CC=C3)N4CCN(CC4)C5=CC=CC=C5
DMDU6GN IK XREFXUCWSYMIOG-UHFFFAOYSA-N
DMDU6GN IU N-[[4-(4-phenylpiperazin-1-yl)oxan-4-yl]methyl]-2-phenylsulfanylpyridine-3-carboxamide
DMDU6GN DE Alzheimer disease
DM2NZ6K ID DM2NZ6K
DM2NZ6K DN KGP94
DM2NZ6K HS Clinical trial
DM2NZ6K SN CHEMBL1269632; BDBM50330030
DM2NZ6K DT Small molecular drug
DM2NZ6K PC 25234575
DM2NZ6K MW 350.24
DM2NZ6K FM C14H12BrN3OS
DM2NZ6K IC InChI=1S/C14H12BrN3OS/c15-11-5-1-3-9(7-11)13(17-18-14(16)20)10-4-2-6-12(19)8-10/h1-8,19H,(H3,16,18,20)/b17-13+
DM2NZ6K CS C1=CC(=CC(=C1)O)/C(=N/NC(=S)N)/C2=CC(=CC=C2)Br
DM2NZ6K IK ZDBKSZKTCPOBFR-GHRIWEEISA-N
DM2NZ6K IU [(Z)-[(3-bromophenyl)-(3-hydroxyphenyl)methylidene]amino]thiourea
DM2NZ6K DE Coagulation defect
DMR1NYF ID DMR1NYF
DMR1NYF DN KH064
DMR1NYF HS Clinical trial
DMR1NYF SN sPLA2-2A inhibitor, compound 2b
DMR1NYF DT Small molecular drug
DMR1NYF PC 446400
DMR1NYF MW 487.6
DMR1NYF FM C31H37NO4
DMR1NYF IC InChI=1S/C31H37NO4/c33-30(16-10-2-1-5-11-25-12-6-3-7-13-25)32-28(19-22-31(34)35)23-26-17-20-29(21-18-26)36-24-27-14-8-4-9-15-27/h3-4,6-9,12-15,17-18,20-21,28H,1-2,5,10-11,16,19,22-24H2,(H,32,33)(H,34,35)/t28-/m0/s1
DMR1NYF CS C1=CC=C(C=C1)CCCCCCC(=O)N[C@@H](CCC(=O)O)CC2=CC=C(C=C2)OCC3=CC=CC=C3
DMR1NYF IK KWLUIYFCMHKLKY-NDEPHWFRSA-N
DMR1NYF IU (4S)-4-(7-phenylheptanoylamino)-5-(4-phenylmethoxyphenyl)pentanoic acid
DMR1NYF CA CAS 393569-31-8
DMR1NYF DE Breast cancer
DMWA5XP ID DMWA5XP
DMWA5XP DN KU-60019
DMWA5XP HS Clinical trial
DMWA5XP SN KU-60019; 925701-49-1; ku60019; 925701-46-8; KU 60019; UNII-IAN358A69K; IAN358A69K; CHEMBL2140173; 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide; C30H33N3O5S; 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide; 2-[(2R,6S)-2,6-Dimethylmorpholin-4-yl]-N-{5-[6-(morpholin-4-yl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl}acetamide; MLS006011020; cc-509; SCHEMBL3681453; GTPL8041; EX-A658; DTXSID00580453; AOB3627
DMWA5XP DT Small molecular drug
DMWA5XP PC 15953870
DMWA5XP MW 547.7
DMWA5XP FM C30H33N3O5S
DMWA5XP IC InChI=1S/C30H33N3O5S/c1-19-16-32(17-20(2)37-19)18-28(35)31-23-6-7-27-22(13-23)12-21-4-3-5-25(30(21)39-27)26-14-24(34)15-29(38-26)33-8-10-36-11-9-33/h3-7,13-15,19-20H,8-12,16-18H2,1-2H3,(H,31,35)/t19-,20+
DMWA5XP CS C[C@@H]1CN(C[C@@H](O1)C)CC(=O)NC2=CC3=C(C=C2)SC4=C(C3)C=CC=C4C5=CC(=O)C=C(O5)N6CCOCC6
DMWA5XP IK SCELLOWTHJGVIC-BGYRXZFFSA-N
DMWA5XP IU 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide
DMWA5XP CA CAS 925701-49-1
DMWA5XP DE Non-small-cell lung cancer
DMCMOS8 ID DMCMOS8
DMCMOS8 DN L-Cysteine
DMCMOS8 HS Clinical trial
DMCMOS8 SN 52-90-4; Cystein; Half-cystine; (R)-Cysteine; Thioserine; (R)-2-Amino-3-mercaptopropanoic acid; L-(+)-Cysteine; L-Cystein; (2R)-2-amino-3-sulfanylpropanoic acid; beta-Mercaptoalanine; Half cystine; FREE CYSTEINE; Cysteine, L-; L-Cys; L-Alanine, 3-mercapto-; L-Zystein; H-Cys-OH; Cisteinum [Latin]; L-2-Amino-3-mercaptopropionic acid; Cisteina [Spanish]; cisteina; Polycysteine; Cysteinum; Cisteinum; (R)-2-Amino-3-mercaptopropionic acid; L Cysteine; alpha-Amino-beta-thiolpropionic acid; L-2-Amino-3-mercaptopropanoic a
DMCMOS8 DT Small molecular drug
DMCMOS8 PC 5862
DMCMOS8 MW 121.16
DMCMOS8 FM C3H7NO2S
DMCMOS8 IC InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
DMCMOS8 CS C([C@@H](C(=O)O)N)S
DMCMOS8 IK XUJNEKJLAYXESH-REOHCLBHSA-N
DMCMOS8 IU (2R)-2-amino-3-sulfanylpropanoic acid
DMCMOS8 CA CAS 52-90-4
DMCMOS8 CB CHEBI:17561
DMCMOS8 DE Non-small-cell lung cancer
DMW15TC ID DMW15TC
DMW15TC DN methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate
DMW15TC HS Clinical trial
DMW15TC SN MLS001003740; SMR000347588; methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate; AC1M4T6W; Oprea1_530669; Oprea1_180448; GTPL6553; SCHEMBL14688402; CHEMBL1595992; cid_2314952; BDBM33902; CHEBI:109731; HMS2702F21; methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate; AB00577675-02; SR-01000028101; SR-01000028101-1; 3-[[(4-tert-butylphenyl)-oxomethyl]amino]-1H-1,2,4-triazole-5-carboxylic acid methyl ester; methyl 3-[(4-tert-butylphenyl)carbonylamino]-1H-1,2,4-triazole-5-carboxylate
DMW15TC DT Small molecular drug
DMW15TC PC 2314952
DMW15TC MW 302.33
DMW15TC FM C15H18N4O3
DMW15TC IC InChI=1S/C15H18N4O3/c1-15(2,3)10-7-5-9(6-8-10)12(20)17-14-16-11(18-19-14)13(21)22-4/h5-8H,1-4H3,(H2,16,17,18,19,20)
DMW15TC CS CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=NNC(=N2)C(=O)OC
DMW15TC IK LVKKWCOINMSBPK-UHFFFAOYSA-N
DMW15TC IU methyl 3-[(4-tert-butylbenzoyl)amino]-1H-1,2,4-triazole-5-carboxylate
DMW15TC CA CAS 326618-93-3
DMW15TC CB CHEBI:109731
DMW15TC DE Alzheimer disease
DMAPV6J ID DMAPV6J
DMAPV6J DN MK-0249
DMAPV6J HS Clinical trial
DMAPV6J SN MK 0249; MK0249
DMAPV6J DT Small molecular drug
DMAPV6J PC 11697697
DMAPV6J MW 431.4
DMAPV6J FM C23H24F3N3O2
DMAPV6J IC InChI=1S/C23H24F3N3O2/c1-16-27-20-7-4-6-19(23(24,25)26)21(20)22(30)29(16)17-8-10-18(11-9-17)31-15-5-14-28-12-2-3-13-28/h4,6-11H,2-3,5,12-15H2,1H3
DMAPV6J CS CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OCCCN4CCCC4)C(F)(F)F
DMAPV6J IK DDDZBLNULGDPGA-UHFFFAOYSA-N
DMAPV6J IU 2-methyl-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5-(trifluoromethyl)quinazolin-4-one
DMAPV6J CA CAS 1167574-41-5
DMAPV6J DE Insulin-resistant disorder
DM3ADQW ID DM3ADQW
DM3ADQW DN NIA-114
DM3ADQW HS Clinical trial
DM3ADQW CP Niadyne Pharma Fort Worth, TX
DM3ADQW DE Plaque psoriasis
DMXFI90 ID DMXFI90
DMXFI90 DN oxazine 89
DMXFI90 HS Clinical trial
DMXFI90 SN CHEMBL2347208; N-{3-[(4s,6s)-2-Amino-4-Methyl-6-(Trifluoromethyl)-5,6-Dihydro-4h-1,3-Oxazin-4-Yl]-4-Fluorophenyl}-5-Cyanopyridine-2-Carboxamide; oxazine 89; GTPL6944; SCHEMBL15991481; BDBM50432601; 1HL
DMXFI90 DT Small molecular drug
DMXFI90 PC 71305058
DMXFI90 MW 421.3
DMXFI90 FM C19H15F4N5O2
DMXFI90 IC InChI=1S/C19H15F4N5O2/c1-18(7-15(19(21,22)23)30-17(25)28-18)12-6-11(3-4-13(12)20)27-16(29)14-5-2-10(8-24)9-26-14/h2-6,9,15H,7H2,1H3,(H2,25,28)(H,27,29)/t15-,18-/m0/s1
DMXFI90 CS C[C@]1(C[C@H](OC(=N1)N)C(F)(F)F)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F
DMXFI90 IK MELQHVBGGSKVJQ-YJBOKZPZSA-N
DMXFI90 IU N-[3-[(4S,6S)-2-amino-4-methyl-6-(trifluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
DMXFI90 DE Diabetic nephropathy
DMO0892 ID DMO0892
DMO0892 DN PF-4708671
DMO0892 HS Clinical trial
DMO0892 SN PF4708671; PF 4708671
DMO0892 DT Small molecular drug
DMO0892 PC 51371303
DMO0892 MW 390.4
DMO0892 FM C19H21F3N6
DMO0892 IC InChI=1S/C19H21F3N6/c1-2-13-10-23-12-24-18(13)28-7-5-27(6-8-28)11-17-25-15-4-3-14(19(20,21)22)9-16(15)26-17/h3-4,9-10,12H,2,5-8,11H2,1H3,(H,25,26)
DMO0892 CS CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F
DMO0892 IK FBLPQCAQRNSVHB-UHFFFAOYSA-N
DMO0892 IU 2-[[4-(5-ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-6-(trifluoromethyl)-1H-benzimidazole
DMO0892 CA CAS 1255517-76-0
DMO0892 DE Ulcerative colitis
DM4XAU7 ID DM4XAU7
DM4XAU7 DN PGF2alpha
DM4XAU7 HS Clinical trial
DM4XAU7 SN Amoglandin; Cerviprost; Cyclosin; Enzaprost; Panacelan; prostaglandin F2alpha
DM4XAU7 DT Small molecular drug
DM4XAU7 PC 5280363
DM4XAU7 MW 354.5
DM4XAU7 FM C20H34O5
DM4XAU7 IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
DM4XAU7 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O)O
DM4XAU7 IK PXGPLTODNUVGFL-YNNPMVKQSA-N
DM4XAU7 IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
DM4XAU7 CA CAS 551-11-1
DM4XAU7 CB CHEBI:15553
DM4XAU7 DE Solid tumour/cancer
DMXE0F2 ID DMXE0F2
DMXE0F2 DN PMID10498202C1
DMXE0F2 HS Clinical trial
DMXE0F2 SN 4oc6; GTPL6541; BDBM50080960
DMXE0F2 DT Small molecular drug
DMXE0F2 PC 9876120
DMXE0F2 MW 889.6
DMXE0F2 FM C44H40BrCl2N3O8
DMXE0F2 IC InChI=1S/C44H40BrCl2N3O8/c1-56-39-24-34(35(45)25-40(39)57-2)42(53)48-37(22-27-9-8-12-31(21-27)58-30-10-4-3-5-11-30)38(51)26-49(19-17-28-15-16-29(46)23-36(28)47)41(52)18-20-50-43(54)32-13-6-7-14-33(32)44(50)55/h3-16,21,23-25,37-38,51H,17-20,22,26H2,1-2H3,(H,48,53)/t37-,38-/m0/s1
DMXE0F2 CS COC1=C(C=C(C(=C1)C(=O)N[C@@H](CC2=CC(=CC=C2)OC3=CC=CC=C3)[C@H](CN(CCC4=C(C=C(C=C4)Cl)Cl)C(=O)CCN5C(=O)C6=CC=CC=C6C5=O)O)Br)OC
DMXE0F2 IK DQHKQRXAVNDAFY-UWXQCODUSA-N
DMXE0F2 IU 2-bromo-N-[(2S,3S)-4-[2-(2,4-dichlorophenyl)ethyl-[3-(1,3-dioxoisoindol-2-yl)propanoyl]amino]-3-hydroxy-1-(3-phenoxyphenyl)butan-2-yl]-4,5-dimethoxybenzamide
DMXE0F2 DE Multiple sclerosis
DMJGFLD ID DMJGFLD
DMJGFLD DN PMID15026062C41
DMJGFLD HS Clinical trial
DMJGFLD SN GTPL6702; BDBM50142719
DMJGFLD DT Small molecular drug
DMJGFLD PC 10453818
DMJGFLD MW 403.5
DMJGFLD FM C22H33N3O4
DMJGFLD IC InChI=1S/C22H33N3O4/c1-22(2,3)17-6-4-16(5-7-17)20(26)23-18-8-10-19(11-9-18)29-21(27)24-25-12-14-28-15-13-25/h8-11,16-17H,4-7,12-15H2,1-3H3,(H,23,26)(H,24,27)
DMJGFLD CS CC(C)(C)C1CCC(CC1)C(=O)NC2=CC=C(C=C2)OC(=O)NN3CCOCC3
DMJGFLD IK XSLDWDIQZLTRHG-UHFFFAOYSA-N
DMJGFLD IU [4-[(4-tert-butylcyclohexanecarbonyl)amino]phenyl] N-morpholin-4-ylcarbamate
DMJGFLD DE Pancreatitis
DMO1IHL ID DMO1IHL
DMO1IHL DN PMID17935984C1
DMO1IHL HS Clinical trial
DMO1IHL SN CHEBI:45030; 1you; AC1LCVYP; GTPL6526; BDBM50224854; DB08388
DMO1IHL DT Small molecular drug
DMO1IHL PC 657061
DMO1IHL MW 402.4
DMO1IHL FM C20H19FN2O6
DMO1IHL IC InChI=1S/C20H19FN2O6/c1-2-27-12-11-20(17(24)22-19(26)23-18(20)25)29-16-9-7-15(8-10-16)28-14-5-3-13(21)4-6-14/h3-10H,2,11-12H2,1H3,(H2,22,23,24,25,26)
DMO1IHL CS CCOCCC1(C(=O)NC(=O)NC1=O)OC2=CC=C(C=C2)OC3=CC=C(C=C3)F
DMO1IHL IK XRSYNYGEEYTXJV-UHFFFAOYSA-N
DMO1IHL IU 5-(2-ethoxyethyl)-5-[4-(4-fluorophenoxy)phenoxy]-1,3-diazinane-2,4,6-trione
DMO1IHL CB CHEBI:45030
DMO1IHL DE Pain
DMHPME3 ID DMHPME3
DMHPME3 DN PMID18163548C4
DMHPME3 HS Clinical trial
DMHPME3 SN 7IN; 1vja; AC1L9MNX; GTPL6545; BDBM50231520; US8476306, 6.12
DMHPME3 DT Small molecular drug
DMHPME3 PC 449051
DMHPME3 MW 477.5
DMHPME3 FM C21H27N5O6S
DMHPME3 IC InChI=1S/C21H27N5O6S/c22-19(23)16-8-6-14(7-9-16)10-24-20(29)17(11-27)25-21(30)18(12-28)26-33(31,32)13-15-4-2-1-3-5-15/h1-9,17-18,26-28H,10-13H2,(H3,22,23)(H,24,29)(H,25,30)/t17-,18+/m0/s1
DMHPME3 CS C1=CC=C(C=C1)CS(=O)(=O)N[C@H](CO)C(=O)N[C@@H](CO)C(=O)NCC2=CC=C(C=C2)C(=N)N
DMHPME3 IK ZNOKJHWJKULOGM-ZWKOTPCHSA-N
DMHPME3 IU (2S)-2-[[(2R)-2-(benzylsulfonylamino)-3-hydroxypropanoyl]amino]-N-[(4-carbamimidoylphenyl)methyl]-3-hydroxypropanamide
DMHPME3 DE Reperfusion injury; Myocardial ischemia
DM5UWH3 ID DM5UWH3
DM5UWH3 DN PMID22911925C2
DM5UWH3 HS Clinical trial
DM5UWH3 SN compound 37 [PMID: 22468684]; GTPL6950; BDBM50397703; 0K9
DM5UWH3 DT Small molecular drug
DM5UWH3 PC 60202321
DM5UWH3 MW 592.8
DM5UWH3 FM C33H44N4O4S
DM5UWH3 IC InChI=1S/C33H44N4O4S/c1-21(40-5)29(39)37-26(16-22-8-6-9-24(14-22)31-34-12-13-42-31)28(38)20-35-27-18-33(10-7-11-33)41-30-25(27)15-23(19-36-30)17-32(2,3)4/h6,8-9,12-15,19,21,26-28,35,38H,7,10-11,16-18,20H2,1-5H3,(H,37,39)/t21-,26+,27+,28-/m1/s1
DM5UWH3 CS C[C@H](C(=O)N[C@@H](CC1=CC(=CC=C1)C2=NC=CS2)[C@@H](CN[C@H]3CC4(CCC4)OC5=C3C=C(C=N5)CC(C)(C)C)O)OC
DM5UWH3 IK IUSARDYWEPUTPN-OZBXUNDUSA-N
DM5UWH3 IU (2R)-N-[(2S,3R)-4-[[(4S)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide
DM5UWH3 DE Diabetic complication
DMX1IZ9 ID DMX1IZ9
DMX1IZ9 DN PMID23981898C11d
DMX1IZ9 HS Clinical trial
DMX1IZ9 SN GTPL6946; BDBM50440419
DMX1IZ9 DT Small molecular drug
DMX1IZ9 PC 51003469
DMX1IZ9 MW 560.6
DMX1IZ9 FM C27H36F4N2O4S
DMX1IZ9 IC InChI=1S/C27H36F4N2O4S/c1-26(2,3)19-7-5-6-16(9-19)12-33-21-15-38(35)14-18(25(21)34)8-17-10-20(28)24(32)22(11-17)37-23(13-36-4)27(29,30)31/h5-7,9-11,18,21,23,25,33-34H,8,12-15,32H2,1-4H3/t18-,21+,23-,25+,38-/m1/s1
DMX1IZ9 CS CC(C)(C)C1=CC=CC(=C1)CN[C@H]2C[S@](=O)C[C@H]([C@@H]2O)CC3=CC(=C(C(=C3)F)N)O[C@H](COC)C(F)(F)F
DMX1IZ9 IK FIUDDEQHPBHZBI-XPLIUGCLSA-N
DMX1IZ9 IU (1R,3S,4S,5R)-3-[[4-amino-3-fluoro-5-[(2R)-1,1,1-trifluoro-3-methoxypropan-2-yl]oxyphenyl]methyl]-5-[(3-tert-butylphenyl)methylamino]-1-oxothian-4-ol
DMX1IZ9 DE Cardiovascular disease
DMCM5GK ID DMCM5GK
DMCM5GK DN TAK-070
DMCM5GK HS Clinical trial
DMCM5GK SN UNII-PNM9E64544; PNM9E64544; TAK-070; (2R)-N,N-Dimethyl-6-(4-biphenylylmethoxy)-1,2,3,4-tetrahydronaphthalene-2alpha-ethanamine; TAK-070 free base; N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine; N,N-Dimethyl-2-((2R)-6-((4-phenylphenyl)methoxy)-1,2,3,4-tetrahydronaphthalen-2-yl)ethanamine; SCHEMBL361018; GTPL6940; 212571-56-7; J3.229.705F; 2-((2R)-6-(4-Biphenylylmethoxy)-1,2,3,4-tetrahydro-2-naphthalenyl)-N,N-dimethylethanamine; 2-Naphthaleneethanamine, 6-((1,1'-biphenyl)-
DMCM5GK DT Small molecular drug
DMCM5GK PC 23519711
DMCM5GK MW 440
DMCM5GK FM C27H34ClNO2
DMCM5GK IC InChI=1S/C27H31NO.ClH.H2O/c1-28(2)17-16-21-8-13-26-19-27(15-14-25(26)18-21)29-20-22-9-11-24(12-10-22)23-6-4-3-5-7-23;;/h3-7,9-12,14-15,19,21H,8,13,16-18,20H2,1-2H3;1H;1H2/t21-;;/m0../s1
DMCM5GK CS CN(C)CC[C@@H]1CCC2=C(C1)C=CC(=C2)OCC3=CC=C(C=C3)C4=CC=CC=C4.O.Cl
DMCM5GK IK VBMPTAUGUUBFJK-FGJQBABTSA-N
DMCM5GK IU N,N-dimethyl-2-[(2R)-6-[(4-phenylphenyl)methoxy]-1,2,3,4-tetrahydronaphthalen-2-yl]ethanamine;hydrate;hydrochloride
DMCM5GK CA CAS 365276-12-6
DMCM5GK DE Solid tumour/cancer
DMGANIC ID DMGANIC
DMGANIC DN tamatinib
DMGANIC HS Clinical trial
DMGANIC SN R 406; R-406; R406 free base
DMGANIC DT Small molecular drug
DMGANIC PC 11213558
DMGANIC MW 470.5
DMGANIC FM C22H23FN6O5
DMGANIC IC InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
DMGANIC CS CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C
DMGANIC IK NHHQJBCNYHBUSI-UHFFFAOYSA-N
DMGANIC IU 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
DMGANIC CA CAS 841290-80-0
DMGANIC CB CHEBI:91348
DMGANIC DE Solid tumour/cancer
DMZO6CV ID DMZO6CV
DMZO6CV DN tiratricol
DMZO6CV HS Clinical trial
DMZO6CV SN TRIAC; 3,3',5-triiodothyroacetic acid
DMZO6CV DT Small molecular drug
DMZO6CV PC 5803
DMZO6CV MW 621.93
DMZO6CV FM C14H9I3O4
DMZO6CV IC InChI=1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
DMZO6CV CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)O)I)I)O
DMZO6CV IK UOWZUVNAGUAEQC-UHFFFAOYSA-N
DMZO6CV IU 2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
DMZO6CV CA CAS 51-24-1
DMZO6CV DE Wound healing
DMSRK2A ID DMSRK2A
DMSRK2A DN UK-356202
DMSRK2A HS Clinical trial
DMSRK2A SN compound 13j [PMID: 15149680]; UK-356,202
DMSRK2A DT Small molecular drug
DMSRK2A PC 9885167
DMSRK2A MW 340.8
DMSRK2A FM C17H13ClN4O2
DMSRK2A IC InChI=1S/C17H13ClN4O2/c18-14-8-21-15(22-17(19)20)13-7-10(4-5-12(13)14)9-2-1-3-11(6-9)16(23)24/h1-8H,(H,23,24)(H4,19,20,21,22)
DMSRK2A CS C1=CC(=CC(=C1)C(=O)O)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl
DMSRK2A IK UXNWIRHZMHGOCE-UHFFFAOYSA-N
DMSRK2A IU 3-[4-chloro-1-(diaminomethylideneamino)isoquinolin-7-yl]benzoic acid
DMSRK2A CA CAS 223671-94-1
DMSRK2A DE Myocardial hypertrophy
DMOI0TN ID DMOI0TN
DMOI0TN DN VU0364739
DMOI0TN HS Clinical trial
DMOI0TN SN VU 0364739
DMOI0TN DT Small molecular drug
DMOI0TN PC 46937439
DMOI0TN MW 446.5
DMOI0TN FM C26H27FN4O2
DMOI0TN IC InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-18-29-25(33)26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)
DMOI0TN CS C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC5=CC=CC=C5C=C4
DMOI0TN IK MSTXJJGAXXJCBY-UHFFFAOYSA-N
DMOI0TN IU N-[2-[1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]ethyl]naphthalene-2-carboxamide
DMOI0TN DE Coagulation defect
DMMLQAS ID DMMLQAS
DMMLQAS DN (-)-deprenyl
DMMLQAS HS Patented
DMMLQAS CP BRANDON UNIVERSITY
DMMLQAS DE Alopecia
DMGYZQ2 ID DMGYZQ2
DMGYZQ2 DN 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1
DMGYZQ2 HS Patented
DMGYZQ2 SN PMID25416646-Compound-Figure5-F
DMGYZQ2 CP KOWA COMPANY, LTD. MIURA, Toru YAMADA, Hajime TAGASHIRA, Junya WATANABE, Gen
DMGYZQ2 DT Small molecular drug
DMW5DC1 ID DMW5DC1
DMW5DC1 DN 1,2,3,4-tetrahydroisoquinoline derivative 1
DMW5DC1 HS Patented
DMW5DC1 SN PMID28454500-Compound-61
DMW5DC1 CP RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY THE BROAD INSTITUTE, INC
DMW5DC1 DT Small molecular drug
DMKHF39 ID DMKHF39
DMKHF39 DN 1,2,3-triazole derivative 1
DMKHF39 HS Patented
DMKHF39 SN PMID26161824-Compound-90
DMKHF39 DT Small molecular drug
DMKHF39 PC 44571486
DMKHF39 MW 473.2
DMKHF39 FM C20H17Cl4N3O2
DMKHF39 IC InChI=1S/C20H17Cl4N3O2/c1-2-3-8-29-18(28)11-27-25-19(14-6-4-12(21)9-16(14)23)20(26-27)15-7-5-13(22)10-17(15)24/h4-7,9-10H,2-3,8,11H2,1H3
DMKHF39 CS CCCCOC(=O)CN1N=C(C(=N1)C2=C(C=C(C=C2)Cl)Cl)C3=C(C=C(C=C3)Cl)Cl
DMKHF39 IK JHYLDWFPNBXQGK-UHFFFAOYSA-N
DMKHF39 IU butyl 2-[4,5-bis(2,4-dichlorophenyl)triazol-2-yl]acetate
DMKHF39 DE Obesity
DMFR23C ID DMFR23C
DMFR23C DN 1,2,3-triazole derivative 2
DMFR23C HS Patented
DMFR23C SN PMID26161824-Compound-91
DMFR23C DT Small molecular drug
DMFR23C PC 44571565
DMFR23C MW 524.2
DMFR23C FM C23H15Cl4FN4O
DMFR23C IC InChI=1S/C23H15Cl4FN4O/c24-14-3-7-17(19(26)9-14)22-23(18-8-4-15(25)10-20(18)27)31-32(30-22)12-21(33)29-11-13-1-5-16(28)6-2-13/h1-10H,11-12H2,(H,29,33)
DMFR23C CS C1=CC(=CC=C1CNC(=O)CN2N=C(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=C(C=C(C=C4)Cl)Cl)F
DMFR23C IK MDVQABZPIQBGMA-UHFFFAOYSA-N
DMFR23C IU 2-[4,5-bis(2,4-dichlorophenyl)triazol-2-yl]-N-[(4-fluorophenyl)methyl]acetamide
DMFR23C DE Obesity
DMLAYG7 ID DMLAYG7
DMLAYG7 DN 1,2,4,5-tetra-substituted imidazole derivative 1
DMLAYG7 HS Patented
DMLAYG7 SN PMID26161824-Compound-81
DMLAYG7 DT Small molecular drug
DMLAYG7 PC 46889224
DMLAYG7 MW 481.8
DMLAYG7 FM C21H19Cl3N4OS
DMLAYG7 IC InChI=1S/C21H19Cl3N4OS/c1-30-21-18(20(29)26-27-10-2-3-11-27)25-19(16-9-6-14(23)12-17(16)24)28(21)15-7-4-13(22)5-8-15/h4-9,12H,2-3,10-11H2,1H3,(H,26,29)
DMLAYG7 CS CSC1=C(N=C(N1C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCC4
DMLAYG7 IK HYQPTXFCPLFWMJ-UHFFFAOYSA-N
DMLAYG7 IU 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylsulfanyl-N-pyrrolidin-1-ylimidazole-4-carboxamide
DMLAYG7 DE Obesity
DMMCYI5 ID DMMCYI5
DMMCYI5 DN 1,2,4,5-tetra-substituted imidazole derivative 2
DMMCYI5 HS Patented
DMMCYI5 SN PMID26161824-Compound-82
DMMCYI5 DT Small molecular drug
DMMCYI5 PC 11555526
DMMCYI5 MW 527.8
DMMCYI5 FM C22H21Cl3N4O3S
DMMCYI5 IC InChI=1S/C22H21Cl3N4O3S/c1-33(31,32)22-19(21(30)27-28-11-3-2-4-12-28)26-20(17-10-7-15(24)13-18(17)25)29(22)16-8-5-14(23)6-9-16/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMMCYI5 CS CS(=O)(=O)C1=C(N=C(N1C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCCC4
DMMCYI5 IK XHUGETFAQBCPHR-UHFFFAOYSA-N
DMMCYI5 IU 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylsulfonyl-N-piperidin-1-ylimidazole-4-carboxamide
DMMCYI5 DE Obesity
DMESOA8 ID DMESOA8
DMESOA8 DN 1,2,4-oxadiazole derivative 1
DMESOA8 HS Patented
DMESOA8 SN PMID30107136-Compound-Example39
DMESOA8 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMESOA8 DT Small molecule immunotherapy
DMESOA8 PC 134354913
DMESOA8 MW 338.36
DMESOA8 FM C14H22N6O4
DMESOA8 IC InChI=1S/C14H22N6O4/c15-11(22)6-10(17-12(23)9-5-8(21)7-16-9)13-18-14(19-24-13)20-3-1-2-4-20/h8-10,16,21H,1-7H2,(H2,15,22)(H,17,23)/t8-,9-,10-/m0/s1
DMESOA8 CS C1CCN(C1)C2=NOC(=N2)[C@H](CC(=O)N)NC(=O)[C@@H]3C[C@@H](CN3)O
DMESOA8 IK SFGGVDXQGJRZAI-GUBZILKMSA-N
DMESOA8 IU (2S,4S)-N-[(1S)-3-amino-3-oxo-1-(3-pyrrolidin-1-yl-1,2,4-oxadiazol-5-yl)propyl]-4-hydroxypyrrolidine-2-carboxamide
DMESOA8 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMA42SB ID DMA42SB
DMA42SB DN 1,2,4-oxadiazole derivative 2
DMA42SB HS Patented
DMA42SB SN PMID30107136-Compound-Example40
DMA42SB CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMA42SB DT Small molecule immunotherapy
DMA42SB DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMT6EDP ID DMT6EDP
DMT6EDP DN 1,2,4-oxadiazole derivative 4
DMT6EDP HS Patented
DMT6EDP SN PMID30107136-Compound-Example31
DMT6EDP CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMT6EDP DT Small molecule immunotherapy
DMT6EDP PC 91663290
DMT6EDP MW 215.21
DMT6EDP FM C7H13N5O3
DMT6EDP IC InChI=1S/C7H13N5O3/c8-3(1-5(10)14)7-11-6(12-15-7)4(9)2-13/h3-4,13H,1-2,8-9H2,(H2,10,14)/t3-,4-/m0/s1
DMT6EDP CS C([C@@H](C1=NC(=NO1)[C@H](CO)N)N)C(=O)N
DMT6EDP IK GBRIVGUQMYWVTC-IMJSIDKUSA-N
DMT6EDP IU (3S)-3-amino-3-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]propanamide
DMT6EDP DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM683R7 ID DM683R7
DM683R7 DN 1,2,4-oxadiazole derivative 5
DM683R7 HS Patented
DM683R7 SN PMID30107136-Compound-Example32
DM683R7 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM683R7 DT Small molecule immunotherapy
DM683R7 PC 117943678
DM683R7 MW 360.32
DM683R7 FM C12H20N6O7
DM683R7 IC InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-17-9(18-25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4?,5-,6-,8+/m0/s1
DM683R7 CS CC([C@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)[C@H](CO)N)O
DM683R7 IK HFOBENSCBRZVSP-FMKRDQFVSA-N
DM683R7 IU (2R)-2-[[(1S)-3-amino-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid
DM683R7 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMFYKBJ ID DMFYKBJ
DMFYKBJ DN 1,2,4-oxadiazole derivative 6
DMFYKBJ HS Patented
DMFYKBJ SN PMID30107136-Compound-Example35
DMFYKBJ CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMFYKBJ DT Small molecule immunotherapy
DMFYKBJ PC 122541621
DMFYKBJ MW 416.43
DMFYKBJ FM C16H28N6O7
DMFYKBJ IC InChI=1S/C16H28N6O7/c1-3-6-18-11(25)5-4-10(14-21-13(22-29-14)9(17)7-23)19-16(28)20-12(8(2)24)15(26)27/h8-10,12,23-24H,3-7,17H2,1-2H3,(H,18,25)(H,26,27)(H2,19,20,28)/t8?,9-,10-,12-/m0/s1
DMFYKBJ CS CCCNC(=O)CC[C@@H](C1=NC(=NO1)[C@H](CO)N)NC(=O)N[C@@H](C(C)O)C(=O)O
DMFYKBJ IK YZLYUYDWVJSYRO-BCBKFXIMSA-N
DMFYKBJ IU (2S)-2-[[(1S)-1-[3-[(1R)-1-amino-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl]-4-oxo-4-(propylamino)butyl]carbamoylamino]-3-hydroxybutanoic acid
DMFYKBJ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMBT4RJ ID DMBT4RJ
DMBT4RJ DN 1,2,4-oxadiazole derivative 7
DMBT4RJ HS Patented
DMBT4RJ SN PMID30107136-Compound-Example36
DMBT4RJ CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMBT4RJ DT Small molecule immunotherapy
DMBT4RJ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMQF62D ID DMQF62D
DMQF62D DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1
DMQF62D HS Patented
DMQF62D SN PMID27321640-Compound-39
DMQF62D CP DART NEUROSCIENCE (CAYMAN) LTD
DMQF62D DT Small molecular drug
DM8KWQ9 ID DM8KWQ9
DM8KWQ9 DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2
DM8KWQ9 HS Patented
DM8KWQ9 SN PMID27321640-Compound-40
DM8KWQ9 CP DART NEUROSCIENCE (CAYMAN) LTD
DM8KWQ9 DT Small molecular drug
DMR1QP4 ID DMR1QP4
DMR1QP4 DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3
DMR1QP4 HS Patented
DMR1QP4 SN PMID27321640-Compound-41
DMR1QP4 CP DART NEUROSCIENCE (CAYMAN) LTD
DMR1QP4 DT Small molecular drug
DMD9QW2 ID DMD9QW2
DMD9QW2 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 1
DMD9QW2 HS Patented
DMD9QW2 SN PMID27321640-Compound-33
DMD9QW2 CP BOEHRINGER INGELHEIM INTERNATIONAL GmbH
DMD9QW2 DT Small molecular drug
DMD9QW2 PC 56933838
DMD9QW2 MW 294.74
DMD9QW2 FM C16H11ClN4
DMD9QW2 IC InChI=1S/C16H11ClN4/c1-10-15-19-20-16(11-6-2-3-7-12(11)17)21(15)14-9-5-4-8-13(14)18-10/h2-9H,1H3
DMD9QW2 CS CC1=NC2=CC=CC=C2N3C1=NN=C3C4=CC=CC=C4Cl
DMD9QW2 IK CTBSIWZADWNGPL-UHFFFAOYSA-N
DMD9QW2 IU 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline
DM3DIW9 ID DM3DIW9
DM3DIW9 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 2
DM3DIW9 HS Patented
DM3DIW9 SN PMID27321640-Compound-34
DM3DIW9 CP BOEHRINGER INGELHEIM INTERNATIONAL GmbH
DM3DIW9 DT Small molecular drug
DM3DIW9 PC 60151243
DM3DIW9 MW 366.8
DM3DIW9 FM C20H19ClN4O
DM3DIW9 IC InChI=1S/C20H19ClN4O/c1-3-4-11-26-14-9-10-16(21)15(12-14)20-24-23-19-13(2)22-17-7-5-6-8-18(17)25(19)20/h5-10,12H,3-4,11H2,1-2H3
DM3DIW9 CS CCCCOC1=CC(=C(C=C1)Cl)C2=NN=C3N2C4=CC=CC=C4N=C3C
DM3DIW9 IK ITEIGISUTJIFPA-UHFFFAOYSA-N
DM3DIW9 IU 1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline
DMKXRYM ID DMKXRYM
DMKXRYM DN 1,2,4-triazole [4,3-a]quinoxaline derivative 3
DMKXRYM HS Patented
DMKXRYM SN PMID27321640-Compound-35
DMKXRYM CP BOEHRINGER INGELHEIM INTERNATIONAL GmbH
DMKXRYM DT Small molecular drug
DME8MN1 ID DME8MN1
DME8MN1 DN 1,2,4-triazole derivative 1
DME8MN1 HS Patented
DME8MN1 SN PMID26161824-Compound-92
DME8MN1 DT Small molecular drug
DME8MN1 PC 10005052
DME8MN1 MW 436.7
DME8MN1 FM C19H16Cl3N5O
DME8MN1 IC InChI=1S/C19H16Cl3N5O/c20-13-5-3-12(4-6-13)18-23-17(19(28)25-26-9-1-2-10-26)24-27(18)16-8-7-14(21)11-15(16)22/h3-8,11H,1-2,9-10H2,(H,25,28)
DME8MN1 CS C1CCN(C1)NC(=O)C2=NN(C(=N2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DME8MN1 IK ONYKENLNZNVNBN-UHFFFAOYSA-N
DME8MN1 IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-pyrrolidin-1-yl-1,2,4-triazole-3-carboxamide
DME8MN1 DE Obesity
DM91Z8B ID DM91Z8B
DM91Z8B DN 1,2,4-triazole derivative 2
DM91Z8B HS Patented
DM91Z8B SN PMID26161824-Compound-93
DM91Z8B DT Small molecular drug
DM91Z8B DE Obesity
DMU9XMV ID DMU9XMV
DMU9XMV DN 1,2,4-triazole derivative 3
DMU9XMV HS Patented
DMU9XMV SN PMID28051882-Compound-2
DMU9XMV CP LABORATORIOS DEL DR. ESTEVE, S.A
DMU9XMV DT Small molecular drug
DMU9XMV PC 24794804
DMU9XMV MW 371.3
DMU9XMV FM C16H20Cl2N4S
DMU9XMV IC InChI=1S/C16H20Cl2N4S/c1-12-19-16(23-10-9-21-7-3-2-4-8-21)20-22(12)13-5-6-14(17)15(18)11-13/h5-6,11H,2-4,7-10H2,1H3
DMU9XMV CS CC1=NC(=NN1C2=CC(=C(C=C2)Cl)Cl)SCCN3CCCCC3
DMU9XMV IK BCOSIWNFJNBROD-UHFFFAOYSA-N
DMU9XMV IU 1-[2-[[1-(3,4-dichlorophenyl)-5-methyl-1,2,4-triazol-3-yl]sulfanyl]ethyl]piperidine
DMHBJFN ID DMHBJFN
DMHBJFN DN 1,2,4-triazole derivative 4
DMHBJFN HS Patented
DMHBJFN SN PMID28051882-Compound-II
DMHBJFN CP LABORATORIOS DEL DR. ESTEVE, S.A
DMHBJFN DT Small molecular drug
DMIUPSA ID DMIUPSA
DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1
DMIUPSA HS Patented
DMIUPSA SN PMID27774824-Compound-Figure8compoundA
DMIUPSA CP CEPHALON, INC
DMIUPSA DT Small molecular drug
DMZFILT ID DMZFILT
DMZFILT DN 1,2,4-triazolo[1,5a]pyridine derivative 2
DMZFILT HS Patented
DMZFILT SN PMID27774824-Compound-Figure8compoundIII
DMZFILT CP CEPHALON, INC
DMZFILT DT Small molecular drug
DMMNVZ5 ID DMMNVZ5
DMMNVZ5 DN 1,2,4-tri-substituted imidazoline derivative 1
DMMNVZ5 HS Patented
DMMNVZ5 SN PMID26161824-Compound-113
DMMNVZ5 DT Small molecular drug
DMMNVZ5 PC 16755469
DMMNVZ5 MW 450.8
DMMNVZ5 FM C22H22Cl3N3O
DMMNVZ5 IC InChI=1S/C22H22Cl3N3O/c23-14-6-9-17(10-7-14)28-13-20(22(29)26-16-4-2-1-3-5-16)27-21(28)18-11-8-15(24)12-19(18)25/h6-12,16,20H,1-5,13H2,(H,26,29)
DMMNVZ5 CS C1CCC(CC1)NC(=O)C2CN(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMMNVZ5 IK AUDPPCIKFUVJJY-UHFFFAOYSA-N
DMMNVZ5 IU 1-(4-chlorophenyl)-N-cyclohexyl-2-(2,4-dichlorophenyl)-4,5-dihydroimidazole-4-carboxamide
DMMNVZ5 DE Obesity
DMNH8GW ID DMNH8GW
DMNH8GW DN 1,2-diamino cyclopentane-based derivative 1
DMNH8GW HS Patented
DMNH8GW SN PMID26593218-Compound-23
DMNH8GW CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMNH8GW DT Small molecular drug
DM3ZF95 ID DM3ZF95
DM3ZF95 DN 1,2-diamino cyclopentane-based derivative 10
DM3ZF95 HS Patented
DM3ZF95 SN PMID26593218-Compound-32
DM3ZF95 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM3ZF95 DT Small molecular drug
DM3ZF95 PC 118034926
DM3ZF95 MW 433.9
DM3ZF95 FM C20H20ClN3O4S
DM3ZF95 IC InChI=1S/C20H20ClN3O4S/c1-26-15-4-3-5-16(27-2)18(15)19(25)22-13-9-28-10-14(13)24-20-23-12-7-6-11(21)8-17(12)29-20/h3-8,13-14H,9-10H2,1-2H3,(H,22,25)(H,23,24)
DM3ZF95 CS COC1=C(C(=CC=C1)OC)C(=O)NC2COCC2NC3=NC4=C(S3)C=C(C=C4)Cl
DM3ZF95 IK VWEKNQAXJFBOQH-UHFFFAOYSA-N
DM3ZF95 IU N-[4-[(6-chloro-1,3-benzothiazol-2-yl)amino]oxolan-3-yl]-2,6-dimethoxybenzamide
DMPZECW ID DMPZECW
DMPZECW DN 1,2-diamino cyclopentane-based derivative 11
DMPZECW HS Patented
DMPZECW SN PMID26593218-Compound-33
DMPZECW CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMPZECW DT Small molecular drug
DMWV53X ID DMWV53X
DMWV53X DN 1,2-diamino cyclopentane-based derivative 12
DMWV53X HS Patented
DMWV53X SN PMID26593218-Compound-34
DMWV53X CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMWV53X DT Small molecular drug
DM10UX4 ID DM10UX4
DM10UX4 DN 1,2-diamino cyclopentane-based derivative 13
DM10UX4 HS Patented
DM10UX4 SN PMID26593218-Compound-35
DM10UX4 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM10UX4 DT Small molecular drug
DM10UX4 PC 123568419
DM10UX4 MW 431.9
DM10UX4 FM C21H22ClN3O3S
DM10UX4 IC InChI=1S/C21H22ClN3O3S/c1-27-16-7-4-8-17(28-2)19(16)20(26)23-13-5-3-6-14(13)24-21-25-15-10-9-12(22)11-18(15)29-21/h4,7-11,13-14H,3,5-6H2,1-2H3,(H,23,26)(H,24,25)
DM10UX4 CS COC1=C(C(=CC=C1)OC)C(=O)NC2CCCC2NC3=NC4=C(S3)C=C(C=C4)Cl
DM10UX4 IK XFIKRNAXHULGOU-UHFFFAOYSA-N
DM10UX4 IU N-[2-[(6-chloro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2,6-dimethoxybenzamide
DMTZDUV ID DMTZDUV
DMTZDUV DN 1,2-diamino cyclopentane-based derivative 14
DMTZDUV HS Patented
DMTZDUV SN PMID26593218-Compound-36
DMTZDUV CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTZDUV DT Small molecular drug
DMTZDUV PC 118025684
DMTZDUV MW 421.5
DMTZDUV FM C22H20FN5OS
DMTZDUV IC InChI=1S/C22H20FN5OS/c23-14-9-10-18-20(13-14)30-22(27-18)26-17-7-3-6-16(17)25-21(29)15-5-1-2-8-19(15)28-12-4-11-24-28/h1-2,4-5,8-13,16-17H,3,6-7H2,(H,25,29)(H,26,27)/t16-,17-/m0/s1
DMTZDUV CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3C=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
DMTZDUV IK IJDOZFOBWAKVFH-IRXDYDNUSA-N
DMTZDUV IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-pyrazol-1-ylbenzamide
DMBY65W ID DMBY65W
DMBY65W DN 1,2-diamino cyclopentane-based derivative 15
DMBY65W HS Patented
DMBY65W SN PMID26593218-Compound-37
DMBY65W CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBY65W DT Small molecular drug
DMBY65W PC 122438665
DMBY65W MW 440.5
DMBY65W FM C21H18F2N6OS
DMBY65W IC InChI=1S/C21H18F2N6OS/c22-12-5-7-18(29-24-8-9-25-29)14(10-12)20(30)26-15-2-1-3-16(15)27-21-28-17-6-4-13(23)11-19(17)31-21/h4-11,15-16H,1-3H2,(H,26,30)(H,27,28)/t15-,16-/m0/s1
DMBY65W CS C1C[C@@H]([C@H](C1)NC(=O)C2=C(C=CC(=C2)F)N3N=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
DMBY65W IK WLEKLMFGOMPGEX-HOTGVXAUSA-N
DMBY65W IU 5-fluoro-N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DMHEX1Q ID DMHEX1Q
DMHEX1Q DN 1,2-diamino cyclopentane-based derivative 16
DMHEX1Q HS Patented
DMHEX1Q SN PMID26593218-Compound-38
DMHEX1Q CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMHEX1Q DT Small molecular drug
DMHEX1Q PC 122438757
DMHEX1Q MW 437.5
DMHEX1Q FM C22H20FN5O2S
DMHEX1Q IC InChI=1S/C22H20FN5O2S/c1-12-24-21(30-28-12)15-6-3-2-5-14(15)20(29)25-16-7-4-8-17(16)26-22-27-18-10-9-13(23)11-19(18)31-22/h2-3,5-6,9-11,16-17H,4,7-8H2,1H3,(H,25,29)(H,26,27)/t16-,17-/m0/s1
DMHEX1Q CS CC1=NOC(=N1)C2=CC=CC=C2C(=O)N[C@H]3CCC[C@@H]3NC4=NC5=C(S4)C=C(C=C5)F
DMHEX1Q IK HAQWTGIMJAZGBJ-IRXDYDNUSA-N
DMHEX1Q IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide
DMBC9UK ID DMBC9UK
DMBC9UK DN 1,2-diamino cyclopentane-based derivative 17
DMBC9UK HS Patented
DMBC9UK SN PMID26593218-Compound-39
DMBC9UK CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBC9UK DT Small molecular drug
DMBC9UK PC 118034890
DMBC9UK MW 435.5
DMBC9UK FM C23H22FN5OS
DMBC9UK IC InChI=1S/C23H22FN5OS/c1-28(22(30)16-6-2-3-8-19(16)29-13-5-12-25-29)20-9-4-7-17(20)26-23-27-18-11-10-15(24)14-21(18)31-23/h2-3,5-6,8,10-14,17,20H,4,7,9H2,1H3,(H,26,27)/t17-,20-/m0/s1
DMBC9UK CS CN([C@H]1CCC[C@@H]1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=CC=CC=C4N5C=CC=N5
DMBC9UK IK OQAWFCAOFHFFQS-PXNSSMCTSA-N
DMBC9UK IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-N-methyl-2-pyrazol-1-ylbenzamide
DMCNQAF ID DMCNQAF
DMCNQAF DN 1,2-diamino cyclopentane-based derivative 18
DMCNQAF HS Patented
DMCNQAF SN PMID26593218-Compound-40
DMCNQAF CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMCNQAF DT Small molecular drug
DMCNQAF PC 118034891
DMCNQAF MW 454.5
DMCNQAF FM C22H20F2N6OS
DMCNQAF IC InChI=1S/C22H20F2N6OS/c1-29(21(31)15-11-13(23)6-8-18(15)30-25-9-10-26-30)19-4-2-3-16(19)27-22-28-17-7-5-14(24)12-20(17)32-22/h5-12,16,19H,2-4H2,1H3,(H,27,28)/t16-,19-/m0/s1
DMCNQAF CS CN([C@H]1CCC[C@@H]1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=C(C=CC(=C4)F)N5N=CC=N5
DMCNQAF IK AWDZNHIULYTTNC-LPHOPBHVSA-N
DMCNQAF IU 5-fluoro-N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-N-methyl-2-(triazol-2-yl)benzamide
DMCBPI4 ID DMCBPI4
DMCBPI4 DN 1,2-diamino cyclopentane-based derivative 19
DMCBPI4 HS Patented
DMCBPI4 SN PMID26593218-Compound-41
DMCBPI4 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMCBPI4 DT Small molecular drug
DMCBPI4 PC 118034933
DMCBPI4 MW 451.5
DMCBPI4 FM C23H22FN5O2S
DMCBPI4 IC InChI=1S/C23H22FN5O2S/c1-13-25-21(31-28-13)15-6-3-4-7-16(15)22(30)29(2)19-9-5-8-17(19)26-23-27-18-11-10-14(24)12-20(18)32-23/h3-4,6-7,10-12,17,19H,5,8-9H2,1-2H3,(H,26,27)/t17-,19-/m0/s1
DMCBPI4 CS CC1=NOC(=N1)C2=CC=CC=C2C(=O)N(C)[C@H]3CCC[C@@H]3NC4=NC5=C(S4)C=C(C=C5)F
DMCBPI4 IK ZZOMOANEXSPUDO-HKUYNNGSSA-N
DMCBPI4 IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-N-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide
DM7RG5I ID DM7RG5I
DM7RG5I DN 1,2-diamino cyclopentane-based derivative 2
DM7RG5I HS Patented
DM7RG5I SN PMID26593218-Compound-24
DM7RG5I CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM7RG5I DT Small molecular drug
DM7RG5I PC 122438624
DM7RG5I MW 392.5
DM7RG5I FM C22H24N4O3
DM7RG5I IC InChI=1S/C22H24N4O3/c1-28-18-11-6-12-19(29-2)21(18)22(27)26-17-10-5-9-16(17)25-20-13-23-14-7-3-4-8-15(14)24-20/h3-4,6-8,11-13,16-17H,5,9-10H2,1-2H3,(H,24,25)(H,26,27)/t16-,17-/m0/s1
DM7RG5I CS COC1=C(C(=CC=C1)OC)C(=O)N[C@H]2CCC[C@@H]2NC3=NC4=CC=CC=C4N=C3
DM7RG5I IK GIWGNHDZELXXNP-IRXDYDNUSA-N
DM7RG5I IU 2,6-dimethoxy-N-[(1S,2S)-2-(quinoxalin-2-ylamino)cyclopentyl]benzamide
DM9PHIK ID DM9PHIK
DM9PHIK DN 1,2-diamino cyclopentane-based derivative 20
DM9PHIK HS Patented
DM9PHIK SN PMID26593218-Compound-42
DM9PHIK CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM9PHIK DT Small molecular drug
DM9PHIK PC 118025611
DM9PHIK MW 388.4
DM9PHIK FM C21H20N6O2
DM9PHIK IC InChI=1S/C21H20N6O2/c28-20(14-6-1-3-10-18(14)27-22-12-13-23-27)24-15-8-5-9-16(15)25-21-26-17-7-2-4-11-19(17)29-21/h1-4,6-7,10-13,15-16H,5,8-9H2,(H,24,28)(H,25,26)/t15-,16-/m0/s1
DM9PHIK CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=CC=CC=C5O4
DM9PHIK IK BYPDPBCQZDTPSH-HOTGVXAUSA-N
DM9PHIK IU N-[(1S,2S)-2-(1,3-benzoxazol-2-ylamino)cyclopentyl]-2-(triazol-2-yl)benzamide
DM5Y1DC ID DM5Y1DC
DM5Y1DC DN 1,2-diamino cyclopentane-based derivative 21
DM5Y1DC HS Patented
DM5Y1DC SN PMID26593218-Compound-43
DM5Y1DC CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM5Y1DC DT Small molecular drug
DM5Y1DC PC 122438916
DM5Y1DC MW 404.5
DM5Y1DC FM C21H20N6OS
DM5Y1DC IC InChI=1S/C21H20N6OS/c28-20(14-6-1-3-10-18(14)27-22-12-13-23-27)24-15-8-5-9-16(15)25-21-26-17-7-2-4-11-19(17)29-21/h1-4,6-7,10-13,15-16H,5,8-9H2,(H,24,28)(H,25,26)/t15-,16-/m0/s1
DM5Y1DC CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=CC=CC=C5S4
DM5Y1DC IK XAHDEDDXRWKNQO-HOTGVXAUSA-N
DM5Y1DC IU N-[(1S,2S)-2-(1,3-benzothiazol-2-ylamino)cyclopentyl]-2-(triazol-2-yl)benzamide
DMXRLI6 ID DMXRLI6
DMXRLI6 DN 1,2-diamino cyclopentane-based derivative 22
DMXRLI6 HS Patented
DMXRLI6 SN PMID26593218-Compound-44
DMXRLI6 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMXRLI6 DT Small molecular drug
DMXRLI6 PC 122438723
DMXRLI6 MW 406.4
DMXRLI6 FM C21H19FN6O2
DMXRLI6 IC InChI=1S/C21H19FN6O2/c22-13-8-9-19-17(12-13)27-21(30-19)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DMXRLI6 CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(O4)C=CC(=C5)F
DMXRLI6 IK JFPYMDXVSVUGTP-HOTGVXAUSA-N
DMXRLI6 IU N-[(1S,2S)-2-[(5-fluoro-1,3-benzoxazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DM0HIQU ID DM0HIQU
DM0HIQU DN 1,2-diamino cyclopentane-based derivative 23
DM0HIQU HS Patented
DM0HIQU SN PMID26593218-Compound-45
DM0HIQU CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM0HIQU DT Small molecular drug
DM0HIQU PC 122438724
DM0HIQU MW 422.5
DM0HIQU FM C21H19FN6OS
DM0HIQU IC InChI=1S/C21H19FN6OS/c22-13-8-9-19-17(12-13)27-21(30-19)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DM0HIQU CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(S4)C=CC(=C5)F
DM0HIQU IK QOKFERXTHYZAHW-HOTGVXAUSA-N
DM0HIQU IU N-[(1S,2S)-2-[(5-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DMC26MT ID DMC26MT
DMC26MT DN 1,2-diamino cyclopentane-based derivative 24
DMC26MT HS Patented
DMC26MT SN PMID26593218-Compound-46
DMC26MT CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMC26MT DT Small molecular drug
DMC26MT PC 122438643
DMC26MT MW 438.9
DMC26MT FM C21H19ClN6OS
DMC26MT IC InChI=1S/C21H19ClN6OS/c22-13-8-9-19-17(12-13)27-21(30-19)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DMC26MT CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(S4)C=CC(=C5)Cl
DMC26MT IK XRCGVDTUCHXOPF-HOTGVXAUSA-N
DMC26MT IU N-[(1S,2S)-2-[(5-chloro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DMEW0AT ID DMEW0AT
DMEW0AT DN 1,2-diamino cyclopentane-based derivative 25
DMEW0AT HS Patented
DMEW0AT SN PMID26593218-Compound-47
DMEW0AT CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMEW0AT DT Small molecular drug
DMEW0AT PC 122438685
DMEW0AT MW 438.9
DMEW0AT FM C21H19ClN6OS
DMEW0AT IC InChI=1S/C21H19ClN6OS/c22-13-8-9-17-19(12-13)30-21(27-17)26-16-6-3-5-15(16)25-20(29)14-4-1-2-7-18(14)28-23-10-11-24-28/h1-2,4,7-12,15-16H,3,5-6H2,(H,25,29)(H,26,27)/t15-,16-/m0/s1
DMEW0AT CS C1C[C@@H]([C@H](C1)NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC5=C(S4)C=C(C=C5)Cl
DMEW0AT IK PCFLJOMEOCZUJL-HOTGVXAUSA-N
DMEW0AT IU N-[(1S,2S)-2-[(6-chloro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DMTFG4J ID DMTFG4J
DMTFG4J DN 1,2-diamino cyclopentane-based derivative 26
DMTFG4J HS Patented
DMTFG4J SN PMID26593218-Compound-48
DMTFG4J CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTFG4J DT Small molecular drug
DM5LQJW ID DM5LQJW
DM5LQJW DN 1,2-diamino cyclopentane-based derivative 27
DM5LQJW HS Patented
DM5LQJW SN PMID26593218-Compound-49
DM5LQJW CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM5LQJW DT Small molecular drug
DMUTF17 ID DMUTF17
DMUTF17 DN 1,2-diamino cyclopentane-based derivative 28
DMUTF17 HS Patented
DMUTF17 SN PMID26593218-Compound-5
DMUTF17 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMUTF17 DT Small molecular drug
DM5FVH0 ID DM5FVH0
DM5FVH0 DN 1,2-diamino cyclopentane-based derivative 29
DM5FVH0 HS Patented
DM5FVH0 SN PMID26593218-Compound-50
DM5FVH0 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM5FVH0 DT Small molecular drug
DM5FVH0 PC 118308114
DM5FVH0 MW 431.4
DM5FVH0 FM C20H20F3N7O
DM5FVH0 IC InChI=1S/C20H20F3N7O/c1-19(29-17-12-24-16(11-25-17)20(21,22)23)8-4-7-15(19)28-18(31)13-5-2-3-6-14(13)30-26-9-10-27-30/h2-3,5-6,9-12,15H,4,7-8H2,1H3,(H,25,29)(H,28,31)/t15-,19-/m0/s1
DM5FVH0 CS C[C@@]1(CCC[C@@H]1NC(=O)C2=CC=CC=C2N3N=CC=N3)NC4=NC=C(N=C4)C(F)(F)F
DM5FVH0 IK HMHQKDBOHKCIIS-KXBFYZLASA-N
DM5FVH0 IU N-[(1S,2S)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DM143OK ID DM143OK
DM143OK DN 1,2-diamino cyclopentane-based derivative 3
DM143OK HS Patented
DM143OK SN PMID26593218-Compound-25
DM143OK CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM143OK DT Small molecular drug
DM143OK PC 122438686
DM143OK MW 397.5
DM143OK FM C21H23N3O3S
DM143OK IC InChI=1S/C21H23N3O3S/c1-26-16-10-6-11-17(27-2)19(16)20(25)22-13-8-5-9-14(13)23-21-24-15-7-3-4-12-18(15)28-21/h3-4,6-7,10-14H,5,8-9H2,1-2H3,(H,22,25)(H,23,24)/t13-,14+/m0/s1
DM143OK CS COC1=C(C(=CC=C1)OC)C(=O)N[C@H]2CCC[C@H]2NC3=NC4=CC=CC=C4S3
DM143OK IK PQSRJJBKNVQRDI-UONOGXRCSA-N
DM143OK IU N-[(1S,2R)-2-(1,3-benzothiazol-2-ylamino)cyclopentyl]-2,6-dimethoxybenzamide
DMZ4NJQ ID DMZ4NJQ
DMZ4NJQ DN 1,2-diamino cyclopentane-based derivative 30
DMZ4NJQ HS Patented
DMZ4NJQ SN PMID26593218-Compound-51
DMZ4NJQ CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMZ4NJQ DT Small molecular drug
DMVZ5EP ID DMVZ5EP
DMVZ5EP DN 1,2-diamino cyclopentane-based derivative 31
DMVZ5EP HS Patented
DMVZ5EP SN PMID26593218-Compound-52
DMVZ5EP CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMVZ5EP DT Small molecular drug
DMVZ5EP PC 118308285
DMVZ5EP MW 465.9
DMVZ5EP FM C20H19ClF3N7O
DMVZ5EP IC InChI=1S/C20H19ClF3N7O/c1-19(30-17-11-25-16(10-26-17)20(22,23)24)6-2-3-15(19)29-18(32)13-9-12(21)4-5-14(13)31-27-7-8-28-31/h4-5,7-11,15H,2-3,6H2,1H3,(H,26,30)(H,29,32)/t15-,19-/m0/s1
DMVZ5EP CS C[C@@]1(CCC[C@@H]1NC(=O)C2=C(C=CC(=C2)Cl)N3N=CC=N3)NC4=NC=C(N=C4)C(F)(F)F
DMVZ5EP IK WFGSTTYRNIKJJI-KXBFYZLASA-N
DMVZ5EP IU 5-chloro-N-[(1S,2S)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-(triazol-2-yl)benzamide
DMQX8SD ID DMQX8SD
DMQX8SD DN 1,2-diamino cyclopentane-based derivative 32
DMQX8SD HS Patented
DMQX8SD SN PMID26593218-Compound-53
DMQX8SD CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMQX8SD DT Small molecular drug
DMQX8SD PC 118308140
DMQX8SD MW 442.4
DMQX8SD FM C22H21F3N6O
DMQX8SD IC InChI=1S/C22H21F3N6O/c1-21(31-18-13-28-17(12-29-18)22(23,24)25)9-4-8-16(21)30-20(32)15-7-3-2-6-14(15)19-26-10-5-11-27-19/h2-3,5-7,10-13,16H,4,8-9H2,1H3,(H,29,31)(H,30,32)/t16-,21-/m0/s1
DMQX8SD CS C[C@@]1(CCC[C@@H]1NC(=O)C2=CC=CC=C2C3=NC=CC=N3)NC4=NC=C(N=C4)C(F)(F)F
DMQX8SD IK WZNUKPZCVKITNK-KKSFZXQISA-N
DMQX8SD IU N-[(1S,2S)-2-methyl-2-[[5-(trifluoromethyl)pyrazin-2-yl]amino]cyclopentyl]-2-pyrimidin-2-ylbenzamide
DMBOLSU ID DMBOLSU
DMBOLSU DN 1,2-diamino cyclopentane-based derivative 33
DMBOLSU HS Patented
DMBOLSU SN PMID26593218-Compound-54
DMBOLSU CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBOLSU DT Small molecular drug
DMVHL3W ID DMVHL3W
DMVHL3W DN 1,2-diamino cyclopentane-based derivative 34
DMVHL3W HS Patented
DMVHL3W SN PMID26593218-Compound-55
DMVHL3W CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMVHL3W DT Small molecular drug
DMVHL3W PC 126666451
DMVHL3W MW 422.5
DMVHL3W FM C21H19FN6OS
DMVHL3W IC InChI=1S/C21H19FN6OS/c22-13-7-8-16-18(12-13)30-21(27-16)26-15-5-1-4-14(15)25-20(29)19-17(6-2-9-23-19)28-11-3-10-24-28/h2-3,6-12,14-15H,1,4-5H2,(H,25,29)(H,26,27)/t14-,15-/m0/s1
DMVHL3W CS C1C[C@@H]([C@H](C1)NC(=O)C2=C(C=CC=N2)N3C=CC=N3)NC4=NC5=C(S4)C=C(C=C5)F
DMVHL3W IK ZNHYIIOVQSLYRA-GJZGRUSLSA-N
DMVHL3W IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-3-pyrazol-1-ylpyridine-2-carboxamide
DMFBPSX ID DMFBPSX
DMFBPSX DN 1,2-diamino cyclopentane-based derivative 4
DMFBPSX HS Patented
DMFBPSX SN PMID26593218-Compound-26
DMFBPSX CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMFBPSX DT Small molecular drug
DMCP15K ID DMCP15K
DMCP15K DN 1,2-diamino cyclopentane-based derivative 5
DMCP15K HS Patented
DMCP15K SN PMID26593218-Compound-27
DMCP15K CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMCP15K DT Small molecular drug
DMCP15K PC 122438647
DMCP15K MW 415.5
DMCP15K FM C21H22FN3O3S
DMCP15K IC InChI=1S/C21H22FN3O3S/c1-27-16-7-4-8-17(28-2)19(16)20(26)23-13-5-3-6-14(13)24-21-25-15-10-9-12(22)11-18(15)29-21/h4,7-11,13-14H,3,5-6H2,1-2H3,(H,23,26)(H,24,25)/t13-,14-/m0/s1
DMCP15K CS COC1=C(C(=CC=C1)OC)C(=O)N[C@H]2CCC[C@@H]2NC3=NC4=C(S3)C=C(C=C4)F
DMCP15K IK FFLQAHCLFLUGAV-KBPBESRZSA-N
DMCP15K IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2,6-dimethoxybenzamide
DMJ4ACP ID DMJ4ACP
DMJ4ACP DN 1,2-diamino cyclopentane-based derivative 6
DMJ4ACP HS Patented
DMJ4ACP SN PMID26593218-Compound-28
DMJ4ACP CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMJ4ACP DT Small molecular drug
DMJ4ACP PC 122438920
DMJ4ACP MW 429.5
DMJ4ACP FM C22H24FN3O3S
DMJ4ACP IC InChI=1S/C22H24FN3O3S/c1-26(22-25-15-11-10-13(23)12-19(15)30-22)16-7-4-6-14(16)24-21(27)20-17(28-2)8-5-9-18(20)29-3/h5,8-12,14,16H,4,6-7H2,1-3H3,(H,24,27)/t14-,16-/m0/s1
DMJ4ACP CS CN([C@H]1CCC[C@@H]1NC(=O)C2=C(C=CC=C2OC)OC)C3=NC4=C(S3)C=C(C=C4)F
DMJ4ACP IK TWWJAOFWTFXPRC-HOCLYGCPSA-N
DMJ4ACP IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)-methylamino]cyclopentyl]-2,6-dimethoxybenzamide
DMHIV24 ID DMHIV24
DMHIV24 DN 1,2-diamino cyclopentane-based derivative 7
DMHIV24 HS Patented
DMHIV24 SN PMID26593218-Compound-29
DMHIV24 CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMHIV24 DT Small molecular drug
DMHIV24 PC 122438852
DMHIV24 MW 429.5
DMHIV24 FM C22H24FN3O3S
DMHIV24 IC InChI=1S/C22H24FN3O3S/c1-26(21(27)20-17(28-2)8-5-9-18(20)29-3)16-7-4-6-14(16)24-22-25-15-11-10-13(23)12-19(15)30-22/h5,8-12,14,16H,4,6-7H2,1-3H3,(H,24,25)/t14-,16-/m0/s1
DMHIV24 CS CN([C@H]1CCC[C@@H]1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=C(C=CC=C4OC)OC
DMHIV24 IK QIQQOZYTKFYTFE-HOCLYGCPSA-N
DMHIV24 IU N-[(1S,2S)-2-[(6-fluoro-1,3-benzothiazol-2-yl)amino]cyclopentyl]-2,6-dimethoxy-N-methylbenzamide
DM7JX8U ID DM7JX8U
DM7JX8U DN 1,2-diamino cyclopentane-based derivative 8
DM7JX8U HS Patented
DM7JX8U SN PMID26593218-Compound-30
DM7JX8U CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM7JX8U DT Small molecular drug
DM7JX8U PC 118034889
DM7JX8U MW 567.1
DM7JX8U FM C28H27ClN4O5S
DM7JX8U IC InChI=1S/C28H27ClN4O5S/c1-36-22-9-6-10-23(37-2)25(22)26(34)30-20-14-33(28(35)38-16-17-7-4-3-5-8-17)15-21(20)32-27-31-19-12-11-18(29)13-24(19)39-27/h3-13,20-21H,14-16H2,1-2H3,(H,30,34)(H,31,32)
DM7JX8U CS COC1=C(C(=CC=C1)OC)C(=O)NC2CN(CC2NC3=NC4=C(S3)C=C(C=C4)Cl)C(=O)OCC5=CC=CC=C5
DM7JX8U IK YUAQEWZWSNKNGF-UHFFFAOYSA-N
DM7JX8U IU benzyl 3-[(6-chloro-1,3-benzothiazol-2-yl)amino]-4-[(2,6-dimethoxybenzoyl)amino]pyrrolidine-1-carboxylate
DM7I8ZV ID DM7I8ZV
DM7I8ZV DN 1,2-diamino cyclopentane-based derivative 9
DM7I8ZV HS Patented
DM7I8ZV SN PMID26593218-Compound-31
DM7I8ZV CP TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM7I8ZV DT Small molecular drug
DMRFXMB ID DMRFXMB
DMRFXMB DN 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1
DMRFXMB HS Patented
DMRFXMB SN PMID25684022-Compound-WO2010120854
DMRFXMB CP GLAXOSMITHKLINE LLC AXTEN, Jeffrey, Michael BRADY, Gerald, Patrick, Jr. GALLAGHER, Timothy, Francis HEERDING, Dirk, A. MEDINA, Jesus, Raul ROMERIL, Stuart, Paul
DMRFXMB DT Small molecular drug
DMRFXMB DE Solid tumour/cancer; Metastatic cancer
DMJMCNP ID DMJMCNP
DMJMCNP DN 1,3,4-oxadiazole derivative 1
DMJMCNP HS Patented
DMJMCNP SN PMID30107136-Compound-Example37
DMJMCNP CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMJMCNP DT Small molecule immunotherapy
DMJMCNP PC 134358044
DMJMCNP MW 438.5
DMJMCNP FM C19H26N4O6S
DMJMCNP IC InChI=1S/C19H26N4O6S/c1-27-12-11-20-17(24)10-9-15(23-30(25,26)13-7-8-13)19-22-21-18(29-19)14-5-3-4-6-16(14)28-2/h3-6,13,15,23H,7-12H2,1-2H3,(H,20,24)/t15-/m0/s1
DMJMCNP CS COCCNC(=O)CC[C@@H](C1=NN=C(O1)C2=CC=CC=C2OC)NS(=O)(=O)C3CC3
DMJMCNP IK FYAJXXVCAGXKAN-HNNXBMFYSA-N
DMJMCNP IU (4S)-4-(cyclopropylsulfonylamino)-N-(2-methoxyethyl)-4-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]butanamide
DMJMCNP DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMH26EO ID DMH26EO
DMH26EO DN 1,3,4-oxadiazole derivative 2
DMH26EO HS Patented
DMH26EO SN PMID30107136-Compound-Example38
DMH26EO CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMH26EO DT Small molecule immunotherapy
DMH26EO PC 134358045
DMH26EO MW 471.5
DMH26EO FM C22H25N5O5S
DMH26EO IC InChI=1S/C22H25N5O5S/c1-31-19-7-3-2-6-17(19)21-25-26-22(32-21)18(27-33(29,30)16-8-9-16)10-11-20(28)24-14-15-5-4-12-23-13-15/h2-7,12-13,16,18,27H,8-11,14H2,1H3,(H,24,28)/t18-/m0/s1
DMH26EO CS COC1=CC=CC=C1C2=NN=C(O2)[C@H](CCC(=O)NCC3=CN=CC=C3)NS(=O)(=O)C4CC4
DMH26EO IK JHNLLRMWPHPFLP-SFHVURJKSA-N
DMH26EO IU (4S)-4-(cyclopropylsulfonylamino)-4-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-N-(pyridin-3-ylmethyl)butanamide
DMH26EO DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMSR0X6 ID DMSR0X6
DMSR0X6 DN 1,3,4-oxadiazole derivative 3
DMSR0X6 HS Patented
DMSR0X6 SN PMID30107136-Compound-Example25
DMSR0X6 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMSR0X6 DT Small molecule immunotherapy
DMSR0X6 PC 122535659
DMSR0X6 MW 429.43
DMSR0X6 FM C16H27N7O7
DMSR0X6 IC InChI=1S/C16H27N7O7/c17-6-2-1-3-8(18)13-22-23-14(30-13)10(7-11(19)24)21-16(29)20-9(15(27)28)4-5-12(25)26/h8-10H,1-7,17-18H2,(H2,19,24)(H,25,26)(H,27,28)(H2,20,21,29)/t8-,9-,10-/m0/s1
DMSR0X6 CS C(CCN)C[C@@H](C1=NN=C(O1)[C@H](CC(=O)N)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DMSR0X6 IK SIMOVBGEPUKIIM-GUBZILKMSA-N
DMSR0X6 IU (2S)-2-[[(1S)-3-amino-1-[5-[(1S)-1,5-diaminopentyl]-1,3,4-oxadiazol-2-yl]-3-oxopropyl]carbamoylamino]pentanedioic acid
DMSR0X6 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM4GR2C ID DM4GR2C
DM4GR2C DN 1,3,4-oxadiazole derivative 4
DM4GR2C HS Patented
DM4GR2C SN PMID30107136-Compound-Example26
DM4GR2C CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM4GR2C DT Small molecule immunotherapy
DM4GR2C PC 122535663
DM4GR2C MW 459.5
DM4GR2C FM C20H25N7O6
DM4GR2C IC InChI=1S/C20H25N7O6/c21-12(7-10-8-23-13-4-2-1-3-11(10)13)17-26-27-18(33-17)15(9-28)25-20(32)24-14(19(30)31)5-6-16(22)29/h1-4,8,12,14-15,23,28H,5-7,9,21H2,(H2,22,29)(H,30,31)(H2,24,25,32)/t12-,14-,15-/m0/s1
DM4GR2C CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C3=NN=C(O3)[C@H](CO)NC(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DM4GR2C IK WXNTYOHOKYKDDS-QEJZJMRPSA-N
DM4GR2C IU (2S)-5-amino-2-[[(1S)-1-[5-[(1S)-1-amino-2-(1H-indol-3-yl)ethyl]-1,3,4-oxadiazol-2-yl]-2-hydroxyethyl]carbamoylamino]-5-oxopentanoic acid
DM4GR2C DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMI5VZN ID DMI5VZN
DMI5VZN DN 1,3,4-oxadiazole derivative 5
DMI5VZN HS Patented
DMI5VZN SN PMID30107136-Compound-Example27
DMI5VZN CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMI5VZN DT Small molecule immunotherapy
DMI5VZN PC 122542131
DMI5VZN MW 379.33
DMI5VZN FM C14H17N7O6
DMI5VZN IC InChI=1S/C14H17N7O6/c1-6(22)10(13(24)25)19-14(26)18-7(4-9(15)23)11-20-21-12(27-11)8-5-16-2-3-17-8/h2-3,5-7,10,22H,4H2,1H3,(H2,15,23)(H,24,25)(H2,18,19,26)/t6?,7-,10-/m0/s1
DMI5VZN CS CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NN=C(O1)C2=NC=CN=C2)O
DMI5VZN IK FQAXMNWDINGSGZ-MXMVMAASSA-N
DMI5VZN IU (2S)-2-[[(1S)-3-amino-3-oxo-1-(5-pyrazin-2-yl-1,3,4-oxadiazol-2-yl)propyl]carbamoylamino]-3-hydroxybutanoic acid
DMI5VZN DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMIEZ6L ID DMIEZ6L
DMIEZ6L DN 1,3,4-oxadiazole derivative 6
DMIEZ6L HS Patented
DMIEZ6L SN PMID30107136-Compound-Example28
DMIEZ6L CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMIEZ6L DT Small molecule immunotherapy
DMIEZ6L PC 122542123
DMIEZ6L MW 434.4
DMIEZ6L FM C19H26N6O6
DMIEZ6L IC InChI=1S/C19H26N6O6/c1-30-14-8-3-2-6-11(14)16-24-25-17(31-16)13(10-15(21)26)23-19(29)22-12(18(27)28)7-4-5-9-20/h2-3,6,8,12-13H,4-5,7,9-10,20H2,1H3,(H2,21,26)(H,27,28)(H2,22,23,29)/t12-,13-/m0/s1
DMIEZ6L CS COC1=CC=CC=C1C2=NN=C(O2)[C@H](CC(=O)N)NC(=O)N[C@@H](CCCCN)C(=O)O
DMIEZ6L IK SAUWXUYDAXFMAR-STQMWFEESA-N
DMIEZ6L IU (2S)-6-amino-2-[[(1S)-3-amino-1-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-3-oxopropyl]carbamoylamino]hexanoic acid
DMIEZ6L DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMAB8QF ID DMAB8QF
DMAB8QF DN 1,3,4-thiadiazole derivative 1
DMAB8QF HS Patented
DMAB8QF SN PMID30107136-Compound-Example29
DMAB8QF CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMAB8QF DT Small molecule immunotherapy
DMAB8QF PC 117947861
DMAB8QF MW 360.32
DMAB8QF FM C12H20N6O7
DMAB8QF IC InChI=1S/C12H20N6O7/c1-4(20)8(11(22)23)16-12(24)15-6(2-7(14)21)10-18-17-9(25-10)5(13)3-19/h4-6,8,19-20H,2-3,13H2,1H3,(H2,14,21)(H,22,23)(H2,15,16,24)/t4?,5-,6-,8-/m0/s1
DMAB8QF CS CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NN=C(O1)[C@H](CO)N)O
DMAB8QF IK HODUKYLKCHJNCA-WHFCDURNSA-N
DMAB8QF IU (2S)-2-[[(1S)-3-amino-1-[5-[(1S)-1-amino-2-hydroxyethyl]-1,3,4-oxadiazol-2-yl]-3-oxopropyl]carbamoylamino]-3-hydroxybutanoic acid
DMAB8QF DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMXIG07 ID DMXIG07
DMXIG07 DN 1,3,4-thiadiazole derivative 2
DMXIG07 HS Patented
DMXIG07 SN PMID30107136-Compound-Example30
DMXIG07 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMXIG07 DT Small molecule immunotherapy
DMXIG07 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMLD7JU ID DMLD7JU
DMLD7JU DN 1,3,5-triazine derivative 1
DMLD7JU HS Patented
DMLD7JU SN PMID27215781-Compound-17
DMLD7JU CP SANOFI
DMLD7JU DT Small molecular drug
DMUS7O3 ID DMUS7O3
DMUS7O3 DN 1,3-dihydroxy phenyl derivative 1
DMUS7O3 HS Patented
DMUS7O3 SN PMID30107136-Compound-Example5
DMUS7O3 CP BRISTOL-MYERS SQUIBB COMPANY
DMUS7O3 DT Small molecule immunotherapy
DMUS7O3 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM63NX5 ID DM63NX5
DM63NX5 DN 1,3-dihydroxy phenyl derivative 2
DM63NX5 HS Patented
DM63NX5 SN PMID30107136-Compound-Example6
DM63NX5 CP BRISTOL-MYERS SQUIBB COMPANY
DM63NX5 DT Small molecule immunotherapy
DM63NX5 PC 138748934
DM63NX5 MW 624.1
DM63NX5 FM C34H30ClN5O5
DM63NX5 IC InChI=1S/C34H30ClN5O5/c1-21-24(6-5-7-26(21)30-17-38-28-8-3-4-9-29(28)40-30)19-45-32-12-31(44-18-23-10-22(13-36)14-37-15-23)25(11-27(32)35)16-39-34(2,20-41)33(42)43/h3-12,14-15,17,39,41H,16,18-20H2,1-2H3,(H,42,43)/t34-/m1/s1
DM63NX5 CS CC1=C(C=CC=C1C2=NC3=CC=CC=C3N=C2)COC4=C(C=C(C(=C4)OCC5=CC(=CN=C5)C#N)CN[C@](C)(CO)C(=O)O)Cl
DM63NX5 IK KJGBSKXWCFJEDI-UUWRZZSWSA-N
DM63NX5 IU (2R)-2-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[(2-methyl-3-quinoxalin-2-ylphenyl)methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DM63NX5 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMZY3HC ID DMZY3HC
DMZY3HC DN 1,5-diphenylpyrrolidin-2-one derivative 1
DMZY3HC HS Patented
DMZY3HC SN PMID26161824-Compound-114
DMZY3HC CP ELI LILLY AND COMPANY SCHAUS, John, Mehner
DMZY3HC DT Small molecular drug
DMZY3HC DE Obesity
DMBR2Y9 ID DMBR2Y9
DMBR2Y9 DN 1,5-diphenylpyrrolidin-2-one derivative 2
DMBR2Y9 HS Patented
DMBR2Y9 SN PMID26161824-Compound-115
DMBR2Y9 CP ELI LILLY AND COMPANY SCHAUS, John, Mehner
DMBR2Y9 DT Small molecular drug
DMBR2Y9 PC 44468756
DMBR2Y9 MW 524.5
DMBR2Y9 FM C25H22F6N4O2
DMBR2Y9 IC InChI=1S/C25H22F6N4O2/c1-23(2,20-12-13-32-22(33-20)24(26,27)28)34-18-14-19(15-6-4-3-5-7-15)35(21(18)36)16-8-10-17(11-9-16)37-25(29,30)31/h3-13,18-19,34H,14H2,1-2H3/t18-,19-/m1/s1
DMBR2Y9 CS CC(C)(C1=NC(=NC=C1)C(F)(F)F)N[C@@H]2C[C@@H](N(C2=O)C3=CC=C(C=C3)OC(F)(F)F)C4=CC=CC=C4
DMBR2Y9 IK RZNGNBDYOQOCCY-RTBURBONSA-N
DMBR2Y9 IU (3R,5R)-5-phenyl-1-[4-(trifluoromethoxy)phenyl]-3-[2-[2-(trifluoromethyl)pyrimidin-4-yl]propan-2-ylamino]pyrrolidin-2-one
DMBR2Y9 DE Obesity
DMEUO8G ID DMEUO8G
DMEUO8G DN 1,5-di-substituted pyridine derivative 1
DMEUO8G HS Patented
DMEUO8G SN PMID26161698-Compound-26
DMEUO8G CP LEAD DISCOVERY CENTER GMBH [DEBAYER IP GMBH [DE];
DMEUO8G DT Small molecular drug
DMEUO8G PC 60197050
DMEUO8G MW 369.4
DMEUO8G FM C19H19N3O3S
DMEUO8G IC InChI=1S/C19H19N3O3S/c1-25-18-8-3-2-7-17(18)15-9-10-21-19(12-15)22-16-6-4-5-14(11-16)13-26(20,23)24/h2-12H,13H2,1H3,(H,21,22)(H2,20,23,24)
DMEUO8G CS COC1=CC=CC=C1C2=CC(=NC=C2)NC3=CC=CC(=C3)CS(=O)(=O)N
DMEUO8G IK WIMRMIUJTYQVQS-UHFFFAOYSA-N
DMEUO8G IU [3-[[4-(2-methoxyphenyl)pyridin-2-yl]amino]phenyl]methanesulfonamide
DMUQ9CF ID DMUQ9CF
DMUQ9CF DN 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1
DMUQ9CF HS Patented
DMUQ9CF SN PMID27410995-Compound-Figure3e
DMUQ9CF DT Small molecular drug
DMPZ0U8 ID DMPZ0U8
DMPZ0U8 DN 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2
DMPZ0U8 HS Patented
DMPZ0U8 SN PMID27410995-Compound-Figure3f
DMPZ0U8 DT Small molecular drug
DMF6W2Y ID DMF6W2Y
DMF6W2Y DN 1,6-naphyridine-4-ketone fused heterocyclic derivative 1
DMF6W2Y HS Patented
DMF6W2Y SN PMID28621580-Compound-WO2013097753c65
DMF6W2Y CP JIANGSU SIMCERE PHARMACEUTICAL CO LTD [CN]
DMF6W2Y DT Small molecular drug
DMHNPSO ID DMHNPSO
DMHNPSO DN 1190312-92-5
DMHNPSO HS Patented
DMHNPSO SN 3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 1190312-92-5; 3-CHLORO-4-AZAINDOLE-7-CARBOXYLIC ACID; SCHEMBL16157363; US10174026, Example 1; UAFNSWUBMGTOQA-UHFFFAOYSA-N; BDBM320361; ZINC44713035; 3-chloro-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid
DMHNPSO DT Small molecular drug
DMHNPSO PC 53412620
DMHNPSO MW 196.59
DMHNPSO FM C8H5ClN2O2
DMHNPSO IC InChI=1S/C8H5ClN2O2/c9-5-3-11-6-4(8(12)13)1-2-10-7(5)6/h1-3,11H,(H,12,13)
DMHNPSO CS C1=CN=C2C(=CNC2=C1C(=O)O)Cl
DMHNPSO IK UAFNSWUBMGTOQA-UHFFFAOYSA-N
DMHNPSO IU 3-chloro-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid
DMJRK9D ID DMJRK9D
DMJRK9D DN 1313212-89-3
DMJRK9D HS Patented
DMJRK9D SN Ethyl N-[(4-Aminobenzyl)carbamoyl]glycinate; ethyl 2-(3-(4-aminobenzyl)ureido)acetate; SCHEMBL2044119; CHEMBL3647424; BDBM139995; 1313212-89-3; US8901295, F428
DMJRK9D DT Small molecular drug
DMJRK9D PC 53259809
DMJRK9D MW 251.28
DMJRK9D FM C12H17N3O3
DMJRK9D IC InChI=1S/C12H17N3O3/c1-2-18-11(16)8-15-12(17)14-7-9-3-5-10(13)6-4-9/h3-6H,2,7-8,13H2,1H3,(H2,14,15,17)
DMJRK9D CS CCOC(=O)CNC(=O)NCC1=CC=C(C=C1)N
DMJRK9D IK UCMPTJMHPJQEED-UHFFFAOYSA-N
DMJRK9D IU ethyl 2-[(4-aminophenyl)methylcarbamoylamino]acetate
DMM2N4T ID DMM2N4T
DMM2N4T DN 1607004-34-1
DMM2N4T HS Patented
DMM2N4T SN ADAMTS Inhibitor C7; SCHEMBL15692551; CHEMBL3980860; BDBM194644; 1607004-34-1; US9206139, 3
DMM2N4T DT Small molecular drug
DMM2N4T PC 74221072
DMM2N4T MW 409.4
DMM2N4T FM C20H22F3N3O3
DMM2N4T IC InChI=1S/C20H22F3N3O3/c21-20(22,23)14-5-1-11(2-6-14)9-15(12-3-4-12)16(27)24-10-19(13-7-8-13)17(28)25-18(29)26-19/h1-2,5-6,12-13,15H,3-4,7-10H2,(H,24,27)(H2,25,26,28,29)/t15-,19-/m0/s1
DMM2N4T CS C1CC1[C@H](CC2=CC=C(C=C2)C(F)(F)F)C(=O)NC[C@@]3(C(=O)NC(=O)N3)C4CC4
DMM2N4T IK JHOUEQAOHDTLPY-KXBFYZLASA-N
DMM2N4T IU (2S)-2-cyclopropyl-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-3-[4-(trifluoromethyl)phenyl]propanamide
DMWNKQ8 ID DMWNKQ8
DMWNKQ8 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1
DMWNKQ8 HS Patented
DMWNKQ8 SN PMID27321640-Compound-[18F]-46
DMWNKQ8 CP JANSSEN PHARMACEUTICA NV [BE]
DMWNKQ8 DT Small molecular drug
DMU6ST7 ID DMU6ST7
DMU6ST7 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2
DMU6ST7 HS Patented
DMU6ST7 SN PMID27321640-Compound-[3H]-44
DMU6ST7 CP JANSSEN PHARMACEUTICA NV [BE]
DMU6ST7 DT Small molecular drug
DM62K40 ID DM62K40
DM62K40 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3
DM62K40 HS Patented
DM62K40 SN PMID27321640-Compound-42
DM62K40 CP JANSSEN PHARMACEUTICA NV [BE]
DM62K40 DT Small molecular drug
DMQSTG9 ID DMQSTG9
DMQSTG9 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4
DMQSTG9 HS Patented
DMQSTG9 SN PMID27321640-Compound-43
DMQSTG9 CP JANSSEN PHARMACEUTICA NV [BE]
DMQSTG9 DT Small molecular drug
DM9E0ZD ID DM9E0ZD
DM9E0ZD DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5
DM9E0ZD HS Patented
DM9E0ZD SN PMID27321640-Compound-44
DM9E0ZD CP JANSSEN PHARMACEUTICA NV [BE]
DM9E0ZD DT Small molecular drug
DM826JW ID DM826JW
DM826JW DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6
DM826JW HS Patented
DM826JW SN PMID27321640-Compound-45
DM826JW CP JANSSEN PHARMACEUTICA NV [BE]
DM826JW DT Small molecular drug
DML8RVS ID DML8RVS
DML8RVS DN 1-Benzyl-3-bromo-1H-pyrrole-2,5-dione
DML8RVS HS Patented
DML8RVS SN 1-benzyl-3-bromo-1H-pyrrole-2,5-dione; 112749-49-2; 3-bromo-2,5-dihydro-1-benzyl-1h-pyrrole-2,5-dione; SCHEMBL4848605; CHEMBL3653656; LLBVECSKMXUDOT-UHFFFAOYSA-N; BDBM136369; ZINC34614650; AKOS027470535; 1-BENZYL-3-BROMOPYRROLE-2,5-DIONE; US8865750, CCG- 203780
DML8RVS DT Small molecular drug
DML8RVS PC 15628904
DML8RVS MW 266.09
DML8RVS FM C11H8BrNO2
DML8RVS IC InChI=1S/C11H8BrNO2/c12-9-6-10(14)13(11(9)15)7-8-4-2-1-3-5-8/h1-6H,7H2
DML8RVS CS C1=CC=C(C=C1)CN2C(=O)C=C(C2=O)Br
DML8RVS IK LLBVECSKMXUDOT-UHFFFAOYSA-N
DML8RVS IU 1-benzyl-3-bromopyrrole-2,5-dione
DMWY9GM ID DMWY9GM
DMWY9GM DN 1-Benzyl-3-p-tolyl-1H-pyrrole-2,5-dione
DMWY9GM HS Patented
DMWY9GM SN CHEMBL2037371; SCHEMBL13517162; PLQCDKKQKRJJDK-UHFFFAOYSA-N; BDBM50384773; 1-benzyl-3-p-tolyl-1H-pyrrole-2,5-dione
DMWY9GM DT Small molecular drug
DMWY9GM PC 70690209
DMWY9GM MW 277.3
DMWY9GM FM C18H15NO2
DMWY9GM IC InChI=1S/C18H15NO2/c1-13-7-9-15(10-8-13)16-11-17(20)19(18(16)21)12-14-5-3-2-4-6-14/h2-11H,12H2,1H3
DMWY9GM CS CC1=CC=C(C=C1)C2=CC(=O)N(C2=O)CC3=CC=CC=C3
DMWY9GM IK PLQCDKKQKRJJDK-UHFFFAOYSA-N
DMWY9GM IU 1-benzyl-3-(4-methylphenyl)pyrrole-2,5-dione
DMK75BT ID DMK75BT
DMK75BT DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1
DMK75BT HS Patented
DMK75BT SN PMID25553724-Compound-US2014000406629
DMK75BT DT Small molecular drug
DMK75BT DE Skin disease; Muscular wasting
DMIWQZ5 ID DMIWQZ5
DMIWQZ5 DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2
DMIWQZ5 HS Patented
DMIWQZ5 SN PMID25553724-Compound-US2014000406829
DMIWQZ5 DT Small molecular drug
DMIWQZ5 DE Skin disease; Muscular wasting
DMNXAUZ ID DMNXAUZ
DMNXAUZ DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3
DMNXAUZ HS Patented
DMNXAUZ SN PMID25553724-Compound-US2014000527529
DMNXAUZ DT Small molecular drug
DMNXAUZ DE Skin disease; Muscular wasting
DMV2W9Z ID DMV2W9Z
DMV2W9Z DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4
DMV2W9Z HS Patented
DMV2W9Z SN PMID25553724-Compound-US2014000527629
DMV2W9Z DT Small molecular drug
DMV2W9Z DE Skin disease; Muscular wasting
DMS5EHL ID DMS5EHL
DMS5EHL DN 1-phenyl-1,3,4-triazole derivative 1
DMS5EHL HS Patented
DMS5EHL SN PMID28454500-Compound-76
DMS5EHL CP THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DMS5EHL DT Small molecular drug
DMS5EHL PC 74229666
DMS5EHL MW 455.5
DMS5EHL FM C24H17N5O3S
DMS5EHL IC InChI=1S/C24H17N5O3S/c30-29(31)20-13-14-21(23-19(20)12-7-15-25-23)33-24-27-26-22(16-32-18-10-5-2-6-11-18)28(24)17-8-3-1-4-9-17/h1-15H,16H2
DMS5EHL CS C1=CC=C(C=C1)N2C(=NN=C2SC3=C4C(=C(C=C3)[N+](=O)[O-])C=CC=N4)COC5=CC=CC=C5
DMS5EHL IK RVYWJVIYWKCDEE-UHFFFAOYSA-N
DMS5EHL IU 5-nitro-8-[[5-(phenoxymethyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]quinoline
DMO7310 ID DMO7310
DMO7310 DN 1-phenyl-1,3,4-triazole derivative 2
DMO7310 HS Patented
DMO7310 SN PMID28454500-Compound-77
DMO7310 CP THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DMO7310 DT Small molecular drug
DMO7310 PC 1327659
DMO7310 MW 405.4
DMO7310 FM C20H15N5O3S
DMO7310 IC InChI=1S/C20H15N5O3S/c26-25(27)16-11-12-19(21-13-16)29-20-23-22-18(14-28-17-9-5-2-6-10-17)24(20)15-7-3-1-4-8-15/h1-13H,14H2
DMO7310 CS C1=CC=C(C=C1)N2C(=NN=C2SC3=NC=C(C=C3)[N+](=O)[O-])COC4=CC=CC=C4
DMO7310 IK OZUBDKIROJPQGE-UHFFFAOYSA-N
DMO7310 IU 5-nitro-2-[[5-(phenoxymethyl)-4-phenyl-1,2,4-triazol-3-yl]sulfanyl]pyridine
DMU8FC1 ID DMU8FC1
DMU8FC1 DN 1-phenyl-1,3,4-triazole derivative 3
DMU8FC1 HS Patented
DMU8FC1 SN PMID28454500-Compound-78
DMU8FC1 CP THE GENERAL HOSPITAL CORPORATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DMU8FC1 DT Small molecular drug
DMU8FC1 PC 3071025
DMU8FC1 MW 425.5
DMU8FC1 FM C23H15N5O2S
DMU8FC1 IC InChI=1S/C23H15N5O2S/c29-28(30)19-13-14-20(21-18(19)12-7-15-24-21)31-23-26-25-22(16-8-3-1-4-9-16)27(23)17-10-5-2-6-11-17/h1-15H
DMU8FC1 CS C1=CC=C(C=C1)C2=NN=C(N2C3=CC=CC=C3)SC4=C5C(=C(C=C4)[N+](=O)[O-])C=CC=N5
DMU8FC1 IK RAPJMMAHETVTFD-UHFFFAOYSA-N
DMU8FC1 IU 8-[(4,5-diphenyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline
DMU8FC1 CA CAS 87236-38-2
DMOY5EK ID DMOY5EK
DMOY5EK DN 2-(substituted ethynyl)quinoline derivative 1
DMOY5EK HS Patented
DMOY5EK SN PMID28067079-Compound-34
DMOY5EK CP Korea Institute of Science and Technology
DMOY5EK DT Small molecular drug
DMOY5EK PC 71562840
DMOY5EK MW 259.3
DMOY5EK FM C18H13NO
DMOY5EK IC InChI=1S/C18H13NO/c1-20-18-9-5-8-17-16(18)13-12-15(19-17)11-10-14-6-3-2-4-7-14/h2-9,12-13H,1H3
DMOY5EK CS COC1=CC=CC2=C1C=CC(=N2)C#CC3=CC=CC=C3
DMOY5EK IK JKTIXUXRNOXCFC-UHFFFAOYSA-N
DMOY5EK IU 5-methoxy-2-(2-phenylethynyl)quinoline
DMPCYSW ID DMPCYSW
DMPCYSW DN 2-(substituted ethynyl)quinoline derivative 2
DMPCYSW HS Patented
DMPCYSW SN PMID28067079-Compound-35
DMPCYSW CP Korea Institute of Science and Technology
DMPCYSW DT Small molecular drug
DMMF8A1 ID DMMF8A1
DMMF8A1 DN 2-(substituted ethynyl)quinoline derivative 3
DMMF8A1 HS Patented
DMMF8A1 SN PMID28067079-Compound-36
DMMF8A1 CP Korea Institute of Science and Technology
DMMF8A1 DT Small molecular drug
DMTXZUF ID DMTXZUF
DMTXZUF DN 2-(substituted ethynyl)quinoline derivative 4
DMTXZUF HS Patented
DMTXZUF SN PMID28067079-Compound-37
DMTXZUF CP Korea Institute of Science and Technology
DMTXZUF DT Small molecular drug
DMTXZUF PC 71563215
DMTXZUF MW 255.27
DMTXZUF FM C17H9N3
DMTXZUF IC InChI=1S/C17H9N3/c18-12-16-6-3-5-14(19-16)10-11-15-9-8-13-4-1-2-7-17(13)20-15/h1-9H
DMTXZUF CS C1=CC=C2C(=C1)C=CC(=N2)C#CC3=NC(=CC=C3)C#N
DMTXZUF IK SAXYXSCAJSSRCR-UHFFFAOYSA-N
DMTXZUF IU 6-(2-quinolin-2-ylethynyl)pyridine-2-carbonitrile
DMRTDOA ID DMRTDOA
DMRTDOA DN 2,2-bipyridyl derivative 1
DMRTDOA HS Patented
DMRTDOA SN PMID25468267-Compound-17
DMRTDOA CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMRTDOA DT Small molecular drug
DMYLQZ1 ID DMYLQZ1
DMYLQZ1 DN 2,2-bipyridyl derivative 2
DMYLQZ1 HS Patented
DMYLQZ1 SN PMID25468267-Compound-18
DMYLQZ1 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMYLQZ1 DT Small molecular drug
DMPQF78 ID DMPQF78
DMPQF78 DN 2,2-bipyridyl derivative 3
DMPQF78 HS Patented
DMPQF78 SN PMID25468267-Compound-19
DMPQF78 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMPQF78 DT Small molecular drug
DMTYPBM ID DMTYPBM
DMTYPBM DN 2,2-bipyridyl derivative 4
DMTYPBM HS Patented
DMTYPBM SN PMID25468267-Compound-20
DMTYPBM CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMTYPBM DT Small molecular drug
DMEJOPL ID DMEJOPL
DMEJOPL DN 2,2-bipyridyl derivative 5
DMEJOPL HS Patented
DMEJOPL SN PMID25468267-Compound-21
DMEJOPL CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMEJOPL DT Small molecular drug
DMWRBSP ID DMWRBSP
DMWRBSP DN 2,2-dimethylbenzopyran derivative 1
DMWRBSP HS Patented
DMWRBSP SN PMID26882240-Compound-10
DMWRBSP CP EMORY UNIVERSITY GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION VAN MEIR, Erwin WANG, Binghe
DMWRBSP DT Small molecular drug
DMWRBSP PC 54575622
DMWRBSP MW 444.5
DMWRBSP FM C23H28N2O5S
DMWRBSP IC InChI=1S/C23H28N2O5S/c1-23(2)13-12-19-20(30-23)10-8-16(24-19)15-25(17-6-5-7-17)31(26,27)18-9-11-21(28-3)22(14-18)29-4/h8-14,17H,5-7,15H2,1-4H3
DMWRBSP CS CC1(C=CC2=C(O1)C=CC(=N2)CN(C3CCC3)S(=O)(=O)C4=CC(=C(C=C4)OC)OC)C
DMWRBSP IK CQGIUFASDNXPRB-UHFFFAOYSA-N
DMWRBSP IU N-cyclobutyl-N-[(2,2-dimethylpyrano[3,2-b]pyridin-6-yl)methyl]-3,4-dimethoxybenzenesulfonamide
DM9XUYM ID DM9XUYM
DM9XUYM DN 2,2-dimethylbenzopyran derivative 2
DM9XUYM HS Patented
DM9XUYM SN PMID26882240-Compound-11
DM9XUYM CP SNU R&DB Foundation, S. Korea
DM9XUYM DT Small molecular drug
DM9XUYM PC 71453910
DM9XUYM MW 368.4
DM9XUYM FM C22H24O5
DM9XUYM IC InChI=1S/C22H24O5/c1-22(2)11-10-16-18(27-22)9-7-15(21(16)26-5)17(23)12-14-6-8-19(24-3)20(13-14)25-4/h6-11,13H,12H2,1-5H3
DM9XUYM CS CC1(C=CC2=C(O1)C=CC(=C2OC)C(=O)CC3=CC(=C(C=C3)OC)OC)C
DM9XUYM IK TZRPLTHVBYHDBJ-UHFFFAOYSA-N
DM9XUYM IU 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethylchromen-6-yl)ethanone
DMTCPSQ ID DMTCPSQ
DMTCPSQ DN 2,2-dimethylbenzopyran derivative 3
DMTCPSQ HS Patented
DMTCPSQ SN PMID26882240-Compound-12
DMTCPSQ CP Shenyang Pharmaceutical University, Peop. Rep. China
DMTCPSQ DT Small molecular drug
DMTCPSQ PC 42636766
DMTCPSQ MW 352.4
DMTCPSQ FM C21H20O5
DMTCPSQ IC InChI=1S/C21H20O5/c1-21(2)11-10-15-18(26-21)9-6-14(20(15)24)16(22)7-4-13-5-8-19(25-3)17(23)12-13/h4-12,23-24H,1-3H3/b7-4+
DMTCPSQ CS CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)/C=C/C3=CC(=C(C=C3)OC)O)C
DMTCPSQ IK XCJXATSREUCGQN-QPJJXVBHSA-N
DMTCPSQ IU (E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-en-1-one
DMD2KRW ID DMD2KRW
DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1
DMD2KRW HS Patented
DMD2KRW SN PMID27172114-Compound-31
DMD2KRW CP CURADEV PHARMA PRIVATE LTDCuradev Pharma Private Ltd
DMD2KRW DT Small molecular drug
DMDYXKT ID DMDYXKT
DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2
DMDYXKT HS Patented
DMDYXKT SN PMID27172114-Compound-33
DMDYXKT CP CURADEV PHARMA PRIVATE LTD
DMDYXKT DT Small molecular drug
DMR7QKL ID DMR7QKL
DMR7QKL DN 2,3-diamino-benzo[b]thiophene derivative 3
DMR7QKL HS Patented
DMR7QKL SN PMID27172114-Compound-34
DMR7QKL CP CURADEV PHARMA PRIVATE LTD
DMR7QKL DT Small molecular drug
DMEDFNC ID DMEDFNC
DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4
DMEDFNC HS Patented
DMEDFNC SN PMID27172114-Compound-35
DMEDFNC CP CURADEV PHARMA PRIVATE LTD
DMEDFNC DT Small molecular drug
DM05WXD ID DM05WXD
DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5
DM05WXD HS Patented
DM05WXD SN PMID27172114-Compound-36
DM05WXD CP CURADEV PHARMA PRIVATE LTD
DM05WXD DT Small molecular drug
DMINE6V ID DMINE6V
DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6
DMINE6V HS Patented
DMINE6V SN PMID27172114-Compound-37
DMINE6V CP CURADEV PHARMA PRIVATE LTD
DMINE6V DT Small molecular drug
DMQVMNJ ID DMQVMNJ
DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7
DMQVMNJ HS Patented
DMQVMNJ SN PMID27172114-Compound-38
DMQVMNJ CP CURADEV PHARMA PRIVATE LTD
DMQVMNJ DT Small molecular drug
DM5O8K0 ID DM5O8K0
DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8
DM5O8K0 HS Patented
DM5O8K0 SN PMID27172114-Compound-40
DM5O8K0 CP CURADEV PHARMA PRIVATE LTD
DM5O8K0 DT Small molecular drug
DMMFZKC ID DMMFZKC
DMMFZKC DN 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1
DMMFZKC HS Patented
DMMFZKC SN PMID26560530-Compound-36
DMMFZKC CP Dongguk University Industry-Academic Cooperation Foundation
DMMFZKC DT Small molecular drug
DMMFZKC PC 56682080
DMMFZKC MW 344.4
DMMFZKC FM C21H20N4O
DMMFZKC IC InChI=1S/C21H20N4O/c1-2-7-17(8-3-1)10-11-19-21(26-16-15-25-13-4-5-14-25)24-18-9-6-12-22-20(18)23-19/h1-3,6-9,12H,4-5,13-16H2
DMMFZKC CS C1CCN(C1)CCOC2=NC3=C(N=CC=C3)N=C2C#CC4=CC=CC=C4
DMMFZKC IK MNYJJHBAEYKXEG-UHFFFAOYSA-N
DMMFZKC IU 3-(2-phenylethynyl)-2-(2-pyrrolidin-1-ylethoxy)pyrido[2,3-b]pyrazine
DMLXQET ID DMLXQET
DMLXQET DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 1
DMLXQET HS Patented
DMLXQET SN PMID27215781-Compound-43
DMLXQET CP NORTHEASTERN UNIVERSITY
DMLXQET DT Small molecular drug
DMB65TO ID DMB65TO
DMB65TO DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 2
DMB65TO HS Patented
DMB65TO SN PMID27215781-Compound-44
DMB65TO CP NORTHEASTERN UNIVERSITY
DMB65TO DT Small molecular drug
DMTJ1G8 ID DMTJ1G8
DMTJ1G8 DN 2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1
DMTJ1G8 HS Patented
DMTJ1G8 SN PMID27537201-Compound-Figure13e
DMTJ1G8 CP the Shanghai Institute of Pharmaceutical Industry
DMTJ1G8 DT Small molecular drug
DMHYIAV ID DMHYIAV
DMHYIAV DN 2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1
DMHYIAV HS Patented
DMHYIAV SN PMID27414413-Compound-Figure10
DMHYIAV CP Shenyang Pharmaceutical University and Santa (ZhangJiakou) Pharmaceutical Co., Ltd
DMHYIAV DT Small molecular drug
DMER2ZQ ID DMER2ZQ
DMER2ZQ DN 2-hydroxybenzamide derivative 1
DMER2ZQ HS Patented
DMER2ZQ SN PMID28454500-Compound-38
DMER2ZQ CP Keio University
DMER2ZQ DT Small molecular drug
DM9FRN6 ID DM9FRN6
DM9FRN6 DN 2-hydroxybenzamide derivative 2
DM9FRN6 HS Patented
DM9FRN6 SN PMID28454500-Compound-39
DM9FRN6 CP Keio University
DM9FRN6 DT Small molecular drug
DMI4KBC ID DMI4KBC
DMI4KBC DN 2-PAM derivative 1
DMI4KBC HS Patented
DMI4KBC SN PMID27967267-Compound-45
DMI4KBC CP University of Iowa Research Foundation
DMI4KBC DT Small molecular drug
DMQ1FAH ID DMQ1FAH
DMQ1FAH DN 2-piperidine thiazole derivative 1
DMQ1FAH HS Patented
DMQ1FAH SN PMID27539678-Compound-1
DMQ1FAH CP Merck Patent GmBH
DMQ1FAH DT Small molecular drug
DMSJ1C0 ID DMSJ1C0
DMSJ1C0 DN 2-piperidine thiazole derivative 2
DMSJ1C0 HS Patented
DMSJ1C0 SN PMID27539678-Compound-2
DMSJ1C0 CP Merck Patent GmBH
DMSJ1C0 DT Small molecular drug
DMWXUS4 ID DMWXUS4
DMWXUS4 DN 2-pyrazinone derivative 1
DMWXUS4 HS Patented
DMWXUS4 SN PMID26118988-Compound-28
DMWXUS4 DT Small molecular drug
DMLEH4U ID DMLEH4U
DMLEH4U DN 2-pyrazinone derivative 2
DMLEH4U HS Patented
DMLEH4U SN PMID26118988-Compound-29
DMLEH4U DT Small molecular drug
DMLEH4U PC 68752099
DMLEH4U MW 464.4
DMLEH4U FM C23H15F3N6O2
DMLEH4U IC InChI=1S/C23H15F3N6O2/c1-13-19(18-9-10-29-32(18)16-7-5-14(12-27)6-8-16)30-20(21(28)33)22(34)31(13)17-4-2-3-15(11-17)23(24,25)26/h2-11H,1H3,(H2,28,33)
DMLEH4U CS CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=CC=NN3C4=CC=C(C=C4)C#N
DMLEH4U IK IKJNJNORSFGSID-UHFFFAOYSA-N
DMLEH4U IU 6-[2-(4-cyanophenyl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide
DME5WLD ID DME5WLD
DME5WLD DN 2-pyrazinone derivative 3
DME5WLD HS Patented
DME5WLD SN PMID26118988-Compound-30
DME5WLD DT Small molecular drug
DME5WLD PC 59564942
DME5WLD MW 473.8
DME5WLD FM C22H15ClF3N5O2
DME5WLD IC InChI=1S/C22H15ClF3N5O2/c1-12-18(17-9-10-28-31(17)15-7-5-14(23)6-8-15)29-19(20(27)32)21(33)30(12)16-4-2-3-13(11-16)22(24,25)26/h2-11H,1H3,(H2,27,32)
DME5WLD CS CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=CC=NN3C4=CC=C(C=C4)Cl
DME5WLD IK CESXSDAPOCNYPG-UHFFFAOYSA-N
DME5WLD IU 6-[2-(4-chlorophenyl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide
DMJRHS4 ID DMJRHS4
DMJRHS4 DN 2-pyrazinone derivative 4
DMJRHS4 HS Patented
DMJRHS4 SN PMID26118988-Compound-31
DMJRHS4 DT Small molecular drug
DMJRHS4 PC 59564944
DMJRHS4 MW 474.8
DMJRHS4 FM C21H14ClF3N6O2
DMJRHS4 IC InChI=1S/C21H14ClF3N6O2/c1-11-17(15-7-8-28-31(15)16-6-5-13(22)10-27-16)29-18(19(26)32)20(33)30(11)14-4-2-3-12(9-14)21(23,24)25/h2-10H,1H3,(H2,26,32)
DMJRHS4 CS CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=CC=NN3C4=NC=C(C=C4)Cl
DMJRHS4 IK DZKSYFBPXVHKDO-UHFFFAOYSA-N
DMJRHS4 IU 6-[2-(5-chloropyridin-2-yl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide
DMBIRMA ID DMBIRMA
DMBIRMA DN 2-pyrazinone derivative 5
DMBIRMA HS Patented
DMBIRMA SN PMID26118988-Compound-32
DMBIRMA DT Small molecular drug
DMHIEBN ID DMHIEBN
DMHIEBN DN 2-pyrazinone derivative 6
DMHIEBN HS Patented
DMHIEBN SN PMID26118988-Compound-33
DMHIEBN DT Small molecular drug
DMHIEBN PC 59564943
DMHIEBN MW 461.5
DMHIEBN FM C26H19N7O2
DMHIEBN IC InChI=1S/C26H19N7O2/c1-16-23(22-11-12-29-33(22)20-9-5-17(14-27)6-10-20)31-24(25(34)30-19-7-8-19)26(35)32(16)21-4-2-3-18(13-21)15-28/h2-6,9-13,19H,7-8H2,1H3,(H,30,34)
DMHIEBN CS CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C#N)C(=O)NC3CC3)C4=CC=NN4C5=CC=C(C=C5)C#N
DMHIEBN IK GJIYKCWSHGJDFQ-UHFFFAOYSA-N
DMHIEBN IU 4-(3-cyanophenyl)-6-[2-(4-cyanophenyl)pyrazol-3-yl]-N-cyclopropyl-5-methyl-3-oxopyrazine-2-carboxamide
DMTG6X9 ID DMTG6X9
DMTG6X9 DN 2-pyrazinone derivative 7
DMTG6X9 HS Patented
DMTG6X9 SN PMID26118988-Compound-34
DMTG6X9 DT Small molecular drug
DMTG6X9 PC 25263589
DMTG6X9 MW 494.5
DMTG6X9 FM C25H21F3N6O2
DMTG6X9 IC InChI=1S/C25H21F3N6O2/c1-14-19(22-32-24(2,3)13-33(22)17-9-7-15(12-29)8-10-17)31-20(21(30)35)23(36)34(14)18-6-4-5-16(11-18)25(26,27)28/h4-11H,13H2,1-3H3,(H2,30,35)
DMTG6X9 CS CC1=C(N=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)N)C3=NC(CN3C4=CC=C(C=C4)C#N)(C)C
DMTG6X9 IK CMHWRRKHSAWOMT-UHFFFAOYSA-N
DMTG6X9 IU 6-[3-(4-cyanophenyl)-5,5-dimethyl-4H-imidazol-2-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]pyrazine-2-carboxamide
DM0DYAU ID DM0DYAU
DM0DYAU DN 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM0DYAU HS Patented
DM0DYAU SN CHEMBL2069315; SCHEMBL14574842; CHEMBL2079230; BDBM50389688; 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM0DYAU DT Small molecular drug
DM0DYAU PC 53344793
DM0DYAU MW 414.5
DM0DYAU FM C24H26N6O
DM0DYAU IC InChI=1S/C24H26N6O/c1-2-11-31-20-6-5-17-12-19(4-3-18(17)13-20)22-21-23(25)27-15-28-24(21)30(29-22)14-16-7-9-26-10-8-16/h2-6,12-13,15-16,26H,1,7-11,14H2,(H2,25,27,28)
DM0DYAU CS C=CCOC1=CC2=C(C=C1)C=C(C=C2)C3=NN(C4=NC=NC(=C34)N)CC5CCNCC5
DM0DYAU IK LQRGSXMDDSWGQL-UHFFFAOYSA-N
DM0DYAU IU 1-(piperidin-4-ylmethyl)-3-(6-prop-2-enoxynaphthalen-2-yl)pyrazolo[3,4-d]pyrimidin-4-amine
DM9YJWU ID DM9YJWU
DM9YJWU DN 3-(phenoxymethyl) benzylamine derivative 1
DM9YJWU HS Patented
DM9YJWU SN PMID26815044-Compound-102
DM9YJWU DT Small molecular drug
DM9YJWU DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMGN9IX ID DMGN9IX
DMGN9IX DN 3-(phenoxymethyl) benzylamine derivative 2
DMGN9IX HS Patented
DMGN9IX SN PMID26815044-Compound-103
DMGN9IX DT Small molecular drug
DMGN9IX DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM43EKN ID DM43EKN
DM43EKN DN 3-(phenoxymethyl) benzylamine derivative 3
DM43EKN HS Patented
DM43EKN SN PMID26815044-Compound-104
DM43EKN DT Small molecular drug
DM43EKN DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM58X6N ID DM58X6N
DM58X6N DN 3-(phenoxymethyl) benzylamine derivative 4
DM58X6N HS Patented
DM58X6N SN PMID26815044-Compound-105
DM58X6N DT Small molecular drug
DM58X6N PC 18070637
DM58X6N MW 249.31
DM58X6N FM C17H15NO
DM58X6N IC InChI=1S/C17H15NO/c18-15-8-3-5-13(11-15)12-19-17-10-4-7-14-6-1-2-9-16(14)17/h1-11H,12,18H2
DM58X6N CS C1=CC=C2C(=C1)C=CC=C2OCC3=CC(=CC=C3)N
DM58X6N IK OPMLHBFHZXOITN-UHFFFAOYSA-N
DM58X6N IU 3-(naphthalen-1-yloxymethyl)aniline
DM58X6N DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM84HG2 ID DM84HG2
DM84HG2 DN 3-(phenoxymethyl) benzylamine derivative 5
DM84HG2 HS Patented
DM84HG2 SN PMID26815044-Compound-106
DM84HG2 DT Small molecular drug
DM84HG2 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM0WBM3 ID DM0WBM3
DM0WBM3 DN 3-(phenoxymethyl) benzylamine derivative 6
DM0WBM3 HS Patented
DM0WBM3 SN PMID26815044-Compound-107
DM0WBM3 DT Small molecular drug
DM0WBM3 PC 54126573
DM0WBM3 MW 255.35
DM0WBM3 FM C17H21NO
DM0WBM3 IC InChI=1S/C17H21NO/c1-3-18(4-2)16-10-8-9-15(13-16)14-19-17-11-6-5-7-12-17/h5-13H,3-4,14H2,1-2H3
DM0WBM3 CS CCN(CC)C1=CC=CC(=C1)COC2=CC=CC=C2
DM0WBM3 IK NRJLSCXDEWCXHU-UHFFFAOYSA-N
DM0WBM3 IU N,N-diethyl-3-(phenoxymethyl)aniline
DM0WBM3 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM4O3DW ID DM4O3DW
DM4O3DW DN 3,4-Dihydroxybenzaldehyde
DM4O3DW HS Patented
DM4O3DW CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM4O3DW PC 8768
DM4O3DW MW 138.12
DM4O3DW FM C7H6O3
DM4O3DW IC InChI=1S/C7H6O3/c8-4-5-1-2-6(9)7(10)3-5/h1-4,9-10H
DM4O3DW CS C1=CC(=C(C=C1C=O)O)O
DM4O3DW IK IBGBGRVKPALMCQ-UHFFFAOYSA-N
DM4O3DW IU 3,4-dihydroxybenzaldehyde
DM4O3DW CA CAS 139-85-5
DM4O3DW CB CHEBI:50205
DM8L0MN ID DM8L0MN
DM8L0MN DN 3-acylidene-2-oxoindole derivative 1
DM8L0MN HS Patented
DM8L0MN SN PMID26560530-Compound-29
DM8L0MN CP NUMERATE, INC. THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY GRIFFIN, John RAIMUNDO, Brian MADRID, Peter KHOSLA, Chaitan JIN, Xi KLOECK, Cornelius
DM8L0MN DT Small molecular drug
DM8L0MN PC 54586674
DM8L0MN MW 360.8
DM8L0MN FM C21H13ClN2O2
DM8L0MN IC InChI=1S/C21H13ClN2O2/c22-17-9-4-10-18-20(17)16(12-19(25)14-6-5-11-23-13-14)21(26)24(18)15-7-2-1-3-8-15/h1-13H/b16-12+
DM8L0MN CS C1=CC=C(C=C1)N2C3=C(C(=CC=C3)Cl)/C(=C\\C(=O)C4=CN=CC=C4)/C2=O
DM8L0MN IK MAXLUMXHDRQNGJ-FOWTUZBSSA-N
DM8L0MN IU (3E)-4-chloro-3-(2-oxo-2-pyridin-3-ylethylidene)-1-phenylindol-2-one
DMJ98VG ID DMJ98VG
DMJ98VG DN 3-acylidene-2-oxoindole derivative 2
DMJ98VG HS Patented
DMJ98VG SN PMID26560530-Compound-30
DMJ98VG CP NUMERATE, INC. THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY GRIFFIN, John RAIMUNDO, Brian MADRID, Peter KHOSLA, Chaitan JIN, Xi KLOECK, Cornelius
DMJ98VG DT Small molecular drug
DMJ98VG PC 54584758
DMJ98VG MW 313.7
DMJ98VG FM C17H12ClNO3
DMJ98VG IC InChI=1S/C17H12ClNO3/c1-22-15-8-3-2-5-10(15)14(20)9-11-16-12(18)6-4-7-13(16)19-17(11)21/h2-9H,1H3,(H,19,21)/b11-9+
DMJ98VG CS COC1=CC=CC=C1C(=O)/C=C/2\\C3=C(C=CC=C3Cl)NC2=O
DMJ98VG IK ULAXMAMZNHGQMV-PKNBQFBNSA-N
DMJ98VG IU (3E)-4-chloro-3-[2-(2-methoxyphenyl)-2-oxoethylidene]-1H-indol-2-one
DMFDURZ ID DMFDURZ
DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1
DMFDURZ HS Patented
DMFDURZ SN PMID28270021-Compound-WO2010106028Entrectinib (RXDX-101)
DMFDURZ CP NERVIANO MEDICAL
DMFDURZ DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMB6M3Y ID DMB6M3Y
DMB6M3Y DN 3-benzyloxyphenyloxoacetic acid derivative 1
DMB6M3Y HS Patented
DMB6M3Y SN PMID27414413-Compound-Figure4down
DMB6M3Y CP WELLSTAT THERAPEUTICS CORPORATION SHARMA, Shalini VON BORSTEL, Reid, W
DMB6M3Y DT Small molecular drug
DM9GPKR ID DM9GPKR
DM9GPKR DN 3-Hydroxy-2-butanone
DM9GPKR HS Patented
DM9GPKR CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM9GPKR DT Small molecular drug
DM9GPKR PC 179
DM9GPKR MW 88.11
DM9GPKR FM C4H8O2
DM9GPKR IC InChI=1S/C4H8O2/c1-3(5)4(2)6/h3,5H,1-2H3
DM9GPKR CS CC(C(=O)C)O
DM9GPKR IK ROWKJAVDOGWPAT-UHFFFAOYSA-N
DM9GPKR IU 3-hydroxybutan-2-one
DM9GPKR CA CAS 513-86-0
DM9GPKR CB CHEBI:15688
DMAR2OX ID DMAR2OX
DMAR2OX DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1
DMAR2OX HS Patented
DMAR2OX SN PMID27841036-Compound-6
DMAR2OX CP Nerviano Medical Sciences S.r.l
DMAR2OX DT Small molecular drug
DMEVMU9 ID DMEVMU9
DMEVMU9 DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2
DMEVMU9 HS Patented
DMEVMU9 SN PMID27841036-Compound-7
DMEVMU9 CP Nerviano Medical Sciences S.r.l
DMEVMU9 DT Small molecular drug
DMRQ74I ID DMRQ74I
DMRQ74I DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3
DMRQ74I HS Patented
DMRQ74I SN PMID27841036-Compound-8
DMRQ74I CP Nerviano Medical Sciences S.r.l
DMRQ74I DT Small molecular drug
DM8Q19H ID DM8Q19H
DM8Q19H DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4
DM8Q19H HS Patented
DM8Q19H SN PMID27841036-Compound-9
DM8Q19H CP Nerviano Medical Sciences S.r.l
DM8Q19H DT Small molecular drug
DMXJ837 ID DMXJ837
DMXJ837 DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5
DMXJ837 HS Patented
DMXJ837 SN PMID27841036-Compound-IV
DMXJ837 CP Nerviano Medical Sciences S.r.l
DMXJ837 DT Small molecular drug
DMXMV6N ID DMXMV6N
DMXMV6N DN 3-phenyl acrylic acid derivative 1
DMXMV6N HS Patented
DMXMV6N SN PMID25416646-Compound-Figure2-B
DMXMV6N CP Galderma Research & Development
DMXMV6N DT Small molecular drug
DMB40HC ID DMB40HC
DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1
DMB40HC HS Patented
DMB40HC SN PMID27841036-Compound-20
DMB40HC CP NERVIANO MEDICAL SCIENCES S.R.L
DMB40HC DT Small molecular drug
DMB40HC PC 89588629
DMB40HC MW 413.7
DMB40HC FM C17H15BrClFN2O2
DMB40HC IC InChI=1S/C17H14BrFN2O2.ClH/c18-11-3-1-10(2-4-11)15-16(23-8-7-20)13-6-5-12(19)9-14(13)17(22)21-15;/h1-6,9H,7-8,20H2,(H,21,22);1H
DMB40HC CS C1=CC(=CC=C1C2=C(C3=C(C=C(C=C3)F)C(=O)N2)OCCN)Br.Cl
DMB40HC IK BSCLHAQBYMRPSH-UHFFFAOYSA-N
DMB40HC IU 4-(2-aminoethoxy)-3-(4-bromophenyl)-7-fluoro-2H-isoquinolin-1-one;hydrochloride
DMA749P ID DMA749P
DMA749P DN 3-phenyl isoquinolin-1(2H) derivative 2
DMA749P HS Patented
DMA749P SN PMID27841036-Compound-VII
DMA749P CP NERVIANO MEDICAL SCIENCES S.R.L
DMA749P DT Small molecular drug
DMW86YI ID DMW86YI
DMW86YI DN 3-phenyl propanoic derivative 1
DMW86YI HS Patented
DMW86YI SN PMID28454500-Compound-67
DMW86YI CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ASTEX THERAPEUTICS LIMITED
DMW86YI DT Small molecular drug
DMW86YI PC 4685764
DMW86YI MW 183.61
DMW86YI FM C9H8ClO2-
DMW86YI IC InChI=1S/C9H9ClO2/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-2,4-5H,3,6H2,(H,11,12)/p-1
DMW86YI CS C1=CC(=CC=C1CCC(=O)[O-])Cl
DMW86YI IK BBSLOKZINKEUCR-UHFFFAOYSA-M
DMW86YI IU 3-(4-chlorophenyl)propanoate
DM17D30 ID DM17D30
DM17D30 DN 3-phenyl propanoic derivative 2
DM17D30 HS Patented
DM17D30 SN PMID28454500-Compound-68
DM17D30 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ASTEX THERAPEUTICS LIMITED
DM17D30 DT Small molecular drug
DM5GKS6 ID DM5GKS6
DM5GKS6 DN 3-phenyl propanoic derivative 3
DM5GKS6 HS Patented
DM5GKS6 SN PMID28454500-Compound-69
DM5GKS6 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ASTEX THERAPEUTICS LIMITED
DM5GKS6 DT Small molecular drug
DM3VB6G ID DM3VB6G
DM3VB6G DN 3-phenyl pyrazole derivative 1
DM3VB6G HS Patented
DM3VB6G SN PMID26609882-Compound-33
DM3VB6G CP Arena Pharmaceuticals, Inc
DM3VB6G DT Small molecular drug
DMB1JG2 ID DMB1JG2
DMB1JG2 DN 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1
DMB1JG2 HS Patented
DMB1JG2 SN PMID28621580-Compound-WO2013101954c67
DMB1JG2 CP ALLERGAN, INC
DMB1JG2 DT Small molecular drug
DMB1JG2 DE Cell proliferative disorder; Metabolic disorder; Blood vessel proliferative disorder
DMWCT04 ID DMWCT04
DMWCT04 DN 3-substituted-1,2,4-oxadiazole derivative 1
DMWCT04 HS Patented
DMWCT04 SN PMID30107136-Compound-Example33
DMWCT04 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMWCT04 DT Small molecule immunotherapy
DMWCT04 PC 122541390
DMWCT04 MW 384.39
DMWCT04 FM C15H24N6O6
DMWCT04 IC InChI=1S/C15H24N6O6/c1-8(22)11(13(24)25)18-15(26)17-9(7-10(16)23)12-19-14(20-27-12)21-5-3-2-4-6-21/h8-9,11,22H,2-7H2,1H3,(H2,16,23)(H,24,25)(H2,17,18,26)/t8?,9-,11-/m0/s1
DMWCT04 CS CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C1=NC(=NO1)N2CCCCC2)O
DMWCT04 IK YPPJFPAGRYMZTM-PCFYAGROSA-N
DMWCT04 IU (2S)-2-[[(1S)-3-amino-3-oxo-1-(3-piperidin-1-yl-1,2,4-oxadiazol-5-yl)propyl]carbamoylamino]-3-hydroxybutanoic acid
DMWCT04 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMB3806 ID DMB3806
DMB3806 DN 3-substituted-1,2,4-oxadiazole derivative 2
DMB3806 HS Patented
DMB3806 SN PMID30107136-Compound-Example34
DMB3806 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMB3806 DT Small molecule immunotherapy
DMB3806 PC 122541471
DMB3806 MW 360.32
DMB3806 FM C15H16N6O5
DMB3806 IC InChI=1S/C15H16N6O5/c1-3-4-9(18-15(25)19-11(8(2)22)14(23)24)13-20-12(21-26-13)10-7-16-5-6-17-10/h1,5-9,11,22H,4H2,2H3,(H,23,24)(H2,18,19,25)/t8?,9-,11-/m0/s1
DMB3806 CS CC([C@@H](C(=O)O)NC(=O)N[C@@H](CC#C)C1=NC(=NO1)C2=NC=CN=C2)O
DMB3806 IK DGLNBPSKIUYJIJ-PCFYAGROSA-N
DMB3806 IU (2S)-3-hydroxy-2-[[(1S)-1-(3-pyrazin-2-yl-1,2,4-oxadiazol-5-yl)but-3-ynyl]carbamoylamino]butanoic acid
DMB3806 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMKEOH8 ID DMKEOH8
DMKEOH8 DN 3-substituted-2-furancarboxylic acid hydrazide derivative 1
DMKEOH8 HS Patented
DMKEOH8 SN PMID25828189-Compound-1
DMKEOH8 CP DAINIPPON SUMITOMO PHARMA CO [JPDAINIPPON SUMITOMO PHARMA CO., LTD. FUJII, Akihito NIIDOME, Kazumi MIGIHASHI, Chiaki
DMKEOH8 DT Small molecular drug
DMLK29E ID DMLK29E
DMLK29E DN 3-substituted-2-furancarboxylic acid hydrazide derivative 5
DMLK29E HS Patented
DMLK29E SN PMID25828189-Compound-5
DMLK29E CP DAINIPPON SUMITOMO PHARMA CO [JP]
DMLK29E DT Small molecular drug
DMLK29E PC 70805956
DMLK29E MW 487.5
DMLK29E FM C26H21N3O7
DMLK29E IC InChI=1S/C26H21N3O7/c1-16-2-9-20(10-3-16)36-15-17-4-6-18(7-5-17)21-12-13-35-24(21)26(32)28-27-25(31)19-8-11-23(30)22(14-19)29(33)34/h2-14,30H,15H2,1H3,(H,27,31)(H,28,32)
DMLK29E CS CC1=CC=C(C=C1)OCC2=CC=C(C=C2)C3=C(OC=C3)C(=O)NNC(=O)C4=CC(=C(C=C4)O)[N+](=O)[O-]
DMLK29E IK BTGUVNBWMLTDRT-UHFFFAOYSA-N
DMLK29E IU N'-(4-hydroxy-3-nitrobenzoyl)-3-[4-[(4-methylphenoxy)methyl]phenyl]furan-2-carbohydrazide
DMCJHK2 ID DMCJHK2
DMCJHK2 DN 3ts4
DMCJHK2 HS Patented
DMCJHK2 SN N-{3-[4-(4-Phenylthiophen-2-Yl)phenyl]propanoyl}-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide; US8691753, 96; 3ts4; SCHEMBL6868348; CHEMBL1232492; BDBM120246; US8691753, 95; N-{3-[4-(4-phenylthiophen-2-yl)phenyl]propanoyl}-L-alpha-glutamyl-L-alpha-glutamine
DMCJHK2 DT Small molecular drug
DMCJHK2 PC 46861563
DMCJHK2 MW 565.6
DMCJHK2 FM C29H31N3O7S
DMCJHK2 IC InChI=1S/C29H31N3O7S/c30-28(38)22(11-14-26(34)35)32-29(39)23(12-15-27(36)37)31-25(33)13-8-18-6-9-20(10-7-18)24-16-21(17-40-24)19-4-2-1-3-5-19/h1-7,9-10,16-17,22-23H,8,11-15H2,(H2,30,38)(H,31,33)(H,32,39)(H,34,35)(H,36,37)/t22-,23-/m0/s1
DMCJHK2 CS C1=CC=C(C=C1)C2=CSC(=C2)C3=CC=C(C=C3)CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DMCJHK2 IK MMIHYNVQXYWTFM-GOTSBHOMSA-N
DMCJHK2 IU (4S)-5-amino-4-[[(2S)-4-carboxy-2-[3-[4-(4-phenylthiophen-2-yl)phenyl]propanoylamino]butanoyl]amino]-5-oxopentanoic acid
DME30O6 ID DME30O6
DME30O6 DN 4-(2-cyclohexylethoxy) aniline derivative 1
DME30O6 HS Patented
DME30O6 SN PMID28454500-Compound-87
DME30O6 CP Korea institute of radiological & medical sciences, S
DME30O6 DT Small molecular drug
DME30O6 PC 15943048
DME30O6 MW 219.32
DME30O6 FM C14H21NO
DME30O6 IC InChI=1S/C14H21NO/c15-13-6-8-14(9-7-13)16-11-10-12-4-2-1-3-5-12/h6-9,12H,1-5,10-11,15H2
DME30O6 CS C1CCC(CC1)CCOC2=CC=C(C=C2)N
DME30O6 IK KZIPKNLJWRDAKV-UHFFFAOYSA-N
DME30O6 IU 4-(2-cyclohexylethoxy)aniline
DME30O6 CA CAS 76253-34-4
DM8F4QP ID DM8F4QP
DM8F4QP DN 4-(2-cyclohexylethoxy) aniline derivative 2
DM8F4QP HS Patented
DM8F4QP SN PMID28454500-Compound-88
DM8F4QP CP Korea institute of radiological & medical sciences, S
DM8F4QP DT Small molecular drug
DM8F4QP PC 3365475
DM8F4QP MW 319.4
DM8F4QP FM C18H25NO4
DM8F4QP IC InChI=1S/C18H25NO4/c20-17(10-11-18(21)22)19-15-6-8-16(9-7-15)23-13-12-14-4-2-1-3-5-14/h6-9,14H,1-5,10-13H2,(H,19,20)(H,21,22)
DM8F4QP CS C1CCC(CC1)CCOC2=CC=C(C=C2)NC(=O)CCC(=O)O
DM8F4QP IK NUDKZKXLJIDEDG-UHFFFAOYSA-N
DM8F4QP IU 4-[4-(2-cyclohexylethoxy)anilino]-4-oxobutanoic acid
DMJU0SO ID DMJU0SO
DMJU0SO DN 4-(2-cyclohexylethoxy) aniline derivative 3
DMJU0SO HS Patented
DMJU0SO SN PMID28454500-Compound-89
DMJU0SO CP Korea institute of radiological & medical sciences, S
DMJU0SO DT Small molecular drug
DMJU0SO PC 15943058
DMJU0SO MW 261.36
DMJU0SO FM C16H23NO2
DMJU0SO IC InChI=1S/C16H23NO2/c1-13(18)17-15-7-9-16(10-8-15)19-12-11-14-5-3-2-4-6-14/h7-10,14H,2-6,11-12H2,1H3,(H,17,18)
DMJU0SO CS CC(=O)NC1=CC=C(C=C1)OCCC2CCCCC2
DMJU0SO IK XXEWOEJZHUIISK-UHFFFAOYSA-N
DMJU0SO IU N-[4-(2-cyclohexylethoxy)phenyl]acetamide
DMPULIC ID DMPULIC
DMPULIC DN 4-(2-cyclohexylethoxy) aniline derivative 4
DMPULIC HS Patented
DMPULIC SN PMID28454500-Compound-90
DMPULIC CP Korea institute of radiological & medical sciences, S
DMPULIC DT Small molecular drug
DMPULIC PC 3886018
DMPULIC MW 489.4
DMPULIC FM C24H29BrN2O4
DMPULIC IC InChI=1S/C24H29BrN2O4/c25-19-7-4-8-21(15-19)27-24(29)17-30-16-23(28)26-20-9-11-22(12-10-20)31-14-13-18-5-2-1-3-6-18/h4,7-12,15,18H,1-3,5-6,13-14,16-17H2,(H,26,28)(H,27,29)
DMPULIC CS C1CCC(CC1)CCOC2=CC=C(C=C2)NC(=O)COCC(=O)NC3=CC(=CC=C3)Br
DMPULIC IK SUIJKJPCTOXCER-UHFFFAOYSA-N
DMPULIC IU 2-[2-(3-bromoanilino)-2-oxoethoxy]-N-[4-(2-cyclohexylethoxy)phenyl]acetamide
DM7B81V ID DM7B81V
DM7B81V DN 4-(thiazol-5-yl)-pyrimidine derivative 1
DM7B81V HS Patented
DM7B81V SN PMID26161698-Compound-35
DM7B81V CP THE UNIVERSITY OF NOTTINGHAM WANG, Shudong SHI, Shenhua ZAYTSEV, Andrey FISCHER, Peter MartiCYCLACEL LIMITED WANG, Shudong MEADES, Christopher WOOD, Gavin OSNOWSKI, Andrew FISCHER, Peter, MartiCYCLACEL LIMITED FISCHER, Peter, Martin WANG, Shudong WOOD, Gavin
DM7B81V DT Small molecular drug
DM7B81V PC 44253187
DM7B81V MW 338.4
DM7B81V FM C16H14N6OS
DM7B81V IC InChI=1S/C16H14N6OS/c1-9-14(24-16(18-2)20-9)13-10(7-17)8-19-15(22-13)21-11-4-3-5-12(23)6-11/h3-6,8,23H,1-2H3,(H,18,20)(H,19,21,22)
DM7B81V CS CC1=C(SC(=N1)NC)C2=NC(=NC=C2C#N)NC3=CC(=CC=C3)O
DM7B81V IK NYRVLHGVDPPWJS-UHFFFAOYSA-N
DM7B81V IU 2-(3-hydroxyanilino)-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidine-5-carbonitrile
DMMQFCN ID DMMQFCN
DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2
DMMQFCN HS Patented
DMMQFCN SN PMID26161698-Compound-36
DMMQFCN CP CHANGZHOU LE SUN PHARMACEUTICALS LIMITED
DMMQFCN DT Small molecular drug
DMMQFCN PC 71561915
DMMQFCN MW 394.5
DMMQFCN FM C15H15FN6O2S2
DMMQFCN IC InChI=1S/C15H15FN6O2S2/c1-8-13(25-15(18-2)20-8)12-11(16)7-19-14(22-12)21-9-4-3-5-10(6-9)26(17,23)24/h3-7H,1-2H3,(H,18,20)(H2,17,23,24)(H,19,21,22)
DMMQFCN CS CC1=C(SC(=N1)NC)C2=NC(=NC=C2F)NC3=CC(=CC=C3)S(=O)(=O)N
DMMQFCN IK GAIOPWBQKZMUNO-UHFFFAOYSA-N
DMMQFCN IU 3-[[5-fluoro-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]benzenesulfonamide
DMCISHW ID DMCISHW
DMCISHW DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1
DMCISHW HS Patented
DMCISHW SN PMID27788040-Compound-2
DMCISHW CP RESEARCH TRIANGLE INSTITUTE
DMCISHW DT Small molecular drug
DMPTRQD ID DMPTRQD
DMPTRQD DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2
DMPTRQD HS Patented
DMPTRQD SN PMID27788040-Compound-2a
DMPTRQD CP RESEARCH TRIANGLE INSTITUTE
DMPTRQD DT Small molecular drug
DMPTRQD PC 89615818
DMPTRQD MW 502.6
DMPTRQD FM C30H38N4O3
DMPTRQD IC InChI=1S/C30H38N4O3/c1-22(2)19-30(24-10-5-4-6-11-24)26-21-34(14-13-25(26)28(35)37-30)29(36)31-20-23-9-7-8-12-27(23)33-17-15-32(3)16-18-33/h4-12,22H,13-21H2,1-3H3,(H,31,36)
DMPTRQD CS CC(C)CC1(C2=C(CCN(C2)C(=O)NCC3=CC=CC=C3N4CCN(CC4)C)C(=O)O1)C5=CC=CC=C5
DMPTRQD IK VAJNMLPRDFYTCT-UHFFFAOYSA-N
DMPTRQD IU N-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]-3-(2-methylpropyl)-1-oxo-3-phenyl-6,7-dihydro-4H-furo[3,4-c]pyridine-5-carboxamide
DMFOBM9 ID DMFOBM9
DMFOBM9 DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3
DMFOBM9 HS Patented
DMFOBM9 SN PMID27788040-Compound-2b
DMFOBM9 CP RESEARCH TRIANGLE INSTITUTE
DMFOBM9 DT Small molecular drug
DMFOBM9 PC 89615787
DMFOBM9 MW 424.6
DMFOBM9 FM C26H36N2O3
DMFOBM9 IC InChI=1S/C26H36N2O3/c1-20(2)18-26(21-10-6-5-7-11-21)23-19-28(17-12-22(23)25(30)31-26)24(29)13-16-27-14-8-3-4-9-15-27/h5-7,10-11,20H,3-4,8-9,12-19H2,1-2H3
DMFOBM9 CS CC(C)CC1(C2=C(CCN(C2)C(=O)CCN3CCCCCC3)C(=O)O1)C4=CC=CC=C4
DMFOBM9 IK GPTJWUZEJKIMBY-UHFFFAOYSA-N
DMFOBM9 IU 5-[3-(azepan-1-yl)propanoyl]-3-(2-methylpropyl)-3-phenyl-6,7-dihydro-4H-furo[3,4-c]pyridin-1-one
DM6MCBU ID DM6MCBU
DM6MCBU DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4
DM6MCBU HS Patented
DM6MCBU SN PMID27788040-Compound-2c
DM6MCBU CP RESEARCH TRIANGLE INSTITUTE
DM6MCBU DT Small molecular drug
DM6MCBU PC 78118680
DM6MCBU MW 430.5
DM6MCBU FM C27H30N2O3
DM6MCBU IC InChI=1S/C27H30N2O3/c1-18(2)15-27(21-10-4-3-5-11-21)23-17-29(13-12-22(23)26(31)32-27)25(30)24-14-19-8-6-7-9-20(19)16-28-24/h3-11,18,24,28H,12-17H2,1-2H3
DM6MCBU CS CC(C)CC1(C2=C(CCN(C2)C(=O)C3CC4=CC=CC=C4CN3)C(=O)O1)C5=CC=CC=C5
DM6MCBU IK XMIBEMVACFABOS-UHFFFAOYSA-N
DM6MCBU IU 3-(2-methylpropyl)-3-phenyl-5-(1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-6,7-dihydro-4H-furo[3,4-c]pyridin-1-one
DMMELYI ID DMMELYI
DMMELYI DN 4-amino-3,5-di-substituted-thiazole derivative 1
DMMELYI HS Patented
DMMELYI SN PMID26161698-Compound-54
DMMELYI DT Small molecular drug
DMEMYDZ ID DMEMYDZ
DMEMYDZ DN 4-aryl quinol derivative 1
DMEMYDZ HS Patented
DMEMYDZ SN PMID27977313-Compound-20
DMEMYDZ CP CANCER RESEARCH TECHNOLOGY LIMITED
DMEMYDZ DT Small molecular drug
DMEMYDZ PC 482698
DMEMYDZ MW 242.29
DMEMYDZ FM C14H10O2S
DMEMYDZ IC InChI=1S/C14H10O2S/c15-11-5-7-14(16,8-6-11)13-9-10-3-1-2-4-12(10)17-13/h1-9,16H
DMEMYDZ CS C1=CC=C2C(=C1)C=C(S2)C3(C=CC(=O)C=C3)O
DMEMYDZ IK TXEIZQHZDIXJLD-UHFFFAOYSA-N
DMEMYDZ IU 4-(1-benzothiophen-2-yl)-4-hydroxycyclohexa-2,5-dien-1-one
DM7TW5Z ID DM7TW5Z
DM7TW5Z DN 4-aryl quinol derivative 2
DM7TW5Z HS Patented
DM7TW5Z SN PMID27977313-Compound-21
DM7TW5Z CP CANCER RESEARCH TECHNOLOGY LIMITED
DM7TW5Z DT Small molecular drug
DM7TW5Z PC 482697
DM7TW5Z MW 243.28
DM7TW5Z FM C13H9NO2S
DM7TW5Z IC InChI=1S/C13H9NO2S/c15-9-5-7-13(16,8-6-9)12-14-10-3-1-2-4-11(10)17-12/h1-8,16H
DM7TW5Z CS C1=CC=C2C(=C1)N=C(S2)C3(C=CC(=O)C=C3)O
DM7TW5Z IK SDYBYKXWYDVVKP-UHFFFAOYSA-N
DM7TW5Z IU 4-(1,3-benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-one
DM7TW5Z CA CAS 485842-97-5
DM05V8Q ID DM05V8Q
DM05V8Q DN 4-aryl quinol derivative 3
DM05V8Q HS Patented
DM05V8Q SN PMID27977313-Compound-22
DM05V8Q CP CANCER RESEARCH TECHNOLOGY LIMITED
DM05V8Q DT Small molecular drug
DM05V8Q PC 9907134
DM05V8Q MW 365.4
DM05V8Q FM C20H15NO4S
DM05V8Q IC InChI=1S/C20H15NO4S/c22-16-10-12-20(23,13-11-16)19-14-15-6-4-5-9-18(15)21(19)26(24,25)17-7-2-1-3-8-17/h1-14,23H
DM05V8Q CS C1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C=C2C4(C=CC(=O)C=C4)O
DM05V8Q IK HWKQYGBAAMKHDY-UHFFFAOYSA-N
DM05V8Q IU 4-[1-(benzenesulfonyl)indol-2-yl]-4-hydroxycyclohexa-2,5-dien-1-one
DM05V8Q CA CAS 719308-90-4
DM5IWX2 ID DM5IWX2
DM5IWX2 DN 4-aryl quinol derivative 4
DM5IWX2 HS Patented
DM5IWX2 SN PMID27977313-Compound-23
DM5IWX2 CP CANCER RESEARCH TECHNOLOGY LIMITED
DM5IWX2 DT Small molecular drug
DM5IWX2 PC 10430033
DM5IWX2 MW 383.4
DM5IWX2 FM C20H14FNO4S
DM5IWX2 IC InChI=1S/C20H14FNO4S/c21-15-6-7-18-14(12-15)13-19(20(24)10-8-16(23)9-11-20)22(18)27(25,26)17-4-2-1-3-5-17/h1-13,24H
DM5IWX2 CS C1=CC=C(C=C1)S(=O)(=O)N2C3=C(C=C(C=C3)F)C=C2C4(C=CC(=O)C=C4)O
DM5IWX2 IK KASRNHWIQQCDNO-UHFFFAOYSA-N
DM5IWX2 IU 4-[1-(benzenesulfonyl)-5-fluoroindol-2-yl]-4-hydroxycyclohexa-2,5-dien-1-one
DMWB2YX ID DMWB2YX
DMWB2YX DN 4-aryl quinol derivative 5
DMWB2YX HS Patented
DMWB2YX SN PMID27977313-Compound-24
DMWB2YX CP CANCER RESEARCH TECHNOLOGY LIMITED
DMWB2YX DT Small molecular drug
DMWB2YX PC 10474852
DMWB2YX MW 379.4
DMWB2YX FM C21H17NO4S
DMWB2YX IC InChI=1S/C21H17NO4S/c1-15-6-8-18(9-7-15)27(25,26)22-19-5-3-2-4-16(19)14-20(22)21(24)12-10-17(23)11-13-21/h2-14,24H,1H3
DMWB2YX CS CC1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C=C2C4(C=CC(=O)C=C4)O
DMWB2YX IK NLFCLJPNQJYXHL-UHFFFAOYSA-N
DMWB2YX IU 4-hydroxy-4-[1-(4-methylphenyl)sulfonylindol-2-yl]cyclohexa-2,5-dien-1-one
DMC3KTB ID DMC3KTB
DMC3KTB DN 4-aryl quinol derivative 7
DMC3KTB HS Patented
DMC3KTB SN PMID27977313-Compound-Figure5a
DMC3KTB CP CANCER RESEARCH TECHNOLOGY LIMITED
DMC3KTB DT Small molecular drug
DMZDUNT ID DMZDUNT
DMZDUNT DN 4-benzylidene-1-(cyclobutylo)piperidine derivative 1
DMZDUNT HS Patented
DMZDUNT SN PMID29334795-Compound-54
DMZDUNT CP TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMZDUNT DT Small molecular drug
DMM9I1R ID DMM9I1R
DMM9I1R DN 4-Carboxamido-isoindolinone derivative 1
DMM9I1R HS Patented
DMM9I1R SN PMID27841036-Compound-2
DMM9I1R CP NERVIANO MEDICAL SCIENCES S.R.L
DMM9I1R DT Small molecular drug
DM3EHSN ID DM3EHSN
DM3EHSN DN 4-Carboxamido-isoindolinone derivative 2
DM3EHSN HS Patented
DM3EHSN SN PMID27841036-Compound-3
DM3EHSN CP NERVIANO MEDICAL SCIENCES S.R.L
DM3EHSN DT Small molecular drug
DM43YA0 ID DM43YA0
DM43YA0 DN 4-Carboxamido-isoindolinone derivative 3
DM43YA0 HS Patented
DM43YA0 SN PMID27841036-Compound-4
DM43YA0 CP NERVIANO MEDICAL SCIENCES S.R.L
DM43YA0 DT Small molecular drug
DMTGEFW ID DMTGEFW
DMTGEFW DN 4-Carboxamido-isoindolinone derivative 4
DMTGEFW HS Patented
DMTGEFW SN PMID27841036-Compound-5
DMTGEFW CP NERVIANO MEDICAL SCIENCES S.R.L
DMTGEFW DT Small molecular drug
DMIYVOC ID DMIYVOC
DMIYVOC DN 4-Carboxamido-isoindolinone derivative 5
DMIYVOC HS Patented
DMIYVOC SN PMID27841036-Compound-III
DMIYVOC CP NERVIANO MEDICAL SCIENCES S.R.L
DMIYVOC DT Small molecular drug
DM9L5KO ID DM9L5KO
DM9L5KO DN 4-Hydroxy-2,5-dimethyl-3(2H)-furanone
DM9L5KO HS Patented
DM9L5KO CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM9L5KO PC 19309
DM9L5KO MW 128.13
DM9L5KO FM C6H8O3
DM9L5KO IC InChI=1S/C6H8O3/c1-3-5(7)6(8)4(2)9-3/h3,8H,1-2H3
DM9L5KO CS CC1C(=O)C(=C(O1)C)O
DM9L5KO IK INAXVXBDKKUCGI-UHFFFAOYSA-N
DM9L5KO IU 4-hydroxy-2,5-dimethylfuran-3-one
DM9L5KO CA CAS 3658-77-3
DM9L5KO CB CHEBI:76247
DM471P5 ID DM471P5
DM471P5 DN 4-hydroxybenzaldehyde
DM471P5 HS Patented
DM471P5 SN 4-hydroxybenzaldehyde; p-Hydroxybenzaldehyde; 123-08-0; 4-Formylphenol; p-Formylphenol; p-Oxybenzaldehyde; Benzaldehyde, 4-hydroxy-; Parahydroxybenzaldehyde; Benzaldehyde, p-hydroxy-; 4-HYDROXY-BENZALDEHYDE; USAF M-6; 4-Hydroxy benzaldehyde; NSC 2127; p-Hydroxy-benzaldehyde; UNII-O1738X3Y38; Para-Hydroxybenzaldehyde; 4-Hydroxybenzenecarbonal; EINECS 204-599-1; BRN 0471352; CHEMBL14193; AI3-15366; PARA-HYDROXY BENZALDEHYDE; CHEBI:17597; RGHHSNMVTDWUBI-UHFFFAOYSA-N; MFCD00006939; O1738X3Y38; 4-Hydroxybenzaldehyde, 99%; Benzaldehyde, 4-
DM471P5 DT Small molecular drug
DM471P5 PC 126
DM471P5 MW 122.12
DM471P5 FM C7H6O2
DM471P5 IC InChI=1S/C7H6O2/c8-5-6-1-3-7(9)4-2-6/h1-5,9H
DM471P5 CS C1=CC(=CC=C1C=O)O
DM471P5 IK RGHHSNMVTDWUBI-UHFFFAOYSA-N
DM471P5 IU 4-hydroxybenzaldehyde
DM471P5 CA CAS 123-08-0
DM471P5 CB CHEBI:17597
DM471P5 DE Discovery agent
DM3WQNY ID DM3WQNY
DM3WQNY DN 4-Hydroxybenzoicacid
DM3WQNY HS Patented
DM3WQNY CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM3WQNY PC 135
DM3WQNY MW 138.12
DM3WQNY FM C7H6O3
DM3WQNY IC InChI=1S/C7H6O3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H,(H,9,10)
DM3WQNY CS C1=CC(=CC=C1C(=O)O)O
DM3WQNY IK FJKROLUGYXJWQN-UHFFFAOYSA-N
DM3WQNY IU 4-hydroxybenzoic acid
DM3WQNY CA CAS 99-96-7
DM3WQNY CB CHEBI:30763
DMKDZMQ ID DMKDZMQ
DMKDZMQ DN 4-Hydroxybenzylalcohol
DMKDZMQ HS Patented
DMKDZMQ CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMKDZMQ PC 125
DMKDZMQ MW 124.14
DMKDZMQ FM C7H8O2
DMKDZMQ IC InChI=1S/C7H8O2/c8-5-6-1-3-7(9)4-2-6/h1-4,8-9H,5H2
DMKDZMQ CS C1=CC(=CC=C1CO)O
DMKDZMQ IK BVJSUAQZOZWCKN-UHFFFAOYSA-N
DMKDZMQ IU 4-(hydroxymethyl)phenol
DMKDZMQ CA CAS 623-05-2
DMKDZMQ CB CHEBI:67410
DMN6GTZ ID DMN6GTZ
DMN6GTZ DN 4-Methoxybenzaldehyde
DMN6GTZ HS Patented
DMN6GTZ CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMN6GTZ PC 31244
DMN6GTZ MW 136.15
DMN6GTZ FM C8H8O2
DMN6GTZ IC InChI=1S/C8H8O2/c1-10-8-4-2-7(6-9)3-5-8/h2-6H,1H3
DMN6GTZ CS COC1=CC=C(C=C1)C=O
DMN6GTZ IK ZRSNZINYAWTAHE-UHFFFAOYSA-N
DMN6GTZ IU 4-methoxybenzaldehyde
DMN6GTZ CA CAS 123-11-5
DMN6GTZ CB CHEBI:28235
DMNTOZV ID DMNTOZV
DMNTOZV DN 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1
DMNTOZV HS Patented
DMNTOZV SN PMID26161824-Compound-112
DMNTOZV CP LABORATORIOS DEL DR. ESTEVE, S. A. VELA HERNANDEZ, Jose, Miguel YENES MINGUEZ, Susan
DMNTOZV DT Small molecular drug
DMNTOZV DE Obesity
DMWFHKR ID DMWFHKR
DMWFHKR DN 4-oxadiazole derivative 1
DMWFHKR HS Patented
DMWFHKR SN PMID25470667-Compound-Figure5-11
DMWFHKR CP ASTRAZENECA AB ASTRAZENECA UK LIMITED BIRCH, Alan Martin PAL, Sharmistha PETTERSEN, Anna TOMKINSON, Gary Peter
DMWFHKR DT Small molecular drug
DMN37BI ID DMN37BI
DMN37BI DN 4-PAM derivative 1
DMN37BI HS Patented
DMN37BI SN PMID27967267-Compound-46
DMN37BI CP Mississippi State University
DMN37BI DT Small molecular drug
DMMBUGK ID DMMBUGK
DMMBUGK DN 4-pyridone derivative 1
DMMBUGK HS Patented
DMMBUGK SN PMID26118988-Compound-37
DMMBUGK DT Small molecular drug
DMS1O0G ID DMS1O0G
DMS1O0G DN 4-pyridone derivative 2
DMS1O0G HS Patented
DMS1O0G SN PMID26118988-Compound-38
DMS1O0G DT Small molecular drug
DMN2B87 ID DMN2B87
DMN2B87 DN 5-azolone derivative 1
DMN2B87 HS Patented
DMN2B87 SN PMID25399719-Compound-2
DMN2B87 CP UNIV ALCALA HENARES [ES]
DMN2B87 DT Small molecular drug
DMHXKFB ID DMHXKFB
DMHXKFB DN 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1
DMHXKFB HS Patented
DMHXKFB SN PMID26161698-Compound-28
DMHXKFB CP BAYER PHARMA AKTIENGESELLSCHAFT
DMHXKFB DT Small molecular drug
DMHXKFB PC 74767011
DMHXKFB MW 434.5
DMHXKFB FM C20H20F2N4O3S
DMHXKFB IC InChI=1S/C20H20F2N4O3S/c1-28-17-8-13(21)4-5-14(17)15-9-18(24-10-16(15)22)25-19-6-12(11-30(3,23)27)7-20(26-19)29-2/h4-10,23H,11H2,1-3H3,(H,24,25,26)
DMHXKFB CS COC1=CC(=CC(=N1)NC2=NC=C(C(=C2)C3=C(C=C(C=C3)F)OC)F)CS(=N)(=O)C
DMHXKFB IK OOPSDSZASQDBNK-UHFFFAOYSA-N
DMHXKFB IU N-[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl]-6-methoxy-4-[(methylsulfonimidoyl)methyl]pyridin-2-amine
DMOIKB3 ID DMOIKB3
DMOIKB3 DN 5-Hydrazino-1H-tetrazole
DMOIKB3 HS Patented
DMOIKB3 SN 5-Hydrazino-1H-tetrazole; 5-hydrazinyl-1H-tetrazole; FXYYVODGZXUHLT-UHFFFAOYSA-N; 5-hydrazinotetrazole; AC1LA0KS; 2H-tetrazol-5-ylhydrazine; 1H-tetrazol-5-ylhydrazine; SCHEMBL94795; CTK7F1894; ZX-AN011348; ALBB-012551; NSC206227; STL421139; AKOS000295392; ZINC100158257; NSC-206227; 1H-1,2,3,4-Tetrazole, 5-hydrazino-; 1H-tetrazole, 5-hydrazino-, hydrochloride; BB 0259716
DMOIKB3 DT Small molecular drug
DMOIKB3 PC 459489
DMOIKB3 MW 100.08
DMOIKB3 FM CH4N6
DMOIKB3 IC InChI=1S/CH4N6/c2-3-1-4-6-7-5-1/h2H2,(H2,3,4,5,6,7)
DMOIKB3 CS C1(=NNN=N1)NN
DMOIKB3 IK FXYYVODGZXUHLT-UHFFFAOYSA-N
DMOIKB3 IU 2H-tetrazol-5-ylhydrazine
DMOIKB3 CA CAS 40925-73-3
DM0VEBI ID DM0VEBI
DM0VEBI DN 6,6-fused nitrogenous heterocyclic compound 1
DM0VEBI HS Patented
DM0VEBI SN PMID25656651-Compound-32a
DM0VEBI CP F. HOFFMANN-LA ROCHE AG GAZZARD, Lewis J. HANAN, Emily KINTZ, Samuel LYSSIKATOS, Joseph P. PURKEY, Hans Edward
DM0VEBI DT Small molecular drug
DM0VEBI PC 68095484
DM0VEBI MW 318.4
DM0VEBI FM C20H18N2O2
DM0VEBI IC InChI=1S/C20H18N2O2/c1-12-2-7-17(23)10-18(12)15-6-5-14-9-19(21-11-16(14)8-15)22-20(24)13-3-4-13/h2,5-11,13,23H,3-4H2,1H3,(H,21,22,24)
DM0VEBI CS CC1=C(C=C(C=C1)O)C2=CC3=CN=C(C=C3C=C2)NC(=O)C4CC4
DM0VEBI IK JLLTUBSBILQEOE-UHFFFAOYSA-N
DM0VEBI IU N-[7-(5-hydroxy-2-methylphenyl)isoquinolin-3-yl]cyclopropanecarboxamide
DMB1EAW ID DMB1EAW
DMB1EAW DN 6,6-fused nitrogenous heterocyclic compound 2
DMB1EAW HS Patented
DMB1EAW SN PMID25656651-Compound-32b
DMB1EAW CP F. HOFFMANN-LA ROCHE AG GAZZARD, Lewis J. HANAN, Emily KINTZ, Samuel LYSSIKATOS, Joseph P. PURKEY, Hans Edward
DMB1EAW DT Small molecular drug
DMB1EAW PC 67974814
DMB1EAW MW 321.3
DMB1EAW FM C19H16FN3O
DMB1EAW IC InChI=1S/C19H16FN3O/c1-11-16(9-21-10-17(11)20)14-5-4-13-7-18(22-8-15(13)6-14)23-19(24)12-2-3-12/h4-10,12H,2-3H2,1H3,(H,22,23,24)
DMB1EAW CS CC1=C(C=NC=C1C2=CC3=CN=C(C=C3C=C2)NC(=O)C4CC4)F
DMB1EAW IK GSLMJIPSSNUWRV-UHFFFAOYSA-N
DMB1EAW IU N-[7-(5-fluoro-4-methylpyridin-3-yl)isoquinolin-3-yl]cyclopropanecarboxamide
DMX3VCO ID DMX3VCO
DMX3VCO DN 6,6-fused nitrogenous heterocyclic compound 3
DMX3VCO HS Patented
DMX3VCO SN PMID25656651-Compound-32c
DMX3VCO CP F. HOFFMANN-LA ROCHE AG GAZZARD, Lewis J. HANAN, Emily KINTZ, Samuel LYSSIKATOS, Joseph P. PURKEY, Hans Edward
DMX3VCO DT Small molecular drug
DMX3VCO PC 71140595
DMX3VCO MW 419.4
DMX3VCO FM C21H17F4N3O2
DMX3VCO IC InChI=1S/C21H17F4N3O2/c1-10-4-17(19(29)21(23,24)25)26-9-15(10)12-3-2-11-6-18(27-8-13(11)5-12)28-20(30)14-7-16(14)22/h2-6,8-9,14,16,19,29H,7H2,1H3,(H,27,28,30)/t14-,16+,19+/m1/s1
DMX3VCO CS CC1=CC(=NC=C1C2=CC3=CN=C(C=C3C=C2)NC(=O)[C@@H]4C[C@@H]4F)[C@@H](C(F)(F)F)O
DMX3VCO IK LTXJULOSIPKSDB-ALKREAHSSA-N
DMX3VCO IU (1S,2S)-2-fluoro-N-[7-[4-methyl-6-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]pyridin-3-yl]isoquinolin-3-yl]cyclopropane-1-carboxamide
DMJL1MB ID DMJL1MB
DMJL1MB DN 67S
DMJL1MB HS Patented
DMJL1MB SN CHEMBL3814206; {2-[(2r)-4-[4-(Hydroxymethyl)-3-(Methylsulfonyl)phenyl]-2-(Propan-2-Yl)piperazin-1-Yl]-4-(Trifluoromethyl)pyrimidin-5-Yl}methanol; SCHEMBL17519333; BDBM50177015; 67S
DMJL1MB DT Small molecular drug
DMJL1MB PC 91827457
DMJL1MB MW 488.5
DMJL1MB FM C21H27F3N4O4S
DMJL1MB IC InChI=1S/C21H27F3N4O4S/c1-13(2)17-10-27(16-5-4-14(11-29)18(8-16)33(3,31)32)6-7-28(17)20-25-9-15(12-30)19(26-20)21(22,23)24/h4-5,8-9,13,17,29-30H,6-7,10-12H2,1-3H3/t17-/m0/s1
DMJL1MB CS CC(C)[C@@H]1CN(CCN1C2=NC=C(C(=N2)C(F)(F)F)CO)C3=CC(=C(C=C3)CO)S(=O)(=O)C
DMJL1MB IK FPVIRRAMNBCEDK-KRWDZBQOSA-N
DMJL1MB IU [4-[(3R)-4-[5-(hydroxymethyl)-4-(trifluoromethyl)pyrimidin-2-yl]-3-propan-2-ylpiperazin-1-yl]-2-methylsulfonylphenyl]methanol
DMTXGYS ID DMTXGYS
DMTXGYS DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1
DMTXGYS HS Patented
DMTXGYS SN PMID28067079-Compound-109
DMTXGYS DT Small molecular drug
DMTXGYS PC 121263121
DMTXGYS MW 350.4
DMTXGYS FM C17H14N6OS
DMTXGYS IC InChI=1S/C17H14N6OS/c1-10-3-4-18-6-14(10)12-5-13(15-19-9-20-23(15)7-12)16(24)22-17-21-11(2)8-25-17/h3-9H,1-2H3,(H,21,22,24)
DMTXGYS CS CC1=C(C=NC=C1)C2=CN3C(=NC=N3)C(=C2)C(=O)NC4=NC(=CS4)C
DMTXGYS IK BKRWMNODROTBAW-UHFFFAOYSA-N
DMTXGYS IU 6-(4-methylpyridin-3-yl)-N-(4-methyl-1,3-thiazol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide
DMFKTBM ID DMFKTBM
DMFKTBM DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2
DMFKTBM HS Patented
DMFKTBM SN PMID28067079-Compound-110
DMFKTBM DT Small molecular drug
DMFKTBM PC 121263153
DMFKTBM MW 339.4
DMFKTBM FM C15H13N7OS
DMFKTBM IC InChI=1S/C15H13N7OS/c1-8-3-12(21-20-8)10-4-11(13-16-7-17-22(13)5-10)14(23)19-15-18-9(2)6-24-15/h3-7H,1-2H3,(H,20,21)(H,18,19,23)
DMFKTBM CS CC1=CC(=NN1)C2=CN3C(=NC=N3)C(=C2)C(=O)NC4=NC(=CS4)C
DMFKTBM IK VNZBTWWCDKRKLN-UHFFFAOYSA-N
DMFKTBM IU 6-(5-methyl-1H-pyrazol-3-yl)-N-(4-methyl-1,3-thiazol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide
DMXMTLP ID DMXMTLP
DMXMTLP DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3
DMXMTLP HS Patented
DMXMTLP SN PMID28067079-Compound-111
DMXMTLP DT Small molecular drug
DMXMTLP PC 121263181
DMXMTLP MW 339.4
DMXMTLP FM C15H13N7OS
DMXMTLP IC InChI=1S/C15H13N7OS/c1-9-7-24-15(19-9)20-14(23)11-5-10(12-3-4-17-21(12)2)6-22-13(11)16-8-18-22/h3-8H,1-2H3,(H,19,20,23)
DMXMTLP CS CC1=CSC(=N1)NC(=O)C2=CC(=CN3C2=NC=N3)C4=CC=NN4C
DMXMTLP IK POJPLPZXVLFMAM-UHFFFAOYSA-N
DMXMTLP IU 6-(2-methylpyrazol-3-yl)-N-(4-methyl-1,3-thiazol-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide
DMN082G ID DMN082G
DMN082G DN 6EP
DMN082G HS Patented
DMN082G SN 2-{5-[(4-Chloro-2-Methylphenyl)methoxy]-1h-Pyrazol-1-Yl}pyridine-4-Carboxylic Acid; 1613410-75-5; CHEMBL3786952; SCHEMBL15778339; BDBM191600; NCGC00390881-02; QC3611,QC-3611,QC 3611; 2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19); 6EP
DMN082G DT Small molecular drug
DMN082G PC 74766595
DMN082G MW 343.8
DMN082G FM C17H14ClN3O3
DMN082G IC InChI=1S/C17H14ClN3O3/c1-11-8-14(18)3-2-13(11)10-24-16-5-7-20-21(16)15-9-12(17(22)23)4-6-19-15/h2-9H,10H2,1H3,(H,22,23)
DMN082G CS CC1=C(C=CC(=C1)Cl)COC2=CC=NN2C3=NC=CC(=C3)C(=O)O
DMN082G IK PSOBPHXKKHPWMU-UHFFFAOYSA-N
DMN082G IU 2-[5-[(4-chloro-2-methylphenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylic acid
DMV5XR7 ID DMV5XR7
DMV5XR7 DN 6-Phenylquinazolin-4-amine
DMV5XR7 HS Patented
DMV5XR7 SN CHEMBL3262570; 6-phenyl quinazolin-4-amine; SCHEMBL15587451; BDBM50011551
DMV5XR7 DT Small molecular drug
DMV5XR7 PC 90054733
DMV5XR7 MW 221.26
DMV5XR7 FM C14H11N3
DMV5XR7 IC InChI=1S/C14H11N3/c15-14-12-8-11(10-4-2-1-3-5-10)6-7-13(12)16-9-17-14/h1-9H,(H2,15,16,17)
DMV5XR7 CS C1=CC=C(C=C1)C2=CC3=C(C=C2)N=CN=C3N
DMV5XR7 IK KLSNPRMSQXGJND-UHFFFAOYSA-N
DMV5XR7 IU 6-phenylquinazolin-4-amine
DMQL5B7 ID DMQL5B7
DMQL5B7 DN 7-azaindole derivative 1
DMQL5B7 HS Patented
DMQL5B7 SN PMID25991433-Compound-I1
DMQL5B7 CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMQL5B7 DT Small molecular drug
DMQL5B7 PC 10040667
DMQL5B7 MW 303.4
DMQL5B7 FM C18H17N5
DMQL5B7 IC InChI=1S/C18H17N5/c1-23(2)15-5-3-12(4-6-15)13-7-16-17(14-9-21-22-10-14)11-20-18(16)19-8-13/h3-11H,1-2H3,(H,19,20)(H,21,22)
DMQL5B7 CS CN(C)C1=CC=C(C=C1)C2=CC3=C(NC=C3C4=CNN=C4)N=C2
DMQL5B7 IK IPPNJZWFNCNYSG-UHFFFAOYSA-N
DMQL5B7 IU N,N-dimethyl-4-[3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]aniline
DMZRM2Q ID DMZRM2Q
DMZRM2Q DN 7-azaindole derivative 2
DMZRM2Q HS Patented
DMZRM2Q SN PMID25991433-Compound-I2
DMZRM2Q CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMZRM2Q DT Small molecular drug
DMQ7BV4 ID DMQ7BV4
DMQ7BV4 DN 7-azaindole derivative 3
DMQ7BV4 HS Patented
DMQ7BV4 SN PMID25991433-Compound-I3
DMQ7BV4 CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMQ7BV4 DT Small molecular drug
DMW3EMH ID DMW3EMH
DMW3EMH DN 7-azaindole derivative 4
DMW3EMH HS Patented
DMW3EMH SN PMID25991433-Compound-I4
DMW3EMH CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMW3EMH DT Small molecular drug
DMV3H98 ID DMV3H98
DMV3H98 DN 7-azaindole derivative 5
DMV3H98 HS Patented
DMV3H98 SN PMID25991433-Compound-I5
DMV3H98 CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMV3H98 DT Small molecular drug
DMV3H98 PC 59238862
DMV3H98 MW 280.37
DMV3H98 FM C17H20N4
DMV3H98 IC InChI=1S/C17H20N4/c1-21-11-14(9-20-21)16-10-19-17-15(16)7-13(8-18-17)12-5-3-2-4-6-12/h7-12H,2-6H2,1H3,(H,18,19)
DMV3H98 CS CN1C=C(C=N1)C2=CNC3=C2C=C(C=N3)C4CCCCC4
DMV3H98 IK FZQRKZMGFGTWJG-UHFFFAOYSA-N
DMV3H98 IU 5-cyclohexyl-3-(1-methylpyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM8X5GP ID DM8X5GP
DM8X5GP DN 7-azaindole derivative 6
DM8X5GP HS Patented
DM8X5GP SN PMID25991433-Compound-I6
DM8X5GP CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DM8X5GP DT Small molecular drug
DM8X5GP PC 44633908
DM8X5GP MW 281.36
DM8X5GP FM C16H19N5
DM8X5GP IC InChI=1S/C16H19N5/c1-21-10-13(9-18-21)15-14-7-12(8-17-16(14)20-19-15)11-5-3-2-4-6-11/h7-11H,2-6H2,1H3,(H,17,19,20)
DM8X5GP CS CN1C=C(C=N1)C2=C3C=C(C=NC3=NN2)C4CCCCC4
DM8X5GP IK RKYRUOWFAUYZLA-UHFFFAOYSA-N
DM8X5GP IU 5-cyclohexyl-3-(1-methylpyrazol-4-yl)-2H-pyrazolo[3,4-b]pyridine
DMB1WQZ ID DMB1WQZ
DMB1WQZ DN 7-azaindole derivative 7
DMB1WQZ HS Patented
DMB1WQZ SN PMID25991433-Compound-I7
DMB1WQZ CP EISAI R & D MANAGEMENT CO. LTD GRACZYK, Piotr BHATIA, Gurpreet, SingEISAI R&D MANAGEMENT CO. LTD
DMB1WQZ DT Small molecular drug
DMB1WQZ PC 44622836
DMB1WQZ MW 281.36
DMB1WQZ FM C16H19N5
DMB1WQZ IC InChI=1S/C16H19N5/c1-21-10-12(7-19-21)13-8-17-16-15(13)20-14(9-18-16)11-5-3-2-4-6-11/h7-11H,2-6H2,1H3,(H,17,18)
DMB1WQZ CS CN1C=C(C=N1)C2=CNC3=NC=C(N=C23)C4CCCCC4
DMB1WQZ IK KOKYJLMPOHNWTA-UHFFFAOYSA-N
DMB1WQZ IU 2-cyclohexyl-7-(1-methylpyrazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine
DMO1920 ID DMO1920
DMO1920 DN 7-azaindole derivative 8
DMO1920 HS Patented
DMO1920 SN PMID27841036-Compound-10
DMO1920 CP SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
DMO1920 DT Small molecular drug
DMO1920 PC 73669300
DMO1920 MW 334.4
DMO1920 FM C20H22N4O
DMO1920 IC InChI=1S/C20H22N4O/c21-20(25)24-13-10-17-8-9-18(22-19(17)24)16-6-4-15(5-7-16)14-23-11-2-1-3-12-23/h4-10,13H,1-3,11-12,14H2,(H2,21,25)
DMO1920 CS C1CCN(CC1)CC2=CC=C(C=C2)C3=NC4=C(C=C3)C=CN4C(=O)N
DMO1920 IK HIBOPBGHLVWFCH-UHFFFAOYSA-N
DMO1920 IU 6-[4-(piperidin-1-ylmethyl)phenyl]pyrrolo[2,3-b]pyridine-1-carboxamide
DMAY4G1 ID DMAY4G1
DMAY4G1 DN 7-azaindole derivative 9
DMAY4G1 HS Patented
DMAY4G1 SN PMID27841036-Compound-VI
DMAY4G1 CP SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
DMAY4G1 DT Small molecular drug
DMP04Z6 ID DMP04Z6
DMP04Z6 DN 879325-11-8
DMP04Z6 HS Patented
DMP04Z6 SN 3-bromo-8-formyl-7-hydroxy-4-methylcoumarin; 879325-11-8; SCHEMBL2555897; CHEMBL272811; BDBM160334; US9040714, 1
DMP04Z6 DT Small molecular drug
DMP04Z6 PC 24799272
DMP04Z6 MW 283.07
DMP04Z6 FM C11H7BrO4
DMP04Z6 IC InChI=1S/C11H7BrO4/c1-5-6-2-3-8(14)7(4-13)10(6)16-11(15)9(5)12/h2-4,14H,1H3
DMP04Z6 CS CC1=C(C(=O)OC2=C1C=CC(=C2C=O)O)Br
DMP04Z6 IK YMUFHKSSNMFQIZ-UHFFFAOYSA-N
DMP04Z6 IU 3-bromo-7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde
DMPQ2L9 ID DMPQ2L9
DMPQ2L9 DN 936563-93-8
DMPQ2L9 HS Patented
DMPQ2L9 SN SCHEMBL793463; SCHEMBL793304; SCHEMBL201745; SCHEMBL460731; SCHEMBL201744; CHEMBL3647967; CHEMBL3912266; BDBM97672; BDBM191614; 936563-93-8; US9181263, 10; US8476284, 40; 2-PropenaMide,N-[cis-4-[4-aMino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]cyclohexyl];
DMPQ2L9 DT Small molecular drug
DMPQ2L9 PC 24821881
DMPQ2L9 MW 454.5
DMPQ2L9 FM C26H26N6O2
DMPQ2L9 IC InChI=1S/C26H26N6O2/c1-2-22(33)30-18-10-12-19(13-11-18)32-26-23(25(27)28-16-29-26)24(31-32)17-8-14-21(15-9-17)34-20-6-4-3-5-7-20/h2-9,14-16,18-19H,1,10-13H2,(H,30,33)(H2,27,28,29)
DMPQ2L9 CS C=CC(=O)NC1CCC(CC1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
DMPQ2L9 IK SSDFTYWIYVWCIE-UHFFFAOYSA-N
DMPQ2L9 IU N-[4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexyl]prop-2-enamide
DM9ESPR ID DM9ESPR
DM9ESPR DN A1-10436
DM9ESPR HS Patented
DM9ESPR SN N-{[4-(2-tert-Butylphenyl)piperazin-1-yl]carbonyl}glycine; SCHEMBL630380; CHEMBL3644467; BAZIXHMBHKLDIK-UHFFFAOYSA-N; BDBM135826; US8853215, 6; A1-10436
DM9ESPR DT Small molecular drug
DM9ESPR PC 46931248
DM9ESPR MW 319.4
DM9ESPR FM C17H25N3O3
DM9ESPR IC InChI=1S/C17H25N3O3/c1-17(2,3)13-6-4-5-7-14(13)19-8-10-20(11-9-19)16(23)18-12-15(21)22/h4-7H,8-12H2,1-3H3,(H,18,23)(H,21,22)
DM9ESPR CS CC(C)(C)C1=CC=CC=C1N2CCN(CC2)C(=O)NCC(=O)O
DM9ESPR IK BAZIXHMBHKLDIK-UHFFFAOYSA-N
DM9ESPR IU 2-[[4-(2-tert-butylphenyl)piperazine-1-carbonyl]amino]acetic acid
DMJD1S6 ID DMJD1S6
DMJD1S6 DN A1-10438
DMJD1S6 HS Patented
DMJD1S6 SN 3-[4-(2-tert-butylphenyl)piperazin-1-yl]-3-oxopropanoic acid; SCHEMBL631591; CHEMBL3644468; BJJSTQNQWBMPNN-UHFFFAOYSA-N; BDBM135827; US8853215, 9; A1-10438
DMJD1S6 DT Small molecular drug
DMJD1S6 PC 49764239
DMJD1S6 MW 304.4
DMJD1S6 FM C17H24N2O3
DMJD1S6 IC InChI=1S/C17H24N2O3/c1-17(2,3)13-6-4-5-7-14(13)18-8-10-19(11-9-18)15(20)12-16(21)22/h4-7H,8-12H2,1-3H3,(H,21,22)
DMJD1S6 CS CC(C)(C)C1=CC=CC=C1N2CCN(CC2)C(=O)CC(=O)O
DMJD1S6 IK BJJSTQNQWBMPNN-UHFFFAOYSA-N
DMJD1S6 IU 3-[4-(2-tert-butylphenyl)piperazin-1-yl]-3-oxopropanoic acid
DMFWYKE ID DMFWYKE
DMFWYKE DN AC1LCOK0
DMFWYKE HS Patented
DMFWYKE SN CHEMBL349763; 2-(2-Iodo-phenyl)-6,7-dimethoxy-benzo[d][1,3]oxazin-4-one; 2-(2-Iodophenyl)-6,7-dimethoxy-4H-3,1-benzoxazin-4-one; BAS 00763013; AC1LCOK0; Oprea1_230794; Oprea1_104130; SCHEMBL913416; HKRJBRGRGFMQJI-UHFFFAOYSA-N; ZINC832897; STK295881; BDBM50289001; AKOS000642901; MCULE-9727934711; ST50239885; AB00095356-01; SR-01000441631; SR-01000441631-1; 2-(2-iodophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one; 2-(2-iodophenyl)-6,7-dimethoxybenzo[d]1,3-oxazin-4-one; 2-(2-Iodophenyl)-6,7-dimethoxy-4H-3,1-benzoxazin-4-one #
DMFWYKE DT Small molecular drug
DMFWYKE PC 634264
DMFWYKE MW 409.17
DMFWYKE FM C16H12INO4
DMFWYKE IC InChI=1S/C16H12INO4/c1-20-13-7-10-12(8-14(13)21-2)18-15(22-16(10)19)9-5-3-4-6-11(9)17/h3-8H,1-2H3
DMFWYKE CS COC1=C(C=C2C(=C1)C(=O)OC(=N2)C3=CC=CC=C3I)OC
DMFWYKE IK HKRJBRGRGFMQJI-UHFFFAOYSA-N
DMFWYKE IU 2-(2-iodophenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one
DMKTMCH ID DMKTMCH
DMKTMCH DN AC1LDDOQ
DMKTMCH HS Patented
DMKTMCH SN SMR000046381; AC1LDDOQ; MLS002583553; MLS000082533; SCHEMBL17225576; CHEMBL1583701; HMS2304B12; BDBM289593; ZINC4295838; US10092575, Example 81; STL226884; AKOS025272232; MCULE-1732953744; 6-(2-chlorobenzyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 6-(2-Chlorobenzyl)-8,9,10,11-tetrahydrobenzo[4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 861645-11-6
DMKTMCH DT Small molecular drug
DMKTMCH PC 665384
DMKTMCH MW 370.9
DMKTMCH FM C18H15ClN4OS
DMKTMCH IC InChI=1S/C18H15ClN4OS/c19-13-7-3-1-5-11(13)9-22-17-15(12-6-2-4-8-14(12)25-17)16-20-10-21-23(16)18(22)24/h1,3,5,7,10H,2,4,6,8-9H2
DMKTMCH CS C1CCC2=C(C1)C3=C(S2)N(C(=O)N4C3=NC=N4)CC5=CC=CC=C5Cl
DMKTMCH IK CXMQSCNDPBVQEJ-UHFFFAOYSA-N
DMKTMCH IU 8-[(2-chlorophenyl)methyl]-10-thia-3,5,6,8-tetrazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one
DMPOR3G ID DMPOR3G
DMPOR3G DN AC1LE05K
DMPOR3G HS Patented
DMPOR3G SN 2-cyclohexyl-N-(4H-1,2,4-triazol-3-yl)acetamide; MLS-0072999.0001; 2-cyclohexyl-N-(1H-1,2,4-triazol-5-yl)acetamide; 2-Cyclohexyl-N-(4H-[1,2,4]triazol-3-yl)-acetamide; AC1LE05K; Cambridge id 6726786; MLS000527850; cid_704227; SCHEMBL13934556; CHEMBL1408713; BDBM51399; HMS3315G01; HMS2154C10; ZINC5731798; STK222766; AKOS000643541; MCULE-3724123277; SMR000120424; BAS 04087149; EU-0013407; MLS-0072999.0002; 2-cyclohexyl-N-(1H-1,2,4-triazol-5-yl)ethanamide; Z57261898; 432007-38-0
DMPOR3G DT Small molecular drug
DMPOR3G PC 704227
DMPOR3G MW 208.26
DMPOR3G FM C10H16N4O
DMPOR3G IC InChI=1S/C10H16N4O/c15-9(13-10-11-7-12-14-10)6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H2,11,12,13,14,15)
DMPOR3G CS C1CCC(CC1)CC(=O)NC2=NC=NN2
DMPOR3G IK WOQYWVDZSFPTSS-UHFFFAOYSA-N
DMPOR3G IU 2-cyclohexyl-N-(1H-1,2,4-triazol-5-yl)acetamide
DMXI3O0 ID DMXI3O0
DMXI3O0 DN AC1LFGWU
DMXI3O0 HS Patented
DMXI3O0 SN AC1LFGWU; Oprea1_144688; SCHEMBL16409995; ZINC310666; STK508156; AKOS003273711; MCULE-1481833521; ST45014551; SR-01000248344; SR-01000248344-1; 8-(4-methyl(1,2,4-triazol-3-ylthio))-5-nitroquinoline; 8-[(4-methyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline; 8-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline
DMXI3O0 DT Small molecular drug
DMXI3O0 PC 802800
DMXI3O0 MW 287.3
DMXI3O0 FM C12H9N5O2S
DMXI3O0 IC InChI=1S/C12H9N5O2S/c1-16-7-14-15-12(16)20-10-5-4-9(17(18)19)8-3-2-6-13-11(8)10/h2-7H,1H3
DMXI3O0 CS CN1C=NN=C1SC2=C3C(=C(C=C2)[N+](=O)[O-])C=CC=N3
DMXI3O0 IK RMYCZXRLBFQOFF-UHFFFAOYSA-N
DMXI3O0 IU 8-[(4-methyl-1,2,4-triazol-3-yl)sulfanyl]-5-nitroquinoline
DMXI3O0 CA CAS 345991-02-8
DMEVBZW ID DMEVBZW
DMEVBZW DN AC1LFXA6
DMEVBZW HS Patented
DMEVBZW SN 2-(3-methylphenyl)-2,3-dihydro-1H-perimidine; CHEMBL1449583; AC1LFXA6; ChemDiv1_022121; CBMicro_008460; AC1Q2H4W; Oprea1_720651; MLS001197334; SCHEMBL2031646; HMS649N11; HMS2885F10; ZINC232263; SMSF0013139; STL335355; BDBM50069104; AKOS001615822; CCG-107154; MCULE-2061703540; SMR000555270; 315231-02-8; BIM-0008433.P001; SR-01000439027; SR-01000439027-1; 3-(3-methylphenyl)-2,4-diazatricyclo[7.3.1.0^{5,13}]trideca-1(12),5,7,9(13),10-pentaene
DMEVBZW DT Small molecular drug
DMEVBZW PC 761639
DMEVBZW MW 260.3
DMEVBZW FM C18H16N2
DMEVBZW IC InChI=1S/C18H16N2/c1-12-5-2-8-14(11-12)18-19-15-9-3-6-13-7-4-10-16(20-18)17(13)15/h2-11,18-20H,1H3
DMEVBZW CS CC1=CC(=CC=C1)C2NC3=CC=CC4=C3C(=CC=C4)N2
DMEVBZW IK HPFJVSRZYNTHHT-UHFFFAOYSA-N
DMEVBZW IU 2-(3-methylphenyl)-2,3-dihydro-1H-perimidine
DM9Q0EC ID DM9Q0EC
DM9Q0EC DN AC1LJNG0
DM9Q0EC HS Patented
DM9Q0EC SN NadD inhibitor 3_15; AC1LJNG0; SCHEMBL10016382; CHEMBL1552586; BDBM81358; ZINC660291; HMS1801G16; RSC005720; MCULE-5644016932; NCGC00100440-01; US8785499, 3_15; 3-amino-N-(4-chloro-2-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide; 3-amino-N-(4-chloro-2-fluorophenyl)-6-thien-2-ylthieno[2,3-b]pyridine-2-carboxamide
DM9Q0EC DT Small molecular drug
DM9Q0EC PC 1003444
DM9Q0EC MW 403.9
DM9Q0EC FM C18H11ClFN3OS2
DM9Q0EC IC InChI=1S/C18H11ClFN3OS2/c19-9-3-5-12(11(20)8-9)22-17(24)16-15(21)10-4-6-13(23-18(10)26-16)14-2-1-7-25-14/h1-8H,21H2,(H,22,24)
DM9Q0EC CS C1=CSC(=C1)C2=NC3=C(C=C2)C(=C(S3)C(=O)NC4=C(C=C(C=C4)Cl)F)N
DM9Q0EC IK NSFJHJZRXLGMGP-UHFFFAOYSA-N
DM9Q0EC IU 3-amino-N-(4-chloro-2-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide
DMVX9NK ID DMVX9NK
DMVX9NK DN AC1LOJYQ
DMVX9NK HS Patented
DMVX9NK SN AC1LOJYQ; SCHEMBL16409996; ZINC1076986; 3-[(4-nitrophenyl)methylsulfanyl]-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole; MCULE-8783896159
DMVX9NK DT Small molecular drug
DMVX9NK PC 1264500
DMVX9NK MW 418.5
DMVX9NK FM C22H18N4O3S
DMVX9NK IC InChI=1S/C22H18N4O3S/c27-26(28)19-13-11-17(12-14-19)16-30-22-24-23-21(15-29-20-9-5-2-6-10-20)25(22)18-7-3-1-4-8-18/h1-14H,15-16H2
DMVX9NK CS C1=CC=C(C=C1)N2C(=NN=C2SCC3=CC=C(C=C3)[N+](=O)[O-])COC4=CC=CC=C4
DMVX9NK IK WMFDORZAJHGLBJ-UHFFFAOYSA-N
DMVX9NK IU 3-[(4-nitrophenyl)methylsulfanyl]-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole
DMEW5LD ID DMEW5LD
DMEW5LD DN AC1M1SP5
DMEW5LD HS Patented
DMEW5LD SN 3-(2-methoxyphenyl)-2-(propylthio)-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one; 850915-31-0; AC1M1SP5; SCHEMBL16200721; CHEMBL3913943; BDBM86646; ZINC2719834; AKOS024584906; MCULE-4663000139; BC11-38-4; SR-01000120201; SR-01000120201-1; F0579-0260; 3-(2-methoxyphenyl)-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DMEW5LD DT Small molecular drug
DMEW5LD PC 2155273
DMEW5LD MW 334.5
DMEW5LD FM C16H18N2O2S2
DMEW5LD IC InChI=1S/C16H18N2O2S2/c1-3-9-22-16-17-11-8-10-21-14(11)15(19)18(16)12-6-4-5-7-13(12)20-2/h4-7H,3,8-10H2,1-2H3
DMEW5LD CS CCCSC1=NC2=C(C(=O)N1C3=CC=CC=C3OC)SCC2
DMEW5LD IK MXDVDZKXHJWBLR-UHFFFAOYSA-N
DMEW5LD IU 3-(2-methoxyphenyl)-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DM6293C ID DM6293C
DM6293C DN AC1MOZOL
DM6293C HS Patented
DM6293C SN 686770-82-1; AC1MOZOL; CHEMBL3919432; SCHEMBL16200742; BDBM86644; AKOS024584761; MCULE-1812319467; BC11-38-2; EU-0022203; SR-01000120183; SR-01000120183-1; F0579-0063; 2-(sec-butylthio)-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one; 2-butan-2-ylsulfanyl-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DM6293C DT Small molecular drug
DM6293C PC 3403301
DM6293C MW 318.5
DM6293C FM C16H18N2OS2
DM6293C IC InChI=1S/C16H18N2OS2/c1-3-11(2)21-16-17-13-9-10-20-14(13)15(19)18(16)12-7-5-4-6-8-12/h4-8,11H,3,9-10H2,1-2H3
DM6293C CS CCC(C)SC1=NC2=C(C(=O)N1C3=CC=CC=C3)SCC2
DM6293C IK UWXVMIBCJRNBBP-UHFFFAOYSA-N
DM6293C IU 2-butan-2-ylsulfanyl-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DMO4YAB ID DMO4YAB
DMO4YAB DN Acrylamide compound 1
DMO4YAB HS Patented
DMO4YAB SN PMID29334795-Compound-50
DMO4YAB CP SUVEN LIFE SCIENCES LIMITED
DMO4YAB DT Small molecular drug
DM7EOG4 ID DM7EOG4
DM7EOG4 DN Acrylamide compound 2
DM7EOG4 HS Patented
DM7EOG4 SN PMID29334795-Compound-51A
DM7EOG4 CP SUVEN LIFE SCIENCES LIMITED
DM7EOG4 DT Small molecular drug
DM7EOG4 PC 73295197
DM7EOG4 MW 370.5
DM7EOG4 FM C22H30N2O3
DM7EOG4 IC InChI=1S/C22H30N2O3/c25-22(24-14-16-26-17-15-24)9-6-18-4-7-20(8-5-18)27-21-10-12-23(13-11-21)19-2-1-3-19/h4-9,19,21H,1-3,10-17H2/b9-6+
DM7EOG4 CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)/C=C/C(=O)N4CCOCC4
DM7EOG4 IK MXFWFZGVHOHBHI-RMKNXTFCSA-N
DM7EOG4 IU (E)-3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-1-morpholin-4-ylprop-2-en-1-one
DM7JARB ID DM7JARB
DM7JARB DN Acrylamide compound 3
DM7JARB HS Patented
DM7JARB SN PMID29334795-Compound-51B
DM7JARB CP SUVEN LIFE SCIENCES LIMITED
DM7JARB DT Small molecular drug
DM7JARB PC 73295197
DM7JARB MW 370.5
DM7JARB FM C22H30N2O3
DM7JARB IC InChI=1S/C22H30N2O3/c25-22(24-14-16-26-17-15-24)9-6-18-4-7-20(8-5-18)27-21-10-12-23(13-11-21)19-2-1-3-19/h4-9,19,21H,1-3,10-17H2/b9-6+
DM7JARB CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)/C=C/C(=O)N4CCOCC4
DM7JARB IK MXFWFZGVHOHBHI-RMKNXTFCSA-N
DM7JARB IU (E)-3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-1-morpholin-4-ylprop-2-en-1-one
DMZL6D8 ID DMZL6D8
DMZL6D8 DN Acrylamide compound 4
DMZL6D8 HS Patented
DMZL6D8 SN PMID29334795-Compound-53
DMZL6D8 CP SUVEN LIFE SCIENCES LIMITED
DMZL6D8 DT Small molecular drug
DMXTUE1 ID DMXTUE1
DMXTUE1 DN Acyl oxymethyl acrylamide ester derivative 1
DMXTUE1 HS Patented
DMXTUE1 SN PMID27977313-Compound-26
DMXTUE1 CP INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK [PLWARSZAWSKI UNIV MEDYCZNY [PL]
DMXTUE1 DT Small molecular drug
DMXTUE1 PC 56945839
DMXTUE1 MW 540.5
DMXTUE1 FM C23H26F6N2O6
DMXTUE1 IC InChI=1S/C23H26F6N2O6/c1-5-36-17(32)10-30-20(34)16(9-12(2)3)31-19(33)13(4)11-37-21(35)18-14(22(24,25)26)7-6-8-15(18)23(27,28)29/h6-8,12,16H,4-5,9-11H2,1-3H3,(H,30,34)(H,31,33)
DMXTUE1 CS CCOC(=O)CNC(=O)C(CC(C)C)NC(=O)C(=C)COC(=O)C1=C(C=CC=C1C(F)(F)F)C(F)(F)F
DMXTUE1 IK PIBIRGYHHYAZIQ-UHFFFAOYSA-N
DMXTUE1 IU 2-[[1-[(2-ethoxy-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]prop-2-enyl 2,6-bis(trifluoromethyl)benzoate
DMU8OIL ID DMU8OIL
DMU8OIL DN Acyl oxymethyl acrylamide ester derivative 2
DMU8OIL HS Patented
DMU8OIL SN PMID27977313-Compound-Figure5b
DMU8OIL CP INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK [PLWARSZAWSKI UNIV MEDYCZNY [PL]
DMU8OIL DT Small molecular drug
DMX9J1C ID DMX9J1C
DMX9J1C DN Acyl piperidine derivative 1
DMX9J1C HS Patented
DMX9J1C SN PMID29473428-Compound-31
DMX9J1C CP NEWLINK GENETICS CORPORATION MAUTINO, Mario KUMAR, Sanjeev WALDO, Jesse JAIPURI, Firoz KESHARWANI, Tanay ZHANG, Xiaoxia
DMX9J1C DT Small molecular drug
DMX9J1C PC 70874141
DMX9J1C MW 393.5
DMX9J1C FM C24H31N3O2
DMX9J1C IC InChI=1S/C24H31N3O2/c28-23(14-21-19-8-4-5-9-20(19)22-15-25-16-27(21)22)17-10-12-26(13-11-17)24(29)18-6-2-1-3-7-18/h4-5,8-9,15-18,21,23,28H,1-3,6-7,10-14H2
DMX9J1C CS C1CCC(CC1)C(=O)N2CCC(CC2)C(CC3C4=CC=CC=C4C5=CN=CN35)O
DMX9J1C IK FDUHADIZUWTWAZ-UHFFFAOYSA-N
DMX9J1C IU cyclohexyl-[4-[1-hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone
DM2FUIB ID DM2FUIB
DM2FUIB DN Acyl piperidine derivative 2
DM2FUIB HS Patented
DM2FUIB SN PMID26560530-Compound-44
DM2FUIB CP ASTON UNIVERSITY
DM2FUIB DT Small molecular drug
DM2FUIB PC 73504704
DM2FUIB MW 456.3
DM2FUIB FM C18H22BrN3O6
DM2FUIB IC InChI=1S/C18H22BrN3O6/c1-27-17(25)14-4-2-13(3-5-14)12-28-18(26)22-8-6-21(7-9-22)16(24)11-20-15(23)10-19/h2-5H,6-12H2,1H3,(H,20,23)
DM2FUIB CS COC(=O)C1=CC=C(C=C1)COC(=O)N2CCN(CC2)C(=O)CNC(=O)CBr
DM2FUIB IK DHKHYJYAEPJCDA-UHFFFAOYSA-N
DM2FUIB IU (4-methoxycarbonylphenyl)methyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate
DMIDUB4 ID DMIDUB4
DMIDUB4 DN Acyl piperidine derivative 3
DMIDUB4 HS Patented
DMIDUB4 SN PMID26560530-Compound-45
DMIDUB4 CP ASTON UNIVERSITY
DMIDUB4 DT Small molecular drug
DMIDUB4 PC 73775396
DMIDUB4 MW 426.3
DMIDUB4 FM C19H28BrN3O3
DMIDUB4 IC InChI=1S/C19H28BrN3O3/c20-11-16(24)21-12-17(25)22-1-3-23(4-2-22)18(26)19-8-13-5-14(9-19)7-15(6-13)10-19/h13-15H,1-12H2,(H,21,24)
DMIDUB4 CS C1CN(CCN1C(=O)CNC(=O)CBr)C(=O)C23CC4CC(C2)CC(C4)C3
DMIDUB4 IK SCSKGYPISIGLDU-UHFFFAOYSA-N
DMIDUB4 IU N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxoethyl]-2-bromoacetamide
DMA1RVN ID DMA1RVN
DMA1RVN DN Ac-YVAD-cmk
DMA1RVN HS Patented
DMA1RVN CP UNIVERSITY OF COPENHAGEN
DMA1RVN DT Peptide
DMA1RVN DE Photocontact dermatitis; Irritant contact dermatitis; Allergic contact dermatitis
DM7K256 ID DM7K256
DM7K256 DN Ac-YVAD-FMK
DM7K256 HS Patented
DM7K256 CP UNIVERSITY OF COPENHAGEN
DM7K256 DT Peptide
DM7K256 DE Photocontact dermatitis; Irritant contact dermatitis; Allergic contact dermatitis
DMD94MP ID DMD94MP
DMD94MP DN Adamantyl derivative 1
DMD94MP HS Patented
DMD94MP SN PMID27215781-Compound-10
DMD94MP CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMD94MP DT Small molecular drug
DMD94MP PC 90022221
DMD94MP MW 296.4
DMD94MP FM C19H24N2O
DMD94MP IC InChI=1S/C19H24N2O/c22-18(21-6-5-16-3-1-2-4-17(16)21)20-19-10-13-7-14(11-19)9-15(8-13)12-19/h1-4,13-15H,5-12H2,(H,20,22)
DMD94MP CS C1CN(C2=CC=CC=C21)C(=O)NC34CC5CC(C3)CC(C5)C4
DMD94MP IK CQDFSOMWSQOSOR-UHFFFAOYSA-N
DMD94MP IU N-(1-adamantyl)-2,3-dihydroindole-1-carboxamide
DM2L83Y ID DM2L83Y
DM2L83Y DN AGGGWZCOULSEER-PYUWXLGESA-N
DM2L83Y HS Patented
DM2L83Y SN CHEMBL1922121; SCHEMBL3858001; AGGGWZCOULSEER-PYUWXLGESA-N; BDBM50358222; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol
DM2L83Y DT Small molecular drug
DM2L83Y PC 12111411
DM2L83Y MW 397.5
DM2L83Y FM C21H31N7O
DM2L83Y IC InChI=1S/C21H31N7O/c1-6-16(18(29)13(2)3)25-21-26-19(23-11-15-8-7-9-22-10-15)17-20(27-21)28(12-24-17)14(4)5/h7-10,12-14,16,18,29H,6,11H2,1-5H3,(H2,23,25,26,27)/t16-,18?/m1/s1
DM2L83Y CS CC[C@H](C(C(C)C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=CC=C3
DM2L83Y IK AGGGWZCOULSEER-PYUWXLGESA-N
DM2L83Y IU (4R)-2-methyl-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol
DM0P2U3 ID DM0P2U3
DM0P2U3 DN AKOS003197197
DM0P2U3 HS Patented
DM0P2U3 SN CHEMBL3207533; SCHEMBL16922115; AKOS003197197
DM0P2U3 DT Small molecular drug
DM0P2U3 PC 9693619
DM0P2U3 MW 222.63
DM0P2U3 FM C8H7ClN6
DM0P2U3 IC InChI=1S/C8H7ClN6/c9-7-3-1-6(2-4-7)5-10-11-8-12-14-15-13-8/h1-5H,(H2,11,12,13,14,15)/b10-5+
DM0P2U3 CS C1=CC(=CC=C1/C=N/NC2=NNN=N2)Cl
DM0P2U3 IK SZFUMFNPTAQHAI-BJMVGYQFSA-N
DM0P2U3 IU N-[(E)-(4-chlorophenyl)methylideneamino]-2H-tetrazol-5-amine
DMWHN1O ID DMWHN1O
DMWHN1O DN AKOS020330481
DMWHN1O HS Patented
DMWHN1O SN 3-[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid; SCHEMBL4855920; US9611221, Example 7; XKZFNTZMCLZYHZ-UHFFFAOYSA-N; BDBM314103; AKOS020330481; 3[(4-methoxybenzyl)amino]pyridine-4-carboxylic acid
DMWHN1O DT Small molecular drug
DMWHN1O PC 59699608
DMWHN1O MW 258.269
DMWHN1O FM C14H14N2O3
DMWHN1O IC InChI=1S/C14H14N2O3/c1-19-11-4-2-10(3-5-11)8-16-13-9-15-7-6-12(13)14(17)18/h2-7,9,16H,8H2,1H3,(H,17,18)
DMWHN1O CS COC1=CC=C(C=C1)CNC2=C(C=CN=C2)C(=O)O
DMWHN1O IK XKZFNTZMCLZYHZ-UHFFFAOYSA-N
DMWHN1O IU 3-[(4-methoxyphenyl)methylamino]pyridine-4-carboxylic acid
DMNIE4M ID DMNIE4M
DMNIE4M DN AKOS020330656
DMNIE4M HS Patented
DMNIE4M SN CHEMBL3774545; SCHEMBL15820618; RFUZGPWCXINBNW-UHFFFAOYSA-N; BDBM50153334; AKOS020330656; ZINC123452149; 3-{[(5-methylthiophen-2-yl)methyl]amino}pyridine-4-carboxylic acid
DMNIE4M DT Small molecular drug
DMNIE4M PC 77106317
DMNIE4M MW 248.3
DMNIE4M FM C12H12N2O2S
DMNIE4M IC InChI=1S/C12H12N2O2S/c1-8-2-3-9(17-8)6-14-11-7-13-5-4-10(11)12(15)16/h2-5,7,14H,6H2,1H3,(H,15,16)
DMNIE4M CS CC1=CC=C(S1)CNC2=C(C=CN=C2)C(=O)O
DMNIE4M IK RFUZGPWCXINBNW-UHFFFAOYSA-N
DMNIE4M IU 3-[(5-methylthiophen-2-yl)methylamino]pyridine-4-carboxylic acid
DMPXAGD ID DMPXAGD
DMPXAGD DN Alkaloid derivative 4
DMPXAGD HS Patented
DMPXAGD SN PMID26882240-Compound-37
DMPXAGD CP UCL BUSINESS PLC
DMPXAGD DT Small molecular drug
DMPXAGD PC 3246466
DMPXAGD MW 418.6
DMPXAGD FM C27H34N2O2
DMPXAGD IC InChI=1S/C27H34N2O2/c1-4-18-17-29-12-10-19-7-5-6-8-22(19)25(29)14-21(18)13-24-23-16-27(31-3)26(30-2)15-20(23)9-11-28-24/h5-8,15-16,24-25,28H,4,9-14,17H2,1-3H3/t24-,25+/m1/s1
DMPXAGD CS CCC1=C(C[C@H]2C3=CC=CC=C3CCN2C1)C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC
DMPXAGD IK GAUYNTGXYGJOSH-RPBOFIJWSA-N
DMPXAGD IU (11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine
DMW57UB ID DMW57UB
DMW57UB DN Alkyl mannoside derivative 1
DMW57UB HS Patented
DMW57UB SN PMID26651364-Compound-1a
DMW57UB CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMW57UB DT Small molecular drug
DMW57UB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMHD51F ID DMHD51F
DMHD51F DN Alkyl mannoside derivative 10
DMHD51F HS Patented
DMHD51F SN PMID26651364-Compound-Table2R1=n-aryl01
DMHD51F CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMHD51F DT Carbohydrates
DMHD51F DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMNZ2U ID DMMNZ2U
DMMNZ2U DN Alkyl mannoside derivative 11
DMMNZ2U HS Patented
DMMNZ2U SN PMID26651364-Compound-Table2R1=n-aryl02
DMMNZ2U CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMMNZ2U DT Carbohydrates
DMMNZ2U DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMX1OZF ID DMX1OZF
DMX1OZF DN Alkyl mannoside derivative 12
DMX1OZF HS Patented
DMX1OZF SN PMID26651364-Compound-Table2R1=n-aryl03
DMX1OZF CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMX1OZF DT Carbohydrates
DMX1OZF DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMNQUKP ID DMNQUKP
DMNQUKP DN Alkyl mannoside derivative 2
DMNQUKP HS Patented
DMNQUKP SN PMID26651364-Compound-1b
DMNQUKP CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMNQUKP DT Small molecular drug
DMNQUKP DE Crohn disease; Ulcerative colitis; Urinary tract infection
DML2B58 ID DML2B58
DML2B58 DN Alkyl mannoside derivative 3
DML2B58 HS Patented
DML2B58 SN PMID26651364-Compound-Table2R1=n-alkyl01
DML2B58 CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DML2B58 DT Carbohydrates
DML2B58 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZR71O ID DMZR71O
DMZR71O DN Alkyl mannoside derivative 4
DMZR71O HS Patented
DMZR71O SN PMID26651364-Compound-Table2R1=n-alkyl02
DMZR71O CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMZR71O DT Carbohydrates
DMZR71O DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM04ZJ2 ID DM04ZJ2
DM04ZJ2 DN Alkyl mannoside derivative 5
DM04ZJ2 HS Patented
DM04ZJ2 SN PMID26651364-Compound-Table2R1=n-alkyl03
DM04ZJ2 CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DM04ZJ2 DT Carbohydrates
DM04ZJ2 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMCIV32 ID DMCIV32
DMCIV32 DN Alkyl mannoside derivative 6
DMCIV32 HS Patented
DMCIV32 SN PMID26651364-Compound-Table2R1=n-alkyl04
DMCIV32 CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMCIV32 DT Carbohydrates
DMCIV32 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMBLSH1 ID DMBLSH1
DMBLSH1 DN Alkyl mannoside derivative 7
DMBLSH1 HS Patented
DMBLSH1 SN PMID26651364-Compound-Table2R1=n-alkyl05
DMBLSH1 CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMBLSH1 DT Carbohydrates
DMBLSH1 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZP1JT ID DMZP1JT
DMZP1JT DN Alkyl mannoside derivative 8
DMZP1JT HS Patented
DMZP1JT SN PMID26651364-Compound-Table2R1=n-alkyl06
DMZP1JT CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMZP1JT DT Carbohydrates
DMZP1JT DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMV1QUX ID DMV1QUX
DMV1QUX DN Alkyl mannoside derivative 9
DMV1QUX HS Patented
DMV1QUX SN PMID26651364-Compound-Table2R1=n-alkyl07
DMV1QUX CP VIB vzw VRIJE UNIVERSITEIT BRUSSEL
DMV1QUX DT Carbohydrates
DMV1QUX DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM06U3J ID DM06U3J
DM06U3J DN Alkyl sulfone derivative 1
DM06U3J HS Patented
DM06U3J SN PMID26161698-Compound-29
DM06U3J CP BAYER PHARMA AKTIENGESELLSCHAFT
DM06U3J DT Small molecular drug
DM06U3J PC 73672849
DM06U3J MW 519.4
DM06U3J FM C18H13F8N3O2S2
DM06U3J IC InChI=1S/C18H13F8N3O2S2/c1-32(30,31)9-10-4-12(7-13(5-10)33(22,23,24,25)26)28-18-27-8-16(21)17(29-18)14-3-2-11(19)6-15(14)20/h2-8H,9H2,1H3,(H,27,28,29)
DM06U3J CS CS(=O)(=O)CC1=CC(=CC(=C1)S(F)(F)(F)(F)F)NC2=NC=C(C(=N2)C3=C(C=C(C=C3)F)F)F
DM06U3J IK QPEXAIXCVQPMDQ-UHFFFAOYSA-N
DM06U3J IU 4-(2,4-difluorophenyl)-5-fluoro-N-[3-(methylsulfonylmethyl)-5-(pentafluoro-lambda6-sulfanyl)phenyl]pyrimidin-2-amine
DMEZDQ4 ID DMEZDQ4
DMEZDQ4 DN Alkynyl-heteroaromatic ring compound 1
DMEZDQ4 HS Patented
DMEZDQ4 SN PMID25656651-Compound-39
DMEZDQ4 CP NANJING SANHOME PHARMACEUTICAL CO LTD [CN]
DMEZDQ4 DT Small molecular drug
DMEZDQ4 PC 73504220
DMEZDQ4 MW 543.6
DMEZDQ4 FM C31H28F3N5O
DMEZDQ4 IC InChI=1S/C31H28F3N5O/c1-21-6-7-24(16-23(21)9-8-22-4-3-5-29-27(22)18-35-20-36-29)30(40)37-26-11-10-25(28(17-26)31(32,33)34)19-39-14-12-38(2)13-15-39/h3-7,10-11,16-18,20H,12-15,19H2,1-2H3,(H,37,40)
DMEZDQ4 CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=C5C=NC=NC5=CC=C4
DMEZDQ4 IK KLHNJZVWTSMTCC-UHFFFAOYSA-N
DMEZDQ4 IU 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-(2-quinazolin-5-ylethynyl)benzamide
DMK7DJ2 ID DMK7DJ2
DMK7DJ2 DN Alkynyl-substituted pyrimidinyl-pyrrole derivative 1
DMK7DJ2 HS Patented
DMK7DJ2 SN PMID27774822-Compound-Figure3compound11
DMK7DJ2 CP NERVIANO MEDICAL SCIENCES S.R.L
DMK7DJ2 DT Small molecular drug
DMWX0QK ID DMWX0QK
DMWX0QK DN Alpha-substituted pirinixic acid and pirinixic acid ester derivative 1
DMWX0QK HS Patented
DMWX0QK SN PMID28627961-Compound-38
DMWX0QK CP MEDEON PHARMACEUTICALS GMBH UNIVERSIT TINGEN WERZ, Oliver KOEBERLE, Andreas SCHUBERT-ZSILAVECZ, Manfred POPESCU, Laura SYHA, Yvonne
DMWX0QK DT Small molecular drug
DMO64LA ID DMO64LA
DMO64LA DN Amide derivative 1
DMO64LA HS Patented
DMO64LA SN PMID26161824-Compound-21
DMO64LA DT Small molecular drug
DMO64LA PC 9868408
DMO64LA MW 450.8
DMO64LA FM C22H22Cl3N3O
DMO64LA IC InChI=1S/C22H22Cl3N3O/c1-3-4-5-12-26-22(29)20-14(2)21(15-6-8-16(23)9-7-15)28(27-20)19-11-10-17(24)13-18(19)25/h6-11,13H,3-5,12H2,1-2H3,(H,26,29)
DMO64LA CS CCCCCNC(=O)C1=NN(C(=C1C)C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl
DMO64LA IK JDBOTXIRNSWBCG-UHFFFAOYSA-N
DMO64LA IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-pentylpyrazole-3-carboxamide
DMO64LA CA CAS 336615-64-6
DMO64LA DE Obesity
DMBKIR0 ID DMBKIR0
DMBKIR0 DN Amide derivative 2
DMBKIR0 HS Patented
DMBKIR0 SN PMID29473428-Compound-73
DMBKIR0 CP FLEXUS BIOSCIENCES, INC
DMBKIR0 DT Small molecular drug
DM1FUOY ID DM1FUOY
DM1FUOY DN amidepsines
DM1FUOY HS Patented
DMUPT9A ID DMUPT9A
DMUPT9A DN Amidine compound 1
DMUPT9A HS Patented
DMUPT9A SN PMID26936077-Compound-28
DMUPT9A CP PROXIMAGEN LIMITED
DMUPT9A DT Small molecular drug
DMUPT9A PC 72737267
DMUPT9A MW 343.4
DMUPT9A FM C22H21N3O
DMUPT9A IC InChI=1S/C22H21N3O/c1-15-19(17-6-3-2-4-7-17)8-5-9-20(15)22(26)25-14-16-10-12-18(13-11-16)21(23)24/h2-13H,14H2,1H3,(H3,23,24)(H,25,26)
DMUPT9A CS CC1=C(C=CC=C1C(=O)NCC2=CC=C(C=C2)C(=N)N)C3=CC=CC=C3
DMUPT9A IK RNDNSLVKMYCGOO-UHFFFAOYSA-N
DMUPT9A IU N-[(4-carbamimidoylphenyl)methyl]-2-methyl-3-phenylbenzamide
DMUPT9A DE Inflammation
DM2UWSX ID DM2UWSX
DM2UWSX DN Amidine compound 2
DM2UWSX HS Patented
DM2UWSX SN PMID26936077-Compound-29
DM2UWSX CP PROXIMAGEN LIMITED
DM2UWSX DT Small molecular drug
DM2UWSX PC 73051852
DM2UWSX MW 363.8
DM2UWSX FM C21H18ClN3O
DM2UWSX IC InChI=1S/C21H18ClN3O/c22-19-17(15-5-2-1-3-6-15)7-4-8-18(19)21(26)25-13-14-9-11-16(12-10-14)20(23)24/h1-12H,13H2,(H3,23,24)(H,25,26)
DM2UWSX CS C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N)Cl
DM2UWSX IK HZBJZCWAIZICKW-UHFFFAOYSA-N
DM2UWSX IU N-[(4-carbamimidoylphenyl)methyl]-2-chloro-3-phenylbenzamide
DM2UWSX DE Inflammation
DMV0QJ4 ID DMV0QJ4
DMV0QJ4 DN Amidine compound 3
DMV0QJ4 HS Patented
DMV0QJ4 SN PMID26936077-Compound-30
DMV0QJ4 CP PROXIMAGEN LIMITED
DMV0QJ4 DT Small molecular drug
DMV0QJ4 PC 73051857
DMV0QJ4 MW 408.5
DMV0QJ4 FM C21H20N4O3S
DMV0QJ4 IC InChI=1S/C21H20N4O3S/c22-20(23)16-6-4-14(5-7-16)13-25-21(26)18-3-1-2-17(12-18)15-8-10-19(11-9-15)29(24,27)28/h1-12H,13H2,(H3,22,23)(H,25,26)(H2,24,27,28)
DMV0QJ4 CS C1=CC(=CC(=C1)C(=O)NCC2=CC=C(C=C2)C(=N)N)C3=CC=C(C=C3)S(=O)(=O)N
DMV0QJ4 IK TZCOUVBQGJRRJR-UHFFFAOYSA-N
DMV0QJ4 IU N-[(4-carbamimidoylphenyl)methyl]-3-(4-sulfamoylphenyl)benzamide
DMV0QJ4 DE Inflammation
DM9EGVN ID DM9EGVN
DM9EGVN DN Amidine compound 4
DM9EGVN HS Patented
DM9EGVN SN PMID26936077-Compound-31
DM9EGVN CP PROXIMAGEN LIMITED
DM9EGVN DT Small molecular drug
DM9EGVN PC 73052013
DM9EGVN MW 436.5
DM9EGVN FM C23H24N4O3S
DM9EGVN IC InChI=1S/C23H24N4O3S/c1-27(2)31(29,30)21-9-4-3-8-20(21)18-6-5-7-19(14-18)23(28)26-15-16-10-12-17(13-11-16)22(24)25/h3-14H,15H2,1-2H3,(H3,24,25)(H,26,28)
DM9EGVN CS CN(C)S(=O)(=O)C1=CC=CC=C1C2=CC(=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DM9EGVN IK PJHSDMZESVNZHU-UHFFFAOYSA-N
DM9EGVN IU N-[(4-carbamimidoylphenyl)methyl]-3-[2-(dimethylsulfamoyl)phenyl]benzamide
DM9EGVN DE Inflammation
DMMN8OY ID DMMN8OY
DMMN8OY DN Amidine compound 5
DMMN8OY HS Patented
DMMN8OY SN PMID26936077-Compound-32
DMMN8OY CP PROXIMAGEN LIMITED
DMMN8OY DT Small molecular drug
DMMN8OY PC 73052182
DMMN8OY MW 422.5
DMMN8OY FM C22H22N4O3S
DMMN8OY IC InChI=1S/C22H22N4O3S/c1-14-11-19(30(25,28)29)9-10-20(14)17-3-2-4-18(12-17)22(27)26-13-15-5-7-16(8-6-15)21(23)24/h2-12H,13H2,1H3,(H3,23,24)(H,26,27)(H2,25,28,29)
DMMN8OY CS CC1=C(C=CC(=C1)S(=O)(=O)N)C2=CC(=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DMMN8OY IK QDCYPEUVWUOSBP-UHFFFAOYSA-N
DMMN8OY IU N-[(4-carbamimidoylphenyl)methyl]-3-(2-methyl-4-sulfamoylphenyl)benzamide
DMMN8OY DE Inflammation
DMFNK0L ID DMFNK0L
DMFNK0L DN Amidine compound 6
DMFNK0L HS Patented
DMFNK0L SN PMID26936077-Compound-33
DMFNK0L CP PROXIMAGEN LIMITED
DMFNK0L DT Small molecular drug
DMFNK0L DE Inflammation
DM8STUQ ID DM8STUQ
DM8STUQ DN Amidine oxime derivative 1
DM8STUQ HS Patented
DM8STUQ SN PMID27967267-Compound-50
DM8STUQ CP HUMAN BIOMOLECULAR RESEARCH INSTITUTE CASHMAN, John, R. KALISIAK, Jaroslaw
DM8STUQ DT Small molecular drug
DM5X92S ID DM5X92S
DM5X92S DN Amidopyrazole derivative 1
DM5X92S HS Patented
DM5X92S SN PMID27310003-Compound-40
DM5X92S CP MERCK SHARP & DOHME CORP. SEGANISH, W. Michael MCELROY, William, T. BRUMFIELD, Stephanie HERR, R. Jason YET, Larry YANG, Jinhai HARDING, James, P., III HO, Ginny Dai TULSHIAN, Deen, B. YU, Wensheng WONG, Michael, K. C. LAVEY, Brian, J. KOZLOWSKI, Joseph, A
DM5X92S DT Small molecular drug
DMGO9WY ID DMGO9WY
DMGO9WY DN Amidopyrazole derivative 2
DMGO9WY HS Patented
DMGO9WY SN PMID27310003-Compound-41
DMGO9WY CP MERCK SHARP & DOHME CORP. SEGANISH, W. Michael MCELROY, William, T. BRUMFIELD, Stephanie HERR, R. Jason YET, Larry YANG, Jinhai HARDING, James, P., III HO, Ginny Dai TULSHIAN, Deen, B. YU, Wensheng WONG, Michael, K. C. LAVEY, Brian, J. KOZLOWSKI, Joseph, A
DMGO9WY DT Small molecular drug
DMTHS3L ID DMTHS3L
DMTHS3L DN Amidopyrazole derivative 3
DMTHS3L HS Patented
DMTHS3L SN PMID27310003-Compound-42
DMTHS3L CP Astellas Pharma Inc. INAMI, Hiroshi MIZUTANI, Tsuyoshi MAEDA, Junko USUDA, Hiroyuki NAGASHIMA, Shinya ITO, Tomonori AOYAMA, Naohiro
DMTHS3L DT Small molecular drug
DMF6N7Z ID DMF6N7Z
DMF6N7Z DN Amidopyrazole derivative 4
DMF6N7Z HS Patented
DMF6N7Z SN PMID27310003-Compound-61
DMF6N7Z CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMF6N7Z DT Small molecular drug
DMJ37V2 ID DMJ37V2
DMJ37V2 DN Amidopyrazole derivative 5
DMJ37V2 HS Patented
DMJ37V2 SN PMID27310003-Compound-62
DMJ37V2 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMJ37V2 DT Small molecular drug
DMJZ1IG ID DMJZ1IG
DMJZ1IG DN Amidopyrazole derivative 6
DMJZ1IG HS Patented
DMJZ1IG SN PMID27310003-Compound-63
DMJZ1IG CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMJZ1IG DT Small molecular drug
DMQVZY5 ID DMQVZY5
DMQVZY5 DN Aminoarylpyridine derivative 1
DMQVZY5 HS Patented
DMQVZY5 SN PMID26161698-Compound-42
DMQVZY5 CP NOVARTIS AG
DMQVZY5 DT Small molecular drug
DMNI0M1 ID DMNI0M1
DMNI0M1 DN Aminoazetidine derivative 1
DMNI0M1 HS Patented
DMNI0M1 SN PMID26161824-Compound-164
DMNI0M1 DT Small molecular drug
DMNI0M1 PC 44194212
DMNI0M1 MW 590.4
DMNI0M1 FM C29H27Cl2F2N3O4
DMNI0M1 IC InChI=1S/C29H27Cl2F2N3O4/c1-2-40-28(39)15-34-26(37)14-27(38)36(24-12-22(32)11-23(33)13-24)25-16-35(17-25)29(18-3-7-20(30)8-4-18)19-5-9-21(31)10-6-19/h3-13,25,29H,2,14-17H2,1H3,(H,34,37)
DMNI0M1 CS CCOC(=O)CNC(=O)CC(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F
DMNI0M1 IK JLIDBGJVXRJCFP-UHFFFAOYSA-N
DMNI0M1 IU ethyl 2-[[3-(N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-3,5-difluoroanilino)-3-oxopropanoyl]amino]acetate
DMNI0M1 DE Obesity
DMHSNA5 ID DMHSNA5
DMHSNA5 DN Aminoazetidine derivative 2
DMHSNA5 HS Patented
DMHSNA5 SN PMID26161824-Compound-165
DMHSNA5 DT Small molecular drug
DMHSNA5 DE Obesity
DMOQHA9 ID DMOQHA9
DMOQHA9 DN Aminoazetidine derivative 3
DMOQHA9 HS Patented
DMOQHA9 SN PMID26161824-Compound-166
DMOQHA9 DT Small molecular drug
DMOQHA9 DE Obesity
DM50E4Y ID DM50E4Y
DM50E4Y DN Aminoazetidine derivative 4
DM50E4Y HS Patented
DM50E4Y SN PMID26161824-Compound-167
DM50E4Y DT Small molecular drug
DM50E4Y DE Obesity
DMYPD4Z ID DMYPD4Z
DMYPD4Z DN Aminoazetidine derivative 5
DMYPD4Z HS Patented
DMYPD4Z SN PMID26161824-Compound-168
DMYPD4Z DT Small molecular drug
DMYPD4Z PC 44180558
DMYPD4Z MW 569.4
DMYPD4Z FM C26H24Cl2F2N2O4S
DMYPD4Z IC InChI=1S/C26H24Cl2F2N2O4S/c1-3-36-26(33)25-23(32(37(2,34)35)22-13-20(29)12-21(30)14-22)15-31(25)24(16-4-8-18(27)9-5-16)17-6-10-19(28)11-7-17/h4-14,23-25H,3,15H2,1-2H3
DMYPD4Z CS CCOC(=O)C1C(CN1C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)N(C4=CC(=CC(=C4)F)F)S(=O)(=O)C
DMYPD4Z IK LOJPJQZCZJCZBS-UHFFFAOYSA-N
DMYPD4Z IU ethyl 1-[bis(4-chlorophenyl)methyl]-3-(3,5-difluoro-N-methylsulfonylanilino)azetidine-2-carboxylate
DMYPD4Z DE Obesity
DM3LNQG ID DM3LNQG
DM3LNQG DN Aminoazetidine derivative 7
DM3LNQG HS Patented
DM3LNQG SN PMID26161824-Compound-170
DM3LNQG DT Small molecular drug
DM3LNQG DE Obesity
DMLOIHD ID DMLOIHD
DMLOIHD DN Aminoazetidine derivative 8
DMLOIHD HS Patented
DMLOIHD SN PMID26161824-Compound-171
DMLOIHD DT Small molecular drug
DMLOIHD DE Obesity
DMUASHT ID DMUASHT
DMUASHT DN Aminoazetidine derivative 9
DMUASHT HS Patented
DMUASHT SN PMID26161824-Compound-172
DMUASHT DT Small molecular drug
DMUASHT PC 44180784
DMUASHT MW 512.4
DMUASHT FM C24H23Cl2F2N2O2S+
DMUASHT IC InChI=1S/C24H23Cl2F2N2O2S/c1-30(24(16-3-7-18(25)8-4-16)17-5-9-19(26)10-6-17)14-23(15-30)29(33(2,31)32)22-12-20(27)11-21(28)13-22/h3-13,23-24H,14-15H2,1-2H3/q+1
DMUASHT CS C[N+]1(CC(C1)N(C2=CC(=CC(=C2)F)F)S(=O)(=O)C)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl
DMUASHT IK DQQUOWSXOJKTEJ-UHFFFAOYSA-N
DMUASHT IU N-[1-[bis(4-chlorophenyl)methyl]-1-methylazetidin-1-ium-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
DMUASHT DE Obesity
DM1RQIU ID DM1RQIU
DM1RQIU DN Aminobenzoxazole analog 1
DM1RQIU HS Patented
DM1RQIU SN PMID27724045-Compound-11
DM1RQIU CP Roche
DM1RQIU DT Small molecular drug
DM1RQIU PC 67955081
DM1RQIU MW 468.5
DM1RQIU FM C24H21FN2O5S
DM1RQIU IC InChI=1S/C24H21FN2O5S/c1-33(30,31)19-9-5-17(6-10-19)20(12-15-2-7-18(25)8-3-15)23(29)27-24-26-21-11-4-16(14-28)13-22(21)32-24/h2-11,13,20,28H,12,14H2,1H3,(H,26,27,29)
DM1RQIU CS CS(=O)(=O)C1=CC=C(C=C1)C(CC2=CC=C(C=C2)F)C(=O)NC3=NC4=C(O3)C=C(C=C4)CO
DM1RQIU IK BSRLERQMZLOWBH-UHFFFAOYSA-N
DM1RQIU IU 3-(4-fluorophenyl)-N-[6-(hydroxymethyl)-1,3-benzoxazol-2-yl]-2-(4-methylsulfonylphenyl)propanamide
DMYHRJD ID DMYHRJD
DMYHRJD DN Aminocyclopentenone compound 1
DMYHRJD HS Patented
DMYHRJD SN PMID26924192-Compound-93
DMYHRJD CP ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMYHRJD DT Small molecular drug
DMYHRJD PC 117928501
DMYHRJD MW 354.8
DMYHRJD FM C20H19ClN2O2
DMYHRJD IC InChI=1S/C20H19ClN2O2/c1-12-5-3-4-6-15(12)20(25)22-14-7-8-16(21)18(11-14)23-17-9-10-19(24)13(17)2/h3-8,11,23H,9-10H2,1-2H3,(H,22,25)
DMYHRJD CS CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)Cl)NC3=C(C(=O)CC3)C
DMYHRJD IK FVUVHLFQVZUBCL-UHFFFAOYSA-N
DMYHRJD IU N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-2-methylbenzamide
DMAYHNI ID DMAYHNI
DMAYHNI DN Aminocyclopentenone compound 2
DMAYHNI HS Patented
DMAYHNI SN PMID26924192-Compound-94
DMAYHNI CP ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMAYHNI DT Small molecular drug
DMAYHNI PC 117928438
DMAYHNI MW 390.9
DMAYHNI FM C23H19ClN2O2
DMAYHNI IC InChI=1S/C23H19ClN2O2/c1-14-20(11-12-22(14)27)26-21-13-16(9-10-19(21)24)25-23(28)18-8-4-6-15-5-2-3-7-17(15)18/h2-10,13,26H,11-12H2,1H3,(H,25,28)
DMAYHNI CS CC1=C(CCC1=O)NC2=C(C=CC(=C2)NC(=O)C3=CC=CC4=CC=CC=C43)Cl
DMAYHNI IK HRGRBMHGQQBNSK-UHFFFAOYSA-N
DMAYHNI IU N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]naphthalene-1-carboxamide
DMFXK03 ID DMFXK03
DMFXK03 DN Aminocyclopentenone compound 3
DMFXK03 HS Patented
DMFXK03 SN PMID26924192-Compound-95
DMFXK03 CP ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMFXK03 DT Small molecular drug
DMFXK03 PC 117928427
DMFXK03 MW 390.9
DMFXK03 FM C19H19ClN2O3S
DMFXK03 IC InChI=1S/C19H19ClN2O3S/c1-13-17(9-10-19(13)23)21-18-11-15(7-8-16(18)20)22-26(24,25)12-14-5-3-2-4-6-14/h2-8,11,21-22H,9-10,12H2,1H3
DMFXK03 CS CC1=C(CCC1=O)NC2=C(C=CC(=C2)NS(=O)(=O)CC3=CC=CC=C3)Cl
DMFXK03 IK NCJRKRWVOHVDGS-UHFFFAOYSA-N
DMFXK03 IU N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-1-phenylmethanesulfonamide
DM745TN ID DM745TN
DM745TN DN Aminocyclopentenone compound 4
DM745TN HS Patented
DM745TN SN PMID26924192-Compound-96
DM745TN CP ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DM745TN DT Small molecular drug
DM745TN PC 117928624
DM745TN MW 390.9
DM745TN FM C19H19ClN2O3S
DM745TN IC InChI=1S/C19H19ClN2O3S/c1-12-5-3-4-6-19(12)26(24,25)22-14-7-8-15(20)17(11-14)21-16-9-10-18(23)13(16)2/h3-8,11,21-22H,9-10H2,1-2H3
DM745TN CS CC1=CC=CC=C1S(=O)(=O)NC2=CC(=C(C=C2)Cl)NC3=C(C(=O)CC3)C
DM745TN IK GGISCUHENYTWDU-UHFFFAOYSA-N
DM745TN IU N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-2-methylbenzenesulfonamide
DMPW9ES ID DMPW9ES
DMPW9ES DN Aminocyclopentenone compound 5
DMPW9ES HS Patented
DMPW9ES SN PMID26924192-Compound-97
DMPW9ES CP ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DMPW9ES DT Small molecular drug
DMPW9ES PC 117928680
DMPW9ES MW 383.9
DMPW9ES FM C17H22ClN3O3S
DMPW9ES IC InChI=1S/C17H22ClN3O3S/c1-12-15(7-8-17(12)22)19-16-11-13(5-6-14(16)18)20-25(23,24)21-9-3-2-4-10-21/h5-6,11,19-20H,2-4,7-10H2,1H3
DMPW9ES CS CC1=C(CCC1=O)NC2=C(C=CC(=C2)NS(=O)(=O)N3CCCCC3)Cl
DMPW9ES IK SJCLYADRAFNYBC-UHFFFAOYSA-N
DMPW9ES IU N-[4-chloro-3-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]piperidine-1-sulfonamide
DM0NJFZ ID DM0NJFZ
DM0NJFZ DN Aminocyclopentenone compound 6
DM0NJFZ HS Patented
DM0NJFZ SN PMID26924192-Compound-98
DM0NJFZ CP ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
DM0NJFZ DT Small molecular drug
DMDHGPN ID DMDHGPN
DMDHGPN DN Aminooxazole carboxamide derivative 1
DMDHGPN HS Patented
DMDHGPN SN PMID27774822-Compound-Figure6Example25
DMDHGPN CP SAREUM LIMITED
DMDHGPN DT Small molecular drug
DMFKTJL ID DMFKTJL
DMFKTJL DN Aminopiperidine derivative 1
DMFKTJL HS Patented
DMFKTJL SN PMID25482888-Compound-48
DMFKTJL CP CADILA HEALTHCARE LIMITED
DMFKTJL DT Small molecular drug
DMFKTJL PC 73673008
DMFKTJL MW 415.5
DMFKTJL FM C19H27F2N3O3S
DMFKTJL IC InChI=1S/C19H27F2N3O3S/c1-28(25,26)24-7-5-19(12-24)4-6-23(11-19)14-9-17(22)18(27-10-14)15-8-13(20)2-3-16(15)21/h2-3,8,14,17-18H,4-7,9-12,22H2,1H3/t14-,17+,18-,19?/m1/s1
DMFKTJL CS CS(=O)(=O)N1CCC2(C1)CCN(C2)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DMFKTJL IK ICJHPFIPAVQZIX-HCGGPHHBSA-N
DMFKTJL IU (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-2,7-diazaspiro[4.4]nonan-7-yl)oxan-3-amine
DM4JDHO ID DM4JDHO
DM4JDHO DN Aminopiperidine derivative 2
DM4JDHO HS Patented
DM4JDHO SN PMID25482888-Compound-49
DM4JDHO CP CADILA HEALTHCARE LIMITED
DM4JDHO DT Small molecular drug
DM4JDHO PC 73673132
DM4JDHO MW 430.5
DM4JDHO FM C19H28F2N4O3S
DM4JDHO IC InChI=1S/C19H28F2N4O3S/c1-23(2)29(26,27)25-9-12-7-24(8-13(12)10-25)15-6-18(22)19(28-11-15)16-5-14(20)3-4-17(16)21/h3-5,12-13,15,18-19H,6-11,22H2,1-2H3/t12?,13?,15-,18+,19-/m1/s1
DM4JDHO CS CN(C)S(=O)(=O)N1CC2CN(CC2C1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N
DM4JDHO IK YOZMZFRQIDLSLZ-RVBDROBCSA-N
DM4JDHO IU 2-[(3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)oxan-3-yl]-N,N-dimethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-sulfonamide
DMYE1A7 ID DMYE1A7
DMYE1A7 DN Aminopyridine derivative 1
DMYE1A7 HS Patented
DMYE1A7 SN PMID27774822-Compound-Figure9Example1bottomleft
DMYE1A7 DT Small molecular drug
DMUGZNL ID DMUGZNL
DMUGZNL DN Aminopyridine derivative 2
DMUGZNL HS Patented
DMUGZNL SN PMID28117607-Compound-8
DMUGZNL CP LUNDBECK & CO AS H [DKVERNALIS R & D LTD [GB]
DMUGZNL DT Small molecular drug
DMSLJE8 ID DMSLJE8
DMSLJE8 DN Aminopyridine derivative 3
DMSLJE8 HS Patented
DMSLJE8 SN PMID28117607-Compound-9
DMSLJE8 CP LUNDBECK & CO AS H [DKVERNALIS R & D LTD [GB]
DMSLJE8 DT Small molecular drug
DMK1UJV ID DMK1UJV
DMK1UJV DN Aminopyrimidine derivative 1
DMK1UJV HS Patented
DMK1UJV SN PMID25656651-Compound-12a
DMK1UJV CP VERTEX PHARMACEUTICALS INCORPORATED
DMK1UJV DT Small molecular drug
DMK1UJV PC 25071810
DMK1UJV MW 506.7
DMK1UJV FM C26H34N8OS
DMK1UJV IC InChI=1S/C26H34N8OS/c1-4-24(35)27-19-5-7-20(8-6-19)36-25-29-21(28-22-15-18(2)31-32-22)16-23(30-25)34-13-10-26(11-14-34)9-12-33(3)17-26/h5-8,15-16H,4,9-14,17H2,1-3H3,(H,27,35)(H2,28,29,30,31,32)
DMK1UJV CS CCC(=O)NC1=CC=C(C=C1)SC2=NC(=CC(=N2)N3CCC4(CCN(C4)C)CC3)NC5=NNC(=C5)C
DMK1UJV IK ODMCGDLIMBCHLX-UHFFFAOYSA-N
DMK1UJV IU N-[4-[4-(2-methyl-2,8-diazaspiro[4.5]decan-8-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide
DM2TF64 ID DM2TF64
DM2TF64 DN Aminopyrimidine derivative 10
DM2TF64 HS Patented
DM2TF64 SN PMID26293650-Compound-47
DM2TF64 CP Myrexis
DM2TF64 DT Small molecular drug
DM2TF64 PC 67114635
DM2TF64 MW 530.6
DM2TF64 FM C29H34N6O4
DM2TF64 IC InChI=1S/C29H34N6O4/c1-34(2)13-14-35(3)28(36)24-7-6-22(18-27(24)37-4)32-29-31-12-9-25(33-29)20-5-8-26(21(17-20)19-30)39-23-10-15-38-16-11-23/h5-9,12,17-18,23H,10-11,13-16H2,1-4H3,(H,31,32,33)
DM2TF64 CS CN(C)CCN(C)C(=O)C1=C(C=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)OC4CCOCC4)C#N)OC
DM2TF64 IK XAXIBPFXBWPLTP-UHFFFAOYSA-N
DM2TF64 IU 4-[[4-[3-cyano-4-(oxan-4-yloxy)phenyl]pyrimidin-2-yl]amino]-N-[2-(dimethylamino)ethyl]-2-methoxy-N-methylbenzamide
DMKNITP ID DMKNITP
DMKNITP DN Aminopyrimidine derivative 2
DMKNITP HS Patented
DMKNITP SN PMID25656651-Compound-12b
DMKNITP CP VERTEX PHARMACEUTICALS INCORPORATED
DMKNITP DT Small molecular drug
DMDP4GY ID DMDP4GY
DMDP4GY DN Aminopyrimidine derivative 3
DMDP4GY HS Patented
DMDP4GY SN PMID25656651-Compound-12c
DMDP4GY CP VERTEX PHARMACEUTICALS INCORPORATED
DMDP4GY DT Small molecular drug
DMDP4GY PC 25072757
DMDP4GY MW 560.6
DMDP4GY FM C26H31F3N8OS
DMDP4GY IC InChI=1S/C26H31F3N8OS/c1-17-14-22(35-34-17)31-21-15-23(37-12-8-19(9-13-37)36-10-2-3-11-36)33-25(32-21)39-20-6-4-18(5-7-20)30-24(38)16-26(27,28)29/h4-7,14-15,19H,2-3,8-13,16H2,1H3,(H,30,38)(H2,31,32,33,34,35)
DMDP4GY CS CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)CC(F)(F)F)N4CCC(CC4)N5CCCC5
DMDP4GY IK SFNFDXQNCXVCLJ-UHFFFAOYSA-N
DMDP4GY IU 3,3,3-trifluoro-N-[4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-2-yl]sulfanylphenyl]propanamide
DMW039D ID DMW039D
DMW039D DN Aminopyrimidine derivative 4
DMW039D HS Patented
DMW039D SN PMID25656651-Compound-13
DMW039D CP VERTEX PHARMACEUTICALS INCORPORATED
DMW039D DT Small molecular drug
DMW039D PC 25015762
DMW039D MW 583.7
DMW039D FM C28H32F3N9S
DMW039D IC InChI=1S/C28H32F3N9S/c1-18-15-25(37-36-18)33-24-17-26(40-13-11-39(12-14-40)20-7-9-38(2)10-8-20)35-27(34-24)41-21-4-5-22-19(16-21)3-6-23(32-22)28(29,30)31/h3-6,15-17,20H,7-14H2,1-2H3,(H2,33,34,35,36,37)
DMW039D CS CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC4=C(C=C3)N=C(C=C4)C(F)(F)F)N5CCN(CC5)C6CCN(CC6)C
DMW039D IK CBMIRUJKKBNHQV-UHFFFAOYSA-N
DMW039D IU 6-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)quinolin-6-yl]sulfanylpyrimidin-4-amine
DM5OZPV ID DM5OZPV
DM5OZPV DN Aminopyrimidine derivative 5
DM5OZPV HS Patented
DM5OZPV SN PMID27774822-Compound-Figure9Example1bottomright
DM5OZPV DT Small molecular drug
DMZF0DK ID DMZF0DK
DMZF0DK DN Aminopyrimidine derivative 6
DMZF0DK HS Patented
DMZF0DK SN PMID26293650-Compound-43
DMZF0DK CP Myrexis
DMZF0DK DT Small molecular drug
DMZF0DK PC 51357830
DMZF0DK MW 456.5
DMZF0DK FM C26H28N6O2
DMZF0DK IC InChI=1S/C26H28N6O2/c1-18(2)15-25(33)30-23-8-3-19(16-20(23)17-27)24-9-10-28-26(31-24)29-21-4-6-22(7-5-21)32-11-13-34-14-12-32/h3-10,16,18H,11-15H2,1-2H3,(H,30,33)(H,28,29,31)
DMZF0DK CS CC(C)CC(=O)NC1=C(C=C(C=C1)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4)C#N
DMZF0DK IK MIMBVFVOQLKELD-UHFFFAOYSA-N
DMZF0DK IU N-[2-cyano-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]-3-methylbutanamide
DMW98RI ID DMW98RI
DMW98RI DN Aminopyrimidine derivative 7
DMW98RI HS Patented
DMW98RI SN PMID26293650-Compound-44
DMW98RI CP Myrexis
DMW98RI DT Small molecular drug
DMW98RI PC 51049969
DMW98RI MW 457.5
DMW98RI FM C26H27N5O3
DMW98RI IC InChI=1S/C26H27N5O3/c27-18-20-17-19(1-6-25(20)34-23-8-13-32-14-9-23)24-7-10-28-26(30-24)29-21-2-4-22(5-3-21)31-11-15-33-16-12-31/h1-7,10,17,23H,8-9,11-16H2,(H,28,29,30)
DMW98RI CS C1COCCC1OC2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5)C#N
DMW98RI IK BWABTWGSXHTHCG-UHFFFAOYSA-N
DMW98RI IU 5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-2-(oxan-4-yloxy)benzonitrile
DML83KW ID DML83KW
DML83KW DN Aminopyrimidine derivative 8
DML83KW HS Patented
DML83KW SN PMID26293650-Compound-45
DML83KW CP Myrexis
DML83KW DT Small molecular drug
DML83KW PC 67114730
DML83KW MW 530.6
DML83KW FM C29H34N6O4
DML83KW IC InChI=1S/C29H34N6O4/c1-37-27-19-21(18-22(20-30)28(27)39-25-7-16-38-17-8-25)26-6-9-31-29(33-26)32-23-2-4-24(5-3-23)35-12-10-34(11-13-35)14-15-36/h2-6,9,18-19,25,36H,7-8,10-17H2,1H3,(H,31,32,33)
DML83KW CS COC1=CC(=CC(=C1OC2CCOCC2)C#N)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCN(CC5)CCO
DML83KW IK XDKGLOMIIQBBCB-UHFFFAOYSA-N
DML83KW IU 5-[2-[4-[4-(2-hydroxyethyl)piperazin-1-yl]anilino]pyrimidin-4-yl]-3-methoxy-2-(oxan-4-yloxy)benzonitrile
DM5VRXW ID DM5VRXW
DM5VRXW DN Aminopyrimidine derivative 9
DM5VRXW HS Patented
DM5VRXW SN PMID26293650-Compound-46
DM5VRXW CP Myrexis
DM5VRXW DT Small molecular drug
DM5VRXW PC 67114761
DM5VRXW MW 443.5
DM5VRXW FM C25H25N5O3
DM5VRXW IC InChI=1S/C25H25N5O3/c1-17(31)28-16-18-2-5-21(6-3-18)29-25-27-11-8-23(30-25)19-4-7-24(20(14-19)15-26)33-22-9-12-32-13-10-22/h2-8,11,14,22H,9-10,12-13,16H2,1H3,(H,28,31)(H,27,29,30)
DM5VRXW CS CC(=O)NCC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)OC4CCOCC4)C#N
DM5VRXW IK AZLRFMPKDVYEQH-UHFFFAOYSA-N
DM5VRXW IU N-[[4-[[4-[3-cyano-4-(oxan-4-yloxy)phenyl]pyrimidin-2-yl]amino]phenyl]methyl]acetamide
DMW2LZ0 ID DMW2LZ0
DMW2LZ0 DN Aminotriazolopyridine derivative 1
DMW2LZ0 HS Patented
DMW2LZ0 SN PMID27774824-Compound-Figure11Example1down
DMW2LZ0 CP GALAPAGOS NV
DMW2LZ0 DT Small molecular drug
DM2V31C ID DM2V31C
DM2V31C DN Ampicidin analog 1
DM2V31C HS Patented
DM2V31C SN PMID26566576-Compound-3
DM2V31C DT Small molecular drug
DMZH8S9 ID DMZH8S9
DMZH8S9 DN Ampicidin analog 2
DMZH8S9 HS Patented
DMZH8S9 SN PMID26566576-Compound-4
DMZH8S9 DT Small molecular drug
DMDSUGF ID DMDSUGF
DMDSUGF DN Aniline derivative 1
DMDSUGF HS Patented
DMDSUGF SN PMID26161698-Compound-33
DMDSUGF CP GILEAD SCIENCES, INC. MELVIN, Lawrence, S., Jr. GRAUPE, Michael VENKATARAMANI, Chandrasekar
DMDSUGF DT Small molecular drug
DMDSUGF PC 59176838
DMDSUGF MW 346.3
DMDSUGF FM C18H14N6O2
DMDSUGF IC InChI=1S/C18H14N6O2/c25-17(23-26)12-4-6-13(7-5-12)21-18-19-9-8-14(22-18)15-11-20-16-3-1-2-10-24(15)16/h1-11,26H,(H,23,25)(H,19,21,22)
DMDSUGF CS C1=CC2=NC=C(N2C=C1)C3=NC(=NC=C3)NC4=CC=C(C=C4)C(=O)NO
DMDSUGF IK YUKQHEDCOBZZTJ-UHFFFAOYSA-N
DMDSUGF IU N-hydroxy-4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzamide
DMY5J23 ID DMY5J23
DMY5J23 DN Antibodie derivative 1
DMY5J23 HS Patented
DMY5J23 SN PMID28621580-Compound-WO2012004631
DMY5J23 CP TUBITAK ERDAG, Berrin
DMY5J23 DT Antibody
DMGP5AR ID DMGP5AR
DMGP5AR DN Antibodie derivative 10
DMGP5AR HS Patented
DMGP5AR SN PMID28621580-Compound-WO2016057726
DMGP5AR CP KADMON CORPORATION, LLC
DMGP5AR DT Antibody
DMGP5AR DE Neoplasm; Angiogenesis disorder
DMPG3Y8 ID DMPG3Y8
DMPG3Y8 DN Antibodie derivative 11
DMPG3Y8 HS Patented
DMPG3Y8 SN PMID28621580-Compound-WO2016059057
DMPG3Y8 CP AFFIBODY AB
DMPG3Y8 DT Antibody
DMU7YC2 ID DMU7YC2
DMU7YC2 DN Antibodie derivative 2
DMU7YC2 HS Patented
DMU7YC2 SN PMID28621580-Compound-WO2012088563
DMU7YC2 CP VEGENICS PTY LIMITED
DMU7YC2 DT Antibody
DMNPBRG ID DMNPBRG
DMNPBRG DN Antibodie derivative 3
DMNPBRG HS Patented
DMNPBRG SN PMID28621580-Compound-WO2012125123
DMNPBRG CP NATIONAL UNIVERSITY OF SINGAPORE RAGHUNATH, Michael BLOCKI, Anna
DMNPBRG DT Antibody
DM2WMGO ID DM2WMGO
DM2WMGO DN Antibodie derivative 4
DM2WMGO HS Patented
DM2WMGO SN PMID28621580-Compound-WO2012161372
DM2WMGO CP PHARMABCINE INC. SAMSUNG LIFE PUBLIC WELFARE FOUNDATION YOO, Jin San LEE, Sang Hoon LEE, Weon Sup KIM, Sung-Woo SHIM, Sang Ryeol YOO, Jin Sang KIM, Yeun Ju SHIN, Hee Young KIM, Joong Kyu NAM, Ju Ryung
DM2WMGO DT Antibody
DMRTZE4 ID DMRTZE4
DMRTZE4 DN Antibodie derivative 5
DMRTZE4 HS Patented
DMRTZE4 SN PMID28621580-Compound-WO2013137686
DMRTZE4 CP SNU R&DB FOUNDATION KIM, Hyun Kee
DMRTZE4 DT Antibody
DMUG6YT ID DMUG6YT
DMUG6YT DN Antibodie derivative 6
DMUG6YT HS Patented
DMUG6YT SN PMID28621580-Compound-WO2014019520
DMUG6YT CP SUZHOU INSTITUTE OF NANO-TECH AND NANO-BIONICS(SINANO), CAS
DMUG6YT DT Antibody
DMJN37O ID DMJN37O
DMJN37O DN Antibodie derivative 7
DMJN37O HS Patented
DMJN37O SN PMID28621580-Compound-WO2014055998
DMJN37O CP KADMON CORPORATION, LLC
DMJN37O DT Antibody
DMJN37O DE Solid tumour/cancer
DM0CEJM ID DM0CEJM
DM0CEJM DN Antibodie derivative 8
DM0CEJM HS Patented
DM0CEJM SN PMID28621580-Compound-WO2014081202
DM0CEJM CP PHARMABCINE INC
DM0CEJM DT Antibody
DMDRJ31 ID DMDRJ31
DMDRJ31 DN Antibodie derivative 9
DMDRJ31 HS Patented
DMDRJ31 SN PMID28621580-Compound-WO2016044219
DMDRJ31 CP TRUSTEES OF BOSTON UNIVERSITY
DMDRJ31 DT Antibody
DMDRJ31 DE Corneal neovascularization; Carotid artery disease; Macular degeneration; Solid tumour/cancer
DMLQ8N1 ID DMLQ8N1
DMLQ8N1 DN AphanamgrandiolA
DMLQ8N1 HS Patented
DM7AXSM ID DM7AXSM
DM7AXSM DN Apogossypolone
DM7AXSM HS Patented
DM7AXSM DT Small molecular drug
DM7AXSM PC 135513044
DM7AXSM MW 490.5
DM7AXSM FM C28H26O8
DM7AXSM IC InChI=1S/C28H26O8/c1-9(2)17-21-13(7-15(29)27(17)35)25(33)19(11(5)23(21)31)20-12(6)24(32)22-14(26(20)34)8-16(30)28(36)18(22)10(3)4/h7-10,29,31,33,35H,1-6H3
DM7AXSM CS CC1=C(C(=O)C2=CC(=O)C(=O)C(=C2C1=O)C(C)C)C3=C(C4=CC(=C(C(=C4C(=C3C)O)C(C)C)O)O)O
DM7AXSM IK PXSGRWNXASCGTJ-UHFFFAOYSA-N
DM7AXSM IU 3-methyl-5-propan-2-yl-2-(1,4,6,7-tetrahydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,4,6,7-tetrone
DM7AXSM CA CAS 886578-07-0
DMUPN01 ID DMUPN01
DMUPN01 DN AR-A014418
DMUPN01 HS Patented
DMUPN01 SN 487021-52-3; GSK-3beta Inhibitor VIII; 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea; A Inhibitor VIII; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; UNII-87KSH90Q6D; AR-AO 14418; SN 4521; AR-A 014418; CHEMBL259850; 87KSH90Q6D; N-[(4-Methoxyphenyl)methyl]-N'-(5-nitro-2-thiazolyl)urea; AK175829; C12H12N4O4S; N-(4-Methoxybenzyl)-N& -(5-nitro-1,3-thiazol-2-yl)urea; AR 014418; GSK 3be
DMUPN01 DT Small molecular drug
DMUPN01 PC 448014
DMUPN01 MW 308.32
DMUPN01 FM C12H12N4O4S
DMUPN01 IC InChI=1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)
DMUPN01 CS COC1=CC=C(C=C1)CNC(=O)NC2=NC=C(S2)[N+](=O)[O-]
DMUPN01 IK YAEMHJKFIIIULI-UHFFFAOYSA-N
DMUPN01 IU 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea
DMUPN01 CA CAS 487021-52-3
DMUPN01 DE Ovarian cancer
DMGR6X1 ID DMGR6X1
DMGR6X1 DN Aromatic acetylene derivative 1
DMGR6X1 HS Patented
DMGR6X1 SN PMID30107136-Compound-Example24
DMGR6X1 CP UANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD [CN]
DMGR6X1 DT Small molecule immunotherapy
DMGR6X1 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMXW0PV ID DMXW0PV
DMXW0PV DN Aromatic and heteroaryl compound 1
DMXW0PV HS Patented
DMXW0PV SN PMID26882240-Compound-17
DMXW0PV CP Leland Stanford Junior University, USA
DMXW0PV DT Small molecular drug
DMXW0PV PC 421494
DMXW0PV MW 418.6
DMXW0PV FM C27H34N2O2
DMXW0PV IC InChI=1S/C27H34N2O2/c1-4-18-17-29-12-10-20-15-26(30-2)27(31-3)16-23(20)25(29)14-21(18)13-24-22-8-6-5-7-19(22)9-11-28-24/h5-8,15-16,24-25,28H,4,9-14,17H2,1-3H3
DMXW0PV CS CCC1=C(CC2C3=CC(=C(C=C3CCN2C1)OC)OC)CC4C5=CC=CC=C5CCN4
DMXW0PV IK HDIJLRXRAJUXQB-UHFFFAOYSA-N
DMXW0PV IU 3-ethyl-9,10-dimethoxy-2-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine
DMVLQ2P ID DMVLQ2P
DMVLQ2P DN Aromatic bicyclic compound 1
DMVLQ2P HS Patented
DMVLQ2P SN PMID26394986-Compound-34
DMVLQ2P CP DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMVLQ2P DT Small molecular drug
DMVLQ2P PC 53354771
DMVLQ2P MW 615.6
DMVLQ2P FM C33H32F3N7O2
DMVLQ2P IC InChI=1S/C33H32F3N7O2/c1-21-6-7-25(38-30(44)22-4-3-5-23(18-22)33(34,35)36)19-29(21)43-13-12-28-27(31(43)45)20-37-32(40-28)39-24-8-10-26(11-9-24)42-16-14-41(2)15-17-42/h3-11,18-20H,12-17H2,1-2H3,(H,38,44)(H,37,39,40)
DMVLQ2P CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)N3CCC4=NC(=NC=C4C3=O)NC5=CC=C(C=C5)N6CCN(CC6)C
DMVLQ2P IK WVGSOXRZIVSEQO-UHFFFAOYSA-N
DMVLQ2P IU N-[4-methyl-3-[2-[4-(4-methylpiperazin-1-yl)anilino]-5-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6-yl]phenyl]-3-(trifluoromethyl)benzamide
DMKFV67 ID DMKFV67
DMKFV67 DN Aromatic bicyclic compound 2
DMKFV67 HS Patented
DMKFV67 SN PMID26394986-Compound-35
DMKFV67 CP DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMKFV67 DT Small molecular drug
DMKFV67 PC 53372213
DMKFV67 MW 636.1
DMKFV67 FM C32H29ClF3N7O2
DMKFV67 IC InChI=1S/C32H29ClF3N7O2/c1-41-13-15-42(16-14-41)24-8-5-22(6-9-24)39-31-37-19-25-27(40-31)11-12-43(30(25)45)28-18-23(7-10-26(28)33)38-29(44)20-3-2-4-21(17-20)32(34,35)36/h2-10,17-19H,11-16H2,1H3,(H,38,44)(H,37,39,40)
DMKFV67 CS CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4C(=N3)CCN(C4=O)C5=C(C=CC(=C5)NC(=O)C6=CC(=CC=C6)C(F)(F)F)Cl
DMKFV67 IK SGLDXZLAQLSXFP-UHFFFAOYSA-N
DMKFV67 IU N-[4-chloro-3-[2-[4-(4-methylpiperazin-1-yl)anilino]-5-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6-yl]phenyl]-3-(trifluoromethyl)benzamide
DMRXN94 ID DMRXN94
DMRXN94 DN Aromatic bicyclic compound 3
DMRXN94 HS Patented
DMRXN94 SN PMID26394986-Compound-36
DMRXN94 CP DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMRXN94 DT Small molecular drug
DM3E75P ID DM3E75P
DM3E75P DN Aromatic bicyclic compound 4
DM3E75P HS Patented
DM3E75P SN PMID26394986-Compound-37
DM3E75P CP DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DM3E75P DT Small molecular drug
DMALF06 ID DMALF06
DMALF06 DN Aromatic bicyclic compound 5
DMALF06 HS Patented
DMALF06 SN PMID26394986-Compound-38
DMALF06 CP DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DMALF06 DT Small molecular drug
DM8L3KM ID DM8L3KM
DM8L3KM DN Aromatic bicyclic compound 6
DM8L3KM HS Patented
DM8L3KM SN PMID26394986-Compound-39
DM8L3KM CP DEBIOPHARM SA [CHAURIGENE DISCOVERY TECH LTD [IN]
DM8L3KM DT Small molecular drug
DMSRKON ID DMSRKON
DMSRKON DN Aromatic ethylene derivative 1
DMSRKON HS Patented
DMSRKON SN PMID30107136-Compound-Example23
DMSRKON CP UANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD [CN]
DMSRKON DT Small molecule immunotherapy
DMSRKON PC 138632287
DMSRKON MW 527.5
DMSRKON FM C29H28F3NO5
DMSRKON IC InChI=1S/C29H28F3NO5/c1-18-20(4-3-5-23(18)21-9-11-25-26(15-21)38-13-12-37-25)7-8-22-14-19(6-10-24(22)29(30,31)32)16-33-28(2,17-34)27(35)36/h3-11,14-15,33-34H,12-13,16-17H2,1-2H3,(H,35,36)/b8-7+
DMSRKON CS CC1=C(C=CC=C1C2=CC3=C(C=C2)OCCO3)/C=C/C4=C(C=CC(=C4)CNC(C)(CO)C(=O)O)C(F)(F)F
DMSRKON IK PTGUEPRQUFAZLN-BQYQJAHWSA-N
DMSRKON IU 2-[[3-[(E)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DMSRKON DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMJ8X7A ID DMJ8X7A
DMJ8X7A DN Aromatic hydrazine carboxyimidoamide derivative 1
DMJ8X7A HS Patented
DMJ8X7A SN PMID26815044-Compound-108
DMJ8X7A DT Small molecular drug
DMJ8X7A DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMYH4D1 ID DMYH4D1
DMYH4D1 DN Aromatic hydrazine carboxyimidoamide derivative 2
DMYH4D1 HS Patented
DMYH4D1 SN PMID26815044-Compound-109
DMYH4D1 DT Small molecular drug
DMYH4D1 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DML63B7 ID DML63B7
DML63B7 DN Aromatic hydrazine carboxyimidoamide derivative 3
DML63B7 HS Patented
DML63B7 SN PMID26815044-Compound-110
DML63B7 DT Small molecular drug
DML63B7 PC 90229391
DML63B7 MW 292.33
DML63B7 FM C17H16N4O
DML63B7 IC InChI=1S/C17H16N4O/c18-17(19-11-13-6-2-1-3-7-13)21-20-12-15-10-14-8-4-5-9-16(14)22-15/h1-10,12H,11H2,(H3,18,19,21)/b20-12+
DML63B7 CS C1=CC=C(C=C1)CN=C(N)N/N=C/C2=CC3=CC=CC=C3O2
DML63B7 IK BUHIWIPIXBWCOP-UDWIEESQSA-N
DML63B7 IU 1-[(E)-1-benzofuran-2-ylmethylideneamino]-2-benzylguanidine
DML63B7 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMKE5PB ID DMKE5PB
DMKE5PB DN Aromatic hydrazine carboxyimidoamide derivative 4
DMKE5PB HS Patented
DMKE5PB SN PMID26815044-Compound-111
DMKE5PB DT Small molecular drug
DMKE5PB PC 90229466
DMKE5PB MW 350.4
DMKE5PB FM C19H18N4O3
DMKE5PB IC InChI=1S/C19H18N4O3/c1-25-18(24)14-8-6-13(7-9-14)11-21-19(20)23-22-12-16-10-15-4-2-3-5-17(15)26-16/h2-10,12H,11H2,1H3,(H3,20,21,23)/b22-12+
DMKE5PB CS COC(=O)C1=CC=C(C=C1)CN=C(N)N/N=C/C2=CC3=CC=CC=C3O2
DMKE5PB IK WGIBSILJKFPWDM-WSDLNYQXSA-N
DMKE5PB IU methyl 4-[[[amino-[(2E)-2-(1-benzofuran-2-ylmethylidene)hydrazinyl]methylidene]amino]methyl]benzoate
DMKE5PB DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM4AM1E ID DM4AM1E
DM4AM1E DN Aromatic hydrazine carboxyimidoamide derivative 5
DM4AM1E HS Patented
DM4AM1E SN PMID26815044-Compound-112
DM4AM1E DT Small molecular drug
DM4AM1E DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM8HDQT ID DM8HDQT
DM8HDQT DN Aromatic hydrazine carboxyimidoamide derivative 6
DM8HDQT HS Patented
DM8HDQT SN PMID26815044-Compound-113
DM8HDQT DT Small molecular drug
DM8HDQT DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMJX6DV ID DMJX6DV
DMJX6DV DN Aromatic ring compound 1
DMJX6DV HS Patented
DMJX6DV SN PMID25828189-Compound-41
DMJX6DV DT Small molecular drug
DMMAS3G ID DMMAS3G
DMMAS3G DN Aromatic ring compound 2
DMMAS3G HS Patented
DMMAS3G SN PMID25828189-Compound-42
DMMAS3G DT Small molecular drug
DMMAS3G PC 71748058
DMMAS3G MW 561
DMMAS3G FM C28H28ClF3N4O3
DMMAS3G IC InChI=1S/C28H28ClF3N4O3/c1-17-13-19(25-33-14-21(29)15-34-25)6-9-23(17)24(10-11-28(30,31)32)35-22-7-4-18(5-8-22)26(37)36-12-2-3-20(16-36)27(38)39/h4-9,13-15,20,24,35H,2-3,10-12,16H2,1H3,(H,38,39)/t20-,24?/m1/s1
DMMAS3G CS CC1=C(C=CC(=C1)C2=NC=C(C=N2)Cl)C(CCC(F)(F)F)NC3=CC=C(C=C3)C(=O)N4CCC[C@H](C4)C(=O)O
DMMAS3G IK IDBHHYNBIVBFSI-CGHJUBPDSA-N
DMMAS3G IU (3R)-1-[4-[[1-[4-(5-chloropyrimidin-2-yl)-2-methylphenyl]-4,4,4-trifluorobutyl]amino]benzoyl]piperidine-3-carboxylic acid
DM43APD ID DM43APD
DM43APD DN Aromatic ring compound 3
DM43APD HS Patented
DM43APD SN PMID25828189-Compound-43
DM43APD DT Small molecular drug
DM43APD PC 71767732
DM43APD MW 594.5
DM43APD FM C29H28F6N4O3
DM43APD IC InChI=1S/C29H28F6N4O3/c1-17-13-19(25-36-14-21(15-37-25)29(33,34)35)6-9-23(17)24(10-11-28(30,31)32)38-22-7-4-18(5-8-22)26(40)39-12-2-3-20(16-39)27(41)42/h4-9,13-15,20,24,38H,2-3,10-12,16H2,1H3,(H,41,42)/t20-,24?/m1/s1
DM43APD CS CC1=C(C=CC(=C1)C2=NC=C(C=N2)C(F)(F)F)C(CCC(F)(F)F)NC3=CC=C(C=C3)C(=O)N4CCC[C@H](C4)C(=O)O
DM43APD IK HYBIWCXMSAEBQK-CGHJUBPDSA-N
DM43APD IU (3R)-1-[4-[[4,4,4-trifluoro-1-[2-methyl-4-[5-(trifluoromethyl)pyrimidin-2-yl]phenyl]butyl]amino]benzoyl]piperidine-3-carboxylic acid
DMXGLST ID DMXGLST
DMXGLST DN Aromatic ring compound 4
DMXGLST HS Patented
DMXGLST SN PMID25828189-Compound-44
DMXGLST DT Small molecular drug
DMXGLST PC 71767733
DMXGLST MW 568.6
DMXGLST FM C31H35F3N4O3
DMXGLST IC InChI=1S/C31H35F3N4O3/c1-20-17-25(38-19-22-5-2-3-7-27(22)36-38)12-13-26(20)28(14-15-31(32,33)34)35-24-10-8-21(9-11-24)29(39)37-16-4-6-23(18-37)30(40)41/h8-13,17,19,23,28,35H,2-7,14-16,18H2,1H3,(H,40,41)/t23-,28?/m1/s1
DMXGLST CS CC1=C(C=CC(=C1)N2C=C3CCCCC3=N2)C(CCC(F)(F)F)NC4=CC=C(C=C4)C(=O)N5CCC[C@H](C5)C(=O)O
DMXGLST IK ZEUDUNQWXOYIFC-YFIOFSHDSA-N
DMXGLST IU (3R)-1-[4-[[4,4,4-trifluoro-1-[2-methyl-4-(4,5,6,7-tetrahydroindazol-2-yl)phenyl]butyl]amino]benzoyl]piperidine-3-carboxylic acid
DMSDRNQ ID DMSDRNQ
DMSDRNQ DN Aryl 1,2-diamine derivative 1
DMSDRNQ HS Patented
DMSDRNQ SN PMID29473428-Compound-67
DMSDRNQ CP INVENTISBIO INC
DMSDRNQ DT Small molecular drug
DMSDRNQ PC 130331124
DMSDRNQ MW 420.5
DMSDRNQ FM C24H28N4O3
DMSDRNQ IC InChI=1S/C24H28N4O3/c1-2-28(20-8-12-31-13-9-20)22-21(27-19-6-4-17(15-25)5-7-19)14-18(16-26-22)24(23(29)30)10-3-11-24/h4-7,14,16,20,27H,2-3,8-13H2,1H3,(H,29,30)
DMSDRNQ CS CCN(C1CCOCC1)C2=C(C=C(C=N2)C3(CCC3)C(=O)O)NC4=CC=C(C=C4)C#N
DMSDRNQ IK OQNDTVBPYVYWIY-UHFFFAOYSA-N
DMSDRNQ IU 1-[5-(4-cyanoanilino)-6-[ethyl(oxan-4-yl)amino]pyridin-3-yl]cyclobutane-1-carboxylic acid
DM417XY ID DM417XY
DM417XY DN Aryl alkanolamine derivative 1
DM417XY HS Patented
DM417XY SN PMID28051882-Compound-7
DM417XY CP UNIVERSITA' DEGLI STUDI DI PAVIA
DM417XY DT Small molecular drug
DM417XY PC 91884637
DM417XY MW 309.4
DM417XY FM C21H27NO
DM417XY IC InChI=1S/C21H27NO/c23-17-21(13-16-22-14-5-2-6-15-22)20-11-9-19(10-12-20)18-7-3-1-4-8-18/h1,3-4,7-12,21,23H,2,5-6,13-17H2
DM417XY CS C1CCN(CC1)CCC(CO)C2=CC=C(C=C2)C3=CC=CC=C3
DM417XY IK DUVDSTKOGVWACP-UHFFFAOYSA-N
DM417XY IU 2-(4-phenylphenyl)-4-piperidin-1-ylbutan-1-ol
DMUP0WH ID DMUP0WH
DMUP0WH DN Aryl alkanolamine derivative 2
DMUP0WH HS Patented
DMUP0WH SN PMID28051882-Compound-V
DMUP0WH CP UNIVERSITA' DEGLI STUDI DI PAVIA
DMUP0WH DT Small molecular drug
DMA9B0V ID DMA9B0V
DMA9B0V DN Aryl azepine derivative 1
DMA9B0V HS Patented
DMA9B0V SN PMID30185082-Compound-36
DMA9B0V CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMA9B0V DT Small molecular drug
DMI4XBC ID DMI4XBC
DMI4XBC DN Aryl azepine derivative 2
DMI4XBC HS Patented
DMI4XBC SN PMID30185082-Compound-37
DMI4XBC CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMI4XBC DT Small molecular drug
DMGZHRT ID DMGZHRT
DMGZHRT DN Aryl carbamate analog 1
DMGZHRT HS Patented
DMGZHRT SN PMID26882240-Compound-19
DMGZHRT CP Italfarmaco, S.A., Spain
DMGZHRT DT Small molecular drug
DMGZHRT PC 71541820
DMGZHRT MW 377.4
DMGZHRT FM C21H19N3O4
DMGZHRT IC InChI=1S/C21H19N3O4/c1-24(16-7-3-2-4-8-16)21(27)28-17-9-10-19(25)18(12-17)20(26)23-14-15-6-5-11-22-13-15/h2-13,25H,14H2,1H3,(H,23,26)
DMGZHRT CS CN(C1=CC=CC=C1)C(=O)OC2=CC(=C(C=C2)O)C(=O)NCC3=CN=CC=C3
DMGZHRT IK DSHOFHQFNJBXHY-UHFFFAOYSA-N
DMGZHRT IU [4-hydroxy-3-(pyridin-3-ylmethylcarbamoyl)phenyl] N-methyl-N-phenylcarbamate
DMTZRCW ID DMTZRCW
DMTZRCW DN Aryl carboxamide derivative 1
DMTZRCW HS Patented
DMTZRCW SN PMID25539043-Compound-WO2010137351Example37
DMTZRCW CP RAQUALIA PHARMA INC. INOUE, Tadashi WATANABE, Shuzo YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio SHIMADA, Kaoru
DMTZRCW DT Small molecular drug
DM146TA ID DM146TA
DM146TA DN Aryl carboxamide derivative 2
DM146TA HS Patented
DM146TA SN PMID25539043-Compound-WO2010137351Example38
DM146TA CP RAQUALIA PHARMA INC. INOUE, Tadashi WATANABE, Shuzo YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio SHIMADA, Kaoru
DM146TA DT Small molecular drug
DM6FQ8L ID DM6FQ8L
DM6FQ8L DN Aryl carboxamide derivative 3
DM6FQ8L HS Patented
DM6FQ8L SN PMID25539043-Compound-WO2011058766Example39
DM6FQ8L CP RAQUALIA PHARMA INC. YAMAGISHI, Tatsuya ARANO, Yoshimasa MORITA, Mikio INOUE, Tadashi
DM6FQ8L DT Small molecular drug
DMNBW8P ID DMNBW8P
DMNBW8P DN Aryl carboxamide derivative 4
DMNBW8P HS Patented
DMNBW8P SN PMID25539043-Compound-WO2011103196Example36
DMNBW8P CP AMGEN INC. BREGMAN, Howard BUCHANAN, John, L. CHAKKA, Nagasree DIMAURO, Erin, F. DU, Bingfan NGUYEN, Hanh, Nho ZHENG, Xiao, Mei
DMNBW8P DT Small molecular drug
DMZECH7 ID DMZECH7
DMZECH7 DN Aryl cyclopropylamine derivative 3
DMZECH7 HS Patented
DMZECH7 SN PMID27019002-Compound-25a
DMZECH7 CP Duke University, USA
DMZECH7 DT Small molecular drug
DM0C1ZO ID DM0C1ZO
DM0C1ZO DN Aryl cyclopropylamine derivative 4
DM0C1ZO HS Patented
DM0C1ZO SN PMID27019002-Compound-25b
DM0C1ZO CP Duke University, USA
DM0C1ZO DT Small molecular drug
DM6CK7J ID DM6CK7J
DM6CK7J DN Aryl cyclopropylamine derivative 5
DM6CK7J HS Patented
DM6CK7J SN PMID27019002-Compound-25c
DM6CK7J CP Duke University, USA
DM6CK7J DT Small molecular drug
DM1TV6F ID DM1TV6F
DM1TV6F DN Aryl mannoside derivative 1
DM1TV6F HS Patented
DM1TV6F SN PMID26651364-Compound-12
DM1TV6F CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM1TV6F DT Carbohydrates
DM1TV6F DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM251GL ID DM251GL
DM251GL DN Aryl mannoside derivative 10
DM251GL HS Patented
DM251GL SN PMID26651364-Compound-21
DM251GL CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM251GL DT Carbohydrates
DM251GL DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMRVIPL ID DMRVIPL
DMRVIPL DN Aryl mannoside derivative 11
DMRVIPL HS Patented
DMRVIPL SN PMID26651364-Compound-22
DMRVIPL CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMRVIPL DT Carbohydrates
DMRVIPL DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMOG8XT ID DMOG8XT
DMOG8XT DN Aryl mannoside derivative 12
DMOG8XT HS Patented
DMOG8XT SN PMID26651364-Compound-23
DMOG8XT CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMOG8XT DT Carbohydrates
DMOG8XT DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM2W7JE ID DM2W7JE
DM2W7JE DN Aryl mannoside derivative 13
DM2W7JE HS Patented
DM2W7JE SN PMID26651364-Compound-24
DM2W7JE CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM2W7JE DT Carbohydrates
DM2W7JE DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMR648Z ID DMR648Z
DMR648Z DN Aryl mannoside derivative 14
DMR648Z HS Patented
DMR648Z SN PMID26651364-Compound-76
DMR648Z CP VERTEX PHARMACEUTICALS INCORPORATED
DMR648Z DT Carbohydrates
DMR648Z DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQS8CF ID DMQS8CF
DMQS8CF DN Aryl mannoside derivative 15
DMQS8CF HS Patented
DMQS8CF SN PMID26651364-Compound-77
DMQS8CF CP VERTEX PHARMACEUTICALS INCORPORATED
DMQS8CF DT Carbohydrates
DMQS8CF DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMP6QEC ID DMP6QEC
DMP6QEC DN Aryl mannoside derivative 16
DMP6QEC HS Patented
DMP6QEC SN PMID26651364-Compound-78
DMP6QEC CP VERTEX PHARMACEUTICALS INCORPORATED
DMP6QEC DT Carbohydrates
DMP6QEC DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM0FSPQ ID DM0FSPQ
DM0FSPQ DN Aryl mannoside derivative 17
DM0FSPQ HS Patented
DM0FSPQ SN PMID26651364-Compound-79
DM0FSPQ CP VERTEX PHARMACEUTICALS INCORPORATED
DM0FSPQ DT Carbohydrates
DM0FSPQ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM0YUBR ID DM0YUBR
DM0YUBR DN Aryl mannoside derivative 18
DM0YUBR HS Patented
DM0YUBR SN PMID26651364-Compound-80
DM0YUBR CP VERTEX PHARMACEUTICALS INCORPORATED
DM0YUBR DT Carbohydrates
DM0YUBR DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6K29H ID DM6K29H
DM6K29H DN Aryl mannoside derivative 19
DM6K29H HS Patented
DM6K29H SN PMID26651364-Compound-81
DM6K29H CP VERTEX PHARMACEUTICALS INCORPORATED
DM6K29H DT Carbohydrates
DM6K29H DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4S2U5 ID DM4S2U5
DM4S2U5 DN Aryl mannoside derivative 2
DM4S2U5 HS Patented
DM4S2U5 SN PMID26651364-Compound-13
DM4S2U5 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM4S2U5 DT Carbohydrates
DM4S2U5 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZ2RV3 ID DMZ2RV3
DMZ2RV3 DN Aryl mannoside derivative 20
DMZ2RV3 HS Patented
DMZ2RV3 SN PMID26651364-Compound-82
DMZ2RV3 CP VERTEX PHARMACEUTICALS INCORPORATED
DMZ2RV3 DT Carbohydrates
DMZ2RV3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMJBY68 ID DMJBY68
DMJBY68 DN Aryl mannoside derivative 21
DMJBY68 HS Patented
DMJBY68 SN PMID26651364-Compound-83
DMJBY68 CP VERTEX PHARMACEUTICALS INCORPORATED
DMJBY68 DT Carbohydrates
DMJBY68 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMJFDNB ID DMJFDNB
DMJFDNB DN Aryl mannoside derivative 22
DMJFDNB HS Patented
DMJFDNB SN PMID26651364-Compound-84
DMJFDNB CP VERTEX PHARMACEUTICALS INCORPORATED
DMJFDNB DT Carbohydrates
DMJFDNB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMWUNRV ID DMWUNRV
DMWUNRV DN Aryl mannoside derivative 23
DMWUNRV HS Patented
DMWUNRV SN PMID26651364-Compound-85
DMWUNRV CP VERTEX PHARMACEUTICALS INCORPORATED
DMWUNRV DT Carbohydrates
DMWUNRV DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMF5XU8 ID DMF5XU8
DMF5XU8 DN Aryl mannoside derivative 3
DMF5XU8 HS Patented
DMF5XU8 SN PMID26651364-Compound-14
DMF5XU8 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMF5XU8 DT Carbohydrates
DMF5XU8 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMO19Y6 ID DMO19Y6
DMO19Y6 DN Aryl mannoside derivative 4
DMO19Y6 HS Patented
DMO19Y6 SN PMID26651364-Compound-15
DMO19Y6 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMO19Y6 DT Carbohydrates
DMO19Y6 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMC31R ID DMMC31R
DMMC31R DN Aryl mannoside derivative 5
DMMC31R HS Patented
DMMC31R SN PMID26651364-Compound-16
DMMC31R CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMMC31R DT Carbohydrates
DMMC31R DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM5MIEC ID DM5MIEC
DM5MIEC DN Aryl mannoside derivative 6
DM5MIEC HS Patented
DM5MIEC SN PMID26651364-Compound-17
DM5MIEC CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM5MIEC DT Carbohydrates
DM5MIEC DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM9YS40 ID DM9YS40
DM9YS40 DN Aryl mannoside derivative 7
DM9YS40 HS Patented
DM9YS40 SN PMID26651364-Compound-18
DM9YS40 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM9YS40 DT Carbohydrates
DM9YS40 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMK6PFQ ID DMK6PFQ
DMK6PFQ DN Aryl mannoside derivative 8
DMK6PFQ HS Patented
DMK6PFQ SN PMID26651364-Compound-19
DMK6PFQ CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMK6PFQ DT Carbohydrates
DMK6PFQ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMNSK7U ID DMNSK7U
DMNSK7U DN Aryl mannoside derivative 9
DMNSK7U HS Patented
DMNSK7U SN PMID26651364-Compound-20
DMNSK7U CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMNSK7U DT Carbohydrates
DMNSK7U DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMBWH3O ID DMBWH3O
DMBWH3O DN Aryl methoxyacrylate derivative 1
DMBWH3O HS Patented
DMBWH3O SN PMID26882240-Compound-20A
DMBWH3O CP OSCOTEC INC [KR]
DMBWH3O DT Small molecular drug
DMBWH3O PC 88531173
DMBWH3O MW 397.5
DMBWH3O FM C23H27NO5
DMBWH3O IC InChI=1S/C23H27NO5/c1-15-12-22(16(2)11-20(15)17(3)24-28-6)29-13-18-9-7-8-10-19(18)21(14-26-4)23(25)27-5/h7-12,14H,13H2,1-6H3/b21-14+,24-17+
DMBWH3O CS CC1=CC(=C(C=C1OCC2=CC=CC=C2/C(=C\\OC)/C(=O)OC)C)/C(=N/OC)/C
DMBWH3O IK LMRXZYBAUUHKCX-UDLHRNPOSA-N
DMBWH3O IU methyl (E)-3-methoxy-2-[2-[[4-[(E)-N-methoxy-C-methylcarbonimidoyl]-2,5-dimethylphenoxy]methyl]phenyl]prop-2-enoate
DMNC0RX ID DMNC0RX
DMNC0RX DN Aryl methoxyacrylate derivative 2
DMNC0RX HS Patented
DMNC0RX SN PMID26882240-Compound-20B
DMNC0RX CP OSCOTEC INC [KR]
DMNC0RX DT Small molecular drug
DMNC0RX PC 88531325
DMNC0RX MW 439.5
DMNC0RX FM C26H33NO5
DMNC0RX IC InChI=1S/C26H33NO5/c1-7-13-32-27-24(8-2)22-14-19(4)25(15-18(22)3)31-16-20-11-9-10-12-21(20)23(17-29-5)26(28)30-6/h9-12,14-15,17H,7-8,13,16H2,1-6H3/b23-17+,27-24+
DMNC0RX CS CCCO/N=C(\\CC)/C1=C(C=C(C(=C1)C)OCC2=CC=CC=C2/C(=C\\OC)/C(=O)OC)C
DMNC0RX IK SLZOIVOTSYQKJP-FQGYVBMWSA-N
DMNC0RX IU methyl (E)-2-[2-[[4-[(E)-C-ethyl-N-propoxycarbonimidoyl]-2,5-dimethylphenoxy]methyl]phenyl]-3-methoxyprop-2-enoate
DML1IXV ID DML1IXV
DML1IXV DN Aryl oxyanilide derivative 1
DML1IXV HS Patented
DML1IXV SN PMID27607364-Compound-52
DML1IXV CP TAISHO PHARMACEUTICAL CO., LTD. NIHON, NOHYAKU CO., LTD. NAKAZATO, Atsuro OKUBO, Taketoshi NAKAMURA, Toshio CHAKI, Shigeyuki TOMISAWA, Kazuyuki NAGAMINE, Masashi YAMAMOTO, Kenji HARADA, Koichiro YOSHIDA, Masanori
DML1IXV DT Small molecular drug
DML1IXV PC 9844410
DML1IXV MW 409.9
DML1IXV FM C24H24ClNO3
DML1IXV IC InChI=1S/C24H24ClNO3/c1-17(2)28-23-12-8-7-9-19(23)16-26(18(3)27)22-14-13-20(25)15-24(22)29-21-10-5-4-6-11-21/h4-15,17H,16H2,1-3H3
DML1IXV CS CC(C)OC1=CC=CC=C1CN(C2=C(C=C(C=C2)Cl)OC3=CC=CC=C3)C(=O)C
DML1IXV IK CGUBOFYHGYNUDL-UHFFFAOYSA-N
DML1IXV IU N-(4-chloro-2-phenoxyphenyl)-N-[(2-propan-2-yloxyphenyl)methyl]acetamide
DML1IXV CA CAS 220551-79-1
DM47V3I ID DM47V3I
DM47V3I DN Aryl oxyanilide derivative 2
DM47V3I HS Patented
DM47V3I SN PMID27607364-Compound-54
DM47V3I DT Small molecular drug
DMSGO7D ID DMSGO7D
DMSGO7D DN Aryl oxyanilide derivative 3
DMSGO7D HS Patented
DMSGO7D SN PMID27607364-Compound-9
DMSGO7D CP TAISHO PHARMACEUTICAL CO., LTD. NIHON, NOHYAKU CO., LTD. NAKAZATO, Atsuro OKUBO, Taketoshi NAKAMURA, Toshio CHAKI, Shigeyuki TOMISAWA, Kazuyuki NAGAMINE, Masashi YAMAMOTO, Kenji HARADA, Koichiro YOSHIDA, Masanor
DMSGO7D DT Small molecular drug
DMSGO7D PC 10430788
DMSGO7D MW 395.4
DMSGO7D FM C23H22FNO4
DMSGO7D IC InChI=1S/C23H22FNO4/c1-16(26)25(15-17-13-20(27-2)10-12-22(17)28-3)21-14-18(24)9-11-23(21)29-19-7-5-4-6-8-19/h4-14H,15H2,1-3H3
DMSGO7D CS CC(=O)N(CC1=C(C=CC(=C1)OC)OC)C2=C(C=CC(=C2)F)OC3=CC=CC=C3
DMSGO7D IK DCRZYADKQRHHSF-UHFFFAOYSA-N
DMSGO7D IU N-[(2,5-dimethoxyphenyl)methyl]-N-(5-fluoro-2-phenoxyphenyl)acetamide
DMSGO7D CA CAS 220551-92-8
DM9DJGU ID DM9DJGU
DM9DJGU DN Aryl piperazine derivative 1
DM9DJGU HS Patented
DM9DJGU SN PMID30124346-Compound-I-1
DM9DJGU CP SHANGHAI INST PHARM INDUSTRY [CNCAI ZHENGYAN [CNZHOU WEICHENG [CNHAO QUN [CN
DM9DJGU DT Small molecular drug
DM5EGBY ID DM5EGBY
DM5EGBY DN Aryl piperazine derivative 10
DM5EGBY HS Patented
DM5EGBY SN PMID26609882-Compound-48
DM5EGBY CP ARENA PHARMACEUTICALS, INC
DM5EGBY DT Small molecular drug
DMY8NEL ID DMY8NEL
DMY8NEL DN Aryl piperazine derivative 14
DMY8NEL HS Patented
DMY8NEL SN PMID30124346-Compound-31TABLE3
DMY8NEL DT Small molecular drug
DMY8NEL PC 118190937
DMY8NEL MW 501.6
DMY8NEL FM C32H31N5O
DMY8NEL IC InChI=1S/C32H31N5O/c33-22-24-8-13-31-30(21-24)26(23-34-31)6-3-4-15-35-17-19-36(20-18-35)27-9-11-28(12-10-27)37-16-14-25-5-1-2-7-29(25)32(37)38/h1-2,5,7-14,16,21,23,34H,3-4,6,15,17-20H2
DMY8NEL CS C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC=C(C=C4)N5C=CC6=CC=CC=C6C5=O
DMY8NEL IK AMDZNENPETWKSQ-UHFFFAOYSA-N
DMY8NEL IU 3-[4-[4-[4-(1-oxoisoquinolin-2-yl)phenyl]piperazin-1-yl]butyl]-1H-indole-5-carbonitrile
DMRK4IE ID DMRK4IE
DMRK4IE DN Aryl piperazine derivative 15
DMRK4IE HS Patented
DMRK4IE SN PMID30124346-Compound-33TABLE3
DMRK4IE DT Small molecular drug
DMRK4IE PC 118190855
DMRK4IE MW 502.6
DMRK4IE FM C31H30N6O
DMRK4IE IC InChI=1S/C31H30N6O/c32-21-23-6-11-29-28(20-23)24(22-34-29)4-1-2-14-35-16-18-36(19-17-35)25-7-9-26(10-8-25)37-15-12-30-27(31(37)38)5-3-13-33-30/h3,5-13,15,20,22,34H,1-2,4,14,16-19H2
DMRK4IE CS C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC=C(C=C4)N5C=CC6=C(C5=O)C=CC=N6
DMRK4IE IK FGYLPIJGSRWQAL-UHFFFAOYSA-N
DMRK4IE IU 3-[4-[4-[4-(5-oxo-1,6-naphthyridin-6-yl)phenyl]piperazin-1-yl]butyl]-1H-indole-5-carbonitrile
DM63XHT ID DM63XHT
DM63XHT DN Aryl piperazine derivative 16
DM63XHT HS Patented
DM63XHT SN PMID30124346-Compound-34TABLE3
DM63XHT DT Small molecular drug
DM63XHT PC 118191039
DM63XHT MW 488.6
DM63XHT FM C30H28N6O
DM63XHT IC InChI=1S/C30H28N6O/c31-20-22-5-10-28-27(19-22)23(21-33-28)3-2-13-34-15-17-35(18-16-34)24-6-8-25(9-7-24)36-14-11-29-26(30(36)37)4-1-12-32-29/h1,4-12,14,19,21,33H,2-3,13,15-18H2
DM63XHT CS C1CN(CCN1CCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC=C(C=C4)N5C=CC6=C(C5=O)C=CC=N6
DM63XHT IK QGUBOPJCHFVENQ-UHFFFAOYSA-N
DM63XHT IU 3-[3-[4-[4-(5-oxo-1,6-naphthyridin-6-yl)phenyl]piperazin-1-yl]propyl]-1H-indole-5-carbonitrile
DMZ3DS5 ID DMZ3DS5
DMZ3DS5 DN Aryl piperazine derivative 6
DMZ3DS5 HS Patented
DMZ3DS5 SN PMID30124346-Compound-III-2
DMZ3DS5 CP SHANGHAI INST PHARM INDUSTRY [CNCAI ZHENGYAN [CNZHOU WEICHENG [CNHAO QUN [CN
DMZ3DS5 DT Small molecular drug
DM7BRIT ID DM7BRIT
DM7BRIT DN Aryl piperazine derivative 8
DM7BRIT HS Patented
DM7BRIT SN PMID26609882-Compound-46
DM7BRIT CP ARENA PHARMACEUTICALS, INC
DM7BRIT DT Small molecular drug
DMLKNWF ID DMLKNWF
DMLKNWF DN Aryl piperazine derivative 9
DMLKNWF HS Patented
DMLKNWF SN PMID26609882-Compound-47
DMLKNWF CP ARENA PHARMACEUTICALS, INC
DMLKNWF DT Small molecular drug
DM3CVWU ID DM3CVWU
DM3CVWU DN Aryl pyrimidine derivative 1
DM3CVWU HS Patented
DM3CVWU SN PMID26161698-Compound-43
DM3CVWU CP INGENIUM PHARMACEUTICALS GMBH ALLGEIER, HANS AUGUSTIN, MARTIN MUELLER, ANKE ZEITLMANN, LUTZ MARQUARDT, ANDREAS PLEISS, MICHAEL A. HEISER, ULRICH NIESTROJ, ANDR JOHANNES
DM3CVWU DT Small molecular drug
DM3CVWU PC 25227433
DM3CVWU MW 312.37
DM3CVWU FM C17H20N4O2
DM3CVWU IC InChI=1S/C17H20N4O2/c1-23-15-7-3-2-6-13(15)14-9-16(20-11-19-14)21-17(22)12-5-4-8-18-10-12/h2-3,6-7,9,11-12,18H,4-5,8,10H2,1H3,(H,19,20,21,22)
DM3CVWU CS COC1=CC=CC=C1C2=CC(=NC=N2)NC(=O)C3CCCNC3
DM3CVWU IK HWNURWPCYJPMQP-UHFFFAOYSA-N
DM3CVWU IU N-[6-(2-methoxyphenyl)pyrimidin-4-yl]piperidine-3-carboxamide
DMU9Y4B ID DMU9Y4B
DMU9Y4B DN Aryl pyrimidine derivative 2
DMU9Y4B HS Patented
DMU9Y4B SN PMID27172114-Compound-41
DMU9Y4B CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMU9Y4B DT Small molecular drug
DMXND26 ID DMXND26
DMXND26 DN Aryl pyrimidine derivative 3
DMXND26 HS Patented
DMXND26 SN PMID27172114-Compound-42
DMXND26 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMXND26 DT Small molecular drug
DMWSAL5 ID DMWSAL5
DMWSAL5 DN Aryl pyrimidine derivative 4
DMWSAL5 HS Patented
DMWSAL5 SN PMID27172114-Compound-43
DMWSAL5 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMWSAL5 DT Small molecular drug
DMEP9O8 ID DMEP9O8
DMEP9O8 DN Aryl pyrimidine derivative 5
DMEP9O8 HS Patented
DMEP9O8 SN PMID27172114-Compound-46
DMEP9O8 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMEP9O8 DT Small molecular drug
DMMF9U6 ID DMMF9U6
DMMF9U6 DN Aryl pyrimidine derivative 6
DMMF9U6 HS Patented
DMMF9U6 SN PMID27172114-Compound-48
DMMF9U6 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMMF9U6 DT Small molecular drug
DM8FAW3 ID DM8FAW3
DM8FAW3 DN Aryl pyrimidine derivative 7
DM8FAW3 HS Patented
DM8FAW3 SN PMID27172114-Compound-51
DM8FAW3 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DM8FAW3 DT Small molecular drug
DM7OA9E ID DM7OA9E
DM7OA9E DN Aryl pyrimidine derivative 8
DM7OA9E HS Patented
DM7OA9E SN PMID27172114-Compound-52
DM7OA9E CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DM7OA9E DT Small molecular drug
DMBEYD1 ID DMBEYD1
DMBEYD1 DN Aryl pyrimidine derivative 9
DMBEYD1 HS Patented
DMBEYD1 SN PMID27172114-Compound-53
DMBEYD1 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMBEYD1 DT Small molecular drug
DMW7HKS ID DMW7HKS
DMW7HKS DN Aryl sulphoxide imine derivative 1
DMW7HKS HS Patented
DMW7HKS SN PMID29473428-Compound-19
DMW7HKS DT Small molecular drug
DMW7HKS PC 137199860
DMW7HKS MW 435.27
DMW7HKS FM C13H16BrFN6O3S
DMW7HKS IC InChI=1S/C13H16BrFN6O3S/c1-16-25(2,23)6-5-17-12-11(20-24-21-12)13(19-22)18-8-3-4-10(15)9(14)7-8/h3-4,7,22H,5-6H2,1-2H3,(H,17,21)(H,18,19)
DMW7HKS CS CN=S(=O)(C)CCNC1=NON=C1C(=NC2=CC(=C(C=C2)F)Br)NO
DMW7HKS IK LLCCKYPCVYUSQH-UHFFFAOYSA-N
DMW7HKS IU N'-(3-bromo-4-fluorophenyl)-4-[2-(N,S-dimethylsulfonimidoyl)ethylamino]-N-hydroxy-1,2,5-oxadiazole-3-carboximidamide
DM0B9SP ID DM0B9SP
DM0B9SP DN Aryl urea derivative 1
DM0B9SP HS Patented
DM0B9SP SN PMID26413912-Compound-36
DM0B9SP CP PFIZER INC. FAY, Lorraine Kathleen JOHNSON, Douglas Scott MEYERS, Marvin Jay THORARENSEN, Atli WANG, Lijuan Jane
DM0B9SP DT Small molecular drug
DMQWJ12 ID DMQWJ12
DMQWJ12 DN Aryl urea derivative 2
DMQWJ12 HS Patented
DMQWJ12 SN PMID26413912-Compound-37
DMQWJ12 CP PFIZER INC
DMQWJ12 DT Small molecular drug
DM1G7KI ID DM1G7KI
DM1G7KI DN Aryl urea derivative 3
DM1G7KI HS Patented
DM1G7KI SN PMID26413912-Compound-38
DM1G7KI CP PFIZER INC
DM1G7KI DT Small molecular drug
DM0HOJW ID DM0HOJW
DM0HOJW DN Aryl urea derivative 4
DM0HOJW HS Patented
DM0HOJW SN PMID26413912-Compound-39
DM0HOJW CP PFIZER INC
DM0HOJW DT Small molecular drug
DM54V1R ID DM54V1R
DM54V1R DN Aryl urea derivative 5
DM54V1R HS Patented
DM54V1R SN PMID26413912-Compound-40
DM54V1R CP PFIZER INC. LONG, Scott Allen MEYERS, Marvin Jay PELC, Matthew James SCHWEITZER, Barbara Ann THORARENSEN, Atli WANG, Lijuan Jane
DM54V1R DT Small molecular drug
DMGM72Q ID DMGM72Q
DMGM72Q DN A-substituted phenylpropionic acid derivative 1
DMGM72Q HS Patented
DMGM72Q SN PMID25416646-Compound-Figure2-c
DMGM72Q DT Small molecular drug
DMH5FEO ID DMH5FEO
DMH5FEO DN A-substituted phenylpropionic acid derivative 2
DMH5FEO HS Patented
DMH5FEO SN PMID25416646-Compound-Figure2-E
DMH5FEO CP Okayama University
DMH5FEO DT Small molecular drug
DMRG1NL ID DMRG1NL
DMRG1NL DN Atorvastatin lactole derivative 1
DMRG1NL HS Patented
DMRG1NL SN PMID27537201-Compound-Figure3
DMRG1NL CP REDX PHARMA LIMITED LINDSAY, Derek JACKSON, PeteREDX PHARMA LIMITED LINDSAY, Derek JACKSON, Peter HINDLEY, Stephen BHAMRA, IndeREDX PHARMA LTD [GB]BRADFORD PHARMA LTD [GBREDX PHARMA LTD [GBBRADFORD PHARMA LTD [GB]REDX PHARMA LTBRADFORD PHARMA LTD
DMRG1NL DT Small molecular drug
DMVD5TA ID DMVD5TA
DMVD5TA DN Azachalcone derivative 1
DMVD5TA HS Patented
DMVD5TA SN PMID26560530-Compound-41
DMVD5TA CP Universit de Montral
DMVD5TA DT Small molecular drug
DMVD5TA PC 5872358
DMVD5TA MW 254.24
DMVD5TA FM C14H10N2O3
DMVD5TA IC InChI=1S/C14H10N2O3/c17-14(12-2-1-9-15-10-12)8-5-11-3-6-13(7-4-11)16(18)19/h1-10H/b8-5+
DMVD5TA CS C1=CC(=CN=C1)C(=O)/C=C/C2=CC=C(C=C2)[N+](=O)[O-]
DMVD5TA IK DFXQMCHHZQLWHB-VMPITWQZSA-N
DMVD5TA IU (E)-3-(4-nitrophenyl)-1-pyridin-3-ylprop-2-en-1-one
DMJWH4B ID DMJWH4B
DMJWH4B DN Azaindazole amide derivative 1
DMJWH4B HS Patented
DMJWH4B SN PMID28270021-Compound-WO2014016434Example30
DMJWH4B CP PIERRE FABRE MEDICAMENT
DMJWH4B DE Pruritus; Chronic pain; Neuropathic pain; Thymic cancer
DM3S0LI ID DM3S0LI
DM3S0LI DN Azaindazole derivative 1
DM3S0LI HS Patented
DM3S0LI SN PMID28117607-Compound-31
DM3S0LI CP Genentech, Inc., USA. assignee
DM3S0LI DT Small molecular drug
DMEYS3V ID DMEYS3V
DMEYS3V DN Azaindazole derivative 2
DMEYS3V HS Patented
DMEYS3V SN PMID28117607-Compound-32
DMEYS3V CP Genentech, Inc., USA. assignee
DMEYS3V DT Small molecular drug
DMOV9XA ID DMOV9XA
DMOV9XA DN Azaindazole derivative 3
DMOV9XA HS Patented
DMOV9XA SN PMID28117607-Compound-33
DMOV9XA CP Genentech, Inc., USA. assignee
DMOV9XA DT Small molecular drug
DMX3MNT ID DMX3MNT
DMX3MNT DN Azaindazole derivative 4
DMX3MNT HS Patented
DMX3MNT SN PMID28117607-Compound-34
DMX3MNT CP Genentech, Inc., USA. assignee
DMX3MNT DT Small molecular drug
DMSMXK3 ID DMSMXK3
DMSMXK3 DN Azaindole derivative 1
DMSMXK3 HS Patented
DMSMXK3 SN PMID25656651-Compound-43
DMSMXK3 CP ORIBASE PHARMA
DMSMXK3 DT Small molecular drug
DMSMXK3 PC 90269487
DMSMXK3 MW 580.6
DMSMXK3 FM C30H31F3N6O3
DMSMXK3 IC InChI=1S/C30H31F3N6O3/c1-18-3-6-23(12-22(18)15-34-24-11-21-14-26(29(41)42)37-27(21)35-16-24)36-28(40)19-4-5-20(25(13-19)30(31,32)33)17-39-9-7-38(2)8-10-39/h3-6,11-14,16,34H,7-10,15,17H2,1-2H3,(H,35,37)(H,36,40)(H,41,42)
DMSMXK3 CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)CNC4=CN=C5C(=C4)C=C(N5)C(=O)O
DMSMXK3 IK DZMBOVWOPRYRNU-UHFFFAOYSA-N
DMSMXK3 IU 5-[[2-methyl-5-[[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzoyl]amino]phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid
DMXBYHV ID DMXBYHV
DMXBYHV DN Azaindole derivative 2
DMXBYHV HS Patented
DMXBYHV SN PMID25656651-Compound-44
DMXBYHV CP ORIBASE PHARMA
DMXBYHV DT Small molecular drug
DMXBYHV PC 76903081
DMXBYHV MW 482.5
DMXBYHV FM C25H21F3N4O3
DMXBYHV IC InChI=1S/C25H21F3N4O3/c1-14-6-7-19(31-23(33)15-4-3-5-18(8-15)25(26,27)28)10-17(14)12-29-20-9-16-11-21(24(34)35-2)32-22(16)30-13-20/h3-11,13,29H,12H2,1-2H3,(H,30,32)(H,31,33)
DMXBYHV CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)CNC3=CN=C4C(=C3)C=C(N4)C(=O)OC
DMXBYHV IK QERVGYYPIGRNLQ-UHFFFAOYSA-N
DMXBYHV IU methyl 5-[[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
DM2EDOM ID DM2EDOM
DM2EDOM DN Azaindole derivative 3
DM2EDOM HS Patented
DM2EDOM SN PMID27841045-Compound-138
DM2EDOM CP Kissei Pharmaceutical Co. Ltd
DM2EDOM DT Small molecular drug
DM2EDOM PC 56949434
DM2EDOM MW 309.28
DM2EDOM FM C16H11N3O4
DM2EDOM IC InChI=1S/C16H11N3O4/c1-23-15-5-4-13-12(7-10(8-17)19(13)18-15)9-2-3-11(16(21)22)14(20)6-9/h2-7,20H,1H3,(H,21,22)
DM2EDOM CS COC1=NN2C(=C(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O)C=C1
DM2EDOM IK QEYWGQCVGIFYQF-UHFFFAOYSA-N
DM2EDOM IU 4-(7-cyano-2-methoxypyrrolo[1,2-b]pyridazin-5-yl)-2-hydroxybenzoic acid
DMCKSJ8 ID DMCKSJ8
DMCKSJ8 DN Azaindole derivative 4
DMCKSJ8 HS Patented
DMCKSJ8 SN PMID27841045-Compound-139
DMCKSJ8 CP Kissei Pharmaceutical Co. Ltd
DMCKSJ8 DT Small molecular drug
DMD2BL3 ID DMD2BL3
DMD2BL3 DN Azaindole derivative 5
DMD2BL3 HS Patented
DMD2BL3 SN PMID27841045-Compound-140
DMD2BL3 CP Kissei Pharmaceutical Co. Ltd
DMD2BL3 DT Small molecular drug
DMD2BL3 PC 56949445
DMD2BL3 MW 279.25
DMD2BL3 FM C15H9N3O3
DMD2BL3 IC InChI=1S/C15H9N3O3/c16-8-10-6-13(18-12(10)2-1-5-17-18)9-3-4-11(15(20)21)14(19)7-9/h1-7,19H,(H,20,21)
DMD2BL3 CS C1=CC2=C(C=C(N2N=C1)C3=CC(=C(C=C3)C(=O)O)O)C#N
DMD2BL3 IK NSOWXVMDKNRRTI-UHFFFAOYSA-N
DMD2BL3 IU 4-(5-cyanopyrrolo[1,2-b]pyridazin-7-yl)-2-hydroxybenzoic acid
DMJBGHL ID DMJBGHL
DMJBGHL DN Azaindole derivative 6
DMJBGHL HS Patented
DMJBGHL SN PMID27841045-Compound-141
DMJBGHL CP Kissei Pharmaceutical Co. Ltd
DMJBGHL DT Small molecular drug
DMJBGHL PC 56949422
DMJBGHL MW 293.28
DMJBGHL FM C16H11N3O3
DMJBGHL IC InChI=1S/C16H11N3O3/c1-9-2-5-14-13(7-11(8-17)19(14)18-9)10-3-4-12(16(21)22)15(20)6-10/h2-7,20H,1H3,(H,21,22)
DMJBGHL CS CC1=NN2C(=C(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O)C=C1
DMJBGHL IK OVRDXWKIIUUQMR-UHFFFAOYSA-N
DMJBGHL IU 4-(7-cyano-2-methylpyrrolo[1,2-b]pyridazin-5-yl)-2-hydroxybenzoic acid
DMA2JGU ID DMA2JGU
DMA2JGU DN Azaindole derivative 7
DMA2JGU HS Patented
DMA2JGU SN PMID27841045-Compound-142
DMA2JGU CP Kissei Pharmaceutical Co. Ltd
DMA2JGU DT Small molecular drug
DMA2JGU PC 56949332
DMA2JGU MW 279.25
DMA2JGU FM C15H9N3O3
DMA2JGU IC InChI=1S/C15H9N3O3/c16-8-10-7-12(13-2-1-5-17-18(10)13)9-3-4-11(15(20)21)14(19)6-9/h1-7,19H,(H,20,21)
DMA2JGU CS C1=CC2=C(C=C(N2N=C1)C#N)C3=CC(=C(C=C3)C(=O)O)O
DMA2JGU IK CMWZLOJCASLPFW-UHFFFAOYSA-N
DMA2JGU IU 4-(7-cyanopyrrolo[1,2-b]pyridazin-5-yl)-2-hydroxybenzoic acid
DMEUHCD ID DMEUHCD
DMEUHCD DN Aza-phenalene-3-ketone derivative 1
DMEUHCD HS Patented
DMEUHCD SN PMID27841036-Compound-27
DMEUHCD CP Suzhou Kangrun Pharmaceutical Inc
DMEUHCD DT Small molecular drug
DM76XH4 ID DM76XH4
DM76XH4 DN Azepan-4-one derivative 1
DM76XH4 HS Patented
DM76XH4 SN PMID26077642-Compound-Figure3E
DM76XH4 DT Small molecular drug
DM7O0MD ID DM7O0MD
DM7O0MD DN Azepan-4-one derivative 2
DM7O0MD HS Patented
DM7O0MD SN PMID26077642-Compound-Figure3F
DM7O0MD DT Small molecular drug
DMXEFUD ID DMXEFUD
DMXEFUD DN Azetidine derivative 1
DMXEFUD HS Patented
DMXEFUD SN PMID26161824-Compound-157
DMXEFUD DT Small molecular drug
DMXEFUD PC 11167515
DMXEFUD MW 479.4
DMXEFUD FM C23H21Cl2FN2O2S
DMXEFUD IC InChI=1S/C23H21Cl2FN2O2S/c1-15-22(27-31(29,30)21-12-10-20(26)11-13-21)14-28(15)23(16-2-6-18(24)7-3-16)17-4-8-19(25)9-5-17/h2-13,15,22-23,27H,14H2,1H3/t15-,22?/m0/s1
DMXEFUD CS C[C@H]1C(CN1C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)NS(=O)(=O)C4=CC=C(C=C4)F
DMXEFUD IK BNBGRXOGPFOPLL-UEDXYCIISA-N
DMXEFUD IU N-[(2S)-1-[bis(4-chlorophenyl)methyl]-2-methylazetidin-3-yl]-4-fluorobenzenesulfonamide
DMXEFUD DE Obesity
DMTB3KS ID DMTB3KS
DMTB3KS DN Azetidine derivative 2
DMTB3KS HS Patented
DMTB3KS SN PMID28594589-Compound-TABLE3c11
DMTB3KS CP Exelixis
DMTB3KS DT Small molecular drug
DMTB3KS PC 16222298
DMTB3KS MW 519.299
DMTB3KS FM C19H17F3IN3O3
DMTB3KS IC InChI=1S/C19H17F3IN3O3/c20-13-3-2-12(19(29)26-8-10(9-26)18(28)24-5-6-27)17(16(13)22)25-15-4-1-11(23)7-14(15)21/h1-4,7,10,25,27H,5-6,8-9H2,(H,24,28)
DMTB3KS CS C1C(CN1C(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)F)C(=O)NCCO
DMTB3KS IK GNOFJPRIPYVPCR-UHFFFAOYSA-N
DMTB3KS IU 1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-N-(2-hydroxyethyl)azetidine-3-carboxamide
DMIKSVG ID DMIKSVG
DMIKSVG DN Azetidine derivative 3
DMIKSVG HS Patented
DMIKSVG SN PMID26161824-Compound-173
DMIKSVG DT Small molecular drug
DMIKSVG PC 68631346
DMIKSVG MW 630.5
DMIKSVG FM C28H28Cl2F3N3O4S
DMIKSVG IC InChI=1S/C28H28Cl2F3N3O4S/c1-17(16-37)34-27(38)20-11-21(28(31,32)33)13-24(12-20)36(41(2,39)40)25-14-35(15-25)26(18-3-7-22(29)8-4-18)19-5-9-23(30)10-6-19/h3-13,17,25-26,37H,14-16H2,1-2H3,(H,34,38)
DMIKSVG CS CC(CO)NC(=O)C1=CC(=CC(=C1)N(C2CN(C2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)S(=O)(=O)C)C(F)(F)F
DMIKSVG IK CVPMSFUZFFYDBR-UHFFFAOYSA-N
DMIKSVG IU 3-[[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-methylsulfonylamino]-N-(1-hydroxypropan-2-yl)-5-(trifluoromethyl)benzamide
DMIKSVG DE Obesity
DMXL2V9 ID DMXL2V9
DMXL2V9 DN Azetidine derivative 4
DMXL2V9 HS Patented
DMXL2V9 SN PMID26161824-Compound-174
DMXL2V9 DT Small molecular drug
DMXL2V9 PC 68639490
DMXL2V9 MW 660.5
DMXL2V9 FM C29H30Cl2F3N3O5S
DMXL2V9 IC InChI=1S/C29H30Cl2F3N3O5S/c1-28(16-38,17-39)35-27(40)20-11-21(29(32,33)34)13-24(12-20)37(43(2,41)42)25-14-36(15-25)26(18-3-7-22(30)8-4-18)19-5-9-23(31)10-6-19/h3-13,25-26,38-39H,14-17H2,1-2H3,(H,35,40)
DMXL2V9 CS CC(CO)(CO)NC(=O)C1=CC(=CC(=C1)N(C2CN(C2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)S(=O)(=O)C)C(F)(F)F
DMXL2V9 IK OMKQCMZJBZXEKN-UHFFFAOYSA-N
DMXL2V9 IU 3-[[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-methylsulfonylamino]-N-(1,3-dihydroxy-2-methylpropan-2-yl)-5-(trifluoromethyl)benzamide
DMXL2V9 DE Obesity
DMJ9U0E ID DMJ9U0E
DMJ9U0E DN Azetidine derivative 5
DMJ9U0E HS Patented
DMJ9U0E SN PMID29473428-Compound-32
DMJ9U0E CP NEWLINK GENETICS CORPORATION MAUTINO, Mario KUMAR, Sanjeev WALDO, Jesse JAIPURI, Firoz KESHARWANI, Tanay ZHANG, Xiaoxia
DMJ9U0E DT Small molecular drug
DMJ9U0E PC 70874002
DMJ9U0E MW 373.4
DMJ9U0E FM C23H23N3O2
DMJ9U0E IC InChI=1S/C23H23N3O2/c27-22(17-13-25(14-17)23(28)10-16-6-2-1-3-7-16)11-20-18-8-4-5-9-19(18)21-12-24-15-26(20)21/h1-9,12,15,17,20,22,27H,10-11,13-14H2
DMJ9U0E CS C1C(CN1C(=O)CC2=CC=CC=C2)C(CC3C4=CC=CC=C4C5=CN=CN35)O
DMJ9U0E IK XCPKPBVNKDRBNO-UHFFFAOYSA-N
DMJ9U0E IU 1-[3-[1-hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl]azetidin-1-yl]-2-phenylethanone
DMH942E ID DMH942E
DMH942E DN Azetidine urea derivative 1
DMH942E HS Patented
DMH942E SN PMID26413912-Compound-43
DMH942E CP VERNALIS (R&D) LTD. ROUGHLEY, Stephen WALLS, Steven HART, Terrence PARSONS, Rachel BROUGH, Paul GRAHAM, Christopher MACIAS, Alba
DMH942E DT Small molecular drug
DMJY8XI ID DMJY8XI
DMJY8XI DN Azetidine urea derivative 2
DMJY8XI HS Patented
DMJY8XI SN PMID26413912-Compound-50
DMJY8XI CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
DMJY8XI DT Small molecular drug
DMJY8XI PC 49839765
DMJY8XI MW 463.9
DMJY8XI FM C24H22ClN5O3
DMJY8XI IC InChI=1S/C24H22ClN5O3/c25-18-6-8-19(9-7-18)33-21-4-1-3-20(13-21)32-12-10-17-15-29(16-17)24(31)28-23-14-26-22-5-2-11-27-30(22)23/h1-9,11,13-14,17H,10,12,15-16H2,(H,28,31)
DMJY8XI CS C1C(CN1C(=O)NC2=CN=C3N2N=CC=C3)CCOC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
DMJY8XI IK DUGFOZRFNIVGIA-UHFFFAOYSA-N
DMJY8XI IU 3-[2-[3-(4-chlorophenoxy)phenoxy]ethyl]-N-imidazo[1,2-b]pyridazin-3-ylazetidine-1-carboxamide
DM48PIO ID DM48PIO
DM48PIO DN Azetidine urea derivative 3
DM48PIO HS Patented
DM48PIO SN PMID26413912-Compound-51
DM48PIO CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
DM48PIO DT Small molecular drug
DM48PIO PC 49838571
DM48PIO MW 462.9
DM48PIO FM C25H23ClN4O3
DM48PIO IC InChI=1S/C25H23ClN4O3/c26-19-4-6-21(7-5-19)33-23-3-1-2-22(13-23)32-11-9-17-15-30(16-17)25(31)29-20-12-18-8-10-27-24(18)28-14-20/h1-8,10,12-14,17H,9,11,15-16H2,(H,27,28)(H,29,31)
DM48PIO CS C1C(CN1C(=O)NC2=CN=C3C(=C2)C=CN3)CCOC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
DM48PIO IK XAYGGDSGTNLICL-UHFFFAOYSA-N
DM48PIO IU 3-[2-[3-(4-chlorophenoxy)phenoxy]ethyl]-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)azetidine-1-carboxamide
DMZX8Y0 ID DMZX8Y0
DMZX8Y0 DN Azetidine-1-carboxamide derivative 1
DMZX8Y0 HS Patented
DMZX8Y0 SN PMID26161824-Compound-161
DMZX8Y0 DT Small molecular drug
DMZX8Y0 PC 68904215
DMZX8Y0 MW 407.3
DMZX8Y0 FM C21H24Cl2N2O2
DMZX8Y0 IC InChI=1S/C21H24Cl2N2O2/c1-21(2,3)24-20(26)25-12-18(13-25)27-19(14-4-8-16(22)9-5-14)15-6-10-17(23)11-7-15/h4-11,18-19H,12-13H2,1-3H3,(H,24,26)
DMZX8Y0 CS CC(C)(C)NC(=O)N1CC(C1)OC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMZX8Y0 IK JIJVOTYIBJGZDJ-UHFFFAOYSA-N
DMZX8Y0 IU 3-[bis(4-chlorophenyl)methoxy]-N-tert-butylazetidine-1-carboxamide
DMZX8Y0 DE Obesity
DMONQ4L ID DMONQ4L
DMONQ4L DN Azetidine-1-carboxamide derivative 2
DMONQ4L HS Patented
DMONQ4L SN PMID26161824-Compound-162
DMONQ4L DT Small molecular drug
DMONQ4L PC 9935850
DMONQ4L MW 503.3
DMONQ4L FM C22H23BrF4N2O2
DMONQ4L IC InChI=1S/C22H23BrF4N2O2/c1-21(2,3)28-20(30)29-11-14(12-29)31-19(16-9-8-13(23)10-18(16)24)15-6-4-5-7-17(15)22(25,26)27/h4-10,14,19H,11-12H2,1-3H3,(H,28,30)
DMONQ4L CS CC(C)(C)NC(=O)N1CC(C1)OC(C2=C(C=C(C=C2)Br)F)C3=CC=CC=C3C(F)(F)F
DMONQ4L IK PTVKXSFBTUPKHX-UHFFFAOYSA-N
DMONQ4L IU 3-[(4-bromo-2-fluorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]-N-tert-butylazetidine-1-carboxamide
DMONQ4L DE Obesity
DM2UGK3 ID DM2UGK3
DM2UGK3 DN Azetidine-1-carboxamide derivative 3
DM2UGK3 HS Patented
DM2UGK3 SN PMID26161824-Compound-163
DM2UGK3 DT Small molecular drug
DM2UGK3 PC 68902536
DM2UGK3 MW 440.9
DM2UGK3 FM C22H24ClF3N2O2
DM2UGK3 IC InChI=1S/C22H24ClF3N2O2/c1-21(2,3)27-20(29)28-12-16(13-28)30-19(14-8-10-15(23)11-9-14)17-6-4-5-7-18(17)22(24,25)26/h4-11,16,19H,12-13H2,1-3H3,(H,27,29)/t19-/m1/s1
DM2UGK3 CS CC(C)(C)NC(=O)N1CC(C1)O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=C3C(F)(F)F
DM2UGK3 IK BNLYOVHLLDBOFZ-LJQANCHMSA-N
DM2UGK3 IU N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide
DM2UGK3 DE Obesity
DMRMED4 ID DMRMED4
DMRMED4 DN Azetidine-benzoxazin-3(4H)-one derivative 1
DMRMED4 HS Patented
DMRMED4 SN PMID29053063-Compound-16a
DMRMED4 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMRMED4 DT Small molecular drug
DMMSPX7 ID DMMSPX7
DMMSPX7 DN Azetidine-benzoxazin-3(4H)-one derivative 2
DMMSPX7 HS Patented
DMMSPX7 SN PMID29053063-Compound-16b
DMMSPX7 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMMSPX7 DT Small molecular drug
DMA430E ID DMA430E
DMA430E DN Azetidine-benzoxazin-3(4H)-one derivative 3
DMA430E HS Patented
DMA430E SN PMID29053063-Compound-16c
DMA430E CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMA430E DT Small molecular drug
DMMWK3E ID DMMWK3E
DMMWK3E DN Azetidinyl-piperazine derivative 1
DMMWK3E HS Patented
DMMWK3E SN PMID29053063-Compound-1
DMMWK3E CP JANSSEN PHARMACEUTICA NV FLORES, Christopher, M. NELEN, Marina, I. NULTON, Erica, L. PROUTY, Stephen TODD, Matthew ZHANG, Sui-PJANSSEN PHARMACEUTICA NV CHEVALIER, Kristen, M. DAX, Scott, L. FLORES, Christopher, M. LIU, Li MACIELAG, Mark, J. MCDONNELL, Mark, E. NELEN, Marina, I. PROUTY, Stephen TODD, Matthew ZHANG, Sui-Po ZHU, Bin NULTON, Erica, L. CLEMENTE, Jose
DMMWK3E DT Small molecular drug
DM0C48S ID DM0C48S
DM0C48S DN Azetidinyl-piperazine derivative 2
DM0C48S HS Patented
DM0C48S SN PMID29053063-Compound-2a
DM0C48S CP JANSSEN PHARMACEUTICA NV
DM0C48S DT Small molecular drug
DM3WHL2 ID DM3WHL2
DM3WHL2 DN Azetidinyl-piperazine derivative 3
DM3WHL2 HS Patented
DM3WHL2 SN PMID29053063-Compound-2b
DM3WHL2 CP JANSSEN PHARMACEUTICA NV
DM3WHL2 DT Small molecular drug
DM3WHL2 PC 66840555
DM3WHL2 MW 515
DM3WHL2 FM C21H18ClF3N4O2S2
DM3WHL2 IC InChI=1S/C21H18ClF3N4O2S2/c22-17-14-2-1-12(21(23,24)25)7-16(14)33-18(17)20(31)29-8-13(9-29)27-3-5-28(6-4-27)19(30)15-10-32-11-26-15/h1-2,7,10-11,13H,3-6,8-9H2
DM3WHL2 CS C1CN(CCN1C2CN(C2)C(=O)C3=C(C4=C(S3)C=C(C=C4)C(F)(F)F)Cl)C(=O)C5=CSC=N5
DM3WHL2 IK HKKPDZNDQBHUOD-UHFFFAOYSA-N
DM3WHL2 IU [4-[1-[3-chloro-6-(trifluoromethyl)-1-benzothiophene-2-carbonyl]azetidin-3-yl]piperazin-1-yl]-(1,3-thiazol-4-yl)methanone
DM0IJYQ ID DM0IJYQ
DM0IJYQ DN Azetidinyl-piperidine derivative 1
DM0IJYQ HS Patented
DM0IJYQ SN PMID29053063-Compound-3a
DM0IJYQ DT Small molecular drug
DMNQLJU ID DMNQLJU
DMNQLJU DN Azetidinyl-piperidine derivative 2
DMNQLJU HS Patented
DMNQLJU SN PMID29053063-Compound-3b
DMNQLJU DT Small molecular drug
DM2UDV8 ID DM2UDV8
DM2UDV8 DN Azetidinyl-piperidine derivative 3
DM2UDV8 HS Patented
DM2UDV8 SN PMID29053063-Compound-6
DM2UDV8 CP INSERM INST NAT DE LA SANT ET DE LA RECH M DICALE [FRUNIVERSIT PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
DM2UDV8 DT Small molecular drug
DM0E8YF ID DM0E8YF
DM0E8YF DN Azole benzene derivative 1
DM0E8YF HS Patented
DM0E8YF SN PMID27841045-Compound-146
DM0E8YF CP Teizin Pharma Ltd
DM0E8YF DT Small molecular drug
DM0E8YF PC 76900398
DM0E8YF MW 358.4
DM0E8YF FM C17H18N4O3S
DM0E8YF IC InChI=1S/C17H18N4O3S/c1-10(2)9-24-14-5-4-12(8-13(14)21-7-6-18-20-21)16-19-11(3)15(25-16)17(22)23/h4-8,10H,9H2,1-3H3,(H,22,23)
DM0E8YF CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)N3C=CN=N3)C(=O)O
DM0E8YF IK VBUUZRSRCDYYFW-UHFFFAOYSA-N
DM0E8YF IU 4-methyl-2-[4-(2-methylpropoxy)-3-(triazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid
DMJG7M6 ID DMJG7M6
DMJG7M6 DN Azole benzene derivative 2
DMJG7M6 HS Patented
DMJG7M6 SN PMID27841045-Compound-147
DMJG7M6 CP Teizin Pharma Ltd
DMJG7M6 DT Small molecular drug
DMJG7M6 PC 78322305
DMJG7M6 MW 345.4
DMJG7M6 FM C15H15N5O3S
DMJG7M6 IC InChI=1S/C15H15N5O3S/c1-8(2)23-12-5-4-10(6-11(12)20-7-16-18-19-20)14-17-9(3)13(24-14)15(21)22/h4-8H,1-3H3,(H,21,22)
DMJG7M6 CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OC(C)C)N3C=NN=N3)C(=O)O
DMJG7M6 IK GTRJSEARYANTGP-UHFFFAOYSA-N
DMJG7M6 IU 4-methyl-2-[4-propan-2-yloxy-3-(tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid
DMH8Q4T ID DMH8Q4T
DMH8Q4T DN Azole benzene derivative 3
DMH8Q4T HS Patented
DMH8Q4T SN PMID27841045-Compound-148
DMH8Q4T CP Teizin Pharma Ltd
DMH8Q4T DT Small molecular drug
DMH8Q4T PC 78322612
DMH8Q4T MW 359.4
DMH8Q4T FM C16H17N5O3S
DMH8Q4T IC InChI=1S/C16H17N5O3S/c1-9(2)7-24-13-5-4-11(6-12(13)21-8-17-19-20-21)15-18-10(3)14(25-15)16(22)23/h4-6,8-9H,7H2,1-3H3,(H,22,23)
DMH8Q4T CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)N3C=NN=N3)C(=O)O
DMH8Q4T IK DKEWYKIZSPDHOY-UHFFFAOYSA-N
DMH8Q4T IU 4-methyl-2-[4-(2-methylpropoxy)-3-(tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid
DMDPHT1 ID DMDPHT1
DMDPHT1 DN Azole benzene derivative 4
DMDPHT1 HS Patented
DMDPHT1 SN PMID27841045-Compound-149
DMDPHT1 CP Teizin Pharma Ltd
DMDPHT1 DT Small molecular drug
DMDPHT1 PC 118555053
DMDPHT1 MW 372.4
DMDPHT1 FM C18H20N4O3S
DMDPHT1 IC InChI=1S/C18H20N4O3S/c1-11-15(17(23)24)26-16(20-11)12-5-6-14(25-10-18(2,3)4)13(9-12)22-8-7-19-21-22/h5-9H,10H2,1-4H3,(H,23,24)
DMDPHT1 CS CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)(C)C)N3C=CN=N3)C(=O)O
DMDPHT1 IK MWDSDCKUTZIOBZ-UHFFFAOYSA-N
DMDPHT1 IU 2-[4-(2,2-dimethylpropoxy)-3-(triazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
DM76HXA ID DM76HXA
DM76HXA DN Azole derivative 1
DM76HXA HS Patented
DM76HXA SN PMID26413912-Compound-64
DM76HXA CP MERCK SHARP &amDOHME CORP. LIN, Linus, S. CHANG, Linda, L. CHOBANIAN, Harry NARGUND, Ravi, P
DM76HXA DT Small molecular drug
DMOPNJ6 ID DMOPNJ6
DMOPNJ6 DN Azole derivative 2
DMOPNJ6 HS Patented
DMOPNJ6 SN PMID26413912-Compound-65
DMOPNJ6 CP MERCK SHARP &amDOHME CORP. LIN, Linus, S. CHIODA, Marc, D. LIU, Ping NARGUND, Ravi, P
DMOPNJ6 DT Small molecular drug
DMN9KTJ ID DMN9KTJ
DMN9KTJ DN Azole derivative 3
DMN9KTJ HS Patented
DMN9KTJ SN PMID26413912-Compound-66
DMN9KTJ CP MERCK SHARP & DOHME CORP. YANG, ZhiQiang NANTERMET, Philippe, G. KREATSOULAS, Constantine MOORE, Keith, P. SHALEN, Evan Foster
DMN9KTJ DT Small molecular drug
DMOW01E ID DMOW01E
DMOW01E DN Azole derivative 4
DMOW01E HS Patented
DMOW01E SN PMID26413912-Compound-67
DMOW01E CP MERCK SHARP & DOHME CORP. WALJI, Abbas, M. NANTERMET, Philippe, G. MOORE, Keith, P. STORR, Rachel Anne VASSALLO, Laura KREATSOULAS, Constantine
DMOW01E DT Small molecular drug
DM36QM5 ID DM36QM5
DM36QM5 DN Azole derivative 5
DM36QM5 HS Patented
DM36QM5 SN PMID26413912-Compound-68
DM36QM5 CP MERCK SHARP &amDOHME CORP. LIU, Ping DEVITA, Robert, J. LIN, Linus, S. CHIODA, Marc, D. HAMILL, Terence, G. LI, Wenping
DM36QM5 DT Small molecular drug
DMTMJ7S ID DMTMJ7S
DMTMJ7S DN Azole derivative 6
DMTMJ7S HS Patented
DMTMJ7S SN PMID25470667-Compound-Figure5-10
DMTMJ7S CP MERCK SHARP &amDOHME CORP. DEVITA, Robert, J. YU, Yang LIU, Jian HE, Shuwen KRIKORIAN, Arto, D. MILLER, Daniel, J. WU, Zhicai YANG, Ginger Xu-Qiang HONG, Quingmei LAI, Zhong ZORN, Nicolas TING, Pauline, C
DMTMJ7S DT Small molecular drug
DMTMJ7S PC 71696715
DMTMJ7S MW 439.9
DMTMJ7S FM C23H19ClFN3O3
DMTMJ7S IC InChI=1S/C23H19ClFN3O3/c1-23(2,22(29)30)12-31-20-8-4-14(11-26-20)13-3-6-16(17(25)9-13)21-27-18-7-5-15(24)10-19(18)28-21/h3-11H,12H2,1-2H3,(H,27,28)(H,29,30)
DMTMJ7S CS CC(C)(COC1=NC=C(C=C1)C2=CC(=C(C=C2)C3=NC4=C(N3)C=C(C=C4)Cl)F)C(=O)O
DMTMJ7S IK VDSPJLXCWHECIK-UHFFFAOYSA-N
DMTMJ7S IU 3-[5-[4-(6-chloro-1H-benzimidazol-2-yl)-3-fluorophenyl]pyridin-2-yl]oxy-2,2-dimethylpropanoic acid
DMVUJGI ID DMVUJGI
DMVUJGI DN Azole derivative 7
DMVUJGI HS Patented
DMVUJGI SN PMID25470667-Compound-Figure5-9
DMVUJGI CP MERCK SHARP &amDOHME CORP. DEVITA, Robert, J. HE, Shuwen LIU, Jian CERNAK, Timothy, A. KRIKORIAN, Arto, D. YANG, Ginger XuQiang WU, Zhicai YU, Yang SHEN, Dong-Ming LAI, Zhong HONG, Qingmei NARGUND, Ravi, P
DMVUJGI DT Small molecular drug
DMVUJGI PC 71585251
DMVUJGI MW 456.5
DMVUJGI FM C27H25FN4O2
DMVUJGI IC InChI=1S/C27H25FN4O2/c28-23-3-1-2-21(15-23)26-30-27(32-31-26)22-12-13-24(29-16-22)20-10-8-19(9-11-20)18-6-4-17(5-7-18)14-25(33)34/h1-3,8-13,15-18H,4-7,14H2,(H,33,34)(H,30,31,32)
DMVUJGI CS C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)C4=NNC(=N4)C5=CC(=CC=C5)F
DMVUJGI IK IMVHPASOWCDZEL-UHFFFAOYSA-N
DMVUJGI IU 2-[4-[4-[5-[5-(3-fluorophenyl)-1H-1,2,4-triazol-3-yl]pyridin-2-yl]phenyl]cyclohexyl]acetic acid
DM2DT6L ID DM2DT6L
DM2DT6L DN BB 0223767
DM2DT6L HS Patented
DM2DT6L SN 2-Hydroxy-5-(5-pyrimidinyl)benzaldehyde; 893737-59-2; 2-hydroxy-5-(pyrimidin-5-yl)benzaldehyde; SCHEMBL6639266; CHEMBL3639592; BDBM111246; ZINC16947735; AKOS004118729; BB 0223767; US8614253, 43-6
DM2DT6L DT Small molecular drug
DM2DT6L PC 20100145
DM2DT6L MW 200.19
DM2DT6L FM C11H8N2O2
DM2DT6L IC InChI=1S/C11H8N2O2/c14-6-9-3-8(1-2-11(9)15)10-4-12-7-13-5-10/h1-7,15H
DM2DT6L CS C1=CC(=C(C=C1C2=CN=CN=C2)C=O)O
DM2DT6L IK HPQAHGRGPPOWML-UHFFFAOYSA-N
DM2DT6L IU 2-hydroxy-5-pyrimidin-5-ylbenzaldehyde
DMTWIE2 ID DMTWIE2
DMTWIE2 DN BC11-28
DMTWIE2 HS Patented
DMTWIE2 SN BDBM86641; 7-(4-fluorophenyl)-N-(2-methylphenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; AC1MM8WN; Oprea1_524381; CHEMBL2132713; SCHEMBL14998917; BDBM60812; HMS1911I05; ZINC2713985; STK859438; AKOS002104616; MCULE-7713625102; BC11-28; NCGC00138975-01; ST50069829; EU-0095146; US9173884, BC11-28; SR-01000567887; SR-01000567887-1; K405-0344; 7-(4-fluorophenyl)-N-(2-methylphenyl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine; [7-(4-fluorophenyl)-5-phenylpyrrolo[3,2-e]pyrimidin-4-yl](2-methylphenyl)amine
DMTWIE2 DT Small molecular drug
DMTWIE2 PC 3257208
DMTWIE2 MW 394.4
DMTWIE2 FM C25H19FN4
DMTWIE2 IC InChI=1S/C25H19FN4/c1-17-7-5-6-10-22(17)29-24-23-21(18-8-3-2-4-9-18)15-30(25(23)28-16-27-24)20-13-11-19(26)12-14-20/h2-16H,1H3,(H,27,28,29)
DMTWIE2 CS CC1=CC=CC=C1NC2=C3C(=CN(C3=NC=N2)C4=CC=C(C=C4)F)C5=CC=CC=C5
DMTWIE2 IK KCNWFXKVXRZIGO-UHFFFAOYSA-N
DMTWIE2 IU 7-(4-fluorophenyl)-N-(2-methylphenyl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine
DMZD6IJ ID DMZD6IJ
DMZD6IJ DN BDBM108945
DMZD6IJ HS Patented
DMZD6IJ SN SCHEMBL12780004; BDBM108945
DMZD6IJ DT Small molecular drug
DMZD6IJ PC 58170113
DMZD6IJ MW 405.5
DMZD6IJ FM C26H23N5
DMZD6IJ IC InChI=1S/C26H23N5/c1-2-4-25-23(3-1)22(11-14-28-25)24-16-30-31-17-21(15-29-26(24)31)19-7-5-18(6-8-19)20-9-12-27-13-10-20/h1-8,11,14-17,20,27H,9-10,12-13H2
DMZD6IJ CS C1CNCCC1C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
DMZD6IJ IK WTMROIBZVGJXRP-UHFFFAOYSA-N
DMZD6IJ IU 4-[6-(4-piperidin-4-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
DMW5SD6 ID DMW5SD6
DMW5SD6 DN BDBM50011552
DMW5SD6 HS Patented
DMW5SD6 SN CHEMBL3262571; SCHEMBL15587269; BDBM50011552
DMW5SD6 DT Small molecular drug
DMW5SD6 PC 90054621
DMW5SD6 MW 251.28
DMW5SD6 FM C15H13N3O
DMW5SD6 IC InChI=1S/C15H13N3O/c1-19-14-5-3-2-4-11(14)10-6-7-13-12(8-10)15(16)18-9-17-13/h2-9H,1H3,(H2,16,17,18)
DMW5SD6 CS COC1=CC=CC=C1C2=CC3=C(C=C2)N=CN=C3N
DMW5SD6 IK CUSAKFRCIPMPMS-UHFFFAOYSA-N
DMW5SD6 IU 6-(2-methoxyphenyl)quinazolin-4-amine
DMHNYQU ID DMHNYQU
DMHNYQU DN BDBM50011553
DMHNYQU HS Patented
DMHNYQU SN CHEMBL3262572; SCHEMBL15587284; BDBM50011553
DMHNYQU DT Small molecular drug
DMHNYQU PC 90054634
DMHNYQU MW 251.28
DMHNYQU FM C15H13N3O
DMHNYQU IC InChI=1S/C15H13N3O/c1-19-12-4-2-3-10(7-12)11-5-6-14-13(8-11)15(16)18-9-17-14/h2-9H,1H3,(H2,16,17,18)
DMHNYQU CS COC1=CC=CC(=C1)C2=CC3=C(C=C2)N=CN=C3N
DMHNYQU IK HAFNABUNLVCDOP-UHFFFAOYSA-N
DMHNYQU IU 6-(3-methoxyphenyl)quinazolin-4-amine
DMA7JB6 ID DMA7JB6
DMA7JB6 DN BDBM50054344
DMA7JB6 HS Patented
DMA7JB6 SN CHEMBL3319356; SCHEMBL16375396; BDBM50054344
DMA7JB6 DT Small molecular drug
DMA7JB6 PC 86298439
DMA7JB6 MW 637.4
DMA7JB6 FM C28H20IN3O5S
DMA7JB6 IC InChI=1S/C28H20IN3O5S/c1-32-22-13-23(33)21(28(36)37)12-20(22)24(29)25(32)16-3-2-4-19(11-16)31-27(35)26(34)30-18-7-5-15(6-8-18)17-9-10-38-14-17/h2-14,33H,1H3,(H,30,34)(H,31,35)(H,36,37)
DMA7JB6 CS CN1C2=CC(=C(C=C2C(=C1C3=CC(=CC=C3)NC(=O)C(=O)NC4=CC=C(C=C4)C5=CSC=C5)I)C(=O)O)O
DMA7JB6 IK WILZWITYAQZYKV-UHFFFAOYSA-N
DMA7JB6 IU 6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid
DMQ4TUE ID DMQ4TUE
DMQ4TUE DN BDBM50061601
DMQ4TUE HS Patented
DMQ4TUE SN CHEMBL3394073; SCHEMBL12696208; BDBM50061601
DMQ4TUE DT Small molecular drug
DMQ4TUE PC 68356857
DMQ4TUE MW 379.4
DMQ4TUE FM C18H17N7OS
DMQ4TUE IC InChI=1S/C18H17N7OS/c19-18-24-23-17(27-18)11-1-2-14-12(7-11)13(8-21-14)15-9-20-10-16(22-15)25-3-5-26-6-4-25/h1-2,7-10,21H,3-6H2,(H2,19,24)
DMQ4TUE CS C1COCCN1C2=NC(=CN=C2)C3=CNC4=C3C=C(C=C4)C5=NN=C(S5)N
DMQ4TUE IK JHCXRIDGVGVKMB-UHFFFAOYSA-N
DMQ4TUE IU 5-[3-(6-morpholin-4-ylpyrazin-2-yl)-1H-indol-5-yl]-1,3,4-thiadiazol-2-amine
DM3MRD9 ID DM3MRD9
DM3MRD9 DN BDBM50061608
DM3MRD9 HS Patented
DM3MRD9 SN CHEMBL3394165; SCHEMBL12696206; BDBM50061608
DM3MRD9 DT Small molecular drug
DM3MRD9 PC 68356855
DM3MRD9 MW 391.5
DM3MRD9 FM C20H21N7S
DM3MRD9 IC InChI=1S/C20H21N7S/c21-20-27-26-19(28-20)12-6-7-16-14(8-12)15(9-23-16)17-10-22-11-18(25-17)24-13-4-2-1-3-5-13/h6-11,13,23H,1-5H2,(H2,21,27)(H,24,25)
DM3MRD9 CS C1CCC(CC1)NC2=NC(=CN=C2)C3=CNC4=C3C=C(C=C4)C5=NN=C(S5)N
DM3MRD9 IK NZRCHCMMQGWKLZ-UHFFFAOYSA-N
DM3MRD9 IU 5-[3-[6-(cyclohexylamino)pyrazin-2-yl]-1H-indol-5-yl]-1,3,4-thiadiazol-2-amine
DMM8IDC ID DMM8IDC
DMM8IDC DN BDBM50061612
DMM8IDC HS Patented
DMM8IDC SN CHEMBL3394168; SCHEMBL12614651; BDBM50061612
DMM8IDC DT Small molecular drug
DMM8IDC PC 68327881
DMM8IDC MW 377.5
DMM8IDC FM C20H19N5OS
DMM8IDC IC InChI=1S/C20H19N5OS/c21-20-25-24-19(27-20)12-8-9-16-14(10-12)15(11-22-16)17-6-3-7-18(23-17)26-13-4-1-2-5-13/h3,6-11,13,22H,1-2,4-5H2,(H2,21,25)
DMM8IDC CS C1CCC(C1)OC2=CC=CC(=N2)C3=CNC4=C3C=C(C=C4)C5=NN=C(S5)N
DMM8IDC IK PNAYFCPGKVJMMN-UHFFFAOYSA-N
DMM8IDC IU 5-[3-(6-cyclopentyloxypyridin-2-yl)-1H-indol-5-yl]-1,3,4-thiadiazol-2-amine
DM4I829 ID DM4I829
DM4I829 DN BDBM50080408
DM4I829 HS Patented
DM4I829 SN BDBM50080408
DM4I829 DT Small molecular drug
DM4I829 PC 118988040
DM4I829 MW 579.4
DM4I829 FM C23H23Cl2F3N4O4S
DM4I829 IC InChI=1S/C23H23Cl2F3N4O4S/c1-2-37(35,36)18-4-3-14(24)9-13(18)11-32-21(33)15-10-17(23(26,27)28)16(12-31-7-5-29-6-8-31)19(25)20(15)30-22(32)34/h3-4,9-10,19,29H,2,5-8,11-12H2,1H3
DM4I829 CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(C3=NC2=O)Cl)CN4CCNCC4)C(F)(F)F
DM4I829 IK MFENBMQVIBVYSX-UHFFFAOYSA-N
DM4I829 IU 8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-7-(piperazin-1-ylmethyl)-6-(trifluoromethyl)-8H-quinazoline-2,4-dione
DMJNOB9 ID DMJNOB9
DMJNOB9 DN BDBM50080559
DMJNOB9 HS Patented
DMJNOB9 SN CHEMBL3126433; SCHEMBL16055655; BDBM50080559
DMJNOB9 DT Small molecular drug
DMJNOB9 PC 76325522
DMJNOB9 MW 480.6
DMJNOB9 FM C26H32N4O5
DMJNOB9 IC InChI=1S/C26H32N4O5/c1-3-17-11-20(10-16(2)24(17)34-15-21(32)13-28-23(33)14-31)25-29-26(35-30-25)19-8-9-27-22(12-19)18-6-4-5-7-18/h8-12,18,21,31-32H,3-7,13-15H2,1-2H3,(H,28,33)/t21-/m0/s1
DMJNOB9 CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC=C3)C4CCCC4)C)OC[C@H](CNC(=O)CO)O
DMJNOB9 IK XRJPXSNXMMSPIZ-NRFANRHFSA-N
DMJNOB9 IU N-[(2S)-3-[4-[5-(2-cyclopentylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide
DM3VNK0 ID DM3VNK0
DM3VNK0 DN BDBM50080563
DM3VNK0 HS Patented
DM3VNK0 SN CHEMBL3422425; SCHEMBL16055775; BDBM50080563
DM3VNK0 DT Small molecular drug
DM3VNK0 PC 86299710
DM3VNK0 MW 482.6
DM3VNK0 FM C26H34N4O5
DM3VNK0 IC InChI=1S/C26H34N4O5/c1-5-18-11-20(10-17(4)24(18)34-15-22(32)13-28-23(33)14-31)25-29-26(35-30-25)19-8-9-27-21(12-19)7-6-16(2)3/h8-12,16,22,31-32H,5-7,13-15H2,1-4H3,(H,28,33)/t22-/m0/s1
DM3VNK0 CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC=C3)CCC(C)C)C)OC[C@H](CNC(=O)CO)O
DM3VNK0 IK PFJWQQDDQKRIRR-QFIPXVFZSA-N
DM3VNK0 IU N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[2-(3-methylbutyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide
DMLJU5P ID DMLJU5P
DMLJU5P DN BDBM50080570
DMLJU5P HS Patented
DMLJU5P SN CHEMBL3126605; SCHEMBL16055394; BDBM50080570
DMLJU5P DT Small molecular drug
DMLJU5P PC 76325532
DMLJU5P MW 468.5
DMLJU5P FM C25H32N4O5
DMLJU5P IC InChI=1S/C25H32N4O5/c1-5-17-10-19(9-16(4)23(17)33-14-21(31)12-27-22(32)13-30)24-28-25(34-29-24)18-6-7-26-20(11-18)8-15(2)3/h6-7,9-11,15,21,30-31H,5,8,12-14H2,1-4H3,(H,27,32)/t21-/m0/s1
DMLJU5P CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC=C3)CC(C)C)C)OC[C@H](CNC(=O)CO)O
DMLJU5P IK FIZLCOHGMMUGTO-NRFANRHFSA-N
DMLJU5P IU N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[2-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide
DMS7ZLK ID DMS7ZLK
DMS7ZLK DN BDBM50158703
DMS7ZLK HS Patented
DMS7ZLK SN CHEMBL3785832; SCHEMBL15777940; BDBM50158703
DMS7ZLK DT Small molecular drug
DMS7ZLK PC 90204862
DMS7ZLK MW 329.74
DMS7ZLK FM C16H12ClN3O3
DMS7ZLK IC InChI=1S/C16H12ClN3O3/c17-13-3-1-11(2-4-13)10-23-15-6-8-19-20(15)14-9-12(16(21)22)5-7-18-14/h1-9H,10H2,(H,21,22)
DMS7ZLK CS C1=CC(=CC=C1COC2=CC=NN2C3=NC=CC(=C3)C(=O)O)Cl
DMS7ZLK IK SMXDPQZYSIFABV-UHFFFAOYSA-N
DMS7ZLK IU 2-[5-[(4-chlorophenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylic acid
DMYJF70 ID DMYJF70
DMYJF70 DN BDBM50158755
DMYJF70 HS Patented
DMYJF70 SN CHEMBL3786579; SCHEMBL15778210; BDBM50158755
DMYJF70 DT Small molecular drug
DMYJF70 PC 90205053
DMYJF70 MW 357.3
DMYJF70 FM C18H16FN3O4
DMYJF70 IC InChI=1S/C18H16FN3O4/c19-15-3-1-12(2-4-15)11-26-17-14(6-8-23)10-21-22(17)16-9-13(18(24)25)5-7-20-16/h1-5,7,9-10,23H,6,8,11H2,(H,24,25)
DMYJF70 CS C1=CC(=CC=C1COC2=C(C=NN2C3=NC=CC(=C3)C(=O)O)CCO)F
DMYJF70 IK MAYCQAAYKTWJKJ-UHFFFAOYSA-N
DMYJF70 IU 2-[5-[(4-fluorophenyl)methoxy]-4-(2-hydroxyethyl)pyrazol-1-yl]pyridine-4-carboxylic acid
DMU07MO ID DMU07MO
DMU07MO DN BDBM50158791
DMU07MO HS Patented
DMU07MO SN CHEMBL3786596; SCHEMBL15818867; SCHEMBL19646964; BDBM50158791
DMU07MO DT Small molecular drug
DMU07MO PC 77106319
DMU07MO MW 286.37
DMU07MO FM C17H22N2O2
DMU07MO IC InChI=1S/C17H22N2O2/c20-16(21)14-1-2-18-9-15(14)19-10-17-6-11-3-12(7-17)5-13(4-11)8-17/h1-2,9,11-13,19H,3-8,10H2,(H,20,21)
DMU07MO CS C1C2CC3CC1CC(C2)(C3)CNC4=C(C=CN=C4)C(=O)O
DMU07MO IK TUXVCHDESZTZON-UHFFFAOYSA-N
DMU07MO IU 3-(1-adamantylmethylamino)pyridine-4-carboxylic acid
DMWJZU9 ID DMWJZU9
DMWJZU9 DN BDBM50158794
DMWJZU9 HS Patented
DMWJZU9 SN CHEMBL3785470; SCHEMBL15792416; BDBM50158794
DMWJZU9 DT Small molecular drug
DMWJZU9 PC 76282772
DMWJZU9 MW 340.4
DMWJZU9 FM C18H17FN4O2
DMWJZU9 IC InChI=1S/C18H17FN4O2/c19-11-5-6-16-14(9-11)17(22-23(16)12-3-1-2-4-12)21-15-10-20-8-7-13(15)18(24)25/h5-10,12H,1-4H2,(H,21,22)(H,24,25)
DMWJZU9 CS C1CCC(C1)N2C3=C(C=C(C=C3)F)C(=N2)NC4=C(C=CN=C4)C(=O)O
DMWJZU9 IK LJHFNRZRNINLGH-UHFFFAOYSA-N
DMWJZU9 IU 3-[(1-cyclopentyl-5-fluoroindazol-3-yl)amino]pyridine-4-carboxylic acid
DMTWI1H ID DMTWI1H
DMTWI1H DN BDBM50158803
DMTWI1H HS Patented
DMTWI1H SN CHEMBL3787438; SCHEMBL15792889; BDBM50158803
DMTWI1H DT Small molecular drug
DMTWI1H PC 90216982
DMTWI1H MW 352.4
DMTWI1H FM C18H17FN6O
DMTWI1H IC InChI=1S/C18H17FN6O/c1-11(2)9-25-16-4-3-12(19)7-14(16)17(24-25)23-15-8-21-6-5-13(15)18(26)22-10-20/h3-8,11H,9H2,1-2H3,(H,22,26)(H,23,24)
DMTWI1H CS CC(C)CN1C2=C(C=C(C=C2)F)C(=N1)NC3=C(C=CN=C3)C(=O)NC#N
DMTWI1H IK HHHITATYTCPWBZ-UHFFFAOYSA-N
DMTWI1H IU N-cyano-3-[[5-fluoro-1-(2-methylpropyl)indazol-3-yl]amino]pyridine-4-carboxamide
DMSTD28 ID DMSTD28
DMSTD28 DN BDBM50173306
DMSTD28 HS Patented
DMSTD28 SN CHEMBL3808565; SCHEMBL17525405; BDBM50173306
DMSTD28 DT Small molecular drug
DMSTD28 PC 118888923
DMSTD28 MW 513.5
DMSTD28 FM C27H24FN7O3
DMSTD28 IC InChI=1S/C27H24FN7O3/c1-15-23(26(37)33-19-3-5-22-18(12-19)14-31-35-22)24(34-27(38)32-15)17-2-4-21(28)20(13-17)25(36)30-11-8-16-6-9-29-10-7-16/h2-7,9-10,12-14,24H,8,11H2,1H3,(H,30,36)(H,31,35)(H,33,37)(H2,32,34,38)
DMSTD28 CS CC1=C(C(NC(=O)N1)C2=CC(=C(C=C2)F)C(=O)NCCC3=CC=NC=C3)C(=O)NC4=CC5=C(C=C4)NN=C5
DMSTD28 IK GJTSGDBPSODHKH-UHFFFAOYSA-N
DMSTD28 IU 4-[4-fluoro-3-(2-pyridin-4-ylethylcarbamoyl)phenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide
DM7RTQP ID DM7RTQP
DM7RTQP DN BDBM50173323
DM7RTQP HS Patented
DM7RTQP SN CHEMBL3808621; SCHEMBL17525424; BDBM50173323
DM7RTQP DT Small molecular drug
DM7RTQP PC 118888942
DM7RTQP MW 534.5
DM7RTQP FM C27H21F3N6O3
DM7RTQP IC InChI=1S/C27H21F3N6O3/c1-13-23(26(38)34-16-6-8-22-15(9-16)11-32-36-22)24(35-27(39)33-13)14-5-7-21(30)17(10-14)25(37)31-12-18-19(28)3-2-4-20(18)29/h2-11,24H,12H2,1H3,(H,31,37)(H,32,36)(H,34,38)(H2,33,35,39)
DM7RTQP CS CC1=C(C(NC(=O)N1)C2=CC(=C(C=C2)F)C(=O)NCC3=C(C=CC=C3F)F)C(=O)NC4=CC5=C(C=C4)NN=C5
DM7RTQP IK YJQKIQOVJOGHMP-UHFFFAOYSA-N
DM7RTQP IU 4-[3-[(2,6-difluorophenyl)methylcarbamoyl]-4-fluorophenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide
DMKEVDL ID DMKEVDL
DMKEVDL DN BDBM50173327
DMKEVDL HS Patented
DMKEVDL SN CHEMBL3808499; SCHEMBL17525395; BDBM50173327
DMKEVDL DT Small molecular drug
DMKEVDL PC 118888913
DMKEVDL MW 540.6
DMKEVDL FM C30H29FN6O3
DMKEVDL IC InChI=1S/C30H29FN6O3/c1-16-5-4-6-17(2)23(16)15-32-26(38)13-20-11-19(7-9-24(20)31)28-27(18(3)34-30(40)36-28)29(39)35-22-8-10-25-21(12-22)14-33-37-25/h4-12,14,28H,13,15H2,1-3H3,(H,32,38)(H,33,37)(H,35,39)(H2,34,36,40)
DMKEVDL CS CC1=C(C(=CC=C1)C)CNC(=O)CC2=C(C=CC(=C2)C3C(=C(NC(=O)N3)C)C(=O)NC4=CC5=C(C=C4)NN=C5)F
DMKEVDL IK IDOAXNXBZZZOFX-UHFFFAOYSA-N
DMKEVDL IU 4-[3-[2-[(2,6-dimethylphenyl)methylamino]-2-oxoethyl]-4-fluorophenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide
DM1PU37 ID DM1PU37
DM1PU37 DN BDBM50173330
DM1PU37 HS Patented
DM1PU37 SN CHEMBL3808657; SCHEMBL17525387; BDBM50173330
DM1PU37 DT Small molecular drug
DM1PU37 PC 118888905
DM1PU37 MW 634.5
DM1PU37 FM C29H21F7N6O3
DM1PU37 IC InChI=1S/C29H21F7N6O3/c1-13-23(26(44)40-19-3-5-22-16(8-19)12-38-42-22)24(41-27(45)39-13)15-2-4-21(30)20(9-15)25(43)37-11-14-6-17(28(31,32)33)10-18(7-14)29(34,35)36/h2-10,12,24H,11H2,1H3,(H,37,43)(H,38,42)(H,40,44)(H2,39,41,45)
DM1PU37 CS CC1=C(C(NC(=O)N1)C2=CC(=C(C=C2)F)C(=O)NCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)NC4=CC5=C(C=C4)NN=C5
DM1PU37 IK VUCAOBMPSJTWFL-UHFFFAOYSA-N
DM1PU37 IU 4-[3-[[3,5-bis(trifluoromethyl)phenyl]methylcarbamoyl]-4-fluorophenyl]-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide
DM52IQF ID DM52IQF
DM52IQF DN BDBM50177012
DM52IQF HS Patented
DM52IQF SN CHEMBL3814153; SCHEMBL17519222; BDBM50177012
DM52IQF DT Small molecular drug
DM52IQF PC 118883427
DM52IQF MW 446.5
DM52IQF FM C19H22F4N4O2S
DM52IQF IC InChI=1S/C19H22F4N4O2S/c1-12(2)15-11-26(13-4-5-14(20)16(10-13)30(3,28)29)8-9-27(15)18-24-7-6-17(25-18)19(21,22)23/h4-7,10,12,15H,8-9,11H2,1-3H3/t15-/m0/s1
DM52IQF CS CC(C)[C@@H]1CN(CCN1C2=NC=CC(=N2)C(F)(F)F)C3=CC(=C(C=C3)F)S(=O)(=O)C
DM52IQF IK YTEDTWJJQBCOTI-HNNXBMFYSA-N
DM52IQF IU 2-[(2R)-4-(4-fluoro-3-methylsulfonylphenyl)-2-propan-2-ylpiperazin-1-yl]-4-(trifluoromethyl)pyrimidine
DMEL28G ID DMEL28G
DMEL28G DN BDBM50177019
DMEL28G HS Patented
DMEL28G SN CHEMBL3813863; SCHEMBL17519302; BDBM50177019
DMEL28G DT Small molecular drug
DMEL28G PC 118883505
DMEL28G MW 488.5
DMEL28G FM C21H27F3N4O4S
DMEL28G IC InChI=1S/C21H27F3N4O4S/c1-13(2)17-10-27(16-5-4-14(11-29)18(8-16)33(3,31)32)6-7-28(17)20-25-9-15(12-30)19(26-20)21(22,23)24/h4-5,8-9,13,17,29-30H,6-7,10-12H2,1-3H3/t17-/m1/s1
DMEL28G CS CC(C)[C@H]1CN(CCN1C2=NC=C(C(=N2)C(F)(F)F)CO)C3=CC(=C(C=C3)CO)S(=O)(=O)C
DMEL28G IK FPVIRRAMNBCEDK-QGZVFWFLSA-N
DMEL28G IU [4-[(3S)-4-[5-(hydroxymethyl)-4-(trifluoromethyl)pyrimidin-2-yl]-3-propan-2-ylpiperazin-1-yl]-2-methylsulfonylphenyl]methanol
DM7TASJ ID DM7TASJ
DM7TASJ DN BDBM50363773
DM7TASJ HS Patented
DM7TASJ SN CHEMBL1945137; CHEMBL1962885; BDBM50363773
DM7TASJ DT Small molecular drug
DM7TASJ PC 49847196
DM7TASJ MW 440.6
DM7TASJ FM C24H32N4O2S
DM7TASJ IC InChI=1S/C24H32N4O2S/c1-17(2)18-8-10-19(11-9-18)23(30)27-24(31)26-21-14-12-20(13-15-21)25-22(29)7-5-6-16-28(3)4/h8-15,17H,5-7,16H2,1-4H3,(H,25,29)(H2,26,27,30,31)
DM7TASJ CS CC(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C
DM7TASJ IK UTQHGPPEEJLEOE-UHFFFAOYSA-N
DM7TASJ IU N-[[4-[5-(dimethylamino)pentanoylamino]phenyl]carbamothioyl]-4-propan-2-ylbenzamide
DM46UPM ID DM46UPM
DM46UPM DN BDBM50363780
DM46UPM HS Patented
DM46UPM SN CHEMBL1945260; CHEMBL1962973; BDBM50363780
DM46UPM DT Small molecular drug
DM46UPM PC 49847188
DM46UPM MW 477.4
DM46UPM FM C21H25BrN4O2S
DM46UPM IC InChI=1S/C21H25BrN4O2S/c1-26(2)14-4-3-5-19(27)23-17-10-12-18(13-11-17)24-21(29)25-20(28)15-6-8-16(22)9-7-15/h6-13H,3-5,14H2,1-2H3,(H,23,27)(H2,24,25,28,29)
DM46UPM CS CN(C)CCCCC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC=C(C=C2)Br
DM46UPM IK NWWFPYSNQAXIIL-UHFFFAOYSA-N
DM46UPM IU 4-bromo-N-[[4-[5-(dimethylamino)pentanoylamino]phenyl]carbamothioyl]benzamide
DMUQI15 ID DMUQI15
DMUQI15 DN BDBM50363782
DMUQI15 HS Patented
DMUQI15 SN CHEMBL1945264; CHEMBL1962780; BDBM50363782
DMUQI15 DT Small molecular drug
DMUQI15 PC 49847118
DMUQI15 MW 477.4
DMUQI15 FM C21H25BrN4O2S
DMUQI15 IC InChI=1S/C21H25BrN4O2S/c1-26(2)13-4-3-8-19(27)23-17-9-11-18(12-10-17)24-21(29)25-20(28)15-6-5-7-16(22)14-15/h5-7,9-12,14H,3-4,8,13H2,1-2H3,(H,23,27)(H2,24,25,28,29)
DMUQI15 CS CN(C)CCCCC(=O)NC1=CC=C(C=C1)NC(=S)NC(=O)C2=CC(=CC=C2)Br
DMUQI15 IK UZNNTHWEMCFBAY-UHFFFAOYSA-N
DMUQI15 IU 3-bromo-N-[[4-[5-(dimethylamino)pentanoylamino]phenyl]carbamothioyl]benzamide
DMPOVZ6 ID DMPOVZ6
DMPOVZ6 DN BDBM50379214
DMPOVZ6 HS Patented
DMPOVZ6 SN CHEMBL2011291; SCHEMBL14839289; BDBM50379214
DMPOVZ6 DT Small molecular drug
DMPOVZ6 PC 56924694
DMPOVZ6 MW 433.7
DMPOVZ6 FM C20H12Cl3FN4
DMPOVZ6 IC InChI=1S/C20H12Cl3FN4/c21-13-9-15(22)19(16(23)10-13)28-20(25)17(11-1-3-14(24)4-2-11)18(27-28)12-5-7-26-8-6-12/h1-10H,25H2
DMPOVZ6 CS C1=CC(=CC=C1C2=C(N(N=C2C3=CC=NC=C3)C4=C(C=C(C=C4Cl)Cl)Cl)N)F
DMPOVZ6 IK MOHYPRXHKRXDSE-UHFFFAOYSA-N
DMPOVZ6 IU 4-(4-fluorophenyl)-5-pyridin-4-yl-2-(2,4,6-trichlorophenyl)pyrazol-3-amine
DMQJ5S8 ID DMQJ5S8
DMQJ5S8 DN BDBM50382283
DMQJ5S8 HS Patented
DMQJ5S8 SN CHEMBL2022530; SCHEMBL15138748; BDBM50382283
DMQJ5S8 DT Small molecular drug
DMQJ5S8 PC 66561557
DMQJ5S8 MW 343.3
DMQJ5S8 FM C18H15F2N3O2
DMQJ5S8 IC InChI=1S/C18H15F2N3O2/c19-18(20)8-13(9-21)23(11-18)16(24)10-22-17(25)15-7-3-5-12-4-1-2-6-14(12)15/h1-7,13H,8,10-11H2,(H,22,25)/t13-/m0/s1
DMQJ5S8 CS C1[C@H](N(CC1(F)F)C(=O)CNC(=O)C2=CC=CC3=CC=CC=C32)C#N
DMQJ5S8 IK YJNMDFARAFJSEZ-ZDUSSCGKSA-N
DMQJ5S8 IU N-[2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]naphthalene-1-carboxamide
DM6DFTX ID DM6DFTX
DM6DFTX DN BDBM50434164
DM6DFTX HS Patented
DM6DFTX SN CHEMBL2385272; SCHEMBL15129855; BDBM50434164
DM6DFTX DT Small molecular drug
DM6DFTX PC 73356493
DM6DFTX MW 342.8
DM6DFTX FM C17H15ClN4O2
DM6DFTX IC InChI=1S/C17H15ClN4O2/c18-11-3-4-13-14(5-6-20-15(13)8-11)17(24)21-10-16(23)22-7-1-2-12(22)9-19/h3-6,8,12H,1-2,7,10H2,(H,21,24)/t12-/m0/s1
DM6DFTX CS C1C[C@H](N(C1)C(=O)CNC(=O)C2=C3C=CC(=CC3=NC=C2)Cl)C#N
DM6DFTX IK NERXNBIHCGOYFQ-LBPRGKRZSA-N
DM6DFTX IU 7-chloro-N-[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]quinoline-4-carboxamide
DMDTYJ9 ID DMDTYJ9
DMDTYJ9 DN BDBM50434165
DMDTYJ9 HS Patented
DMDTYJ9 SN CHEMBL2385271; SCHEMBL15129912; BDBM50434165
DMDTYJ9 DT Small molecular drug
DMDTYJ9 PC 71667377
DMDTYJ9 MW 338.4
DMDTYJ9 FM C18H18N4O3
DMDTYJ9 IC InChI=1S/C18H18N4O3/c1-25-13-4-5-16-15(9-13)14(6-7-20-16)18(24)21-11-17(23)22-8-2-3-12(22)10-19/h4-7,9,12H,2-3,8,11H2,1H3,(H,21,24)/t12-/m0/s1
DMDTYJ9 CS COC1=CC2=C(C=CN=C2C=C1)C(=O)NCC(=O)N3CCC[C@H]3C#N
DMDTYJ9 IK YPWQFVMQCFSLCP-LBPRGKRZSA-N
DMDTYJ9 IU N-[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]-6-methoxyquinoline-4-carboxamide
DM9GLQB ID DM9GLQB
DM9GLQB DN BDBM50444058
DM9GLQB HS Patented
DM9GLQB SN CHEMBL3092769; SCHEMBL16435582; BDBM50444058
DM9GLQB DT Small molecular drug
DM9GLQB PC 72793043
DM9GLQB MW 315.4
DM9GLQB FM C17H25N5O
DM9GLQB IC InChI=1S/C17H25N5O/c1-2-3-9-20-17-21-13-14(15-8-4-5-10-18-15)16(22-17)19-11-6-7-12-23/h4-5,8,10,13,23H,2-3,6-7,9,11-12H2,1H3,(H2,19,20,21,22)
DM9GLQB CS CCCCNC1=NC=C(C(=N1)NCCCCO)C2=CC=CC=N2
DM9GLQB IK KKAICBOHJLVDCE-UHFFFAOYSA-N
DM9GLQB IU 4-[[2-(butylamino)-5-pyridin-2-ylpyrimidin-4-yl]amino]butan-1-ol
DMS0EMU ID DMS0EMU
DMS0EMU DN BDBM50444059
DMS0EMU HS Patented
DMS0EMU SN CHEMBL3092768; SCHEMBL16435583; BDBM50444059
DMS0EMU DT Small molecular drug
DMS0EMU PC 72793042
DMS0EMU MW 301.39
DMS0EMU FM C16H23N5O
DMS0EMU IC InChI=1S/C16H23N5O/c1-2-3-8-19-16-20-12-13(14-7-4-5-9-17-14)15(21-16)18-10-6-11-22/h4-5,7,9,12,22H,2-3,6,8,10-11H2,1H3,(H2,18,19,20,21)
DMS0EMU CS CCCCNC1=NC=C(C(=N1)NCCCO)C2=CC=CC=N2
DMS0EMU IK BQWLIDAUTKRGNB-UHFFFAOYSA-N
DMS0EMU IU 3-[[2-(butylamino)-5-pyridin-2-ylpyrimidin-4-yl]amino]propan-1-ol
DMR2UGC ID DMR2UGC
DMR2UGC DN BDBM50444062
DMR2UGC HS Patented
DMR2UGC SN CHEMBL3092765; SCHEMBL16438343; BDBM50444062
DMR2UGC DT Small molecular drug
DMR2UGC PC 72792975
DMR2UGC MW 340.5
DMR2UGC FM C19H28N6
DMR2UGC IC InChI=1S/C19H28N6/c1-2-3-9-22-19-24-14-16(17-6-4-5-10-21-17)18(25-19)23-13-15-7-11-20-12-8-15/h4-6,10,14-15,20H,2-3,7-9,11-13H2,1H3,(H2,22,23,24,25)
DMR2UGC CS CCCCNC1=NC=C(C(=N1)NCC2CCNCC2)C3=CC=CC=N3
DMR2UGC IK HVIDXJFXDHKCMO-UHFFFAOYSA-N
DMR2UGC IU 2-N-butyl-4-N-(piperidin-4-ylmethyl)-5-pyridin-2-ylpyrimidine-2,4-diamine
DMDOCTB ID DMDOCTB
DMDOCTB DN Benzamide derivative 1
DMDOCTB HS Patented
DMDOCTB SN PMID28051882-Compound-18
DMDOCTB CP Washington University
DMDOCTB DT Small molecular drug
DMDOCTB PC 9543532
DMDOCTB MW 503.4
DMDOCTB FM C24H31BrN2O5
DMDOCTB IC InChI=1S/C24H31BrN2O5/c1-29-20-11-16-7-10-27(15-17(16)12-21(20)30-2)9-6-5-8-26-24(28)19-13-18(25)14-22(31-3)23(19)32-4/h11-14H,5-10,15H2,1-4H3,(H,26,28)/i25-4
DMDOCTB CS COC1=CC(=CC(=C1OC)C(=O)NCCCCN2CCC3=CC(=C(C=C3C2)OC)OC)[76Br]
DMDOCTB IK UNYNHWPKQAKANT-VEFBWTBNSA-N
DMDOCTB IU 5-(76Br)bromanyl-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2,3-dimethoxybenzamide
DM9PKU2 ID DM9PKU2
DM9PKU2 DN Benzamide derivative 10
DM9PKU2 HS Patented
DM9PKU2 SN PMID30185082-Compound-61
DM9PKU2 CP UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DM9PKU2 DT Small molecular drug
DM4V3Y5 ID DM4V3Y5
DM4V3Y5 DN Benzamide derivative 11
DM4V3Y5 HS Patented
DM4V3Y5 SN PMID30185082-Compound-62
DM4V3Y5 CP UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DM4V3Y5 DT Small molecular drug
DM4V3Y5 PC 41306362
DM4V3Y5 MW 316.8
DM4V3Y5 FM C18H21ClN2O
DM4V3Y5 IC InChI=1S/C18H21ClN2O/c1-21(14-15-6-3-2-4-7-15)13-5-12-20-18(22)16-8-10-17(19)11-9-16/h2-4,6-11H,5,12-14H2,1H3,(H,20,22)
DM4V3Y5 CS CN(CCCNC(=O)C1=CC=C(C=C1)Cl)CC2=CC=CC=C2
DM4V3Y5 IK TVEZSZAKGLHZOD-UHFFFAOYSA-N
DM4V3Y5 IU N-[3-[benzyl(methyl)amino]propyl]-4-chlorobenzamide
DMS527F ID DMS527F
DMS527F DN Benzamide derivative 12
DMS527F HS Patented
DMS527F SN PMID27724045-Compound-18
DMS527F CP ACTELION PHARMACEUTICALS LTD HILPERT, Kurt HUBLER, Francis MURPHY, Mark RENNEBERG, Dorte
DMS527F DT Small molecular drug
DMS527F PC 60152975
DMS527F MW 393.9
DMS527F FM C18H20ClN3O3S
DMS527F IC InChI=1S/C18H20ClN3O3S/c19-14-5-4-12(26-15-6-9-20-17(24)22-15)10-13(14)16(23)21-11-18(25)7-2-1-3-8-18/h4-6,9-10,25H,1-3,7-8,11H2,(H,21,23)(H,20,22,24)
DMS527F CS C1CCC(CC1)(CNC(=O)C2=C(C=CC(=C2)SC3=CC=NC(=O)N3)Cl)O
DMS527F IK VFMSFNBMUAXYTM-UHFFFAOYSA-N
DMS527F IU 2-chloro-N-[(1-hydroxycyclohexyl)methyl]-5-[(2-oxo-1H-pyrimidin-6-yl)sulfanyl]benzamide
DMYSH9J ID DMYSH9J
DMYSH9J DN Benzamide derivative 13
DMYSH9J HS Patented
DMYSH9J SN PMID27724045-Compound-34
DMYSH9J CP Pfizer Product Inc
DMYSH9J DT Small molecular drug
DMYSH9J PC 21093787
DMYSH9J MW 439.7
DMYSH9J FM C18H13Cl3N4O3
DMYSH9J IC InChI=1S/C18H13Cl3N4O3/c19-13-4-2-11(25-18(28)24-16(26)9-23-25)8-12(13)17(27)22-6-5-10-1-3-14(20)15(21)7-10/h1-4,7-9H,5-6H2,(H,22,27)(H,24,26,28)
DMYSH9J CS C1=CC(=C(C=C1CCNC(=O)C2=C(C=CC(=C2)N3C(=O)NC(=O)C=N3)Cl)Cl)Cl
DMYSH9J IK VLOHQHGTVRQRSC-UHFFFAOYSA-N
DMYSH9J IU 2-chloro-N-[2-(3,4-dichlorophenyl)ethyl]-5-(3,5-dioxo-1,2,4-triazin-2-yl)benzamide
DMP2LDC ID DMP2LDC
DMP2LDC DN Benzamide derivative 14
DMP2LDC HS Patented
DMP2LDC SN PMID28627961-Compound-17
DMP2LDC CP NOVASAID AB WANNBERG, Johan ALTERMAN, Mathias STENBERG, Patric WESTMAN, Jacob
DMP2LDC DT Small molecular drug
DMP2LDC PC 44206332
DMP2LDC MW 482.4
DMP2LDC FM C23H16F6N2O3
DMP2LDC IC InChI=1S/C23H16F6N2O3/c24-22(25,26)18-10-3-2-9-17(18)21(33)31-16-8-5-7-14(12-16)20(32)30-13-15-6-1-4-11-19(15)34-23(27,28)29/h1-12H,13H2,(H,30,32)(H,31,33)
DMP2LDC CS C1=CC=C(C(=C1)CNC(=O)C2=CC(=CC=C2)NC(=O)C3=CC=CC=C3C(F)(F)F)OC(F)(F)F
DMP2LDC IK BLXNFXQRCFAJKN-UHFFFAOYSA-N
DMP2LDC IU N-[3-[[2-(trifluoromethoxy)phenyl]methylcarbamoyl]phenyl]-2-(trifluoromethyl)benzamide
DMAEBJ4 ID DMAEBJ4
DMAEBJ4 DN Benzamide derivative 15
DMAEBJ4 HS Patented
DMAEBJ4 SN PMID28627961-Compound-18
DMAEBJ4 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk ROENN, Robert PELCMAN, Benjamin
DMAEBJ4 DT Small molecular drug
DMAEBJ4 PC 52919085
DMAEBJ4 MW 577.3
DMAEBJ4 FM C26H24BrCl2N3O3
DMAEBJ4 IC InChI=1S/C26H24BrCl2N3O3/c1-26(2,3)25(35)30-14-15-4-10-21(28)19(12-15)23(33)32-18-9-11-22(29)20(13-18)24(34)31-17-7-5-16(27)6-8-17/h4-13H,14H2,1-3H3,(H,30,35)(H,31,34)(H,32,33)
DMAEBJ4 CS CC(C)(C)C(=O)NCC1=CC(=C(C=C1)Cl)C(=O)NC2=CC(=C(C=C2)Cl)C(=O)NC3=CC=C(C=C3)Br
DMAEBJ4 IK YFQGXIHVHCEKFN-UHFFFAOYSA-N
DMAEBJ4 IU N-[3-[(4-bromophenyl)carbamoyl]-4-chlorophenyl]-2-chloro-5-[(2,2-dimethylpropanoylamino)methyl]benzamide
DMOAXKF ID DMOAXKF
DMOAXKF DN Benzamide derivative 16
DMOAXKF HS Patented
DMOAXKF SN PMID28627961-Compound-19
DMOAXKF CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk ROENN, Robert PELCMAN, Benjamin
DMOAXKF DT Small molecular drug
DMOAXKF PC 52919477
DMOAXKF MW 663.3
DMOAXKF FM C29H20BrCl2F2N3O4
DMOAXKF IC InChI=1S/C29H20BrCl2F2N3O4/c1-41-24-11-7-18(13-20(24)28(39)36-17-5-3-16(30)4-6-17)37-27(38)19-12-15(2-8-21(19)31)14-35-29(40)25-22(33)9-10-23(34)26(25)32/h2-13H,14H2,1H3,(H,35,40)(H,36,39)(H,37,38)
DMOAXKF CS COC1=C(C=C(C=C1)NC(=O)C2=C(C=CC(=C2)CNC(=O)C3=C(C=CC(=C3Cl)F)F)Cl)C(=O)NC4=CC=C(C=C4)Br
DMOAXKF IK OKMLKFQCNOUSOP-UHFFFAOYSA-N
DMOAXKF IU N-[[3-[[3-[(4-bromophenyl)carbamoyl]-4-methoxyphenyl]carbamoyl]-4-chlorophenyl]methyl]-2-chloro-3,6-difluorobenzamide
DMD7640 ID DMD7640
DMD7640 DN Benzamide derivative 18
DMD7640 HS Patented
DMD7640 SN PMID28627961-Compound-24
DMD7640 CP GLENMARK PHARMACEUTICALS S.A
DMD7640 DT Small molecular drug
DM5YNTM ID DM5YNTM
DM5YNTM DN Benzamide derivative 19
DM5YNTM HS Patented
DM5YNTM SN PMID25470667-Compound-Figure5-14
DM5YNTM CP ELI LILLY AND COMPANY ARNOLD, Macklin, Brian BEAUCHAMP, Thomas, James CANADA, Emily, Jane HEMBRE, Erik, James LU, Jianliang RIZZO, John, Robert SCHAUS, John, Mehnert SHI, Qing
DM5YNTM DT Small molecular drug
DM5YNTM PC 53242014
DM5YNTM MW 430.5
DM5YNTM FM C25H26N4O3
DM5YNTM IC InChI=1S/C25H26N4O3/c1-2-32-19-10-7-18(8-11-19)23(30)28-25(13-14-25)24(31)27-20-12-9-17-5-3-4-6-21(17)29-16-15-26-22(20)29/h3-8,10-11,15-16,20H,2,9,12-14H2,1H3,(H,27,31)(H,28,30)/t20-/m1/s1
DM5YNTM CS CCOC1=CC=C(C=C1)C(=O)NC2(CC2)C(=O)N[C@@H]3CCC4=CC=CC=C4N5C3=NC=C5
DM5YNTM IK JIKPZJNVLNBRBQ-HXUWFJFHSA-N
DM5YNTM IU N-[1-[[(4R)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]carbamoyl]cyclopropyl]-4-ethoxybenzamide
DM0UWNY ID DM0UWNY
DM0UWNY DN Benzamide derivative 2
DM0UWNY HS Patented
DM0UWNY SN PMID28051882-Compound-VI
DM0UWNY CP Washington University
DM0UWNY DT Small molecular drug
DMFY78L ID DMFY78L
DMFY78L DN Benzamide derivative 3
DMFY78L HS Patented
DMFY78L SN PMID28051882-Compound-VII
DMFY78L CP Washington University
DMFY78L DT Small molecular drug
DMNKYL9 ID DMNKYL9
DMNKYL9 DN Benzamide derivative 4
DMNKYL9 HS Patented
DMNKYL9 SN PMID28051882-Compound-VIII
DMNKYL9 CP Washington University
DMNKYL9 DT Small molecular drug
DM6W0TM ID DM6W0TM
DM6W0TM DN Benzamide derivative 5
DM6W0TM HS Patented
DM6W0TM SN PMID28454500-Compound-85
DM6W0TM CP THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DM6W0TM DT Small molecular drug
DM80TDC ID DM80TDC
DM80TDC DN Benzamide derivative 6
DM80TDC HS Patented
DM80TDC SN PMID28454500-Compound-86
DM80TDC CP THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DM80TDC DT Small molecular drug
DM80TDC PC 90448888
DM80TDC MW 477.6
DM80TDC FM C26H27N3O4S
DM80TDC IC InChI=1S/C26H27N3O4S/c30-26(27-23-7-11-25(12-8-23)34(31,32)29-15-17-33-18-16-29)21-5-9-24(10-6-21)28-14-13-20-3-1-2-4-22(20)19-28/h1-12H,13-19H2,(H,27,30)
DM80TDC CS C1CN(CC2=CC=CC=C21)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)N5CCOCC5
DM80TDC IK AXIVYOPFBOAPKD-UHFFFAOYSA-N
DM80TDC IU 4-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(4-morpholin-4-ylsulfonylphenyl)benzamide
DM7UEJT ID DM7UEJT
DM7UEJT DN Benzamide derivative 7
DM7UEJT HS Patented
DM7UEJT SN PMID30185082-Compound-58
DM7UEJT CP UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DM7UEJT DT Small molecular drug
DMAIJHC ID DMAIJHC
DMAIJHC DN Benzamide derivative 8
DMAIJHC HS Patented
DMAIJHC SN PMID30185082-Compound-59
DMAIJHC CP UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DMAIJHC DT Small molecular drug
DMAIJHC PC 118607347
DMAIJHC MW 351.3
DMAIJHC FM C18H20Cl2N2O
DMAIJHC IC InChI=1S/C18H20Cl2N2O/c1-22(13-14-6-3-2-4-7-14)9-5-8-21-18(23)15-10-16(19)12-17(20)11-15/h2-4,6-7,10-12H,5,8-9,13H2,1H3,(H,21,23)
DMAIJHC CS CN(CCCNC(=O)C1=CC(=CC(=C1)Cl)Cl)CC2=CC=CC=C2
DMAIJHC IK KXRBNMSGFUSFLX-UHFFFAOYSA-N
DMAIJHC IU N-[3-[benzyl(methyl)amino]propyl]-3,5-dichlorobenzamide
DMVFSJZ ID DMVFSJZ
DMVFSJZ DN Benzamide derivative 9
DMVFSJZ HS Patented
DMVFSJZ SN PMID30185082-Compound-60
DMVFSJZ CP UNIVERSITE DE LILLE 2 DROIT ET SANTE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU)
DMVFSJZ DT Small molecular drug
DM4TOGU ID DM4TOGU
DM4TOGU DN Benzanilide compound 1
DM4TOGU HS Patented
DM4TOGU SN PMID26882240-Compound-21A
DM4TOGU CP Eisai R & D Management Co., Ltd., Japan
DM4TOGU DT Small molecular drug
DM4TOGU PC 101913833
DM4TOGU MW 515.6
DM4TOGU FM C32H29N5O2
DM4TOGU IC InChI=1S/C32H29N5O2/c33-30-29(7-4-18-34-30)32(39)37-21-19-36(20-22-37)23-26-10-14-27(15-11-26)31(38)35-28-16-12-25(13-17-28)9-8-24-5-2-1-3-6-24/h1-7,10-18H,19-23H2,(H2,33,34)(H,35,38)
DM4TOGU CS C1CN(CCN1CC2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C#CC4=CC=CC=C4)C(=O)C5=C(N=CC=C5)N
DM4TOGU IK YPMOWWPVPPPBET-UHFFFAOYSA-N
DM4TOGU IU 4-[[4-(2-aminopyridine-3-carbonyl)piperazin-1-yl]methyl]-N-[4-(2-phenylethynyl)phenyl]benzamide
DMDM806 ID DMDM806
DMDM806 DN Benzanilide compound 2
DMDM806 HS Patented
DMDM806 SN PMID26882240-Compound-21B
DMDM806 CP Eisai R & D Management Co., Ltd., Japan
DMDM806 DT Small molecular drug
DMA3BCU ID DMA3BCU
DMA3BCU DN Benzazepine derivative 1
DMA3BCU HS Patented
DMA3BCU SN PMID26609882-Compound-40
DMA3BCU CP ARENA PHARMACEUTICALS, INC
DMA3BCU DT Small molecular drug
DMKREJ2 ID DMKREJ2
DMKREJ2 DN Benzazepine derivative 2
DMKREJ2 HS Patented
DMKREJ2 SN PMID26609882-Compound-41
DMKREJ2 CP ARENA PHARMACEUTICALS, INC
DMKREJ2 DT Small molecular drug
DM3BGEN ID DM3BGEN
DM3BGEN DN Benzazepine derivative 3
DM3BGEN HS Patented
DM3BGEN SN PMID26609882-Compound-42
DM3BGEN CP ARENA PHARMACEUTICALS, INC
DM3BGEN DT Small molecular drug
DMM72LS ID DMM72LS
DMM72LS DN Benzazepine derivative 4
DMM72LS HS Patented
DMM72LS SN PMID26609882-Compound-43
DMM72LS CP ARENA PHARMACEUTICALS, INC
DMM72LS DT Small molecular drug
DM6XRDH ID DM6XRDH
DM6XRDH DN Benzazepine derivative 5
DM6XRDH HS Patented
DM6XRDH SN PMID26609882-Compound-44
DM6XRDH CP ARENA PHARMACEUTICALS, INC
DM6XRDH DT Small molecular drug
DMCGX5S ID DMCGX5S
DMCGX5S DN Benzazepine derivative 6
DMCGX5S HS Patented
DMCGX5S SN PMID26609882-Compound-45
DMCGX5S CP ARENA PHARMACEUTICALS, INC
DMCGX5S DT Small molecular drug
DM6PMZC ID DM6PMZC
DM6PMZC DN Benzenamine derivative 1
DM6PMZC HS Patented
DM6PMZC SN PMID27019002-Compound-14
DM6PMZC CP THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DM6PMZC DT Small molecular drug
DMDZ7QS ID DMDZ7QS
DMDZ7QS DN Benzenamine derivative 2
DMDZ7QS HS Patented
DMDZ7QS SN PMID27019002-Compound-35
DMDZ7QS CP THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DMDZ7QS DT Small molecular drug
DM8UXZ3 ID DM8UXZ3
DM8UXZ3 DN Benzenamine derivative 3
DM8UXZ3 HS Patented
DM8UXZ3 SN PMID27019002-Compound-35a
DM8UXZ3 CP THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DM8UXZ3 DT Small molecular drug
DMQT7HV ID DMQT7HV
DMQT7HV DN Benzenamine derivative 4
DMQT7HV HS Patented
DMQT7HV SN PMID27019002-Compound-36
DMQT7HV CP THE JOHNS HOPKINS UNIVERSITY CASERO, Robert, A. BYTHEWAY, Ian WOSTER, Patrick, M
DMQT7HV DT Small molecular drug
DMB9VEH ID DMB9VEH
DMB9VEH DN Benzene sulfonamide derivative 1
DMB9VEH HS Patented
DMB9VEH SN PMID27172114-Compound-65
DMB9VEH CP The J. David Gladstone InstitutUniversity of Maryland
DMB9VEH DT Small molecular drug
DML9TF7 ID DML9TF7
DML9TF7 DN Benzene sulfonamide derivative 11
DML9TF7 HS Patented
DML9TF7 SN PMID25539043-Compound-WO2013064983Example54
DML9TF7 CP XENON PHARMACEUTICALS INC
DML9TF7 DT Small molecular drug
DMESKY1 ID DMESKY1
DMESKY1 DN Benzene sulfonamide derivative 12
DMESKY1 HS Patented
DMESKY1 SN PMID25539043-Compound-WO2013064983Example55
DMESKY1 CP XENON PHARMACEUTICALS INC
DMESKY1 DT Small molecular drug
DMFJTE9 ID DMFJTE9
DMFJTE9 DN Benzene sulfonamide derivative 15
DMFJTE9 HS Patented
DMFJTE9 SN PMID25539043-Compound-WO2014061970Example56
DMFJTE9 CP DAEWOONG PHARMACEUTICAL CO., LTD
DMFJTE9 DT Small molecular drug
DMATBZW ID DMATBZW
DMATBZW DN Benzene sulfonamide derivative 16
DMATBZW HS Patented
DMATBZW SN PMID27414413-Compound-Figure3upright
DMATBZW CP PFIZER LIMITED
DMATBZW DT Small molecular drug
DMATBZW PC 46840946
DMATBZW MW 500.4
DMATBZW FM C18H12Cl2FN5O3S2
DMATBZW IC InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25)
DMATBZW CS C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
DMATBZW IK ZYSCOUXLBXGGIM-UHFFFAOYSA-N
DMATBZW IU 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide
DMATBZW CA CAS 1235403-62-9
DMUZQLR ID DMUZQLR
DMUZQLR DN Benzene sulfonamide derivative 2
DMUZQLR HS Patented
DMUZQLR SN PMID27172114-Compound-66
DMUZQLR DT Small molecular drug
DMCQLJY ID DMCQLJY
DMCQLJY DN Benzene sulfonamide derivative 3
DMCQLJY HS Patented
DMCQLJY SN PMID27172114-Compound-67
DMCQLJY DT Small molecular drug
DMCQLJY PC 24812126
DMCQLJY MW 518.6
DMCQLJY FM C23H26N4O6S2
DMCQLJY IC InChI=1S/C23H26N4O6S2/c1-32-19-10-9-18(14-20(19)33-2)35(30,31)25-23-24-22(16-7-6-8-17(13-16)27(28)29)21(34-23)15-26-11-4-3-5-12-26/h6-10,13-14H,3-5,11-12,15H2,1-2H3,(H,24,25)
DMCQLJY CS COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=C(S2)CN3CCCCC3)C4=CC(=CC=C4)[N+](=O)[O-])OC
DMCQLJY IK AOZLMMDVJOGGEQ-UHFFFAOYSA-N
DMCQLJY IU 3,4-dimethoxy-N-[4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)-1,3-thiazol-2-yl]benzenesulfonamide
DMCQLJY CA CAS 1008119-83-2
DMXCUEG ID DMXCUEG
DMXCUEG DN Benzene sulfonamide derivative 4
DMXCUEG HS Patented
DMXCUEG SN PMID27172114-Compound-68
DMXCUEG DT Small molecular drug
DMXCUEG PC 24812127
DMXCUEG MW 520.6
DMXCUEG FM C22H24N4O7S2
DMXCUEG IC InChI=1S/C22H24N4O7S2/c1-31-18-7-6-17(13-19(18)32-2)35(29,30)24-22-23-21(15-4-3-5-16(12-15)26(27)28)20(34-22)14-25-8-10-33-11-9-25/h3-7,12-13H,8-11,14H2,1-2H3,(H,23,24)
DMXCUEG CS COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=C(S2)CN3CCOCC3)C4=CC(=CC=C4)[N+](=O)[O-])OC
DMXCUEG IK GOWBSGKWACGSGN-UHFFFAOYSA-N
DMXCUEG IU 3,4-dimethoxy-N-[5-(morpholin-4-ylmethyl)-4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide
DMW4NXV ID DMW4NXV
DMW4NXV DN Benzene sulfonamide derivative 5
DMW4NXV HS Patented
DMW4NXV SN PMID27172114-Compound-69
DMW4NXV DT Small molecular drug
DMD4UMP ID DMD4UMP
DMD4UMP DN Benzene sulfonamide derivative 6
DMD4UMP HS Patented
DMD4UMP SN PMID27172114-Compound-70
DMD4UMP DT Small molecular drug
DM0TKP2 ID DM0TKP2
DM0TKP2 DN Benzene sulfonamide derivative 7
DM0TKP2 HS Patented
DM0TKP2 SN PMID27172114-Compound-71
DM0TKP2 DT Small molecular drug
DMATU1X ID DMATU1X
DMATU1X DN Benzene sulfonamide derivative 8
DMATU1X HS Patented
DMATU1X SN PMID26882240-Compound-13
DMATU1X CP INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY KWON, Ho Jeong HAN, Gyoon Hee
DMATU1X DT Small molecular drug
DMATU1X PC 894213
DMATU1X MW 325.4
DMATU1X FM C18H15NO3S
DMATU1X IC InChI=1S/C18H15NO3S/c20-17-10-8-16(9-11-17)19-23(21,22)18-12-6-15(7-13-18)14-4-2-1-3-5-14/h1-13,19-20H
DMATU1X CS C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NC3=CC=C(C=C3)O
DMATU1X IK SZOPCHOOHZIDKC-UHFFFAOYSA-N
DMATU1X IU N-(4-hydroxyphenyl)-4-phenylbenzenesulfonamide
DMLET14 ID DMLET14
DMLET14 DN Benzene sulfonamide derivative 9
DMLET14 HS Patented
DMLET14 SN PMID25539043-Compound-WO2012004706Example53
DMLET14 CP PFIZER LIMITED ICAGEN, INC. MARKWORTH, Christopher John MARRON, Brian Edward RAWSON, David James STORER, Robert Ian SWAIN, Nigel Alan WEST, Christopher William ZHOU, Shulan
DMLET14 DT Small molecular drug
DM1IZA7 ID DM1IZA7
DM1IZA7 DN Benzimidazole
DM1IZA7 HS Patented
DM1IZA7 SN BENZIMIDAZOLE; 51-17-2; 1H-Benzimidazole; 1H-Benzo[d]imidazole; 1,3-Benzodiazole; Benzoimidazole; o-Benzimidazole; 3-Azaindole; Benziminazole; Benzoglyoxaline; Azindole; 1,3-Diazaindene; 1H-Benzoimidazole; N,N'-Methenyl-o-phenylenediamine; NSC 759; Benzimidazol; 1H-1,3-benzodiazole; BZI; UNII-E24GX49LD8; CCRIS 5967; Benzimidazole, 98%; CHEBI:41275; HSDB 2797; EINECS 200-081-4; BRN 0109682; AI3-03737; E24GX49LD8; HYZJCKYKOHLVJF-UHFFFAOYSA-N; DSSTox_CID_4573; DSSTox_RID_77454; DSSTox_GSID_24573; F3366-5347; CAS-51-17-2; bezimidazole
DM1IZA7 DT Small molecular drug
DM1IZA7 PC 5798
DM1IZA7 MW 118.14
DM1IZA7 FM C7H6N2
DM1IZA7 IC InChI=1S/C7H6N2/c1-2-4-7-6(3-1)8-5-9-7/h1-5H,(H,8,9)
DM1IZA7 CS C1=CC=C2C(=C1)NC=N2
DM1IZA7 IK HYZJCKYKOHLVJF-UHFFFAOYSA-N
DM1IZA7 IU 1H-benzimidazole
DM1IZA7 CA CAS 51-17-2
DM1IZA7 CB CHEBI:41275
DM1IZA7 DE Cytomegalovirus Disease
DM2G83R ID DM2G83R
DM2G83R DN Benzimidazole and imadazopyridine carboximidamide compound 1
DM2G83R HS Patented
DM2G83R SN PMID29473428-Compound-23
DM2G83R DT Small molecular drug
DM2G83R PC 122687657
DM2G83R MW 468.9
DM2G83R FM C20H20ClF3N6O2
DM2G83R IC InChI=1S/C20H20ClF3N6O2/c1-32-11-8-30(9-11)5-4-25-20-27-17-12(7-15(23)16(24)18(17)28-20)19(29-31)26-10-2-3-14(22)13(21)6-10/h2-3,6-7,11,31H,4-5,8-9H2,1H3,(H,26,29)(H2,25,27,28)
DM2G83R CS COC1CN(C1)CCNC2=NC3=C(N2)C(=CC(=C3F)F)C(=NC4=CC(=C(C=C4)F)Cl)NO
DM2G83R IK DZOQWZPMCBWTQQ-UHFFFAOYSA-N
DM2G83R IU N'-(3-chloro-4-fluorophenyl)-6,7-difluoro-N-hydroxy-2-[2-(3-methoxyazetidin-1-yl)ethylamino]-3H-benzimidazole-4-carboximidamide
DMJ2CIY ID DMJ2CIY
DMJ2CIY DN Benzimidazole and imadazopyridine carboximidamide compound 2
DMJ2CIY HS Patented
DMJ2CIY SN PMID29473428-Compound-24
DMJ2CIY DT Small molecular drug
DMJ2CIY PC 137097618
DMJ2CIY MW 332.16
DMJ2CIY FM C13H10BrN5O
DMJ2CIY IC InChI=1S/C13H10BrN5O/c14-8-2-1-3-9(6-8)18-12(19-20)10-4-5-15-13-11(10)16-7-17-13/h1-7,20H,(H,18,19)(H,15,16,17)
DMJ2CIY CS C1=CC(=CC(=C1)Br)N=C(C2=C3C(=NC=C2)N=CN3)NO
DMJ2CIY IK UPPKJOIPXZWQCK-UHFFFAOYSA-N
DMJ2CIY IU N'-(3-bromophenyl)-N-hydroxy-1H-imidazo[4,5-b]pyridine-7-carboximidamide
DMIXERP ID DMIXERP
DMIXERP DN Benzimidazole and imidazopyridine derivative 1
DMIXERP HS Patented
DMIXERP SN PMID25684022-Compound-WO2011006567
DMIXERP CP MERCK PATENT GMBH
DMIXERP DT Small molecular drug
DMIXERP DE Solid tumour/cancer; Metastatic cancer
DMB1L32 ID DMB1L32
DMB1L32 DN Benzimidazole carboxamide derivative 1
DMB1L32 HS Patented
DMB1L32 SN PMID27841036-Compound-I
DMB1L32 CP Angion Biomedica Corp
DMB1L32 DT Small molecular drug
DML8W16 ID DML8W16
DML8W16 DN Benzimidazole derivative 1
DML8W16 HS Patented
DML8W16 SN PMID26161824-Compound-179
DML8W16 CP ASTRAZENECA AB BROWN, William PAGE, Daniel SRIVASTAVA, Sanjay WALPOLE, Christopher WEI, Zhong-yong YANG, Hua
DML8W16 DT Small molecular drug
DML8W16 PC 24872457
DML8W16 MW 464.6
DML8W16 FM C28H40N4O2
DML8W16 IC InChI=1S/C28H40N4O2/c1-28(2,3)27-30-23-17-21(9-12-24(23)32(27)18-19-7-5-4-6-8-19)26(34)31-15-13-20(14-16-31)25(33)29-22-10-11-22/h9,12,17,19-20,22H,4-8,10-11,13-16,18H2,1-3H3,(H,29,33)
DML8W16 CS CC(C)(C)C1=NC2=C(N1CC3CCCCC3)C=CC(=C2)C(=O)N4CCC(CC4)C(=O)NC5CC5
DML8W16 IK UNNYHANBNOQKCU-UHFFFAOYSA-N
DML8W16 IU 1-[2-tert-butyl-1-(cyclohexylmethyl)benzimidazole-5-carbonyl]-N-cyclopropylpiperidine-4-carboxamide
DML8W16 DE Obesity
DML3PE4 ID DML3PE4
DML3PE4 DN Benzimidazole derivative 10
DML3PE4 HS Patented
DML3PE4 SN PMID26936077-Compound-27
DML3PE4 CP NEOPHARM CO.,LTD. ( ) GWAK, Hyung Sub KIM, Yong Zu KIM, Uk Il PARK, Byeong Deog PARK, Tae Kyo WOO, Sung Ho
DML3PE4 DT Small molecular drug
DML3PE4 PC 56848369
DML3PE4 MW 430.5
DML3PE4 FM C26H30N4O2
DML3PE4 IC InChI=1S/C26H30N4O2/c1-19-24(20-8-4-2-5-9-20)30-18-22(12-13-23(30)27-19)26(32)29-16-14-28(15-17-29)25(31)21-10-6-3-7-11-21/h2,4-5,8-9,12-13,18,21H,3,6-7,10-11,14-17H2,1H3
DML3PE4 CS CC1=C(N2C=C(C=CC2=N1)C(=O)N3CCN(CC3)C(=O)C4CCCCC4)C5=CC=CC=C5
DML3PE4 IK BQTLJTZGAMQFGS-UHFFFAOYSA-N
DML3PE4 IU cyclohexyl-[4-(2-methyl-3-phenylimidazo[1,2-a]pyridine-6-carbonyl)piperazin-1-yl]methanone
DMGRD8B ID DMGRD8B
DMGRD8B DN Benzimidazole derivative 11
DMGRD8B HS Patented
DMGRD8B SN PMID28627961-Compound-10
DMGRD8B CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk PELCMAN, Benjamin ROENN, Robert
DMGRD8B DT Small molecular drug
DMGRD8B PC 86669641
DMGRD8B MW 638.9
DMGRD8B FM C29H28Cl3F2N5O3
DMGRD8B IC InChI=1S/C29H28Cl3F2N5O3/c1-29(2,3)27(41)35-14-15-5-7-18(30)25(24(15)32)38-28-37-21-12-17(23(42-10-9-33)13-22(21)39(28)4)26(40)36-16-6-8-20(34)19(31)11-16/h5-8,11-13H,9-10,14H2,1-4H3,(H,35,41)(H,36,40)(H,37,38)
DMGRD8B CS CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)NC2=NC3=C(N2C)C=C(C(=C3)C(=O)NC4=CC(=C(C=C4)F)Cl)OCCF)Cl
DMGRD8B IK MJNRUPMNPGZLRT-UHFFFAOYSA-N
DMGRD8B IU N-(3-chloro-4-fluorophenyl)-2-[2,6-dichloro-3-[(2,2-dimethylpropanoylamino)methyl]anilino]-6-(2-fluoroethoxy)-1-methylbenzimidazole-5-carboxamide
DMOHERV ID DMOHERV
DMOHERV DN Benzimidazole derivative 12
DMOHERV HS Patented
DMOHERV SN PMID28627961-Compound-11
DMOHERV CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMOHERV DT Small molecular drug
DMOHERV PC 57336796
DMOHERV MW 689.5
DMOHERV FM C31H35Cl2F5N6O2
DMOHERV IC InChI=1S/C31H35Cl2F5N6O2/c1-29(2,3)27(46)39-15-16-5-6-20(32)25(24(16)33)42-28-41-21-11-19(26(45)40-18-13-30(34,35)14-18)22(12-23(21)43(28)4)44-9-7-17(8-10-44)31(36,37)38/h5-6,11-12,17-18H,7-10,13-15H2,1-4H3,(H,39,46)(H,40,45)(H,41,42)
DMOHERV CS CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)NC2=NC3=C(N2C)C=C(C(=C3)C(=O)NC4CC(C4)(F)F)N5CCC(CC5)C(F)(F)F)Cl
DMOHERV IK WROFUPVHFCAUPE-UHFFFAOYSA-N
DMOHERV IU 2-[2,6-dichloro-3-[(2,2-dimethylpropanoylamino)methyl]anilino]-N-(3,3-difluorocyclobutyl)-1-methyl-6-[4-(trifluoromethyl)piperidin-1-yl]benzimidazole-5-carboxamide
DMV4DQI ID DMV4DQI
DMV4DQI DN Benzimidazole derivative 13
DMV4DQI HS Patented
DMV4DQI SN PMID28627961-Compound-12
DMV4DQI CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMV4DQI DT Small molecular drug
DMCY5M7 ID DMCY5M7
DMCY5M7 DN Benzimidazole derivative 14
DMCY5M7 HS Patented
DMCY5M7 SN PMID28627961-Compound-13
DMCY5M7 CP Boehringer Ingelheim International GMBH
DMCY5M7 DT Small molecular drug
DMCY5M7 PC 57336792
DMCY5M7 MW 685.5
DMCY5M7 FM C31H28Cl2F6N6O
DMCY5M7 IC InChI=1S/C31H28Cl2F6N6O/c1-43-26-16-25(45-12-10-44(11-13-45)20-5-3-19(4-6-20)30(34,35)36)22(33)15-24(26)42-28(43)41-23-14-18(2-7-21(23)32)17-40-27(46)29(8-9-29)31(37,38)39/h2-7,14-16H,8-13,17H2,1H3,(H,40,46)(H,41,42)
DMCY5M7 CS CN1C2=CC(=C(C=C2N=C1NC3=C(C=CC(=C3)CNC(=O)C4(CC4)C(F)(F)F)Cl)Cl)N5CCN(CC5)C6=CC=C(C=C6)C(F)(F)F
DMCY5M7 IK YVXLODVZVGRVRR-UHFFFAOYSA-N
DMCY5M7 IU N-[[4-chloro-3-[[5-chloro-1-methyl-6-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]benzimidazol-2-yl]amino]phenyl]methyl]-1-(trifluoromethyl)cyclopropane-1-carboxamide
DMJ3AZ4 ID DMJ3AZ4
DMJ3AZ4 DN Benzimidazole derivative 15
DMJ3AZ4 HS Patented
DMJ3AZ4 SN PMID28627961-Compound-7
DMJ3AZ4 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri KLINDER, Klaus KUELZER, Raimund LUBRIKS, Dimitrijs MACK, Juergen PELCMAN, Benjamin PRIEPKE, Henning ROENN, Robert STENKAMP, Dirk SUNA, Edgars
DMJ3AZ4 DT Small molecular drug
DMJ3AZ4 PC 46909123
DMJ3AZ4 MW 663.6
DMJ3AZ4 FM C30H33F8N5O3
DMJ3AZ4 IC InChI=1S/C30H33F8N5O3/c1-28(2,3)26(45)39-13-15-4-9-19(30(36,37)38)20(10-15)41-27-42-21-11-18(23(12-22(21)43-27)46-14-24(31)32)25(44)40-17-7-5-16(6-8-17)29(33,34)35/h4,9-12,16-17,24H,5-8,13-14H2,1-3H3,(H,39,45)(H,40,44)(H2,41,42,43)
DMJ3AZ4 CS CC(C)(C)C(=O)NCC1=CC(=C(C=C1)C(F)(F)F)NC2=NC3=C(N2)C=C(C(=C3)OCC(F)F)C(=O)NC4CCC(CC4)C(F)(F)F
DMJ3AZ4 IK QUJFMVVWDBGGPL-UHFFFAOYSA-N
DMJ3AZ4 IU 6-(2,2-difluoroethoxy)-2-[5-[(2,2-dimethylpropanoylamino)methyl]-2-(trifluoromethyl)anilino]-N-[4-(trifluoromethyl)cyclohexyl]-3H-benzimidazole-5-carboxamide
DMHEQDT ID DMHEQDT
DMHEQDT DN Benzimidazole derivative 16
DMHEQDT HS Patented
DMHEQDT SN PMID28627961-Compound-8
DMHEQDT CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund MACK, Juergen PRIEPKE, Henning STENKAMP, Dirk
DMHEQDT DT Small molecular drug
DMHEQDT PC 58562295
DMHEQDT MW 473
DMHEQDT FM C25H30ClFN4O2
DMHEQDT IC InChI=1S/C25H30ClFN4O2/c1-14-6-7-17(26)22(21(14)27)30-24-29-18-12-16(20(33-5)13-19(18)31(24)4)23(32)28-15-8-10-25(2,3)11-9-15/h6-7,12-13,15H,8-11H2,1-5H3,(H,28,32)(H,29,30)
DMHEQDT CS CC1=C(C(=C(C=C1)Cl)NC2=NC3=C(N2C)C=C(C(=C3)C(=O)NC4CCC(CC4)(C)C)OC)F
DMHEQDT IK GHWPMCBIOYWZCT-UHFFFAOYSA-N
DMHEQDT IU 2-(6-chloro-2-fluoro-3-methylanilino)-N-(4,4-dimethylcyclohexyl)-6-methoxy-1-methylbenzimidazole-5-carboxamide
DM1DXME ID DM1DXME
DM1DXME DN Benzimidazole derivative 17
DM1DXME HS Patented
DM1DXME SN PMID28627961-Compound-9
DM1DXME CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund MACK, Juergen STENKAMP, Dirk
DM1DXME DT Small molecular drug
DM4ZUDY ID DM4ZUDY
DM4ZUDY DN Benzimidazole derivative 2
DM4ZUDY HS Patented
DM4ZUDY SN PMID26161824-Compound-180
DM4ZUDY CP ASTRAZENECA AB BROWN, William PAGE, Daniel SRIVASTAVA, Sanjay WALPOLE, Christopher WEI, Zhong-yong YANG, Hua
DM4ZUDY DT Small molecular drug
DM4ZUDY PC 59608060
DM4ZUDY MW 500.6
DM4ZUDY FM C28H38F2N4O2
DM4ZUDY IC InChI=1S/C28H38F2N4O2/c1-27(2,3)26-32-22-16-20(4-7-23(22)34(26)17-18-8-12-28(29,30)13-9-18)25(36)33-14-10-19(11-15-33)24(35)31-21-5-6-21/h4,7,16,18-19,21H,5-6,8-15,17H2,1-3H3,(H,31,35)
DM4ZUDY CS CC(C)(C)C1=NC2=C(N1CC3CCC(CC3)(F)F)C=CC(=C2)C(=O)N4CCC(CC4)C(=O)NC5CC5
DM4ZUDY IK XZJQGNKKTKJFJW-UHFFFAOYSA-N
DM4ZUDY IU 1-[2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]benzimidazole-5-carbonyl]-N-cyclopropylpiperidine-4-carboxamide
DM4ZUDY DE Obesity
DMY93WG ID DMY93WG
DMY93WG DN Benzimidazole derivative 3
DMY93WG HS Patented
DMY93WG SN PMID26815044-Compound-42
DMY93WG DT Small molecular drug
DMY93WG PC 5268800
DMY93WG MW 226.23
DMY93WG FM C13H10N2O2
DMY93WG IC InChI=1S/C13H10N2O2/c16-8-5-6-9(12(17)7-8)13-14-10-3-1-2-4-11(10)15-13/h1-7,16-17H,(H,14,15)
DMY93WG CS C1=CC=C2C(=C1)NC(=N2)C3=C(C=C(C=C3)O)O
DMY93WG IK MTDSHRDWHUXPQH-UHFFFAOYSA-N
DMY93WG IU 4-(1H-benzimidazol-2-yl)benzene-1,3-diol
DMY93WG CA CAS 63899-32-1
DMY93WG DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM9PL3F ID DM9PL3F
DM9PL3F DN Benzimidazole derivative 4
DM9PL3F HS Patented
DM9PL3F SN PMID26815044-Compound-43
DM9PL3F DT Small molecular drug
DM9PL3F PC 135665562
DM9PL3F MW 270.28
DM9PL3F FM C15H14N2O3
DM9PL3F IC InChI=1S/C15H14N2O3/c1-19-12-7-9(8-13(20-2)14(12)18)15-16-10-5-3-4-6-11(10)17-15/h3-8,18H,1-2H3,(H,16,17)
DM9PL3F CS COC1=CC(=CC(=C1O)OC)C2=NC3=CC=CC=C3N2
DM9PL3F IK LEEVVCNLICRBQX-UHFFFAOYSA-N
DM9PL3F IU 4-(1H-benzimidazol-2-yl)-2,6-dimethoxyphenol
DM9PL3F DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMWOJLX ID DMWOJLX
DMWOJLX DN Benzimidazole derivative 5
DMWOJLX HS Patented
DMWOJLX SN PMID27774822-Compound-Figure1Example21(compound 121)
DMWOJLX CP LIGAND PHARMACEUTICALS INCORPORATED COLE, Andrew, G. JAMES, Ray, A. SHAO, Yuefei LETOURNEAU, Jeffrey, J. QUINTERO, Jorge, G. RIVIELLO, Christopher, Mark ZHI, Lin
DMV7TMB ID DMV7TMB
DMV7TMB DN Benzimidazole derivative 6
DMV7TMB HS Patented
DMV7TMB SN PMID28270010-Compound-Figure7-1
DMV7TMB CP TESARO, INCAMGEN INC. BOEZIO, Christiane M. CHENG, Alan, C. CHOQUETTE, Deborah LEWIS, Richard, T. POTASHMAN, Michele, H. ROMERO, Karina STELLWAGEN, John, C. WHITTINGTON, Douglas, A
DMV7TMB DT Small molecular drug
DMV7TMB PC 57345941
DMV7TMB MW 577.7
DMV7TMB FM C33H44FN5O3
DMV7TMB IC InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)
DMV7TMB CS CC(C)NC(=O)C1CCC(CC1)N2C3=C(C=CC(=C3)CN4CCC(CC4)C(C)(C)O)N=C2NC(=O)C5=CC=C(C=C5)F
DMV7TMB IK WSTUJEXAPHIEIM-UHFFFAOYSA-N
DMV7TMB IU 4-fluoro-N-[6-[[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl]-1-[4-(propan-2-ylcarbamoyl)cyclohexyl]benzimidazol-2-yl]benzamide
DMV7TMB CA CAS 1357920-84-3
DMV7TMB DE Solid tumour/cancer
DMDK4RI ID DMDK4RI
DMDK4RI DN Benzimidazole derivative 7
DMDK4RI HS Patented
DMDK4RI SN PMID27774824-Compound-Figure11Example15
DMDK4RI CP GALAPAGOS NV
DMDK4RI DT Small molecular drug
DMQ75BN ID DMQ75BN
DMQ75BN DN Benzimidazole derivative 8
DMQ75BN HS Patented
DMQ75BN SN PMID26936077-Compound-25
DMQ75BN CP NEOPHARM CO.,LTD. ( ) GWAK, Hyung Sub KIM, Yong Zu KIM, Uk Il PARK, Byeong Deog PARK, Tae Kyo WOO, Sung Ho
DMQ75BN DT Small molecular drug
DMQ75BN PC 56848967
DMQ75BN MW 347.5
DMQ75BN FM C22H25N3O
DMQ75BN IC InChI=1S/C22H25N3O/c1-16-7-6-8-18(13-16)15-25-17(2)23-20-14-19(9-10-21(20)25)22(26)24-11-4-3-5-12-24/h6-10,13-14H,3-5,11-12,15H2,1-2H3
DMQ75BN CS CC1=CC(=CC=C1)CN2C(=NC3=C2C=CC(=C3)C(=O)N4CCCCC4)C
DMQ75BN IK FWLBCCWBWAZRLY-UHFFFAOYSA-N
DMQ75BN IU [2-methyl-1-[(3-methylphenyl)methyl]benzimidazol-5-yl]-piperidin-1-ylmethanone
DMQ75BN CA CAS 1234208-67-3
DMHJ98M ID DMHJ98M
DMHJ98M DN Benzimidazole derivative 9
DMHJ98M HS Patented
DMHJ98M SN PMID26936077-Compound-26
DMHJ98M CP NEOPHARM CO.,LTD. ( ) GWAK, Hyung Sub KIM, Yong Zu KIM, Uk Il PARK, Byeong Deog PARK, Tae Kyo WOO, Sung Ho
DMHJ98M DT Small molecular drug
DMHJ98M PC 56832519
DMHJ98M MW 333.4
DMHJ98M FM C21H23N3O
DMHJ98M IC InChI=1S/C21H23N3O/c1-15-7-6-8-17(13-15)20-16(2)22-19-10-9-18(14-24(19)20)21(25)23-11-4-3-5-12-23/h6-10,13-14H,3-5,11-12H2,1-2H3
DMHJ98M CS CC1=CC(=CC=C1)C2=C(N=C3N2C=C(C=C3)C(=O)N4CCCCC4)C
DMHJ98M IK RKISYXMPLQOYPU-UHFFFAOYSA-N
DMHJ98M IU [2-methyl-3-(3-methylphenyl)imidazo[1,2-a]pyridin-6-yl]-piperidin-1-ylmethanone
DMRZELF ID DMRZELF
DMRZELF DN Benzimidazolone acetamide derivative 1
DMRZELF HS Patented
DMRZELF SN PMID27607364-Compound-181
DMRZELF DT Small molecular drug
DMRZELF PC 23153799
DMRZELF MW 357.4
DMRZELF FM C22H19N3O2
DMRZELF IC InChI=1S/C22H19N3O2/c1-24(18-10-6-3-7-11-18)21(26)15-25-20-14-17(16-8-4-2-5-9-16)12-13-19(20)23-22(25)27/h2-14H,15H2,1H3,(H,23,27)
DMRZELF CS CN(C1=CC=CC=C1)C(=O)CN2C3=C(C=CC(=C3)C4=CC=CC=C4)NC2=O
DMRZELF IK ORIMXDOWDCMRCI-UHFFFAOYSA-N
DMRZELF IU N-methyl-2-(2-oxo-6-phenyl-3H-benzimidazol-1-yl)-N-phenylacetamide
DMD9VC1 ID DMD9VC1
DMD9VC1 DN Benzimidazolone acetamide derivative 2
DMD9VC1 HS Patented
DMD9VC1 SN PMID27607364-Compound-182
DMD9VC1 DT Small molecular drug
DMD9VC1 PC 71716969
DMD9VC1 MW 371.4
DMD9VC1 FM C23H21N3O2
DMD9VC1 IC InChI=1S/C23H21N3O2/c1-24(19-11-7-4-8-12-19)22(27)16-26-21-15-18(17-9-5-3-6-10-17)13-14-20(21)25(2)23(26)28/h3-15H,16H2,1-2H3
DMD9VC1 CS CN1C2=C(C=C(C=C2)C3=CC=CC=C3)N(C1=O)CC(=O)N(C)C4=CC=CC=C4
DMD9VC1 IK KWRWRRZPFCLHLS-UHFFFAOYSA-N
DMD9VC1 IU N-methyl-2-(3-methyl-2-oxo-6-phenylbenzimidazol-1-yl)-N-phenylacetamide
DMF01AR ID DMF01AR
DMF01AR DN Benzisoselenazolone difluorocytidine derivative 1
DMF01AR HS Patented
DMF01AR SN PMID27977313-Compound-Figure6b
DMF01AR DT Small molecular drug
DM4VXY1 ID DM4VXY1
DM4VXY1 DN Benzo(b)carbazol-11-one compound 1
DM4VXY1 HS Patented
DM4VXY1 SN PMID27646564-Compound-10
DM4VXY1 CP Chugai Pharmaceutical
DM4VXY1 DT Small molecular drug
DMGCHW9 ID DMGCHW9
DMGCHW9 DN Benzo(b)carbazol-11-one compound 2
DMGCHW9 HS Patented
DMGCHW9 SN PMID27646564-Compound-10-1
DMGCHW9 CP Chugai Pharmaceutical
DMGCHW9 DT Small molecular drug
DMKXD2V ID DMKXD2V
DMKXD2V DN Benzo[d]oxazol-2(3H)-one derivative 1
DMKXD2V HS Patented
DMKXD2V SN PMID29334795-Compound-63
DMKXD2V CP AAPA B.V
DMKXD2V DT Small molecular drug
DM47KWB ID DM47KWB
DM47KWB DN Benzo[d]oxazol-2(3H)-one derivative 2
DM47KWB HS Patented
DM47KWB SN PMID29334795-Compound-64
DM47KWB CP AAPA B.V
DM47KWB DT Small molecular drug
DM47KWB PC 71816205
DM47KWB MW 453.6
DM47KWB FM C26H35N3O4
DM47KWB IC InChI=1S/C26H35N3O4/c1-3-24(26-25(4-1)32-19-20-33-26)29-12-10-27(11-13-29)9-2-16-31-23-7-5-22(6-8-23)21-28-14-17-30-18-15-28/h1,3-8H,2,9-21H2
DM47KWB CS C1CN(CCN1CCCOC2=CC=C(C=C2)CN3CCOCC3)C4=C5C(=CC=C4)OCCO5
DM47KWB IK VZAPQDNGQVGEES-UHFFFAOYSA-N
DM47KWB IU 4-[[4-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propoxy]phenyl]methyl]morpholine
DM3Z5UQ ID DM3Z5UQ
DM3Z5UQ DN Benzo[d]oxazol-2(3H)-one derivative 3
DM3Z5UQ HS Patented
DM3Z5UQ SN PMID29334795-Compound-65
DM3Z5UQ CP AAPA B.V
DM3Z5UQ DT Small molecular drug
DM3Z5UQ PC 118064262
DM3Z5UQ MW 463.6
DM3Z5UQ FM C28H37N3O3
DM3Z5UQ IC InChI=1S/C28H37N3O3/c1-3-23(4-1)30-13-11-25(12-14-30)34-24-9-7-22(8-10-24)21-29-15-17-31(18-16-29)26-5-2-6-27-28(26)33-20-19-32-27/h2,5-10,23,25H,1,3-4,11-21H2
DM3Z5UQ CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)CN4CCN(CC4)C5=C6C(=CC=C5)OCCO6
DM3Z5UQ IK DOVAYWNSWPTVKL-UHFFFAOYSA-N
DM3Z5UQ IU 1-[[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]methyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine
DMNIPE6 ID DMNIPE6
DMNIPE6 DN Benzo[d]oxazole derivative 1
DMNIPE6 HS Patented
DMNIPE6 SN PMID28454500-Compound-79
DMNIPE6 CP Korea Institute of Radiological & Medical Sciences, S
DMNIPE6 DT Small molecular drug
DMNIPE6 PC 736095
DMNIPE6 MW 339.2
DMNIPE6 FM C17H11BrN2O
DMNIPE6 IC InChI=1S/C17H11BrN2O/c18-14-6-2-3-11-12(14)4-1-5-13(11)17-20-15-9-10(19)7-8-16(15)21-17/h1-9H,19H2
DMNIPE6 CS C1=CC2=C(C=CC=C2Br)C(=C1)C3=NC4=C(O3)C=CC(=C4)N
DMNIPE6 IK XWSBTBHNERIRTD-UHFFFAOYSA-N
DMNIPE6 IU 2-(5-bromonaphthalen-1-yl)-1,3-benzoxazol-5-amine
DMR5V2A ID DMR5V2A
DMR5V2A DN Benzo[d]oxazole derivative 2
DMR5V2A HS Patented
DMR5V2A SN PMID28454500-Compound-80
DMR5V2A CP Korea Institute of Radiological & Medical Sciences, S
DMR5V2A DT Small molecular drug
DMR5V2A PC 650480
DMR5V2A MW 260.29
DMR5V2A FM C17H12N2O
DMR5V2A IC InChI=1S/C17H12N2O/c18-12-8-9-16-15(10-12)19-17(20-16)14-7-3-5-11-4-1-2-6-13(11)14/h1-10H,18H2
DMR5V2A CS C1=CC=C2C(=C1)C=CC=C2C3=NC4=C(O3)C=CC(=C4)N
DMR5V2A IK NCQQMVULPNMPEH-UHFFFAOYSA-N
DMR5V2A IU 2-naphthalen-1-yl-1,3-benzoxazol-5-amine
DM712Y0 ID DM712Y0
DM712Y0 DN Benzo[d]oxazole derivative 3
DM712Y0 HS Patented
DM712Y0 SN PMID28454500-Compound-81
DM712Y0 CP Korea Institute of Radiological & Medical Sciences, S
DM712Y0 DT Small molecular drug
DM0RAC6 ID DM0RAC6
DM0RAC6 DN Benzo[d]oxazole derivative 4
DM0RAC6 HS Patented
DM0RAC6 SN PMID28454500-Compound-82
DM0RAC6 CP Korea Institute of Radiological & Medical Sciences, S
DM0RAC6 DT Small molecular drug
DM0RAC6 PC 17609434
DM0RAC6 MW 300.31
DM0RAC6 FM C16H16N2O4
DM0RAC6 IC InChI=1S/C16H16N2O4/c1-19-13-6-9(7-14(20-2)15(13)21-3)16-18-11-8-10(17)4-5-12(11)22-16/h4-8H,17H2,1-3H3
DM0RAC6 CS COC1=CC(=CC(=C1OC)OC)C2=NC3=C(O2)C=CC(=C3)N
DM0RAC6 IK HVSQIFZUOAJQOV-UHFFFAOYSA-N
DM0RAC6 IU 2-(3,4,5-trimethoxyphenyl)-1,3-benzoxazol-5-amine
DMFXC5L ID DMFXC5L
DMFXC5L DN Benzodiazepine derivative 1
DMFXC5L HS Patented
DMFXC5L SN PMID27607364-Compound-3
DMFXC5L CP COCENSYS, INC
DMFXC5L DT Small molecular drug
DMFXC5L PC 1688
DMFXC5L MW 319.2
DMFXC5L FM C16H12Cl2N2O
DMFXC5L IC InChI=1S/C16H12Cl2N2O/c1-20-14-7-6-12(18)8-13(14)16(19-9-15(20)21)10-2-4-11(17)5-3-10/h2-8H,9H2,1H3
DMFXC5L CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=C(C=C3)Cl
DMFXC5L IK PUMYFTJOWAJIKF-UHFFFAOYSA-N
DMFXC5L IU 7-chloro-5-(4-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
DMFXC5L CA CAS 14439-61-3
DM5ZGNK ID DM5ZGNK
DM5ZGNK DN Benzodiazepine derivative 2
DM5ZGNK HS Patented
DM5ZGNK SN PMID27321640-Compound-15
DM5ZGNK CP NEURO3D UNIVERSITE LOUIS PASTEUR CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE FORENAP BOURGUIGNON, Jean-Jacques LUGNIER, Claire ABARGHAZ, Mustapha LAGOUGE, Yan WAGNER, Patrick MONDADORI, Cesare MACHER, Jean-Paul SCHULTZ, Dominique RABOISSON, PierrNeuro3d
DM5ZGNK DT Small molecular drug
DM249KU ID DM249KU
DM249KU DN Benzodihydroisofuran derivative 1
DM249KU HS Patented
DM249KU SN PMID28699813-Compound-6
DM249KU CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DM249KU DT Small molecular drug
DM249KU PC 54577783
DM249KU MW 474.9
DM249KU FM C25H22ClF3N2O2
DM249KU IC InChI=1S/C25H22ClF3N2O2/c26-18-9-12-30-22(15-18)23-20-3-1-2-4-21(20)24(33-23)10-13-31(14-11-24)16-17-5-7-19(8-6-17)32-25(27,28)29/h1-9,12,15,23H,10-11,13-14,16H2
DM249KU CS C1CN(CCC12C3=CC=CC=C3C(O2)C4=NC=CC(=C4)Cl)CC5=CC=C(C=C5)OC(F)(F)F
DM249KU IK LFFCKQUVNSOFQR-UHFFFAOYSA-N
DM249KU IU 1-(4-chloropyridin-2-yl)-1'-[[4-(trifluoromethoxy)phenyl]methyl]spiro[1H-2-benzofuran-3,4'-piperidine]
DMGK0FD ID DMGK0FD
DMGK0FD DN Benzodihydroisofuran derivative 2
DMGK0FD HS Patented
DMGK0FD SN PMID28699813-Compound-7
DMGK0FD CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DMGK0FD DT Small molecular drug
DMGK0FD PC 57393568
DMGK0FD MW 503.9
DMGK0FD FM C26H25ClF3N3O2
DMGK0FD IC InChI=1S/C26H25ClF3N3O2/c1-24(2,17-5-7-19(8-6-17)34-26(28,29)30)33-14-10-25(11-15-33)23-20(4-3-12-32-23)22(35-25)21-16-18(27)9-13-31-21/h3-9,12-13,16,22H,10-11,14-15H2,1-2H3
DMGK0FD CS CC(C)(C1=CC=C(C=C1)OC(F)(F)F)N2CCC3(CC2)C4=C(C=CC=N4)C(O3)C5=NC=CC(=C5)Cl
DMGK0FD IK YOXWNCRWJMZYKR-UHFFFAOYSA-N
DMGK0FD IU 5-(4-chloropyridin-2-yl)-1'-[2-[4-(trifluoromethoxy)phenyl]propan-2-yl]spiro[5H-furo[3,4-b]pyridine-7,4'-piperidine]
DMF6B1I ID DMF6B1I
DMF6B1I DN Benzodihydroisofuran derivative 3
DMF6B1I HS Patented
DMF6B1I SN PMID28699813-Compound-8
DMF6B1I CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DMF6B1I DT Small molecular drug
DMF6B1I PC 57404019
DMF6B1I MW 509.3
DMF6B1I FM C25H21Cl2F3N2O2
DMF6B1I IC InChI=1S/C25H21Cl2F3N2O2/c26-18-12-17(13-19(27)14-18)22-21-2-1-9-31-23(21)24(34-22)7-10-32(11-8-24)15-16-3-5-20(6-4-16)33-25(28,29)30/h1-6,9,12-14,22H,7-8,10-11,15H2
DMF6B1I CS C1CN(CCC12C3=C(C=CC=N3)C(O2)C4=CC(=CC(=C4)Cl)Cl)CC5=CC=C(C=C5)OC(F)(F)F
DMF6B1I IK LKCGVBONYVRCLD-UHFFFAOYSA-N
DMF6B1I IU 5-(3,5-dichlorophenyl)-1'-[[4-(trifluoromethoxy)phenyl]methyl]spiro[5H-furo[3,4-b]pyridine-7,4'-piperidine]
DM5IH2O ID DM5IH2O
DM5IH2O DN Benzodihydroisofuran derivative 4
DM5IH2O HS Patented
DM5IH2O SN PMID28699813-Compound-A
DM5IH2O CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason LouiMerck & Co., Inc., Kenilworth, NJ, USA
DM5IH2O DT Small molecular drug
DM4198Z ID DM4198Z
DM4198Z DN Benzofurans derivative 1
DM4198Z HS Patented
DM4198Z SN PMID27414413-Compound-Figure6left
DM4198Z CP J-PHARMA CO., LTD. WEMPE, Michael, F. ENDOU, Hitoshi
DM4198Z DT Small molecular drug
DM3K25J ID DM3K25J
DM3K25J DN Benzoheterocyclic compound 1
DM3K25J HS Patented
DM3K25J SN PMID28594589-Compound-TABLE3c5
DM3K25J CP Shanghai Kechow Pharma
DM3K25J DT Small molecular drug
DM3K25J PC 71668126
DM3K25J MW 550.9
DM3K25J FM C19H18BrClFN3O4S2
DM3K25J IC InChI=1S/C19H18BrClFN3O4S2/c20-10-1-2-13(12(21)5-10)24-17-14(6-15-18(16(17)22)23-9-30-15)25-31(28,29)19(3-4-19)7-11(27)8-26/h1-2,5-6,9,11,24-27H,3-4,7-8H2
DM3K25J CS C1CC1(CC(CO)O)S(=O)(=O)NC2=CC3=C(C(=C2NC4=C(C=C(C=C4)Br)Cl)F)N=CS3
DM3K25J IK AITYBOUARXLEQK-UHFFFAOYSA-N
DM3K25J IU N-[5-(4-bromo-2-chloroanilino)-4-fluoro-1,3-benzothiazol-6-yl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
DM5ZKR2 ID DM5ZKR2
DM5ZKR2 DN Benzoic acid derivative 1
DM5ZKR2 HS Patented
DM5ZKR2 SN PMID27414413-Compound-Figure4up
DM5ZKR2 CP WELLSTAT THERAPEUTICS CORPORATION SHARMA, Shalini VON BORSTEL, Reid, W
DM5ZKR2 DT Small molecular drug
DMND8R0 ID DMND8R0
DMND8R0 DN Benzoic acid linked peptide analog 1
DMND8R0 HS Patented
DMND8R0 SN PMID26815044-Compound-79
DMND8R0 DT Peptide
DMND8R0 SQ Gallic acid KECG
DMND8R0 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMUBG20 ID DMUBG20
DMUBG20 DN Benzoic acid linked peptide analog 2
DMUBG20 HS Patented
DMUBG20 SN PMID26815044-Compound-80
DMUBG20 DT Peptide
DMUBG20 SQ (Gallic acid)2 KECG
DMUBG20 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM42BU9 ID DM42BU9
DM42BU9 DN Benzoic acid linked peptide analog 3
DM42BU9 HS Patented
DM42BU9 SN PMID26815044-Compound-81
DM42BU9 DT Peptide
DM42BU9 SQ Gallic acid ECG
DM42BU9 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMNX5EU ID DMNX5EU
DMNX5EU DN Benzoic acid linked peptide analog 4
DMNX5EU HS Patented
DMNX5EU SN PMID26815044-Compound-82
DMNX5EU DT Peptide
DMNX5EU SQ Gallic acid YHY
DMNX5EU DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMNIZAR ID DMNIZAR
DMNIZAR DN Benzoic acid linked peptide analog 5
DMNIZAR HS Patented
DMNIZAR SN PMID26815044-Compound-83
DMNIZAR DT Peptide
DMNIZAR SQ (Gallic acid)2 KYHY
DMNIZAR DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMTHKES ID DMTHKES
DMTHKES DN Benzoic acid linked peptide analog 6
DMTHKES HS Patented
DMTHKES SN PMID26815044-Compound-84
DMTHKES DT Peptide
DMTHKES SQ Gallic acid YGGFLRFKYPK
DMTHKES DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMUJFCK ID DMUJFCK
DMUJFCK DN Benzoimidazole derivative 1
DMUJFCK HS Patented
DMUJFCK SN PMID28594589-Compound-TABLE3c6
DMUJFCK CP Array BioPharma
DMUJFCK DT Small molecular drug
DMUJFCK PC 73775787
DMUJFCK MW 497.3
DMUJFCK FM C21H23BrF2N4O3
DMUJFCK IC InChI=1S/C21H23BrF2N4O3/c1-21(2,3)30-7-8-31-27-20(29)13-10-16-19(25-11-28(16)4)17(24)18(13)26-15-6-5-12(22)9-14(15)23/h5-6,9-11,26H,7-8H2,1-4H3,(H,27,29)
DMUJFCK CS CC(C)(C)OCCONC(=O)C1=CC2=C(C(=C1NC3=C(C=C(C=C3)Br)F)F)N=CN2C
DMUJFCK IK MZHRFHRSYBBMON-UHFFFAOYSA-N
DMUJFCK IU 6-(4-bromo-2-fluoroanilino)-7-fluoro-3-methyl-N-[2-[(2-methylpropan-2-yl)oxy]ethoxy]benzimidazole-5-carboxamide
DMUJFCK CA CAS 1604812-70-5
DMHX5VO ID DMHX5VO
DMHX5VO DN Benzoimidazole derivative 2
DMHX5VO HS Patented
DMHX5VO SN PMID28594589-Compound-TABLE3c7
DMHX5VO CP Array BioPharma
DMHX5VO DT Small molecular drug
DMM9J34 ID DMM9J34
DMM9J34 DN Benzonaphthyridine derivative 1
DMM9J34 HS Patented
DMM9J34 SN PMID25684022-Compound-WO2008109599
DMM9J34 CP WYETH WISSNER, Allan VENKATESAN, Aranapakam, M
DMM9J34 DT Small molecular drug
DMM9J34 DE Solid tumour/cancer; Metastatic cancer
DMB74LZ ID DMB74LZ
DMB74LZ DN Benzonaphthyridine derivative 2
DMB74LZ HS Patented
DMB74LZ SN PMID25684022-Compound-WO2008109613
DMB74LZ CP WYETH WISSNER, Allan FLOYD, Middleton, Brawner, Jr. DUSHIN, Russell FRASER, Heidi, L. HU, Yongbo MADERNA, Andreas NITTOLI, Thomas WANG, Yanong, Daniel
DMB74LZ DT Small molecular drug
DMB74LZ DE Solid tumour/cancer; Metastatic cancer
DM9FPK1 ID DM9FPK1
DM9FPK1 DN Benzothiazepine analog 1
DM9FPK1 HS Patented
DM9FPK1 SN PMID27607364-Compound-67
DM9FPK1 CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giusepp
DM9FPK1 DT Small molecular drug
DM9FPK1 PC 10317281
DM9FPK1 MW 374.4
DM9FPK1 FM C23H22N2O3
DM9FPK1 IC InChI=1S/C23H22N2O3/c1-3-24(4-2)23(26)28-22-19-14-10-16-25(19)18-13-8-9-15-20(18)27-21(22)17-11-6-5-7-12-17/h5-16H,3-4H2,1-2H3
DM9FPK1 CS CCN(CC)C(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DM9FPK1 IK ZLLBRSQVPPSYMP-UHFFFAOYSA-N
DM9FPK1 IU (6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N,N-diethylcarbamate
DMR6XF4 ID DMR6XF4
DMR6XF4 DN Benzothiazepine analog 10
DMR6XF4 HS Patented
DMR6XF4 SN PMID26924192-Compound-100
DMR6XF4 CP FORMA THERAPEUTICS, INC
DMR6XF4 DT Small molecular drug
DMR6XF4 PC 118079255
DMR6XF4 MW 430.5
DMR6XF4 FM C22H27FN4O4
DMR6XF4 IC InChI=1S/C22H27FN4O4/c1-14-9-25(21(29)31-13-22(3,4)23)20-7-16(5-6-19(20)27(14)15(2)28)17-8-24-26(10-17)18-11-30-12-18/h5-8,10,14,18H,9,11-13H2,1-4H3/t14-/m0/s1
DMR6XF4 CS C[C@H]1CN(C2=C(N1C(=O)C)C=CC(=C2)C3=CN(N=C3)C4COC4)C(=O)OCC(C)(C)F
DMR6XF4 IK HUMZKOSJUNGVKQ-AWEZNQCLSA-N
DMR6XF4 IU (2-fluoro-2-methylpropyl) (3S)-4-acetyl-3-methyl-7-[1-(oxetan-3-yl)pyrazol-4-yl]-2,3-dihydroquinoxaline-1-carboxylate
DMVC51O ID DMVC51O
DMVC51O DN Benzothiazepine analog 11
DMVC51O HS Patented
DMVC51O SN PMID26924192-Compound-101
DMVC51O CP FORMA THERAPEUTICS, INC
DMVC51O DT Small molecular drug
DMVC51O PC 118080527
DMVC51O MW 486.6
DMVC51O FM C24H30N4O5S
DMVC51O IC InChI=1S/C24H30N4O5S/c1-16-14-26(24(30)33-21-4-3-5-21)23-12-18(6-7-22(23)28(16)17(2)29)19-13-25-27(15-19)20-8-10-34(31,32)11-9-20/h6-7,12-13,15-16,20-21H,3-5,8-11,14H2,1-2H3/t16-/m0/s1
DMVC51O CS C[C@H]1CN(C2=C(N1C(=O)C)C=CC(=C2)C3=CN(N=C3)C4CCS(=O)(=O)CC4)C(=O)OC5CCC5
DMVC51O IK OCRGMHCAJOHZLW-INIZCTEOSA-N
DMVC51O IU cyclobutyl (3S)-4-acetyl-7-[1-(1,1-dioxothian-4-yl)pyrazol-4-yl]-3-methyl-2,3-dihydroquinoxaline-1-carboxylate
DM7XQ18 ID DM7XQ18
DM7XQ18 DN Benzothiazepine analog 12
DM7XQ18 HS Patented
DM7XQ18 SN PMID26924192-Compound-99
DM7XQ18 CP FORMA THERAPEUTICS, INC
DM7XQ18 DT Small molecular drug
DM7XQ18 PC 118080061
DM7XQ18 MW 422.5
DM7XQ18 FM C24H30N4O3
DM7XQ18 IC InChI=1S/C24H30N4O3/c1-16-14-26(24(30)31-21-8-3-4-9-21)23-12-18(10-11-22(23)28(16)17(2)29)19-13-25-27(15-19)20-6-5-7-20/h10-13,15-16,20-21H,3-9,14H2,1-2H3/t16-/m0/s1
DM7XQ18 CS C[C@H]1CN(C2=C(N1C(=O)C)C=CC(=C2)C3=CN(N=C3)C4CCC4)C(=O)OC5CCCC5
DM7XQ18 IK YYISYQUFPYKFLD-INIZCTEOSA-N
DM7XQ18 IU cyclopentyl (3S)-4-acetyl-7-(1-cyclobutylpyrazol-4-yl)-3-methyl-2,3-dihydroquinoxaline-1-carboxylate
DMZ3NSJ ID DMZ3NSJ
DMZ3NSJ DN Benzothiazepine analog 2
DMZ3NSJ HS Patented
DMZ3NSJ SN PMID27607364-Compound-68
DMZ3NSJ CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMZ3NSJ DT Small molecular drug
DMZ3NSJ PC 10668139
DMZ3NSJ MW 390.5
DMZ3NSJ FM C23H22N2O2S
DMZ3NSJ IC InChI=1S/C23H22N2O2S/c1-3-24(4-2)23(26)27-21-19-14-10-16-25(19)18-13-8-9-15-20(18)28-22(21)17-11-6-5-7-12-17/h5-16H,3-4H2,1-2H3
DMZ3NSJ CS CCN(CC)C(=O)OC1=C(SC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMZ3NSJ IK LEFJQLQZGXZKSP-UHFFFAOYSA-N
DMZ3NSJ IU (6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-yl) N,N-diethylcarbamate
DM24NZG ID DM24NZG
DM24NZG DN Benzothiazepine analog 3
DM24NZG HS Patented
DM24NZG SN PMID27607364-Compound-69
DM24NZG CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DM24NZG DT Small molecular drug
DM24NZG PC 9950117
DM24NZG MW 346.4
DM24NZG FM C21H18N2O3
DM24NZG IC InChI=1S/C21H18N2O3/c1-22(2)21(24)26-20-17-12-8-14-23(17)16-11-6-7-13-18(16)25-19(20)15-9-4-3-5-10-15/h3-14H,1-2H3
DM24NZG CS CN(C)C(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DM24NZG IK ROZBXXFOBQMJQB-UHFFFAOYSA-N
DM24NZG IU (6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N,N-dimethylcarbamate
DMV4OTD ID DMV4OTD
DMV4OTD DN Benzothiazepine analog 4
DMV4OTD HS Patented
DMV4OTD SN PMID27607364-Compound-70
DMV4OTD CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMV4OTD DT Small molecular drug
DMV4OTD PC 10338693
DMV4OTD MW 362.4
DMV4OTD FM C21H18N2O2S
DMV4OTD IC InChI=1S/C21H18N2O2S/c1-22(2)21(24)25-19-17-12-8-14-23(17)16-11-6-7-13-18(16)26-20(19)15-9-4-3-5-10-15/h3-14H,1-2H3
DMV4OTD CS CN(C)C(=O)OC1=C(SC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMV4OTD IK FGXDSIINDRBSII-UHFFFAOYSA-N
DMV4OTD IU (6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-yl) N,N-dimethylcarbamate
DMCH1WX ID DMCH1WX
DMCH1WX DN Benzothiazepine analog 5
DMCH1WX HS Patented
DMCH1WX SN PMID27607364-Compound-71
DMCH1WX CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMCH1WX DT Small molecular drug
DMCH1WX PC 9927532
DMCH1WX MW 331.4
DMCH1WX FM C21H17NO3
DMCH1WX IC InChI=1S/C21H17NO3/c1-14-9-11-16(12-10-14)20-21(24-15(2)23)18-7-5-13-22(18)17-6-3-4-8-19(17)25-20/h3-13H,1-2H3
DMCH1WX CS CC1=CC=C(C=C1)C2=C(C3=CC=CN3C4=CC=CC=C4O2)OC(=O)C
DMCH1WX IK SJEIIHOXPXOSSN-UHFFFAOYSA-N
DMCH1WX IU [6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7-yl] acetate
DMB5KLD ID DMB5KLD
DMB5KLD DN Benzothiazepine analog 6
DMB5KLD HS Patented
DMB5KLD SN PMID27607364-Compound-72
DMB5KLD CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMB5KLD DT Small molecular drug
DMB5KLD PC 9798976
DMB5KLD MW 360.4
DMB5KLD FM C22H20N2O3
DMB5KLD IC InChI=1S/C22H20N2O3/c1-15-10-12-16(13-11-15)20-21(27-22(25)23(2)3)18-8-6-14-24(18)17-7-4-5-9-19(17)26-20/h4-14H,1-3H3
DMB5KLD CS CC1=CC=C(C=C1)C2=C(C3=CC=CN3C4=CC=CC=C4O2)OC(=O)N(C)C
DMB5KLD IK KVEJUNNTLYYMDH-UHFFFAOYSA-N
DMB5KLD IU [6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7-yl] N,N-dimethylcarbamate
DM25ZY4 ID DM25ZY4
DM25ZY4 DN Benzothiazepine analog 7
DM25ZY4 HS Patented
DM25ZY4 SN PMID27607364-Compound-73
DM25ZY4 CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DM25ZY4 DT Small molecular drug
DM25ZY4 PC 10045805
DM25ZY4 MW 388.5
DM25ZY4 FM C24H24N2O3
DM25ZY4 IC InChI=1S/C24H24N2O3/c1-4-25(5-2)24(27)29-23-20-10-8-16-26(20)19-9-6-7-11-21(19)28-22(23)18-14-12-17(3)13-15-18/h6-16H,4-5H2,1-3H3
DM25ZY4 CS CCN(CC)C(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=C(C=C4)C
DM25ZY4 IK DUPMTWWDEZKFAZ-UHFFFAOYSA-N
DM25ZY4 IU [6-(4-methylphenyl)pyrrolo[2,1-d][1,5]benzoxazepin-7-yl] N,N-diethylcarbamate
DMAXDV5 ID DMAXDV5
DMAXDV5 DN Benzothiazepine analog 8
DMAXDV5 HS Patented
DMAXDV5 SN PMID27607364-Compound-74
DMAXDV5 CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMAXDV5 DT Small molecular drug
DMAXDV5 PC 10809833
DMAXDV5 MW 380.8
DMAXDV5 FM C21H17ClN2O3
DMAXDV5 IC InChI=1S/C21H17ClN2O3/c1-23(2)21(25)27-20-17-12-7-13-24(17)16-11-6-10-15(22)19(16)26-18(20)14-8-4-3-5-9-14/h3-13H,1-2H3
DMAXDV5 CS CN(C)C(=O)OC1=C(OC2=C(C=CC=C2Cl)N3C1=CC=C3)C4=CC=CC=C4
DMAXDV5 IK PGDWEEZRRKJANX-UHFFFAOYSA-N
DMAXDV5 IU (4-chloro-6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N,N-dimethylcarbamate
DMONDMG ID DMONDMG
DMONDMG DN Benzothiazepine analog 9
DMONDMG HS Patented
DMONDMG SN PMID27607364-Compound-75
DMONDMG CP THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN UNIVERSITA' DI SIENA WILLIAMS, David, Clive ZISTERER, Daniela, M. NACCI, Vito CAMPIANI, Giuseppe
DMONDMG DT Small molecular drug
DMONDMG PC 10250172
DMONDMG MW 396.9
DMONDMG FM C21H17ClN2O2S
DMONDMG IC InChI=1S/C21H17ClN2O2S/c1-23(2)21(25)26-18-16-12-7-13-24(16)17-11-6-10-15(22)20(17)27-19(18)14-8-4-3-5-9-14/h3-13H,1-2H3
DMONDMG CS CN(C)C(=O)OC1=C(SC2=C(C=CC=C2Cl)N3C1=CC=C3)C4=CC=CC=C4
DMONDMG IK VCZPXCAFIGMLIM-UHFFFAOYSA-N
DMONDMG IU (4-chloro-6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-yl) N,N-dimethylcarbamate
DMMVHY4 ID DMMVHY4
DMMVHY4 DN Benzothiazine derivative 1
DMMVHY4 HS Patented
DMMVHY4 SN PMID26161698-Compound-50
DMMVHY4 DT Small molecular drug
DMMVHY4 PC 90074871
DMMVHY4 MW 537.4
DMMVHY4 FM C22H14Cl2N2O6S2
DMMVHY4 IC InChI=1S/C22H14Cl2N2O6S2/c23-15-2-1-3-16(24)14(15)11-34(31,32)13-5-7-20-17(10-13)25-22(28)21(33-20)9-12-4-6-19(27)18(8-12)26(29)30/h1-10,27H,11H2,(H,25,28)/b21-9-
DMMVHY4 CS C1=CC(=C(C(=C1)Cl)CS(=O)(=O)C2=CC3=C(C=C2)S/C(=C\\C4=CC(=C(C=C4)O)[N+](=O)[O-])/C(=O)N3)Cl
DMMVHY4 IK DOMBZVXKSRQDOJ-NKVSQWTQSA-N
DMMVHY4 IU (2Z)-6-[(2,6-dichlorophenyl)methylsulfonyl]-2-[(4-hydroxy-3-nitrophenyl)methylidene]-4H-1,4-benzothiazin-3-one
DMJ51VZ ID DMJ51VZ
DMJ51VZ DN Benzothiazine-carboxamide compound 1
DMJ51VZ HS Patented
DMJ51VZ SN PMID26936077-Compound-35
DMJ51VZ CP Amorepacific Corp
DMJ51VZ DT Small molecular drug
DMJ51VZ DE Skin inflammation
DMMP2RT ID DMMP2RT
DMMP2RT DN Benzothiazine-carboxamide compound 2
DMMP2RT HS Patented
DMMP2RT SN PMID26936077-Compound-36
DMMP2RT CP Amorepacific Corp
DMMP2RT DT Small molecular drug
DMMP2RT DE Skin inflammation
DMI31OD ID DMI31OD
DMI31OD DN Benzothiazine-carboxamide compound 3
DMI31OD HS Patented
DMI31OD SN PMID26936077-Compound-37
DMI31OD CP Amorepacific Corp
DMI31OD DT Small molecular drug
DMI31OD DE Skin inflammation
DMSR918 ID DMSR918
DMSR918 DN Benzothiazine-carboxamide compound 4
DMSR918 HS Patented
DMSR918 SN PMID26936077-Compound-38
DMSR918 CP Amorepacific Corp
DMSR918 DT Small molecular drug
DMSR918 DE Skin inflammation
DMM7N5E ID DMM7N5E
DMM7N5E DN Benzothiazine-carboxamide compound 5
DMM7N5E HS Patented
DMM7N5E SN PMID26936077-Compound-39
DMM7N5E CP Amorepacific Corp
DMM7N5E DT Small molecular drug
DMM7N5E DE Skin inflammation
DMW94IQ ID DMW94IQ
DMW94IQ DN Benzothiazine-carboxamide compound 6
DMW94IQ HS Patented
DMW94IQ SN PMID26936077-Compound-40
DMW94IQ CP Amorepacific Corp
DMW94IQ DT Small molecular drug
DMW94IQ DE Skin inflammation
DMHXFCQ ID DMHXFCQ
DMHXFCQ DN Benzothiazole analog 1
DMHXFCQ HS Patented
DMHXFCQ SN PMID26815044-Compound-36
DMHXFCQ DT Small molecular drug
DMHXFCQ PC 95745
DMHXFCQ MW 227.28
DMHXFCQ FM C13H9NOS
DMHXFCQ IC InChI=1S/C13H9NOS/c15-10-7-5-9(6-8-10)13-14-11-3-1-2-4-12(11)16-13/h1-8,15H
DMHXFCQ CS C1=CC=C2C(=C1)N=C(S2)C3=CC=C(C=C3)O
DMHXFCQ IK ODMDLCWSMSFWCW-UHFFFAOYSA-N
DMHXFCQ IU 4-(1,3-benzothiazol-2-yl)phenol
DMHXFCQ CA CAS 6265-55-0
DMHXFCQ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMUKNXF ID DMUKNXF
DMUKNXF DN Benzothiazole analog 2
DMUKNXF HS Patented
DMUKNXF SN PMID26815044-Compound-37
DMUKNXF DT Small molecular drug
DMUKNXF PC 136165239
DMUKNXF MW 311.28
DMUKNXF FM C14H8F3NO2S
DMUKNXF IC InChI=1S/C14H8F3NO2S/c15-14(16,17)7-1-4-12-10(5-7)18-13(21-12)9-3-2-8(19)6-11(9)20/h1-6,19-20H
DMUKNXF CS C1=CC2=C(C=C1C(F)(F)F)N=C(S2)C3=C(C=C(C=C3)O)O
DMUKNXF IK XQUCXFZBRZZCKD-UHFFFAOYSA-N
DMUKNXF IU 4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]benzene-1,3-diol
DMUKNXF DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMDLY38 ID DMDLY38
DMDLY38 DN Benzothiazole analog 3
DMDLY38 HS Patented
DMDLY38 SN PMID26815044-Compound-38
DMDLY38 DT Small molecular drug
DMDLY38 PC 1190414
DMDLY38 MW 497.7
DMDLY38 FM C24H23N3O3S3
DMDLY38 IC InChI=1S/C24H23N3O3S3/c1-16-4-9-20-21(15-16)32-24(26-20)18-5-7-19(8-6-18)25-23(28)17-10-12-27(13-11-17)33(29,30)22-3-2-14-31-22/h2-9,14-15,17H,10-13H2,1H3,(H,25,28)
DMDLY38 CS CC1=CC2=C(C=C1)N=C(S2)C3=CC=C(C=C3)NC(=O)C4CCN(CC4)S(=O)(=O)C5=CC=CS5
DMDLY38 IK IVGKSFUEBSXSAE-UHFFFAOYSA-N
DMDLY38 IU N-[4-(6-methyl-1,3-benzothiazol-2-yl)phenyl]-1-thiophen-2-ylsulfonylpiperidine-4-carboxamide
DMDLY38 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMNDAT0 ID DMNDAT0
DMNDAT0 DN Benzothiazole analog 4
DMNDAT0 HS Patented
DMNDAT0 SN PMID26815044-Compound-39
DMNDAT0 DT Small molecular drug
DMNDAT0 PC 136183500
DMNDAT0 MW 277.73
DMNDAT0 FM C13H8ClNO2S
DMNDAT0 IC InChI=1S/C13H8ClNO2S/c14-8-2-4-12-9(6-8)15-13(18-12)7-1-3-10(16)11(17)5-7/h1-6,16-17H
DMNDAT0 CS C1=CC(=C(C=C1C2=NC3=C(S2)C=CC(=C3)Cl)O)O
DMNDAT0 IK XSTUFGUKBUSBMM-UHFFFAOYSA-N
DMNDAT0 IU 4-(5-chloro-1,3-benzothiazol-2-yl)benzene-1,2-diol
DMNDAT0 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMN1J09 ID DMN1J09
DMN1J09 DN Benzothiazole analog 5
DMN1J09 HS Patented
DMN1J09 SN PMID26815044-Compound-40
DMN1J09 DT Small molecular drug
DMN1J09 PC 68279301
DMN1J09 MW 347.8
DMN1J09 FM C17H14ClNO3S
DMN1J09 IC InChI=1S/C17H14ClNO3S/c1-17(2,16(20)21)22-12-6-3-10(4-7-12)15-19-13-9-11(18)5-8-14(13)23-15/h3-9H,1-2H3,(H,20,21)
DMN1J09 CS CC(C)(C(=O)O)OC1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)Cl
DMN1J09 IK HJOJVKDSEPDKSE-UHFFFAOYSA-N
DMN1J09 IU 2-[4-(5-chloro-1,3-benzothiazol-2-yl)phenoxy]-2-methylpropanoic acid
DMN1J09 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMJDC5T ID DMJDC5T
DMJDC5T DN Benzothiazoline derivative 1
DMJDC5T HS Patented
DMJDC5T SN PMID26815044-Compound-41
DMJDC5T DT Small molecular drug
DMJDC5T PC 68279544
DMJDC5T MW 323.8
DMJDC5T FM C15H14ClNO3S
DMJDC5T IC InChI=1S/C15H14ClNO3S/c1-19-11-5-8(6-12(20-2)14(11)18)15-17-10-7-9(16)3-4-13(10)21-15/h3-7,15,17-18H,1-2H3
DMJDC5T CS COC1=CC(=CC(=C1O)OC)C2NC3=C(S2)C=CC(=C3)Cl
DMJDC5T IK LQDWIAAYFSZPAR-UHFFFAOYSA-N
DMJDC5T IU 4-(5-chloro-2,3-dihydro-1,3-benzothiazol-2-yl)-2,6-dimethoxyphenol
DMJDC5T DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMCO0ZS ID DMCO0ZS
DMCO0ZS DN Benzotriazole derivative 1
DMCO0ZS HS Patented
DMCO0ZS SN PMID26560530-Compound-40
DMCO0ZS CP Universit de Montral
DMCO0ZS DT Small molecular drug
DMCO0ZS PC 25023511
DMCO0ZS MW 364.4
DMCO0ZS FM C20H20N4O3
DMCO0ZS IC InChI=1S/C20H20N4O3/c1-20(2,3)27-19(26)21-15-11-8-14(9-12-15)10-13-18(25)24-17-7-5-4-6-16(17)22-23-24/h4-13H,1-3H3,(H,21,26)/b13-10+
DMCO0ZS CS CC(C)(C)OC(=O)NC1=CC=C(C=C1)/C=C/C(=O)N2C3=CC=CC=C3N=N2
DMCO0ZS IK HXHBNXDLCDLAKO-JLHYYAGUSA-N
DMCO0ZS IU tert-butyl N-[4-[(E)-3-(benzotriazol-1-yl)-3-oxoprop-1-enyl]phenyl]carbamate
DMIYXS8 ID DMIYXS8
DMIYXS8 DN Benzoxazepine analog 1
DMIYXS8 HS Patented
DMIYXS8 SN PMID27607364-Compound-76
DMIYXS8 DT Small molecular drug
DMIYXS8 PC 9798301
DMIYXS8 MW 346.4
DMIYXS8 FM C21H18N2O3
DMIYXS8 IC InChI=1S/C21H18N2O3/c1-2-22-21(24)26-20-17-12-8-14-23(17)16-11-6-7-13-18(16)25-19(20)15-9-4-3-5-10-15/h3-14H,2H2,1H3,(H,22,24)
DMIYXS8 CS CCNC(=O)OC1=C(OC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMIYXS8 IK KPYJFQDJNXSVFL-UHFFFAOYSA-N
DMIYXS8 IU (6-phenylpyrrolo[2,1-d][1,5]benzoxazepin-7-yl) N-ethylcarbamate
DM4FHTG ID DM4FHTG
DM4FHTG DN Benzoxazinone derivative 2
DM4FHTG HS Patented
DM4FHTG SN PMID29171765-Compound-Figure3
DM4FHTG CP UNIVERSITEIT ANTWERPESIXERA PHARMA AUNIVERSITE PIERRE ET MARIE CURIE (PARIS 6QUEENSLAND UNIVERSITY OF TECHNOLOGY HARRIS, Jonathan Malcolm DE VEER, Simon John SWEDBERG, Joakim Erik
DMY01FU ID DMY01FU
DMY01FU DN Benzoxazole derivative 1
DMY01FU HS Patented
DMY01FU SN PMID26413912-Compound-83
DMY01FU CP RENOVIS, INC. KAUB, Carl GOWLUGARI, Sumithra KINCAID, John JOHNSON, Russell, James O'MAHONY, Donogh, John Roger ESTIARTE-MARTINEZ, Maria, de los Angeles DUNCTON, Matthew
DMY01FU DT Small molecular drug
DMY01FU PC 45109843
DMY01FU MW 379.5
DMY01FU FM C25H21N3O
DMY01FU IC InChI=1S/C25H21N3O/c1-2-27-12-11-19-13-17(7-9-23(19)27)18-8-10-24-22(14-18)26-25(29-24)28-15-20-5-3-4-6-21(20)16-28/h3-14H,2,15-16H2,1H3
DMY01FU CS CCN1C=CC2=C1C=CC(=C2)C3=CC4=C(C=C3)OC(=N4)N5CC6=CC=CC=C6C5
DMY01FU IK JRHOETSWOCHDIA-UHFFFAOYSA-N
DMY01FU IU 2-(1,3-dihydroisoindol-2-yl)-5-(1-ethylindol-5-yl)-1,3-benzoxazole
DMJBOL0 ID DMJBOL0
DMJBOL0 DN Benzoyl-piperidine derivative 1
DMJBOL0 HS Patented
DMJBOL0 SN PMID26609882-Compound-59
DMJBOL0 CP F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DMJBOL0 DT Small molecular drug
DMFKX1M ID DMFKX1M
DMFKX1M DN Benzoyl-piperidine derivative 2
DMFKX1M HS Patented
DMFKX1M SN PMID26609882-Compound-60
DMFKX1M CP F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DMFKX1M DT Small molecular drug
DMOU84B ID DMOU84B
DMOU84B DN Benzyl amine derivative 1
DMOU84B HS Patented
DMOU84B SN PMID29171765-Compound-Figure2a
DMOU84B CP Kalvista Pharmaceuticals Limited
DMOU84B DT Small molecular drug
DMOU84B PC 86290439
DMOU84B MW 428.5
DMOU84B FM C25H28N6O
DMOU84B IC InChI=1S/C25H28N6O/c1-18-11-28-30(14-18)15-20-3-5-21(6-4-20)16-31-17-24(13-29-31)25(32)27-12-23-8-7-22(10-26)9-19(23)2/h3-9,11,13-14,17H,10,12,15-16,26H2,1-2H3,(H,27,32)
DMOU84B CS CC1=C(C=CC(=C1)CN)CNC(=O)C2=CN(N=C2)CC3=CC=C(C=C3)CN4C=C(C=N4)C
DMOU84B IK KMRPNZXNLYKBNI-UHFFFAOYSA-N
DMOU84B IU N-[[4-(aminomethyl)-2-methylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide
DMFK7EL ID DMFK7EL
DMFK7EL DN Benzyl amine derivative 2
DMFK7EL HS Patented
DMFK7EL SN PMID29171765-Compound-Figure2b
DMFK7EL CP Kalvista Pharmaceuticals Limited
DMFK7EL DT Small molecular drug
DMFK7EL PC 86290530
DMFK7EL MW 514.5
DMFK7EL FM C26H26F4N6O
DMFK7EL IC InChI=1S/C26H26F4N6O/c1-16-10-33-35(12-16)13-18-3-5-19(6-4-18)14-36-15-22(24(34-36)26(28,29)30)25(37)32-11-21-8-7-20(9-31)23(27)17(21)2/h3-8,10,12,15H,9,11,13-14,31H2,1-2H3,(H,32,37)
DMFK7EL CS CC1=CN(N=C1)CC2=CC=C(C=C2)CN3C=C(C(=N3)C(F)(F)F)C(=O)NCC4=C(C(=C(C=C4)CN)F)C
DMFK7EL IK PKZHZUNPMZRBCV-UHFFFAOYSA-N
DMFK7EL IU N-[[4-(aminomethyl)-3-fluoro-2-methylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide
DM6PTOX ID DM6PTOX
DM6PTOX DN Benzyl phenyl ether derivative 1
DM6PTOX HS Patented
DM6PTOX SN PMID30107136-Compound-Example19
DM6PTOX CP INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DM6PTOX DT Small molecule immunotherapy
DM6PTOX PC 132181249
DM6PTOX MW 621.9
DM6PTOX FM C31H26BrClN2O5
DM6PTOX IC InChI=1S/C31H26BrClN2O5/c32-30-23(10-5-11-25(30)22-8-2-1-3-9-22)19-40-29-14-28(39-18-21-7-4-6-20(12-21)15-34)24(13-26(29)33)16-35-27(17-36)31(37)38/h1-14,27,35-36H,16-19H2,(H,37,38)
DM6PTOX CS C1=CC=C(C=C1)C2=CC=CC(=C2Br)COC3=C(C=C(C(=C3)OCC4=CC(=CC=C4)C#N)CNC(CO)C(=O)O)Cl
DM6PTOX IK GSJUKYYDHBOJEP-UHFFFAOYSA-N
DM6PTOX IU 2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanoic acid
DM6PTOX DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMMS4EI ID DMMS4EI
DMMS4EI DN Benzyl phenyl ether derivative 2
DMMS4EI HS Patented
DMMS4EI SN PMID30107136-Compound-Example20
DMMS4EI CP INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMMS4EI DT Small molecule immunotherapy
DMMS4EI PC 132181275
DMMS4EI MW 577.9
DMMS4EI FM C30H26BrClN2O3
DMMS4EI IC InChI=1S/C30H26BrClN2O3/c31-30-24(10-5-11-26(30)23-8-2-1-3-9-23)20-37-29-16-28(25(15-27(29)32)18-34-12-13-35)36-19-22-7-4-6-21(14-22)17-33/h1-11,14-16,34-35H,12-13,18-20H2
DMMS4EI CS C1=CC=C(C=C1)C2=CC=CC(=C2Br)COC3=C(C=C(C(=C3)OCC4=CC(=CC=C4)C#N)CNCCO)Cl
DMMS4EI IK WFKSDDBJJFYOET-UHFFFAOYSA-N
DMMS4EI IU 3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-4-chloro-2-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile
DMMS4EI DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMIAB94 ID DMIAB94
DMIAB94 DN Benzyl pyrrolyloxoacetamide derivative 1
DMIAB94 HS Patented
DMIAB94 SN PMID26413912-Compound-89
DMIAB94 CP IRONWOOD PHARMACEUTICALS, INC. HUDSON, Colleen BARDEN, Timothy, C. JIA, James MERMERIAN, Ara PENG, Bo YANG, Jane YU, Xiang, Y. SPROTT, Kevin FRETZEN, AngelikIRONWOOD PHARMACEUTICALS, INC. SPROTT, Kevin TALLEY, John, Jeffrey YANG, Jane PENG, Bo
DMIAB94 DT Small molecular drug
DMIAB94 PC 53482754
DMIAB94 MW 453.9
DMIAB94 FM C23H20ClN3O3S
DMIAB94 IC InChI=1S/C23H20ClN3O3S/c1-13-10-18-22(31-13)20(14(2)27(18)12-15-4-6-16(24)7-5-15)21(28)23(29)26-17-8-9-25-19(11-17)30-3/h4-11H,12H2,1-3H3,(H,25,26,29)
DMIAB94 CS CC1=CC2=C(S1)C(=C(N2CC3=CC=C(C=C3)Cl)C)C(=O)C(=O)NC4=CC(=NC=C4)OC
DMIAB94 IK KJJWMDHJTAKZAD-UHFFFAOYSA-N
DMIAB94 IU 2-[4-[(4-chlorophenyl)methyl]-2,5-dimethylthieno[3,2-b]pyrrol-6-yl]-N-(2-methoxypyridin-4-yl)-2-oxoacetamide
DMHOLQF ID DMHOLQF
DMHOLQF DN Benzyl pyrrolyloxoacetamide derivative 2
DMHOLQF HS Patented
DMHOLQF SN PMID26413912-Compound-90
DMHOLQF CP IRONWOOD PHARMACEUTICALS, INCIRONWOOD PHARMACEUTICALS, INC
DMHOLQF DT Small molecular drug
DMHOLQF PC 67984463
DMHOLQF MW 484.4
DMHOLQF FM C24H19F3N4O4
DMHOLQF IC InChI=1S/C24H19F3N4O4/c1-12-22(23(32)24(33)30-14-4-5-28-21(7-14)35-3)15-8-20(34-2)17(27)9-19(15)31(12)11-18-16(26)6-13(25)10-29-18/h4-10H,11H2,1-3H3,(H,28,30,33)
DMHOLQF CS CC1=C(C2=CC(=C(C=C2N1CC3=C(C=C(C=N3)F)F)F)OC)C(=O)C(=O)NC4=CC(=NC=C4)OC
DMHOLQF IK SUOOBQNAIURDKV-UHFFFAOYSA-N
DMHOLQF IU 2-[1-[(3,5-difluoropyridin-2-yl)methyl]-6-fluoro-5-methoxy-2-methylindol-3-yl]-N-(2-methoxypyridin-4-yl)-2-oxoacetamide
DMD7Z3H ID DMD7Z3H
DMD7Z3H DN Benzylcinnamate
DMD7Z3H HS Patented
DMD7Z3H CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMD7Z3H DT Small molecular drug
DMD7Z3H PC 5273469
DMD7Z3H MW 238.28
DMD7Z3H FM C16H14O2
DMD7Z3H IC InChI=1S/C16H14O2/c17-16(12-11-14-7-3-1-4-8-14)18-13-15-9-5-2-6-10-15/h1-12H,13H2/b12-11+
DMD7Z3H CS C1=CC=C(C=C1)COC(=O)/C=C/C2=CC=CC=C2
DMD7Z3H IK NGHOLYJTSCBCGC-VAWYXSNFSA-N
DMD7Z3H IU benzyl (E)-3-phenylprop-2-enoate
DMD7Z3H CA CAS 103-41-3
DMD7Z3H CB CHEBI:146174
DMZKTHL ID DMZKTHL
DMZKTHL DN Beta-cyclodextrin conjugate derivative 1
DMZKTHL HS Patented
DMZKTHL SN PMID26651364-Compound-129
DMZKTHL CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMZKTHL DT Carbohydrates
DMZKTHL DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM9W1FO ID DM9W1FO
DM9W1FO DN Beta-cyclodextrin conjugate derivative 2
DM9W1FO HS Patented
DM9W1FO SN PMID26651364-Compound-130
DM9W1FO CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DM9W1FO DT Carbohydrates
DM9W1FO DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQJF4P ID DMQJF4P
DMQJF4P DN Beta-cyclodextrin conjugate derivative 3
DMQJF4P HS Patented
DMQJF4P SN PMID26651364-Compound-131
DMQJF4P CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMQJF4P DT Carbohydrates
DMQJF4P DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMO9RE8 ID DMO9RE8
DMO9RE8 DN Beta-cyclodextrin conjugate derivative 4
DMO9RE8 HS Patented
DMO9RE8 SN PMID26651364-Compound-132
DMO9RE8 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMO9RE8 DT Carbohydrates
DMO9RE8 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DML2B7G ID DML2B7G
DML2B7G DN Beta-cyclodextrin conjugate derivative 5
DML2B7G HS Patented
DML2B7G SN PMID26651364-Compound-133
DML2B7G CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DML2B7G DT Carbohydrates
DML2B7G DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMCDR7 ID DMMCDR7
DMMCDR7 DN Betais-sulfonylamino derivative 1
DMMCDR7 HS Patented
DMMCDR7 SN PMID28627961-Compound-40
DMMCDR7 CP ASTRAZENECA AB [SE]
DMMCDR7 DT Small molecular drug
DMMCDR7 PC 42596932
DMMCDR7 MW 486.5
DMMCDR7 FM C22H18N2O7S2
DMMCDR7 IC InChI=1S/C22H18N2O7S2/c1-30-18-13-15(10-11-16(18)19-12-14-6-2-3-7-17(14)31-19)22(25)24-33(28,29)21-9-5-4-8-20(21)32(23,26)27/h2-13H,1H3,(H,24,25)(H2,23,26,27)
DMMCDR7 CS COC1=C(C=CC(=C1)C(=O)NS(=O)(=O)C2=CC=CC=C2S(=O)(=O)N)C3=CC4=CC=CC=C4O3
DMMCDR7 IK JTTOZXONFHYBAF-UHFFFAOYSA-N
DMMCDR7 IU 4-(1-benzofuran-2-yl)-3-methoxy-N-(2-sulfamoylphenyl)sulfonylbenzamide
DM5KTDY ID DM5KTDY
DM5KTDY DN Beta-naphthylacetic acids derivative 1
DM5KTDY HS Patented
DM5KTDY SN PMID28895472-Compound-26
DM5KTDY CP THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA VANDERBILT UNIVERSITY
DM5KTDY DT Small molecular drug
DM5KTDY PC 66706413
DM5KTDY MW 244.28
DM5KTDY FM C15H16O3
DM5KTDY IC InChI=1S/C15H16O3/c1-3-14(15(16)17)12-5-4-11-9-13(18-2)7-6-10(11)8-12/h4-9,14H,3H2,1-2H3,(H,16,17)/t14-/m1/s1
DM5KTDY CS CC[C@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
DM5KTDY IK LSDAHSHHKKHOKE-CQSZACIVSA-N
DM5KTDY IU (2R)-2-(6-methoxynaphthalen-2-yl)butanoic acid
DM8D3FG ID DM8D3FG
DM8D3FG DN Beta-phe compound 1
DM8D3FG HS Patented
DM8D3FG SN PMID25482888-Compound-39
DM8D3FG DT Peptide
DM786OD ID DM786OD
DM786OD DN Beta-phe compound 2
DM786OD HS Patented
DM786OD SN PMID25482888-Compound-40
DM786OD DT Peptide
DM0G8XP ID DM0G8XP
DM0G8XP DN Beta-phe compound 3
DM0G8XP HS Patented
DM0G8XP SN PMID25482888-Compound-41
DM0G8XP DT Peptide
DM79WI1 ID DM79WI1
DM79WI1 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1
DM79WI1 HS Patented
DM79WI1 SN PMID26815044-Compound-65
DM79WI1 DT Small molecular drug
DM79WI1 PC 1276529
DM79WI1 MW 221.23
DM79WI1 FM C10H7NO3S
DM79WI1 IC InChI=1S/C10H7NO3S/c12-7-3-1-6(2-4-7)5-8-9(13)11-10(14)15-8/h1-5,12H,(H,11,13,14)/b8-5-
DM79WI1 CS C1=CC(=CC=C1/C=C\\2/C(=O)NC(=O)S2)O
DM79WI1 IK ARHIHDVVUHVQCP-YVMONPNESA-N
DM79WI1 IU (5Z)-5-[(4-hydroxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DM79WI1 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMRXMCH ID DMRXMCH
DMRXMCH DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10
DMRXMCH HS Patented
DMRXMCH SN PMID26815044-Compound-74
DMRXMCH DT Small molecular drug
DMRXMCH PC 5751025
DMRXMCH MW 253.3
DMRXMCH FM C10H7NO3S2
DMRXMCH IC InChI=1S/C10H7NO3S2/c12-6-2-1-5(7(13)4-6)3-8-9(14)11-10(15)16-8/h1-4,12-13H,(H,11,14,15)/b8-3-
DMRXMCH CS C1=CC(=C(C=C1O)O)/C=C\\2/C(=O)NC(=S)S2
DMRXMCH IK GZGFGVYXIOPNPH-BAQGIRSFSA-N
DMRXMCH IU (5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
DMRXMCH DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMVPR1D ID DMVPR1D
DMVPR1D DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11
DMVPR1D HS Patented
DMVPR1D SN PMID26815044-Compound-75
DMVPR1D DT Small molecular drug
DMVPR1D PC 1379698
DMVPR1D MW 267.3
DMVPR1D FM C11H9NO3S2
DMVPR1D IC InChI=1S/C11H9NO3S2/c1-15-8-3-2-6(4-7(8)13)5-9-10(14)12-11(16)17-9/h2-5,13H,1H3,(H,12,14,16)/b9-5-
DMVPR1D CS COC1=C(C=C(C=C1)/C=C\\2/C(=O)NC(=S)S2)O
DMVPR1D IK PCTZLDOIVAVMME-UITAMQMPSA-N
DMVPR1D IU (5Z)-5-[(3-hydroxy-4-methoxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
DMVPR1D DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMOHBCN ID DMOHBCN
DMOHBCN DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12
DMOHBCN HS Patented
DMOHBCN SN PMID26815044-Compound-76
DMOHBCN DT Small molecular drug
DMOHBCN PC 5851417
DMOHBCN MW 250.28
DMOHBCN FM C11H10N2O3S
DMOHBCN IC InChI=1S/C11H10N2O3S/c1-16-8-3-2-6(4-7(8)14)5-9-10(15)13-11(12)17-9/h2-5,14H,1H3,(H2,12,13,15)/b9-5-
DMOHBCN CS COC1=C(C=C(C=C1)/C=C\\2/C(=O)N=C(S2)N)O
DMOHBCN IK WCHCAGWRYJMMPY-UITAMQMPSA-N
DMOHBCN IU (5Z)-2-amino-5-[(3-hydroxy-4-methoxyphenyl)methylidene]-1,3-thiazol-4-one
DMOHBCN DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMKDBQG ID DMKDBQG
DMKDBQG DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13
DMKDBQG HS Patented
DMKDBQG SN PMID26815044-Compound-77
DMKDBQG DT Small molecular drug
DMKDBQG PC 46861776
DMKDBQG MW 285.29
DMKDBQG FM C16H15NO4
DMKDBQG IC InChI=1S/C16H15NO4/c1-21-13-6-4-12(5-7-13)17-16(20)9-3-11-2-8-14(18)15(19)10-11/h2-10,18-19H,1H3,(H,17,20)/b9-3+
DMKDBQG CS COC1=CC=C(C=C1)NC(=O)/C=C/C2=CC(=C(C=C2)O)O
DMKDBQG IK MGXQKQSEWXXTPE-YCRREMRBSA-N
DMKDBQG IU (E)-3-(3,4-dihydroxyphenyl)-N-(4-methoxyphenyl)prop-2-enamide
DMKDBQG DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMWUAXM ID DMWUAXM
DMWUAXM DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14
DMWUAXM HS Patented
DMWUAXM SN PMID26815044-Compound-78
DMWUAXM DT Small molecular drug
DMWUAXM PC 46932910
DMWUAXM MW 362.2
DMWUAXM FM C17H16BrNO3
DMWUAXM IC InChI=1S/C17H16BrNO3/c18-14-5-1-12(2-6-14)9-10-19-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,20-21H,9-10H2,(H,19,22)/b8-4+
DMWUAXM CS C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)Br
DMWUAXM IK QIQBGDXOXRDDBP-XBXARRHUSA-N
DMWUAXM IU (E)-N-[2-(4-bromophenyl)ethyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide
DMWUAXM DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMAEQ0I ID DMAEQ0I
DMAEQ0I DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2
DMAEQ0I HS Patented
DMAEQ0I SN PMID26815044-Compound-66
DMAEQ0I DT Small molecular drug
DMAEQ0I PC 6280959
DMAEQ0I MW 237.23
DMAEQ0I FM C10H7NO4S
DMAEQ0I IC InChI=1S/C10H7NO4S/c12-6-2-1-5(7(13)4-6)3-8-9(14)11-10(15)16-8/h1-4,12-13H,(H,11,14,15)/b8-3-
DMAEQ0I CS C1=CC(=C(C=C1O)O)/C=C\\2/C(=O)NC(=O)S2
DMAEQ0I IK CPVBTHMWQGHRIR-BAQGIRSFSA-N
DMAEQ0I IU (5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DMAEQ0I DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMGV8T9 ID DMGV8T9
DMGV8T9 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3
DMGV8T9 HS Patented
DMGV8T9 SN PMID26815044-Compound-67
DMGV8T9 DT Small molecular drug
DMGV8T9 PC 1394178
DMGV8T9 MW 251.26
DMGV8T9 FM C11H9NO4S
DMGV8T9 IC InChI=1S/C11H9NO4S/c1-16-8-3-2-6(4-7(8)13)5-9-10(14)12-11(15)17-9/h2-5,13H,1H3,(H,12,14,15)/b9-5-
DMGV8T9 CS COC1=C(C=C(C=C1)/C=C\\2/C(=O)NC(=O)S2)O
DMGV8T9 IK MHRJJGJJVMGLRQ-UITAMQMPSA-N
DMGV8T9 IU (5Z)-5-[(3-hydroxy-4-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione
DMGV8T9 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMNQF9S ID DMNQF9S
DMNQF9S DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4
DMNQF9S HS Patented
DMNQF9S SN PMID26815044-Compound-68
DMNQF9S DT Small molecular drug
DMNQF9S PC 5337602
DMNQF9S MW 248.19
DMNQF9S FM C11H8N2O5
DMNQF9S IC InChI=1S/C11H8N2O5/c14-7-2-1-5(4-8(7)15)3-6-9(16)12-11(18)13-10(6)17/h1-4,14-15H,(H2,12,13,16,17,18)
DMNQF9S CS C1=CC(=C(C=C1C=C2C(=O)NC(=O)NC2=O)O)O
DMNQF9S IK PJCLRLDOILEINS-UHFFFAOYSA-N
DMNQF9S IU 5-[(3,4-dihydroxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
DMNQF9S CA CAS 5131-88-4
DMNQF9S DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMBC48K ID DMBC48K
DMBC48K DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5
DMBC48K HS Patented
DMBC48K SN PMID26815044-Compound-69
DMBC48K DT Small molecular drug
DMBC48K PC 5497727
DMBC48K MW 248.19
DMBC48K FM C11H8N2O5
DMBC48K IC InChI=1S/C11H8N2O5/c14-6-2-1-5(8(15)4-6)3-7-9(16)12-11(18)13-10(7)17/h1-4,14-15H,(H2,12,13,16,17,18)
DMBC48K CS C1=CC(=C(C=C1O)O)C=C2C(=O)NC(=O)NC2=O
DMBC48K IK XGRANFKYXNDTDO-UHFFFAOYSA-N
DMBC48K IU 5-[(2,4-dihydroxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
DMBC48K DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMK9XV8 ID DMK9XV8
DMK9XV8 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6
DMK9XV8 HS Patented
DMK9XV8 SN PMID26815044-Compound-70
DMK9XV8 DT Small molecular drug
DMK9XV8 PC 10059907
DMK9XV8 MW 234.21
DMK9XV8 FM C11H10N2O4
DMK9XV8 IC InChI=1S/C11H10N2O4/c1-17-9-3-2-6(5-8(9)14)4-7-10(15)13-11(16)12-7/h2-5,14H,1H3,(H2,12,13,15,16)/b7-4-
DMK9XV8 CS COC1=C(C=C(C=C1)/C=C\\2/C(=O)NC(=O)N2)O
DMK9XV8 IK CVEPZWFFKVWAMM-DAXSKMNVSA-N
DMK9XV8 IU (5Z)-5-[(3-hydroxy-4-methoxyphenyl)methylidene]imidazolidine-2,4-dione
DMK9XV8 CA CAS 4368-00-7
DMK9XV8 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMES41R ID DMES41R
DMES41R DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7
DMES41R HS Patented
DMES41R SN PMID26815044-Compound-71
DMES41R DT Small molecular drug
DMES41R PC 89613043
DMES41R MW 219.19
DMES41R FM C11H9NO4
DMES41R IC InChI=1S/C11H9NO4/c13-8-2-1-6(9(14)5-8)3-7-4-10(15)12-11(7)16/h1-3,5,13-14H,4H2,(H,12,15,16)/b7-3+
DMES41R CS C1/C(=C\\C2=C(C=C(C=C2)O)O)/C(=O)NC1=O
DMES41R IK PTHHGONJHHJYIU-XVNBXDOJSA-N
DMES41R IU (3E)-3-[(2,4-dihydroxyphenyl)methylidene]pyrrolidine-2,5-dione
DMES41R DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMRIPVG ID DMRIPVG
DMRIPVG DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8
DMRIPVG HS Patented
DMRIPVG SN PMID26815044-Compound-72
DMRIPVG DT Small molecular drug
DMRIPVG PC 89928116
DMRIPVG MW 233.22
DMRIPVG FM C12H11NO4
DMRIPVG IC InChI=1S/C12H11NO4/c1-17-10-3-2-7(5-9(10)14)4-8-6-11(15)13-12(8)16/h2-5,14H,6H2,1H3,(H,13,15,16)/b8-4+
DMRIPVG CS COC1=C(C=C(C=C1)/C=C/2\\CC(=O)NC2=O)O
DMRIPVG IK NXKPYDPDZWALNH-XBXARRHUSA-N
DMRIPVG IU (3E)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]pyrrolidine-2,5-dione
DMRIPVG DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM7U20W ID DM7U20W
DM7U20W DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9
DM7U20W HS Patented
DM7U20W SN PMID26815044-Compound-73
DM7U20W DT Small molecular drug
DM7U20W PC 5331378
DM7U20W MW 264.26
DM7U20W FM C11H8N2O4S
DM7U20W IC InChI=1S/C11H8N2O4S/c14-7-2-1-5(4-8(7)15)3-6-9(16)12-11(18)13-10(6)17/h1-4,14-15H,(H2,12,13,16,17,18)
DM7U20W CS C1=CC(=C(C=C1C=C2C(=O)NC(=S)NC2=O)O)O
DM7U20W IK DELWWBDBFMAAMG-UHFFFAOYSA-N
DM7U20W IU 5-[(3,4-dihydroxyphenyl)methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
DM7U20W DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMJG1ZS ID DMJG1ZS
DMJG1ZS DN Biaromatic compound 1
DMJG1ZS HS Patented
DMJG1ZS SN PMID25416646-Compound-Figure2-A
DMJG1ZS CP Galderma Researh & Development
DMJG1ZS DT Small molecular drug
DMHEAJQ ID DMHEAJQ
DMHEAJQ DN Biaryl compound 1
DMHEAJQ HS Patented
DMHEAJQ SN PMID30107136-Compound-Example10
DMHEAJQ CP BRISTOL-MYERS SQUIBB COMPANY
DMHEAJQ DT Small molecule immunotherapy
DMHEAJQ PC 134298944
DMHEAJQ MW 900.8
DMHEAJQ FM C49H43Cl2N5O8
DMHEAJQ IC InChI=1S/C49H43Cl2N5O8/c1-29-36(26-63-46-15-44(61-24-34-11-32(17-52)19-54-21-34)38(13-42(46)50)23-56-49(4,28-57)48(59)60)7-5-9-39(29)40-10-6-8-37(30(40)2)27-64-47-16-45(41(31(3)58)14-43(47)51)62-25-35-12-33(18-53)20-55-22-35/h5-16,19-22,56-57H,23-28H2,1-4H3,(H,59,60)
DMHEAJQ CS CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C(=C3)OCC4=CC(=CN=C4)C#N)C(=O)C)Cl)COC5=C(C=C(C(=C5)OCC6=CC(=CN=C6)C#N)CNC(C)(CO)C(=O)O)Cl
DMHEAJQ IK LBEJCLGFPBJTDE-UHFFFAOYSA-N
DMHEAJQ IU 2-[[4-[[3-[3-[[4-acetyl-2-chloro-5-[(5-cyanopyridin-3-yl)methoxy]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DMHEAJQ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMS8VYE ID DMS8VYE
DMS8VYE DN Biaryl compound 2
DMS8VYE HS Patented
DMS8VYE SN PMID30107136-Compound-Example9
DMS8VYE CP BRISTOL-MYERS SQUIBB COMPANY
DMS8VYE DT Small molecule immunotherapy
DMS8VYE PC 134282588
DMS8VYE MW 989.9
DMS8VYE FM C52H50Cl2N6O10
DMS8VYE IC InChI=1S/C52H50Cl2N6O10/c1-31-37(27-69-47-15-45(67-25-35-11-33(17-55)19-57-21-35)39(13-43(47)53)23-59-51(3,29-61)49(63)64)7-5-9-41(31)42-10-6-8-38(32(42)2)28-70-48-16-46(68-26-36-12-34(18-56)20-58-22-36)40(14-44(48)54)24-60-52(4,30-62)50(65)66/h5-16,19-22,59-62H,23-30H2,1-4H3,(H,63,64)(H,65,66)
DMS8VYE CS CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C(=C3)OCC4=CC(=CN=C4)C#N)CNC(C)(CO)C(=O)O)Cl)COC5=C(C=C(C(=C5)OCC6=CC(=CN=C6)C#N)CNC(C)(CO)C(=O)O)Cl
DMS8VYE IK JQCFAYBBTOJHLG-UHFFFAOYSA-N
DMS8VYE IU 2-[[4-[[3-[3-[[4-[[(2-carboxy-1-hydroxypropan-2-yl)amino]methyl]-2-chloro-5-[(5-cyanopyridin-3-yl)methoxy]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid
DMS8VYE DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMX6YGS ID DMX6YGS
DMX6YGS DN Biaryl mannoside derivative 1
DMX6YGS HS Patented
DMX6YGS SN PMID26651364-Compound-2a
DMX6YGS CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMX6YGS DT Carbohydrates
DMX6YGS DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMPF37N ID DMPF37N
DMPF37N DN Biaryl mannoside derivative 10
DMPF37N HS Patented
DMPF37N SN PMID26651364-Compound-3b
DMPF37N CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMPF37N DT Carbohydrates
DMPF37N DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMKES0G ID DMKES0G
DMKES0G DN Biaryl mannoside derivative 11
DMKES0G HS Patented
DMKES0G SN PMID26651364-Compound-3c
DMKES0G CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMKES0G DT Carbohydrates
DMKES0G DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM5T29W ID DM5T29W
DM5T29W DN Biaryl mannoside derivative 12
DM5T29W HS Patented
DM5T29W SN PMID26651364-Compound-3d
DM5T29W CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM5T29W DT Carbohydrates
DM5T29W DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM1Y8OM ID DM1Y8OM
DM1Y8OM DN Biaryl mannoside derivative 13
DM1Y8OM HS Patented
DM1Y8OM SN PMID26651364-Compound-3e
DM1Y8OM CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM1Y8OM DT Carbohydrates
DM1Y8OM DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4C5QY ID DM4C5QY
DM4C5QY DN Biaryl mannoside derivative 14
DM4C5QY HS Patented
DM4C5QY SN PMID26651364-Compound-3f
DM4C5QY CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM4C5QY DT Carbohydrates
DM4C5QY DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMKXT7H ID DMKXT7H
DMKXT7H DN Biaryl mannoside derivative 15
DMKXT7H HS Patented
DMKXT7H SN PMID26651364-Compound-3g
DMKXT7H CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMKXT7H DT Carbohydrates
DMKXT7H DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMP9742 ID DMP9742
DMP9742 DN Biaryl mannoside derivative 16
DMP9742 HS Patented
DMP9742 SN PMID26651364-Compound-3h
DMP9742 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMP9742 DT Carbohydrates
DMP9742 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMIXV6G ID DMIXV6G
DMIXV6G DN Biaryl mannoside derivative 17
DMIXV6G HS Patented
DMIXV6G SN PMID26651364-Compound-3i
DMIXV6G CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMIXV6G DT Carbohydrates
DMIXV6G DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMHOPE0 ID DMHOPE0
DMHOPE0 DN Biaryl mannoside derivative 18
DMHOPE0 HS Patented
DMHOPE0 SN PMID26651364-Compound-40
DMHOPE0 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMHOPE0 DT Carbohydrates
DMHOPE0 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DME8DQ0 ID DME8DQ0
DME8DQ0 DN Biaryl mannoside derivative 19
DME8DQ0 HS Patented
DME8DQ0 SN PMID26651364-Compound-41
DME8DQ0 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DME8DQ0 DT Carbohydrates
DME8DQ0 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMB60X ID DMMB60X
DMMB60X DN Biaryl mannoside derivative 2
DMMB60X HS Patented
DMMB60X SN PMID26651364-Compound-2b
DMMB60X CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMMB60X DT Carbohydrates
DMMB60X DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMNC5S0 ID DMNC5S0
DMNC5S0 DN Biaryl mannoside derivative 20
DMNC5S0 HS Patented
DMNC5S0 SN PMID26651364-Compound-42
DMNC5S0 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMNC5S0 DT Carbohydrates
DMNC5S0 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMGSLHN ID DMGSLHN
DMGSLHN DN Biaryl mannoside derivative 21
DMGSLHN HS Patented
DMGSLHN SN PMID26651364-Compound-43
DMGSLHN CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMGSLHN DT Carbohydrates
DMGSLHN DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMYLVB3 ID DMYLVB3
DMYLVB3 DN Biaryl mannoside derivative 22
DMYLVB3 HS Patented
DMYLVB3 SN PMID26651364-Compound-44
DMYLVB3 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMYLVB3 DT Carbohydrates
DMYLVB3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM2YVGH ID DM2YVGH
DM2YVGH DN Biaryl mannoside derivative 23
DM2YVGH HS Patented
DM2YVGH SN PMID26651364-Compound-59
DM2YVGH CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM2YVGH DT Carbohydrates
DM2YVGH DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMF5TB4 ID DMF5TB4
DMF5TB4 DN Biaryl mannoside derivative 24
DMF5TB4 HS Patented
DMF5TB4 SN PMID26651364-Compound-60
DMF5TB4 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMF5TB4 DT Carbohydrates
DMF5TB4 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMRM3E9 ID DMRM3E9
DMRM3E9 DN Biaryl mannoside derivative 25
DMRM3E9 HS Patented
DMRM3E9 SN PMID26651364-Compound-61
DMRM3E9 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMRM3E9 DT Carbohydrates
DMRM3E9 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMYXLCJ ID DMYXLCJ
DMYXLCJ DN Biaryl mannoside derivative 26
DMYXLCJ HS Patented
DMYXLCJ SN PMID26651364-Compound-62
DMYXLCJ CP WASHINGTON UNIVERSITY
DMYXLCJ DT Carbohydrates
DMYXLCJ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMTDPHY ID DMTDPHY
DMTDPHY DN Biaryl mannoside derivative 27
DMTDPHY HS Patented
DMTDPHY SN PMID26651364-Compound-63
DMTDPHY CP WASHINGTON UNIVERSITY
DMTDPHY DT Carbohydrates
DMTDPHY DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMSNMZ2 ID DMSNMZ2
DMSNMZ2 DN Biaryl mannoside derivative 28
DMSNMZ2 HS Patented
DMSNMZ2 SN PMID26651364-Compound-64
DMSNMZ2 CP WASHINGTON UNIVERSITY
DMSNMZ2 DT Carbohydrates
DMSNMZ2 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMCLTY3 ID DMCLTY3
DMCLTY3 DN Biaryl mannoside derivative 29
DMCLTY3 HS Patented
DMCLTY3 SN PMID26651364-Compound-65
DMCLTY3 CP WASHINGTON UNIVERSITY
DMCLTY3 DT Carbohydrates
DMCLTY3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMAITK3 ID DMAITK3
DMAITK3 DN Biaryl mannoside derivative 3
DMAITK3 HS Patented
DMAITK3 SN PMID26651364-Compound-2c
DMAITK3 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMAITK3 DT Carbohydrates
DMAITK3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMPLAWQ ID DMPLAWQ
DMPLAWQ DN Biaryl mannoside derivative 30
DMPLAWQ HS Patented
DMPLAWQ SN PMID26651364-Compound-66
DMPLAWQ CP WASHINGTON UNIVERSITY
DMPLAWQ DT Carbohydrates
DMPLAWQ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMPJ3E ID DMMPJ3E
DMMPJ3E DN Biaryl mannoside derivative 31
DMMPJ3E HS Patented
DMMPJ3E SN PMID26651364-Compound-67
DMMPJ3E CP WASHINGTON UNIVERSITY
DMMPJ3E DT Carbohydrates
DMMPJ3E DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMVF63N ID DMVF63N
DMVF63N DN Biaryl mannoside derivative 4
DMVF63N HS Patented
DMVF63N SN PMID26651364-Compound-2d
DMVF63N CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMVF63N DT Carbohydrates
DMVF63N DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMRS1WG ID DMRS1WG
DMRS1WG DN Biaryl mannoside derivative 5
DMRS1WG HS Patented
DMRS1WG SN PMID26651364-Compound-2e
DMRS1WG CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMRS1WG DT Carbohydrates
DMRS1WG DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMEWA7U ID DMEWA7U
DMEWA7U DN Biaryl mannoside derivative 6
DMEWA7U HS Patented
DMEWA7U SN PMID26651364-Compound-2f
DMEWA7U CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMEWA7U DT Carbohydrates
DMEWA7U DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMD7053 ID DMD7053
DMD7053 DN Biaryl mannoside derivative 7
DMD7053 HS Patented
DMD7053 SN PMID26651364-Compound-2g
DMD7053 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMD7053 DT Carbohydrates
DMD7053 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMWF2VG ID DMWF2VG
DMWF2VG DN Biaryl mannoside derivative 8
DMWF2VG HS Patented
DMWF2VG SN PMID26651364-Compound-2h
DMWF2VG CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMWF2VG DT Carbohydrates
DMWF2VG DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM1Q7AL ID DM1Q7AL
DM1Q7AL DN Biaryl mannoside derivative 9
DM1Q7AL HS Patented
DM1Q7AL SN PMID26651364-Compound-3a
DM1Q7AL CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM1Q7AL DT Carbohydrates
DM1Q7AL DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMDK7LQ ID DMDK7LQ
DMDK7LQ DN Bicarboxylic and tricarboxylic ethynyl derivative 1
DMDK7LQ HS Patented
DMDK7LQ SN PMID28067079-Compound-24
DMDK7LQ CP H. LUNDBECK A/S
DMDK7LQ DT Small molecular drug
DMG9O7D ID DMG9O7D
DMG9O7D DN Bicarboxylic and tricarboxylic ethynyl derivative 2
DMG9O7D HS Patented
DMG9O7D SN PMID28067079-Compound-25
DMG9O7D CP H. LUNDBECK A/S
DMG9O7D DT Small molecular drug
DMG9O7D PC 117702606
DMG9O7D MW 331.4
DMG9O7D FM C21H21N3O
DMG9O7D IC InChI=1S/C21H21N3O/c25-19(18-7-2-4-15-23-18)24-21-10-5-9-20(16-21,12-13-21)11-8-17-6-1-3-14-22-17/h1-4,6-7,14-15H,5,9-10,12-13,16H2,(H,24,25)/t20-,21+/m1/s1
DMG9O7D CS C1C[C@]2(CC[C@@](C1)(C2)NC(=O)C3=CC=CC=N3)C#CC4=CC=CC=N4
DMG9O7D IK ISUZZRVMDCKBEJ-RTWAWAEBSA-N
DMG9O7D IU N-[(1S,5R)-5-(2-pyridin-2-ylethynyl)-1-bicyclo[3.2.1]octanyl]pyridine-2-carboxamide
DM1KVTZ ID DM1KVTZ
DM1KVTZ DN Bicarboxylic and tricarboxylic ethynyl derivative 3
DM1KVTZ HS Patented
DM1KVTZ SN PMID28067079-Compound-26
DM1KVTZ CP H. LUNDBECK A/S
DM1KVTZ DT Small molecular drug
DM1KVTZ PC 71536957
DM1KVTZ MW 372.5
DM1KVTZ FM C23H24N4O
DM1KVTZ IC InChI=1S/C23H24N4O/c1-16-12-25-14-20(26-16)21(28)27-23-10-18-7-19(11-23)9-22(8-18,15-23)5-4-17-3-2-6-24-13-17/h2-3,6,12-14,18-19H,7-11,15H2,1H3,(H,27,28)
DM1KVTZ CS CC1=CN=CC(=N1)C(=O)NC23CC4CC(C2)CC(C4)(C3)C#CC5=CN=CC=C5
DM1KVTZ IK LHOOHRUEDKJGBG-UHFFFAOYSA-N
DM1KVTZ IU 6-methyl-N-[3-(2-pyridin-3-ylethynyl)-1-adamantyl]pyrazine-2-carboxamide
DMOFI09 ID DMOFI09
DMOFI09 DN Bicyclic heteroaryl amide derivative 1
DMOFI09 HS Patented
DMOFI09 SN PMID27724045-Compound-23
DMOFI09 CP H. LUNDBECK A/S
DMOFI09 DT Small molecular drug
DMOFI09 PC 25164165
DMOFI09 MW 425.5
DMOFI09 FM C26H27N5O
DMOFI09 IC InChI=1S/C26H27N5O/c1-19-8-5-10-22-23(19)21(17-31(22)25-28-14-7-15-29-25)24(32)30-18-26(11-3-2-4-12-26)20-9-6-13-27-16-20/h5-10,13-17H,2-4,11-12,18H2,1H3,(H,30,32)
DMOFI09 CS CC1=C2C(=CC=C1)N(C=C2C(=O)NCC3(CCCCC3)C4=CN=CC=C4)C5=NC=CC=N5
DMOFI09 IK OIKQYDBRBPIGDB-UHFFFAOYSA-N
DMOFI09 IU 4-methyl-N-[(1-pyridin-3-ylcyclohexyl)methyl]-1-pyrimidin-2-ylindole-3-carboxamide
DM69HL5 ID DM69HL5
DM69HL5 DN Bicyclic heteroaryl amide derivative 2
DM69HL5 HS Patented
DM69HL5 SN PMID27724045-Compound-24
DM69HL5 CP H. LUNDBECK A/S
DM69HL5 DT Small molecular drug
DM69HL5 PC 89521474
DM69HL5 MW 426.5
DM69HL5 FM C24H31FN4O2
DM69HL5 IC InChI=1S/C24H31FN4O2/c1-24(2)16-7-6-15(18(24)12-16)13-26-22(30)20-4-3-5-21-27-19(14-29(20)21)23(31)28-10-8-17(25)9-11-28/h3-5,14-18H,6-13H2,1-2H3,(H,26,30)/t15-,16-,18-/m0/s1
DM69HL5 CS CC1([C@H]2CC[C@H]([C@@H]1C2)CNC(=O)C3=CC=CC4=NC(=CN43)C(=O)N5CCC(CC5)F)C
DM69HL5 IK AOWWKPWFEIOIDV-BQFCYCMXSA-N
DM69HL5 IU N-[[(1S,2R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl]-2-(4-fluoropiperidine-1-carbonyl)imidazo[1,2-a]pyridine-5-carboxamide
DM0OYCX ID DM0OYCX
DM0OYCX DN Bicyclic heteroaryl amide derivative 3
DM0OYCX HS Patented
DM0OYCX SN PMID27724045-Compound-25
DM0OYCX CP H. LUNDBECK A/S
DM0OYCX DT Small molecular drug
DM0OYCX PC 25097947
DM0OYCX MW 421.5
DM0OYCX FM C24H31N5O2
DM0OYCX IC InChI=1S/C24H31N5O2/c25-18-3-5-28(14-18)23(31)20-9-21-19(2-1-4-29(21)27-20)26-22(30)13-24-10-15-6-16(11-24)8-17(7-15)12-24/h1-2,4,9,15-18H,3,5-8,10-14,25H2,(H,26,30)/t15?,16?,17?,18-,24?/m1/s1
DM0OYCX CS C1CN(C[C@@H]1N)C(=O)C2=NN3C=CC=C(C3=C2)NC(=O)CC45CC6CC(C4)CC(C6)C5
DM0OYCX IK CHANXFBBIWKIAI-ZWGBCBFGSA-N
DM0OYCX IU 2-(1-adamantyl)-N-[2-[(3R)-3-aminopyrrolidine-1-carbonyl]pyrazolo[1,5-a]pyridin-4-yl]acetamide
DMTBWC9 ID DMTBWC9
DMTBWC9 DN Bicyclic heteroaryl benzamide derivative 1
DMTBWC9 HS Patented
DMTBWC9 SN PMID28270021-Compound-WO2015148354Example21(R or S)
DMTBWC9 CP MERCK SHARP & DOHME CORP
DMTBWC9 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM5MT4R ID DM5MT4R
DM5MT4R DN Bicyclic heteroaryl benzamide derivative 2
DM5MT4R HS Patented
DM5MT4R SN PMID28270021-Compound-WO2015148354Example33(R or S)
DM5MT4R CP MERCK SHARP & DOHME CORP
DM5MT4R DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM54EV2 ID DM54EV2
DM54EV2 DN Bicyclic heteroaryl benzamide derivative 3
DM54EV2 HS Patented
DM54EV2 SN PMID28270021-Compound-WO2015148354Example41
DM54EV2 CP MERCK SHARP & DOHME CORP
DM54EV2 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMUBDYG ID DMUBDYG
DMUBDYG DN Bicyclic heteroaryl benzamide derivative 4
DMUBDYG HS Patented
DMUBDYG SN PMID28270021-Compound-WO2015148354Example99
DMUBDYG CP MERCK SHARP & DOHME CORP
DMUBDYG DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMFOVPT ID DMFOVPT
DMFOVPT DN Bicyclic heteroaryl benzamide derivative 5
DMFOVPT HS Patented
DMFOVPT SN PMID28270021-Compound-WO2015148373Example104
DMFOVPT CP MERCK SHARP & DOHME CORP
DMFOVPT DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMQGYWV ID DMQGYWV
DMQGYWV DN Bicyclic heteroaryl benzamide derivative 6
DMQGYWV HS Patented
DMQGYWV SN PMID28270021-Compound-WO2015148373Example111
DMQGYWV CP MERCK SHARP & DOHME CORP
DMQGYWV DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMM1LKF ID DMM1LKF
DMM1LKF DN Bicyclic heteroaryl benzamide derivative 7
DMM1LKF HS Patented
DMM1LKF SN PMID28270021-Compound-WO2015148373Example36
DMM1LKF CP MERCK SHARP & DOHME CORP
DMM1LKF DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMVBQJ1 ID DMVBQJ1
DMVBQJ1 DN Bicyclic heteroaryl benzamide derivative 8
DMVBQJ1 HS Patented
DMVBQJ1 SN PMID28270021-Compound-WO2015148373Example41(S)
DMVBQJ1 CP MERCK SHARP & DOHME CORP
DMVBQJ1 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMGONY4 ID DMGONY4
DMGONY4 DN Bicyclic heteroaryl benzamide derivative 9
DMGONY4 HS Patented
DMGONY4 SN PMID28270021-Compound-WO2015148373Example42(R)
DMGONY4 CP MERCK SHARP & DOHME CORP
DMGONY4 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMB5XDM ID DMB5XDM
DMB5XDM DN Bicyclic heteroaryl carboxamide analog 1
DMB5XDM HS Patented
DMB5XDM SN PMID28067079-Compound-101
DMB5XDM DT Small molecular drug
DMB5XDM PC 50990953
DMB5XDM MW 330.3
DMB5XDM FM C15H11FN4O2S
DMB5XDM IC InChI=1S/C15H11FN4O2S/c1-9-7-23-15(19-9)20-14(21)10-2-11(16)4-12(3-10)22-13-5-17-8-18-6-13/h2-8H,1H3,(H,19,20,21)
DMB5XDM CS CC1=CSC(=N1)NC(=O)C2=CC(=CC(=C2)F)OC3=CN=CN=C3
DMB5XDM IK AXVLPJHYYFHCHK-UHFFFAOYSA-N
DMB5XDM IU 3-fluoro-N-(4-methyl-1,3-thiazol-2-yl)-5-pyrimidin-5-yloxybenzamide
DMKT7MD ID DMKT7MD
DMKT7MD DN Bicyclic heteroaryl carboxamide analog 2
DMKT7MD HS Patented
DMKT7MD SN PMID28067079-Compound-102
DMKT7MD DT Small molecular drug
DMKT7MD PC 60197821
DMKT7MD MW 342.3
DMKT7MD FM C17H12F2N4O2
DMKT7MD IC InChI=1S/C17H12F2N4O2/c1-10-4-13(25-14-5-12(19)7-20-9-14)6-15(22-10)17(24)23-16-3-2-11(18)8-21-16/h2-9H,1H3,(H,21,23,24)
DMKT7MD CS CC1=CC(=CC(=N1)C(=O)NC2=NC=C(C=C2)F)OC3=CC(=CN=C3)F
DMKT7MD IK MBSANIMQXDBICP-UHFFFAOYSA-N
DMKT7MD IU N-(5-fluoropyridin-2-yl)-4-(5-fluoropyridin-3-yl)oxy-6-methylpyridine-2-carboxamide
DM3QMA0 ID DM3QMA0
DM3QMA0 DN Bicyclic heteroaryl carboxamide analog 3
DM3QMA0 HS Patented
DM3QMA0 SN PMID28067079-Compound-114
DM3QMA0 DT Small molecular drug
DM3QMA0 PC 91886057
DM3QMA0 MW 397.4
DM3QMA0 FM C19H13F2N5OS
DM3QMA0 IC InChI=1S/C19H13F2N5OS/c1-11-9-28-18(25-11)26-17(27)15-6-13(5-12-3-2-4-24-16(12)15)19(20,21)14-7-22-10-23-8-14/h2-10H,1H3,(H,25,26,27)
DM3QMA0 CS CC1=CSC(=N1)NC(=O)C2=C3C(=CC(=C2)C(C4=CN=CN=C4)(F)F)C=CC=N3
DM3QMA0 IK WMANVHZDYKNLDT-UHFFFAOYSA-N
DM3QMA0 IU 6-[difluoro(pyrimidin-5-yl)methyl]-N-(4-methyl-1,3-thiazol-2-yl)quinoline-8-carboxamide
DMWTCM8 ID DMWTCM8
DMWTCM8 DN Bicyclic hexapeptide derivative 1
DMWTCM8 HS Patented
DMWTCM8 SN PMID25726713-Compound-40
DMWTCM8 DT Small molecular drug
DMJP1IK ID DMJP1IK
DMJP1IK DN Bicyclic hexapeptide derivative 2
DMJP1IK HS Patented
DMJP1IK SN PMID25726713-Compound-41
DMJP1IK DT Small molecular drug
DMAJ74C ID DMAJ74C
DMAJ74C DN Bicyclic pyrimidine derivative 1
DMAJ74C HS Patented
DMAJ74C SN PMID25470667-Compound-Figure6-21
DMAJ74C CP DAINIPPON SUMITOMO PHARMA CO [JP]
DMAJ74C DT Small molecular drug
DMJP16K ID DMJP16K
DMJP16K DN Bicyclic pyrimidine derivative 2
DMJP16K HS Patented
DMJP16K SN PMID27718763-Compound-4
DMJP16K CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
DMJP16K DT Small molecular drug
DMJP16K PC 76853231
DMJP16K MW 464.4
DMJP16K FM C22H20F4N4O3
DMJP16K IC InChI=1S/C22H20F4N4O3/c1-21(2)12-30-19(29(21)3)8-18(28-20(30)31)32-11-13-4-5-17(16(23)6-13)33-15-7-14(9-27-10-15)22(24,25)26/h4-10H,11-12H2,1-3H3
DMJP16K CS CC1(CN2C(=CC(=NC2=O)OCC3=CC(=C(C=C3)OC4=CN=CC(=C4)C(F)(F)F)F)N1C)C
DMJP16K IK PPKNPJKYLRQSCE-UHFFFAOYSA-N
DMJP16K IU 7-[[3-fluoro-4-[5-(trifluoromethyl)pyridin-3-yl]oxyphenyl]methoxy]-1,2,2-trimethyl-3H-imidazo[1,2-c]pyrimidin-5-one
DMGESCP ID DMGESCP
DMGESCP DN Bicyclo-heptan-2-amine derivative 1
DMGESCP HS Patented
DMGESCP SN PMID28051882-Compound-19
DMGESCP DT Small molecular drug
DMGESCP PC 57519221
DMGESCP MW 312.5
DMGESCP FM C21H32N2
DMGESCP IC InChI=1S/C21H32N2/c1-3-8-19(9-4-1)21(17-18-10-11-20(21)16-18)22-12-7-15-23-13-5-2-6-14-23/h1,3-4,8-9,18,20,22H,2,5-7,10-17H2
DMGESCP CS C1CCN(CC1)CCCNC2(CC3CCC2C3)C4=CC=CC=C4
DMGESCP IK XUIHNTYMWPNMJK-UHFFFAOYSA-N
DMGESCP IU 2-phenyl-N-(3-piperidin-1-ylpropyl)bicyclo[2.2.1]heptan-2-amine
DM9WUH5 ID DM9WUH5
DM9WUH5 DN Bicyclo-heptan-2-amine derivative 2
DM9WUH5 HS Patented
DM9WUH5 SN PMID28051882-Compound-20
DM9WUH5 DT Small molecular drug
DM9WUH5 PC 57519222
DM9WUH5 MW 330.5
DM9WUH5 FM C21H31FN2
DM9WUH5 IC InChI=1S/C21H31FN2/c22-20-9-7-18(8-10-20)21(16-17-5-6-19(21)15-17)23-11-4-14-24-12-2-1-3-13-24/h7-10,17,19,23H,1-6,11-16H2
DM9WUH5 CS C1CCN(CC1)CCCNC2(CC3CCC2C3)C4=CC=C(C=C4)F
DM9WUH5 IK DJXNOCLZKSUJMI-UHFFFAOYSA-N
DM9WUH5 IU 2-(4-fluorophenyl)-N-(3-piperidin-1-ylpropyl)bicyclo[2.2.1]heptan-2-amine
DM8ZRXE ID DM8ZRXE
DM8ZRXE DN Bicyclo-heptan-2-amine derivative 3
DM8ZRXE HS Patented
DM8ZRXE SN PMID28051882-Compound-21
DM8ZRXE DT Small molecular drug
DMPRIS0 ID DMPRIS0
DMPRIS0 DN Bicyclo-heptan-2-amine derivative 4
DMPRIS0 HS Patented
DMPRIS0 SN PMID28051882-Compound-IX
DMPRIS0 DT Small molecular drug
DMB08D3 ID DMB08D3
DMB08D3 DN Bidentate ligands of Markush derivative 1
DMB08D3 HS Patented
DMB08D3 SN PMID28117607-Compound-35
DMB08D3 CP THE SCRIPPS RESEARCH INSTITUTE
DMB08D3 DT Small molecular drug
DM2QNMC ID DM2QNMC
DM2QNMC DN Bidentate ligands of Markush derivative 2
DM2QNMC HS Patented
DM2QNMC SN PMID28117607-Compound-36
DM2QNMC CP THE SCRIPPS RESEARCH INSTITUTE
DM2QNMC DT Small molecular drug
DMPWKAH ID DMPWKAH
DMPWKAH DN Bidentate pyrazolopyrimidine acetamide analog 1
DMPWKAH HS Patented
DMPWKAH SN PMID27607364-Compound-142
DMPWKAH DT Small molecular drug
DM6SPTJ ID DM6SPTJ
DM6SPTJ DN Bidentate pyrazolopyrimidine acetamide analog 2
DM6SPTJ HS Patented
DM6SPTJ SN PMID27607364-Compound-143
DM6SPTJ DT Small molecular drug
DMC7UHT ID DMC7UHT
DMC7UHT DN Bidentate pyrazolopyrimidine acetamide analog 3
DMC7UHT HS Patented
DMC7UHT SN PMID27607364-Compound-144
DMC7UHT DT Small molecular drug
DMKZLCQ ID DMKZLCQ
DMKZLCQ DN Bidentate pyrazolopyrimidine acetamide analog 4
DMKZLCQ HS Patented
DMKZLCQ SN PMID27607364-Compound-145
DMKZLCQ DT Small molecular drug
DMKZLCQ PC 58299418
DMKZLCQ MW 744.9
DMKZLCQ FM C43H52N8O4
DMKZLCQ IC InChI=1S/C43H52N8O4/c1-9-48(10-2)38(52)26-36-40(46-50-30(7)24-28(5)44-42(36)50)32-14-18-34(19-15-32)54-22-13-23-55-35-20-16-33(17-21-35)41-37(27-39(53)49(11-3)12-4)43-45-29(6)25-31(8)51(43)47-41/h14-21,24-25H,9-13,22-23,26-27H2,1-8H3
DMKZLCQ CS CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OCCCOC4=CC=C(C=C4)C5=NN6C(=CC(=NC6=C5CC(=O)N(CC)CC)C)C)C)C
DMKZLCQ IK NTCLVQPBPKMEFJ-UHFFFAOYSA-N
DMKZLCQ IU 2-[2-[4-[3-[4-[3-[2-(diethylamino)-2-oxoethyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl]phenoxy]propoxy]phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-N,N-diethylacetamide
DM5WN0U ID DM5WN0U
DM5WN0U DN Binuclear gold(I) compound 1
DM5WN0U HS Patented
DM5WN0U SN PMID27977313-Compound-15
DM5WN0U CP THE UNIVERSITY OF HONG KON
DM5WN0U DT Small molecular drug
DM5WAGC ID DM5WAGC
DM5WAGC DN Binuclear gold(I) compound 2
DM5WAGC HS Patented
DM5WAGC SN PMID27977313-Compound-16
DM5WAGC CP THE UNIVERSITY OF HONG KON
DM5WAGC DT Small molecular drug
DM94TKW ID DM94TKW
DM94TKW DN Binuclear gold(I) compound 3
DM94TKW HS Patented
DM94TKW SN PMID27977313-Compound-Figure4f
DM94TKW CP THE UNIVERSITY OF HONG KON
DM94TKW DT Small molecular drug
DM1VYZ9 ID DM1VYZ9
DM1VYZ9 DN Biphenyl 1,2-diamine derivative 1
DM1VYZ9 HS Patented
DM1VYZ9 SN PMID29473428-Compound-66
DM1VYZ9 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DM1VYZ9 DT Small molecular drug
DM1VYZ9 PC 126722195
DM1VYZ9 MW 490.7
DM1VYZ9 FM C28H34N4O2S
DM1VYZ9 IC InChI=1S/C28H34N4O2S/c1-18(2)17-32(21-8-4-3-5-9-21)25-15-14-20(22-10-6-7-11-23(22)27(33)34)16-24(25)29-28-31-30-26(35-28)19-12-13-19/h6-7,10-11,14-16,18-19,21H,3-5,8-9,12-13,17H2,1-2H3,(H,29,31)(H,33,34)
DM1VYZ9 CS CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)C3=CC=CC=C3C(=O)O)NC4=NN=C(S4)C5CC5
DM1VYZ9 IK PWIBECCFTAUDGG-UHFFFAOYSA-N
DM1VYZ9 IU 2-[4-[cyclohexyl(2-methylpropyl)amino]-3-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)amino]phenyl]benzoic acid
DM6803W ID DM6803W
DM6803W DN Biphenyl carboxamidopropanoic acid derivative 1
DM6803W HS Patented
DM6803W SN PMID25828189-Compound-6
DM6803W CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, RuJANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DM6803W DT Small molecular drug
DMQF2XN ID DMQF2XN
DMQF2XN DN Biphenyl carboxamidopropanoic acid derivative 2
DMQF2XN HS Patented
DMQF2XN SN PMID25828189-Compound-7
DMQF2XN CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, Rui
DMQF2XN DT Small molecular drug
DMQF2XN PC 71472289
DMQF2XN MW 635
DMQF2XN FM C32H25ClF6N2O3
DMQF2XN IC InChI=1S/C32H25ClF6N2O3/c1-18-14-22(31(34,35)36)8-10-25(18)26-11-9-24(16-28(26)33)41-17-21-6-7-23(32(37,38)39)15-27(21)19-2-4-20(5-3-19)30(44)40-13-12-29(42)43/h2-11,14-16,41H,12-13,17H2,1H3,(H,40,44)(H,42,43)
DMQF2XN CS CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=C(C=C2)NCC3=C(C=C(C=C3)C(F)(F)F)C4=CC=C(C=C4)C(=O)NCCC(=O)O)Cl
DMQF2XN IK XNDCNDSKAXXGMD-UHFFFAOYSA-N
DMQF2XN IU 3-[[4-[2-[[3-chloro-4-[2-methyl-4-(trifluoromethyl)phenyl]anilino]methyl]-5-(trifluoromethyl)phenyl]benzoyl]amino]propanoic acid
DMLOVMP ID DMLOVMP
DMLOVMP DN Biphenyl carboxamidopropanoic acid derivative 3
DMLOVMP HS Patented
DMLOVMP SN PMID25828189-Compound-8
DMLOVMP CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, Rui
DMLOVMP DT Small molecular drug
DMLOVMP PC 71059966
DMLOVMP MW 533.4
DMLOVMP FM C30H26Cl2N2O3
DMLOVMP IC InChI=1S/C30H26Cl2N2O3/c1-19(34-26-13-8-21(9-14-26)20-6-10-24(31)11-7-20)27-15-12-25(32)18-28(27)22-2-4-23(5-3-22)30(37)33-17-16-29(35)36/h2-15,18-19,34H,16-17H2,1H3,(H,33,37)(H,35,36)
DMLOVMP CS CC(C1=C(C=C(C=C1)Cl)C2=CC=C(C=C2)C(=O)NCCC(=O)O)NC3=CC=C(C=C3)C4=CC=C(C=C4)Cl
DMLOVMP IK VTPFIFMNWSMPMA-UHFFFAOYSA-N
DMLOVMP IU 3-[[4-[5-chloro-2-[1-[4-(4-chlorophenyl)anilino]ethyl]phenyl]benzoyl]amino]propanoic acid
DM715E8 ID DM715E8
DM715E8 DN Biphenyl carboxamidopropanoic acid derivative 4
DM715E8 HS Patented
DM715E8 SN PMID25828189-Compound-9
DM715E8 CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj GRECO, Michael, N. SHOOK, Brian XU, Guozhang ZHANG, Rui
DM715E8 DT Small molecular drug
DM715E8 PC 71472344
DM715E8 MW 649
DM715E8 FM C33H27ClF6N2O3
DM715E8 IC InChI=1S/C33H27ClF6N2O3/c1-18-13-20(31(45)41-12-11-30(43)44)4-8-26(18)28-15-23(33(38,39)40)5-3-21(28)17-42-24-7-10-27(29(34)16-24)25-9-6-22(14-19(25)2)32(35,36)37/h3-10,13-16,42H,11-12,17H2,1-2H3,(H,41,45)(H,43,44)
DM715E8 CS CC1=C(C=CC(=C1)C(=O)NCCC(=O)O)C2=C(C=CC(=C2)C(F)(F)F)CNC3=CC(=C(C=C3)C4=C(C=C(C=C4)C(F)(F)F)C)Cl
DM715E8 IK DUDZHUBPDPKULT-UHFFFAOYSA-N
DM715E8 IU 3-[[4-[2-[[3-chloro-4-[2-methyl-4-(trifluoromethyl)phenyl]anilino]methyl]-5-(trifluoromethyl)phenyl]-3-methylbenzoyl]amino]propanoic acid
DMPWFJN ID DMPWFJN
DMPWFJN DN Biphenyl carboxylic acid derivative 1
DMPWFJN HS Patented
DMPWFJN SN PMID27744724-Compound-1
DMPWFJN CP ABBOTT LABORATORIES WENDT, Michael, D. SHEN, Wang DICKMAN, Daniel, A. DING, Hong THOMAS, Sheela, A. AUGERI, David ELMORE, Steven, W
DMPWFJN DT Small molecular drug
DM6TXF4 ID DM6TXF4
DM6TXF4 DN Biphenyl carboxylic acid derivative 2
DM6TXF4 HS Patented
DM6TXF4 SN PMID27744724-Compound-Fomula1
DM6TXF4 CP ABBOTT LABORATORIES WENDT, Michael, D. SHEN, Wang DICKMAN, Daniel, A. DING, Hong THOMAS, Sheela, A. AUGERI, David ELMORE, Steven, W
DM6TXF4 DT Small molecular drug
DMG4WQB ID DMG4WQB
DMG4WQB DN Biphenyl derivative 1
DMG4WQB HS Patented
DMG4WQB SN PMID29473428-Compound-55
DMG4WQB CP BRISTOL-MYERS SQUIBB COMPANY
DMG4WQB DT Small molecular drug
DMG4WQB PC 121354643
DMG4WQB MW 510.7
DMG4WQB FM C31H38N6O
DMG4WQB IC InChI=1S/C31H38N6O/c1-6-25(7-2)37(20-21(3)4)29-17-16-24(26-10-8-9-11-27(26)31-33-35-36-34-31)19-28(29)32-30(38)18-23-14-12-22(5)13-15-23/h8-17,19,21,25H,6-7,18,20H2,1-5H3,(H,32,38)(H,33,34,35,36)
DMG4WQB CS CCC(CC)N(CC(C)C)C1=C(C=C(C=C1)C2=CC=CC=C2C3=NNN=N3)NC(=O)CC4=CC=C(C=C4)C
DMG4WQB IK CERFYCIXDOVMJH-UHFFFAOYSA-N
DMG4WQB IU 2-(4-methylphenyl)-N-[2-[2-methylpropyl(pentan-3-yl)amino]-5-[2-(2H-tetrazol-5-yl)phenyl]phenyl]acetamide
DMJ4TZX ID DMJ4TZX
DMJ4TZX DN Biphenyl derivative 2
DMJ4TZX HS Patented
DMJ4TZX SN PMID29473428-Compound-56
DMJ4TZX CP BRISTOL-MYERS SQUIBB COMPANY
DMJ4TZX DT Small molecular drug
DMJ4TZX PC 121474565
DMJ4TZX MW 540
DMJ4TZX FM C29H31ClFN3O4
DMJ4TZX IC InChI=1S/C29H31ClFN3O4/c1-38-16-15-34(21-7-3-2-4-8-21)27-14-11-19(22-9-5-6-10-23(22)28(35)36)17-26(27)33-29(37)32-25-13-12-20(30)18-24(25)31/h5-6,9-14,17-18,21H,2-4,7-8,15-16H2,1H3,(H,35,36)(H2,32,33,37)
DMJ4TZX CS COCCN(C1CCCCC1)C2=C(C=C(C=C2)C3=CC=CC=C3C(=O)O)NC(=O)NC4=C(C=C(C=C4)Cl)F
DMJ4TZX IK KUVXHGKRYSVGPP-UHFFFAOYSA-N
DMJ4TZX IU 2-[3-[(4-chloro-2-fluorophenyl)carbamoylamino]-4-[cyclohexyl(2-methoxyethyl)amino]phenyl]benzoic acid
DMM3SWV ID DMM3SWV
DMM3SWV DN Biphenyl derivative 3
DMM3SWV HS Patented
DMM3SWV SN PMID29473428-Compound-57
DMM3SWV CP BRISTOL-MYERS SQUIBB COMPANY
DMM3SWV DT Small molecular drug
DMM3SWV PC 121469252
DMM3SWV MW 655.6
DMM3SWV FM C32H27F6N7O2
DMM3SWV IC InChI=1S/C32H27F6N7O2/c1-20-6-11-23(12-7-20)39-30(46)40-27-18-22(25-4-2-3-5-26(25)29-41-43-44-42-29)10-15-28(27)45(17-16-31(33,34)35)19-21-8-13-24(14-9-21)47-32(36,37)38/h2-15,18H,16-17,19H2,1H3,(H2,39,40,46)(H,41,42,43,44)
DMM3SWV CS CC1=CC=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C3=CC=CC=C3C4=NNN=N4)N(CCC(F)(F)F)CC5=CC=C(C=C5)OC(F)(F)F
DMM3SWV IK ZBBKUFMLKWFYDD-UHFFFAOYSA-N
DMM3SWV IU 1-(4-methylphenyl)-3-[5-[2-(2H-tetrazol-5-yl)phenyl]-2-[[4-(trifluoromethoxy)phenyl]methyl-(3,3,3-trifluoropropyl)amino]phenyl]urea
DMIPVYW ID DMIPVYW
DMIPVYW DN Biphenyl derivative 4
DMIPVYW HS Patented
DMIPVYW SN PMID29334795-Compound-29
DMIPVYW CP ARENA PHARMACEUTICALS, INC
DMIPVYW DT Small molecular drug
DMIPVYW DE Histamine H3-associated disorder
DMS5UFX ID DMS5UFX
DMS5UFX DN Biphenyl mannoside derivative 1
DMS5UFX HS Patented
DMS5UFX SN PMID26651364-Compound-25
DMS5UFX CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, CorinnTHE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMS5UFX DT Carbohydrates
DMS5UFX DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMITLPW ID DMITLPW
DMITLPW DN Biphenyl mannoside derivative 10
DMITLPW HS Patented
DMITLPW SN PMID26651364-Compound-34
DMITLPW CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMITLPW DT Carbohydrates
DMITLPW DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZF5XI ID DMZF5XI
DMZF5XI DN Biphenyl mannoside derivative 11
DMZF5XI HS Patented
DMZF5XI SN PMID26651364-Compound-35
DMZF5XI CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMZF5XI DT Carbohydrates
DMZF5XI DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMU0YST ID DMU0YST
DMU0YST DN Biphenyl mannoside derivative 12
DMU0YST HS Patented
DMU0YST SN PMID26651364-Compound-36
DMU0YST CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMU0YST DT Carbohydrates
DMU0YST DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM83LTH ID DM83LTH
DM83LTH DN Biphenyl mannoside derivative 13
DM83LTH HS Patented
DM83LTH SN PMID26651364-Compound-37
DM83LTH CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, CorinnTHE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM83LTH DT Carbohydrates
DM83LTH DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMRTWG ID DMMRTWG
DMMRTWG DN Biphenyl mannoside derivative 14
DMMRTWG HS Patented
DMMRTWG SN PMID26651364-Compound-38
DMMRTWG CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMMRTWG DT Carbohydrates
DMMRTWG DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM97BIQ ID DM97BIQ
DM97BIQ DN Biphenyl mannoside derivative 15
DM97BIQ HS Patented
DM97BIQ SN PMID26651364-Compound-39
DM97BIQ CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM97BIQ DT Carbohydrates
DM97BIQ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMECZVG ID DMECZVG
DMECZVG DN Biphenyl mannoside derivative 16
DMECZVG HS Patented
DMECZVG SN PMID26651364-Compound-51
DMECZVG CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMECZVG DT Carbohydrates
DMECZVG DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM7L8T5 ID DM7L8T5
DM7L8T5 DN Biphenyl mannoside derivative 17
DM7L8T5 HS Patented
DM7L8T5 SN PMID26651364-Compound-52
DM7L8T5 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM7L8T5 DT Carbohydrates
DM7L8T5 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM2GZ5Y ID DM2GZ5Y
DM2GZ5Y DN Biphenyl mannoside derivative 18
DM2GZ5Y HS Patented
DM2GZ5Y SN PMID26651364-Compound-53
DM2GZ5Y CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DM2GZ5Y DT Carbohydrates
DM2GZ5Y DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMGA0R6 ID DMGA0R6
DMGA0R6 DN Biphenyl mannoside derivative 19
DMGA0R6 HS Patented
DMGA0R6 SN PMID26651364-Compound-54
DMGA0R6 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMGA0R6 DT Carbohydrates
DMGA0R6 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQB4DR ID DMQB4DR
DMQB4DR DN Biphenyl mannoside derivative 2
DMQB4DR HS Patented
DMQB4DR SN PMID26651364-Compound-26
DMQB4DR CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, CorinnTHE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMQB4DR DT Carbohydrates
DMQB4DR DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMDIYJ1 ID DMDIYJ1
DMDIYJ1 DN Biphenyl mannoside derivative 20
DMDIYJ1 HS Patented
DMDIYJ1 SN PMID26651364-Compound-55
DMDIYJ1 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMDIYJ1 DT Carbohydrates
DMDIYJ1 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMTR6BX ID DMTR6BX
DMTR6BX DN Biphenyl mannoside derivative 21
DMTR6BX HS Patented
DMTR6BX SN PMID26651364-Compound-56
DMTR6BX CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMTR6BX DT Carbohydrates
DMTR6BX DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQGFKY ID DMQGFKY
DMQGFKY DN Biphenyl mannoside derivative 22
DMQGFKY HS Patented
DMQGFKY SN PMID26651364-Compound-68a
DMQGFKY CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE NANTES UNIVERSITE DE PICARDIE JULES VERNE UNIVERSITE LILLE 1 SCIENCES ET TECHNOLOGIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) UNIVERSITE D'AUVERGNE - CLERMONT-FERRAND 1
DMQGFKY DT Carbohydrates
DMQGFKY DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMC8OVU ID DMC8OVU
DMC8OVU DN Biphenyl mannoside derivative 23
DMC8OVU HS Patented
DMC8OVU SN PMID26651364-Compound-68b
DMC8OVU CP WASHINGTON UNIVERSITY
DMC8OVU DT Carbohydrates
DMC8OVU DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMLUZ3K ID DMLUZ3K
DMLUZ3K DN Biphenyl mannoside derivative 24
DMLUZ3K HS Patented
DMLUZ3K SN PMID26651364-Compound-69
DMLUZ3K CP WASHINGTON UNIVERSITY
DMLUZ3K DT Carbohydrates
DMLUZ3K DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMBWQ8L ID DMBWQ8L
DMBWQ8L DN Biphenyl mannoside derivative 25
DMBWQ8L HS Patented
DMBWQ8L SN PMID26651364-Compound-70
DMBWQ8L CP WASHINGTON UNIVERSITY
DMBWQ8L DT Carbohydrates
DMBWQ8L DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM5Q4T2 ID DM5Q4T2
DM5Q4T2 DN Biphenyl mannoside derivative 26
DM5Q4T2 HS Patented
DM5Q4T2 SN PMID26651364-Compound-71
DM5Q4T2 CP WASHINGTON UNIVERSITY
DM5Q4T2 DT Carbohydrates
DM5Q4T2 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMWQ6FJ ID DMWQ6FJ
DMWQ6FJ DN Biphenyl mannoside derivative 27
DMWQ6FJ HS Patented
DMWQ6FJ SN PMID26651364-Compound-72
DMWQ6FJ CP WASHINGTON UNIVERSITY
DMWQ6FJ DT Carbohydrates
DMWQ6FJ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMOTWK ID DMMOTWK
DMMOTWK DN Biphenyl mannoside derivative 28
DMMOTWK HS Patented
DMMOTWK SN PMID26651364-Compound-73
DMMOTWK CP WASHINGTON UNIVERSITY
DMMOTWK DT Carbohydrates
DMMOTWK DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM9H0Q3 ID DM9H0Q3
DM9H0Q3 DN Biphenyl mannoside derivative 29
DM9H0Q3 HS Patented
DM9H0Q3 SN PMID26651364-Compound-74
DM9H0Q3 CP WASHINGTON UNIVERSITY
DM9H0Q3 DT Carbohydrates
DM9H0Q3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMOKJEP ID DMOKJEP
DMOKJEP DN Biphenyl mannoside derivative 3
DMOKJEP HS Patented
DMOKJEP SN PMID26651364-Compound-27
DMOKJEP CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMOKJEP DT Carbohydrates
DMOKJEP DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM81RIY ID DM81RIY
DM81RIY DN Biphenyl mannoside derivative 30
DM81RIY HS Patented
DM81RIY SN PMID26651364-Compound-75
DM81RIY CP WASHINGTON UNIVERSITY
DM81RIY DT Carbohydrates
DM81RIY DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM0VR23 ID DM0VR23
DM0VR23 DN Biphenyl mannoside derivative 4
DM0VR23 HS Patented
DM0VR23 SN PMID26651364-Compound-28
DM0VR23 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM0VR23 DT Carbohydrates
DM0VR23 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMOS03R ID DMOS03R
DMOS03R DN Biphenyl mannoside derivative 5
DMOS03R HS Patented
DMOS03R SN PMID26651364-Compound-29
DMOS03R CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMOS03R DT Carbohydrates
DMOS03R DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM93VEB ID DM93VEB
DM93VEB DN Biphenyl mannoside derivative 6
DM93VEB HS Patented
DM93VEB SN PMID26651364-Compound-30
DM93VEB CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM93VEB DT Carbohydrates
DM93VEB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM46NRV ID DM46NRV
DM46NRV DN Biphenyl mannoside derivative 7
DM46NRV HS Patented
DM46NRV SN PMID26651364-Compound-31
DM46NRV CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM46NRV DT Carbohydrates
DM46NRV DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZCWM5 ID DMZCWM5
DMZCWM5 DN Biphenyl mannoside derivative 8
DMZCWM5 HS Patented
DMZCWM5 SN PMID26651364-Compound-32
DMZCWM5 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMZCWM5 DT Carbohydrates
DMZCWM5 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMP52HJ ID DMP52HJ
DMP52HJ DN Biphenyl mannoside derivative 9
DMP52HJ HS Patented
DMP52HJ SN PMID26651364-Compound-33
DMP52HJ CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMP52HJ DT Carbohydrates
DMP52HJ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6KGUB ID DM6KGUB
DM6KGUB DN Bipyrazole derivative 1
DM6KGUB HS Patented
DM6KGUB SN PMID27774824-Compound-Figure13Example17
DM6KGUB CP INCYTE CORPORATION
DM6KGUB DT Small molecular drug
DMPUXL3 ID DMPUXL3
DMPUXL3 DN Bipyridine derivative 1
DMPUXL3 HS Patented
DMPUXL3 SN PMID26161698-Compound-39
DMPUXL3 CP NOVARTIS AG BARSANTI, Paul A. HU, Cheng JIN, Xianming NG, Simon C. PFISTER, Keith B. SENDZIK, Martin SUTTON, James
DMPUXL3 DT Small molecular drug
DMQL34C ID DMQL34C
DMQL34C DN Bis-aminopyrimidine derivative 1
DMQL34C HS Patented
DMQL34C SN PMID27774824-Compound-Figure7compound23
DMQL34C CP CELLZOME LIMITED FREEMAN, Jay READER, Valerie ADDISON, Glynn RAMSDEN, Nigel SCANLON, Jane Elizabeth HARRISON, Richard John
DMJXNO1 ID DMJXNO1
DMJXNO1 DN Bis-aminopyrimidine derivative 2
DMJXNO1 HS Patented
DMJXNO1 SN PMID27774824-Compound-Figure7Example103
DMJXNO1 CP CELLZOME LIMITED HOBSON, Andrew ADDISON, Glynn RAMSDEN, Nigel HARRISON, John
DMJXNO1 DT Small molecular drug
DMUNSYX ID DMUNSYX
DMUNSYX DN Bis-aminopyrimidine derivative 3
DMUNSYX HS Patented
DMUNSYX SN PMID27774824-Compound-Figure7Example25
DMUNSYX CP CELLZOME LIMITED HOBSON, Andrew ADDISON, Glynn RAMSDEN, Nigel HARRISON, John
DMUNSYX DT Small molecular drug
DMO1ZIG ID DMO1ZIG
DMO1ZIG DN Bis-aminopyrimidine derivative 4
DMO1ZIG HS Patented
DMO1ZIG SN PMID27774824-Compound-Figure7Example83
DMO1ZIG CP CELLZOME LIMITED HOBSON, Andrew ADDISON, Glynn RAMSDEN, Nigel HARRISON, John
DMO1ZIG DT Small molecular drug
DMWXLK1 ID DMWXLK1
DMWXLK1 DN Bis-aminopyrimidine derivative 5
DMWXLK1 HS Patented
DMWXLK1 SN PMID27774824-Compound-Figure7ExampleI-13
DMWXLK1 CP CELLZOME LIMITED HARRISON, Richard John RAMSDEN, Nigel MAJOR, Jeremy MOREL, Adeline CONVERY, Laura SUNOSE, Mihiro LYNCH, Rosemary ADREGO, Rita JONES, Alison
DMWXLK1 DT Small molecular drug
DMOR9ZA ID DMOR9ZA
DMOR9ZA DN Bis-indolylmaleimide derivative 1
DMOR9ZA HS Patented
DMOR9ZA SN PMID25684022-Compound-WO2005041953
DMOR9ZA CP ELI LILLY AND COMPANY GRAFF, Jeremy, Richard
DMOR9ZA DT Small molecular drug
DMOR9ZA DE Solid tumour/cancer; Metastatic cancer
DMLV9UR ID DMLV9UR
DMLV9UR DN Bis-sulfonamide derivative 1
DMLV9UR HS Patented
DMLV9UR SN PMID27977313-Compound-49
DMLV9UR CP UNIVERSITY OF SUNDERLAND
DMLV9UR DT Small molecular drug
DMLV9UR PC 75593317
DMLV9UR MW 525.6
DMLV9UR FM C25H23N3O6S2
DMLV9UR IC InChI=1S/C25H23N3O6S2/c1-17-5-10-20(11-6-17)35(30,31)27-22-14-9-19(26-25(29)24-4-3-15-34-24)16-23(22)28-36(32,33)21-12-7-18(2)8-13-21/h3-16,27-28H,1-2H3,(H,26,29)
DMLV9UR CS CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=C(C=C2)NC(=O)C3=CC=CO3)NS(=O)(=O)C4=CC=C(C=C4)C
DMLV9UR IK CFHMKQXRBRHXQD-UHFFFAOYSA-N
DMLV9UR IU N-[3,4-bis[(4-methylphenyl)sulfonylamino]phenyl]furan-2-carboxamide
DMR0ANI ID DMR0ANI
DMR0ANI DN Bis-sulfonamide derivative 2
DMR0ANI HS Patented
DMR0ANI SN PMID27977313-Compound-Figure7a
DMR0ANI CP UNIVERSITY OF SUNDERLAND
DMR0ANI DT Small molecular drug
DM6YQO3 ID DM6YQO3
DM6YQO3 DN BK3
DM6YQO3 HS Patented
DM6YQO3 SN CHEMBL1231372; MMV676182; 3-(Naphthalen-1-Ylmethyl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine; BK3; SCHEMBL12437018; BDBM50345712; 3-(1-naphthylmethyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DM6YQO3 DT Small molecular drug
DM6YQO3 PC 46398830
DM6YQO3 MW 372.5
DM6YQO3 FM C22H24N6
DM6YQO3 IC InChI=1S/C22H24N6/c23-21-20-19(12-17-6-3-5-16-4-1-2-7-18(16)17)27-28(22(20)26-14-25-21)13-15-8-10-24-11-9-15/h1-7,14-15,24H,8-13H2,(H2,23,25,26)
DM6YQO3 CS C1CNCCC1CN2C3=NC=NC(=C3C(=N2)CC4=CC=CC5=CC=CC=C54)N
DM6YQO3 IK MMRLNUFECMEMSQ-UHFFFAOYSA-N
DM6YQO3 IU 3-(naphthalen-1-ylmethyl)-1-(piperidin-4-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DMQD4X2 ID DMQD4X2
DMQD4X2 DN BK7
DMQD4X2 HS Patented
DMQD4X2 SN CHEMBL2030554; 3-(6-Ethoxynaphthalen-2-Yl)-1-(Piperidin-4-Ylmethyl)-1h-Pyrazolo[3,4-D]pyrimidin-4-Amine; BK7; SCHEMBL14574630; BDBM50383381; RM-1-132; 3-(6-ethoxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DMQD4X2 DT Small molecular drug
DMQD4X2 PC 53346432
DMQD4X2 MW 402.5
DMQD4X2 FM C23H26N6O
DMQD4X2 IC InChI=1S/C23H26N6O/c1-2-30-19-6-5-16-11-18(4-3-17(16)12-19)21-20-22(24)26-14-27-23(20)29(28-21)13-15-7-9-25-10-8-15/h3-6,11-12,14-15,25H,2,7-10,13H2,1H3,(H2,24,26,27)
DMQD4X2 CS CCOC1=CC2=C(C=C1)C=C(C=C2)C3=NN(C4=NC=NC(=C34)N)CC5CCNCC5
DMQD4X2 IK DLMBMHOJKBPKLK-UHFFFAOYSA-N
DMQD4X2 IU 3-(6-ethoxynaphthalen-2-yl)-1-(piperidin-4-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
DMMRXEQ ID DMMRXEQ
DMMRXEQ DN Boronic acid derivative 1
DMMRXEQ HS Patented
DMMRXEQ SN PMID26413912-Compound-58
DMMRXEQ CP INFINITY PHARMACEUTICALS, INC. AUSTAD, Brian, C. GRENIER, Louis GROGAN, Michael, J. LIU, Tao LO, Ching Kam MARTINOT, Theodore, A. YU, Lin-Chen
DMMRXEQ DT Small molecular drug
DMMRXEQ PC 53328040
DMMRXEQ MW 234.01
DMMRXEQ FM C12H9BF2O2
DMMRXEQ IC InChI=1S/C12H9BF2O2/c14-10-3-1-2-8(6-10)9-4-5-11(13(16)17)12(15)7-9/h1-7,16-17H
DMMRXEQ CS B(C1=C(C=C(C=C1)C2=CC(=CC=C2)F)F)(O)O
DMMRXEQ IK WAWBMXWYDGQRBT-UHFFFAOYSA-N
DMMRXEQ IU [2-fluoro-4-(3-fluorophenyl)phenyl]boronic acid
DMLJH5T ID DMLJH5T
DMLJH5T DN Boronic acid derivative 2
DMLJH5T HS Patented
DMLJH5T SN PMID26413912-Compound-59
DMLJH5T CP INFINITY PHARMACEUTICALS, INC BEHNKE, Mark, L. CASTRO, Alfredo, C. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LIU, Tao SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMLJH5T DT Small molecular drug
DMQ8X94 ID DMQ8X94
DMQ8X94 DN Boronic acid derivative 3
DMQ8X94 HS Patented
DMQ8X94 SN PMID26413912-Compound-60
DMQ8X94 CP INFINITY PHARMACEUTICALS, INC BEHNKE, Mark, L. CASTRO, Alfredo, C. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LIU, Tao SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMQ8X94 DT Small molecular drug
DMQ8X94 PC 58343925
DMQ8X94 MW 267.05
DMQ8X94 FM C13H10BN3O3
DMQ8X94 IC InChI=1S/C13H10BN3O3/c18-14(19)11-5-3-9(4-6-11)12-16-17-13(20-12)10-2-1-7-15-8-10/h1-8,18-19H
DMQ8X94 CS B(C1=CC=C(C=C1)C2=NN=C(O2)C3=CN=CC=C3)(O)O
DMQ8X94 IK GUJFLRGCBMMKFL-UHFFFAOYSA-N
DMQ8X94 IU [4-(5-pyridin-3-yl-1,3,4-oxadiazol-2-yl)phenyl]boronic acid
DMVIFXR ID DMVIFXR
DMVIFXR DN Boronic acid derivative 4
DMVIFXR HS Patented
DMVIFXR SN PMID26413912-Compound-61
DMVIFXR CP INFINITY PHARMACEUTICALS, INC. CASTRO, Alfredo, C. GROGAN, Michael, J. SNYDER, Daniel, A
DMVIFXR DT Small molecular drug
DMVIFXR PC 46917082
DMVIFXR MW 293.1
DMVIFXR FM C17H16BNO3
DMVIFXR IC InChI=1S/C17H16BNO3/c20-17-16-7-6-15(18(21)22)12-14(16)9-11-19(17)10-8-13-4-2-1-3-5-13/h1-7,9,11-12,21-22H,8,10H2
DMVIFXR CS B(C1=CC2=C(C=C1)C(=O)N(C=C2)CCC3=CC=CC=C3)(O)O
DMVIFXR IK MPFOFZNQFUHKAK-UHFFFAOYSA-N
DMVIFXR IU [1-oxo-2-(2-phenylethyl)isoquinolin-6-yl]boronic acid
DMUCW9Y ID DMUCW9Y
DMUCW9Y DN Boronic acid derivative 5
DMUCW9Y HS Patented
DMUCW9Y SN PMID26413912-Compound-62
DMUCW9Y CP INFINITY PHARMACEUTICALS, INC. CASTRO, Alfredo, C. GROGAN, Michael, J. SNYDER, Daniel, A
DMUCW9Y DT Small molecular drug
DMUCW9Y PC 46947813
DMUCW9Y MW 281.1
DMUCW9Y FM C16H16BNO3
DMUCW9Y IC InChI=1S/C16H16BNO3/c19-16-15-7-6-14(17(20)21)10-13(15)11-18(16)9-8-12-4-2-1-3-5-12/h1-7,10,20-21H,8-9,11H2
DMUCW9Y CS B(C1=CC2=C(C=C1)C(=O)N(C2)CCC3=CC=CC=C3)(O)O
DMUCW9Y IK OWKXCKRUGQYZKS-UHFFFAOYSA-N
DMUCW9Y IU [1-oxo-2-(2-phenylethyl)-3H-isoindol-5-yl]boronic acid
DMLMV4O ID DMLMV4O
DMLMV4O DN Boronic acid derivative 6
DMLMV4O HS Patented
DMLMV4O SN PMID26413912-Compound-63
DMLMV4O CP INFINITY PHARMACEUTICALS, INC. CASTRO, Alfredo, C. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J
DMLMV4O DT Small molecular drug
DMLMV4O PC 46940954
DMLMV4O MW 289.2
DMLMV4O FM C16H24BNO3
DMLMV4O IC InChI=1S/C16H24BNO3/c19-16(18-12-10-15(11-13-18)17(20)21)9-5-4-8-14-6-2-1-3-7-14/h1-3,6-7,15,20-21H,4-5,8-13H2
DMLMV4O CS B(C1CCN(CC1)C(=O)CCCCC2=CC=CC=C2)(O)O
DMLMV4O IK WOTYQRKKBABLCX-UHFFFAOYSA-N
DMLMV4O IU [1-(5-phenylpentanoyl)piperidin-4-yl]boronic acid
DMCLB5D ID DMCLB5D
DMCLB5D DN Boswellia acid derivative 1
DMCLB5D HS Patented
DMCLB5D SN PMID28627961-Compound-42
DMCLB5D CP AureliaSan GBH
DMCLB5D DT Small molecular drug
DMCLB5D PC 46195157
DMCLB5D MW 454.7
DMCLB5D FM C30H46O3
DMCLB5D IC InChI=1S/C30H46O3/c1-19(2)9-8-10-20(26(32)33)21-13-17-30(7)23-11-12-24-27(3,4)25(31)15-16-28(24,5)22(23)14-18-29(21,30)6/h9,20-21,24H,8,10-18H2,1-7H3,(H,32,33)/t20-,21-,24?,28?,29-,30+/m0/s1
DMCLB5D CS CC(=CCC[C@@H]([C@@H]1CC[C@]2([C@]1(CCC3=C2CCC4C3(CCC(=O)C4(C)C)C)C)C)C(=O)O)C
DMCLB5D IK XLPAINGDLCDYQV-MSEQJIGISA-N
DMCLB5D IU (2S)-6-methyl-2-[(13S,14S,17S)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]hept-5-enoic acid
DMMXQJU ID DMMXQJU
DMMXQJU DN Bromo benzyl ether derivative 1
DMMXQJU HS Patented
DMMXQJU SN PMID30107136-Compound-Example17
DMMXQJU CP INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMMXQJU DT Small molecule immunotherapy
DMMXQJU DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMVBAUC ID DMVBAUC
DMVBAUC DN Bromo benzyl ether derivative 2
DMVBAUC HS Patented
DMVBAUC SN PMID30107136-Compound-Example18
DMVBAUC CP INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMVBAUC DT Small molecule immunotherapy
DMVBAUC DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMVYNJZ ID DMVYNJZ
DMVYNJZ DN BUTAPROST
DMVYNJZ HS Patented
DMVYNJZ SN Butaprost; (R)-Butaprost; 69648-38-0; UNII-HP16WVP23Y; TR-4979; HP16WVP23Y; NCGC00165753-01; Butaprostum; (1R,2R,3R)-3-Hydroxy-2-[(1E,4R)-4-hydroxy-4-(1-propylcyclobutyl)-1-butenyl]-5-oxo-cyclopentaneheptanoic acid methyl ester; Butaprostum [Latin]; Bay q 4218; Butaprost [USAN:INN:BAN]; Butaprost (free acid); AC1NSJVB; Butaprost (USAN/INN); DSSTox_RID_83186; DSSTox_CID_28919; SCHEMBL94764; DSSTox_GSID_48993; CHEMBL271896; GTPL3379; DTXSID8048993; BDBM85602; BAY-Q-4218; ZINC4215145; Tox21_113480; MFCD00867055; 1090AH; PDSP2_001674
DMVYNJZ DT Small molecular drug
DMVYNJZ PC 5311035
DMVYNJZ MW 408.6
DMVYNJZ FM C24H40O5
DMVYNJZ IC InChI=1S/C24H40O5/c1-3-14-24(15-9-16-24)22(27)12-8-11-19-18(20(25)17-21(19)26)10-6-4-5-7-13-23(28)29-2/h8,11,18-19,21-22,26-27H,3-7,9-10,12-17H2,1-2H3/b11-8+/t18-,19-,21-,22-/m1/s1
DMVYNJZ CS CCCC1(CCC1)[C@@H](C/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)OC)O)O
DMVYNJZ IK XRISENIKJUKIHD-LHQZMKCDSA-N
DMVYNJZ IU methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,4R)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate
DMVYNJZ CA CAS 69648-38-0
DMVYNJZ DE Discovery agent
DMJPW7C ID DMJPW7C
DMJPW7C DN C06909
DMJPW7C HS Patented
DMJPW7C SN Cidofovir - Vistide; AC1LAD1W; SCHEMBL151807; CHEMBL27710; US10071110, Compound CDV; BDBM275767; AKOS015901501; RL00545; US10071110, Compound Cidofovir(CDV); SC-20872; AB0109968; C06909; A803101; I14-14184; Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; [1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; [1-(4-amino-2-oxo-1-pyrimidinyl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid; [1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphon
DMJPW7C DT Small molecular drug
DMJPW7C PC 466146
DMJPW7C MW 279.19
DMJPW7C FM C8H14N3O6P
DMJPW7C IC InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)
DMJPW7C CS C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
DMJPW7C IK VWFCHDSQECPREK-UHFFFAOYSA-N
DMJPW7C IU [1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
DMW46GY ID DMW46GY
DMW46GY DN CAMBINOL
DMW46GY HS Patented
DMW46GY SN cambinol; 14513-15-6; SIRT1/2 Inhibitor IV, Cambinol; NSC112546; NSC-112546; NSC-1125476; 5-[(2-hydroxy-1-naphthyl)methyl]-2-mercapto-6-phenyl-4(3H)-Pyrimidinone; 5-(2-Hydroxynaphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; 5-(2-Hydroxy-naphthalen-1-ylmethyl)-6-phenyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one; Tetrahydro-5-[(2-hydroxy-1-naphthalenyl)methyl]-6-phenyl-2-thioxo-4(1H)-Pyrimidinone; AC1MMYEF; NCIStruc2_001159; NCIStruc1_001428; SCHEMBL2538372; CHEMBL491960; CTK8G3107; BDBM29040
DMW46GY DT Small molecular drug
DMW46GY PC 3246390
DMW46GY MW 360.4
DMW46GY FM C21H16N2O2S
DMW46GY IC InChI=1S/C21H16N2O2S/c24-18-11-10-13-6-4-5-9-15(13)16(18)12-17-19(14-7-2-1-3-8-14)22-21(26)23-20(17)25/h1-11,24H,12H2,(H2,22,23,25,26)
DMW46GY CS C1=CC=C(C=C1)C2=C(C(=O)NC(=S)N2)CC3=C(C=CC4=CC=CC=C43)O
DMW46GY IK RVNSQVIUFZVNAU-UHFFFAOYSA-N
DMW46GY IU 5-[(2-hydroxynaphthalen-1-yl)methyl]-6-phenyl-2-sulfanylidene-1H-pyrimidin-4-one
DMW46GY CA CAS 14513-15-6
DMW46GY DE Discovery agent
DM81SYN ID DM81SYN
DM81SYN DN Cannabinoid quinone derivative 1
DM81SYN HS Patented
DM81SYN SN PMID25416646-Compound-Figure3-A
DM81SYN CP VIVACELL BIOTECHNOLOGY ESPANA S L [ES]
DM81SYN DT Small molecular drug
DMNDPEA ID DMNDPEA
DMNDPEA DN Carbamate derivative 1
DMNDPEA HS Patented
DMNDPEA SN PMID26413912-Compound-25
DMNDPEA CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA UNIVERSITA DEGLI STUDI DI URBINO "CARLO BO&quoUNIVERSITA DEGLI STUDI DI PARMA PIOMELLI, Daniele CLAPPER, Jason, R. MORENO-SANZ, Guillermo DURANTI, Andrea TONTINI, Andrea MOR, Marco TARZIA, Giorgio
DMNDPEA DT Small molecular drug
DMP98CL ID DMP98CL
DMP98CL DN Carbamate derivative 10
DMP98CL HS Patented
DMP98CL SN PMID29053063-Compound-10b
DMP98CL CP PFIZER INC
DMP98CL DT Small molecular drug
DM3CF91 ID DM3CF91
DM3CF91 DN Carbamate derivative 11
DM3CF91 HS Patented
DM3CF91 SN PMID29053063-Compound-10c
DM3CF91 CP PFIZER INC
DM3CF91 DT Small molecular drug
DMMH27J ID DMMH27J
DMMH27J DN Carbamate derivative 12
DMMH27J HS Patented
DMMH27J SN PMID29053063-Compound-10d
DMMH27J CP PFIZER INC
DMMH27J DT Small molecular drug
DMLH45M ID DMLH45M
DMLH45M DN Carbamate derivative 13
DMLH45M HS Patented
DMLH45M SN PMID29053063-Compound-10e
DMLH45M CP PFIZER INC
DMLH45M DT Small molecular drug
DMZS0HT ID DMZS0HT
DMZS0HT DN Carbamate derivative 14
DMZS0HT HS Patented
DMZS0HT SN PMID29053063-Compound-10f
DMZS0HT CP PFIZER INC
DMZS0HT DT Small molecular drug
DMOKC41 ID DMOKC41
DMOKC41 DN Carbamate derivative 15
DMOKC41 HS Patented
DMOKC41 SN PMID29053063-Compound-10g
DMOKC41 CP PFIZER INC
DMOKC41 DT Small molecular drug
DMOKC41 PC 126502896
DMOKC41 MW 494.5
DMOKC41 FM C21H29F3N2O6S
DMOKC41 IC InChI=1S/C21H29F3N2O6S/c1-15(2)26(33(29,30)17-6-4-3-5-7-17)16-12-20(31-14-16)8-10-25(11-9-20)19(28)32-18(13-27)21(22,23)24/h3-7,15-16,18,27H,8-14H2,1-2H3/t16-,18-/m1/s1
DMOKC41 CS CC(C)N([C@@H]1CC2(CCN(CC2)C(=O)O[C@H](CO)C(F)(F)F)OC1)S(=O)(=O)C3=CC=CC=C3
DMOKC41 IK FNERRHFFFPJRAG-SJLPKXTDSA-N
DMOKC41 IU [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] (3R)-3-[benzenesulfonyl(propan-2-yl)amino]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate
DMPLZSE ID DMPLZSE
DMPLZSE DN Carbamate derivative 16
DMPLZSE HS Patented
DMPLZSE SN PMID29053063-Compound-10h
DMPLZSE CP PFIZER INC
DMPLZSE DT Small molecular drug
DMYSRPT ID DMYSRPT
DMYSRPT DN Carbamate derivative 17
DMYSRPT HS Patented
DMYSRPT SN PMID29053063-Compound-12d
DMYSRPT CP NORTHEASTERN UNIVERSITY
DMYSRPT DT Small molecular drug
DMEWPQ6 ID DMEWPQ6
DMEWPQ6 DN Carbamate derivative 2
DMEWPQ6 HS Patented
DMEWPQ6 SN PMID26413912-Compound-27
DMEWPQ6 CP FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA
DMEWPQ6 DT Small molecular drug
DMO6NWD ID DMO6NWD
DMO6NWD DN Carbamate derivative 3
DMO6NWD HS Patented
DMO6NWD SN PMID26413912-Compound-30
DMO6NWD CP SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. CABRI, Walter MINETTI, Patrizia CAMPIANI, Giuseppe BUTINI, Stefania
DMO6NWD DT Small molecular drug
DM9MFDH ID DM9MFDH
DM9MFDH DN Carbamate derivative 4
DM9MFDH HS Patented
DM9MFDH SN PMID26413912-Compound-31
DM9MFDH CP SANOFI-AVENTIS
DM9MFDH DT Small molecular drug
DMHB5XG ID DMHB5XG
DMHB5XG DN Carbamate derivative 5
DMHB5XG HS Patented
DMHB5XG SN PMID26413912-Compound-32
DMHB5XG CP SANOFI-AVENTIS ABOUABDELLAH, Ahmed CHEREZE, Nathalie FAYOL, Aude SAADY, Mourad VACHE, Julien VERONIQUE, Corinne YAICHE, Philippe
DMHB5XG DT Small molecular drug
DMMOSKZ ID DMMOSKZ
DMMOSKZ DN Carbamate derivative 6
DMMOSKZ HS Patented
DMMOSKZ SN PMID26413912-Compound-33
DMMOSKZ CP SANOFI
DMMOSKZ DT Small molecular drug
DMOPF9N ID DMOPF9N
DMOPF9N DN Carbamate derivative 7
DMOPF9N HS Patented
DMOPF9N SN PMID26413912-Compound-34
DMOPF9N CP Astellas Pharma Inc. AOKI, Satoshi MUNAKATA, Ryosuke KAWANO, Noriyuki
DMOPF9N DT Small molecular drug
DMEAO42 ID DMEAO42
DMEAO42 DN Carbamate derivative 8
DMEAO42 HS Patented
DMEAO42 SN PMID26413912-Compound-35
DMEAO42 CP Astellas Pharma Inc. AOKI, Satoshi MUNAKATA, Ryosuke KAWANO, Noriyuki
DMEAO42 DT Small molecular drug
DMW4B1U ID DMW4B1U
DMW4B1U DN Carbamate derivative 9
DMW4B1U HS Patented
DMW4B1U SN PMID29053063-Compound-10a
DMW4B1U CP PFIZER INC
DMW4B1U DT Small molecular drug
DMW4B1U PC 126502770
DMW4B1U MW 452.4
DMW4B1U FM C18H23F3N2O6S
DMW4B1U IC InChI=1S/C18H23F3N2O6S/c19-18(20,21)15(11-24)29-16(25)23-8-6-17(7-9-23)10-13(12-28-17)22-30(26,27)14-4-2-1-3-5-14/h1-5,13,15,22,24H,6-12H2/t13-,15-/m1/s1
DMW4B1U CS C1CN(CCC12C[C@H](CO2)NS(=O)(=O)C3=CC=CC=C3)C(=O)O[C@H](CO)C(F)(F)F
DMW4B1U IK KBPUJKKMMQDFKB-UKRRQHHQSA-N
DMW4B1U IU [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] (3R)-3-(benzenesulfonamido)-1-oxa-8-azaspiro[4.5]decane-8-carboxylate
DMXQTPJ ID DMXQTPJ
DMXQTPJ DN Carbamide derivative 1
DMXQTPJ HS Patented
DMXQTPJ SN PMID26413912-Compound-49
DMXQTPJ CP JANSSEN PHARMACEUTICA NV KEITH, John, M. LIU, Jing
DMXQTPJ DT Small molecular drug
DMXQTPJ PC 54576693
DMXQTPJ MW 410.8
DMXQTPJ FM C18H17ClF2N4O3
DMXQTPJ IC InChI=1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
DMXQTPJ CS C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl
DMXQTPJ IK YWGYNGCRVZLMCS-UHFFFAOYSA-N
DMXQTPJ IU N-(4-chloropyridin-3-yl)-4-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]piperazine-1-carboxamide
DMXQTPJ CA CAS 1346528-50-4
DM9O56W ID DM9O56W
DM9O56W DN Carbamide derivative 10
DM9O56W HS Patented
DM9O56W SN PMID28074661-Compound-WO2003053958c50
DM9O56W CP CELLTECH R&D LIMITED DYKE, Hazel, Joan RICHARD, Marianna, Dilani HAUGHAN, Alan, Findlay SHARPE, Andrew
DM9O56W DT Small molecular drug
DMK7DJR ID DMK7DJR
DMK7DJR DN Carbamide derivative 11
DMK7DJR HS Patented
DMK7DJR SN PMID28074661-Compound-WO2003053958c51
DMK7DJR CP CELLTECH R&D LIMITED DYKE, Hazel, Joan RICHARD, Marianna, Dilani HAUGHAN, Alan, Findlay SHARPE, Andrew
DMK7DJR DT Small molecular drug
DMCAD64 ID DMCAD64
DMCAD64 DN Carbamide derivative 13
DMCAD64 HS Patented
DMCAD64 SN PMID29473428-Compound-74
DMCAD64 CP FLEXUS BIOSCIENCES, INC
DMCAD64 DT Small molecular drug
DMU04PM ID DMU04PM
DMU04PM DN Carbamide derivative 14
DMU04PM HS Patented
DMU04PM SN PMID28621580-Compound-US20140256819c19
DMU04PM CP Allergan, Inc
DMU04PM DT Small molecular drug
DM2TDXW ID DM2TDXW
DM2TDXW DN Carbamide derivative 15
DM2TDXW HS Patented
DM2TDXW SN PMID28621580-Compound-US20160096828c21
DM2TDXW CP Allergan, Inc
DM2TDXW DT Small molecular drug
DMLPOUR ID DMLPOUR
DMLPOUR DN Carbamide derivative 16
DMLPOUR HS Patented
DMLPOUR SN PMID28621580-Compound-WO2012028106c12
DMLPOUR CP ASCEPION PHARMACEUTICALS, INC. JIANG, Shan GAO, Xiaoyong WANG, Qishan
DMLPOUR DT Small molecular drug
DMUF5AC ID DMUF5AC
DMUF5AC DN Carbamide derivative 17
DMUF5AC HS Patented
DMUF5AC SN PMID28621580-Compound-WO2012089137c13
DMUF5AC CP SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY ZHANG, Qingwen
DMUF5AC DT Small molecular drug
DMZ37XI ID DMZ37XI
DMZ37XI DN Carbamide derivative 18
DMZ37XI HS Patented
DMZ37XI SN PMID28621580-Compound-WO2012094451c15
DMZ37XI CP BETA PHARMA CANADA INC. WANG, Zhaoyin YU, Chunrong
DMZ37XI DT Small molecular drug
DMLDXOB ID DMLDXOB
DMLDXOB DN Carbamide derivative 19
DMLDXOB HS Patented
DMLDXOB SN PMID28621580-Compound-WO2012139499c14
DMLDXOB CP SHANGHAI INSITITUTE OF PHARMACEUTICAL INDUSTRY ZHANG, Qingwen
DMLDXOB DT Small molecular drug
DMW5GI3 ID DMW5GI3
DMW5GI3 DN Carbamide derivative 2
DMW5GI3 HS Patented
DMW5GI3 SN PMID25470667-Compound-Figure5-19
DMW5GI3 CP GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMW5GI3 DT Small molecular drug
DMW5GI3 PC 71473500
DMW5GI3 MW 526.5
DMW5GI3 FM C27H25F3N4O4
DMW5GI3 IC InChI=1S/C27H25F3N4O4/c1-2-16-3-6-19(7-4-16)33-25(38)34-22-14-31-21(13-32-22)18-5-8-20-17(11-18)9-10-26(24(20)37,12-23(35)36)15-27(28,29)30/h3-8,11,13-14H,2,9-10,12,15H2,1H3,(H,35,36)(H2,32,33,34,38)
DMW5GI3 CS CCC1=CC=C(C=C1)NC(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3)C(=O)C(CC4)(CC(=O)O)CC(F)(F)F
DMW5GI3 IK YPGWBIYAJJSEDN-UHFFFAOYSA-N
DMW5GI3 IU 2-[6-[5-[(4-ethylphenyl)carbamoylamino]pyrazin-2-yl]-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydronaphthalen-2-yl]acetic acid
DMYSWG1 ID DMYSWG1
DMYSWG1 DN Carbamide derivative 20
DMYSWG1 HS Patented
DMYSWG1 SN PMID28621580-Compound-WO2013037292c17
DMYSWG1 CP HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD
DMYSWG1 DT Small molecular drug
DMYSWG1 PC 60171803
DMYSWG1 MW 487.9
DMYSWG1 FM C23H17ClF3N5O2
DMYSWG1 IC InChI=1S/C23H17ClF3N5O2/c1-28-21-20-16(8-10-30-21)19(9-11-29-20)34-15-5-2-13(3-6-15)31-22(33)32-14-4-7-18(24)17(12-14)23(25,26)27/h2-12H,1H3,(H,28,30)(H2,31,32,33)
DMYSWG1 CS CNC1=NC=CC2=C(C=CN=C21)OC3=CC=C(C=C3)NC(=O)NC4=CC(=C(C=C4)Cl)C(F)(F)F
DMYSWG1 IK ORNWLDOEVOUMBW-UHFFFAOYSA-N
DMYSWG1 IU 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[4-[[8-(methylamino)-1,7-naphthyridin-4-yl]oxy]phenyl]urea
DMD03J5 ID DMD03J5
DMD03J5 DN Carbamide derivative 21
DMD03J5 HS Patented
DMD03J5 SN PMID28621580-Compound-WO2013107225c16
DMD03J5 CP HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD
DMD03J5 DT Small molecular drug
DMC3TJI ID DMC3TJI
DMC3TJI DN Carbamide derivative 22
DMC3TJI HS Patented
DMC3TJI SN PMID28621580-Compound-WO2014040243c18
DMC3TJI CP HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD. ZHANG, Shixi
DMC3TJI DT Small molecular drug
DM0IRPO ID DM0IRPO
DM0IRPO DN Carbamide derivative 23
DM0IRPO HS Patented
DM0IRPO SN PMID28621580-Compound-WO2014201127c20
DM0IRPO CP Kala Pharmaceuticals, Inc
DM0IRPO DT Small molecular drug
DMD6Y73 ID DMD6Y73
DMD6Y73 DN Carbamide derivative 24
DMD6Y73 HS Patented
DMD6Y73 SN PMID29053063-Compound-12a
DMD6Y73 CP NORTHEASTERN UNIVERSITY
DMD6Y73 DT Small molecular drug
DM8ONCL ID DM8ONCL
DM8ONCL DN Carbamide derivative 25
DM8ONCL HS Patented
DM8ONCL SN PMID29053063-Compound-12b
DM8ONCL CP NORTHEASTERN UNIVERSITY
DM8ONCL DT Small molecular drug
DMDU9XF ID DMDU9XF
DMDU9XF DN Carbamide derivative 26
DMDU9XF HS Patented
DMDU9XF SN PMID29053063-Compound-12c
DMDU9XF CP NORTHEASTERN UNIVERSITY
DMDU9XF DT Small molecular drug
DM4ISCQ ID DM4ISCQ
DM4ISCQ DN Carbamide derivative 3
DM4ISCQ HS Patented
DM4ISCQ SN PMID25470667-Compound-Figure5-3
DM4ISCQ CP BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM4ISCQ DT Small molecular drug
DM5V2D9 ID DM5V2D9
DM5V2D9 DN Carbamide derivative 4
DM5V2D9 HS Patented
DM5V2D9 SN PMID28074661-Compound-US20056919335BMS-566419
DM5V2D9 DT Small molecular drug
DM951HL ID DM951HL
DM951HL DN Carbamide derivative 5
DM951HL HS Patented
DM951HL SN PMID28074661-Compound-US20056919335c41
DM951HL CP Bristol-Myers Squibb Co
DM951HL DT Small molecular drug
DMORBE3 ID DMORBE3
DMORBE3 DN Carbamide derivative 6
DMORBE3 HS Patented
DMORBE3 SN PMID28074661-Compound-US20056919335c42
DMORBE3 CP Bristol-Myers Squibb Co
DMORBE3 DT Small molecular drug
DMWKXN4 ID DMWKXN4
DMWKXN4 DN Carbamide derivative 7
DMWKXN4 HS Patented
DMWKXN4 SN PMID28074661-Compound-US20056919335c45
DMWKXN4 DT Small molecular drug
DMZ3FJO ID DMZ3FJO
DMZ3FJO DN Carbamide derivative 8
DMZ3FJO HS Patented
DMZ3FJO SN PMID28074661-Compound-US20067008958c52
DMZ3FJO CP Bristol-Myers Squibb Co
DMZ3FJO DT Small molecular drug
DMY06VC ID DMY06VC
DMY06VC DN Carbamide derivative 9
DMY06VC HS Patented
DMY06VC SN PMID28074661-Compound-WO2003053958c49
DMY06VC CP CELLTECH R&D LIMITED DYKE, Hazel, Joan RICHARD, Marianna, Dilani HAUGHAN, Alan, Findlay SHARPE, Andrew
DMY06VC DT Small molecular drug
DM0EBS8 ID DM0EBS8
DM0EBS8 DN Carbamoyl oxime derivative 1
DM0EBS8 HS Patented
DM0EBS8 SN PMID26413912-Compound-29
DM0EBS8 CP SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. MINETTI, Patrizia CABRI, Walter BORSINI, Franco CAPRIOLI, Antonio PENCO, Sergio DALLAVALLE, Sabrina MERLINI, Lucio MACCARRONE, Mauro
DM0EBS8 DT Small molecular drug
DM3B5RS ID DM3B5RS
DM3B5RS DN Carbazole-3-carboxamide analog 1
DM3B5RS HS Patented
DM3B5RS SN PMID27215781-Compound-35
DM3B5RS DT Small molecular drug
DM3B5RS PC 46871948
DM3B5RS MW 378.5
DM3B5RS FM C24H30N2O2
DM3B5RS IC InChI=1S/C24H30N2O2/c1-3-4-6-15-26-22-12-9-18(24(27)25-13-7-5-8-14-25)16-21(22)20-11-10-19(28-2)17-23(20)26/h9-12,16-17H,3-8,13-15H2,1-2H3
DM3B5RS CS CCCCCN1C2=C(C=C(C=C2)C(=O)N3CCCCC3)C4=C1C=C(C=C4)OC
DM3B5RS IK LHILAHDXYGCIPJ-UHFFFAOYSA-N
DM3B5RS IU (7-methoxy-9-pentylcarbazol-3-yl)-piperidin-1-ylmethanone
DM5GEBH ID DM5GEBH
DM5GEBH DN Carboxamide derivative 1
DM5GEBH HS Patented
DM5GEBH SN PMID26161824-Compound-94
DM5GEBH DT Small molecular drug
DM5GEBH PC 6918856
DM5GEBH MW 417.3
DM5GEBH FM C21H22Cl2N4O
DM5GEBH IC InChI=1S/C21H22Cl2N4O/c22-16-9-10-19(17(23)13-16)27-20(15-7-3-1-4-8-15)14-18(24-27)21(28)25-26-11-5-2-6-12-26/h1,3-4,7-10,13,20H,2,5-6,11-12,14H2,(H,25,28)
DM5GEBH CS C1CCN(CC1)NC(=O)C2=NN(C(C2)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl
DM5GEBH IK IAMSOYSVSFMFLR-UHFFFAOYSA-N
DM5GEBH IU 2-(2,4-dichlorophenyl)-3-phenyl-N-piperidin-1-yl-3,4-dihydropyrazole-5-carboxamide
DM5GEBH DE Obesity
DM5WMO9 ID DM5WMO9
DM5WMO9 DN Carboxamide derivative 10
DM5WMO9 HS Patented
DM5WMO9 SN PMID25399719-Compound-8
DM5WMO9 CP ABBVIE DEUTSCHLAND [DEABBVIE INC [US]
DM5WMO9 DT Small molecular drug
DM1DN94 ID DM1DN94
DM1DN94 DN Carboxamide derivative 11
DM1DN94 HS Patented
DM1DN94 SN PMID25399719-Compound-9
DM1DN94 CP ABBVIE DEUTSCHLAND [DEABBVIE INC [US]
DM1DN94 DT Small molecular drug
DM1DN94 PC 117932484
DM1DN94 MW 502.6
DM1DN94 FM C27H30N6O4
DM1DN94 IC InChI=1S/C27H30N6O4/c34-24(27(36)29-20-8-9-20)23(17-19-5-2-1-3-6-19)30-26(35)22-7-4-11-28-25(22)33-12-10-21(31-33)18-32-13-15-37-16-14-32/h1-7,10-12,20,23H,8-9,13-18H2,(H,29,36)(H,30,35)
DM1DN94 CS C1CC1NC(=O)C(=O)C(CC2=CC=CC=C2)NC(=O)C3=C(N=CC=C3)N4C=CC(=N4)CN5CCOCC5
DM1DN94 IK POGBERZVWORYJW-UHFFFAOYSA-N
DM1DN94 IU N-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-2-[3-(morpholin-4-ylmethyl)pyrazol-1-yl]pyridine-3-carboxamide
DMU5GKC ID DMU5GKC
DMU5GKC DN Carboxamide derivative 4
DMU5GKC HS Patented
DMU5GKC SN PMID27646564-Compound-11-V
DMU5GKC CP ASTELLAS PHARMA INC. KOTOBUKI PHARMACEUTICAL CO., LTD. SHIMADA, Itsuro MATSUYA, Takahiro KUROSAWA, Kazuo IIKUBO, Kazuhiko KAMIKAWA, Akio KUROMITSU, Sadao SHINDOU, Nobuaki
DMU5GKC DT Small molecular drug
DM149WN ID DM149WN
DM149WN DN Carboxamide derivative 5
DM149WN HS Patented
DM149WN SN PMID25399719-Compound-3
DM149WN DT Small molecular drug
DM6GZW4 ID DM6GZW4
DM6GZW4 DN Carboxamide derivative 6
DM6GZW4 HS Patented
DM6GZW4 SN PMID25399719-Compound-4
DM6GZW4 DT Small molecular drug
DM6GZW4 PC 66644706
DM6GZW4 MW 484.5
DM6GZW4 FM C28H28N4O4
DM6GZW4 IC InChI=1S/C28H28N4O4/c33-25-15-14-23(31-25)28(36)32(19-21-11-5-2-6-12-21)24(17-20-9-3-1-4-10-20)26(34)27(35)30-18-22-13-7-8-16-29-22/h1-13,16,23-24H,14-15,17-19H2,(H,30,35)(H,31,33)/t23-,24?/m0/s1
DM6GZW4 CS C1CC(=O)N[C@@H]1C(=O)N(CC2=CC=CC=C2)C(CC3=CC=CC=C3)C(=O)C(=O)NCC4=CC=CC=N4
DM6GZW4 IK BRJIMUOJPNOLKS-UXMRNZNESA-N
DM6GZW4 IU (2S)-N-benzyl-N-[3,4-dioxo-1-phenyl-4-(pyridin-2-ylmethylamino)butan-2-yl]-5-oxopyrrolidine-2-carboxamide
DM8TQS4 ID DM8TQS4
DM8TQS4 DN Carboxamide derivative 7
DM8TQS4 HS Patented
DM8TQS4 SN PMID25399719-Compound-5
DM8TQS4 CP ABBVIE DEUTSCHLAND [DEABBVIE INC [US]
DM8TQS4 DT Small molecular drug
DM6HI34 ID DM6HI34
DM6HI34 DN Carboxamide derivative 8
DM6HI34 HS Patented
DM6HI34 SN PMID25399719-Compound-6
DM6HI34 CP ABBVIE DEUTSCHLAND [DEABBVIE INC [US]
DM6HI34 DT Small molecular drug
DMVISYC ID DMVISYC
DMVISYC DN Carboxamide derivative 9
DMVISYC HS Patented
DMVISYC SN PMID25399719-Compound-7
DMVISYC CP ABBVIE DEUTSCHLAND [DEABBVIE INC [US]
DMVISYC DT Small molecular drug
DMVISYC PC 89852695
DMVISYC MW 462.5
DMVISYC FM C24H26N6O4
DMVISYC IC InChI=1S/C24H26N6O4/c25-22(32)21(31)20(15-17-5-2-1-3-6-17)27-24(33)19-7-4-9-26-23(19)30-10-8-18(28-30)16-29-11-13-34-14-12-29/h1-10,20H,11-16H2,(H2,25,32)(H,27,33)
DMVISYC CS C1COCCN1CC2=NN(C=C2)C3=C(C=CC=N3)C(=O)NC(CC4=CC=CC=C4)C(=O)C(=O)N
DMVISYC IK LNYKWHMNUSKRNS-UHFFFAOYSA-N
DMVISYC IU N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-2-[3-(morpholin-4-ylmethyl)pyrazol-1-yl]pyridine-3-carboxamide
DM86E2P ID DM86E2P
DM86E2P DN Carboxylic acid derivative 1
DM86E2P HS Patented
DM86E2P SN PMID28627961-Compound-37
DM86E2P CP ELI LILLY AND COMPANY
DM86E2P DT Small molecular drug
DM86E2P DE Neoplasm; Angiogenesis disorder
DM7INA1 ID DM7INA1
DM7INA1 DN Central azetidine derivative 1
DM7INA1 HS Patented
DM7INA1 SN PMID28067079-Compound-27
DM7INA1 CP HUA MEDICINE (SHANGHAI) LTD
DM7INA1 DT Small molecular drug
DM7INA1 PC 77108120
DM7INA1 MW 286.73
DM7INA1 FM C16H12ClFN2
DM7INA1 IC InChI=1S/C16H12ClFN2/c17-13-4-3-6-15(10-13)20-11-16(18,12-20)8-7-14-5-1-2-9-19-14/h1-6,9-10H,11-12H2
DM7INA1 CS C1C(CN1C2=CC(=CC=C2)Cl)(C#CC3=CC=CC=N3)F
DM7INA1 IK KUOSCBGVFZTWCN-UHFFFAOYSA-N
DM7INA1 IU 2-[2-[1-(3-chlorophenyl)-3-fluoroazetidin-3-yl]ethynyl]pyridine
DM2BLJ6 ID DM2BLJ6
DM2BLJ6 DN Central azetidine derivative 2
DM2BLJ6 HS Patented
DM2BLJ6 SN PMID28067079-Compound-28
DM2BLJ6 CP HUA MEDICINE (SHANGHAI) LTD
DM2BLJ6 DT Small molecular drug
DM2BLJ6 PC 86291449
DM2BLJ6 MW 300.8
DM2BLJ6 FM C17H14ClFN2
DM2BLJ6 IC InChI=1S/C17H14ClFN2/c1-13-6-8-20-15(9-13)5-7-17(19)11-21(12-17)16-4-2-3-14(18)10-16/h2-4,6,8-10H,11-12H2,1H3
DM2BLJ6 CS CC1=CC(=NC=C1)C#CC2(CN(C2)C3=CC(=CC=C3)Cl)F
DM2BLJ6 IK CCKHKYMAGHMQLN-UHFFFAOYSA-N
DM2BLJ6 IU 2-[2-[1-(3-chlorophenyl)-3-fluoroazetidin-3-yl]ethynyl]-4-methylpyridine
DMSMBCO ID DMSMBCO
DMSMBCO DN Chalcone derivative 1
DMSMBCO HS Patented
DMSMBCO SN PMID28454500-Compound-16
DMSMBCO CP THE JOHNS HOPKINS UNIVERSITY BISWAL, Shyam THIMMULAPPA, Rajesh KUMAR, Sarvesh MALHOTRA, Sanjay, V. KUMAR, Vineet JUNG-HYUN, Kim
DMSMBCO DT Small molecular drug
DMSMBCO PC 53262706
DMSMBCO MW 306.28
DMSMBCO FM C17H13F3O2
DMSMBCO IC InChI=1S/C17H13F3O2/c1-22-16-9-5-3-7-13(16)15(21)11-10-12-6-2-4-8-14(12)17(18,19)20/h2-11H,1H3/b11-10+
DMSMBCO CS COC1=CC=CC=C1C(=O)/C=C/C2=CC=CC=C2C(F)(F)F
DMSMBCO IK BDZOPPCXQXPRKH-ZHACJKMWSA-N
DMSMBCO IU (E)-1-(2-methoxyphenyl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
DMG84D3 ID DMG84D3
DMG84D3 DN Chalcone derivative 2
DMG84D3 HS Patented
DMG84D3 SN PMID28454500-Compound-17
DMG84D3 CP CUREVEDA, LLC
DMG84D3 DT Small molecular drug
DMG84D3 PC 118567519
DMG84D3 MW 307.27
DMG84D3 FM C16H12F3NO2
DMG84D3 IC InChI=1S/C16H12F3NO2/c1-22-15-8-9-20-10-12(15)14(21)7-6-11-4-2-3-5-13(11)16(17,18)19/h2-10H,1H3/b7-6+
DMG84D3 CS COC1=C(C=NC=C1)C(=O)/C=C/C2=CC=CC=C2C(F)(F)F
DMG84D3 IK ZYPJWXKOHCZQCI-VOTSOKGWSA-N
DMG84D3 IU (E)-1-(4-methoxypyridin-3-yl)-3-[2-(trifluoromethyl)phenyl]prop-2-en-1-one
DMFS7C3 ID DMFS7C3
DMFS7C3 DN Chalcone derivative 3
DMFS7C3 HS Patented
DMFS7C3 SN PMID28454500-Compound-18
DMFS7C3 CP CUREVEDA, LLC
DMFS7C3 DT Small molecular drug
DM45COR ID DM45COR
DM45COR DN Chalcone derivative 4
DM45COR HS Patented
DM45COR SN PMID28454500-Compound-19
DM45COR CP CUREVEDA, LLC
DM45COR DT Small molecular drug
DM45COR PC 118567653
DM45COR MW 273.71
DM45COR FM C15H12ClNO2
DM45COR IC InChI=1S/C15H12ClNO2/c1-19-14-7-4-10-17-15(14)13(18)9-8-11-5-2-3-6-12(11)16/h2-10H,1H3/b9-8+
DM45COR CS COC1=C(N=CC=C1)C(=O)/C=C/C2=CC=CC=C2Cl
DM45COR IK ADUCKBZUFASKCP-CMDGGOBGSA-N
DM45COR IU (E)-3-(2-chlorophenyl)-1-(3-methoxypyridin-2-yl)prop-2-en-1-one
DMJZGT8 ID DMJZGT8
DMJZGT8 DN Chalcone derivative 5
DMJZGT8 HS Patented
DMJZGT8 SN PMID26560530-Compound-37
DMJZGT8 CP Toray Industries, Inc
DMJZGT8 DT Small molecular drug
DMB8MNU ID DMB8MNU
DMB8MNU DN CHIR-99021
DMB8MNU HS Patented
DMB8MNU SN CHIR99021; CHIR 99021; CT-99021; CT99021
DMB8MNU DT Small molecular drug
DMB8MNU PC 9956119
DMB8MNU MW 465.3
DMB8MNU FM C22H18Cl2N8
DMB8MNU IC InChI=1S/C22H18Cl2N8/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32)
DMB8MNU CS CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N
DMB8MNU IK AQGNHMOJWBZFQQ-UHFFFAOYSA-N
DMB8MNU IU 6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile
DMB8MNU CA CAS 252917-06-9
DMB8MNU CB CHEBI:91091
DMB8MNU DE Graft rejection; Allergic inflammation
DMW4J0P ID DMW4J0P
DMW4J0P DN Chloroacetyl ester derivative 1
DMW4J0P HS Patented
DMW4J0P SN PMID26560530-Compound-10
DMW4J0P CP N Zyme Biotech GmbH
DMW4J0P DT Small molecular drug
DMW4J0P PC 88174183
DMW4J0P MW 372.76
DMW4J0P FM C15H17ClN2O7
DMW4J0P IC InChI=1S/C15H17ClN2O7/c16-6-13(21)24-9-11(14(22)17-7-12(19)20)18-15(23)25-8-10-4-2-1-3-5-10/h1-5,11H,6-9H2,(H,17,22)(H,18,23)(H,19,20)/t11-/m0/s1
DMW4J0P CS C1=CC=C(C=C1)COC(=O)N[C@@H](COC(=O)CCl)C(=O)NCC(=O)O
DMW4J0P IK UEILGHHGUUQOCS-NSHDSACASA-N
DMW4J0P IU 2-[[(2S)-3-(2-chloroacetyl)oxy-2-(phenylmethoxycarbonylamino)propanoyl]amino]acetic acid
DMR39ZY ID DMR39ZY
DMR39ZY DN Chlorobenzamide derivative 1
DMR39ZY HS Patented
DMR39ZY SN PMID27724045-Compound-26
DMR39ZY CP H. LUNDBECK A/S
DMR39ZY DT Small molecular drug
DMR39ZY PC 73673308
DMR39ZY MW 450.8
DMR39ZY FM C20H17ClF6N2O
DMR39ZY IC InChI=1S/C20H17ClF6N2O/c21-15-4-2-1-3-14(15)17(30)29-11-13(9-18(7-8-18)20(25,26)27)12-5-6-16(28-10-12)19(22,23)24/h1-6,10,13H,7-9,11H2,(H,29,30)
DMR39ZY CS C1CC1(CC(CNC(=O)C2=CC=CC=C2Cl)C3=CN=C(C=C3)C(F)(F)F)C(F)(F)F
DMR39ZY IK GRQCSOYTLVIPEY-UHFFFAOYSA-N
DMR39ZY IU 2-chloro-N-[3-[1-(trifluoromethyl)cyclopropyl]-2-[6-(trifluoromethyl)pyridin-3-yl]propyl]benzamide
DMKS7O3 ID DMKS7O3
DMKS7O3 DN Chlorobenzamide derivative 2
DMKS7O3 HS Patented
DMKS7O3 SN PMID27724045-Compound-27
DMKS7O3 CP H. LUNDBECK A/S
DMKS7O3 DT Small molecular drug
DMKS7O3 PC 73442861
DMKS7O3 MW 431.3
DMKS7O3 FM C20H19Cl2F3N2O
DMKS7O3 IC InChI=1S/C20H19Cl2F3N2O/c21-16-3-1-2-15(18(16)22)19(28)26-12-17(13-4-6-14(23)7-5-13)27-10-8-20(24,25)9-11-27/h1-7,17H,8-12H2,(H,26,28)
DMKS7O3 CS C1CN(CCC1(F)F)C(CNC(=O)C2=C(C(=CC=C2)Cl)Cl)C3=CC=C(C=C3)F
DMKS7O3 IK ASROAJWWBQODIW-UHFFFAOYSA-N
DMKS7O3 IU 2,3-dichloro-N-[2-(4,4-difluoropiperidin-1-yl)-2-(4-fluorophenyl)ethyl]benzamide
DM7SOZN ID DM7SOZN
DM7SOZN DN Chromene derivative 1
DM7SOZN HS Patented
DM7SOZN SN PMID26609882-Compound-86
DM7SOZN CP WYETH HEFFERNAN, Gavin, David STACK, Gary, Paul GROSS, Jonathan, Laird ZHOU, Dahui GAO, Hong
DM7SOZN DT Small molecular drug
DMINXMY ID DMINXMY
DMINXMY DN CID 138805970
DMINXMY HS Patented
DMINXMY DT Small molecular drug
DMINXMY PC 138805970
DMINXMY MW 399.4
DMINXMY FM C23H21N5O2
DMINXMY IC InChI=1S/C23H21N5O2/c1-15-11-24-23(30)21-10-17-9-19(7-8-20(17)28(15)21)26-22(29)18-12-25-27(14-18)13-16-5-3-2-4-6-16/h2-10,12,14-15H,11,13H2,1H3,(H,24,30)(H,26,29)/t15-/m1/s1
DMINXMY CS C[C@@H]1CNC(=O)C2=CC3=C(N12)C=CC(=C3)NC(=O)C4=CN(N=C4)CC5=CC=CC=C5
DMINXMY IK DWRUMXZDNGCUDK-OAHLLOKOSA-N
DMINXMY IU 1-benzyl-N-[(4R)-4-methyl-1-oxo-3,4-dihydro-2H-pyrazino[1,2-a]indol-8-yl]pyrazole-4-carboxamide
DMITX1G ID DMITX1G
DMITX1G DN Citalopram derivative 1
DMITX1G HS Patented
DMITX1G SN PMID29334795-Compound-59
DMITX1G DT Small molecular drug
DMITX1G PC 2771
DMITX1G MW 324.4
DMITX1G FM C20H21FN2O
DMITX1G IC InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
DMITX1G CS CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
DMITX1G IK WSEQXVZVJXJVFP-UHFFFAOYSA-N
DMITX1G IU 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
DMITX1G CA CAS 59729-33-8
DMITX1G CB CHEBI:77397
DMV6H95 ID DMV6H95
DMV6H95 DN C-linked disaccharide biphenyl mannoside derivative 1
DMV6H95 HS Patented
DMV6H95 SN PMID26651364-Compound-86
DMV6H95 CP VERTEX PHARMACEUTICALS INCORPORATED
DMV6H95 DT Carbohydrates
DMV6H95 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMJT1WG ID DMJT1WG
DMJT1WG DN C-linked disaccharide biphenyl mannoside derivative 2
DMJT1WG HS Patented
DMJT1WG SN PMID26651364-Compound-87
DMJT1WG CP VERTEX PHARMACEUTICALS INCORPORATED
DMJT1WG DT Carbohydrates
DMJT1WG DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMY10T2 ID DMY10T2
DMY10T2 DN C-linked disaccharide biphenyl mannoside derivative 3
DMY10T2 HS Patented
DMY10T2 SN PMID26651364-Compound-88
DMY10T2 CP VERTEX PHARMACEUTICALS INCORPORATED
DMY10T2 DT Carbohydrates
DMY10T2 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMRLE65 ID DMRLE65
DMRLE65 DN C-linked disaccharide biphenyl mannoside derivative 4
DMRLE65 HS Patented
DMRLE65 SN PMID26651364-Compound-89
DMRLE65 CP VERTEX PHARMACEUTICALS INCORPORATED
DMRLE65 DT Carbohydrates
DMRLE65 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMUG7E9 ID DMUG7E9
DMUG7E9 DN C-linked disaccharide biphenyl mannoside derivative 5
DMUG7E9 HS Patented
DMUG7E9 SN PMID26651364-Compound-90
DMUG7E9 CP VERTEX PHARMACEUTICALS INCORPORATED
DMUG7E9 DT Carbohydrates
DMUG7E9 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMUILMD ID DMUILMD
DMUILMD DN C-linked disaccharide biphenyl mannoside derivative 6
DMUILMD HS Patented
DMUILMD SN PMID26651364-Compound-91
DMUILMD CP VERTEX PHARMACEUTICALS INCORPORATED
DMUILMD DT Carbohydrates
DMUILMD DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMWYJF6 ID DMWYJF6
DMWYJF6 DN Complex heterocyclic compound 1
DMWYJF6 HS Patented
DMWYJF6 SN PMID28447479-Compound-30
DMWYJF6 CP GALAPAGOS NV
DMWYJF6 DT Small molecular drug
DMWYJF6 PC 78427770
DMWYJF6 MW 592.7
DMWYJF6 FM C29H30F2N8O2S
DMWYJF6 IC InChI=1S/C29H30F2N8O2S/c1-3-23-28(35(2)29-34-26(24(13-32)42-29)18-4-6-19(30)7-5-18)39-14-20(12-22(31)27(39)33-23)37-10-8-36(9-11-37)17-25(41)38-15-21(40)16-38/h4-7,12,14,21,40H,3,8-11,15-17H2,1-2H3
DMWYJF6 CS CCC1=C(N2C=C(C=C(C2=N1)F)N3CCN(CC3)CC(=O)N4CC(C4)O)N(C)C5=NC(=C(S5)C#N)C6=CC=C(C=C6)F
DMWYJF6 IK XWIATKKSLBPZTC-UHFFFAOYSA-N
DMWYJF6 IU 2-[[2-ethyl-8-fluoro-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]imidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile
DMWYJF6 DE Inflammation
DMLZMIG ID DMLZMIG
DMLZMIG DN Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1
DMLZMIG HS Patented
DMLZMIG SN PMID28621580-Compound-WO2012084683c62
DMLZMIG CP UNIV MAINZ JOHANNES GUTENBERG [DE]
DMLZMIG DT Small molecular drug
DMLZMIG DE Gastric adenocarcinoma
DM3ZGBH ID DM3ZGBH
DM3ZGBH DN Coumaricacid
DM3ZGBH HS Patented
DM3ZGBH CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMI1BKA ID DMI1BKA
DMI1BKA DN Coumarin/resveratrol hybrid derivative 1
DMI1BKA HS Patented
DMI1BKA SN PMID29324067-Compound-63
DMI1BKA CP University Hefei Technology
DMI1BKA DT Small molecular drug
DMK12OT ID DMK12OT
DMK12OT DN Coumarin/resveratrol hybrid derivative 2
DMK12OT HS Patented
DMK12OT SN PMID29324067-Compound-71
DMK12OT CP University Hefei Technology
DMK12OT DT Small molecular drug
DMXP073 ID DMXP073
DMXP073 DN CQ7
DMXP073 HS Patented
DMXP073 SN cc-671; 1618658-88-0; CC671; 4-{[4-(Cyclopentyloxy)-5-(2-Methyl-1,3-Benzoxazol-6-Yl)-7h-Pyrrolo[2,3-D]pyrimidin-2-Yl]amino}-3-Methoxy-N-Methylbenzamide; SCHEMBL16476100; CHEMBL4062218; US9623028, Compound 38; BDBM317462; EX-A1868; CS-8218; 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide; HY-108709; 4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide; CQ7
DMXP073 DT Small molecular drug
DMXP073 PC 117881270
DMXP073 MW 512.6
DMXP073 FM C28H28N6O4
DMXP073 IC InChI=1S/C28H28N6O4/c1-15-31-21-10-8-16(12-23(21)37-15)19-14-30-25-24(19)27(38-18-6-4-5-7-18)34-28(33-25)32-20-11-9-17(26(35)29-2)13-22(20)36-3/h8-14,18H,4-7H2,1-3H3,(H,29,35)(H2,30,32,33,34)
DMXP073 CS CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NC)OC)OC6CCCC6
DMXP073 IK CWJLAVRXVFHDSJ-UHFFFAOYSA-N
DMXP073 IU 4-[[4-cyclopentyloxy-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-N-methylbenzamide
DMBV5Z0 ID DMBV5Z0
DMBV5Z0 DN CRWCYVOHVXAEMF-LBPRGKRZSA-N
DMBV5Z0 HS Patented
DMBV5Z0 SN CHEMBL2385270; SCHEMBL15138926; CRWCYVOHVXAEMF-LBPRGKRZSA-N; BDBM50434166; (S)-N-(2-(2-Cyanopyrrolidine-1-yl)-2-oxoethyl)-6-fluoroquinoline-4-carboxamide
DMBV5Z0 DT Small molecular drug
DMBV5Z0 PC 71667229
DMBV5Z0 MW 326.32
DMBV5Z0 FM C17H15FN4O2
DMBV5Z0 IC InChI=1S/C17H15FN4O2/c18-11-3-4-15-14(8-11)13(5-6-20-15)17(24)21-10-16(23)22-7-1-2-12(22)9-19/h3-6,8,12H,1-2,7,10H2,(H,21,24)/t12-/m0/s1
DMBV5Z0 CS C1C[C@H](N(C1)C(=O)CNC(=O)C2=C3C=C(C=CC3=NC=C2)F)C#N
DMBV5Z0 IK CRWCYVOHVXAEMF-LBPRGKRZSA-N
DMBV5Z0 IU N-[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]-6-fluoroquinoline-4-carboxamide
DM76Q10 ID DM76Q10
DM76Q10 DN Crystalline anhydrous toluene derivative 1
DM76Q10 HS Patented
DM76Q10 SN PMID25416646-Compound-Figure2-H
DM76Q10 CP MERCK & CO., INC. LEYES, Aquiles, E
DM76Q10 DT Small molecular drug
DM5BFJO ID DM5BFJO
DM5BFJO DN CS-W011402
DM5BFJO HS Patented
DM5BFJO SN DICHLOROBIS[DI-TERT-BUTYL(4-DIMETHYLAMINOPHENYL)PHOSPHINO]PALLADIUM(II); bis(di-tert-butyl(4-dimethylaminophenyl)-phosphine)dichloropalladium(II); DICHLOROBIS[DI-TERT-BUTYL(4-DIMETHYLAMINOPHENYL)PHOSPHINE]PALLADIUM(II); SCHEMBL113074; US9598421, Example 8; KS-00000ESS; AWOFSUFKCXRJMV-UHFFFAOYSA-N; XRZMZNIQMNUFBE-UHFFFAOYSA-L; AJBUBMMXJAOMTF-UHFFFAOYSA-N; BDBM302439; CS-W011402; bis(di-tert-butyl(4-dimethylaminophenyl)phosphino)dichloropalladium; dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]phosphoranyl})palladium
DM5BFJO DT Small molecular drug
DM5BFJO PC 58567970
DM5BFJO MW 710.1
DM5BFJO FM C32H58Cl2N2P2Pd+2
DM5BFJO IC InChI=1S/2C16H28NP.2ClH.Pd/c2*1-15(2,3)18(16(4,5)6)14-11-9-13(10-12-14)17(7)8;;;/h2*9-12H,1-8H3;2*1H;/q;;;;+2
DM5BFJO CS CC(C)(C)[PH+](C1=CC=C(C=C1)N(C)C)C(C)(C)C.CC(C)(C)[PH+](C1=CC=C(C=C1)N(C)C)C(C)(C)C.Cl[Pd]Cl
DM5BFJO IK DWOZNANUEDYIOF-UHFFFAOYSA-N
DM5BFJO IU ditert-butyl-[4-(dimethylamino)phenyl]phosphanium;dichloropalladium
DM4765M ID DM4765M
DM4765M DN Curcumin analog 1
DM4765M HS Patented
DM4765M SN PMID26394986-Compound-32
DM4765M CP The Ohio State University Research Foundation
DM4765M DT Small molecular drug
DM4765M PC 11487078
DM4765M MW 424.5
DM4765M FM C25H28O6
DM4765M IC InChI=1S/C25H28O6/c1-25(2,23(26)13-9-17-7-11-19(28-3)21(15-17)30-5)24(27)14-10-18-8-12-20(29-4)22(16-18)31-6/h7-16H,1-6H3/b13-9+,14-10+
DM4765M CS CC(C(=O)/C=C/C1=CC(=C(C=C1)OC)OC)(C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)C
DM4765M IK VMMZAMVBGQWOHT-UTLPMFLDSA-N
DM4765M IU (1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4,4-dimethylhepta-1,6-diene-3,5-dione
DM4765M CA CAS 52328-97-9
DMZ8S6X ID DMZ8S6X
DMZ8S6X DN Curcumin analog 2
DMZ8S6X HS Patented
DMZ8S6X SN PMID26394986-Compound-33
DMZ8S6X CP The Ohio State University Research Foundation
DMZ8S6X DT Small molecular drug
DMZ8S6X PC 68019246
DMZ8S6X MW 464.5
DMZ8S6X FM C28H32O6
DMZ8S6X IC InChI=1S/C28H32O6/c1-31-22-12-8-20(18-24(22)33-3)10-14-26(29)28(16-6-5-7-17-28)27(30)15-11-21-9-13-23(32-2)25(19-21)34-4/h8-15,18-19H,5-7,16-17H2,1-4H3/b14-10+,15-11+
DMZ8S6X CS COC1=C(C=C(C=C1)/C=C/C(=O)C2(CCCCC2)C(=O)/C=C/C3=CC(=C(C=C3)OC)OC)OC
DMZ8S6X IK NQDROBVIYYEMDQ-WFYKWJGLSA-N
DMZ8S6X IU (E)-3-(3,4-dimethoxyphenyl)-1-[1-[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]cyclohexyl]prop-2-en-1-one
DMMX1ZE ID DMMX1ZE
DMMX1ZE DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1
DMMX1ZE HS Patented
DMMX1ZE SN PMID27215781-Compound-14
DMMX1ZE CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMMX1ZE DT Small molecular drug
DMMX1ZE PC 86297384
DMMX1ZE MW 348.4
DMMX1ZE FM C18H28N4O3
DMMX1ZE IC InChI=1S/C18H28N4O3/c1-17(2,12-19)14-10-15(25-21-14)20-16(23)18(3,4)22(5)11-13-6-8-24-9-7-13/h10,13H,6-9,11H2,1-5H3,(H,20,23)
DMMX1ZE CS CC(C)(C#N)C1=NOC(=C1)NC(=O)C(C)(C)N(C)CC2CCOCC2
DMMX1ZE IK OLLDWVBPHQUDHP-UHFFFAOYSA-N
DMMX1ZE IU N-[3-(2-cyanopropan-2-yl)-1,2-oxazol-5-yl]-2-methyl-2-[methyl(oxan-4-ylmethyl)amino]propanamide
DM6GTDM ID DM6GTDM
DM6GTDM DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2
DM6GTDM HS Patented
DM6GTDM SN PMID27215781-Compound-15
DM6GTDM CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM6GTDM DT Small molecular drug
DM6GTDM PC 49849167
DM6GTDM MW 367.5
DM6GTDM FM C19H33N3O4
DM6GTDM IC InChI=1S/C19H33N3O4/c1-18(2,13-24-6)15-11-16(26-21-15)20-17(23)19(3,4)22(5)12-14-7-9-25-10-8-14/h11,14H,7-10,12-13H2,1-6H3,(H,20,23)
DM6GTDM CS CC(C)(COC)C1=NOC(=C1)NC(=O)C(C)(C)N(C)CC2CCOCC2
DM6GTDM IK FTTMRXSESRGDGE-UHFFFAOYSA-N
DM6GTDM IU N-[3-(1-methoxy-2-methylpropan-2-yl)-1,2-oxazol-5-yl]-2-methyl-2-[methyl(oxan-4-ylmethyl)amino]propanamide
DMD198F ID DMD198F
DMD198F DN Cyanomethyl pypazole carboxamide derivative 1
DMD198F HS Patented
DMD198F SN PMID27774822-Compound-Figure2Example40-85
DMD198F CP MERCK SHARP & DOHME CORP. BRUBAKER, Jason CHILDERS, Matthew Lloyd CHRISTOPHER, Matthew CLOSE, Joshua, T. KATZ, Jason David JUNG, Joon PETERSON, Scott SILIPHAIVANH, Phieng SIU, Tony SMITH, Graham Frank TORRES, Luis, E. WOO, Hyun Chong YOUNG, Jonathan, R. ZHANG, Hongjun
DMD198F DT Small molecular drug
DMSVMUT ID DMSVMUT
DMSVMUT DN Cyclic compound 1
DMSVMUT HS Patented
DMSVMUT SN PMID30107136-Compound-Example80
DMSVMUT CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMSVMUT DT Small molecule immunotherapy
DMSVMUT DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMGRBAJ ID DMGRBAJ
DMGRBAJ DN Cyclic compound 2
DMGRBAJ HS Patented
DMGRBAJ SN PMID30107136-Compound-Example81
DMGRBAJ CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMGRBAJ DT Small molecule immunotherapy
DMGRBAJ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMVOEN7 ID DMVOEN7
DMVOEN7 DN Cyclic compound 3
DMVOEN7 HS Patented
DMVOEN7 SN PMID30107136-Compound-Example82
DMVOEN7 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMVOEN7 DT Small molecule immunotherapy
DMVOEN7 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM2BZI0 ID DM2BZI0
DM2BZI0 DN Cyclic cyanoethypypazole derivative 1
DM2BZI0 HS Patented
DM2BZI0 SN PMID27774822-Compound-Figure2Example14-1
DM2BZI0 CP MERCK SHARP & DOHME [US]
DM2BZI0 DT Small molecular drug
DM0K62M ID DM0K62M
DM0K62M DN Cyclic hydroxamate derivative 1
DM0K62M HS Patented
DM0K62M SN PMID29473428-Compound-28
DM0K62M CP CURADEV PHARMA PVT. LTD
DM0K62M DT Small molecular drug
DM0K62M PC 130405851
DM0K62M MW 350.29
DM0K62M FM C17H13F3N2O3
DM0K62M IC InChI=1S/C17H13F3N2O3/c18-17(19,20)13-8-4-7-12(9-13)15-21(10-14(23)22(15)25)16(24)11-5-2-1-3-6-11/h1-9,15,25H,10H2
DM0K62M CS C1C(=O)N(C(N1C(=O)C2=CC=CC=C2)C3=CC(=CC=C3)C(F)(F)F)O
DM0K62M IK KDNAARNFNBRRTM-UHFFFAOYSA-N
DM0K62M IU 1-benzoyl-3-hydroxy-2-[3-(trifluoromethyl)phenyl]imidazolidin-4-one
DM1ZIPN ID DM1ZIPN
DM1ZIPN DN Cyclic octapeptide derivative 1
DM1ZIPN HS Patented
DM1ZIPN SN PMID26882240-Compound-33
DM1ZIPN CP ONCOIMMUNE INC. SUNVITA THERAPEUTICS,
DM1ZIPN DT Small molecular drug
DM78NOU ID DM78NOU
DM78NOU DN Cyclic peptide derivative 1
DM78NOU HS Patented
DM78NOU SN PMID27019002-Compound-compound11
DM78NOU CP MUSC Foundation for Research Development, USA
DM78NOU DT Peptide
DMV2UQ5 ID DMV2UQ5
DMV2UQ5 DN Cyclic peptidomimetic derivative 1
DMV2UQ5 HS Patented
DMV2UQ5 SN PMID30107136-Compound-Example77
DMV2UQ5 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMV2UQ5 DT Small molecule immunotherapy
DMV2UQ5 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMWH3FP ID DMWH3FP
DMWH3FP DN Cyclic peptidomimetic derivative 2
DMWH3FP HS Patented
DMWH3FP SN PMID30107136-Compound-Example78
DMWH3FP CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMWH3FP DT Small molecule immunotherapy
DMWH3FP DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMI7KG4 ID DMI7KG4
DMI7KG4 DN Cyclic peptidomimetic derivative 3
DMI7KG4 HS Patented
DMI7KG4 SN PMID30107136-Compound-Example79
DMI7KG4 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMI7KG4 DT Small molecule immunotherapy
DMI7KG4 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMJMWDV ID DMJMWDV
DMJMWDV DN Cyclic sulfonamide derivative 1
DMJMWDV HS Patented
DMJMWDV SN PMID25726713-Compound-52
DMJMWDV CP NANT HOLDINGS IP, LLC
DMJMWDV DT Small molecular drug
DMXSZ5B ID DMXSZ5B
DMXSZ5B DN Cyclic sulfonamide derivative 2
DMXSZ5B HS Patented
DMXSZ5B SN PMID25726713-Compound-53
DMXSZ5B CP NANT HOLDINGS IP, LLC
DMXSZ5B DT Small molecular drug
DMBANT7 ID DMBANT7
DMBANT7 DN Cyclic sulfonamide derivative 3
DMBANT7 HS Patented
DMBANT7 SN PMID25726713-Compound-54
DMBANT7 CP NANT HOLDINGS IP, LLC
DMBANT7 DT Small molecular drug
DMWAU49 ID DMWAU49
DMWAU49 DN Cyclic sulfonamide derivative 4
DMWAU49 HS Patented
DMWAU49 SN PMID25726713-Compound-55
DMWAU49 CP NANT HOLDINGS IP, LLC
DMWAU49 DT Small molecular drug
DMXMGSP ID DMXMGSP
DMXMGSP DN Cycloalkyl acid derivative 1
DMXMGSP HS Patented
DMXMGSP SN PMID27414413-Compound-Figure9left
DMXMGSP CP SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. JIANGSU HENGRUI MEDICINE CO., LTD
DMXMGSP DT Small molecular drug
DM09LY3 ID DM09LY3
DM09LY3 DN Cycloalkyl acid derivative 2
DM09LY3 HS Patented
DM09LY3 SN PMID27414413-Compound-Figure9right
DM09LY3 CP SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. JIANGSU HENGRUI MEDICINE CO., LTD
DM09LY3 DT Small molecular drug
DM09LY3 PC 86294127
DM09LY3 MW 338.22
DM09LY3 FM C14H12BrNO2S
DM09LY3 IC InChI=1S/C14H12BrNO2S/c15-9-2-3-11-10(8-9)12(4-7-16-11)19-14(13(17)18)5-1-6-14/h2-4,7-8H,1,5-6H2,(H,17,18)
DM09LY3 CS C1CC(C1)(C(=O)O)SC2=C3C=C(C=CC3=NC=C2)Br
DM09LY3 IK QGBWIYLNOBYNDL-UHFFFAOYSA-N
DM09LY3 IU 1-(6-bromoquinolin-4-yl)sulfanylcyclobutane-1-carboxylic acid
DM09LY3 CA CAS 1638327-48-6
DM3RK0S ID DM3RK0S
DM3RK0S DN Cycloalkyl nitrile pyrazole carboxamide derivative 1
DM3RK0S HS Patented
DM3RK0S SN PMID27774822-Compound-Figure2Example1-4
DM3RK0S CP MERCK SHARP & DOHME CORP. BRUBAKER, Jason DINSMORE, Christopher J. HOFFMAN, Dawn Marie JUNG, Joon LIU, Duan PETERSON, Scott SIU, Tony TORRES, Luis E. ZHANG, Hongjun WEI, Zhongyong SHI, Feng
DM3RK0S DT Small molecular drug
DMD3LK1 ID DMD3LK1
DMD3LK1 DN Cycloalkyl nitrile pyrazolo pyridone derivative 1
DMD3LK1 HS Patented
DMD3LK1 SN PMID27774822-Compound-Figure2Example15-71
DMD3LK1 CP MERCK SHARP & DOHME CORP. CHILDERS, Matthew Lloyd DINSMORE, Christopher FULLER, Peter GUERIN, David KATZ, Jason David PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. ZHANG, Hongjun FALCONE, Danielle TORRES, Luis BRUBAKER, Jason ZENG, Hongbo CAI, Jiaqiang DU, Xiaoxing WANG, Chonggang BAI, Yunfeng KONG, Norman LIU, Yumei ZHENG, Zhixiang
DMD3LK1 DT Small molecular drug
DMW4JB0 ID DMW4JB0
DMW4JB0 DN Cycloalkyl nitrile pyrazolo pyridone derivative 2
DMW4JB0 HS Patented
DMW4JB0 SN PMID27774822-Compound-Figure2Example3-9
DMW4JB0 CP MERCK SHARP & DOHME CORP. CHILDERS, Matthew L. DINSMORE, Christopher FULLER, Peter H. GUERIN, David J. KATZ, Jason David PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. ZHANG, Hongjun CAI, Jiaqiang DU, Xiaoxing WANG, Chonggang KONG, Norman LIU, Yumei
DMW4JB0 DT Small molecular drug
DMN3WID ID DMN3WID
DMN3WID DN Cyclohexane carboxamide derivative 1
DMN3WID HS Patented
DMN3WID SN PMID28699813-Compound-17
DMN3WID CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMN3WID DT Small molecular drug
DMN3WID PC 54670056
DMN3WID MW 586.9
DMN3WID FM C29H30BrClFN3O2
DMN3WID IC InChI=1S/C29H30BrClFN3O2/c30-22-5-1-19(2-6-22)26-18-24(35-13-15-37-16-14-35)9-10-25(26)29(36)34-28(20-3-7-23(31)8-4-20)21-11-12-33-27(32)17-21/h1-8,11-12,17,24-26,28H,9-10,13-16,18H2,(H,34,36)/t24-,25-,26+,28?/m1/s1
DMN3WID CS C1C[C@H]([C@@H](C[C@@H]1N2CCOCC2)C3=CC=C(C=C3)Br)C(=O)NC(C4=CC=C(C=C4)Cl)C5=CC(=NC=C5)F
DMN3WID IK ABJSOROVZZKJGI-OCYUSGCXSA-N
DMN3WID IU (1R,2R,4R)-2-(4-bromophenyl)-N-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide
DM1A0WU ID DM1A0WU
DM1A0WU DN Cyclohexane carboxamide derivative 2
DM1A0WU HS Patented
DM1A0WU SN PMID28699813-Compound-18
DM1A0WU CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM1A0WU DT Small molecular drug
DM1A0WU PC 54670150
DM1A0WU MW 570.5
DM1A0WU FM C29H30BrF2N3O2
DM1A0WU IC InChI=1S/C29H30BrF2N3O2/c30-22-5-1-19(2-6-22)26-18-24(35-13-15-37-16-14-35)9-10-25(26)29(36)34-28(20-3-7-23(31)8-4-20)21-11-12-33-27(32)17-21/h1-8,11-12,17,24-26,28H,9-10,13-16,18H2,(H,34,36)/t24-,25-,26+,28?/m1/s1
DM1A0WU CS C1C[C@H]([C@@H](C[C@@H]1N2CCOCC2)C3=CC=C(C=C3)Br)C(=O)NC(C4=CC=C(C=C4)F)C5=CC(=NC=C5)F
DM1A0WU IK SPLGKYRHYYLJLJ-OCYUSGCXSA-N
DM1A0WU IU (1R,2R,4R)-2-(4-bromophenyl)-N-[(4-fluorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide
DMQLZUW ID DMQLZUW
DMQLZUW DN Cyclohexane carboxamide derivative 3
DMQLZUW HS Patented
DMQLZUW SN PMID28699813-Compound-I
DMQLZUW CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMQLZUW DT Small molecular drug
DMRBI5X ID DMRBI5X
DMRBI5X DN Cyclohexyl azetidine derivative 1
DMRBI5X HS Patented
DMRBI5X SN PMID27774824-Compound-Figure13Example1
DMRBI5X CP INCYTE CORPORATION RODGERS, James D. ARVANITIS, Argyrios G
DMRBI5X DT Small molecular drug
DMORFPT ID DMORFPT
DMORFPT DN Cyclohexyl carbamate derivative 1
DMORFPT HS Patented
DMORFPT SN PMID26815044-Compound-85
DMORFPT DT Small molecular drug
DMORFPT DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM6VPIR ID DM6VPIR
DM6VPIR DN Cyclohexyl carbamate derivative 2
DM6VPIR HS Patented
DM6VPIR SN PMID26815044-Compound-86
DM6VPIR DT Small molecular drug
DM6VPIR DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMVIZTY ID DMVIZTY
DMVIZTY DN Cyclohexyl carbamate derivative 3
DMVIZTY HS Patented
DMVIZTY SN PMID26815044-Compound-87
DMVIZTY DT Small molecular drug
DMVIZTY PC 54670072
DMVIZTY MW 275.4
DMVIZTY FM C17H25NO2
DMVIZTY IC InChI=1S/C17H25NO2/c1-17(2,3)14-11-7-8-12-15(14)20-16(19)18-13-9-5-4-6-10-13/h4-6,9-10,14-15H,7-8,11-12H2,1-3H3,(H,18,19)
DMVIZTY CS CC(C)(C)C1CCCCC1OC(=O)NC2=CC=CC=C2
DMVIZTY IK IQFJKVNORUXJJY-UHFFFAOYSA-N
DMVIZTY IU (2-tert-butylcyclohexyl) N-phenylcarbamate
DMVIZTY DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMLD49W ID DMLD49W
DMLD49W DN Cyclohexyl carbamate derivative 4
DMLD49W HS Patented
DMLD49W SN PMID26815044-Compound-88
DMLD49W DT Small molecular drug
DMLD49W PC 49787364
DMLD49W MW 277.36
DMLD49W FM C16H23NO3
DMLD49W IC InChI=1S/C16H23NO3/c1-11-8-12(10-16(2,3)9-11)20-15(19)17-13-6-4-5-7-14(13)18/h4-7,11-12,18H,8-10H2,1-3H3,(H,17,19)
DMLD49W CS CC1CC(CC(C1)(C)C)OC(=O)NC2=CC=CC=C2O
DMLD49W IK XMUAVVZKNAMDEP-UHFFFAOYSA-N
DMLD49W IU (3,3,5-trimethylcyclohexyl) N-(2-hydroxyphenyl)carbamate
DMLD49W DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMS68DP ID DMS68DP
DMS68DP DN Cyclohexyl carbamate derivative 5
DMS68DP HS Patented
DMS68DP SN PMID26815044-Compound-89
DMS68DP DT Small molecular drug
DMS68DP PC 49787363
DMS68DP MW 257.37
DMS68DP FM C14H27NO3
DMS68DP IC InChI=1S/C14H27NO3/c1-11-8-12(10-14(2,3)9-11)18-13(16)15-6-5-7-17-4/h11-12H,5-10H2,1-4H3,(H,15,16)
DMS68DP CS CC1CC(CC(C1)(C)C)OC(=O)NCCCOC
DMS68DP IK XKPVQQCVMUKNEK-UHFFFAOYSA-N
DMS68DP IU (3,3,5-trimethylcyclohexyl) N-(3-methoxypropyl)carbamate
DMS68DP DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMSD2TN ID DMSD2TN
DMSD2TN DN Cyclohexyl carbamate derivative 6
DMSD2TN HS Patented
DMSD2TN SN PMID26815044-Compound-90
DMSD2TN DT Small molecular drug
DMSD2TN DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM2URPE ID DM2URPE
DM2URPE DN Cyclohexyl carbamate derivative 7
DM2URPE HS Patented
DM2URPE SN PMID26815044-Compound-91
DM2URPE DT Small molecular drug
DM2URPE PC 46898982
DM2URPE MW 227.34
DM2URPE FM C13H25NO2
DM2URPE IC InChI=1S/C13H25NO2/c1-4-5-9-14-13(15)16-12-8-6-7-10(2)11(12)3/h10-12H,4-9H2,1-3H3,(H,14,15)
DM2URPE CS CCCCNC(=O)OC1CCCC(C1C)C
DM2URPE IK NRBLABNDLCTIGX-UHFFFAOYSA-N
DM2URPE IU (2,3-dimethylcyclohexyl) N-butylcarbamate
DM2URPE DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMB9DEO ID DMB9DEO
DMB9DEO DN Cyclohexyl carbamate derivative 8
DMB9DEO HS Patented
DMB9DEO SN PMID26815044-Compound-92
DMB9DEO DT Small molecular drug
DMB9DEO PC 46899063
DMB9DEO MW 241.37
DMB9DEO FM C14H27NO2
DMB9DEO IC InChI=1S/C14H27NO2/c1-6-11(3)15-13(16)17-12-7-10(2)8-14(4,5)9-12/h10-12H,6-9H2,1-5H3,(H,15,16)
DMB9DEO CS CCC(C)NC(=O)OC1CC(CC(C1)(C)C)C
DMB9DEO IK UJUIRNFIDXYYDT-UHFFFAOYSA-N
DMB9DEO IU (3,3,5-trimethylcyclohexyl) N-butan-2-ylcarbamate
DMB9DEO DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMI2T1D ID DMI2T1D
DMI2T1D DN Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1
DMI2T1D HS Patented
DMI2T1D SN PMID29473428-Compound-38
DMI2T1D CP MERCK PATENT GMBH SHERER, Brian A
DMI2T1D DT Small molecular drug
DMI2T1D PC 118917034
DMI2T1D MW 318.4
DMI2T1D FM C18H20F2N2O
DMI2T1D IC InChI=1S/C18H20F2N2O/c19-14-3-1-2-13-16-10-21-11-22(16)15(17(13)14)6-9-18(20)7-4-12(23)5-8-18/h1-3,10-12,15,23H,4-9H2
DMI2T1D CS C1CC(CCC1O)(CCC2C3=C(C=CC=C3F)C4=CN=CN24)F
DMI2T1D IK AHMWQTITKYANIA-UHFFFAOYSA-N
DMI2T1D IU 4-fluoro-4-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexan-1-ol
DMKM6BY ID DMKM6BY
DMKM6BY DN Cyclopenta[d]pyrimidine derivative 1
DMKM6BY HS Patented
DMKM6BY SN PMID28270010-Compound-Figure28
DMKM6BY CP MEDIVATION TECHNOLOGIES, INC
DMKM6BY DT Small molecular drug
DMKM6BY PC 76283234
DMKM6BY MW 450.5
DMKM6BY FM C23H27FN8O
DMKM6BY IC InChI=1S/C23H27FN8O/c1-13(2)17-11-20(31-30-17)28-21-15-5-3-6-16(15)27-23(29-21)32-10-4-7-18(32)22(33)26-14-8-9-19(24)25-12-14/h8-9,11-13,18H,3-7,10H2,1-2H3,(H,26,33)(H2,27,28,29,30,31)
DMKM6BY CS CC(C)C1=CC(=NN1)NC2=NC(=NC3=C2CCC3)N4CCCC4C(=O)NC5=CN=C(C=C5)F
DMKM6BY IK GZDATWXVIVEVAM-UHFFFAOYSA-N
DMKM6BY IU N-(6-fluoropyridin-3-yl)-1-[4-[(5-propan-2-yl-1H-pyrazol-3-yl)amino]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
DMH7PGC ID DMH7PGC
DMH7PGC DN Cyclopentane carboxamide derivative 1
DMH7PGC HS Patented
DMH7PGC SN PMID28699813-Compound-20
DMH7PGC CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMH7PGC DT Small molecular drug
DMH7PGC PC 72837058
DMH7PGC MW 575.5
DMH7PGC FM C30H34Cl2F2N4O
DMH7PGC IC InChI=1S/C30H34Cl2F2N4O/c1-18-13-28(38(35-18)21-6-8-25(31)26(32)15-21)19-9-11-37(12-10-19)29(39)24-17-30(2,36(3)4)16-23(24)22-7-5-20(33)14-27(22)34/h5-8,13-15,19,23-24H,9-12,16-17H2,1-4H3/t23-,24+,30-/m0/s1
DMH7PGC CS CC1=NN(C(=C1)C2CCN(CC2)C(=O)[C@@H]3C[C@@](C[C@H]3C4=C(C=C(C=C4)F)F)(C)N(C)C)C5=CC(=C(C=C5)Cl)Cl
DMH7PGC IK XMOICBGWKUUJPT-BBANNHEPSA-N
DMH7PGC IU [4-[2-(3,4-dichlorophenyl)-5-methylpyrazol-3-yl]piperidin-1-yl]-[(1R,2R,4S)-2-(2,4-difluorophenyl)-4-(dimethylamino)-4-methylcyclopentyl]methanone
DMYP5FK ID DMYP5FK
DMYP5FK DN Cyclopentane carboxamide derivative 2
DMYP5FK HS Patented
DMYP5FK SN PMID28699813-Compound-J
DMYP5FK CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMYP5FK DT Small molecular drug
DMNXBPQ ID DMNXBPQ
DMNXBPQ DN Cyclopropane 1-carboxylic acid derivative 1
DMNXBPQ HS Patented
DMNXBPQ SN PMID27172114-Compound-72
DMNXBPQ CP CHDI FOUNDATION, INC
DMNXBPQ DT Small molecular drug
DM3M169 ID DM3M169
DM3M169 DN Cyclopropane 1-carboxylic acid derivative 10
DM3M169 HS Patented
DM3M169 SN PMID27172114-Compound-81
DM3M169 CP CHDI FOUNDATION, INC
DM3M169 DT Small molecular drug
DMSXB58 ID DMSXB58
DMSXB58 DN Cyclopropane 1-carboxylic acid derivative 2
DMSXB58 HS Patented
DMSXB58 SN PMID27172114-Compound-73
DMSXB58 CP CHDI FOUNDATION, INC
DMSXB58 DT Small molecular drug
DM6K59I ID DM6K59I
DM6K59I DN Cyclopropane 1-carboxylic acid derivative 3
DM6K59I HS Patented
DM6K59I SN PMID27172114-Compound-74
DM6K59I CP CHDI FOUNDATION, INC
DM6K59I DT Small molecular drug
DM6K59I PC 117902626
DM6K59I MW 273.11
DM6K59I FM C12H10Cl2O3
DM6K59I IC InChI=1S/C12H10Cl2O3/c1-5-9(10(5)12(16)17)11(15)6-2-3-7(13)8(14)4-6/h2-5,9-10H,1H3,(H,16,17)/t5-,9-,10-/m0/s1
DM6K59I CS C[C@H]1[C@@H]([C@H]1C(=O)O)C(=O)C2=CC(=C(C=C2)Cl)Cl
DM6K59I IK JFJFPXNBPGWPNH-AGEOJFDCSA-N
DM6K59I IU (1S,2S,3S)-2-(3,4-dichlorobenzoyl)-3-methylcyclopropane-1-carboxylic acid
DM8PVN3 ID DM8PVN3
DM8PVN3 DN Cyclopropane 1-carboxylic acid derivative 4
DM8PVN3 HS Patented
DM8PVN3 SN PMID27172114-Compound-75
DM8PVN3 CP CHDI FOUNDATION, INC
DM8PVN3 DT Small molecular drug
DMCSIYG ID DMCSIYG
DMCSIYG DN Cyclopropane 1-carboxylic acid derivative 5
DMCSIYG HS Patented
DMCSIYG SN PMID27172114-Compound-76
DMCSIYG CP CHDI FOUNDATION, INC
DMCSIYG DT Small molecular drug
DMCSIYG PC 117903050
DMCSIYG MW 287.13
DMCSIYG FM C13H12Cl2O3
DMCSIYG IC InChI=1S/C13H12Cl2O3/c1-13(2)9(10(13)12(17)18)11(16)6-3-4-7(14)8(15)5-6/h3-5,9-10H,1-2H3,(H,17,18)/t9-,10-/m0/s1
DMCSIYG CS CC1([C@@H]([C@H]1C(=O)O)C(=O)C2=CC(=C(C=C2)Cl)Cl)C
DMCSIYG IK LZXZDLJRRHTOOA-UWVGGRQHSA-N
DMCSIYG IU (1R,3R)-3-(3,4-dichlorobenzoyl)-2,2-dimethylcyclopropane-1-carboxylic acid
DM0OMBW ID DM0OMBW
DM0OMBW DN Cyclopropane 1-carboxylic acid derivative 6
DM0OMBW HS Patented
DM0OMBW SN PMID27172114-Compound-77
DM0OMBW CP CHDI FOUNDATION, INC
DM0OMBW DT Small molecular drug
DM4RTMO ID DM4RTMO
DM4RTMO DN Cyclopropane 1-carboxylic acid derivative 7
DM4RTMO HS Patented
DM4RTMO SN PMID27172114-Compound-78
DM4RTMO CP CHDI FOUNDATION, INC
DM4RTMO DT Small molecular drug
DM4P9HL ID DM4P9HL
DM4P9HL DN Cyclopropane 1-carboxylic acid derivative 8
DM4P9HL HS Patented
DM4P9HL SN PMID27172114-Compound-79
DM4P9HL CP CHDI FOUNDATION, INC
DM4P9HL DT Small molecular drug
DMLH9AQ ID DMLH9AQ
DMLH9AQ DN Cyclopropane 1-carboxylic acid derivative 9
DMLH9AQ HS Patented
DMLH9AQ SN PMID27172114-Compound-80
DMLH9AQ CP CHDI FOUNDATION, INC
DMLH9AQ DT Small molecular drug
DMXN361 ID DMXN361
DMXN361 DN Cyclopropylamine derivative 1
DMXN361 HS Patented
DMXN361 SN PMID27019002-Compound-23
DMXN361 CP ORYZON GENOMICS SA [ESORYZON GENOMICS S.A
DMXN361 DT Small molecular drug
DMZ5WN8 ID DMZ5WN8
DMZ5WN8 DN Cyclopropylamine derivative 10
DMZ5WN8 HS Patented
DMZ5WN8 SN PMID27019002-Compound-33b
DMZ5WN8 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMZ5WN8 DT Small molecular drug
DMMJ0YN ID DMMJ0YN
DMMJ0YN DN Cyclopropylamine derivative 11
DMMJ0YN HS Patented
DMMJ0YN SN PMID27019002-Compound-33c
DMMJ0YN CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMMJ0YN DT Small molecular drug
DMV4I0K ID DMV4I0K
DMV4I0K DN Cyclopropylamine derivative 12
DMV4I0K HS Patented
DMV4I0K SN PMID27019002-Compound-33d
DMV4I0K CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMV4I0K DT Small molecular drug
DMXNVD4 ID DMXNVD4
DMXNVD4 DN Cyclopropylamine derivative 13
DMXNVD4 HS Patented
DMXNVD4 SN PMID27019002-Compound-33e
DMXNVD4 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMXNVD4 DT Small molecular drug
DM6E9L4 ID DM6E9L4
DM6E9L4 DN Cyclopropylamine derivative 3
DM6E9L4 HS Patented
DM6E9L4 SN PMID27019002-Compound-29a
DM6E9L4 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DM6E9L4 DT Small molecular drug
DMOCF4Y ID DMOCF4Y
DMOCF4Y DN Cyclopropylamine derivative 4
DMOCF4Y HS Patented
DMOCF4Y SN PMID27019002-Compound-29b
DMOCF4Y CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DMOCF4Y DT Small molecular drug
DM5BCGD ID DM5BCGD
DM5BCGD DN Cyclopropylamine derivative 5
DM5BCGD HS Patented
DM5BCGD SN PMID27019002-Compound-29c
DM5BCGD CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DM5BCGD DT Small molecular drug
DMB2RKC ID DMB2RKC
DMB2RKC DN Cyclopropylamine derivative 6
DMB2RKC HS Patented
DMB2RKC SN PMID27019002-Compound-29d
DMB2RKC CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DMB2RKC DT Small molecular drug
DM3X4PJ ID DM3X4PJ
DM3X4PJ DN Cyclopropylamine derivative 7
DM3X4PJ HS Patented
DM3X4PJ SN PMID27019002-Compound-29e
DM3X4PJ CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED JOHNSON, Neil, W. KASPAREC, Jiri MILLER, William, Henry ROUSE, Meagan, B. SUAREZ, Dominic TIAN, Xinrong
DM3X4PJ DT Small molecular drug
DMA89WQ ID DMA89WQ
DMA89WQ DN Cyclopropylamine derivative 8
DMA89WQ HS Patented
DMA89WQ SN PMID27019002-Compound-32
DMA89WQ CP Incyte Corporation, USA
DMA89WQ DT Small molecular drug
DMX7YAL ID DMX7YAL
DMX7YAL DN Cyclopropylamine derivative 9
DMX7YAL HS Patented
DMX7YAL SN PMID27019002-Compound-33a
DMX7YAL CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMX7YAL DT Small molecular drug
DM0YTGS ID DM0YTGS
DM0YTGS DN Cyclopropyl-spiro piperidine derivative 1
DM0YTGS HS Patented
DM0YTGS SN PMID25539043-Compound-WO2012047703Example19
DM0YTGS CP MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DM0YTGS DT Small molecular drug
DMM0R65 ID DMM0R65
DMM0R65 DN Cyclopropyl-spiro piperidine derivative 2
DMM0R65 HS Patented
DMM0R65 SN PMID25539043-Compound-WO2012047703Example20
DMM0R65 CP MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DMM0R65 DT Small molecular drug
DM0IZW8 ID DM0IZW8
DM0IZW8 DN Cyclopropyl-spiro piperidine derivative 3
DM0IZW8 HS Patented
DM0IZW8 SN PMID25539043-Compound-WO2012047703Example21
DM0IZW8 CP MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DM0IZW8 DT Small molecular drug
DM2ZWSM ID DM2ZWSM
DM2ZWSM DN Cyclopropyl-spiro piperidine derivative 4
DM2ZWSM HS Patented
DM2ZWSM SN PMID25539043-Compound-WO2012047703Example22
DM2ZWSM CP MERCK SHARP & DOHME CORP. HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R
DM2ZWSM DT Small molecular drug
DMXKUMJ ID DMXKUMJ
DMXKUMJ DN Decyle nelycorine dibromo salt derivative 1
DMXKUMJ HS Patented
DMXKUMJ SN PMID29757691-Compound-12
DMXKUMJ DT Small molecular drug
DM3Q9OX ID DM3Q9OX
DM3Q9OX DN Deuterated 3-cyanoquinoline derivative 1
DM3Q9OX HS Patented
DM3Q9OX SN PMID25656651-Compound-45
DM3Q9OX CP SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
DM3Q9OX DT Small molecular drug
DM3Q9OX PC 76283824
DM3Q9OX MW 537.1
DM3Q9OX FM C29H34ClN5O3
DM3Q9OX IC InChI=1S/C29H34ClN5O3/c1-34-8-10-35(11-9-34)7-4-12-38-28-15-24-22(14-27(28)37-3)29(20(17-31)18-32-24)33-25-16-26(36-2)23(30)13-21(25)19-5-6-19/h13-16,18-19H,4-12H2,1-3H3,(H,32,33)/i1D
DM3Q9OX CS [2H]CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4C5CC5)Cl)OC)C#N)OC
DM3Q9OX IK YHGWVQSJPYSYIE-MICDWDOJSA-N
DM3Q9OX IU 4-(4-chloro-2-cyclopropyl-5-methoxyanilino)-7-[3-[4-(deuteriomethyl)piperazin-1-yl]propoxy]-6-methoxyquinoline-3-carbonitrile
DM02V5Q ID DM02V5Q
DM02V5Q DN Diamidothiazole derivative 1
DM02V5Q HS Patented
DM02V5Q SN PMID26161698-Compound-53
DM02V5Q CP SCHERING CORPORATION TADIKONDA, Praveen, K. CAUBLE, David, F., Jr. GUZI, Timothy, J. SIDDIQUI, Arshad, MSCHERING CORPORATION LABROLI, Marc, A. POKER, Cory, Seth WONG, Tzu, T. REDDY, Panduranga, Adulla, P. GUZI, Timothy, J. SIDDIQUI, M. ArshaSCHERING CORPORATION SHIPPS, Gerald, W., Jr. RICHARDS, Matthew CHENG, Cliff, C. HUANG, Xiaohua
DM02V5Q DT Small molecular drug
DM02V5Q PC 25256147
DM02V5Q MW 409.5
DM02V5Q FM C19H19N7O2S
DM02V5Q IC InChI=1S/C19H19N7O2S/c27-17(23-13-2-1-4-21-10-13)15-12-29-19(25-15)18(28)24-14-11-22-5-3-16(14)26-8-6-20-7-9-26/h1-5,10-12,20H,6-9H2,(H,23,27)(H,24,28)
DM02V5Q CS C1CN(CCN1)C2=C(C=NC=C2)NC(=O)C3=NC(=CS3)C(=O)NC4=CN=CC=C4
DM02V5Q IK VFDWSNCXADMJQH-UHFFFAOYSA-N
DM02V5Q IU 2-N-(4-piperazin-1-ylpyridin-3-yl)-4-N-pyridin-3-yl-1,3-thiazole-2,4-dicarboxamide
DMUG69Q ID DMUG69Q
DMUG69Q DN Diamine derivative 1
DMUG69Q HS Patented
DMUG69Q SN PMID26815044-Compound-100
DMUG69Q DT Small molecular drug
DMUG69Q PC 51362613
DMUG69Q MW 282.4
DMUG69Q FM C19H26N2
DMUG69Q IC InChI=1S/C19H26N2/c1-17-9-11-19(12-10-17)16-21(14-13-20(2)3)15-18-7-5-4-6-8-18/h4-12H,13-16H2,1-3H3
DMUG69Q CS CC1=CC=C(C=C1)CN(CCN(C)C)CC2=CC=CC=C2
DMUG69Q IK FAKZYZYSFVGBEY-UHFFFAOYSA-N
DMUG69Q IU N'-benzyl-N,N-dimethyl-N'-[(4-methylphenyl)methyl]ethane-1,2-diamine
DMUG69Q DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMQEYTJ ID DMQEYTJ
DMQEYTJ DN Diamine derivative 2
DMQEYTJ HS Patented
DMQEYTJ SN PMID26815044-Compound-101
DMQEYTJ DT Small molecular drug
DMQEYTJ PC 129279
DMQEYTJ MW 268.4
DMQEYTJ FM C18H24N2
DMQEYTJ IC InChI=1S/C18H24N2/c1-19(2)13-14-20(15-17-9-5-3-6-10-17)16-18-11-7-4-8-12-18/h3-12H,13-16H2,1-2H3
DMQEYTJ CS CN(C)CCN(CC1=CC=CC=C1)CC2=CC=CC=C2
DMQEYTJ IK XFOYZAKVZYMLET-UHFFFAOYSA-N
DMQEYTJ IU N',N'-dibenzyl-N,N-dimethylethane-1,2-diamine
DMQEYTJ CA CAS 68156-59-2
DMQEYTJ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMSYX4U ID DMSYX4U
DMSYX4U DN Diamine derivative 3
DMSYX4U HS Patented
DMSYX4U SN PMID26815044-Compound-99
DMSYX4U DT Small molecular drug
DMSYX4U PC 20628588
DMSYX4U MW 318.5
DMSYX4U FM C22H26N2
DMSYX4U IC InChI=1S/C22H26N2/c1-23(2)14-15-24(17-19-8-4-3-5-9-19)18-20-12-13-21-10-6-7-11-22(21)16-20/h3-13,16H,14-15,17-18H2,1-2H3
DMSYX4U CS CN(C)CCN(CC1=CC=CC=C1)CC2=CC3=CC=CC=C3C=C2
DMSYX4U IK MOXMQBPFKXNWCD-UHFFFAOYSA-N
DMSYX4U IU N'-benzyl-N,N-dimethyl-N'-(naphthalen-2-ylmethyl)ethane-1,2-diamine
DMSYX4U DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMPUH4Z ID DMPUH4Z
DMPUH4Z DN Diaminopyridine analog 4
DMPUH4Z HS Patented
DMPUH4Z SN PMID27310003-Compound-21
DMPUH4Z CP BRISTOL-MYERS SQUIBB COMPANY
DMPUH4Z DT Small molecular drug
DMPUH4Z PC 71656368
DMPUH4Z MW 522.7
DMPUH4Z FM C24H26N8O2S2
DMPUH4Z IC InChI=1S/C24H26N8O2S2/c1-13(2)27-19-9-21(29-15-4-5-18-20(8-15)35-12-26-18)25-10-17(19)22-30-31-23(36-22)24(34)32-7-6-16(11-32)28-14(3)33/h4-5,8-10,12-13,16H,6-7,11H2,1-3H3,(H,28,33)(H2,25,27,29)
DMPUH4Z CS CC(C)NC1=CC(=NC=C1C2=NN=C(S2)C(=O)N3CCC(C3)NC(=O)C)NC4=CC5=C(C=C4)N=CS5
DMPUH4Z IK OYYXHUJLHDYELY-UHFFFAOYSA-N
DMPUH4Z IU N-[1-[5-[6-(1,3-benzothiazol-6-ylamino)-4-(propan-2-ylamino)pyridin-3-yl]-1,3,4-thiadiazole-2-carbonyl]pyrrolidin-3-yl]acetamide
DM5B0F3 ID DM5B0F3
DM5B0F3 DN Diaminopyridine analog 5
DM5B0F3 HS Patented
DM5B0F3 SN PMID27310003-Compound-22
DM5B0F3 CP BRISTOL-MYERS SQUIBB COMPANY
DM5B0F3 DT Small molecular drug
DM06MJH ID DM06MJH
DM06MJH DN Diaryl amine derivative 1
DM06MJH HS Patented
DM06MJH SN PMID26161698-Compound-23
DM06MJH CP BAYER INTELLECTUAL PROPERTY GMBBAYER IP GMBH [DE]
DM06MJH DT Small molecular drug
DM06MJH PC 71515733
DM06MJH MW 443.5
DM06MJH FM C21H19F2N5O2S
DM06MJH IC InChI=1S/C21H19F2N5O2S/c1-3-31(29,26-13-24)12-14-5-4-6-16(9-14)27-21-25-11-18(23)20(28-21)17-8-7-15(22)10-19(17)30-2/h4-11H,3,12H2,1-2H3,(H,25,27,28)
DM06MJH CS CCS(=NC#N)(=O)CC1=CC(=CC=C1)NC2=NC=C(C(=N2)C3=C(C=C(C=C3)F)OC)F
DM06MJH IK QEYANDLEJXFZFA-UHFFFAOYSA-N
DM06MJH IU [ethyl-[[3-[[5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyrimidin-2-yl]amino]phenyl]methyl]-oxo-lambda6-sulfanylidene]cyanamide
DMRBYAV ID DMRBYAV
DMRBYAV DN Diaryl amine derivative 2
DMRBYAV HS Patented
DMRBYAV SN PMID28092474-Compound-10
DMRBYAV CP PRESIDENT AND FELLOWS OF HARVARD COLLEGE DANA-FARBER CANCER INSTITUTE, INC. TANG, Weiping BRADNER, James, Elliot SCHREIBER, Stuart, L
DMRBYAV DT Small molecular drug
DMLBN1T ID DMLBN1T
DMLBN1T DN Diaryl amine derivative 3
DMLBN1T HS Patented
DMLBN1T SN PMID28092474-Compound-11
DMLBN1T CP KARUS THERAPEUTICS LIMITED SHUTTLEWORTH, Stephen Joseph TOMASSI, Cyrille Davy
DMLBN1T DT Small molecular drug
DMZL6AX ID DMZL6AX
DMZL6AX DN Diaryl amine derivative 4
DMZL6AX HS Patented
DMZL6AX SN PMID28092474-Compound-9
DMZL6AX CP MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMZL6AX DT Small molecular drug
DMIQOY7 ID DMIQOY7
DMIQOY7 DN Diaryl morpholine derivative 1
DMIQOY7 HS Patented
DMIQOY7 SN PMID26161824-Compound-124
DMIQOY7 CP SCHERING CORPORATION SCOTT, Jack, D. STAMFORD, Andre
DMIQOY7 DT Small molecular drug
DMIQOY7 PC 25125705
DMIQOY7 MW 470.8
DMIQOY7 FM C22H22Cl3NO4
DMIQOY7 IC InChI=1S/C22H22Cl3NO4/c1-22(2,3)30-20(27)11-19-21(28)26(15-7-4-13(23)5-8-15)18(12-29-19)16-9-6-14(24)10-17(16)25/h4-10,18-19H,11-12H2,1-3H3
DMIQOY7 CS CC(C)(C)OC(=O)CC1C(=O)N(C(CO1)C2=C(C=C(C=C2)Cl)Cl)C3=CC=C(C=C3)Cl
DMIQOY7 IK XAGXRDZNWDXEAM-UHFFFAOYSA-N
DMIQOY7 IU tert-butyl 2-[4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-3-oxomorpholin-2-yl]acetate
DMIQOY7 DE Obesity
DMERQ7V ID DMERQ7V
DMERQ7V DN Diaryl piperazine derivative 1
DMERQ7V HS Patented
DMERQ7V SN PMID26161824-Compound-127
DMERQ7V CP INTERVET INTERNATIONAL B.V. DEMONG, Duane, Eugene MILLER, Michael, W. GILBERT, Eric, J. SCOTT, Jack, D. STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekher
DMERQ7V DT Small molecular drug
DMERQ7V PC 25165933
DMERQ7V MW 441.3
DMERQ7V FM C24H22Cl2N2O2
DMERQ7V IC InChI=1S/C24H22Cl2N2O2/c1-30-23-10-6-5-9-19(23)24(29)27-13-14-28(21-12-11-18(25)15-20(21)26)22(16-27)17-7-3-2-4-8-17/h2-12,15,22H,13-14,16H2,1H3
DMERQ7V CS COC1=CC=CC=C1C(=O)N2CCN(C(C2)C3=CC=CC=C3)C4=C(C=C(C=C4)Cl)Cl
DMERQ7V IK HXMSNSZTEVRLDE-UHFFFAOYSA-N
DMERQ7V IU [4-(2,4-dichlorophenyl)-3-phenylpiperazin-1-yl]-(2-methoxyphenyl)methanone
DMERQ7V DE Obesity
DMDOB20 ID DMDOB20
DMDOB20 DN Diaryl piperazine derivative 2
DMDOB20 HS Patented
DMDOB20 SN PMID26161824-Compound-128
DMDOB20 CP INTERVET INTERNATIONAL B.V. DEMONG, Duane, Eugene MILLER, Michael, W. GILBERT, Eric, J. SCOTT, Jack, D. STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekher
DMDOB20 DT Small molecular drug
DMDOB20 DE Obesity
DMXFNOD ID DMXFNOD
DMXFNOD DN Diarylamine and arylheteroarylamine pyrazole derivative 1
DMXFNOD HS Patented
DMXFNOD SN PMID26609882-Compound-37
DMXFNOD CP Arena Pharmaceuticals, Inc
DMXFNOD DT Small molecular drug
DMXFNOD PC 9978021
DMXFNOD MW 396.2
DMXFNOD FM C17H13BrF3N3
DMXFNOD IC InChI=1S/C17H13BrF3N3/c1-24-16(15(18)10-22-24)11-3-2-4-14(9-11)23-13-7-5-12(6-8-13)17(19,20)21/h2-10,23H,1H3
DMXFNOD CS CN1C(=C(C=N1)Br)C2=CC(=CC=C2)NC3=CC=C(C=C3)C(F)(F)F
DMXFNOD IK ZAIICAYGFBFTHL-UHFFFAOYSA-N
DMXFNOD IU 3-(4-bromo-2-methylpyrazol-3-yl)-N-[4-(trifluoromethyl)phenyl]aniline
DM6NR9Y ID DM6NR9Y
DM6NR9Y DN Diarylamine and arylheteroarylamine pyrazole derivative 2
DM6NR9Y HS Patented
DM6NR9Y SN PMID26609882-Compound-38
DM6NR9Y CP Arena Pharmaceuticals, Inc
DM6NR9Y DT Small molecular drug
DM6NR9Y PC 10361306
DM6NR9Y MW 362.65
DM6NR9Y FM C16H13BrClN3
DM6NR9Y IC InChI=1S/C16H13BrClN3/c1-21-16(15(17)10-19-21)11-3-2-4-14(9-11)20-13-7-5-12(18)6-8-13/h2-10,20H,1H3
DM6NR9Y CS CN1C(=C(C=N1)Br)C2=CC(=CC=C2)NC3=CC=C(C=C3)Cl
DM6NR9Y IK CEDWMDLRVLLSQK-UHFFFAOYSA-N
DM6NR9Y IU 3-(4-bromo-2-methylpyrazol-3-yl)-N-(4-chlorophenyl)aniline
DMLZ1UB ID DMLZ1UB
DMLZ1UB DN Diarylamine and arylheteroarylamine pyrazole derivative 3
DMLZ1UB HS Patented
DMLZ1UB SN PMID26609882-Compound-39
DMLZ1UB CP Arena Pharmaceuticals, Inc
DMLZ1UB DT Small molecular drug
DM9YD0Q ID DM9YD0Q
DM9YD0Q DN Diazepinone derivative 1
DM9YD0Q HS Patented
DM9YD0Q SN PMID28067079-Compound-84
DM9YD0Q CP NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DM9YD0Q DT Small molecular drug
DM9YD0Q PC 73334944
DM9YD0Q MW 322.4
DM9YD0Q FM C19H18N2O3
DM9YD0Q IC InChI=1S/C19H18N2O3/c1-12-6-7-18(24-12)15-10-16-13-4-3-5-17(23-2)14(13)8-9-21(16)19(22)11-20-15/h3-7,10H,8-9,11H2,1-2H3
DM9YD0Q CS CC1=CC=C(O1)C2=NCC(=O)N3CCC4=C(C3=C2)C=CC=C4OC
DM9YD0Q IK JTMQTEDUASKITJ-UHFFFAOYSA-N
DM9YD0Q IU 9-methoxy-2-(5-methylfuran-2-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DM9YD0Q DE Reflux disease; Parkinson disease
DMLQ7PG ID DMLQ7PG
DMLQ7PG DN Diazepinone derivative 2
DMLQ7PG HS Patented
DMLQ7PG SN PMID28067079-Compound-85
DMLQ7PG CP NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DMLQ7PG DT Small molecular drug
DMLQ7PG PC 73335337
DMLQ7PG MW 446.3
DMLQ7PG FM C19H19IN4O
DMLQ7PG IC InChI=1S/C19H19IN4O/c1-12(2)24-11-13(9-22-24)17-8-18-15-4-3-5-16(20)14(15)6-7-23(18)19(25)10-21-17/h3-5,8-9,11-12H,6-7,10H2,1-2H3
DMLQ7PG CS CC(C)N1C=C(C=N1)C2=NCC(=O)N3CCC4=C(C3=C2)C=CC=C4I
DMLQ7PG IK WBNYTWXVORUJBL-UHFFFAOYSA-N
DMLQ7PG IU 9-iodo-2-(1-propan-2-ylpyrazol-4-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DMLQ7PG DE Reflux disease; Parkinson disease
DMPTZ69 ID DMPTZ69
DMPTZ69 DN Diazepinone derivative 3
DMPTZ69 HS Patented
DMPTZ69 SN PMID28067079-Compound-86
DMPTZ69 CP NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DMPTZ69 DT Small molecular drug
DMPTZ69 PC 73334942
DMPTZ69 MW 324.4
DMPTZ69 FM C18H16N2O2S
DMPTZ69 IC InChI=1S/C18H16N2O2S/c1-22-16-5-2-4-12-13(16)7-8-20-15(12)10-14(19-11-18(20)21)17-6-3-9-23-17/h2-6,9-10H,7-8,11H2,1H3
DMPTZ69 CS COC1=CC=CC2=C1CCN3C2=CC(=NCC3=O)C4=CC=CS4
DMPTZ69 IK ZCPJZMIIRATEAI-UHFFFAOYSA-N
DMPTZ69 IU 9-methoxy-2-thiophen-2-yl-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DMPTZ69 DE Reflux disease; Parkinson disease
DM389YD ID DM389YD
DM389YD DN Diazepinone derivative 4
DM389YD HS Patented
DM389YD SN PMID28067079-Compound-87
DM389YD CP NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DM389YD DT Small molecular drug
DM389YD PC 73335441
DM389YD MW 414.4
DM389YD FM C24H19FN4O2
DM389YD IC InChI=1S/C24H19FN4O2/c1-31-23-11-15(7-9-26-23)20-12-21-19-4-2-3-17(16-5-6-22(25)28-13-16)18(19)8-10-29(21)24(30)14-27-20/h2-7,9,11-13H,8,10,14H2,1H3
DM389YD CS COC1=NC=CC(=C1)C2=NCC(=O)N3CCC4=C(C=CC=C4C3=C2)C5=CN=C(C=C5)F
DM389YD IK GISRGWUSGUAUMX-UHFFFAOYSA-N
DM389YD IU 9-(6-fluoropyridin-3-yl)-2-(2-methoxypyridin-4-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DM389YD DE Reflux disease; Parkinson disease
DM2U1QH ID DM2U1QH
DM2U1QH DN Diazepinone derivative 5
DM2U1QH HS Patented
DM2U1QH SN PMID28067079-Compound-91
DM2U1QH CP NOVARTIS AG BEHNKE, Dirk CARCACHE, David ERTL, Peter KOLLER, Manuel ORAIN, David
DM2U1QH DT Small molecular drug
DM2U1QH PC 73335827
DM2U1QH MW 347.4
DM2U1QH FM C20H21N5O
DM2U1QH IC InChI=1S/C20H21N5O/c1-13-22-12-25(23-13)19-10-18-17-7-3-6-15(14-4-2-5-14)16(17)8-9-24(18)20(26)11-21-19/h3,6-7,10,12,14H,2,4-5,8-9,11H2,1H3
DM2U1QH CS CC1=NN(C=N1)C2=NCC(=O)N3CCC4=C(C=CC=C4C3=C2)C5CCC5
DM2U1QH IK DDWMQMPXDUENHH-UHFFFAOYSA-N
DM2U1QH IU 9-cyclobutyl-2-(3-methyl-1,2,4-triazol-1-yl)-7,8-dihydro-4H-[1,4]diazepino[7,1-a]isoquinolin-5-one
DM2U1QH DE Reflux disease; Parkinson disease
DMRM5I1 ID DMRM5I1
DMRM5I1 DN Dibenzo [c,f]-[2,7]naphthyridine derivative 1
DMRM5I1 HS Patented
DMRM5I1 SN PMID25684022-Compound-US20070135429
DMRM5I1 CP Wyeth
DMRM5I1 DT Small molecular drug
DMRM5I1 DE Solid tumour/cancer; Metastatic cancer
DMUNFAT ID DMUNFAT
DMUNFAT DN Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1
DMUNFAT HS Patented
DMUNFAT SN PMID25539043-Compound-WO2013122897Example51
DMUNFAT CP AMGEN INC
DMUNFAT DT Small molecular drug
DMC3IN2 ID DMC3IN2
DMC3IN2 DN Dihydrodiazepinocarbazolone derivative 1
DMC3IN2 HS Patented
DMC3IN2 SN PMID27841036-Compound-26
DMC3IN2 CP BeiGene Ltd
DMC3IN2 DT Small molecular drug
DMC3IN2 PC 71626523
DMC3IN2 MW 364.5
DMC3IN2 FM C22H28N4O
DMC3IN2 IC InChI=1S/C22H28N4O/c1-22(2)13-16-20-18(14-22)26(12-11-25-9-4-3-5-10-25)17-8-6-7-15(19(17)20)21(27)24-23-16/h6-8H,3-5,9-14H2,1-2H3,(H,24,27)
DMC3IN2 CS CC1(CC2=C3C(=NNC(=O)C4=C3C(=CC=C4)N2CCN5CCCCC5)C1)C
DMC3IN2 IK LNWPRZVIPZXIHL-UHFFFAOYSA-N
DMC3IN2 IU 3,3-dimethyl-16-(2-piperidin-1-ylethyl)-6,7,16-triazatetracyclo[11.2.1.05,15.09,14]hexadeca-1(15),5,9(14),10,12-pentaen-8-one
DM1R0FJ ID DM1R0FJ
DM1R0FJ DN Dihydrodiazepinocarbazolone derivative 2
DM1R0FJ HS Patented
DM1R0FJ SN PMID27841036-Compound-XIV
DM1R0FJ CP BeiGene Ltd
DM1R0FJ DT Small molecular drug
DM5UPGZ ID DM5UPGZ
DM5UPGZ DN Dihydroisoquinoline carboxamide analog 1
DM5UPGZ HS Patented
DM5UPGZ SN PMID27724045-Compound-28
DM5UPGZ CP Evotec
DM5UPGZ DT Small molecular drug
DMQRECT ID DMQRECT
DMQRECT DN Dihydroisoxazole derivative 1
DMQRECT HS Patented
DMQRECT SN PMID26560530-Compound-51
DMQRECT CP Leland Stanford Junior University
DMQRECT DT Small molecular drug
DMQRECT PC 644315
DMQRECT MW 499.4
DMQRECT FM C23H23BrN4O4
DMQRECT IC InChI=1S/C23H23BrN4O4/c24-21-11-17(32-28-21)13-26-22(29)20(10-16-12-25-19-9-5-4-8-18(16)19)27-23(30)31-14-15-6-2-1-3-7-15/h1-9,12,17,20,25H,10-11,13-14H2,(H,26,29)(H,27,30)/t17?,20-/m0/s1
DMQRECT CS C1C(ON=C1Br)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC=CC=C4
DMQRECT IK MAQVWGRATZCTBU-OZBJMMHXSA-N
DMQRECT IU benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate
DMQRECT CA CAS 744198-17-2
DMLTZKX ID DMLTZKX
DMLTZKX DN Dihydroisoxazole derivative 2
DMLTZKX HS Patented
DMLTZKX SN PMID26560530-Compound-52
DMLTZKX CP Leland Stanford Junior University
DMLTZKX DT Small molecular drug
DMLTZKX PC 16094738
DMLTZKX MW 568.4
DMLTZKX FM C26H23BrFN5O4
DMLTZKX IC InChI=1S/C26H23BrFN5O4/c27-24-10-19(37-33-24)13-31-25(34)23(8-17-12-30-22-6-5-18(28)9-20(17)22)32-26(35)36-14-15-7-16-3-1-2-4-21(16)29-11-15/h1-7,9,11-12,19,23,30H,8,10,13-14H2,(H,31,34)(H,32,35)/t19?,23-/m0/s1
DMLTZKX CS C1C(ON=C1Br)CNC(=O)[C@H](CC2=CNC3=C2C=C(C=C3)F)NC(=O)OCC4=CC5=CC=CC=C5N=C4
DMLTZKX IK SUDBOOMQYSPULE-BVHINDKJSA-N
DMLTZKX IU quinolin-3-ylmethyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl]carbamate
DM16M4A ID DM16M4A
DM16M4A DN Dihydropyridine compound 1
DM16M4A HS Patented
DM16M4A SN PMID27646564-Compound-6-1
DM16M4A CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DM16M4A DT Small molecular drug
DM6RGOY ID DM6RGOY
DM6RGOY DN Dihydropyridine compound 2
DM6RGOY HS Patented
DM6RGOY SN PMID27646564-Compound-6-2
DM6RGOY CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DM6RGOY DT Small molecular drug
DMR3AVK ID DMR3AVK
DMR3AVK DN Dihydropyridine compound 3
DMR3AVK HS Patented
DMR3AVK SN PMID27646564-Compound-6-3
DMR3AVK CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMR3AVK DT Small molecular drug
DMIFZLG ID DMIFZLG
DMIFZLG DN Dihydropyridine compound 4
DMIFZLG HS Patented
DMIFZLG SN PMID27646564-Compound-6-4
DMIFZLG CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMIFZLG DT Small molecular drug
DMC41TK ID DMC41TK
DMC41TK DN Dihydropyridine compound 5
DMC41TK HS Patented
DMC41TK SN PMID27646564-Compound-6a
DMC41TK CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMC41TK DT Small molecular drug
DMEXT6J ID DMEXT6J
DMEXT6J DN Dihydropyridine compound 6
DMEXT6J HS Patented
DMEXT6J SN PMID27646564-Compound-6b
DMEXT6J CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEGlaxoSmithKline
DMEXT6J DT Small molecular drug
DMWIYFQ ID DMWIYFQ
DMWIYFQ DN Dihydropyrido phthalazinone derivative 1
DMWIYFQ HS Patented
DMWIYFQ SN PMID27841036-Compound-21
DMWIYFQ DT Small molecular drug
DMWIYFQ PC 136265073
DMWIYFQ MW 394.4
DMWIYFQ FM C20H16F2N6O
DMWIYFQ IC InChI=1S/C20H16F2N6O/c1-28-19(24-9-25-28)17-14(10-2-4-11(21)5-3-10)8-23-15-7-12(22)6-13-16(15)18(17)26-27-20(13)29/h2-7,9,14,17,23H,8H2,1H3,(H,27,29)
DMWIYFQ CS CN1C(=NC=N1)C2C(CNC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DMWIYFQ IK BGMPCZSIPWMURU-UHFFFAOYSA-N
DMWIYFQ IU 7-fluoro-12-(4-fluorophenyl)-13-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.4.1.05,14]tetradeca-1,5(14),6,8-tetraen-4-one
DMR4PQN ID DMR4PQN
DMR4PQN DN Dihydropyrido phthalazinone derivative 2
DMR4PQN HS Patented
DMR4PQN SN PMID27841036-Compound-22
DMR4PQN DT Small molecular drug
DMR4PQN PC 136334008
DMR4PQN MW 395.4
DMR4PQN FM C19H15F2N7O
DMR4PQN IC InChI=1S/C19H15F2N7O/c1-28-18(22-8-23-28)15-16(9-2-4-10(20)5-3-9)25-24-13-7-11(21)6-12-14(13)17(15)26-27-19(12)29/h2-8,15-16,24-25H,1H3,(H,27,29)
DMR4PQN CS CN1C(=NC=N1)C2C(NNC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
DMR4PQN IK VGIBCJTZZYLWON-UHFFFAOYSA-N
DMR4PQN IU 7-fluoro-12-(4-fluorophenyl)-13-(2-methyl-1,2,4-triazol-3-yl)-2,3,10,11-tetrazatricyclo[7.4.1.05,14]tetradeca-1,5(14),6,8-tetraen-4-one
DMMFBI3 ID DMMFBI3
DMMFBI3 DN Dihydropyrido phthalazinone derivative 3
DMMFBI3 HS Patented
DMMFBI3 SN PMID27841036-Compound-IX
DMMFBI3 CP BIOMARIN PHARMACEUTICAL INC. FENG, Ying GUTIERREZ, Andres, A. SHEN, Yuqiao WANG, Evelyn, W. OKHAMAFE, Augustus, O. PRICE, Christopher, P. CHOU, TianweBIOMARIN PHARMACEUTICAL INC. WANG, Bing CHU, Daniel
DMMFBI3 DT Small molecular drug
DMWEJ6U ID DMWEJ6U
DMWEJ6U DN Dihydropyrido phthalazinone derivative 4
DMWEJ6U HS Patented
DMWEJ6U SN PMID27841036-Compound-X
DMWEJ6U DT Small molecular drug
DM8S7NQ ID DM8S7NQ
DM8S7NQ DN Dihydropyrido pyrazinone compound 1
DM8S7NQ HS Patented
DM8S7NQ SN PMID26924192-Compound-58
DM8S7NQ CP BAYER PHARMA AKTIENGESELLSCHAFT
DM8S7NQ DT Small molecular drug
DMOTG2Y ID DMOTG2Y
DMOTG2Y DN Dihydropyrido pyrazinone compound 2
DMOTG2Y HS Patented
DMOTG2Y SN PMID26924192-Compound-59
DMOTG2Y CP BAYER PHARMA AKTIENGESELLSCHAFT
DMOTG2Y DT Small molecular drug
DM3PEUN ID DM3PEUN
DM3PEUN DN Dihydropyrido pyrazinone compound 3
DM3PEUN HS Patented
DM3PEUN SN PMID26924192-Compound-60
DM3PEUN CP BAYER PHARMA AKTIENGESELLSCHAFT
DM3PEUN DT Small molecular drug
DMSTC9Z ID DMSTC9Z
DMSTC9Z DN Dihydropyrido pyrimidine derivative 1
DMSTC9Z HS Patented
DMSTC9Z SN PMID28447479-Compound-3
DMSTC9Z CP ELI LILLY AND COMPANY
DMSTC9Z DT Small molecular drug
DMA25XH ID DMA25XH
DMA25XH DN Dihydropyrimidinone derivative 1
DMA25XH HS Patented
DMA25XH SN PMID26118988-Compound-19
DMA25XH DT Small molecular drug
DM5Y13R ID DM5Y13R
DM5Y13R DN Dihydropyrimidinone derivative 2
DM5Y13R HS Patented
DM5Y13R SN PMID26118988-Compound-20
DM5Y13R DT Small molecular drug
DMA1S6Q ID DMA1S6Q
DMA1S6Q DN Dihydropyrimidinone derivative 3
DMA1S6Q HS Patented
DMA1S6Q SN PMID25470667-Compound-Figure6-24
DMA1S6Q CP BRISTOL-MYERS SQUIBB COMPANY
DMA1S6Q DT Small molecular drug
DMNEKOZ ID DMNEKOZ
DMNEKOZ DN Dihydropyrimidinone derivative 4
DMNEKOZ HS Patented
DMNEKOZ SN PMID25470667-Compound-Figure6-25
DMNEKOZ CP BRISTOL-MYERS SQUIBB COMPANY
DMNEKOZ DT Small molecular drug
DMHGE1T ID DMHGE1T
DMHGE1T DN Dihydropyrrolopyrazole derivative 1
DMHGE1T HS Patented
DMHGE1T SN PMID25482888-Compound-47
DMHGE1T CP MERCK SHARP & DOHME CORP. BIFTU, Tesfaye KHAN, Tanweer, A
DMHGE1T DT Small molecular drug
DMUJ3XK ID DMUJ3XK
DMUJ3XK DN Dihydrothieno [2,3-e]indazole derivative 1
DMUJ3XK HS Patented
DMUJ3XK SN PMID25553724-Compound-WO2011077502 17
DMUJ3XK CP KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]
DM0D3HU ID DM0D3HU
DM0D3HU DN Dihydrothieno [2,3-e]indazole derivative 2
DM0D3HU HS Patented
DM0D3HU SN PMID25553724-Compound-WO2011077502 18
DM0D3HU CP KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]
DM85VQR ID DM85VQR
DM85VQR DN Dihydrothieno [2,3-e]indazole derivative 3
DM85VQR HS Patented
DM85VQR SN PMID25553724-Compound-WO2011077502 19
DM85VQR CP KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]
DMR4LPO ID DMR4LPO
DMR4LPO DN Dihydrothieno [2,3-e]indazole derivative 4
DMR4LPO HS Patented
DMR4LPO SN PMID25553724-Compound-WO2011077502 20
DMR4LPO CP KYORIN SEIYAKU KK [JPTAKAHASHI HIROYASU [JPHIGUCHI HIROMI [JP]
DMAH1EP ID DMAH1EP
DMAH1EP DN Dihydroxyfumaric acid derivative 1
DMAH1EP HS Patented
DMAH1EP SN PMID26815044-Compound-119
DMAH1EP DT Small molecular drug
DMAH1EP DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMZ4B3W ID DMZ4B3W
DMZ4B3W DN Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1
DMZ4B3W HS Patented
DMZ4B3W SN PMID27998201-Compound-16
DMZ4B3W DT Small molecular drug
DMZ4B3W PC 1720818
DMZ4B3W MW 264.3
DMZ4B3W FM C12H12N2O3S
DMZ4B3W IC InChI=1S/C12H12N2O3S/c1-16-8-3-7(4-9(6-8)17-2)5-10-11(15)14-12(18)13-10/h3-6H,1-2H3,(H2,13,14,15,18)/b10-5-
DMZ4B3W CS COC1=CC(=CC(=C1)/C=C\\2/C(=O)NC(=S)N2)OC
DMZ4B3W IK SXBGOUWIALXAOL-YHYXMXQVSA-N
DMZ4B3W IU (5Z)-5-[(3,5-dimethoxyphenyl)methylidene]-2-sulfanylideneimidazolidin-4-one
DMZ4B3W DE Cerebral ischemia
DM2OTJS ID DM2OTJS
DM2OTJS DN Dipeptide analog 1
DM2OTJS HS Patented
DM2OTJS SN PMID29865878-Compound-2
DM2OTJS CP THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL MOUNT SINAL SCHOOL OF MEDICINE ORLOWSKI, Robert, Z. ORLOWSKI, Marian
DM2OTJS DT Small molecular drug
DMMAF2S ID DMMAF2S
DMMAF2S DN Dipeptide analog 2
DMMAF2S HS Patented
DMMAF2S SN PMID26560530-Compound-20
DMMAF2S CP Aston University
DMMAF2S DT Small molecular drug
DM6RLTV ID DM6RLTV
DM6RLTV DN Dipeptide analog 3
DM6RLTV HS Patented
DM6RLTV SN PMID26560530-Compound-21
DM6RLTV CP Aston University
DM6RLTV DT Small molecular drug
DMXOPIJ ID DMXOPIJ
DMXOPIJ DN Dipeptide analog 4
DMXOPIJ HS Patented
DMXOPIJ SN PMID26560530-Compound-22
DMXOPIJ CP Aston University
DMXOPIJ DT Small molecular drug
DM2DYMS ID DM2DYMS
DM2DYMS DN Diphenyl purine derivative 1
DM2DYMS HS Patented
DM2DYMS SN PMID26161824-Compound-150
DM2DYMS CP RESEARCH TRIANGLE INSTITUTE
DM2DYMS DT Small molecular drug
DM2DYMS PC 71714624
DM2DYMS MW 560.5
DM2DYMS FM C25H27Cl2N7O2S
DM2DYMS IC InChI=1S/C25H27Cl2N7O2S/c26-18-9-11-19(12-10-18)34-24(20-3-1-2-4-21(20)27)33-22-23(30-15-31-25(22)34)29-13-16-5-7-17(8-6-16)14-32-37(28,35)36/h1-4,9-12,15-17,32H,5-8,13-14H2,(H2,28,35,36)(H,29,30,31)
DM2DYMS CS C1CC(CCC1CNC2=C3C(=NC=N2)N(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)CNS(=O)(=O)N
DM2DYMS IK FSGQETVZTNOSAH-UHFFFAOYSA-N
DM2DYMS IU 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-[[4-[(sulfamoylamino)methyl]cyclohexyl]methylamino]purine
DM2DYMS DE Obesity
DMG8MCJ ID DMG8MCJ
DMG8MCJ DN Diphenyl purine derivative 2
DMG8MCJ HS Patented
DMG8MCJ SN PMID26161824-Compound-151
DMG8MCJ CP RESEARCH TRIANGLE INSTITUTE
DMG8MCJ DT Small molecular drug
DMG8MCJ PC 72713199
DMG8MCJ MW 535.5
DMG8MCJ FM C28H28Cl2N6O
DMG8MCJ IC InChI=1S/C28H28Cl2N6O/c29-19-9-11-21(12-10-19)36-25(22-7-3-4-8-23(22)30)34-24-26(31-17-32-27(24)36)35-15-13-20(14-16-35)33-28(37)18-5-1-2-6-18/h3-4,7-12,17-18,20H,1-2,5-6,13-16H2,(H,33,37)
DMG8MCJ CS C1CCC(C1)C(=O)NC2CCN(CC2)C3=NC=NC4=C3N=C(N4C5=CC=C(C=C5)Cl)C6=CC=CC=C6Cl
DMG8MCJ IK XCAAVBMCEMDRAB-UHFFFAOYSA-N
DMG8MCJ IU N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]cyclopentanecarboxamide
DMG8MCJ DE Obesity
DMY5CFW ID DMY5CFW
DMY5CFW DN Diphenyl purine derivative 3
DMY5CFW HS Patented
DMY5CFW SN PMID26161824-Compound-152
DMY5CFW CP RESEARCH TRIANGLE INSTITUTE
DMY5CFW DT Small molecular drug
DMY5CFW PC 72713197
DMY5CFW MW 563.5
DMY5CFW FM C30H32Cl2N6O
DMY5CFW IC InChI=1S/C30H32Cl2N6O/c31-21-10-12-23(13-11-21)38-28(24-8-4-5-9-25(24)32)36-27-29(33-19-34-30(27)38)37-16-14-22(15-17-37)35-26(39)18-20-6-2-1-3-7-20/h4-5,8-13,19-20,22H,1-3,6-7,14-18H2,(H,35,39)
DMY5CFW CS C1CCC(CC1)CC(=O)NC2CCN(CC2)C3=NC=NC4=C3N=C(N4C5=CC=C(C=C5)Cl)C6=CC=CC=C6Cl
DMY5CFW IK ZGMMGSCAIDATIP-UHFFFAOYSA-N
DMY5CFW IU N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]-2-cyclohexylacetamide
DMY5CFW DE Obesity
DMP3JF4 ID DMP3JF4
DMP3JF4 DN Diphenyl purine derivative 4
DMP3JF4 HS Patented
DMP3JF4 SN PMID26161824-Compound-153
DMP3JF4 CP RESEARCH TRIANGLE INSTITUTE
DMP3JF4 DT Small molecular drug
DMP3JF4 PC 72712999
DMP3JF4 MW 511.4
DMP3JF4 FM C25H24Cl2N6O2
DMP3JF4 IC InChI=1S/C25H24Cl2N6O2/c1-2-35-25(34)30-17-11-13-32(14-12-17)23-21-24(29-15-28-23)33(18-9-7-16(26)8-10-18)22(31-21)19-5-3-4-6-20(19)27/h3-10,15,17H,2,11-14H2,1H3,(H,30,34)
DMP3JF4 CS CCOC(=O)NC1CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMP3JF4 IK YNFZOBCSHAKXPA-UHFFFAOYSA-N
DMP3JF4 IU ethyl N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]carbamate
DMP3JF4 DE Obesity
DMC2T4H ID DMC2T4H
DMC2T4H DN Diphenyl purine derivative 5
DMC2T4H HS Patented
DMC2T4H SN PMID26161824-Compound-154
DMC2T4H CP RESEARCH TRIANGLE INSTITUTE
DMC2T4H DT Small molecular drug
DMC2T4H PC 72713196
DMC2T4H MW 523.5
DMC2T4H FM C27H28Cl2N6O
DMC2T4H IC InChI=1S/C27H28Cl2N6O/c1-2-3-8-23(36)32-19-13-15-34(16-14-19)26-24-27(31-17-30-26)35(20-11-9-18(28)10-12-20)25(33-24)21-6-4-5-7-22(21)29/h4-7,9-12,17,19H,2-3,8,13-16H2,1H3,(H,32,36)
DMC2T4H CS CCCCC(=O)NC1CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMC2T4H IK JSIOAJBHLWGADL-UHFFFAOYSA-N
DMC2T4H IU N-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]piperidin-4-yl]pentanamide
DMC2T4H DE Obesity
DM3OCXI ID DM3OCXI
DM3OCXI DN Di-substituted piperidine derivative 1
DM3OCXI HS Patented
DM3OCXI SN PMID29757691-Compound-3a
DM3OCXI CP UNIVERZA V LJUBLJANI [SI]
DM3OCXI DT Small molecular drug
DM23XQL ID DM23XQL
DM23XQL DN Di-substituted piperidine derivative 2
DM23XQL HS Patented
DM23XQL SN PMID29757691-Compound-3a-i
DM23XQL CP UNIVERZA V LJUBLJANI [SI]
DM23XQL DT Small molecular drug
DM2IBX9 ID DM2IBX9
DM2IBX9 DN Di-substituted piperidine derivative 3
DM2IBX9 HS Patented
DM2IBX9 SN PMID29757691-Compound-3b
DM2IBX9 CP UNIVERZA V LJUBLJANI [SI]
DM2IBX9 DT Small molecular drug
DMTYL68 ID DMTYL68
DMTYL68 DN Disulfide compound 1
DMTYL68 HS Patented
DMTYL68 SN PMID27977313-Compound-38
DMTYL68 DT Small molecular drug
DMTYL68 PC 219104
DMTYL68 MW 188.3
DMTYL68 FM C7H12N2S2
DMTYL68 IC InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DMTYL68 CS CCC(C)SSC1=NC=CN1
DMTYL68 IK BPBPYQWMFCTCNG-UHFFFAOYSA-N
DMTYL68 IU 2-(butan-2-yldisulfanyl)-1H-imidazole
DMTYL68 CA CAS 141400-58-0
DMTYL68 CB CHEBI:94291
DM6ON31 ID DM6ON31
DM6ON31 DN Disulfide compound 2
DM6ON31 HS Patented
DM6ON31 SN PMID27977313-Compound-Figure6a
DM6ON31 DT Small molecular drug
DMOEFD3 ID DMOEFD3
DMOEFD3 DN Disulfiram analog 1
DMOEFD3 HS Patented
DMOEFD3 SN PMID25468267-Compound-26
DMOEFD3 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMOEFD3 DT Small molecular drug
DMOEFD3 PC 6451399
DMOEFD3 MW 240.4
DMOEFD3 FM C6H12N2S4
DMOEFD3 IC InChI=1S/C6H12N2S4/c1-3-7-5(9)11-12-6(10)8-4-2/h3-4H2,1-2H3,(H,7,9)(H,8,10)
DMOEFD3 CS CCNC(=S)SSC(=S)NCC
DMOEFD3 IK AMFIBVNSEBYBAM-UHFFFAOYSA-N
DMOEFD3 IU ethylcarbamothioylsulfanyl N-ethylcarbamodithioate
DMOEFD3 CA CAS 2438-91-7
DMOMGU5 ID DMOMGU5
DMOMGU5 DN Disulfiram analog 2
DMOMGU5 HS Patented
DMOMGU5 SN PMID25468267-Compound-27
DMOMGU5 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMOMGU5 DT Small molecular drug
DMOMGU5 PC 575125
DMOMGU5 MW 292.5
DMOMGU5 FM C10H16N2S4
DMOMGU5 IC InChI=1S/C10H16N2S4/c13-9(11-5-1-2-6-11)15-16-10(14)12-7-3-4-8-12/h1-8H2
DMOMGU5 CS C1CCN(C1)C(=S)SSC(=S)N2CCCC2
DMOMGU5 IK KCGUGVQODCQMBI-UHFFFAOYSA-N
DMOMGU5 IU pyrrolidine-1-carbothioylsulfanyl pyrrolidine-1-carbodithioate
DMOMGU5 CA CAS 496-08-2
DMYQHER ID DMYQHER
DMYQHER DN Diterpene triepoxide derivative 1
DMYQHER HS Patented
DMYQHER SN PMID27977313-Compound-37
DMYQHER DT Small molecular drug
DMYQHER PC 133613148
DMYQHER MW 360.4
DMYQHER FM C20H24O6
DMYQHER IC InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m1/s1
DMYQHER CS CC(C)[C@]12[C@H](O1)[C@@H]3[C@]4(O3)[C@@]5(CCC6=C([C@H]5C[C@@H]7[C@@]4([C@H]2O)O7)COC6=O)C
DMYQHER IK DFBIRQPKNDILPW-IJWWASSVSA-N
DMYQHER IU (1R,2R,4R,5R,7S,8S,9R,11R,13R)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
DMYQHER CA CAS 38748-32-2
DMAZOH4 ID DMAZOH4
DMAZOH4 DN Diterpenoid derivative 1
DMAZOH4 HS Patented
DMAZOH4 SN PMID28454500-Compound-47
DMAZOH4 CP BIOGEN MA INC
DMAZOH4 DT Small molecular drug
DMAZOH4 PC 132210477
DMAZOH4 MW 320.4
DMAZOH4 FM C19H28O4
DMAZOH4 IC InChI=1S/C19H28O4/c1-11-4-6-15-12(2)16(20)8-9-19(15,3)14(11)7-5-13-17(21)10-23-18(13)22/h5,12,14-17,20-21H,1,4,6-10H2,2-3H3/b13-5+/t12-,14-,15-,16-,17-,19+/m1/s1
DMAZOH4 CS C[C@@H]1[C@H]2CCC(=C)[C@H]([C@@]2(CC[C@H]1O)C)C/C=C/3\\[C@@H](COC3=O)O
DMAZOH4 IK VIGAUKOHNZARKF-YGQNBZPJSA-N
DMAZOH4 IU (3E,4S)-3-[2-[(1R,4aR,5R,6R,8aR)-6-hydroxy-5,8a-dimethyl-2-methylidene-1,3,4,4a,5,6,7,8-octahydronaphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one
DMKT19M ID DMKT19M
DMKT19M DN Diterpenoid derivative 2
DMKT19M HS Patented
DMKT19M SN PMID28454500-Compound-48
DMKT19M CP BIOGEN MA INC
DMKT19M DT Small molecular drug
DMKT19M PC 132210549
DMKT19M MW 388.4
DMKT19M FM C20H27F3O4
DMKT19M IC InChI=1S/C20H27F3O4/c1-11-4-6-15-12(2)19(26,20(21,22)23)9-8-18(15,3)14(11)7-5-13-16(24)10-27-17(13)25/h5,12,14-16,24,26H,1,4,6-10H2,2-3H3/b13-5+/t12-,14-,15-,16-,18+,19+/m1/s1
DMKT19M CS C[C@@H]1[C@H]2CCC(=C)[C@H]([C@@]2(CC[C@]1(C(F)(F)F)O)C)C/C=C/3\\[C@@H](COC3=O)O
DMKT19M IK NDMPTVODOMVTKE-YDWKZQRASA-N
DMKT19M IU (3E,4S)-3-[2-[(1R,4aR,5R,6S,8aR)-6-hydroxy-5,8a-dimethyl-2-methylidene-6-(trifluoromethyl)-3,4,4a,5,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one
DM6BU7N ID DM6BU7N
DM6BU7N DN Doramapimod
DM6BU7N HS Patented
DM6BU7N SN Doramapimod; 285983-48-4; BIRB-796; BIRB 796; BIRB 796 (Doramapimod); BIRB796; UNII-HO1A8B3YVV; 1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA; 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; HO1A8B3YVV; CHEMBL103667; 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea; CHEBI:40953; MVCOAUNKQVWQHZ-UHFFFAOYSA-N; C31H37N5O3; 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2
DM6BU7N DT Small molecular drug
DM6BU7N PC 156422
DM6BU7N MW 527.7
DM6BU7N FM C31H37N5O3
DM6BU7N IC InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)
DM6BU7N CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5
DM6BU7N IK MVCOAUNKQVWQHZ-UHFFFAOYSA-N
DM6BU7N IU 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
DM6BU7N CA CAS 285983-48-4
DM6BU7N CB CHEBI:40953
DM6BU7N DE Inflammatory bowel disease
DM2HLGC ID DM2HLGC
DM2HLGC DN DZ9
DM2HLGC HS Patented
DM2HLGC SN CHEMBL1084955; 3-amino-N-(3-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide; 3hfj; NadD inhibitor 3_02; AC1MMP3S; SCHEMBL11887601; HMS1801K16; RSC004746; BDBM50318653; NCGC00100444-01; EU-0014464; US8785499, 3_02; 3-amino-N-(3-fluorophenyl)-6-(thiophen-2-yl)thieno[2,3-b]pyridine-2-carboxamide; DZ9
DM2HLGC DT Small molecular drug
DM2HLGC PC 3289443
DM2HLGC MW 369.4
DM2HLGC FM C18H12FN3OS2
DM2HLGC IC InChI=1S/C18H12FN3OS2/c19-10-3-1-4-11(9-10)21-17(23)16-15(20)12-6-7-13(22-18(12)25-16)14-5-2-8-24-14/h1-9H,20H2,(H,21,23)
DM2HLGC CS C1=CC(=CC(=C1)F)NC(=O)C2=C(C3=C(S2)N=C(C=C3)C4=CC=CS4)N
DM2HLGC IK UCTSEHMMSSIODN-UHFFFAOYSA-N
DM2HLGC IU 3-amino-N-(3-fluorophenyl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide
DM5UM8I ID DM5UM8I
DM5UM8I DN EEA
DM5UM8I HS Patented
DM5UM8I SN N-{3-[3-(3'-Chlorobiphenyl-4-Yl)isoxazol-5-Yl]propanoyl}-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide; SCHEMBL14122533; CHEMBL1232487; BDBM120155; US8691753, 3; N-{3-[3-(3'-chlorobiphenyl-4-yl)-1,2-oxazol-5-yl]propanoyl}-L-alpha-glutamyl-L-alpha-glutamine; EEA
DM5UM8I DT Small molecular drug
DM5UM8I PC 46861564
DM5UM8I MW 585
DM5UM8I FM C28H29ClN4O8
DM5UM8I IC InChI=1S/C28H29ClN4O8/c29-19-3-1-2-18(14-19)16-4-6-17(7-5-16)23-15-20(41-33-23)8-11-24(34)31-22(10-13-26(37)38)28(40)32-21(27(30)39)9-12-25(35)36/h1-7,14-15,21-22H,8-13H2,(H2,30,39)(H,31,34)(H,32,40)(H,35,36)(H,37,38)/t21-,22-/m0/s1
DM5UM8I CS C1=CC(=CC(=C1)Cl)C2=CC=C(C=C2)C3=NOC(=C3)CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DM5UM8I IK KOVQMCGGWATESY-VXKWHMMOSA-N
DM5UM8I IU (4S)-5-amino-4-[[(2S)-4-carboxy-2-[3-[3-[4-(3-chlorophenyl)phenyl]-1,2-oxazol-5-yl]propanoylamino]butanoyl]amino]-5-oxopentanoic acid
DMR9IE5 ID DMR9IE5
DMR9IE5 DN EEC
DMR9IE5 HS Patented
DMR9IE5 SN N-[3-(3-Phenylisoxazol-5-Yl)propanoyl]-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide; SCHEMBL14122610; CHEMBL1232489; BDBM120166; US8691753, 14; N-[3-(3-phenyl-1,2-oxazol-5-yl)propanoyl]-L-alpha-glutamyl-L-alpha-glutamine; EEC
DMR9IE5 DT Small molecular drug
DMR9IE5 PC 46861565
DMR9IE5 MW 474.5
DMR9IE5 FM C22H26N4O8
DMR9IE5 IC InChI=1S/C22H26N4O8/c23-21(32)15(7-10-19(28)29)25-22(33)16(8-11-20(30)31)24-18(27)9-6-14-12-17(26-34-14)13-4-2-1-3-5-13/h1-5,12,15-16H,6-11H2,(H2,23,32)(H,24,27)(H,25,33)(H,28,29)(H,30,31)/t15-,16-/m0/s1
DMR9IE5 CS C1=CC=C(C=C1)C2=NOC(=C2)CCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N
DMR9IE5 IK LIIRZRQVACDFBI-HOTGVXAUSA-N
DMR9IE5 IU (4S)-5-amino-4-[[(2S)-4-carboxy-2-[3-(3-phenyl-1,2-oxazol-5-yl)propanoylamino]butanoyl]amino]-5-oxopentanoic acid
DMQF1UM ID DMQF1UM
DMQF1UM DN Egonol compound 1
DMQF1UM HS Patented
DMQF1UM SN PMID27967267-Compound-44
DMQF1UM CP Univ Guangzhou Chinese Medicine
DMQF1UM DT Small molecular drug
DMNBAZH ID DMNBAZH
DMNBAZH DN Enol carbamate derivative 1
DMNBAZH HS Patented
DMNBAZH SN PMID26413912-Compound-28
DMNBAZH CP SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. MINETTI, Patrizia CABRI, Walter DALLAVALLE, Sabrina MERLINI, Lucio PENCO, Sergio BORSINI, Franco CAPRIOLI, Antonio MACCARRONE, Mauro
DMNBAZH DT Small molecular drug
DMJSIN8 ID DMJSIN8
DMJSIN8 DN Enzoxazolinone sulfonamide derivative 1
DMJSIN8 HS Patented
DMJSIN8 SN PMID25539043-Compound-WO2013063459Example50
DMJSIN8 CP MERCK SHARP &amDOHME CORP. LAYTON, Mark, E. PERO, Joseph, E. FIJI, Hannah KELLY, Michael, J., III DE LEON, Pablo ROSSI, Michael, A. GILBERT, Kevin, F. ROECKER, Anthony, J. ZHAO, Zhijian MERCER, Swati Pal WOLKENBERG, Scott MULHEARN, James ZHAO, Lianyun LI, Dansu
DMJSIN8 DT Small molecular drug
DMU8LPN ID DMU8LPN
DMU8LPN DN Epoxysuccinate derivative 1
DMU8LPN HS Patented
DMU8LPN SN PMID25399719-Compound-18
DMU8LPN CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMU8LPN DT Small molecular drug
DMYF39U ID DMYF39U
DMYF39U DN Epoxysuccinate derivative 10
DMYF39U HS Patented
DMYF39U SN PMID25399719-Compound-27
DMYF39U CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMYF39U DT Small molecular drug
DMEV9O3 ID DMEV9O3
DMEV9O3 DN Epoxysuccinate derivative 2
DMEV9O3 HS Patented
DMEV9O3 SN PMID25399719-Compound-19
DMEV9O3 CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMEV9O3 DT Small molecular drug
DMEV9O3 PC 71679189
DMEV9O3 MW 356.32
DMEV9O3 FM C16H18F2N2O5
DMEV9O3 IC InChI=1S/C16H18F2N2O5/c1-7(2)6-10(19-15(22)12-13(25-12)16(23)24)14(21)20-11-8(17)4-3-5-9(11)18/h3-5,7,10,12-13H,6H2,1-2H3,(H,19,22)(H,20,21)(H,23,24)/t10-,12-,13-/m0/s1
DMEV9O3 CS CC(C)C[C@@H](C(=O)NC1=C(C=CC=C1F)F)NC(=O)[C@@H]2[C@H](O2)C(=O)O
DMEV9O3 IK RZWURLBUPSDTKT-DRZSPHRISA-N
DMEV9O3 IU (2S,3S)-3-[[(2S)-1-(2,6-difluoroanilino)-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMMETW5 ID DMMETW5
DMMETW5 DN Epoxysuccinate derivative 3
DMMETW5 HS Patented
DMMETW5 SN PMID25399719-Compound-20
DMMETW5 CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMMETW5 DT Small molecular drug
DMMETW5 PC 71818387
DMMETW5 MW 356.32
DMMETW5 FM C16H18F2N2O5
DMMETW5 IC InChI=1S/C16H18F2N2O5/c1-7(2)6-10(19-15(22)12-13(25-12)16(23)24)14(21)20-11-8(17)4-3-5-9(11)18/h3-5,7,10,12-13H,6H2,1-2H3,(H,19,22)(H,20,21)(H,23,24)/t10-,12+,13+/m0/s1
DMMETW5 CS CC(C)C[C@@H](C(=O)NC1=C(C=CC=C1F)F)NC(=O)[C@H]2[C@@H](O2)C(=O)O
DMMETW5 IK RZWURLBUPSDTKT-CYZMBNFOSA-N
DMMETW5 IU (2R,3R)-3-[[(2S)-1-(2,6-difluoroanilino)-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMCF6M8 ID DMCF6M8
DMCF6M8 DN Epoxysuccinate derivative 4
DMCF6M8 HS Patented
DMCF6M8 SN PMID25399719-Compound-21
DMCF6M8 CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMCF6M8 DT Small molecular drug
DMCF6M8 PC 71679021
DMCF6M8 MW 421.4
DMCF6M8 FM C19H20FN3O5S
DMCF6M8 IC InChI=1S/C19H20FN3O5S/c1-9(2)7-12(21-17(25)14-15(28-14)18(26)27)16(24)23-19-22-13(8-29-19)10-3-5-11(20)6-4-10/h3-6,8-9,12,14-15H,7H2,1-2H3,(H,21,25)(H,26,27)(H,22,23,24)/t12-,14-,15-/m0/s1
DMCF6M8 CS CC(C)C[C@@H](C(=O)NC1=NC(=CS1)C2=CC=C(C=C2)F)NC(=O)[C@@H]3[C@H](O3)C(=O)O
DMCF6M8 IK WVMZJHSGEWZNEO-QEJZJMRPSA-N
DMCF6M8 IU (2S,3S)-3-[[(2S)-1-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DM37MCN ID DM37MCN
DM37MCN DN Epoxysuccinate derivative 5
DM37MCN HS Patented
DM37MCN SN PMID25399719-Compound-22
DM37MCN CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM37MCN DT Small molecular drug
DMQM6ZS ID DMQM6ZS
DMQM6ZS DN Epoxysuccinate derivative 6
DMQM6ZS HS Patented
DMQM6ZS SN PMID25399719-Compound-23
DMQM6ZS CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMQM6ZS DT Small molecular drug
DMQM6ZS PC 71817936
DMQM6ZS MW 361.4
DMQM6ZS FM C16H15N3O5S
DMQM6ZS IC InChI=1S/C16H15N3O5S/c20-14(18-9-4-2-1-3-5-9)11(6-10-7-25-8-17-10)19-15(21)12-13(24-12)16(22)23/h1-5,7-8,11-13H,6H2,(H,18,20)(H,19,21)(H,22,23)/t11-,12-,13-/m0/s1
DMQM6ZS CS C1=CC=C(C=C1)NC(=O)[C@H](CC2=CSC=N2)NC(=O)[C@@H]3[C@H](O3)C(=O)O
DMQM6ZS IK SLAUAVANSQIASN-AVGNSLFASA-N
DMQM6ZS IU (2S,3S)-3-[[(2S)-1-anilino-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMTSPVF ID DMTSPVF
DMTSPVF DN Epoxysuccinate derivative 7
DMTSPVF HS Patented
DMTSPVF SN PMID25399719-Compound-24
DMTSPVF CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMTSPVF DT Small molecular drug
DMTSPVF PC 89737599
DMTSPVF MW 462.5
DMTSPVF FM C19H15FN4O5S2
DMTSPVF IC InChI=1S/C19H15FN4O5S2/c20-10-3-1-9(2-4-10)13-7-31-19(23-13)24-16(25)12(5-11-6-30-8-21-11)22-17(26)14-15(29-14)18(27)28/h1-4,6-8,12,14-15H,5H2,(H,22,26)(H,27,28)(H,23,24,25)/t12-,14+,15+/m0/s1
DMTSPVF CS C1=CC(=CC=C1C2=CSC(=N2)NC(=O)[C@H](CC3=CSC=N3)NC(=O)[C@H]4[C@@H](O4)C(=O)O)F
DMTSPVF IK WRGOUJJZKXTKBL-NWANDNLSSA-N
DMTSPVF IU (2R,3R)-3-[[(2S)-1-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMQTVPC ID DMQTVPC
DMQTVPC DN Epoxysuccinate derivative 8
DMQTVPC HS Patented
DMQTVPC SN PMID25399719-Compound-25
DMQTVPC CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMQTVPC DT Small molecular drug
DM49FU0 ID DM49FU0
DM49FU0 DN Epoxysuccinate derivative 9
DM49FU0 HS Patented
DM49FU0 SN PMID25399719-Compound-26
DM49FU0 CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM49FU0 DT Small molecular drug
DM49FU0 PC 73356676
DM49FU0 MW 445.4
DM49FU0 FM C19H16FN5O5S
DM49FU0 IC InChI=1S/C19H16FN5O5S/c20-10-3-1-9(2-4-10)13-7-31-19(24-13)25-16(26)12(5-11-6-21-8-22-11)23-17(27)14-15(30-14)18(28)29/h1-4,6-8,12,14-15H,5H2,(H,21,22)(H,23,27)(H,28,29)(H,24,25,26)/t12-,14+,15+/m0/s1
DM49FU0 CS C1=CC(=CC=C1C2=CSC(=N2)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H]4[C@@H](O4)C(=O)O)F
DM49FU0 IK LWEKDSQGUMPMSP-NWANDNLSSA-N
DM49FU0 IU (2R,3R)-3-[[(2S)-1-[[4-(4-fluorophenyl)-1,3-thiazol-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DM7XYRA ID DM7XYRA
DM7XYRA DN Eptastatin derivative 1
DM7XYRA HS Patented
DM7XYRA SN PMID27537201-Compound-Figure14right
DM7XYRA DT Small molecular drug
DMLOBAQ ID DMLOBAQ
DMLOBAQ DN Ethinyl-pyrazole derivative 1
DMLOBAQ HS Patented
DMLOBAQ SN PMID25435285-Compound-68
DMLOBAQ CP TAISHO PHARMACEUTICAL CO., LTD. NAKAMURA Toshio SAKAGAMI Kazunari KONISHI Kazuhide YAMAMOTO Kanako MASUDA Seiji
DMLOBAQ DT Small molecular drug
DMA3PE7 ID DMA3PE7
DMA3PE7 DN Ethinyl-pyrazole derivative 2
DMA3PE7 HS Patented
DMA3PE7 SN PMID25435285-Compound-72
DMA3PE7 CP TAISHO PHARMACEUTICAL CO., LTD. NAKAMURA Toshio SAKAGAMI Kazunari KONISHI Kazuhide YAMAMOTO Kanako MASUDA Seiji
DMA3PE7 DT Small molecular drug
DMA3PE7 PC 56642741
DMA3PE7 MW 435.4
DMA3PE7 FM C20H16F3N3O3S
DMA3PE7 IC InChI=1S/C20H16F3N3O3S/c1-26-19(13-29-17-9-7-16(8-10-17)20(21,22)23)15(12-25-26)6-5-14-3-2-4-18(11-14)30(24,27)28/h2-4,7-12H,13H2,1H3,(H2,24,27,28)
DMA3PE7 CS CN1C(=C(C=N1)C#CC2=CC(=CC=C2)S(=O)(=O)N)COC3=CC=C(C=C3)C(F)(F)F
DMA3PE7 IK RTQHVIORPPJRPP-UHFFFAOYSA-N
DMA3PE7 IU 3-[2-[1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazol-4-yl]ethynyl]benzenesulfonamide
DM87DOX ID DM87DOX
DM87DOX DN Ethinyl-pyrazole derivative 3
DM87DOX HS Patented
DM87DOX SN PMID25435285-Compound-73
DM87DOX CP TAISHO PHARMACEUTICAL CO., LTD. NAKAMURA Toshio SAKAGAMI Kazunari KONISHI Kazuhide YAMAMOTO Kanako MASUDA Seiji
DM87DOX DT Small molecular drug
DM87DOX PC 56642739
DM87DOX MW 412.9
DM87DOX FM C20H17ClN4O2S
DM87DOX IC InChI=1S/C20H17ClN4O2S/c1-24-20(25-12-16-6-7-18(21)10-17(16)13-25)15(11-23-24)5-2-14-3-8-19(9-4-14)28(22,26)27/h3-4,6-11H,12-13H2,1H3,(H2,22,26,27)
DM87DOX CS CN1C(=C(C=N1)C#CC2=CC=C(C=C2)S(=O)(=O)N)N3CC4=C(C3)C=C(C=C4)Cl
DM87DOX IK CAOKQZMINRCCBM-UHFFFAOYSA-N
DM87DOX IU 4-[2-[5-(5-chloro-1,3-dihydroisoindol-2-yl)-1-methylpyrazol-4-yl]ethynyl]benzenesulfonamide
DMTBG39 ID DMTBG39
DMTBG39 DN Ethylaminopyrimidine derivative 1
DMTBG39 HS Patented
DMTBG39 SN PMID26413912-Compound-73
DMTBG39 CP JANSSEN PHARMACEUTICA N.V. APODACA, Richard BREITENBUCHER, J., Guy CHAMBERS, Alison, L. DENG, Xiaohu HAWRYLUK, Natalie, A. KEITH, John, M. MANI, Neelakandha, S. MERIT, Jeffrey, E. PIERCE, Joan, M. SEIERSTAD, Mark XIAO, Wei
DMTBG39 DT Small molecular drug
DMTBG39 PC 44203832
DMTBG39 MW 369.8
DMTBG39 FM C20H20ClN3O2
DMTBG39 IC InChI=1S/C20H20ClN3O2/c1-2-26-19-9-8-15(10-16(19)21)17-11-20(24-13-23-17)22-12-18(25)14-6-4-3-5-7-14/h3-11,13,18,25H,2,12H2,1H3,(H,22,23,24)/t18-/m0/s1
DMTBG39 CS CCOC1=C(C=C(C=C1)C2=CC(=NC=N2)NC[C@@H](C3=CC=CC=C3)O)Cl
DMTBG39 IK MOEQPDYTFQLEOK-SFHVURJKSA-N
DMTBG39 IU (1R)-2-[[6-(3-chloro-4-ethoxyphenyl)pyrimidin-4-yl]amino]-1-phenylethanol
DM9WMJ1 ID DM9WMJ1
DM9WMJ1 DN Ethylvanillin
DM9WMJ1 HS Patented
DM9WMJ1 CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM9WMJ1 PC 8467
DM9WMJ1 MW 166.17
DM9WMJ1 FM C9H10O3
DM9WMJ1 IC InChI=1S/C9H10O3/c1-2-12-9-5-7(6-10)3-4-8(9)11/h3-6,11H,2H2,1H3
DM9WMJ1 CS CCOC1=C(C=CC(=C1)C=O)O
DM9WMJ1 IK CBOQJANXLMLOSS-UHFFFAOYSA-N
DM9WMJ1 IU 3-ethoxy-4-hydroxybenzaldehyde
DM9WMJ1 CA CAS 121-32-4
DM9WMJ1 CB CHEBI:48408
DMWXKRZ ID DMWXKRZ
DMWXKRZ DN Ethynyl compound 1
DMWXKRZ HS Patented
DMWXKRZ SN PMID28067079-Compound-13
DMWXKRZ CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMWXKRZ DT Small molecular drug
DMWXKRZ PC 73775704
DMWXKRZ MW 355.8
DMWXKRZ FM C19H18ClN3O2
DMWXKRZ IC InChI=1S/C19H18ClN3O2/c1-19(2)13-25-9-8-23(19)18(24)17-21-11-15(12-22-17)7-6-14-4-3-5-16(20)10-14/h3-5,10-12H,8-9,13H2,1-2H3
DMWXKRZ CS CC1(COCCN1C(=O)C2=NC=C(C=N2)C#CC3=CC(=CC=C3)Cl)C
DMWXKRZ IK UOYREAVBKXAAFN-UHFFFAOYSA-N
DMWXKRZ IU [5-[2-(3-chlorophenyl)ethynyl]pyrimidin-2-yl]-(3,3-dimethylmorpholin-4-yl)methanone
DMJDG37 ID DMJDG37
DMJDG37 DN Ethynyl compound 2
DMJDG37 HS Patented
DMJDG37 SN PMID28067079-Compound-19
DMJDG37 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMJDG37 DT Small molecular drug
DMD9PZQ ID DMD9PZQ
DMD9PZQ DN Ethynyl compound 3
DMD9PZQ HS Patented
DMD9PZQ SN PMID28067079-Compound-3
DMD9PZQ CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMD9PZQ DT Small molecular drug
DMLDMO8 ID DMLDMO8
DMLDMO8 DN Ethynyl compound 4
DMLDMO8 HS Patented
DMLDMO8 SN PMID28067079-Compound-4
DMLDMO8 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMLDMO8 DT Small molecular drug
DM53ZPE ID DM53ZPE
DM53ZPE DN Ethynyl compound 5
DM53ZPE HS Patented
DM53ZPE SN PMID28067079-Compound-5
DM53ZPE CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM53ZPE DT Small molecular drug
DMDOEFC ID DMDOEFC
DMDOEFC DN Ethynyl compound 6
DMDOEFC HS Patented
DMDOEFC SN PMID28067079-Compound-6
DMDOEFC CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMDOEFC DT Small molecular drug
DMPUG2M ID DMPUG2M
DMPUG2M DN Ethynyl compound 7
DMPUG2M HS Patented
DMPUG2M SN PMID28067079-Compound-9
DMPUG2M CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMPUG2M DT Small molecular drug
DM7US1H ID DM7US1H
DM7US1H DN Eugenol
DM7US1H HS Patented
DM7US1H SN eugenol; 97-53-0; 4-Allyl-2-methoxyphenol; 4-Allylguaiacol; Eugenic acid; Allylguaiacol; Caryophyllic acid; p-Allylguaiacol; p-Eugenol; 2-Methoxy-4-prop-2-enylphenol; Engenol; 2-Methoxy-4-allylphenol; Phenol, 2-methoxy-4-(2-propenyl)-; 1,3,4-Eugenol; 4-Allylcatechol-2-methyl ether; Synthetic eugenol; 2-Methoxy-4-(2-propenyl)phenol; 2-Methoxy-1-hydroxy-4-allylbenzene; 4-Allyl-1-hydroxy-2-methoxybenzene; 1-Hydroxy-2-methoxy-4-allylbenzene; 5-Allylguaiacol; 1-Hydroxy-2-methoxy-4-prop-2-enylbenzene
DM7US1H DT Small molecular drug
DM7US1H PC 3314
DM7US1H MW 164.2
DM7US1H FM C10H12O2
DM7US1H IC InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3
DM7US1H CS COC1=C(C=CC(=C1)CC=C)O
DM7US1H IK RRAFCDWBNXTKKO-UHFFFAOYSA-N
DM7US1H IU 2-methoxy-4-prop-2-enylphenol
DM7US1H CA CAS 97-53-0
DM7US1H CB CHEBI:4917
DM7US1H DE Discovery agent
DMJC7NF ID DMJC7NF
DMJC7NF DN Ferulic Acid
DMJC7NF HS Patented
DMJC7NF SN ferulic acid; trans-Ferulic Acid; 1135-24-6; 4-Hydroxy-3-methoxycinnamic acid; 537-98-4; trans-4-Hydroxy-3-methoxycinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; (E)-Ferulic acid; ferulate; Coniferic acid; Ferulic acid, trans-; (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; Cinnamic acid, 4-hydroxy-3-methoxy-; 3-methoxy-4-hydroxycinnamic acid; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; UNII-AVM951ZWST; Cinnamic acid, 4-hydroxy-3-methoxy-, (E)-
DMJC7NF DT Small molecular drug
DMJC7NF PC 445858
DMJC7NF MW 194.18
DMJC7NF FM C10H10O4
DMJC7NF IC InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
DMJC7NF CS COC1=C(C=CC(=C1)/C=C/C(=O)O)O
DMJC7NF IK KSEBMYQBYZTDHS-HWKANZROSA-N
DMJC7NF IU (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid
DMJC7NF CA CAS 537-98-4
DMJC7NF CB CHEBI:17620
DMJC7NF DE Discovery agent
DMPFAST ID DMPFAST
DMPFAST DN Five membered heterocyclic benzamide derivative 1
DMPFAST HS Patented
DMPFAST SN PMID28270021-Compound-WO2015148350Example36
DMPFAST CP MERCK SHARP & DOHME CORP
DMPFAST DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM4U63E ID DM4U63E
DM4U63E DN Five membered heterocyclic benzamide derivative 2
DM4U63E HS Patented
DM4U63E SN PMID28270021-Compound-WO2015148350Example76
DM4U63E CP MERCK SHARP & DOHME CORP
DM4U63E DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMUS4Z0 ID DMUS4Z0
DMUS4Z0 DN Five membered heterocyclic benzamide derivative 3
DMUS4Z0 HS Patented
DMUS4Z0 SN PMID28270021-Compound-WO2015148350Example81
DMUS4Z0 CP MERCK SHARP & DOHME CORP
DMUS4Z0 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM7SK5Q ID DM7SK5Q
DM7SK5Q DN Five-and-six-membered heterocyclic compound 1
DM7SK5Q HS Patented
DM7SK5Q SN PMID27774822-Compound-Figure8compoundT-38
DM7SK5Q CP SHANGHAI YUNYI HEALTHCARE MANAGEMENT CO., LTD CHINA GATEWAY TECHNOLOGY DEVELOPMENT
DM7SK5Q DT Small molecular drug
DMO8UKD ID DMO8UKD
DMO8UKD DN Five-membered heteroaromatic compound 1
DMO8UKD HS Patented
DMO8UKD SN PMID29473428-Compound-44
DMO8UKD DT Small molecular drug
DMO8UKD PC 130361031
DMO8UKD MW 288.4
DMO8UKD FM C16H20N2OS
DMO8UKD IC InChI=1S/C16H20N2OS/c19-15(11-4-2-1-3-5-11)8-13-16-12(6-7-20-16)14-9-17-10-18(13)14/h6-7,9-11,13,15,19H,1-5,8H2
DMO8UKD CS C1CCC(CC1)C(CC2C3=C(C=CS3)C4=CN=CN24)O
DMO8UKD IK ZPMZNNITKQQNAG-UHFFFAOYSA-N
DMO8UKD IU 1-cyclohexyl-2-(9-thia-4,6-diazatricyclo[6.3.0.02,6]undeca-1(8),2,4,10-tetraen-7-yl)ethanol
DM1QH8Z ID DM1QH8Z
DM1QH8Z DN Five-membered heteroaromatic compound 2
DM1QH8Z HS Patented
DM1QH8Z SN PMID29473428-Compound-45
DM1QH8Z DT Small molecular drug
DMS0P9E ID DMS0P9E
DMS0P9E DN Five-membered heteroaromatic compound 3
DMS0P9E HS Patented
DMS0P9E SN PMID29473428-Compound-46
DMS0P9E DT Small molecular drug
DMS0P9E PC 130360247
DMS0P9E MW 290.4
DMS0P9E FM C16H19FN2S
DMS0P9E IC InChI=1S/C16H19FN2S/c17-16(6-2-1-3-7-16)8-4-13-15-12(5-9-20-15)14-10-18-11-19(13)14/h5,9-11,13H,1-4,6-8H2
DMS0P9E CS C1CCC(CC1)(CCC2C3=C(C=CS3)C4=CN=CN24)F
DMS0P9E IK AQNGWMVFAXPUTC-UHFFFAOYSA-N
DMS0P9E IU 7-[2-(1-fluorocyclohexyl)ethyl]-9-thia-4,6-diazatricyclo[6.3.0.02,6]undeca-1(8),2,4,10-tetraene
DMCQP0B ID DMCQP0B
DMCQP0B DN Flavonoid derivative 1
DMCQP0B HS Patented
DMCQP0B SN PMID26394986-Compound-45
DMCQP0B CP UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMCQP0B DT Small molecular drug
DMCQP0B PC 5280445
DMCQP0B MW 286.24
DMCQP0B FM C15H10O6
DMCQP0B IC InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H
DMCQP0B CS C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMCQP0B IK IQPNAANSBPBGFQ-UHFFFAOYSA-N
DMCQP0B IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMCQP0B CA CAS 491-70-3
DMCQP0B CB CHEBI:15864
DMWZARV ID DMWZARV
DMWZARV DN Flavonoid derivative 2
DMWZARV HS Patented
DMWZARV SN PMID26394986-Compound-46
DMWZARV CP UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMWZARV DT Small molecular drug
DMT7ZEL ID DMT7ZEL
DMT7ZEL DN Flavonoid derivative 3
DMT7ZEL HS Patented
DMT7ZEL SN PMID26394986-Compound-47
DMT7ZEL CP UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMT7ZEL DT Small molecular drug
DMT7ZEL PC 5281612
DMT7ZEL MW 300.26
DMT7ZEL FM C16H12O6
DMT7ZEL IC InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3
DMT7ZEL CS COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMT7ZEL IK MBNGWHIJMBWFHU-UHFFFAOYSA-N
DMT7ZEL IU 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
DMT7ZEL CA CAS 520-34-3
DMT7ZEL CB CHEBI:4630
DMMOSVD ID DMMOSVD
DMMOSVD DN Flavonoid derivative 4
DMMOSVD HS Patented
DMMOSVD SN PMID26394986-Compound-48
DMMOSVD CP UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMMOSVD DT Small molecular drug
DMMOSVD PC 5280343
DMMOSVD MW 302.23
DMMOSVD FM C15H10O7
DMMOSVD IC InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
DMMOSVD CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DMMOSVD IK REFJWTPEDVJJIY-UHFFFAOYSA-N
DMMOSVD IU 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DMMOSVD CA CAS 117-39-5
DMMOSVD CB CHEBI:16243
DMTWAJX ID DMTWAJX
DMTWAJX DN Flavonoid derivative 5
DMTWAJX HS Patented
DMTWAJX SN PMID26394986-Compound-49
DMTWAJX CP UNIVERSITY OF SOUTH FLORIDA TAN, Jun LUO, Deyan
DMTWAJX DT Small molecular drug
DM0E38G ID DM0E38G
DM0E38G DN Flavonoid derivative 6
DM0E38G HS Patented
DM0E38G SN PMID25468267-Compound-1
DM0E38G CP Kenhavns Universitet CLOOS, Paul AGGER, Karl CHRISTENSEN, Jesper HANSEN, Klaus H. HELIN, Kristian
DM0E38G DT Small molecular drug
DM6A9UR ID DM6A9UR
DM6A9UR DN Flavonoid derivative 7
DM6A9UR HS Patented
DM6A9UR SN PMID26161698-Compound-6
DM6A9UR CP THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY IP, Nancy Yuk-Yu IP, Fanny Chui-Fun FU, Wing Yu FU, Guangmiao
DM6A9UR DT Small molecular drug
DM6A9UR PC 74978523
DM6A9UR MW 448.4
DM6A9UR FM C21H20O11
DM6A9UR IC InChI=1S/C21H20O11/c1-7-13(25)15(27)17(29)21(30-7)32-19-11(24)6-10(23)12-14(26)16(28)18(31-20(12)19)8-2-4-9(22)5-3-8/h2-7,13,15,17,21-25,27-29H,1H3
DM6A9UR CS CC1C(C(C(C(O1)OC2=C(C=C(C3=C2OC(=C(C3=O)O)C4=CC=C(C=C4)O)O)O)O)O)O
DM6A9UR IK PJZKCQPCHMMPJZ-UHFFFAOYSA-N
DM6A9UR IU 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxychromen-4-one
DM4O9T3 ID DM4O9T3
DM4O9T3 DN Flavonoid derivative 8
DM4O9T3 HS Patented
DM4O9T3 SN PMID25416646-Compound-Figure5-B
DM4O9T3 CP Huawei Technologies Co., Ltd
DM4O9T3 DT Small molecular drug
DMXL3A5 ID DMXL3A5
DMXL3A5 DN Flavopiridol analog 1
DMXL3A5 HS Patented
DMXL3A5 SN PMID26161698-Compound-5
DMXL3A5 CP COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
DMXL3A5 DT Small molecular drug
DMXL3A5 PC 86272549
DMXL3A5 MW 462.3
DMXL3A5 FM C23H21Cl2NO5
DMXL3A5 IC InChI=1S/C23H21Cl2NO5/c1-26-8-7-14(20(30)11-26)21-18(28)10-19(29)22-17(27)9-12(31-23(21)22)5-6-13-15(24)3-2-4-16(13)25/h2-6,9-10,14,20,28-30H,7-8,11H2,1H3/b6-5+
DMXL3A5 CS CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)/C=C/C4=C(C=CC=C4Cl)Cl)O)O
DMXL3A5 IK NFTJDXGFOUFNKG-AATRIKPKSA-N
DMXL3A5 IU 2-[(E)-2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)chromen-4-one
DMGOSN2 ID DMGOSN2
DMGOSN2 DN Fluorinated compound 1
DMGOSN2 HS Patented
DMGOSN2 SN PMID26161698-Compound-15
DMGOSN2 CP ANYGEN CO., LTD. KIM, Yong-Chul KIM, Jae-Il BAN, Soo-Ho JEONG, Soon-Young CHOI, Soo-Jeong LEE, Jung-Eun
DMGOSN2 DT Small molecular drug
DMQOGHN ID DMQOGHN
DMQOGHN DN Fluorinated donepezil derivative 1
DMQOGHN HS Patented
DMQOGHN SN PMID27967267-Compound-1
DMQOGHN DT Small molecular drug
DMQOGHN PC 72710841
DMQOGHN MW 415.5
DMQOGHN FM C24H27F2NO3
DMQOGHN IC InChI=1S/C24H27F2NO3/c1-29-20-12-18-14-24(26,22(28)19(18)13-21(20)30-2)16-23(25)8-10-27(11-9-23)15-17-6-4-3-5-7-17/h3-7,12-13H,8-11,14-16H2,1-2H3
DMQOGHN CS COC1=C(C=C2C(=C1)CC(C2=O)(CC3(CCN(CC3)CC4=CC=CC=C4)F)F)OC
DMQOGHN IK FMFDCMLVUWZCIV-UHFFFAOYSA-N
DMQOGHN IU 2-[(1-benzyl-4-fluoropiperidin-4-yl)methyl]-2-fluoro-5,6-dimethoxy-3H-inden-1-one
DMV1SCA ID DMV1SCA
DMV1SCA DN Fluorinated donepezil derivative 2
DMV1SCA HS Patented
DMV1SCA SN PMID27967267-Compound-2
DMV1SCA DT Small molecular drug
DMTS8O9 ID DMTS8O9
DMTS8O9 DN Fluorophenyl-substituted heterocyclic amide analog 1
DMTS8O9 HS Patented
DMTS8O9 SN PMID27724045-Compound-9
DMTS8O9 CP Roche
DMTS8O9 DT Small molecular drug
DMTS8O9 PC 46220501
DMTS8O9 MW 361.4
DMTS8O9 FM C21H16FN3O2
DMTS8O9 IC InChI=1S/C21H16FN3O2/c22-15-8-6-14(7-9-15)20-13-16(26)10-12-25(20)21(27)24-19-5-1-4-18-17(19)3-2-11-23-18/h1-12,20H,13H2,(H,24,27)/t20-/m0/s1
DMTS8O9 CS C1[C@H](N(C=CC1=O)C(=O)NC2=CC=CC3=C2C=CC=N3)C4=CC=C(C=C4)F
DMTS8O9 IK ZREAHQPXWUVTDX-FQEVSTJZSA-N
DMTS8O9 IU (2S)-2-(4-fluorophenyl)-4-oxo-N-quinolin-5-yl-2,3-dihydropyridine-1-carboxamide
DM2QXVW ID DM2QXVW
DM2QXVW DN Furopyridine derivative 1
DM2QXVW HS Patented
DM2QXVW SN PMID26161824-Compound-120
DM2QXVW DT Small molecular drug
DM2QXVW PC 25062281
DM2QXVW MW 565.4
DM2QXVW FM C28H22Cl2N4O5
DM2QXVW IC InChI=1S/C28H22Cl2N4O5/c1-28(2,3)25(37)24-23(32-21(36)12-35)19-11-18(14-4-7-16(29)8-5-14)22(33-27(19)39-24)17-9-6-15(10-20(17)30)26-31-13-38-34-26/h4-11,13,35H,12H2,1-3H3,(H,32,36)
DM2QXVW CS CC(C)(C)C(=O)C1=C(C2=CC(=C(N=C2O1)C3=C(C=C(C=C3)C4=NOC=N4)Cl)C5=CC=C(C=C5)Cl)NC(=O)CO
DM2QXVW IK SPKFHHXBXRKREW-UHFFFAOYSA-N
DM2QXVW IU N-[6-[2-chloro-4-(1,2,4-oxadiazol-3-yl)phenyl]-5-(4-chlorophenyl)-2-(2,2-dimethylpropanoyl)furo[2,3-b]pyridin-3-yl]-2-hydroxyacetamide
DM2QXVW DE Obesity
DMEU3J9 ID DMEU3J9
DMEU3J9 DN Furopyridine derivative 2
DMEU3J9 HS Patented
DMEU3J9 SN PMID26161824-Compound-121
DMEU3J9 DT Small molecular drug
DMEU3J9 DE Obesity
DM4EUFL ID DM4EUFL
DM4EUFL DN Fused aromatic compound 1
DM4EUFL HS Patented
DM4EUFL SN PMID25416646-Compound-Figure2-F
DM4EUFL CP MERCK & CO., INC. MEINKE, Peter, T. DENKER, Andrew MEININGER, Gary, E. UEMURA, Naoto WAGNER, John, A. CHARNICK, Steven
DM4EUFL DT Small molecular drug
DMFAM8B ID DMFAM8B
DMFAM8B DN Fused aryl carbocycle derivative 1
DMFAM8B HS Patented
DMFAM8B SN PMID30185082-Compound-44
DMFAM8B CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMFAM8B DT Small molecular drug
DMAQBJP ID DMAQBJP
DMAQBJP DN Fused aryl carbocycle derivative 2
DMAQBJP HS Patented
DMAQBJP SN PMID30185082-Compound-45
DMAQBJP CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMAQBJP DT Small molecular drug
DM5I4CA ID DM5I4CA
DM5I4CA DN Fused aryl carbocycle derivative 3
DM5I4CA HS Patented
DM5I4CA SN PMID30185082-Compound-46
DM5I4CA CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DM5I4CA DT Small molecular drug
DMOU8T3 ID DMOU8T3
DMOU8T3 DN Fused aryl carbocycle derivative 4
DMOU8T3 HS Patented
DMOU8T3 SN PMID30185082-Compound-47
DMOU8T3 CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMOU8T3 DT Small molecular drug
DMPBMEU ID DMPBMEU
DMPBMEU DN Fused aryl carbocycle derivative 8
DMPBMEU HS Patented
DMPBMEU SN PMID30185082-Compound-51
DMPBMEU CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMPBMEU DT Small molecular drug
DMQ2X6O ID DMQ2X6O
DMQ2X6O DN Fused aryl carbocycle derivative 9
DMQ2X6O HS Patented
DMQ2X6O SN PMID30185082-Compound-52
DMQ2X6O CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMQ2X6O DT Small molecular drug
DMQ2X6O PC 132060412
DMQ2X6O MW 421.6
DMQ2X6O FM C26H35N3O2
DMQ2X6O IC InChI=1S/C26H35N3O2/c1-3-15-28-16-18-29(19-17-28)25-14-8-11-22-23(25)12-7-13-24(22)27(2)26(30)31-20-21-9-5-4-6-10-21/h4-6,8-11,14,24H,3,7,12-13,15-20H2,1-2H3
DMQ2X6O CS CCCN1CCN(CC1)C2=CC=CC3=C2CCCC3N(C)C(=O)OCC4=CC=CC=C4
DMQ2X6O IK YZQOEMNLUIMOMX-UHFFFAOYSA-N
DMQ2X6O IU benzyl N-methyl-N-[5-(4-propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamate
DMKLO2H ID DMKLO2H
DMKLO2H DN Fused benzoheterocycle amide derivative 1
DMKLO2H HS Patented
DMKLO2H SN PMID27310003-Compound-4
DMKLO2H CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED ANIMA, Boruah HOSAHALLI, Subramanya SUBHENDU, Mukherjee
DMKLO2H DT Small molecular drug
DM9NMHS ID DM9NMHS
DM9NMHS DN Fused benzoheterocycle amide derivative 2
DM9NMHS HS Patented
DM9NMHS SN PMID27310003-Compound-5
DM9NMHS CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED ANIMA, Boruah HOSAHALLI, Subramanya SUBHENDU, Mukherjee
DM9NMHS DT Small molecular drug
DMVU9RG ID DMVU9RG
DMVU9RG DN Fused heterocyclic compound 1
DMVU9RG HS Patented
DMVU9RG SN PMID27841045-Compound-123
DMVU9RG CP Kissei Pharmaceutical Co. Ltd
DMVU9RG DT Small molecular drug
DMVU9RG PC 58400451
DMVU9RG MW 317.32
DMVU9RG FM C14H11N3O4S
DMVU9RG IC InChI=1S/C14H11N3O4S/c1-7-12(14(18)19)22-13(15-7)9-5-8-3-4-16(2)11(8)10(6-9)17(20)21/h3-6H,1-2H3,(H,18,19)
DMVU9RG CS CC1=C(SC(=N1)C2=CC(=C3C(=C2)C=CN3C)[N+](=O)[O-])C(=O)O
DMVU9RG IK YGQCHVOXQFVYAB-UHFFFAOYSA-N
DMVU9RG IU 4-methyl-2-(1-methyl-7-nitroindol-5-yl)-1,3-thiazole-5-carboxylic acid
DMALDZ6 ID DMALDZ6
DMALDZ6 DN Fused heterocyclic compound 10
DMALDZ6 HS Patented
DMALDZ6 SN PMID27841045-Compound-153
DMALDZ6 CP Kissei Pharmaceutical Co. Ltd
DMALDZ6 DT Small molecular drug
DMJC4UZ ID DMJC4UZ
DMJC4UZ DN Fused heterocyclic compound 11
DMJC4UZ HS Patented
DMJC4UZ SN PMID27841045-Compound-154
DMJC4UZ CP Kissei Pharmaceutical Co. Ltd
DMJC4UZ DT Small molecular drug
DMSYD6Z ID DMSYD6Z
DMSYD6Z DN Fused heterocyclic compound 12
DMSYD6Z HS Patented
DMSYD6Z SN PMID27414413-Compound-Figure8left
DMSYD6Z DT Small molecular drug
DM361J8 ID DM361J8
DM361J8 DN Fused heterocyclic compound 2
DM361J8 HS Patented
DM361J8 SN PMID27841045-Compound-124
DM361J8 CP Kissei Pharmaceutical Co. Ltd
DM361J8 DT Small molecular drug
DM2QVHY ID DM2QVHY
DM2QVHY DN Fused heterocyclic compound 3
DM2QVHY HS Patented
DM2QVHY SN PMID27841045-Compound-125
DM2QVHY CP Kissei Pharmaceutical Co. Ltd
DM2QVHY DT Small molecular drug
DMHTS5G ID DMHTS5G
DMHTS5G DN Fused heterocyclic compound 4
DMHTS5G HS Patented
DMHTS5G SN PMID27841045-Compound-126
DMHTS5G CP Kissei Pharmaceutical Co. Ltd
DMHTS5G DT Small molecular drug
DMHTS5G PC 46199345
DMHTS5G MW 283.31
DMHTS5G FM C14H9N3O2S
DMHTS5G IC InChI=1S/C14H9N3O2S/c1-7-12(14(18)19)20-13(17-7)9-4-8-2-3-16-11(8)10(5-9)6-15/h2-5,16H,1H3,(H,18,19)
DMHTS5G CS CC1=C(SC(=N1)C2=CC(=C3C(=C2)C=CN3)C#N)C(=O)O
DMHTS5G IK QJWAUWFGCGISKV-UHFFFAOYSA-N
DMHTS5G IU 2-(7-cyano-1H-indol-5-yl)-4-methyl-1,3-thiazole-5-carboxylic acid
DM10CGB ID DM10CGB
DM10CGB DN Fused heterocyclic compound 5
DM10CGB HS Patented
DM10CGB SN PMID27841045-Compound-127
DM10CGB CP Kissei Pharmaceutical Co. Ltd
DM10CGB DT Small molecular drug
DM10CGB PC 46199187
DM10CGB MW 297.3
DM10CGB FM C15H11N3O2S
DM10CGB IC InChI=1S/C15H11N3O2S/c1-8-13(15(19)20)21-14(17-8)10-5-9-3-4-18(2)12(9)11(6-10)7-16/h3-6H,1-2H3,(H,19,20)
DM10CGB CS CC1=C(SC(=N1)C2=CC(=C3C(=C2)C=CN3C)C#N)C(=O)O
DM10CGB IK UKMCFVVQXUWRFF-UHFFFAOYSA-N
DM10CGB IU 2-(7-cyano-1-methylindol-5-yl)-4-methyl-1,3-thiazole-5-carboxylic acid
DM9DC3U ID DM9DC3U
DM9DC3U DN Fused heterocyclic compound 6
DM9DC3U HS Patented
DM9DC3U SN PMID27841045-Compound-128
DM9DC3U CP Kissei Pharmaceutical Co. Ltd
DM9DC3U DT Small molecular drug
DMGNWJD ID DMGNWJD
DMGNWJD DN Fused heterocyclic compound 7
DMGNWJD HS Patented
DMGNWJD SN PMID27841045-Compound-150
DMGNWJD CP Kissei Pharmaceutical Co. Ltd
DMGNWJD DT Small molecular drug
DMO8JE7 ID DMO8JE7
DMO8JE7 DN Fused heterocyclic compound 8
DMO8JE7 HS Patented
DMO8JE7 SN PMID27841045-Compound-151
DMO8JE7 CP Kissei Pharmaceutical Co. Ltd
DMO8JE7 DT Small molecular drug
DM25IMA ID DM25IMA
DM25IMA DN Fused heterocyclic compound 9
DM25IMA HS Patented
DM25IMA SN PMID27841045-Compound-152
DM25IMA CP Kissei Pharmaceutical Co. Ltd
DM25IMA DT Small molecular drug
DMPHL3J ID DMPHL3J
DMPHL3J DN Fused ring compound 1
DMPHL3J HS Patented
DMPHL3J SN PMID25416646-Compound-Figure2-G
DMPHL3J CP TAKEDA PHARMACEUTICAL COMPANY LIMITED TAWARAISHI, Taisuke IMOTO, Hiroshi CHO, Nobuo
DMPHL3J DT Small molecular drug
DMV7IX4 ID DMV7IX4
DMV7IX4 DN Fused thiophene derivative 1
DMV7IX4 HS Patented
DMV7IX4 SN PMID28117607-Compound-17
DMV7IX4 CP MERCK SHARP & DOHME CORP
DMV7IX4 DT Small molecular drug
DM4Z72S ID DM4Z72S
DM4Z72S DN Fused triazoloamino-phenyl analog 1
DM4Z72S HS Patented
DM4Z72S SN PMID27724045-Compound-10
DM4Z72S CP Roche
DM4Z72S DT Small molecular drug
DM5BVCS ID DM5BVCS
DM5BVCS DN Galantamine analog 1
DM5BVCS HS Patented
DM5BVCS SN PMID27967267-Compound-5
DM5BVCS CP Univ East China Science & Tech
DM5BVCS DT Small molecular drug
DMK6RFS ID DMK6RFS
DMK6RFS DN Geminally-substituted cyanoethylpypazolo pyridone derivative 1
DMK6RFS HS Patented
DMK6RFS SN PMID27774822-Compound-Figure2Example17-32
DMK6RFS CP MERCK SHARP & DOHME CORP. CHILDERS, Matthew L. FULLER, Peter H. GUERIN, David J. KATZ, Jason David MARTINEZ, Michelle PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. CAI, Jiaqiang KONG, Norman LIU, Yumei
DMK6RFS DT Small molecular drug
DMB2INX ID DMB2INX
DMB2INX DN Geminally-substituted cyanoethylpypazolo pyridone derivative 2
DMB2INX HS Patented
DMB2INX SN PMID27774822-Compound-Figure2Example5-84
DMB2INX CP MERCK SHARP & DOHME CORP. CHILDERS, Matthew L. FULLER, Peter H. GUERIN, David J. KATZ, Jason David MARTINEZ, Michelle PU, Qinglin SCOTT, Mark E. THOMPSON, Christopher F. CAI, Jiaqiang KONG, Norman LIU, Yumei
DMB2INX DT Small molecular drug
DMT1EH9 ID DMT1EH9
DMT1EH9 DN Gold-complexed thiosaccharide derivative 1
DMT1EH9 HS Patented
DMT1EH9 SN PMID26394986-Compound-66
DMT1EH9 CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM PRIEBE, Waldemar KATO, Takayuki FOKT, Izabela CONRAD, Charles MADDEN, Timothy SKORA, Stanislaw
DMT1EH9 DT Small molecular drug
DM9U4OZ ID DM9U4OZ
DM9U4OZ DN Gold-complexed thiosaccharide derivative 2
DM9U4OZ HS Patented
DM9U4OZ SN PMID26394986-Compound-67
DM9U4OZ CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM PRIEBE, Waldemar KATO, Takayuki FOKT, Izabela CONRAD, Charles MADDEN, Timothy SKORA, Stanislaw
DM9U4OZ DT Small molecular drug
DM9U4OZ PC 56946870
DM9U4OZ MW 678.5
DM9U4OZ FM C20H34AuO9PS
DM9U4OZ IC InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13+,14+;;/m1../s1
DM9U4OZ CS CCP(CC)CC.CC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
DM9U4OZ IK AUJRCFUBUPVWSZ-QAZNCASESA-M
DM9U4OZ IU gold(1+);(2S,3S,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
DMMOGL8 ID DMMOGL8
DMMOGL8 DN Gold-complexed thiosaccharide derivative 3
DMMOGL8 HS Patented
DMMOGL8 SN PMID26394986-Compound-68
DMMOGL8 CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM PRIEBE, Waldemar KATO, Takayuki FOKT, Izabela CONRAD, Charles MADDEN, Timothy SKORA, Stanislaw
DMMOGL8 DT Small molecular drug
DMVAKUI ID DMVAKUI
DMVAKUI DN Golden phosphorous acetyletic compound 1
DMVAKUI HS Patented
DMVAKUI SN PMID27977313-Compound-11
DMVAKUI DT Small molecular drug
DMYJ15A ID DMYJ15A
DMYJ15A DN Golden phosphorous acetyletic compound 2
DMYJ15A HS Patented
DMYJ15A SN PMID27977313-Compound-12
DMYJ15A DT Small molecular drug
DMRUCK8 ID DMRUCK8
DMRUCK8 DN Golden phosphorous acetyletic compound 3
DMRUCK8 HS Patented
DMRUCK8 SN PMID27977313-Compound-Figure4d
DMRUCK8 DT Small molecular drug
DMFHC0O ID DMFHC0O
DMFHC0O DN GypensapogeninA
DMFHC0O HS Patented
DMX4ET5 ID DMX4ET5
DMX4ET5 DN GypensapogeninB
DMX4ET5 HS Patented
DMM78UR ID DMM78UR
DMM78UR DN H3K7T
DMM78UR HS Patented
DMM78UR CP CORNELL UNIVERSITY LIN, Hening CERIONE, Richard
DMPA5WD ID DMPA5WD
DMPA5WD DN Harmine
DMPA5WD HS Patented
DMPA5WD SN Harmine; 442-51-3; 7-Methoxy-1-methyl-9H-pyrido[3,4-b]indole; Banisterine; Leucoharmine; Telepathine; Yageine; Yajeine; 7-Methoxy-1-methyl-9H-beta-carboline; 9H-Pyrido[3,4-b]indole, 7-methoxy-1-methyl-; Telepathin; Banisterin; Yagein; Harmin; 1-Methyl-7-methoxy-beta-carboline; UNII-4FHH5G48T7; 7-Methoxy-1-methyl-9H-pyrido(3,4-b)indole; Harmin hydrochloride; Harmine, 98%; Banisterine monohydrate; EINECS 207-131-4; 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl-; BRN 0178813; 4FHH5G48T7; C13H12N2O; CHEBI:28121; 7-METHOXY-1-METHYL-9H-BETA-CARBOLINE
DMPA5WD DT Small molecular drug
DMPA5WD PC 5280953
DMPA5WD MW 212.25
DMPA5WD FM C13H12N2O
DMPA5WD IC InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3
DMPA5WD CS CC1=NC=CC2=C1NC3=C2C=CC(=C3)OC
DMPA5WD IK BXNJHAXVSOCGBA-UHFFFAOYSA-N
DMPA5WD IU 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole
DMPA5WD CA CAS 442-51-3
DMPA5WD CB CHEBI:28121
DMPA5WD DE Discovery agent
DMI732U ID DMI732U
DMI732U DN Heteroaromatic ring derivative 1
DMI732U HS Patented
DMI732U SN PMID28447479-Compound-16
DMI732U CP FURMINGER, Vikki HUGHES, Owen LEGRAND, Darren STANLEY, Emily THOMSON, Christopher WILLIAMS, Gareth NOVARTIS ANOVARTIS AG FURMINGER, Vikki HUGHES, Owen THOMSON, Christopher LEGRAND, Darren, Mark STANLEY, Emil
DMI732U DT Small molecular drug
DM5YD4W ID DM5YD4W
DM5YD4W DN Heteroaromatic ring derivative 2
DM5YD4W HS Patented
DM5YD4W SN PMID28447479-Compound-17
DM5YD4W CP FURMINGER, Vikki HUGHES, Owen LEGRAND, Darren STANLEY, Emily THOMSON, Christopher WILLIAMS, Gareth NOVARTIS ANOVARTIS AG FURMINGER, Vikki HUGHES, Owen THOMSON, Christopher LEGRAND, Darren, Mark STANLEY, Emil
DM5YD4W DT Small molecular drug
DM5YD4W PC 75203906
DM5YD4W MW 440.3
DM5YD4W FM C19H23Cl2N5O3
DM5YD4W IC InChI=1S/C19H23Cl2N5O3/c20-14-8-13(9-15(21)10-14)12-29-19(28)26-6-4-16(5-7-26)23-18(27)3-1-2-17-11-22-25-24-17/h8-11,16H,1-7,12H2,(H,23,27)(H,22,24,25)
DM5YD4W CS C1CN(CCC1NC(=O)CCCC2=NNN=C2)C(=O)OCC3=CC(=CC(=C3)Cl)Cl
DM5YD4W IK GAMSNABJTRSYDT-UHFFFAOYSA-N
DM5YD4W IU (3,5-dichlorophenyl)methyl 4-[4-(2H-triazol-4-yl)butanoylamino]piperidine-1-carboxylate
DMKJL5T ID DMKJL5T
DMKJL5T DN Heteroaromatic ring derivative 3
DMKJL5T HS Patented
DMKJL5T SN PMID28447479-Compound-18
DMKJL5T CP NOVARTIS AG BEATTIE, David BAETTIG, Urs LEGRAND, Darren Mark LISTER, Andrew Stuart MCKENNA, Jeffrey PEARCE, David William SANDHAM, David Andrew STEWARD, Oliver Ross THOMSON, Christopher
DMKJL5T DT Small molecular drug
DM9IL5Q ID DM9IL5Q
DM9IL5Q DN Heteroaromatic ring derivative 4
DM9IL5Q HS Patented
DM9IL5Q SN PMID28447479-Compound-19
DM9IL5Q CP NOVARTIS AG BEATTIE, David BAETTIG, Urs LEGRAND, Darren Mark LISTER, Andrew Stuart MCKENNA, Jeffrey PEARCE, David William SANDHAM, David Andrew STEWARD, Oliver Ross THOMSON, Christopher
DM9IL5Q DT Small molecular drug
DM9IL5Q PC 117822606
DM9IL5Q MW 518.6
DM9IL5Q FM C25H33F3N8O
DM9IL5Q IC InChI=1S/C25H33F3N8O/c1-18-30-34-36(32-18)17-21-15-22(25(26,27)28)9-7-20(21)8-10-24(37)35-13-11-19(12-14-35)5-3-2-4-6-23-16-29-33-31-23/h7,9,15-16,19H,2-6,8,10-14,17H2,1H3,(H,29,31,33)
DM9IL5Q CS CC1=NN(N=N1)CC2=C(C=CC(=C2)C(F)(F)F)CCC(=O)N3CCC(CC3)CCCCCC4=NNN=C4
DM9IL5Q IK KVDZWWLIQHBBCT-UHFFFAOYSA-N
DM9IL5Q IU 3-[2-[(5-methyltetrazol-2-yl)methyl]-4-(trifluoromethyl)phenyl]-1-[4-[5-(2H-triazol-4-yl)pentyl]piperidin-1-yl]propan-1-one
DMDOQKY ID DMDOQKY
DMDOQKY DN Heteroaryl-azepine derivative 1
DMDOQKY HS Patented
DMDOQKY SN PMID26609882-Compound-64
DMDOQKY CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMDOQKY DT Small molecular drug
DMMZ8LE ID DMMZ8LE
DMMZ8LE DN Heteroaryl-azepine derivative 10
DMMZ8LE HS Patented
DMMZ8LE SN PMID26609882-Compound-73
DMMZ8LE CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMMZ8LE DT Small molecular drug
DM5BF6H ID DM5BF6H
DM5BF6H DN Heteroaryl-azepine derivative 11
DM5BF6H HS Patented
DM5BF6H SN PMID26609882-Compound-74
DM5BF6H CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DM5BF6H DT Small molecular drug
DMOG72B ID DMOG72B
DMOG72B DN Heteroaryl-azepine derivative 12
DMOG72B HS Patented
DMOG72B SN PMID26609882-Compound-75
DMOG72B CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMOG72B DT Small molecular drug
DME86DP ID DME86DP
DME86DP DN Heteroaryl-azepine derivative 13
DME86DP HS Patented
DME86DP SN PMID26609882-Compound-76
DME86DP CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DME86DP DT Small molecular drug
DMG1TIF ID DMG1TIF
DMG1TIF DN Heteroaryl-azepine derivative 14
DMG1TIF HS Patented
DMG1TIF SN PMID26609882-Compound-77
DMG1TIF CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMG1TIF DT Small molecular drug
DMS3WEJ ID DMS3WEJ
DMS3WEJ DN Heteroaryl-azepine derivative 15
DMS3WEJ HS Patented
DMS3WEJ SN PMID26609882-Compound-78
DMS3WEJ CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMS3WEJ DT Small molecular drug
DMDFL6B ID DMDFL6B
DMDFL6B DN Heteroaryl-azepine derivative 2
DMDFL6B HS Patented
DMDFL6B SN PMID26609882-Compound-65
DMDFL6B CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMDFL6B DT Small molecular drug
DMG14E3 ID DMG14E3
DMG14E3 DN Heteroaryl-azepine derivative 3
DMG14E3 HS Patented
DMG14E3 SN PMID26609882-Compound-66
DMG14E3 CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMG14E3 DT Small molecular drug
DMZVLH2 ID DMZVLH2
DMZVLH2 DN Heteroaryl-azepine derivative 4
DMZVLH2 HS Patented
DMZVLH2 SN PMID26609882-Compound-67
DMZVLH2 CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMZVLH2 DT Small molecular drug
DMON5RD ID DMON5RD
DMON5RD DN Heteroaryl-azepine derivative 5
DMON5RD HS Patented
DMON5RD SN PMID26609882-Compound-68
DMON5RD CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMON5RD DT Small molecular drug
DM3O7UG ID DM3O7UG
DM3O7UG DN Heteroaryl-azepine derivative 6
DM3O7UG HS Patented
DM3O7UG SN PMID26609882-Compound-69
DM3O7UG CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DM3O7UG DT Small molecular drug
DMS6HOG ID DMS6HOG
DMS6HOG DN Heteroaryl-azepine derivative 7
DMS6HOG HS Patented
DMS6HOG SN PMID26609882-Compound-70
DMS6HOG CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMS6HOG DT Small molecular drug
DMBJH8N ID DMBJH8N
DMBJH8N DN Heteroaryl-azepine derivative 8
DMBJH8N HS Patented
DMBJH8N SN PMID26609882-Compound-71
DMBJH8N CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMBJH8N DT Small molecular drug
DMBJH8N PC 46849907
DMBJH8N MW 223.34
DMBJH8N FM C12H17NOS
DMBJH8N IC InChI=1S/C12H17NOS/c1-8(2)12-11(14-3)9-4-6-13-7-5-10(9)15-12/h13H,1,4-7H2,2-3H3
DMBJH8N CS CC(=C)C1=C(C2=C(S1)CCNCC2)OC
DMBJH8N IK BQUIRHQLEFJFBK-UHFFFAOYSA-N
DMBJH8N IU 3-methoxy-2-prop-1-en-2-yl-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine
DMUZR3X ID DMUZR3X
DMUZR3X DN Heteroaryl-azepine derivative 9
DMUZR3X HS Patented
DMUZR3X SN PMID26609882-Compound-72
DMUZR3X CP ATHERSYS, INC. BENNANI, Youssef, L. ROBARGE, Michael, J. BOM, David, C. VARGA, Norbert TUMEY, Lawrence, NBIOVITRUM AB [SENILSSON BJOERN [SE]
DMUZR3X DT Small molecular drug
DMPRF1K ID DMPRF1K
DMPRF1K DN Heteroaryl-carboxamide derivative 1
DMPRF1K HS Patented
DMPRF1K SN PMID25684022-Compound-WO2012058176 24(47)
DMPRF1K CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMPRF1K DE Solid tumour/cancer; Metastatic cancer
DMVTARK ID DMVTARK
DMVTARK DN Heteroaryl-carboxamide derivative 10
DMVTARK HS Patented
DMVTARK SN PMID25684022-Compound-WO2012058176 33(21)
DMVTARK CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMVTARK DE Solid tumour/cancer; Metastatic cancer
DM1CWU7 ID DM1CWU7
DM1CWU7 DN Heteroaryl-carboxamide derivative 11
DM1CWU7 HS Patented
DM1CWU7 SN PMID29171765-Compound-Figure2
DM1CWU7 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBNOVARTIS AKalvista Pharmaceuticals LimiteRa Rharmaceuticals Inc
DMGEFIW ID DMGEFIW
DMGEFIW DN Heteroaryl-carboxamide derivative 2
DMGEFIW HS Patented
DMGEFIW SN PMID25684022-Compound-WO2012058176 25(3)
DMGEFIW CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMGEFIW DE Solid tumour/cancer; Metastatic cancer
DMBGTNM ID DMBGTNM
DMBGTNM DN Heteroaryl-carboxamide derivative 3
DMBGTNM HS Patented
DMBGTNM SN PMID25684022-Compound-WO2012058176 26(5)
DMBGTNM CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMBGTNM DE Solid tumour/cancer; Metastatic cancer
DMHUIXR ID DMHUIXR
DMHUIXR DN Heteroaryl-carboxamide derivative 4
DMHUIXR HS Patented
DMHUIXR SN PMID25684022-Compound-WO2012058176 27(6)
DMHUIXR CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMHUIXR DE Solid tumour/cancer; Metastatic cancer
DMMX6V4 ID DMMX6V4
DMMX6V4 DN Heteroaryl-carboxamide derivative 5
DMMX6V4 HS Patented
DMMX6V4 SN PMID25684022-Compound-WO2012058176 28(7)
DMMX6V4 CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMMX6V4 DE Solid tumour/cancer; Metastatic cancer
DM9IPDU ID DM9IPDU
DM9IPDU DN Heteroaryl-carboxamide derivative 6
DM9IPDU HS Patented
DM9IPDU SN PMID25684022-Compound-WO2012058176 29(8)
DM9IPDU CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DM9IPDU DE Solid tumour/cancer; Metastatic cancer
DMOAYEV ID DMOAYEV
DMOAYEV DN Heteroaryl-carboxamide derivative 7
DMOAYEV HS Patented
DMOAYEV SN PMID25684022-Compound-WO2012058176 30(12)
DMOAYEV CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMOAYEV DE Solid tumour/cancer; Metastatic cancer
DMJTN91 ID DMJTN91
DMJTN91 DN Heteroaryl-carboxamide derivative 8
DMJTN91 HS Patented
DMJTN91 SN PMID25684022-Compound-WO2012058176 31(13)
DMJTN91 CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMJTN91 DE Solid tumour/cancer; Metastatic cancer
DMI627Z ID DMI627Z
DMI627Z DN Heteroaryl-carboxamide derivative 9
DMI627Z HS Patented
DMI627Z SN PMID25684022-Compound-WO2012058176 32(20)
DMI627Z CP MERCK SHARP & DOHME CORP. PALIWAL, Sunil TSUI, Hon-Chung GAO, Xiaolei KIM, Hyunjin, M. CAPLEN, Mary Ann FISCHMANN, Thierry, O. DUCA, Jose, S
DMI627Z DE Solid tumour/cancer; Metastatic cancer
DMRF58Q ID DMRF58Q
DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1
DMRF58Q HS Patented
DMRF58Q SN PMID27019002-Compound-22d
DMRF58Q CP ORYZON GENOMICS, S.AORYZON GENOMICS SA [ES]
DMRF58Q DT Small molecular drug
DM9NE5T ID DM9NE5T
DM9NE5T DN Heteroaryl-cyclopropylamine derivative 2
DM9NE5T HS Patented
DM9NE5T SN PMID27019002-Compound-22a
DM9NE5T CP ORYZON GENOMICS SA [ES]
DM9NE5T DT Small molecular drug
DMH9EQ1 ID DMH9EQ1
DMH9EQ1 DN Heteroaryl-cyclopropylamine derivative 3
DMH9EQ1 HS Patented
DMH9EQ1 SN PMID27019002-Compound-22b
DMH9EQ1 CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, CarloORYZON GENOMICS SA [ES]
DMH9EQ1 DT Small molecular drug
DMMU01R ID DMMU01R
DMMU01R DN Heteroaryl-cyclopropylamine derivative 4
DMMU01R HS Patented
DMMU01R SN PMID27019002-Compound-22c
DMMU01R CP ORYZON GENOMICS SA [ESORYZON GENOMICS S.A. BAKER, Jonathan, Alleman CASTRO PALOMINO, Julio FYFE, Matthew, Colin, Thor MAES, Tamara MARTINELL PEDEMONTE, MarORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMMU01R DT Small molecular drug
DM9LQCH ID DM9LQCH
DM9LQCH DN Heteroaryl-pyrazole derivative 1
DM9LQCH HS Patented
DM9LQCH SN PMID25435285-Compound-69
DM9LQCH DT Small molecular drug
DMIG0TQ ID DMIG0TQ
DMIG0TQ DN Heteroaryl-pyrazole derivative 2
DMIG0TQ HS Patented
DMIG0TQ SN PMID25435285-Compound-74
DMIG0TQ DT Small molecular drug
DMIG0TQ PC 89585736
DMIG0TQ MW 479.4
DMIG0TQ FM C20H16F3N5O4S
DMIG0TQ IC InChI=1S/C20H16F3N5O4S/c1-28-17(11-31-14-7-5-13(6-8-14)20(21,22)23)16(10-25-28)19-26-18(27-32-19)12-3-2-4-15(9-12)33(24,29)30/h2-10H,11H2,1H3,(H2,24,29,30)
DMIG0TQ CS CN1C(=C(C=N1)C2=NC(=NO2)C3=CC(=CC=C3)S(=O)(=O)N)COC4=CC=C(C=C4)C(F)(F)F
DMIG0TQ IK ZHBWEWSSDGSLAK-UHFFFAOYSA-N
DMIG0TQ IU 3-[5-[1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzenesulfonamide
DMO45G3 ID DMO45G3
DMO45G3 DN Heteroaryl-pyrazole derivative 3
DMO45G3 HS Patented
DMO45G3 SN PMID25435285-Compound-75
DMO45G3 DT Small molecular drug
DMO45G3 PC 89585740
DMO45G3 MW 495.5
DMO45G3 FM C21H17F4N5O3S
DMO45G3 IC InChI=1S/C21H17F4N5O3S/c22-12-30-18(9-6-13-4-7-15(8-5-13)21(23,24)25)17(11-27-30)20-28-19(29-33-20)14-2-1-3-16(10-14)34(26,31)32/h1-5,7-8,10-11H,6,9,12H2,(H2,26,31,32)
DMO45G3 CS C1=CC(=CC(=C1)S(=O)(=O)N)C2=NOC(=N2)C3=C(N(N=C3)CF)CCC4=CC=C(C=C4)C(F)(F)F
DMO45G3 IK ZBFNZSWRIVRSIR-UHFFFAOYSA-N
DMO45G3 IU 3-[5-[1-(fluoromethyl)-5-[2-[4-(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzenesulfonamide
DM2BM1L ID DM2BM1L
DM2BM1L DN Heteroaryl-substituted urea derivative 1
DM2BM1L HS Patented
DM2BM1L SN PMID26413912-Compound-44
DM2BM1L CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, J., Guy KEITH, John, M. TICHENOR, Mark, S. CHAMBERS, Alison, L. JONES, William, M. HAWRYLUK, Natalie, A. TIMMONS, Amy, K. MERIT, Jeffrey, E. SEIERSTAD, Mark, JJanssen Pharmaceutica N.V
DM2BM1L DT Small molecular drug
DMHFQLC ID DMHFQLC
DMHFQLC DN Heteroaryl-substituted urea derivative 2
DMHFQLC HS Patented
DMHFQLC SN PMID26413912-Compound-45
DMHFQLC CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, J., Guy KEITH, John, M. TICHENOR, Mark, S. CHAMBERS, Alison, L. JONES, William, M. HAWRYLUK, Natalie, A. TIMMONS, Amy, K. MERIT, Jeffrey, E. SEIERSTAD, Mark, JJanssen Pharmaceutica N.V
DMHFQLC DT Small molecular drug
DM8PHBG ID DM8PHBG
DM8PHBG DN Heterocycle-containing compound 1
DM8PHBG HS Patented
DM8PHBG SN PMID25828189-Compound-13
DM8PHBG CP PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM8PHBG DT Small molecular drug
DM2KVMT ID DM2KVMT
DM2KVMT DN Heterocycle-containing compound 2
DM2KVMT HS Patented
DM2KVMT SN PMID25828189-Compound-14
DM2KVMT CP PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM2KVMT DT Small molecular drug
DM2KVMT PC 11591405
DM2KVMT MW 499.5
DM2KVMT FM C28H28F3NO4
DM2KVMT IC InChI=1S/C28H28F3NO4/c1-18(2)17-25(21-3-5-22(6-4-21)27(35)32-16-15-26(33)34)36-24-13-9-20(10-14-24)19-7-11-23(12-8-19)28(29,30)31/h3-14,18,25H,15-17H2,1-2H3,(H,32,35)(H,33,34)
DM2KVMT CS CC(C)CC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F
DM2KVMT IK KVQXZASOMKRHSG-UHFFFAOYSA-N
DM2KVMT IU 3-[[4-[3-methyl-1-[4-[4-(trifluoromethyl)phenyl]phenoxy]butyl]benzoyl]amino]propanoic acid
DMHMTF7 ID DMHMTF7
DMHMTF7 DN Heterocycle-containing compound 3
DMHMTF7 HS Patented
DMHMTF7 SN PMID25828189-Compound-15
DMHMTF7 CP PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DMHMTF7 DT Small molecular drug
DMHMTF7 PC 57389844
DMHMTF7 MW 514.5
DMHMTF7 FM C27H29F3N4O3
DMHMTF7 IC InChI=1S/C27H29F3N4O3/c1-16(2)12-23(22-9-6-19(14-32-22)26(37)31-11-10-24(35)36)34-21-13-17(3)25(33-15-21)18-4-7-20(8-5-18)27(28,29)30/h4-9,13-16,23,34H,10-12H2,1-3H3,(H,31,37)(H,35,36)
DMHMTF7 CS CC1=CC(=CN=C1C2=CC=C(C=C2)C(F)(F)F)NC(CC(C)C)C3=NC=C(C=C3)C(=O)NCCC(=O)O
DMHMTF7 IK XWKCFFJMDVSXKD-UHFFFAOYSA-N
DMHMTF7 IU 3-[[6-[3-methyl-1-[[5-methyl-6-[4-(trifluoromethyl)phenyl]pyridin-3-yl]amino]butyl]pyridine-3-carbonyl]amino]propanoic acid
DM6IRJL ID DM6IRJL
DM6IRJL DN Heterocycle-containing compound 4
DM6IRJL HS Patented
DM6IRJL SN PMID25828189-Compound-16
DM6IRJL CP PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM6IRJL DT Small molecular drug
DM6IRJL PC 67981277
DM6IRJL MW 500.5
DM6IRJL FM C26H27F3N4O3
DM6IRJL IC InChI=1S/C26H27F3N4O3/c1-16(2)13-22(33-23-10-7-19(14-32-23)25(36)30-12-11-24(34)35)18-5-3-17(4-6-18)21-9-8-20(15-31-21)26(27,28)29/h3-10,14-16,22H,11-13H2,1-2H3,(H,30,36)(H,32,33)(H,34,35)/t22-/m0/s1
DM6IRJL CS CC(C)C[C@@H](C1=CC=C(C=C1)C2=NC=C(C=C2)C(F)(F)F)NC3=NC=C(C=C3)C(=O)NCCC(=O)O
DM6IRJL IK MSWXTYSARYGQHP-QFIPXVFZSA-N
DM6IRJL IU 3-[[6-[[(1S)-3-methyl-1-[4-[5-(trifluoromethyl)pyridin-2-yl]phenyl]butyl]amino]pyridine-3-carbonyl]amino]propanoic acid
DM6EY5Z ID DM6EY5Z
DM6EY5Z DN Heterocycle-containing compound 5
DM6EY5Z HS Patented
DM6EY5Z SN PMID25828189-Compound-17
DM6EY5Z CP PFIZER INC. ASPNES, Gary, Erik DIDIUK, Mary, Theresa FILIPSKI, Kevin, James GUZMAN-PEREZ, Angel PFEFFERKORN, Jeffrey, Allen STEVENS, Benjamin, Dawson TU, Meihua, Mik
DM6EY5Z DT Small molecular drug
DM6EY5Z PC 57388936
DM6EY5Z MW 501.5
DM6EY5Z FM C25H26F3N5O3
DM6EY5Z IC InChI=1S/C25H26F3N5O3/c1-15(2)11-20(33-21-8-5-17(12-30-21)24(36)29-10-9-22(34)35)18-13-31-23(32-14-18)16-3-6-19(7-4-16)25(26,27)28/h3-8,12-15,20H,9-11H2,1-2H3,(H,29,36)(H,30,33)(H,34,35)/t20-/m0/s1
DM6EY5Z CS CC(C)C[C@@H](C1=CN=C(N=C1)C2=CC=C(C=C2)C(F)(F)F)NC3=NC=C(C=C3)C(=O)NCCC(=O)O
DM6EY5Z IK DROAORWMIULFBS-FQEVSTJZSA-N
DM6EY5Z IU 3-[[6-[[(1S)-3-methyl-1-[2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl]butyl]amino]pyridine-3-carbonyl]amino]propanoic acid
DMJ5X46 ID DMJ5X46
DMJ5X46 DN Heterocyclic derivative 1
DMJ5X46 HS Patented
DMJ5X46 SN PMID28067079-Compound-21
DMJ5X46 CP Merz Pharma GmbH & Co KGaA
DMJ5X46 DT Small molecular drug
DMJ5X46 PC 71766537
DMJ5X46 MW 307.4
DMJ5X46 FM C19H21N3O
DMJ5X46 IC InChI=1S/C19H21N3O/c1-19(2)10-16-15(17(11-19)23-3)9-13(12-21-16)7-8-14-5-4-6-18(20)22-14/h4-6,9,12,17H,10-11H2,1-3H3,(H2,20,22)
DMJ5X46 CS CC1(CC(C2=C(C1)N=CC(=C2)C#CC3=NC(=CC=C3)N)OC)C
DMJ5X46 IK MVVPJGFFGSEZEE-UHFFFAOYSA-N
DMJ5X46 IU 6-[2-(5-methoxy-7,7-dimethyl-6,8-dihydro-5H-quinolin-3-yl)ethynyl]pyridin-2-amine
DMN580F ID DMN580F
DMN580F DN Heterocyclic derivative 10
DMN580F HS Patented
DMN580F SN PMID25684022-Compound-US20120208819 7(402)
DMN580F DE Solid tumour/cancer; Metastatic cancer
DMUOI92 ID DMUOI92
DMUOI92 DN Heterocyclic derivative 11
DMUOI92 HS Patented
DMUOI92 SN PMID25684022-Compound-US20120208819 8(443)
DMUOI92 DE Solid tumour/cancer; Metastatic cancer
DMQJW9R ID DMQJW9R
DMQJW9R DN Heterocyclic derivative 12
DMQJW9R HS Patented
DMQJW9R SN PMID25684022-Compound-WO2012044157 1(1.5)
DMQJW9R CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMQJW9R DE Solid tumour/cancer; Metastatic cancer
DMWOBHM ID DMWOBHM
DMWOBHM DN Heterocyclic derivative 13
DMWOBHM HS Patented
DMWOBHM SN PMID25684022-Compound-WO2012044157 2(2.4)
DMWOBHM CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMWOBHM DE Solid tumour/cancer; Metastatic cancer
DMJ0WVR ID DMJ0WVR
DMJ0WVR DN Heterocyclic derivative 14
DMJ0WVR HS Patented
DMJ0WVR SN PMID25684022-Compound-WO2012044157 3(7.6)
DMJ0WVR CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMJ0WVR DE Solid tumour/cancer; Metastatic cancer
DMWZNDO ID DMWZNDO
DMWZNDO DN Heterocyclic derivative 15
DMWZNDO HS Patented
DMWZNDO SN PMID25684022-Compound-WO2012044157 4(58)
DMWZNDO CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMWZNDO DE Solid tumour/cancer; Metastatic cancer
DM6NJV7 ID DM6NJV7
DM6NJV7 DN Heterocyclic derivative 16
DM6NJV7 HS Patented
DM6NJV7 SN PMID25684022-Compound-WO2012044157 5(355)
DM6NJV7 CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DM6NJV7 DE Solid tumour/cancer; Metastatic cancer
DMD1K7E ID DMD1K7E
DMD1K7E DN Heterocyclic derivative 17
DMD1K7E HS Patented
DMD1K7E SN PMID25684022-Compound-WO2012044157 6(360)
DMD1K7E CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMD1K7E DE Solid tumour/cancer; Metastatic cancer
DMFUEDL ID DMFUEDL
DMFUEDL DN Heterocyclic derivative 18
DMFUEDL HS Patented
DMFUEDL SN PMID25684022-Compound-WO2012044157 7(402)
DMFUEDL CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMFUEDL DE Solid tumour/cancer; Metastatic cancer
DMNG0WH ID DMNG0WH
DMNG0WH DN Heterocyclic derivative 19
DMNG0WH HS Patented
DMNG0WH SN PMID25684022-Compound-WO2012044157 8(443)
DMNG0WH CP BEHEERSMAATSCHAPPIJ G.A.CH.M. JENTJENS B.V. ILMER, Wilhelmus, Antonius, Maria THOONSEN, Paulus, Johannes, Maria
DMNG0WH DE Solid tumour/cancer; Metastatic cancer
DM2QCBF ID DM2QCBF
DM2QCBF DN Heterocyclic derivative 2
DM2QCBF HS Patented
DM2QCBF SN PMID28067079-Compound-22
DM2QCBF CP Merz Pharma GmbH & Co KGaA
DM2QCBF DT Small molecular drug
DM2QCBF PC 71767411
DM2QCBF MW 330.4
DM2QCBF FM C20H18N4O
DM2QCBF IC InChI=1S/C20H18N4O/c1-23(2)20(25)24-9-8-19-18(14-24)11-17(13-22-19)7-6-15-4-3-5-16(10-15)12-21/h3-5,10-11,13H,8-9,14H2,1-2H3
DM2QCBF CS CN(C)C(=O)N1CCC2=C(C1)C=C(C=N2)C#CC3=CC(=CC=C3)C#N
DM2QCBF IK TUOMBETVTQCJRF-UHFFFAOYSA-N
DM2QCBF IU 3-[2-(3-cyanophenyl)ethynyl]-N,N-dimethyl-7,8-dihydro-5H-1,6-naphthyridine-6-carboxamide
DM56T1P ID DM56T1P
DM56T1P DN Heterocyclic derivative 26
DM56T1P HS Patented
DM56T1P SN PMID27410995-Compound-Figure3h
DM56T1P DT Small molecular drug
DMCD0MS ID DMCD0MS
DMCD0MS DN Heterocyclic derivative 3
DMCD0MS HS Patented
DMCD0MS SN PMID28067079-Compound-23
DMCD0MS CP Merz Pharma GmbH & Co KGaA
DMCD0MS DT Small molecular drug
DMCD0MS PC 71767837
DMCD0MS MW 297.4
DMCD0MS FM C17H15NO2S
DMCD0MS IC InChI=1S/C17H15NO2S/c1-13-3-2-4-14(9-13)5-6-15-10-16-12-21(19,20)8-7-17(16)18-11-15/h2-4,9-11H,7-8,12H2,1H3
DMCD0MS CS CC1=CC(=CC=C1)C#CC2=CC3=C(CCS(=O)(=O)C3)N=C2
DMCD0MS IK QSNHNADSPWYHPP-UHFFFAOYSA-N
DMCD0MS IU 3-[2-(3-methylphenyl)ethynyl]-7,8-dihydro-5H-thiopyrano[4,3-b]pyridine 6,6-dioxide
DM7VP8M ID DM7VP8M
DM7VP8M DN Heterocyclic derivative 4
DM7VP8M HS Patented
DM7VP8M SN PMID25684022-Compound-US20120208819 1(1.5)
DM7VP8M DE Solid tumour/cancer; Metastatic cancer
DMWJDEO ID DMWJDEO
DMWJDEO DN Heterocyclic derivative 5
DMWJDEO HS Patented
DMWJDEO SN PMID25684022-Compound-US20120208819 2(2.4)
DMWJDEO DE Solid tumour/cancer; Metastatic cancer
DM6HWN3 ID DM6HWN3
DM6HWN3 DN Heterocyclic derivative 6
DM6HWN3 HS Patented
DM6HWN3 SN PMID25684022-Compound-US20120208819 3(7.6)
DM6HWN3 DE Solid tumour/cancer; Metastatic cancer
DMU6LS4 ID DMU6LS4
DMU6LS4 DN Heterocyclic derivative 7
DMU6LS4 HS Patented
DMU6LS4 SN PMID25684022-Compound-US20120208819 4(58)
DMU6LS4 DE Solid tumour/cancer; Metastatic cancer
DMKPSIA ID DMKPSIA
DMKPSIA DN Heterocyclic derivative 8
DMKPSIA HS Patented
DMKPSIA SN PMID25684022-Compound-US20120208819 5(355)
DMKPSIA DE Solid tumour/cancer; Metastatic cancer
DMY4LB7 ID DMY4LB7
DMY4LB7 DN Heterocyclic derivative 9
DMY4LB7 HS Patented
DMY4LB7 SN PMID25684022-Compound-US20120208819 6(360)
DMY4LB7 DE Solid tumour/cancer; Metastatic cancer
DMA91IJ ID DMA91IJ
DMA91IJ DN Heterocyclic-carboxamide derivative 1
DMA91IJ HS Patented
DMA91IJ SN PMID25684022-Compound-WO2010065384
DMA91IJ CP Merck & Co., Inc
DMA91IJ DT Small molecular drug
DMA91IJ DE Solid tumour/cancer; Metastatic cancer
DMSQK50 ID DMSQK50
DMSQK50 DN Heterocyclic-carboxamide derivative 2
DMSQK50 HS Patented
DMSQK50 SN PMID25684022-Compound-WO2011044157
DMSQK50 CP Sunesis & Biogen
DMSQK50 DT Small molecular drug
DMSQK50 DE Solid tumour/cancer; Metastatic cancer
DMEGK3Q ID DMEGK3Q
DMEGK3Q DN Heterocyclic-fused piperazine derivative 1
DMEGK3Q HS Patented
DMEGK3Q SN PMID27724045-Compound-5
DMEGK3Q CP GSK
DMEGK3Q DT Small molecular drug
DMEGK3Q PC 66599260
DMEGK3Q MW 413.8
DMEGK3Q FM C16H11ClF3N5OS
DMEGK3Q IC InChI=1S/C16H11ClF3N5OS/c17-13-9(2-1-3-10(13)16(18,19)20)15(26)24-4-5-25-12(6-24)22-23-14(25)11-7-27-8-21-11/h1-3,7-8H,4-6H2
DMEGK3Q CS C1CN2C(=NN=C2C3=CSC=N3)CN1C(=O)C4=C(C(=CC=C4)C(F)(F)F)Cl
DMEGK3Q IK BDKXTJZVSCTDFF-UHFFFAOYSA-N
DMEGK3Q IU [2-chloro-3-(trifluoromethyl)phenyl]-[3-(1,3-thiazol-4-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
DMJEX3D ID DMJEX3D
DMJEX3D DN Heterocyclic-substituted 3-alkyl azetidine derivative 1
DMJEX3D HS Patented
DMJEX3D SN PMID26161824-Compound-158
DMJEX3D CP MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
DMJEX3D DT Small molecular drug
DMJEX3D PC 58882003
DMJEX3D MW 535
DMJEX3D FM C29H25ClF2N4O2
DMJEX3D IC InChI=1S/C29H25ClF2N4O2/c1-29(2,32)25(20-11-21(13-24(31)12-20)27-34-35-28(37)38-27)22-15-36(16-22)26(18-6-8-23(30)9-7-18)19-5-3-4-17(10-19)14-33/h3-13,22,25-26H,15-16H2,1-2H3,(H,35,37)/t25-,26?/m1/s1
DMJEX3D CS CC(C)([C@@H](C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=CC(=C3)C#N)C4=CC(=CC(=C4)C5=NNC(=O)O5)F)F
DMJEX3D IK DQKCYKJTBAXWFL-DCWQJPKNSA-N
DMJEX3D IU 3-[(4-chlorophenyl)-[3-[(1S)-2-fluoro-1-[3-fluoro-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl]-2-methylpropyl]azetidin-1-yl]methyl]benzonitrile
DMJEX3D DE Obesity
DMEX7PV ID DMEX7PV
DMEX7PV DN Heterocyclic-substituted 3-alkyl azetidine derivative 2
DMEX7PV HS Patented
DMEX7PV SN PMID26161824-Compound-159
DMEX7PV CP MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
DMEX7PV DT Small molecular drug
DMEX7PV PC 68977099
DMEX7PV MW 524.6
DMEX7PV FM C30H26F2N6O
DMEX7PV IC InChI=1S/C30H26F2N6O/c1-30(2,32)26(23-10-19(15-34)11-25(31)13-23)24-16-38(17-24)27(20-8-6-18(14-33)7-9-20)21-4-3-5-22(12-21)28-36-37-29(35)39-28/h3-13,24,26-27H,16-17H2,1-2H3,(H2,35,37)
DMEX7PV CS CC(C)(C(C1CN(C1)C(C2=CC=C(C=C2)C#N)C3=CC=CC(=C3)C4=NN=C(O4)N)C5=CC(=CC(=C5)C#N)F)F
DMEX7PV IK AKSVEYGFHNXCSL-UHFFFAOYSA-N
DMEX7PV IU 3-[1-[1-[[3-(5-amino-1,3,4-oxadiazol-2-yl)phenyl]-(4-cyanophenyl)methyl]azetidin-3-yl]-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile
DMEX7PV DE Obesity
DMO1Y30 ID DMO1Y30
DMO1Y30 DN Heterocyclic-substituted 3-alkyl azetidine derivative 3
DMO1Y30 HS Patented
DMO1Y30 SN PMID26161824-Compound-160
DMO1Y30 CP MERCK & CO., INC. BAKER, Robert, K. HALE, Jeffrey, J. MIAO, Shouwu RUPPRECHT, Kathleen, M
DMO1Y30 DT Small molecular drug
DMO1Y30 PC 68394740
DMO1Y30 MW 518.5
DMO1Y30 FM C29H25F3N4O2
DMO1Y30 IC InChI=1S/C29H25F3N4O2/c1-29(2,32)25(21-11-23(30)13-24(31)12-21)22-15-36(16-22)26(20-5-3-4-17(10-20)14-33)18-6-8-19(9-7-18)27-34-35-28(37)38-27/h3-13,22,25-26H,15-16H2,1-2H3,(H,35,37)
DMO1Y30 CS CC(C)(C(C1CN(C1)C(C2=CC=C(C=C2)C3=NNC(=O)O3)C4=CC=CC(=C4)C#N)C5=CC(=CC(=C5)F)F)F
DMO1Y30 IK SROKVDFDVQITLS-UHFFFAOYSA-N
DMO1Y30 IU 3-[[3-[1-(3,5-difluorophenyl)-2-fluoro-2-methylpropyl]azetidin-1-yl]-[4-(2-oxo-3H-1,3,4-oxadiazol-5-yl)phenyl]methyl]benzonitrile
DMO1Y30 DE Obesity
DMNJVR6 ID DMNJVR6
DMNJVR6 DN Heterocyclic-tetracyclic tetrahydrofuran derivative 1
DMNJVR6 HS Patented
DMNJVR6 SN PMID26609882-Compound-49
DMNJVR6 CP JANSSEN PHARMACEUTICA NV [BE]
DMNJVR6 DT Small molecular drug
DMC1ZIX ID DMC1ZIX
DMC1ZIX DN Hexahydro azepinone derivative 1
DMC1ZIX HS Patented
DMC1ZIX SN PMID28048944-Compound-27
DMC1ZIX DT Small molecular drug
DMT2Z0I ID DMT2Z0I
DMT2Z0I DN Hexahydro naphthalene derivative 1
DMT2Z0I HS Patented
DMT2Z0I SN PMID27537201-Compound-Figure10left
DMT2Z0I CP Academia Sinica (Taipei, TW), National Taiwan University (Taipei, TW)
DMT2Z0I DT Small molecular drug
DMFG9HP ID DMFG9HP
DMFG9HP DN Hexahydro naphthalene derivative 2
DMFG9HP HS Patented
DMFG9HP SN PMID27537201-Compound-Figure9left
DMFG9HP DT Small molecular drug
DM1KT4I ID DM1KT4I
DM1KT4I DN Hexahydro naphthalene derivative 3
DM1KT4I HS Patented
DM1KT4I SN PMID27537201-Compound-Figure9right
DM1KT4I CP BEIJING LABWORLD BIO MEDICINE TECHNOLOGY CO LTD
DM1KT4I DT Small molecular drug
DM4VNWX ID DM4VNWX
DM4VNWX DN Hexahydro quinoline derivative 1
DM4VNWX HS Patented
DM4VNWX SN PMID29473428-Compound-77
DM4VNWX CP IOMET PHARMA LTD
DM4VNWX DT Small molecular drug
DM4VNWX PC 121325265
DM4VNWX MW 346.4
DM4VNWX FM C18H22N2O3S
DM4VNWX IC InChI=1S/C18H22N2O3S/c1-13(2)23-15-6-8-16(9-7-15)24(21,22)20-18-5-3-4-14-12-19-11-10-17(14)18/h6-13,18,20H,3-5H2,1-2H3
DM4VNWX CS CC(C)OC1=CC=C(C=C1)S(=O)(=O)NC2CCCC3=C2C=CN=C3
DM4VNWX IK XINKWGLXVLWLIU-UHFFFAOYSA-N
DM4VNWX IU 4-propan-2-yloxy-N-(5,6,7,8-tetrahydroisoquinolin-5-yl)benzenesulfonamide
DMU5JC0 ID DMU5JC0
DMU5JC0 DN HouttuynoidA
DMU5JC0 HS Patented
DMFIG8C ID DMFIG8C
DMFIG8C DN Hydoxyamidine derivative 1
DMFIG8C HS Patented
DMFIG8C SN PMID29473428-Compound-18
DMFIG8C CP INCYTE CORPORATIOINCYTE HOLDINGS CORPORATION
DMFIG8C DT Small molecular drug
DMUA740 ID DMUA740
DMUA740 DN Hydrazide derivative 1
DMUA740 HS Patented
DMUA740 SN PMID26161824-Compound-22
DMUA740 DT Small molecular drug
DMUA740 DE Obesity
DM3U79M ID DM3U79M
DM3U79M DN Hydrazide derivative 3
DM3U79M HS Patented
DM3U79M SN PMID28117607-Compound-23
DM3U79M CP ELAN PHARMACEUTICALS, LLC
DM3U79M DT Small molecular drug
DM3U79M PC 86293786
DM3U79M MW 369.8
DM3U79M FM C14H9ClFN3O2S2
DM3U79M IC InChI=1S/C14H9ClFN3O2S2/c15-11-6-5-10(23-11)13(21)17-18-14-19(12(20)7-22-14)9-3-1-8(16)2-4-9/h1-6H,7H2,(H,17,21)/b18-14+
DM3U79M CS C1C(=O)N(/C(=N\\NC(=O)C2=CC=C(S2)Cl)/S1)C3=CC=C(C=C3)F
DM3U79M IK SDAYOLNMRBBFQH-NBVRZTHBSA-N
DM3U79M IU 5-chloro-N-[(E)-[3-(4-fluorophenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]thiophene-2-carboxamide
DM1HI8Q ID DM1HI8Q
DM1HI8Q DN Hydrazide derivative 4
DM1HI8Q HS Patented
DM1HI8Q SN PMID28117607-Compound-24
DM1HI8Q CP ELAN PHARMACEUTICALS, LLC
DM1HI8Q DT Small molecular drug
DM6RLVB ID DM6RLVB
DM6RLVB DN Hydrazide derivative 5
DM6RLVB HS Patented
DM6RLVB SN PMID28117607-Compound-25
DM6RLVB CP ELAN PHARMACEUTICALS, LLC
DM6RLVB DT Small molecular drug
DMEQBTO ID DMEQBTO
DMEQBTO DN Hydrazinoacetic acid
DMEQBTO HS Patented
DMEQBTO SN Hydrazinoacetic acid; 2-hydrazinylacetic acid; 14150-64-2; EINECS 237-995-8; 2-diazanylethanoic acid; Acetic acid, hydrazino-; Acetic acid,2-hydrazinyl-; AC1Q5WP6; AC1L371G; CTK4C2660; DTXSID40161745; ZINC19170177; FT-0717156; A808018
DMEQBTO DT Small molecular drug
DMEQBTO PC 84227
DMEQBTO MW 90.08
DMEQBTO FM C2H6N2O2
DMEQBTO IC InChI=1S/C2H6N2O2/c3-4-1-2(5)6/h4H,1,3H2,(H,5,6)
DMEQBTO CS C(C(=O)O)NN
DMEQBTO IK RRBZUCWNYQUCTR-UHFFFAOYSA-N
DMEQBTO IU 2-hydrazinylacetic acid
DMEQBTO CA CAS 14150-64-2
DMGATHZ ID DMGATHZ
DMGATHZ DN Hydroxamate analog 1
DMGATHZ HS Patented
DMGATHZ SN PMID25468267-Compound-31
DMGATHZ DT Small molecular drug
DMBMG1S ID DMBMG1S
DMBMG1S DN Hydroxamate analog 2
DMBMG1S HS Patented
DMBMG1S SN PMID25468267-Compound-32
DMBMG1S DT Small molecular drug
DMDQYJ1 ID DMDQYJ1
DMDQYJ1 DN Hydroxamate analog 3
DMDQYJ1 HS Patented
DMDQYJ1 SN PMID25468267-Compound-33
DMDQYJ1 DT Small molecular drug
DMBHIL2 ID DMBHIL2
DMBHIL2 DN Hydroxy amidine derivative 1
DMBHIL2 HS Patented
DMBHIL2 SN PMID29473428-Compound-25
DMBHIL2 CP JIANGSU HENGRUI MEDICINE CO., LTD. SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD
DMBHIL2 DT Small molecular drug
DM7SUFJ ID DM7SUFJ
DM7SUFJ DN Hydroxy amidine derivative 2
DM7SUFJ HS Patented
DM7SUFJ SN PMID29473428-Compound-26
DM7SUFJ CP JIANGSU HENGRUI MEDICINE CO., LTD. SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD
DM7SUFJ DT Small molecular drug
DMAJFDT ID DMAJFDT
DMAJFDT DN Hydroxyqunoline analog 1
DMAJFDT HS Patented
DMAJFDT SN PMID25468267-Compound-41
DMAJFDT DT Small molecular drug
DMAJFDT PC 459617
DMAJFDT MW 189.17
DMAJFDT FM C10H7NO3
DMAJFDT IC InChI=1S/C10H7NO3/c12-8-4-3-7(10(13)14)6-2-1-5-11-9(6)8/h1-5,12H,(H,13,14)
DMAJFDT CS C1=CC2=C(C=CC(=C2N=C1)O)C(=O)O
DMAJFDT IK JGRPKOGHYBAVMW-UHFFFAOYSA-N
DMAJFDT IU 8-hydroxyquinoline-5-carboxylic acid
DMAJFDT CA CAS 5852-78-8
DMAJFDT CB CHEBI:93239
DMX3TZ7 ID DMX3TZ7
DMX3TZ7 DN Hydroxyqunoline analog 2
DMX3TZ7 HS Patented
DMX3TZ7 SN PMID25468267-Compound-42
DMX3TZ7 DT Small molecular drug
DMX3TZ7 PC 97394
DMX3TZ7 MW 189.17
DMX3TZ7 FM C10H7NO3
DMX3TZ7 IC InChI=1S/C10H7NO3/c12-8-3-1-2-6-7(10(13)14)4-5-11-9(6)8/h1-5,12H,(H,13,14)
DMX3TZ7 CS C1=CC2=C(C=CN=C2C(=C1)O)C(=O)O
DMX3TZ7 IK KPTUKANGPPVLMD-UHFFFAOYSA-N
DMX3TZ7 IU 8-hydroxyquinoline-4-carboxylic acid
DMX3TZ7 CA CAS 55698-67-4
DMCMKIL ID DMCMKIL
DMCMKIL DN Hydroxyqunoline analog 3
DMCMKIL HS Patented
DMCMKIL SN PMID25468267-Compound-43
DMCMKIL DT Small molecular drug
DMCMKIL PC 49853311
DMCMKIL MW 349.4
DMCMKIL FM C21H23N3O2
DMCMKIL IC InChI=1S/C21H23N3O2/c1-24(2)12-4-11-22-21(26)16-9-7-15(8-10-16)18-13-17-5-3-6-19(25)20(17)23-14-18/h3,5-10,13-14,25H,4,11-12H2,1-2H3,(H,22,26)
DMCMKIL CS CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CN=C3C(=C2)C=CC=C3O
DMCMKIL IK USYGLVCNYUDJNL-UHFFFAOYSA-N
DMCMKIL IU N-[3-(dimethylamino)propyl]-4-(8-hydroxyquinolin-3-yl)benzamide
DMGQMCZ ID DMGQMCZ
DMGQMCZ DN Hydroxyqunoline analog 4
DMGQMCZ HS Patented
DMGQMCZ SN PMID25468267-Compound-44
DMGQMCZ DT Small molecular drug
DMGQMCZ PC 44143209
DMGQMCZ MW 349.4
DMGQMCZ FM C21H23N3O2
DMGQMCZ IC InChI=1S/C21H23N3O2/c1-24(2)12-4-11-23-21(26)16-8-6-15(7-9-16)18-13-17-5-3-10-22-20(17)19(25)14-18/h3,5-10,13-14,25H,4,11-12H2,1-2H3,(H,23,26)
DMGQMCZ CS CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CC(=C3C(=C2)C=CC=N3)O
DMGQMCZ IK QDBVSOZTVKXUES-UHFFFAOYSA-N
DMGQMCZ IU N-[3-(dimethylamino)propyl]-4-(8-hydroxyquinolin-6-yl)benzamide
DM5QAKR ID DM5QAKR
DM5QAKR DN Hydroxyqunoline analog 5
DM5QAKR HS Patented
DM5QAKR SN PMID25468267-Compound-45
DM5QAKR DT Small molecular drug
DM5QAKR PC 70679266
DM5QAKR MW 472.6
DM5QAKR FM C29H36N4O2
DM5QAKR IC InChI=1S/C29H36N4O2/c1-31(2)20-21-8-13-32(14-9-21)26-10-15-33(16-11-26)29(35)24-6-3-5-22(17-24)25-18-23-7-4-12-30-28(23)27(34)19-25/h3-7,12,17-19,21,26,34H,8-11,13-16,20H2,1-2H3
DM5QAKR CS CN(C)CC1CCN(CC1)C2CCN(CC2)C(=O)C3=CC=CC(=C3)C4=CC(=C5C(=C4)C=CC=N5)O
DM5QAKR IK CILGUWSVIMKGON-UHFFFAOYSA-N
DM5QAKR IU [4-[4-[(dimethylamino)methyl]piperidin-1-yl]piperidin-1-yl]-[3-(8-hydroxyquinolin-6-yl)phenyl]methanone
DMMFI5G ID DMMFI5G
DMMFI5G DN Hypersulfated disaccharide compound 1
DMMFI5G HS Patented
DMMFI5G SN PMID26118988-Compound-40
DMMFI5G DT Small molecular drug
DMMJTUW ID DMMJTUW
DMMJTUW DN Imatinib and nilotinib derivative 1
DMMJTUW HS Patented
DMMJTUW SN PMID30074415-Compound-22
DMMJTUW CP UNIVERSITY OF TAMPERE SUPURAN, Claudiu PARKKILA, Seppo
DMMJTUW DT Small molecular drug
DMMJTUW PC 4369496
DMMJTUW MW 479.6
DMMJTUW FM C28H29N7O
DMMJTUW IC InChI=1S/C28H29N7O/c1-34-14-16-35(17-15-34)20-21-7-9-22(10-8-21)27(36)31-24-5-2-6-25(18-24)32-28-30-13-11-26(33-28)23-4-3-12-29-19-23/h2-13,18-19H,14-17,20H2,1H3,(H,31,36)(H,30,32,33)
DMMJTUW CS CN1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC=CC(=C3)NC4=NC=CC(=N4)C5=CN=CC=C5
DMMJTUW IK JHMBUEWQJDGKGS-UHFFFAOYSA-N
DMMJTUW IU 4-[(4-methylpiperazin-1-yl)methyl]-N-[3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMMJTUW DE Cas mediated disorder
DM34NZ8 ID DM34NZ8
DM34NZ8 DN Imatinib and nilotinib derivative 2
DM34NZ8 HS Patented
DM34NZ8 SN PMID30074415-Compound-23
DM34NZ8 CP UNIVERSITY OF TAMPERE SUPURAN, Claudiu PARKKILA, Seppo
DM34NZ8 DT Small molecular drug
DM34NZ8 DE Cas mediated disorder
DMWUFKO ID DMWUFKO
DMWUFKO DN Imidamide derivative 1
DMWUFKO HS Patented
DMWUFKO SN PMID27539678-Compound-5
DMWUFKO CP UNIVERSITY OF VIRGINIA PATENT FOUNDATION LYNCH, Kevin, R. MACDONALD, Timothy, L. MATHEWS, Thomas, P. KENNEDY, Andrew KHAREL, Yugesh
DMWUFKO DT Small molecular drug
DMWUFKO PC 88866380
DMWUFKO MW 395.6
DMWUFKO FM C22H41N3O3
DMWUFKO IC InChI=1S/C22H41N3O3/c23-20(25-27)22(14-15-22)21(26)24-16-10-5-3-1-2-4-6-11-17-28-18-19-12-8-7-9-13-19/h19,27H,1-18H2,(H2,23,25)(H,24,26)
DMWUFKO CS C1CCC(CC1)COCCCCCCCCCCNC(=O)C2(CC2)/C(=N/O)/N
DMWUFKO IK CHCOBYPQLKIPPD-UHFFFAOYSA-N
DMWUFKO IU N-[10-(cyclohexylmethoxy)decyl]-1-[(Z)-N'-hydroxycarbamimidoyl]cyclopropane-1-carboxamide
DMWABOJ ID DMWABOJ
DMWABOJ DN Imidazo [1,2-a]pyridine compound 1
DMWABOJ HS Patented
DMWABOJ SN PMID26882240-Compound-18
DMWABOJ CP ELARA PHARMACEUTICALS GMBH [DE]
DMWABOJ DT Small molecular drug
DMWABOJ PC 60203900
DMWABOJ MW 413.5
DMWABOJ FM C24H23N5O2
DMWABOJ IC InChI=1S/C24H23N5O2/c30-29(31)21-9-6-19(7-10-21)24-22(17-27-14-12-25-13-15-27)28-16-20(8-11-23(28)26-24)18-4-2-1-3-5-18/h1-11,16,25H,12-15,17H2
DMWABOJ CS C1CN(CCN1)CC2=C(N=C3N2C=C(C=C3)C4=CC=CC=C4)C5=CC=C(C=C5)[N+](=O)[O-]
DMWABOJ IK VFRSRPDPDQUSDK-UHFFFAOYSA-N
DMWABOJ IU 2-(4-nitrophenyl)-6-phenyl-3-(piperazin-1-ylmethyl)imidazo[1,2-a]pyridine
DM01RXU ID DM01RXU
DM01RXU DN Imidazo bicyclic iminium derivative 1
DM01RXU HS Patented
DM01RXU SN PMID26666870-Compound-17
DM01RXU CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITThe Board of Trustees of the Leland Stanford Junior University
DM01RXU DT Small molecular drug
DMA7DI6 ID DMA7DI6
DMA7DI6 DN Imidazo bicyclic iminium derivative 2
DMA7DI6 HS Patented
DMA7DI6 SN PMID26666870-Compound-18
DMA7DI6 CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITThe Board of Trustees of the Leland Stanford Junior University
DMA7DI6 DT Small molecular drug
DMENYZ0 ID DMENYZ0
DMENYZ0 DN Imidazo bicyclic iminium derivative 3
DMENYZ0 HS Patented
DMENYZ0 SN PMID25726713-Compound-71
DMENYZ0 CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMENYZ0 DT Small molecular drug
DMHRV8J ID DMHRV8J
DMHRV8J DN Imidazo bicyclic iminium derivative 4
DMHRV8J HS Patented
DMHRV8J SN PMID25726713-Compound-72
DMHRV8J CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMHRV8J DT Small molecular drug
DMS8GIU ID DMS8GIU
DMS8GIU DN Imidazo bicyclic iminium derivative 5
DMS8GIU HS Patented
DMS8GIU SN PMID25726713-Compound-73
DMS8GIU CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMS8GIU DT Small molecular drug
DMEP5MJ ID DMEP5MJ
DMEP5MJ DN Imidazo bicyclic iminium derivative 6
DMEP5MJ HS Patented
DMEP5MJ SN PMID25726713-Compound-74
DMEP5MJ CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMEP5MJ DT Small molecular drug
DM0Y4X8 ID DM0Y4X8
DM0Y4X8 DN Imidazo bicyclic iminium derivative 7
DM0Y4X8 HS Patented
DM0Y4X8 SN PMID25726713-Compound-75
DM0Y4X8 CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DM0Y4X8 DT Small molecular drug
DMBMFPC ID DMBMFPC
DMBMFPC DN Imidazo bicyclic iminium derivative 8
DMBMFPC HS Patented
DMBMFPC SN PMID25726713-Compound-76
DMBMFPC CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMBMFPC DT Small molecular drug
DMQXCT1 ID DMQXCT1
DMQXCT1 DN Imidazo bicyclic iminium derivative 9
DMQXCT1 HS Patented
DMQXCT1 SN PMID25726713-Compound-77
DMQXCT1 CP THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMQXCT1 DT Small molecular drug
DM34ZCG ID DM34ZCG
DM34ZCG DN Imidazo cyclohexylamine derivative 1
DM34ZCG HS Patented
DM34ZCG SN PMID25482888-Compound-42
DM34ZCG CP SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong LEI, Ming ZHANG, Huajie WANG, Longcheng ZHANG, Jian FANG, Bo LIU, Xia ZHOU, Zuwen
DM34ZCG DT Small molecular drug
DMKPAN3 ID DMKPAN3
DMKPAN3 DN Imidazo cyclohexylamine derivative 2
DMKPAN3 HS Patented
DMKPAN3 SN PMID25482888-Compound-43
DMKPAN3 CP SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong LEI, Ming ZHANG, Huajie WANG, Longcheng ZHANG, Jian FANG, Bo LIU, Xia ZHOU, Zuwen
DMKPAN3 DT Small molecular drug
DMCQBZK ID DMCQBZK
DMCQBZK DN Imidazo cyclohexylamine derivative 3
DMCQBZK HS Patented
DMCQBZK SN PMID25482888-Compound-44
DMCQBZK CP SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong LEI, Ming ZHANG, Huajie WANG, Longcheng ZHANG, Jian FANG, Bo LIU, Xia ZHOU, Zuwen
DMCQBZK DT Small molecular drug
DM1JXKY ID DM1JXKY
DM1JXKY DN Imidazo isoindole derivative 1
DM1JXKY HS Patented
DM1JXKY SN PMID29473428-Compound-35
DM1JXKY CP JIANGSU HENGRUI MEDICINE CO [CNSHANGHAI HENGRUI PHARMACEUTICAL CO LTD [CN]
DM1JXKY DT Small molecular drug
DM1JXKY PC 122650373
DM1JXKY MW 413.5
DM1JXKY FM C25H24FN5
DM1JXKY IC InChI=1S/C25H24FN5/c1-29-15-19(13-28-29)17-5-7-20(8-6-17)30-11-9-18(10-12-30)25-24-21(3-2-4-22(24)26)23-14-27-16-31(23)25/h2-8,13-16,18,25H,9-12H2,1H3/t25-/m0/s1
DM1JXKY CS CN1C=C(C=N1)C2=CC=C(C=C2)N3CCC(CC3)[C@H]4C5=C(C=CC=C5F)C6=CN=CN46
DM1JXKY IK UJGQDAMZVUNFBQ-VWLOTQADSA-N
DM1JXKY IU (5S)-6-fluoro-5-[1-[4-(1-methylpyrazol-4-yl)phenyl]piperidin-4-yl]-5H-imidazo[5,1-a]isoindole
DMCXHGW ID DMCXHGW
DMCXHGW DN Imidazo pyridine derivative 1
DMCXHGW HS Patented
DMCXHGW SN PMID28270021-Compound-WO2015200341Example96
DMCXHGW CP DR. REDDY'S LABORATORIES LTD
DMCXHGW DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMC49SV ID DMC49SV
DMC49SV DN Imidazo pyridine derivative 2
DMC49SV HS Patented
DMC49SV SN PMID25482888-Compound-51
DMC49SV CP SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong ZOU, Chunlan ZHANG, Huajie ZHANG, Weipeng LIU, Caiping TIAN, Qiang
DMC49SV DT Small molecular drug
DMPCLZB ID DMPCLZB
DMPCLZB DN Imidazo pyridine derivative 3
DMPCLZB HS Patented
DMPCLZB SN PMID26161698-Compound-22
DMPCLZB CP NOVARTIS AG ASTEX THERAPEUTICS LIMITED HOWARD, Steven MORTENSON, Paul Neil HISCOCK, Steven Douglas WOOLFORD, Alison Jo-Anne WOODHEAD, Andrew James CHESSARI, Gianni O'REILLY, Marc CONGREVE, Miles Stuart DAGOSTIN, Claudio CHO, Young Shin YANG, Fan CHEN, Christine Hiu-Tung BRAIN, Christopher Thomas LAGU, Bharat WANG, Yaping KIM, Sunkyu GRIALDES, John LUZZIO, Michael Joseph PEREZ, Lawrence Blas LU, Yipin
DMPCLZB DT Small molecular drug
DMPCLZB PC 46937330
DMPCLZB MW 501.6
DMPCLZB FM C30H27N7O
DMPCLZB IC InChI=1S/C30H27N7O/c1-36(2)22-11-13-37(14-12-22)27-10-9-26-29(34-27)35-30(33-26)28(38)19-7-8-20(16-31)24(15-19)25-18-32-17-21-5-3-4-6-23(21)25/h3-10,15,17-18,22H,11-14H2,1-2H3,(H,33,34,35)
DMPCLZB CS CN(C)C1CCN(CC1)C2=NC3=C(C=C2)NC(=N3)C(=O)C4=CC(=C(C=C4)C#N)C5=CN=CC6=CC=CC=C65
DMPCLZB IK AZXYPCBAGCXZPP-UHFFFAOYSA-N
DMPCLZB IU 4-[5-[4-(dimethylamino)piperidin-1-yl]-1H-imidazo[4,5-b]pyridine-2-carbonyl]-2-isoquinolin-4-ylbenzonitrile
DM3YMHP ID DM3YMHP
DM3YMHP DN Imidazo pyridine derivative 4
DM3YMHP HS Patented
DM3YMHP SN PMID27788040-Compound-4
DM3YMHP CP THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES MARUGAN, Juan J. PATNAIK, Samarjit HEILIG, Markus A. SOUTHALL, Noel T. ZHENG, Wei
DM3YMHP DT Small molecular drug
DMOVJ35 ID DMOVJ35
DMOVJ35 DN Imidazo pyridine derivative 5
DMOVJ35 HS Patented
DMOVJ35 SN PMID27788040-Compound-4a
DMOVJ35 CP THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES MARUGAN, Juan J. PATNAIK, Samarjit HEILIG, Markus A. SOUTHALL, Noel T. ZHENG, Wei
DMOVJ35 DT Small molecular drug
DMG6W3O ID DMG6W3O
DMG6W3O DN Imidazo pyridine derivative 6
DMG6W3O HS Patented
DMG6W3O SN PMID27788040-Compound-4b
DMG6W3O CP THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES MARUGAN, Juan J. PATNAIK, Samarjit HEILIG, Markus A. SOUTHALL, Noel T. ZHENG, Wei
DMG6W3O DT Small molecular drug
DMGDMWA ID DMGDMWA
DMGDMWA DN Imidazo quinoline derivative 1
DMGDMWA HS Patented
DMGDMWA SN PMID25684022-Compound-WO2008054238
DMGDMWA CP KUTUSHOV MIKHAIL VLADIMIROVICH [RUGERMANOV EVGENY PAVLOVICH [RU]
DMGDMWA DT Small molecular drug
DMGDMWA DE Solid tumour/cancer; Metastatic cancer
DMLVY7A ID DMLVY7A
DMLVY7A DN Imidazo triazine derivative 1
DMLVY7A HS Patented
DMLVY7A SN PMID27321640-Compound-64
DMLVY7A CP Pfizer Incorporated
DMLVY7A DT Small molecular drug
DMLVY7A PC 68182028
DMLVY7A MW 401.4
DMLVY7A FM C19H18F3N7
DMLVY7A IC InChI=1S/C19H18F3N7/c1-11-26-15(17-18(27(2)3)23-10-25-29(11)17)14-9-24-28(4)16(14)12-5-7-13(8-6-12)19(20,21)22/h5-10H,1-4H3
DMLVY7A CS CC1=NC(=C2N1N=CN=C2N(C)C)C3=C(N(N=C3)C)C4=CC=C(C=C4)C(F)(F)F
DMLVY7A IK UXZUQMRCSXERSI-UHFFFAOYSA-N
DMLVY7A IU N,N,7-trimethyl-5-[1-methyl-5-[4-(trifluoromethyl)phenyl]pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazin-4-amine
DMZFG68 ID DMZFG68
DMZFG68 DN Imidazo triazine derivative 2
DMZFG68 HS Patented
DMZFG68 SN PMID27321640-Compound-65
DMZFG68 CP Pfizer Incorporated
DMZFG68 DT Small molecular drug
DM142HI ID DM142HI
DM142HI DN Imidazo triazine derivative 3
DM142HI HS Patented
DM142HI SN PMID27321640-Compound-66
DM142HI CP Pfizer Incorporated
DM142HI DT Small molecular drug
DMZTS2O ID DMZTS2O
DMZTS2O DN Imidazo triazine derivative 4
DMZTS2O HS Patented
DMZTS2O SN PMID27321640-Compound-67
DMZTS2O CP Pfizer Incorporated
DMZTS2O DT Small molecular drug
DM18P4N ID DM18P4N
DM18P4N DN Imidazo triazine derivative 5
DM18P4N HS Patented
DM18P4N SN PMID27321640-Compound-68
DM18P4N CP Pfizer Incorporated
DM18P4N DT Small molecular drug
DM5NEQ2 ID DM5NEQ2
DM5NEQ2 DN Imidazo[1,2-a]pyridine derivative 1
DM5NEQ2 HS Patented
DM5NEQ2 SN PMID28067079-Compound-46
DM5NEQ2 DT Small molecular drug
DM654Z0 ID DM654Z0
DM654Z0 DN Imidazo[1,2-b]pyridazine acetamide derivative 1
DM654Z0 HS Patented
DM654Z0 SN PMID27607364-Compound-146
DM654Z0 DT Small molecular drug
DMVX7YB ID DMVX7YB
DMVX7YB DN Imidazo[1,2-b]pyridazine acetamide derivative 2
DMVX7YB HS Patented
DMVX7YB SN PMID27607364-Compound-147
DMVX7YB DT Small molecular drug
DMVX7YB PC 44197007
DMVX7YB MW 366.5
DMVX7YB FM C21H26N4O2
DMVX7YB IC InChI=1S/C21H26N4O2/c1-6-24(7-2)19(26)13-18-20(16-8-10-17(27-5)11-9-16)22-21-14(3)12-15(4)23-25(18)21/h8-12H,6-7,13H2,1-5H3
DMVX7YB CS CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)OC
DMVX7YB IK RGPSCAJBNWAKNP-UHFFFAOYSA-N
DMVX7YB IU N,N-diethyl-2-[2-(4-methoxyphenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]acetamide
DMARLZ6 ID DMARLZ6
DMARLZ6 DN Imidazo[1,2-b]pyridazine acetamide derivative 3
DMARLZ6 HS Patented
DMARLZ6 SN PMID27607364-Compound-148
DMARLZ6 DT Small molecular drug
DMARLZ6 PC 44197008
DMARLZ6 MW 350.5
DMARLZ6 FM C21H26N4O
DMARLZ6 IC InChI=1S/C21H26N4O/c1-6-24(7-2)19(26)13-18-20(17-10-8-14(3)9-11-17)22-21-15(4)12-16(5)23-25(18)21/h8-12H,6-7,13H2,1-5H3
DMARLZ6 CS CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)C
DMARLZ6 IK CUGGTIFWWSZRMG-UHFFFAOYSA-N
DMARLZ6 IU 2-[6,8-dimethyl-2-(4-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-diethylacetamide
DM5J09E ID DM5J09E
DM5J09E DN Imidazo[1,2-b]pyridazine acetamide derivative 4
DM5J09E HS Patented
DM5J09E SN PMID27607364-Compound-149
DM5J09E DT Small molecular drug
DM5J09E PC 44197009
DM5J09E MW 370.9
DM5J09E FM C20H23ClN4O
DM5J09E IC InChI=1S/C20H23ClN4O/c1-5-24(6-2)18(26)12-17-19(15-7-9-16(21)10-8-15)22-20-13(3)11-14(4)23-25(17)20/h7-11H,5-6,12H2,1-4H3
DM5J09E CS CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)Cl
DM5J09E IK SNOFNBFMBXYLMZ-UHFFFAOYSA-N
DM5J09E IU 2-[2-(4-chlorophenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]-N,N-diethylacetamide
DMGWYJR ID DMGWYJR
DMGWYJR DN Imidazo[1,2-b]pyridazine acetamide derivative 5
DMGWYJR HS Patented
DMGWYJR SN PMID27607364-Compound-150
DMGWYJR DT Small molecular drug
DMGWYJR PC 44197010
DMGWYJR MW 415.3
DMGWYJR FM C20H23BrN4O
DMGWYJR IC InChI=1S/C20H23BrN4O/c1-5-24(6-2)18(26)12-17-19(15-7-9-16(21)10-8-15)22-20-13(3)11-14(4)23-25(17)20/h7-11H,5-6,12H2,1-4H3
DMGWYJR CS CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)Br
DMGWYJR IK WBBNDNCIVIIEMF-UHFFFAOYSA-N
DMGWYJR IU 2-[2-(4-bromophenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]-N,N-diethylacetamide
DM73ESA ID DM73ESA
DM73ESA DN Imidazo[1,2-b]pyridazine acetamide derivative 6
DM73ESA HS Patented
DM73ESA SN PMID27607364-Compound-151
DM73ESA DT Small molecular drug
DM73ESA PC 44197027
DM73ESA MW 354.4
DM73ESA FM C20H23FN4O
DM73ESA IC InChI=1S/C20H23FN4O/c1-5-24(6-2)18(26)12-17-19(15-7-9-16(21)10-8-15)22-20-13(3)11-14(4)23-25(17)20/h7-11H,5-6,12H2,1-4H3
DM73ESA CS CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)F
DM73ESA IK DARQBLUTJIXEJM-UHFFFAOYSA-N
DM73ESA IU N,N-diethyl-2-[2-(4-fluorophenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]acetamide
DMQLJU2 ID DMQLJU2
DMQLJU2 DN Imidazo[1,2-b]pyridazine acetamide derivative 7
DMQLJU2 HS Patented
DMQLJU2 SN PMID27607364-Compound-152
DMQLJU2 DT Small molecular drug
DMQLJU2 PC 44197028
DMQLJU2 MW 352.4
DMQLJU2 FM C20H24N4O2
DMQLJU2 IC InChI=1S/C20H24N4O2/c1-5-23(6-2)18(26)12-17-19(15-7-9-16(25)10-8-15)21-20-13(3)11-14(4)22-24(17)20/h7-11,25H,5-6,12H2,1-4H3
DMQLJU2 CS CCN(CC)C(=O)CC1=C(N=C2N1N=C(C=C2C)C)C3=CC=C(C=C3)O
DMQLJU2 IK AHZVLZZEKQYWAC-UHFFFAOYSA-N
DMQLJU2 IU N,N-diethyl-2-[2-(4-hydroxyphenyl)-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl]acetamide
DMULTAI ID DMULTAI
DMULTAI DN Imidazo[1,2-b]pyridazine derivative 1
DMULTAI HS Patented
DMULTAI SN PMID28270010-Compound-Figure22-1
DMULTAI DT Small molecular drug
DMULTAI PC 72695720
DMULTAI MW 417.5
DMULTAI FM C24H24FN5O
DMULTAI IC InChI=1S/C24H24FN5O/c1-16(18-3-2-4-19(25)13-18)28-23-9-10-24-27-14-22(30(24)29-23)17-5-7-21(8-6-17)31-15-20-11-12-26-20/h2-10,13-14,16,20,26H,11-12,15H2,1H3,(H,28,29)/t16-,20+/m1/s1
DMULTAI CS C[C@H](C1=CC(=CC=C1)F)NC2=NN3C(=NC=C3C4=CC=C(C=C4)OC[C@@H]5CCN5)C=C2
DMULTAI IK FQCGOBGLJQWKJA-UZLBHIALSA-N
DMULTAI IU 3-[4-[[(2S)-azetidin-2-yl]methoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DMULTAI DE Solid tumour/cancer
DM1JYNW ID DM1JYNW
DM1JYNW DN Imidazo[1,2-b]pyridazine derivative 2
DM1JYNW HS Patented
DM1JYNW SN PMID28270010-Compound-Figure22-2
DM1JYNW DT Small molecular drug
DM1JYNW PC 72695721
DM1JYNW MW 405.5
DM1JYNW FM C23H24FN5O
DM1JYNW IC InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)/t15-,16+/m0/s1
DM1JYNW CS C[C@@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N
DM1JYNW IK HEVHTYMYEMEBPX-JKSUJKDBSA-N
DM1JYNW IU 3-[4-[(2S)-2-aminopropoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine
DM1JYNW DE Solid tumour/cancer
DMPDTG0 ID DMPDTG0
DMPDTG0 DN Imidazo[1,2-b]pyridazine derivative 3
DMPDTG0 HS Patented
DMPDTG0 SN PMID28270010-Compound-Figure22-3
DMPDTG0 DT Small molecular drug
DMPDTG0 DE Solid tumour/cancer
DM2DL4I ID DM2DL4I
DM2DL4I DN Imidazo[1,2-b]pyridazine derivative 4
DM2DL4I HS Patented
DM2DL4I SN PMID28270010-Compound-Figure8-1
DM2DL4I CP ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DM2DL4I DT Small molecular drug
DM2DL4I PC 45274003
DM2DL4I MW 428.4
DM2DL4I FM C21H22F2N6O2
DM2DL4I IC InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)17-2-1-8-28(17)19-6-5-18-24-11-20(29(18)26-19)25-21(31)27-9-7-14(30)12-27/h3-6,10-11,14,17,30H,1-2,7-9,12H2,(H,25,31)/t14-,17+/m0/s1
DM2DL4I CS C1C[C@@H](N(C1)C2=NN3C(=NC=C3NC(=O)N4CC[C@@H](C4)O)C=C2)C5=C(C=CC(=C5)F)F
DM2DL4I IK JSJOUFCSIYXYAC-WMLDXEAASA-N
DM2DL4I IU (3S)-N-[6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
DMK8V7A ID DMK8V7A
DMK8V7A DN Imidazo[1,2-b]pyridazine derivative 5
DMK8V7A HS Patented
DMK8V7A SN PMID28270010-Compound-Figure8-2
DMK8V7A CP ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DMK8V7A DT Small molecular drug
DMSIRC2 ID DMSIRC2
DMSIRC2 DN Imidazo[1,2-b]pyridazine derivative 6
DMSIRC2 HS Patented
DMSIRC2 SN PMID28270010-Compound-Figure8-3
DMSIRC2 CP ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DMSIRC2 DT Small molecular drug
DMDQLUP ID DMDQLUP
DMDQLUP DN Imidazo[1,2-b]pyridazine derivative 7
DMDQLUP HS Patented
DMDQLUP SN PMID28270010-Compound-Figure8-4
DMDQLUP CP ARRAY BIOPHARMA INC. ANDREWS, Steven, W. HAAS, Julia JIANG, Yutong ZHANG, Gan
DMDQLUP DT Small molecular drug
DMDQLUP PC 46182706
DMDQLUP MW 512.5
DMDQLUP FM C24H22F2N6O3S
DMDQLUP IC InChI=1S/C24H22F2N6O3S/c1-36(34,35)30-17-7-4-15(5-8-17)24(33)28-23-14-27-21-10-11-22(29-32(21)23)31-12-2-3-20(31)18-13-16(25)6-9-19(18)26/h4-11,13-14,20,30H,2-3,12H2,1H3,(H,28,33)/t20-/m1/s1
DMDQLUP CS CS(=O)(=O)NC1=CC=C(C=C1)C(=O)NC2=CN=C3N2N=C(C=C3)N4CCC[C@@H]4C5=C(C=CC(=C5)F)F
DMDQLUP IK CDMQMPKUGUVGIR-HXUWFJFHSA-N
DMDQLUP IU N-[6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazin-3-yl]-4-(methanesulfonamido)benzamide
DMFIP0D ID DMFIP0D
DMFIP0D DN Imidazo[1,5-a]pyridine derivative 1
DMFIP0D HS Patented
DMFIP0D SN PMID29473428-Compound-12
DMFIP0D CP BEIGENE, LTD. WANG, Hexiang
DMFIP0D DT Small molecular drug
DMFIP0D PC 122604981
DMFIP0D MW 264.75
DMFIP0D FM C14H17ClN2O
DMFIP0D IC InChI=1S/C14H17ClN2O/c15-11-6-12-8-16-9-17(12)13(7-11)14(18)10-4-2-1-3-5-10/h6-10,14,18H,1-5H2/t14-/m0/s1
DMFIP0D CS C1CCC(CC1)[C@@H](C2=CC(=CC3=CN=CN23)Cl)O
DMFIP0D IK AVJCRIIDMDBAQC-AWEZNQCLSA-N
DMFIP0D IU (S)-(7-chloroimidazo[1,5-a]pyridin-5-yl)-cyclohexylmethanol
DMU3PAR ID DMU3PAR
DMU3PAR DN Imidazo[1,5-a]pyridine derivative 2
DMU3PAR HS Patented
DMU3PAR SN PMID29473428-Compound-13
DMU3PAR CP BEIGENE, LTD. WANG, Hexiang
DMU3PAR DT Small molecular drug
DMU3PAR PC 122609311
DMU3PAR MW 282.4
DMU3PAR FM C18H22N2O
DMU3PAR IC InChI=1S/C18H22N2O/c21-18(15-8-11-1-2-13(15)7-11)17-14(12-3-4-12)5-6-20-10-19-9-16(17)20/h5-6,9-13,15,18,21H,1-4,7-8H2/t11?,13?,15?,18-/m0/s1
DMU3PAR CS C1CC1C2=C(C3=CN=CN3C=C2)[C@H](C4CC5CCC4C5)O
DMU3PAR IK AYNGHFYFVHELEJ-NNIVULJMSA-N
DMU3PAR IU (S)-2-bicyclo[2.2.1]heptanyl-(7-cyclopropylimidazo[1,5-a]pyridin-8-yl)methanol
DM4KBZQ ID DM4KBZQ
DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1
DM4KBZQ HS Patented
DM4KBZQ SN PMID27774824-Compound-Figure11Example228
DM4KBZQ CP GALAPAGOS NV
DM4KBZQ DT Small molecular drug
DMFDRJT ID DMFDRJT
DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2
DMFDRJT HS Patented
DMFDRJT SN PMID27774824-Compound-Figure11Example82
DMFDRJT CP GALAPAGOS NV
DMFDRJT DT Small molecular drug
DMUB4QL ID DMUB4QL
DMUB4QL DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 1
DMUB4QL HS Patented
DMUB4QL SN PMID27321640-Compound-19
DMUB4QL CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMUB4QL DT Small molecular drug
DMB8AJP ID DMB8AJP
DMB8AJP DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 2
DMB8AJP HS Patented
DMB8AJP SN PMID27321640-Compound-20
DMB8AJP CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMB8AJP DT Small molecular drug
DMYX684 ID DMYX684
DMYX684 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 3
DMYX684 HS Patented
DMYX684 SN PMID27321640-Compound-21
DMYX684 CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMYX684 DT Small molecular drug
DMWF4S7 ID DMWF4S7
DMWF4S7 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 4
DMWF4S7 HS Patented
DMWF4S7 SN PMID27321640-Compound-22
DMWF4S7 CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael S. ERDEI, James Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMWF4S7 DT Small molecular drug
DMQBH81 ID DMQBH81
DMQBH81 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1
DMQBH81 HS Patented
DMQBH81 SN PMID27321640-Compound-23
DMQBH81 CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMQBH81 DT Small molecular drug
DMS3ROL ID DMS3ROL
DMS3ROL DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2
DMS3ROL HS Patented
DMS3ROL SN PMID27321640-Compound-24
DMS3ROL CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMS3ROL DT Small molecular drug
DMZ61T8 ID DMZ61T8
DMZ61T8 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3
DMZ61T8 HS Patented
DMZ61T8 SN PMID27321640-Compound-25
DMZ61T8 CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMZ61T8 DT Small molecular drug
DMZ61T8 PC 46200734
DMZ61T8 MW 339.32
DMZ61T8 FM C17H14FN5O2
DMZ61T8 IC InChI=1S/C17H14FN5O2/c1-9-15-22-21-13-6-7-14(25-3)20-17(13)23(15)16(19-9)11-8-10(24-2)4-5-12(11)18/h4-8H,1-3H3
DMZ61T8 CS CC1=C2N=NC3=C(N2C(=N1)C4=C(C=CC(=C4)OC)F)N=C(C=C3)OC
DMZ61T8 IK HLUWBLAYMFWHOF-UHFFFAOYSA-N
DMZ61T8 IU 3-(2-fluoro-5-methoxyphenyl)-12-methoxy-5-methyl-2,4,7,8,13-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene
DMKR5ZO ID DMKR5ZO
DMKR5ZO DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4
DMKR5ZO HS Patented
DMKR5ZO SN PMID27321640-Compound-26
DMKR5ZO CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMKR5ZO DT Small molecular drug
DM7UAKH ID DM7UAKH
DM7UAKH DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5
DM7UAKH HS Patented
DM7UAKH SN PMID27321640-Compound-27
DM7UAKH CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DM7UAKH DT Small molecular drug
DMKRUAN ID DMKRUAN
DMKRUAN DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6
DMKRUAN HS Patented
DMKRUAN SN PMID27321640-Compound-28
DMKRUAN CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMKRUAN DT Small molecular drug
DMINBJM ID DMINBJM
DMINBJM DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7
DMINBJM HS Patented
DMINBJM SN PMID27321640-Compound-29
DMINBJM CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DMINBJM DT Small molecular drug
DM42EST ID DM42EST
DM42EST DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8
DM42EST HS Patented
DM42EST SN PMID27321640-Compound-30
DM42EST CP STANGE, Hans LANGEN, Barbara EGERLAND, Ute HOEFGEN, Norbert PRIEBS, Martina MALAMAS, Michael, S. ERDEI, James, Joseph NI, Yike BIOTIE THERAPIES GMBH WYETH
DM42EST DT Small molecular drug
DM0SOKJ ID DM0SOKJ
DM0SOKJ DN Imidazole benzamide derivative 1
DM0SOKJ HS Patented
DM0SOKJ SN PMID28627961-Compound-21
DM0SOKJ CP ELI LILLY AND COMPANY HUGHES, Norman Earle WOODS, Timothy Andrew NORMAN, Bryan Hurst
DM0SOKJ DT Small molecular drug
DM0SOKJ PC 71059525
DM0SOKJ MW 495.4
DM0SOKJ FM C23H22F5N5O2
DM0SOKJ IC InChI=1S/C23H22F5N5O2/c1-11(2)20(34)30-10-13-8-16(18(19(24)25)29-9-13)21(35)33-22-31-12(3)17(32-22)14-4-6-15(7-5-14)23(26,27)28/h4-9,11,19H,10H2,1-3H3,(H,30,34)(H2,31,32,33,35)
DM0SOKJ CS CC1=C(N=C(N1)NC(=O)C2=C(N=CC(=C2)CNC(=O)C(C)C)C(F)F)C3=CC=C(C=C3)C(F)(F)F
DM0SOKJ IK BZYSILFNUIGABU-UHFFFAOYSA-N
DM0SOKJ IU 2-(difluoromethyl)-5-[(2-methylpropanoylamino)methyl]-N-[5-methyl-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
DM0SOKJ DE Knee pain
DM14KHX ID DM14KHX
DM14KHX DN Imidazole derivative 1
DM14KHX HS Patented
DM14KHX SN PMID26161824-Compound-83
DM14KHX CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DM14KHX DT Small molecular drug
DM14KHX DE Obesity
DMI7W3K ID DMI7W3K
DMI7W3K DN Imidazole derivative 10
DMI7W3K HS Patented
DMI7W3K SN PMID26560362-Compound-19
DMI7W3K DT Small molecular drug
DMTJ0DP ID DMTJ0DP
DMTJ0DP DN Imidazole derivative 11
DMTJ0DP HS Patented
DMTJ0DP SN PMID26560362-Compound-20
DMTJ0DP DT Small molecular drug
DMTJ0DP PC 9930072
DMTJ0DP MW 386.5
DMTJ0DP FM C17H14N4O3S2
DMTJ0DP IC InChI=1S/C17H14N4O3S2/c1-24-14-7-6-11(16-19-12-4-2-8-18-17(12)20-16)10-13(14)21-26(22,23)15-5-3-9-25-15/h2-10,21H,1H3,(H,18,19,20)
DMTJ0DP CS COC1=C(C=C(C=C1)C2=NC3=C(N2)C=CC=N3)NS(=O)(=O)C4=CC=CS4
DMTJ0DP IK WCSLLVSWFDOVCR-UHFFFAOYSA-N
DMTJ0DP IU N-[5-(1H-imidazo[4,5-b]pyridin-2-yl)-2-methoxyphenyl]thiophene-2-sulfonamide
DM8GCVO ID DM8GCVO
DM8GCVO DN Imidazole derivative 2
DM8GCVO HS Patented
DM8GCVO SN PMID26161824-Compound-84
DM8GCVO CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DM8GCVO DT Small molecular drug
DM8GCVO PC 25003715
DM8GCVO MW 519.299
DM8GCVO FM C24H22BrCl2N3O
DM8GCVO IC InChI=1S/C24H22BrCl2N3O/c1-5-19-21(23-28-13-20(31-23)24(2,3)4)29-22(17-11-8-15(26)12-18(17)27)30(19)16-9-6-14(25)7-10-16/h6-13H,5H2,1-4H3
DM8GCVO CS CCC1=C(N=C(N1C2=CC=C(C=C2)Br)C3=C(C=C(C=C3)Cl)Cl)C4=NC=C(O4)C(C)(C)C
DM8GCVO IK PLHFPYNOQHOWQO-UHFFFAOYSA-N
DM8GCVO IU 2-[1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethylimidazol-4-yl]-5-tert-butyl-1,3-oxazole
DM8GCVO DE Obesity
DMV1ER2 ID DMV1ER2
DMV1ER2 DN Imidazole derivative 3
DMV1ER2 HS Patented
DMV1ER2 SN PMID26161824-Compound-85
DMV1ER2 CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DMV1ER2 DT Small molecular drug
DMV1ER2 DE Obesity
DMPGMX2 ID DMPGMX2
DMPGMX2 DN Imidazole derivative 4
DMPGMX2 HS Patented
DMPGMX2 SN PMID26161824-Compound-86
DMPGMX2 CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeongmin JUNG, Myung Eun KIM, Jong Yup AHN, Kwangwoo SEO, Hee Jeong LEE, Sung-Han LEE, Suk Ho
DMPGMX2 DT Small molecular drug
DMPGMX2 PC 59786166
DMPGMX2 MW 580.8
DMPGMX2 FM C24H15Cl3F3N7O
DMPGMX2 IC InChI=1S/C24H15Cl3F3N7O/c25-13-1-4-15(5-2-13)37-18(10-36-12-31-11-32-36)19(33-20(37)16-6-3-14(26)9-17(16)27)21-34-35-22(38-21)23(7-8-23)24(28,29)30/h1-6,9,11-12H,7-8,10H2
DMPGMX2 CS C1CC1(C2=NN=C(O2)C3=C(N(C(=N3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)CN6C=NC=N6)C(F)(F)F
DMPGMX2 IK UFJZESYUYSJRPI-UHFFFAOYSA-N
DMPGMX2 IU 2-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(1,2,4-triazol-1-ylmethyl)imidazol-4-yl]-5-[1-(trifluoromethyl)cyclopropyl]-1,3,4-oxadiazole
DMPGMX2 DE Obesity
DMVSXUM ID DMVSXUM
DMVSXUM DN Imidazole derivative 5
DMVSXUM HS Patented
DMVSXUM SN PMID26161824-Compound-87
DMVSXUM DT Small molecular drug
DMVSXUM DE Obesity
DMOXHZJ ID DMOXHZJ
DMOXHZJ DN Imidazole derivative 6
DMOXHZJ HS Patented
DMOXHZJ SN PMID26161824-Compound-88
DMOXHZJ DT Small molecular drug
DMOXHZJ PC 11541445
DMOXHZJ MW 569.3
DMOXHZJ FM C23H23Cl2IN4O
DMOXHZJ IC InChI=1S/C23H23Cl2IN4O/c1-14-21(29-23(31)27-17-5-3-2-4-6-17)28-22(19-12-7-15(24)13-20(19)25)30(14)18-10-8-16(26)9-11-18/h7-13,17H,2-6H2,1H3,(H2,27,29,31)
DMOXHZJ CS CC1=C(N=C(N1C2=CC=C(C=C2)I)C3=C(C=C(C=C3)Cl)Cl)NC(=O)NC4CCCCC4
DMOXHZJ IK KINYNFFISOBDBZ-UHFFFAOYSA-N
DMOXHZJ IU 1-cyclohexyl-3-[2-(2,4-dichlorophenyl)-1-(4-iodophenyl)-5-methylimidazol-4-yl]urea
DMOXHZJ DE Obesity
DMLPQ7E ID DMLPQ7E
DMLPQ7E DN Imidazole derivative 7
DMLPQ7E HS Patented
DMLPQ7E SN PMID26161824-Compound-89
DMLPQ7E DT Small molecular drug
DMLPQ7E PC 11606083
DMLPQ7E MW 522.4
DMLPQ7E FM C26H25Cl2N7O
DMLPQ7E IC InChI=1S/C26H25Cl2N7O/c1-18-24(26(36)33(2)34-15-4-3-5-16-34)31-25(22-13-10-20(27)17-23(22)28)35(18)21-11-8-19(9-12-21)7-6-14-30-32-29/h8-13,17H,3-5,14-16H2,1-2H3
DMLPQ7E CS CC1=C(N=C(N1C2=CC=C(C=C2)C#CCN=[N+]=[N-])C3=C(C=C(C=C3)Cl)Cl)C(=O)N(C)N4CCCCC4
DMLPQ7E IK ZHBIOSWRXRWSAO-UHFFFAOYSA-N
DMLPQ7E IU 1-[4-(3-azidoprop-1-ynyl)phenyl]-2-(2,4-dichlorophenyl)-N,5-dimethyl-N-piperidin-1-ylimidazole-4-carboxamide
DMLPQ7E DE Obesity
DMK9P7S ID DMK9P7S
DMK9P7S DN Imidazole derivative 8
DMK9P7S HS Patented
DMK9P7S SN PMID28699813-Compound-16
DMK9P7S CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMK9P7S DT Small molecular drug
DMK9P7S PC 54670731
DMK9P7S MW 444
DMK9P7S FM C26H26ClN5
DMK9P7S IC InChI=1S/C26H26ClN5/c27-22-9-7-21(8-10-22)25-30-23(24(31-25)26-28-14-4-15-29-26)20-12-17-32(18-13-20)16-11-19-5-2-1-3-6-19/h1-10,14-15,20H,11-13,16-18H2,(H,30,31)
DMK9P7S CS C1CN(CCC1C2=C(N=C(N2)C3=CC=C(C=C3)Cl)C4=NC=CC=N4)CCC5=CC=CC=C5
DMK9P7S IK CQQKTUASFMHQMA-UHFFFAOYSA-N
DMK9P7S IU 2-[2-(4-chlorophenyl)-5-[1-(2-phenylethyl)piperidin-4-yl]-1H-imidazol-4-yl]pyrimidine
DMSV42L ID DMSV42L
DMSV42L DN Imidazole derivative 9
DMSV42L HS Patented
DMSV42L SN PMID28699813-Compound-H
DMSV42L CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMSV42L DT Small molecular drug
DM7UMW2 ID DM7UMW2
DM7UMW2 DN Imidazoleisoindoles derivative 1
DM7UMW2 HS Patented
DM7UMW2 SN PMID29473428-Compound-36
DM7UMW2 CP HANGZHOU INNOGATE PHARMA CO., LTD
DM7UMW2 DT Small molecular drug
DM7UMW2 PC 122628163
DM7UMW2 MW 342.4
DM7UMW2 FM C20H23FN2O2
DM7UMW2 IC InChI=1S/C20H23FN2O2/c21-14-3-1-2-13-16-11-22-12-23(16)15(18(13)14)10-17(24)19-4-7-20(25,8-5-19)9-6-19/h1-3,11-12,15,17,24-25H,4-10H2
DM7UMW2 CS C1CC2(CCC1(CC2)C(CC3C4=C(C=CC=C4F)C5=CN=CN35)O)O
DM7UMW2 IK IUJILQYRZOXDQY-UHFFFAOYSA-N
DM7UMW2 IU 4-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]bicyclo[2.2.2]octan-1-ol
DMRJKIQ ID DMRJKIQ
DMRJKIQ DN Imidazoleisoindoles derivative 2
DMRJKIQ HS Patented
DMRJKIQ SN PMID29473428-Compound-37
DMRJKIQ CP HANGZHOU INNOGATE PHARMA CO., LTD
DMRJKIQ DT Small molecular drug
DMRJKIQ PC 122498962
DMRJKIQ MW 368.4
DMRJKIQ FM C22H25FN2O2
DMRJKIQ IC InChI=1S/C22H25FN2O2/c23-16-3-1-2-15-18-10-24-11-25(18)17(20(15)16)6-19(26)22-7-12-4-13(8-22)21(27)14(5-12)9-22/h1-3,10-14,17,19,21,26-27H,4-9H2
DMRJKIQ CS C1C2CC3CC(C2)(CC1C3O)C(CC4C5=C(C=CC=C5F)C6=CN=CN46)O
DMRJKIQ IK SPKRAWSVCLOAAN-UHFFFAOYSA-N
DMRJKIQ IU 5-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]adamantan-2-ol
DMECJDM ID DMECJDM
DMECJDM DN Imidazolidine derivative 1
DMECJDM HS Patented
DMECJDM SN PMID27724045-Compound-1
DMECJDM CP GSK
DMECJDM DT Small molecular drug
DMECJDM PC 25097731
DMECJDM MW 413.8
DMECJDM FM C17H15ClF3N5O2
DMECJDM IC InChI=1S/C17H15ClF3N5O2/c1-25-12(9-26(16(25)28)15-22-6-3-7-23-15)14(27)24-8-10-4-2-5-11(13(10)18)17(19,20)21/h2-7,12H,8-9H2,1H3,(H,24,27)
DMECJDM CS CN1C(CN(C1=O)C2=NC=CC=N2)C(=O)NCC3=C(C(=CC=C3)C(F)(F)F)Cl
DMECJDM IK VEJSCJTUSBXATQ-UHFFFAOYSA-N
DMECJDM IU N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-3-methyl-2-oxo-1-pyrimidin-2-ylimidazolidine-4-carboxamide
DMUFSQ2 ID DMUFSQ2
DMUFSQ2 DN Imidazolidine-2,4-dione derivative 1
DMUFSQ2 HS Patented
DMUFSQ2 SN PMID26161824-Compound-175
DMUFSQ2 DT Small molecular drug
DMUFSQ2 PC 58257169
DMUFSQ2 MW 430.6
DMUFSQ2 FM C26H26N2O2S
DMUFSQ2 IC InChI=1S/C26H26N2O2S/c1-26(2)24(29)28(22-14-9-15-23(17-22)31-3)25(30)27(26)18-21-13-8-7-12-20(21)16-19-10-5-4-6-11-19/h4-15,17H,16,18H2,1-3H3
DMUFSQ2 CS CC1(C(=O)N(C(=O)N1CC2=CC=CC=C2CC3=CC=CC=C3)C4=CC(=CC=C4)SC)C
DMUFSQ2 IK WURWRZROHLTLFU-UHFFFAOYSA-N
DMUFSQ2 IU 1-[(2-benzylphenyl)methyl]-5,5-dimethyl-3-(3-methylsulfanylphenyl)imidazolidine-2,4-dione
DMUFSQ2 DE Obesity
DMVMD2O ID DMVMD2O
DMVMD2O DN Imidazolidine-2,4-dione derivative 2
DMVMD2O HS Patented
DMVMD2O SN PMID26161824-Compound-176
DMVMD2O DT Small molecular drug
DMVMD2O DE Obesity
DM847I2 ID DM847I2
DM847I2 DN Imidazolyl urea derivative 1
DM847I2 HS Patented
DM847I2 SN PMID26413912-Compound-56
DM847I2 CP NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros PANDARINATHAN, Lakshimpathi ZVONOK, Nikolai PARKKARI, Teija CHAPMAN, Lauren
DM847I2 DT Small molecular drug
DM847I2 PC 44252357
DM847I2 MW 291.77
DM847I2 FM C15H18ClN3O
DM847I2 IC InChI=1S/C15H18ClN3O/c1-18(10-6-5-9-16)15(20)19-11-14(17-12-19)13-7-3-2-4-8-13/h2-4,7-8,11-12H,5-6,9-10H2,1H3
DM847I2 CS CN(CCCCCl)C(=O)N1C=C(N=C1)C2=CC=CC=C2
DM847I2 IK ULOIHJOBJLPNOI-UHFFFAOYSA-N
DM847I2 IU N-(4-chlorobutyl)-N-methyl-4-phenylimidazole-1-carboxamide
DMEY6L8 ID DMEY6L8
DMEY6L8 DN Imidazopyridazine derivative 1
DMEY6L8 HS Patented
DMEY6L8 SN PMID27774824-Compound-Figure5Example1
DMEY6L8 CP BRISTOL-MYERS SQUIBB COMPANY
DMEY6L8 DT Small molecular drug
DMZORKY ID DMZORKY
DMZORKY DN Imidazopyridazine derivative 2
DMZORKY HS Patented
DMZORKY SN PMID27774824-Compound-Figure5Example75
DMZORKY CP BRISTOL-MYERS SQUIBB COMPANY
DMZORKY DT Small molecular drug
DMXVOP3 ID DMXVOP3
DMXVOP3 DN Imidazopyridazine derivative 3
DMXVOP3 HS Patented
DMXVOP3 SN PMID26936077-Compound-41
DMXVOP3 DT Small molecular drug
DMXVOP3 PC 16000598
DMXVOP3 MW 480.9
DMXVOP3 FM C22H20ClF3N4O3
DMXVOP3 IC InChI=1S/C22H20ClF3N4O3/c1-2-33-21(32)14-7-9-29(10-8-14)20(31)17-12-19-27-16(13-3-5-15(23)6-4-13)11-18(22(24,25)26)30(19)28-17/h3-6,11-12,14H,2,7-10H2,1H3
DMXVOP3 CS CCOC(=O)C1CCN(CC1)C(=O)C2=NN3C(=CC(=NC3=C2)C4=CC=C(C=C4)Cl)C(F)(F)F
DMXVOP3 IK GQAPMAOCKZPCGZ-UHFFFAOYSA-N
DMXVOP3 IU ethyl 1-[5-(4-chlorophenyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]piperidine-4-carboxylate
DMXVOP3 DE Pain; Inflammation
DMIAJMO ID DMIAJMO
DMIAJMO DN Imidazopyridazine derivative 4
DMIAJMO HS Patented
DMIAJMO SN PMID26936077-Compound-42
DMIAJMO CP VERTEX PHARMACEUTICALS INCORPORATED
DMIAJMO DT Small molecular drug
DMIAJMO PC 117977934
DMIAJMO MW 423.5
DMIAJMO FM C23H26FN5O2
DMIAJMO IC InChI=1S/C23H26FN5O2/c1-22(2,3)16-12-17(14-6-8-15(24)9-7-14)27-29-13-18(26-19(16)29)20(30)28-11-10-25-21(31)23(28,4)5/h6-9,12-13H,10-11H2,1-5H3,(H,25,31)
DMIAJMO CS CC1(C(=O)NCCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)F)C(C)(C)C)C
DMIAJMO IK DTASTQAQBOZSRR-UHFFFAOYSA-N
DMIAJMO IU 4-[8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-2-one
DMIAJMO DE Pain; Inflammation
DM9SXYH ID DM9SXYH
DM9SXYH DN Imidazopyridazine derivative 5
DM9SXYH HS Patented
DM9SXYH SN PMID26936077-Compound-43
DM9SXYH CP VERTEX PHARMACEUTICALS INCORPORATED
DM9SXYH DT Small molecular drug
DM9SXYH PC 91667550
DM9SXYH MW 503.6
DM9SXYH FM C27H30FN7O2
DM9SXYH IC InChI=1S/C27H30FN7O2/c1-26(2,3)19-14-21(17-6-8-18(28)9-7-17)32-35-15-22(30-23(19)35)25(37)34-13-12-33(16-27(34,4)5)24(36)20-10-11-29-31-20/h6-11,14-15H,12-13,16H2,1-5H3,(H,29,31)
DM9SXYH CS CC1(CN(CCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)F)C(C)(C)C)C(=O)C5=CC=NN5)C
DM9SXYH IK DUTWPNVXOWFNEY-UHFFFAOYSA-N
DM9SXYH IU [4-[8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-1-yl]-(1H-pyrazol-5-yl)methanone
DM9SXYH DE Pain; Inflammation
DM5F1LR ID DM5F1LR
DM5F1LR DN Imidazopyridazine derivative 6
DM5F1LR HS Patented
DM5F1LR SN PMID26936077-Compound-44
DM5F1LR CP VERTEX PHARMACEUTICALS INCORPORATED
DM5F1LR DT Small molecular drug
DM5F1LR DE Pain; Inflammation
DM5X160 ID DM5X160
DM5X160 DN Imidazopyridazine derivative 7
DM5X160 HS Patented
DM5X160 SN PMID26936077-Compound-45
DM5X160 CP VERTEX PHARMACEUTICALS INCORPORATED
DM5X160 DT Small molecular drug
DM5X160 PC 117977937
DM5X160 MW 473.5
DM5X160 FM C24H26F3N5O2
DM5X160 IC InChI=1S/C24H26F3N5O2/c1-22(2,3)16-12-17(14-6-8-15(9-7-14)24(25,26)27)30-32-13-18(29-19(16)32)20(33)31-11-10-28-21(34)23(31,4)5/h6-9,12-13H,10-11H2,1-5H3,(H,28,34)
DM5X160 CS CC1(C(=O)NCCN1C(=O)C2=CN3C(=N2)C(=CC(=N3)C4=CC=C(C=C4)C(F)(F)F)C(C)(C)C)C
DM5X160 IK GVNHDAXNAQFWSN-UHFFFAOYSA-N
DM5X160 IU 4-[8-tert-butyl-6-[4-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine-2-carbonyl]-3,3-dimethylpiperazin-2-one
DM5X160 DE Pain; Inflammation
DMF7NXJ ID DMF7NXJ
DMF7NXJ DN Imidazopyridazine derivative 8
DMF7NXJ HS Patented
DMF7NXJ SN PMID26936077-Compound-46
DMF7NXJ CP VERTEX PHARMACEUTICALS INCORPORATED
DMF7NXJ DT Small molecular drug
DMF7NXJ PC 117978132
DMF7NXJ MW 518.6
DMF7NXJ FM C27H31FN8O2
DMF7NXJ IC InChI=1S/C27H31FN8O2/c1-16-29-22(32-31-16)25(38)34-11-12-35(27(5,6)15-34)24(37)21-14-36-23(30-21)19(26(2,3)4)13-20(33-36)17-7-9-18(28)10-8-17/h7-10,13-14H,11-12,15H2,1-6H3,(H,29,31,32)
DMF7NXJ CS CC1=NC(=NN1)C(=O)N2CCN(C(C2)(C)C)C(=O)C3=CN4C(=N3)C(=CC(=N4)C5=CC=C(C=C5)F)C(C)(C)C
DMF7NXJ IK DWEGVIUHJKAMGX-UHFFFAOYSA-N
DMF7NXJ IU [8-tert-butyl-6-(4-fluorophenyl)imidazo[1,2-b]pyridazin-2-yl]-[2,2-dimethyl-4-(5-methyl-1H-1,2,4-triazole-3-carbonyl)piperazin-1-yl]methanone
DMF7NXJ DE Pain; Inflammation
DMO41ZB ID DMO41ZB
DMO41ZB DN Imidazopyridine acetamide analog 1
DMO41ZB HS Patented
DMO41ZB SN PMID27607364-Compound-109
DMO41ZB DT Small molecular drug
DMIKMBO ID DMIKMBO
DMIKMBO DN Imidazopyridine acetamide analog 2
DMIKMBO HS Patented
DMIKMBO SN PMID27607364-Compound-110
DMIKMBO DT Small molecular drug
DMZ08LD ID DMZ08LD
DMZ08LD DN Imidazopyridine acetamide analog 3
DMZ08LD HS Patented
DMZ08LD SN PMID27607364-Compound-111
DMZ08LD DT Small molecular drug
DMPHK87 ID DMPHK87
DMPHK87 DN Imidazopyridine acetamide analog 4
DMPHK87 HS Patented
DMPHK87 SN PMID27607364-Compound-112
DMPHK87 DT Small molecular drug
DMMFCRU ID DMMFCRU
DMMFCRU DN Imidazopyridine acetamide analog 5
DMMFCRU HS Patented
DMMFCRU SN PMID27607364-Compound-113
DMMFCRU DT Small molecular drug
DME7M5R ID DME7M5R
DME7M5R DN Imidazopyridine acetamide analog 6
DME7M5R HS Patented
DME7M5R SN PMID27607364-Compound-114
DME7M5R DT Small molecular drug
DMQDA3I ID DMQDA3I
DMQDA3I DN Imidazopyridine acetamide analog 7
DMQDA3I HS Patented
DMQDA3I SN PMID27607364-Compound-115
DMQDA3I DT Small molecular drug
DMTUS0Y ID DMTUS0Y
DMTUS0Y DN Imidazopyridine and triazolopyridine compound 1
DMTUS0Y HS Patented
DMTUS0Y SN PMID28067079-Compound-105
DMTUS0Y CP VANDERBILT UNIVERSITY
DMTUS0Y DT Small molecular drug
DMTUS0Y PC 118103874
DMTUS0Y MW 367.3
DMTUS0Y FM C18H11F2N5O2
DMTUS0Y IC InChI=1S/C18H11F2N5O2/c19-11-1-2-16(23-8-11)24-18(26)15-6-14(10-25-4-3-22-17(15)25)27-13-5-12(20)7-21-9-13/h1-10H,(H,23,24,26)
DMTUS0Y CS C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=C3)OC4=CC(=CN=C4)F
DMTUS0Y IK GVUNIJCXLHRUNZ-UHFFFAOYSA-N
DMTUS0Y IU N-(5-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yl)oxyimidazo[1,2-a]pyridine-8-carboxamide
DMYCLAM ID DMYCLAM
DMYCLAM DN Imidazopyridine and triazolopyridine compound 2
DMYCLAM HS Patented
DMYCLAM SN PMID28067079-Compound-106
DMYCLAM CP VANDERBILT UNIVERSITY
DMYCLAM DT Small molecular drug
DMYCLAM PC 118096899
DMYCLAM MW 368.3
DMYCLAM FM C17H10F2N6O2
DMYCLAM IC InChI=1S/C17H10F2N6O2/c18-10-1-2-15(21-6-10)23-17(26)14-4-13(8-25-9-22-24-16(14)25)27-12-3-11(19)5-20-7-12/h1-9H,(H,21,23,26)
DMYCLAM CS C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NN=C3)OC4=CC(=CN=C4)F
DMYCLAM IK LDLCJJXQJNSUAB-UHFFFAOYSA-N
DMYCLAM IU N-(5-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yl)oxy-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide
DMWU8VM ID DMWU8VM
DMWU8VM DN Imidazopyridine and triazolopyridine compound 3
DMWU8VM HS Patented
DMWU8VM SN PMID28067079-Compound-107
DMWU8VM CP VANDERBILT UNIVERSITY
DMWU8VM DT Small molecular drug
DMWU8VM PC 91799365
DMWU8VM MW 368.3
DMWU8VM FM C17H10F2N6O2
DMWU8VM IC InChI=1S/C17H10F2N6O2/c18-10-1-2-15(21-6-10)24-17(26)14-4-13(8-25-16(14)22-9-23-25)27-12-3-11(19)5-20-7-12/h1-9H,(H,21,24,26)
DMWU8VM CS C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=N3)OC4=CC(=CN=C4)F
DMWU8VM IK UQYDLTVGUNGXDW-UHFFFAOYSA-N
DMWU8VM IU N-(5-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yl)oxy-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide
DMI1OWK ID DMI1OWK
DMI1OWK DN Imidazopyridine and triazolopyridine compound 4
DMI1OWK HS Patented
DMI1OWK SN PMID28067079-Compound-108
DMI1OWK CP VANDERBILT UNIVERSITY
DMI1OWK DT Small molecular drug
DMI1OWK PC 118096900
DMI1OWK MW 351.29
DMI1OWK FM C16H10FN7O2
DMI1OWK IC InChI=1S/C16H10FN7O2/c17-10-1-2-14(20-4-10)23-16(25)13-3-11(7-24-15(13)21-9-22-24)26-12-5-18-8-19-6-12/h1-9H,(H,20,23,25)
DMI1OWK CS C1=CC(=NC=C1F)NC(=O)C2=CC(=CN3C2=NC=N3)OC4=CN=CN=C4
DMI1OWK IK CBMXXEDRQZKTGZ-UHFFFAOYSA-N
DMI1OWK IU N-(5-fluoropyridin-2-yl)-6-pyrimidin-5-yloxy-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide
DM8EB57 ID DM8EB57
DM8EB57 DN Imidazopyridine derivative 1
DM8EB57 HS Patented
DM8EB57 SN PMID27607364-Compound-107
DM8EB57 CP AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION THE UNIVERSITY OF SYDNE
DM8EB57 DT Small molecular drug
DM9FRV7 ID DM9FRV7
DM9FRV7 DN Imidazopyridine derivative 2
DM9FRV7 HS Patented
DM9FRV7 SN PMID27607364-Compound-108
DM9FRV7 CP AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION THE UNIVERSITY OF SYDNEY
DM9FRV7 DT Small molecular drug
DMJCSL3 ID DMJCSL3
DMJCSL3 DN Imidazopyridine derivative 3
DMJCSL3 HS Patented
DMJCSL3 SN PMID27774822-Compound-Figure7Example2
DMJCSL3 CP F. HOFFMANN-LA ROCHE AG LAI, Yingjie LIANG, Jun MAGNUSON, Steven, R. ROBARGE, Kirk, D. TSUI, Vickie, Hsaio-Wei ZHANG, Birong
DMJCSL3 DT Small molecular drug
DMP2AXV ID DMP2AXV
DMP2AXV DN Imidazopyridine derivative 4
DMP2AXV HS Patented
DMP2AXV SN PMID27774824-Compound-Figure12Example14
DMP2AXV CP HANMI PHARM. CO., LTD
DMP2AXV DT Small molecular drug
DMUKBGD ID DMUKBGD
DMUKBGD DN Imidazopyridine derivative 5
DMUKBGD HS Patented
DMUKBGD SN PMID28627961-Compound-14
DMUKBGD CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund
DMUKBGD DT Small molecular drug
DMUKBGD PC 45137506
DMUKBGD MW 481.3
DMUKBGD FM C20H13Cl2F3N6O
DMUKBGD IC InChI=1S/C20H13Cl2F3N6O/c1-31-15-9-27-14(18(32)29-16-7-10(5-6-26-16)20(23,24)25)8-13(15)28-19(31)30-17-11(21)3-2-4-12(17)22/h2-9H,1H3,(H,28,30)(H,26,29,32)
DMUKBGD CS CN1C2=CN=C(C=C2N=C1NC3=C(C=CC=C3Cl)Cl)C(=O)NC4=NC=CC(=C4)C(F)(F)F
DMUKBGD IK STCXSHUPLPUMJZ-UHFFFAOYSA-N
DMUKBGD IU 2-(2,6-dichloroanilino)-3-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]imidazo[4,5-c]pyridine-6-carboxamide
DMA0V4F ID DMA0V4F
DMA0V4F DN Imidazopyridine derivative 6
DMA0V4F HS Patented
DMA0V4F SN PMID28627961-Compound-15
DMA0V4F CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFAU, Roland ARNDT, Kirsten DOODS, Henri HAUEL, Norbert KLINDER, Klaus KUELZER, Raimund
DMA0V4F DT Small molecular drug
DMA0V4F PC 45138740
DMA0V4F MW 570.3
DMA0V4F FM C23H17BrF5N5O2
DMA0V4F IC InChI=1S/C23H17BrF5N5O2/c1-34-19-17(32-22(34)31-16-5-3-2-4-15(16)23(27,28)29)10-14(21(33-19)36-11-18(25)26)20(35)30-13-8-6-12(24)7-9-13/h2-10,18H,11H2,1H3,(H,30,35)(H,31,32)
DMA0V4F CS CN1C2=C(C=C(C(=N2)OCC(F)F)C(=O)NC3=CC=C(C=C3)Br)N=C1NC4=CC=CC=C4C(F)(F)F
DMA0V4F IK KPWHFPJALLFSPY-UHFFFAOYSA-N
DMA0V4F IU N-(4-bromophenyl)-5-(2,2-difluoroethoxy)-3-methyl-2-[2-(trifluoromethyl)anilino]imidazo[4,5-b]pyridine-6-carboxamide
DMI3XPJ ID DMI3XPJ
DMI3XPJ DN Imidazopyridine derivative 7
DMI3XPJ HS Patented
DMI3XPJ SN PMID28627961-Compound-16
DMI3XPJ CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRIEPKE, Henning DOODS, Henri KUELZER, Raimund PFAU, Roland STENKAMP, Dirk PELCMAN, Benjamin ROENN, Robert LUBRIKS, Dimitrijs SUNA, Edgars
DMI3XPJ DT Small molecular drug
DMWN17V ID DMWN17V
DMWN17V DN Imidazopyrimidinone derivative 1
DMWN17V HS Patented
DMWN17V SN PMID28447479-Compound-5
DMWN17V DT Small molecular drug
DMWN17V PC 118631422
DMWN17V MW 486
DMWN17V FM C24H28ClN5O4
DMWN17V IC InChI=1S/C24H28ClN5O4/c1-2-3-4-11-29-20(28-12-5-6-19(28)23(34)26-14-22(32)33)13-21(31)30-15-18(27-24(29)30)16-7-9-17(25)10-8-16/h7-10,13,15,19H,2-6,11-12,14H2,1H3,(H,26,34)(H,32,33)/t19-/m0/s1
DMWN17V CS CCCCCN1C(=CC(=O)N2C1=NC(=C2)C3=CC=C(C=C3)Cl)N4CCC[C@H]4C(=O)NCC(=O)O
DMWN17V IK VHDLUVVGLIPRGY-IBGZPJMESA-N
DMWN17V IU 2-[[(2S)-1-[2-(4-chlorophenyl)-5-oxo-8-pentylimidazo[1,2-a]pyrimidin-7-yl]pyrrolidine-2-carbonyl]amino]acetic acid
DMX34PU ID DMX34PU
DMX34PU DN Imidazotriazinone derivative 1
DMX34PU HS Patented
DMX34PU SN PMID27321640-Compound-12
DMX34PU CP BAYER AG [DE]
DMX34PU DT Small molecular drug
DMBURAZ ID DMBURAZ
DMBURAZ DN IncarviatoneA
DMBURAZ HS Patented
DMBURAZ CP Nanjing Zhengliang Med. Tech. CO
DMA6BCH ID DMA6BCH
DMA6BCH DN Indandione derivative 1
DMA6BCH HS Patented
DMA6BCH SN PMID27788040-Compound-3a
DMA6BCH CP ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DMA6BCH DT Small molecular drug
DMA6BCH PC 8088007
DMA6BCH MW 396.5
DMA6BCH FM C26H24N2O2
DMA6BCH IC InChI=1S/C26H24N2O2/c29-24-22-13-7-8-14-23(22)25(30)26(24,21-11-5-2-6-12-21)28-17-15-27(16-18-28)19-20-9-3-1-4-10-20/h1-14H,15-19H2
DMA6BCH CS C1CN(CCN1CC2=CC=CC=C2)C3(C(=O)C4=CC=CC=C4C3=O)C5=CC=CC=C5
DMA6BCH IK NYQQLNFEZNJIIX-UHFFFAOYSA-N
DMA6BCH IU 2-(4-benzylpiperazin-1-yl)-2-phenylindene-1,3-dione
DMVR04K ID DMVR04K
DMVR04K DN Indandione derivative 2
DMVR04K HS Patented
DMVR04K SN PMID27788040-Compound-3b
DMVR04K CP ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DMVR04K DT Small molecular drug
DMVR04K PC 89560333
DMVR04K MW 410.5
DMVR04K FM C27H26N2O2
DMVR04K IC InChI=1S/C27H26N2O2/c1-20-9-5-6-10-21(20)19-28-15-17-29(18-16-28)27(22-11-3-2-4-12-22)25(30)23-13-7-8-14-24(23)26(27)31/h2-14H,15-19H2,1H3
DMVR04K CS CC1=CC=CC=C1CN2CCN(CC2)C3(C(=O)C4=CC=CC=C4C3=O)C5=CC=CC=C5
DMVR04K IK SOPZMNPHLBGVQQ-UHFFFAOYSA-N
DMVR04K IU 2-[4-[(2-methylphenyl)methyl]piperazin-1-yl]-2-phenylindene-1,3-dione
DM0TURE ID DM0TURE
DM0TURE DN Indandione derivative 3
DM0TURE HS Patented
DM0TURE SN PMID27788040-Compound-3c
DM0TURE CP ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DM0TURE DT Small molecular drug
DM0TURE PC 89559486
DM0TURE MW 426.5
DM0TURE FM C27H26N2O3
DM0TURE IC InChI=1S/C27H26N2O3/c1-32-24-14-8-5-9-20(24)19-28-15-17-29(18-16-28)27(21-10-3-2-4-11-21)25(30)22-12-6-7-13-23(22)26(27)31/h2-14H,15-19H2,1H3
DM0TURE CS COC1=CC=CC=C1CN2CCN(CC2)C3(C(=O)C4=CC=CC=C4C3=O)C5=CC=CC=C5
DM0TURE IK DLIPFFRYKOCUMK-UHFFFAOYSA-N
DM0TURE IU 2-[4-[(2-methoxyphenyl)methyl]piperazin-1-yl]-2-phenylindene-1,3-dione
DMQPTEJ ID DMQPTEJ
DMQPTEJ DN Indanone and indandione derivative 1
DMQPTEJ HS Patented
DMQPTEJ SN PMID27788040-Compound-3
DMQPTEJ CP ACTELION PHARMACEUTICALS LTD FRETZ, Heinz GATFIELD, John ISLER, Markus KIMMERLIN, Thierry KOBERSTEIN, Ralf LYOTHIER, Isabelle MONNIER, Lucile POTHIER, Julien VALDENAIRE, Anja
DMQPTEJ DT Small molecular drug
DMKUT6S ID DMKUT6S
DMKUT6S DN Indazole amide derivative 1
DMKUT6S HS Patented
DMKUT6S SN PMID27310003-Compound-13
DMKUT6S CP BAYER PHARMA AKTIENGESELLSCHAFT
DMKUT6S DT Small molecular drug
DMRPT5O ID DMRPT5O
DMRPT5O DN Indazole amide derivative 2
DMRPT5O HS Patented
DMRPT5O SN PMID27310003-Compound-14
DMRPT5O CP BAYER PHARMA AKTIENGESELLSCHAFT
DMRPT5O DT Small molecular drug
DME8JTW ID DME8JTW
DME8JTW DN Indazole derivative 1
DME8JTW HS Patented
DME8JTW SN PMID25684022-Compound-WO2003064397
DME8JTW CP VERTEX PHARMACEUTICALS INCORPORATED BINCH, Hayley BRENCHLEY, Guy GOLEC, Julian, M., C. KNEGTEL, Ronald MORTIMORE, Michael PATEL, Sanjay RUTHERFORD, Alistair
DME8JTW DT Small molecular drug
DME8JTW DE Solid tumour/cancer; Metastatic cancer
DMV7AX9 ID DMV7AX9
DMV7AX9 DN Indazole derivative 2
DMV7AX9 HS Patented
DMV7AX9 SN PMID29473428-Compound-7
DMV7AX9 CP IOMET PHARMA LTD
DMV7AX9 DT Small molecular drug
DMV7AX9 PC 121326386
DMV7AX9 MW 342.8
DMV7AX9 FM C14H19ClN4O2S
DMV7AX9 IC InChI=1S/C14H19ClN4O2S/c1-14(2)9-18(4-5-19(14)22(3,20)21)13-7-10(15)6-12-11(13)8-16-17-12/h6-8H,4-5,9H2,1-3H3,(H,16,17)
DMV7AX9 CS CC1(CN(CCN1S(=O)(=O)C)C2=CC(=CC3=C2C=NN3)Cl)C
DMV7AX9 IK RJWPSUXKQOQTSP-UHFFFAOYSA-N
DMV7AX9 IU 6-chloro-4-(3,3-dimethyl-4-methylsulfonylpiperazin-1-yl)-1H-indazole
DMVUWLK ID DMVUWLK
DMVUWLK DN Indazole derivative 3
DMVUWLK HS Patented
DMVUWLK SN PMID29473428-Compound-8
DMVUWLK CP IOMET PHARMA LTD
DMVUWLK DT Small molecular drug
DMVUWLK PC 121326772
DMVUWLK MW 347.8
DMVUWLK FM C16H18ClN5O2
DMVUWLK IC InChI=1S/C16H18ClN5O2/c1-15(2)8-22(4-3-16(15)13(23)19-14(24)20-16)12-6-9(17)5-11-10(12)7-18-21-11/h5-7H,3-4,8H2,1-2H3,(H,18,21)(H2,19,20,23,24)
DMVUWLK CS CC1(CN(CCC12C(=O)NC(=O)N2)C3=CC(=CC4=C3C=NN4)Cl)C
DMVUWLK IK JZDRNRKIZBGYLY-UHFFFAOYSA-N
DMVUWLK IU 8-(6-chloro-1H-indazol-4-yl)-6,6-dimethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
DMJ2CRO ID DMJ2CRO
DMJ2CRO DN Indazole derivative 4
DMJ2CRO HS Patented
DMJ2CRO SN PMID29473428-Compound-9
DMJ2CRO DT Small molecular drug
DMM1I8R ID DMM1I8R
DMM1I8R DN Indazole derivative 5
DMM1I8R HS Patented
DMM1I8R SN PMID25656651-Compound-35
DMM1I8R CP PFIZER INC
DMM1I8R DT Small molecular drug
DMM1I8R PC 6450551
DMM1I8R MW 386.5
DMM1I8R FM C22H18N4OS
DMM1I8R IC InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
DMM1I8R CS CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
DMM1I8R IK RITAVMQDGBJQJZ-FMIVXFBMSA-N
DMM1I8R IU N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
DMM1I8R CA CAS 319460-85-0
DMM1I8R CB CHEBI:66910
DMGO1CB ID DMGO1CB
DMGO1CB DN Indazole derivative 6
DMGO1CB HS Patented
DMGO1CB SN PMID27828716-Compound-12
DMGO1CB DT Small molecular drug
DMGO1CB PC 71680628
DMGO1CB MW 428.5
DMGO1CB FM C23H26F2N4O2
DMGO1CB IC InChI=1S/C23H26F2N4O2/c1-31-12-11-29-9-7-15(8-10-29)14-26-23(30)22-18-13-16(5-6-20(18)27-28-22)17-3-2-4-19(24)21(17)25/h2-6,13,15H,7-12,14H2,1H3,(H,26,30)(H,27,28)
DMGO1CB CS COCCN1CCC(CC1)CNC(=O)C2=NNC3=C2C=C(C=C3)C4=C(C(=CC=C4)F)F
DMGO1CB IK QCLXNOBXQUWUEW-UHFFFAOYSA-N
DMGO1CB IU 5-(2,3-difluorophenyl)-N-[[1-(2-methoxyethyl)piperidin-4-yl]methyl]-1H-indazole-3-carboxamide
DMHJDU6 ID DMHJDU6
DMHJDU6 DN Indazoletriazolephenyl derivative 1
DMHJDU6 HS Patented
DMHJDU6 SN PMID27310003-Compound-34
DMHJDU6 CP MERCK SERONO S.A. JORAND-LEBRUN, Catherine CROSIGNANI, Stefano DORBAIS, Jerome GRIPPI-VALLOTTON, Tania PRETRE, Adeline
DMHJDU6 DT Small molecular drug
DMWZLK6 ID DMWZLK6
DMWZLK6 DN Indazoletriazolephenyl derivative 2
DMWZLK6 HS Patented
DMWZLK6 SN PMID27310003-Compound-35
DMWZLK6 CP MERCK SERONO S.A. JORAND-LEBRUN, Catherine CROSIGNANI, Stefano DORBAIS, Jerome GRIPPI-VALLOTTON, Tania PRETRE, Adeline
DMWZLK6 DT Small molecular drug
DMR2GW1 ID DMR2GW1
DMR2GW1 DN Indazolyl-thiadiazolamine derivative 1
DMR2GW1 HS Patented
DMR2GW1 SN PMID28048944-Compound-8
DMR2GW1 CP LYCERA CORPORATION
DMR2GW1 DT Small molecular drug
DMR2GW1 PC 122507561
DMR2GW1 MW 446.5
DMR2GW1 FM C21H18N8O2S
DMR2GW1 IC InChI=1S/C21H18N8O2S/c30-7-6-29-12-15(11-23-29)19(31)24-16-3-1-2-13(8-16)20-27-28-21(32-20)25-17-4-5-18-14(9-17)10-22-26-18/h1-5,8-12,30H,6-7H2,(H,22,26)(H,24,31)(H,25,28)
DMR2GW1 CS C1=CC(=CC(=C1)NC(=O)C2=CN(N=C2)CCO)C3=NN=C(S3)NC4=CC5=C(C=C4)NN=C5
DMR2GW1 IK QFQWUHMXGFJZJO-UHFFFAOYSA-N
DMR2GW1 IU 1-(2-hydroxyethyl)-N-[3-[5-(1H-indazol-5-ylamino)-1,3,4-thiadiazol-2-yl]phenyl]pyrazole-4-carboxamide
DMB8673 ID DMB8673
DMB8673 DN Indirubin derivative 1
DMB8673 HS Patented
DMB8673 SN PMID26394986-Compound-58
DMB8673 CP City of Hope, Durate, CA
DMB8673 DT Small molecular drug
DMLX183 ID DMLX183
DMLX183 DN Indirubin derivative 2
DMLX183 HS Patented
DMLX183 SN PMID27828716-Compound-BIO
DMLX183 CP KATHOLIEKE UNIVERSITEIT LEUVEN VRIJE UNIVERSITEIT BRUSSEL UNIVERSITY OF STRATHCLYDE SALAMA NEUROSCIENCE CENTRCELLARTIS AB [SESTEM CELLS FOR SAFER MEDICINES LIMITED BONE, Heather Karyn TOSH, David WELHAM, Melanie Joann
DMLX183 DT Small molecular drug
DM5F8J1 ID DM5F8J1
DM5F8J1 DN Indol-5-ol derivative 1
DM5F8J1 HS Patented
DM5F8J1 SN PMID25656651-Compound-41
DM5F8J1 CP NANT HOLDINGS IP, LLC
DM5F8J1 DT Small molecular drug
DM5F8J1 PC 74221651
DM5F8J1 MW 480.5
DM5F8J1 FM C24H26F2N8O
DM5F8J1 IC InChI=1S/C24H26F2N8O/c1-13-9-15-22(26)18(10-16(25)23(15)27-13)35-24-29-19(28-20-11-17(31-32-20)14-3-4-14)12-21(30-24)34-7-5-33(2)6-8-34/h9-12,14,27H,3-8H2,1-2H3,(H2,28,29,30,31,32)
DM5F8J1 CS CC1=CC2=C(C(=CC(=C2N1)F)OC3=NC(=CC(=N3)N4CCN(CC4)C)NC5=NNC(=C5)C6CC6)F
DM5F8J1 IK UUZGSTUXCIFCOJ-UHFFFAOYSA-N
DM5F8J1 IU N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[(4,7-difluoro-2-methyl-1H-indol-5-yl)oxy]-6-(4-methylpiperazin-1-yl)pyrimidin-4-amine
DMS0169 ID DMS0169
DMS0169 DN Indole and benzimidazole derivative 1
DMS0169 HS Patented
DMS0169 SN PMID26560362-Compound-15
DMS0169 DT Small molecular drug
DMS0169 PC 10297819
DMS0169 MW 453.5
DMS0169 FM C23H17F2N3O3S
DMS0169 IC InChI=1S/C23H17F2N3O3S/c1-31-21-6-5-12(18-10-14-8-16(24)17(25)11-19(14)27-18)9-20(21)28-23(32)26-15-4-2-3-13(7-15)22(29)30/h2-11,27H,1H3,(H,29,30)(H2,26,28,32)
DMS0169 CS COC1=C(C=C(C=C1)C2=CC3=CC(=C(C=C3N2)F)F)NC(=S)NC4=CC=CC(=C4)C(=O)O
DMS0169 IK WDBLIHVXAGLYCZ-UHFFFAOYSA-N
DMS0169 IU 3-[[5-(5,6-difluoro-1H-indol-2-yl)-2-methoxyphenyl]carbamothioylamino]benzoic acid
DMLHGC9 ID DMLHGC9
DMLHGC9 DN Indole carboxamide derivative 1
DMLHGC9 HS Patented
DMLHGC9 SN PMID27724045-Compound-21
DMLHGC9 CP ACTELION PHARMACEUTICALS LTD
DMLHGC9 DT Small molecular drug
DMIGS81 ID DMIGS81
DMIGS81 DN Indole-based analog 1
DMIGS81 HS Patented
DMIGS81 SN PMID27744724-Compound-15
DMIGS81 CP VANDERBILT UNIVERSITY
DMIGS81 DT Small molecular drug
DMAM6YC ID DMAM6YC
DMAM6YC DN Indole-based analog 10
DMAM6YC HS Patented
DMAM6YC SN PMID27599163-Compound-(S)-70
DMAM6YC CP GE HEALTHCARE LIMITED
DMAM6YC DT Small molecular drug
DMVRX7S ID DMVRX7S
DMVRX7S DN Indole-based analog 11
DMVRX7S HS Patented
DMVRX7S SN PMID26161698-Compound-16
DMVRX7S CP GILEAD SCIENCES, INC. GRAUPE, Michael VENKATARAMANI, Chandrasekar
DMVRX7S DT Small molecular drug
DM1CNRH ID DM1CNRH
DM1CNRH DN Indole-based analog 12
DM1CNRH HS Patented
DM1CNRH SN PMID26161698-Compound-19
DM1CNRH DT Small molecular drug
DM1CNRH PC 25164141
DM1CNRH MW 352.4
DM1CNRH FM C24H20N2O
DM1CNRH IC InChI=1S/C24H20N2O/c27-24(21-12-5-4-10-18(21)17-8-2-1-3-9-17)26-15-14-20-19-11-6-7-13-22(19)25-23(20)16-26/h1-13,25H,14-16H2
DM1CNRH CS C1CN(CC2=C1C3=CC=CC=C3N2)C(=O)C4=CC=CC=C4C5=CC=CC=C5
DM1CNRH IK UCWAWBWZKYMCRY-UHFFFAOYSA-N
DM1CNRH IU (2-phenylphenyl)-(1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)methanone
DMV7DFM ID DMV7DFM
DMV7DFM DN Indole-based analog 13
DMV7DFM HS Patented
DMV7DFM SN PMID26161698-Compound-20
DMV7DFM DT Small molecular drug
DMV7DFM PC 73293
DMV7DFM MW 271.3
DMV7DFM FM C18H11N2O+
DMV7DFM IC InChI=1S/C18H10N2O/c21-18-13-6-2-4-8-15(13)20-10-9-12-11-5-1-3-7-14(11)19-16(12)17(18)20/h1-10H/p+1
DMV7DFM CS C1=CC=C2C(=C1)C3=C(N2)C4=[N+](C=C3)C5=CC=CC=C5C4=O
DMV7DFM IK WYQIPCUPNMRAKP-UHFFFAOYSA-O
DMV7DFM IU 3-aza-13-azoniapentacyclo[11.7.0.02,10.04,9.014,19]icosa-1(13),2(10),4,6,8,11,14,16,18-nonaen-20-one
DMV7DFM CB CHEBI:93765
DMQURWZ ID DMQURWZ
DMQURWZ DN Indole-based analog 14
DMQURWZ HS Patented
DMQURWZ SN PMID27410995-Compound-Figure3a
DMQURWZ DT Small molecular drug
DMQURWZ PC 53246690
DMQURWZ MW 350.4
DMQURWZ FM C19H18N4O3
DMQURWZ IC InChI=1S/C19H18N4O3/c1-26-17-11-14(5-7-20-17)22-18(24)13-4-3-12-9-16-19(25)21-6-2-8-23(16)15(12)10-13/h3-5,7,9-11H,2,6,8H2,1H3,(H,21,25)(H,20,22,24)
DMQURWZ CS COC1=NC=CC(=C1)NC(=O)C2=CC3=C(C=C2)C=C4N3CCCNC4=O
DMQURWZ IK IGJVUIUYHUKAST-UHFFFAOYSA-N
DMQURWZ IU N-(2-methoxypyridin-4-yl)-1-oxo-2,3,4,5-tetrahydro-[1,4]diazepino[1,2-a]indole-8-carboxamide
DM0NEVC ID DM0NEVC
DM0NEVC DN Indole-based analog 2
DM0NEVC HS Patented
DM0NEVC SN PMID27744724-Compound-16
DM0NEVC CP VANDERBILT UNIVERSITY
DM0NEVC DT Small molecular drug
DMTEYQJ ID DMTEYQJ
DMTEYQJ DN Indole-based analog 3
DMTEYQJ HS Patented
DMTEYQJ SN PMID27744724-Compound-17
DMTEYQJ CP VANDERBILT UNIVERSITY
DMTEYQJ DT Small molecular drug
DM5JUR2 ID DM5JUR2
DM5JUR2 DN Indole-based analog 5
DM5JUR2 HS Patented
DM5JUR2 SN PMID27599163-Compound-(R)-56
DM5JUR2 CP GE HEALTHCARE LIMITED
DM5JUR2 DT Small molecular drug
DMFI2H6 ID DMFI2H6
DMFI2H6 DN Indole-based analog 9
DMFI2H6 HS Patented
DMFI2H6 SN PMID27599163-Compound-(S)-66
DMFI2H6 CP GE HEALTHCARE LIMITED
DMFI2H6 DT Small molecular drug
DMJ41UI ID DMJ41UI
DMJ41UI DN Indoline derivative 1
DMJ41UI HS Patented
DMJ41UI SN PMID29757691-Compound-1
DMJ41UI DT Small molecular drug
DMJ41UI PC 46865499
DMJ41UI MW 408.5
DMJ41UI FM C25H32N2O3
DMJ41UI IC InChI=1S/C25H32N2O3/c1-25(2)18-27(17-19-7-5-4-6-8-19)23-10-9-21(15-22(23)25)30-24(28)26(3)16-20-11-13-29-14-12-20/h4-10,15,20H,11-14,16-18H2,1-3H3
DMJ41UI CS CC1(CN(C2=C1C=C(C=C2)OC(=O)N(C)CC3CCOCC3)CC4=CC=CC=C4)C
DMJ41UI IK LZXDNQGOGJJABM-UHFFFAOYSA-N
DMJ41UI IU (1-benzyl-3,3-dimethyl-2H-indol-5-yl) N-methyl-N-(oxan-4-ylmethyl)carbamate
DMTPGRO ID DMTPGRO
DMTPGRO DN Indoline derivative 10
DMTPGRO HS Patented
DMTPGRO SN PMID27646439-Compound-18
DMTPGRO CP JANSSEN PHARMACEUTICA NV
DMTPGRO DT Small molecular drug
DMTPGRO PC 86281829
DMTPGRO MW 493.6
DMTPGRO FM C29H27N5O3
DMTPGRO IC InChI=1S/C29H27N5O3/c1-17-21(20-6-4-5-7-23(20)32-17)14-28(35)34-11-10-18-12-19(8-9-25(18)34)33-29-22-13-26(36-2)27(37-3)15-24(22)30-16-31-29/h4-9,12-13,15-16,32H,10-11,14H2,1-3H3,(H,30,31,33)
DMTPGRO CS CC1=C(C2=CC=CC=C2N1)CC(=O)N3CCC4=C3C=CC(=C4)NC5=NC=NC6=CC(=C(C=C65)OC)OC
DMTPGRO IK XPDZQQQJQXPBBO-UHFFFAOYSA-N
DMTPGRO IU 1-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2,3-dihydroindol-1-yl]-2-(2-methyl-1H-indol-3-yl)ethanone
DM6JR3X ID DM6JR3X
DM6JR3X DN Indoline derivative 11
DM6JR3X HS Patented
DM6JR3X SN PMID27646439-Compound-19
DM6JR3X CP JANSSEN PHARMACEUTICA NV
DM6JR3X DT Small molecular drug
DM6JR3X PC 117636505
DM6JR3X MW 523.4
DM6JR3X FM C24H23BrN6O3
DM6JR3X IC InChI=1S/C24H23BrN6O3/c1-30-20(17(25)12-28-30)11-23(32)31-7-6-14-8-15(4-5-19(14)31)29-24-16-9-21(33-2)22(34-3)10-18(16)26-13-27-24/h4-5,8-10,12-13H,6-7,11H2,1-3H3,(H,26,27,29)
DM6JR3X CS CN1C(=C(C=N1)Br)CC(=O)N2CCC3=C2C=CC(=C3)NC4=NC=NC5=CC(=C(C=C54)OC)OC
DM6JR3X IK KVVYJCRBQJOKHQ-UHFFFAOYSA-N
DM6JR3X IU 2-(4-bromo-2-methylpyrazol-3-yl)-1-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]-2,3-dihydroindol-1-yl]ethanone
DMJURBM ID DMJURBM
DMJURBM DN Indoline derivative 12
DMJURBM HS Patented
DMJURBM SN PMID28621580-Compound-WO2012088506c22
DMJURBM CP NEKTAR THERAPEUTICS RIGGS-SAUTHIER, Jennifer ALLUMS-DONALD, Stephanie CULBERTSON, Sean, M
DMJURBM DT Small molecular drug
DM982GD ID DM982GD
DM982GD DN Indoline derivative 13
DM982GD HS Patented
DM982GD SN PMID28621580-Compound-WO2012088506c23
DM982GD CP NEKTAR THERAPEUTICS RIGGS-SAUTHIER, Jennifer ALLUMS-DONALD, Stephanie CULBERTSON, Sean, M
DM982GD DT Small molecular drug
DM8DHRN ID DM8DHRN
DM8DHRN DN Indoline derivative 14
DM8DHRN HS Patented
DM8DHRN SN PMID28621580-Compound-WO2012139019c24
DM8DHRN CP BETA PHARMA, INC. ZHANG, Don XIE, Guojian
DM8DHRN DT Small molecular drug
DMRFEH4 ID DMRFEH4
DMRFEH4 DN Indoline derivative 15
DMRFEH4 HS Patented
DMRFEH4 SN PMID28621580-Compound-WO2012139019c25
DMRFEH4 CP BETA PHARMA, INC. ZHANG, Don XIE, Guojian
DMRFEH4 DT Small molecular drug
DM9AGBT ID DM9AGBT
DM9AGBT DN Indoline derivative 16
DM9AGBT HS Patented
DM9AGBT SN PMID28621580-Compound-WO2013037293c26
DM9AGBT CP HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD
DM9AGBT DT Small molecular drug
DMXSFJ8 ID DMXSFJ8
DMXSFJ8 DN Indoline derivative 17
DMXSFJ8 HS Patented
DMXSFJ8 SN PMID28621580-Compound-WO2014086102c28
DMXSFJ8 CP KBP BIOSCIENCES CO., LTD
DMXSFJ8 DT Small molecular drug
DMX640D ID DMX640D
DMX640D DN Indoline derivative 18
DMX640D HS Patented
DMX640D SN PMID28621580-Compound-WO2014086102c29
DMX640D CP KBP BIOSCIENCES CO., LTD
DMX640D DT Small molecular drug
DMOHITL ID DMOHITL
DMOHITL DN Indoline derivative 19
DMOHITL HS Patented
DMOHITL SN PMID28621580-Compound-WO2014102377c27
DMOHITL CP ORIBASE PHARMA
DMOHITL DT Small molecular drug
DMASXR5 ID DMASXR5
DMASXR5 DN Indoline derivative 2
DMASXR5 HS Patented
DMASXR5 SN PMID27646439-Compound-1
DMASXR5 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITEGLAXOSMITHKLINE LLC AXTEN, Jeffrey, Michael GRANT, Seth, Wilson HEERDING, Dirk, A. MEDINA, Jesus, Raul ROMERIL, Stuart, Paul TANG, Jun
DMASXR5 DT Small molecular drug
DM4JNLQ ID DM4JNLQ
DM4JNLQ DN Indoline derivative 20
DM4JNLQ HS Patented
DM4JNLQ SN PMID28621580-Compound-WO2015117551c24
DM4JNLQ CP SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD
DM4JNLQ DT Small molecular drug
DM3YPX1 ID DM3YPX1
DM3YPX1 DN Indoline derivative 21
DM3YPX1 HS Patented
DM3YPX1 SN PMID28621580-Compound-WO2015117551c25
DM3YPX1 CP SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD
DM3YPX1 DT Small molecular drug
DM20YBJ ID DM20YBJ
DM20YBJ DN Indoline derivative 3
DM20YBJ HS Patented
DM20YBJ SN PMID27646439-Compound-2
DM20YBJ CP GLAXOSMITHKLINE LLC AXTEN, Jeffrey, Michael GRANT, Seth, Wilson HEERDING, Dirk, A. MEDINA, Jesus, Raul ROMERIL, Stuart, Paul TANG, Jun
DM20YBJ DT Small molecular drug
DMU5KWC ID DMU5KWC
DMU5KWC DN Indoline derivative 6
DMU5KWC HS Patented
DMU5KWC SN PMID27646439-Compound-5
DMU5KWC CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMU5KWC DT Small molecular drug
DMXS46Y ID DMXS46Y
DMXS46Y DN Indoline derivative 7
DMXS46Y HS Patented
DMXS46Y SN PMID27646439-Compound-15
DMXS46Y CP JANSSEN PHARMACEUTICA NV
DMXS46Y DT Small molecular drug
DMS8KMB ID DMS8KMB
DMS8KMB DN Indoline derivative 8
DMS8KMB HS Patented
DMS8KMB SN PMID27646439-Compound-16
DMS8KMB CP JANSSEN PHARMACEUTICA NV
DMS8KMB DT Small molecular drug
DMS8KMB PC 85468833
DMS8KMB MW 494.5
DMS8KMB FM C26H21F3N4O3
DMS8KMB IC InChI=1S/C26H21F3N4O3/c1-35-22-11-17-20(12-23(22)36-2)30-13-31-26(17)32-19-5-6-21-16(25(19)29)7-8-33(21)24(34)10-14-9-15(27)3-4-18(14)28/h3-6,9,11-13H,7-8,10H2,1-2H3,(H,30,31,32)
DMS8KMB CS COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C4=C(C=C3)N(CC4)C(=O)CC5=C(C=CC(=C5)F)F)F)OC
DMS8KMB IK BJJFQLVMCHTWRM-UHFFFAOYSA-N
DMS8KMB IU 2-(2,5-difluorophenyl)-1-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]-4-fluoro-2,3-dihydroindol-1-yl]ethanone
DMCORT3 ID DMCORT3
DMCORT3 DN Indoline derivative 9
DMCORT3 HS Patented
DMCORT3 SN PMID27646439-Compound-17
DMCORT3 CP JANSSEN PHARMACEUTICA NV
DMCORT3 DT Small molecular drug
DMTC129 ID DMTC129
DMTC129 DN Indolinone derivative 1
DMTC129 HS Patented
DMTC129 SN PMID25684022-Compound-US200607105563
DMTC129 CP Schering AG
DMTC129 DT Small molecular drug
DMTC129 PC 11161844
DMTC129 MW 282.3
DMTC129 FM C15H14N4O2
DMTC129 IC InChI=1S/C15H14N4O2/c1-8(11-3-2-6-17-11)13-10-7-9(18-15(16)21)4-5-12(10)19-14(13)20/h2-7,17H,1H3,(H,19,20)(H3,16,18,21)/b13-8-
DMTC129 CS C/C(=C/1\\C2=C(C=CC(=C2)NC(=O)N)NC1=O)/C3=CC=CN3
DMTC129 IK DFURSNCTQGJRRX-JYRVWZFOSA-N
DMTC129 IU [(3Z)-2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-1H-indol-5-yl]urea
DMTC129 CA CAS 946843-63-6
DMTC129 DE Solid tumour/cancer; Metastatic cancer
DM4GZBI ID DM4GZBI
DM4GZBI DN Indolizine derivative 1
DM4GZBI HS Patented
DM4GZBI SN PMID27718763-Compound-5
DM4GZBI DT Small molecular drug
DM4GZBI PC 71679723
DM4GZBI MW 407.4
DM4GZBI FM C24H16F3NO2
DM4GZBI IC InChI=1S/C24H16F3NO2/c1-15(29)22-20(16-7-3-2-4-8-16)21(19-9-5-6-14-28(19)22)23(30)17-10-12-18(13-11-17)24(25,26)27/h2-14H,1H3
DM4GZBI CS CC(=O)C1=C(C(=C2N1C=CC=C2)C(=O)C3=CC=C(C=C3)C(F)(F)F)C4=CC=CC=C4
DM4GZBI IK GLIRMGCILWOVQU-UHFFFAOYSA-N
DM4GZBI IU 1-[2-phenyl-1-[4-(trifluoromethyl)benzoyl]indolizin-3-yl]ethanone
DM3E5V6 ID DM3E5V6
DM3E5V6 DN Indomethacin analog 1
DM3E5V6 HS Patented
DM3E5V6 SN PMID28895472-Compound-20
DM3E5V6 CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIVANDERBILT UNIVERSITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANI
DM3E5V6 DT Small molecular drug
DM3E5V6 PC 11394647
DM3E5V6 MW 371.8
DM3E5V6 FM C20H18ClNO4
DM3E5V6 IC InChI=1S/C20H18ClNO4/c1-12-16(8-10-19(23)24)17-11-15(26-2)7-9-18(17)22(12)20(25)13-3-5-14(21)6-4-13/h3-7,9,11H,8,10H2,1-2H3,(H,23,24)
DM3E5V6 CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CCC(=O)O
DM3E5V6 IK ZXFPVIQVVULPBC-UHFFFAOYSA-N
DM3E5V6 IU 3-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]propanoic acid
DMKFPJ7 ID DMKFPJ7
DMKFPJ7 DN Indomethacin analog 2
DMKFPJ7 HS Patented
DMKFPJ7 SN PMID28895472-Compound-21
DMKFPJ7 CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIVANDERBILT UNIVERSITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANI
DMKFPJ7 DT Small molecular drug
DMKFPJ7 PC 4711697
DMKFPJ7 MW 343.8
DMKFPJ7 FM C18H14ClNO4
DMKFPJ7 IC InChI=1S/C18H14ClNO4/c1-24-14-6-7-16-15(9-14)12(8-17(21)22)10-20(16)18(23)11-2-4-13(19)5-3-11/h2-7,9-10H,8H2,1H3,(H,21,22)
DMKFPJ7 CS COC1=CC2=C(C=C1)N(C=C2CC(=O)O)C(=O)C3=CC=C(C=C3)Cl
DMKFPJ7 IK DHEMTWWLRLOBKI-UHFFFAOYSA-N
DMKFPJ7 IU 2-[1-(4-chlorobenzoyl)-5-methoxyindol-3-yl]acetic acid
DMKFPJ7 CB CHEBI:71026
DM53JXE ID DM53JXE
DM53JXE DN Indomethacin analog 3
DM53JXE HS Patented
DM53JXE SN PMID28895472-Compound-22
DM53JXE CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIVANDERBILT UNIVERSITY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANI
DM53JXE DT Small molecular drug
DM53JXE PC 71523527
DM53JXE MW 448.9
DM53JXE FM C21H21ClN2O5S
DM53JXE IC InChI=1S/C21H21ClN2O5S/c1-13-17-12-16(29-2)8-9-19(17)24(21(26)14-4-6-15(22)7-5-14)18(13)10-11-20(25)23-30(3,27)28/h4-9,12H,10-11H2,1-3H3,(H,23,25)
DM53JXE CS CC1=C(N(C2=C1C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl)CCC(=O)NS(=O)(=O)C
DM53JXE IK PLYKGAOPLXCEPT-UHFFFAOYSA-N
DM53JXE IU 3-[1-(4-chlorobenzoyl)-5-methoxy-3-methylindol-2-yl]-N-methylsulfonylpropanamide
DMI3YO7 ID DMI3YO7
DMI3YO7 DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1
DMI3YO7 HS Patented
DMI3YO7 SN PMID27607364-Compound-21
DMI3YO7 DT Small molecular drug
DMI3YO7 PC 15870543
DMI3YO7 MW 448.3
DMI3YO7 FM C20H18FIN2O
DMI3YO7 IC InChI=1S/C20H18FIN2O/c1-24(12-6-11-21)20(25)18-13-14-7-2-3-8-15(14)19(23-18)16-9-4-5-10-17(16)22/h2-5,7-10,13H,6,11-12H2,1H3
DMI3YO7 CS CN(CCCF)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3I
DMI3YO7 IK JYVUQBFGPOGZEN-UHFFFAOYSA-N
DMI3YO7 IU N-(3-fluoropropyl)-1-(2-iodophenyl)-N-methylisoquinoline-3-carboxamide
DM8LNXQ ID DM8LNXQ
DM8LNXQ DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2
DM8LNXQ HS Patented
DM8LNXQ SN PMID27607364-Compound-22
DM8LNXQ DT Small molecular drug
DM8LNXQ PC 19601673
DM8LNXQ MW 448.3
DM8LNXQ FM C20H18FIN2O
DM8LNXQ IC InChI=1S/C20H18FIN2O/c1-24(11-5-10-21)20(25)18-13-14-6-2-3-9-17(14)19(23-18)15-7-4-8-16(22)12-15/h2-4,6-9,12-13H,5,10-11H2,1H3
DM8LNXQ CS CN(CCCF)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC(=CC=C3)I
DM8LNXQ IK KIEVJKCKQLQTJL-UHFFFAOYSA-N
DM8LNXQ IU N-(3-fluoropropyl)-1-(3-iodophenyl)-N-methylisoquinoline-3-carboxamide
DM39H1F ID DM39H1F
DM39H1F DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3
DM39H1F HS Patented
DM39H1F SN PMID27607364-Compound-23
DM39H1F DT Small molecular drug
DM39H1F PC 19601663
DM39H1F MW 448.3
DM39H1F FM C20H18FIN2O
DM39H1F IC InChI=1S/C20H18FIN2O/c1-24(12-4-11-21)20(25)18-13-15-5-2-3-6-17(15)19(23-18)14-7-9-16(22)10-8-14/h2-3,5-10,13H,4,11-12H2,1H3
DM39H1F CS CN(CCCF)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=C(C=C3)I
DM39H1F IK QJIFXKOIKACWEI-UHFFFAOYSA-N
DM39H1F IU N-(3-fluoropropyl)-1-(4-iodophenyl)-N-methylisoquinoline-3-carboxamide
DMDBK6O ID DMDBK6O
DMDBK6O DN Isochroman-4-ketone derivative 1
DMDBK6O HS Patented
DMDBK6O SN PMID29757691-Compound-9
DMDBK6O DT Small molecular drug
DMDBK6O PC 122193616
DMDBK6O MW 406.4
DMDBK6O FM C24H21FNO4+
DMDBK6O IC InChI=1S/C24H21FNO4/c1-28-21-8-7-19-20(24(21)29-2)15-30-22(23(19)27)13-16-9-11-26(12-10-16)14-17-3-5-18(25)6-4-17/h3-13H,14-15H2,1-2H3/q+1/b22-13-
DMDBK6O CS COC1=C(C2=C(C=C1)C(=O)/C(=C/C3=CC=[N+](C=C3)CC4=CC=C(C=C4)F)/OC2)OC
DMDBK6O IK WLIFEPXXMAJAQJ-XKZIYDEJSA-N
DMDBK6O IU (3Z)-3-[[1-[(4-fluorophenyl)methyl]pyridin-1-ium-4-yl]methylidene]-7,8-dimethoxy-1H-isochromen-4-one
DMMCWH9 ID DMMCWH9
DMMCWH9 DN Isoflavone derivative 1
DMMCWH9 HS Patented
DMMCWH9 SN PMID26666870-Compound-19
DMMCWH9 CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMMCWH9 DT Small molecular drug
DMTWAH3 ID DMTWAH3
DMTWAH3 DN Isoflavone derivative 2
DMTWAH3 HS Patented
DMTWAH3 SN PMID26666870-Compound-20
DMTWAH3 CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMTWAH3 DT Small molecular drug
DMYFKR2 ID DMYFKR2
DMYFKR2 DN Isoflavone derivative 3
DMYFKR2 HS Patented
DMYFKR2 SN PMID26666870-Compound-21
DMYFKR2 CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMYFKR2 DT Small molecular drug
DMYRU7I ID DMYRU7I
DMYRU7I DN Isoflavone derivative 4
DMYRU7I HS Patented
DMYRU7I SN PMID26666870-Compound-22
DMYRU7I CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMYRU7I DT Small molecular drug
DM2GL47 ID DM2GL47
DM2GL47 DN Isoflavone derivative 5
DM2GL47 HS Patented
DM2GL47 SN PMID26666870-Compound-23
DM2GL47 CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DM2GL47 DT Small molecular drug
DM2ZYVL ID DM2ZYVL
DM2ZYVL DN Isoflavone derivative 6
DM2ZYVL HS Patented
DM2ZYVL SN PMID26666870-Compound-24
DM2ZYVL CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DM2ZYVL DT Small molecular drug
DMNCHBL ID DMNCHBL
DMNCHBL DN Isoflavone derivative 7
DMNCHBL HS Patented
DMNCHBL SN PMID26666870-Compound-25
DMNCHBL CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMNCHBL DT Small molecular drug
DMN0XJQ ID DMN0XJQ
DMN0XJQ DN Isoflavone derivative 8
DMN0XJQ HS Patented
DMN0XJQ SN PMID26666870-Compound-26
DMN0XJQ CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMN0XJQ DT Small molecular drug
DMA78MD ID DMA78MD
DMA78MD DN Isoflavone derivative 9
DMA78MD HS Patented
DMA78MD SN PMID26666870-Compound-27
DMA78MD CP UNIVERSITA' DEGLI STUDI DI SIENA,UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"
DMA78MD DT Small molecular drug
DMWTU8X ID DMWTU8X
DMWTU8X DN Isoindole 1,3-dione analog 1
DMWTU8X HS Patented
DMWTU8X SN PMID27724045-Compound-12
DMWTU8X CP Roche
DMWTU8X DT Small molecular drug
DMD19QC ID DMD19QC
DMD19QC DN Isoindoline derivative 1
DMD19QC HS Patented
DMD19QC SN PMID30185082-Compound-66
DMD19QC CP COGNITION THERAPEUTICS, INC
DMD19QC DT Small molecular drug
DMD19QC PC 118278079
DMD19QC MW 423.5
DMD19QC FM C25H33N3O3
DMD19QC IC InChI=1S/C25H33N3O3/c1-25(2,10-9-18-7-8-22(29)23(15-18)31-3)28-16-19-5-4-6-20(21(19)17-28)24(30)27-13-11-26-12-14-27/h4-8,15,26,29H,9-14,16-17H2,1-3H3
DMD19QC CS CC(C)(CCC1=CC(=C(C=C1)O)OC)N2CC3=C(C2)C(=CC=C3)C(=O)N4CCNCC4
DMD19QC IK XNAGJLRFPOQPPM-UHFFFAOYSA-N
DMD19QC IU [2-[4-(4-hydroxy-3-methoxyphenyl)-2-methylbutan-2-yl]-1,3-dihydroisoindol-4-yl]-piperazin-1-ylmethanone
DMTE0S3 ID DMTE0S3
DMTE0S3 DN Isoindoline derivative 2
DMTE0S3 HS Patented
DMTE0S3 SN PMID30185082-Compound-67
DMTE0S3 CP COGNITION THERAPEUTICS, INC
DMTE0S3 DT Small molecular drug
DMTE0S3 PC 118282969
DMTE0S3 MW 380.3
DMTE0S3 FM C20H23Cl2NO2
DMTE0S3 IC InChI=1S/C20H23Cl2NO2/c1-13(4-5-14-6-7-17(21)18(22)8-14)23-11-15-9-19(24-2)20(25-3)10-16(15)12-23/h6-10,13H,4-5,11-12H2,1-3H3/t13-/m1/s1
DMTE0S3 CS C[C@H](CCC1=CC(=C(C=C1)Cl)Cl)N2CC3=CC(=C(C=C3C2)OC)OC
DMTE0S3 IK QOXCLDKXSCBOOF-CYBMUJFWSA-N
DMTE0S3 IU 2-[(2R)-4-(3,4-dichlorophenyl)butan-2-yl]-5,6-dimethoxy-1,3-dihydroisoindole
DM2MYL9 ID DM2MYL9
DM2MYL9 DN Isoindoline derivative 3
DM2MYL9 HS Patented
DM2MYL9 SN PMID30185082-Compound-68
DM2MYL9 CP COGNITION THERAPEUTICS, INC
DM2MYL9 DT Small molecular drug
DM2MYL9 PC 118282967
DM2MYL9 MW 370.3
DM2MYL9 FM C22H21Cl2N
DM2MYL9 IC InChI=1S/C22H21Cl2N/c1-15(6-7-16-8-11-21(23)22(24)12-16)25-13-18-10-9-17-4-2-3-5-19(17)20(18)14-25/h2-5,8-12,15H,6-7,13-14H2,1H3
DM2MYL9 CS CC(CCC1=CC(=C(C=C1)Cl)Cl)N2CC3=C(C2)C4=CC=CC=C4C=C3
DM2MYL9 IK SNYFWQWLZIRNKD-UHFFFAOYSA-N
DM2MYL9 IU 2-[4-(3,4-dichlorophenyl)butan-2-yl]-1,3-dihydrobenzo[e]isoindole
DMP1NKI ID DMP1NKI
DMP1NKI DN Isoindoline derivative 4
DMP1NKI HS Patented
DMP1NKI SN PMID30185082-Compound-69
DMP1NKI CP COGNITION THERAPEUTICS, INC
DMP1NKI DT Small molecular drug
DMIUTQW ID DMIUTQW
DMIUTQW DN Isoindoline derivative 5
DMIUTQW HS Patented
DMIUTQW SN PMID30185082-Compound-70
DMIUTQW CP COGNITION THERAPEUTICS, INC
DMIUTQW DT Small molecular drug
DMIUTQW PC 118282942
DMIUTQW MW 443.5
DMIUTQW FM C21H24F3NO4S
DMIUTQW IC InChI=1S/C21H24F3NO4S/c1-20(2,10-9-14-7-8-17(26)18(11-14)29-21(22,23)24)25-12-15-5-4-6-19(16(15)13-25)30(3,27)28/h4-8,11,26H,9-10,12-13H2,1-3H3
DMIUTQW CS CC(C)(CCC1=CC(=C(C=C1)O)OC(F)(F)F)N2CC3=C(C2)C(=CC=C3)S(=O)(=O)C
DMIUTQW IK ZBXIRNVCPMZPFS-UHFFFAOYSA-N
DMIUTQW IU 4-[3-methyl-3-(4-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-(trifluoromethoxy)phenol
DMIYUAN ID DMIYUAN
DMIYUAN DN Isoquinoline 1,3-dione derivative 1
DMIYUAN HS Patented
DMIYUAN SN PMID26161698-Compound-49
DMOAY3Q ID DMOAY3Q
DMOAY3Q DN Isoquinoline carboxamide derivative 1
DMOAY3Q HS Patented
DMOAY3Q SN PMID27607364-Compound-1
DMOAY3Q CP COCENSYS, INC
DMOAY3Q DT Small molecular drug
DMOAY3Q PC 1345
DMOAY3Q MW 352.9
DMOAY3Q FM C21H21ClN2O
DMOAY3Q IC InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3
DMOAY3Q CS CCC(C)N(C)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3Cl
DMOAY3Q IK RAVIZVQZGXBOQO-UHFFFAOYSA-N
DMOAY3Q IU N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide
DMOAY3Q CA CAS 85532-75-8
DMOAY3Q CB CHEBI:73290
DMR0Y3K ID DMR0Y3K
DMR0Y3K DN Isoquinoline derivative 1
DMR0Y3K HS Patented
DMR0Y3K SN PMID27215781-Compound-22
DMR0Y3K CP LUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu ZADE, Seema, Prabhakar SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar MAHANGARE, Sachin, Jaysing TALE, Prashant, Vitthalrao ZADE, Seema, Prabhakar PATIL, Amolsing, Dattu CHEEMALA, Narasimha, Murthy PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, Kumar
DMR0Y3K DT Small molecular drug
DMR0Y3K PC 57525223
DMR0Y3K MW 379.9
DMR0Y3K FM C22H22ClN3O
DMR0Y3K IC InChI=1S/C22H22ClN3O/c1-15-7-5-10-18-20(15)19(22(27)26-11-3-2-4-12-26)14-24-21(18)25-17-9-6-8-16(23)13-17/h5-10,13-14H,2-4,11-12H2,1H3,(H,24,25)
DMR0Y3K CS CC1=C2C(=CC=C1)C(=NC=C2C(=O)N3CCCCC3)NC4=CC(=CC=C4)Cl
DMR0Y3K IK RSQQKPIPFGRLQX-UHFFFAOYSA-N
DMR0Y3K IU [1-(3-chloroanilino)-5-methylisoquinolin-4-yl]-piperidin-1-ylmethanone
DMR0Y3K DE Neuropathic pain
DMRHBLD ID DMRHBLD
DMRHBLD DN Isoquinoline derivative 2
DMRHBLD HS Patented
DMRHBLD SN PMID27215781-Compound-23
DMRHBLD CP LUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu ZADE, Seema, Prabhakar SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar MAHANGARE, Sachin, Jaysing TALE, Prashant, Vitthalrao ZADE, Seema, Prabhakar PATIL, Amolsing, Dattu CHEEMALA, Narasimha, Murthy PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, Kumar
DMRHBLD DT Small molecular drug
DMRHBLD PC 57411003
DMRHBLD MW 365.4
DMRHBLD FM C21H20FN3O2
DMRHBLD IC InChI=1S/C21H20FN3O2/c1-14-4-2-7-17-19(14)18(21(26)25-8-10-27-11-9-25)13-23-20(17)24-16-6-3-5-15(22)12-16/h2-7,12-13H,8-11H2,1H3,(H,23,24)
DMRHBLD CS CC1=C2C(=CC=C1)C(=NC=C2C(=O)N3CCOCC3)NC4=CC(=CC=C4)F
DMRHBLD IK QKTNWXFWLOHPFJ-UHFFFAOYSA-N
DMRHBLD IU [1-(3-fluoroanilino)-5-methylisoquinolin-4-yl]-morpholin-4-ylmethanone
DMRHBLD DE Neuropathic pain
DM4R1MK ID DM4R1MK
DM4R1MK DN Isoquinoline derivative 3
DM4R1MK HS Patented
DM4R1MK SN PMID27215781-Compound-24
DM4R1MK CP LUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu ZADE, Seema, Prabhakar SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar MAHANGARE, Sachin, Jaysing TALE, Prashant, Vitthalrao ZADE, Seema, Prabhakar PATIL, Amolsing, Dattu CHEEMALA, Narasimha, Murthy PALLE, Venkata, P. KAMBOJ, Rajender, KumaLUPIN LIMITED KULKARNI, Sanjeev, Anant MADAN, Sachin JANA, Nirmal, Kumar TALE, Prashant, Vitthalrao CHEEMALA, Narasimha, Murthy MAHANGARE, Sachin, Jaysing VIDHATE, Prashant, Popatrao KULKARNI, Chaitanya, Prabhakar PATEL, Sapana, Suresh PATIL, Amolsing, Dattu SHINDE, Rohan, Mahadev PALLE, Venkata, P. KAMBOJ, Rajender, Kumar
DM4R1MK DT Small molecular drug
DM4R1MK PC 57525218
DM4R1MK MW 415.4
DM4R1MK FM C22H20F3N3O2
DM4R1MK IC InChI=1S/C22H20F3N3O2/c1-14-4-2-7-17-19(14)18(21(29)28-8-10-30-11-9-28)13-26-20(17)27-16-6-3-5-15(12-16)22(23,24)25/h2-7,12-13H,8-11H2,1H3,(H,26,27)
DM4R1MK CS CC1=C2C(=CC=C1)C(=NC=C2C(=O)N3CCOCC3)NC4=CC=CC(=C4)C(F)(F)F
DM4R1MK IK GPXLPNZECOPGPJ-UHFFFAOYSA-N
DM4R1MK IU [5-methyl-1-[3-(trifluoromethyl)anilino]isoquinolin-4-yl]-morpholin-4-ylmethanone
DM4R1MK DE Neuropathic pain
DMB5F8Q ID DMB5F8Q
DMB5F8Q DN Isoquinoline derivative 4
DMB5F8Q HS Patented
DMB5F8Q SN PMID28048944-Compound-10
DMB5F8Q CP AMAKEM NV
DMB5F8Q DT Small molecular drug
DMNJ2R9 ID DMNJ2R9
DMNJ2R9 DN Isoquinoline derivative 5
DMNJ2R9 HS Patented
DMNJ2R9 SN PMID28048944-Compound-9
DMNJ2R9 CP AMAKEM NV
DMNJ2R9 DT Small molecular drug
DMM5BDS ID DMM5BDS
DMM5BDS DN Isoquinoline sulfonamide derivative 1
DMM5BDS HS Patented
DMM5BDS SN PMID28048944-Compound-17
DMM5BDS CP MEDSHINE DISCOVERY INC
DMM5BDS DT Small molecular drug
DMQVYL0 ID DMQVYL0
DMQVYL0 DN Isoquinoline sulfonamide derivative 2
DMQVYL0 HS Patented
DMQVYL0 SN PMID28048944-Compound-18
DMQVYL0 CP MEDSHINE DISCOVERY INC
DMQVYL0 DT Small molecular drug
DMC5F3H ID DMC5F3H
DMC5F3H DN Isoquinoline sulfonyl derivative 1
DMC5F3H HS Patented
DMC5F3H SN PMID28048944-Compound-13
DMC5F3H CP MEDSHINE DISCOVERY INC
DMC5F3H DT Small molecular drug
DMC5F3H PC 126511157
DMC5F3H MW 331.4
DMC5F3H FM C17H21N3O2S
DMC5F3H IC InChI=1S/C17H21N3O2S/c1-12-8-18-9-13-4-2-6-16(17(12)13)23(21,22)20-10-14-5-3-7-19-15(14)11-20/h2,4,6,8-9,14-15,19H,3,5,7,10-11H2,1H3
DMC5F3H CS CC1=CN=CC2=C1C(=CC=C2)S(=O)(=O)N3CC4CCCNC4C3
DMC5F3H IK GPOFEWOVDWONOA-UHFFFAOYSA-N
DMC5F3H IU 5-(1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-ylsulfonyl)-4-methylisoquinoline
DMT5E7M ID DMT5E7M
DMT5E7M DN Isoquinoline sulfonyl derivative 2
DMT5E7M HS Patented
DMT5E7M SN PMID28048944-Compound-14
DMT5E7M CP MEDSHINE DISCOVERY INC
DMT5E7M DT Small molecular drug
DMHIAVW ID DMHIAVW
DMHIAVW DN Isoquinoline sulfonyl derivative 3
DMHIAVW HS Patented
DMHIAVW SN PMID28048944-Compound-15
DMHIAVW CP MEDSHINE DISCOVERY INC
DMHIAVW DT Small molecular drug
DMHIAVW PC 118488070
DMHIAVW MW 331.4
DMHIAVW FM C17H21N3O2S
DMHIAVW IC InChI=1S/C17H21N3O2S/c1-12-10-18-11-13-4-2-6-16(17(12)13)23(21,22)20-9-7-14-15(20)5-3-8-19-14/h2,4,6,10-11,14-15,19H,3,5,7-9H2,1H3
DMHIAVW CS CC1=CN=CC2=C1C(=CC=C2)S(=O)(=O)N3CCC4C3CCCN4
DMHIAVW IK WDKSGCASJPRCLY-UHFFFAOYSA-N
DMHIAVW IU 5-(2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-b]pyridin-1-ylsulfonyl)-4-methylisoquinoline
DMW6R0H ID DMW6R0H
DMW6R0H DN Isoquinolone derivative 1
DMW6R0H HS Patented
DMW6R0H SN PMID28895472-Compound-27
DMW6R0H CP GTX, INC
DMW6R0H DT Small molecular drug
DMP2QDM ID DMP2QDM
DMP2QDM DN Isosteric imidazolyl pyrimidine derivative 1
DMP2QDM HS Patented
DMP2QDM SN PMID26161698-Compound-37
DMP2QDM DT Small molecular drug
DMP2QDM PC 44555024
DMP2QDM MW 358.4
DMP2QDM FM C16H18N6O2S
DMP2QDM IC InChI=1S/C16H18N6O2S/c1-9(2)22-10(3)18-8-12(22)11-6-7-17-16(19-11)20-14-5-4-13(25-14)15(23)21-24/h4-9,24H,1-3H3,(H,21,23)(H,17,19,20)
DMP2QDM CS CC1=NC=C(N1C(C)C)C2=NC(=NC=C2)NC3=CC=C(S3)C(=O)NO
DMP2QDM IK CKZXHZVEFKLZPB-UHFFFAOYSA-N
DMP2QDM IU N-hydroxy-5-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]thiophene-2-carboxamide
DMLSUH3 ID DMLSUH3
DMLSUH3 DN Isothiazolidine derivative 1
DMLSUH3 HS Patented
DMLSUH3 SN PMID27724045-Compound-2
DMLSUH3 CP GLAXO GROUP LIMITED DEAN, David, Kenneth WALTER, Daryl, Simon
DMLSUH3 DT Small molecular drug
DMLSUH3 PC 52912204
DMLSUH3 MW 385.79
DMLSUH3 FM C13H15ClF3N3O3S
DMLSUH3 IC InChI=1S/C13H15ClF3N3O3S/c1-19-7-10(20(2)24(19,22)23)12(21)18-6-8-4-3-5-9(11(8)14)13(15,16)17/h3-5,10H,6-7H2,1-2H3,(H,18,21)
DMLSUH3 CS CN1CC(N(S1(=O)=O)C)C(=O)NCC2=C(C(=CC=C2)C(F)(F)F)Cl
DMLSUH3 IK FDFVMILOAWFGGO-UHFFFAOYSA-N
DMLSUH3 IU N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-2,5-dimethyl-1,1-dioxo-1,2,5-thiadiazolidine-3-carboxamide
DMHAJCM ID DMHAJCM
DMHAJCM DN Isothiazolone derivative 1
DMHAJCM HS Patented
DMHAJCM SN PMID26560362-Compound-33
DMHAJCM DT Small molecular drug
DMHAJCM PC 23287881
DMHAJCM MW 349.5
DMHAJCM FM C16H23N5O2S
DMHAJCM IC InChI=1S/C16H23N5O2S/c22-15-13-12-17-16(20-8-10-23-11-9-20)18-14(13)24-21(15)7-6-19-4-2-1-3-5-19/h12H,1-11H2
DMHAJCM CS C1CCN(CC1)CCN2C(=O)C3=CN=C(N=C3S2)N4CCOCC4
DMHAJCM IK YVQWBBJPPJKQIM-UHFFFAOYSA-N
DMHAJCM IU 6-morpholin-4-yl-2-(2-piperidin-1-ylethyl)-[1,2]thiazolo[5,4-d]pyrimidin-3-one
DMK31M6 ID DMK31M6
DMK31M6 DN Isothiocyanate derivative 1
DMK31M6 HS Patented
DMK31M6 SN PMID26560530-Compound-9
DMK31M6 CP Medicis Corp
DMK31M6 DT Small molecular drug
DMK31M6 PC 10290770
DMK31M6 MW 116.14
DMK31M6 FM C3H4N2OS
DMK31M6 IC InChI=1S/C3H4N2OS/c4-3(6)1-5-2-7/h1H2,(H2,4,6)
DMK31M6 CS C(C(=O)N)N=C=S
DMK31M6 IK LXDZRHJIMQYSSD-UHFFFAOYSA-N
DMK31M6 IU 2-isothiocyanatoacetamide
DMUMPZX ID DMUMPZX
DMUMPZX DN Isoxazole derivative 1
DMUMPZX HS Patented
DMUMPZX SN PMID27774822-Compound-Figure11compound1
DMUMPZX CP ZHEJIANG DTRM BIOPHARMA [CN]
DMUMPZX DT Small molecular drug
DMT842O ID DMT842O
DMT842O DN Isoxazole derivative 2
DMT842O HS Patented
DMT842O SN PMID27774822-Compound-Figure11compound2
DMT842O CP ZHEJIANG DTRM BIOPHARMA [CN]
DMT842O DT Small molecular drug
DM5CXQT ID DM5CXQT
DM5CXQT DN Isoxazole-based bicyclic compound 1
DM5CXQT HS Patented
DM5CXQT SN PMID26924192-Compound-61
DM5CXQT CP ZENITH EPIGENETICS CORP
DM5CXQT DT Small molecular drug
DM5CXQT PC 86566737
DM5CXQT MW 318.4
DM5CXQT FM C19H18N4O
DM5CXQT IC InChI=1S/C19H18N4O/c1-12-18(13(2)24-22-12)15-8-16(20)19-17(9-15)23(11-21-19)10-14-6-4-3-5-7-14/h3-9,11H,10,20H2,1-2H3
DM5CXQT CS CC1=C(C(=NO1)C)C2=CC(=C3C(=C2)N(C=N3)CC4=CC=CC=C4)N
DM5CXQT IK JNHVPJQTAXBUHN-UHFFFAOYSA-N
DM5CXQT IU 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)benzimidazol-4-amine
DMAYKZ9 ID DMAYKZ9
DMAYKZ9 DN Isoxazole-based bicyclic compound 10
DMAYKZ9 HS Patented
DMAYKZ9 SN PMID26924192-Compound-70
DMAYKZ9 CP ZENITH EPIGENETICS CORP
DMAYKZ9 DT Small molecular drug
DM1G8SM ID DM1G8SM
DM1G8SM DN Isoxazole-based bicyclic compound 11
DM1G8SM HS Patented
DM1G8SM SN PMID26924192-Compound-71
DM1G8SM CP ZENITH EPIGENETICS CORP
DM1G8SM DT Small molecular drug
DMVA8KL ID DMVA8KL
DMVA8KL DN Isoxazole-based bicyclic compound 12
DMVA8KL HS Patented
DMVA8KL SN PMID26924192-Compound-72
DMVA8KL CP ZENITH EPIGENETICS CORP
DMVA8KL DT Small molecular drug
DM7OBVT ID DM7OBVT
DM7OBVT DN Isoxazole-based bicyclic compound 13
DM7OBVT HS Patented
DM7OBVT SN PMID26924192-Compound-73
DM7OBVT CP ZENITH EPIGENETICS CORP
DM7OBVT DT Small molecular drug
DMS3CDT ID DMS3CDT
DMS3CDT DN Isoxazole-based bicyclic compound 14
DMS3CDT HS Patented
DMS3CDT SN PMID26924192-Compound-74
DMS3CDT CP ZENITH EPIGENETICS CORP
DMS3CDT DT Small molecular drug
DMPXK1C ID DMPXK1C
DMPXK1C DN Isoxazole-based bicyclic compound 15
DMPXK1C HS Patented
DMPXK1C SN PMID26924192-Compound-75
DMPXK1C CP ZENITH EPIGENETICS CORP
DMPXK1C DT Small molecular drug
DM614F8 ID DM614F8
DM614F8 DN Isoxazole-based bicyclic compound 16
DM614F8 HS Patented
DM614F8 SN PMID26924192-Compound-76
DM614F8 CP ORION CORPORATION
DM614F8 DT Small molecular drug
DM614F8 PC 91824133
DM614F8 MW 384.9
DM614F8 FM C21H21ClN2O3
DM614F8 IC InChI=1S/C21H21ClN2O3/c1-13-21(14(2)27-23-13)17-10-20-18(11-19(17)25-3)24(8-9-26-20)12-15-4-6-16(22)7-5-15/h4-7,10-11H,8-9,12H2,1-3H3
DM614F8 CS CC1=C(C(=NO1)C)C2=CC3=C(C=C2OC)N(CCO3)CC4=CC=C(C=C4)Cl
DM614F8 IK QYWOLKVTQWOHRO-UHFFFAOYSA-N
DM614F8 IU 4-[(4-chlorophenyl)methyl]-7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-2,3-dihydro-1,4-benzoxazine
DM2SUCK ID DM2SUCK
DM2SUCK DN Isoxazole-based bicyclic compound 17
DM2SUCK HS Patented
DM2SUCK SN PMID26924192-Compound-77
DM2SUCK CP ORION CORPORATION
DM2SUCK DT Small molecular drug
DM2SUCK PC 118224715
DM2SUCK MW 362.4
DM2SUCK FM C20H18N4O3
DM2SUCK IC InChI=1S/C20H18N4O3/c1-12-20(13(2)27-23-12)15-9-14-5-6-19(25)24(16(14)10-17(15)26-3)11-18-21-7-4-8-22-18/h4-10H,11H2,1-3H3
DM2SUCK CS CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)C=CC(=O)N3CC4=NC=CC=N4)OC
DM2SUCK IK NWOCKSNGLNHMMB-UHFFFAOYSA-N
DM2SUCK IU 6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-methoxy-1-(pyrimidin-2-ylmethyl)quinolin-2-one
DME8CQA ID DME8CQA
DME8CQA DN Isoxazole-based bicyclic compound 18
DME8CQA HS Patented
DME8CQA SN PMID26924192-Compound-78
DME8CQA CP ORION CORPORATION
DME8CQA DT Small molecular drug
DME8CQA PC 124137024
DME8CQA MW 391.4
DME8CQA FM C22H21N3O4
DME8CQA IC InChI=1S/C22H21N3O4/c1-14-22(15(2)29-24-14)18-11-16-6-7-21(27)25(13-17-5-3-4-8-23-17)19(16)12-20(18)28-10-9-26/h3-8,11-12,26H,9-10,13H2,1-2H3
DME8CQA CS CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)C=CC(=O)N3CC4=CC=CC=N4)OCCO
DME8CQA IK OAVYHERNZVHDFP-UHFFFAOYSA-N
DME8CQA IU 6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-hydroxyethoxy)-1-(pyridin-2-ylmethyl)quinolin-2-one
DM01FD3 ID DM01FD3
DM01FD3 DN Isoxazole-based bicyclic compound 19
DM01FD3 HS Patented
DM01FD3 SN PMID26924192-Compound-79
DM01FD3 CP ORION CORPORATION
DM01FD3 DT Small molecular drug
DM01FD3 PC 118224629
DM01FD3 MW 459.4
DM01FD3 FM C23H20F3N3O4
DM01FD3 IC InChI=1S/C23H20F3N3O4/c1-12-20(13(2)33-28-12)16-8-14-9-17(21(30)23(24,25)26)22(31)29(18(14)10-19(16)32-3)11-15-6-4-5-7-27-15/h4-10,21,30H,11H2,1-3H3
DM01FD3 CS CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)C=C(C(=O)N3CC4=CC=CC=N4)C(C(F)(F)F)O)OC
DM01FD3 IK KORFDBDOHJBIRP-UHFFFAOYSA-N
DM01FD3 IU 6-(3,5-dimethyl-1,2-oxazol-4-yl)-7-methoxy-1-(pyridin-2-ylmethyl)-3-(2,2,2-trifluoro-1-hydroxyethyl)quinolin-2-one
DMYLR2S ID DMYLR2S
DMYLR2S DN Isoxazole-based bicyclic compound 2
DMYLR2S HS Patented
DMYLR2S SN PMID26924192-Compound-62
DMYLR2S CP ZENITH EPIGENETICS CORP
DMYLR2S DT Small molecular drug
DMYLR2S PC 87057166
DMYLR2S MW 320.3
DMYLR2S FM C18H16N4O2
DMYLR2S IC InChI=1S/C18H16N4O2/c1-11-16(12(2)24-21-11)14-8-15-17(19-9-14)20-18(23)22(15)10-13-6-4-3-5-7-13/h3-9H,10H2,1-2H3,(H,19,20,23)
DMYLR2S CS CC1=C(C(=NO1)C)C2=CC3=C(NC(=O)N3CC4=CC=CC=C4)N=C2
DMYLR2S IK QUVHLUHSXDYNJU-UHFFFAOYSA-N
DMYLR2S IU 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-one
DMWMRKJ ID DMWMRKJ
DMWMRKJ DN Isoxazole-based bicyclic compound 3
DMWMRKJ HS Patented
DMWMRKJ SN PMID26924192-Compound-63
DMWMRKJ CP ZENITH EPIGENETICS CORP
DMWMRKJ DT Small molecular drug
DMWMRKJ PC 87057247
DMWMRKJ MW 334.4
DMWMRKJ FM C19H18N4O2
DMWMRKJ IC InChI=1S/C19H18N4O2/c1-11-17(12(2)25-22-11)14-8-15(20)18-16(9-14)23(19(24)21-18)10-13-6-4-3-5-7-13/h3-9H,10,20H2,1-2H3,(H,21,24)
DMWMRKJ CS CC1=C(C(=NO1)C)C2=CC(=C3C(=C2)N(C(=O)N3)CC4=CC=CC=C4)N
DMWMRKJ IK HWHJKVNNLYESRW-UHFFFAOYSA-N
DMWMRKJ IU 7-amino-3-benzyl-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-benzimidazol-2-one
DMNI0PH ID DMNI0PH
DMNI0PH DN Isoxazole-based bicyclic compound 4
DMNI0PH HS Patented
DMNI0PH SN PMID26924192-Compound-64
DMNI0PH CP ZENITH EPIGENETICS CORP
DMNI0PH DT Small molecular drug
DMNI0PH PC 87057249
DMNI0PH MW 362.4
DMNI0PH FM C21H22N4O2
DMNI0PH IC InChI=1S/C21H22N4O2/c1-4-26-21-23-20-17(22)10-16(19-13(2)24-27-14(19)3)11-18(20)25(21)12-15-8-6-5-7-9-15/h5-11H,4,12,22H2,1-3H3
DMNI0PH CS CCOC1=NC2=C(C=C(C=C2N1CC3=CC=CC=C3)C4=C(ON=C4C)C)N
DMNI0PH IK AURDBDSAYLFHPT-UHFFFAOYSA-N
DMNI0PH IU 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-2-ethoxybenzimidazol-4-amine
DMT46PS ID DMT46PS
DMT46PS DN Isoxazole-based bicyclic compound 5
DMT46PS HS Patented
DMT46PS SN PMID26924192-Compound-65
DMT46PS CP ZENITH EPIGENETICS CORP
DMT46PS DT Small molecular drug
DMT46PS PC 121375944
DMT46PS MW 391.4
DMT46PS FM C21H21N5O3
DMT46PS IC InChI=1S/C21H21N5O3/c1-4-22-21-23-20-17(25(21)12-15-8-6-5-7-9-15)10-16(11-18(20)26(27)28)19-13(2)24-29-14(19)3/h5-11H,4,12H2,1-3H3,(H,22,23)
DMT46PS CS CCNC1=NC2=C(N1CC3=CC=CC=C3)C=C(C=C2[N+](=O)[O-])C4=C(ON=C4C)C
DMT46PS IK ANFSRXMOJNUJCH-UHFFFAOYSA-N
DMT46PS IU 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-N-ethyl-4-nitrobenzimidazol-2-amine
DMKSNZG ID DMKSNZG
DMKSNZG DN Isoxazole-based bicyclic compound 6
DMKSNZG HS Patented
DMKSNZG SN PMID26924192-Compound-66
DMKSNZG CP ZENITH EPIGENETICS CORP
DMKSNZG DT Small molecular drug
DM3T840 ID DM3T840
DM3T840 DN Isoxazole-based bicyclic compound 7
DM3T840 HS Patented
DM3T840 SN PMID26924192-Compound-67
DM3T840 CP ZENITH EPIGENETICS CORP
DM3T840 DT Small molecular drug
DM3IV7K ID DM3IV7K
DM3IV7K DN Isoxazole-based bicyclic compound 8
DM3IV7K HS Patented
DM3IV7K SN PMID26924192-Compound-68
DM3IV7K CP ZENITH EPIGENETICS CORP
DM3IV7K DT Small molecular drug
DMWA7RB ID DMWA7RB
DMWA7RB DN Isoxazole-based bicyclic compound 9
DMWA7RB HS Patented
DMWA7RB SN PMID26924192-Compound-69
DMWA7RB CP ZENITH EPIGENETICS CORP
DMWA7RB DT Small molecular drug
DMRML9B ID DMRML9B
DMRML9B DN Isoxazoles and isoxazoline derivative 1
DMRML9B HS Patented
DMRML9B SN PMID27172114-Compound-82
DMRML9B DT Small molecular drug
DMKCYSD ID DMKCYSD
DMKCYSD DN Isoxazoles and isoxazoline derivative 2
DMKCYSD HS Patented
DMKCYSD SN PMID27172114-Compound-83
DMKCYSD DT Small molecular drug
DMKCYSD PC 44634450
DMKCYSD MW 274.1
DMKCYSD FM C11H9Cl2NO3
DMKCYSD IC InChI=1S/C11H9Cl2NO3/c12-8-2-1-6(3-9(8)13)11-7(4-10(15)16)5-17-14-11/h1-3,7H,4-5H2,(H,15,16)
DMKCYSD CS C1C(C(=NO1)C2=CC(=C(C=C2)Cl)Cl)CC(=O)O
DMKCYSD IK JUWLIQWWDGCIRH-UHFFFAOYSA-N
DMKCYSD IU 2-[3-(3,4-dichlorophenyl)-4,5-dihydro-1,2-oxazol-4-yl]acetic acid
DMULJOS ID DMULJOS
DMULJOS DN Isoxazoles and isoxazoline derivative 3
DMULJOS HS Patented
DMULJOS SN PMID27172114-Compound-84
DMULJOS DT Small molecular drug
DMW3JZV ID DMW3JZV
DMW3JZV DN Isoxazoles and isoxazoline derivative 4
DMW3JZV HS Patented
DMW3JZV SN PMID27172114-Compound-85
DMW3JZV DT Small molecular drug
DMCWFU1 ID DMCWFU1
DMCWFU1 DN Isoxazoles and isoxazoline derivative 5
DMCWFU1 HS Patented
DMCWFU1 SN PMID27172114-Compound-86
DMCWFU1 DT Small molecular drug
DMIKBV5 ID DMIKBV5
DMIKBV5 DN Isoxazoles and isoxazoline derivative 6
DMIKBV5 HS Patented
DMIKBV5 SN PMID27172114-Compound-87
DMIKBV5 DT Small molecular drug
DMLR8MS ID DMLR8MS
DMLR8MS DN Isoxazoline derivative 1
DMLR8MS HS Patented
DMLR8MS SN PMID26413912-Compound-85
DMLR8MS CP INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMLR8MS DT Small molecular drug
DMLR8MS PC 58126505
DMLR8MS MW 256.1
DMLR8MS FM C10H10BrNO2
DMLR8MS IC InChI=1S/C10H10BrNO2/c1-13-8-4-2-3-7(5-8)9-6-10(11)12-14-9/h2-5,9H,6H2,1H3/t9-/m1/s1
DMLR8MS CS COC1=CC=CC(=C1)[C@H]2CC(=NO2)Br
DMLR8MS IK IWLKUWXPADWQAT-SECBINFHSA-N
DMLR8MS IU (5R)-3-bromo-5-(3-methoxyphenyl)-4,5-dihydro-1,2-oxazole
DMK5M8Q ID DMK5M8Q
DMK5M8Q DN Isoxazoline derivative 2
DMK5M8Q HS Patented
DMK5M8Q SN PMID26413912-Compound-86
DMK5M8Q CP INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMK5M8Q DT Small molecular drug
DMK5M8Q PC 58126487
DMK5M8Q MW 256.1
DMK5M8Q FM C10H10BrNO2
DMK5M8Q IC InChI=1S/C10H10BrNO2/c1-13-8-4-2-3-7(5-8)9-6-10(11)12-14-9/h2-5,9H,6H2,1H3/t9-/m0/s1
DMK5M8Q CS COC1=CC=CC(=C1)[C@@H]2CC(=NO2)Br
DMK5M8Q IK IWLKUWXPADWQAT-VIFPVBQESA-N
DMK5M8Q IU (5S)-3-bromo-5-(3-methoxyphenyl)-4,5-dihydro-1,2-oxazole
DMBVDHK ID DMBVDHK
DMBVDHK DN Isoxazoline derivative 3
DMBVDHK HS Patented
DMBVDHK SN PMID26413912-Compound-87
DMBVDHK CP INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DMBVDHK DT Small molecular drug
DMBVDHK PC 88979391
DMBVDHK MW 356.4
DMBVDHK FM C22H16N2O3
DMBVDHK IC InChI=1S/C22H16N2O3/c23-15-16-6-10-20(11-7-16)26-22-14-21(27-24-22)17-8-12-19(13-9-17)25-18-4-2-1-3-5-18/h1-13,21H,14H2/t21-/m1/s1
DMBVDHK CS C1[C@@H](ON=C1OC2=CC=C(C=C2)C#N)C3=CC=C(C=C3)OC4=CC=CC=C4
DMBVDHK IK QRYXBMPYZGEVSA-OAQYLSRUSA-N
DMBVDHK IU 4-[[(5R)-5-(4-phenoxyphenyl)-4,5-dihydro-1,2-oxazol-3-yl]oxy]benzonitrile
DM01DG4 ID DM01DG4
DM01DG4 DN Isoxazoline derivative 4
DM01DG4 HS Patented
DM01DG4 SN PMID26413912-Compound-88
DM01DG4 CP INFINITY PHARMACEUTICALS, INC. BEHNKE, Mark, L. CASTRO, Alfredo, C. CHAN, Lawrence, K. EVANS, Catherine, A. GRENIER, Louis GROGAN, Michael, J. LEBLANC, Yves LIU, Tao PELUSO, Stephane SNYDER, Daniel, A. TIBBITTS, Thomas, T
DM01DG4 DT Small molecular drug
DM01DG4 PC 88979392
DM01DG4 MW 356.4
DM01DG4 FM C22H16N2O3
DM01DG4 IC InChI=1S/C22H16N2O3/c23-15-16-6-10-20(11-7-16)26-22-14-21(27-24-22)17-8-12-19(13-9-17)25-18-4-2-1-3-5-18/h1-13,21H,14H2/t21-/m0/s1
DM01DG4 CS C1[C@H](ON=C1OC2=CC=C(C=C2)C#N)C3=CC=C(C=C3)OC4=CC=CC=C4
DM01DG4 IK QRYXBMPYZGEVSA-NRFANRHFSA-N
DM01DG4 IU 4-[[(5S)-5-(4-phenoxyphenyl)-4,5-dihydro-1,2-oxazol-3-yl]oxy]benzonitrile
DMER7QX ID DMER7QX
DMER7QX DN JCXGHZCWAHCYGY-UHFFFAOYSA-N
DMER7QX HS Patented
DMER7QX SN CHEMBL1076723; N-(2-chloro-4-hydroxyphenyl)-6-(cyclohexylamino)pyrimidine-4-carboxamide; SCHEMBL3035358; JCXGHZCWAHCYGY-UHFFFAOYSA-N; BDBM50313327
DMER7QX DT Small molecular drug
DMER7QX PC 25182746
DMER7QX MW 346.8
DMER7QX FM C17H19ClN4O2
DMER7QX IC InChI=1S/C17H19ClN4O2/c18-13-8-12(23)6-7-14(13)22-17(24)15-9-16(20-10-19-15)21-11-4-2-1-3-5-11/h6-11,23H,1-5H2,(H,22,24)(H,19,20,21)
DMER7QX CS C1CCC(CC1)NC2=NC=NC(=C2)C(=O)NC3=C(C=C(C=C3)O)Cl
DMER7QX IK JCXGHZCWAHCYGY-UHFFFAOYSA-N
DMER7QX IU N-(2-chloro-4-hydroxyphenyl)-6-(cyclohexylamino)pyrimidine-4-carboxamide
DMS3HNM ID DMS3HNM
DMS3HNM DN Jte 013
DMS3HNM HS Patented
DMS3HNM SN Jte 013; JTE-013; 383150-41-2; CHEMBL1368758; S1P2 Receptor Antagonist, JTE-013; N-(2,6-dichloropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide; 1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea; 1-(1,3-Dimethyl-4-isopropyl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-4-(3,5-dichloro-4-pyridinyl)-semicarbazide; pyrazolopyridine analog; C17H19Cl2N7O; GTPL2917; SCHEMBL5911940; CHEBI:92763; CTK8F0047; SYN5010; DTXSID60436982; AOB1935; HMS3650O12;
DMS3HNM DT Small molecular drug
DMS3HNM PC 10223146
DMS3HNM MW 408.3
DMS3HNM FM C17H19Cl2N7O
DMS3HNM IC InChI=1S/C17H19Cl2N7O/c1-8(2)11-7-14(22-16-15(11)9(3)25-26(16)4)23-24-17(27)20-10-5-12(18)21-13(19)6-10/h5-8H,1-4H3,(H,22,23)(H2,20,21,24,27)
DMS3HNM CS CC1=NN(C2=C1C(=CC(=N2)NNC(=O)NC3=CC(=NC(=C3)Cl)Cl)C(C)C)C
DMS3HNM IK RNSLRQNDXRSASX-UHFFFAOYSA-N
DMS3HNM IU 1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea
DMS3HNM CA CAS 383150-41-2
DMS3HNM CB CHEBI:92763
DMS3HNM DE Discovery agent
DMGTSCP ID DMGTSCP
DMGTSCP DN JWH-015
DMGTSCP HS Patented
DMGTSCP SN JWH-015; 155471-08-2; JWH 015; UNII-W4FL204T10; (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; JWH015; (2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone; CHEMBL306764; W4FL204T10; MFCD02094630; (2-methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-yl)methanone; JHW 015; SR-01000597570; (2-Methyl-1-propylindol-3-yl)(naphthalen-1-yl)methanone; NCGC00025117-01; Tocris-1341; PubChem19328; MLS002153392; SCHEMBL497044; GTPL5558; AC1N784D; BDBM21282; CHEBI:92318; DTXSID60165902; AOB5643; MolPort-003-983-602
DMGTSCP DT Small molecular drug
DMGTSCP PC 4273754
DMGTSCP MW 327.4
DMGTSCP FM C23H21NO
DMGTSCP IC InChI=1S/C23H21NO/c1-3-15-24-16(2)22(20-12-6-7-14-21(20)24)23(25)19-13-8-10-17-9-4-5-11-18(17)19/h4-14H,3,15H2,1-2H3
DMGTSCP CS CCCN1C(=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43)C
DMGTSCP IK LJSBBBWQTLXQEN-UHFFFAOYSA-N
DMGTSCP IU (2-methyl-1-propylindol-3-yl)-naphthalen-1-ylmethanone
DMGTSCP CA CAS 155471-08-2
DMGTSCP CB CHEBI:92318
DMGTSCP DE Organ transplant rejection
DM7UK5E ID DM7UK5E
DM7UK5E DN KadcoccitoneA
DM7UK5E HS Patented
DM7UK5E CP Nanjing Zhengliang Med. Tech. CO
DMAGVXW ID DMAGVXW
DMAGVXW DN KENPAULLONE
DMAGVXW HS Patented
DMAGVXW SN kenpaullone; 142273-20-9; 9-Bromopaullone; NSC 664704; 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; NSC-664704; NSC664704; MLS002702152; CHEMBL296586; 9-Bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one; Indolo[3,2-d][1]benzazepin-6(5H)-one,9-bromo-7,12-dihydro-; QQUXFYAWXPMDOE-UHFFFAOYSA-N; 9-Bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one; 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Bromo-7,12-dihydro-indolo-[3,2-d]-[1]benzazepin-6(5H)-one
DMAGVXW DT Small molecular drug
DMAGVXW PC 3820
DMAGVXW MW 327.17
DMAGVXW FM C16H11BrN2O
DMAGVXW IC InChI=1S/C16H11BrN2O/c17-9-5-6-14-11(7-9)12-8-15(20)18-13-4-2-1-3-10(13)16(12)19-14/h1-7,19H,8H2,(H,18,20)
DMAGVXW CS C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)Br
DMAGVXW IK QQUXFYAWXPMDOE-UHFFFAOYSA-N
DMAGVXW IU 9-bromo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one
DMAGVXW CA CAS 142273-20-9
DMAGVXW CB CHEBI:92658
DMAGVXW DE Discovery agent
DM1ZK7E ID DM1ZK7E
DM1ZK7E DN Ketoheterocycle derivative 1
DM1ZK7E HS Patented
DM1ZK7E SN PMID26413912-Compound-17
DM1ZK7E CP THE SCRIPPS RESEARCH INSTITUTE
DM1ZK7E DT Small molecular drug
DM3KW2A ID DM3KW2A
DM3KW2A DN Ketoheterocycle derivative 2
DM3KW2A HS Patented
DM3KW2A SN PMID26413912-Compound-18
DM3KW2A CP THE SCRIPPS RESEARCH INSTITUTE
DM3KW2A DT Small molecular drug
DMFHD05 ID DMFHD05
DMFHD05 DN Ketoheterocycle derivative 3
DMFHD05 HS Patented
DMFHD05 SN PMID26413912-Compound-22
DMFHD05 CP Janssen Pharmaceutica N.V
DMFHD05 DT Small molecular drug
DM2LQXY ID DM2LQXY
DM2LQXY DN Ketoheterocycle derivative 4
DM2LQXY HS Patented
DM2LQXY SN PMID26413912-Compound-23
DM2LQXY CP Janssen Pharmaceutica N.V
DM2LQXY DT Small molecular drug
DMRY7KV ID DMRY7KV
DMRY7KV DN KRDULPYOVRWKMA-UHFFFAOYSA-N
DMRY7KV HS Patented
DMRY7KV SN CHEMBL2216867; SCHEMBL2014247; KRDULPYOVRWKMA-UHFFFAOYSA-N; BDBM50004539; N-{1-[5-Chloro-8-(3-fluorophenyl)cinnolin-7-yl]ethyl}-9H-purin-6-amine
DMRY7KV DT Small molecular drug
DMRY7KV PC 53235521
DMRY7KV MW 419.8
DMRY7KV FM C21H15ClFN7
DMRY7KV IC InChI=1S/C21H15ClFN7/c1-11(29-21-19-20(25-9-24-19)26-10-27-21)15-8-16(22)14-5-6-28-30-18(14)17(15)12-3-2-4-13(23)7-12/h2-11H,1H3,(H2,24,25,26,27,29)
DMRY7KV CS CC(C1=CC(=C2C=CN=NC2=C1C3=CC(=CC=C3)F)Cl)NC4=NC=NC5=C4NC=N5
DMRY7KV IK KRDULPYOVRWKMA-UHFFFAOYSA-N
DMRY7KV IU N-[1-[5-chloro-8-(3-fluorophenyl)cinnolin-7-yl]ethyl]-7H-purin-6-amine
DMDYKPC ID DMDYKPC
DMDYKPC DN Lactam derivative 1
DMDYKPC HS Patented
DMDYKPC SN PMID25470667-Compound-Figure5-13
DMDYKPC CP ASTRAZENECA AB ASTRAZENECA UK LIMITED
DMDYKPC DT Small molecular drug
DMDYKPC PC 53472374
DMDYKPC MW 401.2
DMDYKPC FM C19H14Cl2N4O2
DMDYKPC IC InChI=1S/C19H14Cl2N4O2/c20-12-3-6-14(15(21)9-12)11-1-4-13(5-2-11)25-7-8-27-18-16(19(25)26)17(22)23-10-24-18/h1-6,9-10H,7-8H2,(H2,22,23,24)
DMDYKPC CS C1COC2=NC=NC(=C2C(=O)N1C3=CC=C(C=C3)C4=C(C=C(C=C4)Cl)Cl)N
DMDYKPC IK QDUBGZSEYIQVEI-UHFFFAOYSA-N
DMDYKPC IU 4-amino-6-[4-(2,4-dichlorophenyl)phenyl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one
DMT58QE ID DMT58QE
DMT58QE DN Lactam derivative 2
DMT58QE HS Patented
DMT58QE SN PMID25470667-Compound-Figure5-15
DMT58QE CP GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMT58QE DT Small molecular drug
DMT58QE PC 71062853
DMT58QE MW 406.8
DMT58QE FM C20H15ClN6O2
DMT58QE IC InChI=1S/C20H15ClN6O2/c21-13-2-1-3-14(9-13)26-5-4-12-8-15(10-23-18(12)26)27-6-7-29-19-16(20(27)28)17(22)24-11-25-19/h1-5,8-11H,6-7H2,(H2,22,24,25)
DMT58QE CS C1COC2=NC=NC(=C2C(=O)N1C3=CN=C4C(=C3)C=CN4C5=CC(=CC=C5)Cl)N
DMT58QE IK IHNUTZUAQGMDQV-UHFFFAOYSA-N
DMT58QE IU 4-amino-6-[1-(3-chlorophenyl)pyrrolo[2,3-b]pyridin-5-yl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one
DMD0XIL ID DMD0XIL
DMD0XIL DN Lactam derivative 3
DMD0XIL HS Patented
DMD0XIL SN PMID25470667-Compound-Figure5-16
DMD0XIL CP GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMD0XIL DT Small molecular drug
DMD0XIL PC 74763144
DMD0XIL MW 455.4
DMD0XIL FM C22H16F3N5O3
DMD0XIL IC InChI=1S/C22H16F3N5O3/c23-22(24,25)33-16-3-1-2-14(11-16)29-7-6-13-10-15(4-5-17(13)29)30-8-9-32-20-18(21(30)31)19(26)27-12-28-20/h1-7,10-12H,8-9H2,(H2,26,27,28)
DMD0XIL CS C1COC2=NC=NC(=C2C(=O)N1C3=CC4=C(C=C3)N(C=C4)C5=CC(=CC=C5)OC(F)(F)F)N
DMD0XIL IK QBBURCWZLKKIPV-UHFFFAOYSA-N
DMD0XIL IU 4-amino-6-[1-[3-(trifluoromethoxy)phenyl]indol-5-yl]-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one
DMJ3ZAI ID DMJ3ZAI
DMJ3ZAI DN Lactam derivative 4
DMJ3ZAI HS Patented
DMJ3ZAI SN PMID25470667-Compound-Figure5-7
DMJ3ZAI CP MERCK SHARP & DOHME CORP. GRAHAM, Thomas SHEN, Dong-Ming NARGUND, Ravi, P. WU, Zhicai LIU, Wenshen
DMJ3ZAI DT Small molecular drug
DMJ3ZAI PC 60164075
DMJ3ZAI MW 508.7
DMJ3ZAI FM C29H40N4O4
DMJ3ZAI IC InChI=1S/C29H40N4O4/c1-2-3-4-5-6-7-8-24-31-27(30)26-28(32-24)37-18-17-33(29(26)36)23-15-13-22(14-16-23)21-11-9-20(10-12-21)19-25(34)35/h13-16,20-21H,2-12,17-19H2,1H3,(H,34,35)(H2,30,31,32)
DMJ3ZAI CS CCCCCCCCC1=NC(=C2C(=N1)OCCN(C2=O)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)N
DMJ3ZAI IK AGYANLSXRVBLRK-UHFFFAOYSA-N
DMJ3ZAI IU 2-[4-[4-(4-amino-2-octyl-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid
DMX5FYZ ID DMX5FYZ
DMX5FYZ DN Lactam derivative 5
DMX5FYZ HS Patented
DMX5FYZ SN PMID25470667-Compound-Figure5-8
DMX5FYZ CP MERCK SHARP & DOHME CORP. GRAHAM, Thomas SHEN, Dong-Ming NARGUND, Ravi, P. WU, Zhicai LIU, Wenshen
DMX5FYZ DT Small molecular drug
DMX5FYZ PC 60194497
DMX5FYZ MW 510.6
DMX5FYZ FM C28H38N4O5
DMX5FYZ IC InChI=1S/C28H38N4O5/c1-2-3-4-5-6-16-37-28-30-25(29)24-26(31-28)36-17-15-32(27(24)35)22-13-11-21(12-14-22)20-9-7-19(8-10-20)18-23(33)34/h11-14,19-20H,2-10,15-18H2,1H3,(H,33,34)(H2,29,30,31)
DMX5FYZ CS CCCCCCCOC1=NC(=C2C(=N1)OCCN(C2=O)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)N
DMX5FYZ IK ZERDUDAYCJCZOG-UHFFFAOYSA-N
DMX5FYZ IU 2-[4-[4-(4-amino-2-heptoxy-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid
DMWC3P5 ID DMWC3P5
DMWC3P5 DN Lactol derivative 1
DMWC3P5 HS Patented
DMWC3P5 SN PMID27537201-Compound-Figure5down
DMWC3P5 CP RedX Pharma Limited (Manchester, GB)
DMWC3P5 DT Small molecular drug
DMP3GRA ID DMP3GRA
DMP3GRA DN Lactol derivative 2
DMP3GRA HS Patented
DMP3GRA SN PMID27537201-Compound-Figure6
DMP3GRA CP REDX PHARMA LIMITED LINDSAY, Derek JACKSON, PeteREDX PHARMA LIMITED LINDSAY, Derek JACKSON, Peter HINDLEY, Stephen BHAMRA, IndeREDX PHARMA LTD [GBREDX PHARMA LTD [GB]BRADFORD PHARMA LTD [GBBRADFORD PHARMA LTREDX PHARMA LTD
DMP3GRA DT Small molecular drug
DMCULK7 ID DMCULK7
DMCULK7 DN Lazabemide
DMCULK7 HS Patented
DMCULK7 SN 103878-84-8; Ro-19-6327; N-(2-Aminoethyl)-5-chloropicolinamide; CCRIS 7301; UNII-420HD787N9; N-(2-aminoethyl)-5-chloropyridine-2-carboxamide; Ro 19-6327 hydrate; CHEMBL279390; Ro 19-6327/000; 420HD787N9; C8H10ClN3O; 2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide; NCGC00167737-01; Lazabemide [USAN:INN]; Lazabemide [USAN:INN:BAN]; Lazabemine; Pakio; Tempium; Ro-41-3776; Ro-19-6327/000; LAZEBEMIDE
DMCULK7 CP Roche Holding AG
DMCULK7 DT Small molecular drug
DMCULK7 PC 71307
DMCULK7 MW 199.64
DMCULK7 FM C8H10ClN3O
DMCULK7 IC InChI=1S/C8H10ClN3O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10/h1-2,5H,3-4,10H2,(H,11,13)
DMCULK7 CS C1=CC(=NC=C1Cl)C(=O)NCCN
DMCULK7 IK JZXRLKWWVNUZRB-UHFFFAOYSA-N
DMCULK7 IU N-(2-aminoethyl)-5-chloropyridine-2-carboxamide
DMCULK7 CA CAS 103878-84-8
DMCULK7 DE Skin imperfections; Cognitive impairment
DM189D7 ID DM189D7
DM189D7 DN Lazabemide analog 1
DM189D7 HS Patented
DM189D7 SN PMID29324067-Compound-23
DM189D7 CP University Zhejiang Technology
DM189D7 DT Small molecular drug
DM1STAD ID DM1STAD
DM1STAD DN L-piperazino-3-phenyl-indane derivative 1
DM1STAD HS Patented
DM1STAD SN PMID26609882-Compound-57
DM1STAD CP H. LUNDBECK A/S HOLM, Ren BRUUN, LonH. Lundbeck A/S
DM1STAD DT Small molecular drug
DMGKQXP ID DMGKQXP
DMGKQXP DN Lycorine dimer salt derivative 1
DMGKQXP HS Patented
DMGKQXP SN PMID27967267-Compound-40
DMGKQXP CP Kunming Inst Botany CN ACAD
DMGKQXP DT Small molecular drug
DMN7I9C ID DMN7I9C
DMN7I9C DN Macrocycle derivative 1
DMN7I9C HS Patented
DMN7I9C SN PMID30107136-Compound-Example65
DMN7I9C CP Bristol-Myers Squibb Company
DMN7I9C DT Small molecule immunotherapy
DMN7I9C DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM1KBSV ID DM1KBSV
DM1KBSV DN Macrocycle derivative 13
DM1KBSV HS Patented
DM1KBSV SN PMID28270010-Compound-Figure21-a
DM1KBSV CP CS THERAPEUTICS INC
DM1KBSV DT Small molecular drug
DM1KBSV PC 123787452
DM1KBSV MW 395.4
DM1KBSV FM C20H18FN5O3
DM1KBSV IC InChI=1S/C20H18FN5O3/c1-11-14-8-13(21)3-4-16(14)27-5-6-28-20-18(15(9-22)26(2)25-20)12-7-17(29-11)19(23)24-10-12/h3-4,7-8,10-11H,5-6H2,1-2H3,(H2,23,24)
DM1KBSV CS CC1C2=C(C=CC(=C2)F)OCCOC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C
DM1KBSV IK IAURDDBZTWBKOT-UHFFFAOYSA-N
DM1KBSV IU 20-amino-14-fluoro-4,17-dimethyl-7,10,18-trioxa-4,5,21-triazatetracyclo[17.3.1.02,6.011,16]tricosa-1(23),2,5,11(16),12,14,19,21-octaene-3-carbonitrile
DM1KBSV DE Cell proliferative disorder
DMXSRPH ID DMXSRPH
DMXSRPH DN Macrocycle derivative 14
DMXSRPH HS Patented
DMXSRPH SN PMID26161698-Compound-7
DMXSRPH CP CT NAC INVESTIGACIONES ONCOLOGICAS CNIO [ES]
DMXSRPH DT Small molecular drug
DMXSRPH PC 136644752
DMXSRPH MW 309.4
DMXSRPH FM C17H19N5O
DMXSRPH IC InChI=1S/C17H19N5O/c1-3-13-11-14(4-1)23-10-9-18-7-2-8-19-16-5-6-17-20-12-15(13)22(17)21-16/h1,3-6,11-12,18H,2,7-10H2,(H,19,21)
DMXSRPH CS C1CNCCOC2=CC=CC(=C2)C3=CN=C4N3N=C(C=C4)NC1
DMXSRPH IK LGJSILJEEDDVAZ-UHFFFAOYSA-N
DMXSRPH IU 7-oxa-10,14,19,21,22-pentazatetracyclo[13.5.2.12,6.018,21]tricosa-1(20),2(23),3,5,15(22),16,18-heptaene
DM5OEQZ ID DM5OEQZ
DM5OEQZ DN Macrocycle derivative 2
DM5OEQZ HS Patented
DM5OEQZ SN PMID30107136-Compound-Example66
DM5OEQZ CP Bristol-Myers Squibb Company
DM5OEQZ DT Small molecule immunotherapy
DM5OEQZ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMYGFTI ID DMYGFTI
DMYGFTI DN Macrocycle derivative 3
DMYGFTI HS Patented
DMYGFTI SN PMID30107136-Compound-Example67
DMYGFTI CP Bristol-Myers Squibb Company
DMYGFTI DT Small molecule immunotherapy
DMYGFTI DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMOQBN4 ID DMOQBN4
DMOQBN4 DN Macrocycle derivative 4
DMOQBN4 HS Patented
DMOQBN4 SN PMID30107136-Compound-Example68
DMOQBN4 CP BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMOQBN4 DT Small molecule immunotherapy
DMOQBN4 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMK3UJY ID DMK3UJY
DMK3UJY DN Macrocycle derivative 5
DMK3UJY HS Patented
DMK3UJY SN PMID30107136-Compound-Example69
DMK3UJY CP BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMK3UJY DT Small molecule immunotherapy
DMK3UJY DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMQ84KW ID DMQ84KW
DMQ84KW DN Macrocycle derivative 6
DMQ84KW HS Patented
DMQ84KW SN PMID30107136-Compound-Example70
DMQ84KW CP BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMQ84KW DT Small molecule immunotherapy
DMQ84KW DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMP2JF0 ID DMP2JF0
DMP2JF0 DN Macrocycle derivative 7
DMP2JF0 HS Patented
DMP2JF0 SN PMID30107136-Compound-Example71
DMP2JF0 CP BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMP2JF0 DT Small molecule immunotherapy
DMP2JF0 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMOMTBE ID DMOMTBE
DMOMTBE DN Macrocycle derivative 8
DMOMTBE HS Patented
DMOMTBE SN PMID30107136-Compound-Example72
DMOMTBE CP BRISTOL-MYERS SQUIBB COMPANBristol-Myers Squibb Company
DMOMTBE DT Small molecule immunotherapy
DMOMTBE DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMARU0E ID DMARU0E
DMARU0E DN Macrocycle derivative 9
DMARU0E HS Patented
DMARU0E SN PMID30107136-Compound-Example73
DMARU0E CP BRISTOL-MYERS SQUIBB COMPANY
DMARU0E DT Small molecule immunotherapy
DMARU0E DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMS65IT ID DMS65IT
DMS65IT DN Macrocyclic peptide analog 1
DMS65IT HS Patented
DMS65IT SN PMID30107136-Compound-Example74
DMS65IT CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMS65IT DT Small molecule immunotherapy
DMS65IT DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMOGLBZ ID DMOGLBZ
DMOGLBZ DN Macrocyclic peptide analog 2
DMOGLBZ HS Patented
DMOGLBZ SN PMID30107136-Compound-Example75
DMOGLBZ CP Aurigene Discovery Technologies Limited
DMOGLBZ DT Small molecule immunotherapy
DMOGLBZ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMV172W ID DMV172W
DMV172W DN Macrocyclic peptide analog 3
DMV172W HS Patented
DMV172W SN PMID30107136-Compound-Example76
DMV172W CP Aurigene Discovery Technologies Limited
DMV172W DT Small molecule immunotherapy
DMV172W DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM0ON7S ID DM0ON7S
DM0ON7S DN Macrolactam derivative 1
DM0ON7S HS Patented
DM0ON7S SN PMID27310003-Compound-15
DM0ON7S CP BIOGEN MA INC
DM0ON7S DT Small molecular drug
DME72VA ID DME72VA
DME72VA DN Macrolactam derivative 2
DME72VA HS Patented
DME72VA SN PMID27310003-Compound-16
DME72VA CP BIOGEN MA INC
DME72VA DT Small molecular drug
DMFNGUV ID DMFNGUV
DMFNGUV DN Macrolactam derivative 3
DMFNGUV HS Patented
DMFNGUV SN PMID27310003-Compound-17
DMFNGUV CP BIOGEN MA INC
DMFNGUV DT Small molecular drug
DM5AXHF ID DM5AXHF
DM5AXHF DN Macrolactam derivative 4
DM5AXHF HS Patented
DM5AXHF SN PMID27310003-Compound-18
DM5AXHF CP BIOGEN MA INC
DM5AXHF DT Small molecular drug
DMINM8F ID DMINM8F
DMINM8F DN Maleimides derivative 1
DMINM8F HS Patented
DMINM8F SN PMID27828716-Compound-1M
DMINM8F CP STEM CELLS FOR SAFER MEDICINES LIMITED BONE, Heather Karyn TOSH, David WELHAM, Melanie Joanne
DMINM8F DT Small molecular drug
DMUVYWE ID DMUVYWE
DMUVYWE DN Maleimides derivative 2
DMUVYWE HS Patented
DMUVYWE SN PMID27828716-Compound-SB216763
DMUVYWE CP RUDD, ChristopheChung-Ang University
DMEFQND ID DMEFQND
DMEFQND DN Maleimides derivative 3
DMEFQND HS Patented
DMEFQND SN PMID27828716-Compound-SB415286
DMEFQND CP RUDD, Christopher
DMIE7U3 ID DMIE7U3
DMIE7U3 DN Mannoside derivative 1
DMIE7U3 HS Patented
DMIE7U3 SN PMID26651364-Compound-100
DMIE7U3 CP VERTEX PHARMACEUTICALS INCORPORATED
DMIE7U3 DT Carbohydrates
DMIE7U3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZYRHN ID DMZYRHN
DMZYRHN DN Mannoside derivative 10
DMZYRHN HS Patented
DMZYRHN SN PMID26651364-Compound-96
DMZYRHN CP VERTEX PHARMACEUTICALS INCORPORATED
DMZYRHN DT Carbohydrates
DMZYRHN DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM8I051 ID DM8I051
DM8I051 DN Mannoside derivative 11
DM8I051 HS Patented
DM8I051 SN PMID26651364-Compound-97
DM8I051 CP VERTEX PHARMACEUTICALS INCORPORATED
DM8I051 DT Carbohydrates
DM8I051 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4QUY0 ID DM4QUY0
DM4QUY0 DN Mannoside derivative 12
DM4QUY0 HS Patented
DM4QUY0 SN PMID26651364-Compound-98
DM4QUY0 CP VERTEX PHARMACEUTICALS INCORPORATED
DM4QUY0 DT Carbohydrates
DM4QUY0 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM0U7P9 ID DM0U7P9
DM0U7P9 DN Mannoside derivative 13
DM0U7P9 HS Patented
DM0U7P9 SN PMID26651364-Compound-99
DM0U7P9 CP VERTEX PHARMACEUTICALS INCORPORATED
DM0U7P9 DT Carbohydrates
DM0U7P9 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMFEQD2 ID DMFEQD2
DMFEQD2 DN Mannoside derivative 2
DMFEQD2 HS Patented
DMFEQD2 SN PMID26651364-Compound-101
DMFEQD2 CP VERTEX PHARMACEUTICALS INCORPORATED
DMFEQD2 DT Carbohydrates
DMFEQD2 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMPF2UG ID DMPF2UG
DMPF2UG DN Mannoside derivative 3
DMPF2UG HS Patented
DMPF2UG SN PMID26651364-Compound-102
DMPF2UG CP VERTEX PHARMACEUTICALS INCORPORATED
DMPF2UG DT Carbohydrates
DMPF2UG DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZBY73 ID DMZBY73
DMZBY73 DN Mannoside derivative 4
DMZBY73 HS Patented
DMZBY73 SN PMID26651364-Compound-103
DMZBY73 CP VERTEX PHARMACEUTICALS INCORPORATED
DMZBY73 DT Carbohydrates
DMZBY73 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMXNY8 ID DMMXNY8
DMMXNY8 DN Mannoside derivative 5
DMMXNY8 HS Patented
DMMXNY8 SN PMID26651364-Compound-104
DMMXNY8 CP VERTEX PHARMACEUTICALS INCORPORATED
DMMXNY8 DT Carbohydrates
DMMXNY8 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMCM3NW ID DMCM3NW
DMCM3NW DN Mannoside derivative 6
DMCM3NW HS Patented
DMCM3NW SN PMID26651364-Compound-92
DMCM3NW CP VERTEX PHARMACEUTICALS INCORPORATED
DMCM3NW DT Carbohydrates
DMCM3NW DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMOUT1F ID DMOUT1F
DMOUT1F DN Mannoside derivative 7
DMOUT1F HS Patented
DMOUT1F SN PMID26651364-Compound-93
DMOUT1F CP VERTEX PHARMACEUTICALS INCORPORATED
DMOUT1F DT Carbohydrates
DMOUT1F DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMKTJAH ID DMKTJAH
DMKTJAH DN Mannoside derivative 8
DMKTJAH HS Patented
DMKTJAH SN PMID26651364-Compound-94
DMKTJAH CP VERTEX PHARMACEUTICALS INCORPORATED
DMKTJAH DT Carbohydrates
DMKTJAH DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMIKZXD ID DMIKZXD
DMIKZXD DN Mannoside derivative 9
DMIKZXD HS Patented
DMIKZXD SN PMID26651364-Compound-95
DMIKZXD CP VERTEX PHARMACEUTICALS INCORPORATED
DMIKZXD DT Carbohydrates
DMIKZXD DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMCS9P ID DMMCS9P
DMMCS9P DN Matairesinol derivative 1
DMMCS9P HS Patented
DMMCS9P SN PMID26882240-Compound-39
DMMCS9P CP Office of Research Affairs/UIF, Yonsei University, S. Korea
DMMCS9P DT Small molecular drug
DMUOW3T ID DMUOW3T
DMUOW3T DN Metal complex derivative 1
DMUOW3T HS Patented
DMUOW3T SN PMID27977313-Compound-13
DMUOW3T DT Small molecular drug
DM0BTH8 ID DM0BTH8
DM0BTH8 DN Metal complex derivative 2
DM0BTH8 HS Patented
DM0BTH8 SN PMID27977313-Compound-14
DM0BTH8 DT Small molecular drug
DM31BMP ID DM31BMP
DM31BMP DN Metal complex derivative 3
DM31BMP HS Patented
DM31BMP SN PMID27977313-Compound-Figure4e
DM31BMP DT Small molecular drug
DM9BYJ0 ID DM9BYJ0
DM9BYJ0 DN Methyl 2-amino-4-phenylthiophene-3-carboxylate
DM9BYJ0 HS Patented
DM9BYJ0 SN methyl 2-amino-4-phenylthiophene-3-carboxylate; 67171-55-5; 2-Amino-4-phenyl-thiophene-3-carboxylic acid methyl ester; 2-Amino-4-phenylthiophene-3-carboxylic acid methyl ester; 2-amino-4-phenylthiophene-3-carboxylic acidmethyl ester; AC1LEGNM; SMR000122717; ChemDiv3_014276; MLS000523644; SCHEMBL688523; METHYL2-AMINO-4-PHENYLTHIOPHENE-3-CARBOXYLATE; CHEMBL1456242; CTK6I8713; ZINC52966; DTXSID30350681; HMS1513I20; BDBM139491; HMS2354F24; KS-00003KD2; ALBB-001671; BBL015795; SBB006989; MFCD01050444; 7878AE; STK256668; AKOS000220131; FS
DM9BYJ0 DT Small molecular drug
DM9BYJ0 PC 685886
DM9BYJ0 MW 233.29
DM9BYJ0 FM C12H11NO2S
DM9BYJ0 IC InChI=1S/C12H11NO2S/c1-15-12(14)10-9(7-16-11(10)13)8-5-3-2-4-6-8/h2-7H,13H2,1H3
DM9BYJ0 CS COC(=O)C1=C(SC=C1C2=CC=CC=C2)N
DM9BYJ0 IK KHNSKPUYBBZGLW-UHFFFAOYSA-N
DM9BYJ0 IU methyl 2-amino-4-phenylthiophene-3-carboxylate
DM9BYJ0 CA CAS 67171-55-5
DMUNME2 ID DMUNME2
DMUNME2 DN Methylbenzenesulfonamide derivative 1
DMUNME2 HS Patented
DMUNME2 SN PMID27539678-Compound-15
DMUNME2 CP UNIVERSITY OF SOUTH AUSTRALIA CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC
DMUNME2 DT Small molecular drug
DM5PS6K ID DM5PS6K
DM5PS6K DN Methyl-piperidine compound 1
DM5PS6K HS Patented
DM5PS6K SN PMID28627961-Compound-36
DM5PS6K CP ELI LILLY AND COMPANY
DM5PS6K DT Small molecular drug
DM5PS6K DE Neoplasm; Angiogenesis disorder
DMHVZ4M ID DMHVZ4M
DMHVZ4M DN Methylsulfonylbenzamide derivative 2
DMHVZ4M HS Patented
DMHVZ4M SN PMID25539043-Compound-WO2013088315Example52
DMHVZ4M CP PFIZER LIMITED
DMHVZ4M DT Small molecular drug
DM8UOY6 ID DM8UOY6
DM8UOY6 DN MHHFJYABEVJNEG-UHFFFAOYSA-N
DM8UOY6 HS Patented
DM8UOY6 SN CHEMBL1076743; SCHEMBL3036046; MHHFJYABEVJNEG-UHFFFAOYSA-N; BDBM50313340; 6-(dipropylamino)-N-(2-methyl-4-sulfamoylphenyl)pyrimidine-4-carboxamide; N-[4-(aminosulfonyl)-2-methylphenyl]-6-(dipropylamino)pyrimidine-4-carboxamide
DM8UOY6 DT Small molecular drug
DM8UOY6 PC 25182905
DM8UOY6 MW 391.5
DM8UOY6 FM C18H25N5O3S
DM8UOY6 IC InChI=1S/C18H25N5O3S/c1-4-8-23(9-5-2)17-11-16(20-12-21-17)18(24)22-15-7-6-14(10-13(15)3)27(19,25)26/h6-7,10-12H,4-5,8-9H2,1-3H3,(H,22,24)(H2,19,25,26)
DM8UOY6 CS CCCN(CCC)C1=NC=NC(=C1)C(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)C
DM8UOY6 IK MHHFJYABEVJNEG-UHFFFAOYSA-N
DM8UOY6 IU 6-(dipropylamino)-N-(2-methyl-4-sulfamoylphenyl)pyrimidine-4-carboxamide
DMNEY58 ID DMNEY58
DMNEY58 DN ML272
DMNEY58 HS Patented
DMNEY58 SN N-(2-(4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-2-naphthamide; CHEMBL492797; 1130067-18-3; ML272; VU0155056-2; SCHEMBL2724877; BDBM87245; cid_53481919; CHEBI:131157; NCGC00386898-01; VU0155056-3; VU0155056-1; US9453017, 3; VU0156056 (1); N-[2-[4-(2-keto-3H-benzimidazol-1-yl)piperidino]ethyl]-2-naphthamide;hydrochloride; N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide;hydrochloride; N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]naphthalene-2-carboxamide
DMNEY58 DT Small molecular drug
DMNEY58 PC 25105704
DMNEY58 MW 414.5
DMNEY58 FM C25H26N4O2
DMNEY58 IC InChI=1S/C25H26N4O2/c30-24(20-10-9-18-5-1-2-6-19(18)17-20)26-13-16-28-14-11-21(12-15-28)29-23-8-4-3-7-22(23)27-25(29)31/h1-10,17,21H,11-16H2,(H,26,30)(H,27,31)
DMNEY58 CS C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCNC(=O)C4=CC5=CC=CC=C5C=C4
DMNEY58 IK IXLLRNNFUYEADZ-UHFFFAOYSA-N
DMNEY58 IU N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]naphthalene-2-carboxamide
DMNEY58 CB CHEBI:131157
DMRWNAY ID DMRWNAY
DMRWNAY DN Monoamine derivative 1
DMRWNAY HS Patented
DMRWNAY SN PMID26815044-Compound-94
DMRWNAY CP UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DMRWNAY DT Small molecular drug
DMRWNAY PC 65055
DMRWNAY MW 211.3
DMRWNAY FM C15H17N
DMRWNAY IC InChI=1S/C15H17N/c1-3-7-14(8-4-1)11-12-16-13-15-9-5-2-6-10-15/h1-10,16H,11-13H2
DMRWNAY CS C1=CC=C(C=C1)CCNCC2=CC=CC=C2
DMRWNAY IK UPABQMWFWCMOFV-UHFFFAOYSA-N
DMRWNAY IU N-benzyl-2-phenylethanamine
DMRWNAY CA CAS 3647-71-0
DMRWNAY CB CHEBI:52148
DMRWNAY DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMAZ6DI ID DMAZ6DI
DMAZ6DI DN Monoamine derivative 2
DMAZ6DI HS Patented
DMAZ6DI SN PMID26815044-Compound-95
DMAZ6DI CP UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DMAZ6DI DT Small molecular drug
DMAZ6DI PC 4260604
DMAZ6DI MW 303.4
DMAZ6DI FM C21H21NO
DMAZ6DI IC InChI=1S/C21H21NO/c1-3-8-18(9-4-1)14-15-22-17-19-10-7-13-21(16-19)23-20-11-5-2-6-12-20/h1-13,16,22H,14-15,17H2
DMAZ6DI CS C1=CC=C(C=C1)CCNCC2=CC(=CC=C2)OC3=CC=CC=C3
DMAZ6DI IK VXWOCJGIIONIQR-UHFFFAOYSA-N
DMAZ6DI IU N-[(3-phenoxyphenyl)methyl]-2-phenylethanamine
DMAZ6DI DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM4I75L ID DM4I75L
DM4I75L DN Monoamine derivative 3
DM4I75L HS Patented
DM4I75L SN PMID26815044-Compound-96
DM4I75L CP UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DM4I75L DT Small molecular drug
DM4I75L PC 43220319
DM4I75L MW 239.35
DM4I75L FM C17H21N
DM4I75L IC InChI=1S/C17H21N/c1-14-8-9-17(12-15(14)2)13-18-11-10-16-6-4-3-5-7-16/h3-9,12,18H,10-11,13H2,1-2H3
DM4I75L CS CC1=C(C=C(C=C1)CNCCC2=CC=CC=C2)C
DM4I75L IK XXTJZYJWHSDDJG-UHFFFAOYSA-N
DM4I75L IU N-[(3,4-dimethylphenyl)methyl]-2-phenylethanamine
DM4I75L DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMYFKP2 ID DMYFKP2
DMYFKP2 DN Monoamine derivative 4
DMYFKP2 HS Patented
DMYFKP2 SN PMID26815044-Compound-97
DMYFKP2 CP UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DMYFKP2 DT Small molecular drug
DMYFKP2 PC 1990821
DMYFKP2 MW 271.35
DMYFKP2 FM C17H21NO2
DMYFKP2 IC InChI=1S/C17H21NO2/c1-19-16-8-9-17(20-2)15(12-16)13-18-11-10-14-6-4-3-5-7-14/h3-9,12,18H,10-11,13H2,1-2H3
DMYFKP2 CS COC1=CC(=C(C=C1)OC)CNCCC2=CC=CC=C2
DMYFKP2 IK IAEIRIQVUSGNFI-UHFFFAOYSA-N
DMYFKP2 IU N-[(2,5-dimethoxyphenyl)methyl]-2-phenylethanamine
DMYFKP2 CA CAS 353773-38-3
DMYFKP2 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM3PF60 ID DM3PF60
DM3PF60 DN Monoamine derivative 5
DM3PF60 HS Patented
DM3PF60 SN PMID26815044-Compound-98
DM3PF60 CP UNILEVER PLC UNILEVER N.V. HINDUSTAN UNILEVER LIMITED ROSA, Jose, Guillermo HARICHIAN, Bijan DRENNAN, Diana, Jean BAJOR, John, Steven BOSKO, Carol, Annette
DM3PF60 DT Small molecular drug
DM3PF60 PC 17206454
DM3PF60 MW 237.34
DM3PF60 FM C14H23NO2
DM3PF60 IC InChI=1S/C14H23NO2/c1-11(2)7-8-15-10-12-5-6-13(16-3)14(9-12)17-4/h5-6,9,11,15H,7-8,10H2,1-4H3
DM3PF60 CS CC(C)CCNCC1=CC(=C(C=C1)OC)OC
DM3PF60 IK BDUIJHAHSRAUGH-UHFFFAOYSA-N
DM3PF60 IU N-[(3,4-dimethoxyphenyl)methyl]-3-methylbutan-1-amine
DM3PF60 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMCI6YH ID DMCI6YH
DMCI6YH DN Monoaryl-1,2-diamine derivative 1
DMCI6YH HS Patented
DMCI6YH SN PMID29473428-Compound-62
DMCI6YH CP BRISTOL-MYERS SQUIBB COMPANY
DMCI6YH DT Small molecular drug
DMXUNZ1 ID DMXUNZ1
DMXUNZ1 DN Monoaryl-1,2-diamine derivative 2
DMXUNZ1 HS Patented
DMXUNZ1 SN PMID29473428-Compound-63
DMXUNZ1 CP BRISTOL-MYERS SQUIBB COMPANY
DMXUNZ1 DT Small molecular drug
DMXUNZ1 PC 122587053
DMXUNZ1 MW 415
DMXUNZ1 FM C24H31ClN2O2
DMXUNZ1 IC InChI=1S/C24H31ClN2O2/c1-3-13-27(16-17-5-6-17)23-12-7-19(18(4-2)15-24(28)29)14-22(23)26-21-10-8-20(25)9-11-21/h7-12,14,17-18,26H,3-6,13,15-16H2,1-2H3,(H,28,29)
DMXUNZ1 CS CCCN(CC1CC1)C2=C(C=C(C=C2)C(CC)CC(=O)O)NC3=CC=C(C=C3)Cl
DMXUNZ1 IK XRVVTNJDVWWYSU-UHFFFAOYSA-N
DMXUNZ1 IU 3-[3-(4-chloroanilino)-4-[cyclopropylmethyl(propyl)amino]phenyl]pentanoic acid
DMAXKPC ID DMAXKPC
DMAXKPC DN Monoaryl-1,2-diamine derivative 3
DMAXKPC HS Patented
DMAXKPC SN PMID29473428-Compound-64
DMAXKPC CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMAXKPC DT Small molecular drug
DMAXKPC PC 126722449
DMAXKPC MW 482.6
DMAXKPC FM C23H29F3N4O2S
DMAXKPC IC InChI=1S/C23H29F3N4O2S/c1-13(2)12-30(15-6-4-3-5-7-15)19-9-8-14(16-11-17(16)20(31)32)10-18(19)27-22-28-21(29-33-22)23(24,25)26/h8-10,13,15-17H,3-7,11-12H2,1-2H3,(H,31,32)(H,27,28,29)
DMAXKPC CS CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)C3CC3C(=O)O)NC4=NC(=NS4)C(F)(F)F
DMAXKPC IK NXZKEHFQEXBLSD-UHFFFAOYSA-N
DMAXKPC IU 2-[4-[cyclohexyl(2-methylpropyl)amino]-3-[[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]phenyl]cyclopropane-1-carboxylic acid
DMD8AKH ID DMD8AKH
DMD8AKH DN Monoaryl-1,2-diamine derivative 4
DMD8AKH HS Patented
DMD8AKH SN PMID29473428-Compound-65
DMD8AKH CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMD8AKH DT Small molecular drug
DMJ8YZK ID DMJ8YZK
DMJ8YZK DN Monofluorine derivative 1
DMJ8YZK HS Patented
DMJ8YZK SN PMID29473428-Compound-40
DMJ8YZK CP MERCK PATENT GMBH SHERER, Brian A
DMJ8YZK DT Small molecular drug
DMJ8YZK PC 118917109
DMJ8YZK MW 336.4
DMJ8YZK FM C18H19F3N2O
DMJ8YZK IC InChI=1S/C18H19F3N2O/c19-14-3-1-2-13-16-9-22-10-23(16)15(17(13)14)8-18(20,21)11-4-6-12(24)7-5-11/h1-3,9-12,15,24H,4-8H2
DMJ8YZK CS C1CC(CCC1C(CC2C3=C(C=CC=C3F)C4=CN=CN24)(F)F)O
DMJ8YZK IK UNSORNINUVZBRF-UHFFFAOYSA-N
DMJ8YZK IU 4-[1,1-difluoro-2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexan-1-ol
DMNGQ3I ID DMNGQ3I
DMNGQ3I DN MRL20
DMNGQ3I HS Patented
DMNGQ3I SN MRL20; CHEMBL181937; (2s)-2-(2-{[1-(4-Methoxybenzoyl)-2-Methyl-5-(Trifluoromethoxy)-1h-Indol-3-Yl]methyl}phenoxy)propanoic Acid; SCHEMBL5172443; GTPL6742; BDBM50157936; (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid; (2S)-2-[2-({1-[(4-methoxyphenyl)carbonyl]-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl}methyl)phenoxy]propanoic acid; (S)-2-{2-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid
DMNGQ3I DT Small molecular drug
DMNGQ3I PC 10143056
DMNGQ3I MW 527.5
DMNGQ3I FM C28H24F3NO6
DMNGQ3I IC InChI=1S/C28H24F3NO6/c1-16-22(14-19-6-4-5-7-25(19)37-17(2)27(34)35)23-15-21(38-28(29,30)31)12-13-24(23)32(16)26(33)18-8-10-20(36-3)11-9-18/h4-13,15,17H,14H2,1-3H3,(H,34,35)/t17-/m0/s1
DMNGQ3I CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)OC)C=CC(=C2)OC(F)(F)F)CC4=CC=CC=C4O[C@@H](C)C(=O)O
DMNGQ3I IK BWTOBMCYVACNJZ-KRWDZBQOSA-N
DMNGQ3I IU (2S)-2-[2-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid
DMNGQ3I DE Discovery agent
DM8NS7U ID DM8NS7U
DM8NS7U DN MRL24
DM8NS7U HS Patented
DM8NS7U SN MRL 24
DM8NS7U DT Small molecular drug
DM8NS7U PC 9958543
DM8NS7U MW 527.5
DM8NS7U FM C28H24F3NO6
DM8NS7U IC InChI=1S/C28H24F3NO6/c1-16-23(14-18-5-4-6-21(13-18)37-17(2)27(34)35)24-15-22(38-28(29,30)31)11-12-25(24)32(16)26(33)19-7-9-20(36-3)10-8-19/h4-13,15,17H,14H2,1-3H3,(H,34,35)/t17-/m0/s1
DM8NS7U CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)OC)C=CC(=C2)OC(F)(F)F)CC4=CC(=CC=C4)O[C@@H](C)C(=O)O
DM8NS7U IK OFCWBJAYEIROGZ-KRWDZBQOSA-N
DM8NS7U IU (2S)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid
DM8NS7U DE Discovery agent
DMOZTUE ID DMOZTUE
DMOZTUE DN Mycophenolic acid/nucleotide derivative 1
DMOZTUE HS Patented
DMOZTUE SN PMID28074661-Compound-US20040023901c70
DMOZTUE CP Biota Inc
DMOZTUE DT Small molecular drug
DMHD8RK ID DMHD8RK
DMHD8RK DN Mycophenolic acid/nucleotide derivative 10
DMHD8RK HS Patented
DMHD8RK SN PMID28074661-Compound-US20087427636c61
DMHD8RK CP Gilead Sciences Inc
DMHD8RK DT Small molecular drug
DMXWOAG ID DMXWOAG
DMXWOAG DN Mycophenolic acid/nucleotide derivative 11
DMXWOAG HS Patented
DMXWOAG SN PMID28074661-Compound-US20087427636c62
DMXWOAG CP Gilead Sciences Inc
DMXWOAG DT Small molecular drug
DM47L9Q ID DM47L9Q
DM47L9Q DN Mycophenolic acid/nucleotide derivative 12
DM47L9Q HS Patented
DM47L9Q SN PMID28074661-Compound-US20087427636c63
DM47L9Q CP Gilead Sciences Inc
DM47L9Q DT Small molecular drug
DMAT9NE ID DMAT9NE
DMAT9NE DN Mycophenolic acid/nucleotide derivative 2
DMAT9NE HS Patented
DMAT9NE SN PMID28074661-Compound-US20087427636c53
DMAT9NE CP Gilead Sciences Inc
DMAT9NE DT Small molecular drug
DM5UX7B ID DM5UX7B
DM5UX7B DN Mycophenolic acid/nucleotide derivative 3
DM5UX7B HS Patented
DM5UX7B SN PMID28074661-Compound-US20087427636c54
DM5UX7B CP Gilead Sciences Inc
DM5UX7B DT Small molecular drug
DMEHMKY ID DMEHMKY
DMEHMKY DN Mycophenolic acid/nucleotide derivative 4
DMEHMKY HS Patented
DMEHMKY SN PMID28074661-Compound-US20087427636c55
DMEHMKY CP Gilead Sciences Inc
DMEHMKY DT Small molecular drug
DM74UP5 ID DM74UP5
DM74UP5 DN Mycophenolic acid/nucleotide derivative 5
DM74UP5 HS Patented
DM74UP5 SN PMID28074661-Compound-US20087427636c56
DM74UP5 CP Gilead Sciences Inc
DM74UP5 DT Small molecular drug
DMGFORB ID DMGFORB
DMGFORB DN Mycophenolic acid/nucleotide derivative 6
DMGFORB HS Patented
DMGFORB SN PMID28074661-Compound-US20087427636c57
DMGFORB CP Gilead Sciences Inc
DMGFORB DT Small molecular drug
DMC27TO ID DMC27TO
DMC27TO DN Mycophenolic acid/nucleotide derivative 7
DMC27TO HS Patented
DMC27TO SN PMID28074661-Compound-US20087427636c58
DMC27TO CP Gilead Sciences Inc
DMC27TO DT Small molecular drug
DMWGIJS ID DMWGIJS
DMWGIJS DN Mycophenolic acid/nucleotide derivative 8
DMWGIJS HS Patented
DMWGIJS SN PMID28074661-Compound-US20087427636c59
DMWGIJS CP Gilead Sciences Inc
DMWGIJS DT Small molecular drug
DMYQTLK ID DMYQTLK
DMYQTLK DN Mycophenolic acid/nucleotide derivative 9
DMYQTLK HS Patented
DMYQTLK SN PMID28074661-Compound-US20087427636c60
DMYQTLK CP Gilead Sciences Inc
DMYQTLK DT Small molecular drug
DMA8BLZ ID DMA8BLZ
DMA8BLZ DN MyriberineA
DMA8BLZ HS Patented
DMA8BLZ CP Nanjing Zhengliang Med. Tech. CO
DMH7T8C ID DMH7T8C
DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1
DMH7T8C HS Patented
DMH7T8C SN PMID27019002-Compound-19
DMH7T8C CP ORYZON GENOMICS SA [ESOryzon Genomics S.A., Spain
DMH7T8C DT Small molecular drug
DM6YV3O ID DM6YV3O
DM6YV3O DN N-(2-phenylcyclopropyl) amino acid derivative 2
DM6YV3O HS Patented
DM6YV3O SN PMID27019002-Compound-19a
DM6YV3O CP ORYZON GENOMICS SA [ESOryzon Genomics S.A., Spain
DM6YV3O DT Small molecular drug
DMFBRSL ID DMFBRSL
DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3
DMFBRSL HS Patented
DMFBRSL SN PMID27019002-Compound-19b
DMFBRSL CP ORYZON GENOMICS SA [ESOryzon Genomics S.A., Spain
DMFBRSL DT Small molecular drug
DM6TYM0 ID DM6TYM0
DM6TYM0 DN N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1
DM6TYM0 HS Patented
DM6TYM0 SN PMID26161824-Compound-186
DM6TYM0 CP THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN GREIG, lain Robert ROSS, Ruth Alexandra PERTWEE, Roger Guy TREMBLEAU, Laurent Alain Claude ABDEL-RAHMAN, Mostafa Hamed BAILLIE, Gemma Louise
DM6TYM0 DT Small molecular drug
DM6TYM0 PC 66547077
DM6TYM0 MW 346.4
DM6TYM0 FM C17H18N2O4S
DM6TYM0 IC InChI=1S/C17H18N2O4S/c1-22-14-5-3-12(4-6-14)11-18-24(20,21)17-10-13-9-15(23-2)7-8-16(13)19-17/h3-10,18-19H,11H2,1-2H3
DM6TYM0 CS COC1=CC=C(C=C1)CNS(=O)(=O)C2=CC3=C(N2)C=CC(=C3)OC
DM6TYM0 IK ZYAIUNMZKGHCRV-UHFFFAOYSA-N
DM6TYM0 IU 5-methoxy-N-[(4-methoxyphenyl)methyl]-1H-indole-2-sulfonamide
DM6TYM0 DE Obesity
DM2MPN0 ID DM2MPN0
DM2MPN0 DN N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2
DM2MPN0 HS Patented
DM2MPN0 SN PMID26161824-Compound-187
DM2MPN0 CP THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN GREIG, lain Robert ROSS, Ruth Alexandra PERTWEE, Roger Guy TREMBLEAU, Laurent Alain Claude ABDEL-RAHMAN, Mostafa Hamed BAILLIE, Gemma Louise
DM2MPN0 DT Small molecular drug
DM2MPN0 PC 66547073
DM2MPN0 MW 380.4
DM2MPN0 FM C21H17FN2O2S
DM2MPN0 IC InChI=1S/C21H17FN2O2S/c22-19-11-9-17(10-12-19)16-7-5-15(6-8-16)14-23-27(25,26)21-13-18-3-1-2-4-20(18)24-21/h1-13,23-24H,14H2
DM2MPN0 CS C1=CC=C2C(=C1)C=C(N2)S(=O)(=O)NCC3=CC=C(C=C3)C4=CC=C(C=C4)F
DM2MPN0 IK ZYXQIXCJTWOQOB-UHFFFAOYSA-N
DM2MPN0 IU N-[[4-(4-fluorophenyl)phenyl]methyl]-1H-indole-2-sulfonamide
DM2MPN0 DE Obesity
DM8GJA7 ID DM8GJA7
DM8GJA7 DN N-(arylamino)sulfonamide derivative 1
DM8GJA7 HS Patented
DM8GJA7 SN PMID28594589-Compound-TABLE3c8
DM8GJA7 CP Ardea Biosciences
DM8GJA7 DT Small molecular drug
DM8GJA7 PC 15985394
DM8GJA7 MW 560.3
DM8GJA7 FM C18H17F4IN2O4S
DM8GJA7 IC InChI=1S/C18H17F4IN2O4S/c19-11-5-9(23)1-2-14(11)24-17-15(22)12(20)6-13(21)16(17)25-30(28,29)18(3-4-18)7-10(27)8-26/h1-2,5-6,10,24-27H,3-4,7-8H2
DM8GJA7 CS C1CC1(CC(CO)O)S(=O)(=O)NC2=C(C(=C(C=C2F)F)F)NC3=C(C=C(C=C3)I)F
DM8GJA7 IK DDZSGPZIFZFUSF-UHFFFAOYSA-N
DM8GJA7 IU 1-(2,3-dihydroxypropyl)-N-[3,4,6-trifluoro-2-(2-fluoro-4-iodoanilino)phenyl]cyclopropane-1-sulfonamide
DMGQWKH ID DMGQWKH
DMGQWKH DN N-(benzimidazole/indole) benzoic acid derivative 1
DMGQWKH HS Patented
DMGQWKH SN PMID28895472-Compound-17
DMGQWKH CP ASTELLAS PHARMA INC. FURUTANI, Takashi ENJO, Kentaro KIKUCHI, AyaAstellas Pharma Inc. KAKEFUDA, Akio KONDOH, Yutaka HIRANO, Masaak
DMGQWKH DT Small molecular drug
DMOPUFM ID DMOPUFM
DMOPUFM DN N-(benzimidazole/indole) benzoic acid derivative 2
DMOPUFM HS Patented
DMOPUFM SN PMID28895472-Compound-18
DMOPUFM CP ASTELLAS PHARMA INC. FURUTANI, Takashi ENJO, Kentaro KIKUCHI, AyaAstellas Pharma Inc. KAKEFUDA, Akio KONDOH, Yutaka HIRANO, Masaak
DMOPUFM DT Small molecular drug
DM541QW ID DM541QW
DM541QW DN N-(benzimidazolylcarbonyl)-piperidine derivative 1
DM541QW HS Patented
DM541QW SN PMID28895472-Compound-14
DM541QW DT Small molecular drug
DM541QW PC 46909812
DM541QW MW 301.4
DM541QW FM C17H23N3O2
DM541QW IC InChI=1S/C17H23N3O2/c1-17(2,22)11-12-7-9-20(10-8-12)16(21)15-18-13-5-3-4-6-14(13)19-15/h3-6,12,22H,7-11H2,1-2H3,(H,18,19)
DM541QW CS CC(C)(CC1CCN(CC1)C(=O)C2=NC3=CC=CC=C3N2)O
DM541QW IK ZCKTVNQIWGZETA-UHFFFAOYSA-N
DM541QW IU 1H-benzimidazol-2-yl-[4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]methanone
DM0OMAL ID DM0OMAL
DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1
DM0OMAL HS Patented
DM0OMAL SN PMID27774824-Compound-Figure5Example25
DM0OMAL CP CADILA HEALTHCARE LIMITED
DM0OMAL DT Small molecular drug
DMARHJ9 ID DMARHJ9
DMARHJ9 DN N-(indolylcarbonyl)-piperidine derivative 1
DMARHJ9 HS Patented
DMARHJ9 SN PMID28895472-Compound-15
DMARHJ9 CP ASTELLAS PHARMA INC. AZAMI, Hidenori ABE, Tomoaki KAKEFUDA, Akio
DMARHJ9 DT Small molecular drug
DMARHJ9 PC 25210792
DMARHJ9 MW 330.4
DMARHJ9 FM C19H26N2O3
DMARHJ9 IC InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3
DMARHJ9 CS CC(C)(CC1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)OC)O
DMARHJ9 IK OXSCPDKUZWPWFR-UHFFFAOYSA-N
DMARHJ9 IU [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone
DM310ES ID DM310ES
DM310ES DN N-(naphthylamino)-benzoate derivative 1
DM310ES HS Patented
DM310ES SN PMID28895472-Compound-28
DM310ES DT Small molecular drug
DM310ES PC 56851703
DM310ES MW 308.29
DM310ES FM C17H12N2O4
DM310ES IC InChI=1S/C17H12N2O4/c20-17(21)11-4-3-5-12(10-11)18-15-8-9-16(19(22)23)14-7-2-1-6-13(14)15/h1-10,18H,(H,20,21)
DM310ES CS C1=CC=C2C(=C1)C(=CC=C2[N+](=O)[O-])NC3=CC=CC(=C3)C(=O)O
DM310ES IK ZLIDMWNTWSBTSM-UHFFFAOYSA-N
DM310ES IU 3-[(4-nitronaphthalen-1-yl)amino]benzoic acid
DMNIWVG ID DMNIWVG
DMNIWVG DN N-(phenylamino)-benzoate derivative 1
DMNIWVG HS Patented
DMNIWVG SN PMID28895472-Compound-24
DMNIWVG CP EXXONMOBIL RESEARCH AND ENGINEERING COMPANY OLIVERI, Christopher, G. LAI, Wenyih, Frank DANDEKAR, Ajit, B. WEIGEL, Scott, J. KAY, Robert, Ellis WU, Jianxin, Jaso
DMNIWVG DT Small molecular drug
DM0ZJX7 ID DM0ZJX7
DM0ZJX7 DN N-(phenylpyrazolyl)benzamide derivative 1
DM0ZJX7 HS Patented
DM0ZJX7 SN PMID28270021-Compound-WO2013132376Example157
DM0ZJX7 CP PFIZER INC
DM0ZJX7 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM305UL ID DM305UL
DM305UL DN N-(pyridin-2-yl)pyridine methylsulfone derivative 1
DM305UL HS Patented
DM305UL SN PMID26161698-Compound-27
DM305UL CP BAYER PHARMA AKTIENGESELLSCHAFT
DM305UL DT Small molecular drug
DM305UL PC 73508010
DM305UL MW 405.4
DM305UL FM C19H17F2N3O3S
DM305UL IC InChI=1S/C19H17F2N3O3S/c1-27-17-8-13(20)3-4-14(17)15-9-19(23-10-16(15)21)24-18-7-12(5-6-22-18)11-28(2,25)26/h3-10H,11H2,1-2H3,(H,22,23,24)
DM305UL CS COC1=C(C=CC(=C1)F)C2=CC(=NC=C2F)NC3=NC=CC(=C3)CS(=O)(=O)C
DM305UL IK VRHHAMWTRSVIEX-UHFFFAOYSA-N
DM305UL IU 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-(methylsulfonylmethyl)pyridin-2-yl]pyridin-2-amine
DMRE2I3 ID DMRE2I3
DMRE2I3 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 1
DMRE2I3 HS Patented
DMRE2I3 SN PMID26161698-Compound-24
DMRE2I3 CP BAYER PHARMA AKTIENGESELLSCHAFT
DMRE2I3 DT Small molecular drug
DMRE2I3 PC 73672657
DMRE2I3 MW 456.4
DMRE2I3 FM C19H16F4N4O3S
DMRE2I3 IC InChI=1S/C19H16F4N4O3S/c1-30-15-7-12(20)3-4-13(15)14-8-17(25-10-24-14)27-18-6-11(9-31(2,28)29)5-16(26-18)19(21,22)23/h3-8,10H,9H2,1-2H3,(H,24,25,26,27)
DMRE2I3 CS COC1=C(C=CC(=C1)F)C2=CC(=NC=N2)NC3=CC(=CC(=N3)C(F)(F)F)CS(=O)(=O)C
DMRE2I3 IK WUAZMKUDCHZMEP-UHFFFAOYSA-N
DMRE2I3 IU 6-(4-fluoro-2-methoxyphenyl)-N-[4-(methylsulfonylmethyl)-6-(trifluoromethyl)pyridin-2-yl]pyrimidin-4-amine
DMTZ6K9 ID DMTZ6K9
DMTZ6K9 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 2
DMTZ6K9 HS Patented
DMTZ6K9 SN PMID26161698-Compound-31
DMTZ6K9 CP BAYER PHARMA AKTIENGESELLSCHAFT
DMTZ6K9 DT Small molecular drug
DMTZ6K9 PC 73891126
DMTZ6K9 MW 455.4
DMTZ6K9 FM C19H17F4N5O2S
DMTZ6K9 IC InChI=1S/C19H17F4N5O2S/c1-30-15-7-12(20)3-4-13(15)14-8-17(26-10-25-14)28-18-6-11(9-31(2,24)29)5-16(27-18)19(21,22)23/h3-8,10,24H,9H2,1-2H3,(H,25,26,27,28)
DMTZ6K9 CS COC1=C(C=CC(=C1)F)C2=CC(=NC=N2)NC3=CC(=CC(=N3)C(F)(F)F)CS(=N)(=O)C
DMTZ6K9 IK BYCJOJLDGATDTD-UHFFFAOYSA-N
DMTZ6K9 IU 6-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]-6-(trifluoromethyl)pyridin-2-yl]pyrimidin-4-amine
DMA85UD ID DMA85UD
DMA85UD DN N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1
DMA85UD HS Patented
DMA85UD SN PMID28895472-Compound-16
DMA85UD CP ASTELLAS PHARMA INC. AZAMI, Hidenori ABE, Tomoaki KAKEFUDA, Akio HIRANO, Masaaki WATANABE, Kazushi
DMA85UD DT Small molecular drug
DMA85UD PC 70848785
DMA85UD MW 301.4
DMA85UD FM C17H23N3O2
DMA85UD IC InChI=1S/C17H23N3O2/c1-17(2,22)10-12-4-7-20(8-5-12)16(21)14-9-13-3-6-18-11-15(13)19-14/h3,6,9,11-12,19,22H,4-5,7-8,10H2,1-2H3
DMA85UD CS CC(C)(CC1CCN(CC1)C(=O)C2=CC3=C(N2)C=NC=C3)O
DMA85UD IK HSSJHQZLKSLBPS-UHFFFAOYSA-N
DMA85UD IU [4-(2-hydroxy-2-methylpropyl)piperidin-1-yl]-(1H-pyrrolo[2,3-c]pyridin-2-yl)methanone
DMSD4G0 ID DMSD4G0
DMSD4G0 DN N,N-bis(5-pyrazoyl)urea derivative 1
DMSD4G0 HS Patented
DMSD4G0 SN PMID28270010-Compound-Figure15-a
DMSD4G0 CP ARRAY BIOPHARMA INC
DMSD4G0 DT Small molecular drug
DMSD4G0 PC 90168931
DMSD4G0 MW 506.5
DMSD4G0 FM C25H21F3N8O
DMSD4G0 IC InChI=1S/C25H21F3N8O/c1-16-22(17-14-29-34(2)15-17)33-36(19-11-7-4-8-12-19)23(16)31-24(37)30-21-13-20(25(26,27)28)32-35(21)18-9-5-3-6-10-18/h3-15H,1-2H3,(H2,30,31,37)
DMSD4G0 CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=CC(=NN4C5=CC=CC=C5)C(F)(F)F
DMSD4G0 IK QJVHIMLGONEYEE-UHFFFAOYSA-N
DMSD4G0 IU 1-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]-3-[2-phenyl-5-(trifluoromethyl)pyrazol-3-yl]urea
DMEXPAU ID DMEXPAU
DMEXPAU DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1
DMEXPAU HS Patented
DMEXPAU SN PMID27215781-Compound-38
DMEXPAU DT Small molecular drug
DMEXPAU PC 4296438
DMEXPAU MW 401.5
DMEXPAU FM C25H27N3O2
DMEXPAU IC InChI=1S/C25H27N3O2/c1-28(2)22-15-13-21(14-16-22)25(26-23(29)17-19-9-5-3-6-10-19)27-24(30)18-20-11-7-4-8-12-20/h3-16,25H,17-18H2,1-2H3,(H,26,29)(H,27,30)
DMEXPAU CS CN(C)C1=CC=C(C=C1)C(NC(=O)CC2=CC=CC=C2)NC(=O)CC3=CC=CC=C3
DMEXPAU IK XZLHEBHGANHBEG-UHFFFAOYSA-N
DMEXPAU IU N-[[4-(dimethylamino)phenyl]-[(2-phenylacetyl)amino]methyl]-2-phenylacetamide
DMEXPAU DE Osteoporosis
DMD4CU5 ID DMD4CU5
DMD4CU5 DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
DMD4CU5 HS Patented
DMD4CU5 SN PMID27215781-Compound-39
DMD4CU5 DT Small molecular drug
DMD4CU5 PC 71584280
DMD4CU5 MW 438.6
DMD4CU5 FM C25H30N2O3S
DMD4CU5 IC InChI=1S/C25H30N2O3S/c1-5-26(6-2)22-13-9-21(10-14-22)19-27(23-11-7-20(3)8-12-23)31(28,29)25-17-15-24(30-4)16-18-25/h7-18H,5-6,19H2,1-4H3
DMD4CU5 CS CCN(CC)C1=CC=C(C=C1)CN(C2=CC=C(C=C2)C)S(=O)(=O)C3=CC=C(C=C3)OC
DMD4CU5 IK FKEFNETYRMRPCY-UHFFFAOYSA-N
DMD4CU5 IU N-[[4-(diethylamino)phenyl]methyl]-4-methoxy-N-(4-methylphenyl)benzenesulfonamide
DMD4CU5 DE Osteoporosis
DMM78VS ID DMM78VS
DMM78VS DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3
DMM78VS HS Patented
DMM78VS SN PMID27215781-Compound-40
DMM78VS DT Small molecular drug
DMM78VS DE Osteoporosis
DM6R34M ID DM6R34M
DM6R34M DN N-{4
DM6R34M HS Patented
DM6R34M SN LGB321; CHEMBL3105022; 1210417-75-6; N-{4-[(3r,4r,5s)-3-Amino-4-Hydroxy-5-Methylpiperidin-1-Yl]pyridin-3-Yl}-6-(2,6-Difluorophenyl)-5-Fluoropyridine-2-Carboxamide; N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide; NVP-LGB321; GTPL9367; SCHEMBL1711617; BDBM106896; EX-A1572; AMX10208; SB19299; n-(4-((3r,4r,5s)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide; US8592455, 96; LGB321 1210415-88-5; N-{4
DM6R34M DT Small molecular drug
DM6R34M PC 46179018
DM6R34M MW 457.4
DM6R34M FM C23H22F3N5O2
DM6R34M IC InChI=1S/C23H22F3N5O2/c1-12-10-31(11-16(27)22(12)32)19-7-8-28-9-18(19)30-23(33)17-6-5-15(26)21(29-17)20-13(24)3-2-4-14(20)25/h2-9,12,16,22,32H,10-11,27H2,1H3,(H,30,33)/t12-,16+,22+/m0/s1
DM6R34M CS C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DM6R34M IK ODZZYKUYGVLOTQ-ONJZCGHCSA-N
DM6R34M IU N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DMRHVWA ID DMRHVWA
DMRHVWA DN N6-cyclopropyllydine derivative 1
DMRHVWA HS Patented
DMRHVWA SN PMID27019002-Compound-30
DMRHVWA CP IMAGO BIOSCIENCEKYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY EDUCATIONAL CORPORATION KANSAI BUNRI SOUGOUGAKUEN FRONTIER PHARMA INC. KYOTO UNIVERSITY
DMRHVWA DT Small molecular drug
DM5GCUR ID DM5GCUR
DM5GCUR DN N-acylpiperidine ether derivative 1
DM5GCUR HS Patented
DM5GCUR SN PMID28270021-Compound-WO2015092610Example113
DM5GCUR CP PFIZER LIMITED
DM5GCUR DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM02RQ4 ID DM02RQ4
DM02RQ4 DN N-acylpiperidine ether derivative 2
DM02RQ4 HS Patented
DM02RQ4 SN PMID28270021-Compound-WO2015092610Example114
DM02RQ4 CP PFIZER LIMITED
DM02RQ4 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMXWE5R ID DMXWE5R
DMXWE5R DN N-acylpiperidine ether derivative 3
DMXWE5R HS Patented
DMXWE5R SN PMID28270021-Compound-WO2015092610Example164
DMXWE5R CP PFIZER LIMITED
DMXWE5R DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMBUQDR ID DMBUQDR
DMBUQDR DN N-acylpiperidine ether derivative 4
DMBUQDR HS Patented
DMBUQDR SN PMID28270021-Compound-WO2015092610Example2
DMBUQDR CP PFIZER LIMITED
DMBUQDR DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMQ2MKT ID DMQ2MKT
DMQ2MKT DN N-acylpiperidine ether derivative 5
DMQ2MKT HS Patented
DMQ2MKT SN PMID28270021-Compound-WO2015092610Example3
DMQ2MKT CP PFIZER LIMITED
DMQ2MKT DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMAS01P ID DMAS01P
DMAS01P DN N-acylpiperidine ether derivative 6
DMAS01P HS Patented
DMAS01P SN PMID28270021-Compound-WO2015092610Example9
DMAS01P CP PFIZER LIMITED
DMAS01P DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMCJR4N ID DMCJR4N
DMCJR4N DN N-acylpiperidine ether derivative 7
DMCJR4N HS Patented
DMCJR4N SN PMID28270021-Compound-WO2016009296Example15
DMCJR4N CP PFIZER INC
DMCJR4N DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMQ4ULC ID DMQ4ULC
DMQ4ULC DN N-acylpyrrolidine ether derivative 1
DMQ4ULC HS Patented
DMQ4ULC SN PMID28270021-Compound-WO2016020784Example11
DMQ4ULC CP PFIZER INC
DMQ4ULC DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMK4Y71 ID DMK4Y71
DMK4Y71 DN N-acylpyrrolidine ether derivative 2
DMK4Y71 HS Patented
DMK4Y71 SN PMID28270021-Compound-WO2016020784Example12
DMK4Y71 CP PFIZER INC
DMK4Y71 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMU2WGL ID DMU2WGL
DMU2WGL DN N-alkyl-4-oxazolecar boxamide derivative 1
DMU2WGL HS Patented
DMU2WGL SN PMID26413912-Compound-92
DMU2WGL CP ALLERGAN, INC. WOODWARD, David F. MARTOS, Jose L. CARLING, William R. POLOSO, Neil J. WANG, Jenny W
DMU2WGL DT Small molecular drug
DMU2WGL PC 70896334
DMU2WGL MW 525.6
DMU2WGL FM C29H39N3O6
DMU2WGL IC InChI=1S/C29H39N3O6/c1-37-22-14-12-21(13-15-26(33)34)23(18-22)29(36)32-17-7-11-25(32)28-31-24(19-38-28)27(35)30-16-6-5-10-20-8-3-2-4-9-20/h12,14,18-20,25H,2-11,13,15-17H2,1H3,(H,30,35)(H,33,34)/t25-/m0/s1
DMU2WGL CS COC1=CC(=C(C=C1)CCC(=O)O)C(=O)N2CCC[C@H]2C3=NC(=CO3)C(=O)NCCCCC4CCCCC4
DMU2WGL IK CQXXOQIYQSPKKU-VWLOTQADSA-N
DMU2WGL IU 3-[2-[(2S)-2-[4-(4-cyclohexylbutylcarbamoyl)-1,3-oxazol-2-yl]pyrrolidine-1-carbonyl]-4-methoxyphenyl]propanoic acid
DMR6YAD ID DMR6YAD
DMR6YAD DN N-alkyl-4-oxazolecar boxamide derivative 2
DMR6YAD HS Patented
DMR6YAD SN PMID26413912-Compound-93
DMR6YAD CP ALLERGAN, INC. WOODWARD, David F. MARTOS, Jose L. CARLING, William R. POLOSO, Neil J. WANG, Jenny W
DMR6YAD DT Small molecular drug
DMR6YAD PC 66560857
DMR6YAD MW 616.8
DMR6YAD FM C31H44N4O7S
DMR6YAD IC InChI=1S/C31H44N4O7S/c1-3-43(39,40)34-28(36)17-15-23-14-16-24(41-2)20-25(23)31(38)35-19-9-13-27(35)30-33-26(21-42-30)29(37)32-18-8-7-12-22-10-5-4-6-11-22/h14,16,20-22,27H,3-13,15,17-19H2,1-2H3,(H,32,37)(H,34,36)/t27-/m0/s1
DMR6YAD CS CCS(=O)(=O)NC(=O)CCC1=C(C=C(C=C1)OC)C(=O)N2CCC[C@H]2C3=NC(=CO3)C(=O)NCCCCC4CCCCC4
DMR6YAD IK CARRKGKFLQFOPT-MHZLTWQESA-N
DMR6YAD IU N-(4-cyclohexylbutyl)-2-[(2S)-1-[2-[3-(ethylsulfonylamino)-3-oxopropyl]-5-methoxybenzoyl]pyrrolidin-2-yl]-1,3-oxazole-4-carboxamide
DMXPBL5 ID DMXPBL5
DMXPBL5 DN N-alkylamide derivative 1
DMXPBL5 HS Patented
DMXPBL5 SN PMID28067079-Compound-48
DMXPBL5 DT Small molecular drug
DMXPBL5 PC 118204326
DMXPBL5 MW 401.9
DMXPBL5 FM C19H20ClN5OS
DMXPBL5 IC InChI=1S/C19H20ClN5OS/c1-3-4-16(25-18(26)19-21-7-8-27-19)13-9-15(20)17(23-10-13)24-14-6-5-12(2)22-11-14/h5-11,16H,3-4H2,1-2H3,(H,23,24)(H,25,26)
DMXPBL5 CS CCCC(C1=CC(=C(N=C1)NC2=CN=C(C=C2)C)Cl)NC(=O)C3=NC=CS3
DMXPBL5 IK QMMHYPPKJAWXON-UHFFFAOYSA-N
DMXPBL5 IU N-[1-[5-chloro-6-[(6-methylpyridin-3-yl)amino]pyridin-3-yl]butyl]-1,3-thiazole-2-carboxamide
DM568TX ID DM568TX
DM568TX DN N-alkylamide derivative 2
DM568TX HS Patented
DM568TX SN PMID28067079-Compound-50
DM568TX DT Small molecular drug
DMWLPEB ID DMWLPEB
DMWLPEB DN Naphthalene derivative 1
DMWLPEB HS Patented
DMWLPEB SN PMID28454500-Compound-62
DMWLPEB CP RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY THE BROAD INSTITUTE, INC
DMWLPEB DT Small molecular drug
DMWLPEB PC 3294285
DMWLPEB MW 523.5
DMWLPEB FM C25H24F3NO6S
DMWLPEB IC InChI=1S/C25H24F3NO6S/c1-13(2)35-24(32)21(23(31)25(26,27)28)18-12-19(16-7-5-6-8-17(16)22(18)30)29-36(33,34)20-10-9-14(3)11-15(20)4/h5-13,21,29-30H,1-4H3
DMWLPEB CS CC1=CC(=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C(C(=O)C(F)(F)F)C(=O)OC(C)C)C
DMWLPEB IK PCUXRYBEDDOJPT-UHFFFAOYSA-N
DMWLPEB IU propan-2-yl 2-[4-[(2,4-dimethylphenyl)sulfonylamino]-1-hydroxynaphthalen-2-yl]-4,4,4-trifluoro-3-oxobutanoate
DMTGIP7 ID DMTGIP7
DMTGIP7 DN Naphthyridine and isoquinoline derivative 1
DMTGIP7 HS Patented
DMTGIP7 SN PMID26161698-Compound-51
DMTGIP7 DT Small molecular drug
DMQHAU1 ID DMQHAU1
DMQHAU1 DN N-arylmethyl-N-phenyl cyclic urea derivative 1
DMQHAU1 HS Patented
DMQHAU1 SN PMID28270010-Compound-Figure25-1
DMQHAU1 CP GENZYME CORPORATION
DMQHAU1 DT Small molecular drug
DMQHAU1 PC 59694319
DMQHAU1 MW 487.5
DMQHAU1 FM C23H20F3N5O2S
DMQHAU1 IC InChI=1S/C23H20F3N5O2S/c1-22(2)20(32)31(16-6-8-17(9-7-16)34-23(24,25)26)21(33)30(22)14-15-10-12-28-19(13-15)29-18-5-3-4-11-27-18/h3-13H,14H2,1-2H3,(H,27,28,29)
DMQHAU1 CS CC1(C(=O)N(C(=O)N1CC2=CC(=NC=C2)NC3=CC=CC=N3)C4=CC=C(C=C4)SC(F)(F)F)C
DMQHAU1 IK CYMSBDAPHJQPRL-UHFFFAOYSA-N
DMQHAU1 IU 5,5-dimethyl-1-[[2-(pyridin-2-ylamino)pyridin-4-yl]methyl]-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidine-2,4-dione
DMWVQDA ID DMWVQDA
DMWVQDA DN N-arylmethyl-N-phenyl cyclic urea derivative 2
DMWVQDA HS Patented
DMWVQDA SN PMID28270010-Compound-Figure25-2
DMWVQDA CP GENZYME CORPORATION
DMWVQDA DT Small molecular drug
DMWVQDA PC 68914518
DMWVQDA MW 538.6
DMWVQDA FM C24H29F3N6O3S
DMWVQDA IC InChI=1S/C24H29F3N6O3S/c1-23(2)20(34)33(17-6-8-18(9-7-17)37-24(25,26)27)22(36)32(23)15-16-10-12-28-19(14-16)30-21(35)29-11-5-13-31(3)4/h6-10,12,14H,5,11,13,15H2,1-4H3,(H2,28,29,30,35)
DMWVQDA CS CC1(C(=O)N(C(=O)N1CC2=CC(=NC=C2)NC(=O)NCCCN(C)C)C3=CC=C(C=C3)SC(F)(F)F)C
DMWVQDA IK GDSXQEMDEPFVIA-UHFFFAOYSA-N
DMWVQDA IU 1-[3-(dimethylamino)propyl]-3-[4-[[5,5-dimethyl-2,4-dioxo-3-[4-(trifluoromethylsulfanyl)phenyl]imidazolidin-1-yl]methyl]pyridin-2-yl]urea
DMEU12W ID DMEU12W
DMEU12W DN NCGC00381656-01
DMEU12W HS Patented
DMEU12W SN CHEMBL4100530; SCHEMBL16157407; BDBM320423; US10174026, Example 88; NCGC00381656-01; 2-[(2-chlorophenyl)-propoxy- methyl]-1H-pyrrolo[3,2-b]- pyridine-7-carboxylic acid
DMEU12W DT Small molecular drug
DMEU12W PC 117637389
DMEU12W MW 344.8
DMEU12W FM C18H17ClN2O3
DMEU12W IC InChI=1S/C18H17ClN2O3/c1-2-9-24-17(11-5-3-4-6-13(11)19)15-10-14-16(21-15)12(18(22)23)7-8-20-14/h3-8,10,17,21H,2,9H2,1H3,(H,22,23)
DMEU12W CS CCCOC(C1=CC=CC=C1Cl)C2=CC3=NC=CC(=C3N2)C(=O)O
DMEU12W IK NXCXDWJNFKFGCO-UHFFFAOYSA-N
DMEU12W IU 2-[(2-chlorophenyl)-propoxymethyl]-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid
DM6TMXL ID DM6TMXL
DM6TMXL DN N-containing heterocyclic derivative 1
DM6TMXL HS Patented
DM6TMXL SN PMID25470667-Compound-Figure6-22
DM6TMXL DT Small molecular drug
DMW1PL7 ID DMW1PL7
DMW1PL7 DN NG7
DMW1PL7 HS Patented
DMW1PL7 SN 3-{2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide; 3-(2-(cyclopropanecarboxamido)thiazolo[5,4-b]pyridin-5-yl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; HG-7-85-01; MLS003230942; SCHEMBL1696179; CHEMBL2148124; BDBM124970; SMR001913507; 1258391-13-7; US8765747, 2; NG7
DMW1PL7 DT Small molecular drug
DMW1PL7 PC 51359962
DMW1PL7 MW 608.7
DMW1PL7 FM C31H31F3N6O2S
DMW1PL7 IC InChI=1S/C31H31F3N6O2S/c1-2-39-12-14-40(15-13-39)18-22-8-9-23(17-24(22)31(32,33)34)35-28(42)21-5-3-4-20(16-21)25-10-11-26-29(36-25)43-30(37-26)38-27(41)19-6-7-19/h3-5,8-11,16-17,19H,2,6-7,12-15,18H2,1H3,(H,35,42)(H,37,38,41)
DMW1PL7 CS CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC=CC(=C3)C4=NC5=C(C=C4)N=C(S5)NC(=O)C6CC6)C(F)(F)F
DMW1PL7 IK VTWWRKFUHCSCEW-UHFFFAOYSA-N
DMW1PL7 IU 3-[2-(cyclopropanecarbonylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]-N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMW2LD5 ID DMW2LD5
DMW2LD5 DN Nicotinyl hydroxamic acid derivative 1
DMW2LD5 HS Patented
DMW2LD5 SN PMID26815044-Compound-120
DMW2LD5 DT Small molecular drug
DMW2LD5 PC 71211
DMW2LD5 MW 138.12
DMW2LD5 FM C6H6N2O2
DMW2LD5 IC InChI=1S/C6H6N2O2/c9-6(8-10)5-2-1-3-7-4-5/h1-4,10H,(H,8,9)
DMW2LD5 CS C1=CC(=CN=C1)C(=O)NO
DMW2LD5 IK IYCHDNQCHLMLJZ-UHFFFAOYSA-N
DMW2LD5 IU N-hydroxypyridine-3-carboxamide
DMW2LD5 CA CAS 5657-61-4
DMW2LD5 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMXDSYU ID DMXDSYU
DMXDSYU DN Nitrogen mustard derivative 1
DMXDSYU HS Patented
DMXDSYU SN PMID26161698-Compound-55
DMXDSYU CP EURO-CELTIQUE S.A. CRYSTAL BIOPHARMACEUTICALS LLC PURDUE PHARMACEUTICAL PRODUCTS L.P
DMXDSYU DT Small molecular drug
DMXDSYU PC 71515463
DMXDSYU MW 527.5
DMXDSYU FM C23H28Cl2N4O2S2
DMXDSYU IC InChI=1S/C23H28Cl2N4O2S2/c1-23(2,3)18-13-26-20(31-18)15-32-21-14-27-22(33-21)28-19(30)12-16-4-6-17(7-5-16)29(10-8-24)11-9-25/h4-7,13-14H,8-12,15H2,1-3H3,(H,27,28,30)
DMXDSYU CS CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)CC3=CC=C(C=C3)N(CCCl)CCCl
DMXDSYU IK WETDPIQQVIMQAF-UHFFFAOYSA-N
DMXDSYU IU 2-[4-[bis(2-chloroethyl)amino]phenyl]-N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide
DMD7OW0 ID DMD7OW0
DMD7OW0 DN Nitrogen/sulfur-substituted estrene derivative 1
DMD7OW0 HS Patented
DMD7OW0 SN PMID28895472-Compound-30
DMD7OW0 CP BAYER PHARMA AKTIENGESELLSCHAFBAYER INTELLECTUAL PROPERTY GMBH BAYER PHARMA AKTIENGESELLSCHAFT
DMD7OW0 DT Small molecular drug
DMIVK7D ID DMIVK7D
DMIVK7D DN N-methylmethanesulfonamide derivative 1
DMIVK7D HS Patented
DMIVK7D SN PMID27774822-Compound-Figure4Example22
DMIVK7D CP NOVARTIS TIERGESUNDHEIT AG
DMIVK7D DT Small molecular drug
DMCVBPF ID DMCVBPF
DMCVBPF DN N-naphtyl-N-benzylurea derivative 1
DMCVBPF HS Patented
DMCVBPF SN PMID27828716-Compound-1
DMCVBPF DT Small molecular drug
DMCVBPF PC 668231
DMCVBPF MW 276.3
DMCVBPF FM C18H16N2O
DMCVBPF IC InChI=1S/C18H16N2O/c21-18(19-13-14-7-2-1-3-8-14)20-17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2,(H2,19,20,21)
DMCVBPF CS C1=CC=C(C=C1)CNC(=O)NC2=CC=CC3=CC=CC=C32
DMCVBPF IK FWIZGBBRZIIRBG-UHFFFAOYSA-N
DMCVBPF IU 1-benzyl-3-naphthalen-1-ylurea
DM2P509 ID DM2P509
DM2P509 DN N-oxalyl-D-tyrosine derivative 1
DM2P509 HS Patented
DM2P509 SN PMID25468267-Compound-10
DM2P509 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM2P509 DT Small molecular drug
DMWSZMC ID DMWSZMC
DMWSZMC DN N-oxalyl-D-tyrosine derivative 2
DMWSZMC HS Patented
DMWSZMC SN PMID25468267-Compound-11
DMWSZMC CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMWSZMC DT Small molecular drug
DM7XS9G ID DM7XS9G
DM7XS9G DN N-oxalyl-D-tyrosine derivative 3
DM7XS9G HS Patented
DM7XS9G SN PMID25468267-Compound-12
DM7XS9G CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM7XS9G DT Small molecular drug
DMUE7R5 ID DMUE7R5
DMUE7R5 DN N-oxalyl-D-tyrosine derivative 4
DMUE7R5 HS Patented
DMUE7R5 SN PMID25468267-Compound-13
DMUE7R5 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMUE7R5 DT Small molecular drug
DM673GR ID DM673GR
DM673GR DN N-oxalyl-D-tyrosine derivative 5
DM673GR HS Patented
DM673GR SN PMID25468267-Compound-14
DM673GR CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM673GR DT Small molecular drug
DM106SU ID DM106SU
DM106SU DN N-oxalyl-D-tyrosine derivative 6
DM106SU HS Patented
DM106SU SN PMID25468267-Compound-15
DM106SU CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM106SU DT Small molecular drug
DM13K8R ID DM13K8R
DM13K8R DN N-oxalyl-D-tyrosine derivative 7
DM13K8R HS Patented
DM13K8R SN PMID25468267-Compound-16
DM13K8R CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM13K8R DT Small molecular drug
DMNV0OA ID DMNV0OA
DMNV0OA DN N-oxalyl-D-tyrosine derivative 8
DMNV0OA HS Patented
DMNV0OA SN PMID25468267-Compound-8
DMNV0OA CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMNV0OA DT Small molecular drug
DMNV0OA PC 45376646
DMNV0OA MW 449.5
DMNV0OA FM C21H23NO8S
DMNV0OA IC InChI=1S/C21H23NO8S/c1-21(2,3)14-6-10-16(11-7-14)31(28,29)30-15-8-4-13(5-9-15)12-17(19(24)25)22-18(23)20(26)27/h4-11,17H,12H2,1-3H3,(H,22,23)(H,24,25)(H,26,27)/t17-/m1/s1
DMNV0OA CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)C[C@H](C(=O)O)NC(=O)C(=O)O
DMNV0OA IK GZIYVGKVNVGZAL-QGZVFWFLSA-N
DMNV0OA IU (2R)-3-[4-(4-tert-butylphenyl)sulfonyloxyphenyl]-2-(oxaloamino)propanoic acid
DMTMYJ6 ID DMTMYJ6
DMTMYJ6 DN N-oxalyl-D-tyrosine derivative 9
DMTMYJ6 HS Patented
DMTMYJ6 SN PMID25468267-Compound-9
DMTMYJ6 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMTMYJ6 DT Small molecular drug
DMTMYJ6 PC 45376513
DMTMYJ6 MW 393.4
DMTMYJ6 FM C17H15NO8S
DMTMYJ6 IC InChI=1S/C17H15NO8S/c19-15(17(22)23)18-14(16(20)21)10-11-6-8-12(9-7-11)26-27(24,25)13-4-2-1-3-5-13/h1-9,14H,10H2,(H,18,19)(H,20,21)(H,22,23)/t14-/m1/s1
DMTMYJ6 CS C1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)C[C@H](C(=O)O)NC(=O)C(=O)O
DMTMYJ6 IK DNGSYQKIFPNAEQ-CQSZACIVSA-N
DMTMYJ6 IU (2R)-3-[4-(benzenesulfonyloxy)phenyl]-2-(oxaloamino)propanoic acid
DMUHFLQ ID DMUHFLQ
DMUHFLQ DN N-oxalylglycine derivative 1
DMUHFLQ HS Patented
DMUHFLQ SN PMID25468267-Compound-2
DMUHFLQ CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMUHFLQ DT Small molecular drug
DMDJC96 ID DMDJC96
DMDJC96 DN N-oxalylglycine derivative 2
DMDJC96 HS Patented
DMDJC96 SN PMID25468267-Compound-3
DMDJC96 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMDJC96 DT Small molecular drug
DMQF0RY ID DMQF0RY
DMQF0RY DN N-oxalylglycine derivative 3
DMQF0RY HS Patented
DMQF0RY SN PMID25468267-Compound-4
DMQF0RY CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMQF0RY DT Small molecular drug
DM9A8L5 ID DM9A8L5
DM9A8L5 DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1
DM9A8L5 HS Patented
DM9A8L5 SN PMID26161824-Compound-100
DM9A8L5 DT Small molecular drug
DM9A8L5 PC 44470246
DM9A8L5 MW 509.8
DM9A8L5 FM C23H23Cl3N4O3
DM9A8L5 IC InChI=1S/C23H23Cl3N4O3/c1-2-33-23(32)20-4-3-11-29(20)28-22(31)18-13-21(14-5-7-15(24)8-6-14)30(27-18)19-10-9-16(25)12-17(19)26/h5-10,12,20-21H,2-4,11,13H2,1H3,(H,28,31)
DM9A8L5 CS CCOC(=O)C1CCCN1NC(=O)C2=NN(C(C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DM9A8L5 IK SXZDWKSALIBFCB-UHFFFAOYSA-N
DM9A8L5 IU ethyl 1-[[3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-3,4-dihydropyrazole-5-carbonyl]amino]pyrrolidine-2-carboxylate
DM9A8L5 DE Obesity
DM8T2LV ID DM8T2LV
DM8T2LV DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2
DM8T2LV HS Patented
DM8T2LV SN PMID26161824-Compound-101
DM8T2LV DT Small molecular drug
DM8T2LV DE Obesity
DMEH0RC ID DMEH0RC
DMEH0RC DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3
DMEH0RC HS Patented
DMEH0RC SN PMID26161824-Compound-102
DMEH0RC DT Small molecular drug
DMEH0RC DE Obesity
DMMDYAV ID DMMDYAV
DMMDYAV DN N-phenyl-pyridine-2-carboxamide derivative 1
DMMDYAV HS Patented
DMMDYAV SN PMID30107136-Compound-Example55
DMMDYAV CP INCYTE CORPORATION
DMMDYAV DT Small molecule immunotherapy
DMMDYAV PC 129240409
DMMDYAV MW 375.5
DMMDYAV FM C23H25N3O2
DMMDYAV IC InChI=1S/C23H25N3O2/c1-16-13-22(25-15-19(16)14-24-11-12-27)23(28)26-21-10-6-9-20(17(21)2)18-7-4-3-5-8-18/h3-10,13,15,24,27H,11-12,14H2,1-2H3,(H,26,28)
DMMDYAV CS CC1=CC(=NC=C1CNCCO)C(=O)NC2=CC=CC(=C2C)C3=CC=CC=C3
DMMDYAV IK JIWMSDANMZCAFN-UHFFFAOYSA-N
DMMDYAV IU 5-[(2-hydroxyethylamino)methyl]-4-methyl-N-(2-methyl-3-phenylphenyl)pyridine-2-carboxamide
DMMDYAV DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM6OG2Y ID DM6OG2Y
DM6OG2Y DN N-phenyl-pyridine-2-carboxamide derivative 2
DM6OG2Y HS Patented
DM6OG2Y SN PMID30107136-Compound-Example56
DM6OG2Y CP INCYTE CORPORATION
DM6OG2Y DT Small molecule immunotherapy
DM6OG2Y DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMAV8LM ID DMAV8LM
DMAV8LM DN N-phenyl-pyrimidin-4-amine derivative 1
DMAV8LM HS Patented
DMAV8LM SN PMID26161698-Compound-30
DMAV8LM CP BAYER PHARMA AKTIENGESELLSCHAFT
DMAV8LM DT Small molecular drug
DMAV8LM PC 74763288
DMAV8LM MW 543.5
DMAV8LM FM C19H13F8N5OS2
DMAV8LM IC InChI=1S/C19H13F8N5OS2/c1-34(33,30-10-28)9-11-4-13(7-14(5-11)35(23,24,25,26)27)31-19-29-8-17(22)18(32-19)15-3-2-12(20)6-16(15)21/h2-8H,9H2,1H3,(H,29,31,32)
DMAV8LM CS CS(=NC#N)(=O)CC1=CC(=CC(=C1)S(F)(F)(F)(F)F)NC2=NC=C(C(=N2)C3=C(C=C(C=C3)F)F)F
DMAV8LM IK ASMMFFMWZUTPQZ-UHFFFAOYSA-N
DMAV8LM IU [[3-[[4-(2,4-difluorophenyl)-5-fluoropyrimidin-2-yl]amino]-5-(pentafluoro-lambda6-sulfanyl)phenyl]methyl-methyl-oxo-lambda6-sulfanylidene]cyanamide
DMLSK97 ID DMLSK97
DMLSK97 DN N-quinolin-benzene sulphonamide derivative 1
DMLSK97 HS Patented
DMLSK97 SN PMID25553724-Compound-US20140073668 22
DMH65CX ID DMH65CX
DMH65CX DN N-quinolin-benzene sulphonamide derivative 2
DMH65CX HS Patented
DMH65CX SN PMID25553724-Compound-US20140073668 23
DMU65YX ID DMU65YX
DMU65YX DN N-quinolin-benzene sulphonamide derivative 3
DMU65YX HS Patented
DMU65YX SN PMID25553724-Compound-US20140073668 24
DMEYKXL ID DMEYKXL
DMEYKXL DN NSC-87877
DMEYKXL HS Patented
DMEYKXL SN CHEMBL472004
DMEYKXL DT Small molecular drug
DMEYKXL PC 92577
DMEYKXL MW 459.5
DMEYKXL FM C19H13N3O7S2
DMEYKXL IC InChI=1S/C19H13N3O7S2/c23-19-16(10-17(31(27,28)29)15-2-1-7-20-18(15)19)22-21-13-5-3-12-9-14(30(24,25)26)6-4-11(12)8-13/h1-10,23H,(H,24,25,26)(H,27,28,29)
DMEYKXL CS C1=CC2=C(C=C(C(=C2N=C1)O)N=NC3=CC4=C(C=C3)C=C(C=C4)S(=O)(=O)O)S(=O)(=O)O
DMEYKXL IK XGMFVZOKHBRUTL-UHFFFAOYSA-N
DMEYKXL IU 8-hydroxy-7-[(6-sulfonaphthalen-2-yl)diazenyl]quinoline-5-sulfonic acid
DMEYKXL CA CAS 56990-57-9
DMEYKXL CB CHEBI:95064
DMEYKXL DE Discovery agent
DMSU80N ID DMSU80N
DMSU80N DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1
DMSU80N HS Patented
DMSU80N SN PMID28051882-Compound-10
DMSU80N DT Small molecular drug
DMSU80N PC 24968537
DMSU80N MW 386.3
DMSU80N FM C21H24BrNO
DMSU80N IC InChI=1S/C21H24BrNO/c22-18-8-4-7-16(11-18)21(24)14-23-19-9-10-20(23)13-17(12-19)15-5-2-1-3-6-15/h1-8,11,17,19-21,24H,9-10,12-14H2/t17?,19?,20?,21-/m0/s1
DMSU80N CS C1CC2CC(CC1N2C[C@@H](C3=CC(=CC=C3)Br)O)C4=CC=CC=C4
DMSU80N IK OPZPEBWJFYVOEI-SLQSYFLNSA-N
DMSU80N IU (1R)-1-(3-bromophenyl)-2-(3-phenyl-8-azabicyclo[3.2.1]octan-8-yl)ethanol
DMPW1GI ID DMPW1GI
DMPW1GI DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2
DMPW1GI HS Patented
DMPW1GI SN PMID28051882-Compound-8
DMPW1GI DT Small molecular drug
DMPW1GI PC 24968536
DMPW1GI MW 403.6
DMPW1GI FM C23H37N3O3
DMPW1GI IC InChI=1S/C23H37N3O3/c1-17-10-11-22(28-2)21(14-17)25-23(27)29-20-15-18-8-7-9-19(16-20)26(18)13-6-4-3-5-12-24/h10-11,14,18-20H,3-9,12-13,15-16,24H2,1-2H3,(H,25,27)
DMPW1GI CS CC1=CC(=C(C=C1)OC)NC(=O)OC2CC3CCCC(C2)N3CCCCCCN
DMPW1GI IK LKFLCBUCBHTSTF-UHFFFAOYSA-N
DMPW1GI IU [9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3-yl] N-(2-methoxy-5-methylphenyl)carbamate
DMZF9TM ID DMZF9TM
DMZF9TM DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3
DMZF9TM HS Patented
DMZF9TM SN PMID28051882-Compound-9
DMZF9TM DT Small molecular drug
DMZF9TM PC 24968535
DMZF9TM MW 437.6
DMZF9TM FM C26H35N3O3
DMZF9TM IC InChI=1S/C26H35N3O3/c1-18-8-13-25(31-4)24(14-18)27-26(30)32-23-15-21-6-5-7-22(16-23)29(21)17-19-9-11-20(12-10-19)28(2)3/h8-14,21-23H,5-7,15-17H2,1-4H3,(H,27,30)
DMZF9TM CS CC1=CC(=C(C=C1)OC)NC(=O)OC2CC3CCCC(C2)N3CC4=CC=C(C=C4)N(C)C
DMZF9TM IK LLKXKYKXJPUWCM-UHFFFAOYSA-N
DMZF9TM IU [9-[[4-(dimethylamino)phenyl]methyl]-9-azabicyclo[3.3.1]nonan-3-yl] N-(2-methoxy-5-methylphenyl)carbamate
DMHTVGM ID DMHTVGM
DMHTVGM DN N-substituted pyrazole derivative 1
DMHTVGM HS Patented
DMHTVGM SN PMID25435285-Compound-71
DMHTVGM CP TAISHO PHARMACEUTICAL CO., LTD
DMHTVGM DT Small molecular drug
DMQWODI ID DMQWODI
DMQWODI DN N-substituted pyrazole derivative 2
DMQWODI HS Patented
DMQWODI SN PMID25435285-Compound-79
DMQWODI CP TAISHO PHARMACEUTICAL CO., LTD
DMQWODI DT Small molecular drug
DM5TIFH ID DM5TIFH
DM5TIFH DN N-substituted pyrazole derivative 3
DM5TIFH HS Patented
DM5TIFH SN PMID25435285-Compound-80
DM5TIFH CP TAISHO PHARMACEUTICAL CO., LTD
DM5TIFH DT Small molecular drug
DM5TIFH PC 89721849
DM5TIFH MW 494.4
DM5TIFH FM C20H17F3N6O4S
DM5TIFH IC InChI=1S/C20H17F3N6O4S/c1-29-16(10-32-17-7-6-14(8-25-17)20(21,22)23)15(9-26-29)19-27-18(28-33-19)13-4-2-12(3-5-13)11-34(24,30)31/h2-9H,10-11H2,1H3,(H2,24,30,31)
DM5TIFH CS CN1C(=C(C=N1)C2=NC(=NO2)C3=CC=C(C=C3)CS(=O)(=O)N)COC4=NC=C(C=C4)C(F)(F)F
DM5TIFH IK VICSEUMXTLYERW-UHFFFAOYSA-N
DM5TIFH IU [4-[5-[1-methyl-5-[[5-(trifluoromethyl)pyridin-2-yl]oxymethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]phenyl]methanesulfonamide
DM0ECWR ID DM0ECWR
DM0ECWR DN Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1
DM0ECWR HS Patented
DM0ECWR SN PMID28447479-Compound-7
DM0ECWR CP HOFFMANN LA ROCHE [CHHOFFMANN LA ROCHE [US]
DM0ECWR DT Small molecular drug
DM0ECWR PC 86299031
DM0ECWR MW 529.5
DM0ECWR FM C23H23F4N3O5S
DM0ECWR IC InChI=1S/C23H23F4N3O5S/c24-20-9-18(35-23(25,26)27)5-1-14(20)4-8-21(31)29-10-16-12-30(13-17(16)11-29)22(32)15-2-6-19(7-3-15)36(28,33)34/h1-3,5-7,9,16-17H,4,8,10-13H2,(H2,28,33,34)/t16-,17+
DM0ECWR CS C1[C@@H]2CN(C[C@@H]2CN1C(=O)CCC3=C(C=C(C=C3)OC(F)(F)F)F)C(=O)C4=CC=C(C=C4)S(=O)(=O)N
DM0ECWR IK MRXFENNJFHPMOW-CALCHBBNSA-N
DM0ECWR IU 4-[(3aS,6aR)-2-[3-[2-fluoro-4-(trifluoromethoxy)phenyl]propanoyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carbonyl]benzenesulfonamide
DMZIALN ID DMZIALN
DMZIALN DN Olenolic acid acetate derivative 1
DMZIALN HS Patented
DMZIALN SN PMID25553724-Compound-WO2012148247 21
DMZIALN CP KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY RHO, Mun Chual LEE, Woo Song OH, Hyun Mee KIM, Young Min
DM74T5L ID DM74T5L
DM74T5L DN Oligooxopiperazine derivative 1
DM74T5L HS Patented
DM74T5L SN PMID26882240-Compound-29
DM74T5L CP NEW YORK UNIVERSITY UNIVERSITY OF SOUTHERN CALIFORNIA ARORA, Paramjit S. OLENYUK, Bogdan LAU, Brooke Bullock GRISHAGIN, Ivan
DM74T5L DT Small molecular drug
DM74T5L PC 71664643
DM74T5L MW 494.6
DM74T5L FM C24H42N6O5
DM74T5L IC InChI=1S/C24H42N6O5/c1-14(2)12-17-23(34)29(9-8-27-17)19(13-15(3)4)24(35)28-10-11-30(22(33)16(28)5)18(21(26)32)6-7-20(25)31/h14-19,27H,6-13H2,1-5H3,(H2,25,31)(H2,26,32)/t16-,17-,18-,19-/m0/s1
DM74T5L CS C[C@H]1C(=O)N(CCN1C(=O)[C@H](CC(C)C)N2CCN[C@H](C2=O)CC(C)C)[C@@H](CCC(=O)N)C(=O)N
DM74T5L IK FMTAQWMOLHFOLT-VJANTYMQSA-N
DM74T5L IU (2S)-2-[(3S)-3-methyl-4-[(2S)-4-methyl-2-[(3S)-3-(2-methylpropyl)-2-oxopiperazin-1-yl]pentanoyl]-2-oxopiperazin-1-yl]pentanediamide
DM7Y2RL ID DM7Y2RL
DM7Y2RL DN Oxazole derivative 1
DM7Y2RL HS Patented
DM7Y2RL SN PMID26394986-Compound-8
DM7Y2RL CP UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. TURKSON, James HAMILTON, Andrew, D. JOVE, Richard SEBTI, Said, MUniversity of Central Florida research foundation, Inc
DM7Y2RL DT Small molecular drug
DM7Y2RL PC 24768190
DM7Y2RL MW 508.5
DM7Y2RL FM C27H29N2O6P
DM7Y2RL IC InChI=1S/C27H29N2O6P/c1-2-3-4-7-17-28-26(30)25-24(18-19-13-15-21(16-14-19)35-36(31,32)33)34-27(29-25)23-12-8-10-20-9-5-6-11-22(20)23/h5-6,8-16H,2-4,7,17-18H2,1H3,(H,28,30)(H2,31,32,33)
DM7Y2RL CS CCCCCCNC(=O)C1=C(OC(=N1)C2=CC=CC3=CC=CC=C32)CC4=CC=C(C=C4)OP(=O)(O)O
DM7Y2RL IK NUEVMWXZKGBDPT-UHFFFAOYSA-N
DM7Y2RL IU [4-[[4-(hexylcarbamoyl)-2-naphthalen-1-yl-1,3-oxazol-5-yl]methyl]phenyl] dihydrogen phosphate
DMPZ81S ID DMPZ81S
DMPZ81S DN Oxazolo[3,4-a]pyrazine derivative 1
DMPZ81S HS Patented
DMPZ81S SN PMID27788040-Compound-1
DMPZ81S CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DMPZ81S DT Small molecular drug
DM28E0A ID DM28E0A
DM28E0A DN Oxazolo[3,4-a]pyrazine derivative 2
DM28E0A HS Patented
DM28E0A SN PMID27788040-Compound-1a
DM28E0A CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM28E0A DT Small molecular drug
DM28E0A PC 11374217
DM28E0A MW 445.5
DM28E0A FM C26H24FN3O3
DM28E0A IC InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31)
DM28E0A CS C1CN2C(CN1C(=O)NCC3=CC=C(C=C3)F)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DM28E0A IK SFRQIPRTNYHJHP-UHFFFAOYSA-N
DM28E0A IU N-[(4-fluorophenyl)methyl]-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
DM1LPKH ID DM1LPKH
DM1LPKH DN Oxazolo[3,4-a]pyrazine derivative 3
DM1LPKH HS Patented
DM1LPKH SN PMID27788040-Compound-1b
DM1LPKH CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM1LPKH DT Small molecular drug
DM1LPKH PC 11177829
DM1LPKH MW 427.5
DM1LPKH FM C26H25N3O3
DM1LPKH IC InChI=1S/C26H25N3O3/c30-24(27-18-20-10-4-1-5-11-20)28-16-17-29-23(19-28)26(32-25(29)31,21-12-6-2-7-13-21)22-14-8-3-9-15-22/h1-15,23H,16-19H2,(H,27,30)
DM1LPKH CS C1CN2C(CN1C(=O)NCC3=CC=CC=C3)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DM1LPKH IK WPBWKKIZKTUNIP-UHFFFAOYSA-N
DM1LPKH IU N-benzyl-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
DM1B74D ID DM1B74D
DM1B74D DN Oxazolo[3,4-a]pyrazine derivative 4
DM1B74D HS Patented
DM1B74D SN PMID27788040-Compound-1c
DM1B74D CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM1B74D DT Small molecular drug
DM1B74D PC 23121947
DM1B74D MW 448.6
DM1B74D FM C26H32N4O3
DM1B74D IC InChI=1S/C26H32N4O3/c31-24(27-14-17-28-15-8-3-9-16-28)29-18-19-30-23(20-29)26(33-25(30)32,21-10-4-1-5-11-21)22-12-6-2-7-13-22/h1-2,4-7,10-13,23H,3,8-9,14-20H2,(H,27,31)
DM1B74D CS C1CCN(CC1)CCNC(=O)N2CCN3C(C2)C(OC3=O)(C4=CC=CC=C4)C5=CC=CC=C5
DM1B74D IK JJDDRYMIPIEXKX-UHFFFAOYSA-N
DM1B74D IU 3-oxo-1,1-diphenyl-N-(2-piperidin-1-ylethyl)-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
DMC5G76 ID DMC5G76
DMC5G76 DN Oxazolo[3,4-a]pyrazine derivative 5
DMC5G76 HS Patented
DMC5G76 SN PMID27788040-Compound-1d
DMC5G76 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DMC5G76 DT Small molecular drug
DMC5G76 PC 23122056
DMC5G76 MW 428.5
DMC5G76 FM C25H24N4O3
DMC5G76 IC InChI=1S/C25H24N4O3/c30-23(27-17-21-13-7-8-14-26-21)28-15-16-29-22(18-28)25(32-24(29)31,19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-14,22H,15-18H2,(H,27,30)
DMC5G76 CS C1CN2C(CN1C(=O)NCC3=CC=CC=N3)C(OC2=O)(C4=CC=CC=C4)C5=CC=CC=C5
DMC5G76 IK ONMOMQJIMXCMOJ-UHFFFAOYSA-N
DMC5G76 IU 3-oxo-1,1-diphenyl-N-(pyridin-2-ylmethyl)-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
DM5DC9A ID DM5DC9A
DM5DC9A DN Oxazolo[3,4-a]pyrazine derivative 6
DM5DC9A HS Patented
DM5DC9A SN PMID27788040-Compound-1e
DM5DC9A CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DM5DC9A DT Small molecular drug
DMEX5VK ID DMEX5VK
DMEX5VK DN Oxazolo[3,4-a]pyrazine derivative 7
DMEX5VK HS Patented
DMEX5VK SN PMID27788040-Compound-1f
DMEX5VK CP TAKEDA PHARMACEUTICAL COMPANY LIMITED Fukatsu, Kohji Nakayama, Yutaka Tarui, Naoki Mori, Masaaki Matsumoto, Hirokazu Kurasawa, Osamu Banno, Hiroshi
DMEX5VK DT Small molecular drug
DMZM6FW ID DMZM6FW
DMZM6FW DN Oxazolyl methylthiothiazole derivative 1
DMZM6FW HS Patented
DMZM6FW SN PMID26161698-Compound-52
DMZM6FW CP CURIS, INC. QIAN, Changgeng CAI, Xiong ZHAI, Haixiao
DMZM6FW DT Small molecular drug
DMZM6FW PC 25195503
DMZM6FW MW 504.6
DMZM6FW FM C23H28N4O5S2
DMZM6FW IC InChI=1S/C23H28N4O5S2/c1-23(2,3)17-12-24-20(32-17)14-33-21-13-25-22(34-21)26-19(29)11-15-6-8-16(9-7-15)31-10-4-5-18(28)27-30/h6-9,12-13,30H,4-5,10-11,14H2,1-3H3,(H,27,28)(H,25,26,29)
DMZM6FW CS CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)CC3=CC=C(C=C3)OCCCC(=O)NO
DMZM6FW IK VGEVFXUUILGVIP-UHFFFAOYSA-N
DMZM6FW IU 4-[4-[2-[[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]amino]-2-oxoethyl]phenoxy]-N-hydroxybutanamide
DMSB09X ID DMSB09X
DMSB09X DN Oxetane 3,3-dicarboxamide compound 1
DMSB09X HS Patented
DMSB09X SN PMID28621580-Compound-WO2013032797c63
DMSB09X CP NEW HOPE R & D BIOSCIENCE, INC. CHEN, Xiao-Tao
DMSB09X DT Small molecular drug
DMSB09X DE Virus infection
DMMCTAK ID DMMCTAK
DMMCTAK DN Oxetane 3,3-dicarboxamide compound 2
DMMCTAK HS Patented
DMMCTAK SN PMID28621580-Compound-WO2013032797c64
DMMCTAK CP NEW HOPE R & D BIOSCIENCE, INC. CHEN, Xiao-Tao
DMMCTAK DT Small molecular drug
DMMCTAK DE Virus infection
DMWUYIB ID DMWUYIB
DMWUYIB DN Oxime derivative 1
DMWUYIB HS Patented
DMWUYIB SN PMID29757691-Compound-13
DMWUYIB DT Small molecular drug
DMMSVW5 ID DMMSVW5
DMMSVW5 DN Oxindole derivative 1
DMMSVW5 HS Patented
DMMSVW5 SN PMID27321640-Compound-16
DMMSVW5 CP PFIZER PRODUCTS INC. CHAMBERS, Robert, James LAM, Kelvin, T
DMMSVW5 DT Small molecular drug
DM6ZYMC ID DM6ZYMC
DM6ZYMC DN Oxindole derivative 2
DM6ZYMC HS Patented
DM6ZYMC SN PMID28117607-Compound-37
DM6ZYMC CP CONSEJO SUPERIOR INVESTIGACION [ES]
DM6ZYMC DT Small molecular drug
DM0ENF3 ID DM0ENF3
DM0ENF3 DN Oxindole derivative 3
DM0ENF3 HS Patented
DM0ENF3 SN PMID28117607-Compound-39
DM0ENF3 CP CONSEJO SUPERIOR INVESTIGACION [ES]
DM0ENF3 DT Small molecular drug
DM3U58I ID DM3U58I
DM3U58I DN Oxindole derivative 4
DM3U58I HS Patented
DM3U58I SN PMID28117607-Compound-40
DM3U58I CP CONSEJO SUPERIOR INVESTIGACION [ES]
DM3U58I DT Small molecular drug
DM1SH5R ID DM1SH5R
DM1SH5R DN Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1
DM1SH5R HS Patented
DM1SH5R SN PMID27998201-Compound-14
DM1SH5R CP AMURA THERAPEUTICS LIMITED QUIBELL, Martin WATTS, John, Paul FLINN, Nicholas, Sean
DM1SH5R DT Small molecular drug
DM1SH5R PC 44229370
DM1SH5R MW 470.9
DM1SH5R FM C24H27ClN4O4
DM1SH5R IC InChI=1S/C24H27ClN4O4/c25-18-12-29(21-19(30)13-33-22(18)21)24(32)20(14-5-2-1-3-6-14)28-23(31)16-8-4-7-15(9-16)17-10-26-27-11-17/h4,7-11,14,18,20-22H,1-3,5-6,12-13H2,(H,26,27)(H,28,31)/t18-,20-,21+,22+/m0/s1
DM1SH5R CS C1CCC(CC1)[C@@H](C(=O)N2C[C@@H]([C@@H]3[C@H]2C(=O)CO3)Cl)NC(=O)C4=CC=CC(=C4)C5=CNN=C5
DM1SH5R IK CTSFUIJCUAXDOL-VXSCBNMQSA-N
DM1SH5R IU N-[(1S)-2-[(3aS,6S,6aS)-6-chloro-3-oxo-3a,5,6,6a-tetrahydrofuro[3,2-b]pyrrol-4-yl]-1-cyclohexyl-2-oxoethyl]-3-(1H-pyrazol-4-yl)benzamide
DM1SH5R DE Pain
DM0RI7F ID DM0RI7F
DM0RI7F DN Palbociclib/ribociclib analog 1
DM0RI7F HS Patented
DM0RI7F SN PMID26161698-Compound-4
DM0RI7F CP G1 THERAPEUTICS, INCG1 THERAPEUTICS, INC. STRUM, Jay C. TAVARES, Francis, X
DM0RI7F DT Small molecular drug
DM0RI7F PC 89798202
DM0RI7F MW 432.5
DM0RI7F FM C23H28N8O
DM0RI7F IC InChI=1S/C23H28N8O/c32-21-18-12-16-13-26-22(28-19-5-4-17(14-25-19)30-10-8-24-9-11-30)29-20(16)31(18)23(15-27-21)6-2-1-3-7-23/h4-5,12-14,24H,1-3,6-11,15H2,(H,27,32)(H,25,26,28,29)
DM0RI7F CS C1CCC2(CC1)CNC(=O)C3=CC4=CN=C(N=C4N23)NC5=NC=C(C=C5)N6CCNCC6
DM0RI7F IK TWTKMJWAXOPXSX-UHFFFAOYSA-N
DM0RI7F IU 4-[(5-piperazin-1-ylpyridin-2-yl)amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
DM0RI7F CA CAS 1374743-01-7
DM859ZQ ID DM859ZQ
DM859ZQ DN Palmarumycin derivative 1
DM859ZQ HS Patented
DM859ZQ SN PMID27977313-Compound-33
DM859ZQ CP ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DM859ZQ DT Small molecular drug
DM859ZQ PC 196959
DM859ZQ MW 316.3
DM859ZQ FM C20H12O4
DM859ZQ IC InChI=1S/C20H12O4/c21-14-7-3-6-13-19(14)15(22)10-11-20(13)23-16-8-1-4-12-5-2-9-17(24-20)18(12)16/h1-11,21H
DM859ZQ CS C1=CC2=C3C(=C1)OC4(C=CC(=O)C5=C4C=CC=C5O)OC3=CC=C2
DM859ZQ IK LVOXAJYEGVDSQA-UHFFFAOYSA-N
DM859ZQ IU 8'-hydroxyspiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,4'-naphthalene]-1'-one
DM859ZQ CA CAS 159933-90-1
DMRLWZI ID DMRLWZI
DMRLWZI DN Palmarumycin derivative 2
DMRLWZI HS Patented
DMRLWZI SN PMID27977313-Compound-34
DMRLWZI CP ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DMRLWZI DT Small molecular drug
DM198BY ID DM198BY
DM198BY DN Palmarumycin derivative 3
DM198BY HS Patented
DM198BY SN PMID27977313-Compound-35
DM198BY CP ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DM198BY DT Small molecular drug
DM198BY PC 11684799
DM198BY MW 503.4
DM198BY FM C24H16F3NO8
DM198BY IC InChI=1S/C22H15NO6.C2HF3O2/c23-11-19(26)27-16-7-8-18-20-12(16)3-1-6-17(20)28-22(29-18)10-9-15(25)21-13(22)4-2-5-14(21)24;3-2(4,5)1(6)7/h1-10,24H,11,23H2;(H,6,7)
DM198BY CS C1=CC2=C(C=CC3=C2C(=C1)OC4(O3)C=CC(=O)C5=C4C=CC=C5O)OC(=O)CN.C(=O)(C(F)(F)F)O
DM198BY IK BRTORUASIGAKNH-UHFFFAOYSA-N
DM198BY IU (5'-hydroxy-4'-oxospiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaene-3,1'-naphthalene]-8-yl) 2-aminoacetate;2,2,2-trifluoroacetic acid
DMZGI0R ID DMZGI0R
DMZGI0R DN Palmarumycin derivative 4
DMZGI0R HS Patented
DMZGI0R SN PMID27977313-Compound-36
DMZGI0R CP ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE UNIVERSITY OF ARIZONA UNIVERSITY OF PITTSBURGH POWIS, Garth WIPF, Pete
DMZGI0R DT Small molecular drug
DM231WS ID DM231WS
DM231WS DN P-coumaric acid derivative 1
DM231WS HS Patented
DM231WS SN PMID26815044-Compound-58
DM231WS DT Small molecular drug
DM231WS PC 16119330
DM231WS MW 329.3
DM231WS FM C18H19NO5
DM231WS IC InChI=1S/C18H19NO5/c1-24-17-11-12(3-6-15(17)21)4-7-18(23)19-9-8-13-2-5-14(20)16(22)10-13/h2-7,10-11,20-22H,8-9H2,1H3,(H,19,23)/b7-4+
DM231WS CS COC1=C(C=CC(=C1)/C=C/C(=O)NCCC2=CC(=C(C=C2)O)O)O
DM231WS IK ZRLYUFOWFPPSTD-QPJJXVBHSA-N
DM231WS IU (E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamide
DM231WS CA CAS 142350-99-0
DM231WS DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMFTZBY ID DMFTZBY
DMFTZBY DN P-coumaric acid derivative 2
DMFTZBY HS Patented
DMFTZBY SN PMID26815044-Compound-59
DMFTZBY DT Small molecular drug
DMFTZBY PC 10171904
DMFTZBY MW 315.32
DMFTZBY FM C17H17NO5
DMFTZBY IC InChI=1S/C17H17NO5/c19-13-4-1-11(9-15(13)21)3-6-17(23)18-8-7-12-2-5-14(20)16(22)10-12/h1-6,9-10,19-22H,7-8H2,(H,18,23)/b6-3+
DMFTZBY CS C1=CC(=C(C=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
DMFTZBY IK FSMGGLPUXCKRGT-ZZXKWVIFSA-N
DMFTZBY IU (E)-3-(3,4-dihydroxyphenyl)-N-[2-(3,4-dihydroxyphenyl)ethyl]prop-2-enamide
DMFTZBY CA CAS 103188-49-4
DMFTZBY DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMFE4IY ID DMFE4IY
DMFE4IY DN P-coumaric acid derivative 3
DMFE4IY HS Patented
DMFE4IY SN PMID26815044-Compound-60
DMFE4IY DT Small molecular drug
DMFE4IY PC 15086380
DMFE4IY MW 343.4
DMFE4IY FM C19H21NO5
DMFE4IY IC InChI=1S/C19H21NO5/c1-24-17-7-4-14(12-18(17)25-2)9-10-20-19(23)8-5-13-3-6-15(21)16(22)11-13/h3-8,11-12,21-22H,9-10H2,1-2H3,(H,20,23)/b8-5+
DMFE4IY CS COC1=C(C=C(C=C1)CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC
DMFE4IY IK WWELEILTWYPGMY-VMPITWQZSA-N
DMFE4IY IU (E)-3-(3,4-dihydroxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]prop-2-enamide
DMFE4IY DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM5WQP3 ID DM5WQP3
DM5WQP3 DN P-coumaric acid derivative 4
DM5WQP3 HS Patented
DM5WQP3 SN PMID26815044-Compound-61
DM5WQP3 DT Small molecular drug
DM5WQP3 PC 16119668
DM5WQP3 MW 301.34
DM5WQP3 FM C17H19NO4
DM5WQP3 IC InChI=1S/C17H19NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-3,5-7,11,19-21H,4,8-10H2,(H,18,22)
DM5WQP3 CS C1=CC(=CC=C1CCNC(=O)CCC2=CC(=C(C=C2)O)O)O
DM5WQP3 IK RIYORZPRGANLCW-UHFFFAOYSA-N
DM5WQP3 IU 3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]propanamide
DM5WQP3 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMFKGZ7 ID DMFKGZ7
DMFKGZ7 DN P-coumaric acid derivative 5
DMFKGZ7 HS Patented
DMFKGZ7 SN PMID26815044-Compound-62
DMFKGZ7 DT Small molecular drug
DMFKGZ7 PC 9994897
DMFKGZ7 MW 299.32
DMFKGZ7 FM C17H17NO4
DMFKGZ7 IC InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+
DMFKGZ7 CS C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)O
DMFKGZ7 IK VSHUQLRHTJOKTA-XBXARRHUSA-N
DMFKGZ7 IU (E)-3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
DMFKGZ7 CA CAS 103188-48-3
DMFKGZ7 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMF4YGC ID DMF4YGC
DMF4YGC DN P-coumaric acid derivative 6
DMF4YGC HS Patented
DMF4YGC SN PMID26815044-Compound-63
DMF4YGC DT Small molecular drug
DMF4YGC PC 5372945
DMF4YGC MW 283.32
DMF4YGC FM C17H17NO3
DMF4YGC IC InChI=1S/C17H17NO3/c19-15-6-1-13(2-7-15)5-10-17(21)18-12-11-14-3-8-16(20)9-4-14/h1-10,19-20H,11-12H2,(H,18,21)/b10-5+
DMF4YGC CS C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC=C(C=C2)O)O
DMF4YGC IK RXGUTQNKCXHALN-BJMVGYQFSA-N
DMF4YGC IU (E)-3-(4-hydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
DMF4YGC CA CAS 36417-86-4
DMF4YGC CB CHEBI:65665
DMF4YGC DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMF3LIX ID DMF3LIX
DMF3LIX DN Peptide analog 1
DMF3LIX HS Patented
DMF3LIX SN PMID30107136-Compound-Example61
DMF3LIX CP Aurigene Discovery Technologies Limited
DMF3LIX DT Peptide
DMF3LIX DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMYKOAM ID DMYKOAM
DMYKOAM DN Peptide analog 10
DMYKOAM HS Patented
DMYKOAM SN PMID29865878-Compound-10
DMYKOAM CP ONYX THERAPEUTICS, INC
DMYKOAM DT Small molecular drug
DML9C64 ID DML9C64
DML9C64 DN Peptide analog 11
DML9C64 HS Patented
DML9C64 SN PMID29865878-Compound-11
DML9C64 CP ONYX THERAPEUTICS, INC
DML9C64 DT Small molecular drug
DMSJHV3 ID DMSJHV3
DMSJHV3 DN Peptide analog 12
DMSJHV3 HS Patented
DMSJHV3 SN PMID29865878-Compound-12
DMSJHV3 CP ONYX THERAPEUTICS, INC
DMSJHV3 DT Small molecular drug
DMWI6V3 ID DMWI6V3
DMWI6V3 DN Peptide analog 13
DMWI6V3 HS Patented
DMWI6V3 SN PMID29865878-Compound-13
DMWI6V3 CP ONYX THERAPEUTICS, INC
DMWI6V3 DT Small molecular drug
DMN97QF ID DMN97QF
DMN97QF DN Peptide analog 14
DMN97QF HS Patented
DMN97QF SN PMID29865878-Compound-14
DMN97QF CP ONYX THERAPEUTICS, INC
DMN97QF DT Small molecular drug
DM0K5Q1 ID DM0K5Q1
DM0K5Q1 DN Peptide analog 15
DM0K5Q1 HS Patented
DM0K5Q1 SN PMID29865878-Compound-15
DM0K5Q1 CP KEZAR LIFE SCIENCES
DM0K5Q1 DT Small molecular drug
DMKJ27D ID DMKJ27D
DMKJ27D DN Peptide analog 16
DMKJ27D HS Patented
DMKJ27D SN PMID29865878-Compound-16
DMKJ27D CP ONYX THERAPEUTICS, INC. SHENK, Kevin D. PARLATI, Francesco BENNETT, Mark K
DMKJ27D DT Small molecular drug
DMJ91EM ID DMJ91EM
DMJ91EM DN Peptide analog 17
DMJ91EM HS Patented
DMJ91EM SN PMID29865878-Compound-17
DMJ91EM CP ONYX THERAPEUTICS, INC. SHENK, Kevin D. PARLATI, Francesco BENNETT, Mark K
DMJ91EM DT Small molecular drug
DMF1TR6 ID DMF1TR6
DMF1TR6 DN Peptide analog 18
DMF1TR6 HS Patented
DMF1TR6 SN PMID29865878-Compound-18
DMF1TR6 CP University of Kentucky Research Foundation
DMF1TR6 DT Small molecular drug
DMLIVT6 ID DMLIVT6
DMLIVT6 DN Peptide analog 19
DMLIVT6 HS Patented
DMLIVT6 SN PMID29865878-Compound-19
DMLIVT6 CP University of Kentucky Research Foundation
DMLIVT6 DT Small molecular drug
DMYFUM6 ID DMYFUM6
DMYFUM6 DN Peptide analog 2
DMYFUM6 HS Patented
DMYFUM6 SN PMID30107136-Compound-Example62
DMYFUM6 CP Aurigene Discovery Technologies Limited
DMYFUM6 DT Peptide
DMYFUM6 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM2L9KI ID DM2L9KI
DM2L9KI DN Peptide analog 20
DM2L9KI HS Patented
DM2L9KI SN PMID29865878-Compound-20
DM2L9KI CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM2L9KI DT Small molecular drug
DMJDFS1 ID DMJDFS1
DMJDFS1 DN Peptide analog 21
DMJDFS1 HS Patented
DMJDFS1 SN PMID29865878-Compound-21
DMJDFS1 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMJDFS1 DT Small molecular drug
DMTLO1E ID DMTLO1E
DMTLO1E DN Peptide analog 22
DMTLO1E HS Patented
DMTLO1E SN PMID29865878-Compound-22
DMTLO1E CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMTLO1E DT Small molecular drug
DMDU21R ID DMDU21R
DMDU21R DN Peptide analog 23
DMDU21R HS Patented
DMDU21R SN PMID29865878-Compound-23
DMDU21R CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMDU21R DT Small molecular drug
DM904T7 ID DM904T7
DM904T7 DN Peptide analog 24
DM904T7 HS Patented
DM904T7 SN PMID29865878-Compound-24
DM904T7 CP PRINCIPIA BIOPHARMA INC
DM904T7 DT Small molecular drug
DMFBQHZ ID DMFBQHZ
DMFBQHZ DN Peptide analog 25
DMFBQHZ HS Patented
DMFBQHZ SN PMID29865878-Compound-25
DMFBQHZ CP PRINCIPIA BIOPHARMA INC
DMFBQHZ DT Small molecular drug
DM8FGZB ID DM8FGZB
DM8FGZB DN Peptide analog 26
DM8FGZB HS Patented
DM8FGZB SN PMID29865878-Compound-26
DM8FGZB CP CORNELL UNIVERSITY
DM8FGZB DT Small molecular drug
DML4XJ2 ID DML4XJ2
DML4XJ2 DN Peptide analog 27
DML4XJ2 HS Patented
DML4XJ2 SN PMID29865878-Compound-27
DML4XJ2 CP CORNELL UNIVERSITY
DML4XJ2 DT Small molecular drug
DMHT4PF ID DMHT4PF
DMHT4PF DN Peptide analog 28
DMHT4PF HS Patented
DMHT4PF SN PMID29865878-Compound-28
DMHT4PF CP CORNELL UNIVERSITY
DMHT4PF DT Small molecular drug
DM1NMR6 ID DM1NMR6
DM1NMR6 DN Peptide analog 29
DM1NMR6 HS Patented
DM1NMR6 SN PMID29865878-Compound-29
DM1NMR6 CP CORNELL UNIVERSITY
DM1NMR6 DT Small molecular drug
DMYMJV3 ID DMYMJV3
DMYMJV3 DN Peptide analog 3
DMYMJV3 HS Patented
DMYMJV3 SN PMID30107136-Compound-Example63
DMYMJV3 CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DMYMJV3 DT Peptide
DMYMJV3 PC 91664324
DMYMJV3 MW 405.41
DMYMJV3 FM C14H27N7O7
DMYMJV3 IC InChI=1S/C14H27N7O7/c15-4-2-1-3-8(13(26)27)18-14(28)19-9(5-10(17)23)12(25)21-20-11(24)7(16)6-22/h7-9,22H,1-6,15-16H2,(H2,17,23)(H,20,24)(H,21,25)(H,26,27)(H2,18,19,28)/t7-,8-,9-/m0/s1
DMYMJV3 CS C(CCN)C[C@@H](C(=O)O)NC(=O)N[C@@H](CC(=O)N)C(=O)NNC(=O)[C@H](CO)N
DMYMJV3 IK ATJFXPNBJOTGGR-CIUDSAMLSA-N
DMYMJV3 IU (2S)-6-amino-2-[[(2S)-4-amino-1-[2-[(2S)-2-amino-3-hydroxypropanoyl]hydrazinyl]-1,4-dioxobutan-2-yl]carbamoylamino]hexanoic acid
DMYMJV3 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMYEJV0 ID DMYEJV0
DMYEJV0 DN Peptide analog 30
DMYEJV0 HS Patented
DMYEJV0 SN PMID29865878-Compound-3
DMYEJV0 CP UNIV DARMSTADT TECH [DECHARITE UNIVERSITAETSMEDIZIN [DE]
DMYEJV0 DT Small molecular drug
DMS9O6I ID DMS9O6I
DMS9O6I DN Peptide analog 31
DMS9O6I HS Patented
DMS9O6I SN PMID29865878-Compound-30
DMS9O6I CP CORNELL UNIVERSITY
DMS9O6I DT Small molecular drug
DMGQ1PK ID DMGQ1PK
DMGQ1PK DN Peptide analog 32
DMGQ1PK HS Patented
DMGQ1PK SN PMID29865878-Compound-31
DMGQ1PK CP CORNELL UNIVERSITY
DMGQ1PK DT Small molecular drug
DML5P6O ID DML5P6O
DML5P6O DN Peptide analog 33
DML5P6O HS Patented
DML5P6O SN PMID29865878-Compound-32
DML5P6O CP CORNELL UNIVERSITY
DML5P6O DT Small molecular drug
DMG4EOP ID DMG4EOP
DMG4EOP DN Peptide analog 34
DMG4EOP HS Patented
DMG4EOP SN PMID29865878-Compound-33
DMG4EOP CP CORNELL UNIVERSITY
DMG4EOP DT Small molecular drug
DMSOQG7 ID DMSOQG7
DMSOQG7 DN Peptide analog 35
DMSOQG7 HS Patented
DMSOQG7 SN PMID29865878-Compound-34
DMSOQG7 CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DMSOQG7 DT Small molecular drug
DMB4LNI ID DMB4LNI
DMB4LNI DN Peptide analog 36
DMB4LNI HS Patented
DMB4LNI SN PMID29865878-Compound-35
DMB4LNI CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DMB4LNI DT Small molecular drug
DMVX71N ID DMVX71N
DMVX71N DN Peptide analog 37
DMVX71N HS Patented
DMVX71N SN PMID29865878-Compound-36
DMVX71N CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DMVX71N DT Small molecular drug
DM9FL81 ID DM9FL81
DM9FL81 DN Peptide analog 38
DM9FL81 HS Patented
DM9FL81 SN PMID29865878-Compound-37
DM9FL81 CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
DM9FL81 DT Small molecular drug
DMYJOTP ID DMYJOTP
DMYJOTP DN Peptide analog 39
DMYJOTP HS Patented
DMYJOTP SN PMID29865878-Compound-4
DMYJOTP CP UNIV DARMSTADT TECH [DECHARITE UNIVERSITAETSMEDIZIN [DE]
DMYJOTP DT Small molecular drug
DM5KEVG ID DM5KEVG
DM5KEVG DN Peptide analog 4
DM5KEVG HS Patented
DM5KEVG SN PMID30107136-Compound-Example64
DM5KEVG CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM5KEVG DT Peptide
DM5KEVG DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM12VO9 ID DM12VO9
DM12VO9 DN Peptide analog 40
DM12VO9 HS Patented
DM12VO9 SN PMID29865878-Compound-5
DM12VO9 CP PROTEOLIX, INC. BENNETT, Mark, K. BUCHHOLZ, Tonia, J. DEMO, Susan LAIDIG, Guy, J. LEWIS, Evan, R. SMYTH, Mark, S
DM12VO9 DT Small molecular drug
DM96KXE ID DM96KXE
DM96KXE DN Peptide analog 41
DM96KXE HS Patented
DM96KXE SN PMID29865878-Compound-6
DM96KXE CP PROTEOLIX, INC. BENNETT, Mark, K. BUCHHOLZ, Tonia, J. DEMO, Susan LAIDIG, Guy, J. LEWIS, Evan, R. SMYTH, Mark, S
DM96KXE DT Small molecular drug
DMF1MZ4 ID DMF1MZ4
DMF1MZ4 DN Peptide analog 42
DMF1MZ4 HS Patented
DMF1MZ4 SN PMID29865878-Compound-7
DMF1MZ4 CP ONYX THERAPEUTICS, INC. PHIASIVONGSA, PasiPROTEOLIX, INC. SHENK, Kevin, D. PARLATI, Francesco ZHOU, Han-jie SYLVAIN, Catherine SMYTH, Mark, S. BENNETT, Mark, K. LAIDIG, Guy, J
DMF1MZ4 DT Small molecular drug
DMYMPF9 ID DMYMPF9
DMYMPF9 DN Peptide analog 43
DMYMPF9 HS Patented
DMYMPF9 SN PMID29865878-Compound-9
DMYMPF9 CP ONYX THERAPEUTICS, INC. PHIASIVONGSA, Pasit SEHL, Louis, C
DMYMPF9 DT Small molecular drug
DMOJDQF ID DMOJDQF
DMOJDQF DN Peptide analog 44
DMOJDQF HS Patented
DMOJDQF SN PMID25482888-Compound-22
DMOJDQF DT Peptide
DMGA3U8 ID DMGA3U8
DMGA3U8 DN Peptide analog 45
DMGA3U8 HS Patented
DMGA3U8 SN PMID25482888-Compound-23
DMGA3U8 DT Peptide
DMC48AX ID DMC48AX
DMC48AX DN Peptide analog 46
DMC48AX HS Patented
DMC48AX SN PMID25482888-Compound-24
DMC48AX DT Peptide
DM7U8WD ID DM7U8WD
DM7U8WD DN Peptide analog 47
DM7U8WD HS Patented
DM7U8WD SN PMID25482888-Compound-25
DM7U8WD DT Peptide
DMM2WA4 ID DMM2WA4
DMM2WA4 DN Peptide analog 48
DMM2WA4 HS Patented
DMM2WA4 SN PMID25482888-Compound-26
DMM2WA4 DT Peptide
DMP5SA2 ID DMP5SA2
DMP5SA2 DN Peptide analog 49
DMP5SA2 HS Patented
DMP5SA2 SN PMID25482888-Compound-28
DMP5SA2 DT Peptide
DM8B13I ID DM8B13I
DM8B13I DN Peptide analog 5
DM8B13I HS Patented
DM8B13I SN PMID30107136-Compound-General structure31
DM8B13I CP Aurigene Discovery Technologies Limited
DM8B13I DT Peptide
DM8B13I DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMM8K7R ID DMM8K7R
DMM8K7R DN Peptide analog 50
DMM8K7R HS Patented
DMM8K7R SN PMID25482888-Compound-29
DMM8K7R DT Peptide
DM1D7CE ID DM1D7CE
DM1D7CE DN Peptide analog 51
DM1D7CE HS Patented
DM1D7CE SN PMID25482888-Compound-30
DM1D7CE DT Peptide
DMDG5T9 ID DMDG5T9
DMDG5T9 DN Peptide analog 52
DMDG5T9 HS Patented
DMDG5T9 SN PMID26560530-Compound-38
DMDG5T9 CP Zedira GmbH
DMDG5T9 DT Small molecular drug
DM9FJXS ID DM9FJXS
DM9FJXS DN Peptide analog 53
DM9FJXS HS Patented
DM9FJXS SN PMID26560530-Compound-39
DM9FJXS CP Zedira GmbH
DM9FJXS DT Small molecular drug
DMZVB5U ID DMZVB5U
DMZVB5U DN Peptide analog 54
DMZVB5U HS Patented
DMZVB5U SN PMID26560530-Compound-43
DMZVB5U CP DOMINGUEZ, Celia PRIME, Michael MARSTON, Richard BROOKFIELD, Frederick, A. COURTNEY, Stephen, M. MACDONALD, Douglas WITYAK, John YARNOLD, Christopher, John VAIDYA, Darshan
DMZVB5U DT Small molecular drug
DMZVB5U PC 71459385
DMZVB5U MW 513
DMZVB5U FM C27H33ClN4O4
DMZVB5U IC InChI=1S/C27H33ClN4O4/c1-2-25(33)29-15-9-8-13-23(30-27(35)36-20-21-10-4-3-5-11-21)26(34)32-18-16-31(17-19-32)24-14-7-6-12-22(24)28/h2-7,10-12,14,23H,1,8-9,13,15-20H2,(H,29,33)(H,30,35)/t23-/m0/s1
DMZVB5U CS C=CC(=O)NCCCC[C@@H](C(=O)N1CCN(CC1)C2=CC=CC=C2Cl)NC(=O)OCC3=CC=CC=C3
DMZVB5U IK KYVYJVRZPFRADU-QHCPKHFHSA-N
DMZVB5U IU benzyl N-[(2S)-1-[4-(2-chlorophenyl)piperazin-1-yl]-1-oxo-6-(prop-2-enoylamino)hexan-2-yl]carbamate
DMVLP8H ID DMVLP8H
DMVLP8H DN Peptide analog 55
DMVLP8H HS Patented
DMVLP8H SN PMID26118988-Compound-10
DMVLP8H DT Peptide
DMVLP8H SQ AlaCysCysGlnIleNleProProSerThrTyr
DMBCFJU ID DMBCFJU
DMBCFJU DN Peptide analog 56
DMBCFJU HS Patented
DMBCFJU SN PMID26118988-Compound-11
DMBCFJU DT Peptide
DMBCFJU SQ AlaCysCysGlnGlnhPheOctGProProSerThr
DM6IQWE ID DM6IQWE
DM6IQWE DN Peptide analog 57
DM6IQWE HS Patented
DM6IQWE SN PMID26118988-Compound-12
DM6IQWE DT Small molecular drug
DM7X62M ID DM7X62M
DM7X62M DN Peptide analog 58
DM7X62M HS Patented
DM7X62M SN PMID26118988-Compound-13
DM7X62M DT Peptide
DM7X62M SQ AlaChaCysCysGlnhPhePheProProSerThr
DMZAMNX ID DMZAMNX
DMZAMNX DN Peptide analog 59
DMZAMNX HS Patented
DMZAMNX SN PMID26118988-Compound-14
DMZAMNX DT Small molecular drug
DM68M0G ID DM68M0G
DM68M0G DN Peptide analog 6
DM68M0G HS Patented
DM68M0G SN PMID30107136-Compound-General structure32
DM68M0G CP AURIGENE DISCOVERY TECHNOLOGIES LIMITED
DM68M0G DT Peptide
DM68M0G DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMMSTNA ID DMMSTNA
DMMSTNA DN Peptide analog 60
DMMSTNA HS Patented
DMMSTNA SN PMID26118988-Compound-15
DMMSTNA DT Peptide
DMMSTNA SQ AlaChaCysCysGlnGlnhPheProProSerThr
DM45JMT ID DM45JMT
DM45JMT DN Peptide analog 61
DM45JMT HS Patented
DM45JMT SN PMID26118988-Compound-16
DM45JMT DT Peptide
DM45JMT SQ AlaChaCysCysGlnGlnOctGProPro4NHCOPheSerThr
DM28NK0 ID DM28NK0
DM28NK0 DN Peptide analog 62
DM28NK0 HS Patented
DM28NK0 SN PMID26118988-Compound-17
DM28NK0 DT Small molecular drug
DMGC7NW ID DMGC7NW
DMGC7NW DN Peptide analog 63
DMGC7NW HS Patented
DMGC7NW SN PMID26118988-Compound-2
DMGC7NW DT Peptide
DMGC7NW SQ HLArgPhgLValPhgOH
DM1G2J5 ID DM1G2J5
DM1G2J5 DN Peptide analog 64
DM1G2J5 HS Patented
DM1G2J5 SN PMID26118988-Compound-3
DM1G2J5 DT Peptide
DM1G2J5 SQ HLArgPhgLValGlyOH
DMAJLM1 ID DMAJLM1
DMAJLM1 DN Peptide analog 65
DMAJLM1 HS Patented
DMAJLM1 SN PMID26118988-Compound-4
DMAJLM1 DT Peptide
DMAJLM1 SQ HLArgPhgLTrpPhgOH
DMW502M ID DMW502M
DMW502M DN Peptide analog 66
DMW502M HS Patented
DMW502M SN PMID26118988-Compound-5
DMW502M DT Peptide
DMW502M SQ AlaChaCysCysGlnOctGPheProProSerThr
DMJ8QTX ID DMJ8QTX
DMJ8QTX DN Peptide analog 67
DMJ8QTX HS Patented
DMJ8QTX SN PMID26118988-Compound-6
DMJ8QTX DT Peptide
DMJ8QTX SQ AlaChaCysCysGlnGlnOctGProProSerThr
DMFG2KT ID DMFG2KT
DMFG2KT DN Peptide analog 68
DMFG2KT HS Patented
DMFG2KT SN PMID26118988-Compound-7
DMFG2KT DT Peptide
DMFG2KT SQ AlaCysCysGlnhPheOctGProProSerThrTyr
DM2OXW3 ID DM2OXW3
DM2OXW3 DN Peptide analog 69
DM2OXW3 HS Patented
DM2OXW3 SN PMID26118988-Compound-8
DM2OXW3 DT Peptide
DM2OXW3 SQ AlaCysCysGlnGlnOctGOctGProProSerThr
DMKYOLV ID DMKYOLV
DMKYOLV DN Peptide analog 7
DMKYOLV HS Patented
DMKYOLV SN PMID26394986-Compound-1
DMKYOLV CP THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES TARASOVA, Nadya I. TRINCHIERI, Giorgio YOUNG, Howard A. STEWART, C. Andrew CARDONE, Marco A. PERANTONI, Alan O
DMKYOLV DT Small molecular drug
DMN43Q5 ID DMN43Q5
DMN43Q5 DN Peptide analog 70
DMN43Q5 HS Patented
DMN43Q5 SN PMID26118988-Compound-9
DMN43Q5 DT Peptide
DMN43Q5 SQ AlaCysCysGlnGlnIleNleProProSerThr
DMSEKZG ID DMSEKZG
DMSEKZG DN Peptide analog 71
DMSEKZG HS Patented
DMSEKZG SN PMID26936077-Compound-1
DMSEKZG CP Peptron Inc
DMSEKZG DT Small molecular drug
DMXU71M ID DMXU71M
DMXU71M DN Peptide analog 72
DMXU71M HS Patented
DMXU71M SN PMID26936077-Compound-5
DMXU71M CP The University of Queensland
DMXU71M DT Small molecular drug
DMFG7A8 ID DMFG7A8
DMFG7A8 DN Peptide analog 8
DMFG7A8 HS Patented
DMFG7A8 SN PMID26394986-Compound-2
DMFG7A8 CP THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES TARASOVA, Nadya I. TRINCHIERI, Giorgio YOUNG, Howard A. STEWART, C. Andrew CARDONE, Marco A. PERANTONI, Alan O
DMFG7A8 DT Small molecular drug
DM953EV ID DM953EV
DM953EV DN Peptide analog 9
DM953EV HS Patented
DM953EV SN PMID29865878-Compound-1
DM953EV CP THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL MOUNT SINAL SCHOOL OF MEDICINE ORLOWSKI, Robert, Z. ORLOWSKI, Marian
DM953EV DT Small molecular drug
DMMP9N7 ID DMMP9N7
DMMP9N7 DN Peptidomimetic analog 1
DMMP9N7 HS Patented
DMMP9N7 SN PMID26394986-Compound-3
DMMP9N7 DT Small molecular drug
DMN2VZW ID DMN2VZW
DMN2VZW DN Peptidomimetic analog 2
DMN2VZW HS Patented
DMN2VZW SN PMID26394986-Compound-4
DMN2VZW DT Small molecular drug
DMPWS9N ID DMPWS9N
DMPWS9N DN Peptidomimetic analog 3
DMPWS9N HS Patented
DMPWS9N SN PMID26394986-Compound-5
DMPWS9N DT Small molecular drug
DMPWS9N PC 24772856
DMPWS9N MW 846.8
DMPWS9N FM C41H53F2N4O11P
DMPWS9N IC InChI=1S/C41H53F2N4O11P/c1-24(26-13-16-29(17-14-26)41(42,43)59(54,57-22-55-37(52)39(3,4)5)58-23-56-38(53)40(6,7)8)20-33(49)46-30-18-15-27-10-9-11-28-21-31(47(34(27)28)36(30)51)35(50)45-25(2)12-19-32(44)48/h9-11,13-14,16-17,20,25,30-31H,12,15,18-19,21-23H2,1-8H3,(H2,44,48)(H,45,50)(H,46,49)/b24-20+/t25-,30+,31+/m1/s1
DMPWS9N CS C[C@H](CCC(=O)N)NC(=O)[C@@H]1CC2=CC=CC3=C2N1C(=O)[C@H](CC3)NC(=O)/C=C(\\C)/C4=CC=C(C=C4)C(F)(F)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C
DMPWS9N IK FPJJYMKTWVMUCU-GCFVZNOFSA-N
DMPWS9N IU [[[4-[(E)-4-[[(2S,11S)-2-[[(2R)-5-amino-5-oxopentan-2-yl]carbamoyl]-12-oxo-1-azatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-11-yl]amino]-4-oxobut-2-en-2-yl]phenyl]-difluoromethyl]-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
DM9Q0JS ID DM9Q0JS
DM9Q0JS DN Peptidomimetic analog 4
DM9Q0JS HS Patented
DM9Q0JS SN PMID26394986-Compound-6
DM9Q0JS DT Small molecular drug
DMF0DE2 ID DMF0DE2
DMF0DE2 DN Peptidomimetic analog 5
DMF0DE2 HS Patented
DMF0DE2 SN PMID26394986-Compound-7
DMF0DE2 CP UNIVERSITY OF SOUTH FLORIDA TURKSON, James JOVE, Richard SEBTI, Said, M. HAMILTON, Andrew, D
DMF0DE2 DT Small molecular drug
DMF0DE2 PC 9870708
DMF0DE2 MW 503.4
DMF0DE2 FM C23H26N3O8P
DMF0DE2 IC InChI=1S/C23H26N3O8P/c1-14(2)11-20(23(29)30)26-22(28)19(25-21(27)17-7-3-16(13-24)4-8-17)12-15-5-9-18(10-6-15)34-35(31,32)33/h3-10,14,19-20H,11-12H2,1-2H3,(H,25,27)(H,26,28)(H,29,30)(H2,31,32,33)/t19-,20-/m0/s1
DMF0DE2 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)OP(=O)(O)O)NC(=O)C2=CC=C(C=C2)C#N
DMF0DE2 IK HXSAWUQKNZJUNW-PMACEKPBSA-N
DMF0DE2 IU (2S)-2-[[(2S)-2-[(4-cyanobenzoyl)amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMSUD5X ID DMSUD5X
DMSUD5X DN Peptidomimetic analog 6
DMSUD5X HS Patented
DMSUD5X SN PMID26936077-Compound-2
DMSUD5X CP Peptron Inc
DMSUD5X DT Small molecular drug
DM15TMH ID DM15TMH
DM15TMH DN Peptidomimetic analog 7
DM15TMH HS Patented
DM15TMH SN PMID26882240-Compound-28
DM15TMH CP University of Southern California, USNew York University
DM15TMH DT Small molecular drug
DM0PBJT ID DM0PBJT
DM0PBJT DN Phenoxypiperidine derivative 1
DM0PBJT HS Patented
DM0PBJT SN PMID29334795-Compound-36
DM0PBJT CP RICHTER GEDEON NYRT
DM0PBJT DT Small molecular drug
DMC5G8P ID DMC5G8P
DMC5G8P DN Phenoxypiperidine derivative 2
DMC5G8P HS Patented
DMC5G8P SN PMID29334795-Compound-37
DMC5G8P CP RICHTER GEDEON NYRT
DMC5G8P DT Small molecular drug
DMC5G8P PC 86299782
DMC5G8P MW 318.5
DMC5G8P FM C19H30N2O2
DMC5G8P IC InChI=1S/C19H30N2O2/c1-2-13-21(14-3-1)15-4-16-22-17-5-7-18(8-6-17)23-19-9-11-20-12-10-19/h5-8,19-20H,1-4,9-16H2
DMC5G8P CS C1CCN(CC1)CCCOC2=CC=C(C=C2)OC3CCNCC3
DMC5G8P IK IRTTXYWMHFLYFK-UHFFFAOYSA-N
DMC5G8P IU 1-[3-(4-piperidin-4-yloxyphenoxy)propyl]piperidine
DMVYP8K ID DMVYP8K
DMVYP8K DN Phenylalanine derivative 1
DMVYP8K HS Patented
DMVYP8K SN PMID27998201-Compound-21
DMVYP8K DT Small molecular drug
DMVYP8K DE Glioma
DMEO9QB ID DMEO9QB
DMEO9QB DN Phenylate derivative 1
DMEO9QB HS Patented
DMEO9QB SN PMID30107136-Compound-Example21
DMEO9QB CP INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMEO9QB DT Small molecule immunotherapy
DMEO9QB PC 132183784
DMEO9QB MW 574.9
DMEO9QB FM C28H29BrClNO5
DMEO9QB IC InChI=1S/C28H29BrClNO5/c1-18(2)11-12-35-25-14-26(23(30)13-21(25)15-31-24(16-32)28(33)34)36-17-20-9-6-10-22(27(20)29)19-7-4-3-5-8-19/h3-11,13-14,24,31-32H,12,15-17H2,1-2H3,(H,33,34)
DMEO9QB CS CC(=CCOC1=CC(=C(C=C1CNC(CO)C(=O)O)Cl)OCC2=C(C(=CC=C2)C3=CC=CC=C3)Br)C
DMEO9QB IK HXFYELRCMXNMTR-UHFFFAOYSA-N
DMEO9QB IU 2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-(3-methylbut-2-enoxy)phenyl]methylamino]-3-hydroxypropanoic acid
DMEO9QB DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMG0ZSY ID DMG0ZSY
DMG0ZSY DN Phenylate derivative 2
DMG0ZSY HS Patented
DMG0ZSY SN PMID30107136-Compound-Example22
DMG0ZSY CP INST OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES [CN]
DMG0ZSY DT Small molecule immunotherapy
DMG0ZSY PC 132183436
DMG0ZSY MW 644.9
DMG0ZSY FM C31H31BrClNO7
DMG0ZSY IC InChI=1S/C31H31BrClNO7/c32-30-20(2-1-3-23(30)19-6-7-26-29(11-19)39-9-8-38-26)17-41-28-13-27(40-16-18-4-5-18)21(10-24(28)33)14-34-15-22(35)12-25(34)31(36)37/h1-3,6-7,10-11,13,18,22,25,35H,4-5,8-9,12,14-17H2,(H,36,37)/t22-,25-/m0/s1
DMG0ZSY CS C1CC1COC2=CC(=C(C=C2CN3C[C@H](C[C@H]3C(=O)O)O)Cl)OCC4=C(C(=CC=C4)C5=CC6=C(C=C5)OCCO6)Br
DMG0ZSY IK JLLTUBDWNGWHPK-DHLKQENFSA-N
DMG0ZSY IU (2S,4S)-1-[[4-[[2-bromo-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]methoxy]-5-chloro-2-(cyclopropylmethoxy)phenyl]methyl]-4-hydroxypyrrolidine-2-carboxylic acid
DMG0ZSY DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM1BIY4 ID DM1BIY4
DM1BIY4 DN Phenylmethanesulfonamide derivative 1
DM1BIY4 HS Patented
DM1BIY4 SN PMID25470667-Compound-Figure6-23
DM1BIY4 CP ELI LILLY AND COMPANY
DM1BIY4 DT Small molecular drug
DMTEJRB ID DMTEJRB
DMTEJRB DN Phenylpropionic acid derivative 1
DMTEJRB HS Patented
DMTEJRB SN PMID25416646-Compound-Figure2-D
DMTEJRB CP DONG-A PHARM. CO., LTD. YUHAN CO., LTD. MOON, Ho-Sang YOO, Moo-Hi KIM, Soon-Hoe LIM, Joong-In SON, Moon-Ho KIM, Mi-Kyung SHIN, Chang-Yell KIM, Jin-Kwan PARK, Sang-Kuk CHAE, Yu-Na SHIM, Hyun-Joo JEON, Sun-Ho KIM, Hae-Sun WIE, Gil-Tae KIM, Dong-Hwan LEE, Byung-Kyu PARK, Chan-Sun AHN, Byung-Nak KIM, Eunkyung BAE, Myung-Ho SHIN, Young-Ah HUR, Youn LEE, Chun-Ho CHOI, Hyun-Ho KIM, Bongtae CHONG, Wonee KANG, So Mi
DMTEJRB DT Small molecular drug
DMVCKZT ID DMVCKZT
DMVCKZT DN Phenylpropylamine derivative 1
DMVCKZT HS Patented
DMVCKZT SN PMID28051882-Compound-3
DMVCKZT CP Wisconsin Alumni Research Foundation
DMVCKZT DT Small molecular drug
DMVCKZT PC 20534903
DMVCKZT MW 278.39
DMVCKZT FM C16H26N2O2
DMVCKZT IC InChI=1S/C16H26N2O2/c1-2-3-4-5-6-13-17-14-7-8-15-9-11-16(12-10-15)18(19)20/h9-12,17H,2-8,13-14H2,1H3
DMVCKZT CS CCCCCCCNCCCC1=CC=C(C=C1)[N+](=O)[O-]
DMVCKZT IK LAKCRRVRMIUBSO-UHFFFAOYSA-N
DMVCKZT IU N-[3-(4-nitrophenyl)propyl]heptan-1-amine
DMTDIA6 ID DMTDIA6
DMTDIA6 DN Phenylpropylamine derivative 2
DMTDIA6 HS Patented
DMTDIA6 SN PMID28051882-Compound-4
DMTDIA6 CP Wisconsin Alumni Research Foundation
DMTDIA6 DT Small molecular drug
DMTDIA6 PC 46196429
DMTDIA6 MW 348.5
DMTDIA6 FM C21H36N2O2
DMTDIA6 IC InChI=1S/C21H36N2O2/c1-2-3-4-5-6-7-8-9-10-11-18-22-19-12-13-20-14-16-21(17-15-20)23(24)25/h14-17,22H,2-13,18-19H2,1H3
DMTDIA6 CS CCCCCCCCCCCCNCCCC1=CC=C(C=C1)[N+](=O)[O-]
DMTDIA6 IK HPQAMSDOLBKJBM-UHFFFAOYSA-N
DMTDIA6 IU N-[3-(4-nitrophenyl)propyl]dodecan-1-amine
DMH3FUR ID DMH3FUR
DMH3FUR DN Phenylpropylamine derivative 3
DMH3FUR HS Patented
DMH3FUR SN PMID28051882-Compound-5
DMH3FUR CP Wisconsin Alumni Research Foundation
DMH3FUR DT Small molecular drug
DMH3FUR PC 46212857
DMH3FUR MW 292.4
DMH3FUR FM C17H28N2O2
DMH3FUR IC InChI=1S/C17H28N2O2/c1-3-5-13-18(14-6-4-2)15-7-8-16-9-11-17(12-10-16)19(20)21/h9-12H,3-8,13-15H2,1-2H3
DMH3FUR CS CCCCN(CCCC)CCCC1=CC=C(C=C1)[N+](=O)[O-]
DMH3FUR IK RQYGHCATHJZLFY-UHFFFAOYSA-N
DMH3FUR IU N-butyl-N-[3-(4-nitrophenyl)propyl]butan-1-amine
DM0R653 ID DM0R653
DM0R653 DN Phenylpropylamine derivative 4
DM0R653 HS Patented
DM0R653 SN PMID28051882-Compound-6
DM0R653 CP Wisconsin Alumni Research Foundation
DM0R653 DT Small molecular drug
DMU0S2W ID DMU0S2W
DMU0S2W DN Phenylpropylamine derivative 5
DMU0S2W HS Patented
DMU0S2W SN PMID28051882-Compound-IV
DMU0S2W CP Wisconsin Alumni Research Foundation
DMU0S2W DT Small molecular drug
DMLSWKR ID DMLSWKR
DMLSWKR DN Phenylpurine acetamide analog 1
DMLSWKR HS Patented
DMLSWKR SN PMID27607364-Compound-165
DMLSWKR DT Small molecular drug
DMMGBLC ID DMMGBLC
DMMGBLC DN Phenylpurine acetamide analog 2
DMMGBLC HS Patented
DMMGBLC SN PMID27607364-Compound-5
DMMGBLC DT Small molecular drug
DMVHLQM ID DMVHLQM
DMVHLQM DN Phenylpyridine derivative 1
DMVHLQM HS Patented
DMVHLQM SN PMID26161698-Compound-40
DMVHLQM CP NOVARTIS AG PFISTER, Keith B SENDZIK, Martin
DMVHLQM DT Small molecular drug
DMVHLQM PC 50991417
DMVHLQM MW 429
DMVHLQM FM C23H29ClN4O2
DMVHLQM IC InChI=1S/C23H29ClN4O2/c24-21-15-27-22(28-23(29)18-4-2-8-25-14-18)12-20(21)17-3-1-5-19(11-17)26-13-16-6-9-30-10-7-16/h1,3,5,11-12,15-16,18,25-26H,2,4,6-10,13-14H2,(H,27,28,29)
DMVHLQM CS C1CC(CNC1)C(=O)NC2=NC=C(C(=C2)C3=CC(=CC=C3)NCC4CCOCC4)Cl
DMVHLQM IK UUPXZCDRKZMXRB-UHFFFAOYSA-N
DMVHLQM IU N-[5-chloro-4-[3-(oxan-4-ylmethylamino)phenyl]pyridin-2-yl]piperidine-3-carboxamide
DMTRPE6 ID DMTRPE6
DMTRPE6 DN Phenylpyridine derivative 2
DMTRPE6 HS Patented
DMTRPE6 SN PMID26161698-Compound-41
DMTRPE6 CP NOVARTIS AG ANTONIOS-MCCREA, William R. BARSANTI, Paul A. HU, Cheng JIN, Xianming MARTIN, Eric J. PAN, Yue PFISTER, Keith B. SENDZIK, Martin SUTTON, James WAN, Lifeng
DMTRPE6 DT Small molecular drug
DMDT5JI ID DMDT5JI
DMDT5JI DN Phenylpyridine derivative 3
DMDT5JI HS Patented
DMDT5JI SN PMID25416646-Compound-Figure5-G
DMDT5JI DT Small molecular drug
DMPAI5C ID DMPAI5C
DMPAI5C DN Phenylpyrrolidinone derivative 1
DMPAI5C HS Patented
DMPAI5C SN PMID27646439-Compound-10
DMPAI5C CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMPAI5C DT Small molecular drug
DMPAI5C PC 118373075
DMPAI5C MW 468.4
DMPAI5C FM C23H19F3N6O2
DMPAI5C IC InChI=1S/C23H19F3N6O2/c1-31-11-15(18-19(27)28-12-29-20(18)31)13-5-7-14(8-6-13)32-10-9-22(34,21(32)33)16-3-2-4-17(30-16)23(24,25)26/h2-8,11-12,34H,9-10H2,1H3,(H2,27,28,29)
DMPAI5C CS CN1C=C(C2=C(N=CN=C21)N)C3=CC=C(C=C3)N4CCC(C4=O)(C5=NC(=CC=C5)C(F)(F)F)O
DMPAI5C IK DHELRXCAKDZMKY-UHFFFAOYSA-N
DMPAI5C IU 1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-hydroxy-3-[6-(trifluoromethyl)pyridin-2-yl]pyrrolidin-2-one
DMF3NCO ID DMF3NCO
DMF3NCO DN Phenylpyrrolidinone derivative 2
DMF3NCO HS Patented
DMF3NCO SN PMID27646439-Compound-6
DMF3NCO CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMF3NCO DT Small molecular drug
DMPZKQN ID DMPZKQN
DMPZKQN DN Phenylpyrrolidinone derivative 3
DMPZKQN HS Patented
DMPZKQN SN PMID27646439-Compound-7
DMPZKQN CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMPZKQN DT Small molecular drug
DMPZKQN PC 118368356
DMPZKQN MW 397.5
DMPZKQN FM C24H23N5O
DMPZKQN IC InChI=1S/C24H23N5O/c1-24(17-6-4-3-5-7-17)12-13-29(23(24)30)18-10-8-16(9-11-18)19-14-28(2)22-20(19)21(25)26-15-27-22/h3-11,14-15H,12-13H2,1-2H3,(H2,25,26,27)
DMPZKQN CS CC1(CCN(C1=O)C2=CC=C(C=C2)C3=CN(C4=NC=NC(=C34)N)C)C5=CC=CC=C5
DMPZKQN IK CMUGNAXHKVXXNK-UHFFFAOYSA-N
DMPZKQN IU 1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-methyl-3-phenylpyrrolidin-2-one
DMSX47Q ID DMSX47Q
DMSX47Q DN Phenylpyrrolidinone derivative 4
DMSX47Q HS Patented
DMSX47Q SN PMID27646439-Compound-8
DMSX47Q CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMSX47Q DT Small molecular drug
DMSX47Q PC 118373037
DMSX47Q MW 437.4
DMSX47Q FM C23H18F3N5O
DMSX47Q IC InChI=1S/C23H18F3N5O/c1-30-10-18(20-21(27)28-11-29-22(20)30)17-3-2-15(9-19(17)26)31-5-4-16(23(31)32)12-6-13(24)8-14(25)7-12/h2-3,6-11,16H,4-5H2,1H3,(H2,27,28,29)
DMSX47Q CS CN1C=C(C2=C(N=CN=C21)N)C3=C(C=C(C=C3)N4CCC(C4=O)C5=CC(=CC(=C5)F)F)F
DMSX47Q IK JZSDPOSETBCTOH-UHFFFAOYSA-N
DMSX47Q IU 1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-3-(3,5-difluorophenyl)pyrrolidin-2-one
DMZSTLH ID DMZSTLH
DMZSTLH DN Phenylpyrrolidinone derivative 5
DMZSTLH HS Patented
DMZSTLH SN PMID27646439-Compound-9
DMZSTLH CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMZSTLH DT Small molecular drug
DMZSTLH PC 118373061
DMZSTLH MW 401.5
DMZSTLH FM C22H23N7O
DMZSTLH IC InChI=1S/C22H23N7O/c1-13-10-14(2)29(26-13)18-8-9-28(22(18)30)16-6-4-15(5-7-16)17-11-27(3)21-19(17)20(23)24-12-25-21/h4-7,10-12,18H,8-9H2,1-3H3,(H2,23,24,25)
DMZSTLH CS CC1=CC(=NN1C2CCN(C2=O)C3=CC=C(C=C3)C4=CN(C5=NC=NC(=C45)N)C)C
DMZSTLH IK WBRYMNNSAHRQTO-UHFFFAOYSA-N
DMZSTLH IU 1-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]-3-(3,5-dimethylpyrazol-1-yl)pyrrolidin-2-one
DM9NOP3 ID DM9NOP3
DM9NOP3 DN Phenylsulfonyl derivative 1
DM9NOP3 HS Patented
DM9NOP3 SN PMID29334795-Compound-46
DM9NOP3 CP OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DM9NOP3 DT Small molecular drug
DM9NOP3 DE Central nervous system disease
DM63128 ID DM63128
DM63128 DN Phenylsulfonyl derivative 2
DM63128 HS Patented
DM63128 SN PMID29334795-Compound-47
DM63128 CP OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DM63128 DT Small molecular drug
DM63128 PC 89588522
DM63128 MW 409.5
DM63128 FM C23H27N3O2S
DM63128 IC InChI=1S/C23H27N3O2S/c27-22(9-6-14-25-12-4-5-13-25)24-19-10-11-21-20(17-19)26(15-16-29-21)23(28)18-7-2-1-3-8-18/h1-3,7-8,10-11,17H,4-6,9,12-16H2,(H,24,27)
DM63128 CS C1CCN(C1)CCCC(=O)NC2=CC3=C(C=C2)SCCN3C(=O)C4=CC=CC=C4
DM63128 IK NSMKNQYJLDRTTI-UHFFFAOYSA-N
DM63128 IU N-(4-benzoyl-2,3-dihydro-1,4-benzothiazin-6-yl)-4-pyrrolidin-1-ylbutanamide
DM63128 DE Central nervous system disease
DME6FLN ID DME6FLN
DME6FLN DN Phenylsulfonyl derivative 3
DME6FLN HS Patented
DME6FLN SN PMID29334795-Compound-48
DME6FLN CP OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DME6FLN DT Small molecular drug
DME6FLN PC 71555928
DME6FLN MW 432.6
DME6FLN FM C22H28N2O3S2
DME6FLN IC InChI=1S/C22H28N2O3S2/c25-29(26,20-8-3-1-4-9-20)24-15-17-28-22-11-10-19(18-21(22)24)27-16-7-14-23-12-5-2-6-13-23/h1,3-4,8-11,18H,2,5-7,12-17H2
DME6FLN CS C1CCN(CC1)CCCOC2=CC3=C(C=C2)SCCN3S(=O)(=O)C4=CC=CC=C4
DME6FLN IK DHYQKBDAADLGAK-UHFFFAOYSA-N
DME6FLN IU 4-(benzenesulfonyl)-6-(3-piperidin-1-ylpropoxy)-2,3-dihydro-1,4-benzothiazine
DME6FLN DE Central nervous system disease
DM1HYW4 ID DM1HYW4
DM1HYW4 DN Phenylsulfonyl derivative 4
DM1HYW4 HS Patented
DM1HYW4 SN PMID29334795-Compound-49
DM1HYW4 CP OXYGEN HEALTHCARE RESEARCH PVT. LTD SHIRSATH, Vikas S. PATEL, Shailesh M SHETH, Nehal M. SINGH, Jitendra K. PATIL, Pawan D. PAWAR, Anil D. MOTIVARAS, Jitendra D
DM1HYW4 DT Small molecular drug
DM1HYW4 PC 78119142
DM1HYW4 MW 432.6
DM1HYW4 FM C22H28N2O3S2
DM1HYW4 IC InChI=1S/C22H28N2O3S2/c1-18-7-5-12-23(18)13-6-15-27-19-10-11-22-21(17-19)24(14-16-28-22)29(25,26)20-8-3-2-4-9-20/h2-4,8-11,17-18H,5-7,12-16H2,1H3
DM1HYW4 CS CC1CCCN1CCCOC2=CC3=C(C=C2)SCCN3S(=O)(=O)C4=CC=CC=C4
DM1HYW4 IK OBXKKQAGOFTSNE-UHFFFAOYSA-N
DM1HYW4 IU 4-(benzenesulfonyl)-6-[3-(2-methylpyrrolidin-1-yl)propoxy]-2,3-dihydro-1,4-benzothiazine
DM1HYW4 DE Central nervous system disease
DMTHXUC ID DMTHXUC
DMTHXUC DN Phenylthioacetate derivative 1
DMTHXUC HS Patented
DMTHXUC SN PMID27414413-Compound-Figure2right
DMTHXUC CP ARDEA BIOSCIENCES, INC. OUK, Samedy VERNIER, Jean-michel GUNIC, Esmir
DMTHXUC DT Small molecular drug
DMZPHN5 ID DMZPHN5
DMZPHN5 DN Phthalazine derivative 1
DMZPHN5 HS Patented
DMZPHN5 SN PMID27841036-Compound-14
DMZPHN5 CP Janssen Pharmaceutica NV
DMZPHN5 DT Small molecular drug
DMZPHN5 PC 11514425
DMZPHN5 MW 258.32
DMZPHN5 FM C14H18N4O
DMZPHN5 IC InChI=1S/C14H18N4O/c15-9-10-5-7-18(8-6-10)13-11-3-1-2-4-12(11)14(19)17-16-13/h1-4,10H,5-9,15H2,(H,17,19)
DMZPHN5 CS C1CN(CCC1CN)C2=NNC(=O)C3=CC=CC=C32
DMZPHN5 IK CLUMMMKUUCOEBB-UHFFFAOYSA-N
DMZPHN5 IU 4-[4-(aminomethyl)piperidin-1-yl]-2H-phthalazin-1-one
DMODTSC ID DMODTSC
DMODTSC DN Phthalazine derivative 2
DMODTSC HS Patented
DMODTSC SN PMID27841036-Compound-15
DMODTSC CP Janssen Pharmaceutica NV
DMODTSC DT Small molecular drug
DMODTSC PC 11610964
DMODTSC MW 397.4
DMODTSC FM C22H24FN3O3
DMODTSC IC InChI=1S/C22H24FN3O3/c23-16-5-7-18(8-6-16)29-14-17(27)13-26-11-9-15(10-12-26)21-19-3-1-2-4-20(19)22(28)25-24-21/h1-8,15,17,27H,9-14H2,(H,25,28)
DMODTSC CS C1CN(CCC1C2=NNC(=O)C3=CC=CC=C32)CC(COC4=CC=C(C=C4)F)O
DMODTSC IK KVBJGGXSNXZAOH-UHFFFAOYSA-N
DMODTSC IU 4-[1-[3-(4-fluorophenoxy)-2-hydroxypropyl]piperidin-4-yl]-2H-phthalazin-1-one
DMA1OEF ID DMA1OEF
DMA1OEF DN Phthalazine derivative 3
DMA1OEF HS Patented
DMA1OEF SN PMID27841036-Compound-19
DMA1OEF CP Shanghai Institute of Materia Medica
DMA1OEF DT Small molecular drug
DMA1OEF PC 71678316
DMA1OEF MW 474.4
DMA1OEF FM C21H14F4N6O3
DMA1OEF IC InChI=1S/C21H14F4N6O3/c22-15-6-5-11(34-18-13-4-2-1-3-12(13)17(32)27-28-18)9-14(15)19(33)30-7-8-31-16(10-30)26-29-20(31)21(23,24)25/h1-6,9H,7-8,10H2,(H,27,32)
DMA1OEF CS C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)OC4=NNC(=O)C5=CC=CC=C54)F
DMA1OEF IK MZFDEPWODAICMP-UHFFFAOYSA-N
DMA1OEF IU 4-[4-fluoro-3-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl]phenoxy]-2H-phthalazin-1-one
DMD2R1H ID DMD2R1H
DMD2R1H DN Phthalazine ketone derivative 1
DMD2R1H HS Patented
DMD2R1H SN PMID27841036-Compound-16
DMD2R1H CP CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD [CN]
DMD2R1H DT Small molecular drug
DMD2R1H PC 89608436
DMD2R1H MW 479.5
DMD2R1H FM C25H26FN5O4
DMD2R1H IC InChI=1S/C25H26FN5O4/c1-29(2)25(9-10-25)24(34)31-13-11-30(12-14-31)23(33)19-15-16(7-8-20(19)26)35-22-18-6-4-3-5-17(18)21(32)27-28-22/h3-8,15H,9-14H2,1-2H3,(H,27,32)
DMD2R1H CS CN(C)C1(CC1)C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)OC4=NNC(=O)C5=CC=CC=C54)F
DMD2R1H IK DZWVGXKLZPKLKS-UHFFFAOYSA-N
DMD2R1H IU 4-[3-[4-[1-(dimethylamino)cyclopropanecarbonyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2H-phthalazin-1-one
DM07C1I ID DM07C1I
DM07C1I DN Phthalazine ketone derivative 2
DM07C1I HS Patented
DM07C1I SN PMID27841036-Compound-17
DM07C1I CP CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD [CN]
DM07C1I DT Small molecular drug
DM07C1I PC 71571973
DM07C1I MW 466.5
DM07C1I FM C25H27FN4O4
DM07C1I IC InChI=1S/C25H27FN4O4/c1-3-16(4-2)24(32)29-11-13-30(14-12-29)25(33)20-15-17(9-10-21(20)26)34-23-19-8-6-5-7-18(19)22(31)27-28-23/h5-10,15-16H,3-4,11-14H2,1-2H3,(H,27,31)
DM07C1I CS CCC(CC)C(=O)N1CCN(CC1)C(=O)C2=C(C=CC(=C2)OC3=NNC(=O)C4=CC=CC=C43)F
DM07C1I IK IJSAVXZCXLCXRP-UHFFFAOYSA-N
DM07C1I IU 4-[3-[4-(2-ethylbutanoyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2H-phthalazin-1-one
DMIWY93 ID DMIWY93
DMIWY93 DN Phthalazine ketone derivative 3
DMIWY93 HS Patented
DMIWY93 SN PMID27841036-Compound-18
DMIWY93 CP CHENGDU DI AO PHARMACEUTICAL GROUP CO LTD [CN]
DMIWY93 DT Small molecular drug
DMIWY93 PC 71598692
DMIWY93 MW 479.5
DMIWY93 FM C25H26FN5O4
DMIWY93 IC InChI=1S/C25H26FN5O4/c26-21-9-8-17(35-23-19-7-3-2-6-18(19)22(32)27-28-23)16-20(21)24(33)29-12-14-31(15-13-29)25(34)30-10-4-1-5-11-30/h2-3,6-9,16H,1,4-5,10-15H2,(H,27,32)
DMIWY93 CS C1CCN(CC1)C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)OC4=NNC(=O)C5=CC=CC=C54)F
DMIWY93 IK BCFBHNMOIFYWBS-UHFFFAOYSA-N
DMIWY93 IU 4-[4-fluoro-3-[4-(piperidine-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2H-phthalazin-1-one
DMNA941 ID DMNA941
DMNA941 DN Phthalazinone derivative 1
DMNA941 HS Patented
DMNA941 SN PMID28627961-Compound-23
DMNA941 CP GLENMARK PHARMACEUTICALS S.A
DMNA941 DT Small molecular drug
DMNA941 PC 71525311
DMNA941 MW 524.9
DMNA941 FM C27H23ClF2N4O3
DMNA941 IC InChI=1S/C27H23ClF2N4O3/c1-27(2,3)26(37)31-13-15-4-8-21(28)20(10-15)24(35)33-18-7-5-16-14-32-34(25(36)19(16)12-18)23-9-6-17(29)11-22(23)30/h4-12,14H,13H2,1-3H3,(H,31,37)(H,33,35)
DMNA941 CS CC(C)(C)C(=O)NCC1=CC(=C(C=C1)Cl)C(=O)NC2=CC3=C(C=C2)C=NN(C3=O)C4=C(C=C(C=C4)F)F
DMNA941 IK UWLKNQSOSOPRPR-UHFFFAOYSA-N
DMNA941 IU 2-chloro-N-[3-(2,4-difluorophenyl)-4-oxophthalazin-6-yl]-5-[(2,2-dimethylpropanoylamino)methyl]benzamide
DM5H3R8 ID DM5H3R8
DM5H3R8 DN PhyllanthoidA
DM5H3R8 HS Patented
DMM9F8D ID DMM9F8D
DMM9F8D DN Phytocannabinoid/aminoalkylindole derivative 1
DMM9F8D HS Patented
DMM9F8D SN PMID27215781-Compound-47
DMM9F8D CP NORTHEASTERN UNIVERSITY
DMM9F8D DT Small molecular drug
DMOXJ7Q ID DMOXJ7Q
DMOXJ7Q DN Phytocannabinoid/aminoalkylindole derivative 2
DMOXJ7Q HS Patented
DMOXJ7Q SN PMID27215781-Compound-48
DMOXJ7Q CP NORTHEASTERN UNIVERSITY
DMOXJ7Q DT Small molecular drug
DMUP4DX ID DMUP4DX
DMUP4DX DN Picolinamido propanoic acid derivative 1
DMUP4DX HS Patented
DMUP4DX SN PMID25828189-Compound-10
DMUP4DX CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DMUP4DX DT Small molecular drug
DMUP4DX PC 71472272
DMUP4DX MW 636
DMUP4DX FM C31H24ClF6N3O3
DMUP4DX IC InChI=1S/C31H24ClF6N3O3/c1-17-12-20(30(33,34)35)5-7-23(17)24-8-6-22(14-26(24)32)40-15-18-2-4-21(31(36,37)38)13-25(18)19-3-9-27(41-16-19)29(44)39-11-10-28(42)43/h2-9,12-14,16,40H,10-11,15H2,1H3,(H,39,44)(H,42,43)
DMUP4DX CS CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=C(C=C2)NCC3=C(C=C(C=C3)C(F)(F)F)C4=CN=C(C=C4)C(=O)NCCC(=O)O)Cl
DMUP4DX IK GPKUFXAKPUJEDG-UHFFFAOYSA-N
DMUP4DX IU 3-[[5-[2-[[3-chloro-4-[2-methyl-4-(trifluoromethyl)phenyl]anilino]methyl]-5-(trifluoromethyl)phenyl]pyridine-2-carbonyl]amino]propanoic acid
DMR74ET ID DMR74ET
DMR74ET DN Picolinamido propanoic acid derivative 2
DMR74ET HS Patented
DMR74ET SN PMID25828189-Compound-11
DMR74ET CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DMR74ET DT Small molecular drug
DMR74ET PC 71059831
DMR74ET MW 602.4
DMR74ET FM C30H24Cl2F3N3O3
DMR74ET IC InChI=1S/C30H24Cl2F3N3O3/c1-17-12-21(31)5-8-23(17)18-2-6-22(7-3-18)37-16-25-24(13-20(14-26(25)32)30(33,34)35)19-4-9-27(38-15-19)29(41)36-11-10-28(39)40/h2-9,12-15,37H,10-11,16H2,1H3,(H,36,41)(H,39,40)
DMR74ET CS CC1=C(C=CC(=C1)Cl)C2=CC=C(C=C2)NCC3=C(C=C(C=C3Cl)C(F)(F)F)C4=CN=C(C=C4)C(=O)NCCC(=O)O
DMR74ET IK OUHVBZQQNWUOOU-UHFFFAOYSA-N
DMR74ET IU 3-[[5-[3-chloro-2-[[4-(4-chloro-2-methylphenyl)anilino]methyl]-5-(trifluoromethyl)phenyl]pyridine-2-carbonyl]amino]propanoic acid
DMP1RV5 ID DMP1RV5
DMP1RV5 DN Picolinamido propanoic acid derivative 3
DMP1RV5 HS Patented
DMP1RV5 SN PMID25828189-Compound-12
DMP1RV5 CP JANSSEN PHARMACEUTICA NV CHAKRAVARTY, Devraj KREUTTER, Kevin POWELL, Mark SHOOK, Brian SONG, Fengbin XU, Guozhang YANG, Shyh-ming ZHANG, Rui ZHAO, Bao-pin
DMP1RV5 DT Small molecular drug
DMP1RV5 PC 71060110
DMP1RV5 MW 582
DMP1RV5 FM C30H23ClF3N3O4
DMP1RV5 IC InChI=1S/C30H23ClF3N3O4/c1-17-14-21(31)6-10-23(17)18-2-7-22(8-3-18)37-28(40)24-9-5-20(30(32,33)34)15-25(24)19-4-11-26(36-16-19)29(41)35-13-12-27(38)39/h2-11,14-16H,12-13H2,1H3,(H,35,41)(H,37,40)(H,38,39)
DMP1RV5 CS CC1=C(C=CC(=C1)Cl)C2=CC=C(C=C2)NC(=O)C3=C(C=C(C=C3)C(F)(F)F)C4=CN=C(C=C4)C(=O)NCCC(=O)O
DMP1RV5 IK QISSKZBXYOVUJU-UHFFFAOYSA-N
DMP1RV5 IU 3-[[5-[2-[[4-(4-chloro-2-methylphenyl)phenyl]carbamoyl]-5-(trifluoromethyl)phenyl]pyridine-2-carbonyl]amino]propanoic acid
DMCIXD4 ID DMCIXD4
DMCIXD4 DN Piperazine carbamate/urea derivative 1
DMCIXD4 HS Patented
DMCIXD4 SN PMID29334795-Compound-39
DMCIXD4 CP NOVARTIS AG AUBERSON, Yves BOCK, Mark Gary BRAGA, Dario CURZI, Marco DODD, Stephanie Kay GIAFFREDA, Stefano Luca JIANG, Haiyang KARPINSKI, Piotr TROXLER, Thomas J. WANG, Tielin WANG, Xiaoyang ZHANG, XuechuNOVARTIS AG
DMCIXD4 DT Small molecular drug
DMCG6BE ID DMCG6BE
DMCG6BE DN Piperazine carbamate/urea derivative 2
DMCG6BE HS Patented
DMCG6BE SN PMID29334795-Compound-40
DMCG6BE CP Novartis AG
DMCG6BE DT Small molecular drug
DMCG6BE PC 71533679
DMCG6BE MW 375.5
DMCG6BE FM C19H29N5O3
DMCG6BE IC InChI=1S/C19H29N5O3/c1-14(2)22-9-11-24(12-10-22)19(26)27-16-5-7-23(8-6-16)17-4-3-15(13-21-17)18(20)25/h3-4,13-14,16H,5-12H2,1-2H3,(H2,20,25)
DMCG6BE CS CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=NC=C(C=C3)C(=O)N
DMCG6BE IK SLFVKTUERQHULI-UHFFFAOYSA-N
DMCG6BE IU [1-(5-carbamoylpyridin-2-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate
DM2R468 ID DM2R468
DM2R468 DN Piperazine carbamate/urea derivative 3
DM2R468 HS Patented
DM2R468 SN PMID29334795-Compound-41
DM2R468 CP Novartis AG
DM2R468 DT Small molecular drug
DM2R468 PC 89487899
DM2R468 MW 375.5
DM2R468 FM C19H29N5O3
DM2R468 IC InChI=1S/C19H29N5O3/c1-14(2)22-9-11-24(12-10-22)19(26)27-16-5-7-23(8-6-16)15-3-4-17(18(20)25)21-13-15/h3-4,13-14,16H,5-12H2,1-2H3,(H2,20,25)
DM2R468 CS CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=CN=C(C=C3)C(=O)N
DM2R468 IK NJPLXPIWGPHUGQ-UHFFFAOYSA-N
DM2R468 IU [1-(6-carbamoylpyridin-3-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate
DM75J4T ID DM75J4T
DM75J4T DN Piperazine carbamate/urea derivative 4
DM75J4T HS Patented
DM75J4T SN PMID29334795-Compound-42
DM75J4T CP Novartis AG
DM75J4T DT Small molecular drug
DM75J4T PC 89487751
DM75J4T MW 385.5
DM75J4T FM C21H31N5O2
DM75J4T IC InChI=1S/C21H31N5O2/c1-16(2)23-10-12-25(13-11-23)21(27)28-19-5-8-24(9-6-19)18-4-7-26-15-17(3)22-20(26)14-18/h4,7,14-16,19H,5-6,8-13H2,1-3H3
DM75J4T CS CC1=CN2C=CC(=CC2=N1)N3CCC(CC3)OC(=O)N4CCN(CC4)C(C)C
DM75J4T IK XAQBWJISZRMNHF-UHFFFAOYSA-N
DM75J4T IU [1-(2-methylimidazo[1,2-a]pyridin-7-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate
DMJ80IZ ID DMJ80IZ
DMJ80IZ DN Piperazine carbamate/urea derivative 5
DMJ80IZ HS Patented
DMJ80IZ SN PMID29334795-Compound-43
DMJ80IZ CP Novartis AG
DMJ80IZ DT Small molecular drug
DMJ80IZ PC 72948213
DMJ80IZ MW 363.5
DMJ80IZ FM C18H29N5O3
DMJ80IZ IC InChI=1S/C18H29N5O3/c1-14(2)21-10-12-23(13-11-21)18(25)26-15-6-8-22(9-7-15)16-4-5-17(24)20(3)19-16/h4-5,14-15H,6-13H2,1-3H3
DMJ80IZ CS CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=NN(C(=O)C=C3)C
DMJ80IZ IK JXFIKXGRFYNISW-UHFFFAOYSA-N
DMJ80IZ IU [1-(1-methyl-6-oxopyridazin-3-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate
DMZEPU3 ID DMZEPU3
DMZEPU3 DN Piperazine carbamate/urea derivative 6
DMZEPU3 HS Patented
DMZEPU3 SN PMID29334795-Compound-44
DMZEPU3 CP Novartis AG
DMZEPU3 DT Small molecular drug
DMZEPU3 PC 72948405
DMZEPU3 MW 348.4
DMZEPU3 FM C18H28N4O3
DMZEPU3 IC InChI=1S/C18H28N4O3/c1-14(2)20-9-11-22(12-10-20)18(24)25-16-5-7-21(8-6-16)15-3-4-17(23)19-13-15/h3-4,13-14,16H,5-12H2,1-2H3,(H,19,23)
DMZEPU3 CS CC(C)N1CCN(CC1)C(=O)OC2CCN(CC2)C3=CNC(=O)C=C3
DMZEPU3 IK ONRCNWHOGZJSOB-UHFFFAOYSA-N
DMZEPU3 IU [1-(6-oxo-1H-pyridin-3-yl)piperidin-4-yl] 4-propan-2-ylpiperazine-1-carboxylate
DM067UC ID DM067UC
DM067UC DN Piperazine carbamate/urea derivative 7
DM067UC HS Patented
DM067UC SN PMID29334795-Compound-45
DM067UC CP NOVARTIS AG AUBERSON, Yves BOCK, Mark Gary BRAGA, Dario CURZI, Marco DODD, Stephanie Kay GIAFFREDA, Stefano Luca JIANG, Haiyang KARPINSKI, Piotr TROXLER, Thomas J. WANG, Tielin WANG, Xiaoyang ZHANG, XuechuNOVARTIS AG
DM067UC DT Small molecular drug
DM067UC PC 72948400
DM067UC MW 375.5
DM067UC FM C19H29N5O3
DM067UC IC InChI=1S/C19H29N5O3/c1-21-18(25)6-5-17(20-21)23-9-7-16(8-10-23)27-19(26)24-13-11-22(12-14-24)15-3-2-4-15/h5-6,15-16H,2-4,7-14H2,1H3
DM067UC CS CN1C(=O)C=CC(=N1)N2CCC(CC2)OC(=O)N3CCN(CC3)C4CCC4
DM067UC IK BVUJMFFRMZRNAT-UHFFFAOYSA-N
DM067UC IU [1-(1-methyl-6-oxopyridazin-3-yl)piperidin-4-yl] 4-cyclobutylpiperazine-1-carboxylate
DMZSYU4 ID DMZSYU4
DMZSYU4 DN Piperazine carbamic compound 1
DMZSYU4 HS Patented
DMZSYU4 SN PMID29053063-Compound-8a
DMZSYU4 CP ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMZSYU4 DT Small molecular drug
DMMQ0ZO ID DMMQ0ZO
DMMQ0ZO DN Piperazine carbamic compound 2
DMMQ0ZO HS Patented
DMMQ0ZO SN PMID29053063-Compound-8b
DMMQ0ZO CP ABIDE THERAPEUTICS, INCABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMMQ0ZO DT Small molecular drug
DM8IU1G ID DM8IU1G
DM8IU1G DN Piperazine carbamic compound 3
DM8IU1G HS Patented
DM8IU1G SN PMID29053063-Compound-8c
DM8IU1G CP ABIDE THERAPEUTICS, INC
DM8IU1G DT Small molecular drug
DMKZUO4 ID DMKZUO4
DMKZUO4 DN Piperazine carbamic compound 4
DMKZUO4 HS Patented
DMKZUO4 SN PMID29053063-Compound-9a
DMKZUO4 CP ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMKZUO4 DT Small molecular drug
DMXH65Z ID DMXH65Z
DMXH65Z DN Piperazine carbamic compound 5
DMXH65Z HS Patented
DMXH65Z SN PMID29053063-Compound-9b
DMXH65Z CP ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMXH65Z DT Small molecular drug
DMJ7F1Q ID DMJ7F1Q
DMJ7F1Q DN Piperazine derivative 1
DMJ7F1Q HS Patented
DMJ7F1Q SN PMID26161824-Compound-129
DMJ7F1Q CP INTERVET INTERNATIONAL B.V. GILBERT, Eric, J. MILLER, Michael, W. SCOTT, Jack, D. DEMONG, Duane, Eugene STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekhe
DMJ7F1Q DT Small molecular drug
DMJ7F1Q PC 57662641
DMJ7F1Q MW 504.4
DMJ7F1Q FM C24H27Cl2N5O3
DMJ7F1Q IC InChI=1S/C24H27Cl2N5O3/c25-18-3-1-17(2-4-18)23-15-29(7-8-30-14-21(24(27)33)28-16-30)9-10-31(23)22-6-5-19(13-20(22)26)34-12-11-32/h1-6,13-14,16,23,32H,7-12,15H2,(H2,27,33)/t23-/m0/s1
DMJ7F1Q CS C1CN([C@@H](CN1CCN2C=C(N=C2)C(=O)N)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)OCCO)Cl
DMJ7F1Q IK LYKRPBPENHGRNR-QHCPKHFHSA-N
DMJ7F1Q IU 1-[2-[(3R)-4-[2-chloro-4-(2-hydroxyethoxy)phenyl]-3-(4-chlorophenyl)piperazin-1-yl]ethyl]imidazole-4-carboxamide
DMJ7F1Q DE Obesity
DM4JZ2T ID DM4JZ2T
DM4JZ2T DN Piperazine derivative 2
DM4JZ2T HS Patented
DM4JZ2T SN PMID26161824-Compound-130
DM4JZ2T CP INTERVET INTERNATIONAL B.V. GILBERT, Eric, J. MILLER, Michael, W. SCOTT, Jack, D. DEMONG, Duane, Eugene STAMFORD, Andrew GREENLEE, William, J. CELLY, Chander, Shekhe
DM4JZ2T DT Small molecular drug
DM4JZ2T DE Obesity
DM8MZR6 ID DM8MZR6
DM8MZR6 DN Piperazine derivative 3
DM8MZR6 HS Patented
DM8MZR6 SN PMID26609882-Compound-61
DM8MZR6 CP F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DM8MZR6 DT Small molecular drug
DM2XGNY ID DM2XGNY
DM2XGNY DN Piperazine derivative 4
DM2XGNY HS Patented
DM2XGNY SN PMID26609882-Compound-62
DM2XGNY CP F. HOFFMANN-LA ROCHE AG GOBBI, Luca JAESCHKE, Georg RODRIGUEZ SARMIENTO, Rosa Maria STEWARD, LucindHoffmann-La Roche Inc
DM2XGNY DT Small molecular drug
DMDFUBH ID DMDFUBH
DMDFUBH DN Piperazine derivative 5
DMDFUBH HS Patented
DMDFUBH SN PMID26936077-Compound-16
DMDFUBH CP NeoPharm Co. Ltd
DMDFUBH DT Small molecular drug
DMDFUBH PC 53244427
DMDFUBH MW 283.37
DMDFUBH FM C14H25N3O3
DMDFUBH IC InChI=1S/C14H25N3O3/c1-12(18)11-14(20)17-9-7-16(8-10-17)13(19)5-3-2-4-6-15/h2-11,15H2,1H3
DMDFUBH CS CC(=O)CC(=O)N1CCN(CC1)C(=O)CCCCCN
DMDFUBH IK ISBLYNHHDOKBBQ-UHFFFAOYSA-N
DMDFUBH IU 1-[4-(6-aminohexanoyl)piperazin-1-yl]butane-1,3-dione
DMDFUBH DE Atopic dermatitis
DMDL3A5 ID DMDL3A5
DMDL3A5 DN Piperazine derivative 6
DMDL3A5 HS Patented
DMDL3A5 SN PMID27724045-Compound-4
DMDL3A5 CP GSK
DMDL3A5 DT Small molecular drug
DMDL3A5 PC 25241867
DMDL3A5 MW 418.7
DMDL3A5 FM C18H12ClF5N2O2
DMDL3A5 IC InChI=1S/C18H12ClF5N2O2/c19-16-11(2-1-3-12(16)18(22,23)24)17(28)25-6-7-26(15(27)9-25)14-5-4-10(20)8-13(14)21/h1-5,8H,6-7,9H2
DMDL3A5 CS C1CN(C(=O)CN1C(=O)C2=C(C(=CC=C2)C(F)(F)F)Cl)C3=C(C=C(C=C3)F)F
DMDL3A5 IK VNEYCAAUOFFQMB-UHFFFAOYSA-N
DMDL3A5 IU 4-[2-chloro-3-(trifluoromethyl)benzoyl]-1-(2,4-difluorophenyl)piperazin-2-one
DM9Y4ZV ID DM9Y4ZV
DM9Y4ZV DN Piperazine derivative 7
DM9Y4ZV HS Patented
DM9Y4ZV SN PMID28051882-Compound-XIII
DM9Y4ZV CP Merk Patent GMBH
DM9Y4ZV DT Small molecular drug
DM1XUVB ID DM1XUVB
DM1XUVB DN Piperazine derivative 8
DM1XUVB HS Patented
DM1XUVB SN PMID28447479-Compound-25
DM1XUVB CP BIOGEN MA INC
DM1XUVB DT Small molecular drug
DM1XUVB PC 74767919
DM1XUVB MW 456.7
DM1XUVB FM C28H44N2O3
DM1XUVB IC InChI=1S/C28H44N2O3/c1-2-3-4-5-6-7-22-33-25-10-8-24(9-11-25)30-20-18-29(19-21-30)23-27-12-15-28(16-13-27,17-14-27)26(31)32/h8-11H,2-7,12-23H2,1H3,(H,31,32)
DM1XUVB CS CCCCCCCCOC1=CC=C(C=C1)N2CCN(CC2)CC34CCC(CC3)(CC4)C(=O)O
DM1XUVB IK BBLBOXJIVAKNRT-UHFFFAOYSA-N
DM1XUVB IU 4-[[4-(4-octoxyphenyl)piperazin-1-yl]methyl]bicyclo[2.2.2]octane-1-carboxylic acid
DMEWAQ9 ID DMEWAQ9
DMEWAQ9 DN Piperazine urea derivative 1
DMEWAQ9 HS Patented
DMEWAQ9 SN PMID26413912-Compound-13
DMEWAQ9 DT Small molecular drug
DMEWAQ9 PC 2809273
DMEWAQ9 MW 365.5
DMEWAQ9 FM C19H19N5OS
DMEWAQ9 IC InChI=1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)
DMEWAQ9 CS C1CN(CCN1C2=NC(=NS2)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DMEWAQ9 IK BHBOSTKQCZEAJM-UHFFFAOYSA-N
DMEWAQ9 IU N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
DMEWAQ9 CA CAS 681136-29-8
DM5OCM7 ID DM5OCM7
DM5OCM7 DN Piperazine urea derivative 2
DM5OCM7 HS Patented
DM5OCM7 SN PMID26413912-Compound-48
DM5OCM7 CP JANSEN PHARMACEUTICA NV HAWRYLUK, Natalie, A
DM5OCM7 DT Small molecular drug
DMNAJWQ ID DMNAJWQ
DMNAJWQ DN Piperazine urea derivative 3
DMNAJWQ HS Patented
DMNAJWQ SN PMID26936077-Compound-18
DMNAJWQ CP PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DMNAJWQ DT Small molecular drug
DMNAJWQ DE Inflammation; Solid tumour/cancer
DM3K7IM ID DM3K7IM
DM3K7IM DN Piperazine urea derivative 4
DM3K7IM HS Patented
DM3K7IM SN PMID26936077-Compound-19
DM3K7IM CP PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DM3K7IM DT Small molecular drug
DM3K7IM PC 60141847
DM3K7IM MW 350.5
DM3K7IM FM C21H26N4O
DM3K7IM IC InChI=1S/C21H26N4O/c22-20(23)19-8-6-18(7-9-19)15-24-21(26)25-12-10-17(11-13-25)14-16-4-2-1-3-5-16/h1-9,17H,10-15H2,(H3,22,23)(H,24,26)
DM3K7IM CS C1CN(CCC1CC2=CC=CC=C2)C(=O)NCC3=CC=C(C=C3)C(=N)N
DM3K7IM IK PPLAJHCOIUEWGN-UHFFFAOYSA-N
DM3K7IM IU 4-benzyl-N-[(4-carbamimidoylphenyl)methyl]piperidine-1-carboxamide
DM3K7IM DE Inflammation; Solid tumour/cancer
DM7WOD9 ID DM7WOD9
DM7WOD9 DN Piperazinyl methyl quinazolinone derivative 1
DM7WOD9 HS Patented
DM7WOD9 SN PMID30185082-Compound-29
DM7WOD9 CP WASHINGTON UNIVERSITY
DM7WOD9 DT Small molecular drug
DM913KS ID DM913KS
DM913KS DN Piperazinyl methyl quinazolinone derivative 2
DM913KS HS Patented
DM913KS SN PMID30185082-Compound-30
DM913KS CP WASHINGTON UNIVERSITY
DM913KS DT Small molecular drug
DM913KS PC 11214940
DM913KS MW 547
DM913KS FM C30H31ClN4O4
DM913KS IC InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3
DM913KS CS CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl
DM913KS IK BKQFRNYHFIQEKN-UHFFFAOYSA-N
DM913KS IU 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one
DM913KS CA CAS 571203-78-6
DM913KS CB CHEBI:94287
DMYH4AZ ID DMYH4AZ
DMYH4AZ DN Piperazinyl methyl quinazolinone derivative 3
DMYH4AZ HS Patented
DMYH4AZ SN PMID30185082-Compound-31
DMYH4AZ CP WASHINGTON UNIVERSITY
DMYH4AZ DT Small molecular drug
DM3LKTE ID DM3LKTE
DM3LKTE DN Piperazinyl norbenzomorphane compound 1
DM3LKTE HS Patented
DM3LKTE SN PMID30185082-Compound-32
DM3LKTE CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DM3LKTE DT Small molecular drug
DMD2CX1 ID DMD2CX1
DMD2CX1 DN Piperazinyl norbenzomorphane compound 2
DMD2CX1 HS Patented
DMD2CX1 SN PMID30185082-Compound-33
DMD2CX1 CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMD2CX1 DT Small molecular drug
DMD2CX1 PC 129056976
DMD2CX1 MW 419.6
DMD2CX1 FM C26H33N3O2
DMD2CX1 IC InChI=1S/C26H33N3O2/c1-2-11-27-13-15-28(16-14-27)22-8-9-23-21-10-12-29(25(17-21)24(23)18-22)26(30)31-19-20-6-4-3-5-7-20/h3-9,18,21,25H,2,10-17,19H2,1H3
DMD2CX1 CS CCCN1CCN(CC1)C2=CC3=C(C=C2)C4CCN(C3C4)C(=O)OCC5=CC=CC=C5
DMD2CX1 IK FFCRKESJGXTNRJ-UHFFFAOYSA-N
DMD2CX1 IU benzyl 5-(4-propylpiperazin-1-yl)-9-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene-9-carboxylate
DMZYJKG ID DMZYJKG
DMZYJKG DN Piperazinyl norbenzomorphane compound 3
DMZYJKG HS Patented
DMZYJKG SN PMID30185082-Compound-34
DMZYJKG CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMZYJKG DT Small molecular drug
DMZYJKG PC 44825925
DMZYJKG MW 391.5
DMZYJKG FM C24H29N3O2
DMZYJKG IC InChI=1S/C24H29N3O2/c1-25-11-13-26(14-12-25)20-7-8-21-19-9-10-27(23(15-19)22(21)16-20)24(28)29-17-18-5-3-2-4-6-18/h2-8,16,19,23H,9-15,17H2,1H3
DMZYJKG CS CN1CCN(CC1)C2=CC3=C(C=C2)C4CCN(C3C4)C(=O)OCC5=CC=CC=C5
DMZYJKG IK CQQWIHMDQBNBBE-UHFFFAOYSA-N
DMZYJKG IU benzyl 5-(4-methylpiperazin-1-yl)-9-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene-9-carboxylate
DMZYJKG CA CAS 1644629-60-6
DMRSCJ7 ID DMRSCJ7
DMRSCJ7 DN Piperazinyl norbenzomorphane compound 4
DMRSCJ7 HS Patented
DMRSCJ7 SN PMID30185082-Compound-35
DMRSCJ7 CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DMRSCJ7 DT Small molecular drug
DMY8QIG ID DMY8QIG
DMY8QIG DN Piperidine carboxamide derivative 1
DMY8QIG HS Patented
DMY8QIG SN PMID28627961-Compound-26
DMY8QIG CP NOVASAID AB WANNBERG, Johan ALTERMAN, Mathias MALM, Johan STENBERG, Patric WESTMAN, Jacob WALLBERG, Hans
DMY8QIG DT Small molecular drug
DMY8QIG PC 50997187
DMY8QIG MW 468.6
DMY8QIG FM C29H32N4O2
DMY8QIG IC InChI=1S/C29H32N4O2/c1-19-15-26-27(16-20(19)2)33(25-8-7-21-5-3-4-6-23(21)17-25)29(31-26)32-12-9-22(10-13-32)28(34)30-24-11-14-35-18-24/h3-8,15-17,22,24H,9-14,18H2,1-2H3,(H,30,34)
DMY8QIG CS CC1=CC2=C(C=C1C)N(C(=N2)N3CCC(CC3)C(=O)NC4CCOC4)C5=CC6=CC=CC=C6C=C5
DMY8QIG IK CPCIYGHUPLRYBW-UHFFFAOYSA-N
DMY8QIG IU 1-(5,6-dimethyl-1-naphthalen-2-ylbenzimidazol-2-yl)-N-(oxolan-3-yl)piperidine-4-carboxamide
DMHN5KW ID DMHN5KW
DMHN5KW DN Piperidine derivative 1
DMHN5KW HS Patented
DMHN5KW SN PMID29334795-Compound-60
DMHN5KW DT Small molecular drug
DMHN5KW PC 72792768
DMHN5KW MW 396.5
DMHN5KW FM C25H33FN2O
DMHN5KW IC InChI=1S/C25H33FN2O/c1-27(2)14-6-13-25(22-8-10-23(26)11-9-22)24-12-7-20(17-21(24)19-29-25)18-28-15-4-3-5-16-28/h7-12,17H,3-6,13-16,18-19H2,1-2H3
DMHN5KW CS CN(C)CCCC1(C2=C(CO1)C=C(C=C2)CN3CCCCC3)C4=CC=C(C=C4)F
DMHN5KW IK UWNUOIHSSBTGRY-UHFFFAOYSA-N
DMHN5KW IU 3-[1-(4-fluorophenyl)-5-(piperidin-1-ylmethyl)-3H-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine
DMHXMB4 ID DMHXMB4
DMHXMB4 DN Piperidine derivative 2
DMHXMB4 HS Patented
DMHXMB4 SN PMID26936077-Compound-17
DMHXMB4 CP PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DMHXMB4 DT Small molecular drug
DMHXMB4 DE Inflammation; Solid tumour/cancer
DM80XRM ID DM80XRM
DM80XRM DN Piperidine derivative 3
DM80XRM HS Patented
DM80XRM SN PMID26936077-Compound-20
DM80XRM CP PROXIMAGEN LTD. BOYD, Joe William MEO, Paul HIGGINBOTTOM, Michael SIMPSON, Iain MOUNTFORD, David Mark SAVORY, Edward Daniel
DM80XRM DT Small molecular drug
DM80XRM DE Inflammation; Solid tumour/cancer
DM6C5DR ID DM6C5DR
DM6C5DR DN Piperidine derivative 4
DM6C5DR HS Patented
DM6C5DR SN PMID28051882-Compound-I
DM6C5DR CP Australian Nuclear Science & Technology Organisation
DM6C5DR DT Small molecular drug
DMQ0VK4 ID DMQ0VK4
DMQ0VK4 DN Piperidine derivative 5
DMQ0VK4 HS Patented
DMQ0VK4 SN PMID28051882-Compound-1
DMQ0VK4 CP Australian Nuclear Science & Technology Organisation
DMQ0VK4 DT Small molecular drug
DM0GCTY ID DM0GCTY
DM0GCTY DN Piperidine derivative 6
DM0GCTY HS Patented
DM0GCTY SN PMID28051882-Compound-XII
DM0GCTY CP Merk Patent GMBH
DM0GCTY DT Small molecular drug
DMAM50X ID DMAM50X
DMAM50X DN Piperidinone derivative 1
DMAM50X HS Patented
DMAM50X SN PMID27724045-Compound-3
DMAM50X CP GSK
DMAM50X DT Small molecular drug
DMAM50X PC 25016092
DMAM50X MW 348.75
DMAM50X FM C15H16ClF3N2O2
DMAM50X IC InChI=1S/C15H16ClF3N2O2/c1-21-11(6-3-7-12(21)22)14(23)20-8-9-4-2-5-10(13(9)16)15(17,18)19/h2,4-5,11H,3,6-8H2,1H3,(H,20,23)
DMAM50X CS CN1C(CCCC1=O)C(=O)NCC2=C(C(=CC=C2)C(F)(F)F)Cl
DMAM50X IK YGCMKVHDGGAEFD-UHFFFAOYSA-N
DMAM50X IU N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-6-oxopiperidine-2-carboxamide
DMWAYXP ID DMWAYXP
DMWAYXP DN Piperidinyl pyrazole derivative 1
DMWAYXP HS Patented
DMWAYXP SN PMID28699813-Compound-10
DMWAYXP CP MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DMWAYXP DT Small molecular drug
DMWAYXP PC 68206832
DMWAYXP MW 443.5
DMWAYXP FM C28H27F2N3
DMWAYXP IC InChI=1S/C28H27F2N3/c29-23-10-6-21(7-11-23)26-19-33(16-14-20-4-2-1-3-5-20)17-15-25(26)28-18-27(31-32-28)22-8-12-24(30)13-9-22/h1-13,18,25-26H,14-17,19H2,(H,31,32)/t25-,26+/m1/s1
DMWAYXP CS C1CN(C[C@H]([C@@H]1C2=CC(=NN2)C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CCC5=CC=CC=C5
DMWAYXP IK HJPVPXYGXWGSIG-FTJBHMTQSA-N
DMWAYXP IU (3R,4R)-3-(4-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-5-yl]-1-(2-phenylethyl)piperidine
DM21S5G ID DM21S5G
DM21S5G DN Piperidinyl pyrazole derivative 2
DM21S5G HS Patented
DM21S5G SN PMID28699813-Compound-9
DM21S5G CP MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DM21S5G DT Small molecular drug
DM21S5G PC 54576061
DM21S5G MW 440.6
DM21S5G FM C28H29FN4
DM21S5G IC InChI=1S/C28H29FN4/c1-32-27(21-25(31-32)23-10-12-24(29)13-11-23)28(26-9-5-6-17-30-26)15-19-33(20-16-28)18-14-22-7-3-2-4-8-22/h2-13,17,21H,14-16,18-20H2,1H3
DM21S5G CS CN1C(=CC(=N1)C2=CC=C(C=C2)F)C3(CCN(CC3)CCC4=CC=CC=C4)C5=CC=CC=N5
DM21S5G IK KJFTYICXBUEONK-UHFFFAOYSA-N
DM21S5G IU 2-[4-[5-(4-fluorophenyl)-2-methylpyrazol-3-yl]-1-(2-phenylethyl)piperidin-4-yl]pyridine
DMX2V0W ID DMX2V0W
DMX2V0W DN Piperidinyl pyrazole derivative 3
DMX2V0W HS Patented
DMX2V0W SN PMID28699813-Compound-B
DMX2V0W CP MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DMX2V0W DT Small molecular drug
DMS8NFJ ID DMS8NFJ
DMS8NFJ DN Piperidinyl pyrazole derivative 4
DMS8NFJ HS Patented
DMS8NFJ SN PMID28699813-Compound-c
DMS8NFJ CP MERCK SHARP &amDOHME CORP. GRAHAM, Thomas, H. SHEN, Dong-Ming SHU, Min
DMS8NFJ DT Small molecular drug
DMTSX7J ID DMTSX7J
DMTSX7J DN Piperidinyl triazole derivative 1
DMTSX7J HS Patented
DMTSX7J SN PMID28699813-Compound-11
DMTSX7J CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMTSX7J DT Small molecular drug
DMTSX7J PC 53497458
DMTSX7J MW 444
DMTSX7J FM C26H26ClN5
DMTSX7J IC InChI=1S/C26H26ClN5/c27-23-9-7-21(8-10-23)24-19-25(32(30-24)26-28-14-4-15-29-26)22-12-17-31(18-13-22)16-11-20-5-2-1-3-6-20/h1-10,14-15,19,22H,11-13,16-18H2
DMTSX7J CS C1CN(CCC1C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)Cl)CCC5=CC=CC=C5
DMTSX7J IK SVHYVLJAAMPZJM-UHFFFAOYSA-N
DMTSX7J IU 2-[3-(4-chlorophenyl)-5-[1-(2-phenylethyl)piperidin-4-yl]pyrazol-1-yl]pyrimidine
DM2FZPE ID DM2FZPE
DM2FZPE DN Piperidinyl triazole derivative 2
DM2FZPE HS Patented
DM2FZPE SN PMID28699813-Compound-12
DM2FZPE CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM2FZPE DT Small molecular drug
DM2FZPE PC 68212658
DM2FZPE MW 485.6
DM2FZPE FM C28H28FN5O2
DM2FZPE IC InChI=1S/C28H28FN5O2/c1-36-27(35)24(20-6-3-2-4-7-20)19-33-16-12-22(13-17-33)26-18-25(21-8-10-23(29)11-9-21)32-34(26)28-30-14-5-15-31-28/h2-11,14-15,18,22,24H,12-13,16-17,19H2,1H3
DM2FZPE CS COC(=O)C(CN1CCC(CC1)C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)F)C5=CC=CC=C5
DM2FZPE IK SVWGQADPJAOQRT-UHFFFAOYSA-N
DM2FZPE IU methyl 3-[4-[5-(4-fluorophenyl)-2-pyrimidin-2-ylpyrazol-3-yl]piperidin-1-yl]-2-phenylpropanoate
DM0J2TE ID DM0J2TE
DM0J2TE DN Piperidinyl triazole derivative 3
DM0J2TE HS Patented
DM0J2TE SN PMID28699813-Compound-13
DM0J2TE CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM0J2TE DT Small molecular drug
DM0J2TE PC 54597250
DM0J2TE MW 471.5
DM0J2TE FM C27H26FN5O2
DM0J2TE IC InChI=1S/C27H26FN5O2/c28-22-9-7-20(8-10-22)24-17-25(33(31-24)27-29-13-4-14-30-27)21-11-15-32(16-12-21)18-23(26(34)35)19-5-2-1-3-6-19/h1-10,13-14,17,21,23H,11-12,15-16,18H2,(H,34,35)
DM0J2TE CS C1CN(CCC1C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)F)CC(C5=CC=CC=C5)C(=O)O
DM0J2TE IK ASWVEQWRTMUNCF-UHFFFAOYSA-N
DM0J2TE IU 3-[4-[5-(4-fluorophenyl)-2-pyrimidin-2-ylpyrazol-3-yl]piperidin-1-yl]-2-phenylpropanoic acid
DMOQJMU ID DMOQJMU
DMOQJMU DN Piperidinyl triazole derivative 4
DMOQJMU HS Patented
DMOQJMU SN PMID28699813-Compound-14
DMOQJMU CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMOQJMU DT Small molecular drug
DMOQJMU PC 54597177
DMOQJMU MW 460
DMOQJMU FM C26H26ClN5O
DMOQJMU IC InChI=1S/C26H26ClN5O/c27-22-9-7-19(8-10-22)23-17-24(32(30-23)26-28-13-4-14-29-26)20-11-15-31(16-12-20)18-25(33)21-5-2-1-3-6-21/h1-10,13-14,17,20,25,33H,11-12,15-16,18H2
DMOQJMU CS C1CN(CCC1C2=CC(=NN2C3=NC=CC=N3)C4=CC=C(C=C4)Cl)CC(C5=CC=CC=C5)O
DMOQJMU IK VSNXVFRRZXFFLD-UHFFFAOYSA-N
DMOQJMU IU 2-[4-[5-(4-chlorophenyl)-2-pyrimidin-2-ylpyrazol-3-yl]piperidin-1-yl]-1-phenylethanol
DM4QVD0 ID DM4QVD0
DM4QVD0 DN Piperidinyl triazole derivative 5
DM4QVD0 HS Patented
DM4QVD0 SN PMID28699813-Compound-D
DM4QVD0 CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DM4QVD0 DT Small molecular drug
DMG5HI1 ID DMG5HI1
DMG5HI1 DN Piperidinyl triazole derivative 6
DMG5HI1 HS Patented
DMG5HI1 SN PMID28699813-Compound-E
DMG5HI1 CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, CangminMerck & Co., Inc., Kenilworth, NJ, USA
DMG5HI1 DT Small molecular drug
DME26SY ID DME26SY
DME26SY DN Piperonal
DME26SY HS Patented
DME26SY CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DME26SY PC 8438
DME26SY MW 150.13
DME26SY FM C8H6O3
DME26SY IC InChI=1S/C8H6O3/c9-4-6-1-2-7-8(3-6)11-5-10-7/h1-4H,5H2
DME26SY CS C1OC2=C(O1)C=C(C=C2)C=O
DME26SY IK SATCULPHIDQDRE-UHFFFAOYSA-N
DME26SY IU 1,3-benzodioxole-5-carbaldehyde
DME26SY CA CAS 120-57-0
DME26SY CB CHEBI:8240
DMFZ9Q3 ID DMFZ9Q3
DMFZ9Q3 DN Pitavastatin derivative 1
DMFZ9Q3 HS Patented
DMFZ9Q3 SN PMID27537201-Compound-Figure12
DMFZ9Q3 CP the Shanghai Institute of Technology and the Shanghai Ecust Biomedicine Company
DMFZ9Q3 DT Small molecular drug
DM8OYI4 ID DM8OYI4
DM8OYI4 DN Platinum IV complexe 1
DM8OYI4 HS Patented
DM8OYI4 SN PMID26394986-Compound-69
DM8OYI4 CP H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE TURKSON, James JOVE, Richard SEBTI, Said
DM8OYI4 DT Small molecular drug
DMRXKJZ ID DMRXKJZ
DMRXKJZ DN PMID25399719-Compound-17
DMRXKJZ HS Patented
DMRXKJZ CP THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
DMRXKJZ DT Small molecular drug
DM23NEX ID DM23NEX
DM23NEX DN PMID25399762-Compound-Figure1-Aphanamixoid A
DM23NEX HS Patented
DMRHNOY ID DMRHNOY
DMRHNOY DN PMID25399762-Compound-Figure1-Chukrasone A
DMRHNOY HS Patented
DM0K4XE ID DM0K4XE
DM0K4XE DN PMID25399762-Compound-Figure1-Chukrasone B
DM0K4XE HS Patented
DMDX1MK ID DMDX1MK
DMDX1MK DN PMID25399762-Compound-Figure1-Eryngiolide A
DMDX1MK HS Patented
DMSYGHO ID DMSYGHO
DMSYGHO DN PMID25399762-Compound-Figure1-Neonectrolide A
DMSYGHO HS Patented
DMRIEH3 ID DMRIEH3
DMRIEH3 DN PMID25399762-Compound-Figure1-Sarcaboside A
DMRIEH3 HS Patented
DMDL6TG ID DMDL6TG
DMDL6TG DN PMID25399762-Compound-Figure1-Sarcaboside B
DMDL6TG HS Patented
DMG1EKV ID DMG1EKV
DMG1EKV DN PMID25399762-Compound-Figure2-Artoxanthochromane
DMG1EKV HS Patented
DMG1EKV CP Changzhou Kelixin Medical Devices CO LTD
DMG1EKV DT Small molecular drug
DMYJ0I8 ID DMYJ0I8
DMYJ0I8 DN PMID25399762-Compound-Figure2-Spirooliganone B
DMYJ0I8 HS Patented
DMP5Y19 ID DMP5Y19
DMP5Y19 DN PMID25399762-Compound-Figure3-Aspeverin
DMP5Y19 HS Patented
DMP5Y19 DT Small molecular drug
DMP5Y19 PC 71712961
DMP5Y19 MW 376.5
DMP5Y19 FM C22H24N4O2
DMP5Y19 IC InChI=1S/C22H24N4O2/c1-20(2)16-10-13-6-5-9-26(13)17(11-23)21(16)12-22(28-19(27)25-21)14-7-3-4-8-15(14)24-18(20)22/h3-4,7-8,13,16-17H,5-6,9-10,12H2,1-2H3,(H,25,27)/t13-,16-,17-,21+,22+/m0/s1
DMP5Y19 CS CC1([C@@H]2C[C@@H]3CCCN3[C@H]([C@@]24C[C@@]5(C1=NC6=CC=CC=C65)OC(=O)N4)C#N)C
DMP5Y19 IK MJAHQBSZAYUSFL-MKGFCTCPSA-N
DMP5Y19 IU (1R,11S,13S,18R,19R)-10,10-dimethyl-21-oxo-22-oxa-8,17,20-triazahexacyclo[17.3.1.01,9.02,7.011,19.013,17]tricosa-2,4,6,8-tetraene-18-carbonitrile
DM9KTRA ID DM9KTRA
DM9KTRA DN PMID25399762-Compound-Figure3-Fluevirosine A
DM9KTRA HS Patented
DMBSP1G ID DMBSP1G
DMBSP1G DN PMID25399762-Compound-Figure3-Lycojaponicumin A
DMBSP1G HS Patented
DMBSP1G CP Nanjing Guangkangxie Biolog. Medical Technology CO LTD
DMKP64Z ID DMKP64Z
DMKP64Z DN PMID25399762-Compound-Figure3-Lycojaponicumin B
DMKP64Z HS Patented
DMKP64Z CP Nanjing Guangkangxie Biolog. Medical Technology CO LTD
DM7NUT2 ID DM7NUT2
DM7NUT2 DN PMID25399762-Compound-Figure3-Lycojaponicumin C
DM7NUT2 HS Patented
DM7NUT2 CP Nanjing Guangkangxie Biolog. Medical Technology CO LTD
DMLAS7K ID DMLAS7K
DMLAS7K DN PMID25399762-Compound-Table 5-8
DMLAS7K HS Patented
DMLAS7K CP Varinel, Inc
DM18FP4 ID DM18FP4
DM18FP4 DN PMID25399762-Compound-Table 5-O-methyl-M30
DM18FP4 HS Patented
DM18FP4 CP Varinel, Inc
DM4UM03 ID DM4UM03
DM4UM03 DN PMID25399762-Compound-Table 6-10
DM4UM03 HS Patented
DM4UM03 CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMYGTU2 ID DMYGTU2
DMYGTU2 DN PMID25399762-Compound-Table 6-11
DMYGTU2 HS Patented
DMYGTU2 CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMZ07RP ID DMZ07RP
DMZ07RP DN PMID25399762-Compound-Table 6-12
DMZ07RP HS Patented
DMZ07RP CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DM6LR42 ID DM6LR42
DM6LR42 DN PMID25399762-Compound-Table 6-13
DM6LR42 HS Patented
DM6LR42 CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMZHB9Y ID DMZHB9Y
DMZHB9Y DN PMID25399762-Compound-Table 6-14
DMZHB9Y HS Patented
DMZHB9Y CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMCHWSF ID DMCHWSF
DMCHWSF DN PMID25399762-Compound-Table 6-15
DMCHWSF HS Patented
DMCHWSF CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMDWIPG ID DMDWIPG
DMDWIPG DN PMID25399762-Compound-Table 6-9
DMDWIPG HS Patented
DMDWIPG CP ORYZON GENOMICS S.A. MAES, Tamara BUESA ARJOL, Carlos
DMSL3MB ID DMSL3MB
DMSL3MB DN PMID25399762-Compound-Table 7-Vanillic acid
DMSL3MB HS Patented
DMSL3MB CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM759MJ ID DM759MJ
DM759MJ DN PMID25399762-Compound-Table 7-Vanillyl alcohol
DM759MJ HS Patented
DM759MJ CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DM4J2SM ID DM4J2SM
DM4J2SM DN PMID25399762-Compound-Table 7-Veratraldehyde
DM4J2SM HS Patented
DM4J2SM CP UNILEVER PLC UNILEVER N.V. CONOPCO, INC., D/B/A UNILEVER
DMMP7HX ID DMMP7HX
DMMP7HX DN PMID25399762-Compound-Table1-C1
DMMP7HX HS Patented
DMMP7HX CP NTZ LAB LTD [BG]
DMMP7HX DT Small molecular drug
DMWY5XT ID DMWY5XT
DMWY5XT DN PMID25399762-Compound-Table1-C10
DMWY5XT HS Patented
DMWY5XT CP NTZ LAB LTD [BG]
DMWY5XT DT Small molecular drug
DMVASXW ID DMVASXW
DMVASXW DN PMID25399762-Compound-Table1-C11
DMVASXW HS Patented
DMVASXW CP NTZ LAB LTD [BG]
DMVASXW DT Small molecular drug
DMF9X6P ID DMF9X6P
DMF9X6P DN PMID25399762-Compound-Table1-C12
DMF9X6P HS Patented
DMF9X6P CP NTZ LAB LTD [BG]
DMF9X6P DT Small molecular drug
DMD80Q6 ID DMD80Q6
DMD80Q6 DN PMID25399762-Compound-Table1-C13
DMD80Q6 HS Patented
DMD80Q6 CP NTZ LAB LTD [BG]
DMD80Q6 DT Small molecular drug
DM7960M ID DM7960M
DM7960M DN PMID25399762-Compound-Table1-C14
DM7960M HS Patented
DM7960M CP NTZ LAB LTD [BG]
DM7960M DT Small molecular drug
DMR0P1U ID DMR0P1U
DMR0P1U DN PMID25399762-Compound-Table1-C15
DMR0P1U HS Patented
DMR0P1U CP NTZ LAB LTD [BG]
DMR0P1U DT Small molecular drug
DMR0P1U PC 77844717
DMR0P1U MW 319.2
DMR0P1U FM C16H12Cl2N2O
DMR0P1U IC InChI=1S/C16H12Cl2N2O/c1-20-7-6-10-8-11(2-5-15(10)20)16(21)19-12-3-4-13(17)14(18)9-12/h2-9H,1H3,(H,19,21)
DMR0P1U CS CN1C=CC2=C1C=CC(=C2)C(=O)NC3=CC(=C(C=C3)Cl)Cl
DMR0P1U IK XHTKCMHMWMUSIE-UHFFFAOYSA-N
DMR0P1U IU N-(3,4-dichlorophenyl)-1-methylindole-5-carboxamide
DMYTEAC ID DMYTEAC
DMYTEAC DN PMID25399762-Compound-Table1-C16
DMYTEAC HS Patented
DMYTEAC CP NTZ LAB LTD [BG]
DMYTEAC DT Small molecular drug
DMYTEAC PC 77844718
DMYTEAC MW 303.72
DMYTEAC FM C15H11ClFN3O
DMYTEAC IC InChI=1S/C15H11ClFN3O/c1-20-14-5-2-9(6-10(14)8-18-20)15(21)19-11-3-4-13(17)12(16)7-11/h2-8H,1H3,(H,19,21)
DMYTEAC CS CN1C2=C(C=C(C=C2)C(=O)NC3=CC(=C(C=C3)F)Cl)C=N1
DMYTEAC IK ISZVIYGCASWHFG-UHFFFAOYSA-N
DMYTEAC IU N-(3-chloro-4-fluorophenyl)-1-methylindazole-5-carboxamide
DMNMU3R ID DMNMU3R
DMNMU3R DN PMID25399762-Compound-Table1-C17
DMNMU3R HS Patented
DMNMU3R CP NTZ LAB LTD [BG]
DMNMU3R DT Small molecular drug
DM2ZUVH ID DM2ZUVH
DM2ZUVH DN PMID25399762-Compound-Table1-C18
DM2ZUVH HS Patented
DM2ZUVH CP NTZ LAB LTD [BG]
DM2ZUVH DT Small molecular drug
DM2ZUVH PC 77844720
DM2ZUVH MW 287.26
DM2ZUVH FM C15H11F2N3O
DM2ZUVH IC InChI=1S/C15H11F2N3O/c1-20-14-5-2-9(6-10(14)8-18-20)15(21)19-11-3-4-12(16)13(17)7-11/h2-8H,1H3,(H,19,21)
DM2ZUVH CS CN1C2=C(C=C(C=C2)C(=O)NC3=CC(=C(C=C3)F)F)C=N1
DM2ZUVH IK MDOHBHVKAWMFFN-UHFFFAOYSA-N
DM2ZUVH IU N-(3,4-difluorophenyl)-1-methylindazole-5-carboxamide
DMMO3F1 ID DMMO3F1
DMMO3F1 DN PMID25399762-Compound-Table1-C19
DMMO3F1 HS Patented
DMMO3F1 CP NTZ LAB LTD [BG]
DMMO3F1 DT Small molecular drug
DMPFLGO ID DMPFLGO
DMPFLGO DN PMID25399762-Compound-Table1-C2
DMPFLGO HS Patented
DMPFLGO CP NTZ LAB LTD [BG]
DMPFLGO DT Small molecular drug
DMPFLGO PC 77844666
DMPFLGO MW 307.13
DMPFLGO FM C13H8Cl2N4O
DMPFLGO IC InChI=1S/C13H8Cl2N4O/c14-10-4-9(6-16-12(10)15)18-13(20)7-1-2-11-8(3-7)5-17-19-11/h1-6H,(H,17,19)(H,18,20)
DMPFLGO CS C1=CC2=C(C=C1C(=O)NC3=CC(=C(N=C3)Cl)Cl)C=NN2
DMPFLGO IK JLABGNSHSHVIHC-UHFFFAOYSA-N
DMPFLGO IU N-(5,6-dichloropyridin-3-yl)-1H-indazole-5-carboxamide
DMITNWZ ID DMITNWZ
DMITNWZ DN PMID25399762-Compound-Table1-C20
DMITNWZ HS Patented
DMITNWZ CP NTZ LAB LTD [BG]
DMITNWZ DT Small molecular drug
DMITNWZ PC 77844722
DMITNWZ MW 364.2
DMITNWZ FM C17H15Cl2N3O2
DMITNWZ IC InChI=1S/C17H15Cl2N3O2/c1-24-7-6-22-16-5-2-11(8-12(16)10-20-22)17(23)21-13-3-4-14(18)15(19)9-13/h2-5,8-10H,6-7H2,1H3,(H,21,23)
DMITNWZ CS COCCN1C2=C(C=C(C=C2)C(=O)NC3=CC(=C(C=C3)Cl)Cl)C=N1
DMITNWZ IK CTHLAPNHCMOVBE-UHFFFAOYSA-N
DMITNWZ IU N-(3,4-dichlorophenyl)-1-(2-methoxyethyl)indazole-5-carboxamide
DMMFILA ID DMMFILA
DMMFILA DN PMID25399762-Compound-Table1-C21
DMMFILA HS Patented
DMMFILA CP NTZ LAB LTD [BG]
DMMFILA DT Small molecular drug
DMBE0R2 ID DMBE0R2
DMBE0R2 DN PMID25399762-Compound-Table1-C22
DMBE0R2 HS Patented
DMBE0R2 CP NTZ LAB LTD [BG]
DMBE0R2 DT Small molecular drug
DMF89PY ID DMF89PY
DMF89PY DN PMID25399762-Compound-Table1-C23
DMF89PY HS Patented
DMF89PY CP NTZ LAB LTD [BG]
DMF89PY DT Small molecular drug
DMJK296 ID DMJK296
DMJK296 DN PMID25399762-Compound-Table1-C24
DMJK296 HS Patented
DMJK296 CP NTZ LAB LTD [BG]
DMJK296 DT Small molecular drug
DMHT41B ID DMHT41B
DMHT41B DN PMID25399762-Compound-Table1-C25
DMHT41B HS Patented
DMHT41B CP NTZ LAB LTD [BG]
DMHT41B DT Small molecular drug
DMXAKNH ID DMXAKNH
DMXAKNH DN PMID25399762-Compound-Table1-C3
DMXAKNH HS Patented
DMXAKNH CP NTZ LAB LTD [BG]
DMXAKNH DT Small molecular drug
DMJCVBM ID DMJCVBM
DMJCVBM DN PMID25399762-Compound-Table1-C4
DMJCVBM HS Patented
DMJCVBM CP NTZ LAB LTD [BG]
DMJCVBM DT Small molecular drug
DMEJNUG ID DMEJNUG
DMEJNUG DN PMID25399762-Compound-Table1-C5
DMEJNUG HS Patented
DMEJNUG CP NTZ LAB LTD [BG]
DMEJNUG DT Small molecular drug
DMEJNUG PC 77844660
DMEJNUG MW 287.7
DMEJNUG FM C14H10ClN3O2
DMEJNUG IC InChI=1S/C14H10ClN3O2/c15-11-6-10(2-4-13(11)19)17-14(20)8-1-3-12-9(5-8)7-16-18-12/h1-7,19H,(H,16,18)(H,17,20)
DMEJNUG CS C1=CC2=C(C=C1C(=O)NC3=CC(=C(C=C3)O)Cl)C=NN2
DMEJNUG IK VNFLUMWXDOMPIE-UHFFFAOYSA-N
DMEJNUG IU N-(3-chloro-4-hydroxyphenyl)-1H-indazole-5-carboxamide
DMY3UKC ID DMY3UKC
DMY3UKC DN PMID25399762-Compound-Table1-C6
DMY3UKC HS Patented
DMY3UKC CP NTZ LAB LTD [BG]
DMY3UKC DT Small molecular drug
DMY3UKC PC 90281692
DMY3UKC MW 287.7
DMY3UKC FM C14H10ClN3O2
DMY3UKC IC InChI=1S/C14H10ClN3O2/c15-11-3-2-10(6-13(11)19)17-14(20)8-1-4-12-9(5-8)7-16-18-12/h1-7,19H,(H,16,18)(H,17,20)
DMY3UKC CS C1=CC2=C(C=C1C(=O)NC3=CC(=C(C=C3)Cl)O)C=NN2
DMY3UKC IK HSMCXXGJZHHZDS-UHFFFAOYSA-N
DMY3UKC IU N-(4-chloro-3-hydroxyphenyl)-1H-indazole-5-carboxamide
DMQJV3L ID DMQJV3L
DMQJV3L DN PMID25399762-Compound-Table1-C7
DMQJV3L HS Patented
DMQJV3L CP NTZ LAB LTD [BG]
DMQJV3L DT Small molecular drug
DMRCPKV ID DMRCPKV
DMRCPKV DN PMID25399762-Compound-Table1-C8
DMRCPKV HS Patented
DMRCPKV CP NTZ LAB LTD [BG]
DMRCPKV DT Small molecular drug
DMRCPKV PC 77844662
DMRCPKV MW 306.1
DMRCPKV FM C14H9Cl2N3O
DMRCPKV IC InChI=1S/C14H9Cl2N3O/c15-10-4-11(16)6-12(5-10)18-14(20)8-1-2-13-9(3-8)7-17-19-13/h1-7H,(H,17,19)(H,18,20)
DMRCPKV CS C1=CC2=C(C=C1C(=O)NC3=CC(=CC(=C3)Cl)Cl)C=NN2
DMRCPKV IK XXLZLPDHTLLSMN-UHFFFAOYSA-N
DMRCPKV IU N-(3,5-dichlorophenyl)-1H-indazole-5-carboxamide
DMVMT26 ID DMVMT26
DMVMT26 DN PMID25399762-Compound-Table1-C9
DMVMT26 HS Patented
DMVMT26 CP NTZ LAB LTD [BG]
DMVMT26 DT Small molecular drug
DMVMT26 PC 77844663
DMVMT26 MW 289.69
DMVMT26 FM C14H9ClFN3O
DMVMT26 IC InChI=1S/C14H9ClFN3O/c15-11-6-10(2-3-12(11)16)18-14(20)8-1-4-13-9(5-8)7-17-19-13/h1-7H,(H,17,19)(H,18,20)
DMVMT26 CS C1=CC2=C(C=C1C(=O)NC3=CC(=C(C=C3)F)Cl)C=NN2
DMVMT26 IK IMFUMEKCOMLOPY-UHFFFAOYSA-N
DMVMT26 IU N-(3-chloro-4-fluorophenyl)-1H-indazole-5-carboxamide
DMJETVH ID DMJETVH
DMJETVH DN PMID25416646-Compound-Figure2-J
DMJETVH HS Patented
DMJETVH CP METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC TANIS, Steven, P. PARKER, Timothy GADWOOD, Robert, C. ZELLER, James, R. ARTMAN, Gerald, D., III LARSEN, Scott, D
DMJETVH DT Small molecular drug
DMNTAYK ID DMNTAYK
DMNTAYK DN PMID25416646-Compound-Figure2-K
DMNTAYK HS Patented
DMNTAYK CP INTEKRIN THERAPEUTICS, INC
DMNTAYK DT Small molecular drug
DMNTAYK PC 10229498
DMNTAYK MW 514.2
DMNTAYK FM C21H12Cl4N2O3S
DMNTAYK IC InChI=1S/C21H12Cl4N2O3S/c22-13-5-6-20(16(23)8-13)31(28,29)27-14-9-17(24)21(18(25)10-14)30-15-7-12-3-1-2-4-19(12)26-11-15/h1-11,27H
DMNTAYK CS C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl
DMNTAYK IK NMRWDFUZLLQSBN-UHFFFAOYSA-N
DMNTAYK IU 2,4-dichloro-N-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide
DMNTAYK CA CAS 315224-26-1
DMLDPGY ID DMLDPGY
DMLDPGY DN PMID25416646-Compound-Figure2-N
DMLDPGY HS Patented
DMLDPGY CP PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED FINCH, Harry FOX, Craig
DMLDPGY DT Small molecular drug
DM9OHAN ID DM9OHAN
DM9OHAN DN PMID25416646-Compound-Figure5-A
DM9OHAN HS Patented
DM9OHAN CP THE UNIVERSITY OF SYDNEY HIBBS, David, Edward SALAM, Noeris, Kris ROUBIN, Rebecca MATIN, Azadeh GAVANDE, Navnath, S
DM9OHAN DT Small molecular drug
DM17FKL ID DM17FKL
DM17FKL DN PMID25416646-Compound-Figure5-C
DM17FKL HS Patented
DM17FKL CP Sanofi-Aventis
DM17FKL DT Small molecular drug
DMYO7VH ID DMYO7VH
DMYO7VH DN PMID25416646-Compound-Figure5-E
DMYO7VH HS Patented
DMYO7VH CP KOWA COMPANY, LTD. MIURA, Toru ONOGI, Kazuhiro TAGASHIRA, Junya
DMYO7VH DT Small molecular drug
DMCJTU1 ID DMCJTU1
DMCJTU1 DN PMID25416646-Compound-Figure5-H
DMCJTU1 HS Patented
DMCJTU1 CP PUSAN NAT UNIVERSITY INDUSTRYUNIVERSITY [KR]
DMCJTU1 DT Small molecular drug
DMMRUVT ID DMMRUVT
DMMRUVT DN PMID25435179-Compound-EP20142759295NP-1
DMMRUVT HS Patented
DMXJT8R ID DMXJT8R
DMXJT8R DN PMID25435179-Compound-US2012165330(I)
DMXJT8R HS Patented
DMMRT0Q ID DMMRT0Q
DMMRT0Q DN PMID25435179-Compound-WO2012006391H3K9TSu
DMMRT0Q HS Patented
DMMRT0Q CP CORNELL UNIVERSITY LIN, Hening
DM2F1T0 ID DM2F1T0
DM2F1T0 DN PMID25435179-Compound-WO2012106509CAY10602
DM2F1T0 HS Patented
DM2F1T0 CP THE TRUSTEES OF PRINCETON UNIVERSITY SHENK, Thomas KOYUNCU, Emre CRISTEA, Ileana
DMLAH39 ID DMLAH39
DMLAH39 DN PMID25435179-Compound-WO2012106509Salermide
DMLAH39 HS Patented
DMLAH39 CP THE TRUSTEES OF PRINCETON UNIVERSITY SHENK, Thomas KOYUNCU, Emre CRISTEA, Ileana
DMBSOED ID DMBSOED
DMBSOED DN PMID25435179-Compound-WO2012106509Tenovin-6
DMBSOED HS Patented
DMBSOED CP THE TRUSTEES OF PRINCETON UNIVERSITY SHENK, Thomas KOYUNCU, Emre CRISTEA, Ileana
DMBSOED DT RNA
DM79BFU ID DM79BFU
DM79BFU DN PMID25435179-Compound-WO2012149608USYDS1
DM79BFU HS Patented
DM79BFU CP THE UNIVERSITY OF SYDNEY DUKE, Colin Charles TRAN, Van Hoan DUKE, Rujee Kyokajee
DMIHRG4 ID DMIHRG4
DMIHRG4 DN PMID25435179-Compound-WO2013059587(V, 1st set)
DMIHRG4 HS Patented
DMIHRG4 CP GLAXOSMITHKLINE LLC CASAUBON, Rebecca, L. NARAYAN, Radha OALMANN, Christopher VU, Chi, B
DM7YJ4L ID DM7YJ4L
DM7YJ4L DN PMID25435179-Compound-WO2013059587(VI, 2nd set)
DM7YJ4L HS Patented
DM7YJ4L CP GLAXOSMITHKLINE LLC CASAUBON, Rebecca, L. NARAYAN, Radha OALMANN, Christopher VU, Chi, B
DMLUWCD ID DMLUWCD
DMLUWCD DN PMID25435179-Compound-WO2013059594(III)
DMLUWCD HS Patented
DMLUWCD CP GLAXOSMITHKLINE LLC BLUM, Charles, A. DISCH, Jeremy, S. SPRINGER, Stephanie, K
DMK90ED ID DMK90ED
DMK90ED DN PMID25435179-Compound-WO2013059594(IV)
DMK90ED HS Patented
DMK90ED CP GLAXOSMITHKLINE LLC BLUM, Charles, A. DISCH, Jeremy, S. SPRINGER, Stephanie, K
DMXC3UP ID DMXC3UP
DMXC3UP DN PMID25435179-Compound-WO2014110399Splitomycin
DMXC3UP HS Patented
DMXC3UP CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
DM12QO7 ID DM12QO7
DM12QO7 DN PMID25435285-Compound-10
DM12QO7 HS Patented
DM12QO7 CP BRAINCELLS, INCBRAINCELLS, INC. BLEICHER, Leo
DM12QO7 DT Small molecular drug
DM12QO7 PC 11641449
DM12QO7 MW 476.4
DM12QO7 FM C22H28Cl2FNO5
DM12QO7 IC InChI=1S/C22H28Cl2FNO5/c1-2-3-4-5-6-9-30-20(29)21(25)14-11-17(22(26,18(14)21)19(27)28)31-12-13-7-8-15(23)16(24)10-13/h7-8,10,14,17-18H,2-6,9,11-12,26H2,1H3,(H,27,28)/t14-,17-,18+,21-,22+/m1/s1
DM12QO7 CS CCCCCCCOC(=O)[C@]1([C@H]2[C@@H]1[C@@]([C@@H](C2)OCC3=CC(=C(C=C3)Cl)Cl)(C(=O)O)N)F
DM12QO7 IK SVZJNGHWEHDHLT-OUSKECTQSA-N
DM12QO7 IU (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluoro-6-heptoxycarbonylbicyclo[3.1.0]hexane-2-carboxylic acid
DMHBWNS ID DMHBWNS
DMHBWNS DN PMID25435285-Compound-15
DMHBWNS HS Patented
DMHBWNS CP ELI LILLY AND COMPANY
DMHBWNS DT Small molecular drug
DMHBWNS PC 57338826
DMHBWNS MW 376.2
DMHBWNS FM C15H15Cl2NO6
DMHBWNS IC InChI=1S/C15H15Cl2NO6/c16-6-2-1-5(3-7(6)17)4-24-12-11(19)8-9(13(20)21)10(8)15(12,18)14(22)23/h1-3,8-12,19H,4,18H2,(H,20,21)(H,22,23)/t8-,9-,10-,11-,12+,15+/m0/s1
DMHBWNS CS C1=CC(=C(C=C1CO[C@@H]2[C@H]([C@H]3[C@@H]([C@H]3[C@@]2(C(=O)O)N)C(=O)O)O)Cl)Cl
DMHBWNS IK WNOZOUHFGZKGNT-ANYOLZDRSA-N
DMHBWNS IU (1S,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMKFX2G ID DMKFX2G
DMKFX2G DN PMID25435285-Compound-16
DMKFX2G HS Patented
DMKFX2G CP ELI LILLY AND COMPANY
DMKFX2G DT Small molecular drug
DMKFX2G PC 67705089
DMKFX2G MW 459.3
DMKFX2G FM C17H16Cl2N4O5S
DMKFX2G IC InChI=1S/C17H16Cl2N4O5S/c18-7-2-1-6(3-8(7)19)4-28-13-12(29-16-21-5-22-23-16)9-10(14(24)25)11(9)17(13,20)15(26)27/h1-3,5,9-13H,4,20H2,(H,24,25)(H,26,27)(H,21,22,23)/t9-,10-,11-,12-,13+,17+/m0/s1
DMKFX2G CS C1=CC(=C(C=C1CO[C@@H]2[C@H]([C@H]3[C@@H]([C@H]3[C@@]2(C(=O)O)N)C(=O)O)SC4=NC=NN4)Cl)Cl
DMKFX2G IK QHBLXVIRCXAIGL-WNAOHANSSA-N
DMKFX2G IU (1R,2R,3S,4S,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-4-(1H-1,2,4-triazol-5-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMG9FYH ID DMG9FYH
DMG9FYH DN PMID25435285-Compound-20
DMG9FYH HS Patented
DMG9FYH CP ELI LILLY AND COMPANY
DMG9FYH DT Small molecular drug
DM27U1F ID DM27U1F
DM27U1F DN PMID25435285-Compound-22
DM27U1F HS Patented
DM27U1F CP ELI LILLY AND COMPANY
DM27U1F DT Small molecular drug
DMIVJMO ID DMIVJMO
DMIVJMO DN PMID25435285-Compound-25
DMIVJMO HS Patented
DMIVJMO CP F. HOFFMANN-LA ROCHE AF. Hoffmann-La Roche AG
DMIVJMO DT Small molecular drug
DMIVJMO PC 353213
DMIVJMO MW 250.29
DMIVJMO FM C16H14N2O
DMIVJMO IC InChI=1S/C16H14N2O/c1-11-7-8-13-15(9-11)18-16(19)10-14(17-13)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,18,19)
DMIVJMO CS CC1=CC2=C(C=C1)N=C(CC(=O)N2)C3=CC=CC=C3
DMIVJMO IK SCWDIXHHIUWDED-UHFFFAOYSA-N
DMIVJMO IU 8-methyl-4-phenyl-1,3-dihydro-1,5-benzodiazepin-2-one
DMIVJMO CA CAS 64376-00-7
DMTJHAK ID DMTJHAK
DMTJHAK DN PMID25435285-Compound-26
DMTJHAK HS Patented
DMTJHAK CP F. HOFFMANN-LA ROCHE AF. Hoffmann-La Roche AG
DMTJHAK DT Small molecular drug
DMTJHAK PC 9820321
DMTJHAK MW 361.4
DMTJHAK FM C24H15N3O
DMTJHAK IC InChI=1S/C24H15N3O/c25-16-19-7-4-8-20(13-19)22-15-24(28)27-23-14-18(11-12-21(23)26-22)10-9-17-5-2-1-3-6-17/h1-8,11-14H,15H2,(H,27,28)
DMTJHAK CS C1C(=NC2=C(C=C(C=C2)C#CC3=CC=CC=C3)NC1=O)C4=CC=CC(=C4)C#N
DMTJHAK IK YQYIKKPJWMTPST-UHFFFAOYSA-N
DMTJHAK IU 3-[2-oxo-8-(2-phenylethynyl)-1,3-dihydro-1,5-benzodiazepin-4-yl]benzonitrile
DMTYHCU ID DMTYHCU
DMTYHCU DN PMID25435285-Compound-37
DMTYHCU HS Patented
DMTYHCU CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMTYHCU DT Small molecular drug
DMTYHCU PC 57468863
DMTYHCU MW 473.4
DMTYHCU FM C25H17F6N3
DMTYHCU IC InChI=1S/C25H17F6N3/c1-14-10-19(11-15(2)32-14)17-4-3-5-18(12-17)23-33-21(13-22(34-23)25(29,30)31)16-6-8-20(9-7-16)24(26,27)28/h3-13H,1-2H3
DMTYHCU CS CC1=CC(=CC(=N1)C)C2=CC(=CC=C2)C3=NC(=CC(=N3)C(F)(F)F)C4=CC=C(C=C4)C(F)(F)F
DMTYHCU IK UTZMRRRZFDOYFQ-UHFFFAOYSA-N
DMTYHCU IU 2-[3-(2,6-dimethylpyridin-4-yl)phenyl]-4-(trifluoromethyl)-6-[4-(trifluoromethyl)phenyl]pyrimidine
DMSIKM2 ID DMSIKM2
DMSIKM2 DN PMID25435285-Compound-38
DMSIKM2 HS Patented
DMSIKM2 CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMSIKM2 DT Small molecular drug
DMSIKM2 PC 3415095
DMSIKM2 MW 324.69
DMSIKM2 FM C14H8ClF3N4
DMSIKM2 IC InChI=1S/C14H8ClF3N4/c15-10-3-1-9(2-4-10)11-7-12(14(16,17)18)21-13(20-11)22-6-5-19-8-22/h1-8H
DMSIKM2 CS C1=CC(=CC=C1C2=CC(=NC(=N2)N3C=CN=C3)C(F)(F)F)Cl
DMSIKM2 IK LXVWPYFCJFOEJE-UHFFFAOYSA-N
DMSIKM2 IU 4-(4-chlorophenyl)-2-imidazol-1-yl-6-(trifluoromethyl)pyrimidine
DMG2ES1 ID DMG2ES1
DMG2ES1 DN PMID25435285-Compound-39
DMG2ES1 HS Patented
DMG2ES1 CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMG2ES1 DT Small molecular drug
DMG2ES1 PC 57468846
DMG2ES1 MW 481.8
DMG2ES1 FM C19H11ClF3N5O3S
DMG2ES1 IC InChI=1S/C19H11ClF3N5O3S/c20-12-6-4-10(5-7-12)14-9-15(19(21,22)23)26-16(25-14)17-27-18(31-28-17)11-2-1-3-13(8-11)32(24,29)30/h1-9H,(H2,24,29,30)
DMG2ES1 CS C1=CC(=CC(=C1)S(=O)(=O)N)C2=NC(=NO2)C3=NC(=CC(=N3)C(F)(F)F)C4=CC=C(C=C4)Cl
DMG2ES1 IK BODKDPJDJKXVIU-UHFFFAOYSA-N
DMG2ES1 IU 3-[3-[4-(4-chlorophenyl)-6-(trifluoromethyl)pyrimidin-2-yl]-1,2,4-oxadiazol-5-yl]benzenesulfonamide
DMW2C19 ID DMW2C19
DMW2C19 DN PMID25435285-Compound-40
DMW2C19 HS Patented
DMW2C19 CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMW2C19 DT Small molecular drug
DMW2C19 PC 60209409
DMW2C19 MW 559.4
DMW2C19 FM C24H14F9N5O
DMW2C19 IC InChI=1S/C24H14F9N5O/c25-22(26,27)11-39-18-7-13(4-5-16(18)23(28,29)30)17-8-19(24(31,32)33)38-20(37-17)14-3-1-2-12(6-14)15-9-35-21(34)36-10-15/h1-10H,11H2,(H2,34,35,36)
DMW2C19 CS C1=CC(=CC(=C1)C2=NC(=CC(=N2)C(F)(F)F)C3=CC(=C(C=C3)C(F)(F)F)OCC(F)(F)F)C4=CN=C(N=C4)N
DMW2C19 IK YCJPDEUHPPTQFR-UHFFFAOYSA-N
DMW2C19 IU 5-[3-[4-[3-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-yl]phenyl]pyrimidin-2-amine
DMJ5LGA ID DMJ5LGA
DMJ5LGA DN PMID25435285-Compound-41
DMJ5LGA HS Patented
DMJ5LGA CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMJ5LGA DT Small molecular drug
DMTN79G ID DMTN79G
DMTN79G DN PMID25435285-Compound-42
DMTN79G HS Patented
DMTN79G CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMTN79G DT Small molecular drug
DMTN79G PC 60209373
DMTN79G MW 405.4
DMTN79G FM C24H18F3N3
DMTN79G IC InChI=1S/C24H18F3N3/c1-15-11-20(16-5-8-21(9-6-16)24(25,26)27)13-22(30-15)18-4-2-3-17(12-18)19-7-10-23(28)29-14-19/h2-14H,1H3,(H2,28,29)
DMTN79G CS CC1=CC(=CC(=N1)C2=CC=CC(=C2)C3=CN=C(C=C3)N)C4=CC=C(C=C4)C(F)(F)F
DMTN79G IK PGUYKLHAVPKWNB-UHFFFAOYSA-N
DMTN79G IU 5-[3-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]phenyl]pyridin-2-amine
DMEGJ73 ID DMEGJ73
DMEGJ73 DN PMID25435285-Compound-43
DMEGJ73 HS Patented
DMEGJ73 CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMEGJ73 DT Small molecular drug
DMEGJ73 PC 60209453
DMEGJ73 MW 459.4
DMEGJ73 FM C24H15F6N3
DMEGJ73 IC InChI=1S/C24H15F6N3/c25-23(26,27)19-7-4-14(5-8-19)18-11-20(33-21(12-18)24(28,29)30)16-3-1-2-15(10-16)17-6-9-22(31)32-13-17/h1-13H,(H2,31,32)
DMEGJ73 CS C1=CC(=CC(=C1)C2=NC(=CC(=C2)C3=CC=C(C=C3)C(F)(F)F)C(F)(F)F)C4=CN=C(C=C4)N
DMEGJ73 IK VLHFNIFTVTULIS-UHFFFAOYSA-N
DMEGJ73 IU 5-[3-[6-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]phenyl]pyridin-2-amine
DM4K3AU ID DM4K3AU
DM4K3AU DN PMID25435285-Compound-44
DM4K3AU HS Patented
DM4K3AU CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DM4K3AU DT Small molecular drug
DM4K3AU PC 24760659
DM4K3AU MW 407.4
DM4K3AU FM C22H16F3N5
DM4K3AU IC InChI=1S/C22H16F3N5/c1-13-10-16(14-2-4-17(5-3-14)22(23,24)25)11-19(29-13)18-7-9-28-21(30-18)15-6-8-27-20(26)12-15/h2-12H,1H3,(H2,26,27)
DM4K3AU CS CC1=CC(=CC(=N1)C2=NC(=NC=C2)C3=CC(=NC=C3)N)C4=CC=C(C=C4)C(F)(F)F
DM4K3AU IK RODNKGNVQQLSIE-UHFFFAOYSA-N
DM4K3AU IU 4-[4-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]pyrimidin-2-yl]pyridin-2-amine
DM74WSJ ID DM74WSJ
DM74WSJ DN PMID25435285-Compound-45
DM74WSJ HS Patented
DM74WSJ CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DM74WSJ DT Small molecular drug
DMC6HPV ID DMC6HPV
DMC6HPV DN PMID25435285-Compound-46
DMC6HPV HS Patented
DMC6HPV CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DMC6HPV DT Small molecular drug
DMC6HPV PC 24760738
DMC6HPV MW 469.5
DMC6HPV FM C24H18F3N3O2S
DMC6HPV IC InChI=1S/C24H18F3N3O2S/c1-15-12-18(16-8-10-19(11-9-16)24(25,26)27)14-23(29-15)22-7-3-6-21(30-22)17-4-2-5-20(13-17)33(28,31)32/h2-14H,1H3,(H2,28,31,32)
DMC6HPV CS CC1=CC(=CC(=N1)C2=CC=CC(=N2)C3=CC(=CC=C3)S(=O)(=O)N)C4=CC=C(C=C4)C(F)(F)F
DMC6HPV IK DQITWECLUPKXEE-UHFFFAOYSA-N
DMC6HPV IU 3-[6-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]pyridin-2-yl]benzenesulfonamide
DM92F1C ID DM92F1C
DM92F1C DN PMID25435285-Compound-47
DM92F1C HS Patented
DM92F1C CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia GOETSCHI, Erwin WICHMANN, Juergen WOLTERING, Thomas Johannes
DM92F1C DT Small molecular drug
DM92F1C PC 24760017
DM92F1C MW 525.5
DM92F1C FM C27H22F3N3O3S
DM92F1C IC InChI=1S/C27H22F3N3O3S/c1-3-26(34)33-37(35,36)22-7-4-6-19(15-22)23-8-5-9-24(32-23)25-16-20(14-17(2)31-25)18-10-12-21(13-11-18)27(28,29)30/h4-16H,3H2,1-2H3,(H,33,34)
DM92F1C CS CCC(=O)NS(=O)(=O)C1=CC=CC(=C1)C2=NC(=CC=C2)C3=NC(=CC(=C3)C4=CC=C(C=C4)C(F)(F)F)C
DM92F1C IK OCTDFPIPOMIKKG-UHFFFAOYSA-N
DM92F1C IU N-[3-[6-[6-methyl-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl]pyridin-2-yl]phenyl]sulfonylpropanamide
DM7G51M ID DM7G51M
DM7G51M DN PMID25435285-Compound-49
DM7G51M HS Patented
DM7G51M CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DM7G51M DT Small molecular drug
DM7G51M PC 25097193
DM7G51M MW 495.9
DM7G51M FM C21H13ClF3N3O2S2
DM7G51M IC InChI=1S/C21H13ClF3N3O2S2/c22-19-8-7-17(31-19)16-11-18(21(23,24)25)28-20(27-16)14-5-1-3-12(9-14)13-4-2-6-15(10-13)32(26,29)30/h1-11H,(H2,26,29,30)
DM7G51M CS C1=CC(=CC(=C1)C2=NC(=CC(=N2)C(F)(F)F)C3=CC=C(S3)Cl)C4=CC(=CC=C4)S(=O)(=O)N
DM7G51M IK PNTBWHIVXJKWAT-UHFFFAOYSA-N
DM7G51M IU 3-[3-[4-(5-chlorothiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-yl]phenyl]benzenesulfonamide
DML48NA ID DML48NA
DML48NA DN PMID25435285-Compound-50
DML48NA HS Patented
DML48NA CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DML48NA DT Small molecular drug
DML48NA PC 67393308
DML48NA MW 496.4
DML48NA FM C20H13F5N6O2S
DML48NA IC InChI=1S/C20H13F5N6O2S/c21-18(22)15-7-14(12-4-5-17(27-8-12)20(23,24)25)29-19(30-15)31-9-16(28-10-31)11-2-1-3-13(6-11)34(26,32)33/h1-10,18H,(H2,26,32,33)
DML48NA CS C1=CC(=CC(=C1)S(=O)(=O)N)C2=CN(C=N2)C3=NC(=CC(=N3)C(F)F)C4=CN=C(C=C4)C(F)(F)F
DML48NA IK OGTCWWKKFTYEFV-UHFFFAOYSA-N
DML48NA IU 3-[1-[4-(difluoromethyl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-2-yl]imidazol-4-yl]benzenesulfonamide
DM2VZG6 ID DM2VZG6
DM2VZG6 DN PMID25435285-Compound-51
DM2VZG6 HS Patented
DM2VZG6 CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DM2VZG6 DT Small molecular drug
DM2VZG6 PC 86624638
DM2VZG6 MW 462.3
DM2VZG6 FM C21H12F6N6
DM2VZG6 IC InChI=1S/C21H12F6N6/c22-20(23,24)16-3-1-13(9-30-16)15-8-17(21(25,26)27)33-19(32-15)11-5-6-29-14(7-11)12-2-4-18(28)31-10-12/h1-10H,(H2,28,31)
DM2VZG6 CS C1=CC(=NC=C1C2=CC(=NC(=N2)C3=CC(=NC=C3)C4=CN=C(C=C4)N)C(F)(F)F)C(F)(F)F
DM2VZG6 IK XWOLECIBHRHRCW-UHFFFAOYSA-N
DM2VZG6 IU 5-[4-[4-(trifluoromethyl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-2-yl]pyridin-2-yl]pyridin-2-amine
DMXD8L1 ID DMXD8L1
DMXD8L1 DN PMID25435285-Compound-52
DMXD8L1 HS Patented
DMXD8L1 CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DMXD8L1 DT Small molecular drug
DMXD8L1 PC 25096944
DMXD8L1 MW 461.4
DMXD8L1 FM C22H13F6N5
DMXD8L1 IC InChI=1S/C22H13F6N5/c23-21(24,25)17-6-4-15(11-30-17)16-9-18(22(26,27)28)33-20(32-16)13-3-1-2-12(8-13)14-5-7-19(29)31-10-14/h1-11H,(H2,29,31)
DMXD8L1 CS C1=CC(=CC(=C1)C2=NC(=CC(=N2)C(F)(F)F)C3=CN=C(C=C3)C(F)(F)F)C4=CN=C(C=C4)N
DMXD8L1 IK RUFVODIMOVLNAI-UHFFFAOYSA-N
DMXD8L1 IU 5-[3-[4-(trifluoromethyl)-6-[6-(trifluoromethyl)pyridin-3-yl]pyrimidin-2-yl]phenyl]pyridin-2-amine
DMSRYIP ID DMSRYIP
DMSRYIP DN PMID25435285-Compound-53
DMSRYIP HS Patented
DMSRYIP CP F. HOFFMANN-LA ROCHE AG GATTI MCARTHUR, Silvia WICHMANN, Juergen WOLTERING, Thomas
DMSRYIP DT Small molecular drug
DMSRYIP PC 67393923
DMSRYIP MW 470.5
DMSRYIP FM C23H17F3N4O2S
DMSRYIP IC InChI=1S/C23H17F3N4O2S/c1-14-10-17(16-8-9-22(28-13-16)23(24,25)26)12-21(29-14)20-7-3-6-19(30-20)15-4-2-5-18(11-15)33(27,31)32/h2-13H,1H3,(H2,27,31,32)
DMSRYIP CS CC1=CC(=CC(=N1)C2=CC=CC(=N2)C3=CC(=CC=C3)S(=O)(=O)N)C4=CN=C(C=C4)C(F)(F)F
DMSRYIP IK SNOQZNIOGMOXDJ-UHFFFAOYSA-N
DMSRYIP IU 3-[6-[6-methyl-4-[6-(trifluoromethyl)pyridin-3-yl]pyridin-2-yl]pyridin-2-yl]benzenesulfonamide
DMSKCEH ID DMSKCEH
DMSKCEH DN PMID25468267-Compound-46
DMSKCEH HS Patented
DMSKCEH DT Small molecular drug
DMSKCEH PC 53392492
DMSKCEH MW 491.5
DMSKCEH FM C27H29N3O6
DMSKCEH IC InChI=1S/C27H29N3O6/c31-25(14-15-26(32)33)30(35)17-4-3-16-28-18-20-10-12-21(13-11-20)19-36-27(34)29-24-9-5-7-22-6-1-2-8-23(22)24/h1-2,5-15,28,35H,3-4,16-19H2,(H,29,34)(H,32,33)/b15-14+
DMSKCEH CS C1=CC=C2C(=C1)C=CC=C2NC(=O)OCC3=CC=C(C=C3)CNCCCCN(C(=O)/C=C/C(=O)O)O
DMSKCEH IK FOJNYQXAAPCEPX-CCEZHUSRSA-N
DMSKCEH IU (E)-4-[hydroxy-[4-[[4-(naphthalen-1-ylcarbamoyloxymethyl)phenyl]methylamino]butyl]amino]-4-oxobut-2-enoic acid
DMG2JEK ID DMG2JEK
DMG2JEK DN PMID25468267-Compound-47
DMG2JEK HS Patented
DMG2JEK DT Small molecular drug
DMG2JEK PC 53392493
DMG2JEK MW 505.6
DMG2JEK FM C28H31N3O6
DMG2JEK IC InChI=1S/C28H31N3O6/c1-36-27(33)16-15-26(32)31(35)18-5-4-17-29-19-21-11-13-22(14-12-21)20-37-28(34)30-25-10-6-8-23-7-2-3-9-24(23)25/h2-3,6-16,29,35H,4-5,17-20H2,1H3,(H,30,34)/b16-15+
DMG2JEK CS COC(=O)/C=C/C(=O)N(CCCCNCC1=CC=C(C=C1)COC(=O)NC2=CC=CC3=CC=CC=C32)O
DMG2JEK IK MUJOCHRZXRZONW-FOCLMDBBSA-N
DMG2JEK IU methyl (E)-4-[hydroxy-[4-[[4-(naphthalen-1-ylcarbamoyloxymethyl)phenyl]methylamino]butyl]amino]-4-oxobut-2-enoate
DMG2JEK CB CHEBI:95078
DMBPT9Z ID DMBPT9Z
DMBPT9Z DN PMID25468267-Compound-48
DMBPT9Z HS Patented
DMBPT9Z DT Small molecular drug
DMBPT9Z PC 89592590
DMBPT9Z MW 421.5
DMBPT9Z FM C22H35N3O5
DMBPT9Z IC InChI=1S/C22H35N3O5/c26-20(24-19-11-5-3-6-12-19)13-7-4-9-17-23-16-8-1-2-10-18-25(30)21(27)14-15-22(28)29/h3,5-6,11-12,23,30H,1-2,4,7-10,13-18H2,(H,24,26)(H,28,29)
DMBPT9Z CS C1=CC=C(C=C1)NC(=O)CCCCCNCCCCCCN(C(=O)CCC(=O)O)O
DMBPT9Z IK FJNPYJKFIGGTME-UHFFFAOYSA-N
DMBPT9Z IU 4-[6-[(6-anilino-6-oxohexyl)amino]hexyl-hydroxyamino]-4-oxobutanoic acid
DM2HG9U ID DM2HG9U
DM2HG9U DN PMID25468267-Compound-49
DM2HG9U HS Patented
DM2HG9U DT Small molecular drug
DMIVJ2W ID DMIVJ2W
DMIVJ2W DN PMID25468267-Compound-50
DMIVJ2W HS Patented
DMIVJ2W CP EPITHERAPEUTICS APS
DMIVJ2W DT Small molecular drug
DMIVJ2W PC 90093815
DMIVJ2W MW 260.29
DMIVJ2W FM C13H16N4O2
DMIVJ2W IC InChI=1S/C13H16N4O2/c18-13(19)11-2-4-16-12(8-11)9-14-3-1-6-17-7-5-15-10-17/h2,4-5,7-8,10,14H,1,3,6,9H2,(H,18,19)
DMIVJ2W CS C1=CN=C(C=C1C(=O)O)CNCCCN2C=CN=C2
DMIVJ2W IK HGXLVPBZRFKRHK-UHFFFAOYSA-N
DMIVJ2W IU 2-[(3-imidazol-1-ylpropylamino)methyl]pyridine-4-carboxylic acid
DMNPC0H ID DMNPC0H
DMNPC0H DN PMID25468267-Compound-51
DMNPC0H HS Patented
DMNPC0H CP EPITHERAPEUTICS APS
DMNPC0H DT Small molecular drug
DMNPC0H PC 73670709
DMNPC0H MW 223.27
DMNPC0H FM C11H17N3O2
DMNPC0H IC InChI=1S/C11H17N3O2/c1-14(2)6-5-12-8-10-7-9(11(15)16)3-4-13-10/h3-4,7,12H,5-6,8H2,1-2H3,(H,15,16)
DMNPC0H CS CN(C)CCNCC1=NC=CC(=C1)C(=O)O
DMNPC0H IK SAAOFVWGGZSWSS-UHFFFAOYSA-N
DMNPC0H IU 2-[[2-(dimethylamino)ethylamino]methyl]pyridine-4-carboxylic acid
DMAH1G7 ID DMAH1G7
DMAH1G7 DN PMID25468267-Compound-52
DMAH1G7 HS Patented
DMAH1G7 CP EPITHERAPEUTICS APS
DMAH1G7 DT Small molecular drug
DMAH1G7 PC 73670714
DMAH1G7 MW 232.23
DMAH1G7 FM C12H12N2O3
DMAH1G7 IC InChI=1S/C12H12N2O3/c15-12(16)9-3-4-14-10(6-9)7-13-8-11-2-1-5-17-11/h1-6,13H,7-8H2,(H,15,16)
DMAH1G7 CS C1=COC(=C1)CNCC2=NC=CC(=C2)C(=O)O
DMAH1G7 IK WAXTXDDUSDCZNA-UHFFFAOYSA-N
DMAH1G7 IU 2-[(furan-2-ylmethylamino)methyl]pyridine-4-carboxylic acid
DMONWYI ID DMONWYI
DMONWYI DN PMID25468267-Compound-53
DMONWYI HS Patented
DMONWYI CP EPITHERAPEUTICS APS
DMONWYI DT Small molecular drug
DMONWYI PC 73670871
DMONWYI MW 226.3
DMONWYI FM C10H14N2O2S
DMONWYI IC InChI=1S/C10H14N2O2S/c1-15-5-4-11-7-9-6-8(10(13)14)2-3-12-9/h2-3,6,11H,4-5,7H2,1H3,(H,13,14)
DMONWYI CS CSCCNCC1=NC=CC(=C1)C(=O)O
DMONWYI IK RTKPPOFYHYGKKG-UHFFFAOYSA-N
DMONWYI IU 2-[(2-methylsulfanylethylamino)methyl]pyridine-4-carboxylic acid
DMI93AX ID DMI93AX
DMI93AX DN PMID25468267-Compound-54
DMI93AX HS Patented
DMI93AX CP EPITHERAPEUTICS APS
DMI93AX DT Small molecular drug
DMI93AX PC 73670872
DMI93AX MW 279.33
DMI93AX FM C14H21N3O3
DMI93AX IC InChI=1S/C14H21N3O3/c1-3-4-7-17(2)13(18)10-15-9-12-8-11(14(19)20)5-6-16-12/h5-6,8,15H,3-4,7,9-10H2,1-2H3,(H,19,20)
DMI93AX CS CCCCN(C)C(=O)CNCC1=NC=CC(=C1)C(=O)O
DMI93AX IK ZASDPPHIPJCPAA-UHFFFAOYSA-N
DMI93AX IU 2-[[[2-[butyl(methyl)amino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylic acid
DMIXQRY ID DMIXQRY
DMIXQRY DN PMID25468267-Compound-55
DMIXQRY HS Patented
DMIXQRY CP EPITHERAPEUTICS APS
DMIXQRY DT Small molecular drug
DMAI19Z ID DMAI19Z
DMAI19Z DN PMID25468267-Compound-56
DMAI19Z HS Patented
DMAI19Z CP EPITHERAPEUTICS APS
DMAI19Z DT Small molecular drug
DMAI19Z PC 90093146
DMAI19Z MW 414.5
DMAI19Z FM C22H30N4O4
DMAI19Z IC InChI=1S/C22H30N4O4/c1-5-26(13-12-25(2)3)21(27)16-23-15-18-14-17(10-11-24-18)22(28)30-20-8-6-19(29-4)7-9-20/h6-11,14,23H,5,12-13,15-16H2,1-4H3
DMAI19Z CS CCN(CCN(C)C)C(=O)CNCC1=NC=CC(=C1)C(=O)OC2=CC=C(C=C2)OC
DMAI19Z IK VCJMVGNCXKDPNL-UHFFFAOYSA-N
DMAI19Z IU (4-methoxyphenyl) 2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylate
DM6EN54 ID DM6EN54
DM6EN54 DN PMID25470667-Compound-AZD3988
DM6EN54 HS Patented
DM6EN54 CP BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM6EN54 DT Small molecular drug
DMY3140 ID DMY3140
DMY3140 DN PMID25470667-Compound-BAY744113
DMY3140 HS Patented
DMY3140 CP BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DMY3140 DT Small molecular drug
DMMVQW8 ID DMMVQW8
DMMVQW8 DN PMID25470667-Compound-Figure4-1A
DMMVQW8 HS Patented
DMMVQW8 CP PFIZER INC
DMMVQW8 DT Small molecular drug
DME40TS ID DME40TS
DME40TS DN PMID25470667-Compound-GO-CoA-Tat
DME40TS HS Patented
DME40TS CP THE JOHNS HOPKINS UNIVERSITY COLE, Philip A. BARNETT, Bradley P. HWANG, Yousang BOEKE, Jef D
DME40TS DT Small molecular drug
DME40TS DE Type-2 diabetes; Obesity
DMYZ2UA ID DMYZ2UA
DMYZ2UA DN PMID25470667-Compound-K-604
DMYZ2UA HS Patented
DMYZ2UA CP KOWA COMPANY, LTD
DMYZ2UA DT Small molecular drug
DMYZ2UA PC 9892288
DMYZ2UA MW 502.7
DMYZ2UA FM C23H30N6OS3
DMYZ2UA IC InChI=1S/C23H30N6OS3/c1-16-14-19(31-2)21(22(24-16)32-3)27-20(30)15-29-10-8-28(9-11-29)12-13-33-23-25-17-6-4-5-7-18(17)26-23/h4-7,14H,8-13,15H2,1-3H3,(H,25,26)(H,27,30)
DMYZ2UA CS CC1=CC(=C(C(=N1)SC)NC(=O)CN2CCN(CC2)CCSC3=NC4=CC=CC=C4N3)SC
DMYZ2UA IK VGGMTOYKEDKFLN-UHFFFAOYSA-N
DMYZ2UA IU 2-[4-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]piperazin-1-yl]-N-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]acetamide
DMYZ2UA CA CAS 561023-90-3
DM0OBAW ID DM0OBAW
DM0OBAW DN PMID25470667-Compound-PF-04620110
DM0OBAW HS Patented
DM0OBAW CP BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM0OBAW DT Small molecular drug
DMCF2G7 ID DMCF2G7
DMCF2G7 DN PMID25470667-Compound-roselipins
DMCF2G7 HS Patented
DMCF2G7 CP KITASATO INST [JPOMURA SATOSHI [JPTOMODA HIROSHI [JPMASUMA ROKURO [JP]
DMCF2G7 DT Small molecular drug
DMQB4LE ID DMQB4LE
DMQB4LE DN PMID25482888-Compound-11
DMQB4LE HS Patented
DMQB4LE DT Small molecular drug
DMQB4LE PC 24853009
DMQB4LE MW 354.4
DMQB4LE FM C19H26N6O
DMQB4LE IC InChI=1S/C19H26N6O/c20-8-16-2-1-3-25(16)17(26)9-22-19-6-14-4-15(19)7-18(5-14,10-19)11-24-13-21-12-23-24/h12-16,22H,1-7,9-11H2/t14?,15?,16-,18?,19?/m0/s1
DMQB4LE CS C1C[C@H](N(C1)C(=O)CNC23CC4CC2CC(C4)(C3)CN5C=NC=N5)C#N
DMQB4LE IK IGRDXWYZILJAIK-YYSDWXCKSA-N
DMQB4LE IU (2S)-1-[2-[[1-(1,2,4-triazol-1-ylmethyl)-3-tricyclo[3.3.1.03,7]nonanyl]amino]acetyl]pyrrolidine-2-carbonitrile
DM8JIDR ID DM8JIDR
DM8JIDR DN PMID25482888-Compound-12
DM8JIDR HS Patented
DM8JIDR DT Small molecular drug
DM8JIDR PC 69163062
DM8JIDR MW 427.5
DM8JIDR FM C25H25N5O2
DM8JIDR IC InChI=1S/C25H25N5O2/c26-17-20-4-3-15-30(20)25(31)23(27)16-18-6-10-21(11-7-18)32-22-12-8-19(9-13-22)29-24-5-1-2-14-28-24/h1-2,5-14,20,23H,3-4,15-16,27H2,(H,28,29)/t20?,23-/m0/s1
DM8JIDR CS C1CC(N(C1)C(=O)[C@H](CC2=CC=C(C=C2)OC3=CC=C(C=C3)NC4=CC=CC=N4)N)C#N
DM8JIDR IK UTSGGYFCIGGJDF-AKRCKQFNSA-N
DM8JIDR IU 1-[(2S)-2-amino-3-[4-[4-(pyridin-2-ylamino)phenoxy]phenyl]propanoyl]pyrrolidine-2-carbonitrile
DMBS2FT ID DMBS2FT
DMBS2FT DN PMID25482888-Compound-13
DMBS2FT HS Patented
DMBS2FT CP MSN LABORATORIES LIMITED THIRUMALAI RAJAN, Srinivasan ESWARAIAH, Sajja VENKAT REDDY, Ghojala
DMBS2FT DT Small molecular drug
DMBS2FT PC 58819012
DMBS2FT MW 315.4
DMBS2FT FM C18H25N3O2
DMBS2FT IC InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15?,17?,18?/m1/s1
DMBS2FT CS C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
DMBS2FT IK QGJUIPDUBHWZPV-UGTKGIOISA-N
DMBS2FT IU (1S,3S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
DMC82UR ID DMC82UR
DMC82UR DN PMID25482888-Compound-14
DMC82UR HS Patented
DMC82UR DT Small molecular drug
DMO913H ID DMO913H
DMO913H DN PMID25482888-Compound-15
DMO913H HS Patented
DMO913H DT Small molecular drug
DMO913H PC 22387295
DMO913H MW 235.33
DMO913H FM C13H21N3O
DMO913H IC InChI=1S/C13H21N3O/c14-9-11-7-4-8-16(11)13(17)12(15)10-5-2-1-3-6-10/h10-12H,1-8,15H2
DMO913H CS C1CCC(CC1)C(C(=O)N2CCCC2C#N)N
DMO913H IK SXNUNNAPZNTPQV-UHFFFAOYSA-N
DMO913H IU 1-(2-amino-2-cyclohexylacetyl)pyrrolidine-2-carbonitrile
DMIFVXE ID DMIFVXE
DMIFVXE DN PMID25482888-Compound-16
DMIFVXE HS Patented
DMIFVXE DT Small molecular drug
DMY4AJ7 ID DMY4AJ7
DMY4AJ7 DN PMID25482888-Compound-17
DMY4AJ7 HS Patented
DMY4AJ7 CP Sunshine Lake Pharma Co., Ltd
DMY4AJ7 DT Small molecular drug
DM0W5UA ID DM0W5UA
DM0W5UA DN PMID25482888-Compound-18
DM0W5UA HS Patented
DM0W5UA CP Sunshine Lake Pharma Co., Ltd
DM0W5UA DT Small molecular drug
DM2W9AP ID DM2W9AP
DM2W9AP DN PMID25482888-Compound-21
DM2W9AP HS Patented
DM2W9AP DT Peptide
DMX5R9N ID DMX5R9N
DMX5R9N DN PMID25482888-Compound-34
DMX5R9N HS Patented
DMX5R9N DT Small molecular drug
DMX5R9N PC 70975627
DMX5R9N MW 376.5
DMX5R9N FM C21H24N6O
DMX5R9N IC InChI=1S/C21H24N6O/c1-14-10-18(26-9-5-8-17(23)13-26)19-20(24-14)25(2)21(28)27(19)12-16-7-4-3-6-15(16)11-22/h3-4,6-7,10,17H,5,8-9,12-13,23H2,1-2H3
DMX5R9N CS CC1=CC(=C2C(=N1)N(C(=O)N2CC3=CC=CC=C3C#N)C)N4CCCC(C4)N
DMX5R9N IK UWSKGQJKQNVRJZ-UHFFFAOYSA-N
DMX5R9N IU 2-[[7-(3-aminopiperidin-1-yl)-3,5-dimethyl-2-oxoimidazo[4,5-b]pyridin-1-yl]methyl]benzonitrile
DMMZO8Y ID DMMZO8Y
DMMZO8Y DN PMID25482888-Compound-37
DMMZO8Y HS Patented
DMMZO8Y DT Small molecular drug
DMJOPEL ID DMJOPEL
DMJOPEL DN PMID25482888-Compound-38
DMJOPEL HS Patented
DMJOPEL DT Small molecular drug
DMMLJ5E ID DMMLJ5E
DMMLJ5E DN PMID25482888-Compound-50
DMMLJ5E HS Patented
DMMLJ5E CP MERCK SHARP & DOHME CORP. BIFTU, Tesfaye
DMMLJ5E DT Small molecular drug
DMDLPB7 ID DMDLPB7
DMDLPB7 DN PMID25482888-Compound-52
DMDLPB7 HS Patented
DMDLPB7 DT Small molecular drug
DMB3DMR ID DMB3DMR
DMB3DMR DN PMID25482888-Compound-56
DMB3DMR HS Patented
DMB3DMR DT Small molecular drug
DMB3DMR PC 73388310
DMB3DMR MW 534.6
DMB3DMR FM C28H26N10O2
DMB3DMR IC InChI=1S/C28H26N10O2/c1-2-3-13-36-24-25(34-27(36)35-12-6-9-21(31)18-35)37(16-19-7-4-10-32-22(19)14-29)28(40)38(26(24)39)17-20-8-5-11-33-23(20)15-30/h4-5,7-8,10-11,21H,6,9,12-13,16-18,31H2,1H3/t21-/m1/s1
DMB3DMR CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=C(N=CC=C4)C#N)CC5=C(N=CC=C5)C#N
DMB3DMR IK BQCBNCZDTPPBMN-OAQYLSRUSA-N
DMB3DMR IU 3-[[8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-1-[(2-cyanopyridin-3-yl)methyl]-2,6-dioxopurin-3-yl]methyl]pyridine-2-carbonitrile
DM03UK2 ID DM03UK2
DM03UK2 DN PMID25482888-Compound-6
DM03UK2 HS Patented
DM03UK2 CP CADILA HEALTHCARE LIMITED PANDEY, Bipin DAVE, Mayank, Ghanshyambhai KOTHARI, Himanshu, M. SHUKLA, Bhavin, Shriprasad
DM03UK2 DT Small molecular drug
DMPY8NU ID DMPY8NU
DMPY8NU DN PMID25482888-Compound-69
DMPY8NU HS Patented
DMPY8NU DT Small molecular drug
DMPY8NU PC 71731242
DMPY8NU MW 418.5
DMPY8NU FM C23H26N6O2
DMPY8NU IC InChI=1S/C23H26N6O2/c1-3-4-12-28-21(27-11-7-8-17(24)14-27)13-22(30)29(23(28)31)15-20-25-16(2)18-9-5-6-10-19(18)26-20/h5-6,9-10,13,17H,7-8,11-12,14-15,24H2,1-2H3/t17-/m1/s1
DMPY8NU CS CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C(=N2)C)N4CCC[C@H](C4)N
DMPY8NU IK GHHYMLIQMIXJDE-QGZVFWFLSA-N
DMPY8NU IU 6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(4-methylquinazolin-2-yl)methyl]pyrimidine-2,4-dione
DMEYLM2 ID DMEYLM2
DMEYLM2 DN PMID25482888-Compound-70
DMEYLM2 HS Patented
DMEYLM2 DT Small molecular drug
DMZB140 ID DMZB140
DMZB140 DN PMID25482888-Compound-71
DMZB140 HS Patented
DMZB140 DT Small molecular drug
DMZB140 PC 77844155
DMZB140 MW 452.9
DMZB140 FM C23H25ClN6O2
DMZB140 IC InChI=1S/C23H25ClN6O2/c1-3-4-10-29-21(28-9-5-6-17(25)13-28)12-22(31)30(23(29)32)14-20-26-15(2)18-11-16(24)7-8-19(18)27-20/h7-8,11-12,17H,5-6,9-10,13-14,25H2,1-2H3/t17-/m1/s1
DMZB140 CS CC#CCN1C(=CC(=O)N(C1=O)CC2=NC(=C3C=C(C=CC3=N2)Cl)C)N4CCC[C@H](C4)N
DMZB140 IK NESYRYDEOFUJRC-QGZVFWFLSA-N
DMZB140 IU 6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(6-chloro-4-methylquinazolin-2-yl)methyl]pyrimidine-2,4-dione
DMQOVKF ID DMQOVKF
DMQOVKF DN PMID25482888-Compound-72
DMQOVKF HS Patented
DMQOVKF DT Small molecular drug
DMQOVKF PC 77844211
DMQOVKF MW 430.5
DMQOVKF FM C24H26N6O2
DMQOVKF IC InChI=1S/C24H26N6O2/c1-2-3-12-29-21(28-11-5-7-17(25)14-28)13-22(31)30(24(29)32)15-20-26-18-8-4-6-16-9-10-19(27-20)23(16)18/h4,6,8,13,17H,5,7,9-12,14-15,25H2,1H3/t17-/m1/s1
DMQOVKF CS CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC4=C3C(=N2)CC4)N5CCC[C@H](C5)N
DMQOVKF IK VRAJXOQRFSNNNZ-QGZVFWFLSA-N
DMQOVKF IU 6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-(5,7-diazatricyclo[6.3.1.04,12]dodeca-1(12),4,6,8,10-pentaen-6-ylmethyl)pyrimidine-2,4-dione
DME0XS4 ID DME0XS4
DME0XS4 DN PMID25514969-Compound-10
DME0XS4 HS Patented
DME0XS4 CP Takeda Pharmaceutical Co. Ltd
DME0XS4 DT Small molecular drug
DME0XS4 PC 118378889
DME0XS4 MW 364.4
DME0XS4 FM C20H20N4O3
DME0XS4 IC InChI=1S/C20H20N4O3/c25-20(24-14-3-4-15(24)10-26-9-14)17-6-22-19-16(18-7-21-11-27-18)5-13(8-23(17)19)12-1-2-12/h5-8,11-12,14-15H,1-4,9-10H2
DME0XS4 CS C1CC1C2=CN3C(=CN=C3C(=C2)C4=CN=CO4)C(=O)N5C6CCC5COC6
DME0XS4 IK SESFIBLYIKNNRP-UHFFFAOYSA-N
DME0XS4 IU [6-cyclopropyl-8-(1,3-oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methanone
DMUPL0W ID DMUPL0W
DMUPL0W DN PMID25514969-Compound-11
DMUPL0W HS Patented
DMUPL0W CP Takeda Pharmaceutical Co. Ltd
DMUPL0W DT Small molecular drug
DMUPL0W PC 118379012
DMUPL0W MW 342.32
DMUPL0W FM C17H15FN4O3
DMUPL0W IC InChI=1S/C17H15FN4O3/c18-10-3-13(15-5-19-9-25-15)16-20-4-14(21(16)6-10)17(23)22-11-1-2-12(22)8-24-7-11/h3-6,9,11-12H,1-2,7-8H2
DMUPL0W CS C1CC2COCC1N2C(=O)C3=CN=C4N3C=C(C=C4C5=CN=CO5)F
DMUPL0W IK AVXVHVNSDORSDK-UHFFFAOYSA-N
DMUPL0W IU [6-fluoro-8-(1,3-oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methanone
DMOE5N0 ID DMOE5N0
DMOE5N0 DN PMID25514969-Compound-12
DMOE5N0 HS Patented
DMOE5N0 CP Takeda Pharmaceutical Co. Ltd
DMOE5N0 DT Small molecular drug
DMQB03U ID DMQB03U
DMQB03U DN PMID25514969-Compound-13
DMQB03U HS Patented
DMQB03U CP Takeda Pharmaceutical Co. Ltd
DMQB03U DT Small molecular drug
DMQB03U PC 118378871
DMQB03U MW 387.3
DMQB03U FM C18H12F3N5O2
DMQB03U IC InChI=1S/C18H12F3N5O2/c19-18(20,21)12-6-13(14-8-22-10-28-14)15-24-25-16(26(15)9-12)17(27)23-7-11-4-2-1-3-5-11/h1-6,8-10H,7H2,(H,23,27)
DMQB03U CS C1=CC=C(C=C1)CNC(=O)C2=NN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
DMQB03U IK QZZRSTUQIGEDKT-UHFFFAOYSA-N
DMQB03U IU N-benzyl-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide
DM2NVLZ ID DM2NVLZ
DM2NVLZ DN PMID25514969-Compound-8
DM2NVLZ HS Patented
DM2NVLZ CP Takeda Pharmaceutical Co. Ltd
DM2NVLZ DT Small molecular drug
DM2NVLZ PC 118378988
DM2NVLZ MW 386.3
DM2NVLZ FM C19H13F3N4O2
DM2NVLZ IC InChI=1S/C19H13F3N4O2/c20-19(21,22)13-6-14(16-9-23-11-28-16)17-24-8-15(26(17)10-13)18(27)25-7-12-4-2-1-3-5-12/h1-6,8-11H,7H2,(H,25,27)
DM2NVLZ CS C1=CC=C(C=C1)CNC(=O)C2=CN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
DM2NVLZ IK PSHYVANCPSFWJM-UHFFFAOYSA-N
DM2NVLZ IU N-benzyl-8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide
DMAEZB1 ID DMAEZB1
DMAEZB1 DN PMID25514969-Compound-9
DMAEZB1 HS Patented
DMAEZB1 CP Takeda Pharmaceutical Co. Ltd
DMAEZB1 DT Small molecular drug
DMAEZB1 PC 118379029
DMAEZB1 MW 372.3
DMAEZB1 FM C18H11F3N4O2
DMAEZB1 IC InChI=1S/C18H11F3N4O2/c19-18(20,21)11-6-13(15-8-22-10-27-15)16-23-7-14(25(16)9-11)17(26)24-12-4-2-1-3-5-12/h1-10H,(H,24,26)
DMAEZB1 CS C1=CC=C(C=C1)NC(=O)C2=CN=C3N2C=C(C=C3C4=CN=CO4)C(F)(F)F
DMAEZB1 IK SNIXWKGBBMUCPJ-UHFFFAOYSA-N
DMAEZB1 IU 8-(1,3-oxazol-5-yl)-N-phenyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carboxamide
DMC6S0W ID DMC6S0W
DMC6S0W DN PMID25514969-Compound-Figure2-2
DMC6S0W HS Patented
DMC6S0W CP Takeda Pharmaceutical Co. Ltd
DMC6S0W DT Small molecular drug
DMUYVOP ID DMUYVOP
DMUYVOP DN PMID25514969-Compound-Figure2-3
DMUYVOP HS Patented
DMUYVOP CP Takeda Pharmaceutical Co. Ltd
DMUYVOP DT Small molecular drug
DMUYVOP PC 73437845
DMUYVOP MW 373.4
DMUYVOP FM C23H23N3O2
DMUYVOP IC InChI=1S/C23H23N3O2/c27-22(20-7-4-12-25-21(20)19-8-13-24-14-9-19)26-15-10-23(28,11-16-26)17-18-5-2-1-3-6-18/h1-9,12-14,28H,10-11,15-17H2
DMUYVOP CS C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4
DMUYVOP IK XKUZMIUSBMCVPP-UHFFFAOYSA-N
DMUYVOP IU (4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone
DMUYVOP CA CAS 1429505-03-2
DMXSAN7 ID DMXSAN7
DMXSAN7 DN PMID25514969-Compound-Figure2-4
DMXSAN7 HS Patented
DMXSAN7 CP Takeda Pharmaceutical Co. Ltd
DMXSAN7 DT Small molecular drug
DMXSAN7 PC 118379001
DMXSAN7 MW 392.3
DMXSAN7 FM C18H15F3N4O3
DMXSAN7 IC InChI=1S/C18H15F3N4O3/c19-18(20,21)10-3-13(15-5-22-9-28-15)16-23-4-14(24(16)6-10)17(26)25-11-1-2-12(25)8-27-7-11/h3-6,9,11-12H,1-2,7-8H2
DMXSAN7 CS C1CC2COCC1N2C(=O)C3=CN=C4N3C=C(C=C4C5=CN=CO5)C(F)(F)F
DMXSAN7 IK OANZLTUUAVMTHM-UHFFFAOYSA-N
DMXSAN7 IU 3-oxa-8-azabicyclo[3.2.1]octan-8-yl-[8-(1,3-oxazol-5-yl)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methanone
DM7D12Y ID DM7D12Y
DM7D12Y DN PMID25514969-Compound-Figure3
DM7D12Y HS Patented
DM7D12Y CP Takeda Pharmaceutical Co. Ltd
DM7D12Y DT Small molecular drug
DMRJ30G ID DMRJ30G
DMRJ30G DN PMID25522065-Compound-10
DMRJ30G HS Patented
DMRJ30G DT Small molecular drug
DM410Z6 ID DM410Z6
DM410Z6 DN PMID25522065-Compound-11
DM410Z6 HS Patented
DM410Z6 CP ASTRAZENECA AB ASTRAZENECA UK LIMITED JOHANSSON, Lars, Anders, Mikael JUDKINS, Robert, Andrew LI, Lanna LOFBERG, Bjorn, Christian, Ingvar PERSSON, Joachim
DM410Z6 DT Small molecular drug
DM410Z6 PC 46937295
DM410Z6 MW 466.9
DM410Z6 FM C24H23ClN4O4
DM410Z6 IC InChI=1S/C24H23ClN4O4/c25-18-5-3-17(4-6-18)21-26-27-22(33-21)23(30)29-10-20(11-29)32-19-7-1-16(2-8-19)9-28-12-24(13-28)14-31-15-24/h1-8,20H,9-15H2
DM410Z6 CS C1C(CN1C(=O)C2=NN=C(O2)C3=CC=C(C=C3)Cl)OC4=CC=C(C=C4)CN5CC6(C5)COC6
DM410Z6 IK OVCNWJXOBLGBEA-UHFFFAOYSA-N
DM410Z6 IU [5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-[3-[4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy]azetidin-1-yl]methanone
DMVKO9C ID DMVKO9C
DMVKO9C DN PMID25522065-Compound-12
DMVKO9C HS Patented
DMVKO9C CP ASTRAZENECA AB [SEASTRAZENECA UK LTD [GBBOEKMAN-WINIWARTER SUSANNE DORIS MARGIT [SEFREDENWALL MARLENE [SEHOGNER CARL ANDERS [SEJOHANSSON LARS ANDERS MIKAEL [SEJUDKINS ROBERT ANDREW [SELI LANNA [SELOEFBERG BJOERN CHRISTIAN INGVAR [SEUNGE SVERKER VON [SE]
DMVKO9C DT Small molecular drug
DMVKO9C PC 56597688
DMVKO9C MW 468.9
DMVKO9C FM C24H25ClN4O4
DMVKO9C IC InChI=1S/C24H25ClN4O4/c1-16-12-17(13-28-8-10-31-11-9-28)2-7-21(16)32-20-14-29(15-20)24(30)23-27-26-22(33-23)18-3-5-19(25)6-4-18/h2-7,12,20H,8-11,13-15H2,1H3
DMVKO9C CS CC1=C(C=CC(=C1)CN2CCOCC2)OC3CN(C3)C(=O)C4=NN=C(O4)C5=CC=C(C=C5)Cl
DMVKO9C IK PGIWDCQJRFXKTN-UHFFFAOYSA-N
DMVKO9C IU [5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-[3-[2-methyl-4-(morpholin-4-ylmethyl)phenoxy]azetidin-1-yl]methanone
DM92HZG ID DM92HZG
DM92HZG DN PMID25522065-Compound-13
DM92HZG HS Patented
DM92HZG CP ASTRAZENECA AB ASTRAZENECA UK LIMITED JOHANSSON, Lars, Anders, Mikael
DM92HZG DT Small molecular drug
DM92HZG PC 71226268
DM92HZG MW 460.5
DM92HZG FM C26H28N4O4
DM92HZG IC InChI=1S/C26H28N4O4/c1-18-11-21(8-7-20(18)12-29-15-26(16-29)9-10-32-17-26)33-22-13-30(14-22)25(31)24-28-27-23(34-24)19-5-3-2-4-6-19/h2-8,11,22H,9-10,12-17H2,1H3
DM92HZG CS CC1=C(C=CC(=C1)OC2CN(C2)C(=O)C3=NN=C(O3)C4=CC=CC=C4)CN5CC6(C5)CCOC6
DM92HZG IK FMNDCDNBXCVEBC-UHFFFAOYSA-N
DM92HZG IU [3-[3-methyl-4-(6-oxa-2-azaspiro[3.4]octan-2-ylmethyl)phenoxy]azetidin-1-yl]-(5-phenyl-1,3,4-oxadiazol-2-yl)methanone
DMGZER5 ID DMGZER5
DMGZER5 DN PMID25522065-Compound-14
DMGZER5 HS Patented
DMGZER5 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMGZER5 DT Small molecular drug
DMGZER5 PC 71731806
DMGZER5 MW 390.5
DMGZER5 FM C24H26N2O3
DMGZER5 IC InChI=1S/C24H26N2O3/c1-18-13-20(15-25(2)3)9-10-22(18)23(27)16-26-12-11-21(14-24(26)28)29-17-19-7-5-4-6-8-19/h4-14H,15-17H2,1-3H3
DMGZER5 CS CC1=C(C=CC(=C1)CN(C)C)C(=O)CN2C=CC(=CC2=O)OCC3=CC=CC=C3
DMGZER5 IK QONJYPHKWHUJOW-UHFFFAOYSA-N
DMGZER5 IU 1-[2-[4-[(dimethylamino)methyl]-2-methylphenyl]-2-oxoethyl]-4-phenylmethoxypyridin-2-one
DMZMQFW ID DMZMQFW
DMZMQFW DN PMID25522065-Compound-15
DMZMQFW HS Patented
DMZMQFW DT Small molecular drug
DMZMQFW PC 25117272
DMZMQFW MW 456.9
DMZMQFW FM C23H21ClN2O4S
DMZMQFW IC InChI=1S/C23H21ClN2O4S/c1-23(2,28)13-30-18-9-8-17(11-19(18)29-3)26-22(27)21-15(12-25-26)10-20(31-21)14-4-6-16(24)7-5-14/h4-12,28H,13H2,1-3H3
DMZMQFW CS CC(C)(COC1=C(C=C(C=C1)N2C(=O)C3=C(C=C(S3)C4=CC=C(C=C4)Cl)C=N2)OC)O
DMZMQFW IK QOXWOBOEWLTLQE-UHFFFAOYSA-N
DMZMQFW IU 2-(4-chlorophenyl)-6-[4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl]thieno[2,3-d]pyridazin-7-one
DMAN3BT ID DMAN3BT
DMAN3BT DN PMID25522065-Compound-16
DMAN3BT HS Patented
DMAN3BT CP BRISTOL-MYERS SQUIBB COMPANY
DMAN3BT DT Small molecular drug
DMAN3BT PC 118282530
DMAN3BT MW 459.5
DMAN3BT FM C28H29NO5
DMAN3BT IC InChI=1S/C28H29NO5/c1-32-27-17-22(11-14-25(27)33-18-24(30)21-7-8-21)29-16-15-26(28(29)31)34-23-12-9-20(10-13-23)19-5-3-2-4-6-19/h2-6,9-14,17,21,24,26,30H,7-8,15-16,18H2,1H3/t24-,26+/m0/s1
DMAN3BT CS COC1=C(C=CC(=C1)N2CC[C@H](C2=O)OC3=CC=C(C=C3)C4=CC=CC=C4)OC[C@@H](C5CC5)O
DMAN3BT IK GLIZEOCMOXBOFJ-AZGAKELHSA-N
DMAN3BT IU (3R)-1-[4-[(2R)-2-cyclopropyl-2-hydroxyethoxy]-3-methoxyphenyl]-3-(4-phenylphenoxy)pyrrolidin-2-one
DM7X6HR ID DM7X6HR
DM7X6HR DN PMID25522065-Compound-17
DM7X6HR HS Patented
DM7X6HR CP BRISTOL-MYERS SQUIBB COMPANY
DM7X6HR DT Small molecular drug
DM7X6HR PC 89996639
DM7X6HR MW 465.6
DM7X6HR FM C26H27NO5S
DM7X6HR IC InChI=1S/C26H27NO5S/c1-19-18-22(10-13-24(19)31-16-17-33(2,29)30)27-15-14-25(26(27)28)32-23-11-8-21(9-12-23)20-6-4-3-5-7-20/h3-13,18,25H,14-17H2,1-2H3/t25-/m1/s1
DM7X6HR CS CC1=C(C=CC(=C1)N2CC[C@H](C2=O)OC3=CC=C(C=C3)C4=CC=CC=C4)OCCS(=O)(=O)C
DM7X6HR IK FNCUHIWLQCDGMI-RUZDIDTESA-N
DM7X6HR IU (3R)-1-[3-methyl-4-(2-methylsulfonylethoxy)phenyl]-3-(4-phenylphenoxy)pyrrolidin-2-one
DMTPJI8 ID DMTPJI8
DMTPJI8 DN PMID25522065-Compound-18
DMTPJI8 HS Patented
DMTPJI8 CP BRISTOL-MYERS SQUIBB COMPANY
DMTPJI8 DT Small molecular drug
DMTPJI8 PC 118284274
DMTPJI8 MW 472.6
DMTPJI8 FM C29H32N2O4
DMTPJI8 IC InChI=1S/C29H32N2O4/c1-33-28-21-24(11-14-26(28)34-20-19-30-16-5-6-17-30)31-18-15-27(29(31)32)35-25-12-9-23(10-13-25)22-7-3-2-4-8-22/h2-4,7-14,21,27H,5-6,15-20H2,1H3/t27-/m0/s1
DMTPJI8 CS COC1=C(C=CC(=C1)N2CC[C@@H](C2=O)OC3=CC=C(C=C3)C4=CC=CC=C4)OCCN5CCCC5
DMTPJI8 IK QXWLILWORIGJCR-MHZLTWQESA-N
DMTPJI8 IU (3S)-1-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-3-(4-phenylphenoxy)pyrrolidin-2-one
DMP4VYQ ID DMP4VYQ
DMP4VYQ DN PMID25522065-Compound-19
DMP4VYQ HS Patented
DMP4VYQ CP BRISTOL-MYERS SQUIBB COMPANY
DMP4VYQ DT Small molecular drug
DMP4VYQ PC 89996843
DMP4VYQ MW 434.5
DMP4VYQ FM C26H30N2O4
DMP4VYQ IC InChI=1S/C26H30N2O4/c1-30-25-18-21(8-11-23(25)31-17-16-27-13-2-3-14-27)28-15-12-24(26(28)29)32-22-9-6-20(7-10-22)19-4-5-19/h6-12,18-19H,2-5,13-17H2,1H3
DMP4VYQ CS COC1=C(C=CC(=C1)N2CC=C(C2=O)OC3=CC=C(C=C3)C4CC4)OCCN5CCCC5
DMP4VYQ IK NDQYSDBXPKTXCY-UHFFFAOYSA-N
DMP4VYQ IU 4-(4-cyclopropylphenoxy)-1-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-2H-pyrrol-5-one
DM3I6OF ID DM3I6OF
DM3I6OF DN PMID25522065-Compound-2
DM3I6OF HS Patented
DM3I6OF CP ALBANY MOLECULAR RESEARCH, INC
DM3I6OF DT Small molecular drug
DM3I6OF PC 49869488
DM3I6OF MW 399.5
DM3I6OF FM C25H25N3O2
DM3I6OF IC InChI=1S/C25H25N3O2/c1-27-23-14-19(9-10-22(23)21-8-5-12-26-16-24(21)27)28-13-11-20(15-25(28)29)30-17-18-6-3-2-4-7-18/h2-4,6-7,9-11,13-15,26H,5,8,12,16-17H2,1H3
DM3I6OF CS CN1C2=C(CCCNC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5
DM3I6OF IK BCAMBGJXPGJPAB-UHFFFAOYSA-N
DM3I6OF IU 1-(10-methyl-2,3,4,5-tetrahydro-1H-azepino[3,4-b]indol-8-yl)-4-phenylmethoxypyridin-2-one
DMG5J9Z ID DMG5J9Z
DMG5J9Z DN PMID25522065-Compound-20
DMG5J9Z HS Patented
DMG5J9Z CP GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui CHEN, Shenglin HUANG, Xing LI, Di LI, Fei LIN, Xiaojuan LU, Shi LV, Maoyun WU, Chengde XU, Weiliang YAN, Gang YUAN, Jianxing ZHANG, Weina ZHANG, Zhiliu
DMG5J9Z DT Small molecular drug
DMG5J9Z PC 49793232
DMG5J9Z MW 412.9
DMG5J9Z FM C21H21ClN4O3
DMG5J9Z IC InChI=1S/C21H21ClN4O3/c22-15-3-4-16(23-11-15)14-29-19-7-9-26(21(28)10-19)17-5-6-20(24-12-17)25-8-1-2-18(25)13-27/h3-7,9-12,18,27H,1-2,8,13-14H2/t18-/m1/s1
DMG5J9Z CS C1C[C@@H](N(C1)C2=NC=C(C=C2)N3C=CC(=CC3=O)OCC4=NC=C(C=C4)Cl)CO
DMG5J9Z IK FLLZLALIXHIFNL-GOSISDBHSA-N
DMG5J9Z IU 4-[(5-chloropyridin-2-yl)methoxy]-1-[6-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]pyridin-3-yl]pyridin-2-one
DMRZMH5 ID DMRZMH5
DMRZMH5 DN PMID25522065-Compound-21
DMRZMH5 HS Patented
DMRZMH5 CP GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui CHEN, Shenglin HUANG, Xing LI, Di LI, Fei LI, Lei LIN, Xiaojuan LU, Shi LU, Zhen LV, Maoyun WANG, Chuanning WU, Chengde XIAO, Mei YU, Haiyu ZHANG, Weina ZHANG, Zhiliu
DMRZMH5 DT Small molecular drug
DMRZMH5 PC 49793259
DMRZMH5 MW 427.9
DMRZMH5 FM C22H26ClN5O2
DMRZMH5 IC InChI=1S/C22H26ClN5O2/c1-3-27(4-2)12-10-24-21-8-7-19(15-26-21)28-11-9-20(13-22(28)29)30-16-18-6-5-17(23)14-25-18/h5-9,11,13-15H,3-4,10,12,16H2,1-2H3,(H,24,26)
DMRZMH5 CS CCN(CC)CCNC1=NC=C(C=C1)N2C=CC(=CC2=O)OCC3=NC=C(C=C3)Cl
DMRZMH5 IK QZSXDTLVUJGVDX-UHFFFAOYSA-N
DMRZMH5 IU 4-[(5-chloropyridin-2-yl)methoxy]-1-[6-[2-(diethylamino)ethylamino]pyridin-3-yl]pyridin-2-one
DM1N5UH ID DM1N5UH
DM1N5UH DN PMID25522065-Compound-22
DM1N5UH HS Patented
DM1N5UH CP GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui LU, Shi WEI, Shuai YANG, Nianyong ZHANG, Zhiliu
DM1N5UH DT Small molecular drug
DM1N5UH PC 49793263
DM1N5UH MW 437.9
DM1N5UH FM C23H24ClN5O2
DM1N5UH IC InChI=1S/C23H24ClN5O2/c1-22-13-23(22,25-2)15-28(14-22)20-6-5-18(11-27-20)29-8-7-19(9-21(29)30)31-12-17-4-3-16(24)10-26-17/h3-11,25H,12-15H2,1-2H3/t22-,23-/m0/s1
DM1N5UH CS C[C@@]12C[C@@]1(CN(C2)C3=NC=C(C=C3)N4C=CC(=CC4=O)OCC5=NC=C(C=C5)Cl)NC
DM1N5UH IK KROAARZZGJOXPL-GOTSBHOMSA-N
DM1N5UH IU 4-[(5-chloropyridin-2-yl)methoxy]-1-[6-[(1S,5R)-1-methyl-5-(methylamino)-3-azabicyclo[3.1.0]hexan-3-yl]pyridin-3-yl]pyridin-2-one
DMHSGPU ID DMHSGPU
DMHSGPU DN PMID25522065-Compound-23
DMHSGPU HS Patented
DMHSGPU CP GLAXOSMITHKLINE LLC CHRISTENSEN, Siegfried, Benjamin, IV QIN, Donghui CHEN, Shuhui LU, Shi
DMHSGPU DT Small molecular drug
DMHSGPU PC 49793260
DMHSGPU MW 451.9
DMHSGPU FM C23H22ClN5O3
DMHSGPU IC InChI=1S/C23H22ClN5O3/c24-16-1-2-17(26-12-16)14-32-19-5-10-28(21(30)11-19)18-3-4-20(27-13-18)29-15-23(22(29)31)6-8-25-9-7-23/h1-5,10-13,25H,6-9,14-15H2
DMHSGPU CS C1CNCCC12CN(C2=O)C3=NC=C(C=C3)N4C=CC(=CC4=O)OCC5=NC=C(C=C5)Cl
DMHSGPU IK SIMRWGQXBPBXAH-UHFFFAOYSA-N
DMHSGPU IU 2-[5-[4-[(5-chloropyridin-2-yl)methoxy]-2-oxopyridin-1-yl]pyridin-2-yl]-2,7-diazaspiro[3.5]nonan-3-one
DM9MLQ6 ID DM9MLQ6
DM9MLQ6 DN PMID25522065-Compound-24
DM9MLQ6 HS Patented
DM9MLQ6 CP GLAXOSMITHKLINE LLC QIN, Donghui CHRISTENSEN, Sieg WU, Chengde ZHANG, Zhiliu YU, Haiyu YUAN, Jiangxing
DM9MLQ6 DT Small molecular drug
DM9MLQ6 PC 71745113
DM9MLQ6 MW 511.7
DM9MLQ6 FM C26H29N3O4S2
DM9MLQ6 IC InChI=1S/C26H29N3O4S2/c1-18-17-34-25(28-18)16-33-24-6-9-29(26(30)14-24)23-5-4-20-12-19(2-3-21(20)13-23)15-27-22-7-10-35(31,32)11-8-22/h2-3,6,9,12-14,17,22,27H,4-5,7-8,10-11,15-16H2,1H3
DM9MLQ6 CS CC1=CSC(=N1)COC2=CC(=O)N(C=C2)C3=CC4=C(CC3)C=C(C=C4)CNC5CCS(=O)(=O)CC5
DM9MLQ6 IK XVQJOVCBLFUQMO-UHFFFAOYSA-N
DM9MLQ6 IU 1-[6-[[(1,1-dioxothian-4-yl)amino]methyl]-3,4-dihydronaphthalen-2-yl]-4-[(4-methyl-1,3-thiazol-2-yl)methoxy]pyridin-2-one
DMUM3YW ID DMUM3YW
DMUM3YW DN PMID25522065-Compound-25
DMUM3YW HS Patented
DMUM3YW CP GLAXOSMITHKLINE LLC QIN, Donghui CHRISTENSEN, IV, Siegfried Benjamin WU, Chengde ZHANG, Zhiliu YU, Haiyu YUAN, Jiangxing LIN, Xiaojuan XU, Shanli LV, Maoyun YAO, Chen LI, Lei HUANG, Xing GAO, Min
DMUM3YW DT Small molecular drug
DMUM3YW PC 72195244
DMUM3YW MW 478
DMUM3YW FM C28H32ClN3O2
DMUM3YW IC InChI=1S/C28H32ClN3O2/c1-20(2)31-13-12-30-18-22-3-6-24-16-26(10-7-23(24)15-22)32-14-11-27(17-28(32)33)34-19-21-4-8-25(29)9-5-21/h3-6,8-9,11,14-17,20,30-31H,7,10,12-13,18-19H2,1-2H3
DMUM3YW CS CC(C)NCCNCC1=CC2=C(C=C1)C=C(CC2)N3C=CC(=CC3=O)OCC4=CC=C(C=C4)Cl
DMUM3YW IK SCTPFHKOHPCDLG-UHFFFAOYSA-N
DMUM3YW IU 4-[(4-chlorophenyl)methoxy]-1-[6-[[2-(propan-2-ylamino)ethylamino]methyl]-3,4-dihydronaphthalen-2-yl]pyridin-2-one
DMY07NA ID DMY07NA
DMY07NA DN PMID25522065-Compound-26
DMY07NA HS Patented
DMY07NA DT Small molecular drug
DMXN4KB ID DMXN4KB
DMXN4KB DN PMID25522065-Compound-27
DMXN4KB HS Patented
DMXN4KB DT Small molecular drug
DMXN4KB PC 71483227
DMXN4KB MW 467.5
DMXN4KB FM C23H23F2N7O2
DMXN4KB IC InChI=1S/C23H23F2N7O2/c1-34-22-21(28-19-9-16(24)17(25)10-20(19)29-22)30-23(33)27-15-4-6-32(7-5-15)12-13-2-3-14-11-26-31-18(14)8-13/h2-3,8-11,15H,4-7,12H2,1H3,(H,26,31)(H2,27,28,30,33)
DMXN4KB CS COC1=NC2=CC(=C(C=C2N=C1NC(=O)NC3CCN(CC3)CC4=CC5=C(C=C4)C=NN5)F)F
DMXN4KB IK XSQADOWIAZCVIY-UHFFFAOYSA-N
DMXN4KB IU 1-(6,7-difluoro-3-methoxyquinoxalin-2-yl)-3-[1-(1H-indazol-6-ylmethyl)piperidin-4-yl]urea
DMB93QU ID DMB93QU
DMB93QU DN PMID25522065-Compound-28
DMB93QU HS Patented
DMB93QU DT Small molecular drug
DMB93QU PC 71496168
DMB93QU MW 443.9
DMB93QU FM C23H26ClN3O4
DMB93QU IC InChI=1S/C23H26ClN3O4/c1-28-21-14-18(6-9-20(21)30-13-12-27-10-2-3-11-27)23-25-22(31-26-23)16-29-15-17-4-7-19(24)8-5-17/h4-9,14H,2-3,10-13,15-16H2,1H3
DMB93QU CS COC1=C(C=CC(=C1)C2=NOC(=N2)COCC3=CC=C(C=C3)Cl)OCCN4CCCC4
DMB93QU IK KTSBQVGVFAEOBK-UHFFFAOYSA-N
DMB93QU IU 5-[(4-chlorophenyl)methoxymethyl]-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-oxadiazole
DMBNAK9 ID DMBNAK9
DMBNAK9 DN PMID25522065-Compound-29
DMBNAK9 HS Patented
DMBNAK9 DT Small molecular drug
DMBNAK9 PC 60169095
DMBNAK9 MW 461.6
DMBNAK9 FM C26H27N3O3S
DMBNAK9 IC InChI=1S/C26H27N3O3S/c1-31-23-17-20(10-11-22(23)32-16-15-28-13-5-6-14-28)29-18-19-9-12-24(27-25(19)26(29)30)33-21-7-3-2-4-8-21/h2-4,7-12,17H,5-6,13-16,18H2,1H3
DMBNAK9 CS COC1=C(C=CC(=C1)N2CC3=C(C2=O)N=C(C=C3)SC4=CC=CC=C4)OCCN5CCCC5
DMBNAK9 IK PULOMQYOCPKDEH-UHFFFAOYSA-N
DMBNAK9 IU 6-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-2-phenylsulfanyl-5H-pyrrolo[3,4-b]pyridin-7-one
DM54DXT ID DM54DXT
DM54DXT DN PMID25522065-Compound-3
DM54DXT HS Patented
DM54DXT CP ALBANY MOLECULAR RESEARCH, INC
DM54DXT DT Small molecular drug
DM54DXT PC 49869209
DM54DXT MW 438.4
DM54DXT FM C24H21F3N4O
DM54DXT IC InChI=1S/C24H21F3N4O/c1-30-21-3-2-9-28-14-19(21)18-6-5-17(12-22(18)30)31-10-8-15(11-23(31)32)20-7-4-16(13-29-20)24(25,26)27/h4-8,10-13,28H,2-3,9,14H2,1H3
DM54DXT CS CN1C2=C(CNCCC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)C5=NC=C(C=C5)C(F)(F)F
DM54DXT IK KTVJCRABCWFUNK-UHFFFAOYSA-N
DM54DXT IU 1-(6-methyl-2,3,4,5-tetrahydro-1H-azepino[4,3-b]indol-8-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]pyridin-2-one
DMMOV67 ID DMMOV67
DMMOV67 DN PMID25522065-Compound-30
DMMOV67 HS Patented
DMMOV67 DT Small molecular drug
DMMOV67 PC 60169096
DMMOV67 MW 479.6
DMMOV67 FM C26H26FN3O3S
DMMOV67 IC InChI=1S/C26H26FN3O3S/c1-32-23-16-20(7-10-22(23)33-15-14-29-12-2-3-13-29)30-17-18-4-11-24(28-25(18)26(30)31)34-21-8-5-19(27)6-9-21/h4-11,16H,2-3,12-15,17H2,1H3
DMMOV67 CS COC1=C(C=CC(=C1)N2CC3=C(C2=O)N=C(C=C3)SC4=CC=C(C=C4)F)OCCN5CCCC5
DMMOV67 IK IOVNPTLMMFSPCO-UHFFFAOYSA-N
DMMOV67 IU 2-(4-fluorophenyl)sulfanyl-6-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5H-pyrrolo[3,4-b]pyridin-7-one
DMEMBOW ID DMEMBOW
DMEMBOW DN PMID25522065-Compound-31
DMEMBOW HS Patented
DMEMBOW DT Small molecular drug
DMEMBOW PC 71719525
DMEMBOW MW 457.6
DMEMBOW FM C28H31N3O3
DMEMBOW IC InChI=1S/C28H31N3O3/c1-3-20-6-8-21(9-7-20)24-12-10-22-19-31(28(32)27(22)29-24)23-11-13-25(26(18-23)33-2)34-17-16-30-14-4-5-15-30/h6-13,18H,3-5,14-17,19H2,1-2H3
DMEMBOW CS CCC1=CC=C(C=C1)C2=NC3=C(CN(C3=O)C4=CC(=C(C=C4)OCCN5CCCC5)OC)C=C2
DMEMBOW IK JRDLEMTYNVKHFV-UHFFFAOYSA-N
DMEMBOW IU 2-(4-ethylphenyl)-6-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]-5H-pyrrolo[3,4-b]pyridin-7-one
DM5H3YA ID DM5H3YA
DM5H3YA DN PMID25522065-Compound-32
DM5H3YA HS Patented
DM5H3YA DT Small molecular drug
DM5H3YA PC 56835134
DM5H3YA MW 516.6
DM5H3YA FM C30H30F2N4O2
DM5H3YA IC InChI=1S/C30H30F2N4O2/c1-20(37)33-24-7-4-6-22(18-24)21-12-16-35(17-13-21)14-5-15-36-30(38)26-9-3-2-8-25(26)29(34-36)23-10-11-27(31)28(32)19-23/h2-4,6-11,18-19,21H,5,12-17H2,1H3,(H,33,37)
DM5H3YA CS CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCN3C(=O)C4=CC=CC=C4C(=N3)C5=CC(=C(C=C5)F)F
DM5H3YA IK YVVMAGRTTSOPEO-UHFFFAOYSA-N
DM5H3YA IU N-[3-[1-[3-[4-(3,4-difluorophenyl)-1-oxophthalazin-2-yl]propyl]piperidin-4-yl]phenyl]acetamide
DMYMJIW ID DMYMJIW
DMYMJIW DN PMID25522065-Compound-33
DMYMJIW HS Patented
DMYMJIW DT Small molecular drug
DMZDIRQ ID DMZDIRQ
DMZDIRQ DN PMID25522065-Compound-34
DMZDIRQ HS Patented
DMZDIRQ DT Small molecular drug
DMZDIRQ PC 71727344
DMZDIRQ MW 505.7
DMZDIRQ FM C28H35N5O2S
DMZDIRQ IC InChI=1S/C28H35N5O2S/c1-21(34)29-24-7-4-6-23(20-24)22-10-14-31(15-11-22)12-5-13-33-28(35)26-9-3-2-8-25(26)27(30-33)32-16-18-36-19-17-32/h2-4,6-9,20,22H,5,10-19H2,1H3,(H,29,34)
DMZDIRQ CS CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCN3C(=O)C4=CC=CC=C4C(=N3)N5CCSCC5
DMZDIRQ IK XXBGKRFICBGOCH-UHFFFAOYSA-N
DMZDIRQ IU N-[3-[1-[3-(1-oxo-4-thiomorpholin-4-ylphthalazin-2-yl)propyl]piperidin-4-yl]phenyl]acetamide
DM1JAFV ID DM1JAFV
DM1JAFV DN PMID25522065-Compound-35
DM1JAFV HS Patented
DM1JAFV DT Small molecular drug
DM1JAFV PC 70675668
DM1JAFV MW 506.6
DM1JAFV FM C31H30N4O3
DM1JAFV IC InChI=1S/C31H30N4O3/c1-21(36)34-28-4-2-3-25(18-28)24-11-14-35(15-12-24)16-13-33-31(37)30-19-27-17-26(9-10-29(27)38-30)23-7-5-22(20-32)6-8-23/h2-10,17-19,24H,11-16H2,1H3,(H,33,37)(H,34,36)
DM1JAFV CS CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCNC(=O)C3=CC4=C(O3)C=CC(=C4)C5=CC=C(C=C5)C#N
DM1JAFV IK FYWPSNHXRLJIKV-UHFFFAOYSA-N
DM1JAFV IU N-[2-[4-(3-acetamidophenyl)piperidin-1-yl]ethyl]-5-(4-cyanophenyl)-1-benzofuran-2-carboxamide
DMNISGE ID DMNISGE
DMNISGE DN PMID25522065-Compound-36
DMNISGE HS Patented
DMNISGE DT Small molecular drug
DMNISGE PC 72715352
DMNISGE MW 532.6
DMNISGE FM C33H32N4O3
DMNISGE IC InChI=1S/C33H32N4O3/c1-22(38)36-27-6-4-5-25(19-27)23-11-16-37(17-12-23)18-15-35-33(39)31-21-26-20-30(24-9-13-34-14-10-24)28-7-2-3-8-29(28)32(26)40-31/h2-10,13-14,19-21,23H,11-12,15-18H2,1H3,(H,35,39)(H,36,38)
DMNISGE CS CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCNC(=O)C3=CC4=C(O3)C5=CC=CC=C5C(=C4)C6=CC=NC=C6
DMNISGE IK KFXQNHZULSOCEW-UHFFFAOYSA-N
DMNISGE IU N-[2-[4-(3-acetamidophenyl)piperidin-1-yl]ethyl]-5-pyridin-4-ylbenzo[g][1]benzofuran-2-carboxamide
DMH3CK0 ID DMH3CK0
DMH3CK0 DN PMID25522065-Compound-37
DMH3CK0 HS Patented
DMH3CK0 CP MERCK SHARP &amDOHME CORP. LIN, Linus SOLL, Richard DONG, Jingchao WU, Hao SUZUKI, Takao HU, Bin LIU, Dejun HAO, Jinglai XU, Ming
DMH3CK0 DT Small molecular drug
DMH3CK0 PC 46911512
DMH3CK0 MW 397.4
DMH3CK0 FM C23H24FNO4
DMH3CK0 IC InChI=1S/C23H24FNO4/c1-16-12-19(8-9-21(16)29-15-23(2,3)27)25-11-10-20(13-22(25)26)28-14-17-4-6-18(24)7-5-17/h4-13,27H,14-15H2,1-3H3
DMH3CK0 CS CC1=C(C=CC(=C1)N2C=CC(=CC2=O)OCC3=CC=C(C=C3)F)OCC(C)(C)O
DMH3CK0 IK WCMFUWBVIKILDJ-UHFFFAOYSA-N
DMH3CK0 IU 4-[(4-fluorophenyl)methoxy]-1-[4-(2-hydroxy-2-methylpropoxy)-3-methylphenyl]pyridin-2-one
DMQLBAJ ID DMQLBAJ
DMQLBAJ DN PMID25522065-Compound-38
DMQLBAJ HS Patented
DMQLBAJ CP MERCK SHARP &amDOHME CORP. LIN, Linus SOLL, Richard DONG, Jingchao WU, Hao SUZUKI, Takao HU, Bin LIU, Dejun HAO, Jinglai XU, Ming
DMQLBAJ DT Small molecular drug
DMQLBAJ PC 53476614
DMQLBAJ MW 395.4
DMQLBAJ FM C23H22FNO4
DMQLBAJ IC InChI=1S/C23H22FNO4/c1-16-12-19(6-7-21(16)29-15-23(27)9-10-23)25-11-8-20(13-22(25)26)28-14-17-2-4-18(24)5-3-17/h2-8,11-13,27H,9-10,14-15H2,1H3
DMQLBAJ CS CC1=C(C=CC(=C1)N2C=CC(=CC2=O)OCC3=CC=C(C=C3)F)OCC4(CC4)O
DMQLBAJ IK DSXGYSJOEHCCMA-UHFFFAOYSA-N
DMQLBAJ IU 4-[(4-fluorophenyl)methoxy]-1-[4-[(1-hydroxycyclopropyl)methoxy]-3-methylphenyl]pyridin-2-one
DM5YMQH ID DM5YMQH
DM5YMQH DN PMID25522065-Compound-39
DM5YMQH HS Patented
DM5YMQH CP MERCK SHARP & DOHME CORP. MSD K.K. LIN, Linus, S. SUZUKI, Takao
DM5YMQH DT Small molecular drug
DM84U7F ID DM84U7F
DM84U7F DN PMID25522065-Compound-4
DM84U7F HS Patented
DM84U7F CP ALBANY MOLECULAR RESEARCH, INC
DM84U7F DT Small molecular drug
DM84U7F PC 49868803
DM84U7F MW 439.4
DM84U7F FM C23H20F3N5O
DM84U7F IC InChI=1S/C23H20F3N5O/c1-30-19-7-10-27-9-6-17(19)16-3-2-15(13-20(16)30)31-11-8-14(12-22(31)32)18-4-5-21(29-28-18)23(24,25)26/h2-5,8,11-13,27H,6-7,9-10H2,1H3
DM84U7F CS CN1C2=C(CCNCC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)C5=NN=C(C=C5)C(F)(F)F
DM84U7F IK RTHGRJZORFROEE-UHFFFAOYSA-N
DM84U7F IU 1-(6-methyl-2,3,4,5-tetrahydro-1H-azepino[4,5-b]indol-8-yl)-4-[6-(trifluoromethyl)pyridazin-3-yl]pyridin-2-one
DMCIQ01 ID DMCIQ01
DMCIQ01 DN PMID25522065-Compound-40
DMCIQ01 HS Patented
DMCIQ01 CP MERCK SHARP & DOHME CORP. MSD K.K. LIN, Linus, S. SUZUKI, Takao
DMCIQ01 DT Small molecular drug
DMWALOT ID DMWALOT
DMWALOT DN PMID25522065-Compound-41
DMWALOT HS Patented
DMWALOT CP RICHTER GEDEON NYRT [HU]
DMWALOT DT Small molecular drug
DMWALOT PC 70982502
DMWALOT MW 510
DMWALOT FM C26H24ClN3O4S
DMWALOT IC InChI=1S/C26H24ClN3O4S/c1-32-22-10-19(6-7-21(22)34-9-8-29-12-26(13-29)14-33-15-26)30-16-28-20-11-23(35-24(20)25(30)31)17-2-4-18(27)5-3-17/h2-7,10-11,16H,8-9,12-15H2,1H3
DMWALOT CS COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OCCN5CC6(C5)COC6
DMWALOT IK RYWKRAVYOFTFPJ-UHFFFAOYSA-N
DMWALOT IU 6-(4-chlorophenyl)-3-[3-methoxy-4-[2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)ethoxy]phenyl]thieno[3,2-d]pyrimidin-4-one
DMAUO6C ID DMAUO6C
DMAUO6C DN PMID25522065-Compound-42
DMAUO6C HS Patented
DMAUO6C CP OMORI, Naoki et al
DMAUO6C DT Small molecular drug
DMS1FKC ID DMS1FKC
DMS1FKC DN PMID25522065-Compound-43
DMS1FKC HS Patented
DMS1FKC CP OMORI, Naoki et al
DMS1FKC DT Small molecular drug
DMJKOFB ID DMJKOFB
DMJKOFB DN PMID25522065-Compound-44
DMJKOFB HS Patented
DMJKOFB CP TAISHO PHARMACEUTICAL CO., LTD
DMJKOFB DT Small molecular drug
DMJKOFB PC 45255788
DMJKOFB MW 393.5
DMJKOFB FM C23H27N3O3
DMJKOFB IC InChI=1S/C23H27N3O3/c1-29-20-4-2-3-18(14-20)23(28)24-19-9-11-26(12-10-19)15-16-5-6-17-7-8-22(27)25-21(17)13-16/h2-6,13-14,19H,7-12,15H2,1H3,(H,24,28)(H,25,27)
DMJKOFB CS COC1=CC=CC(=C1)C(=O)NC2CCN(CC2)CC3=CC4=C(CCC(=O)N4)C=C3
DMJKOFB IK SWKXQUKCAIDRHK-UHFFFAOYSA-N
DMJKOFB IU 3-methoxy-N-[1-[(2-oxo-3,4-dihydro-1H-quinolin-7-yl)methyl]piperidin-4-yl]benzamide
DMONJLT ID DMONJLT
DMONJLT DN PMID25522065-Compound-45
DMONJLT HS Patented
DMONJLT CP TAKEDA PHARMACEUTICAL COMPANY LIMITED MASADA, Shinichi
DMONJLT DT Small molecular drug
DMONJLT PC 53303548
DMONJLT MW 435.6
DMONJLT FM C26H33N3O3
DMONJLT IC InChI=1S/C26H33N3O3/c1-17-22-13-20(14-27-16-26(2,3)31)29(4)24(22)12-11-23(17)28-25(30)19-7-9-21(10-8-19)32-15-18-5-6-18/h7-13,18,27,31H,5-6,14-16H2,1-4H3,(H,28,30)
DMONJLT CS CC1=C(C=CC2=C1C=C(N2C)CNCC(C)(C)O)NC(=O)C3=CC=C(C=C3)OCC4CC4
DMONJLT IK LYUFDXWEPKVSLW-UHFFFAOYSA-N
DMONJLT IU 4-(cyclopropylmethoxy)-N-[2-[[(2-hydroxy-2-methylpropyl)amino]methyl]-1,4-dimethylindol-5-yl]benzamide
DMBH97R ID DMBH97R
DMBH97R DN PMID25522065-Compound-46
DMBH97R HS Patented
DMBH97R CP TAKEDA PHARMACEUTICAL COMPANY LIMITED MASADA, Shinichi
DMBH97R DT Small molecular drug
DMBH97R PC 53303549
DMBH97R MW 491.6
DMBH97R FM C29H37N3O4
DMBH97R IC InChI=1S/C29H37N3O4/c1-20-26-16-23(18-30-17-21-11-14-34-15-12-21)32(2)28(26)10-9-27(20)31-29(33)22-5-7-24(8-6-22)36-19-25-4-3-13-35-25/h5-10,16,21,25,30H,3-4,11-15,17-19H2,1-2H3,(H,31,33)/t25-/m0/s1
DMBH97R CS CC1=C(C=CC2=C1C=C(N2C)CNCC3CCOCC3)NC(=O)C4=CC=C(C=C4)OC[C@@H]5CCCO5
DMBH97R IK ODYOYEADBNGJGQ-VWLOTQADSA-N
DMBH97R IU N-[1,4-dimethyl-2-[(oxan-4-ylmethylamino)methyl]indol-5-yl]-4-[[(2S)-oxolan-2-yl]methoxy]benzamide
DMXRI5J ID DMXRI5J
DMXRI5J DN PMID25522065-Compound-47
DMXRI5J HS Patented
DMXRI5J DT Small molecular drug
DMXRI5J PC 72198297
DMXRI5J MW 446.9
DMXRI5J FM C25H19ClN2O4
DMXRI5J IC InChI=1S/C25H19ClN2O4/c1-30-23-12-18(6-7-21(23)31-15-25(14-27)9-10-25)28-11-8-20-19(24(28)29)13-22(32-20)16-2-4-17(26)5-3-16/h2-8,11-13H,9-10,15H2,1H3
DMXRI5J CS COC1=C(C=CC(=C1)N2C=CC3=C(C2=O)C=C(O3)C4=CC=C(C=C4)Cl)OCC5(CC5)C#N
DMXRI5J IK RMJJVTXKEKNHEK-UHFFFAOYSA-N
DMXRI5J IU 1-[[4-[2-(4-chlorophenyl)-4-oxofuro[3,2-c]pyridin-5-yl]-2-methoxyphenoxy]methyl]cyclopropane-1-carbonitrile
DMHI4L6 ID DMHI4L6
DMHI4L6 DN PMID25522065-Compound-48
DMHI4L6 HS Patented
DMHI4L6 DT Small molecular drug
DMHI4L6 PC 71816529
DMHI4L6 MW 439.9
DMHI4L6 FM C24H22ClNO5
DMHI4L6 IC InChI=1S/C24H22ClNO5/c1-24(2,28)14-30-20-9-8-17(12-22(20)29-3)26-11-10-19-18(23(26)27)13-21(31-19)15-4-6-16(25)7-5-15/h4-13,28H,14H2,1-3H3
DMHI4L6 CS CC(C)(COC1=C(C=C(C=C1)N2C=CC3=C(C2=O)C=C(O3)C4=CC=C(C=C4)Cl)OC)O
DMHI4L6 IK UBVMNCOEYQICSI-UHFFFAOYSA-N
DMHI4L6 IU 2-(4-chlorophenyl)-5-[4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl]furo[3,2-c]pyridin-4-one
DMNI03Z ID DMNI03Z
DMNI03Z DN PMID25522065-Compound-49
DMNI03Z HS Patented
DMNI03Z DT Small molecular drug
DMNI03Z PC 71816518
DMNI03Z MW 415.9
DMNI03Z FM C24H18ClN3O2
DMNI03Z IC InChI=1S/C24H18ClN3O2/c1-14-23(16-2-3-16)26-22-9-8-18(13-28(14)22)27-11-10-20-19(24(27)29)12-21(30-20)15-4-6-17(25)7-5-15/h4-13,16H,2-3H2,1H3
DMNI03Z CS CC1=C(N=C2N1C=C(C=C2)N3C=CC4=C(C3=O)C=C(O4)C5=CC=C(C=C5)Cl)C6CC6
DMNI03Z IK FBRSISPMXWGFQN-UHFFFAOYSA-N
DMNI03Z IU 2-(4-chlorophenyl)-5-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)furo[3,2-c]pyridin-4-one
DMA8G6B ID DMA8G6B
DMA8G6B DN PMID25522065-Compound-5
DMA8G6B HS Patented
DMA8G6B CP ALBANY MOLECULAR RESEARCH, INC
DMA8G6B DT Small molecular drug
DMA8G6B PC 50903067
DMA8G6B MW 430.5
DMA8G6B FM C25H23FN4O2
DMA8G6B IC InChI=1S/C25H23FN4O2/c1-29-22-11-18(5-6-20(22)25-21-7-4-16(28-21)10-23(25)29)30-9-8-19(12-24(30)31)32-14-17-3-2-15(26)13-27-17/h2-3,5-6,8-9,11-13,16,21,28H,4,7,10,14H2,1H3
DMA8G6B CS CN1C2=C(C3CCC(C2)N3)C4=C1C=C(C=C4)N5C=CC(=CC5=O)OCC6=NC=C(C=C6)F
DMA8G6B IK WIHBSZQMVJUBGL-UHFFFAOYSA-N
DMA8G6B IU 4-[(5-fluoropyridin-2-yl)methoxy]-1-(9-methyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraen-6-yl)pyridin-2-one
DMBWA0V ID DMBWA0V
DMBWA0V DN PMID25522065-Compound-50
DMBWA0V HS Patented
DMBWA0V CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMBWA0V DT Small molecular drug
DMBWA0V PC 71660914
DMBWA0V MW 377.4
DMBWA0V FM C22H20FN3O2
DMBWA0V IC InChI=1S/C22H20FN3O2/c1-3-21-24-19-9-8-17(12-20(19)25(21)2)26-11-10-18(13-22(26)27)28-14-15-4-6-16(23)7-5-15/h4-13H,3,14H2,1-2H3
DMBWA0V CS CCC1=NC2=C(N1C)C=C(C=C2)N3C=CC(=CC3=O)OCC4=CC=C(C=C4)F
DMBWA0V IK UDLQRAVGQUJISV-UHFFFAOYSA-N
DMBWA0V IU 1-(2-ethyl-3-methylbenzimidazol-5-yl)-4-[(4-fluorophenyl)methoxy]pyridin-2-one
DMEU48I ID DMEU48I
DMEU48I DN PMID25522065-Compound-51
DMEU48I HS Patented
DMEU48I CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMEU48I DT Small molecular drug
DMEU48I PC 71660917
DMEU48I MW 363.4
DMEU48I FM C21H18FN3O2
DMEU48I IC InChI=1S/C21H18FN3O2/c1-14-23-19-8-7-17(11-20(19)24(14)2)25-10-9-18(12-21(25)26)27-13-15-3-5-16(22)6-4-15/h3-12H,13H2,1-2H3
DMEU48I CS CC1=NC2=C(N1C)C=C(C=C2)N3C=CC(=CC3=O)OCC4=CC=C(C=C4)F
DMEU48I IK WSKXMIQVCMWHGL-UHFFFAOYSA-N
DMEU48I IU 1-(2,3-dimethylbenzimidazol-5-yl)-4-[(4-fluorophenyl)methoxy]pyridin-2-one
DMU1PEZ ID DMU1PEZ
DMU1PEZ DN PMID25522065-Compound-6
DMU1PEZ HS Patented
DMU1PEZ CP ALBANY MOLECULAR RESEARCH, INC
DMU1PEZ DT Small molecular drug
DMU1PEZ PC 50903153
DMU1PEZ MW 450.5
DMU1PEZ FM C25H21F3N4O
DMU1PEZ IC InChI=1S/C25H21F3N4O/c1-31-20-12-17(4-5-18(20)24-19-6-3-16(30-19)11-21(24)31)32-9-8-14(10-23(32)33)15-2-7-22(29-13-15)25(26,27)28/h2,4-5,7-10,12-13,16,19,30H,3,6,11H2,1H3
DMU1PEZ CS CN1C2=C(C3CCC(C2)N3)C4=C1C=C(C=C4)N5C=CC(=CC5=O)C6=CN=C(C=C6)C(F)(F)F
DMU1PEZ IK NAYVWRUHNOMLBF-UHFFFAOYSA-N
DMU1PEZ IU 1-(9-methyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraen-6-yl)-4-[6-(trifluoromethyl)pyridin-3-yl]pyridin-2-one
DMYZMX6 ID DMYZMX6
DMYZMX6 DN PMID25522065-Compound-7
DMYZMX6 HS Patented
DMYZMX6 CP ALBANY MOLECULAR RESEARCH, INC
DMYZMX6 DT Small molecular drug
DMYZMX6 PC 58092191
DMYZMX6 MW 414.5
DMYZMX6 FM C26H30N4O
DMYZMX6 IC InChI=1S/C26H30N4O/c1-28-23-16-20(8-9-21(23)26-22-10-7-19(27-22)15-24(26)28)30-14-13-29(17-25(30)31)12-11-18-5-3-2-4-6-18/h2-6,8-9,16,19,22,27H,7,10-15,17H2,1H3
DMYZMX6 CS CN1C2=C(C3CCC(C2)N3)C4=C1C=C(C=C4)N5CCN(CC5=O)CCC6=CC=CC=C6
DMYZMX6 IK JXBCIEBMTZBYLB-UHFFFAOYSA-N
DMYZMX6 IU 1-(9-methyl-9,15-diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3(8),4,6-tetraen-6-yl)-4-(2-phenylethyl)piperazin-2-one
DMJMCKD ID DMJMCKD
DMJMCKD DN PMID25522065-Compound-8
DMJMCKD HS Patented
DMJMCKD CP ALBANY MOLECULAR RESEARCH, INC
DMJMCKD DT Small molecular drug
DMJMCKD PC 49836016
DMJMCKD MW 411.5
DMJMCKD FM C26H25N3O2
DMJMCKD IC InChI=1S/C26H25N3O2/c1-27-24-13-20(7-8-22(24)23-16-28-11-9-19(15-28)26(23)27)29-12-10-21(14-25(29)30)31-17-18-5-3-2-4-6-18/h2-8,10,12-14,19H,9,11,15-17H2,1H3
DMJMCKD CS CN1C2=C(C=CC(=C2)N3C=CC(=CC3=O)OCC4=CC=CC=C4)C5=C1C6CCN(C6)C5
DMJMCKD IK UPOGSKZLDRHZBU-UHFFFAOYSA-N
DMJMCKD IU 1-(3-methyl-3,12-diazatetracyclo[10.2.1.02,10.04,9]pentadeca-2(10),4(9),5,7-tetraen-6-yl)-4-phenylmethoxypyridin-2-one
DMAMRPW ID DMAMRPW
DMAMRPW DN PMID25522065-Compound-9
DMAMRPW HS Patented
DMAMRPW DT Small molecular drug
DMAMRPW PC 57524505
DMAMRPW MW 386.4
DMAMRPW FM C23H22N4O2
DMAMRPW IC InChI=1S/C23H22N4O2/c1-26-20-9-11-24-14-19(20)18-7-8-21(25-23(18)26)27-12-10-17(13-22(27)28)29-15-16-5-3-2-4-6-16/h2-8,10,12-13,24H,9,11,14-15H2,1H3
DMAMRPW CS CN1C2=C(CNCC2)C3=C1N=C(C=C3)N4C=CC(=CC4=O)OCC5=CC=CC=C5
DMAMRPW IK SXWOYRGICAISET-UHFFFAOYSA-N
DMAMRPW IU 1-(8-methyl-4,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-11-yl)-4-phenylmethoxypyridin-2-one
DM4GQJH ID DM4GQJH
DM4GQJH DN PMID25553724-Compound-EP20132578214 2
DM4GQJH HS Patented
DM4GQJH CP Korea Ocean Research and Development Institute
DMM3QEW ID DMM3QEW
DMM3QEW DN PMID25553724-Compound-US2011000295210
DMM3QEW HS Patented
DMM3QEW DT Small molecular drug
DMM3QEW DE Immune System disease
DMZCO6J ID DMZCO6J
DMZCO6J DN PMID25553724-Compound-US2011788838110
DMZCO6J HS Patented
DMZCO6J DT Small molecular drug
DMZCO6J DE Immune System disease
DMH4DMY ID DMH4DMY
DMH4DMY DN PMID25553724-Compound-US2011796857710
DMH4DMY HS Patented
DMH4DMY DT Small molecular drug
DMH4DMY DE Immune System disease
DMIZ64O ID DMIZ64O
DMIZ64O DN PMID25553724-Compound-US2011799419010
DMIZ64O HS Patented
DMIZ64O DT Small molecular drug
DMIZ64O DE Immune System disease
DMZ96CG ID DMZ96CG
DMZ96CG DN PMID25553724-Compound-US2011801300410
DMZ96CG HS Patented
DMZ96CG DT Small molecular drug
DMZ96CG DE Immune System disease
DMCDHZT ID DMCDHZT
DMCDHZT DN PMID25553724-Compound-US2011803494010
DMCDHZT HS Patented
DMCDHZT DT Small molecular drug
DMCDHZT DE Immune System disease
DMIAV5M ID DMIAV5M
DMIAV5M DN PMID25553724-Compound-US2011806744710
DMIAV5M HS Patented
DMIAV5M DT Small molecular drug
DMIAV5M DE Immune System disease
DM9KAF1 ID DM9KAF1
DM9KAF1 DN PMID25553724-Compound-US2012810604610
DM9KAF1 HS Patented
DM9KAF1 DT Small molecular drug
DM9KAF1 DE Immune System disease
DMS7RYP ID DMS7RYP
DMS7RYP DN PMID25553724-Compound-US2012819831110
DMS7RYP HS Patented
DMS7RYP DT Small molecular drug
DMS7RYP DE Immune System disease
DMDQ6H7 ID DMDQ6H7
DMDQ6H7 DN PMID25553724-Compound-US2012820715110
DMDQ6H7 HS Patented
DMDQ6H7 DT Small molecular drug
DMDQ6H7 DE Immune System disease
DMCUMSV ID DMCUMSV
DMCUMSV DN PMID25553724-Compound-US2012830453910
DMCUMSV HS Patented
DMCUMSV DT Small molecular drug
DMCUMSV DE Immune System disease
DMFCE51 ID DMFCE51
DMFCE51 DN PMID25553724-Compound-US2012832440110
DMFCE51 HS Patented
DMFCE51 DT Small molecular drug
DMFCE51 DE Immune System disease
DMUBZO3 ID DMUBZO3
DMUBZO3 DN PMID25553724-Compound-US20130116324 2
DMUBZO3 HS Patented
DMUBZO3 CP Korea Ocean Research and Development Institute
DMYGB2O ID DMYGB2O
DMYGB2O DN PMID25553724-Compound-US20130237529 35
DMYGB2O HS Patented
DM9NGDI ID DM9NGDI
DM9NGDI DN PMID25553724-Compound-US20130237529 36
DM9NGDI HS Patented
DMV7SQH ID DMV7SQH
DMV7SQH DN PMID25553724-Compound-US20138552206 4
DMV7SQH HS Patented
DMRVE7Z ID DMRVE7Z
DMRVE7Z DN PMID25553724-Compound-US20138552206 5
DMRVE7Z HS Patented
DM5ATIV ID DM5ATIV
DM5ATIV DN PMID25553724-Compound-WO2011127048 31
DM5ATIV HS Patented
DM5ATIV CP VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina
DMH3NOZ ID DMH3NOZ
DMH3NOZ DN PMID25553724-Compound-WO2011127048 32
DMH3NOZ HS Patented
DMH3NOZ CP VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina
DMH7496 ID DMH7496
DMH7496 DN PMID25553724-Compound-WO2011127048 33
DMH7496 HS Patented
DMH7496 CP VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina
DM4YE8W ID DM4YE8W
DM4YE8W DN PMID25553724-Compound-WO2011127048 34
DM4YE8W HS Patented
DM4YE8W CP VALIDUS BIOPHARMA MCCALL, John, M. HOFFMAN, Eric NAGARAJU, Kanneboyina
DMPQ175 ID DMPQ175
DMPQ175 DN PMID25553724-Compound-WO2011152671 2
DMPQ175 HS Patented
DMPQ175 CP KOREA OCEAN RESEARCH AND DEVELOPMENT INSITUTE YIM, Joung Han KIM, Il Chan LEE, Sung Gu KIM, Doc Kyu HAN, Se Jong LEE, Hyoung Seok
DMPFMSJ ID DMPFMSJ
DMPFMSJ DN PMID25553724-Compound-WO2013082253 31
DMPFMSJ HS Patented
DMPFMSJ CP REVERAGEN BIOPHARMA, INC
DMXYSO1 ID DMXYSO1
DMXYSO1 DN PMID25553724-Compound-WO2013082253 32
DMXYSO1 HS Patented
DMXYSO1 CP REVERAGEN BIOPHARMA, INC
DMR1YH9 ID DMR1YH9
DMR1YH9 DN PMID25553724-Compound-WO2013082253 33
DMR1YH9 HS Patented
DMR1YH9 CP REVERAGEN BIOPHARMA, INC
DML1U69 ID DML1U69
DML1U69 DN PMID25553724-Compound-WO2013082253 34
DML1U69 HS Patented
DML1U69 CP REVERAGEN BIOPHARMA, INC
DMA2IMQ ID DMA2IMQ
DMA2IMQ DN PMID25623274-Compound-WO2014132220C1
DMA2IMQ HS Patented
DMA2IMQ CP NOVARTIS AG BRUCE, Ian CHAMOIN, Sylvie COLLINGWOOD, Stephen Paul FURET, Pascal FURMINGER, Vikki LEWIS, Sarah LOREN, Jon LV, Lin MOLTENI, Valentina SAUNDERS, Alex Michael SHAW, Duncan TURNER, Roy YEH, Vince
DMA2IMQ DT Small molecular drug
DMA2IMQ DE Pulmonary arterial hypertension
DMXEZWP ID DMXEZWP
DMXEZWP DN PMID25623274-Compound-WO2014132220C2
DMXEZWP HS Patented
DMXEZWP CP NOVARTIS AG BRUCE, Ian CHAMOIN, Sylvie COLLINGWOOD, Stephen Paul FURET, Pascal FURMINGER, Vikki LEWIS, Sarah LOREN, Jon LV, Lin MOLTENI, Valentina SAUNDERS, Alex Michael SHAW, Duncan TURNER, Roy YEH, Vince
DMXEZWP DT Small molecular drug
DMXEZWP DE Pulmonary arterial hypertension
DM8POGS ID DM8POGS
DM8POGS DN PMID25656651-Compound-10
DM8POGS HS Patented
DM8POGS CP IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
DM8POGS DT Small molecular drug
DM8POGS PC 44129660
DM8POGS MW 418.4
DM8POGS FM C20H17F3N4O3
DM8POGS IC InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-6-4-15(5-7-16)27-18-11-17(25-12-26-18)13-2-1-3-14(10-13)19(29)24-8-9-28/h1-7,10-12,28H,8-9H2,(H,24,29)(H,25,26,27)
DM8POGS CS C1=CC(=CC(=C1)C(=O)NCCO)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F
DM8POGS IK IIQUYGWWHIHOCF-UHFFFAOYSA-N
DM8POGS IU N-(2-hydroxyethyl)-3-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
DM8POGS CA CAS 778277-15-9
DM5ECH2 ID DM5ECH2
DM5ECH2 DN PMID25656651-Compound-11a
DM5ECH2 HS Patented
DM5ECH2 CP CURIS, INC
DM5ECH2 DT Small molecular drug
DM5ECH2 PC 24756907
DM5ECH2 MW 547.1
DM5ECH2 FM C24H31ClN8O3S
DM5ECH2 IC InChI=1S/C24H31ClN8O3S/c1-15-7-6-8-17(25)22(15)32-23(35)18-14-28-24(37-18)31-20-13-19(29-16(2)30-20)27-12-11-26-10-5-3-4-9-21(34)33-36/h6-8,13-14,26,36H,3-5,9-12H2,1-2H3,(H,32,35)(H,33,34)(H2,27,28,29,30,31)
DM5ECH2 CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)NCCNCCCCCC(=O)NO)C
DM5ECH2 IK FVPJJDVBEPNQCD-UHFFFAOYSA-N
DM5ECH2 IU N-(2-chloro-6-methylphenyl)-2-[[6-[2-[[6-(hydroxyamino)-6-oxohexyl]amino]ethylamino]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DM5ECH2 DE Chronic myeloid leukaemia
DMP580J ID DMP580J
DMP580J DN PMID25656651-Compound-11b
DMP580J HS Patented
DMP580J CP CURIS, INC
DMP580J DT Small molecular drug
DMP580J DE Chronic myeloid leukaemia
DMAYINQ ID DMAYINQ
DMAYINQ DN PMID25656651-Compound-11c
DMAYINQ HS Patented
DMAYINQ CP CURIS, INC
DMAYINQ DT Small molecular drug
DMAYINQ PC 24856901
DMAYINQ MW 518
DMAYINQ FM C23H28ClN7O3S
DMAYINQ IC InChI=1S/C23H28ClN7O3S/c1-14-8-7-9-16(24)21(14)30-22(33)17-13-26-23(35-17)29-19-12-18(27-15(2)28-19)25-11-6-4-3-5-10-20(32)31-34/h7-9,12-13,34H,3-6,10-11H2,1-2H3,(H,30,33)(H,31,32)(H2,25,26,27,28,29)
DMAYINQ CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)NCCCCCCC(=O)NO)C
DMAYINQ IK UHHSKEMLNIATAI-UHFFFAOYSA-N
DMAYINQ IU N-(2-chloro-6-methylphenyl)-2-[[6-[[7-(hydroxyamino)-7-oxoheptyl]amino]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMAYINQ DE Chronic myeloid leukaemia
DM0C9YL ID DM0C9YL
DM0C9YL DN PMID25656651-Compound-15a
DM0C9YL HS Patented
DM0C9YL DT Small molecular drug
DM0C9YL PC 25156740
DM0C9YL MW 580.6
DM0C9YL FM C32H23F3N6O2
DM0C9YL IC InChI=1S/C32H23F3N6O2/c1-20-18-41(19-38-20)24-15-22(32(33,34)35)14-23(16-24)39-31(42)28-6-4-5-21-13-25(8-9-27(21)28)43-26-10-12-37-30(17-26)40-29-7-2-3-11-36-29/h2-19H,1H3,(H,39,42)(H,36,37,40)
DM0C9YL CS CC1=CN(C=N1)C2=CC(=CC(=C2)NC(=O)C3=CC=CC4=C3C=CC(=C4)OC5=CC(=NC=C5)NC6=CC=CC=N6)C(F)(F)F
DM0C9YL IK YLFSQHDNZXYOOB-UHFFFAOYSA-N
DM0C9YL IU N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-6-[2-(pyridin-2-ylamino)pyridin-4-yl]oxynaphthalene-1-carboxamide
DMJ4DRI ID DMJ4DRI
DMJ4DRI DN PMID25656651-Compound-15b
DMJ4DRI HS Patented
DMJ4DRI DT Small molecular drug
DMJ4DRI PC 59314436
DMJ4DRI MW 571.5
DMJ4DRI FM C31H24F3N5O3
DMJ4DRI IC InChI=1S/C31H24F3N5O3/c1-17-36-16-27(37-17)20-11-21(31(32,33)34)14-22(12-20)38-30(41)26-4-2-3-19-13-23(7-8-25(19)26)42-24-9-10-35-28(15-24)39-29(40)18-5-6-18/h2-4,7-16,18H,5-6H2,1H3,(H,36,37)(H,38,41)(H,35,39,40)
DMJ4DRI CS CC1=NC=C(N1)C2=CC(=CC(=C2)NC(=O)C3=CC=CC4=C3C=CC(=C4)OC5=CC(=NC=C5)NC(=O)C6CC6)C(F)(F)F
DMJ4DRI IK LFBDVPDAUGENGX-UHFFFAOYSA-N
DMJ4DRI IU 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(2-methyl-1H-imidazol-5-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide
DMNK2DQ ID DMNK2DQ
DMNK2DQ DN PMID25656651-Compound-15c
DMNK2DQ HS Patented
DMNK2DQ DT Small molecular drug
DM9XRYU ID DM9XRYU
DM9XRYU DN PMID25656651-Compound-16a
DM9XRYU HS Patented
DM9XRYU CP NATCO PHARMA LIMITED KOMPELLA, Amala, Kishan RACHAKONDA, Sreenivas ADIBHATLA KALISATYA, Bhujanga, Rao VENKAIAH CHOWDARY, Nannapanen
DM9XRYU DT Small molecular drug
DM9XRYU PC 11562629
DM9XRYU MW 517.4
DM9XRYU FM C25H17F6N5O
DM9XRYU IC InChI=1S/C25H17F6N5O/c1-14-4-5-19(12-21(14)36-23-33-8-6-20(35-23)15-3-2-7-32-13-15)34-22(37)16-9-17(24(26,27)28)11-18(10-16)25(29,30)31/h2-13H,1H3,(H,34,37)(H,33,35,36)
DM9XRYU CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4
DM9XRYU IK LCPGCGAJBOWMIP-UHFFFAOYSA-N
DM9XRYU IU N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide
DM9XRYU CA CAS 879507-25-2
DM5EHK2 ID DM5EHK2
DM5EHK2 DN PMID25656651-Compound-16b
DM5EHK2 HS Patented
DM5EHK2 CP NATCO PHARMA LIMITED KOMPELLA, Amala, Kishan RACHAKONDA, Sreenivas ADIBHATLA KALISATYA, Bhujanga, Rao VENKAIAH CHOWDARY, Nannapanen
DM5EHK2 DT Small molecular drug
DM5EHK2 PC 11548024
DM5EHK2 MW 513.5
DM5EHK2 FM C24H18F3N5O3S
DM5EHK2 IC InChI=1S/C24H18F3N5O3S/c1-15-7-8-18(30-22(33)16-4-2-6-19(12-16)36(34,35)24(25,26)27)13-21(15)32-23-29-11-9-20(31-23)17-5-3-10-28-14-17/h2-14H,1H3,(H,30,33)(H,29,31,32)
DM5EHK2 CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)S(=O)(=O)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4
DM5EHK2 IK SCDUZEXJWFANOL-UHFFFAOYSA-N
DM5EHK2 IU N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethylsulfonyl)benzamide
DMAIVEN ID DMAIVEN
DMAIVEN DN PMID25656651-Compound-18
DMAIVEN HS Patented
DMAIVEN CP IRM LLC HUANG, Shenlin LIU, Zuosheng ALBAUGH, Pamela, A. WANG, Xing PAN, Shifeng XIE, Yongping ZHANG, Guobao
DMAIVEN DT Small molecular drug
DMAIVEN PC 25110837
DMAIVEN MW 468.4
DMAIVEN FM C22H19F3N8O
DMAIVEN IC InChI=1S/C22H19F3N8O/c1-13-6-7-16(31-20(34)14-4-3-5-15(8-14)22(23,24)25)9-17(13)32-21-29-12-30-33(21)19-10-18(26-2)27-11-28-19/h3-12H,1-2H3,(H,31,34)(H,26,27,28)(H,29,30,32)
DMAIVEN CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(F)(F)F)NC3=NC=NN3C4=NC=NC(=C4)NC
DMAIVEN IK ZHABTPLXVWUNPN-UHFFFAOYSA-N
DMAIVEN IU N-[4-methyl-3-[[2-[6-(methylamino)pyrimidin-4-yl]-1,2,4-triazol-3-yl]amino]phenyl]-3-(trifluoromethyl)benzamide
DMSNUVZ ID DMSNUVZ
DMSNUVZ DN PMID25656651-Compound-19a
DMSNUVZ HS Patented
DMSNUVZ CP 4SC AG [DE]
DMSNUVZ DT Small molecular drug
DMSNUVZ PC 42613483
DMSNUVZ MW 471.5
DMSNUVZ FM C25H21N5O3S
DMSNUVZ IC InChI=1S/C25H21N5O3S/c1-16-4-10-20(27-24(32)18-8-5-17(6-9-18)7-11-23(31)30-33)13-21(16)28-25-29-22(15-34-25)19-3-2-12-26-14-19/h2-15,33H,1H3,(H,27,32)(H,28,29)(H,30,31)/b11-7+
DMSNUVZ CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)/C=C/C(=O)NO)NC3=NC(=CS3)C4=CN=CC=C4
DMSNUVZ IK OINCRSHJNMRVSX-YRNVUSSQSA-N
DMSNUVZ IU 4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
DMI1Z7D ID DMI1Z7D
DMI1Z7D DN PMID25656651-Compound-19b
DMI1Z7D HS Patented
DMI1Z7D CP 4SC AG [DE]
DMI1Z7D DT Small molecular drug
DMI1Z7D PC 42626200
DMI1Z7D MW 477.6
DMI1Z7D FM C23H19N5O3S2
DMI1Z7D IC InChI=1S/C23H19N5O3S2/c1-14-4-5-16(25-22(30)20-8-6-17(33-20)7-9-21(29)28-31)11-18(14)26-23-27-19(13-32-23)15-3-2-10-24-12-15/h2-13,31H,1H3,(H,25,30)(H,26,27)(H,28,29)/b9-7+
DMI1Z7D CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(S2)/C=C/C(=O)NO)NC3=NC(=CS3)C4=CN=CC=C4
DMI1Z7D IK DFZFLIGZEDFNOL-VQHVLOKHSA-N
DMI1Z7D IU 5-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]thiophene-2-carboxamide
DM7R2X0 ID DM7R2X0
DM7R2X0 DN PMID25656651-Compound-20a
DM7R2X0 HS Patented
DM7R2X0 CP IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
DM7R2X0 DT Small molecular drug
DM7R2X0 PC 49782106
DM7R2X0 MW 386.3
DM7R2X0 FM C18H13F3N6O
DM7R2X0 IC InChI=1S/C18H13F3N6O/c19-18(20,21)28-14-5-3-13(4-6-14)26-16-15-9-25-27(17(15)24-11-23-16)10-12-2-1-7-22-8-12/h1-9,11H,10H2,(H,23,24,26)
DM7R2X0 CS C1=CC(=CN=C1)CN2C3=NC=NC(=C3C=N2)NC4=CC=C(C=C4)OC(F)(F)F
DM7R2X0 IK JOLSWPYDQLCFEP-UHFFFAOYSA-N
DM7R2X0 IU 1-(pyridin-3-ylmethyl)-N-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-d]pyrimidin-4-amine
DMLUFB2 ID DMLUFB2
DMLUFB2 DN PMID25656651-Compound-20b
DMLUFB2 HS Patented
DMLUFB2 CP IRM LLC DING, Qiang SIM, Tae-bo ZHANG, Guobao ADRIAN, Francisco GRAY, Nathanael, S
DMLUFB2 DT Small molecular drug
DMLUFB2 PC 42628828
DMLUFB2 MW 424.4
DMLUFB2 FM C18H15F3N4O3S
DMLUFB2 IC InChI=1S/C18H15F3N4O3S/c1-29(26,27)25-14-4-2-12(3-5-14)16-10-17(23-11-22-16)24-13-6-8-15(9-7-13)28-18(19,20)21/h2-11,25H,1H3,(H,22,23,24)
DMLUFB2 CS CS(=O)(=O)NC1=CC=C(C=C1)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F
DMLUFB2 IK IQTSERMRWSERDI-UHFFFAOYSA-N
DMLUFB2 IU N-[4-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]phenyl]methanesulfonamide
DMCKAON ID DMCKAON
DMCKAON DN PMID25656651-Compound-21a
DMCKAON HS Patented
DMCKAON CP SUN PHARMA ADVANCED RESEARCH COMPANY LTD., SENGUPTA, Prabal PURI, Chetan Surjitsingh CHOKSHI, Hemantkumar CHITTURI, Trinadha Rao THENNATI, Rajamannar
DMCKAON DT Small molecular drug
DMCKAON PC 44225624
DMCKAON MW 472.9
DMCKAON FM C25H21ClN6O2
DMCKAON IC InChI=1S/C25H21ClN6O2/c1-15-8-9-17(23(33)31-32-24(34)22-16(2)5-3-7-19(22)26)13-21(15)30-25-28-12-10-20(29-25)18-6-4-11-27-14-18/h3-14H,1-2H3,(H,31,33)(H,32,34)(H,28,29,30)
DMCKAON CS CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMCKAON IK RCYQHUIWHIZRQI-UHFFFAOYSA-N
DMCKAON IU 2-chloro-6-methyl-N'-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzoyl]benzohydrazide
DMVABXI ID DMVABXI
DMVABXI DN PMID25656651-Compound-21b
DMVABXI HS Patented
DMVABXI CP SUN PHARMA ADVANCED RESEARCH COMPANY LTD., SENGUPTA, Prabal PURI, Chetan Surjitsingh CHOKSHI, Hemantkumar CHITTURI, Trinadha Rao THENNATI, Rajamannar
DMVABXI DT Small molecular drug
DMVABXI PC 44227512
DMVABXI MW 564.4
DMVABXI FM C25H21IN6O2
DMVABXI IC InChI=1S/C25H21IN6O2/c1-15-8-9-17(23(33)31-32-24(34)22-16(2)5-3-7-19(22)26)13-21(15)30-25-28-12-10-20(29-25)18-6-4-11-27-14-18/h3-14H,1-2H3,(H,31,33)(H,32,34)(H,28,29,30)
DMVABXI CS CC1=C(C(=CC=C1)I)C(=O)NNC(=O)C2=CC(=C(C=C2)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMVABXI IK KRUFMIXJJSFERC-UHFFFAOYSA-N
DMVABXI IU 2-iodo-6-methyl-N'-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzoyl]benzohydrazide
DMZUB3D ID DMZUB3D
DMZUB3D DN PMID25656651-Compound-23a
DMZUB3D HS Patented
DMZUB3D CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA DAR, Arvin SHOKAT, Kevan M
DMZUB3D DT Small molecular drug
DMZUB3D PC 25011745
DMZUB3D MW 455.4
DMZUB3D FM C22H20F3N7O
DMZUB3D IC InChI=1S/C22H20F3N7O/c1-12(2)32-20-17(19(26)27-11-28-20)18(31-32)13-6-8-15(9-7-13)29-21(33)30-16-5-3-4-14(10-16)22(23,24)25/h3-12H,1-2H3,(H2,26,27,28)(H2,29,30,33)
DMZUB3D CS CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)N
DMZUB3D IK LEERPLGXOHLQPF-UHFFFAOYSA-N
DMZUB3D IU 1-[4-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea
DMTOFGH ID DMTOFGH
DMTOFGH DN PMID25656651-Compound-23b
DMTOFGH HS Patented
DMTOFGH CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA DAR, Arvin SHOKAT, Kevan M
DMTOFGH DT Small molecular drug
DMTOFGH PC 45381436
DMTOFGH MW 523.5
DMTOFGH FM C26H24F3N7O2
DMTOFGH IC InChI=1S/C26H24F3N7O2/c1-14(2)36-23-20(22(30-13-31-23)34-24(37)16-6-7-16)21(35-36)15-8-10-18(11-9-15)32-25(38)33-19-5-3-4-17(12-19)26(27,28)29/h3-5,8-14,16H,6-7H2,1-2H3,(H2,32,33,38)(H,30,31,34,37)
DMTOFGH CS CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)NC(=O)C5CC5
DMTOFGH IK UNZJMBBOGIRTFD-UHFFFAOYSA-N
DMTOFGH IU N-[1-propan-2-yl-3-[4-[[3-(trifluoromethyl)phenyl]carbamoylamino]phenyl]pyrazolo[3,4-d]pyrimidin-4-yl]cyclopropanecarboxamide
DMLTR9E ID DMLTR9E
DMLTR9E DN PMID25656651-Compound-23c
DMLTR9E HS Patented
DMLTR9E CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA DAR, Arvin SHOKAT, Kevan M
DMLTR9E DT Small molecular drug
DMLTR9E PC 45381323
DMLTR9E MW 551.6
DMLTR9E FM C28H28F3N7O2
DMLTR9E IC InChI=1S/C28H28F3N7O2/c1-16(2)38-25-22(24(32-15-33-25)36-26(39)18-6-3-4-7-18)23(37-38)17-10-12-20(13-11-17)34-27(40)35-21-9-5-8-19(14-21)28(29,30)31/h5,8-16,18H,3-4,6-7H2,1-2H3,(H2,34,35,40)(H,32,33,36,39)
DMLTR9E CS CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)NC(=O)C5CCCC5
DMLTR9E IK HXLONDQXUGAZKS-UHFFFAOYSA-N
DMLTR9E IU N-[1-propan-2-yl-3-[4-[[3-(trifluoromethyl)phenyl]carbamoylamino]phenyl]pyrazolo[3,4-d]pyrimidin-4-yl]cyclopentanecarboxamide
DMAYSNQ ID DMAYSNQ
DMAYSNQ DN PMID25656651-Compound-25
DMAYSNQ HS Patented
DMAYSNQ CP SYNTECH SOLUTION LLC CHEN, Yongsheng
DMAYSNQ DT Small molecular drug
DMAYSNQ PC 46861598
DMAYSNQ MW 555.6
DMAYSNQ FM C30H24F3N7O
DMAYSNQ IC InChI=1S/C30H24F3N7O/c1-18-4-5-20(11-26(18)39-29-35-10-8-25(38-29)21-3-2-9-34-15-21)28(41)37-23-12-22(30(31,32)33)13-24(14-23)40-16-27(36-17-40)19-6-7-19/h2-5,8-17,19H,6-7H2,1H3,(H,37,41)(H,35,38,39)
DMAYSNQ CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C4CC4)NC5=NC=CC(=N5)C6=CN=CC=C6
DMAYSNQ IK GKVZSPCAKFODTN-UHFFFAOYSA-N
DMAYSNQ IU N-[3-(4-cyclopropylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
DMXM98J ID DMXM98J
DMXM98J DN PMID25656651-Compound-26a
DMXM98J HS Patented
DMXM98J DT Small molecular drug
DMXM98J PC 46928937
DMXM98J MW 420.4
DMXM98J FM C22H15F3N6
DMXM98J IC InChI=1S/C22H15F3N6/c23-22(24,25)14-4-1-3-13(9-14)10-28-21-29-11-17-15-6-8-26-12-18(15)30-20-16(19(17)31-21)5-2-7-27-20/h1-9,11-12H,10H2,(H,27,30)(H,28,29,31)
DMXM98J CS C1=CC(=CC(=C1)C(F)(F)F)CNC2=NC=C3C4=C(C=NC=C4)NC5=C(C3=N2)C=CC=N5
DMXM98J IK BJNZVGIKBDSXJO-UHFFFAOYSA-N
DMXM98J IU N-[[3-(trifluoromethyl)phenyl]methyl]-3,5,11,14,16-pentazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),2,4,6,8(13),9,11,16,18-nonaen-4-amine
DMWG95Z ID DMWG95Z
DMWG95Z DN PMID25656651-Compound-26b
DMWG95Z HS Patented
DMWG95Z DT Small molecular drug
DMWG95Z PC 46929350
DMWG95Z MW 386.8
DMWG95Z FM C21H15ClN6
DMWG95Z IC InChI=1S/C21H15ClN6/c22-14-5-3-13(4-6-14)10-25-21-26-11-17-15-7-9-23-12-18(15)27-20-16(19(17)28-21)2-1-8-24-20/h1-9,11-12H,10H2,(H,24,27)(H,25,26,28)
DMWG95Z CS C1=CC2=C(NC3=C(C=CN=C3)C4=CN=C(N=C24)NCC5=CC=C(C=C5)Cl)N=C1
DMWG95Z IK PBJUHSSYAPBPIB-UHFFFAOYSA-N
DMWG95Z IU N-[(4-chlorophenyl)methyl]-3,5,11,14,16-pentazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),2,4,6,8(13),9,11,16,18-nonaen-4-amine
DMR7A58 ID DMR7A58
DMR7A58 DN PMID25656651-Compound-26c
DMR7A58 HS Patented
DMR7A58 DT Small molecular drug
DMR7A58 PC 46909564
DMR7A58 MW 388.4
DMR7A58 FM C21H14F2N6
DMR7A58 IC InChI=1S/C21H14F2N6/c22-16-4-3-12(8-17(16)23)9-26-21-27-10-15-13-5-7-24-11-18(13)28-20-14(19(15)29-21)2-1-6-25-20/h1-8,10-11H,9H2,(H,25,28)(H,26,27,29)
DMR7A58 CS C1=CC2=C(NC3=C(C=CN=C3)C4=CN=C(N=C24)NCC5=CC(=C(C=C5)F)F)N=C1
DMR7A58 IK HIVDOLJVFRYLKP-UHFFFAOYSA-N
DMR7A58 IU N-[(3,4-difluorophenyl)methyl]-3,5,11,14,16-pentazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),2,4,6,8(13),9,11,16,18-nonaen-4-amine
DMXK43O ID DMXK43O
DMXK43O DN PMID25656651-Compound-27
DMXK43O HS Patented
DMXK43O DT Small molecular drug
DM06LDV ID DM06LDV
DM06LDV DN PMID25656651-Compound-28a
DM06LDV HS Patented
DM06LDV CP ZHANG, Dawei
DM06LDV DT Small molecular drug
DM06LDV PC 49872881
DM06LDV MW 593.6
DM06LDV FM C31H31F4N7O
DM06LDV IC InChI=1S/C31H31F4N7O/c1-3-41-11-13-42(14-12-41)19-23-7-6-21(15-25(23)31(33,34)35)29(43)38-24-16-26(32)20(2)28(17-24)40-30-37-10-8-27(39-30)22-5-4-9-36-18-22/h4-10,15-18H,3,11-14,19H2,1-2H3,(H,38,43)(H,37,39,40)
DM06LDV CS CCN1CCN(CC1)CC2=C(C=C(C=C2)C(=O)NC3=CC(=C(C(=C3)F)C)NC4=NC=CC(=N4)C5=CN=CC=C5)C(F)(F)F
DM06LDV IK CQBGILGFZXYQMT-UHFFFAOYSA-N
DM06LDV IU 4-[(4-ethylpiperazin-1-yl)methyl]-N-[3-fluoro-4-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3-(trifluoromethyl)benzamide
DMKB7XV ID DMKB7XV
DMKB7XV DN PMID25656651-Compound-28b
DMKB7XV HS Patented
DMKB7XV CP ZHANG, Dawei
DMKB7XV DT Small molecular drug
DMKB7XV PC 49872974
DMKB7XV MW 511.6
DMKB7XV FM C29H30FN7O
DMKB7XV IC InChI=1S/C29H30FN7O/c1-20-25(30)16-24(17-27(20)35-29-32-11-9-26(34-29)23-4-3-10-31-18-23)33-28(38)22-7-5-21(6-8-22)19-37-14-12-36(2)13-15-37/h3-11,16-18H,12-15,19H2,1-2H3,(H,33,38)(H,32,34,35)
DMKB7XV CS CC1=C(C=C(C=C1F)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
DMKB7XV IK ZRPUCWORBBVKGL-UHFFFAOYSA-N
DMKB7XV IU N-[3-fluoro-4-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide
DMCEST4 ID DMCEST4
DMCEST4 DN PMID25656651-Compound-29a
DMCEST4 HS Patented
DMCEST4 CP HANMI SCIENCE CO., LTD. KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION SON, Jung Beom JUNG, Seung Hyun CHOI, Wha Il JUNG, Young Hee CHOI, Jae Yul SONG, Ji Yeon LEE, Kyu Hang LEE, Jae Chul KIM, Eun Young AHN, Young Gil KIM, Maeng Sup CHOI, Hwan Geun SIM, Tae Bo HAM, Young Jin PARK, Dong-sik KIM, Hwan KIM, Dong-Wook
DMCEST4 DT Small molecular drug
DMCEST4 PC 53345642
DMCEST4 MW 556.7
DMCEST4 FM C29H32N8O2S
DMCEST4 IC InChI=1S/C29H32N8O2S/c1-3-36-10-12-37(13-11-36)24-9-8-21(15-30-24)34-28(38)19-5-4-18(2)23(14-19)35-29(39)22-16-40-26-25(22)31-17-32-27(26)33-20-6-7-20/h4-5,8-9,14-17,20H,3,6-7,10-13H2,1-2H3,(H,34,38)(H,35,39)(H,31,32,33)
DMCEST4 CS CCN1CCN(CC1)C2=NC=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)NC(=O)C4=CSC5=C4N=CN=C5NC6CC6
DMCEST4 IK VVZVKYOPIITGGL-UHFFFAOYSA-N
DMCEST4 IU 4-(cyclopropylamino)-N-[5-[[6-(4-ethylpiperazin-1-yl)pyridin-3-yl]carbamoyl]-2-methylphenyl]thieno[3,2-d]pyrimidine-7-carboxamide
DMBKRY7 ID DMBKRY7
DMBKRY7 DN PMID25656651-Compound-29b
DMBKRY7 HS Patented
DMBKRY7 CP HANMI SCIENCE CO., LTD. KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION SON, Jung Beom JUNG, Seung Hyun CHOI, Wha Il JUNG, Young Hee CHOI, Jae Yul SONG, Ji Yeon LEE, Kyu Hang LEE, Jae Chul KIM, Eun Young AHN, Young Gil KIM, Maeng Sup CHOI, Hwan Geun SIM, Tae Bo HAM, Young Jin PARK, Dong-sik KIM, Hwan KIM, Dong-Wook
DMBKRY7 DT Small molecular drug
DMBKRY7 PC 53345434
DMBKRY7 MW 515.6
DMBKRY7 FM C26H22FN7O2S
DMBKRY7 IC InChI=1S/C26H22FN7O2S/c1-14-3-8-18(10-20(14)32-25(35)19-12-37-23-22(19)29-13-30-24(23)28)31-26(36)21-9-15(2)33-34(21)11-16-4-6-17(27)7-5-16/h3-10,12-13H,11H2,1-2H3,(H,31,36)(H,32,35)(H2,28,29,30)
DMBKRY7 CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=NN2CC3=CC=C(C=C3)F)C)NC(=O)C4=CSC5=C4N=CN=C5N
DMBKRY7 IK XYZZDCAVPVYIRF-UHFFFAOYSA-N
DMBKRY7 IU 4-amino-N-[5-[[2-[(4-fluorophenyl)methyl]-5-methylpyrazole-3-carbonyl]amino]-2-methylphenyl]thieno[3,2-d]pyrimidine-7-carboxamide
DMVMSQ2 ID DMVMSQ2
DMVMSQ2 DN PMID25656651-Compound-30a
DMVMSQ2 HS Patented
DMVMSQ2 CP PIRAMAL HEALTHCARE LIMITED SIVAKUMAR, Meenakshi JOSHI, Kalpana Sanjay AWARE, Valmik Sopan SARDE, Ankush Gangaram BAGUL, Sandeep Mukunda MANOHAR, Sonal Mohan
DMVMSQ2 DT Small molecular drug
DMVMSQ2 PC 135565531
DMVMSQ2 MW 246.26
DMVMSQ2 FM C13H14N2O3
DMVMSQ2 IC InChI=1S/C13H14N2O3/c1-2-3-12-14-13(18-15-12)7-5-9-4-6-10(16)11(17)8-9/h4-8,16-17H,2-3H2,1H3/b7-5+
DMVMSQ2 CS CCCC1=NOC(=N1)/C=C/C2=CC(=C(C=C2)O)O
DMVMSQ2 IK MAWOOXDYMFRJNN-FNORWQNLSA-N
DMVMSQ2 IU 4-[(E)-2-(3-propyl-1,2,4-oxadiazol-5-yl)ethenyl]benzene-1,2-diol
DMVMSQ2 CA CAS 1332498-21-1
DMEJMPD ID DMEJMPD
DMEJMPD DN PMID25656651-Compound-30b
DMEJMPD HS Patented
DMEJMPD CP PIRAMAL HEALTHCARE LIMITED SIVAKUMAR, Meenakshi JOSHI, Kalpana Sanjay AWARE, Valmik Sopan SARDE, Ankush Gangaram BAGUL, Sandeep Mukunda MANOHAR, Sonal Mohan
DMEJMPD DT Small molecular drug
DMEJMPD PC 136344503
DMEJMPD MW 294.3
DMEJMPD FM C17H14N2O3
DMEJMPD IC InChI=1S/C17H14N2O3/c20-14-8-6-13(10-15(14)21)7-9-17-18-16(19-22-17)11-12-4-2-1-3-5-12/h1-10,20-21H,11H2/b9-7+
DMEJMPD CS C1=CC=C(C=C1)CC2=NOC(=N2)/C=C/C3=CC(=C(C=C3)O)O
DMEJMPD IK BJLAYSATLVCCDW-VQHVLOKHSA-N
DMEJMPD IU 4-[(E)-2-(3-benzyl-1,2,4-oxadiazol-5-yl)ethenyl]benzene-1,2-diol
DMSVQMO ID DMSVQMO
DMSVQMO DN PMID25656651-Compound-31a
DMSVQMO HS Patented
DMSVQMO CP NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
DMSVQMO DT Small molecular drug
DMSVQMO PC 56599744
DMSVQMO MW 429.5
DMSVQMO FM C24H23N5O3
DMSVQMO IC InChI=1S/C24H23N5O3/c1-14-19(30)11-20(32-24(14)8-9-24)16-7-10-26-12-18(16)29-23(31)21-22(25)27-13-17(28-21)15-5-3-2-4-6-15/h2-7,10,12-13,19-20,30H,1,8-9,11H2,(H2,25,27)(H,29,31)/t19-,20-/m0/s1
DMSVQMO CS C=C1[C@H](C[C@H](OC12CC2)C3=C(C=NC=C3)NC(=O)C4=NC(=CN=C4N)C5=CC=CC=C5)O
DMSVQMO IK WHESOVNDWAKAQI-PMACEKPBSA-N
DMSVQMO IU 3-amino-N-[4-[(5S,7S)-7-hydroxy-8-methylidene-4-oxaspiro[2.5]octan-5-yl]pyridin-3-yl]-6-phenylpyrazine-2-carboxamide
DM6TGUR ID DM6TGUR
DM6TGUR DN PMID25656651-Compound-31b
DM6TGUR HS Patented
DM6TGUR CP NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
DM6TGUR DT Small molecular drug
DMDJGPC ID DMDJGPC
DMDJGPC DN PMID25656651-Compound-31c
DMDJGPC HS Patented
DMDJGPC CP NOVARTIS AG BURGER, Matthew DING, Yu HAN, Wooseok LINDVALL, Mika NISHIGUCHI, Gisele A. RICO, Alice SMITH, Aaron TANNER, Huw WAN, Lifeng
DMDJGPC DT Small molecular drug
DMDJGPC PC 89534789
DMDJGPC MW 461.5
DMDJGPC FM C25H27N5O4
DMDJGPC IC InChI=1S/C25H27N5O4/c26-23-22(29-17(14-28-23)15-6-2-1-3-7-15)24(32)30-18-13-27-11-9-16(18)19-12-20(31)25(33)10-5-4-8-21(25)34-19/h1-3,6-7,9,11,13-14,19-21,31,33H,4-5,8,10,12H2,(H2,26,28)(H,30,32)/t19-,20-,21-,25+/m1/s1
DMDJGPC CS C1CC[C@]2([C@@H](C1)O[C@H](C[C@H]2O)C3=C(C=NC=C3)NC(=O)C4=NC(=CN=C4N)C5=CC=CC=C5)O
DMDJGPC IK MHELWFWYAKEXOQ-YCFYUYSTSA-N
DMDJGPC IU N-[4-[(2R,4R,4aS,8aR)-4,4a-dihydroxy-2,3,4,5,6,7,8,8a-octahydrochromen-2-yl]pyridin-3-yl]-3-amino-6-phenylpyrazine-2-carboxamide
DMCRA2U ID DMCRA2U
DMCRA2U DN PMID25656651-Compound-33a
DMCRA2U HS Patented
DMCRA2U CP PF MEDICAMENT [FR]
DMCRA2U DT Small molecular drug
DMCRA2U PC 57521300
DMCRA2U MW 579.7
DMCRA2U FM C29H31F2N7O2S
DMCRA2U IC InChI=1S/C29H31F2N7O2S/c1-37-6-8-38(9-7-37)21-2-3-24(26(15-21)33-20-4-10-40-11-5-20)29(39)34-28-25-16-23(17-32-27(25)35-36-28)41-22-13-18(30)12-19(31)14-22/h2-3,12-17,20,33H,4-11H2,1H3,(H2,32,34,35,36,39)
DMCRA2U CS CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=C4C=C(C=NC4=NN3)SC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMCRA2U IK DNSGDBHRFQIANM-UHFFFAOYSA-N
DMCRA2U IU N-[5-(3,5-difluorophenyl)sulfanyl-2H-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
DMU8ZI3 ID DMU8ZI3
DMU8ZI3 DN PMID25656651-Compound-33b
DMU8ZI3 HS Patented
DMU8ZI3 CP PF MEDICAMENT [FR]
DMU8ZI3 DT Small molecular drug
DMU8ZI3 PC 60143177
DMU8ZI3 MW 561.6
DMU8ZI3 FM C30H33F2N7O2
DMU8ZI3 IC InChI=1S/C30H33F2N7O2/c1-38-6-8-39(9-7-38)24-2-3-25(27(17-24)34-23-4-10-41-11-5-23)30(40)35-29-26-15-20(18-33-28(26)36-37-29)12-19-13-21(31)16-22(32)14-19/h2-3,13-18,23,34H,4-12H2,1H3,(H2,33,35,36,37,40)
DMU8ZI3 CS CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=C4C=C(C=NC4=NN3)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
DMU8ZI3 IK HHXDZBJLUOYVEU-UHFFFAOYSA-N
DMU8ZI3 IU N-[5-[(3,5-difluorophenyl)methyl]-2H-pyrazolo[3,4-b]pyridin-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
DMWOR8B ID DMWOR8B
DMWOR8B DN PMID25656651-Compound-34a
DMWOR8B HS Patented
DMWOR8B CP UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DMWOR8B DT Small molecular drug
DMBD706 ID DMBD706
DMBD706 DN PMID25656651-Compound-34b
DMBD706 HS Patented
DMBD706 CP UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DMBD706 DT Small molecular drug
DMG5I41 ID DMG5I41
DMG5I41 DN PMID25656651-Compound-34c
DMG5I41 HS Patented
DMG5I41 CP UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DMG5I41 DT Small molecular drug
DMNXVY9 ID DMNXVY9
DMNXVY9 DN PMID25656651-Compound-36a
DMNXVY9 HS Patented
DMNXVY9 CP NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMNXVY9 DT Small molecular drug
DMNXVY9 PC 72203009
DMNXVY9 MW 375.8
DMNXVY9 FM C18H12ClF2N3O2
DMNXVY9 IC InChI=1S/C18H12ClF2N3O2/c19-18(20,21)26-16-6-4-15(5-7-16)24-17(25)13-3-1-2-12(8-13)14-9-22-11-23-10-14/h1-11H,(H,24,25)
DMNXVY9 CS C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)Cl)C3=CN=CN=C3
DMNXVY9 IK IEPKEELESQZYDU-UHFFFAOYSA-N
DMNXVY9 IU N-[4-[chloro(difluoro)methoxy]phenyl]-3-pyrimidin-5-ylbenzamide
DMHYDM7 ID DMHYDM7
DMHYDM7 DN PMID25656651-Compound-36b
DMHYDM7 HS Patented
DMHYDM7 CP NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMHYDM7 DT Small molecular drug
DMHYDM7 PC 72203013
DMHYDM7 MW 373.3
DMHYDM7 FM C19H14F3N3O2
DMHYDM7 IC InChI=1S/C19H14F3N3O2/c1-12-2-3-13(8-17(12)14-9-23-11-24-10-14)18(26)25-15-4-6-16(7-5-15)27-19(20,21)22/h2-11H,1H3,(H,25,26)
DMHYDM7 CS CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)C3=CN=CN=C3
DMHYDM7 IK CHZIAMJENFGBCI-UHFFFAOYSA-N
DMHYDM7 IU 4-methyl-3-pyrimidin-5-yl-N-[4-(trifluoromethoxy)phenyl]benzamide
DMOGKSW ID DMOGKSW
DMOGKSW DN PMID25656651-Compound-36c
DMOGKSW HS Patented
DMOGKSW CP NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMOGKSW DT Small molecular drug
DMOGKSW PC 72203014
DMOGKSW MW 361.3
DMOGKSW FM C18H14F3N3O2
DMOGKSW IC InChI=1S/C18H14F3N3O2/c1-12-2-3-13(10-16(12)24-9-8-22-11-24)17(25)23-14-4-6-15(7-5-14)26-18(19,20)21/h2-11H,1H3,(H,23,25)
DMOGKSW CS CC1=C(C=C(C=C1)C(=O)NC2=CC=C(C=C2)OC(F)(F)F)N3C=CN=C3
DMOGKSW IK VTOBGTLKLODAIL-UHFFFAOYSA-N
DMOGKSW IU 3-imidazol-1-yl-4-methyl-N-[4-(trifluoromethoxy)phenyl]benzamide
DMKMY4I ID DMKMY4I
DMKMY4I DN PMID25656651-Compound-36d
DMKMY4I HS Patented
DMKMY4I CP NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
DMKMY4I DT Small molecular drug
DMKMY4I PC 89906474
DMKMY4I MW 411.2
DMKMY4I FM C17H10Cl2F2N4O2
DMKMY4I IC InChI=1S/C17H10Cl2F2N4O2/c18-15-14(11-6-22-9-23-7-11)5-10(8-24-15)16(26)25-12-1-3-13(4-2-12)27-17(19,20)21/h1-9H,(H,25,26)
DMKMY4I CS C1=CC(=CC=C1NC(=O)C2=CC(=C(N=C2)Cl)C3=CN=CN=C3)OC(F)(F)Cl
DMKMY4I IK BHFPNMRGSVUFLM-UHFFFAOYSA-N
DMKMY4I IU 6-chloro-N-[4-[chloro(difluoro)methoxy]phenyl]-5-pyrimidin-5-ylpyridine-3-carboxamide
DM0P4F3 ID DM0P4F3
DM0P4F3 DN PMID25656651-Compound-37a
DM0P4F3 HS Patented
DM0P4F3 CP NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
DM0P4F3 DT Small molecular drug
DM0P4F3 PC 72544218
DM0P4F3 MW 466.8
DM0P4F3 FM C21H18ClF3N4O3
DM0P4F3 IC InChI=1S/C21H18ClF3N4O3/c22-21(24,25)32-15-4-2-13(3-5-15)27-20(31)12-1-6-18(29-8-7-14(30)11-29)16(9-12)19-17(23)10-26-28-19/h1-6,9-10,14,30H,7-8,11H2,(H,26,28)(H,27,31)/t14-/m1/s1
DM0P4F3 CS C1CN(C[C@@H]1O)C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
DM0P4F3 IK XFHOXKYPYFGBCJ-CQSZACIVSA-N
DM0P4F3 IU N-[4-[chloro(difluoro)methoxy]phenyl]-3-(4-fluoro-1H-pyrazol-5-yl)-4-[(3R)-3-hydroxypyrrolidin-1-yl]benzamide
DMX98YV ID DMX98YV
DMX98YV DN PMID25656651-Compound-37b
DMX98YV HS Patented
DMX98YV CP NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
DMX98YV DT Small molecular drug
DMX98YV PC 72545600
DMX98YV MW 467.8
DMX98YV FM C20H17ClF3N5O3
DMX98YV IC InChI=1S/C20H17ClF3N5O3/c21-20(23,24)32-14-3-1-12(2-4-14)27-19(31)11-7-15(17-16(22)9-26-28-17)18(25-8-11)29-6-5-13(30)10-29/h1-4,7-9,13,30H,5-6,10H2,(H,26,28)(H,27,31)/t13-/m1/s1
DMX98YV CS C1CN(C[C@@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
DMX98YV IK NAXNSUPRCUTVTP-CYBMUJFWSA-N
DMX98YV IU N-[4-[chloro(difluoro)methoxy]phenyl]-5-(4-fluoro-1H-pyrazol-5-yl)-6-[(3R)-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxamide
DM684IK ID DM684IK
DM684IK DN PMID25656651-Compound-37c
DM684IK HS Patented
DM684IK CP NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
DM684IK DT Small molecular drug
DM684IK PC 72545851
DM684IK MW 467.8
DM684IK FM C20H17ClF3N5O3
DM684IK IC InChI=1S/C20H17ClF3N5O3/c21-20(23,24)32-14-3-1-12(2-4-14)27-19(31)11-7-15(17-16(22)9-26-28-17)18(25-8-11)29-6-5-13(30)10-29/h1-4,7-9,13,30H,5-6,10H2,(H,26,28)(H,27,31)/t13-/m0/s1
DM684IK CS C1CN(C[C@H]1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
DM684IK IK NAXNSUPRCUTVTP-ZDUSSCGKSA-N
DM684IK IU N-[4-[chloro(difluoro)methoxy]phenyl]-5-(4-fluoro-1H-pyrazol-5-yl)-6-[(3S)-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxamide
DMECOY7 ID DMECOY7
DMECOY7 DN PMID25656651-Compound-38
DMECOY7 HS Patented
DMECOY7 CP ASTAR BIOTECH LLC HUANG, Haihong YU, Chunrong ZHANG, Dongfeng LI, Peng
DMECOY7 DT Small molecular drug
DMECOY7 PC 72725269
DMECOY7 MW 526.6
DMECOY7 FM C30H28F2N6O
DMECOY7 IC InChI=1S/C30H28F2N6O/c1-20-5-6-22(16-21(20)7-9-24-19-33-28-4-3-11-34-38(24)28)29(39)35-23-8-10-25-26(17-23)30(31,32)18-27(25)37-14-12-36(2)13-15-37/h3-6,8,10-11,16-17,19,27H,12-15,18H2,1-2H3,(H,35,39)
DMECOY7 CS CC1=C(C=C(C=C1)C(=O)NC2=CC3=C(C=C2)C(CC3(F)F)N4CCN(CC4)C)C#CC5=CN=C6N5N=CC=C6
DMECOY7 IK BPLVEFPXYUJTQJ-UHFFFAOYSA-N
DMECOY7 IU N-[3,3-difluoro-1-(4-methylpiperazin-1-yl)-1,2-dihydroinden-5-yl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide
DMLGD52 ID DMLGD52
DMLGD52 DN PMID25656651-Compound-40
DMLGD52 HS Patented
DMLGD52 CP NANJING SANHOME PHARMACEUTICAL CO LTD [CN]
DMLGD52 DT Small molecular drug
DMLGD52 PC 136248912
DMLGD52 MW 629.6
DMLGD52 FM C31H29F6N7O
DMLGD52 IC InChI=1S/C31H29F6N7O/c1-19-4-5-21(14-20(19)6-9-24-18-43(3)28(39-24)27-38-16-26(41-27)31(35,36)37)29(45)40-23-8-7-22(25(15-23)30(32,33)34)17-44-12-10-42(2)11-13-44/h4-5,7-8,14-16,18H,10-13,17H2,1-3H3,(H,38,41)(H,40,45)
DMLGD52 CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN(C(=N4)C5=NC=C(N5)C(F)(F)F)C
DMLGD52 IK HTQFCQUXHWQFLM-UHFFFAOYSA-N
DMLGD52 IU 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-[1-methyl-2-[5-(trifluoromethyl)-1H-imidazol-2-yl]imidazol-4-yl]ethynyl]benzamide
DMTUA6E ID DMTUA6E
DMTUA6E DN PMID25656651-Compound-42
DMTUA6E HS Patented
DMTUA6E CP AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
DMTUA6E DT Small molecular drug
DMTUA6E PC 76071870
DMTUA6E MW 498.5
DMTUA6E FM C27H29F3N4O2
DMTUA6E IC InChI=1S/C27H29F3N4O2/c1-2-33-12-14-34(15-13-33)18-22-5-8-23(16-25(22)27(28,29)30)32-26(35)19-36-24-9-6-20(7-10-24)21-4-3-11-31-17-21/h3-11,16-17H,2,12-15,18-19H2,1H3,(H,32,35)
DMTUA6E CS CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)COC3=CC=C(C=C3)C4=CN=CC=C4)C(F)(F)F
DMTUA6E IK UXNUQVZRIJPJBL-UHFFFAOYSA-N
DMTUA6E IU N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-2-(4-pyridin-3-ylphenoxy)acetamide
DM7XQUT ID DM7XQUT
DM7XQUT DN PMID25656651-Compound-46
DM7XQUT HS Patented
DM7XQUT CP TERRABAY PHARMACEUTICALS, INC
DM7XQUT DT Small molecular drug
DM7XQUT PC 76286469
DM7XQUT MW 605.6
DM7XQUT FM C31H24F5N7O
DM7XQUT IC InChI=1S/C31H24F5N7O/c1-18-4-5-19(9-26(18)42-29-38-8-6-25(41-29)20-3-2-7-37-15-20)28(44)40-23-10-22(31(34,35)36)11-24(12-23)43-16-27(39-17-43)21-13-30(32,33)14-21/h2-12,15-17,21H,13-14H2,1H3,(H,40,44)(H,38,41,42)
DM7XQUT CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C4CC(C4)(F)F)NC5=NC=CC(=N5)C6=CN=CC=C6
DM7XQUT IK FHMNIXSTLJZGDP-UHFFFAOYSA-N
DM7XQUT IU N-[3-[4-(3,3-difluorocyclobutyl)imidazol-1-yl]-5-(trifluoromethyl)phenyl]-4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
DMAI95U ID DMAI95U
DMAI95U DN PMID25656651-Compound-5
DMAI95U HS Patented
DMAI95U CP ARIAD PHARMACEUTICALS, INC. HUANG, Wei-sheng RIVERA, Victor, M. CLACKSON, Timothy, P. SHAKESPEARE, William, C. SQUILLACE, Rachel, M. GOZGIT, Joseph, M
DMAI95U DT Small molecular drug
DMAI95U PC 24826799
DMAI95U MW 532.6
DMAI95U FM C29H27F3N6O
DMAI95U IC InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
DMAI95U CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
DMAI95U IK PHXJVRSECIGDHY-UHFFFAOYSA-N
DMAI95U IU 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
DMAI95U CA CAS 943319-70-8
DMAI95U CB CHEBI:78543
DMAI95U DE Chronic myeloid leukaemia
DMK3TMD ID DMK3TMD
DMK3TMD DN PMID25656651-Compound-7
DMK3TMD HS Patented
DMK3TMD CP DECIPHERA PHARMACEUTICALS, LLC PETILLO, Peter, A. KAUFMAN, Michael, D. FLYNN, Daniel, L
DMK3TMD DT Small molecular drug
DMK3TMD PC 25066467
DMK3TMD MW 553.6
DMK3TMD FM C30H28FN7O3
DMK3TMD IC InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
DMK3TMD CS CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5
DMK3TMD IK WVXNSAVVKYZVOE-UHFFFAOYSA-N
DMK3TMD IU 4-[4-[(5-tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
DMK3TMD CA CAS 1020172-07-9
DMK3TMD CB CHEBI:62166
DMEL1WX ID DMEL1WX
DMEL1WX DN PMID25666693-Compound-1
DMEL1WX HS Patented
DMEL1WX CP ABBVIE INC
DMEL1WX DT Small molecular drug
DMEL1WX PC 68313317
DMEL1WX MW 363.4
DMEL1WX FM C22H22FN3O
DMEL1WX IC InChI=1S/C22H22FN3O/c1-14-11-19-17(13-24-14)8-10-20(23)21(19)26-22(27)25-18-9-7-16(12-18)15-5-3-2-4-6-15/h2-6,8,10-11,13,16,18H,7,9,12H2,1H3,(H2,25,26,27)/t16-,18+/m0/s1
DMEL1WX CS CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@@H](C3)C4=CC=CC=C4)F)C=N1
DMEL1WX IK BLFYIBROKHRKEJ-FUHWJXTLSA-N
DMEL1WX IU 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-phenylcyclopentyl]urea
DMEL1WX DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQP3TD ID DMQP3TD
DMQP3TD DN PMID25666693-Compound-10
DMQP3TD HS Patented
DMQP3TD CP ABBVIE INC
DMQP3TD DT Small molecular drug
DMQP3TD PC 66551086
DMQP3TD MW 363.4
DMQP3TD FM C22H22FN3O
DMQP3TD IC InChI=1S/C22H22FN3O/c1-14-11-19-17(13-24-14)8-10-20(23)21(19)26-22(27)25-18-9-7-16(12-18)15-5-3-2-4-6-15/h2-6,8,10-11,13,16,18H,7,9,12H2,1H3,(H2,25,26,27)/t16-,18-/m1/s1
DMQP3TD CS CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@H](C3)C4=CC=CC=C4)F)C=N1
DMQP3TD IK BLFYIBROKHRKEJ-SJLPKXTDSA-N
DMQP3TD IU 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3R)-3-phenylcyclopentyl]urea
DMQP3TD DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMYTZFP ID DMYTZFP
DMYTZFP DN PMID25666693-Compound-100
DMYTZFP HS Patented
DMYTZFP CP PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
DMYTZFP DT Small molecular drug
DMYTZFP PC 71480662
DMYTZFP MW 449.5
DMYTZFP FM C20H21F2N5O3S
DMYTZFP IC InChI=1S/C20H21F2N5O3S/c1-11-9-26(18-14(22)6-12(8-23-18)16(29)10-28)4-5-27(11)20(30)25-19-24-15-7-13(21)2-3-17(15)31-19/h2-3,6-8,11,16,28-29H,4-5,9-10H2,1H3,(H,24,25,30)/t11-,16+/m0/s1
DMYTZFP CS C[C@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=CC(=C3)F)C4=C(C=C(C=N4)[C@@H](CO)O)F
DMYTZFP IK GVENNMJXQHKHOV-MEDUHNTESA-N
DMYTZFP IU (2S)-4-[5-[(1S)-1,2-dihydroxyethyl]-3-fluoropyridin-2-yl]-N-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazine-1-carboxamide
DMYTZFP DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMNOD4A ID DMNOD4A
DMNOD4A DN PMID25666693-Compound-101
DMNOD4A HS Patented
DMNOD4A CP PURDUE PHARMA L.P
DMNOD4A DT Small molecular drug
DMNOD4A PC 71609207
DMNOD4A MW 423.5
DMNOD4A FM C22H18FN3O3S
DMNOD4A IC InChI=1S/C22H18FN3O3S/c23-17-10-13(9-16(28)12-27)11-24-20(17)14-5-7-15(8-6-14)21(29)26-22-25-18-3-1-2-4-19(18)30-22/h1-8,10-11,16,27-28H,9,12H2,(H,25,26,29)/t16-/m0/s1
DMNOD4A CS C1=CC=C2C(=C1)N=C(S2)NC(=O)C3=CC=C(C=C3)C4=C(C=C(C=N4)C[C@@H](CO)O)F
DMNOD4A IK AMBUADZXQKAOQQ-INIZCTEOSA-N
DMNOD4A IU N-(1,3-benzothiazol-2-yl)-4-[5-[(2S)-2,3-dihydroxypropyl]-3-fluoropyridin-2-yl]benzamide
DMNOD4A DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM0OY5D ID DM0OY5D
DM0OY5D DN PMID25666693-Compound-102
DM0OY5D HS Patented
DM0OY5D CP PURDUE PHARMA L.P
DM0OY5D DT Small molecular drug
DM0OY5D DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM8DZA6 ID DM8DZA6
DM8DZA6 DN PMID25666693-Compound-103
DM8DZA6 HS Patented
DM8DZA6 CP PURDUE PHARMA L.P
DM8DZA6 DT Small molecular drug
DM8DZA6 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMYCT5B ID DMYCT5B
DMYCT5B DN PMID25666693-Compound-104
DMYCT5B HS Patented
DMYCT5B CP Purdue Pharma L.P
DMYCT5B DT Small molecular drug
DMYCT5B PC 25104368
DMYCT5B MW 461.8
DMYCT5B FM C20H20ClF4N3O3
DMYCT5B IC InChI=1S/C20H20ClF4N3O3/c21-15-9-12(16(30)11-29)10-26-17(15)19(22)5-7-28(8-6-19)18(31)27-14-3-1-13(2-4-14)20(23,24)25/h1-4,9-10,16,29-30H,5-8,11H2,(H,27,31)/t16-/m1/s1
DMYCT5B CS C1CN(CCC1(C2=C(C=C(C=N2)[C@@H](CO)O)Cl)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F
DMYCT5B IK DSVBUDHKIZVCPH-MRXNPFEDSA-N
DMYCT5B IU 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]pyridin-2-yl]-4-fluoro-N-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DMYCT5B DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMV509A ID DMV509A
DMV509A DN PMID25666693-Compound-105
DMV509A HS Patented
DMV509A CP Purdue Pharma L.P
DMV509A DT Small molecular drug
DMV509A PC 25027804
DMV509A MW 476.3
DMV509A FM C20H18Cl2F3N3O3
DMV509A IC InChI=1S/C20H18Cl2F3N3O3/c21-15-8-13(1-2-14(15)20(23,24)25)27-19(31)28-5-3-11(4-6-28)18-16(22)7-12(9-26-18)17(30)10-29/h1-3,7-9,17,29-30H,4-6,10H2,(H,27,31)/t17-/m1/s1
DMV509A CS C1CN(CC=C1C2=C(C=C(C=N2)[C@@H](CO)O)Cl)C(=O)NC3=CC(=C(C=C3)C(F)(F)F)Cl
DMV509A IK CJDYNMVVGNTWLD-QGZVFWFLSA-N
DMV509A IU 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]pyridin-2-yl]-N-[3-chloro-4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxamide
DMV509A DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMEG8CB ID DMEG8CB
DMEG8CB DN PMID25666693-Compound-106
DMEG8CB HS Patented
DMEG8CB DT Small molecular drug
DMEG8CB PC 51349065
DMEG8CB MW 389
DMEG8CB FM C19H25ClN4OSi
DMEG8CB IC InChI=1S/C19H25ClN4OSi/c1-26(2,3)16-8-6-15(7-9-16)22-19(25)24-13-11-23(12-14-24)18-17(20)5-4-10-21-18/h4-10H,11-14H2,1-3H3,(H,22,25)
DMEG8CB CS C[Si](C)(C)C1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl
DMEG8CB IK VOWXQOSAQUYVQK-UHFFFAOYSA-N
DMEG8CB IU 4-(3-chloropyridin-2-yl)-N-(4-trimethylsilylphenyl)piperazine-1-carboxamide
DMEG8CB DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMB2RML ID DMB2RML
DMB2RML DN PMID25666693-Compound-107
DMB2RML HS Patented
DMB2RML DT Small molecular drug
DMB2RML PC 51349201
DMB2RML MW 414.5
DMB2RML FM C22H21F3N2OSi
DMB2RML IC InChI=1S/C22H21F3N2OSi/c1-29(2,3)18-12-10-17(11-13-18)27-21(28)16-8-6-15(7-9-16)20-19(22(23,24)25)5-4-14-26-20/h4-14H,1-3H3,(H,27,28)
DMB2RML CS C[Si](C)(C)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=C(C=CC=N3)C(F)(F)F
DMB2RML IK ATDYJIBFGKJFQE-UHFFFAOYSA-N
DMB2RML IU 4-[3-(trifluoromethyl)pyridin-2-yl]-N-(4-trimethylsilylphenyl)benzamide
DMB2RML DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMN0FCA ID DMN0FCA
DMN0FCA DN PMID25666693-Compound-108
DMN0FCA HS Patented
DMN0FCA DT Small molecular drug
DMN0FCA PC 51349341
DMN0FCA MW 386
DMN0FCA FM C20H24ClN3OSi
DMN0FCA IC InChI=1S/C20H24ClN3OSi/c1-26(2,3)17-8-6-16(7-9-17)23-20(25)15-10-13-24(14-11-15)19-18(21)5-4-12-22-19/h4-10,12H,11,13-14H2,1-3H3,(H,23,25)
DMN0FCA CS C[Si](C)(C)C1=CC=C(C=C1)NC(=O)C2=CCN(CC2)C3=C(C=CC=N3)Cl
DMN0FCA IK DYKDTFQPEROGHZ-UHFFFAOYSA-N
DMN0FCA IU 1-(3-chloropyridin-2-yl)-N-(4-trimethylsilylphenyl)-3,6-dihydro-2H-pyridine-4-carboxamide
DMN0FCA DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMWGIS7 ID DMWGIS7
DMWGIS7 DN PMID25666693-Compound-109
DMWGIS7 HS Patented
DMWGIS7 CP Purdue Pharma L.P
DMWGIS7 DT Small molecular drug
DMWGIS7 PC 11187857
DMWGIS7 MW 370.9
DMWGIS7 FM C20H23ClN4O
DMWGIS7 IC InChI=1S/C20H23ClN4O/c1-20(2,3)15-4-6-16(7-5-15)24-19(26)25-12-8-14(9-13-25)17-18(21)23-11-10-22-17/h4-8,10-11H,9,12-13H2,1-3H3,(H,24,26)
DMWGIS7 CS CC(C)(C)C1=CC=C(C=C1)NC(=O)N2CCC(=CC2)C3=NC=CN=C3Cl
DMWGIS7 IK SOOFDEGWVPVUAQ-UHFFFAOYSA-N
DMWGIS7 IU N-(4-tert-butylphenyl)-4-(3-chloropyrazin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxamide
DMWGIS7 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM9HOM6 ID DM9HOM6
DM9HOM6 DN PMID25666693-Compound-11
DM9HOM6 HS Patented
DM9HOM6 CP ABBVIE INC
DM9HOM6 DT Small molecular drug
DM9HOM6 PC 66549650
DM9HOM6 MW 381.4
DM9HOM6 FM C22H21F2N3O
DM9HOM6 IC InChI=1S/C22H21F2N3O/c1-13-10-18-15(12-25-13)7-9-20(24)21(18)27-22(28)26-16-8-6-14(11-16)17-4-2-3-5-19(17)23/h2-5,7,9-10,12,14,16H,6,8,11H2,1H3,(H2,26,27,28)/t14-,16-/m1/s1
DM9HOM6 CS CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@H](C3)C4=CC=CC=C4F)F)C=N1
DM9HOM6 IK PJVXUKARZNCIRA-GDBMZVCRSA-N
DM9HOM6 IU 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3R)-3-(2-fluorophenyl)cyclopentyl]urea
DM9HOM6 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMNGD2S ID DMNGD2S
DMNGD2S DN PMID25666693-Compound-110
DMNGD2S HS Patented
DMNGD2S CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMNGD2S DT Small molecular drug
DMNGD2S DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMNKW1E ID DMNKW1E
DMNKW1E DN PMID25666693-Compound-111
DMNKW1E HS Patented
DMNKW1E CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMNKW1E DT Small molecular drug
DMNKW1E DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQOSH5 ID DMQOSH5
DMQOSH5 DN PMID25666693-Compound-112
DMQOSH5 HS Patented
DMQOSH5 CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMQOSH5 DT Small molecular drug
DMQOSH5 PC 70652314
DMQOSH5 MW 455.9
DMQOSH5 FM C21H21ClF3N3O3
DMQOSH5 IC InChI=1S/C21H21ClF3N3O3/c22-18-10-13(9-17(30)12-29)11-26-19(18)14-5-7-28(8-6-14)20(31)27-16-3-1-15(2-4-16)21(23,24)25/h1-5,10-11,17,29-30H,6-9,12H2,(H,27,31)
DMQOSH5 CS C1CN(CC=C1C2=C(C=C(C=N2)CC(CO)O)Cl)C(=O)NC3=CC=C(C=C3)C(F)(F)F
DMQOSH5 IK DMTZGKUBPJHALY-UHFFFAOYSA-N
DMQOSH5 IU 4-[3-chloro-5-(2,3-dihydroxypropyl)pyridin-2-yl]-N-[4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxamide
DMQOSH5 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM02O5V ID DM02O5V
DM02O5V DN PMID25666693-Compound-113
DM02O5V HS Patented
DM02O5V CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DM02O5V DT Small molecular drug
DM02O5V PC 70652315
DM02O5V MW 490.3
DM02O5V FM C21H20Cl2F3N3O3
DM02O5V IC InChI=1S/C21H20Cl2F3N3O3/c22-17-9-14(1-2-16(17)21(24,25)26)28-20(32)29-5-3-13(4-6-29)19-18(23)8-12(10-27-19)7-15(31)11-30/h1-3,8-10,15,30-31H,4-7,11H2,(H,28,32)
DM02O5V CS C1CN(CC=C1C2=C(C=C(C=N2)CC(CO)O)Cl)C(=O)NC3=CC(=C(C=C3)C(F)(F)F)Cl
DM02O5V IK XRTGOKOICCLLQT-UHFFFAOYSA-N
DM02O5V IU 4-[3-chloro-5-(2,3-dihydroxypropyl)pyridin-2-yl]-N-[3-chloro-4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxamide
DM02O5V DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMA9YDK ID DMA9YDK
DMA9YDK DN PMID25666693-Compound-114
DMA9YDK HS Patented
DMA9YDK CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMA9YDK DT Small molecular drug
DMA9YDK PC 89556774
DMA9YDK MW 465.9
DMA9YDK FM C20H21ClFN5O3S
DMA9YDK IC InChI=1S/C20H21ClFN5O3S/c21-15-8-12(7-14(29)11-28)10-23-18(15)26-3-5-27(6-4-26)20(30)25-19-24-16-2-1-13(22)9-17(16)31-19/h1-2,8-10,14,28-29H,3-7,11H2,(H,24,25,30)/t14-/m1/s1
DMA9YDK CS C1CN(CCN1C2=C(C=C(C=N2)C[C@H](CO)O)Cl)C(=O)NC3=NC4=C(S3)C=C(C=C4)F
DMA9YDK IK GUCBTAMMWIOHHO-CQSZACIVSA-N
DMA9YDK IU 4-[3-chloro-5-[(2R)-2,3-dihydroxypropyl]pyridin-2-yl]-N-(6-fluoro-1,3-benzothiazol-2-yl)piperazine-1-carboxamide
DMA9YDK DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMF5ODZ ID DMF5ODZ
DMF5ODZ DN PMID25666693-Compound-115
DMF5ODZ HS Patented
DMF5ODZ CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMF5ODZ DT Small molecular drug
DMF5ODZ PC 88875843
DMF5ODZ MW 480
DMF5ODZ FM C21H23ClFN5O3S
DMF5ODZ IC InChI=1S/C21H23ClFN5O3S/c1-12-10-27(19-16(22)7-13(9-24-19)6-15(30)11-29)4-5-28(12)21(31)26-20-25-17-3-2-14(23)8-18(17)32-20/h2-3,7-9,12,15,29-30H,4-6,10-11H2,1H3,(H,25,26,31)/t12-,15-/m1/s1
DMF5ODZ CS C[C@@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=C(C=C3)F)C4=C(C=C(C=N4)C[C@H](CO)O)Cl
DMF5ODZ IK SRAUTTLRNBOIMG-IUODEOHRSA-N
DMF5ODZ IU (2R)-4-[3-chloro-5-[(2R)-2,3-dihydroxypropyl]pyridin-2-yl]-N-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazine-1-carboxamide
DMF5ODZ DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMNEBXL ID DMNEBXL
DMNEBXL DN PMID25666693-Compound-116
DMNEBXL HS Patented
DMNEBXL CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMNEBXL DT Small molecular drug
DMNEBXL PC 88875796
DMNEBXL MW 465.9
DMNEBXL FM C20H21ClFN5O3S
DMNEBXL IC InChI=1S/C20H21ClFN5O3S/c21-13-1-2-16-17(9-13)31-19(24-16)25-20(30)27-5-3-26(4-6-27)18-15(22)8-12(10-23-18)7-14(29)11-28/h1-2,8-10,14,28-29H,3-7,11H2,(H,24,25,30)/t14-/m1/s1
DMNEBXL CS C1CN(CCN1C2=C(C=C(C=N2)C[C@H](CO)O)F)C(=O)NC3=NC4=C(S3)C=C(C=C4)Cl
DMNEBXL IK STXPENJJMUYCAL-CQSZACIVSA-N
DMNEBXL IU N-(6-chloro-1,3-benzothiazol-2-yl)-4-[5-[(2R)-2,3-dihydroxypropyl]-3-fluoropyridin-2-yl]piperazine-1-carboxamide
DMNEBXL DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMN9LDH ID DMN9LDH
DMN9LDH DN PMID25666693-Compound-117
DMN9LDH HS Patented
DMN9LDH CP Shionogi & Co., Ltd. KUROSE, Noriyuki
DMN9LDH DT Small molecular drug
DMN9LDH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMBIQMS ID DMBIQMS
DMBIQMS DN PMID25666693-Compound-118
DMBIQMS HS Patented
DMBIQMS CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMBIQMS DT Small molecular drug
DMBIQMS PC 53386424
DMBIQMS MW 400.9
DMBIQMS FM C20H21ClN4O3
DMBIQMS IC InChI=1S/C20H21ClN4O3/c21-14-7-6-13(17(10-14)25-8-1-2-9-25)11-22-20(27)24-16-5-3-4-15-19(16)28-12-18(26)23-15/h3-7,10H,1-2,8-9,11-12H2,(H,23,26)(H2,22,24,27)
DMBIQMS CS C1CCN(C1)C2=C(C=CC(=C2)Cl)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
DMBIQMS IK IMKHWDHGNGTOSD-UHFFFAOYSA-N
DMBIQMS IU 1-[(4-chloro-2-pyrrolidin-1-ylphenyl)methyl]-3-(3-oxo-4H-1,4-benzoxazin-8-yl)urea
DMBIQMS DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMD0WIA ID DMD0WIA
DMD0WIA DN PMID25666693-Compound-119
DMD0WIA HS Patented
DMD0WIA CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMD0WIA DT Small molecular drug
DMD0WIA PC 53477385
DMD0WIA MW 393.4
DMD0WIA FM C18H18F3N5O2
DMD0WIA IC InChI=1S/C18H18F3N5O2/c1-26(2)14-8-11(18(19,20)21)7-6-10(14)9-22-16(27)23-12-4-3-5-13-15(12)25-17(28)24-13/h3-8H,9H2,1-2H3,(H2,22,23,27)(H2,24,25,28)
DMD0WIA CS CN(C)C1=C(C=CC(=C1)C(F)(F)F)CNC(=O)NC2=CC=CC3=C2NC(=O)N3
DMD0WIA IK GUTYAMHQYWODRM-UHFFFAOYSA-N
DMD0WIA IU 1-[[2-(dimethylamino)-4-(trifluoromethyl)phenyl]methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea
DMD0WIA DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMVSFNE ID DMVSFNE
DMVSFNE DN PMID25666693-Compound-12
DMVSFNE HS Patented
DMVSFNE CP ABBVIE INC
DMVSFNE DT Small molecular drug
DMVSFNE PC 66549652
DMVSFNE MW 381.4
DMVSFNE FM C22H21F2N3O
DMVSFNE IC InChI=1S/C22H21F2N3O/c1-13-9-19-16(12-25-13)6-8-20(24)21(19)27-22(28)26-18-7-5-15(11-18)14-3-2-4-17(23)10-14/h2-4,6,8-10,12,15,18H,5,7,11H2,1H3,(H2,26,27,28)/t15-,18-/m1/s1
DMVSFNE CS CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@H](C3)C4=CC(=CC=C4)F)F)C=N1
DMVSFNE IK PAFRMBKESKKSIA-CRAIPNDOSA-N
DMVSFNE IU 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3R)-3-(3-fluorophenyl)cyclopentyl]urea
DMVSFNE DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMVREIM ID DMVREIM
DMVREIM DN PMID25666693-Compound-120
DMVREIM HS Patented
DMVREIM CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMVREIM DT Small molecular drug
DMVREIM PC 53477386
DMVREIM MW 419.4
DMVREIM FM C20H20F3N5O2
DMVREIM IC InChI=1S/C20H20F3N5O2/c21-20(22,23)13-7-6-12(16(10-13)28-8-1-2-9-28)11-24-18(29)25-14-4-3-5-15-17(14)27-19(30)26-15/h3-7,10H,1-2,8-9,11H2,(H2,24,25,29)(H2,26,27,30)
DMVREIM CS C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMVREIM IK GUWJRCUFOIXCMK-UHFFFAOYSA-N
DMVREIM IU 1-(2-oxo-1,3-dihydrobenzimidazol-4-yl)-3-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DMVREIM DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMC1QDB ID DMC1QDB
DMC1QDB DN PMID25666693-Compound-121
DMC1QDB HS Patented
DMC1QDB CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMC1QDB DT Small molecular drug
DMC1QDB PC 53477387
DMC1QDB MW 433.4
DMC1QDB FM C21H22F3N5O2
DMC1QDB IC InChI=1S/C21H22F3N5O2/c22-21(23,24)14-8-7-13(17(11-14)29-9-2-1-3-10-29)12-25-19(30)26-15-5-4-6-16-18(15)28-20(31)27-16/h4-8,11H,1-3,9-10,12H2,(H2,25,26,30)(H2,27,28,31)
DMC1QDB CS C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMC1QDB IK ILFYSMXXQODUJS-UHFFFAOYSA-N
DMC1QDB IU 1-(2-oxo-1,3-dihydrobenzimidazol-4-yl)-3-[[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DMC1QDB DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMR63O2 ID DMR63O2
DMR63O2 DN PMID25666693-Compound-122
DMR63O2 HS Patented
DMR63O2 CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMR63O2 DT Small molecular drug
DMR63O2 PC 53476470
DMR63O2 MW 408.4
DMR63O2 FM C19H19F3N4O3
DMR63O2 IC InChI=1S/C19H19F3N4O3/c1-26(2)15-8-12(19(20,21)22)7-6-11(15)9-23-18(28)25-14-5-3-4-13-17(14)29-10-16(27)24-13/h3-8H,9-10H2,1-2H3,(H,24,27)(H2,23,25,28)
DMR63O2 CS CN(C)C1=C(C=CC(=C1)C(F)(F)F)CNC(=O)NC2=CC=CC3=C2OCC(=O)N3
DMR63O2 IK NEPJFAHBBJEELA-UHFFFAOYSA-N
DMR63O2 IU 1-[[2-(dimethylamino)-4-(trifluoromethyl)phenyl]methyl]-3-(3-oxo-4H-1,4-benzoxazin-8-yl)urea
DMR63O2 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM9358G ID DM9358G
DM9358G DN PMID25666693-Compound-123
DM9358G HS Patented
DM9358G CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DM9358G DT Small molecular drug
DM9358G PC 53476471
DM9358G MW 434.4
DM9358G FM C21H21F3N4O3
DM9358G IC InChI=1S/C21H21F3N4O3/c22-21(23,24)14-7-6-13(17(10-14)28-8-1-2-9-28)11-25-20(30)27-16-5-3-4-15-19(16)31-12-18(29)26-15/h3-7,10H,1-2,8-9,11-12H2,(H,26,29)(H2,25,27,30)
DM9358G CS C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
DM9358G IK ABNCWKBVNWSWPZ-UHFFFAOYSA-N
DM9358G IU 1-(3-oxo-4H-1,4-benzoxazin-8-yl)-3-[[2-pyrrolidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DM9358G DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM6ODU7 ID DM6ODU7
DM6ODU7 DN PMID25666693-Compound-124
DM6ODU7 HS Patented
DM6ODU7 CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DM6ODU7 DT Small molecular drug
DM6ODU7 PC 53476472
DM6ODU7 MW 448.4
DM6ODU7 FM C22H23F3N4O3
DM6ODU7 IC InChI=1S/C22H23F3N4O3/c23-22(24,25)15-8-7-14(18(11-15)29-9-2-1-3-10-29)12-26-21(31)28-17-6-4-5-16-20(17)32-13-19(30)27-16/h4-8,11H,1-3,9-10,12-13H2,(H,27,30)(H2,26,28,31)
DM6ODU7 CS C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)CNC(=O)NC3=CC=CC4=C3OCC(=O)N4
DM6ODU7 IK FSBAINYERQVPNQ-UHFFFAOYSA-N
DM6ODU7 IU 1-(3-oxo-4H-1,4-benzoxazin-8-yl)-3-[[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]methyl]urea
DM6ODU7 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMR0WM1 ID DMR0WM1
DMR0WM1 DN PMID25666693-Compound-125
DMR0WM1 HS Patented
DMR0WM1 CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMR0WM1 DT Small molecular drug
DMR0WM1 PC 53475699
DMR0WM1 MW 385.8
DMR0WM1 FM C19H20ClN5O2
DMR0WM1 IC InChI=1S/C19H20ClN5O2/c20-13-7-6-12(16(10-13)25-8-1-2-9-25)11-21-18(26)22-14-4-3-5-15-17(14)24-19(27)23-15/h3-7,10H,1-2,8-9,11H2,(H2,21,22,26)(H2,23,24,27)
DMR0WM1 CS C1CCN(C1)C2=C(C=CC(=C2)Cl)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMR0WM1 IK HZDOWKSLUNQEPU-UHFFFAOYSA-N
DMR0WM1 IU 1-[(4-chloro-2-pyrrolidin-1-ylphenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea
DMR0WM1 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMKN72Y ID DMKN72Y
DMKN72Y DN PMID25666693-Compound-126
DMKN72Y HS Patented
DMKN72Y CP PHARMESTE S.R.L. NAPOLETANO, Mauro TREVISANI, Marcello PAVANI, Maria Giovanna FRUTTAROLO, Francesca
DMKN72Y DT Small molecular drug
DMKN72Y PC 53475700
DMKN72Y MW 399.9
DMKN72Y FM C20H22ClN5O2
DMKN72Y IC InChI=1S/C20H22ClN5O2/c21-14-8-7-13(17(11-14)26-9-2-1-3-10-26)12-22-19(27)23-15-5-4-6-16-18(15)25-20(28)24-16/h4-8,11H,1-3,9-10,12H2,(H2,22,23,27)(H2,24,25,28)
DMKN72Y CS C1CCN(CC1)C2=C(C=CC(=C2)Cl)CNC(=O)NC3=CC=CC4=C3NC(=O)N4
DMKN72Y IK UDSQXLZVIWKXME-UHFFFAOYSA-N
DMKN72Y IU 1-[(4-chloro-2-piperidin-1-ylphenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea
DMKN72Y DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMCE6MB ID DMCE6MB
DMCE6MB DN PMID25666693-Compound-127
DMCE6MB HS Patented
DMCE6MB CP Sanofi-Aventis
DMCE6MB DT Small molecular drug
DMCE6MB PC 24759759
DMCE6MB MW 439.5
DMCE6MB FM C26H22FN5O
DMCE6MB IC InChI=1S/C26H22FN5O/c27-19-4-6-22-18(13-19)14-24(32(22)16-17-8-10-28-11-9-17)26(33)29-20-5-7-23-21(15-20)30-25-3-1-2-12-31(23)25/h4-11,13-15H,1-3,12,16H2,(H,29,33)
DMCE6MB CS C1CCN2C(=NC3=C2C=CC(=C3)NC(=O)C4=CC5=C(N4CC6=CC=NC=C6)C=CC(=C5)F)C1
DMCE6MB IK NFRFMCDNQXJWRI-UHFFFAOYSA-N
DMCE6MB IU 5-fluoro-1-(pyridin-4-ylmethyl)-N-(1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-7-yl)indole-2-carboxamide
DMCE6MB DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM6QHGV ID DM6QHGV
DM6QHGV DN PMID25666693-Compound-128
DM6QHGV HS Patented
DM6QHGV CP Sanofi-Aventis
DM6QHGV DT Small molecular drug
DM6QHGV PC 24758063
DM6QHGV MW 425.5
DM6QHGV FM C25H20FN5O
DM6QHGV IC InChI=1S/C25H20FN5O/c26-18-3-5-21-17(12-18)13-23(31(21)15-16-7-9-27-10-8-16)25(32)28-19-4-6-22-20(14-19)29-24-2-1-11-30(22)24/h3-10,12-14H,1-2,11,15H2,(H,28,32)
DM6QHGV CS C1CC2=NC3=C(N2C1)C=CC(=C3)NC(=O)C4=CC5=C(N4CC6=CC=NC=C6)C=CC(=C5)F
DM6QHGV IK GBRKESHSZHLQFC-UHFFFAOYSA-N
DM6QHGV IU N-(2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-6-yl)-5-fluoro-1-(pyridin-4-ylmethyl)indole-2-carboxamide
DM6QHGV DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM74NBY ID DM74NBY
DM74NBY DN PMID25666693-Compound-129
DM74NBY HS Patented
DM74NBY CP Sanofi-Aventis
DM74NBY DT Small molecular drug
DM74NBY DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMI0YWU ID DMI0YWU
DMI0YWU DN PMID25666693-Compound-13
DMI0YWU HS Patented
DMI0YWU CP ABBVIE INC
DMI0YWU DT Small molecular drug
DMI0YWU PC 66549649
DMI0YWU MW 379.4
DMI0YWU FM C22H22FN3O2
DMI0YWU IC InChI=1S/C22H22FN3O2/c1-26-20-8-4-7-19(17(20)11-12-21(26)27)25-22(28)24-15-10-9-14(13-15)16-5-2-3-6-18(16)23/h2-8,11-12,14-15H,9-10,13H2,1H3,(H2,24,25,28)/t14-,15-/m1/s1
DMI0YWU CS CN1C(=O)C=CC2=C(C=CC=C21)NC(=O)N[C@@H]3CC[C@H](C3)C4=CC=CC=C4F
DMI0YWU IK NGJOCHXSRSVEDI-HUUCEWRRSA-N
DMI0YWU IU 1-[(1R,3R)-3-(2-fluorophenyl)cyclopentyl]-3-(1-methyl-2-oxoquinolin-5-yl)urea
DMI0YWU DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMIX1K0 ID DMIX1K0
DMIX1K0 DN PMID25666693-Compound-130
DMIX1K0 HS Patented
DMIX1K0 CP Sanofi-Aventis
DMIX1K0 DT Small molecular drug
DMIX1K0 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DML7SYH ID DML7SYH
DML7SYH DN PMID25666693-Compound-131
DML7SYH HS Patented
DML7SYH CP Sanofi
DML7SYH DT Small molecular drug
DML7SYH PC 25094155
DML7SYH MW 443.4
DML7SYH FM C22H17F4N5O
DML7SYH IC InChI=1S/C22H17F4N5O/c1-27-19-6-5-17(11-28-19)30-21(32)18-9-14-8-15(22(24,25)26)10-29-20(14)31(18)12-13-3-2-4-16(23)7-13/h2-11H,12H2,1H3,(H,27,28)(H,30,32)
DML7SYH CS CNC1=NC=C(C=C1)NC(=O)C2=CC3=CC(=CN=C3N2CC4=CC(=CC=C4)F)C(F)(F)F
DML7SYH IK XTNRHSVPOQBJCX-UHFFFAOYSA-N
DML7SYH IU 1-[(3-fluorophenyl)methyl]-N-[6-(methylamino)pyridin-3-yl]-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-2-carboxamide
DML7SYH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHQM8W ID DMHQM8W
DMHQM8W DN PMID25666693-Compound-132
DMHQM8W HS Patented
DMHQM8W CP Sanofi
DMHQM8W DT Small molecular drug
DMHQM8W PC 66908117
DMHQM8W MW 483.5
DMHQM8W FM C25H21F4N5O
DMHQM8W IC InChI=1S/C25H21F4N5O/c26-19-5-3-4-16(10-19)15-34-21(12-17-11-18(25(27,28)29)13-31-23(17)34)24(35)32-20-6-7-22(30-14-20)33-8-1-2-9-33/h3-7,10-14H,1-2,8-9,15H2,(H,32,35)
DMHQM8W CS C1CCN(C1)C2=NC=C(C=C2)NC(=O)C3=CC4=CC(=CN=C4N3CC5=CC(=CC=C5)F)C(F)(F)F
DMHQM8W IK IZIWMKBKLZPSFO-UHFFFAOYSA-N
DMHQM8W IU 1-[(3-fluorophenyl)methyl]-N-(6-pyrrolidin-1-ylpyridin-3-yl)-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-2-carboxamide
DMHQM8W DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHEPR3 ID DMHEPR3
DMHEPR3 DN PMID25666693-Compound-133
DMHEPR3 HS Patented
DMHEPR3 CP Sanofi
DMHEPR3 DT Small molecular drug
DMHEPR3 PC 25094231
DMHEPR3 MW 469.4
DMHEPR3 FM C24H19F4N5O
DMHEPR3 IC InChI=1S/C24H19F4N5O/c25-18-4-1-3-15(9-18)14-33-20(11-16-10-17(24(26,27)28)12-30-22(16)33)23(34)31-19-5-6-21(29-13-19)32-7-2-8-32/h1,3-6,9-13H,2,7-8,14H2,(H,31,34)
DMHEPR3 CS C1CN(C1)C2=NC=C(C=C2)NC(=O)C3=CC4=CC(=CN=C4N3CC5=CC(=CC=C5)F)C(F)(F)F
DMHEPR3 IK DXPFHQMFHSGNDI-UHFFFAOYSA-N
DMHEPR3 IU N-[6-(azetidin-1-yl)pyridin-3-yl]-1-[(3-fluorophenyl)methyl]-5-(trifluoromethyl)pyrrolo[2,3-b]pyridine-2-carboxamide
DMHEPR3 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM2WJKR ID DM2WJKR
DM2WJKR DN PMID25666693-Compound-134
DM2WJKR HS Patented
DM2WJKR CP Novartis AG
DM2WJKR DT Small molecular drug
DM2WJKR PC 11674039
DM2WJKR MW 313.8
DM2WJKR FM C17H16ClN3O
DM2WJKR IC InChI=1S/C17H16ClN3O/c1-10(2)16-20-15-9-12(19)5-8-14(15)17(22)21(16)13-6-3-11(18)4-7-13/h3-10H,19H2,1-2H3
DM2WJKR CS CC(C)C1=NC2=C(C=CC(=C2)N)C(=O)N1C3=CC=C(C=C3)Cl
DM2WJKR IK XBLNKLVBZMWWLK-UHFFFAOYSA-N
DM2WJKR IU 7-amino-3-(4-chlorophenyl)-2-propan-2-ylquinazolin-4-one
DM2WJKR DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMYZVPD ID DMYZVPD
DMYZVPD DN PMID25666693-Compound-135
DMYZVPD HS Patented
DMYZVPD CP Novartis AG
DMYZVPD DT Small molecular drug
DMYZVPD PC 58387673
DMYZVPD MW 347.3
DMYZVPD FM C18H16F3N3O
DMYZVPD IC InChI=1S/C18H16F3N3O/c1-10(2)16-23-15-9-12(22)5-8-14(15)17(25)24(16)13-6-3-11(4-7-13)18(19,20)21/h3-10H,22H2,1-2H3
DMYZVPD CS CC(C)C1=NC2=C(C=CC(=C2)N)C(=O)N1C3=CC=C(C=C3)C(F)(F)F
DMYZVPD IK BRVXMMDZSNVASE-UHFFFAOYSA-N
DMYZVPD IU 7-amino-2-propan-2-yl-3-[4-(trifluoromethyl)phenyl]quinazolin-4-one
DMYZVPD DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMPY1QC ID DMPY1QC
DMPY1QC DN PMID25666693-Compound-136
DMPY1QC HS Patented
DMPY1QC CP Novartis AG
DMPY1QC DT Small molecular drug
DMPY1QC PC 58387639
DMPY1QC MW 348.2
DMPY1QC FM C17H15Cl2N3O
DMPY1QC IC InChI=1S/C17H15Cl2N3O/c1-9(2)16-21-15-12(7-8-13(20)14(15)19)17(23)22(16)11-5-3-10(18)4-6-11/h3-9H,20H2,1-2H3
DMPY1QC CS CC(C)C1=NC2=C(C=CC(=C2Cl)N)C(=O)N1C3=CC=C(C=C3)Cl
DMPY1QC IK KVPDVXGLZNHXJL-UHFFFAOYSA-N
DMPY1QC IU 7-amino-8-chloro-3-(4-chlorophenyl)-2-propan-2-ylquinazolin-4-one
DMPY1QC DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMZ7LAO ID DMZ7LAO
DMZ7LAO DN PMID25666693-Compound-137
DMZ7LAO HS Patented
DMZ7LAO CP Novartis AG
DMZ7LAO DT Small molecular drug
DMZ7LAO DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMJLFEN ID DMJLFEN
DMJLFEN DN PMID25666693-Compound-138
DMJLFEN HS Patented
DMJLFEN CP Novartis AG
DMJLFEN DT Small molecular drug
DMJLFEN DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMLMEPI ID DMLMEPI
DMLMEPI DN PMID25666693-Compound-139
DMLMEPI HS Patented
DMLMEPI CP Novartis AG
DMLMEPI DT Small molecular drug
DMLMEPI DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM3D4RI ID DM3D4RI
DM3D4RI DN PMID25666693-Compound-14
DM3D4RI HS Patented
DM3D4RI CP ABBVIE INC
DM3D4RI DT Small molecular drug
DM3D4RI PC 60202428
DM3D4RI MW 338.4
DM3D4RI FM C19H19FN4O
DM3D4RI IC InChI=1S/C19H19FN4O/c20-16-5-2-1-4-14(16)12-8-9-13(10-12)22-19(25)23-17-6-3-7-18-15(17)11-21-24-18/h1-7,11-13H,8-10H2,(H,21,24)(H2,22,23,25)/t12-,13-/m1/s1
DM3D4RI CS C1C[C@H](C[C@@H]1C2=CC=CC=C2F)NC(=O)NC3=CC=CC4=C3C=NN4
DM3D4RI IK MNXPYZUSFURMKS-CHWSQXEVSA-N
DM3D4RI IU 1-[(1R,3R)-3-(2-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DM3D4RI DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMVQU9T ID DMVQU9T
DMVQU9T DN PMID25666693-Compound-140
DMVQU9T HS Patented
DMVQU9T CP Novartis AG
DMVQU9T DT Small molecular drug
DMVQU9T PC 23585453
DMVQU9T MW 314.8
DMVQU9T FM C17H15ClN2O2
DMVQU9T IC InChI=1S/C17H15ClN2O2/c1-10(2)16-19-15-9-13(21)7-8-14(15)17(22)20(16)12-5-3-11(18)4-6-12/h3-10,21H,1-2H3
DMVQU9T CS CC(C)C1=NC2=C(C=CC(=C2)O)C(=O)N1C3=CC=C(C=C3)Cl
DMVQU9T IK OJVMSICJWQFIOS-UHFFFAOYSA-N
DMVQU9T IU 3-(4-chlorophenyl)-7-hydroxy-2-propan-2-ylquinazolin-4-one
DMVQU9T DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQGTYE ID DMQGTYE
DMQGTYE DN PMID25666693-Compound-141
DMQGTYE HS Patented
DMQGTYE CP Novartis AG
DMQGTYE DT Small molecular drug
DMQGTYE PC 53402973
DMQGTYE MW 348.3
DMQGTYE FM C18H15F3N2O2
DMQGTYE IC InChI=1S/C18H15F3N2O2/c1-10(2)16-22-15-9-13(24)7-8-14(15)17(25)23(16)12-5-3-11(4-6-12)18(19,20)21/h3-10,24H,1-2H3
DMQGTYE CS CC(C)C1=NC2=C(C=CC(=C2)O)C(=O)N1C3=CC=C(C=C3)C(F)(F)F
DMQGTYE IK BQCYMHBVGHVCTM-UHFFFAOYSA-N
DMQGTYE IU 7-hydroxy-2-propan-2-yl-3-[4-(trifluoromethyl)phenyl]quinazolin-4-one
DMQGTYE DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMFKN1O ID DMFKN1O
DMFKN1O DN PMID25666693-Compound-142
DMFKN1O HS Patented
DMFKN1O CP Novartis AG
DMFKN1O DT Small molecular drug
DMFKN1O PC 58387658
DMFKN1O MW 393.7
DMFKN1O FM C17H14BrClN2O2
DMFKN1O IC InChI=1S/C17H14BrClN2O2/c1-9(2)16-20-15-12(7-8-13(22)14(15)18)17(23)21(16)11-5-3-10(19)4-6-11/h3-9,22H,1-2H3
DMFKN1O CS CC(C)C1=NC2=C(C=CC(=C2Br)O)C(=O)N1C3=CC=C(C=C3)Cl
DMFKN1O IK RGGBBKIVAZMLNK-UHFFFAOYSA-N
DMFKN1O IU 8-bromo-3-(4-chlorophenyl)-7-hydroxy-2-propan-2-ylquinazolin-4-one
DMFKN1O DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMJP0NB ID DMJP0NB
DMJP0NB DN PMID25666693-Compound-143
DMJP0NB HS Patented
DMJP0NB CP DAEWOONG PHARMACEUTICAL CO., LTD. KIM, Ji Duck YOON, Hong Chul KIM, In Woo CHO, Min Jae LEE, In Young LEE, Sang Ho PARK, Eun Kyung LIM, Kwon Jo NAM, Sang Hyun
DMJP0NB DT Small molecular drug
DMJP0NB DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMCXELD ID DMCXELD
DMCXELD DN PMID25666693-Compound-144
DMCXELD HS Patented
DMCXELD CP DAEWOONG PHARMACEUTICAL CO., LTD. KIM, Ji Duck YOON, Hong Chul KIM, In Woo CHO, Min Jae LEE, In Young LEE, Sang Ho PARK, Eun Kyung LIM, Kwon Jo NAM, Sang Hyun
DMCXELD DT Small molecular drug
DMCXELD PC 67412556
DMCXELD MW 440.9
DMCXELD FM C22H18ClFN4O3
DMCXELD IC InChI=1S/C22H18ClFN4O3/c1-30-13-5-6-20(25-9-13)28-12(10-29)11-31-21-14(3-2-4-19(21)28)22-26-17-7-15(23)16(24)8-18(17)27-22/h2-9,12,29H,10-11H2,1H3,(H,26,27)/t12-/m0/s1
DMCXELD CS COC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C4=NC5=CC(=C(C=C5N4)F)Cl)CO
DMCXELD IK KALRQYKXWDYSRI-LBPRGKRZSA-N
DMCXELD IU [(3S)-8-(5-chloro-6-fluoro-1H-benzimidazol-2-yl)-4-(5-methoxypyridin-2-yl)-2,3-dihydro-1,4-benzoxazin-3-yl]methanol
DMCXELD DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMP89E4 ID DMP89E4
DMP89E4 DN PMID25666693-Compound-145
DMP89E4 HS Patented
DMP89E4 CP DAEWOONG PHARMACEUTICAL CO., LTD. KIM, Ji Duck YOON, Hong Chul KIM, In Woo CHO, Min Jae LEE, In Young LEE, Sang Ho PARK, Eun Kyung LIM, Kwon Jo NAM, Sang Hyun
DMP89E4 DT Small molecular drug
DMP89E4 PC 67412506
DMP89E4 MW 490.9
DMP89E4 FM C23H18ClF3N4O3
DMP89E4 IC InChI=1S/C23H18ClF3N4O3/c1-33-14-5-6-19(28-9-14)31-13(10-32)11-34-21-15(3-2-4-18(21)31)22-29-17-8-12(23(25,26)27)7-16(24)20(17)30-22/h2-9,13,32H,10-11H2,1H3,(H,29,30)/t13-/m0/s1
DMP89E4 CS COC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C4=NC5=C(N4)C=C(C=C5Cl)C(F)(F)F)CO
DMP89E4 IK CKJDUPIYRSXWAL-ZDUSSCGKSA-N
DMP89E4 IU [(3S)-8-[4-chloro-6-(trifluoromethyl)-1H-benzimidazol-2-yl]-4-(5-methoxypyridin-2-yl)-2,3-dihydro-1,4-benzoxazin-3-yl]methanol
DMP89E4 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMLE5BK ID DMLE5BK
DMLE5BK DN PMID25666693-Compound-146
DMLE5BK HS Patented
DMLE5BK CP Xention Ltd
DMLE5BK DT Small molecular drug
DMLE5BK PC 59730981
DMLE5BK MW 430.5
DMLE5BK FM C26H26N2O4
DMLE5BK IC InChI=1S/C26H26N2O4/c1-2-32-25(30)19-11-9-17(10-12-19)20-6-3-7-21(15-20)27-26(31)28-24-8-4-5-18-13-14-22(29)16-23(18)24/h3-12,15,22,29H,2,13-14,16H2,1H3,(H2,27,28,31)
DMLE5BK CS CCOC(=O)C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)NC3=CC=CC4=C3CC(CC4)O
DMLE5BK IK IWMJRJDFRWWJBW-UHFFFAOYSA-N
DMLE5BK IU ethyl 4-[3-[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamoylamino]phenyl]benzoate
DMLE5BK DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMG1SYN ID DMG1SYN
DMG1SYN DN PMID25666693-Compound-147
DMG1SYN HS Patented
DMG1SYN CP Xention Ltd
DMG1SYN DT Small molecular drug
DMG1SYN PC 59731029
DMG1SYN MW 410.9
DMG1SYN FM C23H20ClFN2O2
DMG1SYN IC InChI=1S/C23H20ClFN2O2/c24-20-10-8-16(12-21(20)25)15-4-1-5-17(11-15)26-23(29)27-22-6-2-3-14-7-9-18(28)13-19(14)22/h1-6,8,10-12,18,28H,7,9,13H2,(H2,26,27,29)
DMG1SYN CS C1CC2=C(CC1O)C(=CC=C2)NC(=O)NC3=CC=CC(=C3)C4=CC(=C(C=C4)Cl)F
DMG1SYN IK VIQQVXGGWBFLTG-UHFFFAOYSA-N
DMG1SYN IU 1-[3-(4-chloro-3-fluorophenyl)phenyl]-3-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea
DMG1SYN DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM0EYON ID DM0EYON
DM0EYON DN PMID25666693-Compound-148
DM0EYON HS Patented
DM0EYON CP Xention Ltd
DM0EYON DT Small molecular drug
DM0EYON PC 59731038
DM0EYON MW 379.4
DM0EYON FM C23H19F2NO2
DM0EYON IC InChI=1S/C23H19F2NO2/c24-20-11-9-17(12-21(20)25)14-4-6-16(7-5-14)23(28)26-22-3-1-2-15-8-10-18(27)13-19(15)22/h1-7,9,11-12,18,27H,8,10,13H2,(H,26,28)
DM0EYON CS C1CC2=C(CC1O)C(=CC=C2)NC(=O)C3=CC=C(C=C3)C4=CC(=C(C=C4)F)F
DM0EYON IK BBXIMYHEGLSHKN-UHFFFAOYSA-N
DM0EYON IU 4-(3,4-difluorophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)benzamide
DM0EYON DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMPU19H ID DMPU19H
DMPU19H DN PMID25666693-Compound-149
DMPU19H HS Patented
DMPU19H CP Xention Ltd
DMPU19H DT Small molecular drug
DMPU19H DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM1G6AE ID DM1G6AE
DM1G6AE DN PMID25666693-Compound-15
DM1G6AE HS Patented
DM1G6AE CP ABBOTT LABORATORIES
DM1G6AE DT Small molecular drug
DM1G6AE PC 25263680
DM1G6AE MW 417.4
DM1G6AE FM C21H18F3N3O3
DM1G6AE IC InChI=1S/C21H18F3N3O3/c1-12-10-15-13(11-25-12)4-2-6-16(15)26-20(28)27-17-8-9-29-19-14(17)5-3-7-18(19)30-21(22,23)24/h2-7,10-11,17H,8-9H2,1H3,(H2,26,27,28)/t17-/m1/s1
DM1G6AE CS CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CCOC4=C3C=CC=C4OC(F)(F)F)C=N1
DM1G6AE IK JPPAKTWQFHCNDQ-QGZVFWFLSA-N
DM1G6AE IU 1-(3-methylisoquinolin-5-yl)-3-[(4R)-8-(trifluoromethoxy)-3,4-dihydro-2H-chromen-4-yl]urea
DM1G6AE DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHMEFY ID DMHMEFY
DMHMEFY DN PMID25666693-Compound-150
DMHMEFY HS Patented
DMHMEFY CP Amorepacific Corp
DMHMEFY DT Small molecular drug
DMHMEFY PC 68324561
DMHMEFY MW 479.6
DMHMEFY FM C22H23F2N3O3S2
DMHMEFY IC InChI=1S/C22H23F2N3O3S2/c1-12(2)14-6-5-7-15(8-14)22-26-19(11-31-22)21(28)25-13(3)16-9-17(23)20(18(24)10-16)27-32(4,29)30/h5-13,27H,1-4H3,(H,25,28)/t13-/m1/s1
DMHMEFY CS C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CSC(=N2)C3=CC(=CC=C3)C(C)C
DMHMEFY IK PCULXRGTXBQRDF-CYBMUJFWSA-N
DMHMEFY IU N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-2-(3-propan-2-ylphenyl)-1,3-thiazole-4-carboxamide
DMHMEFY DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM5CY86 ID DM5CY86
DM5CY86 DN PMID25666693-Compound-151
DM5CY86 HS Patented
DM5CY86 CP Amorepacific Corp
DM5CY86 DT Small molecular drug
DM5CY86 PC 68324656
DM5CY86 MW 461.5
DM5CY86 FM C22H21F2N3O4S
DM5CY86 IC InChI=1S/C22H21F2N3O4S/c1-12(16-9-17(23)20(18(24)10-16)27-32(2,29)30)25-21(28)19-11-31-22(26-19)15-5-3-4-14(8-15)13-6-7-13/h3-5,8-13,27H,6-7H2,1-2H3,(H,25,28)/t12-/m1/s1
DM5CY86 CS C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=COC(=N2)C3=CC(=CC=C3)C4CC4
DM5CY86 IK PCQJGNGGTPQUOG-GFCCVEGCSA-N
DM5CY86 IU 2-(3-cyclopropylphenyl)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-1,3-oxazole-4-carboxamide
DM5CY86 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM27154 ID DM27154
DM27154 DN PMID25666693-Compound-152
DM27154 HS Patented
DM27154 CP Amorepacific Corp
DM27154 DT Small molecular drug
DM27154 PC 44548476
DM27154 MW 488.4
DM27154 FM C21H17F5N2O4S
DM27154 IC InChI=1S/C21H17F5N2O4S/c1-11(13-9-15(22)19(16(23)10-13)28-33(2,30)31)27-20(29)18-7-6-17(32-18)12-4-3-5-14(8-12)21(24,25)26/h3-11,28H,1-2H3,(H,27,29)/t11-/m1/s1
DM27154 CS C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CC=C(O2)C3=CC(=CC=C3)C(F)(F)F
DM27154 IK UBEWFMQQEXOLKY-LLVKDONJSA-N
DM27154 IU N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-5-[3-(trifluoromethyl)phenyl]furan-2-carboxamide
DM27154 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM1FTV6 ID DM1FTV6
DM1FTV6 DN PMID25666693-Compound-153
DM1FTV6 HS Patented
DM1FTV6 CP Amorepacific Corp
DM1FTV6 DT Small molecular drug
DM1FTV6 PC 88937082
DM1FTV6 MW 556.4
DM1FTV6 FM C22H16F8N2O4S
DM1FTV6 IC InChI=1S/C22H16F8N2O4S/c1-10(11-7-15(23)19(16(24)8-11)32-37(2,34)35)31-20(33)18-4-3-17(36-18)12-5-13(21(25,26)27)9-14(6-12)22(28,29)30/h3-10,32H,1-2H3,(H,31,33)/t10-/m1/s1
DM1FTV6 CS C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CC=C(O2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DM1FTV6 IK RGPMLUVMZUYQEJ-SNVBAGLBSA-N
DM1FTV6 IU 5-[3,5-bis(trifluoromethyl)phenyl]-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]furan-2-carboxamide
DM1FTV6 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMKNU0Z ID DMKNU0Z
DMKNU0Z DN PMID25666693-Compound-154
DMKNU0Z HS Patented
DMKNU0Z CP Amorepacific Corp
DMKNU0Z DT Small molecular drug
DMKNU0Z PC 88937150
DMKNU0Z MW 506.4
DMKNU0Z FM C21H16F6N2O4S
DMKNU0Z IC InChI=1S/C21H16F6N2O4S/c1-10(12-8-15(23)19(16(24)9-12)29-34(2,31)32)28-20(30)18-6-5-17(33-18)11-3-4-14(22)13(7-11)21(25,26)27/h3-10,29H,1-2H3,(H,28,30)/t10-/m1/s1
DMKNU0Z CS C[C@H](C1=CC(=C(C(=C1)F)NS(=O)(=O)C)F)NC(=O)C2=CC=C(O2)C3=CC(=C(C=C3)F)C(F)(F)F
DMKNU0Z IK UERGSQUAPFQUKE-SNVBAGLBSA-N
DMKNU0Z IU N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]furan-2-carboxamide
DMKNU0Z DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMZLB07 ID DMZLB07
DMZLB07 DN PMID25666693-Compound-155
DMZLB07 HS Patented
DMZLB07 CP Janssen Pharmaceutica NV
DMZLB07 DT Small molecular drug
DMZLB07 PC 24782891
DMZLB07 MW 441.5
DMZLB07 FM C24H26F3N5
DMZLB07 IC InChI=1S/C24H26F3N5/c1-23(2,3)16-6-8-17(9-7-16)31-21-18-10-13-32(14-11-20(18)29-15-30-21)22-19(24(25,26)27)5-4-12-28-22/h4-9,12,15H,10-11,13-14H2,1-3H3,(H,29,30,31)
DMZLB07 CS CC(C)(C)C1=CC=C(C=C1)NC2=NC=NC3=C2CCN(CC3)C4=C(C=CC=N4)C(F)(F)F
DMZLB07 IK HUWDXCSRDAPMOC-UHFFFAOYSA-N
DMZLB07 IU N-(4-tert-butylphenyl)-7-[3-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DMZLB07 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMTVAUP ID DMTVAUP
DMTVAUP DN PMID25666693-Compound-156
DMTVAUP HS Patented
DMTVAUP CP Janssen Pharmaceutica NV
DMTVAUP DT Small molecular drug
DMTVAUP PC 24783142
DMTVAUP MW 483.6
DMTVAUP FM C27H32F3N5
DMTVAUP IC InChI=1S/C27H32F3N5/c1-17(2)23-33-22-13-16-35(25-21(27(28,29)30)7-6-14-31-25)15-12-20(22)24(34-23)32-19-10-8-18(9-11-19)26(3,4)5/h6-11,14,17H,12-13,15-16H2,1-5H3,(H,32,33,34)
DMTVAUP CS CC(C)C1=NC2=C(CCN(CC2)C3=C(C=CC=N3)C(F)(F)F)C(=N1)NC4=CC=C(C=C4)C(C)(C)C
DMTVAUP IK KJNMKUGTDFIAPJ-UHFFFAOYSA-N
DMTVAUP IU N-(4-tert-butylphenyl)-2-propan-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DMTVAUP DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DME8LUY ID DME8LUY
DME8LUY DN PMID25666693-Compound-157
DME8LUY HS Patented
DME8LUY CP Janssen Pharmaceutica NV
DME8LUY DT Small molecular drug
DME8LUY PC 52949700
DME8LUY MW 496.5
DME8LUY FM C23H22F6N6
DME8LUY IC InChI=1S/C23H22F6N6/c1-13(2)19-32-17-8-11-35(21-16(23(27,28)29)4-3-9-30-21)10-7-15(17)20(34-19)33-18-6-5-14(12-31-18)22(24,25)26/h3-6,9,12-13H,7-8,10-11H2,1-2H3,(H,31,32,33,34)
DME8LUY CS CC(C)C1=NC2=C(CCN(CC2)C3=C(C=CC=N3)C(F)(F)F)C(=N1)NC4=NC=C(C=C4)C(F)(F)F
DME8LUY IK NACDTTPBPBGLSZ-UHFFFAOYSA-N
DME8LUY IU 2-propan-2-yl-7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DME8LUY DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM2BTCU ID DM2BTCU
DM2BTCU DN PMID25666693-Compound-158
DM2BTCU HS Patented
DM2BTCU CP Janssen Pharmaceutica NV
DM2BTCU DT Small molecular drug
DM2BTCU PC 16742146
DM2BTCU MW 536.5
DM2BTCU FM C26H26F6N6
DM2BTCU IC InChI=1S/C26H26F6N6/c27-25(28,29)17-6-8-18(9-7-17)34-22-19-10-15-37(23-20(26(30,31)32)5-4-12-33-23)16-11-21(19)35-24(36-22)38-13-2-1-3-14-38/h4-9,12H,1-3,10-11,13-16H2,(H,34,35,36)
DM2BTCU CS C1CCN(CC1)C2=NC3=C(CCN(CC3)C4=C(C=CC=N4)C(F)(F)F)C(=N2)NC5=CC=C(C=C5)C(F)(F)F
DM2BTCU IK MRHHSXHMRZMNIM-UHFFFAOYSA-N
DM2BTCU IU 2-piperidin-1-yl-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]-5,6,8,9-tetrahydropyrimido[4,5-d]azepin-4-amine
DM2BTCU CA CAS 951135-00-5
DM2BTCU DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM74OGS ID DM74OGS
DM74OGS DN PMID25666693-Compound-159
DM74OGS HS Patented
DM74OGS CP Janssen Pharmaceutica NV
DM74OGS DT Small molecular drug
DM74OGS DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM6SL9D ID DM6SL9D
DM6SL9D DN PMID25666693-Compound-16
DM6SL9D HS Patented
DM6SL9D CP ABBOTT LABORATORIES
DM6SL9D DT Small molecular drug
DM6SL9D PC 46191563
DM6SL9D MW 481.4
DM6SL9D FM C23H20F5N3O3
DM6SL9D IC InChI=1S/C23H20F5N3O3/c1-13-8-16-14(10-29-13)4-2-6-17(16)30-21(32)31-18-9-22(11-24,12-25)34-20-15(18)5-3-7-19(20)33-23(26,27)28/h2-8,10,18H,9,11-12H2,1H3,(H2,30,31,32)/t18-/m1/s1
DM6SL9D CS CC1=CC2=C(C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC=C4OC(F)(F)F)(CF)CF)C=N1
DM6SL9D IK NCTHKPLEGMZRNY-GOSISDBHSA-N
DM6SL9D IU 1-[(4R)-2,2-bis(fluoromethyl)-8-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3-(3-methylisoquinolin-5-yl)urea
DM6SL9D DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM2KTAB ID DM2KTAB
DM2KTAB DN PMID25666693-Compound-160
DM2KTAB HS Patented
DM2KTAB CP Janssen Pharmaceutica NV
DM2KTAB DT Small molecular drug
DM2KTAB DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM06IWA ID DM06IWA
DM06IWA DN PMID25666693-Compound-161
DM06IWA HS Patented
DM06IWA CP Janssen Pharmaceutica NV
DM06IWA DT Small molecular drug
DM06IWA DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMXS5WY ID DMXS5WY
DMXS5WY DN PMID25666693-Compound-162
DMXS5WY HS Patented
DMXS5WY CP Janssen Pharmaceutica NV
DMXS5WY DT Small molecular drug
DMXS5WY DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMRK1W7 ID DMRK1W7
DMRK1W7 DN PMID25666693-Compound-17
DMRK1W7 HS Patented
DMRK1W7 CP ABBOTT LABORATORIES
DMRK1W7 DT Small molecular drug
DMRK1W7 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMKU6C3 ID DMKU6C3
DMKU6C3 DN PMID25666693-Compound-18
DMKU6C3 HS Patented
DMKU6C3 CP ABBOTT LABORATORIES
DMKU6C3 DT Small molecular drug
DMKU6C3 PC 25265637
DMKU6C3 MW 407.5
DMKU6C3 FM C24H26FN3O2
DMKU6C3 IC InChI=1S/C24H26FN3O2/c1-4-24(5-2)13-21(17-9-7-10-19(25)22(17)30-24)28-23(29)27-20-11-6-8-16-14-26-15(3)12-18(16)20/h6-12,14,21H,4-5,13H2,1-3H3,(H2,27,28,29)/t21-/m1/s1
DMKU6C3 CS CCC1(C[C@H](C2=C(O1)C(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC
DMKU6C3 IK KRCMLCOREROPCP-OAQYLSRUSA-N
DMKU6C3 IU 1-[(4R)-2,2-diethyl-8-fluoro-3,4-dihydrochromen-4-yl]-3-(3-methylisoquinolin-5-yl)urea
DMKU6C3 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM63UM8 ID DM63UM8
DM63UM8 DN PMID25666693-Compound-19
DM63UM8 HS Patented
DM63UM8 CP ABBOTT LABORATORIES
DM63UM8 DT Small molecular drug
DM63UM8 PC 25263543
DM63UM8 MW 423.9
DM63UM8 FM C24H26ClN3O2
DM63UM8 IC InChI=1S/C24H26ClN3O2/c1-4-24(5-2)13-21(18-10-9-17(25)12-22(18)30-24)28-23(29)27-20-8-6-7-16-14-26-15(3)11-19(16)20/h6-12,14,21H,4-5,13H2,1-3H3,(H2,27,28,29)/t21-/m1/s1
DM63UM8 CS CCC1(C[C@H](C2=C(O1)C=C(C=C2)Cl)NC(=O)NC3=CC=CC4=C3C=C(N=C4)C)CC
DM63UM8 IK PETMJQMEMLSBKV-OAQYLSRUSA-N
DM63UM8 IU 1-[(4R)-7-chloro-2,2-diethyl-3,4-dihydrochromen-4-yl]-3-(3-methylisoquinolin-5-yl)urea
DM63UM8 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMERD39 ID DMERD39
DMERD39 DN PMID25666693-Compound-2
DMERD39 HS Patented
DMERD39 CP ABBVIE INC
DMERD39 DT Small molecular drug
DMERD39 PC 66549276
DMERD39 MW 381.4
DMERD39 FM C22H21F2N3O
DMERD39 IC InChI=1S/C22H21F2N3O/c1-13-10-18-15(12-25-13)7-9-20(24)21(18)27-22(28)26-16-8-6-14(11-16)17-4-2-3-5-19(17)23/h2-5,7,9-10,12,14,16H,6,8,11H2,1H3,(H2,26,27,28)/t14-,16+/m0/s1
DMERD39 CS CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@@H](C3)C4=CC=CC=C4F)F)C=N1
DMERD39 IK PJVXUKARZNCIRA-GOEBONIOSA-N
DMERD39 IU 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-(2-fluorophenyl)cyclopentyl]urea
DMERD39 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM3I90D ID DM3I90D
DM3I90D DN PMID25666693-Compound-20
DM3I90D HS Patented
DM3I90D CP ABBOTT LABORATORIES
DM3I90D DT Small molecular drug
DM3I90D DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMUXO47 ID DMUXO47
DMUXO47 DN PMID25666693-Compound-21
DMUXO47 HS Patented
DMUXO47 CP ABBOTT LABORATORIES
DMUXO47 DT Small molecular drug
DMUXO47 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHPW3X ID DMHPW3X
DMHPW3X DN PMID25666693-Compound-22
DMHPW3X HS Patented
DMHPW3X CP ABBOTT LABORATORIES
DMHPW3X DT Small molecular drug
DMHPW3X DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMJ3YDT ID DMJ3YDT
DMJ3YDT DN PMID25666693-Compound-23
DMJ3YDT HS Patented
DMJ3YDT CP ABBOTT LABORATORIES
DMJ3YDT DT Small molecular drug
DMJ3YDT DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMUMYKX ID DMUMYKX
DMUMYKX DN PMID25666693-Compound-24
DMUMYKX HS Patented
DMUMYKX CP AbbVie, Inc
DMUMYKX DT Small molecular drug
DMUMYKX DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMI8CB3 ID DMI8CB3
DMI8CB3 DN PMID25666693-Compound-25
DMI8CB3 HS Patented
DMI8CB3 CP ABBVIE INC
DMI8CB3 DT Small molecular drug
DMI8CB3 PC 71599909
DMI8CB3 MW 404.9
DMI8CB3 FM C21H22ClFN2O3
DMI8CB3 IC InChI=1S/C21H22ClFN2O3/c1-21(2)10-17(13-6-7-15(23)18(22)19(13)28-21)25-20(27)24-16-5-3-4-11-8-12(26)9-14(11)16/h3-7,12,17,26H,8-10H2,1-2H3,(H2,24,25,27)/t12-,17-/m1/s1
DMI8CB3 CS CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)Cl)NC(=O)NC3=CC=CC4=C3C[C@@H](C4)O)C
DMI8CB3 IK NXZOBNXJGCHNTQ-SJKOYZFVSA-N
DMI8CB3 IU 1-[(4R)-8-chloro-7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMI8CB3 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQBFI2 ID DMQBFI2
DMQBFI2 DN PMID25666693-Compound-26
DMQBFI2 HS Patented
DMQBFI2 CP ABBVIE INC
DMQBFI2 DT Small molecular drug
DMQBFI2 PC 71599484
DMQBFI2 MW 436.4
DMQBFI2 FM C22H23F3N2O4
DMQBFI2 IC InChI=1S/C22H23F3N2O4/c1-21(2)11-17(14-6-4-8-18(19(14)31-21)30-22(23,24)25)27-20(29)26-16-7-3-5-12-9-13(28)10-15(12)16/h3-8,13,17,28H,9-11H2,1-2H3,(H2,26,27,29)/t13-,17+/m0/s1
DMQBFI2 CS CC1(C[C@H](C2=C(O1)C(=CC=C2)OC(F)(F)F)NC(=O)NC3=CC=CC4=C3C[C@H](C4)O)C
DMQBFI2 IK VGEBXDOPNDGVPV-SUMWQHHRSA-N
DMQBFI2 IU 1-[(4R)-2,2-dimethyl-8-(trifluoromethoxy)-3,4-dihydrochromen-4-yl]-3-[(2S)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMQBFI2 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMKHO8T ID DMKHO8T
DMKHO8T DN PMID25666693-Compound-27
DMKHO8T HS Patented
DMKHO8T CP ABBVIE INC
DMKHO8T DT Small molecular drug
DMKHO8T PC 71599827
DMKHO8T MW 422.9
DMKHO8T FM C21H21ClF2N2O3
DMKHO8T IC InChI=1S/C21H21ClF2N2O3/c22-13-4-5-15-18(9-21(10-23,11-24)29-19(15)7-13)26-20(28)25-17-3-1-2-12-6-14(27)8-16(12)17/h1-5,7,14,18,27H,6,8-11H2,(H2,25,26,28)/t14-,18-/m1/s1
DMKHO8T CS C1[C@H](CC2=C1C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)Cl)(CF)CF)O
DMKHO8T IK UKGBTQWQSDNAQR-RDTXWAMCSA-N
DMKHO8T IU 1-[(4R)-7-chloro-2,2-bis(fluoromethyl)-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMKHO8T DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM7T962 ID DM7T962
DM7T962 DN PMID25666693-Compound-28
DM7T962 HS Patented
DM7T962 CP ABBVIE INC
DM7T962 DT Small molecular drug
DM7T962 PC 71580510
DM7T962 MW 456.4
DM7T962 FM C22H21F5N2O3
DM7T962 IC InChI=1S/C22H21F5N2O3/c23-10-21(11-24)9-18(15-5-4-13(22(25,26)27)7-19(15)32-21)29-20(31)28-17-3-1-2-12-6-14(30)8-16(12)17/h1-5,7,14,18,30H,6,8-11H2,(H2,28,29,31)/t14-,18-/m1/s1
DM7T962 CS C1[C@H](CC2=C1C=CC=C2NC(=O)N[C@@H]3CC(OC4=C3C=CC(=C4)C(F)(F)F)(CF)CF)O
DM7T962 IK PPTIROVBLCDDBO-RDTXWAMCSA-N
DM7T962 IU 1-[(4R)-2,2-bis(fluoromethyl)-7-(trifluoromethyl)-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DM7T962 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM02D1B ID DM02D1B
DM02D1B DN PMID25666693-Compound-29
DM02D1B HS Patented
DM02D1B CP ABBVIE INC
DM02D1B DT Small molecular drug
DM02D1B PC 71599906
DM02D1B MW 388.4
DM02D1B FM C21H22F2N2O3
DM02D1B IC InChI=1S/C21H22F2N2O3/c1-21(2)10-17(13-6-7-15(22)18(23)19(13)28-21)25-20(27)24-16-5-3-4-11-8-12(26)9-14(11)16/h3-7,12,17,26H,8-10H2,1-2H3,(H2,24,25,27)/t12-,17-/m1/s1
DM02D1B CS CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)F)NC(=O)NC3=CC=CC4=C3C[C@@H](C4)O)C
DM02D1B IK YOPCFYQBNUSQMJ-SJKOYZFVSA-N
DM02D1B IU 1-[(4R)-7,8-difluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DM02D1B DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMN692C ID DMN692C
DMN692C DN PMID25666693-Compound-3
DMN692C HS Patented
DMN692C CP ABBVIE INC
DMN692C DT Small molecular drug
DMN692C PC 66549466
DMN692C MW 381.4
DMN692C FM C22H21F2N3O
DMN692C IC InChI=1S/C22H21F2N3O/c1-13-9-19-16(12-25-13)6-8-20(24)21(19)27-22(28)26-18-7-5-15(11-18)14-3-2-4-17(23)10-14/h2-4,6,8-10,12,15,18H,5,7,11H2,1H3,(H2,26,27,28)/t15-,18+/m0/s1
DMN692C CS CC1=CC2=C(C=CC(=C2NC(=O)N[C@@H]3CC[C@@H](C3)C4=CC(=CC=C4)F)F)C=N1
DMN692C IK PAFRMBKESKKSIA-MAUKXSAKSA-N
DMN692C IU 1-(6-fluoro-3-methylisoquinolin-5-yl)-3-[(1R,3S)-3-(3-fluorophenyl)cyclopentyl]urea
DMN692C DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMC3DT7 ID DMC3DT7
DMC3DT7 DN PMID25666693-Compound-30
DMC3DT7 HS Patented
DMC3DT7 CP ABBVIE INC
DMC3DT7 DT Small molecular drug
DMC3DT7 PC 71598766
DMC3DT7 MW 404.9
DMC3DT7 FM C21H22ClFN2O3
DMC3DT7 IC InChI=1S/C21H22ClFN2O3/c1-21(2)10-17(13-6-7-15(23)18(22)19(13)28-21)25-20(27)24-16-5-3-4-11-8-12(26)9-14(11)16/h3-7,12,17,26H,8-10H2,1-2H3,(H2,24,25,27)/t12-,17+/m0/s1
DMC3DT7 CS CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)Cl)NC(=O)NC3=CC=CC4=C3C[C@H](C4)O)C
DMC3DT7 IK NXZOBNXJGCHNTQ-YVEFUNNKSA-N
DMC3DT7 IU 1-[(4R)-8-chloro-7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-[(2S)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]urea
DMC3DT7 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM853Y7 ID DM853Y7
DM853Y7 DN PMID25666693-Compound-31
DM853Y7 HS Patented
DM853Y7 CP ABBVIE INC
DM853Y7 DT Small molecular drug
DM853Y7 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM58Z4M ID DM58Z4M
DM58Z4M DN PMID25666693-Compound-32
DM58Z4M HS Patented
DM58Z4M CP ABBVIE INC
DM58Z4M DT Small molecular drug
DM58Z4M DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMW7981 ID DMW7981
DMW7981 DN PMID25666693-Compound-33
DMW7981 HS Patented
DMW7981 CP ABBVIE INC
DMW7981 DT Small molecular drug
DMW7981 PC 71611619
DMW7981 MW 434.4
DMW7981 FM C21H21F3N4O3
DMW7981 IC InChI=1S/C21H21F3N4O3/c1-20(21(22,23)24)10-16(14-5-3-4-6-17(14)31-20)26-18(29)25-13-8-7-12-11-28(2)19(30)27-15(12)9-13/h3-9,16H,10-11H2,1-2H3,(H,27,30)(H2,25,26,29)/t16-,20-/m1/s1
DMW7981 CS C[C@@]1(C[C@H](C2=CC=CC=C2O1)NC(=O)NC3=CC4=C(CN(C(=O)N4)C)C=C3)C(F)(F)F
DMW7981 IK OFCQSAHGUNDUTK-OXQOHEQNSA-N
DMW7981 IU 1-(3-methyl-2-oxo-1,4-dihydroquinazolin-7-yl)-3-[(2R,4R)-2-methyl-2-(trifluoromethyl)-3,4-dihydrochromen-4-yl]urea
DMW7981 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMWGAQU ID DMWGAQU
DMWGAQU DN PMID25666693-Compound-34
DMWGAQU HS Patented
DMWGAQU CP ABBVIE INC
DMWGAQU DT Small molecular drug
DMWGAQU PC 71611907
DMWGAQU MW 401.4
DMWGAQU FM C21H21F2N3O3
DMWGAQU IC InChI=1S/C21H21F2N3O3/c1-21(2)10-16(13-6-7-14(22)18(23)19(13)29-21)26-20(28)24-12-5-3-11-4-8-17(27)25-15(11)9-12/h3,5-7,9,16H,4,8,10H2,1-2H3,(H,25,27)(H2,24,26,28)/t16-/m1/s1
DMWGAQU CS CC1(C[C@H](C2=C(O1)C(=C(C=C2)F)F)NC(=O)NC3=CC4=C(CCC(=O)N4)C=C3)C
DMWGAQU IK UDVRSQKMFMPYID-MRXNPFEDSA-N
DMWGAQU IU 1-[(4R)-7,8-difluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-(2-oxo-3,4-dihydro-1H-quinolin-7-yl)urea
DMWGAQU DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMG9CPH ID DMG9CPH
DMG9CPH DN PMID25666693-Compound-35
DMG9CPH HS Patented
DMG9CPH CP ABBVIE INC
DMG9CPH DT Small molecular drug
DMG9CPH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMWVR81 ID DMWVR81
DMWVR81 DN PMID25666693-Compound-36
DMWVR81 HS Patented
DMWVR81 CP ABBVIE INC
DMWVR81 DT Small molecular drug
DMWVR81 PC 71611910
DMWVR81 MW 385.4
DMWVR81 FM C20H20FN3O4
DMWVR81 IC InChI=1S/C20H20FN3O4/c1-20(2)9-15(13-5-3-11(21)7-17(13)28-20)24-19(26)22-12-4-6-16-14(8-12)23-18(25)10-27-16/h3-8,15H,9-10H2,1-2H3,(H,23,25)(H2,22,24,26)/t15-/m1/s1
DMWVR81 CS CC1(C[C@H](C2=C(O1)C=C(C=C2)F)NC(=O)NC3=CC4=C(C=C3)OCC(=O)N4)C
DMWVR81 IK GBNGQHMENHKOCY-OAHLLOKOSA-N
DMWVR81 IU 1-[(4R)-7-fluoro-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-(3-oxo-4H-1,4-benzoxazin-6-yl)urea
DMWVR81 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMSR218 ID DMSR218
DMSR218 DN PMID25666693-Compound-37
DMSR218 HS Patented
DMSR218 CP GRUENENTHAL GMBH [DE]
DMSR218 DT Small molecular drug
DMSR218 PC 49802515
DMSR218 MW 458.9
DMSR218 FM C23H18ClF3N4O
DMSR218 IC InChI=1S/C23H18ClF3N4O/c1-14(19-7-2-4-15-12-28-9-8-20(15)19)22(32)29-13-18-11-21(23(25,26)27)30-31(18)17-6-3-5-16(24)10-17/h2-12,14H,13H2,1H3,(H,29,32)
DMSR218 CS CC(C1=CC=CC2=C1C=CN=C2)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DMSR218 IK ZBOCDMVUEHZVGP-UHFFFAOYSA-N
DMSR218 IU N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-isoquinolin-5-ylpropanamide
DMSR218 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMBW36Y ID DMBW36Y
DMBW36Y DN PMID25666693-Compound-38
DMBW36Y HS Patented
DMBW36Y CP GRUENENTHAL GMBH [DE]
DMBW36Y DT Small molecular drug
DMBW36Y PC 87087836
DMBW36Y MW 493.3
DMBW36Y FM C23H17Cl2F3N4O
DMBW36Y IC InChI=1S/C23H17Cl2F3N4O/c1-13(18-7-2-4-14-11-29-21(25)10-19(14)18)22(33)30-12-17-9-20(23(26,27)28)31-32(17)16-6-3-5-15(24)8-16/h2-11,13H,12H2,1H3,(H,30,33)
DMBW36Y CS CC(C1=CC=CC2=CN=C(C=C21)Cl)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DMBW36Y IK IMGRGGRJBGEWLE-UHFFFAOYSA-N
DMBW36Y IU 2-(3-chloroisoquinolin-5-yl)-N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide
DMBW36Y DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DML3KHF ID DML3KHF
DML3KHF DN PMID25666693-Compound-39
DML3KHF HS Patented
DML3KHF CP GRUENENTHAL GMBH [DE]
DML3KHF DT Small molecular drug
DML3KHF PC 57335613
DML3KHF MW 476.9
DML3KHF FM C23H20ClF3N4O2
DML3KHF IC InChI=1S/C23H20ClF3N4O2/c1-13(19-12-30(2)20-7-6-17(32)10-18(19)20)22(33)28-11-16-9-21(23(25,26)27)29-31(16)15-5-3-4-14(24)8-15/h3-10,12-13,32H,11H2,1-2H3,(H,28,33)
DML3KHF CS CC(C1=CN(C2=C1C=C(C=C2)O)C)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DML3KHF IK OSCHEDGPGHRWRA-UHFFFAOYSA-N
DML3KHF IU N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-(5-hydroxy-1-methylindol-3-yl)propanamide
DML3KHF DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMBD9S5 ID DMBD9S5
DMBD9S5 DN PMID25666693-Compound-4
DMBD9S5 HS Patented
DMBD9S5 CP ABBVIE INC
DMBD9S5 DT Small molecular drug
DMBD9S5 PC 66551282
DMBD9S5 MW 320.4
DMBD9S5 FM C19H20N4O
DMBD9S5 IC InChI=1S/C19H20N4O/c24-19(22-17-7-4-8-18-16(17)12-20-23-18)21-15-10-9-14(11-15)13-5-2-1-3-6-13/h1-8,12,14-15H,9-11H2,(H,20,23)(H2,21,22,24)/t14-,15+/m1/s1
DMBD9S5 CS C1C[C@@H](C[C@@H]1C2=CC=CC=C2)NC(=O)NC3=CC=CC4=C3C=NN4
DMBD9S5 IK JSEHDPNFIUYQLO-CABCVRRESA-N
DMBD9S5 IU 1-(1H-indazol-4-yl)-3-[(1S,3R)-3-phenylcyclopentyl]urea
DMBD9S5 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM58QW1 ID DM58QW1
DM58QW1 DN PMID25666693-Compound-40
DM58QW1 HS Patented
DM58QW1 CP GRENTHAL GMBH FRANK, Robert BAHRENBERG, Gregor CHRISTOPH, Thomas SCHIENE, Klaus DE VRY, Jean DAMANN, Nils FRORMANN, Sven LESCH, Bernhard LEE, Jeewoo KIM, Yong-Soo KIM, Myeon-Seop
DM58QW1 DT Small molecular drug
DM58QW1 PC 66644325
DM58QW1 MW 518.9
DM58QW1 FM C21H19ClF4N4O3S
DM58QW1 IC InChI=1S/C21H19ClF4N4O3S/c1-12(13-6-7-18(17(23)8-13)29-34(2,32)33)20(31)27-11-16-10-19(21(24,25)26)28-30(16)15-5-3-4-14(22)9-15/h3-10,12,29H,11H2,1-2H3,(H,27,31)/t12-/m0/s1
DM58QW1 CS C[C@@H](C1=CC(=C(C=C1)NS(=O)(=O)C)F)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(F)(F)F
DM58QW1 IK REFSKWWRGFCGDO-LBPRGKRZSA-N
DM58QW1 IU (2S)-N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-[3-fluoro-4-(methanesulfonamido)phenyl]propanamide
DM58QW1 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DML76MF ID DML76MF
DML76MF DN PMID25666693-Compound-41
DML76MF HS Patented
DML76MF CP GRENTHAL GMBH FRANK, Robert BAHRENBERG, Gregor CHRISTOPH, Thomas SCHIENE, Klaus DE VRY, Jean DAMANN, Nils FRORMANN, Sven LESCH, Bernhard LEE, Jeewoo KIM, Yong-Soo KIM, Myeon-Seop
DML76MF DT Small molecular drug
DML76MF PC 66644203
DML76MF MW 507
DML76MF FM C24H28ClFN4O3S
DML76MF IC InChI=1S/C24H28ClFN4O3S/c1-15(16-9-10-21(20(26)11-16)29-34(5,32)33)23(31)27-14-19-13-22(24(2,3)4)28-30(19)18-8-6-7-17(25)12-18/h6-13,15,29H,14H2,1-5H3,(H,27,31)/t15-/m0/s1
DML76MF CS C[C@@H](C1=CC(=C(C=C1)NS(=O)(=O)C)F)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(C)(C)C
DML76MF IK WVJARZWJWNGZDX-HNNXBMFYSA-N
DML76MF IU (2S)-N-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-2-[3-fluoro-4-(methanesulfonamido)phenyl]propanamide
DML76MF DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM6I49E ID DM6I49E
DM6I49E DN PMID25666693-Compound-42
DM6I49E HS Patented
DM6I49E CP GRUENENTHAL GMBH [DE]
DM6I49E DT Small molecular drug
DM6I49E PC 70816270
DM6I49E MW 504
DM6I49E FM C24H30ClN5O3S
DM6I49E IC InChI=1S/C24H30ClN5O3S/c1-16(18-10-8-17(9-11-18)14-28-34(26,32)33)23(31)27-15-21-13-22(24(2,3)4)29-30(21)20-7-5-6-19(25)12-20/h5-13,16,28H,14-15H2,1-4H3,(H,27,31)(H2,26,32,33)
DM6I49E CS CC(C1=CC=C(C=C1)CNS(=O)(=O)N)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(C)(C)C
DM6I49E IK DACXYKBLLKSFLC-UHFFFAOYSA-N
DM6I49E IU N-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-2-[4-[(sulfamoylamino)methyl]phenyl]propanamide
DM6I49E DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMTN25V ID DMTN25V
DMTN25V DN PMID25666693-Compound-43
DMTN25V HS Patented
DMTN25V CP GRUENENTHAL GMBH [DE]
DMTN25V DT Small molecular drug
DMTN25V DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM0I72B ID DM0I72B
DM0I72B DN PMID25666693-Compound-44
DM0I72B HS Patented
DM0I72B CP GRUENENTHAL GMBH [DE]
DM0I72B DT Small molecular drug
DM0I72B PC 70816274
DM0I72B MW 463.5
DM0I72B FM C24H25F4N3O2
DM0I72B IC InChI=1S/C24H25F4N3O2/c1-14(2)16-5-4-6-19(9-16)31-20(11-22(30-31)24(26,27)28)12-29-23(33)15(3)17-7-8-18(13-32)21(25)10-17/h4-11,14-15,32H,12-13H2,1-3H3,(H,29,33)
DM0I72B CS CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)C(C)C3=CC(=C(C=C3)CO)F
DM0I72B IK WEWXHMWEKISRRJ-UHFFFAOYSA-N
DM0I72B IU 2-[3-fluoro-4-(hydroxymethyl)phenyl]-N-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide
DM0I72B DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMVDKXY ID DMVDKXY
DMVDKXY DN PMID25666693-Compound-45
DMVDKXY HS Patented
DMVDKXY CP GRUENENTHAL GMBH [DE]
DMVDKXY DT Small molecular drug
DMVDKXY PC 70816331
DMVDKXY MW 477.5
DMVDKXY FM C25H27F4N3O2
DMVDKXY IC InChI=1S/C25H27F4N3O2/c1-15(2)18-5-4-6-20(11-18)32-21(13-23(31-32)25(27,28)29)14-30-24(34)16(3)19-8-7-17(9-10-33)22(26)12-19/h4-8,11-13,15-16,33H,9-10,14H2,1-3H3,(H,30,34)
DMVDKXY CS CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)C(C)C3=CC(=C(C=C3)CCO)F
DMVDKXY IK VKEXSUFTMBHDFU-UHFFFAOYSA-N
DMVDKXY IU 2-[3-fluoro-4-(2-hydroxyethyl)phenyl]-N-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]propanamide
DMVDKXY DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM0MEXT ID DM0MEXT
DM0MEXT DN PMID25666693-Compound-46
DM0MEXT HS Patented
DM0MEXT CP GRUENENTHAL GMBH [DE]
DM0MEXT DT Small molecular drug
DM0MEXT DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHBN5M ID DMHBN5M
DMHBN5M DN PMID25666693-Compound-47
DMHBN5M HS Patented
DMHBN5M CP GRUENENTHAL GMBH [DE]
DMHBN5M DT Small molecular drug
DMHBN5M PC 88995251
DMHBN5M MW 562.9
DMHBN5M FM C27H20ClF5N4O2
DMHBN5M IC InChI=1S/C27H20ClF5N4O2/c1-15(16-5-10-22(23(30)11-16)26(39)35-19-8-6-18(29)7-9-19)25(38)34-14-21-13-24(27(31,32)33)36-37(21)20-4-2-3-17(28)12-20/h2-13,15H,14H2,1H3,(H,34,38)(H,35,39)
DMHBN5M CS CC(C1=CC(=C(C=C1)C(=O)NC2=CC=C(C=C2)F)F)C(=O)NCC3=CC(=NN3C4=CC(=CC=C4)Cl)C(F)(F)F
DMHBN5M IK SRQSJNYCMNVXTK-UHFFFAOYSA-N
DMHBN5M IU 4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methylamino]-1-oxopropan-2-yl]-2-fluoro-N-(4-fluorophenyl)benzamide
DMHBN5M DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMEVL0S ID DMEVL0S
DMEVL0S DN PMID25666693-Compound-48
DMEVL0S HS Patented
DMEVL0S CP GRUENENTHAL GMBH [DE]
DMEVL0S DT Small molecular drug
DMEVL0S DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM67DEG ID DM67DEG
DM67DEG DN PMID25666693-Compound-49
DM67DEG HS Patented
DM67DEG CP GRUENENTHAL GMBH [DE]
DM67DEG DT Small molecular drug
DM67DEG PC 71238636
DM67DEG MW 438.8
DM67DEG FM C20H18ClF3N4O2
DM67DEG IC InChI=1S/C20H18ClF3N4O2/c1-12(13-5-6-15(11-29)25-9-13)19(30)26-10-17-8-18(20(22,23)24)27-28(17)16-4-2-3-14(21)7-16/h2-9,12,29H,10-11H2,1H3,(H,26,30)
DM67DEG CS CC(C1=CN=C(C=C1)CO)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(F)(F)F
DM67DEG IK BPOYGEDVQYUUIM-UHFFFAOYSA-N
DM67DEG IU N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-[6-(hydroxymethyl)pyridin-3-yl]propanamide
DM67DEG DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM53PBG ID DM53PBG
DM53PBG DN PMID25666693-Compound-5
DM53PBG HS Patented
DM53PBG CP ABBVIE INC
DM53PBG DT Small molecular drug
DM53PBG DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM4GUZO ID DM4GUZO
DM4GUZO DN PMID25666693-Compound-50
DM4GUZO HS Patented
DM4GUZO CP GRUENENTHAL GMBH [DE]
DM4GUZO DT Small molecular drug
DM4GUZO PC 71237925
DM4GUZO MW 467.9
DM4GUZO FM C21H21ClF3N5O2
DM4GUZO IC InChI=1S/C21H21ClF3N5O2/c1-13(14-5-6-19(27-11-14)26-7-8-31)20(32)28-12-17-10-18(21(23,24)25)29-30(17)16-4-2-3-15(22)9-16/h2-6,9-11,13,31H,7-8,12H2,1H3,(H,26,27)(H,28,32)
DM4GUZO CS CC(C1=CN=C(C=C1)NCCO)C(=O)NCC2=CC(=NN2C3=CC(=CC=C3)Cl)C(F)(F)F
DM4GUZO IK QZMPZIHZYACLIU-UHFFFAOYSA-N
DM4GUZO IU N-[[2-(3-chlorophenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]-2-[6-(2-hydroxyethylamino)pyridin-3-yl]propanamide
DM4GUZO DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM3KSV9 ID DM3KSV9
DM3KSV9 DN PMID25666693-Compound-51
DM3KSV9 HS Patented
DM3KSV9 CP GRUENENTHAL GMBH [DE]
DM3KSV9 DT Small molecular drug
DM3KSV9 PC 57335038
DM3KSV9 MW 453
DM3KSV9 FM C25H29ClN4O2
DM3KSV9 IC InChI=1S/C25H29ClN4O2/c1-25(2,3)23-13-19(30(29-23)18-8-5-7-17(26)12-18)15-27-24(32)28-22-9-4-6-16-10-11-20(31)14-21(16)22/h5,7-8,10-14,22,31H,4,6,9,15H2,1-3H3,(H2,27,28,32)
DM3KSV9 CS CC(C)(C)C1=NN(C(=C1)CNC(=O)NC2CCCC3=C2C=C(C=C3)O)C4=CC(=CC=C4)Cl
DM3KSV9 IK RUCBWZCSOLTLOQ-UHFFFAOYSA-N
DM3KSV9 IU 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)urea
DM3KSV9 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQPOGC ID DMQPOGC
DMQPOGC DN PMID25666693-Compound-52
DMQPOGC HS Patented
DMQPOGC CP GRUENENTHAL GMBH [DE]
DMQPOGC DT Small molecular drug
DMQPOGC PC 70816169
DMQPOGC MW 528.5
DMQPOGC FM C22H24F4N6O3S
DMQPOGC IC InChI=1S/C22H24F4N6O3S/c1-13(2)14-4-3-5-17(8-14)32-18(10-20(31-32)22(24,25)26)12-28-21(33)30-16-7-6-15(19(23)9-16)11-29-36(27,34)35/h3-10,13,29H,11-12H2,1-2H3,(H2,27,34,35)(H2,28,30,33)
DMQPOGC CS CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CNS(=O)(=O)N)F
DMQPOGC IK PXYVSPVUKXZTLN-UHFFFAOYSA-N
DMQPOGC IU 1-[3-fluoro-4-[(sulfamoylamino)methyl]phenyl]-3-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea
DMQPOGC DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMKCARH ID DMKCARH
DMKCARH DN PMID25666693-Compound-53
DMKCARH HS Patented
DMKCARH CP GRUENENTHAL GMBH [DE]
DMKCARH DT Small molecular drug
DMKCARH PC 70816499
DMKCARH MW 526.5
DMKCARH FM C24H26F4N4O3S
DMKCARH IC InChI=1S/C24H26F4N4O3S/c1-15(2)17-5-4-6-19(11-17)32-20(13-22(31-32)24(26,27)28)14-29-23(33)30-18-8-7-16(21(25)12-18)9-10-36(3,34)35/h4-8,11-13,15H,9-10,14H2,1-3H3,(H2,29,30,33)
DMKCARH CS CC(C)C1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CCS(=O)(=O)C)F
DMKCARH IK XUFAPWVIHXCCMT-UHFFFAOYSA-N
DMKCARH IU 1-[3-fluoro-4-(2-methylsulfonylethyl)phenyl]-3-[[2-(3-propan-2-ylphenyl)-5-(trifluoromethyl)pyrazol-3-yl]methyl]urea
DMKCARH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMLW95Y ID DMLW95Y
DMLW95Y DN PMID25666693-Compound-54
DMLW95Y HS Patented
DMLW95Y CP GRUENENTHAL GMBH [DE]
DMLW95Y DT Small molecular drug
DMLW95Y PC 70816505
DMLW95Y MW 472
DMLW95Y FM C24H27ClFN5O2
DMLW95Y IC InChI=1S/C24H27ClFN5O2/c1-24(2,3)22-11-18(31(29-22)17-6-4-5-15(25)9-17)12-27-23(33)28-16-7-8-21(20(26)10-16)30-13-19(32)14-30/h4-11,19,32H,12-14H2,1-3H3,(H2,27,28,33)
DMLW95Y CS CC(C)(C)C1=NN(C(=C1)CNC(=O)NC2=CC(=C(C=C2)N3CC(C3)O)F)C4=CC(=CC=C4)Cl
DMLW95Y IK BLMVABKWVMAQJO-UHFFFAOYSA-N
DMLW95Y IU 1-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-3-[3-fluoro-4-(3-hydroxyazetidin-1-yl)phenyl]urea
DMLW95Y DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMPE7M8 ID DMPE7M8
DMPE7M8 DN PMID25666693-Compound-55
DMPE7M8 HS Patented
DMPE7M8 CP GRENTHAL GMBH FRANK, Robert BAHRENBERG, Gregor CHRISTOPH, Thomas SCHIENE, Klaus DE VRY, Jean
DMPE7M8 DT Small molecular drug
DMPE7M8 PC 56836246
DMPE7M8 MW 487.4
DMPE7M8 FM C24H28Cl2N6O
DMPE7M8 IC InChI=1S/C24H28Cl2N6O/c1-24(2,3)21-15-19(32(29-21)18-7-4-6-17(25)14-18)16-28-23(33)31-12-10-30(11-13-31)22-20(26)8-5-9-27-22/h4-9,14-15H,10-13,16H2,1-3H3,(H,28,33)
DMPE7M8 CS CC(C)(C)C1=NN(C(=C1)CNC(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl)C4=CC(=CC=C4)Cl
DMPE7M8 IK UGDIRECFVAQSNI-UHFFFAOYSA-N
DMPE7M8 IU N-[[5-tert-butyl-2-(3-chlorophenyl)pyrazol-3-yl]methyl]-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
DMPE7M8 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM82BAM ID DM82BAM
DM82BAM DN PMID25666693-Compound-56
DM82BAM HS Patented
DM82BAM CP GRUENENTHAL GMBH [DE]
DM82BAM DT Small molecular drug
DM82BAM PC 71238385
DM82BAM MW 517.5
DM82BAM FM C22H27F4N5O3S
DM82BAM IC InChI=1S/C22H27F4N5O3S/c1-13-6-8-31(9-7-13)20-15(4-5-18(29-20)22(24,25)26)11-28-21(32)14(2)16-10-17(23)19(27-12-16)30-35(3,33)34/h4-5,10,12-14H,6-9,11H2,1-3H3,(H,27,30)(H,28,32)
DM82BAM CS CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)C(C)C3=CC(=C(N=C3)NS(=O)(=O)C)F
DM82BAM IK PZSVFYQEXXZEFT-UHFFFAOYSA-N
DM82BAM IU 2-[5-fluoro-6-(methanesulfonamido)pyridin-3-yl]-N-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide
DM82BAM DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQRFXT ID DMQRFXT
DMQRFXT DN PMID25666693-Compound-57
DMQRFXT HS Patented
DMQRFXT CP Grunenthal GmbH
DMQRFXT DT Small molecular drug
DMQRFXT PC 71537379
DMQRFXT MW 516.6
DMQRFXT FM C23H28F4N4O3S
DMQRFXT IC InChI=1S/C23H28F4N4O3S/c1-15-7-9-31(10-8-15)22-18(5-6-20(30-22)23(25,26)27)13-28-21(32)12-16-3-4-17(19(24)11-16)14-29-35(2,33)34/h3-6,11,15,29H,7-10,12-14H2,1-2H3,(H,28,32)
DMQRFXT CS CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)CC3=CC(=C(C=C3)CNS(=O)(=O)C)F
DMQRFXT IK DAEWVVDOSOXCOU-UHFFFAOYSA-N
DMQRFXT IU 2-[3-fluoro-4-(methanesulfonamidomethyl)phenyl]-N-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]acetamide
DMQRFXT DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMJEH0F ID DMJEH0F
DMJEH0F DN PMID25666693-Compound-58
DMJEH0F HS Patented
DMJEH0F CP GRUENENTHAL GMBH [DE]
DMJEH0F DT Small molecular drug
DMJEH0F DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMLI1YR ID DMLI1YR
DMLI1YR DN PMID25666693-Compound-59
DMLI1YR HS Patented
DMLI1YR CP GRUENENTHAL GMBH [DE]
DMLI1YR DT Small molecular drug
DMLI1YR PC 71539690
DMLI1YR MW 510.5
DMLI1YR FM C23H22F4N4O3S
DMLI1YR IC InChI=1S/C23H22F4N4O3S/c1-14-4-3-5-15(10-14)21-17(7-9-20(31-21)23(25,26)27)12-28-22(32)30-18-8-6-16(19(24)11-18)13-29-35(2,33)34/h3-11,29H,12-13H2,1-2H3,(H2,28,30,32)
DMLI1YR CS CC1=CC(=CC=C1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CNS(=O)(=O)C)F
DMLI1YR IK RKDUDSFOPJMGMR-UHFFFAOYSA-N
DMLI1YR IU 1-[3-fluoro-4-(methanesulfonamidomethyl)phenyl]-3-[[2-(3-methylphenyl)-6-(trifluoromethyl)pyridin-3-yl]methyl]urea
DMLI1YR DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMC5W1Y ID DMC5W1Y
DMC5W1Y DN PMID25666693-Compound-6
DMC5W1Y HS Patented
DMC5W1Y CP ABBVIE INC
DMC5W1Y DT Small molecular drug
DMC5W1Y PC 66549275
DMC5W1Y MW 338.4
DMC5W1Y FM C19H19FN4O
DMC5W1Y IC InChI=1S/C19H19FN4O/c20-14-4-1-3-12(9-14)13-7-8-15(10-13)22-19(25)23-17-5-2-6-18-16(17)11-21-24-18/h1-6,9,11,13,15H,7-8,10H2,(H,21,24)(H2,22,23,25)/t13-,15+/m1/s1
DMC5W1Y CS C1C[C@@H](C[C@@H]1C2=CC(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=NN4
DMC5W1Y IK ROOFFAWDIFZLQB-HIFRSBDPSA-N
DMC5W1Y IU 1-[(1S,3R)-3-(3-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DMC5W1Y DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM2C58A ID DM2C58A
DM2C58A DN PMID25666693-Compound-60
DM2C58A HS Patented
DM2C58A CP GRUENENTHAL GMBH [DE]
DM2C58A DT Small molecular drug
DM2C58A DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM0B578 ID DM0B578
DM0B578 DN PMID25666693-Compound-61
DM0B578 HS Patented
DM0B578 CP GRUENENTHAL GMBH [DE]
DM0B578 DT Small molecular drug
DM0B578 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMDMFJG ID DMDMFJG
DMDMFJG DN PMID25666693-Compound-62
DMDMFJG HS Patented
DMDMFJG CP GRUENENTHAL GMBH [DE]
DMDMFJG DT Small molecular drug
DMDMFJG PC 71506872
DMDMFJG MW 500.5
DMDMFJG FM C21H27F3N6O3S
DMDMFJG IC InChI=1S/C21H27F3N6O3S/c1-14-8-10-30(11-9-14)19-16(4-7-18(29-19)21(22,23)24)13-26-20(31)28-17-5-2-15(3-6-17)12-27-34(25,32)33/h2-7,14,27H,8-13H2,1H3,(H2,25,32,33)(H2,26,28,31)
DMDMFJG CS CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC=C(C=C3)CNS(=O)(=O)N
DMDMFJG IK OTVBHAAUANCTTG-UHFFFAOYSA-N
DMDMFJG IU 1-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]-3-[4-[(sulfamoylamino)methyl]phenyl]urea
DMDMFJG DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM6DFAK ID DM6DFAK
DM6DFAK DN PMID25666693-Compound-63
DM6DFAK HS Patented
DM6DFAK CP GRUENENTHAL GMBH [DE]
DM6DFAK DT Small molecular drug
DM6DFAK PC 71534837
DM6DFAK MW 518.5
DM6DFAK FM C21H26F4N6O3S
DM6DFAK IC InChI=1S/C21H26F4N6O3S/c1-13-6-8-31(9-7-13)19-15(3-5-18(30-19)21(23,24)25)11-27-20(32)29-16-4-2-14(17(22)10-16)12-28-35(26,33)34/h2-5,10,13,28H,6-9,11-12H2,1H3,(H2,26,33,34)(H2,27,29,32)
DM6DFAK CS CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CC(=C(C=C3)CNS(=O)(=O)N)F
DM6DFAK IK ULLMJBDXTPAPKF-UHFFFAOYSA-N
DM6DFAK IU 1-[3-fluoro-4-[(sulfamoylamino)methyl]phenyl]-3-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]urea
DM6DFAK DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMDWH8T ID DMDWH8T
DMDWH8T DN PMID25666693-Compound-64
DMDWH8T HS Patented
DMDWH8T CP GRUENENTHAL GMBH [DE]
DMDWH8T DT Small molecular drug
DMDWH8T DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM1A0GT ID DM1A0GT
DM1A0GT DN PMID25666693-Compound-65
DM1A0GT HS Patented
DM1A0GT CP GRUENENTHAL GMBH [DE]
DM1A0GT DT Small molecular drug
DM1A0GT PC 71238361
DM1A0GT MW 452.5
DM1A0GT FM C21H27F3N6O2
DM1A0GT IC InChI=1S/C21H27F3N6O2/c1-14-6-9-30(10-7-14)19-15(2-4-17(29-19)21(22,23)24)12-27-20(32)28-16-3-5-18(26-13-16)25-8-11-31/h2-5,13-14,31H,6-12H2,1H3,(H,25,26)(H2,27,28,32)
DM1A0GT CS CC1CCN(CC1)C2=C(C=CC(=N2)C(F)(F)F)CNC(=O)NC3=CN=C(C=C3)NCCO
DM1A0GT IK YIEBGPCORZIWJQ-UHFFFAOYSA-N
DM1A0GT IU 1-[6-(2-hydroxyethylamino)pyridin-3-yl]-3-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]urea
DM1A0GT DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMD13OS ID DMD13OS
DMD13OS DN PMID25666693-Compound-66
DMD13OS HS Patented
DMD13OS CP Japan Tobacco, Inc
DMD13OS DT Small molecular drug
DMD13OS PC 23627957
DMD13OS MW 483.5
DMD13OS FM C26H27F2N3O4
DMD13OS IC InChI=1S/C26H27F2N3O4/c1-15-8-9-22(29-12-15)31-17(13-32)14-34-23-18(6-5-7-21(23)31)25(33)30-16-10-19(27)24(20(28)11-16)35-26(2,3)4/h5-12,17,32H,13-14H2,1-4H3,(H,30,33)/t17-/m0/s1
DMD13OS CS CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)(C)C)F)CO
DMD13OS IK XZRDDTOOBFNFRB-KRWDZBQOSA-N
DMD13OS IU (3S)-N-[3,5-difluoro-4-[(2-methylpropan-2-yl)oxy]phenyl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMD13OS DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMPV9L2 ID DMPV9L2
DMPV9L2 DN PMID25666693-Compound-67
DMPV9L2 HS Patented
DMPV9L2 CP Japan Tobacco, Inc
DMPV9L2 DT Small molecular drug
DMPV9L2 PC 23628014
DMPV9L2 MW 469.5
DMPV9L2 FM C25H25F2N3O4
DMPV9L2 IC InChI=1S/C25H25F2N3O4/c1-14(2)34-24-19(26)9-16(10-20(24)27)29-25(32)18-5-4-6-21-23(18)33-13-17(12-31)30(21)22-8-7-15(3)11-28-22/h4-11,14,17,31H,12-13H2,1-3H3,(H,29,32)/t17-/m0/s1
DMPV9L2 CS CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)C)F)CO
DMPV9L2 IK IUQNHNNDFBOZEL-KRWDZBQOSA-N
DMPV9L2 IU (3S)-N-(3,5-difluoro-4-propan-2-yloxyphenyl)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMPV9L2 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM87HTO ID DM87HTO
DM87HTO DN PMID25666693-Compound-68
DM87HTO HS Patented
DM87HTO CP Japan Tobacco, Inc
DM87HTO DT Small molecular drug
DM87HTO PC 23628075
DM87HTO MW 509.4
DM87HTO FM C24H20F5N3O4
DM87HTO IC InChI=1S/C24H20F5N3O4/c1-13-5-6-20(30-9-13)32-15(10-33)11-35-21-16(3-2-4-19(21)32)23(34)31-14-7-17(25)22(18(26)8-14)36-12-24(27,28)29/h2-9,15,33H,10-12H2,1H3,(H,31,34)/t15-/m0/s1
DM87HTO CS CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OCC(F)(F)F)F)CO
DM87HTO IK RPAMBIQBMQRYLH-HNNXBMFYSA-N
DM87HTO IU (3S)-N-[3,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DM87HTO DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMIPFO3 ID DMIPFO3
DMIPFO3 DN PMID25666693-Compound-69
DMIPFO3 HS Patented
DMIPFO3 CP Japan Tobacco, Inc
DMIPFO3 DT Small molecular drug
DMIPFO3 PC 23628077
DMIPFO3 MW 499.5
DMIPFO3 FM C26H27F2N3O5
DMIPFO3 IC InChI=1S/C26H27F2N3O5/c1-15-7-8-22(29-11-15)31-17(12-32)13-35-23-18(5-4-6-21(23)31)25(34)30-16-9-19(27)24(20(28)10-16)36-26(2,3)14-33/h4-11,17,32-33H,12-14H2,1-3H3,(H,30,34)/t17-/m0/s1
DMIPFO3 CS CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CC(=C(C(=C4)F)OC(C)(C)CO)F)CO
DMIPFO3 IK HVUQTZHOXKBNTC-KRWDZBQOSA-N
DMIPFO3 IU (3S)-N-[3,5-difluoro-4-(1-hydroxy-2-methylpropan-2-yl)oxyphenyl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMIPFO3 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMNTVFH ID DMNTVFH
DMNTVFH DN PMID25666693-Compound-7
DMNTVFH HS Patented
DMNTVFH CP ABBVIE INC
DMNTVFH DT Small molecular drug
DMNTVFH PC 66551085
DMNTVFH MW 320.4
DMNTVFH FM C19H20N4O
DMNTVFH IC InChI=1S/C19H20N4O/c24-19(22-17-7-4-8-18-16(17)12-20-23-18)21-15-10-9-14(11-15)13-5-2-1-3-6-13/h1-8,12,14-15H,9-11H2,(H,20,23)(H2,21,22,24)/t14-,15-/m0/s1
DMNTVFH CS C1C[C@@H](C[C@H]1C2=CC=CC=C2)NC(=O)NC3=CC=CC4=C3C=NN4
DMNTVFH IK JSEHDPNFIUYQLO-GJZGRUSLSA-N
DMNTVFH IU 1-(1H-indazol-4-yl)-3-[(1S,3S)-3-phenylcyclopentyl]urea
DMNTVFH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMEPYGQ ID DMEPYGQ
DMEPYGQ DN PMID25666693-Compound-70
DMEPYGQ HS Patented
DMEPYGQ CP Japan Tobacco, Inc
DMEPYGQ DT Small molecular drug
DMEPYGQ PC 58416270
DMEPYGQ MW 462.5
DMEPYGQ FM C26H30N4O4
DMEPYGQ IC InChI=1S/C26H30N4O4/c1-17-8-10-22(27-12-17)30-19(14-31)15-33-24-20(6-5-7-21(24)30)25(32)29-18-9-11-23(28-13-18)34-16-26(2,3)4/h5-13,19,31H,14-16H2,1-4H3,(H,29,32)/t19-/m0/s1
DMEPYGQ CS CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CN=C(C=C4)OCC(C)(C)C)CO
DMEPYGQ IK LMURYRLZRMJVEI-IBGZPJMESA-N
DMEPYGQ IU (3S)-N-[6-(2,2-dimethylpropoxy)pyridin-3-yl]-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DMEPYGQ DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM4VAQ3 ID DM4VAQ3
DM4VAQ3 DN PMID25666693-Compound-71
DM4VAQ3 HS Patented
DM4VAQ3 CP Japan Tobacco, Inc
DM4VAQ3 DT Small molecular drug
DM4VAQ3 PC 23628017
DM4VAQ3 MW 474.4
DM4VAQ3 FM C23H21F3N4O4
DM4VAQ3 IC InChI=1S/C23H21F3N4O4/c1-14-5-7-19(27-9-14)30-16(11-31)12-33-21-17(3-2-4-18(21)30)22(32)29-15-6-8-20(28-10-15)34-13-23(24,25)26/h2-10,16,31H,11-13H2,1H3,(H,29,32)/t16-/m0/s1
DM4VAQ3 CS CC1=CN=C(C=C1)N2[C@H](COC3=C(C=CC=C32)C(=O)NC4=CN=C(C=C4)OCC(F)(F)F)CO
DM4VAQ3 IK QZUCKCLSVBFSOS-INIZCTEOSA-N
DM4VAQ3 IU (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-2,3-dihydro-1,4-benzoxazine-8-carboxamide
DM4VAQ3 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMW8XD2 ID DMW8XD2
DMW8XD2 DN PMID25666693-Compound-72
DMW8XD2 HS Patented
DMW8XD2 CP Japan Tobacco, Inc
DMW8XD2 DT Small molecular drug
DMW8XD2 PC 11582721
DMW8XD2 MW 428.4
DMW8XD2 FM C23H23Cl2N3O
DMW8XD2 IC InChI=1S/C23H23Cl2N3O/c1-23(2,3)16-8-10-17(11-9-16)27-22(29)15-7-12-18(24)20(14-15)28(4)21-19(25)6-5-13-26-21/h5-14H,1-4H3,(H,27,29)
DMW8XD2 CS CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(C)C3=C(C=CC=N3)Cl
DMW8XD2 IK KDJDFSOSSGWODT-UHFFFAOYSA-N
DMW8XD2 IU N-(4-tert-butylphenyl)-4-chloro-3-[(3-chloropyridin-2-yl)-methylamino]benzamide
DMW8XD2 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM9LZJ5 ID DM9LZJ5
DM9LZJ5 DN PMID25666693-Compound-73
DM9LZJ5 HS Patented
DM9LZJ5 CP Japan Tobacco, Inc
DM9LZJ5 DT Small molecular drug
DM9LZJ5 PC 11532940
DM9LZJ5 MW 472.4
DM9LZJ5 FM C25H27Cl2N3O2
DM9LZJ5 IC InChI=1S/C25H27Cl2N3O2/c1-25(2,3)18-8-10-19(11-9-18)29-24(31)17-7-12-20(26)22(16-17)30(14-15-32-4)23-21(27)6-5-13-28-23/h5-13,16H,14-15H2,1-4H3,(H,29,31)
DM9LZJ5 CS CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCOC)C3=C(C=CC=N3)Cl
DM9LZJ5 IK ZYJYGKAKEUKYMJ-UHFFFAOYSA-N
DM9LZJ5 IU N-(4-tert-butylphenyl)-4-chloro-3-[(3-chloropyridin-2-yl)-(2-methoxyethyl)amino]benzamide
DM9LZJ5 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM80E3F ID DM80E3F
DM80E3F DN PMID25666693-Compound-74
DM80E3F HS Patented
DM80E3F CP Japan Tobacco, Inc
DM80E3F DT Small molecular drug
DM80E3F PC 11676921
DM80E3F MW 458.4
DM80E3F FM C24H25Cl2N3O2
DM80E3F IC InChI=1S/C24H25Cl2N3O2/c1-24(2,3)17-7-9-18(10-8-17)28-23(31)16-6-11-19(25)21(15-16)29(13-14-30)22-20(26)5-4-12-27-22/h4-12,15,30H,13-14H2,1-3H3,(H,28,31)
DM80E3F CS CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCO)C3=C(C=CC=N3)Cl
DM80E3F IK PUELSMJKWSTCFR-UHFFFAOYSA-N
DM80E3F IU N-(4-tert-butylphenyl)-4-chloro-3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]benzamide
DM80E3F DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMNATSQ ID DMNATSQ
DMNATSQ DN PMID25666693-Compound-75
DMNATSQ HS Patented
DMNATSQ CP Japan Tobacco, Inc
DMNATSQ DT Small molecular drug
DMNATSQ PC 11598064
DMNATSQ MW 474.4
DMNATSQ FM C24H25Cl2N3O3
DMNATSQ IC InChI=1S/C24H25Cl2N3O3/c1-16(2)15-32-19-8-6-18(7-9-19)28-24(31)17-5-10-20(25)22(14-17)29(12-13-30)23-21(26)4-3-11-27-23/h3-11,14,16,30H,12-13,15H2,1-2H3,(H,28,31)
DMNATSQ CS CC(C)COC1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCO)C3=C(C=CC=N3)Cl
DMNATSQ IK BQRACGGWLNJTKY-UHFFFAOYSA-N
DMNATSQ IU 4-chloro-3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]-N-[4-(2-methylpropoxy)phenyl]benzamide
DMNATSQ DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMYH429 ID DMYH429
DMYH429 DN PMID25666693-Compound-76
DMYH429 HS Patented
DMYH429 CP Japan Tobacco, Inc
DMYH429 DT Small molecular drug
DMYH429 PC 11532887
DMYH429 MW 470
DMYH429 FM C25H28ClN3O4
DMYH429 IC InChI=1S/C25H28ClN3O4/c1-17(2)16-33-20-9-7-19(8-10-20)28-25(31)18-6-11-23(32-3)22(15-18)29(13-14-30)24-21(26)5-4-12-27-24/h4-12,15,17,30H,13-14,16H2,1-3H3,(H,28,31)
DMYH429 CS CC(C)COC1=CC=C(C=C1)NC(=O)C2=CC(=C(C=C2)OC)N(CCO)C3=C(C=CC=N3)Cl
DMYH429 IK QGYXTXVZRNIAOQ-UHFFFAOYSA-N
DMYH429 IU 3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]-4-methoxy-N-[4-(2-methylpropoxy)phenyl]benzamide
DMYH429 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM05D48 ID DM05D48
DM05D48 DN PMID25666693-Compound-77
DM05D48 HS Patented
DM05D48 CP Japan Tobacco, Inc
DM05D48 DT Small molecular drug
DM05D48 PC 11562798
DM05D48 MW 531.4
DM05D48 FM C26H28Cl2N4O4
DM05D48 IC InChI=1S/C26H28Cl2N4O4/c1-16(2)15-36-23-9-7-18(14-19(23)26(35)29-3)31-25(34)17-6-8-20(27)22(13-17)32(11-12-33)24-21(28)5-4-10-30-24/h4-10,13-14,16,33H,11-12,15H2,1-3H3,(H,29,35)(H,31,34)
DM05D48 CS CC(C)COC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)N(CCO)C3=C(C=CC=N3)Cl)C(=O)NC
DM05D48 IK VOVIFBICMYYQQM-UHFFFAOYSA-N
DM05D48 IU 4-chloro-3-[(3-chloropyridin-2-yl)-(2-hydroxyethyl)amino]-N-[3-(methylcarbamoyl)-4-(2-methylpropoxy)phenyl]benzamide
DM05D48 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMQI1YN ID DMQI1YN
DMQI1YN DN PMID25666693-Compound-78
DMQI1YN HS Patented
DMQI1YN CP Japan Tobacco, Inc
DMQI1YN DT Small molecular drug
DMQI1YN DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMTQ26G ID DMTQ26G
DMTQ26G DN PMID25666693-Compound-79
DMTQ26G HS Patented
DMTQ26G CP Japan Tobacco, Inc
DMTQ26G DT Small molecular drug
DMTQ26G PC 11677423
DMTQ26G MW 483.3
DMTQ26G FM C21H15Cl2F3N4O2
DMTQ26G IC InChI=1S/C21H15Cl2F3N4O2/c22-15-8-3-12(20(32)29-14-6-4-13(5-7-14)21(24,25)26)10-17(15)30(11-18(27)31)19-16(23)2-1-9-28-19/h1-10H,11H2,(H2,27,31)(H,29,32)
DMTQ26G CS C1=CC(=C(N=C1)N(CC(=O)N)C2=C(C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(F)(F)F)Cl)Cl
DMTQ26G IK LLVCZHNGUDERCY-UHFFFAOYSA-N
DMTQ26G IU 3-[(2-amino-2-oxoethyl)-(3-chloropyridin-2-yl)amino]-4-chloro-N-[4-(trifluoromethyl)phenyl]benzamide
DMTQ26G DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMZQ6HC ID DMZQ6HC
DMZQ6HC DN PMID25666693-Compound-8
DMZQ6HC HS Patented
DMZQ6HC CP ABBVIE INC
DMZQ6HC DT Small molecular drug
DMZQ6HC PC 66549082
DMZQ6HC MW 338.4
DMZQ6HC FM C19H19FN4O
DMZQ6HC IC InChI=1S/C19H19FN4O/c20-16-5-2-1-4-14(16)12-8-9-13(10-12)22-19(25)23-17-6-3-7-18-15(17)11-21-24-18/h1-7,11-13H,8-10H2,(H,21,24)(H2,22,23,25)/t12-,13-/m0/s1
DMZQ6HC CS C1C[C@@H](C[C@H]1C2=CC=CC=C2F)NC(=O)NC3=CC=CC4=C3C=NN4
DMZQ6HC IK MNXPYZUSFURMKS-STQMWFEESA-N
DMZQ6HC IU 1-[(1S,3S)-3-(2-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DMZQ6HC DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMB56LS ID DMB56LS
DMB56LS DN PMID25666693-Compound-80
DMB56LS HS Patented
DMB56LS CP Japan Tobacco, Inc
DMB56LS DT Small molecular drug
DMB56LS PC 11656215
DMB56LS MW 497.3
DMB56LS FM C22H17Cl2F3N4O2
DMB56LS IC InChI=1S/C22H17Cl2F3N4O2/c1-28-19(32)12-31(20-17(24)3-2-10-29-20)18-11-13(4-9-16(18)23)21(33)30-15-7-5-14(6-8-15)22(25,26)27/h2-11H,12H2,1H3,(H,28,32)(H,30,33)
DMB56LS CS CNC(=O)CN(C1=C(C=CC(=C1)C(=O)NC2=CC=C(C=C2)C(F)(F)F)Cl)C3=C(C=CC=N3)Cl
DMB56LS IK OGONHQFOPUHELI-UHFFFAOYSA-N
DMB56LS IU 4-chloro-3-[(3-chloropyridin-2-yl)-[2-(methylamino)-2-oxoethyl]amino]-N-[4-(trifluoromethyl)phenyl]benzamide
DMB56LS DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM5ZELW ID DM5ZELW
DM5ZELW DN PMID25666693-Compound-81
DM5ZELW HS Patented
DM5ZELW CP Japan Tobacco, Inc
DM5ZELW DT Small molecular drug
DM5ZELW PC 11706654
DM5ZELW MW 551.3
DM5ZELW FM C22H14Cl2F6N4O2
DM5ZELW IC InChI=1S/C22H14Cl2F6N4O2/c23-15-6-1-11(20(36)33-14-4-2-12(3-5-14)21(25,26)27)7-17(15)34(10-18(31)35)19-16(24)8-13(9-32-19)22(28,29)30/h1-9H,10H2,(H2,31,35)(H,33,36)
DM5ZELW CS C1=CC(=CC=C1C(F)(F)F)NC(=O)C2=CC(=C(C=C2)Cl)N(CC(=O)N)C3=C(C=C(C=N3)C(F)(F)F)Cl
DM5ZELW IK YLOQUQYZKPTZAV-UHFFFAOYSA-N
DM5ZELW IU 3-[(2-amino-2-oxoethyl)-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-4-chloro-N-[4-(trifluoromethyl)phenyl]benzamide
DM5ZELW DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM1MZ70 ID DM1MZ70
DM1MZ70 DN PMID25666693-Compound-82
DM1MZ70 HS Patented
DM1MZ70 CP Japan Tobacco, Inc
DM1MZ70 DT Small molecular drug
DM1MZ70 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM2ZVXD ID DM2ZVXD
DM2ZVXD DN PMID25666693-Compound-83
DM2ZVXD HS Patented
DM2ZVXD CP Japan Tobacco, Inc
DM2ZVXD DT Small molecular drug
DM2ZVXD PC 11720246
DM2ZVXD MW 499.3
DM2ZVXD FM C21H15Cl2F3N4O3
DM2ZVXD IC InChI=1S/C21H15Cl2F3N4O3/c22-15-8-3-12(20(32)29-13-4-6-14(7-5-13)33-21(24,25)26)10-17(15)30(11-18(27)31)19-16(23)2-1-9-28-19/h1-10H,11H2,(H2,27,31)(H,29,32)
DM2ZVXD CS C1=CC(=C(N=C1)N(CC(=O)N)C2=C(C=CC(=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)F)Cl)Cl
DM2ZVXD IK OHISWWFMRZTNTO-UHFFFAOYSA-N
DM2ZVXD IU 3-[(2-amino-2-oxoethyl)-(3-chloropyridin-2-yl)amino]-4-chloro-N-[4-(trifluoromethoxy)phenyl]benzamide
DM2ZVXD DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM4QYIJ ID DM4QYIJ
DM4QYIJ DN PMID25666693-Compound-84
DM4QYIJ HS Patented
DM4QYIJ CP Japan Tobacco, Inc
DM4QYIJ DT Small molecular drug
DM4QYIJ PC 11613881
DM4QYIJ MW 567.3
DM4QYIJ FM C22H14Cl2F6N4O3
DM4QYIJ IC InChI=1S/C22H14Cl2F6N4O3/c23-15-6-1-11(20(36)33-13-2-4-14(5-3-13)37-22(28,29)30)7-17(15)34(10-18(31)35)19-16(24)8-12(9-32-19)21(25,26)27/h1-9H,10H2,(H2,31,35)(H,33,36)
DM4QYIJ CS C1=CC(=CC=C1NC(=O)C2=CC(=C(C=C2)Cl)N(CC(=O)N)C3=C(C=C(C=N3)C(F)(F)F)Cl)OC(F)(F)F
DM4QYIJ IK FZDJPSLGLZJDRY-UHFFFAOYSA-N
DM4QYIJ IU 3-[(2-amino-2-oxoethyl)-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]-4-chloro-N-[4-(trifluoromethoxy)phenyl]benzamide
DM4QYIJ DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMGVU7M ID DMGVU7M
DMGVU7M DN PMID25666693-Compound-85
DMGVU7M HS Patented
DMGVU7M CP Japan Tobacco, Inc
DMGVU7M DT Small molecular drug
DMGVU7M PC 11671115
DMGVU7M MW 543.3
DMGVU7M FM C23H19Cl2F3N4O4
DMGVU7M IC InChI=1S/C23H19Cl2F3N4O4/c1-35-12-13-8-18(25)21(30-10-13)32(11-20(29)33)19-9-14(2-7-17(19)24)22(34)31-15-3-5-16(6-4-15)36-23(26,27)28/h2-10H,11-12H2,1H3,(H2,29,33)(H,31,34)
DMGVU7M CS COCC1=CC(=C(N=C1)N(CC(=O)N)C2=C(C=CC(=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)F)Cl)Cl
DMGVU7M IK DQUAXWYLWLLDLL-UHFFFAOYSA-N
DMGVU7M IU 3-[(2-amino-2-oxoethyl)-[3-chloro-5-(methoxymethyl)pyridin-2-yl]amino]-4-chloro-N-[4-(trifluoromethoxy)phenyl]benzamide
DMGVU7M DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMFZ3S4 ID DMFZ3S4
DMFZ3S4 DN PMID25666693-Compound-86
DMFZ3S4 HS Patented
DMFZ3S4 CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMFZ3S4 DT Small molecular drug
DMFZ3S4 PC 56949431
DMFZ3S4 MW 373.4
DMFZ3S4 FM C20H21F2N3O2
DMFZ3S4 IC InChI=1S/C20H21F2N3O2/c1-20(2,3)18-15(21)10-13(11-16(18)22)27-9-7-23-19(26)14-12-24-25-8-5-4-6-17(14)25/h4-6,8,10-12H,7,9H2,1-3H3,(H,23,26)
DMFZ3S4 CS CC(C)(C)C1=C(C=C(C=C1F)OCCNC(=O)C2=C3C=CC=CN3N=C2)F
DMFZ3S4 IK SDAKWMHNXUGINA-UHFFFAOYSA-N
DMFZ3S4 IU N-[2-(4-tert-butyl-3,5-difluorophenoxy)ethyl]pyrazolo[1,5-a]pyridine-3-carboxamide
DMFZ3S4 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMAV4XY ID DMAV4XY
DMAV4XY DN PMID25666693-Compound-87
DMAV4XY HS Patented
DMAV4XY CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMAV4XY DT Small molecular drug
DMAV4XY PC 56961050
DMAV4XY MW 403.4
DMAV4XY FM C21H23F2N3O3
DMAV4XY IC InChI=1S/C21H23F2N3O3/c1-21(2,3)19-16(22)9-14(10-17(19)23)29-8-7-24-20(28)15-11-25-26-13(12-27)5-4-6-18(15)26/h4-6,9-11,27H,7-8,12H2,1-3H3,(H,24,28)
DMAV4XY CS CC(C)(C)C1=C(C=C(C=C1F)OCCNC(=O)C2=C3C=CC=C(N3N=C2)CO)F
DMAV4XY IK SNBOLRWYZPETPJ-UHFFFAOYSA-N
DMAV4XY IU N-[2-(4-tert-butyl-3,5-difluorophenoxy)ethyl]-7-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxamide
DMAV4XY DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMT9EJL ID DMT9EJL
DMT9EJL DN PMID25666693-Compound-88
DMT9EJL HS Patented
DMT9EJL CP SNU R&DB Foundation
DMT9EJL DT Small molecular drug
DMT9EJL DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM6RQKH ID DM6RQKH
DM6RQKH DN PMID25666693-Compound-89
DM6RQKH HS Patented
DM6RQKH CP SNU R&DB Foundation
DM6RQKH DT Small molecular drug
DM6RQKH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM8A4B5 ID DM8A4B5
DM8A4B5 DN PMID25666693-Compound-9
DM8A4B5 HS Patented
DM8A4B5 CP ABBVIE INC
DM8A4B5 DT Small molecular drug
DM8A4B5 PC 66549271
DM8A4B5 MW 338.4
DM8A4B5 FM C19H19FN4O
DM8A4B5 IC InChI=1S/C19H19FN4O/c20-14-4-1-3-12(9-14)13-7-8-15(10-13)22-19(25)23-17-5-2-6-18-16(17)11-21-24-18/h1-6,9,11,13,15H,7-8,10H2,(H,21,24)(H2,22,23,25)/t13-,15-/m0/s1
DM8A4B5 CS C1C[C@@H](C[C@H]1C2=CC(=CC=C2)F)NC(=O)NC3=CC=CC4=C3C=NN4
DM8A4B5 IK ROOFFAWDIFZLQB-ZFWWWQNUSA-N
DM8A4B5 IU 1-[(1S,3S)-3-(3-fluorophenyl)cyclopentyl]-3-(1H-indazol-4-yl)urea
DM8A4B5 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM26NQE ID DM26NQE
DM26NQE DN PMID25666693-Compound-90
DM26NQE HS Patented
DM26NQE CP SNU R&DB Foundation
DM26NQE DT Small molecular drug
DM26NQE DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMXU3IE ID DMXU3IE
DMXU3IE DN PMID25666693-Compound-91
DMXU3IE HS Patented
DMXU3IE CP SNU R&DB Foundation
DMXU3IE DT Small molecular drug
DMXU3IE DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMRGOZ8 ID DMRGOZ8
DMRGOZ8 DN PMID25666693-Compound-92
DMRGOZ8 HS Patented
DMRGOZ8 CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMRGOZ8 DT Small molecular drug
DMRGOZ8 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMM5EI4 ID DMM5EI4
DMM5EI4 DN PMID25666693-Compound-93
DMM5EI4 HS Patented
DMM5EI4 CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMM5EI4 DT Small molecular drug
DMM5EI4 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHREX9 ID DMHREX9
DMHREX9 DN PMID25666693-Compound-94
DMHREX9 HS Patented
DMHREX9 CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMHREX9 DT Small molecular drug
DMHREX9 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMFNB1T ID DMFNB1T
DMFNB1T DN PMID25666693-Compound-95
DMFNB1T HS Patented
DMFNB1T CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMFNB1T DT Small molecular drug
DMFNB1T DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DME3NTB ID DME3NTB
DME3NTB DN PMID25666693-Compound-96
DME3NTB HS Patented
DME3NTB CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DME3NTB DT Small molecular drug
DME3NTB DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMHJOP7 ID DMHJOP7
DMHJOP7 DN PMID25666693-Compound-97
DMHJOP7 HS Patented
DMHJOP7 CP GLAXO GROUP LIMITED BIGGADIKE, Keith BIRAULT, Veronique CHAMPIGNY, Aurelie Cecile COE, Diane Mary HUGHES, Owen Rhys NEEDHAM, Deborah TAPE, Daniel Terence
DMHJOP7 DT Small molecular drug
DMHJOP7 DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DM2ZR8M ID DM2ZR8M
DM2ZR8M DN PMID25666693-Compound-98
DM2ZR8M HS Patented
DM2ZR8M CP PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
DM2ZR8M DT Small molecular drug
DM2ZR8M PC 71480662
DM2ZR8M MW 449.5
DM2ZR8M FM C20H21F2N5O3S
DM2ZR8M IC InChI=1S/C20H21F2N5O3S/c1-11-9-26(18-14(22)6-12(8-23-18)16(29)10-28)4-5-27(11)20(30)25-19-24-15-7-13(21)2-3-17(15)31-19/h2-3,6-8,11,16,28-29H,4-5,9-10H2,1H3,(H,24,25,30)/t11-,16+/m0/s1
DM2ZR8M CS C[C@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=CC(=C3)F)C4=C(C=C(C=N4)[C@@H](CO)O)F
DM2ZR8M IK GVENNMJXQHKHOV-MEDUHNTESA-N
DM2ZR8M IU (2S)-4-[5-[(1S)-1,2-dihydroxyethyl]-3-fluoropyridin-2-yl]-N-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazine-1-carboxamide
DM2ZR8M DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMOISDH ID DMOISDH
DMOISDH DN PMID25666693-Compound-99
DMOISDH HS Patented
DMOISDH CP PURDUE PHARMA LP [USSHIONOGI & CO [JPTAFESSE LAYKEA [USANDO SHIGERU [JPKUROSE NORIYUKI [JP]
DMOISDH DT Small molecular drug
DMOISDH PC 71498842
DMOISDH MW 445.5
DMOISDH FM C21H24FN5O3S
DMOISDH IC InChI=1S/C21H24FN5O3S/c1-12-3-4-16-18(7-12)31-20(24-16)25-21(30)27-6-5-26(10-13(27)2)19-15(22)8-14(9-23-19)17(29)11-28/h3-4,7-9,13,17,28-29H,5-6,10-11H2,1-2H3,(H,24,25,30)/t13-,17+/m0/s1
DMOISDH CS C[C@H]1CN(CCN1C(=O)NC2=NC3=C(S2)C=C(C=C3)C)C4=C(C=C(C=N4)[C@@H](CO)O)F
DMOISDH IK MOYYIRTYGZTKTA-SUMWQHHRSA-N
DMOISDH IU (2S)-4-[5-[(1S)-1,2-dihydroxyethyl]-3-fluoropyridin-2-yl]-2-methyl-N-(6-methyl-1,3-benzothiazol-2-yl)piperazine-1-carboxamide
DMOISDH DE Osteoarthritis pain; Cancer related pain; Neuropathic pain; Inflammatory pain
DMDZT7Y ID DMDZT7Y
DMDZT7Y DN PMID25684022-Compound-EP20041486488
DMDZT7Y HS Patented
DMDZT7Y CP Phosphosites GmbH
DMDZT7Y DT Small molecular drug
DMDZT7Y DE Solid tumour/cancer; Metastatic cancer
DMR4MSH ID DMR4MSH
DMR4MSH DN PMID25684022-Compound-US20120277229 39(1.1)
DMR4MSH HS Patented
DMR4MSH DE Solid tumour/cancer; Metastatic cancer
DMR3J9A ID DMR3J9A
DMR3J9A DN PMID25684022-Compound-US20120277229 40(1.2)
DMR3J9A HS Patented
DMR3J9A DE Solid tumour/cancer; Metastatic cancer
DM7V6E0 ID DM7V6E0
DM7V6E0 DN PMID25684022-Compound-US20120277229 41(1.3)
DM7V6E0 HS Patented
DM7V6E0 DE Solid tumour/cancer; Metastatic cancer
DMUQ04C ID DMUQ04C
DMUQ04C DN PMID25684022-Compound-US20120277229 44(1.4)
DMUQ04C HS Patented
DMUQ04C DE Solid tumour/cancer; Metastatic cancer
DMEIA6Y ID DMEIA6Y
DMEIA6Y DN PMID25684022-Compound-US20120277229 45(1.5)
DMEIA6Y HS Patented
DMEIA6Y DE Solid tumour/cancer; Metastatic cancer
DMDHJMU ID DMDHJMU
DMDHJMU DN PMID25684022-Compound-US20130053382 35(1-11)
DMDHJMU HS Patented
DMDHJMU DE Solid tumour/cancer; Metastatic cancer
DM40FVN ID DM40FVN
DM40FVN DN PMID25684022-Compound-US20130053382 36(3-5)
DM40FVN HS Patented
DM40FVN DE Solid tumour/cancer; Metastatic cancer
DMY7Z85 ID DMY7Z85
DMY7Z85 DN PMID25684022-Compound-US20130053382 37(4-6)
DMY7Z85 HS Patented
DMY7Z85 DE Solid tumour/cancer; Metastatic cancer
DMHLQ2T ID DMHLQ2T
DMHLQ2T DN PMID25684022-Compound-US20130053382 38(5-7)
DMHLQ2T HS Patented
DMHLQ2T DE Solid tumour/cancer; Metastatic cancer
DM809AX ID DM809AX
DM809AX DN PMID25684022-Compound-WO2004087707
DM809AX HS Patented
DM809AX CP Vernalis Cambridge Ltd
DM809AX DT Small molecular drug
DM809AX DE Solid tumour/cancer; Metastatic cancer
DMV7PNF ID DMV7PNF
DMV7PNF DN PMID25684022-Compound-WO2006015124
DMV7PNF HS Patented
DMV7PNF CP SGX PHARMACEUTICALS, INC. ARNOLD, William, D. GOSBERG, Andreas LI, Zhe STEENSMA, Ruo, W. WILSON, Mark, E
DMV7PNF DT Small molecular drug
DMV7PNF DE Solid tumour/cancer; Metastatic cancer
DMDMJYL ID DMDMJYL
DMDMJYL DN PMID25684022-Compound-WO2008005457
DMDMJYL HS Patented
DMDMJYL CP SUNESIS PHARMACEUTICALS BIOGEN IDEC MA INC. LIND, Kenneth, Egnard CAO, Kathy LIN, Edward, Yin-shiang NGUYEN, Thinh, Ba TANGONAN, Bradley, T. ERLANSON, Daniel, A. GUCKIAN, Kevin SIMMONS, Robert, Lowell LEE, Wen-cherng BIOGEN IDEC, INC. SUN, Lihong HANSEN, Stig PATHAN, Nuzhat ZHANG, Lei
DMDMJYL DT Small molecular drug
DMDMJYL DE Solid tumour/cancer; Metastatic cancer
DMKJ1HC ID DMKJ1HC
DMKJ1HC DN PMID25684022-Compound-WO2008079988
DMKJ1HC HS Patented
DMKJ1HC CP Novartis
DMKJ1HC DT Small molecular drug
DMKJ1HC DE Solid tumour/cancer; Metastatic cancer
DM8L5JR ID DM8L5JR
DM8L5JR DN PMID25684022-Compound-WO2008107444
DM8L5JR HS Patented
DM8L5JR CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM8L5JR DT Small molecular drug
DM8L5JR DE Solid tumour/cancer; Metastatic cancer
DMTP02Q ID DMTP02Q
DMTP02Q DN PMID25684022-Compound-WO2009153313
DMTP02Q HS Patented
DMTP02Q CP NOVARTIS AG JAIN, Rama LIN, Xiaodong NG, Simon C. PFISTER, Keith B. RAMURTHY, Savithri RICO, Alice SUBRAMANIAN, Sharadha WANG, Xiaojing Michael
DMTP02Q DT Small molecular drug
DMTP02Q DE Solid tumour/cancer; Metastatic cancer
DM37FDV ID DM37FDV
DM37FDV DN PMID25684022-Compound-WO2010127754
DM37FDV HS Patented
DM37FDV CP MERCK PATENT GMBH DORSCH, Dieter WUCHERER-PLIETKER, Margarita MUELLER, Thomas, J., J. MERKUL, Eugen
DM37FDV DT Small molecular drug
DM37FDV DE Solid tumour/cancer; Metastatic cancer
DM3IZ0H ID DM3IZ0H
DM3IZ0H DN PMID25684022-Compound-WO2011137219 35(1-11)
DM3IZ0H HS Patented
DM3IZ0H CP MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DM3IZ0H DE Solid tumour/cancer; Metastatic cancer
DMAQHI5 ID DMAQHI5
DMAQHI5 DN PMID25684022-Compound-WO2011137219 36(3-5)
DMAQHI5 HS Patented
DMAQHI5 CP MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DMAQHI5 DE Solid tumour/cancer; Metastatic cancer
DMSQ5J8 ID DMSQ5J8
DMSQ5J8 DN PMID25684022-Compound-WO2011137219 37(4-6)
DMSQ5J8 HS Patented
DMSQ5J8 CP MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DMSQ5J8 DE Solid tumour/cancer; Metastatic cancer
DM4NXBK ID DM4NXBK
DM4NXBK DN PMID25684022-Compound-WO2011137219 38(5-7)
DM4NXBK HS Patented
DM4NXBK CP MERCK SHARP & DOHME CORP. KEENAN, Kevin, A. NORTHRUP, Alan, B
DM4NXBK DE Solid tumour/cancer; Metastatic cancer
DMSDRA4 ID DMSDRA4
DMSDRA4 DN PMID25684022-Compound-WO2012135799 42(1.4)
DMSDRA4 HS Patented
DMSDRA4 CP UNIVERSITY OF UTAH RESEARCH FOUNDATION BEARSS, David, J. VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steven, L. SHARMA, Sunil
DMSDRA4 DE Solid tumour/cancer; Metastatic cancer
DMHI3O1 ID DMHI3O1
DMHI3O1 DN PMID25684022-Compound-WO2012135799 43(1.5)
DMHI3O1 HS Patented
DMHI3O1 CP UNIVERSITY OF UTAH RESEARCH FOUNDATION BEARSS, David, J. VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steven, L. SHARMA, Sunil
DMHI3O1 DE Solid tumour/cancer; Metastatic cancer
DMZ73D9 ID DMZ73D9
DMZ73D9 DN PMID25726713-Compound-10
DMZ73D9 HS Patented
DMZ73D9 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DMZ73D9 DT Small molecular drug
DMN42OT ID DMN42OT
DMN42OT DN PMID25726713-Compound-11
DMN42OT HS Patented
DMN42OT CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DMN42OT DT Small molecular drug
DMD3AHN ID DMD3AHN
DMD3AHN DN PMID25726713-Compound-12
DMD3AHN HS Patented
DMD3AHN CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DMD3AHN DT Small molecular drug
DM8LZ60 ID DM8LZ60
DM8LZ60 DN PMID25726713-Compound-13
DM8LZ60 HS Patented
DM8LZ60 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DM8LZ60 DT Small molecular drug
DM6ORB9 ID DM6ORB9
DM6ORB9 DN PMID25726713-Compound-14
DM6ORB9 HS Patented
DM6ORB9 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DM6ORB9 DT Small molecular drug
DM67WM4 ID DM67WM4
DM67WM4 DN PMID25726713-Compound-15
DM67WM4 HS Patented
DM67WM4 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DM67WM4 DT Small molecular drug
DM3BOZP ID DM3BOZP
DM3BOZP DN PMID25726713-Compound-16
DM3BOZP HS Patented
DM3BOZP CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE STRASBOURG RUAT, Martial FAURE, Hélène ROUDAUT, Hermine HOCH, Lucile SCHOENFELDER, Angèle TADDEI, Maurizio MANN, André
DM3BOZP DT Small molecular drug
DM9MFUN ID DM9MFUN
DM9MFUN DN PMID25726713-Compound-17
DM9MFUN HS Patented
DM9MFUN CP DUKE UNIVERSITY
DM9MFUN DT Small molecular drug
DMP7C5L ID DMP7C5L
DMP7C5L DN PMID25726713-Compound-18
DMP7C5L HS Patented
DMP7C5L CP DUKE UNIVERSITY
DMP7C5L DT Small molecular drug
DMQJZLI ID DMQJZLI
DMQJZLI DN PMID25726713-Compound-19
DMQJZLI HS Patented
DMQJZLI CP IMPACT THERAPEUTICS, INC. CAI, Suixiong TIAN, Ye Edward WANG, Xiaozhu XIE, Kai LI, Sicun YU, Zenghui GU, Chengyun LIU, Lijun
DMQJZLI DT Small molecular drug
DMZOG9S ID DMZOG9S
DMZOG9S DN PMID25726713-Compound-20
DMZOG9S HS Patented
DMZOG9S CP IMPACT THERAPEUTICS, INC. CAI, Suixiong TIAN, Ye Edward WANG, Xiaozhu XIE, Kai LI, Sicun YU, Zenghui GU, Chengyun LIU, Lijun
DMZOG9S DT Small molecular drug
DMZOG9S PC 71484081
DMZOG9S MW 490
DMZOG9S FM C26H24ClN5O3
DMZOG9S IC InChI=1S/C26H24ClN5O3/c1-14(2)35-16-6-8-21-22(11-16)32-26(31-21)18-9-15(5-7-20(18)27)30-25-19-10-17(33-3)12-23(34-4)24(19)28-13-29-25/h5-14H,1-4H3,(H,31,32)(H,28,29,30)
DMZOG9S CS CC(C)OC1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)NC4=NC=NC5=C4C=C(C=C5OC)OC)Cl
DMZOG9S IK UTABPCPBPRTBQJ-UHFFFAOYSA-N
DMZOG9S IU N-[4-chloro-3-(6-propan-2-yloxy-1H-benzimidazol-2-yl)phenyl]-6,8-dimethoxyquinazolin-4-amine
DMB0DS5 ID DMB0DS5
DMB0DS5 DN PMID25726713-Compound-21
DMB0DS5 HS Patented
DMB0DS5 CP IMPACT THERAPEUTICS, INC. CAI, Suixiong TIAN, Ye Edward WANG, Xiaozhu XIE, Kai LI, Sicun YU, Zenghui GU, Chengyun LIU, Lijun
DMB0DS5 DT Small molecular drug
DMJUHXB ID DMJUHXB
DMJUHXB DN PMID25726713-Compound-22
DMJUHXB HS Patented
DMJUHXB CP IMPACT THERAPEUTICS, INC. CAI, Suixiong TIAN, Ye Edward WANG, Xiaozhu XIE, Kai LI, Sicun YU, Zenghui GU, Chengyun LIU, Lijun
DMJUHXB DT Small molecular drug
DMEXNOP ID DMEXNOP
DMEXNOP DN PMID25726713-Compound-23
DMEXNOP HS Patented
DMEXNOP CP IMPACT THERAPEUTICS, INC. CAI, Suixiong TIAN, Ye Edward WANG, Xiaozhu XIE, Kai LI, Sicun YU, Zenghui GU, Chengyun LIU, Lijun
DMEXNOP DT Small molecular drug
DMMFK2Q ID DMMFK2Q
DMMFK2Q DN PMID25726713-Compound-24
DMMFK2Q HS Patented
DMMFK2Q CP IMPACT THERAPEUTICS, INC. CAI, Suixiong TIAN, Ye Edward WANG, Xiaozhu XIE, Kai LI, Sicun YU, Zenghui GU, Chengyun LIU, Lijun
DMMFK2Q DT Small molecular drug
DMLCPWT ID DMLCPWT
DMLCPWT DN PMID25726713-Compound-25
DMLCPWT HS Patented
DMLCPWT CP IMPACT THERAPEUTICS, INC
DMLCPWT DT Small molecular drug
DMJ8MXZ ID DMJ8MXZ
DMJ8MXZ DN PMID25726713-Compound-26
DMJ8MXZ HS Patented
DMJ8MXZ CP IMPACT THERAPEUTICS, INC
DMJ8MXZ DT Small molecular drug
DMTL73W ID DMTL73W
DMTL73W DN PMID25726713-Compound-27
DMTL73W HS Patented
DMTL73W CP IMPACT THERAPEUTICS, INC
DMTL73W DT Small molecular drug
DMYM60P ID DMYM60P
DMYM60P DN PMID25726713-Compound-28
DMYM60P HS Patented
DMYM60P CP IMPACT THERAPEUTICS, INC
DMYM60P DT Small molecular drug
DM3QU80 ID DM3QU80
DM3QU80 DN PMID25726713-Compound-29
DM3QU80 HS Patented
DM3QU80 CP IMPACT THERAPEUTICS, INC
DM3QU80 DT Small molecular drug
DMFBHAC ID DMFBHAC
DMFBHAC DN PMID25726713-Compound-30
DMFBHAC HS Patented
DMFBHAC CP IMPACT THERAPEUTICS, INC
DMFBHAC DT Small molecular drug
DMN13BI ID DMN13BI
DMN13BI DN PMID25726713-Compound-31
DMN13BI HS Patented
DMN13BI DT Small molecular drug
DMIFH8T ID DMIFH8T
DMIFH8T DN PMID25726713-Compound-32
DMIFH8T HS Patented
DMIFH8T DT Small molecular drug
DMEQ9BN ID DMEQ9BN
DMEQ9BN DN PMID25726713-Compound-33
DMEQ9BN HS Patented
DMEQ9BN DT Small molecular drug
DMCXDKS ID DMCXDKS
DMCXDKS DN PMID25726713-Compound-34
DMCXDKS HS Patented
DMCXDKS DT Small molecular drug
DMYCABN ID DMYCABN
DMYCABN DN PMID25726713-Compound-35
DMYCABN HS Patented
DMYCABN DT Small molecular drug
DMYPT63 ID DMYPT63
DMYPT63 DN PMID25726713-Compound-36
DMYPT63 HS Patented
DMYPT63 DT Small molecular drug
DMGXOJK ID DMGXOJK
DMGXOJK DN PMID25726713-Compound-37
DMGXOJK HS Patented
DMGXOJK DT Small molecular drug
DM4XJST ID DM4XJST
DM4XJST DN PMID25726713-Compound-38
DM4XJST HS Patented
DM4XJST DT Small molecular drug
DM4XJST PC 118706742
DM4XJST MW 617.6
DM4XJST FM C32H30F3N7O3
DM4XJST IC InChI=1S/C32H30F3N7O3/c1-20-3-4-21(18-42-13-15-44-16-14-42)17-26(20)38-30(43)23-5-9-24(10-6-23)37-31-39-27(28-29(40-31)41(2)19-36-28)22-7-11-25(12-8-22)45-32(33,34)35/h3-12,17,19H,13-16,18H2,1-2H3,(H,38,43)(H,37,39,40)
DM4XJST CS CC1=C(C=C(C=C1)CN2CCOCC2)NC(=O)C3=CC=C(C=C3)NC4=NC(=C5C(=N4)N(C=N5)C)C6=CC=C(C=C6)OC(F)(F)F
DM4XJST IK RXPJNNAJKCJKEX-UHFFFAOYSA-N
DM4XJST IU N-[2-methyl-5-(morpholin-4-ylmethyl)phenyl]-4-[[9-methyl-6-[4-(trifluoromethoxy)phenyl]purin-2-yl]amino]benzamide
DMVL25C ID DMVL25C
DMVL25C DN PMID25726713-Compound-39
DMVL25C HS Patented
DMVL25C DT Small molecular drug
DM5E2B3 ID DM5E2B3
DM5E2B3 DN PMID25726713-Compound-42
DM5E2B3 HS Patented
DM5E2B3 CP MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DM5E2B3 DT Small molecular drug
DME9QCM ID DME9QCM
DME9QCM DN PMID25726713-Compound-43
DME9QCM HS Patented
DME9QCM CP MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DME9QCM DT Small molecular drug
DMEFA20 ID DMEFA20
DMEFA20 DN PMID25726713-Compound-44
DMEFA20 HS Patented
DMEFA20 CP MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DMEFA20 DT Small molecular drug
DMR8OVI ID DMR8OVI
DMR8OVI DN PMID25726713-Compound-45
DMR8OVI HS Patented
DMR8OVI CP MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DMR8OVI DT Small molecular drug
DM27DQP ID DM27DQP
DM27DQP DN PMID25726713-Compound-46
DM27DQP HS Patented
DM27DQP CP MEMORIAL SLOAN-KETTERING CANCER CENTER THE ROCKEFELLER UNIVERSITY
DM27DQP DT Small molecular drug
DMXE5KM ID DMXE5KM
DMXE5KM DN PMID25726713-Compound-47
DMXE5KM HS Patented
DMXE5KM DT Small molecular drug
DMSIOUA ID DMSIOUA
DMSIOUA DN PMID25726713-Compound-48
DMSIOUA HS Patented
DMSIOUA DT Small molecular drug
DM2CT4G ID DM2CT4G
DM2CT4G DN PMID25726713-Compound-49
DM2CT4G HS Patented
DM2CT4G DT Small molecular drug
DM3BDFV ID DM3BDFV
DM3BDFV DN PMID25726713-Compound-50
DM3BDFV HS Patented
DM3BDFV DT Small molecular drug
DMF0OW4 ID DMF0OW4
DMF0OW4 DN PMID25726713-Compound-51
DMF0OW4 HS Patented
DMF0OW4 DT Small molecular drug
DMUHEP8 ID DMUHEP8
DMUHEP8 DN PMID25726713-Compound-56
DMUHEP8 HS Patented
DMUHEP8 DT Small molecular drug
DMMZHB1 ID DMMZHB1
DMMZHB1 DN PMID25726713-Compound-57
DMMZHB1 HS Patented
DMMZHB1 DT Small molecular drug
DMPDX3L ID DMPDX3L
DMPDX3L DN PMID25726713-Compound-58
DMPDX3L HS Patented
DMPDX3L DT Small molecular drug
DMBF1OG ID DMBF1OG
DMBF1OG DN PMID25726713-Compound-59
DMBF1OG HS Patented
DMBF1OG DT Small molecular drug
DMR8HSU ID DMR8HSU
DMR8HSU DN PMID25726713-Compound-60
DMR8HSU HS Patented
DMR8HSU DT Small molecular drug
DMYXK7I ID DMYXK7I
DMYXK7I DN PMID25726713-Compound-61
DMYXK7I HS Patented
DMYXK7I DT Small molecular drug
DMXNLTR ID DMXNLTR
DMXNLTR DN PMID25726713-Compound-62
DMXNLTR HS Patented
DMXNLTR DT Small molecular drug
DMT0QLO ID DMT0QLO
DMT0QLO DN PMID25726713-Compound-63
DMT0QLO HS Patented
DMT0QLO DT Small molecular drug
DM6A8TS ID DM6A8TS
DM6A8TS DN PMID25726713-Compound-64
DM6A8TS HS Patented
DM6A8TS DT Small molecular drug
DM048C1 ID DM048C1
DM048C1 DN PMID25747044-Compound-miRNA
DM048C1 HS Patented
DM048C1 CP UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
DM048C1 DT miRNA
DMVWF6I ID DMVWF6I
DMVWF6I DN PMID25772215-Compound-EP20082149552C9
DMVWF6I HS Patented
DMVWF6I DT Small molecular drug
DM48YKE ID DM48YKE
DM48YKE DN PMID25772215-Compound-EP2149552diaminopyrimidines
DM48YKE HS Patented
DM48YKE CP BAYER SCHERING PHARMA AG [DE]
DM48YKE DT Small molecular drug
DM7EKZ6 ID DM7EKZ6
DM7EKZ6 DN PMID25772215-Compound-US02014179750M1
DM7EKZ6 HS Patented
DM7EKZ6 DT Small molecular drug
DMC50F3 ID DMC50F3
DMC50F3 DN PMID25772215-Compound-US02014179750M2
DMC50F3 HS Patented
DMC50F3 DT Small molecular drug
DMJA1XC ID DMJA1XC
DMJA1XC DN PMID25772215-Compound-US02014179750M3
DMJA1XC HS Patented
DMJA1XC DT Small molecular drug
DMWD1FP ID DMWD1FP
DMWD1FP DN PMID25772215-Compound-US02014179750TG6-10-1
DMWD1FP HS Patented
DMWD1FP CP EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMWD1FP DT Small molecular drug
DMRLZD2 ID DMRLZD2
DMRLZD2 DN PMID25772215-Compound-US02014179750TG6-129
DMRLZD2 HS Patented
DMRLZD2 CP EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMRLZD2 DT Small molecular drug
DMB87WZ ID DMB87WZ
DMB87WZ DN PMID25772215-Compound-US02014179750TG7-112-2
DMB87WZ HS Patented
DMB87WZ DT Small molecular drug
DMORK8H ID DMORK8H
DMORK8H DN PMID25772215-Compound-US02014179750TG7-170
DMORK8H HS Patented
DMORK8H DT Small molecular drug
DM9I4EV ID DM9I4EV
DM9I4EV DN PMID25772215-Compound-US02014179750TG7-74
DM9I4EV HS Patented
DM9I4EV DT Small molecular drug
DMRTZC4 ID DMRTZC4
DMRTZC4 DN PMID25772215-Compound-US02014179750TG7-76
DMRTZC4 HS Patented
DMRTZC4 DT Small molecular drug
DM8IL6Y ID DM8IL6Y
DM8IL6Y DN PMID25772215-Compound-US02014179750TG8-15
DM8IL6Y HS Patented
DM8IL6Y DT Small molecular drug
DMD3CB4 ID DMD3CB4
DMD3CB4 DN PMID25772215-Compound-WO2012177618M4
DMD3CB4 HS Patented
DMD3CB4 CP EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMD3CB4 DT Small molecular drug
DMWUK9X ID DMWUK9X
DMWUK9X DN PMID25772215-Compound-WO2012177618M5
DMWUK9X HS Patented
DMWUK9X CP EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMWUK9X DT Small molecular drug
DMDCZVI ID DMDCZVI
DMDCZVI DN PMID25772215-Compound-WO2012177618M6
DMDCZVI HS Patented
DMDCZVI CP EMORY UNIVERSITY JIANG, Jianxiong GANESH, Thota DU, Yuhong THEPCHATRI, Pahk QUAN, Yi DINGLEDINE, Ray J
DMDCZVI DT Small molecular drug
DMGHSR9 ID DMGHSR9
DMGHSR9 DN PMID25776143-Compound-1
DMGHSR9 HS Patented
DMGHSR9 CP Ferring BV
DMGHSR9 DT Small molecular drug
DMTZRFP ID DMTZRFP
DMTZRFP DN PMID25776143-Compound-2
DMTZRFP HS Patented
DMTZRFP CP Ferring BV
DMTZRFP DT Small molecular drug
DMCULI1 ID DMCULI1
DMCULI1 DN PMID25776143-Compound-3
DMCULI1 HS Patented
DMCULI1 CP Hoffmann-La Roche Ag
DMCULI1 DT Small molecular drug
DMMVETJ ID DMMVETJ
DMMVETJ DN PMID25776143-Compound-4
DMMVETJ HS Patented
DMMVETJ CP Hoffmann-La Roche Ag
DMMVETJ DT Small molecular drug
DM7QIMN ID DM7QIMN
DM7QIMN DN PMID25776143-Compound-7
DM7QIMN HS Patented
DM7QIMN CP Vantia Ltd
DM7QIMN DT Small molecular drug
DM7QIMN PC 135468116
DM7QIMN MW 597.6
DM7QIMN FM C31H38Cl2N6O2
DM7QIMN IC InChI=1S/C31H38Cl2N6O2/c1-31(2,3)11-14-38-12-9-20(10-13-38)29(40)34-17-22-6-5-21(15-25(22)33)30(41)39-19-23-18-35-37(4)28(23)36-26-16-24(32)7-8-27(26)39/h5-8,15-16,18,20,36H,9-14,17,19H2,1-4H3,(H,34,40)
DM7QIMN CS CC(C)(C)CCN1CCC(CC1)C(=O)NCC2=C(C=C(C=C2)C(=O)N3CC4=C(NC5=C3C=CC(=C5)Cl)N(N=C4)C)Cl
DM7QIMN IK QYCFYRDBJAXOJI-UHFFFAOYSA-N
DM7QIMN IU N-[[2-chloro-4-(8-chloro-1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)phenyl]methyl]-1-(3,3-dimethylbutyl)piperidine-4-carboxamide
DMUKFJ0 ID DMUKFJ0
DMUKFJ0 DN PMID25776143-Compound-8
DMUKFJ0 HS Patented
DMUKFJ0 CP Ferring BV
DMUKFJ0 DT Small molecular drug
DMUKFJ0 PC 136396729
DMUKFJ0 MW 449.9
DMUKFJ0 FM C24H24ClN5O2
DMUKFJ0 IC InChI=1S/C24H24ClN5O2/c1-14-9-16(5-6-17(14)11-26-23(31)15-3-4-15)24(32)30-13-18-12-27-29(2)22(18)28-20-10-19(25)7-8-21(20)30/h5-10,12,15,28H,3-4,11,13H2,1-2H3,(H,26,31)
DMUKFJ0 CS CC1=C(C=CC(=C1)C(=O)N2CC3=C(NC4=C2C=CC(=C4)Cl)N(N=C3)C)CNC(=O)C5CC5
DMUKFJ0 IK DZLYFDUKRUYUIP-UHFFFAOYSA-N
DMUKFJ0 IU N-[[4-(8-chloro-1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)-2-methylphenyl]methyl]cyclopropanecarboxamide
DMEC1TR ID DMEC1TR
DMEC1TR DN PMID25828189-Compound-19
DMEC1TR HS Patented
DMEC1TR DT Small molecular drug
DM7D0CT ID DM7D0CT
DM7D0CT DN PMID25828189-Compound-21
DM7D0CT HS Patented
DM7D0CT DT Small molecular drug
DM7D0CT PC 60152347
DM7D0CT MW 502.5
DM7D0CT FM C24H25F3N6O3
DM7D0CT IC InChI=1S/C24H25F3N6O3/c25-24(26,27)19-13-33(14-31-19)23-29-11-18(12-30-23)32-21(15-3-1-2-4-15)16-5-7-17(8-6-16)22(36)28-10-9-20(34)35/h5-8,11-15,21,32H,1-4,9-10H2,(H,28,36)(H,34,35)
DM7D0CT CS C1CCC(C1)C(C2=CC=C(C=C2)C(=O)NCCC(=O)O)NC3=CN=C(N=C3)N4C=C(N=C4)C(F)(F)F
DM7D0CT IK KUIQXXFGGIPRIS-UHFFFAOYSA-N
DM7D0CT IU 3-[[4-[cyclopentyl-[[2-[4-(trifluoromethyl)imidazol-1-yl]pyrimidin-5-yl]amino]methyl]benzoyl]amino]propanoic acid
DMC2O0Q ID DMC2O0Q
DMC2O0Q DN PMID25828189-Compound-22
DMC2O0Q HS Patented
DMC2O0Q DT Small molecular drug
DMC2O0Q PC 68178614
DMC2O0Q MW 461.6
DMC2O0Q FM C27H31N3O4
DMC2O0Q IC InChI=1S/C27H31N3O4/c1-2-5-25(19-8-10-20(11-9-19)27(33)28-17-16-26(31)32)34-23-14-12-22(13-15-23)30-18-21-6-3-4-7-24(21)29-30/h8-15,18,25H,2-7,16-17H2,1H3,(H,28,33)(H,31,32)
DMC2O0Q CS CCCC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)OC2=CC=C(C=C2)N3C=C4CCCCC4=N3
DMC2O0Q IK BFFBGZWQVKRFRU-UHFFFAOYSA-N
DMC2O0Q IU 3-[[4-[1-[4-(4,5,6,7-tetrahydroindazol-2-yl)phenoxy]butyl]benzoyl]amino]propanoic acid
DMYPT2H ID DMYPT2H
DMYPT2H DN PMID25980951-Compound-1
DMYPT2H HS Patented
DMYPT2H CP PHARMASCIENCE INC. LAURENT, Alain PROULX, Melanie ROSE, Yannick DENISSOVA, Irina DAIRI, Kenza JARVIS, Scott JAQUITH, James, B
DMYPT2H DT Small molecular drug
DMYPT2H PC 68265428
DMYPT2H MW 565.7
DMYPT2H FM C30H40FN7O3
DMYPT2H IC InChI=1S/C30H40FN7O3/c1-20(32-5)26(39)35-25(30(2,3)4)28(41)38-16-6-8-23(38)18-36(17-13-21-9-11-22(31)12-10-21)27(40)24-19-37-15-7-14-33-29(37)34-24/h7,9-12,14-15,19-20,23,25,32H,6,8,13,16-18H2,1-5H3,(H,35,39)/t20-,23-,25+/m0/s1
DMYPT2H CS C[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1CN(CCC2=CC=C(C=C2)F)C(=O)C3=CN4C=CC=NC4=N3)C(C)(C)C)NC
DMYPT2H IK HWFGTCIBSHAQOY-GRYUFTJMSA-N
DMYPT2H IU N-[[(2S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-N-[2-(4-fluorophenyl)ethyl]imidazo[1,2-a]pyrimidine-2-carboxamide
DME3ZJO ID DME3ZJO
DME3ZJO DN PMID25980951-Compound-10
DME3ZJO HS Patented
DME3ZJO CP GENENTECH, INC. BERGERON, Philippe KOEHLER, Michael, F. T
DME3ZJO DT Small molecular drug
DME3ZJO PC 46175910
DME3ZJO MW 489.6
DME3ZJO FM C28H35N5O3
DME3ZJO IC InChI=1S/C28H35N5O3/c1-18(29-2)27(34)32-26(20-11-15-36-16-12-20)28(35)33-14-6-9-23(33)22-17-21-10-13-30-24(25(21)31-22)19-7-4-3-5-8-19/h3-5,7-8,10,13,17-18,20,23,26,29,31H,6,9,11-12,14-16H2,1-2H3,(H,32,34)/t18-,23-,26-/m0/s1
DME3ZJO CS C[C@@H](C(=O)N[C@@H](C1CCOCC1)C(=O)N2CCC[C@H]2C3=CC4=C(N3)C(=NC=C4)C5=CC=CC=C5)NC
DME3ZJO IK IKVUPSWUHVVHKV-WMDMVVLCSA-N
DME3ZJO IU (2S)-2-(methylamino)-N-[(1S)-1-(oxan-4-yl)-2-oxo-2-[(2S)-2-(7-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl)pyrrolidin-1-yl]ethyl]propanamide
DMZ9LSY ID DMZ9LSY
DMZ9LSY DN PMID25980951-Compound-11
DMZ9LSY HS Patented
DMZ9LSY CP HANMI HOLDINGS CO., LTD. BAE, In Hwan JUN, Mi Ae SONG, Ji Young JU, Hae Kyoung SONG, Tae Hun CHO, Ju Hyun KWEON, Eun Kyung AHN, Young Gil KIM, Cheol Kyung KIM, Maeng Sup
DMZ9LSY DT Small molecular drug
DMG8K1P ID DMG8K1P
DMG8K1P DN PMID25980951-Compound-12
DMG8K1P HS Patented
DMG8K1P CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMG8K1P DT Small molecular drug
DMGHR4D ID DMGHR4D
DMGHR4D DN PMID25980951-Compound-13
DMGHR4D HS Patented
DMGHR4D CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMGHR4D DT Small molecular drug
DMGHR4D PC 73296970
DMGHR4D MW 472.5
DMGHR4D FM C25H30F2N4O3
DMGHR4D IC InChI=1S/C25H30F2N4O3/c1-14(28-5)22(32)30-21(25(2,3)4)24(34)31-13-15-9-6-7-10-16(15)20(31)23(33)29-19-17(26)11-8-12-18(19)27/h6-12,14,20-21,28H,13H2,1-5H3,(H,29,33)(H,30,32)/t14-,20-,21+/m0/s1
DMGHR4D CS C[C@@H](C(=O)N[C@H](C(=O)N1CC2=CC=CC=C2[C@H]1C(=O)NC3=C(C=CC=C3F)F)C(C)(C)C)NC
DMGHR4D IK YVSLGVHZPIUKJU-SZFUDVHCSA-N
DMGHR4D IU (1S)-N-(2,6-difluorophenyl)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-1,3-dihydroisoindole-1-carboxamide
DM637IC ID DM637IC
DM637IC DN PMID25980951-Compound-14
DM637IC HS Patented
DM637IC CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM637IC DT Small molecular drug
DMB2MIT ID DMB2MIT
DMB2MIT DN PMID25980951-Compound-15
DMB2MIT HS Patented
DMB2MIT CP SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
DMB2MIT DT Small molecular drug
DM1J3LE ID DM1J3LE
DM1J3LE DN PMID25980951-Compound-16
DM1J3LE HS Patented
DM1J3LE CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM1J3LE DT Small molecular drug
DM1J3LE PC 50913339
DM1J3LE MW 605.7
DM1J3LE FM C31H45F2N5O5
DM1J3LE IC InChI=1S/C31H45F2N5O5/c1-4-42-22-15-21-16-38(30(41)27(36-28(39)19(2)34-3)20-9-12-31(32,33)13-10-20)25(18-37(21)17-22)29(40)35-24-11-14-43-26-8-6-5-7-23(24)26/h5-8,19-22,24-25,27,34H,4,9-18H2,1-3H3,(H,35,40)(H,36,39)/t19-,21+,22+,24+,25-,27-/m0/s1
DM1J3LE CS CCO[C@@H]1C[C@@H]2CN([C@@H](CN2C1)C(=O)N[C@@H]3CCOC4=CC=CC=C34)C(=O)[C@H](C5CCC(CC5)(F)F)NC(=O)[C@H](C)NC
DM1J3LE IK WQLHYSFOEZZZDD-QAPMSZJWSA-N
DM1J3LE IU (3S,7R,8aR)-2-[(2S)-2-(4,4-difluorocyclohexyl)-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-7-ethoxy-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-3-carboxamide
DMSC8B6 ID DMSC8B6
DMSC8B6 DN PMID25980951-Compound-17
DMSC8B6 HS Patented
DMSC8B6 DT Small molecular drug
DMC3NHJ ID DMC3NHJ
DMC3NHJ DN PMID25980951-Compound-18
DMC3NHJ HS Patented
DMC3NHJ DT Small molecular drug
DMGIV0M ID DMGIV0M
DMGIV0M DN PMID25980951-Compound-19
DMGIV0M HS Patented
DMGIV0M CP TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. LAPORTE, Matthew, G
DMGIV0M DT Small molecular drug
DMM45AC ID DMM45AC
DMM45AC DN PMID25980951-Compound-20
DMM45AC HS Patented
DMM45AC CP TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. DENG, Yijun LAPORTE, Matthew, G
DMM45AC DT Small molecular drug
DMM45AC PC 67478013
DMM45AC MW 558.7
DMM45AC FM C27H38N6O5S
DMM45AC IC InChI=1S/C27H38N6O5S/c1-16(28-5)24(34)31-23(27(2,3)4)26(36)32-14-12-20-22(32)18(15-33(20)39(6,37)38)25(35)30-19-11-7-9-17-10-8-13-29-21(17)19/h7-11,13,16,18,20,22-23,28H,12,14-15H2,1-6H3,(H,30,35)(H,31,34)/t16-,18-,20+,22+,23+/m0/s1
DMM45AC CS C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1[C@H](CN2S(=O)(=O)C)C(=O)NC3=CC=CC4=C3N=CC=C4)C(C)(C)C)NC
DMM45AC IK VDNCJSPAMUEWDC-VBEIARHESA-N
DMM45AC IU (3aR,6S,6aR)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-4-methylsulfonyl-N-quinolin-8-yl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrole-6-carboxamide
DMIE0MR ID DMIE0MR
DMIE0MR DN PMID25980951-Compound-21
DMIE0MR HS Patented
DMIE0MR CP TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. DENG, Yijun ALEXANDER, Matthew, D. LAPORTE, Matthew, G
DMIE0MR DT Small molecular drug
DMIE0MR PC 49818910
DMIE0MR MW 516.6
DMIE0MR FM C23H34F2N4O5S
DMIE0MR IC InChI=1S/C23H34F2N4O5S/c1-13(26-5)21(30)27-20(23(2,3)4)22(31)28-10-9-17-19(28)18(12-29(17)35(6,32)33)34-14-7-8-15(24)16(25)11-14/h7-8,11,13,17-20,26H,9-10,12H2,1-6H3,(H,27,30)/t13-,17+,18-,19-,20+/m0/s1
DMIE0MR CS C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1[C@H](CN2S(=O)(=O)C)OC3=CC(=C(C=C3)F)F)C(C)(C)C)NC
DMIE0MR IK JFUYRIMMOJAVPX-FOGBYNIYSA-N
DMIE0MR IU (2S)-N-[(2S)-1-[(3aR,6S,6aS)-6-(3,4-difluorophenoxy)-4-methylsulfonyl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrol-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-2-(methylamino)propanamide
DM6OEHK ID DM6OEHK
DM6OEHK DN PMID25980951-Compound-22
DM6OEHK HS Patented
DM6OEHK CP TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen M. LAPORTE, Matthew G. HAIMOWITZ, Thomas
DM6OEHK DT Small molecular drug
DM6OEHK PC 53239649
DM6OEHK MW 580.7
DM6OEHK FM C30H40N6O4S
DM6OEHK IC InChI=1S/C30H40N6O4S/c1-19(31-5)28(37)33-26(30(2,3)4)29(38)35-16-14-24-25(35)22(17-36(24)41(6,39)40)23-18-34-15-10-13-21(27(34)32-23)20-11-8-7-9-12-20/h7-13,15,18-19,22,24-26,31H,14,16-17H2,1-6H3,(H,33,37)/t19-,22+,24+,25+,26+/m0/s1
DM6OEHK CS C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1[C@H](CN2S(=O)(=O)C)C3=CN4C=CC=C(C4=N3)C5=CC=CC=C5)C(C)(C)C)NC
DM6OEHK IK CDYZPYAGGGZKJG-PFCQFSIYSA-N
DM6OEHK IU (2S)-N-[(2S)-1-[(3aR,6S,6aR)-4-methylsulfonyl-6-(8-phenylimidazo[1,2-a]pyridin-2-yl)-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrol-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]-2-(methylamino)propanamide
DMK9DH7 ID DMK9DH7
DMK9DH7 DN PMID25980951-Compound-26
DMK9DH7 HS Patented
DMK9DH7 CP ENSEMBLE THERAPEUTICS CORPORATION
DMK9DH7 DT Small molecular drug
DMXAH9F ID DMXAH9F
DMXAH9F DN PMID25980951-Compound-27
DMXAH9F HS Patented
DMXAH9F CP ASTRAZENECA AB ASTRAZENECA UK LIMITED AQUILA, Brian HENNESSY, Edward HIRD, Alexander OZA, Vibha SAEH, Jamal Carlos SHA, Li
DMXAH9F DT Small molecular drug
DMXAH9F PC 49847690
DMXAH9F MW 1015.3
DMXAH9F FM C58H78N8O8
DMXAH9F IC InChI=1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16,25-28,37-40,45-52,59-60H,7-12,19-24,29-36H2,1-4H3,(H,61,67)(H,62,68)(H,63,69)(H,64,70)/t37-,38-,45-,46-,47+,48+,49-,50-,51-,52-/m0/s1
DMXAH9F CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)OCC#CC#CCO[C@@H]5CC6=CC=CC=C6[C@@H]5NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC
DMXAH9F IK WLMCRYCCYXHPQF-ZVMUOSSASA-N
DMXAH9F IU (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1S,2R)-2-[6-[[(1S,2R)-1-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]hexa-2,4-diynoxy]-2,3-dihydro-1H-inden-1-yl]pyrrolidine-2-carboxamide
DMV0EIA ID DMV0EIA
DMV0EIA DN PMID25980951-Compound-28
DMV0EIA HS Patented
DMV0EIA DT Small molecular drug
DM5WIX3 ID DM5WIX3
DM5WIX3 DN PMID25980951-Compound-29
DM5WIX3 HS Patented
DM5WIX3 CP ENSEMBLE THERAPEUTICS CORPORATION
DM5WIX3 DT Small molecular drug
DM5WIX3 PC 90155550
DM5WIX3 MW 1505.7
DM5WIX3 FM C80H96N16O14
DM5WIX3 IC InChI=1S/C80H96N16O14/c1-45(81-9)69(97)87-67(79(3,4)5)75(103)93-33-31-63-65(93)73(101)83-59(39-49-19-25-51-15-11-13-17-53(51)35-49)71(99)85-61(77(105)106)37-47-23-29-58(30-24-47)110-44-56-42-96(92-90-56)64-32-34-94(76(104)68(80(6,7)8)88-70(98)46(2)82-10)66(64)74(102)84-60(40-50-20-26-52-16-12-14-18-54(52)36-50)72(100)86-62(78(107)108)38-48-21-27-57(28-22-48)109-43-55-41-95(63)91-89-55/h11-30,35-36,41-42,45-46,59-68,81-82H,31-34,37-40,43-44H2,1-10H3,(H,83,101)(H,84,102)(H,85,99)(H,86,100)(H,87,97)(H,88,98)(H,105,106)(H,107,108)/t45-,46-,59-,60-,61-,62-,63+,64+,65-,66-,67+,68+/m0/s1
DM5WIX3 CS C[C@@H](C(=O)N[C@H](C(=O)N1CC[C@@H]2[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC3=CC=C(C=C3)OCC4=CN([C@@H]5CCN([C@@H]5C(=O)N[C@H](C(=O)N[C@@H](CC6=CC=C(C=C6)OCC7=CN2N=N7)C(=O)O)CC8=CC9=CC=CC=C9C=C8)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)N=N4)C(=O)O)CC1=CC2=CC=CC=C2C=C1)C(C)(C)C)NC
DM5WIX3 IK MBKNBOLIPVRUSC-YZMHPAFASA-N
DM5WIX3 IU (8R,12S,15S,18S,30R,34S,37S,40S)-11,33-bis[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-15,37-bis(naphthalen-2-ylmethyl)-13,16,35,38-tetraoxo-2,24-dioxa-5,6,7,11,14,17,27,28,29,33,36,39-dodecazaheptacyclo[40.2.2.220,23.14,7.126,29.08,12.030,34]pentaconta-1(45),4(50),5,20,22,26(47),27,42(46),43,48-decaene-18,40-dicarboxylic acid
DMPSWXU ID DMPSWXU
DMPSWXU DN PMID25980951-Compound-3
DMPSWXU HS Patented
DMPSWXU CP ASTEX THERAPEUTICS LIMITED
DMPSWXU DT Small molecular drug
DMPSWXU PC 90126716
DMPSWXU MW 541.7
DMPSWXU FM C32H36FN5O2
DMPSWXU IC InChI=1S/C32H36FN5O2/c1-21-16-36(26(14-34-21)18-37-17-23-6-4-5-7-27(23)31(37)40)19-30(39)38-20-32(2,3)28-15-35-25(13-29(28)38)12-22-8-10-24(33)11-9-22/h4-11,13,15,21,26,34H,12,14,16-20H2,1-3H3/t21-,26-/m1/s1
DMPSWXU CS C[C@@H]1CN([C@H](CN1)CN2CC3=CC=CC=C3C2=O)CC(=O)N4CC(C5=C4C=C(N=C5)CC6=CC=C(C=C6)F)(C)C
DMPSWXU IK LINGVLYPDLNMKZ-QFQXNSOFSA-N
DMPSWXU IU 2-[[(2R,5R)-1-[2-[6-[(4-fluorophenyl)methyl]-3,3-dimethyl-2H-pyrrolo[3,2-c]pyridin-1-yl]-2-oxoethyl]-5-methylpiperazin-2-yl]methyl]-3H-isoindol-1-one
DMXCSHE ID DMXCSHE
DMXCSHE DN PMID25980951-Compound-30
DMXCSHE HS Patented
DMXCSHE CP BRISTOL-MYERS SQUIBB COMPANY
DMXCSHE DT Small molecular drug
DMXCSHE PC 73603510
DMXCSHE MW 1070.3
DMXCSHE FM C61H80FN9O7
DMXCSHE IC InChI=1S/C61H80FN9O7/c1-36(63-10)53(72)67-51(60(4,5)6)58(77)70-34-43-21-13-12-20-42(43)31-50(70)57(76)69(38(3)45-23-16-17-25-47(45)62)33-39-27-29-41(30-28-39)55(74)65-44-32-49(56(75)66-48-26-18-22-40-19-14-15-24-46(40)48)71(35-44)59(78)52(61(7,8)9)68-54(73)37(2)64-11/h12-17,19-21,23-25,27-30,36-38,44,48-52,63-64H,18,22,26,31-35H2,1-11H3,(H,65,74)(H,66,75)(H,67,72)(H,68,73)/t36-,37-,38+,44-,48+,49-,50-,51+,52+/m0/s1
DMXCSHE CS C[C@H](C1=CC=CC=C1F)N(CC2=CC=C(C=C2)C(=O)N[C@H]3C[C@H](N(C3)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)C(=O)N[C@@H]4CCCC5=CC=CC=C45)C(=O)[C@@H]6CC7=CC=CC=C7CN6C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC
DMXCSHE IK SUVGZSPIXFUCLS-NQFXVQPCSA-N
DMXCSHE IU (3S)-2-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-N-[[4-[[(3S,5S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-5-[[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]pyrrolidin-3-yl]carbamoyl]phenyl]methyl]-N-[(1R)-1-(2-fluorophenyl)ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMC1Y2T ID DMC1Y2T
DMC1Y2T DN PMID25980951-Compound-31
DMC1Y2T HS Patented
DMC1Y2T CP BRISTOL-MYERS SQUIBB COMPANY
DMC1Y2T DT Small molecular drug
DMXETA8 ID DMXETA8
DMXETA8 DN PMID25980951-Compound-32
DMXETA8 HS Patented
DMXETA8 CP BRISTOL-MYERS SQUIBB COMPANY
DMXETA8 DT Small molecular drug
DMXETA8 PC 72710867
DMXETA8 MW 1028.4
DMXETA8 FM C57H77N9O7Si
DMXETA8 IC InChI=1S/C57H77N9O7Si/c1-35(58-6)51(68)63-46(55(72)66-34-74(8,9)33-48(66)54(71)62-45-23-15-19-40-17-11-13-21-43(40)45)30-38-26-24-37(25-27-38)28-29-49(67)60-41-31-47(53(70)61-44-22-14-18-39-16-10-12-20-42(39)44)65(32-41)56(73)50(57(3,4)5)64-52(69)36(2)59-7/h10-13,16-17,20-21,24-27,35-36,41,44-48,50,58-59H,14-15,18-19,22-23,30-34H2,1-9H3,(H,60,67)(H,61,70)(H,62,71)(H,63,68)(H,64,69)/t35-,36-,41-,44+,45+,46-,47-,48-,50+/m0/s1
DMXETA8 CS C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)C#CC(=O)N[C@H]2C[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C)NC)C(=O)N[C@@H]3CCCC4=CC=CC=C34)C(=O)N5C[Si](C[C@H]5C(=O)N[C@@H]6CCCC7=CC=CC=C67)(C)C)NC
DMXETA8 IK SOUZAGJRYQSXAP-UZNJVIDBSA-N
DMXETA8 IU (5R)-1-[(2S)-3-[4-[3-[[(3S,5S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]-5-[[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]pyrrolidin-3-yl]amino]-3-oxoprop-1-ynyl]phenyl]-2-[[(2S)-2-(methylamino)propanoyl]amino]propanoyl]-3,3-dimethyl-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-azasilolidine-5-carboxamide
DMYO9UD ID DMYO9UD
DMYO9UD DN PMID25980951-Compound-33
DMYO9UD HS Patented
DMYO9UD CP BRISTOL-MYERS SQUIBB COMPANY
DMYO9UD DT Small molecular drug
DMBD4K9 ID DMBD4K9
DMBD4K9 DN PMID25980951-Compound-36
DMBD4K9 HS Patented
DMBD4K9 CP NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang
DMBD4K9 DT Small molecular drug
DMHP6J2 ID DMHP6J2
DMHP6J2 DN PMID25980951-Compound-37
DMHP6J2 HS Patented
DMHP6J2 CP NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang
DMHP6J2 DT Small molecular drug
DMHP6J2 PC 57389344
DMHP6J2 MW 1197.5
DMHP6J2 FM C70H82F2N10O6
DMHP6J2 IC InChI=1S/C70H82F2N10O6/c1-43(73-3)65(83)79-63(47-13-7-5-8-14-47)69(87)81-31-11-17-61(81)55-33-51(37-75-39-55)59-29-27-57(71)35-53(59)41-77-67(85)49-23-19-45(20-24-49)46-21-25-50(26-22-46)68(86)78-42-54-36-58(72)28-30-60(54)52-34-56(40-76-38-52)62-18-12-32-82(62)70(88)64(48-15-9-6-10-16-48)80-66(84)44(2)74-4/h19-30,33-40,43-44,47-48,61-64,73-74H,5-18,31-32,41-42H2,1-4H3,(H,77,85)(H,78,86)(H,79,83)(H,80,84)/t43-,44-,61-,62-,63-,64-/m0/s1
DMHP6J2 CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=CN=CC(=C3)C4=C(C=C(C=C4)F)CNC(=O)C5=CC=C(C=C5)C6=CC=C(C=C6)C(=O)NCC7=C(C=CC(=C7)F)C8=CC(=CN=C8)[C@@H]9CCCN9C(=O)[C@H](C1CCCCC1)NC(=O)[C@H](C)NC)NC
DMHP6J2 IK MZOSJSCTFRNVMS-PDAHXLKQSA-N
DMHP6J2 IU N-[[2-[5-[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidin-2-yl]pyridin-3-yl]-5-fluorophenyl]methyl]-4-[4-[[2-[5-[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidin-2-yl]pyridin-3-yl]-5-fluorophenyl]methylcarbamoyl]phenyl]benzamide
DMEUBDA ID DMEUBDA
DMEUBDA DN PMID25980951-Compound-38
DMEUBDA HS Patented
DMEUBDA CP NOVARTIS AG STRAUB, Christopher Sean CHEN, Zhuoliang PALERMO, Mark G
DMEUBDA DT Small molecular drug
DMEZ3QV ID DMEZ3QV
DMEZ3QV DN PMID25980951-Compound-39
DMEZ3QV HS Patented
DMEZ3QV CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMEZ3QV DT Small molecular drug
DMEZ3QV PC 76283048
DMEZ3QV MW 1152.9
DMEZ3QV FM C58H56Br2N8O8
DMEZ3QV IC InChI=1S/C58H56Br2N8O8/c1-33(61-3)53(69)63-45-31-67(49-13-9-7-11-47(49)65(57(45)73)29-43-41-23-21-39(59)27-37(41)19-25-51(43)75-5)55(71)35-15-17-36(18-16-35)56(72)68-32-46(64-54(70)34(2)62-4)58(74)66(48-12-8-10-14-50(48)68)30-44-42-24-22-40(60)28-38(42)20-26-52(44)76-6/h7-28,33-34,45-46,61-62H,29-32H2,1-6H3,(H,63,69)(H,64,70)/t33-,34-,45-,46-/m0/s1
DMEZ3QV CS C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)C(=O)N6C[C@@H](C(=O)N(C7=CC=CC=C76)CC8=C(C=CC9=C8C=CC(=C9)Br)OC)NC(=O)[C@H](C)NC)NC
DMEZ3QV IK PBGWEJJBQUBSJN-MLLHAFNLSA-N
DMEZ3QV IU (2S)-N-[(3S)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-1-[4-[(3S)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-3-[[(2S)-2-(methylamino)propanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]benzoyl]-4-oxo-2,3-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide
DM9RZSH ID DM9RZSH
DM9RZSH DN PMID25980951-Compound-4
DM9RZSH HS Patented
DM9RZSH CP ASTEX THERAPEUTICS LIMITED
DM9RZSH DT Small molecular drug
DMJOD8I ID DMJOD8I
DMJOD8I DN PMID25980951-Compound-40
DMJOD8I HS Patented
DMJOD8I CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMJOD8I DT Small molecular drug
DMJOD8I PC 76282560
DMJOD8I MW 1125.2
DMJOD8I FM C60H70BrN9O8
DMJOD8I IC InChI=1S/C60H70BrN9O8/c1-35(62-3)54(71)66-48-34-70(50-21-12-11-20-49(50)69(59(48)76)33-46-44-28-27-42(61)30-41(44)26-29-52(46)78-5)58(75)40-24-22-39(23-25-40)56(73)64-43-31-51(57(74)65-47-19-13-17-37-14-9-10-18-45(37)47)68(32-43)60(77)53(38-15-7-6-8-16-38)67-55(72)36(2)63-4/h9-12,14,18,20-30,35-36,38,43,47-48,51,53,62-63H,6-8,13,15-17,19,31-34H2,1-5H3,(H,64,73)(H,65,74)(H,66,71)(H,67,72)/t35-,36-,43-,47+,48-,51-,53-/m0/s1
DMJOD8I CS C[C@@H](C(=O)N[C@H]1CN(C2=CC=CC=C2N(C1=O)CC3=C(C=CC4=C3C=CC(=C4)Br)OC)C(=O)C5=CC=C(C=C5)C(=O)N[C@H]6C[C@H](N(C6)C(=O)[C@H](C7CCCCC7)NC(=O)[C@H](C)NC)C(=O)N[C@@H]8CCCC9=CC=CC=C89)NC
DMJOD8I IK OVCDDAXIBKWFRB-SFDZCEMOSA-N
DMJOD8I IU (2S,4S)-4-[[4-[(3S)-5-[(6-bromo-2-methoxynaphthalen-1-yl)methyl]-3-[[(2S)-2-(methylamino)propanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]benzoyl]amino]-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]pyrrolidine-2-carboxamide
DMNROIP ID DMNROIP
DMNROIP DN PMID25980951-Compound-41
DMNROIP HS Patented
DMNROIP CP TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. LAPORTE, Matthew, G
DMNROIP DT Small molecular drug
DM8XESD ID DM8XESD
DM8XESD DN PMID25980951-Compound-42
DM8XESD HS Patented
DM8XESD CP TETRALOGIC PHARMACEUTICALS CORP. CONDON, Stephen, M. DENG, Yijun LAPORTE, Matthew, G
DM8XESD DT Small molecular drug
DMTJRCS ID DMTJRCS
DMTJRCS DN PMID25980951-Compound-43
DMTJRCS HS Patented
DMTJRCS CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN WANG, Shaomeng SUN, Haiying
DMTJRCS DT Small molecular drug
DMTJRCS PC 52919959
DMTJRCS MW 1103.4
DMTJRCS FM C62H78N12O7
DMTJRCS IC InChI=1S/C62H78N12O7/c1-39(63-3)59(77)67-49-37-71(33-31-43-27-29-51(73(43)61(49)79)57-65-47-23-15-21-45(55(47)69-57)41-17-7-5-8-18-41)53(75)25-11-13-35-81-36-14-12-26-54(76)72-34-32-44-28-30-52(74(44)62(80)50(38-72)68-60(78)40(2)64-4)58-66-48-24-16-22-46(56(48)70-58)42-19-9-6-10-20-42/h5-10,15-24,39-40,43-44,49-52,63-64H,11-14,25-38H2,1-4H3,(H,65,69)(H,66,70)(H,67,77)(H,68,78)/t39-,40-,43+,44+,49-,50-,51-,52-/m0/s1
DMTJRCS CS C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C3=NC4=C(C=CC=C4N3)C5=CC=CC=C5)C(=O)CCCCOCCCCC(=O)N6CC[C@H]7CC[C@H](N7C(=O)[C@H](C6)NC(=O)[C@H](C)NC)C8=NC9=C(C=CC=C9N8)C1=CC=CC=C1)NC
DMTJRCS IK ZPYWWTKXCOYJBE-LLUFGHGUSA-N
DMTJRCS IU (2S)-N-[(5S,8S,10aR)-3-[5-[5-[(5S,8S,10aR)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-8-(4-phenyl-1H-benzimidazol-2-yl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-3-yl]-5-oxopentoxy]pentanoyl]-6-oxo-8-(4-phenyl-1H-benzimidazol-2-yl)-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]-2-(methylamino)propanamide
DMS5896 ID DMS5896
DMS5896 DN PMID25980951-Compound-44
DMS5896 HS Patented
DMS5896 CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DMS5896 DT Small molecular drug
DMS5896 PC 71661892
DMS5896 MW 1115.3
DMS5896 FM C62H74N12O8
DMS5896 IC InChI=1S/C62H74N12O8/c1-39(63-3)55(75)67-49-37-71(35-33-47-29-31-51(73(47)59(49)79)57(77)69-53(41-17-9-5-10-18-41)42-19-11-6-12-20-42)61(81)65-45-25-27-46(28-26-45)66-62(82)72-36-34-48-30-32-52(74(48)60(80)50(38-72)68-56(76)40(2)64-4)58(78)70-54(43-21-13-7-14-22-43)44-23-15-8-16-24-44/h5-28,39-40,47-54,63-64H,29-38H2,1-4H3,(H,65,81)(H,66,82)(H,67,75)(H,68,76)(H,69,77)(H,70,78)/t39-,40-,47+,48+,49-,50-,51-,52-/m0/s1
DMS5896 CS C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)NC5=CC=C(C=C5)NC(=O)N6CC[C@H]7CC[C@H](N7C(=O)[C@H](C6)NC(=O)[C@H](C)NC)C(=O)NC(C8=CC=CC=C8)C9=CC=CC=C9)NC
DMS5896 IK SGWUDLNUDPDRSR-CEQBHCGOSA-N
DMS5896 IU (5S,8S,10aR)-3-N-[4-[[(5S,8S,10aR)-8-(benzhydrylcarbamoyl)-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-3-carbonyl]amino]phenyl]-8-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-3,8-dicarboxamide
DM1EU06 ID DM1EU06
DM1EU06 DN PMID25980951-Compound-45
DM1EU06 HS Patented
DM1EU06 CP HANMI SCIENCE CO., LTD. BAE, In Hwan BYUN, Eun Young JU, Hae Kyoung SONG, Ji Young JUNG, Seung Hyun JUN, Seung Ah KIM, Ho Seok JUNG, Young Hee SHIM, Mi Yon AHN, Young Gil KIM, Maeng Sup
DM1EU06 DT Small molecular drug
DM1EU06 PC 56924622
DM1EU06 MW 632.1
DM1EU06 FM C30H36ClF2N7O4
DM1EU06 IC InChI=1S/C30H36ClF2N7O4/c1-15(34-5)27(41)39-25(30(2,3)4)29(43)40-11-7-8-21(40)28(42)38-20-12-16-19(13-22(20)44-6)35-14-36-26(16)37-18-10-9-17(32)23(31)24(18)33/h9-10,12-15,21,25,34H,7-8,11H2,1-6H3,(H,38,42)(H,39,41)(H,35,36,37)/t15-,21-,25+/m0/s1
DM1EU06 CS C[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=C(C=C4)F)Cl)F)OC)C(C)(C)C)NC
DM1EU06 IK KJLMHHDQQFRBTF-HHCYOLOASA-N
DM1EU06 IU (2S)-N-[4-(3-chloro-2,4-difluoroanilino)-7-methoxyquinazolin-6-yl]-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidine-2-carboxamide
DMB3IZT ID DMB3IZT
DMB3IZT DN PMID25980951-Compound-5
DMB3IZT HS Patented
DMB3IZT CP ASTEX THERAPEUTICS LIMITED
DMB3IZT DT Small molecular drug
DMVSW5N ID DMVSW5N
DMVSW5N DN PMID25980951-Compound-6
DMVSW5N HS Patented
DMVSW5N CP AVILA THERAPEUTICS, INC. PETTER, Russell C. JEWELL, Charles F. LEE, Kwangho MEDIKONDA, Aravind Prasad NIU, Deqiang QIAO, Lixin SINGH, Juswinder ZHU, Zhendong
DMVSW5N DT Small molecular drug
DMVSW5N PC 58491512
DMVSW5N MW 469.6
DMVSW5N FM C25H35N5O4
DMVSW5N IC InChI=1S/C25H35N5O4/c1-4-22(31)28-18-9-7-8-17(14-18)15-27-24(33)21-13-12-19-10-5-6-11-20(25(34)30(19)21)29-23(32)16(2)26-3/h4,7-9,14,16,19-21,26H,1,5-6,10-13,15H2,2-3H3,(H,27,33)(H,28,31)(H,29,32)/t16-,19-,20-,21-/m0/s1
DMVSW5N CS C[C@@H](C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)NCC3=CC(=CC=C3)NC(=O)C=C)NC
DMVSW5N IK KIYJPROOFKKHPR-FIRPJDEBSA-N
DMVSW5N IU (3S,6S,10aS)-6-[[(2S)-2-(methylamino)propanoyl]amino]-5-oxo-N-[[3-(prop-2-enoylamino)phenyl]methyl]-2,3,6,7,8,9,10,10a-octahydro-1H-pyrrolo[1,2-a]azocine-3-carboxamide
DMF8V5J ID DMF8V5J
DMF8V5J DN PMID25980951-Compound-7
DMF8V5J HS Patented
DMF8V5J DT Small molecular drug
DM89LF0 ID DM89LF0
DM89LF0 DN PMID25991433-Compound-A1
DM89LF0 HS Patented
DM89LF0 CP F. HOFFMANN-LA ROCHE AG GONG, Leyi JAHANGIR, Alam REUTER, Deborah CaroF. HOFFMANN-LA ROCHE AG GOLDSTEIN, David Michael GONG, Leyi MICHOUD, Christophe PALMER, Wylie Solang SIDDURI, Achyutharao
DM89LF0 DT Small molecular drug
DM39NBT ID DM39NBT
DM39NBT DN PMID25991433-Compound-A10
DM39NBT HS Patented
DM39NBT DT Small molecular drug
DMD59C2 ID DMD59C2
DMD59C2 DN PMID25991433-Compound-A11
DMD59C2 HS Patented
DMD59C2 DT Small molecular drug
DMX7MHC ID DMX7MHC
DMX7MHC DN PMID25991433-Compound-A2
DMX7MHC HS Patented
DMX7MHC CP F. HOFFMANN-LA ROCHE AG GONG, Leyi JAHANGIR, Alam REUTER, Deborah Carol
DMX7MHC DT Small molecular drug
DMX7MHC PC 46834072
DMX7MHC MW 453.5
DMX7MHC FM C20H23N9O2S
DMX7MHC IC InChI=1S/C20H23N9O2S/c1-13-16(12-22-25-13)15-4-3-5-17-19(15)26-27-29(17)18-6-9-21-20(24-18)23-14-7-10-28(11-8-14)32(2,30)31/h3-6,9,12,14H,7-8,10-11H2,1-2H3,(H,22,25)(H,21,23,24)
DMX7MHC CS CC1=C(C=NN1)C2=C3C(=CC=C2)N(N=N3)C4=NC(=NC=C4)NC5CCN(CC5)S(=O)(=O)C
DMX7MHC IK VBKBWWKTPBEGBH-UHFFFAOYSA-N
DMX7MHC IU 4-[4-(5-methyl-1H-pyrazol-4-yl)benzotriazol-1-yl]-N-(1-methylsulfonylpiperidin-4-yl)pyrimidin-2-amine
DMJ1X53 ID DMJ1X53
DMJ1X53 DN PMID25991433-Compound-A3
DMJ1X53 HS Patented
DMJ1X53 CP F. HOFFMANN-LA ROCHE AG GONG, Leyi JAHANGIR, Alam REUTER, Deborah Carol
DMJ1X53 DT Small molecular drug
DM5YD1K ID DM5YD1K
DM5YD1K DN PMID25991433-Compound-A5
DM5YD1K HS Patented
DM5YD1K CP F. HOFFMANN-LA ROCHE AG BUETTELMANN, Bernd GOYAL, Bindu PALMER, Wylie Solang
DM5YD1K DT Small molecular drug
DMFSB9Y ID DMFSB9Y
DMFSB9Y DN PMID25991433-Compound-A6
DMFSB9Y HS Patented
DMFSB9Y CP F. HOFFMANN-LA ROCHE AG BUETTELMANN, Bernd GOYAL, Bindu PALMER, Wylie Solang
DMFSB9Y DT Small molecular drug
DM2ISDH ID DM2ISDH
DM2ISDH DN PMID25991433-Compound-A7
DM2ISDH HS Patented
DM2ISDH CP F. HOFFMANN-LA ROCHE AG BUETTELMANN, Bernd GOYAL, Bindu PALMER, Wylie Solang
DM2ISDH DT Small molecular drug
DMHG4WD ID DMHG4WD
DMHG4WD DN PMID25991433-Compound-A8
DMHG4WD HS Patented
DMHG4WD DT Small molecular drug
DMPYCIM ID DMPYCIM
DMPYCIM DN PMID25991433-Compound-A9
DMPYCIM HS Patented
DMPYCIM DT Small molecular drug
DMJTO69 ID DMJTO69
DMJTO69 DN PMID25991433-Compound-B1
DMJTO69 HS Patented
DMJTO69 CP F. HOFFMANN-LA ROCHE AG ARZENO, Humberto, Bartolome FILONOVA, Lubov GOLDSTEIN, David, Michael GONG, Leyi LOE, Bradley, E. O'BRIEN, Erin, M. PALMER, Wylie, Solang ROTSTEIN, David, Mark SILVA, Tania TAN, Yun-chou
DMJTO69 DT Small molecular drug
DMTYQOF ID DMTYQOF
DMTYQOF DN PMID25991433-Compound-B2
DMTYQOF HS Patented
DMTYQOF CP F. HOFFMANN-LA ROCHE AG ARZENO, Humberto, Bartolome FILONOVA, Lubov GOLDSTEIN, David, Michael GONG, Leyi LOE, Bradley, E. O'BRIEN, Erin, M. PALMER, Wylie, Solang ROTSTEIN, David, Mark SILVA, Tania TAN, Yun-chou
DMTYQOF DT Small molecular drug
DMWSGV2 ID DMWSGV2
DMWSGV2 DN PMID25991433-Compound-B3
DMWSGV2 HS Patented
DMWSGV2 CP F. HOFFMANN-LA ROCHE AG ARZENO, Humberto, Bartolome FILONOVA, Lubov GOLDSTEIN, David, Michael GONG, Leyi LOE, Bradley, E. O'BRIEN, Erin, M. PALMER, Wylie, Solang ROTSTEIN, David, Mark SILVA, Tania TAN, Yun-chou
DMWSGV2 DT Small molecular drug
DM3KWFQ ID DM3KWFQ
DM3KWFQ DN PMID25991433-Compound-C1
DM3KWFQ HS Patented
DM3KWFQ CP F. HOFFMANN-LA ROCHE AG GONG, Leyi TAN, Yun-chou
DM3KWFQ DT Small molecular drug
DMOAU09 ID DMOAU09
DMOAU09 DN PMID25991433-Compound-C2
DMOAU09 HS Patented
DMOAU09 CP F. HOFFMANN-LA ROCHE AG GONG, Leyi TAN, Yun-chou
DMOAU09 DT Small molecular drug
DMSKWBE ID DMSKWBE
DMSKWBE DN PMID25991433-Compound-C3
DMSKWBE HS Patented
DMSKWBE CP F. HOFFMANN-LA ROCHE AG GONG, Leyi TAN, Yun-chou
DMSKWBE DT Small molecular drug
DMXSK8Y ID DMXSK8Y
DMXSK8Y DN PMID25991433-Compound-D1
DMXSK8Y HS Patented
DMXSK8Y CP F. HOFFMANN-LA ROCHE AG BOICE, Genevieve N. GONG, Leyi MCCALEB, Kristen Lynn PALMER, Wylie Solang
DMXSK8Y DT Small molecular drug
DMXSK8Y PC 45257202
DMXSK8Y MW 316.4
DMXSK8Y FM C17H24N4O2
DMXSK8Y IC InChI=1S/C17H24N4O2/c1-12(9-10-22)21-15(23)8-7-13-11-18-17(20-16(13)21)19-14-5-3-2-4-6-14/h7-8,11-12,14,22H,2-6,9-10H2,1H3,(H,18,19,20)
DMXSK8Y CS CC(CCO)N1C(=O)C=CC2=CN=C(N=C21)NC3CCCCC3
DMXSK8Y IK WWOJIYPDCCGHSL-UHFFFAOYSA-N
DMXSK8Y IU 2-(cyclohexylamino)-8-(4-hydroxybutan-2-yl)pyrido[2,3-d]pyrimidin-7-one
DMLWSNA ID DMLWSNA
DMLWSNA DN PMID25991433-Compound-D2
DMLWSNA HS Patented
DMLWSNA CP F. HOFFMANN-LA ROCHE AG BOICE, Genevieve N. GONG, Leyi MCCALEB, Kristen Lynn PALMER, Wylie Solang
DMLWSNA DT Small molecular drug
DMKWFVP ID DMKWFVP
DMKWFVP DN PMID25991433-Compound-E1
DMKWFVP HS Patented
DMKWFVP CP F. HOFFMANN-LA ROCHE AG
DMKWFVP DT Small molecular drug
DMKWFVP PC 25104303
DMKWFVP MW 490.9
DMKWFVP FM C27H23ClN2O5
DMKWFVP IC InChI=1S/C27H23ClN2O5/c1-35-27(34)24-22(15-17-7-9-18(10-8-17)26(33)29-13-14-31)25(32)21-12-11-19(28)16-23(21)30(24)20-5-3-2-4-6-20/h2-12,16,31H,13-15H2,1H3,(H,29,33)
DMKWFVP CS COC(=O)C1=C(C(=O)C2=C(N1C3=CC=CC=C3)C=C(C=C2)Cl)CC4=CC=C(C=C4)C(=O)NCCO
DMKWFVP IK STNCBMGTCZRJPA-UHFFFAOYSA-N
DMKWFVP IU methyl 7-chloro-3-[[4-(2-hydroxyethylcarbamoyl)phenyl]methyl]-4-oxo-1-phenylquinoline-2-carboxylate
DM8YR1V ID DM8YR1V
DM8YR1V DN PMID25991433-Compound-E2
DM8YR1V HS Patented
DM8YR1V CP F. HOFFMANN-LA ROCHE AG
DM8YR1V DT Small molecular drug
DM62XNE ID DM62XNE
DM62XNE DN PMID25991433-Compound-E3
DM62XNE HS Patented
DM62XNE CP F. HOFFMANN-LA ROCHE AG
DM62XNE DT Small molecular drug
DM62XNE PC 71217329
DM62XNE MW 563
DM62XNE FM C32H23ClN4O4
DM62XNE IC InChI=1S/C32H23ClN4O4/c33-23-11-12-25-27(18-23)37(24-9-5-2-6-10-24)29(32-34-14-16-41-32)26(30(25)39)19-35-31(40)22-13-15-36(28(38)17-22)20-21-7-3-1-4-8-21/h1-18H,19-20H2,(H,35,40)
DM62XNE CS C1=CC=C(C=C1)CN2C=CC(=CC2=O)C(=O)NCC3=C(N(C4=C(C3=O)C=CC(=C4)Cl)C5=CC=CC=C5)C6=NC=CO6
DM62XNE IK CDEQUNLOBIAUNN-UHFFFAOYSA-N
DM62XNE IU 1-benzyl-N-[[7-chloro-2-(1,3-oxazol-2-yl)-4-oxo-1-phenylquinolin-3-yl]methyl]-2-oxopyridine-4-carboxamide
DM1VHYX ID DM1VHYX
DM1VHYX DN PMID25991433-Compound-E4
DM1VHYX HS Patented
DM1VHYX CP F. HOFFMANN-LA ROCHE AG
DM1VHYX DT Small molecular drug
DM1VHYX PC 71208846
DM1VHYX MW 458.9
DM1VHYX FM C26H23ClN4O2
DM1VHYX IC InChI=1S/C26H23ClN4O2/c27-20-9-10-22-23(14-20)31(21-6-2-1-3-7-21)17-19(25(22)32)16-29-26(33)18-8-11-24(28-15-18)30-12-4-5-13-30/h1-3,6-11,14-15,17H,4-5,12-13,16H2,(H,29,33)
DM1VHYX CS C1CCN(C1)C2=NC=C(C=C2)C(=O)NCC3=CN(C4=C(C3=O)C=CC(=C4)Cl)C5=CC=CC=C5
DM1VHYX IK RUQWOHJJIMCQMH-UHFFFAOYSA-N
DM1VHYX IU N-[(7-chloro-4-oxo-1-phenylquinolin-3-yl)methyl]-6-pyrrolidin-1-ylpyridine-3-carboxamide
DM2ZCTW ID DM2ZCTW
DM2ZCTW DN PMID25991433-Compound-E5
DM2ZCTW HS Patented
DM2ZCTW CP F. HOFFMANN-LA ROCHE AG
DM2ZCTW DT Small molecular drug
DM2ZCTW PC 71208512
DM2ZCTW MW 560.5
DM2ZCTW FM C25H19F3N4O6S
DM2ZCTW IC InChI=1S/C25H19F3N4O6S/c1-38-24(35)20-18(13-30-23(34)14-7-9-16(10-8-14)39(29,36)37)21(33)17-11-12-19(25(26,27)28)31-22(17)32(20)15-5-3-2-4-6-15/h2-12H,13H2,1H3,(H,30,34)(H2,29,36,37)
DM2ZCTW CS COC(=O)C1=C(C(=O)C2=C(N1C3=CC=CC=C3)N=C(C=C2)C(F)(F)F)CNC(=O)C4=CC=C(C=C4)S(=O)(=O)N
DM2ZCTW IK HRBSYTKTEPLYNB-UHFFFAOYSA-N
DM2ZCTW IU methyl 4-oxo-1-phenyl-3-[[(4-sulfamoylbenzoyl)amino]methyl]-7-(trifluoromethyl)-1,8-naphthyridine-2-carboxylate
DM536JN ID DM536JN
DM536JN DN PMID25991433-Compound-Eb
DM536JN HS Patented
DM536JN CP F. HOFFMANN-LA ROCHE AG
DM536JN DT Small molecular drug
DMFS2YL ID DMFS2YL
DMFS2YL DN PMID25991433-Compound-F1
DMFS2YL HS Patented
DMFS2YL CP SIGNAL PHARMACEUTICALS, LLC BEAUCHAMPS, Marie, Georges HARRIS, Louise, Michelle KOTHARE, Mohit, Atul SAINDANE, Manohar, T
DMFS2YL DT Small molecular drug
DMFS2YL PC 11647397
DMFS2YL MW 418.5
DMFS2YL FM C23H23FN6O
DMFS2YL IC InChI=1S/C23H23FN6O/c1-31-17-12-10-15(11-13-17)26-22-25-14-20-21(29-22)30(16-6-2-3-7-16)23(28-20)27-19-9-5-4-8-18(19)24/h4-5,8-14,16H,2-3,6-7H2,1H3,(H,27,28)(H,25,26,29)
DMFS2YL CS COC1=CC=C(C=C1)NC2=NC=C3C(=N2)N(C(=N3)NC4=CC=CC=C4F)C5CCCC5
DMFS2YL IK IMFVPVKPQOQCBY-UHFFFAOYSA-N
DMFS2YL IU 9-cyclopentyl-8-N-(2-fluorophenyl)-2-N-(4-methoxyphenyl)purine-2,8-diamine
DMFS2YL CB CHEBI:90530
DM37VIQ ID DM37VIQ
DM37VIQ DN PMID25991433-Compound-F2
DM37VIQ HS Patented
DM37VIQ CP SIGNAL PHARMACEUTICALS, LLC BEAUCHAMPS, Marie, Georges HARRIS, Louise, Michelle KOTHARE, Mohit, Atul SAINDANE, Manohar, T
DM37VIQ DT Small molecular drug
DMHS3ZW ID DMHS3ZW
DMHS3ZW DN PMID25991433-Compound-G1
DMHS3ZW HS Patented
DMHS3ZW CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMHS3ZW DT Small molecular drug
DMHS3ZW PC 71237169
DMHS3ZW MW 300.36
DMHS3ZW FM C15H20N6O
DMHS3ZW IC InChI=1S/C15H20N6O/c1-21(2)9-8-17-15-18-10-12(13(16)22)14(20-15)19-11-6-4-3-5-7-11/h3-7,10H,8-9H2,1-2H3,(H2,16,22)(H2,17,18,19,20)
DMHS3ZW CS CN(C)CCNC1=NC=C(C(=N1)NC2=CC=CC=C2)C(=O)N
DMHS3ZW IK GTNNAVLREWBUPQ-UHFFFAOYSA-N
DMHS3ZW IU 4-anilino-2-[2-(dimethylamino)ethylamino]pyrimidine-5-carboxamide
DMU3XBH ID DMU3XBH
DMU3XBH DN PMID25991433-Compound-G2
DMU3XBH HS Patented
DMU3XBH CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMU3XBH DT Small molecular drug
DMACWQY ID DMACWQY
DMACWQY DN PMID25991433-Compound-G4
DMACWQY HS Patented
DMACWQY CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMACWQY DT Small molecular drug
DMACWQY PC 71237626
DMACWQY MW 340.4
DMACWQY FM C17H20N6O2
DMACWQY IC InChI=1S/C17H20N6O2/c18-14(24)11-6-8-23(9-7-11)17-20-10-13(15(19)25)16(22-17)21-12-4-2-1-3-5-12/h1-5,10-11H,6-9H2,(H2,18,24)(H2,19,25)(H,20,21,22)
DMACWQY CS C1CN(CCC1C(=O)N)C2=NC=C(C(=N2)NC3=CC=CC=C3)C(=O)N
DMACWQY IK KEVAFBBLBKUMEB-UHFFFAOYSA-N
DMACWQY IU 4-anilino-2-(4-carbamoylpiperidin-1-yl)pyrimidine-5-carboxamide
DMRJ1KY ID DMRJ1KY
DMRJ1KY DN PMID25991433-Compound-G5
DMRJ1KY HS Patented
DMRJ1KY CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMRJ1KY DT Small molecular drug
DMRJ1KY PC 66576636
DMRJ1KY MW 321.34
DMRJ1KY FM C16H15N7O
DMRJ1KY IC InChI=1S/C16H15N7O/c1-10-7-8-18-15(20-10)23-16-19-9-12(13(17)24)14(22-16)21-11-5-3-2-4-6-11/h2-9H,1H3,(H2,17,24)(H2,18,19,20,21,22,23)
DMRJ1KY CS CC1=NC(=NC=C1)NC2=NC=C(C(=N2)NC3=CC=CC=C3)C(=O)N
DMRJ1KY IK YVTIEYHXPXUHLT-UHFFFAOYSA-N
DMRJ1KY IU 4-anilino-2-[(4-methylpyrimidin-2-yl)amino]pyrimidine-5-carboxamide
DM0Q37R ID DM0Q37R
DM0Q37R DN PMID25991433-Compound-H1
DM0Q37R HS Patented
DM0Q37R CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DM0Q37R DT Small molecular drug
DM0Q37R PC 71237973
DM0Q37R MW 293.4
DM0Q37R FM C17H19N5
DM0Q37R IC InChI=1S/C17H19N5/c18-11-13-12-19-17(21-15-9-5-2-6-10-15)22-16(13)20-14-7-3-1-4-8-14/h1,3-4,7-8,12,15H,2,5-6,9-10H2,(H2,19,20,21,22)
DM0Q37R CS C1CCC(CC1)NC2=NC=C(C(=N2)NC3=CC=CC=C3)C#N
DM0Q37R IK HKWATPBSDKRVFA-UHFFFAOYSA-N
DM0Q37R IU 4-anilino-2-(cyclohexylamino)pyrimidine-5-carbonitrile
DMZ9BTN ID DMZ9BTN
DMZ9BTN DN PMID25991433-Compound-H2
DMZ9BTN HS Patented
DMZ9BTN CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMZ9BTN DT Small molecular drug
DMQKLX0 ID DMQKLX0
DMQKLX0 DN PMID25991433-Compound-H3
DMQKLX0 HS Patented
DMQKLX0 CP SIGNAL PHARMACEUTICALS, LLC BENNETT, Brydon, L. ELSNER, Jan ERDMAN, Paul HILGRAF, Robert LEBRUN, Laurie, Ann MCCARRICK, Meg MOGHADDAM, Mehran, F. NAGY, Mark, A. NORRIS, Stephen PAISNER, David, A. SLOSS, Marianne ROMANOW, William, J. SATOH, Yoshitaka TIKHE, Jayashree YOON, Won, Hyung DELGADO, Mercedes
DMQKLX0 DT Small molecular drug
DMQGUMN ID DMQGUMN
DMQGUMN DN PMID25991433-Compound-J1
DMQGUMN HS Patented
DMQGUMN CP DANA-FARBER CANCER INSTITUTE, INC
DMQGUMN DT Small molecular drug
DMQGUMN PC 25123232
DMQGUMN MW 507.6
DMQGUMN FM C29H29N7O2
DMQGUMN IC InChI=1S/C29H29N7O2/c1-20-8-11-24(18-26(20)35-29-31-16-14-25(34-29)22-6-4-15-30-19-22)33-28(38)21-9-12-23(13-10-21)32-27(37)7-5-17-36(2)3/h4-16,18-19H,17H2,1-3H3,(H,32,37)(H,33,38)(H,31,34,35)/b7-5+
DMQGUMN CS CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)NC(=O)/C=C/CN(C)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMQGUMN IK YFRXAAWSVLQGDR-FNORWQNLSA-N
DMQGUMN IU 4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMZSOCK ID DMZSOCK
DMZSOCK DN PMID25991433-Compound-J2
DMZSOCK HS Patented
DMZSOCK CP DANA-FARBER CANCER INSTITUTE, INC
DMZSOCK DT Small molecular drug
DM17P3F ID DM17P3F
DM17P3F DN PMID25991433-Compound-J3
DM17P3F HS Patented
DM17P3F CP DANA-FARBER CANCER INSTITUTE, INC
DM17P3F DT Small molecular drug
DM17P3F PC 57340683
DM17P3F MW 436.5
DM17P3F FM C25H20N6O2
DM17P3F IC InChI=1S/C25H20N6O2/c1-2-23(32)28-21-7-3-5-17(15-21)24(33)29-19-8-10-20(11-9-19)30-25-27-14-12-22(31-25)18-6-4-13-26-16-18/h2-16H,1H2,(H,28,32)(H,29,33)(H,27,30,31)
DM17P3F CS C=CC(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CN=CC=C4
DM17P3F IK LUFRTLQRKNBFAZ-UHFFFAOYSA-N
DM17P3F IU 3-(prop-2-enoylamino)-N-[4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMU75ZX ID DMU75ZX
DMU75ZX DN PMID25991433-Compound-J5
DMU75ZX HS Patented
DMU75ZX CP DANA-FARBER CANCER INSTITUTE, INC
DMU75ZX DT Small molecular drug
DMU75ZX PC 57340689
DMU75ZX MW 608.7
DMU75ZX FM C36H32N8O2
DMU75ZX IC InChI=1S/C36H32N8O2/c1-43(2)22-9-15-32(45)38-29-13-8-12-26(24-29)35(46)39-27-16-18-28(19-17-27)40-36-37-21-20-30(41-36)33-31-14-6-7-23-44(31)42-34(33)25-10-4-3-5-11-25/h3-21,23-24H,22H2,1-2H3,(H,38,45)(H,39,46)(H,37,40,41)/b15-9+
DMU75ZX CS CN(C)C/C=C/C(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)C4=C5C=CC=CN5N=C4C6=CC=CC=C6
DMU75ZX IK OCZDPFMSAKKNRH-OQLLNIDSSA-N
DMU75ZX IU 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[4-[[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide
DMU75ZX CB CHEBI:124926
DMOWULJ ID DMOWULJ
DMOWULJ DN PMID25991433-Compound-J6
DMOWULJ HS Patented
DMOWULJ CP DANA-FARBER CANCER INSTITUTE, INC
DMOWULJ DT Small molecular drug
DMOWULJ PC 57340690
DMOWULJ MW 588.7
DMOWULJ FM C32H28N8O2S
DMOWULJ IC InChI=1S/C32H28N8O2S/c1-40(2)18-6-11-29(41)35-24-8-5-7-21(19-24)30(42)36-22-12-14-23(15-13-22)37-32-34-17-16-26(39-32)25(20-33)31-38-27-9-3-4-10-28(27)43-31/h3-17,19,38H,18H2,1-2H3,(H,35,41)(H,36,42)(H,34,37,39)/b11-6+,31-25+
DMOWULJ CS CN(C)C/C=C/C(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)/C(=C/4\\NC5=CC=CC=C5S4)/C#N
DMOWULJ IK HOHLJRLTAVJARA-KCBYSLGISA-N
DMOWULJ IU N-[4-[[4-[(Z)-3H-1,3-benzothiazol-2-ylidene(cyano)methyl]pyrimidin-2-yl]amino]phenyl]-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide
DMLT8PA ID DMLT8PA
DMLT8PA DN PMID25991433-Compound-K1
DMLT8PA HS Patented
DMLT8PA CP PFIZER PRODUCTS INC. HUANG, Liming LIU, Song LUNNEY, Elizabeth, Ann PLANKEN, Simon, Paul
DMLT8PA DT Small molecular drug
DMBS4LE ID DMBS4LE
DMBS4LE DN PMID25991433-Compound-K2
DMBS4LE HS Patented
DMBS4LE CP PFIZER PRODUCTS INC. HUANG, Liming LIU, Song LUNNEY, Elizabeth, Ann PLANKEN, Simon, Paul
DMBS4LE DT Small molecular drug
DM5U8WT ID DM5U8WT
DM5U8WT DN PMID25991433-Compound-L
DM5U8WT HS Patented
DM5U8WT CP SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM5U8WT DT Small molecular drug
DM2135Y ID DM2135Y
DM2135Y DN PMID25991433-Compound-L1
DM2135Y HS Patented
DM2135Y CP SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM2135Y DT Small molecular drug
DM58UO9 ID DM58UO9
DM58UO9 DN PMID25991433-Compound-L2
DM58UO9 HS Patented
DM58UO9 CP SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM58UO9 DT Small molecular drug
DM3LWUR ID DM3LWUR
DM3LWUR DN PMID25991433-Compound-L3
DM3LWUR HS Patented
DM3LWUR CP SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE PELLECCHIA, Maurizio
DM3LWUR DT Small molecular drug
DMN27QB ID DMN27QB
DMN27QB DN PMID25991433-Compound-N1
DMN27QB HS Patented
DMN27QB CP VERTEX PHARMACEUTICALS INCORPORATED YANG, Xiaoqing HADIDA RUAH, Sara, S. GROOTENHUIS, Peter, D.J. VAN GOOR, Fredrick, F. BOTFIELD, Martyn, C. ZLOKARNIK, Gregor
DMN27QB DT Small molecular drug
DMN27QB PC 2190145
DMN27QB MW 338.4
DMN27QB FM C19H18N2O2S
DMN27QB IC InChI=1S/C19H18N2O2S/c1-11-12(2)24-19(17(11)18(20)23)21-16(22)10-14-8-5-7-13-6-3-4-9-15(13)14/h3-9H,10H2,1-2H3,(H2,20,23)(H,21,22)
DMN27QB CS CC1=C(SC(=C1C(=O)N)NC(=O)CC2=CC=CC3=CC=CC=C32)C
DMN27QB IK WKFBSIRAGVAYFT-UHFFFAOYSA-N
DMN27QB IU 4,5-dimethyl-2-[(2-naphthalen-1-ylacetyl)amino]thiophene-3-carboxamide
DMXY4BE ID DMXY4BE
DMXY4BE DN PMID25991433-Compound-N2
DMXY4BE HS Patented
DMXY4BE CP VERTEX PHARMACEUTICALS INCORPORATED YANG, Xiaoqing HADIDA RUAH, Sara, S. GROOTENHUIS, Peter, D.J. VAN GOOR, Fredrick, F. BOTFIELD, Martyn, C. ZLOKARNIK, Gregor
DMXY4BE DT Small molecular drug
DMXY4BE PC 46926710
DMXY4BE MW 288.4
DMXY4BE FM C15H16N2O2S
DMXY4BE IC InChI=1S/C15H16N2O2S/c1-9-5-10(2)7-11(6-9)8-13(18)17-15-12(14(16)19)3-4-20-15/h3-7H,8H2,1-2H3,(H2,16,19)(H,17,18)
DMXY4BE CS CC1=CC(=CC(=C1)CC(=O)NC2=C(C=CS2)C(=O)N)C
DMXY4BE IK DXUHHRPREFMGHI-UHFFFAOYSA-N
DMXY4BE IU 2-[[2-(3,5-dimethylphenyl)acetyl]amino]thiophene-3-carboxamide
DMLHC5V ID DMLHC5V
DMLHC5V DN PMID25991433-Compound-N3
DMLHC5V HS Patented
DMLHC5V CP VERTEX PHARMACEUTICALS INCORPORATED YANG, Xiaoqing HADIDA RUAH, Sara, S. GROOTENHUIS, Peter, D.J. VAN GOOR, Fredrick, F. BOTFIELD, Martyn, C. ZLOKARNIK, Gregor
DMLHC5V DT Small molecular drug
DMLHC5V PC 46926788
DMLHC5V MW 316.4
DMLHC5V FM C15H12N2O2S2
DMLHC5V IC InChI=1S/C15H12N2O2S2/c16-14(19)11-5-6-20-15(11)17-13(18)7-9-8-21-12-4-2-1-3-10(9)12/h1-6,8H,7H2,(H2,16,19)(H,17,18)
DMLHC5V CS C1=CC=C2C(=C1)C(=CS2)CC(=O)NC3=C(C=CS3)C(=O)N
DMLHC5V IK ZZKGJVRSUVIYIJ-UHFFFAOYSA-N
DMLHC5V IU 2-[[2-(1-benzothiophen-3-yl)acetyl]amino]thiophene-3-carboxamide
DMH073T ID DMH073T
DMH073T DN PMID25991433-Compound-O1
DMH073T HS Patented
DMH073T CP UNIVERSITY OF LAUSANNE BONNY, Christophe
DMH073T DT Peptide
DMH073T SQ H2N-GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD-CONH2
DMTROIQ ID DMTROIQ
DMTROIQ DN PMID25991433-Compound-O2
DMTROIQ HS Patented
DMTROIQ CP UNIVERSITY OF LAUSANNE BONNY, Christophe
DMTROIQ DT Peptide
DMTROIQ SQ H2N-dqsrpvqpflnlttprkprpprrrqrrkkrg-CONH2
DMVOWS5 ID DMVOWS5
DMVOWS5 DN PMID25991433-Compound-O3
DMVOWS5 HS Patented
DMVOWS5 CP XIGEN S.A. COMBETTE, Jean-Marc DELOCHE, Catherine
DMVOWS5 DT Peptide
DMVOWS5 SQ H2N-rKKRrQRRrRPkRPaTLNLf-CONH2
DMD8AX6 ID DMD8AX6
DMD8AX6 DN PMID25991433-Compound-P1
DMD8AX6 HS Patented
DMD8AX6 CP ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMD8AX6 DT Small molecular drug
DMEGS7U ID DMEGS7U
DMEGS7U DN PMID25991433-Compound-P2
DMEGS7U HS Patented
DMEGS7U CP ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMEGS7U DT Small molecular drug
DMEGS7U PC 46869000
DMEGS7U MW 314.4
DMEGS7U FM C16H14N2O3S
DMEGS7U IC InChI=1S/C16H14N2O3S/c1-20-12-4-2-11(3-5-12)10-14(19)18-13-6-9-22-15(13)16-17-7-8-21-16/h2-9H,10H2,1H3,(H,18,19)
DMEGS7U CS COC1=CC=C(C=C1)CC(=O)NC2=C(SC=C2)C3=NC=CO3
DMEGS7U IK KSZHRLGDJPCAID-UHFFFAOYSA-N
DMEGS7U IU 2-(4-methoxyphenyl)-N-[2-(1,3-oxazol-2-yl)thiophen-3-yl]acetamide
DMAFZLP ID DMAFZLP
DMAFZLP DN PMID25991433-Compound-P3
DMAFZLP HS Patented
DMAFZLP CP ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMAFZLP DT Small molecular drug
DMVF1D6 ID DMVF1D6
DMVF1D6 DN PMID25991433-Compound-P4
DMVF1D6 HS Patented
DMVF1D6 CP ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMVF1D6 DT Small molecular drug
DM6FCS9 ID DM6FCS9
DM6FCS9 DN PMID25991433-Compound-P5
DM6FCS9 HS Patented
DM6FCS9 CP ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DM6FCS9 DT Small molecular drug
DM6FCS9 PC 46868926
DM6FCS9 MW 498.3
DM6FCS9 FM C18H11BrF3N5O2S
DM6FCS9 IC InChI=1S/C18H11BrF3N5O2S/c19-11-7-30-17(15(11)16-23-8-24-26-16)25-13(28)6-27-12-3-2-10(18(20,21)22)5-9(12)1-4-14(27)29/h1-5,7-8H,6H2,(H,25,28)(H,23,24,26)
DM6FCS9 CS C1=CC2=C(C=CC(=O)N2CC(=O)NC3=C(C(=CS3)Br)C4=NC=NN4)C=C1C(F)(F)F
DM6FCS9 IK CRWXJGJNJZPMRW-UHFFFAOYSA-N
DM6FCS9 IU N-[4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl]-2-[2-oxo-6-(trifluoromethyl)quinolin-1-yl]acetamide
DMNDVC9 ID DMNDVC9
DMNDVC9 DN PMID25991433-Compound-P6
DMNDVC9 HS Patented
DMNDVC9 CP ELAN PHARMACEUTICALS, INC. SHAM, Hing, L. KONRADI, Andrei, W. HOM, Roy, K. PROBST, Gary, D. BOWERS, Simeon TRUONG, Anh NEITZ, R., Jeffrey SEALY, Jennifer TOTH, Gergely
DMNDVC9 DT Small molecular drug
DMNDVC9 PC 45102739
DMNDVC9 MW 369.8
DMNDVC9 FM C17H12ClN5OS
DMNDVC9 IC InChI=1S/C17H12ClN5OS/c18-13-8-25-17(15(13)16-20-9-21-23-16)22-14(24)6-10-2-1-3-11-7-19-5-4-12(10)11/h1-5,7-9H,6H2,(H,22,24)(H,20,21,23)
DMNDVC9 CS C1=CC2=C(C=CN=C2)C(=C1)CC(=O)NC3=C(C(=CS3)Cl)C4=NC=NN4
DMNDVC9 IK MYLVKAPPYVXQKQ-UHFFFAOYSA-N
DMNDVC9 IU N-[4-chloro-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl]-2-isoquinolin-5-ylacetamide
DMNDVC9 CA CAS 1239461-27-8
DMEMSB2 ID DMEMSB2
DMEMSB2 DN PMID25991433-Compound-Q1
DMEMSB2 HS Patented
DMEMSB2 CP UNIVERSIT DEGLI STUDI DI BARI [IT]
DMEMSB2 DT Small molecular drug
DMEMSB2 PC 56946834
DMEMSB2 MW 444.4
DMEMSB2 FM C22H18F2N2O6
DMEMSB2 IC InChI=1S/C22H18F2N2O6/c1-30-19-9-14(10-20(31-2)21(19)32-3)22(27)25-17-5-4-12(8-18(17)26(28)29)13-6-15(23)11-16(24)7-13/h4-11H,1-3H3,(H,25,27)
DMEMSB2 CS COC1=CC(=CC(=C1OC)OC)C(=O)NC2=C(C=C(C=C2)C3=CC(=CC(=C3)F)F)[N+](=O)[O-]
DMEMSB2 IK UCSAAECBPXPZFV-UHFFFAOYSA-N
DMEMSB2 IU N-[4-(3,5-difluorophenyl)-2-nitrophenyl]-3,4,5-trimethoxybenzamide
DMAIKJV ID DMAIKJV
DMAIKJV DN PMID25991433-Compound-Q2
DMAIKJV HS Patented
DMAIKJV CP UNIVERSIT DEGLI STUDI DI BARI [IT]
DMAIKJV DT Small molecular drug
DMAIKJV PC 56946615
DMAIKJV MW 408.4
DMAIKJV FM C22H20N2O6
DMAIKJV IC InChI=1S/C22H20N2O6/c1-28-19-12-16(13-20(29-2)21(19)30-3)23-22(25)17-10-9-15(11-18(17)24(26)27)14-7-5-4-6-8-14/h4-13H,1-3H3,(H,23,25)
DMAIKJV CS COC1=CC(=CC(=C1OC)OC)NC(=O)C2=C(C=C(C=C2)C3=CC=CC=C3)[N+](=O)[O-]
DMAIKJV IK RCEYITFFDFXLHB-UHFFFAOYSA-N
DMAIKJV IU 2-nitro-4-phenyl-N-(3,4,5-trimethoxyphenyl)benzamide
DM8FQJB ID DM8FQJB
DM8FQJB DN PMID26004420-Compound-U2014S0288042A
DM8FQJB HS Patented
DM8FQJB CP Merck Sharp & Dohme Corp
DM8FQJB DT Small molecular drug
DM8RJTQ ID DM8RJTQ
DM8RJTQ DN PMID26004420-Compound-U2014S0288042C
DM8RJTQ HS Patented
DM8RJTQ CP Merck Sharp & Dohme Corp
DM8RJTQ DT Small molecular drug
DMVQSYT ID DMVQSYT
DMVQSYT DN PMID26004420-Compound-US20140031349A
DMVQSYT HS Patented
DMVQSYT CP Merck Sharp & Dohme Corp
DMVQSYT DT Small molecular drug
DM3M1NB ID DM3M1NB
DM3M1NB DN PMID26004420-Compound-US20140031349B
DM3M1NB HS Patented
DM3M1NB CP Merck Sharp & Dohme Corp
DM3M1NB DT Small molecular drug
DMDP8J0 ID DMDP8J0
DMDP8J0 DN PMID26004420-Compound-US20140031349C
DMDP8J0 HS Patented
DMDP8J0 CP Merck Sharp & Dohme Corp
DMDP8J0 DT Small molecular drug
DMUD7IB ID DMUD7IB
DMUD7IB DN PMID26004420-Compound-US20140031349D
DMUD7IB HS Patented
DMUD7IB CP Merck Sharp & Dohme Corp
DMUD7IB DT Small molecular drug
DMIXVNQ ID DMIXVNQ
DMIXVNQ DN PMID26004420-Compound-US20140142115A
DMIXVNQ HS Patented
DMIXVNQ CP Merck Sharp & Dohme Corp
DMIXVNQ DT Small molecular drug
DM07DC6 ID DM07DC6
DM07DC6 DN PMID26004420-Compound-US20140142115B
DM07DC6 HS Patented
DM07DC6 CP Merck Sharp & Dohme Corp
DM07DC6 DT Small molecular drug
DMQ7Z5F ID DMQ7Z5F
DMQ7Z5F DN PMID26004420-Compound-US20140142115C
DMQ7Z5F HS Patented
DMQ7Z5F CP Merck Sharp & Dohme Corp
DMQ7Z5F DT Small molecular drug
DMQ5AIT ID DMQ5AIT
DMQ5AIT DN PMID26004420-Compound-US20140275020D
DMQ5AIT HS Patented
DMQ5AIT CP Merck Sharp & Dohme Corp
DMQ5AIT DT Small molecular drug
DMH7JKI ID DMH7JKI
DMH7JKI DN PMID26004420-Compound-US20140275020E
DMH7JKI HS Patented
DMH7JKI CP Merck Sharp & Dohme Corp
DMH7JKI DT Small molecular drug
DMH8M1D ID DMH8M1D
DMH8M1D DN PMID26004420-Compound-US20140309213A
DMH8M1D HS Patented
DMH8M1D CP Merck Sharp & Dohme Corp
DMH8M1D DT Small molecular drug
DM0P4TA ID DM0P4TA
DM0P4TA DN PMID26004420-Compound-US20140309213B
DM0P4TA HS Patented
DM0P4TA CP Merck Sharp & Dohme Corp
DM0P4TA DT Small molecular drug
DM4M2TU ID DM4M2TU
DM4M2TU DN PMID26004420-Compound-US20140336177D
DM4M2TU HS Patented
DM4M2TU CP Merck Sharp & Dohme Corp
DM4M2TU DT Small molecular drug
DMCRJO1 ID DMCRJO1
DMCRJO1 DN PMID26004420-Compound-US20140336177E
DMCRJO1 HS Patented
DMCRJO1 CP Merck Sharp & Dohme Corp
DMCRJO1 DT Small molecular drug
DM37GMQ ID DM37GMQ
DM37GMQ DN PMID26004420-Compound-WO2010129379A
DM37GMQ HS Patented
DM37GMQ CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM37GMQ DT Small molecular drug
DM62A1H ID DM62A1H
DM62A1H DN PMID26004420-Compound-WO2010129379B
DM62A1H HS Patented
DM62A1H CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM62A1H DT Small molecular drug
DMV3X64 ID DMV3X64
DMV3X64 DN PMID26004420-Compound-WO2010129379C
DMV3X64 HS Patented
DMV3X64 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMV3X64 DT Small molecular drug
DMR9B2D ID DMR9B2D
DMR9B2D DN PMID26004420-Compound-WO2012058116A
DMR9B2D HS Patented
DMR9B2D CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMR9B2D DT Small molecular drug
DMD41UF ID DMD41UF
DMD41UF DN PMID26004420-Compound-WO2012058116B
DMD41UF HS Patented
DMD41UF CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMD41UF DT Small molecular drug
DM2Y64W ID DM2Y64W
DM2Y64W DN PMID26004420-Compound-WO2012058116C
DM2Y64W HS Patented
DM2Y64W CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM2Y64W DT Small molecular drug
DMUX0SG ID DMUX0SG
DMUX0SG DN PMID26004420-Compound-WO2012058134A
DMUX0SG HS Patented
DMUX0SG CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMUX0SG DT Small molecular drug
DMGVXCL ID DMGVXCL
DMGVXCL DN PMID26004420-Compound-WO2012058134B
DMGVXCL HS Patented
DMGVXCL CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMGVXCL DT Small molecular drug
DM9AJVK ID DM9AJVK
DM9AJVK DN PMID26004420-Compound-WO2012058134C
DM9AJVK HS Patented
DM9AJVK CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM9AJVK DT Small molecular drug
DMIV92A ID DMIV92A
DMIV92A DN PMID26004420-Compound-WO2013028474A
DMIV92A HS Patented
DMIV92A CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMIV92A DT Small molecular drug
DMCP0WF ID DMCP0WF
DMCP0WF DN PMID26004420-Compound-WO2013028474B
DMCP0WF HS Patented
DMCP0WF CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMCP0WF DT Small molecular drug
DMTCPNY ID DMTCPNY
DMTCPNY DN PMID26004420-Compound-WO2013028474C
DMTCPNY HS Patented
DMTCPNY CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMTCPNY DT Small molecular drug
DMT7GQ1 ID DMT7GQ1
DMT7GQ1 DN PMID26004420-Compound-WO2013039802A
DMT7GQ1 HS Patented
DMT7GQ1 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMT7GQ1 DT Small molecular drug
DMP130R ID DMP130R
DMP130R DN PMID26004420-Compound-WO2013039802B
DMP130R HS Patented
DMP130R CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMP130R DT Small molecular drug
DMV7ISR ID DMV7ISR
DMV7ISR DN PMID26004420-Compound-WO2013039802C
DMV7ISR HS Patented
DMV7ISR CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMV7ISR DT Small molecular drug
DMH7E38 ID DMH7E38
DMH7E38 DN PMID26004420-Compound-WO2013062892D
DMH7E38 HS Patented
DMH7E38 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMH7E38 DT Small molecular drug
DMMHLA9 ID DMMHLA9
DMMHLA9 DN PMID26004420-Compound-WO2013062892E
DMMHLA9 HS Patented
DMMHLA9 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMMHLA9 DT Small molecular drug
DM5N9M4 ID DM5N9M4
DM5N9M4 DN PMID26004420-Compound-WO2013062900A
DM5N9M4 HS Patented
DM5N9M4 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM5N9M4 DT Small molecular drug
DMIM8UF ID DMIM8UF
DMIM8UF DN PMID26004420-Compound-WO2013062900B
DMIM8UF HS Patented
DMIM8UF CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMIM8UF DT Small molecular drug
DMDZHAB ID DMDZHAB
DMDZHAB DN PMID26004420-Compound-WO2013062900C
DMDZHAB HS Patented
DMDZHAB CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMDZHAB DT Small molecular drug
DMDZHAB PC 71519588
DMDZHAB MW 415.5
DMDZHAB FM C25H25N3O3
DMDZHAB IC InChI=1S/C25H25N3O3/c26-14-18-1-3-20-13-22(5-4-19(20)12-18)28-10-9-27(15-24(28)29)8-7-17-2-6-23-21(11-17)16-31-25(23)30/h1-3,6,11-12,22H,4-5,7-10,13,15-16H2
DMDZHAB CS C1CC2=C(CC1N3CCN(CC3=O)CCC4=CC5=C(C=C4)C(=O)OC5)C=CC(=C2)C#N
DMDZHAB IK IXHFMRBAJKIWFU-UHFFFAOYSA-N
DMDZHAB IU 6-[2-oxo-4-[2-(1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile
DMRDUS9 ID DMRDUS9
DMRDUS9 DN PMID26004420-Compound-WO2014015495A
DMRDUS9 HS Patented
DMRDUS9 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMRDUS9 DT Small molecular drug
DMLH637 ID DMLH637
DMLH637 DN PMID26004420-Compound-WO2014015495B
DMLH637 HS Patented
DMLH637 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMLH637 DT Small molecular drug
DMHA18O ID DMHA18O
DMHA18O DN PMID26004420-Compound-WO2014015495C
DMHA18O HS Patented
DMHA18O CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMHA18O DT Small molecular drug
DM3QO5R ID DM3QO5R
DM3QO5R DN PMID26004420-Compound-WO2014015495D
DM3QO5R HS Patented
DM3QO5R CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM3QO5R DT Small molecular drug
DMY6JAB ID DMY6JAB
DMY6JAB DN PMID26004420-Compound-WO2014085210A
DMY6JAB HS Patented
DMY6JAB CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMY6JAB DT Small molecular drug
DMTD0RK ID DMTD0RK
DMTD0RK DN PMID26004420-Compound-WO2014085210B
DMTD0RK HS Patented
DMTD0RK CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMTD0RK DT Small molecular drug
DMKC6SA ID DMKC6SA
DMKC6SA DN PMID26004420-Compound-WO2014085210C
DMKC6SA HS Patented
DMKC6SA CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMKC6SA DT Small molecular drug
DMJIZWR ID DMJIZWR
DMJIZWR DN PMID26004420-Compound-WO2014099633D
DMJIZWR HS Patented
DMJIZWR CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMJIZWR DT Small molecular drug
DMSPG8Y ID DMSPG8Y
DMSPG8Y DN PMID26004420-Compound-WO2014099633E
DMSPG8Y HS Patented
DMSPG8Y CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMSPG8Y DT Small molecular drug
DM59INV ID DM59INV
DM59INV DN PMID26004420-Compound-WO2014126944A
DM59INV HS Patented
DM59INV CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM59INV DT Small molecular drug
DMH0LBI ID DMH0LBI
DMH0LBI DN PMID26004420-Compound-WO2014126944B
DMH0LBI HS Patented
DMH0LBI CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMH0LBI DT Small molecular drug
DMN1B3F ID DMN1B3F
DMN1B3F DN PMID26004420-Compound-WO2014150132A
DMN1B3F HS Patented
DMN1B3F CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMN1B3F DT Small molecular drug
DMJX8WY ID DMJX8WY
DMJX8WY DN PMID26004420-Compound-WO2014150132B
DMJX8WY HS Patented
DMJX8WY CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMJX8WY DT Small molecular drug
DM2FDCT ID DM2FDCT
DM2FDCT DN PMID26004420-Compound-WO2014150132C
DM2FDCT HS Patented
DM2FDCT CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DM2FDCT DT Small molecular drug
DMI30GA ID DMI30GA
DMI30GA DN PMID26004420-Compound-WO2015017305D
DMI30GA HS Patented
DMI30GA CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMI30GA DT Small molecular drug
DMV4HQ5 ID DMV4HQ5
DMV4HQ5 DN PMID26004420-Compound-WO2015017305E
DMV4HQ5 HS Patented
DMV4HQ5 CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMV4HQ5 DT Small molecular drug
DMLV6IY ID DMLV6IY
DMLV6IY DN PMID26004420-Compound-WO2015017305F
DMLV6IY HS Patented
DMLV6IY CP MERCK SHARP & DOHME CORP. PASTERNAK, Alexander DEJESUS, Reynalda, K. ZHU, Yuping YANG, Lihu WALSH, Shawn PIO, Barbara SHAHRIPOUR, Aurash TANG, Haifeng BELYK, Kevin KIM, Dooseop
DMLV6IY DT Small molecular drug
DMENX90 ID DMENX90
DMENX90 DN PMID26077642-Compound-Figure3A
DMENX90 HS Patented
DMENX90 CP VIVOLUX AB LINDER, Stig LARSSON, Rolf
DMENX90 DT Small molecular drug
DM9A8PN ID DM9A8PN
DM9A8PN DN PMID26077642-Compound-Figure3G
DM9A8PN HS Patented
DM9A8PN CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN DONATO, Nicholas, J. WOBUS, Christiane SHOWALTER, H. D. Hollis TALPAZ, Moshe PERRY, Jeffrey, William SORENSON, Roderick, Joseph O'RIORDAN, Mary, Xuan Dziem JIN, Yafei
DM9A8PN DT Small molecular drug
DMQYWBR ID DMQYWBR
DMQYWBR DN PMID26077642-Compound-Figure3H
DMQYWBR HS Patented
DMQYWBR DT Small molecular drug
DMS9KCF ID DMS9KCF
DMS9KCF DN PMID26077642-Compound-Vif1
DMS9KCF HS Patented
DMS9KCF DT Peptide
DMYXIS7 ID DMYXIS7
DMYXIS7 DN PMID26077642-Compound-Vif2
DMYXIS7 HS Patented
DMYXIS7 DT Peptide
DM2PUBI ID DM2PUBI
DM2PUBI DN PMID26099857-Compound-WO2011037610Formula(I)
DM2PUBI HS Patented
DM2PUBI CP ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY SCHUSTER, Victor, L. CHI, Yuling WASMUTH, Andrew, S. POTTORF, Richard, S. OLSON, Gary, L
DM2PUBI DT Small molecular drug
DMXVCHZ ID DMXVCHZ
DMXVCHZ DN PMID26161698-Compound-10
DMXVCHZ HS Patented
DMXVCHZ CP SCHERING CORPORATION PARUCH, Kamil GUZI, Timothy J. DWYER, Michael P
DMXVCHZ DT Small molecular drug
DMB92RA ID DMB92RA
DMB92RA DN PMID26161698-Compound-17
DMB92RA HS Patented
DMB92RA CP SENEX BIOTECHNOLOGY, INC
DMB92RA DT Small molecular drug
DMB92RA PC 739323
DMB92RA MW 229.1
DMB92RA FM C10H10Cl2N2
DMB92RA IC InChI=1S/C10H10Cl2N2/c11-7-3-8-6(1-2-13)5-14-10(8)9(12)4-7/h3-5,14H,1-2,13H2
DMB92RA CS C1=C(C=C(C2=C1C(=CN2)CCN)Cl)Cl
DMB92RA IK MOPMGVMKLSZZPB-UHFFFAOYSA-N
DMB92RA IU 2-(5,7-dichloro-1H-indol-3-yl)ethanamine
DM6JVR5 ID DM6JVR5
DM6JVR5 DN PMID26161698-Compound-18
DM6JVR5 HS Patented
DM6JVR5 CP NOSCIRA, S.A
DM6JVR5 DT Small molecular drug
DM6JVR5 PC 136273305
DM6JVR5 MW 260.68
DM6JVR5 FM C12H9ClN4O
DM6JVR5 IC InChI=1S/C12H9ClN4O/c13-6-1-2-8-7(5-6)10(11(18)16-8)9-3-4-15-12(14)17-9/h1-5,16,18H,(H2,14,15,17)
DM6JVR5 CS C1=CC2=C(C=C1Cl)C(=C(N2)O)C3=NC(=NC=C3)N
DM6JVR5 IK LHICLFBRLYHBGK-UHFFFAOYSA-N
DM6JVR5 IU 3-(2-aminopyrimidin-4-yl)-5-chloro-1H-indol-2-ol
DM4AFHY ID DM4AFHY
DM4AFHY DN PMID26161698-Compound-25
DM4AFHY HS Patented
DM4AFHY CP BAYER INTELLECTUAL PROPERTY GMBH
DM4AFHY DT Small molecular drug
DM4AFHY PC 71618654
DM4AFHY MW 481.5
DM4AFHY FM C24H21F2N5O2S
DM4AFHY IC InChI=1S/C24H21F2N5O2S/c1-34(27,32)14-17-5-3-7-20(11-17)30-24-29-15-28-23(31-24)21-9-8-19(26)12-22(21)33-13-16-4-2-6-18(25)10-16/h2-12,15,27H,13-14H2,1H3,(H,28,29,30,31)
DM4AFHY CS CS(=N)(=O)CC1=CC(=CC=C1)NC2=NC=NC(=N2)C3=C(C=C(C=C3)F)OCC4=CC(=CC=C4)F
DM4AFHY IK YPAQXRURXUKFGB-UHFFFAOYSA-N
DM4AFHY IU 4-[4-fluoro-2-[(3-fluorophenyl)methoxy]phenyl]-N-[3-[(methylsulfonimidoyl)methyl]phenyl]-1,3,5-triazin-2-amine
DMRIWKV ID DMRIWKV
DMRIWKV DN PMID26161698-Compound-32
DMRIWKV HS Patented
DMRIWKV CP LEAD DISCOVERY CENTER GMBH MAX-PLANCK-GESELLSCHAFT ZUR FDERUNG DER WISSENSCHAFTEN E.V. CHOIDAS, Axel KLEBL, Bert HABENBERGER, Peter EICKHOFF, Jan THOMAS, Roman HEUCKMANN, Johannes
DMRIWKV DT Small molecular drug
DMRIWKV PC 53491923
DMRIWKV MW 371.4
DMRIWKV FM C17H17N5O3S
DMRIWKV IC InChI=1S/C17H17N5O3S/c1-25-15-8-3-2-7-14(15)16-19-11-20-17(22-16)21-13-6-4-5-12(9-13)10-26(18,23)24/h2-9,11H,10H2,1H3,(H2,18,23,24)(H,19,20,21,22)
DMRIWKV CS COC1=CC=CC=C1C2=NC(=NC=N2)NC3=CC=CC(=C3)CS(=O)(=O)N
DMRIWKV IK BQJUSTFHSZCQFK-UHFFFAOYSA-N
DMRIWKV IU [3-[[4-(2-methoxyphenyl)-1,3,5-triazin-2-yl]amino]phenyl]methanesulfonamide
DMTIM1E ID DMTIM1E
DMTIM1E DN PMID26161698-Compound-34
DMTIM1E HS Patented
DMTIM1E CP DANA-FARBER CANCER INSTITUTE, INC
DMTIM1E DT Small molecular drug
DM8UPO3 ID DM8UPO3
DM8UPO3 DN PMID26161698-Compound-44
DM8UPO3 HS Patented
DM8UPO3 CP NERVIANO MEDICAL SCIENCES S.R.L. ZAMPIERI, Massimo VANOTTI, Ermes CIVAROLI, Paola FORNARETTO, Maria, Gioia
DM8UPO3 DT Small molecular drug
DMF9C4I ID DMF9C4I
DMF9C4I DN PMID26161824-Compound-68
DMF9C4I HS Patented
DMF9C4I DT Small molecular drug
DMF9C4I PC 24881103
DMF9C4I MW 461.8
DMF9C4I FM C24H23Cl3N2O
DMF9C4I IC InChI=1S/C24H23Cl3N2O/c1-15-23(22(30)13-16-5-3-2-4-6-16)28-29(21-12-11-19(26)14-20(21)27)24(15)17-7-9-18(25)10-8-17/h7-12,14,16H,2-6,13H2,1H3
DMF9C4I CS CC1=C(N(N=C1C(=O)CC2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMF9C4I IK XMPCPPFFIBUKLW-UHFFFAOYSA-N
DMF9C4I IU 1-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-2-cyclohexylethanone
DMF9C4I DE Obesity
DMKOSN5 ID DMKOSN5
DMKOSN5 DN PMID26161824-Compound-69
DMKOSN5 HS Patented
DMKOSN5 DT Small molecular drug
DMKOSN5 PC 25003056
DMKOSN5 MW 455.8
DMKOSN5 FM C24H17Cl3N2O
DMKOSN5 IC InChI=1S/C24H17Cl3N2O/c1-15-23(22(30)13-16-5-3-2-4-6-16)28-29(21-12-11-19(26)14-20(21)27)24(15)17-7-9-18(25)10-8-17/h2-12,14H,13H2,1H3
DMKOSN5 CS CC1=C(N(N=C1C(=O)CC2=CC=CC=C2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMKOSN5 IK GTXRPIMCNZXFIC-UHFFFAOYSA-N
DMKOSN5 IU 1-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-2-phenylethanone
DMKOSN5 DE Obesity
DMHXT12 ID DMHXT12
DMHXT12 DN PMID26293650-Compound-34
DMHXT12 HS Patented
DMHXT12 CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMHXT12 DT Small molecular drug
DMHXT12 PC 72950600
DMHXT12 MW 426.5
DMHXT12 FM C25H26N6O
DMHXT12 IC InChI=1S/C25H26N6O/c1-17(2)28-24(32)18-5-8-21(9-6-18)29-25-27-12-11-22(30-25)19-7-10-23(20(15-19)16-26)31-13-3-4-14-31/h5-12,15,17H,3-4,13-14H2,1-2H3,(H,28,32)(H,27,29,30)
DMHXT12 CS CC(C)NC(=O)C1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)N4CCCC4)C#N
DMHXT12 IK FJNGYFUMQJIPOQ-UHFFFAOYSA-N
DMHXT12 IU 4-[[4-(3-cyano-4-pyrrolidin-1-ylphenyl)pyrimidin-2-yl]amino]-N-propan-2-ylbenzamide
DMPG8MF ID DMPG8MF
DMPG8MF DN PMID26293650-Compound-35
DMPG8MF HS Patented
DMPG8MF CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMPG8MF DT Small molecular drug
DMP8RQ4 ID DMP8RQ4
DMP8RQ4 DN PMID26394986-Compound-10
DMP8RQ4 HS Patented
DMP8RQ4 CP H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMP8RQ4 DT Small molecular drug
DMP8RQ4 PC 252682
DMP8RQ4 MW 365.4
DMP8RQ4 FM C16H15NO7S
DMP8RQ4 IC InChI=1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)
DMP8RQ4 CS CC1=CC=C(C=C1)S(=O)(=O)OCC(=O)NC2=CC(=C(C=C2)C(=O)O)O
DMP8RQ4 IK HWNUSGNZBAISFM-UHFFFAOYSA-N
DMP8RQ4 IU 2-hydroxy-4-[[2-(4-methylphenyl)sulfonyloxyacetyl]amino]benzoic acid
DMP8RQ4 CA CAS 501919-59-1
DMP8RQ4 CB CHEBI:91224
DMWMZE4 ID DMWMZE4
DMWMZE4 DN PMID26394986-Compound-11
DMWMZE4 HS Patented
DMWMZE4 CP H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMWMZE4 DT Small molecular drug
DMWMZE4 PC 341
DMWMZE4 MW 322.22
DMWMZE4 FM C14H10O9
DMWMZE4 IC InChI=1S/C14H10O9/c15-7-2-6(3-8(16)11(7)18)14(22)23-10-4-5(13(20)21)1-9(17)12(10)19/h1-4,15-19H,(H,20,21)
DMWMZE4 CS C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)O
DMWMZE4 IK COVFEVWNJUOYRL-UHFFFAOYSA-N
DMWMZE4 IU 3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoic acid
DMWMZE4 CA CAS 536-08-3
DMWMZE4 CB CHEBI:30814
DMTSQXE ID DMTSQXE
DMTSQXE DN PMID26394986-Compound-12
DMTSQXE HS Patented
DMTSQXE CP H. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMTSQXE DT Small molecular drug
DMTSQXE PC 237973
DMTSQXE MW 637.5
DMTSQXE FM C25H19NO15S2
DMTSQXE IC InChI=1S/C25H19NO15S2/c27-17-4-11(24(32)33)5-19(22(17)30)41-25(34)15-8-18(28)23(31)21(29)16(15)9-26-12-2-1-10-3-13(42(35,36)37)7-20(14(10)6-12)43(38,39)40/h1-8,26-31H,9H2,(H,32,33)(H,35,36,37)(H,38,39,40)
DMTSQXE CS C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)O)S(=O)(=O)O)NCC3=C(C(=C(C=C3C(=O)OC4=CC(=CC(=C4O)O)C(=O)O)O)O)O
DMTSQXE IK AIBIWCKHWTUBPW-UHFFFAOYSA-N
DMTSQXE IU 3-[2-[[(6,8-disulfonaphthalen-2-yl)amino]methyl]-3,4,5-trihydroxybenzoyl]oxy-4,5-dihydroxybenzoic acid
DMTSQXE CA CAS 6635-00-3
DMBUZHO ID DMBUZHO
DMBUZHO DN PMID26394986-Compound-13
DMBUZHO HS Patented
DMBUZHO DT Small molecular drug
DMBUZHO PC 24767791
DMBUZHO MW 550.7
DMBUZHO FM C30H34N2O6S
DMBUZHO IC InChI=1S/C30H34N2O6S/c1-21-8-15-26(16-9-21)39(37,38)31(2)20-29(34)32(25-14-17-27(30(35)36)28(33)18-25)19-22-10-12-24(13-11-22)23-6-4-3-5-7-23/h8-18,23,33H,3-7,19-20H2,1-2H3,(H,35,36)
DMBUZHO CS CC1=CC=C(C=C1)S(=O)(=O)N(C)CC(=O)N(CC2=CC=C(C=C2)C3CCCCC3)C4=CC(=C(C=C4)C(=O)O)O
DMBUZHO IK DMZMMAPPHDCECB-UHFFFAOYSA-N
DMBUZHO IU 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid
DMF9J0Y ID DMF9J0Y
DMF9J0Y DN PMID26394986-Compound-20
DMF9J0Y HS Patented
DMF9J0Y CP H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INCH. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMF9J0Y DT Small molecular drug
DMF9J0Y PC 76336555
DMF9J0Y MW 550.7
DMF9J0Y FM C30H34N2O6S
DMF9J0Y IC InChI=1S/C30H34N2O6S/c1-21-8-15-26(16-9-21)39(37,38)31(2)20-29(34)32(25-14-17-28(33)27(18-25)30(35)36)19-22-10-12-24(13-11-22)23-6-4-3-5-7-23/h8-18,23,33H,3-7,19-20H2,1-2H3,(H,35,36)
DMF9J0Y CS CC1=CC=C(C=C1)S(=O)(=O)N(C)CC(=O)N(CC2=CC=C(C=C2)C3CCCCC3)C4=CC(=C(C=C4)O)C(=O)O
DMF9J0Y IK PTAQXAOGPHGSTK-UHFFFAOYSA-N
DMF9J0Y IU 5-[(4-cyclohexylphenyl)methyl-[2-[methyl-(4-methylphenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid
DMLMQD4 ID DMLMQD4
DMLMQD4 DN PMID26394986-Compound-21
DMLMQD4 HS Patented
DMLMQD4 CP H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INCH. Lee Moffitt Cancer Center and Research Institute, University of Central Florida Research Foundation
DMLMQD4 DT Small molecular drug
DMLMQD4 PC 73672447
DMLMQD4 MW 521.6
DMLMQD4 FM C33H31NO5
DMLMQD4 IC InChI=1S/C33H31NO5/c35-31-20-17-27(21-30(31)33(37)38)34(22-23-11-13-25(14-12-23)24-7-3-1-4-8-24)32(36)26-15-18-29(19-16-26)39-28-9-5-2-6-10-28/h2,5-6,9-21,24,35H,1,3-4,7-8,22H2,(H,37,38)
DMLMQD4 CS C1CCC(CC1)C2=CC=C(C=C2)CN(C3=CC(=C(C=C3)O)C(=O)O)C(=O)C4=CC=C(C=C4)OC5=CC=CC=C5
DMLMQD4 IK ZJMHQDKLWUWPDR-UHFFFAOYSA-N
DMLMQD4 IU 5-[(4-cyclohexylphenyl)methyl-(4-phenoxybenzoyl)amino]-2-hydroxybenzoic acid
DM43Z1G ID DM43Z1G
DM43Z1G DN PMID26394986-Compound-22
DM43Z1G HS Patented
DM43Z1G CP G. D. SEARLE & CO. GAO, Danchen HLINAK, Anthony, J. MAZHARY, Ahmad, M. TRUELOVE, James, E. VAUGHN, Margaret, B., Woodhull
DM43Z1G DT Small molecular drug
DM43Z1G PC 2662
DM43Z1G MW 381.4
DM43Z1G FM C17H14F3N3O2S
DM43Z1G IC InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
DM43Z1G CS CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
DM43Z1G IK RZEKVGVHFLEQIL-UHFFFAOYSA-N
DM43Z1G IU 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DM43Z1G CA CAS 169590-42-5
DM43Z1G CB CHEBI:41423
DM2E6M7 ID DM2E6M7
DM2E6M7 DN PMID26394986-Compound-42
DM2E6M7 HS Patented
DM2E6M7 DT Small molecular drug
DM2E6M7 PC 9799188
DM2E6M7 MW 364.6
DM2E6M7 FM C24H44O2
DM2E6M7 IC InChI=1S/C24H44O2/c1-21-22(24(2,3)19-18-23(21)26)17-15-13-11-9-7-5-4-6-8-10-12-14-16-20-25/h25H,4-20H2,1-3H3
DM2E6M7 CS CC1=C(C(CCC1=O)(C)C)CCCCCCCCCCCCCCCO
DM2E6M7 IK FGMAOXGOTRUOKJ-UHFFFAOYSA-N
DM2E6M7 IU 3-(15-hydroxypentadecyl)-2,4,4-trimethylcyclohex-2-en-1-one
DM2E6M7 CA CAS 220757-88-0
DM1HIEZ ID DM1HIEZ
DM1HIEZ DN PMID26394986-Compound-43
DM1HIEZ HS Patented
DM1HIEZ CP The Ohio University
DM1HIEZ DT Small molecular drug
DM1HIEZ PC 46911017
DM1HIEZ MW 303.29
DM1HIEZ FM C14H9NO5S
DM1HIEZ IC InChI=1S/C14H9NO5S/c15-21(19,20)10-6-2-4-8-12(10)14(18)7-3-1-5-9(16)11(7)13(8)17/h1-6,16H,(H2,15,19,20)
DM1HIEZ CS C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C(=CC=C3)S(=O)(=O)N
DM1HIEZ IK CQBHSRLUQDYPBU-UHFFFAOYSA-N
DM1HIEZ IU 5-hydroxy-9,10-dioxoanthracene-1-sulfonamide
DM1HIEZ CA CAS 1260247-42-4
DMOJ52P ID DMOJ52P
DMOJ52P DN PMID26394986-Compound-44
DMOJ52P HS Patented
DMOJ52P DT Small molecular drug
DMOJ52P PC 65064
DMOJ52P MW 458.4
DMOJ52P FM C22H18O11
DMOJ52P IC InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMOJ52P CS C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMOJ52P IK WMBWREPUVVBILR-WIYYLYMNSA-N
DMOJ52P IU [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMOJ52P CA CAS 989-51-5
DMOJ52P CB CHEBI:4806
DML5I9K ID DML5I9K
DML5I9K DN PMID26394986-Compound-50
DML5I9K HS Patented
DML5I9K CP BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DML5I9K DT Small molecular drug
DML5I9K PC 9881541
DML5I9K MW 256.209
DML5I9K FM C14H8O5
DML5I9K IC InChI=1S/C14H8O5/c1-6(15)10-5-8-12(17)7-3-2-4-9(16)11(7)13(18)14(8)19-10/h2-5,16H,1H3
DML5I9K CS CC(=O)C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC=C3O
DML5I9K IK MYDAXHYLQBNETF-UHFFFAOYSA-N
DML5I9K IU 2-acetyl-8-hydroxybenzo[f][1]benzofuran-4,9-dione
DML5I9K CA CAS 123297-91-6
DMV6GIC ID DMV6GIC
DMV6GIC DN PMID26394986-Compound-51
DMV6GIC HS Patented
DMV6GIC CP BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMV6GIC DT Small molecular drug
DMV6GIC PC 118707758
DMV6GIC MW 334.3
DMV6GIC FM C19H10O4S
DMV6GIC IC InChI=1S/C19H10O4S/c20-13-8-4-7-11-15(13)18(23)19-12(17(11)22)9-14(24-19)16(21)10-5-2-1-3-6-10/h1-9,20H
DMV6GIC CS C1=CC=C(C=C1)C(=O)C2=CC3=C(S2)C(=O)C4=C(C3=O)C=CC=C4O
DMV6GIC IK FLMLYZNKLBTMFK-UHFFFAOYSA-N
DMV6GIC IU 2-benzoyl-8-hydroxybenzo[f][1]benzothiole-4,9-dione
DMSZWAM ID DMSZWAM
DMSZWAM DN PMID26394986-Compound-52
DMSZWAM HS Patented
DMSZWAM CP BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMSZWAM DT Small molecular drug
DMS6EDU ID DMS6EDU
DMS6EDU DN PMID26394986-Compound-53
DMS6EDU HS Patented
DMS6EDU CP BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMS6EDU DT Small molecular drug
DMS6EDU PC 25226944
DMS6EDU MW 274.65
DMS6EDU FM C14H7ClO4
DMS6EDU IC InChI=1S/C14H7ClO4/c1-6(16)11-5-10-12(17)8-3-2-7(15)4-9(8)13(18)14(10)19-11/h2-5H,1H3
DMS6EDU CS CC(=O)C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC(=C3)Cl
DMS6EDU IK RVIUPSHRLLQFOH-UHFFFAOYSA-N
DMS6EDU IU 2-acetyl-7-chlorobenzo[f][1]benzofuran-4,9-dione
DMY8FZA ID DMY8FZA
DMY8FZA DN PMID26394986-Compound-54
DMY8FZA HS Patented
DMY8FZA CP BOSTON BIOMEDICAL, INC. JIANG, Zhiwei LI, Chiang, Jia LI, Wei LEGGETT, David
DMY8FZA DT Small molecular drug
DMY8FZA PC 25226945
DMY8FZA MW 258.2
DMY8FZA FM C14H7FO4
DMY8FZA IC InChI=1S/C14H7FO4/c1-6(16)11-5-10-12(17)8-3-2-7(15)4-9(8)13(18)14(10)19-11/h2-5H,1H3
DMY8FZA CS CC(=O)C1=CC2=C(O1)C(=O)C3=C(C2=O)C=CC(=C3)F
DMY8FZA IK RPCXZIRGAHYOKZ-UHFFFAOYSA-N
DMY8FZA IU 2-acetyl-7-fluorobenzo[f][1]benzofuran-4,9-dione
DMPNJ4X ID DMPNJ4X
DMPNJ4X DN PMID26394986-Compound-56
DMPNJ4X HS Patented
DMPNJ4X CP THOMAS JEFFERSON UNIVERSITY
DMPNJ4X DT Small molecular drug
DMILUT8 ID DMILUT8
DMILUT8 DN PMID26394986-Compound-57
DMILUT8 HS Patented
DMILUT8 CP THOMAS JEFFERSON UNIVERSITY
DMILUT8 DT Small molecular drug
DMNEGA0 ID DMNEGA0
DMNEGA0 DN PMID26394986-Compound-Figure16
DMNEGA0 HS Patented
DMNEGA0 CP OTSUKA PHARMACEUTICAL CO., LTD. SEKIGUCHI, Kazuo SUZUKI, Takashi OHBUCHI, Yutaka OKUNO, Mitsuhiro OHI, Naoto OHNISHI, Kenji MOTOYAMA, Masaaki YOSHIDA, Kenji KODAMA, Takeshi SUGIYAMA, Kazuhisa AKAMATSU, Seiji KIYONO, Kunihiko YANAGIHARA, Yasuo WATANABE, Takashi HAYASHI, Kazuhiko TANAKA, Hideo SUMIDA, Takumi
DMNEGA0 DT Small molecular drug
DMEGBHP ID DMEGBHP
DMEGBHP DN PMID26394986-Compound-Figure17
DMEGBHP HS Patented
DMEGBHP CP Meiji Dairies Corporation
DMEGBHP DT Small molecular drug
DMNOJGW ID DMNOJGW
DMNOJGW DN PMID26413912-Compound-84
DMNOJGW HS Patented
DMNOJGW CP BIAL-Portela & Ca., S.A
DMNOJGW DT Small molecular drug
DMNOJGW PC 91008342
DMNOJGW MW 379.31
DMNOJGW FM C17H15F2N3O5
DMNOJGW IC InChI=1S/C17H15F2N3O5/c1-24-6-7-25-15-9-11(3-4-13(15)20)22-17(23)27-16(21-22)26-14-5-2-10(18)8-12(14)19/h2-5,8-9H,6-7,20H2,1H3
DMNOJGW CS COCCOC1=C(C=CC(=C1)N2C(=O)OC(=N2)OC3=C(C=C(C=C3)F)F)N
DMNOJGW IK AYJCMQZJZQQNKN-UHFFFAOYSA-N
DMNOJGW IU 3-[4-amino-3-(2-methoxyethoxy)phenyl]-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one
DM9V13U ID DM9V13U
DM9V13U DN PMID26560362-Compound-90
DM9V13U HS Patented
DM9V13U DT Small molecular drug
DM9V13U PC 9948627
DM9V13U MW 311.2
DM9V13U FM C14H12Cl2N2O2
DM9V13U IC InChI=1S/C14H12Cl2N2O2/c1-20-13-5-2-8(6-12(13)17)14(19)18-9-3-4-10(15)11(16)7-9/h2-7H,17H2,1H3,(H,18,19)
DM9V13U CS COC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)Cl)N
DM9V13U IK ZKXFJDCWWSKUHN-UHFFFAOYSA-N
DM9V13U IU 3-amino-N-(3,4-dichlorophenyl)-4-methoxybenzamide
DMSI7F2 ID DMSI7F2
DMSI7F2 DN PMID26560530-Compound-1
DMSI7F2 HS Patented
DMSI7F2 CP Syntex, Inc
DMSI7F2 DT Small molecular drug
DMZ5UST ID DMZ5UST
DMZ5UST DN PMID26560530-Compound-11
DMZ5UST HS Patented
DMZ5UST CP N Zyme Biotech GmbH
DMZ5UST DT Small molecular drug
DMA8JGP ID DMA8JGP
DMA8JGP DN PMID26560530-Compound-12
DMA8JGP HS Patented
DMA8JGP CP N Zyme Biotech GmbH
DMA8JGP DT Small molecular drug
DMKF26Z ID DMKF26Z
DMKF26Z DN PMID26560530-Compound-13
DMKF26Z HS Patented
DMKF26Z CP Apotex Inc
DMKF26Z DT Small molecular drug
DMKF26Z PC 11202494
DMKF26Z MW 482.5
DMKF26Z FM C18H22N6O6S2
DMKF26Z IC InChI=1S/C18H22N6O6S2/c25-16(26)13-22(17-21-31-18-19-10-12-23(17)18)11-6-2-1-5-9-20-32(29,30)15-8-4-3-7-14(15)24(27)28/h3-4,7-8,10,12,20H,1-2,5-6,9,11,13H2,(H,25,26)
DMKF26Z CS C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)NCCCCCCN(CC(=O)O)C2=NSC3=NC=CN23
DMKF26Z IK NCXBWLQKBKSTHD-UHFFFAOYSA-N
DMKF26Z IU 2-[imidazo[1,2-d][1,2,4]thiadiazol-3-yl-[6-[(2-nitrophenyl)sulfonylamino]hexyl]amino]acetic acid
DM52MIK ID DM52MIK
DM52MIK DN PMID26560530-Compound-14
DM52MIK HS Patented
DM52MIK CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. STEIN, Ross, L. CASE, April YEH, Li-An CUNY, Greg DUVAL, Eric
DM52MIK DT Small molecular drug
DM52MIK PC 1150683
DM52MIK MW 408.5
DM52MIK FM C20H16N4O2S2
DM52MIK IC InChI=1S/C20H16N4O2S2/c21-23-16(25)12-28-20-22-18-17(15(11-27-18)13-7-3-1-4-8-13)19(26)24(20)14-9-5-2-6-10-14/h1-11H,12,21H2,(H,23,25)
DM52MIK CS C1=CC=C(C=C1)C2=CSC3=C2C(=O)N(C(=N3)SCC(=O)NN)C4=CC=CC=C4
DM52MIK IK WLBUICQBNZXIDJ-UHFFFAOYSA-N
DM52MIK IU 2-(4-oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)sulfanylacetohydrazide
DM1ZSEI ID DM1ZSEI
DM1ZSEI DN PMID26560530-Compound-15
DM1ZSEI HS Patented
DM1ZSEI CP ALVINE PHARMACEUTICALS, INC. PHARMIX CORPORATION GRIFFIN, John LANZA, Guido BOARDMAN, Paul SPENCER, Andrew
DM1ZSEI DT Small molecular drug
DM1ZSEI PC 3604365
DM1ZSEI MW 306.27
DM1ZSEI FM C17H10N2O4
DM1ZSEI IC InChI=1S/C17H10N2O4/c20-14-10-6-8(1-3-12(10)18-16(14)22)5-9-2-4-13-11(7-9)15(21)17(23)19-13/h1-4,6-7H,5H2,(H,18,20,22)(H,19,21,23)
DM1ZSEI CS C1=CC2=C(C=C1CC3=CC4=C(C=C3)NC(=O)C4=O)C(=O)C(=O)N2
DM1ZSEI IK ZWPNSXUXJWRFIZ-UHFFFAOYSA-N
DM1ZSEI IU 5-[(2,3-dioxo-1H-indol-5-yl)methyl]-1H-indole-2,3-dione
DM8UI4Z ID DM8UI4Z
DM8UI4Z DN PMID26560530-Compound-16
DM8UI4Z HS Patented
DM8UI4Z CP ALVINE PHARMACEUTICALS, INC. PHARMIX CORPORATION GRIFFIN, John LANZA, Guido BOARDMAN, Paul SPENCER, Andrew
DM8UI4Z DT Small molecular drug
DMITU83 ID DMITU83
DMITU83 DN PMID26560530-Compound-17
DMITU83 HS Patented
DMITU83 CP NATIONAL CANCER CENTER KIM, Soo Youl
DMITU83 DT Small molecular drug
DMK39S5 ID DMK39S5
DMK39S5 DN PMID26560530-Compound-18
DMK39S5 HS Patented
DMK39S5 CP Stanford University
DMK39S5 DT Small molecular drug
DMK39S5 PC 644315
DMK39S5 MW 499.4
DMK39S5 FM C23H23BrN4O4
DMK39S5 IC InChI=1S/C23H23BrN4O4/c24-21-11-17(32-28-21)13-26-22(29)20(10-16-12-25-19-9-5-4-8-18(16)19)27-23(30)31-14-15-6-2-1-3-7-15/h1-9,12,17,20,25H,10-11,13-14H2,(H,26,29)(H,27,30)/t17?,20-/m0/s1
DMK39S5 CS C1C(ON=C1Br)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC=CC=C4
DMK39S5 IK MAQVWGRATZCTBU-OZBJMMHXSA-N
DMK39S5 IU benzyl N-[(2S)-1-[(3-bromo-4,5-dihydro-1,2-oxazol-5-yl)methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate
DMK39S5 CA CAS 744198-17-2
DMC7AXQ ID DMC7AXQ
DMC7AXQ DN PMID26560530-Compound-2
DMC7AXQ HS Patented
DMC7AXQ CP Syntex, Inc
DMC7AXQ DT Small molecular drug
DMDS2CU ID DMDS2CU
DMDS2CU DN PMID26560530-Compound-23
DMDS2CU HS Patented
DMDS2CU CP National Cancer Center (S. Korea)
DMDS2CU DT Small molecular drug
DMDS2CU PC 5281767
DMDS2CU MW 368.4
DMDS2CU FM C21H20O6
DMDS2CU IC InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13-
DMDS2CU CS COC1=C(C=CC(=C1)/C=C/C(=C/C(=O)/C=C/C2=CC(=C(C=C2)O)OC)/O)O
DMDS2CU IK ZIUSSTSXXLLKKK-KOBPDPAPSA-N
DMDS2CU IU (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
DMWCM2I ID DMWCM2I
DMWCM2I DN PMID26560530-Compound-24
DMWCM2I HS Patented
DMWCM2I CP NATIONAL CANCER CENTER KIM, Soo Youl LEE, Chang Hoon
DMWCM2I DT Small molecular drug
DMWCM2I PC 4534
DMWCM2I MW 302.4
DMWCM2I FM C18H22O4
DMWCM2I IC InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3
DMWCM2I CS CC(CC1=CC(=C(C=C1)O)O)C(C)CC2=CC(=C(C=C2)O)O
DMWCM2I IK HCZKYJDFEPMADG-UHFFFAOYSA-N
DMWCM2I IU 4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
DMWCM2I CA CAS 500-38-9
DMWCM2I CB CHEBI:7625
DMZ43OM ID DMZ43OM
DMZ43OM DN PMID26560530-Compound-25
DMZ43OM HS Patented
DMZ43OM CP National Cancer Center (S. Korea)
DMZ43OM DT Small molecular drug
DMZ43OM PC 2194
DMZ43OM MW 240.4
DMZ43OM FM C10H8OS3
DMZ43OM IC InChI=1S/C10H8OS3/c1-11-8-4-2-7(3-5-8)9-6-10(12)14-13-9/h2-6H,1H3
DMZ43OM CS COC1=CC=C(C=C1)C2=CC(=S)SS2
DMZ43OM IK KYLIZBIRMBGUOP-UHFFFAOYSA-N
DMZ43OM IU 5-(4-methoxyphenyl)dithiole-3-thione
DMZ43OM CA CAS 532-11-6
DMZ43OM CB CHEBI:31221
DMVEQ2P ID DMVEQ2P
DMVEQ2P DN PMID26560530-Compound-26
DMVEQ2P HS Patented
DMVEQ2P CP National Cancer Center (S. Korea)
DMVEQ2P DT Small molecular drug
DMVEQ2P PC 65064
DMVEQ2P MW 458.4
DMVEQ2P FM C22H18O11
DMVEQ2P IC InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1
DMVEQ2P CS C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMVEQ2P IK WMBWREPUVVBILR-WIYYLYMNSA-N
DMVEQ2P IU [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMVEQ2P CA CAS 989-51-5
DMVEQ2P CB CHEBI:4806
DM8WP3D ID DM8WP3D
DM8WP3D DN PMID26560530-Compound-27
DM8WP3D HS Patented
DM8WP3D CP NATIONAL CANCER CENTER KIM, Soo Youl LEE, Chang Hoon
DM8WP3D DT Small molecular drug
DM92OT0 ID DM92OT0
DM92OT0 DN PMID26560530-Compound-3
DM92OT0 HS Patented
DM92OT0 CP Merck & Co., Inc
DM92OT0 DT Small molecular drug
DM74GUB ID DM74GUB
DM74GUB DN PMID26560530-Compound-31
DM74GUB HS Patented
DM74GUB CP Aston University
DM74GUB DT Small molecular drug
DM74GUB PC 11433028
DM74GUB MW 487.6
DM74GUB FM C25H31N2O6S+
DM74GUB IC InChI=1S/C25H30N2O6S/c1-34(2)17-20(28)13-14-21(24(30)31)26-23(29)22(15-18-9-5-3-6-10-18)27-25(32)33-16-19-11-7-4-8-12-19/h3-12,21-22H,13-17H2,1-2H3,(H2-,26,27,29,30,31,32)/p+1/t21-,22-/m0/s1
DM74GUB CS C[S+](C)CC(=O)CC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
DM74GUB IK MQKDBWQFOOQINN-VXKWHMMOSA-O
DM74GUB IU [(5S)-5-carboxy-2-oxo-5-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentyl]-dimethylsulfanium
DM2QWXF ID DM2QWXF
DM2QWXF DN PMID26560530-Compound-32
DM2QWXF HS Patented
DM2QWXF CP Aston University
DM2QWXF DT Small molecular drug
DM2QWXF PC 16049202
DM2QWXF MW 437.5
DM2QWXF FM C21H29N2O6S+
DM2QWXF IC InChI=1S/C21H28N2O6S/c1-30(2)14-16(24)10-11-17(20(26)27)22-19(25)18-9-6-12-23(18)21(28)29-13-15-7-4-3-5-8-15/h3-5,7-8,17-18H,6,9-14H2,1-2H3,(H-,22,25,26,27)/p+1/t17-,18-/m0/s1
DM2QWXF CS C[S+](C)CC(=O)CC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)OCC2=CC=CC=C2
DM2QWXF IK SKEWALVSEUJDCH-ROUUACIJSA-O
DM2QWXF IU [(5S)-5-carboxy-2-oxo-5-[[(2S)-1-phenylmethoxycarbonylpyrrolidine-2-carbonyl]amino]pentyl]-dimethylsulfanium
DMUL84D ID DMUL84D
DMUL84D DN PMID26560530-Compound-33
DMUL84D HS Patented
DMUL84D CP National Cancer Center (S. Korea)
DMUL84D DT Small molecular drug
DMLGZPO ID DMLGZPO
DMLGZPO DN PMID26560530-Compound-34
DMLGZPO HS Patented
DMLGZPO CP National Cancer Center (S. Korea)
DMLGZPO DT Small molecular drug
DMLGZPO PC 47318
DMLGZPO MW 226.3
DMLGZPO FM C8H6N2S3
DMLGZPO IC InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3
DMLGZPO CS CC1=C(SSC1=S)C2=NC=CN=C2
DMLGZPO IK CKNAQFVBEHDJQV-UHFFFAOYSA-N
DMLGZPO IU 4-methyl-5-pyrazin-2-yldithiole-3-thione
DMLGZPO CA CAS 64224-21-1
DMLGZPO CB CHEBI:77319
DMO36RL ID DMO36RL
DMO36RL DN PMID26560530-Compound-35
DMO36RL HS Patented
DMO36RL CP University of Texas
DMO36RL DT Small molecular drug
DMO36RL PC 5281847
DMO36RL MW 516.5
DMO36RL FM C30H28O8
DMO36RL IC InChI=1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+
DMO36RL CS CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)/C=C/C4=CC=CC=C4)O)O
DMO36RL IK DEZFNHCVIZBHBI-ZHACJKMWSA-N
DMO36RL IU (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
DMO36RL CA CAS 82-08-6
DMO36RL CB CHEBI:8899
DMEZLBQ ID DMEZLBQ
DMEZLBQ DN PMID26560530-Compound-4
DMEZLBQ HS Patented
DMEZLBQ CP Merck & Co., Inc
DMEZLBQ DT Small molecular drug
DMTOJCG ID DMTOJCG
DMTOJCG DN PMID26560530-Compound-46
DMTOJCG HS Patented
DMTOJCG CP Leland Stanford Junior University
DMTOJCG DT Small molecular drug
DMWC1IY ID DMWC1IY
DMWC1IY DN PMID26560530-Compound-47
DMWC1IY HS Patented
DMWC1IY CP Leland Stanford Junior University
DMWC1IY DT Small molecular drug
DMXV0CK ID DMXV0CK
DMXV0CK DN PMID26560530-Compound-48
DMXV0CK HS Patented
DMXV0CK CP Leland Stanford Junior University
DMXV0CK DT Small molecular drug
DMST6C2 ID DMST6C2
DMST6C2 DN PMID26560530-Compound-49
DMST6C2 HS Patented
DMST6C2 CP University of Texas
DMST6C2 DT Small molecular drug
DMST6C2 PC 2810536
DMST6C2 MW 420.8
DMST6C2 FM C17H14ClFN6O2S
DMST6C2 IC InChI=1S/C17H14ClFN6O2S/c1-10(26)20-11-3-2-4-13(7-11)25-23-17(22-24-25)28-9-16(27)21-12-5-6-15(19)14(18)8-12/h2-8H,9H2,1H3,(H,20,26)(H,21,27)
DMST6C2 CS CC(=O)NC1=CC(=CC=C1)N2N=C(N=N2)SCC(=O)NC3=CC(=C(C=C3)F)Cl
DMST6C2 IK NIWRZNPQACMKRY-UHFFFAOYSA-N
DMST6C2 IU 2-[2-(3-acetamidophenyl)tetrazol-5-yl]sulfanyl-N-(3-chloro-4-fluorophenyl)acetamide
DM6G2WJ ID DM6G2WJ
DM6G2WJ DN PMID26560530-Compound-5
DM6G2WJ HS Patented
DM6G2WJ CP Merck & Co., Inc
DM6G2WJ DT Small molecular drug
DMHZ8N1 ID DMHZ8N1
DMHZ8N1 DN PMID26560530-Compound-50
DMHZ8N1 HS Patented
DMHZ8N1 CP University of Texas
DMHZ8N1 DT Small molecular drug
DMHZ8N1 PC 2810543
DMHZ8N1 MW 420.4
DMHZ8N1 FM C20H16N6O3S
DMHZ8N1 IC InChI=1S/C20H16N6O3S/c1-13(27)21-15-8-5-9-16(10-15)26-23-20(22-25-26)30-12-18(28)19-11-17(24-29-19)14-6-3-2-4-7-14/h2-11H,12H2,1H3,(H,21,27)
DMHZ8N1 CS CC(=O)NC1=CC(=CC=C1)N2N=C(N=N2)SCC(=O)C3=CC(=NO3)C4=CC=CC=C4
DMHZ8N1 IK ZSSIYCOJZBCFEO-UHFFFAOYSA-N
DMHZ8N1 IU N-[3-[5-[2-oxo-2-(3-phenyl-1,2-oxazol-5-yl)ethyl]sulfanyltetrazol-2-yl]phenyl]acetamide
DM2X4R0 ID DM2X4R0
DM2X4R0 DN PMID26560530-Compound-54
DM2X4R0 HS Patented
DM2X4R0 CP Japan Science and Technology Agency
DM2X4R0 DT Small molecular drug
DM2X4R0 PC 46231396
DM2X4R0 MW 225.28
DM2X4R0 FM C12H19NO3
DM2X4R0 IC InChI=1S/C12H19NO3/c1-10(2)13(7-8-14)6-5-11(15)12-4-3-9-16-12/h3-4,9-10,14H,5-8H2,1-2H3
DM2X4R0 CS CC(C)N(CCC(=O)C1=CC=CO1)CCO
DM2X4R0 IK DCZMNFQBOIDRNH-UHFFFAOYSA-N
DM2X4R0 IU 1-(furan-2-yl)-3-[2-hydroxyethyl(propan-2-yl)amino]propan-1-one
DMMHL2C ID DMMHL2C
DMMHL2C DN PMID26560530-Compound-6
DMMHL2C HS Patented
DMMHL2C CP Merck & Co., Inc
DMMHL2C DT Small molecular drug
DMRAXD1 ID DMRAXD1
DMRAXD1 DN PMID26560530-Compound-7
DMRAXD1 HS Patented
DMRAXD1 CP Merck & Co., Inc
DMRAXD1 DT Small molecular drug
DMRAXD1 PC 6193963
DMRAXD1 MW 188.18
DMRAXD1 FM C10H8N2O2
DMRAXD1 IC InChI=1S/C10H8N2O2/c13-10(14)6-5-9-11-7-3-1-2-4-8(7)12-9/h1-6H,(H,11,12)(H,13,14)/b6-5+
DMRAXD1 CS C1=CC=C2C(=C1)NC(=N2)/C=C/C(=O)O
DMRAXD1 IK FEGNPBYZFFAMCR-AATRIKPKSA-N
DMRAXD1 IU (E)-3-(1H-benzimidazol-2-yl)prop-2-enoic acid
DMN6TG7 ID DMN6TG7
DMN6TG7 DN PMID26560530-Compound-8
DMN6TG7 HS Patented
DMN6TG7 CP University of Texas
DMN6TG7 DT Small molecular drug
DMN6TG7 PC 4247
DMN6TG7 MW 335.5
DMN6TG7 FM C17H25N3O2S
DMN6TG7 IC InChI=1S/C17H25N3O2S/c1-20(2)16-10-6-9-15-14(16)8-7-11-17(15)23(21,22)19-13-5-3-4-12-18/h6-11,19H,3-5,12-13,18H2,1-2H3
DMN6TG7 CS CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCCCN
DMN6TG7 IK MLEBFEHOJICQQS-UHFFFAOYSA-N
DMN6TG7 IU N-(5-aminopentyl)-5-(dimethylamino)naphthalene-1-sulfonamide
DMN6TG7 CA CAS 10121-91-2
DMN6TG7 CB CHEBI:52007
DMBYTSI ID DMBYTSI
DMBYTSI DN PMID26609882-Compound-34
DMBYTSI HS Patented
DMBYTSI CP ARENA PHARMACEUTICALS, INC. TEEGARDEN, Bradley JAYAKUMAR, Honnappa LI, Hongmei STRAH-PLEYNET, Sonja DOSA, Peter, Ian
DMBYTSI DT Small molecular drug
DM8OLYQ ID DM8OLYQ
DM8OLYQ DN PMID26609882-Compound-35
DM8OLYQ HS Patented
DM8OLYQ CP ARENA PHARMACEUTICALS, INC. TEEGARDEN, Bradley JAYAKUMAR, Honnappa LI, Hongmei STRAH-PLEYNET, Sonja DOSA, Peter, Ian
DM8OLYQ DT Small molecular drug
DMFT3RM ID DMFT3RM
DMFT3RM DN PMID26609882-Compound-36
DMFT3RM HS Patented
DMFT3RM CP ARENA PHARMACEUTICALS, INC. SELVEY, Lee, Alani CARLOS, Marlon V. MAFFUID, Paul SHAN, Yun BETTS, William, L., III GIVEN, Deam, Windate, III HART, Ryan, M. SHAO, Zezhi, Jesse
DMFT3RM DT Small molecular drug
DMFT3RM PC 11683556
DMFT3RM MW 437.2
DMFT3RM FM C18H15BrF2N4O2
DMFT3RM IC InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)
DMFT3RM CS CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC
DMFT3RM IK COSPVUFTLGQDQL-UHFFFAOYSA-N
DMFT3RM IU 1-[3-(4-bromo-2-methylpyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
DMFT3RM CA CAS 839713-36-9
DMD3T1Q ID DMD3T1Q
DMD3T1Q DN PMID26609882-Compound-58
DMD3T1Q HS Patented
DMD3T1Q CP LUNDBECK & CO AS H [DK]
DMD3T1Q DT Small molecular drug
DM6C45G ID DM6C45G
DM6C45G DN PMID26609882-Compound-83
DM6C45G HS Patented
DM6C45G CP Apotex Pharmachem IncTeva Pharmaceutical Industries LtdSynthon Ip IncU & I Pharmaceuticals, LtdGeneva Pharmaceuticals, IncEli Lilly and CompanLilly Industries LimitedKRKA, Tovarna Zdravil, D.D
DM6C45G DT Small molecular drug
DMOJVK6 ID DMOJVK6
DMOJVK6 DN PMID26651364-Compound-105
DMOJVK6 HS Patented
DMOJVK6 CP WASHINGTON UNIVERSITY
DMOJVK6 DT Carbohydrates
DMOJVK6 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQZJDF ID DMQZJDF
DMQZJDF DN PMID26651364-Compound-106
DMQZJDF HS Patented
DMQZJDF CP WASHINGTON UNIVERSITY
DMQZJDF DT Carbohydrates
DMQZJDF DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMZ1WL ID DMMZ1WL
DMMZ1WL DN PMID26651364-Compound-107
DMMZ1WL HS Patented
DMMZ1WL CP WASHINGTON UNIVERSITY
DMMZ1WL DT Carbohydrates
DMMZ1WL DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMA7D3K ID DMA7D3K
DMA7D3K DN PMID26651364-Compound-108
DMA7D3K HS Patented
DMA7D3K CP UNIVERSITY OF BASEL ERNST, Beat
DMA7D3K DT Carbohydrates
DMA7D3K DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM01IWV ID DM01IWV
DM01IWV DN PMID26651364-Compound-109
DM01IWV HS Patented
DM01IWV CP UNIVERSITY OF BASEL ERNST, Beat
DM01IWV DT Carbohydrates
DM01IWV DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMTPBNY ID DMTPBNY
DMTPBNY DN PMID26651364-Compound-10a
DMTPBNY HS Patented
DMTPBNY CP VERTEX PHARMACEUTICALS INCORPORATED
DMTPBNY DT Carbohydrates
DMTPBNY DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM16ANH ID DM16ANH
DM16ANH DN PMID26651364-Compound-10b
DM16ANH HS Patented
DM16ANH CP VERTEX PHARMACEUTICALS INCORPORATED
DM16ANH DT Carbohydrates
DM16ANH DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMCRNWA ID DMCRNWA
DMCRNWA DN PMID26651364-Compound-10c
DMCRNWA HS Patented
DMCRNWA CP VERTEX PHARMACEUTICALS INCORPORATED
DMCRNWA DT Carbohydrates
DMCRNWA DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMGIV3C ID DMGIV3C
DMGIV3C DN PMID26651364-Compound-10d
DMGIV3C HS Patented
DMGIV3C CP VERTEX PHARMACEUTICALS INCORPORATED
DMGIV3C DT Carbohydrates
DMGIV3C DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMPA3IX ID DMPA3IX
DMPA3IX DN PMID26651364-Compound-110
DMPA3IX HS Patented
DMPA3IX CP UNIVERSITY OF BASEL ERNST, Beat
DMPA3IX DT Carbohydrates
DMPA3IX DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMY9R58 ID DMY9R58
DMY9R58 DN PMID26651364-Compound-111
DMY9R58 HS Patented
DMY9R58 CP UNIVERSITY OF BASEL ERNST, Beat
DMY9R58 DT Carbohydrates
DMY9R58 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM1LIRP ID DM1LIRP
DM1LIRP DN PMID26651364-Compound-112
DM1LIRP HS Patented
DM1LIRP CP UNIVERSITY OF BASEL ERNST, Beat
DM1LIRP DT Carbohydrates
DM1LIRP DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6OQKM ID DM6OQKM
DM6OQKM DN PMID26651364-Compound-113
DM6OQKM HS Patented
DM6OQKM CP UNIVERSITY OF BASEL ERNST, Beat
DM6OQKM DT Carbohydrates
DM6OQKM DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM5GHJA ID DM5GHJA
DM5GHJA DN PMID26651364-Compound-114
DM5GHJA HS Patented
DM5GHJA CP UNIVERSITY OF BASEL ERNST, Beat
DM5GHJA DT Carbohydrates
DM5GHJA DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMHIA26 ID DMHIA26
DMHIA26 DN PMID26651364-Compound-115
DMHIA26 HS Patented
DMHIA26 CP UNIVERSITY OF BASEL ERNST, Beat
DMHIA26 DT Carbohydrates
DMHIA26 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMJ3201 ID DMJ3201
DMJ3201 DN PMID26651364-Compound-116
DMJ3201 HS Patented
DMJ3201 CP UNIVERSITY OF BASEL ERNST, Beat
DMJ3201 DT Carbohydrates
DMJ3201 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6LXHS ID DM6LXHS
DM6LXHS DN PMID26651364-Compound-117a
DM6LXHS HS Patented
DM6LXHS CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DM6LXHS DT Carbohydrates
DM6LXHS DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMUQSM1 ID DMUQSM1
DMUQSM1 DN PMID26651364-Compound-117b
DMUQSM1 HS Patented
DMUQSM1 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corrine
DMUQSM1 DT Carbohydrates
DMUQSM1 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6ZRV4 ID DM6ZRV4
DM6ZRV4 DN PMID26651364-Compound-118
DM6ZRV4 HS Patented
DM6ZRV4 CP VERTEX PHARMACEUTICALS INCORPORATED
DM6ZRV4 DT Carbohydrates
DM6ZRV4 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMONAZI ID DMONAZI
DMONAZI DN PMID26651364-Compound-119
DMONAZI HS Patented
DMONAZI CP VERTEX PHARMACEUTICALS INCORPORATED
DMONAZI DT Carbohydrates
DMONAZI DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMGBFK3 ID DMGBFK3
DMGBFK3 DN PMID26651364-Compound-11b
DMGBFK3 HS Patented
DMGBFK3 CP CENTRE NAT RECH SCIENT [FRUNIV D AUVERGNE [FRUNIV LILLE SCIENCES TECH [FRUNIV NANTES [FRINST NAT SANTE RECH MED [FR]
DMGBFK3 DT Carbohydrates
DMGBFK3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM76WBP ID DM76WBP
DM76WBP DN PMID26651364-Compound-11c
DM76WBP HS Patented
DM76WBP CP CENTRE NAT RECH SCIENT [FRUNIV D AUVERGNE [FRUNIV LILLE SCIENCES TECH [FRUNIV NANTES [FRINST NAT SANTE RECH MED [FR]
DM76WBP DT Carbohydrates
DM76WBP DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMZTBEQ ID DMZTBEQ
DMZTBEQ DN PMID26651364-Compound-120
DMZTBEQ HS Patented
DMZTBEQ CP VERTEX PHARMACEUTICALS INCORPORATED
DMZTBEQ DT Carbohydrates
DMZTBEQ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4ZG0Q ID DM4ZG0Q
DM4ZG0Q DN PMID26651364-Compound-121
DM4ZG0Q HS Patented
DM4ZG0Q CP VERTEX PHARMACEUTICALS INCORPORATED
DM4ZG0Q DT Carbohydrates
DM4ZG0Q DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMVFTIL ID DMVFTIL
DMVFTIL DN PMID26651364-Compound-122
DMVFTIL HS Patented
DMVFTIL CP VERTEX PHARMACEUTICALS INCORPORATED
DMVFTIL DT Carbohydrates
DMVFTIL DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMR0E5W ID DMR0E5W
DMR0E5W DN PMID26651364-Compound-123
DMR0E5W HS Patented
DMR0E5W CP VERTEX PHARMACEUTICALS INCORPORATED
DMR0E5W DT Carbohydrates
DMR0E5W DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6VER5 ID DM6VER5
DM6VER5 DN PMID26651364-Compound-124
DM6VER5 HS Patented
DM6VER5 CP VERTEX PHARMACEUTICALS INCORPORATED
DM6VER5 DT Carbohydrates
DM6VER5 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMINUDB ID DMINUDB
DMINUDB DN PMID26651364-Compound-125
DMINUDB HS Patented
DMINUDB CP VERTEX PHARMACEUTICALS INCORPORATED
DMINUDB DT Carbohydrates
DMINUDB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMSTKH6 ID DMSTKH6
DMSTKH6 DN PMID26651364-Compound-126a
DMSTKH6 HS Patented
DMSTKH6 CP VERTEX PHARMACEUTICALS INCORPORATED
DMSTKH6 DT Carbohydrates
DMSTKH6 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM2I1QZ ID DM2I1QZ
DM2I1QZ DN PMID26651364-Compound-126b
DM2I1QZ HS Patented
DM2I1QZ CP VERTEX PHARMACEUTICALS INCORPORATED
DM2I1QZ DT Carbohydrates
DM2I1QZ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM80PI1 ID DM80PI1
DM80PI1 DN PMID26651364-Compound-126c
DM80PI1 HS Patented
DM80PI1 CP VERTEX PHARMACEUTICALS INCORPORATED
DM80PI1 DT Carbohydrates
DM80PI1 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMEN8RA ID DMEN8RA
DMEN8RA DN PMID26651364-Compound-127
DMEN8RA HS Patented
DMEN8RA CP VERTEX PHARMACEUTICALS INCORPORATED
DMEN8RA DT Carbohydrates
DMEN8RA DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4W0BX ID DM4W0BX
DM4W0BX DN PMID26651364-Compound-128
DM4W0BX HS Patented
DM4W0BX CP VERTEX PHARMACEUTICALS INCORPORATED
DM4W0BX DT Carbohydrates
DM4W0BX DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMY0HP1 ID DMY0HP1
DMY0HP1 DN PMID26651364-Compound-4
DMY0HP1 HS Patented
DMY0HP1 CP THE WASHINGTON UNIVERSITY JANETKA, James W. HAN, Zhenfu HULTGREN, Scott PINKNER, Jerry CUSUMANO, Corinne
DMY0HP1 DT Carbohydrates
DMY0HP1 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMLBZGO ID DMLBZGO
DMLBZGO DN PMID26651364-Compound-45
DMLBZGO HS Patented
DMLBZGO CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMLBZGO DT Carbohydrates
DMLBZGO DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQFDU8 ID DMQFDU8
DMQFDU8 DN PMID26651364-Compound-46
DMQFDU8 HS Patented
DMQFDU8 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMQFDU8 DT Carbohydrates
DMQFDU8 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4S5PB ID DM4S5PB
DM4S5PB DN PMID26651364-Compound-47
DM4S5PB HS Patented
DM4S5PB CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM4S5PB DT Carbohydrates
DM4S5PB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMHXFGU ID DMHXFGU
DMHXFGU DN PMID26651364-Compound-48
DMHXFGU HS Patented
DMHXFGU CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMHXFGU DT Carbohydrates
DMHXFGU DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMV5A9 ID DMMV5A9
DMMV5A9 DN PMID26651364-Compound-49
DMMV5A9 HS Patented
DMMV5A9 CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DMMV5A9 DT Carbohydrates
DMMV5A9 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMH7XL3 ID DMH7XL3
DMH7XL3 DN PMID26651364-Compound-5
DMH7XL3 HS Patented
DMH7XL3 CP WASHINGTON UNIVERSITY
DMH7XL3 DT Carbohydrates
DMH7XL3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6GFYR ID DM6GFYR
DM6GFYR DN PMID26651364-Compound-50
DM6GFYR HS Patented
DM6GFYR CP UNIVERSITY OF BASEL ERNST, Beat HEROLD, Janno
DM6GFYR DT Carbohydrates
DM6GFYR DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM01GVE ID DM01GVE
DM01GVE DN PMID26651364-Compound-5a
DM01GVE HS Patented
DM01GVE CP WASHINGTON UNIVERSITY
DM01GVE DT Carbohydrates
DM01GVE DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMLHJ1E ID DMLHJ1E
DMLHJ1E DN PMID26651364-Compound-5b
DMLHJ1E HS Patented
DMLHJ1E CP WASHINGTON UNIVERSITY
DMLHJ1E DT Carbohydrates
DMLHJ1E DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMDQTA2 ID DMDQTA2
DMDQTA2 DN PMID26651364-Compound-5c
DMDQTA2 HS Patented
DMDQTA2 CP WASHINGTON UNIVERSITY
DMDQTA2 DT Carbohydrates
DMDQTA2 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMF6Z5I ID DMF6Z5I
DMF6Z5I DN PMID26651364-Compound-5d
DMF6Z5I HS Patented
DMF6Z5I CP WASHINGTON UNIVERSITY
DMF6Z5I DT Carbohydrates
DMF6Z5I DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM9TJR5 ID DM9TJR5
DM9TJR5 DN PMID26651364-Compound-5e
DM9TJR5 HS Patented
DM9TJR5 CP WASHINGTON UNIVERSITY
DM9TJR5 DT Carbohydrates
DM9TJR5 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMAZIY6 ID DMAZIY6
DMAZIY6 DN PMID26651364-Compound-5f
DMAZIY6 HS Patented
DMAZIY6 CP WASHINGTON UNIVERSITY
DMAZIY6 DT Carbohydrates
DMAZIY6 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMSW0HB ID DMSW0HB
DMSW0HB DN PMID26651364-Compound-5g
DMSW0HB HS Patented
DMSW0HB CP WASHINGTON UNIVERSITY
DMSW0HB DT Carbohydrates
DMSW0HB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM8HAJ3 ID DM8HAJ3
DM8HAJ3 DN PMID26651364-Compound-6a
DM8HAJ3 HS Patented
DM8HAJ3 CP VERTEX PHARMACEUTICALS INCORPORATED
DM8HAJ3 DT Carbohydrates
DM8HAJ3 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMBINOJ ID DMBINOJ
DMBINOJ DN PMID26651364-Compound-6b
DMBINOJ HS Patented
DMBINOJ CP VERTEX PHARMACEUTICALS INCORPORATED
DMBINOJ DT Carbohydrates
DMBINOJ DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMPF86L ID DMPF86L
DMPF86L DN PMID26651364-Compound-6c
DMPF86L HS Patented
DMPF86L CP VERTEX PHARMACEUTICALS INCORPORATED
DMPF86L DT Carbohydrates
DMPF86L DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM9J57W ID DM9J57W
DM9J57W DN PMID26651364-Compound-6d
DM9J57W HS Patented
DM9J57W CP VERTEX PHARMACEUTICALS INCORPORATED
DM9J57W DT Carbohydrates
DM9J57W DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM4LF0X ID DM4LF0X
DM4LF0X DN PMID26651364-Compound-6e
DM4LF0X HS Patented
DM4LF0X CP VERTEX PHARMACEUTICALS INCORPORATED
DM4LF0X DT Carbohydrates
DM4LF0X DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMQMBY9 ID DMQMBY9
DMQMBY9 DN PMID26651364-Compound-7a
DMQMBY9 HS Patented
DMQMBY9 CP VERTEX PHARMACEUTICALS INCORPORATED
DMQMBY9 DT Carbohydrates
DMQMBY9 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM3LCIM ID DM3LCIM
DM3LCIM DN PMID26651364-Compound-7b
DM3LCIM HS Patented
DM3LCIM CP VERTEX PHARMACEUTICALS INCORPORATED
DM3LCIM DT Carbohydrates
DM3LCIM DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMGCUJB ID DMGCUJB
DMGCUJB DN PMID26651364-Compound-7c
DMGCUJB HS Patented
DMGCUJB CP VERTEX PHARMACEUTICALS INCORPORATED
DMGCUJB DT Carbohydrates
DMGCUJB DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM89VQT ID DM89VQT
DM89VQT DN PMID26651364-Compound-7d
DM89VQT HS Patented
DM89VQT CP VERTEX PHARMACEUTICALS INCORPORATED
DM89VQT DT Carbohydrates
DM89VQT DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM2SZ0B ID DM2SZ0B
DM2SZ0B DN PMID26651364-Compound-7e
DM2SZ0B HS Patented
DM2SZ0B CP VERTEX PHARMACEUTICALS INCORPORATED
DM2SZ0B DT Carbohydrates
DM2SZ0B DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM1M3WF ID DM1M3WF
DM1M3WF DN PMID26651364-Compound-8a
DM1M3WF HS Patented
DM1M3WF CP VERTEX PHARMACEUTICALS INCORPORATED
DM1M3WF DT Carbohydrates
DM1M3WF DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMYVU36 ID DMYVU36
DMYVU36 DN PMID26651364-Compound-8b
DMYVU36 HS Patented
DMYVU36 CP VERTEX PHARMACEUTICALS INCORPORATED
DMYVU36 DT Carbohydrates
DMYVU36 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DME7UNT ID DME7UNT
DME7UNT DN PMID26651364-Compound-8c
DME7UNT HS Patented
DME7UNT CP VERTEX PHARMACEUTICALS INCORPORATED
DME7UNT DT Carbohydrates
DME7UNT DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMSO2F8 ID DMSO2F8
DMSO2F8 DN PMID26651364-Compound-8d
DMSO2F8 HS Patented
DMSO2F8 CP VERTEX PHARMACEUTICALS INCORPORATED
DMSO2F8 DT Carbohydrates
DMSO2F8 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMAXWPS ID DMAXWPS
DMAXWPS DN PMID26651364-Compound-9a
DMAXWPS HS Patented
DMAXWPS CP UNIVERSITY OF BASEL ERNST, Beat
DMAXWPS DT Carbohydrates
DMAXWPS DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM6HTU0 ID DM6HTU0
DM6HTU0 DN PMID26651364-Compound-9b
DM6HTU0 HS Patented
DM6HTU0 CP UNIVERSITY OF BASEL ERNST, Beat
DM6HTU0 DT Carbohydrates
DM6HTU0 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM49V8G ID DM49V8G
DM49V8G DN PMID26651364-Compound-9c
DM49V8G HS Patented
DM49V8G CP UNIVERSITY OF BASEL ERNST, Beat
DM49V8G DT Carbohydrates
DM49V8G DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMF0L3E ID DMF0L3E
DMF0L3E DN PMID26651364-Compound-9d
DMF0L3E HS Patented
DMF0L3E CP UNIVERSITY OF BASEL ERNST, Beat
DMF0L3E DT Carbohydrates
DMF0L3E DE Crohn disease; Ulcerative colitis; Urinary tract infection
DM9FIKD ID DM9FIKD
DM9FIKD DN PMID26651364-Compound-9e
DM9FIKD HS Patented
DM9FIKD CP UNIVERSITY OF BASEL ERNST, Beat
DM9FIKD DT Carbohydrates
DM9FIKD DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMF1MV6 ID DMF1MV6
DMF1MV6 DN PMID26651364-Compound-9f
DMF1MV6 HS Patented
DMF1MV6 CP UNIVERSITY OF BASEL ERNST, Beat
DMF1MV6 DT Carbohydrates
DMF1MV6 DE Crohn disease; Ulcerative colitis; Urinary tract infection
DMMGQ7Z ID DMMGQ7Z
DMMGQ7Z DN PMID26666870-Compound-16
DMMGQ7Z HS Patented
DMMGQ7Z CP THE REGENTS OF THE UNIVERSITY OF CALIFORNITHE REGENTS OF THE UNIVERSITY OF CALIFORNIA HE, Biao FUJII, Naoaki YOU, Liang XU, Zhidong JABLONS, David M
DMMGQ7Z DT Small molecular drug
DMWJXRO ID DMWJXRO
DMWJXRO DN PMID26666989-Compound-Figure11Ala down
DMWJXRO HS Patented
DMWJXRO DT Nucleotide
DMGU914 ID DMGU914
DMGU914 DN PMID26666989-Compound-Figure11Ala up
DMGU914 HS Patented
DMGU914 DT Nucleotide
DMA59QF ID DMA59QF
DMA59QF DN PMID26666989-Compound-Figure11topright
DMA59QF HS Patented
DMA59QF DT Nucleotide
DMGIPDH ID DMGIPDH
DMGIPDH DN PMID26666989-Compound-Figure12bottommiddle01
DMGIPDH HS Patented
DMGIPDH DT Nucleotide
DM2VHJ7 ID DM2VHJ7
DM2VHJ7 DN PMID26666989-Compound-Figure12bottommiddle02
DM2VHJ7 HS Patented
DM2VHJ7 DT Nucleotide
DMDLVXU ID DMDLVXU
DMDLVXU DN PMID26666989-Compound-Figure12bottomright
DMDLVXU HS Patented
DMDLVXU DT Nucleotide
DMF5LNK ID DMF5LNK
DMF5LNK DN PMID26666989-Compound-Figure12left
DMF5LNK HS Patented
DMF5LNK DT Nucleotide
DMEUSGR ID DMEUSGR
DMEUSGR DN PMID26666989-Compound-Figure12topmiddile
DMEUSGR HS Patented
DMEUSGR DT Nucleotide
DMISJDH ID DMISJDH
DMISJDH DN PMID26666989-Compound-Figure9bottomright
DMISJDH HS Patented
DMISJDH CP DEBRECENI EGYETEM
DMISJDH DT Carbohydrates
DM0NM1Y ID DM0NM1Y
DM0NM1Y DN PMID26666989-Compound-Figure9left01
DM0NM1Y HS Patented
DM0NM1Y CP DEBRECENI EGYETEM
DM0NM1Y DT Small molecular drug
DM7L6WS ID DM7L6WS
DM7L6WS DN PMID26666989-Compound-Figure9left02
DM7L6WS HS Patented
DM7L6WS CP DEBRECENI EGYETEM
DM7L6WS DT Small molecular drug
DM4MA2X ID DM4MA2X
DM4MA2X DN PMID26666989-Compound-Figure9middle01
DM4MA2X HS Patented
DM4MA2X CP DEBRECENI EGYETEM
DM4MA2X DT Small molecular drug
DM2ANJ7 ID DM2ANJ7
DM2ANJ7 DN PMID26666989-Compound-Figure9middle02
DM2ANJ7 HS Patented
DM2ANJ7 CP DEBRECENI EGYETEM
DM2ANJ7 DT Carbohydrates
DMOPR7A ID DMOPR7A
DMOPR7A DN PMID26666989-Compound-Figure9middle03
DMOPR7A HS Patented
DMOPR7A CP DEBRECENI EGYETEM
DMOPR7A DT Carbohydrates
DMNWRA0 ID DMNWRA0
DMNWRA0 DN PMID26666989-Compound-Figure9middle04
DMNWRA0 HS Patented
DMNWRA0 CP DEBRECENI EGYETEM
DMNWRA0 DT Carbohydrates
DMN73KO ID DMN73KO
DMN73KO DN PMID26666989-Compound-Figure9middle05
DMN73KO HS Patented
DMN73KO CP DEBRECENI EGYETEM
DMN73KO DT Carbohydrates
DMYKPHX ID DMYKPHX
DMYKPHX DN PMID26666989-Compound-Figure9middle06
DMYKPHX HS Patented
DMYKPHX CP DEBRECENI EGYETEM
DMYKPHX DT Carbohydrates
DMA02ED ID DMA02ED
DMA02ED DN PMID26666989-Compound-Figure9middle07
DMA02ED HS Patented
DMA02ED CP DEBRECENI EGYETEM
DMA02ED DT Carbohydrates
DM8KF15 ID DM8KF15
DM8KF15 DN PMID26666989-Compound-Figure9middle08
DM8KF15 HS Patented
DM8KF15 CP DEBRECENI EGYETEM
DM8KF15 DT Carbohydrates
DMB4SH8 ID DMB4SH8
DMB4SH8 DN PMID26666989-Compound-Figure9middle10
DMB4SH8 HS Patented
DMB4SH8 CP DEBRECENI EGYETEM
DMB4SH8 DT Carbohydrates
DMT6CNM ID DMT6CNM
DMT6CNM DN PMID26666989-Compound-Figure9middle11
DMT6CNM HS Patented
DMT6CNM CP DEBRECENI EGYETEM
DMT6CNM DT Carbohydrates
DMX612V ID DMX612V
DMX612V DN PMID26666989-Compound-Figure9middle12
DMX612V HS Patented
DMX612V CP DEBRECENI EGYETEM
DMX612V DT Carbohydrates
DMKZTVR ID DMKZTVR
DMKZTVR DN PMID26666989-Compound-Figure9middle13
DMKZTVR HS Patented
DMKZTVR CP DEBRECENI EGYETEM
DMKZTVR DT Carbohydrates
DMVS1TU ID DMVS1TU
DMVS1TU DN PMID26666989-Compound-Figure9topright01
DMVS1TU HS Patented
DMVS1TU CP DEBRECENI EGYETEM
DMVS1TU DT Carbohydrates
DMJ3GX6 ID DMJ3GX6
DMJ3GX6 DN PMID26666989-Compound-Figure9toprightR02
DMJ3GX6 HS Patented
DMJ3GX6 CP DEBRECENI EGYETEM
DMJ3GX6 DT Carbohydrates
DMOJ936 ID DMOJ936
DMOJ936 DN PMID26815044-Compound-114
DMOJ936 HS Patented
DMOJ936 DT Small molecular drug
DMOJ936 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM8SWHO ID DM8SWHO
DM8SWHO DN PMID26815044-Compound-115
DM8SWHO HS Patented
DM8SWHO DT Small molecular drug
DM8SWHO PC 51036643
DM8SWHO MW 314.5
DM8SWHO FM C17H34N2O3
DM8SWHO IC InChI=1S/C17H34N2O3/c1-14(2)19(15(3)4)13-12-18-16(20)10-8-6-5-7-9-11-17(21)22/h14-15H,5-13H2,1-4H3,(H,18,20)(H,21,22)
DM8SWHO CS CC(C)N(CCNC(=O)CCCCCCCC(=O)O)C(C)C
DM8SWHO IK LAOKJSWBEZVBIK-UHFFFAOYSA-N
DM8SWHO IU 9-[2-[di(propan-2-yl)amino]ethylamino]-9-oxononanoic acid
DM8SWHO DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMDUXRT ID DMDUXRT
DMDUXRT DN PMID26815044-Compound-116
DMDUXRT HS Patented
DMDUXRT DT Small molecular drug
DMDUXRT PC 51036037
DMDUXRT MW 272.38
DMDUXRT FM C14H28N2O3
DMDUXRT IC InChI=1S/C14H28N2O3/c1-16(2)12-8-11-15-13(17)9-6-4-3-5-7-10-14(18)19/h3-12H2,1-2H3,(H,15,17)(H,18,19)
DMDUXRT CS CN(C)CCCNC(=O)CCCCCCCC(=O)O
DMDUXRT IK GACCFZXBPOHVCL-UHFFFAOYSA-N
DMDUXRT IU 9-[3-(dimethylamino)propylamino]-9-oxononanoic acid
DMDUXRT DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM2GON6 ID DM2GON6
DM2GON6 DN PMID26815044-Compound-117
DM2GON6 HS Patented
DM2GON6 DT Small molecular drug
DM2GON6 PC 51038800
DM2GON6 MW 272.38
DM2GON6 FM C14H28N2O3
DM2GON6 IC InChI=1S/C14H28N2O3/c1-16(2)12-11-15-13(17)9-7-5-3-4-6-8-10-14(18)19/h3-12H2,1-2H3,(H,15,17)(H,18,19)
DM2GON6 CS CN(C)CCNC(=O)CCCCCCCCC(=O)O
DM2GON6 IK RGOJAAXJOLYDHR-UHFFFAOYSA-N
DM2GON6 IU 10-[2-(dimethylamino)ethylamino]-10-oxodecanoic acid
DM2GON6 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMC28VB ID DMC28VB
DMC28VB DN PMID26815044-Compound-118
DMC28VB HS Patented
DMC28VB DT Small molecular drug
DMC28VB PC 51038580
DMC28VB MW 286.41
DMC28VB FM C15H30N2O3
DMC28VB IC InChI=1S/C15H30N2O3/c1-17(2)13-9-12-16-14(18)10-7-5-3-4-6-8-11-15(19)20/h3-13H2,1-2H3,(H,16,18)(H,19,20)
DMC28VB CS CN(C)CCCNC(=O)CCCCCCCCC(=O)O
DMC28VB IK GWKPWGKMVDEOGQ-UHFFFAOYSA-N
DMC28VB IU 10-[3-(dimethylamino)propylamino]-10-oxodecanoic acid
DMC28VB DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMMNXA1 ID DMMNXA1
DMMNXA1 DN PMID26815044-Compound-121
DMMNXA1 HS Patented
DMMNXA1 DT Small molecular drug
DMMNXA1 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM1HAGJ ID DM1HAGJ
DM1HAGJ DN PMID26815044-Compound-122
DM1HAGJ HS Patented
DM1HAGJ DT Small molecular drug
DM1HAGJ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMFTE3Y ID DMFTE3Y
DMFTE3Y DN PMID26815044-Compound-123
DMFTE3Y HS Patented
DMFTE3Y DT Small molecular drug
DMFTE3Y PC 57094730
DMFTE3Y MW 301.4
DMFTE3Y FM C22H23N
DMFTE3Y IC InChI=1S/C22H23N/c23-18-10-17-22(19-11-4-1-5-12-19,20-13-6-2-7-14-20)21-15-8-3-9-16-21/h1-9,11-16H,10,17-18,23H2
DMFTE3Y CS C1=CC=C(C=C1)C(CCCN)(C2=CC=CC=C2)C3=CC=CC=C3
DMFTE3Y IK PVCHAKQXNCGVFU-UHFFFAOYSA-N
DMFTE3Y IU 4,4,4-triphenylbutan-1-amine
DMFTE3Y DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM25WGP ID DM25WGP
DM25WGP DN PMID26815044-Compound-124
DM25WGP HS Patented
DM25WGP DT Small molecular drug
DM25WGP PC 15372344
DM25WGP MW 327.5
DM25WGP FM C24H25N
DM25WGP IC InChI=1S/C24H25N/c1-5-13-21(14-6-1)24(22-15-7-2-8-16-22,23-17-9-3-10-18-23)25-19-11-4-12-20-25/h1-3,5-10,13-18H,4,11-12,19-20H2
DM25WGP CS C1CCN(CC1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DM25WGP IK ZDTBBCYZMFEIHU-UHFFFAOYSA-N
DM25WGP IU 1-tritylpiperidine
DM25WGP DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM6EFIN ID DM6EFIN
DM6EFIN DN PMID26815044-Compound-125
DM6EFIN HS Patented
DM6EFIN DT Small molecular drug
DM6EFIN PC 15372343
DM6EFIN MW 313.4
DM6EFIN FM C23H23N
DM6EFIN IC InChI=1S/C23H23N/c1-4-12-20(13-5-1)23(24-18-10-11-19-24,21-14-6-2-7-15-21)22-16-8-3-9-17-22/h1-9,12-17H,10-11,18-19H2
DM6EFIN CS C1CCN(C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DM6EFIN IK DVFDHIZVAQOEMX-UHFFFAOYSA-N
DM6EFIN IU 1-tritylpyrrolidine
DM6EFIN DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMMJK0L ID DMMJK0L
DMMJK0L DN PMID26815044-Compound-126
DMMJK0L HS Patented
DMMJK0L DT Small molecular drug
DMMJK0L DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMO97LR ID DMO97LR
DMO97LR DN PMID26815044-Compound-127
DMO97LR HS Patented
DMO97LR DT Small molecular drug
DMO97LR PC 67427052
DMO97LR MW 334.4
DMO97LR FM C22H22O3
DMO97LR IC InChI=1S/C22H22O3/c1-24-21-14-12-20(13-15-21)22(25-17-16-23,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-15,23H,16-17H2,1H3
DMO97LR CS COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCO
DMO97LR IK JOXFVFZKGOUGOT-UHFFFAOYSA-N
DMO97LR IU 2-[(4-methoxyphenyl)-diphenylmethoxy]ethanol
DMO97LR DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMH8E7S ID DMH8E7S
DMH8E7S DN PMID26815044-Compound-30
DMH8E7S HS Patented
DMH8E7S DT Small molecular drug
DMH8E7S PC 46207833
DMH8E7S MW 194.23
DMH8E7S FM C11H14O3
DMH8E7S IC InChI=1S/C11H14O3/c12-9-1-2-10(11(13)7-9)8-3-5-14-6-4-8/h1-2,7-8,12-13H,3-6H2
DMH8E7S CS C1COCCC1C2=C(C=C(C=C2)O)O
DMH8E7S IK YVJHGULPEXKTIJ-UHFFFAOYSA-N
DMH8E7S IU 4-(oxan-4-yl)benzene-1,3-diol
DMH8E7S DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMBINQ9 ID DMBINQ9
DMBINQ9 DN PMID26815044-Compound-31
DMBINQ9 HS Patented
DMBINQ9 DT Small molecular drug
DMBINQ9 PC 46218697
DMBINQ9 MW 210.29
DMBINQ9 FM C11H14O2S
DMBINQ9 IC InChI=1S/C11H14O2S/c12-9-1-2-10(11(13)7-9)8-3-5-14-6-4-8/h1-2,7-8,12-13H,3-6H2
DMBINQ9 CS C1CSCCC1C2=C(C=C(C=C2)O)O
DMBINQ9 IK OLWFCALCIRMVMM-UHFFFAOYSA-N
DMBINQ9 IU 4-(thian-4-yl)benzene-1,3-diol
DMBINQ9 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMN5H3C ID DMN5H3C
DMN5H3C DN PMID26815044-Compound-32
DMN5H3C HS Patented
DMN5H3C DT Small molecular drug
DMN5H3C PC 88936412
DMN5H3C MW 323.4
DMN5H3C FM C16H21NO4S
DMN5H3C IC InChI=1S/C16H21NO4S/c1-3-12(2)11-22(20,21)17-8-6-13(7-9-17)15-5-4-14(18)10-16(15)19/h3-5,10,13,18-19H,1-2,6-9,11H2
DMN5H3C CS C=CC(=C)CS(=O)(=O)N1CCC(CC1)C2=C(C=C(C=C2)O)O
DMN5H3C IK JCJFASCAOSDZDC-UHFFFAOYSA-N
DMN5H3C IU 4-[1-(2-methylidenebut-3-enylsulfonyl)piperidin-4-yl]benzene-1,3-diol
DMN5H3C DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMM3FJO ID DMM3FJO
DMM3FJO DN PMID26815044-Compound-47
DMM3FJO HS Patented
DMM3FJO CP Boiteau JG, Barbuis CM, Bouquet K
DMM3FJO DT Small molecular drug
DMM3FJO PC 25142954
DMM3FJO MW 196.3
DMM3FJO FM C8H8N2S2
DMM3FJO IC InChI=1S/C8H8N2S2/c1-5-2-7(12-4-5)6-3-9-8(11)10-6/h2-4H,1H3,(H2,9,10,11)
DMM3FJO CS CC1=CSC(=C1)C2=CNC(=S)N2
DMM3FJO IK KEJRMOMLDKMMDC-UHFFFAOYSA-N
DMM3FJO IU 4-(4-methylthiophen-2-yl)-1,3-dihydroimidazole-2-thione
DMM3FJO DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMJ1Z7U ID DMJ1Z7U
DMJ1Z7U DN PMID26815044-Compound-48
DMJ1Z7U HS Patented
DMJ1Z7U CP Boiteau JG, Barbuis CM, Bouquet K
DMJ1Z7U DT Small molecular drug
DMJ1Z7U PC 25142950
DMJ1Z7U MW 196.3
DMJ1Z7U FM C8H8N2S2
DMJ1Z7U IC InChI=1S/C8H8N2S2/c1-5-2-3-7(12-5)6-4-9-8(11)10-6/h2-4H,1H3,(H2,9,10,11)
DMJ1Z7U CS CC1=CC=C(S1)C2=CNC(=S)N2
DMJ1Z7U IK VLDBRCXNFRGTRR-UHFFFAOYSA-N
DMJ1Z7U IU 4-(5-methylthiophen-2-yl)-1,3-dihydroimidazole-2-thione
DMJ1Z7U DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMD9WRS ID DMD9WRS
DMD9WRS DN PMID26815044-Compound-49
DMD9WRS HS Patented
DMD9WRS CP Boiteau JG, Barbuis CM, Bouquet K
DMD9WRS DT Small molecular drug
DMD9WRS PC 25124260
DMD9WRS MW 220.25
DMD9WRS FM C10H8N2O2S
DMD9WRS IC InChI=1S/C10H8N2O2S/c13-9(14)7-3-1-6(2-4-7)8-5-11-10(15)12-8/h1-5H,(H,13,14)(H2,11,12,15)
DMD9WRS CS C1=CC(=CC=C1C2=CNC(=S)N2)C(=O)O
DMD9WRS IK RUEHTYRZLLKGKE-UHFFFAOYSA-N
DMD9WRS IU 4-(2-sulfanylidene-1,3-dihydroimidazol-4-yl)benzoic acid
DMD9WRS DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMYI1SX ID DMYI1SX
DMYI1SX DN PMID26815044-Compound-50
DMYI1SX HS Patented
DMYI1SX CP Boiteau J-G, Barbuis CM, Talano S
DMYI1SX DT Small molecular drug
DMYI1SX PC 25124264
DMYI1SX MW 206.27
DMYI1SX FM C10H10N2OS
DMYI1SX IC InChI=1S/C10H10N2OS/c13-6-7-1-3-8(4-2-7)9-5-11-10(14)12-9/h1-5,13H,6H2,(H2,11,12,14)
DMYI1SX CS C1=CC(=CC=C1CO)C2=CNC(=S)N2
DMYI1SX IK BTFQSXRRGYWCHB-UHFFFAOYSA-N
DMYI1SX IU 4-[4-(hydroxymethyl)phenyl]-1,3-dihydroimidazole-2-thione
DMYI1SX DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMQGTJ5 ID DMQGTJ5
DMQGTJ5 DN PMID26815044-Compound-51
DMQGTJ5 HS Patented
DMQGTJ5 CP Boiteau J-G, Barbuis CM, Talano S
DMQGTJ5 DT Small molecular drug
DMQGTJ5 PC 25124267
DMQGTJ5 MW 242.25
DMQGTJ5 FM C10H8F2N2OS
DMQGTJ5 IC InChI=1S/C10H8F2N2OS/c11-9(12)15-7-3-1-6(2-4-7)8-5-13-10(16)14-8/h1-5,9H,(H2,13,14,16)
DMQGTJ5 CS C1=CC(=CC=C1C2=CNC(=S)N2)OC(F)F
DMQGTJ5 IK RSUPNTVGCZRJCF-UHFFFAOYSA-N
DMQGTJ5 IU 4-[4-(difluoromethoxy)phenyl]-1,3-dihydroimidazole-2-thione
DMQGTJ5 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMN4C2O ID DMN4C2O
DMN4C2O DN PMID26815044-Compound-52
DMN4C2O HS Patented
DMN4C2O CP Boiteau J-G, Barbuis CM, Talano S
DMN4C2O DT Small molecular drug
DMN4C2O PC 25124592
DMN4C2O MW 206.27
DMN4C2O FM C10H10N2OS
DMN4C2O IC InChI=1S/C10H10N2OS/c1-13-8-4-2-3-7(5-8)9-6-11-10(14)12-9/h2-6H,1H3,(H2,11,12,14)
DMN4C2O CS COC1=CC=CC(=C1)C2=CNC(=S)N2
DMN4C2O IK NAHCKRAVJDCJKM-UHFFFAOYSA-N
DMN4C2O IU 4-(3-methoxyphenyl)-1,3-dihydroimidazole-2-thione
DMN4C2O DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMEKBOG ID DMEKBOG
DMEKBOG DN PMID26815044-Compound-64
DMEKBOG HS Patented
DMEKBOG CP JOHNSON & JOHNSON CONSUMER COMPANIES, INC
DMEKBOG DT Small molecular drug
DMEKBOG PC 44594137
DMEKBOG MW 330.4
DMEKBOG FM C22H18O3
DMEKBOG IC InChI=1S/C22H18O3/c23-20-9-5-16(6-10-20)1-3-18-13-19(15-22(25)14-18)4-2-17-7-11-21(24)12-8-17/h1-15,23-25H/b3-1+,4-2+
DMEKBOG CS C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)/C=C/C3=CC=C(C=C3)O)O
DMEKBOG IK ICUPUOLNNGGWKO-ZPUQHVIOSA-N
DMEKBOG IU 3,5-bis[(E)-2-(4-hydroxyphenyl)ethenyl]phenol
DMEKBOG DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMV46DG ID DMV46DG
DMV46DG DN PMID26815044-Compound-93
DMV46DG HS Patented
DMV46DG DT Small molecular drug
DMV46DG PC 71079964
DMV46DG MW 306.26
DMV46DG FM C13H16F2O6
DMV46DG IC InChI=1S/C13H16F2O6/c14-13(15)8(5-16)9(18)10(19)11(20)12(13)21-7-3-1-6(17)2-4-7/h1-4,8-12,16-20H,5H2/t8-,9-,10+,11-,12+/m1/s1
DMV46DG CS C1=CC(=CC=C1O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](C2(F)F)CO)O)O)O
DMV46DG IK PIRSYSBZACJVMC-ZIQFBCGOSA-N
DMV46DG IU (1R,2S,3R,4R,6S)-5,5-difluoro-4-(hydroxymethyl)-6-(4-hydroxyphenoxy)cyclohexane-1,2,3-triol
DMV46DG DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMI3QLT ID DMI3QLT
DMI3QLT DN PMID26815044-Compound-H
DMI3QLT HS Patented
DMI3QLT DT Small molecular drug
DMI3QLT DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMZISDR ID DMZISDR
DMZISDR DN PMID26815044-Compound-I
DMZISDR HS Patented
DMZISDR DT Small molecular drug
DMZISDR DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMPAE8N ID DMPAE8N
DMPAE8N DN PMID26882240-Compound-1
DMPAE8N HS Patented
DMPAE8N CP YUNG SHIN PHARM. IND. CO., LTD
DMPAE8N DT Small molecular drug
DMPAE8N PC 5712
DMPAE8N MW 304.3
DMPAE8N FM C19H16N2O2
DMPAE8N IC InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
DMPAE8N CS C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO
DMPAE8N IK OQQVFCKUDYMWGV-UHFFFAOYSA-N
DMPAE8N IU [5-(1-benzylindazol-3-yl)furan-2-yl]methanol
DMPAE8N CA CAS 170632-47-0
DMPAE8N CB CHEBI:93060
DMQVZ01 ID DMQVZ01
DMQVZ01 DN PMID26882240-Compound-14
DMQVZ01 HS Patented
DMQVZ01 CP ELARA PHARMACEUTICALS GMBH [DE]
DMQVZ01 DT Small molecular drug
DMQVZ01 PC 66563603
DMQVZ01 MW 419.5
DMQVZ01 FM C23H21N3O3S
DMQVZ01 IC InChI=1S/C23H21N3O3S/c1-16-3-4-19(15-24-16)17-5-8-23-22(14-17)26(11-12-29-23)30(27,28)20-6-7-21-18(13-20)9-10-25(21)2/h3-10,13-15H,11-12H2,1-2H3
DMQVZ01 CS CC1=NC=C(C=C1)C2=CC3=C(C=C2)OCCN3S(=O)(=O)C4=CC5=C(C=C4)N(C=C5)C
DMQVZ01 IK FPMLAMSVUUIGOG-UHFFFAOYSA-N
DMQVZ01 IU 4-(1-methylindol-5-yl)sulfonyl-6-(6-methylpyridin-3-yl)-2,3-dihydro-1,4-benzoxazine
DMZ12V4 ID DMZ12V4
DMZ12V4 DN PMID26882240-Compound-15
DMZ12V4 HS Patented
DMZ12V4 CP ELARA PHARMACEUTICALS GMBH [DE]
DMZ12V4 DT Small molecular drug
DMZ12V4 PC 52934476
DMZ12V4 MW 396.5
DMZ12V4 FM C20H16N2O3S2
DMZ12V4 IC InChI=1S/C20H16N2O3S2/c1-14-2-6-17(7-3-14)27(23,24)22-10-11-25-19-8-4-15(12-18(19)22)20-9-5-16(13-21)26-20/h2-9,12H,10-11H2,1H3
DMZ12V4 CS CC1=CC=C(C=C1)S(=O)(=O)N2CCOC3=C2C=C(C=C3)C4=CC=C(S4)C#N
DMZ12V4 IK VIWNRKLYEZMKCY-UHFFFAOYSA-N
DMZ12V4 IU 5-[4-(4-methylphenyl)sulfonyl-2,3-dihydro-1,4-benzoxazin-6-yl]thiophene-2-carbonitrile
DMX7Y52 ID DMX7Y52
DMX7Y52 DN PMID26882240-Compound-2
DMX7Y52 HS Patented
DMX7Y52 CP CASE WESTERN RESERVE UNIVERSITY
DMX7Y52 DT Small molecular drug
DMX7Y52 PC 219104
DMX7Y52 MW 188.3
DMX7Y52 FM C7H12N2S2
DMX7Y52 IC InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
DMX7Y52 CS CCC(C)SSC1=NC=CN1
DMX7Y52 IK BPBPYQWMFCTCNG-UHFFFAOYSA-N
DMX7Y52 IU 2-(butan-2-yldisulfanyl)-1H-imidazole
DMX7Y52 CA CAS 141400-58-0
DMX7Y52 CB CHEBI:94291
DMFZM3X ID DMFZM3X
DMFZM3X DN PMID26882240-Compound-3
DMFZM3X HS Patented
DMFZM3X CP NORTHWESTERN UNIVERSITY ONCOTHYREON INC. GORDON, Leo I. EVENS, Andrew PESTANO, Linda FOWLER, Kerry PETERSON, Scott
DMFZM3X DT Small molecular drug
DMJS4RP ID DMJS4RP
DMJS4RP DN PMID26882240-Compound-32
DMJS4RP HS Patented
DMJS4RP CP MEDICAL RESEARCH COUNCIL CHEESEMAN, Michael, T BROWN, Steve. D. M
DMJS4RP DT Small molecular drug
DMJS4RP PC 5288674
DMJS4RP MW 616.7
DMJS4RP FM C32H48N4O8
DMJS4RP IC InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1
DMJS4RP CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)/C)OC)OC(=O)N)\\C)C)O)OC
DMJS4RP IK KUFRQPKVAWMTJO-LMZWQJSESA-N
DMJS4RP IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[2-(dimethylamino)ethylamino]-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMJS4RP CA CAS 467214-20-6
DMJS4RP CB CHEBI:65324
DMS4RLZ ID DMS4RLZ
DMS4RLZ DN PMID26882240-Compound-4
DMS4RLZ HS Patented
DMS4RLZ CP ONCOTHYREON INC. PETERSON, Scott PESTANO, Linda FOWLER, Kerry VO, Cong, Hung
DMS4RLZ DT Small molecular drug
DMS4RLZ PC 67516319
DMS4RLZ MW 198.69
DMS4RLZ FM C10H15ClN2
DMS4RLZ IC InChI=1S/C10H15ClN2/c11-6-8-13-10-3-1-9(2-4-10)5-7-12/h1-4,13H,5-8,12H2
DMS4RLZ CS C1=CC(=CC=C1CCN)NCCCl
DMS4RLZ IK CPOKZPJUSOYUNW-UHFFFAOYSA-N
DMS4RLZ IU 4-(2-aminoethyl)-N-(2-chloroethyl)aniline
DM61NOP ID DM61NOP
DM61NOP DN PMID26882240-Compound-6
DM61NOP HS Patented
DM61NOP CP Korea Research Institute of Bioscience and Biotechnology Dongguk University Industry-Academic Cooperation Foundation WON, Mi-Sun KIM, Hwan-Mook LEE, Kyeong PARK, Song-Kyu LEE, Ki-Ho LEE, Chang-Woo LEE, Jung-Joon CHUNG, Kyung-Sook KIM, Bo-Kyung JIN, Ying-Lan
DM61NOP DT Small molecular drug
DM61NOP PC 16124726
DM61NOP MW 435.5
DM61NOP FM C26H29NO5
DM61NOP IC InChI=1S/C26H29NO5/c1-31-25(30)19-2-7-23(28)22(11-19)27-24(29)15-32-21-5-3-20(4-6-21)26-12-16-8-17(13-26)10-18(9-16)14-26/h2-7,11,16-18,28H,8-10,12-15H2,1H3,(H,27,29)
DM61NOP CS COC(=O)C1=CC(=C(C=C1)O)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)C4
DM61NOP IK BJRPPNOJYFZSLY-UHFFFAOYSA-N
DM61NOP IU methyl 3-[[2-[4-(1-adamantyl)phenoxy]acetyl]amino]-4-hydroxybenzoate
DMOX8E3 ID DMOX8E3
DMOX8E3 DN PMID26882240-Compound-7
DMOX8E3 HS Patented
DMOX8E3 CP KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
DMOX8E3 DT Small molecular drug
DMOX8E3 PC 118364731
DMOX8E3 MW 543.6
DMOX8E3 FM C32H33NO7
DMOX8E3 IC InChI=1S/C32H33NO7/c1-37-29(35)23-4-2-5-25(13-23)33-28(34)19-39-26-9-7-24(8-10-26)31-14-21-12-22(15-31)17-32(16-21,20-31)30(36)40-18-27-6-3-11-38-27/h2-11,13,21-22H,12,14-20H2,1H3,(H,33,34)
DMOX8E3 CS COC(=O)C1=CC(=CC=C1)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)(C4)C(=O)OCC6=CC=CO6
DMOX8E3 IK GQISNYKUWPQVDL-UHFFFAOYSA-N
DMOX8E3 IU furan-2-ylmethyl 3-[4-[2-(3-methoxycarbonylanilino)-2-oxoethoxy]phenyl]adamantane-1-carboxylate
DMWJRY7 ID DMWJRY7
DMWJRY7 DN PMID26882240-Compound-8
DMWJRY7 HS Patented
DMWJRY7 CP Ildong Pharmaceutical Co., Ltd., S. Korea
DMWJRY7 DT Small molecular drug
DMWJRY7 PC 625381
DMWJRY7 MW 286.4
DMWJRY7 FM C18H22O3
DMWJRY7 IC InChI=1S/C18H22O3/c19-17(20)11-21-16-3-1-15(2-4-16)18-8-12-5-13(9-18)7-14(6-12)10-18/h1-4,12-14H,5-11H2,(H,19,20)
DMWJRY7 CS C1C2CC3CC1CC(C2)(C3)C4=CC=C(C=C4)OCC(=O)O
DMWJRY7 IK WIWCHWGNONICJI-UHFFFAOYSA-N
DMWJRY7 IU 2-[4-(1-adamantyl)phenoxy]acetic acid
DMWJRY7 CA CAS 52804-26-9
DMEJ107 ID DMEJ107
DMEJ107 DN PMID26924192-Compound-102
DMEJ107 HS Patented
DMEJ107 CP MEDIVATION TECHNOLOGIES, INC
DMEJ107 DT Small molecular drug
DMEJ107 PC 102004282
DMEJ107 MW 367.4
DMEJ107 FM C22H25NO4
DMEJ107 IC InChI=1S/C22H25NO4/c1-6-19(24)23(5)17-12-16(20(25)15-10-8-7-9-11-15)13-18(14-17)27-21(26)22(2,3)4/h6-14,20,25H,1H2,2-5H3
DMEJ107 CS CC(C)(C)C(=O)OC1=CC(=CC(=C1)N(C)C(=O)C=C)C(C2=CC=CC=C2)O
DMEJ107 IK ZPLXDAHNNDDTEM-UHFFFAOYSA-N
DMEJ107 IU [3-[hydroxy(phenyl)methyl]-5-[methyl(prop-2-enoyl)amino]phenyl] 2,2-dimethylpropanoate
DMWOCP7 ID DMWOCP7
DMWOCP7 DN PMID26924192-Compound-103
DMWOCP7 HS Patented
DMWOCP7 CP MEDIVATION TECHNOLOGIES, INC
DMWOCP7 DT Small molecular drug
DMWOCP7 PC 118542373
DMWOCP7 MW 283.32
DMWOCP7 FM C17H17NO3
DMWOCP7 IC InChI=1S/C17H17NO3/c1-3-16(20)18(2)14-9-13(10-15(19)11-14)17(21)12-7-5-4-6-8-12/h3-11,17,19,21H,1H2,2H3
DMWOCP7 CS CN(C1=CC(=CC(=C1)C(C2=CC=CC=C2)O)O)C(=O)C=C
DMWOCP7 IK ISTAOAGDLRWZMS-UHFFFAOYSA-N
DMWOCP7 IU N-[3-hydroxy-5-[hydroxy(phenyl)methyl]phenyl]-N-methylprop-2-enamide
DM346EU ID DM346EU
DM346EU DN PMID26924192-Compound-104
DM346EU HS Patented
DM346EU CP MEDIVATION TECHNOLOGIES, INC
DM346EU DT Small molecular drug
DM346EU PC 118548317
DM346EU MW 283.32
DM346EU FM C17H17NO3
DM346EU IC InChI=1S/C17H17NO3/c1-3-16(20)18(2)14-9-13(10-15(19)11-14)17(21)12-7-5-4-6-8-12/h3-11,17,19,21H,1H2,2H3/t17-/m1/s1
DM346EU CS CN(C1=CC(=CC(=C1)[C@@H](C2=CC=CC=C2)O)O)C(=O)C=C
DM346EU IK ISTAOAGDLRWZMS-QGZVFWFLSA-N
DM346EU IU N-[3-hydroxy-5-[(R)-hydroxy(phenyl)methyl]phenyl]-N-methylprop-2-enamide
DMAWLGI ID DMAWLGI
DMAWLGI DN PMID26924192-Compound-105
DMAWLGI HS Patented
DMAWLGI CP MEDIVATION TECHNOLOGIES, INC
DMAWLGI DT Small molecular drug
DMAWLGI PC 118548311
DMAWLGI MW 283.32
DMAWLGI FM C17H17NO3
DMAWLGI IC InChI=1S/C17H17NO3/c1-3-16(20)18(2)14-9-13(10-15(19)11-14)17(21)12-7-5-4-6-8-12/h3-11,17,19,21H,1H2,2H3/t17-/m0/s1
DMAWLGI CS CN(C1=CC(=CC(=C1)[C@H](C2=CC=CC=C2)O)O)C(=O)C=C
DMAWLGI IK ISTAOAGDLRWZMS-KRWDZBQOSA-N
DMAWLGI IU N-[3-hydroxy-5-[(S)-hydroxy(phenyl)methyl]phenyl]-N-methylprop-2-enamide
DM9HRZJ ID DM9HRZJ
DM9HRZJ DN PMID26924192-Compound-106
DM9HRZJ HS Patented
DM9HRZJ CP UNIVERSITY OF DUNDEE CAMBRIDGE ENTERPRISE LIMITED
DM9HRZJ DT Small molecular drug
DM9HRZJ PC 86277842
DM9HRZJ MW 424.9
DM9HRZJ FM C22H21ClN4O3
DM9HRZJ IC InChI=1S/C22H21ClN4O3/c1-12(22(28)30-4)19-21-26-25-13(2)27(21)18-10-9-16(29-3)11-17(18)20(24-19)14-5-7-15(23)8-6-14/h5-12,19H,1-4H3/t12-,19+/m1/s1
DM9HRZJ CS CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2[C@@H](C)C(=O)OC)C4=CC=C(C=C4)Cl
DM9HRZJ IK FENXDXHDXYVGRJ-BLVKFPJESA-N
DM9HRZJ IU methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]propanoate
DMHAOF1 ID DMHAOF1
DMHAOF1 DN PMID26924192-Compound-20
DMHAOF1 HS Patented
DMHAOF1 CP KAINOS MEDICINE, INC
DMHAOF1 DT Small molecular drug
DMHAOF1 PC 118437927
DMHAOF1 MW 497
DMHAOF1 FM C23H21ClN6O3S
DMHAOF1 IC InChI=1S/C23H21ClN6O3S/c1-14-27-28-23-20(13-33-34(3,31)32)26-22(15-4-7-18(24)8-5-15)19-10-16(6-9-21(19)30(14)23)17-11-25-29(2)12-17/h4-12,20H,13H2,1-3H3/t20-/m0/s1
DMHAOF1 CS CC1=NN=C2N1C3=C(C=C(C=C3)C4=CN(N=C4)C)C(=N[C@H]2COS(=O)(=O)C)C5=CC=C(C=C5)Cl
DMHAOF1 IK YAFLYAXZAFQVAT-FQEVSTJZSA-N
DMHAOF1 IU [(4R)-6-(4-chlorophenyl)-1-methyl-8-(1-methylpyrazol-4-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate
DM4MZ29 ID DM4MZ29
DM4MZ29 DN PMID26924192-Compound-21
DM4MZ29 HS Patented
DM4MZ29 CP KAINOS MEDICINE, INC
DM4MZ29 DT Small molecular drug
DM4MZ29 PC 118437931
DM4MZ29 MW 540
DM4MZ29 FM C24H22ClN7O4S
DM4MZ29 IC InChI=1S/C24H22ClN7O4S/c1-14-29-30-24-20(13-36-37(2,34)35)28-23(15-3-6-18(25)7-4-15)19-9-16(5-8-21(19)32(14)24)17-10-27-31(11-17)12-22(26)33/h3-11,20H,12-13H2,1-2H3,(H2,26,33)/t20-/m0/s1
DM4MZ29 CS CC1=NN=C2N1C3=C(C=C(C=C3)C4=CN(N=C4)CC(=O)N)C(=N[C@H]2COS(=O)(=O)C)C5=CC=C(C=C5)Cl
DM4MZ29 IK ZZJJMUOPZJGNMG-FQEVSTJZSA-N
DM4MZ29 IU [(4R)-8-[1-(2-amino-2-oxoethyl)pyrazol-4-yl]-6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate
DMX964E ID DMX964E
DMX964E DN PMID26924192-Compound-22
DMX964E HS Patented
DMX964E CP KAINOS MEDICINE, INC
DMX964E DT Small molecular drug
DMX964E PC 118437971
DMX964E MW 568
DMX964E FM C26H26ClN7O4S
DMX964E IC InChI=1S/C26H26ClN7O4S/c1-16-30-31-26-22(15-38-39(4,36)37)29-25(17-5-8-20(27)9-6-17)21-11-18(7-10-23(21)34(16)26)19-12-28-33(13-19)14-24(35)32(2)3/h5-13,22H,14-15H2,1-4H3/t22-/m0/s1
DMX964E CS CC1=NN=C2N1C3=C(C=C(C=C3)C4=CN(N=C4)CC(=O)N(C)C)C(=N[C@H]2COS(=O)(=O)C)C5=CC=C(C=C5)Cl
DMX964E IK FLSJIUPJVTYGIO-QFIPXVFZSA-N
DMX964E IU [(4R)-6-(4-chlorophenyl)-8-[1-[2-(dimethylamino)-2-oxoethyl]pyrazol-4-yl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate
DME60LY ID DME60LY
DME60LY DN PMID26924192-Compound-23
DME60LY HS Patented
DME60LY CP KAINOS MEDICINE, INC
DME60LY DT Small molecular drug
DME60LY PC 118437924
DME60LY MW 472.9
DME60LY FM C22H21ClN4O4S
DME60LY IC InChI=1S/C22H21ClN4O4S/c1-13-25-26-22-19(12-31-32(28,29)17-8-9-17)24-21(14-3-5-15(23)6-4-14)18-11-16(30-2)7-10-20(18)27(13)22/h3-7,10-11,17,19H,8-9,12H2,1-2H3/t19-/m0/s1
DME60LY CS CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2COS(=O)(=O)C4CC4)C5=CC=C(C=C5)Cl
DME60LY IK BTVRKLXZFWPBGV-IBGZPJMESA-N
DME60LY IU [(4R)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl cyclopropanesulfonate
DMDN5Q4 ID DMDN5Q4
DMDN5Q4 DN PMID26924192-Compound-24
DMDN5Q4 HS Patented
DMDN5Q4 CP KAINOS MEDICINE, INC
DMDN5Q4 DT Small molecular drug
DMDN5Q4 PC 91971319
DMDN5Q4 MW 446.9
DMDN5Q4 FM C20H19ClN4O4S
DMDN5Q4 IC InChI=1S/C20H19ClN4O4S/c1-12-23-24-20-17(11-29-30(3,26)27)22-19(13-4-6-14(21)7-5-13)16-10-15(28-2)8-9-18(16)25(12)20/h4-10,17H,11H2,1-3H3/t17-/m0/s1
DMDN5Q4 CS CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2COS(=O)(=O)C)C4=CC=C(C=C4)Cl
DMDN5Q4 IK LELNYTXQJUOJKQ-KRWDZBQOSA-N
DMDN5Q4 IU [(4R)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl methanesulfonate
DMEL7XA ID DMEL7XA
DMEL7XA DN PMID26924192-Compound-25
DMEL7XA HS Patented
DMEL7XA CP KAINOS MEDICINE, INC
DMEL7XA DT Small molecular drug
DMEL7XA PC 118437925
DMEL7XA MW 460.9
DMEL7XA FM C21H21ClN4O4S
DMEL7XA IC InChI=1S/C21H21ClN4O4S/c1-4-31(27,28)30-12-18-21-25-24-13(2)26(21)19-10-9-16(29-3)11-17(19)20(23-18)14-5-7-15(22)8-6-14/h5-11,18H,4,12H2,1-3H3/t18-/m0/s1
DMEL7XA CS CCS(=O)(=O)OC[C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C
DMEL7XA IK YVHHEUZAFNGTKI-SFHVURJKSA-N
DMEL7XA IU [(4R)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]methyl ethanesulfonate
DMWXNIJ ID DMWXNIJ
DMWXNIJ DN PMID26924192-Compound-30
DMWXNIJ HS Patented
DMWXNIJ CP KYORIN PHARMACEUTICAL CO., LTD
DMWXNIJ DT Small molecular drug
DMWXNIJ PC 124182286
DMWXNIJ MW 583.7
DMWXNIJ FM C33H41N7O3
DMWXNIJ IC InChI=1S/C33H41N7O3/c1-5-43-30-18-22(32(41)40-17-14-24(21-40)35-23-12-15-37(2)16-13-23)10-11-26(30)36-31-19-28-29(20-34-31)39(4)33(42)25-8-6-7-9-27(25)38(28)3/h6-11,18-20,23-24,35H,5,12-17,21H2,1-4H3,(H,34,36)/t24-/m0/s1
DMWXNIJ CS CCOC1=C(C=CC(=C1)C(=O)N2CC[C@@H](C2)NC3CCN(CC3)C)NC4=NC=C5C(=C4)N(C6=CC=CC=C6C(=O)N5C)C
DMWXNIJ IK SXKDARBSSREUSH-DEOSSOPVSA-N
DMWXNIJ IU 2-[2-ethoxy-4-[(3S)-3-[(1-methylpiperidin-4-yl)amino]pyrrolidine-1-carbonyl]anilino]-5,11-dimethylpyrido[4,3-b][1,4]benzodiazepin-6-one
DMIFV58 ID DMIFV58
DMIFV58 DN PMID26924192-Compound-31
DMIFV58 HS Patented
DMIFV58 CP KYORIN PHARMACEUTICAL CO., LTD
DMIFV58 DT Small molecular drug
DMIFV58 PC 124182114
DMIFV58 MW 530.6
DMIFV58 FM C29H34N6O4
DMIFV58 IC InChI=1S/C29H34N6O4/c1-4-38-25-15-19(28(36)35-13-9-20(18-35)34-11-5-6-12-34)7-8-21(25)31-26-16-23-24(17-30-26)33(3)29(37)27-22(32(23)2)10-14-39-27/h7-8,10,14-17,20H,4-6,9,11-13,18H2,1-3H3,(H,30,31)
DMIFV58 CS CCOC1=C(C=CC(=C1)C(=O)N2CCC(C2)N3CCCC3)NC4=NC=C5C(=C4)N(C6=C(C(=O)N5C)OC=C6)C
DMIFV58 IK MABJPFUJXNIKGP-UHFFFAOYSA-N
DMIFV58 IU 13-[2-ethoxy-4-(3-pyrrolidin-1-ylpyrrolidine-1-carbonyl)anilino]-2,9-dimethyl-6-oxa-2,9,12-triazatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
DM0JSOZ ID DM0JSOZ
DM0JSOZ DN PMID26924192-Compound-32
DM0JSOZ HS Patented
DM0JSOZ CP KYORIN PHARMACEUTICAL CO., LTD
DM0JSOZ DT Small molecular drug
DM0JSOZ PC 91864635
DM0JSOZ MW 554.7
DM0JSOZ FM C32H38N6O3
DM0JSOZ IC InChI=1S/C32H38N6O3/c1-4-41-29-19-22(31(39)38-17-13-23(14-18-38)37-15-7-8-16-37)11-12-25(29)34-30-20-27-28(21-33-30)36(3)32(40)24-9-5-6-10-26(24)35(27)2/h5-6,9-12,19-21,23H,4,7-8,13-18H2,1-3H3,(H,33,34)
DM0JSOZ CS CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCCC3)NC4=NC=C5C(=C4)N(C6=CC=CC=C6C(=O)N5C)C
DM0JSOZ IK CBWCJYFVVHOTAZ-UHFFFAOYSA-N
DM0JSOZ IU 2-[2-ethoxy-4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)anilino]-5,11-dimethylpyrido[4,3-b][1,4]benzodiazepin-6-one
DM9NWXM ID DM9NWXM
DM9NWXM DN PMID26924192-Compound-33
DM9NWXM HS Patented
DM9NWXM CP KYORIN PHARMACEUTICAL CO., LTD
DM9NWXM DT Small molecular drug
DM9NWXM PC 124182231
DM9NWXM MW 597.7
DM9NWXM FM C34H43N7O3
DM9NWXM IC InChI=1S/C34H43N7O3/c1-5-44-31-21-24(33(42)41-17-13-25(14-18-41)40-16-8-15-37(2)19-20-40)11-12-27(31)36-32-22-29-30(23-35-32)39(4)34(43)26-9-6-7-10-28(26)38(29)3/h6-7,9-12,21-23,25H,5,8,13-20H2,1-4H3,(H,35,36)
DM9NWXM CS CCOC1=C(C=CC(=C1)C(=O)N2CCC(CC2)N3CCCN(CC3)C)NC4=NC=C5C(=C4)N(C6=CC=CC=C6C(=O)N5C)C
DM9NWXM IK YZJHEYIGGRFZOH-UHFFFAOYSA-N
DM9NWXM IU 2-[2-ethoxy-4-[4-(4-methyl-1,4-diazepan-1-yl)piperidine-1-carbonyl]anilino]-5,11-dimethylpyrido[4,3-b][1,4]benzodiazepin-6-one
DMTVZWM ID DMTVZWM
DMTVZWM DN PMID26924192-Compound-50
DMTVZWM HS Patented
DMTVZWM CP INCYTE CORPORATIOIncyte Corporation
DMTVZWM DT Small molecular drug
DMTVZWM PC 118467688
DMTVZWM MW 371.4
DMTVZWM FM C22H17N3O3
DMTVZWM IC InChI=1S/C22H17N3O3/c1-25-12-16(14-10-11-23-18(14)22(25)27)15-8-5-9-17-20(15)28-19(21(26)24-17)13-6-3-2-4-7-13/h2-12,19,23H,1H3,(H,24,26)
DMTVZWM CS CN1C=C(C2=C(C1=O)NC=C2)C3=C4C(=CC=C3)NC(=O)C(O4)C5=CC=CC=C5
DMTVZWM IK DWZVOOLKEMMANA-UHFFFAOYSA-N
DMTVZWM IU 8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-2-phenyl-4H-1,4-benzoxazin-3-one
DMB2MH3 ID DMB2MH3
DMB2MH3 DN PMID26924192-Compound-51
DMB2MH3 HS Patented
DMB2MH3 CP INCYTE CORPORATIOIncyte Corporation
DMB2MH3 DT Small molecular drug
DMB2MH3 PC 118467741
DMB2MH3 MW 353.4
DMB2MH3 FM C19H19N3O4
DMB2MH3 IC InChI=1S/C19H19N3O4/c1-19(2)18(24)21-14-8-10(25-4)7-12(16(14)26-19)13-9-22(3)17(23)15-11(13)5-6-20-15/h5-9,20H,1-4H3,(H,21,24)
DMB2MH3 CS CC1(C(=O)NC2=CC(=CC(=C2O1)C3=CN(C(=O)C4=C3C=CN4)C)OC)C
DMB2MH3 IK YAGDWXZVBYSOAH-UHFFFAOYSA-N
DMB2MH3 IU 6-methoxy-2,2-dimethyl-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-4H-1,4-benzoxazin-3-one
DMFU6JR ID DMFU6JR
DMFU6JR DN PMID26924192-Compound-52
DMFU6JR HS Patented
DMFU6JR CP INCYTE CORPORATIOIncyte Corporation
DMFU6JR DT Small molecular drug
DMFU6JR PC 118467707
DMFU6JR MW 393.4
DMFU6JR FM C22H23N3O4
DMFU6JR IC InChI=1S/C22H23N3O4/c1-25-11-16(14-7-8-23-18(14)22(25)27)15-9-13(28-2)10-17-20(15)29-19(21(26)24-17)12-5-3-4-6-12/h7-12,19,23H,3-6H2,1-2H3,(H,24,26)
DMFU6JR CS CN1C=C(C2=C(C1=O)NC=C2)C3=C4C(=CC(=C3)OC)NC(=O)C(O4)C5CCCC5
DMFU6JR IK APVTWFGLNNDNFT-UHFFFAOYSA-N
DMFU6JR IU 2-cyclopentyl-6-methoxy-8-(6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)-4H-1,4-benzoxazin-3-one
DMFN1AR ID DMFN1AR
DMFN1AR DN PMID26924192-Compound-53
DMFN1AR HS Patented
DMFN1AR CP BAYER PHARMA AKTIENGESELLSCHAFT
DMFN1AR DT Small molecular drug
DMFN1AR PC 121412319
DMFN1AR MW 459.6
DMFN1AR FM C22H29N5O4S
DMFN1AR IC InChI=1S/C22H29N5O4S/c1-4-23-32(29,30)18-7-5-6-16(14-18)24-20-9-8-19-21(25-20)27(15(2)22(28)26(19)3)17-10-12-31-13-11-17/h5-9,14-15,17,23H,4,10-13H2,1-3H3,(H,24,25)/t15-/m1/s1
DMFN1AR CS CCNS(=O)(=O)C1=CC=CC(=C1)NC2=NC3=C(C=C2)N(C(=O)[C@H](N3C4CCOCC4)C)C
DMFN1AR IK IVGZHVCCAQPDME-OAHLLOKOSA-N
DMFN1AR IU 3-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-N-ethylbenzenesulfonamide
DMODT8F ID DMODT8F
DMODT8F DN PMID26924192-Compound-54
DMODT8F HS Patented
DMODT8F CP BAYER PHARMA AKTIENGESELLSCHAFT
DMODT8F DT Small molecular drug
DMODT8F PC 86582981
DMODT8F MW 582.6
DMODT8F FM C26H33F3N6O4S
DMODT8F IC InChI=1S/C26H33F3N6O4S/c1-18-25(36)32(2)22-6-7-23(31-24(22)35(18)20-8-14-39-15-9-20)30-19-4-3-5-21(16-19)40(37,38)34-12-10-33(11-13-34)17-26(27,28)29/h3-7,16,18,20H,8-15,17H2,1-2H3,(H,30,31)/t18-/m1/s1
DMODT8F CS C[C@@H]1C(=O)N(C2=C(N1C3CCOCC3)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)N5CCN(CC5)CC(F)(F)F)C
DMODT8F IK DRCMYKRSYNVVMM-GOSISDBHSA-N
DMODT8F IU (3R)-1,3-dimethyl-4-(oxan-4-yl)-6-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]sulfonylanilino]-3H-pyrido[2,3-b]pyrazin-2-one
DMGWQVT ID DMGWQVT
DMGWQVT DN PMID26924192-Compound-55
DMGWQVT HS Patented
DMGWQVT CP BAYER PHARMA AKTIENGESELLSCHAFT
DMGWQVT DT Small molecular drug
DMGWQVT PC 87055858
DMGWQVT MW 528.7
DMGWQVT FM C26H36N6O4S
DMGWQVT IC InChI=1S/C26H36N6O4S/c1-18-26(33)31(3)23-7-8-24(28-25(23)32(18)21-11-15-36-16-12-21)27-20-5-4-6-22(17-20)37(34,35)29-19-9-13-30(2)14-10-19/h4-8,17-19,21,29H,9-16H2,1-3H3,(H,27,28)/t18-/m1/s1
DMGWQVT CS C[C@@H]1C(=O)N(C2=C(N1C3CCOCC3)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)NC5CCN(CC5)C)C
DMGWQVT IK NYFZHTKDUXWZDU-GOSISDBHSA-N
DMGWQVT IU 3-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]-N-(1-methylpiperidin-4-yl)benzenesulfonamide
DM6YGLT ID DM6YGLT
DM6YGLT DN PMID26924192-Compound-56
DM6YGLT HS Patented
DM6YGLT CP BAYER PHARMA AKTIENGESELLSCHAFT
DM6YGLT DT Small molecular drug
DM6YGLT PC 87055861
DM6YGLT MW 498.6
DM6YGLT FM C25H34N6O3S
DM6YGLT IC InChI=1S/C25H34N6O3S/c1-18-25(32)29(3)22-9-10-23(27-24(22)31(18)20-11-15-28(2)16-12-20)26-19-7-6-8-21(17-19)35(33,34)30-13-4-5-14-30/h6-10,17-18,20H,4-5,11-16H2,1-3H3,(H,26,27)/t18-/m1/s1
DM6YGLT CS C[C@@H]1C(=O)N(C2=C(N1C3CCN(CC3)C)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)N5CCCC5)C
DM6YGLT IK IIDSCXUAKMUCPQ-GOSISDBHSA-N
DM6YGLT IU (3R)-1,3-dimethyl-4-(1-methylpiperidin-4-yl)-6-(3-pyrrolidin-1-ylsulfonylanilino)-3H-pyrido[2,3-b]pyrazin-2-one
DM3NXP8 ID DM3NXP8
DM3NXP8 DN PMID26924192-Compound-57
DM3NXP8 HS Patented
DM3NXP8 CP BAYER PHARMA AKTIENGESELLSCHAFT
DM3NXP8 DT Small molecular drug
DM3NXP8 PC 87055862
DM3NXP8 MW 471.6
DM3NXP8 FM C23H29N5O4S
DM3NXP8 IC InChI=1S/C23H29N5O4S/c1-15-23(29)27(2)20-8-9-21(25-22(20)28(15)18-10-12-32-13-11-18)24-17-4-3-5-19(14-17)33(30,31)26-16-6-7-16/h3-5,8-9,14-16,18,26H,6-7,10-13H2,1-2H3,(H,24,25)/t15-/m1/s1
DM3NXP8 CS C[C@@H]1C(=O)N(C2=C(N1C3CCOCC3)N=C(C=C2)NC4=CC(=CC=C4)S(=O)(=O)NC5CC5)C
DM3NXP8 IK XMBSYBXAJSVFRE-OAHLLOKOSA-N
DM3NXP8 IU N-cyclopropyl-3-[[(3R)-1,3-dimethyl-4-(oxan-4-yl)-2-oxo-3H-pyrido[2,3-b]pyrazin-6-yl]amino]benzenesulfonamide
DMXK6LV ID DMXK6LV
DMXK6LV DN PMID26936077-Compound-13
DMXK6LV HS Patented
DMXK6LV CP THE UNIVERSITY OF QUEENSLAND FAIRLIE, David Paul LIU, Ligong YAU, Mei-Kwan SUEN, Jacky Yung REID, Robert LOHMAN, Rink-Jan IYER, Abishek Venkatasubramanian LIM, Junxian BROWN, Lindsay CharleThe University of Queensland
DMXK6LV DT Small molecular drug
DMXK6LV DE Type-2 diabetes; Metabolic disorder; Gastric ulcer
DMIZL8D ID DMIZL8D
DMIZL8D DN PMID26936077-Compound-34
DMIZL8D HS Patented
DMIZL8D CP THE UNIVERSITY OF QUEENSLAND FAIRLIE, David Paul LIU, Ligong YAU, Mei-Kwan SUEN, Jacky Yung REID, Robert LOHMAN, Rink-Jan IYER, Abishek Venkatasubramanian LIM, Junxian BROWN, Lindsay CharleThe University of Queensland
DMIZL8D DT Small molecular drug
DMIZL8D DE Type-2 diabetes; Metabolic disorder; Gastric ulcer
DMD0HAT ID DMD0HAT
DMD0HAT DN PMID27019002-Compound-13
DMD0HAT HS Patented
DMD0HAT CP NEVADA CANCER INSTITUTE SHENZHEN GRADUATE SCHOOL OF PEKING UNIVERSITY ZHANG, Hui YE, Tao QUAN, Junmin WANG, Jing
DMD0HAT DT Small molecular drug
DMZ9T8H ID DMZ9T8H
DMZ9T8H DN PMID27019002-Compound-16
DMZ9T8H HS Patented
DMZ9T8H CP MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
DMZ9T8H DT Small molecular drug
DM7JASU ID DM7JASU
DM7JASU DN PMID27019002-Compound-17
DM7JASU HS Patented
DM7JASU CP UNIVERSITY OF UTAUNIVERSITY OF UTAH RESEARCH FOUNDATIOUNIVERSITY OF UTAH RESEARCH FOUNDATION VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steve, L. BEARSS, David, J. SHARMA, Sunil STEPHENS, BreUniversity of Utah, USA
DM7JASU DT Small molecular drug
DMRX748 ID DMRX748
DMRX748 DN PMID27019002-Compound-20a
DMRX748 HS Patented
DMRX748 CP ORYZON GENOMICS SA [ES]
DMRX748 DT Small molecular drug
DMYRV8I ID DMYRV8I
DMYRV8I DN PMID27019002-Compound-20b
DMYRV8I HS Patented
DMYRV8I CP ORYZON GENOMICS SA [ES]
DMYRV8I DT Small molecular drug
DMC6AF2 ID DMC6AF2
DMC6AF2 DN PMID27019002-Compound-21a
DMC6AF2 HS Patented
DMC6AF2 CP ORYZON GENOMICS, S.A. BAKER, Jonathan, A. FYFE, Matthew, Colin, ThoORYZON GENOMICS, S.A. BAKER, Jonathan, Alleman FYFE, Matthew, Colin Thor
DMC6AF2 DT Small molecular drug
DMMC31N ID DMMC31N
DMMC31N DN PMID27019002-Compound-21b
DMMC31N HS Patented
DMMC31N CP ORYZON GENOMICS SA [ESORYZON GENOMICS S.A. BAKER, Jonathan, Alleman CASTRO PALOMINO, Julio FYFE, Matthew, Colin, Thor MAES, Tamara MARTINELL PEDEMONTE, MarORYZON GENOMICS, S.A. BAKER, Jonathan, Alleman FYFE, Matthew, Colin Thor
DMMC31N DT Small molecular drug
DMWZOKP ID DMWZOKP
DMWZOKP DN PMID27019002-Compound-21c
DMWZOKP HS Patented
DMWZOKP CP ORYZON GENOMICS SA [ESORYZON GENOMICS S.A. BAKER, Jonathan, Alleman CASTRO PALOMINO, Julio FYFE, Matthew, Colin, Thor MAES, Tamara MARTINELL PEDEMONTE, MarORYZON GENOMICS, S.A. BAKER, Jonathan, Alleman FYFE, Matthew, Colin Thor
DMWZOKP DT Small molecular drug
DM1R6GA ID DM1R6GA
DM1R6GA DN PMID27019002-Compound-28
DM1R6GA HS Patented
DM1R6GA CP IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L
DM1R6GA DT Small molecular drug
DM954C8 ID DM954C8
DM954C8 DN PMID27019002-Compound-28a
DM954C8 HS Patented
DM954C8 CP IEO - ISTITUTO EUROPEO DI ONCOLOGIA S.R.L
DM954C8 DT Small molecular drug
DMRWGHN ID DMRWGHN
DMRWGHN DN PMID27019002-Compound-31a
DMRWGHN HS Patented
DMRWGHN CP THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF NEVADA, LAS VEGAS
DMRWGHN DT Small molecular drug
DMJ1K4Y ID DMJ1K4Y
DMJ1K4Y DN PMID27019002-Compound-31b
DMJ1K4Y HS Patented
DMJ1K4Y CP THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION on behalf of THE UNIVERSITY OF NEVADA, LAS VEGAS
DMJ1K4Y DT Small molecular drug
DMMB6XC ID DMMB6XC
DMMB6XC DN PMID27019002-Compound-37a
DMMB6XC HS Patented
DMMB6XC CP NEVADA CANCER INSTITUTE SHENZHEN GRADUATE SCHOOL OF PEKING UNIVERSITY ZHANG, Hui YE, Tao QUAN, Junmin WANG, Jing
DMMB6XC DT Small molecular drug
DMCIT5A ID DMCIT5A
DMCIT5A DN PMID27019002-Compound-37b
DMCIT5A HS Patented
DMCIT5A CP NEVADA CANCER INSTITUTE SHENZHEN GRADUATE SCHOOL OF PEKING UNIVERSITY ZHANG, Hui YE, Tao QUAN, Junmin WANG, Jing
DMCIT5A DT Small molecular drug
DMVLXRB ID DMVLXRB
DMVLXRB DN PMID27019002-Compound-41
DMVLXRB HS Patented
DMVLXRB CP UNIVERSITY OF UTAUNIVERSITY OF UTAH RESEARCH FOUNDATIOUNIVERSITY OF UTAH RESEARCH FOUNDATION VANKAYALAPATI, Hariprasad SORNA, Venkataswamy WARNER, Steve, L. BEARSS, David, J. SHARMA, Sunil STEPHENS, BreUniversity of Utah, USA
DMVLXRB DT Small molecular drug
DM42VUQ ID DM42VUQ
DM42VUQ DN PMID27019002-Compound-42a
DM42VUQ HS Patented
DM42VUQ CP UNIVERSITY OF UTAH RESEARCH FOUNDATIOUniversity of Utah, USA
DM42VUQ DT Small molecular drug
DMHJBRO ID DMHJBRO
DMHJBRO DN PMID27019002-Compound-42b
DMHJBRO HS Patented
DMHJBRO CP UNIVERSITY OF UTAH RESEARCH FOUNDATIOUniversity of Utah, USA
DMHJBRO DT Small molecular drug
DMMOVGU ID DMMOVGU
DMMOVGU DN PMID27019002-Compound-43a
DMMOVGU HS Patented
DMMOVGU CP UNIVERSITY OF UTAH
DMMOVGU DT Small molecular drug
DMIMFND ID DMIMFND
DMIMFND DN PMID27019002-Compound-43b
DMIMFND HS Patented
DMIMFND CP UNIVERSITY OF UTAH
DMIMFND DT Small molecular drug
DM72TBJ ID DM72TBJ
DM72TBJ DN PMID27019002-Compound-43c
DM72TBJ HS Patented
DM72TBJ CP UNIVERSITY OF UTAH
DM72TBJ DT Small molecular drug
DM5HUCR ID DM5HUCR
DM5HUCR DN PMID27019002-Compound-44
DM5HUCR HS Patented
DM5HUCR CP MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
DM5HUCR DT Small molecular drug
DM3G6YV ID DM3G6YV
DM3G6YV DN PMID27019002-Compound-45
DM3G6YV HS Patented
DM3G6YV CP UNIVERSITY OF CANBERRKYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY EDUCATIONAL CORPORATION KANSAI BUNRI SOUGOUGAKUEN FRONTIER PHARMA INC. KYOTO UNIVERSITY
DM3G6YV DT Small molecular drug
DMQPU7K ID DMQPU7K
DMQPU7K DN PMID27019002-Compound-46
DMQPU7K HS Patented
DMQPU7K CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. SHI, Yujiang Geno LIAN, Christine Guo
DMQPU7K DT Small molecular drug
DMRLWP9 ID DMRLWP9
DMRLWP9 DN PMID27019002-Compound-47
DMRLWP9 HS Patented
DMRLWP9 CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. SHI, Yujiang Geno LIAN, Christine Guo
DMRLWP9 DT Small molecular drug
DMIO8J3 ID DMIO8J3
DMIO8J3 DN PMID27019002-Compound-48
DMIO8J3 HS Patented
DMIO8J3 CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. SHI, Yujiang Geno LIAN, Christine Guo
DMIO8J3 DT Small molecular drug
DMP6WCX ID DMP6WCX
DMP6WCX DN PMID27019002-Compound-49
DMP6WCX HS Patented
DMP6WCX CP MCCORD, Darlene E. KARAGIANNIS, Thomas
DMP6WCX DT Small molecular drug
DM4D75L ID DM4D75L
DM4D75L DN PMID27019002-Compound-50
DM4D75L HS Patented
DM4D75L CP MCCORD, Darlene E. KARAGIANNIS, Thomas
DM4D75L DT Small molecular drug
DMB0S52 ID DMB0S52
DMB0S52 DN PMID27019002-Compound-7
DMB0S52 HS Patented
DMB0S52 CP THE JOHNS HOPKINS UNIVERSITY INTONATION RESEARCH LABORATORIES
DMB0S52 DT Small molecular drug
DMW2N5D ID DMW2N5D
DMW2N5D DN PMID27109571-Compound-1
DMW2N5D HS Patented
DMW2N5D DT Small molecular drug
DMW2N5D PC 68053067
DMW2N5D MW 236.27
DMW2N5D FM C12H16N2O3
DMW2N5D IC InChI=1S/C12H16N2O3/c15-12(16)10-1-2-11(13-9-10)3-4-14-5-7-17-8-6-14/h1-2,9H,3-8H2,(H,15,16)
DMW2N5D CS C1COCCN1CCC2=NC=C(C=C2)C(=O)O
DMW2N5D IK IAYFDTNYXBOKKE-UHFFFAOYSA-N
DMW2N5D IU 6-(2-morpholin-4-ylethyl)pyridine-3-carboxylic acid
DMW60HU ID DMW60HU
DMW60HU DN PMID27109571-Compound-10
DMW60HU HS Patented
DMW60HU DT Small molecular drug
DMMI4KQ ID DMMI4KQ
DMMI4KQ DN PMID27109571-Compound-11
DMMI4KQ HS Patented
DMMI4KQ DT Small molecular drug
DM6HWBK ID DM6HWBK
DM6HWBK DN PMID27109571-Compound-12
DM6HWBK HS Patented
DM6HWBK DT Small molecular drug
DM6HWBK PC 71556165
DM6HWBK MW 323.8
DM6HWBK FM C19H14ClNO2
DM6HWBK IC InChI=1S/C19H14ClNO2/c20-13-8-9-15-14(10-13)16(11-4-2-1-3-5-11)17(19(22)23)18(21-15)12-6-7-12/h1-5,8-10,12H,6-7H2,(H,22,23)
DM6HWBK CS C1CC1C2=NC3=C(C=C(C=C3)Cl)C(=C2C(=O)O)C4=CC=CC=C4
DM6HWBK IK OKOHKZNRTKWMBM-UHFFFAOYSA-N
DM6HWBK IU 6-chloro-2-cyclopropyl-4-phenylquinoline-3-carboxylic acid
DMUKOGJ ID DMUKOGJ
DMUKOGJ DN PMID27109571-Compound-13
DMUKOGJ HS Patented
DMUKOGJ DT Small molecular drug
DMUKOGJ PC 71556619
DMUKOGJ MW 375.2
DMUKOGJ FM C19H16Cl2N2O2
DMUKOGJ IC InChI=1S/C19H16Cl2N2O2/c1-3-23(2)18-16(19(24)25)15(11-7-5-4-6-8-11)13-9-12(20)10-14(21)17(13)22-18/h4-10H,3H2,1-2H3,(H,24,25)
DMUKOGJ CS CCN(C)C1=C(C(=C2C=C(C=C(C2=N1)Cl)Cl)C3=CC=CC=C3)C(=O)O
DMUKOGJ IK RNRWKMXASDHXSW-UHFFFAOYSA-N
DMUKOGJ IU 6,8-dichloro-2-[ethyl(methyl)amino]-4-phenylquinoline-3-carboxylic acid
DMVY6B9 ID DMVY6B9
DMVY6B9 DN PMID27109571-Compound-14
DMVY6B9 HS Patented
DMVY6B9 DT Small molecular drug
DMVY6B9 PC 89542132
DMVY6B9 MW 364.8
DMVY6B9 FM C19H17ClN6
DMVY6B9 IC InChI=1S/C19H17ClN6/c1-3-26(2)19-17(18-22-24-25-23-18)16(12-7-5-4-6-8-12)14-11-13(20)9-10-15(14)21-19/h4-11H,3H2,1-2H3,(H,22,23,24,25)
DMVY6B9 CS CCN(C)C1=NC2=C(C=C(C=C2)Cl)C(=C1C3=NNN=N3)C4=CC=CC=C4
DMVY6B9 IK DNKGOGCNEVPJAB-UHFFFAOYSA-N
DMVY6B9 IU 6-chloro-N-ethyl-N-methyl-4-phenyl-3-(2H-tetrazol-5-yl)quinolin-2-amine
DMUR3FY ID DMUR3FY
DMUR3FY DN PMID27109571-Compound-15
DMUR3FY HS Patented
DMUR3FY DT Small molecular drug
DMUR3FY PC 71555922
DMUR3FY MW 422.9
DMUR3FY FM C22H19ClN4OS
DMUR3FY IC InChI=1S/C22H19ClN4OS/c23-15-9-10-17-16(13-15)18(14-7-3-1-4-8-14)19(21-25-26-22(29)28-21)20(24-17)27-11-5-2-6-12-27/h1,3-4,7-10,13H,2,5-6,11-12H2,(H,26,29)
DMUR3FY CS C1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=C2C4=NNC(=S)O4)C5=CC=CC=C5
DMUR3FY IK QNSIEZUINFOQFH-UHFFFAOYSA-N
DMUR3FY IU 5-(6-chloro-4-phenyl-2-piperidin-1-ylquinolin-3-yl)-3H-1,3,4-oxadiazole-2-thione
DMZI25U ID DMZI25U
DMZI25U DN PMID27109571-Compound-16
DMZI25U HS Patented
DMZI25U DT Small molecular drug
DMZI25U PC 86683056
DMZI25U MW 424.4
DMZI25U FM C22H19F3N6
DMZI25U IC InChI=1S/C22H19F3N6/c23-22(24,25)15-9-10-17-16(13-15)18(14-7-3-1-4-8-14)19(20-27-29-30-28-20)21(26-17)31-11-5-2-6-12-31/h1,3-4,7-10,13H,2,5-6,11-12H2,(H,27,28,29,30)
DMZI25U CS C1CCN(CC1)C2=NC3=C(C=C(C=C3)C(F)(F)F)C(=C2C4=NNN=N4)C5=CC=CC=C5
DMZI25U IK SUXQAVNHOCPUSH-UHFFFAOYSA-N
DMZI25U IU 4-phenyl-2-piperidin-1-yl-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)quinoline
DMBETU6 ID DMBETU6
DMBETU6 DN PMID27109571-Compound-17
DMBETU6 HS Patented
DMBETU6 DT Small molecular drug
DMBETU6 PC 86683057
DMBETU6 MW 412.4
DMBETU6 FM C21H19F3N6
DMBETU6 IC InChI=1S/C21H19F3N6/c1-3-30(4-2)20-18(19-26-28-29-27-19)17(13-8-6-5-7-9-13)15-12-14(21(22,23)24)10-11-16(15)25-20/h5-12H,3-4H2,1-2H3,(H,26,27,28,29)
DMBETU6 CS CCN(CC)C1=NC2=C(C=C(C=C2)C(F)(F)F)C(=C1C3=NNN=N3)C4=CC=CC=C4
DMBETU6 IK RVTWZFXKPCJMAI-UHFFFAOYSA-N
DMBETU6 IU N,N-diethyl-4-phenyl-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)quinolin-2-amine
DM4S5ME ID DM4S5ME
DM4S5ME DN PMID27109571-Compound-18
DM4S5ME HS Patented
DM4S5ME DT Small molecular drug
DM4S5ME PC 89542341
DM4S5ME MW 395.9
DM4S5ME FM C21H19ClFN5
DM4S5ME IC InChI=1S/C21H19ClFN5/c1-3-12(4-2)20-19(21-25-27-28-26-21)18(13-8-6-5-7-9-13)14-10-15(22)16(23)11-17(14)24-20/h5-12H,3-4H2,1-2H3,(H,25,26,27,28)
DM4S5ME CS CCC(CC)C1=NC2=CC(=C(C=C2C(=C1C3=NNN=N3)C4=CC=CC=C4)Cl)F
DM4S5ME IK OTAAEQZYEFGHGG-UHFFFAOYSA-N
DM4S5ME IU 6-chloro-7-fluoro-2-pentan-3-yl-4-phenyl-3-(2H-tetrazol-5-yl)quinoline
DMIJGLB ID DMIJGLB
DMIJGLB DN PMID27109571-Compound-19
DMIJGLB HS Patented
DMIJGLB DT Small molecular drug
DMIJGLB PC 86683063
DMIJGLB MW 408.9
DMIJGLB FM C21H18ClFN6
DMIJGLB IC InChI=1S/C21H18ClFN6/c22-15-11-14-17(12-16(15)23)24-21(29-9-5-2-6-10-29)19(20-25-27-28-26-20)18(14)13-7-3-1-4-8-13/h1,3-4,7-8,11-12H,2,5-6,9-10H2,(H,25,26,27,28)
DMIJGLB CS C1CCN(CC1)C2=NC3=CC(=C(C=C3C(=C2C4=NNN=N4)C5=CC=CC=C5)Cl)F
DMIJGLB IK APFHIGYPDALGOX-UHFFFAOYSA-N
DMIJGLB IU 6-chloro-7-fluoro-4-phenyl-2-piperidin-1-yl-3-(2H-tetrazol-5-yl)quinoline
DMTD1X8 ID DMTD1X8
DMTD1X8 DN PMID27109571-Compound-2
DMTD1X8 HS Patented
DMTD1X8 DT Small molecular drug
DMTD1X8 PC 56592602
DMTD1X8 MW 264.32
DMTD1X8 FM C14H20N2O3
DMTD1X8 IC InChI=1S/C14H20N2O3/c1-2-19-14(17)12-3-4-13(15-11-12)5-6-16-7-9-18-10-8-16/h3-4,11H,2,5-10H2,1H3
DMTD1X8 CS CCOC(=O)C1=CN=C(C=C1)CCN2CCOCC2
DMTD1X8 IK XIDYSJNRQHEJQG-UHFFFAOYSA-N
DMTD1X8 IU ethyl 6-(2-morpholin-4-ylethyl)pyridine-3-carboxylate
DMQU9XP ID DMQU9XP
DMQU9XP DN PMID27109571-Compound-20
DMQU9XP HS Patented
DMQU9XP DT Small molecular drug
DMQU9XP PC 86683065
DMQU9XP MW 396.8
DMQU9XP FM C20H18ClFN6
DMQU9XP IC InChI=1S/C20H18ClFN6/c1-3-28(4-2)20-18(19-24-26-27-25-19)17(12-8-6-5-7-9-12)13-10-14(21)15(22)11-16(13)23-20/h5-11H,3-4H2,1-2H3,(H,24,25,26,27)
DMQU9XP CS CCN(CC)C1=NC2=CC(=C(C=C2C(=C1C3=NNN=N3)C4=CC=CC=C4)Cl)F
DMQU9XP IK CVFVCWWTTQCZRK-UHFFFAOYSA-N
DMQU9XP IU 6-chloro-N,N-diethyl-7-fluoro-4-phenyl-3-(2H-tetrazol-5-yl)quinolin-2-amine
DM0R5Y8 ID DM0R5Y8
DM0R5Y8 DN PMID27109571-Compound-21
DM0R5Y8 HS Patented
DM0R5Y8 DT Small molecular drug
DM0R5Y8 PC 118589228
DM0R5Y8 MW 374.5
DM0R5Y8 FM C22H26N6
DM0R5Y8 IC InChI=1S/C22H26N6/c1-3-7-16(8-4-1)21-20(22-25-27-28-26-22)19(15-11-13-23-14-12-15)17-9-5-2-6-10-18(17)24-21/h11-14,16H,1-10H2,(H,25,26,27,28)
DM0R5Y8 CS C1CCC(CC1)C2=NC3=C(CCCCC3)C(=C2C4=NNN=N4)C5=CC=NC=C5
DM0R5Y8 IK FMTDJMYDWZGVPK-UHFFFAOYSA-N
DM0R5Y8 IU 2-cyclohexyl-4-pyridin-4-yl-3-(2H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
DMC52VP ID DMC52VP
DMC52VP DN PMID27109571-Compound-22
DMC52VP HS Patented
DMC52VP DT Small molecular drug
DMC52VP PC 118589197
DMC52VP MW 442.5
DMC52VP FM C23H25F3N6
DMC52VP IC InChI=1S/C23H25F3N6/c1-13-11-15(9-10-27-13)19-17-12-16(23(24,25)26)7-8-18(17)28-21(14-5-3-2-4-6-14)20(19)22-29-31-32-30-22/h9-11,14,16H,2-8,12H2,1H3,(H,29,30,31,32)
DMC52VP CS CC1=NC=CC(=C1)C2=C(C(=NC3=C2CC(CC3)C(F)(F)F)C4CCCCC4)C5=NNN=N5
DMC52VP IK ALFQKPZYXQRVDU-UHFFFAOYSA-N
DMC52VP IU 2-cyclohexyl-4-(2-methylpyridin-4-yl)-3-(2H-tetrazol-5-yl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroquinoline
DML49UI ID DML49UI
DML49UI DN PMID27109571-Compound-23
DML49UI HS Patented
DML49UI DT Small molecular drug
DML49UI PC 73295099
DML49UI MW 374.5
DML49UI FM C22H26N6
DML49UI IC InChI=1S/C22H26N6/c1-13-7-8-18-17(11-13)19(16-9-10-23-14(2)12-16)20(22-25-27-28-26-22)21(24-18)15-5-3-4-6-15/h9-10,12-13,15H,3-8,11H2,1-2H3,(H,25,26,27,28)
DML49UI CS CC1CCC2=C(C1)C(=C(C(=N2)C3CCCC3)C4=NNN=N4)C5=CC(=NC=C5)C
DML49UI IK LSPFDXQDUWKIKF-UHFFFAOYSA-N
DML49UI IU 2-cyclopentyl-6-methyl-4-(2-methylpyridin-4-yl)-3-(2H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline
DMPHTC0 ID DMPHTC0
DMPHTC0 DN PMID27109571-Compound-24
DMPHTC0 HS Patented
DMPHTC0 DT Small molecular drug
DM435GR ID DM435GR
DM435GR DN PMID27109571-Compound-25
DM435GR HS Patented
DM435GR DT Small molecular drug
DM435GR PC 90043846
DM435GR MW 404.5
DM435GR FM C23H28N6O
DM435GR IC InChI=1S/C23H28N6O/c1-15-13-16(9-12-24-15)19-17-7-3-2-4-8-18(17)25-21(20(19)22-26-28-29-27-22)23(14-30)10-5-6-11-23/h9,12-13,30H,2-8,10-11,14H2,1H3,(H,26,27,28,29)
DM435GR CS CC1=NC=CC(=C1)C2=C(C(=NC3=C2CCCCC3)C4(CCCC4)CO)C5=NNN=N5
DM435GR IK JDONBBWFRSZVOY-UHFFFAOYSA-N
DM435GR IU [1-[4-(2-methylpyridin-4-yl)-3-(2H-tetrazol-5-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl]cyclopentyl]methanol
DMJCL53 ID DMJCL53
DMJCL53 DN PMID27109571-Compound-26
DMJCL53 HS Patented
DMJCL53 DT Small molecular drug
DMJCL53 PC 118589084
DMJCL53 MW 459.6
DMJCL53 FM C28H37N5O
DMJCL53 IC InChI=1S/C28H37N5O/c1-3-4-6-11-20-14-15-23-22(18-20)24(21-12-7-5-8-13-21)25(27-30-32-33-31-27)26(29-23)28(19-34-2)16-9-10-17-28/h5,7-8,12-13,20H,3-4,6,9-11,14-19H2,1-2H3,(H,30,31,32,33)
DMJCL53 CS CCCCCC1CCC2=C(C1)C(=C(C(=N2)C3(CCCC3)COC)C4=NNN=N4)C5=CC=CC=C5
DMJCL53 IK OGYHUAQNUJEKHA-UHFFFAOYSA-N
DMJCL53 IU 2-[1-(methoxymethyl)cyclopentyl]-6-pentyl-4-phenyl-3-(2H-tetrazol-5-yl)-5,6,7,8-tetrahydroquinoline
DMXRTH4 ID DMXRTH4
DMXRTH4 DN PMID27109571-Compound-27
DMXRTH4 HS Patented
DMXRTH4 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMXRTH4 DT Small molecular drug
DMXRTH4 PC 86270841
DMXRTH4 MW 358.8
DMXRTH4 FM C19H19ClN2O3
DMXRTH4 IC InChI=1S/C19H19ClN2O3/c20-14-8-9-15(13-6-2-1-3-7-13)16(12-14)21-18(25)22-19(17(23)24)10-4-5-11-19/h1-3,6-9,12H,4-5,10-11H2,(H,23,24)(H2,21,22,25)
DMXRTH4 CS C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C=CC(=C2)Cl)C3=CC=CC=C3
DMXRTH4 IK YBQHFZNBCISVBS-UHFFFAOYSA-N
DMXRTH4 IU 1-[(5-chloro-2-phenylphenyl)carbamoylamino]cyclopentane-1-carboxylic acid
DMTZVY3 ID DMTZVY3
DMTZVY3 DN PMID27109571-Compound-28
DMTZVY3 HS Patented
DMTZVY3 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMTZVY3 DT Small molecular drug
DMTZVY3 PC 86270934
DMTZVY3 MW 376.8
DMTZVY3 FM C19H18ClFN2O3
DMTZVY3 IC InChI=1S/C19H18ClFN2O3/c20-13-5-8-15(12-3-6-14(21)7-4-12)16(11-13)22-18(26)23-19(17(24)25)9-1-2-10-19/h3-8,11H,1-2,9-10H2,(H,24,25)(H2,22,23,26)
DMTZVY3 CS C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C=CC(=C2)Cl)C3=CC=C(C=C3)F
DMTZVY3 IK PDTYXZFDMKYTCF-UHFFFAOYSA-N
DMTZVY3 IU 1-[[5-chloro-2-(4-fluorophenyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid
DMDMEHQ ID DMDMEHQ
DMDMEHQ DN PMID27109571-Compound-29
DMDMEHQ HS Patented
DMDMEHQ CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMDMEHQ DT Small molecular drug
DMDMEHQ PC 86270939
DMDMEHQ MW 376.8
DMDMEHQ FM C19H18ClFN2O3
DMDMEHQ IC InChI=1S/C19H18ClFN2O3/c20-14-11-16(13(10-15(14)21)12-6-2-1-3-7-12)22-18(26)23-19(17(24)25)8-4-5-9-19/h1-3,6-7,10-11H,4-5,8-9H2,(H,24,25)(H2,22,23,26)
DMDMEHQ CS C1CCC(C1)(C(=O)O)NC(=O)NC2=CC(=C(C=C2C3=CC=CC=C3)F)Cl
DMDMEHQ IK OZCRNUIWAXZIST-UHFFFAOYSA-N
DMDMEHQ IU 1-[(5-chloro-4-fluoro-2-phenylphenyl)carbamoylamino]cyclopentane-1-carboxylic acid
DMDXMH9 ID DMDXMH9
DMDXMH9 DN PMID27109571-Compound-3
DMDXMH9 HS Patented
DMDXMH9 DT Small molecular drug
DMDXMH9 PC 56592603
DMDXMH9 MW 352.4
DMDXMH9 FM C21H24N2O3
DMDXMH9 IC InChI=1S/C21H24N2O3/c24-21(26-20-7-5-16-2-1-3-17(16)14-20)18-4-6-19(22-15-18)8-9-23-10-12-25-13-11-23/h4-7,14-15H,1-3,8-13H2
DMDXMH9 CS C1CC2=C(C1)C=C(C=C2)OC(=O)C3=CN=C(C=C3)CCN4CCOCC4
DMDXMH9 IK YBXFSMTZUPPQRJ-UHFFFAOYSA-N
DMDXMH9 IU 2,3-dihydro-1H-inden-5-yl 6-(2-morpholin-4-ylethyl)pyridine-3-carboxylate
DM24FSP ID DM24FSP
DM24FSP DN PMID27109571-Compound-30
DM24FSP HS Patented
DM24FSP CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM24FSP DT Small molecular drug
DM24FSP PC 78319116
DM24FSP MW 393.3
DM24FSP FM C19H18Cl2N2O3
DM24FSP IC InChI=1S/C19H18Cl2N2O3/c20-13-10-14(21)16(12-6-2-1-3-7-12)15(11-13)22-18(26)23-19(17(24)25)8-4-5-9-19/h1-3,6-7,10-11H,4-5,8-9H2,(H,24,25)(H2,22,23,26)
DM24FSP CS C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C(=CC(=C2)Cl)Cl)C3=CC=CC=C3
DM24FSP IK XKZSVPIUPDFCIQ-UHFFFAOYSA-N
DM24FSP IU 1-[(3,5-dichloro-2-phenylphenyl)carbamoylamino]cyclopentane-1-carboxylic acid
DMU690T ID DMU690T
DMU690T DN PMID27109571-Compound-31
DMU690T HS Patented
DMU690T CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMU690T DT Small molecular drug
DMU690T PC 86271032
DMU690T MW 392.4
DMU690T FM C20H19F3N2O3
DMU690T IC InChI=1S/C20H19F3N2O3/c21-20(22,23)14-8-9-15(13-6-2-1-3-7-13)16(12-14)24-18(28)25-19(17(26)27)10-4-5-11-19/h1-3,6-9,12H,4-5,10-11H2,(H,26,27)(H2,24,25,28)
DMU690T CS C1CCC(C1)(C(=O)O)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)C3=CC=CC=C3
DMU690T IK LZSZOARSNJNBDV-UHFFFAOYSA-N
DMU690T IU 1-[[2-phenyl-5-(trifluoromethyl)phenyl]carbamoylamino]cyclopentane-1-carboxylic acid
DM4IS6Q ID DM4IS6Q
DM4IS6Q DN PMID27109571-Compound-32
DM4IS6Q HS Patented
DM4IS6Q DT Small molecular drug
DMGR2JC ID DMGR2JC
DMGR2JC DN PMID27109571-Compound-33
DMGR2JC HS Patented
DMGR2JC DT Small molecular drug
DM5OXUK ID DM5OXUK
DM5OXUK DN PMID27109571-Compound-34
DM5OXUK HS Patented
DM5OXUK DT Small molecular drug
DMGV4PT ID DMGV4PT
DMGV4PT DN PMID27109571-Compound-35
DMGV4PT HS Patented
DMGV4PT DT Small molecular drug
DMGV4PT PC 58448012
DMGV4PT MW 366.8
DMGV4PT FM C19H15ClN4O2
DMGV4PT IC InChI=1S/C19H15ClN4O2/c1-12-15(20)8-5-9-16(12)26-11-14-10-17(25)24-19(21-14)22-18(23-24)13-6-3-2-4-7-13/h2-10H,11H2,1H3,(H,21,22,23)
DMGV4PT CS CC1=C(C=CC=C1Cl)OCC2=CC(=O)N3C(=N2)N=C(N3)C4=CC=CC=C4
DMGV4PT IK DHVPJCVPOZYDTH-UHFFFAOYSA-N
DMGV4PT IU 5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
DMCJ48G ID DMCJ48G
DMCJ48G DN PMID27109571-Compound-36
DMCJ48G HS Patented
DMCJ48G DT Small molecular drug
DMCJ48G PC 73442005
DMCJ48G MW 389.5
DMCJ48G FM C18H19N3O3S2
DMCJ48G IC InChI=1S/C18H19N3O3S2/c1-8-13(17-19-9(2)21-26-17)16(25-14(8)10-6-7-10)20-15(22)11-4-3-5-12(11)18(23)24/h10H,3-7H2,1-2H3,(H,20,22)(H,23,24)
DMCJ48G CS CC1=C(SC(=C1C2=NC(=NS2)C)NC(=O)C3=C(CCC3)C(=O)O)C4CC4
DMCJ48G IK PPVLCUXVOGWJMY-UHFFFAOYSA-N
DMCJ48G IU 2-[[5-cyclopropyl-4-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)thiophen-2-yl]carbamoyl]cyclopentene-1-carboxylic acid
DMJCAOD ID DMJCAOD
DMJCAOD DN PMID27109571-Compound-37
DMJCAOD HS Patented
DMJCAOD DT Small molecular drug
DMJCAOD PC 73442653
DMJCAOD MW 467.5
DMJCAOD FM C21H20F3N3O4S
DMJCAOD IC InChI=1S/C21H20F3N3O4S/c1-8-12(9-2-3-9)15(17-26-20(27-31-17)21(22,23)24)18(32-8)25-16(28)13-10-4-6-11(7-5-10)14(13)19(29)30/h9-11H,2-7H2,1H3,(H,25,28)(H,29,30)
DMJCAOD CS CC1=C(C(=C(S1)NC(=O)C2=C(C3CCC2CC3)C(=O)O)C4=NC(=NO4)C(F)(F)F)C5CC5
DMJCAOD IK HXCOCQVXJUKVAX-UHFFFAOYSA-N
DMJCAOD IU 3-[[4-cyclopropyl-5-methyl-3-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]thiophen-2-yl]carbamoyl]bicyclo[2.2.2]oct-2-ene-2-carboxylic acid
DMRQHDF ID DMRQHDF
DMRQHDF DN PMID27109571-Compound-38
DMRQHDF HS Patented
DMRQHDF DT Small molecular drug
DMRQHDF PC 73442650
DMRQHDF MW 313.4
DMRQHDF FM C17H15NO3S
DMRQHDF IC InChI=1S/C17H15NO3S/c19-15(13-7-4-8-14(13)17(20)21)18-16-12(9-10-22-16)11-5-2-1-3-6-11/h1-3,5-6,9-10H,4,7-8H2,(H,18,19)(H,20,21)
DMRQHDF CS C1CC(=C(C1)C(=O)O)C(=O)NC2=C(C=CS2)C3=CC=CC=C3
DMRQHDF IK WTIMMZFOZTXDOY-UHFFFAOYSA-N
DMRQHDF IU 2-[(3-phenylthiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid
DMBHJDR ID DMBHJDR
DMBHJDR DN PMID27109571-Compound-39
DMBHJDR HS Patented
DMBHJDR CP THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
DMBHJDR DT Small molecular drug
DMYRG0Q ID DMYRG0Q
DMYRG0Q DN PMID27109571-Compound-4
DMYRG0Q HS Patented
DMYRG0Q DT Small molecular drug
DMYRG0Q PC 68060544
DMYRG0Q MW 248.32
DMYRG0Q FM C14H20N2O2
DMYRG0Q IC InChI=1S/C14H20N2O2/c1-2-18-14(17)12-5-6-13(15-11-12)7-10-16-8-3-4-9-16/h5-6,11H,2-4,7-10H2,1H3
DMYRG0Q CS CCOC(=O)C1=CN=C(C=C1)CCN2CCCC2
DMYRG0Q IK MBNVMBKJYZXTNI-UHFFFAOYSA-N
DMYRG0Q IU ethyl 6-(2-pyrrolidin-1-ylethyl)pyridine-3-carboxylate
DMQ83EV ID DMQ83EV
DMQ83EV DN PMID27109571-Compound-40
DMQ83EV HS Patented
DMQ83EV CP THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
DMQ83EV DT Small molecular drug
DMY4IAV ID DMY4IAV
DMY4IAV DN PMID27109571-Compound-41
DMY4IAV HS Patented
DMY4IAV CP THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
DMY4IAV DT Small molecular drug
DMZOI3K ID DMZOI3K
DMZOI3K DN PMID27109571-Compound-42
DMZOI3K HS Patented
DMZOI3K CP THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
DMZOI3K DT Small molecular drug
DMYZ42W ID DMYZ42W
DMYZ42W DN PMID27109571-Compound-43
DMYZ42W HS Patented
DMYZ42W CP THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
DMYZ42W DT Small molecular drug
DM3AUZS ID DM3AUZS
DM3AUZS DN PMID27109571-Compound-44
DM3AUZS HS Patented
DM3AUZS CP THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
DM3AUZS DT Small molecular drug
DMOZKAH ID DMOZKAH
DMOZKAH DN PMID27109571-Compound-5
DMOZKAH HS Patented
DMOZKAH DT Small molecular drug
DMOZKAH PC 23728673
DMOZKAH MW 260.329
DMOZKAH FM C15H20N2O2
DMOZKAH IC InChI=1S/C15H20N2O2/c18-15(19)5-3-4-13-6-7-14(16-12-13)8-11-17-9-1-2-10-17/h3-4,6-7,12H,1-2,5,8-11H2,(H,18,19)/b4-3+
DMOZKAH CS C1CCN(C1)CCC2=NC=C(C=C2)/C=C/CC(=O)O
DMOZKAH IK YAJGYOKZMAZQGT-ONEGZZNKSA-N
DMOZKAH IU (E)-4-[6-(2-pyrrolidin-1-ylethyl)pyridin-3-yl]but-3-enoic acid
DMPHMTR ID DMPHMTR
DMPHMTR DN PMID27109571-Compound-6
DMPHMTR HS Patented
DMPHMTR DT Small molecular drug
DM8GYCD ID DM8GYCD
DM8GYCD DN PMID27109571-Compound-7
DM8GYCD HS Patented
DM8GYCD DT Small molecular drug
DMTKFX7 ID DMTKFX7
DMTKFX7 DN PMID27109571-Compound-8
DMTKFX7 HS Patented
DMTKFX7 DT Small molecular drug
DMTKFX7 PC 68749983
DMTKFX7 MW 383.8
DMTKFX7 FM C20H18ClN3O3
DMTKFX7 IC InChI=1S/C20H18ClN3O3/c21-13-6-3-5-12(11-13)18(25)16-9-4-10-24(16)20(27)17-19(26)23-15-8-2-1-7-14(15)22-17/h1-3,5-8,11,16,18,25H,4,9-10H2,(H,23,26)
DMTKFX7 CS C1CC(N(C1)C(=O)C2=NC3=CC=CC=C3NC2=O)C(C4=CC(=CC=C4)Cl)O
DMTKFX7 IK FORQANAYPSMAGB-UHFFFAOYSA-N
DMTKFX7 IU 3-[2-[(3-chlorophenyl)-hydroxymethyl]pyrrolidine-1-carbonyl]-1H-quinoxalin-2-one
DMWM03O ID DMWM03O
DMWM03O DN PMID27109571-Compound-9
DMWM03O HS Patented
DMWM03O DT Small molecular drug
DMBWLSA ID DMBWLSA
DMBWLSA DN PMID27172114-Compound-30
DMBWLSA HS Patented
DMBWLSA CP CURADEV PHARMA PRIVATE LTDCuradev Pharma Private Ltd
DMBWLSA DT Small molecular drug
DMTIQYD ID DMTIQYD
DMTIQYD DN PMID27172114-Compound-47
DMTIQYD HS Patented
DMTIQYD CP DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia, M. COURTNEY, Stephen, Martin PRIME, Michael MITCHELL, William BROWN, Christopher, John DE AGUIAR PENA, Paula, C. JOHNSON, Peter
DMTIQYD DT Small molecular drug
DMSXJVY ID DMSXJVY
DMSXJVY DN PMID27172114-Compound-49
DMSXJVY HS Patented
DMSXJVY CP DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia, M. COURTNEY, Stephen, Martin PRIME, Michael MITCHELL, William BROWN, Christopher, John DE AGUIAR PENA, Paula, C. JOHNSON, Peter
DMSXJVY DT Small molecular drug
DM84RES ID DM84RES
DM84RES DN PMID27215781-Compound-1
DM84RES HS Patented
DM84RES CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM84RES DT Small molecular drug
DM84RES PC 78428089
DM84RES MW 314.4
DM84RES FM C19H26N2O2
DM84RES IC InChI=1S/C19H26N2O2/c1-3-19(4-2)12-23-18(21-19)16-9-17(22-11-13-5-6-13)15(10-20-16)14-7-8-14/h9-10,13-14H,3-8,11-12H2,1-2H3
DM84RES CS CCC1(COC(=N1)C2=NC=C(C(=C2)OCC3CC3)C4CC4)CC
DM84RES IK NMHFZCVAQZPHOP-UHFFFAOYSA-N
DM84RES IU 2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole
DMIX90M ID DMIX90M
DMIX90M DN PMID27215781-Compound-11
DMIX90M HS Patented
DMIX90M CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH HICKEY, Eugene Richard RIETHER, Doris ERMANN, Monika
DMIX90M DT Small molecular drug
DMIX90M PC 59662643
DMIX90M MW 448.5
DMIX90M FM C19H23F3N2O3S2
DMIX90M IC InChI=1S/C19H23F3N2O3S2/c1-11-14(17(2,3)4)28-16(23-11)24-15(25)18(5,6)29(26,27)13-9-7-12(8-10-13)19(20,21)22/h7-10H,1-6H3,(H,23,24,25)
DMIX90M CS CC1=C(SC(=N1)NC(=O)C(C)(C)S(=O)(=O)C2=CC=C(C=C2)C(F)(F)F)C(C)(C)C
DMIX90M IK GQVUAMKUPFMNNE-UHFFFAOYSA-N
DMIX90M IU N-(5-tert-butyl-4-methyl-1,3-thiazol-2-yl)-2-methyl-2-[4-(trifluoromethyl)phenyl]sulfonylpropanamide
DMR9GLW ID DMR9GLW
DMR9GLW DN PMID27215781-Compound-12
DMR9GLW HS Patented
DMR9GLW CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH HICKEY, Eugene Richard RIETHER, Doris ERMANN, Monika
DMR9GLW DT Small molecular drug
DMR9GLW PC 56639654
DMR9GLW MW 389.5
DMR9GLW FM C16H27N3O4S2
DMR9GLW IC InChI=1S/C16H27N3O4S2/c1-15(2,3)13-18-19-14(24-13)17-12(20)16(4,5)10-25(21,22)11-6-8-23-9-7-11/h11H,6-10H2,1-5H3,(H,17,19,20)
DMR9GLW CS CC(C)(C)C1=NN=C(S1)NC(=O)C(C)(C)CS(=O)(=O)C2CCOCC2
DMR9GLW IK YNOMXHGERFXVDK-UHFFFAOYSA-N
DMR9GLW IU N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-2,2-dimethyl-3-(oxan-4-ylsulfonyl)propanamide
DMNKH07 ID DMNKH07
DMNKH07 DN PMID27215781-Compound-13
DMNKH07 HS Patented
DMNKH07 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH HICKEY, Eugene Richard RIETHER, Doris ERMANN, Monika
DMNKH07 DT Small molecular drug
DMYMTSL ID DMYMTSL
DMYMTSL DN PMID27215781-Compound-19
DMYMTSL HS Patented
DMYMTSL CP ARENA PHARMACEUTICALS, INC. BLACKBURN, Anthony C. HAN, Sangdon JONES, Robert M. MONTALBAN, Anthony Garrido PAL, Biman B. RUETER, Jaimie Karyn
DMYMTSL DT Small molecular drug
DMBOX0K ID DMBOX0K
DMBOX0K DN PMID27215781-Compound-2
DMBOX0K HS Patented
DMBOX0K CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMBOX0K DT Small molecular drug
DMBOX0K PC 76283339
DMBOX0K MW 365.4
DMBOX0K FM C19H25F2N3O2
DMBOX0K IC InChI=1S/C19H25F2N3O2/c1-18(2)8-3-9-24(18)17(25)14-6-7-15(23-11-19(20,21)12-23)16(22-14)26-10-13-4-5-13/h6-7,13H,3-5,8-12H2,1-2H3
DMBOX0K CS CC1(CCCN1C(=O)C2=NC(=C(C=C2)N3CC(C3)(F)F)OCC4CC4)C
DMBOX0K IK AOQJVECXJNNKAZ-UHFFFAOYSA-N
DMBOX0K IU [6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-(2,2-dimethylpyrrolidin-1-yl)methanone
DMKZF8E ID DMKZF8E
DMKZF8E DN PMID27215781-Compound-25
DMKZF8E HS Patented
DMKZF8E CP ISIS INNOVATION LIMITED
DMKZF8E DT Small molecular drug
DMKZF8E PC 5752181
DMKZF8E MW 258.339
DMKZF8E FM C13H14N4S
DMKZF8E IC InChI=1S/C13H14N4S/c1-2-3-8-18-13-15-12-11(16-17-13)9-6-4-5-7-10(9)14-12/h4-7H,2-3,8H2,1H3,(H,14,15,17)
DMKZF8E CS CCCCSC1=NC2=C(C3=CC=CC=C3N2)N=N1
DMKZF8E IK JLINGBANGFPKNS-UHFFFAOYSA-N
DMKZF8E IU 3-butylsulfanyl-5H-[1,2,4]triazino[5,6-b]indole
DMTJHC2 ID DMTJHC2
DMTJHC2 DN PMID27215781-Compound-27
DMTJHC2 HS Patented
DMTJHC2 CP ISIS INNOVATION LIMITED
DMTJHC2 DT Small molecular drug
DMTJHC2 PC 71539748
DMTJHC2 MW 412.4
DMTJHC2 FM C21H12N6O2S
DMTJHC2 IC InChI=1S/C21H12N6O2S/c22-11-13-5-1-2-6-14(13)12-30-21-24-19-18(25-26-21)15-7-3-4-8-16(15)27(19)20(28)17-9-10-23-29-17/h1-10H,12H2
DMTJHC2 CS C1=CC=C(C(=C1)CSC2=NC3=C(C4=CC=CC=C4N3C(=O)C5=CC=NO5)N=N2)C#N
DMTJHC2 IK DRIBOKZNLIGADO-UHFFFAOYSA-N
DMTJHC2 IU 2-[[5-(1,2-oxazole-5-carbonyl)-[1,2,4]triazino[5,6-b]indol-3-yl]sulfanylmethyl]benzonitrile
DM9ZF3P ID DM9ZF3P
DM9ZF3P DN PMID27215781-Compound-28
DM9ZF3P HS Patented
DM9ZF3P CP BAYER INTELLECTUAL PROPERTY GMBH KOCH, Markus WOLF, Siegmund BUCHMANN, Bernd FUHRMANN, Ulrike DROESCHER, Peter ZOLLNER, Thomas
DM9ZF3P DT Small molecular drug
DM9ZF3P DE Endometriosis
DMDJM1Y ID DMDJM1Y
DMDJM1Y DN PMID27215781-Compound-29
DMDJM1Y HS Patented
DMDJM1Y DT Small molecular drug
DMDJM1Y PC 89597397
DMDJM1Y MW 468.4
DMDJM1Y FM C18H14F6N2O4S
DMDJM1Y IC InChI=1S/C18H14F6N2O4S/c19-17(20,21)29-12-3-1-2-11(7-12)26-13-8-25-16(30-31(27,28)18(22,23)24)15-10-5-4-9(6-10)14(13)15/h1-3,7-10,26H,4-6H2
DMDJM1Y CS C1CC2CC1C3=C2C(=NC=C3NC4=CC(=CC=C4)OC(F)(F)F)OS(=O)(=O)C(F)(F)F
DMDJM1Y IK DQBACBSLAAPBLG-UHFFFAOYSA-N
DMDJM1Y IU [6-[3-(trifluoromethoxy)anilino]-4-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-3-yl] trifluoromethanesulfonate
DM7USO9 ID DM7USO9
DM7USO9 DN PMID27215781-Compound-30
DM7USO9 HS Patented
DM7USO9 DT Small molecular drug
DM7USO9 PC 89608962
DM7USO9 MW 360.4
DM7USO9 FM C21H26F2N2O
DM7USO9 IC InChI=1S/C21H26F2N2O/c1-26-18-17-14-3-2-13(4-14)16(17)15(8-24-18)25-21-7-12-5-19(22,10-21)9-20(23,6-12)11-21/h8,12-14,25H,2-7,9-11H2,1H3
DM7USO9 CS COC1=NC=C(C2=C1C3CCC2C3)NC45CC6CC(C4)(CC(C6)(C5)F)F
DM7USO9 IK YKIONNFZUQIKPS-UHFFFAOYSA-N
DM7USO9 IU N-(3,5-difluoro-1-adamantyl)-3-methoxy-4-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-6-amine
DMJMO72 ID DMJMO72
DMJMO72 DN PMID27215781-Compound-31
DMJMO72 HS Patented
DMJMO72 DT Small molecular drug
DM7IYRM ID DM7IYRM
DM7IYRM DN PMID27215781-Compound-32
DM7IYRM HS Patented
DM7IYRM CP C4T S.C. A.R.L
DM7IYRM DT Small molecular drug
DM7IYRM PC 76285830
DM7IYRM MW 469.6
DM7IYRM FM C24H23NO5S2
DM7IYRM IC InChI=1S/C24H23NO5S2/c26-23-20-12-11-19(30-32(27,28)22-10-7-15-31-22)16-21(20)29-24(13-5-2-6-14-24)25(23)17-18-8-3-1-4-9-18/h1,3-4,7-12,15-16H,2,5-6,13-14,17H2
DM7IYRM CS C1CCC2(CC1)N(C(=O)C3=C(O2)C=C(C=C3)OS(=O)(=O)C4=CC=CS4)CC5=CC=CC=C5
DM7IYRM IK XBCSLRKNSRBEMJ-UHFFFAOYSA-N
DM7IYRM IU (3-benzyl-4-oxospiro[1,3-benzoxazine-2,1'-cyclohexane]-7-yl) thiophene-2-sulfonate
DMX4W2R ID DMX4W2R
DMX4W2R DN PMID27215781-Compound-33
DMX4W2R HS Patented
DMX4W2R CP C4T S.C. A.R.L
DMX4W2R DT Small molecular drug
DMX4W2R PC 75593310
DMX4W2R MW 455.5
DMX4W2R FM C24H22FNO5S
DMX4W2R IC InChI=1S/C24H22FNO5S/c1-16-4-11-20(12-5-16)32(28,29)31-19-10-13-21-22(14-19)30-24(2,3)26(23(21)27)15-17-6-8-18(25)9-7-17/h4-14H,15H2,1-3H3
DMX4W2R CS CC1=CC=C(C=C1)S(=O)(=O)OC2=CC3=C(C=C2)C(=O)N(C(O3)(C)C)CC4=CC=C(C=C4)F
DMX4W2R IK RDCDFXNTJYTRNH-UHFFFAOYSA-N
DMX4W2R IU [3-[(4-fluorophenyl)methyl]-2,2-dimethyl-4-oxo-1,3-benzoxazin-7-yl] 4-methylbenzenesulfonate
DMTAZBC ID DMTAZBC
DMTAZBC DN PMID27215781-Compound-34
DMTAZBC HS Patented
DMTAZBC CP C4T S.C. A.R.L
DMTAZBC DT Small molecular drug
DM0L68P ID DM0L68P
DM0L68P DN PMID27215781-Compound-37
DM0L68P HS Patented
DM0L68P CP CONSEJO SUPERIOR DE INVESTIGACIONES CIENTICAS (CSIC) UNIVERSIDAD DE ALCAL DE HENARES UNIVERSIDAD COMPLUTENSE DE MADRID
DM0L68P DT Small molecular drug
DM0L68P PC 60148509
DM0L68P MW 356.5
DM0L68P FM C21H28N2O3
DM0L68P IC InChI=1S/C21H28N2O3/c1-6-7-8-9-10-20(2,3)13-11-15(24)16-17-14(12-22-23-17)21(4,5)26-19(16)18(13)25/h11-12H,6-10H2,1-5H3,(H,22,23)
DM0L68P CS CCCCCCC(C)(C)C1=CC(=O)C2=C(C1=O)OC(C3=C2NN=C3)(C)C
DM0L68P IK XRDIITMVNDBOHN-UHFFFAOYSA-N
DM0L68P IU 4,4-dimethyl-7-(2-methyloctan-2-yl)-1H-chromeno[4,3-c]pyrazole-6,9-dione
DM0L68P DE Prostate cancer
DMRU0BL ID DMRU0BL
DMRU0BL DN PMID27215781-Compound-4
DMRU0BL HS Patented
DMRU0BL CP F. HOFFMANN-LA ROCHE AG BISSANTZ, Caterina DHURWASULU, Baledi GRETHER, Uwe HAZRA, Anindya HEBEISEN, Paul ROEVER, Stephan ROGERS-EVANS, Mark
DMRU0BL DT Small molecular drug
DMRU0BL PC 71526408
DMRU0BL MW 410.4
DMRU0BL FM C19H24F2N4O4
DMRU0BL IC InChI=1S/C19H24F2N4O4/c1-18(12-5-6-12,17(27)28-2)24-15(26)13-7-22-14(25-9-19(20,21)10-25)16(23-13)29-8-11-3-4-11/h7,11-12H,3-6,8-10H2,1-2H3,(H,24,26)
DMRU0BL CS CC(C1CC1)(C(=O)OC)NC(=O)C2=CN=C(C(=N2)OCC3CC3)N4CC(C4)(F)F
DMRU0BL IK ZVGNNTZBRRKTHH-UHFFFAOYSA-N
DMRU0BL IU methyl 2-cyclopropyl-2-[[6-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyrazine-2-carbonyl]amino]propanoate
DM0NYK3 ID DM0NYK3
DM0NYK3 DN PMID27321640-Compound-58
DM0NYK3 HS Patented
DM0NYK3 CP LUNDBECK & CO AS H [DK]
DM0NYK3 DT Small molecular drug
DM41B5O ID DM41B5O
DM41B5O DN PMID27321640-Compound-59
DM41B5O HS Patented
DM41B5O CP LUNDBECK & CO AS H [DK]
DM41B5O DT Small molecular drug
DMHWV67 ID DMHWV67
DMHWV67 DN PMID27321640-Compound-74
DMHWV67 HS Patented
DMHWV67 DT Small molecular drug
DM2P5J9 ID DM2P5J9
DM2P5J9 DN PMID27321640-Compound-75
DM2P5J9 HS Patented
DM2P5J9 DT Small molecular drug
DM40LIN ID DM40LIN
DM40LIN DN PMID27321640-Compound-76
DM40LIN HS Patented
DM40LIN DT Small molecular drug
DMYUP6G ID DMYUP6G
DMYUP6G DN PMID27336223-Compound-10
DMYUP6G HS Patented
DMYUP6G DT Small molecular drug
DMYUP6G PC 5381
DMYUP6G MW 351.5
DMYUP6G FM C21H21NO2S
DMYUP6G IC InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3
DMYUP6G CS CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C
DMYUP6G IK OGQICQVSFDPSEI-UHFFFAOYSA-N
DMYUP6G IU ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate
DMYUP6G CA CAS 118292-40-3
DMYUP6G CB CHEBI:32184
DMBN6KU ID DMBN6KU
DMBN6KU DN PMID27336223-Compound-11
DMBN6KU HS Patented
DMBN6KU DT Small molecular drug
DMBN6KU PC 60164
DMBN6KU MW 412.5
DMBN6KU FM C28H28O3
DMBN6KU IC InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
DMBN6KU CS COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DMBN6KU IK LZCDAPDGXCYOEH-UHFFFAOYSA-N
DMBN6KU IU 6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
DMBN6KU CA CAS 106685-40-9
DMBN6KU CB CHEBI:31174
DMT4P7K ID DMT4P7K
DMT4P7K DN PMID27336223-Compound-12
DMT4P7K HS Patented
DMT4P7K DT Small molecular drug
DMT4P7K PC 135411
DMT4P7K MW 398.5
DMT4P7K FM C27H26O3
DMT4P7K IC InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
DMT4P7K CS C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O
DMT4P7K IK LDGIHZJOIQSHPB-UHFFFAOYSA-N
DMT4P7K IU 6-[3-(1-adamantyl)-4-hydroxyphenyl]naphthalene-2-carboxylic acid
DMT4P7K CA CAS 125316-60-1
DMT4P7K CB CHEBI:88334
DMSZLYD ID DMSZLYD
DMSZLYD DN PMID27336223-Compound-13
DMSZLYD HS Patented
DMSZLYD DT Small molecular drug
DMC41MA ID DMC41MA
DMC41MA DN PMID27336223-Compound-14
DMC41MA HS Patented
DMC41MA DT Small molecular drug
DMC41MA PC 445455
DMC41MA MW 399.5
DMC41MA FM C23H26FNO4
DMC41MA IC InChI=1S/C23H26FNO4/c1-22(2)9-10-23(3,4)16-11-13(5-7-15(16)22)19(26)20(27)25-18-8-6-14(21(28)29)12-17(18)24/h5-8,11-12,19,26H,9-10H2,1-4H3,(H,25,27)(H,28,29)/t19-/m1/s1
DMC41MA CS CC1(CCC(C2=C1C=CC(=C2)[C@H](C(=O)NC3=C(C=C(C=C3)C(=O)O)F)O)(C)C)C
DMC41MA IK AANFHDFOMFRLLR-LJQANCHMSA-N
DMC41MA IU 3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid
DMIYCFE ID DMIYCFE
DMIYCFE DN PMID27336223-Compound-15
DMIYCFE HS Patented
DMIYCFE DT Small molecular drug
DMIYCFE PC 445455
DMIYCFE MW 399.5
DMIYCFE FM C23H26FNO4
DMIYCFE IC InChI=1S/C23H26FNO4/c1-22(2)9-10-23(3,4)16-11-13(5-7-15(16)22)19(26)20(27)25-18-8-6-14(21(28)29)12-17(18)24/h5-8,11-12,19,26H,9-10H2,1-4H3,(H,25,27)(H,28,29)/t19-/m1/s1
DMIYCFE CS CC1(CCC(C2=C1C=CC(=C2)[C@H](C(=O)NC3=C(C=C(C=C3)C(=O)O)F)O)(C)C)C
DMIYCFE IK AANFHDFOMFRLLR-LJQANCHMSA-N
DMIYCFE IU 3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid
DMJFSOM ID DMJFSOM
DMJFSOM DN PMID27336223-Compound-4
DMJFSOM HS Patented
DMJFSOM CP KEMPHYS LTD
DMJFSOM DT Small molecular drug
DMJFSOM PC 108143
DMJFSOM MW 351.4
DMJFSOM FM C22H25NO3
DMJFSOM IC InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DMJFSOM CS CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
DMJFSOM IK MUTNCGKQJGXKEM-UHFFFAOYSA-N
DMJFSOM IU 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
DMJFSOM CA CAS 94497-51-5
DMJFSOM CB CHEBI:32181
DM6E50A ID DM6E50A
DM6E50A DN PMID27336223-Compound-5
DM6E50A HS Patented
DM6E50A CP CORNELL UNIVERSITY
DM6E50A DT Small molecular drug
DM6E50A PC 2126
DM6E50A MW 351.4
DM6E50A FM C22H25NO3
DM6E50A IC InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)
DM6E50A CS CC1(CCC(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)(C)C)C
DM6E50A IK SZWKGOZKRMMLAJ-UHFFFAOYSA-N
DM6E50A IU 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]benzoic acid
DM6E50A CA CAS 102121-60-8
DM6E50A CB CHEBI:64210
DM9QM6I ID DM9QM6I
DM9QM6I DN PMID27336223-Compound-7
DM9QM6I HS Patented
DM9QM6I CP CORNELL UNIVERSITY
DM9QM6I DT Small molecular drug
DM460D1 ID DM460D1
DM460D1 DN PMID27336223-Compound-8
DM460D1 HS Patented
DM460D1 CP CORNELL UNIVERSITY
DM460D1 DT Small molecular drug
DM460D1 PC 1714884
DM460D1 MW 310.4
DM460D1 FM C21H26O2
DM460D1 IC InChI=1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)
DM460D1 CS CCCCCCCCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)O
DM460D1 IK HXBKPYIEQLLNBK-UHFFFAOYSA-N
DM460D1 IU 4-(4-octylphenyl)benzoic acid
DM460D1 CA CAS 59662-49-6
DM460D1 CB CHEBI:95048
DM6V13W ID DM6V13W
DM6V13W DN PMID27336223-Compound-9
DM6V13W HS Patented
DM6V13W CP CORNELL UNIVERSITY GUDAS, Lorraine J TANG, Xiao-Han OSEI-SARFO, Kwame URVALEK, Aliso
DM6V13W DT Small molecular drug
DM6V13W PC 9952709
DM6V13W MW 398.5
DM6V13W FM C27H26O3
DM6V13W IC InChI=1S/C27H26O3/c28-25-12-22-6-5-21(19-1-3-20(4-2-19)26(29)30)10-23(22)11-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
DM6V13W CS C1C2CC3CC1CC(C2)(C3)C4=C(C=C5C=CC(=CC5=C4)C6=CC=C(C=C6)C(=O)O)O
DM6V13W IK VCQGNUWOMLYNNG-UHFFFAOYSA-N
DM6V13W IU 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid
DM6V13W CA CAS 107430-66-0
DMTQRVC ID DMTQRVC
DMTQRVC DN PMID27376512-Compound-asCEBP-1
DMTQRVC HS Patented
DMTQRVC CP NEW ENGLAND BIOLABS INC
DMTQRVC DT Nucleotide
DMTQRVC SQ CCGGGACGCAGGCGGCGUCAGGC
DMLAY8B ID DMLAY8B
DMLAY8B DN PMID27376512-Compound-asCEBP-1HPE
DMLAY8B HS Patented
DMLAY8B CP NEW ENGLAND BIOLABS INC
DMLAY8B DT Nucleotide
DMLAY8B SQ CCGGGAAGCAGGCGGCGUCAGGC
DMJUL1A ID DMJUL1A
DMJUL1A DN PMID27376512-Compound-asCEBP-2
DMJUL1A HS Patented
DMJUL1A CP NEW ENGLAND BIOLABS INC
DMJUL1A DT Nucleotide
DMJUL1A SQ GCCAGUGGCGAGGGGCGGCGCGG
DM9QEIV ID DM9QEIV
DM9QEIV DN PMID27376512-Compound-asCEBP-2HPE
DM9QEIV HS Patented
DM9QEIV CP NEW ENGLAND BIOLABS INC
DM9QEIV DT Nucleotide
DM9QEIV SQ GACAGUGGAGAGGGGCGGAGCGG
DMBFUTL ID DMBFUTL
DMBFUTL DN PMID27376512-Compound-CROs
DMBFUTL HS Patented
DMBFUTL CP BETH ISRAEL DEACONESS MEDICAL CENTER, INC. DIRUSCIO, Annalisa EBRALIDZE, Alexander, K. TENEN, Daniel, G. LEONE, Giuseppe UNIVERSITA CATTOLICA DEL SACRO CUOR
DMBFUTL DT siRNA drug
DMP59OX ID DMP59OX
DMP59OX DN PMID27376512-Compound-Figure2aExample1
DMP59OX HS Patented
DMP59OX CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED HENDRICKSON, Thomas, Francis HO, Koc-Kan SAUNDERS, Michael, David STEVENS, Brian, John SWIERCZEK, Krzysztof WRIGHT, Kevin, Bret
DMP59OX DT Small molecular drug
DMP59OX PC 71521835
DMP59OX MW 438.9
DMP59OX FM C16H19ClN8O3S
DMP59OX IC InChI=1S/C16H19ClN8O3S/c17-9-1-2-19-16(24-9)20-3-4-29-5-8-11(26)12(27)15(28-8)25-7-23-10-13(18)21-6-22-14(10)25/h1-2,6-8,11-12,15,26-27H,3-5H2,(H2,18,21,22)(H,19,20,24)/t8-,11-,12-,15-/m0/s1
DMP59OX CS C1=CN=C(N=C1Cl)NCCSC[C@H]2[C@@H]([C@@H]([C@H](O2)N3C=NC4=C(N=CN=C43)N)O)O
DMP59OX IK ZWBSJRQJKXXDKA-REXDEQPNSA-N
DMP59OX IU (2S,3S,4R,5R)-2-(6-aminopurin-9-yl)-5-[2-[(4-chloropyrimidin-2-yl)amino]ethylsulfanylmethyl]oxolane-3,4-diol
DMZIKN6 ID DMZIKN6
DMZIKN6 DN PMID27376512-Compound-Figure3CG
DMZIKN6 HS Patented
DMZIKN6 CP PIERRE FABRE MEDICAMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMZIKN6 DT Small molecular drug
DMZIKN6 PC 117967861
DMZIKN6 MW 546.7
DMZIKN6 FM C34H38N6O
DMZIKN6 IC InChI=1S/C34H38N6O/c1-2-7-26(8-3-1)9-6-17-37-34-30-13-12-28(23-33(30)38-25-39-34)41-24-27-15-20-40(21-16-27)22-19-36-32-14-18-35-31-11-5-4-10-29(31)32/h1-5,7-8,10-14,18,23,25,27H,6,9,15-17,19-22,24H2,(H,35,36)(H,37,38,39)
DMZIKN6 CS C1CN(CCC1COC2=CC3=C(C=C2)C(=NC=N3)NCCCC4=CC=CC=C4)CCNC5=CC=NC6=CC=CC=C65
DMZIKN6 IK DPNGRMNVFKZZSM-UHFFFAOYSA-N
DMZIKN6 IU N-(3-phenylpropyl)-7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-amine
DMIS4H0 ID DMIS4H0
DMIS4H0 DN PMID27376512-Compound-Figure3CM
DMIS4H0 HS Patented
DMIS4H0 CP PIERRE FABRE MEDICAMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMIS4H0 DT Small molecular drug
DMIS4H0 PC 117976053
DMIS4H0 MW 599.7
DMIS4H0 FM C36H37N7O2
DMIS4H0 IC InChI=1S/C36H37N7O2/c44-36-30-10-9-27(23-35(30)41-25-43(36)22-18-40-34-12-16-38-32-8-4-2-6-29(32)34)45-24-26-13-19-42(20-14-26)21-17-39-33-11-15-37-31-7-3-1-5-28(31)33/h1-12,15-16,23,25-26H,13-14,17-22,24H2,(H,37,39)(H,38,40)
DMIS4H0 CS C1CN(CCC1COC2=CC3=C(C=C2)C(=O)N(C=N3)CCNC4=CC=NC5=CC=CC=C54)CCNC6=CC=NC7=CC=CC=C76
DMIS4H0 IK ZJSGNMNKODEYPA-UHFFFAOYSA-N
DMIS4H0 IU 3-[2-(quinolin-4-ylamino)ethyl]-7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-one
DMP7DL6 ID DMP7DL6
DMP7DL6 DN PMID27376512-Compound-Figure3CN
DMP7DL6 HS Patented
DMP7DL6 CP PIERRE FABRE MEDICAMENT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMP7DL6 DT Small molecular drug
DMP7DL6 PC 117968550
DMP7DL6 MW 594.7
DMP7DL6 FM C38H38N6O
DMP7DL6 IC InChI=1S/C38H38N6O/c1-2-6-30(7-3-1)31-12-10-28(11-13-31)25-41-38-34-15-14-32(24-37(34)42-27-43-38)45-26-29-17-21-44(22-18-29)23-20-40-36-16-19-39-35-9-5-4-8-33(35)36/h1-16,19,24,27,29H,17-18,20-23,25-26H2,(H,39,40)(H,41,42,43)
DMP7DL6 CS C1CN(CCC1COC2=CC3=C(C=C2)C(=NC=N3)NCC4=CC=C(C=C4)C5=CC=CC=C5)CCNC6=CC=NC7=CC=CC=C76
DMP7DL6 IK GPQPTJSUKRSGBL-UHFFFAOYSA-N
DMP7DL6 IU N-[(4-phenylphenyl)methyl]-7-[[1-[2-(quinolin-4-ylamino)ethyl]piperidin-4-yl]methoxy]quinazolin-4-amine
DM67VNW ID DM67VNW
DM67VNW DN PMID27376512-Compound-miR-155-5p
DM67VNW HS Patented
DM67VNW CP NEW ENGLAND BIOLABS INC
DM67VNW DT Nucleotide
DM67VNW SQ UUAAUGCUAAUCGUGAUAGGGGU
DM1MVQD ID DM1MVQD
DM1MVQD DN PMID27376512-Compound-MTC-422
DM1MVQD HS Patented
DM1MVQD CP METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM1MVQD DT Nucleotide
DM9RSDX ID DM9RSDX
DM9RSDX DN PMID27376512-Compound-MTC-423
DM9RSDX HS Patented
DM9RSDX CP METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM9RSDX DT Nucleotide
DM9RSDX SQ 5CCTATGCGATCGAGTTTTCT[zebularine (pyrimidin-2-one ribonucleoside)]GAT[zebularine (pyrimidin-2-one ribonucleoside)]GCATAGG3
DMGNRZU ID DMGNRZU
DMGNRZU DN PMID27376512-Compound-MTC-424
DMGNRZU HS Patented
DMGNRZU CP METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DMGNRZU DT Nucleotide
DMGNRZU SQ 5GTACATG[X]GCTCCAGA3
DMWXEZD ID DMWXEZD
DMWXEZD DN PMID27376512-Compound-MTC-427
DMWXEZD HS Patented
DMWXEZD CP METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DMWXEZD DT Nucleotide
DMWXEZD SQ 5CCTATG[methylcytosine]GAT[methylcytosine]GAGTTTTCT[zebularine]GCATAGG3
DM7OS5E ID DM7OS5E
DM7OS5E DN PMID27376512-Compound-MTC-433
DM7OS5E HS Patented
DM7OS5E CP METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM7OS5E DT Nucleotide
DM7OS5E SQ 5CCTATG[5-methylcytosine]GAT[5-methylcytosine]GAGTTTTCT[deoxyzebularine]GAT[deoxyzebularine]GCATAGG3
DM70CTE ID DM70CTE
DM70CTE DN PMID27376512-Compound-MTC-434
DM70CTE HS Patented
DM70CTE CP METHEOR THERAPEUTICS CORPORATION SLEDZIEWSKI, Andrew, Z. DEVOS, Theodore KOLE, Ryszard
DM70CTE DT Nucleotide
DM70CTE SQ 5CCTATGGCATGCAGTTTTCTGCATGCCATAGG3
DM5K4YF ID DM5K4YF
DM5K4YF DN PMID27376512-Compound-PG-11047
DM5K4YF HS Patented
DM5K4YF DT Small molecular drug
DM5K4YF PC 6475492
DM5K4YF MW 256.43
DM5K4YF FM C14H32N4
DM5K4YF IC InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5-
DM5K4YF CS CCNCCCNC/C=C\\CNCCCNCC
DM5K4YF IK XFWLTFZLLXVKDY-WAYWQWQTSA-N
DM5K4YF IU (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM5K4YF CA CAS 308145-19-9
DM3U7RN ID DM3U7RN
DM3U7RN DN PMID27376512-Compound-PG-11048
DM3U7RN HS Patented
DM3U7RN DT Small molecular drug
DM3U7RN PC 6532281
DM3U7RN MW 256.43
DM3U7RN FM C14H32N4
DM3U7RN IC InChI=1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5+
DM3U7RN CS CCNCCCNC/C=C/CNCCCNCC
DM3U7RN IK XFWLTFZLLXVKDY-AATRIKPKSA-N
DM3U7RN IU (E)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine
DM3U7RN CB CHEBI:93760
DMIFTUN ID DMIFTUN
DMIFTUN DN PMID27376512-Compound-Table1Example11
DMIFTUN HS Patented
DMIFTUN CP IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMIFTUN DT Small molecular drug
DMIFTUN PC 75201485
DMIFTUN MW 467.4
DMIFTUN FM C24H21NO9
DMIFTUN IC InChI=1S/C24H21NO9/c1-33-11-7-15-20(19(8-11)34-2)14(12-3-5-16(26)23(31)21(12)29)9-25(15)10-18(28)13-4-6-17(27)24(32)22(13)30/h3-9,26-27,29-32H,10H2,1-2H3
DMIFTUN CS COC1=CC2=C(C(=C1)OC)C(=CN2CC(=O)C3=C(C(=C(C=C3)O)O)O)C4=C(C(=C(C=C4)O)O)O
DMIFTUN IK GBDRNHMXDAEPNN-UHFFFAOYSA-N
DMIFTUN IU 2-[4,6-dimethoxy-3-(2,3,4-trihydroxyphenyl)indol-1-yl]-1-(2,3,4-trihydroxyphenyl)ethanone
DMM3VA8 ID DMM3VA8
DMM3VA8 DN PMID27376512-Compound-Table1Example16
DMM3VA8 HS Patented
DMM3VA8 CP IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMM3VA8 DT Small molecular drug
DMM3VA8 PC 75201537
DMM3VA8 MW 379.4
DMM3VA8 FM C22H15F2NO3
DMM3VA8 IC InChI=1S/C22H15F2NO3/c23-15-9-19(24)22-18(13-1-5-16(26)6-2-13)11-25(20(22)10-15)12-21(28)14-3-7-17(27)8-4-14/h1-11,26-27H,12H2
DMM3VA8 CS C1=CC(=CC=C1C2=CN(C3=C2C(=CC(=C3)F)F)CC(=O)C4=CC=C(C=C4)O)O
DMM3VA8 IK ZSLQOKAZOXSRMM-UHFFFAOYSA-N
DMM3VA8 IU 2-[4,6-difluoro-3-(4-hydroxyphenyl)indol-1-yl]-1-(4-hydroxyphenyl)ethanone
DM5RX9D ID DM5RX9D
DM5RX9D DN PMID27376512-Compound-Table1Example30
DM5RX9D HS Patented
DM5RX9D CP IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DM5RX9D DT Small molecular drug
DM5RX9D PC 75201638
DM5RX9D MW 603.6
DM5RX9D FM C32H29NO11
DM5RX9D IC InChI=1S/C32H29NO11/c1-17(34)41-27-9-7-21(11-29(27)43-19(3)36)24-15-33(25-13-23(39-5)14-31(40-6)32(24)25)16-26(38)22-8-10-28(42-18(2)35)30(12-22)44-20(4)37/h7-15H,16H2,1-6H3
DM5RX9D CS CC(=O)OC1=C(C=C(C=C1)C2=CN(C3=C2C(=CC(=C3)OC)OC)CC(=O)C4=CC(=C(C=C4)OC(=O)C)OC(=O)C)OC(=O)C
DM5RX9D IK NMWWCTXMWYUUNT-UHFFFAOYSA-N
DM5RX9D IU [2-acetyloxy-4-[1-[2-(3,4-diacetyloxyphenyl)-2-oxoethyl]-4,6-dimethoxyindol-3-yl]phenyl] acetate
DMFJG7P ID DMFJG7P
DMFJG7P DN PMID27376512-Compound-Table1Example4
DMFJG7P HS Patented
DMFJG7P CP IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMFJG7P DT Small molecular drug
DMFJG7P PC 75201432
DMFJG7P MW 405.4
DMFJG7P FM C23H19NO6
DMFJG7P IC InChI=1S/C23H19NO6/c1-30-15-4-5-16-17(13-2-6-19(25)21(27)8-13)11-24(18(16)10-15)12-23(29)14-3-7-20(26)22(28)9-14/h2-11,25-28H,12H2,1H3
DMFJG7P CS COC1=CC2=C(C=C1)C(=CN2CC(=O)C3=CC(=C(C=C3)O)O)C4=CC(=C(C=C4)O)O
DMFJG7P IK YPZMHCJTRFQAIG-UHFFFAOYSA-N
DMFJG7P IU 1-(3,4-dihydroxyphenyl)-2-[3-(3,4-dihydroxyphenyl)-6-methoxyindol-1-yl]ethanone
DM4Q6XZ ID DM4Q6XZ
DM4Q6XZ DN PMID27376512-Compound-Table1Example5
DM4Q6XZ HS Patented
DM4Q6XZ CP IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DM4Q6XZ DT Small molecular drug
DM4Q6XZ PC 73774653
DM4Q6XZ MW 437.4
DM4Q6XZ FM C23H19NO8
DM4Q6XZ IC InChI=1S/C23H19NO8/c1-32-11-2-3-12-15(13-4-6-17(25)22(30)20(13)28)9-24(16(12)8-11)10-19(27)14-5-7-18(26)23(31)21(14)29/h2-9,25-26,28-31H,10H2,1H3
DM4Q6XZ CS COC1=CC2=C(C=C1)C(=CN2CC(=O)C3=C(C(=C(C=C3)O)O)O)C4=C(C(=C(C=C4)O)O)O
DM4Q6XZ IK SFHIQZITSGPFGB-UHFFFAOYSA-N
DM4Q6XZ IU 2-[6-methoxy-3-(2,3,4-trihydroxyphenyl)indol-1-yl]-1-(2,3,4-trihydroxyphenyl)ethanone
DMKU7GD ID DMKU7GD
DMKU7GD DN PMID27376512-Compound-Table1Example8
DMKU7GD HS Patented
DMKU7GD CP IKERCHEM S L [ESUNIV DEL PA S VASCO [ES]
DMKU7GD DT Small molecular drug
DMKU7GD PC 75201482
DMKU7GD MW 435.4
DMKU7GD FM C24H21NO7
DMKU7GD IC InChI=1S/C24H21NO7/c1-31-15-9-17-24(23(10-15)32-2)16(13-3-5-18(26)20(28)7-13)11-25(17)12-22(30)14-4-6-19(27)21(29)8-14/h3-11,26-29H,12H2,1-2H3
DMKU7GD CS COC1=CC2=C(C(=C1)OC)C(=CN2CC(=O)C3=CC(=C(C=C3)O)O)C4=CC(=C(C=C4)O)O
DMKU7GD IK VZIMIRNNOGRJFC-UHFFFAOYSA-N
DMKU7GD IU 1-(3,4-dihydroxyphenyl)-2-[3-(3,4-dihydroxyphenyl)-4,6-dimethoxyindol-1-yl]ethanone
DMD4CIU ID DMD4CIU
DMD4CIU DN PMID27387065-Compound-6
DMD4CIU HS Patented
DMD4CIU DT Small molecular drug
DMD4CIU PC 3154
DMD4CIU MW 324.4
DMD4CIU FM C10H16N2O4S3
DMD4CIU IC InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)
DMD4CIU CS CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
DMD4CIU IK IAVUPMFITXYVAF-UHFFFAOYSA-N
DMD4CIU IU 4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMD4CIU CA CAS 120280-13-9
DMDQMZT ID DMDQMZT
DMDQMZT DN PMID27410995-Compound-Figure3c
DMDQMZT HS Patented
DMDQMZT DT Small molecular drug
DMJRZLB ID DMJRZLB
DMJRZLB DN PMID27410995-Compound-Figure3j
DMJRZLB HS Patented
DMJRZLB DT Small molecular drug
DMJ0QLB ID DMJ0QLB
DMJ0QLB DN PMID27410995-Compound-Figure3k
DMJ0QLB HS Patented
DMJ0QLB DT Small molecular drug
DMUG9X0 ID DMUG9X0
DMUG9X0 DN PMID27414413-Compound-Figure6right
DMUG9X0 HS Patented
DMUG9X0 CP J-PHARMA CO., LTD. WEMPE, Michael, F. ENDOU, Hitoshi
DMUG9X0 DT Small molecular drug
DMUG9X0 PC 2333
DMUG9X0 MW 424.1
DMUG9X0 FM C17H12Br2O3
DMUG9X0 IC InChI=1S/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3
DMUG9X0 CS CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
DMUG9X0 IK WHQCHUCQKNIQEC-UHFFFAOYSA-N
DMUG9X0 IU (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
DMUG9X0 CA CAS 3562-84-3
DMUG9X0 CB CHEBI:3023
DMTZNSM ID DMTZNSM
DMTZNSM DN PMID27414413-Compound-Figure8right
DMTZNSM HS Patented
DMTZNSM DT Small molecular drug
DMTZNSM PC 71532153
DMTZNSM MW 298.3
DMTZNSM FM C15H10N2O3S
DMTZNSM IC InChI=1S/C15H10N2O3S/c1-8-4-12-14(21-8)9(6-16)7-17(12)10-2-3-11(15(19)20)13(18)5-10/h2-5,7,18H,1H3,(H,19,20)
DMTZNSM CS CC1=CC2=C(S1)C(=CN2C3=CC(=C(C=C3)C(=O)O)O)C#N
DMTZNSM IK CBQIUEMJMYALSV-UHFFFAOYSA-N
DMTZNSM IU 4-(6-cyano-2-methylthieno[3,2-b]pyrrol-4-yl)-2-hydroxybenzoic acid
DM5LOST ID DM5LOST
DM5LOST DN PMID27454349-Compound-100
DM5LOST HS Patented
DM5LOST CP Nanjing-University-of-Science-and-Technology
DM5LOST DT Small molecular drug
DMQIYM6 ID DMQIYM6
DMQIYM6 DN PMID27454349-Compound-101
DMQIYM6 HS Patented
DMQIYM6 CP UNIV SANTIAGO COMPOSTELA [ESUNIV DA CORU A [ESSERVIZO GALEGO DE SAUDE SERGAS [ES]
DMQIYM6 DT Small molecular drug
DMEGRMX ID DMEGRMX
DMEGRMX DN PMID27454349-Compound-102
DMEGRMX HS Patented
DMEGRMX CP UNIV SANTIAGO COMPOSTELA [ESUNIV DA CORU A [ESSERVIZO GALEGO DE SAUDE SERGAS [ES]
DMEGRMX DT Small molecular drug
DMAN7CG ID DMAN7CG
DMAN7CG DN PMID27454349-Compound-91
DMAN7CG HS Patented
DMAN7CG CP Wisconsin-Alumni-Research-Foundation
DMAN7CG DT Small molecular drug
DMAN7CG PC 11366080
DMAN7CG MW 416.6
DMAN7CG FM C27H44O3
DMAN7CG IC InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)22-12-13-23-21(9-7-15-27(22,23)5)11-10-20-16-24(28)19(2)25(29)17-20/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b21-11+/t18-,22?,23-,24+,25+,27+/m0/s1
DMAN7CG CS C[C@@H](CCCC(C)(C)O)C1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C(=C)[C@@H](C3)O)O)C
DMAN7CG IK UHMPCVGLSKFXHR-NFZXMVPNSA-N
DMAN7CG IU (1R,3R)-5-[(2E)-2-[(3aS,7aR)-1-[(2S)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol
DMAN7CG CA CAS 213250-70-5
DMOEYVT ID DMOEYVT
DMOEYVT DN PMID27454349-Compound-92
DMOEYVT HS Patented
DMOEYVT CP Wisconsin-Alumni-Research-Foundation
DMOEYVT DT Small molecular drug
DMCTMB1 ID DMCTMB1
DMCTMB1 DN PMID27454349-Compound-93
DMCTMB1 HS Patented
DMCTMB1 CP Wisconsin-Alumni-Research-Foundation
DMCTMB1 DT Small molecular drug
DMK0SIM ID DMK0SIM
DMK0SIM DN PMID27454349-Compound-94
DMK0SIM HS Patented
DMK0SIM CP Wisconsin-Alumni-Research-Foundation
DMK0SIM DT Small molecular drug
DM17KL2 ID DM17KL2
DM17KL2 DN PMID27454349-Compound-95
DM17KL2 HS Patented
DM17KL2 CP CYTOCHROMA INC. JOHNS HOPKINS UNIVERSITY POSNER, Gary, H. HESS, Lindsey, C. KALINDA, Alvin, S. SLACK, Rachel, D. SAHA, Uttam PETKOVICH, P., Martin
DM17KL2 DT Small molecular drug
DMW0TM1 ID DMW0TM1
DMW0TM1 DN PMID27454349-Compound-96
DMW0TM1 HS Patented
DMW0TM1 CP CYTOCHROMA INC. JOHNS HOPKINS UNIVERSITY POSNER, Gary, H. HESS, Lindsey, C. KALINDA, Alvin, S. SLACK, Rachel, D. SAHA, Uttam PETKOVICH, P., Martin
DMW0TM1 DT Small molecular drug
DMEXV6L ID DMEXV6L
DMEXV6L DN PMID27454349-Compound-97
DMEXV6L HS Patented
DMEXV6L CP CYTOCHROMA INC. JOHNS HOPKINS UNIVERSITY POSNER, Gary, H. HESS, Lindsey, C. KALINDA, Alvin, S. SLACK, Rachel, D. SAHA, Uttam PETKOVICH, P., Martin
DMEXV6L DT Small molecular drug
DMZKYMI ID DMZKYMI
DMZKYMI DN PMID27454349-Compound-98
DMZKYMI HS Patented
DMZKYMI CP Celus-Pharmaceuticals
DMZKYMI DT Small molecular drug
DMZKYMI PC 11396600
DMZKYMI MW 442.6
DMZKYMI FM C29H43FO2
DMZKYMI IC InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1
DMZKYMI CS CCC(CC)(/C=C/C[C@H](C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)F)O)C)O
DMZKYMI IK LRLWXBHFPGSUOX-GJQYOBCGSA-N
DMZKYMI IU (1R,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(E,2S)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
DMZKYMI CA CAS 199798-84-0
DMH0CQU ID DMH0CQU
DMH0CQU DN PMID27454349-Compound-99
DMH0CQU HS Patented
DMH0CQU CP Nanjing-University-of-Science-and-Technology
DMH0CQU DT Small molecular drug
DM9C4XH ID DM9C4XH
DM9C4XH DN PMID27537201-Compound-Figure11
DM9C4XH HS Patented
DM9C4XH DT Small molecular drug
DMPDTHQ ID DMPDTHQ
DMPDTHQ DN PMID27537201-Compound-Figure13b
DMPDTHQ HS Patented
DMPDTHQ CP the Shanghai Institute of Pharmaceutical Industry
DMPDTHQ DT Small molecular drug
DMWZ1PD ID DMWZ1PD
DMWZ1PD DN PMID27537201-Compound-Figure13c
DMWZ1PD HS Patented
DMWZ1PD CP the Shanghai Institute of Pharmaceutical Industry
DMWZ1PD DT Small molecular drug
DMVBJKH ID DMVBJKH
DMVBJKH DN PMID27537201-Compound-Figure15a
DMVBJKH HS Patented
DMVBJKH CP the Shanghai Institute of Technology together with the East China University of Science and Technology
DMVBJKH DT Small molecular drug
DMZ6N2J ID DMZ6N2J
DMZ6N2J DN PMID27537201-Compound-Figure15b
DMZ6N2J HS Patented
DMZ6N2J CP the Shanghai Institute of Technology
DMZ6N2J DT Small molecular drug
DMWKVZD ID DMWKVZD
DMWKVZD DN PMID27537201-Compound-Figure17
DMWKVZD HS Patented
DMWKVZD CP HANS JOACHIM [DEGROTHE TORSTEN [DEWOEHRLE INGO [DEMOLDENHAUER JANA [DEKOEPCKE BAERBEL [DEKUEPER THOMAS [DEBITZER JENS [DEREINHARDT KATHRIN [DE
DMWKVZD DT Small molecular drug
DM61SR0 ID DM61SR0
DM61SR0 DN PMID27539678-Compound-10
DM61SR0 HS Patented
DM61SR0 CP RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK UNIVERSITY OF STRATHCLYDE BITTMAN, Robert PYNE, Nigel J. PYNE, Susan BAEK, Dong Jae LIU, Zheng BYUN, Hoe Sup
DM61SR0 DT Small molecular drug
DM61SR0 PC 72735621
DM61SR0 MW 373.6
DM61SR0 FM C25H43NO
DM61SR0 IC InChI=1S/C25H43NO/c1-2-3-4-5-6-7-8-9-10-11-13-23-15-17-24(18-16-23)19-21-26-20-12-14-25(26)22-27/h15-18,25,27H,2-14,19-22H2,1H3/t25-/m1/s1
DM61SR0 CS CCCCCCCCCCCCC1=CC=C(C=C1)CCN2CCC[C@@H]2CO
DM61SR0 IK PNEOFQRNMJSTMT-RUZDIDTESA-N
DM61SR0 IU [(2R)-1-[2-(4-dodecylphenyl)ethyl]pyrrolidin-2-yl]methanol
DMIKAJC ID DMIKAJC
DMIKAJC DN PMID27539678-Compound-11
DMIKAJC HS Patented
DMIKAJC CP AJINOMOTO CO., INC
DMIKAJC DT Small molecular drug
DMIKAJC PC 78426051
DMIKAJC MW 362.5
DMIKAJC FM C24H30N2O
DMIKAJC IC InChI=1S/C24H30N2O/c1-24(2,3)20-7-4-6-17(13-20)18-9-10-23-19(12-18)14-21(25-23)15-26-11-5-8-22(26)16-27/h4,6-7,9-10,12-14,22,25,27H,5,8,11,15-16H2,1-3H3/t22-/m1/s1
DMIKAJC CS CC(C)(C)C1=CC=CC(=C1)C2=CC3=C(C=C2)NC(=C3)CN4CCC[C@@H]4CO
DMIKAJC IK WJXINPLKVRUVDV-JOCHJYFZSA-N
DMIKAJC IU [(2R)-1-[[5-(3-tert-butylphenyl)-1H-indol-2-yl]methyl]pyrrolidin-2-yl]methanol
DMNIKTA ID DMNIKTA
DMNIKTA DN PMID27539678-Compound-12
DMNIKTA HS Patented
DMNIKTA CP AJINOMOTO CO., INC
DMNIKTA DT Small molecular drug
DMNIKTA PC 86274705
DMNIKTA MW 404.5
DMNIKTA FM C26H32N2O2
DMNIKTA IC InChI=1S/C26H32N2O2/c29-17-24-7-4-12-28(24)16-23-15-22-14-21(10-11-26(22)27-23)20-6-3-5-19(13-20)18-30-25-8-1-2-9-25/h3,5-6,10-11,13-15,24-25,27,29H,1-2,4,7-9,12,16-18H2/t24-/m1/s1
DMNIKTA CS C1CCC(C1)OCC2=CC(=CC=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCC[C@@H]5CO
DMNIKTA IK GCKSLJXLYRTNCV-XMMPIXPASA-N
DMNIKTA IU [(2R)-1-[[5-[3-(cyclopentyloxymethyl)phenyl]-1H-indol-2-yl]methyl]pyrrolidin-2-yl]methanol
DM1J2V8 ID DM1J2V8
DM1J2V8 DN PMID27539678-Compound-13
DM1J2V8 HS Patented
DM1J2V8 CP AJINOMOTO CO., INC
DM1J2V8 DT Small molecular drug
DM1J2V8 PC 86275654
DM1J2V8 MW 386.5
DM1J2V8 FM C26H30N2O
DM1J2V8 IC InChI=1S/C26H30N2O/c29-18-25-10-5-13-28(25)17-24-16-23-15-22(11-12-26(23)27-24)21-9-4-8-20(14-21)19-6-2-1-3-7-19/h4,6,8-9,11-12,14-16,25,27,29H,1-3,5,7,10,13,17-18H2/t25-/m1/s1
DM1J2V8 CS C1CCC(=CC1)C2=CC=CC(=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCC[C@@H]5CO
DM1J2V8 IK VGAFMTJLEJHSLL-RUZDIDTESA-N
DM1J2V8 IU [(2R)-1-[[5-[3-(cyclohexen-1-yl)phenyl]-1H-indol-2-yl]methyl]pyrrolidin-2-yl]methanol
DMZ02LA ID DMZ02LA
DMZ02LA DN PMID27539678-Compound-14
DMZ02LA HS Patented
DMZ02LA CP AJINOMOTO CO., INC
DMZ02LA DT Small molecular drug
DMZ02LA PC 117626498
DMZ02LA MW 428.6
DMZ02LA FM C28H32N2O2
DMZ02LA IC InChI=1S/C28H32N2O2/c1-28(2)11-10-27(32)25(16-28)21-6-3-5-19(13-21)20-8-9-26-22(14-20)15-23(29-26)17-30-12-4-7-24(30)18-31/h3,5-6,8-9,13-16,24,29,31H,4,7,10-12,17-18H2,1-2H3/t24-/m1/s1
DMZ02LA CS CC1(CCC(=O)C(=C1)C2=CC=CC(=C2)C3=CC4=C(C=C3)NC(=C4)CN5CCC[C@@H]5CO)C
DMZ02LA IK PNODTUCQTPQANY-XMMPIXPASA-N
DMZ02LA IU 2-[3-[2-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-1H-indol-5-yl]phenyl]-4,4-dimethylcyclohex-2-en-1-one
DMMDJH8 ID DMMDJH8
DMMDJH8 DN PMID27539678-Compound-16
DMMDJH8 HS Patented
DMMDJH8 CP GENZYME CORPORATION XIANG, Yibin HIRTH, Bradford KANE, John, L. LIAO, Junkai NOSON, Kevin YEE, Christopher
DMMDJH8 DT Small molecular drug
DMMDJH8 PC 46911228
DMMDJH8 MW 398.5
DMMDJH8 FM C22H30N4O3
DMMDJH8 IC InChI=1S/C22H30N4O3/c1-14(24-22(28)20-18(27)12-13-23-20)16-7-9-17(10-8-16)21-25-19(29-26-21)11-6-15-4-2-3-5-15/h7-10,14-15,18,20,23,27H,2-6,11-13H2,1H3,(H,24,28)/t14-,18-,20-/m0/s1
DMMDJH8 CS C[C@@H](C1=CC=C(C=C1)C2=NOC(=N2)CCC3CCCC3)NC(=O)[C@@H]4[C@H](CCN4)O
DMMDJH8 IK GDJANRNMFHNVOW-DCPHZVHLSA-N
DMMDJH8 IU (2S,3S)-N-[(1S)-1-[4-[5-(2-cyclopentylethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl]-3-hydroxypyrrolidine-2-carboxamide
DMVG7A5 ID DMVG7A5
DMVG7A5 DN PMID27539678-Compound-17
DMVG7A5 HS Patented
DMVG7A5 CP GENZYME CORPORATION XIANG, Yibin HIRTH, Bradford KANE, John, L. LIAO, Junkai NOSON, Kevin YEE, Christopher
DMVG7A5 DT Small molecular drug
DMVG7A5 PC 45256914
DMVG7A5 MW 386.5
DMVG7A5 FM C21H30N4O3
DMVG7A5 IC InChI=1S/C21H30N4O3/c1-2-3-4-5-6-7-18-24-20(25-28-18)16-10-8-15(9-11-16)14-23-21(27)19-17(26)12-13-22-19/h8-11,17,19,22,26H,2-7,12-14H2,1H3,(H,23,27)/t17-,19-/m0/s1
DMVG7A5 CS CCCCCCCC1=NC(=NO1)C2=CC=C(C=C2)CNC(=O)[C@@H]3[C@H](CCN3)O
DMVG7A5 IK CMLALAZUOVTKKV-HKUYNNGSSA-N
DMVG7A5 IU (2S,3S)-N-[[4-(5-heptyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]-3-hydroxypyrrolidine-2-carboxamide
DMRNBP3 ID DMRNBP3
DMRNBP3 DN PMID27539678-Compound-3
DMRNBP3 HS Patented
DMRNBP3 CP Merck Patent GmBH
DMRNBP3 DT Small molecular drug
DMRNBP3 PC 53250556
DMRNBP3 MW 421.6
DMRNBP3 FM C27H39N3O
DMRNBP3 IC InChI=1S/C27H39N3O/c1-26(2)12-13-27(3,4)23-20-21(10-11-22(23)26)24-8-7-9-25(28-24)30-17-15-29(16-18-30)14-5-6-19-31/h7-11,20,31H,5-6,12-19H2,1-4H3
DMRNBP3 CS CC1(CCC(C2=C1C=CC(=C2)C3=NC(=CC=C3)N4CCN(CC4)CCCCO)(C)C)C
DMRNBP3 IK NSOIVUTZXMNIJX-UHFFFAOYSA-N
DMRNBP3 IU 4-[4-[6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyridin-2-yl]piperazin-1-yl]butan-1-ol
DMJ8BAS ID DMJ8BAS
DMJ8BAS DN PMID27539678-Compound-4
DMJ8BAS HS Patented
DMJ8BAS CP University of Virginia Patent Foundation
DMJ8BAS DT Small molecular drug
DMJ8BAS PC 50916701
DMJ8BAS MW 379.6
DMJ8BAS FM C22H41N3O2
DMJ8BAS IC InChI=1S/C22H41N3O2/c23-20(24)22(14-15-22)21(26)25-16-10-5-3-1-2-4-6-11-17-27-18-19-12-8-7-9-13-19/h19H,1-18H2,(H3,23,24)(H,25,26)
DMJ8BAS CS C1CCC(CC1)COCCCCCCCCCCNC(=O)C2(CC2)C(=N)N
DMJ8BAS IK DCHHZPQOGYUREG-UHFFFAOYSA-N
DMJ8BAS IU 1-carbamimidoyl-N-[10-(cyclohexylmethoxy)decyl]cyclopropane-1-carboxamide
DMBKNDE ID DMBKNDE
DMBKNDE DN PMID27539678-Compound-6
DMBKNDE HS Patented
DMBKNDE CP ALMAC DISCOVERY LIMITED HARRISON, Timothy BURKAMP, Frank JORDAN, Linda BELL, Mark JANSSEN, Dominic MIEL, Hugues MCFARLAND, Mary
DMBKNDE DT Small molecular drug
DMBKNDE PC 53250711
DMBKNDE MW 407.6
DMBKNDE FM C26H37N3O
DMBKNDE IC InChI=1S/C26H37N3O/c1-25(2)11-12-26(3,4)22-19-20(9-10-21(22)25)23-7-5-8-24(27-23)29-16-14-28(15-17-29)13-6-18-30/h5,7-10,19,30H,6,11-18H2,1-4H3
DMBKNDE CS CC1(CCC(C2=C1C=CC(=C2)C3=NC(=CC=C3)N4CCN(CC4)CCCO)(C)C)C
DMBKNDE IK ITCPVAVDRJPVOV-UHFFFAOYSA-N
DMBKNDE IU 3-[4-[6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyridin-2-yl]piperazin-1-yl]propan-1-ol
DMQAC4K ID DMQAC4K
DMQAC4K DN PMID27539678-Compound-7
DMQAC4K HS Patented
DMQAC4K CP ALMAC DISCOVERY LIMITED HARRISON, Timothy BURKAMP, Frank JORDAN, Linda BELL, Mark JANSSEN, Dominic MIEL, Hugues MCFARLAND, Mary
DMQAC4K DT Small molecular drug
DMQAC4K PC 67609351
DMQAC4K MW 384.5
DMQAC4K FM C25H28N4
DMQAC4K IC InChI=1S/C25H28N4/c1-24(2)12-13-25(3,4)20-15-18(9-10-19(20)24)21-11-14-28-23(29-21)17-7-5-16(6-8-17)22(26)27/h5-11,14-15H,12-13H2,1-4H3,(H3,26,27)
DMQAC4K CS CC1(CCC(C2=C1C=CC(=C2)C3=NC(=NC=C3)C4=CC=C(C=C4)C(=N)N)(C)C)C
DMQAC4K IK HBVOXJWWSHTROQ-UHFFFAOYSA-N
DMQAC4K IU 4-[4-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)pyrimidin-2-yl]benzenecarboximidamide
DMHWUEV ID DMHWUEV
DMHWUEV DN PMID27539678-Compound-8
DMHWUEV HS Patented
DMHWUEV CP RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK UNIVERSITY OF STRATHCLYDE BITTMAN, Robert PYNE, Nigel J. PYNE, Susan BAEK, Dong Jae LIU, Zheng BYUN, Hoe Sup
DMHWUEV DT Small molecular drug
DMHWUEV PC 42611957
DMHWUEV MW 383.5
DMHWUEV FM C20H34NO4P
DMHWUEV IC InChI=1S/C20H34NO4P/c1-2-3-4-5-6-7-8-18-9-11-19(12-10-18)13-14-20(21,17-22)15-16-26(23,24)25/h9-12,15-16,22H,2-8,13-14,17,21H2,1H3,(H2,23,24,25)/b16-15+/t20-/m0/s1
DMHWUEV CS CCCCCCCCC1=CC=C(C=C1)CC[C@@](CO)(/C=C/P(=O)(O)O)N
DMHWUEV IK YWQUROWPKWKDNA-APHAIJBRSA-N
DMHWUEV IU [(E,3S)-3-amino-3-(hydroxymethyl)-5-(4-octylphenyl)pent-1-enyl]phosphonic acid
DM0Y5NU ID DM0Y5NU
DM0Y5NU DN PMID27539678-Compound-9
DM0Y5NU HS Patented
DM0Y5NU CP RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK UNIVERSITY OF STRATHCLYDE BITTMAN, Robert PYNE, Nigel J. PYNE, Susan BAEK, Dong Jae LIU, Zheng BYUN, Hoe Sup
DM0Y5NU DT Small molecular drug
DM0Y5NU PC 72735440
DM0Y5NU MW 316.5
DM0Y5NU FM C21H36N2
DM0Y5NU IC InChI=1S/C21H36N2/c1-2-3-4-5-6-7-8-19-9-11-20(12-10-19)13-16-23-17-14-21(22)15-18-23/h9-12,21H,2-8,13-18,22H2,1H3
DM0Y5NU CS CCCCCCCCC1=CC=C(C=C1)CCN2CCC(CC2)N
DM0Y5NU IK ILDHJXNNCSUCMI-UHFFFAOYSA-N
DM0Y5NU IU 1-[2-(4-octylphenyl)ethyl]piperidin-4-amine
DM5OQBR ID DM5OQBR
DM5OQBR DN PMID27551786-Compound-106
DM5OQBR HS Patented
DM5OQBR CP Merck Sharp & Dohme
DM5OQBR DT Small molecular drug
DM4IZUH ID DM4IZUH
DM4IZUH DN PMID27551786-Compound-138
DM4IZUH HS Patented
DM4IZUH CP Merck Sharp & Dohme
DM4IZUH DT Small molecular drug
DMA7H63 ID DMA7H63
DMA7H63 DN PMID27551786-Compound-I
DMA7H63 HS Patented
DMA7H63 CP Merck Sharp & DohmeMerck Sharp & Dohme
DMA7H63 DT Small molecular drug
DMJADXV ID DMJADXV
DMJADXV DN PMID27551786-Compound-II
DMJADXV HS Patented
DMJADXV CP Merck Sharp & Dohme
DMJADXV DT Small molecular drug
DMBQ981 ID DMBQ981
DMBQ981 DN PMID27551786-Compound-III
DMBQ981 HS Patented
DMBQ981 CP Merck Sharp & Dohme
DMBQ981 DT Small molecular drug
DM7IB8L ID DM7IB8L
DM7IB8L DN PMID27551786-Compound-IV
DM7IB8L HS Patented
DM7IB8L CP Merck Sharp & DohmMerck Sharp & Dohme
DM7IB8L DT Small molecular drug
DM5KARO ID DM5KARO
DM5KARO DN PMID27599163-Compound-52
DM5KARO HS Patented
DM5KARO CP GE HEALTHCARE LIMITED WADSWORTH, Harry, John SHAN, Bo O'SHEA, Dennis PASSMORE, Joanna, Marie TRIGG, William, John
DM5KARO DT Small molecular drug
DMYCQR4 ID DMYCQR4
DMYCQR4 DN PMID27599163-Compound-75
DMYCQR4 HS Patented
DMYCQR4 CP Verleye M, Guern MEL, Girard P, et alMsn Laboratories Limited, India
DMYCQR4 DT Small molecular drug
DMODPFU ID DMODPFU
DMODPFU DN PMID27599163-Compound-76
DMODPFU HS Patented
DMODPFU CP Verleye M, Guern MEL, Girard P, et al
DMODPFU DT Small molecular drug
DM2TNH4 ID DM2TNH4
DM2TNH4 DN PMID27599163-Compound-77
DM2TNH4 HS Patented
DM2TNH4 CP BIOCODEX
DM2TNH4 DT Small molecular drug
DMZC58R ID DMZC58R
DMZC58R DN PMID27599163-Compound-78
DMZC58R HS Patented
DMZC58R CP BIOCODEX
DMZC58R DT Small molecular drug
DMVUWYB ID DMVUWYB
DMVUWYB DN PMID27599163-Compound-79
DMVUWYB HS Patented
DMVUWYB CP Owen D, Wilkins M
DMVUWYB DT Small molecular drug
DMZ5QC4 ID DMZ5QC4
DMZ5QC4 DN PMID27599163-Compound-81
DMZ5QC4 HS Patented
DMZ5QC4 CP RICHTER GEDEON NYRT
DMZ5QC4 DT Small molecular drug
DMO74I9 ID DMO74I9
DMO74I9 DN PMID27599163-Compound-82
DMO74I9 HS Patented
DMO74I9 DT Small molecular drug
DM5RBFC ID DM5RBFC
DM5RBFC DN PMID27607364-Compound-10
DM5RBFC HS Patented
DM5RBFC DT Small molecular drug
DM5RBFC PC 9841240
DM5RBFC MW 348.4
DM5RBFC FM C21H20N2O3
DM5RBFC IC InChI=1S/C21H20N2O3/c1-16(24)23(15-17-8-6-7-11-20(17)25-2)19-14-22-13-12-21(19)26-18-9-4-3-5-10-18/h3-14H,15H2,1-2H3
DM5RBFC CS CC(=O)N(CC1=CC=CC=C1OC)C2=C(C=CN=C2)OC3=CC=CC=C3
DM5RBFC IK DHZBNHMEIOBPAE-UHFFFAOYSA-N
DM5RBFC IU N-[(2-methoxyphenyl)methyl]-N-(4-phenoxypyridin-3-yl)acetamide
DMMF4XO ID DMMF4XO
DMMF4XO DN PMID27607364-Compound-141
DMMF4XO HS Patented
DMMF4XO DT Small molecular drug
DMMF4XO PC 45108357
DMMF4XO MW 490.4
DMMF4XO FM C21H25IN4O2
DMMF4XO IC InChI=1S/C21H25IN4O2/c1-6-25(7-2)19(27)12-16-20(15-8-9-18(28-5)17(22)11-15)24-26-14(4)10-13(3)23-21(16)26/h8-11H,6-7,12H2,1-5H3/i22-2
DMMF4XO CS CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC(=C(C=C3)OC)[125I])C)C
DMMF4XO IK TYBYEGAEDKDDES-ONBQKKEBSA-N
DMMF4XO IU N,N-diethyl-2-[2-(3-(125I)iodanyl-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide
DMMF4XO CA CAS 1192559-24-2
DM0F6VU ID DM0F6VU
DM0F6VU DN PMID27607364-Compound-162
DM0F6VU HS Patented
DM0F6VU CP Dainippon Pharmaceutical Co., Ltd
DM0F6VU DT Small molecular drug
DMKBZDP ID DMKBZDP
DMKBZDP DN PMID27607364-Compound-4
DMKBZDP HS Patented
DMKBZDP CP COCENSYS, INC
DMKBZDP DT Small molecular drug
DMKBZDP PC 3016
DMKBZDP MW 284.74
DMKBZDP FM C16H13ClN2O
DMKBZDP IC InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
DMKBZDP CS CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMKBZDP IK AAOVKJBEBIDNHE-UHFFFAOYSA-N
DMKBZDP IU 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
DMKBZDP CA CAS 439-14-5
DMKBZDP CB CHEBI:49575
DMXJVW4 ID DMXJVW4
DMXJVW4 DN PMID27607364-Compound-58
DMXJVW4 HS Patented
DMXJVW4 DT Small molecular drug
DMLY7I3 ID DMLY7I3
DMLY7I3 DN PMID27607364-Compound-59
DMLY7I3 HS Patented
DMLY7I3 CP BIO IMAGING KOREA CO., LTD
DMLY7I3 DT Small molecular drug
DM584EP ID DM584EP
DM584EP DN PMID27607364-Compound-60
DM584EP HS Patented
DM584EP CP BAYER SCHERING PHARMA AKTIENGESELLSCHAFT LEHMANN, Lutz THIELE, Andrea HEINRICH, Tobias VOLLMER, Sonja
DM584EP DT Small molecular drug
DM584EP PC 44632752
DM584EP MW 439.5
DM584EP FM C24H25FN2O5
DM584EP IC InChI=1S/C24H25FN2O5/c1-17(28)27(16-18-15-21(30-3)10-11-23(18)31-14-12-25)22-5-4-13-26-24(22)32-20-8-6-19(29-2)7-9-20/h4-11,13,15H,12,14,16H2,1-3H3/i25-1
DM584EP CS CC(=O)N(CC1=C(C=CC(=C1)OC)OCC[18F])C2=C(N=CC=C2)OC3=CC=C(C=C3)OC
DM584EP IK WDCDJYGFOQXTQD-FNNGWQQSSA-N
DM584EP IU N-[[2-(2-(18F)fluoranylethoxy)-5-methoxyphenyl]methyl]-N-[2-(4-methoxyphenoxy)pyridin-3-yl]acetamide
DM584EP CA CAS 1207345-42-3
DMWE6NZ ID DMWE6NZ
DMWE6NZ DN PMID27607364-Compound-61
DMWE6NZ HS Patented
DMWE6NZ CP BAYER SCHERING PHARMA AKTIENGESELLSCHAFT LEHMANN, Lutz THIELE, Andrea HEINRICH, Tobias VOLLMER, Sonja
DMWE6NZ DT Small molecular drug
DMWE6NZ PC 44622012
DMWE6NZ MW 437.5
DMWE6NZ FM C25H27FN2O4
DMWE6NZ IC InChI=1S/C25H27FN2O4/c1-17-7-5-9-23(18(17)2)32-25-22(8-6-13-27-25)28(19(3)29)16-20-15-21(30-4)10-11-24(20)31-14-12-26/h5-11,13,15H,12,14,16H2,1-4H3/i26-1
DMWE6NZ CS CC1=C(C(=CC=C1)OC2=C(C=CC=N2)N(CC3=C(C=CC(=C3)OC)OCC[18F])C(=O)C)C
DMWE6NZ IK JBDICOKSGXRRSY-KPVNRNJOSA-N
DMWE6NZ IU N-[2-(2,3-dimethylphenoxy)pyridin-3-yl]-N-[[2-(2-(18F)fluoranylethoxy)-5-methoxyphenyl]methyl]acetamide
DMXGT2A ID DMXGT2A
DMXGT2A DN PMID27607364-Compound-62
DMXGT2A HS Patented
DMXGT2A CP BAYER SCHERING PHARMA AKTIENGESELLSCHAFT LEHMANN, Lutz THIELE, Andrea HEINRICH, Tobias VOLLMER, Sonja
DMXGT2A DT Small molecular drug
DMVTPHY ID DMVTPHY
DMVTPHY DN PMID27607364-Compound-63
DMVTPHY HS Patented
DMVTPHY DT Small molecular drug
DMVTPHY PC 53245866
DMVTPHY MW 376.4
DMVTPHY FM C23H20FNO3
DMVTPHY IC InChI=1S/C23H20FNO3/c24-15-22(26)25(16-18-8-6-7-17-13-14-27-23(17)18)20-11-4-5-12-21(20)28-19-9-2-1-3-10-19/h1-12H,13-16H2/i24-1
DMVTPHY CS C1COC2=C1C=CC=C2CN(C3=CC=CC=C3OC4=CC=CC=C4)C(=O)C[18F]
DMVTPHY IK RDJNEDDYELAPBM-MIGPCILRSA-N
DMVTPHY IU N-(2,3-dihydro-1-benzofuran-7-ylmethyl)-2-(18F)fluoranyl-N-(2-phenoxyphenyl)acetamide
DMZSI15 ID DMZSI15
DMZSI15 DN PMID27607364-Compound-64
DMZSI15 HS Patented
DMZSI15 DT Small molecular drug
DMZSI15 PC 53245982
DMZSI15 MW 378.4
DMZSI15 FM C22H18FNO4
DMZSI15 IC InChI=1S/C22H18FNO4/c23-13-21(25)24(14-16-7-6-12-20-22(16)27-15-26-20)18-10-4-5-11-19(18)28-17-8-2-1-3-9-17/h1-12H,13-15H2/i23-1
DMZSI15 CS C1OC2=CC=CC(=C2O1)CN(C3=CC=CC=C3OC4=CC=CC=C4)C(=O)C[18F]
DMZSI15 IK JHMUPOREYLLSRB-VNRZBHCFSA-N
DMZSI15 IU N-(1,3-benzodioxol-4-ylmethyl)-2-(18F)fluoranyl-N-(2-phenoxyphenyl)acetamide
DM9NEFG ID DM9NEFG
DM9NEFG DN PMID27607364-Compound-65
DM9NEFG HS Patented
DM9NEFG DT Small molecular drug
DM9NEFG PC 53245983
DM9NEFG MW 392.4
DM9NEFG FM C23H20FNO4
DM9NEFG IC InChI=1S/C23H20FNO4/c24-15-22(26)25(16-17-7-6-12-21-23(17)28-14-13-27-21)19-10-4-5-11-20(19)29-18-8-2-1-3-9-18/h1-12H,13-16H2/i24-1
DM9NEFG CS C1COC2=C(C=CC=C2O1)CN(C3=CC=CC=C3OC4=CC=CC=C4)C(=O)C[18F]
DM9NEFG IK UDPFMHCLCUMIOF-MIGPCILRSA-N
DM9NEFG IU N-(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)-2-(18F)fluoranyl-N-(2-phenoxyphenyl)acetamide
DMTJ0LB ID DMTJ0LB
DMTJ0LB DN PMID27724045-Compound-14
DMTJ0LB HS Patented
DMTJ0LB CP Janssen Pharmaceutica
DMTJ0LB DT Small molecular drug
DMTJ0LB PC 90414893
DMTJ0LB MW 466.8
DMTJ0LB FM C20H15ClF4N6O
DMTJ0LB IC InChI=1S/C20H15ClF4N6O/c21-15-12(4-2-5-13(15)20(23,24)25)19(32)31-11-3-1-6-14(31)17-28-29-18(30(17)9-11)16-26-7-10(22)8-27-16/h2,4-5,7-8,11,14H,1,3,6,9H2/t11-,14+/m1/s1
DMTJ0LB CS C1C[C@@H]2CN3C(=NN=C3C4=NC=C(C=N4)F)[C@H](C1)N2C(=O)C5=C(C(=CC=C5)C(F)(F)F)Cl
DMTJ0LB IK OKEUHBTYCIUVSL-RISCZKNCSA-N
DMTJ0LB IU [2-chloro-3-(trifluoromethyl)phenyl]-[(1S,8R)-5-(5-fluoropyrimidin-2-yl)-3,4,6,12-tetrazatricyclo[6.3.1.02,6]dodeca-2,4-dien-12-yl]methanone
DMVN5BD ID DMVN5BD
DMVN5BD DN PMID27724045-Compound-15
DMVN5BD HS Patented
DMVN5BD CP Janssen Pharmaceutica
DMVN5BD DT Small molecular drug
DMVN5BD PC 86281295
DMVN5BD MW 421.8
DMVN5BD FM C19H15ClF3N5O
DMVN5BD IC InChI=1S/C19H15ClF3N5O/c1-10-16-12(17(25-9-24-16)14-5-7-26-27-14)6-8-28(10)18(29)11-3-2-4-13(15(11)20)19(21,22)23/h2-5,7,9-10H,6,8H2,1H3,(H,26,27)/t10-/m1/s1
DMVN5BD CS C[C@@H]1C2=NC=NC(=C2CCN1C(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=NN4
DMVN5BD IK CJGMJEYIRWOWHA-SNVBAGLBSA-N
DMVN5BD IU [2-chloro-3-(trifluoromethyl)phenyl]-[(8R)-8-methyl-4-(1H-pyrazol-5-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]methanone
DM4W72V ID DM4W72V
DM4W72V DN PMID27724045-Compound-17
DM4W72V HS Patented
DM4W72V CP Janssen Pharmaceutica
DM4W72V DT Small molecular drug
DM4W72V PC 86278949
DM4W72V MW 436.8
DM4W72V FM C19H16ClF3N6O
DM4W72V IC InChI=1S/C19H16ClF3N6O/c1-2-12-10-29-16(14-8-24-6-7-25-14)26-27-17(29)18(30)28(12)9-11-4-3-5-13(15(11)20)19(21,22)23/h3-8,12H,2,9-10H2,1H3/t12-/m0/s1
DM4W72V CS CC[C@H]1CN2C(=NN=C2C(=O)N1CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=NC=CN=C4
DM4W72V IK XOUUTQMOXWSZSL-LBPRGKRZSA-N
DM4W72V IU (6S)-7-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-6-ethyl-3-pyrazin-2-yl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8-one
DMVDBHT ID DMVDBHT
DMVDBHT DN PMID27724045-Compound-19
DMVDBHT HS Patented
DMVDBHT CP Actelion pharmaceuticals Ltd
DMVDBHT DT Small molecular drug
DMKTQX8 ID DMKTQX8
DMKTQX8 DN PMID27724045-Compound-29
DMKTQX8 HS Patented
DMKTQX8 CP Evotec
DMKTQX8 DT Small molecular drug
DMOS7ZP ID DMOS7ZP
DMOS7ZP DN PMID27724045-Compound-33
DMOS7ZP HS Patented
DMOS7ZP CP Aventis Pharmaceuticals, Inc
DMOS7ZP DT Small molecular drug
DMFKS2P ID DMFKS2P
DMFKS2P DN PMID27744724-Compound-10
DMFKS2P HS Patented
DMFKS2P CP VANDERBILT UNIVERSITY
DMFKS2P DT Small molecular drug
DMCFOXP ID DMCFOXP
DMCFOXP DN PMID27744724-Compound-13
DMCFOXP HS Patented
DMCFOXP CP VANDERBILT UNIVERSITY
DMCFOXP DT Small molecular drug
DM73S2C ID DM73S2C
DM73S2C DN PMID27744724-Compound-18
DM73S2C HS Patented
DM73S2C CP THE REGENTS OF THE UNIVERSITY OF MICHGIAN NIKOLOVSKA-COLESKA, Zaneta SHOWALTER, Hollis D. LIAO, Chenzhong MOHAMMAD, Ramzi ABULWERDI, Fardokht WAYNE STATE UNIVERSITY
DM73S2C DT Small molecular drug
DM214WA ID DM214WA
DM214WA DN PMID27744724-Compound-19
DM214WA HS Patented
DM214WA CP THE REGENTS OF THE UNIVERSITY OF MICHGIAN NIKOLOVSKA-COLESKA, Zaneta SHOWALTER, Hollis D. LIAO, Chenzhong MOHAMMAD, Ramzi ABULWERDI, Fardokht WAYNE STATE UNIVERSITY
DM214WA DT Small molecular drug
DMD0T6S ID DMD0T6S
DMD0T6S DN PMID27744724-Compound-20
DMD0T6S HS Patented
DMD0T6S CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN NIKOLOVSKA-COLESKA, Zaneta BAJWA, Naval LIAO, Chenzhong MIAO, Lei
DMD0T6S DT Small molecular drug
DM18UA5 ID DM18UA5
DM18UA5 DN PMID27744724-Compound-21
DM18UA5 HS Patented
DM18UA5 CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DM18UA5 DT Small molecular drug
DMM6FOW ID DMM6FOW
DMM6FOW DN PMID27744724-Compound-22
DMM6FOW HS Patented
DMM6FOW CP DANA FARBER CANCER INSTITUTE, INCDANA-FARBER CANCER INSTITUTE, INC WALENSKY, Loren, D. STEWART, Michelle, L. COHEN, Nicole
DMM6FOW DT Small molecular drug
DMXA70C ID DMXA70C
DMXA70C DN PMID27744724-Compound-23
DMXA70C HS Patented
DMXA70C CP DANA FARBER CANCER INSTITUTE, INCDANA-FARBER CANCER INSTITUTE, INC WALENSKY, Loren, D. STEWART, Michelle, L. COHEN, Nicole
DMXA70C DT Small molecular drug
DM8GOH3 ID DM8GOH3
DM8GOH3 DN PMID27744724-Compound-26
DM8GOH3 HS Patented
DM8GOH3 CP AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH NATIONAL UNIVERSITY OF SINGAPORE CHAI, Christina, L., L. BERNARDO, Paul, H. XU, Jin YU, Victor, C. WAN, Kah-Fei MOK, Henry, Y., K. SIVARAMAN, Thirunavukkarasu KJRISHNAMOORTHY, Janarthanan
DM8GOH3 DT Small molecular drug
DMV6MLC ID DMV6MLC
DMV6MLC DN PMID27744724-Compound-27
DMV6MLC HS Patented
DMV6MLC CP AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH NATIONAL UNIVERSITY OF SINGAPORE CHAI, Christina, L., L. BERNARDO, Paul, H. XU, Jin YU, Victor, C. WAN, Kah-Fei MOK, Henry, Y., K. SIVARAMAN, Thirunavukkarasu KJRISHNAMOORTHY, Janarthanan
DMV6MLC DT Small molecular drug
DMB018S ID DMB018S
DMB018S DN PMID27744724-Compound-28
DMB018S HS Patented
DMB018S CP SERVIER LAB [FRVERNALIS R & D LTD [GB]
DMB018S DT Small molecular drug
DM2GDXH ID DM2GDXH
DM2GDXH DN PMID27744724-Compound-29
DM2GDXH HS Patented
DM2GDXH CP AMGEN INC
DM2GDXH DT Small molecular drug
DMWKYU4 ID DMWKYU4
DMWKYU4 DN PMID27744724-Compound-3
DMWKYU4 HS Patented
DMWKYU4 CP ABBOTT LABORATORIES
DMWKYU4 DT Small molecular drug
DMV1WND ID DMV1WND
DMV1WND DN PMID27744724-Compound-4
DMV1WND HS Patented
DMV1WND CP ABBOTT LABORATORIES
DMV1WND DT Small molecular drug
DM6UTAQ ID DM6UTAQ
DM6UTAQ DN PMID27744724-Compound-5
DM6UTAQ HS Patented
DM6UTAQ CP ABBOTT LABORATORIES
DM6UTAQ DT Small molecular drug
DMV7P4N ID DMV7P4N
DMV7P4N DN PMID27744724-Compound-6
DMV7P4N HS Patented
DMV7P4N CP ABBOTT LABORATORIES
DMV7P4N DT Small molecular drug
DMT2W97 ID DMT2W97
DMT2W97 DN PMID27744724-Compound-Fomula2
DMT2W97 HS Patented
DMT2W97 CP ABBOTT LABORATORIES
DMT2W97 DT Small molecular drug
DMFAGOZ ID DMFAGOZ
DMFAGOZ DN PMID27774822-Compound-Figure10Compound12
DMFAGOZ HS Patented
DMFAGOZ CP TOLERO PHARMACEUTICALS, INC
DMFAGOZ DT Small molecular drug
DMMJVTW ID DMMJVTW
DMMJVTW DN PMID27774822-Compound-Figure10Compound4
DMMJVTW HS Patented
DMMJVTW CP TOLERO PHARMACEUTICALS, INC
DMMJVTW DT Small molecular drug
DM3M6SE ID DM3M6SE
DM3M6SE DN PMID27774822-Compound-Figure10CompoundA
DM3M6SE HS Patented
DM3M6SE CP SUPERGEN, INC. VANKAYALAPATI, Hariprasad LIU, Xiao-hui BEARSS, David, J
DM3M6SE DT Small molecular drug
DMCTXPQ ID DMCTXPQ
DMCTXPQ DN PMID27774822-Compound-Figure10Example1
DMCTXPQ HS Patented
DMCTXPQ CP VERTEX PHARMACEUTICALS INCORPORATED
DMCTXPQ DT Small molecular drug
DMNXYZP ID DMNXYZP
DMNXYZP DN PMID27774822-Compound-Figure10Example19
DMNXYZP HS Patented
DMNXYZP CP VERTEX PHARMACEUTICALS INCORPORATED
DMNXYZP DT Small molecular drug
DMAHFXV ID DMAHFXV
DMAHFXV DN PMID27774822-Compound-Figure11Example5
DMAHFXV HS Patented
DMAHFXV CP YM BIOSCIENCES AUSTRALIA PTY LTD
DMAHFXV DT Small molecular drug
DMCL19N ID DMCL19N
DMCL19N DN PMID27774822-Compound-Figure1Example20
DMCL19N HS Patented
DMCL19N CP JIANGSU CAREFREE PHARMACEUTICAL CO., LTD
DMCL19N DT Small molecular drug
DM86M7D ID DM86M7D
DM86M7D DN PMID27774822-Compound-Figure2Example1-1left
DM86M7D HS Patented
DM86M7D CP MERCK SHARP &amDOHME CORP. AHEARN, Sean, P. CHRISTOPHER, Matthew JUNG, Joon PU, Qinglin RIVKIN, Alexey SCOTT, Mark, E. WITTER, David, J. WOO, Hyun Chong CASH, Brandon DINSMORE, Christopher GUERIN, David
DM86M7D DT Small molecular drug
DM2YPLF ID DM2YPLF
DM2YPLF DN PMID27774822-Compound-Figure2Example1-1right
DM2YPLF HS Patented
DM2YPLF CP MERCK SHARP & DOHME CORP. BUTCHER, John, W. WITTER, David DINSMORE, Christopher KIM, June HENDRIX, John ARCHARYA, Raksha AHEARN, Sean, P. JUNG, Joon RIVKIN, Alexey JONES, Philip
DM2YPLF DT Small molecular drug
DMEHIS4 ID DMEHIS4
DMEHIS4 DN PMID27774822-Compound-Figure2Example4-3
DMEHIS4 HS Patented
DMEHIS4 CP MERCK SHARP &amDOHME CORP. AHEARN, Sean, P. CHRISTOPHER, Matthew JUNG, Joon PU, Qinglin RIVKIN, Alexey SCOTT, Mark, E. WITTER, David, J. WOO, Hyun Chong CASH, Brandon DINSMORE, Christopher GUERIN, David
DMEHIS4 DT Small molecular drug
DMOENP4 ID DMOENP4
DMOENP4 DN PMID27774822-Compound-Figure3CompoundI-165
DMOENP4 HS Patented
DMOENP4 CP NIMBUS LAKSHMI, INC
DMOENP4 DT Small molecular drug
DMCD19T ID DMCD19T
DMCD19T DN PMID27774822-Compound-Figure6Example2
DMCD19T HS Patented
DMCD19T CP PRINCIPIA BIOPHARMA INC
DMCD19T DT Small molecular drug
DM3FY85 ID DM3FY85
DM3FY85 DN PMID27774822-Compound-Figure6Example3
DM3FY85 HS Patented
DM3FY85 CP PRINCIPIA BIOPHARMA INC
DM3FY85 DT Small molecular drug
DMF5IWB ID DMF5IWB
DMF5IWB DN PMID27774822-Compound-Figure7Example63
DMF5IWB HS Patented
DMF5IWB CP F. HOFFMANN-LA ROCHE AG GENENTECH, INC
DMF5IWB DT Small molecular drug
DMRHZF3 ID DMRHZF3
DMRHZF3 DN PMID27774822-Compound-Figure8Example5
DMRHZF3 HS Patented
DMRHZF3 CP INCYTE CORPORATION
DMRHZF3 DT Small molecular drug
DMSHIT2 ID DMSHIT2
DMSHIT2 DN PMID27774822-Compound-Figure9Example15
DMSHIT2 HS Patented
DMSHIT2 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMSHIT2 DT Small molecular drug
DMH1W8F ID DMH1W8F
DMH1W8F DN PMID27774824-Compound-Figure11Example1up
DMH1W8F HS Patented
DMH1W8F CP GALAPAGOS NV
DMH1W8F DT Small molecular drug
DMAGKNJ ID DMAGKNJ
DMAGKNJ DN PMID27774824-Compound-Figure12Example1
DMAGKNJ HS Patented
DMAGKNJ CP HANMI PHARM CO., LTD
DMAGKNJ DT Small molecular drug
DMYOSIA ID DMYOSIA
DMYOSIA DN PMID27774824-Compound-Figure12Example10
DMYOSIA HS Patented
DMYOSIA CP BEIJING HANMI PHARMACEUTICAL CO., LTD
DMYOSIA DT Small molecular drug
DMNIZD7 ID DMNIZD7
DMNIZD7 DN PMID27774824-Compound-Figure12Example61
DMNIZD7 HS Patented
DMNIZD7 CP BEIJING HANMI PHARMACEUTICAL CO., LTD
DMNIZD7 DT Small molecular drug
DMQHYMJ ID DMQHYMJ
DMQHYMJ DN PMID27774824-Compound-Figure2Example4
DMQHYMJ HS Patented
DMQHYMJ CP ALMIRALL SA [ESEASTWOOD PAUL ROBERT [ESBACH TANA JORDI [ESPAGES SANTACANA LLUIS MIQUEL [ES]
DMQHYMJ DT Small molecular drug
DMYZ6XQ ID DMYZ6XQ
DMYZ6XQ DN PMID27774824-Compound-Figure3Example18
DMYZ6XQ HS Patented
DMYZ6XQ CP ARRAY BIOPHARMA INC
DMYZ6XQ DT Small molecular drug
DMXDOGK ID DMXDOGK
DMXDOGK DN PMID27774824-Compound-Figure3Example7
DMXDOGK HS Patented
DMXDOGK CP ARRIEN PHARMACEUTICALS LLC
DMXDOGK DT Small molecular drug
DMDZKXC ID DMDZKXC
DMDZKXC DN PMID27774824-Compound-Figure5Example13
DMDZKXC HS Patented
DMDZKXC CP CADILA HEALTHCARE LIMITED THOMBARE, Pravin, S. ARGADE, Anil JAIN, Mukul, R. GITE, Sanjay
DMDZKXC DT Small molecular drug
DM1CM7S ID DM1CM7S
DM1CM7S DN PMID27774824-Compound-Figure6Example12
DM1CM7S HS Patented
DM1CM7S CP CALITOR SCIENCES, LLC SUNSHINE LAKE PHARMA CO., LTD
DM1CM7S DT Small molecular drug
DMB18V5 ID DMB18V5
DMB18V5 DN PMID27774824-Compound-Figure6Example6
DMB18V5 HS Patented
DMB18V5 CP CALITOR SCIENCES, LLC SUNSHINE LAKE PHARMA CO., LTD
DMB18V5 DT Small molecular drug
DMT85AH ID DMT85AH
DMT85AH DN PMID27774824-Compound-Figure7Example10
DMT85AH HS Patented
DMT85AH CP CALITOR SCIENCES, LLC SUNSHINE LAKE PHARMA CO., LTD
DM6OCSJ ID DM6OCSJ
DM6OCSJ DN PMID27774824-Compound-Figure8Example22
DM6OCSJ HS Patented
DM6OCSJ CP CELON PHARMA S.A
DM6OCSJ DT Small molecular drug
DM1VOPH ID DM1VOPH
DM1VOPH DN PMID27774824-Compound-Figure8Example99
DM1VOPH HS Patented
DM1VOPH CP CELON PHARMA S.A
DM1VOPH DT Small molecular drug
DMXAV42 ID DMXAV42
DMXAV42 DN PMID27774824-Compound-Figure9Example2down
DMXAV42 HS Patented
DMXAV42 CP DANA-FARBER CANCER INSTITUTE, INC
DMXAV42 DT Small molecular drug
DME3TMS ID DME3TMS
DME3TMS DN PMID27774824-Compound-Figure9Example2up
DME3TMS HS Patented
DME3TMS CP DANA-FARBER CANCER INSTITUTE, INC
DME3TMS DT Small molecular drug
DMHPK31 ID DMHPK31
DMHPK31 DN PMID27788040-Compound-5
DMHPK31 HS Patented
DMHPK31 CP MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMHPK31 DT Small molecular drug
DMW3X1I ID DMW3X1I
DMW3X1I DN PMID27788040-Compound-5a
DMW3X1I HS Patented
DMW3X1I CP MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMW3X1I DT Small molecular drug
DMW3X1I PC 46208464
DMW3X1I MW 492.7
DMW3X1I FM C30H44N4O2
DMW3X1I IC InChI=1S/C30H44N4O2/c1-31-17-19-34(20-18-31)30(15-9-4-10-16-30)23-33(29(36)24-11-5-3-6-12-24)22-26-21-25-13-7-8-14-27(25)32(2)28(26)35/h7-8,13-14,21,24H,3-6,9-12,15-20,22-23H2,1-2H3
DMW3X1I CS CN1CCN(CC1)C2(CCCCC2)CN(CC3=CC4=CC=CC=C4N(C3=O)C)C(=O)C5CCCCC5
DMW3X1I IK PJVMTTZJMVQBDL-UHFFFAOYSA-N
DMW3X1I IU N-[(1-methyl-2-oxoquinolin-3-yl)methyl]-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]cyclohexanecarboxamide
DMPQKXR ID DMPQKXR
DMPQKXR DN PMID27788040-Compound-5b
DMPQKXR HS Patented
DMPQKXR CP MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMPQKXR DT Small molecular drug
DMPQKXR PC 49862986
DMPQKXR MW 465.7
DMPQKXR FM C29H43N3O2
DMPQKXR IC InChI=1S/C29H43N3O2/c1-4-29(2,17-20-31-18-11-6-12-19-31)32(28(34)23-13-7-5-8-14-23)22-25-21-24-15-9-10-16-26(24)30(3)27(25)33/h9-10,15-16,21,23H,4-8,11-14,17-20,22H2,1-3H3
DMPQKXR CS CCC(C)(CCN1CCCCC1)N(CC2=CC3=CC=CC=C3N(C2=O)C)C(=O)C4CCCCC4
DMPQKXR IK LQTUVTFQPOMQHL-UHFFFAOYSA-N
DMPQKXR IU N-[(1-methyl-2-oxoquinolin-3-yl)methyl]-N-(3-methyl-1-piperidin-1-ylpentan-3-yl)cyclohexanecarboxamide
DMK72JS ID DMK72JS
DMK72JS DN PMID27788040-Compound-5c
DMK72JS HS Patented
DMK72JS CP MERCK SHARP & DOHME CORP. BARROW, James, C. BILODEAU, Mark, T. COX, Christopher, D. HARTNETT, John, C. KETT, Nathan, R. LI, Yiwei MANLEY, Peter MELAMED, Jeffrey SHIPE, William, D. TROTTER, B. Wesley ZARTMAN, Amy, E
DMK72JS DT Small molecular drug
DMK72JS PC 44156964
DMK72JS MW 467.6
DMK72JS FM C28H41N3O3
DMK72JS IC InChI=1S/C28H41N3O3/c1-4-28(2,14-15-30-16-18-34-19-17-30)31(27(33)22-10-6-5-7-11-22)21-24-20-23-12-8-9-13-25(23)29(3)26(24)32/h8-9,12-13,20,22H,4-7,10-11,14-19,21H2,1-3H3
DMK72JS CS CCC(C)(CCN1CCOCC1)N(CC2=CC3=CC=CC=C3N(C2=O)C)C(=O)C4CCCCC4
DMK72JS IK FWHNGUFKFXDMER-UHFFFAOYSA-N
DMK72JS IU N-(3-methyl-1-morpholin-4-ylpentan-3-yl)-N-[(1-methyl-2-oxoquinolin-3-yl)methyl]cyclohexanecarboxamide
DMHX8OF ID DMHX8OF
DMHX8OF DN PMID27788040-Compound-6
DMHX8OF HS Patented
DMHX8OF CP MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DMHX8OF DT Small molecular drug
DM4QA6X ID DM4QA6X
DM4QA6X DN PMID27788040-Compound-6a
DM4QA6X HS Patented
DM4QA6X CP MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DM4QA6X DT Small molecular drug
DMD3U96 ID DMD3U96
DMD3U96 DN PMID27788040-Compound-6b
DMD3U96 HS Patented
DMD3U96 CP MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DMD3U96 DT Small molecular drug
DMD3U96 PC 46202376
DMD3U96 MW 394.9
DMD3U96 FM C23H23ClN2O2
DMD3U96 IC InChI=1S/C23H23ClN2O2/c1-27-19-6-7-20-21(14-19)23(26-11-10-25-22(20)26,15-16-8-12-28-13-9-16)17-2-4-18(24)5-3-17/h2-7,10-11,14,16H,8-9,12-13,15H2,1H3
DMD3U96 CS COC1=CC2=C(C=C1)C3=NC=CN3C2(CC4CCOCC4)C5=CC=C(C=C5)Cl
DMD3U96 IK XRZGTQYRLUSRHL-UHFFFAOYSA-N
DMD3U96 IU 5-(4-chlorophenyl)-7-methoxy-5-(oxan-4-ylmethyl)imidazo[2,1-a]isoindole
DMNRU35 ID DMNRU35
DMNRU35 DN PMID27788040-Compound-6c
DMNRU35 HS Patented
DMNRU35 CP MERCK SHARP & DOHME CORP. MANLEY, Peter, J. NANDA, Kausik, K. TROTTER, B. Wesley
DMNRU35 DT Small molecular drug
DMNRU35 PC 58415473
DMNRU35 MW 423.9
DMNRU35 FM C24H26ClN3O2
DMNRU35 IC InChI=1S/C24H26ClN3O2/c1-4-27(5-2)22(29)12-13-24(17-6-8-18(25)9-7-17)21-16-19(30-3)10-11-20(21)23-26-14-15-28(23)24/h6-11,14-16H,4-5,12-13H2,1-3H3
DMNRU35 CS CCN(CC)C(=O)CCC1(C2=C(C=CC(=C2)OC)C3=NC=CN31)C4=CC=C(C=C4)Cl
DMNRU35 IK YBMSTCJKQQMCAW-UHFFFAOYSA-N
DMNRU35 IU 3-[5-(4-chlorophenyl)-7-methoxyimidazo[1,2-b]isoindol-5-yl]-N,N-diethylpropanamide
DM3G21F ID DM3G21F
DM3G21F DN PMID27828716-Compound-15
DM3G21F HS Patented
DM3G21F DT Small molecular drug
DM9VXY7 ID DM9VXY7
DM9VXY7 DN PMID27828716-Compound-16
DM9VXY7 HS Patented
DM9VXY7 DT Small molecular drug
DM9VXY7 PC 23122113
DM9VXY7 MW 443.7
DM9VXY7 FM C14H8Cl3F3N4OS
DM9VXY7 IC InChI=1S/C14H8Cl3F3N4OS/c15-6-1-4-26-11(6)9-7(16)8-10(12(17)23-5-22-8)24(9)3-2-21-13(25)14(18,19)20/h1,4-5H,2-3H2,(H,21,25)
DM9VXY7 CS C1=CSC(=C1Cl)C2=C(C3=C(N2CCNC(=O)C(F)(F)F)C(=NC=N3)Cl)Cl
DM9VXY7 IK OHSATPMXJJAETD-UHFFFAOYSA-N
DM9VXY7 IU N-[2-[4,7-dichloro-6-(3-chlorothiophen-2-yl)pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-2,2,2-trifluoroacetamide
DMR7V9E ID DMR7V9E
DMR7V9E DN PMID27828716-Compound-17
DMR7V9E HS Patented
DMR7V9E DT Small molecular drug
DMR7V9E PC 10065515
DMR7V9E MW 335.32
DMR7V9E FM C16H13N7O2
DMR7V9E IC InChI=1S/C16H13N7O2/c1-25-11-5-3-10(4-6-11)23-13(24)9-12-14(22-23)15(21-20-12)19-16-17-7-2-8-18-16/h2-9,20H,1H3,(H,17,18,19,21)
DMR7V9E CS COC1=CC=C(C=C1)N2C(=O)C=C3C(=N2)C(=NN3)NC4=NC=CC=N4
DMR7V9E IK SSEXHPVKWUREDI-UHFFFAOYSA-N
DMR7V9E IU 5-(4-methoxyphenyl)-3-(pyrimidin-2-ylamino)-1H-pyrazolo[4,3-c]pyridazin-6-one
DMNR6KL ID DMNR6KL
DMNR6KL DN PMID27828716-Compound-18
DMNR6KL HS Patented
DMNR6KL DT Small molecular drug
DMNR6KL PC 9944655
DMNR6KL MW 313.78
DMNR6KL FM C16H16ClN5
DMNR6KL IC InChI=1S/C16H16ClN5/c1-9-8-14(22-21-9)19-15-10(2)11(3)18-16(20-15)12-6-4-5-7-13(12)17/h4-8H,1-3H3,(H2,18,19,20,21,22)
DMNR6KL CS CC1=CC(=NN1)NC2=NC(=NC(=C2C)C)C3=CC=CC=C3Cl
DMNR6KL IK ONBXAMQNBSFIQS-UHFFFAOYSA-N
DMNR6KL IU 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine
DM8V7QH ID DM8V7QH
DM8V7QH DN PMID27828716-Compound-19
DM8V7QH HS Patented
DM8V7QH DT Small molecular drug
DM8V7QH PC 9800945
DM8V7QH MW 397.4
DM8V7QH FM C21H19N9
DM8V7QH IC InChI=1S/C21H19N9/c1-13-9-19(30-28-13)26-21-25-18(10-14-5-3-2-4-6-14)24-20(27-21)23-16-8-7-15-12-22-29-17(15)11-16/h2-9,11-12H,10H2,1H3,(H,22,29)(H3,23,24,25,26,27,28,30)
DM8V7QH CS CC1=CC(=NN1)NC2=NC(=NC(=N2)NC3=CC4=C(C=C3)C=NN4)CC5=CC=CC=C5
DM8V7QH IK OKPNIPFZIIYESG-UHFFFAOYSA-N
DM8V7QH IU 6-benzyl-4-N-(1H-indazol-6-yl)-2-N-(5-methyl-1H-pyrazol-3-yl)-1,3,5-triazine-2,4-diamine
DMDA3PN ID DMDA3PN
DMDA3PN DN PMID27828716-Compound-20
DMDA3PN HS Patented
DMDA3PN DT Small molecular drug
DMDA3PN PC 57521263
DMDA3PN MW 364.4
DMDA3PN FM C20H17FN4O2
DMDA3PN IC InChI=1S/C20H17FN4O2/c21-15-4-1-3-14-17(7-10-22-19(14)15)24-20(26)25-18-6-2-5-16(23-18)13-8-11-27-12-9-13/h1-8,10H,9,11-12H2,(H2,22,23,24,25,26)
DMDA3PN CS C1COCC=C1C2=NC(=CC=C2)NC(=O)NC3=C4C=CC=C(C4=NC=C3)F
DMDA3PN IK BYKSEVADXIBXTH-UHFFFAOYSA-N
DMDA3PN IU 1-[6-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yl]-3-(8-fluoroquinolin-4-yl)urea
DMDA3PN CA CAS 1384424-60-5
DMO1NAR ID DMO1NAR
DMO1NAR DN PMID27828716-Compound-21
DMO1NAR HS Patented
DMO1NAR DT Small molecular drug
DMO1NAR PC 49831011
DMO1NAR MW 305.3
DMO1NAR FM C18H15N3O2
DMO1NAR IC InChI=1S/C18H15N3O2/c19-9-10-4-6-14-12(8-10)17(18(23)21-14)15-7-5-11-13(20-15)2-1-3-16(11)22/h4-8,16-17,22H,1-3H2,(H,21,23)
DMO1NAR CS C1CC(C2=C(C1)N=C(C=C2)C3C4=C(C=CC(=C4)C#N)NC3=O)O
DMO1NAR IK XZWVOUQIYLZUCJ-UHFFFAOYSA-N
DMO1NAR IU 3-(5-hydroxy-5,6,7,8-tetrahydroquinolin-2-yl)-2-oxo-1,3-dihydroindole-5-carbonitrile
DMUM5L6 ID DMUM5L6
DMUM5L6 DN PMID27828716-Compound-BIO-acetoxime
DMUM5L6 HS Patented
DMUM5L6 CP UNIVERSITAET BASEL
DMUM5L6 DT Small molecular drug
DMUM5L6 DE Malignant glioma
DMY9WHZ ID DMY9WHZ
DMY9WHZ DN PMID27841036-Compound-23
DMY9WHZ HS Patented
DMY9WHZ CP Janssen Pharmaceutica NV
DMY9WHZ DT Small molecular drug
DMY9WHZ PC 44514723
DMY9WHZ MW 404.5
DMY9WHZ FM C23H24N4O3
DMY9WHZ IC InChI=1S/C23H24N4O3/c1-23(13-24,12-19-26-20(29-2)11-21(27-19)30-3)14-8-9-16-15-6-4-5-7-17(15)22(28)25-18(16)10-14/h8-11H,4-7,12H2,1-3H3,(H,25,28)
DMY9WHZ CS CC(CC1=NC(=CC(=N1)OC)OC)(C#N)C2=CC3=C(C=C2)C4=C(CCCC4)C(=O)N3
DMY9WHZ IK FITDTEZFVLDGBX-UHFFFAOYSA-N
DMY9WHZ IU 3-(4,6-dimethoxypyrimidin-2-yl)-2-methyl-2-(6-oxo-7,8,9,10-tetrahydro-5H-phenanthridin-3-yl)propanenitrile
DM9VMJ3 ID DM9VMJ3
DM9VMJ3 DN PMID27841036-Compound-24
DM9VMJ3 HS Patented
DM9VMJ3 CP Janssen Pharmaceutica NV
DM9VMJ3 DT Small molecular drug
DM9VMJ3 PC 44515029
DM9VMJ3 MW 368.4
DM9VMJ3 FM C23H20N4O
DM9VMJ3 IC InChI=1S/C23H20N4O/c1-23(14-25,12-16-5-4-6-17(13-24)26-16)15-9-10-19-18-7-2-3-8-20(18)22(28)27-21(19)11-15/h4-6,9-11H,2-3,7-8,12H2,1H3,(H,27,28)
DM9VMJ3 CS CC(CC1=NC(=CC=C1)C#N)(C#N)C2=CC3=C(C=C2)C4=C(CCCC4)C(=O)N3
DM9VMJ3 IK WVGLSASLDWFLFS-UHFFFAOYSA-N
DM9VMJ3 IU 6-[2-cyano-2-(6-oxo-7,8,9,10-tetrahydro-5H-phenanthridin-3-yl)propyl]pyridine-2-carbonitrile
DMGXI95 ID DMGXI95
DMGXI95 DN PMID27841036-Compound-33
DMGXI95 HS Patented
DMGXI95 CP SHANGHAI HENGRUI PHARM CO LTD [CNJIANGSU HENGRUI MEDICINE CO [CNTANG PENGCHO [CNLI XIN [CNLI XIANGQIN [CNCHEN YANG [CNWANG BIN [CNZHU ZHE [CN]
DMGXI95 DT Small molecular drug
DMGXI95 PC 56649297
DMGXI95 MW 472.4
DMGXI95 FM C22H16F4N6O2
DMGXI95 IC InChI=1S/C22H16F4N6O2/c23-16-6-5-12(10-17-13-3-1-2-4-14(13)19(33)29-28-17)9-15(16)20(34)31-7-8-32-18(11-31)27-21(30-32)22(24,25)26/h1-6,9H,7-8,10-11H2,(H,29,33)
DMGXI95 CS C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
DMGXI95 IK XJGXCBHXFWBOTN-UHFFFAOYSA-N
DMGXI95 IU 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2H-phthalazin-1-one
DMGXI95 CA CAS 1358715-18-0
DMHIV2L ID DMHIV2L
DMHIV2L DN PMID27841036-Compound-36
DMHIV2L HS Patented
DMHIV2L CP MGI GP, INC. XU, Weizheng DELAHANTY, Greg ZHANG, Jie
DMHIV2L DT Small molecular drug
DMHIV2L PC 11660296
DMHIV2L MW 349.4
DMHIV2L FM C20H19N3O3
DMHIV2L IC InChI=1S/C20H19N3O3/c24-13-6-8-23(9-7-13)11-12-4-5-16-15(10-12)19-18-14(20(25)22-21-19)2-1-3-17(18)26-16/h1-5,10,13,24H,6-9,11H2,(H,22,25)
DMHIV2L CS C1CN(CCC1O)CC2=CC3=C(C=C2)OC4=CC=CC5=C4C3=NNC5=O
DMHIV2L IK HAVFFEMDLROBGI-UHFFFAOYSA-N
DMHIV2L IU 4-[(4-hydroxypiperidin-1-yl)methyl]-8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17)-heptaen-14-one
DMHIV2L CA CAS 902128-92-1
DM1KJAQ ID DM1KJAQ
DM1KJAQ DN PMID27841036-Compound-38
DM1KJAQ HS Patented
DM1KJAQ CP CEPHALON, INC. BIERLMAIER, Stephen CHRISTIE, Michael COURVOISIER, Laurent FIELD, R. Scott HALTIWANGER, R. Curtis HE, Linli JACOBS, Martin J. KRESS, Michael MCKEAN, Robert E. MOWREY, Dale R. PETRAITIS, Joseph YAZDANIAN, MehraCEPHALON, INC. DIEBOLD, James, L. HUDKINS, Robert, L. MIKNYOCZKI, Sheila, J. RUGGERI, BrucTEVA(Cephalon,Inc.)
DM1KJAQ DT Small molecular drug
DM1KJAQ PC 24780387
DM1KJAQ MW 418.5
DM1KJAQ FM C24H26N4O3
DM1KJAQ IC InChI=1S/C24H26N4O3/c1-26-9-11-27(12-10-26)13-28-23(29)18-14-5-3-6-15(14)22-20(21(18)24(28)30)19-16(25-22)7-4-8-17(19)31-2/h4,7-8,25H,3,5-6,9-13H2,1-2H3
DM1KJAQ CS CN1CCN(CC1)CN2C(=O)C3=C(C2=O)C4=C(C5=C3CCC5)NC6=C4C(=CC=C6)OC
DM1KJAQ IK CTLOSZHDGZLOQE-UHFFFAOYSA-N
DM1KJAQ IU 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione
DM1KJAQ CA CAS 916574-83-9
DM3FAIS ID DM3FAIS
DM3FAIS DN PMID27841036-Compound-V
DM3FAIS HS Patented
DM3FAIS CP Medshine Discovery Inc
DM3FAIS DT Small molecular drug
DM1HPY7 ID DM1HPY7
DM1HPY7 DN PMID27841036-Compound-XI
DM1HPY7 HS Patented
DM1HPY7 CP Janssen Pharmaceutica NV
DM1HPY7 DT Small molecular drug
DM9K5BZ ID DM9K5BZ
DM9K5BZ DN PMID27841036-Compound-XVII
DM9K5BZ HS Patented
DM9K5BZ CP Santen Pharmaceutical Co
DM9K5BZ DT Small molecular drug
DME2IHD ID DME2IHD
DME2IHD DN PMID27841045-Compound-129
DME2IHD HS Patented
DME2IHD CP Korea Bio Health Co. Ltd
DME2IHD DT Small molecular drug
DME2IHD PC 442126
DME2IHD MW 328.4
DME2IHD FM C19H20O5
DME2IHD IC InChI=1S/C19H20O5/c1-11(2)7-18(21)23-16-9-13-8-12-5-6-17(20)22-14(12)10-15(13)24-19(16,3)4/h5-8,10,16H,9H2,1-4H3/t16-/m0/s1
DME2IHD CS CC(=CC(=O)O[C@H]1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C)C
DME2IHD IK CUKSFECWKQBVED-INIZCTEOSA-N
DME2IHD IU [(3S)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] 3-methylbut-2-enoate
DME2IHD CA CAS 5928-25-6
DME2IHD CB CHEBI:4353
DM2AVEG ID DM2AVEG
DM2AVEG DN PMID27841045-Compound-130
DM2AVEG HS Patented
DM2AVEG CP Korea Bio Health Co. Ltd
DM2AVEG DT Small molecular drug
DM2AVEG PC 776126
DM2AVEG MW 328.4
DM2AVEG FM C19H20O5
DM2AVEG IC InChI=1S/C19H20O5/c1-5-11(2)18(21)23-16-9-13-8-12-6-7-17(20)22-14(12)10-15(13)24-19(16,3)4/h5-8,10,16H,9H2,1-4H3/b11-5-/t16-/m1/s1
DM2AVEG CS C/C=C(/C)\\C(=O)O[C@@H]1CC2=C(C=C3C(=C2)C=CC(=O)O3)OC1(C)C
DM2AVEG IK AGABNGOXUSXQDD-YLBKJFSISA-N
DM2AVEG IU [(3R)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (Z)-2-methylbut-2-enoate
DMIKTVL ID DMIKTVL
DMIKTVL DN PMID27841045-Compound-131
DMIKTVL HS Patented
DMIKTVL CP Astellas Pharma Inc
DMIKTVL DT Small molecular drug
DMCQB93 ID DMCQB93
DMCQB93 DN PMID27841045-Compound-132
DMCQB93 HS Patented
DMCQB93 CP Kissei Pharmaceutical Co. Ltd
DMCQB93 DT Small molecular drug
DMCQB93 PC 59478131
DMCQB93 MW 294.26
DMCQB93 FM C16H10N2O4
DMCQB93 IC InChI=1S/C16H10N2O4/c17-7-10-8-18(9-13(10)15-2-1-5-22-15)11-3-4-12(16(20)21)14(19)6-11/h1-6,8-9,19H,(H,20,21)
DMCQB93 CS C1=COC(=C1)C2=CN(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O
DMCQB93 IK ZWZQFNSOFGQISH-UHFFFAOYSA-N
DMCQB93 IU 4-[3-cyano-4-(furan-2-yl)pyrrol-1-yl]-2-hydroxybenzoic acid
DMXPO6T ID DMXPO6T
DMXPO6T DN PMID27841045-Compound-133
DMXPO6T HS Patented
DMXPO6T CP Kissei Pharmaceutical Co. Ltd
DMXPO6T DT Small molecular drug
DMXPO6T PC 25052195
DMXPO6T MW 289.29
DMXPO6T FM C17H11N3O2
DMXPO6T IC InChI=1S/C17H11N3O2/c18-9-14-10-20(11-15(14)12-4-2-1-3-5-12)16-8-13(17(21)22)6-7-19-16/h1-8,10-11H,(H,21,22)
DMXPO6T CS C1=CC=C(C=C1)C2=CN(C=C2C#N)C3=NC=CC(=C3)C(=O)O
DMXPO6T IK XMNOTSLRNISRFW-UHFFFAOYSA-N
DMXPO6T IU 2-(3-cyano-4-phenylpyrrol-1-yl)pyridine-4-carboxylic acid
DMY3U7N ID DMY3U7N
DMY3U7N DN PMID27841045-Compound-134
DMY3U7N HS Patented
DMY3U7N CP Kissei Pharmaceutical Co. Ltd
DMY3U7N DT Small molecular drug
DMY3U7N PC 59478031
DMY3U7N MW 310.3
DMY3U7N FM C16H10N2O3S
DMY3U7N IC InChI=1S/C16H10N2O3S/c17-7-10-8-18(9-13(10)15-2-1-5-22-15)11-3-4-12(16(20)21)14(19)6-11/h1-6,8-9,19H,(H,20,21)
DMY3U7N CS C1=CSC(=C1)C2=CN(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O
DMY3U7N IK DWSLFJUREKSUNF-UHFFFAOYSA-N
DMY3U7N IU 4-(3-cyano-4-thiophen-2-ylpyrrol-1-yl)-2-hydroxybenzoic acid
DMVR9TJ ID DMVR9TJ
DMVR9TJ DN PMID27841045-Compound-135
DMVR9TJ HS Patented
DMVR9TJ CP Kissei Pharmaceutical Co. Ltd
DMVR9TJ DT Small molecular drug
DMVR9TJ PC 59477845
DMVR9TJ MW 284.31
DMVR9TJ FM C16H16N2O3
DMVR9TJ IC InChI=1S/C16H16N2O3/c1-2-3-4-11-9-18(10-12(11)8-17)13-5-6-14(16(20)21)15(19)7-13/h5-7,9-10,19H,2-4H2,1H3,(H,20,21)
DMVR9TJ CS CCCCC1=CN(C=C1C#N)C2=CC(=C(C=C2)C(=O)O)O
DMVR9TJ IK IFZIPYWLVUUWDL-UHFFFAOYSA-N
DMVR9TJ IU 4-(3-butyl-4-cyanopyrrol-1-yl)-2-hydroxybenzoic acid
DM0KR8E ID DM0KR8E
DM0KR8E DN PMID27841045-Compound-136
DM0KR8E HS Patented
DM0KR8E CP Kissei Pharmaceutical Co. Ltd
DM0KR8E DT Small molecular drug
DM0KR8E PC 59477789
DM0KR8E MW 304.3
DM0KR8E FM C18H12N2O3
DM0KR8E IC InChI=1S/C18H12N2O3/c19-9-13-10-20(11-16(13)12-4-2-1-3-5-12)14-6-7-15(18(22)23)17(21)8-14/h1-8,10-11,21H,(H,22,23)
DM0KR8E CS C1=CC=C(C=C1)C2=CN(C=C2C#N)C3=CC(=C(C=C3)C(=O)O)O
DM0KR8E IK KTIOENPGGRVZED-UHFFFAOYSA-N
DM0KR8E IU 4-(3-cyano-4-phenylpyrrol-1-yl)-2-hydroxybenzoic acid
DML25WY ID DML25WY
DML25WY DN PMID27841045-Compound-137
DML25WY HS Patented
DML25WY CP Kissei Pharmaceutical Co. Ltd
DML25WY DT Small molecular drug
DML25WY PC 59477603
DML25WY MW 310.3
DML25WY FM C16H10N2O3S
DML25WY IC InChI=1S/C16H10N2O3S/c17-6-11-7-18(8-14(11)10-3-4-22-9-10)12-1-2-13(16(20)21)15(19)5-12/h1-5,7-9,19H,(H,20,21)
DML25WY CS C1=CC(=C(C=C1N2C=C(C(=C2)C3=CSC=C3)C#N)O)C(=O)O
DML25WY IK ZWWRXUXPUSYNGI-UHFFFAOYSA-N
DML25WY IU 4-(3-cyano-4-thiophen-3-ylpyrrol-1-yl)-2-hydroxybenzoic acid
DMR7MBY ID DMR7MBY
DMR7MBY DN PMID27841045-Compound-143
DMR7MBY HS Patented
DMR7MBY CP LG Life Sciences Ltd
DMR7MBY DT Small molecular drug
DMR7MBY PC 51353128
DMR7MBY MW 317.3
DMR7MBY FM C19H15N3O2
DMR7MBY IC InChI=1S/C19H15N3O2/c20-9-15-11-22(10-12-1-2-12)18-4-3-13(7-16(15)18)17-8-14(19(23)24)5-6-21-17/h3-8,11-12H,1-2,10H2,(H,23,24)
DMR7MBY CS C1CC1CN2C=C(C3=C2C=CC(=C3)C4=NC=CC(=C4)C(=O)O)C#N
DMR7MBY IK MHJSHOXSYFENTO-UHFFFAOYSA-N
DMR7MBY IU 2-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]pyridine-4-carboxylic acid
DMR43JE ID DMR43JE
DMR43JE DN PMID27841045-Compound-144
DMR43JE HS Patented
DMR43JE CP LG Life Sciences Ltd
DMR43JE DT Small molecular drug
DMR43JE PC 51352995
DMR43JE MW 306.32
DMR43JE FM C17H14N4O2
DMR43JE IC InChI=1S/C17H14N4O2/c18-6-12-9-20(8-11-1-2-11)16-4-3-14(5-15(12)16)21-10-13(7-19-21)17(22)23/h3-5,7,9-11H,1-2,8H2,(H,22,23)
DMR43JE CS C1CC1CN2C=C(C3=C2C=CC(=C3)N4C=C(C=N4)C(=O)O)C#N
DMR43JE IK MHZLIWHOFCJYKU-UHFFFAOYSA-N
DMR43JE IU 1-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]pyrazole-4-carboxylic acid
DMAJRP1 ID DMAJRP1
DMAJRP1 DN PMID27841045-Compound-145
DMAJRP1 HS Patented
DMAJRP1 CP LG Life Sciences Ltd
DMAJRP1 DT Small molecular drug
DMAJRP1 PC 51039100
DMAJRP1 MW 294.31
DMAJRP1 FM C16H14N4O2
DMAJRP1 IC InChI=1S/C16H14N4O2/c1-10(2)19-8-11(6-17)14-5-13(3-4-15(14)19)20-9-12(7-18-20)16(21)22/h3-5,7-10H,1-2H3,(H,21,22)
DMAJRP1 CS CC(C)N1C=C(C2=C1C=CC(=C2)N3C=C(C=N3)C(=O)O)C#N
DMAJRP1 IK JLQQRYOWGCIMMZ-UHFFFAOYSA-N
DMAJRP1 IU 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid
DM675SX ID DM675SX
DM675SX DN PMID27841045-Compound-155
DM675SX HS Patented
DM675SX CP National Taiwan University
DM675SX DT Small molecular drug
DM675SX PC 15560442
DM675SX MW 302.23
DM675SX FM C15H10O7
DM675SX IC InChI=1S/C15H10O7/c16-8-3-1-6(5-10(8)18)14-13(21)11(19)7-2-4-9(17)12(20)15(7)22-14/h1-5,16-18,20-21H
DM675SX CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3)O)O)O)O)O
DM675SX IK RHTZDFORBKRGQU-UHFFFAOYSA-N
DM675SX IU 2-(3,4-dihydroxyphenyl)-3,7,8-trihydroxychromen-4-one
DML4AVX ID DML4AVX
DML4AVX DN PMID27841045-Compound-156
DML4AVX HS Patented
DML4AVX CP National Taiwan University
DML4AVX DT Small molecular drug
DML4AVX PC 5281294
DML4AVX MW 288.25
DML4AVX FM C15H12O6
DML4AVX IC InChI=1S/C15H12O6/c16-10(9-3-6-12(18)15(21)14(9)20)4-1-8-2-5-11(17)13(19)7-8/h1-7,17-21H/b4-1+
DML4AVX CS C1=CC(=C(C=C1/C=C/C(=O)C2=C(C(=C(C=C2)O)O)O)O)O
DML4AVX IK GSBNFGRTUCCBTK-DAFODLJHSA-N
DML4AVX IU (E)-3-(3,4-dihydroxyphenyl)-1-(2,3,4-trihydroxyphenyl)prop-2-en-1-one
DML4AVX CA CAS 484-76-4
DML4AVX CB CHEBI:7734
DM7EXNI ID DM7EXNI
DM7EXNI DN PMID27841045-Compound-157
DM7EXNI HS Patented
DM7EXNI CP Baylor College of Medicine
DM7EXNI DT Small molecular drug
DM7EXNI PC 5748957
DM7EXNI MW 183.12
DM7EXNI FM C7H5NO5
DM7EXNI IC InChI=1S/C7H5NO5/c9-3-4-1-5(8(12)13)7(11)6(10)2-4/h1-3,10-11H
DM7EXNI CS C1=C(C=C(C(=C1[N+](=O)[O-])O)O)C=O
DM7EXNI IK BBFJODMCHICIAA-UHFFFAOYSA-N
DM7EXNI IU 3,4-dihydroxy-5-nitrobenzaldehyde
DM7EXNI CA CAS 116313-85-0
DMBNHI7 ID DMBNHI7
DMBNHI7 DN PMID27967267-Compound-12
DMBNHI7 HS Patented
DMBNHI7 CP Centrum Medyczne
DMBNHI7 DT Small molecular drug
DMY5UB8 ID DMY5UB8
DMY5UB8 DN PMID27967267-Compound-13
DMY5UB8 HS Patented
DMY5UB8 CP Centrum Medyczne
DMY5UB8 DT Small molecular drug
DMGI5Z8 ID DMGI5Z8
DMGI5Z8 DN PMID27967267-Compound-14
DMGI5Z8 HS Patented
DMGI5Z8 CP Centrum Medyczne
DMGI5Z8 DT Small molecular drug
DMEW46T ID DMEW46T
DMEW46T DN PMID27967267-Compound-15
DMEW46T HS Patented
DMEW46T CP Centrum Medyczne
DMEW46T DT Small molecular drug
DMO0QME ID DMO0QME
DMO0QME DN PMID27967267-Compound-27
DMO0QME HS Patented
DMO0QME DT Small molecular drug
DMVM31E ID DMVM31E
DMVM31E DN PMID27967267-Compound-28
DMVM31E HS Patented
DMVM31E CP JIANGSU SIMCERE PHARMACEUTICAL CO., LTD
DMVM31E DT Small molecular drug
DM7JIF0 ID DM7JIF0
DM7JIF0 DN PMID27967267-Compound-3
DM7JIF0 HS Patented
DM7JIF0 CP INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUS) DE ROUEN CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) UNIVERSITE DE ROUEN VFP THAPIES
DM7JIF0 DT Small molecular drug
DM7CWZ4 ID DM7CWZ4
DM7CWZ4 DN PMID27967267-Compound-36
DM7CWZ4 HS Patented
DM7CWZ4 CP Zhejiang University
DM7CWZ4 DT Small molecular drug
DMQOAJP ID DMQOAJP
DMQOAJP DN PMID27967267-Compound-39
DMQOAJP HS Patented
DMQOAJP CP Kunming Inst Botany CN ACAD
DMQOAJP DT Small molecular drug
DM68KPS ID DM68KPS
DM68KPS DN PMID27967267-Compound-42
DM68KPS HS Patented
DM68KPS CP Univ Shenyang Chemical Tech
DM68KPS DT Small molecular drug
DM12X0P ID DM12X0P
DM12X0P DN PMID27967267-Compound-43
DM12X0P HS Patented
DM12X0P CP Univ Shenyang Chemical Tech
DM12X0P DT Small molecular drug
DMEXATH ID DMEXATH
DMEXATH DN PMID27967267-Compound-47
DMEXATH HS Patented
DMEXATH CP Southwest Res Inst
DMEXATH DT Small molecular drug
DM81A50 ID DM81A50
DM81A50 DN PMID27967267-Compound-48
DM81A50 HS Patented
DM81A50 CP Southwest Res Inst
DM81A50 DT Small molecular drug
DMQTRFX ID DMQTRFX
DMQTRFX DN PMID27967267-Compound-49
DMQTRFX HS Patented
DMQTRFX CP Univ California, Scripps Research Inst
DMQTRFX DT Small molecular drug
DMNH891 ID DMNH891
DMNH891 DN PMID27967267-Compound-51
DMNH891 HS Patented
DMNH891 CP UNIVERSITE DE STRASBOURG COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITE DE ROUEN L'ETAT (MINISTE DE LA DENSE), REPRENT PAR LE DIRECTEUR CENTRAL DU SERVICE DE SANT DES ARMS
DMNH891 DT Small molecular drug
DMRH7ZY ID DMRH7ZY
DMRH7ZY DN PMID27967267-Compound-52
DMRH7ZY HS Patented
DMRH7ZY CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
DMRH7ZY DT Small molecular drug
DMAN71J ID DMAN71J
DMAN71J DN PMID27967267-Compound-7
DMAN71J HS Patented
DMAN71J CP COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
DMAN71J DT Small molecular drug
DM7TLDW ID DM7TLDW
DM7TLDW DN PMID27967267-Compound-neostenine
DM7TLDW HS Patented
DM7TLDW CP Univ Lanzhou Tech
DM7TLDW DT Small molecular drug
DM3CPJQ ID DM3CPJQ
DM3CPJQ DN PMID27967267-Compound-neotuberostemonine
DM3CPJQ HS Patented
DM3CPJQ CP Univ Lanzhou Tech
DM3CPJQ DT Small molecular drug
DM2K54D ID DM2K54D
DM2K54D DN PMID27967267-Compound-stenine
DM2K54D HS Patented
DM2K54D CP Univ Lanzhou Tech
DM2K54D DT Small molecular drug
DMTI5E3 ID DMTI5E3
DMTI5E3 DN PMID27977313-Compound-17
DMTI5E3 HS Patented
DMTI5E3 CP THE UNIVERSITY OF HONG KON
DMTI5E3 DT Small molecular drug
DMIA3GH ID DMIA3GH
DMIA3GH DN PMID27977313-Compound-18
DMIA3GH HS Patented
DMIA3GH CP THE UNIVERSITY OF HONG KON
DMIA3GH DT Small molecular drug
DM5JSI3 ID DM5JSI3
DM5JSI3 DN PMID27977313-Compound-19
DM5JSI3 HS Patented
DM5JSI3 CP THE UNIVERSITY OF HONG KON
DM5JSI3 DT Small molecular drug
DMVYO09 ID DMVYO09
DMVYO09 DN PMID27977313-Compound-27
DMVYO09 HS Patented
DMVYO09 DT Small molecular drug
DMVYO09 PC 387473
DMVYO09 MW 245.19
DMVYO09 FM C10H7N5O3
DMVYO09 IC InChI=1S/C10H7N5O3/c1-14-7-5-3-2-4-6(7)8(12-13-11)9(10(14)16)15(17)18/h2-5H,1H3
DMVYO09 CS CN1C2=CC=CC=C2C(=C(C1=O)[N+](=O)[O-])N=[N+]=[N-]
DMVYO09 IK PVHDZPYQHVOXSW-UHFFFAOYSA-N
DMVYO09 IU 4-azido-1-methyl-3-nitroquinolin-2-one
DM67NBI ID DM67NBI
DM67NBI DN PMID27977313-Compound-28
DM67NBI HS Patented
DM67NBI DT Small molecular drug
DMIF7KG ID DMIF7KG
DMIF7KG DN PMID27977313-Compound-29
DMIF7KG HS Patented
DMIF7KG DT Small molecular drug
DMIF7KG PC 436058
DMIF7KG MW 217.31
DMIF7KG FM C14H19NO
DMIF7KG IC InChI=1S/C14H19NO/c1-10-6-7-13(11(2)8-10)14(16)12(3)9-15(4)5/h6-8H,3,9H2,1-2,4-5H3
DMIF7KG CS CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C
DMIF7KG IK QXLQZLBNPTZMRK-UHFFFAOYSA-N
DMIF7KG IU 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one
DMIF7KG CA CAS 116218-49-6
DMWHAKG ID DMWHAKG
DMWHAKG DN PMID27977313-Compound-30
DMWHAKG HS Patented
DMWHAKG DT Small molecular drug
DMWHAKG PC 99298
DMWHAKG MW 374.3
DMWHAKG FM C22H14O6
DMWHAKG IC InChI=1S/C22H14O6/c1-9-7-11-12(23)3-4-13(24)19(11)22(28)18(9)17-10(2)8-16(27)20-14(25)5-6-15(26)21(17)20/h3-8,27-28H,1-2H3
DMWHAKG CS CC1=CC2=C(C(=O)C=CC2=O)C(=C1C3=C4C(=O)C=CC(=O)C4=C(C=C3C)O)O
DMWHAKG IK OEEOHKZVBKYMBA-UHFFFAOYSA-N
DMWHAKG IU 5-hydroxy-6-(4-hydroxy-2-methyl-5,8-dioxonaphthalen-1-yl)-7-methylnaphthalene-1,4-dione
DMWHAKG CA CAS 20175-84-2
DMWHAKG CB CHEBI:6002
DMBL5J9 ID DMBL5J9
DMBL5J9 DN PMID27977313-Compound-31
DMBL5J9 HS Patented
DMBL5J9 DT Small molecular drug
DMBL5J9 PC 2781092
DMBL5J9 MW 316.2
DMBL5J9 FM C14H15Cl2NO3
DMBL5J9 IC InChI=1S/C14H15Cl2NO3/c1-3-8-6-5-7-9(4-2)12(8)17-13(18)10(15)11(16)14(19)20/h5-7H,3-4H2,1-2H3,(H,17,18)(H,19,20)/b11-10+
DMBL5J9 CS CCC1=C(C(=CC=C1)CC)NC(=O)/C(=C(/C(=O)O)\\Cl)/Cl
DMBL5J9 IK JDSFJBVJTZVNIT-ZHACJKMWSA-N
DMBL5J9 IU (E)-2,3-dichloro-4-(2,6-diethylanilino)-4-oxobut-2-enoic acid
DMZNM52 ID DMZNM52
DMZNM52 DN PMID27977313-Compound-32
DMZNM52 HS Patented
DMZNM52 DT Small molecular drug
DMZNM52 PC 3004002
DMZNM52 MW 274.1
DMZNM52 FM C11H9Cl2NO3
DMZNM52 IC InChI=1S/C11H9Cl2NO3/c1-6-2-4-7(5-3-6)14-10(15)8(12)9(13)11(16)17/h2-5H,1H3,(H,14,15)(H,16,17)/b9-8+
DMZNM52 CS CC1=CC=C(C=C1)NC(=O)/C(=C(/C(=O)O)\\Cl)/Cl
DMZNM52 IK LYXYEAXSHFSVNI-CMDGGOBGSA-N
DMZNM52 IU (E)-2,3-dichloro-4-(4-methylanilino)-4-oxobut-2-enoic acid
DM0LB21 ID DM0LB21
DM0LB21 DN PMID27977313-Compound-39
DM0LB21 HS Patented
DM0LB21 DT Small molecular drug
DM0LB21 PC 123132501
DM0LB21 MW 328.4
DM0LB21 FM C4H10Na2O6S4+2
DM0LB21 IC InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1
DM0LB21 CS C(CS(=O)(=O)O)SSCCS(=O)(=O)O.[Na+].[Na+]
DM0LB21 IK KQYGMURBTJPBPQ-UHFFFAOYSA-N
DM0LB21 IU disodium;2-(2-sulfoethyldisulfanyl)ethanesulfonic acid
DML4C6D ID DML4C6D
DML4C6D DN PMID27977313-Compound-42
DML4C6D HS Patented
DML4C6D DT Small molecular drug
DMTFLVN ID DMTFLVN
DMTFLVN DN PMID27977313-Compound-43
DMTFLVN HS Patented
DMTFLVN DT Small molecular drug
DM9S2UP ID DM9S2UP
DM9S2UP DN PMID27977313-Compound-44
DM9S2UP HS Patented
DM9S2UP DT Small molecular drug
DMSZ0GE ID DMSZ0GE
DMSZ0GE DN PMID27977313-Compound-45
DMSZ0GE HS Patented
DMSZ0GE DT Small molecular drug
DMGF04T ID DMGF04T
DMGF04T DN PMID27977313-Compound-46
DMGF04T HS Patented
DMGF04T DT Small molecular drug
DMGF04T PC 140895
DMGF04T MW 259.92
DMGF04T FM C5H8Br2O2
DMGF04T IC InChI=1S/C5H8Br2O2/c1-9-5(8)4(2-6)3-7/h4H,2-3H2,1H3
DMGF04T CS COC(=O)C(CBr)CBr
DMGF04T IK USXVPPOARMSYGY-UHFFFAOYSA-N
DMGF04T IU methyl 3-bromo-2-(bromomethyl)propanoate
DMGF04T CA CAS 22262-60-8
DMI61KF ID DMI61KF
DMI61KF DN PMID27977313-Compound-47
DMI61KF HS Patented
DMI61KF CP TRUSTEES OF BOSTON UNIVERSITY SCHAUS, Scott, E. EASTWOOD, Erin, L
DMI61KF DT Small molecular drug
DMI61KF PC 53261455
DMI61KF MW 266.32
DMI61KF FM C11H14N4O2S
DMI61KF IC InChI=1S/C11H14N4O2S/c1-2-3-9-18(16,17)11-12-13-14-15(11)10-7-5-4-6-8-10/h4-8H,2-3,9H2,1H3
DMI61KF CS CCCCS(=O)(=O)C1=NN=NN1C2=CC=CC=C2
DMI61KF IK FSUGWNZPOPKNAK-UHFFFAOYSA-N
DMI61KF IU 5-butylsulfonyl-1-phenyltetrazole
DM4EFRL ID DM4EFRL
DM4EFRL DN PMID27977313-Compound-48
DM4EFRL HS Patented
DM4EFRL CP RIGAS, Basil
DM4EFRL DT Small molecular drug
DM4EFRL PC 25193001
DM4EFRL MW 526.4
DM4EFRL FM C20H32O12P2
DM4EFRL IC InChI=1S/C20H32O12P2/c1-6-26-33(23,27-7-2)30-15-17(32-34(24,28-8-3)29-9-4)14-25-20(22)18-12-10-11-13-19(18)31-16(5)21/h10-13,17H,6-9,14-15H2,1-5H3
DM4EFRL CS CCOP(=O)(OCC)OCC(COC(=O)C1=CC=CC=C1OC(=O)C)OP(=O)(OCC)OCC
DM4EFRL IK UISLTGPOZYGIOG-UHFFFAOYSA-N
DM4EFRL IU 2,3-bis(diethoxyphosphoryloxy)propyl 2-acetyloxybenzoate
DMTUNW4 ID DMTUNW4
DMTUNW4 DN PMID27977313-Compound-5
DMTUNW4 HS Patented
DMTUNW4 CP CENTRE NAT RECH SCIENT [FR
DMTUNW4 DT Small molecular drug
DMCUAO9 ID DMCUAO9
DMCUAO9 DN PMID27977313-Compound-6
DMCUAO9 HS Patented
DMCUAO9 CP CENTRE NAT RECH SCIENT [FR
DMCUAO9 DT Small molecular drug
DMWIMN9 ID DMWIMN9
DMWIMN9 DN PMID27977313-Compound-7
DMWIMN9 HS Patented
DMWIMN9 CP CENTRE NAT RECH SCIENT [FR
DMWIMN9 DT Small molecular drug
DMYFV3D ID DMYFV3D
DMYFV3D DN PMID27977313-Compound-8
DMYFV3D HS Patented
DMYFV3D CP CENTRE NAT RECH SCIENT [FR
DMYFV3D DT Small molecular drug
DMJ6CI5 ID DMJ6CI5
DMJ6CI5 DN PMID27977313-Compound-Figure4b
DMJ6CI5 HS Patented
DMJ6CI5 CP CENTRE NAT RECH SCIENT [FR
DMJ6CI5 DT Small molecular drug
DMICBFK ID DMICBFK
DMICBFK DN PMID27977313-Compound-Figure6C
DMICBFK HS Patented
DMICBFK DT Small molecular drug
DM5QH4C ID DM5QH4C
DM5QH4C DN PMID27998201-Compound-1
DM5QH4C HS Patented
DM5QH4C CP THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS PRABHAKAR, Bellur, S. ELSHABRAWY, Hatem, A
DM5QH4C DT Small molecular drug
DM5QH4C PC 826236
DM5QH4C MW 307.35
DM5QH4C FM C13H21N7O2
DM5QH4C IC InChI=1S/C13H21N7O2/c1-8(2)15-11-17-12(16-9(3)4)19-13(18-11)20(7-14)6-10(21)22-5/h8-9H,6H2,1-5H3,(H2,15,16,17,18,19)
DM5QH4C CS CC(C)NC1=NC(=NC(=N1)N(CC(=O)OC)C#N)NC(C)C
DM5QH4C IK QYAYANIDXCPTDU-UHFFFAOYSA-N
DM5QH4C IU methyl 2-[[4,6-bis(propan-2-ylamino)-1,3,5-triazin-2-yl]-cyanoamino]acetate
DM5QH4C DE Coronavirus infection; Henipavirus Encephalitis
DMVXTIL ID DMVXTIL
DMVXTIL DN PMID27998201-Compound-10
DMVXTIL HS Patented
DMVXTIL DT Small molecular drug
DMVXTIL PC 71813529
DMVXTIL MW 411.5
DMVXTIL FM C27H29N3O
DMVXTIL IC InChI=1S/C27H29N3O/c1-20(2)17-26(27(31)30(4)29(3)19-28)25-12-8-11-24(18-25)23-15-13-22(14-16-23)21-9-6-5-7-10-21/h5-16,18,20,26H,17H2,1-4H3
DMVXTIL CS CC(C)CC(C1=CC=CC(=C1)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N(C)N(C)C#N
DMVXTIL IK VUAQQIIYDSXRAP-UHFFFAOYSA-N
DMVXTIL IU methyl-[methyl-[4-methyl-2-[3-(4-phenylphenyl)phenyl]pentanoyl]amino]cyanamide
DMVXTIL DE Osteoporosis
DMTV5NU ID DMTV5NU
DMTV5NU DN PMID27998201-Compound-11
DMTV5NU HS Patented
DMTV5NU CP VIROBAY, INC
DMTV5NU DT Small molecular drug
DMTV5NU PC 77846164
DMTV5NU MW 578.4
DMTV5NU FM C25H25Cl2F4N3O4
DMTV5NU IC InChI=1S/C25H25Cl2F4N3O4/c1-2-18(21(36)24(38)32-15-7-8-15)34-23(37)19(11-12-9-16(26)20(35)17(27)10-12)33-22(25(29,30)31)13-3-5-14(28)6-4-13/h3-6,9-10,15,18-19,22,33,35H,2,7-8,11H2,1H3,(H,32,38)(H,34,37)/t18-,19-,22-/m0/s1
DMTV5NU CS CC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H](CC2=CC(=C(C(=C2)Cl)O)Cl)N[C@@H](C3=CC=C(C=C3)F)C(F)(F)F
DMTV5NU IK HNEZRIRYWXIOJA-IPJJNNNSSA-N
DMTV5NU IU (3S)-N-cyclopropyl-3-[[(2S)-3-(3,5-dichloro-4-hydroxyphenyl)-2-[[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino]propanoyl]amino]-2-oxopentanamide
DMTV5NU DE Metastatic cancer
DM8QZNC ID DM8QZNC
DM8QZNC DN PMID27998201-Compound-12
DM8QZNC HS Patented
DM8QZNC CP VIROBAY, INC. BOOTH, Rober
DM8QZNC DT Small molecular drug
DM8QZNC DE Cancer related pain; Bone cancer
DMZHIM8 ID DMZHIM8
DMZHIM8 DN PMID27998201-Compound-13
DMZHIM8 HS Patented
DMZHIM8 CP VIROBAY, INC. HOLSINGER, Lesli
DMZHIM8 DT Small molecular drug
DMZHIM8 PC 25233001
DMZHIM8 MW 758.9
DMZHIM8 FM C40H54N8O7
DMZHIM8 IC InChI=1S/C40H54N8O7/c1-39(2,3)34(45-38(53)46-40(4,5)6)37(52)47-22-26(55-31-21-32(48-17-9-16-41-48)43-28-19-25(54-7)14-15-27(28)31)20-30(47)35(50)44-29(18-23-10-8-11-23)33(49)36(51)42-24-12-13-24/h9,14-17,19,21,23-24,26,29-30,34H,8,10-13,18,20,22H2,1-7H3,(H,42,51)(H,44,50)(H2,45,46,53)/t26-,29+,30+,34-/m1/s1
DMZHIM8 CS CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](CC2CCC2)C(=O)C(=O)NC3CC3)OC4=CC(=NC5=C4C=CC(=C5)OC)N6C=CC=N6)NC(=O)NC(C)(C)C
DMZHIM8 IK YOTPWZLVXAMQNL-GUXYKIAJSA-N
DMZHIM8 IU (2S,4R)-1-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-N-[(2S)-1-cyclobutyl-4-(cyclopropylamino)-3,4-dioxobutan-2-yl]-4-(7-methoxy-2-pyrazol-1-ylquinolin-4-yl)oxypyrrolidine-2-carboxamide
DMZHIM8 DE Hepatic fibrosis
DMOB8LU ID DMOB8LU
DMOB8LU DN PMID27998201-Compound-15
DMOB8LU HS Patented
DMOB8LU CP GRUENENTHAL GMBH [DE
DMOB8LU DT Small molecular drug
DMOB8LU DE Pain
DMAZVHJ ID DMAZVHJ
DMAZVHJ DN PMID27998201-Compound-17
DMAZVHJ HS Patented
DMAZVHJ CP THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA DIAMOND, Scott, L. BEAVERS, Mary, Pat HURYN, Donna MYERS, Michael, C. SMITH, Amos, B. SHAH, Parag, P. LIU, Zhuqin
DMAZVHJ DT Small molecular drug
DMAZVHJ DE Hair loss
DM67RMX ID DM67RMX
DM67RMX DN PMID27998201-Compound-19
DM67RMX HS Patented
DM67RMX DT Small molecular drug
DM67RMX PC 100951597
DM67RMX MW 629.6
DM67RMX FM C30H33BrN2O6S
DM67RMX IC InChI=1S/C30H33BrN2O6S/c1-22(2)19-26(17-18-40(36,37)39-27-15-13-25(31)14-16-27)32-29(34)28(20-23-9-5-3-6-10-23)33-30(35)38-21-24-11-7-4-8-12-24/h3-18,22,26,28H,19-21H2,1-2H3,(H,32,34)(H,33,35)/b18-17+/t26-,28+/m1/s1
DM67RMX CS CC(C)C[C@@H](/C=C/S(=O)(=O)OC1=CC=C(C=C1)Br)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3
DM67RMX IK FMZWJWZKFKZMSS-FMPLDUIVSA-N
DM67RMX IU (4-bromophenyl) (E,3S)-5-methyl-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hex-1-ene-1-sulfonate
DM67RMX DE Solid tumour/cancer
DMMAE3C ID DMMAE3C
DMMAE3C DN PMID27998201-Compound-2
DMMAE3C HS Patented
DMMAE3C CP MERCK FROSST CANADA LTD. GAUTHIER, Jacques-Yves TRUONG, Vouy-Lin
DMMAE3C DT Small molecular drug
DMMAE3C DE Alzheimer disease
DMS9QA7 ID DMS9QA7
DMS9QA7 DN PMID27998201-Compound-22
DMS9QA7 HS Patented
DMS9QA7 DT Small molecular drug
DMS9QA7 PC 19910
DMS9QA7 MW 190.16
DMS9QA7 FM C9H6N2O3
DMS9QA7 IC InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H
DMS9QA7 CS C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-]
DMS9QA7 IK RJIWZDNTCBHXAL-UHFFFAOYSA-N
DMS9QA7 IU 5-nitroquinolin-8-ol
DMS9QA7 CA CAS 4008-48-4
DMS9QA7 CB CHEBI:67121
DMS9QA7 DE Neurodegenerative disorder; Pancreatitis; Alzheimer disease; Osteoarthritis
DM25BNZ ID DM25BNZ
DM25BNZ DN PMID27998201-Compound-24
DM25BNZ HS Patented
DM25BNZ DT Small molecular drug
DM25BNZ PC 6431125
DM25BNZ MW 272.5
DM25BNZ FM C20H32
DM25BNZ IC InChI=1S/C20H32/c1-14(2)15-7-9-17-16(13-15)8-10-18-19(3,4)11-6-12-20(17,18)5/h7,14,18H,6,8-13H2,1-5H3/t18?,20-/m1/s1
DM25BNZ CS CC(C)C1=CCC2=C(C1)CCC3[C@@]2(CCCC3(C)C)C
DM25BNZ IK BGVUIJDZTQIJIO-ROPPNANJSA-N
DM25BNZ IU (4bS)-4b,8,8-trimethyl-2-propan-2-yl-1,4,5,6,7,8a,9,10-octahydrophenanthrene
DM25BNZ DE Meningioma tumour; Glioma
DMVZ0ND ID DMVZ0ND
DMVZ0ND DN PMID27998201-Compound-5
DMVZ0ND HS Patented
DMVZ0ND DT Small molecular drug
DMVZ0ND PC 46202117
DMVZ0ND MW 479.6
DMVZ0ND FM C23H27F2N3O2S2
DMVZ0ND IC InChI=1S/C23H27F2N3O2S2/c1-3-4-20(23(24,25)30-17-7-9-18(31-2)10-8-17)27-19(14-32-13-16-5-6-16)21(29)28-22(15-26)11-12-22/h7-10,16,19-20,27H,5-6,11-14H2,1-2H3,(H,28,29)/t19-,20-/m0/s1
DMVZ0ND CS CC#C[C@@H](C(OC1=CC=C(C=C1)SC)(F)F)N[C@@H](CSCC2CC2)C(=O)NC3(CC3)C#N
DMVZ0ND IK UKRDTRXIEUADJU-PMACEKPBSA-N
DMVZ0ND IU (2R)-N-(1-cyanocyclopropyl)-3-(cyclopropylmethylsulfanyl)-2-[[(2S)-1,1-difluoro-1-(4-methylsulfanylphenoxy)pent-3-yn-2-yl]amino]propanamide
DMVZ0ND DE Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis; Gastrointestinal disease
DM0LGTY ID DM0LGTY
DM0LGTY DN PMID27998201-Compound-6
DM0LGTY HS Patented
DM0LGTY CP F. HOFFMANN-LA ROCHE AG ALVAREZ SANCHEZ, Ruben BANNER, David CECCARELLI, Simona M. GRETHER, Uwe HAAP, Wolfgang HARTMAN, Peter HARTMANN, Guido HILPERT, Hans KUEHNE, Holger MAUSER, Harald PLANCHER, Jean-Mar
DM0LGTY DT Small molecular drug
DMU4QYR ID DMU4QYR
DMU4QYR DN PMID27998201-Compound-7
DMU4QYR HS Patented
DMU4QYR CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMU4QYR DT Small molecular drug
DMU4QYR PC 73294953
DMU4QYR MW 626.4
DMU4QYR FM C24H21F2IN4O4S
DMU4QYR IC InChI=1S/C24H21F2IN4O4S/c25-16-3-1-2-4-19(16)36(34,35)15-10-18(21(32)30-23(13-28)5-6-23)31(12-15)22(33)24(7-8-24)20-17(26)9-14(27)11-29-20/h1-4,9,11,15,18H,5-8,10,12H2,(H,30,32)/t15-,18+/m1/s1
DMU4QYR CS C1CC1(C#N)NC(=O)[C@@H]2C[C@H](CN2C(=O)C3(CC3)C4=C(C=C(C=N4)I)F)S(=O)(=O)C5=CC=CC=C5F
DMU4QYR IK ZEFHIBBPLAGQMT-QAPCUYQASA-N
DMU4QYR IU (2S,4R)-N-(1-cyanocyclopropyl)-1-[1-(3-fluoro-5-iodopyridin-2-yl)cyclopropanecarbonyl]-4-(2-fluorophenyl)sulfonylpyrrolidine-2-carboxamide
DMU4QYR DE Abdominal aortic aneurysm
DMZK0SY ID DMZK0SY
DMZK0SY DN PMID27998201-Compound-8
DMZK0SY HS Patented
DMZK0SY CP F. HOFFMANN-LA ROCHE AG BANNER, David CECCARELLI, Simona M. GRETHER, Uwe HAAP, Wolfgang HILPERT, Hans KUEHNE, Holger MAUSER, Harald PLANCHER, Jean-Marc SANCHEZ, Rub Alvare
DMZK0SY DT Small molecular drug
DM1JOZN ID DM1JOZN
DM1JOZN DN PMID27998201-Compound-9
DM1JOZN HS Patented
DM1JOZN DT Small molecular drug
DM1JOZN PC 78108715
DM1JOZN MW 454.6
DM1JOZN FM C28H30N4O2
DM1JOZN IC InChI=1S/C28H30N4O2/c1-20(2)17-26(28(34)32(4)31(3)19-29)30-27(33)25-12-8-11-24(18-25)23-15-13-22(14-16-23)21-9-6-5-7-10-21/h5-16,18,20,26H,17H2,1-4H3,(H,30,33)
DM1JOZN CS CC(C)CC(C(=O)N(C)N(C)C#N)NC(=O)C1=CC=CC(=C1)C2=CC=C(C=C2)C3=CC=CC=C3
DM1JOZN IK PYEQDWCBKMTPFO-UHFFFAOYSA-N
DM1JOZN IU N-[1-[[cyano(methyl)amino]-methylamino]-4-methyl-1-oxopentan-2-yl]-3-(4-phenylphenyl)benzamide
DM1JOZN DE Rheumatoid arthritis
DMQ6WEN ID DMQ6WEN
DMQ6WEN DN PMID28048944-Compound-11
DMQ6WEN HS Patented
DMQ6WEN CP AMAKEM NV
DMQ6WEN DT Small molecular drug
DMQ6WEN PC 76955629
DMQ6WEN MW 556.6
DMQ6WEN FM C30H25FN4O4S
DMQ6WEN IC InChI=1S/C30H25FN4O4S/c31-25-17-33-12-10-26(25)35-29(37)20-4-5-21(16-32)24(15-20)19-2-1-3-22(14-19)34-28(36)18-6-8-23(9-7-18)40-27-11-13-39-30(27)38/h1-10,12,14-15,17,27H,11,13,16,32H2,(H,34,36)(H,33,35,37)
DMQ6WEN CS C1COC(=O)C1SC2=CC=C(C=C2)C(=O)NC3=CC=CC(=C3)C4=C(C=CC(=C4)C(=O)NC5=C(C=NC=C5)F)CN
DMQ6WEN IK QKLHHIYLYLZRFM-UHFFFAOYSA-N
DMQ6WEN IU 4-(aminomethyl)-N-(3-fluoropyridin-4-yl)-3-[3-[[4-(2-oxooxolan-3-yl)sulfanylbenzoyl]amino]phenyl]benzamide
DMPT3V9 ID DMPT3V9
DMPT3V9 DN PMID28048944-Compound-19
DMPT3V9 HS Patented
DMPT3V9 CP H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC
DMPT3V9 DT Small molecular drug
DMPT3V9 PC 56596554
DMPT3V9 MW 280.32
DMPT3V9 FM C16H16N4O
DMPT3V9 IC InChI=1S/C16H16N4O/c21-16(17-9-8-12-4-2-1-3-5-12)19-14-6-7-15-13(10-14)11-18-20-15/h1-7,10-11H,8-9H2,(H,18,20)(H2,17,19,21)
DMPT3V9 CS C1=CC=C(C=C1)CCNC(=O)NC2=CC3=C(C=C2)NN=C3
DMPT3V9 IK XEZOXLSEWZHMQY-UHFFFAOYSA-N
DMPT3V9 IU 1-(1H-indazol-5-yl)-3-(2-phenylethyl)urea
DM9ZXOP ID DM9ZXOP
DM9ZXOP DN PMID28048944-Compound-2
DM9ZXOP HS Patented
DM9ZXOP CP KADMON CORPORATION, LLC
DM9ZXOP DT Small molecular drug
DM9ZXOP PC 90096055
DM9ZXOP MW 388.5
DM9ZXOP FM C22H24N6O
DM9ZXOP IC InChI=1S/C22H24N6O/c1-15(2)23-10-11-29-19-5-3-4-16(13-19)22-24-9-8-21(27-22)26-18-6-7-20-17(12-18)14-25-28-20/h3-9,12-15,23H,10-11H2,1-2H3,(H,25,28)(H,24,26,27)
DM9ZXOP CS CC(C)NCCOC1=CC=CC(=C1)C2=NC=CC(=N2)NC3=CC4=C(C=C3)NN=C4
DM9ZXOP IK CBUNAFRZRCOJEX-UHFFFAOYSA-N
DM9ZXOP IU N-[2-[3-[2-(propan-2-ylamino)ethoxy]phenyl]pyrimidin-4-yl]-1H-indazol-5-amine
DM19BQ6 ID DM19BQ6
DM19BQ6 DN PMID28048944-Compound-20
DM19BQ6 HS Patented
DM19BQ6 CP LES LABORATOIRES SERVIER
DM19BQ6 DT Small molecular drug
DM19BQ6 PC 129114209
DM19BQ6 MW 312.3
DM19BQ6 FM C18H14F2N2O
DM19BQ6 IC InChI=1S/C18H14F2N2O/c1-10(21)12-7-15(19)17(16(20)8-12)18(23)14-4-2-3-11-9-22-6-5-13(11)14/h2-10H,21H2,1H3
DM19BQ6 CS CC(C1=CC(=C(C(=C1)F)C(=O)C2=CC=CC3=C2C=CN=C3)F)N
DM19BQ6 IK MZQREGYHCORZLY-UHFFFAOYSA-N
DM19BQ6 IU [4-(1-aminoethyl)-2,6-difluorophenyl]-isoquinolin-5-ylmethanone
DMPNG9C ID DMPNG9C
DMPNG9C DN PMID28048944-Compound-21
DMPNG9C HS Patented
DMPNG9C CP LES LABORATOIRES SERVIER
DMPNG9C DT Small molecular drug
DMPNG9C PC 118326165
DMPNG9C MW 342.3
DMPNG9C FM C19H16F2N2O2
DMPNG9C IC InChI=1S/C19H16F2N2O2/c1-19(2,22)10-8-14(20)16(15(21)9-10)17(24)12-4-3-5-13-11(12)6-7-23-18(13)25/h3-9H,22H2,1-2H3,(H,23,25)
DMPNG9C CS CC(C)(C1=CC(=C(C(=C1)F)C(=O)C2=CC=CC3=C2C=CNC3=O)F)N
DMPNG9C IK FBSSVAIINOQLST-UHFFFAOYSA-N
DMPNG9C IU 5-[4-(2-aminopropan-2-yl)-2,6-difluorobenzoyl]-2H-isoquinolin-1-one
DM1BN74 ID DM1BN74
DM1BN74 DN PMID28048944-Compound-3
DM1BN74 HS Patented
DM1BN74 CP KADMON CORPORATION, LLC
DM1BN74 DT Small molecular drug
DM1BN74 PC 73603819
DM1BN74 MW 442.5
DM1BN74 FM C25H26N6O2
DM1BN74 IC InChI=1S/C25H26N6O2/c1-15-16(2)27-25(30-24(15)29-20-9-10-22-18(11-20)13-26-31-22)17-5-3-8-21(12-17)33-14-23(32)28-19-6-4-7-19/h3,5,8-13,19H,4,6-7,14H2,1-2H3,(H,26,31)(H,28,32)(H,27,29,30)
DM1BN74 CS CC1=C(N=C(N=C1NC2=CC3=C(C=C2)NN=C3)C4=CC(=CC=C4)OCC(=O)NC5CCC5)C
DM1BN74 IK FFIBTGFOEVIJLU-UHFFFAOYSA-N
DM1BN74 IU N-cyclobutyl-2-[3-[4-(1H-indazol-5-ylamino)-5,6-dimethylpyrimidin-2-yl]phenoxy]acetamide
DMJAUWG ID DMJAUWG
DMJAUWG DN PMID28048944-Compound-4
DMJAUWG HS Patented
DMJAUWG CP KADMON CORPORATION, LLC
DMJAUWG DT Small molecular drug
DMAB987 ID DMAB987
DMAB987 DN PMID28048944-Compound-5
DMAB987 HS Patented
DMAB987 CP KADMON CORPORATION, LLC
DMAB987 DT Small molecular drug
DMAB987 PC 91669217
DMAB987 MW 358.4
DMAB987 FM C20H18N6O
DMAB987 IC InChI=1S/C20H18N6O/c1-27-17-4-2-13-11-26(12-15(13)9-17)20-21-7-6-19(24-20)23-16-3-5-18-14(8-16)10-22-25-18/h2-10H,11-12H2,1H3,(H,22,25)(H,21,23,24)
DMAB987 CS COC1=CC2=C(CN(C2)C3=NC=CC(=N3)NC4=CC5=C(C=C4)NN=C5)C=C1
DMAB987 IK SWHUIIODYNUMNO-UHFFFAOYSA-N
DMAB987 IU N-[2-(5-methoxy-1,3-dihydroisoindol-2-yl)pyrimidin-4-yl]-1H-indazol-5-amine
DM5RCBV ID DM5RCBV
DM5RCBV DN PMID28048944-Compound-6
DM5RCBV HS Patented
DM5RCBV CP KADMON CORPORATION, LLC
DM5RCBV DT Small molecular drug
DM5RCBV PC 118010994
DM5RCBV MW 384.4
DM5RCBV FM C22H20N6O
DM5RCBV IC InChI=1S/C22H20N6O/c1-29-20-7-4-16-13-28(14-17(16)10-20)22-23-9-8-21(27-22)26-19-5-2-15(3-6-19)18-11-24-25-12-18/h2-12H,13-14H2,1H3,(H,24,25)(H,23,26,27)
DM5RCBV CS COC1=CC2=C(CN(C2)C3=NC=CC(=N3)NC4=CC=C(C=C4)C5=CNN=C5)C=C1
DM5RCBV IK QWVKCTINPBKQMS-UHFFFAOYSA-N
DM5RCBV IU 2-(5-methoxy-1,3-dihydroisoindol-2-yl)-N-[4-(1H-pyrazol-4-yl)phenyl]pyrimidin-4-amine
DMXZ368 ID DMXZ368
DMXZ368 DN PMID28048944-Compound-7
DMXZ368 HS Patented
DMXZ368 CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN GLICK, Gary D
DMXZ368 DT Small molecular drug
DMRANS2 ID DMRANS2
DMRANS2 DN PMID28051882-Compound-Figure9
DMRANS2 HS Patented
DMRANS2 CP WASHINGTON UNIVERSITY
DMRANS2 DT Small molecular drug
DMRANS2 PC 124197470
DMRANS2 MW 914.1
DMRANS2 FM C53H67N7O7
DMRANS2 IC InChI=1S/C53H67N7O7/c1-4-65-49-19-10-9-18-47(49)60-50(55-45-17-8-7-16-44(45)52(60)62)36-57-28-30-58(31-29-57)51(61)37-66-42-23-21-39(22-24-42)35-54-26-11-5-6-12-27-59-40-14-13-15-41(59)34-43(33-40)67-53(63)56-46-32-38(2)20-25-48(46)64-3/h7-10,16-25,32,40-41,43,54H,4-6,11-15,26-31,33-37H2,1-3H3,(H,56,63)
DMRANS2 CS CCOC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)CN4CCN(CC4)C(=O)COC5=CC=C(C=C5)CNCCCCCCN6C7CCCC6CC(C7)OC(=O)NC8=C(C=CC(=C8)C)OC
DMRANS2 IK NMJRVPZKOISERX-UHFFFAOYSA-N
DMRANS2 IU [9-[6-[[4-[2-[4-[[3-(2-ethoxyphenyl)-4-oxoquinazolin-2-yl]methyl]piperazin-1-yl]-2-oxoethoxy]phenyl]methylamino]hexyl]-9-azabicyclo[3.3.1]nonan-3-yl] N-(2-methoxy-5-methylphenyl)carbamate
DMLNA8P ID DMLNA8P
DMLNA8P DN PMID28051882-Compound-XI
DMLNA8P HS Patented
DMLNA8P CP WASHINGTON UNIVERSITY
DMLNA8P DT Small molecular drug
DM1RN89 ID DM1RN89
DM1RN89 DN PMID28051882-Compound-XIV
DM1RN89 HS Patented
DM1RN89 CP VAMVAKIDES, Alexandre
DM1RN89 DT Small molecular drug
DMG2PCZ ID DMG2PCZ
DMG2PCZ DN PMID28067079-Compound-95
DMG2PCZ HS Patented
DMG2PCZ CP HEPTARES THERAPEUTICS LIMITED
DMG2PCZ DT Small molecular drug
DMCUX42 ID DMCUX42
DMCUX42 DN PMID28067079-Compound-97
DMCUX42 HS Patented
DMCUX42 CP HEPTARES THERAPEUTICS LIMITED
DMCUX42 DT Small molecular drug
DMLKP1O ID DMLKP1O
DMLKP1O DN PMID28067079-Compound-98
DMLKP1O HS Patented
DMLKP1O CP HEPTARES THERAPEUTICS LIMITED
DMLKP1O DT Small molecular drug
DMLKP1O PC 90646678
DMLKP1O MW 281.7
DMLKP1O FM C14H8ClN5
DMLKP1O IC InChI=1S/C14H8ClN5/c15-12-5-10(8-16)4-11(6-12)13-7-14(18-9-17-13)20-3-1-2-19-20/h1-7,9H
DMLKP1O CS C1=CN(N=C1)C2=NC=NC(=C2)C3=CC(=CC(=C3)C#N)Cl
DMLKP1O IK RDPNIWXBEYDORQ-UHFFFAOYSA-N
DMLKP1O IU 3-chloro-5-(6-pyrazol-1-ylpyrimidin-4-yl)benzonitrile
DMQW470 ID DMQW470
DMQW470 DN PMID28074661-Compound-US20100022547C80
DMQW470 HS Patented
DMQW470 CP Brandeis University and University of Georgia Research Foundation, Inc
DMQW470 DT Small molecular drug
DMM9E1U ID DMM9E1U
DMM9E1U DN PMID28074661-Compound-US20100022547C81
DMM9E1U HS Patented
DMM9E1U CP Brandeis University and University of Georgia Research Foundation, Inc
DMM9E1U DT Small molecular drug
DM94MT3 ID DM94MT3
DM94MT3 DN PMID28074661-Compound-US20100022547C82
DM94MT3 HS Patented
DM94MT3 CP Brandeis University and University of Georgia Research Foundation, Inc
DM94MT3 DT Small molecular drug
DM18LO7 ID DM18LO7
DM18LO7 DN PMID28074661-Compound-US20100022547C83
DM18LO7 HS Patented
DM18LO7 CP Brandeis University and University of Georgia Research Foundation, Inc
DM18LO7 DT Small molecular drug
DMONEJ4 ID DMONEJ4
DMONEJ4 DN PMID28074661-Compound-US20100022547C86
DMONEJ4 HS Patented
DMONEJ4 CP Brandeis University and University of Georgia Research Foundation, Inc
DMONEJ4 DT Small molecular drug
DM8E702 ID DM8E702
DM8E702 DN PMID28074661-Compound-US20100022547C87
DM8E702 HS Patented
DM8E702 CP Brandeis University and University of Georgia Research Foundation, Inc
DM8E702 DT Small molecular drug
DMNUR8E ID DMNUR8E
DMNUR8E DN PMID28074661-Compound-US20100022547C88
DMNUR8E HS Patented
DMNUR8E CP Brandeis University and University of Georgia Research Foundation, Inc
DMNUR8E DT Small molecular drug
DM75QVW ID DM75QVW
DM75QVW DN PMID28074661-Compound-US20120264760C80
DM75QVW HS Patented
DM75QVW CP Brandeis University and University of Georgia Research Foundation, Inc
DM75QVW DT Small molecular drug
DMH249S ID DMH249S
DMH249S DN PMID28074661-Compound-US20120264760C81
DMH249S HS Patented
DMH249S CP Brandeis University and University of Georgia Research Foundation, Inc
DMH249S DT Small molecular drug
DM18PRU ID DM18PRU
DM18PRU DN PMID28074661-Compound-US20120264760C82
DM18PRU HS Patented
DM18PRU CP Brandeis University and University of Georgia Research Foundation, Inc
DM18PRU DT Small molecular drug
DMD7AU3 ID DMD7AU3
DMD7AU3 DN PMID28074661-Compound-US20120264760C83
DMD7AU3 HS Patented
DMD7AU3 CP Brandeis University and University of Georgia Research Foundation, Inc
DMD7AU3 DT Small molecular drug
DMKFEO4 ID DMKFEO4
DMKFEO4 DN PMID28074661-Compound-US20120264760C86
DMKFEO4 HS Patented
DMKFEO4 CP Brandeis University and University of Georgia Research Foundation, Inc
DMKFEO4 DT Small molecular drug
DM85XKT ID DM85XKT
DM85XKT DN PMID28074661-Compound-US20120264760C87
DM85XKT HS Patented
DM85XKT CP Brandeis University and University of Georgia Research Foundation, Inc
DM85XKT DT Small molecular drug
DMIKRCM ID DMIKRCM
DMIKRCM DN PMID28074661-Compound-US20120264760C88
DMIKRCM HS Patented
DMIKRCM CP Brandeis University and University of Georgia Research Foundation, Inc
DMIKRCM DT Small molecular drug
DMEJ4LW ID DMEJ4LW
DMEJ4LW DN PMID28074661-Compound-US20128202889C90
DMEJ4LW HS Patented
DMEJ4LW CP Vertex Pharmaceuticals Inc
DMEJ4LW DT Small molecular drug
DM1QUN0 ID DM1QUN0
DM1QUN0 DN PMID28074661-Compound-US20158969342C84
DM1QUN0 HS Patented
DM1QUN0 CP Brandeis University, University of Georgia Research Foundation, Inc., and The Brigham and Womens Hospital, Inc
DM1QUN0 DT Small molecular drug
DMMYH82 ID DMMYH82
DMMYH82 DN PMID28074661-Compound-US20169447134C85
DMMYH82 HS Patented
DMMYH82 CP Brandeis University and The Brigham and Womens Hospital, Inc
DMMYH82 DT Small molecular drug
DMFORUW ID DMFORUW
DMFORUW DN PMID28074661-Compound-WO2009018344C78
DMFORUW HS Patented
DMFORUW CP REGENTS OF THE UNIVERSITY OF MINNESOTA PANKIEWICZ, Krzysztof CHEN, Liqiang VINCE, Robert
DMFORUW DT Small molecular drug
DM64QNL ID DM64QNL
DM64QNL DN PMID28074661-Compound-WO2009018344C79
DM64QNL HS Patented
DM64QNL CP REGENTS OF THE UNIVERSITY OF MINNESOTA PANKIEWICZ, Krzysztof CHEN, Liqiang VINCE, Robert
DM64QNL DT Small molecular drug
DMC4TQL ID DMC4TQL
DMC4TQL DN PMID28092474-Compound-32
DMC4TQL HS Patented
DMC4TQL CP KARUS THERAPEUTICS LTD
DMC4TQL DT Small molecular drug
DMGZ61E ID DMGZ61E
DMGZ61E DN PMID28092474-Compound-32a
DMGZ61E HS Patented
DMGZ61E CP KARUS THERAPEUTICS LTD
DMGZ61E DT Small molecular drug
DMT2B5A ID DMT2B5A
DMT2B5A DN PMID28092474-Compound-32b
DMT2B5A HS Patented
DMT2B5A CP KARUS THERAPEUTICS LTD
DMT2B5A DT Small molecular drug
DMT2B5A PC 86282589
DMT2B5A MW 325.32
DMT2B5A FM C16H15N5O3
DMT2B5A IC InChI=1S/C16H15N5O3/c1-11-18-16(24-20-11)21(14-4-2-3-9-17-14)10-12-5-7-13(8-6-12)15(22)19-23/h2-9,23H,10H2,1H3,(H,19,22)
DMT2B5A CS CC1=NOC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=CC=CC=N3
DMT2B5A IK DUVRIRNTROCZMI-UHFFFAOYSA-N
DMT2B5A IU N-hydroxy-4-[[(3-methyl-1,2,4-oxadiazol-5-yl)-pyridin-2-ylamino]methyl]benzamide
DMGA3XL ID DMGA3XL
DMGA3XL DN PMID28092474-Compound-32c
DMGA3XL HS Patented
DMGA3XL CP KARUS THERAPEUTICS LTD
DMGA3XL DT Small molecular drug
DMW21U4 ID DMW21U4
DMW21U4 DN PMID28092474-Compound-32d
DMW21U4 HS Patented
DMW21U4 CP KARUS THERAPEUTICS LTD
DMW21U4 DT Small molecular drug
DMW21U4 PC 86282452
DMW21U4 MW 327.4
DMW21U4 FM C15H13N5O2S
DMW21U4 IC InChI=1S/C15H13N5O2S/c21-14(19-22)12-6-4-11(5-7-12)9-20(15-18-17-10-23-15)13-3-1-2-8-16-13/h1-8,10,22H,9H2,(H,19,21)
DMW21U4 CS C1=CC=NC(=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NN=CS3
DMW21U4 IK BQMQOALHRWIFDX-UHFFFAOYSA-N
DMW21U4 IU N-hydroxy-4-[[pyridin-2-yl(1,3,4-thiadiazol-2-yl)amino]methyl]benzamide
DM8NHQS ID DM8NHQS
DM8NHQS DN PMID28092474-Compound-32e
DM8NHQS HS Patented
DM8NHQS CP KARUS THERAPEUTICS LTD
DM8NHQS DT Small molecular drug
DMEIZ6Y ID DMEIZ6Y
DMEIZ6Y DN PMID28092474-Compound-32f
DMEIZ6Y HS Patented
DMEIZ6Y CP KARUS THERAPEUTICS LTD
DMEIZ6Y DT Small molecular drug
DMTKLEP ID DMTKLEP
DMTKLEP DN PMID28092474-Compound-32g
DMTKLEP HS Patented
DMTKLEP CP KARUS THERAPEUTICS LTD
DMTKLEP DT Small molecular drug
DME1WHT ID DME1WHT
DME1WHT DN PMID28092474-Compound-32h
DME1WHT HS Patented
DME1WHT CP KARUS THERAPEUTICS LTD
DME1WHT DT Small molecular drug
DMN3ZEF ID DMN3ZEF
DMN3ZEF DN PMID28092474-Compound-32i
DMN3ZEF HS Patented
DMN3ZEF CP KARUS THERAPEUTICS LTD
DMN3ZEF DT Small molecular drug
DMSGWTX ID DMSGWTX
DMSGWTX DN PMID28092474-Compound-32j
DMSGWTX HS Patented
DMSGWTX CP KARUS THERAPEUTICS LTD
DMSGWTX DT Small molecular drug
DMHSJ65 ID DMHSJ65
DMHSJ65 DN PMID28092474-Compound-32k
DMHSJ65 HS Patented
DMHSJ65 CP KARUS THERAPEUTICS LTD
DMHSJ65 DT Small molecular drug
DMSP5IA ID DMSP5IA
DMSP5IA DN PMID28092474-Compound-32l
DMSP5IA HS Patented
DMSP5IA CP KARUS THERAPEUTICS LTD
DMSP5IA DT Small molecular drug
DMADMWB ID DMADMWB
DMADMWB DN PMID28092474-Compound-32m
DMADMWB HS Patented
DMADMWB CP KARUS THERAPEUTICS LTD
DMADMWB DT Small molecular drug
DMADMWB PC 117703481
DMADMWB MW 339.32
DMADMWB FM C17H14FN5O2
DMADMWB IC InChI=1S/C17H14FN5O2/c18-14-5-6-15(21-9-14)23(16-10-19-7-8-20-16)11-12-1-3-13(4-2-12)17(24)22-25/h1-10,25H,11H2,(H,22,24)
DMADMWB CS C1=CC(=CC=C1CN(C2=NC=C(C=C2)F)C3=NC=CN=C3)C(=O)NO
DMADMWB IK GEFHLXDMZNZOPQ-UHFFFAOYSA-N
DMADMWB IU 4-[[(5-fluoropyridin-2-yl)-pyrazin-2-ylamino]methyl]-N-hydroxybenzamide
DMJO3RW ID DMJO3RW
DMJO3RW DN PMID28092474-Compound-32n
DMJO3RW HS Patented
DMJO3RW CP KARUS THERAPEUTICS LTD
DMJO3RW DT Small molecular drug
DMJO3RW PC 86282455
DMJO3RW MW 343.31
DMJO3RW FM C16H14FN5O3
DMJO3RW IC InChI=1S/C16H14FN5O3/c1-10-19-16(25-21-10)22(14-7-6-13(17)8-18-14)9-11-2-4-12(5-3-11)15(23)20-24/h2-8,24H,9H2,1H3,(H,20,23)
DMJO3RW CS CC1=NOC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)F
DMJO3RW IK YHMSVHVCVQHZRX-UHFFFAOYSA-N
DMJO3RW IU 4-[[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-oxadiazol-5-yl)amino]methyl]-N-hydroxybenzamide
DMV9BQN ID DMV9BQN
DMV9BQN DN PMID28092474-Compound-32o
DMV9BQN HS Patented
DMV9BQN CP KARUS THERAPEUTICS LTD
DMV9BQN DT Small molecular drug
DMV9BQN PC 86282321
DMV9BQN MW 341.34
DMV9BQN FM C17H16FN5O2
DMV9BQN IC InChI=1S/C17H16FN5O2/c1-22-9-8-16(20-22)23(15-7-6-14(18)10-19-15)11-12-2-4-13(5-3-12)17(24)21-25/h2-10,25H,11H2,1H3,(H,21,24)
DMV9BQN CS CN1C=CC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)F
DMV9BQN IK YBRKYFUMBLZQCO-UHFFFAOYSA-N
DMV9BQN IU 4-[[(5-fluoropyridin-2-yl)-(1-methylpyrazol-3-yl)amino]methyl]-N-hydroxybenzamide
DM4ZO21 ID DM4ZO21
DM4ZO21 DN PMID28092474-Compound-32p
DM4ZO21 HS Patented
DM4ZO21 CP KARUS THERAPEUTICS LTD
DM4ZO21 DT Small molecular drug
DM4ZO21 PC 86282322
DM4ZO21 MW 359.4
DM4ZO21 FM C16H14FN5O2S
DM4ZO21 IC InChI=1S/C16H14FN5O2S/c1-10-19-16(25-21-10)22(14-7-6-13(17)8-18-14)9-11-2-4-12(5-3-11)15(23)20-24/h2-8,24H,9H2,1H3,(H,20,23)
DM4ZO21 CS CC1=NSC(=N1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)F
DM4ZO21 IK RBFLOFRQBMMVRY-UHFFFAOYSA-N
DM4ZO21 IU 4-[[(5-fluoropyridin-2-yl)-(3-methyl-1,2,4-thiadiazol-5-yl)amino]methyl]-N-hydroxybenzamide
DMEASZY ID DMEASZY
DMEASZY DN PMID28092474-Compound-32q
DMEASZY HS Patented
DMEASZY CP KARUS THERAPEUTICS LTD
DMEASZY DT Small molecular drug
DMEASZY PC 86282451
DMEASZY MW 413.4
DMEASZY FM C16H11F4N5O2S
DMEASZY IC InChI=1S/C16H11F4N5O2S/c17-11-5-6-12(21-7-11)25(15-22-14(24-28-15)16(18,19)20)8-9-1-3-10(4-2-9)13(26)23-27/h1-7,27H,8H2,(H,23,26)
DMEASZY CS C1=CC(=CC=C1CN(C2=NC=C(C=C2)F)C3=NC(=NS3)C(F)(F)F)C(=O)NO
DMEASZY IK XGHLBDLYNQPBIS-UHFFFAOYSA-N
DMEASZY IU 4-[[(5-fluoropyridin-2-yl)-[3-(trifluoromethyl)-1,2,4-thiadiazol-5-yl]amino]methyl]-N-hydroxybenzamide
DMLTKMS ID DMLTKMS
DMLTKMS DN PMID28092474-Compound-32r
DMLTKMS HS Patented
DMLTKMS CP KARUS THERAPEUTICS LTD
DMLTKMS DT Small molecular drug
DMLTKMS PC 86282178
DMLTKMS MW 391.4
DMLTKMS FM C21H18FN5O2
DMLTKMS IC InChI=1S/C21H18FN5O2/c1-26-18-5-3-2-4-17(18)24-21(26)27(19-11-10-16(22)12-23-19)13-14-6-8-15(9-7-14)20(28)25-29/h2-12,29H,13H2,1H3,(H,25,28)
DMLTKMS CS CN1C2=CC=CC=C2N=C1N(CC3=CC=C(C=C3)C(=O)NO)C4=NC=C(C=C4)F
DMLTKMS IK DTDCFCPAKQGZSU-UHFFFAOYSA-N
DMLTKMS IU 4-[[(5-fluoropyridin-2-yl)-(1-methylbenzimidazol-2-yl)amino]methyl]-N-hydroxybenzamide
DMS103B ID DMS103B
DMS103B DN PMID28092474-Compound-32s
DMS103B HS Patented
DMS103B CP KARUS THERAPEUTICS LTD
DMS103B DT Small molecular drug
DMS103B PC 117703493
DMS103B MW 378.4
DMS103B FM C20H15FN4O3
DMS103B IC InChI=1S/C20H15FN4O3/c21-15-9-10-18(22-11-15)25(20-23-16-3-1-2-4-17(16)28-20)12-13-5-7-14(8-6-13)19(26)24-27/h1-11,27H,12H2,(H,24,26)
DMS103B CS C1=CC=C2C(=C1)N=C(O2)N(CC3=CC=C(C=C3)C(=O)NO)C4=NC=C(C=C4)F
DMS103B IK CJXJBYDELMRNKR-UHFFFAOYSA-N
DMS103B IU 4-[[1,3-benzoxazol-2-yl-(5-fluoropyridin-2-yl)amino]methyl]-N-hydroxybenzamide
DM2JF0T ID DM2JF0T
DM2JF0T DN PMID28092474-Compound-32t
DM2JF0T HS Patented
DM2JF0T CP KARUS THERAPEUTICS LTD
DM2JF0T DT Small molecular drug
DM2JF0T PC 86282179
DM2JF0T MW 364.4
DM2JF0T FM C20H20N4O3
DM2JF0T IC InChI=1S/C20H20N4O3/c1-14-5-10-18(22-12-14)24(19-17(27-2)4-3-11-21-19)13-15-6-8-16(9-7-15)20(25)23-26/h3-12,26H,13H2,1-2H3,(H,23,25)
DM2JF0T CS CC1=CN=C(C=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=C(C=CC=N3)OC
DM2JF0T IK JGXHNVLWEATQAQ-UHFFFAOYSA-N
DM2JF0T IU N-hydroxy-4-[[(3-methoxypyridin-2-yl)-(5-methylpyridin-2-yl)amino]methyl]benzamide
DM805ZN ID DM805ZN
DM805ZN DN PMID28092474-Compound-32u
DM805ZN HS Patented
DM805ZN CP KARUS THERAPEUTICS LTD
DM805ZN DT Small molecular drug
DMHV3ES ID DMHV3ES
DMHV3ES DN PMID28092474-Compound-32v
DMHV3ES HS Patented
DMHV3ES CP KARUS THERAPEUTICS LTD
DMHV3ES DT Small molecular drug
DML79XQ ID DML79XQ
DML79XQ DN PMID28092474-Compound-32x
DML79XQ HS Patented
DML79XQ CP KARUS THERAPEUTICS LTD
DML79XQ DT Small molecular drug
DML79XQ PC 117703583
DML79XQ MW 435.5
DML79XQ FM C23H25N5O4
DML79XQ IC InChI=1S/C23H25N5O4/c1-31-20-7-9-22(25-15-20)28(16-17-2-4-18(5-3-17)23(29)26-30)21-8-6-19(14-24-21)27-10-12-32-13-11-27/h2-9,14-15,30H,10-13,16H2,1H3,(H,26,29)
DML79XQ CS COC1=CN=C(C=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=NC=C(C=C3)N4CCOCC4
DML79XQ IK ATEJVBHLZROGEX-UHFFFAOYSA-N
DML79XQ IU N-hydroxy-4-[[(5-methoxypyridin-2-yl)-(5-morpholin-4-ylpyridin-2-yl)amino]methyl]benzamide
DMLR03U ID DMLR03U
DMLR03U DN PMID28092474-Compound-32y
DMLR03U HS Patented
DMLR03U CP KARUS THERAPEUTICS LTD
DMLR03U DT Small molecular drug
DMEPWGH ID DMEPWGH
DMEPWGH DN PMID28092474-Compound-32z
DMEPWGH HS Patented
DMEPWGH CP KARUS THERAPEUTICS LTD
DMEPWGH DT Small molecular drug
DMRE6GP ID DMRE6GP
DMRE6GP DN PMID28092474-Compound-33
DMRE6GP HS Patented
DMRE6GP CP KARUS THERAPEUTICS LTD
DMRE6GP DT Small molecular drug
DM7GH4Y ID DM7GH4Y
DM7GH4Y DN PMID28092474-Compound-33a
DM7GH4Y HS Patented
DM7GH4Y CP KARUS THERAPEUTICS LTD
DM7GH4Y DT Small molecular drug
DMIJQZV ID DMIJQZV
DMIJQZV DN PMID28092474-Compound-33b
DMIJQZV HS Patented
DMIJQZV CP KARUS THERAPEUTICS LTD
DMIJQZV DT Small molecular drug
DM51JP6 ID DM51JP6
DM51JP6 DN PMID28092474-Compound-33c
DM51JP6 HS Patented
DM51JP6 CP KARUS THERAPEUTICS LTD
DM51JP6 DT Small molecular drug
DMW38MK ID DMW38MK
DMW38MK DN PMID28092474-Compound-33d
DMW38MK HS Patented
DMW38MK CP KARUS THERAPEUTICS LTD
DMW38MK DT Small molecular drug
DMW38MK PC 117703486
DMW38MK MW 340.31
DMW38MK FM C16H13FN6O2
DMW38MK IC InChI=1S/C16H13FN6O2/c17-13-7-11(16(24)22-25)1-2-12(13)10-23(14-8-18-3-5-20-14)15-9-19-4-6-21-15/h1-9,25H,10H2,(H,22,24)
DMW38MK CS C1=CC(=C(C=C1C(=O)NO)F)CN(C2=NC=CN=C2)C3=NC=CN=C3
DMW38MK IK PLETUCDALFTIQN-UHFFFAOYSA-N
DMW38MK IU 4-[[di(pyrazin-2-yl)amino]methyl]-3-fluoro-N-hydroxybenzamide
DMGTSXL ID DMGTSXL
DMGTSXL DN PMID28092474-Compound-33e
DMGTSXL HS Patented
DMGTSXL CP KARUS THERAPEUTICS LTD
DMGTSXL DT Small molecular drug
DMA360M ID DMA360M
DMA360M DN PMID28092474-Compound-33f
DMA360M HS Patented
DMA360M CP KARUS THERAPEUTICS LTD
DMA360M DT Small molecular drug
DM18DY6 ID DM18DY6
DM18DY6 DN PMID28092474-Compound-33g
DM18DY6 HS Patented
DM18DY6 CP KARUS THERAPEUTICS LTD
DM18DY6 DT Small molecular drug
DM18DY6 PC 117703541
DM18DY6 MW 369.3
DM18DY6 FM C18H16FN5O3
DM18DY6 IC InChI=1S/C18H16FN5O3/c1-27-15-3-2-6-22-17(15)24(16-10-20-7-8-21-16)11-13-5-4-12(9-14(13)19)18(25)23-26/h2-10,26H,11H2,1H3,(H,23,25)
DM18DY6 CS COC1=C(N=CC=C1)N(CC2=C(C=C(C=C2)C(=O)NO)F)C3=NC=CN=C3
DM18DY6 IK APGUTSIVBNKJKQ-UHFFFAOYSA-N
DM18DY6 IU 3-fluoro-N-hydroxy-4-[[(3-methoxypyridin-2-yl)-pyrazin-2-ylamino]methyl]benzamide
DM1DN6V ID DM1DN6V
DM1DN6V DN PMID28092474-Compound-33h
DM1DN6V HS Patented
DM1DN6V CP KARUS THERAPEUTICS LTD
DM1DN6V DT Small molecular drug
DM16E95 ID DM16E95
DM16E95 DN PMID28092474-Compound-33i
DM16E95 HS Patented
DM16E95 CP KARUS THERAPEUTICS LTD
DM16E95 DT Small molecular drug
DMNTRIZ ID DMNTRIZ
DMNTRIZ DN PMID28092474-Compound-33j
DMNTRIZ HS Patented
DMNTRIZ CP KARUS THERAPEUTICS LTD
DMNTRIZ DT Small molecular drug
DMNTRIZ PC 117703439
DMNTRIZ MW 340.31
DMNTRIZ FM C16H13FN6O2
DMNTRIZ IC InChI=1S/C16H13FN6O2/c17-13-8-11(16(24)22-25)3-4-12(13)10-23(14-2-1-5-20-21-14)15-9-18-6-7-19-15/h1-9,25H,10H2,(H,22,24)
DMNTRIZ CS C1=CC(=NN=C1)N(CC2=C(C=C(C=C2)C(=O)NO)F)C3=NC=CN=C3
DMNTRIZ IK JRLWVTOAMRASSS-UHFFFAOYSA-N
DMNTRIZ IU 3-fluoro-N-hydroxy-4-[[pyrazin-2-yl(pyridazin-3-yl)amino]methyl]benzamide
DMF2ZNT ID DMF2ZNT
DMF2ZNT DN PMID28092474-Compound-33k
DMF2ZNT HS Patented
DMF2ZNT CP KARUS THERAPEUTICS LTD
DMF2ZNT DT Small molecular drug
DMPJSB2 ID DMPJSB2
DMPJSB2 DN PMID28092474-Compound-33l
DMPJSB2 HS Patented
DMPJSB2 CP KARUS THERAPEUTICS LTD
DMPJSB2 DT Small molecular drug
DMXSPT9 ID DMXSPT9
DMXSPT9 DN PMID28092474-Compound-33m
DMXSPT9 HS Patented
DMXSPT9 CP KARUS THERAPEUTICS LTD
DMXSPT9 DT Small molecular drug
DM6DJZ7 ID DM6DJZ7
DM6DJZ7 DN PMID28092474-Compound-33o
DM6DJZ7 HS Patented
DM6DJZ7 CP KARUS THERAPEUTICS LTD
DM6DJZ7 DT Small molecular drug
DMI8ZBK ID DMI8ZBK
DMI8ZBK DN PMID28092474-Compound-33p
DMI8ZBK HS Patented
DMI8ZBK CP KARUS THERAPEUTICS LTD
DMI8ZBK DT Small molecular drug
DM6JRCW ID DM6JRCW
DM6JRCW DN PMID28092474-Compound-34
DM6JRCW HS Patented
DM6JRCW CP KARUS THERAPEUTICS LTD
DM6JRCW DT Small molecular drug
DMXQE7C ID DMXQE7C
DMXQE7C DN PMID28092474-Compound-34a
DMXQE7C HS Patented
DMXQE7C CP KARUS THERAPEUTICS LTD
DMXQE7C DT Small molecular drug
DM6X2CO ID DM6X2CO
DM6X2CO DN PMID28092474-Compound-34b
DM6X2CO HS Patented
DM6X2CO CP KARUS THERAPEUTICS LTD
DM6X2CO DT Small molecular drug
DMMI7DY ID DMMI7DY
DMMI7DY DN PMID28092474-Compound-34c
DMMI7DY HS Patented
DMMI7DY CP KARUS THERAPEUTICS LTD
DMMI7DY DT Small molecular drug
DMAXS57 ID DMAXS57
DMAXS57 DN PMID28117607-Compound-20
DMAXS57 HS Patented
DMAXS57 CP IPSEN PHARMA S.A.S. ONCODESIGN S.A
DMAXS57 DT Small molecular drug
DMS8OTG ID DMS8OTG
DMS8OTG DN PMID28117607-Compound-21
DMS8OTG HS Patented
DMS8OTG CP ONCODESIGN S.A. IPSEN PHARMA S.A.S
DMS8OTG DT Small molecular drug
DMVIY73 ID DMVIY73
DMVIY73 DN PMID28117607-Compound-4
DMVIY73 HS Patented
DMVIY73 CP ORIGENIS GMBH
DMVIY73 DT Small molecular drug
DMPBNFM ID DMPBNFM
DMPBNFM DN PMID28117607-Compound-5
DMPBNFM HS Patented
DMPBNFM CP ORIGENIS GMBH
DMPBNFM DT Small molecular drug
DM68B1R ID DM68B1R
DM68B1R DN PMID28117607-Compound-6
DM68B1R HS Patented
DM68B1R CP ORIGENIS GMBH
DM68B1R DT Small molecular drug
DMJZREU ID DMJZREU
DMJZREU DN PMID28117607-Compound-7
DMJZREU HS Patented
DMJZREU CP ORIGENIS GMBH
DMJZREU DT Small molecular drug
DMBHRUP ID DMBHRUP
DMBHRUP DN PMID28270010-Compound-Figure16-a
DMBHRUP HS Patented
DMBHRUP CP ARRAY BIOPHARMA INC
DMBHRUP DT Small molecular drug
DMBHRUP PC 74220979
DMBHRUP MW 513.4
DMBHRUP FM C25H26Cl2N6O2
DMBHRUP IC InChI=1S/C25H26Cl2N6O2/c1-16-23(18-14-28-32(2)15-18)31-33(19-9-5-4-6-10-19)24(16)30-25(34)29-22-13-21(27)20(26)12-17(22)8-7-11-35-3/h4-6,9-10,12-15H,7-8,11H2,1-3H3,(H2,29,30,34)
DMBHRUP CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=CC(=C(C=C4CCCOC)Cl)Cl
DMBHRUP IK UZWKONVGWZDEMU-UHFFFAOYSA-N
DMBHRUP IU 1-[4,5-dichloro-2-(3-methoxypropyl)phenyl]-3-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]urea
DMAIRL2 ID DMAIRL2
DMAIRL2 DN PMID28270010-Compound-Figure16-b-1
DMAIRL2 HS Patented
DMAIRL2 CP ARRAY BIOPHARMA INC
DMAIRL2 DT Small molecular drug
DM6YLMB ID DM6YLMB
DM6YLMB DN PMID28270010-Compound-Figure16-b-2
DM6YLMB HS Patented
DM6YLMB CP ARRAY BIOPHARMA INC
DM6YLMB DT Small molecular drug
DM6YLMB PC 76071100
DM6YLMB MW 498.5
DM6YLMB FM C25H25F3N6O2
DM6YLMB IC InChI=1S/C25H25F3N6O2/c1-16-22(19-13-30-33(2)14-19)32-34(20-7-5-4-6-8-20)23(16)31-24(35)29-12-18-11-17(15-36-3)9-10-21(18)25(26,27)28/h4-11,13-14H,12,15H2,1-3H3,(H2,29,31,35)
DM6YLMB CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NCC4=C(C=CC(=C4)COC)C(F)(F)F
DM6YLMB IK SBSBZPNKXQZAIG-UHFFFAOYSA-N
DM6YLMB IU 1-[[5-(methoxymethyl)-2-(trifluoromethyl)phenyl]methyl]-3-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]urea
DMPOI27 ID DMPOI27
DMPOI27 DN PMID28270010-Compound-Figure17-1
DMPOI27 HS Patented
DMPOI27 CP ARRAY BIOPHARMA INC
DMPOI27 DT Small molecular drug
DMPOI27 PC 92135967
DMPOI27 MW 529.6
DMPOI27 FM C29H32FN7O2
DMPOI27 IC InChI=1S/C29H32FN7O2/c1-19-27(22-15-31-20(2)32-16-22)35-37(24-10-5-4-6-11-24)28(19)34-29(38)33-26-18-36(12-13-39-3)17-25(26)21-8-7-9-23(30)14-21/h4-11,14-16,25-26H,12-13,17-18H2,1-3H3,(H2,33,34,38)/t25-,26+/m0/s1
DMPOI27 CS CC1=C(N(N=C1C2=CN=C(N=C2)C)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=CC=C5)F)CCOC
DMPOI27 IK BGKSBHPSVMJTFL-IZZNHLLZSA-N
DMPOI27 IU 1-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(2-methylpyrimidin-5-yl)-2-phenylpyrazol-3-yl]urea
DM7QLX8 ID DM7QLX8
DM7QLX8 DN PMID28270010-Compound-Figure17-2
DM7QLX8 HS Patented
DM7QLX8 CP ARRAY BIOPHARMA INC
DM7QLX8 DT Small molecular drug
DM7QLX8 PC 71041449
DM7QLX8 MW 547.6
DM7QLX8 FM C29H31F2N7O2
DM7QLX8 IC InChI=1S/C29H31F2N7O2/c1-18-27(21-14-32-19(2)33-15-21)36-38(22-7-5-4-6-8-22)28(18)35-29(39)34-26-17-37(11-12-40-3)16-23(26)20-9-10-24(30)25(31)13-20/h4-10,13-15,23,26H,11-12,16-17H2,1-3H3,(H2,34,35,39)/t23-,26+/m0/s1
DM7QLX8 CS CC1=C(N(N=C1C2=CN=C(N=C2)C)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DM7QLX8 IK HMZMJVUIFWVPPL-JYFHCDHNSA-N
DM7QLX8 IU 1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(2-methylpyrimidin-5-yl)-2-phenylpyrazol-3-yl]urea
DME0TUJ ID DME0TUJ
DME0TUJ DN PMID28270010-Compound-Figure17-3
DME0TUJ HS Patented
DME0TUJ CP ARRAY BIOPHARMA INC
DME0TUJ DT Small molecular drug
DME0TUJ PC 71041443
DME0TUJ MW 517.6
DME0TUJ FM C28H32FN7O2
DME0TUJ IC InChI=1S/C28H32FN7O2/c1-19-26(21-15-30-34(2)16-21)33-36(23-7-5-4-6-8-23)27(19)32-28(37)31-25-18-35(13-14-38-3)17-24(25)20-9-11-22(29)12-10-20/h4-12,15-16,24-25H,13-14,17-18H2,1-3H3,(H2,31,32,37)/t24-,25+/m0/s1
DME0TUJ CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC=C(C=C5)F)CCOC
DME0TUJ IK JNTHQYPNOWOSDA-LOSJGSFVSA-N
DME0TUJ IU 1-[(3S,4R)-4-(4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]urea
DM6IYAT ID DM6IYAT
DM6IYAT DN PMID28270010-Compound-Figure21-b
DM6IYAT HS Patented
DM6IYAT CP PFIZER INC
DM6IYAT DT Small molecular drug
DM6IYAT PC 71731823
DM6IYAT MW 406.4
DM6IYAT FM C21H19FN6O2
DM6IYAT IC InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
DM6IYAT CS C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
DM6IYAT IK IIXWYSCJSQVBQM-LLVKDONJSA-N
DM6IYAT IU (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
DM6IYAT CA CAS 1454846-35-5
DM6IYAT CB CHEBI:143117
DM6IYAT DE Brain metastases
DMNTQL5 ID DMNTQL5
DMNTQL5 DN PMID28270010-Compound-Figure24-a
DMNTQL5 HS Patented
DMNTQL5 DT Small molecular drug
DMNTQL5 PC 11617559
DMNTQL5 MW 366.4
DMNTQL5 FM C20H22N4O3
DMNTQL5 IC InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)
DMNTQL5 CS COC1=CC=C(C=C1)COC2=C(C=C(C=C2)CC3=CN=C(N=C3N)N)OC
DMNTQL5 IK MYQAUKPBNJWPIE-UHFFFAOYSA-N
DMNTQL5 IU 5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine
DMNTQL5 CA CAS 870483-87-7
DM0QHLK ID DM0QHLK
DM0QHLK DN PMID28270010-Compound-Figure24-b
DM0QHLK HS Patented
DM0QHLK CP GENZYME CORPORATION
DM0QHLK DT Small molecular drug
DM0QHLK PC 118009787
DM0QHLK MW 470.5
DM0QHLK FM C26H26N6O3
DM0QHLK IC InChI=1S/C26H26N6O3/c1-31-15-20(13-29-31)19-11-22-25(28-12-19)32(26(27)30-22)14-18-6-9-23(24(10-18)34-3)35-16-17-4-7-21(33-2)8-5-17/h4-13,15H,14,16H2,1-3H3,(H2,27,30)
DM0QHLK CS CN1C=C(C=N1)C2=CC3=C(N=C2)N(C(=N3)N)CC4=CC(=C(C=C4)OCC5=CC=C(C=C5)OC)OC
DM0QHLK IK HVRWZFQFSQUILC-UHFFFAOYSA-N
DM0QHLK IU 3-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]-6-(1-methylpyrazol-4-yl)imidazo[4,5-b]pyridin-2-amine
DM0QHLK CA CAS 1788906-96-6
DM2YAPJ ID DM2YAPJ
DM2YAPJ DN PMID28270010-Compound-Figure5-1
DM2YAPJ HS Patented
DM2YAPJ CP ABBVIE INC
DM2YAPJ DT Small molecular drug
DM2YAPJ PC 118256282
DM2YAPJ MW 512.6
DM2YAPJ FM C29H32N6O3
DM2YAPJ IC InChI=1S/C29H32N6O3/c30-28-27-24(32-33-28)16-20(18-26(27)38-22-8-14-37-15-9-22)19-6-7-23(29(31)36)25(17-19)35-12-10-34(11-13-35)21-4-2-1-3-5-21/h1-7,16-18,22H,8-15H2,(H2,31,36)(H3,30,32,33)
DM2YAPJ CS C1COCCC1OC2=CC(=CC3=C2C(=NN3)N)C4=CC(=C(C=C4)C(=O)N)N5CCN(CC5)C6=CC=CC=C6
DM2YAPJ IK UDESEJHYZQLNDD-UHFFFAOYSA-N
DM2YAPJ IU 4-[3-amino-4-(oxan-4-yloxy)-1H-indazol-6-yl]-2-(4-phenylpiperazin-1-yl)benzamide
DMK3GRZ ID DMK3GRZ
DMK3GRZ DN PMID28270010-Compound-Figure5-2
DMK3GRZ HS Patented
DMK3GRZ CP ABBVIE INC
DMK3GRZ DT Small molecular drug
DMK3GRZ PC 118256311
DMK3GRZ MW 524.5
DMK3GRZ FM C27H27F3N6O2
DMK3GRZ IC InChI=1S/C27H27F3N6O2/c1-16(27(28,29)30)38-23-15-18(13-21-24(23)25(31)34-33-21)17-7-8-20(26(32)37)22(14-17)36-11-9-35(10-12-36)19-5-3-2-4-6-19/h2-8,13-16H,9-12H2,1H3,(H2,32,37)(H3,31,33,34)
DMK3GRZ CS CC(C(F)(F)F)OC1=CC(=CC2=C1C(=NN2)N)C3=CC(=C(C=C3)C(=O)N)N4CCN(CC4)C5=CC=CC=C5
DMK3GRZ IK NRNLAILVLWFKCG-UHFFFAOYSA-N
DMK3GRZ IU 4-[3-amino-4-(1,1,1-trifluoropropan-2-yloxy)-1H-indazol-6-yl]-2-(4-phenylpiperazin-1-yl)benzamide
DMSOT1R ID DMSOT1R
DMSOT1R DN PMID28270010-Compound-Figure5-3
DMSOT1R HS Patented
DMSOT1R CP ABBVIE INC
DMSOT1R DT Small molecular drug
DMSOT1R PC 118256189
DMSOT1R MW 532.7
DMSOT1R FM C30H40N6O3
DMSOT1R IC InChI=1S/C30H40N6O3/c1-32-30(37)24-8-7-20(18-26(24)36-13-11-35(12-14-36)22-5-3-2-4-6-22)21-17-25-28(29(31)34-33-25)27(19-21)39-23-9-15-38-16-10-23/h7-8,17-19,22-23H,2-6,9-16H2,1H3,(H,32,37)(H3,31,33,34)
DMSOT1R CS CNC(=O)C1=C(C=C(C=C1)C2=CC3=C(C(=C2)OC4CCOCC4)C(=NN3)N)N5CCN(CC5)C6CCCCC6
DMSOT1R IK QLRPXVWKEWQCQV-UHFFFAOYSA-N
DMSOT1R IU 4-[3-amino-4-(oxan-4-yloxy)-1H-indazol-6-yl]-2-(4-cyclohexylpiperazin-1-yl)-N-methylbenzamide
DM437ZC ID DM437ZC
DM437ZC DN PMID28270021-Compound-WO2010077680 103
DM437ZC HS Patented
DM437ZC CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM437ZC DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMNUA21 ID DMNUA21
DMNUA21 DN PMID28270021-Compound-WO2010077680 109
DMNUA21 HS Patented
DMNUA21 CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DMNUA21 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMQAZMC ID DMQAZMC
DMQAZMC DN PMID28270021-Compound-WO2010077680 201
DMQAZMC HS Patented
DMQAZMC CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DMQAZMC DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM6VAS2 ID DM6VAS2
DM6VAS2 DN PMID28270021-Compound-WO2010077680 481
DM6VAS2 HS Patented
DM6VAS2 CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM6VAS2 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMQ9CBS ID DMQ9CBS
DMQ9CBS DN PMID28270021-Compound-WO2010077680 495
DMQ9CBS HS Patented
DMQ9CBS CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DMQ9CBS DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM6TJU0 ID DM6TJU0
DM6TJU0 DN PMID28270021-Compound-WO2010077680 803
DM6TJU0 HS Patented
DM6TJU0 CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM6TJU0 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM47FNS ID DM47FNS
DM47FNS DN PMID28270021-Compound-WO2010077680 811
DM47FNS HS Patented
DM47FNS CP VM PHARMA LLC WU, Jay Jie-Qiang WANG, Ling
DM47FNS DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMVS7CJ ID DMVS7CJ
DMVS7CJ DN PMID28270021-Compound-WO2013009582Example16
DMVS7CJ HS Patented
DMVS7CJ CP MERCK SHARP & DOHME CORP
DMVS7CJ DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMQK4IX ID DMQK4IX
DMQK4IX DN PMID28270021-Compound-WO2013009582Example76
DMQK4IX HS Patented
DMQK4IX CP MERCK SHARP & DOHME CORP
DMQK4IX DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM2XKTB ID DM2XKTB
DM2XKTB DN PMID28270021-Compound-WO2013161919Example85-117
DM2XKTB HS Patented
DM2XKTB DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMO02EL ID DMO02EL
DMO02EL DN PMID28270021-Compound-WO2014078408Example1
DMO02EL HS Patented
DMO02EL CP ARRAY BIOPHARMA INC
DMO02EL DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMVCBSK ID DMVCBSK
DMVCBSK DN PMID28270021-Compound-WO2014078408Example26
DMVCBSK HS Patented
DMVCBSK CP ARRAY BIOPHARMA INC
DMVCBSK DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMKO4ZH ID DMKO4ZH
DMKO4ZH DN PMID28270021-Compound-WO2014129431Example8-1
DMKO4ZH HS Patented
DMKO4ZH CP ONO PHARMACEUTICAL CO., LTD
DMKO4ZH DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMA04P6 ID DMA04P6
DMA04P6 DN PMID28270021-Compound-WO2014152663 701
DMA04P6 HS Patented
DMA04P6 CP MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED
DMA04P6 DE Osteoarthritis pain; Pruritus; Chronic pain; Neuropathic pain; Thymic cancer
DM16URY ID DM16URY
DM16URY DN PMID28270021-Compound-WO2015042088Example11
DM16URY HS Patented
DM16URY CP MERCK SHARP & DOHME CORP
DM16URY DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMOZHGU ID DMOZHGU
DMOZHGU DN PMID28270021-Compound-WO2015042088Example12
DMOZHGU HS Patented
DMOZHGU CP MERCK SHARP & DOHME CORP
DMOZHGU DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM6KXOQ ID DM6KXOQ
DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4
DM6KXOQ HS Patented
DM6KXOQ CP MERCK SHARP & DOHME CORP
DM6KXOQ DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMD5QEL ID DMD5QEL
DMD5QEL DN PMID28270021-Compound-WO2016054807Example1
DMD5QEL HS Patented
DMD5QEL CP MERCK SHARP & DOHME CORP
DMD5QEL DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMW2ZRM ID DMW2ZRM
DMW2ZRM DN PMID28270021-Compound-WO2016054807Example112
DMW2ZRM HS Patented
DMW2ZRM CP MERCK SHARP & DOHME CORP
DMW2ZRM DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMREZ9I ID DMREZ9I
DMREZ9I DN PMID28270021-Compound-WO2016054807Example71
DMREZ9I HS Patented
DMREZ9I CP MERCK SHARP & DOHME CORP
DMREZ9I DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMPI86D ID DMPI86D
DMPI86D DN PMID28270021-Compound-WO2016054807Example80
DMPI86D HS Patented
DMPI86D CP MERCK SHARP & DOHME CORP
DMPI86D DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM9ADSN ID DM9ADSN
DM9ADSN DN PMID28270021-Compound-WO2016054807Example82
DM9ADSN HS Patented
DM9ADSN CP MERCK SHARP & DOHME CORP
DM9ADSN DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMSEIL0 ID DMSEIL0
DMSEIL0 DN PMID28350212-Compound-1
DMSEIL0 HS Patented
DMSEIL0 CP WONKWANG UNIVERSITY CENTER FOR INDUSTRY-ACADEMY COOPERATION
DMSEIL0 DT Small molecular drug
DME72ZH ID DME72ZH
DME72ZH DN PMID28350212-Compound-12
DME72ZH HS Patented
DME72ZH CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. WOLFE, Michael, S
DME72ZH DT Peptide
DME72ZH SQ Boc-D-Val-Gly-Aib-D-Val-D-Val-D-IIe-Aib-D-Thr(OBn)-D-Val-Aib-D-Val-D-IIe-Aib-Ome
DMPWYL8 ID DMPWYL8
DMPWYL8 DN PMID28350212-Compound-13
DMPWYL8 HS Patented
DMPWYL8 DT Small molecular drug
DMSFL5B ID DMSFL5B
DMSFL5B DN PMID28350212-Compound-15
DMSFL5B HS Patented
DMSFL5B DT Small molecular drug
DMA1RP9 ID DMA1RP9
DMA1RP9 DN PMID28350212-Compound-16
DMA1RP9 HS Patented
DMA1RP9 CP PFIZER PRODUCTS INC. BRODNEY, Michael, Aaron CHEN, Yuhpyng, Liang COFFMAN, Karen, Jean KLEINMAN, Edward, Fox O'NEILL, Brian, Thomas
DMA1RP9 DT Small molecular drug
DMH8GC6 ID DMH8GC6
DMH8GC6 DN PMID28350212-Compound-18
DMH8GC6 HS Patented
DMH8GC6 DT Small molecular drug
DMH8GC6 DE Alzheimer disease
DMI4US6 ID DMI4US6
DMI4US6 DN PMID28350212-Compound-19
DMI4US6 HS Patented
DMI4US6 CP PFIZER PRODUCTS INC. BRODNEY, Michael, Aaron CHEN, Yuhpyng, Liang COFFMAN, Karen, Jean KLEINMAN, Edward, Fox O'NEILL, Brian, Thomas
DMI4US6 DT Small molecular drug
DMI4US6 DE Alzheimer disease
DMM5G7S ID DMM5G7S
DMM5G7S DN PMID28350212-Compound-20
DMM5G7S HS Patented
DMM5G7S DT Small molecular drug
DMM5G7S DE Alzheimer disease
DMFTGZC ID DMFTGZC
DMFTGZC DN PMID28350212-Compound-21
DMFTGZC HS Patented
DMFTGZC CP WYETH KREFT, Anthony, Frank RESNICK, Lynn MAYER, Scott, Christian DIAMANTIDIS, George COLE, Derek, Cecil WANG, Tingzhong GALANTE, Rocco, John HOKE, Molly HARRISON, Boyd, Lynn ZHANG, Minshen
DMFTGZC DT Small molecular drug
DMKXZYC ID DMKXZYC
DMKXZYC DN PMID28350212-Compound-22
DMKXZYC HS Patented
DMKXZYC CP WYETH KREFT, Anthony, Frank RESNICK, Lynn MAYER, Scott, Christian DIAMANTIDIS, George COLE, Derek, Cecil WANG, Tingzhong GALANTE, Rocco, John HOKE, Molly HARRISON, Boyd, Lynn ZHANG, Minsheng
DMKXZYC DT Small molecular drug
DMKXZYC PC 25159185
DMKXZYC MW 391.7
DMKXZYC FM C9H8ClF6NO3S2
DMKXZYC IC InChI=1S/C9H8ClF6NO3S2/c10-5-1-2-6(21-5)22(19,20)17-4(3-18)7(8(11,12)13)9(14,15)16/h1-2,4,7,17-18H,3H2/t4-/m0/s1
DMKXZYC CS C1=C(SC(=C1)Cl)S(=O)(=O)N[C@@H](CO)C(C(F)(F)F)C(F)(F)F
DMKXZYC IK PSXOKXJMVRSARX-BYPYZUCNSA-N
DMKXZYC IU 5-chloro-N-[(2R)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide
DM3MVW1 ID DM3MVW1
DM3MVW1 DN PMID28350212-Compound-23
DM3MVW1 HS Patented
DM3MVW1 CP WYETH KREFT, Anthony, Frank RESNICK, Lynn MAYER, Scott, Christian DIAMANTIDIS, George COLE, Derek, Cecil WANG, Tingzhong GALANTE, Rocco, John HOKE, Molly HARRISON, Boyd, Lynn ZHANG, Minsheng
DM3MVW1 DT Small molecular drug
DMPJH6L ID DMPJH6L
DMPJH6L DN PMID28350212-Compound-24
DMPJH6L HS Patented
DMPJH6L CP BRISTOL-MYERS SQUIBB COMPANY
DMPJH6L DT Small molecular drug
DML2VUC ID DML2VUC
DML2VUC DN PMID28350212-Compound-25
DML2VUC HS Patented
DML2VUC CP F. HOFFMANN-LA ROCHE AG HOFFMANN-EMERY, Fabienne JAKOB-ROETNE, Rolan
DML2VUC DT Small molecular drug
DMF1ZJ3 ID DMF1ZJ3
DMF1ZJ3 DN PMID28350212-Compound-30
DMF1ZJ3 HS Patented
DMF1ZJ3 CP MERCK SHARP &amDOHME LIMITED CHURCHER, Ian HARRISON, Timothy KERRAD, Sonia NADIN, Alan, John OWENS, Andrew, Pate SHAW, Duncan, Edward THOMSON, Joanne WILLIAMS, Susannah
DMF1ZJ3 DT Small molecular drug
DMSKE2O ID DMSKE2O
DMSKE2O DN PMID28350212-Compound-35
DMSKE2O HS Patented
DMSKE2O CP MERCK SHARP &amDOHME CORP. PISSARNITSKI, Dmitri ZHAO, Zhiqiang
DMSKE2O DT Small molecular drug
DM7ULWD ID DM7ULWD
DM7ULWD DN PMID28350212-Compound-36
DM7ULWD HS Patented
DM7ULWD CP MERCK SHARP & DOHME CORP. WU, Wen-Lian BURNETT, Duane, A
DM7ULWD DT Small molecular drug
DMUBSFV ID DMUBSFV
DMUBSFV DN PMID28350212-Compound-7
DMUBSFV HS Patented
DMUBSFV CP WONKWANG UNIVERSITY CENTER FOR INDUSTRY-ACADEMY COOPERATION
DMUBSFV DT Small molecular drug
DMUBSFV DE Herpes simplex virus infection
DMR0PUA ID DMR0PUA
DMR0PUA DN PMID28394193-Compound-10
DMR0PUA HS Patented
DMR0PUA DT Small molecular drug
DMJ23AL ID DMJ23AL
DMJ23AL DN PMID28394193-Compound-11
DMJ23AL HS Patented
DMJ23AL DT Small molecular drug
DMA7H9T ID DMA7H9T
DMA7H9T DN PMID28394193-Compound-12
DMA7H9T HS Patented
DMA7H9T DT Small molecular drug
DMGZ9MW ID DMGZ9MW
DMGZ9MW DN PMID28394193-Compound-13
DMGZ9MW HS Patented
DMGZ9MW CP EPIZYME, INC
DMGZ9MW DT Small molecular drug
DMGZ9MW PC 86765324
DMGZ9MW MW 529.7
DMGZ9MW FM C30H39N7O2
DMGZ9MW IC InChI=1S/C30H39N7O2/c1-6-20(4)36-18-19(3)28-24(29(38)33-17-25-21(5)37(7-2)34-30(25)39)14-23(15-26(28)36)22-8-9-27(32-16-22)35-12-10-31-11-13-35/h8-9,14-16,18,20,31H,6-7,10-13,17H2,1-5H3,(H,33,38)(H,34,39)
DMGZ9MW CS CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(N(NC5=O)CC)C)C
DMGZ9MW IK MQDSSXUQHUNJLJ-UHFFFAOYSA-N
DMGZ9MW IU 1-butan-2-yl-N-[(2-ethyl-3-methyl-5-oxo-1H-pyrazol-4-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
DM6T2FM ID DM6T2FM
DM6T2FM DN PMID28394193-Compound-14
DM6T2FM HS Patented
DM6T2FM CP EPIZYME, INC
DM6T2FM DT Small molecular drug
DM6T2FM PC 90467336
DM6T2FM MW 543.7
DM6T2FM FM C31H41N7O2
DM6T2FM IC InChI=1S/C31H41N7O2/c1-7-21(4)37-19-20(3)29-25(30(39)34-18-26-22(5)38(8-2)35-31(26)40-6)15-24(16-27(29)37)23-9-10-28(33-17-23)36-13-11-32-12-14-36/h9-10,15-17,19,21,32H,7-8,11-14,18H2,1-6H3,(H,34,39)
DM6T2FM CS CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(N(N=C5OC)CC)C)C
DM6T2FM IK NMLLGPWQRDDVGB-UHFFFAOYSA-N
DM6T2FM IU 1-butan-2-yl-N-[(1-ethyl-3-methoxy-5-methylpyrazol-4-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
DMXMP92 ID DMXMP92
DMXMP92 DN PMID28394193-Compound-15
DMXMP92 HS Patented
DMXMP92 CP EPIZYME, INC
DMXMP92 DT Small molecular drug
DMQDRUT ID DMQDRUT
DMQDRUT DN PMID28394193-Compound-16
DMQDRUT HS Patented
DMQDRUT CP EPIZYME, INC
DMQDRUT DT Small molecular drug
DMPR9GA ID DMPR9GA
DMPR9GA DN PMID28394193-Compound-17
DMPR9GA HS Patented
DMPR9GA CP EPIZYME, INC
DMPR9GA DT Small molecular drug
DMIBZ2H ID DMIBZ2H
DMIBZ2H DN PMID28394193-Compound-18
DMIBZ2H HS Patented
DMIBZ2H CP EPIZYME, INC
DMIBZ2H DT Small molecular drug
DM4ZAE8 ID DM4ZAE8
DM4ZAE8 DN PMID28394193-Compound-19
DM4ZAE8 HS Patented
DM4ZAE8 CP EPIZYME, INC
DM4ZAE8 DT Small molecular drug
DMC5NR0 ID DMC5NR0
DMC5NR0 DN PMID28394193-Compound-20
DMC5NR0 HS Patented
DMC5NR0 CP EPIZYME, INC
DMC5NR0 DT Small molecular drug
DMLD8K3 ID DMLD8K3
DMLD8K3 DN PMID28394193-Compound-21
DMLD8K3 HS Patented
DMLD8K3 CP EPIZYME, INC
DMLD8K3 DT Small molecular drug
DM8PJ3F ID DM8PJ3F
DM8PJ3F DN PMID28394193-Compound-22
DM8PJ3F HS Patented
DM8PJ3F CP EPIZYME, INC
DM8PJ3F DT Small molecular drug
DMNHCMY ID DMNHCMY
DMNHCMY DN PMID28394193-Compound-23
DMNHCMY HS Patented
DMNHCMY CP EPIZYME, INC
DMNHCMY DT Small molecular drug
DMNHCMY PC 117807623
DMNHCMY MW 421.5
DMNHCMY FM C25H31N3O3
DMNHCMY IC InChI=1S/C25H31N3O3/c1-15-13-16(2)27-24(29)21(15)14-26-25(30)23-18(4)28(22-8-6-5-7-20(22)23)17(3)19-9-11-31-12-10-19/h5-8,13,17,19H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)
DMNHCMY CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCOCC4)C)C
DMNHCMY IK HFMSKVHOEPULNV-UHFFFAOYSA-N
DMNHCMY IU N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-(oxan-4-yl)ethyl]indole-3-carboxamide
DMYCVWZ ID DMYCVWZ
DMYCVWZ DN PMID28394193-Compound-24
DMYCVWZ HS Patented
DMYCVWZ CP EPIZYME, INC
DMYCVWZ DT Small molecular drug
DMYCVWZ PC 117807842
DMYCVWZ MW 437.5
DMYCVWZ FM C25H31N3O4
DMYCVWZ IC InChI=1S/C25H31N3O4/c1-15-13-22(31-4)20(24(29)27-15)14-26-25(30)23-17(3)28(21-8-6-5-7-19(21)23)16(2)18-9-11-32-12-10-18/h5-8,13,16,18H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)
DMYCVWZ CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCOCC4)C)OC
DMYCVWZ IK PFPSFENQCNMITC-UHFFFAOYSA-N
DMYCVWZ IU N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-(oxan-4-yl)ethyl]indole-3-carboxamide
DMPIXAO ID DMPIXAO
DMPIXAO DN PMID28394193-Compound-25
DMPIXAO HS Patented
DMPIXAO CP EPIZYME, INC
DMPIXAO DT Small molecular drug
DMPIXAO PC 117807842
DMPIXAO MW 437.5
DMPIXAO FM C25H31N3O4
DMPIXAO IC InChI=1S/C25H31N3O4/c1-15-13-22(31-4)20(24(29)27-15)14-26-25(30)23-17(3)28(21-8-6-5-7-19(21)23)16(2)18-9-11-32-12-10-18/h5-8,13,16,18H,9-12,14H2,1-4H3,(H,26,30)(H,27,29)
DMPIXAO CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCOCC4)C)OC
DMPIXAO IK PFPSFENQCNMITC-UHFFFAOYSA-N
DMPIXAO IU N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-(oxan-4-yl)ethyl]indole-3-carboxamide
DMNWCUJ ID DMNWCUJ
DMNWCUJ DN PMID28394193-Compound-26
DMNWCUJ HS Patented
DMNWCUJ CP EPIZYME, INC
DMNWCUJ DT Small molecular drug
DMNWCUJ PC 75203283
DMNWCUJ MW 526.7
DMNWCUJ FM C31H38N6O2
DMNWCUJ IC InChI=1S/C31H38N6O2/c1-6-21(4)37-18-19(2)30-25(31(39)34-17-26-22(5)35-20(3)13-28(26)38)14-24(15-27(30)37)23-7-8-29(33-16-23)36-11-9-32-10-12-36/h7-8,13-16,18,21,32H,6,9-12,17H2,1-5H3,(H,34,39)(H,35,38)
DMNWCUJ CS CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(NC(=CC5=O)C)C)C
DMNWCUJ IK GSJUSSJURDTFPS-UHFFFAOYSA-N
DMNWCUJ IU 1-butan-2-yl-N-[(2,6-dimethyl-4-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
DM2KVDH ID DM2KVDH
DM2KVDH DN PMID28394193-Compound-27
DM2KVDH HS Patented
DM2KVDH CP EPIZYME, INC
DM2KVDH DT Small molecular drug
DM2KVDH PC 76684269
DM2KVDH MW 542.7
DM2KVDH FM C31H38N6O3
DM2KVDH IC InChI=1S/C31H38N6O3/c1-6-21(4)37-18-19(2)29-24(30(39)34-17-25-27(38)13-20(3)35-31(25)40-5)14-23(15-26(29)37)22-7-8-28(33-16-22)36-11-9-32-10-12-36/h7-8,13-16,18,21,32H,6,9-12,17H2,1-5H3,(H,34,39)(H,35,38)
DM2KVDH CS CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(NC(=CC5=O)C)OC)C
DM2KVDH IK RKSMELDENOCZPF-UHFFFAOYSA-N
DM2KVDH IU 1-butan-2-yl-N-[(2-methoxy-6-methyl-4-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide
DMC24OL ID DMC24OL
DMC24OL DN PMID28394193-Compound-28
DMC24OL HS Patented
DMC24OL CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMC24OL DT Small molecular drug
DMC24OL PC 91884579
DMC24OL MW 550.7
DMC24OL FM C33H38N6O2
DMC24OL IC InChI=1S/C33H38N6O2/c1-21(2)39-20-25-8-6-4-5-7-23-15-22(3)37-33(41)28(23)19-36-32(40)27-16-26(17-29(39)31(25)27)24-9-10-30(35-18-24)38-13-11-34-12-14-38/h4,6,9-10,15-18,20-21,34H,5,7-8,11-14,19H2,1-3H3,(H,36,40)(H,37,41)/b6-4+
DMC24OL CS CC1=CC2=C(CNC(=O)C3=C4C(=CN(C4=CC(=C3)C5=CN=C(C=C5)N6CCNCC6)C(C)C)C/C=C/CC2)C(=O)N1
DMC24OL IK GMAFAVDEQFGQCC-GQCTYLIASA-N
DMC24OL IU (13E)-8-methyl-21-(6-piperazin-1-ylpyridin-3-yl)-18-propan-2-yl-3,7,18-triazatetracyclo[14.6.1.05,10.019,23]tricosa-1(23),5(10),8,13,16,19,21-heptaene-2,6-dione
DMBVI7L ID DMBVI7L
DMBVI7L DN PMID28394193-Compound-29
DMBVI7L HS Patented
DMBVI7L CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMBVI7L DT Small molecular drug
DMGEZT8 ID DMGEZT8
DMGEZT8 DN PMID28394193-Compound-30
DMGEZT8 HS Patented
DMGEZT8 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMGEZT8 DT Small molecular drug
DMJ02N1 ID DMJ02N1
DMJ02N1 DN PMID28394193-Compound-31
DMJ02N1 HS Patented
DMJ02N1 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMJ02N1 DT Small molecular drug
DM628MP ID DM628MP
DM628MP DN PMID28394193-Compound-32
DM628MP HS Patented
DM628MP CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DM628MP DT Small molecular drug
DMEOHX2 ID DMEOHX2
DMEOHX2 DN PMID28394193-Compound-33
DMEOHX2 HS Patented
DMEOHX2 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMEOHX2 DT Small molecular drug
DMEOHX2 PC 121305270
DMEOHX2 MW 517.7
DMEOHX2 FM C31H39N3O2S
DMEOHX2 IC InChI=1S/C31H39N3O2S/c1-5-25(24-11-14-32-15-12-24)29-22(4)28-27(37-29)13-16-34(31(28)35)18-26-20(2)17-21(3)33-30(26)36-19-23-9-7-6-8-10-23/h6-10,17,24-25,32H,5,11-16,18-19H2,1-4H3
DMEOHX2 CS CCC(C1CCNCC1)C2=C(C3=C(S2)CCN(C3=O)CC4=C(N=C(C=C4C)C)OCC5=CC=CC=C5)C
DMEOHX2 IK SJBPGCIWHCAKKL-UHFFFAOYSA-N
DMEOHX2 IU 5-[(4,6-dimethyl-2-phenylmethoxypyridin-3-yl)methyl]-3-methyl-2-(1-piperidin-4-ylpropyl)-6,7-dihydrothieno[3,2-c]pyridin-4-one
DMB7WNP ID DMB7WNP
DMB7WNP DN PMID28394193-Compound-34
DMB7WNP HS Patented
DMB7WNP CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMB7WNP DT Small molecular drug
DMV1AGC ID DMV1AGC
DMV1AGC DN PMID28394193-Compound-35
DMV1AGC HS Patented
DMV1AGC CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DMV1AGC DT Small molecular drug
DM658HJ ID DM658HJ
DM658HJ DN PMID28394193-Compound-36
DM658HJ HS Patented
DM658HJ CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
DM658HJ DT Small molecular drug
DM73CA5 ID DM73CA5
DM73CA5 DN PMID28394193-Compound-37
DM73CA5 HS Patented
DM73CA5 DT Small molecular drug
DM73CA5 PC 78320107
DM73CA5 MW 500.6
DM73CA5 FM C27H34F2N4O3
DM73CA5 IC InChI=1S/C27H34F2N4O3/c1-16-13-23(36-4)21(26(34)31-16)14-30-27(35)25-18(3)33(22-8-6-5-7-20(22)25)17(2)19-9-11-32(12-10-19)15-24(28)29/h5-8,13,17,19,24H,9-12,14-15H2,1-4H3,(H,30,35)(H,31,34)
DM73CA5 CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCN(CC4)CC(F)F)C)OC
DM73CA5 IK RQOXQFWLPWTPPB-UHFFFAOYSA-N
DM73CA5 IU 1-[1-[1-(2,2-difluoroethyl)piperidin-4-yl]ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methylindole-3-carboxamide
DM25PMQ ID DM25PMQ
DM25PMQ DN PMID28394193-Compound-38
DM25PMQ HS Patented
DM25PMQ DT Small molecular drug
DM25PMQ PC 78320108
DM25PMQ MW 518.6
DM25PMQ FM C27H33F3N4O3
DM25PMQ IC InChI=1S/C27H33F3N4O3/c1-16-13-23(37-4)21(25(35)32-16)14-31-26(36)24-18(3)34(22-8-6-5-7-20(22)24)17(2)19-9-11-33(12-10-19)15-27(28,29)30/h5-8,13,17,19H,9-12,14-15H2,1-4H3,(H,31,36)(H,32,35)
DM25PMQ CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C(N(C3=CC=CC=C32)C(C)C4CCN(CC4)CC(F)(F)F)C)OC
DM25PMQ IK HPODOLXTMDHLLC-UHFFFAOYSA-N
DM25PMQ IU N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-1-[1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]ethyl]indole-3-carboxamide
DM2NS5T ID DM2NS5T
DM2NS5T DN PMID28394193-Compound-39
DM2NS5T HS Patented
DM2NS5T CP CONSTELLATION PHARMACEUTICALS, INC
DM2NS5T DT Small molecular drug
DMO5479 ID DMO5479
DMO5479 DN PMID28394193-Compound-40
DMO5479 HS Patented
DMO5479 CP BRISTOL-MYERS SQUIBB COMPANY
DMO5479 DT Small molecular drug
DMO5479 PC 118095598
DMO5479 MW 628.8
DMO5479 FM C37H45FN4O4
DMO5479 IC InChI=1S/C37H45FN4O4/c1-4-42(29-12-16-45-17-13-29)34-21-28(27-10-8-26(9-11-27)23-41-14-18-46-19-15-41)20-31(24(34)2)36(43)39-22-32-35-30(6-5-7-33(35)38)25(3)40-37(32)44/h5-11,20-21,25,29,32H,4,12-19,22-23H2,1-3H3,(H,39,43)(H,40,44)
DMO5479 CS CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3C4=C(C=CC=C4F)C(NC3=O)C)C5=CC=C(C=C5)CN6CCOCC6
DMO5479 IK FUYGRYVZMCQDEP-UHFFFAOYSA-N
DMO5479 IU 3-[ethyl(oxan-4-yl)amino]-N-[(5-fluoro-1-methyl-3-oxo-2,4-dihydro-1H-isoquinolin-4-yl)methyl]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide
DMYLVTQ ID DMYLVTQ
DMYLVTQ DN PMID28394193-Compound-41
DMYLVTQ HS Patented
DMYLVTQ CP BRISTOL-MYERS SQUIBB COMPANY
DMYLVTQ DT Small molecular drug
DMYLVTQ PC 118101320
DMYLVTQ MW 662.8
DMYLVTQ FM C39H46N6O4
DMYLVTQ IC InChI=1S/C39H46N6O4/c1-8-25(3)45-23-24(2)35-31(36(46)41-22-32-30-12-10-9-11-29(30)26(4)42-37(32)47)19-28(20-33(35)45)27-13-14-34(40-21-27)43-15-17-44(18-16-43)38(48)49-39(5,6)7/h9-14,19-21,23,25H,8,15-18,22H2,1-7H3,(H,41,46)(H,42,47)
DMYLVTQ CS CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCN(CC4)C(=O)OC(C)(C)C)C(=O)NCC5=C6C=CC=CC6=C(NC5=O)C)C
DMYLVTQ IK LTHICEHOVQKREU-UHFFFAOYSA-N
DMYLVTQ IU tert-butyl 4-[5-[1-butan-2-yl-3-methyl-4-[(1-methyl-3-oxo-2H-isoquinolin-4-yl)methylcarbamoyl]indol-6-yl]pyridin-2-yl]piperazine-1-carboxylate
DMLI7TG ID DMLI7TG
DMLI7TG DN PMID28394193-Compound-42
DMLI7TG HS Patented
DMLI7TG CP BRISTOL-MYERS SQUIBB COMPANY
DMLI7TG DT Small molecular drug
DMLI7TG PC 118096643
DMLI7TG MW 405.3
DMLI7TG FM C19H21BrN2O3
DMLI7TG IC InChI=1S/C19H21BrN2O3/c1-10-5-11(2)22-18(24)14(10)9-21-17(23)12-6-13-8-19(3,4)25-16(13)15(20)7-12/h5-7H,8-9H2,1-4H3,(H,21,23)(H,22,24)
DMLI7TG CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC3=C(C(=C2)Br)OC(C3)(C)C)C
DMLI7TG IK HDXJPZKHNBTZOX-UHFFFAOYSA-N
DMLI7TG IU 7-bromo-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,2-dimethyl-3H-1-benzofuran-5-carboxamide
DMASV8I ID DMASV8I
DMASV8I DN PMID28394193-Compound-43
DMASV8I HS Patented
DMASV8I CP BRISTOL-MYERS SQUIBB COMPANY
DMASV8I DT Small molecular drug
DMASV8I PC 118096796
DMASV8I MW 486.6
DMASV8I FM C29H34N4O3
DMASV8I IC InChI=1S/C29H34N4O3/c1-18-13-19(2)32-28(35)25(18)17-31-27(34)21-14-22-16-29(3,4)36-26(22)24(15-21)20-5-7-23(8-6-20)33-11-9-30-10-12-33/h5-8,13-15,30H,9-12,16-17H2,1-4H3,(H,31,34)(H,32,35)
DMASV8I CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=CC3=C(C(=C2)C4=CC=C(C=C4)N5CCNCC5)OC(C3)(C)C)C
DMASV8I IK ZIIBOHIVIFEGAI-UHFFFAOYSA-N
DMASV8I IU N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,2-dimethyl-7-(4-piperazin-1-ylphenyl)-3H-1-benzofuran-5-carboxamide
DME6FWY ID DME6FWY
DME6FWY DN PMID28394193-Compound-44
DME6FWY HS Patented
DME6FWY CP BRISTOL-MYERS SQUIBB COMPANY
DME6FWY DT Small molecular drug
DME6FWY PC 118096614
DME6FWY MW 417.3
DME6FWY FM C20H21BrN2O3
DME6FWY IC InChI=1S/C20H21BrN2O3/c1-11-4-5-26-18-14(6-11)8-15(9-17(18)21)19(24)22-10-16-12(2)7-13(3)23-20(16)25/h4,7-9H,5-6,10H2,1-3H3,(H,22,24)(H,23,25)
DME6FWY CS CC1=CCOC2=C(C1)C=C(C=C2Br)C(=O)NCC3=C(C=C(NC3=O)C)C
DME6FWY IK FKDNRFGIZCNPMK-UHFFFAOYSA-N
DME6FWY IU 9-bromo-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methyl-2,5-dihydro-1-benzoxepine-7-carboxamide
DMZJXPF ID DMZJXPF
DMZJXPF DN PMID28394193-Compound-45
DMZJXPF HS Patented
DMZJXPF CP PFIZER INC
DMZJXPF DT Small molecular drug
DMZJXPF PC 118607675
DMZJXPF MW 337.4
DMZJXPF FM C19H19N3O3
DMZJXPF IC InChI=1S/C19H19N3O3/c1-11-8-12(2)21-18(23)15(11)10-22-7-6-13-4-5-16(25-3)14(9-20)17(13)19(22)24/h4-5,8H,6-7,10H2,1-3H3,(H,21,23)
DMZJXPF CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C2=O)C(=C(C=C3)OC)C#N)C
DMZJXPF IK SJAPTZBKLVFZLU-UHFFFAOYSA-N
DMZJXPF IU 2-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-7-methoxy-1-oxo-3,4-dihydroisoquinoline-8-carbonitrile
DMYMPNA ID DMYMPNA
DMYMPNA DN PMID28394193-Compound-46
DMYMPNA HS Patented
DMYMPNA CP PFIZER INC
DMYMPNA DT Small molecular drug
DMYMPNA PC 102593999
DMYMPNA MW 462.3
DMYMPNA FM C22H21Cl2N3O4
DMYMPNA IC InChI=1S/C22H21Cl2N3O4/c1-10-6-11(2)25-21(29)15(10)8-27-5-4-13-16(23)7-14(20(24)19(13)22(27)30)18-12(3)31-26-17(18)9-28/h6-7,28H,4-5,8-9H2,1-3H3,(H,25,29)
DMYMPNA CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C4=C(ON=C4CO)C)Cl)C
DMYMPNA IK WZHICSHLNWIANY-UHFFFAOYSA-N
DMYMPNA IU 5,8-dichloro-2-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[3-(hydroxymethyl)-5-methyl-1,2-oxazol-4-yl]-3,4-dihydroisoquinolin-1-one
DM7UDIM ID DM7UDIM
DM7UDIM DN PMID28394193-Compound-47
DM7UDIM HS Patented
DM7UDIM CP PFIZER INC
DM7UDIM DT Small molecular drug
DM7UDIM PC 118616529
DM7UDIM MW 462.3
DM7UDIM FM C22H21Cl2N3O4
DM7UDIM IC InChI=1S/C22H21Cl2N3O4/c1-10-7-17(30-4)15(21(28)25-10)9-27-6-5-13-16(23)8-14(20(24)19(13)22(27)29)18-11(2)26-31-12(18)3/h7-8H,5-6,9H2,1-4H3,(H,25,28)
DM7UDIM CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C4=C(ON=C4C)C)Cl)OC
DM7UDIM IK HCXPMZKLLCLZQX-UHFFFAOYSA-N
DM7UDIM IU 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one
DMEU4Y1 ID DMEU4Y1
DMEU4Y1 DN PMID28394193-Compound-49
DMEU4Y1 HS Patented
DMEU4Y1 CP BRISTOL-MYERS SQUIBB COMPANY
DMEU4Y1 DT Small molecular drug
DMEU4Y1 PC 118572078
DMEU4Y1 MW 464.4
DMEU4Y1 FM C23H27Cl2N3O3
DMEU4Y1 IC InChI=1S/C23H27Cl2N3O3/c1-12-7-19(31-4)17(22(29)26-12)11-28-6-5-15-18(24)8-16(21(25)20(15)23(28)30)13(2)14-9-27(3)10-14/h7-8,13-14H,5-6,9-11H2,1-4H3,(H,26,29)
DMEU4Y1 CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C)C4CN(C4)C)Cl)OC
DMEU4Y1 IK YSHFYFJAQGEFJV-UHFFFAOYSA-N
DMEU4Y1 IU 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-7-[1-(1-methylazetidin-3-yl)ethyl]-3,4-dihydroisoquinolin-1-one
DM4NVTB ID DM4NVTB
DM4NVTB DN PMID28394193-Compound-50
DM4NVTB HS Patented
DM4NVTB CP BRISTOL-MYERS SQUIBB COMPANY
DM4NVTB DT Small molecular drug
DM4NVTB PC 118580552
DM4NVTB MW 430.9
DM4NVTB FM C23H27ClN2O4
DM4NVTB IC InChI=1S/C23H27ClN2O4/c1-12-7-17(14(3)15-10-30-11-15)21(24)20-16(12)5-6-26(23(20)28)9-18-19(29-4)8-13(2)25-22(18)27/h7-8,14-15H,5-6,9-11H2,1-4H3,(H,25,27)
DM4NVTB CS CC1=CC(=C(C2=C1CCN(C2=O)CC3=C(C=C(NC3=O)C)OC)Cl)C(C)C4COC4
DM4NVTB IK ZUDMACKBEPQTPV-UHFFFAOYSA-N
DM4NVTB IU 8-chloro-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-5-methyl-7-[1-(oxetan-3-yl)ethyl]-3,4-dihydroisoquinolin-1-one
DM0KPQ9 ID DM0KPQ9
DM0KPQ9 DN PMID28394193-Compound-51
DM0KPQ9 HS Patented
DM0KPQ9 CP BRISTOL-MYERS SQUIBB COMPANY
DM0KPQ9 DT Small molecular drug
DM0KPQ9 PC 118580509
DM0KPQ9 MW 520.4
DM0KPQ9 FM C26H31Cl2N3O4
DM0KPQ9 IC InChI=1S/C26H31Cl2N3O4/c1-14-11-15(2)29-25(33)20(14)13-31-10-7-18-21(27)12-19(23(28)22(18)26(31)34)24(35-4)17-5-8-30(9-6-17)16(3)32/h11-12,17,24H,5-10,13H2,1-4H3,(H,29,33)
DM0KPQ9 CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C4CCN(CC4)C(=O)C)OC)Cl)C
DM0KPQ9 IK PCBQYEOJXRGLFI-UHFFFAOYSA-N
DM0KPQ9 IU 7-[(1-acetylpiperidin-4-yl)-methoxymethyl]-5,8-dichloro-2-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one
DM2I9HY ID DM2I9HY
DM2I9HY DN PMID28394193-Compound-52
DM2I9HY HS Patented
DM2I9HY CP BRISTOL-MYERS SQUIBB COMPANY
DM2I9HY DT Small molecular drug
DM2I9HY PC 118580510
DM2I9HY MW 552.4
DM2I9HY FM C26H31Cl2N3O6
DM2I9HY IC InChI=1S/C26H31Cl2N3O6/c1-14-10-20(36-2)18(25(34)29-14)12-31-9-6-16-19(27)11-17(23(28)22(16)26(31)35)24(37-3)15-4-7-30(8-5-15)21(33)13-32/h10-11,15,24,32H,4-9,12-13H2,1-3H3,(H,29,34)
DM2I9HY CS CC1=CC(=C(C(=O)N1)CN2CCC3=C(C=C(C(=C3C2=O)Cl)C(C4CCN(CC4)C(=O)CO)OC)Cl)OC
DM2I9HY IK AARGZKBSIZRPJQ-UHFFFAOYSA-N
DM2I9HY IU 5,8-dichloro-7-[[1-(2-hydroxyacetyl)piperidin-4-yl]-methoxymethyl]-2-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1-one
DMXMRQP ID DMXMRQP
DMXMRQP DN PMID28394193-Compound-53
DMXMRQP HS Patented
DMXMRQP CP DANA-FARBER CANCER INSTITUTE, INC
DMXMRQP DT Small molecular drug
DMXMRQP PC 121322599
DMXMRQP MW 542.7
DMXMRQP FM C30H38N8O2
DMXMRQP IC InChI=1S/C30H38N8O2/c1-6-7-21-14-20(4)34-30(40)24(21)17-32-29(39)23-15-26(35-28-25(23)18-33-38(28)19(2)3)22-8-9-27(31-16-22)37-12-10-36(5)11-13-37/h8-9,14-16,18-19H,6-7,10-13,17H2,1-5H3,(H,32,39)(H,34,40)
DMXMRQP CS CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=CC(=NC3=C2C=NN3C(C)C)C4=CN=C(C=C4)N5CCN(CC5)C
DMXMRQP IK LQTWDAYNGMMHLV-UHFFFAOYSA-N
DMXMRQP IU N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-6-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide
DMMQ3UG ID DMMQ3UG
DMMQ3UG DN PMID28394193-Compound-54
DMMQ3UG HS Patented
DMMQ3UG CP DANA-FARBER CANCER INSTITUTE, INC
DMMQ3UG DT Small molecular drug
DM2FPHZ ID DM2FPHZ
DM2FPHZ DN PMID28394193-Compound-55
DM2FPHZ HS Patented
DM2FPHZ CP BAYER PHARMA AKTIENGESELLSCHAFT THE BROAD INSTITUTE INC
DM2FPHZ DT Small molecular drug
DMQRFZK ID DMQRFZK
DMQRFZK DN PMID28394193-Compound-56
DMQRFZK HS Patented
DMQRFZK CP ELI LILLY AND COMPANY
DMQRFZK DT Small molecular drug
DM4Y3US ID DM4Y3US
DM4Y3US DN PMID28394193-Compound-57
DM4Y3US HS Patented
DM4Y3US CP ELI LILLY AND COMPANY
DM4Y3US DT Small molecular drug
DMXK2GA ID DMXK2GA
DMXK2GA DN PMID28394193-Compound-Figure3bI
DMXK2GA HS Patented
DMXK2GA CP EPIZYME, INC
DMXK2GA DT Small molecular drug
DML6PE0 ID DML6PE0
DML6PE0 DN PMID28394193-Compound-Figure3bII
DML6PE0 HS Patented
DML6PE0 CP EPIZYME, INC
DML6PE0 DT Small molecular drug
DMUI385 ID DMUI385
DMUI385 DN PMID28394193-Compound-Figure3bIII
DMUI385 HS Patented
DMUI385 CP EPIZYME, INC
DMUI385 DT Small molecular drug
DMKVRTM ID DMKVRTM
DMKVRTM DN PMID28394193-Compound-Figure5aVIII
DMKVRTM HS Patented
DMKVRTM DT Small molecular drug
DMA7OEF ID DMA7OEF
DMA7OEF DN PMID28447479-Compound-10
DMA7OEF HS Patented
DMA7OEF CP BIOGEN IDEC MA INC
DMA7OEF DT Small molecular drug
DMOYMWZ ID DMOYMWZ
DMOYMWZ DN PMID28447479-Compound-11
DMOYMWZ HS Patented
DMOYMWZ CP BIOGEN IDEC MA INC
DMOYMWZ DT Small molecular drug
DMA91X2 ID DMA91X2
DMA91X2 DN PMID28447479-Compound-14
DMA91X2 HS Patented
DMA91X2 CP PHARMAKEA, INC
DMA91X2 DT Small molecular drug
DMA91X2 PC 118103593
DMA91X2 MW 478.5
DMA91X2 FM C26H27FN4O4
DMA91X2 IC InChI=1S/C26H27FN4O4/c1-25(2,23(33)34)14-31-22(32)20-26(3,4)19-17-6-5-11-28-21(17)29(18(19)13-30(20)24(31)35)12-15-7-9-16(27)10-8-15/h5-11,20H,12-14H2,1-4H3,(H,33,34)
DMA91X2 CS CC1(C2C(=O)N(C(=O)N2CC3=C1C4=C(N3CC5=CC=C(C=C5)F)N=CC=C4)CC(C)(C)C(=O)O)C
DMA91X2 IK PZDULKFJLQEMQQ-UHFFFAOYSA-N
DMA91X2 IU 3-[8-[(4-fluorophenyl)methyl]-16,16-dimethyl-12,14-dioxo-6,8,11,13-tetrazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2(7),3,5-tetraen-13-yl]-2,2-dimethylpropanoic acid
DMWSL5G ID DMWSL5G
DMWSL5G DN PMID28447479-Compound-20
DMWSL5G HS Patented
DMWSL5G CP BIOGEN MA INC
DMWSL5G DT Small molecular drug
DMWSL5G PC 78425825
DMWSL5G MW 479.4
DMWSL5G FM C20H19F6N3O4
DMWSL5G IC InChI=1S/C20H19F6N3O4/c1-2-32-17(30)16-9-15-10-28(4-3-5-29(15)27-16)18(31)33-11-12-6-13(19(21,22)23)8-14(7-12)20(24,25)26/h6-9H,2-5,10-11H2,1H3
DMWSL5G CS CCOC(=O)C1=NN2CCCN(CC2=C1)C(=O)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMWSL5G IK UVKJSSLAVQPIDP-UHFFFAOYSA-N
DMWSL5G IU 5-O-[[3,5-bis(trifluoromethyl)phenyl]methyl] 2-O-ethyl 4,6,7,8-tetrahydropyrazolo[1,5-a][1,4]diazepine-2,5-dicarboxylate
DM8PET6 ID DM8PET6
DM8PET6 DN PMID28447479-Compound-21
DM8PET6 HS Patented
DM8PET6 CP BIOGEN MA INC
DM8PET6 DT Small molecular drug
DMRCM1O ID DMRCM1O
DMRCM1O DN PMID28447479-Compound-22
DMRCM1O HS Patented
DMRCM1O CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMRCM1O DT Small molecular drug
DMM0BVE ID DMM0BVE
DMM0BVE DN PMID28447479-Compound-23
DMM0BVE HS Patented
DMM0BVE CP X-RX, INC
DMM0BVE DT Small molecular drug
DMM0BVE PC 118417827
DMM0BVE MW 632.5
DMM0BVE FM C28H27F7N4O5
DMM0BVE IC InChI=1S/C28H27F7N4O5/c1-15(2)21(36-22(40)19-14-16(27(30,31)32)4-9-20(19)29)23(41)38-12-10-26(11-13-38)24(42)37(3)25(43)39(26)17-5-7-18(8-6-17)44-28(33,34)35/h4-9,14-15,21H,10-13H2,1-3H3,(H,36,40)/t21-/m1/s1
DMM0BVE CS CC(C)[C@H](C(=O)N1CCC2(CC1)C(=O)N(C(=O)N2C3=CC=C(C=C3)OC(F)(F)F)C)NC(=O)C4=C(C=CC(=C4)C(F)(F)F)F
DMM0BVE IK BYITUQUWMVRENA-OAQYLSRUSA-N
DMM0BVE IU 2-fluoro-N-[(2R)-3-methyl-1-[3-methyl-2,4-dioxo-1-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]decan-8-yl]-1-oxobutan-2-yl]-5-(trifluoromethyl)benzamide
DMDOVIZ ID DMDOVIZ
DMDOVIZ DN PMID28447479-Compound-24
DMDOVIZ HS Patented
DMDOVIZ CP X-RX DISCOVERY, INC
DMDOVIZ DT Small molecular drug
DMJZSWF ID DMJZSWF
DMJZSWF DN PMID28447479-Compound-26
DMJZSWF HS Patented
DMJZSWF CP BIOGEN MA INC
DMJZSWF DT Small molecular drug
DMVZPIO ID DMVZPIO
DMVZPIO DN PMID28447479-Compound-27
DMVZPIO HS Patented
DMVZPIO CP BIOGEN MA INC
DMVZPIO DT Small molecular drug
DMUBM1Y ID DMUBM1Y
DMUBM1Y DN PMID28447479-Compound-4
DMUBM1Y HS Patented
DMUBM1Y DT Small molecular drug
DMD9W6H ID DMD9W6H
DMD9W6H DN PMID28454500-Compound-10
DMD9W6H HS Patented
DMD9W6H CP REATA PHARMACEUTICALS, INC
DMD9W6H DT Small molecular drug
DMD9W6H PC 68066062
DMD9W6H MW 518.7
DMD9W6H FM C33H46N2O3
DMD9W6H IC InChI=1S/C33H46N2O3/c1-9-25(37)35-33-14-12-28(2,3)18-21(33)26-22(36)16-24-30(6)17-20(19-34)27(38)29(4,5)23(30)10-11-31(24,7)32(26,8)13-15-33/h16-17,21,23,26H,9-15,18H2,1-8H3,(H,35,37)/t21?,23-,26?,30-,31+,32+,33-/m0/s1
DMD9W6H CS CCC(=O)N[C@@]12CC[C@@]3(C(C1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C
DMD9W6H IK GTBWGDPMQABIQD-RYMYCHIXSA-N
DMD9W6H IU N-[(4aS,6aR,6bS,8aR,12aS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]propanamide
DM1ZFC9 ID DM1ZFC9
DM1ZFC9 DN PMID28454500-Compound-11
DM1ZFC9 HS Patented
DM1ZFC9 CP REATA PHARMACEUTICALS, INC
DM1ZFC9 DT Small molecular drug
DM1ZFC9 PC 68066028
DM1ZFC9 MW 504.7
DM1ZFC9 FM C32H44N2O3
DM1ZFC9 IC InChI=1S/C32H44N2O3/c1-19(35)34-32-13-11-27(2,3)17-21(32)25-22(36)15-24-29(6)16-20(18-33)26(37)28(4,5)23(29)9-10-30(24,7)31(25,8)12-14-32/h15-16,21,23,25H,9-14,17H2,1-8H3,(H,34,35)/t21?,23-,25?,29-,30+,31+,32-/m0/s1
DM1ZFC9 CS CC(=O)N[C@@]12CC[C@@]3(C(C1CC(CC2)(C)C)C(=O)C=C4[C@]3(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)C
DM1ZFC9 IK MXZQJSKPUZWONN-CCCNGEJOSA-N
DM1ZFC9 IU N-[(4aS,6aR,6bS,8aR,12aS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]acetamide
DMUY4LS ID DMUY4LS
DMUY4LS DN PMID28454500-Compound-12
DMUY4LS HS Patented
DMUY4LS CP REATA PHARMACEUTICALS, INC
DMUY4LS DT Small molecular drug
DM7SIVA ID DM7SIVA
DM7SIVA DN PMID28454500-Compound-13
DM7SIVA HS Patented
DM7SIVA CP REATA PHARMACEUTICALS, INC
DM7SIVA DT Small molecular drug
DM7SIVA PC 73335601
DM7SIVA MW 521.7
DM7SIVA FM C32H43NO5
DM7SIVA IC InChI=1S/C32H43NO5/c1-26(2)11-13-31(25(36)38-8)14-12-30(7)29(6)10-9-20-27(3,4)24(35)19(18-33)16-28(20,5)21(29)15-23(34)32(30,37)22(31)17-26/h15-16,20,22,37H,9-14,17H2,1-8H3/t20-,22?,28-,29+,30-,31-,32+/m0/s1
DM7SIVA CS C[C@@]12CC[C@@H]3[C@@](C1=CC(=O)[C@]4([C@]2(CC[C@@]5(C4CC(CC5)(C)C)C(=O)OC)C)O)(C=C(C(=O)C3(C)C)C#N)C
DM7SIVA IK QBHNHKNDTFTWNV-BTIYJVALSA-N
DM7SIVA IU methyl (4aS,6aS,6bR,8aR,12aS,14aS)-11-cyano-14a-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-3,4,5,6,7,8,8a,14b-octahydro-1H-picene-4a-carboxylate
DMAGVHX ID DMAGVHX
DMAGVHX DN PMID28454500-Compound-3
DMAGVHX HS Patented
DMAGVHX CP Chengdu Sourcebio Limited Liability Company, Peop. Rep. China.Zhenjiang Shengan Pharmaceutical Co., Ltd., Peop. Rep. China
DMAGVHX DT Small molecular drug
DMAIGJP ID DMAIGJP
DMAIGJP DN PMID28454500-Compound-32
DMAIGJP HS Patented
DMAIGJP CP FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DMAIGJP DT Small molecular drug
DMAIGJP PC 121289291
DMAIGJP MW 286.33
DMAIGJP FM C16H18N2O3
DMAIGJP IC InChI=1S/C16H18N2O3/c1-3-4-16(20)21-13-5-6-15-14(9-13)12(10-18-15)7-8-17-11(2)19/h3-6,9-10,18H,7-8H2,1-2H3,(H,17,19)/b4-3+
DMAIGJP CS C/C=C/C(=O)OC1=CC2=C(C=C1)NC=C2CCNC(=O)C
DMAIGJP IK YKWJUNJYDNSFHV-ONEGZZNKSA-N
DMAIGJP IU [3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-but-2-enoate
DMYXQU3 ID DMYXQU3
DMYXQU3 DN PMID28454500-Compound-33
DMYXQU3 HS Patented
DMYXQU3 CP FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DMYXQU3 DT Small molecular drug
DMYXQU3 PC 121289344
DMYXQU3 MW 348.4
DMYXQU3 FM C21H20N2O3
DMYXQU3 IC InChI=1S/C21H20N2O3/c1-15(24)22-12-11-17-14-23-20-9-8-18(13-19(17)20)26-21(25)10-7-16-5-3-2-4-6-16/h2-10,13-14,23H,11-12H2,1H3,(H,22,24)/b10-7+
DMYXQU3 CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=CC=C3
DMYXQU3 IK NDJABQJCUZPRSD-JXMROGBWSA-N
DMYXQU3 IU [3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-phenylprop-2-enoate
DMN2910 ID DMN2910
DMN2910 DN PMID28454500-Compound-34
DMN2910 HS Patented
DMN2910 CP FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DMN2910 DT Small molecular drug
DMN2910 PC 121289250
DMN2910 MW 362.4
DMN2910 FM C22H22N2O3
DMN2910 IC InChI=1S/C22H22N2O3/c1-15-3-5-17(6-4-15)7-10-22(26)27-19-8-9-21-20(13-19)18(14-24-21)11-12-23-16(2)25/h3-10,13-14,24H,11-12H2,1-2H3,(H,23,25)/b10-7+
DMN2910 CS CC1=CC=C(C=C1)/C=C/C(=O)OC2=CC3=C(C=C2)NC=C3CCNC(=O)C
DMN2910 IK FKXPVWWTKVQISE-JXMROGBWSA-N
DMN2910 IU [3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-methylphenyl)prop-2-enoate
DM2OM4Z ID DM2OM4Z
DM2OM4Z DN PMID28454500-Compound-35
DM2OM4Z HS Patented
DM2OM4Z CP FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DM2OM4Z DT Small molecular drug
DM2OM4Z PC 121289348
DM2OM4Z MW 378.4
DM2OM4Z FM C22H22N2O4
DM2OM4Z IC InChI=1S/C22H22N2O4/c1-15(25)23-12-11-17-14-24-21-9-8-19(13-20(17)21)28-22(26)10-5-16-3-6-18(27-2)7-4-16/h3-10,13-14,24H,11-12H2,1-2H3,(H,23,25)/b10-5+
DM2OM4Z CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=C(C=C3)OC
DM2OM4Z IK XTKZTJVFEUTPPV-BJMVGYQFSA-N
DM2OM4Z IU [3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-methoxyphenyl)prop-2-enoate
DM5RZWG ID DM5RZWG
DM5RZWG DN PMID28454500-Compound-36
DM5RZWG HS Patented
DM5RZWG CP FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DM5RZWG DT Small molecular drug
DM5RZWG PC 121289252
DM5RZWG MW 366.4
DM5RZWG FM C21H19FN2O3
DM5RZWG IC InChI=1S/C21H19FN2O3/c1-14(25)23-11-10-16-13-24-20-8-7-18(12-19(16)20)27-21(26)9-4-15-2-5-17(22)6-3-15/h2-9,12-13,24H,10-11H2,1H3,(H,23,25)/b9-4+
DM5RZWG CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=C(C=C3)F
DM5RZWG IK SAMHXGDYEAOVQC-RUDMXATFSA-N
DM5RZWG IU [3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-fluorophenyl)prop-2-enoate
DM83P6H ID DM83P6H
DM83P6H DN PMID28454500-Compound-37
DM83P6H HS Patented
DM83P6H CP FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
DM83P6H DT Small molecular drug
DM83P6H PC 121289347
DM83P6H MW 393.4
DM83P6H FM C21H19N3O5
DM83P6H IC InChI=1S/C21H19N3O5/c1-14(25)22-11-10-16-13-23-20-8-7-18(12-19(16)20)29-21(26)9-4-15-2-5-17(6-3-15)24(27)28/h2-9,12-13,23H,10-11H2,1H3,(H,22,25)/b9-4+
DM83P6H CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC(=O)/C=C/C3=CC=C(C=C3)[N+](=O)[O-]
DM83P6H IK HAJBAZSPWITWPC-RUDMXATFSA-N
DM83P6H IU [3-(2-acetamidoethyl)-1H-indol-5-yl] (E)-3-(4-nitrophenyl)prop-2-enoate
DM9TVWJ ID DM9TVWJ
DM9TVWJ DN PMID28454500-Compound-40
DM9TVWJ HS Patented
DM9TVWJ CP China Pharmaceutical University
DM9TVWJ DT Small molecular drug
DM9TVWJ PC 5316743
DM9TVWJ MW 278.3
DM9TVWJ FM C18H14O3
DM9TVWJ IC InChI=1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3
DM9TVWJ CS CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C
DM9TVWJ IK HARGZZNYNSYSGJ-UHFFFAOYSA-N
DM9TVWJ IU 1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione
DM9TVWJ CA CAS 87205-99-0
DMGAW81 ID DMGAW81
DMGAW81 DN PMID28454500-Compound-41
DMGAW81 HS Patented
DMGAW81 CP Guangdong Hospital of Traditional Chinese Medicine
DMGAW81 DT Small molecular drug
DMGAW81 PC 11000442
DMGAW81 MW 280.32
DMGAW81 FM C15H20O5
DMGAW81 IC InChI=1S/C15H20O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8,10-11,13H,2,4-7H2,1,3H3/t8-,10+,11+,13-,14-,15-/m1/s1
DMGAW81 CS C[C@@H]1CC[C@H]2C(=C)C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C
DMGAW81 IK IGEBZMMCKFUABB-KPHNHPKPSA-N
DMGAW81 IU (1R,4S,5R,8S,12S,13R)-1,5-dimethyl-9-methylidene-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
DM5NJDK ID DM5NJDK
DM5NJDK DN PMID28454500-Compound-49
DM5NJDK HS Patented
DM5NJDK CP China Medical University
DM5NJDK DT Small molecular drug
DMQPKCD ID DMQPKCD
DMQPKCD DN PMID28454500-Compound-50
DMQPKCD HS Patented
DMQPKCD CP Tsukuba University, JapaKyorin Pharmaceutical Co., Ltd
DMQPKCD DT Small molecular drug
DMQPKCD PC 193653
DMQPKCD MW 179.2
DMQPKCD FM C5H9NO4S
DMQPKCD IC InChI=1S/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DMQPKCD CS C([C@@H](C(=O)O)N)SCC(=O)O
DMQPKCD IK GBFLZEXEOZUWRN-VKHMYHEASA-N
DMQPKCD IU (2R)-2-amino-3-(carboxymethylsulfanyl)propanoic acid
DMQPKCD CA CAS 638-23-3
DMQPKCD CB CHEBI:16163
DMTK9M6 ID DMTK9M6
DMTK9M6 DN PMID28454500-Compound-57
DMTK9M6 HS Patented
DMTK9M6 CP China Pharmaceutical University
DMTK9M6 DT Small molecular drug
DMTK9M6 PC 135315519
DMTK9M6 MW 577.6
DMTK9M6 FM C31H31NO8S
DMTK9M6 IC InChI=1S/C31H31NO8S/c1-19-15-20(2)31(21(3)16-19)41(37,38)32(18-30(35)36)26-13-14-27(25-8-6-5-7-24(25)26)40-28(17-29(33)34)22-9-11-23(39-4)12-10-22/h5-16,28H,17-18H2,1-4H3,(H,33,34)(H,35,36)
DMTK9M6 CS CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC(=O)O)C2=CC=C(C3=CC=CC=C32)OC(CC(=O)O)C4=CC=C(C=C4)OC)C
DMTK9M6 IK PSPVUIANHULZSQ-UHFFFAOYSA-N
DMTK9M6 IU 3-[4-[carboxymethyl-(2,4,6-trimethylphenyl)sulfonylamino]naphthalen-1-yl]oxy-3-(4-methoxyphenyl)propanoic acid
DMDEHYR ID DMDEHYR
DMDEHYR DN PMID28454500-Compound-58
DMDEHYR HS Patented
DMDEHYR CP China Pharmaceutical University
DMDEHYR DT Small molecular drug
DMQWPSF ID DMQWPSF
DMQWPSF DN PMID28454500-Compound-59
DMQWPSF HS Patented
DMQWPSF CP China Pharmaceutical University
DMQWPSF DT Small molecular drug
DM1I9JC ID DM1I9JC
DM1I9JC DN PMID28454500-Compound-60
DM1I9JC HS Patented
DM1I9JC CP China Pharmaceutical University
DM1I9JC DT Small molecular drug
DM6BQFA ID DM6BQFA
DM6BQFA DN PMID28454500-Compound-8
DM6BQFA HS Patented
DM6BQFA CP REATA PHARMACEUTICALS, INC. ANDERSON, Eric JIANG, Xin VISNICK, Melean BENDER, Christopher, F. LIU, Xiaofeng
DM6BQFA DT Small molecular drug
DM6BQFA PC 66546002
DM6BQFA MW 491.7
DM6BQFA FM C31H41NO4
DM6BQFA IC InChI=1S/C31H41NO4/c1-18-20-8-9-29(5)23(28(20,4)15-19(17-32)25(18)34)14-22(33)24-21-16-27(2,3)10-12-31(21,26(35)36-7)13-11-30(24,29)6/h14-15,18,20-21,24H,8-13,16H2,1-7H3/t18-,20-,21?,24?,28-,29+,30+,31-/m0/s1
DM6BQFA CS C[C@H]1[C@@H]2CC[C@@]3(C(=CC(=O)C4[C@]3(CC[C@@]5(C4CC(CC5)(C)C)C(=O)OC)C)[C@]2(C=C(C1=O)C#N)C)C
DM6BQFA IK MAOZWESYDBKVCY-HZCQYKMZSA-N
DM6BQFA IU methyl (4aS,6aR,6bS,8aS,9S,12aR)-11-cyano-2,2,6a,6b,9,12a-hexamethyl-10,14-dioxo-3,4,5,6,7,8,8a,9,14a,14b-decahydro-1H-picene-4a-carboxylate
DM3HR7F ID DM3HR7F
DM3HR7F DN PMID28454500-Compound-9
DM3HR7F HS Patented
DM3HR7F CP REATA PHARMACEUTICALS, INC. ANDERSON, Eric JIANG, Xin VISNICK, Melean BENDER, Christopher, F. LIU, Xiaofeng
DM3HR7F DT Small molecular drug
DM3HR7F PC 66546189
DM3HR7F MW 463.7
DM3HR7F FM C30H41NO3
DM3HR7F IC InChI=1S/C30H41NO3/c1-18-20-7-8-28(5)23(27(20,4)14-19(16-31)25(18)34)13-22(33)24-21-15-26(2,3)9-11-30(21,17-32)12-10-29(24,28)6/h13-14,18,20-21,24,32H,7-12,15,17H2,1-6H3/t18-,20-,21?,24?,27-,28+,29+,30+/m0/s1
DM3HR7F CS C[C@H]1[C@@H]2CC[C@@]3(C(=CC(=O)C4[C@]3(CC[C@@]5(C4CC(CC5)(C)C)CO)C)[C@]2(C=C(C1=O)C#N)C)C
DM3HR7F IK UHGNLMUWOYPXQG-WDPAWIMBSA-N
DM3HR7F IU (4S,4aS,6aS,6bR,8aS,14bR)-8a-(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydro-4H-picene-2-carbonitrile
DMJ1KFO ID DMJ1KFO
DMJ1KFO DN PMID28454500-Compound-91
DMJ1KFO HS Patented
DMJ1KFO CP THE HAMNER INSTITUTES
DMJ1KFO DT Small molecular drug
DM1RS4X ID DM1RS4X
DM1RS4X DN PMID28454500-Compound-92
DM1RS4X HS Patented
DM1RS4X CP THE HAMNER INSTITUTES
DM1RS4X DT Small molecular drug
DMMDK6B ID DMMDK6B
DMMDK6B DN PMID28454500-Compound-93
DMMDK6B HS Patented
DMMDK6B CP THE HAMNER INSTITUTES
DMMDK6B DT Small molecular drug
DMMDK6B PC 77174
DMMDK6B MW 150.18
DMMDK6B FM C8H10N2O
DMMDK6B IC InChI=1S/C8H10N2O/c1-6-2-4-7(5-3-6)8(11)10-9/h2-5H,9H2,1H3,(H,10,11)
DMMDK6B CS CC1=CC=C(C=C1)C(=O)NN
DMMDK6B IK MFFVZXOPRXMVET-UHFFFAOYSA-N
DMMDK6B IU 4-methylbenzohydrazide
DMMDK6B CA CAS 3619-22-5
DM5Q962 ID DM5Q962
DM5Q962 DN PMID28454500-Compound-94
DM5Q962 HS Patented
DM5Q962 CP THE HAMNER INSTITUTES
DM5Q962 DT Small molecular drug
DM5Q962 PC 23527
DM5Q962 MW 114.19
DM5Q962 FM C6H14N2
DM5Q962 IC InChI=1S/C6H14N2/c7-5-6-1-3-8-4-2-6/h6,8H,1-5,7H2
DM5Q962 CS C1CNCCC1CN
DM5Q962 IK LTEKQAPRXFBRNN-UHFFFAOYSA-N
DM5Q962 IU piperidin-4-ylmethanamine
DM5Q962 CA CAS 7144-05-0
DM9L2VR ID DM9L2VR
DM9L2VR DN PMID28454500-Compound-95
DM9L2VR HS Patented
DM9L2VR CP THE HAMNER INSTITUTES
DM9L2VR DT Small molecular drug
DM9L2VR PC 21450
DM9L2VR MW 151.17
DM9L2VR FM C7H9N3O
DM9L2VR IC InChI=1S/C7H9N3O/c8-6-3-1-5(2-4-6)7(11)10-9/h1-4H,8-9H2,(H,10,11)
DM9L2VR CS C1=CC(=CC=C1C(=O)NN)N
DM9L2VR IK WPBZMCGPFHZRHJ-UHFFFAOYSA-N
DM9L2VR IU 4-aminobenzohydrazide
DM9L2VR CA CAS 5351-17-7
DM2A75P ID DM2A75P
DM2A75P DN PMID28454500-Compound-96
DM2A75P HS Patented
DM2A75P CP THE HAMNER INSTITUTES
DM2A75P DT Small molecular drug
DM2A75P PC 2761171
DM2A75P MW 166.25
DM2A75P FM C8H10N2S
DM2A75P IC InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)
DM2A75P CS CCC1=NC=CC(=C1)C(=S)N
DM2A75P IK AEOCXXJPGCBFJA-UHFFFAOYSA-N
DM2A75P IU 2-ethylpyridine-4-carbothioamide
DM2A75P CA CAS 536-33-4
DM2A75P CB CHEBI:4885
DMHV75N ID DMHV75N
DMHV75N DN PMID28460551-Compound-1
DMHV75N HS Patented
DMHV75N CP BOSTON BIOMEDICAL, INC
DMHV75N DT Small molecular drug
DMHV75N PC 25190990
DMHV75N MW 539.7
DMHV75N FM C31H33N5O2S
DMHV75N IC InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-
DMHV75N CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)C4=CSC(=N4)C5=CC=CC=C5)NC2=O)C
DMHV75N IK QDWKGEFGLQMDAM-ULJHMMPZSA-N
DMHV75N IU N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-[(Z)-[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1H-indol-3-ylidene]methyl]-1H-pyrrole-3-carboxamide
DMHV75N CA CAS 1129403-56-0
DMHV75N DE Breast cancer; Pancreatic cancer; Lung cancer; Gastric adenocarcinoma; Colon cancer; Colorectal cancer; Prostate cancer
DM4DOUB ID DM4DOUB
DM4DOUB DN PMID28460551-Compound-2
DM4DOUB HS Patented
DM4DOUB DT Small molecular drug
DM4DOUB PC 5329102
DM4DOUB MW 398.5
DM4DOUB FM C22H27FN4O2
DM4DOUB IC InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
DM4DOUB CS CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
DM4DOUB IK WINHZLLDWRZWRT-ATVHPVEESA-N
DM4DOUB IU N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DM4DOUB CA CAS 557795-19-4
DM4DOUB CB CHEBI:38940
DMA1FRM ID DMA1FRM
DMA1FRM DN PMID28460551-Compound-3
DMA1FRM HS Patented
DMA1FRM CP Whitehead Institute for Biomedical Research
DMA1FRM DT Small molecular drug
DMA1FRM PC 5083
DMA1FRM MW 457.5
DMA1FRM FM C25H23N5O2S
DMA1FRM IC InChI=1S/C25H23N5O2S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32)
DMA1FRM CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N
DMA1FRM IK DSXXEELGXBCYNQ-UHFFFAOYSA-N
DMA1FRM IU 3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate
DMA1FRM CA CAS 125314-64-9
DMA1FRM CB CHEBI:38912
DMT7U1O ID DMT7U1O
DMT7U1O DN PMID28460551-Compound-6
DMT7U1O HS Patented
DMT7U1O DT Small molecular drug
DMLZV70 ID DMLZV70
DMLZV70 DN PMID28594589-Compound-TABLE3C1
DMLZV70 HS Patented
DMLZV70 CP Novartis
DMLZV70 DT Small molecular drug
DMPK7IU ID DMPK7IU
DMPK7IU DN PMID28594589-Compound-TABLE3C12
DMPK7IU HS Patented
DMPK7IU CP Allomek Therapeutics
DMPK7IU DT Small molecular drug
DM4KWVF ID DM4KWVF
DM4KWVF DN PMID28594589-Compound-TABLE3C14
DM4KWVF HS Patented
DM4KWVF CP The Regents of the University of Michigan
DM4KWVF DT Small molecular drug
DMVYG0U ID DMVYG0U
DMVYG0U DN PMID28594589-Compound-TABLE3C2
DMVYG0U HS Patented
DMVYG0U CP Novartis
DMVYG0U DT Small molecular drug
DMBTZ8I ID DMBTZ8I
DMBTZ8I DN PMID28621580-Compound-WO2013036866C66
DMBTZ8I HS Patented
DMBTZ8I CP THE JOHNS HOPKINS UNIVERSITY LIU, Jun, O. SHI, Wei PASUNOOTI, Kalyan, Kumar
DMBTZ8I DT Small molecular drug
DMBTZ8I DE Solid tumour/cancer
DM15OKA ID DM15OKA
DM15OKA DN PMID28621580-Compound-WO2013112959C68
DM15OKA HS Patented
DM15OKA CP ANGION BIOMEDICA CORP
DM15OKA DT Small molecular drug
DM15OKA DE Fibrosis
DMR58TX ID DMR58TX
DMR58TX DN PMID28621580-Compound-WO2014079545C69
DMR58TX HS Patented
DMR58TX CP KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
DMR58TX DT Small molecular drug
DMX96FI ID DMX96FI
DMX96FI DN PMID28621580-Compound-WO2015089220C70
DMX96FI HS Patented
DMX96FI CP ALLERGAN, INC
DMX96FI DT Small molecular drug
DMX96FI DE Retinopathy; Age-related macular degeneration
DM36P7T ID DM36P7T
DM36P7T DN PMID28627961-Compound-22
DM36P7T HS Patented
DM36P7T CP Glenmark Pharmaceuticals S.A
DM36P7T DT Small molecular drug
DM36P7T PC 86692276
DM36P7T MW 574
DM36P7T FM C28H24ClF4N5O2
DM36P7T IC InChI=1S/C28H24ClF4N5O2/c1-27(2,3)26(40)34-13-15-10-11-19(29)21(22(15)30)25(39)38-20-9-5-8-18-23(20)35-14-36-24(18)37-17-7-4-6-16(12-17)28(31,32)33/h4-12,14H,13H2,1-3H3,(H,34,40)(H,38,39)(H,35,36,37)
DM36P7T CS CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)C(=O)NC2=CC=CC3=C2N=CN=C3NC4=CC=CC(=C4)C(F)(F)F)F
DM36P7T IK NPMRJEGXUPKUTE-UHFFFAOYSA-N
DM36P7T IU 6-chloro-3-[(2,2-dimethylpropanoylamino)methyl]-2-fluoro-N-[4-[3-(trifluoromethyl)anilino]quinazolin-8-yl]benzamide
DMRLU8I ID DMRLU8I
DMRLU8I DN PMID28627961-Compound-30
DMRLU8I HS Patented
DMRLU8I CP GLENMARK PHARMACEUTICALS S.A
DMRLU8I DT Small molecular drug
DMLGYXW ID DMLGYXW
DMLGYXW DN PMID28627961-Compound-31
DMLGYXW HS Patented
DMLGYXW CP GLENMARK PHARMACEUTICALS S.A
DMLGYXW DT Small molecular drug
DMLGYXW PC 71766655
DMLGYXW MW 520.9
DMLGYXW FM C27H19ClF2N4O3
DMLGYXW IC InChI=1S/C27H19ClF2N4O3/c28-18-2-1-3-19(29)22(18)33-27-32-21-13-17(24-25(23(21)34-27)37-11-10-36-24)26(35)31-16-9-8-15(20(30)12-16)7-6-14-4-5-14/h1-3,8-9,12-14H,4-5,10-11H2,(H,31,35)(H2,32,33,34)
DMLGYXW CS C1CC1C#CC2=C(C=C(C=C2)NC(=O)C3=CC4=C(C5=C3OCCO5)N=C(N4)NC6=C(C=CC=C6Cl)F)F
DMLGYXW IK CSOLVYOAIFCMHY-UHFFFAOYSA-N
DMLGYXW IU 2-(2-chloro-6-fluoroanilino)-N-[4-(2-cyclopropylethynyl)-3-fluorophenyl]-7,8-dihydro-3H-[1,4]dioxino[2,3-e]benzimidazole-5-carboxamide
DM5IZKD ID DM5IZKD
DM5IZKD DN PMID28627961-Compound-32
DM5IZKD HS Patented
DM5IZKD CP NOVASAID AB [SE]
DM5IZKD DT Small molecular drug
DMWV4YE ID DMWV4YE
DMWV4YE DN PMID28627961-Compound-33
DMWV4YE HS Patented
DMWV4YE CP GLENMARK PHARMACEUTICALS S.A
DMWV4YE DT Small molecular drug
DMODL3P ID DMODL3P
DMODL3P DN PMID28627961-Compound-41
DMODL3P HS Patented
DMODL3P CP Astra Zeneca AB
DMODL3P DT Small molecular drug
DMODL3P PC 42630323
DMODL3P MW 453.9
DMODL3P FM C18H16ClN3O5S2
DMODL3P IC InChI=1S/C18H16ClN3O5S2/c1-27-18-15(19)10-13(11-21-18)12-5-4-6-14(9-12)29(25,26)22-16-7-2-3-8-17(16)28(20,23)24/h2-11,22H,1H3,(H2,20,23,24)
DMODL3P CS COC1=C(C=C(C=N1)C2=CC(=CC=C2)S(=O)(=O)NC3=CC=CC=C3S(=O)(=O)N)Cl
DMODL3P IK WVXMZKAIOMLXRH-UHFFFAOYSA-N
DMODL3P IU 2-[[3-(5-chloro-6-methoxypyridin-3-yl)phenyl]sulfonylamino]benzenesulfonamide
DM7ATLP ID DM7ATLP
DM7ATLP DN PMID28627961-Compound-44
DM7ATLP HS Patented
DM7ATLP CP EBERHARD KARLS UNIVERSIT TINGEN WERZ, Oliver KOEBERLE, Andreas
DM7ATLP DT Small molecular drug
DM7ATLP PC 10327116
DM7ATLP MW 668.8
DM7ATLP FM C38H52O10
DM7ATLP IC InChI=1S/C38H52O10/c1-15(2)18(22-29(43)35(7,8)33(47)36(9,10)30(22)44)20-26(40)21(28(42)24(27(20)41)25(39)17(5)6)19(16(3)4)23-31(45)37(11,12)34(48)38(13,14)32(23)46/h15-19,40-43,45H,1-14H3
DM7ATLP CS CC(C)C(C1=C(C(=C(C(=C1O)C(=O)C(C)C)O)C(C2=C(C(C(=O)C(C2=O)(C)C)(C)C)O)C(C)C)O)C3=C(C(C(=O)C(C3=O)(C)C)(C)C)O
DM7ATLP IK BIHONVMOJSPPFL-UHFFFAOYSA-N
DM7ATLP IU 5-hydroxy-2,2,6,6-tetramethyl-4-[2-methyl-1-[2,4,6-trihydroxy-3-[1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohexen-1-yl)-2-methylpropyl]-5-(2-methylpropanoyl)phenyl]propyl]cyclohex-4-ene-1,3-dione
DMBN3X4 ID DMBN3X4
DMBN3X4 DN PMID28766366-Compound-Scheme11
DMBN3X4 HS Patented
DMBN3X4 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE UNIVERSITE PARIS DIDEROT PARIS 7
DMBN3X4 DT Small molecular drug
DMBN3X4 PC 72792831
DMBN3X4 MW 318.3
DMBN3X4 FM C19H14N2O3
DMBN3X4 IC InChI=1S/C19H14N2O3/c22-14-4-1-11(2-5-14)16-10-21-19-15(16)7-13(9-20-19)12-3-6-17(23)18(24)8-12/h1-10,22-24H,(H,20,21)
DMBN3X4 CS C1=CC(=CC=C1C2=CNC3=C2C=C(C=N3)C4=CC(=C(C=C4)O)O)O
DMBN3X4 IK HBCKPNCVCXUSEU-UHFFFAOYSA-N
DMBN3X4 IU 4-[3-(4-hydroxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzene-1,2-diol
DMMJ5SN ID DMMJ5SN
DMMJ5SN DN PMID28766366-Compound-Scheme12-1
DMMJ5SN HS Patented
DMMJ5SN CP SAMUMED, LLC
DMMJ5SN DT Small molecular drug
DMMJ5SN PC 89450758
DMMJ5SN MW 412.5
DMMJ5SN FM C24H24N6O
DMMJ5SN IC InChI=1S/C24H24N6O/c31-24(27-20-5-4-8-25-15-20)23-21-12-18(6-7-22(21)28-29-23)19-11-17(13-26-14-19)16-30-9-2-1-3-10-30/h4-8,11-15H,1-3,9-10,16H2,(H,27,31)(H,28,29)
DMMJ5SN CS C1CCN(CC1)CC2=CC(=CN=C2)C3=CC4=C(C=C3)NN=C4C(=O)NC5=CN=CC=C5
DMMJ5SN IK VCNIUYPAMGFBLR-UHFFFAOYSA-N
DMMJ5SN IU 5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-N-pyridin-3-yl-1H-indazole-3-carboxamide
DM3BA1L ID DM3BA1L
DM3BA1L DN PMID28766366-Compound-Scheme12-2
DM3BA1L HS Patented
DM3BA1L CP SAMUMED, LLC
DM3BA1L DT Small molecular drug
DM3BA1L PC 118381061
DM3BA1L MW 426.5
DM3BA1L FM C25H26N6O
DM3BA1L IC InChI=1S/C25H26N6O/c1-17-9-21(15-26-12-17)28-25(32)24-22-11-19(5-6-23(22)29-30-24)20-10-18(13-27-14-20)16-31-7-3-2-4-8-31/h5-6,9-15H,2-4,7-8,16H2,1H3,(H,28,32)(H,29,30)
DM3BA1L CS CC1=CC(=CN=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5
DM3BA1L IK LIXXQBRPVXEVJX-UHFFFAOYSA-N
DM3BA1L IU N-(5-methylpyridin-3-yl)-5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide
DM4V3AY ID DM4V3AY
DM4V3AY DN PMID28766366-Compound-Scheme12-3
DM4V3AY HS Patented
DM4V3AY CP SAMUMED, LLC
DM4V3AY DT Small molecular drug
DM4V3AY PC 89458694
DM4V3AY MW 426.5
DM4V3AY FM C25H26N6O
DM4V3AY IC InChI=1S/C25H26N6O/c1-17-5-7-21(15-27-17)28-25(32)24-22-12-19(6-8-23(22)29-30-24)20-11-18(13-26-14-20)16-31-9-3-2-4-10-31/h5-8,11-15H,2-4,9-10,16H2,1H3,(H,28,32)(H,29,30)
DM4V3AY CS CC1=NC=C(C=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5
DM4V3AY IK HVEOEVJLUUUHNZ-UHFFFAOYSA-N
DM4V3AY IU N-(6-methylpyridin-3-yl)-5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-1H-indazole-3-carboxamide
DM5BG6L ID DM5BG6L
DM5BG6L DN PMID28766366-Compound-Scheme12-4
DM5BG6L HS Patented
DM5BG6L CP SAMUMED, LLC
DM5BG6L DT Small molecular drug
DM5BG6L PC 118381715
DM5BG6L MW 470.6
DM5BG6L FM C27H30N6O2
DM5BG6L IC InChI=1S/C27H30N6O2/c1-18(2)35-25-9-7-22(16-29-25)30-27(34)26-23-13-20(6-8-24(23)31-32-26)21-12-19(14-28-15-21)17-33-10-4-3-5-11-33/h6-9,12-16,18H,3-5,10-11,17H2,1-2H3,(H,30,34)(H,31,32)
DM5BG6L CS CC(C)OC1=NC=C(C=C1)NC(=O)C2=NNC3=C2C=C(C=C3)C4=CN=CC(=C4)CN5CCCCC5
DM5BG6L IK QWXGMMPJHDIFKI-UHFFFAOYSA-N
DM5BG6L IU 5-[5-(piperidin-1-ylmethyl)pyridin-3-yl]-N-(6-propan-2-yloxypyridin-3-yl)-1H-indazole-3-carboxamide
DMLQCYV ID DMLQCYV
DMLQCYV DN PMID28766366-Compound-Scheme13INDY
DMLQCYV HS Patented
DMLQCYV CP SIRTRIS PHARMACEUTICALS, INC. PERNI, Robert, B. BEMIS, Jean NUNES, Joseph, J. SZCZEPANKIEWICZ, Bruce, G
DMLQCYV DT Small molecular drug
DMLQCYV PC 44136031
DMLQCYV MW 235.3
DMLQCYV FM C12H13NO2S
DMLQCYV IC InChI=1S/C12H13NO2S/c1-3-13-10-7-9(15)4-5-11(10)16-12(13)6-8(2)14/h4-7,15H,3H2,1-2H3/b12-6-
DMLQCYV CS CCN\\1C2=C(C=CC(=C2)O)S/C1=C\\C(=O)C
DMLQCYV IK GCSZJMUFYOAHFY-SDQBBNPISA-N
DMLQCYV IU (1Z)-1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one
DMBQ0RN ID DMBQ0RN
DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY
DMBQ0RN HS Patented
DMBQ0RN CP KYOTO UNIVERSITY
DMBQ0RN DT Small molecular drug
DMVG275 ID DMVG275
DMVG275 DN PMID28766366-Compound-Scheme15-1
DMVG275 HS Patented
DMVG275 CP LYTIX BIOPHARMA AS
DMVG275 DT Small molecular drug
DMVG275 PC 655817
DMVG275 MW 222.27
DMVG275 FM C10H10N2O2S
DMVG275 IC InChI=1S/C10H10N2O2S/c1-6(13)11-10-12-8-5-7(14-2)3-4-9(8)15-10/h3-5H,1-2H3,(H,11,12,13)
DMVG275 CS CC(=O)NC1=NC2=C(S1)C=CC(=C2)OC
DMVG275 IK ZKNFVQNHIHCHEW-UHFFFAOYSA-N
DMVG275 IU N-(5-methoxy-1,3-benzothiazol-2-yl)acetamide
DMU8ENF ID DMU8ENF
DMU8ENF DN PMID28766366-Compound-Scheme15-2
DMU8ENF HS Patented
DMU8ENF CP LYTIX BIOPHARMA AS
DMU8ENF DT Small molecular drug
DMU8ENF PC 118295558
DMU8ENF MW 208.24
DMU8ENF FM C9H8N2O2S
DMU8ENF IC InChI=1S/C9H8N2O2S/c1-5(12)10-9-11-7-4-6(13)2-3-8(7)14-9/h2-4,13H,1H3,(H,10,11,12)
DMU8ENF CS CC(=O)NC1=NC2=C(S1)C=CC(=C2)O
DMU8ENF IK YOMAHEQEXVNJNF-UHFFFAOYSA-N
DMU8ENF IU N-(5-hydroxy-1,3-benzothiazol-2-yl)acetamide
DMA423P ID DMA423P
DMA423P DN PMID28766366-Compound-Scheme15-3
DMA423P HS Patented
DMA423P CP LYTIX BIOPHARMA AS
DMA423P DT Small molecular drug
DMA423P PC 731719
DMA423P MW 237.24
DMA423P FM C9H7N3O3S
DMA423P IC InChI=1S/C9H7N3O3S/c1-5(13)10-9-11-7-3-2-6(12(14)15)4-8(7)16-9/h2-4H,1H3,(H,10,11,13)
DMA423P CS CC(=O)NC1=NC2=C(S1)C=C(C=C2)[N+](=O)[O-]
DMA423P IK XARDSBCDZPSYTN-UHFFFAOYSA-N
DMA423P IU N-(6-nitro-1,3-benzothiazol-2-yl)acetamide
DMA423P CA CAS 80395-50-2
DMQ5UEA ID DMQ5UEA
DMQ5UEA DN PMID28766366-Compound-Scheme16DMAT
DMQ5UEA HS Patented
DMQ5UEA CP SELVITA S.A
DMQ5UEA DT Small molecular drug
DMQ5UEA PC 5326976
DMQ5UEA MW 476.79
DMQ5UEA FM C9H7Br4N3
DMQ5UEA IC InChI=1S/C9H7Br4N3/c1-16(2)9-14-7-5(12)3(10)4(11)6(13)8(7)15-9/h1-2H3,(H,14,15)
DMQ5UEA CS CN(C)C1=NC2=C(N1)C(=C(C(=C2Br)Br)Br)Br
DMQ5UEA IK SLPJGDQJLTYWCI-UHFFFAOYSA-N
DMQ5UEA IU 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine
DMQ5UEA CA CAS 749234-11-5
DMBQ21J ID DMBQ21J
DMBQ21J DN PMID28766366-Compound-Scheme18
DMBQ21J HS Patented
DMBQ21J CP SERVIER LAB [FRVERNALIS (R&D) LTD [GB]
DMBQ21J DT Small molecular drug
DMHIUWX ID DMHIUWX
DMHIUWX DN PMID28766366-Compound-Scheme1WO2011135259
DMHIUWX HS Patented
DMHIUWX CP CENTRE NAT RECH SCIENT [FRUNIV ORLEANS [FRROUTIER SYLVAIN [FRGUILLAUMET GERALD [FRTIKAD ABDELLATIF [BEDEHBI OUSSAMA [FR]
DMHIUWX DT Small molecular drug
DMHIUWX PC 136335012
DMHIUWX MW 320.3
DMHIUWX FM C18H16N4O2
DMHIUWX IC InChI=1S/C18H16N4O2/c23-14-6-4-12(5-7-14)18-20-11-16-15(21-18)9-13(10-19-16)22-8-2-1-3-17(22)24/h4-7,9-11,23H,1-3,8H2
DMHIUWX CS C1CCN(C(=O)C1)C2=CC3=NC(=NC=C3N=C2)C4=CC=C(C=C4)O
DMHIUWX IK GIUNPBXEXJKOFE-UHFFFAOYSA-N
DMHIUWX IU 1-[2-(4-hydroxyphenyl)pyrido[3,2-d]pyrimidin-7-yl]piperidin-2-one
DMWTRUK ID DMWTRUK
DMWTRUK DN PMID28766366-Compound-Scheme21Left
DMWTRUK HS Patented
DMWTRUK CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. HIGGINS, Jonathan PATNAIK, Debasis ULYANOVA, Natalia STEIN, Ross L. XIAN, Jun GLICKSMAN, Marcie CUNY, Gregory D
DMWTRUK DT Small molecular drug
DMF3X40 ID DMF3X40
DMF3X40 DN PMID28766366-Compound-Scheme21Right
DMF3X40 HS Patented
DMF3X40 CP THE BRIGHAM AND WOMEN'S HOSPITAL, INC. PRESIDENT AND FELLOWS OF HARVARD COLLEGE UNIVERSITY PAUL CEZANNE MARSEILLE III/AIX
DMF3X40 DT Small molecular drug
DMF3X40 PC 53390843
DMF3X40 MW 328.4
DMF3X40 FM C18H20N2O2S
DMF3X40 IC InChI=1S/C18H20N2O2S/c1-21-12-4-6-16-14(10-12)18(23-9-3-8-19)15-11-13(22-2)5-7-17(15)20-16/h4-7,10-11H,3,8-9,19H2,1-2H3
DMF3X40 CS COC1=CC2=C(C=C1)N=C3C=CC(=CC3=C2SCCCN)OC
DMF3X40 IK ZFOMCSNUEHMROO-UHFFFAOYSA-N
DMF3X40 IU 3-(2,7-dimethoxyacridin-9-yl)sulfanylpropan-1-amine
DMD8N5O ID DMD8N5O
DMD8N5O DN PMID28766366-Compound-Scheme22Middle
DMD8N5O HS Patented
DMD8N5O CP TRANSLATIONAL GENOMICS RESEARCH INSTITUTE DUNCKLEY, Travis
DMD8N5O DT Small molecular drug
DMRLSKV ID DMRLSKV
DMRLSKV DN PMID28766366-Compound-Scheme23MPPDerivatives
DMRLSKV HS Patented
DMRLSKV CP MEDIPROPHARMA, INC. SHCHERBAKOVA, Irina NIKOLICH, Karoly NIKOLYUKIN, Yuri
DMRLSKV DT Small molecular drug
DMBWAV7 ID DMBWAV7
DMBWAV7 DN PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole
DMBWAV7 HS Patented
DMBWAV7 CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMBWAV7 DT Small molecular drug
DMBWAV7 PC 12248893
DMBWAV7 MW 243.26
DMBWAV7 FM C16H9N3
DMBWAV7 IC InChI=1S/C16H9N3/c17-8-10-7-11-9-18-6-5-12(11)16-15(10)13-3-1-2-4-14(13)19-16/h1-7,9,19H
DMBWAV7 CS C1=CC=C2C(=C1)C3=C(C=C4C=NC=CC4=C3N2)C#N
DMBWAV7 IK DCPBIOSSTDLFHO-UHFFFAOYSA-N
DMBWAV7 IU 11H-pyrido[4,3-a]carbazole-6-carbonitrile
DMNKRSZ ID DMNKRSZ
DMNKRSZ DN PMID28766366-Compound-Scheme24Paprotrain
DMNKRSZ HS Patented
DMNKRSZ CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMNKRSZ DT Small molecular drug
DMNKRSZ PC 12248889
DMNKRSZ MW 245.28
DMNKRSZ FM C16H11N3
DMNKRSZ IC InChI=1S/C16H11N3/c17-9-13(8-12-4-3-7-18-10-12)15-11-19-16-6-2-1-5-14(15)16/h1-8,10-11,19H/b13-8+
DMNKRSZ CS C1=CC=C2C(=C1)C(=CN2)/C(=C/C3=CN=CC=C3)/C#N
DMNKRSZ IK YMYYQRZCCKBFBE-MDWZMJQESA-N
DMNKRSZ IU (Z)-2-(1H-indol-3-yl)-3-pyridin-3-ylprop-2-enenitrile
DM7OGWH ID DM7OGWH
DM7OGWH DN PMID28766366-Compound-Scheme25-2
DM7OGWH HS Patented
DM7OGWH CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DM7OGWH DT Small molecular drug
DM7OGWH PC 77105816
DM7OGWH MW 273.29
DM7OGWH FM C17H11N3O
DM7OGWH IC InChI=1S/C17H11N3O/c1-21-12-2-3-14-15(7-12)20-17-13-4-5-19-9-11(13)6-10(8-18)16(14)17/h2-7,9,20H,1H3
DM7OGWH CS COC1=CC2=C(C=C1)C3=C(C=C4C=NC=CC4=C3N2)C#N
DM7OGWH IK UVJQEKJPAVSBTA-UHFFFAOYSA-N
DM7OGWH IU 9-methoxy-11H-pyrido[4,3-a]carbazole-6-carbonitrile
DMGVT5Y ID DMGVT5Y
DMGVT5Y DN PMID28766366-Compound-Scheme25-3
DMGVT5Y HS Patented
DMGVT5Y CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMGVT5Y DT Small molecular drug
DMGVT5Y PC 77105818
DMGVT5Y MW 303.3
DMGVT5Y FM C18H13N3O2
DMGVT5Y IC InChI=1S/C18H13N3O2/c1-22-12-3-4-13-14(6-12)21-18-16(13)10(7-19)5-11-8-20-9-15(23-2)17(11)18/h3-6,8-9,21H,1-2H3
DMGVT5Y CS COC1=CC2=C(C=C1)C3=C(C=C4C=NC=C(C4=C3N2)OC)C#N
DMGVT5Y IK WAJNOEPHTZIWTO-UHFFFAOYSA-N
DMGVT5Y IU 1,9-dimethoxy-11H-pyrido[4,3-a]carbazole-6-carbonitrile
DMOD9BY ID DMOD9BY
DMOD9BY DN PMID28766366-Compound-Scheme25-4
DMOD9BY HS Patented
DMOD9BY CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
DMOD9BY DT Small molecular drug
DM3Q1FT ID DM3Q1FT
DM3Q1FT DN PMID28766366-Compound-Scheme27LeucettamineB
DM3Q1FT HS Patented
DM3Q1FT CP GAMBRO LUNDIA AB [SEJOENSSON LENNART [SENILSSON EDDIE [SESTERNBY JAN [SE]
DM3Q1FT DT Small molecular drug
DM3Q1FT PC 10037501
DM3Q1FT MW 245.23
DM3Q1FT FM C12H11N3O3
DM3Q1FT IC InChI=1S/C12H11N3O3/c1-15-11(16)8(14-12(15)13)4-7-2-3-9-10(5-7)18-6-17-9/h2-5H,6H2,1H3,(H2,13,14)/b8-4-
DM3Q1FT CS CN1C(=O)/C(=C/C2=CC3=C(C=C2)OCO3)/N=C1N
DM3Q1FT IK PKEDBIGNILOTHW-YWEYNIOJSA-N
DM3Q1FT IU (5Z)-2-amino-5-(1,3-benzodioxol-5-ylmethylidene)-3-methylimidazol-4-one
DMLX26R ID DMLX26R
DMLX26R DN PMID28766366-Compound-Scheme27LeucettineL41
DMLX26R HS Patented
DMLX26R CP GAMBRO LUNDIA AB [SEJOENSSON LENNART [SENILSSON EDDIE [SESTERNBY JAN [SE]
DMLX26R DT Small molecular drug
DMLX26R PC 135398522
DMLX26R MW 307.3
DMLX26R FM C17H13N3O3
DMLX26R IC InChI=1S/C17H13N3O3/c21-16-13(8-11-6-7-14-15(9-11)23-10-22-14)19-17(20-16)18-12-4-2-1-3-5-12/h1-9H,10H2,(H2,18,19,20,21)/b13-8-
DMLX26R CS C1OC2=C(O1)C=C(C=C2)/C=C\\3/C(=O)NC(=N3)NC4=CC=CC=C4
DMLX26R IK PGPHHJBZEGSUNE-JYRVWZFOSA-N
DMLX26R IU (4Z)-2-anilino-4-(1,3-benzodioxol-5-ylmethylidene)-1H-imidazol-5-one
DMPVZ6W ID DMPVZ6W
DMPVZ6W DN PMID28766366-Compound-Scheme27LeucettineL41derivatives
DMPVZ6W HS Patented
DMPVZ6W CP GAMBRO LUNDIA AB [SEJOENSSON LENNART [SENILSSON EDDIE [SESTERNBY JAN [SE]
DMPVZ6W DT Small molecular drug
DMO4Q95 ID DMO4Q95
DMO4Q95 DN PMID28766366-Compound-Scheme2WO2012/098065bottom
DMO4Q95 HS Patented
DMO4Q95 CP F. HOFFMANN-LA ROCHE AG ANDERSON, Kevin William CHEN, Yi CHEN, Zhi LUK, Kin-Chun Thomas ROSSMAN, Pamela Loreen SUN, Hongmao WOVKULICH, Peter Michael
DMVJDRI ID DMVJDRI
DMVJDRI DN PMID28766366-Compound-Scheme2WO2012/098065upper
DMVJDRI HS Patented
DMVJDRI CP F. HOFFMANN-LA ROCHE AG ANDERSON, Kevin William CHEN, Yi CHEN, Zhi LUK, Kin-Chun Thomas ROSSMAN, Pamela Loreen SUN, Hongmao WOVKULICH, Peter Michael
DMDXIU9 ID DMDXIU9
DMDXIU9 DN PMID28766366-Compound-Scheme4Bottom
DMDXIU9 HS Patented
DMDXIU9 CP F. HOFFMANN-LA ROCHE AG LUK, Kin-Chun Thomas
DMDXIU9 DT Small molecular drug
DMPH4JV ID DMPH4JV
DMPH4JV DN PMID28766366-Compound-Scheme4Upper
DMPH4JV HS Patented
DMPH4JV CP F. HOFFMANN-LA ROCHE AG LUK, Kin-Chun Thomas
DMPH4JV DT Small molecular drug
DMO6KZ5 ID DMO6KZ5
DMO6KZ5 DN PMID28766366-Compound-Scheme5
DMO6KZ5 HS Patented
DMO6KZ5 CP F. HOFFMANN-LA ROCHE AG LIU, Wenjian LUK, Kin-Chun Thomas ZHANG, Xiaoh
DMO6KZ5 DT Small molecular drug
DMJOG3W ID DMJOG3W
DMJOG3W DN PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines
DMJOG3W HS Patented
DMJOG3W CP SERVIER LAB [FRVERNALIS (R&D) LTD [GB]
DMJOG3W DT Small molecular drug
DMQV6R0 ID DMQV6R0
DMQV6R0 DN PMID28766366-Compound-Scheme7WO2012/098070bottom
DMQV6R0 HS Patented
DMQV6R0 CP F. HOFFMANN-LA ROCHE AG DOMINIQUE, Romyr LUK, Kin-Chun Thomas QIAO, Qi ROSSMAN, Pamela Loreen
DMGAQR5 ID DMGAQR5
DMGAQR5 DN PMID28766366-Compound-Scheme7WO2012/098070upper
DMGAQR5 HS Patented
DMGAQR5 CP F. HOFFMANN-LA ROCHE AG DOMINIQUE, Romyr LUK, Kin-Chun Thomas QIAO, Qi ROSSMAN, Pamela Loreen
DMSX09A ID DMSX09A
DMSX09A DN PMID28766366-Compound-Scheme8NCGC-00010037
DMSX09A HS Patented
DMSX09A CP Department of Health and Human Services (NIH, Bethesda, US)
DMSX09A DT Small molecular drug
DMSX09A PC 3232621
DMSX09A MW 361.4
DMSX09A FM C20H15N3O2S
DMSX09A IC InChI=1S/C20H15N3O2S/c1-2-15(26-7-1)10-21-20-16-8-13(3-5-17(16)22-11-23-20)14-4-6-18-19(9-14)25-12-24-18/h1-9,11H,10,12H2,(H,21,22,23)
DMSX09A CS C1OC2=C(O1)C=C(C=C2)C3=CC4=C(C=C3)N=CN=C4NCC5=CC=CS5
DMSX09A IK QFBOPHGXTBOQRN-UHFFFAOYSA-N
DMSX09A IU 6-(1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)quinazolin-4-amine
DMSX09A CB CHEBI:93238
DMDUSN5 ID DMDUSN5
DMDUSN5 DN PMID28766366-Compound-Scheme8NCGC-00185981
DMDUSN5 HS Patented
DMDUSN5 CP Department of Health and Human Services (NIH, Bethesda, US)
DMDUSN5 DT Small molecular drug
DMUWZD9 ID DMUWZD9
DMUWZD9 DN PMID28766366-Compound-Scheme8NCGC-00189310
DMUWZD9 HS Patented
DMUWZD9 CP Department of Health and Human Services (NIH, Bethesda, US)
DMUWZD9 DT Small molecular drug
DMUWZD9 PC 46916176
DMUWZD9 MW 335.4
DMUWZD9 FM C20H21N3O2
DMUWZD9 IC InChI=1S/C20H21N3O2/c1-20(2,3)10-21-19-15-8-13(4-6-16(15)22-11-23-19)14-5-7-17-18(9-14)25-12-24-17/h4-9,11H,10,12H2,1-3H3,(H,21,22,23)
DMUWZD9 CS CC(C)(C)CNC1=NC=NC2=C1C=C(C=C2)C3=CC4=C(C=C3)OCO4
DMUWZD9 IK OSWHZHVVVZAPRN-UHFFFAOYSA-N
DMUWZD9 IU 6-(1,3-benzodioxol-5-yl)-N-(2,2-dimethylpropyl)quinazolin-4-amine
DMMZGC8 ID DMMZGC8
DMMZGC8 DN PMID28766366-Compound-Scheme9EHT1610
DMMZGC8 HS Patented
DMMZGC8 CP DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DMMZGC8 DT Small molecular drug
DMMZGC8 PC 71529602
DMMZGC8 MW 383.4
DMMZGC8 FM C18H14FN5O2S
DMMZGC8 IC InChI=1S/C18H14FN5O2S/c1-25-9-3-4-11(10(19)7-9)23-17-14-12(21-8-22-17)5-6-13-15(14)27-18(24-13)16(20)26-2/h3-8,20H,1-2H3,(H,21,22,23)
DMMZGC8 CS COC1=CC(=C(C=C1)NC2=NC=NC3=C2C4=C(C=C3)N=C(S4)C(=N)OC)F
DMMZGC8 IK RYBNARZBIXTFJS-UHFFFAOYSA-N
DMMZGC8 IU methyl 9-(2-fluoro-4-methoxyanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DMVBPML ID DMVBPML
DMVBPML DN PMID28766366-Compound-Scheme9EHT3356
DMVBPML HS Patented
DMVBPML CP DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DMVBPML DT Small molecular drug
DMVBPML PC 71529599
DMVBPML MW 349.4
DMVBPML FM C18H15N5OS
DMVBPML IC InChI=1S/C18H15N5OS/c1-10-3-5-11(6-4-10)22-17-14-12(20-9-21-17)7-8-13-15(14)25-18(23-13)16(19)24-2/h3-9,19H,1-2H3,(H,20,21,22)
DMVBPML CS CC1=CC=C(C=C1)NC2=NC=NC3=C2C4=C(C=C3)N=C(S4)C(=N)OC
DMVBPML IK AVKKQBJQERVCTD-UHFFFAOYSA-N
DMVBPML IU methyl 9-(4-methylanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DM0O18N ID DM0O18N
DM0O18N DN PMID28766366-Compound-Scheme9EHT5372
DM0O18N HS Patented
DM0O18N CP DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DM0O18N DT Small molecular drug
DM0O18N PC 71529610
DM0O18N MW 404.3
DM0O18N FM C17H11Cl2N5OS
DM0O18N IC InChI=1S/C17H11Cl2N5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DM0O18N CS COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)Cl)Cl
DM0O18N IK QSGKPYRFWJINEH-UHFFFAOYSA-N
DM0O18N IU methyl 9-(2,4-dichloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DMVY6PX ID DMVY6PX
DMVY6PX DN PMID28766366-Compound-Scheme9EHT6840
DMVY6PX HS Patented
DMVY6PX CP DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DMVY6PX DT Small molecular drug
DMVY6PX PC 71529609
DMVY6PX MW 387.8
DMVY6PX FM C17H11ClFN5OS
DMVY6PX IC InChI=1S/C17H11ClFN5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DMVY6PX CS COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)Cl)F
DMVY6PX IK RFRICXRVXVFZMF-UHFFFAOYSA-N
DMVY6PX IU methyl 9-(4-chloro-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DM7RPKM ID DM7RPKM
DM7RPKM DN PMID28766366-Compound-Scheme9EHT9851
DM7RPKM HS Patented
DM7RPKM CP DIAXONHIT LEBLOND, Bertrand CASAGRANDE, Anne-Sophie DESIRE, Laurent FOUCOURT, Alicia BESSON, Thierry
DM7RPKM DT Small molecular drug
DM7RPKM PC 71529622
DM7RPKM MW 371.4
DM7RPKM FM C17H11F2N5OS
DM7RPKM IC InChI=1S/C17H11F2N5OS/c1-25-15(20)17-24-12-5-4-11-13(14(12)26-17)16(22-7-21-11)23-10-3-2-8(18)6-9(10)19/h2-7,20H,1H3,(H,21,22,23)
DM7RPKM CS COC(=N)C1=NC2=C(S1)C3=C(C=C2)N=CN=C3NC4=C(C=C(C=C4)F)F
DM7RPKM IK VONVAHFLRYRXSJ-UHFFFAOYSA-N
DM7RPKM IU methyl 9-(2,4-difluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate
DMQJF15 ID DMQJF15
DMQJF15 DN PMID28870136-Compound-36
DMQJF15 HS Patented
DMQJF15 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMQJF15 DT Small molecular drug
DMQJF15 PC 64115
DMQJF15 MW 208.22
DMQJF15 FM C9H12N4O2
DMQJF15 IC InChI=1S/C9H12N4O2/c1-5-10-7-6(11(5)2)8(14)13(4)9(15)12(7)3/h1-4H3
DMQJF15 CS CC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C
DMQJF15 IK LFHHOHMIVKIHMG-UHFFFAOYSA-N
DMQJF15 IU 1,3,7,8-tetramethylpurine-2,6-dione
DMQJF15 CA CAS 832-66-6
DMAPMG2 ID DMAPMG2
DMAPMG2 DN PMID28870136-Compound-37
DMAPMG2 HS Patented
DMAPMG2 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMAPMG2 DT Small molecular drug
DMAPMG2 PC 134222455
DMAPMG2 MW 383.5
DMAPMG2 FM C21H29N5O2
DMAPMG2 IC InChI=1S/C21H29N5O2/c1-5-12-25(6-2)13-14-26-17(15-16-10-8-7-9-11-16)22-19-18(26)20(27)24(4)21(28)23(19)3/h7-11H,5-6,12-15H2,1-4H3
DMAPMG2 CS CCCN(CC)CCN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3
DMAPMG2 IK PKUZGRWGAWHGEF-UHFFFAOYSA-N
DMAPMG2 IU 8-benzyl-7-[2-[ethyl(propyl)amino]ethyl]-1,3-dimethylpurine-2,6-dione
DM67XSL ID DM67XSL
DM67XSL DN PMID28870136-Compound-38
DM67XSL HS Patented
DM67XSL CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM67XSL DT Small molecular drug
DM67XSL PC 1329
DM67XSL MW 304.39
DM67XSL FM C16H24N4O2
DM67XSL IC InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)
DM67XSL CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3CCCC3
DM67XSL IK FFBDFADSZUINTG-UHFFFAOYSA-N
DM67XSL IU 8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione
DM67XSL CA CAS 102146-07-6
DM67XSL CB CHEBI:73282
DMU18W6 ID DMU18W6
DMU18W6 DN PMID28870136-Compound-39
DMU18W6 HS Patented
DMU18W6 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMU18W6 DT Small molecular drug
DMJP0AG ID DMJP0AG
DMJP0AG DN PMID28870136-Compound-40
DMJP0AG HS Patented
DMJP0AG CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMJP0AG DT Small molecular drug
DMSWM9Q ID DMSWM9Q
DMSWM9Q DN PMID28870136-Compound-41
DMSWM9Q HS Patented
DMSWM9Q CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMSWM9Q DT Small molecular drug
DMSWM9Q PC 95030
DMSWM9Q MW 194.19
DMSWM9Q FM C8H10N4O2
DMSWM9Q IC InChI=1S/C8H10N4O2/c1-4-9-5-6(10-4)11(2)8(14)12(3)7(5)13/h1-3H3,(H,9,10)
DMSWM9Q CS CC1=NC2=C(N1)C(=O)N(C(=O)N2C)C
DMSWM9Q IK WZBKGWBHAPBSBF-UHFFFAOYSA-N
DMSWM9Q IU 1,3,8-trimethyl-7H-purine-2,6-dione
DMSWM9Q CA CAS 830-65-9
DMV0R2X ID DMV0R2X
DMV0R2X DN PMID28870136-Compound-42
DMV0R2X HS Patented
DMV0R2X CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMV0R2X DT Small molecular drug
DMWGV8N ID DMWGV8N
DMWGV8N DN PMID28870136-Compound-43
DMWGV8N HS Patented
DMWGV8N CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMWGV8N DT Small molecular drug
DMWGV8N PC 3182
DMWGV8N MW 254.24
DMWGV8N FM C10H14N4O4
DMWGV8N IC InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3
DMWGV8N CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
DMWGV8N IK KSCFJBIXMNOVSH-UHFFFAOYSA-N
DMWGV8N IU 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione
DMWGV8N CA CAS 479-18-5
DMWGV8N CB CHEBI:4728
DMNOAQB ID DMNOAQB
DMNOAQB DN PMID28870136-Compound-44
DMNOAQB HS Patented
DMNOAQB CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMNOAQB DT Small molecular drug
DMNOAQB PC 128784
DMNOAQB MW 312.37
DMNOAQB FM C17H20N4O2
DMNOAQB IC InChI=1S/C17H20N4O2/c1-3-10-20-15-13(16(22)21(11-4-2)17(20)23)18-14(19-15)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3,(H,18,19)
DMNOAQB CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=CC=C3
DMNOAQB IK CLIGSMOZKDCDRZ-UHFFFAOYSA-N
DMNOAQB IU 8-phenyl-1,3-dipropyl-7H-purine-2,6-dione
DMNOAQB CA CAS 85872-53-3
DMNOAQB CB CHEBI:107631
DM1QHV0 ID DM1QHV0
DM1QHV0 DN PMID28870136-Compound-45
DM1QHV0 HS Patented
DM1QHV0 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM1QHV0 DT Small molecular drug
DM4FD7C ID DM4FD7C
DM4FD7C DN PMID28870136-Compound-46
DM4FD7C HS Patented
DM4FD7C CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM4FD7C DT Small molecular drug
DMYWBRX ID DMYWBRX
DMYWBRX DN PMID28870136-Compound-47
DMYWBRX HS Patented
DMYWBRX CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMYWBRX DT Small molecular drug
DMYWBRX PC 1676
DMYWBRX MW 194.19
DMYWBRX FM C8H10N4O2
DMYWBRX IC InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
DMYWBRX CS CCCN1C2=C(C(=O)NC1=O)NC=N2
DMYWBRX IK SIQPXVQCUCHWDI-UHFFFAOYSA-N
DMYWBRX IU 3-propyl-7H-purine-2,6-dione
DMYWBRX CA CAS 41078-02-8
DMYWBRX CB CHEBI:126237
DMPIM9L ID DMPIM9L
DMPIM9L DN PMID28870136-Compound-48
DMPIM9L HS Patented
DMPIM9L CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMPIM9L DT Small molecular drug
DMPIM9L PC 2153
DMPIM9L MW 180.16
DMPIM9L FM C7H8N4O2
DMPIM9L IC InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
DMPIM9L CS CN1C2=C(C(=O)N(C1=O)C)NC=N2
DMPIM9L IK ZFXYFBGIUFBOJW-UHFFFAOYSA-N
DMPIM9L IU 1,3-dimethyl-7H-purine-2,6-dione
DMPIM9L CA CAS 58-55-9
DMPIM9L CB CHEBI:28177
DMTUC9E ID DMTUC9E
DMTUC9E DN PMID28870136-Compound-49
DMTUC9E HS Patented
DMTUC9E CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMTUC9E DT Small molecular drug
DMTUC9E PC 4740
DMTUC9E MW 278.31
DMTUC9E FM C13H18N4O3
DMTUC9E IC InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
DMTUC9E CS CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
DMTUC9E IK BYPFEZZEUUWMEJ-UHFFFAOYSA-N
DMTUC9E IU 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
DMTUC9E CA CAS 6493-05-6
DMTUC9E CB CHEBI:7986
DM42OYU ID DM42OYU
DM42OYU DN PMID28870136-Compound-50
DM42OYU HS Patented
DM42OYU CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM42OYU DT Small molecular drug
DM42OYU PC 5429
DM42OYU MW 180.16
DM42OYU FM C7H8N4O2
DM42OYU IC InChI=1S/C7H8N4O2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3H,1-2H3,(H,9,12,13)
DM42OYU CS CN1C=NC2=C1C(=O)NC(=O)N2C
DM42OYU IK YAPQBXQYLJRXSA-UHFFFAOYSA-N
DM42OYU IU 3,7-dimethylpurine-2,6-dione
DM42OYU CA CAS 83-67-0
DM42OYU CB CHEBI:28946
DMU3MQB ID DMU3MQB
DMU3MQB DN PMID28870136-Compound-51
DMU3MQB HS Patented
DMU3MQB CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMU3MQB DT Small molecular drug
DMFDERP ID DMFDERP
DMFDERP DN PMID28870136-Compound-52
DMFDERP HS Patented
DMFDERP CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMFDERP DT Small molecular drug
DMFDERP PC 2519
DMFDERP MW 194.19
DMFDERP FM C8H10N4O2
DMFDERP IC InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DMFDERP CS CN1C=NC2=C1C(=O)N(C(=O)N2C)C
DMFDERP IK RYYVLZVUVIJVGH-UHFFFAOYSA-N
DMFDERP IU 1,3,7-trimethylpurine-2,6-dione
DMFDERP CA CAS 58-08-2
DMFDERP CB CHEBI:27732
DMLEWY6 ID DMLEWY6
DMLEWY6 DN PMID28870136-Compound-53
DMLEWY6 HS Patented
DMLEWY6 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMLEWY6 DT Small molecular drug
DMLEWY6 PC 67565716
DMLEWY6 MW 292.4
DMLEWY6 FM C18H20N4
DMLEWY6 IC InChI=1S/C18H20N4/c1-3-7-13(8-4-1)16-21-17-15(11-12-19-17)18(22-16)20-14-9-5-2-6-10-14/h1,3-4,7-8,11-12,14H,2,5-6,9-10H2,(H2,19,20,21,22)
DMLEWY6 CS C1CCC(CC1)NC2=NC(=NC3=C2C=CN3)C4=CC=CC=C4
DMLEWY6 IK QWRCXRFAIZINSM-UHFFFAOYSA-N
DMLEWY6 IU N-cyclohexyl-2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
DM6HOES ID DM6HOES
DM6HOES DN PMID28870136-Compound-54
DM6HOES HS Patented
DM6HOES CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM6HOES DT Small molecular drug
DMVRJZX ID DMVRJZX
DMVRJZX DN PMID28870136-Compound-55
DMVRJZX HS Patented
DMVRJZX CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMVRJZX DT Small molecular drug
DMVRJZX PC 3007918
DMVRJZX MW 266.25
DMVRJZX FM C11H14N4O4
DMVRJZX IC InChI=1S/C11H14N4O4/c12-9-5-1-2-15(10(5)14-4-13-9)11-8(18)7(17)6(3-16)19-11/h1-2,4,6-8,11,16-18H,3H2,(H2,12,13,14)/t6-,7-,8+,11-/m1/s1
DMVRJZX CS C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O
DMVRJZX IK HDZZVAMISRMYHH-HGIWHZBTSA-N
DMVRJZX IU (2R,3S,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMVRJZX CA CAS 64526-34-7
DMK0RTV ID DMK0RTV
DMK0RTV DN PMID28870136-Compound-56
DMK0RTV HS Patented
DMK0RTV CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMK0RTV DT Small molecular drug
DME3HLC ID DME3HLC
DME3HLC DN PMID28870136-Compound-57
DME3HLC HS Patented
DME3HLC CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DME3HLC DT Small molecular drug
DME3HLC PC 135156846
DME3HLC MW 302.69
DME3HLC FM C11H12ClFN4O3
DME3HLC IC InChI=1S/C11H12ClFN4O3/c12-11-15-8(14)4-1-2-17(9(4)16-11)10-6(13)7(19)5(3-18)20-10/h1-2,5-7,10,18-19H,3H2,(H2,14,15,16)/t5-,6+,7-,10-/m1/s1
DME3HLC CS C1=CN(C2=NC(=NC(=C21)N)Cl)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F
DME3HLC IK VLXMLGCQJSJFSY-JTGULSINSA-N
DME3HLC IU (2R,3R,4S,5R)-5-(4-amino-2-chloropyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
DMQIUD9 ID DMQIUD9
DMQIUD9 DN PMID28870136-Compound-58
DMQIUD9 HS Patented
DMQIUD9 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMQIUD9 DT Small molecular drug
DMHP90Q ID DMHP90Q
DMHP90Q DN PMID28870136-Compound-59
DMHP90Q HS Patented
DMHP90Q CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMHP90Q DT Small molecular drug
DMHP90Q PC 3035594
DMHP90Q MW 374.4
DMHP90Q FM C21H18N4O3
DMHP90Q IC InChI=1S/C21H18N4O3/c26-18-12-11-16(22-25(18)14-6-10-19(27)28)20-17-9-4-5-13-24(17)23-21(20)15-7-2-1-3-8-15/h1-5,7-9,11-13H,6,10,14H2,(H,27,28)
DMHP90Q CS C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=NN(C(=O)C=C4)CCCC(=O)O
DMHP90Q IK FKJPZJACCBMNKZ-UHFFFAOYSA-N
DMHP90Q IU 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]butanoic acid
DMHP90Q CA CAS 131185-37-0
DM39QU8 ID DM39QU8
DM39QU8 DN PMID28870136-Compound-60
DM39QU8 HS Patented
DM39QU8 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM39QU8 DT Small molecular drug
DM39QU8 PC 11110698
DM39QU8 MW 344.4
DM39QU8 FM C20H16N4O2
DM39QU8 IC InChI=1S/C20H16N4O2/c1-14(25)13-24-18(26)11-10-16(21-24)19-17-9-5-6-12-23(17)22-20(19)15-7-3-2-4-8-15/h2-12H,13H2,1H3
DM39QU8 CS CC(=O)CN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DM39QU8 IK QATXIDMQXCGKIY-UHFFFAOYSA-N
DM39QU8 IU 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMFNU9D ID DMFNU9D
DMFNU9D DN PMID28870136-Compound-61
DMFNU9D HS Patented
DMFNU9D CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMFNU9D DT Small molecular drug
DMFNU9D PC 134222456
DMFNU9D MW 358.4
DMFNU9D FM C22H22N4O
DMFNU9D IC InChI=1S/C22H22N4O/c1-22(2,3)15-26-19(27)13-12-17(23-26)20-18-11-7-8-14-25(18)24-21(20)16-9-5-4-6-10-16/h4-14H,15H2,1-3H3
DMFNU9D CS CC(C)(C)CN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMFNU9D IK XGZUBYNARGEPRB-UHFFFAOYSA-N
DMFNU9D IU 2-(2,2-dimethylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMNKXJ2 ID DMNKXJ2
DMNKXJ2 DN PMID28870136-Compound-62
DMNKXJ2 HS Patented
DMNKXJ2 CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMNKXJ2 DT Small molecular drug
DMNKXJ2 PC 11110698
DMNKXJ2 MW 344.4
DMNKXJ2 FM C20H16N4O2
DMNKXJ2 IC InChI=1S/C20H16N4O2/c1-14(25)13-24-18(26)11-10-16(21-24)19-17-9-5-6-12-23(17)22-20(19)15-7-3-2-4-8-15/h2-12H,13H2,1H3
DMNKXJ2 CS CC(=O)CN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMNKXJ2 IK QATXIDMQXCGKIY-UHFFFAOYSA-N
DMNKXJ2 IU 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DM26WNY ID DM26WNY
DM26WNY DN PMID28870136-Compound-63
DM26WNY HS Patented
DM26WNY CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DM26WNY DT Small molecular drug
DM26WNY PC 10544406
DM26WNY MW 330.4
DM26WNY FM C20H18N4O
DM26WNY IC InChI=1S/C20H18N4O/c1-2-13-24-18(25)12-11-16(21-24)19-17-10-6-7-14-23(17)22-20(19)15-8-4-3-5-9-15/h3-12,14H,2,13H2,1H3
DM26WNY CS CCCN1C(=O)C=CC(=N1)C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DM26WNY IK ATTQDJZYFIDUQX-UHFFFAOYSA-N
DM26WNY IU 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propylpyridazin-3-one
DMBKSVH ID DMBKSVH
DMBKSVH DN PMID28870136-Compound-64
DMBKSVH HS Patented
DMBKSVH CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMBKSVH DT Small molecular drug
DMBKSVH PC 9821511
DMBKSVH MW 385.5
DMBKSVH FM C23H23N5O
DMBKSVH IC InChI=1S/C23H23N5O/c1-26-15-12-18(13-16-26)28-21(29)11-10-19(24-28)22-20-9-5-6-14-27(20)25-23(22)17-7-3-2-4-8-17/h2-11,14,18H,12-13,15-16H2,1H3
DMBKSVH CS CN1CCC(CC1)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMBKSVH IK YHDRUTMZCJZJAL-UHFFFAOYSA-N
DMBKSVH IU 2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMBKSVH CA CAS 202646-80-8
DMF5K9J ID DMF5K9J
DMF5K9J DN PMID28870136-Compound-65
DMF5K9J HS Patented
DMF5K9J CP ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC
DMF5K9J DT Small molecular drug
DMF5K9J PC 9821511
DMF5K9J MW 385.5
DMF5K9J FM C23H23N5O
DMF5K9J IC InChI=1S/C23H23N5O/c1-26-15-12-18(13-16-26)28-21(29)11-10-19(24-28)22-20-9-5-6-14-27(20)25-23(22)17-7-3-2-4-8-17/h2-11,14,18H,12-13,15-16H2,1H3
DMF5K9J CS CN1CCC(CC1)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMF5K9J IK YHDRUTMZCJZJAL-UHFFFAOYSA-N
DMF5K9J IU 2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMF5K9J CA CAS 202646-80-8
DME3YRI ID DME3YRI
DME3YRI DN PMID28870136-Compound-67
DME3YRI HS Patented
DME3YRI CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -,HOSPICES CIVILS DE LYON,ECOLE NORMALE SUPERIEURE DE LYON,UNIVERSITE CLAUDE BERNARD LYON 1,UNIVERSITE DE MONTPELLIER
DME3YRI DT Small molecular drug
DMFTM8X ID DMFTM8X
DMFTM8X DN PMID28870136-Compound-68
DMFTM8X HS Patented
DMFTM8X CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -,HOSPICES CIVILS DE LYON,ECOLE NORMALE SUPERIEURE DE LYON,UNIVERSITE CLAUDE BERNARD LYON 1,UNIVERSITE DE MONTPELLIER
DMFTM8X DT Small molecular drug
DMVCQKB ID DMVCQKB
DMVCQKB DN PMID28870136-Compound-69
DMVCQKB HS Patented
DMVCQKB CP CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -,HOSPICES CIVILS DE LYON,ECOLE NORMALE SUPERIEURE DE LYON,UNIVERSITE CLAUDE BERNARD LYON 1,UNIVERSITE DE MONTPELLIER
DMVCQKB DT Small molecular drug
DMECU90 ID DMECU90
DMECU90 DN PMID28906174-Compound-figure1g
DMECU90 HS Patented
DMECU90 CP Ixchelsis Ltd
DMECU90 DT Small molecular drug
DMLMHR5 ID DMLMHR5
DMLMHR5 DN PMID29053063-Compound-11c
DMLMHR5 HS Patented
DMLMHR5 CP ABIDE THERAPEUTICS, INC
DMLMHR5 DT Small molecular drug
DMLMHR5 PC 90467446
DMLMHR5 MW 472.4
DMLMHR5 FM C23H22F6N2O2
DMLMHR5 IC InChI=1S/C23H22F6N2O2/c24-22(25,26)20(23(27,28)29)33-21(32)31-13-18-11-30(12-19(18)14-31)10-15-6-8-17(9-7-15)16-4-2-1-3-5-16/h1-9,18-20H,10-14H2
DMLMHR5 CS C1C2CN(CC2CN1CC3=CC=C(C=C3)C4=CC=CC=C4)C(=O)OC(C(F)(F)F)C(F)(F)F
DMLMHR5 IK YPFURSFOBNHDRO-UHFFFAOYSA-N
DMLMHR5 IU 1,1,1,3,3,3-hexafluoropropan-2-yl 2-[(4-phenylphenyl)methyl]-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate
DMDRK68 ID DMDRK68
DMDRK68 DN PMID29053063-Compound-11d
DMDRK68 HS Patented
DMDRK68 CP ABIDE THERAPEUTICS, INC
DMDRK68 DT Small molecular drug
DMBR72X ID DMBR72X
DMBR72X DN PMID29053063-Compound-14
DMBR72X HS Patented
DMBR72X CP DR. AUGUST WOLFF GMBH &amCO. KG ARZNEIMITTEL
DMBR72X DT Small molecular drug
DM07U5R ID DM07U5R
DM07U5R DN PMID29053063-Compound-15
DM07U5R HS Patented
DM07U5R CP NORTHEASTERN UNIVERSITY
DM07U5R DT Small molecular drug
DMRHPN0 ID DMRHPN0
DMRHPN0 DN PMID29053063-Compound-17
DMRHPN0 HS Patented
DMRHPN0 CP INFINITY PHARMACEUTICALS, INC
DMRHPN0 DT Small molecular drug
DM8RAK0 ID DM8RAK0
DM8RAK0 DN PMID29053063-Compound-4
DM8RAK0 HS Patented
DM8RAK0 CP INSERM INST NAT DE LA SANT ET DE LA RECH M DICALE [FRUNIVERSIT PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
DM8RAK0 DT Small molecular drug
DM2P05S ID DM2P05S
DM2P05S DN PMID29053063-Compound-5
DM2P05S HS Patented
DM2P05S CP INSERM INST NAT DE LA SANT ET DE LA RECH M DICALE [FRUNIVERSIT PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
DM2P05S DT Small molecular drug
DMTOHNQ ID DMTOHNQ
DMTOHNQ DN PMID29053063-Compound-7a
DMTOHNQ HS Patented
DMTOHNQ CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTOHNQ DT Small molecular drug
DMDJ6O8 ID DMDJ6O8
DMDJ6O8 DN PMID29053063-Compound-7b
DMDJ6O8 HS Patented
DMDJ6O8 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMDJ6O8 DT Small molecular drug
DMNZO7V ID DMNZO7V
DMNZO7V DN PMID29053063-Compound-7c
DMNZO7V HS Patented
DMNZO7V CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMNZO7V DT Small molecular drug
DMUNXAR ID DMUNXAR
DMUNXAR DN PMID29053063-Compound-7d
DMUNXAR HS Patented
DMUNXAR CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMUNXAR DT Small molecular drug
DM6XYFB ID DM6XYFB
DM6XYFB DN PMID29053063-Compound-7e
DM6XYFB HS Patented
DM6XYFB CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DM6XYFB DT Small molecular drug
DM6XYFB PC 118196736
DM6XYFB MW 539.6
DM6XYFB FM C27H24F3N5O2S
DM6XYFB IC InChI=1S/C27H24F3N5O2S/c28-27(29,30)19-1-3-20(4-2-19)34-8-7-18-13-21(5-6-24(18)34)35-15-22(14-25(35)36)32-9-11-33(12-10-32)26(37)23-16-38-17-31-23/h1-8,13,16-17,22H,9-12,14-15H2/t22-/m1/s1
DM6XYFB CS C1CN(CCN1[C@@H]2CC(=O)N(C2)C3=CC4=C(C=C3)N(C=C4)C5=CC=C(C=C5)C(F)(F)F)C(=O)C6=CSC=N6
DM6XYFB IK ACWGPXVJPMRMHD-JOCHJYFZSA-N
DM6XYFB IU (4R)-4-[4-(1,3-thiazole-4-carbonyl)piperazin-1-yl]-1-[1-[4-(trifluoromethyl)phenyl]indol-5-yl]pyrrolidin-2-one
DMIQ263 ID DMIQ263
DMIQ263 DN PMID29053063-Compound-7f
DMIQ263 HS Patented
DMIQ263 CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMIQ263 DT Small molecular drug
DMFWXPS ID DMFWXPS
DMFWXPS DN PMID29130358-Compound-Figure10(2a)
DMFWXPS HS Patented
DMFWXPS DT Small molecular drug
DMSME2B ID DMSME2B
DMSME2B DN PMID29130358-Compound-Figure11(3)
DMSME2B HS Patented
DMSME2B DT Small molecular drug
DMDFPIO ID DMDFPIO
DMDFPIO DN PMID29130358-Compound-Figure13(4)
DMDFPIO HS Patented
DMDFPIO DT Small molecular drug
DMB6KS9 ID DMB6KS9
DMB6KS9 DN PMID29130358-Compound-Figure14(5)
DMB6KS9 HS Patented
DMB6KS9 CP UNIVERSITY OF NOTRE DAME DU LAC CHANG, Mayland MOBASHERY, Shahriar LEE, Mijoon
DMB6KS9 DT Small molecular drug
DMFMJIN ID DMFMJIN
DMFMJIN DN PMID29130358-Compound-Figure14(6)
DMFMJIN HS Patented
DMFMJIN CP UNIVERSITY OF NOTRE DAME DU LAC
DMFMJIN DT Small molecular drug
DM85ETX ID DM85ETX
DM85ETX DN PMID29130358-Compound-Figure15(7)
DM85ETX HS Patented
DM85ETX DT Small molecular drug
DML8FUD ID DML8FUD
DML8FUD DN PMID29130358-Compound-Figure15(8)
DML8FUD HS Patented
DML8FUD DT Small molecular drug
DMKX5R8 ID DMKX5R8
DMKX5R8 DN PMID29130358-Compound-Figure16(9a)
DMKX5R8 HS Patented
DMKX5R8 DT Small molecular drug
DMKX5R8 PC 58107501
DMKX5R8 MW 388.7
DMKX5R8 FM C14H11BrClNO3S
DMKX5R8 IC InChI=1S/C14H11BrClNO3S/c1-8-2-4-10(11(15)6-8)14(18)9-3-5-12(16)13(7-9)21(17,19)20/h2-7H,1H3,(H2,17,19,20)
DMKX5R8 CS CC1=CC(=C(C=C1)C(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N)Br
DMKX5R8 IK IWYFDCPQQNBMTJ-UHFFFAOYSA-N
DMKX5R8 IU 5-(2-bromo-4-methylbenzoyl)-2-chlorobenzenesulfonamide
DMPAQLZ ID DMPAQLZ
DMPAQLZ DN PMID29130358-Compound-Figure16(9b)
DMPAQLZ HS Patented
DMPAQLZ DT Small molecular drug
DM0ZRI9 ID DM0ZRI9
DM0ZRI9 DN PMID29130358-Compound-Figure16(9c)
DM0ZRI9 HS Patented
DM0ZRI9 DT Small molecular drug
DMVA15O ID DMVA15O
DMVA15O DN PMID29130358-Compound-Figure17(10)
DMVA15O HS Patented
DMVA15O CP RANBAXY LABORATORIES LIMITED KHERA, Manoj, Kumar SATTIGERI, Jitendra SATTIGERI, Viswajanani YADAV, Neeraj, Kumar KUMAR, Kewal RAUF, Abdul, Rehman, Abdul CLIFFE, Ian, A. BHATNAGAR, Pradip, Kumar RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda, Ghosh
DMVA15O DT Small molecular drug
DMSZA9L ID DMSZA9L
DMSZA9L DN PMID29130358-Compound-Figure17(11)
DMSZA9L HS Patented
DMSZA9L CP RANBAXY LABORATORIES LIMITED KHERA, Manoj Kumar SONI, Ajay SATTIGERI, Jitendra SATTIGERI, Viswajanani DAS, Biswajit CLIFFE, Ian A. BHATNAGAR, Pradip Kumar RAUF, Abdul Rehman Abdul MUSIB, Arpita SAHA, Subham YADAV, Neeraj Kumar AHAMMED, Sabir REDDY, Ranadheer R. RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda Ghosh
DMSZA9L DT Small molecular drug
DMML4PA ID DMML4PA
DMML4PA DN PMID29130358-Compound-Figure17(12)
DMML4PA HS Patented
DMML4PA CP RANBAXY LABORATORIES LIMITED KHERA, Manoj Kumar PALLE, Venkata P. SATTIGERI, Viswajanani SATTIGERI, Jitendra SONI, Ajay RAUF, Abdul Rehman Abdul SIVAKUMAR, R. REDDY, Ranadheer R. MUSIB, Arpita CLIFFE, Ian A. BHATNAGAR, Pradip Kumar RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda Ghosh
DMML4PA DT Small molecular drug
DM2QRIW ID DM2QRIW
DM2QRIW DN PMID29130358-Compound-Figure17(13)
DM2QRIW HS Patented
DM2QRIW CP RANBAXY LABORATORIES LIMITED KHERA, Manoj Kumar SATTIGERI, Jitendra YADAV, Neeraj Kumar RAUF, Abdul Rehman Abdul CLIFFE, Ian A. BHATNAGAR, Pradip Kumar RAY, Abhijit SRIVASTAVA, Punit DASTIDAR, Sunanda Ghosh
DM2QRIW DT Small molecular drug
DM7WXJ9 ID DM7WXJ9
DM7WXJ9 DN PMID29130358-Compound-Figure18(14)
DM7WXJ9 HS Patented
DM7WXJ9 CP PHARMAHUNGARY 2000 KFT [HUINFARMATIK KFT [HUTARGETEX KFT [HU]
DM7WXJ9 DT Small molecular drug
DMHIBTZ ID DMHIBTZ
DMHIBTZ DN PMID29130358-Compound-Figure18(14a)
DMHIBTZ HS Patented
DMHIBTZ CP PHARMAHUNGARY 2000 KFT [HUINFARMATIK KFT [HUTARGETEX KFT [HU]
DMHIBTZ DT Small molecular drug
DMMX5I6 ID DMMX5I6
DMMX5I6 DN PMID29130358-Compound-Figure9(1)
DMMX5I6 HS Patented
DMMX5I6 DT Small molecular drug
DMTJEU5 ID DMTJEU5
DMTJEU5 DN PMID29130358-Compound-LonimacranthoideVI
DMTJEU5 HS Patented
DMTJEU5 DT Small molecular drug
DMOGIAU ID DMOGIAU
DMOGIAU DN PMID29130358-Compound-LonimacranthoideVII
DMOGIAU HS Patented
DMOGIAU DT Small molecular drug
DMC64XQ ID DMC64XQ
DMC64XQ DN PMID29130358-Compound-SB-3CT
DMC64XQ HS Patented
DMC64XQ DT Small molecular drug
DMDN4KP ID DMDN4KP
DMDN4KP DN PMID29166791-Compound-AMPCP
DMDN4KP HS Patented
DMDN4KP CP ARCUS BIOSCIENCES, INCVITAE PHARMACEUTICALS, INC
DMDN4KP DT Small molecular drug
DM0DAR1 ID DM0DAR1
DM0DAR1 DN PMID29324067-Compound-25
DM0DAR1 HS Patented
DM0DAR1 DT Small molecular drug
DMPXZYN ID DMPXZYN
DMPXZYN DN PMID29324067-Compound-38
DMPXZYN HS Patented
DMPXZYN DT Small molecular drug
DM69A05 ID DM69A05
DM69A05 DN PMID29324067-Compound-40
DM69A05 HS Patented
DM69A05 DT Small molecular drug
DMTOA1Q ID DMTOA1Q
DMTOA1Q DN PMID29334795-Compound-21
DMTOA1Q HS Patented
DMTOA1Q CP SANOFSANOFI LANGEVIN, Beverly C. FARR, Robert Allan SHAH, Dinubhai H. SHERER, DanieSANOFI-AVENTIS DIAZ MARTIN, Juan Antonio JIMENEZ BARGUENO, Maria Dolores
DMTOA1Q DT Small molecular drug
DMTOA1Q DE Progressive supranuclear palsy; Corticobasal degeneration
DM8N10A ID DM8N10A
DM8N10A DN PMID29334795-Compound-22
DM8N10A HS Patented
DM8N10A CP LES LABORATOIRES SERVIELES LABORATOIRES SERVIER ROBERT, Nicolas LERESTIF, Jean-Michel LECOUVE, Jean-Pierre GAILLARD, Marina DELCROIX - MEUNIER, Julie LETELLIER, Philippe BOIRET, MathieLES LABORATOIRES SERVIER TROCME-THIBIERGE, Caryn SORS, Aurore KEIME GUIBERT, FlorencLES LABORATOIRES SERVIER CASARA, Patrick CHOLLET, Anne-Marie DHAINAUT, Alain BERT, Lionel LESTAGE, Pierre LOCKHART, Brian
DM8N10A DT Small molecular drug
DM8N10A DE Neuropathic pain; Alzheimer disease
DM3VL64 ID DM3VL64
DM3VL64 DN PMID29334795-Compound-23
DM3VL64 HS Patented
DM3VL64 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAMFORD, Mark, James DEAN, David, Kenneth SEHMI, Sanjeet, Singh WILSON, David, Matthew WITHERINGTON, Jason
DM3VL64 DT Small molecular drug
DM3VL64 PC 9976892
DM3VL64 MW 377.5
DM3VL64 FM C23H27N3O2
DM3VL64 IC InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
DM3VL64 CS C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
DM3VL64 IK YFRBKEVUUCQYOW-UHFFFAOYSA-N
DM3VL64 IU 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
DM3VL64 CA CAS 720691-69-0
DM3VL64 DE Schizophrenia
DMTUQV0 ID DMTUQV0
DMTUQV0 DN PMID29334795-Compound-24
DMTUQV0 HS Patented
DMTUQV0 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAILEY, James, Matthew BRUTON, Gordon HUXLEY, Anthony MILNER, Peter, Henry ORLEK, Barry, Sidney
DMTUQV0 DT Small molecular drug
DMTUQV0 PC 69354506
DMTUQV0 MW 327.5
DMTUQV0 FM C20H29N3O
DMTUQV0 IC InChI=1S/C20H29N3O/c1-16(2)22-11-7-19(8-12-22)24-20-9-13-23(14-10-20)18-5-3-17(15-21)4-6-18/h3-6,16,19-20H,7-14H2,1-2H3
DMTUQV0 CS CC(C)N1CCC(CC1)OC2CCN(CC2)C3=CC=C(C=C3)C#N
DMTUQV0 IK RIRWRSQXDDJXDS-UHFFFAOYSA-N
DMTUQV0 IU 4-[4-(1-propan-2-ylpiperidin-4-yl)oxypiperidin-1-yl]benzonitrile
DMGEWVP ID DMGEWVP
DMGEWVP DN PMID29334795-Compound-25
DMGEWVP HS Patented
DMGEWVP CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, Hongtao
DMGEWVP DT Small molecular drug
DMGEWVP PC 71664257
DMGEWVP MW 341.4
DMGEWVP FM C19H23N3O3
DMGEWVP IC InChI=1S/C19H23N3O3/c1-2-15(3-1)22-8-6-13(7-9-22)10-18-20-19(21-25-18)14-4-5-16-17(11-14)24-12-23-16/h4-5,11,13,15H,1-3,6-10,12H2
DMGEWVP CS C1CC(C1)N2CCC(CC2)CC3=NC(=NO3)C4=CC5=C(C=C4)OCO5
DMGEWVP IK ATGQONNRRWKPGJ-UHFFFAOYSA-N
DMGEWVP IU 3-(1,3-benzodioxol-5-yl)-5-[(1-cyclobutylpiperidin-4-yl)methyl]-1,2,4-oxadiazole
DM1SWYU ID DM1SWYU
DM1SWYU DN PMID29334795-Compound-28
DM1SWYU HS Patented
DM1SWYU CP ARENA PHARMACEUTICALS, INC
DM1SWYU DT Small molecular drug
DM1SWYU DE Histamine H3-associated disorder
DMM30LJ ID DMM30LJ
DMM30LJ DN PMID29334795-Compound-55
DMM30LJ HS Patented
DMM30LJ CP TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMM30LJ DT Small molecular drug
DMM30LJ PC 71271072
DMM30LJ MW 369.5
DMM30LJ FM C24H35NO2
DMM30LJ IC InChI=1S/C24H35NO2/c1-27-23-11-14-24(26,15-12-23)21-9-7-20(8-10-21)18-19-4-3-16-25(17-13-19)22-5-2-6-22/h7-10,18,22-23,26H,2-6,11-17H2,1H3/b19-18+
DMM30LJ CS COC1CCC(CC1)(C2=CC=C(C=C2)/C=C/3\\CCCN(CC3)C4CCC4)O
DMM30LJ IK CVCLZBKTZVQEGU-VHEBQXMUSA-N
DMM30LJ IU 1-[4-[(E)-(1-cyclobutylazepan-4-ylidene)methyl]phenyl]-4-methoxycyclohexan-1-ol
DMS9Q3U ID DMS9Q3U
DMS9Q3U DN PMID29334795-Compound-56
DMS9Q3U HS Patented
DMS9Q3U CP TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMS9Q3U DT Small molecular drug
DMS9Q3U PC 71271008
DMS9Q3U MW 355.5
DMS9Q3U FM C23H33NO2
DMS9Q3U IC InChI=1S/C23H33NO2/c1-26-22-9-13-23(25,14-10-22)20-7-5-18(6-8-20)17-19-11-15-24(16-12-19)21-3-2-4-21/h5-8,17,21-22,25H,2-4,9-16H2,1H3
DMS9Q3U CS COC1CCC(CC1)(C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4)O
DMS9Q3U IK PTJSNMGOBXREIH-UHFFFAOYSA-N
DMS9Q3U IU 1-[4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl]-4-methoxycyclohexan-1-ol
DMGO1PA ID DMGO1PA
DMGO1PA DN PMID29334795-Compound-57
DMGO1PA HS Patented
DMGO1PA CP TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMGO1PA DT Small molecular drug
DMGO1PA PC 71271826
DMGO1PA MW 307.4
DMGO1PA FM C20H25N3
DMGO1PA IC InChI=1S/C20H25N3/c1-22-15-19(14-21-22)18-7-5-16(6-8-18)13-17-9-11-23(12-10-17)20-3-2-4-20/h5-8,13-15,20H,2-4,9-12H2,1H3
DMGO1PA CS CN1C=C(C=N1)C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4
DMGO1PA IK JKRRUTHXHYUIML-UHFFFAOYSA-N
DMGO1PA IU 1-cyclobutyl-4-[[4-(1-methylpyrazol-4-yl)phenyl]methylidene]piperidine
DMB8GHJ ID DMB8GHJ
DMB8GHJ DN PMID29334795-Compound-58
DMB8GHJ HS Patented
DMB8GHJ CP TAKEDA PHARMACEUTICAL COMPANY LIMITED RUPRAH, Parminder, Kaur MERCHANT, Kevin, John WALSH, Louise, Marie KERR, Catrina, Morven FIELDHOUSE, Charlotte HARRISSON, David MAINE, Stephanie HAZEL, Katherine
DMB8GHJ DT Small molecular drug
DMB8GHJ PC 71271057
DMB8GHJ MW 325.5
DMB8GHJ FM C22H31NO
DMB8GHJ IC InChI=1S/C22H31NO/c24-22(19-4-1-2-5-19)20-10-8-17(9-11-20)16-18-12-14-23(15-13-18)21-6-3-7-21/h8-11,16,19,21-22,24H,1-7,12-15H2
DMB8GHJ CS C1CCC(C1)C(C2=CC=C(C=C2)C=C3CCN(CC3)C4CCC4)O
DMB8GHJ IK UWSZCEKCJNGAAH-UHFFFAOYSA-N
DMB8GHJ IU [4-[(1-cyclobutylpiperidin-4-ylidene)methyl]phenyl]-cyclopentylmethanol
DM9H3LI ID DM9H3LI
DM9H3LI DN PMID29334795-Compound-61
DM9H3LI HS Patented
DM9H3LI DT Small molecular drug
DM9H3LI PC 122460116
DM9H3LI MW 411.6
DM9H3LI FM C25H34FN3O
DM9H3LI IC InChI=1S/C25H34FN3O/c1-27(2)12-4-11-25(22-6-8-23(26)9-7-22)24-10-5-20(17-21(24)19-30-25)18-29-15-13-28(3)14-16-29/h5-10,17H,4,11-16,18-19H2,1-3H3
DM9H3LI CS CN1CCN(CC1)CC2=CC3=C(C=C2)C(OC3)(CCCN(C)C)C4=CC=C(C=C4)F
DM9H3LI IK SJDALWQXTPZZQB-UHFFFAOYSA-N
DM9H3LI IU 3-[1-(4-fluorophenyl)-5-[(4-methylpiperazin-1-yl)methyl]-3H-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine
DMKAFPC ID DMKAFPC
DMKAFPC DN PMID29334795-Compound-62
DMKAFPC HS Patented
DMKAFPC CP AAPA B.V
DMKAFPC DT Small molecular drug
DMKAFPC PC 71819442
DMKAFPC MW 452.5
DMKAFPC FM C25H32N4O4
DMKAFPC IC InChI=1S/C25H32N4O4/c30-25-26-22-3-1-4-23(24(22)33-25)29-12-10-27(11-13-29)9-2-16-32-21-7-5-20(6-8-21)19-28-14-17-31-18-15-28/h1,3-8H,2,9-19H2,(H,26,30)
DMKAFPC CS C1CN(CCN1CCCOC2=CC=C(C=C2)CN3CCOCC3)C4=CC=CC5=C4OC(=O)N5
DMKAFPC IK JHTDAMZJAOPBAK-UHFFFAOYSA-N
DMKAFPC IU 7-[4-[3-[4-(morpholin-4-ylmethyl)phenoxy]propyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DMQOF53 ID DMQOF53
DMQOF53 DN PMID29334795-Compound-66
DMQOF53 HS Patented
DMQOF53 CP AAPA B.V
DMQOF53 DT Small molecular drug
DMQOF53 PC 118063527
DMQOF53 MW 462.6
DMQOF53 FM C27H34N4O3
DMQOF53 IC InChI=1S/C27H34N4O3/c32-27-28-24-5-2-6-25(26(24)34-27)31-17-15-29(16-18-31)19-20-7-9-22(10-8-20)33-23-11-13-30(14-12-23)21-3-1-4-21/h2,5-10,21,23H,1,3-4,11-19H2,(H,28,32)
DMQOF53 CS C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)CN4CCN(CC4)C5=CC=CC6=C5OC(=O)N6
DMQOF53 IK MCJUAFCGICUNIN-UHFFFAOYSA-N
DMQOF53 IU 7-[4-[[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DMC95N7 ID DMC95N7
DMC95N7 DN PMID29334795-Compound-67
DMC95N7 HS Patented
DMC95N7 CP AAPA B.V
DMC95N7 DT Small molecular drug
DMC95N7 PC 118064808
DMC95N7 MW 504.7
DMC95N7 FM C30H40N4O3
DMC95N7 IC InChI=1S/C30H40N4O3/c1-22-30(35)31(2)27-7-4-8-28(29(27)36-22)34-19-17-32(18-20-34)21-23-9-11-25(12-10-23)37-26-13-15-33(16-14-26)24-5-3-6-24/h4,7-12,22,24,26H,3,5-6,13-21H2,1-2H3
DMC95N7 CS CC1C(=O)N(C2=C(O1)C(=CC=C2)N3CCN(CC3)CC4=CC=C(C=C4)OC5CCN(CC5)C6CCC6)C
DMC95N7 IK FPIGKLIJDSBXLG-UHFFFAOYSA-N
DMC95N7 IU 8-[4-[[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]methyl]piperazin-1-yl]-2,4-dimethyl-1,4-benzoxazin-3-one
DMDJFUX ID DMDJFUX
DMDJFUX DN PMID29338548-Compound-13
DMDJFUX HS Patented
DMDJFUX CP GLAXO GROUP LIMITED BRADLEY, Daniel, Marcus BRANCH, Clive, Leslie CHAN, Wai, Ngor COULTON, Steven GILPIN, Martin, Leonard HARRIS, Andrew, Jonathan JAXA-CHAMIEC, Albert, Andrzej LAI, Justine, Yeun, Quai MARSHALL, Howard, Robert MACRITCHIE, Jacqueline, Anne NASH, David, John PORTER, Roderick, Alan SPADA, Simone THEWLIS, Kevin, Michael WARD, Simon, Edward
DMDJFUX DT Small molecular drug
DMDJFUX DE Schizophrenia
DMXIO9A ID DMXIO9A
DMXIO9A DN PMID29338548-Compound-14
DMXIO9A HS Patented
DMXIO9A DT Small molecular drug
DM6J0Z8 ID DM6J0Z8
DM6J0Z8 DN PMID29338548-Compound-15
DM6J0Z8 HS Patented
DM6J0Z8 DT Small molecular drug
DMQNVUB ID DMQNVUB
DMQNVUB DN PMID29338548-Compound-16
DMQNVUB HS Patented
DMQNVUB CP F. HOFFMANN-LA ROCHE AG KOLCZEWSKI, Sabine PINARD, Emmanuel
DMQNVUB DT Small molecular drug
DMQNVUB PC 58567900
DMQNVUB MW 478.6
DMQNVUB FM C25H29F3N2O2S
DMQNVUB IC InChI=1S/C25H29F3N2O2S/c1-32-19-15-18(25(26,27)28)16-20(33-2)22(19)23(31)29-24(17-9-4-3-5-10-17)12-8-14-30-13-7-6-11-21(24)30/h3-5,9-10,15-16,21H,6-8,11-14H2,1-2H3,(H,29,31)/t21-,24+/m1/s1
DMQNVUB CS COC1=C(C(=CC(=C1)C(F)(F)F)SC)C(=O)N[C@@]2(CCCN3[C@@H]2CCCC3)C4=CC=CC=C4
DMQNVUB IK VEQWRPXCFYIVLR-QPPBQGQZSA-N
DMQNVUB IU N-[(1S,9aR)-1-phenyl-2,3,4,6,7,8,9,9a-octahydroquinolizin-1-yl]-2-methoxy-6-methylsulfanyl-4-(trifluoromethyl)benzamide
DMFXCPQ ID DMFXCPQ
DMFXCPQ DN PMID29338548-Compound-17
DMFXCPQ HS Patented
DMFXCPQ CP F. HOFFMANN-LA ROCHE AG
DMFXCPQ DT Small molecular drug
DM0XA3D ID DM0XA3D
DM0XA3D DN PMID29338548-Compound-18
DM0XA3D HS Patented
DM0XA3D CP F. HOFFMANN-LA ROCHE AG
DM0XA3D DT Small molecular drug
DMKHTE1 ID DMKHTE1
DMKHTE1 DN PMID29338548-Compound-19
DMKHTE1 HS Patented
DMKHTE1 CP F. HOFFMANN-LA ROCHE AG KOLCZEWSKI, Sabine PINARD, Emmanuel
DMKHTE1 DT Small molecular drug
DMZ3EHV ID DMZ3EHV
DMZ3EHV DN PMID29338548-Compound-20
DMZ3EHV HS Patented
DMZ3EHV DT Small molecular drug
DMRTBKC ID DMRTBKC
DMRTBKC DN PMID29338548-Compound-21
DMRTBKC HS Patented
DMRTBKC CP ALBANY MOLECULAR RESEARCH, INC. CIOFFI, Christopher, L. WOLF, Mark, A. GUZZO, Peter, R. LIU, Shuang SADALAPURE, Kashinath PARTHASARATHY, Visweswaren MAENG, Jun-ho
DMRTBKC DT Small molecular drug
DMRTBKC DE Schizophrenia
DMT3AL5 ID DMT3AL5
DMT3AL5 DN PMID29338548-Compound-22
DMT3AL5 HS Patented
DMT3AL5 CP ALBANY MOLECULAR RESEARCH, INC. CIOFFI, Christopher, L. WOLF, Mark, A. GUZZO, Peter, R. LIU, Shuang SADALAPURE, Kashinath PARTHASARATHY, Visweswaren MAENG, Jun-ho
DMT3AL5 DT Small molecular drug
DMTA3D8 ID DMTA3D8
DMTA3D8 DN PMID29338548-Compound-23
DMTA3D8 HS Patented
DMTA3D8 CP ALBANY MOLECULAR RESEARCH, INC. CIOFFI, Christopher, L. WOLF, Mark, A. GUZZO, Peter, R. LIU, Shuang SADALAPURE, Kashinath PARTHASARATHY, Visweswaren MAENG, Jun-ho
DMTA3D8 DT Small molecular drug
DMWRGOX ID DMWRGOX
DMWRGOX DN PMID29338548-Compound-24
DMWRGOX HS Patented
DMWRGOX CP ABBOTT GMBH &amCO. KG ABBOTT LABORATORIES AMBERG, Wilhelm OCHSE, Michael LANGE, Udo BEHL, Berthold HORNBERGER, Wilfried MEZLER, Mario POHLKI, Frauke TURNER, Sean HUTCHINS, Charles
DMWRGOX DT Small molecular drug
DM83LWC ID DM83LWC
DM83LWC DN PMID29338548-Compound-25
DM83LWC HS Patented
DM83LWC DT Small molecular drug
DMT2D5H ID DMT2D5H
DMT2D5H DN PMID29338548-Compound-26
DMT2D5H HS Patented
DMT2D5H CP ABBVIE DEUTSCHLAND [DEABBVIE INC [US]
DMT2D5H DT Small molecular drug
DMNW37Y ID DMNW37Y
DMNW37Y DN PMID29338548-Compound-27
DMNW37Y HS Patented
DMNW37Y CP ABBVIE DEUTSCHLAND GMBH &amCO. KG ABBVIE INC. AMBERG, Wilhelm LANGE, Udo OCHSE, Michael POHLKI, Frauke BEHL, Berthold MEZLER, Mario HORNBERGER, Wilfried HUTCHINS, Charles W
DMNW37Y DT Small molecular drug
DMNBT3K ID DMNBT3K
DMNBT3K DN PMID29338548-Compound-28
DMNBT3K HS Patented
DMNBT3K CP ABBOTT GMBH & CO. KG LANGE, Udo HEUTLING, Andreas AMBERG, Wilhelm OCHSE, Michael BEHL, Berthold HORNBERGER, Wilfried MEZLER, Mario
DMNBT3K DT Small molecular drug
DMUGC53 ID DMUGC53
DMUGC53 DN PMID29338548-Compound-29
DMUGC53 HS Patented
DMUGC53 CP ABBVIE DEUTSCHLAND GMBH &amCO. KG ABBVIE INC
DMUGC53 DT Small molecular drug
DM8JK2D ID DM8JK2D
DM8JK2D DN PMID29338548-Compound-30
DM8JK2D HS Patented
DM8JK2D DT Small molecular drug
DMWMPE2 ID DMWMPE2
DMWMPE2 DN PMID29338548-Compound-31
DMWMPE2 HS Patented
DMWMPE2 CP ABBVIE DEUTSCHLAND GMBH & CO. KG ABBVIE INC
DMWMPE2 DT Small molecular drug
DM4Q5SW ID DM4Q5SW
DM4Q5SW DN PMID29338548-Compound-33
DM4Q5SW HS Patented
DM4Q5SW CP TAISHO PHARMACEUTICAL CO., LTD. YASUHARA, Akito SAKAGAMI, Kazunari OHTA, Hiroshi HAYASHI, Masato SHIRASAKI, Yoshihisa YAMAMOTO, Shuji SHIMAZAKI, Youichi ARAKI, Yuko ABE, Kumi SUN, Xiang-Min
DM4Q5SW DT Small molecular drug
DM839NQ ID DM839NQ
DM839NQ DN PMID29338548-Compound-34
DM839NQ HS Patented
DM839NQ DT Small molecular drug
DMG675B ID DMG675B
DMG675B DN PMID29338548-Compound-36
DMG675B HS Patented
DMG675B CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH GIOVANNINI, Riccardo BERTANI, Barbara FERRARA, Marco LINGARD, Iain MAZZAFERRO, Rocco ROSENBROCK, Holger
DMG675B DT Small molecular drug
DMAM0US ID DMAM0US
DMAM0US DN PMID29338548-Compound-37
DMAM0US HS Patented
DMAM0US CP DART NEUROSCIENCE (CAYMAN) LTD
DMAM0US DT Small molecular drug
DM6BKQ8 ID DM6BKQ8
DM6BKQ8 DN PMID29338548-Compound-38
DM6BKQ8 HS Patented
DM6BKQ8 CP DART NEUROSCIENCE (CAYMAN) LTD
DM6BKQ8 DT Small molecular drug
DM69Y7R ID DM69Y7R
DM69Y7R DN PMID29338548-Compound-39
DM69Y7R HS Patented
DM69Y7R DT Small molecular drug
DMLAHC1 ID DMLAHC1
DMLAHC1 DN PMID29338548-Compound-40
DMLAHC1 HS Patented
DMLAHC1 DT Small molecular drug
DM2L7ES ID DM2L7ES
DM2L7ES DN PMID29338548-Compound-41
DM2L7ES HS Patented
DM2L7ES DT Small molecular drug
DMJYQLC ID DMJYQLC
DMJYQLC DN PMID29338548-Compound-44
DMJYQLC HS Patented
DMJYQLC DT Small molecular drug
DMO4JYK ID DMO4JYK
DMO4JYK DN PMID29338548-Compound-45
DMO4JYK HS Patented
DMO4JYK CP TAISHO PHARMA CO LTD [JP]
DMO4JYK DT Small molecular drug
DMRKIA1 ID DMRKIA1
DMRKIA1 DN PMID29338548-Compound-46
DMRKIA1 HS Patented
DMRKIA1 CP TAISHO PHARMA CO LTD [JP]
DMRKIA1 DT Small molecular drug
DMHBOK6 ID DMHBOK6
DMHBOK6 DN PMID29338548-Compound-47
DMHBOK6 HS Patented
DMHBOK6 CP TAISHO PHARMA CO LTD [JP]
DMHBOK6 DT Small molecular drug
DMDRJHO ID DMDRJHO
DMDRJHO DN PMID29338548-Compound-48
DMDRJHO HS Patented
DMDRJHO CP GLAXO GROUP LIMITED BLUNT, Richard EATHERTON, Andrew John GARZYA, Vincenzo HEALY, Mark Patrick MYATT, James PORTER, Roderick Alan
DMDRJHO DT Small molecular drug
DM1NJ3U ID DM1NJ3U
DM1NJ3U DN PMID29338548-Compound-49
DM1NJ3U HS Patented
DM1NJ3U DT Small molecular drug
DM7EW5U ID DM7EW5U
DM7EW5U DN PMID29473428-Compound-10
DM7EW5U HS Patented
DM7EW5U CP IOMET PHARMA LTD. MERCK SHARP & DOHME CORP. COWLEY, Phillip, M. WISE, Alan BROWN, Thomas, J. MCGOWAN, Meredeth, A. ZHOU, Hua HAN, Yongxin
DM7EW5U DT Small molecular drug
DM7EW5U PC 124189844
DM7EW5U MW 387.3
DM7EW5U FM C14H19BrN4O2S
DM7EW5U IC InChI=1S/C14H19BrN4O2S/c1-14(2)9-17(4-5-19(14)22(3,20)21)13-7-11(15)6-12-8-16-10-18(12)13/h6-8,10H,4-5,9H2,1-3H3
DM7EW5U CS CC1(CN(CCN1S(=O)(=O)C)C2=CC(=CC3=CN=CN23)Br)C
DM7EW5U IK MJEJSWKBPXDOCH-UHFFFAOYSA-N
DM7EW5U IU 7-bromo-5-(3,3-dimethyl-4-methylsulfonylpiperazin-1-yl)imidazo[1,5-a]pyridine
DM5MXFK ID DM5MXFK
DM5MXFK DN PMID29473428-Compound-11
DM5MXFK HS Patented
DM5MXFK CP IOMET PHARMA LTD. MERCK SHARP & DOHME CORP. COWLEY, Phillip, M. WISE, Alan BROWN, Thomas, J. MCGOWAN, Meredeth, A. ZHOU, Hua HAN, Yongxin
DM5MXFK DT Small molecular drug
DMCB0D6 ID DMCB0D6
DMCB0D6 DN PMID29473428-Compound-14
DMCB0D6 HS Patented
DMCB0D6 CP AUCKLAND UNISERVICES LIMITED
DMCB0D6 DT Small molecular drug
DMCB0D6 PC 5305899
DMCB0D6 MW 197.62
DMCB0D6 FM C8H8ClN3O
DMCB0D6 IC InChI=1S/C8H8ClN3O/c1-3-5-7(10)12-13-8(5)11-4(2)6(3)9/h1-2H3,(H2,10,12)
DMCB0D6 CS CC1=C2C(=NOC2=NC(=C1Cl)C)N
DMCB0D6 IK XEYWCHKONZUDGB-UHFFFAOYSA-N
DMCB0D6 IU 5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-amine
DM571JP ID DM571JP
DM571JP DN PMID29473428-Compound-15
DM571JP HS Patented
DM571JP CP AUCKLAND UNISERVICES LIMITED
DM571JP DT Small molecular drug
DM571JP PC 126640018
DM571JP MW 317.72
DM571JP FM C15H12ClN3O3
DM571JP IC InChI=1S/C15H12ClN3O3/c1-8-11-13(19-22-14(11)17-9(2)12(8)16)18-15(20)21-10-6-4-3-5-7-10/h3-7H,1-2H3,(H,18,19,20)
DM571JP CS CC1=C2C(=NOC2=NC(=C1Cl)C)NC(=O)OC3=CC=CC=C3
DM571JP IK WUNZBHVIWUQNNS-UHFFFAOYSA-N
DM571JP IU phenyl N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)carbamate
DM21QCE ID DM21QCE
DM21QCE DN PMID29473428-Compound-16
DM21QCE HS Patented
DM21QCE CP AUCKLAND UNISERVICES LIMITED
DM21QCE DT Small molecular drug
DM21QCE PC 118867679
DM21QCE MW 183.59
DM21QCE FM C7H6ClN3O
DM21QCE IC InChI=1S/C7H6ClN3O/c1-3-2-4(8)10-7-5(3)6(9)11-12-7/h2H,1H3,(H2,9,11)
DM21QCE CS CC1=CC(=NC2=C1C(=NO2)N)Cl
DM21QCE IK FQUKGVSRJVUOPA-UHFFFAOYSA-N
DM21QCE IU 6-chloro-4-methyl-[1,2]oxazolo[5,4-b]pyridin-3-amine
DMI04GC ID DMI04GC
DMI04GC DN PMID29473428-Compound-17
DMI04GC HS Patented
DMI04GC CP AUCKLAND UNISERVICES LIMITED
DMI04GC DT Small molecular drug
DMI04GC PC 118867629
DMI04GC MW 187.56
DMI04GC FM C6H3ClFN3O
DMI04GC IC InChI=1S/C6H3ClFN3O/c7-4-3(8)1-2-5(9)11-12-6(2)10-4/h1H,(H2,9,11)
DMI04GC CS C1=C2C(=NOC2=NC(=C1F)Cl)N
DMI04GC IK MTIDNIWREKNKHM-UHFFFAOYSA-N
DMI04GC IU 6-chloro-5-fluoro-[1,2]oxazolo[5,4-b]pyridin-3-amine
DMZGNWO ID DMZGNWO
DMZGNWO DN PMID29473428-Compound-21
DMZGNWO HS Patented
DMZGNWO CP MERCK SHARP &amDOHME CORP. HAN, Yongxin ACHAB, Abdelghani BIJU, Purakkattle DENG, Yongqi FRADERA, Xavier GUO, Liangqin HE, Shuwen KOZLOWSKI, Joseph KURUKULASURIYA, Ravi LIU, Kun MCGOWAN, Meredeth, A. PU, Qinglin SCIAMMETTA, Nunzio ZHANG, Hongjun ZHOU, Hua
DMZGNWO DT Small molecular drug
DMCNSZD ID DMCNSZD
DMCNSZD DN PMID29473428-Compound-22
DMCNSZD HS Patented
DMCNSZD CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
DMCNSZD DT Small molecular drug
DMBMTUV ID DMBMTUV
DMBMTUV DN PMID29473428-Compound-29
DMBMTUV HS Patented
DMBMTUV CP NEWLINK GENETICS CORPORATION MAUTINO, Mario KUMAR, Sanjeev WALDO, Jesse JAIPURI, Firoz KESHARWANI, Tanay ZHANG, Xiaoxia
DMBMTUV DT Small molecular drug
DMZA3FL ID DMZA3FL
DMZA3FL DN PMID29473428-Compound-33
DMZA3FL HS Patented
DMZA3FL DT Small molecular drug
DMZA3FL PC 78426054
DMZA3FL MW 282.4
DMZA3FL FM C18H22N2O
DMZA3FL IC InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-15-14-8-4-5-9-16(14)20-12-19-11-17(15)20/h4-5,8-9,11-13,15,18,21H,1-3,6-7,10H2
DMZA3FL CS C1CCC(CC1)C(CC2C3=CC=CC=C3N4C2=CN=C4)O
DMZA3FL IK MENMLCRHDMAGQE-UHFFFAOYSA-N
DMZA3FL IU 1-cyclohexyl-2-(4H-imidazo[1,5-a]indol-4-yl)ethanol
DM7BRPI ID DM7BRPI
DM7BRPI DN PMID29473428-Compound-34
DM7BRPI HS Patented
DM7BRPI CP REDX PHARMA PLC
DM7BRPI DT Small molecular drug
DM7BRPI PC 121254849
DM7BRPI MW 262.3
DM7BRPI FM C17H14N2O
DM7BRPI IC InChI=1S/C17H14N2O/c1-12-6-2-5-9-16(12)20-17-13-7-3-4-8-14(13)19-11-18-10-15(17)19/h2-11,17H,1H3
DM7BRPI CS CC1=CC=CC=C1OC2C3=CC=CC=C3N4C2=CN=C4
DM7BRPI IK OZIYVKPSWZBCSG-UHFFFAOYSA-N
DM7BRPI IU 4-(2-methylphenoxy)-4H-imidazo[1,5-a]indole
DMKRUPW ID DMKRUPW
DMKRUPW DN PMID29473428-Compound-39
DMKRUPW HS Patented
DMKRUPW CP MERCK PATENT GMBH SHERER, Brian A
DMKRUPW DT Small molecular drug
DMKRUPW PC 118916909
DMKRUPW MW 302.4
DMKRUPW FM C18H20F2N2
DMKRUPW IC InChI=1S/C18H20F2N2/c19-14-8-4-7-13-17-10-21-11-22(17)16(18(13)14)9-15(20)12-5-2-1-3-6-12/h4,7-8,10-12,15-16H,1-3,5-6,9H2
DMKRUPW CS C1CCC(CC1)C(CC2C3=C(C=CC=C3F)C4=CN=CN24)F
DMKRUPW IK OHWIXLJBJCDWBA-UHFFFAOYSA-N
DMKRUPW IU 5-(2-cyclohexyl-2-fluoroethyl)-6-fluoro-5H-imidazo[5,1-a]isoindole
DM9KVOD ID DM9KVOD
DM9KVOD DN PMID29473428-Compound-4
DM9KVOD HS Patented
DM9KVOD DT Small molecular drug
DM9KVOD PC 71941441
DM9KVOD MW 295.33
DM9KVOD FM C13H14FN3O2S
DM9KVOD IC InChI=1S/C13H14FN3O2S/c14-10-1-2-11-12(8-16-13(11)7-10)9-3-5-17(6-4-9)20(15,18)19/h1-3,7-8,16H,4-6H2,(H2,15,18,19)
DM9KVOD CS C1CN(CC=C1C2=CNC3=C2C=CC(=C3)F)S(=O)(=O)N
DM9KVOD IK JQVNNQIVDXRAAV-UHFFFAOYSA-N
DM9KVOD IU 4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-sulfonamide
DM4AOIR ID DM4AOIR
DM4AOIR DN PMID29473428-Compound-41
DM4AOIR HS Patented
DM4AOIR CP MERCK PATENT GMBH SHERER, Brian A
DM4AOIR DT Small molecular drug
DM4AOIR PC 118917121
DM4AOIR MW 301.36
DM4AOIR FM C17H20FN3O
DM4AOIR IC InChI=1S/C17H20FN3O/c18-17-6-12-13(8-20-17)15-9-19-10-21(15)14(12)7-16(22)11-4-2-1-3-5-11/h6,8-11,14,16,22H,1-5,7H2
DM4AOIR CS C1CCC(CC1)C(CC2C3=CC(=NC=C3C4=CN=CN24)F)O
DM4AOIR IK QUDWXPLDIKCCKW-UHFFFAOYSA-N
DM4AOIR IU 1-cyclohexyl-2-(10-fluoro-4,6,11-triazatricyclo[6.4.0.02,6]dodeca-1(12),2,4,8,10-pentaen-7-yl)ethanol
DMQ8EYV ID DMQ8EYV
DMQ8EYV DN PMID29473428-Compound-43
DMQ8EYV HS Patented
DMQ8EYV CP REDX PHARMA PLC
DMQ8EYV DT Small molecular drug
DMQ8EYV PC 121288667
DMQ8EYV MW 390.7
DMQ8EYV FM C17H13BrClN3O
DMQ8EYV IC InChI=1S/C17H13BrClN3O/c18-10-1-2-12(14(19)5-10)17(23)6-15-11-3-4-20-7-13(11)16-8-21-9-22(15)16/h1-5,7-9,15,17,23H,6H2
DMQ8EYV CS C1=CC(=C(C=C1Br)Cl)C(CC2C3=C(C=NC=C3)C4=CN=CN24)O
DMQ8EYV IK FULOIPPDAZMZJS-UHFFFAOYSA-N
DMQ8EYV IU 1-(4-bromo-2-chlorophenyl)-2-(4,6,11-triazatricyclo[6.4.0.02,6]dodeca-1(8),2,4,9,11-pentaen-7-yl)ethanol
DMCLJ0M ID DMCLJ0M
DMCLJ0M DN PMID29473428-Compound-47
DMCLJ0M HS Patented
DMCLJ0M CP SCIFLUOR LIFE SCIENCES, INC
DMCLJ0M DT Small molecular drug
DMCLJ0M PC 129072590
DMCLJ0M MW 298.4
DMCLJ0M FM C19H23FN2
DMCLJ0M IC InChI=1S/C19H23FN2/c20-18(14-6-2-1-3-7-14)11-16-10-15-8-4-5-9-17(15)19-12-21-13-22(16)19/h4-5,8-9,12-14,16,18H,1-3,6-7,10-11H2
DMCLJ0M CS C1CCC(CC1)C(CC2CC3=CC=CC=C3C4=CN=CN24)F
DMCLJ0M IK MCRCDKJVHBJTQP-UHFFFAOYSA-N
DMCLJ0M IU 5-(2-cyclohexyl-2-fluoroethyl)-5,6-dihydroimidazo[5,1-a]isoquinoline
DMAYT2E ID DMAYT2E
DMAYT2E DN PMID29473428-Compound-48
DMAYT2E HS Patented
DMAYT2E CP EMCURE PHARMACEUTICALS LIMITED
DMAYT2E DT Small molecular drug
DMXUVDH ID DMXUVDH
DMXUVDH DN PMID29473428-Compound-50
DMXUVDH HS Patented
DMXUVDH CP EMCURE PHARMACEUTICALS LIMITED
DMXUVDH DT Small molecular drug
DMXUVDH PC 130300332
DMXUVDH MW 427.5
DMXUVDH FM C27H29N3O2
DMXUVDH IC InChI=1S/C27H29N3O2/c1-19-24-17-28-18-30(24)23(26(19)21-8-4-2-5-9-21)16-25(31)20-12-14-29(15-13-20)27(32)22-10-6-3-7-11-22/h2-11,17-18,20,23,25,31H,12-16H2,1H3
DMXUVDH CS CC1=C(C(N2C1=CN=C2)CC(C3CCN(CC3)C(=O)C4=CC=CC=C4)O)C5=CC=CC=C5
DMXUVDH IK AJSXKLLHMGVTFL-UHFFFAOYSA-N
DMXUVDH IU [4-[1-hydroxy-2-(7-methyl-6-phenyl-5H-pyrrolo[1,2-c]imidazol-5-yl)ethyl]piperidin-1-yl]-phenylmethanone
DMSXKP6 ID DMSXKP6
DMSXKP6 DN PMID29473428-Compound-52
DMSXKP6 HS Patented
DMSXKP6 CP KYOWA HAKKO KIRIN CO., LTD
DMSXKP6 DT Small molecular drug
DMOASLQ ID DMOASLQ
DMOASLQ DN PMID29473428-Compound-53
DMOASLQ HS Patented
DMOASLQ CP BRISTOL-MYERS SQUIBB COMPANY
DMOASLQ DT Small molecular drug
DMOASLQ PC 121339539
DMOASLQ MW 500.6
DMOASLQ FM C28H29FN6O2
DMOASLQ IC InChI=1S/C28H29FN6O2/c1-3-5-6-11-19-17-20(21-12-7-8-13-22(21)27-32-34-35-33-27)18-25(26(19)37-16-4-2)31-28(36)30-24-15-10-9-14-23(24)29/h5-10,12-15,17-18H,3-4,11,16H2,1-2H3,(H2,30,31,36)(H,32,33,34,35)/b6-5+
DMOASLQ CS CCCOC1=C(C=C(C=C1NC(=O)NC2=CC=CC=C2F)C3=CC=CC=C3C4=NNN=N4)C/C=C/CC
DMOASLQ IK KTJPMWGPZICNCM-AATRIKPKSA-N
DMOASLQ IU 1-(2-fluorophenyl)-3-[3-[(E)-pent-2-enyl]-2-propoxy-5-[2-(2H-tetrazol-5-yl)phenyl]phenyl]urea
DMKIS26 ID DMKIS26
DMKIS26 DN PMID29473428-Compound-54
DMKIS26 HS Patented
DMKIS26 CP BRISTOL-MYERS SQUIBB COMPANY
DMKIS26 DT Small molecular drug
DMKIS26 PC 121339537
DMKIS26 MW 567.5
DMKIS26 FM C27H28BrFN6O2
DMKIS26 IC InChI=1S/C27H28BrFN6O2/c1-3-9-18(10-4-2)37-25-21(28)15-17(19-11-5-6-12-20(19)26-32-34-35-33-26)16-24(25)31-27(36)30-23-14-8-7-13-22(23)29/h5-8,11-16,18H,3-4,9-10H2,1-2H3,(H2,30,31,36)(H,32,33,34,35)
DMKIS26 CS CCCC(CCC)OC1=C(C=C(C=C1Br)C2=CC=CC=C2C3=NNN=N3)NC(=O)NC4=CC=CC=C4F
DMKIS26 IK RCDIDCDPBBVKLP-UHFFFAOYSA-N
DMKIS26 IU 1-[3-bromo-2-heptan-4-yloxy-5-[2-(2H-tetrazol-5-yl)phenyl]phenyl]-3-(2-fluorophenyl)urea
DMVP7DL ID DMVP7DL
DMVP7DL DN PMID29473428-Compound-58
DMVP7DL HS Patented
DMVP7DL CP BRISTOL-MYERS SQUIBB COMPANY
DMVP7DL DT Small molecular drug
DMVP7DL PC 118898844
DMVP7DL MW 515.5
DMVP7DL FM C25H30F5N3O3
DMVP7DL IC InChI=1S/C25H30F5N3O3/c1-14(2)12-33(13-15(3)4)22-8-5-16(18(11-23(34)35)25(28,29)30)9-21(22)32-24(36)31-20-7-6-17(26)10-19(20)27/h5-10,14-15,18H,11-13H2,1-4H3,(H,34,35)(H2,31,32,36)
DMVP7DL CS CC(C)CN(CC(C)C)C1=C(C=C(C=C1)C(CC(=O)O)C(F)(F)F)NC(=O)NC2=C(C=C(C=C2)F)F
DMVP7DL IK LLRWXYAXYSABOE-UHFFFAOYSA-N
DMVP7DL IU 3-[4-[bis(2-methylpropyl)amino]-3-[(2,4-difluorophenyl)carbamoylamino]phenyl]-4,4,4-trifluorobutanoic acid
DMJYUN2 ID DMJYUN2
DMJYUN2 DN PMID29473428-Compound-59
DMJYUN2 HS Patented
DMJYUN2 CP BRISTOL-MYERS SQUIBB COMPANY
DMJYUN2 DT Small molecular drug
DMJYUN2 PC 117614378
DMJYUN2 MW 454.6
DMJYUN2 FM C25H34N4O4
DMJYUN2 IC InChI=1S/C25H34N4O4/c1-15(2)14-29(18-7-5-4-6-8-18)22-10-9-17(19-13-20(19)24(30)31)12-21(22)26-25(32)27-23-11-16(3)28-33-23/h9-12,15,18-20H,4-8,13-14H2,1-3H3,(H,30,31)(H2,26,27,32)/t19-,20-/m0/s1
DMJYUN2 CS CC1=NOC(=C1)NC(=O)NC2=C(C=CC(=C2)[C@@H]3C[C@@H]3C(=O)O)N(CC(C)C)C4CCCCC4
DMJYUN2 IK JFOVWQVFKHJGRN-PMACEKPBSA-N
DMJYUN2 IU (1S,2R)-2-[4-[cyclohexyl(2-methylpropyl)amino]-3-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]phenyl]cyclopropane-1-carboxylic acid
DMOVPWD ID DMOVPWD
DMOVPWD DN PMID29473428-Compound-6
DMOVPWD HS Patented
DMOVPWD CP IOMET PHARMA LTD
DMOVPWD DT Small molecular drug
DMOVPWD PC 7323927
DMOVPWD MW 298.8
DMOVPWD FM C17H15ClN2O
DMOVPWD IC InChI=1S/C17H15ClN2O/c1-11(12-5-3-2-4-6-12)19-17(21)16-10-13-9-14(18)7-8-15(13)20-16/h2-11,20H,1H3,(H,19,21)/t11-/m0/s1
DMOVPWD CS C[C@@H](C1=CC=CC=C1)NC(=O)C2=CC3=C(N2)C=CC(=C3)Cl
DMOVPWD IK KNBUEFQZZKXGIC-NSHDSACASA-N
DMOVPWD IU 5-chloro-N-[(1S)-1-phenylethyl]-1H-indole-2-carboxamide
DMRKWPQ ID DMRKWPQ
DMRKWPQ DN PMID29473428-Compound-60
DMRKWPQ HS Patented
DMRKWPQ CP BRISTOL-MYERS SQUIBB COMPANY
DMRKWPQ DT Small molecular drug
DMRKWPQ PC 124158753
DMRKWPQ MW 492
DMRKWPQ FM C25H31ClFN3O4
DMRKWPQ IC InChI=1S/C25H31ClFN3O4/c1-16(2)14-30(18-6-4-3-5-7-18)23-11-9-19(34-15-24(31)32)13-22(23)29-25(33)28-21-10-8-17(26)12-20(21)27/h8-13,16,18H,3-7,14-15H2,1-2H3,(H,31,32)(H2,28,29,33)
DMRKWPQ CS CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)OCC(=O)O)NC(=O)NC3=C(C=C(C=C3)Cl)F
DMRKWPQ IK TVQUEBMGNJZEOT-UHFFFAOYSA-N
DMRKWPQ IU 2-[3-[(4-chloro-2-fluorophenyl)carbamoylamino]-4-[cyclohexyl(2-methylpropyl)amino]phenoxy]acetic acid
DMMV5KI ID DMMV5KI
DMMV5KI DN PMID29473428-Compound-70
DMMV5KI HS Patented
DMMV5KI CP FLEXUS BIOSCIENCES, INC
DMMV5KI DT Small molecular drug
DMMV5KI PC 121318124
DMMV5KI MW 427.9
DMMV5KI FM C23H23ClFN3O2
DMMV5KI IC InChI=1S/C23H23ClFN3O2/c1-15(23(29)27-18-5-2-16(24)3-6-18)28-12-9-19(10-13-28)30-22-8-11-26-21-7-4-17(25)14-20(21)22/h2-8,11,14-15,19H,9-10,12-13H2,1H3,(H,27,29)
DMMV5KI CS CC(C(=O)NC1=CC=C(C=C1)Cl)N2CCC(CC2)OC3=C4C=C(C=CC4=NC=C3)F
DMMV5KI IK JOMPEBQANPZAPO-UHFFFAOYSA-N
DMMV5KI IU N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)oxypiperidin-1-yl]propanamide
DML5G6D ID DML5G6D
DML5G6D DN PMID29473428-Compound-71
DML5G6D HS Patented
DML5G6D CP FLEXUS BIOSCIENCES, INC
DML5G6D DT Small molecular drug
DML5G6D PC 138490227
DML5G6D MW 410.9
DML5G6D FM C21H22ClF3N2O
DML5G6D IC InChI=1S/C21H22ClF3N2O/c1-13(20(28)27-18-8-6-17(22)7-9-18)14-2-4-15(5-3-14)16-10-11-26-19(12-16)21(23,24)25/h6-15H,2-5H2,1H3,(H,27,28)
DML5G6D CS CC(C1CCC(CC1)C2=CC(=NC=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)Cl
DML5G6D IK WSWKMGSCQQQPBU-UHFFFAOYSA-N
DML5G6D IU N-(4-chlorophenyl)-2-[4-[2-(trifluoromethyl)pyridin-4-yl]cyclohexyl]propanamide
DMJOBUZ ID DMJOBUZ
DMJOBUZ DN PMID29473428-Compound-72
DMJOBUZ HS Patented
DMJOBUZ CP FLEXUS BIOSCIENCES, INC
DMJOBUZ DT Small molecular drug
DM8PZ46 ID DM8PZ46
DM8PZ46 DN PMID29473428-Compound-76
DM8PZ46 HS Patented
DM8PZ46 CP IOMET PHARMA LTD
DM8PZ46 DT Small molecular drug
DM8PZ46 PC 121325256
DM8PZ46 MW 342.4
DM8PZ46 FM C17H14N2O4S
DM8PZ46 IC InChI=1S/C17H14N2O4S/c20-24(21,13-4-5-16-17(10-13)23-9-8-22-16)19-15-3-1-2-12-11-18-7-6-14(12)15/h1-7,10-11,19H,8-9H2
DM8PZ46 CS C1COC2=C(O1)C=CC(=C2)S(=O)(=O)NC3=CC=CC4=C3C=CN=C4
DM8PZ46 IK QYTGSNGNCQHITP-UHFFFAOYSA-N
DM8PZ46 IU N-isoquinolin-5-yl-2,3-dihydro-1,4-benzodioxine-6-sulfonamide
DM8VBU2 ID DM8VBU2
DM8VBU2 DN PMID29473428-Compound-80
DM8VBU2 HS Patented
DM8VBU2 CP VERTEX PHARMACEUTICALS INCORPORATED
DM8VBU2 DT Small molecular drug
DM8VBU2 PC 75202660
DM8VBU2 MW 252.7
DM8VBU2 FM C11H13ClN4O
DM8VBU2 IC InChI=1S/C11H13ClN4O/c1-17-5-4-8-6-9(12)2-3-10(8)14-11-7-13-16-15-11/h2-3,6-7H,4-5H2,1H3,(H2,13,14,15,16)
DM8VBU2 CS COCCC1=C(C=CC(=C1)Cl)NC2=NNN=C2
DM8VBU2 IK ZVGDDDHHESZRQT-UHFFFAOYSA-N
DM8VBU2 IU N-[4-chloro-2-(2-methoxyethyl)phenyl]-2H-triazol-4-amine
DMDKT9X ID DMDKT9X
DMDKT9X DN PMID29649907-Compound-1
DMDKT9X HS Patented
DMDKT9X CP INTERCEPT PHARMACEUTICALS, INC
DMDKT9X DT Small molecular drug
DMDKT9X PC 126582691
DMDKT9X MW 420.6
DMDKT9X FM C26H44O4
DMDKT9X IC InChI=1S/C26H44O4/c1-5-16-18-8-6-7-13-25(18,3)23-20(27)14-26(4)17(15(2)9-12-21(28)29)10-11-19(26)22(23)24(16)30/h15-20,22-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18+,19?,20+,22?,23?,24-,25+,26-/m1/s1
DMDKT9X CS CC[C@@H]1[C@@H]2CCCC[C@@]2(C3[C@H](C[C@@]4([C@H](CCC4C3[C@@H]1O)[C@H](C)CCC(=O)O)C)O)C
DMDKT9X IK IMDDBKRWRHUMNT-QAUCXMOESA-N
DMDKT9X IU (4R)-4-[(5S,6R,7R,10S,11S,13R,17R)-6-ethyl-7,11-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMNE9AX ID DMNE9AX
DMNE9AX DN PMID29649907-Compound-10
DMNE9AX HS Patented
DMNE9AX CP ENANTA PHARMACEUTICALS, INC
DMNE9AX DT Small molecular drug
DMSC9MH ID DMSC9MH
DMSC9MH DN PMID29649907-Compound-11
DMSC9MH HS Patented
DMSC9MH CP ENANTA PHARMACEUTICALS, INC
DMSC9MH DT Small molecular drug
DMBHT2E ID DMBHT2E
DMBHT2E DN PMID29649907-Compound-12
DMBHT2E HS Patented
DMBHT2E CP ENANTA PHARMACEUTICALS, INC
DMBHT2E DT Small molecular drug
DMLBQUS ID DMLBQUS
DMLBQUS DN PMID29649907-Compound-13
DMLBQUS HS Patented
DMLBQUS CP ENANTA PHARMACEUTICALS, INC
DMLBQUS DT Small molecular drug
DMQAV30 ID DMQAV30
DMQAV30 DN PMID29649907-Compound-14
DMQAV30 HS Patented
DMQAV30 CP ENANTA PHARMACEUTICALS, INC
DMQAV30 DT Small molecular drug
DMMIKFU ID DMMIKFU
DMMIKFU DN PMID29649907-Compound-15
DMMIKFU HS Patented
DMMIKFU CP ENANTA PHARMACEUTICALS, INC
DMMIKFU DT Small molecular drug
DMBVOZK ID DMBVOZK
DMBVOZK DN PMID29649907-Compound-18
DMBVOZK HS Patented
DMBVOZK CP GILEAD SCIENCES, INC
DMBVOZK DT Small molecular drug
DMBVOZK PC 121414040
DMBVOZK MW 600.9
DMBVOZK FM C29H24Cl3N3O5
DMBVOZK IC InChI=1S/C29H24Cl3N3O5/c30-21-2-1-3-22(31)25(21)26-19(27(40-34-26)16-4-5-16)14-39-18-7-8-20(23(32)12-18)29(38)10-11-35(15-29)24-9-6-17(13-33-24)28(36)37/h1-3,6-9,12-13,16,38H,4-5,10-11,14-15H2,(H,36,37)
DMBVOZK CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CCN(C5)C6=NC=C(C=C6)C(=O)O)O)Cl
DMBVOZK IK YGRGAPWBPFVISR-UHFFFAOYSA-N
DMBVOZK IU 6-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxypyrrolidin-1-yl]pyridine-3-carboxylic acid
DMFL38V ID DMFL38V
DMFL38V DN PMID29649907-Compound-19
DMFL38V HS Patented
DMFL38V CP SUNSHINE LAKE PHARMA CO., LTD
DMFL38V DT Small molecular drug
DMFL38V PC 122491783
DMFL38V MW 572.4
DMFL38V FM C27H19Cl2NO7S
DMFL38V IC InChI=1S/C27H19Cl2NO7S/c28-19-2-1-3-20(29)24(19)25-18(26(37-30-25)14-4-5-14)12-35-17-8-9-21-23(11-17)38(33,34)13-16-7-6-15(27(31)32)10-22(16)36-21/h1-3,6-11,14H,4-5,12-13H2,(H,31,32)
DMFL38V CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC5=C(C=C4)OC6=C(CS5(=O)=O)C=CC(=C6)C(=O)O
DMFL38V IK LTDMSLKNDBRACZ-UHFFFAOYSA-N
DMFL38V IU 3-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-5,5-dioxo-6H-benzo[b][1,5]benzoxathiepine-9-carboxylic acid
DMM4TBH ID DMM4TBH
DMM4TBH DN PMID29649907-Compound-2
DMM4TBH HS Patented
DMM4TBH CP INTERCEPT PHARMACEUTICALS, INC
DMM4TBH DT Small molecular drug
DMGNW34 ID DMGNW34
DMGNW34 DN PMID29649907-Compound-20
DMGNW34 HS Patented
DMGNW34 CP SUNSHINE LAKE PHARMA CO., LTD
DMGNW34 DT Small molecular drug
DMGNW34 PC 122491785
DMGNW34 MW 600.5
DMGNW34 FM C28H23Cl2N3O6S
DMGNW34 IC InChI=1S/C28H23Cl2N3O6S/c1-40(35,36)33-28(34)17-8-5-15-9-10-21-22(38-23(15)13-17)11-12-24(31-21)37-14-18-26(32-39-27(18)16-6-7-16)25-19(29)3-2-4-20(25)30/h2-5,8,11-13,16H,6-7,9-10,14H2,1H3,(H,33,34)
DMGNW34 CS CS(=O)(=O)NC(=O)C1=CC2=C(CCC3=C(O2)C=CC(=N3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C=C1
DMGNW34 IK ADZBYRFCADJPGB-UHFFFAOYSA-N
DMGNW34 IU 3-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-N-methylsulfonyl-5,6-dihydro-[1]benzoxepino[3,2-b]pyridine-9-carboxamide
DMES0UY ID DMES0UY
DMES0UY DN PMID29649907-Compound-21
DMES0UY HS Patented
DMES0UY CP ALIOS BIOPHARMA, INC
DMES0UY DT Small molecular drug
DMES0UY PC 130366919
DMES0UY MW 570.8
DMES0UY FM C29H22Cl3NO5
DMES0UY IC InChI=1S/C29H22Cl3NO5/c30-21-5-2-6-22(31)25(21)26-20(27(38-33-26)15-7-8-15)14-36-19-12-17-9-10-24(37-28(17)23(32)13-19)16-3-1-4-18(11-16)29(34)35/h1-6,11-13,15,24H,7-10,14H2,(H,34,35)
DMES0UY CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC5=C(C(=C4)Cl)OC(CC5)C6=CC(=CC=C6)C(=O)O
DMES0UY IK KCNYPNKMQPDXHA-UHFFFAOYSA-N
DMES0UY IU 3-[8-chloro-6-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-3,4-dihydro-2H-chromen-2-yl]benzoic acid
DMXW108 ID DMXW108
DMXW108 DN PMID29649907-Compound-22
DMXW108 HS Patented
DMXW108 CP ALIOS BIOPHARMA, INC
DMXW108 DT Small molecular drug
DMXW108 PC 130366935
DMXW108 MW 549.4
DMXW108 FM C30H26Cl2N2O4
DMXW108 IC InChI=1S/C30H26Cl2N2O4/c1-34-25(18-4-2-5-20(14-18)30(35)36)12-10-19-15-21(11-13-26(19)34)37-16-22-28(33-38-29(22)17-8-9-17)27-23(31)6-3-7-24(27)32/h2-7,11,13-15,17,25H,8-10,12,16H2,1H3,(H,35,36)
DMXW108 CS CN1C(CCC2=C1C=CC(=C2)OCC3=C(ON=C3C4=C(C=CC=C4Cl)Cl)C5CC5)C6=CC(=CC=C6)C(=O)O
DMXW108 IK WROIATMBIYLPMI-UHFFFAOYSA-N
DMXW108 IU 3-[6-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-1-methyl-3,4-dihydro-2H-quinolin-2-yl]benzoic acid
DMW7T45 ID DMW7T45
DMW7T45 DN PMID29649907-Compound-23
DMW7T45 HS Patented
DMW7T45 CP Gilead Sciences
DMW7T45 DT Small molecular drug
DMUHNS7 ID DMUHNS7
DMUHNS7 DN PMID29649907-Compound-24
DMUHNS7 HS Patented
DMUHNS7 CP Gilead Sciences
DMUHNS7 DT Small molecular drug
DMALOEW ID DMALOEW
DMALOEW DN PMID29649907-Compound-25
DMALOEW HS Patented
DMALOEW CP ENANTA PHARMACEUTICALS, INC
DMALOEW DT Small molecular drug
DMALOEW PC 132042402
DMALOEW MW 650.6
DMALOEW FM C28H29Cl2N5O5S2
DMALOEW IC InChI=1S/C28H29Cl2N5O5S2/c1-34(2)42(37,38)33-27(36)17-8-9-22-23(14-17)41-28(31-22)35-12-10-18(11-13-35)39-15-19-25(32-40-26(19)16-6-7-16)24-20(29)4-3-5-21(24)30/h3-5,8-9,14,16,18H,6-7,10-13,15H2,1-2H3,(H,33,36)
DMALOEW CS CN(C)S(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(S2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6
DMALOEW IK FJNHJIMGAHRBKJ-UHFFFAOYSA-N
DMALOEW IU 2-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-N-(dimethylsulfamoyl)-1,3-benzothiazole-6-carboxamide
DM6O78C ID DM6O78C
DM6O78C DN PMID29649907-Compound-26
DM6O78C HS Patented
DM6O78C CP ENANTA PHARMACEUTICALS, INC
DM6O78C DT Small molecular drug
DMQDGZL ID DMQDGZL
DMQDGZL DN PMID29649907-Compound-27
DMQDGZL HS Patented
DMQDGZL CP SALK INSTITUTE FOR BIOLOGICAL STUDIE
DMQDGZL DT Small molecular drug
DMQDGZL PC 126652833
DMQDGZL MW 515.6
DMQDGZL FM C32H35FN2O3
DMQDGZL IC InChI=1S/C32H35FN2O3/c1-34(2)28-17-15-24(16-18-28)26-13-14-27(30(33)21-26)22-35(32(37)25-9-5-4-6-10-25)29-11-7-8-23(20-29)12-19-31(36)38-3/h7-8,11-21,25H,4-6,9-10,22H2,1-3H3/b19-12+/i22D
DMQDGZL CS [2H]C(C1=C(C=C(C=C1)C2=CC=C(C=C2)N(C)C)F)N(C3=CC=CC(=C3)/C=C/C(=O)OC)C(=O)C4CCCCC4
DMQDGZL IK BRNNEWSVEXDLGK-OFSGRHOTSA-N
DMQDGZL IU methyl (E)-3-[3-[cyclohexanecarbonyl-[deuterio-[4-[4-(dimethylamino)phenyl]-2-fluorophenyl]methyl]amino]phenyl]prop-2-enoate
DMYMKZC ID DMYMKZC
DMYMKZC DN PMID29649907-Compound-28
DMYMKZC HS Patented
DMYMKZC CP SALK INSTITUTE FOR BIOLOGICAL STUDIE
DMYMKZC DT Small molecular drug
DMYMKZC PC 126652917
DMYMKZC MW 527.6
DMYMKZC FM C33H35FN2O3
DMYMKZC IC InChI=1S/C33H35FN2O3/c1-35(2)29-13-11-26(12-14-29)25-8-4-22(5-9-25)21-36(33(38)31-19-23-6-10-27(31)16-23)30-18-24(17-28(34)20-30)7-15-32(37)39-3/h4-5,7-9,11-15,17-18,20,23,27,31H,6,10,16,19,21H2,1-3H3/b15-7+/t23-,27+,31?/m0/s1/i21D/t21?,23-,27+,31?
DMYMKZC CS [2H]C(C1=CC=C(C=C1)C2=CC=C(C=C2)N(C)C)N(C3=CC(=CC(=C3)/C=C/C(=O)OC)F)C(=O)C4C[C@H]5CC[C@@H]4C5
DMYMKZC IK OQLFJJIBJUSVIK-YNEPWPPESA-N
DMYMKZC IU methyl (E)-3-[3-[[(1R,4S)-bicyclo[2.2.1]heptane-2-carbonyl]-[deuterio-[4-[4-(dimethylamino)phenyl]phenyl]methyl]amino]-5-fluorophenyl]prop-2-enoate
DMEVZIK ID DMEVZIK
DMEVZIK DN PMID29649907-Compound-29
DMEVZIK HS Patented
DMEVZIK CP SALK INSTITUTE FOR BIOLOGICAL STUDIE
DMEVZIK DT Small molecular drug
DMEVZIK PC 91885586
DMEVZIK MW 545.6
DMEVZIK FM C33H34F2N2O3
DMEVZIK IC InChI=1S/C33H34F2N2O3/c1-36(2)28-11-9-23(10-12-28)24-7-8-26(31(35)18-24)20-37(33(39)30-17-21-4-6-25(30)14-21)29-16-22(15-27(34)19-29)5-13-32(38)40-3/h5,7-13,15-16,18-19,21,25,30H,4,6,14,17,20H2,1-3H3/b13-5+/t21-,25+,30?/m0/s1/i20D/t20?,21-,25+,30?
DMEVZIK CS [2H]C(C1=C(C=C(C=C1)C2=CC=C(C=C2)N(C)C)F)N(C3=CC(=CC(=C3)/C=C/C(=O)OC)F)C(=O)C4C[C@H]5CC[C@@H]4C5
DMEVZIK IK AYPFTLSDFVNKEW-TZCKJPFISA-N
DMEVZIK IU methyl (E)-3-[3-[[(1R,4S)-bicyclo[2.2.1]heptane-2-carbonyl]-[deuterio-[4-[4-(dimethylamino)phenyl]-2-fluorophenyl]methyl]amino]-5-fluorophenyl]prop-2-enoate
DMPVSG9 ID DMPVSG9
DMPVSG9 DN PMID29649907-Compound-3
DMPVSG9 HS Patented
DMPVSG9 CP INTERCEPT PHARMACEUTICALS, INC
DMPVSG9 DT Small molecular drug
DM0SY7Q ID DM0SY7Q
DM0SY7Q DN PMID29649907-Compound-30
DM0SY7Q HS Patented
DM0SY7Q CP SALK INSTITUTE FOR BIOLOGICAL STUDIE
DM0SY7Q DT Small molecular drug
DM0SY7Q PC 126652862
DM0SY7Q MW 526.6
DM0SY7Q FM C32H32FN3O3
DM0SY7Q IC InChI=1S/C32H32FN3O3/c1-35-30-15-14-24(18-27(30)20-34-35)25-12-13-26(29(33)19-25)21-36(32(38)23-8-4-3-5-9-23)28-10-6-7-22(17-28)11-16-31(37)39-2/h6-7,10-20,23H,3-5,8-9,21H2,1-2H3/b16-11+/i21D
DM0SY7Q CS [2H]C(C1=C(C=C(C=C1)C2=CC3=C(C=C2)N(N=C3)C)F)N(C4=CC=CC(=C4)/C=C/C(=O)OC)C(=O)C5CCCCC5
DM0SY7Q IK NOJHCAUXLPQOOD-STTMTRHISA-N
DM0SY7Q IU methyl (E)-3-[3-[cyclohexanecarbonyl-[deuterio-[2-fluoro-4-(1-methylindazol-5-yl)phenyl]methyl]amino]phenyl]prop-2-enoate
DME6H8Q ID DME6H8Q
DME6H8Q DN PMID29649907-Compound-31
DME6H8Q HS Patented
DME6H8Q CP SALK INSTITUTE FOR BIOLOGICAL STUDIE
DME6H8Q DT Small molecular drug
DME6H8Q PC 126652837
DME6H8Q MW 544.6
DME6H8Q FM C32H31F2N3O3
DME6H8Q IC InChI=1S/C32H31F2N3O3/c1-36-30-12-11-23(16-26(30)19-35-36)24-9-10-25(29(34)17-24)20-37(32(39)22-6-4-3-5-7-22)28-15-21(14-27(33)18-28)8-13-31(38)40-2/h8-19,22H,3-7,20H2,1-2H3/b13-8+/i20D
DME6H8Q CS [2H]C(C1=C(C=C(C=C1)C2=CC3=C(C=C2)N(N=C3)C)F)N(C4=CC(=CC(=C4)/C=C/C(=O)OC)F)C(=O)C5CCCCC5
DME6H8Q IK FCAAOLBKZMXHIT-CPVMVVEOSA-N
DME6H8Q IU methyl (E)-3-[3-[cyclohexanecarbonyl-[deuterio-[2-fluoro-4-(1-methylindazol-5-yl)phenyl]methyl]amino]-5-fluorophenyl]prop-2-enoate
DM7E9HA ID DM7E9HA
DM7E9HA DN PMID29649907-Compound-32
DM7E9HA HS Patented
DM7E9HA CP METACRINE, INC
DM7E9HA DT Small molecular drug
DM7E9HA PC 126696931
DM7E9HA MW 470.6
DM7E9HA FM C30H34N2O3
DM7E9HA IC InChI=1S/C30H34N2O3/c1-30(2,3)29(34)32(27-9-7-8-22(20-27)12-19-28(33)35-6)21-23-10-13-24(14-11-23)25-15-17-26(18-16-25)31(4)5/h7-20H,21H2,1-6H3/b19-12+
DM7E9HA CS CC(C)(C)C(=O)N(CC1=CC=C(C=C1)C2=CC=C(C=C2)N(C)C)C3=CC=CC(=C3)/C=C/C(=O)OC
DM7E9HA IK CROILKLCCCWJNU-XDHOZWIPSA-N
DM7E9HA IU methyl (E)-3-[3-[[4-[4-(dimethylamino)phenyl]phenyl]methyl-(2,2-dimethylpropanoyl)amino]phenyl]prop-2-enoate
DM39HCU ID DM39HCU
DM39HCU DN PMID29649907-Compound-33
DM39HCU HS Patented
DM39HCU CP METACRINE, INC
DM39HCU DT Small molecular drug
DM39HCU PC 126696428
DM39HCU MW 519.7
DM39HCU FM C34H37N3O2
DM39HCU IC InChI=1S/C34H37N3O2/c1-36(2)31-18-16-27(17-19-31)26-14-12-25(13-15-26)24-37(34(38)28-8-5-4-6-9-28)32-11-7-10-29(20-32)30-21-33(39-3)23-35-22-30/h7,10-23,28H,4-6,8-9,24H2,1-3H3
DM39HCU CS CN(C)C1=CC=C(C=C1)C2=CC=C(C=C2)CN(C3=CC=CC(=C3)C4=CC(=CN=C4)OC)C(=O)C5CCCCC5
DM39HCU IK GNROXEVONXEHCJ-UHFFFAOYSA-N
DM39HCU IU N-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]-N-[3-(5-methoxypyridin-3-yl)phenyl]cyclohexanecarboxamide
DMUDKE0 ID DMUDKE0
DMUDKE0 DN PMID29649907-Compound-34
DMUDKE0 HS Patented
DMUDKE0 CP METACRINE, INC
DMUDKE0 DT Small molecular drug
DMSWJPO ID DMSWJPO
DMSWJPO DN PMID29649907-Compound-35
DMSWJPO HS Patented
DMSWJPO CP METACRINE, INC
DMSWJPO DT Small molecular drug
DMP5KEW ID DMP5KEW
DMP5KEW DN PMID29649907-Compound-36
DMP5KEW HS Patented
DMP5KEW CP ALIOS BIOPHARMA, INC
DMP5KEW DT Small molecular drug
DMP5KEW PC 121439420
DMP5KEW MW 439.5
DMP5KEW FM C24H23F2N3O3
DMP5KEW IC InChI=1S/C24H23F2N3O3/c1-13(2)32-23(31)16-11-29(22(30)14-7-8-17(25)18(26)10-14)12-24(3,4)19-15-6-5-9-27-21(15)28-20(16)19/h5-11,13H,12H2,1-4H3,(H,27,28)
DMP5KEW CS CC(C)OC(=O)C1=CN(CC(C2=C1NC3=C2C=CC=N3)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DMP5KEW IK PKWPSFIXOLFFPB-UHFFFAOYSA-N
DMP5KEW IU propan-2-yl 12-(3,4-difluorobenzoyl)-14,14-dimethyl-6,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5,10-pentaene-10-carboxylate
DM8WKYT ID DM8WKYT
DM8WKYT DN PMID29649907-Compound-37
DM8WKYT HS Patented
DM8WKYT CP ALIOS BIOPHARMA, INC
DM8WKYT DT Small molecular drug
DM8WKYT PC 121439394
DM8WKYT MW 439.5
DM8WKYT FM C24H23F2N3O3
DM8WKYT IC InChI=1S/C24H23F2N3O3/c1-13(2)32-23(31)15-11-29(22(30)14-7-8-16(25)17(26)10-14)12-24(3,4)19-20(15)28-18-6-5-9-27-21(18)19/h5-11,13,28H,12H2,1-4H3
DM8WKYT CS CC(C)OC(=O)C1=CN(CC(C2=C1NC3=C2N=CC=C3)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DM8WKYT IK LHMOWNHVOCSXKQ-UHFFFAOYSA-N
DM8WKYT IU propan-2-yl 12-(3,4-difluorobenzoyl)-14,14-dimethyl-3,8,12-triazatricyclo[7.5.0.02,7]tetradeca-1(9),2(7),3,5,10-pentaene-10-carboxylate
DMMP09F ID DMMP09F
DMMP09F DN PMID29649907-Compound-38
DMMP09F HS Patented
DMMP09F CP AKARNA THERAPEUTICS, LTDAKARNA THERAPEUTICS, LTD. PRATT, Benjamin Anthony
DMMP09F DT Small molecular drug
DMI3ELU ID DMI3ELU
DMI3ELU DN PMID29649907-Compound-39
DMI3ELU HS Patented
DMI3ELU CP AKARNA THERAPEUTICS, LTD
DMI3ELU DT Small molecular drug
DMI3ELU PC 134472051
DMI3ELU MW 511.6
DMI3ELU FM C28H39N4O5+
DMI3ELU IC InChI=1S/C28H39N4O5/c1-19(2)37-27(34)23-17-31(18-28(4,5)24-20(3)29-30-25(23)24)26(33)21-7-9-22(10-8-21)36-16-13-32(6)11-14-35-15-12-32/h7-10,17,19H,11-16,18H2,1-6H3,(H,29,30)/q+1
DMI3ELU CS CC1=C2C(=NN1)C(=CN(CC2(C)C)C(=O)C3=CC=C(C=C3)OCC[N+]4(CCOCC4)C)C(=O)OC(C)C
DMI3ELU IK BFMZLOKFIVIHGO-UHFFFAOYSA-N
DMI3ELU IU propan-2-yl 3,4,4-trimethyl-6-[4-[2-(4-methylmorpholin-4-ium-4-yl)ethoxy]benzoyl]-2,5-dihydropyrazolo[3,4-d]azepine-8-carboxylate
DMO45VP ID DMO45VP
DMO45VP DN PMID29649907-Compound-4
DMO45VP HS Patented
DMO45VP CP INTERCEPT PHARMACEUTICALS, INC
DMO45VP DT Small molecular drug
DMS6UD2 ID DMS6UD2
DMS6UD2 DN PMID29649907-Compound-40
DMS6UD2 HS Patented
DMS6UD2 CP AKARNA THERAPEUTICS, LTD
DMS6UD2 DT Small molecular drug
DM26IRH ID DM26IRH
DM26IRH DN PMID29649907-Compound-41
DM26IRH HS Patented
DM26IRH CP NOVARTIS AG CHIANELLI, Donatella LIU, Xiaodong MOLTENI, Valentina NELSON, John ROLAND, Jason RUCKER, Paul TULLY, David
DM26IRH DT Small molecular drug
DM26IRH PC 91758306
DM26IRH MW 566.9
DM26IRH FM C28H21ClF2N4O5
DM26IRH IC InChI=1S/C28H21ClF2N4O5/c1-34-26-19-11-17(29)6-8-23(19)40-14-20(26)25(33-34)27(37)35(12-15-3-2-4-18(30)9-15)13-24(36)32-22-10-16(28(38)39)5-7-21(22)31/h2-11H,12-14H2,1H3,(H,32,36)(H,38,39)
DM26IRH CS CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC(=CC=C4)F)CC(=O)NC5=C(C=CC(=C5)C(=O)O)F
DM26IRH IK VJLVLEHRWCLRBO-UHFFFAOYSA-N
DM26IRH IU 3-[[2-[(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)-[(3-fluorophenyl)methyl]amino]acetyl]amino]-4-fluorobenzoic acid
DMSAD9B ID DMSAD9B
DMSAD9B DN PMID29649907-Compound-42
DMSAD9B HS Patented
DMSAD9B CP NOVARTIS AG CHIANELLI, Donatella LIU, Xiaodong MOLTENI, Valentina NELSON, John ROLAND, Jason RUCKER, Paul Vincent TULLY, David Charles
DMSAD9B DT Small molecular drug
DMSAD9B PC 122657506
DMSAD9B MW 482.9
DMSAD9B FM C25H24ClFN4O3
DMSAD9B IC InChI=1S/C25H24ClFN4O3/c1-30-24-18-10-17(26)8-9-21(18)34-14-19(24)23(29-30)25(33)31(12-16-4-2-3-5-20(16)27)13-22(32)28-11-15-6-7-15/h2-5,8-10,15H,6-7,11-14H2,1H3,(H,28,32)
DMSAD9B CS CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4F)CC(=O)NCC5CC5
DMSAD9B IK CQPYMJNUAFOXPI-UHFFFAOYSA-N
DMSAD9B IU 8-chloro-N-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-[(2-fluorophenyl)methyl]-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carboxamide
DMBA2S3 ID DMBA2S3
DMBA2S3 DN PMID29649907-Compound-44
DMBA2S3 HS Patented
DMBA2S3 CP CITY OF HOPE FOREMAN, Barry
DMBA2S3 DT Small molecular drug
DMDWSIE ID DMDWSIE
DMDWSIE DN PMID29649907-Compound-5
DMDWSIE HS Patented
DMDWSIE CP INTERCEPT PHARMACEUTICALS, INC
DMDWSIE DT Small molecular drug
DMV2D5M ID DMV2D5M
DMV2D5M DN PMID29649907-Compound-8
DMV2D5M HS Patented
DMV2D5M CP INTERCEPT PHARMACEUTICALS, INC
DMV2D5M DT Small molecular drug
DMA6H4W ID DMA6H4W
DMA6H4W DN PMID29649907-Compound-9
DMA6H4W HS Patented
DMA6H4W CP ENANTA PHARMACEUTICALS, INC
DMA6H4W DT Small molecular drug
DMA6H4W PC 121355122
DMA6H4W MW 444.7
DMA6H4W FM C26H44N4O2
DMA6H4W IC InChI=1S/C26H44N4O2/c1-5-17-21-14-16(31)10-12-26(21,4)20-11-13-25(3)18(7-8-19(25)23(20)24(17)32)15(2)6-9-22-27-29-30-28-22/h15-21,23-24,31-32H,5-14H2,1-4H3,(H,27,28,29,30)/t15-,16-,17-,18-,19?,20?,21+,23?,24-,25-,26-/m1/s1
DMA6H4W CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2(C3CC[C@@]4([C@H](CCC4C3[C@@H]1O)[C@H](C)CCC5=NNN=N5)C)C)O
DMA6H4W IK NGMMYLUHCOHSOR-AMGBFIHRSA-N
DMA6H4W IU (3R,5S,6R,7R,10S,13R,17R)-6-ethyl-10,13-dimethyl-17-[(2R)-4-(2H-tetrazol-5-yl)butan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMA0RI8 ID DMA0RI8
DMA0RI8 DN PMID29649907-Compound-INT767
DMA0RI8 HS Patented
DMA0RI8 CP INTERCEPT PHARMACEUTICALS, INC. PELLICCIARI, Roberto FIORUCCI, Stefano PRUZANSKI, Mark
DMA0RI8 DT Small molecular drug
DMNKABH ID DMNKABH
DMNKABH DN PMID29671355-Compound-11
DMNKABH HS Patented
DMNKABH CP ACETYLON PHARMACEUTICALS, INC
DMNKABH DT Small molecular drug
DMNKABH PC 118005782
DMNKABH MW 462.5
DMNKABH FM C24H26N6O4
DMNKABH IC InChI=1S/C24H26N6O4/c1-34-20-9-7-19(8-10-20)27-23(32)30-13-11-24(12-14-30,18-5-3-2-4-6-18)28-22-25-15-17(16-26-22)21(31)29-33/h2-10,15-16,33H,11-14H2,1H3,(H,27,32)(H,29,31)(H,25,26,28)
DMNKABH CS COC1=CC=C(C=C1)NC(=O)N2CCC(CC2)(C3=CC=CC=C3)NC4=NC=C(C=N4)C(=O)NO
DMNKABH IK LFKIEMRCUDLUJN-UHFFFAOYSA-N
DMNKABH IU N-hydroxy-2-[[1-[(4-methoxyphenyl)carbamoyl]-4-phenylpiperidin-4-yl]amino]pyrimidine-5-carboxamide
DMBQOW4 ID DMBQOW4
DMBQOW4 DN PMID29671355-Compound-12
DMBQOW4 HS Patented
DMBQOW4 CP CHDI FOUNDATION, INC
DMBQOW4 DT Small molecular drug
DMBQOW4 PC 78425879
DMBQOW4 MW 335.4
DMBQOW4 FM C18H13N3O2S
DMBQOW4 IC InChI=1S/C18H13N3O2S/c22-18(20-23)16-11-15(19-21(16)13-6-2-1-3-7-13)14-8-4-5-12-9-10-24-17(12)14/h1-11,23H,(H,20,22)
DMBQOW4 CS C1=CC=C(C=C1)N2C(=CC(=N2)C3=CC=CC4=C3SC=C4)C(=O)NO
DMBQOW4 IK OYRFBDZKQFEJSC-UHFFFAOYSA-N
DMBQOW4 IU 5-(1-benzothiophen-7-yl)-N-hydroxy-2-phenylpyrazole-3-carboxamide
DMALXYR ID DMALXYR
DMALXYR DN PMID29671355-Compound-13
DMALXYR HS Patented
DMALXYR DT Small molecular drug
DMALXYR PC 71811260
DMALXYR MW 427.5
DMALXYR FM C26H25N3O3
DMALXYR IC InChI=1S/C26H25N3O3/c1-2-24-27-23-13-10-20(16-19-8-11-21(12-9-19)25(30)28-32)17-22(23)26(31)29(24)15-14-18-6-4-3-5-7-18/h3-13,17,32H,2,14-16H2,1H3,(H,28,30)
DMALXYR CS CCC1=NC2=C(C=C(C=C2)CC3=CC=C(C=C3)C(=O)NO)C(=O)N1CCC4=CC=CC=C4
DMALXYR IK VLBQAJZSHGGUBQ-UHFFFAOYSA-N
DMALXYR IU 4-[[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-6-yl]methyl]-N-hydroxybenzamide
DM8UMQH ID DM8UMQH
DM8UMQH DN PMID29671355-Compound-14
DM8UMQH HS Patented
DM8UMQH DT Small molecular drug
DMAEPD4 ID DMAEPD4
DMAEPD4 DN PMID29671355-Compound-15
DMAEPD4 HS Patented
DMAEPD4 DT Small molecular drug
DMAEPD4 PC 122439227
DMAEPD4 MW 334.4
DMAEPD4 FM C17H22N2O5
DMAEPD4 IC InChI=1S/C17H22N2O5/c20-16(18-22)13-2-3-14-11-19(6-1-7-24-15(14)10-13)17(21)12-4-8-23-9-5-12/h2-3,10,12,22H,1,4-9,11H2,(H,18,20)
DMAEPD4 CS C1CN(CC2=C(C=C(C=C2)C(=O)NO)OC1)C(=O)C3CCOCC3
DMAEPD4 IK UIDRHDHNNBIRIS-UHFFFAOYSA-N
DMAEPD4 IU N-hydroxy-5-(oxane-4-carbonyl)-2,3,4,6-tetrahydro-1,5-benzoxazocine-9-carboxamide
DM2C6ZF ID DM2C6ZF
DM2C6ZF DN PMID29671355-Compound-16
DM2C6ZF HS Patented
DM2C6ZF CP FORMA THERAPEUTICS, INC
DM2C6ZF DT Small molecular drug
DM2C6ZF PC 122616384
DM2C6ZF MW 364.4
DM2C6ZF FM C22H24N2O3
DM2C6ZF IC InChI=1S/C22H24N2O3/c25-20(23-27)18-7-8-19-14-22(11-9-17(19)13-18)10-4-12-24(21(22)26)15-16-5-2-1-3-6-16/h1-3,5-8,13,27H,4,9-12,14-15H2,(H,23,25)
DM2C6ZF CS C1CC2(CCC3=C(C2)C=CC(=C3)C(=O)NO)C(=O)N(C1)CC4=CC=CC=C4
DM2C6ZF IK PRTQLYSHPNDHIG-UHFFFAOYSA-N
DM2C6ZF IU 1'-benzyl-N-hydroxy-2'-oxospiro[7,8-dihydro-5H-naphthalene-6,3'-piperidine]-2-carboxamide
DMUY53P ID DMUY53P
DMUY53P DN PMID29671355-Compound-18
DMUY53P HS Patented
DMUY53P CP KARUS THERAPEUTICS LTD
DMUY53P DT Small molecular drug
DMUY53P PC 86302675
DMUY53P MW 320.3
DMUY53P FM C18H16N4O2
DMUY53P IC InChI=1S/C18H16N4O2/c23-18(21-24)15-9-7-14(8-10-15)13-22(16-5-1-3-11-19-16)17-6-2-4-12-20-17/h1-12,24H,13H2,(H,21,23)
DMUY53P CS C1=CC=NC(=C1)N(CC2=CC=C(C=C2)C(=O)NO)C3=CC=CC=N3
DMUY53P IK FWQCLQYFYHSYHY-UHFFFAOYSA-N
DMUY53P IU 4-[(dipyridin-2-ylamino)methyl]-N-hydroxybenzamide
DM9LMNB ID DM9LMNB
DM9LMNB DN PMID29671355-Compound-19
DM9LMNB HS Patented
DM9LMNB CP KARUS THERAPEUTICS LTD
DM9LMNB DT Small molecular drug
DMPJN0M ID DMPJN0M
DMPJN0M DN PMID29671355-Compound-21
DMPJN0M HS Patented
DMPJN0M CP CHONG KUN DANG PHARMACEUTICAL CORP
DMPJN0M DT Small molecular drug
DMPJN0M PC 86295624
DMPJN0M MW 423.4
DMPJN0M FM C20H20F3N3O4
DMPJN0M IC InChI=1S/C20H20F3N3O4/c21-20(22,23)16-2-1-3-17(12-16)26(19(28)25-8-10-30-11-9-25)13-14-4-6-15(7-5-14)18(27)24-29/h1-7,12,29H,8-11,13H2,(H,24,27)
DMPJN0M CS C1COCCN1C(=O)N(CC2=CC=C(C=C2)C(=O)NO)C3=CC=CC(=C3)C(F)(F)F
DMPJN0M IK SOEPWATUUFBVRJ-UHFFFAOYSA-N
DMPJN0M IU N-[[4-(hydroxycarbamoyl)phenyl]methyl]-N-[3-(trifluoromethyl)phenyl]morpholine-4-carboxamide
DMRGV83 ID DMRGV83
DMRGV83 DN PMID29671355-Compound-22
DMRGV83 HS Patented
DMRGV83 CP THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH BRESLOW, Ronald MARKS, Paul, A
DMRGV83 DT Small molecular drug
DMRGV83 PC 71532921
DMRGV83 MW 314.34
DMRGV83 FM C17H18N2O4
DMRGV83 IC InChI=1S/C17H18N2O4/c20-11-10-19(15-4-2-1-3-5-15)16(21)12-13-6-8-14(9-7-13)17(22)18-23/h1-9,20,23H,10-12H2,(H,18,22)
DMRGV83 CS C1=CC=C(C=C1)N(CCO)C(=O)CC2=CC=C(C=C2)C(=O)NO
DMRGV83 IK RFAZNTABYJYOAR-UHFFFAOYSA-N
DMRGV83 IU N-hydroxy-4-[2-[N-(2-hydroxyethyl)anilino]-2-oxoethyl]benzamide
DMUBOEX ID DMUBOEX
DMUBOEX DN PMID29671355-Compound-23
DMUBOEX HS Patented
DMUBOEX CP UNIVERSIT T REGENSBURG [DEFRIEDRICH SCHILLER UNIVERSIT T JENA [DEUNIVERSIT TSKLINIKUM JENA [DE]
DMUBOEX DT Small molecular drug
DMUBOEX PC 118884610
DMUBOEX MW 404.4
DMUBOEX FM C22H20N4O4
DMUBOEX IC InChI=1S/C22H20N4O4/c1-24-21(28)16-11-25(22(24)29)12-18-19(16)15-4-2-3-5-17(15)26(18)10-13-6-8-14(9-7-13)20(27)23-30/h2-9,16,30H,10-12H2,1H3,(H,23,27)
DMUBOEX CS CN1C(=O)C2CN(C1=O)CC3=C2C4=CC=CC=C4N3CC5=CC=C(C=C5)C(=O)NO
DMUBOEX IK ZCAIUGLOTHAUQX-UHFFFAOYSA-N
DMUBOEX IU N-hydroxy-4-[(14-methyl-13,15-dioxo-9,12,14-triazatetracyclo[10.3.1.02,10.03,8]hexadeca-2(10),3,5,7-tetraen-9-yl)methyl]benzamide
DMCIGJ1 ID DMCIGJ1
DMCIGJ1 DN PMID29671355-Compound-24
DMCIGJ1 HS Patented
DMCIGJ1 CP CHONG KUN DANG PHARMACEUTICAL CORP
DMCIGJ1 DT Small molecular drug
DMPV0KZ ID DMPV0KZ
DMPV0KZ DN PMID29671355-Compound-25
DMPV0KZ HS Patented
DMPV0KZ DT Small molecular drug
DMPV0KZ PC 126569528
DMPV0KZ MW 301.32
DMPV0KZ FM C14H11N3O3S
DMPV0KZ IC InChI=1S/C14H11N3O3S/c18-12(16-20)10-5-3-9(4-6-10)8-17-14(19)11-2-1-7-15-13(11)21-17/h1-7,20H,8H2,(H,16,18)
DMPV0KZ CS C1=CC2=C(N=C1)SN(C2=O)CC3=CC=C(C=C3)C(=O)NO
DMPV0KZ IK VLJAVCKTTLIBDT-UHFFFAOYSA-N
DMPV0KZ IU N-hydroxy-4-[(3-oxo-[1,2]thiazolo[5,4-b]pyridin-2-yl)methyl]benzamide
DM5K6MG ID DM5K6MG
DM5K6MG DN PMID29671355-Compound-26
DM5K6MG HS Patented
DM5K6MG CP THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM5K6MG DT Small molecular drug
DM5K6MG PC 130361892
DM5K6MG MW 283.32
DM5K6MG FM C16H17N3O2
DM5K6MG IC InChI=1S/C16H17N3O2/c20-16(18-21)13-7-5-12(6-8-13)11-19-10-9-17-14-3-1-2-4-15(14)19/h1-8,17,21H,9-11H2,(H,18,20)
DM5K6MG CS C1CN(C2=CC=CC=C2N1)CC3=CC=C(C=C3)C(=O)NO
DM5K6MG IK RGVWNOQFULPCMK-UHFFFAOYSA-N
DM5K6MG IU 4-(3,4-dihydro-2H-quinoxalin-1-ylmethyl)-N-hydroxybenzamide
DMP7S9E ID DMP7S9E
DMP7S9E DN PMID29671355-Compound-27
DMP7S9E HS Patented
DMP7S9E CP CHARIT UNIVERSIT TSMEDIZIN BERLIN [DEUNIVERSIT T BAYREUTH [DE]
DMP7S9E DT Small molecular drug
DMP7S9E PC 130227480
DMP7S9E MW 363.4
DMP7S9E FM C21H21N3O3
DMP7S9E IC InChI=1S/C21H21N3O3/c1-3-24-14-22-20(16-9-11-18(27-2)12-10-16)21(24)17-7-4-15(5-8-17)6-13-19(25)23-26/h4-14,26H,3H2,1-2H3,(H,23,25)/b13-6+
DMP7S9E CS CCN1C=NC(=C1C2=CC=C(C=C2)/C=C/C(=O)NO)C3=CC=C(C=C3)OC
DMP7S9E IK JRABOCDIAYUFQB-AWNIVKPZSA-N
DMP7S9E IU (E)-3-[4-[3-ethyl-5-(4-methoxyphenyl)imidazol-4-yl]phenyl]-N-hydroxyprop-2-enamide
DMLXSHW ID DMLXSHW
DMLXSHW DN PMID29671355-Compound-28
DMLXSHW HS Patented
DMLXSHW CP CHARIT UNIVERSIT TSMEDIZIN BERLIN [DEUNIVERSIT T BAYREUTH [DE]
DMLXSHW DT Small molecular drug
DM3H78D ID DM3H78D
DM3H78D DN PMID29671355-Compound-31
DM3H78D HS Patented
DM3H78D CP THE GENERAL HOSPITAL CORPORATION
DM3H78D DT Small molecular drug
DM3H78D PC 90479372
DM3H78D MW 354.5
DM3H78D FM C22H30N2O2
DM3H78D IC InChI=1S/C22H30N2O2/c1-24(14-17-4-2-16(3-5-17)6-7-21(25)23-26)15-22-11-18-8-19(12-22)10-20(9-18)13-22/h2-7,18-20,26H,8-15H2,1H3,(H,23,25)/b7-6+
DM3H78D CS CN(CC1=CC=C(C=C1)/C=C/C(=O)NO)CC23CC4CC(C2)CC(C4)C3
DM3H78D IK WNIDBXBLQFPAJA-VOTSOKGWSA-N
DM3H78D IU (E)-3-[4-[[1-adamantylmethyl(methyl)amino]methyl]phenyl]-N-hydroxyprop-2-enamide
DM3H78D CA CAS 1629052-58-9
DMQJ3TC ID DMQJ3TC
DMQJ3TC DN PMID29671355-Compound-36
DMQJ3TC HS Patented
DMQJ3TC CP UNIVERSITE PARIS-SUD CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
DMQJ3TC DT Small molecular drug
DMJ1O5R ID DMJ1O5R
DMJ1O5R DN PMID29671355-Compound-37
DMJ1O5R HS Patented
DMJ1O5R CP INCYTE CORPORATION
DMJ1O5R DT Small molecular drug
DMYATB5 ID DMYATB5
DMYATB5 DN PMID29671355-Compound-38a
DMYATB5 HS Patented
DMYATB5 CP KARUS THERAPEUTICS LTD
DMYATB5 DT Small molecular drug
DMYATB5 PC 121304883
DMYATB5 MW 316.36
DMYATB5 FM C15H20N6O2
DMYATB5 IC InChI=1S/C15H20N6O2/c22-15(20-23)5-3-1-2-4-8-21(13-9-17-12-18-10-13)14-11-16-6-7-19-14/h6-7,9-12,23H,1-5,8H2,(H,20,22)
DMYATB5 CS C1=CN=C(C=N1)N(CCCCCCC(=O)NO)C2=CN=CN=C2
DMYATB5 IK SQFSXNZGZJNPJZ-UHFFFAOYSA-N
DMYATB5 IU N-hydroxy-7-[pyrazin-2-yl(pyrimidin-5-yl)amino]heptanamide
DMYXE4J ID DMYXE4J
DMYXE4J DN PMID29671355-Compound-38b
DMYXE4J HS Patented
DMYXE4J CP KARUS THERAPEUTICS LTD
DMYXE4J DT Small molecular drug
DMYXE4J PC 73774655
DMYXE4J MW 335.4
DMYXE4J FM C15H21N5O2S
DMYXE4J IC InChI=1S/C15H21N5O2S/c1-12-17-15(23-19-12)20(13-8-5-6-10-16-13)11-7-3-2-4-9-14(21)18-22/h5-6,8,10,22H,2-4,7,9,11H2,1H3,(H,18,21)
DMYXE4J CS CC1=NSC(=N1)N(CCCCCCC(=O)NO)C2=CC=CC=N2
DMYXE4J IK OMIWXFMPPYEWJD-UHFFFAOYSA-N
DMYXE4J IU N-hydroxy-7-[(3-methyl-1,2,4-thiadiazol-5-yl)-pyridin-2-ylamino]heptanamide
DM6EJ93 ID DM6EJ93
DM6EJ93 DN PMID29671355-Compound-39
DM6EJ93 HS Patented
DM6EJ93 CP CHONG KUN DANG PHARMACEUTICAL CORP
DM6EJ93 DT Small molecular drug
DM6EJ93 PC 124093354
DM6EJ93 MW 438.6
DM6EJ93 FM C25H34N4O3
DM6EJ93 IC InChI=1S/C25H34N4O3/c30-23(27-32)15-9-1-2-10-16-26-25(31)29-19-17-28(18-20-29)24(21-11-5-3-6-12-21)22-13-7-4-8-14-22/h3-8,11-14,24,32H,1-2,9-10,15-20H2,(H,26,31)(H,27,30)
DM6EJ93 CS C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCCCCCCC(=O)NO
DM6EJ93 IK GFDQSOACLIFRIQ-UHFFFAOYSA-N
DM6EJ93 IU 4-benzhydryl-N-[7-(hydroxyamino)-7-oxoheptyl]piperazine-1-carboxamide
DMXY103 ID DMXY103
DMXY103 DN PMID29671355-Compound-42
DMXY103 HS Patented
DMXY103 CP AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
DMXY103 DT Small molecular drug
DMXY103 PC 118366974
DMXY103 MW 509.6
DMXY103 FM C26H35N7O4
DMXY103 IC InChI=1S/C26H35N7O4/c1-18(2)33-17-27-24-23(29-26(30-25(24)33)32-12-14-37-15-13-32)19-8-7-9-20(16-19)28-21(34)10-5-3-4-6-11-22(35)31-36/h7-9,16-18,36H,3-6,10-15H2,1-2H3,(H,28,34)(H,31,35)
DMXY103 CS CC(C)N1C=NC2=C(N=C(N=C21)N3CCOCC3)C4=CC(=CC=C4)NC(=O)CCCCCCC(=O)NO
DMXY103 IK QWBHGNUFZYWTSG-UHFFFAOYSA-N
DMXY103 IU N'-hydroxy-N-[3-(2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)phenyl]octanediamide
DMVPMWJ ID DMVPMWJ
DMVPMWJ DN PMID29671355-Compound-43
DMVPMWJ HS Patented
DMVPMWJ CP THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
DMVPMWJ DT Small molecular drug
DMVPMWJ PC 118515590
DMVPMWJ MW 481.6
DMVPMWJ FM C25H35N7O3
DMVPMWJ IC InChI=1S/C25H35N7O3/c1-32-17-26-23-22(32)24(27-18-9-5-4-6-10-18)30-25(29-23)28-19-12-14-20(15-13-19)35-16-8-3-2-7-11-21(33)31-34/h12-15,17-18,34H,2-11,16H2,1H3,(H,31,33)(H2,27,28,29,30)
DMVPMWJ CS CN1C=NC2=C1C(=NC(=N2)NC3=CC=C(C=C3)OCCCCCCC(=O)NO)NC4CCCCC4
DMVPMWJ IK RYYJQDSPRGRHMH-UHFFFAOYSA-N
DMVPMWJ IU 7-[4-[[6-(cyclohexylamino)-7-methylpurin-2-yl]amino]phenoxy]-N-hydroxyheptanamide
DM80A3V ID DM80A3V
DM80A3V DN PMID29671355-Compound-44
DM80A3V HS Patented
DM80A3V CP SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
DM80A3V DT Small molecular drug
DM80A3V PC 72710871
DM80A3V MW 458.4
DM80A3V FM C20H25F3N4O5
DM80A3V IC InChI=1S/C20H25F3N4O5/c21-20(22,23)12-5-4-6-13(11-12)24-18(30)14(7-2-1-3-8-17(29)27-32)26-19(31)15-9-10-16(28)25-15/h4-6,11,14-15,32H,1-3,7-10H2,(H,24,30)(H,25,28)(H,26,31)(H,27,29)/t14-,15+/m0/s1
DM80A3V CS C1CC(=O)N[C@H]1C(=O)N[C@@H](CCCCCC(=O)NO)C(=O)NC2=CC=CC(=C2)C(F)(F)F
DM80A3V IK XVGBJXUAVWXLJX-LSDHHAIUSA-N
DM80A3V IU (2S)-N'-hydroxy-2-[[(2R)-5-oxopyrrolidine-2-carbonyl]amino]-N-[3-(trifluoromethyl)phenyl]octanediamide
DM5LYKR ID DM5LYKR
DM5LYKR DN PMID29671355-Compound-45a
DM5LYKR HS Patented
DM5LYKR CP CHDI FOUNDATION, INC
DM5LYKR DT Small molecular drug
DM5LYKR PC 86302836
DM5LYKR MW 337.3
DM5LYKR FM C19H16FN3O2
DM5LYKR IC InChI=1S/C19H16FN3O2/c1-12-21-10-15(11-22-12)13-6-8-14(9-7-13)18(19(24)23-25)16-4-2-3-5-17(16)20/h2-11,18,25H,1H3,(H,23,24)
DM5LYKR CS CC1=NC=C(C=N1)C2=CC=C(C=C2)C(C3=CC=CC=C3F)C(=O)NO
DM5LYKR IK SFXMVIQZYOMYOF-UHFFFAOYSA-N
DM5LYKR IU 2-(2-fluorophenyl)-N-hydroxy-2-[4-(2-methylpyrimidin-5-yl)phenyl]acetamide
DM5I1QV ID DM5I1QV
DM5I1QV DN PMID29671355-Compound-47a
DM5I1QV HS Patented
DM5I1QV CP CHDI FOUNDATION, INC
DM5I1QV DT Small molecular drug
DM5I1QV PC 72722126
DM5I1QV MW 367.3
DM5I1QV FM C20H15F2N3O2
DM5I1QV IC InChI=1S/C20H15F2N3O2/c21-15-10-23-18(24-11-15)14-8-6-13(7-9-14)17-16(12-4-2-1-3-5-12)20(17,22)19(26)25-27/h1-11,16-17,27H,(H,25,26)/t16-,17-,20+/m1/s1
DM5I1QV CS C1=CC=C(C=C1)[C@@H]2[C@H]([C@@]2(C(=O)NO)F)C3=CC=C(C=C3)C4=NC=C(C=N4)F
DM5I1QV IK MREATSZIGJDNKB-HLIPFELVSA-N
DM5I1QV IU (1S,2S,3S)-1-fluoro-2-[4-(5-fluoropyrimidin-2-yl)phenyl]-N-hydroxy-3-phenylcyclopropane-1-carboxamide
DMBUJ39 ID DMBUJ39
DMBUJ39 DN PMID29671355-Compound-47b
DMBUJ39 HS Patented
DMBUJ39 CP CHDI FOUNDATION, INC
DMBUJ39 DT Small molecular drug
DMBUJ39 PC 72950863
DMBUJ39 MW 363.4
DMBUJ39 FM C21H18FN3O2
DMBUJ39 IC InChI=1S/C21H18FN3O2/c1-13-11-23-19(24-12-13)16-9-7-15(8-10-16)18-17(14-5-3-2-4-6-14)21(18,22)20(26)25-27/h2-12,17-18,27H,1H3,(H,25,26)/t17-,18-,21+/m1/s1
DMBUJ39 CS CC1=CN=C(N=C1)C2=CC=C(C=C2)[C@@H]3[C@H]([C@]3(C(=O)NO)F)C4=CC=CC=C4
DMBUJ39 IK LERFWXLGVNOQCJ-OPYAIIAOSA-N
DMBUJ39 IU (1S,2S,3S)-1-fluoro-N-hydroxy-2-[4-(5-methylpyrimidin-2-yl)phenyl]-3-phenylcyclopropane-1-carboxamide
DMAH982 ID DMAH982
DMAH982 DN PMID29671355-Compound-47c
DMAH982 HS Patented
DMAH982 CP CHDI FOUNDATION, INC
DMAH982 DT Small molecular drug
DMAH982 PC 72948227
DMAH982 MW 415.4
DMAH982 FM C21H16F3N3O3
DMAH982 IC InChI=1S/C21H16F3N3O3/c22-20(23)30-15-10-25-18(26-11-15)14-8-6-13(7-9-14)17-16(12-4-2-1-3-5-12)21(17,24)19(28)27-29/h1-11,16-17,20,29H,(H,27,28)/t16-,17-,21+/m1/s1
DMAH982 CS C1=CC=C(C=C1)[C@@H]2[C@H]([C@@]2(C(=O)NO)F)C3=CC=C(C=C3)C4=NC=C(C=N4)OC(F)F
DMAH982 IK RUTGGTYDBCHEPE-LZJOCLMNSA-N
DMAH982 IU (1S,2S,3S)-2-[4-[5-(difluoromethoxy)pyrimidin-2-yl]phenyl]-1-fluoro-N-hydroxy-3-phenylcyclopropane-1-carboxamide
DMPA9OY ID DMPA9OY
DMPA9OY DN PMID29671355-Compound-47d
DMPA9OY HS Patented
DMPA9OY CP CHDI FOUNDATION, INC
DMPA9OY DT Small molecular drug
DMPA9OY PC 72948224
DMPA9OY MW 417.4
DMPA9OY FM C21H15F4N3O2
DMPA9OY IC InChI=1S/C21H15F4N3O2/c22-20(19(29)28-30)16(12-4-2-1-3-5-12)17(20)13-6-8-14(9-7-13)18-26-11-10-15(27-18)21(23,24)25/h1-11,16-17,30H,(H,28,29)/t16-,17-,20+/m1/s1
DMPA9OY CS C1=CC=C(C=C1)[C@@H]2[C@H]([C@@]2(C(=O)NO)F)C3=CC=C(C=C3)C4=NC=CC(=N4)C(F)(F)F
DMPA9OY IK DDTXYXHMSVMLET-HLIPFELVSA-N
DMPA9OY IU (1S,2S,3S)-1-fluoro-N-hydroxy-2-phenyl-3-[4-[4-(trifluoromethyl)pyrimidin-2-yl]phenyl]cyclopropane-1-carboxamide
DMLDFVN ID DMLDFVN
DMLDFVN DN PMID29671355-Compound-50
DMLDFVN HS Patented
DMLDFVN CP CHDI FOUNDATION, INC
DMLDFVN DT Small molecular drug
DMEUZM3 ID DMEUZM3
DMEUZM3 DN PMID29671355-Compound-52
DMEUZM3 HS Patented
DMEUZM3 CP CHDI FOUNDATION, INC
DMEUZM3 DT Small molecular drug
DMEUZM3 PC 117603070
DMEUZM3 MW 385.4
DMEUZM3 FM C21H21F2N3O2
DMEUZM3 IC InChI=1S/C21H21F2N3O2/c1-12-16(4-3-5-17(12)22)21(20(27)25-28)9-8-13(10-21)15-7-6-14-11-24-26(2)19(14)18(15)23/h3-7,11,13,28H,8-10H2,1-2H3,(H,25,27)
DMEUZM3 CS CC1=C(C=CC=C1F)C2(CCC(C2)C3=C(C4=C(C=C3)C=NN4C)F)C(=O)NO
DMEUZM3 IK CFMBAUBXRNMZPH-UHFFFAOYSA-N
DMEUZM3 IU 3-(7-fluoro-1-methylindazol-6-yl)-1-(3-fluoro-2-methylphenyl)-N-hydroxycyclopentane-1-carboxamide
DMCRWV3 ID DMCRWV3
DMCRWV3 DN PMID29671355-Compound-53
DMCRWV3 HS Patented
DMCRWV3 CP UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
DMCRWV3 DT Small molecular drug
DMCRWV3 PC 97324
DMCRWV3 MW 196.27
DMCRWV3 FM C10H12O2S
DMCRWV3 IC InChI=1S/C10H12O2S/c11-10(12)7-4-8-13-9-5-2-1-3-6-9/h1-3,5-6H,4,7-8H2,(H,11,12)
DMCRWV3 CS C1=CC=C(C=C1)SCCCC(=O)O
DMCRWV3 IK HHZVQLOVHIDMBD-UHFFFAOYSA-N
DMCRWV3 IU 4-phenylsulfanylbutanoic acid
DMCRWV3 CA CAS 17742-51-7
DMJV1SY ID DMJV1SY
DMJV1SY DN PMID29671355-Compound-55
DMJV1SY HS Patented
DMJV1SY CP BIOMARIN PHARMACEUTICAL INC
DMJV1SY DT Small molecular drug
DMJV1SY PC 60198673
DMJV1SY MW 408.5
DMJV1SY FM C26H24N4O
DMJV1SY IC InChI=1S/C26H24N4O/c27-23-3-1-2-4-24(23)29-26(31)22-9-5-18(6-10-22)13-20-16-30(17-20)15-19-7-8-21-11-12-28-25(21)14-19/h1-14,28H,15-17,27H2,(H,29,31)
DMJV1SY CS C1C(=CC2=CC=C(C=C2)C(=O)NC3=CC=CC=C3N)CN1CC4=CC5=C(C=C4)C=CN5
DMJV1SY IK YLZQVWHBPTVEHO-UHFFFAOYSA-N
DMJV1SY IU N-(2-aminophenyl)-4-[[1-(1H-indol-6-ylmethyl)azetidin-3-ylidene]methyl]benzamide
DM0VBMI ID DM0VBMI
DM0VBMI DN PMID29671355-Compound-56
DM0VBMI HS Patented
DM0VBMI CP CANCER RESEARCH TECHNOLOGY LIMITED GRIGG, Ronald Ernest INMAN, Martyn PACKHAM, Graham
DM0VBMI DT Small molecular drug
DM0VBMI PC 56965342
DM0VBMI MW 383.4
DM0VBMI FM C24H21N3O2
DM0VBMI IC InChI=1S/C24H21N3O2/c1-16-14-27(24(29)20-7-3-2-6-19(16)20)15-17-10-12-18(13-11-17)23(28)26-22-9-5-4-8-21(22)25/h2-13H,1,14-15,25H2,(H,26,28)
DM0VBMI CS C=C1CN(C(=O)C2=CC=CC=C12)CC3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N
DM0VBMI IK GTLTXEIKQVWSRF-UHFFFAOYSA-N
DM0VBMI IU N-(2-aminophenyl)-4-[(4-methylidene-1-oxo-3H-isoquinolin-2-yl)methyl]benzamide
DM57N3Y ID DM57N3Y
DM57N3Y DN PMID29671355-Compound-57
DM57N3Y HS Patented
DM57N3Y CP BIOMARIN PHARMACEUTICAL INC
DM57N3Y DT Small molecular drug
DM2F0CQ ID DM2F0CQ
DM2F0CQ DN PMID29671355-Compound-59
DM2F0CQ HS Patented
DM2F0CQ CP REGENACY PHARMACEUTICALS, LLC
DM2F0CQ DT Small molecular drug
DM2F0CQ PC 130319551
DM2F0CQ MW 429.5
DM2F0CQ FM C24H23N5OS
DM2F0CQ IC InChI=1S/C24H23N5OS/c25-20-6-4-17(23-2-1-11-31-23)14-21(20)28-24(30)22-13-16-3-5-19(12-18(16)15-27-22)29-9-7-26-8-10-29/h1-6,11-15,26H,7-10,25H2,(H,28,30)
DM2F0CQ CS C1CN(CCN1)C2=CC3=CN=C(C=C3C=C2)C(=O)NC4=C(C=CC(=C4)C5=CC=CS5)N
DM2F0CQ IK SRWKZCCXNJSFMX-UHFFFAOYSA-N
DM2F0CQ IU N-(2-amino-5-thiophen-2-ylphenyl)-7-piperazin-1-ylisoquinoline-3-carboxamide
DMXH1G3 ID DMXH1G3
DMXH1G3 DN PMID29671355-Compound-61
DMXH1G3 HS Patented
DMXH1G3 CP UWM RESEARCH FOUNDATION, INC
DMXH1G3 DT Small molecular drug
DMWRS34 ID DMWRS34
DMWRS34 DN PMID29671355-Compound-62
DMWRS34 HS Patented
DMWRS34 CP SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A
DMWRS34 DT Small molecular drug
DMY3Q58 ID DMY3Q58
DMY3Q58 DN PMID29671355-Compound-65a
DMY3Q58 HS Patented
DMY3Q58 CP THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DMY3Q58 DT Small molecular drug
DMY3Q58 PC 126720707
DMY3Q58 MW 303.4
DMY3Q58 FM C16H21N3OS
DMY3Q58 IC InChI=1S/C16H21N3OS/c20-15(12-21)18-10-3-1-2-9-17-14-8-4-6-13-7-5-11-19-16(13)14/h4-8,11,17,21H,1-3,9-10,12H2,(H,18,20)
DMY3Q58 CS C1=CC2=C(C(=C1)NCCCCCNC(=O)CS)N=CC=C2
DMY3Q58 IK WCTPLVYFIGGBJC-UHFFFAOYSA-N
DMY3Q58 IU N-[5-(quinolin-8-ylamino)pentyl]-2-sulfanylacetamide
DM1RPL4 ID DM1RPL4
DM1RPL4 DN PMID29671355-Compound-67
DM1RPL4 HS Patented
DM1RPL4 CP HOCHSCHULE DARMSTADT
DM1RPL4 DT Small molecular drug
DM1RPL4 PC 60201048
DM1RPL4 MW 235.28
DM1RPL4 FM C11H10FN3S
DM1RPL4 IC InChI=1S/C11H10FN3S/c12-7-2-3-8-9(6-7)16-11(13)15-5-1-4-14-10(8)15/h2-3,6,13H,1,4-5H2
DM1RPL4 CS C1CN=C2C3=C(C=C(C=C3)F)SC(=N)N2C1
DM1RPL4 IK QEVWRCSULVKULZ-UHFFFAOYSA-N
DM1RPL4 IU 9-fluoro-3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine
DMLGBR6 ID DMLGBR6
DMLGBR6 DN PMID29671355-Compound-68b
DMLGBR6 HS Patented
DMLGBR6 CP UNIVERSITY OF CONNECTICUT
DMLGBR6 DT Small molecular drug
DMU61XP ID DMU61XP
DMU61XP DN PMID29671355-Compound-69
DMU61XP HS Patented
DMU61XP CP IRBM - SCIENCE PARK S.P.A. C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
DMU61XP DT Small molecular drug
DMU61XP PC 72793856
DMU61XP MW 478.6
DMU61XP FM C27H34N4O4
DMU61XP IC InChI=1S/C27H34N4O4/c1-4-20(32)11-6-5-7-13-23(29-25(33)19-16-31(2)17-19)27-28-15-24(35-27)21-14-18-10-8-9-12-22(18)30-26(21)34-3/h8-10,12,14-15,19,23H,4-7,11,13,16-17H2,1-3H3,(H,29,33)/t23-/m0/s1
DMU61XP CS CCC(=O)CCCCC[C@@H](C1=NC=C(O1)C2=CC3=CC=CC=C3N=C2OC)NC(=O)C4CN(C4)C
DMU61XP IK YOCBGMVQRJHNRU-QHCPKHFHSA-N
DMU61XP IU N-[(1S)-1-[5-(2-methoxyquinolin-3-yl)-1,3-oxazol-2-yl]-7-oxononyl]-1-methylazetidine-3-carboxamide
DM394WH ID DM394WH
DM394WH DN PMID29671355-Compound-70
DM394WH HS Patented
DM394WH CP CHDI FOUNDATION, INC
DM394WH DT Small molecular drug
DM394WH PC 122669618
DM394WH MW 408.4
DM394WH FM C20H23F3N4O2
DM394WH IC InChI=1S/C20H23F3N4O2/c1-13(11-27-10-2-7-19(12-27)8-9-19)24-17(28)15-5-3-14(4-6-15)16-25-18(29-26-16)20(21,22)23/h3-6,13H,2,7-12H2,1H3,(H,24,28)/t13-/m1/s1
DM394WH CS C[C@H](CN1CCCC2(C1)CC2)NC(=O)C3=CC=C(C=C3)C4=NOC(=N4)C(F)(F)F
DM394WH IK DPJWEPTZTQMWTC-CYBMUJFWSA-N
DM394WH IU N-[(2R)-1-(5-azaspiro[2.5]octan-5-yl)propan-2-yl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
DMUAC1T ID DMUAC1T
DMUAC1T DN PMID29671355-Compound-71a
DMUAC1T HS Patented
DMUAC1T CP CHDI FOUNDATION, INC
DMUAC1T DT Small molecular drug
DM8VG4Q ID DM8VG4Q
DM8VG4Q DN PMID29671355-Compound-71b
DM8VG4Q HS Patented
DM8VG4Q CP CHDI FOUNDATION, INC
DM8VG4Q DT Small molecular drug
DMICDV6 ID DMICDV6
DMICDV6 DN PMID29671355-Compound-72a
DMICDV6 HS Patented
DMICDV6 CP CHDI FOUNDATION, INC
DMICDV6 DT Small molecular drug
DM08OV7 ID DM08OV7
DM08OV7 DN PMID29671355-Compound-72b
DM08OV7 HS Patented
DM08OV7 CP CHDI FOUNDATION, INC
DM08OV7 DT Small molecular drug
DMCNF36 ID DMCNF36
DMCNF36 DN PMID29671355-Compound-73
DMCNF36 HS Patented
DMCNF36 DT Small molecular drug
DMCNF36 PC 124194015
DMCNF36 MW 345.27
DMCNF36 FM C17H10F3N3O2
DMCNF36 IC InChI=1S/C17H10F3N3O2/c18-17(19,20)16-21-14(22-25-16)10-6-7-13-11(8-10)9-23(15(13)24)12-4-2-1-3-5-12/h1-8H,9H2
DMCNF36 CS C1C2=C(C=CC(=C2)C3=NOC(=N3)C(F)(F)F)C(=O)N1C4=CC=CC=C4
DMCNF36 IK FROSXYATWLHDNN-UHFFFAOYSA-N
DMCNF36 IU 2-phenyl-5-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]-3H-isoindol-1-one
DM49YTU ID DM49YTU
DM49YTU DN PMID29671355-Compound-74
DM49YTU HS Patented
DM49YTU CP UNIVERSITY OF CONNECTICUT
DM49YTU DT Small molecular drug
DM49YTU PC 72946782
DM49YTU MW 278.35
DM49YTU FM C15H22N2O3
DM49YTU IC InChI=1S/C15H22N2O3/c1-2-20-15(19)17-11-6-9-14(18)16-12-10-13-7-4-3-5-8-13/h3-5,7-8H,2,6,9-12H2,1H3,(H,16,18)(H,17,19)
DM49YTU CS CCOC(=O)NCCCC(=O)NCCC1=CC=CC=C1
DM49YTU IK HTOYBIILVCHURC-UHFFFAOYSA-N
DM49YTU IU ethyl N-[4-oxo-4-(2-phenylethylamino)butyl]carbamate
DM7YQJK ID DM7YQJK
DM7YQJK DN PMID29671355-Compound-8
DM7YQJK HS Patented
DM7YQJK CP THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
DM7YQJK DT Small molecular drug
DMXL96M ID DMXL96M
DMXL96M DN PMID29671355-Compound-9
DMXL96M HS Patented
DMXL96M CP ACETYLON PHARMACEUTICALS, INC. VIB VZW KATHOLIEKE UNVERSITEIT LEUVEN LIFE SCIENCES RESEARCH PARTNERS VZW
DMXL96M DT Small molecular drug
DMXL96M PC 57381425
DMXL96M MW 270.29
DMXL96M FM C14H14N4O2
DMXL96M IC InChI=1S/C14H14N4O2/c19-12(18-20)10-8-15-13(16-9-10)17-14(6-7-14)11-4-2-1-3-5-11/h1-5,8-9,20H,6-7H2,(H,18,19)(H,15,16,17)
DMXL96M CS C1CC1(C2=CC=CC=C2)NC3=NC=C(C=N3)C(=O)NO
DMXL96M IK LIIWIMDSZVNYHY-UHFFFAOYSA-N
DMXL96M IU N-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide
DMZBHR9 ID DMZBHR9
DMZBHR9 DN PMID29757691-Compound-10
DMZBHR9 HS Patented
DMZBHR9 CP FARGEM FARMAS T K ARA TIRMA GEL T RME MERKEZ SANAY VE T&Id [TR]
DMZBHR9 DT Small molecular drug
DMEUC04 ID DMEUC04
DMEUC04 DN PMID29757691-Compound-2a
DMEUC04 HS Patented
DMEUC04 CP UNIV WARSZAWSKI [PLCT MEDYCZNE KSZTALCENIA PODYPLOMOWEGO [PL]
DMEUC04 DT Small molecular drug
DMBRQP1 ID DMBRQP1
DMBRQP1 DN PMID29757691-Compound-2a-i
DMBRQP1 HS Patented
DMBRQP1 CP UNIV WARSZAWSKI [PLCT MEDYCZNE KSZTALCENIA PODYPLOMOWEGO [PL]
DMBRQP1 DT Small molecular drug
DMBRQP1 PC 71078245
DMBRQP1 MW 555.7
DMBRQP1 FM C33H41N5O3
DMBRQP1 IC InChI=1S/C33H41N5O3/c1-22(39)35-18-15-23(20-31(41-33(34)40)25-13-14-28-24(21-25)16-19-36-28)8-6-7-17-37-32-26-9-2-4-11-29(26)38-30-12-5-3-10-27(30)32/h2,4,9,11,13-14,16,19,21,23,31,36H,3,5-8,10,12,15,17-18,20H2,1H3,(H2,34,40)(H,35,39)(H,37,38)
DMBRQP1 CS CC(=O)NCCC(CCCCNC1=C2CCCCC2=NC3=CC=CC=C31)CC(C4=CC5=C(C=C4)NC=C5)OC(=O)N
DMBRQP1 IK YSPYIIMVNQAFBG-UHFFFAOYSA-N
DMBRQP1 IU [3-(2-acetamidoethyl)-1-(1H-indol-5-yl)-7-(1,2,3,4-tetrahydroacridin-9-ylamino)heptyl] carbamate
DMFD9UZ ID DMFD9UZ
DMFD9UZ DN PMID29757691-Compound-4
DMFD9UZ HS Patented
DMFD9UZ DT Small molecular drug
DM7TPBF ID DM7TPBF
DM7TPBF DN PMID29757691-Compound-7
DM7TPBF HS Patented
DM7TPBF DT Small molecular drug
DM7TPBF PC 71451207
DM7TPBF MW 494
DM7TPBF FM C28H32ClN3O3
DM7TPBF IC InChI=1S/C28H32ClN3O3/c29-20-11-12-22-24(18-20)32-23-8-4-3-7-21(23)28(22)31-16-6-2-1-5-15-30-27(35)14-10-19-9-13-25(33)26(34)17-19/h9-14,17-18,33-34H,1-8,15-16H2,(H,30,35)(H,31,32)/b14-10+
DM7TPBF CS C1CCC2=NC3=C(C=CC(=C3)Cl)C(=C2C1)NCCCCCCNC(=O)/C=C/C4=CC(=C(C=C4)O)O
DM7TPBF IK PBISLIYZMJMPKF-GXDHUFHOSA-N
DM7TPBF IU (E)-N-[6-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]hexyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide
DM5IFBV ID DM5IFBV
DM5IFBV DN PMID29757691-Compound-8a
DM5IFBV HS Patented
DM5IFBV DT Small molecular drug
DM5IFBV PC 42602188
DM5IFBV MW 432.6
DM5IFBV FM C28H36N2O2
DM5IFBV IC InChI=1S/C28H36N2O2/c31-27(15-21-29-17-3-1-4-18-29)25-11-7-23(8-12-25)24-9-13-26(14-10-24)28(32)16-22-30-19-5-2-6-20-30/h7-14H,1-6,15-22H2
DM5IFBV CS C1CCN(CC1)CCC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)CCN4CCCCC4
DM5IFBV IK OEJCMWCXCHXDOS-UHFFFAOYSA-N
DM5IFBV IU 3-piperidin-1-yl-1-[4-[4-(3-piperidin-1-ylpropanoyl)phenyl]phenyl]propan-1-one
DM5IFBV CA CAS 1092934-23-0
DMEOZKF ID DMEOZKF
DMEOZKF DN PMID29757691-Compound-8b
DMEOZKF HS Patented
DMEOZKF DT Small molecular drug
DMEOZKF PC 42602271
DMEOZKF MW 436.5
DMEOZKF FM C26H32N2O4
DMEOZKF IC InChI=1S/C26H32N2O4/c29-25(9-11-27-13-17-31-18-14-27)23-5-1-21(2-6-23)22-3-7-24(8-4-22)26(30)10-12-28-15-19-32-20-16-28/h1-8H,9-20H2
DMEOZKF CS C1COCCN1CCC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)CCN4CCOCC4
DMEOZKF IK UKUXOYHUMOANRU-UHFFFAOYSA-N
DMEOZKF IU 3-morpholin-4-yl-1-[4-[4-(3-morpholin-4-ylpropanoyl)phenyl]phenyl]propan-1-one
DMHL7SW ID DMHL7SW
DMHL7SW DN PMID29757691-Compound-8c
DMHL7SW HS Patented
DMHL7SW DT Small molecular drug
DMHL7SW PC 42602187
DMHL7SW MW 408.6
DMHL7SW FM C26H36N2O2
DMHL7SW IC InChI=1S/C26H36N2O2/c1-5-27(6-2)19-17-25(29)23-13-9-21(10-14-23)22-11-15-24(16-12-22)26(30)18-20-28(7-3)8-4/h9-16H,5-8,17-20H2,1-4H3
DMHL7SW CS CCN(CC)CCC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCN(CC)CC
DMHL7SW IK BFCHHHLQSJIBJK-UHFFFAOYSA-N
DMHL7SW IU 3-(diethylamino)-1-[4-[4-[3-(diethylamino)propanoyl]phenyl]phenyl]propan-1-one
DM6PDEH ID DM6PDEH
DM6PDEH DN PMID29757691-Compound-8d
DM6PDEH HS Patented
DM6PDEH DT Small molecular drug
DM6PDEH PC 42602272
DM6PDEH MW 352.5
DM6PDEH FM C22H28N2O2
DM6PDEH IC InChI=1S/C22H28N2O2/c1-23(2)15-13-21(25)19-9-5-17(6-10-19)18-7-11-20(12-8-18)22(26)14-16-24(3)4/h5-12H,13-16H2,1-4H3
DM6PDEH CS CN(C)CCC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCN(C)C
DM6PDEH IK KDKCLSBOSGNKSF-UHFFFAOYSA-N
DM6PDEH IU 3-(dimethylamino)-1-[4-[4-[3-(dimethylamino)propanoyl]phenyl]phenyl]propan-1-one
DMCZ3SH ID DMCZ3SH
DMCZ3SH DN PMID29865878-Compound-38
DMCZ3SH HS Patented
DMCZ3SH CP University of Kentucky Research Foundation
DMCZ3SH DT Small molecular drug
DMSCWZF ID DMSCWZF
DMSCWZF DN PMID29865878-Compound-39
DMSCWZF HS Patented
DMSCWZF CP University of Kentucky Research Foundation
DMSCWZF DT Small molecular drug
DMGXUNA ID DMGXUNA
DMGXUNA DN PMID29865878-Compound-40
DMGXUNA HS Patented
DMGXUNA CP University of Kentucky Research Foundation
DMGXUNA DT Small molecular drug
DMSAO52 ID DMSAO52
DMSAO52 DN PMID29865878-Compound-41
DMSAO52 HS Patented
DMSAO52 CP University of Kentucky Research Foundation
DMSAO52 DT Small molecular drug
DMY2PTU ID DMY2PTU
DMY2PTU DN PMID29865878-Compound-42
DMY2PTU HS Patented
DMY2PTU CP ARES TRADING S.A
DMY2PTU DT Small molecular drug
DMQUE6D ID DMQUE6D
DMQUE6D DN PMID29865878-Compound-43
DMQUE6D HS Patented
DMQUE6D CP ARES TRADING S.A
DMQUE6D DT Small molecular drug
DMRTQ4I ID DMRTQ4I
DMRTQ4I DN PMID29865878-Compound-44
DMRTQ4I HS Patented
DMRTQ4I CP ARES TRADING S.A
DMRTQ4I DT Small molecular drug
DM462XZ ID DM462XZ
DM462XZ DN PMID29865878-Compound-45
DM462XZ HS Patented
DM462XZ CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM462XZ DT Small molecular drug
DMP3MXK ID DMP3MXK
DMP3MXK DN PMID29865878-Compound-46
DMP3MXK HS Patented
DMP3MXK CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMP3MXK DT Small molecular drug
DMX31I2 ID DMX31I2
DMX31I2 DN PMID29865878-Compound-47
DMX31I2 HS Patented
DMX31I2 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMX31I2 DT Small molecular drug
DMVQTR2 ID DMVQTR2
DMVQTR2 DN PMID29865878-Compound-48
DMVQTR2 HS Patented
DMVQTR2 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMVQTR2 DT Small molecular drug
DMK0GTV ID DMK0GTV
DMK0GTV DN PMID29865878-Compound-49
DMK0GTV HS Patented
DMK0GTV CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMK0GTV DT Small molecular drug
DMZ8BJX ID DMZ8BJX
DMZ8BJX DN PMID29865878-Compound-50
DMZ8BJX HS Patented
DMZ8BJX CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMZ8BJX DT Small molecular drug
DM0LXT2 ID DM0LXT2
DM0LXT2 DN PMID29865878-Compound-51
DM0LXT2 HS Patented
DM0LXT2 CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM0LXT2 DT Small molecular drug
DM47M2U ID DM47M2U
DM47M2U DN PMID29865878-Compound-52
DM47M2U HS Patented
DM47M2U CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM47M2U DT Small molecular drug
DM6JV1W ID DM6JV1W
DM6JV1W DN PMID29865878-Compound-53
DM6JV1W HS Patented
DM6JV1W CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM6JV1W DT Small molecular drug
DMED71P ID DMED71P
DMED71P DN PMID29865878-Compound-54
DMED71P HS Patented
DMED71P CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMED71P DT Small molecular drug
DMY52ZB ID DMY52ZB
DMY52ZB DN PMID29865878-Compound-55
DMY52ZB HS Patented
DMY52ZB CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DMY52ZB DT Small molecular drug
DM45QW1 ID DM45QW1
DM45QW1 DN PMID29865878-Compound-56
DM45QW1 HS Patented
DM45QW1 CP UNIVERZA V LJUBLJANI
DM45QW1 DT Small molecular drug
DM3VQ1Y ID DM3VQ1Y
DM3VQ1Y DN PMID29865878-Compound-57
DM3VQ1Y HS Patented
DM3VQ1Y CP UNIVERZA V LJUBLJANI
DM3VQ1Y DT Small molecular drug
DMO108N ID DMO108N
DMO108N DN PMID29865878-Compound-58
DMO108N HS Patented
DMO108N CP UNIVERZA V LJUBLJANI
DMO108N DT Small molecular drug
DMM73VG ID DMM73VG
DMM73VG DN PMID29865878-Compound-59
DMM73VG HS Patented
DMM73VG CP UNIVERZA V LJUBLJANI
DMM73VG DT Small molecular drug
DMPQX8R ID DMPQX8R
DMPQX8R DN PMID29865878-Compound-60
DMPQX8R HS Patented
DMPQX8R CP MERCK PATENT GMBH
DMPQX8R DT Small molecular drug
DMG7VF1 ID DMG7VF1
DMG7VF1 DN PMID29865878-Compound-61
DMG7VF1 HS Patented
DMG7VF1 CP MERCK PATENT GMBH
DMG7VF1 DT Small molecular drug
DML47KS ID DML47KS
DML47KS DN PMID29865878-Compound-62
DML47KS HS Patented
DML47KS CP MERCK PATENT GMBH
DML47KS DT Small molecular drug
DMEM2I8 ID DMEM2I8
DMEM2I8 DN PMID29865878-Compound-63
DMEM2I8 HS Patented
DMEM2I8 CP MERCK PATENT GMBH
DMEM2I8 DT Small molecular drug
DM1U6H2 ID DM1U6H2
DM1U6H2 DN PMID29865878-Compound-64
DM1U6H2 HS Patented
DM1U6H2 CP MERCK PATENT GMBH
DM1U6H2 DT Small molecular drug
DMX1E6O ID DMX1E6O
DMX1E6O DN PMID29865878-Compound-8
DMX1E6O HS Patented
DMX1E6O CP PROTEOLIX, INC. SHENK, Kevin, D. PARLATI, Francesco ZHOU, Han-jie SYLVAIN, Catherine SMYTH, Mark, S. BENNETT, Mark, K. LAIDIG, Guy, J
DMX1E6O DT Small molecular drug
DM7K3A0 ID DM7K3A0
DM7K3A0 DN PMID30074415-Compound-12
DM7K3A0 HS Patented
DM7K3A0 DT Small molecular drug
DM06PX4 ID DM06PX4
DM06PX4 DN PMID30074415-Compound-19
DM06PX4 HS Patented
DM06PX4 CP METASIGNAL THERAPEUTICS INC. SUPURAN, Claudiu DEDHAR, Shoukat CARTA, Fabrizio WINUM, Jean-Yves MCDONALD, Paul C UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES CNRS - DIRE
DM06PX4 DT Small molecular drug
DMX9LGW ID DMX9LGW
DMX9LGW DN PMID30074415-Compound-20
DMX9LGW HS Patented
DMX9LGW CP METASIGNAL THERAPEUTICS INC. SUPURAN, Claudiu DEDHAR, Shoukat CARTA, Fabrizio WINUM, Jean-Yves MCDONALD, Paul C UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES CNRS - DIRE
DMX9LGW DT Small molecular drug
DMX9LGW PC 19890
DMX9LGW MW 162.21
DMX9LGW FM C9H6OS
DMX9LGW IC InChI=1S/C9H6OS/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-6H
DMX9LGW CS C1=CC=C2C(=C1)C=CC(=S)O2
DMX9LGW IK FRZDLTCXOSFHJC-UHFFFAOYSA-N
DMX9LGW IU chromene-2-thione
DMX9LGW CA CAS 3986-98-9
DM3NPOU ID DM3NPOU
DM3NPOU DN PMID30074415-Compound-21
DM3NPOU HS Patented
DM3NPOU CP METASIGNAL THERAPEUTICS INC. SUPURAN, Claudiu DEDHAR, Shoukat CARTA, Fabrizio WINUM, Jean-Yves MCDONALD, Paul C UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES CNRS - DIRE
DM3NPOU DT Small molecular drug
DM2G8DN ID DM2G8DN
DM2G8DN DN PMID30074415-Compound-GS3
DM2G8DN HS Patented
DM2G8DN DT Small molecular drug
DMY37VQ ID DMY37VQ
DMY37VQ DN PMID30107136-Compound-Example1
DMY37VQ HS Patented
DMY37VQ CP BRISTOL-MYERS SQUIBB COMPANY
DMY37VQ DT Small molecule immunotherapy
DMY37VQ PC 117951478
DMY37VQ MW 419.5
DMY37VQ FM C25H29N3O3
DMY37VQ IC InChI=1S/C25H29N3O3/c1-18-22(10-7-11-23(18)20-8-5-4-6-9-20)17-31-24-13-12-21(25(28-24)30-3)16-26-14-15-27-19(2)29/h4-13,26H,14-17H2,1-3H3,(H,27,29)
DMY37VQ CS CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC
DMY37VQ IK JEDPSOYOYVELLZ-UHFFFAOYSA-N
DMY37VQ IU N-[2-[[2-methoxy-6-[(2-methyl-3-phenylphenyl)methoxy]pyridin-3-yl]methylamino]ethyl]acetamide
DMY37VQ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMD65GU ID DMD65GU
DMD65GU DN PMID30107136-Compound-Example11
DMD65GU HS Patented
DMD65GU CP ARISING INTERNATIONAL, INC
DMD65GU DT Small molecule immunotherapy
DMD65GU PC 134230940
DMD65GU MW 568.7
DMD65GU FM C36H44N2O4
DMD65GU IC InChI=1S/C36H44N2O4/c1-25-19-29(21-37-15-17-39)11-13-35(25)41-23-31-7-5-9-33(27(31)3)34-10-6-8-32(28(34)4)24-42-36-14-12-30(20-26(36)2)22-38-16-18-40/h5-14,19-20,37-40H,15-18,21-24H2,1-4H3
DMD65GU CS CC1=C(C=CC(=C1)CNCCO)OCC2=C(C(=CC=C2)C3=CC=CC(=C3C)COC4=C(C=C(C=C4)CNCCO)C)C
DMD65GU IK OXBVQSJSNDTUEX-UHFFFAOYSA-N
DMD65GU IU 2-[[4-[[3-[3-[[4-[(2-hydroxyethylamino)methyl]-2-methylphenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-3-methylphenyl]methylamino]ethanol
DMD65GU DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMN2K10 ID DMN2K10
DMN2K10 DN PMID30107136-Compound-Example12
DMN2K10 HS Patented
DMN2K10 CP ARISING INTERNATIONAL, INC
DMN2K10 DT Small molecule immunotherapy
DMN2K10 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM4CN9K ID DM4CN9K
DM4CN9K DN PMID30107136-Compound-Example13
DM4CN9K HS Patented
DM4CN9K CP POLARIS PHARMACEUTICALS, INC
DM4CN9K DT Small molecule immunotherapy
DM4CN9K PC 134305040
DM4CN9K MW 834.6
DM4CN9K FM C42H46Br2N2O6
DM4CN9K IC InChI=1S/C42H46Br2N2O6/c1-27-31(25-51-39-17-15-29(21-35(39)43)23-45-19-5-3-13-37(45)41(47)48)9-7-11-33(27)34-12-8-10-32(28(34)2)26-52-40-18-16-30(22-36(40)44)24-46-20-6-4-14-38(46)42(49)50/h7-12,15-18,21-22,37-38H,3-6,13-14,19-20,23-26H2,1-2H3,(H,47,48)(H,49,50)/t37-,38-/m0/s1
DM4CN9K CS CC1=C(C=CC=C1C2=CC=CC(=C2C)COC3=C(C=C(C=C3)CN4CCCC[C@H]4C(=O)O)Br)COC5=C(C=C(C=C5)CN6CCCC[C@H]6C(=O)O)Br
DM4CN9K IK SDCCYXRWWJGRKC-UWXQCODUSA-N
DM4CN9K IU (2S)-1-[[3-bromo-4-[[3-[3-[[2-bromo-4-[[(2S)-2-carboxypiperidin-1-yl]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DM4CN9K DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMAUFS7 ID DMAUFS7
DMAUFS7 DN PMID30107136-Compound-Example14
DMAUFS7 HS Patented
DMAUFS7 CP POLARIS PHARMACEUTICALS, INC
DMAUFS7 DT Small molecule immunotherapy
DMAUFS7 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMYHQ0S ID DMYHQ0S
DMYHQ0S DN PMID30107136-Compound-Example15
DMYHQ0S HS Patented
DMYHQ0S CP CHEMOCENTRYX, INC
DMYHQ0S DT Small molecule immunotherapy
DMYHQ0S DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM6EKIV ID DM6EKIV
DM6EKIV DN PMID30107136-Compound-Example16
DM6EKIV HS Patented
DM6EKIV CP CHEMOCENTRYX, INC
DM6EKIV DT Small molecule immunotherapy
DM6EKIV DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM9HMB4 ID DM9HMB4
DM9HMB4 DN PMID30107136-Compound-Example2
DM9HMB4 HS Patented
DM9HMB4 CP BRISTOL-MYERS SQUIBB COMPANY
DM9HMB4 DT Small molecule immunotherapy
DM9HMB4 PC 117941742
DM9HMB4 MW 494.4
DM9HMB4 FM C27H28BrNO3
DM9HMB4 IC InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)
DM9HMB4 CS CC1=C(C=CC=C1C2=CC=CC=C2)COC3=C(C=C(C=C3)CN4CCCCC4C(=O)O)Br
DM9HMB4 IK QRXBPPWUGITQLE-UHFFFAOYSA-N
DM9HMB4 IU 1-[[3-bromo-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DM9HMB4 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMDCN43 ID DMDCN43
DMDCN43 DN PMID30107136-Compound-Example3
DMDCN43 HS Patented
DMDCN43 CP BRISTOL-MYERS SQUIBB COMPANY
DMDCN43 DT Small molecule immunotherapy
DMDCN43 PC 118434705
DMDCN43 MW 594.7
DMDCN43 FM C35H34N2O7
DMDCN43 IC InChI=1S/C35H34N2O7/c1-22-13-28(18-37-30(19-38)35(39)40)33(43-20-25-6-3-5-24(14-25)17-36)16-32(22)44-21-27-7-4-8-29(23(27)2)26-9-10-31-34(15-26)42-12-11-41-31/h3-10,13-16,30,37-38H,11-12,18-21H2,1-2H3,(H,39,40)
DMDCN43 CS CC1=CC(=C(C=C1OCC2=C(C(=CC=C2)C3=CC4=C(C=C3)OCCO4)C)OCC5=CC(=CC=C5)C#N)CNC(CO)C(=O)O
DMDCN43 IK UWNXGZKSIKQKAH-UHFFFAOYSA-N
DMDCN43 IU 2-[[2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-5-methylphenyl]methylamino]-3-hydroxypropanoic acid
DMDCN43 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMRKLTE ID DMRKLTE
DMRKLTE DN PMID30107136-Compound-Example4
DMRKLTE HS Patented
DMRKLTE CP BRISTOL-MYERS SQUIBB COMPANY
DMRKLTE DT Small molecule immunotherapy
DMRKLTE DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMQPIK4 ID DMQPIK4
DMQPIK4 DN PMID30107136-Compound-Example41
DMQPIK4 HS Patented
DMQPIK4 CP INCYTE CORPORATION
DMQPIK4 DT Small molecule immunotherapy
DMQPIK4 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM95FIN ID DM95FIN
DM95FIN DN PMID30107136-Compound-Example42
DM95FIN HS Patented
DM95FIN CP INCYTE CORPORATION
DM95FIN DT Small molecule immunotherapy
DM95FIN PC 132166412
DM95FIN MW 443.5
DM95FIN FM C26H29N5O2
DM95FIN IC InChI=1S/C26H29N5O2/c1-30-18-19(17-29-30)7-10-28-21-8-11-31(12-9-21)24-4-2-3-22(23(24)16-27)20-5-6-25-26(15-20)33-14-13-32-25/h2-6,15,17-18,21,28H,7-14H2,1H3
DM95FIN CS CN1C=C(C=N1)CCNC2CCN(CC2)C3=CC=CC(=C3C#N)C4=CC5=C(C=C4)OCCO5
DM95FIN IK YIQQKUGTBUPKTJ-UHFFFAOYSA-N
DM95FIN IU 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[4-[2-(1-methylpyrazol-4-yl)ethylamino]piperidin-1-yl]benzonitrile
DM95FIN DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMJSH0F ID DMJSH0F
DMJSH0F DN PMID30107136-Compound-Example43
DMJSH0F HS Patented
DMJSH0F CP Incyte Corporation
DMJSH0F DT Small molecule immunotherapy
DMJSH0F PC 129019494
DMJSH0F MW 359.4
DMJSH0F FM C21H21N5O
DMJSH0F IC InChI=1S/C21H21N5O/c1-15-18(16-6-3-2-4-7-16)8-5-9-19(15)20-14-26-21(24-20)23-13-17(25-26)12-22-10-11-27/h2-9,13-14,22,27H,10-12H2,1H3
DMJSH0F CS CC1=C(C=CC=C1C2=CN3C(=N2)N=CC(=N3)CNCCO)C4=CC=CC=C4
DMJSH0F IK SIYAOZFRXTVXSP-UHFFFAOYSA-N
DMJSH0F IU 2-[[6-(2-methyl-3-phenylphenyl)imidazo[1,2-b][1,2,4]triazin-2-yl]methylamino]ethanol
DMJSH0F DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM8KAIY ID DM8KAIY
DM8KAIY DN PMID30107136-Compound-Example44
DM8KAIY HS Patented
DM8KAIY CP Incyte Corporation
DM8KAIY DT Small molecule immunotherapy
DM8KAIY DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMC075A ID DMC075A
DMC075A DN PMID30107136-Compound-Example45
DMC075A HS Patented
DMC075A CP INCYTE CORPORATION
DMC075A DT Small molecule immunotherapy
DMC075A PC 132085809
DMC075A MW 306.4
DMC075A FM C19H18N2S
DMC075A IC InChI=1S/C19H18N2S/c1-13-15(14-6-3-2-4-7-14)8-5-9-16(13)19-21-17-10-11-20-12-18(17)22-19/h2-9,20H,10-12H2,1H3
DMC075A CS CC1=C(C=CC=C1C2=NC3=C(S2)CNCC3)C4=CC=CC=C4
DMC075A IK DISXBCWMOVBSKF-UHFFFAOYSA-N
DMC075A IU 2-(2-methyl-3-phenylphenyl)-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine
DMC075A DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMYFSAD ID DMYFSAD
DMYFSAD DN PMID30107136-Compound-Example46
DMYFSAD HS Patented
DMYFSAD CP INCYTE CORPORATION
DMYFSAD DT Small molecule immunotherapy
DMYFSAD PC 132085903
DMYFSAD MW 364.5
DMYFSAD FM C22H24N2OS
DMYFSAD IC InChI=1S/C22H24N2OS/c1-15(25)13-24-12-11-20-21(14-24)26-22(23-20)19-10-6-9-18(16(19)2)17-7-4-3-5-8-17/h3-10,15,25H,11-14H2,1-2H3/t15-/m0/s1
DMYFSAD CS CC1=C(C=CC=C1C2=NC3=C(S2)CN(CC3)C[C@H](C)O)C4=CC=CC=C4
DMYFSAD IK HABSDVBVXAIOBF-HNNXBMFYSA-N
DMYFSAD IU (2S)-1-[2-(2-methyl-3-phenylphenyl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-5-yl]propan-2-ol
DMYFSAD DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM1TCBQ ID DM1TCBQ
DM1TCBQ DN PMID30107136-Compound-Example47
DM1TCBQ HS Patented
DM1TCBQ CP Incyte Corporation
DM1TCBQ DT Small molecule immunotherapy
DM1TCBQ PC 134282250
DM1TCBQ MW 435.5
DM1TCBQ FM C24H25N3O3S
DM1TCBQ IC InChI=1S/C24H25N3O3S/c1-16-19(17-8-3-2-4-9-17)10-7-11-20(16)26-22(28)23-25-14-18(31-23)15-27-13-6-5-12-21(27)24(29)30/h2-4,7-11,14,21H,5-6,12-13,15H2,1H3,(H,26,28)(H,29,30)/t21-/m0/s1
DM1TCBQ CS CC1=C(C=CC=C1NC(=O)C2=NC=C(S2)CN3CCCC[C@H]3C(=O)O)C4=CC=CC=C4
DM1TCBQ IK UBENHLQYILNMML-NRFANRHFSA-N
DM1TCBQ IU (2S)-1-[[2-[(2-methyl-3-phenylphenyl)carbamoyl]-1,3-thiazol-5-yl]methyl]piperidine-2-carboxylic acid
DM1TCBQ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMH57FG ID DMH57FG
DMH57FG DN PMID30107136-Compound-Example48
DMH57FG HS Patented
DMH57FG CP Incyte Corporation
DMH57FG DT Small molecule immunotherapy
DMH57FG PC 134282238
DMH57FG MW 364.4
DMH57FG FM C21H24N4O2
DMH57FG IC InChI=1S/C21H24N4O2/c1-15-18(16-7-4-3-5-8-16)9-6-10-19(15)24-21(27)20-23-14-17(25(20)2)13-22-11-12-26/h3-10,14,22,26H,11-13H2,1-2H3,(H,24,27)
DMH57FG CS CC1=C(C=CC=C1NC(=O)C2=NC=C(N2C)CNCCO)C3=CC=CC=C3
DMH57FG IK NMRCIXCIRVZQNY-UHFFFAOYSA-N
DMH57FG IU 5-[(2-hydroxyethylamino)methyl]-1-methyl-N-(2-methyl-3-phenylphenyl)imidazole-2-carboxamide
DMH57FG DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM4D1WK ID DM4D1WK
DM4D1WK DN PMID30107136-Compound-Example49
DM4D1WK HS Patented
DM4D1WK CP INCYTE CORPORATION
DM4D1WK DT Small molecule immunotherapy
DM4D1WK PC 134177894
DM4D1WK MW 459.5
DM4D1WK FM C27H29N3O4
DM4D1WK IC InChI=1S/C27H29N3O4/c1-18-21(20-9-4-3-5-10-20)11-8-12-23(18)28-25(31)22-15-19(16-29(2)26(22)32)17-30-14-7-6-13-24(30)27(33)34/h3-5,8-12,15-16,24H,6-7,13-14,17H2,1-2H3,(H,28,31)(H,33,34)/t24-/m0/s1
DM4D1WK CS CC1=C(C=CC=C1NC(=O)C2=CC(=CN(C2=O)C)CN3CCCC[C@H]3C(=O)O)C4=CC=CC=C4
DM4D1WK IK DNPQQJGPLXEEDA-DEOSSOPVSA-N
DM4D1WK IU (2S)-1-[[1-methyl-5-[(2-methyl-3-phenylphenyl)carbamoyl]-6-oxopyridin-3-yl]methyl]piperidine-2-carboxylic acid
DM4D1WK DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMV15GM ID DMV15GM
DMV15GM DN PMID30107136-Compound-Example50
DMV15GM HS Patented
DMV15GM CP INCYTE CORPORATION
DMV15GM DT Small molecule immunotherapy
DMV15GM PC 134178079
DMV15GM MW 460.5
DMV15GM FM C25H24N4O5
DMV15GM IC InChI=1S/C25H24N4O5/c1-29-15-16(14-27-7-8-30)11-19(25(29)32)24(31)28-21-4-2-3-18(20(21)13-26)17-5-6-22-23(12-17)34-10-9-33-22/h2-6,11-12,15,27,30H,7-10,14H2,1H3,(H,28,31)
DMV15GM CS CN1C=C(C=C(C1=O)C(=O)NC2=CC=CC(=C2C#N)C3=CC4=C(C=C3)OCCO4)CNCCO
DMV15GM IK CAWQORGXRONNAU-UHFFFAOYSA-N
DMV15GM IU N-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-5-[(2-hydroxyethylamino)methyl]-1-methyl-2-oxopyridine-3-carboxamide
DMV15GM DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM08CBJ ID DM08CBJ
DM08CBJ DN PMID30107136-Compound-Example51
DM08CBJ HS Patented
DM08CBJ CP Incyte Corporation
DM08CBJ DT Small molecule immunotherapy
DM08CBJ PC 132229919
DM08CBJ MW 418.5
DM08CBJ FM C22H18N4O3S
DM08CBJ IC InChI=1S/C22H18N4O3S/c23-11-15-14(13-4-5-18-19(10-13)29-9-8-28-18)2-1-3-16(15)25-21(27)22-26-17-6-7-24-12-20(17)30-22/h1-5,10,24H,6-9,12H2,(H,25,27)
DM08CBJ CS C1CNCC2=C1N=C(S2)C(=O)NC3=CC=CC(=C3C#N)C4=CC5=C(C=C4)OCCO5
DM08CBJ IK CJCNMXQYXKRQRK-UHFFFAOYSA-N
DM08CBJ IU N-[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine-2-carboxamide
DM08CBJ DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMJ1C0A ID DMJ1C0A
DMJ1C0A DN PMID30107136-Compound-Example52
DMJ1C0A HS Patented
DMJ1C0A CP Incyte Corporation
DMJ1C0A DT Small molecule immunotherapy
DMJ1C0A PC 132229917
DMJ1C0A MW 414.5
DMJ1C0A FM C22H18N6OS
DMJ1C0A IC InChI=1S/C22H18N6OS/c1-28-19-7-3-5-14(16(19)11-25-28)13-4-2-6-17(15(13)10-23)26-21(29)22-27-18-8-9-24-12-20(18)30-22/h2-7,11,24H,8-9,12H2,1H3,(H,26,29)
DMJ1C0A CS CN1C2=CC=CC(=C2C=N1)C3=C(C(=CC=C3)NC(=O)C4=NC5=C(S4)CNCC5)C#N
DMJ1C0A IK UPRJKKJMZSATGW-UHFFFAOYSA-N
DMJ1C0A IU N-[2-cyano-3-(1-methylindazol-4-yl)phenyl]-4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridine-2-carboxamide
DMJ1C0A DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM39FDV ID DM39FDV
DM39FDV DN PMID30107136-Compound-Example53
DM39FDV HS Patented
DM39FDV CP INCYTE CORPORATION
DM39FDV DT Small molecule immunotherapy
DM39FDV DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM9DL1E ID DM9DL1E
DM9DL1E DN PMID30107136-Compound-Example54
DM9DL1E HS Patented
DM9DL1E CP INCYTE CORPORATION
DM9DL1E DT Small molecule immunotherapy
DM9DL1E PC 129138000
DM9DL1E MW 440.5
DM9DL1E FM C28H28N2O3
DM9DL1E IC InChI=1S/C28H28N2O3/c1-18-15-20(17-30-14-7-6-13-25(30)28(31)32)16-24-26(18)33-27(29-24)23-12-8-11-22(19(23)2)21-9-4-3-5-10-21/h3-5,8-12,15-16,25H,6-7,13-14,17H2,1-2H3,(H,31,32)/t25-/m0/s1
DM9DL1E CS CC1=CC(=CC2=C1OC(=N2)C3=CC=CC(=C3C)C4=CC=CC=C4)CN5CCCC[C@H]5C(=O)O
DM9DL1E IK UWWIGOJLOPXCJZ-VWLOTQADSA-N
DM9DL1E IU (2S)-1-[[7-methyl-2-(2-methyl-3-phenylphenyl)-1,3-benzoxazol-5-yl]methyl]piperidine-2-carboxylic acid
DM9DL1E DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMZXC0D ID DMZXC0D
DMZXC0D DN PMID30107136-Compound-Example57
DMZXC0D HS Patented
DMZXC0D CP Incyte Corporation
DMZXC0D DT Small molecule immunotherapy
DMZXC0D DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM3AY9K ID DM3AY9K
DM3AY9K DN PMID30107136-Compound-Example58
DM3AY9K HS Patented
DM3AY9K CP Incyte Corporation
DM3AY9K DT Small molecule immunotherapy
DM3AY9K PC 129244901
DM3AY9K MW 452.5
DM3AY9K FM C28H28N4O2
DM3AY9K IC InChI=1S/C28H28N4O2/c1-19-22(20-8-3-2-4-9-20)10-7-11-24(19)31-27-26-23(14-16-30-27)21(13-15-29-26)18-32-17-6-5-12-25(32)28(33)34/h2-4,7-11,13-16,25H,5-6,12,17-18H2,1H3,(H,30,31)(H,33,34)
DM3AY9K CS CC1=C(C=CC=C1NC2=NC=CC3=C(C=CN=C32)CN4CCCCC4C(=O)O)C5=CC=CC=C5
DM3AY9K IK PDWPVFMFNAKOIU-UHFFFAOYSA-N
DM3AY9K IU 1-[[8-(2-methyl-3-phenylanilino)-1,7-naphthyridin-4-yl]methyl]piperidine-2-carboxylic acid
DM3AY9K DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DM6XWL9 ID DM6XWL9
DM6XWL9 DN PMID30107136-Compound-Example59
DM6XWL9 HS Patented
DM6XWL9 CP RIJKSUNIVERSITEIT GRONINGEN
DM6XWL9 DT Small molecule immunotherapy
DM6XWL9 PC 130219614
DM6XWL9 MW 571.7
DM6XWL9 FM C35H33N5O3
DM6XWL9 IC InChI=1S/C35H33N5O3/c36-23-31-30(28-9-5-2-6-10-28)15-16-38-35(31)42-25-33-39-34(29-13-11-27(12-14-29)26-7-3-1-4-8-26)32(43-33)24-37-17-18-40-19-21-41-22-20-40/h1-16,37H,17-22,24-25H2
DM6XWL9 CS C1COCCN1CCNCC2=C(N=C(O2)COC3=NC=CC(=C3C#N)C4=CC=CC=C4)C5=CC=C(C=C5)C6=CC=CC=C6
DM6XWL9 IK LEMZNPCBMGJIOU-UHFFFAOYSA-N
DM6XWL9 IU 2-[[5-[(2-morpholin-4-ylethylamino)methyl]-4-(4-phenylphenyl)-1,3-oxazol-2-yl]methoxy]-4-phenylpyridine-3-carbonitrile
DM6XWL9 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMUZ85A ID DMUZ85A
DMUZ85A DN PMID30107136-Compound-Example60
DMUZ85A HS Patented
DMUZ85A CP RIJKSUNIVERSITEIT GRONINGEN
DMUZ85A DT Small molecule immunotherapy
DMUZ85A PC 130220023
DMUZ85A MW 478.5
DMUZ85A FM C25H30N6O4
DMUZ85A IC InChI=1S/C25H30N6O4/c1-17-21(15-28-8-7-27-2)31(9-10-32)24(30-17)16-35-25-20(14-26)19(5-6-29-25)18-3-4-22-23(13-18)34-12-11-33-22/h3-6,13,27-28,32H,7-12,15-16H2,1-2H3
DMUZ85A CS CC1=C(N(C(=N1)COC2=NC=CC(=C2C#N)C3=CC4=C(C=C3)OCCO4)CCO)CNCCNC
DMUZ85A IK WQHRKWCRQIAXRG-UHFFFAOYSA-N
DMUZ85A IU 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[1-(2-hydroxyethyl)-4-methyl-5-[[2-(methylamino)ethylamino]methyl]imidazol-2-yl]methoxy]pyridine-3-carbonitrile
DMUZ85A DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMS42KH ID DMS42KH
DMS42KH DN PMID30107136-Compound-Example7
DMS42KH HS Patented
DMS42KH CP BRISTOL-MYERS SQUIBB COMPANY
DMS42KH DT Small molecule immunotherapy
DMS42KH PC 129019915
DMS42KH MW 753.3
DMS42KH FM C43H49ClN4O6
DMS42KH IC InChI=1S/C43H49ClN4O6/c1-29-33(8-5-9-36(29)37-10-6-12-40(30(37)2)52-19-7-15-47-17-13-35(49)14-18-47)28-54-42-22-41(53-27-32-20-31(23-45)24-46-25-32)34(21-38(42)44)26-48-16-4-3-11-39(48)43(50)51/h5-6,8-10,12,20-22,24-25,35,39,49H,3-4,7,11,13-19,26-28H2,1-2H3,(H,50,51)
DMS42KH CS CC1=C(C=CC=C1C2=C(C(=CC=C2)OCCCN3CCC(CC3)O)C)COC4=C(C=C(C(=C4)OCC5=CC(=CN=C5)C#N)CN6CCCCC6C(=O)O)Cl
DMS42KH IK VDKPFVAEXSRQOY-UHFFFAOYSA-N
DMS42KH IU 1-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-[3-[3-(4-hydroxypiperidin-1-yl)propoxy]-2-methylphenyl]-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DMS42KH DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMBIK28 ID DMBIK28
DMBIK28 DN PMID30107136-Compound-Example8
DMBIK28 HS Patented
DMBIK28 CP BRISTOL-MYERS SQUIBB COMPANY
DMBIK28 DT Small molecule immunotherapy
DMBIK28 PC 129019689
DMBIK28 MW 765.3
DMBIK28 FM C41H47ClF2N4O6
DMBIK28 IC InChI=1S/C41H47ClF2N4O6/c1-28-32(7-4-8-34(28)35-9-5-10-37(29(35)2)52-14-6-12-48-13-11-41(43,44)24-48)23-54-39-17-38(53-22-31-15-30(18-45)19-46-20-31)33(16-36(39)42)21-47(3)40(25-49,26-50)27-51/h4-5,7-10,15-17,19-20,49-51H,6,11-14,21-27H2,1-3H3
DMBIK28 CS CC1=C(C=CC=C1C2=C(C(=CC=C2)OCCCN3CCC(C3)(F)F)C)COC4=C(C=C(C(=C4)OCC5=CC(=CN=C5)C#N)CN(C)C(CO)(CO)CO)Cl
DMBIK28 IK KNCHTQJZTIPCIA-UHFFFAOYSA-N
DMBIK28 IU 5-[[4-chloro-5-[[3-[3-[3-(3,3-difluoropyrrolidin-1-yl)propoxy]-2-methylphenyl]-2-methylphenyl]methoxy]-2-[[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]-methylamino]methyl]phenoxy]methyl]pyridine-3-carbonitrile
DMBIK28 DE Solid tumour/cancer; Infectious disease; Human immunodeficiency virus infection; Hepatitis
DMHTJVA ID DMHTJVA
DMHTJVA DN PMID30124346-Compound-13TABLE4
DMHTJVA HS Patented
DMHTJVA CP INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK,UNIWERSYTET JAGIELLO SKI
DMHTJVA DT Small molecular drug
DMHTJVA DE Attention deficit hyperactivity disorder
DM2G3VE ID DM2G3VE
DM2G3VE DN PMID30124346-Compound-34TABLE4
DM2G3VE HS Patented
DM2G3VE CP INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK,UNIWERSYTET JAGIELLO SKI
DM2G3VE DT Small molecular drug
DM2G3VE DE Attention deficit hyperactivity disorder
DM3QX0R ID DM3QX0R
DM3QX0R DN PMID30124346-Compound-60TABLE5
DM3QX0R HS Patented
DM3QX0R CP NEUROLIXIS UNIVERSITE JAGELLONNE
DM3QX0R DT Small molecular drug
DM3QX0R DE Parkinson disease; Dyskinesia
DMJMTNL ID DMJMTNL
DMJMTNL DN PMID30124346-Compound-LDT66
DMJMTNL HS Patented
DMJMTNL CP LAUNIER, Benoi
DMJMTNL DT Small molecular drug
DMJMTNL PC 11778231
DMJMTNL MW 276.4
DMJMTNL FM C17H28N2O
DMJMTNL IC InChI=1S/C17H28N2O/c1-3-4-5-8-11-18-12-14-19(15-13-18)16-9-6-7-10-17(16)20-2/h6-7,9-10H,3-5,8,11-15H2,1-2H3
DMJMTNL CS CCCCCCN1CCN(CC1)C2=CC=CC=C2OC
DMJMTNL IK QLLNEODTUOCQKR-UHFFFAOYSA-N
DMJMTNL IU 1-hexyl-4-(2-methoxyphenyl)piperazine
DMJMTNL DE Benign prostatic hyperplasia
DM5MUNG ID DM5MUNG
DM5MUNG DN PMID30124346-Compound-LDT8
DM5MUNG HS Patented
DM5MUNG CP UNIV RIO DE JANEIRO [BRUNIAO BRASILIENSE DE EDUCACAO E CULTURA UBEC [BR
DM5MUNG DT Small molecular drug
DM5MUNG DE Benign prostatic hyperplasia
DMQU10C ID DMQU10C
DMQU10C DN PMID30185082-Compound-14
DMQU10C HS Patented
DMQU10C DT Small molecular drug
DMQU10C PC 16737780
DMQU10C MW 443.5
DMQU10C FM C25H33FN2O4
DMQU10C IC InChI=1S/C25H33FN2O4/c1-18-6-7-22(32-13-9-26)21(14-18)25(29)27-10-4-5-11-28-12-8-19-15-23(30-2)24(31-3)16-20(19)17-28/h6-7,14-16H,4-5,8-13,17H2,1-3H3,(H,27,29)/i26-1
DMQU10C CS CC1=CC(=C(C=C1)OCC[18F])C(=O)NCCCCN2CCC3=CC(=C(C=C3C2)OC)OC
DMQU10C IK QVRVXSZKCXFBTE-KPVNRNJOSA-N
DMQU10C IU N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2-(2-(18F)fluoranylethoxy)-5-methylbenzamide
DMQU10C CA CAS 945992-47-2
DMYFLT1 ID DMYFLT1
DMYFLT1 DN PMID30185082-Compound-27
DMYFLT1 HS Patented
DMYFLT1 CP THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
DMYFLT1 DT Small molecular drug
DMI0WHE ID DMI0WHE
DMI0WHE DN PMID30185082-Compound-28
DMI0WHE HS Patented
DMI0WHE CP THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
DMI0WHE DT Small molecular drug
DM9GX0F ID DM9GX0F
DM9GX0F DN PMID30185082-Compound-53
DM9GX0F HS Patented
DM9GX0F CP THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DM9GX0F DT Small molecular drug
DMKP14O ID DMKP14O
DMKP14O DN PMID30185082-Compound-54
DMKP14O HS Patented
DMKP14O CP THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMKP14O DT Small molecular drug
DMKP14O PC 24807084
DMKP14O MW 373.6
DMKP14O FM C21H31N3OS
DMKP14O IC InChI=1S/C21H31N3OS/c25-21-24(19-10-4-5-11-20(19)26-21)13-7-6-12-22-14-16-23(17-15-22)18-8-2-1-3-9-18/h4-5,10-11,18H,1-3,6-9,12-17H2
DMKP14O CS C1CCC(CC1)N2CCN(CC2)CCCCN3C4=CC=CC=C4SC3=O
DMKP14O IK ZACKDLLCPUTVQK-UHFFFAOYSA-N
DMKP14O IU 3-[4-(4-cyclohexylpiperazin-1-yl)butyl]-1,3-benzothiazol-2-one
DMW8V4R ID DMW8V4R
DMW8V4R DN PMID30185082-Compound-55
DMW8V4R HS Patented
DMW8V4R CP THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMW8V4R DT Small molecular drug
DMW8V4R PC 24763643
DMW8V4R MW 411.5
DMW8V4R FM C23H26FN3O3
DMW8V4R IC InChI=1S/C23H26FN3O3/c1-17(28)18-4-9-21-22(16-18)30-23(29)27(21)11-3-2-10-25-12-14-26(15-13-25)20-7-5-19(24)6-8-20/h4-9,16H,2-3,10-15H2,1H3
DMW8V4R CS CC(=O)C1=CC2=C(C=C1)N(C(=O)O2)CCCCN3CCN(CC3)C4=CC=C(C=C4)F
DMW8V4R IK VGDFDVKDWFJQHD-UHFFFAOYSA-N
DMW8V4R IU 6-acetyl-3-[4-[4-(4-fluorophenyl)piperazin-1-yl]butyl]-1,3-benzoxazol-2-one
DMLGKYI ID DMLGKYI
DMLGKYI DN PMID30185082-Compound-56
DMLGKYI HS Patented
DMLGKYI CP THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMLGKYI DT Small molecular drug
DMLGKYI PC 17756659
DMLGKYI MW 389.6
DMLGKYI FM C21H31N3S2
DMLGKYI IC InChI=1S/C21H31N3S2/c25-21-24(19-10-4-5-11-20(19)26-21)13-7-6-12-22-14-16-23(17-15-22)18-8-2-1-3-9-18/h4-5,10-11,18H,1-3,6-9,12-17H2
DMLGKYI CS C1CCC(CC1)N2CCN(CC2)CCCCN3C4=CC=CC=C4SC3=S
DMLGKYI IK FJGOTAJCEJCFEV-UHFFFAOYSA-N
DMLGKYI IU 3-[4-(4-cyclohexylpiperazin-1-yl)butyl]-1,3-benzothiazole-2-thione
DMNDF1Z ID DMNDF1Z
DMNDF1Z DN PMID30185082-Compound-57
DMNDF1Z HS Patented
DMNDF1Z CP THE UNIVERSITY OF MISSISSIPPI THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
DMNDF1Z DT Small molecular drug
DMNDF1Z PC 58511957
DMNDF1Z MW 336.5
DMNDF1Z FM C18H25FN2OS
DMNDF1Z IC InChI=1S/C18H25FN2OS/c19-9-5-6-15-7-8-16-17(14-15)23-18(22)21(16)13-12-20-10-3-1-2-4-11-20/h7-8,14H,1-6,9-13H2
DMNDF1Z CS C1CCCN(CC1)CCN2C3=C(C=C(C=C3)CCCF)SC2=O
DMNDF1Z IK DNGYIBDXSUNKMV-UHFFFAOYSA-N
DMNDF1Z IU 3-[2-(azepan-1-yl)ethyl]-6-(3-fluoropropyl)-1,3-benzothiazol-2-one
DMNDF1Z CA CAS 1350296-21-7
DMW2S0J ID DMW2S0J
DMW2S0J DN PMID30185082-Compound-63
DMW2S0J HS Patented
DMW2S0J CP COGNITION THERAPEUTICS, INC. CATALANO, Susan, M. RISHTON, Gilbert IZZO, Nicholas, J
DMW2S0J DT Small molecular drug
DMKD470 ID DMKD470
DMKD470 DN PMID30185082-Compound-64
DMKD470 HS Patented
DMKD470 CP COGNITION THERAPEUTICS, INC. CATALANO, Susan, M. RISHTON, Gilbert IZZO, Nicholas, J
DMKD470 DT Small molecular drug
DMKD470 PC 66731659
DMKD470 MW 353.4
DMKD470 FM C19H22F3NO2
DMKD470 IC InChI=1S/C19H22F3NO2/c1-13(3-4-14-7-10-17(24)18(11-14)25-2)23-12-15-5-8-16(9-6-15)19(20,21)22/h5-11,13,23-24H,3-4,12H2,1-2H3
DMKD470 CS CC(CCC1=CC(=C(C=C1)O)OC)NCC2=CC=C(C=C2)C(F)(F)F
DMKD470 IK JWMMMNZRBWMHKZ-UHFFFAOYSA-N
DMKD470 IU 2-methoxy-4-[3-[[4-(trifluoromethyl)phenyl]methylamino]butyl]phenol
DME0RJ2 ID DME0RJ2
DME0RJ2 DN PMID30259754-Compound-INT-767
DME0RJ2 HS Patented
DME0RJ2 CP INTERCEPT PHARMACEUTICALS, INC. PELLICCIARI, Roberto FIORUCCI, Stefano PRUZANSKI, Mark
DME0RJ2 DT Small molecular drug
DME0RJ2 PC 121356085
DME0RJ2 MW 470.7
DME0RJ2 FM C26H46O5S
DME0RJ2 IC InChI=1S/C26H46O5S/c1-5-18-22-15-17(27)10-12-26(22,4)21-11-13-25(3)19(8-9-20(25)23(21)24(18)28)16(2)7-6-14-32(29,30)31/h16-24,27-28H,5-15H2,1-4H3,(H,29,30,31)/t16-,17-,18-,19-,20+,21+,22+,23+,24-,25-,26-/m1/s1
DME0RJ2 CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCCS(=O)(=O)O)C)C)O
DME0RJ2 IK VJHHZJYLJUGVGO-JDCMAIOWSA-N
DME0RJ2 IU (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentane-1-sulfonic acid
DMZ5CDY ID DMZ5CDY
DMZ5CDY DN PMID30259754-Compound-LY2562175
DMZ5CDY HS Patented
DMZ5CDY CP ELI LILLY AND COMPANY GENIN, Michael, James AGEJAS-CHICHARRO, Francisco, Javier BUENO MELENDO, Ana, Belen MANNINEN, Peter, Rudolph WARSHAWSKY, Alan, M
DMZ5CDY DT Small molecular drug
DMZ5CDY PC 25204767
DMZ5CDY MW 540.4
DMZ5CDY FM C28H27Cl2N3O4
DMZ5CDY IC InChI=1S/C28H27Cl2N3O4/c1-32-14-20(28(34)35)19-8-7-17(13-24(19)32)33-11-9-18(10-12-33)36-15-21-26(31-37-27(21)16-5-6-16)25-22(29)3-2-4-23(25)30/h2-4,7-8,13-14,16,18H,5-6,9-12,15H2,1H3,(H,34,35)
DMZ5CDY CS CN1C=C(C2=C1C=C(C=C2)N3CCC(CC3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)C(=O)O
DMZ5CDY IK RPVDFHPBGBMWID-UHFFFAOYSA-N
DMZ5CDY IU 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]-1-methylindole-3-carboxylic acid
DMZ5CDY CA CAS 1103500-20-4
DM78IN5 ID DM78IN5
DM78IN5 DN PMID30259754-Compound-Px-102
DM78IN5 HS Patented
DM78IN5 CP PHENEX PHARMACEUTICALS AG KREMOSER, Claus ABEL, Ulrich STEENECK, Christoph KINZEL, Olaf
DM78IN5 DT Small molecular drug
DM78IN5 PC 50943003
DM78IN5 MW 554.8
DM78IN5 FM C29H22Cl3NO4
DM78IN5 IC InChI=1S/C29H22Cl3NO4/c30-23-2-1-3-24(31)26(23)27-22(28(37-33-27)16-6-7-16)14-36-18-10-11-19(25(32)12-18)21-13-20(21)15-4-8-17(9-5-15)29(34)35/h1-5,8-12,16,20-21H,6-7,13-14H2,(H,34,35)
DM78IN5 CS C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5CC5C6=CC=C(C=C6)C(=O)O)Cl
DM78IN5 IK XBUXXJUEBFDQHD-UHFFFAOYSA-N
DM78IN5 IU 4-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]cyclopropyl]benzoic acid
DMVP16K ID DMVP16K
DMVP16K DN PMID30259754-Compound-pyrrole[2,3-d]azepines
DMVP16K HS Patented
DMVP16K DT Small molecular drug
DMVP16K PC 42601440
DMVP16K MW 415.4
DMVP16K FM C22H23F2N3O3
DMVP16K IC InChI=1S/C22H23F2N3O3/c1-12(2)30-21(29)15-10-27(20(28)13-5-6-17(23)18(24)7-13)11-22(3,4)16-8-14(9-25)26-19(15)16/h5-8,12,15,26H,10-11H2,1-4H3
DMVP16K CS CC(C)OC(=O)C1CN(CC(C2=C1NC(=C2)C#N)(C)C)C(=O)C3=CC(=C(C=C3)F)F
DMVP16K IK JTWLRQHGXNKRJB-UHFFFAOYSA-N
DMVP16K IU propan-2-yl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,5,7,8-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate
DMDKSJQ ID DMDKSJQ
DMDKSJQ DN PMID30259754-Compound-WAY-362450
DMDKSJQ HS Patented
DMDKSJQ DT Small molecular drug
DMDKSJQ PC 10026128
DMDKSJQ MW 438.5
DMDKSJQ FM C25H24F2N2O3
DMDKSJQ IC InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
DMDKSJQ CS CC(C)OC(=O)C1=CN(CC(C2=C1NC3=CC=CC=C32)(C)C)C(=O)C4=CC(=C(C=C4)F)F
DMDKSJQ IK INASOKQDNHHMRE-UHFFFAOYSA-N
DMDKSJQ IU propan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-2,6-dihydroazepino[4,5-b]indole-5-carboxylate
DMDKSJQ CA CAS 629664-81-9
DM52MKV ID DM52MKV
DM52MKV DN PMID30273516-Compound-1
DM52MKV HS Patented
DM52MKV DT Small molecular drug
DMIWEZH ID DMIWEZH
DMIWEZH DN PMID30273516-Compound-12
DMIWEZH HS Patented
DMIWEZH CP CALITHERA BIOSCIENCES, INC
DMIWEZH DT Small molecular drug
DMK9TJP ID DMK9TJP
DMK9TJP DN PMID30273516-Compound-13
DMK9TJP HS Patented
DMK9TJP CP CORNELL UNIVERSITY ITHACA COLLEGE
DMK9TJP DT Small molecular drug
DMURZHA ID DMURZHA
DMURZHA DN PMID30273516-Compound-14
DMURZHA HS Patented
DMURZHA CP CORNELL UNIVERSITY ITHACA COLLEGE
DMURZHA DT Small molecular drug
DMSD647 ID DMSD647
DMSD647 DN PMID30273516-Compound-15
DMSD647 HS Patented
DMSD647 CP UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION CORNELL UNIVERSITY
DMSD647 DT Small molecular drug
DMVZA0U ID DMVZA0U
DMVZA0U DN PMID30273516-Compound-22a
DMVZA0U HS Patented
DMVZA0U CP ASTRAZENECA AB CANCER RESEARCH TECHNOLOGY LIMITED
DMVZA0U DT Small molecular drug
DMZ5O3K ID DMZ5O3K
DMZ5O3K DN PMID30273516-Compound-22b
DMZ5O3K HS Patented
DMZ5O3K CP ASTRAZENECA AB CANCER RESEARCH TECHNOLOGY LIMITED
DMZ5O3K DT Small molecular drug
DM8NBJV ID DM8NBJV
DM8NBJV DN PMID30273516-Compound-37
DM8NBJV HS Patented
DM8NBJV CP HANGZHOU GAMMA BIOTECH CO., LTD
DM8NBJV DT Small molecular drug
DMRPJBF ID DMRPJBF
DMRPJBF DN PMID30273516-Compound-38
DMRPJBF HS Patented
DMRPJBF CP HANGZHOU GAMMA BIOTECH CO., LTD
DMRPJBF DT Small molecular drug
DMBF3ZE ID DMBF3ZE
DMBF3ZE DN PMID30273516-Compound-39
DMBF3ZE HS Patented
DMBF3ZE DT Small molecular drug
DM5N8YJ ID DM5N8YJ
DM5N8YJ DN PMID30273516-Compound-40
DM5N8YJ HS Patented
DM5N8YJ DT Small molecular drug
DM5UBMJ ID DM5UBMJ
DM5UBMJ DN PMID30273516-Compound-41
DM5UBMJ HS Patented
DM5UBMJ CP BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
DM5UBMJ DT Small molecular drug
DMM83WL ID DMM83WL
DMM83WL DN PMID30280939-Compound-US20170128558
DMM83WL HS Patented
DMM83WL DT Vaccine
DMM83WL DE Malaria
DMPVW2Q ID DMPVW2Q
DMPVW2Q DN PMID30280939-Compound-US20179642901
DMPVW2Q HS Patented
DMPVW2Q DT Vaccine
DMPVW2Q DE Malaria
DM6VP5K ID DM6VP5K
DM6VP5K DN PMID30280939-Compound-WO2005070959
DM6VP5K HS Patented
DM6VP5K CP VIEVAX CORP. MAHAIRAS, Gregory, G
DM6VP5K DT Vaccine
DMLVSEK ID DMLVSEK
DMLVSEK DN PMID30280939-Compound-WO200606195
DMLVSEK HS Patented
DMLVSEK DT Vaccine
DM7DG0M ID DM7DG0M
DM7DG0M DN PMID30280939-Compound-WO2008009652
DM7DG0M HS Patented
DM7DG0M CP GLAXOSMITHKLINE BIOLOGICALS S.A. THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY COHEN, Joseph D MARCHAND, Martine OCKENHOUSE, Christian F YADAVA, Anjali
DM7DG0M DT Vaccine
DM7DG0M DE Malaria
DMXRHCJ ID DMXRHCJ
DMXRHCJ DN PMID30280939-Compound-WO2009082440
DMXRHCJ HS Patented
DMXRHCJ CP VAXINNATE CORPORATION NEW YORK UNIVERSITY POWELL, Thomas, J. NAKAAR, Valerian MCDONALD, William, F. NARDIN, Elizabeth, H
DMXRHCJ DT Vaccine
DMRB7LI ID DMRB7LI
DMRB7LI DN PMID30280939-Compound-WO2013119856
DMRB7LI HS Patented
DMRB7LI CP INFECTIOUS DISEASE RESEARCH INSTITUTE
DMRB7LI DT Vaccine
DMUKIEJ ID DMUKIEJ
DMUKIEJ DN PMID30280939-Compound-WO2013148426
DMUKIEJ HS Patented
DMUKIEJ CP ARTIFICIAL CELL TECHNOLOGIES, INC
DMUKIEJ DT Vaccine
DMUKIEJ DE Malaria
DM4Z2KY ID DM4Z2KY
DM4Z2KY DN PMID30280939-Compound-WO2013148427
DM4Z2KY HS Patented
DM4Z2KY CP ARTIFICIAL CELL TECHNOLOGIES, INC
DM4Z2KY DT Vaccine
DM4ILAK ID DM4ILAK
DM4ILAK DN PMID30280939-Compound-WO2015035128
DM4ILAK HS Patented
DM4ILAK CP ALTIMMUNE INC
DM4ILAK DT Vaccine
DM5K3DF ID DM5K3DF
DM5K3DF DN PMID30280939-Compound-WO2015091734
DM5K3DF HS Patented
DM5K3DF CP GLAXOSMITHKLINE BIOLOGICALS S.A. UNITED STATES DEPARTMENT OF THE ARMY, AS REPRESENTED BY THE SECRETARY OF THE US ARMY
DM5K3DF DT Vaccine
DM5K3DF DE Malaria
DMGCE3Z ID DMGCE3Z
DMGCE3Z DN PMID30280939-Compound-WO2015150568
DMGCE3Z HS Patented
DMGCE3Z CP GLAXOSMITHKLINE BIOLOGICALS S.A
DMGCE3Z DT Vaccine
DMSWI67 ID DMSWI67
DMSWI67 DN Polycyclic compound 1
DMSWI67 HS Patented
DMSWI67 SN PMID28627961-Compound-29
DMSWI67 CP GLENMARK PHARMACEUTICALS S.A. GHARAT, Laxmikant Atmaram GAJERA, Jitendra Maganbhai NARAYANA, Lakshminarayana KHAIRATKAR-JOSHI, Neelima KATTIGE, Vidya Ganapati
DMSWI67 DT Small molecular drug
DMPHCJ5 ID DMPHCJ5
DMPHCJ5 DN Polyhydroxy benzamide derivative 1
DMPHCJ5 HS Patented
DMPHCJ5 SN PMID26815044-Compound-53
DMPHCJ5 DT Small molecular drug
DMPHCJ5 PC 70681015
DMPHCJ5 MW 409.5
DMPHCJ5 FM C24H27NO5
DMPHCJ5 IC InChI=1S/C24H27NO5/c26-17-2-1-16(20(27)6-17)12-25-23(30)18-7-19(22(29)8-21(18)28)24-9-13-3-14(10-24)5-15(4-13)11-24/h1-2,6-8,13-15,26-29H,3-5,9-12H2,(H,25,30)
DMPHCJ5 CS C1C2CC3CC1CC(C2)(C3)C4=C(C=C(C(=C4)C(=O)NCC5=C(C=C(C=C5)O)O)O)O
DMPHCJ5 IK DHXXJPGHCYCRET-UHFFFAOYSA-N
DMPHCJ5 IU 5-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-2,4-dihydroxybenzamide
DMPHCJ5 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM0BRNU ID DM0BRNU
DM0BRNU DN Polyhydroxy benzamide derivative 2
DM0BRNU HS Patented
DM0BRNU SN PMID26815044-Compound-54
DM0BRNU DT Small molecular drug
DM0BRNU PC 57328616
DM0BRNU MW 423.5
DM0BRNU FM C25H29NO5
DM0BRNU IC InChI=1S/C25H29NO5/c1-31-23-9-22(29)19(24(30)26-13-17-2-3-18(27)7-21(17)28)8-20(23)25-10-14-4-15(11-25)6-16(5-14)12-25/h2-3,7-9,14-16,27-29H,4-6,10-13H2,1H3,(H,26,30)
DM0BRNU CS COC1=C(C=C(C(=C1)O)C(=O)NCC2=C(C=C(C=C2)O)O)C34CC5CC(C3)CC(C5)C4
DM0BRNU IK SQCLSKGGXIWWPU-UHFFFAOYSA-N
DM0BRNU IU 5-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-2-hydroxy-4-methoxybenzamide
DM0BRNU DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMCLZWS ID DMCLZWS
DMCLZWS DN Polyhydroxy benzamide derivative 3
DMCLZWS HS Patented
DMCLZWS SN PMID26815044-Compound-55
DMCLZWS DT Small molecular drug
DMCLZWS PC 57328615
DMCLZWS MW 437.5
DMCLZWS FM C26H31NO5
DMCLZWS IC InChI=1S/C26H31NO5/c1-31-23-10-24(32-2)21(26-11-15-5-16(12-26)7-17(6-15)13-26)9-20(23)25(30)27-14-18-3-4-19(28)8-22(18)29/h3-4,8-10,15-17,28-29H,5-7,11-14H2,1-2H3,(H,27,30)
DMCLZWS CS COC1=CC(=C(C=C1C(=O)NCC2=C(C=C(C=C2)O)O)C34CC5CC(C3)CC(C5)C4)OC
DMCLZWS IK WDLDXQVTSRCDMN-UHFFFAOYSA-N
DMCLZWS IU 5-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-2,4-dimethoxybenzamide
DMCLZWS DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM6QBV2 ID DM6QBV2
DM6QBV2 DN Polyhydroxy benzamide derivative 4
DM6QBV2 HS Patented
DM6QBV2 SN PMID26815044-Compound-56
DM6QBV2 DT Small molecular drug
DM6QBV2 PC 70681016
DM6QBV2 MW 393.5
DM6QBV2 FM C24H27NO4
DM6QBV2 IC InChI=1S/C24H27NO4/c26-19-3-1-18(22(28)9-19)13-25-23(29)17-2-4-21(27)20(8-17)24-10-14-5-15(11-24)7-16(6-14)12-24/h1-4,8-9,14-16,26-28H,5-7,10-13H2,(H,25,29)
DM6QBV2 CS C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C(=O)NCC5=C(C=C(C=C5)O)O)O
DM6QBV2 IK FXWMRZHJFYXBFU-UHFFFAOYSA-N
DM6QBV2 IU 3-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-4-hydroxybenzamide
DM6QBV2 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMZC6AI ID DMZC6AI
DMZC6AI DN Polyhydroxy benzamide derivative 5
DMZC6AI HS Patented
DMZC6AI SN PMID26815044-Compound-57
DMZC6AI DT Small molecular drug
DMZC6AI PC 70685217
DMZC6AI MW 407.5
DMZC6AI FM C25H29NO4
DMZC6AI IC InChI=1S/C25H29NO4/c1-30-23-5-3-18(24(29)26-14-19-2-4-20(27)10-22(19)28)9-21(23)25-11-15-6-16(12-25)8-17(7-15)13-25/h2-5,9-10,15-17,27-28H,6-8,11-14H2,1H3,(H,26,29)
DMZC6AI CS COC1=C(C=C(C=C1)C(=O)NCC2=C(C=C(C=C2)O)O)C34CC5CC(C3)CC(C5)C4
DMZC6AI IK MZAJLDVRKVEVKU-UHFFFAOYSA-N
DMZC6AI IU 3-(1-adamantyl)-N-[(2,4-dihydroxyphenyl)methyl]-4-methoxybenzamide
DMZC6AI DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMDLS54 ID DMDLS54
DMDLS54 DN Poly-substituted azoles statin lactone derivative 1
DMDLS54 HS Patented
DMDLS54 SN PMID27537201-Compound-Figure15c
DMDLS54 CP the Shanghai Institute of Technology and the Shanghai Ecust Biomedicine Company
DMDLS54 DT Small molecular drug
DM5G3CN ID DM5G3CN
DM5G3CN DN Poly-substituted azoles statin lactone derivative 2
DM5G3CN HS Patented
DM5G3CN SN PMID27537201-Compound-Figure4
DM5G3CN DT Small molecular drug
DMQJ38W ID DMQJ38W
DMQJ38W DN Poly-substituted miazine derivative 1
DMQJ38W HS Patented
DMQJ38W SN PMID27537201-Compound-Figure7
DMQJ38W DT Small molecular drug
DMH2AYV ID DMH2AYV
DMH2AYV DN Proline amide derivative 1
DMH2AYV HS Patented
DMH2AYV SN PMID28699813-Compound-21
DMH2AYV CP THE UNIVERSITY OF MISSISSIPPI SHARIAT-MADAR, Ziaeddin RIMOLDI, John, Matthew GADEPALLI, Rama Sarma, Venkata SubbarahmanyUniversity of Mississippi
DMH2AYV DT Small molecular drug
DMH2AYV PC 57325416
DMH2AYV MW 379.6
DMH2AYV FM C22H41N3O2
DMH2AYV IC InChI=1S/C22H41N3O2/c1-2-3-4-5-6-7-8-9-10-11-16-24-21(26)20-15-13-18-25(20)22(27)19-14-12-17-23-19/h19-20,23H,2-18H2,1H3,(H,24,26)/t19-,20-/m0/s1
DMH2AYV CS CCCCCCCCCCCCNC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CCCN2
DMH2AYV IK VWPVALOPPKNSFP-PMACEKPBSA-N
DMH2AYV IU (2S)-N-dodecyl-1-[(2S)-pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide
DME57SJ ID DME57SJ
DME57SJ DN P-toluenesulfonate derivative 1
DME57SJ HS Patented
DME57SJ SN PMID28594589-Compound-TABLE3c4
DME57SJ CP JIANGSU HENGRUI MEDICINE CO., LTD
DME57SJ DT Small molecular drug
DM92SWJ ID DM92SWJ
DM92SWJ DN Purin-6-one derivative 1
DM92SWJ HS Patented
DM92SWJ SN PMID27321640-Compound-13
DM92SWJ CP ALTANA PHARMA AG TENOR, Hermann BAER, Thomas HATZELMANN, Armin
DM92SWJ DT Small molecular drug
DMB65Z4 ID DMB65Z4
DMB65Z4 DN Purine derivative 1
DMB65Z4 HS Patented
DMB65Z4 SN PMID26161824-Compound-147
DMB65Z4 DT Small molecular drug
DMB65Z4 DE Obesity
DMNRG0P ID DMNRG0P
DMNRG0P DN Purine derivative 2
DMNRG0P HS Patented
DMNRG0P SN PMID26161824-Compound-148
DMNRG0P DT Small molecular drug
DMNRG0P DE Obesity
DMPI2S9 ID DMPI2S9
DMPI2S9 DN Purine derivative 3
DMPI2S9 HS Patented
DMPI2S9 SN PMID26161824-Compound-149
DMPI2S9 DT Small molecular drug
DMPI2S9 DE Obesity
DMYD5SQ ID DMYD5SQ
DMYD5SQ DN Purine derivative 4
DMYD5SQ HS Patented
DMYD5SQ SN PMID26161698-Compound-9
DMYD5SQ CP GEORGETOWN UNIVERSITY YENUGONDA, Venkata, Mahidhar BROWN, Milton, L
DMYD5SQ DT Small molecular drug
DMYD5SQ PC 44626421
DMYD5SQ MW 708.3
DMYD5SQ FM C34H42ClN9O4S
DMYD5SQ IC InChI=1S/C34H42ClN9O4S/c1-20(2)27(18-45)40-34-41-31(30-32(42-34)44(19-37-30)21(3)4)39-22-13-14-25(26(35)17-22)33(46)36-15-16-38-49(47,48)29-12-8-9-23-24(29)10-7-11-28(23)43(5)6/h7-14,17,19-21,27,38,45H,15-16,18H2,1-6H3,(H,36,46)(H2,39,40,41,42)/t27-/m0/s1
DMYD5SQ CS CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=C(C=C3)C(=O)NCCNS(=O)(=O)C4=CC=CC5=C4C=CC=C5N(C)C)Cl
DMYD5SQ IK NJNQGMFCZFMREY-MHZLTWQESA-N
DMYD5SQ IU 2-chloro-N-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]ethyl]-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzamide
DMMVG2O ID DMMVG2O
DMMVG2O DN Pyrano[2,3-b]pyridine derivative 1
DMMVG2O HS Patented
DMMVG2O SN PMID26161824-Compound-122
DMMVG2O CP MERCK & CO., INC. DEBENHAM, John, S. HALE, Jeffrey, J. HUO, Pei MADSEN-DUGGAN, Christina, B. WALSH, Thomas, F. YAN, Li
DMMVG2O DT Small molecular drug
DMMVG2O DE Obesity
DMOJ8P1 ID DMOJ8P1
DMOJ8P1 DN Pyrano[2,3-b]pyridine derivative 2
DMOJ8P1 HS Patented
DMOJ8P1 SN PMID26161824-Compound-123
DMOJ8P1 CP MERCK & CO., INC. DEBENHAM, John, S. HALE, Jeffrey, J. HUO, Pei MADSEN-DUGGAN, Christina, B. WALSH, Thomas, F. YAN, Li
DMOJ8P1 DT Small molecular drug
DMOJ8P1 DE Obesity
DM3RAU4 ID DM3RAU4
DM3RAU4 DN Pyrazine carboxamide derivative 1
DM3RAU4 HS Patented
DM3RAU4 SN PMID25470667-Compound-Figure5-12
DM3RAU4 CP ASTRAZENECA AB ASTRAZENECA UK LIMITED BIRCH, Alan Martin BUTLIN, Roger John CAMPBELL, Leonie GREEN, Clive LEACH, Andrew MURRAY, Paul Michael RYBERG, Per Olof WARING, Michael James
DM3RAU4 DT Small molecular drug
DM3RAU4 PC 49817370
DM3RAU4 MW 480.9
DM3RAU4 FM C25H25ClN4O4
DM3RAU4 IC InChI=1S/C25H25ClN4O4/c1-13-21(29-22(23(27)32)14(2)28-13)17-8-6-16(7-9-17)18-10-5-15(11-19(18)26)12-20(31)30-25(3,4)24(33)34/h5-11H,12H2,1-4H3,(H2,27,32)(H,30,31)(H,33,34)
DM3RAU4 CS CC1=C(N=C(C(=N1)C)C(=O)N)C2=CC=C(C=C2)C3=C(C=C(C=C3)CC(=O)NC(C)(C)C(=O)O)Cl
DM3RAU4 IK XXCQLRBQKLTUDU-UHFFFAOYSA-N
DM3RAU4 IU 2-[[2-[4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]-3-chlorophenyl]acetyl]amino]-2-methylpropanoic acid
DMP1MDV ID DMP1MDV
DMP1MDV DN Pyrazino[2,1-a]isoquinolin derivative 1
DMP1MDV HS Patented
DMP1MDV SN PMID28454500-Compound-28
DMP1MDV CP China Pharmaceutical University
DMP1MDV DT Small molecular drug
DMYXKQ3 ID DMYXKQ3
DMYXKQ3 DN Pyrazino[2,1-a]isoquinolin derivative 2
DMYXKQ3 HS Patented
DMYXKQ3 SN PMID28454500-Compound-29
DMYXKQ3 CP China Pharmaceutical University
DMYXKQ3 DT Small molecular drug
DMXYU3I ID DMXYU3I
DMXYU3I DN Pyrazino[2,1-a]isoquinolin derivative 3
DMXYU3I HS Patented
DMXYU3I SN PMID28454500-Compound-30
DMXYU3I CP China Pharmaceutical University
DMXYU3I DT Small molecular drug
DMKTNBC ID DMKTNBC
DMKTNBC DN Pyrazino[2,1-a]isoquinolin derivative 4
DMKTNBC HS Patented
DMKTNBC SN PMID28454500-Compound-31
DMKTNBC CP China Pharmaceutical University
DMKTNBC DT Small molecular drug
DMUXQST ID DMUXQST
DMUXQST DN Pyrazinylpyridine derivative 1
DMUXQST HS Patented
DMUXQST SN PMID26161698-Compound-38
DMUXQST CP NOVARTIS AG BARSANTI, Paul A. HU, Cheng PFISTER, Keith B. SENDZIK, Martin SUTTON, James
DMUXQST DT Small molecular drug
DM05S2X ID DM05S2X
DM05S2X DN Pyrazole and benzimidazole derivative 1
DM05S2X HS Patented
DM05S2X SN PMID27828716-Compound-14
DM05S2X DT Small molecular drug
DMKTFJ2 ID DMKTFJ2
DMKTFJ2 DN Pyrazole and thiophene derivative 1
DMKTFJ2 HS Patented
DMKTFJ2 SN PMID26924192-Compound-89
DMKTFJ2 CP SignalRx Pharmaceuticals, Inc
DMKTFJ2 DT Small molecular drug
DMKTFJ2 PC 92045047
DMKTFJ2 MW 310.31
DMKTFJ2 FM C16H14N4O3
DMKTFJ2 IC InChI=1S/C16H14N4O3/c21-13-8-4-5-9-19(13)16-18-14(22)12-10-17-20(15(12)23-16)11-6-2-1-3-7-11/h1-3,6-7,10H,4-5,8-9H2
DMKTFJ2 CS C1CCN(C(=O)C1)C2=NC(=O)C3=C(O2)N(N=C3)C4=CC=CC=C4
DMKTFJ2 IK GHCGOVANSHYUTA-UHFFFAOYSA-N
DMKTFJ2 IU 6-(2-oxopiperidin-1-yl)-1-phenylpyrazolo[4,3-e][1,3]oxazin-4-one
DMD51HM ID DMD51HM
DMD51HM DN Pyrazole and thiophene derivative 2
DMD51HM HS Patented
DMD51HM SN PMID26924192-Compound-90
DMD51HM CP SignalRx Pharmaceuticals, Inc
DMD51HM DT Small molecular drug
DMD51HM PC 118487503
DMD51HM MW 296.32
DMD51HM FM C16H16N4O2
DMD51HM IC InChI=1S/C16H16N4O2/c21-14-13-11-17-20(12-7-3-1-4-8-12)15(13)22-16(18-14)19-9-5-2-6-10-19/h1,3-4,7-8,11H,2,5-6,9-10H2
DMD51HM CS C1CCN(CC1)C2=NC(=O)C3=C(O2)N(N=C3)C4=CC=CC=C4
DMD51HM IK FXNLCONPKYSXSM-UHFFFAOYSA-N
DMD51HM IU 1-phenyl-6-piperidin-1-ylpyrazolo[4,3-e][1,3]oxazin-4-one
DMIKUN9 ID DMIKUN9
DMIKUN9 DN Pyrazole and thiophene derivative 3
DMIKUN9 HS Patented
DMIKUN9 SN PMID26924192-Compound-91
DMIKUN9 CP SignalRx Pharmaceuticals, Inc
DMIKUN9 DT Small molecular drug
DMIKUN9 PC 136991243
DMIKUN9 MW 295.34
DMIKUN9 FM C16H17N5O
DMIKUN9 IC InChI=1S/C16H17N5O/c22-15-13-11-17-21(12-7-3-1-4-8-12)14(13)18-16(19-15)20-9-5-2-6-10-20/h1,3-4,7-8,11H,2,5-6,9-10H2,(H,18,19,22)
DMIKUN9 CS C1CCN(CC1)C2=NC3=C(C=NN3C4=CC=CC=C4)C(=O)N2
DMIKUN9 IK ULYRISNPZZRBFO-UHFFFAOYSA-N
DMIKUN9 IU 1-phenyl-6-piperidin-1-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMDETKY ID DMDETKY
DMDETKY DN Pyrazole and thiophene derivative 4
DMDETKY HS Patented
DMDETKY SN PMID26924192-Compound-92
DMDETKY CP SignalRx Pharmaceuticals, Inc
DMDETKY DT Small molecular drug
DMDETKY PC 118487470
DMDETKY MW 372.4
DMDETKY FM C18H16N2O5S
DMDETKY IC InChI=1S/C18H16N2O5S/c21-17-16-15(25-18(19-17)20-3-5-22-6-4-20)12(10-26-16)11-1-2-13-14(9-11)24-8-7-23-13/h1-2,9-10H,3-8H2
DMDETKY CS C1COCCN1C2=NC(=O)C3=C(O2)C(=CS3)C4=CC5=C(C=C4)OCCO5
DMDETKY IK RQLXBUCYHIVDGH-UHFFFAOYSA-N
DMDETKY IU 7-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-morpholin-4-ylthieno[2,3-e][1,3]oxazin-4-one
DM3R9PL ID DM3R9PL
DM3R9PL DN Pyrazole derivative 1
DM3R9PL HS Patented
DM3R9PL SN PMID26161824-Compound-11
DM3R9PL CP SOLVAY PHARMACEUTICALS B.V. LANGE, Josephus H.M. KRUSE, Cornelis G. VAN VLIET, Bernard J
DM3R9PL DT Small molecular drug
DM3R9PL PC 23624319
DM3R9PL MW 495.8
DM3R9PL FM C22H21Cl3N4OS
DM3R9PL IC InChI=1S/C22H21Cl3N4OS/c1-31-21-19(22(30)27-28-11-3-2-4-12-28)26-29(18-10-9-16(24)13-17(18)25)20(21)14-5-7-15(23)8-6-14/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DM3R9PL CS CSC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DM3R9PL IK MDNGVPOVESSODT-UHFFFAOYSA-N
DM3R9PL IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylsulfanyl-N-piperidin-1-ylpyrazole-3-carboxamide
DM3R9PL DE Obesity
DMH7PGU ID DMH7PGU
DMH7PGU DN Pyrazole derivative 11
DMH7PGU HS Patented
DMH7PGU SN PMID26161824-Compound-23
DMH7PGU CP 7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DMH7PGU DT Small molecular drug
DMH7PGU PC 25157097
DMH7PGU MW 468.3
DMH7PGU FM C22H15Cl2N5O3
DMH7PGU IC InChI=1S/C22H15Cl2N5O3/c23-14-7-5-13(6-8-14)20-16(11-18(30)31)19(22(32)27-15-3-1-9-25-12-15)28-29(20)21-17(24)4-2-10-26-21/h1-10,12H,11H2,(H,27,32)(H,30,31)
DMH7PGU CS C1=CC(=CN=C1)NC(=O)C2=NN(C(=C2CC(=O)O)C3=CC=C(C=C3)Cl)C4=C(C=CC=N4)Cl
DMH7PGU IK RHWMIURMWNGDKU-UHFFFAOYSA-N
DMH7PGU IU 2-[5-(4-chlorophenyl)-1-(3-chloropyridin-2-yl)-3-(pyridin-3-ylcarbamoyl)pyrazol-4-yl]acetic acid
DMH7PGU DE Obesity
DM7LFNG ID DM7LFNG
DM7LFNG DN Pyrazole derivative 12
DM7LFNG HS Patented
DM7LFNG SN PMID26161824-Compound-24
DM7LFNG CP 7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DM7LFNG DT Small molecular drug
DM7LFNG DE Obesity
DM5S3L0 ID DM5S3L0
DM5S3L0 DN Pyrazole derivative 13
DM5S3L0 HS Patented
DM5S3L0 SN PMID26161824-Compound-25
DM5S3L0 CP 7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DM5S3L0 DT Small molecular drug
DM5S3L0 PC 24824727
DM5S3L0 MW 573.4
DM5S3L0 FM C25H17Cl2F3N8O
DM5S3L0 IC InChI=1S/C25H17Cl2F3N8O/c26-17-9-5-15(6-10-17)22-18(12-20-33-36-37-34-20)21(35-38(22)23-19(27)2-1-11-31-23)24(39)32-13-14-3-7-16(8-4-14)25(28,29)30/h1-11H,12-13H2,(H,32,39)(H,33,34,36,37)
DM5S3L0 CS C1=CC(=C(N=C1)N2C(=C(C(=N2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F)CC4=NNN=N4)C5=CC=C(C=C5)Cl)Cl
DM5S3L0 IK FXZYLULQTVQTLV-UHFFFAOYSA-N
DM5S3L0 IU 5-(4-chlorophenyl)-1-(3-chloropyridin-2-yl)-4-(2H-tetrazol-5-ylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]pyrazole-3-carboxamide
DM5S3L0 DE Obesity
DMEDXW9 ID DMEDXW9
DMEDXW9 DN Pyrazole derivative 14
DMEDXW9 HS Patented
DMEDXW9 SN PMID26161824-Compound-26
DMEDXW9 CP 7TM PHARMA A/S COOPER, Martin RECEVEUR, Jean-Marie HOEGBERG, Thomas NIELSEN, Peter, Aadal LINGET, Jean-Michel NOEREGAARD, Pia, Karina
DMEDXW9 DT Small molecular drug
DMEDXW9 DE Obesity
DMJCX8M ID DMJCX8M
DMJCX8M DN Pyrazole derivative 15
DMJCX8M HS Patented
DMJCX8M SN PMID26161824-Compound-27
DMJCX8M DT Small molecular drug
DMJCX8M PC 59146323
DMJCX8M MW 526.4
DMJCX8M FM C27H22Cl2FN3O3
DMJCX8M IC InChI=1S/C27H22Cl2FN3O3/c1-27(2,17-9-13-19(30)14-10-17)31-26(36)24-20(15-23(34)35)25(16-7-11-18(28)12-8-16)33(32-24)22-6-4-3-5-21(22)29/h3-14H,15H2,1-2H3,(H,31,36)(H,34,35)
DMJCX8M CS CC(C)(C1=CC=C(C=C1)F)NC(=O)C2=NN(C(=C2CC(=O)O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl
DMJCX8M IK YBFWRMNFSYACJD-UHFFFAOYSA-N
DMJCX8M IU 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-[2-(4-fluorophenyl)propan-2-ylcarbamoyl]pyrazol-4-yl]acetic acid
DMJCX8M DE Obesity
DM5A8F3 ID DM5A8F3
DM5A8F3 DN Pyrazole derivative 16
DM5A8F3 HS Patented
DM5A8F3 SN PMID26161824-Compound-28
DM5A8F3 DT Small molecular drug
DM5A8F3 DE Obesity
DM7F9V4 ID DM7F9V4
DM7F9V4 DN Pyrazole derivative 17
DM7F9V4 HS Patented
DM7F9V4 SN PMID26161824-Compound-29
DM7F9V4 DT Small molecular drug
DM7F9V4 DE Obesity
DMVZ8KD ID DMVZ8KD
DMVZ8KD DN Pyrazole derivative 18
DMVZ8KD HS Patented
DMVZ8KD SN PMID26161824-Compound-30
DMVZ8KD DT Small molecular drug
DMVZ8KD DE Obesity
DMM7OR3 ID DMM7OR3
DMM7OR3 DN Pyrazole derivative 19
DMM7OR3 HS Patented
DMM7OR3 SN PMID26161824-Compound-31
DMM7OR3 DT Small molecular drug
DMM7OR3 PC 24984175
DMM7OR3 MW 468.8
DMM7OR3 FM C21H20Cl3N3OS
DMM7OR3 IC InChI=1S/C21H20Cl3N3OS/c1-12-16(11-25-21(28)13-4-2-3-5-13)26-27(17-7-6-14(22)10-15(17)23)20(12)18-8-9-19(24)29-18/h6-10,13H,2-5,11H2,1H3,(H,25,28)
DMM7OR3 CS CC1=C(N(N=C1CNC(=O)C2CCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(S4)Cl
DMM7OR3 IK WBIDOYNZOLUBQY-UHFFFAOYSA-N
DMM7OR3 IU N-[[5-(5-chlorothiophen-2-yl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]methyl]cyclopentanecarboxamide
DMM7OR3 DE Obesity
DMIS97T ID DMIS97T
DMIS97T DN Pyrazole derivative 2
DMIS97T HS Patented
DMIS97T SN PMID26161824-Compound-12
DMIS97T CP SOLVAY PHARMACEUTICALS B.V. LANGE, Josephus H.M. KRUSE, Cornelis G. VAN VLIET, Bernard J
DMIS97T DT Small molecular drug
DMIS97T PC 24863732
DMIS97T MW 511.8
DMIS97T FM C22H21Cl3N4O2S
DMIS97T IC InChI=1S/C22H21Cl3N4O2S/c1-32(31)21-19(22(30)27-28-11-3-2-4-12-28)26-29(18-10-9-16(24)13-17(18)25)20(21)14-5-7-15(23)8-6-14/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMIS97T CS CS(=O)C1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMIS97T IK LMXGOWNIGCDDEQ-UHFFFAOYSA-N
DMIS97T IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylsulfinyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMIS97T DE Obesity
DM2HO1S ID DM2HO1S
DM2HO1S DN Pyrazole derivative 20
DM2HO1S HS Patented
DM2HO1S SN PMID26161824-Compound-32
DM2HO1S DT Small molecular drug
DM2HO1S PC 24857045
DM2HO1S MW 503.5
DM2HO1S FM C25H28Cl2N4OS
DM2HO1S IC InChI=1S/C25H28Cl2N4OS/c1-3-4-6-9-19-11-13-22(33-19)24-17(2)23(25(32)29-30-14-7-5-8-15-30)28-31(24)21-12-10-18(26)16-20(21)27/h6,9-13,16H,3-5,7-8,14-15H2,1-2H3,(H,29,32)/b9-6+
DM2HO1S CS CCC/C=C/C1=CC=C(S1)C2=C(C(=NN2C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCCC4)C
DM2HO1S IK IHFQVFSRVQQXSC-RMKNXTFCSA-N
DM2HO1S IU 1-(2,4-dichlorophenyl)-4-methyl-5-[5-[(E)-pent-1-enyl]thiophen-2-yl]-N-piperidin-1-ylpyrazole-3-carboxamide
DM2HO1S DE Obesity
DMUPNHA ID DMUPNHA
DMUPNHA DN Pyrazole derivative 21
DMUPNHA HS Patented
DMUPNHA SN PMID26161824-Compound-33
DMUPNHA DT Small molecular drug
DMUPNHA PC 24805936
DMUPNHA MW 531.5
DMUPNHA FM C27H32Cl2N4OS
DMUPNHA IC InChI=1S/C27H32Cl2N4OS/c1-3-4-6-11-21-13-15-25(35-21)26-18(2)23(17-30-27(34)31-20-9-7-5-8-10-20)32-33(26)24-14-12-19(28)16-22(24)29/h6,11-16,20H,3-5,7-10,17H2,1-2H3,(H2,30,31,34)/b11-6+
DMUPNHA CS CCC/C=C/C1=CC=C(S1)C2=C(C(=NN2C3=C(C=C(C=C3)Cl)Cl)CNC(=O)NC4CCCCC4)C
DMUPNHA IK RKQZPZUIJRISOY-IZZDOVSWSA-N
DMUPNHA IU 1-cyclohexyl-3-[[1-(2,4-dichlorophenyl)-4-methyl-5-[5-[(E)-pent-1-enyl]thiophen-2-yl]pyrazol-3-yl]methyl]urea
DMUPNHA DE Obesity
DMCS08K ID DMCS08K
DMCS08K DN Pyrazole derivative 22
DMCS08K HS Patented
DMCS08K SN PMID26161824-Compound-34
DMCS08K DT Small molecular drug
DMCS08K DE Obesity
DMH2LFS ID DMH2LFS
DMH2LFS DN Pyrazole derivative 23
DMH2LFS HS Patented
DMH2LFS SN PMID26161824-Compound-35
DMH2LFS DT Small molecular drug
DMH2LFS PC 24983527
DMH2LFS MW 559.2
DMH2LFS FM C20H17BrCl2N4OSe
DMH2LFS IC InChI=1S/C20H17BrCl2N4OSe/c1-10-16(18-24-19(26-28-18)20(2,3)4)25-27(13-6-5-11(22)9-12(13)23)17(10)14-7-8-15(21)29-14/h5-9H,1-4H3
DMH2LFS CS CC1=C(N(N=C1C2=NC(=NO2)C(C)(C)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C([Se]4)Br
DMH2LFS IK YUVJAEGOFXSXNJ-UHFFFAOYSA-N
DMH2LFS IU 5-[5-(5-bromoselenophen-2-yl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-3-tert-butyl-1,2,4-oxadiazole
DMH2LFS DE Obesity
DMVX2D0 ID DMVX2D0
DMVX2D0 DN Pyrazole derivative 24
DMVX2D0 HS Patented
DMVX2D0 SN PMID26161824-Compound-36
DMVX2D0 DT Small molecular drug
DMVX2D0 PC 25051295
DMVX2D0 MW 459.4
DMVX2D0 FM C22H20Cl2N4OS
DMVX2D0 IC InChI=1S/C22H20Cl2N4OS/c1-5-6-15-8-10-18(30-15)20-13(4)19(22-25-21(12(2)3)27-29-22)26-28(20)17-9-7-14(23)11-16(17)24/h5-12H,1-4H3/b6-5+
DMVX2D0 CS C/C=C/C1=CC=C(S1)C2=C(C(=NN2C3=C(C=C(C=C3)Cl)Cl)C4=NC(=NO4)C(C)C)C
DMVX2D0 IK WDHLKRONMIKUBC-AATRIKPKSA-N
DMVX2D0 IU 5-[1-(2,4-dichlorophenyl)-4-methyl-5-[5-[(E)-prop-1-enyl]thiophen-2-yl]pyrazol-3-yl]-3-propan-2-yl-1,2,4-oxadiazole
DMVX2D0 DE Obesity
DMM2RYG ID DMM2RYG
DMM2RYG DN Pyrazole derivative 25
DMM2RYG HS Patented
DMM2RYG SN PMID26161824-Compound-37
DMM2RYG DT Small molecular drug
DMM2RYG PC 25051779
DMM2RYG MW 497.4
DMM2RYG FM C25H22Cl2N4OS
DMM2RYG IC InChI=1S/C25H22Cl2N4OS/c1-3-22-28-25(32-30-22)23-15(2)24(31(29-23)20-12-9-17(26)14-19(20)27)21-13-11-18(33-21)10-8-16-6-4-5-7-16/h9,11-14,16H,3-7H2,1-2H3
DMM2RYG CS CCC1=NOC(=N1)C2=NN(C(=C2C)C3=CC=C(S3)C#CC4CCCC4)C5=C(C=C(C=C5)Cl)Cl
DMM2RYG IK NIKGOEACQPFNCK-UHFFFAOYSA-N
DMM2RYG IU 5-[5-[5-(2-cyclopentylethynyl)thiophen-2-yl]-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-3-ethyl-1,2,4-oxadiazole
DMM2RYG DE Obesity
DMX92ZK ID DMX92ZK
DMX92ZK DN Pyrazole derivative 26
DMX92ZK HS Patented
DMX92ZK SN PMID26161824-Compound-38
DMX92ZK CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMX92ZK DT Small molecular drug
DMX92ZK PC 87176790
DMX92ZK MW 594.8
DMX92ZK FM C25H17Cl3F3N7O
DMX92ZK IC InChI=1S/C25H17Cl3F3N7O/c26-15-4-2-14(3-5-15)21-17(11-37-13-32-12-33-37)20(36-38(21)19-7-6-16(27)10-18(19)28)22-34-35-23(39-22)24(8-1-9-24)25(29,30)31/h2-7,10,12-13H,1,8-9,11H2
DMX92ZK CS C1CC(C1)(C2=NN=C(O2)C3=NN(C(=C3CN4C=NC=N4)C5=CC=C(C=C5)Cl)C6=C(C=C(C=C6)Cl)Cl)C(F)(F)F
DMX92ZK IK MXDYVLWGDAKEMQ-UHFFFAOYSA-N
DMX92ZK IU 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1,2,4-triazol-1-ylmethyl)pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]-1,3,4-oxadiazole
DMX92ZK DE Obesity
DMDB5FH ID DMDB5FH
DMDB5FH DN Pyrazole derivative 27
DMDB5FH HS Patented
DMDB5FH SN PMID26161824-Compound-39
DMDB5FH CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMDB5FH DT Small molecular drug
DMDB5FH PC 49865188
DMDB5FH MW 604.9
DMDB5FH FM C29H20Cl3N7S
DMDB5FH IC InChI=1S/C29H20Cl3N7S/c30-20-8-6-18(7-9-20)26-22(15-38-17-33-16-34-38)25(37-39(26)24-11-10-21(31)14-23(24)32)27-35-36-28(40-27)29(12-13-29)19-4-2-1-3-5-19/h1-11,14,16-17H,12-13,15H2
DMDB5FH CS C1CC1(C2=CC=CC=C2)C3=NN=C(S3)C4=NN(C(=C4CN5C=NC=N5)C6=CC=C(C=C6)Cl)C7=C(C=C(C=C7)Cl)Cl
DMDB5FH IK IYLHAOFOPKLWMF-UHFFFAOYSA-N
DMDB5FH IU 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1,2,4-triazol-1-ylmethyl)pyrazol-3-yl]-5-(1-phenylcyclopropyl)-1,3,4-thiadiazole
DMDB5FH DE Obesity
DMYEFW1 ID DMYEFW1
DMYEFW1 DN Pyrazole derivative 28
DMYEFW1 HS Patented
DMYEFW1 SN PMID26161824-Compound-40
DMYEFW1 CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMYEFW1 DT Small molecular drug
DMYEFW1 DE Obesity
DM7DTYS ID DM7DTYS
DM7DTYS DN Pyrazole derivative 29
DM7DTYS HS Patented
DM7DTYS SN PMID26161824-Compound-41
DM7DTYS CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DM7DTYS DT Small molecular drug
DM7DTYS PC 24810743
DM7DTYS MW 502.9
DM7DTYS FM C25H26Cl3N5
DM7DTYS IC InChI=1S/C25H26Cl3N5/c1-6-15(4)25-29-24(31-32(25)14(2)3)22-16(5)23(17-7-9-18(26)10-8-17)33(30-22)21-12-11-19(27)13-20(21)28/h7-15H,6H2,1-5H3
DM7DTYS CS CCC(C)C1=NC(=NN1C(C)C)C2=NN(C(=C2C)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DM7DTYS IK WWSDQOOUHRYSSK-UHFFFAOYSA-N
DM7DTYS IU 5-butan-2-yl-3-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-1-propan-2-yl-1,2,4-triazole
DM7DTYS DE Obesity
DMX2NQW ID DMX2NQW
DMX2NQW DN Pyrazole derivative 3
DMX2NQW HS Patented
DMX2NQW SN PMID26161824-Compound-13
DMX2NQW CP SOLVAY PHARMACEUTICALS B.V. LANGE, Josephus H.M. KRUSE, Cornelis G. VAN VLIET, Bernard J
DMX2NQW DT Small molecular drug
DMX2NQW PC 24863731
DMX2NQW MW 527.8
DMX2NQW FM C22H21Cl3N4O3S
DMX2NQW IC InChI=1S/C22H21Cl3N4O3S/c1-33(31,32)21-19(22(30)27-28-11-3-2-4-12-28)26-29(18-10-9-16(24)13-17(18)25)20(21)14-5-7-15(23)8-6-14/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMX2NQW CS CS(=O)(=O)C1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMX2NQW IK WUMRQUSTSNHTOT-UHFFFAOYSA-N
DMX2NQW IU 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylsulfonyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMX2NQW DE Obesity
DMT1DJP ID DMT1DJP
DMT1DJP DN Pyrazole derivative 30
DMT1DJP HS Patented
DMT1DJP SN PMID26161824-Compound-42
DMT1DJP CP GREEN CROSS CORPORATION LEE, Jinhwa KIM, Jeong Min CHANG, Chong-Hwan Jonathan LEE, Suk Ho SEO, Hee Jeong KANG, Suk Youn SONG, Kwang-Seop KIM, Jong Yup KIM, Min Ju LEE, Sung-Han AHN, Kwang-Woo JUNG, Myung Eu
DMT1DJP DT Small molecular drug
DMT1DJP PC 66844441
DMT1DJP MW 460.8
DMT1DJP FM C23H20Cl3N3O
DMT1DJP IC InChI=1S/C23H20Cl3N3O/c1-13-20(22-27-12-19(30-22)23(2,3)4)28-29(18-10-9-16(25)11-17(18)26)21(13)14-5-7-15(24)8-6-14/h5-12H,1-4H3
DMT1DJP CS CC1=C(N(N=C1C2=NC=C(O2)C(C)(C)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl
DMT1DJP IK ILTATKGFTNWDTG-UHFFFAOYSA-N
DMT1DJP IU 5-tert-butyl-2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]-1,3-oxazole
DMT1DJP DE Obesity
DMDTQCG ID DMDTQCG
DMDTQCG DN Pyrazole derivative 31
DMDTQCG HS Patented
DMDTQCG SN PMID26161824-Compound-45
DMDTQCG CP GREEN CROSS CORPORATION LEE, Sung-Han SEO, Hee Jeong LEE, Jinhwa KIM, Min-ah KIM, Jeong Min KANG, Suk Youn AHN, Kwang-Woo LEE, Suk Ho
DMDTQCG DT Small molecular drug
DMDTQCG PC 44247611
DMDTQCG MW 567.8
DMDTQCG FM C27H21Cl3N6O2
DMDTQCG IC InChI=1S/C27H21Cl3N6O2/c1-27(2,3)26-34-33-25(38-26)22-21(24(37)32-20-6-4-5-13-31-20)23(15-7-9-16(28)10-8-15)36(35-22)19-12-11-17(29)14-18(19)30/h4-14H,1-3H3,(H,31,32,37)
DMDTQCG CS CC(C)(C)C1=NN=C(O1)C2=NN(C(=C2C(=O)NC3=CC=CC=N3)C4=CC=C(C=C4)Cl)C5=C(C=C(C=C5)Cl)Cl
DMDTQCG IK UGTKDMCWCRRUHZ-UHFFFAOYSA-N
DMDTQCG IU 3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-pyridin-2-ylpyrazole-4-carboxamide
DMDTQCG DE Obesity
DMU59IJ ID DMU59IJ
DMU59IJ DN Pyrazole derivative 32
DMU59IJ HS Patented
DMU59IJ SN PMID26161824-Compound-46
DMU59IJ CP GREEN CROSS CORPORATION LEE, Sung-Han SEO, Hee Jeong LEE, Jinhwa KIM, Min-ah KIM, Jeong Min KANG, Suk Youn AHN, Kwang-Woo LEE, Suk Ho
DMU59IJ DT Small molecular drug
DMU59IJ PC 44247650
DMU59IJ MW 591.3
DMU59IJ FM C25H22BrCl2N5OS
DMU59IJ IC InChI=1S/C25H22BrCl2N5OS/c1-25(2,3)24-31-30-23(35-24)20-19(22(34)29-16-9-10-16)21(13-4-6-14(26)7-5-13)33(32-20)18-11-8-15(27)12-17(18)28/h4-8,11-12,16H,9-10H2,1-3H3,(H,29,34)
DMU59IJ CS CC(C)(C)C1=NN=C(S1)C2=NN(C(=C2C(=O)NC3CC3)C4=CC=C(C=C4)Br)C5=C(C=C(C=C5)Cl)Cl
DMU59IJ IK GBQKLVGYQWGQEF-UHFFFAOYSA-N
DMU59IJ IU 5-(4-bromophenyl)-3-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-N-cyclopropyl-1-(2,4-dichlorophenyl)pyrazole-4-carboxamide
DMU59IJ DE Obesity
DMUNLK8 ID DMUNLK8
DMUNLK8 DN Pyrazole derivative 33
DMUNLK8 HS Patented
DMUNLK8 SN PMID26161824-Compound-47
DMUNLK8 CP GREEN CROSS CORPORATION LEE, Jinhwa SEO, Hee Jeong KIM, Min-Ah KIM, Jeongmin LEE, Sung-Han JUNG, Myung Eun KIM, Mi-Soo
DMUNLK8 DT Small molecular drug
DMUNLK8 DE Obesity
DMRH2EJ ID DMRH2EJ
DMRH2EJ DN Pyrazole derivative 34
DMRH2EJ HS Patented
DMRH2EJ SN PMID26161824-Compound-48
DMRH2EJ CP GREEN CROSS CORPORATION LEE, Jinhwa SEO, Hee Jeong KIM, Min-Ah KIM, Jeongmin LEE, Sung-Han JUNG, Myung Eun KIM, Mi-Soo
DMRH2EJ DT Small molecular drug
DMRH2EJ PC 45102594
DMRH2EJ MW 573.4
DMRH2EJ FM C23H17Cl2F3N4O2S2
DMRH2EJ IC InChI=1S/C23H17Cl2F3N4O2S2/c1-36(33,34)19-17(20-29-30-21(35-20)22(11-4-12-22)23(26,27)28)31-32(16-6-3-2-5-15(16)25)18(19)13-7-9-14(24)10-8-13/h2-3,5-10H,4,11-12H2,1H3
DMRH2EJ CS CS(=O)(=O)C1=C(N(N=C1C2=NN=C(S2)C3(CCC3)C(F)(F)F)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
DMRH2EJ IK JEHNKOMECQRUIV-UHFFFAOYSA-N
DMRH2EJ IU 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylsulfonylpyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]-1,3,4-thiadiazole
DMRH2EJ DE Obesity
DM6KROX ID DM6KROX
DM6KROX DN Pyrazole derivative 35
DM6KROX HS Patented
DM6KROX SN PMID26161824-Compound-49
DM6KROX CP 7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DM6KROX DT Small molecular drug
DM6KROX DE Obesity
DMSDVI1 ID DMSDVI1
DMSDVI1 DN Pyrazole derivative 36
DMSDVI1 HS Patented
DMSDVI1 SN PMID26161824-Compound-50
DMSDVI1 CP 7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMSDVI1 DT Small molecular drug
DMSDVI1 DE Obesity
DMZJ5FN ID DMZJ5FN
DMZJ5FN DN Pyrazole derivative 37
DMZJ5FN HS Patented
DMZJ5FN SN PMID26161824-Compound-51
DMZJ5FN CP 7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMZJ5FN DT Small molecular drug
DMZJ5FN DE Obesity
DMPVDSC ID DMPVDSC
DMPVDSC DN Pyrazole derivative 38
DMPVDSC HS Patented
DMPVDSC SN PMID26161824-Compound-52
DMPVDSC CP 7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMPVDSC DT Small molecular drug
DMPVDSC PC 71101125
DMPVDSC MW 504.4
DMPVDSC FM C26H19Cl2N5O2
DMPVDSC IC InChI=1S/C26H19Cl2N5O2/c27-19-11-9-18(10-12-19)25-20(13-23(30)34)24(32-33(25)22-4-2-1-3-21(22)28)26(35)31-15-17-7-5-16(14-29)6-8-17/h1-12H,13,15H2,(H2,30,34)(H,31,35)
DMPVDSC CS C1=CC=C(C(=C1)N2C(=C(C(=N2)C(=O)NCC3=CC=C(C=C3)C#N)CC(=O)N)C4=CC=C(C=C4)Cl)Cl
DMPVDSC IK XBSLPZFPNMDPEG-UHFFFAOYSA-N
DMPVDSC IU 4-(2-amino-2-oxoethyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-[(4-cyanophenyl)methyl]pyrazole-3-carboxamide
DMPVDSC DE Obesity
DMMGWKE ID DMMGWKE
DMMGWKE DN Pyrazole derivative 39
DMMGWKE HS Patented
DMMGWKE SN PMID26161824-Compound-53
DMMGWKE CP 7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DMMGWKE DT Small molecular drug
DMMGWKE PC 25027058
DMMGWKE MW 482.3
DMMGWKE FM C24H18Cl2FN5O
DMMGWKE IC InChI=1S/C24H18Cl2FN5O/c25-15-7-5-14(6-8-15)23-18(13-21(28)29)22(24(33)30-17-11-9-16(27)10-12-17)31-32(23)20-4-2-1-3-19(20)26/h1-12H,13H2,(H3,28,29)(H,30,33)
DMMGWKE CS C1=CC=C(C(=C1)N2C(=C(C(=N2)C(=O)NC3=CC=C(C=C3)F)CC(=N)N)C4=CC=C(C=C4)Cl)Cl
DMMGWKE IK QWOVGBHZFLBBHN-UHFFFAOYSA-N
DMMGWKE IU 4-(2-amino-2-iminoethyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-(4-fluorophenyl)pyrazole-3-carboxamide
DMMGWKE DE Obesity
DM2DK1E ID DM2DK1E
DM2DK1E DN Pyrazole derivative 4
DM2DK1E HS Patented
DM2DK1E SN PMID26161824-Compound-14
DM2DK1E CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DM2DK1E DT Small molecular drug
DM2DK1E PC 66863165
DM2DK1E MW 531.4
DM2DK1E FM C25H28Cl2N6O3
DM2DK1E IC InChI=1S/C25H28Cl2N6O3/c1-2-28-25(35)29-13-16-36-23-21(24(34)31-32-14-5-6-15-32)30-33(20-8-4-3-7-19(20)27)22(23)17-9-11-18(26)12-10-17/h3-4,7-12H,2,5-6,13-16H2,1H3,(H,31,34)(H2,28,29,35)
DM2DK1E CS CCNC(=O)NCCOC1=C(N(N=C1C(=O)NN2CCCC2)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl
DM2DK1E IK ZDSBVGULFYUNNF-UHFFFAOYSA-N
DM2DK1E IU 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-[2-(ethylcarbamoylamino)ethoxy]-N-pyrrolidin-1-ylpyrazole-3-carboxamide
DM2DK1E DE Obesity
DM7CMV6 ID DM7CMV6
DM7CMV6 DN Pyrazole derivative 40
DM7CMV6 HS Patented
DM7CMV6 SN PMID26161824-Compound-54
DM7CMV6 CP 7TM PHARMA A/S RECEVEUR, Jean-Marie NIELSEN, Peter, Aadal HOEGBERG, Thomas LINGET, Jean-Michel COOPER, Martin NOERREGAARD, Pia, Karina
DM7CMV6 DT Small molecular drug
DM7CMV6 DE Obesity
DMDGSKH ID DMDGSKH
DMDGSKH DN Pyrazole derivative 5
DMDGSKH HS Patented
DMDGSKH SN PMID26161824-Compound-15
DMDGSKH CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMDGSKH DT Small molecular drug
DMDGSKH DE Obesity
DMMIOZ5 ID DMMIOZ5
DMMIOZ5 DN Pyrazole derivative 53
DMMIOZ5 HS Patented
DMMIOZ5 SN PMID26161824-Compound-67
DMMIOZ5 DT Small molecular drug
DMMIOZ5 DE Obesity
DM9PNTF ID DM9PNTF
DM9PNTF DN Pyrazole derivative 54
DM9PNTF HS Patented
DM9PNTF SN PMID26161824-Compound-70
DM9PNTF CP UNIVERSITY OF CONNECTICUT MAKRIYANNIS, Alexandros VEMURI, Venkata, Kiran THOTAPALLY, Rajesh OLSZEWSKA, Teresa
DM9PNTF DT Small molecular drug
DM9PNTF PC 46894021
DM9PNTF MW 524.4
DM9PNTF FM C26H23Cl2N5O3
DM9PNTF IC InChI=1S/C26H23Cl2N5O3/c27-20-9-10-23(22(28)16-20)33-25(19-7-5-18(6-8-19)4-2-1-3-11-29)21(17-34)24(30-33)26(35)31-32-12-14-36-15-13-32/h5-10,16,34H,1,3,12-15,17H2,(H,31,35)
DM9PNTF CS C1COCCN1NC(=O)C2=NN(C(=C2CO)C3=CC=C(C=C3)C#CCCC#N)C4=C(C=C(C=C4)Cl)Cl
DM9PNTF IK VQXIVPLXEIZJTH-UHFFFAOYSA-N
DM9PNTF IU 5-[4-(4-cyanobut-1-ynyl)phenyl]-1-(2,4-dichlorophenyl)-4-(hydroxymethyl)-N-morpholin-4-ylpyrazole-3-carboxamide
DM9PNTF DE Obesity
DMZ3J78 ID DMZ3J78
DMZ3J78 DN Pyrazole derivative 57
DMZ3J78 HS Patented
DMZ3J78 SN PMID26161824-Compound-77
DMZ3J78 CP RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMZ3J78 DT Small molecular drug
DMZ3J78 DE Obesity
DMZIOW0 ID DMZIOW0
DMZIOW0 DN Pyrazole derivative 58
DMZIOW0 HS Patented
DMZIOW0 SN PMID26161824-Compound-78
DMZIOW0 CP RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMZIOW0 DT Small molecular drug
DMZIOW0 DE Obesity
DMXZC8K ID DMXZC8K
DMXZC8K DN Pyrazole derivative 59
DMXZC8K HS Patented
DMXZC8K SN PMID26161824-Compound-79
DMXZC8K CP RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMXZC8K DT Small molecular drug
DMXZC8K DE Obesity
DMIDN6T ID DMIDN6T
DMIDN6T DN Pyrazole derivative 6
DMIDN6T HS Patented
DMIDN6T SN PMID26161824-Compound-16
DMIDN6T CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMIDN6T DT Small molecular drug
DMIDN6T PC 16718290
DMIDN6T MW 444.2
DMIDN6T FM C19H14Cl2F3N3O2
DMIDN6T IC InChI=1S/C19H14Cl2F3N3O2/c1-29-17-15(18(28)25-10-19(22,23)24)26-27(14-5-3-2-4-13(14)21)16(17)11-6-8-12(20)9-7-11/h2-9H,10H2,1H3,(H,25,28)
DMIDN6T CS COC1=C(N(N=C1C(=O)NCC(F)(F)F)C2=CC=CC=C2Cl)C3=CC=C(C=C3)Cl
DMIDN6T IK SOPUIDIJDHHXJF-UHFFFAOYSA-N
DMIDN6T IU 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methoxy-N-(2,2,2-trifluoroethyl)pyrazole-3-carboxamide
DMIDN6T DE Obesity
DMQ08BM ID DMQ08BM
DMQ08BM DN Pyrazole derivative 60
DMQ08BM HS Patented
DMQ08BM SN PMID26161824-Compound-80
DMQ08BM CP RESEARCH TRIANGLE INSTITUTE FULP, Alan Bradley MAITRA, Rangan ZHANG, Yanan SELTZMAN, Herbert H
DMQ08BM DT Small molecular drug
DMQ08BM DE Obesity
DMO6M1Q ID DMO6M1Q
DMO6M1Q DN Pyrazole derivative 61
DMO6M1Q HS Patented
DMO6M1Q SN PMID25684022-Compound-US20090111799
DMO6M1Q CP The Ohio State University Research Foundation
DMO6M1Q DT Small molecular drug
DMO6M1Q DE Solid tumour/cancer; Metastatic cancer
DMN53R0 ID DMN53R0
DMN53R0 DN Pyrazole derivative 62
DMN53R0 HS Patented
DMN53R0 SN PMID26394986-Compound-23
DMN53R0 CP MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMN53R0 DT Small molecular drug
DMN53R0 PC 72543768
DMN53R0 MW 612.5
DMN53R0 FM C27H26BrN5O5S
DMN53R0 IC InChI=1S/C27H26BrN5O5S/c1-30-26(34)16-38-17-27(35)31-21-8-2-18(3-9-21)14-22-15-25(19-4-6-20(28)7-5-19)33(32-22)23-10-12-24(13-11-23)39(29,36)37/h2-13,15H,14,16-17H2,1H3,(H,30,34)(H,31,35)(H2,29,36,37)
DMN53R0 CS CNC(=O)COCC(=O)NC1=CC=C(C=C1)CC2=NN(C(=C2)C3=CC=C(C=C3)Br)C4=CC=C(C=C4)S(=O)(=O)N
DMN53R0 IK WRRXKPVOAFTNLS-UHFFFAOYSA-N
DMN53R0 IU 2-[2-[4-[[5-(4-bromophenyl)-1-(4-sulfamoylphenyl)pyrazol-3-yl]methyl]anilino]-2-oxoethoxy]-N-methylacetamide
DMTVAJ0 ID DMTVAJ0
DMTVAJ0 DN Pyrazole derivative 63
DMTVAJ0 HS Patented
DMTVAJ0 SN PMID26394986-Compound-24
DMTVAJ0 CP MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMTVAJ0 DT Small molecular drug
DMTVAJ0 PC 72705159
DMTVAJ0 MW 525.4
DMTVAJ0 FM C24H21BrN4O3S
DMTVAJ0 IC InChI=1S/C24H21BrN4O3S/c1-16(30)27-20-8-2-17(3-9-20)14-21-15-24(18-4-6-19(25)7-5-18)29(28-21)22-10-12-23(13-11-22)33(26,31)32/h2-13,15H,14H2,1H3,(H,27,30)(H2,26,31,32)
DMTVAJ0 CS CC(=O)NC1=CC=C(C=C1)CC2=NN(C(=C2)C3=CC=C(C=C3)Br)C4=CC=C(C=C4)S(=O)(=O)N
DMTVAJ0 IK RPELRWHDWCPVAL-UHFFFAOYSA-N
DMTVAJ0 IU N-[4-[[5-(4-bromophenyl)-1-(4-sulfamoylphenyl)pyrazol-3-yl]methyl]phenyl]acetamide
DMXAURE ID DMXAURE
DMXAURE DN Pyrazole derivative 64
DMXAURE HS Patented
DMXAURE SN PMID26394986-Compound-25
DMXAURE CP MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMXAURE DT Small molecular drug
DMXAURE PC 72705347
DMXAURE MW 587.5
DMXAURE FM C29H23BrN4O3S
DMXAURE IC InChI=1S/C29H23BrN4O3S/c30-23-10-8-21(9-11-23)28-19-25(33-34(28)26-14-16-27(17-15-26)38(31,36)37)18-20-6-12-24(13-7-20)32-29(35)22-4-2-1-3-5-22/h1-17,19H,18H2,(H,32,35)(H2,31,36,37)
DMXAURE CS C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)CC3=NN(C(=C3)C4=CC=C(C=C4)Br)C5=CC=C(C=C5)S(=O)(=O)N
DMXAURE IK BOVRIAJBTGLLDC-UHFFFAOYSA-N
DMXAURE IU N-[4-[[5-(4-bromophenyl)-1-(4-sulfamoylphenyl)pyrazol-3-yl]methyl]phenyl]benzamide
DMYTLRJ ID DMYTLRJ
DMYTLRJ DN Pyrazole derivative 65
DMYTLRJ HS Patented
DMYTLRJ SN PMID26394986-Compound-26
DMYTLRJ CP MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMYTLRJ DT Small molecular drug
DMYTLRJ PC 72705348
DMYTLRJ MW 448.4
DMYTLRJ FM C20H22BrN3O2S
DMYTLRJ IC InChI=1S/C20H22BrN3O2S/c1-14(2)3-8-17-13-20(15-4-6-16(21)7-5-15)24(23-17)18-9-11-19(12-10-18)27(22,25)26/h4-7,9-14H,3,8H2,1-2H3,(H2,22,25,26)
DMYTLRJ CS CC(C)CCC1=NN(C(=C1)C2=CC=C(C=C2)Br)C3=CC=C(C=C3)S(=O)(=O)N
DMYTLRJ IK BDSMHQBMCUYDCT-UHFFFAOYSA-N
DMYTLRJ IU 4-[5-(4-bromophenyl)-3-(3-methylbutyl)pyrazol-1-yl]benzenesulfonamide
DMBYWJI ID DMBYWJI
DMBYWJI DN Pyrazole derivative 66
DMBYWJI HS Patented
DMBYWJI SN PMID26394986-Compound-27
DMBYWJI CP MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
DMBYWJI DT Small molecular drug
DMNZUHX ID DMNZUHX
DMNZUHX DN Pyrazole derivative 67
DMNZUHX HS Patented
DMNZUHX SN PMID26609882-Compound-24
DMNZUHX CP ARENA PHARMACEUTICALS, INC. XIONG, Yifeng CHERRIER, Martin, C. CHOI, Jin Sun, Karoline DOSA, Peter, I. SMITH, Brian, M. STRAH-PLEYNET, Sonja ULLMAN, Bret TEEGARDEN, Bradley
DMNZUHX DT Small molecular drug
DMVY0JT ID DMVY0JT
DMVY0JT DN Pyrazole derivative 68
DMVY0JT HS Patented
DMVY0JT SN PMID26609882-Compound-25
DMVY0JT CP ARENA PHARMACEUTICALS, INC. XIONG, Yifeng CHERRIER, Martin, C. CHOI, Jin Sun, Karoline DOSA, Peter, I. SMITH, Brian, M. STRAH-PLEYNET, Sonja ULLMAN, Bret TEEGARDEN, Bradley
DMVY0JT DT Small molecular drug
DMKCJE1 ID DMKCJE1
DMKCJE1 DN Pyrazole derivative 69
DMKCJE1 HS Patented
DMKCJE1 SN PMID26609882-Compound-26
DMKCJE1 CP Arena Pharmaceuticals, Inc
DMKCJE1 DT Small molecular drug
DMYKU0T ID DMYKU0T
DMYKU0T DN Pyrazole derivative 7
DMYKU0T HS Patented
DMYKU0T SN PMID26161824-Compound-17
DMYKU0T CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMYKU0T DT Small molecular drug
DMYKU0T PC 16717804
DMYKU0T MW 586.4
DMYKU0T FM C28H23Cl2F2N5O3
DMYKU0T IC InChI=1S/C28H23Cl2F2N5O3/c1-40-26-24(33-37(23-5-3-2-4-21(23)30)25(26)17-6-8-18(29)9-7-17)27(38)34-36-14-12-35(13-15-36)28(39)20-11-10-19(31)16-22(20)32/h2-11,16H,12-15H2,1H3,(H,34,38)
DMYKU0T CS COC1=C(N(N=C1C(=O)NN2CCN(CC2)C(=O)C3=C(C=C(C=C3)F)F)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
DMYKU0T IK RXXJWLVGDKFAMN-UHFFFAOYSA-N
DMYKU0T IU 1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-[4-(2,4-difluorobenzoyl)piperazin-1-yl]-4-methoxypyrazole-3-carboxamide
DMYKU0T DE Obesity
DMR6VIG ID DMR6VIG
DMR6VIG DN Pyrazole derivative 70
DMR6VIG HS Patented
DMR6VIG SN PMID26609882-Compound-27
DMR6VIG CP Arena Pharmaceuticals, Inc
DMR6VIG DT Small molecular drug
DMSNY3W ID DMSNY3W
DMSNY3W DN Pyrazole derivative 71
DMSNY3W HS Patented
DMSNY3W SN PMID26609882-Compound-28
DMSNY3W CP Arena Pharmaceuticals, Inc
DMSNY3W DT Small molecular drug
DMWFTCN ID DMWFTCN
DMWFTCN DN Pyrazole derivative 72
DMWFTCN HS Patented
DMWFTCN SN PMID26609882-Compound-29
DMWFTCN CP Arena Pharmaceuticals, Inc
DMWFTCN DT Small molecular drug
DMFARIK ID DMFARIK
DMFARIK DN Pyrazole derivative 73
DMFARIK HS Patented
DMFARIK SN PMID26609882-Compound-30
DMFARIK CP Arena Pharmaceuticals, Inc
DMFARIK DT Small molecular drug
DM70QPF ID DM70QPF
DM70QPF DN Pyrazole derivative 74
DM70QPF HS Patented
DM70QPF SN PMID26609882-Compound-31
DM70QPF CP Arena Pharmaceuticals, Inc
DM70QPF DT Small molecular drug
DMAB2EN ID DMAB2EN
DMAB2EN DN Pyrazole derivative 75
DMAB2EN HS Patented
DMAB2EN SN PMID26609882-Compound-32
DMAB2EN CP Arena Pharmaceuticals, Inc
DMAB2EN DT Small molecular drug
DM6Y27J ID DM6Y27J
DM6Y27J DN Pyrazole derivative 76
DM6Y27J HS Patented
DM6Y27J SN PMID25435285-Compound-70
DM6Y27J CP TAISHO PHARMACEUTICAL CO., LTD. MASUDA Seiji MATSUDA Yohei SAKAGAMI Kazunari KONISHI Kazuhide URABE Hiroki SHIMONO Rie OKADA Kumiko
DM6Y27J DT Small molecular drug
DM5E1ZJ ID DM5E1ZJ
DM5E1ZJ DN Pyrazole derivative 77
DM5E1ZJ HS Patented
DM5E1ZJ SN PMID25435285-Compound-76
DM5E1ZJ CP TAISHO PHARMACEUTICAL CO., LTD. MASUDA Seiji MATSUDA Yohei SAKAGAMI Kazunari KONISHI Kazuhide URABE Hiroki SHIMONO Rie OKADA Kumiko
DM5E1ZJ DT Small molecular drug
DM5E1ZJ PC 57520392
DM5E1ZJ MW 458.4
DM5E1ZJ FM C21H17F3N6O3
DM5E1ZJ IC InChI=1S/C21H17F3N6O3/c1-11-7-12(18(25)31)3-5-14(11)19-28-20(33-29-19)15-9-27-30(2)16(15)10-32-17-6-4-13(8-26-17)21(22,23)24/h3-9H,10H2,1-2H3,(H2,25,31)
DM5E1ZJ CS CC1=C(C=CC(=C1)C(=O)N)C2=NOC(=N2)C3=C(N(N=C3)C)COC4=NC=C(C=C4)C(F)(F)F
DM5E1ZJ IK QBSSBYCWTIBHGM-UHFFFAOYSA-N
DM5E1ZJ IU 3-methyl-4-[5-[1-methyl-5-[[5-(trifluoromethyl)pyridin-2-yl]oxymethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzamide
DMMCHOW ID DMMCHOW
DMMCHOW DN Pyrazole derivative 78
DMMCHOW HS Patented
DMMCHOW SN PMID25435285-Compound-77
DMMCHOW CP TAISHO PHARMACEUTICAL CO., LTD. MASUDA Seiji MATSUDA Yohei SAKAGAMI Kazunari KONISHI Kazuhide URABE Hiroki SHIMONO Rie OKADA Kumiko
DMMCHOW DT Small molecular drug
DM9JHYL ID DM9JHYL
DM9JHYL DN Pyrazole derivative 79
DM9JHYL HS Patented
DM9JHYL SN PMID25435285-Compound-78
DM9JHYL CP TAISHO PHARMACEUTICAL CO., LTD. MASUDA Seiji MATSUDA Yohei SAKAGAMI Kazunari KONISHI Kazuhide URABE Hiroki SHIMONO Rie OKADA Kumiko
DM9JHYL DT Small molecular drug
DMMRTAL ID DMMRTAL
DMMRTAL DN Pyrazole derivative 8
DMMRTAL HS Patented
DMMRTAL SN PMID26161824-Compound-18
DMMRTAL CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori IMASHIRO, Ritsuo SATO, Atsush
DMMRTAL DT Small molecular drug
DMMRTAL PC 16049863
DMMRTAL MW 517.299
DMMRTAL FM C22H18Cl2F4N4O2
DMMRTAL IC InChI=1S/C22H18Cl2F4N4O2/c23-14-7-5-13(6-8-14)18-19(34-21(25)26)17(29-32(18)16-4-2-1-3-15(16)24)20(33)30-31-11-9-22(27,28)10-12-31/h1-8,21H,9-12H2,(H,30,33)
DMMRTAL CS C1CN(CCC1(F)F)NC(=O)C2=NN(C(=C2OC(F)F)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl
DMMRTAL IK UTHOXBJQLSAVTJ-UHFFFAOYSA-N
DMMRTAL IU 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(difluoromethoxy)-N-(4,4-difluoropiperidin-1-yl)pyrazole-3-carboxamide
DMMRTAL DE Obesity
DMQ3TGM ID DMQ3TGM
DMQ3TGM DN Pyrazole derivative 80
DMQ3TGM HS Patented
DMQ3TGM SN PMID29053063-Compound-13a
DMQ3TGM CP ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMQ3TGM DT Small molecular drug
DMWT437 ID DMWT437
DMWT437 DN Pyrazole derivative 81
DMWT437 HS Patented
DMWT437 SN PMID29053063-Compound-13b
DMWT437 CP ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMWT437 DT Small molecular drug
DMETCI3 ID DMETCI3
DMETCI3 DN Pyrazole derivative 82
DMETCI3 HS Patented
DMETCI3 SN PMID29053063-Compound-13c
DMETCI3 CP ABIDE THERAPEUTICS, INC. THE SCRIPPS RESEARCH INSTITUTE
DMETCI3 DT Small molecular drug
DMMGLOA ID DMMGLOA
DMMGLOA DN Pyrazole derivative 83
DMMGLOA HS Patented
DMMGLOA SN PMID29053063-Compound-13d
DMMGLOA CP ABIDE THERAPEUTICS, INC
DMMGLOA DT Small molecular drug
DME8Q0F ID DME8Q0F
DME8Q0F DN Pyrazole derivative 84
DME8Q0F HS Patented
DME8Q0F SN PMID29053063-Compound-13e
DME8Q0F CP ABIDE THERAPEUTICS, INC
DME8Q0F DT Small molecular drug
DMNBCKI ID DMNBCKI
DMNBCKI DN Pyrazole derivative 85
DMNBCKI HS Patented
DMNBCKI SN PMID29053063-Compound-13f
DMNBCKI CP ABIDE THERAPEUTICS, INC
DMNBCKI DT Small molecular drug
DMW3PJV ID DMW3PJV
DMW3PJV DN Pyrazole derivative 86
DMW3PJV HS Patented
DMW3PJV SN PMID28051882-Compound-III
DMW3PJV CP ESTEVE LABOR DR [ES]
DMW3PJV DT Small molecular drug
DMGZUAY ID DMGZUAY
DMGZUAY DN Pyrazole derivative 87
DMGZUAY HS Patented
DMGZUAY SN PMID28447479-Compound-9
DMGZUAY DT Small molecular drug
DMGZUAY PC 124165109
DMGZUAY MW 451.5
DMGZUAY FM C22H22FN7O3
DMGZUAY IC InChI=1S/C22H22FN7O3/c1-14-12-29(13-21(32)28(2)7-3-6-24)22(33)19-9-18(27-30(14)19)16-5-4-15(11-25)8-17(16)26-20(31)10-23/h4-5,8-9,14H,3,7,10,12-13H2,1-2H3,(H,26,31)/t14-/m0/s1
DMGZUAY CS C[C@H]1CN(C(=O)C2=CC(=NN12)C3=C(C=C(C=C3)C#N)NC(=O)CF)CC(=O)N(C)CCC#N
DMGZUAY IK TXOZRELGSIJTEA-AWEZNQCLSA-N
DMGZUAY IU N-(2-cyanoethyl)-2-[(7S)-2-[4-cyano-2-[(2-fluoroacetyl)amino]phenyl]-7-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazin-5-yl]-N-methylacetamide
DMVX7YT ID DMVX7YT
DMVX7YT DN Pyrazole N-1 aryl and heteroaryl derivative 1
DMVX7YT HS Patented
DMVX7YT SN PMID27310003-Compound-39
DMVX7YT CP MERCK SHARP & DOHME [US]
DMVX7YT DT Small molecular drug
DMVQXZJ ID DMVQXZJ
DMVQXZJ DN Pyrazole-3-carboxamide derivative 1
DMVQXZJ HS Patented
DMVQXZJ SN PMID26609882-Compound-63
DMVQXZJ DT Small molecular drug
DMGS2ET ID DMGS2ET
DMGS2ET DN Pyrazoline derivative 1
DMGS2ET HS Patented
DMGS2ET SN PMID26161824-Compound-103
DMGS2ET CP JENRIN DISCOVERY MCELROY, John CHORVAT, Rober
DMGS2ET DT Small molecular drug
DMGS2ET DE Obesity
DMCZORA ID DMCZORA
DMCZORA DN Pyrazoline derivative 10
DMCZORA HS Patented
DMCZORA SN PMID26161824-Compound-98
DMCZORA DT Small molecular drug
DMCZORA DE Obesity
DMAB3YG ID DMAB3YG
DMAB3YG DN Pyrazoline derivative 11
DMAB3YG HS Patented
DMAB3YG SN PMID26161824-Compound-99
DMAB3YG DT Small molecular drug
DMAB3YG DE Obesity
DMOA8E4 ID DMOA8E4
DMOA8E4 DN Pyrazoline derivative 2
DMOA8E4 HS Patented
DMOA8E4 SN PMID26161824-Compound-104
DMOA8E4 CP JENRIN DISCOVERY MCELROY, John CHORVAT, Rober
DMOA8E4 DT Small molecular drug
DMOA8E4 DE Obesity
DMGH0LQ ID DMGH0LQ
DMGH0LQ DN Pyrazoline derivative 3
DMGH0LQ HS Patented
DMGH0LQ SN PMID26161824-Compound-105
DMGH0LQ CP JENRIN DISCOVERY MCELROY, John CHORVAT, Robert
DMGH0LQ DT Small molecular drug
DMGH0LQ DE Obesity
DMRT7I8 ID DMRT7I8
DMRT7I8 DN Pyrazoline derivative 4
DMRT7I8 HS Patented
DMRT7I8 SN PMID26161824-Compound-106
DMRT7I8 CP JENRIN DISCOVERY MCELROY, John CHORVAT, Robert
DMRT7I8 DT Small molecular drug
DMRT7I8 DE Obesity
DMEGS9U ID DMEGS9U
DMEGS9U DN Pyrazoline derivative 5
DMEGS9U HS Patented
DMEGS9U SN PMID26161824-Compound-107
DMEGS9U CP JENRIN DISCOVERY MCELROY, John CHORVAT, Robert
DMEGS9U DT Small molecular drug
DMEGS9U DE Obesity
DMOK7CW ID DMOK7CW
DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1
DMOK7CW HS Patented
DMOK7CW SN PMID26161698-Compound-12
DMOK7CW CP CENTRE NAT RECH SCIENT [FR
DMOK7CW DT Small molecular drug
DMH1W89 ID DMH1W89
DMH1W89 DN Pyrazolo[1,5-a]pyridine derivative 1
DMH1W89 HS Patented
DMH1W89 SN PMID28270021-Compound-WO2013088256Example59
DMH1W89 CP DR. REDDY'S LABORATORIES LTD
DMH1W89 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMLS827 ID DMLS827
DMLS827 DN Pyrazolo[1,5-a]pyridine derivative 2
DMLS827 HS Patented
DMLS827 SN PMID28270021-Compound-WO2013088257Example240
DMLS827 CP DR. REDDY'S LABORATORIES LTD
DMLS827 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM0FPMV ID DM0FPMV
DM0FPMV DN Pyrazolo[1,5-a]pyrimidine derivative 1
DM0FPMV HS Patented
DM0FPMV SN PMID26161824-Compound-131
DM0FPMV CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DM0FPMV DT Small molecular drug
DM0FPMV PC 16049464
DM0FPMV MW 465.4
DM0FPMV FM C25H22Cl2N4O
DM0FPMV IC InChI=1S/C25H22Cl2N4O/c26-17-12-10-16(11-13-17)23-20(19-8-4-5-9-22(19)27)14-28-24-21(15-29-31(23)24)25(32)30-18-6-2-1-3-7-18/h4-5,8-15,18H,1-3,6-7H2,(H,30,32)
DM0FPMV CS C1CCC(CC1)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM0FPMV IK ZZBARLOXOSWJIH-UHFFFAOYSA-N
DM0FPMV IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-cyclohexylpyrazolo[1,5-a]pyrimidine-3-carboxamide
DM0FPMV DE Obesity
DM07GEK ID DM07GEK
DM07GEK DN Pyrazolo[1,5-a]pyrimidine derivative 10
DM07GEK HS Patented
DM07GEK SN PMID26161824-Compound-140
DM07GEK CP MITSUBISHI TANABE PHARMA CORPORATION TANIMOTO, Koichi OI, Mariko TSUBOI, Yasunori MORITANI, Yasunor
DM07GEK DT Small molecular drug
DM07GEK DE Obesity
DM0O4WR ID DM0O4WR
DM0O4WR DN Pyrazolo[1,5-a]pyrimidine derivative 11
DM0O4WR HS Patented
DM0O4WR SN PMID26161824-Compound-141
DM0O4WR CP MITSUBISHI TANABE PHARMA CORPORATION TANIMOTO, Koichi OI, Mariko TSUBOI, Yasunori MORITANI, Yasunor
DM0O4WR DT Small molecular drug
DM0O4WR PC 24772341
DM0O4WR MW 575.5
DM0O4WR FM C26H24Cl2N4O5S
DM0O4WR IC InChI=1S/C26H24Cl2N4O5S/c1-26(10-13-38(35,36)15-26)30-24(34)21-23-29-14-19(18-4-2-3-5-20(18)28)22(16-6-8-17(27)9-7-16)32(23)31-25(21)37-12-11-33/h2-9,14,33H,10-13,15H2,1H3,(H,30,34)
DM0O4WR CS CC1(CCS(=O)(=O)C1)NC(=O)C2=C3N=CC(=C(N3N=C2OCCO)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM0O4WR IK UNFBOPQOKSVPNI-UHFFFAOYSA-N
DM0O4WR IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-2-(2-hydroxyethoxy)-N-(3-methyl-1,1-dioxothiolan-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
DM0O4WR DE Obesity
DMMLDUI ID DMMLDUI
DMMLDUI DN Pyrazolo[1,5-a]pyrimidine derivative 12
DMMLDUI HS Patented
DMMLDUI SN PMID26161824-Compound-177
DMMLDUI CP AMOREPACIFIC CORPORATION ( ) SHIN, Song Seok HONG, Yong Deog BYOUN, Kyoung Hee PARK, Mi Young CHOI, Jin Ky
DMMLDUI DT Small molecular drug
DMMLDUI PC 89620957
DMMLDUI MW 466.9
DMMLDUI FM C25H24ClFN4O2
DMMLDUI IC InChI=1S/C25H24ClFN4O2/c1-33-15-21-24(16-7-9-18(26)10-8-16)25-28-23(30-11-3-6-20(30)14-32)13-22(31(25)29-21)17-4-2-5-19(27)12-17/h2,4-5,7-10,12-13,20,32H,3,6,11,14-15H2,1H3/t20-/m0/s1
DMMLDUI CS COCC1=NN2C(=CC(=NC2=C1C3=CC=C(C=C3)Cl)N4CCC[C@H]4CO)C5=CC(=CC=C5)F
DMMLDUI IK USQDDAWNOFWURT-FQEVSTJZSA-N
DMMLDUI IU [(2S)-1-[3-(4-chlorophenyl)-7-(3-fluorophenyl)-2-(methoxymethyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrrolidin-2-yl]methanol
DMMLDUI DE Obesity
DMR5O7T ID DMR5O7T
DMR5O7T DN Pyrazolo[1,5-a]pyrimidine derivative 13
DMR5O7T HS Patented
DMR5O7T SN PMID26161824-Compound-178
DMR5O7T CP AMOREPACIFIC CORPORATION ( ) SHIN, Song Seok HONG, Yong Deog BYOUN, Kyoung Hee PARK, Mi Young CHOI, Jin Ky
DMR5O7T DT Small molecular drug
DMR5O7T PC 89620917
DMR5O7T MW 454.9
DMR5O7T FM C24H24ClFN4O2
DMR5O7T IC InChI=1S/C24H24ClFN4O2/c1-3-32-15-20-23(16-7-9-18(25)10-8-16)24-27-22(29(2)11-12-31)14-21(30(24)28-20)17-5-4-6-19(26)13-17/h4-10,13-14,31H,3,11-12,15H2,1-2H3
DMR5O7T CS CCOCC1=NN2C(=CC(=NC2=C1C3=CC=C(C=C3)Cl)N(C)CCO)C4=CC(=CC=C4)F
DMR5O7T IK HYBHLUDFJVRRSM-UHFFFAOYSA-N
DMR5O7T IU 2-[[3-(4-chlorophenyl)-2-(ethoxymethyl)-7-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-5-yl]-methylamino]ethanol
DMR5O7T DE Obesity
DMB6EFV ID DMB6EFV
DMB6EFV DN Pyrazolo[1,5-a]pyrimidine derivative 14
DMB6EFV HS Patented
DMB6EFV SN PMID28270010-Compound-Figure10a-1
DMB6EFV CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMB6EFV DT Small molecular drug
DMB6EFV PC 67501573
DMB6EFV MW 381.4
DMB6EFV FM C20H20FN5O2
DMB6EFV IC InChI=1S/C20H20FN5O2/c21-13-3-1-2-12(8-13)17-9-15(27)11-25(17)18-6-7-26-19(24-18)16(10-22-26)20(28)23-14-4-5-14/h1-3,6-8,10,14-15,17,27H,4-5,9,11H2,(H,23,28)/t15-,17-/m1/s1
DMB6EFV CS C1CC1NC(=O)C2=C3N=C(C=CN3N=C2)N4C[C@@H](C[C@@H]4C5=CC(=CC=C5)F)O
DMB6EFV IK DHEFBJXZYSKWIF-NVXWUHKLSA-N
DMB6EFV IU N-cyclopropyl-5-[(2R,4R)-2-(3-fluorophenyl)-4-hydroxypyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMAZI3D ID DMAZI3D
DMAZI3D DN Pyrazolo[1,5-a]pyrimidine derivative 15
DMAZI3D HS Patented
DMAZI3D SN PMID28270010-Compound-Figure10a-2
DMAZI3D CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMAZI3D DT Small molecular drug
DMTYN2D ID DMTYN2D
DMTYN2D DN Pyrazolo[1,5-a]pyrimidine derivative 16
DMTYN2D HS Patented
DMTYN2D SN PMID28270010-Compound-Figure10a-3
DMTYN2D CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMTYN2D DT Small molecular drug
DMTYN2D PC 67500657
DMTYN2D MW 494.6
DMTYN2D FM C26H31FN6O3
DMTYN2D IC InChI=1S/C26H31FN6O3/c27-18-3-6-23(36-15-12-31-10-13-35-14-11-31)20(16-18)22-2-1-8-32(22)24-7-9-33-25(30-24)21(17-28-33)26(34)29-19-4-5-19/h3,6-7,9,16-17,19,22H,1-2,4-5,8,10-15H2,(H,29,34)/t22-/m1/s1
DMTYN2D CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)C(=O)NC4CC4)C5=C(C=CC(=C5)F)OCCN6CCOCC6
DMTYN2D IK DXRCURBJOZPWHE-JOCHJYFZSA-N
DMTYN2D IU N-cyclopropyl-5-[(2R)-2-[5-fluoro-2-(2-morpholin-4-ylethoxy)phenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMNIER3 ID DMNIER3
DMNIER3 DN Pyrazolo[1,5-a]pyrimidine derivative 17
DMNIER3 HS Patented
DMNIER3 SN PMID28270010-Compound-Figure10a-4
DMNIER3 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven S. CONDROSKI, Kevin Ronald HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy SEO, Jeongbeob
DMNIER3 DT Small molecular drug
DMNIER3 PC 66853176
DMNIER3 MW 455.5
DMNIER3 FM C23H26FN5O4
DMNIER3 IC InChI=1S/C23H26FN5O4/c24-15-8-14(9-18(10-15)33-13-17(31)12-30)20-2-1-6-28(20)21-5-7-29-22(27-21)19(11-25-29)23(32)26-16-3-4-16/h5,7-11,16-17,20,30-31H,1-4,6,12-13H2,(H,26,32)/t17?,20-/m1/s1
DMNIER3 CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)C(=O)NC4CC4)C5=CC(=CC(=C5)F)OCC(CO)O
DMNIER3 IK YDZSAJWQPHVDHL-UUSAFJCLSA-N
DMNIER3 IU N-cyclopropyl-5-[(2R)-2-[3-(2,3-dihydroxypropoxy)-5-fluorophenyl]pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
DMVEP6Y ID DMVEP6Y
DMVEP6Y DN Pyrazolo[1,5-a]pyrimidine derivative 18
DMVEP6Y HS Patented
DMVEP6Y SN PMID28270010-Compound-Figure11-1
DMVEP6Y CP ARRAY BIOPHARMA INC. ANDREWS, Steven, Wade CONDROSKI, Kevin, Ronald HAAS, Julia JIANG, Yutong KOLAKOWSKI, Gabrielle, R. SEO, Jeongbeob YANG, Hong-Woon ZHAO, Qian
DMVEP6Y DT Small molecular drug
DMVEP6Y PC 70169989
DMVEP6Y MW 398.4
DMVEP6Y FM C19H19FN6O3
DMVEP6Y IC InChI=1S/C19H19FN6O3/c20-11-6-13-15-2-1-4-25(15)16-3-5-26-17(23-16)14(8-22-26)18(28)21-7-12(27)10-24(9-11)19(13)29/h3,5-6,8-9,12,15,27H,1-2,4,7,10H2,(H,21,28)/t12-,15+/m0/s1
DMVEP6Y CS C1C[C@@H]2C3=CC(=CN(C3=O)C[C@H](CNC(=O)C4=C5N=C(N2C1)C=CN5N=C4)O)F
DMVEP6Y IK UHWGZELMUUQSBI-SWLSCSKDSA-N
DMVEP6Y IU (6R,13S)-9-fluoro-13-hydroxy-2,11,15,19,20,23-hexazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione
DMFV36A ID DMFV36A
DMFV36A DN Pyrazolo[1,5-a]pyrimidine derivative 19
DMFV36A HS Patented
DMFV36A SN PMID28270010-Compound-Figure11-2
DMFV36A CP ARRAY BIOPHARMA INC. ANDREWS, Steven, Wade CONDROSKI, Kevin, Ronald HAAS, Julia JIANG, Yutong KOLAKOWSKI, Gabrielle, R. SEO, Jeongbeob YANG, Hong-Woon ZHAO, Qian
DMFV36A DT Small molecular drug
DMO3MJ7 ID DMO3MJ7
DMO3MJ7 DN Pyrazolo[1,5-a]pyrimidine derivative 2
DMO3MJ7 HS Patented
DMO3MJ7 SN PMID26161824-Compound-132
DMO3MJ7 CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DMO3MJ7 DT Small molecular drug
DMO3MJ7 DE Obesity
DMJLU8R ID DMJLU8R
DMJLU8R DN Pyrazolo[1,5-a]pyrimidine derivative 20
DMJLU8R HS Patented
DMJLU8R SN PMID28270010-Compound-Figure11-3
DMJLU8R CP ARRAY BIOPHARMA INC. ANDREWS, Steven, Wade CONDROSKI, Kevin, Ronald HAAS, Julia JIANG, Yutong KOLAKOWSKI, Gabrielle, R. SEO, Jeongbeob YANG, Hong-Woon ZHAO, Qian
DMJLU8R DT Small molecular drug
DMWNZTI ID DMWNZTI
DMWNZTI DN Pyrazolo[1,5-a]pyrimidine derivative 21
DMWNZTI HS Patented
DMWNZTI SN PMID28270010-Compound-Figure19-1
DMWNZTI CP CMG PHARMACEUTICAL CO., LTD. HANDOK INC
DMWNZTI DT Small molecular drug
DMWNZTI PC 121395260
DMWNZTI MW 440.5
DMWNZTI FM C22H22F2N6S
DMWNZTI IC InChI=1S/C22H22F2N6S/c1-22(2,3)21-28-27-20(31-21)15-12-25-30-10-8-18(26-19(15)30)29-9-4-5-17(29)14-11-13(23)6-7-16(14)24/h6-8,10-12,17H,4-5,9H2,1-3H3
DMWNZTI CS CC(C)(C)C1=NN=C(S1)C2=C3N=C(C=CN3N=C2)N4CCCC4C5=C(C=CC(=C5)F)F
DMWNZTI IK ZSOVHNMIBOQEED-UHFFFAOYSA-N
DMWNZTI IU 2-tert-butyl-5-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-1,3,4-thiadiazole
DMG5CXB ID DMG5CXB
DMG5CXB DN Pyrazolo[1,5-a]pyrimidine derivative 22
DMG5CXB HS Patented
DMG5CXB SN PMID28270010-Compound-Figure19-2
DMG5CXB CP CMG PHARMACEUTICAL CO., LTD. HANDOK INC
DMG5CXB DT Small molecular drug
DMQVLP8 ID DMQVLP8
DMQVLP8 DN Pyrazolo[1,5-a]pyrimidine derivative 23
DMQVLP8 HS Patented
DMQVLP8 SN PMID28270010-Compound-Figure19-3
DMQVLP8 CP CMG PHARMACEUTICAL CO., LTD. HANDOK INC
DMQVLP8 DT Small molecular drug
DMQVLP8 PC 121395204
DMQVLP8 MW 439.5
DMQVLP8 FM C23H23F2N5O2
DMQVLP8 IC InChI=1S/C23H23F2N5O2/c24-17-4-5-19(25)18(14-17)20-2-1-8-29(20)21-7-9-30-23(27-21)16(15-26-30)3-6-22(31)28-10-12-32-13-11-28/h3-7,9,14-15,20H,1-2,8,10-13H2/b6-3+/t20-/m1/s1
DMQVLP8 CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)/C=C/C(=O)N4CCOCC4)C5=C(C=CC(=C5)F)F
DMQVLP8 IK FFDHOZJDUKYFPJ-SQZHUTIHSA-N
DMQVLP8 IU (E)-3-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-1-morpholin-4-ylprop-2-en-1-one
DMT4ZP9 ID DMT4ZP9
DMT4ZP9 DN Pyrazolo[1,5-a]pyrimidine derivative 24
DMT4ZP9 HS Patented
DMT4ZP9 SN PMID28270010-Compound-Figure9-1
DMT4ZP9 CP ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DMT4ZP9 DT Small molecular drug
DMKE7YO ID DMKE7YO
DMKE7YO DN Pyrazolo[1,5-a]pyrimidine derivative 25
DMKE7YO HS Patented
DMKE7YO SN PMID28270010-Compound-Figure9-2
DMKE7YO CP ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DMKE7YO DT Small molecular drug
DMKE7YO PC 58386283
DMKE7YO MW 408.4
DMKE7YO FM C21H18F2N6O
DMKE7YO IC InChI=1S/C21H18F2N6O/c22-13-3-4-15(23)14(10-13)17-2-1-8-28(17)18-5-9-29-19(27-18)16(11-25-29)26-20(30)21(12-24)6-7-21/h3-5,9-11,17H,1-2,6-8H2,(H,26,30)/t17-/m1/s1
DMKE7YO CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)C4(CC4)C#N)C5=C(C=CC(=C5)F)F
DMKE7YO IK XFKSYGFIGZCVDN-QGZVFWFLSA-N
DMKE7YO IU 1-cyano-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]cyclopropane-1-carboxamide
DMGZ59Q ID DMGZ59Q
DMGZ59Q DN Pyrazolo[1,5-a]pyrimidine derivative 26
DMGZ59Q HS Patented
DMGZ59Q SN PMID28270010-Compound-Figure9-3
DMGZ59Q CP ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DMGZ59Q DT Small molecular drug
DMGZ59Q PC 58386265
DMGZ59Q MW 454.5
DMGZ59Q FM C23H27FN6O3
DMGZ59Q IC InChI=1S/C23H27FN6O3/c1-33-20-7-6-15(24)12-17(20)19-5-3-10-29(19)21-8-11-30-22(27-21)18(13-25-30)26-23(32)28-9-2-4-16(31)14-28/h6-8,11-13,16,19,31H,2-5,9-10,14H2,1H3,(H,26,32)/t16-,19+/m0/s1
DMGZ59Q CS COC1=C(C=C(C=C1)F)[C@H]2CCCN2C3=NC4=C(C=NN4C=C3)NC(=O)N5CCC[C@@H](C5)O
DMGZ59Q IK RGIQATAASXNYCK-QFBILLFUSA-N
DMGZ59Q IU (3S)-N-[5-[(2R)-2-(5-fluoro-2-methoxyphenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypiperidine-1-carboxamide
DM9OXAB ID DM9OXAB
DM9OXAB DN Pyrazolo[1,5-a]pyrimidine derivative 27
DM9OXAB HS Patented
DM9OXAB SN PMID28270010-Compound-Figure9-4
DM9OXAB CP ARRAY BIOPHARMA INC. HAAS, Julia ANDREWS, Steven, W. JIANG, Yutong ZHANG, Gan
DM9OXAB DT Small molecular drug
DM9OXAB PC 58386288
DM9OXAB MW 428.4
DM9OXAB FM C21H22F2N6O2
DM9OXAB IC InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18-/m1/s1
DM9OXAB CS C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@H](C4)O)C5=C(C=CC(=C5)F)F
DM9OXAB IK NYNZQNWKBKUAII-RDTXWAMCSA-N
DM9OXAB IU (3R)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
DMG1RNL ID DMG1RNL
DMG1RNL DN Pyrazolo[1,5-a]pyrimidine derivative 28
DMG1RNL HS Patented
DMG1RNL SN PMID25470667-Compound-Figure5-17
DMG1RNL CP GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMG1RNL DT Small molecular drug
DMCT6QW ID DMCT6QW
DMCT6QW DN Pyrazolo[1,5-a]pyrimidine derivative 29
DMCT6QW HS Patented
DMCT6QW SN PMID25470667-Compound-Figure5-18
DMCT6QW CP GLAXOSMITHKLINE LLGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED QIN, Donghui CHEUNG, Mui JOSHI, Hemant TANGIRALA, Raghuram BETHI, Sridhar, Reddy
DMCT6QW DT Small molecular drug
DMCT6QW PC 74221584
DMCT6QW MW 291.35
DMCT6QW FM C17H17N5
DMCT6QW IC InChI=1S/C17H17N5/c1-2-8-21-9-6-13-10-12(3-4-15(13)21)14-11-19-16-5-7-20-22(16)17(14)18/h3-7,9-11H,2,8,18H2,1H3
DMCT6QW CS CCCN1C=CC2=C1C=CC(=C2)C3=C(N4C(=CC=N4)N=C3)N
DMCT6QW IK WYJQPMFWZLKCBR-UHFFFAOYSA-N
DMCT6QW IU 6-(1-propylindol-5-yl)pyrazolo[1,5-a]pyrimidin-7-amine
DMHTV47 ID DMHTV47
DMHTV47 DN Pyrazolo[1,5-a]pyrimidine derivative 3
DMHTV47 HS Patented
DMHTV47 SN PMID26161824-Compound-133
DMHTV47 CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DMHTV47 DT Small molecular drug
DMHTV47 PC 16722441
DMHTV47 MW 522.799
DMHTV47 FM C26H18Cl3N5O
DMHTV47 IC InChI=1S/C26H18Cl3N5O/c1-33(19-6-4-5-18(28)13-19)32-26(35)22-15-31-34-24(16-9-11-17(27)12-10-16)21(14-30-25(22)34)20-7-2-3-8-23(20)29/h2-15H,1H3,(H,32,35)
DMHTV47 CS CN(C1=CC(=CC=C1)Cl)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMHTV47 IK VZJOGKVKWHCJNG-UHFFFAOYSA-N
DMHTV47 IU 6-(2-chlorophenyl)-N'-(3-chlorophenyl)-7-(4-chlorophenyl)-N'-methylpyrazolo[1,5-a]pyrimidine-3-carbohydrazide
DMHTV47 DE Obesity
DMCAVF0 ID DMCAVF0
DMCAVF0 DN Pyrazolo[1,5-a]pyrimidine derivative 4
DMCAVF0 HS Patented
DMCAVF0 SN PMID26161824-Compound-134
DMCAVF0 CP Mitsubishi Tanabe Pharma Corporation MORITANI, Yasunori SHIRAI, Kimihiro OI, Marik
DMCAVF0 DT Small molecular drug
DMCAVF0 PC 68920883
DMCAVF0 MW 557.3
DMCAVF0 FM C26H17Cl2F3N6O
DMCAVF0 IC InChI=1S/C26H17Cl2F3N6O/c1-36(20-8-4-5-13-32-20)35-25(38)21-23(26(29,30)31)34-37-22(15-9-11-16(27)12-10-15)18(14-33-24(21)37)17-6-2-3-7-19(17)28/h2-14H,1H3,(H,35,38)
DMCAVF0 CS CN(C1=CC=CC=N1)NC(=O)C2=C3N=CC(=C(N3N=C2C(F)(F)F)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMCAVF0 IK BOANGAFVCNVTRF-UHFFFAOYSA-N
DMCAVF0 IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-N'-methyl-N'-pyridin-2-yl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carbohydrazide
DMCAVF0 DE Obesity
DM3UBG2 ID DM3UBG2
DM3UBG2 DN Pyrazolo[1,5-a]pyrimidine derivative 5
DM3UBG2 HS Patented
DM3UBG2 SN PMID26161824-Compound-135
DM3UBG2 DT Small molecular drug
DM3UBG2 PC 24772732
DM3UBG2 MW 479.4
DM3UBG2 FM C26H24Cl2N4O
DM3UBG2 IC InChI=1S/C26H24Cl2N4O/c1-26(13-5-2-6-14-26)31-25(33)21-16-30-32-23(17-9-11-18(27)12-10-17)20(15-29-24(21)32)19-7-3-4-8-22(19)28/h3-4,7-12,15-16H,2,5-6,13-14H2,1H3,(H,31,33)
DM3UBG2 CS CC1(CCCCC1)NC(=O)C2=C3N=CC(=C(N3N=C2)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM3UBG2 IK UVMYGLSWIQQBTO-UHFFFAOYSA-N
DM3UBG2 IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-(1-methylcyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
DM3UBG2 DE Obesity
DM5E1KS ID DM5E1KS
DM5E1KS DN Pyrazolo[1,5-a]pyrimidine derivative 6
DM5E1KS HS Patented
DM5E1KS SN PMID26161824-Compound-136
DM5E1KS DT Small molecular drug
DM5E1KS PC 67272017
DM5E1KS MW 594.5
DM5E1KS FM C24H21Cl2N5O5S2
DM5E1KS IC InChI=1S/C24H21Cl2N5O5S2/c1-27-38(35,36)24-20(23(32)29-16-10-11-37(33,34)13-16)22-28-12-18(17-4-2-3-5-19(17)26)21(31(22)30-24)14-6-8-15(25)9-7-14/h2-9,12,16,27H,10-11,13H2,1H3,(H,29,32)
DM5E1KS CS CNS(=O)(=O)C1=NN2C(=C(C=NC2=C1C(=O)NC3CCS(=O)(=O)C3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl
DM5E1KS IK OGXPEWYKDODYIH-UHFFFAOYSA-N
DM5E1KS IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-(1,1-dioxothiolan-3-yl)-2-(methylsulfamoyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
DM5E1KS DE Obesity
DMFUSPR ID DMFUSPR
DMFUSPR DN Pyrazolo[1,5-a]pyrimidine derivative 7
DMFUSPR HS Patented
DMFUSPR SN PMID26161824-Compound-137
DMFUSPR DT Small molecular drug
DMFUSPR PC 67272029
DMFUSPR MW 587.5
DMFUSPR FM C26H24Cl2N6O4S
DMFUSPR IC InChI=1S/C26H24Cl2N6O4S/c27-16-11-9-15(10-12-16)23-19(18-7-3-4-8-20(18)28)13-30-24-22(25(36)32-17-5-1-2-6-17)26(33-34(23)24)39(37,38)31-14-21(29)35/h3-4,7-13,17,31H,1-2,5-6,14H2,(H2,29,35)(H,32,36)
DMFUSPR CS C1CCC(C1)NC(=O)C2=C3N=CC(=C(N3N=C2S(=O)(=O)NCC(=O)N)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMFUSPR IK XUKGKEPVXJSMGH-UHFFFAOYSA-N
DMFUSPR IU 2-[(2-amino-2-oxoethyl)sulfamoyl]-6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-cyclopentylpyrazolo[1,5-a]pyrimidine-3-carboxamide
DMFUSPR DE Obesity
DMTQNYZ ID DMTQNYZ
DMTQNYZ DN Pyrazolo[1,5-a]pyrimidine derivative 8
DMTQNYZ HS Patented
DMTQNYZ SN PMID26161824-Compound-138
DMTQNYZ DT Small molecular drug
DMTQNYZ PC 67149150
DMTQNYZ MW 531.4
DMTQNYZ FM C23H20Cl2N6O3S
DMTQNYZ IC InChI=1S/C23H20Cl2N6O3S/c24-15-9-7-14(8-10-15)20-17(16-5-1-2-6-18(16)25)13-27-21-19(22(32)28-30-11-3-4-12-30)23(29-31(20)21)35(26,33)34/h1-2,5-10,13H,3-4,11-12H2,(H,28,32)(H2,26,33,34)
DMTQNYZ CS C1CCN(C1)NC(=O)C2=C3N=CC(=C(N3N=C2S(=O)(=O)N)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMTQNYZ IK WHAZINAXCQYHKF-UHFFFAOYSA-N
DMTQNYZ IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-N-pyrrolidin-1-yl-2-sulfamoylpyrazolo[1,5-a]pyrimidine-3-carboxamide
DMTQNYZ DE Obesity
DMXAW2S ID DMXAW2S
DMXAW2S DN Pyrazolo[1,5-a]pyrimidine derivative 9
DMXAW2S HS Patented
DMXAW2S SN PMID26161824-Compound-139
DMXAW2S DT Small molecular drug
DMXAW2S PC 67273458
DMXAW2S MW 568.4
DMXAW2S FM C25H19Cl2N7O3S
DMXAW2S IC InChI=1S/C25H19Cl2N7O3S/c1-33(20-8-4-5-13-29-20)31-24(35)21-23-30-14-18(17-6-2-3-7-19(17)27)22(15-9-11-16(26)12-10-15)34(23)32-25(21)38(28,36)37/h2-14H,1H3,(H,31,35)(H2,28,36,37)
DMXAW2S CS CN(C1=CC=CC=N1)NC(=O)C2=C3N=CC(=C(N3N=C2S(=O)(=O)N)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DMXAW2S IK SIHKCQZRSPKPIN-UHFFFAOYSA-N
DMXAW2S IU 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[methyl(pyridin-2-yl)amino]carbamoyl]pyrazolo[1,5-a]pyrimidine-2-sulfonamide
DMXAW2S DE Obesity
DMQHCDZ ID DMQHCDZ
DMQHCDZ DN Pyrazolo[3,4-c]pyridine derivative 1
DMQHCDZ HS Patented
DMQHCDZ SN PMID28447479-Compound-8
DMQHCDZ CP BIOGEN MA INC
DMQHCDZ DT Small molecular drug
DMT57C4 ID DMT57C4
DMT57C4 DN Pyrazolo[3,4-d]pyrimidine derivative 1
DMT57C4 HS Patented
DMT57C4 SN PMID27321640-Compound-70
DMT57C4 CP PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMT57C4 DT Small molecular drug
DMO054V ID DMO054V
DMO054V DN Pyrazolo[3,4-d]pyrimidine derivative 2
DMO054V HS Patented
DMO054V SN PMID27321640-Compound-71
DMO054V CP PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMO054V DT Small molecular drug
DMRKVP9 ID DMRKVP9
DMRKVP9 DN Pyrazolo[3,4-d]pyrimidine derivative 3
DMRKVP9 HS Patented
DMRKVP9 SN PMID27321640-Compound-72
DMRKVP9 CP PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMRKVP9 DT Small molecular drug
DMGFAS6 ID DMGFAS6
DMGFAS6 DN Pyrazolo[3,4-d]pyrimidine derivative 4
DMGFAS6 HS Patented
DMGFAS6 SN PMID27321640-Compound-73
DMGFAS6 CP PFIZER INC. HELAL, Christopher J. CHAPPIE, Thomas Allen HUMPHREY, John M
DMGFAS6 DT Small molecular drug
DMIH0F4 ID DMIH0F4
DMIH0F4 DN Pyrazolo[3,4-d]pyrimidine derivative 5
DMIH0F4 HS Patented
DMIH0F4 SN PMID27646564-Compound-9
DMIH0F4 CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DMIH0F4 DT Small molecular drug
DMCTWVY ID DMCTWVY
DMCTWVY DN Pyrazolo[3,4-d]pyrimidine derivative 6
DMCTWVY HS Patented
DMCTWVY SN PMID27646564-Compound-9-1
DMCTWVY CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DMCTWVY DT Small molecular drug
DM4GF58 ID DM4GF58
DM4GF58 DN Pyrazolo[3,4-d]pyrimidine derivative 7
DM4GF58 HS Patented
DM4GF58 SN PMID27646564-Compound-9-2
DM4GF58 CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DM4GF58 DT Small molecular drug
DM89GKE ID DM89GKE
DM89GKE DN Pyrazolo[3,4-d]pyrimidine derivative 8
DM89GKE HS Patented
DM89GKE SN PMID27646564-Compound-9-3
DM89GKE CP THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MOUNT SINAI SCHOOL OF MEDICINE DAR, Arvin, C. DAS, Tirtha, K. SOS, Martin BIVONA, Trever, G. SHOKAT, Kevan, M. CAGAN, Ross, LUniversity of California and Icahn School of Medicine at Mount Sinai
DM89GKE DT Small molecular drug
DMHRUIZ ID DMHRUIZ
DMHRUIZ DN Pyrazolo[4,3-c]pyridine derivative 1
DMHRUIZ HS Patented
DMHRUIZ SN PMID28270021-Compound-WO2014053965Example3
DMHRUIZ CP PFIZER LIMITED
DMHRUIZ DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMCDFLQ ID DMCDFLQ
DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2
DMCDFLQ HS Patented
DMCDFLQ SN PMID27774824-Compound-Figure7compound1
DMCDFLQ CP CELLZOME LIMITED RAMSDEN, Nigel DAGOSTIN, Claudio
DMTM82B ID DMTM82B
DMTM82B DN Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1
DMTM82B HS Patented
DMTM82B SN PMID28270021-Compound-WO2010106028Milciclib (PHA-848125)
DMTM82B CP NERVIANO MEDICAL
DMTM82B DE Malignant thymoma; Pruritus; Chronic pain; Neuropathic pain; Thymic cancer
DMRN2QI ID DMRN2QI
DMRN2QI DN Pyrazolodiazepine derivative 1
DMRN2QI HS Patented
DMRN2QI SN PMID26560530-Compound-28
DMRN2QI CP NATIONAL CANCER CENTER ANYGEN CO., LTD. KIM, Young-Chul LEE, Ju-Yeon KIM, Soo Youl LEE, Byung Il
DMRN2QI DT Small molecular drug
DMRN2QI PC 46236234
DMRN2QI MW 351.6
DMRN2QI FM C18H33N5S
DMRN2QI IC InChI=1S/C18H33N5S/c1-13(2)9-22-11-15(7-5-6-8-19)20-18(24)17-16(22)12-23(21-17)10-14(3)4/h12-15H,5-11,19H2,1-4H3,(H,20,24)/t15-/m0/s1
DMRN2QI CS CC(C)CN1C[C@@H](NC(=S)C2=NN(C=C21)CC(C)C)CCCCN
DMRN2QI IK SRDGVWFRHBVJPL-HNNXBMFYSA-N
DMRN2QI IU (6S)-6-(4-aminobutyl)-2,4-bis(2-methylpropyl)-6,7-dihydro-5H-pyrazolo[4,3-e][1,4]diazepine-8-thione
DMKYX7J ID DMKYX7J
DMKYX7J DN Pyrazolodihydropyridine derivative 1
DMKYX7J HS Patented
DMKYX7J SN PMID27828716-Compound-13
DMKYX7J CP THE BROAD INSTITUTE, INC. DANA-FARBER CANCER INSTITUE, INC. THE GENERAL HOSPITAL CORPORATION D/B/A
DMKYX7J DT Small molecular drug
DMKYX7J PC 1478036
DMKYX7J MW 337.4
DMKYX7J FM C20H23N3O2
DMKYX7J IC InChI=1S/C20H23N3O2/c1-11-16-17(12-7-5-6-8-15(12)25-4)18-13(21-19(16)23-22-11)9-20(2,3)10-14(18)24/h5-8,17H,9-10H2,1-4H3,(H2,21,22,23)/t17-/m0/s1
DMKYX7J CS CC1=C2[C@@H](C3=C(CC(CC3=O)(C)C)NC2=NN1)C4=CC=CC=C4OC
DMKYX7J IK KYFJPYWXCUCRPE-KRWDZBQOSA-N
DMKYX7J IU (4R)-4-(2-methoxyphenyl)-3,7,7-trimethyl-4,6,8,9-tetrahydro-2H-pyrazolo[3,4-b]quinolin-5-one
DMY03RZ ID DMY03RZ
DMY03RZ DN Pyrazolopyridine derivative 1
DMY03RZ HS Patented
DMY03RZ SN PMID27774822-Compound-Figure1Example38compound1138
DMY03RZ CP LIGAND PHARMACEUTICALS INCORPORATED COLE, Andrew, G. JAMES, Ray, A. SHAO, Yuefei LETOURNEAU, Jeffrey, J. QUINTERO, Jorge, G. RIVIELLO, Christopher, Mark ZHI, Lin
DMCJVLR ID DMCJVLR
DMCJVLR DN Pyrazolopyridine derivative 2
DMCJVLR HS Patented
DMCJVLR SN PMID27774822-Compound-Figure1Example53compound153
DMCJVLR CP LIGAND PHARMACEUTICALS INCORPORATED COLE, Andrew, G. JAMES, Ray, A. SHAO, Yuefei LETOURNEAU, Jeffrey, J. QUINTERO, Jorge, G. RIVIELLO, Christopher, Mark ZHI, Lin
DM2VQ4P ID DM2VQ4P
DM2VQ4P DN Pyrazolopyridine derivative 3
DM2VQ4P HS Patented
DM2VQ4P SN PMID27774822-Compound-Figure5Example131
DM2VQ4P CP PFIZER INC
DM2VQ4P DT Small molecular drug
DMX7RWV ID DMX7RWV
DMX7RWV DN Pyrazolopyridine derivative 4
DMX7RWV HS Patented
DMX7RWV SN PMID27774822-Compound-Figure9Example1
DMX7RWV CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTZCLG ID DMTZCLG
DMTZCLG DN Pyrazolopyridine derivative 5
DMTZCLG HS Patented
DMTZCLG SN PMID27774822-Compound-Figure9Example1topleft
DMTZCLG CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMTZCLG DT Small molecular drug
DM5OH8D ID DM5OH8D
DM5OH8D DN Pyrazolopyridine derivative 6
DM5OH8D HS Patented
DM5OH8D SN PMID27774824-Compound-Figure7compoud10
DM5OH8D CP CELLZOME LIMITED OXENFORD, Sally HOBSON, Andrew OLIVER, Kathryn RATCLIFFE, Andrew RAMSDEN, Nigel
DM5OH8D DT Small molecular drug
DMCTQ9O ID DMCTQ9O
DMCTQ9O DN Pyrazolopyridine derivative 7
DMCTQ9O HS Patented
DMCTQ9O SN PMID27774824-Compound-Figure7compoud18
DMCTQ9O CP CELLZOME LIMITED OXENFORD, Sally HOBSON, Andrew OLIVER, Kathryn RATCLIFFE, Andrew RAMSDEN, Nigel
DMCTQ9O DT Small molecular drug
DMSR5FO ID DMSR5FO
DMSR5FO DN Pyrazolopyridines and imidazopyridine derivative 1
DMSR5FO HS Patented
DMSR5FO SN PMID25684022-Compound-WO2010017047
DMSR5FO CP MERCK SHARP & DOHME CORP. MSD K.K. KATZ, Jason JEWELL, James JUNG, Joon KATTAR, Solomon HOU, Yongquan MACCOSS, Rachel ITO, Satoru
DMSR5FO DT Small molecular drug
DMSR5FO DE Solid tumour/cancer; Metastatic cancer
DMRAS8L ID DMRAS8L
DMRAS8L DN Pyrazolopyrimidine acetamide analog 1
DMRAS8L HS Patented
DMRAS8L SN PMID27607364-Compound-116
DMRAS8L DT Small molecular drug
DMRAS8L PC 11595759
DMRAS8L MW 366.5
DMRAS8L FM C21H26N4O2
DMRAS8L IC InChI=1S/C21H26N4O2/c1-6-24(7-2)19(26)13-18-20(16-8-10-17(27-5)11-9-16)23-25-15(4)12-14(3)22-21(18)25/h8-12H,6-7,13H2,1-5H3
DMRAS8L CS CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OC)C)C
DMRAS8L IK ILZWUAWCTNWSFZ-UHFFFAOYSA-N
DMRAS8L IU N,N-diethyl-2-[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide
DMRAS8L CA CAS 386297-97-8
DMK7F3A ID DMK7F3A
DMK7F3A DN Pyrazolopyrimidine acetamide analog 2
DMK7F3A HS Patented
DMK7F3A SN PMID27607364-Compound-117
DMK7F3A DT Small molecular drug
DMK7F3A PC 24895172
DMK7F3A MW 398.5
DMK7F3A FM C22H27FN4O2
DMK7F3A IC InChI=1S/C22H27FN4O2/c1-5-26(6-2)20(28)14-19-21(17-7-9-18(10-8-17)29-12-11-23)25-27-16(4)13-15(3)24-22(19)27/h7-10,13H,5-6,11-12,14H2,1-4H3
DMK7F3A CS CCN(CC)C(=O)CC1=C2N=C(C=C(N2N=C1C3=CC=C(C=C3)OCCF)C)C
DMK7F3A IK FLZZFWBNYJNHMY-UHFFFAOYSA-N
DMK7F3A IU N,N-diethyl-2-[2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide
DMK7F3A CA CAS 958233-07-3
DM6TB4Z ID DM6TB4Z
DM6TB4Z DN Pyrazolopyrimidine and thienopyrimidine amide derivative 1
DM6TB4Z HS Patented
DM6TB4Z SN PMID27310003-Compound-30
DM6TB4Z CP F. HOFFMANN-LA ROCHE AG ARORA, Nidhi CHEN, Shaoqing HERMANN, Johannes, Cornelius KUGLSTATTER, Andreas LABADIE, Sharada, Shenvi LIN, Clara Jeou Jen LUCAS, Matthew, C. MOORE, Amy, Geraldine PAPP, Eva TALAMAS, Francisco, Xavier WANNER, Jutta ZHAI, Yansheng
DM6TB4Z DT Small molecular drug
DMFUNH4 ID DMFUNH4
DMFUNH4 DN Pyrazolopyrimidine and thienopyrimidine amide derivative 2
DMFUNH4 HS Patented
DMFUNH4 SN PMID27310003-Compound-31
DMFUNH4 CP F. HOFFMANN-LA ROCHE AG ARORA, Nidhi CHEN, Shaoqing HERMANN, Johannes, Cornelius KUGLSTATTER, Andreas LABADIE, Sharada, Shenvi LIN, Clara Jeou Jen LUCAS, Matthew, C. MOORE, Amy, Geraldine PAPP, Eva TALAMAS, Francisco, Xavier WANNER, Jutta ZHAI, Yansheng
DMFUNH4 DT Small molecular drug
DMHO3NB ID DMHO3NB
DMHO3NB DN Pyrazolopyrimidine derivative 1
DMHO3NB HS Patented
DMHO3NB SN PMID28067079-Compound-78
DMHO3NB CP MERZ PHARMA GMBH & CO. KGAA RUSS, Hermann BORTA, Andreas HEERS, Cara HAUPTMEIER, Bernhard BODERKE, Peter PURMANN, Brigitte TARDT, AxeMERZ PHARMA GMBH & CO. KGAA DANYSZ, Wojciech DEKUNDY, Andrzej HECHENBERGER, Mirko HENRICH, Markus JATZKE, Claudia NAGEL, Jens PARSONS, Christopher Graham Raphael WEIL, Tanja MLER, Sibylle FOTINS, Juris GUTCAITS, Aleksandra ZEMRIBO, Ronalds KAUSS, Valerjans KAULINA, Larisa ERDMANE, Elina
DMHO3NB DT Small molecular drug
DMHO3NB PC 24810684
DMHO3NB MW 371.2
DMHO3NB FM C17H15BrN4O
DMHO3NB IC InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
DMHO3NB CS C[C@@H]1C2=CC=CC=C2CCN1C(=O)C3=NN4C=C(C=NC4=C3)Br
DMHO3NB IK TUYZYSNXXSTKQX-LLVKDONJSA-N
DMHO3NB IU (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-[(1R)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]methanone
DMHO3NB CA CAS 1309783-00-3
DMZEP5X ID DMZEP5X
DMZEP5X DN Pyrazolopyrimidine derivative 2
DMZEP5X HS Patented
DMZEP5X SN PMID28067079-Compound-79
DMZEP5X CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMZEP5X DT Small molecular drug
DMZEP5X PC 71739469
DMZEP5X MW 406.3
DMZEP5X FM C16H16BrN5OS
DMZEP5X IC InChI=1S/C16H16BrN5OS/c1-2-15-19-11-3-5-21(6-4-13(11)24-15)16(23)12-7-14-18-8-10(17)9-22(14)20-12/h7-9H,2-6H2,1H3
DMZEP5X CS CCC1=NC2=C(S1)CCN(CC2)C(=O)C3=NN4C=C(C=NC4=C3)Br
DMZEP5X IK OEYKQCOFIDDHKA-UHFFFAOYSA-N
DMZEP5X IU (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(2-ethyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone
DMI0J7D ID DMI0J7D
DMI0J7D DN Pyrazolopyrimidine derivative 3
DMI0J7D HS Patented
DMI0J7D SN PMID28067079-Compound-80
DMI0J7D CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMI0J7D DT Small molecular drug
DMI0J7D PC 71748062
DMI0J7D MW 333.8
DMI0J7D FM C14H12ClN5OS
DMI0J7D IC InChI=1S/C14H12ClN5OS/c15-9-6-16-13-5-11(18-20(13)7-9)14(21)19-3-1-10-12(2-4-19)22-8-17-10/h5-8H,1-4H2
DMI0J7D CS C1CN(CCC2=C1N=CS2)C(=O)C3=NN4C=C(C=NC4=C3)Cl
DMI0J7D IK UNBIVDPTRGTTPR-UHFFFAOYSA-N
DMI0J7D IU (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone
DM7XSHK ID DM7XSHK
DM7XSHK DN Pyrazolopyrimidine derivative 4
DM7XSHK HS Patented
DM7XSHK SN PMID28067079-Compound-81
DM7XSHK CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM7XSHK DT Small molecular drug
DM7XSHK PC 71748065
DM7XSHK MW 347.8
DM7XSHK FM C15H14ClN5OS
DM7XSHK IC InChI=1S/C15H14ClN5OS/c1-9-18-11-2-4-20(5-3-13(11)23-9)15(22)12-6-14-17-7-10(16)8-21(14)19-12/h6-8H,2-5H2,1H3
DM7XSHK CS CC1=NC2=C(S1)CCN(CC2)C(=O)C3=NN4C=C(C=NC4=C3)Cl
DM7XSHK IK WOOXFLPCMNOANB-UHFFFAOYSA-N
DM7XSHK IU (6-chloropyrazolo[1,5-a]pyrimidin-2-yl)-(2-methyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone
DMVUSF3 ID DMVUSF3
DMVUSF3 DN Pyrazolopyrimidine derivative 5
DMVUSF3 HS Patented
DMVUSF3 SN PMID28067079-Compound-82
DMVUSF3 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMVUSF3 DT Small molecular drug
DMVUSF3 PC 71748080
DMVUSF3 MW 392.3
DMVUSF3 FM C15H14BrN5OS
DMVUSF3 IC InChI=1S/C15H14BrN5OS/c1-9-18-11-2-4-20(5-3-13(11)23-9)15(22)12-6-14-17-7-10(16)8-21(14)19-12/h6-8H,2-5H2,1H3
DMVUSF3 CS CC1=NC2=C(S1)CCN(CC2)C(=O)C3=NN4C=C(C=NC4=C3)Br
DMVUSF3 IK PPBYGUATKIHBBC-UHFFFAOYSA-N
DMVUSF3 IU (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)-(2-methyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-6-yl)methanone
DMG8V31 ID DMG8V31
DMG8V31 DN Pyrazolopyrimidine derivative 6
DMG8V31 HS Patented
DMG8V31 SN PMID28067079-Compound-83
DMG8V31 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMG8V31 DT Small molecular drug
DMG8V31 PC 71748063
DMG8V31 MW 394.25
DMG8V31 FM C14H12BrN5O2S
DMG8V31 IC InChI=1S/C14H12BrN5O2S/c15-8-6-16-12-5-10(18-20(12)7-8)13(21)19-3-1-9-11(2-4-19)23-14(22)17-9/h5-7H,1-4H2,(H,17,22)
DMG8V31 CS C1CN(CCC2=C1NC(=O)S2)C(=O)C3=NN4C=C(C=NC4=C3)Br
DMG8V31 IK NFUGEPSHTBCNFR-UHFFFAOYSA-N
DMG8V31 IU 6-(6-bromopyrazolo[1,5-a]pyrimidine-2-carbonyl)-4,5,7,8-tetrahydro-3H-[1,3]thiazolo[4,5-d]azepin-2-one
DMTD3C1 ID DMTD3C1
DMTD3C1 DN Pyrazolo-triazine derivative 1
DMTD3C1 HS Patented
DMTD3C1 SN PMID26161698-Compound-13
DMTD3C1 CP LEAD DISCOVERY CENTER GMBH
DMTD3C1 DT Small molecular drug
DMTD3C1 PC 89778898
DMTD3C1 MW 380.5
DMTD3C1 FM C21H28N6O
DMTD3C1 IC InChI=1S/C21H28N6O/c1-14(2)18-13-23-27-19(18)25-21(28-17-10-7-11-22-12-17)26-20(27)24-15(3)16-8-5-4-6-9-16/h4-6,8-9,13-15,17,22H,7,10-12H2,1-3H3,(H,24,25,26)/t15-,17?/m0/s1
DMTD3C1 CS C[C@@H](C1=CC=CC=C1)NC2=NC(=NC3=C(C=NN32)C(C)C)OC4CCCNC4
DMTD3C1 IK GTZAVJAMAXSTOG-MYJWUSKBSA-N
DMTD3C1 IU N-[(1S)-1-phenylethyl]-2-piperidin-3-yloxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DML6V78 ID DML6V78
DML6V78 DN Pyrazolo-triazine derivative 2
DML6V78 HS Patented
DML6V78 SN PMID26161698-Compound-14
DML6V78 CP LEAD DISCOVERY CENTER GMBH
DML6V78 DT Small molecular drug
DML6V78 PC 71731909
DML6V78 MW 446.5
DML6V78 FM C24H30N8O
DML6V78 IC InChI=1S/C24H30N8O/c1-17(2)20-15-27-32-22(20)28-24(33-19-8-11-30(3)12-9-19)29-23(32)26-14-18-6-4-5-7-21(18)31-13-10-25-16-31/h4-7,10,13,15-17,19H,8-9,11-12,14H2,1-3H3,(H,26,28,29)
DML6V78 CS CC(C)C1=C2N=C(N=C(N2N=C1)NCC3=CC=CC=C3N4C=CN=C4)OC5CCN(CC5)C
DML6V78 IK KLTSWTPLJGXFTH-UHFFFAOYSA-N
DML6V78 IU N-[(2-imidazol-1-ylphenyl)methyl]-2-(1-methylpiperidin-4-yl)oxy-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMKJ3PC ID DMKJ3PC
DMKJ3PC DN Pyridazin-3(2H)-one derivative 1
DMKJ3PC HS Patented
DMKJ3PC SN PMID29334795-Compound-20
DMKJ3PC CP CEPHALON, INC. BIERLMAIER, Stephen HALTIWANGER, Ralph, Curtis JACOBS, Martin, JCEPHALON, INC. HUDKINS, Robert, L. JOSEF, Kurt, A. TAO, Ming BECKNELL, Nadine, C. HOSTETLER, Greg KNUTSON, Lars, J., S. ZULLI, Allison, L
DMKJ3PC DT Small molecular drug
DMF7MEB ID DMF7MEB
DMF7MEB DN Pyridazinone derivative 1
DMF7MEB HS Patented
DMF7MEB SN PMID27724045-Compound-32
DMF7MEB CP Nissan chemical industries, Ltd
DMF7MEB DT Small molecular drug
DM3GU7K ID DM3GU7K
DM3GU7K DN Pyridic ketone derivative 1
DM3GU7K HS Patented
DM3GU7K SN PMID28594589-Compound-TABLE3c3
DM3GU7K CP Shanghai Hengrui Pharm
DM3GU7K DT Small molecular drug
DM3GU7K PC 118041703
DM3GU7K MW 618.4
DM3GU7K FM C22H21F2IN4O5S
DM3GU7K IC InChI=1S/C22H21F2IN4O5S/c1-4-35(32,33)28-14-6-5-7-16(11(14)2)34-19-17(20(26)30)21(29(3)22(31)18(19)24)27-15-9-8-12(25)10-13(15)23/h5-10,27-28H,4H2,1-3H3,(H2,26,30)
DM3GU7K CS CCS(=O)(=O)NC1=C(C(=CC=C1)OC2=C(C(=O)N(C(=C2C(=O)N)NC3=C(C=C(C=C3)I)F)C)F)C
DM3GU7K IK ABFMVRPVXUKQEQ-UHFFFAOYSA-N
DM3GU7K IU 4-[3-(ethylsulfonylamino)-2-methylphenoxy]-5-fluoro-2-(2-fluoro-4-iodoanilino)-1-methyl-6-oxopyridine-3-carboxamide
DMGEYJW ID DMGEYJW
DMGEYJW DN Pyridine and pyrimidine derivative 1
DMGEYJW HS Patented
DMGEYJW SN PMID28447479-Compound-1
DMGEYJW CP INHIBITAXIN LIMITED
DMGEYJW DT Small molecular drug
DMGEYJW PC 71543359
DMGEYJW MW 432.5
DMGEYJW FM C24H21FN4OS
DMGEYJW IC InChI=1S/C24H21FN4OS/c25-17-7-5-16(6-8-17)13-21-18-14-29(12-11-19(18)26-15-27-21)24(30)10-9-23-28-20-3-1-2-4-22(20)31-23/h1-8,15H,9-14H2
DMGEYJW CS C1CN(CC2=C1N=CN=C2CC3=CC=C(C=C3)F)C(=O)CCC4=NC5=CC=CC=C5S4
DMGEYJW IK JGNVAVQZDSOAGO-UHFFFAOYSA-N
DMGEYJW IU 3-(1,3-benzothiazol-2-yl)-1-[4-[(4-fluorophenyl)methyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]propan-1-one
DMGEYJW DE Fibrosis; Pain; Solid tumour/cancer
DMSGF8T ID DMSGF8T
DMSGF8T DN Pyridine derivative 1
DMSGF8T HS Patented
DMSGF8T SN PMID29473428-Compound-27
DMSGF8T CP CURADEV PHARMA PVT. LTD
DMSGF8T DT Small molecular drug
DMVL2G3 ID DMVL2G3
DMVL2G3 DN Pyridine derivative 10
DMVL2G3 HS Patented
DMVL2G3 SN PMID28621580-Compound-WO2014040242c47
DMVL2G3 CP HUNAN NONFERROUS METALS GROUP CHEMBIO PHARMACY CO., LTD. ZHANG, Shixi
DMVL2G3 DT Small molecular drug
DMF9VMW ID DMF9VMW
DMF9VMW DN Pyridine derivative 11
DMF9VMW HS Patented
DMF9VMW SN PMID28621580-Compound-WO2015075483c49
DMF9VMW CP CANCER RESEARCH TECHNOLOGY LIMITED INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)
DMF9VMW DT Small molecular drug
DM8KBHX ID DM8KBHX
DM8KBHX DN Pyridine derivative 12
DM8KBHX HS Patented
DM8KBHX SN PMID28067079-Compound-72
DM8KBHX DT Small molecular drug
DM8KBHX PC 118205502
DM8KBHX MW 321.3
DM8KBHX FM C19H16FN3O
DM8KBHX IC InChI=1S/C19H16FN3O/c20-19-15(7-4-10-22-19)16-11-18(23-17-8-3-6-14(16)17)24-12-13-5-1-2-9-21-13/h1-2,4-5,7,9-11H,3,6,8,12H2
DM8KBHX CS C1CC2=C(C1)N=C(C=C2C3=C(N=CC=C3)F)OCC4=CC=CC=N4
DM8KBHX IK NKDIYHWBHMMBTN-UHFFFAOYSA-N
DM8KBHX IU 4-(2-fluoropyridin-3-yl)-2-(pyridin-2-ylmethoxy)-6,7-dihydro-5H-cyclopenta[b]pyridine
DMX8RGH ID DMX8RGH
DMX8RGH DN Pyridine derivative 13
DMX8RGH HS Patented
DMX8RGH SN PMID28067079-Compound-73
DMX8RGH DT Small molecular drug
DMX8RGH PC 73213414
DMX8RGH MW 322.3
DMX8RGH FM C18H15FN4O
DMX8RGH IC InChI=1S/C18H15FN4O/c19-15-4-2-6-22-17(15)10-24-18-7-14(12-8-20-11-21-9-12)13-3-1-5-16(13)23-18/h2,4,6-9,11H,1,3,5,10H2
DMX8RGH CS C1CC2=C(C1)N=C(C=C2C3=CN=CN=C3)OCC4=C(C=CC=N4)F
DMX8RGH IK JQPYBOWMLVSYFJ-UHFFFAOYSA-N
DMX8RGH IU 2-[(3-fluoropyridin-2-yl)methoxy]-4-pyrimidin-5-yl-6,7-dihydro-5H-cyclopenta[b]pyridine
DM7JCM6 ID DM7JCM6
DM7JCM6 DN Pyridine derivative 14
DM7JCM6 HS Patented
DM7JCM6 SN PMID28067079-Compound-74
DM7JCM6 DT Small molecular drug
DM7JCM6 PC 73335671
DM7JCM6 MW 328.4
DM7JCM6 FM C20H16N4O
DM7JCM6 IC InChI=1S/C20H16N4O/c21-9-14-4-6-15(7-5-14)12-25-20-8-18(16-10-22-13-23-11-16)17-2-1-3-19(17)24-20/h4-8,10-11,13H,1-3,12H2
DM7JCM6 CS C1CC2=C(C1)N=C(C=C2C3=CN=CN=C3)OCC4=CC=C(C=C4)C#N
DM7JCM6 IK CZFKXGVEBISLMB-UHFFFAOYSA-N
DM7JCM6 IU 4-[(4-pyrimidin-5-yl-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)oxymethyl]benzonitrile
DMGBR43 ID DMGBR43
DMGBR43 DN Pyridine derivative 15
DMGBR43 HS Patented
DMGBR43 SN PMID28067079-Compound-75
DMGBR43 DT Small molecular drug
DMGBR43 PC 73335272
DMGBR43 MW 343.4
DMGBR43 FM C20H17N5O
DMGBR43 IC InChI=1S/C20H17N5O/c21-10-19-23-11-14(12-24-19)17-9-20(25-18-7-2-1-6-16(17)18)26-13-15-5-3-4-8-22-15/h3-5,8-9,11-12H,1-2,6-7,13H2
DMGBR43 CS C1CCC2=C(C1)C(=CC(=N2)OCC3=CC=CC=N3)C4=CN=C(N=C4)C#N
DMGBR43 IK SBDHHIXJPZSGIC-UHFFFAOYSA-N
DMGBR43 IU 5-[2-(pyridin-2-ylmethoxy)-5,6,7,8-tetrahydroquinolin-4-yl]pyrimidine-2-carbonitrile
DMICZLS ID DMICZLS
DMICZLS DN Pyridine derivative 16
DMICZLS HS Patented
DMICZLS SN PMID28067079-Compound-76
DMICZLS DT Small molecular drug
DMICZLS PC 73335373
DMICZLS MW 350.4
DMICZLS FM C20H19FN4O
DMICZLS IC InChI=1S/C20H19FN4O/c1-13-23-10-14(11-24-13)16-9-20(25-18-7-3-2-5-15(16)18)26-12-19-17(21)6-4-8-22-19/h4,6,8-11H,2-3,5,7,12H2,1H3
DMICZLS CS CC1=NC=C(C=N1)C2=CC(=NC3=C2CCCC3)OCC4=C(C=CC=N4)F
DMICZLS IK SPNLLZYJQZRTPY-UHFFFAOYSA-N
DMICZLS IU 2-[(3-fluoropyridin-2-yl)methoxy]-4-(2-methylpyrimidin-5-yl)-5,6,7,8-tetrahydroquinoline
DMLC5WA ID DMLC5WA
DMLC5WA DN Pyridine derivative 17
DMLC5WA HS Patented
DMLC5WA SN PMID28067079-Compound-77
DMLC5WA DT Small molecular drug
DMLC5WA PC 118205314
DMLC5WA MW 350.4
DMLC5WA FM C20H19FN4O
DMLC5WA IC InChI=1S/C20H19FN4O/c1-13-10-22-11-18(24-13)15-9-20(25-17-7-3-2-5-14(15)17)26-12-19-16(21)6-4-8-23-19/h4,6,8-11H,2-3,5,7,12H2,1H3
DMLC5WA CS CC1=CN=CC(=N1)C2=CC(=NC3=C2CCCC3)OCC4=C(C=CC=N4)F
DMLC5WA IK NVOTVOBVLQBYNP-UHFFFAOYSA-N
DMLC5WA IU 2-[(3-fluoropyridin-2-yl)methoxy]-4-(6-methylpyrazin-2-yl)-5,6,7,8-tetrahydroquinoline
DMBZMYT ID DMBZMYT
DMBZMYT DN Pyridine derivative 18
DMBZMYT HS Patented
DMBZMYT SN PMID27646564-Compound-5
DMBZMYT CP YM BIOSCIENCES AUSTRALIA PTY [AU]
DMBZMYT DT Small molecular drug
DMXYT40 ID DMXYT40
DMXYT40 DN Pyridine derivative 19
DMXYT40 HS Patented
DMXYT40 SN PMID27646564-Compound-5-1
DMXYT40 CP YM BIOSCIENCES AUSTRALIA PTY [AU]
DMXYT40 DT Small molecular drug
DMGSUIV ID DMGSUIV
DMGSUIV DN Pyridine derivative 2
DMGSUIV HS Patented
DMGSUIV SN PMID28621580-Compound-US20130096136c42
DMGSUIV CP MethylGene Inc
DMGSUIV DT Small molecular drug
DMGSUIV PC 71522446
DMGSUIV MW 563.6
DMGSUIV FM C31H25N5O4S
DMGSUIV IC InChI=1S/C31H25N5O4S/c1-38-21-7-5-20(6-8-21)34-31-35-24-15-22(9-11-26(24)40-31)39-27-12-13-32-25-16-28(41-30(25)27)23-10-4-19(17-33-23)18-36-14-2-3-29(36)37/h4-13,15-17H,2-3,14,18H2,1H3,(H,34,35)
DMGSUIV CS COC1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)OC4=C5C(=NC=C4)C=C(S5)C6=NC=C(C=C6)CN7CCCC7=O
DMGSUIV IK NMDJVUTXFINSAW-UHFFFAOYSA-N
DMGSUIV IU 1-[[6-[7-[[2-(4-methoxyanilino)-1,3-benzoxazol-5-yl]oxy]thieno[3,2-b]pyridin-2-yl]pyridin-3-yl]methyl]pyrrolidin-2-one
DMAOF0W ID DMAOF0W
DMAOF0W DN Pyridine derivative 20
DMAOF0W HS Patented
DMAOF0W SN PMID27646564-Compound-5-2
DMAOF0W CP YM BIOSCIENCES AUSTRALIA PTY [AU]
DMAOF0W DT Small molecular drug
DMF3907 ID DMF3907
DMF3907 DN Pyridine derivative 21
DMF3907 HS Patented
DMF3907 SN PMID27646564-Compound-5-3
DMF3907 CP YM BIOSCIENCES AUSTRALIA PTY [AU]
DMF3907 DT Small molecular drug
DMSIERF ID DMSIERF
DMSIERF DN Pyridine derivative 22
DMSIERF HS Patented
DMSIERF SN PMID27646564-Compound-5-4
DMSIERF CP YM BIOSCIENCES AUSTRALIA PTY [AU]
DMSIERF DT Small molecular drug
DMFALQN ID DMFALQN
DMFALQN DN Pyridine derivative 3
DMFALQN HS Patented
DMFALQN SN PMID28621580-Compound-US20140336108c48
DMFALQN CP Allergan, Inc
DMFALQN DT Small molecular drug
DM6N8T3 ID DM6N8T3
DM6N8T3 DN Pyridine derivative 4
DM6N8T3 HS Patented
DM6N8T3 SN PMID28621580-Compound-WO2012169934c40
DM6N8T3 CP ASINEX LTD [RUKAZULKIN DENIS NIKOLAEVICH [RUKOCHUBEY VALERIY SERGEEVICH [RU]
DM6N8T3 DT Small molecular drug
DM6N8T3 DE Solid tumour/cancer
DMXP6W1 ID DMXP6W1
DMXP6W1 DN Pyridine derivative 5
DMXP6W1 HS Patented
DMXP6W1 SN PMID28621580-Compound-WO2013015657c41
DMXP6W1 CP BORYUNG PHARMACEUTICAL CO., LTD. KIM, Ji Han KIM, Je Hak LEE, Joon Kwang JUNG, Hahn-Sun HAN, Nam Seok PARK, Yong
DMXP6W1 DT Small molecular drug
DM8NBM0 ID DM8NBM0
DM8NBM0 DN Pyridine derivative 6
DM8NBM0 HS Patented
DM8NBM0 SN PMID28621580-Compound-WO2013044361c43
DM8NBM0 CP METHYLGENE INC
DM8NBM0 DT Small molecular drug
DMYT1QN ID DMYT1QN
DMYT1QN DN Pyridine derivative 7
DMYT1QN HS Patented
DMYT1QN SN PMID28621580-Compound-WO2013044362c44
DMYT1QN CP METHYLGENE INC
DMYT1QN DT Small molecular drug
DMITVUY ID DMITVUY
DMITVUY DN Pyridine derivative 8
DMITVUY HS Patented
DMITVUY SN PMID28621580-Compound-WO2014029250c45
DMITVUY CP CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
DMITVUY DT Small molecular drug
DMVF1BI ID DMVF1BI
DMVF1BI DN Pyridine derivative 9
DMVF1BI HS Patented
DMVF1BI SN PMID28621580-Compound-WO2014029251c46
DMVF1BI CP CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
DMVF1BI DT Small molecular drug
DMJNE4V ID DMJNE4V
DMJNE4V DN Pyridine-2,4-dicarboxylic acid analog 1
DMJNE4V HS Patented
DMJNE4V SN PMID25468267-Compound-22
DMJNE4V CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMJNE4V DT Small molecular drug
DMCNWPI ID DMCNWPI
DMCNWPI DN Pyridine-2,4-dicarboxylic acid analog 2
DMCNWPI HS Patented
DMCNWPI SN PMID25468267-Compound-23
DMCNWPI CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMCNWPI DT Small molecular drug
DM4XAGS ID DM4XAGS
DM4XAGS DN Pyridine-2,4-dicarboxylic acid analog 3
DM4XAGS HS Patented
DM4XAGS SN PMID25468267-Compound-24
DM4XAGS CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DM4XAGS DT Small molecular drug
DMGPCSR ID DMGPCSR
DMGPCSR DN Pyridine-2,4-dicarboxylic acid analog 4
DMGPCSR HS Patented
DMGPCSR SN PMID25468267-Compound-25
DMGPCSR CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMGPCSR DT Small molecular drug
DMZSTCQ ID DMZSTCQ
DMZSTCQ DN Pyridine-2,4-dicarboxylic acid derivative 1
DMZSTCQ HS Patented
DMZSTCQ SN PMID25468267-Compound-5
DMZSTCQ CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMZSTCQ DT Small molecular drug
DMGCMF5 ID DMGCMF5
DMGCMF5 DN Pyridine-2,4-dicarboxylic acid derivative 2
DMGCMF5 HS Patented
DMGCMF5 SN PMID25468267-Compound-6
DMGCMF5 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMGCMF5 DT Small molecular drug
DMCUP4L ID DMCUP4L
DMCUP4L DN Pyridine-2,4-dicarboxylic acid derivative 3
DMCUP4L HS Patented
DMCUP4L SN PMID25468267-Compound-7
DMCUP4L CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher, Joseph MCDONOUGH, Michael ROSE, Nathan THALHAMMER, Armin
DMCUP4L DT Small molecular drug
DM9KOYX ID DM9KOYX
DM9KOYX DN Pyridine-amide derivative 1
DM9KOYX HS Patented
DM9KOYX SN PMID25470667-Compound-Figure5-4
DM9KOYX CP BRISTOL-MYERS SQUIBB COMPANY HUANG, Yanting SUN, Chongqing LAWRENCE, R., Michael EWING, William, R. TURDI, Huji
DM9KOYX DT Small molecular drug
DM9KOYX PC 16757107
DM9KOYX MW 420.4
DM9KOYX FM C20H19F3N4O3
DM9KOYX IC InChI=1S/C20H19F3N4O3/c1-27(10-11-29-2)15-9-8-14(12-24-15)25-18(28)16-17(20(21,22)23)30-19(26-16)13-6-4-3-5-7-13/h3-9,12H,10-11H2,1-2H3,(H,25,28)
DM9KOYX CS CN(CCOC)C1=NC=C(C=C1)NC(=O)C2=C(OC(=N2)C3=CC=CC=C3)C(F)(F)F
DM9KOYX IK QEZWDFXCTTZZRI-UHFFFAOYSA-N
DM9KOYX IU N-[6-[2-methoxyethyl(methyl)amino]pyridin-3-yl]-2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carboxamide
DM25M8D ID DM25M8D
DM25M8D DN Pyridine-carboximide derivative 1
DM25M8D HS Patented
DM25M8D SN PMID25470667-Compound-Figure5-5
DM25M8D CP SCHERING CORPORATION TING, Pauline, C. LEE, Joe, F. ASLANIAN, Robert, G
DM25M8D DT Small molecular drug
DM25M8D PC 52917274
DM25M8D MW 521.6
DM25M8D FM C31H27N3O5
DM25M8D IC InChI=1S/C31H27N3O5/c1-19-24-15-21(20-7-5-4-6-8-20)9-13-26(24)39-28(19)29(35)34-23-11-12-25(32-17-23)22-10-14-27(33-16-22)38-18-31(2,3)30(36)37/h4-17H,18H2,1-3H3,(H,34,35)(H,36,37)
DM25M8D CS CC1=C(OC2=C1C=C(C=C2)C3=CC=CC=C3)C(=O)NC4=CN=C(C=C4)C5=CN=C(C=C5)OCC(C)(C)C(=O)O
DM25M8D IK WBSJFAVPZLMOLD-UHFFFAOYSA-N
DM25M8D IU 2,2-dimethyl-3-[5-[5-[(3-methyl-5-phenyl-1-benzofuran-2-carbonyl)amino]pyridin-2-yl]pyridin-2-yl]oxypropanoic acid
DMHXWZB ID DMHXWZB
DMHXWZB DN Pyridine-carboximide derivative 2
DMHXWZB HS Patented
DMHXWZB SN PMID25470667-Compound-Figure5-6
DMHXWZB CP MERCK SHARP & DOHME CORP. TING, Pauline, C. ASLANIAN, Robert CAO, Jianhua KIM, David ZORN, Nicolas
DMHXWZB DT Small molecular drug
DMHXWZB PC 56837993
DMHXWZB MW 497.5
DMHXWZB FM C29H27N3O5
DMHXWZB IC InChI=1S/C29H27N3O5/c33-28(26-11-10-25(37-26)21-5-2-1-3-6-21)31-23-9-12-27(30-18-23)32-15-13-20(14-16-32)19-36-24-8-4-7-22(17-24)29(34)35/h1-12,17-18,20H,13-16,19H2,(H,31,33)(H,34,35)
DMHXWZB CS C1CN(CCC1COC2=CC=CC(=C2)C(=O)O)C3=NC=C(C=C3)NC(=O)C4=CC=C(O4)C5=CC=CC=C5
DMHXWZB IK FQDLXNVBCMMHLG-UHFFFAOYSA-N
DMHXWZB IU 3-[[1-[5-[(5-phenylfuran-2-carbonyl)amino]pyridin-2-yl]piperidin-4-yl]methoxy]benzoic acid
DMKQFTY ID DMKQFTY
DMKQFTY DN Pyridino tricyclic compound 1
DMKQFTY HS Patented
DMKQFTY SN PMID29473428-Compound-42
DMKQFTY CP REDX PHARMA PLC
DMKQFTY DT Small molecular drug
DMKQFTY PC 121288581
DMKQFTY MW 283.37
DMKQFTY FM C17H21N3O
DMKQFTY IC InChI=1S/C17H21N3O/c21-17(12-4-2-1-3-5-12)8-15-13-6-7-18-9-14(13)16-10-19-11-20(15)16/h6-7,9-12,15,17,21H,1-5,8H2
DMKQFTY CS C1CCC(CC1)C(CC2C3=C(C=NC=C3)C4=CN=CN24)O
DMKQFTY IK PCYLWVWPFZLSAJ-UHFFFAOYSA-N
DMKQFTY IU 1-cyclohexyl-2-(4,6,11-triazatricyclo[6.4.0.02,6]dodeca-1(8),2,4,9,11-pentaen-7-yl)ethanol
DM3F4KS ID DM3F4KS
DM3F4KS DN Pyridinone carboxamide derivative 1
DM3F4KS HS Patented
DM3F4KS SN PMID25684022-Compound-WO2010007116
DM3F4KS CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH ENGELHARDT, Harald BOEHMELT, Guido KOFINK, Christiane KUHN, Daniel MCCONNELL, Darryl STADTMUELLER, Heinz
DM3F4KS DT Small molecular drug
DM3F4KS DE Solid tumour/cancer; Metastatic cancer
DM2GR5Q ID DM2GR5Q
DM2GR5Q DN Pyridinone compound 1
DM2GR5Q HS Patented
DM2GR5Q SN PMID28594589-Compound-TABLE3c9
DM2GR5Q CP Asan Foundation
DM2GR5Q DT Small molecular drug
DM2GR5Q PC 86582134
DM2GR5Q MW 515.299
DM2GR5Q FM C20H23FIN3O4
DM2GR5Q IC InChI=1S/C20H23FIN3O4/c1-20(2,28)10-29-24-18(26)16-12-5-4-6-13(12)19(27)25(3)17(16)23-15-8-7-11(22)9-14(15)21/h7-9,23,28H,4-6,10H2,1-3H3,(H,24,26)
DM2GR5Q CS CC(C)(CONC(=O)C1=C(N(C(=O)C2=C1CCC2)C)NC3=C(C=C(C=C3)I)F)O
DM2GR5Q IK WMBPVWDVQRPCQY-UHFFFAOYSA-N
DM2GR5Q IU 3-(2-fluoro-4-iodoanilino)-N-(2-hydroxy-2-methylpropoxy)-2-methyl-1-oxo-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carboxamide
DMK5YJI ID DMK5YJI
DMK5YJI DN Pyrido/pyrrolo-fused pyrimidine derivative 1
DMK5YJI HS Patented
DMK5YJI SN PMID28447479-Compound-2
DMK5YJI CP ELI LILLY AND COMPANY
DMK5YJI DT Small molecular drug
DMK5YJI PC 76285327
DMK5YJI MW 405.5
DMK5YJI FM C21H23N7O2
DMK5YJI IC InChI=1S/C21H23N7O2/c29-20(13-30-6-5-17-10-23-27-26-17)28-11-16-9-22-21(25-19(16)12-28)24-18-7-14-3-1-2-4-15(14)8-18/h1-4,9-10,18H,5-8,11-13H2,(H,22,24,25)(H,23,26,27)
DMK5YJI CS C1C(CC2=CC=CC=C21)NC3=NC=C4CN(CC4=N3)C(=O)COCCC5=NNN=C5
DMK5YJI IK ILOFWCAZDNILKY-UHFFFAOYSA-N
DMK5YJI IU 1-[2-(2,3-dihydro-1H-inden-2-ylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl]-2-[2-(2H-triazol-4-yl)ethoxy]ethanone
DMK5YJI DE Pain
DMHKRVL ID DMHKRVL
DMHKRVL DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMHKRVL HS Patented
DMHKRVL SN PMID27321640-Compound-54
DMHKRVL CP LUNDBECK & CO AS H [DKJOERGENSEN MORTEN [DKBRUUN ANNE TECHAU [DKRASMUSSEN LARS KYHN [DK]
DMHKRVL DT Small molecular drug
DMHKRVL PC 71295288
DMHKRVL MW 309.75
DMHKRVL FM C16H12ClN5
DMHKRVL IC InChI=1S/C16H12ClN5/c1-9-5-3-6-11(17)13(9)16-21-20-15-10(2)19-14-12(22(15)16)7-4-8-18-14/h3-8H,1-2H3
DMHKRVL CS CC1=C(C(=CC=C1)Cl)C2=NN=C3N2C4=C(N=CC=C4)N=C3C
DMHKRVL IK GBABEYRPJLOPCN-UHFFFAOYSA-N
DMHKRVL IU 3-(2-chloro-6-methylphenyl)-7-methyl-2,4,5,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene
DMUO25Y ID DMUO25Y
DMUO25Y DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2
DMUO25Y HS Patented
DMUO25Y SN PMID27321640-Compound-55
DMUO25Y CP LUNDBECK & CO AS H [DKJOERGENSEN MORTEN [DKBRUUN ANNE TECHAU [DKRASMUSSEN LARS KYHN [DK]
DMUO25Y DT Small molecular drug
DMUO25Y PC 71295314
DMUO25Y MW 295.72
DMUO25Y FM C15H10ClN5
DMUO25Y IC InChI=1S/C15H10ClN5/c1-9-14-19-20-15(10-4-2-3-5-11(10)16)21(14)13-6-7-17-8-12(13)18-9/h2-8H,1H3
DMUO25Y CS CC1=NC2=C(C=CN=C2)N3C1=NN=C3C4=CC=CC=C4Cl
DMUO25Y IK NUACZBDSBLGPGS-UHFFFAOYSA-N
DMUO25Y IU 3-(2-chlorophenyl)-7-methyl-2,4,5,8,11-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene
DMAEYNT ID DMAEYNT
DMAEYNT DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3
DMAEYNT HS Patented
DMAEYNT SN PMID27321640-Compound-56
DMAEYNT CP LUNDBECK & CO AS H [DKJOERGENSEN MORTEN [DKBRUUN ANNE TECHAU [DKRASMUSSEN LARS KYHN [DK]
DMAEYNT DT Small molecular drug
DMF0XI3 ID DMF0XI3
DMF0XI3 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 1
DMF0XI3 HS Patented
DMF0XI3 SN PMID25468267-Compound-34
DMF0XI3 CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DMF0XI3 DT Small molecular drug
DMF0XI3 PC 56589666
DMF0XI3 MW 355.4
DMF0XI3 FM C19H21N3O4
DMF0XI3 IC InChI=1S/C19H21N3O4/c1-21(2)10-11-26-19(24)17-14-8-7-13(18(23)20-25-3)12-16(14)22-9-5-4-6-15(17)22/h4-9,12H,10-11H2,1-3H3,(H,20,23)
DMF0XI3 CS CN(C)CCOC(=O)C1=C2C=CC=CN2C3=C1C=CC(=C3)C(=O)NOC
DMF0XI3 IK ZZDUDEMXVPDTNG-UHFFFAOYSA-N
DMF0XI3 IU 2-(dimethylamino)ethyl 3-(methoxycarbamoyl)pyrido[1,2-a]indole-10-carboxylate
DMWMV48 ID DMWMV48
DMWMV48 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 2
DMWMV48 HS Patented
DMWMV48 SN PMID25468267-Compound-35
DMWMV48 CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DMWMV48 DT Small molecular drug
DMCLKBY ID DMCLKBY
DMCLKBY DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 3
DMCLKBY HS Patented
DMCLKBY SN PMID25468267-Compound-36
DMCLKBY CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DMCLKBY DT Small molecular drug
DMCLKBY PC 66666946
DMCLKBY MW 381.5
DMCLKBY FM C22H27N3O3
DMCLKBY IC InChI=1S/C22H27N3O3/c1-23(2)12-10-20(26)16-8-9-17-19(15-16)25-11-6-5-7-18(25)21(17)22(27)28-14-13-24(3)4/h5-9,11,15H,10,12-14H2,1-4H3
DMCLKBY CS CN(C)CCC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)OCCN(C)C
DMCLKBY IK HQWDSOCFKBELNH-UHFFFAOYSA-N
DMCLKBY IU 2-(dimethylamino)ethyl 3-[3-(dimethylamino)propanoyl]pyrido[1,2-a]indole-10-carboxylate
DM09FOQ ID DM09FOQ
DM09FOQ DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 4
DM09FOQ HS Patented
DM09FOQ SN PMID25468267-Compound-37
DM09FOQ CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John VILE, Julia GELMAN, Danny M. GAI, Xinjie BARKER, Oliver Robin DEBOVES, Herv Jean Claude EAST, Stephen Peter BOESEN, Thomas
DM09FOQ DT Small molecular drug
DM09FOQ PC 66667765
DM09FOQ MW 294.3
DM09FOQ FM C18H18N2O2
DM09FOQ IC InChI=1S/C18H18N2O2/c1-12(21)13-7-8-14-16(10-13)20-9-5-4-6-15(20)18(14)17(22)11-19(2)3/h4-10H,11H2,1-3H3
DM09FOQ CS CC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)CN(C)C
DM09FOQ IK QISRGBAMCCXAKB-UHFFFAOYSA-N
DM09FOQ IU 1-(3-acetylpyrido[1,2-a]indol-10-yl)-2-(dimethylamino)ethanone
DMO3QDW ID DMO3QDW
DMO3QDW DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 5
DMO3QDW HS Patented
DMO3QDW SN PMID25468267-Compound-38
DMO3QDW CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John
DMO3QDW DT Small molecular drug
DMO3QDW PC 56589667
DMO3QDW MW 325.4
DMO3QDW FM C18H19N3O3
DMO3QDW IC InChI=1S/C18H19N3O3/c1-20(2)10-8-19-17(22)12-6-7-13-15(11-12)21-9-4-3-5-14(21)16(13)18(23)24/h3-7,9,11H,8,10H2,1-2H3,(H,19,22)(H,23,24)
DMO3QDW CS CN(C)CCNC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)O
DMO3QDW IK OMVKEKNQENTGRO-UHFFFAOYSA-N
DMO3QDW IU 3-[2-(dimethylamino)ethylcarbamoyl]pyrido[1,2-a]indole-10-carboxylic acid
DMRQ1ZB ID DMRQ1ZB
DMRQ1ZB DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 6
DMRQ1ZB HS Patented
DMRQ1ZB SN PMID25468267-Compound-39
DMRQ1ZB CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John
DMRQ1ZB DT Small molecular drug
DMRQ1ZB PC 66667268
DMRQ1ZB MW 312.32
DMRQ1ZB FM C17H16N2O4
DMRQ1ZB IC InChI=1S/C17H16N2O4/c1-23-9-7-18-16(20)11-5-6-12-14(10-11)19-8-3-2-4-13(19)15(12)17(21)22/h2-6,8,10H,7,9H2,1H3,(H,18,20)(H,21,22)
DMRQ1ZB CS COCCNC(=O)C1=CC2=C(C=C1)C(=C3N2C=CC=C3)C(=O)O
DMRQ1ZB IK HHIORJMMUBJBIN-UHFFFAOYSA-N
DMRQ1ZB IU 3-(2-methoxyethylcarbamoyl)pyrido[1,2-a]indole-10-carboxylic acid
DMXY3F0 ID DMXY3F0
DMXY3F0 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 7
DMXY3F0 HS Patented
DMXY3F0 SN PMID25468267-Compound-40
DMXY3F0 CP EPITHERAPEUTICS APS LABELLE, Marc MONTALBETTI, Christian A.G.N. MEARS, Richard John
DMXY3F0 DT Small molecular drug
DMXY3F0 PC 56643890
DMXY3F0 MW 298.29
DMXY3F0 FM C16H14N2O4
DMXY3F0 IC InChI=1S/C16H14N2O4/c19-8-6-17-15(20)10-4-5-11-13(9-10)18-7-2-1-3-12(18)14(11)16(21)22/h1-5,7,9,19H,6,8H2,(H,17,20)(H,21,22)
DMXY3F0 CS C1=CC2=C(C3=C(N2C=C1)C=C(C=C3)C(=O)NCCO)C(=O)O
DMXY3F0 IK OVCGCJPQKMNJNJ-UHFFFAOYSA-N
DMXY3F0 IU 3-(2-hydroxyethylcarbamoyl)pyrido[1,2-a]indole-10-carboxylic acid
DMHZLSO ID DMHZLSO
DMHZLSO DN Pyrido[2,3-d]pyrimidine derivative 1
DMHZLSO HS Patented
DMHZLSO SN PMID26161824-Compound-142
DMHZLSO DT Small molecular drug
DMHZLSO PC 25098114
DMHZLSO MW 457.8
DMHZLSO FM C23H19Cl3N4
DMHZLSO IC InChI=1S/C23H19Cl3N4/c1-23(2,3)22-29-20(27)17-11-16(12-4-6-13(24)7-5-12)19(28-21(17)30-22)15-9-8-14(25)10-18(15)26/h4-11H,1-3H3,(H2,27,28,29,30)
DMHZLSO CS CC(C)(C)C1=NC2=NC(=C(C=C2C(=N1)N)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl
DMHZLSO IK QVFUKBUINZLPLW-UHFFFAOYSA-N
DMHZLSO IU 2-tert-butyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)pyrido[2,3-d]pyrimidin-4-amine
DMHZLSO DE Obesity
DMSM53I ID DMSM53I
DMSM53I DN Pyrido[2,3-d]pyrimidine derivative 2
DMSM53I HS Patented
DMSM53I SN PMID26161824-Compound-143
DMSM53I DT Small molecular drug
DMSM53I DE Obesity
DMM8CL4 ID DMM8CL4
DMM8CL4 DN Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1
DMM8CL4 HS Patented
DMM8CL4 SN PMID27321640-Compound-18
DMM8CL4 CP PFIZER PRODUCTS INC. BEYER, Thomas, Arthur CHAMBERS, Robert, James LAM, Kelvin LI, Mei MORRELL, Andrew, Ian THOMPSON, David, Duane
DMM8CL4 DT Small molecular drug
DMRHAU4 ID DMRHAU4
DMRHAU4 DN Pyrido[3,2-d]pyrimidine derivative 2
DMRHAU4 HS Patented
DMRHAU4 SN PMID28270021-Compound-WO2012125668Example12
DMRHAU4 CP MERCK SHARP & DOHME CORP
DMRHAU4 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM6D1XR ID DM6D1XR
DM6D1XR DN Pyrido[3,2-d]pyrimidine derivative 3
DM6D1XR HS Patented
DM6D1XR SN PMID28270021-Compound-WO2012125668Example27
DM6D1XR CP MERCK SHARP & DOHME CORP
DM6D1XR DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMC8935 ID DMC8935
DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1
DMC8935 HS Patented
DMC8935 SN PMID27321640-Compound-37
DMC8935 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DMC8935 DT Small molecular drug
DM4CSBD ID DM4CSBD
DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2
DM4CSBD HS Patented
DM4CSBD SN PMID27321640-Compound-38
DM4CSBD CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DM4CSBD DT Small molecular drug
DMOTGEK ID DMOTGEK
DMOTGEK DN Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1
DMOTGEK HS Patented
DMOTGEK SN PMID25684022-Compound-WO2010019637
DMOTGEK CP GLAXOSMITHKLINE LLC ATKINSON, Francis, Louis AXTEN, Jeffrey, Michael CICHY-KNIGHT, Maria MOORE, Michael, Lee PATEI, Vipulkumar, Kantibhai TIAN, Xinrong WELLAWAY, Christopher, Roland DUNN, Allison, K
DMOTGEK DT Small molecular drug
DMOTGEK DE Solid tumour/cancer; Metastatic cancer
DMP6TUQ ID DMP6TUQ
DMP6TUQ DN Pyridoindole derivative 1
DMP6TUQ HS Patented
DMP6TUQ SN PMID25656651-Compound-22a
DMP6TUQ CP UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA UNIVERSITE DE GENEVE UNIVERSITE CLAUDE BERNARD LYON 1
DMP6TUQ DT Small molecular drug
DMP6TUQ PC 46183444
DMP6TUQ MW 432.5
DMP6TUQ FM C28H24N4O
DMP6TUQ IC InChI=1S/C28H24N4O/c1-2-4-20(5-3-1)6-7-21-16-25-24-17-22(8-10-27(24)31-28(25)30-18-21)26-11-9-23(19-29-26)32-12-14-33-15-13-32/h1-11,16-19H,12-15H2,(H,30,31)/b7-6+
DMP6TUQ CS C1COCCN1C2=CN=C(C=C2)C3=CC4=C(C=C3)NC5=C4C=C(C=N5)/C=C/C6=CC=CC=C6
DMP6TUQ IK RPPRUVFNILNTHG-VOTSOKGWSA-N
DMP6TUQ IU 4-[6-[3-[(E)-2-phenylethenyl]-9H-pyrido[2,3-b]indol-6-yl]pyridin-3-yl]morpholine
DMIXK7Y ID DMIXK7Y
DMIXK7Y DN Pyridoindole derivative 2
DMIXK7Y HS Patented
DMIXK7Y SN PMID25656651-Compound-22b
DMIXK7Y CP UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA UNIVERSITE DE GENEVE UNIVERSITE CLAUDE BERNARD LYON 1
DMIXK7Y DT Small molecular drug
DMIXK7Y PC 58514479
DMIXK7Y MW 270.3
DMIXK7Y FM C19H14N2
DMIXK7Y IC InChI=1S/C19H14N2/c1-2-6-14(7-3-1)10-11-15-12-17-16-8-4-5-9-18(16)21-19(17)20-13-15/h1-13H,(H,20,21)/b11-10+
DMIXK7Y CS C1=CC=C(C=C1)/C=C/C2=CC3=C(NC4=CC=CC=C43)N=C2
DMIXK7Y IK UNSLEGIUCMXDGG-ZHACJKMWSA-N
DMIXK7Y IU 3-[(E)-2-phenylethenyl]-9H-pyrido[2,3-b]indole
DMONCT1 ID DMONCT1
DMONCT1 DN Pyridoindole derivative 3
DMONCT1 HS Patented
DMONCT1 SN PMID25656651-Compound-22c
DMONCT1 CP UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA UNIVERSITE DE GENEVE UNIVERSITE CLAUDE BERNARD LYON 1
DMONCT1 DT Small molecular drug
DMONCT1 PC 66765887
DMONCT1 MW 274.3
DMONCT1 FM C18H14N2O
DMONCT1 IC InChI=1S/C18H14N2O/c1-21-13-8-6-12(7-9-13)14-10-11-19-18-17(14)15-4-2-3-5-16(15)20-18/h2-11H,1H3,(H,19,20)
DMONCT1 CS COC1=CC=C(C=C1)C2=C3C4=CC=CC=C4NC3=NC=C2
DMONCT1 IK PJJCQNCRSXRPLV-UHFFFAOYSA-N
DMONCT1 IU 4-(4-methoxyphenyl)-9H-pyrido[2,3-b]indole
DMTZK6V ID DMTZK6V
DMTZK6V DN Pyridopyrimidine derivative 1
DMTZK6V HS Patented
DMTZK6V SN PMID28594589-Compound-TABLE3c10
DMTZK6V CP LUPIN LIMITED
DMTZK6V DT Small molecular drug
DMTZK6V PC 118918608
DMTZK6V MW 604.4
DMTZK6V FM C24H22FIN6O4
DMTZK6V IC InChI=1S/C24H22FIN6O4/c1-12-20-19(21(30(2)22(12)34)29-17-8-7-13(26)9-16(17)25)23(35)31(3)24(36)32(20)15-6-4-5-14(10-15)28-11-18(27)33/h4-10,28-29H,11H2,1-3H3,(H2,27,33)
DMTZK6V CS CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NCC(=O)N)C
DMTZK6V IK KAVFKXKOUQPGQL-UHFFFAOYSA-N
DMTZK6V IU 2-[3-[5-(2-fluoro-4-iodoanilino)-3,6,8-trimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]anilino]acetamide
DMZ6TSD ID DMZ6TSD
DMZ6TSD DN Pyridopyrimidinone derivative 1
DMZ6TSD HS Patented
DMZ6TSD SN PMID28117607-Compound-45
DMZ6TSD CP Oscotec, Inc., S. Korea. assignee
DMZ6TSD DT Small molecular drug
DMUF63N ID DMUF63N
DMUF63N DN Pyridopyrimidinone derivative 2
DMUF63N HS Patented
DMUF63N SN PMID28117607-Compound-46
DMUF63N CP Oscotec, Inc., S. Korea. assignee
DMUF63N DT Small molecular drug
DMHSDUR ID DMHSDUR
DMHSDUR DN Pyridopyrimidinone derivative 3
DMHSDUR HS Patented
DMHSDUR SN PMID28117607-Compound-47
DMHSDUR CP Oscotec, Inc., S. Korea. assignee
DMHSDUR DT Small molecular drug
DM71UYI ID DM71UYI
DM71UYI DN Pyridotriazolopyrimidine derivative 1
DM71UYI HS Patented
DM71UYI SN PMID26161824-Compound-144
DM71UYI DT Small molecular drug
DM71UYI PC 25095251
DM71UYI MW 497.9
DM71UYI FM C26H20ClN7O2
DM71UYI IC InChI=1S/C26H20ClN7O2/c1-26(2,3)24-30-22-18(23-31-32-25(35)34(23)24)12-17(20(29-22)16-6-4-5-7-19(16)27)14-8-10-15(11-9-14)21-28-13-36-33-21/h4-13H,1-3H3,(H,32,35)
DM71UYI CS CC(C)(C)C1=NC2=NC(=C(C=C2C3=NNC(=O)N31)C4=CC=C(C=C4)C5=NOC=N5)C6=CC=CC=C6Cl
DM71UYI IK CHQLSHSXSIIVFC-UHFFFAOYSA-N
DM71UYI IU 7-tert-butyl-11-(2-chlorophenyl)-12-[4-(1,2,4-oxadiazol-3-yl)phenyl]-3,4,6,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(13),2,7,9,11-pentaen-5-one
DM71UYI DE Obesity
DM0VOY9 ID DM0VOY9
DM0VOY9 DN Pyridotriazolopyrimidine derivative 2
DM0VOY9 HS Patented
DM0VOY9 SN PMID26161824-Compound-145
DM0VOY9 DT Small molecular drug
DM0VOY9 PC 25098092
DM0VOY9 MW 464.3
DM0VOY9 FM C24H19Cl2N5O
DM0VOY9 IC InChI=1S/C24H19Cl2N5O/c1-24(2,3)22-28-20-17(21-29-30-23(32)31(21)22)12-16(13-8-10-14(25)11-9-13)19(27-20)15-6-4-5-7-18(15)26/h4-12H,1-3H3,(H,30,32)
DM0VOY9 CS CC(C)(C)C1=NC2=NC(=C(C=C2C3=NNC(=O)N31)C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl
DM0VOY9 IK RCDDRZOJAVJMCL-UHFFFAOYSA-N
DM0VOY9 IU 7-tert-butyl-11-(2-chlorophenyl)-12-(4-chlorophenyl)-3,4,6,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(13),2,7,9,11-pentaen-5-one
DM0VOY9 DE Obesity
DMYVCTD ID DMYVCTD
DMYVCTD DN Pyridotriazolopyrimidine derivative 3
DMYVCTD HS Patented
DMYVCTD SN PMID26161824-Compound-146
DMYVCTD DT Small molecular drug
DMYVCTD PC 24944528
DMYVCTD MW 489.4
DMYVCTD FM C25H18Cl2N6O
DMYVCTD IC InChI=1S/C25H18Cl2N6O/c1-25(2,3)23-30-21-18(22-31-32-24(34)33(22)23)11-17(14-5-7-15(26)8-6-14)20(29-21)16-9-4-13(12-28)10-19(16)27/h4-11H,1-3H3,(H,32,34)
DMYVCTD CS CC(C)(C)C1=NC2=NC(=C(C=C2C3=NNC(=O)N31)C4=CC=C(C=C4)Cl)C5=C(C=C(C=C5)C#N)Cl
DMYVCTD IK CSEQBOCMDXHKIF-UHFFFAOYSA-N
DMYVCTD IU 4-[7-tert-butyl-12-(4-chlorophenyl)-5-oxo-3,4,6,8,10-pentazatricyclo[7.4.0.02,6]trideca-1(13),2,7,9,11-pentaen-11-yl]-3-chlorobenzonitrile
DMYVCTD DE Obesity
DMUTE5S ID DMUTE5S
DMUTE5S DN Pyridyl compound 1
DMUTE5S HS Patented
DMUTE5S SN PMID28454500-Compound-15
DMUTE5S CP TRUSTEES OF DARTMOUTH COLLEGE
DMUTE5S DT Small molecular drug
DMD6GNO ID DMD6GNO
DMD6GNO DN Pyrimidine benzenesulfonamide derivative 1
DMD6GNO HS Patented
DMD6GNO SN PMID27172114-Compound-62
DMD6GNO CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMD6GNO DT Small molecular drug
DMD6GNO PC 71282692
DMD6GNO MW 401.9
DMD6GNO FM C19H16ClN3O3S
DMD6GNO IC InChI=1S/C19H16ClN3O3S/c20-16-10-13(6-9-18(16)26-14-7-8-14)17-11-19(22-12-21-17)23-27(24,25)15-4-2-1-3-5-15/h1-6,9-12,14H,7-8H2,(H,21,22,23)
DMD6GNO CS C1CC1OC2=C(C=C(C=C2)C3=CC(=NC=N3)NS(=O)(=O)C4=CC=CC=C4)Cl
DMD6GNO IK AJZPXSIAEFVSBW-UHFFFAOYSA-N
DMD6GNO IU N-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]benzenesulfonamide
DMVQ4NS ID DMVQ4NS
DMVQ4NS DN Pyrimidine benzenesulfonamide derivative 2
DMVQ4NS HS Patented
DMVQ4NS SN PMID27172114-Compound-63
DMVQ4NS CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMVQ4NS DT Small molecular drug
DMVQ4NS PC 71285521
DMVQ4NS MW 419.9
DMVQ4NS FM C19H15ClFN3O3S
DMVQ4NS IC InChI=1S/C19H15ClFN3O3S/c20-16-9-12(1-8-18(16)27-14-4-5-14)17-10-19(23-11-22-17)24-28(25,26)15-6-2-13(21)3-7-15/h1-3,6-11,14H,4-5H2,(H,22,23,24)
DMVQ4NS CS C1CC1OC2=C(C=C(C=C2)C3=CC(=NC=N3)NS(=O)(=O)C4=CC=C(C=C4)F)Cl
DMVQ4NS IK NHNNNQMEILXDMV-UHFFFAOYSA-N
DMVQ4NS IU N-[6-(3-chloro-4-cyclopropyloxyphenyl)pyrimidin-4-yl]-4-fluorobenzenesulfonamide
DMJ71Q0 ID DMJ71Q0
DMJ71Q0 DN Pyrimidine benzenesulfonamide derivative 3
DMJ71Q0 HS Patented
DMJ71Q0 SN PMID27172114-Compound-64
DMJ71Q0 CP COURTNEY, Stephen Martin PRIME, Michael MITCHELL, William BROWN, Christopher John DE AGUIAR PENA, Paula C. JOHNSON, Peter DOMINGUEZ, Celia TOLEDO-SHERMAN, Leticia M. MUNOZ, Ignacio
DMJ71Q0 DT Small molecular drug
DMN9VQM ID DMN9VQM
DMN9VQM DN Pyrimidine derivative 1
DMN9VQM HS Patented
DMN9VQM SN PMID25539043-Compound-WO2012020567Example17
DMN9VQM CP RAQUALIA PHARMA INC
DMN9VQM DT Small molecular drug
DMBEZUY ID DMBEZUY
DMBEZUY DN Pyrimidine derivative 10
DMBEZUY HS Patented
DMBEZUY SN PMID28621580-Compound-WO2014000686c53
DMBEZUY CP CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY LI, Jianqi WANG, Wenya ZHOU, Bin XIE, Peng DU, Zhenxin LU, Xiulian WENG, Zhijie ZHANG, Qingwei HUANG, Daowei
DMBEZUY DT Small molecular drug
DMJ4QD5 ID DMJ4QD5
DMJ4QD5 DN Pyrimidine derivative 11
DMJ4QD5 HS Patented
DMJ4QD5 SN PMID28621580-Compound-WO2014139458c54
DMJ4QD5 CP CISEN PHARMACEUTICAL CO., LTD. SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
DMJ4QD5 DT Small molecular drug
DMMBFQH ID DMMBFQH
DMMBFQH DN Pyrimidine derivative 12
DMMBFQH HS Patented
DMMBFQH SN PMID28621580-Compound-WO2014184778c56
DMMBFQH CP NOVARTIS AG GLAENZEL, Ulrike NUFER, Robert
DMMBFQH DT Small molecular drug
DMASGR1 ID DMASGR1
DMASGR1 DN Pyrimidine derivative 13
DMASGR1 HS Patented
DMASGR1 SN PMID28621580-Compound-WO2014184778c57
DMASGR1 CP NOVARTIS AG GLAENZEL, Ulrike NUFER, Robert
DMASGR1 DT Small molecular drug
DM7B2XG ID DM7B2XG
DM7B2XG DN Pyrimidine derivative 14
DM7B2XG HS Patented
DM7B2XG SN PMID28621580-Compound-WO2014197313c51
DM7B2XG CP KALA PHARMACEUTICALS, INC
DM7B2XG DT Small molecular drug
DMV2Y84 ID DMV2Y84
DMV2Y84 DN Pyrimidine derivative 15
DMV2Y84 HS Patented
DMV2Y84 SN PMID28621580-Compound-WO2015123722c58
DMV2Y84 CP BIONOMICS LIMITED
DMV2Y84 DT Small molecular drug
DM3GYPD ID DM3GYPD
DM3GYPD DN Pyrimidine derivative 16
DM3GYPD HS Patented
DM3GYPD SN PMID27019002-Compound-38
DM3GYPD CP CELGENE QUANTICEL RESEARCH, INC
DM3GYPD DT Small molecular drug
DM7YA9Z ID DM7YA9Z
DM7YA9Z DN Pyrimidine derivative 17
DM7YA9Z HS Patented
DM7YA9Z SN PMID27019002-Compound-39
DM7YA9Z CP CELGENE QUANTICEL RESEARCH, INC
DM7YA9Z DT Small molecular drug
DMIZTKS ID DMIZTKS
DMIZTKS DN Pyrimidine derivative 18
DMIZTKS HS Patented
DMIZTKS SN PMID27019002-Compound-40
DMIZTKS CP CELGENE QUANTICEL RESEARCH, INC
DMIZTKS DT Small molecular drug
DMLPO0K ID DMLPO0K
DMLPO0K DN Pyrimidine derivative 19
DMLPO0K HS Patented
DMLPO0K SN PMID25726713-Compound-67
DMLPO0K DT Small molecular drug
DMS8OR3 ID DMS8OR3
DMS8OR3 DN Pyrimidine derivative 2
DMS8OR3 HS Patented
DMS8OR3 SN PMID28627961-Compound-34
DMS8OR3 CP GLENMARK PHARMACEUTICALS S.A
DMS8OR3 DT Small molecular drug
DMS8OR3 PC 118038559
DMS8OR3 MW 482.9
DMS8OR3 FM C22H19ClF4N4O2
DMS8OR3 IC InChI=1S/C22H19ClF4N4O2/c1-21(2,3)19(32)29-10-12-4-6-13(23)17(18(12)24)15-8-14(30-20(33)31-15)11-5-7-16(28-9-11)22(25,26)27/h4-9H,10H2,1-3H3,(H,29,32)(H,30,31,33)
DMS8OR3 CS CC(C)(C)C(=O)NCC1=C(C(=C(C=C1)Cl)C2=CC(=NC(=O)N2)C3=CN=C(C=C3)C(F)(F)F)F
DMS8OR3 IK CHFIXQQTHCXPKE-UHFFFAOYSA-N
DMS8OR3 IU N-[[4-chloro-2-fluoro-3-[2-oxo-4-[6-(trifluoromethyl)pyridin-3-yl]-1H-pyrimidin-6-yl]phenyl]methyl]-2,2-dimethylpropanamide
DMQUEDK ID DMQUEDK
DMQUEDK DN Pyrimidine derivative 20
DMQUEDK HS Patented
DMQUEDK SN PMID25726713-Compound-68
DMQUEDK DT Small molecular drug
DMELA2F ID DMELA2F
DMELA2F DN Pyrimidine derivative 21
DMELA2F HS Patented
DMELA2F SN PMID25726713-Compound-69
DMELA2F DT Small molecular drug
DMN64AK ID DMN64AK
DMN64AK DN Pyrimidine derivative 22
DMN64AK HS Patented
DMN64AK SN PMID25726713-Compound-70
DMN64AK CP ZHANG, Xiaohu
DMN64AK DT Small molecular drug
DM5MLQU ID DM5MLQU
DM5MLQU DN Pyrimidine derivative 23
DM5MLQU HS Patented
DM5MLQU SN PMID26609882-Compound-50
DM5MLQU CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM5MLQU DT Small molecular drug
DMOQ726 ID DMOQ726
DMOQ726 DN Pyrimidine derivative 24
DMOQ726 HS Patented
DMOQ726 SN PMID26609882-Compound-51
DMOQ726 CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DMOQ726 DT Small molecular drug
DM51MFS ID DM51MFS
DM51MFS DN Pyrimidine derivative 25
DM51MFS HS Patented
DM51MFS SN PMID26609882-Compound-52
DM51MFS CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM51MFS DT Small molecular drug
DM90WKN ID DM90WKN
DM90WKN DN Pyrimidine derivative 26
DM90WKN HS Patented
DM90WKN SN PMID26609882-Compound-53
DM90WKN CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM90WKN DT Small molecular drug
DMIQSDW ID DMIQSDW
DMIQSDW DN Pyrimidine derivative 27
DMIQSDW HS Patented
DMIQSDW SN PMID26609882-Compound-54
DMIQSDW CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DMIQSDW DT Small molecular drug
DM1D2AS ID DM1D2AS
DM1D2AS DN Pyrimidine derivative 28
DM1D2AS HS Patented
DM1D2AS SN PMID26609882-Compound-55
DM1D2AS CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DM1D2AS DT Small molecular drug
DMVOYJ8 ID DMVOYJ8
DMVOYJ8 DN Pyrimidine derivative 29
DMVOYJ8 HS Patented
DMVOYJ8 SN PMID26609882-Compound-56
DMVOYJ8 CP JANSSEN PHARMACEUTICA N.V. DVORAK, Curt, A. RUDOLPH, Dale, A. SHIREMAN, Brock, TJanssen Pharmaceutica NV
DMVOYJ8 DT Small molecular drug
DMC3E8M ID DMC3E8M
DMC3E8M DN Pyrimidine derivative 3
DMC3E8M HS Patented
DMC3E8M SN PMID25684022-Compound-WO2011076327
DMC3E8M CP MERCK PATENT GMBH WUCHERER-PLIETKER, Margarita ESDAR, Christina
DMC3E8M DT Small molecular drug
DMC3E8M DE Solid tumour/cancer; Metastatic cancer
DMTQBUD ID DMTQBUD
DMTQBUD DN Pyrimidine derivative 30
DMTQBUD HS Patented
DMTQBUD SN PMID25482888-Compound-32
DMTQBUD DT Small molecular drug
DMOJTLU ID DMOJTLU
DMOJTLU DN Pyrimidine derivative 31
DMOJTLU HS Patented
DMOJTLU SN PMID25482888-Compound-33
DMOJTLU DT Small molecular drug
DMCUQFG ID DMCUQFG
DMCUQFG DN Pyrimidine derivative 32
DMCUQFG HS Patented
DMCUQFG SN PMID25482888-Compound-66
DMCUQFG DT Small molecular drug
DMCUQFG PC 71731242
DMCUQFG MW 418.5
DMCUQFG FM C23H26N6O2
DMCUQFG IC InChI=1S/C23H26N6O2/c1-3-4-12-28-21(27-11-7-8-17(24)14-27)13-22(30)29(23(28)31)15-20-25-16(2)18-9-5-6-10-19(18)26-20/h5-6,9-10,13,17H,7-8,11-12,14-15,24H2,1-2H3/t17-/m1/s1
DMCUQFG CS CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=CC=CC=C3C(=N2)C)N4CCC[C@H](C4)N
DMCUQFG IK GHHYMLIQMIXJDE-QGZVFWFLSA-N
DMCUQFG IU 6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(4-methylquinazolin-2-yl)methyl]pyrimidine-2,4-dione
DMWL5V0 ID DMWL5V0
DMWL5V0 DN Pyrimidine derivative 33
DMWL5V0 HS Patented
DMWL5V0 SN PMID25482888-Compound-67
DMWL5V0 DT Small molecular drug
DMWL5V0 PC 71731606
DMWL5V0 MW 437.9
DMWL5V0 FM C23H24ClN5O2
DMWL5V0 IC InChI=1S/C23H24ClN5O2/c1-2-3-11-28-21(27-10-4-5-18(25)14-27)13-22(30)29(23(28)31)15-19-9-7-16-6-8-17(24)12-20(16)26-19/h6-9,12-13,18H,4-5,10-11,14-15,25H2,1H3/t18-/m1/s1
DMWL5V0 CS CC#CCN1C(=CC(=O)N(C1=O)CC2=NC3=C(C=CC(=C3)Cl)C=C2)N4CCC[C@H](C4)N
DMWL5V0 IK MRWKTDPDQXVRSA-GOSISDBHSA-N
DMWL5V0 IU 6-[(3R)-3-aminopiperidin-1-yl]-1-but-2-ynyl-3-[(7-chloroquinolin-2-yl)methyl]pyrimidine-2,4-dione
DM4192V ID DM4192V
DM4192V DN Pyrimidine derivative 34
DM4192V HS Patented
DM4192V SN PMID26118988-Compound-27
DM4192V CP CHIESI FARMACEUTICI S.p.A. EDWARDS, Christine KULAGOWSKI, Janusz FINCH, Harry
DM4192V DT Small molecular drug
DM8K6IS ID DM8K6IS
DM8K6IS DN Pyrimidine derivative 4
DM8K6IS HS Patented
DM8K6IS SN PMID28621580-Compound-US20080255172c50
DM8K6IS CP Hutchison MediPharma Enterprises Limited, Bahamas
DM8K6IS DT Small molecular drug
DMNET19 ID DMNET19
DMNET19 DN Pyrimidine derivative 5
DMNET19 HS Patented
DMNET19 SN PMID28621580-Compound-US20160096832c60
DMNET19 CP Allergan, Inc
DMNET19 DT Small molecular drug
DMNET19 DE Neurodegenerative disorder; Fibrosis; Blood vessel proliferative disorder
DMBAHYO ID DMBAHYO
DMBAHYO DN Pyrimidine derivative 6
DMBAHYO HS Patented
DMBAHYO SN PMID28621580-Compound-US20160096837c61
DMBAHYO CP Allergan, Inc
DMBAHYO DT Small molecular drug
DMBAHYO DE Neurodegenerative disorder; Fibrosis; Blood vessel proliferative disorder
DMF6DUT ID DMF6DUT
DMF6DUT DN Pyrimidine derivative 7
DMF6DUT HS Patented
DMF6DUT SN PMID28621580-Compound-US20169233968c59
DMF6DUT CP Allergan, Inc
DMF6DUT DT Small molecular drug
DMF6DUT DE Neurodegenerative disorder; Fibrosis; Blood vessel proliferative disorder
DMVW25O ID DMVW25O
DMVW25O DN Pyrimidine derivative 8
DMVW25O HS Patented
DMVW25O SN PMID28621580-Compound-US20169296747c52
DMVW25O CP Allergan, Inc
DMVW25O DT Small molecular drug
DMV6U9Y ID DMV6U9Y
DMV6U9Y DN Pyrimidine derivative 9
DMV6U9Y HS Patented
DMV6U9Y SN PMID28621580-Compound-WO2010066684c55
DMV6U9Y CP NOVARTIS AG ARTMAN III, Gerald David ELLIOTT, Jason Matthew JI, Nan LIU, Donglei MA, Fupeng MAINOLFI, Nello MEREDITH, Erik MIRANDA, Karl POWERS, James J. RAO, Chang
DMV6U9Y DT Small molecular drug
DMT6O1N ID DMT6O1N
DMT6O1N DN Pyrimidine-4(3H)-one derivative 1
DMT6O1N HS Patented
DMT6O1N SN PMID25470667-Compound-Figure6-20
DMT6O1N CP MSD K.K. ARAKAWA, Keisuke ITO, Yoshiki KAWAMOTO, Hiroshi SAKAKI, Junichi SHIMAMURA, Tadashi
DMT6O1N DT Small molecular drug
DML4OYQ ID DML4OYQ
DML4OYQ DN Pyrimidinedione derivative 1
DML4OYQ HS Patented
DML4OYQ SN PMID25482888-Compound-45
DML4OYQ DT Small molecular drug
DM1I7Z6 ID DM1I7Z6
DM1I7Z6 DN Pyrimidinone derivative 1
DM1I7Z6 HS Patented
DM1I7Z6 SN PMID25684022-Compound-WO2010007114
DM1I7Z6 CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH ENGELHARDT, Harald BOEHMELT, Guido KOFINK, Christiane KUHN, Daniel McCONNELL, Darryl STADTMUELLER, Heinz
DM1I7Z6 DT Small molecular drug
DM1I7Z6 DE Solid tumour/cancer; Metastatic cancer
DMDQNKW ID DMDQNKW
DMDQNKW DN Pyrimidinone derivative 4
DMDQNKW HS Patented
DMDQNKW SN PMID26118988-Compound-23
DMDQNKW DT Small molecular drug
DMDQNKW PC 24752875
DMDQNKW MW 982.9
DMDQNKW FM C51H36F6N10O5
DMDQNKW IC InChI=1S/C51H36F6N10O5/c1-29-40(44-17-19-62-66(44)35-13-9-31(25-58)10-14-35)23-42(48(71)64(29)37-7-3-5-33(21-37)50(52,53)54)46(69)60-27-39(68)28-61-47(70)43-24-41(45-18-20-63-67(45)36-15-11-32(26-59)12-16-36)30(2)65(49(43)72)38-8-4-6-34(22-38)51(55,56)57/h3-24,39,68H,27-28H2,1-2H3,(H,60,69)(H,61,70)
DMDQNKW CS CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC(CNC(=O)C3=CC(=C(N(C3=O)C4=CC=CC(=C4)C(F)(F)F)C)C5=CC=NN5C6=CC=C(C=C6)C#N)O)C7=CC=NN7C8=CC=C(C=C8)C#N
DMDQNKW IK KYPHYLQIJUHQAO-UHFFFAOYSA-N
DMDQNKW IU 5-[2-(4-cyanophenyl)pyrazol-3-yl]-N-[3-[[5-[2-(4-cyanophenyl)pyrazol-3-yl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carbonyl]amino]-2-hydroxypropyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide
DMLFY57 ID DMLFY57
DMLFY57 DN Pyrimidinone derivative 5
DMLFY57 HS Patented
DMLFY57 SN PMID28447479-Compound-6
DMLFY57 DT Small molecular drug
DMLFY57 PC 137426105
DMLFY57 MW 419.9
DMLFY57 FM C21H26ClN3O4
DMLFY57 IC InChI=1S/C21H26ClN3O4/c1-2-3-4-6-18-24-17(15-8-10-16(22)11-9-15)13-20(27)25(18)14-19(26)23-12-5-7-21(28)29/h8-11,13H,2-7,12,14H2,1H3,(H,23,26)(H,28,29)
DMLFY57 CS CCCCCC1=NC(=CC(=O)N1CC(=O)NCCCC(=O)O)C2=CC=C(C=C2)Cl
DMLFY57 IK GMCBZWCKSMXZFV-UHFFFAOYSA-N
DMLFY57 IU 4-[[2-[4-(4-chlorophenyl)-6-oxo-2-pentylpyrimidin-1-yl]acetyl]amino]butanoic acid
DMYKHQ8 ID DMYKHQ8
DMYKHQ8 DN Pyrimidinyl compound 1
DMYKHQ8 HS Patented
DMYKHQ8 SN PMID26293650-Compound-36
DMYKHQ8 CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMYKHQ8 DT Small molecular drug
DMYKHQ8 PC 56646025
DMYKHQ8 MW 384.4
DMYKHQ8 FM C22H20N6O
DMYKHQ8 IC InChI=1S/C22H20N6O/c23-14-17-12-15(6-7-20(17)28-10-1-2-11-28)19-8-9-25-22(27-19)26-18-5-3-4-16(13-18)21(24)29/h3-9,12-13H,1-2,10-11H2,(H2,24,29)(H,25,26,27)
DMYKHQ8 CS C1CCN(C1)C2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C(=O)N)C#N
DMYKHQ8 IK KPMCSBDURLKXIY-UHFFFAOYSA-N
DMYKHQ8 IU 3-[[4-(3-cyano-4-pyrrolidin-1-ylphenyl)pyrimidin-2-yl]amino]benzamide
DM9TW5O ID DM9TW5O
DM9TW5O DN Pyrimidinyl compound 2
DM9TW5O HS Patented
DM9TW5O SN PMID26293650-Compound-37
DM9TW5O CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DM9TW5O DT Small molecular drug
DMOE2FZ ID DMOE2FZ
DMOE2FZ DN Pyrimidinyl compound 3
DMOE2FZ HS Patented
DMOE2FZ SN PMID26293650-Compound-38
DMOE2FZ CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMOE2FZ DT Small molecular drug
DM53O9Y ID DM53O9Y
DM53O9Y DN Pyrimidinyl compound 4
DM53O9Y HS Patented
DM53O9Y SN PMID26293650-Compound-39
DM53O9Y CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DM53O9Y DT Small molecular drug
DM53O9Y PC 56646218
DM53O9Y MW 396.4
DM53O9Y FM C23H20N6O
DM53O9Y IC InChI=1S/C23H20N6O/c24-14-17-11-15(3-6-21(17)29-9-1-2-10-29)20-7-8-25-23(28-20)26-18-4-5-19-16(12-18)13-22(30)27-19/h3-8,11-12H,1-2,9-10,13H2,(H,27,30)(H,25,26,28)
DM53O9Y CS C1CCN(C1)C2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC5=C(C=C4)NC(=O)C5)C#N
DM53O9Y IK DHPSFJYFPJRCTN-UHFFFAOYSA-N
DM53O9Y IU 5-[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile
DMCKBGM ID DMCKBGM
DMCKBGM DN Pyrimidinyl compound 5
DMCKBGM HS Patented
DMCKBGM SN PMID26293650-Compound-40
DMCKBGM CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMCKBGM DT Small molecular drug
DMCKBGM PC 56593541
DMCKBGM MW 427.5
DMCKBGM FM C24H25N7O
DMCKBGM IC InChI=1S/C24H25N7O/c25-16-19-15-18(3-5-22(19)30-9-1-2-10-30)21-7-8-26-24(29-21)28-20-4-6-23(27-17-20)31-11-13-32-14-12-31/h3-8,15,17H,1-2,9-14H2,(H,26,28,29)
DMCKBGM CS C1CCN(C1)C2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CN=C(C=C4)N5CCOCC5)C#N
DMCKBGM IK BEWCKABPPSBSRH-UHFFFAOYSA-N
DMCKBGM IU 5-[2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile
DML2E8S ID DML2E8S
DML2E8S DN Pyrimidinyl compound 6
DML2E8S HS Patented
DML2E8S SN PMID26293650-Compound-41
DML2E8S CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DML2E8S DT Small molecular drug
DML2E8S PC 66685711
DML2E8S MW 401.4
DML2E8S FM C21H19N7O2
DML2E8S IC InChI=1S/C21H19N7O2/c1-13(29)25-20-5-3-16(10-24-20)26-21-23-7-6-18(27-21)14-2-4-19(15(8-14)9-22)28-11-17(30)12-28/h2-8,10,17,30H,11-12H2,1H3,(H,23,26,27)(H,24,25,29)
DML2E8S CS CC(=O)NC1=NC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)N4CC(C4)O)C#N
DML2E8S IK ULOABNKVPRZZBK-UHFFFAOYSA-N
DML2E8S IU N-[5-[[4-[3-cyano-4-(3-hydroxyazetidin-1-yl)phenyl]pyrimidin-2-yl]amino]pyridin-2-yl]acetamide
DMMYW2L ID DMMYW2L
DMMYW2L DN Pyrimidinyl compound 7
DMMYW2L HS Patented
DMMYW2L SN PMID26293650-Compound-42
DMMYW2L CP DOMAINEX LIMITED PERRIOR, Trevor, Robert NEWTON, Gary, Karl STEWART, Mark, Richard AQIL, Rehan
DMMYW2L DT Small molecular drug
DMMYW2L PC 89837438
DMMYW2L MW 446.5
DMMYW2L FM C24H27FN8
DMMYW2L IC InChI=1S/C24H27FN8/c1-32(2)12-10-27-23-6-4-20(15-29-23)30-24-28-9-7-21(31-24)17-3-5-22(18(13-17)14-26)33-11-8-19(25)16-33/h3-7,9,13,15,19H,8,10-12,16H2,1-2H3,(H,27,29)(H,28,30,31)
DMMYW2L CS CN(C)CCNC1=NC=C(C=C1)NC2=NC=CC(=N2)C3=CC(=C(C=C3)N4CCC(C4)F)C#N
DMMYW2L IK NGQHJZXAWIBXQH-UHFFFAOYSA-N
DMMYW2L IU 5-[2-[[6-[2-(dimethylamino)ethylamino]pyridin-3-yl]amino]pyrimidin-4-yl]-2-(3-fluoropyrrolidin-1-yl)benzonitrile
DMZ83P1 ID DMZ83P1
DMZ83P1 DN Pyrimidinyl ethylenediamine derivative 1
DMZ83P1 HS Patented
DMZ83P1 SN PMID26413912-Compound-79
DMZ83P1 CP JANSSEN PHARMACEUTICA NV HAWRYLUK, Natalie, A. BREITENBUCHER, J., Guy JONES, William, M. CHAMBERS, Alison, L. KEITH, John, M. SEIERSTAD, Mark
DMZ83P1 DT Small molecular drug
DMZ83P1 PC 51037025
DMZ83P1 MW 428.8
DMZ83P1 FM C19H14ClF5N4
DMZ83P1 IC InChI=1S/C19H14ClF5N4/c20-13-5-11(1-3-12(13)19(23,24)25)17-7-18(29-9-28-17)27-8-16(26)10-2-4-14(21)15(22)6-10/h1-7,9,16H,8,26H2,(H,27,28,29)/t16-/m0/s1
DMZ83P1 CS C1=CC(=C(C=C1C2=CC(=NC=N2)NC[C@@H](C3=CC(=C(C=C3)F)F)N)Cl)C(F)(F)F
DMZ83P1 IK WKWUCPXAFUCNHR-INIZCTEOSA-N
DMZ83P1 IU (1R)-N'-[6-[3-chloro-4-(trifluoromethyl)phenyl]pyrimidin-4-yl]-1-(3,4-difluorophenyl)ethane-1,2-diamine
DM72T58 ID DM72T58
DM72T58 DN Pyrimidinyl pyrazolamine derivative 1
DM72T58 HS Patented
DM72T58 SN PMID25656651-Compound-14
DM72T58 CP IRM LLC NOVARTIS AG ALBAUGH, Pamela CHOPIUK, Gregory S. DING, Qiang HUANG, Shenlin LIU, Zuosheng PAN, Shifeng REN, Pingda WANG, Xia WANG, Xing XIE, Yongping ZHANG, Chengzhi ZHANG, Qiong ZHANG, Guobao POON, Daniel RENHOWE, Paul SENDZIK, Martin
DM72T58 DT Small molecular drug
DM72T58 PC 59173275
DM72T58 MW 552.6
DM72T58 FM C28H31F3N8O
DM72T58 IC InChI=1S/C28H31F3N8O/c1-16(2)33-14-19-9-20(11-21(10-19)28(29,30)31)27(40)36-22-7-6-17(3)23(12-22)37-26-8-18(4)38-39(26)25-13-24(32-5)34-15-35-25/h6-13,15-16,33,37H,14H2,1-5H3,(H,36,40)(H,32,34,35)
DM72T58 CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)CNC(C)C)C(F)(F)F)NC3=CC(=NN3C4=NC=NC(=C4)NC)C
DM72T58 IK ZBUIYGDQZSKXHD-UHFFFAOYSA-N
DM72T58 IU N-[4-methyl-3-[[5-methyl-2-[6-(methylamino)pyrimidin-4-yl]pyrazol-3-yl]amino]phenyl]-3-[(propan-2-ylamino)methyl]-5-(trifluoromethyl)benzamide
DM6O2Q9 ID DM6O2Q9
DM6O2Q9 DN Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1
DM6O2Q9 HS Patented
DM6O2Q9 SN PMID27410995-Compound-Figure3d
DM6O2Q9 DT Small molecular drug
DMB5UF7 ID DMB5UF7
DMB5UF7 DN Pyrimido-indole derivative 1
DMB5UF7 HS Patented
DMB5UF7 SN PMID26924192-Compound-80
DMB5UF7 CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DMB5UF7 DT Small molecular drug
DMB5UF7 PC 118340554
DMB5UF7 MW 443.5
DMB5UF7 FM C24H25N7O2
DMB5UF7 IC InChI=1S/C24H25N7O2/c1-11-21(12(2)33-30-11)16-8-18-15(9-19(16)32-5)22-23(27-18)25-13(3)26-24(22)28-20-10-17(14-6-7-14)29-31(20)4/h8-10,14H,6-7H2,1-5H3,(H2,25,26,27,28)
DMB5UF7 CS CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)NC4=C3C(=NC(=N4)C)NC5=CC(=NN5C)C6CC6)OC
DMB5UF7 IK JIYPVUCBRQNICX-UHFFFAOYSA-N
DMB5UF7 IU N-(5-cyclopropyl-2-methylpyrazol-3-yl)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine
DM3REN5 ID DM3REN5
DM3REN5 DN Pyrimido-indole derivative 2
DM3REN5 HS Patented
DM3REN5 SN PMID26924192-Compound-81
DM3REN5 CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DM3REN5 DT Small molecular drug
DM3REN5 PC 91864675
DM3REN5 MW 471.6
DM3REN5 FM C26H29N7O2
DM3REN5 IC InChI=1S/C26H29N7O2/c1-6-33-26(16-9-7-8-10-19(16)31-33)30-25-23-17-12-21(34-5)18(22-13(2)32-35-14(22)3)11-20(17)29-24(23)27-15(4)28-25/h11-12H,6-10H2,1-5H3,(H2,27,28,29,30)
DM3REN5 CS CCN1C(=C2CCCCC2=N1)NC3=NC(=NC4=C3C5=CC(=C(C=C5N4)C6=C(ON=C6C)C)OC)C
DM3REN5 IK PKOGGTPBCXRZNX-UHFFFAOYSA-N
DM3REN5 IU 7-(3,5-dimethyl-1,2-oxazol-4-yl)-N-(2-ethyl-4,5,6,7-tetrahydroindazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine
DM53LGD ID DM53LGD
DM53LGD DN Pyrimido-indole derivative 3
DM53LGD HS Patented
DM53LGD SN PMID26924192-Compound-82
DM53LGD CP THE REGENTS OF THE UNIVERSITY OF MICHIGAN
DM53LGD DT Small molecular drug
DM53LGD PC 118340734
DM53LGD MW 451.5
DM53LGD FM C26H21N5O3
DM53LGD IC InChI=1S/C26H21N5O3/c1-13-23(14(2)34-31-13)18-11-20-17(12-22(18)32-4)24-25(30-20)28-15(3)29-26(24)33-21-9-10-27-19-8-6-5-7-16(19)21/h5-12H,1-4H3,(H,28,29,30)
DM53LGD CS CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)NC4=C3C(=NC(=N4)C)OC5=CC=NC6=CC=CC=C65)OC
DM53LGD IK RYLREOMADHRZEY-UHFFFAOYSA-N
DM53LGD IU 4-(6-methoxy-2-methyl-4-quinolin-4-yloxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethyl-1,2-oxazole
DM32N7D ID DM32N7D
DM32N7D DN Pyrimidopyridazinone derivative 1
DM32N7D HS Patented
DM32N7D SN PMID27774824-Compound-Figure10Example191
DM32N7D CP ENDO PHARMACEUTICALS INC. VENKATESAN, Aranapakam SMITH, Roger, Astbury HOSAHALLI, Subramanya POTLURI, Vijay PANIGRAHI, Sunil, Kumar BASETTI, Vishnu KUNTU, Karunasree
DM32N7D DT Small molecular drug
DMD1RT0 ID DMD1RT0
DMD1RT0 DN Pyrimidopyridazinone derivative 2
DMD1RT0 HS Patented
DMD1RT0 SN PMID27774824-Compound-Figure10Example7
DMD1RT0 CP ELI LILLY AND COMPANENDO PHARMACEUTICALS INC. VENKATESAN, Aranapakam SMITH, Roger, Astbury HOSAHALLI, Subramanya POTLURI, Vijay PANIGRAHI, Sunil, Kumar BASETTI, Vishnu KUNTU, Karunasree
DMD1RT0 DT Small molecular drug
DM0RC1Z ID DM0RC1Z
DM0RC1Z DN Pyrrole derivative 1
DM0RC1Z HS Patented
DM0RC1Z SN PMID26161824-Compound-10
DM0RC1Z CP SANOFI-AVENTIS BARTH, Francis BICHON, Daniel CONGY, Christian RINALDI-CARMONA, Muriell
DM0RC1Z DT Small molecular drug
DM0RC1Z PC 44481280
DM0RC1Z MW 625
DM0RC1Z FM C33H32Cl3N3O3
DM0RC1Z IC InChI=1S/C33H32Cl3N3O3/c34-23-9-12-25(13-10-23)39-29(8-4-5-19-40)27(21-30(39)26-14-11-24(35)20-28(26)36)31(41)38-17-15-33(16-18-38,32(37)42)22-6-2-1-3-7-22/h1-3,6-7,9-14,20-21,40H,4-5,8,15-19H2,(H2,37,42)
DM0RC1Z CS C1CN(CCC1(C2=CC=CC=C2)C(=O)N)C(=O)C3=C(N(C(=C3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)CCCCO
DM0RC1Z IK JVBKCVQNRQUJHM-UHFFFAOYSA-N
DM0RC1Z IU 1-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-(4-hydroxybutyl)pyrrole-3-carbonyl]-4-phenylpiperidine-4-carboxamide
DM0RC1Z DE Obesity
DMMNKFX ID DMMNKFX
DMMNKFX DN Pyrrole derivative 2
DMMNKFX HS Patented
DMMNKFX SN PMID26161824-Compound-5
DMMNKFX CP SANOFI-AVENTIS BARTH, Francis CONGY, Christian DUCOUX, Jean-Philippe RINALDI-CARMONA, Murielle
DMMNKFX DT Small molecular drug
DMMNKFX PC 44626131
DMMNKFX MW 609.6
DMMNKFX FM C32H30Cl2N2O4S
DMMNKFX IC InChI=1S/C32H30Cl2N2O4S/c33-23-9-12-25(27(34)19-23)29-26(21-7-10-24(11-8-21)40-18-4-17-37)20-28(41-29)30(38)36-15-13-32(14-16-36,31(35)39)22-5-2-1-3-6-22/h1-3,5-12,19-20,37H,4,13-18H2,(H2,35,39)
DMMNKFX CS C1CN(CCC1(C2=CC=CC=C2)C(=O)N)C(=O)C3=CC(=C(S3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)OCCCO
DMMNKFX IK WHNYDESPWWLRBM-UHFFFAOYSA-N
DMMNKFX IU 1-[5-(2,4-dichlorophenyl)-4-[4-(3-hydroxypropoxy)phenyl]thiophene-2-carbonyl]-4-phenylpiperidine-4-carboxamide
DMMNKFX DE Obesity
DMFV64B ID DMFV64B
DMFV64B DN Pyrrole derivative 3
DMFV64B HS Patented
DMFV64B SN PMID26161824-Compound-6
DMFV64B DT Small molecular drug
DMFV64B PC 58367580
DMFV64B MW 575.1
DMFV64B FM C32H31ClN2O4S
DMFV64B IC InChI=1S/C32H31ClN2O4S/c33-27-10-5-4-9-25(27)29-26(22-11-13-24(14-12-22)39-20-6-19-36)21-28(40-29)30(37)35-17-15-32(16-18-35,31(34)38)23-7-2-1-3-8-23/h1-5,7-14,21,36H,6,15-20H2,(H2,34,38)
DMFV64B CS C1CN(CCC1(C2=CC=CC=C2)C(=O)N)C(=O)C3=CC(=C(S3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)OCCCO
DMFV64B IK MWPKIBLLWUZVNJ-UHFFFAOYSA-N
DMFV64B IU 1-[5-(2-chlorophenyl)-4-[4-(3-hydroxypropoxy)phenyl]thiophene-2-carbonyl]-4-phenylpiperidine-4-carboxamide
DMFV64B DE Obesity
DMQDL43 ID DMQDL43
DMQDL43 DN Pyrrole derivative 4
DMQDL43 HS Patented
DMQDL43 SN PMID26161824-Compound-7
DMQDL43 CP SANOFI-AVENTIS BARTH, Francis CONGY, Christian JEANJEAN, Audrey RINALDI-CARMONA, Muriell
DMQDL43 DT Small molecular drug
DMQDL43 PC 58307112
DMQDL43 MW 605.5
DMQDL43 FM C32H30Cl2N4O4
DMQDL43 IC InChI=1S/C32H30Cl2N4O4/c1-37-27(30(40)38-15-13-32(14-16-38,31(36)41)21-5-3-2-4-6-21)18-25(24-12-9-22(33)17-26(24)34)29(37)20-7-10-23(11-8-20)42-19-28(35)39/h2-12,17-18H,13-16,19H2,1H3,(H2,35,39)(H2,36,41)
DMQDL43 CS CN1C(=CC(=C1C2=CC=C(C=C2)OCC(=O)N)C3=C(C=C(C=C3)Cl)Cl)C(=O)N4CCC(CC4)(C5=CC=CC=C5)C(=O)N
DMQDL43 IK LTDLMCVMMICHRM-UHFFFAOYSA-N
DMQDL43 IU 1-[5-[4-(2-amino-2-oxoethoxy)phenyl]-4-(2,4-dichlorophenyl)-1-methylpyrrole-2-carbonyl]-4-phenylpiperidine-4-carboxamide
DMQDL43 DE Obesity
DMJUMC6 ID DMJUMC6
DMJUMC6 DN Pyrrole derivative 5
DMJUMC6 HS Patented
DMJUMC6 SN PMID26161824-Compound-8
DMJUMC6 CP SANOFI-AVENTIS BARTH, Francis CONGY, Christian JEANJEAN, Audrey RINALDI-CARMONA, Muriell
DMJUMC6 DT Small molecular drug
DMJUMC6 PC 44511396
DMJUMC6 MW 619.1
DMJUMC6 FM C34H36ClFN4O4
DMJUMC6 IC InChI=1S/C34H36ClFN4O4/c1-39-30(32(42)40-17-15-34(16-18-40,33(37)43)38-22-23-7-11-25(36)12-8-23)21-28(27-5-2-3-6-29(27)35)31(39)24-9-13-26(14-10-24)44-20-4-19-41/h2-3,5-14,21,38,41H,4,15-20,22H2,1H3,(H2,37,43)
DMJUMC6 CS CN1C(=CC(=C1C2=CC=C(C=C2)OCCCO)C3=CC=CC=C3Cl)C(=O)N4CCC(CC4)(C(=O)N)NCC5=CC=C(C=C5)F
DMJUMC6 IK QZKLHVGMMWBLEQ-UHFFFAOYSA-N
DMJUMC6 IU 1-[4-(2-chlorophenyl)-5-[4-(3-hydroxypropoxy)phenyl]-1-methylpyrrole-2-carbonyl]-4-[(4-fluorophenyl)methylamino]piperidine-4-carboxamide
DMJUMC6 DE Obesity
DM875RE ID DM875RE
DM875RE DN Pyrrole derivative 6
DM875RE HS Patented
DM875RE SN PMID26161824-Compound-9
DM875RE CP SANOFI-AVENTIS BARTH, Francis BICHON, Daniel CONGY, Christian RINALDI-CARMONA, Muriell
DM875RE DT Small molecular drug
DM875RE PC 58319355
DM875RE MW 645.4
DM875RE FM C32H29Cl4N3O3
DM875RE IC InChI=1S/C32H29Cl4N3O3/c33-21-5-3-20(4-6-21)32(31(37)42)13-15-38(16-14-32)30(41)26-19-29(25-12-9-23(35)18-27(25)36)39(28(26)2-1-17-40)24-10-7-22(34)8-11-24/h3-12,18-19,40H,1-2,13-17H2,(H2,37,42)
DM875RE CS C1CN(CCC1(C2=CC=C(C=C2)Cl)C(=O)N)C(=O)C3=C(N(C(=C3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)CCCO
DM875RE IK VICABLXDCCBPMT-UHFFFAOYSA-N
DM875RE IU 4-(4-chlorophenyl)-1-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-(3-hydroxypropyl)pyrrole-3-carbonyl]piperidine-4-carboxamide
DM875RE DE Obesity
DMZCERW ID DMZCERW
DMZCERW DN Pyrrole derivative 7
DMZCERW HS Patented
DMZCERW SN PMID27774822-Compound-Figure3compound229
DMZCERW CP NERVIANO MEDICAL SCIENCES S.R.L
DMZCERW DT Small molecular drug
DM1A0VB ID DM1A0VB
DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1
DM1A0VB HS Patented
DM1A0VB SN PMID27774822-Compound-Figure1Example6
DM1A0VB CP JIANGSU HENGRUI MEDICINE CO [CNSHANGHAI HENGRUI PHARM CO LTD [CN]
DM1A0VB DT Small molecular drug
DMJK98Z ID DMJK98Z
DMJK98Z DN Pyrrolidine carboxamide derivative 1
DMJK98Z HS Patented
DMJK98Z SN PMID26882240-Compound-22
DMJK98Z CP YALE UNIVERSITY GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED CAMBRIDGE ENTERPRISE LIMITED UNIVERSITY OF CAMBRIDGE
DMJK98Z DT Small molecular drug
DMJK98Z PC 56684144
DMJK98Z MW 410.4
DMJK98Z FM C21H22N4O5
DMJK98Z IC InChI=1S/C21H22N4O5/c1-13-6-17(30-24-13)8-20(27)25-11-16(26)7-18(25)21(28)23-9-14-2-4-15(5-3-14)19-10-22-12-29-19/h2-6,10,12,16,18,26H,7-9,11H2,1H3,(H,23,28)/t16-,18+/m1/s1
DMJK98Z CS CC1=NOC(=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)NCC3=CC=C(C=C3)C4=CN=CO4)O
DMJK98Z IK HFCLIEBJTGJKSV-AEFFLSMTSA-N
DMJK98Z IU (2S,4R)-4-hydroxy-1-[2-(3-methyl-1,2-oxazol-5-yl)acetyl]-N-[[4-(1,3-oxazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
DMKDX6W ID DMKDX6W
DMKDX6W DN Pyrrolidine carboxamide derivative 2
DMKDX6W HS Patented
DMKDX6W SN PMID28699813-Compound-19
DMKDX6W CP MERCK SHARP & DOHME CORP. HALE, Jeffrey, J. JIANG, Jinlong SHEN, Dong-Ming SHI, Zhi-Cai SHU, Min WU, Zhicai YANG, Cangming
DMKDX6W DT Small molecular drug
DMKDX6W PC 54670732
DMKDX6W MW 559.1
DMKDX6W FM C30H34ClF3N4O
DMKDX6W IC InChI=1S/C30H34ClF3N4O/c1-18-13-28(38(35-18)21-6-8-26(33)25(31)15-21)19-9-11-36(12-10-19)29(39)24-17-37(30(2,3)4)16-23(24)22-7-5-20(32)14-27(22)34/h5-8,13-15,19,23-24H,9-12,16-17H2,1-4H3/t23-,24+/m0/s1
DMKDX6W CS CC1=NN(C(=C1)C2CCN(CC2)C(=O)[C@@H]3CN(C[C@H]3C4=C(C=C(C=C4)F)F)C(C)(C)C)C5=CC(=C(C=C5)F)Cl
DMKDX6W IK UGINLDOCQNRWSG-BJKOFHAPSA-N
DMKDX6W IU [(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]-[4-[2-(3-chloro-4-fluorophenyl)-5-methylpyrazol-3-yl]piperidin-1-yl]methanone
DMXALJE ID DMXALJE
DMXALJE DN Pyrrolidine derivative 1
DMXALJE HS Patented
DMXALJE SN PMID28067079-Compound-29
DMXALJE CP HUA MEDICINE (SHANGHAI) LTD
DMXALJE DT Small molecular drug
DMXALJE PC 86291149
DMXALJE MW 300.8
DMXALJE FM C17H14ClFN2
DMXALJE IC InChI=1S/C17H14ClFN2/c18-14-4-3-6-16(12-14)21-11-9-17(19,13-21)8-7-15-5-1-2-10-20-15/h1-6,10,12H,9,11,13H2
DMXALJE CS C1CN(CC1(C#CC2=CC=CC=N2)F)C3=CC(=CC=C3)Cl
DMXALJE IK AHSZAMGYMLYSLL-UHFFFAOYSA-N
DMXALJE IU 2-[2-[1-(3-chlorophenyl)-3-fluoropyrrolidin-3-yl]ethynyl]pyridine
DMCQN5M ID DMCQN5M
DMCQN5M DN Pyrrolidine derivative 10
DMCQN5M HS Patented
DMCQN5M SN PMID28906174-Compound-Figure1c
DMCQN5M CP Obseva SA
DMCQN5M DT Small molecular drug
DMIHRV9 ID DMIHRV9
DMIHRV9 DN Pyrrolidine derivative 11
DMIHRV9 HS Patented
DMIHRV9 SN PMID28906174-Compound-Figure1d
DMIHRV9 CP Obseva SA
DMIHRV9 DT Small molecular drug
DMXO8R5 ID DMXO8R5
DMXO8R5 DN Pyrrolidine derivative 12
DMXO8R5 HS Patented
DMXO8R5 SN PMID28906174-Compound-Figure1e
DMXO8R5 CP Obseva SA
DMXO8R5 DT Small molecular drug
DM3VA8P ID DM3VA8P
DM3VA8P DN Pyrrolidine derivative 13
DM3VA8P HS Patented
DM3VA8P SN PMID28906174-Compound-Figure1f
DM3VA8P CP Obseva SA
DM3VA8P DT Small molecular drug
DM5WA29 ID DM5WA29
DM5WA29 DN Pyrrolidine derivative 2
DM5WA29 HS Patented
DM5WA29 SN PMID28067079-Compound-30
DM5WA29 CP HUA MEDICINE (SHANGHAI) LTD
DM5WA29 DT Small molecular drug
DM5WA29 PC 86291200
DM5WA29 MW 291.3
DM5WA29 FM C18H14FN3
DM5WA29 IC InChI=1S/C18H14FN3/c19-18(8-7-16-5-1-2-10-21-16)9-11-22(14-18)17-6-3-4-15(12-17)13-20/h1-6,10,12H,9,11,14H2
DM5WA29 CS C1CN(CC1(C#CC2=CC=CC=N2)F)C3=CC=CC(=C3)C#N
DM5WA29 IK NHUYADGCDLCNRQ-UHFFFAOYSA-N
DM5WA29 IU 3-[3-fluoro-3-(2-pyridin-2-ylethynyl)pyrrolidin-1-yl]benzonitrile
DMHM8WJ ID DMHM8WJ
DMHM8WJ DN Pyrrolidine derivative 3
DMHM8WJ HS Patented
DMHM8WJ SN PMID28067079-Compound-31
DMHM8WJ CP HUA MEDICINE (SHANGHAI) LTD
DMHM8WJ DT Small molecular drug
DMHM8WJ PC 90352795
DMHM8WJ MW 344.4
DMHM8WJ FM C18H17FN2O2S
DMHM8WJ IC InChI=1S/C18H17FN2O2S/c1-24(22,23)17-7-4-6-16(13-17)21-12-10-18(19,14-21)9-8-15-5-2-3-11-20-15/h2-7,11,13H,10,12,14H2,1H3
DMHM8WJ CS CS(=O)(=O)C1=CC=CC(=C1)N2CCC(C2)(C#CC3=CC=CC=N3)F
DMHM8WJ IK FBIPFOUWZKBKQR-UHFFFAOYSA-N
DMHM8WJ IU 2-[2-[3-fluoro-1-(3-methylsulfonylphenyl)pyrrolidin-3-yl]ethynyl]pyridine
DMZ2HBL ID DMZ2HBL
DMZ2HBL DN Pyrrolidine derivative 4
DMZ2HBL HS Patented
DMZ2HBL SN PMID28067079-Compound-32
DMZ2HBL CP HUA MEDICINE (SHANGHAI) LTD
DMZ2HBL DT Small molecular drug
DMZ2HBL PC 86291361
DMZ2HBL MW 274.33
DMZ2HBL FM C16H19FN2O
DMZ2HBL IC InChI=1S/C16H19FN2O/c1-2-3-7-15(20)19-12-10-16(17,13-19)9-8-14-6-4-5-11-18-14/h4-6,11H,2-3,7,10,12-13H2,1H3
DMZ2HBL CS CCCCC(=O)N1CCC(C1)(C#CC2=CC=CC=N2)F
DMZ2HBL IK HKFZZVZBEQGITN-UHFFFAOYSA-N
DMZ2HBL IU 1-[3-fluoro-3-(2-pyridin-2-ylethynyl)pyrrolidin-1-yl]pentan-1-one
DM5NKXO ID DM5NKXO
DM5NKXO DN Pyrrolidine derivative 5
DM5NKXO HS Patented
DM5NKXO SN PMID28067079-Compound-33
DM5NKXO CP HUA MEDICINE (SHANGHAI) LTD
DM5NKXO DT Small molecular drug
DM5NKXO PC 86291332
DM5NKXO MW 290.33
DM5NKXO FM C16H19FN2O2
DM5NKXO IC InChI=1S/C16H19FN2O2/c1-2-3-12-21-15(20)19-11-9-16(17,13-19)8-7-14-6-4-5-10-18-14/h4-6,10H,2-3,9,11-13H2,1H3
DM5NKXO CS CCCCOC(=O)N1CCC(C1)(C#CC2=CC=CC=N2)F
DM5NKXO IK NCBPLEITPLWATL-UHFFFAOYSA-N
DM5NKXO IU butyl 3-fluoro-3-(2-pyridin-2-ylethynyl)pyrrolidine-1-carboxylate
DMJ3ZP2 ID DMJ3ZP2
DMJ3ZP2 DN Pyrrolidine derivative 6
DMJ3ZP2 HS Patented
DMJ3ZP2 SN PMID25828189-Compound-25
DMJ3ZP2 CP SCHERING CORPORATION GILBERT, Eric, J. MILLER, Michael, W. DEMONG, Duane Eugene STAMFORD, Andrew, W. GREENLEE, William, J
DMJ3ZP2 DT Small molecular drug
DMIOJD6 ID DMIOJD6
DMIOJD6 DN Pyrrolidine derivative 7
DMIOJD6 HS Patented
DMIOJD6 SN PMID25828189-Compound-26
DMIOJD6 CP SCHERING CORPORATION GILBERT, Eric, J. MILLER, Michael, W. DEMONG, Duane Eugene STAMFORD, Andrew, W. GREENLEE, William, J
DMIOJD6 DT Small molecular drug
DMIOJD6 PC 51042268
DMIOJD6 MW 591.5
DMIOJD6 FM C33H32Cl2N2O4
DMIOJD6 IC InChI=1S/C33H32Cl2N2O4/c1-20(21-3-5-22(6-4-21)33(40)36-12-11-32(38)39)37-19-27(26-14-28(34)18-29(35)15-26)17-31(37)25-8-7-24-16-30(41-2)10-9-23(24)13-25/h3-10,13-16,18,20,27,31H,11-12,17,19H2,1-2H3,(H,36,40)(H,38,39)/t20?,27-,31-/m1/s1
DMIOJD6 CS CC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C[C@@H](C[C@@H]2C3=CC4=C(C=C3)C=C(C=C4)OC)C5=CC(=CC(=C5)Cl)Cl
DMIOJD6 IK MKGXNUKACRIFNF-JOPCKLHNSA-N
DMIOJD6 IU 3-[[4-[1-[(2R,4S)-4-(3,5-dichlorophenyl)-2-(6-methoxynaphthalen-2-yl)pyrrolidin-1-yl]ethyl]benzoyl]amino]propanoic acid
DMWPXJ5 ID DMWPXJ5
DMWPXJ5 DN Pyrrolidine derivative 8
DMWPXJ5 HS Patented
DMWPXJ5 SN PMID25828189-Compound-27
DMWPXJ5 CP SCHERING CORPORATION GILBERT, Eric, J. MILLER, Michael, W. DEMONG, Duane Eugene STAMFORD, Andrew, W. GREENLEE, William, J
DMWPXJ5 DT Small molecular drug
DMWPXJ5 PC 51042475
DMWPXJ5 MW 627.5
DMWPXJ5 FM C31H28Cl2N2O6S
DMWPXJ5 IC InChI=1S/C31H28Cl2N2O6S/c1-41-27-7-4-20-12-22(3-2-21(20)15-27)29-16-24(23-13-25(32)17-26(33)14-23)18-35(29)42(39,40)28-8-5-19(6-9-28)31(38)34-11-10-30(36)37/h2-9,12-15,17,24,29H,10-11,16,18H2,1H3,(H,34,38)(H,36,37)/t24-,29-/m1/s1
DMWPXJ5 CS COC1=CC2=C(C=C1)C=C(C=C2)[C@H]3C[C@H](CN3S(=O)(=O)C4=CC=C(C=C4)C(=O)NCCC(=O)O)C5=CC(=CC(=C5)Cl)Cl
DMWPXJ5 IK DOKNZWNPLZNQJB-FUFSCUOVSA-N
DMWPXJ5 IU 3-[[4-[(2R,4S)-4-(3,5-dichlorophenyl)-2-(6-methoxynaphthalen-2-yl)pyrrolidin-1-yl]sulfonylbenzoyl]amino]propanoic acid
DMZK658 ID DMZK658
DMZK658 DN Pyrrolidine derivative 9
DMZK658 HS Patented
DMZK658 SN PMID28906174-Compound-Figure1b
DMZK658 CP Obseva SA
DMZK658 DT Small molecular drug
DM7DF6Z ID DM7DF6Z
DM7DF6Z DN Pyrrolidinyl urea derivative 1
DM7DF6Z HS Patented
DM7DF6Z SN PMID26413912-Compound-52
DM7DF6Z CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
DM7DF6Z DT Small molecular drug
DM7DF6Z PC 49839185
DM7DF6Z MW 405.5
DM7DF6Z FM C24H24FN3O2
DM7DF6Z IC InChI=1S/C24H24FN3O2/c25-20-8-10-22(11-9-20)30-23-5-1-3-18(15-23)6-7-19-12-14-28(17-19)24(29)27-21-4-2-13-26-16-21/h1-5,8-11,13,15-16,19H,6-7,12,14,17H2,(H,27,29)
DM7DF6Z CS C1CN(CC1CCC2=CC(=CC=C2)OC3=CC=C(C=C3)F)C(=O)NC4=CN=CC=C4
DM7DF6Z IK BDZREAHMWOSTKO-UHFFFAOYSA-N
DM7DF6Z IU 3-[2-[3-(4-fluorophenoxy)phenyl]ethyl]-N-pyridin-3-ylpyrrolidine-1-carboxamide
DMV6YXJ ID DMV6YXJ
DMV6YXJ DN Pyrrolidinyl urea derivative 10
DMV6YXJ HS Patented
DMV6YXJ SN PMID28270010-Compound-Figure12-6
DMV6YXJ CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMV6YXJ DT Small molecular drug
DMV6YXJ PC 71041571
DMV6YXJ MW 489.5
DMV6YXJ FM C24H26F3N5O3
DMV6YXJ IC InChI=1S/C24H26F3N5O3/c1-14-22(32(30-23(14)33)16-6-4-3-5-7-16)29-24(34)28-20-13-31(8-9-35-2)12-17(20)15-10-18(25)21(27)19(26)11-15/h3-7,10-11,17,20H,8-9,12-13H2,1-2H3,(H,30,33)(H2,28,29,34)/t17-,20+/m0/s1
DMV6YXJ CS CC1=C(N(NC1=O)C2=CC=CC=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C(=C4)F)F)F)CCOC
DMV6YXJ IK YWWGXKZIBWIKLW-FXAWDEMLSA-N
DMV6YXJ IU 1-[(3S,4R)-1-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2-phenyl-1H-pyrazol-3-yl)urea
DMWKSF3 ID DMWKSF3
DMWKSF3 DN Pyrrolidinyl urea derivative 11
DMWKSF3 HS Patented
DMWKSF3 SN PMID28270010-Compound-Figure12-7
DMWKSF3 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMWKSF3 DT Small molecular drug
DMWKSF3 PC 118128775
DMWKSF3 MW 471.5
DMWKSF3 FM C23H27F2N7O2
DMWKSF3 IC InChI=1S/C23H27F2N7O2/c1-14-10-27-20(11-26-14)19-9-22(31(2)30-19)29-23(33)28-21-13-32(6-7-34-3)12-16(21)15-4-5-17(24)18(25)8-15/h4-5,8-11,16,21H,6-7,12-13H2,1-3H3,(H2,28,29,33)/t16-,21+/m0/s1
DMWKSF3 CS CC1=CN=C(C=N1)C2=NN(C(=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C=C4)F)F)CCOC)C
DMWKSF3 IK NPZQKAJVRDLUTI-HRAATJIYSA-N
DMWKSF3 IU 1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[2-methyl-5-(5-methylpyrazin-2-yl)pyrazol-3-yl]urea
DMJ6IE5 ID DMJ6IE5
DMJ6IE5 DN Pyrrolidinyl urea derivative 12
DMJ6IE5 HS Patented
DMJ6IE5 SN PMID28270010-Compound-Figure12-8
DMJ6IE5 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMJ6IE5 DT Small molecular drug
DMJ6IE5 PC 71041077
DMJ6IE5 MW 529.6
DMJ6IE5 FM C27H33F2N5O4
DMJ6IE5 IC InChI=1S/C27H33F2N5O4/c1-33-26(15-24(32-33)18-4-7-20(8-5-18)38-13-12-37-3)31-27(35)30-25-17-34(10-11-36-2)16-21(25)19-6-9-22(28)23(29)14-19/h4-9,14-15,21,25H,10-13,16-17H2,1-3H3,(H2,30,31,35)/t21-,25+/m0/s1
DMJ6IE5 CS CN1C(=CC(=N1)C2=CC=C(C=C2)OCCOC)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C=C4)F)F)CCOC
DMJ6IE5 IK JNRIBRHEHFYMHN-SQJMNOBHSA-N
DMJ6IE5 IU 1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[5-[4-(2-methoxyethoxy)phenyl]-2-methylpyrazol-3-yl]urea
DM3VL82 ID DM3VL82
DM3VL82 DN Pyrrolidinyl urea derivative 13
DM3VL82 HS Patented
DM3VL82 SN PMID28270010-Compound-Figure12-9
DM3VL82 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DM3VL82 DT Small molecular drug
DM3VL82 PC 71471488
DM3VL82 MW 495.5
DM3VL82 FM C25H27F2N7O2
DM3VL82 IC InChI=1S/C25H27F2N7O2/c1-32-24(13-20(31-32)22-4-3-5-23-28-8-9-34(22)23)30-25(35)29-21-15-33(10-11-36-2)14-17(21)16-6-7-18(26)19(27)12-16/h3-9,12-13,17,21H,10-11,14-15H2,1-2H3,(H2,29,30,35)/t17-,21+/m0/s1
DM3VL82 CS CN1C(=CC(=N1)C2=CC=CC3=NC=CN32)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DM3VL82 IK SRPJIAHTEPDSEX-LAUBAEHRSA-N
DM3VL82 IU 1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(5-imidazo[1,2-a]pyridin-5-yl-2-methylpyrazol-3-yl)urea
DMYFP95 ID DMYFP95
DMYFP95 DN Pyrrolidinyl urea derivative 2
DMYFP95 HS Patented
DMYFP95 SN PMID28270010-Compound-Figure12-1
DMYFP95 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMYFP95 DT Small molecular drug
DMYFP95 PC 118129006
DMYFP95 MW 503.6
DMYFP95 FM C28H33N5O4
DMYFP95 IC InChI=1S/C28H33N5O4/c1-36-18-25(27(34)37-2)32-16-22(19-10-5-3-6-11-19)24(17-32)29-28(35)30-26-21-14-9-15-23(21)31-33(26)20-12-7-4-8-13-20/h3-8,10-13,22,24-25H,9,14-18H2,1-2H3,(H2,29,30,35)/t22-,24+,25?/m0/s1
DMYFP95 CS COCC(C(=O)OC)N1C[C@H]([C@@H](C1)NC(=O)NC2=C3CCCC3=NN2C4=CC=CC=C4)C5=CC=CC=C5
DMYFP95 IK JOOGNXILJRJIEZ-LNJIZIIWSA-N
DMYFP95 IU methyl 3-methoxy-2-[(3R,4S)-3-phenyl-4-[(2-phenyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)carbamoylamino]pyrrolidin-1-yl]propanoate
DMFDLHN ID DMFDLHN
DMFDLHN DN Pyrrolidinyl urea derivative 3
DMFDLHN HS Patented
DMFDLHN SN PMID28270010-Compound-Figure12-10
DMFDLHN CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMFDLHN DT Small molecular drug
DMFDLHN PC 71040977
DMFDLHN MW 553.6
DMFDLHN FM C28H30F3N7O2
DMFDLHN IC InChI=1S/C28H30F3N7O2/c1-17-26(19-13-32-36(2)14-19)35-38(21-7-5-20(29)6-8-21)27(17)34-28(39)33-25-16-37(10-11-40-3)15-22(25)18-4-9-23(30)24(31)12-18/h4-9,12-14,22,25H,10-11,15-16H2,1-3H3,(H2,33,34,39)/t22-,25+/m0/s1
DMFDLHN CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=C(C=C3)F)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DMFDLHN IK XWJMJPIDPZSDIR-WIOPSUGQSA-N
DMFDLHN IU 1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[2-(4-fluorophenyl)-4-methyl-5-(1-methylpyrazol-4-yl)pyrazol-3-yl]urea
DM8SZKU ID DM8SZKU
DM8SZKU DN Pyrrolidinyl urea derivative 4
DM8SZKU HS Patented
DM8SZKU SN PMID28270010-Compound-Figure12-11
DM8SZKU CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DM8SZKU DT Small molecular drug
DM8SZKU PC 71041118
DM8SZKU MW 588
DM8SZKU FM C28H29ClF3N7O2
DM8SZKU IC InChI=1S/C28H29ClF3N7O2/c1-16-26(18-12-33-37(2)13-18)36-39(24-6-4-5-20(29)25(24)32)27(16)35-28(40)34-23-15-38(9-10-41-3)14-19(23)17-7-8-21(30)22(31)11-17/h4-8,11-13,19,23H,9-10,14-15H2,1-3H3,(H2,34,35,40)/t19-,23+/m0/s1
DM8SZKU CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=C(C(=CC=C3)Cl)F)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DM8SZKU IK RFVRMWNCZARMFM-WMZHIEFXSA-N
DM8SZKU IU 1-[2-(3-chloro-2-fluorophenyl)-4-methyl-5-(1-methylpyrazol-4-yl)pyrazol-3-yl]-3-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]urea
DMU51T4 ID DMU51T4
DMU51T4 DN Pyrrolidinyl urea derivative 5
DMU51T4 HS Patented
DMU51T4 SN PMID28270010-Compound-Figure12-12
DMU51T4 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMU51T4 DT Small molecular drug
DMU51T4 PC 71041284
DMU51T4 MW 554.6
DMU51T4 FM C27H29F3N8O2
DMU51T4 IC InChI=1S/C27H29F3N8O2/c1-16-25(18-10-32-36(2)13-18)35-38(20-9-19(28)11-31-12-20)26(16)34-27(39)33-24-15-37(6-7-40-3)14-21(24)17-4-5-22(29)23(30)8-17/h4-5,8-13,21,24H,6-7,14-15H2,1-3H3,(H2,33,34,39)/t21-,24+/m0/s1
DMU51T4 CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC(=CN=C3)F)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC(=C(C=C5)F)F)CCOC
DMU51T4 IK UNGZVJKZTCHIBB-XUZZJYLKSA-N
DMU51T4 IU 1-[(3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-[2-(5-fluoropyridin-3-yl)-4-methyl-5-(1-methylpyrazol-4-yl)pyrazol-3-yl]urea
DM01GEB ID DM01GEB
DM01GEB DN Pyrrolidinyl urea derivative 6
DM01GEB HS Patented
DM01GEB SN PMID28270010-Compound-Figure12-2
DM01GEB CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DM01GEB DT Small molecular drug
DM01GEB PC 118128873
DM01GEB MW 499.5
DM01GEB FM C26H28F3N5O2
DM01GEB IC InChI=1S/C26H28F3N5O2/c27-26(28,29)36-15-14-33-16-21(18-8-3-1-4-9-18)23(17-33)30-25(35)31-24-20-12-7-13-22(20)32-34(24)19-10-5-2-6-11-19/h1-6,8-11,21,23H,7,12-17H2,(H2,30,31,35)/t21-,23+/m0/s1
DM01GEB CS C1CC2=C(N(N=C2C1)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC=CC=C5)CCOC(F)(F)F
DM01GEB IK AMRJQXCVKABTNA-JTHBVZDNSA-N
DM01GEB IU 1-(2-phenyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)-3-[(3S,4R)-4-phenyl-1-[2-(trifluoromethoxy)ethyl]pyrrolidin-3-yl]urea
DMYADJP ID DMYADJP
DMYADJP DN Pyrrolidinyl urea derivative 7
DMYADJP HS Patented
DMYADJP SN PMID28270010-Compound-Figure12-3
DMYADJP CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMYADJP DT Small molecular drug
DMYADJP PC 118128612
DMYADJP MW 469.5
DMYADJP FM C25H26F3N5O
DMYADJP IC InChI=1S/C25H26F3N5O/c26-25(27,28)16-32-14-20(17-8-3-1-4-9-17)22(15-32)29-24(34)30-23-19-12-7-13-21(19)31-33(23)18-10-5-2-6-11-18/h1-6,8-11,20,22H,7,12-16H2,(H2,29,30,34)/t20-,22+/m0/s1
DMYADJP CS C1CC2=C(N(N=C2C1)C3=CC=CC=C3)NC(=O)N[C@@H]4CN(C[C@H]4C5=CC=CC=C5)CC(F)(F)F
DMYADJP IK AFWYYOYVHRLTSQ-RBBKRZOGSA-N
DMYADJP IU 1-(2-phenyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-3-yl)-3-[(3S,4R)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]urea
DMW2JG8 ID DMW2JG8
DMW2JG8 DN Pyrrolidinyl urea derivative 8
DMW2JG8 HS Patented
DMW2JG8 SN PMID28270010-Compound-Figure12-4
DMW2JG8 CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMW2JG8 DT Small molecular drug
DMW2JG8 PC 71041580
DMW2JG8 MW 453.5
DMW2JG8 FM C24H28FN5O3
DMW2JG8 IC InChI=1S/C24H28FN5O3/c1-16-22(30(28-23(16)31)19-9-4-3-5-10-19)27-24(32)26-21-15-29(11-12-33-2)14-20(21)17-7-6-8-18(25)13-17/h3-10,13,20-21H,11-12,14-15H2,1-2H3,(H,28,31)(H2,26,27,32)/t20-,21+/m0/s1
DMW2JG8 CS CC1=C(N(NC1=O)C2=CC=CC=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=CC=C4)F)CCOC
DMW2JG8 IK HIHSIUUJZCQIBY-LEWJYISDSA-N
DMW2JG8 IU 1-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2-phenyl-1H-pyrazol-3-yl)urea
DMO1I4W ID DMO1I4W
DMO1I4W DN Pyrrolidinyl urea derivative 9
DMO1I4W HS Patented
DMO1I4W SN PMID28270010-Compound-Figure12-5
DMO1I4W CP ARRAY BIOPHARMA INC. ALLEN, Shelley ANDREWS, Steven, W. BLAKE, James, F. CONDROSKI, Kevin, R. HAAS, Julia HUANG, Lily JIANG, Yutong KERCHER, Timothy KOLAKOWSKI, Gabrielle R. SEO, Jeongbeob
DMO1I4W DT Small molecular drug
DMO1I4W PC 118128691
DMO1I4W MW 488
DMO1I4W FM C24H27ClFN5O3
DMO1I4W IC InChI=1S/C24H27ClFN5O3/c1-15-22(31(29-23(15)32)17-6-4-3-5-7-17)28-24(33)27-21-14-30(10-11-34-2)13-18(21)16-8-9-20(26)19(25)12-16/h3-9,12,18,21H,10-11,13-14H2,1-2H3,(H,29,32)(H2,27,28,33)/t18-,21+/m0/s1
DMO1I4W CS CC1=C(N(NC1=O)C2=CC=CC=C2)NC(=O)N[C@@H]3CN(C[C@H]3C4=CC(=C(C=C4)F)Cl)CCOC
DMO1I4W IK GIFBEFSILNFYRM-GHTZIAJQSA-N
DMO1I4W IU 1-[(3S,4R)-4-(3-chloro-4-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2-phenyl-1H-pyrazol-3-yl)urea
DM5RCW8 ID DM5RCW8
DM5RCW8 DN Pyrrolo[1,2-c]pyrazole derivative 1
DM5RCW8 HS Patented
DM5RCW8 SN PMID29473428-Compound-49
DM5RCW8 CP EMCURE PHARMACEUTICALS LIMITED
DM5RCW8 DT Small molecular drug
DMI0AW7 ID DMI0AW7
DMI0AW7 DN Pyrrolo[1,2-f]triazine derivative 1
DMI0AW7 HS Patented
DMI0AW7 SN PMID25482888-Compound-62
DMI0AW7 DT Small molecular drug
DM7DU9P ID DM7DU9P
DM7DU9P DN Pyrrolo[1,2-f]triazine derivative 2
DM7DU9P HS Patented
DM7DU9P SN PMID25482888-Compound-63
DM7DU9P DT Small molecular drug
DM7DU9P PC 86301498
DM7DU9P MW 517.6
DM7DU9P FM C26H27N7O3S
DM7DU9P IC InChI=1S/C26H27N7O3S/c1-18-8-10-23(11-9-18)37(35,36)30-22-13-24-25(34)32(15-20-6-3-2-5-19(20)14-27)26(29-33(24)17-22)31-12-4-7-21(28)16-31/h2-3,5-6,8-11,13,17,21,30H,4,7,12,15-16,28H2,1H3/t21-/m1/s1
DM7DU9P CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CN3C(=C2)C(=O)N(C(=N3)N4CCC[C@H](C4)N)CC5=CC=CC=C5C#N
DM7DU9P IK ZYJICIOJMGMKDZ-OAQYLSRUSA-N
DM7DU9P IU N-[2-[(3R)-3-aminopiperidin-1-yl]-3-[(2-cyanophenyl)methyl]-4-oxopyrrolo[2,1-f][1,2,4]triazin-6-yl]-4-methylbenzenesulfonamide
DMWXZBF ID DMWXZBF
DMWXZBF DN Pyrrolo[2,3-b]pyridine carboxamide derivative 1
DMWXZBF HS Patented
DMWXZBF SN PMID25656651-Compound-17
DMWXZBF CP IRM LLC REN, Pingda WANG, Xia JIANG, Songchun NAGLE, Advait OKRAM, Barun HE, Yun XIE, Yongping WANG, Xing HUANG, Shenlin WANG, Xiaodong LIU, Yi ALBAUGH, Pamela, A. GRAY, Nathanael, S. ZHANG, Guobao
DMWXZBF DT Small molecular drug
DMWXZBF PC 25123000
DMWXZBF MW 424.4
DMWXZBF FM C22H15F3N4O2
DMWXZBF IC InChI=1S/C22H15F3N4O2/c23-22(24,25)14-4-1-3-13(11-14)20(30)28-15-5-2-6-16(12-15)29-21(31)18-8-10-27-19-17(18)7-9-26-19/h1-12H,(H,26,27)(H,28,30)(H,29,31)
DMWXZBF CS C1=CC(=CC(=C1)C(F)(F)F)C(=O)NC2=CC(=CC=C2)NC(=O)C3=C4C=CNC4=NC=C3
DMWXZBF IK NFUORXLZMPSICI-UHFFFAOYSA-N
DMWXZBF IU N-[3-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide
DMVKCQU ID DMVKCQU
DMVKCQU DN Pyrrolo[2,3-b]pyridine derivative 1
DMVKCQU HS Patented
DMVKCQU SN PMID28270021-Compound-WO2008063888P-0171
DMVKCQU CP PLEXXIKON, INC. ZHANG, Chao ZHANG, Jiazhong IBRAHIM, Prabha N. ARTIS, Dean R. BREMER, Ryan WU, Guoxian ZHU, Hongyao NESPI, Marika
DMVKCQU DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM7IPWB ID DM7IPWB
DM7IPWB DN Pyrrolo[2,3-b]pyridine derivative 2
DM7IPWB HS Patented
DM7IPWB SN PMID28270021-Compound-WO2008063888P-0180
DM7IPWB CP PLEXXIKON, INC. ZHANG, Chao ZHANG, Jiazhong IBRAHIM, Prabha N. ARTIS, Dean R. BREMER, Ryan WU, Guoxian ZHU, Hongyao NESPI, Marika
DM7IPWB DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMCYOL7 ID DMCYOL7
DMCYOL7 DN Pyrrolo[2,3-b]pyridine derivative 3
DMCYOL7 HS Patented
DMCYOL7 SN PMID28270021-Compound-WO2010129570P-2061
DMCYOL7 CP PLEXXIKON, INC. VISOR, Gary Conard IBRAHIM, Prabha N. SPEVAK, Wayne CHO, Hanna SHI, Songyuan WU, Guoxian
DMCYOL7 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMJBTZG ID DMJBTZG
DMJBTZG DN Pyrrolo[2,3-b]pyridine derivative 4
DMJBTZG HS Patented
DMJBTZG SN PMID25656651-Compound-24
DMJBTZG CP NOVA DECISION [FRAZASYNTH [FR]
DMJBTZG DT Small molecular drug
DMJBTZG PC 89899422
DMJBTZG MW 349.31
DMJBTZG FM C17H14F3N3O2
DMJBTZG IC InChI=1S/C17H14F3N3O2/c1-25-16(24)14-7-11-6-12(9-22-15(11)23-14)21-8-10-4-2-3-5-13(10)17(18,19)20/h2-7,9,21H,8H2,1H3,(H,22,23)
DMJBTZG CS COC(=O)C1=CC2=CC(=CN=C2N1)NCC3=CC=CC=C3C(F)(F)F
DMJBTZG IK MFAPLYWBOUSVJJ-UHFFFAOYSA-N
DMJBTZG IU methyl 5-[[2-(trifluoromethyl)phenyl]methylamino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylate
DMYUEA6 ID DMYUEA6
DMYUEA6 DN Pyrrolo[2,3-d]pyrimidine derivative 1
DMYUEA6 HS Patented
DMYUEA6 SN PMID27410995-Compound-Figure3i
DMYUEA6 DT Small molecular drug
DMRWG2E ID DMRWG2E
DMRWG2E DN Pyrrolo[2,3-d]pyrimidine derivative 10
DMRWG2E HS Patented
DMRWG2E SN PMID26161698-Compound-2
DMRWG2E CP NOVARTIS AG BRAIN, Christopher, Thomas CHO, Young Shin GIRALDES, John, William LAGU, Bharat LEVELL, Julian LUZZIO, Michael PEREZ, Lawrence, Blas WANG, Yaping YANG, Fan
DMRWG2E DT Small molecular drug
DMRWG2E PC 53378895
DMRWG2E MW 552.7
DMRWG2E FM C31H36N8O2
DMRWG2E IC InChI=1S/C31H36N8O2/c1-31(2,3)21-7-11-24(12-8-21)39-25(29(41)37(4)5)14-20-16-33-30(36-27(20)39)35-26-13-6-19(15-32-26)28(40)38-17-22-9-10-23(18-38)34-22/h6-8,11-16,22-23,34H,9-10,17-18H2,1-5H3,(H,32,33,35,36)
DMRWG2E CS CC(C)(C)C1=CC=C(C=C1)N2C(=CC3=CN=C(N=C32)NC4=NC=C(C=C4)C(=O)N5CC6CCC(C5)N6)C(=O)N(C)C
DMRWG2E IK VTSDFHMWTKRCAL-UHFFFAOYSA-N
DMRWG2E IU 7-(4-tert-butylphenyl)-2-[[5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-yl]amino]-N,N-dimethylpyrrolo[2,3-d]pyrimidine-6-carboxamide
DM983CY ID DM983CY
DM983CY DN Pyrrolo[2,3-d]pyrimidine derivative 11
DM983CY HS Patented
DM983CY SN PMID27774824-Compound-Figure13Example25
DM983CY CP INCYTE CORPORATION
DM983CY DT Small molecular drug
DMYTV49 ID DMYTV49
DMYTV49 DN Pyrrolo[2,3-d]pyrimidine derivative 12
DMYTV49 HS Patented
DMYTV49 SN PMID28705083-Compound-10
DMYTV49 CP PHARMACYCLICS, INC. CHEN, Wei LOURY, David, J. MODY, Tarak, D. WANG, Longcheng
DMYTV49 DT Small molecular drug
DMYTV49 PC 71217672
DMYTV49 MW 544.6
DMYTV49 FM C33H32N6O2
DMYTV49 IC InChI=1S/C33H32N6O2/c1-37(24-15-16-24)19-7-12-30(40)38(2)25-8-6-9-26(20-25)39-21-29(31-32(34)35-22-36-33(31)39)23-13-17-28(18-14-23)41-27-10-4-3-5-11-27/h3-14,17-18,20-22,24H,15-16,19H2,1-2H3,(H2,34,35,36)/b12-7+
DMYTV49 CS CN(C/C=C/C(=O)N(C)C1=CC=CC(=C1)N2C=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4)OC5=CC=CC=C5)C6CC6
DMYTV49 IK NARJNVJAUDCMNV-KPKJPENVSA-N
DMYTV49 IU (E)-N-[3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]-4-[cyclopropyl(methyl)amino]-N-methylbut-2-enamide
DMTGELI ID DMTGELI
DMTGELI DN Pyrrolo[2,3-d]pyrimidine derivative 13
DMTGELI HS Patented
DMTGELI SN PMID28705083-Compound-11
DMTGELI CP PHARMACYCLICS, INC. CHEN, Wei LOURY, David, J. MODY, Tarak, D. WANG, Longcheng
DMTGELI DT Small molecular drug
DMTGELI PC 71208697
DMTGELI MW 482.6
DMTGELI FM C28H30N6O2
DMTGELI IC InChI=1S/C28H30N6O2/c1-32(2)15-6-9-25(35)33-16-14-21(17-33)34-18-24(26-27(29)30-19-31-28(26)34)20-10-12-23(13-11-20)36-22-7-4-3-5-8-22/h3-13,18-19,21H,14-17H2,1-2H3,(H2,29,30,31)/b9-6+
DMTGELI CS CN(C)C/C=C/C(=O)N1CCC(C1)N2C=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4)OC5=CC=CC=C5
DMTGELI IK QKYMWVAQZSLTKG-RMKNXTFCSA-N
DMTGELI IU (E)-1-[3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]pyrrolidin-1-yl]-4-(dimethylamino)but-2-en-1-one
DMK4LOH ID DMK4LOH
DMK4LOH DN Pyrrolo[2,3-d]pyrimidine derivative 14
DMK4LOH HS Patented
DMK4LOH SN PMID28705083-Compound-12
DMK4LOH CP PHARMACYCLICS, INC
DMK4LOH DT Small molecular drug
DMK4LOH PC 71263162
DMK4LOH MW 470.6
DMK4LOH FM C27H30N6O2
DMK4LOH IC InChI=1S/C27H30N6O2/c1-18-11-12-19(14-23(18)35-5)22-16-33(27-25(22)26(28)29-17-30-27)21-9-6-8-20(15-21)32(4)24(34)10-7-13-31(2)3/h6-12,14-17H,13H2,1-5H3,(H2,28,29,30)/b10-7+
DMK4LOH CS CC1=C(C=C(C=C1)C2=CN(C3=NC=NC(=C23)N)C4=CC(=CC=C4)N(C)C(=O)/C=C/CN(C)C)OC
DMK4LOH IK XIEVUMXHZAXKDT-JXMROGBWSA-N
DMK4LOH IU (E)-N-[3-[4-amino-5-(3-methoxy-4-methylphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]-4-(dimethylamino)-N-methylbut-2-enamide
DMZ4PLC ID DMZ4PLC
DMZ4PLC DN Pyrrolo[2,3-d]pyrimidine derivative 15
DMZ4PLC HS Patented
DMZ4PLC SN PMID28705083-Compound-13
DMZ4PLC CP PHARMACYCLICS, INC
DMZ4PLC DT Small molecular drug
DM1GYZQ ID DM1GYZQ
DM1GYZQ DN Pyrrolo[2,3-d]pyrimidine derivative 16
DM1GYZQ HS Patented
DM1GYZQ SN PMID28705083-Compound-14
DM1GYZQ CP PRINCIPIA BIOPHARMA INCPRINCIPIA BIOPHARMA INC. GOLDSTEIN, David Michael BRAMELD, Kenneth Albert
DM1GYZQ DT Small molecular drug
DM1GYZQ PC 89188538
DM1GYZQ MW 504.6
DM1GYZQ FM C30H28N6O2
DM1GYZQ IC InChI=1S/C30H28N6O2/c31-16-22(15-20-8-9-20)30(37)35-14-4-5-23(17-35)36-18-26(27-28(32)33-19-34-29(27)36)21-10-12-25(13-11-21)38-24-6-2-1-3-7-24/h1-3,6-7,10-13,15,18-20,23H,4-5,8-9,14,17H2,(H2,32,33,34)/b22-15-
DM1GYZQ CS C1CC(CN(C1)C(=O)/C(=C\\C2CC2)/C#N)N3C=C(C4=C(N=CN=C43)N)C5=CC=C(C=C5)OC6=CC=CC=C6
DM1GYZQ IK QBWDAFICRCELKK-JCMHNJIXSA-N
DM1GYZQ IU (Z)-2-[3-[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]piperidine-1-carbonyl]-3-cyclopropylprop-2-enenitrile
DM1GYZQ DE Solid tumour/cancer; Autoimmune disease
DMXWVN2 ID DMXWVN2
DMXWVN2 DN Pyrrolo[2,3-d]pyrimidine derivative 17
DMXWVN2 HS Patented
DMXWVN2 SN PMID28705083-Compound-15
DMXWVN2 CP PRINCIPIA BIOPHARMA INCPRINCIPIA BIOPHARMA INC. GOLDSTEIN, David Michael BRAMELD, Kenneth Albert
DMXWVN2 DT Small molecular drug
DMXWVN2 PC 90002026
DMXWVN2 MW 549.7
DMXWVN2 FM C32H35N7O2
DMXWVN2 IC InChI=1S/C32H35N7O2/c1-32(2,37(3)4)17-23(18-33)31(40)39-16-8-9-24(39)19-38-20-27(28-29(34)35-21-36-30(28)38)22-12-14-26(15-13-22)41-25-10-6-5-7-11-25/h5-7,10-15,17,20-21,24H,8-9,16,19H2,1-4H3,(H2,34,35,36)/b23-17+
DMXWVN2 CS CC(C)(/C=C(\\C#N)/C(=O)N1CCCC1CN2C=C(C3=C(N=CN=C32)N)C4=CC=C(C=C4)OC5=CC=CC=C5)N(C)C
DMXWVN2 IK BJBBMHJDZCVALB-HAVVHWLPSA-N
DMXWVN2 IU (E)-2-[2-[[4-amino-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]methyl]pyrrolidine-1-carbonyl]-4-(dimethylamino)-4-methylpent-2-enenitrile
DMXWVN2 DE Solid tumour/cancer; Autoimmune disease
DMSXH8K ID DMSXH8K
DMSXH8K DN Pyrrolo[2,3-d]pyrimidine derivative 18
DMSXH8K HS Patented
DMSXH8K SN PMID28705083-Compound-16
DMSXH8K CP ADVINUS THERAPEUTICS LIMITED
DMSXH8K DT Small molecular drug
DMSXH8K PC 71760910
DMSXH8K MW 556.7
DMSXH8K FM C34H32N6O2
DMSXH8K IC InChI=1S/C34H32N6O2/c1-21-27(3-2-4-29(21)39-33(41)25-11-7-23(8-12-25)22-5-6-22)31-28-19-30(38-32(28)37-20-36-31)24-9-13-26(14-10-24)34(42)40-17-15-35-16-18-40/h2-4,7-14,19-20,22,35H,5-6,15-18H2,1H3,(H,39,41)(H,36,37,38)
DMSXH8K CS CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C3CC3)C4=C5C=C(NC5=NC=N4)C6=CC=C(C=C6)C(=O)N7CCNCC7
DMSXH8K IK JIGUYYJYCISLMS-UHFFFAOYSA-N
DMSXH8K IU 4-cyclopropyl-N-[2-methyl-3-[6-[4-(piperazine-1-carbonyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]benzamide
DMC9TGM ID DMC9TGM
DMC9TGM DN Pyrrolo[2,3-d]pyrimidine derivative 19
DMC9TGM HS Patented
DMC9TGM SN PMID28705083-Compound-17
DMC9TGM CP ADVINUS THERAPEUTICS LIMITED
DMC9TGM DT Small molecular drug
DMC9TGM PC 72193305
DMC9TGM MW 597.7
DMC9TGM FM C36H35N7O2
DMC9TGM IC InChI=1S/C36H35N7O2/c1-41-13-15-42(16-14-41)20-23-5-7-25(8-6-23)32-18-30-34(37-22-38-35(30)40-32)29-3-2-4-33(31(29)21-44)43-36(45)28-12-11-26(24-9-10-24)17-27(28)19-39-43/h2-8,11-12,17-19,22,24,44H,9-10,13-16,20-21H2,1H3,(H,37,38,40)
DMC9TGM CS CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N=CN=C4N3)C5=C(C(=CC=C5)N6C(=O)C7=C(C=C(C=C7)C8CC8)C=N6)CO
DMC9TGM IK HPYIZQVYHGPMDT-UHFFFAOYSA-N
DMC9TGM IU 6-cyclopropyl-2-[2-(hydroxymethyl)-3-[6-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]phthalazin-1-one
DMJFYK1 ID DMJFYK1
DMJFYK1 DN Pyrrolo[2,3-d]pyrimidine derivative 2
DMJFYK1 HS Patented
DMJFYK1 SN PMID27410995-Compound-Figure3g
DMJFYK1 DT Small molecular drug
DM2E7DJ ID DM2E7DJ
DM2E7DJ DN Pyrrolo[2,3-d]pyrimidine derivative 20
DM2E7DJ HS Patented
DM2E7DJ SN PMID28705083-Compound-18
DM2E7DJ CP ADVINUS THERAPEUTICS LIMITED
DM2E7DJ DT Small molecular drug
DM2E7DJ PC 72188716
DM2E7DJ MW 614.7
DM2E7DJ FM C37H38N6O3
DM2E7DJ IC InChI=1S/C37H38N6O3/c1-41-13-15-42(16-14-41)21-24-5-7-26(8-6-24)32-20-30-35(38-23-39-36(30)40-32)28-3-2-4-33(31(28)22-44)43-17-18-46-34-19-27(25-9-10-25)11-12-29(34)37(43)45/h2-8,11-12,19-20,23,25,44H,9-10,13-18,21-22H2,1H3,(H,38,39,40)
DM2E7DJ CS CN1CCN(CC1)CC2=CC=C(C=C2)C3=CC4=C(N=CN=C4N3)C5=C(C(=CC=C5)N6CCOC7=C(C6=O)C=CC(=C7)C8CC8)CO
DM2E7DJ IK AYQKNTPWCXIAQQ-UHFFFAOYSA-N
DM2E7DJ IU 8-cyclopropyl-4-[2-(hydroxymethyl)-3-[6-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
DM9S07A ID DM9S07A
DM9S07A DN Pyrrolo[2,3-d]pyrimidine derivative 21
DM9S07A HS Patented
DM9S07A SN PMID28705083-Compound-19
DM9S07A DT Small molecular drug
DM9S07A PC 117934513
DM9S07A MW 647.7
DM9S07A FM C36H34FN7O4
DM9S07A IC InChI=1S/C36H34FN7O4/c1-2-32(46)42-10-4-5-24(18-42)44-17-23(16-40-44)29-15-26-34(38-20-39-35(26)41-29)25-6-3-7-30(27(25)19-45)43-11-12-48-31-14-22(21-8-9-21)13-28(37)33(31)36(43)47/h2-3,6-7,13-17,20-21,24,45H,1,4-5,8-12,18-19H2,(H,38,39,41)
DM9S07A CS C=CC(=O)N1CCCC(C1)N2C=C(C=N2)C3=CC4=C(N=CN=C4N3)C5=C(C(=CC=C5)N6CCOC7=C(C6=O)C(=CC(=C7)C8CC8)F)CO
DM9S07A IK SGCPAQMSTLOCLE-UHFFFAOYSA-N
DM9S07A IU 8-cyclopropyl-6-fluoro-4-[2-(hydroxymethyl)-3-[6-[1-(1-prop-2-enoylpiperidin-3-yl)pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
DMHWNSD ID DMHWNSD
DMHWNSD DN Pyrrolo[2,3-d]pyrimidine derivative 22
DMHWNSD HS Patented
DMHWNSD SN PMID28705083-Compound-20
DMHWNSD DT Small molecular drug
DMHWNSD PC 117926799
DMHWNSD MW 719.7
DMHWNSD FM C37H34F5N7O3
DMHWNSD IC InChI=1S/C37H34F5N7O3/c38-24-13-25(27(18-50)31(14-24)49-9-10-52-32-12-23(22-2-3-22)11-28(39)33(32)36(49)51)34-26-15-30(46-35(26)45-20-44-34)29-4-1-21(16-43-29)17-47-5-7-48(8-6-47)19-37(40,41)42/h1,4,11-16,20,22,50H,2-3,5-10,17-19H2,(H,44,45,46)
DMHWNSD CS C1CC1C2=CC3=C(C(=C2)F)C(=O)N(CCO3)C4=CC(=CC(=C4CO)C5=C6C=C(NC6=NC=N5)C7=NC=C(C=C7)CN8CCN(CC8)CC(F)(F)F)F
DMHWNSD IK TYFKEORPONMRPY-UHFFFAOYSA-N
DMHWNSD IU 8-cyclopropyl-6-fluoro-4-[5-fluoro-2-(hydroxymethyl)-3-[6-[5-[[4-(2,2,2-trifluoroethyl)piperazin-1-yl]methyl]pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]-2,3-dihydro-1,4-benzoxazepin-5-one
DMTMWKX ID DMTMWKX
DMTMWKX DN Pyrrolo[2,3-d]pyrimidine derivative 23
DMTMWKX HS Patented
DMTMWKX SN PMID28705083-Compound-21
DMTMWKX CP ACEA BIOSCIENCES INC
DMTMWKX DT Small molecular drug
DMTMWKX PC 72734520
DMTMWKX MW 487.5
DMTMWKX FM C26H26FN7O2
DMTMWKX IC InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)
DMTMWKX CS CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F
DMTMWKX IK UOFYSRZSLXWIQB-UHFFFAOYSA-N
DMTMWKX IU N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
DMTMWKX CA CAS 1557267-42-1
DMZQF9R ID DMZQF9R
DMZQF9R DN Pyrrolo[2,3-d]pyrimidine derivative 24
DMZQF9R HS Patented
DMZQF9R SN PMID28705083-Compound-22
DMZQF9R DT Small molecular drug
DMZQF9R PC 90468938
DMZQF9R MW 445.5
DMZQF9R FM C24H23N5O4
DMZQF9R IC InChI=1S/C24H23N5O4/c1-3-21(30)26-17-5-4-6-19(15-17)33-23-20-11-12-25-22(20)28-24(29-23)27-16-7-9-18(10-8-16)32-14-13-31-2/h3-12,15H,1,13-14H2,2H3,(H,26,30)(H2,25,27,28,29)
DMZQF9R CS COCCOC1=CC=C(C=C1)NC2=NC3=C(C=CN3)C(=N2)OC4=CC=CC(=C4)NC(=O)C=C
DMZQF9R IK GVVINAQSLGCCRZ-UHFFFAOYSA-N
DMZQF9R IU N-[3-[[2-[4-(2-methoxyethoxy)anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
DMWU3O4 ID DMWU3O4
DMWU3O4 DN Pyrrolo[2,3-d]pyrimidine derivative 25
DMWU3O4 HS Patented
DMWU3O4 SN PMID28705083-Compound-23
DMWU3O4 CP MERCK SHARP & DOHME CORP. MERCK SHARP &amDOHME B.V. DE MAN, Adrianus P.A. STERRENBURG, Jan-Gerard RAAIJMAKERS, Hans C.A. KAPTEIN, Allard OUBRIE, Arthur REWINKEL, Johannes B.M. JANS, Christiaan G.J.M. WIJKMANS, Jacobus C.H.M BARF, Tjeerd A. COOPER, Alan B. KIM, Ronald M. BOGA, Sobhana Babu ZHU, Hugh Y. GAO, Xiaolei YAO, Xin ANAND, Rajan WU, Hao LIU, Shilan YANG, Chundao ALHASSAN, Abdul-Basit WANG, James YU, Younong LIU, Jian VACCARO, Henry M
DMWU3O4 DT Small molecular drug
DMX1ANB ID DMX1ANB
DMX1ANB DN Pyrrolo[2,3-d]pyrimidine derivative 26
DMX1ANB HS Patented
DMX1ANB SN PMID28705083-Compound-24
DMX1ANB CP TAIHO PHARMACEUTICAL CO., LTD
DMX1ANB DT Small molecular drug
DMX1ANB PC 118519862
DMX1ANB MW 451.9
DMX1ANB FM C21H18ClN7O3
DMX1ANB IC InChI=1S/C21H18ClN7O3/c1-2-16(30)28-6-5-12(8-28)29-9-13(17-18(23)24-10-25-19(17)29)20(31)27-21-26-14-7-11(22)3-4-15(14)32-21/h2-4,7,9-10,12H,1,5-6,8H2,(H2,23,24,25)(H,26,27,31)
DMX1ANB CS C=CC(=O)N1CCC(C1)N2C=C(C3=C(N=CN=C32)N)C(=O)NC4=NC5=C(O4)C=CC(=C5)Cl
DMX1ANB IK HDJGAVFAWSMJSN-UHFFFAOYSA-N
DMX1ANB IU 4-amino-N-(5-chloro-1,3-benzoxazol-2-yl)-7-(1-prop-2-enoylpyrrolidin-3-yl)pyrrolo[2,3-d]pyrimidine-5-carboxamide
DMCZJ1W ID DMCZJ1W
DMCZJ1W DN Pyrrolo[2,3-d]pyrimidine derivative 27
DMCZJ1W HS Patented
DMCZJ1W SN PMID28705083-Compound-25
DMCZJ1W CP PHARMASCIENCE INC
DMCZJ1W DT Small molecular drug
DMCZJ1W PC 118119806
DMCZJ1W MW 484.5
DMCZJ1W FM C27H25FN6O2
DMCZJ1W IC InChI=1S/C27H25FN6O2/c1-16(2)34-13-21(24-26(29)32-15-33-27(24)34)19-7-9-20(10-8-19)36-23-6-4-5-22(25(23)28)35-14-18-11-30-17(3)31-12-18/h4-13,15-16H,14H2,1-3H3,(H2,29,32,33)
DMCZJ1W CS CC1=NC=C(C=N1)COC2=C(C(=CC=C2)OC3=CC=C(C=C3)C4=CN(C5=NC=NC(=C45)N)C(C)C)F
DMCZJ1W IK HVHZPWHNJSXHGP-UHFFFAOYSA-N
DMCZJ1W IU 5-[4-[2-fluoro-3-[(2-methylpyrimidin-5-yl)methoxy]phenoxy]phenyl]-7-propan-2-ylpyrrolo[2,3-d]pyrimidin-4-amine
DMXRJI2 ID DMXRJI2
DMXRJI2 DN Pyrrolo[2,3-d]pyrimidine derivative 28
DMXRJI2 HS Patented
DMXRJI2 SN PMID28705083-Compound-26
DMXRJI2 CP MEDIVATION TECHNOLOGIES, INC
DMXRJI2 DT Small molecular drug
DMXRJI2 PC 118025736
DMXRJI2 MW 360.4
DMXRJI2 FM C21H17FN4O
DMXRJI2 IC InChI=1S/C21H17FN4O/c22-15-5-14(8-17(27)9-15)18-10-26(21-19(18)20(23)24-11-25-21)16-6-12-3-1-2-4-13(12)7-16/h1-5,8-11,16,27H,6-7H2,(H2,23,24,25)
DMXRJI2 CS C1C(CC2=CC=CC=C21)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC(=C5)F)O
DMXRJI2 IK FOYDQEHGCZAQII-UHFFFAOYSA-N
DMXRJI2 IU 3-[4-amino-7-(2,3-dihydro-1H-inden-2-yl)pyrrolo[2,3-d]pyrimidin-5-yl]-5-fluorophenol
DM6IJRG ID DM6IJRG
DM6IJRG DN Pyrrolo[2,3-d]pyrimidine derivative 29
DM6IJRG HS Patented
DM6IJRG SN PMID28705083-Compound-27
DM6IJRG CP F. HOFFMANN-LA ROCHE AG HOFFMANN-LA ROCHE INC
DM6IJRG DT Small molecular drug
DM6IJRG PC 90125978
DM6IJRG MW 474.5
DM6IJRG FM C24H23FN8O2
DM6IJRG IC InChI=1S/C24H23FN8O2/c1-24(2,3)23-31-21(32-35-23)22(34)26-9-14-6-5-13(7-17(14)25)19-16-8-18(15-10-29-33(4)11-15)30-20(16)28-12-27-19/h5-8,10-12H,9H2,1-4H3,(H,26,34)(H,27,28,30)
DM6IJRG CS CC(C)(C)C1=NC(=NO1)C(=O)NCC2=C(C=C(C=C2)C3=C4C=C(NC4=NC=N3)C5=CN(N=C5)C)F
DM6IJRG IK XRNHJQXCSOAXLV-UHFFFAOYSA-N
DM6IJRG IU 5-tert-butyl-N-[[2-fluoro-4-[6-(1-methylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]methyl]-1,2,4-oxadiazole-3-carboxamide
DMTX1G4 ID DMTX1G4
DMTX1G4 DN Pyrrolo[2,3-d]pyrimidine derivative 3
DMTX1G4 HS Patented
DMTX1G4 SN PMID28270021-Compound-WO2012137089cE-245677
DMTX1G4 CP PFIZER LIMITED ANDREWS, Mark David BAGAL, Sharanjeet Kaur GIBSON, Karl Richard OMOTO, Kiyoyuki RYCKMANS, Thomas SKERRATT, Sarah Elizabeth STUPPLE, Paul Anthony
DMTX1G4 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM57W29 ID DM57W29
DM57W29 DN Pyrrolo[2,3-d]pyrimidine derivative 30
DM57W29 HS Patented
DM57W29 SN PMID28705083-Compound-28
DM57W29 CP NOVARTIS AG HENG, Richard HOEGENAUER, Elizabeth, Kate KOCH, Guido PULZ, Robert, Alexander VULPETTI, Anna WAELCHLI, Rudolf
DM57W29 DT Small molecular drug
DM57W29 PC 71230726
DM57W29 MW 572.7
DM57W29 FM C31H33FN6O2S
DM57W29 IC InChI=1S/C31H33FN6O2S/c1-17-5-6-26-20(11-17)12-27(41-26)30(39)36-24-14-21(32)13-22(18(24)2)28-23-15-25(35-29(23)34-16-33-28)19-7-9-38(10-8-19)31(40)37(3)4/h7,12-17H,5-6,8-11H2,1-4H3,(H,36,39)(H,33,34,35)
DM57W29 CS CC1CCC2=C(C1)C=C(S2)C(=O)NC3=CC(=CC(=C3C)C4=C5C=C(NC5=NC=N4)C6=CCN(CC6)C(=O)N(C)C)F
DM57W29 IK AFEUSBPUCPEXMI-UHFFFAOYSA-N
DM57W29 IU 4-[4-[5-fluoro-2-methyl-3-[(5-methyl-4,5,6,7-tetrahydro-1-benzothiophene-2-carbonyl)amino]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-N,N-dimethyl-3,6-dihydro-2H-pyridine-1-carboxamide
DMA9PM4 ID DMA9PM4
DMA9PM4 DN Pyrrolo[2,3-d]pyrimidine derivative 31
DMA9PM4 HS Patented
DMA9PM4 SN PMID28705083-Compound-29
DMA9PM4 CP BIOGEN MA INC. SUNESIS PHARMACEUTICALS, INC
DMA9PM4 DT Small molecular drug
DMA9PM4 PC 122662718
DMA9PM4 MW 594.7
DMA9PM4 FM C33H34N6O3S
DMA9PM4 IC InChI=1S/C33H34N6O3S/c1-20-15-23(9-10-24(20)17-34-30(40)31-35-18-27(43-31)33(2,3)4)28-25-16-26(38-29(25)37-19-36-28)21-5-7-22(8-6-21)32(41)39-11-13-42-14-12-39/h5-10,15-16,18-19H,11-14,17H2,1-4H3,(H,34,40)(H,36,37,38)
DMA9PM4 CS CC1=C(C=CC(=C1)C2=C3C=C(NC3=NC=N2)C4=CC=C(C=C4)C(=O)N5CCOCC5)CNC(=O)C6=NC=C(S6)C(C)(C)C
DMA9PM4 IK HVNCDYSVQHLXPA-UHFFFAOYSA-N
DMA9PM4 IU 5-tert-butyl-N-[[2-methyl-4-[6-[4-(morpholine-4-carbonyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]methyl]-1,3-thiazole-2-carboxamide
DMQGI0R ID DMQGI0R
DMQGI0R DN Pyrrolo[2,3-d]pyrimidine derivative 32
DMQGI0R HS Patented
DMQGI0R SN PMID28705083-Compound-30
DMQGI0R DT Small molecular drug
DMQGI0R PC 86764737
DMQGI0R MW 427.5
DMQGI0R FM C24H25N7O
DMQGI0R IC InChI=1S/C24H25N7O/c1-2-21(32)30-10-6-9-19(15-30)29-24-22-20(12-25-23(22)26-16-27-24)18-11-28-31(14-18)13-17-7-4-3-5-8-17/h2-5,7-8,11-12,14,16,19H,1,6,9-10,13,15H2,(H2,25,26,27,29)
DMQGI0R CS C=CC(=O)N1CCCC(C1)NC2=NC=NC3=C2C(=CN3)C4=CN(N=C4)CC5=CC=CC=C5
DMQGI0R IK KOFRBWGSVPRLLQ-UHFFFAOYSA-N
DMQGI0R IU 1-[3-[[5-(1-benzylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]prop-2-en-1-one
DM6BTMX ID DM6BTMX
DM6BTMX DN Pyrrolo[2,3-d]pyrimidine derivative 33
DM6BTMX HS Patented
DM6BTMX SN PMID28705083-Compound-31
DM6BTMX CP UNIVERSITY OF UTAH RESEARCH FOUNDATION
DM6BTMX DT Small molecular drug
DM6BTMX PC 73669702
DM6BTMX MW 474.9
DM6BTMX FM C25H23ClN6O2
DM6BTMX IC InChI=1S/C25H23ClN6O2/c1-2-21(33)28-17-6-3-5-16(13-17)23-22-20(26)15-27-24(22)31-25(30-23)29-18-7-4-8-19(14-18)32-9-11-34-12-10-32/h2-8,13-15H,1,9-12H2,(H,28,33)(H2,27,29,30,31)
DM6BTMX CS C=CC(=O)NC1=CC=CC(=C1)C2=C3C(=CNC3=NC(=N2)NC4=CC(=CC=C4)N5CCOCC5)Cl
DM6BTMX IK OQGHSORLLAGPRT-UHFFFAOYSA-N
DM6BTMX IU N-[3-[5-chloro-2-(3-morpholin-4-ylanilino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]phenyl]prop-2-enamide
DMXU08A ID DMXU08A
DMXU08A DN Pyrrolo[2,3-d]pyrimidine derivative 35
DMXU08A HS Patented
DMXU08A SN PMID27410995-Compound-Figure3b
DMXU08A DT Small molecular drug
DME0WSR ID DME0WSR
DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4
DME0WSR HS Patented
DME0WSR SN PMID28270021-Compound-WO2012137089PF-06278121 (Example 9)
DME0WSR CP PFIZER LIMITED ANDREWS, Mark David BAGAL, Sharanjeet Kaur GIBSON, Karl Richard OMOTO, Kiyoyuki RYCKMANS, Thomas SKERRATT, Sarah Elizabeth STUPPLE, Paul Anthony
DME0WSR DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM3D1L6 ID DM3D1L6
DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6
DM3D1L6 HS Patented
DM3D1L6 SN PMID27774822-Compound-Figure5Example10
DM3D1L6 CP PFIZER INC
DM3D1L6 DT Small molecular drug
DM30Y8M ID DM30Y8M
DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7
DM30Y8M HS Patented
DM30Y8M SN PMID27774822-Compound-Figure5Example14
DM30Y8M CP PFIZER INC
DM30Y8M DT Small molecular drug
DMAW6KU ID DMAW6KU
DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8
DMAW6KU HS Patented
DMAW6KU SN PMID27774822-Compound-Figure5Example2
DMAW6KU CP PFIZER INC
DMAW6KU DT Small molecular drug
DM0HU5O ID DM0HU5O
DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9
DM0HU5O HS Patented
DM0HU5O SN PMID26161698-Compound-1
DM0HU5O CP NOVARTIS AG ASTEX THERAPEUTICS LTD. BESONG, Gilbert BRAIN, Christopher Thomas BROOKS, Clinton A. CONGREVE, Miles Stuart DAGOSTIN, Claudio HE, Guo HOU, Ying HOWARD, Steven LI, Yue LU, Yipin MORTENSON, Paul SMITH, Troy SUNG, Moo WOODHEAD, Steven WRONA, Wojciech
DM0HU5O DT Small molecular drug
DM0HU5O PC 44818950
DM0HU5O MW 476.6
DM0HU5O FM C26H36N8O
DM0HU5O IC InChI=1S/C26H36N8O/c1-18(2)32-11-13-33(14-12-32)21-9-10-23(27-17-21)29-26-28-16-19-15-22(25(35)31(3)4)34(24(19)30-26)20-7-5-6-8-20/h9-10,15-18,20H,5-8,11-14H2,1-4H3,(H,27,28,29,30)
DM0HU5O CS CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C(N(C4=N3)C5CCCC5)C(=O)N(C)C
DM0HU5O IK XVVBHKGQHJECBA-UHFFFAOYSA-N
DM0HU5O IU 7-cyclopentyl-N,N-dimethyl-2-[[5-(4-propan-2-ylpiperazin-1-yl)pyridin-2-yl]amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
DMKF8HI ID DMKF8HI
DMKF8HI DN Pyrrolo[3,2-c]pyridine derivative 1
DMKF8HI HS Patented
DMKF8HI SN PMID28270021-Compound-WO2014053968Example5
DMKF8HI CP PFIZER LIMITED
DMKF8HI DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMS4I6B ID DMS4I6B
DMS4I6B DN Pyrrolo-benzo-diazine derivative 1
DMS4I6B HS Patented
DMS4I6B SN PMID25539043-Compound-WO2010151597Example35
DMS4I6B CP SCHERING CORPORATION HO, Ginny, D. TULSHIAN, Deen HEAP, Charles, R. EARLEY, William, G. COURNEYA, Brandy
DMS4I6B DT Small molecular drug
DMP8I02 ID DMP8I02
DMP8I02 DN Pyrrolo-pyrazine derivative 1
DMP8I02 HS Patented
DMP8I02 SN PMID27774822-Compound-Figure5Example168
DMP8I02 CP PFIZER INC
DMP8I02 DT Small molecular drug
DMO9Q8J ID DMO9Q8J
DMO9Q8J DN Pyrrolo-pyrazine derivative 2
DMO9Q8J HS Patented
DMO9Q8J SN PMID27774822-Compound-Figure6Example1
DMO9Q8J CP PRINCIPIA BIOPHARMA INC
DMO9Q8J DT Small molecular drug
DMO9Q8J PC 74223673
DMO9Q8J MW 363.4
DMO9Q8J FM C20H21N5O2
DMO9Q8J IC InChI=1S/C20H21N5O2/c1-5-16(26)23-13-8-6-7-12(9-13)15-11-22-18-17(24-15)14(10-21-18)19(27)25-20(2,3)4/h5-11H,1H2,2-4H3,(H,21,22)(H,23,26)(H,25,27)
DMO9Q8J CS CC(C)(C)NC(=O)C1=CNC2=NC=C(N=C12)C3=CC(=CC=C3)NC(=O)C=C
DMO9Q8J IK RGYYZLGXRYSDRO-UHFFFAOYSA-N
DMO9Q8J IU N-tert-butyl-2-[3-(prop-2-enoylamino)phenyl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide
DMLM6DT ID DMLM6DT
DMLM6DT DN Pyrrolo-pyrazine derivative 3
DMLM6DT HS Patented
DMLM6DT SN PMID27774822-Compound-Figure7ExampleI-29
DMLM6DT CP F. HOFFMANN-LA ROCHE AG CHEN, Shaoqing DE VICENTE FIDALGO, Javier HAMILTON, Matthew Michael HERMANN, Johannes Cornelius KENNEDY-SMITH, Joshua LI, Hongju LOVEY, Allen John LUCAS, Matthew C. LUK, Kin-Chun Thomas LYNCH, Stephen M. O'YANG, Counde PADILLA, Fernando SCHOENFELD, Ryan Craig SIDDURI, Achyutharao SOTH, Michael WANG, Ce WOVKULICH, Peter Michael ZHANG, Xiaohu
DMLM6DT DT Small molecular drug
DMD1S92 ID DMD1S92
DMD1S92 DN Pyrrolo-pyrazine derivative 4
DMD1S92 HS Patented
DMD1S92 SN PMID27774822-Compound-Figure7ExampleI-4
DMD1S92 CP F. HOFFMANN-LA ROCHE AG CHEN, Shaoqing DE VICENTE FIDALGO, Javier HAMILTON, Matthew Michael HERMANN, Johannes Cornelius KENNEDY-SMITH, Joshua LI, Hongju LOVEY, Allen John LUCAS, Matthew C. LUK, Kin-Chun Thomas LYNCH, Stephen M. O'YANG, Counde PADILLA, Fernando SCHOENFELD, Ryan Craig SIDDURI, Achyutharao SOTH, Michael WANG, Ce WOVKULICH, Peter Michael ZHANG, Xiaohu
DMD1S92 DT Small molecular drug
DMQ2U54 ID DMQ2U54
DMQ2U54 DN Pyrrolo-pyridazine derivative 1
DMQ2U54 HS Patented
DMQ2U54 SN PMID28117607-Compound-2
DMQ2U54 CP PFIZER INC
DMQ2U54 DT Small molecular drug
DM9K5CI ID DM9K5CI
DM9K5CI DN Pyrrolo-pyridine derivative 1
DM9K5CI HS Patented
DM9K5CI SN PMID28117607-Compound-10
DM9K5CI CP H. LUNDBECK A/S VERNALIS (R&D) LTD
DM9K5CI DT Small molecular drug
DMVNY5I ID DMVNY5I
DMVNY5I DN Pyrrolo-pyridine derivative 2
DMVNY5I HS Patented
DMVNY5I SN PMID28117607-Compound-11
DMVNY5I CP H. LUNDBECK A/S VERNALIS (R&D) LTD
DMVNY5I DT Small molecular drug
DMSNQEJ ID DMSNQEJ
DMSNQEJ DN Pyrrolo-pyridine derivative 3
DMSNQEJ HS Patented
DMSNQEJ SN PMID27774822-Compound-Figure8Example55
DMSNQEJ DT Small molecular drug
DMK820T ID DMK820T
DMK820T DN Pyrrolo-pyridinone derivative 1
DMK820T HS Patented
DMK820T SN PMID27646564-Compound-8
DMK820T CP NERVIANO MEDICAL SCIENCES S.R.L
DMK820T DT Small molecular drug
DM5G67X ID DM5G67X
DM5G67X DN Pyrrolo-pyridinone derivative 2
DM5G67X HS Patented
DM5G67X SN PMID27646564-Compound-8-1
DM5G67X CP NERVIANO MEDICAL SCIENCES S.R.L
DM5G67X DT Small molecular drug
DME1Q3W ID DME1Q3W
DME1Q3W DN Pyrrolo-pyridinone derivative 3
DME1Q3W HS Patented
DME1Q3W SN PMID27646564-Compound-8-2
DME1Q3W CP NERVIANO MEDICAL SCIENCES S.R.L
DME1Q3W DT Small molecular drug
DM2EVJR ID DM2EVJR
DM2EVJR DN Pyrrolo-pyridinone derivative 4
DM2EVJR HS Patented
DM2EVJR SN PMID27646564-Compound-8-3
DM2EVJR CP NERVIANO MEDICAL SCIENCES S.R.L
DM2EVJR DT Small molecular drug
DMK2FSY ID DMK2FSY
DMK2FSY DN Pyrrolo-pyridinone derivative 5
DMK2FSY HS Patented
DMK2FSY SN PMID25539043-Compound-WO2013161312Example15
DMK2FSY CP RAQUALIA PHARMA INC
DMK2FSY DT Small molecular drug
DMXGNP8 ID DMXGNP8
DMXGNP8 DN Pyrrolo-pyridinone derivative 6
DMXGNP8 HS Patented
DMXGNP8 SN PMID25539043-Compound-WO2013161312Example16
DMXGNP8 CP RAQUALIA PHARMA INC
DMXGNP8 DT Small molecular drug
DMR6QCE ID DMR6QCE
DMR6QCE DN Pyrrolo-pyridone derivative 1
DMR6QCE HS Patented
DMR6QCE SN PMID27774822-Compound-Figure2Example1-19
DMR6QCE CP MERCK SHARP & DOHME CORP. DINSMORE, Christopher FULLER, Peter GUERIN, David THOMPSON, Christopher F. PU, Qinglin SCOTT, Mark E. KATZ, Jason David KURUKULASURIYA, Ravi CLOSE, Joshua T. FALCONE, Danielle BRUBAKER, Jason ZENG, Hongbo BAI, Yunfeng FU, Jianmin KONG, Norman LIU, Yumei ZHENG, Zhixiang
DMR6QCE DT Small molecular drug
DMCZ8UV ID DMCZ8UV
DMCZ8UV DN Pyrrolo-pyridone derivative 2
DMCZ8UV HS Patented
DMCZ8UV SN PMID27774822-Compound-Figure2ExampleII-92
DMCZ8UV CP MERCK SHARP & DOHME [US]
DMCZ8UV DT Small molecular drug
DMUIK3W ID DMUIK3W
DMUIK3W DN Pyrrolo-pyridone derivative 3
DMUIK3W HS Patented
DMUIK3W SN PMID27774822-Compound-Figure9Example4
DMUIK3W CP TAKEDA PHARMACEUTICAL COMPANY LIMITED
DMUIK3W DT Small molecular drug
DMEVXT0 ID DMEVXT0
DMEVXT0 DN Pyrrolo-pyrimidine derivative 1
DMEVXT0 HS Patented
DMEVXT0 SN PMID28117607-Compound-1
DMEVXT0 CP Pfizer Inc., USA. Assignee
DMEVXT0 DT Small molecular drug
DMR0ZU6 ID DMR0ZU6
DMR0ZU6 DN Pyrrolo-pyrimidine derivative 10
DMR0ZU6 HS Patented
DMR0ZU6 SN PMID28117607-Compound-43
DMR0ZU6 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&D COMPANY LIMITED
DMR0ZU6 DT Small molecular drug
DMEIDC0 ID DMEIDC0
DMEIDC0 DN Pyrrolo-pyrimidine derivative 11
DMEIDC0 HS Patented
DMEIDC0 SN PMID28117607-Compound-44
DMEIDC0 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&D COMPANY LIMITED
DMEIDC0 DT Small molecular drug
DMEHYBJ ID DMEHYBJ
DMEHYBJ DN Pyrrolo-pyrimidine derivative 2
DMEHYBJ HS Patented
DMEHYBJ SN PMID27646564-Compound-7
DMEHYBJ CP NERVIANO MEDICAL SCIENCES S.R.L
DMEHYBJ DT Small molecular drug
DMKHWN9 ID DMKHWN9
DMKHWN9 DN Pyrrolo-pyrimidine derivative 3
DMKHWN9 HS Patented
DMKHWN9 SN PMID27646564-Compound-7-1
DMKHWN9 CP NERVIANO MEDICAL SCIENCES S.R.L
DMKHWN9 DT Small molecular drug
DMITK03 ID DMITK03
DMITK03 DN Pyrrolo-pyrimidine derivative 4
DMITK03 HS Patented
DMITK03 SN PMID27646564-Compound-7-2
DMITK03 CP NERVIANO MEDICAL SCIENCES S.R.L
DMITK03 DT Small molecular drug
DMVA95G ID DMVA95G
DMVA95G DN Pyrrolo-pyrimidine derivative 5
DMVA95G HS Patented
DMVA95G SN PMID27646564-Compound-7-3
DMVA95G CP NERVIANO MEDICAL SCIENCES S.R.L
DMVA95G DT Small molecular drug
DMVA95G PC 86292773
DMVA95G MW 417.4
DMVA95G FM C20H15F4N5O
DMVA95G IC InChI=1S/C20H15F4N5O/c21-15-6-3-12(19(30)28-14-4-5-14)7-11(15)1-2-13-8-29(9-20(22,23)24)18-16(13)17(25)26-10-27-18/h3,6-8,10,14H,4-5,9H2,(H,28,30)(H2,25,26,27)
DMVA95G CS C1CC1NC(=O)C2=CC(=C(C=C2)F)C#CC3=CN(C4=NC=NC(=C34)N)CC(F)(F)F
DMVA95G IK SHIKADMSFNHXTC-UHFFFAOYSA-N
DMVA95G IU 3-[2-[4-amino-7-(2,2,2-trifluoroethyl)pyrrolo[2,3-d]pyrimidin-5-yl]ethynyl]-N-cyclopropyl-4-fluorobenzamide
DMGYT81 ID DMGYT81
DMGYT81 DN Pyrrolo-pyrimidine derivative 6
DMGYT81 HS Patented
DMGYT81 SN PMID27646564-Compound-7-4
DMGYT81 CP NERVIANO MEDICAL SCIENCES S.R.L
DMGYT81 DT Small molecular drug
DMZH27I ID DMZH27I
DMZH27I DN Pyrrolo-pyrimidine derivative 8
DMZH27I HS Patented
DMZH27I SN PMID28117607-Compound-41
DMZH27I CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&D COMPANY LIMITED
DMZH27I DT Small molecular drug
DMJEV86 ID DMJEV86
DMJEV86 DN Pyrrolo-pyrimidine derivative 9
DMJEV86 HS Patented
DMJEV86 SN PMID28117607-Compound-42
DMJEV86 CP GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED GLAXOSMITHKLINE (CHINA) R&D COMPANY LIMITED
DMJEV86 DT Small molecular drug
DMN4SE5 ID DMN4SE5
DMN4SE5 DN Pyrrolo-pyrrolone derivative 1
DMN4SE5 HS Patented
DMN4SE5 SN PMID26924192-Compound-34
DMN4SE5 CP NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMN4SE5 DT Small molecular drug
DMN4SE5 PC 122553486
DMN4SE5 MW 515
DMN4SE5 FM C28H27ClN6O2
DMN4SE5 IC InChI=1S/C28H27ClN6O2/c1-15-10-21(13-33-16(2)30-31-27(15)33)35-25(19-6-8-20(29)9-7-19)26-24(28(35)37)23(18-4-5-18)14-34(26)22-11-32(12-22)17(3)36/h6-10,13-14,18,22,25H,4-5,11-12H2,1-3H3
DMN4SE5 CS CC1=CC(=CN2C1=NN=C2C)N3C(C4=C(C3=O)C(=CN4C5CN(C5)C(=O)C)C6CC6)C7=CC=C(C=C7)Cl
DMN4SE5 IK CASINEGODQBEAL-UHFFFAOYSA-N
DMN4SE5 IU 1-(1-acetylazetidin-3-yl)-6-(4-chlorophenyl)-3-cyclopropyl-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-6H-pyrrolo[3,4-b]pyrrol-4-one
DM8VYMA ID DM8VYMA
DM8VYMA DN Pyrrolo-pyrrolone derivative 2
DM8VYMA HS Patented
DM8VYMA SN PMID26924192-Compound-35
DM8VYMA CP NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DM8VYMA DT Small molecular drug
DM8VYMA PC 118095207
DM8VYMA MW 448.9
DM8VYMA FM C23H21ClN6O2
DM8VYMA IC InChI=1S/C23H21ClN6O2/c1-12-9-15(10-17-19(12)26-27-29(17)4)30-20(13-5-7-14(24)8-6-13)21-18(23(30)32)16(11-28(21)3)22(31)25-2/h5-11,20H,1-4H3,(H,25,31)
DM8VYMA CS CC1=CC(=CC2=C1N=NN2C)N3C(C4=C(C3=O)C(=CN4C)C(=O)NC)C5=CC=C(C=C5)Cl
DM8VYMA IK VQZKOWOEYPJMPU-UHFFFAOYSA-N
DM8VYMA IU 6-(4-chlorophenyl)-5-(3,7-dimethylbenzotriazol-5-yl)-N,1-dimethyl-4-oxo-6H-pyrrolo[3,4-b]pyrrole-3-carboxamide
DMHGPU1 ID DMHGPU1
DMHGPU1 DN Pyrrolo-pyrrolone derivative 3
DMHGPU1 HS Patented
DMHGPU1 SN PMID26924192-Compound-36
DMHGPU1 CP NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMHGPU1 DT Small molecular drug
DMHGPU1 PC 122553422
DMHGPU1 MW 516
DMHGPU1 FM C27H26ClN7O2
DMHGPU1 IC InChI=1S/C27H26ClN7O2/c1-14-10-21(29-26-23(14)30-31-32(26)3)35-24(17-6-8-18(28)9-7-17)25-22(27(35)37)20(16-4-5-16)13-34(25)19-11-33(12-19)15(2)36/h6-10,13,16,19,24H,4-5,11-12H2,1-3H3
DMHGPU1 CS CC1=CC(=NC2=C1N=NN2C)N3C(C4=C(C3=O)C(=CN4C5CN(C5)C(=O)C)C6CC6)C7=CC=C(C=C7)Cl
DMHGPU1 IK NBJPFMDWXKYTQF-UHFFFAOYSA-N
DMHGPU1 IU 1-(1-acetylazetidin-3-yl)-6-(4-chlorophenyl)-3-cyclopropyl-5-(3,7-dimethyltriazolo[4,5-b]pyridin-5-yl)-6H-pyrrolo[3,4-b]pyrrol-4-one
DMFJBZI ID DMFJBZI
DMFJBZI DN Pyrrolo-pyrrolone derivative 4
DMFJBZI HS Patented
DMFJBZI SN PMID26924192-Compound-37
DMFJBZI CP NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMFJBZI DT Small molecular drug
DMFJBZI PC 118095161
DMFJBZI MW 500.9
DMFJBZI FM C22H19ClF2N8O2
DMFJBZI IC InChI=1S/C22H19ClF2N8O2/c1-10-8-14(30-33-19(10)28-29-20(33)18(24)25)32-16(11-4-6-12(23)7-5-11)17-15(21(32)34)13(9-31(17)3)27-22(35)26-2/h4-9,16,18H,1-3H3,(H2,26,27,35)
DMFJBZI CS CC1=CC(=NN2C1=NN=C2C(F)F)N3C(C4=C(C3=O)C(=CN4C)NC(=O)NC)C5=CC=C(C=C5)Cl
DMFJBZI IK RNLAJPMWXHNSOJ-UHFFFAOYSA-N
DMFJBZI IU 1-[6-(4-chlorophenyl)-5-[3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-1-methyl-4-oxo-6H-pyrrolo[3,4-b]pyrrol-3-yl]-3-methylurea
DMMX0N5 ID DMMX0N5
DMMX0N5 DN Pyrrolo-pyrrolone derivative 5
DMMX0N5 HS Patented
DMMX0N5 SN PMID26924192-Compound-38
DMMX0N5 CP NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMMX0N5 DT Small molecular drug
DMMX0N5 PC 118095173
DMMX0N5 MW 546
DMMX0N5 FM C29H28ClN5O4
DMMX0N5 IC InChI=1S/C29H28ClN5O4/c1-5-39-29(37)35-24(20-10-12-38-13-11-20)17(3)23-26(35)25(19-6-8-21(30)9-7-19)34(28(23)36)22-14-16(2)27-32-31-18(4)33(27)15-22/h6-10,14-15,25H,5,11-13H2,1-4H3
DMMX0N5 CS CCOC(=O)N1C2=C(C(=C1C3=CCOCC3)C)C(=O)N(C2C4=CC=C(C=C4)Cl)C5=CN6C(=NN=C6C(=C5)C)C
DMMX0N5 IK XQCLLKJYKDIUDW-UHFFFAOYSA-N
DMMX0N5 IU ethyl 6-(4-chlorophenyl)-2-(3,6-dihydro-2H-pyran-4-yl)-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methyl-4-oxo-6H-pyrrolo[3,4-b]pyrrole-1-carboxylate
DMBW208 ID DMBW208
DMBW208 DN Pyrrolo-pyrrolone derivative 6
DMBW208 HS Patented
DMBW208 SN PMID26924192-Compound-39
DMBW208 CP NOVARTIS AG [CHBLANK JUTTA [CHBOLD GUIDO [CHBORDAS VINCENT [CHCOTESTA SIMONA [CHGUAGNANO VITO [CHR EGER HEINRICH [CHVAUPEL ANDREA [CH]
DMBW208 DT Small molecular drug
DMBW208 PC 122553484
DMBW208 MW 506
DMBW208 FM C26H24ClN5O4
DMBW208 IC InChI=1S/C26H24ClN5O4/c1-14-10-17(13-30(2)24(14)33)32-21(15-6-8-16(27)9-7-15)22-18(25(32)34)11-20(31(22)3)19-12-28-26(36-5)29-23(19)35-4/h6-13,21H,1-5H3/t21-/m1/s1
DMBW208 CS CC1=CC(=CN(C1=O)C)N2[C@@H](C3=C(C2=O)C=C(N3C)C4=CN=C(N=C4OC)OC)C5=CC=C(C=C5)Cl
DMBW208 IK QLRYSHYUZMZZPY-OAQYLSRUSA-N
DMBW208 IU (6R)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-5-(1,5-dimethyl-6-oxopyridin-3-yl)-1-methyl-6H-pyrrolo[3,4-b]pyrrol-4-one
DM4DJA7 ID DM4DJA7
DM4DJA7 DN QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7 HS Patented
DM4DJA7 SN ((1R,2R,3S,4R)-2,3-dihydroxy-4-([2-(1-naphthyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino)cyclopentyl)methyl sulfamate; ((1R,2R,3S,4R)-2,3-dihydroxy-4-{[2-(1-naphthyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino}cyclopentyl)methyl sulfamate; SCHEMBL15192059; QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7 DT Small molecular drug
DM4DJA7 PC 71666343
DM4DJA7 MW 469.5
DM4DJA7 FM C22H23N5O5S
DM4DJA7 IC InChI=1S/C22H23N5O5S/c23-33(30,31)32-12-14-10-18(22(29)21(14)28)25-19-8-9-24-20-11-17(26-27(19)20)16-7-3-5-13-4-1-2-6-15(13)16/h1-9,11,14,18,21-22,25,28-29H,10,12H2,(H2,23,30,31)/t14-,18-,21-,22+/m1/s1
DM4DJA7 CS C1[C@@H]([C@H]([C@H]([C@@H]1NC2=CC=NC3=CC(=NN23)C4=CC=CC5=CC=CC=C54)O)O)COS(=O)(=O)N
DM4DJA7 IK QCPOIDRINIAUKU-SRBBEKPSSA-N
DM4DJA7 IU [(1R,2R,3S,4R)-2,3-dihydroxy-4-[(2-naphthalen-1-ylpyrazolo[1,5-a]pyrimidin-7-yl)amino]cyclopentyl]methyl sulfamate
DMH86F2 ID DMH86F2
DMH86F2 DN Quinazoline alkaloid derivative 1
DMH86F2 HS Patented
DMH86F2 SN PMID29757691-Compound-11
DMH86F2 DT Small molecular drug
DMH86F2 PC 442929
DMH86F2 MW 188.23
DMH86F2 FM C11H12N2O
DMH86F2 IC InChI=1S/C11H12N2O/c14-10-5-6-13-7-8-3-1-2-4-9(8)12-11(10)13/h1-4,10,14H,5-7H2/t10-/m1/s1
DMH86F2 CS C1CN2CC3=CC=CC=C3N=C2[C@@H]1O
DMH86F2 IK YIICVSCAKJMMDJ-SNVBAGLBSA-N
DMH86F2 IU (3R)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-3-ol
DMH86F2 CA CAS 18549-38-7
DMH86F2 CB CHEBI:7949
DMOBFAU ID DMOBFAU
DMOBFAU DN Quinazoline derivative 1
DMOBFAU HS Patented
DMOBFAU SN PMID25482888-Compound-68
DMOBFAU CP BOEHRINGER INGELHEIM INTERNATIONAL GMBH PFRENGLE, Waldemar FRANK, Markus KLEIN, Thomas
DMOBFAU DT Small molecular drug
DMOBFAU PC 71487629
DMOBFAU MW 945.1
DMOBFAU FM C50H56N16O4
DMOBFAU IC InChI=1S/C50H56N16O4/c1-6-8-24-63-40-42(56-46(63)61-22-14-16-31(51)27-61)59(4)48(69)65(44(40)67)29-38-53-35-20-12-10-18-33(35)37(55-38)26-50(3)34-19-11-13-21-36(34)54-39(58-50)30-66-45(68)41-43(60(5)49(66)70)57-47(64(41)25-9-7-2)62-23-15-17-32(52)28-62/h10-13,18-21,31-32H,14-17,22-30,51-52H2,1-5H3,(H,54,58)/t31-,32-,50?/m1/s1
DMOBFAU CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC(C5=CC=CC=C5N4)(C)CC6=NC(=NC7=CC=CC=C76)CN8C(=O)C9=C(N=C(N9CC#CC)N1CCC[C@H](C1)N)N(C8=O)C)C
DMOBFAU IK CEWRYIAJQLCIAT-BZDWUGKRSA-N
DMOBFAU IU 8-[(3R)-3-aminopiperidin-1-yl]-1-[[4-[[2-[[8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-2,6-dioxopurin-1-yl]methyl]quinazolin-4-yl]methyl]-4-methyl-1H-quinazolin-2-yl]methyl]-7-but-2-ynyl-3-methylpurine-2,6-dione
DMZ3ORT ID DMZ3ORT
DMZ3ORT DN Quinazoline derivative 10
DMZ3ORT HS Patented
DMZ3ORT SN PMID26936077-Compound-21
DMZ3ORT CP NeoPharm Co. Ltd
DMZ3ORT DT Small molecular drug
DMZ3ORT PC 6737869
DMZ3ORT MW 468.3
DMZ3ORT FM C22H15BrFN3O3
DMZ3ORT IC InChI=1S/C22H15BrFN3O3/c1-30-15-10-11-18(23)17(12-15)21(28)26-27-20(13-6-8-14(24)9-7-13)25-19-5-3-2-4-16(19)22(27)29/h2-12H,1H3,(H,26,28)
DMZ3ORT CS COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4=CC=C(C=C4)F
DMZ3ORT IK NCDCVFJWCCFMHL-UHFFFAOYSA-N
DMZ3ORT IU 2-bromo-N-[2-(4-fluorophenyl)-4-oxoquinazolin-3-yl]-5-methoxybenzamide
DMZ3ORT DE Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis
DMAH435 ID DMAH435
DMAH435 DN Quinazoline derivative 11
DMAH435 HS Patented
DMAH435 SN PMID26936077-Compound-22
DMAH435 CP NeoPharm Co. Ltd
DMAH435 DT Small molecular drug
DMAH435 PC 60163203
DMAH435 MW 456.3
DMAH435 FM C20H14BrN3O3S
DMAH435 IC InChI=1S/C20H14BrN3O3S/c1-27-12-8-9-15(21)14(11-12)19(25)23-24-18(17-7-4-10-28-17)22-16-6-3-2-5-13(16)20(24)26/h2-11H,1H3,(H,23,25)
DMAH435 CS COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4=CC=CS4
DMAH435 IK SIPGYZVTRHQPRD-UHFFFAOYSA-N
DMAH435 IU 2-bromo-5-methoxy-N-(4-oxo-2-thiophen-2-ylquinazolin-3-yl)benzamide
DMAH435 DE Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis; Gastrointestinal disease
DMVKZU2 ID DMVKZU2
DMVKZU2 DN Quinazoline derivative 12
DMVKZU2 HS Patented
DMVKZU2 SN PMID26936077-Compound-23
DMVKZU2 CP NeoPharm Co. Ltd
DMVKZU2 DT Small molecular drug
DMVKZU2 PC 60163336
DMVKZU2 MW 414.3
DMVKZU2 FM C19H16BrN3O3
DMVKZU2 IC InChI=1S/C19H16BrN3O3/c1-26-12-8-9-15(20)14(10-12)18(24)22-23-17(11-6-7-11)21-16-5-3-2-4-13(16)19(23)25/h2-5,8-11H,6-7H2,1H3,(H,22,24)
DMVKZU2 CS COC1=CC(=C(C=C1)Br)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4CC4
DMVKZU2 IK OWJRZOOAIAWSHE-UHFFFAOYSA-N
DMVKZU2 IU 2-bromo-N-(2-cyclopropyl-4-oxoquinazolin-3-yl)-5-methoxybenzamide
DMVKZU2 DE Cirrhosis; Chronic obstructive pulmonary disease; Psoriasis vulgaris; Multiple sclerosis; Gastrointestinal disease
DMFU6OD ID DMFU6OD
DMFU6OD DN Quinazoline derivative 13
DMFU6OD HS Patented
DMFU6OD SN PMID26936077-Compound-24
DMFU6OD CP NeoPharm Co. Ltd
DMFU6OD DT Small molecular drug
DMFU6OD PC 60161489
DMFU6OD MW 369.8
DMFU6OD FM C19H16ClN3O3
DMFU6OD IC InChI=1S/C19H16ClN3O3/c1-26-12-8-9-15(20)14(10-12)18(24)22-23-17(11-6-7-11)21-16-5-3-2-4-13(16)19(23)25/h2-5,8-11H,6-7H2,1H3,(H,22,24)
DMFU6OD CS COC1=CC(=C(C=C1)Cl)C(=O)NN2C(=NC3=CC=CC=C3C2=O)C4CC4
DMFU6OD IK PHWRMNPWLIXVPO-UHFFFAOYSA-N
DMFU6OD IU 2-chloro-N-(2-cyclopropyl-4-oxoquinazolin-3-yl)-5-methoxybenzamide
DMFU6OD DE Multiple sclerosis; Gastrointestinal disease; Atopic dermatitis; Arteriosclerosis
DMHLJA7 ID DMHLJA7
DMHLJA7 DN Quinazoline derivative 14
DMHLJA7 HS Patented
DMHLJA7 SN PMID27646564-Compound-12
DMHLJA7 CP CANCER RESEARCH TECHNOLOGY LIMITED
DMHLJA7 DT Small molecular drug
DMD965S ID DMD965S
DMD965S DN Quinazoline derivative 15
DMD965S HS Patented
DMD965S SN PMID27646564-Compound-12-1
DMD965S CP CANCER RESEARCH TECHNOLOGY LIMITED
DMD965S DT Small molecular drug
DMQ704Z ID DMQ704Z
DMQ704Z DN Quinazoline derivative 16
DMQ704Z HS Patented
DMQ704Z SN PMID27646564-Compound-12-2
DMQ704Z CP CANCER RESEARCH TECHNOLOGY LIMITED
DMQ704Z DT Small molecular drug
DMGECO2 ID DMGECO2
DMGECO2 DN Quinazoline derivative 2
DMGECO2 HS Patented
DMGECO2 SN PMID27607364-Compound-46
DMGECO2 DT Small molecular drug
DMGECO2 PC 24956250
DMGECO2 MW 293.32
DMGECO2 FM C17H15N3O2
DMGECO2 IC InChI=1S/C17H15N3O2/c1-20(2)17(21)22-16-13-10-6-7-11-14(13)18-15(19-16)12-8-4-3-5-9-12/h3-11H,1-2H3
DMGECO2 CS CN(C)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3
DMGECO2 IK NAXSAPGEPBKPDD-UHFFFAOYSA-N
DMGECO2 IU (2-phenylquinazolin-4-yl) N,N-dimethylcarbamate
DMF05GL ID DMF05GL
DMF05GL DN Quinazoline derivative 3
DMF05GL HS Patented
DMF05GL SN PMID27607364-Compound-47
DMF05GL CP TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMF05GL DT Small molecular drug
DMJIDLU ID DMJIDLU
DMJIDLU DN Quinazoline derivative 4
DMJIDLU HS Patented
DMJIDLU SN PMID27607364-Compound-48
DMJIDLU CP TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMJIDLU DT Small molecular drug
DMJIDLU PC 13769184
DMJIDLU MW 321.4
DMJIDLU FM C19H19N3O2
DMJIDLU IC InChI=1S/C19H19N3O2/c1-3-22(4-2)19(23)24-18-15-12-8-9-13-16(15)20-17(21-18)14-10-6-5-7-11-14/h5-13H,3-4H2,1-2H3
DMJIDLU CS CCN(CC)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3
DMJIDLU IK VZRHWILGJDZNKG-UHFFFAOYSA-N
DMJIDLU IU (2-phenylquinazolin-4-yl) N,N-diethylcarbamate
DMEIH73 ID DMEIH73
DMEIH73 DN Quinazoline derivative 5
DMEIH73 HS Patented
DMEIH73 SN PMID27607364-Compound-49
DMEIH73 CP TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMEIH73 DT Small molecular drug
DMEIH73 PC 118479984
DMEIH73 MW 327.8
DMEIH73 FM C17H14ClN3O2
DMEIH73 IC InChI=1S/C17H14ClN3O2/c1-21(2)17(22)23-16-12-8-4-6-10-14(12)19-15(20-16)11-7-3-5-9-13(11)18/h3-10H,1-2H3
DMEIH73 CS CN(C)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3Cl
DMEIH73 IK IKJKKLDPZAPXOQ-UHFFFAOYSA-N
DMEIH73 IU [2-(2-chlorophenyl)quinazolin-4-yl] N,N-dimethylcarbamate
DMKZ6MD ID DMKZ6MD
DMKZ6MD DN Quinazoline derivative 6
DMKZ6MD HS Patented
DMKZ6MD SN PMID27607364-Compound-50
DMKZ6MD CP TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMKZ6MD DT Small molecular drug
DMIBRE5 ID DMIBRE5
DMIBRE5 DN Quinazoline derivative 7
DMIBRE5 HS Patented
DMIBRE5 SN PMID27607364-Compound-51
DMIBRE5 CP TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
DMIBRE5 DT Small molecular drug
DMIBRE5 PC 118472700
DMIBRE5 MW 341.8
DMIBRE5 FM C18H16ClN3O2
DMIBRE5 IC InChI=1S/C18H16ClN3O2/c1-3-22(2)18(23)24-17-13-9-5-7-11-15(13)20-16(21-17)12-8-4-6-10-14(12)19/h4-11H,3H2,1-2H3
DMIBRE5 CS CCN(C)C(=O)OC1=NC(=NC2=CC=CC=C21)C3=CC=CC=C3Cl
DMIBRE5 IK PBHDUERHMVFHLD-UHFFFAOYSA-N
DMIBRE5 IU [2-(2-chlorophenyl)quinazolin-4-yl] N-ethyl-N-methylcarbamate
DMSD04W ID DMSD04W
DMSD04W DN Quinazolinedione derivative 1
DMSD04W HS Patented
DMSD04W SN PMID27841036-Compound-11
DMSD04W CP Impact Therapeutics Inc
DMSD04W DT Small molecular drug
DMSD04W PC 66546486
DMSD04W MW 460.5
DMSD04W FM C24H21FN6O3
DMSD04W IC InChI=1S/C24H21FN6O3/c25-19-7-6-16(15-31-20-5-2-1-4-17(20)21(32)28-24(31)34)14-18(19)22(33)29-10-12-30(13-11-29)23-26-8-3-9-27-23/h1-9,14H,10-13,15H2,(H,28,32,34)
DMSD04W CS C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=CC=CC=C5C(=O)NC4=O)F
DMSD04W IK LYSWZKKQEGTMEA-UHFFFAOYSA-N
DMSD04W IU 1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione
DM3TVI6 ID DM3TVI6
DM3TVI6 DN Quinazolinedione derivative 2
DM3TVI6 HS Patented
DM3TVI6 SN PMID27841036-Compound-12
DM3TVI6 CP Impact Therapeutics Inc
DM3TVI6 DT Small molecular drug
DM3TVI6 PC 68388735
DM3TVI6 MW 460.5
DM3TVI6 FM C24H21FN6O3
DM3TVI6 IC InChI=1S/C24H21FN6O3/c25-18-6-2-7-19-20(18)21(32)28-24(34)31(19)15-16-4-1-5-17(14-16)22(33)29-10-12-30(13-11-29)23-26-8-3-9-27-23/h1-9,14H,10-13,15H2,(H,28,32,34)
DM3TVI6 CS C1CN(CCN1C2=NC=CC=N2)C(=O)C3=CC=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O
DM3TVI6 IK QUTRGYJIPOIOGH-UHFFFAOYSA-N
DM3TVI6 IU 5-fluoro-1-[[3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione
DMZ5GIH ID DMZ5GIH
DMZ5GIH DN Quinazolinedione derivative 3
DMZ5GIH HS Patented
DMZ5GIH SN PMID27841036-Compound-13
DMZ5GIH CP Janssen Pharmaceutica NV
DMZ5GIH DT Small molecular drug
DMZ5GIH PC 59663666
DMZ5GIH MW 402.5
DMZ5GIH FM C24H26N4O2
DMZ5GIH IC InChI=1S/C24H26N4O2/c29-23-19-7-2-4-9-22(19)28(24(30)26-23)13-5-12-27-14-10-17(11-15-27)20-16-25-21-8-3-1-6-18(20)21/h1-4,6-9,16-17,25H,5,10-15H2,(H,26,29,30)
DMZ5GIH CS C1CN(CCC1C2=CNC3=CC=CC=C32)CCCN4C5=CC=CC=C5C(=O)NC4=O
DMZ5GIH IK MAJCEXQEEGYUCA-UHFFFAOYSA-N
DMZ5GIH IU 1-[3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl]quinazoline-2,4-dione
DME24BI ID DME24BI
DME24BI DN Quinazolines and azaquinazoline derivative 1
DME24BI HS Patented
DME24BI SN PMID28594589-Compound-TABLE3c13
DME24BI CP Asana Biosciences
DME24BI DT Small molecular drug
DMSU1PC ID DMSU1PC
DMSU1PC DN Quinazolinone derivative 1
DMSU1PC HS Patented
DMSU1PC SN PMID28074661-Compound-WO2004022554c47
DMSU1PC CP CELLTECH R&D LIMITED HAUGHAN, Alan, Findlay BUCKLEY, George, Martin DAVIES, Natasha DYKE, Hazel, Joan HANNAH, Duncan, Robert MORGAN, Trevor RICHARD, Marianna, Dilani SHARPE, Andrew WILLIAMS, Sophie, Caroline
DMSU1PC DT Small molecular drug
DM0XVQY ID DM0XVQY
DM0XVQY DN Quinazolinone derivative 2
DM0XVQY HS Patented
DM0XVQY SN PMID28074661-Compound-WO2004022554c48
DM0XVQY CP CELLTECH R&D LIMITED HAUGHAN, Alan, Findlay BUCKLEY, George, Martin DAVIES, Natasha DYKE, Hazel, Joan HANNAH, Duncan, Robert MORGAN, Trevor RICHARD, Marianna, Dilani SHARPE, Andrew WILLIAMS, Sophie, Caroline
DM0XVQY DT Small molecular drug
DMDRIZF ID DMDRIZF
DMDRIZF DN Quinazolinone derivative 3
DMDRIZF HS Patented
DMDRIZF SN PMID26924192-Compound-86
DMDRIZF CP ZENITH EPIGENETICS CORP
DMDRIZF DT Small molecular drug
DMDRIZF PC 137051728
DMDRIZF MW 424.5
DMDRIZF FM C23H28N4O4
DMDRIZF IC InChI=1S/C23H28N4O4/c1-27-9-7-14(8-10-27)24-18-11-15(29-2)5-6-17(18)22-25-19-12-16(30-3)13-20(31-4)21(19)23(28)26-22/h5-6,11-14,24H,7-10H2,1-4H3,(H,25,26,28)
DMDRIZF CS CN1CCC(CC1)NC2=C(C=CC(=C2)OC)C3=NC4=C(C(=CC(=C4)OC)OC)C(=O)N3
DMDRIZF IK FRAHQMXXLOFANF-UHFFFAOYSA-N
DMDRIZF IU 5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpiperidin-4-yl)amino]phenyl]-3H-quinazolin-4-one
DM8WH97 ID DM8WH97
DM8WH97 DN Quinazolinone derivative 4
DM8WH97 HS Patented
DM8WH97 SN PMID26924192-Compound-87
DM8WH97 CP ZENITH EPIGENETICS CORP
DM8WH97 DT Small molecular drug
DM8WH97 PC 137051771
DM8WH97 MW 424.5
DM8WH97 FM C23H28N4O4
DM8WH97 IC InChI=1S/C23H28N4O4/c1-27-8-7-14(13-27)12-24-18-9-15(29-2)5-6-17(18)22-25-19-10-16(30-3)11-20(31-4)21(19)23(28)26-22/h5-6,9-11,14,24H,7-8,12-13H2,1-4H3,(H,25,26,28)
DM8WH97 CS CN1CCC(C1)CNC2=C(C=CC(=C2)OC)C3=NC4=C(C(=CC(=C4)OC)OC)C(=O)N3
DM8WH97 IK PRDGUEJBCFBYCA-UHFFFAOYSA-N
DM8WH97 IU 5,7-dimethoxy-2-[4-methoxy-2-[(1-methylpyrrolidin-3-yl)methylamino]phenyl]-3H-quinazolin-4-one
DMXOKH3 ID DMXOKH3
DMXOKH3 DN Quinazolinone derivative 5
DMXOKH3 HS Patented
DMXOKH3 SN PMID26924192-Compound-88
DMXOKH3 CP ZENITH EPIGENETICS CORP
DMXOKH3 DT Small molecular drug
DMKDTO4 ID DMKDTO4
DMKDTO4 DN Quinoline and quinazoline derivative 1
DMKDTO4 HS Patented
DMKDTO4 SN PMID28621580-Compound-US20120219522c30
DMKDTO4 CP Sunshine Lake Pharma Co., LtdCalitor Sciences, LLC
DMKDTO4 DT Small molecular drug
DM6E1N4 ID DM6E1N4
DM6E1N4 DN Quinoline and quinazoline derivative 10
DM6E1N4 HS Patented
DM6E1N4 SN PMID28621580-Compound-WO2014127335c34
DM6E1N4 CP KALA PHARMACEUTICALS, INC
DM6E1N4 DT Small molecular drug
DM9PSI3 ID DM9PSI3
DM9PSI3 DN Quinoline and quinazoline derivative 2
DM9PSI3 HS Patented
DM9PSI3 SN PMID28621580-Compound-US20130165458c38
DM9PSI3 CP Development Center for Biotechnology
DM9PSI3 DT Small molecular drug
DMGY4WO ID DMGY4WO
DMGY4WO DN Quinoline and quinazoline derivative 3
DMGY4WO HS Patented
DMGY4WO SN PMID28621580-Compound-US20150158854c39
DMGY4WO CP Development Center for Biotechnology
DMGY4WO DT Small molecular drug
DM5VCQP ID DM5VCQP
DM5VCQP DN Quinoline and quinazoline derivative 4
DM5VCQP HS Patented
DM5VCQP SN PMID28621580-Compound-WO2012127012c31
DM5VCQP CP UNIVERSITA' DEGLI STUDI DI PADOVA CHILIN, Adriana MARZARO, Giovanni GUIOTTO, Adriano CONCONI, Maria Teresa CASTAGLIUOLO, Ignazio
DM5VCQP DT Small molecular drug
DM7RQ2G ID DM7RQ2G
DM7RQ2G DN Quinoline and quinazoline derivative 5
DM7RQ2G HS Patented
DM7RQ2G SN PMID28621580-Compound-WO2012171487c32
DM7RQ2G CP TIANJIN LONGBOGEN PHARMACEUTICAL CO., LTD
DM7RQ2G DT Small molecular drug
DMZ2TB5 ID DMZ2TB5
DMZ2TB5 DN Quinoline and quinazoline derivative 6
DMZ2TB5 HS Patented
DMZ2TB5 SN PMID28621580-Compound-WO2013040515c36
DMZ2TB5 CP NEUPHARMA, INC. QIAN, Xiangping ZHU, Yong-liang
DMZ2TB5 DT Small molecular drug
DMMJEWB ID DMMJEWB
DMMJEWB DN Quinoline and quinazoline derivative 7
DMMJEWB HS Patented
DMMJEWB SN PMID28621580-Compound-WO2013112950c37
DMMJEWB CP NEUPHARMA, INC. ZHU, Yong-liang QIAN, Xiangping
DMMJEWB DT Small molecular drug
DMW3JH0 ID DMW3JH0
DMW3JH0 DN Quinoline and quinazoline derivative 8
DMW3JH0 HS Patented
DMW3JH0 SN PMID28621580-Compound-WO2014113859c33
DMW3JH0 CP UNIVERSIDADE FEDERAL DO RIO DE JANEIRO
DMW3JH0 DT Small molecular drug
DMBL86O ID DMBL86O
DMBL86O DN Quinoline and quinazoline derivative 9
DMBL86O HS Patented
DMBL86O SN PMID28621580-Compound-WO2014127214c35
DMBL86O CP KALA PHARMACEUTICALS, INC
DMBL86O DT Small molecular drug
DMW5YJB ID DMW5YJB
DMW5YJB DN Quinoline carboxamide derivative 1
DMW5YJB HS Patented
DMW5YJB SN PMID26394986-Compound-28
DMW5YJB CP Pharma. Ip. General, Inc. Mamoto Health Science University
DMW5YJB DT Small molecular drug
DMW5YJB PC 4253236
DMW5YJB MW 382.4
DMW5YJB FM C22H14N4O3
DMW5YJB IC InChI=1S/C22H14N4O3/c27-20(24-22-26-25-21(29-22)19-11-6-12-28-19)16-13-18(14-7-2-1-3-8-14)23-17-10-5-4-9-15(16)17/h1-13H,(H,24,26,27)
DMW5YJB CS C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)NC4=NN=C(O4)C5=CC=CO5
DMW5YJB IK MNPXTRXFUMGQLK-UHFFFAOYSA-N
DMW5YJB IU N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide
DMZTQVF ID DMZTQVF
DMZTQVF DN Quinoline carboxamide derivative 10
DMZTQVF HS Patented
DMZTQVF SN PMID27607364-Compound-20
DMZTQVF CP COCENSYS, INC
DMZTQVF DT Small molecular drug
DM9XQBG ID DM9XQBG
DM9XQBG DN Quinoline carboxamide derivative 2
DM9XQBG HS Patented
DM9XQBG SN PMID26394986-Compound-29
DM9XQBG CP Pharma. Ip. General, Inc. Mamoto Health Science University
DM9XQBG DT Small molecular drug
DM9XQBG PC 67206397
DM9XQBG MW 416.8
DM9XQBG FM C22H13ClN4O3
DM9XQBG IC InChI=1S/C22H13ClN4O3/c23-14-8-9-17-15(11-14)16(12-18(24-17)13-5-2-1-3-6-13)20(28)25-22-27-26-21(30-22)19-7-4-10-29-19/h1-12H,(H,25,27,28)
DM9XQBG CS C1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)Cl)C(=C2)C(=O)NC4=NN=C(O4)C5=CC=CO5
DM9XQBG IK GMIGNWBMEJMRDV-UHFFFAOYSA-N
DM9XQBG IU 6-chloro-N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenylquinoline-4-carboxamide
DMCAS85 ID DMCAS85
DMCAS85 DN Quinoline carboxamide derivative 3
DMCAS85 HS Patented
DMCAS85 SN PMID26394986-Compound-30
DMCAS85 CP Pharma. Ip. General, Inc. Mamoto Health Science University
DMCAS85 DT Small molecular drug
DMCAS85 PC 67204713
DMCAS85 MW 466.4
DMCAS85 FM C23H13F3N4O4
DMCAS85 IC InChI=1S/C23H13F3N4O4/c24-23(25,26)34-14-8-9-17-15(11-14)16(12-18(27-17)13-5-2-1-3-6-13)20(31)28-22-30-29-21(33-22)19-7-4-10-32-19/h1-12H,(H,28,30,31)
DMCAS85 CS C1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)OC(F)(F)F)C(=C2)C(=O)NC4=NN=C(O4)C5=CC=CO5
DMCAS85 IK OGCHQJNHUGTSIR-UHFFFAOYSA-N
DMCAS85 IU N-[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]-2-phenyl-6-(trifluoromethoxy)quinoline-4-carboxamide
DMVUNYD ID DMVUNYD
DMVUNYD DN Quinoline carboxamide derivative 4
DMVUNYD HS Patented
DMVUNYD SN PMID27607364-Compound-14
DMVUNYD CP COCENSYS, INC
DMVUNYD DT Small molecular drug
DM14029 ID DM14029
DM14029 DN Quinoline carboxamide derivative 5
DM14029 HS Patented
DM14029 SN PMID27607364-Compound-15
DM14029 CP COCENSYS, INC
DM14029 DT Small molecular drug
DMQ9ATN ID DMQ9ATN
DMQ9ATN DN Quinoline carboxamide derivative 6
DMQ9ATN HS Patented
DMQ9ATN SN PMID27607364-Compound-16
DMQ9ATN CP COCENSYS, INC
DMQ9ATN DT Small molecular drug
DM8AG0Z ID DM8AG0Z
DM8AG0Z DN Quinoline carboxamide derivative 7
DM8AG0Z HS Patented
DM8AG0Z SN PMID27607364-Compound-17
DM8AG0Z CP COCENSYS, INC
DM8AG0Z DT Small molecular drug
DM3IXYL ID DM3IXYL
DM3IXYL DN Quinoline carboxamide derivative 8
DM3IXYL HS Patented
DM3IXYL SN PMID27607364-Compound-18
DM3IXYL CP COCENSYS, INC
DM3IXYL DT Small molecular drug
DM7YFBT ID DM7YFBT
DM7YFBT DN Quinoline carboxamide derivative 9
DM7YFBT HS Patented
DM7YFBT SN PMID27607364-Compound-19
DM7YFBT CP COCENSYS, INC
DM7YFBT DT Small molecular drug
DMRY2HL ID DMRY2HL
DMRY2HL DN Quinoline derivative 1
DMRY2HL HS Patented
DMRY2HL SN PMID27537201-Compound-Figure13f
DMRY2HL CP the Shanghai Institute of Pharmaceutical Industry
DMRY2HL DT Small molecular drug
DM6GSCV ID DM6GSCV
DM6GSCV DN Quinoline derivative 10
DM6GSCV HS Patented
DM6GSCV SN PMID27724045-Compound-13
DM6GSCV CP Janssen Pharmaceutica
DM6GSCV DT Small molecular drug
DM6GSCV PC 44247634
DM6GSCV MW 550
DM6GSCV FM C25H27ClF3N7O2
DM6GSCV IC InChI=1S/C25H27ClF3N7O2/c26-18-2-3-19-17(1-4-21(34-19)36-6-5-16(30)14-36)22(18)23(37)31-13-20(35-7-9-38-10-8-35)15-11-32-24(33-12-15)25(27,28)29/h1-4,11-12,16,20H,5-10,13-14,30H2,(H,31,37)/t16-,20?/m0/s1
DM6GSCV CS C1CN(C[C@H]1N)C2=NC3=C(C=C2)C(=C(C=C3)Cl)C(=O)NCC(C4=CN=C(N=C4)C(F)(F)F)N5CCOCC5
DM6GSCV IK WVZNREBVNBJZKF-DJZRFWRSSA-N
DM6GSCV IU 2-[(3S)-3-aminopyrrolidin-1-yl]-6-chloro-N-[2-morpholin-4-yl-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]quinoline-5-carboxamide
DMH02JL ID DMH02JL
DMH02JL DN Quinoline derivative 11
DMH02JL HS Patented
DMH02JL SN PMID27724045-Compound-6
DMH02JL CP AstraZeneca
DMH02JL DT Small molecular drug
DM9FXE7 ID DM9FXE7
DM9FXE7 DN Quinoline derivative 12
DM9FXE7 HS Patented
DM9FXE7 SN PMID27724045-Compound-7
DM9FXE7 CP AstraZeneca
DM9FXE7 DT Small molecular drug
DM9FXE7 PC 25015092
DM9FXE7 MW 417.9
DM9FXE7 FM C22H28ClN3O3
DM9FXE7 IC InChI=1S/C22H28ClN3O3/c1-14-3-2-9-22(29,11-14)13-24-21(28)20-16-4-7-19(26-10-8-15(27)12-26)25-18(16)6-5-17(20)23/h4-7,14-15,27,29H,2-3,8-13H2,1H3,(H,24,28)/t14-,15+,22-/m0/s1
DM9FXE7 CS C[C@H]1CCC[C@](C1)(CNC(=O)C2=C(C=CC3=C2C=CC(=N3)N4CC[C@H](C4)O)Cl)O
DM9FXE7 IK GTFTZKPCYSYNOU-KIMHZCHSSA-N
DM9FXE7 IU 6-chloro-N-[[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide
DMAH4P8 ID DMAH4P8
DMAH4P8 DN Quinoline derivative 13
DMAH4P8 HS Patented
DMAH4P8 SN PMID27724045-Compound-8
DMAH4P8 CP AstraZeneca
DMAH4P8 DT Small molecular drug
DMAH4P8 PC 25015093
DMAH4P8 MW 432
DMAH4P8 FM C23H30ClN3O3
DMAH4P8 IC InChI=1S/C23H30ClN3O3/c1-15-3-2-10-23(30,13-15)14-25-22(29)21-17-4-7-20(26-19(17)6-5-18(21)24)27-11-8-16(28)9-12-27/h4-7,15-16,28,30H,2-3,8-14H2,1H3,(H,25,29)/t15-,23-/m0/s1
DMAH4P8 CS C[C@H]1CCC[C@](C1)(CNC(=O)C2=C(C=CC3=C2C=CC(=N3)N4CCC(CC4)O)Cl)O
DMAH4P8 IK BAHOQKHEWZJWME-WNSKOXEYSA-N
DMAH4P8 IU 6-chloro-N-[[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl]-2-(4-hydroxypiperidin-1-yl)quinoline-5-carboxamide
DMSRB8M ID DMSRB8M
DMSRB8M DN Quinoline derivative 14
DMSRB8M HS Patented
DMSRB8M SN PMID27828716-Compound-7
DMSRB8M DT Small molecular drug
DM7HD0T ID DM7HD0T
DM7HD0T DN Quinoline derivative 15
DM7HD0T HS Patented
DM7HD0T SN PMID27828716-Compound-VP0.7
DM7HD0T DT Small molecular drug
DMTHG87 ID DMTHG87
DMTHG87 DN Quinoline derivative 16
DMTHG87 HS Patented
DMTHG87 SN PMID27537201-Compound-Figure13a
DMTHG87 CP SHANGHAI INST PHARM INDUSTRY [CNCAI ZHENGYAN [CNZHOU WEICHENG [CNHAO QUN [CN]the Shanghai Institute of Pharmaceutical Industry
DMTHG87 DT Small molecular drug
DMKULV8 ID DMKULV8
DMKULV8 DN Quinoline derivative 17
DMKULV8 HS Patented
DMKULV8 SN PMID27537201-Compound-Figure13d
DMKULV8 CP the Shanghai Institute of Pharmaceutical Industry
DMKULV8 DT Small molecular drug
DMSG71Z ID DMSG71Z
DMSG71Z DN Quinoline derivative 18
DMSG71Z HS Patented
DMSG71Z SN PMID25435179-Compound-US20148685970(IX)
DM0MLI9 ID DM0MLI9
DM0MLI9 DN Quinoline derivative 19
DM0MLI9 HS Patented
DM0MLI9 SN PMID25435179-Compound-US20148685970(VII)
DMNO2BP ID DMNO2BP
DMNO2BP DN Quinoline derivative 2
DMNO2BP HS Patented
DMNO2BP SN PMID26609882-Compound-84
DMNO2BP CP WYETH RAMAMOORTHY, Sivaramakrishnan, P
DMNO2BP DT Small molecular drug
DMNXCZT ID DMNXCZT
DMNXCZT DN Quinoline derivative 20
DMNXCZT HS Patented
DMNXCZT SN PMID25435179-Compound-US20148685970(VIII)
DMDV6EY ID DMDV6EY
DMDV6EY DN Quinoline derivative 3
DMDV6EY HS Patented
DMDV6EY SN PMID25435285-Compound-100
DMDV6EY CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMDV6EY DT Small molecular drug
DMDV6EY PC 89554768
DMDV6EY MW 397.5
DMDV6EY FM C25H23N3O2
DMDV6EY IC InChI=1S/C25H23N3O2/c1-16(12-17-4-3-11-27-15-17)19-7-10-21-22(18-5-8-20(30-2)9-6-18)14-24(25(26)29)28-23(21)13-19/h3-11,13-16H,12H2,1-2H3,(H2,26,29)
DMDV6EY CS CC(CC1=CN=CC=C1)C2=CC3=C(C=C2)C(=CC(=N3)C(=O)N)C4=CC=C(C=C4)OC
DMDV6EY IK SLSRIELIUCLTJB-UHFFFAOYSA-N
DMDV6EY IU 4-(4-methoxyphenyl)-7-(1-pyridin-3-ylpropan-2-yl)quinoline-2-carboxamide
DMPB4L6 ID DMPB4L6
DMPB4L6 DN Quinoline derivative 4
DMPB4L6 HS Patented
DMPB4L6 SN PMID25435285-Compound-101
DMPB4L6 CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMPB4L6 DT Small molecular drug
DMPB4L6 PC 89554759
DMPB4L6 MW 474.4
DMPB4L6 FM C22H18F4N6O2
DMPB4L6 IC InChI=1S/C22H18F4N6O2/c1-2-21(34,22(24,25)26)19-11-32(31-30-19)10-12-3-5-14-15(16-6-4-13(23)9-28-16)8-18(20(27)33)29-17(14)7-12/h3-9,11,34H,2,10H2,1H3,(H2,27,33)/t21-/m1/s1
DMPB4L6 CS CC[C@@](C1=CN(N=N1)CC2=CC3=C(C=C2)C(=CC(=N3)C(=O)N)C4=NC=C(C=C4)F)(C(F)(F)F)O
DMPB4L6 IK HPUYYHXUYOZNBL-OAQYLSRUSA-N
DMPB4L6 IU 4-(5-fluoropyridin-2-yl)-7-[[4-[(2R)-1,1,1-trifluoro-2-hydroxybutan-2-yl]triazol-1-yl]methyl]quinoline-2-carboxamide
DMS1TOX ID DMS1TOX
DMS1TOX DN Quinoline derivative 5
DMS1TOX HS Patented
DMS1TOX SN PMID25435285-Compound-102
DMS1TOX CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMS1TOX DT Small molecular drug
DMS1TOX PC 89554809
DMS1TOX MW 436.5
DMS1TOX FM C20H19F3N4O2S
DMS1TOX IC InChI=1S/C20H19F3N4O2S/c1-11-25-8-17(30-11)14-7-16(19(24)28)26-15-6-12(2-3-13(14)15)9-27-4-5-29-18(10-27)20(21,22)23/h2-3,6-8,18H,4-5,9-10H2,1H3,(H2,24,28)
DMS1TOX CS CC1=NC=C(S1)C2=CC(=NC3=C2C=CC(=C3)CN4CCOC(C4)C(F)(F)F)C(=O)N
DMS1TOX IK QYGZQJAQOQLFSQ-UHFFFAOYSA-N
DMS1TOX IU 4-(2-methyl-1,3-thiazol-5-yl)-7-[[2-(trifluoromethyl)morpholin-4-yl]methyl]quinoline-2-carboxamide
DMVBPGI ID DMVBPGI
DMVBPGI DN Quinoline derivative 6
DMVBPGI HS Patented
DMVBPGI SN PMID25435285-Compound-103
DMVBPGI CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMVBPGI DT Small molecular drug
DMVBPGI PC 89554734
DMVBPGI MW 419.4
DMVBPGI FM C20H20F3N5O2
DMVBPGI IC InChI=1S/C20H20F3N5O2/c1-27-10-13(8-25-27)15-7-17(19(24)29)26-16-6-12(2-3-14(15)16)9-28-4-5-30-18(11-28)20(21,22)23/h2-3,6-8,10,18H,4-5,9,11H2,1H3,(H2,24,29)/t18-/m1/s1
DMVBPGI CS CN1C=C(C=N1)C2=CC(=NC3=C2C=CC(=C3)CN4CCO[C@H](C4)C(F)(F)F)C(=O)N
DMVBPGI IK PUIAIYDBFPDZPF-GOSISDBHSA-N
DMVBPGI IU 4-(1-methylpyrazol-4-yl)-7-[[(2R)-2-(trifluoromethyl)morpholin-4-yl]methyl]quinoline-2-carboxamide
DM56I8H ID DM56I8H
DM56I8H DN Quinoline derivative 7
DM56I8H HS Patented
DM56I8H SN PMID25435285-Compound-104
DM56I8H CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DM56I8H DT Small molecular drug
DM56I8H PC 89554814
DM56I8H MW 469.4
DM56I8H FM C24H19F4N5O
DM56I8H IC InChI=1S/C24H19F4N5O/c25-16-4-2-15(3-5-16)18-10-20(23(29)34)30-19-9-14(1-6-17(18)19)11-32-7-8-33-12-21(24(26,27)28)31-22(33)13-32/h1-6,9-10,12H,7-8,11,13H2,(H2,29,34)
DM56I8H CS C1CN2C=C(N=C2CN1CC3=CC4=C(C=C3)C(=CC(=N4)C(=O)N)C5=CC=C(C=C5)F)C(F)(F)F
DM56I8H IK CGZZSGTWUICICQ-UHFFFAOYSA-N
DM56I8H IU 4-(4-fluorophenyl)-7-[[2-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,2-a]pyrazin-7-yl]methyl]quinoline-2-carboxamide
DMLIW1X ID DMLIW1X
DMLIW1X DN Quinoline derivative 8
DMLIW1X HS Patented
DMLIW1X SN PMID25435285-Compound-98
DMLIW1X CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMLIW1X DT Small molecular drug
DMLIW1X PC 89545211
DMLIW1X MW 437.4
DMLIW1X FM C20H19F4N5O2
DMLIW1X IC InChI=1S/C20H19F4N5O2/c1-28-8-12(7-26-28)14-6-15(19(25)30)27-18-13(14)3-2-11(17(18)21)9-29-4-5-31-16(10-29)20(22,23)24/h2-3,6-8,16H,4-5,9-10H2,1H3,(H2,25,30)/t16-/m0/s1
DMLIW1X CS CN1C=C(C=N1)C2=CC(=NC3=C2C=CC(=C3F)CN4CCO[C@@H](C4)C(F)(F)F)C(=O)N
DMLIW1X IK GTJVIXLYXAAAKE-INIZCTEOSA-N
DMLIW1X IU 8-fluoro-4-(1-methylpyrazol-4-yl)-7-[[(2S)-2-(trifluoromethyl)morpholin-4-yl]methyl]quinoline-2-carboxamide
DMIC86N ID DMIC86N
DMIC86N DN Quinoline derivative 9
DMIC86N HS Patented
DMIC86N SN PMID25435285-Compound-99
DMIC86N CP MERCK SHARP & DOHME CORP. BUNGARD, Christopher James CONVERSO, Antonella DE LEON, Pablo HANNEY, Barbara HARTINGH, Timothy John MANIKOWSKI, Jesse Josef MANLEY, Peter, J. MEISSNER, Robert MENG, Zhaoyang PERKINS, James, J. RUDD, Michael, T. SHU, Youheng
DMIC86N DT Small molecular drug
DMIC86N PC 89554776
DMIC86N MW 478.4
DMIC86N FM C26H18F4N4O
DMIC86N IC InChI=1S/C26H18F4N4O/c27-17-8-6-16(7-9-17)19-12-22(25(31)35)32-21-11-15(5-10-18(19)21)14-34-23-4-2-1-3-20(23)33-24(34)13-26(28,29)30/h1-12H,13-14H2,(H2,31,35)
DMIC86N CS C1=CC=C2C(=C1)N=C(N2CC3=CC4=C(C=C3)C(=CC(=N4)C(=O)N)C5=CC=C(C=C5)F)CC(F)(F)F
DMIC86N IK OOWXUDJNUOKLDH-UHFFFAOYSA-N
DMIC86N IU 4-(4-fluorophenyl)-7-[[2-(2,2,2-trifluoroethyl)benzimidazol-1-yl]methyl]quinoline-2-carboxamide
DMENZPR ID DMENZPR
DMENZPR DN Quinolinyl compound 1
DMENZPR HS Patented
DMENZPR SN PMID25828189-Compound-23
DMENZPR CP PFIZER INC. DIDIUK, Mary FILIPSKI, Kevin J. GUZMAN-PEREZ, Angel LEE, Esther C. PFEFFERKORN, Jeffrey A. STEVENS, Benjamin TU, Meihua
DMENZPR DT Small molecular drug
DMGLK92 ID DMGLK92
DMGLK92 DN Quinolinyl compound 2
DMGLK92 HS Patented
DMGLK92 SN PMID25828189-Compound-24
DMGLK92 CP PFIZER INC. DIDIUK, Mary FILIPSKI, Kevin J. GUZMAN-PEREZ, Angel LEE, Esther C. PFEFFERKORN, Jeffrey A. STEVENS, Benjamin TU, Meihua
DMGLK92 DT Small molecular drug
DMGLK92 PC 71239286
DMGLK92 MW 405.5
DMGLK92 FM C24H27N3O3
DMGLK92 IC InChI=1S/C24H27N3O3/c1-3-6-20(26-23-16(2)15-19-7-4-5-8-21(19)27-23)17-9-11-18(12-10-17)24(30)25-14-13-22(28)29/h4-5,7-12,15,20H,3,6,13-14H2,1-2H3,(H,25,30)(H,26,27)(H,28,29)
DMGLK92 CS CCCC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)NC2=NC3=CC=CC=C3C=C2C
DMGLK92 IK KQBQZWBDDOVGRD-UHFFFAOYSA-N
DMGLK92 IU 3-[[4-[1-[(3-methylquinolin-2-yl)amino]butyl]benzoyl]amino]propanoic acid
DMCIKR3 ID DMCIKR3
DMCIKR3 DN Quinolinyl pyrazinyl urea derivative 1
DMCIKR3 HS Patented
DMCIKR3 SN PMID27828716-Compound-2
DMCIKR3 DT Small molecular drug
DMCIKR3 PC 24772168
DMCIKR3 MW 265.27
DMCIKR3 FM C14H11N5O
DMCIKR3 IC InChI=1S/C14H11N5O/c20-14(19-13-9-15-7-8-17-13)18-12-5-6-16-11-4-2-1-3-10(11)12/h1-9H,(H2,16,17,18,19,20)
DMCIKR3 CS C1=CC=C2C(=C1)C(=CC=N2)NC(=O)NC3=NC=CN=C3
DMCIKR3 IK LNIDFQVRZCDVBI-UHFFFAOYSA-N
DMCIKR3 IU 1-pyrazin-2-yl-3-quinolin-4-ylurea
DMKJN9G ID DMKJN9G
DMKJN9G DN Quinolinyl pyrazinyl urea derivative 2
DMKJN9G HS Patented
DMKJN9G SN PMID27828716-Compound-3
DMKJN9G DT Small molecular drug
DMKJN9G PC 24858859
DMKJN9G MW 333.27
DMKJN9G FM C15H10F3N5O
DMKJN9G IC InChI=1S/C15H10F3N5O/c16-15(17,18)9-1-2-11-10(7-9)12(3-4-20-11)22-14(24)23-13-8-19-5-6-21-13/h1-8H,(H2,20,21,22,23,24)
DMKJN9G CS C1=CC2=NC=CC(=C2C=C1C(F)(F)F)NC(=O)NC3=NC=CN=C3
DMKJN9G IK GHAZVJQMLWOQLP-UHFFFAOYSA-N
DMKJN9G IU 1-pyrazin-2-yl-3-[6-(trifluoromethyl)quinolin-4-yl]urea
DME6P7T ID DME6P7T
DME6P7T DN Quinolone derivative 1
DME6P7T HS Patented
DME6P7T SN PMID28074661-Compound-US20030105073c44
DME6P7T CP Celltech R&D Ltd
DME6P7T DT Small molecular drug
DMENQ5O ID DMENQ5O
DMENQ5O DN Quinoxaline derivative 1
DMENQ5O HS Patented
DMENQ5O SN PMID25553724-Compound-US20130289041 14
DM031YW ID DM031YW
DM031YW DN Quinoxaline derivative 2
DM031YW HS Patented
DM031YW SN PMID25553724-Compound-US20130289041 15
DMLZRAI ID DMLZRAI
DMLZRAI DN Quinoxaline derivative 3
DMLZRAI HS Patented
DMLZRAI SN PMID25553724-Compound-US20130289041 16
DMS3PRT ID DMS3PRT
DMS3PRT DN Quinoxaline derivative 4
DMS3PRT HS Patented
DMS3PRT SN PMID25553724-Compound-WO2012071414 14
DMS3PRT CP BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA NATARAJAN, Amarnath CHEN, Qianyi BRYANT, Vashti, C. RAJULE, Rajkumar
DM8EY2G ID DM8EY2G
DM8EY2G DN Quinoxaline derivative 5
DM8EY2G HS Patented
DM8EY2G SN PMID25553724-Compound-WO2012071414 15
DM8EY2G CP BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA NATARAJAN, Amarnath CHEN, Qianyi BRYANT, Vashti, C. RAJULE, Rajkumar
DMBRX8D ID DMBRX8D
DMBRX8D DN Quinoxaline derivative 6
DMBRX8D HS Patented
DMBRX8D SN PMID25553724-Compound-WO2012071414 16
DMBRX8D CP BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA NATARAJAN, Amarnath CHEN, Qianyi BRYANT, Vashti, C. RAJULE, Rajkumar
DMG4FYP ID DMG4FYP
DMG4FYP DN Resorcinol compound 1
DMG4FYP HS Patented
DMG4FYP SN PMID26815044-Compound-1
DMG4FYP DT Small molecular drug
DMG4FYP DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMPA26U ID DMPA26U
DMPA26U DN Resorcinol compound 10
DMPA26U HS Patented
DMPA26U SN PMID26815044-Compound-18
DMPA26U DT Small molecular drug
DMPA26U PC 44611571
DMPA26U MW 231.25
DMPA26U FM C13H13NO3
DMPA26U IC InChI=1S/C13H13NO3/c1-17-13-10(3-2-6-14-13)7-9-4-5-11(15)8-12(9)16/h2-6,8,15-16H,7H2,1H3
DMPA26U CS COC1=C(C=CC=N1)CC2=C(C=C(C=C2)O)O
DMPA26U IK DRCOSVLHATXBGT-UHFFFAOYSA-N
DMPA26U IU 4-[(2-methoxypyridin-3-yl)methyl]benzene-1,3-diol
DMPA26U DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMGDLPZ ID DMGDLPZ
DMGDLPZ DN Resorcinol compound 11
DMGDLPZ HS Patented
DMGDLPZ SN PMID26815044-Compound-19
DMGDLPZ DT Small molecular drug
DMGDLPZ PC 44611840
DMGDLPZ MW 204.22
DMGDLPZ FM C12H12O3
DMGDLPZ IC InChI=1S/C12H12O3/c13-10-5-3-9(12(14)8-10)4-6-11-2-1-7-15-11/h1-3,5,7-8,13-14H,4,6H2
DMGDLPZ CS C1=COC(=C1)CCC2=C(C=C(C=C2)O)O
DMGDLPZ IK DRPCFXFFIMCRRN-UHFFFAOYSA-N
DMGDLPZ IU 4-[2-(furan-2-yl)ethyl]benzene-1,3-diol
DMGDLPZ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMEMT3I ID DMEMT3I
DMEMT3I DN Resorcinol compound 12
DMEMT3I HS Patented
DMEMT3I SN PMID26815044-Compound-2
DMEMT3I DT Small molecular drug
DMEMT3I PC 85471319
DMEMT3I MW 156.15
DMEMT3I FM C8H9FO2
DMEMT3I IC InChI=1S/C8H9FO2/c1-2-6-7(9)3-5(10)4-8(6)11/h3-4,10-11H,2H2,1H3
DMEMT3I CS CCC1=C(C=C(C=C1F)O)O
DMEMT3I IK GJVVTWQXSOPPFB-UHFFFAOYSA-N
DMEMT3I IU 4-ethyl-5-fluorobenzene-1,3-diol
DMEMT3I DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMVARUE ID DMVARUE
DMVARUE DN Resorcinol compound 13
DMVARUE HS Patented
DMVARUE SN PMID26815044-Compound-20
DMVARUE DT Small molecular drug
DMVARUE PC 44611708
DMVARUE MW 258.269
DMVARUE FM C15H14O4
DMVARUE IC InChI=1S/C15H14O4/c16-12-5-4-11(13(17)8-12)3-1-10-2-6-14-15(7-10)19-9-18-14/h2,4-8,16-17H,1,3,9H2
DMVARUE CS C1OC2=C(O1)C=C(C=C2)CCC3=C(C=C(C=C3)O)O
DMVARUE IK WYCYXIGYEQHUEJ-UHFFFAOYSA-N
DMVARUE IU 4-[2-(1,3-benzodioxol-5-yl)ethyl]benzene-1,3-diol
DMVARUE DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM6XFA5 ID DM6XFA5
DM6XFA5 DN Resorcinol compound 14
DM6XFA5 HS Patented
DM6XFA5 SN PMID26815044-Compound-21
DM6XFA5 DT Small molecular drug
DM6XFA5 PC 24849532
DM6XFA5 MW 246.26
DM6XFA5 FM C14H14O4
DM6XFA5 IC InChI=1S/C14H14O4/c15-11-5-3-9(13(17)7-11)1-2-10-4-6-12(16)8-14(10)18/h3-8,15-18H,1-2H2
DM6XFA5 CS C1=CC(=C(C=C1O)O)CCC2=C(C=C(C=C2)O)O
DM6XFA5 IK WKIFTWPZTZUMRN-UHFFFAOYSA-N
DM6XFA5 IU 4-[2-(2,4-dihydroxyphenyl)ethyl]benzene-1,3-diol
DM6XFA5 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMSLYVT ID DMSLYVT
DMSLYVT DN Resorcinol compound 15
DMSLYVT HS Patented
DMSLYVT SN PMID26815044-Compound-22
DMSLYVT DT Small molecular drug
DMSLYVT PC 44611713
DMSLYVT MW 288.34
DMSLYVT FM C17H20O4
DMSLYVT IC InChI=1S/C17H20O4/c1-11-16(20-2)9-7-13(17(11)21-3)5-4-12-6-8-14(18)10-15(12)19/h6-10,18-19H,4-5H2,1-3H3
DMSLYVT CS CC1=C(C=CC(=C1OC)CCC2=C(C=C(C=C2)O)O)OC
DMSLYVT IK IUYGPVSGZMZJPS-UHFFFAOYSA-N
DMSLYVT IU 4-[2-(2,4-dimethoxy-3-methylphenyl)ethyl]benzene-1,3-diol
DMSLYVT DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMFDXBJ ID DMFDXBJ
DMFDXBJ DN Resorcinol compound 16
DMFDXBJ HS Patented
DMFDXBJ SN PMID26815044-Compound-23
DMFDXBJ DT Small molecular drug
DMFDXBJ PC 44611835
DMFDXBJ MW 232.27
DMFDXBJ FM C14H16O3
DMFDXBJ IC InChI=1S/C14H16O3/c1-2-12-7-8-13(17-12)6-4-10-3-5-11(15)9-14(10)16/h3,5,7-9,15-16H,2,4,6H2,1H3
DMFDXBJ CS CCC1=CC=C(O1)CCC2=C(C=C(C=C2)O)O
DMFDXBJ IK UPOWUYPZHMWQPH-UHFFFAOYSA-N
DMFDXBJ IU 4-[2-(5-ethylfuran-2-yl)ethyl]benzene-1,3-diol
DMFDXBJ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMFR4S0 ID DMFR4S0
DMFR4S0 DN Resorcinol compound 17
DMFR4S0 HS Patented
DMFR4S0 SN PMID26815044-Compound-24
DMFR4S0 DT Small molecular drug
DMFR4S0 PC 18459633
DMFR4S0 MW 228.29
DMFR4S0 FM C15H16O2
DMFR4S0 IC InChI=1S/C15H16O2/c1-11(9-12-5-3-2-4-6-12)14-8-7-13(16)10-15(14)17/h2-8,10-11,16-17H,9H2,1H3
DMFR4S0 CS CC(CC1=CC=CC=C1)C2=C(C=C(C=C2)O)O
DMFR4S0 IK NGQMLDWNBTVAAC-UHFFFAOYSA-N
DMFR4S0 IU 4-(1-phenylpropan-2-yl)benzene-1,3-diol
DMFR4S0 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM64R2K ID DM64R2K
DM64R2K DN Resorcinol compound 18
DM64R2K HS Patented
DM64R2K SN PMID26815044-Compound-25
DM64R2K DT Small molecular drug
DM64R2K PC 44611843
DM64R2K MW 318.4
DM64R2K FM C18H22O5
DM64R2K IC InChI=1S/C18H22O5/c1-21-14-10-17(22-2)15(18(11-14)23-3)6-4-5-12-7-8-13(19)9-16(12)20/h7-11,19-20H,4-6H2,1-3H3
DM64R2K CS COC1=CC(=C(C(=C1)OC)CCCC2=C(C=C(C=C2)O)O)OC
DM64R2K IK BLSIHFDETVSCHH-UHFFFAOYSA-N
DM64R2K IU 4-[3-(2,4,6-trimethoxyphenyl)propyl]benzene-1,3-diol
DM64R2K DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMJIZPQ ID DMJIZPQ
DMJIZPQ DN Resorcinol compound 19
DMJIZPQ HS Patented
DMJIZPQ SN PMID26815044-Compound-26
DMJIZPQ DT Small molecular drug
DMJIZPQ PC 44611837
DMJIZPQ MW 260.279
DMJIZPQ FM C15H16O4
DMJIZPQ IC InChI=1S/C15H16O4/c16-12-5-4-11(15(19)9-12)3-1-2-10-6-13(17)8-14(18)7-10/h4-9,16-19H,1-3H2
DMJIZPQ CS C1=CC(=C(C=C1O)O)CCCC2=CC(=CC(=C2)O)O
DMJIZPQ IK NQTJPTOXNAMXIJ-UHFFFAOYSA-N
DMJIZPQ IU 4-[3-(3,5-dihydroxyphenyl)propyl]benzene-1,3-diol
DMJIZPQ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMGDQYW ID DMGDQYW
DMGDQYW DN Resorcinol compound 2
DMGDQYW HS Patented
DMGDQYW SN PMID26815044-Compound-10
DMGDQYW DT Small molecular drug
DMGDQYW PC 85471347
DMGDQYW MW 166.22
DMGDQYW FM C10H14O2
DMGDQYW IC InChI=1S/C10H14O2/c1-6(2)10-7(3)4-8(11)5-9(10)12/h4-6,11-12H,1-3H3
DMGDQYW CS CC1=CC(=CC(=C1C(C)C)O)O
DMGDQYW IK FBSIDCYWGKQYRW-UHFFFAOYSA-N
DMGDQYW IU 5-methyl-4-propan-2-ylbenzene-1,3-diol
DMGDQYW DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DME4OGJ ID DME4OGJ
DME4OGJ DN Resorcinol compound 20
DME4OGJ HS Patented
DME4OGJ SN PMID26815044-Compound-27
DME4OGJ DT Small molecular drug
DME4OGJ PC 44611842
DME4OGJ MW 196.24
DME4OGJ FM C11H16O3
DME4OGJ IC InChI=1S/C11H16O3/c12-7-3-1-2-4-9-5-6-10(13)8-11(9)14/h5-6,8,12-14H,1-4,7H2
DME4OGJ CS C1=CC(=C(C=C1O)O)CCCCCO
DME4OGJ IK ZZBHJCFPTVMPAC-UHFFFAOYSA-N
DME4OGJ IU 4-(5-hydroxypentyl)benzene-1,3-diol
DME4OGJ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM8EQPJ ID DM8EQPJ
DM8EQPJ DN Resorcinol compound 21
DM8EQPJ HS Patented
DM8EQPJ SN PMID26815044-Compound-28
DM8EQPJ DT Small molecular drug
DM8EQPJ PC 44611711
DM8EQPJ MW 288.34
DM8EQPJ FM C17H20O4
DM8EQPJ IC InChI=1S/C17H20O4/c1-20-15-8-12(9-16(11-15)21-2)4-3-5-13-6-7-14(18)10-17(13)19/h6-11,18-19H,3-5H2,1-2H3
DM8EQPJ CS COC1=CC(=CC(=C1)CCCC2=C(C=C(C=C2)O)O)OC
DM8EQPJ IK FKEXLBVQKBTEJO-UHFFFAOYSA-N
DM8EQPJ IU 4-[3-(3,5-dimethoxyphenyl)propyl]benzene-1,3-diol
DM8EQPJ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMSW3GB ID DMSW3GB
DMSW3GB DN Resorcinol compound 22
DMSW3GB HS Patented
DMSW3GB SN PMID26815044-Compound-29
DMSW3GB DT Small molecular drug
DMSW3GB DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMU3APC ID DMU3APC
DMU3APC DN Resorcinol compound 23
DMU3APC HS Patented
DMU3APC SN PMID26815044-Compound-3
DMU3APC DT Small molecular drug
DMU3APC PC 85471348
DMU3APC MW 180.24
DMU3APC FM C11H16O2
DMU3APC IC InChI=1S/C11H16O2/c1-3-4-5-10-8(2)6-9(12)7-11(10)13/h6-7,12-13H,3-5H2,1-2H3
DMU3APC CS CCCCC1=C(C=C(C=C1C)O)O
DMU3APC IK IYOQFZBJNROXMO-UHFFFAOYSA-N
DMU3APC IU 4-butyl-5-methylbenzene-1,3-diol
DMU3APC DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM2IKDL ID DM2IKDL
DM2IKDL DN Resorcinol compound 24
DM2IKDL HS Patented
DM2IKDL SN PMID26815044-Compound-4
DM2IKDL DT Small molecular drug
DM2IKDL PC 45097120
DM2IKDL MW 208.3
DM2IKDL FM C13H20O2
DM2IKDL IC InChI=1S/C13H20O2/c1-3-4-5-6-7-12-10(2)8-11(14)9-13(12)15/h8-9,14-15H,3-7H2,1-2H3
DM2IKDL CS CCCCCCC1=C(C=C(C=C1C)O)O
DM2IKDL IK VCKRCCNBIYKEFP-UHFFFAOYSA-N
DM2IKDL IU 4-hexyl-5-methylbenzene-1,3-diol
DM2IKDL DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMEZUN7 ID DMEZUN7
DMEZUN7 DN Resorcinol compound 25
DMEZUN7 HS Patented
DMEZUN7 SN PMID26815044-Compound-5
DMEZUN7 DT Small molecular drug
DMEZUN7 PC 85471349
DMEZUN7 MW 206.28
DMEZUN7 FM C13H18O2
DMEZUN7 IC InChI=1S/C13H18O2/c1-9-7-11(14)8-12(15)13(9)10-5-3-2-4-6-10/h7-8,10,14-15H,2-6H2,1H3
DMEZUN7 CS CC1=CC(=CC(=C1C2CCCCC2)O)O
DMEZUN7 IK NZLWYNBRWDATJO-UHFFFAOYSA-N
DMEZUN7 IU 4-cyclohexyl-5-methylbenzene-1,3-diol
DMEZUN7 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMT21JG ID DMT21JG
DMT21JG DN Resorcinol compound 26
DMT21JG HS Patented
DMT21JG SN PMID26815044-Compound-6
DMT21JG DT Small molecular drug
DMT21JG PC 85471322
DMT21JG MW 260.25
DMT21JG FM C13H15F3O2
DMT21JG IC InChI=1S/C13H15F3O2/c14-13(15,16)10-6-9(17)7-11(18)12(10)8-4-2-1-3-5-8/h6-8,17-18H,1-5H2
DMT21JG CS C1CCC(CC1)C2=C(C=C(C=C2O)O)C(F)(F)F
DMT21JG IK BYAFHGYCRSXCQR-UHFFFAOYSA-N
DMT21JG IU 4-cyclohexyl-5-(trifluoromethyl)benzene-1,3-diol
DMT21JG DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM71R3T ID DM71R3T
DM71R3T DN Resorcinol compound 27
DM71R3T HS Patented
DM71R3T SN PMID26815044-Compound-7
DM71R3T DT Small molecular drug
DM71R3T PC 85471321
DM71R3T MW 206.16
DM71R3T FM C9H9F3O2
DM71R3T IC InChI=1S/C9H9F3O2/c1-2-6-7(9(10,11)12)3-5(13)4-8(6)14/h3-4,13-14H,2H2,1H3
DM71R3T CS CCC1=C(C=C(C=C1O)O)C(F)(F)F
DM71R3T IK KNSOMAAWMTUOTF-UHFFFAOYSA-N
DM71R3T IU 4-ethyl-5-(trifluoromethyl)benzene-1,3-diol
DM71R3T DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMCHLAN ID DMCHLAN
DMCHLAN DN Resorcinol compound 28
DMCHLAN HS Patented
DMCHLAN SN PMID26815044-Compound-8
DMCHLAN DT Small molecular drug
DMCHLAN PC 85471350
DMCHLAN MW 206.16
DMCHLAN FM C9H9F3O2
DMCHLAN IC InChI=1S/C9H9F3O2/c1-5-2-6(13)3-8(14)7(5)4-9(10,11)12/h2-3,13-14H,4H2,1H3
DMCHLAN CS CC1=CC(=CC(=C1CC(F)(F)F)O)O
DMCHLAN IK JMBGLSBPUYZWGE-UHFFFAOYSA-N
DMCHLAN IU 5-methyl-4-(2,2,2-trifluoroethyl)benzene-1,3-diol
DMCHLAN DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DML7ONU ID DML7ONU
DML7ONU DN Resorcinol compound 29
DML7ONU HS Patented
DML7ONU SN PMID26815044-Compound-9
DML7ONU DT Small molecular drug
DML7ONU PC 10560580
DML7ONU MW 214.26
DML7ONU FM C14H14O2
DML7ONU IC InChI=1S/C14H14O2/c1-10-7-12(15)9-14(16)13(10)8-11-5-3-2-4-6-11/h2-7,9,15-16H,8H2,1H3
DML7ONU CS CC1=CC(=CC(=C1CC2=CC=CC=C2)O)O
DML7ONU IK VPHJXVVCNGTIMH-UHFFFAOYSA-N
DML7ONU IU 4-benzyl-5-methylbenzene-1,3-diol
DML7ONU DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMPTK0G ID DMPTK0G
DMPTK0G DN Resorcinol compound 3
DMPTK0G HS Patented
DMPTK0G SN PMID26815044-Compound-11
DMPTK0G DT Small molecular drug
DMPTK0G PC 22001174
DMPTK0G MW 187.19
DMPTK0G FM C11H9NO2
DMPTK0G IC InChI=1S/C11H9NO2/c13-9-3-4-10(11(14)6-9)8-2-1-5-12-7-8/h1-7,13-14H
DMPTK0G CS C1=CC(=CN=C1)C2=C(C=C(C=C2)O)O
DMPTK0G IK QGIIUQKOKJXLED-UHFFFAOYSA-N
DMPTK0G IU 4-pyridin-3-ylbenzene-1,3-diol
DMPTK0G DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMMTVN4 ID DMMTVN4
DMMTVN4 DN Resorcinol compound 30
DMMTVN4 HS Patented
DMMTVN4 SN PMID26815044-Compound-A
DMMTVN4 DT Small molecular drug
DMMTVN4 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMSPCLD ID DMSPCLD
DMSPCLD DN Resorcinol compound 31
DMSPCLD HS Patented
DMSPCLD SN PMID26815044-Compound-B
DMSPCLD DT Small molecular drug
DMSPCLD DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM2RPYB ID DM2RPYB
DM2RPYB DN Resorcinol compound 32
DM2RPYB HS Patented
DM2RPYB SN PMID26815044-Compound-c
DM2RPYB DT Small molecular drug
DM2RPYB DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMLJYS1 ID DMLJYS1
DMLJYS1 DN Resorcinol compound 33
DMLJYS1 HS Patented
DMLJYS1 SN PMID26815044-Compound-D
DMLJYS1 DT Small molecular drug
DMLJYS1 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMQF90E ID DMQF90E
DMQF90E DN Resorcinol compound 34
DMQF90E HS Patented
DMQF90E SN PMID26815044-Compound-E
DMQF90E DT Small molecular drug
DMQF90E DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMIM9EY ID DMIM9EY
DMIM9EY DN Resorcinol compound 4
DMIM9EY HS Patented
DMIM9EY SN PMID26815044-Compound-12
DMIM9EY DT Small molecular drug
DMIM9EY PC 44611437
DMIM9EY MW 216.23
DMIM9EY FM C13H12O3
DMIM9EY IC InChI=1S/C13H12O3/c1-16-11-5-2-9(3-6-11)12-7-4-10(14)8-13(12)15/h2-8,14-15H,1H3
DMIM9EY CS COC1=CC=C(C=C1)C2=C(C=C(C=C2)O)O
DMIM9EY IK QYQMHWNFXIXZGS-UHFFFAOYSA-N
DMIM9EY IU 4-(4-methoxyphenyl)benzene-1,3-diol
DMIM9EY DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMQ5TYK ID DMQ5TYK
DMQ5TYK DN Resorcinol compound 5
DMQ5TYK HS Patented
DMQ5TYK SN PMID26815044-Compound-13
DMQ5TYK DT Small molecular drug
DMQ5TYK PC 20387
DMQ5TYK MW 218.2
DMQ5TYK FM C12H10O4
DMQ5TYK IC InChI=1S/C12H10O4/c13-7-1-3-9(11(15)5-7)10-4-2-8(14)6-12(10)16/h1-6,13-16H
DMQ5TYK CS C1=CC(=C(C=C1O)O)C2=C(C=C(C=C2)O)O
DMQ5TYK IK CFGDTWRKBRQUFB-UHFFFAOYSA-N
DMQ5TYK IU 4-(2,4-dihydroxyphenyl)benzene-1,3-diol
DMQ5TYK CA CAS 4371-31-7
DMQ5TYK DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM809YH ID DM809YH
DM809YH DN Resorcinol compound 6
DM809YH HS Patented
DM809YH SN PMID26815044-Compound-14
DM809YH DT Small molecular drug
DM809YH PC 13035019
DM809YH MW 244.24
DM809YH FM C14H12O4
DM809YH IC InChI=1S/C14H12O4/c15-11-3-2-10(12(16)7-11)5-9-1-4-13-14(6-9)18-8-17-13/h1-4,6-7,15-16H,5,8H2
DM809YH CS C1OC2=C(O1)C=C(C=C2)CC3=C(C=C(C=C3)O)O
DM809YH IK KUMBCKZCFIONIT-UHFFFAOYSA-N
DM809YH IU 4-(1,3-benzodioxol-5-ylmethyl)benzene-1,3-diol
DM809YH DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM031RU ID DM031RU
DM031RU DN Resorcinol compound 7
DM031RU HS Patented
DM031RU SN PMID26815044-Compound-15
DM031RU DT Small molecular drug
DM031RU PC 44611569
DM031RU MW 190.19
DM031RU FM C11H10O3
DM031RU IC InChI=1S/C11H10O3/c12-9-4-3-8(11(13)7-9)6-10-2-1-5-14-10/h1-5,7,12-13H,6H2
DM031RU CS C1=COC(=C1)CC2=C(C=C(C=C2)O)O
DM031RU IK UGOKFADRDRUFRJ-UHFFFAOYSA-N
DM031RU IU 4-(furan-2-ylmethyl)benzene-1,3-diol
DM031RU DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMLF53V ID DMLF53V
DMLF53V DN Resorcinol compound 8
DMLF53V HS Patented
DMLF53V SN PMID26815044-Compound-16
DMLF53V DT Small molecular drug
DMLF53V PC 59152424
DMLF53V MW 201.22
DMLF53V FM C12H11NO2
DMLF53V IC InChI=1S/C12H11NO2/c14-11-4-3-10(12(15)7-11)6-9-2-1-5-13-8-9/h1-5,7-8,14-15H,6H2
DMLF53V CS C1=CC(=CN=C1)CC2=C(C=C(C=C2)O)O
DMLF53V IK ZWKHYPPKPLXBIY-UHFFFAOYSA-N
DMLF53V IU 4-(pyridin-3-ylmethyl)benzene-1,3-diol
DMLF53V DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMCJO0R ID DMCJO0R
DMCJO0R DN Resorcinol compound 9
DMCJO0R HS Patented
DMCJO0R SN PMID26815044-Compound-17
DMCJO0R DT Small molecular drug
DMCJO0R PC 44611570
DMCJO0R MW 190.19
DMCJO0R FM C11H10O3
DMCJO0R IC InChI=1S/C11H10O3/c12-10-2-1-9(11(13)6-10)5-8-3-4-14-7-8/h1-4,6-7,12-13H,5H2
DMCJO0R CS C1=CC(=C(C=C1O)O)CC2=COC=C2
DMCJO0R IK LOAGBHXAWVQEGF-UHFFFAOYSA-N
DMCJO0R IU 4-(furan-3-ylmethyl)benzene-1,3-diol
DMCJO0R DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMUB7RV ID DMUB7RV
DMUB7RV DN Ring-fused compound 1
DMUB7RV HS Patented
DMUB7RV SN PMID27414413-Compound-Figure5left
DMUB7RV DT Small molecular drug
DMD1G3Z ID DMD1G3Z
DMD1G3Z DN Roscovitine derivative 1
DMD1G3Z HS Patented
DMD1G3Z SN PMID26161698-Compound-8
DMD1G3Z CP UNIVERZITA PALACKEHO V OLOMOUCI BIOPATTERNS S.R.O
DMD1G3Z DT Small molecular drug
DMD1G3Z PC 73353575
DMD1G3Z MW 472.6
DMD1G3Z FM C26H32N8O
DMD1G3Z IC InChI=1S/C26H32N8O/c27-18-8-10-19(11-9-18)31-26-32-24(23-25(33-26)34(16-30-23)20-4-1-2-5-20)29-15-17-7-12-21(28-14-17)22-6-3-13-35-22/h3,6-7,12-14,16,18-20H,1-2,4-5,8-11,15,27H2,(H2,29,31,32,33)
DMD1G3Z CS C1CCC(C1)N2C=NC3=C(N=C(N=C32)NC4CCC(CC4)N)NCC5=CN=C(C=C5)C6=CC=CO6
DMD1G3Z IK MDEXMDFOZRJJIN-UHFFFAOYSA-N
DMD1G3Z IU 2-N-(4-aminocyclohexyl)-9-cyclopentyl-6-N-[[6-(furan-2-yl)pyridin-3-yl]methyl]purine-2,6-diamine
DM41ZW9 ID DM41ZW9
DM41ZW9 DN Ruxolitinib derivative 1
DM41ZW9 HS Patented
DM41ZW9 SN PMID27774824-Compound-Figure9Example3
DM41ZW9 CP CONCERT PHARMACEUTICALS, INC
DM41ZW9 DT Small molecular drug
DMSJWZ3 ID DMSJWZ3
DMSJWZ3 DN Ruxolitinib derivative 2
DMSJWZ3 HS Patented
DMSJWZ3 SN PMID27774824-Compound-Figure4Example4
DMSJWZ3 CP JIN, Bohan
DMSJWZ3 DT Small molecular drug
DMB79QJ ID DMB79QJ
DMB79QJ DN Salicylic acid derivative 1
DMB79QJ HS Patented
DMB79QJ SN PMID26394986-Compound-13a
DMB79QJ CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMB79QJ DT Small molecular drug
DMB79QJ PC 68075823
DMB79QJ MW 694.8
DMB79QJ FM C37H37F3N2O6S
DMB79QJ IC InChI=1S/C37H37F3N2O6S/c1-25-11-18-31(19-12-25)49(47,48)41(23-29-9-5-6-10-33(29)37(38,39)40)24-35(44)42(30-17-20-32(36(45)46)34(43)21-30)22-26-13-15-28(16-14-26)27-7-3-2-4-8-27/h5-6,9-21,27,43H,2-4,7-8,22-24H2,1H3,(H,45,46)
DMB79QJ CS CC1=CC=C(C=C1)S(=O)(=O)N(CC2=CC=CC=C2C(F)(F)F)CC(=O)N(CC3=CC=C(C=C3)C4CCCCC4)C5=CC(=C(C=C5)C(=O)O)O
DMB79QJ IK GFASCHAWPQEYTQ-UHFFFAOYSA-N
DMB79QJ IU 4-[(4-cyclohexylphenyl)methyl-[2-[(4-methylphenyl)sulfonyl-[[2-(trifluoromethyl)phenyl]methyl]amino]acetyl]amino]-2-hydroxybenzoic acid
DMD8C9S ID DMD8C9S
DMD8C9S DN Salicylic acid derivative 2
DMD8C9S HS Patented
DMD8C9S SN PMID26394986-Compound-14
DMD8C9S CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMD8C9S DT Small molecular drug
DMD8C9S PC 53388144
DMD8C9S MW 626.6
DMD8C9S FM C29H27F5N2O6S
DMD8C9S IC InChI=1S/C29H27F5N2O6S/c1-35(43(41,42)28-26(33)24(31)23(30)25(32)27(28)34)15-22(38)36(19-11-12-20(29(39)40)21(37)13-19)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h7-13,17,37H,2-6,14-15H2,1H3,(H,39,40)
DMD8C9S CS CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC(=C(C=C3)C(=O)O)O)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DMD8C9S IK WNVSFFVDMUSXSX-UHFFFAOYSA-N
DMD8C9S IU 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid
DM4OGKH ID DM4OGKH
DM4OGKH DN Salicylic acid derivative 3
DM4OGKH HS Patented
DM4OGKH SN PMID26394986-Compound-14a
DM4OGKH CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DM4OGKH DT Small molecular drug
DM4OGKH PC 73333953
DM4OGKH MW 770.7
DM4OGKH FM C36H30F8N2O6S
DM4OGKH IC InChI=1S/C36H30F8N2O6S/c37-29-30(38)32(40)34(33(41)31(29)39)53(51,52)45(18-23-8-4-5-9-26(23)36(42,43)44)19-28(48)46(24-14-15-25(35(49)50)27(47)16-24)17-20-10-12-22(13-11-20)21-6-2-1-3-7-21/h4-5,8-16,21,47H,1-3,6-7,17-19H2,(H,49,50)
DM4OGKH CS C1CCC(CC1)C2=CC=C(C=C2)CN(C3=CC(=C(C=C3)C(=O)O)O)C(=O)CN(CC4=CC=CC=C4C(F)(F)F)S(=O)(=O)C5=C(C(=C(C(=C5F)F)F)F)F
DM4OGKH IK UEUVIKQOEXBPOQ-UHFFFAOYSA-N
DM4OGKH IU 4-[(4-cyclohexylphenyl)methyl-[2-[(2,3,4,5,6-pentafluorophenyl)sulfonyl-[[2-(trifluoromethyl)phenyl]methyl]amino]acetyl]amino]-2-hydroxybenzoic acid
DM4MAHK ID DM4MAHK
DM4MAHK DN Salicylic acid derivative 4
DM4MAHK HS Patented
DM4MAHK SN PMID26394986-Compound-16
DM4MAHK CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DM4MAHK DT Small molecular drug
DM4MAHK PC 72545583
DM4MAHK MW 668.6
DM4MAHK FM C31H29F5N2O7S
DM4MAHK IC InChI=1S/C31H29F5N2O7S/c1-17(39)45-23-14-21(12-13-22(23)31(41)42)38(15-18-8-10-20(11-9-18)19-6-4-3-5-7-19)24(40)16-37(2)46(43,44)30-28(35)26(33)25(32)27(34)29(30)36/h8-14,19H,3-7,15-16H2,1-2H3,(H,41,42)
DM4MAHK CS CC(=O)OC1=C(C=CC(=C1)N(CC2=CC=C(C=C2)C3CCCCC3)C(=O)CN(C)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F)C(=O)O
DM4MAHK IK MXLQNCLPTUVOQV-UHFFFAOYSA-N
DM4MAHK IU 2-acetyloxy-4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]benzoic acid
DM3OZ0F ID DM3OZ0F
DM3OZ0F DN Salicylic acid derivative 5
DM3OZ0F HS Patented
DM3OZ0F SN PMID26394986-Compound-17
DM3OZ0F CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DM3OZ0F DT Small molecular drug
DM3OZ0F PC 72188643
DM3OZ0F MW 610.6
DM3OZ0F FM C29H27F5N2O5S
DM3OZ0F IC InChI=1S/C29H27F5N2O5S/c1-35(42(40,41)28-26(33)24(31)23(30)25(32)27(28)34)16-22(37)36(21-13-11-20(12-14-21)29(38)39)15-17-7-9-19(10-8-17)18-5-3-2-4-6-18/h7-14,18H,2-6,15-16H2,1H3,(H,38,39)
DM3OZ0F CS CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC=C(C=C3)C(=O)O)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DM3OZ0F IK VFPYGNNOSJWBHF-UHFFFAOYSA-N
DM3OZ0F IU 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]benzoic acid
DMLBEPW ID DMLBEPW
DMLBEPW DN Salicylic acid derivative 6
DMLBEPW HS Patented
DMLBEPW SN PMID26394986-Compound-18
DMLBEPW CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMLBEPW DT Small molecular drug
DMLBEPW PC 72550504
DMLBEPW MW 625.6
DMLBEPW FM C29H28F5N3O5S
DMLBEPW IC InChI=1S/C29H28F5N3O5S/c1-36(43(41,42)28-26(33)24(31)23(30)25(32)27(28)34)16-22(38)37(21-13-11-20(12-14-21)29(39)35-40)15-17-7-9-19(10-8-17)18-5-3-2-4-6-18/h7-14,18,40H,2-6,15-16H2,1H3,(H,35,39)
DMLBEPW CS CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC=C(C=C3)C(=O)NO)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DMLBEPW IK QPSUYVALAOXFGL-UHFFFAOYSA-N
DMLBEPW IU 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-N-hydroxybenzamide
DMLBEPW CA CAS 1456632-41-9
DMJFHVN ID DMJFHVN
DMJFHVN DN Salicylic acid derivative 7
DMJFHVN HS Patented
DMJFHVN SN PMID26394986-Compound-19
DMJFHVN CP THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO FISHEL, Melissa, L
DMJFHVN DT Small molecular drug
DMJFHVN PC 72545832
DMJFHVN MW 628.6
DMJFHVN FM C29H26F6N2O5S
DMJFHVN IC InChI=1S/C29H26F6N2O5S/c1-36(43(41,42)28-26(34)24(32)23(31)25(33)27(28)35)15-22(38)37(19-11-12-20(29(39)40)21(30)13-19)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h7-13,17H,2-6,14-15H2,1H3,(H,39,40)
DMJFHVN CS CN(CC(=O)N(CC1=CC=C(C=C1)C2CCCCC2)C3=CC(=C(C=C3)C(=O)O)F)S(=O)(=O)C4=C(C(=C(C(=C4F)F)F)F)F
DMJFHVN IK PSOITMRLZWEHSO-UHFFFAOYSA-N
DMJFHVN IU 4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-fluorobenzoic acid
DM2MQD0 ID DM2MQD0
DM2MQD0 DN SB19065
DM2MQD0 HS Patented
DM2MQD0 SN CHEMBL2336005; SCHEMBL14777163; ZINC95587687; BDBM50430875; SB19065; 3-(2-(3-(morpholinomethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol; 3-({2-[3-(morpholin-4-ylmethyl)phenyl]thieno[3,2-b]pyridin-7-yl}amino)phenol; 1228102-01-9
DM2MQD0 DT Small molecular drug
DM2MQD0 PC 71577234
DM2MQD0 MW 417.5
DM2MQD0 FM C24H23N3O2S
DM2MQD0 IC InChI=1S/C24H23N3O2S/c28-20-6-2-5-19(14-20)26-21-7-8-25-22-15-23(30-24(21)22)18-4-1-3-17(13-18)16-27-9-11-29-12-10-27/h1-8,13-15,28H,9-12,16H2,(H,25,26)
DM2MQD0 CS C1COCCN1CC2=CC(=CC=C2)C3=CC4=NC=CC(=C4S3)NC5=CC(=CC=C5)O
DM2MQD0 IK ZCWXCBKGPJOAFQ-UHFFFAOYSA-N
DM2MQD0 IU 3-[[2-[3-(morpholin-4-ylmethyl)phenyl]thieno[3,2-b]pyridin-7-yl]amino]phenol
DMKQ0GE ID DMKQ0GE
DMKQ0GE DN SCHEMBL15198145
DMKQ0GE HS Patented
DMKQ0GE SN SCHEMBL15198145
DMKQ0GE DT Small molecular drug
DMKQ0GE PC 71715083
DMKQ0GE MW 495.6
DMKQ0GE FM C24H25N5O5S
DMKQ0GE IC InChI=1S/C24H25N5O5S/c25-35(32,33)34-14-18-12-20(24(31)23(18)30)27-21-9-10-26-22-13-19(28-29(21)22)17-8-4-7-16(11-17)15-5-2-1-3-6-15/h1-11,13,18,20,23-24,27,30-31H,12,14H2,(H2,25,32,33)/t18-,20-,23-,24+/m1/s1
DMKQ0GE CS C1[C@@H]([C@H]([C@H]([C@@H]1NC2=CC=NC3=CC(=NN23)C4=CC=CC(=C4)C5=CC=CC=C5)O)O)COS(=O)(=O)N
DMKQ0GE IK OHUBWOCZKZLWIV-ILEGPTGMSA-N
DMKQ0GE IU [(1R,2R,3S,4R)-2,3-dihydroxy-4-[[2-(3-phenylphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl sulfamate
DMHPQI2 ID DMHPQI2
DMHPQI2 DN SCHEMBL15198146
DMHPQI2 HS Patented
DMHPQI2 SN SCHEMBL15198146
DMHPQI2 DT Small molecular drug
DMHPQI2 PC 71715084
DMHPQI2 MW 433.5
DMHPQI2 FM C19H23N5O5S
DMHPQI2 IC InChI=1S/C19H23N5O5S/c1-11-7-16(22-15-8-13(18(25)19(15)26)10-29-30(20,27)28)24-17(21-11)9-14(23-24)12-5-3-2-4-6-12/h2-7,9,13,15,18-19,22,25-26H,8,10H2,1H3,(H2,20,27,28)/t13-,15-,18-,19+/m1/s1
DMHPQI2 CS CC1=NC2=CC(=NN2C(=C1)N[C@@H]3C[C@@H]([C@H]([C@H]3O)O)COS(=O)(=O)N)C4=CC=CC=C4
DMHPQI2 IK LFVBSFKFKWBKIB-LRHNDGHRSA-N
DMHPQI2 IU [(1R,2R,3S,4R)-2,3-dihydroxy-4-[(5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-yl)amino]cyclopentyl]methyl sulfamate
DMK0T9E ID DMK0T9E
DMK0T9E DN SCHEMBL15295829
DMK0T9E HS Patented
DMK0T9E SN SCHEMBL15295829
DMK0T9E DT Small molecular drug
DMK0T9E PC 71738918
DMK0T9E MW 435.3
DMK0T9E FM C19H20Cl2N6O2
DMK0T9E IC InChI=1S/C19H20Cl2N6O2/c1-5-6-27-18-17(11(4)25-27)13(10(2)3)9-16(24-18)29-26-19(28)22-12-7-14(20)23-15(21)8-12/h5,7-10H,1,6H2,2-4H3,(H2,22,23,26,28)
DMK0T9E CS CC1=NN(C2=C1C(=CC(=N2)ONC(=O)NC3=CC(=NC(=C3)Cl)Cl)C(C)C)CC=C
DMK0T9E IK GSDSPSURUKLGBL-UHFFFAOYSA-N
DMK0T9E IU 1-(2,6-dichloropyridin-4-yl)-3-(3-methyl-4-propan-2-yl-1-prop-2-enylpyrazolo[3,4-b]pyridin-6-yl)oxyurea
DM3OB4T ID DM3OB4T
DM3OB4T DN SCHEMBL16322760
DM3OB4T HS Patented
DM3OB4T SN SCHEMBL16322760
DM3OB4T DT Small molecular drug
DM3OB4T PC 86580570
DM3OB4T MW 477.5
DM3OB4T FM C24H21F2N7O2
DM3OB4T IC InChI=1S/C24H21F2N7O2/c1-4-35-16-9-19(25)18(20(26)10-16)13-33-14(2)17(11-27)22(32-33)24-29-12-21(34-3)23(31-24)30-15-5-7-28-8-6-15/h5-10,12H,4,13H2,1-3H3,(H,28,29,30,31)
DM3OB4T CS CCOC1=CC(=C(C(=C1)F)CN2C(=C(C(=N2)C3=NC=C(C(=N3)NC4=CC=NC=C4)OC)C#N)C)F
DM3OB4T IK VNVLBWOVSDGPGB-UHFFFAOYSA-N
DM3OB4T IU 1-[(4-ethoxy-2,6-difluorophenyl)methyl]-3-[5-methoxy-4-(pyridin-4-ylamino)pyrimidin-2-yl]-5-methylpyrazole-4-carbonitrile
DMQARW2 ID DMQARW2
DMQARW2 DN SCHEMBL16365841
DMQARW2 HS Patented
DMQARW2 SN SCHEMBL16365841
DMQARW2 DT Small molecular drug
DMQARW2 PC 86580571
DMQARW2 MW 542.5
DMQARW2 FM C26H25F3N6O4
DMQARW2 IC InChI=1S/C26H25F3N6O4/c1-5-38-15-9-18(27)17(19(28)10-15)13-35-14(3)22(29)23(34-35)25-31-12-21(37-4)24(33-25)32-20-7-8-30-11-16(20)26(36)39-6-2/h7-12H,5-6,13H2,1-4H3,(H,30,31,32,33)
DMQARW2 CS CCOC1=CC(=C(C(=C1)F)CN2C(=C(C(=N2)C3=NC=C(C(=N3)NC4=C(C=NC=C4)C(=O)OCC)OC)F)C)F
DMQARW2 IK GCVMXSOKVYMCOA-UHFFFAOYSA-N
DMQARW2 IU ethyl 4-[[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-4-fluoro-5-methylpyrazol-3-yl]-5-methoxypyrimidin-4-yl]amino]pyridine-3-carboxylate
DMC7PTY ID DMC7PTY
DMC7PTY DN SCHEMBL17766424
DMC7PTY HS Patented
DMC7PTY SN SCHEMBL17766424
DMC7PTY DT Small molecular drug
DMC7PTY PC 86580572
DMC7PTY MW 481.5
DMC7PTY FM C24H25F2N7O2
DMC7PTY IC InChI=1S/C24H25F2N7O2/c1-5-35-16-10-18(25)17(19(26)11-16)13-33-14-20(32(2)3)22(31-33)24-28-12-21(34-4)23(30-24)29-15-6-8-27-9-7-15/h6-12,14H,5,13H2,1-4H3,(H,27,28,29,30)
DMC7PTY CS CCOC1=CC(=C(C(=C1)F)CN2C=C(C(=N2)C3=NC=C(C(=N3)NC4=CC=NC=C4)OC)N(C)C)F
DMC7PTY IK TYXHNCNKIXBYQD-UHFFFAOYSA-N
DMC7PTY IU 2-[4-(dimethylamino)-1-[(4-ethoxy-2,6-difluorophenyl)methyl]pyrazol-3-yl]-5-methoxy-N-pyridin-4-ylpyrimidin-4-amine
DMQD6IL ID DMQD6IL
DMQD6IL DN Schiff base compound 1
DMQD6IL HS Patented
DMQD6IL SN PMID29324067-Compound-43
DMQD6IL CP University China Pharma
DMQD6IL DT Small molecular drug
DMQD6IL DE Alzheimer disease
DMWD20L ID DMWD20L
DMWD20L DN Schiff base compound 2
DMWD20L HS Patented
DMWD20L SN PMID29324067-Compound-53
DMWD20L CP University China Pharma
DMWD20L DT Small molecular drug
DMWD20L DE Alzheimer disease
DMEDNTJ ID DMEDNTJ
DMEDNTJ DN Secondary and tertiary (hetero)arylamide derivative 1
DMEDNTJ HS Patented
DMEDNTJ SN PMID29324067-Compound-1
DMEDNTJ CP University Zhejiang Technology
DMEDNTJ DT Small molecular drug
DMIES9B ID DMIES9B
DMIES9B DN Secondary and tertiary (hetero)arylamide derivative 2
DMIES9B HS Patented
DMIES9B SN PMID29324067-Compound-12
DMIES9B CP University Zhejiang Technology
DMIES9B DT Small molecular drug
DM9C5Z8 ID DM9C5Z8
DM9C5Z8 DN Selenium compound 1
DM9C5Z8 HS Patented
DM9C5Z8 SN PMID25468267-Compound-28
DM9C5Z8 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DM9C5Z8 DT Small molecular drug
DM9C5Z8 PC 23427
DM9C5Z8 MW 189.08
DM9C5Z8 FM C6H6O2Se
DM9C5Z8 IC InChI=1S/C6H6O2Se/c7-9(8)6-4-2-1-3-5-6/h1-5H,(H,7,8)
DM9C5Z8 CS C1=CC=C(C=C1)[Se](=O)O
DM9C5Z8 IK WIHKGDVGLJJAMC-UHFFFAOYSA-N
DM9C5Z8 IU benzeneseleninic acid
DM9C5Z8 CA CAS 6996-92-5
DMLWIJ7 ID DMLWIJ7
DMLWIJ7 DN Selenium compound 2
DMLWIJ7 HS Patented
DMLWIJ7 SN PMID25468267-Compound-29
DMLWIJ7 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMLWIJ7 DT Small molecular drug
DMLWIJ7 PC 21928
DMLWIJ7 MW 191.53
DMLWIJ7 FM C6H5ClSe
DMLWIJ7 IC InChI=1S/C6H5ClSe/c7-8-6-4-2-1-3-5-6/h1-5H
DMLWIJ7 CS C1=CC=C(C=C1)[Se]Cl
DMLWIJ7 IK WJCXADMLESSGRI-UHFFFAOYSA-N
DMLWIJ7 IU phenyl selenohypochlorite
DMLWIJ7 CA CAS 5707-04-0
DMQ5AJ6 ID DMQ5AJ6
DMQ5AJ6 DN Selenium compound 3
DMQ5AJ6 HS Patented
DMQ5AJ6 SN PMID25468267-Compound-30
DMQ5AJ6 CP ISIS INNOVATION LIMITED SCHOFIELD, Christopher Joseph ROSE, Nathan SEKIRNIK, Rok
DMQ5AJ6 DT Small molecular drug
DMQ5AJ6 PC 3194
DMQ5AJ6 MW 274.19
DMQ5AJ6 FM C13H9NOSe
DMQ5AJ6 IC InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
DMQ5AJ6 CS C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
DMQ5AJ6 IK DYEFUKCXAQOFHX-UHFFFAOYSA-N
DMQ5AJ6 IU 2-phenyl-1,2-benzoselenazol-3-one
DMQ5AJ6 CA CAS 60940-34-3
DMQ5AJ6 CB CHEBI:77543
DMYFK85 ID DMYFK85
DMYFK85 DN Six-membered heterocyclic benzamide derivative 1
DMYFK85 HS Patented
DMYFK85 SN PMID28270021-Compound-WO2015143654Example29
DMYFK85 CP MERCK SHARP & DOHME CORP
DMYFK85 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMX6AKV ID DMX6AKV
DMX6AKV DN Six-membered heterocyclic benzamide derivative 2
DMX6AKV HS Patented
DMX6AKV SN PMID28270021-Compound-WO2015143654Example41
DMX6AKV CP MERCK SHARP & DOHME CORP
DMX6AKV DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMEGVD4 ID DMEGVD4
DMEGVD4 DN Six-membered heterocyclic benzamide derivative 3
DMEGVD4 HS Patented
DMEGVD4 SN PMID28270021-Compound-WO2015143654Example60
DMEGVD4 CP MERCK SHARP & DOHME CORP
DMEGVD4 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMB0D1H ID DMB0D1H
DMB0D1H DN Six-membered heterocyclic benzamide derivative 4
DMB0D1H HS Patented
DMB0D1H SN PMID28270021-Compound-WO2015143654Example62
DMB0D1H CP MERCK SHARP & DOHME CORP
DMB0D1H DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM0GTUH ID DM0GTUH
DM0GTUH DN Six-membered heterocyclic benzamide derivative 5
DM0GTUH HS Patented
DM0GTUH SN PMID28270021-Compound-WO2015148344Example152
DM0GTUH CP MERCK SHARP & DOHME CORP
DM0GTUH DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMZU96C ID DMZU96C
DMZU96C DN Six-membered heterocyclic benzamide derivative 6
DMZU96C HS Patented
DMZU96C SN PMID28270021-Compound-WO2015148344Example59
DMZU96C CP MERCK SHARP & DOHME CORP
DMZU96C DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM15AFI ID DM15AFI
DM15AFI DN Six-membered heterocyclic benzamide derivative 7
DM15AFI HS Patented
DM15AFI SN PMID28270021-Compound-WO2015148344Example96
DM15AFI CP MERCK SHARP & DOHME CORP
DM15AFI DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMJF6S0 ID DMJF6S0
DMJF6S0 DN Sphinx
DMJF6S0 HS Patented
DMJF6S0 SN SPHINX; AC1NI3K3; SCHEMBL15648757; US9695160, SPHINX; BDBM221070; ZINC6790230; AKOS001099848; MCULE-7133870197; 5-methyl-N-[2-morpholin-4-yl-5-(trifluoromethyl)phenyl]furan-2-carboxamide; 5-methyl-N-(2-morpholino-5-(trifluoromethyl)phenyl)furan-2-carboxamide; 5-methyl-N-[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]furan-2-carboxamide; 848057-98-7
DMJF6S0 DT Small molecular drug
DMJF6S0 PC 4799939
DMJF6S0 MW 354.32
DMJF6S0 FM C17H17F3N2O3
DMJF6S0 IC InChI=1S/C17H17F3N2O3/c1-11-2-5-15(25-11)16(23)21-13-10-12(17(18,19)20)3-4-14(13)22-6-8-24-9-7-22/h2-5,10H,6-9H2,1H3,(H,21,23)
DMJF6S0 CS CC1=CC=C(O1)C(=O)NC2=C(C=CC(=C2)C(F)(F)F)N3CCOCC3
DMJF6S0 IK FZCPNRVICXFZJR-UHFFFAOYSA-N
DMJF6S0 IU 5-methyl-N-[2-morpholin-4-yl-5-(trifluoromethyl)phenyl]furan-2-carboxamide
DM8XJTH ID DM8XJTH
DM8XJTH DN SPHINX scaffold, 3
DM8XJTH HS Patented
DM8XJTH SN SPHINX scaffold, 3; SCHEMBL18538650; BDBM221073; US9695160, SPHINX7
DM8XJTH DT Small molecular drug
DM8XJTH PC 73672854
DM8XJTH MW 487.5
DM8XJTH FM C25H28F3N5O2
DM8XJTH IC InChI=1S/C25H28F3N5O2/c1-31(2)11-12-32-13-15-33(16-14-32)21-4-3-19(25(26,27)28)17-20(21)30-24(34)23-6-5-22(35-23)18-7-9-29-10-8-18/h3-10,17H,11-16H2,1-2H3,(H,30,34)
DM8XJTH CS CN(C)CCN1CCN(CC1)C2=C(C=C(C=C2)C(F)(F)F)NC(=O)C3=CC=C(O3)C4=CC=NC=C4
DM8XJTH IK ALLIMXLDTJFWHR-UHFFFAOYSA-N
DM8XJTH IU N-[2-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-5-(trifluoromethyl)phenyl]-5-pyridin-4-ylfuran-2-carboxamide
DM4R7OQ ID DM4R7OQ
DM4R7OQ DN Spirocyclic diamine urea derivative 1
DM4R7OQ HS Patented
DM4R7OQ SN PMID26413912-Compound-46
DM4R7OQ CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. KEITH, John, M. JONES, William, M
DM4R7OQ DT Small molecular drug
DMH5N78 ID DMH5N78
DMH5N78 DN Spirocyclic diamine urea derivative 2
DMH5N78 HS Patented
DMH5N78 SN PMID26413912-Compound-47
DMH5N78 CP JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. KEITH, John, M. JONES, William, M
DMH5N78 DT Small molecular drug
DMH5N78 PC 49822348
DMH5N78 MW 497.4
DMH5N78 FM C26H26Cl2N4O2
DMH5N78 IC InChI=1S/C26H26Cl2N4O2/c27-20-4-6-23(7-5-20)34-24-3-1-2-19(12-24)16-31-10-8-26(9-11-31)17-32(18-26)25(33)30-22-13-21(28)14-29-15-22/h1-7,12-15H,8-11,16-18H2,(H,30,33)
DMH5N78 CS C1CN(CCC12CN(C2)C(=O)NC3=CC(=CN=C3)Cl)CC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
DMH5N78 IK UNZBUFAASDCGFU-UHFFFAOYSA-N
DMH5N78 IU 7-[[3-(4-chlorophenoxy)phenyl]methyl]-N-(5-chloropyridin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide
DMCPVRU ID DMCPVRU
DMCPVRU DN Spiroimidazolone derivative 1
DMCPVRU HS Patented
DMCPVRU SN PMID25828189-Compound-28
DMCPVRU CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DMCPVRU DT Small molecular drug
DM3EAHB ID DM3EAHB
DM3EAHB DN Spiroimidazolone derivative 2
DM3EAHB HS Patented
DM3EAHB SN PMID25828189-Compound-29
DM3EAHB CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM3EAHB DT Small molecular drug
DM3EAHB PC 53472814
DM3EAHB MW 644.9
DM3EAHB FM C37H56N8O2
DM3EAHB IC InChI=1S/C37H56N8O2/c1-35(2,3)19-17-30(26-11-13-27(14-12-26)33(46)38-23-31-40-42-43-41-31)45-34(47)32(44-22-18-25-9-7-8-10-28(25)24-44)39-37(45)20-15-29(16-21-37)36(4,5)6/h11-14,25,28-30H,7-10,15-24H2,1-6H3,(H,38,46)(H,40,41,42,43)/t25?,28?,29?,30-,37?/m1/s1
DM3EAHB CS CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCC2=NNN=N2)N3C(=O)C(=NC34CCC(CC4)C(C)(C)C)N5CCC6CCCCC6C5
DM3EAHB IK QRNMPSNUYHYWGG-RLLJVHIDSA-N
DM3EAHB IU 4-[(1R)-1-[2-(3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl)-8-tert-butyl-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl]-4,4-dimethylpentyl]-N-(2H-tetrazol-5-ylmethyl)benzamide
DM02J8N ID DM02J8N
DM02J8N DN Spiroimidazolone derivative 3
DM02J8N HS Patented
DM02J8N SN PMID25828189-Compound-30
DM02J8N CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM02J8N DT Small molecular drug
DM02J8N PC 53377590
DM02J8N MW 524.7
DM02J8N FM C30H44N4O4
DM02J8N IC InChI=1S/C30H44N4O4/c1-5-24(21-9-11-22(12-10-21)27(37)31-18-15-25(35)36)34-28(38)26(33-19-7-6-8-20-33)32-30(34)16-13-23(14-17-30)29(2,3)4/h9-12,23-24H,5-8,13-20H2,1-4H3,(H,31,37)(H,35,36)/t23?,24-,30?/m1/s1
DM02J8N CS CC[C@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=O)C(=NC23CCC(CC3)C(C)(C)C)N4CCCCC4
DM02J8N IK RSTWUMARZLVIKV-OLYGOTPTSA-N
DM02J8N IU 3-[[4-[(1R)-1-(8-tert-butyl-3-oxo-2-piperidin-1-yl-1,4-diazaspiro[4.5]dec-1-en-4-yl)propyl]benzoyl]amino]propanoic acid
DMXIHPT ID DMXIHPT
DMXIHPT DN Spiroimidazolone derivative 4
DMXIHPT HS Patented
DMXIHPT SN PMID25828189-Compound-31
DMXIHPT CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DMXIHPT DT Small molecular drug
DMXIHPT PC 71202253
DMXIHPT MW 589.8
DMXIHPT FM C34H51N7O2
DMXIHPT IC InChI=1S/C34H51N7O2/c1-32(2,3)19-18-27(23-12-14-25(15-13-23)30(42)35-22-28-37-39-40-38-28)41-31(43)29(24-10-8-7-9-11-24)36-34(41)20-16-26(17-21-34)33(4,5)6/h12-15,24,26-27H,7-11,16-22H2,1-6H3,(H,35,42)(H,37,38,39,40)/t26?,27-,34?/m1/s1
DMXIHPT CS CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCC2=NNN=N2)N3C(=O)C(=NC34CCC(CC4)C(C)(C)C)C5CCCCC5
DMXIHPT IK PTRTYSISBCSORS-XSUYSUAISA-N
DMXIHPT IU 4-[(1R)-1-(8-tert-butyl-2-cyclohexyl-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl)-4,4-dimethylpentyl]-N-(2H-tetrazol-5-ylmethyl)benzamide
DM5A62X ID DM5A62X
DM5A62X DN Spiroimidazolone derivative 5
DM5A62X HS Patented
DM5A62X SN PMID25828189-Compound-32
DM5A62X CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM5A62X DT Small molecular drug
DMJN5CI ID DMJN5CI
DMJN5CI DN Spiroimidazolone derivative 6
DMJN5CI HS Patented
DMJN5CI SN PMID25828189-Compound-33
DMJN5CI CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DMJN5CI DT Small molecular drug
DMJN5CI PC 53377591
DMJN5CI MW 683.9
DMJN5CI FM C40H57N7O3
DMJN5CI IC InChI=1S/C40H57N7O3/c1-37(2,3)20-19-32(27-13-15-28(16-14-27)35(48)41-26-33-43-45-46-44-33)47-36(49)34(42-40(47)21-17-30(18-22-40)39(7,8)9)29-11-10-12-31(25-29)50-24-23-38(4,5)6/h10-16,25,30,32H,17-24,26H2,1-9H3,(H,41,48)(H,43,44,45,46)/t30?,32-,40?/m1/s1
DMJN5CI CS CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCC2=NNN=N2)N3C(=O)C(=NC34CCC(CC4)C(C)(C)C)C5=CC(=CC=C5)OCCC(C)(C)C
DMJN5CI IK BKPCTAJENJTTAU-WHPMNUFOSA-N
DMJN5CI IU 4-[(1R)-1-[8-tert-butyl-2-[3-(3,3-dimethylbutoxy)phenyl]-3-oxo-1,4-diazaspiro[4.5]dec-1-en-4-yl]-4,4-dimethylpentyl]-N-(2H-tetrazol-5-ylmethyl)benzamide
DM5A4TP ID DM5A4TP
DM5A4TP DN Spiroimidazolone derivative 7
DM5A4TP HS Patented
DM5A4TP SN PMID25828189-Compound-34
DM5A4TP CP MERCK SHARP & DOHME CORP. DEMONG, Duane, E. MILLER, Michael, W. DAI, Xing WONG, Michael, K. LAVEY, Brian, J. YU, Wensheng ZHOU, Guowei STAMFORD, Andrew, W. KOZLOWSKI, Joseph, A. GREENLEE, William, J. ZHAO, He CHEN, Ping LIN, Peishan DAI, Peng DAVIS, Jason Louis
DM5A4TP DT Small molecular drug
DM5A4TP PC 53467170
DM5A4TP MW 607.8
DM5A4TP FM C34H46FN3O4Si
DM5A4TP IC InChI=1S/C34H46FN3O4Si/c1-33(2,3)18-16-28(23-10-12-24(13-11-23)31(41)36-21-17-29(39)40)38-32(42)30(25-8-7-9-26(35)22-25)37-34(38)19-14-27(15-20-34)43(4,5)6/h7-13,22,27-28H,14-21H2,1-6H3,(H,36,41)(H,39,40)/t27?,28-,34?/m1/s1
DM5A4TP CS CC(C)(C)CC[C@H](C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=O)C(=NC23CCC(CC3)[Si](C)(C)C)C4=CC(=CC=C4)F
DM5A4TP IK RBMROQXTXSWPGO-IXDCWVCYSA-N
DM5A4TP IU 3-[[4-[(1R)-1-[2-(3-fluorophenyl)-3-oxo-8-trimethylsilyl-1,4-diazaspiro[4.5]dec-1-en-4-yl]-4,4-dimethylpentyl]benzoyl]amino]propanoic acid
DMK5G7D ID DMK5G7D
DMK5G7D DN Spirolaxine derivative 1
DMK5G7D HS Patented
DMK5G7D SN PMID25416646-Compound-Figure2-L
DMK5G7D CP SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. CALVANI, Menotti D'IDDIO, Stefania BENATTI, Paola
DMK5G7D DT Small molecular drug
DMYJL2Z ID DMYJL2Z
DMYJL2Z DN Spiroquinolone derivative 1
DMYJL2Z HS Patented
DMYJL2Z SN PMID27828716-Compound-8
DMYJL2Z DT Small molecular drug
DMYJL2Z PC 25253820
DMYJL2Z MW 453.5
DMYJL2Z FM C23H24FN5O4
DMYJL2Z IC InChI=1S/C23H24FN5O4/c24-16-17(25)15-19-21(18(16)28-10-9-27-14-4-1-2-8-26-14)33-11-7-23(5-3-6-23)29(19)12-13(20(15)30)22(31)32/h1-2,4,8,12,28H,3,5-7,9-11,25H2,(H,26,27)(H,31,32)
DMYJL2Z CS C1CC2(C1)CCOC3=C4N2C=C(C(=O)C4=C(C(=C3NCCNC5=CC=CC=N5)F)N)C(=O)O
DMYJL2Z IK FBGUGRUHZTVCSL-UHFFFAOYSA-N
DMYJL2Z IU 6-amino-7-fluoro-4-oxo-8-[2-(pyridin-2-ylamino)ethylamino]spiro[10-oxa-1-azatricyclo[7.4.1.05,14]tetradeca-2,5,7,9(14)-tetraene-13,1'-cyclobutane]-3-carboxylic acid
DMB0NVQ ID DMB0NVQ
DMB0NVQ DN Steroid derivative 1
DMB0NVQ HS Patented
DMB0NVQ SN PMID26882240-Compound-23
DMB0NVQ DT Small molecular drug
DMB0NVQ PC 66414
DMB0NVQ MW 302.4
DMB0NVQ FM C19H26O3
DMB0NVQ IC InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1
DMB0NVQ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)OC)O
DMB0NVQ IK CQOQDQWUFQDJMK-SSTWWWIQSA-N
DMB0NVQ IU (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMB0NVQ CA CAS 362-07-2
DMB0NVQ CB CHEBI:28955
DMQ0RGB ID DMQ0RGB
DMQ0RGB DN Steroid derivative 2
DMQ0RGB HS Patented
DMQ0RGB SN PMID26882240-Compound-25
DMQ0RGB CP Macau University of Science and Technology, Macau
DMQ0RGB DT Small molecular drug
DMQ0RGB PC 11261800
DMQ0RGB MW 587.7
DMQ0RGB FM C31H41NO8S
DMQ0RGB IC InChI=1S/C31H41NO8S/c1-17-13-30(32-9-10-41-30)31(36)26(38-17)39-23-12-19-3-4-22-21(28(19,16-33)14-24(23)40-31)5-7-27(2)20(6-8-29(22,27)35)18-11-25(34)37-15-18/h9,11,16-17,19-24,26,35-36H,3-8,10,12-15H2,1-2H3/t17-,19+,20-,21+,22-,23-,24-,26+,27-,28-,29+,30+,31-/m1/s1
DMQ0RGB CS C[C@@H]1C[C@]2([C@]3([C@@H](O1)O[C@@H]4C[C@@H]5CC[C@@H]6[C@@H]([C@]5(C[C@H]4O3)C=O)CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)N=CCS2
DMQ0RGB IK DONIPVCAKBPJLH-IGACXKNBSA-N
DMQ0RGB IU (1S,3R,5S,7R,9S,10R,12R,14R,15S,18R,19R,22S,23R)-10,22-dihydroxy-7,18-dimethyl-19-(5-oxo-2H-furan-3-yl)spiro[4,6,11-trioxahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosane-9,2'-5H-1,3-thiazole]-14-carbaldehyde
DMQ0RGB CA CAS 24211-81-2
DMETIKC ID DMETIKC
DMETIKC DN Steroid derivative 3
DMETIKC HS Patented
DMETIKC SN PMID26882240-Compound-26
DMETIKC CP Macau University of Science and Technology, Macau
DMETIKC DT Small molecular drug
DMETIKC PC 86301250
DMETIKC MW 587.7
DMETIKC FM C31H41NO8S
DMETIKC IC InChI=1S/C31H41NO8S/c1-17-13-30(32-9-10-41-30)31(36)26(38-17)39-23-12-19-3-4-22-21(28(19,16-33)14-24(23)40-31)5-7-27(2)20(6-8-29(22,27)35)18-11-25(34)37-15-18/h9,11,16-17,19-24,26,35-36H,3-8,10,12-15H2,1-2H3/t17-,19+,20-,21+,22-,23-,24-,26+,27-,28-,29+,30+,31+/m1/s1
DMETIKC CS C[C@@H]1C[C@]2([C@@]3([C@@H](O1)O[C@@H]4C[C@@H]5CC[C@@H]6[C@@H]([C@]5(C[C@H]4O3)C=O)CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)N=CCS2
DMETIKC IK DONIPVCAKBPJLH-NCSQWUIOSA-N
DMETIKC IU (1S,3R,5S,7R,9S,10S,12R,14R,15S,18R,19R,22S,23R)-10,22-dihydroxy-7,18-dimethyl-19-(5-oxo-2H-furan-3-yl)spiro[4,6,11-trioxahexacyclo[12.11.0.03,12.05,10.015,23.018,22]pentacosane-9,2'-5H-1,3-thiazole]-14-carbaldehyde
DMJPYVS ID DMJPYVS
DMJPYVS DN Steroid derivative 4
DMJPYVS HS Patented
DMJPYVS SN PMID26882240-Compound-27
DMJPYVS CP SRI INTERNATIONAL ZHOU, Wei SAMBUCETTI, LidiSRI International, USA
DMJPYVS DT Small molecular drug
DMHLA5V ID DMHLA5V
DMHLA5V DN Steroidal carboxamide derivative 1
DMHLA5V HS Patented
DMHLA5V SN PMID29334795-Compound-34
DMHLA5V CP RICHTER GEDEON NYRT [HU]
DMHLA5V DT Small molecular drug
DM5U36G ID DM5U36G
DM5U36G DN Sterol derivative 1
DM5U36G HS Patented
DM5U36G SN PMID27537201-Compound-Figure16a
DM5U36G CP UNIV BEIJING PEKING WBL BIOTECH CO LTD [CN]
DM5U36G DT Small molecular drug
DME1B23 ID DME1B23
DME1B23 DN Sterol derivative 2
DME1B23 HS Patented
DME1B23 SN PMID27537201-Compound-Figure16b
DME1B23 CP BEIJING PEKING UNIVERSITY WBL BIOTECH CO., LTD. DUAN, ZhenwenUNIV BEIJING PEKING WBL BIOTECH CO LTD [CN]
DME1B23 DT Small molecular drug
DMOT1FQ ID DMOT1FQ
DMOT1FQ DN Sterol derivative 3
DMOT1FQ HS Patented
DMOT1FQ SN PMID27537201-Compound-Figure16c
DMOT1FQ CP BEIJING WBL PEKING UNIV BIOTEC
DMOT1FQ DT Small molecular drug
DM6KPYL ID DM6KPYL
DM6KPYL DN STK296197
DM6KPYL HS Patented
DM6KPYL SN 2-(2,4-dimethoxyphenyl)-6,7-dimethoxy-4H-3,1-benzoxazin-4-one; SCHEMBL18352860; BDBM113301; ZINC8906265; STK296197; AKOS003369098; MCULE-2502072969; 847572-11-6; US9695194, 17; Z223457118
DM6KPYL DT Small molecular drug
DM6KPYL PC 17018602
DM6KPYL MW 343.3
DM6KPYL FM C18H17NO6
DM6KPYL IC InChI=1S/C18H17NO6/c1-21-10-5-6-11(14(7-10)22-2)17-19-13-9-16(24-4)15(23-3)8-12(13)18(20)25-17/h5-9H,1-4H3
DM6KPYL CS COC1=CC(=C(C=C1)C2=NC3=CC(=C(C=C3C(=O)O2)OC)OC)OC
DM6KPYL IK JCFSQIOFMQLSPV-UHFFFAOYSA-N
DM6KPYL IU 2-(2,4-dimethoxyphenyl)-6,7-dimethoxy-3,1-benzoxazin-4-one
DM19GAY ID DM19GAY
DM19GAY DN STK696827
DM19GAY HS Patented
DM19GAY SN CHEMBL1084866; 4-[2-(Anthracen-9-Ylmethylidene)hydrazino]-N-(3-Chlorophenyl)-4-Oxobutanamide; 4-[(2E)-2-(anthracen-9-ylmethylidene)hydrazinyl]-N-(3-chlorophenyl)-4-oxobutanamide; NadD inhibitor 1_02; SCHEMBL11887958; A0640/0029695; STK696827; BDBM50318652; AKOS001707409; US8785499, 1_02; 4-{2-[(E)-1-(9-anthryl)methylidene]hydrazino}-N-(3-chlorophenyl)-4-oxobutanamide; (E)-4-(2-(anthracen-9-ylmethylene)hydrazinyl)-N-(3-chlorophenyl)-4-oxobutanamide
DM19GAY DT Small molecular drug
DM19GAY PC 9597188
DM19GAY MW 429.9
DM19GAY FM C25H20ClN3O2
DM19GAY IC InChI=1S/C25H20ClN3O2/c26-19-8-5-9-20(15-19)28-24(30)12-13-25(31)29-27-16-23-21-10-3-1-6-17(21)14-18-7-2-4-11-22(18)23/h1-11,14-16H,12-13H2,(H,28,30)(H,29,31)/b27-16+
DM19GAY CS C1=CC=C2C(=C1)C=C3C=CC=CC3=C2/C=N/NC(=O)CCC(=O)NC4=CC(=CC=C4)Cl
DM19GAY IK OJLFRDWWYAPUAJ-JVWAILMASA-N
DM19GAY IU N'-[(E)-anthracen-9-ylmethylideneamino]-N-(3-chlorophenyl)butanediamide
DMTXDSG ID DMTXDSG
DMTXDSG DN Succinamide derivative 1
DMTXDSG HS Patented
DMTXDSG SN PMID27414413-Compound-Figure11upright
DMTXDSG CP Yuanqiang Z
DMTXDSG DT Small molecular drug
DMQ0VK9 ID DMQ0VK9
DMQ0VK9 DN Sulfamic acid ester derivative 1
DMQ0VK9 HS Patented
DMQ0VK9 SN PMID29473428-Compound-20
DMQ0VK9 DT Small molecular drug
DMO7ZRW ID DMO7ZRW
DMO7ZRW DN Sulfamoylamide derivative 1
DMO7ZRW HS Patented
DMO7ZRW SN PMID29473428-Compound-61
DMO7ZRW CP BRISTOL-MYERS SQUIBB COMPANY
DMO7ZRW DT Small molecular drug
DMO7ZRW PC 124158767
DMO7ZRW MW 598.1
DMO7ZRW FM C27H37ClFN5O5S
DMO7ZRW IC InChI=1S/C27H37ClFN5O5S/c1-18(2)16-34(20-8-6-5-7-9-20)25-13-11-21(39-17-26(35)32-40(37,38)33(3)4)15-24(25)31-27(36)30-23-12-10-19(28)14-22(23)29/h10-15,18,20H,5-9,16-17H2,1-4H3,(H,32,35)(H2,30,31,36)
DMO7ZRW CS CC(C)CN(C1CCCCC1)C2=C(C=C(C=C2)OCC(=O)NS(=O)(=O)N(C)C)NC(=O)NC3=C(C=C(C=C3)Cl)F
DMO7ZRW IK GXQLSHAYKCFGCU-UHFFFAOYSA-N
DMO7ZRW IU 2-[3-[(4-chloro-2-fluorophenyl)carbamoylamino]-4-[cyclohexyl(2-methylpropyl)amino]phenoxy]-N-(dimethylsulfamoyl)acetamide
DMTX21L ID DMTX21L
DMTX21L DN Sulfonamide derivative 1
DMTX21L HS Patented
DMTX21L SN PMID26161824-Compound-95
DMTX21L DT Small molecular drug
DMTX21L DE Obesity
DMA32GJ ID DMA32GJ
DMA32GJ DN Sulfonamide derivative 10
DMA32GJ HS Patented
DMA32GJ SN PMID27414413-Compound-Figure3bottomleft
DMA32GJ CP PFIZER LIMITED
DMA32GJ DT Small molecular drug
DMA32GJ PC 86294663
DMA32GJ MW 428.8
DMA32GJ FM C19H10ClFN4O3S
DMA32GJ IC InChI=1S/C19H10ClFN4O3S/c20-17-8-15(3-1-12(17)9-22)28-18-5-4-16(7-13(18)10-23)29(26,27)25-19-6-2-14(21)11-24-19/h1-8,11H,(H,24,25)
DMA32GJ CS C1=CC(=C(C=C1OC2=C(C=C(C=C2)S(=O)(=O)NC3=NC=C(C=C3)F)C#N)Cl)C#N
DMA32GJ IK ABKCBHGHCYFDNT-UHFFFAOYSA-N
DMA32GJ IU 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(5-fluoropyridin-2-yl)benzenesulfonamide
DMJBR86 ID DMJBR86
DMJBR86 DN Sulfonamide derivative 11
DMJBR86 HS Patented
DMJBR86 SN PMID27414413-Compound-Figure3bottomright
DMJBR86 CP PFIZER LIMITED
DMJBR86 DT Small molecular drug
DMJBR86 PC 86282507
DMJBR86 MW 416.9
DMJBR86 FM C17H9ClN4O3S2
DMJBR86 IC InChI=1S/C17H9ClN4O3S2/c18-15-8-13(2-1-11(15)9-19)25-16-4-3-14(7-12(16)10-20)27(23,24)22-17-21-5-6-26-17/h1-8H,(H,21,22)
DMJBR86 CS C1=CC(=C(C=C1OC2=C(C=C(C=C2)S(=O)(=O)NC3=NC=CS3)C#N)Cl)C#N
DMJBR86 IK JONVMVCPXBMHHN-UHFFFAOYSA-N
DMJBR86 IU 4-(3-chloro-4-cyanophenoxy)-3-cyano-N-(1,3-thiazol-2-yl)benzenesulfonamide
DMXEL56 ID DMXEL56
DMXEL56 DN Sulfonamide derivative 12
DMXEL56 HS Patented
DMXEL56 SN PMID30074415-Compound-16
DMXEL56 DT Small molecular drug
DMXEL56 PC 71607911
DMXEL56 MW 444.4
DMXEL56 FM C21H15F3N4O2S
DMXEL56 IC InChI=1S/C21H15F3N4O2S/c22-21(23,24)14-7-5-13(6-8-14)19-17-3-1-2-4-18(17)20(28-27-19)26-15-9-11-16(12-10-15)31(25,29)30/h1-12H,(H,26,28)(H2,25,29,30)
DMXEL56 CS C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)C(F)(F)F
DMXEL56 IK DXRJQXFJLLMHKO-UHFFFAOYSA-N
DMXEL56 IU 4-[[4-[4-(trifluoromethyl)phenyl]phthalazin-1-yl]amino]benzenesulfonamide
DM5CUSJ ID DM5CUSJ
DM5CUSJ DN Sulfonamide derivative 15
DM5CUSJ HS Patented
DM5CUSJ SN PMID28460551-Compound-7
DM5CUSJ DT Small molecular drug
DM5CUSJ PC 11964527
DM5CUSJ MW 333.5
DM5CUSJ FM C17H19NO2S2
DM5CUSJ IC InChI=1S/C17H19NO2S2/c19-22(20,16-6-3-9-21-16)18-17-14-7-8-15(17)11-13-5-2-1-4-12(13)10-14/h1-6,9,14-15,17-18H,7-8,10-11H2
DM5CUSJ CS C1CC2CC3=CC=CC=C3CC1C2NS(=O)(=O)C4=CC=CS4
DM5CUSJ IK IFPBWXNUXWIDSN-UHFFFAOYSA-N
DM5CUSJ IU N-(13-tricyclo[8.2.1.03,8]trideca-3,5,7-trienyl)thiophene-2-sulfonamide
DMTFNGM ID DMTFNGM
DMTFNGM DN Sulfonamide derivative 16
DMTFNGM HS Patented
DMTFNGM SN PMID29886770-Compound-Figure6
DMTFNGM CP Chong Kun Dang Pharmaceutical Corp
DMTFNGM DT Small molecular drug
DMIQ1PL ID DMIQ1PL
DMIQ1PL DN Sulfonamide derivative 17
DMIQ1PL HS Patented
DMIQ1PL SN PMID29886770-Compound-Figure7
DMIQ1PL CP UNIVERSITY OF SOUTH AUSTRALIA CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC
DMIQ1PL DT Small molecular drug
DMHTJ7N ID DMHTJ7N
DMHTJ7N DN Sulfonamide derivative 18
DMHTJ7N HS Patented
DMHTJ7N SN PMID25416646-Compound-Figure2-M
DMHTJ7N CP PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED RAMDAS, Vidya FINCH, Harry FOX, Craig
DMHTJ7N DT Small molecular drug
DMD51AV ID DMD51AV
DMD51AV DN Sulfonamide derivative 6
DMD51AV HS Patented
DMD51AV SN PMID29473428-Compound-75
DMD51AV CP FLEXUS BIOSCIENCES, INC
DMD51AV DT Small molecular drug
DMN5YUK ID DMN5YUK
DMN5YUK DN Sulfonamide derivative 7
DMN5YUK HS Patented
DMN5YUK SN PMID29473428-Compound-78
DMN5YUK CP IOMET PHARMA LTD
DMN5YUK DT Small molecular drug
DMN5YUK PC 110402129
DMN5YUK MW 300.3
DMN5YUK FM C15H12N2O3S
DMN5YUK IC InChI=1S/C15H12N2O3S/c18-21(19,13-9-5-2-6-10-13)17-15-14(11-16-20-15)12-7-3-1-4-8-12/h1-11,17H
DMN5YUK CS C1=CC=C(C=C1)C2=C(ON=C2)NS(=O)(=O)C3=CC=CC=C3
DMN5YUK IK KJPWMAIBFGUKIA-UHFFFAOYSA-N
DMN5YUK IU N-(4-phenyl-1,2-oxazol-5-yl)benzenesulfonamide
DMOXIZC ID DMOXIZC
DMOXIZC DN Sulfonamide derivative 8
DMOXIZC HS Patented
DMOXIZC SN PMID29473428-Compound-79
DMOXIZC CP IOMET PHARMA LTD
DMOXIZC DT Small molecular drug
DMOXIZC PC 118895401
DMOXIZC MW 280.34
DMOXIZC FM C13H16N2O3S
DMOXIZC IC InChI=1S/C13H16N2O3S/c1-10(2)9-19(16,17)15-12-8-14-18-13(12)11-6-4-3-5-7-11/h3-8,10,15H,9H2,1-2H3
DMOXIZC CS CC(C)CS(=O)(=O)NC1=C(ON=C1)C2=CC=CC=C2
DMOXIZC IK PNZONOIXJUOMIU-UHFFFAOYSA-N
DMOXIZC IU 2-methyl-N-(5-phenyl-1,2-oxazol-4-yl)propane-1-sulfonamide
DM2RZL8 ID DM2RZL8
DM2RZL8 DN Sulfonamide derivative 9
DM2RZL8 HS Patented
DM2RZL8 SN PMID26560530-Compound-55
DM2RZL8 CP CHDI Foundation, Inc
DM2RZL8 DT Small molecular drug
DMP9Z34 ID DMP9Z34
DMP9Z34 DN Sulfonamide-thiadiazole derivative 1
DMP9Z34 HS Patented
DMP9Z34 SN PMID30074415-Compound-17
DMP9Z34 DT Small molecular drug
DMZAE78 ID DMZAE78
DMZAE78 DN Sulfonamide-thiadiazole derivative 2
DMZAE78 HS Patented
DMZAE78 SN PMID30074415-Compound-18
DMZAE78 DT Small molecular drug
DMCO8JD ID DMCO8JD
DMCO8JD DN Sulfonylated piperazine derivative 1
DMCO8JD HS Patented
DMCO8JD SN PMID26161824-Compound-181
DMCO8JD DT Small molecular drug
DMCO8JD PC 24945152
DMCO8JD MW 387.5
DMCO8JD FM C20H25N3O3S
DMCO8JD IC InChI=1S/C20H25N3O3S/c24-20(21-11-4-1-5-12-21)22-13-15-23(16-14-22)27(25,26)19-10-6-8-17-7-2-3-9-18(17)19/h2-3,6-10H,1,4-5,11-16H2
DMCO8JD CS C1CCN(CC1)C(=O)N2CCN(CC2)S(=O)(=O)C3=CC=CC4=CC=CC=C43
DMCO8JD IK FVGJQXBVEVXXEH-UHFFFAOYSA-N
DMCO8JD IU (4-naphthalen-1-ylsulfonylpiperazin-1-yl)-piperidin-1-ylmethanone
DMCO8JD DE Obesity
DMZYPV3 ID DMZYPV3
DMZYPV3 DN Sulfonylated piperazine derivative 2
DMZYPV3 HS Patented
DMZYPV3 SN PMID26161824-Compound-182
DMZYPV3 DT Small molecular drug
DMZYPV3 PC 44582884
DMZYPV3 MW 412.5
DMZYPV3 FM C23H28N2O3S
DMZYPV3 IC InChI=1S/C23H28N2O3S/c26-23(18-8-2-1-3-9-18)25-19-13-14-20(25)16-24(15-19)29(27,28)22-12-6-10-17-7-4-5-11-21(17)22/h4-7,10-12,18-20H,1-3,8-9,13-16H2
DMZYPV3 CS C1CCC(CC1)C(=O)N2C3CCC2CN(C3)S(=O)(=O)C4=CC=CC5=CC=CC=C54
DMZYPV3 IK REHIEVFQRQVSNB-UHFFFAOYSA-N
DMZYPV3 IU cyclohexyl-(3-naphthalen-1-ylsulfonyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone
DMZYPV3 DE Obesity
DMOJAZ9 ID DMOJAZ9
DMOJAZ9 DN Sulfonylated piperazine derivative 3
DMOJAZ9 HS Patented
DMOJAZ9 SN PMID26161824-Compound-183
DMOJAZ9 DT Small molecular drug
DMOJAZ9 PC 13458368
DMOJAZ9 MW 466.4
DMOJAZ9 FM C19H16F6N2O3S
DMOJAZ9 IC InChI=1S/C19H16F6N2O3S/c20-18(21,22)14-10-15(19(23,24)25)12-16(11-14)31(29,30)27-8-6-26(7-9-27)17(28)13-4-2-1-3-5-13/h1-5,10-12H,6-9H2
DMOJAZ9 CS C1CN(CCN1C(=O)C2=CC=CC=C2)S(=O)(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMOJAZ9 IK PIYWKJKVVMSCGG-UHFFFAOYSA-N
DMOJAZ9 IU [4-[3,5-bis(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-phenylmethanone
DMOJAZ9 DE Obesity
DMZW2XP ID DMZW2XP
DMZW2XP DN Sulfonylated piperazine derivative 4
DMZW2XP HS Patented
DMZW2XP SN PMID26161824-Compound-184
DMZW2XP DT Small molecular drug
DMZW2XP PC 24945235
DMZW2XP MW 538.5
DMZW2XP FM C22H20F6N2O5S
DMZW2XP IC InChI=1S/C22H20F6N2O5S/c1-35-20(32)15-11-17(22(26,27)28)13-18(12-15)36(33,34)30-8-6-29(7-9-30)19(31)10-14-2-4-16(5-3-14)21(23,24)25/h2-5,11-13H,6-10H2,1H3
DMZW2XP CS COC(=O)C1=CC(=CC(=C1)S(=O)(=O)N2CCN(CC2)C(=O)CC3=CC=C(C=C3)C(F)(F)F)C(F)(F)F
DMZW2XP IK GJGRAMGTQURCNW-UHFFFAOYSA-N
DMZW2XP IU methyl 3-(trifluoromethyl)-5-[4-[2-[4-(trifluoromethyl)phenyl]acetyl]piperazin-1-yl]sulfonylbenzoate
DMZW2XP DE Obesity
DM65NBS ID DM65NBS
DM65NBS DN Sulfonylated piperazine derivative 5
DM65NBS HS Patented
DM65NBS SN PMID26161824-Compound-185
DM65NBS DT Small molecular drug
DM65NBS PC 24744027
DM65NBS MW 520.5
DM65NBS FM C23H22F6N2O3S
DM65NBS IC InChI=1S/C23H22F6N2O3S/c24-22(25,26)18-5-1-15(2-6-18)11-21(32)30-7-9-31(10-8-30)35(33,34)20-13-17(16-3-4-16)12-19(14-20)23(27,28)29/h1-2,5-6,12-14,16H,3-4,7-11H2
DM65NBS CS C1CC1C2=CC(=CC(=C2)S(=O)(=O)N3CCN(CC3)C(=O)CC4=CC=C(C=C4)C(F)(F)F)C(F)(F)F
DM65NBS IK DVPAFQJRBKXLSG-UHFFFAOYSA-N
DM65NBS IU 1-[4-[3-cyclopropyl-5-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone
DM65NBS DE Obesity
DMHO29Y ID DMHO29Y
DMHO29Y DN T83193
DMHO29Y HS Patented
DMHO29Y SN vanillin; 4-Hydroxy-3-methoxybenzaldehyde; 121-33-5; Vanillaldehyde; Vanillic aldehyde; Vanilla; p-Vanillin; 2-Methoxy-4-formylphenol; Vanilline; Lioxin; 4-Hydroxy-m-anisaldehyde; 3-Methoxy-4-hydroxybenzaldehyde; Zimco; Benzaldehyde, 4-hydroxy-3-methoxy-; 4-Hydroxy-3-methoxy-benzaldehyde; Vanilin; p-Hydroxy-m-methoxybenzaldehyde; 4-Formyl-2-methoxyphenol; Methylprotocatechuic aldehyde; Vanillin (natural); 4-Hydroxy-5-methoxybenzaldehyde; m-Anisaldehyde, 4-hydroxy-; Protocatechualdehyde, methyl-; Vanillin [USAN]; Vanillin (NF)
DMHO29Y DT Small molecular drug
DMHO29Y PC 1183
DMHO29Y MW 152.15
DMHO29Y FM C8H8O3
DMHO29Y IC InChI=1S/C8H8O3/c1-11-8-4-6(5-9)2-3-7(8)10/h2-5,10H,1H3
DMHO29Y CS COC1=C(C=CC(=C1)C=O)O
DMHO29Y IK MWOOGOJBHIARFG-UHFFFAOYSA-N
DMHO29Y IU 4-hydroxy-3-methoxybenzaldehyde
DMHO29Y CA CAS 121-33-5
DMHO29Y CB CHEBI:18346
DMHO29Y DE Discovery agent
DM86BDS ID DM86BDS
DM86BDS DN T8361
DM86BDS HS Patented
DM86BDS SN 2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde; 20035-42-1; 2,3-Dibromo-6-hydroxy-5-methoxy-benzaldehyde; AC1NN9L0; SCHEMBL12767437; CHEMBL3660308; CTK6J5070; BDBM110970; ZINC2168927; STK037780; MFCD00046151; BBL023774; AKOS000288884; MCULE-3295227366; BB 0244040; T8361; 2,3-Dibromo-6-hydroxy-5-methoxy-benzalde hyde; US8614253, .3-1
DM86BDS DT Small molecular drug
DM86BDS PC 5039109
DM86BDS MW 309.94
DM86BDS FM C8H6Br2O3
DM86BDS IC InChI=1S/C8H6Br2O3/c1-13-6-2-5(9)7(10)4(3-11)8(6)12/h2-3,12H,1H3
DM86BDS CS COC1=CC(=C(C(=C1O)C=O)Br)Br
DM86BDS IK NEQRDPRMCZPVJM-UHFFFAOYSA-N
DM86BDS IU 2,3-dibromo-6-hydroxy-5-methoxybenzaldehyde
DM86BDS CA CAS 20035-42-1
DMX41ZF ID DMX41ZF
DMX41ZF DN T863
DMX41ZF HS Patented
DMX41ZF SN 701232-20-4; DGAT-3; T863; DGAT-1 inhibitor; UNII-OF68Z8HK6V; OF68Z8HK6V; trans-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid; T-863; 2-(4-(4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid; trans-4-(4-(4-amino-7,7-dimethyl-7h-pyrimido(4,5-b)(1,4)oxazin-6-yl)phenyl)cyclohexaneacetic acid; Cyclohexaneacetic acid, 4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]-, trans-; Cyclohexaneacetic acid, 4-(4-(4-amino-7,7-di
DMX41ZF DT Small molecular drug
DMX41ZF PC 9865421
DMX41ZF MW 394.5
DMX41ZF FM C22H26N4O3
DMX41ZF IC InChI=1S/C22H26N4O3/c1-22(2)19(26-18-20(23)24-12-25-21(18)29-22)16-9-7-15(8-10-16)14-5-3-13(4-6-14)11-17(27)28/h7-10,12-14H,3-6,11H2,1-2H3,(H,27,28)(H2,23,24,25)
DMX41ZF CS CC1(C(=NC2=C(N=CN=C2O1)N)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)C
DMX41ZF IK FUIYMYNYUHVDPT-UHFFFAOYSA-N
DMX41ZF IU 2-[4-[4-(4-amino-7,7-dimethylpyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]acetic acid
DMX41ZF CA CAS 701232-20-4
DMX41ZF DE Discovery agent
DMFOKRW ID DMFOKRW
DMFOKRW DN Tacrine heterodimer derivative 1
DMFOKRW HS Patented
DMFOKRW SN PMID29757691-Compound-6
DMFOKRW DT Small molecular drug
DMJ04RQ ID DMJ04RQ
DMJ04RQ DN Tacrine-caffeic acid hybrid derivative 1
DMJ04RQ HS Patented
DMJ04RQ SN PMID27967267-Compound-19
DMJ04RQ CP Univ Sun Yat Sen
DMJ04RQ DT Small molecular drug
DMMVPSY ID DMMVPSY
DMMVPSY DN Tacrine-caffeic acid hybrid derivative 2
DMMVPSY HS Patented
DMMVPSY SN PMID27967267-Compound-20
DMMVPSY CP Univ Sun Yat Sen
DMMVPSY DT Small molecular drug
DM6YBTR ID DM6YBTR
DM6YBTR DN Tacrine-coumarin hybrid derivative 1
DM6YBTR HS Patented
DM6YBTR SN PMID29324067-Compound-96
DM6YBTR CP University Guangdong Technology
DM6YBTR DT Small molecular drug
DMK0S4I ID DMK0S4I
DMK0S4I DN Tacrine-dihydropyridine hybrid derivative 1
DMK0S4I HS Patented
DMK0S4I SN PMID27967267-Compound-29
DMK0S4I CP JIANGSU SIMCERE PHARMACEUTICAL R&D CO., LTD CHEN, Rong LIU, Fei CONG, Xin
DMK0S4I DT Small molecular drug
DMQ3K5B ID DMQ3K5B
DMQ3K5B DN Tacrine-indole hybrid derivative 1
DMQ3K5B HS Patented
DMQ3K5B SN PMID27967267-Compound-16
DMQ3K5B CP Univ China Pharma
DMQ3K5B DT Small molecular drug
DMQ3K5B PC 118717433
DMQ3K5B MW 483.6
DMQ3K5B FM C30H37N5O
DMQ3K5B IC InChI=1S/C30H37N5O/c31-25(19-21-20-34-26-14-6-3-11-22(21)26)30(36)33-18-10-2-1-9-17-32-29-23-12-4-7-15-27(23)35-28-16-8-5-13-24(28)29/h3-4,6-7,11-12,14-15,20,25,34H,1-2,5,8-10,13,16-19,31H2,(H,32,35)(H,33,36)/t25-/m0/s1
DMQ3K5B CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCNC(=O)[C@H](CC4=CNC5=CC=CC=C54)N
DMQ3K5B IK KADKUQSSIRPDHT-VWLOTQADSA-N
DMQ3K5B IU (2S)-2-amino-3-(1H-indol-3-yl)-N-[6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyl]propanamide
DMH9N2T ID DMH9N2T
DMH9N2T DN Tacrine-indole hybrid derivative 2
DMH9N2T HS Patented
DMH9N2T SN PMID27967267-Compound-17
DMH9N2T CP Univ China Pharma
DMH9N2T DT Small molecular drug
DMH9N2T PC 118717425
DMH9N2T MW 491.6
DMH9N2T FM C31H33N5O
DMH9N2T IC InChI=1S/C31H33N5O/c37-31(28-19-24-21-11-3-6-14-25(21)36-29(24)20-34-28)33-18-10-2-1-9-17-32-30-22-12-4-7-15-26(22)35-27-16-8-5-13-23(27)30/h3-4,6-7,11-12,14-15,19-20,36H,1-2,5,8-10,13,16-18H2,(H,32,35)(H,33,37)
DMH9N2T CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCNC(=O)C4=NC=C5C(=C4)C6=CC=CC=C6N5
DMH9N2T IK OLKLOVAJULLISR-UHFFFAOYSA-N
DMH9N2T IU N-[6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyl]-9H-pyrido[3,4-b]indole-3-carboxamide
DMUTKNW ID DMUTKNW
DMUTKNW DN Tacrine-indole hybrid derivative 3
DMUTKNW HS Patented
DMUTKNW SN PMID27967267-Compound-18
DMUTKNW CP Univ China Pharma
DMUTKNW DT Small molecular drug
DMNGY8R ID DMNGY8R
DMNGY8R DN Tacrine-phenothiazine hybrid derivative 1
DMNGY8R HS Patented
DMNGY8R SN PMID27967267-Compound-21
DMNGY8R CP Univ Hefei Technology
DMNGY8R DT Small molecular drug
DMK5HAC ID DMK5HAC
DMK5HAC DN Tarizine derivative 1
DMK5HAC HS Patented
DMK5HAC SN PMID25539043-Compound-WO2010022055Example25
DMK5HAC CP Amgen, Inc
DMK5HAC DT Small molecular drug
DMQKOMR ID DMQKOMR
DMQKOMR DN Tarnylcypromine derivative 1
DMQKOMR HS Patented
DMQKOMR SN PMID27019002-Compound-18
DMQKOMR CP UNIV ROMA [ITFOND IEO [ITUNIV PAVIA [ITUNIV DEGLI STUDI MILANO [ITMINUCCI SAVERIO [ITMAI ANTONELLO [ITMATTEVI ANDREA [IT]
DMQKOMR DT Small molecular drug
DMEJR2F ID DMEJR2F
DMEJR2F DN Tarnylcypromine derivative 2
DMEJR2F HS Patented
DMEJR2F SN PMID27019002-Compound-26a-h
DMEJR2F CP UNIV ROMA [ITFOND IEO [ITUNIV PAVIA [ITUNIV DEGLI STUDI MILANO [ITMINUCCI SAVERIO [ITMAI ANTONELLO [ITMATTEVI ANDREA [IT]
DMEJR2F DT Small molecular drug
DMKJOMC ID DMKJOMC
DMKJOMC DN Tarnylcypromine derivative 3
DMKJOMC HS Patented
DMKJOMC SN PMID27019002-Compound-27a-m
DMKJOMC CP UNIV ROMA [ITFOND IEO [ITUNIV PAVIA [ITUNIV DEGLI STUDI MILANO [ITMINUCCI SAVERIO [ITMAI ANTONELLO [ITMATTEVI ANDREA [IT]
DMKJOMC DT Small molecular drug
DMG6Q45 ID DMG6Q45
DMG6Q45 DN TDZD-8
DMG6Q45 HS Patented
DMG6Q45 SN 327036-89-5; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; GSK-3beta Inhibitor I; TDZD 8; 1,2,4-Thiadiazolidine-3,5-dione, 2-methyl-4-(phenylmethyl)-; MFCD04973552; NP 01139; AK-48153; 4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione; 1,2,4-Thiadiazolidine-3,5-dione,2-methyl-4-(phenylmethyl)-; GSK-3 Inhibitor I; SCHEMBL139834; GTPL5977; CHEMBL284861; BDBM7781; CTK4G9152; ZINC27361; AOB6176; EX-A109; DTXSID30399590; JDSJDASOXWCHPN-UHFFFAOYSA-N; MolPort-003-844-896; HMS3229G12; A Inhibitor I, TDZD-8
DMG6Q45 DT Small molecular drug
DMG6Q45 PC 4124851
DMG6Q45 MW 222.27
DMG6Q45 FM C10H10N2O2S
DMG6Q45 IC InChI=1S/C10H10N2O2S/c1-11-9(13)12(10(14)15-11)7-8-5-3-2-4-6-8/h2-6H,7H2,1H3
DMG6Q45 CS CN1C(=O)N(C(=O)S1)CC2=CC=CC=C2
DMG6Q45 IK JDSJDASOXWCHPN-UHFFFAOYSA-N
DMG6Q45 IU 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
DMG6Q45 CA CAS 327036-89-5
DMG6Q45 CB CHEBI:147411
DMG6Q45 DE Malignant glioma
DMFMZCW ID DMFMZCW
DMFMZCW DN Terpyridineplatinum(II) complexe 1
DMFMZCW HS Patented
DMFMZCW SN PMID27977313-Compound-1
DMFMZCW CP ISIS INNOVATION LIMITED LOWE, Gordon
DMFMZCW DT Small molecular drug
DMLUYR0 ID DMLUYR0
DMLUYR0 DN Terpyridineplatinum(II) complexe 2
DMLUYR0 HS Patented
DMLUYR0 SN PMID27977313-Compound-2
DMLUYR0 CP ISIS INNOVATION LIMITED LOWE, Gordon
DMLUYR0 DT Small molecular drug
DM54EFD ID DM54EFD
DM54EFD DN Terpyridineplatinum(II) complexe 3
DM54EFD HS Patented
DM54EFD SN PMID27977313-Compound-3
DM54EFD CP ISIS INNOVATION LIMITED LOWE, Gordon
DM54EFD DT Small molecular drug
DMOV86T ID DMOV86T
DMOV86T DN Terpyridineplatinum(II) complexe 4
DMOV86T HS Patented
DMOV86T SN PMID27977313-Compound-4
DMOV86T CP ISIS INNOVATION LIMITED LOWE, Gordon
DMOV86T DT Small molecular drug
DMI4MJ2 ID DMI4MJ2
DMI4MJ2 DN Terpyridineplatinum(II) complexe 5
DMI4MJ2 HS Patented
DMI4MJ2 SN PMID27977313-Compound-Figure4a
DMI4MJ2 CP ISIS INNOVATION LIMITED LOWE, Gordon
DMI4MJ2 DT Small molecular drug
DMS3YPJ ID DMS3YPJ
DMS3YPJ DN Tetra/penta-cyclic pyridophthalazinone derivative 1
DMS3YPJ HS Patented
DMS3YPJ SN PMID27841036-Compound-XIII
DMS3YPJ CP BeiGene Ltd
DMS3YPJ DT Small molecular drug
DMLRY53 ID DMLRY53
DMLRY53 DN Tetra-azabenzo[e]azulene derivative 1
DMLRY53 HS Patented
DMLRY53 SN PMID25776143-Compound-5
DMLRY53 CP Hoffmann-La Roche, Inc
DMLRY53 DT Small molecular drug
DMUEI4N ID DMUEI4N
DMUEI4N DN Tetra-azabenzo[e]azulene derivative 2
DMUEI4N HS Patented
DMUEI4N SN PMID25776143-Compound-6
DMUEI4N CP Hoffmann-La Roche, Inc
DMUEI4N DT Small molecular drug
DMS1GJD ID DMS1GJD
DMS1GJD DN Tetra-cyclic compound 1
DMS1GJD HS Patented
DMS1GJD SN PMID27774824-Compound-Figure4compound22j
DMS1GJD CP BIOCRYST PHARMACEUTICALS, INC. BABU, Yarlagadda, S. KOTIAN, Pravin, L. CHINTAREDDY, Venkat, R
DMS1GJD DT Small molecular drug
DMS1GJD PC 46224913
DMS1GJD MW 332.3
DMS1GJD FM C19H13FN4O
DMS1GJD IC InChI=1S/C19H13FN4O/c20-14-7-10(25)5-6-11(14)17-13-8-21-19-16(13)18(22-9-23-19)12-3-1-2-4-15(12)24-17/h1-9,17,24-25H,(H,21,22,23)
DMS1GJD CS C1=CC=C2C(=C1)C3=C4C(=CNC4=NC=N3)C(N2)C5=C(C=C(C=C5)O)F
DMS1GJD IK IROWCEJAOYOCFJ-UHFFFAOYSA-N
DMS1GJD IU 3-fluoro-4-(8,12,14,16-tetrazatetracyclo[8.6.1.02,7.013,17]heptadeca-1(17),2,4,6,10,13,15-heptaen-9-yl)phenol
DMX2EFL ID DMX2EFL
DMX2EFL DN Tetra-cyclic pyridophthalazinone derivative 1
DMX2EFL HS Patented
DMX2EFL SN PMID27841036-Compound-25
DMX2EFL CP BeiGene Ltd
DMX2EFL DT Small molecular drug
DMUXNKG ID DMUXNKG
DMUXNKG DN Tetra-hydro-1H-1,2,6-triazaazulene derivative 1
DMUXNKG HS Patented
DMUXNKG SN PMID26161824-Compound-155
DMUXNKG DT Small molecular drug
DMUXNKG DE Obesity
DMVTZ6S ID DMVTZ6S
DMVTZ6S DN Tetra-hydro-1H-1,2,6-triazaazulene derivative 2
DMVTZ6S HS Patented
DMVTZ6S SN PMID26161824-Compound-156
DMVTZ6S DT Small molecular drug
DMVTZ6S DE Obesity
DM5MVLG ID DM5MVLG
DM5MVLG DN Tetra-hydro-carboline derivative 1
DM5MVLG HS Patented
DM5MVLG SN PMID28447479-Compound-28
DM5MVLG DT Small molecular drug
DMXTL7V ID DMXTL7V
DMXTL7V DN Tetra-hydro-carboline derivative 2
DMXTL7V HS Patented
DMXTL7V SN PMID28447479-Compound-29
DMXTL7V DT Small molecular drug
DMXTL7V PC 66548941
DMXTL7V MW 471.6
DMXTL7V FM C29H33N3O3
DMXTL7V IC InChI=1S/C29H33N3O3/c1-2-20-5-3-6-21(15-20)17-32-24-18-31(14-8-22(24)23-7-4-13-30-26(23)32)25(33)16-28-9-11-29(19-28,12-10-28)27(34)35/h3-7,13,15H,2,8-12,14,16-19H2,1H3,(H,34,35)
DMXTL7V CS CCC1=CC(=CC=C1)CN2C3=C(CCN(C3)C(=O)CC45CCC(C4)(CC5)C(=O)O)C6=C2N=CC=C6
DMXTL7V IK KFNXYFDWAKJOGZ-UHFFFAOYSA-N
DMXTL7V IU 4-[2-[8-[(3-ethylphenyl)methyl]-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraen-5-yl]-2-oxoethyl]bicyclo[2.2.1]heptane-1-carboxylic acid
DM3W5SM ID DM3W5SM
DM3W5SM DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1
DM3W5SM HS Patented
DM3W5SM SN PMID25435285-Compound-91
DM3W5SM CP EISAI R&D MANAGEMENT CO., LTD
DM3W5SM DT Small molecular drug
DM3W5SM PC 131636309
DM3W5SM MW 445.5
DM3W5SM FM C24H26F3N3O2
DM3W5SM IC InChI=1S/C24H26F3N3O2/c1-5-31-21-12-17(6-7-19(21)24(25,26)27)23-29-22(18-10-14(2)28-15(3)11-18)20-8-9-32-16(4)13-30(20)23/h6-7,10-12,16H,5,8-9,13H2,1-4H3/t16-/m1/s1
DM3W5SM CS CCOC1=C(C=CC(=C1)C2=NC(=C3N2C[C@H](OCC3)C)C4=CC(=NC(=C4)C)C)C(F)(F)F
DM3W5SM IK NVGWTIMTJOAYSJ-MRXNPFEDSA-N
DM3W5SM IU (6R)-1-(2,6-dimethylpyridin-4-yl)-3-[3-ethoxy-4-(trifluoromethyl)phenyl]-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine
DMB1T6S ID DMB1T6S
DMB1T6S DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2
DMB1T6S HS Patented
DMB1T6S SN PMID25435285-Compound-92
DMB1T6S CP EISAI R&D MANAGEMENT CO., LTD
DMB1T6S DT Small molecular drug
DM71LVY ID DM71LVY
DM71LVY DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3
DM71LVY HS Patented
DM71LVY SN PMID25435285-Compound-93
DM71LVY CP EISAI R&D MANAGEMENT CO., LTD
DM71LVY DT Small molecular drug
DM71LVY PC 78324632
DM71LVY MW 397.9
DM71LVY FM C22H24ClN3O2
DM71LVY IC InChI=1S/C22H24ClN3O2/c1-13-9-17(10-14(2)24-13)21-19-7-8-28-15(3)12-26(19)22(25-21)16-5-6-18(23)20(11-16)27-4/h5-6,9-11,15H,7-8,12H2,1-4H3/t15-/m1/s1
DM71LVY CS C[C@@H]1CN2C(=C(N=C2C3=CC(=C(C=C3)Cl)OC)C4=CC(=NC(=C4)C)C)CCO1
DM71LVY IK MPBPPCNVMAZSGS-OAHLLOKOSA-N
DM71LVY IU (6R)-3-(4-chloro-3-methoxyphenyl)-1-(2,6-dimethylpyridin-4-yl)-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine
DMLMXT6 ID DMLMXT6
DMLMXT6 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4
DMLMXT6 HS Patented
DMLMXT6 SN PMID25435285-Compound-94
DMLMXT6 CP EISAI R&D MANAGEMENT CO., LTD
DMLMXT6 DT Small molecular drug
DMLMXT6 PC 90354590
DMLMXT6 MW 443.5
DMLMXT6 FM C27H26FN3O2
DMLMXT6 IC InChI=1S/C27H26FN3O2/c1-18-14-22(15-19(2)29-18)26-24-10-12-32-13-11-31(24)27(30-26)21-8-9-25(23(28)16-21)33-17-20-6-4-3-5-7-20/h3-9,14-16H,10-13,17H2,1-2H3
DMLMXT6 CS CC1=CC(=CC(=N1)C)C2=C3CCOCCN3C(=N2)C4=CC(=C(C=C4)OCC5=CC=CC=C5)F
DMLMXT6 IK DNUJOEZUOUPUCH-UHFFFAOYSA-N
DMLMXT6 IU 1-(2,6-dimethylpyridin-4-yl)-3-(3-fluoro-4-phenylmethoxyphenyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine
DM7C0R8 ID DM7C0R8
DM7C0R8 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5
DM7C0R8 HS Patented
DM7C0R8 SN PMID25435285-Compound-95
DM7C0R8 CP EISAI R&D MANAGEMENT CO., LTD
DM7C0R8 DT Small molecular drug
DM7C0R8 PC 131636429
DM7C0R8 MW 421.5
DM7C0R8 FM C25H28FN3O2
DM7C0R8 IC InChI=1S/C25H28FN3O2/c1-15-10-18(4-7-23(15)31-21-5-6-21)25-28-24(19-11-16(2)27-20(12-19)13-26)22-8-9-30-17(3)14-29(22)25/h4,7,10-12,17,21H,5-6,8-9,13-14H2,1-3H3/t17-/m1/s1
DM7C0R8 CS C[C@@H]1CN2C(=C(N=C2C3=CC(=C(C=C3)OC4CC4)C)C5=CC(=NC(=C5)C)CF)CCO1
DM7C0R8 IK AOKFYLVAJDLEJH-QGZVFWFLSA-N
DM7C0R8 IU (6R)-3-(4-cyclopropyloxy-3-methylphenyl)-1-[2-(fluoromethyl)-6-methylpyridin-4-yl]-6-methyl-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepine
DMCE3J0 ID DMCE3J0
DMCE3J0 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6
DMCE3J0 HS Patented
DMCE3J0 SN PMID25435285-Compound-96
DMCE3J0 CP EISAI R&D MANAGEMENT CO., LTD
DMCE3J0 DT Small molecular drug
DMCE3J0 PC 131636416
DMCE3J0 MW 460.4
DMCE3J0 FM C23H20F4N4O2
DMCE3J0 IC InChI=1S/C23H20F4N4O2/c1-13-7-16(8-14(2)29-13)21-19-5-6-32-18(10-24)12-31(19)22(30-21)15-3-4-20(17(9-15)11-28)33-23(25,26)27/h3-4,7-9,18H,5-6,10,12H2,1-2H3/t18-/m1/s1
DMCE3J0 CS CC1=CC(=CC(=N1)C)C2=C3CCO[C@@H](CN3C(=N2)C4=CC(=C(C=C4)OC(F)(F)F)C#N)CF
DMCE3J0 IK XEHQUSUNPCVWGP-GOSISDBHSA-N
DMCE3J0 IU 5-[(6S)-1-(2,6-dimethylpyridin-4-yl)-6-(fluoromethyl)-5,6,8,9-tetrahydroimidazo[1,5-d][1,4]oxazepin-3-yl]-2-(trifluoromethoxy)benzonitrile
DML86IO ID DML86IO
DML86IO DN Tetra-hydro-isoquinoline derivative 1
DML86IO HS Patented
DML86IO SN PMID29757691-Compound-5a
DML86IO DT Small molecular drug
DML86IO PC 46829776
DML86IO MW 336.4
DML86IO FM C21H24N2O2
DML86IO IC InChI=1S/C21H24N2O2/c24-21-9-7-17-6-8-19(14-20(17)22-21)25-13-3-11-23-12-10-16-4-1-2-5-18(16)15-23/h1-2,4-6,8,14H,3,7,9-13,15H2,(H,22,24)
DML86IO CS C1CC(=O)NC2=C1C=CC(=C2)OCCCN3CCC4=CC=CC=C4C3
DML86IO IK VUVLHXICIKCCTI-UHFFFAOYSA-N
DML86IO IU 7-[3-(3,4-dihydro-1H-isoquinolin-2-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one
DM5CKVF ID DM5CKVF
DM5CKVF DN Tetra-hydro-isoquinoline derivative 2
DM5CKVF HS Patented
DM5CKVF SN PMID29757691-Compound-5b
DM5CKVF DT Small molecular drug
DM5CKVF PC 46829772
DM5CKVF MW 350.5
DM5CKVF FM C22H26N2O2
DM5CKVF IC InChI=1S/C22H26N2O2/c25-22-10-8-18-7-9-20(15-21(18)23-22)26-14-4-3-12-24-13-11-17-5-1-2-6-19(17)16-24/h1-2,5-7,9,15H,3-4,8,10-14,16H2,(H,23,25)
DM5CKVF CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCC4=CC=CC=C4C3
DM5CKVF IK WKRADRDLWGKBQG-UHFFFAOYSA-N
DM5CKVF IU 7-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
DMCZA45 ID DMCZA45
DMCZA45 DN Tetra-hydro-isoquinoline derivative 3
DMCZA45 HS Patented
DMCZA45 SN PMID29757691-Compound-5c
DMCZA45 DT Small molecular drug
DMCZA45 PC 137653313
DMCZA45 MW 364.5
DMCZA45 FM C23H28N2O2
DMCZA45 IC InChI=1S/C23H28N2O2/c26-23-11-9-19-8-10-21(16-22(19)24-23)27-15-5-1-4-13-25-14-12-18-6-2-3-7-20(18)17-25/h2-3,6-8,10,16H,1,4-5,9,11-15,17H2,(H,24,26)
DMCZA45 CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCCN3CCC4=CC=CC=C4C3
DMCZA45 IK MANGBYSAGCIUHY-UHFFFAOYSA-N
DMCZA45 IU 7-[5-(3,4-dihydro-1H-isoquinolin-2-yl)pentoxy]-3,4-dihydro-1H-quinolin-2-one
DMDV0MP ID DMDV0MP
DMDV0MP DN Tetra-hydro-isoquinoline derivative 4
DMDV0MP HS Patented
DMDV0MP SN PMID29757691-Compound-5d
DMDV0MP DT Small molecular drug
DMDV0MP PC 137652717
DMDV0MP MW 378.5
DMDV0MP FM C24H30N2O2
DMDV0MP IC InChI=1S/C24H30N2O2/c27-24-12-10-20-9-11-22(17-23(20)25-24)28-16-6-2-1-5-14-26-15-13-19-7-3-4-8-21(19)18-26/h3-4,7-9,11,17H,1-2,5-6,10,12-16,18H2,(H,25,27)
DMDV0MP CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCCCN3CCC4=CC=CC=C4C3
DMDV0MP IK BIIFFVLUGVJJJX-UHFFFAOYSA-N
DMDV0MP IU 7-[6-(3,4-dihydro-1H-isoquinolin-2-yl)hexoxy]-3,4-dihydro-1H-quinolin-2-one
DMURYO0 ID DMURYO0
DMURYO0 DN Tetra-hydro-naphthalene derivative 1
DMURYO0 HS Patented
DMURYO0 SN PMID26413912-Compound-19
DMURYO0 CP THE SCRIPPS RESEARCH INSTITUTE
DMURYO0 DT Small molecular drug
DMEBGZJ ID DMEBGZJ
DMEBGZJ DN Tetra-hydro-naphthalene derivative 2
DMEBGZJ HS Patented
DMEBGZJ SN PMID26413912-Compound-20
DMEBGZJ CP THE SCRIPPS RESEARCH INSTITUTE
DMEBGZJ DT Small molecular drug
DMVBZKF ID DMVBZKF
DMVBZKF DN Tetra-hydro-naphthalene derivative 3
DMVBZKF HS Patented
DMVBZKF SN PMID26413912-Compound-21
DMVBZKF CP THE SCRIPPS RESEARCH INSTITUTE
DMVBZKF DT Small molecular drug
DM5YSTU ID DM5YSTU
DM5YSTU DN Tetra-hydro-naphthyridine derivative 1
DM5YSTU HS Patented
DM5YSTU SN PMID26413912-Compound-80
DM5YSTU CP RENOVIS, INC. KELLY, Michael, G. KINCAID, John GOWLUGARI, Sumithra KAUB, Carl
DM5YSTU DT Small molecular drug
DM5YSTU PC 25138302
DM5YSTU MW 366.5
DM5YSTU FM C24H22N4
DM5YSTU IC InChI=1S/C24H22N4/c1-2-6-18(7-3-1)16-28-13-11-22-20(17-28)10-12-25-24(22)27-21-14-19-8-4-5-9-23(19)26-15-21/h1-10,12,14-15H,11,13,16-17H2,(H,25,27)
DM5YSTU CS C1CN(CC2=C1C(=NC=C2)NC3=CC4=CC=CC=C4N=C3)CC5=CC=CC=C5
DM5YSTU IK WVIVDSQVVHCZNX-UHFFFAOYSA-N
DM5YSTU IU 6-benzyl-N-quinolin-3-yl-7,8-dihydro-5H-2,6-naphthyridin-1-amine
DM72MDA ID DM72MDA
DM72MDA DN Tetra-hydro-oxazolopyridine derivative 1
DM72MDA HS Patented
DM72MDA SN PMID28067079-Compound-59
DM72MDA CP Dainippon Sumitomo Pharma Co Ltd
DM72MDA DT Small molecular drug
DMP65Z4 ID DMP65Z4
DMP65Z4 DN Tetra-hydro-oxazolopyridine derivative 2
DMP65Z4 HS Patented
DMP65Z4 SN PMID28067079-Compound-60
DMP65Z4 CP Dainippon Sumitomo Pharma Co Ltd
DMP65Z4 DT Small molecular drug
DMP65Z4 PC 86275459
DMP65Z4 MW 330.74
DMP65Z4 FM C16H12ClFN4O
DMP65Z4 IC InChI=1S/C16H12ClFN4O/c17-10-5-12(8-19-6-10)22-4-3-15-14(9-22)21-16(23-15)13-2-1-11(18)7-20-13/h1-2,5-8H,3-4,9H2
DMP65Z4 CS C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C4=CC(=CN=C4)Cl
DMP65Z4 IK OEQFRGKRTUFWNP-UHFFFAOYSA-N
DMP65Z4 IU 5-(5-chloropyridin-3-yl)-2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridine
DMQYKT2 ID DMQYKT2
DMQYKT2 DN Tetra-hydro-oxazolopyridine derivative 3
DMQYKT2 HS Patented
DMQYKT2 SN PMID28067079-Compound-63
DMQYKT2 CP DAINIPPON SUMITOMO PHARMA CO., LTD
DMQYKT2 DT Small molecular drug
DMQYKT2 PC 74221950
DMQYKT2 MW 375.8
DMQYKT2 FM C18H12ClF2N3O2
DMQYKT2 IC InChI=1S/C18H12ClF2N3O2/c19-11-5-10(6-13(21)7-11)18(25)24-4-3-16-15(9-24)23-17(26-16)14-2-1-12(20)8-22-14/h1-2,5-8H,3-4,9H2
DMQYKT2 CS C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C(=O)C4=CC(=CC(=C4)Cl)F
DMQYKT2 IK CHAFCAFCZBTARK-UHFFFAOYSA-N
DMQYKT2 IU (3-chloro-5-fluorophenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]methanone
DM21J83 ID DM21J83
DM21J83 DN Tetra-hydro-oxazolopyridine derivative 4
DM21J83 HS Patented
DM21J83 SN PMID28067079-Compound-64
DM21J83 CP DAINIPPON SUMITOMO PHARMA CO., LTD
DM21J83 DT Small molecular drug
DM21J83 PC 137639643
DM21J83 MW 339.8
DM21J83 FM C18H14ClN3O2
DM21J83 IC InChI=1S/C18H14ClN3O2/c19-13-6-7-14(20-10-13)17-21-15-11-22(9-8-16(15)24-17)18(23)12-4-2-1-3-5-12/h1-7,10H,8-9,11H2
DM21J83 CS C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)Cl)C(=O)C4=CC=CC=C4
DM21J83 IK NUNJYRYJNBEYPH-UHFFFAOYSA-N
DM21J83 IU [2-(5-chloropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]-phenylmethanone
DMQGA1I ID DMQGA1I
DMQGA1I DN Tetra-hydro-oxazolopyridine derivative 5
DMQGA1I HS Patented
DMQGA1I SN PMID28067079-Compound-65
DMQGA1I CP DAINIPPON SUMITOMO PHARMA CO., LTD
DMQGA1I DT Small molecular drug
DMQGA1I PC 74222037
DMQGA1I MW 357.8
DMQGA1I FM C18H13ClFN3O2
DMQGA1I IC InChI=1S/C18H13ClFN3O2/c19-12-3-1-2-11(8-12)18(24)23-7-6-16-15(10-23)22-17(25-16)14-5-4-13(20)9-21-14/h1-5,8-9H,6-7,10H2
DMQGA1I CS C1CN(CC2=C1OC(=N2)C3=NC=C(C=C3)F)C(=O)C4=CC(=CC=C4)Cl
DMQGA1I IK NZJPQHNBSVEQFL-UHFFFAOYSA-N
DMQGA1I IU (3-chlorophenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]methanone
DMLW7YO ID DMLW7YO
DMLW7YO DN Tetra-hydro-oxazolopyridine derivative 6
DMLW7YO HS Patented
DMLW7YO SN PMID28067079-Compound-66
DMLW7YO CP DAINIPPON SUMITOMO PHARMA CO., LTD
DMLW7YO DT Small molecular drug
DMLW7YO PC 137637236
DMLW7YO MW 371.8
DMLW7YO FM C19H15ClFN3O2
DMLW7YO IC InChI=1S/C19H15ClFN3O2/c1-11-6-12(8-13(20)7-11)19(25)24-5-4-17-16(10-24)23-18(26-17)15-3-2-14(21)9-22-15/h2-3,6-9H,4-5,10H2,1H3
DMLW7YO CS CC1=CC(=CC(=C1)Cl)C(=O)N2CCC3=C(C2)N=C(O3)C4=NC=C(C=C4)F
DMLW7YO IK NMKCKZQPMUTSIC-UHFFFAOYSA-N
DMLW7YO IU (3-chloro-5-methylphenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-[1,3]oxazolo[4,5-c]pyridin-5-yl]methanone
DM3HVCZ ID DM3HVCZ
DM3HVCZ DN Tetra-hydro-pyrazolopyrazine derivative 1
DM3HVCZ HS Patented
DM3HVCZ SN PMID28067079-Compound-67
DM3HVCZ CP Dainippon Sumitomo Pharma Co Ltd
DM3HVCZ DT Small molecular drug
DMQ027F ID DMQ027F
DMQ027F DN Tetra-hydro-pyrazolopyrazine derivative 2
DMQ027F HS Patented
DMQ027F SN PMID28067079-Compound-68
DMQ027F CP Dainippon Sumitomo Pharma Co Ltd
DMQ027F DT Small molecular drug
DMQ027F PC 137662068
DMQ027F MW 374.8
DMQ027F FM C18H13ClF2N4O
DMQ027F IC InChI=1S/C18H13ClF2N4O/c19-12-5-11(6-14(21)7-12)18(26)24-3-4-25-15(10-24)8-17(23-25)16-2-1-13(20)9-22-16/h1-2,5-9H,3-4,10H2
DMQ027F CS C1CN2C(=CC(=N2)C3=NC=C(C=C3)F)CN1C(=O)C4=CC(=CC(=C4)Cl)F
DMQ027F IK PAVOURBCAONWKJ-UHFFFAOYSA-N
DMQ027F IU (3-chloro-5-fluorophenyl)-[2-(5-fluoropyridin-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-5-yl]methanone
DMKGJ1S ID DMKGJ1S
DMKGJ1S DN Tetra-hydro-pyrazolopyrazine derivative 3
DMKGJ1S HS Patented
DMKGJ1S SN PMID28067079-Compound-69
DMKGJ1S CP Dainippon Sumitomo Pharma Co Ltd
DMKGJ1S DT Small molecular drug
DMRMTF6 ID DMRMTF6
DMRMTF6 DN Tetra-hydro-pyrazolopyrazine derivative 4
DMRMTF6 HS Patented
DMRMTF6 SN PMID28067079-Compound-70
DMRMTF6 CP Dainippon Sumitomo Pharma Co Ltd
DMRMTF6 DT Small molecular drug
DMAM7Y2 ID DMAM7Y2
DMAM7Y2 DN Tetra-hydro-pyrazolopyrazine derivative 5
DMAM7Y2 HS Patented
DMAM7Y2 SN PMID28067079-Compound-71
DMAM7Y2 CP Dainippon Sumitomo Pharma Co Ltd
DMAM7Y2 DT Small molecular drug
DMM06K5 ID DMM06K5
DMM06K5 DN Tetra-hydro-pyrrolopyrimidinedione derivative 1
DMM06K5 HS Patented
DMM06K5 SN PMID26118988-Compound-24
DMM06K5 DT Small molecular drug
DMM92KW ID DMM92KW
DMM92KW DN Tetra-hydro-quinoline derivative 1
DMM92KW HS Patented
DMM92KW SN PMID27841036-Compound-VIII
DMM92KW CP LUPIN LIMITED
DMM92KW DT Small molecular drug
DMEKO71 ID DMEKO71
DMEKO71 DN Tetra-hydro-quinoline derivative 2
DMEKO71 HS Patented
DMEKO71 SN PMID26924192-Compound-83
DMEKO71 CP FORMA THERAPEUTICS INC
DMEKO71 DT Small molecular drug
DMAWY4L ID DMAWY4L
DMAWY4L DN Tetra-hydro-quinoline derivative 3
DMAWY4L HS Patented
DMAWY4L SN PMID26924192-Compound-84
DMAWY4L CP FORMA THERAPEUTICS INC
DMAWY4L DT Small molecular drug
DMAWY4L PC 118076120
DMAWY4L MW 373.4
DMAWY4L FM C20H24FN3O3
DMAWY4L IC InChI=1S/C20H24FN3O3/c1-13-3-6-17-18(24(13)20(25)26-2)8-7-16(19(17)27-10-9-21)14-11-22-23(12-14)15-4-5-15/h7-8,11-13,15H,3-6,9-10H2,1-2H3/t13-/m0/s1
DMAWY4L CS C[C@H]1CCC2=C(N1C(=O)OC)C=CC(=C2OCCF)C3=CN(N=C3)C4CC4
DMAWY4L IK LVOBMWBVNYYGFM-ZDUSSCGKSA-N
DMAWY4L IU methyl (2S)-6-(1-cyclopropylpyrazol-4-yl)-5-(2-fluoroethoxy)-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylate
DMMC3AG ID DMMC3AG
DMMC3AG DN Tetra-hydro-quinoline derivative 4
DMMC3AG HS Patented
DMMC3AG SN PMID26924192-Compound-85
DMMC3AG CP FORMA THERAPEUTICS INC
DMMC3AG DT Small molecular drug
DMMC3AG PC 118076127
DMMC3AG MW 357.4
DMMC3AG FM C20H27N3O3
DMMC3AG IC InChI=1S/C20H27N3O3/c1-4-11-26-20-17(16-12-21-22(13-16)9-10-24)7-8-19-18(20)6-5-14(2)23(19)15(3)25/h7-8,12-14,24H,4-6,9-11H2,1-3H3/t14-/m0/s1
DMMC3AG CS CCCOC1=C(C=CC2=C1CC[C@@H](N2C(=O)C)C)C3=CN(N=C3)CCO
DMMC3AG IK LCUMODKDHNQTRE-AWEZNQCLSA-N
DMMC3AG IU 1-[(2S)-6-[1-(2-hydroxyethyl)pyrazol-4-yl]-2-methyl-5-propoxy-3,4-dihydro-2H-quinolin-1-yl]ethanone
DMI6VG9 ID DMI6VG9
DMI6VG9 DN Tetra-hydro-triazolopyrimidine derivative 2
DMI6VG9 HS Patented
DMI6VG9 SN PMID29171765-Compound-Figure4
DMI6VG9 CP CHIESI FARMACEUTICI S.p.A. BLENCH, Toby Jonathan EDWARDS, Christine HEALD, Robert Andrew KULAGOWSKI, Janusz Jozef SUTTON, Jonathan Mark CAPALDI, CarmelidBoehringer Ingelheim International GmbBayer Intellectual Property GmbH
DMEG5YO ID DMEG5YO
DMEG5YO DN Tetra-substituted urea derivative 1
DMEG5YO HS Patented
DMEG5YO SN PMID26413912-Compound-53
DMEG5YO CP BIAL PORTELA & CA SA [PT]
DMEG5YO DT Small molecular drug
DMEG5YO PC 66681741
DMEG5YO MW 258.32
DMEG5YO FM C14H18N4O
DMEG5YO IC InChI=1S/C14H18N4O/c1-17(11-7-3-2-4-8-11)14(19)18-13-10-6-5-9-12(13)15-16-18/h5-6,9-11H,2-4,7-8H2,1H3
DMEG5YO CS CN(C1CCCCC1)C(=O)N2C3=CC=CC=C3N=N2
DMEG5YO IK ATPCFTJMZOBYDC-UHFFFAOYSA-N
DMEG5YO IU N-cyclohexyl-N-methylbenzotriazole-1-carboxamide
DMKXZUA ID DMKXZUA
DMKXZUA DN Tetra-substituted urea derivative 2
DMKXZUA HS Patented
DMKXZUA SN PMID26413912-Compound-54
DMKXZUA CP BIAL PORTELA & CA SA [PT]
DMKXZUA DT Small molecular drug
DMKXZUA PC 66683059
DMKXZUA MW 303.33
DMKXZUA FM C16H18FN3O2
DMKXZUA IC InChI=1S/C16H18FN3O2/c1-19(12-4-2-3-5-12)16(22)20-9-14(18-10-20)11-6-7-15(21)13(17)8-11/h6-10,12,21H,2-5H2,1H3
DMKXZUA CS CN(C1CCCC1)C(=O)N2C=C(N=C2)C3=CC(=C(C=C3)O)F
DMKXZUA IK IWRLZEZXDCIMHJ-UHFFFAOYSA-N
DMKXZUA IU N-cyclopentyl-4-(3-fluoro-4-hydroxyphenyl)-N-methylimidazole-1-carboxamide
DM52683 ID DM52683
DM52683 DN Tetrazole acetic acid derivative 1
DM52683 HS Patented
DM52683 SN PMID27414413-Compound-Figure11upleft
DM52683 CP Yuanqiang Z
DM52683 DT Small molecular drug
DM1AGSD ID DM1AGSD
DM1AGSD DN Tetrazole derivative 1
DM1AGSD HS Patented
DM1AGSD SN PMID27724045-Compound-31
DM1AGSD CP Abbott
DM1AGSD DT Small molecular drug
DM1AGSD PC 68678249
DM1AGSD MW 507.4
DM1AGSD FM C23H29Cl2FN8
DM1AGSD IC InChI=1S/C23H29Cl2FN8/c1-23(2,3)15-32-10-5-11-33(13-12-32)21-16(6-4-9-27-21)14-28-22-29-30-31-34(22)18-8-7-17(26)19(24)20(18)25/h4,6-9H,5,10-15H2,1-3H3,(H,28,29,31)
DM1AGSD CS CC(C)(C)CN1CCCN(CC1)C2=C(C=CC=N2)CNC3=NN=NN3C4=C(C(=C(C=C4)F)Cl)Cl
DM1AGSD IK JYRXOWVYFHHKEV-UHFFFAOYSA-N
DM1AGSD IU 1-(2,3-dichloro-4-fluorophenyl)-N-[[2-[4-(2,2-dimethylpropyl)-1,4-diazepan-1-yl]pyridin-3-yl]methyl]tetrazol-5-amine
DM2D4WQ ID DM2D4WQ
DM2D4WQ DN Tetrazolyl urea derivative 1
DM2D4WQ HS Patented
DM2D4WQ SN PMID26413912-Compound-55
DM2D4WQ CP NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros PANDARINATHAN, Lakshimpathi ZVONOK, Nikolai PARKKARI, Teija CHAPMAN, Lauren
DM2D4WQ DT Small molecular drug
DM2D4WQ PC 44232540
DM2D4WQ MW 376.7
DM2D4WQ FM C14H16Cl3N5O
DM2D4WQ IC InChI=1S/C14H16Cl3N5O/c1-21(7-3-2-6-15)14(23)22-19-13(18-20-22)8-10-4-5-11(16)9-12(10)17/h4-5,9H,2-3,6-8H2,1H3
DM2D4WQ CS CN(CCCCCl)C(=O)N1N=C(N=N1)CC2=C(C=C(C=C2)Cl)Cl
DM2D4WQ IK OQUPYXJFXDHGPX-UHFFFAOYSA-N
DM2D4WQ IU N-(4-chlorobutyl)-5-[(2,4-dichlorophenyl)methyl]-N-methyltetrazole-2-carboxamide
DMP4HR2 ID DMP4HR2
DMP4HR2 DN TG003
DMP4HR2 HS Patented
DMP4HR2 SN Clk inhibitor; TG 003; TG-003
DMP4HR2 DT Small molecular drug
DMP4HR2 PC 1893668
DMP4HR2 MW 249.33
DMP4HR2 FM C13H15NO2S
DMP4HR2 IC InChI=1S/C13H15NO2S/c1-4-14-11-8-10(16-3)5-6-12(11)17-13(14)7-9(2)15/h5-8H,4H2,1-3H3/b13-7-
DMP4HR2 CS CCN\\1C2=C(C=CC(=C2)OC)S/C1=C\\C(=O)C
DMP4HR2 IK BGVLELSCIHASRV-QPEQYQDCSA-N
DMP4HR2 IU (1Z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one
DMP4HR2 DE Discovery agent
DM1L3ZA ID DM1L3ZA
DM1L3ZA DN Thiadiazolidindione derivative 1
DM1L3ZA HS Patented
DM1L3ZA SN PMID27828716-Compound-4
DM1L3ZA DT Small molecular drug
DM5AUL0 ID DM5AUL0
DM5AUL0 DN Thiadiazolidindione derivative 2
DM5AUL0 HS Patented
DM5AUL0 SN PMID27828716-Compound-5
DM5AUL0 DT Small molecular drug
DM5AUL0 PC 71715288
DM5AUL0 MW 292.36
DM5AUL0 FM C14H16N2O3S
DM5AUL0 IC InChI=1S/C14H16N2O3S/c17-13-15(10-12-7-4-8-19-12)14(18)20-16(13)9-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2
DM5AUL0 CS C1CC(OC1)CN2C(=O)N(SC2=O)CC3=CC=CC=C3
DM5AUL0 IK AGFKNYDGTJNEDN-UHFFFAOYSA-N
DM5AUL0 IU 2-benzyl-4-(oxolan-2-ylmethyl)-1,2,4-thiadiazolidine-3,5-dione
DMNTZ93 ID DMNTZ93
DMNTZ93 DN Thiadiazolidindione derivative 3
DMNTZ93 HS Patented
DMNTZ93 SN PMID27828716-Compound-6
DMNTZ93 DT Small molecular drug
DMNTZ93 PC 71715287
DMNTZ93 MW 252.29
DMNTZ93 FM C11H12N2O3S
DMNTZ93 IC InChI=1S/C11H12N2O3S/c14-7-6-12-10(15)13(17-11(12)16)8-9-4-2-1-3-5-9/h1-5,14H,6-8H2
DMNTZ93 CS C1=CC=C(C=C1)CN2C(=O)N(C(=O)S2)CCO
DMNTZ93 IK DDYFMVMCMQSWNI-UHFFFAOYSA-N
DMNTZ93 IU 2-benzyl-4-(2-hydroxyethyl)-1,2,4-thiadiazolidine-3,5-dione
DMX93AI ID DMX93AI
DMX93AI DN Thiadiazolyl carboxamide derivative 1
DMX93AI HS Patented
DMX93AI SN PMID28270010-Compound-Figure18-1
DMX93AI CP BUCK INSTITUTE FOR RESEARCH ON AGING JOHN, Varghese ZHANG, Qiang BREDESEN, Dale, E
DMX93AI DT Small molecular drug
DMX93AI PC 71263688
DMX93AI MW 366.5
DMX93AI FM C20H22N4OS
DMX93AI IC InChI=1S/C20H22N4OS/c1-5-24(18(25)15-7-6-12-21-13-15)19-23-22-17(26-19)14-8-10-16(11-9-14)20(2,3)4/h6-13H,5H2,1-4H3
DMX93AI CS CCN(C1=NN=C(S1)C2=CC=C(C=C2)C(C)(C)C)C(=O)C3=CN=CC=C3
DMX93AI IK XMRKDXZDAAFZDU-UHFFFAOYSA-N
DMX93AI IU N-[5-(4-tert-butylphenyl)-1,3,4-thiadiazol-2-yl]-N-ethylpyridine-3-carboxamide
DMX93AI DE Alzheimer disease
DMW62LX ID DMW62LX
DMW62LX DN Thiazole carboxamide derivative 1
DMW62LX HS Patented
DMW62LX SN PMID25684022-Compound-US20130165450 10(4)
DMW62LX CP Schering Corp
DMW62LX DE Solid tumour/cancer; Metastatic cancer
DMWKI89 ID DMWKI89
DMWKI89 DN Thiazole carboxamide derivative 10
DMWKI89 HS Patented
DMWKI89 SN PMID25684022-Compound-US20130165450 19(36)
DMWKI89 CP Schering Corp
DMWKI89 DE Solid tumour/cancer; Metastatic cancer
DM0Q3HF ID DM0Q3HF
DM0Q3HF DN Thiazole carboxamide derivative 11
DM0Q3HF HS Patented
DM0Q3HF SN PMID25684022-Compound-US20130165450 20(38)
DM0Q3HF CP Schering Corp
DM0Q3HF DE Solid tumour/cancer; Metastatic cancer
DMG0H73 ID DMG0H73
DMG0H73 DN Thiazole carboxamide derivative 12
DMG0H73 HS Patented
DMG0H73 SN PMID25684022-Compound-US20130165450 21(40)
DMG0H73 CP Schering Corp
DMG0H73 DE Solid tumour/cancer; Metastatic cancer
DMHQCEJ ID DMHQCEJ
DMHQCEJ DN Thiazole carboxamide derivative 13
DMHQCEJ HS Patented
DMHQCEJ SN PMID25684022-Compound-US20130165450 23(41)
DMHQCEJ CP Schering Corp
DMHQCEJ DE Solid tumour/cancer; Metastatic cancer
DMMKNP7 ID DMMKNP7
DMMKNP7 DN Thiazole carboxamide derivative 14
DMMKNP7 HS Patented
DMMKNP7 SN PMID25684022-Compound-US20130165450 24(45)
DMMKNP7 CP Schering Corp
DMMKNP7 DE Solid tumour/cancer; Metastatic cancer
DMCH1DL ID DMCH1DL
DMCH1DL DN Thiazole carboxamide derivative 15
DMCH1DL HS Patented
DMCH1DL SN PMID25684022-Compound-US20130165450 9(2)
DMCH1DL CP Schering Corp
DMCH1DL DE Solid tumour/cancer; Metastatic cancer
DMJQBVH ID DMJQBVH
DMJQBVH DN Thiazole carboxamide derivative 16
DMJQBVH HS Patented
DMJQBVH SN PMID25684022-Compound-WO2012036974 10(4)
DMJQBVH CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMJQBVH DE Solid tumour/cancer; Metastatic cancer
DMPMN92 ID DMPMN92
DMPMN92 DN Thiazole carboxamide derivative 17
DMPMN92 HS Patented
DMPMN92 SN PMID25684022-Compound-WO2012036974 11(5)
DMPMN92 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMPMN92 DE Solid tumour/cancer; Metastatic cancer
DM987MK ID DM987MK
DM987MK DN Thiazole carboxamide derivative 18
DM987MK HS Patented
DM987MK SN PMID25684022-Compound-WO2012036974 12(12)
DM987MK CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DM987MK DE Solid tumour/cancer; Metastatic cancer
DMW59Q4 ID DMW59Q4
DMW59Q4 DN Thiazole carboxamide derivative 19
DMW59Q4 HS Patented
DMW59Q4 SN PMID25684022-Compound-WO2012036974 13(13)
DMW59Q4 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMW59Q4 DE Solid tumour/cancer; Metastatic cancer
DMLIRGM ID DMLIRGM
DMLIRGM DN Thiazole carboxamide derivative 2
DMLIRGM HS Patented
DMLIRGM SN PMID25684022-Compound-US20130165450 11(5)
DMLIRGM CP Schering Corp
DMLIRGM DE Solid tumour/cancer; Metastatic cancer
DMORSH9 ID DMORSH9
DMORSH9 DN Thiazole carboxamide derivative 20
DMORSH9 HS Patented
DMORSH9 SN PMID25684022-Compound-WO2012036974 14(14)
DMORSH9 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMORSH9 DE Solid tumour/cancer; Metastatic cancer
DMTJBCG ID DMTJBCG
DMTJBCG DN Thiazole carboxamide derivative 21
DMTJBCG HS Patented
DMTJBCG SN PMID25684022-Compound-WO2012036974 15(15)
DMTJBCG CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMTJBCG DE Solid tumour/cancer; Metastatic cancer
DM6WTR2 ID DM6WTR2
DM6WTR2 DN Thiazole carboxamide derivative 22
DM6WTR2 HS Patented
DM6WTR2 SN PMID25684022-Compound-WO2012036974 16(16)
DM6WTR2 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DM6WTR2 DE Solid tumour/cancer; Metastatic cancer
DMMO6JY ID DMMO6JY
DMMO6JY DN Thiazole carboxamide derivative 23
DMMO6JY HS Patented
DMMO6JY SN PMID25684022-Compound-WO2012036974 17(23)
DMMO6JY CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMMO6JY DE Solid tumour/cancer; Metastatic cancer
DMZ6YB0 ID DMZ6YB0
DMZ6YB0 DN Thiazole carboxamide derivative 24
DMZ6YB0 HS Patented
DMZ6YB0 SN PMID25684022-Compound-WO2012036974 18(27)
DMZ6YB0 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMZ6YB0 DE Solid tumour/cancer; Metastatic cancer
DMLRTFX ID DMLRTFX
DMLRTFX DN Thiazole carboxamide derivative 25
DMLRTFX HS Patented
DMLRTFX SN PMID25684022-Compound-WO2012036974 19(36)
DMLRTFX CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMLRTFX DE Solid tumour/cancer; Metastatic cancer
DM8DHZ4 ID DM8DHZ4
DM8DHZ4 DN Thiazole carboxamide derivative 26
DM8DHZ4 HS Patented
DM8DHZ4 SN PMID25684022-Compound-WO2012036974 20(38)
DM8DHZ4 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DM8DHZ4 DE Solid tumour/cancer; Metastatic cancer
DMV30QO ID DMV30QO
DMV30QO DN Thiazole carboxamide derivative 27
DMV30QO HS Patented
DMV30QO SN PMID25684022-Compound-WO2012036974 21(40)
DMV30QO CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMV30QO DE Solid tumour/cancer; Metastatic cancer
DMGEIZV ID DMGEIZV
DMGEIZV DN Thiazole carboxamide derivative 28
DMGEIZV HS Patented
DMGEIZV SN PMID25684022-Compound-WO2012036974 23(41)
DMGEIZV CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMGEIZV DE Solid tumour/cancer; Metastatic cancer
DMCRVO5 ID DMCRVO5
DMCRVO5 DN Thiazole carboxamide derivative 29
DMCRVO5 HS Patented
DMCRVO5 SN PMID25684022-Compound-WO2012036974 24(45)
DMCRVO5 CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMCRVO5 DE Solid tumour/cancer; Metastatic cancer
DMLRA3C ID DMLRA3C
DMLRA3C DN Thiazole carboxamide derivative 3
DMLRA3C HS Patented
DMLRA3C SN PMID25684022-Compound-US20130165450 12(12)
DMLRA3C CP Schering Corp
DMLRA3C DE Solid tumour/cancer; Metastatic cancer
DMEOKCB ID DMEOKCB
DMEOKCB DN Thiazole carboxamide derivative 30
DMEOKCB HS Patented
DMEOKCB SN PMID25684022-Compound-WO2012036974 9(2)
DMEOKCB CP MERCK SHARP & DOHME CORP. TSUI, Hon-Chung PALIWAL, Sunil FISCHMANN, Thierry Olivier
DMEOKCB DE Solid tumour/cancer; Metastatic cancer
DMI3X14 ID DMI3X14
DMI3X14 DN Thiazole carboxamide derivative 4
DMI3X14 HS Patented
DMI3X14 SN PMID25684022-Compound-US20130165450 13(13)
DMI3X14 CP Schering Corp
DMI3X14 DE Solid tumour/cancer; Metastatic cancer
DM2H95E ID DM2H95E
DM2H95E DN Thiazole carboxamide derivative 5
DM2H95E HS Patented
DM2H95E SN PMID25684022-Compound-US20130165450 14(14)
DM2H95E CP Schering Corp
DM2H95E DE Solid tumour/cancer; Metastatic cancer
DMWHCOE ID DMWHCOE
DMWHCOE DN Thiazole carboxamide derivative 6
DMWHCOE HS Patented
DMWHCOE SN PMID25684022-Compound-US20130165450 15(15)
DMWHCOE CP Schering Corp
DMWHCOE DE Solid tumour/cancer; Metastatic cancer
DMLBK8V ID DMLBK8V
DMLBK8V DN Thiazole carboxamide derivative 7
DMLBK8V HS Patented
DMLBK8V SN PMID25684022-Compound-US20130165450 16(16)
DMLBK8V CP Schering Corp
DMLBK8V DE Solid tumour/cancer; Metastatic cancer
DMVOTKN ID DMVOTKN
DMVOTKN DN Thiazole carboxamide derivative 8
DMVOTKN HS Patented
DMVOTKN SN PMID25684022-Compound-US20130165450 17(23)
DMVOTKN CP Schering Corp
DMVOTKN DE Solid tumour/cancer; Metastatic cancer
DM5P04R ID DM5P04R
DM5P04R DN Thiazole carboxamide derivative 9
DM5P04R HS Patented
DM5P04R SN PMID25684022-Compound-US20130165450 18(27)
DM5P04R CP Schering Corp
DM5P04R DE Solid tumour/cancer; Metastatic cancer
DM2WDXV ID DM2WDXV
DM2WDXV DN Thiazole derivative 1
DM2WDXV HS Patented
DM2WDXV SN PMID26815044-Compound-44
DM2WDXV DT Small molecular drug
DM2WDXV PC 136183501
DM2WDXV MW 237.23
DM2WDXV FM C10H7NO4S
DM2WDXV IC InChI=1S/C10H7NO4S/c12-5-1-2-6(8(13)3-5)9-11-7(4-16-9)10(14)15/h1-4,12-13H,(H,14,15)
DM2WDXV CS C1=CC(=C(C=C1O)O)C2=NC(=CS2)C(=O)O
DM2WDXV IK ANYJSBBMNGTYRM-UHFFFAOYSA-N
DM2WDXV IU 2-(2,4-dihydroxyphenyl)-1,3-thiazole-4-carboxylic acid
DM2WDXV DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM8ZXBS ID DM8ZXBS
DM8ZXBS DN Thiazole derivative 2
DM8ZXBS HS Patented
DM8ZXBS SN PMID28454500-Compound-83
DM8ZXBS CP THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DM8ZXBS DT Small molecular drug
DM8ZXBS PC 1298265
DM8ZXBS MW 473.4
DM8ZXBS FM C22H14F3N3O4S
DM8ZXBS IC InChI=1S/C22H14F3N3O4S/c23-22(24,25)15-6-4-13(5-7-15)10-17-12-26-21(33-17)27-20(29)19-9-8-18(32-19)14-2-1-3-16(11-14)28(30)31/h1-9,11-12H,10H2,(H,26,27,29)
DM8ZXBS CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(O2)C(=O)NC3=NC=C(S3)CC4=CC=C(C=C4)C(F)(F)F
DM8ZXBS IK GIUVRWFYNOIRLR-UHFFFAOYSA-N
DM8ZXBS IU 5-(3-nitrophenyl)-N-[5-[[4-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]furan-2-carboxamide
DMKU51G ID DMKU51G
DMKU51G DN Thiazole derivative 3
DMKU51G HS Patented
DMKU51G SN PMID28454500-Compound-84
DMKU51G CP THE JOHNS HOPKINS UNIVERSITY The National Institutes of Health
DMKU51G DT Small molecular drug
DMKU51G PC 1383822
DMKU51G MW 511.6
DMKU51G FM C29H25N3O4S
DMKU51G IC InChI=1S/C29H25N3O4S/c1-17-5-3-4-6-22(17)28(34)32-12-11-20-15-21(8-9-23(20)32)27-18(2)37-29(31-27)30-26(33)14-19-7-10-24-25(13-19)36-16-35-24/h3-10,13,15H,11-12,14,16H2,1-2H3,(H,30,31,33)
DMKU51G CS CC1=CC=CC=C1C(=O)N2CCC3=C2C=CC(=C3)C4=C(SC(=N4)NC(=O)CC5=CC6=C(C=C5)OCO6)C
DMKU51G IK LINHYWKZVCNAMQ-UHFFFAOYSA-N
DMKU51G IU 2-(1,3-benzodioxol-5-yl)-N-[5-methyl-4-[1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl]-1,3-thiazol-2-yl]acetamide
DM5UQK6 ID DM5UQK6
DM5UQK6 DN Thiazole derivative 4
DM5UQK6 HS Patented
DM5UQK6 SN PMID28270010-Compound-Figure15-b
DM5UQK6 CP ARRAY BIOPHARMA INC
DM5UQK6 DT Small molecular drug
DM5UQK6 PC 73891136
DM5UQK6 MW 523.5
DM5UQK6 FM C25H20F3N7OS
DM5UQK6 IC InChI=1S/C25H20F3N7OS/c1-15-19(17-13-29-34(2)14-17)33-35(18-11-7-4-8-12-18)21(15)31-24(36)32-22-20(16-9-5-3-6-10-16)30-23(37-22)25(26,27)28/h3-14H,1-2H3,(H2,31,32,36)
DM5UQK6 CS CC1=C(N(N=C1C2=CN(N=C2)C)C3=CC=CC=C3)NC(=O)NC4=C(N=C(S4)C(F)(F)F)C5=CC=CC=C5
DM5UQK6 IK OKQYVMVRBRSVES-UHFFFAOYSA-N
DM5UQK6 IU 1-[4-methyl-5-(1-methylpyrazol-4-yl)-2-phenylpyrazol-3-yl]-3-[4-phenyl-2-(trifluoromethyl)-1,3-thiazol-5-yl]urea
DMESAUL ID DMESAUL
DMESAUL DN Thiazole derivative 5
DMESAUL HS Patented
DMESAUL SN PMID27724045-Compound-36
DMESAUL CP AXXAM S.P.A
DMESAUL DT Small molecular drug
DMESAUL PC 91827420
DMESAUL MW 399.9
DMESAUL FM C18H20ClF2N3OS
DMESAUL IC InChI=1S/C18H20ClF2N3OS/c1-12-3-2-4-13(19)16(12)17(25)23-9-14(15-10-22-11-26-15)24-7-5-18(20,21)6-8-24/h2-4,10-11,14H,5-9H2,1H3,(H,23,25)
DMESAUL CS CC1=C(C(=CC=C1)Cl)C(=O)NCC(C2=CN=CS2)N3CCC(CC3)(F)F
DMESAUL IK WADLCIPMWTXETG-UHFFFAOYSA-N
DMESAUL IU 2-chloro-N-[2-(4,4-difluoropiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]-6-methylbenzamide
DMCPV0D ID DMCPV0D
DMCPV0D DN Thiazole-fused cycloalkyl carboxamide derivative 1
DMCPV0D HS Patented
DMCPV0D SN PMID27724045-Compound-20
DMCPV0D CP Actelion pharmaceuticals Ltd
DMCPV0D DT Small molecular drug
DMCPV0D PC 71239321
DMCPV0D MW 337.2
DMCPV0D FM C16H14Cl2N2O2
DMCPV0D IC InChI=1S/C16H14Cl2N2O2/c1-9-4-10(17)5-13(18)12(9)6-16(21)20-14-8-22-15-7-19-3-2-11(14)15/h2-5,7,14H,6,8H2,1H3,(H,20,21)
DMCPV0D CS CC1=CC(=CC(=C1CC(=O)NC2COC3=C2C=CN=C3)Cl)Cl
DMCPV0D IK CPLYQTQQYXUOCX-UHFFFAOYSA-N
DMCPV0D IU 2-(2,4-dichloro-6-methylphenyl)-N-(2,3-dihydrofuro[2,3-c]pyridin-3-yl)acetamide
DM05VO6 ID DM05VO6
DM05VO6 DN Thiazolidine derivative 1
DM05VO6 HS Patented
DM05VO6 SN PMID26815044-Compound-33
DM05VO6 DT Small molecular drug
DM05VO6 PC 13946769
DM05VO6 MW 225.27
DM05VO6 FM C10H11NO3S
DM05VO6 IC InChI=1S/C10H11NO3S/c12-7-3-1-6(2-4-7)9-11-8(5-15-9)10(13)14/h1-4,8-9,11-12H,5H2,(H,13,14)/t8-,9?/m0/s1
DM05VO6 CS C1[C@H](NC(S1)C2=CC=C(C=C2)O)C(=O)O
DM05VO6 IK TWPYJYQNZHPNGQ-IENPIDJESA-N
DM05VO6 IU (4R)-2-(4-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
DM05VO6 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DM73GNJ ID DM73GNJ
DM73GNJ DN Thiazolidine derivative 2
DM73GNJ HS Patented
DM73GNJ SN PMID26815044-Compound-34
DM73GNJ DT Small molecular drug
DM73GNJ PC 60194536
DM73GNJ MW 241.27
DM73GNJ FM C10H11NO4S
DM73GNJ IC InChI=1S/C10H11NO4S/c12-5-1-2-6(8(13)3-5)9-11-7(4-16-9)10(14)15/h1-3,7,9,11-13H,4H2,(H,14,15)/t7-,9?/m0/s1
DM73GNJ CS C1[C@H](NC(S1)C2=C(C=C(C=C2)O)O)C(=O)O
DM73GNJ IK GYBITJROHWLVSE-JAVCKPHESA-N
DM73GNJ IU (4R)-2-(2,4-dihydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
DM73GNJ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMXFGTZ ID DMXFGTZ
DMXFGTZ DN Thiazolidine derivative 3
DMXFGTZ HS Patented
DMXFGTZ SN PMID26815044-Compound-35
DMXFGTZ DT Small molecular drug
DMXFGTZ PC 6610557
DMXFGTZ MW 269.32
DMXFGTZ FM C12H15NO4S
DMXFGTZ IC InChI=1S/C12H15NO4S/c1-16-7-3-4-8(10(5-7)17-2)11-13-9(6-18-11)12(14)15/h3-5,9,11,13H,6H2,1-2H3,(H,14,15)/t9-,11?/m0/s1
DMXFGTZ CS COC1=CC(=C(C=C1)C2N[C@@H](CS2)C(=O)O)OC
DMXFGTZ IK GXPHSEXJDZAWQX-FTNKSUMCSA-N
DMXFGTZ IU (4R)-2-(2,4-dimethoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
DMXFGTZ DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMLBA4D ID DMLBA4D
DMLBA4D DN Thiazolidine dione crystalline derivative 1
DMLBA4D HS Patented
DMLBA4D SN PMID25416646-Compound-Figure2-I
DMLBA4D CP Daiichi Sankyo Co., Ltd
DMLBA4D DT Small molecular drug
DMLBA4D PC 9832447
DMLBA4D MW 502.6
DMLBA4D FM C27H26N4O4S
DMLBA4D IC InChI=1S/C27H26N4O4S/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33)
DMLBA4D CS CC1=CC(=CC(=C1N)C)OC2=CC3=C(C=C2)N=C(N3C)COC4=CC=C(C=C4)CC5C(=O)NC(=O)S5
DMLBA4D IK JCYNMRJCUYVDBC-UHFFFAOYSA-N
DMLBA4D IU 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methylbenzimidazol-2-yl]methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMLBA4D CA CAS 223132-37-4
DM86HU3 ID DM86HU3
DM86HU3 DN Thiazoline derivative 1
DM86HU3 HS Patented
DM86HU3 SN PMID26815044-Compound-45
DM86HU3 DT Small molecular drug
DM86HU3 DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMXRE1V ID DMXRE1V
DMXRE1V DN Thiazoline derivative 2
DMXRE1V HS Patented
DMXRE1V SN PMID26815044-Compound-46
DMXRE1V DT Small molecular drug
DMXRE1V DE Albinism; Ephelides; Menkes disease; Senile lentigines; Melasma
DMAFE5R ID DMAFE5R
DMAFE5R DN Thiazolopyridine derivative 1
DMAFE5R HS Patented
DMAFE5R SN PMID27774822-Compound-Figure7Example20
DMAFE5R CP F. HOFFMANN-LA ROCHE AG GENENTECH, INC
DMAFE5R DT Small molecular drug
DMLUPV1 ID DMLUPV1
DMLUPV1 DN Thieno[2,3-c]pyridine derivative 1
DMLUPV1 HS Patented
DMLUPV1 SN PMID29473428-Compound-68
DMLUPV1 CP CURADEV PHARMA PRIVATE LTD
DMLUPV1 DT Small molecular drug
DMLUPV1 PC 86581712
DMLUPV1 MW 277.68
DMLUPV1 FM C13H9ClFN3O
DMLUPV1 IC InChI=1S/C13H9ClFN3O/c14-9-5-7(1-2-10(9)15)18-12-8-3-4-17-6-11(8)19-13(12)16/h1-6,18H,16H2
DMLUPV1 CS C1=CC(=C(C=C1NC2=C(OC3=C2C=CN=C3)N)Cl)F
DMLUPV1 IK MAFDXEXXQIAQTR-UHFFFAOYSA-N
DMLUPV1 IU 3-N-(3-chloro-4-fluorophenyl)furo[2,3-c]pyridine-2,3-diamine
DM1C8MA ID DM1C8MA
DM1C8MA DN Thieno[3,2-c]pyridine-7-carboxamide derivative 1
DM1C8MA HS Patented
DM1C8MA SN PMID25684022-Compound-WO2006106326c1
DM1C8MA CP ASTRAZENECA AB ASTRAZENECA UK LIMITED DALY, Kevin HERON, Nicola HIRD, Alexander IOANNIDIS, Stephanos JANETKA, James, Walter LYNE, Paul SCOTT, Jamie TOADER, Dorin VASBINDER, Melissa YU, Dingwei YU, Yan
DM1C8MA DT Small molecular drug
DM1C8MA DE Solid tumour/cancer; Metastatic cancer
DMOWFA5 ID DMOWFA5
DMOWFA5 DN Thieno[3,2-c]pyridine-7-carboxamide derivative 2
DMOWFA5 HS Patented
DMOWFA5 SN PMID25684022-Compound-WO2006106326c2
DMOWFA5 CP ASTRAZENECA AB ASTRAZENECA UK LIMITED DALY, Kevin HERON, Nicola HIRD, Alexander IOANNIDIS, Stephanos JANETKA, James, Walter LYNE, Paul SCOTT, Jamie TOADER, Dorin VASBINDER, Melissa YU, Dingwei YU, Yan
DMOWFA5 DT Small molecular drug
DMOWFA5 DE Solid tumour/cancer; Metastatic cancer
DMZP6KR ID DMZP6KR
DMZP6KR DN Thiomorpholine derivative 1
DMZP6KR HS Patented
DMZP6KR SN PMID25482888-Compound-19
DMZP6KR DT Small molecular drug
DMWOK1D ID DMWOK1D
DMWOK1D DN Thiomorpholine derivative 2
DMWOK1D HS Patented
DMWOK1D SN PMID25482888-Compound-20
DMWOK1D DT Small molecular drug
DM6QHO0 ID DM6QHO0
DM6QHO0 DN Tihoacetate derivative 1
DM6QHO0 HS Patented
DM6QHO0 SN PMID27414413-Compound-Figure2left
DM6QHO0 CP ARDEA BIOSCIENCES, INC. OUK, Samedy VERNIER, Jean-michel GUNIC, Esmir CHEN, Chixu
DM6QHO0 DT Small molecular drug
DM5UI73 ID DM5UI73
DM5UI73 DN Tihotungstate derivative 1
DM5UI73 HS Patented
DM5UI73 SN PMID25553724-Compound-US2011015102237
DM5UI73 DT Small molecular drug
DM5UI73 DE Nervous system disease; Neurodegenerative disorder; Copper metabolism disorder; Aberrant vascularization
DMGR6IJ ID DMGR6IJ
DMGR6IJ DN Tihourea derivative 1
DMGR6IJ HS Patented
DMGR6IJ SN PMID25553724-Compound-WO2012060594 1
DMGR6IJ CP SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY INDUSTRIAL COOPERATION FOUNDATION JEON, Raok
DMHR43K ID DMHR43K
DMHR43K DN Tlouidine sulfonamide derivative 1
DMHR43K HS Patented
DMHR43K SN PMID26882240-Compound-16
DMHR43K CP ELARA PHARMACEUTICALS GMBH MCLAUGHLIN, Fiona LEWIS, Joe
DMHR43K DT Small molecular drug
DM6KJLG ID DM6KJLG
DM6KJLG DN Trepenoid derivative 1
DM6KJLG HS Patented
DM6KJLG SN PMID28454500-Compound-14
DM6KJLG DT Small molecular drug
DM9QB2S ID DM9QB2S
DM9QB2S DN Triazole derivative 1
DM9QB2S HS Patented
DM9QB2S SN PMID26560530-Compound-42
DM9QB2S CP Universit de Montral
DM9QB2S DT Small molecular drug
DM9QB2S PC 25015312
DM9QB2S MW 379.3
DM9QB2S FM C18H13N5O5
DM9QB2S IC InChI=1S/C18H13N5O5/c24-18(10-5-13-1-6-15(7-2-13)22(25)26)17-12-21(20-19-17)11-14-3-8-16(9-4-14)23(27)28/h1-10,12H,11H2/b10-5+
DM9QB2S CS C1=CC(=CC=C1CN2C=C(N=N2)C(=O)/C=C/C3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-]
DM9QB2S IK CVKOJPBBOPIMAL-BJMVGYQFSA-N
DM9QB2S IU (E)-3-(4-nitrophenyl)-1-[1-[(4-nitrophenyl)methyl]triazol-4-yl]prop-2-en-1-one
DM7KNXH ID DM7KNXH
DM7KNXH DN Triazole derivative 2
DM7KNXH HS Patented
DM7KNXH SN PMID27724045-Compound-30
DM7KNXH CP Abbott
DM7KNXH DT Small molecular drug
DM7KNXH PC 16679492
DM7KNXH MW 416.3
DM7KNXH FM C19H15Cl2N5S
DM7KNXH IC InChI=1S/C19H15Cl2N5S/c1-12-24-25-19(26(12)16-6-2-5-15(20)17(16)21)23-10-13-4-3-8-22-18(13)14-7-9-27-11-14/h2-9,11H,10H2,1H3,(H,23,25)
DM7KNXH CS CC1=NN=C(N1C2=C(C(=CC=C2)Cl)Cl)NCC3=C(N=CC=C3)C4=CSC=C4
DM7KNXH IK SMJNWZUHIGQMEW-UHFFFAOYSA-N
DM7KNXH IU 4-(2,3-dichlorophenyl)-5-methyl-N-[(2-thiophen-3-ylpyridin-3-yl)methyl]-1,2,4-triazol-3-amine
DMZR0TH ID DMZR0TH
DMZR0TH DN Triazole derivative 3
DMZR0TH HS Patented
DMZR0TH SN PMID26560362-Compound-32
DMZR0TH DT Small molecular drug
DMZR0TH PC 16663189
DMZR0TH MW 223.62
DMZR0TH FM C8H6ClN5O
DMZR0TH IC InChI=1S/C8H6ClN5O/c9-5-1-2-7(10-3-5)12-8(15)6-4-11-14-13-6/h1-4H,(H,10,12,15)(H,11,13,14)
DMZR0TH CS C1=CC(=NC=C1Cl)NC(=O)C2=NNN=C2
DMZR0TH IK RVQBIGKKUXHYRZ-UHFFFAOYSA-N
DMZR0TH IU N-(5-chloropyridin-2-yl)-2H-triazole-4-carboxamide
DMCFEAS ID DMCFEAS
DMCFEAS DN Triazole derivative 4
DMCFEAS HS Patented
DMCFEAS SN PMID28906174-Compound-Figure1h
DMCFEAS CP Ixchelsis Limited
DMCFEAS DT Small molecular drug
DMA83QK ID DMA83QK
DMA83QK DN Triazole derivative 5
DMA83QK HS Patented
DMA83QK SN PMID28906174-Compound-Figure1i
DMA83QK CP Ixchelsis Limited
DMA83QK DT Small molecular drug
DMU15FW ID DMU15FW
DMU15FW DN Triazole derivative 6
DMU15FW HS Patented
DMU15FW SN PMID28906174-Compound-Figure1j
DMU15FW CP Ixchelsis Limited
DMU15FW DT Small molecular drug
DMRK4AT ID DMRK4AT
DMRK4AT DN Triazole derivative 7
DMRK4AT HS Patented
DMRK4AT SN PMID28906174-Compound-Figure1k
DMRK4AT CP Ixchelsis Limited
DMRK4AT DT Small molecular drug
DMCWES7 ID DMCWES7
DMCWES7 DN Triazole gold complexe 1
DMCWES7 HS Patented
DMCWES7 SN PMID27977313-Compound-10
DMCWES7 DT Small molecular drug
DMJON7D ID DMJON7D
DMJON7D DN Triazole gold complexe 2
DMJON7D HS Patented
DMJON7D SN PMID27977313-Compound-9
DMJON7D DT Small molecular drug
DM5TILQ ID DM5TILQ
DM5TILQ DN Triazole gold complexe 3
DM5TILQ HS Patented
DM5TILQ SN PMID27977313-Compound-Figure4c
DM5TILQ DT Small molecular drug
DMPRGLZ ID DMPRGLZ
DMPRGLZ DN Triazole piperazine derivative 1
DMPRGLZ HS Patented
DMPRGLZ SN PMID25482888-Compound-36
DMPRGLZ DT Small molecular drug
DM8LFGS ID DM8LFGS
DM8LFGS DN Triazole propanedioic acid derivative 1
DM8LFGS HS Patented
DM8LFGS SN PMID27414413-Compound-Figure11down
DM8LFGS CP Yuanqiang Z
DM8LFGS DT Small molecular drug
DM34MCP ID DM34MCP
DM34MCP DN Triazolo[4,3-b]pyridazine derivative 1
DM34MCP HS Patented
DM34MCP SN PMID25435179-Compound-WO2013059589(II)
DM34MCP CP GLAXOSMITHKLINE LLC BLUM, Charles, A. SPRINGER, Stephanie, K. VU, Chi, B
DMMJ1FN ID DMMJ1FN
DMMJ1FN DN Triazolo[4,3-b]pyridazine derivative 2
DMMJ1FN HS Patented
DMMJ1FN SN PMID28270021-Compound-WO2012125667Example24
DMMJ1FN CP MERCK SHARP & DOHME CORP
DMMJ1FN DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DM79KEX ID DM79KEX
DM79KEX DN Triazolo-benzodiazepine derivative 1
DM79KEX HS Patented
DM79KEX SN PMID29334795-Compound-26
DM79KEX DT Small molecular drug
DM79KEX PC 71254559
DM79KEX MW 433.6
DM79KEX FM C26H31N3OS
DM79KEX IC InChI=1S/C26H31N3OS/c1-20-25(31-26-27-18-22-8-3-4-9-23(22)19-29(20)26)21-10-12-24(13-11-21)30-17-7-16-28-14-5-2-6-15-28/h3-4,8-13H,2,5-7,14-19H2,1H3
DM79KEX CS CC1=C(SC2=NCC3=CC=CC=C3CN12)C4=CC=C(C=C4)OCCCN5CCCCC5
DM79KEX IK RUTOALHMLUQLAH-UHFFFAOYSA-N
DM79KEX IU 1-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-5,10-dihydro-[1,3]thiazolo[3,2-b][2,4]benzodiazepine
DMQSCHA ID DMQSCHA
DMQSCHA DN Triazolo-benzodiazepine derivative 2
DMQSCHA HS Patented
DMQSCHA SN PMID29334795-Compound-27
DMQSCHA DT Small molecular drug
DMU9A7V ID DMU9A7V
DMU9A7V DN Triazolo-phthalazine derivative 1
DMU9A7V HS Patented
DMU9A7V SN PMID27321640-Compound-14
DMU9A7V CP ALTANA PHARMA AG [DEALTANA PHARMA AG SCHMIDT, Beate WEINBRENNER, Steffen FLOCKERZI, Dieter KUELZER, Raimund TENOR, Hermann KLEY, Hans-Peter
DMU9A7V DT Small molecular drug
DM1KHGY ID DM1KHGY
DM1KHGY DN Triazolo-pyrazinone derivative 1
DM1KHGY HS Patented
DM1KHGY SN PMID27724045-Compound-35
DM1KHGY CP MERCK SHARP &amDOHME CORP. LABROLI, Marc CZARNIECKI, Michael, F. POKER, Cory Seth
DM1KHGY DT Small molecular drug
DM1KHGY PC 56944547
DM1KHGY MW 559
DM1KHGY FM C26H18ClF3N4O3S
DM1KHGY IC InChI=1S/C26H18ClF3N4O3S/c1-16-21(26(28,29)30)7-4-8-22(16)33-13-14-34-23(24(33)35)31-32-25(34)38(36,37)15-18-5-2-3-6-20(18)17-9-11-19(27)12-10-17/h2-14H,15H2,1H3
DM1KHGY CS CC1=C(C=CC=C1N2C=CN3C(=NN=C3S(=O)(=O)CC4=CC=CC=C4C5=CC=C(C=C5)Cl)C2=O)C(F)(F)F
DM1KHGY IK BEOJDRXHECGYFM-UHFFFAOYSA-N
DM1KHGY IU 3-[[2-(4-chlorophenyl)phenyl]methylsulfonyl]-7-[2-methyl-3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-a]pyrazin-8-one
DM0Q9VY ID DM0Q9VY
DM0Q9VY DN Triazolo-pyridine derivative 1
DM0Q9VY HS Patented
DM0Q9VY SN PMID27774822-Compound-Figure7ExampleI-286
DM0Q9VY CP F.HOFFMANN-LA ROCHE AG GENENTECH, INC LI, Wei
DM0Q9VY DT Small molecular drug
DMXPQ24 ID DMXPQ24
DMXPQ24 DN Triazolo-pyridine derivative 2
DMXPQ24 HS Patented
DMXPQ24 SN PMID27321640-Compound-49
DMXPQ24 CP LUNDBECK & CO AS H [DK]
DMXPQ24 DT Small molecular drug
DMQL1TV ID DMQL1TV
DMQL1TV DN Triazolo-pyridine derivative 3
DMQL1TV HS Patented
DMQL1TV SN PMID27321640-Compound-50
DMQL1TV CP LUNDBECK & CO AS H [DK]
DMQL1TV DT Small molecular drug
DM5ZQKS ID DM5ZQKS
DM5ZQKS DN Triazolo-pyridine derivative 4
DM5ZQKS HS Patented
DM5ZQKS SN PMID27321640-Compound-51
DM5ZQKS CP LUNDBECK & CO AS H [DK]
DM5ZQKS DT Small molecular drug
DM5ZQKS PC 71295299
DM5ZQKS MW 295.72
DM5ZQKS FM C15H10ClN5
DM5ZQKS IC InChI=1S/C15H10ClN5/c1-9-14-19-20-15(10-4-2-3-5-11(10)16)21(14)13-8-17-7-6-12(13)18-9/h2-8H,1H3
DM5ZQKS CS CC1=NC2=C(C=NC=C2)N3C1=NN=C3C4=CC=CC=C4Cl
DM5ZQKS IK SNQXTEAQGLZIDL-UHFFFAOYSA-N
DM5ZQKS IU 3-(2-chlorophenyl)-7-methyl-2,4,5,8,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaene
DM1R205 ID DM1R205
DM1R205 DN Triazolo-pyridine derivative 5
DM1R205 HS Patented
DM1R205 SN PMID27321640-Compound-52
DM1R205 CP LUNDBECK & CO AS H [DK]
DM1R205 DT Small molecular drug
DM1R205 PC 71295652
DM1R205 MW 324.8
DM1R205 FM C17H13ClN4O
DM1R205 IC InChI=1S/C17H13ClN4O/c1-10-16-20-21-17(11-6-3-4-7-12(11)18)22(16)15-13(19-10)8-5-9-14(15)23-2/h3-9H,1-2H3
DM1R205 CS CC1=NC2=C(C(=CC=C2)OC)N3C1=NN=C3C4=CC=CC=C4Cl
DM1R205 IK MGVXODADYYKJPQ-UHFFFAOYSA-N
DM1R205 IU 1-(2-chlorophenyl)-9-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline
DMX4WFP ID DMX4WFP
DMX4WFP DN Triazolo-pyridine derivative 6
DMX4WFP HS Patented
DMX4WFP SN PMID27321640-Compound-53
DMX4WFP CP LUNDBECK & CO AS H [DK]
DMX4WFP DT Small molecular drug
DMX4WFP PC 71295624
DMX4WFP MW 312.73
DMX4WFP FM C16H10ClFN4
DMX4WFP IC InChI=1S/C16H10ClFN4/c1-9-15-20-21-16(10-5-2-3-6-11(10)17)22(15)14-12(18)7-4-8-13(14)19-9/h2-8H,1H3
DMX4WFP CS CC1=NC2=C(C(=CC=C2)F)N3C1=NN=C3C4=CC=CC=C4Cl
DMX4WFP IK ZXWSCYGUZHTXLO-UHFFFAOYSA-N
DMX4WFP IU 1-(2-chlorophenyl)-9-fluoro-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline
DMJN72E ID DMJN72E
DMJN72E DN Triazolo-pyrimidinedione derivative 1
DMJN72E HS Patented
DMJN72E SN PMID25482888-Compound-64
DMJN72E CP SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong YUAN, Quan LIU, Caiping LUO, Lian SHI, Hailong ZOU, Chunlan YAN, Chengyi
DMJN72E DT Small molecular drug
DMLGNB2 ID DMLGNB2
DMLGNB2 DN Triazolo-pyrimidinedione derivative 2
DMLGNB2 HS Patented
DMLGNB2 SN PMID25482888-Compound-65
DMLGNB2 CP SHANGHAI FOCHON PHARMACEUTICAL CO LTD WANG, Weibo ZHAO, Xingdong YUAN, Quan LIU, Caiping LUO, Lian SHI, Hailong ZOU, Chunlan YAN, Chengyi
DMLGNB2 DT Small molecular drug
DMYEDJI ID DMYEDJI
DMYEDJI DN Tricyclic 5-quinolone derivative 1
DMYEDJI HS Patented
DMYEDJI SN PMID27828716-Compound-9
DMYEDJI CP DAIICHI SANKYO CO LTD [JP]
DMYEDJI DT Small molecular drug
DMYEDJI PC 72695231
DMYEDJI MW 447.5
DMYEDJI FM C22H27F2N5O3
DMYEDJI IC InChI=1S/C22H27F2N5O3/c1-10(30)28-8-5-11(6-9-28)27-18-15(23)17(25)14-19(16(18)24)29-12(4-7-22(29,2)3)13(20(14)31)21(26)32/h11,27H,4-9,25H2,1-3H3,(H2,26,32)
DMYEDJI CS CC(=O)N1CCC(CC1)NC2=C(C(=C3C(=C2F)N4C(=C(C3=O)C(=O)N)CCC4(C)C)N)F
DMYEDJI IK KPYGNCXHNQMYPD-UHFFFAOYSA-N
DMYEDJI IU 8-[(1-acetylpiperidin-4-yl)amino]-6-amino-7,9-difluoro-1,1-dimethyl-5-oxo-2,3-dihydropyrrolo[1,2-a]quinoline-4-carboxamide
DM5SD9E ID DM5SD9E
DM5SD9E DN Tricyclic benzimidazole derivative 1
DM5SD9E HS Patented
DM5SD9E SN PMID26161698-Compound-21
DM5SD9E CP SELVITA SA
DM5SD9E DT Small molecular drug
DM5SD9E PC 75201489
DM5SD9E MW 479.01
DM5SD9E FM C14H15Br3N4
DM5SD9E IC InChI=1S/C14H15Br3N4/c15-9-8-2-1-5-21-13(8)12(11(17)10(9)16)19-14(21)20-6-3-18-4-7-20/h18H,1-7H2
DM5SD9E CS C1CC2=C3C(=C(C(=C2Br)Br)Br)N=C(N3C1)N4CCNCC4
DM5SD9E IK FUOROZXAYONUGD-UHFFFAOYSA-N
DM5SD9E IU 5,6,7-tribromo-2-piperazin-1-yl-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene
DMLBR4F ID DMLBR4F
DMLBR4F DN Tricyclic compound 1
DMLBR4F HS Patented
DMLBR4F SN PMID27774824-Compound-Figure1Example1
DMLBR4F CP ALMIRALL, S.AABBVIE INC
DMLBR4F DT Small molecular drug
DMV1RQX ID DMV1RQX
DMV1RQX DN Tricyclic compound 10
DMV1RQX HS Patented
DMV1RQX SN PMID27568917-Compound-Figure7(d)
DMV1RQX DT Small molecular drug
DMV1RQX PC 66546795
DMV1RQX MW 322.4
DMV1RQX FM C20H19FN2O
DMV1RQX IC InChI=1S/C20H19FN2O/c1-12-3-4-14-7-10-17-19(18(14)11-12)22-23(13(2)24)20(17)15-5-8-16(21)9-6-15/h3-6,8-9,11,17,20H,7,10H2,1-2H3
DMV1RQX CS CC1=CC2=C(CCC3C2=NN(C3C4=CC=C(C=C4)F)C(=O)C)C=C1
DMV1RQX IK KSFRHQFENHYLGG-UHFFFAOYSA-N
DMV1RQX IU 1-[3-(4-fluorophenyl)-8-methyl-3,3a,4,5-tetrahydrobenzo[g]indazol-2-yl]ethanone
DMJAZ7D ID DMJAZ7D
DMJAZ7D DN Tricyclic compound 11
DMJAZ7D HS Patented
DMJAZ7D SN PMID27774822-Compound-Figure7Example34
DMJAZ7D CP F. HOFFMANN-LA ROCHE AG BERGERON, Philippe BODIL VAN NIEL, Monique DRAGOVICH, Peter HURLEY, Christopher KULAGOWSKI, Janusz LABADIE, Sharada MCLEAN, Neville James MENDONCA, Rohan PULK, Rebecca ZAK, Mark
DMJAZ7D DT Small molecular drug
DMJAWOI ID DMJAWOI
DMJAWOI DN Tricyclic compound 2
DMJAWOI HS Patented
DMJAWOI SN PMID27774824-Compound-Figure1Example68
DMJAWOI CP ABBVIE INC. WISHART, Neil BONAFOUX, Dominique F. FRANK, Kristine E. HOBSON, Adrian D. KONOPACKI, Donald B, MARTINEZ, Gloria Y. WANG, Lu
DMJAWOI DT Small molecular drug
DM9K7P0 ID DM9K7P0
DM9K7P0 DN Tricyclic compound 3
DM9K7P0 HS Patented
DM9K7P0 SN PMID27774824-Compound-Figure13Example20
DM9K7P0 CP INCYTE CORPORATION
DM9K7P0 DT Small molecular drug
DMEIG16 ID DMEIG16
DMEIG16 DN Tricyclic compound 4
DMEIG16 HS Patented
DMEIG16 SN PMID28048944-Compound-23
DMEIG16 CP BRISTOL-MYERS SQUIBB COMPANY
DMEIG16 DT Small molecular drug
DMEIG16 PC 129159093
DMEIG16 MW 387.4
DMEIG16 FM C23H21N3O3
DMEIG16 IC InChI=1S/C23H21N3O3/c1-2-25-22(27)16-5-3-4-15(10-16)12-26-23(28)17-6-7-19-18(11-17)14-29-21-13-24-9-8-20(19)21/h3-11,13H,2,12,14H2,1H3,(H,25,27)(H,26,28)
DMEIG16 CS CCNC(=O)C1=CC=CC(=C1)CNC(=O)C2=CC3=C(C=C2)C4=C(C=NC=C4)OC3
DMEIG16 IK YKJXZODWOQJHCQ-UHFFFAOYSA-N
DMEIG16 IU N-[[3-(ethylcarbamoyl)phenyl]methyl]-6H-isochromeno[3,4-c]pyridine-8-carboxamide
DMLPMS7 ID DMLPMS7
DMLPMS7 DN Tricyclic compound 5
DMLPMS7 HS Patented
DMLPMS7 SN PMID28048944-Compound-24
DMLPMS7 CP BRISTOL-MYERS SQUIBB COMPANY
DMLPMS7 DT Small molecular drug
DMLPMS7 PC 129159126
DMLPMS7 MW 470.6
DMLPMS7 FM C28H30N4O3
DMLPMS7 IC InChI=1S/C28H30N4O3/c1-2-32-12-4-7-23(32)16-31-27(33)20-6-3-5-19(13-20)15-30-28(34)21-8-9-24-22(14-21)18-35-26-17-29-11-10-25(24)26/h3,5-6,8-11,13-14,17,23H,2,4,7,12,15-16,18H2,1H3,(H,30,34)(H,31,33)
DMLPMS7 CS CCN1CCCC1CNC(=O)C2=CC=CC(=C2)CNC(=O)C3=CC4=C(C=C3)C5=C(C=NC=C5)OC4
DMLPMS7 IK PMNRRBVQSVNKLM-UHFFFAOYSA-N
DMLPMS7 IU N-[[3-[(1-ethylpyrrolidin-2-yl)methylcarbamoyl]phenyl]methyl]-6H-isochromeno[3,4-c]pyridine-8-carboxamide
DMMJ81G ID DMMJ81G
DMMJ81G DN Tricyclic compound 6
DMMJ81G HS Patented
DMMJ81G SN PMID28048944-Compound-25
DMMJ81G CP BRISTOL-MYERS SQUIBB COMPANY
DMMJ81G DT Small molecular drug
DMMJ81G PC 91895903
DMMJ81G MW 333.4
DMMJ81G FM C20H19N3O2
DMMJ81G IC InChI=1S/C20H19N3O2/c1-3-23-18-8-6-5-7-16(18)17-11-15(9-10-19(17)23)22-13-14(12-21)20(24)25-4-2/h5-11,13-14H,3-4H2,1-2H3
DMMJ81G CS CCN1C2=C(C=C(C=C2)N=CC(C#N)C(=O)OCC)C3=CC=CC=C31
DMMJ81G IK ZCSFFBZXCQGHRG-UHFFFAOYSA-N
DMMJ81G IU ethyl 2-cyano-3-(9-ethylcarbazol-3-yl)iminopropanoate
DME84S5 ID DME84S5
DME84S5 DN Tricyclic compound 7
DME84S5 HS Patented
DME84S5 SN PMID28048944-Compound-26
DME84S5 CP BRISTOL-MYERS SQUIBB COMPANY
DME84S5 DT Small molecular drug
DMZI8GK ID DMZI8GK
DMZI8GK DN Tricyclic compound 8
DMZI8GK HS Patented
DMZI8GK SN PMID27568917-Compound-Figure1(a)
DMZI8GK DT Small molecular drug
DMZI8GK PC 194580
DMZI8GK MW 243.26
DMZI8GK FM C13H13N3O2
DMZI8GK IC InChI=1S/C13H13N3O2/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18)
DMZI8GK CS CN1C(=O)C(NC1=O)CC2=CNC3=CC=CC=C32
DMZI8GK IK PANAMPMZPUJRLL-UHFFFAOYSA-N
DMZI8GK IU 5-(1H-indol-3-ylmethyl)-3-methylimidazolidine-2,4-dione
DMZI8GK CA CAS 74311-00-5
DMF5E6U ID DMF5E6U
DMF5E6U DN Tricyclic compound 9
DMF5E6U HS Patented
DMF5E6U SN PMID27568917-Compound-Figure7(c)
DMF5E6U DT Small molecular drug
DMF5E6U PC 135444572
DMF5E6U MW 317.25
DMF5E6U FM C15H11NO7
DMF5E6U IC InChI=1S/C15H11NO7/c1-8-6-13(19)14(15(20)23-8)12(18)5-3-9-2-4-11(17)10(7-9)16(21)22/h2-7,17,19H,1H3/b5-3+
DMF5E6U CS CC1=CC(=C(C(=O)O1)C(=O)/C=C/C2=CC(=C(C=C2)O)[N+](=O)[O-])O
DMF5E6U IK QYYBACCETRXSEX-HWKANZROSA-N
DMF5E6U IU 4-hydroxy-3-[(E)-3-(4-hydroxy-3-nitrophenyl)prop-2-enoyl]-6-methylpyran-2-one
DMXLJH4 ID DMXLJH4
DMXLJH4 DN Tricyclic heterocycle derivative 1
DMXLJH4 HS Patented
DMXLJH4 SN PMID27774822-Compound-Figure3Example81
DMXLJH4 CP NISSAN CHEMICAL INDUSTRIES, LTD. HAYASHI, Keishi WATANABE, Tsuneo TOYAMA, Koji KAMON, Junji MINAMI, Masataka UNI, Miyuki NASU, Mariko
DMXLJH4 DT Small molecular drug
DM1W02D ID DM1W02D
DM1W02D DN Tricyclic heterocycle derivative 2
DM1W02D HS Patented
DM1W02D SN PMID27774824-Compound-Figure4compound118
DM1W02D CP VERTEX PHARMACEUTICALS INCORPORATED BENNANI, Yousseff WANG, Tiansheng SALITURO, Francesco DUFFY, John
DM1W02D DT Small molecular drug
DMJNCD6 ID DMJNCD6
DMJNCD6 DN Tricyclic heterocycle derivative 3
DMJNCD6 HS Patented
DMJNCD6 SN PMID26077642-Compound-Figure3c
DMJNCD6 CP PRESIDENT AND FELLOWS OF HARVARD COLLEGE FINLEY, Daniel KING, Randall, W. LEE, Byung-Hoon LEE, Min, Jae GAHMAN, Timothy, C
DMJNCD6 DT Small molecular drug
DM9XBL4 ID DM9XBL4
DM9XBL4 DN Tricyclic heterocycle derivative 4
DM9XBL4 HS Patented
DM9XBL4 SN PMID26077642-Compound-Figure3D
DM9XBL4 CP PRESIDENT AND FELLOWS OF HARVARD COLLEGE FINLEY, Daniel KING, Randall, W. LEE, Byung-Hoon LEE, Min, Jae GAHMAN, Timothy, C
DM9XBL4 DT Small molecular drug
DM9XBL4 PC 56644389
DM9XBL4 MW 259.37
DM9XBL4 FM C14H17N3S
DM9XBL4 IC InChI=1S/C14H17N3S/c1-17(9-6-7-9)13-12-10-4-2-3-5-11(10)18-14(12)16-8-15-13/h8-9H,2-7H2,1H3
DM9XBL4 CS CN(C1CC1)C2=C3C4=C(CCCC4)SC3=NC=N2
DM9XBL4 IK PGGINYVNLNKQRD-UHFFFAOYSA-N
DM9XBL4 IU N-cyclopropyl-N-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine
DMG1ESV ID DMG1ESV
DMG1ESV DN Tricyclic heterocycle derivative 5
DMG1ESV HS Patented
DMG1ESV SN PMID27774822-Compound-Figure7Example4
DMG1ESV CP F. HOFFMANN-LA ROCHE AG HURLEY, Christopher KULAGOWSKI, Janusz ZAK, Mark
DMG1ESV DT Small molecular drug
DMQJK70 ID DMQJK70
DMQJK70 DN Tricyclic heterocycle derivative 6
DMQJK70 HS Patented
DMQJK70 SN PMID25482888-Compound-55
DMQJK70 CP MERCK SHARP & DOHME CORP. BURNETT, Duane, A. ZHAO, Zhiqiang COLE, David JOSIEN, Hubert PISSARNITSKI, Dmitri, A. SASIKUMAR, Thavalakulamgar WU, Wen-Lian DOMALSKI, Martin
DMQJK70 DT Small molecular drug
DMQJK70 PC 90129657
DMQJK70 MW 455.5
DMQJK70 FM C22H29N7O4
DMQJK70 IC InChI=1S/C22H29N7O4/c1-6-7-11-28-16-17(24-19-26(5)15(30)13-29(19)18(16)31)25-20(28)27-10-8-9-14(12-27)23-21(32)33-22(2,3)4/h14H,8-13H2,1-5H3,(H,23,32)/t14-/m1/s1
DMQJK70 CS CC#CCN1C2=C(N=C3N(C(=O)CN3C2=O)C)N=C1N4CCC[C@H](C4)NC(=O)OC(C)(C)C
DMQJK70 IK CBLPHWVBNDVSJU-CQSZACIVSA-N
DMQJK70 IU tert-butyl N-[(3R)-1-(1-but-2-ynyl-5-methyl-6,9-dioxo-7H-imidazo[1,2-a]purin-2-yl)piperidin-3-yl]carbamate
DM4HBWU ID DM4HBWU
DM4HBWU DN Tricyclic indole compound 1
DM4HBWU HS Patented
DM4HBWU SN PMID27599163-Compound-(R)-2
DM4HBWU CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DM4HBWU DT Small molecular drug
DMK1QTH ID DMK1QTH
DMK1QTH DN Tricyclic indole compound 10
DMK1QTH HS Patented
DMK1QTH SN PMID27599163-Compound-67
DMK1QTH CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMK1QTH DT Small molecular drug
DML724H ID DML724H
DML724H DN Tricyclic indole compound 11
DML724H HS Patented
DML724H SN PMID27599163-Compound-68
DML724H CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DML724H DT Small molecular drug
DMEZQ29 ID DMEZQ29
DMEZQ29 DN Tricyclic indole compound 12
DMEZQ29 HS Patented
DMEZQ29 SN PMID27599163-Compound-69
DMEZQ29 CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMEZQ29 DT Small molecular drug
DMS6XT4 ID DMS6XT4
DMS6XT4 DN Tricyclic indole compound 13
DMS6XT4 HS Patented
DMS6XT4 SN PMID27841036-Compound-XVI
DMS6XT4 CP China Pharmaceutical University
DMS6XT4 DT Small molecular drug
DMXVNSR ID DMXVNSR
DMXVNSR DN Tricyclic indole compound 14
DMXVNSR HS Patented
DMXVNSR SN PMID27599163-Compound-2
DMXVNSR CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMXVNSR DT Small molecular drug
DMHRY63 ID DMHRY63
DMHRY63 DN Tricyclic indole compound 2
DMHRY63 HS Patented
DMHRY63 SN PMID27599163-Compound-(S)-2
DMHRY63 CP GE HEALTHCARE LIMITED JONES, Paul, Alexande
DMHRY63 DT Small molecular drug
DM5B92W ID DM5B92W
DM5B92W DN Tricyclic indole compound 3
DM5B92W HS Patented
DM5B92W SN PMID27599163-Compound-60
DM5B92W CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DM5B92W DT Small molecular drug
DMUZ4L3 ID DMUZ4L3
DMUZ4L3 DN Tricyclic indole compound 4
DMUZ4L3 HS Patented
DMUZ4L3 SN PMID27599163-Compound-61
DMUZ4L3 CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMUZ4L3 DT Small molecular drug
DMX5YG9 ID DMX5YG9
DMX5YG9 DN Tricyclic indole compound 5
DMX5YG9 HS Patented
DMX5YG9 SN PMID27599163-Compound-62
DMX5YG9 CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMX5YG9 DT Small molecular drug
DMXAS8P ID DMXAS8P
DMXAS8P DN Tricyclic indole compound 6
DMXAS8P HS Patented
DMXAS8P SN PMID27599163-Compound-63
DMXAS8P CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMXAS8P DT Small molecular drug
DMFQSU8 ID DMFQSU8
DMFQSU8 DN Tricyclic indole compound 7
DMFQSU8 HS Patented
DMFQSU8 SN PMID27599163-Compound-64
DMFQSU8 CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMFQSU8 DT Small molecular drug
DMYAUVM ID DMYAUVM
DMYAUVM DN Tricyclic indole compound 8
DMYAUVM HS Patented
DMYAUVM SN PMID27599163-Compound-65
DMYAUVM CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMYAUVM DT Small molecular drug
DMVA7BC ID DMVA7BC
DMVA7BC DN Tricyclic indole compound 9
DMVA7BC HS Patented
DMVA7BC SN PMID27599163-Compound-66
DMVA7BC CP GE HEALTHCARE LIMITED JONES, Paul, Alexander
DMVA7BC DT Small molecular drug
DM6QSND ID DM6QSND
DM6QSND DN Tricyclic isoxazoloquinazoline derivative 1
DM6QSND HS Patented
DM6QSND SN PMID27646439-Compound-11
DM6QSND CP NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DM6QSND DT Small molecular drug
DMH4TY1 ID DMH4TY1
DMH4TY1 DN Tricyclic isoxazoloquinazoline derivative 2
DMH4TY1 HS Patented
DMH4TY1 SN PMID27646439-Compound-12
DMH4TY1 CP NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DMH4TY1 DT Small molecular drug
DMH4TY1 PC 66713957
DMH4TY1 MW 406.4
DMH4TY1 FM C21H22N6O3
DMH4TY1 IC InChI=1S/C21H22N6O3/c1-26-8-10-27(11-9-26)14-3-5-15(6-4-14)29-21-23-12-13-2-7-16-18(17(13)24-21)25-30-19(16)20(22)28/h3-6,12H,2,7-11H2,1H3,(H2,22,28)
DMH4TY1 CS CN1CCN(CC1)C2=CC=C(C=C2)OC3=NC=C4CCC5=C(ON=C5C4=N3)C(=O)N
DMH4TY1 IK CMFVPEXDTAEYSG-UHFFFAOYSA-N
DMH4TY1 IU 8-[4-(4-methylpiperazin-1-yl)phenoxy]-4,5-dihydro-[1,2]oxazolo[4,3-h]quinazoline-3-carboxamide
DML2PWF ID DML2PWF
DML2PWF DN Tricyclic isoxazoloquinazoline derivative 3
DML2PWF HS Patented
DML2PWF SN PMID27646439-Compound-13
DML2PWF CP NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DML2PWF DT Small molecular drug
DM8VIM4 ID DM8VIM4
DM8VIM4 DN Tricyclic isoxazoloquinazoline derivative 4
DM8VIM4 HS Patented
DM8VIM4 SN PMID27646439-Compound-14
DM8VIM4 CP NERVIANO MEDICAL SCIENCES S.R.L. CALDARELLI, Marina BERIA, Italo COLOMBO, Nicoletta PIUTTI, Claudia SALSA, Matteo TRAQUANDI, Gabriella
DM8VIM4 DT Small molecular drug
DM94NZF ID DM94NZF
DM94NZF DN Tricyclic phytocannabinoid derivative 1
DM94NZF HS Patented
DM94NZF SN PMID27215781-Compound-41
DM94NZF CP NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros THAKUR, Ganesh, A. SHARMA, Rishi
DM94NZF DT Small molecular drug
DM94NZF PC 73330476
DM94NZF MW 402.5
DM94NZF FM C24H34O5
DM94NZF IC InChI=1S/C24H34O5/c1-6-7-10-28-22(27)23(2,3)16-12-19(26)21-17-11-15(14-25)8-9-18(17)24(4,5)29-20(21)13-16/h8,12-13,17-18,25-26H,6-7,9-11,14H2,1-5H3/t17-,18-/m1/s1
DM94NZF CS CCCCOC(=O)C(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)CO)O
DM94NZF IK AUMCYBWLZBTQLN-QZTJIDSGSA-N
DM94NZF IU butyl 2-[(6aR,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]-2-methylpropanoate
DM94NZF DE Neuropathic pain
DM7YVQL ID DM7YVQL
DM7YVQL DN Tricyclic phytocannabinoid derivative 2
DM7YVQL HS Patented
DM7YVQL SN PMID27215781-Compound-42
DM7YVQL CP NORTHEASTERN UNIVERSITY MAKRIYANNIS, Alexandros THAKUR, Ganesh, A. SHARMA, Rishi
DM7YVQL DT Small molecular drug
DM7YVQL PC 121231416
DM7YVQL MW 404.5
DM7YVQL FM C24H36O5
DM7YVQL IC InChI=1S/C24H36O5/c1-6-7-10-28-22(27)23(2,3)16-12-19(26)21-17-11-15(14-25)8-9-18(17)24(4,5)29-20(21)13-16/h12-13,15,17-18,25-26H,6-11,14H2,1-5H3/t15-,17-,18-/m1/s1
DM7YVQL CS CCCCOC(=O)C(C)(C)C1=CC(=C2[C@@H]3C[C@@H](CC[C@H]3C(OC2=C1)(C)C)CO)O
DM7YVQL IK OSVHLUXLWQLPIY-KBAYOESNSA-N
DM7YVQL IU butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate
DM7YVQL DE Neuropathic pain
DMGY3OR ID DMGY3OR
DMGY3OR DN Tricyclic pyrrolidine derivative 1
DMGY3OR HS Patented
DMGY3OR SN PMID26609882-Compound-79
DMGY3OR CP ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DMGY3OR DT Small molecular drug
DMRD1XJ ID DMRD1XJ
DMRD1XJ DN Tricyclic pyrrolidine derivative 2
DMRD1XJ HS Patented
DMRD1XJ SN PMID26609882-Compound-80
DMRD1XJ CP ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DMRD1XJ DT Small molecular drug
DMK2V6H ID DMK2V6H
DMK2V6H DN Tricyclic pyrrolidine derivative 3
DMK2V6H HS Patented
DMK2V6H SN PMID26609882-Compound-81
DMK2V6H CP ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DMK2V6H DT Small molecular drug
DM0JYWT ID DM0JYWT
DM0JYWT DN Tricyclic pyrrolidine derivative 4
DM0JYWT HS Patented
DM0JYWT SN PMID26609882-Compound-82
DM0JYWT CP ATHERSYS, INC.ATHERSYS, INC. BENNANI, Youssef, L. BOM, David, C. ROBARGE, Michael, J
DM0JYWT DT Small molecular drug
DMFIXW4 ID DMFIXW4
DMFIXW4 DN Tricyclic pyrrolopyridine compound 1
DMFIXW4 HS Patented
DMFIXW4 SN PMID27774822-Compound-Figure3Example45
DMFIXW4 DT Small molecular drug
DMZTPUA ID DMZTPUA
DMZTPUA DN Triptolidenol analog 1
DMZTPUA HS Patented
DMZTPUA SN PMID26882240-Compound-38
DMZTPUA CP Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China
DMZTPUA DT Small molecular drug
DMZTPUA PC 122377866
DMZTPUA MW 524.5
DMZTPUA FM C29H29FO8
DMZTPUA IC InChI=1S/C29H29FO8/c1-25(2,33)28-21(37-28)22-29(38-22)26(3)11-10-16-17(13-34-23(16)32)18(26)12-19-27(29,36-19)24(28)35-20(31)9-6-14-4-7-15(30)8-5-14/h4-9,18-19,21-22,24,33H,10-13H2,1-3H3/b9-6+/t18-,19-,21-,22-,24-,26-,27+,28-,29+/m0/s1
DMZTPUA CS C[C@]12CCC3=C([C@@H]1C[C@H]4[C@@]5([C@@]26[C@@H](O6)[C@H]7[C@@]([C@H]5OC(=O)/C=C/C8=CC=C(C=C8)F)(O7)C(C)(C)O)O4)COC3=O
DMZTPUA IK FVQHGGQECDTHSW-YZAYWNIQSA-N
DMZTPUA IU [(1S,2S,4S,5S,7S,8R,9R,11S,13S)-7-(2-hydroxypropan-2-yl)-1-methyl-17-oxo-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl] (E)-3-(4-fluorophenyl)prop-2-enoate
DMEQ3RD ID DMEQ3RD
DMEQ3RD DN Tri-substituted benzene derivative 1
DMEQ3RD HS Patented
DMEQ3RD SN PMID26560362-Compound-91
DMEQ3RD DT Small molecular drug
DMEQ3RD PC 10113381
DMEQ3RD MW 428.4
DMEQ3RD FM C17H18F2N4O5S
DMEQ3RD IC InChI=1S/C17H18F2N4O5S/c1-23(2)29(26,27)22-17(25)21-14-8-10(4-7-15(14)28-3)16(24)20-11-5-6-12(18)13(19)9-11/h4-9H,1-3H3,(H,20,24)(H2,21,22,25)
DMEQ3RD CS CN(C)S(=O)(=O)NC(=O)NC1=C(C=CC(=C1)C(=O)NC2=CC(=C(C=C2)F)F)OC
DMEQ3RD IK VUAXXZRGLYBYPO-UHFFFAOYSA-N
DMEQ3RD IU N-(3,4-difluorophenyl)-3-(dimethylsulfamoylcarbamoylamino)-4-methoxybenzamide
DM7NTO9 ID DM7NTO9
DM7NTO9 DN Tri-substituted purine derivative 1
DM7NTO9 HS Patented
DM7NTO9 SN PMID26394986-Compound-9
DM7NTO9 CP UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. UNIVERSITY OF TORONTO MISSISSAUGA TURKSON, James GUNNING, Patrick
DM7NTO9 DT Small molecular drug
DM7NTO9 PC 71770709
DM7NTO9 MW 539.6
DM7NTO9 FM C26H30FN7O3S
DM7NTO9 IC InChI=1S/C26H30FN7O3S/c27-21-10-12-22(13-11-21)31-24-23-25(34(17-30-23)14-15-37-38(28,35)36)33-26(32-24)29-16-18-6-8-20(9-7-18)19-4-2-1-3-5-19/h6-13,17,19H,1-5,14-16H2,(H2,28,35,36)(H2,29,31,32,33)
DM7NTO9 CS C1CCC(CC1)C2=CC=C(C=C2)CNC3=NC(=C4C(=N3)N(C=N4)CCOS(=O)(=O)N)NC5=CC=C(C=C5)F
DM7NTO9 IK SDEPDOGWVAMEDD-UHFFFAOYSA-N
DM7NTO9 IU 2-[2-[(4-cyclohexylphenyl)methylamino]-6-(4-fluoroanilino)purin-9-yl]ethyl sulfamate
DMHGRTX ID DMHGRTX
DMHGRTX DN Tri-substituted urea derivative 1
DMHGRTX HS Patented
DMHGRTX SN PMID28270021-Compound-WO2013176970Example1
DMHGRTX CP MERCK SHARP & DOHME CORP
DMHGRTX DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMUVPR8 ID DMUVPR8
DMUVPR8 DN Tri-substituted urea derivative 2
DMUVPR8 HS Patented
DMUVPR8 SN PMID28270021-Compound-WO2013176970Example2
DMUVPR8 CP MERCK SHARP & DOHME CORP
DMUVPR8 DE Pruritus; Solid tumour/cancer; Chronic pain; Neuropathic pain; Thymic cancer
DMLJ2HE ID DMLJ2HE
DMLJ2HE DN Undecylenic acid derivative 1
DMLJ2HE HS Patented
DMLJ2HE SN PMID25399719-Compound-61
DMLJ2HE CP EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION KWON, Young Joo
DMLJ2HE DT Small molecular drug
DMLJ2HE PC 5634
DMLJ2HE MW 184.27
DMLJ2HE FM C11H20O2
DMLJ2HE IC InChI=1S/C11H20O2/c1-2-3-4-5-6-7-8-9-10-11(12)13/h2H,1,3-10H2,(H,12,13)
DMLJ2HE CS C=CCCCCCCCCC(=O)O
DMLJ2HE IK FRPZMMHWLSIFAZ-UHFFFAOYSA-N
DMLJ2HE IU undec-10-enoic acid
DMLJ2HE CA CAS 112-38-9
DMLJ2HE CB CHEBI:35045
DMUD7H8 ID DMUD7H8
DMUD7H8 DN Unii-I92MU0V408
DMUD7H8 HS Patented
DMUD7H8 SN UNII-I92MU0V408; I92MU0V408; SCHEMBL1695326; CHEMBL3695568; RTDCVLCTBQDLBW-UHFFFAOYSA-N; BDBM142597; RV568; US8933228, Ref 1; RV-568; JNJ-49095397; N-(4-(((4-((((3-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)amino)carbonyl)amino)-1-naphthalenyl)oxy)methyl)-2-pyridinyl)-2-methoxyacetamide; Acetamide, N-(4-(((4-((((3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)amino)carbonyl)amino)-1-naphthalenyl)oxy)methyl)-2-pyridinyl)-2-methoxy-; 1220626-82-3; N-[4-({4-[3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ur
DMUD7H8 DT Small molecular drug
DMUD7H8 PC 45109868
DMUD7H8 MW 592.7
DMUD7H8 FM C34H36N6O4
DMUD7H8 IC InChI=1S/C34H36N6O4/c1-22-10-12-24(13-11-22)40-31(19-29(39-40)34(2,3)4)38-33(42)36-27-14-15-28(26-9-7-6-8-25(26)27)44-20-23-16-17-35-30(18-23)37-32(41)21-43-5/h6-19H,20-21H2,1-5H3,(H,35,37,41)(H2,36,38,42)
DMUD7H8 CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCC5=CC(=NC=C5)NC(=O)COC
DMUD7H8 IK RTDCVLCTBQDLBW-UHFFFAOYSA-N
DMUD7H8 IU N-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide
DMUD7H8 CA CAS 1220626-82-3
DMUHSAZ ID DMUHSAZ
DMUHSAZ DN Unii-R228S06soh
DMUHSAZ HS Patented
DMUHSAZ SN UNII-R228S06SOH; R228S06SOH; AB-22; 1463913-43-0; SCHEMBL15295885; SB19630; N-(2-Chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridin-6-yl)hydrazinecarboxamide; Hydrazinecarboxamide, N-(2-chloro-6-propoxy-4-pyridinyl)-2-(1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo(3,4-b)pyridin-6-yl)-2-(2-hydroxyethyl);
DMUHSAZ DT Small molecular drug
DMUHSAZ PC 81689736
DMUHSAZ MW 476
DMUHSAZ FM C22H30ClN7O3
DMUHSAZ IC InChI=1S/C22H30ClN7O3/c1-6-9-33-19-11-15(10-17(23)25-19)24-22(32)28-30(7-8-31)18-12-16(13(2)3)20-14(4)27-29(5)21(20)26-18/h10-13,31H,6-9H2,1-5H3,(H2,24,25,28,32)
DMUHSAZ CS CCCOC1=NC(=CC(=C1)NC(=O)NN(CCO)C2=NC3=C(C(=NN3C)C)C(=C2)C(C)C)Cl
DMUHSAZ IK GOQBSVFOBGVWTA-UHFFFAOYSA-N
DMUHSAZ IU 1-(2-chloro-6-propoxypyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)-(2-hydroxyethyl)amino]urea
DMUHSAZ CA CAS 1463913-43-0
DM5SX8T ID DM5SX8T
DM5SX8T DN Uracil derivative 1
DM5SX8T HS Patented
DM5SX8T SN PMID26118988-Compound-41
DM5SX8T CP D2 BIOSCIENCE GROUP LTD. BAYERL, Thoma
DM5SX8T DT Small molecular drug
DMEQFXZ ID DMEQFXZ
DMEQFXZ DN Urea and carbamate bioisostere derivative 1
DMEQFXZ HS Patented
DMEQFXZ SN PMID28074661-Compound-US20026399773BMS-337197
DMEQFXZ CP Bristol-Myers Squibb Co
DMEQFXZ DT Small molecular drug
DMWNR8I ID DMWNR8I
DMWNR8I DN Urea and carbamate bioisostere derivative 10
DMWNR8I HS Patented
DMWNR8I SN PMID28074661-Compound-US20036617323c29
DMWNR8I CP Bristol-Myers Squibb Co
DMWNR8I DT Small molecular drug
DMAP6YS ID DMAP6YS
DMAP6YS DN Urea and carbamate bioisostere derivative 11
DMAP6YS HS Patented
DMAP6YS SN PMID28074661-Compound-US20036624184c31
DMAP6YS CP Bristol-Myers Squibb Co
DMAP6YS DT Small molecular drug
DM6BJEW ID DM6BJEW
DM6BJEW DN Urea and carbamate bioisostere derivative 13
DM6BJEW HS Patented
DM6BJEW SN PMID28074661-Compound-US20056867299c40
DM6BJEW CP Hoffmann-La Roche Inc
DM6BJEW DT Small molecular drug
DMDP09N ID DMDP09N
DMDP09N DN Urea and carbamate bioisostere derivative 14
DMDP09N HS Patented
DMDP09N SN PMID28074661-Compound-US20067053111c32
DMDP09N CP Bristol-Myers Squibb Co
DMDP09N DT Small molecular drug
DM3SQUD ID DM3SQUD
DM3SQUD DN Urea and carbamate bioisostere derivative 15
DM3SQUD HS Patented
DM3SQUD SN PMID28074661-Compound-US20067060720c32
DM3SQUD CP Bristol-Myers Squibb Co
DM3SQUD DT Small molecular drug
DMRLC4X ID DMRLC4X
DMRLC4X DN Urea and carbamate bioisostere derivative 16
DMRLC4X HS Patented
DMRLC4X SN PMID28074661-Compound-US20077205324c32
DMRLC4X CP Bristol-Myers Squibb Co
DMRLC4X DT Small molecular drug
DM7PSB1 ID DM7PSB1
DM7PSB1 DN Urea and carbamate bioisostere derivative 18
DM7PSB1 HS Patented
DM7PSB1 SN PMID28074661-Compound-WO2003045901c30
DM7PSB1 CP CELLTECH R & D LIMITED DYKE, Hazel, Joan BUCKLEY, George, Martin
DM7PSB1 DT Small molecular drug
DMRTJSC ID DMRTJSC
DMRTJSC DN Urea and carbamate bioisostere derivative 2
DMRTJSC HS Patented
DMRTJSC SN PMID28074661-Compound-US20026399773c21
DMRTJSC CP Bristol-Myers Squibb Co
DMRTJSC DT Small molecular drug
DMPXVWE ID DMPXVWE
DMPXVWE DN Urea and carbamate bioisostere derivative 3
DMPXVWE HS Patented
DMPXVWE SN PMID28074661-Compound-US20026399773c22
DMPXVWE CP Bristol-Myers Squibb Co
DMPXVWE DT Small molecular drug
DM5GZNS ID DM5GZNS
DM5GZNS DN Urea and carbamate bioisostere derivative 4
DM5GZNS HS Patented
DM5GZNS SN PMID28074661-Compound-US20026420403c26
DM5GZNS CP Bristol-Myers Squibb Co
DM5GZNS DT Small molecular drug
DM02ZM4 ID DM02ZM4
DM02ZM4 DN Urea and carbamate bioisostere derivative 5
DM02ZM4 HS Patented
DM02ZM4 SN PMID28074661-Compound-US20026420403c27
DM02ZM4 CP Bristol-Myers Squibb Co
DM02ZM4 DT Small molecular drug
DMP29I0 ID DMP29I0
DMP29I0 DN Urea and carbamate bioisostere derivative 6
DMP29I0 HS Patented
DMP29I0 SN PMID28074661-Compound-US20036518291c24
DMP29I0 CP Vertex Pharmaceuticals, Inc
DMP29I0 DT Small molecular drug
DM2GPLQ ID DM2GPLQ
DM2GPLQ DN Urea and carbamate bioisostere derivative 7
DM2GPLQ HS Patented
DM2GPLQ SN PMID28074661-Compound-US20036518291c25
DM2GPLQ CP Vertex Pharmaceuticals, Inc
DM2GPLQ DT Small molecular drug
DMIYD41 ID DMIYD41
DMIYD41 DN Urea and carbamate bioisostere derivative 9
DMIYD41 HS Patented
DMIYD41 SN PMID28074661-Compound-US20036617323c28
DMIYD41 CP Bristol-Myers Squibb Co
DMIYD41 DT Small molecular drug
DMN51XF ID DMN51XF
DMN51XF DN Ureido-phenyl-substituted triazine derivative 1
DMN51XF HS Patented
DMN51XF SN PMID28270010-Compound-Figure6-1
DMN51XF CP ABRAXIS BIOSCIENCE, LLC
DMN51XF DT Small molecular drug
DMN51XF PC 88588864
DMN51XF MW 414.6
DMN51XF FM C18H22N8S2
DMN51XF IC InChI=1S/C18H22N8S2/c1-12-11-20-17(27-12)22-15-21-16(26-9-7-25(2)8-10-26)24-18(23-15)28-14-5-3-13(19)4-6-14/h3-6,11H,7-10,19H2,1-2H3,(H,20,21,22,23,24)
DMN51XF CS CC1=CN=C(S1)NC2=NC(=NC(=N2)SC3=CC=C(C=C3)N)N4CCN(CC4)C
DMN51XF IK WLWGUMHFVGHNRD-UHFFFAOYSA-N
DMN51XF IU N-[4-(4-aminophenyl)sulfanyl-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl]-5-methyl-1,3-thiazol-2-amine
DMR0JDW ID DMR0JDW
DMR0JDW DN Ureido-phenyl-substituted triazine derivative 2
DMR0JDW HS Patented
DMR0JDW SN PMID28270010-Compound-Figure6-2
DMR0JDW CP ABRAXIS BIOSCIENCE, LLC
DMR0JDW DT Small molecular drug
DMR0JDW PC 49800205
DMR0JDW MW 533.7
DMR0JDW FM C25H27N9OS2
DMR0JDW IC InChI=1S/C25H27N9OS2/c1-17-16-26-24(36-17)30-21-29-22(34-14-12-33(2)13-15-34)32-25(31-21)37-20-10-8-19(9-11-20)28-23(35)27-18-6-4-3-5-7-18/h3-11,16H,12-15H2,1-2H3,(H2,27,28,35)(H,26,29,30,31,32)
DMR0JDW CS CC1=CN=C(S1)NC2=NC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)NC4=CC=CC=C4)N5CCN(CC5)C
DMR0JDW IK RZAWEAWFWJQMTD-UHFFFAOYSA-N
DMR0JDW IU 1-[4-[[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1,3-thiazol-2-yl)amino]-1,3,5-triazin-2-yl]sulfanyl]phenyl]-3-phenylurea
DMVCWXD ID DMVCWXD
DMVCWXD DN US10022354, Example 151
DMVCWXD HS Patented
DMVCWXD SN SCHEMBL19513974; CHEMBL4060968; BDBM281211; US10022354, Example 151
DMVCWXD DT Small molecular drug
DMVCWXD PC 132054530
DMVCWXD MW 290.36
DMVCWXD FM C15H22N4O2
DMVCWXD IC InChI=1S/C15H22N4O2/c1-9(2)12-7-13(18-17-12)15(21)19-6-5-11(8-19)16-14(20)10-3-4-10/h7,9-11H,3-6,8H2,1-2H3,(H,16,20)(H,17,18)
DMVCWXD CS CC(C)C1=CC(=NN1)C(=O)N2CCC(C2)NC(=O)C3CC3
DMVCWXD IK CXEXTVGTDZRKJS-UHFFFAOYSA-N
DMVCWXD IU N-[1-(5-propan-2-yl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl]cyclopropanecarboxamide
DMGDZLP ID DMGDZLP
DMGDZLP DN US10022354, Example 152
DMGDZLP HS Patented
DMGDZLP SN CHEMBL4059597; SCHEMBL17682668; BDBM281212; US10022354, Example 152
DMGDZLP DT Small molecular drug
DMGDZLP PC 121279737
DMGDZLP MW 304.39
DMGDZLP FM C16H24N4O2
DMGDZLP IC InChI=1S/C16H24N4O2/c1-10(2)13-8-14(19-18-13)16(22)20-7-6-12(9-20)17-15(21)11-4-3-5-11/h8,10-12H,3-7,9H2,1-2H3,(H,17,21)(H,18,19)
DMGDZLP CS CC(C)C1=CC(=NN1)C(=O)N2CCC(C2)NC(=O)C3CCC3
DMGDZLP IK WFZQSICPYNAMNU-UHFFFAOYSA-N
DMGDZLP IU N-[1-(5-propan-2-yl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl]cyclobutanecarboxamide
DMIAGPX ID DMIAGPX
DMIAGPX DN US10022354, Example 5
DMIAGPX HS Patented
DMIAGPX SN SCHEMBL17682496; CHEMBL4062756; US10022354, Example 5; BDBM281065
DMIAGPX DT Small molecular drug
DMIAGPX PC 121279569
DMIAGPX MW 369.5
DMIAGPX FM C20H27N5O2
DMIAGPX IC InChI=1S/C20H27N5O2/c1-12(2)16-10-18(23-22-16)20(27)25-7-6-14(11-25)17-9-15(8-13(3)21-17)19(26)24(4)5/h8-10,12,14H,6-7,11H2,1-5H3,(H,22,23)
DMIAGPX CS CC1=CC(=CC(=N1)C2CCN(C2)C(=O)C3=NNC(=C3)C(C)C)C(=O)N(C)C
DMIAGPX IK YAVZAMCCDJRPBX-UHFFFAOYSA-N
DMIAGPX IU N,N,2-trimethyl-6-[1-(5-propan-2-yl-1H-pyrazole-3-carbonyl)pyrrolidin-3-yl]pyridine-4-carboxamide
DMU21PD ID DMU21PD
DMU21PD DN US10023583, Example 13
DMU21PD HS Patented
DMU21PD SN SCHEMBL19774049; BDBM284941; US10023583, Example 13
DMU21PD DT Small molecular drug
DMU21PD PC 134172650
DMU21PD MW 392.5
DMU21PD FM C20H28N2O4S
DMU21PD IC InChI=1S/C20H28N2O4S/c1-2-9-27-12-18(21)20(25,19(23)24)11-16-15-10-14(6-5-13-3-4-13)26-17(15)7-8-22-16/h7-8,10,13,18,25H,2-6,9,11-12,21H2,1H3,(H,23,24)/t18-,20+/m0/s1
DMU21PD CS CCCSC[C@@H]([C@](CC1=NC=CC2=C1C=C(O2)CCC3CC3)(C(=O)O)O)N
DMU21PD IK ZJHMLTXEBYSRTJ-AZUAARDMSA-N
DMU21PD IU (2R,3R)-3-amino-2-[[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl]-2-hydroxy-4-propylsulfanylbutanoic acid
DM5LK6O ID DM5LK6O
DM5LK6O DN US10023583, Example 24
DM5LK6O HS Patented
DM5LK6O SN SCHEMBL19774043; BDBM284952; US10023583, Example 24
DM5LK6O DT Small molecular drug
DM5LK6O PC 134172644
DM5LK6O MW 406.5
DM5LK6O FM C21H30N2O4S
DM5LK6O IC InChI=1S/C21H30N2O4S/c1-13(2)11-28-12-19(22)21(26,20(24)25)10-17-16-9-15(6-5-14-3-4-14)27-18(16)7-8-23-17/h7-9,13-14,19,26H,3-6,10-12,22H2,1-2H3,(H,24,25)/t19-,21+/m0/s1
DM5LK6O CS CC(C)CSC[C@@H]([C@](CC1=NC=CC2=C1C=C(O2)CCC3CC3)(C(=O)O)O)N
DM5LK6O IK HMDRAHWGUKKPQA-PZJWPPBQSA-N
DM5LK6O IU (2R,3R)-3-amino-2-[[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl]-2-hydroxy-4-(2-methylpropylsulfanyl)butanoic acid
DMZR10T ID DMZR10T
DMZR10T DN US10023583, Example 5
DMZR10T HS Patented
DMZR10T SN SCHEMBL19774051; US10023583, Example 5; BDBM284932
DMZR10T DT Small molecular drug
DMZR10T PC 134172652
DMZR10T MW 378.5
DMZR10T FM C19H26N2O4S
DMZR10T IC InChI=1S/C19H26N2O4S/c1-24-18(22)19(23,17(20)11-26-2)10-15-14-9-13(6-5-12-3-4-12)25-16(14)7-8-21-15/h7-9,12,17,23H,3-6,10-11,20H2,1-2H3/t17-,19+/m0/s1
DMZR10T CS COC(=O)[C@@](CC1=NC=CC2=C1C=C(O2)CCC3CC3)([C@H](CSC)N)O
DMZR10T IK GTBZNNHYIZEBEO-PKOBYXMFSA-N
DMZR10T IU methyl (2R,3R)-3-amino-2-[[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl]-2-hydroxy-4-methylsulfanylbutanoate
DM40KU8 ID DM40KU8
DM40KU8 DN US10023583, Example 8
DM40KU8 HS Patented
DM40KU8 SN SCHEMBL19774240; US10023583, Example 8; BDBM284936
DM40KU8 DT Small molecular drug
DM40KU8 PC 134172826
DM40KU8 MW 368.5
DM40KU8 FM C17H24N2O3S2
DM40KU8 IC InChI=1S/C17H24N2O3S2/c1-3-4-5-11-8-12-13(19-7-6-14(12)24-11)9-17(22,16(20)21)15(18)10-23-2/h6-8,15,22H,3-5,9-10,18H2,1-2H3,(H,20,21)/t15-,17+/m0/s1
DM40KU8 CS CCCCC1=CC2=C(S1)C=CN=C2C[C@@]([C@H](CSC)N)(C(=O)O)O
DM40KU8 IK DBCFIUMQYJLFBC-DOTOQJQBSA-N
DM40KU8 IU (2R,3R)-3-amino-2-[(2-butylthieno[3,2-c]pyridin-4-yl)methyl]-2-hydroxy-4-methylsulfanylbutanoic acid
DMG4T13 ID DMG4T13
DMG4T13 DN US10030004, Compound 11a
DMG4T13 HS Patented
DMG4T13 SN SCHEMBL18205771; BDBM280344; US10030004, Compound 11a; Synthesis of (S)-4-(2-(5-chloro-2-fluorophenyl)-5-ethylpyridin-4-ylamino)-N-(2-hydroxy propyl)nicotinamide
DMG4T13 DT Small molecular drug
DMG4T13 PC 91820701
DMG4T13 MW 428.9
DMG4T13 FM C22H22ClFN4O2
DMG4T13 IC InChI=1S/C22H22ClFN4O2/c1-3-14-11-26-21(16-8-15(23)4-5-18(16)24)9-20(14)28-19-6-7-25-12-17(19)22(30)27-10-13(2)29/h4-9,11-13,29H,3,10H2,1-2H3,(H,27,30)(H,25,26,28)/t13-/m0/s1
DMG4T13 CS CCC1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC[C@H](C)O)C3=C(C=CC(=C3)Cl)F
DMG4T13 IK OGPVQKHTKOAKDQ-ZDUSSCGKSA-N
DMG4T13 IU 4-[[2-(5-chloro-2-fluorophenyl)-5-ethylpyridin-4-yl]amino]-N-[(2S)-2-hydroxypropyl]pyridine-3-carboxamide
DM0RAPC ID DM0RAPC
DM0RAPC DN US10030004, Compound 19
DM0RAPC HS Patented
DM0RAPC SN SCHEMBL16879133; BDBM280352; US10030004, Compound 19; Synthesis of N-(2-aminoethyl)-4-[[2-(5-chloro-2-fluoro-phenyl)-5-isopropyl-4-pyridyl]amino]pyridine-3-carboxamide
DM0RAPC DT Small molecular drug
DM0RAPC PC 118211014
DM0RAPC MW 528
DM0RAPC FM C27H31ClFN5O3
DM0RAPC IC InChI=1S/C27H31ClFN5O3/c1-16(2)19-15-33-23(18-12-17(28)6-7-21(18)29)13-24(19)34-22-8-9-30-14-20(22)25(35)31-10-11-32-26(36)37-27(3,4)5/h6-9,12-16H,10-11H2,1-5H3,(H,31,35)(H,32,36)(H,30,33,34)
DM0RAPC CS CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NCCNC(=O)OC(C)(C)C)C3=C(C=CC(=C3)Cl)F
DM0RAPC IK NUVPAWNZKYSCFY-UHFFFAOYSA-N
DM0RAPC IU tert-butyl N-[2-[[4-[[2-(5-chloro-2-fluorophenyl)-5-propan-2-ylpyridin-4-yl]amino]pyridine-3-carbonyl]amino]ethyl]carbamate
DMD0GN6 ID DMD0GN6
DMD0GN6 DN US10030004, Compound 33
DMD0GN6 HS Patented
DMD0GN6 SN SCHEMBL16879197; BDBM280367; US10030004, Compound 33; Synthesis of 4-{[2-(5-chloro-2-fluorophenyl)-5-(pyrrolidin-1-yl)pyridin-4-yl]amino}-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide
DMD0GN6 DT Small molecular drug
DMD0GN6 PC 118211070
DMD0GN6 MW 485.9
DMD0GN6 FM C24H25ClFN5O3
DMD0GN6 IC InChI=1S/C24H25ClFN5O3/c25-15-3-4-19(26)17(9-15)21-10-22(23(12-28-21)31-7-1-2-8-31)30-20-5-6-27-11-18(20)24(34)29-16(13-32)14-33/h3-6,9-12,16,32-33H,1-2,7-8,13-14H2,(H,29,34)(H,27,28,30)
DMD0GN6 CS C1CCN(C1)C2=CN=C(C=C2NC3=C(C=NC=C3)C(=O)NC(CO)CO)C4=C(C=CC(=C4)Cl)F
DMD0GN6 IK FDMRIXRWLAMVEF-UHFFFAOYSA-N
DMD0GN6 IU 4-[[2-(5-chloro-2-fluorophenyl)-5-pyrrolidin-1-ylpyridin-4-yl]amino]-N-(1,3-dihydroxypropan-2-yl)pyridine-3-carboxamide
DMLJV01 ID DMLJV01
DMLJV01 DN US10034861, Example 1
DMLJV01 HS Patented
DMLJV01 SN SCHEMBL19762512; US10034861, Example 1; BDBM278971; 5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]pyrazolo[4,3-b]pyridin-7-amine
DMLJV01 DT Small molecular drug
DMLJV01 PC 132273299
DMLJV01 MW 407.5
DMLJV01 FM C21H25N7O2
DMLJV01 IC InChI=1S/C21H25N7O2/c1-6-29-21-15(8-7-9-22-21)16-10-17(23-11-18-26-25-14(5)30-18)20-19(24-16)13(4)27-28(20)12(2)3/h7-10,12H,6,11H2,1-5H3,(H,23,24)
DMLJV01 CS CCOC1=C(C=CC=N1)C2=NC3=C(C(=C2)NCC4=NN=C(O4)C)N(N=C3C)C(C)C
DMLJV01 IK XEBJMVLHZBRKST-UHFFFAOYSA-N
DMLJV01 IU 5-(2-ethoxypyridin-3-yl)-3-methyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]-1-propan-2-ylpyrazolo[4,3-b]pyridin-7-amine
DM27SFD ID DM27SFD
DM27SFD DN US10034861, Example 164
DM27SFD HS Patented
DM27SFD SN SCHEMBL19762485; BDBM279133; US10034861, Example 164; 5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-7-[(1-methylpyrazol-4-yl)methylsulfanyl]pyrazolo[4,3-b]pyridine
DM27SFD DT Small molecular drug
DM27SFD PC 132273278
DM27SFD MW 456.6
DM27SFD FM C24H32N4O3S
DM27SFD IC InChI=1S/C24H32N4O3S/c1-7-30-24-18(9-8-11-25-24)19-13-20(32-12-10-21(29)31-14-15(2)3)23-22(26-19)17(6)27-28(23)16(4)5/h8-9,11,13,15-16H,7,10,12,14H2,1-6H3
DM27SFD CS CCOC1=C(C=CC=N1)C2=NC3=C(C(=C2)SCCC(=O)OCC(C)C)N(N=C3C)C(C)C
DM27SFD IK HVDCJFCTBUPVCE-UHFFFAOYSA-N
DM27SFD IU 2-methylpropyl 3-[5-(2-ethoxypyridin-3-yl)-3-methyl-1-propan-2-ylpyrazolo[4,3-b]pyridin-7-yl]sulfanylpropanoate
DMD8FS5 ID DMD8FS5
DMD8FS5 DN US10034861, Example 165
DMD8FS5 HS Patented
DMD8FS5 SN SCHEMBL19762492; BDBM279134; US10034861, Example 165; N-[[1-(difluoromethyl)pyrazol-4-yl]methyl]-5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-pyrazolo[4,3-b]pyridin-7-amine
DMD8FS5 DT Small molecular drug
DMD8FS5 PC 132273284
DMD8FS5 MW 561.6
DMD8FS5 FM C30H33F2N7O2
DMD8FS5 IC InChI=1S/C30H33F2N7O2/c1-6-41-29-24(8-7-13-33-29)25-14-26(28-27(35-25)20(4)36-39(28)19(2)3)37(16-21-9-11-23(40-5)12-10-21)17-22-15-34-38(18-22)30(31)32/h7-15,18-19,30H,6,16-17H2,1-5H3
DMD8FS5 CS CCOC1=C(C=CC=N1)C2=NC3=C(C(=C2)N(CC4=CC=C(C=C4)OC)CC5=CN(N=C5)C(F)F)N(N=C3C)C(C)C
DMD8FS5 IK UXTFTMXAFOTATJ-UHFFFAOYSA-N
DMD8FS5 IU N-[[1-(difluoromethyl)pyrazol-4-yl]methyl]-5-(2-ethoxypyridin-3-yl)-N-[(4-methoxyphenyl)methyl]-3-methyl-1-propan-2-ylpyrazolo[4,3-b]pyridin-7-amine
DM28XHN ID DM28XHN
DM28XHN DN US10035778, Example 1
DM28XHN HS Patented
DM28XHN SN SCHEMBL19067133; US10035778, Example 1; BDBM279560; Preparation of (3S)-3-(3,5-dibromophenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
DM28XHN DT Small molecular drug
DM28XHN PC 130177146
DM28XHN MW 613.3
DM28XHN FM C22H23Br2N5O6
DM28XHN IC InChI=1S/C22H23Br2N5O6/c23-13-1-11(2-14(24)5-13)18(7-20(33)34)29-19(32)10-25-21(35)12-3-15(6-16(30)4-12)28-22-26-8-17(31)9-27-22/h1-6,17-18,30-31H,7-10H2,(H,25,35)(H,29,32)(H,33,34)(H2,26,27,28)/t18-/m0/s1
DM28XHN CS C1C(CN=C(N1)NC2=CC(=CC(=C2)C(=O)NCC(=O)N[C@@H](CC(=O)O)C3=CC(=CC(=C3)Br)Br)O)O
DM28XHN IK BWAUVRFZNDRMLY-SFHVURJKSA-N
DM28XHN IU (3S)-3-(3,5-dibromophenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid
DMBN6W2 ID DMBN6W2
DMBN6W2 DN US10035778, Example 12
DMBN6W2 HS Patented
DMBN6W2 SN SCHEMBL19067109; BDBM279571; US10035778, Example 12; Preparation of (3S)-3-[3-chloro-5-methyl-phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
DMBN6W2 DT Small molecular drug
DMBN6W2 PC 130177126
DMBN6W2 MW 503.9
DMBN6W2 FM C23H26ClN5O6
DMBN6W2 IC InChI=1S/C23H26ClN5O6/c1-12-2-13(4-15(24)3-12)19(8-21(33)34)29-20(32)11-25-22(35)14-5-16(7-17(30)6-14)28-23-26-9-18(31)10-27-23/h2-7,18-19,30-31H,8-11H2,1H3,(H,25,35)(H,29,32)(H,33,34)(H2,26,27,28)/t19-/m0/s1
DMBN6W2 CS CC1=CC(=CC(=C1)Cl)[C@H](CC(=O)O)NC(=O)CNC(=O)C2=CC(=CC(=C2)O)NC3=NCC(CN3)O
DMBN6W2 IK UCBYYQWMMNUSGH-IBGZPJMESA-N
DMBN6W2 IU (3S)-3-(3-chloro-5-methylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid
DMJ53DR ID DMJ53DR
DMJ53DR DN US10035778, Example 16
DMJ53DR HS Patented
DMJ53DR SN SCHEMBL19067135; BDBM279575; US10035778, Example 16; Preparation of (3S)-3-[3-chloro-5-(trifluoromethoxy)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid
DMJ53DR DT Small molecular drug
DMJ53DR PC 130177149
DMJ53DR MW 573.9
DMJ53DR FM C23H23ClF3N5O7
DMJ53DR IC InChI=1S/C23H23ClF3N5O7/c24-13-1-11(4-17(5-13)39-23(25,26)27)18(7-20(36)37)32-19(35)10-28-21(38)12-2-14(6-15(33)3-12)31-22-29-8-16(34)9-30-22/h1-6,16,18,33-34H,7-10H2,(H,28,38)(H,32,35)(H,36,37)(H2,29,30,31)/t18-/m0/s1
DMJ53DR CS C1C(CN=C(N1)NC2=CC(=CC(=C2)C(=O)NCC(=O)N[C@@H](CC(=O)O)C3=CC(=CC(=C3)Cl)OC(F)(F)F)O)O
DMJ53DR IK BQYBIJDRTDZCAJ-SFHVURJKSA-N
DMJ53DR IU (3S)-3-[3-chloro-5-(trifluoromethoxy)phenyl]-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid
DMLMV1Y ID DMLMV1Y
DMLMV1Y DN US10040779, Example 1
DMLMV1Y HS Patented
DMLMV1Y SN SCHEMBL15792304; US10040779, Example 1; BDBM277704; 3-[(1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid
DMLMV1Y DT Small molecular drug
DMLMV1Y PC 76282043
DMLMV1Y MW 268.27
DMLMV1Y FM C14H12N4O2
DMLMV1Y IC InChI=1S/C14H12N4O2/c1-18-12-5-3-2-4-10(12)13(17-18)16-11-8-15-7-6-9(11)14(19)20/h2-8H,1H3,(H,16,17)(H,19,20)
DMLMV1Y CS CN1C2=CC=CC=C2C(=N1)NC3=C(C=CN=C3)C(=O)O
DMLMV1Y IK CPZUCKVTDNNRCJ-UHFFFAOYSA-N
DMLMV1Y IU 3-[(1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid
DMWDGCH ID DMWDGCH
DMWDGCH DN US10040779, Example 4
DMWDGCH HS Patented
DMWDGCH SN SCHEMBL15792083; US10040779, Example 4; BDBM277707; 3-[(5-chloro-1-methyl-1H-indazol-3-yl)amino]pyridine-4-carboxylic acid
DMWDGCH DT Small molecular drug
DMWDGCH PC 75202257
DMWDGCH MW 302.71
DMWDGCH FM C14H11ClN4O2
DMWDGCH IC InChI=1S/C14H11ClN4O2/c1-19-12-3-2-8(15)6-10(12)13(18-19)17-11-7-16-5-4-9(11)14(20)21/h2-7H,1H3,(H,17,18)(H,20,21)
DMWDGCH CS CN1C2=C(C=C(C=C2)Cl)C(=N1)NC3=C(C=CN=C3)C(=O)O
DMWDGCH IK TXMBUJQSVXBAFZ-UHFFFAOYSA-N
DMWDGCH IU 3-[(5-chloro-1-methylindazol-3-yl)amino]pyridine-4-carboxylic acid
DMPM8VB ID DMPM8VB
DMPM8VB DN US10053465, 12
DMPM8VB HS Patented
DMPM8VB SN SCHEMBL9894097; SCHEMBL9927070; SCHEMBL9894098; BDBM246873; US10053465, 12; {trans-3-(4-{[4- {[(2S)-2- (hydroxymethyl) pyrrolidin-1-yl] methyl}-6- (trifluoromethyl) pyridin-2- yl]oxy}piperidin-1- yl)-1-[4-(7H- pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]cyclobutyl} acetonitrile
DMPM8VB DT Small molecular drug
DMPM8VB PC 67954458
DMPM8VB MW 635.7
DMPM8VB FM C32H36F3N9O2
DMPM8VB IC InChI=1S/C32H36F3N9O2/c33-32(34,35)27-12-21(17-43-9-1-2-23(43)19-45)13-28(41-27)46-25-4-10-42(11-5-25)24-14-31(15-24,6-7-36)44-18-22(16-40-44)29-26-3-8-37-30(26)39-20-38-29/h3,8,12-13,16,18,20,23-25,45H,1-2,4-6,9-11,14-15,17,19H2,(H,37,38,39)/t23-,24?,31?/m0/s1
DMPM8VB CS C1C[C@H](N(C1)CC2=CC(=NC(=C2)OC3CCN(CC3)C4CC(C4)(CC#N)N5C=C(C=N5)C6=C7C=CNC7=NC=N6)C(F)(F)F)CO
DMPM8VB IK WQXUGBZSZWSUTM-VVTYCJQISA-N
DMPM8VB IU 2-[3-[4-[4-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-1-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclobutyl]acetonitrile
DMV7BF2 ID DMV7BF2
DMV7BF2 DN US10053465, 5
DMV7BF2 HS Patented
DMV7BF2 SN SCHEMBL12780151; BDBM246866; US10053465, 5; 4-[(4-{3-cyano-2-[4- (7H-pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]propyl}piperazin- 1-yl)carbonyl]-3- fluorobenzonitrile
DMV7BF2 DT Small molecular drug
DMV7BF2 PC 58180930
DMV7BF2 MW 483.5
DMV7BF2 FM C25H22FN9O
DMV7BF2 IC InChI=1S/C25H22FN9O/c1-28-18-2-3-20(22(26)12-18)25(36)34-10-8-33(9-11-34)15-19(4-6-27)35-14-17(13-32-35)23-21-5-7-29-24(21)31-16-30-23/h2-3,5,7,12-14,16,19H,4,8-11,15H2,(H,29,30,31)
DMV7BF2 CS [C-]#[N+]C1=CC(=C(C=C1)C(=O)N2CCN(CC2)CC(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)F
DMV7BF2 IK VCJFOLMEZCAWFO-UHFFFAOYSA-N
DMV7BF2 IU 4-[4-(2-fluoro-4-isocyanobenzoyl)piperazin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]butanenitrile
DM42XWO ID DM42XWO
DM42XWO DN US10053465, 8
DM42XWO HS Patented
DM42XWO SN SCHEMBL2395720; CHEMBL3911726; RZUCZMLSGAQMJN-UHFFFAOYSA-N; BDBM246869; US10053465, 8; 4-{3-(Cyanomethyl)- 3-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)- 1H-pyrazol-1- yl]azetidin-1-yl}-N- [4-fluoro-2- (trifluoromethyl) phenyl]piperidine-1- carboxamide; 4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DM42XWO DT Small molecular drug
DM42XWO PC 58431300
DM42XWO MW 567.5
DM42XWO FM C27H25F4N9O
DM42XWO IC InChI=1S/C27H25F4N9O/c28-18-1-2-22(21(11-18)27(29,30)31)37-25(41)38-9-4-19(5-10-38)39-14-26(15-39,6-7-32)40-13-17(12-36-40)23-20-3-8-33-24(20)35-16-34-23/h1-3,8,11-13,16,19H,4-6,9-10,14-15H2,(H,37,41)(H,33,34,35)
DM42XWO CS C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)NC6=C(C=C(C=C6)F)C(F)(F)F
DM42XWO IK RZUCZMLSGAQMJN-UHFFFAOYSA-N
DM42XWO IU 4-[3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-1-yl]-N-[4-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DMBD95S ID DMBD95S
DMBD95S DN US10059720, Example 80
DMBD95S HS Patented
DMBD95S SN SCHEMBL17303615; BDBM271265; US10059720, Example 80
DMBD95S DT Small molecular drug
DMBD95S PC 118549471
DMBD95S MW 416.5
DMBD95S FM C21H28N4O5
DMBD95S IC InChI=1S/C21H28N4O5/c1-14-2-4-16(5-3-14)30-17-6-7-24-15(10-17)11-21(28,20(26)27)18(22)13-29-19-12-23-8-9-25-19/h6-10,12,14,16,18,28H,2-5,11,13,22H2,1H3,(H,26,27)/t14?,16?,18-,21+/m0/s1
DMBD95S CS CC1CCC(CC1)OC2=CC(=NC=C2)C[C@@]([C@H](COC3=NC=CN=C3)N)(C(=O)O)O
DMBD95S IK GDORSLXMLRLKBT-MAQYLPRKSA-N
DMBD95S IU (2R,3S)-3-amino-2-hydroxy-2-[[4-(4-methylcyclohexyl)oxypyridin-2-yl]methyl]-4-pyrazin-2-yloxybutanoic acid
DMJ6GU9 ID DMJ6GU9
DMJ6GU9 DN US10059720, Example 82
DMJ6GU9 HS Patented
DMJ6GU9 SN SCHEMBL17303611; BDBM271267; US10059720, Example 82
DMJ6GU9 DT Small molecular drug
DMJ6GU9 PC 118549467
DMJ6GU9 MW 350.5
DMJ6GU9 FM C19H30N2O4
DMJ6GU9 IC InChI=1S/C19H30N2O4/c1-12(2)8-17(20)19(24,18(22)23)11-15-10-16(6-7-21-15)25-13(3)9-14-4-5-14/h6-7,10,12-14,17,24H,4-5,8-9,11,20H2,1-3H3,(H,22,23)/t13-,17+,19-/m1/s1
DMJ6GU9 CS C[C@H](CC1CC1)OC2=CC(=NC=C2)C[C@@]([C@H](CC(C)C)N)(C(=O)O)O
DMJ6GU9 IK YLKHAUHZCVMCJX-XVGQJIODSA-N
DMJ6GU9 IU (2R,3S)-3-amino-2-[[4-[(2R)-1-cyclopropylpropan-2-yl]oxypyridin-2-yl]methyl]-2-hydroxy-5-methylhexanoic acid
DMKLVE4 ID DMKLVE4
DMKLVE4 DN US10059720, Example 84
DMKLVE4 HS Patented
DMKLVE4 SN SCHEMBL17303614; BDBM271269; US10059720, Example 84
DMKLVE4 DT Small molecular drug
DMKLVE4 PC 118549470
DMKLVE4 MW 433.5
DMKLVE4 FM C22H28FN3O5
DMKLVE4 IC InChI=1S/C22H28FN3O5/c1-14-2-5-17(6-3-14)31-18-8-9-25-16(10-18)11-22(29,21(27)28)19(24)13-30-20-7-4-15(23)12-26-20/h4,7-10,12,14,17,19,29H,2-3,5-6,11,13,24H2,1H3,(H,27,28)/t14?,17?,19-,22+/m0/s1
DMKLVE4 CS CC1CCC(CC1)OC2=CC(=NC=C2)C[C@@]([C@H](COC3=NC=C(C=C3)F)N)(C(=O)O)O
DMKLVE4 IK AOFAGXGTSSPBTM-UCQMRJNNSA-N
DMKLVE4 IU (2R,3S)-3-amino-4-(5-fluoropyridin-2-yl)oxy-2-hydroxy-2-[[4-(4-methylcyclohexyl)oxypyridin-2-yl]methyl]butanoic acid
DMBWJK4 ID DMBWJK4
DMBWJK4 DN US10065972, Example 281
DMBWJK4 HS Patented
DMBWJK4 SN SCHEMBL18335781; BDBM273097; US10065972, Example 281; (R)-N-benzyl-1-(5-difluoromethyl-6-methyl-7-oxo-6,7-dihydro-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide
DMBWJK4 DT Small molecular drug
DMBWJK4 PC 124152707
DMBWJK4 MW 419.5
DMBWJK4 FM C19H19F2N5O2S
DMBWJK4 IC InChI=1S/C19H19F2N5O2S/c1-25-15(14(20)21)24-17-13(18(25)28)23-19(29-17)26-9-5-8-12(26)16(27)22-10-11-6-3-2-4-7-11/h2-4,6-7,12,14H,5,8-10H2,1H3,(H,22,27)/t12-/m1/s1
DMBWJK4 CS CN1C(=O)C2=C(N=C1C(F)F)SC(=N2)N3CCC[C@@H]3C(=O)NCC4=CC=CC=C4
DMBWJK4 IK VIBFDLHDQBMSOA-GFCCVEGCSA-N
DMBWJK4 IU (2R)-N-benzyl-1-[5-(difluoromethyl)-6-methyl-7-oxo-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
DMT8WVZ ID DMT8WVZ
DMT8WVZ DN US10065972, Example 396
DMT8WVZ HS Patented
DMT8WVZ SN SCHEMBL18335771; BDBM273125; US10065972, Example 396; (R)-N-benzyl-1-[6-(2-hydroxyethyl)-7-oxo-5-trifluoromethyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
DMT8WVZ DT Small molecular drug
DMT8WVZ PC 124152697
DMT8WVZ MW 467.5
DMT8WVZ FM C20H20F3N5O3S
DMT8WVZ IC InChI=1S/C20H20F3N5O3S/c21-20(22,23)18-26-16-14(17(31)28(18)9-10-29)25-19(32-16)27-8-4-7-13(27)15(30)24-11-12-5-2-1-3-6-12/h1-3,5-6,13,29H,4,7-11H2,(H,24,30)/t13-/m1/s1
DMT8WVZ CS C1C[C@@H](N(C1)C2=NC3=C(S2)N=C(N(C3=O)CCO)C(F)(F)F)C(=O)NCC4=CC=CC=C4
DMT8WVZ IK SXQHHSSAGQUGBT-CYBMUJFWSA-N
DMT8WVZ IU (2R)-N-benzyl-1-[6-(2-hydroxyethyl)-7-oxo-5-(trifluoromethyl)-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide
DM9QCTJ ID DM9QCTJ
DM9QCTJ DN US10065972, Example 560
DM9QCTJ HS Patented
DM9QCTJ SN SCHEMBL18336240; BDBM273119; BDBM273144; BDBM273143; BDBM273093; BDBM273070; US10065972, Example 560; US10065972, Example 265; US10065972, Example 559; US10065972, Example 178; US10065972, Example 347; N-[dideuterio(phenyl)methyl]-1-[7-oxo-5-phenyl-6-(trideuteriomethyl)-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl]pyrrolidine-2-carboxamide; (R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-6,7-dihydro[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide; (R)-N-benzyl-1-[6-methyl-7-oxo-5-(2,3,4,5,6-pentadeuteriophenyl)-6,7
DM9QCTJ DT Small molecular drug
DM9QCTJ PC 92045015
DM9QCTJ MW 445.5
DM9QCTJ FM C24H23N5O2S
DM9QCTJ IC InChI=1S/C24H23N5O2S/c1-28-20(17-11-6-3-7-12-17)27-22-19(23(28)31)26-24(32-22)29-14-8-13-18(29)21(30)25-15-16-9-4-2-5-10-16/h2-7,9-12,18H,8,13-15H2,1H3,(H,25,30)/t18-/m1/s1
DM9QCTJ CS CN1C(=NC2=C(C1=O)N=C(S2)N3CCC[C@@H]3C(=O)NCC4=CC=CC=C4)C5=CC=CC=C5
DM9QCTJ IK LYGQOCVESZDBMV-GOSISDBHSA-N
DM9QCTJ IU (2R)-N-benzyl-1-(6-methyl-7-oxo-5-phenyl-[1,3]thiazolo[5,4-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide
DM95YLX ID DM95YLX
DM95YLX DN US10071110, Compound cCDV
DM95YLX HS Patented
DM95YLX SN SCHEMBL2380283; BDBM275768; US10071110, Compound cCDV; US10071110, Compound Cyclic Cidofovir (cDCV)
DM95YLX DT Small molecular drug
DM95YLX PC 18914028
DM95YLX MW 261.17
DM95YLX FM C8H12N3O5P
DM95YLX IC InChI=1S/C8H12N3O5P/c9-7-1-2-11(8(12)10-7)3-6-4-16-17(13,14)5-15-6/h1-2,6H,3-5H2,(H,13,14)(H2,9,10,12)
DM95YLX CS C1C(OCP(=O)(O1)O)CN2C=CC(=NC2=O)N
DM95YLX IK YXQUGSXUDFTPLL-UHFFFAOYSA-N
DM95YLX IU 4-amino-1-[(2-hydroxy-2-oxo-1,4,2lambda5-dioxaphosphinan-5-yl)methyl]pyrimidin-2-one
DMOZ84C ID DMOZ84C
DMOZ84C DN US10077269, Example 6
DMOZ84C HS Patented
DMOZ84C SN SCHEMBL17492361; US10077269, Example 6; KZFDLYSKEWBCTB-UHFFFAOYSA-N; BDBM285533; N-Cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazo[1,2-b]pyridazine-2-carboxamide (6); N-Cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl )imidazo[1,2-b]pyridazine-2-carboxamide
DMOZ84C DT Small molecular drug
DMOZ84C PC 118863057
DMOZ84C MW 319.32
DMOZ84C FM C16H13N7O
DMOZ84C IC InChI=1S/C16H13N7O/c24-16(20-11-4-5-11)14-15(23-13(21-14)2-1-7-18-23)10-3-6-12-17-9-19-22(12)8-10/h1-3,6-9,11H,4-5H2,(H,20,24)
DMOZ84C CS C1CC1NC(=O)C2=C(N3C(=N2)C=CC=N3)C4=CN5C(=NC=N5)C=C4
DMOZ84C IK KZFDLYSKEWBCTB-UHFFFAOYSA-N
DMOZ84C IU N-cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazo[1,2-b]pyridazine-2-carboxamide
DM3BDHN ID DM3BDHN
DM3BDHN DN US10081632, Compound 25
DM3BDHN HS Patented
DM3BDHN SN SCHEMBL19252896; BDBM286094; US10081632, Compound 25; Synthesis of (R) inverted question markN-(1-(4-aminobenzyl)-1H-pyrazol-4-yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide hydrochloride salt
DM3BDHN DT Small molecular drug
DM3BDHN PC 130338820
DM3BDHN MW 415.4
DM3BDHN FM C22H21N7O2
DM3BDHN IC InChI=1S/C22H21N7O2/c1-13-9-24-22(31)19-8-15-4-7-18(27-20(15)29(13)19)21(30)26-17-10-25-28(12-17)11-14-2-5-16(23)6-3-14/h2-8,10,12-13H,9,11,23H2,1H3,(H,24,31)(H,26,30)/t13-/m1/s1
DM3BDHN CS C[C@@H]1CNC(=O)C2=CC3=C(N12)N=C(C=C3)C(=O)NC4=CN(N=C4)CC5=CC=C(C=C5)N
DM3BDHN IK IBOJVZMIACTCIV-CYBMUJFWSA-N
DM3BDHN IU (13R)-N-[1-[(4-aminophenyl)methyl]pyrazol-4-yl]-13-methyl-10-oxo-1,3,11-triazatricyclo[7.4.0.02,7]trideca-2(7),3,5,8-tetraene-4-carboxamide
DMM6WAB ID DMM6WAB
DMM6WAB DN US10087167, Compound 3002
DMM6WAB HS Patented
DMM6WAB SN SCHEMBL18034174; BDBM287988; US10087167, Compound 3002
DMM6WAB DT Small molecular drug
DMM6WAB PC 122503924
DMM6WAB MW 703.8
DMM6WAB FM C36H38FN5O7S
DMM6WAB IC InChI=1S/C36H38FN5O7S/c1-7-42(50(6,46)47)29-19-30-28(31(33(43)39-5)32(48-30)22-11-13-25(37)14-12-22)18-27(29)23-9-8-10-24(17-23)34(44)41-16-15-40(21-26(41)20-38)35(45)49-36(2,3)4/h8-14,17-19,26H,7,15-16,21H2,1-6H3,(H,39,43)/t26-/m1/s1
DMM6WAB CS CCN(C1=C(C=C2C(=C1)OC(=C2C(=O)NC)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C(=O)N5CCN(C[C@H]5C#N)C(=O)OC(C)(C)C)S(=O)(=O)C
DMM6WAB IK MBGMGMOYLOFWNU-AREMUKBSSA-N
DMM6WAB IU tert-butyl (3S)-3-cyano-4-[3-[6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-5-yl]benzoyl]piperazine-1-carboxylate
DMITOY6 ID DMITOY6
DMITOY6 DN US10087167, Compound 3003
DMITOY6 HS Patented
DMITOY6 SN SCHEMBL18034173; BDBM287989; US10087167, Compound 3003
DMITOY6 DT Small molecular drug
DMITOY6 PC 122503923
DMITOY6 MW 681.8
DMITOY6 FM C32H32FN5O7S2
DMITOY6 IC InChI=1S/C32H32FN5O7S2/c1-5-37(46(3,41)42)27-17-28-26(29(31(39)35-2)30(45-28)20-9-11-23(33)12-10-20)16-25(27)21-7-6-8-22(15-21)32(40)36-13-14-38(47(4,43)44)24(18-34)19-36/h6-12,15-17,24H,5,13-14,19H2,1-4H3,(H,35,39)
DMITOY6 CS CCN(C1=C(C=C2C(=C1)OC(=C2C(=O)NC)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C(=O)N5CCN(C(C5)C#N)S(=O)(=O)C)S(=O)(=O)C
DMITOY6 IK WEBAERCGMUCGLL-UHFFFAOYSA-N
DMITOY6 IU 5-[3-(3-cyano-4-methylsulfonylpiperazine-1-carbonyl)phenyl]-6-[ethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide
DMAP1DN ID DMAP1DN
DMAP1DN DN US10087167, Compound 4001
DMAP1DN HS Patented
DMAP1DN SN SCHEMBL18034175; BDBM287990; US10087167, Compound 4001
DMAP1DN DT Small molecular drug
DMAP1DN PC 122503925
DMAP1DN MW 692.7
DMAP1DN FM C32H29F5N4O6S
DMAP1DN IC InChI=1S/C32H29F5N4O6S/c1-38-29(42)27-24-17-23(20-4-3-5-21(16-20)30(43)39-12-14-40(15-13-39)31(44)32(35,36)37)25(41(11-10-33)48(2,45)46)18-26(24)47-28(27)19-6-8-22(34)9-7-19/h3-9,16-18H,10-15H2,1-2H3,(H,38,42)
DMAP1DN CS CNC(=O)C1=C(OC2=CC(=C(C=C21)C3=CC(=CC=C3)C(=O)N4CCN(CC4)C(=O)C(F)(F)F)N(CCF)S(=O)(=O)C)C5=CC=C(C=C5)F
DMAP1DN IK QALVUUHEMYLFBN-UHFFFAOYSA-N
DMAP1DN IU 6-[2-fluoroethyl(methylsulfonyl)amino]-2-(4-fluorophenyl)-N-methyl-5-[3-[4-(2,2,2-trifluoroacetyl)piperazine-1-carbonyl]phenyl]-1-benzofuran-3-carboxamide
DMU8CAD ID DMU8CAD
DMU8CAD DN US10092575, Example 101
DMU8CAD HS Patented
DMU8CAD SN SCHEMBL17225595; CHEMBL4068450; AXPVGJNPJSMCLA-UHFFFAOYSA-N; BDBM289613; US10092575, Example 101; 6-(4-Chlorobenzyl)-9-methyl-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 6-(4-Chlorobenzyl)-9-methyl-8,9,10,11-tetrahydropyrido[4'',3'':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one
DMU8CAD DT Small molecular drug
DMU8CAD PC 118485599
DMU8CAD MW 385.9
DMU8CAD FM C18H16ClN5OS
DMU8CAD IC InChI=1S/C18H16ClN5OS/c1-22-7-6-13-14(9-22)26-17-15(13)16-20-10-21-24(16)18(25)23(17)8-11-2-4-12(19)5-3-11/h2-5,10H,6-9H2,1H3
DMU8CAD CS CN1CCC2=C(C1)SC3=C2C4=NC=NN4C(=O)N3CC5=CC=C(C=C5)Cl
DMU8CAD IK AXPVGJNPJSMCLA-UHFFFAOYSA-N
DMU8CAD IU 8-[(4-chlorophenyl)methyl]-13-methyl-10-thia-3,5,6,8,13-pentazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one
DMT47DF ID DMT47DF
DMT47DF DN US10092575, Example 141
DMT47DF HS Patented
DMT47DF SN CHEMBL4067682; SCHEMBL17225636; BDBM289653; US10092575, Example 141; 6-(2-fluoro-4-methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one; 6-(2-Fluoro-4-methoxybenzyl)-9-((tetrahydro-2H-pyran-4-yl)methyl)-8,9,10,11-tetrahydropyrido[4'',3'':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5 (6H)-one
DMT47DF DT Small molecular drug
DMT47DF PC 72706254
DMT47DF MW 483.6
DMT47DF FM C24H26FN5O3S
DMT47DF IC InChI=1S/C24H26FN5O3S/c1-32-17-3-2-16(19(25)10-17)12-29-23-21(22-26-14-27-30(22)24(29)31)18-4-7-28(13-20(18)34-23)11-15-5-8-33-9-6-15/h2-3,10,14-15H,4-9,11-13H2,1H3
DMT47DF CS COC1=CC(=C(C=C1)CN2C3=C(C4=C(S3)CN(CC4)CC5CCOCC5)C6=NC=NN6C2=O)F
DMT47DF IK FOZFBBKUKXGMND-UHFFFAOYSA-N
DMT47DF IU 8-[(2-fluoro-4-methoxyphenyl)methyl]-13-(oxan-4-ylmethyl)-10-thia-3,5,6,8,13-pentazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one
DM7MNE2 ID DM7MNE2
DM7MNE2 DN US10092575, Example 158
DM7MNE2 HS Patented
DM7MNE2 SN CHEMBL4074038; SCHEMBL17225654; BDBM289669; US10092575, Example 158; 6-(4-Chlorobenzyl)-9-(cyclopropanecarbonyl)-8,9,10,11-tetrahydropyrido[4'',3'':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one
DM7MNE2 DT Small molecular drug
DM7MNE2 PC 118485649
DM7MNE2 MW 439.9
DM7MNE2 FM C21H18ClN5O2S
DM7MNE2 IC InChI=1S/C21H18ClN5O2S/c22-14-5-1-12(2-6-14)9-26-20-17(18-23-11-24-27(18)21(26)29)15-7-8-25(10-16(15)30-20)19(28)13-3-4-13/h1-2,5-6,11,13H,3-4,7-10H2
DM7MNE2 CS C1CC1C(=O)N2CCC3=C(C2)SC4=C3C5=NC=NN5C(=O)N4CC6=CC=C(C=C6)Cl
DM7MNE2 IK FYTZTJBBBNSPSE-UHFFFAOYSA-N
DM7MNE2 IU 8-[(4-chlorophenyl)methyl]-13-(cyclopropanecarbonyl)-10-thia-3,5,6,8,13-pentazatetracyclo[7.7.0.02,6.011,16]hexadeca-1(9),2,4,11(16)-tetraen-7-one
DMJKS4X ID DMJKS4X
DMJKS4X DN US10100051, Compound 1
DMJKS4X HS Patented
DMJKS4X SN SCHEMBL18122067; US10100051, Compound 1; BDBM292132; 2-(5-hydroxy-8-methyl-2-phenoxy-1,7-naphthyridine-6-formamido) acetic acid
DMJKS4X DT Small molecular drug
DMJKS4X PC 137094888
DMJKS4X MW 353.3
DMJKS4X FM C18H15N3O5
DMJKS4X IC InChI=1S/C18H15N3O5/c1-10-15-12(17(24)16(20-10)18(25)19-9-14(22)23)7-8-13(21-15)26-11-5-3-2-4-6-11/h2-8,24H,9H2,1H3,(H,19,25)(H,22,23)
DMJKS4X CS CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=CC=C3
DMJKS4X IK FMQZRTFVSFAASE-UHFFFAOYSA-N
DMJKS4X IU 2-[(5-hydroxy-8-methyl-2-phenoxy-1,7-naphthyridine-6-carbonyl)amino]acetic acid
DMQ7ODW ID DMQ7ODW
DMQ7ODW DN US10100051, Compound 10
DMQ7ODW HS Patented
DMQ7ODW SN SCHEMBL18122066; BDBM292141; US10100051, Compound 10; (2-(2-(4-bromophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
DMQ7ODW DT Small molecular drug
DMQ7ODW PC 137094887
DMQ7ODW MW 432.2
DMQ7ODW FM C18H14BrN3O5
DMQ7ODW IC InChI=1S/C18H14BrN3O5/c1-9-15-12(17(25)16(21-9)18(26)20-8-14(23)24)6-7-13(22-15)27-11-4-2-10(19)3-5-11/h2-7,25H,8H2,1H3,(H,20,26)(H,23,24)
DMQ7ODW CS CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=C(C=C3)Br
DMQ7ODW IK PKTKHEQNIDLMBW-UHFFFAOYSA-N
DMQ7ODW IU 2-[[2-(4-bromophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-carbonyl]amino]acetic acid
DM2DEOA ID DM2DEOA
DM2DEOA DN US10100051, Compound 11
DM2DEOA HS Patented
DM2DEOA SN SCHEMBL18122076; BDBM292142; US10100051, Compound 11; 2-(2-(3-(tert-butyl)phenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
DM2DEOA DT Small molecular drug
DM2DEOA PC 137094889
DM2DEOA MW 409.4
DM2DEOA FM C22H23N3O5
DM2DEOA IC InChI=1S/C22H23N3O5/c1-12-18-15(20(28)19(24-12)21(29)23-11-17(26)27)8-9-16(25-18)30-14-7-5-6-13(10-14)22(2,3)4/h5-10,28H,11H2,1-4H3,(H,23,29)(H,26,27)
DM2DEOA CS CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=CC(=C3)C(C)(C)C
DM2DEOA IK NYGCHYPUCCYURU-UHFFFAOYSA-N
DM2DEOA IU 2-[[2-(3-tert-butylphenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-carbonyl]amino]acetic acid
DMWESZ1 ID DMWESZ1
DMWESZ1 DN US10100051, Compound 2
DMWESZ1 HS Patented
DMWESZ1 SN SCHEMBL18122063; US10100051, Compound 2; BDBM292133; (2-(2-(4-fluorophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
DMWESZ1 DT Small molecular drug
DMWESZ1 PC 137094886
DMWESZ1 MW 371.3
DMWESZ1 FM C18H14FN3O5
DMWESZ1 IC InChI=1S/C18H14FN3O5/c1-9-15-12(17(25)16(21-9)18(26)20-8-14(23)24)6-7-13(22-15)27-11-4-2-10(19)3-5-11/h2-7,25H,8H2,1H3,(H,20,26)(H,23,24)
DMWESZ1 CS CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=C(C=C3)F
DMWESZ1 IK ZGAARGWNIMGZMM-UHFFFAOYSA-N
DMWESZ1 IU 2-[[2-(4-fluorophenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-carbonyl]amino]acetic acid
DMEVGR6 ID DMEVGR6
DMEVGR6 DN US10149841, Compound 1
DMEVGR6 HS Patented
DMEVGR6 SN SCHEMBL19808953; US10149841, Compound 1; BDBM306795
DMEVGR6 DT Small molecular drug
DMEVGR6 PC 134204800
DMEVGR6 MW 288.25
DMEVGR6 FM C14H12N2O5
DMEVGR6 IC InChI=1S/C14H12N2O5/c17-11-6-10(21-9-4-2-1-3-5-9)7-15-13(11)14(20)16-8-12(18)19/h1-7,17H,8H2,(H,16,20)(H,18,19)
DMEVGR6 CS C1=CC=C(C=C1)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DMEVGR6 IK SUWPOWJCFOLJFD-UHFFFAOYSA-N
DMEVGR6 IU 2-[(3-hydroxy-5-phenoxypyridine-2-carbonyl)amino]acetic acid
DMYSI9J ID DMYSI9J
DMYSI9J DN US10149841, Compound 19
DMYSI9J HS Patented
DMYSI9J SN SCHEMBL19808937; BDBM306799; US10149841, Compound 19
DMYSI9J DT Small molecular drug
DMYSI9J PC 134204785
DMYSI9J MW 316.31
DMYSI9J FM C16H16N2O5
DMYSI9J IC InChI=1S/C16H16N2O5/c1-9-3-4-13(10(2)5-9)23-11-6-12(19)15(17-7-11)16(22)18-8-14(20)21/h3-7,19H,8H2,1-2H3,(H,18,22)(H,20,21)
DMYSI9J CS CC1=CC(=C(C=C1)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O)C
DMYSI9J IK NRYBEIHDIVNLGM-UHFFFAOYSA-N
DMYSI9J IU 2-[[5-(2,4-dimethylphenoxy)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
DMBS50K ID DMBS50K
DMBS50K DN US10149841, Compound 5
DMBS50K HS Patented
DMBS50K SN SCHEMBL19808950; US10149841, Compound 5; BDBM306796
DMBS50K DT Small molecular drug
DMBS50K PC 134204798
DMBS50K MW 316.31
DMBS50K FM C16H16N2O5
DMBS50K IC InChI=1S/C16H16N2O5/c1-9-4-3-5-13(10(9)2)23-11-6-12(19)15(17-7-11)16(22)18-8-14(20)21/h3-7,19H,8H2,1-2H3,(H,18,22)(H,20,21)
DMBS50K CS CC1=C(C(=CC=C1)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O)C
DMBS50K IK FSLSXJQWQVETMM-UHFFFAOYSA-N
DMBS50K IU 2-[[5-(2,3-dimethylphenoxy)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
DMS415A ID DMS415A
DMS415A DN US10149841, Compound 9
DMS415A HS Patented
DMS415A SN SCHEMBL19808943; US10149841, Compound 9; BDBM306798
DMS415A DT Small molecular drug
DMS415A PC 134204791
DMS415A MW 324.24
DMS415A FM C14H10F2N2O5
DMS415A IC InChI=1S/C14H10F2N2O5/c15-8-2-1-3-10(12(8)16)23-7-4-9(19)13(17-5-7)14(22)18-6-11(20)21/h1-5,19H,6H2,(H,18,22)(H,20,21)
DMS415A CS C1=CC(=C(C(=C1)F)F)OC2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DMS415A IK CTRIOCMSHSAPNW-UHFFFAOYSA-N
DMS415A IU 2-[[5-(2,3-difluorophenoxy)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
DME2AZG ID DME2AZG
DME2AZG DN US10150740, Example 1
DME2AZG HS Patented
DME2AZG SN SCHEMBL18425452; US10150740, Example 1; BDBM307505
DME2AZG DT Small molecular drug
DME2AZG PC 126508802
DME2AZG MW 302.28
DME2AZG FM C15H14N2O5
DME2AZG IC InChI=1S/C15H14N2O5/c1-21-13-3-8-6-16-17-7-10(15(19)20)12(18)5-11(17)9(8)4-14(13)22-2/h3-5,7,16H,6H2,1-2H3,(H,19,20)
DME2AZG CS COC1=C(C=C2C(=C1)CNN3C2=CC(=O)C(=C3)C(=O)O)OC
DME2AZG IK BPBHVSAWZGGVPZ-UHFFFAOYSA-N
DME2AZG IU 9,10-dimethoxy-2-oxo-6,7-dihydropyrido[2,1-a]phthalazine-3-carboxylic acid
DMKM93Q ID DMKM93Q
DMKM93Q DN US10150740, Example 4
DMKM93Q HS Patented
DMKM93Q SN SCHEMBL18426560; US10150740, Example 4; BDBM307508
DMKM93Q DT Small molecular drug
DMKM93Q PC 126509775
DMKM93Q MW 344.4
DMKM93Q FM C18H20N2O5
DMKM93Q IC InChI=1S/C18H20N2O5/c1-10(2)19-8-11-5-16(24-3)17(25-4)6-12(11)14-7-15(21)13(18(22)23)9-20(14)19/h5-7,9-10H,8H2,1-4H3,(H,22,23)
DMKM93Q CS CC(C)N1CC2=CC(=C(C=C2C3=CC(=O)C(=CN31)C(=O)O)OC)OC
DMKM93Q IK PURJTKDWCZADSM-UHFFFAOYSA-N
DMKM93Q IU 9,10-dimethoxy-2-oxo-6-propan-2-yl-7H-pyrido[2,1-a]phthalazine-3-carboxylic acid
DM1VPLU ID DM1VPLU
DM1VPLU DN US10150740, Example 9
DM1VPLU HS Patented
DM1VPLU SN SCHEMBL18425902; US10150740, Example 9; BDBM307513
DM1VPLU DT Small molecular drug
DM1VPLU PC 126509196
DM1VPLU MW 464.5
DM1VPLU FM C22H28N2O7S
DM1VPLU IC InChI=1S/C22H28N2O7S/c1-14(2)11-23-12-15-8-21(31-6-5-7-32(4,28)29)20(30-3)9-16(15)18-10-19(25)17(22(26)27)13-24(18)23/h8-10,13-14H,5-7,11-12H2,1-4H3,(H,26,27)
DM1VPLU CS CC(C)CN1CC2=CC(=C(C=C2C3=CC(=O)C(=CN31)C(=O)O)OC)OCCCS(=O)(=O)C
DM1VPLU IK RECMZXKLBVQDRN-UHFFFAOYSA-N
DM1VPLU IU 10-methoxy-6-(2-methylpropyl)-9-(3-methylsulfonylpropoxy)-2-oxo-7H-pyrido[2,1-a]phthalazine-3-carboxylic acid
DMVMNP1 ID DMVMNP1
DMVMNP1 DN US10166249, Example 695
DMVMNP1 HS Patented
DMVMNP1 SN SCHEMBL17511437; BDBM313178; US10166249, Example 695
DMVMNP1 DT Small molecular drug
DMVMNP1 PC 118877315
DMVMNP1 MW 411.5
DMVMNP1 FM C21H34NO5P
DMVMNP1 IC InChI=1S/C21H34NO5P/c1-2-26-11-3-4-16-5-6-18-13-19(8-7-17(18)12-16)20-9-10-21(22,14-20)15-27-28(23,24)25/h7-8,13,16,20H,2-6,9-12,14-15,22H2,1H3,(H2,23,24,25)/t16?,20-,21+/m0/s1
DMVMNP1 CS CCOCCCC1CCC2=C(C1)C=CC(=C2)[C@H]3CC[C@@](C3)(COP(=O)(O)O)N
DMVMNP1 IK VHKORLDZIRFKDI-KCECWRNFSA-N
DMVMNP1 IU [(1R,3S)-1-amino-3-[6-(3-ethoxypropyl)-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate
DMSYRI3 ID DMSYRI3
DMSYRI3 DN US10174026, Example 2
DMSYRI3 HS Patented
DMSYRI3 SN SCHEMBL16149258; US10174026, Example 2; FEZIKLVLFANZBD-UHFFFAOYSA-N; BDBM320362; 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid; 2-phenyl-1H-pyrrolo[3,2-b] pyridine-7-carboxylic acid
DMSYRI3 DT Small molecular drug
DMSYRI3 PC 86280871
DMSYRI3 MW 238.24
DMSYRI3 FM C14H10N2O2
DMSYRI3 IC InChI=1S/C14H10N2O2/c17-14(18)10-6-7-15-12-8-11(16-13(10)12)9-4-2-1-3-5-9/h1-8,16H,(H,17,18)
DMSYRI3 CS C1=CC=C(C=C1)C2=CC3=NC=CC(=C3N2)C(=O)O
DMSYRI3 IK FEZIKLVLFANZBD-UHFFFAOYSA-N
DMSYRI3 IU 2-phenyl-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid
DMJKTYW ID DMJKTYW
DMJKTYW DN US10174026, Example 99
DMJKTYW HS Patented
DMJKTYW SN SCHEMBL16157351; BDBM320432; US10174026, Example 99; 2-(pyrrolidin-1-ylcarbonyl)-1H- pyrrolo[3,2-b]pyridine-7- carboxylic acid
DMJKTYW DT Small molecular drug
DMJKTYW PC 85469291
DMJKTYW MW 259.26
DMJKTYW FM C13H13N3O3
DMJKTYW IC InChI=1S/C13H13N3O3/c17-12(16-5-1-2-6-16)10-7-9-11(15-10)8(13(18)19)3-4-14-9/h3-4,7,15H,1-2,5-6H2,(H,18,19)
DMJKTYW CS C1CCN(C1)C(=O)C2=CC3=NC=CC(=C3N2)C(=O)O
DMJKTYW IK YVSBFLGSNJSZJQ-UHFFFAOYSA-N
DMJKTYW IU 2-(pyrrolidine-1-carbonyl)-1H-pyrrolo[3,2-b]pyridine-7-carboxylic acid
DMGTBO3 ID DMGTBO3
DMGTBO3 DN US10179791, Compound 171
DMGTBO3 HS Patented
DMGTBO3 SN SCHEMBL10268794; BDBM321321; US10179791, Compound 171
DMGTBO3 DT Small molecular drug
DMGTBO3 PC 56599384
DMGTBO3 MW 381.4
DMGTBO3 FM C23H24FNO3
DMGTBO3 IC InChI=1S/C23H24FNO3/c24-20-4-2-1-3-18(20)7-5-17-6-8-19-21(15-17)28-16-23(19)10-13-25(14-11-23)12-9-22(26)27/h1-8,15H,9-14,16H2,(H,26,27)/b7-5+
DMGTBO3 CS C1CN(CCC12COC3=C2C=CC(=C3)/C=C/C4=CC=CC=C4F)CCC(=O)O
DMGTBO3 IK SWXZUILIRNOBES-FNORWQNLSA-N
DMGTBO3 IU 3-[6-[(E)-2-(2-fluorophenyl)ethenyl]spiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl]propanoic acid
DMRHQLF ID DMRHQLF
DMRHQLF DN US10179791, Compound 176
DMRHQLF HS Patented
DMRHQLF SN SCHEMBL327072; BDBM321322; US10179791, Compound 176
DMRHQLF DT Small molecular drug
DMRHQLF PC 56599386
DMRHQLF MW 432.3
DMRHQLF FM C23H23Cl2NO3
DMRHQLF IC InChI=1S/C23H23Cl2NO3/c24-18-2-1-3-19(25)22(18)16-11-15(16)14-4-5-17-20(10-14)29-13-23(17)6-8-26(9-7-23)12-21(27)28/h1-5,10,15-16H,6-9,11-13H2,(H,27,28)
DMRHQLF CS C1CN(CCC12COC3=C2C=CC(=C3)C4CC4C5=C(C=CC=C5Cl)Cl)CC(=O)O
DMRHQLF IK UTYPIEPGWJMTNG-UHFFFAOYSA-N
DMRHQLF IU 2-[6-[2-(2,6-dichlorophenyl)cyclopropyl]spiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl]acetic acid
DMLZBRM ID DMLZBRM
DMLZBRM DN US10179791, Compound 296
DMLZBRM HS Patented
DMLZBRM SN SCHEMBL10265363; BDBM321333; US10179791, Compound 296
DMLZBRM DT Small molecular drug
DMLZBRM PC 56599299
DMLZBRM MW 464
DMLZBRM FM C24H27ClFNO3S
DMLZBRM IC InChI=1S/C24H27ClFNO3S/c1-2-16-4-3-5-19(25)17(16)14-31-20-7-6-18-23(22(20)26)30-15-24(18)9-12-27(13-10-24)11-8-21(28)29/h3-7H,2,8-15H2,1H3,(H,28,29)
DMLZBRM CS CCC1=C(C(=CC=C1)Cl)CSC2=C(C3=C(C=C2)C4(CCN(CC4)CCC(=O)O)CO3)F
DMLZBRM IK QTCUMVXBAZTPSZ-UHFFFAOYSA-N
DMLZBRM IU 3-[6-[(2-chloro-6-ethylphenyl)methylsulfanyl]-7-fluorospiro[2H-1-benzofuran-3,4'-piperidine]-1'-yl]propanoic acid
DMAE6CK ID DMAE6CK
DMAE6CK DN US20160326143, 28
DMAE6CK HS Patented
DMAE6CK SN CHEMBL3898699; SCHEMBL18205901; BDBM223253; US20160326143, 28; 2-(5-((Cyclopropylmethyl)(2,3-dimethylbenzyl)amino)-3-methoxypicolinoyl)cyclopropanecarboxylic acid
DMAE6CK DT Small molecular drug
DMAE6CK PC 122670152
DMAE6CK MW 408.5
DMAE6CK FM C24H28N2O4
DMAE6CK IC InChI=1S/C24H28N2O4/c1-14-5-4-6-17(15(14)2)13-26(12-16-7-8-16)18-9-21(30-3)22(25-11-18)23(27)19-10-20(19)24(28)29/h4-6,9,11,16,19-20H,7-8,10,12-13H2,1-3H3,(H,28,29)
DMAE6CK CS CC1=C(C(=CC=C1)CN(CC2CC2)C3=CC(=C(N=C3)C(=O)C4CC4C(=O)O)OC)C
DMAE6CK IK LRXJWJPKMGAWTD-UHFFFAOYSA-N
DMAE6CK IU 2-[5-[cyclopropylmethyl-[(2,3-dimethylphenyl)methyl]amino]-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid
DML5KXB ID DML5KXB
DML5KXB DN US20160326143, 3
DML5KXB HS Patented
DML5KXB SN CHEMBL3899164; BDBM223228; US20160326143, 3; 2-(5-((4-Chlorophenyl)((1-(trifluoromethyl)cyclopropyl)methyl)amino)-3-methoxypicolinoyl)cyclopropanecarboxylic acid
DML5KXB DT Small molecular drug
DML5KXB PC 126961660
DML5KXB MW 468.9
DML5KXB FM C22H20ClF3N2O4
DML5KXB IC InChI=1S/C22H20ClF3N2O4/c1-32-17-8-14(10-27-18(17)19(29)15-9-16(15)21(30)31)28(13-6-4-12(23)5-7-13)20(11-2-3-11)22(24,25)26/h4-8,10-11,15-16,20H,2-3,9H2,1H3,(H,30,31)
DML5KXB CS COC1=C(N=CC(=C1)N(C2=CC=C(C=C2)Cl)C(C3CC3)C(F)(F)F)C(=O)C4CC4C(=O)O
DML5KXB IK LWAUMGSKFOFDCB-UHFFFAOYSA-N
DML5KXB IU 2-[5-(4-chloro-N-(1-cyclopropyl-2,2,2-trifluoroethyl)anilino)-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid
DMUDE89 ID DMUDE89
DMUDE89 DN US20160326143, 38
DMUDE89 HS Patented
DMUDE89 SN CHEMBL3901235; SCHEMBL18205890; BDBM223263; US20160326143, 38; 2-(5-((Cyclopropylmethyl)(1,2-dihydroacenaphthylen-3-yl)amino)-3-methoxypicolinoyl)cyclopropanecarboxylic acid
DMUDE89 DT Small molecular drug
DMUDE89 PC 122670142
DMUDE89 MW 442.5
DMUDE89 FM C27H26N2O4
DMUDE89 IC InChI=1S/C27H26N2O4/c1-33-23-11-18(13-28-25(23)26(30)20-12-21(20)27(31)32)29(14-15-5-6-15)22-10-8-17-4-2-3-16-7-9-19(22)24(16)17/h2-4,8,10-11,13,15,20-21H,5-7,9,12,14H2,1H3,(H,31,32)
DMUDE89 CS COC1=C(N=CC(=C1)N(CC2CC2)C3=C4CCC5=CC=CC(=C54)C=C3)C(=O)C6CC6C(=O)O
DMUDE89 IK VUVDRPVJLHQYMJ-UHFFFAOYSA-N
DMUDE89 IU 2-[5-[cyclopropylmethyl(1,2-dihydroacenaphthylen-3-yl)amino]-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid
DM2DU7R ID DM2DU7R
DM2DU7R DN US20160326143, 50
DM2DU7R HS Patented
DM2DU7R SN SCHEMBL18205873; CHEMBL3894959; BDBM223275; US20160326143, 50; 2-(4-((Cyclopropylmethyl)(3,4-dimethylphenyl)amino)-2-methoxybenzoyl)cyclopropanecarboxylic acid
DM2DU7R DT Small molecular drug
DM2DU7R PC 122670126
DM2DU7R MW 393.5
DM2DU7R FM C24H27NO4
DM2DU7R IC InChI=1S/C24H27NO4/c1-14-4-7-17(10-15(14)2)25(13-16-5-6-16)18-8-9-19(22(11-18)29-3)23(26)20-12-21(20)24(27)28/h4,7-11,16,20-21H,5-6,12-13H2,1-3H3,(H,27,28)
DM2DU7R CS CC1=C(C=C(C=C1)N(CC2CC2)C3=CC(=C(C=C3)C(=O)C4CC4C(=O)O)OC)C
DM2DU7R IK HYAQXBPDSJIQND-UHFFFAOYSA-N
DM2DU7R IU 2-[4-[N-(cyclopropylmethyl)-3,4-dimethylanilino]-2-methoxybenzoyl]cyclopropane-1-carboxylic acid
DMH7JVA ID DMH7JVA
DMH7JVA DN US8470836, 2
DMH7JVA HS Patented
DMH7JVA SN SCHEMBL3101345; CHEMBL3644783; BDBM97575; US8470836, 2
DMH7JVA DT Small molecular drug
DMH7JVA PC 42635875
DMH7JVA MW 505.4
DMH7JVA FM C18H19F8N5O3
DMH7JVA IC InChI=1S/C18H19F8N5O3/c19-16(20)3-1-11(32)31(15(16)34)6-8(27)5-12(33)30-4-2-9-10(7-30)28-14(18(24,25)26)29-13(9)17(21,22)23/h8,15,34H,1-7,27H2/t8-,15-/m0/s1
DMH7JVA CS C1CC([C@@H](N(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)O)(F)F
DMH7JVA IK DMXWXVXGQLCKOY-AYVTZFPOSA-N
DMH7JVA IU (6S)-1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoro-6-hydroxypiperidin-2-one
DMH7JVA CA CAS 1173174-99-6
DMYR10P ID DMYR10P
DMYR10P DN US8470836, 5
DMYR10P HS Patented
DMYR10P SN SCHEMBL3111337; CHEMBL3644786; BDBM97578; US8470836, 5
DMYR10P DT Small molecular drug
DMYR10P PC 44126186
DMYR10P MW 491.5
DMYR10P FM C21H26F5N5O3
DMYR10P IC InChI=1S/C21H26F5N5O3/c22-20(23)6-4-15(32)31(19(20)34)9-12(27)8-16(33)30-7-5-13-14(10-30)28-18(11-2-1-3-11)29-17(13)21(24,25)26/h11-12,19,34H,1-10,27H2/t12-,19?/m0/s1
DMYR10P CS C1CC(C1)C2=NC3=C(CCN(C3)C(=O)C[C@@H](CN4C(C(CCC4=O)(F)F)O)N)C(=N2)C(F)(F)F
DMYR10P IK OPWLXRFLOSHBNJ-HSLMYDHPSA-N
DMYR10P IU 1-[(2S)-2-amino-4-[2-cyclobutyl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoro-6-hydroxypiperidin-2-one
DMVYQXH ID DMVYQXH
DMVYQXH DN US8470836, 6
DMVYQXH HS Patented
DMVYQXH SN SCHEMBL13099347; CHEMBL3644787; BDBM97579; US8470836, 6
DMVYQXH DT Small molecular drug
DMVYQXH PC 44126288
DMVYQXH MW 514.4
DMVYQXH FM C22H23F5N6O3
DMVYQXH IC InChI=1S/C22H23F5N6O3/c23-21(24)5-1-16(34)33(20(21)36)10-13(28)9-17(35)32-8-4-14-15(11-32)30-19(12-2-6-29-7-3-12)31-18(14)22(25,26)27/h2-3,6-7,13,20,36H,1,4-5,8-11,28H2/t13-,20-/m0/s1
DMVYQXH CS C1CC([C@@H](N(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C4=CC=NC=C4)N)O)(F)F
DMVYQXH IK JLAXABGHGCBAGV-RBZFPXEDSA-N
DMVYQXH IU (6S)-1-[(2S)-2-amino-4-oxo-4-[2-pyridin-4-yl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5,5-difluoro-6-hydroxypiperidin-2-one
DMM4GLH ID DMM4GLH
DMM4GLH DN US8470836, 8
DMM4GLH HS Patented
DMM4GLH SN SCHEMBL13099353; CHEMBL3644788; BDBM97581; US8470836, 8
DMM4GLH DT Small molecular drug
DMM4GLH PC 59550092
DMM4GLH MW 503.4
DMM4GLH FM C21H22F5N5O4
DMM4GLH IC InChI=1S/C21H22F5N5O4/c22-20(23)5-3-15(32)31(19(20)34)9-11(27)8-16(33)30-6-4-12-13(10-30)28-18(14-2-1-7-35-14)29-17(12)21(24,25)26/h1-2,7,11,19,34H,3-6,8-10,27H2/t11-,19-/m0/s1
DMM4GLH CS C1CC([C@@H](N(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C4=CC=CO4)N)O)(F)F
DMM4GLH IK QGMCXZMURXFXMP-WLRWDXFRSA-N
DMM4GLH IU (6S)-1-[(2S)-2-amino-4-[2-(furan-2-yl)-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoro-6-hydroxypiperidin-2-one
DMFEUMZ ID DMFEUMZ
DMFEUMZ DN US8481586, 15
DMFEUMZ HS Patented
DMFEUMZ SN CHEMBL575336; SCHEMBL844646; BDBM50299246; 7-Bromo-1,10-dihydropyrrolo[2,3-a]carbazole; US8481586, 15
DMFEUMZ DT Small molecular drug
DMFEUMZ PC 44479463
DMFEUMZ MW 285.14
DMFEUMZ FM C14H9BrN2
DMFEUMZ IC InChI=1S/C14H9BrN2/c15-9-2-4-12-11(7-9)10-3-1-8-5-6-16-13(8)14(10)17-12/h1-7,16-17H
DMFEUMZ CS C1=CC2=C(C3=C1C=CN3)NC4=C2C=C(C=C4)Br
DMFEUMZ IK JRPUZUBQJFQSQO-UHFFFAOYSA-N
DMFEUMZ IU 7-bromo-1,10-dihydropyrrolo[2,3-a]carbazole
DM6U3ZR ID DM6U3ZR
DM6U3ZR DN US8481586, 40
DM6U3ZR HS Patented
DM6U3ZR SN CHEMBL575739; SCHEMBL844464; BDBM50299250; US8481586, 40; 7-(2,4-Difluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde
DM6U3ZR DT Small molecular drug
DM6U3ZR PC 44480198
DM6U3ZR MW 346.3
DM6U3ZR FM C21H12F2N2O
DM6U3ZR IC InChI=1S/C21H12F2N2O/c22-13-2-3-14(18(23)8-13)11-1-6-19-17(7-11)16-5-4-15-12(10-26)9-24-20(15)21(16)25-19/h1-10,24-25H
DM6U3ZR CS C1=CC2=C(C=C1C3=C(C=C(C=C3)F)F)C4=C(N2)C5=C(C=C4)C(=CN5)C=O
DM6U3ZR IK BFWHRHJPPAUSLJ-UHFFFAOYSA-N
DM6U3ZR IU 7-(2,4-difluorophenyl)-1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde
DM5W0A2 ID DM5W0A2
DM5W0A2 DN US8481586, 5
DM5W0A2 HS Patented
DM5W0A2 SN CHEMBL573176; SCHEMBL844935; BDBM50299248; US8481586, 5; 1,10-Dihydropyrrolo[2,3-a]carbazole-3-carboxamide
DM5W0A2 DT Small molecular drug
DM5W0A2 PC 44479711
DM5W0A2 MW 249.27
DM5W0A2 FM C15H11N3O
DM5W0A2 IC InChI=1S/C15H11N3O/c16-15(19)11-7-17-13-10(11)6-5-9-8-3-1-2-4-12(8)18-14(9)13/h1-7,17-18H,(H2,16,19)
DM5W0A2 CS C1=CC=C2C(=C1)C3=C(N2)C4=C(C=C3)C(=CN4)C(=O)N
DM5W0A2 IK MXZKCOUOYWSEKW-UHFFFAOYSA-N
DM5W0A2 IU 1,10-dihydropyrrolo[2,3-a]carbazole-3-carboxamide
DMV6FL8 ID DMV6FL8
DMV6FL8 DN US8481733, 106
DMV6FL8 HS Patented
DMV6FL8 SN SCHEMBL1128749; SCHEMBL1128751; CHEMBL2325938; BDBM98294; US8481733, 106
DMV6FL8 DT Small molecular drug
DMV6FL8 PC 44468332
DMV6FL8 MW 414.5
DMV6FL8 FM C25H26N4O2
DMV6FL8 IC InChI=1S/C25H26N4O2/c1-24(30)14-17(15-24)23-28-20(21-22(26)27-12-13-29(21)23)16-8-10-19(11-9-16)25(2,31)18-6-4-3-5-7-18/h3-13,17,30-31H,14-15H2,1-2H3,(H2,26,27)
DMV6FL8 CS CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(C)(C5=CC=CC=C5)O)O
DMV6FL8 IK MUKLAWDKMYGQSN-UHFFFAOYSA-N
DMV6FL8 IU 3-[8-amino-1-[4-(1-hydroxy-1-phenylethyl)phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
DMZQIKL ID DMZQIKL
DMZQIKL DN US8481733, 118
DMZQIKL HS Patented
DMZQIKL SN SCHEMBL1129553; SCHEMBL1129554; CHEMBL2325937; BDBM98306; US8481733, 118
DMZQIKL DT Small molecular drug
DMZQIKL PC 44538590
DMZQIKL MW 420.5
DMZQIKL FM C24H22F2N4O
DMZQIKL IC InChI=1S/C24H22F2N4O/c1-23(31)13-16(14-23)22-29-19(20-21(27)28-11-12-30(20)22)15-7-9-18(10-8-15)24(25,26)17-5-3-2-4-6-17/h2-12,16,31H,13-14H2,1H3,(H2,27,28)
DMZQIKL CS CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(C5=CC=CC=C5)(F)F)O
DMZQIKL IK QXYZHRYXSNHAFM-UHFFFAOYSA-N
DMZQIKL IU 3-[8-amino-1-[4-[difluoro(phenyl)methyl]phenyl]imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
DM36R21 ID DM36R21
DM36R21 DN US8481733, 95
DM36R21 HS Patented
DM36R21 SN SCHEMBL4356213; SCHEMBL4356209; CHEMBL2325936; BDBM98283; US8481733, 95
DM36R21 DT Small molecular drug
DM36R21 PC 57961044
DM36R21 MW 384.5
DM36R21 FM C24H24N4O
DM36R21 IC InChI=1S/C24H24N4O/c1-24(29)14-19(15-24)23-27-20(21-22(25)26-11-12-28(21)23)18-9-7-17(8-10-18)13-16-5-3-2-4-6-16/h2-12,19,29H,13-15H2,1H3,(H2,25,26)
DM36R21 CS CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)CC5=CC=CC=C5)O
DM36R21 IK ZSKAHJMMVVSPKI-UHFFFAOYSA-N
DM36R21 IU 3-[8-amino-1-(4-benzylphenyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
DMCJH4F ID DMCJH4F
DMCJH4F DN US8524917, 10
DMCJH4F HS Patented
DMCJH4F SN SCHEMBL291250; CHEMBL3651713; HYKLZEZGHJEJET-UHFFFAOYSA-N; BDBM101037; US8524917, 10; US8563594, 168; 1-benzyl-N-(3,4-difluorobenzyl)-6-ethoxy-2-isopropyl-1H-indole-3-carboxamide
DMCJH4F DT Small molecular drug
DMCJH4F PC 25059487
DMCJH4F MW 462.5
DMCJH4F FM C28H28F2N2O2
DMCJH4F IC InChI=1S/C28H28F2N2O2/c1-4-34-21-11-12-22-25(15-21)32(17-19-8-6-5-7-9-19)27(18(2)3)26(22)28(33)31-16-20-10-13-23(29)24(30)14-20/h5-15,18H,4,16-17H2,1-3H3,(H,31,33)
DMCJH4F CS CCOC1=CC2=C(C=C1)C(=C(N2CC3=CC=CC=C3)C(C)C)C(=O)NCC4=CC(=C(C=C4)F)F
DMCJH4F IK HYKLZEZGHJEJET-UHFFFAOYSA-N
DMCJH4F IU 1-benzyl-N-[(3,4-difluorophenyl)methyl]-6-ethoxy-2-propan-2-ylindole-3-carboxamide
DMETY0U ID DMETY0U
DMETY0U DN US8524917, 11
DMETY0U HS Patented
DMETY0U SN SCHEMBL289923; CHEMBL3651714; AFDUGVKJXKJJMO-UHFFFAOYSA-N; BDBM101038; US8524917, 11; US8563594, 169; 1-Benzyl-N-(3,4-difluorobenzyl)-2-isopropyl-6-propoxy-1H-indole-3-carboxamide
DMETY0U DT Small molecular drug
DMETY0U PC 25059488
DMETY0U MW 476.6
DMETY0U FM C29H30F2N2O2
DMETY0U IC InChI=1S/C29H30F2N2O2/c1-4-14-35-22-11-12-23-26(16-22)33(18-20-8-6-5-7-9-20)28(19(2)3)27(23)29(34)32-17-21-10-13-24(30)25(31)15-21/h5-13,15-16,19H,4,14,17-18H2,1-3H3,(H,32,34)
DMETY0U CS CCCOC1=CC2=C(C=C1)C(=C(N2CC3=CC=CC=C3)C(C)C)C(=O)NCC4=CC(=C(C=C4)F)F
DMETY0U IK AFDUGVKJXKJJMO-UHFFFAOYSA-N
DMETY0U IU 1-benzyl-N-[(3,4-difluorophenyl)methyl]-2-propan-2-yl-6-propoxyindole-3-carboxamide
DMZ2ECB ID DMZ2ECB
DMZ2ECB DN US8524917, 12
DMZ2ECB HS Patented
DMZ2ECB SN SCHEMBL786644; CHEMBL3651715; UJUPJZYUKBFHHO-UHFFFAOYSA-N; BDBM101039; US8524917, 12; US8563594, 170; 1-Benzyl-N-(3,4-difluorobenzyl)-6-isopropoxy-2-isopropyl-1H-indole-3-carboxamide
DMZ2ECB DT Small molecular drug
DMZ2ECB PC 25059745
DMZ2ECB MW 476.6
DMZ2ECB FM C29H30F2N2O2
DMZ2ECB IC InChI=1S/C29H30F2N2O2/c1-18(2)28-27(29(34)32-16-21-10-13-24(30)25(31)14-21)23-12-11-22(35-19(3)4)15-26(23)33(28)17-20-8-6-5-7-9-20/h5-15,18-19H,16-17H2,1-4H3,(H,32,34)
DMZ2ECB CS CC(C)C1=C(C2=C(N1CC3=CC=CC=C3)C=C(C=C2)OC(C)C)C(=O)NCC4=CC(=C(C=C4)F)F
DMZ2ECB IK UJUPJZYUKBFHHO-UHFFFAOYSA-N
DMZ2ECB IU 1-benzyl-N-[(3,4-difluorophenyl)methyl]-2-propan-2-yl-6-propan-2-yloxyindole-3-carboxamide
DMRPD8U ID DMRPD8U
DMRPD8U DN US8524917, 60
DMRPD8U HS Patented
DMRPD8U SN SCHEMBL4885528; CHEMBL3639543; JRPPHTCHABUGFY-UHFFFAOYSA-N; BDBM101087; US8524917, 60; 1-Benzyl-N-(3,4-difluorobenzyl)-2-isopropyl-6-(1,3,4-oxadiazol-2-yl)-1H-indole-3-carboxamide
DMRPD8U DT Small molecular drug
DMRPD8U PC 59762338
DMRPD8U MW 486.5
DMRPD8U FM C28H24F2N4O2
DMRPD8U IC InChI=1S/C28H24F2N4O2/c1-17(2)26-25(27(35)31-14-19-8-11-22(29)23(30)12-19)21-10-9-20(28-33-32-16-36-28)13-24(21)34(26)15-18-6-4-3-5-7-18/h3-13,16-17H,14-15H2,1-2H3,(H,31,35)
DMRPD8U CS CC(C)C1=C(C2=C(N1CC3=CC=CC=C3)C=C(C=C2)C4=NN=CO4)C(=O)NCC5=CC(=C(C=C5)F)F
DMRPD8U IK JRPPHTCHABUGFY-UHFFFAOYSA-N
DMRPD8U IU 1-benzyl-N-[(3,4-difluorophenyl)methyl]-6-(1,3,4-oxadiazol-2-yl)-2-propan-2-ylindole-3-carboxamide
DMF9LNO ID DMF9LNO
DMF9LNO DN US8536181, A41
DMF9LNO HS Patented
DMF9LNO SN SCHEMBL1770480; CHEMBL3115298; UPJZLOCUUOIMNC-UHFFFAOYSA-N; BDBM102348; US8536181, A41; tert-butyl 4-((1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl)methyl)piperazine-1-carboxylate
DMF9LNO DT Small molecular drug
DMF9LNO PC 52912218
DMF9LNO MW 433.9
DMF9LNO FM C22H28ClN3O4
DMF9LNO IC InChI=1S/C22H28ClN3O4/c1-22(2,3)30-21(29)25-12-10-24(11-13-25)15-17-8-9-26(20(28)19(17)27)14-16-4-6-18(23)7-5-16/h4-9,27H,10-15H2,1-3H3
DMF9LNO CS CC(C)(C)OC(=O)N1CCN(CC1)CC2=C(C(=O)N(C=C2)CC3=CC=C(C=C3)Cl)O
DMF9LNO IK UPJZLOCUUOIMNC-UHFFFAOYSA-N
DMF9LNO IU tert-butyl 4-[[1-[(4-chlorophenyl)methyl]-3-hydroxy-2-oxopyridin-4-yl]methyl]piperazine-1-carboxylate
DMZNF59 ID DMZNF59
DMZNF59 DN US8536181, C14
DMZNF59 HS Patented
DMZNF59 SN SCHEMBL271606; CHEMBL3649594; BDBM102338; US8536181, C14
DMZNF59 DT Small molecular drug
DMZNF59 PC 9997015
DMZNF59 MW 334.4
DMZNF59 FM C21H22N2O2
DMZNF59 IC InChI=1S/C21H22N2O2/c1-16(18-10-6-3-7-11-18)22-14-19-12-13-23(21(25)20(19)24)15-17-8-4-2-5-9-17/h2-13,16,22,24H,14-15H2,1H3
DMZNF59 CS CC(C1=CC=CC=C1)NCC2=C(C(=O)N(C=C2)CC3=CC=CC=C3)O
DMZNF59 IK VGDRCKOTQHHWTA-UHFFFAOYSA-N
DMZNF59 IU 1-benzyl-3-hydroxy-4-[(1-phenylethylamino)methyl]pyridin-2-one
DMRTL63 ID DMRTL63
DMRTL63 DN US8536181, C17
DMRTL63 HS Patented
DMRTL63 SN SCHEMBL272935; CHEMBL3649592; BDBM102336; US8536181, C17
DMRTL63 DT Small molecular drug
DMRTL63 PC 10042063
DMRTL63 MW 326.4
DMRTL63 FM C20H26N2O2
DMRTL63 IC InChI=1S/C20H26N2O2/c1-15-7-9-18(10-8-15)21-13-17-11-12-22(20(24)19(17)23)14-16-5-3-2-4-6-16/h2-6,11-12,15,18,21,23H,7-10,13-14H2,1H3
DMRTL63 CS CC1CCC(CC1)NCC2=C(C(=O)N(C=C2)CC3=CC=CC=C3)O
DMRTL63 IK VJHCNYYTYSQTGD-UHFFFAOYSA-N
DMRTL63 IU 1-benzyl-3-hydroxy-4-[[(4-methylcyclohexyl)amino]methyl]pyridin-2-one
DMAM51Z ID DMAM51Z
DMAM51Z DN US8536181, C35
DMAM51Z HS Patented
DMAM51Z SN SCHEMBL5240905; CHEMBL3649593; BDBM102337; US8536181, C35
DMAM51Z DT Small molecular drug
DMAM51Z PC 10449798
DMAM51Z MW 338.4
DMAM51Z FM C19H22N4O2
DMAM51Z IC InChI=1S/C19H22N4O2/c24-18-17(13-20-8-4-10-22-12-9-21-15-22)7-11-23(19(18)25)14-16-5-2-1-3-6-16/h1-3,5-7,9,11-12,15,20,24H,4,8,10,13-14H2
DMAM51Z CS C1=CC=C(C=C1)CN2C=CC(=C(C2=O)O)CNCCCN3C=CN=C3
DMAM51Z IK VKLSJRDNBKOSAR-UHFFFAOYSA-N
DMAM51Z IU 1-benzyl-3-hydroxy-4-[(3-imidazol-1-ylpropylamino)methyl]pyridin-2-one
DMQRO6G ID DMQRO6G
DMQRO6G DN US8546370, 102
DMQRO6G HS Patented
DMQRO6G SN SCHEMBL1043246; CHEMBL3639414; BDBM103514; US8546370, 102
DMQRO6G DT Small molecular drug
DMQRO6G PC 58094043
DMQRO6G MW 432.9
DMQRO6G FM C24H21ClN4O2
DMQRO6G IC InChI=1S/C24H21ClN4O2/c25-20-4-2-1-3-19(20)21-15-16-9-10-26-24(30)22(16)23(28-21)27-17-5-7-18(8-6-17)29-11-13-31-14-12-29/h1-10,15H,11-14H2,(H,26,30)(H,27,28)
DMQRO6G CS C1COCCN1C2=CC=C(C=C2)NC3=C4C(=CC(=N3)C5=CC=CC=C5Cl)C=CNC4=O
DMQRO6G IK BMPOWIIBXCMAFL-UHFFFAOYSA-N
DMQRO6G IU 6-(2-chlorophenyl)-8-(4-morpholin-4-ylanilino)-2H-2,7-naphthyridin-1-one
DM2K6YU ID DM2K6YU
DM2K6YU DN US8546370, 11
DM2K6YU HS Patented
DM2K6YU SN SCHEMBL1044792; CHEMBL3642577; BDBM103510; US8546370, 11
DM2K6YU DT Small molecular drug
DM2K6YU PC 44193817
DM2K6YU MW 398.5
DM2K6YU FM C24H22N4O2
DM2K6YU IC InChI=1S/C24H22N4O2/c29-24-22-18(10-11-25-24)16-21(17-4-2-1-3-5-17)27-23(22)26-19-6-8-20(9-7-19)28-12-14-30-15-13-28/h1-11,16H,12-15H2,(H,25,29)(H,26,27)
DM2K6YU CS C1COCCN1C2=CC=C(C=C2)NC3=C4C(=CC(=N3)C5=CC=CC=C5)C=CNC4=O
DM2K6YU IK UNLNOESEDGPPCS-UHFFFAOYSA-N
DM2K6YU IU 8-(4-morpholin-4-ylanilino)-6-phenyl-2H-2,7-naphthyridin-1-one
DMGIJZA ID DMGIJZA
DMGIJZA DN US8546370, 17
DMGIJZA HS Patented
DMGIJZA SN SCHEMBL1048459; CHEMBL3642578; BDBM103511; US8546370, 17
DMGIJZA DT Small molecular drug
DMGIJZA PC 44180013
DMGIJZA MW 379.5
DMGIJZA FM C21H25N5O2
DMGIJZA IC InChI=1S/C21H25N5O2/c22-8-1-2-17-14-15-7-9-23-21(27)19(15)20(25-17)24-16-3-5-18(6-4-16)26-10-12-28-13-11-26/h3-7,9,14H,1-2,8,10-13,22H2,(H,23,27)(H,24,25)
DMGIJZA CS C1COCCN1C2=CC=C(C=C2)NC3=C4C(=CC(=N3)CCCN)C=CNC4=O
DMGIJZA IK MKILIVUEQNFIIU-UHFFFAOYSA-N
DMGIJZA IU 6-(3-aminopropyl)-8-(4-morpholin-4-ylanilino)-2H-2,7-naphthyridin-1-one
DMDP87V ID DMDP87V
DMDP87V DN US8563594, 152
DMDP87V HS Patented
DMDP87V SN SCHEMBL805680; CHEMBL3651716; PKIXUSGPPGWLFE-UHFFFAOYSA-N; BDBM103603; US8563594, 152; {3-[(5,6-Diphenylpyridin-2-ylmethyl)-amino]-propyl}-phosphonic Acid
DMDP87V DT Small molecular drug
DMDP87V PC 44234513
DMDP87V MW 382.4
DMDP87V FM C21H23N2O3P
DMDP87V IC InChI=1S/C21H23N2O3P/c24-27(25,26)15-7-14-22-16-19-12-13-20(17-8-3-1-4-9-17)21(23-19)18-10-5-2-6-11-18/h1-6,8-13,22H,7,14-16H2,(H2,24,25,26)
DMDP87V CS C1=CC=C(C=C1)C2=C(N=C(C=C2)CNCCCP(=O)(O)O)C3=CC=CC=C3
DMDP87V IK PKIXUSGPPGWLFE-UHFFFAOYSA-N
DMDP87V IU 3-[(5,6-diphenylpyridin-2-yl)methylamino]propylphosphonic acid
DMZV6YT ID DMZV6YT
DMZV6YT DN US8569313, Inhibitor 14
DMZV6YT HS Patented
DMZV6YT SN SCHEMBL8197672; SCHEMBL19309547; CHEMBL3655685; US8569313, Inhibitor 14; BDBM104906
DMZV6YT DT Small molecular drug
DMZV6YT PC 59603780
DMZV6YT MW 549.7
DMZV6YT FM C28H35N7O3S
DMZV6YT IC InChI=1S/C28H35N7O3S/c29-12-9-19-10-13-35(14-11-19)28(36)25(16-20-3-1-5-22(15-20)27(31)32)34-39(37,38)24-6-2-4-21(17-24)23-7-8-26(30)33-18-23/h1-8,15,17-19,25,34H,9-14,16,29H2,(H2,30,33)(H3,31,32)
DMZV6YT CS C1CN(CCC1CCN)C(=O)C(CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC=CC(=C3)C4=CN=C(C=C4)N
DMZV6YT IK YXXOMQLSCCTIBA-UHFFFAOYSA-N
DMZV6YT IU 3-[3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[3-(6-aminopyridin-3-yl)phenyl]sulfonylamino]-3-oxopropyl]benzenecarboximidamide
DMTMG02 ID DMTMG02
DMTMG02 DN US8569313, Inhibitor 15
DMTMG02 HS Patented
DMTMG02 SN CHEMBL3655686; SCHEMBL19309680; SCHEMBL12998675; US8569313, Inhibitor 15; BDBM104907
DMTMG02 DT Small molecular drug
DMTMG02 PC 25181492
DMTMG02 MW 553.7
DMTMG02 FM C28H39N7O3S
DMTMG02 IC InChI=1S/C28H39N7O3S/c29-12-9-19-10-13-35(14-11-19)28(36)25(16-20-3-1-5-22(15-20)27(31)32)34-39(37,38)24-6-2-4-21(17-24)23-7-8-26(30)33-18-23/h1-6,15,17,19,23,25,34H,7-14,16,18,29H2,(H2,30,33)(H3,31,32)
DMTMG02 CS C1CC(=NCC1C2=CC(=CC=C2)S(=O)(=O)NC(CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCC(CC4)CCN)N
DMTMG02 IK JLKDEEFFWQESQM-UHFFFAOYSA-N
DMTMG02 IU 3-[3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[3-(6-amino-2,3,4,5-tetrahydropyridin-3-yl)phenyl]sulfonylamino]-3-oxopropyl]benzenecarboximidamide
DMXTCGM ID DMXTCGM
DMXTCGM DN US8569313, Inhibitor 18
DMXTCGM HS Patented
DMXTCGM SN SCHEMBL8201065; CHEMBL3655687; US8569313, Inhibitor 18; BDBM104909
DMXTCGM DT Small molecular drug
DMXTCGM PC 25031016
DMXTCGM MW 633.8
DMXTCGM FM C34H43N5O5S
DMXTCGM IC InChI=1S/C34H43N5O5S/c1-3-44-29-15-13-26(14-16-29)27-9-6-11-30(23-27)45(42,43)38-31(22-25-8-4-10-28(21-25)33(35)36)34(41)39-19-17-24(18-20-39)7-5-12-32(40)37-2/h4,6,8-11,13-16,21,23-24,31,38H,3,5,7,12,17-20,22H2,1-2H3,(H3,35,36)(H,37,40)/t31-/m0/s1
DMXTCGM CS CCOC1=CC=C(C=C1)C2=CC(=CC=C2)S(=O)(=O)N[C@@H](CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCC(CC4)CCCC(=O)NC
DMXTCGM IK XXQHDBAWRGBXGY-HKBQPEDESA-N
DMXTCGM IU 4-[1-[(2S)-3-(3-carbamimidoylphenyl)-2-[[3-(4-ethoxyphenyl)phenyl]sulfonylamino]propanoyl]piperidin-4-yl]-N-methylbutanamide
DMLXG43 ID DMLXG43
DMLXG43 DN US8569313, Inhibitor 19
DMLXG43 HS Patented
DMLXG43 SN SCHEMBL8203194; CHEMBL3655688; US8569313, Inhibitor 19; BDBM104910
DMLXG43 DT Small molecular drug
DMLXG43 PC 25031103
DMLXG43 MW 617.8
DMLXG43 FM C34H43N5O4S
DMLXG43 IC InChI=1S/C34H43N5O4S/c1-3-24-13-15-27(16-14-24)28-9-6-11-30(23-28)44(42,43)38-31(22-26-8-4-10-29(21-26)33(35)36)34(41)39-19-17-25(18-20-39)7-5-12-32(40)37-2/h4,6,8-11,13-16,21,23,25,31,38H,3,5,7,12,17-20,22H2,1-2H3,(H3,35,36)(H,37,40)/t31-/m0/s1
DMLXG43 CS CCC1=CC=C(C=C1)C2=CC(=CC=C2)S(=O)(=O)N[C@@H](CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCC(CC4)CCCC(=O)NC
DMLXG43 IK CGNCDGWBKGYOAP-HKBQPEDESA-N
DMLXG43 IU 4-[1-[(2S)-3-(3-carbamimidoylphenyl)-2-[[3-(4-ethylphenyl)phenyl]sulfonylamino]propanoyl]piperidin-4-yl]-N-methylbutanamide
DMKLJ6O ID DMKLJ6O
DMKLJ6O DN US8586571, 12
DMKLJ6O HS Patented
DMKLJ6O SN 4-(3-(2-tert-butylphenoxy)azetidin-1-yl)-4-oxobutanoic acid; 4-[3-(2-tert-butylphenoxy)azetidin-1-yl]-4-oxobutanoic acid; SCHEMBL3104804; CHEMBL3642667; PSHYFYJKCNFREU-UHFFFAOYSA-N; BDBM106683; US8586571, 12
DMKLJ6O DT Small molecular drug
DMKLJ6O PC 25242543
DMKLJ6O MW 305.4
DMKLJ6O FM C17H23NO4
DMKLJ6O IC InChI=1S/C17H23NO4/c1-17(2,3)13-6-4-5-7-14(13)22-12-10-18(11-12)15(19)8-9-16(20)21/h4-7,12H,8-11H2,1-3H3,(H,20,21)
DMKLJ6O CS CC(C)(C)C1=CC=CC=C1OC2CN(C2)C(=O)CCC(=O)O
DMKLJ6O IK PSHYFYJKCNFREU-UHFFFAOYSA-N
DMKLJ6O IU 4-[3-(2-tert-butylphenoxy)azetidin-1-yl]-4-oxobutanoic acid
DMX3A0O ID DMX3A0O
DMX3A0O DN US8586571, 36
DMX3A0O HS Patented
DMX3A0O SN SCHEMBL3105846; CHEMBL3642666; VZDYQTRPYQHMNA-UHFFFAOYSA-N; BDBM106682; US8586571, 36; 3-(3-(2-tert-butylphenoxy)azetidin-1-yl)-3-oxopropanoic acid
DMX3A0O DT Small molecular drug
DMX3A0O PC 59577090
DMX3A0O MW 291.34
DMX3A0O FM C16H21NO4
DMX3A0O IC InChI=1S/C16H21NO4/c1-16(2,3)12-6-4-5-7-13(12)21-11-9-17(10-11)14(18)8-15(19)20/h4-7,11H,8-10H2,1-3H3,(H,19,20)
DMX3A0O CS CC(C)(C)C1=CC=CC=C1OC2CN(C2)C(=O)CC(=O)O
DMX3A0O IK VZDYQTRPYQHMNA-UHFFFAOYSA-N
DMX3A0O IU 3-[3-(2-tert-butylphenoxy)azetidin-1-yl]-3-oxopropanoic acid
DM1N74R ID DM1N74R
DM1N74R DN US8586571, 6
DM1N74R HS Patented
DM1N74R SN SCHEMBL3108837; CHEMBL3642665; BDBM106681; US8586571, 6
DM1N74R DT Small molecular drug
DM1N74R PC 59577179
DM1N74R MW 328.4
DM1N74R FM C19H21FN2O2
DM1N74R IC InChI=1S/C19H21FN2O2/c1-19(2,3)15-10-13(20)7-8-17(15)24-14-11-22(12-14)18(23)16-6-4-5-9-21-16/h4-10,14H,11-12H2,1-3H3
DM1N74R CS CC(C)(C)C1=C(C=CC(=C1)F)OC2CN(C2)C(=O)C3=CC=CC=N3
DM1N74R IK NKBTZZMPHFITPK-UHFFFAOYSA-N
DM1N74R IU [3-(2-tert-butyl-4-fluorophenoxy)azetidin-1-yl]-pyridin-2-ylmethanone
DM29KS1 ID DM29KS1
DM29KS1 DN US8592431, 181
DM29KS1 HS Patented
DM29KS1 SN SCHEMBL1371832; CHEMBL3648562; QMZXPLFRIAZTAV-UHFFFAOYSA-N; BDBM107374; US8592431, 181; 7-propyl-4-(2,2,3,3-tetramethyl-1,4-dioxaspiro[4.5]dec-8-yl)-6-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one
DM29KS1 DT Small molecular drug
DM29KS1 PC 59437703
DM29KS1 MW 608.7
DM29KS1 FM C34H40N8O3
DM29KS1 IC InChI=1S/C34H40N8O3/c1-6-9-28-27(20-22-12-14-23(15-13-22)25-10-7-8-11-26(25)29-37-39-40-38-29)30(43)41(31-35-21-36-42(28)31)24-16-18-34(19-17-24)44-32(2,3)33(4,5)45-34/h7-8,10-15,21,24H,6,9,16-20H2,1-5H3,(H,37,38,39,40)
DM29KS1 CS CCCC1=C(C(=O)N(C2=NC=NN12)C3CCC4(CC3)OC(C(O4)(C)C)(C)C)CC5=CC=C(C=C5)C6=CC=CC=C6C7=NNN=N7
DM29KS1 IK QMZXPLFRIAZTAV-UHFFFAOYSA-N
DM29KS1 IU 7-propyl-4-(2,2,3,3-tetramethyl-1,4-dioxaspiro[4.5]decan-8-yl)-6-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-5-one
DM1K5HS ID DM1K5HS
DM1K5HS DN US8592431, 185
DM1K5HS HS Patented
DM1K5HS SN SCHEMBL1373214; SCHEMBL1373217; CHEMBL3648565; IFFXJMQHLNIFIO-YHBQERECSA-N; BDBM107377; US8592431, 185; 4-[trans-4-(1,3-oxazol-5-yl)cyclohexyl]-7-propyl-6-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one
DM1K5HS DT Small molecular drug
DM1K5HS PC 59437597
DM1K5HS MW 561.6
DM1K5HS FM C31H31N9O2
DM1K5HS IC InChI=1S/C31H31N9O2/c1-2-5-27-26(16-20-8-10-21(11-9-20)24-6-3-4-7-25(24)29-35-37-38-36-29)30(41)39(31-33-18-34-40(27)31)23-14-12-22(13-15-23)28-17-32-19-42-28/h3-4,6-11,17-19,22-23H,2,5,12-16H2,1H3,(H,35,36,37,38)
DM1K5HS CS CCCC1=C(C(=O)N(C2=NC=NN12)C3CCC(CC3)C4=CN=CO4)CC5=CC=C(C=C5)C6=CC=CC=C6C7=NNN=N7
DM1K5HS IK IFFXJMQHLNIFIO-UHFFFAOYSA-N
DM1K5HS IU 4-[4-(1,3-oxazol-5-yl)cyclohexyl]-7-propyl-6-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-[1,2,4]triazolo[1,5-a]pyrimidin-5-one
DMAPGBF ID DMAPGBF
DMAPGBF DN US8592431, 457
DMAPGBF HS Patented
DMAPGBF SN SCHEMBL1374524; SCHEMBL1374521; CHEMBL3651823; LXXPRMLBRPJLIY-RQNOJGIXSA-N; BDBM107466; US8592431, 457; 7-butyl-6-{[3-fluoro-2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-[trans-4-(2-hydroxy-2-methylpropoxy)cyclohexyl][1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one
DMAPGBF DT Small molecular drug
DMAPGBF PC 59437811
DMAPGBF MW 614.7
DMAPGBF FM C33H39FN8O3
DMAPGBF IC InChI=1S/C33H39FN8O3/c1-4-5-10-29-27(17-22-12-11-21(18-28(22)34)25-8-6-7-9-26(25)30-37-39-40-38-30)31(43)41(32-35-20-36-42(29)32)23-13-15-24(16-14-23)45-19-33(2,3)44/h6-9,11-12,18,20,23-24,44H,4-5,10,13-17,19H2,1-3H3,(H,37,38,39,40)
DMAPGBF CS CCCCC1=C(C(=O)N(C2=NC=NN12)C3CCC(CC3)OCC(C)(C)O)CC4=C(C=C(C=C4)C5=CC=CC=C5C6=NNN=N6)F
DMAPGBF IK LXXPRMLBRPJLIY-UHFFFAOYSA-N
DMAPGBF IU 7-butyl-6-[[2-fluoro-4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-[4-(2-hydroxy-2-methylpropoxy)cyclohexyl]-[1,2,4]triazolo[1,5-a]pyrimidin-5-one
DMY8U6J ID DMY8U6J
DMY8U6J DN US8592455, 3
DMY8U6J HS Patented
DMY8U6J SN CHEMBL3105021; SCHEMBL1711372; BDBM106803; US8592455, 3
DMY8U6J DT Small molecular drug
DMY8U6J PC 59226518
DMY8U6J MW 472.5
DMY8U6J FM C23H23F3N6O2
DMY8U6J IC InChI=1S/C23H23F3N6O2/c1-11-9-32(10-16(28)22(11)33)18-5-6-29-8-17(18)30-23(34)21-15(27)7-14(26)20(31-21)19-12(24)3-2-4-13(19)25/h2-8,11,16,22,33H,9-10,27-28H2,1H3,(H,30,34)/t11-,16+,22+/m0/s1
DMY8U6J CS C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3N)F)C4=C(C=CC=C4F)F
DMY8U6J IK QJWGSVNGDURFSA-CNUNAPQTSA-N
DMY8U6J IU 3-amino-N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DMTE8QO ID DMTE8QO
DMTE8QO DN US8592455, 90
DMTE8QO HS Patented
DMTE8QO SN SCHEMBL9608645; CHEMBL3639508; BDBM106890; US8592455, 90
DMTE8QO DT Small molecular drug
DMTE8QO PC 46179670
DMTE8QO MW 423.6
DMTE8QO FM C24H33N5O2
DMTE8QO IC InChI=1S/C24H33N5O2/c1-14-11-16(12-19(26)23(14)30)17-9-10-27-13-21(17)29-24(31)22-18(25)7-8-20(28-22)15-5-3-2-4-6-15/h7-10,13-16,19,23,30H,2-6,11-12,25-26H2,1H3,(H,29,31)/t14-,16+,19+,23+/m0/s1
DMTE8QO CS C[C@H]1C[C@H](C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=C(C=CC(=N3)C4CCCCC4)N
DMTE8QO IK JMHGWOVBMIFUIZ-CBAWVIOQSA-N
DMTE8QO IU 3-amino-N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-cyclohexylpyridine-2-carboxamide
DM0YD3Z ID DM0YD3Z
DM0YD3Z DN US8598172, 1
DM0YD3Z HS Patented
DM0YD3Z SN SCHEMBL1527199; CHEMBL3660143; BDBM108214; US8598172, 1
DM0YD3Z DT Small molecular drug
DM0YD3Z PC 42611166
DM0YD3Z MW 533.6
DM0YD3Z FM C26H34F3N7O2
DM0YD3Z IC InChI=1S/C26H34F3N7O2/c1-4-20-24(37)34(3)21-16-30-25(32-23(21)36(20)17-7-5-6-8-17)31-19-15-18(35-13-11-33(2)12-14-35)9-10-22(19)38-26(27,28)29/h9-10,15-17,20H,4-8,11-14H2,1-3H3,(H,30,31,32)/t20-/m1/s1
DM0YD3Z CS CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=CC(=C4)N5CCN(CC5)C)OC(F)(F)F)C
DM0YD3Z IK UKDYPCZCLRCOMP-HXUWFJFHSA-N
DM0YD3Z IU (7R)-8-cyclopentyl-7-ethyl-5-methyl-2-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-7H-pteridin-6-one
DM9YI3K ID DM9YI3K
DM9YI3K DN US8598210, Table XV, 1
DM9YI3K HS Patented
DM9YI3K SN US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2- carbonyl]-amino}-acetic acid methyl ester; SCHEMBL1921387; CHEMBL3646212; LQWXMRRGVHUWEN-UHFFFAOYSA-N; BDBM107695; US8598210, Table XV, 1; {[5-(3-chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester
DM9YI3K DT Small molecular drug
DM9YI3K PC 24891582
DM9YI3K MW 320.73
DM9YI3K FM C15H13ClN2O4
DM9YI3K IC InChI=1S/C15H13ClN2O4/c1-22-13(20)8-18-15(21)14-12(19)6-10(7-17-14)9-3-2-4-11(16)5-9/h2-7,19H,8H2,1H3,(H,18,21)
DM9YI3K CS COC(=O)CNC(=O)C1=C(C=C(C=N1)C2=CC(=CC=C2)Cl)O
DM9YI3K IK LQWXMRRGVHUWEN-UHFFFAOYSA-N
DM9YI3K IU methyl 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate
DMDK98P ID DMDK98P
DMDK98P DN US8598210, Table XV, 2
DMDK98P HS Patented
DMDK98P SN US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyridine- 2-carbonyl]-amino}-acetic acid methyl ester; SCHEMBL1921358; CHEMBL3646213; BDBM107696; US8598210, Table XV, 2
DMDK98P DT Small molecular drug
DMDK98P PC 24891583
DMDK98P MW 320.73
DMDK98P FM C15H13ClN2O4
DMDK98P IC InChI=1S/C15H13ClN2O4/c1-22-13(20)8-18-15(21)14-12(19)6-10(7-17-14)9-2-4-11(16)5-3-9/h2-7,19H,8H2,1H3,(H,18,21)
DMDK98P CS COC(=O)CNC(=O)C1=C(C=C(C=N1)C2=CC=C(C=C2)Cl)O
DMDK98P IK BYGKIXAXITXFDW-UHFFFAOYSA-N
DMDK98P IU methyl 2-[[5-(4-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate
DM3XWMO ID DM3XWMO
DM3XWMO DN US8598210, Table XV, 4
DM3XWMO HS Patented
DM3XWMO SN US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridine-2- carbonyl)amino]-acetic acid; SCHEMBL1923034; CHEMBL3646215; BDBM107698; US8598210, Table XV, 4
DM3XWMO DT Small molecular drug
DM3XWMO PC 24891734
DM3XWMO MW 286.28
DM3XWMO FM C15H14N2O4
DM3XWMO IC InChI=1S/C15H14N2O4/c1-9-2-4-10(5-3-9)11-6-12(18)14(16-7-11)15(21)17-8-13(19)20/h2-7,18H,8H2,1H3,(H,17,21)(H,19,20)
DM3XWMO CS CC1=CC=C(C=C1)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
DM3XWMO IK VBNCAZJDNCXKIO-UHFFFAOYSA-N
DM3XWMO IU 2-[[3-hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl]amino]acetic acid
DMEU5ST ID DMEU5ST
DMEU5ST DN US8598210, Table XV, 5
DMEU5ST HS Patented
DMEU5ST SN US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4- carbonyl)-amino]-acetic acid; SCHEMBL1921403; CHEMBL3646216; BDBM107699; US8598210, Table XV, 5
DMEU5ST DT Small molecular drug
DMEU5ST PC 24891042
DMEU5ST MW 285.29
DMEU5ST FM C16H15NO4
DMEU5ST IC InChI=1S/C16H15NO4/c1-10-2-4-11(5-3-10)12-6-7-13(14(18)8-12)16(21)17-9-15(19)20/h2-8,18H,9H2,1H3,(H,17,21)(H,19,20)
DMEU5ST CS CC1=CC=C(C=C1)C2=CC(=C(C=C2)C(=O)NCC(=O)O)O
DMEU5ST IK POKDHYRFSOQLCV-UHFFFAOYSA-N
DMEU5ST IU 2-[[2-hydroxy-4-(4-methylphenyl)benzoyl]amino]acetic acid
DM5CULA ID DM5CULA
DM5CULA DN US8609715, A-1
DM5CULA HS Patented
DM5CULA SN CHEMBL3642856; SCHEMBL13641235; BDBM109582; US8609715, A-1
DM5CULA DT Small molecular drug
DM5CULA PC 74982902
DM5CULA MW 401.4
DM5CULA FM C19H19N3O7
DM5CULA IC InChI=1S/C19H19N3O7/c1-10(17(24)22-14(9-23)18(25)26)8-13-6-7-15(28-13)19(27)29-12-4-2-11(3-5-12)16(20)21/h2-8,14,23H,9H2,1H3,(H3,20,21)(H,22,24)(H,25,26)/b10-8+/t14-/m0/s1
DM5CULA CS C/C(=C\\C1=CC=C(O1)C(=O)OC2=CC=C(C=C2)C(=N)N)/C(=O)N[C@@H](CO)C(=O)O
DM5CULA IK NRFIREHTDRUARE-PLWJUESGSA-N
DM5CULA IU (2S)-2-[[(E)-3-[5-(4-carbamimidoylphenoxy)carbonylfuran-2-yl]-2-methylprop-2-enoyl]amino]-3-hydroxypropanoic acid
DMY9SFE ID DMY9SFE
DMY9SFE DN US8609715, A-26
DMY9SFE HS Patented
DMY9SFE SN SCHEMBL12581314; CHEMBL3639417; BDBM109604; US8609715, A-26
DMY9SFE DT Small molecular drug
DMY9SFE PC 53242150
DMY9SFE MW 431.4
DMY9SFE FM C20H21N3O8
DMY9SFE IC InChI=1S/C20H21N3O8/c1-11(19(28)23(9-16(24)25)10-17(26)27)8-14-6-7-15(30-14)20(29)31-13-4-2-12(3-5-13)18(21)22/h2-7,11H,8-10H2,1H3,(H3,21,22)(H,24,25)(H,26,27)
DMY9SFE CS CC(CC1=CC=C(O1)C(=O)OC2=CC=C(C=C2)C(=N)N)C(=O)N(CC(=O)O)CC(=O)O
DMY9SFE IK GTJNXXKNXAEKAD-UHFFFAOYSA-N
DMY9SFE IU 2-[[3-[5-(4-carbamimidoylphenoxy)carbonylfuran-2-yl]-2-methylpropanoyl]-(carboxymethyl)amino]acetic acid
DMU26R7 ID DMU26R7
DMU26R7 DN US8609715, B-61
DMU26R7 HS Patented
DMU26R7 SN CHEMBL3639418; SCHEMBL12581324; BDBM109704; US8609715, B-61
DMU26R7 DT Small molecular drug
DMU26R7 PC 53242141
DMU26R7 MW 465.5
DMU26R7 FM C20H20FN3O7S
DMU26R7 IC InChI=1S/C20H20FN3O7S/c1-9-6-15(20(30)31-13-3-2-10(18(22)23)7-11(13)21)32-14(9)4-5-16(25)24-12(19(28)29)8-17(26)27/h2-3,6-7,12H,4-5,8H2,1H3,(H3,22,23)(H,24,25)(H,26,27)(H,28,29)/t12-/m0/s1
DMU26R7 CS CC1=C(SC(=C1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)CCC(=O)N[C@@H](CC(=O)O)C(=O)O
DMU26R7 IK KUFWXCZSAUGMIW-LBPRGKRZSA-N
DMU26R7 IU (2S)-2-[3-[5-(4-carbamimidoyl-2-fluorophenoxy)carbonyl-3-methylthiophen-2-yl]propanoylamino]butanedioic acid
DMJKFVU ID DMJKFVU
DMJKFVU DN US8614253, 29-1
DMJKFVU HS Patented
DMJKFVU SN CHEMBL3265258; SCHEMBL12767127; WXSWAZIIQXYJAM-UHFFFAOYSA-N; BDBM111341; US8614253, 29-1; methyl 3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate
DMJKFVU DT Small molecular drug
DMJKFVU PC 25160990
DMJKFVU MW 306.3
DMJKFVU FM C19H14O4
DMJKFVU IC InChI=1S/C19H14O4/c1-23-19(22)15-4-2-3-12(10-15)13-5-7-16-14(9-13)6-8-18(21)17(16)11-20/h2-11,21H,1H3
DMJKFVU CS COC(=O)C1=CC=CC(=C1)C2=CC3=C(C=C2)C(=C(C=C3)O)C=O
DMJKFVU IK WXSWAZIIQXYJAM-UHFFFAOYSA-N
DMJKFVU IU methyl 3-(5-formyl-6-hydroxynaphthalen-2-yl)benzoate
DMVI83P ID DMVI83P
DMVI83P DN US8614253, 29-19
DMVI83P HS Patented
DMVI83P SN SCHEMBL12674915; CHEMBL3665044; BDBM111359; US8614253, 29-19
DMVI83P DT Small molecular drug
DMVI83P PC 59599768
DMVI83P MW 319.4
DMVI83P FM C20H17NO3
DMVI83P IC InChI=1S/C20H17NO3/c1-21(2)20(24)16-5-3-4-13(11-16)14-6-8-17-15(10-14)7-9-19(23)18(17)12-22/h3-12,23H,1-2H3
DMVI83P CS CN(C)C(=O)C1=CC=CC(=C1)C2=CC3=C(C=C2)C(=C(C=C3)O)C=O
DMVI83P IK NWWPDKVVFKCCIV-UHFFFAOYSA-N
DMVI83P IU 3-(5-formyl-6-hydroxynaphthalen-2-yl)-N,N-dimethylbenzamide
DMRSP2M ID DMRSP2M
DMRSP2M DN US8614253, 32-4
DMRSP2M HS Patented
DMRSP2M SN SCHEMBL12674916; CHEMBL3665053; BDBM111368; US8614253, 32-4
DMRSP2M DT Small molecular drug
DMRSP2M PC 59599904
DMRSP2M MW 333.4
DMRSP2M FM C21H19NO3
DMRSP2M IC InChI=1S/C21H19NO3/c1-13(2)22-21(25)17-5-3-4-14(11-17)15-6-8-18-16(10-15)7-9-20(24)19(18)12-23/h3-13,24H,1-2H3,(H,22,25)
DMRSP2M CS CC(C)NC(=O)C1=CC=CC(=C1)C2=CC3=C(C=C2)C(=C(C=C3)O)C=O
DMRSP2M IK LCESLTUVSXEGCC-UHFFFAOYSA-N
DMRSP2M IU 3-(5-formyl-6-hydroxynaphthalen-2-yl)-N-propan-2-ylbenzamide
DMSQODK ID DMSQODK
DMSQODK DN US8614253, 32-5
DMSQODK HS Patented
DMSQODK SN SCHEMBL12767163; CHEMBL3639639; BDBM111369; US8614253, 32-5
DMSQODK DT Small molecular drug
DMSQODK PC 59599919
DMSQODK MW 395.4
DMSQODK FM C26H21NO3
DMSQODK IC InChI=1S/C26H21NO3/c1-27(16-18-5-3-2-4-6-18)26(30)20-9-7-19(8-10-20)21-11-13-23-22(15-21)12-14-25(29)24(23)17-28/h2-15,17,29H,16H2,1H3
DMSQODK CS CN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=C(C=C4)O)C=O
DMSQODK IK VYGZNGAQJYQSJI-UHFFFAOYSA-N
DMSQODK IU N-benzyl-4-(5-formyl-6-hydroxynaphthalen-2-yl)-N-methylbenzamide
DM4G3OC ID DM4G3OC
DM4G3OC DN US8669361, 102
DM4G3OC HS Patented
DM4G3OC SN SCHEMBL2521818; CHEMBL3652620; NJUKVCLHVLPDAP-UHFFFAOYSA-N; BDBM119380; US8669361, 102; 5-amino-2-(2,6-difluorophenyl)-N-(1-methyl-1H-pyrazol-4-yl)thiazole-4-carboxamide
DM4G3OC DT Small molecular drug
DM4G3OC PC 58464924
DM4G3OC MW 335.33
DM4G3OC FM C14H11F2N5OS
DM4G3OC IC InChI=1S/C14H11F2N5OS/c1-21-6-7(5-18-21)19-13(22)11-12(17)23-14(20-11)10-8(15)3-2-4-9(10)16/h2-6H,17H2,1H3,(H,19,22)
DM4G3OC CS CN1C=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N
DM4G3OC IK NJUKVCLHVLPDAP-UHFFFAOYSA-N
DM4G3OC IU 5-amino-2-(2,6-difluorophenyl)-N-(1-methylpyrazol-4-yl)-1,3-thiazole-4-carboxamide
DMC67G4 ID DMC67G4
DMC67G4 DN US8669361, 103
DMC67G4 HS Patented
DMC67G4 SN SCHEMBL2525678; CHEMBL3652621; NVTPYRCDKQXUGU-VIFPVBQESA-N; BDBM119381; US8669361, 103; (S)-5-amino-N-(5-(3-aminopiperidin-1-yl)-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide
DMC67G4 DT Small molecular drug
DMC67G4 PC 53482276
DMC67G4 MW 419.5
DMC67G4 FM C18H19F2N7OS
DMC67G4 IC InChI=1S/C18H19F2N7OS/c19-10-4-1-5-11(20)13(10)18-25-14(15(22)29-18)17(28)24-12-7-23-26-16(12)27-6-2-3-9(21)8-27/h1,4-5,7,9H,2-3,6,8,21-22H2,(H,23,26)(H,24,28)/t9-/m0/s1
DMC67G4 CS C1C[C@@H](CN(C1)C2=C(C=NN2)NC(=O)C3=C(SC(=N3)C4=C(C=CC=C4F)F)N)N
DMC67G4 IK NVTPYRCDKQXUGU-VIFPVBQESA-N
DMC67G4 IU 5-amino-N-[5-[(3S)-3-aminopiperidin-1-yl]-1H-pyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
DMIZWM6 ID DMIZWM6
DMIZWM6 DN US8669361, 105
DMIZWM6 HS Patented
DMIZWM6 SN SCHEMBL2523114; CHEMBL3652622; QVHWRVHLJFUJKP-UHFFFAOYSA-N; BDBM119382; US8669361, 105; 5-amino-2-(2,6-difluorophenyl)-N-(1-methyl-5-(piperidin-4-ylmethylamino)-1H-pyrazol-4-yl)thiazole-4-carboxamide
DMIZWM6 DT Small molecular drug
DMIZWM6 PC 53482278
DMIZWM6 MW 447.5
DMIZWM6 FM C20H23F2N7OS
DMIZWM6 IC InChI=1S/C20H23F2N7OS/c1-29-18(25-9-11-5-7-24-8-6-11)14(10-26-29)27-19(30)16-17(23)31-20(28-16)15-12(21)3-2-4-13(15)22/h2-4,10-11,24-25H,5-9,23H2,1H3,(H,27,30)
DMIZWM6 CS CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N)NCC4CCNCC4
DMIZWM6 IK QVHWRVHLJFUJKP-UHFFFAOYSA-N
DMIZWM6 IU 5-amino-2-(2,6-difluorophenyl)-N-[1-methyl-5-(piperidin-4-ylmethylamino)pyrazol-4-yl]-1,3-thiazole-4-carboxamide
DMF8MIB ID DMF8MIB
DMF8MIB DN US8669361, 107
DMF8MIB HS Patented
DMF8MIB SN SCHEMBL2517841; CHEMBL3652623; OEPCHHARAQRIEP-NSHDSACASA-N; BDBM119383; US8669361, 107; (S)-5-amino-N-(5-(3-aminopiperidin-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-fluorophenyl)thiazole-4-carboxamide
DMF8MIB DT Small molecular drug
DMF8MIB PC 53482332
DMF8MIB MW 415.5
DMF8MIB FM C19H22FN7OS
DMF8MIB IC InChI=1S/C19H22FN7OS/c1-26-19(27-8-4-5-11(21)10-27)14(9-23-26)24-17(28)15-16(22)29-18(25-15)12-6-2-3-7-13(12)20/h2-3,6-7,9,11H,4-5,8,10,21-22H2,1H3,(H,24,28)/t11-/m0/s1
DMF8MIB CS CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=CC=CC=C3F)N)N4CCC[C@@H](C4)N
DMF8MIB IK OEPCHHARAQRIEP-NSHDSACASA-N
DMF8MIB IU 5-amino-N-[5-[(3S)-3-aminopiperidin-1-yl]-1-methylpyrazol-4-yl]-2-(2-fluorophenyl)-1,3-thiazole-4-carboxamide
DMKYNB0 ID DMKYNB0
DMKYNB0 DN US8703720, 15
DMKYNB0 HS Patented
DMKYNB0 SN SCHEMBL10036913; CHEMBL3680811; BDBM120771; US8703720, 15
DMKYNB0 DT Small molecular drug
DMKYNB0 PC 68014110
DMKYNB0 MW 600.6
DMKYNB0 FM C28H30F2N6O5S
DMKYNB0 IC InChI=1S/C28H30F2N6O5S/c29-17-8-3-1-6-15(17)19-12-35(33-31-19)21-10-5-11-23(25(21)38)42-28-27(40)24(26(39)22(14-37)41-28)36-13-20(32-34-36)16-7-2-4-9-18(16)30/h1-4,6-9,12-13,21-28,37-40H,5,10-11,14H2/t21?,22?,23-,24+,25?,26+,27?,28+/m1/s1
DMKYNB0 CS C1C[C@H](C(C(C1)N2C=C(N=N2)C3=CC=CC=C3F)O)S[C@H]4C([C@H]([C@H](C(O4)CO)O)N5C=C(N=N5)C6=CC=CC=C6F)O
DMKYNB0 IK BJVVNEYHVCHMBX-NJCBQTTNSA-N
DMKYNB0 IU (2S,4S,5R)-4-[4-(2-fluorophenyl)triazol-1-yl]-2-[(1R)-3-[4-(2-fluorophenyl)triazol-1-yl]-2-hydroxycyclohexyl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol
DMFGIPR ID DMFGIPR
DMFGIPR DN US8703720, Reference Compound 1
DMFGIPR HS Patented
DMFGIPR SN SCHEMBL10036902; CHEMBL3680808; BDBM120768; US8703720, Reference Compound 1
DMFGIPR DT Small molecular drug
DMFGIPR PC 58805972
DMFGIPR MW 194.18
DMFGIPR FM C7H14O6
DMFGIPR IC InChI=1S/C7H14O6/c1-12-7-6(11)5(10)4(9)3(2-8)13-7/h3-11H,2H2,1H3/t3?,4-,5-,6?,7+/m0/s1
DMFGIPR CS CO[C@H]1C([C@H]([C@H](C(O1)CO)O)O)O
DMFGIPR IK HOVAGTYPODGVJG-FSUQTPNVSA-N
DMFGIPR IU (3R,4S,6R)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol
DM536FO ID DM536FO
DM536FO DN US8703720, Reference Compound 2
DM536FO HS Patented
DM536FO SN SCHEMBL17678835; CHEMBL3680809; BDBM120769; US8703720, Reference Compound 2
DM536FO DT Small molecular drug
DM536FO PC 84973162
DM536FO MW 397.37
DM536FO FM C15H27NO11
DM536FO IC InChI=1S/C15H27NO11/c1-5(19)16-8-10(21)13(7(4-18)26-14(8)24-2)27-15-12(23)11(22)9(20)6(3-17)25-15/h6-15,17-18,20-23H,3-4H2,1-2H3,(H,16,19)/t6?,7?,8?,9-,10+,11-,12?,13+,14+,15-/m0/s1
DM536FO CS CC(=O)NC1[C@H]([C@@H](C(O[C@H]1OC)CO)O[C@H]2C([C@H]([C@H](C(O2)CO)O)O)O)O
DM536FO IK PKPZITUQXLANSE-IFUIUTNGSA-N
DM536FO IU N-[(2R,4R,5S)-4-hydroxy-6-(hydroxymethyl)-2-methoxy-5-[(2S,4S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide
DMCNAM9 ID DMCNAM9
DMCNAM9 DN US8710232, 1
DMCNAM9 HS Patented
DMCNAM9 SN SCHEMBL4942017; CHEMBL3694266; BDBM120781; US8710232, 1
DMCNAM9 DT Small molecular drug
DMCNAM9 PC 11702405
DMCNAM9 MW 314.4
DMCNAM9 FM C17H22N4O2
DMCNAM9 IC InChI=1S/C17H22N4O2/c18-16-7-6-12(9-19-16)8-14(17(22)23)15-10-21(11-20-15)13-4-2-1-3-5-13/h6-7,9-11,13-14H,1-5,8H2,(H2,18,19)(H,22,23)
DMCNAM9 CS C1CCC(CC1)N2C=C(N=C2)C(CC3=CN=C(C=C3)N)C(=O)O
DMCNAM9 IK XHKJBNCTUYFLDC-UHFFFAOYSA-N
DMCNAM9 IU 3-(6-aminopyridin-3-yl)-2-(1-cyclohexylimidazol-4-yl)propanoic acid
DMCNS9T ID DMCNS9T
DMCNS9T DN US8710232, 7
DMCNS9T HS Patented
DMCNS9T SN SCHEMBL4947561; CHEMBL3694267; IQZKZQSOVLMDRA-UHFFFAOYSA-N; BDBM120782; US8710232, 7; 3-(6-Aminopyridin-3-yl)-2-(1-cyclopentyl-1H-imidazol-4-yl)propionic acid
DMCNS9T DT Small molecular drug
DMCNS9T PC 69252172
DMCNS9T MW 300.36
DMCNS9T FM C16H20N4O2
DMCNS9T IC InChI=1S/C16H20N4O2/c17-15-6-5-11(8-18-15)7-13(16(21)22)14-9-20(10-19-14)12-3-1-2-4-12/h5-6,8-10,12-13H,1-4,7H2,(H2,17,18)(H,21,22)
DMCNS9T CS C1CCC(C1)N2C=C(N=C2)C(CC3=CN=C(C=C3)N)C(=O)O
DMCNS9T IK IQZKZQSOVLMDRA-UHFFFAOYSA-N
DMCNS9T IU 3-(6-aminopyridin-3-yl)-2-(1-cyclopentylimidazol-4-yl)propanoic acid
DM1MQ7J ID DM1MQ7J
DM1MQ7J DN US8710232, 8
DM1MQ7J HS Patented
DM1MQ7J SN SCHEMBL5148920; CHEMBL3694268; BDBM120783; US8710232, 8
DM1MQ7J DT Small molecular drug
DM1MQ7J PC 11500637
DM1MQ7J MW 315.37
DM1MQ7J FM C16H21N5O2
DM1MQ7J IC InChI=1S/C16H21N5O2/c17-15-2-1-11(8-19-15)7-13(16(22)23)14-9-21(10-20-14)12-3-5-18-6-4-12/h1-2,8-10,12-13,18H,3-7H2,(H2,17,19)(H,22,23)
DM1MQ7J CS C1CNCCC1N2C=C(N=C2)C(CC3=CN=C(C=C3)N)C(=O)O
DM1MQ7J IK ZPMPWZIJWOLMHZ-UHFFFAOYSA-N
DM1MQ7J IU 3-(6-aminopyridin-3-yl)-2-(1-piperidin-4-ylimidazol-4-yl)propanoic acid
DMU9YPV ID DMU9YPV
DMU9YPV DN US8741907-compound-3
DMU9YPV HS Patented
DMU9YPV DT Small molecular drug
DMU9YPV PC 135422930
DMU9YPV MW 302.4
DMU9YPV FM C17H26N4O
DMU9YPV IC InChI=1S/C17H26N4O/c1-3-13(4-2)21-16-14(11-18-21)17(22)20-15(19-16)10-12-8-6-5-7-9-12/h11-13H,3-10H2,1-2H3,(H,19,20,22)
DMU9YPV CS CCC(CC)N1C2=C(C=N1)C(=O)NC(=N2)CC3CCCCC3
DMU9YPV IK GXWSVMJGLJNVHK-UHFFFAOYSA-N
DMU9YPV IU 6-(cyclohexylmethyl)-1-pentan-3-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one
DMSYD3X ID DMSYD3X
DMSYD3X DN US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine
DMSYD3X HS Patented
DMSYD3X SN SCHEMBL686607; CHEMBL3680986; BDBM123923; US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine
DMSYD3X DT Small molecular drug
DMSYD3X PC 66768033
DMSYD3X MW 310.4
DMSYD3X FM C15H14N6S
DMSYD3X IC InChI=1S/C15H14N6S/c1-2-4-13-12(3-1)20-15(22-13)11-8-19-21-14(11)17-6-5-10-7-16-9-18-10/h1-4,7-9H,5-6H2,(H,16,18)(H2,17,19,21)
DMSYD3X CS C1=CC=C2C(=C1)N=C(S2)C3=C(NN=C3)NCCC4=CN=CN4
DMSYD3X IK SKFIGKZRFZMUKR-UHFFFAOYSA-N
DMSYD3X IU 4-(1,3-benzothiazol-2-yl)-N-[2-(1H-imidazol-5-yl)ethyl]-1H-pyrazol-5-amine
DMJPQNH ID DMJPQNH
DMJPQNH DN US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide
DMJPQNH HS Patented
DMJPQNH SN SCHEMBL687220; CHEMBL3639798; BDBM123930; US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide
DMJPQNH DT Small molecular drug
DMJPQNH PC 66768275
DMJPQNH MW 313.3
DMJPQNH FM C10H8FN5O2S2
DMJPQNH IC InChI=1S/C10H8FN5O2S2/c11-5-1-6-7(2-8(5)20(13,17)18)19-10(15-6)4-3-14-16-9(4)12/h1-3H,(H3,12,14,16)(H2,13,17,18)
DMJPQNH CS C1=C2C(=CC(=C1F)S(=O)(=O)N)SC(=N2)C3=C(NN=C3)N
DMJPQNH IK MJSWBRWBMZMVTH-UHFFFAOYSA-N
DMJPQNH IU 2-(5-amino-1H-pyrazol-4-yl)-5-fluoro-1,3-benzothiazole-6-sulfonamide
DMJY0CD ID DMJY0CD
DMJY0CD DN US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine
DMJY0CD HS Patented
DMJY0CD SN SCHEMBL686446; CHEMBL3639845; BDBM123985; US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine
DMJY0CD DT Small molecular drug
DMJY0CD PC 66767960
DMJY0CD MW 358.4
DMJY0CD FM C17H12F2N4OS
DMJY0CD IC InChI=1S/C17H12F2N4OS/c1-24-12-7-13-11(6-10(12)19)21-17(25-13)14-15(22-23-16(14)20)8-4-2-3-5-9(8)18/h2-7H,1H3,(H3,20,22,23)
DMJY0CD CS COC1=C(C=C2C(=C1)SC(=N2)C3=C(NN=C3N)C4=CC=CC=C4F)F
DMJY0CD IK YMZGLBIKIDCVFV-UHFFFAOYSA-N
DMJY0CD IU 4-(5-fluoro-6-methoxy-1,3-benzothiazol-2-yl)-5-(2-fluorophenyl)-1H-pyrazol-3-amine
DMRHNIL ID DMRHNIL
DMRHNIL DN US8759338, 1
DMRHNIL HS Patented
DMRHNIL SN SCHEMBL1710320; CHEMBL3685734; BDBM124897; US8759338, 1
DMRHNIL DT Small molecular drug
DMRHNIL PC 46186002
DMRHNIL MW 429.5
DMRHNIL FM C25H21F2N5
DMRHNIL IC InChI=1S/C25H21F2N5/c26-19-7-3-8-20(27)23(19)25-30-13-16-5-2-9-21(24(16)32-25)31-22-14-29-11-10-18(22)15-4-1-6-17(28)12-15/h2-3,5,7-14,17,31H,1,4,6,28H2
DMRHNIL CS C1CC(C=C(C1)C2=C(C=NC=C2)NC3=CC=CC4=CN=C(N=C43)C5=C(C=CC=C5F)F)N
DMRHNIL IK VWDOGNVHWKGFOS-UHFFFAOYSA-N
DMRHNIL IU N-[4-(3-aminocyclohexen-1-yl)pyridin-3-yl]-2-(2,6-difluorophenyl)quinazolin-8-amine
DMXHN1V ID DMXHN1V
DMXHN1V DN US8759338, 12
DMXHN1V HS Patented
DMXHN1V SN SCHEMBL1710271; CHEMBL3639846; BDBM124908; US8759338, 12
DMXHN1V DT Small molecular drug
DMXHN1V PC 46182813
DMXHN1V MW 433.5
DMXHN1V FM C23H21F2N7
DMXHN1V IC InChI=1S/C23H21F2N7/c24-16-6-2-7-17(25)20(16)22-28-10-14-4-1-8-18(21(14)31-22)30-19-11-27-13-29-23(19)32-9-3-5-15(26)12-32/h1-2,4,6-8,10-11,13,15,30H,3,5,9,12,26H2/t15-/m0/s1
DMXHN1V CS C1C[C@@H](CN(C1)C2=NC=NC=C2NC3=CC=CC4=CN=C(N=C43)C5=C(C=CC=C5F)F)N
DMXHN1V IK XPBFQTIASOFUJQ-HNNXBMFYSA-N
DMXHN1V IU N-[4-[(3S)-3-aminopiperidin-1-yl]pyrimidin-5-yl]-2-(2,6-difluorophenyl)quinazolin-8-amine
DMSBRHJ ID DMSBRHJ
DMSBRHJ DN US8759338, 2
DMSBRHJ HS Patented
DMSBRHJ SN SCHEMBL1710174; CHEMBL3685735; BDBM124898; US8759338, 2
DMSBRHJ DT Small molecular drug
DMSBRHJ PC 46186003
DMSBRHJ MW 448.5
DMSBRHJ FM C24H22F2N6O
DMSBRHJ IC InChI=1S/C24H22F2N6O/c25-15-4-2-5-16(26)22(15)24-29-11-14-3-1-6-18(23(14)31-24)30-19-12-28-9-7-20(19)32-10-8-21(33)17(27)13-32/h1-7,9,11-12,17,21,30,33H,8,10,13,27H2/t17-,21+/m1/s1
DMSBRHJ CS C1CN(C[C@H]([C@H]1O)N)C2=C(C=NC=C2)NC3=CC=CC4=CN=C(N=C43)C5=C(C=CC=C5F)F
DMSBRHJ IK WAISNUDWNYJNMT-UTKZUKDTSA-N
DMSBRHJ IU (3R,4S)-3-amino-1-[3-[[2-(2,6-difluorophenyl)quinazolin-8-yl]amino]pyridin-4-yl]piperidin-4-ol
DM2J8IS ID DM2J8IS
DM2J8IS DN US8772478, 1
DM2J8IS HS Patented
DM2J8IS SN SCHEMBL996444; CHEMBL3643908; MVDTXPPSDKEWJP-FQEVSTJZSA-N; BDBM125917; US8772478, 1; (S)-3-(4-benzyloxybenzenesulfonylamino)-N-hydroxy-2-piperidin-1-ylpropionamide
DM2J8IS DT Small molecular drug
DM2J8IS PC 49854306
DM2J8IS MW 433.5
DM2J8IS FM C21H27N3O5S
DM2J8IS IC InChI=1S/C21H27N3O5S/c25-21(23-26)20(24-13-5-2-6-14-24)15-22-30(27,28)19-11-9-18(10-12-19)29-16-17-7-3-1-4-8-17/h1,3-4,7-12,20,22,26H,2,5-6,13-16H2,(H,23,25)/t20-/m0/s1
DM2J8IS CS C1CCN(CC1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)NO
DM2J8IS IK MVDTXPPSDKEWJP-FQEVSTJZSA-N
DM2J8IS IU (2S)-N-hydroxy-3-[(4-phenylmethoxyphenyl)sulfonylamino]-2-piperidin-1-ylpropanamide
DMFJD5L ID DMFJD5L
DMFJD5L DN US8772478, 2
DMFJD5L HS Patented
DMFJD5L SN SCHEMBL997565; CHEMBL3643909; BDBM125918; US8772478, 2
DMFJD5L DT Small molecular drug
DMFJD5L PC 49854307
DMFJD5L MW 419.5
DMFJD5L FM C20H25N3O5S
DMFJD5L IC InChI=1S/C20H25N3O5S/c24-20(22-25)19(23-12-4-5-13-23)14-21-29(26,27)18-10-8-17(9-11-18)28-15-16-6-2-1-3-7-16/h1-3,6-11,19,21,25H,4-5,12-15H2,(H,22,24)/t19-/m0/s1
DMFJD5L CS C1CCN(C1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC=CC=C3)C(=O)NO
DMFJD5L IK NOUZHOVZVQEFTM-IBGZPJMESA-N
DMFJD5L IU (2S)-N-hydroxy-3-[(4-phenylmethoxyphenyl)sulfonylamino]-2-pyrrolidin-1-ylpropanamide
DMN4FRE ID DMN4FRE
DMN4FRE DN US8772478, 3
DMN4FRE HS Patented
DMN4FRE SN SCHEMBL998690; CHEMBL3643910; BDBM125919; US8772478, 3
DMN4FRE DT Small molecular drug
DMN4FRE PC 49854406
DMN4FRE MW 451.5
DMN4FRE FM C21H26FN3O5S
DMN4FRE IC InChI=1S/C21H26FN3O5S/c22-17-6-4-16(5-7-17)15-30-18-8-10-19(11-9-18)31(28,29)23-14-20(21(26)24-27)25-12-2-1-3-13-25/h4-11,20,23,27H,1-3,12-15H2,(H,24,26)/t20-/m0/s1
DMN4FRE CS C1CCN(CC1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC=C(C=C3)F)C(=O)NO
DMN4FRE IK PDOPZKWZZGOMJC-FQEVSTJZSA-N
DMN4FRE IU (2S)-3-[[4-[(4-fluorophenyl)methoxy]phenyl]sulfonylamino]-N-hydroxy-2-piperidin-1-ylpropanamide
DMHI6RZ ID DMHI6RZ
DMHI6RZ DN US8772478, 5
DMHI6RZ HS Patented
DMHI6RZ SN SCHEMBL996082; CHEMBL3643911; BDBM125920; US8772478, 5
DMHI6RZ DT Small molecular drug
DMHI6RZ PC 49854408
DMHI6RZ MW 483.6
DMHI6RZ FM C25H29N3O5S
DMHI6RZ IC InChI=1S/C25H29N3O5S/c29-25(27-30)24(28-14-4-1-5-15-28)17-26-34(31,32)23-12-10-22(11-13-23)33-18-19-8-9-20-6-2-3-7-21(20)16-19/h2-3,6-13,16,24,26,30H,1,4-5,14-15,17-18H2,(H,27,29)/t24-/m0/s1
DMHI6RZ CS C1CCN(CC1)[C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC3=CC4=CC=CC=C4C=C3)C(=O)NO
DMHI6RZ IK OPHJLUDAYHJCPN-DEOSSOPVSA-N
DMHI6RZ IU (2S)-N-hydroxy-3-[[4-(naphthalen-2-ylmethoxy)phenyl]sulfonylamino]-2-piperidin-1-ylpropanamide
DMUPRX2 ID DMUPRX2
DMUPRX2 DN US8791257, 17
DMUPRX2 HS Patented
DMUPRX2 SN CHEMBL3681194; SCHEMBL12285791; BDBM127319; US8791257, 17
DMUPRX2 DT Small molecular drug
DMUPRX2 PC 68231238
DMUPRX2 MW 453.5
DMUPRX2 FM C22H27N7O4
DMUPRX2 IC InChI=1S/C22H27N7O4/c1-3-33-22(31)28-15-6-4-14(5-7-15)27-21(30)16-11-17(13-8-9-24-18(10-13)32-2)29-19(16)20(23)25-12-26-29/h8-12,14-15H,3-7H2,1-2H3,(H,27,30)(H,28,31)(H2,23,25,26)
DMUPRX2 CS CCOC(=O)NC1CCC(CC1)NC(=O)C2=C3C(=NC=NN3C(=C2)C4=CC(=NC=C4)OC)N
DMUPRX2 IK UOUCFNDSPAGXJQ-UHFFFAOYSA-N
DMUPRX2 IU ethyl N-[4-[[4-amino-7-(2-methoxypyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazine-5-carbonyl]amino]cyclohexyl]carbamate
DMAEHCP ID DMAEHCP
DMAEHCP DN US8791257, 38
DMAEHCP HS Patented
DMAEHCP SN CHEMBL3681195; BDBM127320; US8791257, 38
DMAEHCP DT Small molecular drug
DMAEHCP PC 86766696
DMAEHCP MW 423.5
DMAEHCP FM C21H25N7O3
DMAEHCP IC InChI=1S/C21H25N7O3/c1-2-31-21(30)27-15-5-3-14(4-6-15)26-20(29)16-11-17(13-7-9-23-10-8-13)28-18(16)19(22)24-12-25-28/h7-12,14-15H,2-6H2,1H3,(H,26,29)(H,27,30)(H2,22,24,25)
DMAEHCP CS CCOC(=O)NC1CCC(CC1)NC(=O)C2=C3C(=NC=NN3C(=C2)C4=CC=NC=C4)N
DMAEHCP IK JJHBNGJYDQCBGI-UHFFFAOYSA-N
DMAEHCP IU ethyl N-[4-[(4-amino-7-pyridin-4-ylpyrrolo[2,1-f][1,2,4]triazine-5-carbonyl)amino]cyclohexyl]carbamate
DMIQO8N ID DMIQO8N
DMIQO8N DN US8791257, 4
DMIQO8N HS Patented
DMIQO8N SN SCHEMBL14634987; SCHEMBL12284249; CHEMBL3681193; DZUXIHIXWCKJDW-HAQNSBGRSA-N; BDBM127318; US8791257, 4; 4-Amino-N-(trans-4-hydroxycyclohexyl)-7-(2-fluoro-4-pyridinyl)pyrrolo[2,1-f][1,2,4]triazine-5-carboxamide
DMIQO8N DT Small molecular drug
DMIQO8N PC 68230695
DMIQO8N MW 370.4
DMIQO8N FM C18H19FN6O2
DMIQO8N IC InChI=1S/C18H19FN6O2/c19-15-7-10(5-6-21-15)14-8-13(16-17(20)22-9-23-25(14)16)18(27)24-11-1-3-12(26)4-2-11/h5-9,11-12,26H,1-4H2,(H,24,27)(H2,20,22,23)
DMIQO8N CS C1CC(CCC1NC(=O)C2=C3C(=NC=NN3C(=C2)C4=CC(=NC=C4)F)N)O
DMIQO8N IK DZUXIHIXWCKJDW-UHFFFAOYSA-N
DMIQO8N IU 4-amino-7-(2-fluoropyridin-4-yl)-N-(4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazine-5-carboxamide
DMWKDET ID DMWKDET
DMWKDET DN US8829193, 1
DMWKDET HS Patented
DMWKDET SN SCHEMBL2691319; CHEMBL3676258; BDBM131728; US8829193, 1
DMWKDET DT Small molecular drug
DMWKDET PC 51002052
DMWKDET MW 415.5
DMWKDET FM C20H19F2N5OS
DMWKDET IC InChI=1S/C20H19F2N5OS/c21-13-4-1-5-14(22)18(13)20-26-16(11-29-20)19(28)25-15-9-24-7-6-17(15)27-8-2-3-12(23)10-27/h1,4-7,9,11-12H,2-3,8,10,23H2,(H,25,28)/t12-/m0/s1
DMWKDET CS C1C[C@@H](CN(C1)C2=C(C=NC=C2)NC(=O)C3=CSC(=N3)C4=C(C=CC=C4F)F)N
DMWKDET IK DRSGGAHSPDXOOW-LBPRGKRZSA-N
DMWKDET IU N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
DMBIAQD ID DMBIAQD
DMBIAQD DN US8829193, 2
DMBIAQD HS Patented
DMBIAQD SN SCHEMBL2693373; CHEMBL3676259; BDBM131729; US8829193, 2
DMBIAQD DT Small molecular drug
DMBIAQD PC 59455648
DMBIAQD MW 431.5
DMBIAQD FM C20H19F2N5O2S
DMBIAQD IC InChI=1S/C20H19F2N5O2S/c21-11-2-1-3-12(22)18(11)20-26-15(10-30-20)19(29)25-14-8-24-6-4-16(14)27-7-5-17(28)13(23)9-27/h1-4,6,8,10,13,17,28H,5,7,9,23H2,(H,25,29)/t13-,17-/m1/s1
DMBIAQD CS C1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=CSC(=N3)C4=C(C=CC=C4F)F
DMBIAQD IK LQASHUDUJOBHMP-CXAGYDPISA-N
DMBIAQD IU N-[4-[(3R,4R)-3-amino-4-hydroxypiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
DM5ZGK3 ID DM5ZGK3
DM5ZGK3 DN US8829193, 3
DM5ZGK3 HS Patented
DM5ZGK3 SN SCHEMBL2693572; CHEMBL3676260; BDBM131730; US8829193, 3
DM5ZGK3 DT Small molecular drug
DM5ZGK3 PC 59455638
DM5ZGK3 MW 433.5
DM5ZGK3 FM C20H18F3N5OS
DM5ZGK3 IC InChI=1S/C20H18F3N5OS/c21-11-5-7-28(9-14(11)24)17-4-6-25-8-15(17)26-19(29)16-10-30-20(27-16)18-12(22)2-1-3-13(18)23/h1-4,6,8,10-11,14H,5,7,9,24H2,(H,26,29)/t11-,14-/m1/s1
DM5ZGK3 CS C1CN(C[C@H]([C@@H]1F)N)C2=C(C=NC=C2)NC(=O)C3=CSC(=N3)C4=C(C=CC=C4F)F
DM5ZGK3 IK QQRNXNZMTIFVNK-BXUZGUMPSA-N
DM5ZGK3 IU N-[4-[(3R,4R)-3-amino-4-fluoropiperidin-1-yl]pyridin-3-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
DMRUTJZ ID DMRUTJZ
DMRUTJZ DN US8846654, 11
DMRUTJZ HS Patented
DMRUTJZ SN BDBM135577; US8846654, 11
DMRUTJZ DT Small molecular drug
DMRUTJZ PC 74434786
DMRUTJZ MW 523.6
DMRUTJZ FM C26H35F2N3O6
DMRUTJZ IC InChI=1S/C26H35F2N3O6/c1-35-23-6-3-17(11-24(23)36-2)15-30-25(33)21-12-19(37-20(13-27)14-28)4-5-22(21)31(26(30)34)18-7-9-29(16-32)10-8-18/h3,6,11,16,18-22H,4-5,7-10,12-15H2,1-2H3
DMRUTJZ CS COC1=C(C=C(C=C1)CN2C(=O)C3CC(CCC3N(C2=O)C4CCN(CC4)C=O)OC(CF)CF)OC
DMRUTJZ IK QZWWBGKSFBRQGT-UHFFFAOYSA-N
DMRUTJZ IU 4-[6-(1,3-difluoropropan-2-yloxy)-3-[(3,4-dimethoxyphenyl)methyl]-2,4-dioxo-4a,5,6,7,8,8a-hexahydroquinazolin-1-yl]piperidine-1-carbaldehyde
DMML258 ID DMML258
DMML258 DN US8846654, 251
DMML258 HS Patented
DMML258 SN BDBM135583; US8846654, 251
DMML258 DT Small molecular drug
DMML258 PC 75240056
DMML258 MW 634.7
DMML258 FM C32H44F2N4O7
DMML258 IC InChI=1S/C32H44F2N4O7/c1-43-29-15-22(5-8-28(29)44-20-30(40)36-11-3-2-4-12-36)19-37-31(41)26-16-24(45-25(17-33)18-34)6-7-27(26)38(32(37)42)23-9-13-35(21-39)14-10-23/h5,8,15,21,23-27H,2-4,6-7,9-14,16-20H2,1H3
DMML258 CS COC1=C(C=CC(=C1)CN2C(=O)C3CC(CCC3N(C2=O)C4CCN(CC4)C=O)OC(CF)CF)OCC(=O)N5CCCCC5
DMML258 IK NIQRJBGTHGXCJU-UHFFFAOYSA-N
DMML258 IU 4-[6-(1,3-difluoropropan-2-yloxy)-3-[[3-methoxy-4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]methyl]-2,4-dioxo-4a,5,6,7,8,8a-hexahydroquinazolin-1-yl]piperidine-1-carbaldehyde
DMP3RCH ID DMP3RCH
DMP3RCH DN US8846654, 294
DMP3RCH HS Patented
DMP3RCH SN BDBM135584; US8846654, 294
DMP3RCH DT Small molecular drug
DMP3RCH PC 72333047
DMP3RCH MW 564.6
DMP3RCH FM C31H34F2N4O4
DMP3RCH IC InChI=1S/C31H34F2N4O4/c32-16-26(17-33)41-25-7-9-29-28(15-25)30(39)36(31(40)37(29)24-10-12-35(20-38)13-11-24)19-21-6-8-27(23(14-21)18-34)22-4-2-1-3-5-22/h1-6,8,14,20,24-26,28-29H,7,9-13,15-17,19H2
DMP3RCH CS C1CC2C(CC1OC(CF)CF)C(=O)N(C(=O)N2C3CCN(CC3)C=O)CC4=CC(=C(C=C4)C5=CC=CC=C5)C#N
DMP3RCH IK FDTVWOHILNTAPC-UHFFFAOYSA-N
DMP3RCH IU 5-[[6-(1,3-difluoropropan-2-yloxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-4a,5,6,7,8,8a-hexahydroquinazolin-3-yl]methyl]-2-phenylbenzonitrile
DMX8NLB ID DMX8NLB
DMX8NLB DN US8853215, 3
DMX8NLB HS Patented
DMX8NLB SN SCHEMBL631179; CHEMBL3644466; DISALCDEOIPUGE-UHFFFAOYSA-N; BDBM135825; US8853215, 3; 1-(2-tert-Butylphenyl)-4-(1H-imidazol-4-ylcarbonyl)piperazine
DMX8NLB DT Small molecular drug
DMX8NLB PC 66751133
DMX8NLB MW 312.4
DMX8NLB FM C18H24N4O
DMX8NLB IC InChI=1S/C18H24N4O/c1-18(2,3)14-6-4-5-7-16(14)21-8-10-22(11-9-21)17(23)15-12-19-13-20-15/h4-7,12-13H,8-11H2,1-3H3,(H,19,20)
DMX8NLB CS CC(C)(C)C1=CC=CC=C1N2CCN(CC2)C(=O)C3=CN=CN3
DMX8NLB IK DISALCDEOIPUGE-UHFFFAOYSA-N
DMX8NLB IU [4-(2-tert-butylphenyl)piperazin-1-yl]-(1H-imidazol-5-yl)methanone
DMDN8P1 ID DMDN8P1
DMDN8P1 DN US8877733, 27
DMDN8P1 HS Patented
DMDN8P1 SN BDBM139220; US8877733, 27
DMDN8P1 DT Small molecular drug
DMDN8P1 PC 91669038
DMDN8P1 MW 525.19
DMDN8P1 FM C11H18N3O15P3
DMDN8P1 IC InChI=1S/C11H18N3O15P3/c1-10(18)8(16)6(4-26-31(22,23)29-32(24,25)28-30(19,20)21)27-11(10,5-12)14-3-2-7(15)13-9(14)17/h6,8,16,18H,2-4H2,1H3,(H,22,23)(H,24,25)(H,13,15,17)(H2,19,20,21)/t6-,8-,10-,11-/m0/s1
DMDN8P1 CS C[C@@]1([C@H]([C@@H](O[C@]1(C#N)N2CCC(=O)NC2=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMDN8P1 IK OIFHDPSGRVTKRS-SEZOGAINSA-N
DMDN8P1 IU [[(2S,3S,4S,5S)-5-cyano-5-(2,4-dioxo-1,3-diazinan-1-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMLY3RE ID DMLY3RE
DMLY3RE DN US8877733, 28
DMLY3RE HS Patented
DMLY3RE SN CHEMBL3686494; BDBM139221; US8877733, 28
DMLY3RE DT Small molecular drug
DMLY3RE PC 91669039
DMLY3RE MW 522.19
DMLY3RE FM C11H17N4O14P3
DMLY3RE IC InChI=1S/C11H17N4O14P3/c1-10(18)8(16)6(4-26-31(22,23)29-32(24,25)28-30(19,20)21)27-11(10,5-12)15-3-2-7(13)14-9(15)17/h2-3,6,8,16,18H,4H2,1H3,(H,22,23)(H,24,25)(H2,13,14,17)(H2,19,20,21)/t6-,8-,10-,11-/m0/s1
DMLY3RE CS C[C@@]1([C@H]([C@@H](O[C@]1(C#N)N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMLY3RE IK KAONGDYMRWWDBJ-SEZOGAINSA-N
DMLY3RE IU [[(2S,3S,4S,5S)-5-(4-amino-2-oxopyrimidin-1-yl)-5-cyano-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM8B1Q4 ID DM8B1Q4
DM8B1Q4 DN US8889672, 252-036-001
DM8B1Q4 HS Patented
DM8B1Q4 SN SCHEMBL13837647; CHEMBL2393427; BDBM139472; US8889672, 252-036-001
DM8B1Q4 DT Small molecular drug
DM8B1Q4 PC 71009752
DM8B1Q4 MW 369.4
DM8B1Q4 FM C20H19NO4S
DM8B1Q4 IC InChI=1S/C20H19NO4S/c1-23-16-9-8-14(10-17(16)24-2)15-12-26-19(21)18(15)20(22)25-11-13-6-4-3-5-7-13/h3-10,12H,11,21H2,1-2H3
DM8B1Q4 CS COC1=C(C=C(C=C1)C2=CSC(=C2C(=O)OCC3=CC=CC=C3)N)OC
DM8B1Q4 IK DXFCCKZJJXVRFH-UHFFFAOYSA-N
DM8B1Q4 IU benzyl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate
DMKXRJ4 ID DMKXRJ4
DMKXRJ4 DN US8889696, 39
DMKXRJ4 HS Patented
DMKXRJ4 SN CHEMBL3702566; SCHEMBL13385799; BDBM139539; US8889696, 39
DMKXRJ4 DT Small molecular drug
DMKXRJ4 PC 70895719
DMKXRJ4 MW 417.5
DMKXRJ4 FM C22H16FN5OS
DMKXRJ4 IC InChI=1S/C22H16FN5OS/c1-28-20-14(11-19(21(28)29)30-17-5-2-15(23)3-6-17)12-25-22(27-20)26-16-4-7-18-13(10-16)8-9-24-18/h2-12,24H,1H3,(H,25,26,27)
DMKXRJ4 CS CN1C2=NC(=NC=C2C=C(C1=O)SC3=CC=C(C=C3)F)NC4=CC5=C(C=C4)NC=C5
DMKXRJ4 IK FJECSOOLAWUZAB-UHFFFAOYSA-N
DMKXRJ4 IU 6-(4-fluorophenyl)sulfanyl-2-(1H-indol-5-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DMSYUHK ID DMSYUHK
DMSYUHK DN US8889696, Staurosporine
DMSYUHK HS Patented
DMSYUHK SN US8889696, Staurosporine; CHEMBL3683258; BDBM139540
DMSYUHK DT Small molecular drug
DMSYUHK PC 91669270
DMSYUHK MW 452.5
DMSYUHK FM C27H24N4O3
DMSYUHK IC InChI=1S/C27H24N4O3/c1-28-16-11-19-30-17-9-5-4-8-14(17)21-22-15(12-29-26(22)32)20-13-7-3-6-10-18(13)31(23(20)24(21)30)27(34-19)25(16)33-2/h3-10,16,19,25,27-28H,11-12H2,1-2H3,(H,29,32)/t16-,19?,25-,27?/m1/s1
DMSYUHK CS CN[C@@H]1CC2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)C([C@@H]1OC)O2)CNC6=O
DMSYUHK IK YISMQBFJYDFMAL-AESIHLKFSA-N
DMSYUHK IU (3R,4R)-3-methoxy-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one
DMEAUJT ID DMEAUJT
DMEAUJT DN US8901295, F609
DMEAUJT HS Patented
DMEAUJT SN SCHEMBL2039766; CHEMBL3647430; BDBM140001; US8901295, F609
DMEAUJT DT Small molecular drug
DMEAUJT PC 67257644
DMEAUJT MW 382.5
DMEAUJT FM C21H26N4O3
DMEAUJT IC InChI=1S/C21H26N4O3/c1-28-19-7-3-2-5-17(19)18-6-4-12-25(18)20(26)14-24-21(27)23-13-15-8-10-16(22)11-9-15/h2-3,5,7-11,18H,4,6,12-14,22H2,1H3,(H2,23,24,27)
DMEAUJT CS COC1=CC=CC=C1C2CCCN2C(=O)CNC(=O)NCC3=CC=C(C=C3)N
DMEAUJT IK VJEMAKQKNYWEFQ-UHFFFAOYSA-N
DMEAUJT IU 1-[(4-aminophenyl)methyl]-3-[2-[2-(2-methoxyphenyl)pyrrolidin-1-yl]-2-oxoethyl]urea
DMPICE1 ID DMPICE1
DMPICE1 DN US8901295, F673
DMPICE1 HS Patented
DMPICE1 SN SCHEMBL2039389; CHEMBL3639462; BDBM140003; US8901295, F673
DMPICE1 DT Small molecular drug
DMPICE1 PC 67257505
DMPICE1 MW 386.9
DMPICE1 FM C20H23ClN4O2
DMPICE1 IC InChI=1S/C20H23ClN4O2/c21-17-5-2-1-4-16(17)18-6-3-11-25(18)19(26)13-24-20(27)23-12-14-7-9-15(22)10-8-14/h1-2,4-5,7-10,18H,3,6,11-13,22H2,(H2,23,24,27)
DMPICE1 CS C1CC(N(C1)C(=O)CNC(=O)NCC2=CC=C(C=C2)N)C3=CC=CC=C3Cl
DMPICE1 IK HPUOXERGZUDYRB-UHFFFAOYSA-N
DMPICE1 IU 1-[(4-aminophenyl)methyl]-3-[2-[2-(2-chlorophenyl)pyrrolidin-1-yl]-2-oxoethyl]urea
DM34KXF ID DM34KXF
DM34KXF DN US8921389, 1
DM34KXF HS Patented
DM34KXF SN CHEMBL3671864; SCHEMBL12503126; RKTAODJRDMTRFE-UHFFFAOYSA-N; BDBM141545; US8921389, 1; [(1-Benzyl-5-hydroxy-2-oxo-1,2,3,4-tetrahydro-[1,7]naphthyridine-6-carbonyl)-amino]-acetic acid; [(1-Benzyl-5-hydroxy-2-oxo-1,2,3,4-tetrahydro-[1,7]naphthyridine-6-carbonyl)-amino]acetic acid
DM34KXF DT Small molecular drug
DM34KXF PC 60152762
DM34KXF MW 355.3
DM34KXF FM C18H17N3O5
DM34KXF IC InChI=1S/C18H17N3O5/c22-14-7-6-12-13(21(14)10-11-4-2-1-3-5-11)8-19-16(17(12)25)18(26)20-9-15(23)24/h1-5,8,25H,6-7,9-10H2,(H,20,26)(H,23,24)
DM34KXF CS C1CC(=O)N(C2=CN=C(C(=C21)O)C(=O)NCC(=O)O)CC3=CC=CC=C3
DM34KXF IK RKTAODJRDMTRFE-UHFFFAOYSA-N
DM34KXF IU 2-[(1-benzyl-5-hydroxy-2-oxo-3,4-dihydro-1,7-naphthyridine-6-carbonyl)amino]acetic acid
DM8NE12 ID DM8NE12
DM8NE12 DN US8921389, 123
DM8NE12 HS Patented
DM8NE12 SN SCHEMBL12502342; CHEMBL3639708; CJDQJFHCXLGXOK-UHFFFAOYSA-N; BDBM141666; US8921389, 123; 3-[(1-Benzyl-5-hydroxy-2-oxo-3-phenethyl-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-propionic acid
DM8NE12 DT Small molecular drug
DM8NE12 PC 60151541
DM8NE12 MW 471.5
DM8NE12 FM C27H25N3O5
DM8NE12 IC InChI=1S/C27H25N3O5/c31-23(32)13-14-28-26(34)24-25(33)21-15-20(12-11-18-7-3-1-4-8-18)27(35)30(22(21)16-29-24)17-19-9-5-2-6-10-19/h1-10,15-16,33H,11-14,17H2,(H,28,34)(H,31,32)
DM8NE12 CS C1=CC=C(C=C1)CCC2=CC3=C(C(=NC=C3N(C2=O)CC4=CC=CC=C4)C(=O)NCCC(=O)O)O
DM8NE12 IK CJDQJFHCXLGXOK-UHFFFAOYSA-N
DM8NE12 IU 3-[[1-benzyl-5-hydroxy-2-oxo-3-(2-phenylethyl)-1,7-naphthyridine-6-carbonyl]amino]propanoic acid
DMX7KDR ID DMX7KDR
DMX7KDR DN US8921389, 2
DMX7KDR HS Patented
DMX7KDR SN SCHEMBL12502926; CHEMBL3671865; WGLKJEAEYYHYAM-UHFFFAOYSA-N; BDBM141546; US8921389, 2; [(1-Benzyl-5-hydroxy-3-methyl-2-oxo-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-acetic acid
DMX7KDR DT Small molecular drug
DMX7KDR PC 60152763
DMX7KDR MW 367.4
DMX7KDR FM C19H17N3O5
DMX7KDR IC InChI=1S/C19H17N3O5/c1-11-7-13-14(22(19(11)27)10-12-5-3-2-4-6-12)8-20-16(17(13)25)18(26)21-9-15(23)24/h2-8,25H,9-10H2,1H3,(H,21,26)(H,23,24)
DMX7KDR CS CC1=CC2=C(C(=NC=C2N(C1=O)CC3=CC=CC=C3)C(=O)NCC(=O)O)O
DMX7KDR IK WGLKJEAEYYHYAM-UHFFFAOYSA-N
DMX7KDR IU 2-[(1-benzyl-5-hydroxy-3-methyl-2-oxo-1,7-naphthyridine-6-carbonyl)amino]acetic acid
DME1A80 ID DME1A80
DME1A80 DN US8921389, 210
DME1A80 HS Patented
DME1A80 SN SCHEMBL12502343; CHEMBL3639757; VSKYLKKDQYXUIH-UHFFFAOYSA-N; BDBM141750; US8921389, 210; 3-{[1-Benzyl-5-hydroxy-2-oxo-3-(2-trifluoromethyl-phenyl)-1,2-dihydro-[1,7]naphthyridine-6-carbonyl]-amino}-propionic acid
DME1A80 DT Small molecular drug
DME1A80 PC 60152500
DME1A80 MW 511.4
DME1A80 FM C26H20F3N3O5
DME1A80 IC InChI=1S/C26H20F3N3O5/c27-26(28,29)19-9-5-4-8-16(19)17-12-18-20(32(25(17)37)14-15-6-2-1-3-7-15)13-31-22(23(18)35)24(36)30-11-10-21(33)34/h1-9,12-13,35H,10-11,14H2,(H,30,36)(H,33,34)
DME1A80 CS C1=CC=C(C=C1)CN2C3=CN=C(C(=C3C=C(C2=O)C4=CC=CC=C4C(F)(F)F)O)C(=O)NCCC(=O)O
DME1A80 IK VSKYLKKDQYXUIH-UHFFFAOYSA-N
DME1A80 IU 3-[[1-benzyl-5-hydroxy-2-oxo-3-[2-(trifluoromethyl)phenyl]-1,7-naphthyridine-6-carbonyl]amino]propanoic acid
DMIY68N ID DMIY68N
DMIY68N DN US8921389, 22
DMIY68N HS Patented
DMIY68N SN CHEMBL3639707; SCHEMBL12503102; DKTMWXXXKCITJR-UHFFFAOYSA-N; BDBM141566; US8921389, 22; 3-[(1,3-Dibenzyl-5-hydroxy-2-oxo-8-pyridin-3-yl-1,2-dihydro-[1,7]naphthyridine-6-carbonyl)-amino]-propionic acid
DMIY68N DT Small molecular drug
DMIY68N PC 60152635
DMIY68N MW 534.6
DMIY68N FM C31H26N4O5
DMIY68N IC InChI=1S/C31H26N4O5/c36-25(37)13-15-33-30(39)27-29(38)24-17-23(16-20-8-3-1-4-9-20)31(40)35(19-21-10-5-2-6-11-21)28(24)26(34-27)22-12-7-14-32-18-22/h1-12,14,17-18,38H,13,15-16,19H2,(H,33,39)(H,36,37)
DMIY68N CS C1=CC=C(C=C1)CC2=CC3=C(C(=NC(=C3O)C(=O)NCCC(=O)O)C4=CN=CC=C4)N(C2=O)CC5=CC=CC=C5
DMIY68N IK DKTMWXXXKCITJR-UHFFFAOYSA-N
DMIY68N IU 3-[(1,3-dibenzyl-5-hydroxy-2-oxo-8-pyridin-3-yl-1,7-naphthyridine-6-carbonyl)amino]propanoic acid
DMG3T7E ID DMG3T7E
DMG3T7E DN US8933095, 1
DMG3T7E HS Patented
DMG3T7E SN CHEMBL2347107; SCHEMBL9912514; BDBM107746; US8933095, 1
DMG3T7E DT Small molecular drug
DMG3T7E PC 67962992
DMG3T7E MW 258.279
DMG3T7E FM C13H14N4O2
DMG3T7E IC InChI=1S/C13H14N4O2/c14-11-6-10-8-16(7-9-4-2-1-3-5-9)15-12(10)17(19)13(11)18/h1-5,8,11,19H,6-7,14H2/t11-/m0/s1
DMG3T7E CS C1[C@@H](C(=O)N(C2=NN(C=C21)CC3=CC=CC=C3)O)N
DMG3T7E IK YEHNWRNMGIYLAL-NSHDSACASA-N
DMG3T7E IU (5S)-5-amino-2-benzyl-7-hydroxy-4,5-dihydropyrazolo[3,4-b]pyridin-6-one
DMZUNJ4 ID DMZUNJ4
DMZUNJ4 DN US8933095, 14
DMZUNJ4 HS Patented
DMZUNJ4 SN CHEMBL2347108; SCHEMBL9280114; BDBM107730; US8933095, 14
DMZUNJ4 DT Small molecular drug
DMZUNJ4 PC 67813781
DMZUNJ4 MW 244.25
DMZUNJ4 FM C12H12N4O2
DMZUNJ4 IC InChI=1S/C12H12N4O2/c13-10-6-8-7-15(9-4-2-1-3-5-9)14-11(8)16(18)12(10)17/h1-5,7,10,18H,6,13H2/t10-/m0/s1
DMZUNJ4 CS C1[C@@H](C(=O)N(C2=NN(C=C21)C3=CC=CC=C3)O)N
DMZUNJ4 IK AUAOKUNOKVGYJP-JTQLQIEISA-N
DMZUNJ4 IU (5S)-5-amino-7-hydroxy-2-phenyl-4,5-dihydropyrazolo[3,4-b]pyridin-6-one
DMRN5F4 ID DMRN5F4
DMRN5F4 DN US8933095, 16
DMRN5F4 HS Patented
DMRN5F4 SN CHEMBL2347109; SCHEMBL15493583; BDBM50432200; US8933095, 16
DMRN5F4 DT Small molecular drug
DMRN5F4 PC 71717745
DMRN5F4 MW 244.25
DMRN5F4 FM C12H12N4O2
DMRN5F4 IC InChI=1S/C12H12N4O2/c13-9-6-10-11(16(18)12(9)17)7-15(14-10)8-4-2-1-3-5-8/h1-5,7,9,18H,6,13H2/t9-/m0/s1
DMRN5F4 CS C1[C@@H](C(=O)N(C2=CN(N=C21)C3=CC=CC=C3)O)N
DMRN5F4 IK LHLQHHDRLPOVCF-VIFPVBQESA-N
DMRN5F4 IU (6S)-6-amino-4-hydroxy-2-phenyl-6,7-dihydropyrazolo[4,3-b]pyridin-5-one
DMOZ4FS ID DMOZ4FS
DMOZ4FS DN US8933095, 18
DMOZ4FS HS Patented
DMOZ4FS SN CHEMBL2347111; SCHEMBL9912531; BDBM107734; US8933095, 18
DMOZ4FS DT Small molecular drug
DMOZ4FS PC 67963001
DMOZ4FS MW 182.18
DMOZ4FS FM C7H10N4O2
DMOZ4FS IC InChI=1S/C7H10N4O2/c1-10-6-4(3-9-10)2-5(8)7(12)11(6)13/h3,5,13H,2,8H2,1H3/t5-/m0/s1
DMOZ4FS CS CN1C2=C(C[C@@H](C(=O)N2O)N)C=N1
DMOZ4FS IK OETBHDOEBPITJA-YFKPBYRVSA-N
DMOZ4FS IU (5S)-5-amino-7-hydroxy-1-methyl-4,5-dihydropyrazolo[3,4-b]pyridin-6-one
DMPNCOL ID DMPNCOL
DMPNCOL DN US8933228, 3
DMPNCOL HS Patented
DMPNCOL SN SCHEMBL12434738; CHEMBL1090979; BDBM142601; US8933228, 3
DMPNCOL DT Small molecular drug
DMPNCOL PC 46198319
DMPNCOL MW 561.6
DMPNCOL FM C32H31N7O3
DMPNCOL IC InChI=1S/C32H31N7O3/c1-19-10-12-20(13-11-19)39-27(18-26(37-39)32(2,3)4)35-30(40)34-23-14-15-24(22-9-7-6-8-21(22)23)42-25-16-17-33-29-28(25)38(5)31(41)36-29/h6-18H,1-5H3,(H,33,36,41)(H2,34,35,40)
DMPNCOL CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OC5=C6C(=NC=C5)NC(=O)N6C
DMPNCOL IK JIFZZVZROIFPKB-UHFFFAOYSA-N
DMPNCOL IU 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[(1-methyl-2-oxo-3H-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea
DMKEX51 ID DMKEX51
DMKEX51 DN US8933228, Ref 2
DMKEX51 HS Patented
DMKEX51 SN SCHEMBL2531614; CHEMBL3695569; AVUUHIYJPTWYNX-UHFFFAOYSA-N; BDBM142598; US8933228, Ref 2; N-(4-(4-(3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)-2-methoxyacetamide
DMKEX51 DT Small molecular drug
DMKEX51 PC 46218331
DMKEX51 MW 578.7
DMKEX51 FM C33H34N6O4
DMKEX51 IC InChI=1S/C33H34N6O4/c1-21-10-12-22(13-11-21)39-30(19-28(38-39)33(2,3)4)37-32(41)35-26-14-15-27(25-9-7-6-8-24(25)26)43-23-16-17-34-29(18-23)36-31(40)20-42-5/h6-19H,20H2,1-5H3,(H,34,36,40)(H2,35,37,41)
DMKEX51 CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OC5=CC(=NC=C5)NC(=O)COC
DMKEX51 IK AVUUHIYJPTWYNX-UHFFFAOYSA-N
DMKEX51 IU N-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyridin-2-yl]-2-methoxyacetamide
DM6EMYB ID DM6EMYB
DM6EMYB DN US8937193-compound-6b
DM6EMYB HS Patented
DM6EMYB DT Small molecular drug
DM6EMYB PC 136183441
DM6EMYB MW 518.6
DM6EMYB FM C30H30O8
DM6EMYB IC InChI=1S/C30H30O8/c1-11(2)7-15-23-17(9-19(31)27(15)35)29(37)21(13(5)25(23)33)22-14(6)26(34)24-16(8-12(3)4)28(36)20(32)10-18(24)30(22)38/h9-12,31,33,35,37H,7-8H2,1-6H3
DM6EMYB CS CC1=C(C(=O)C2=CC(=O)C(=O)C(=C2C1=O)CC(C)C)C3=C(C4=CC(=C(C(=C4C(=C3C)O)CC(C)C)O)O)O
DM6EMYB IK WDQZGCJOCKBUQY-UHFFFAOYSA-N
DM6EMYB IU 3-methyl-5-(2-methylpropyl)-2-[1,4,6,7-tetrahydroxy-3-methyl-5-(2-methylpropyl)naphthalen-2-yl]naphthalene-1,4,6,7-tetrone
DMHZJEA ID DMHZJEA
DMHZJEA DN US8937193-compound-7
DMHZJEA HS Patented
DMHZJEA SN CHEMBL1269072
DMHZJEA DT Small molecular drug
DMHZJEA PC 136002683
DMHZJEA MW 642.6
DMHZJEA FM C38H26O10
DMHZJEA IC InChI=1S/C38H26O10/c1-17-27(35(45)21-15-25(41)37(47)31(29(21)33(17)43)23(39)13-19-9-5-3-6-10-19)28-18(2)34(44)30-22(36(28)46)16-26(42)38(48)32(30)24(40)14-20-11-7-4-8-12-20/h3-12,15-16,41,43,45,47H,13-14H2,1-2H3
DMHZJEA CS CC1=C(C(=O)C2=CC(=O)C(=O)C(=C2C1=O)C(=O)CC3=CC=CC=C3)C4=C(C5=CC(=C(C(=C5C(=C4C)O)C(=O)CC6=CC=CC=C6)O)O)O
DMHZJEA IK SAXRAWJDCMFHQD-UHFFFAOYSA-N
DMHZJEA IU 3-methyl-5-(2-phenylacetyl)-2-[1,4,6,7-tetrahydroxy-3-methyl-5-(2-phenylacetyl)naphthalen-2-yl]naphthalene-1,4,6,7-tetrone
DM3PU57 ID DM3PU57
DM3PU57 DN US8940736, 23
DM3PU57 HS Patented
DM3PU57 SN CHEMBL3699236; SCHEMBL15425350; BDBM142776; US8940736, 23
DM3PU57 DT Small molecular drug
DM3PU57 PC 72948498
DM3PU57 MW 460.9
DM3PU57 FM C22H21ClN10
DM3PU57 IC InChI=1S/C22H21ClN10/c1-31-9-22(10-31)11-32(12-22)17-5-13(6-24)4-16(18(17)23)28-21-29-19(27-14-2-3-14)20-26-8-15(7-25)33(20)30-21/h4-5,8,14H,2-3,9-12H2,1H3,(H2,27,28,29,30)
DM3PU57 CS CN1CC2(C1)CN(C2)C3=CC(=CC(=C3Cl)NC4=NN5C(=CN=C5C(=N4)NC6CC6)C#N)C#N
DM3PU57 IK UGYSMTLFOSQOTN-UHFFFAOYSA-N
DM3PU57 IU 2-[2-chloro-5-cyano-3-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile
DMXY4SP ID DMXY4SP
DMXY4SP DN US8940736, 6
DMXY4SP HS Patented
DMXY4SP SN SCHEMBL15408873; CHEMBL3699234; BDBM142774; US8940736, 6
DMXY4SP DT Small molecular drug
DMXY4SP PC 89919749
DMXY4SP MW 370.4
DMXY4SP FM C18H14N10
DMXY4SP IC InChI=1S/C18H14N10/c1-27-15-5-4-11(6-13(15)14(8-20)25-27)23-18-24-16(22-10-2-3-10)17-21-9-12(7-19)28(17)26-18/h4-6,9-10H,2-3H2,1H3,(H2,22,23,24,26)
DMXY4SP CS CN1C2=C(C=C(C=C2)NC3=NN4C(=CN=C4C(=N3)NC5CC5)C#N)C(=N1)C#N
DMXY4SP IK JAQNOWSPKHFMOW-UHFFFAOYSA-N
DMXY4SP IU 2-[(3-cyano-1-methylindazol-5-yl)amino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile
DM9KSVI ID DM9KSVI
DM9KSVI DN US8940736, 7
DM9KSVI HS Patented
DM9KSVI SN CHEMBL3699235; SCHEMBL15408805; BDBM142775; US8940736, 7
DM9KSVI DT Small molecular drug
DM9KSVI PC 89919708
DM9KSVI MW 435.9
DM9KSVI FM C20H18ClN9O
DM9KSVI IC InChI=1S/C20H18ClN9O/c21-17-15(5-11(7-22)6-16(17)29-4-3-14(31)10-29)26-20-27-18(25-12-1-2-12)19-24-9-13(8-23)30(19)28-20/h5-6,9,12,14,31H,1-4,10H2,(H2,25,26,27,28)
DM9KSVI CS C1CC1NC2=NC(=NN3C2=NC=C3C#N)NC4=C(C(=CC(=C4)C#N)N5CCC(C5)O)Cl
DM9KSVI IK XMYPWCUEOAYOMV-UHFFFAOYSA-N
DM9KSVI IU 2-[2-chloro-5-cyano-3-(3-hydroxypyrrolidin-1-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile
DM4S5DF ID DM4S5DF
DM4S5DF DN US8975409, Comparative compound B
DM4S5DF HS Patented
DM4S5DF SN SCHEMBL5912478; CHEMBL3401375; BDBM149711; US8975409, Comparative compound B
DM4S5DF DT Small molecular drug
DM4S5DF PC 23071856
DM4S5DF MW 414.5
DM4S5DF FM C24H31FN2O3
DM4S5DF IC InChI=1S/C24H31FN2O3/c1-3-18(4-2)17-24(29)12-14-27(15-13-24)23(28)26-20-6-5-7-22(16-20)30-21-10-8-19(25)9-11-21/h5-11,16,18,29H,3-4,12-15,17H2,1-2H3,(H,26,28)
DM4S5DF CS CCC(CC)CC1(CCN(CC1)C(=O)NC2=CC(=CC=C2)OC3=CC=C(C=C3)F)O
DM4S5DF IK QDTNDGDKXXSUJU-UHFFFAOYSA-N
DM4S5DF IU 4-(2-ethylbutyl)-N-[3-(4-fluorophenoxy)phenyl]-4-hydroxypiperidine-1-carboxamide
DMVB42P ID DMVB42P
DMVB42P DN US8975409, Example 13
DMVB42P HS Patented
DMVB42P SN SCHEMBL14839321; CHEMBL3703198; US8975409, Example 13; BDBM149706
DMVB42P DT Small molecular drug
DMVB42P PC 89484778
DMVB42P MW 590.7
DMVB42P FM C34H39FN2O6
DMVB42P IC InChI=1S/C34H39FN2O6/c1-3-23(4-2)22-33(41)15-17-37(18-16-33)32(40)36-26-19-29(21-30(20-26)43-28-11-7-25(35)8-12-28)42-27-9-5-24(6-10-27)34(13-14-34)31(38)39/h5-12,19-21,23,41H,3-4,13-18,22H2,1-2H3,(H,36,40)(H,38,39)
DMVB42P CS CCC(CC)CC1(CCN(CC1)C(=O)NC2=CC(=CC(=C2)OC3=CC=C(C=C3)F)OC4=CC=C(C=C4)C5(CC5)C(=O)O)O
DMVB42P IK UZPSRIVFHKJDOL-UHFFFAOYSA-N
DMVB42P IU 1-[4-[3-[[4-(2-ethylbutyl)-4-hydroxypiperidine-1-carbonyl]amino]-5-(4-fluorophenoxy)phenoxy]phenyl]cyclopropane-1-carboxylic acid
DMJQOAE ID DMJQOAE
DMJQOAE DN US8975409, Example 9(3)
DMJQOAE HS Patented
DMJQOAE SN SCHEMBL14839451; CHEMBL3618201; BDBM149705; US8975409, Example 9(3)
DMJQOAE DT Small molecular drug
DMJQOAE PC 71547555
DMJQOAE MW 560.5
DMJQOAE FM C31H26F2N2O6
DMJQOAE IC InChI=1S/C31H26F2N2O6/c32-22-5-3-21(4-6-22)31(39)13-15-35(16-14-31)30(38)34-24-17-27(40-25-9-1-20(2-10-25)29(36)37)19-28(18-24)41-26-11-7-23(33)8-12-26/h1-12,17-19,39H,13-16H2,(H,34,38)(H,36,37)
DMJQOAE CS C1CN(CCC1(C2=CC=C(C=C2)F)O)C(=O)NC3=CC(=CC(=C3)OC4=CC=C(C=C4)F)OC5=CC=C(C=C5)C(=O)O
DMJQOAE IK PZFBUIYFAFMDBM-UHFFFAOYSA-N
DMJQOAE IU 4-[3-(4-fluorophenoxy)-5-[[4-(4-fluorophenyl)-4-hydroxypiperidine-1-carbonyl]amino]phenoxy]benzoic acid
DM4MRP9 ID DM4MRP9
DM4MRP9 DN US8987457, 117
DM4MRP9 HS Patented
DM4MRP9 SN CHEMBL3639863; SCHEMBL16579588; BDBM151923; US8987457, 117
DM4MRP9 DT Small molecular drug
DM4MRP9 PC 91937577
DM4MRP9 MW 570.6
DM4MRP9 FM C30H33F3N4O4
DM4MRP9 IC InChI=1S/C30H33F3N4O4/c1-16-11-17(12-23(34)28(16)40-2)19-5-8-35-15-25(19)37-29(38)24-4-3-20(31)27(36-24)26-21(32)13-18(14-22(26)33)30(39)6-9-41-10-7-30/h3-5,8,13-17,23,28,39H,6-7,9-12,34H2,1-2H3,(H,37,38)/t16-,17+,23+,28+/m0/s1
DM4MRP9 CS C[C@H]1C[C@H](C[C@H]([C@@H]1OC)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=C(C=C4F)C5(CCOCC5)O)F
DM4MRP9 IK KRXHIAQHNCEJEE-XCPDJCNPSA-N
DM4MRP9 IU N-[4-[(1R,3R,4R,5S)-3-amino-4-methoxy-5-methylcyclohexyl]pyridin-3-yl]-6-[2,6-difluoro-4-(4-hydroxyoxan-4-yl)phenyl]-5-fluoropyridine-2-carboxamide
DMAGNEH ID DMAGNEH
DMAGNEH DN US8987457, 15
DMAGNEH HS Patented
DMAGNEH SN CHEMBL3639862; SCHEMBL15588795; XQMOXTIXSKOQJT-LCNIEQOASA-N; BDBM151821; US8987457, 15; N-(4-((1R,3R,4S,5S)-3-amino-4-(2-hydroxyethylsulfonyl)-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide
DMAGNEH DT Small molecular drug
DMAGNEH PC 90055863
DMAGNEH MW 548.6
DMAGNEH FM C26H27F3N4O4S
DMAGNEH IC InChI=1S/C26H27F3N4O4S/c1-14-11-15(12-20(30)25(14)38(36,37)10-9-34)16-7-8-31-13-22(16)33-26(35)21-6-5-19(29)24(32-21)23-17(27)3-2-4-18(23)28/h2-8,13-15,20,25,34H,9-12,30H2,1H3,(H,33,35)/t14-,15+,20+,25-/m0/s1
DMAGNEH CS C[C@H]1C[C@H](C[C@H]([C@H]1S(=O)(=O)CCO)N)C2=C(C=NC=C2)NC(=O)C3=NC(=C(C=C3)F)C4=C(C=CC=C4F)F
DMAGNEH IK XQMOXTIXSKOQJT-LCNIEQOASA-N
DMAGNEH IU N-[4-[(1R,3R,4S,5S)-3-amino-4-(2-hydroxyethylsulfonyl)-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide
DM0O8WS ID DM0O8WS
DM0O8WS DN US8987457, 198
DM0O8WS HS Patented
DM0O8WS SN SCHEMBL16588183; CHEMBL3639908; BDBM152004; US8987457, 198
DM0O8WS DT Small molecular drug
DM0O8WS PC 91937649
DM0O8WS MW 578.6
DM0O8WS FM C29H35FN8O4
DM0O8WS IC InChI=1S/C29H35FN8O4/c1-15(2)34-27(39)17-5-6-19(30)18(11-17)22-8-7-20(31)26(35-22)28(40)36-23-12-33-10-9-24(23)38-13-16(3)25(21(32)14-38)37-29(41)42-4/h5-12,15-16,21,25H,13-14,31-32H2,1-4H3,(H,34,39)(H,36,40)(H,37,41)/t16-,21+,25-/m0/s1
DM0O8WS CS C[C@H]1CN(C[C@H]([C@H]1NC(=O)OC)N)C2=C(C=NC=C2)NC(=O)C3=C(C=CC(=N3)C4=C(C=CC(=C4)C(=O)NC(C)C)F)N
DM0O8WS IK FGLBTUNMAVXKMV-LMNXFLSBSA-N
DM0O8WS IU methyl N-[(3R,4S,5S)-3-amino-1-[3-[[3-amino-6-[2-fluoro-5-(propan-2-ylcarbamoyl)phenyl]pyridine-2-carbonyl]amino]pyridin-4-yl]-5-methylpiperidin-4-yl]carbamate
DMBF1C0 ID DMBF1C0
DMBF1C0 DN US9006244, E1
DMBF1C0 HS Patented
DMBF1C0 SN CHEMBL3672843; SCHEMBL15273081; SEQLXXRHDQNPMX-UHFFFAOYSA-N; US9006244, E1; 1-isopropyl-7-(methylsulfonyl)-2-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyrazine
DMBF1C0 DT Small molecular drug
DMBF1C0 PC 89815984
DMBF1C0 MW 439.5
DMBF1C0 FM C19H20F3N5O2S
DMBF1C0 IC InChI=1S/C19H20F3N5O2S/c1-11(2)16-17-24-13-5-4-12(30(3,28)29)10-14(13)26(17)8-9-27(16)18-23-7-6-15(25-18)19(20,21)22/h4-7,10-11,16H,8-9H2,1-3H3
DMBF1C0 CS CC(C)C1C2=NC3=C(N2CCN1C4=NC=CC(=N4)C(F)(F)F)C=C(C=C3)S(=O)(=O)C
DMBF1C0 IK SEQLXXRHDQNPMX-UHFFFAOYSA-N
DMBF1C0 IU 7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazole
DMPDF9B ID DMPDF9B
DMPDF9B DN US9006244, E2a
DMPDF9B HS Patented
DMPDF9B SN SCHEMBL15272683; CHEMBL3672844; US9006244, E2a
DMPDF9B DT Small molecular drug
DMPDF9B PC 71735263
DMPDF9B MW 469.5
DMPDF9B FM C20H22F3N5O3S
DMPDF9B IC InChI=1S/C20H22F3N5O3S/c1-11(2)17-18-25-13-8-12(10-29)15(32(3,30)31)9-14(13)27(18)6-7-28(17)19-24-5-4-16(26-19)20(21,22)23/h4-5,8-9,11,17,29H,6-7,10H2,1-3H3/t17-/m1/s1
DMPDF9B CS CC(C)[C@@H]1C2=NC3=C(N2CCN1C4=NC=CC(=N4)C(F)(F)F)C=C(C(=C3)CO)S(=O)(=O)C
DMPDF9B IK CABUZECPUSGGRX-QGZVFWFLSA-N
DMPDF9B IU [(1R)-7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]methanol
DMP0TBO ID DMP0TBO
DMP0TBO DN US9006244, E2b
DMP0TBO HS Patented
DMP0TBO SN CHEMBL3672845; SCHEMBL15273196; US9006244, E2b
DMP0TBO DT Small molecular drug
DMP0TBO PC 71735264
DMP0TBO MW 469.5
DMP0TBO FM C20H22F3N5O3S
DMP0TBO IC InChI=1S/C20H22F3N5O3S/c1-11(2)17-18-25-13-8-12(10-29)15(32(3,30)31)9-14(13)27(18)6-7-28(17)19-24-5-4-16(26-19)20(21,22)23/h4-5,8-9,11,17,29H,6-7,10H2,1-3H3/t17-/m0/s1
DMP0TBO CS CC(C)[C@H]1C2=NC3=C(N2CCN1C4=NC=CC(=N4)C(F)(F)F)C=C(C(=C3)CO)S(=O)(=O)C
DMP0TBO IK CABUZECPUSGGRX-KRWDZBQOSA-N
DMP0TBO IU [(1S)-7-methylsulfonyl-1-propan-2-yl-2-[4-(trifluoromethyl)pyrimidin-2-yl]-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]methanol
DMPGY0M ID DMPGY0M
DMPGY0M DN US9024044, 1
DMPGY0M HS Patented
DMPGY0M SN CHEMBL3667879; SCHEMBL15605530; BDBM158073; US9024044, 1
DMPGY0M DT Small molecular drug
DMPGY0M PC 72699917
DMPGY0M MW 491.5
DMPGY0M FM C22H22FN3O7S
DMPGY0M IC InChI=1S/C22H22FN3O7S/c23-13-8-11(18(24)25)2-4-15(13)33-20(31)16-5-3-12(34-16)10-22(6-1-7-22)21(32)26-14(19(29)30)9-17(27)28/h2-5,8,14H,1,6-7,9-10H2,(H3,24,25)(H,26,32)(H,27,28)(H,29,30)/t14-/m0/s1
DMPGY0M CS C1CC(C1)(CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMPGY0M IK CHAXFLSDNLDWPP-AWEZNQCLSA-N
DMPGY0M IU (2S)-2-[[1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]cyclobutanecarbonyl]amino]butanedioic acid
DMWRXS8 ID DMWRXS8
DMWRXS8 DN US9024044, 2
DMWRXS8 HS Patented
DMWRXS8 SN SCHEMBL16623616; CHEMBL3667880; BDBM158074; US9024044, 2
DMWRXS8 DT Small molecular drug
DMWRXS8 PC 90019132
DMWRXS8 MW 505.5
DMWRXS8 FM C23H24FN3O7S
DMWRXS8 IC InChI=1S/C23H24FN3O7S/c24-14-9-12(19(25)26)3-5-16(14)34-21(32)17-6-4-13(35-17)11-23(7-1-2-8-23)22(33)27-15(20(30)31)10-18(28)29/h3-6,9,15H,1-2,7-8,10-11H2,(H3,25,26)(H,27,33)(H,28,29)(H,30,31)/t15-/m0/s1
DMWRXS8 CS C1CCC(C1)(CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMWRXS8 IK HXDKJHJAMFQXBA-HNNXBMFYSA-N
DMWRXS8 IU (2S)-2-[[1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]cyclopentanecarbonyl]amino]butanedioic acid
DMKNDMB ID DMKNDMB
DMKNDMB DN US9024044, 3
DMKNDMB HS Patented
DMKNDMB SN SCHEMBL15605631; CHEMBL3667881; BDBM158075; US9024044, 3
DMKNDMB DT Small molecular drug
DMKNDMB PC 72699918
DMKNDMB MW 421.4
DMKNDMB FM C19H20FN3O5S
DMKNDMB IC InChI=1S/C19H20FN3O5S/c1-19(2,18(27)23-9-15(24)25)8-11-4-6-14(29-11)17(26)28-13-5-3-10(16(21)22)7-12(13)20/h3-7H,8-9H2,1-2H3,(H3,21,22)(H,23,27)(H,24,25)
DMKNDMB CS CC(C)(CC1=CC=C(S1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)C(=O)NCC(=O)O
DMKNDMB IK FBFZNZYSXBOYCU-UHFFFAOYSA-N
DMKNDMB IU 2-[[3-[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]-2,2-dimethylpropanoyl]amino]acetic acid
DMANFK8 ID DMANFK8
DMANFK8 DN US9024044, 4
DMANFK8 HS Patented
DMANFK8 SN SCHEMBL15605510; CHEMBL3667882; BDBM158076; US9024044, 4
DMANFK8 DT Small molecular drug
DMANFK8 PC 72699919
DMANFK8 MW 451.5
DMANFK8 FM C20H22FN3O6S
DMANFK8 IC InChI=1S/C20H22FN3O6S/c1-20(2,19(29)24-13(9-25)17(26)27)8-11-4-6-15(31-11)18(28)30-14-5-3-10(16(22)23)7-12(14)21/h3-7,13,25H,8-9H2,1-2H3,(H3,22,23)(H,24,29)(H,26,27)/t13-/m0/s1
DMANFK8 CS CC(C)(CC1=CC=C(S1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)C(=O)N[C@@H](CO)C(=O)O
DMANFK8 IK PGOXWLZRNRRTHV-ZDUSSCGKSA-N
DMANFK8 IU (2S)-2-[[3-[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]-2,2-dimethylpropanoyl]amino]-3-hydroxypropanoic acid
DMZKGOX ID DMZKGOX
DMZKGOX DN US9024044, 62
DMZKGOX HS Patented
DMZKGOX SN SCHEMBL16623655; CHEMBL3639717; BDBM158134; US9024044, 62
DMZKGOX DT Small molecular drug
DMZKGOX PC 92044970
DMZKGOX MW 491.6
DMZKGOX FM C24H30FN3O5S
DMZKGOX IC InChI=1S/C24H30FN3O5S/c1-3-24(4-2,23(32)28-12-6-5-7-20(29)30)14-16-9-11-19(34-16)22(31)33-18-10-8-15(21(26)27)13-17(18)25/h8-11,13H,3-7,12,14H2,1-2H3,(H3,26,27)(H,28,32)(H,29,30)
DMZKGOX CS CCC(CC)(CC1=CC=C(S1)C(=O)OC2=C(C=C(C=C2)C(=N)N)F)C(=O)NCCCCC(=O)O
DMZKGOX IK JBHHRVQRHSBNTN-UHFFFAOYSA-N
DMZKGOX IU 5-[[2-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]-2-ethylbutanoyl]amino]pentanoic acid
DMDELNU ID DMDELNU
DMDELNU DN US9040714, 155
DMDELNU HS Patented
DMDELNU SN SCHEMBL14916256; CHEMBL3639669; BDBM160441; US9040714, 155
DMDELNU DT Small molecular drug
DMDELNU PC 89541971
DMDELNU MW 377.4
DMDELNU FM C19H23NO7
DMDELNU IC InChI=1S/C19H23NO7/c1-4-20-16(23)6-5-12-11(2)17-15(26-8-7-25-3)9-14(22)13(10-21)18(17)27-19(12)24/h9-10,22H,4-8H2,1-3H3,(H,20,23)
DMDELNU CS CCNC(=O)CCC1=C(C2=C(C=C(C(=C2OC1=O)C=O)O)OCCOC)C
DMDELNU IK LPHJXGTWAKQUGZ-UHFFFAOYSA-N
DMDELNU IU N-ethyl-3-[8-formyl-7-hydroxy-5-(2-methoxyethoxy)-4-methyl-2-oxochromen-3-yl]propanamide
DM53Z4I ID DM53Z4I
DM53Z4I DN US9040714, 7
DM53Z4I HS Patented
DM53Z4I SN SCHEMBL14924888; CHEMBL3639668; BDBM160340; US9040714, 7
DM53Z4I DT Small molecular drug
DM53Z4I PC 89548086
DM53Z4I MW 345.14
DM53Z4I FM C16H9BrO4
DM53Z4I IC InChI=1S/C16H9BrO4/c17-11-4-1-9(2-5-11)12-7-10-3-6-14(19)13(8-18)15(10)21-16(12)20/h1-8,19H
DM53Z4I CS C1=CC(=CC=C1C2=CC3=C(C(=C(C=C3)O)C=O)OC2=O)Br
DM53Z4I IK DJSPMRZGTUKARX-UHFFFAOYSA-N
DM53Z4I IU 3-(4-bromophenyl)-7-hydroxy-2-oxochromene-8-carbaldehyde
DM2Z43I ID DM2Z43I
DM2Z43I DN US9073931, E1
DM2Z43I HS Patented
DM2Z43I SN CHEMBL3673668; SCHEMBL15273071; UVRFHLLVIGMMMM-UHFFFAOYSA-N; BDBM168072; US9073931, E1; 1-(2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)ethanone
DM2Z43I DT Small molecular drug
DM2Z43I PC 71735986
DM2Z43I MW 481.5
DM2Z43I FM C21H22F3N5O3S
DM2Z43I IC InChI=1S/C21H22F3N5O3S/c1-11(2)17-19-26-15-6-5-13(33(4,31)32)9-16(15)28(19)7-8-29(17)20-25-10-14(12(3)30)18(27-20)21(22,23)24/h5-6,9-11,17H,7-8H2,1-4H3
DM2Z43I CS CC(C)C1C2=NC3=C(N2CCN1C4=NC=C(C(=N4)C(F)(F)F)C(=O)C)C=C(C=C3)S(=O)(=O)C
DM2Z43I IK UVRFHLLVIGMMMM-UHFFFAOYSA-N
DM2Z43I IU 1-[2-(7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl)-4-(trifluoromethyl)pyrimidin-5-yl]ethanone
DMK9FJG ID DMK9FJG
DMK9FJG DN US9073931, E2
DMK9FJG HS Patented
DMK9FJG SN SCHEMBL15273082; CHEMBL3673669; LOFRRPNYSLDHRM-UHFFFAOYSA-N; BDBM168073; US9073931, E2; 2-(2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-2-ol
DMK9FJG DT Small molecular drug
DMK9FJG PC 71735987
DMK9FJG MW 497.5
DMK9FJG FM C22H26F3N5O3S
DMK9FJG IC InChI=1S/C22H26F3N5O3S/c1-12(2)17-19-27-15-7-6-13(34(5,32)33)10-16(15)29(19)8-9-30(17)20-26-11-14(21(3,4)31)18(28-20)22(23,24)25/h6-7,10-12,17,31H,8-9H2,1-5H3
DMK9FJG CS CC(C)C1C2=NC3=C(N2CCN1C4=NC=C(C(=N4)C(F)(F)F)C(C)(C)O)C=C(C=C3)S(=O)(=O)C
DMK9FJG IK LOFRRPNYSLDHRM-UHFFFAOYSA-N
DMK9FJG IU 2-[2-(7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl)-4-(trifluoromethyl)pyrimidin-5-yl]propan-2-ol
DMCYM8P ID DMCYM8P
DMCYM8P DN US9073931, E3
DMCYM8P HS Patented
DMCYM8P SN SCHEMBL15273343; CHEMBL3673670; VWVWWPZPLJBDBN-UHFFFAOYSA-N; BDBM168074; US9073931, E3; ethyl 2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2 (1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate; ethyl 2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate
DMCYM8P DT Small molecular drug
DMCYM8P PC 71735988
DMCYM8P MW 511.5
DMCYM8P FM C22H24F3N5O4S
DMCYM8P IC InChI=1S/C22H24F3N5O4S/c1-5-34-20(31)14-11-26-21(28-18(14)22(23,24)25)30-9-8-29-16-10-13(35(4,32)33)6-7-15(16)27-19(29)17(30)12(2)3/h6-7,10-12,17H,5,8-9H2,1-4H3
DMCYM8P CS CCOC(=O)C1=CN=C(N=C1C(F)(F)F)N2CCN3C4=C(C=CC(=C4)S(=O)(=O)C)N=C3C2C(C)C
DMCYM8P IK VWVWWPZPLJBDBN-UHFFFAOYSA-N
DMCYM8P IU ethyl 2-(7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylate
DMZD1L5 ID DMZD1L5
DMZD1L5 DN US9073936, 1
DMZD1L5 HS Patented
DMZD1L5 SN SCHEMBL16036074; CHEMBL3678504; RKEUHNQOPBPRQD-UHFFFAOYSA-N; BDBM168126; US9073936, 1; 7,8-Dihydro-2-(4-acetylbenzyl)-3-(4-fluorophenylamino)-5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one
DMZD1L5 DT Small molecular drug
DMZD1L5 PC 90409046
DMZD1L5 MW 460.5
DMZD1L5 FM C25H25FN6O2
DMZD1L5 IC InChI=1S/C25H25FN6O2/c1-15(33)17-7-5-16(6-8-17)13-32-21(27-19-11-9-18(26)10-12-19)20-22(29-32)31-14-25(2,3)28-24(31)30(4)23(20)34/h5-12,27H,13-14H2,1-4H3
DMZD1L5 CS CC(=O)C1=CC=C(C=C1)CN2C(=C3C(=N2)N4CC(N=C4N(C3=O)C)(C)C)NC5=CC=C(C=C5)F
DMZD1L5 IK RKEUHNQOPBPRQD-UHFFFAOYSA-N
DMZD1L5 IU 4-[(4-acetylphenyl)methyl]-5-(4-fluoroanilino)-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one
DMZH3MX ID DMZH3MX
DMZH3MX DN US9073936, 2
DMZH3MX HS Patented
DMZH3MX SN CHEMBL3678505; SCHEMBL16036012; BDBM168127; US9073936, 2
DMZH3MX DT Small molecular drug
DMZH3MX PC 86279224
DMZH3MX MW 462.5
DMZH3MX FM C25H27FN6O2
DMZH3MX IC InChI=1S/C25H27FN6O2/c1-15(33)17-7-5-16(6-8-17)13-32-21(27-19-11-9-18(26)10-12-19)20-22(29-32)31-14-25(2,3)28-24(31)30(4)23(20)34/h5-12,15,27,33H,13-14H2,1-4H3
DMZH3MX CS CC(C1=CC=C(C=C1)CN2C(=C3C(=N2)N4CC(N=C4N(C3=O)C)(C)C)NC5=CC=C(C=C5)F)O
DMZH3MX IK PSUHAEXBWCRQED-UHFFFAOYSA-N
DMZH3MX IU 5-(4-fluoroanilino)-4-[[4-(1-hydroxyethyl)phenyl]methyl]-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one
DMS9W6O ID DMS9W6O
DMS9W6O DN US9073936, 3
DMS9W6O HS Patented
DMS9W6O SN CHEMBL3678506; SCHEMBL16035729; BDBM168128; US9073936, 3
DMS9W6O DT Small molecular drug
DMS9W6O PC 86279223
DMS9W6O MW 478.5
DMS9W6O FM C25H24F2N6O2
DMS9W6O IC InChI=1S/C25H24F2N6O2/c1-14(34)16-7-5-15(6-8-16)12-33-21(28-17-9-10-18(26)19(27)11-17)20-22(30-33)32-13-25(2,3)29-24(32)31(4)23(20)35/h5-11,28H,12-13H2,1-4H3
DMS9W6O CS CC(=O)C1=CC=C(C=C1)CN2C(=C3C(=N2)N4CC(N=C4N(C3=O)C)(C)C)NC5=CC(=C(C=C5)F)F
DMS9W6O IK ITYGOFCAYSOSFS-UHFFFAOYSA-N
DMS9W6O IU 4-[(4-acetylphenyl)methyl]-5-(3,4-difluoroanilino)-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one
DM8UOKE ID DM8UOKE
DM8UOKE DN US9096594, 3
DM8UOKE HS Patented
DM8UOKE SN BDBM173195; US9096594, 3
DM8UOKE DT Small molecular drug
DM8UOKE PC 118797815
DM8UOKE MW 311.4
DM8UOKE FM C19H25N3O
DM8UOKE IC InChI=1S/C19H25N3O/c1-11-15-16(12-7-5-4-6-8-12)17-13(20-18(15)22-21-11)9-19(2,3)10-14(17)23/h4-8,11,15-16,18,20-22H,9-10H2,1-3H3/t11?,15?,16-,18?/m0/s1
DM8UOKE CS CC1C2[C@@H](C3=C(CC(CC3=O)(C)C)NC2NN1)C4=CC=CC=C4
DM8UOKE IK RWOOXYWACRLYJU-RQWZRZRSSA-N
DM8UOKE IU (4R)-3,7,7-trimethyl-4-phenyl-2,3,3a,4,6,8,9,9a-octahydro-1H-pyrazolo[3,4-b]quinolin-5-one
DMPT2ZS ID DMPT2ZS
DMPT2ZS DN US9108950, 1
DMPT2ZS HS Patented
DMPT2ZS SN CHEMBL3701217; SCHEMBL14837075; BDBM161376; US9108950, 1
DMPT2ZS DT Small molecular drug
DMPT2ZS PC 71547929
DMPT2ZS MW 583.7
DMPT2ZS FM C35H33N7O2
DMPT2ZS IC InChI=1S/C35H33N7O2/c1-23-14-16-25(17-15-23)42-31(22-30(41-42)35(2,3)4)39-34(43)38-28-18-19-29(27-13-9-8-12-26(27)28)44-32-20-21-36-33(40-32)37-24-10-6-5-7-11-24/h5-22H,1-4H3,(H,36,37,40)(H2,38,39,43)
DMPT2ZS CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OC5=NC(=NC=C5)NC6=CC=CC=C6
DMPT2ZS IK DBXJNQABFNNKPN-UHFFFAOYSA-N
DMPT2ZS IU 1-[4-(2-anilinopyrimidin-4-yl)oxynaphthalen-1-yl]-3-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]urea
DMKLYCV ID DMKLYCV
DMKLYCV DN US9127005, P0L
DMKLYCV HS Patented
DMKLYCV SN CHEMBL3902347; SCHEMBL11991856; BDBM179736; US9127005, P0L
DMKLYCV DT Small molecular drug
DMKLYCV PC 50902705
DMKLYCV MW 460.5
DMKLYCV FM C27H29FN4O2
DMKLYCV IC InChI=1S/C27H29FN4O2/c1-18(31-25(33)21-14-20-4-2-3-5-24(20)29-15-21)17-32-12-10-27(11-13-32)23(16-30-26(27)34)19-6-8-22(28)9-7-19/h2-9,14-15,18,23H,10-13,16-17H2,1H3,(H,30,34)(H,31,33)/t18-,23+/m0/s1
DMKLYCV CS C[C@@H](CN1CCC2(CC1)[C@H](CNC2=O)C3=CC=C(C=C3)F)NC(=O)C4=CC5=CC=CC=C5N=C4
DMKLYCV IK VALMDDHRZJXVOR-FDDCHVKYSA-N
DMKLYCV IU N-[(2S)-1-[(4R)-4-(4-fluorophenyl)-1-oxo-2,8-diazaspiro[4.5]decan-8-yl]propan-2-yl]quinoline-3-carboxamide
DM3R7BT ID DM3R7BT
DM3R7BT DN US9127005, P2B
DM3R7BT HS Patented
DM3R7BT SN SCHEMBL12965084; CHEMBL3910701; BDBM179743; US9127005, P2B
DM3R7BT DT Small molecular drug
DM3R7BT PC 50902792
DM3R7BT MW 427.5
DM3R7BT FM C24H27F2N3O2
DM3R7BT IC InChI=1S/C24H27F2N3O2/c1-16(28-22(30)18-4-8-20(26)9-5-18)15-29-12-10-24(11-13-29)21(14-27-23(24)31)17-2-6-19(25)7-3-17/h2-9,16,21H,10-15H2,1H3,(H,27,31)(H,28,30)/t16-,21?/m0/s1
DM3R7BT CS C[C@@H](CN1CCC2(CC1)C(CNC2=O)C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)F
DM3R7BT IK ZRRZCDIHCHFDRR-BJQOMGFOSA-N
DM3R7BT IU 4-fluoro-N-[(2S)-1-[4-(4-fluorophenyl)-1-oxo-2,8-diazaspiro[4.5]decan-8-yl]propan-2-yl]benzamide
DMMT98V ID DMMT98V
DMMT98V DN US9127005, P2C
DMMT98V HS Patented
DMMT98V SN CHEMBL3892578; BDBM179751; US9127005, P2C
DMMT98V DT Small molecular drug
DMMT98V PC 68182802
DMMT98V MW 413.5
DMMT98V FM C23H25F2N3O2
DMMT98V IC InChI=1S/C23H25F2N3O2/c24-18-5-1-16(2-6-18)20-15-27-22(30)23(20)9-12-28(13-10-23)14-11-26-21(29)17-3-7-19(25)8-4-17/h1-8,20H,9-15H2,(H,26,29)(H,27,30)
DMMT98V CS C1CN(CCC12C(CNC2=O)C3=CC=C(C=C3)F)CCNC(=O)C4=CC=C(C=C4)F
DMMT98V IK BPCQYJWHRHUHQC-UHFFFAOYSA-N
DMMT98V IU 4-fluoro-N-[2-[4-(4-fluorophenyl)-1-oxo-2,8-diazaspiro[4.5]decan-8-yl]ethyl]benzamide
DM9RIF4 ID DM9RIF4
DM9RIF4 DN US9132129, Cpd002
DM9RIF4 HS Patented
DM9RIF4 SN SCHEMBL6122927; CHEMBL3964350; NWMYEMJIPIXUNW-UHFFFAOYSA-N; BDBM179821; US9132129, Cpd002; 2-tert-butoxy-2-[2-methyl-4-(p-tolyl)-6,7,8,9-tetrahydrobenzo[g]quinolin-3-yl]acetic acid; tert-butoxy-(2-methyl-4-p-tolyl-6,7,8,9-tetrahydro-benzo[g]quinolin-3-yl)-acetic acid
DM9RIF4 DT Small molecular drug
DM9RIF4 PC 69673878
DM9RIF4 MW 417.5
DM9RIF4 FM C27H31NO3
DM9RIF4 IC InChI=1S/C27H31NO3/c1-16-10-12-18(13-11-16)24-21-14-19-8-6-7-9-20(19)15-22(21)28-17(2)23(24)25(26(29)30)31-27(3,4)5/h10-15,25H,6-9H2,1-5H3,(H,29,30)
DM9RIF4 CS CC1=CC=C(C=C1)C2=C3C=C4CCCCC4=CC3=NC(=C2C(C(=O)O)OC(C)(C)C)C
DM9RIF4 IK NWMYEMJIPIXUNW-UHFFFAOYSA-N
DM9RIF4 IU 2-[2-methyl-4-(4-methylphenyl)-6,7,8,9-tetrahydrobenzo[g]quinolin-3-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid
DMG18XH ID DMG18XH
DMG18XH DN US9132129, Cpd023
DMG18XH HS Patented
DMG18XH SN SCHEMBL6122208; CHEMBL3941519; MNMDSGXKGOEYSF-UHFFFAOYSA-N; BDBM179842; US9132129, Cpd023; 2-(3-methyl-1-p-tolyl-8,9-dihydro-7H-cyclopenta[f]quinolin-2-yl)pentanoic acid; 2-[3-methyl-1-(p-tolyl)-8,9-dihydro-7H-cyclopenta[f]quinolin-2-yl]pentanoic acid
DMG18XH DT Small molecular drug
DMG18XH PC 69673439
DMG18XH MW 373.5
DMG18XH FM C25H27NO2
DMG18XH IC InChI=1S/C25H27NO2/c1-4-6-20(25(27)28)22-16(3)26-21-14-13-17-7-5-8-19(17)24(21)23(22)18-11-9-15(2)10-12-18/h9-14,20H,4-8H2,1-3H3,(H,27,28)
DMG18XH CS CCCC(C1=C(N=C2C=CC3=C(C2=C1C4=CC=C(C=C4)C)CCC3)C)C(=O)O
DMG18XH IK MNMDSGXKGOEYSF-UHFFFAOYSA-N
DMG18XH IU 2-[3-methyl-1-(4-methylphenyl)-8,9-dihydro-7H-cyclopenta[f]quinolin-2-yl]pentanoic acid
DM17YHP ID DM17YHP
DM17YHP DN US9132129, Cpd047
DM17YHP HS Patented
DM17YHP SN SCHEMBL6122355; CHEMBL3910801; ZCHVIKJTLWPNBL-UHFFFAOYSA-N; BDBM179866; US9132129, Cpd047; 2-(2-methyl-4-p-tolylpyrimido[1,2-b]indazol-3-yl)pentanoic acid
DM17YHP DT Small molecular drug
DM17YHP PC 69673524
DM17YHP MW 373.4
DM17YHP FM C23H23N3O2
DM17YHP IC InChI=1S/C23H23N3O2/c1-4-7-18(23(27)28)20-15(3)24-22-17-8-5-6-9-19(17)25-26(22)21(20)16-12-10-14(2)11-13-16/h5-6,8-13,18H,4,7H2,1-3H3,(H,27,28)
DM17YHP CS CCCC(C1=C(N2C(=C3C=CC=CC3=N2)N=C1C)C4=CC=C(C=C4)C)C(=O)O
DM17YHP IK ZCHVIKJTLWPNBL-UHFFFAOYSA-N
DM17YHP IU 2-[2-methyl-4-(4-methylphenyl)pyrimido[1,2-b]indazol-3-yl]pentanoic acid
DMT6HXB ID DMT6HXB
DMT6HXB DN US9156852, 1
DMT6HXB HS Patented
DMT6HXB SN CHEMBL3969260; SCHEMBL15066998; BDBM185584; US9156852, 1
DMT6HXB DT Small molecular drug
DMT6HXB PC 71622578
DMT6HXB MW 460.9
DMT6HXB FM C23H17ClN6OS
DMT6HXB IC InChI=1S/C23H17ClN6OS/c1-12-2-7-16-15(8-9-26-22(16)29-14-5-3-13(24)4-6-14)18(12)30-23(31)17-10-32-20-19(17)27-11-28-21(20)25/h2-11H,1H3,(H,26,29)(H,30,31)(H2,25,27,28)
DMT6HXB CS CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC=C(C=C3)Cl)NC(=O)C4=CSC5=C4N=CN=C5N
DMT6HXB IK FHPTWZJZWOYCKG-UHFFFAOYSA-N
DMT6HXB IU 4-amino-N-[1-(4-chloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
DMZ1RMA ID DMZ1RMA
DMZ1RMA DN US9156852, 105
DMZ1RMA HS Patented
DMZ1RMA SN SCHEMBL15066797; CHEMBL3915720; BDBM185590; US9156852, 105
DMZ1RMA DT Small molecular drug
DMZ1RMA PC 71622865
DMZ1RMA MW 478.9
DMZ1RMA FM C23H16ClFN6OS
DMZ1RMA IC InChI=1S/C23H16ClFN6OS/c1-11-2-4-14-13(6-7-27-22(14)30-12-3-5-17(25)16(24)8-12)18(11)31-23(32)15-9-33-20-19(15)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
DMZ1RMA CS CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=C(C=C3)F)Cl)NC(=O)C4=CSC5=C4N=CN=C5N
DMZ1RMA IK GNDBDDNLWIOKDN-UHFFFAOYSA-N
DMZ1RMA IU 4-amino-N-[1-(3-chloro-4-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
DMFSOQY ID DMFSOQY
DMFSOQY DN US9156852, 38
DMFSOQY HS Patented
DMFSOQY SN SCHEMBL15065881; CHEMBL3954810; BDBM185586; US9156852, 38
DMFSOQY DT Small molecular drug
DMFSOQY PC 89655060
DMFSOQY MW 460.9
DMFSOQY FM C23H17ClN6OS
DMFSOQY IC InChI=1S/C23H17ClN6OS/c1-12-5-6-16-15(7-8-26-22(16)29-14-4-2-3-13(24)9-14)18(12)30-23(31)17-10-32-20-19(17)27-11-28-21(20)25/h2-11H,1H3,(H,26,29)(H,30,31)(H2,25,27,28)
DMFSOQY CS CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)Cl)NC(=O)C4=CSC5=C4N=CN=C5N
DMFSOQY IK RFEWCQAWLXXDQI-UHFFFAOYSA-N
DMFSOQY IU 4-amino-N-[1-(3-chloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
DM1K5T0 ID DM1K5T0
DM1K5T0 DN US9156852, 83
DM1K5T0 HS Patented
DM1K5T0 SN SCHEMBL15067512; CHEMBL3944137; BDBM185589; US9156852, 83
DM1K5T0 DT Small molecular drug
DM1K5T0 PC 71622312
DM1K5T0 MW 468.5
DM1K5T0 FM C25H20N6O2S
DM1K5T0 IC InChI=1S/C25H20N6O2S/c1-13-3-8-18-17(9-10-27-24(18)30-16-6-4-15(5-7-16)14(2)32)20(13)31-25(33)19-11-34-22-21(19)28-12-29-23(22)26/h3-12H,1-2H3,(H,27,30)(H,31,33)(H2,26,28,29)
DM1K5T0 CS CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC=C(C=C3)C(=O)C)NC(=O)C4=CSC5=C4N=CN=C5N
DM1K5T0 IK VDPIYNSZQSYYGQ-UHFFFAOYSA-N
DM1K5T0 IU N-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide
DMOKG3Q ID DMOKG3Q
DMOKG3Q DN US9181182, 34
DMOKG3Q HS Patented
DMOKG3Q SN SCHEMBL565019; CHEMBL3941765; KBLICPOFCCULHE-UHFFFAOYSA-N; BDBM190503; US9181182, 34; 2-Amino-2-((4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)methyl)propane-1,3-diol
DMOKG3Q DT Small molecular drug
DMOKG3Q PC 45255648
DMOKG3Q MW 454.5
DMOKG3Q FM C24H30N4O5
DMOKG3Q IC InChI=1S/C24H30N4O5/c1-3-31-20-9-8-16(12-21(20)32-4-2)23-26-22(27-33-23)18-6-5-7-19-17(18)10-11-28(19)13-24(25,14-29)15-30/h5-9,12,29-30H,3-4,10-11,13-15,25H2,1-2H3
DMOKG3Q CS CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCN(C4=CC=C3)CC(CO)(CO)N)OCC
DMOKG3Q IK KBLICPOFCCULHE-UHFFFAOYSA-N
DMOKG3Q IU 2-amino-2-[[4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydroindol-1-yl]methyl]propane-1,3-diol
DM3QIF4 ID DM3QIF4
DM3QIF4 DN US9181182, 40
DM3QIF4 HS Patented
DM3QIF4 SN SCHEMBL566013; CHEMBL3896342; ARJYSAJMGKMECN-UHFFFAOYSA-N; BDBM190507; US9181182, 40; 2-Amino-2-((5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)methyl)propane-1,3-diol
DM3QIF4 DT Small molecular drug
DM3QIF4 PC 46195170
DM3QIF4 MW 454.5
DM3QIF4 FM C24H30N4O5
DM3QIF4 IC InChI=1S/C24H30N4O5/c1-3-31-20-8-6-18(12-21(20)32-4-2)23-26-22(27-33-23)17-5-7-19-16(11-17)9-10-28(19)13-24(25,14-29)15-30/h5-8,11-12,29-30H,3-4,9-10,13-15,25H2,1-2H3
DM3QIF4 CS CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC4=C(C=C3)N(CC4)CC(CO)(CO)N)OCC
DM3QIF4 IK ARJYSAJMGKMECN-UHFFFAOYSA-N
DM3QIF4 IU 2-amino-2-[[5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydroindol-1-yl]methyl]propane-1,3-diol
DM4OHB5 ID DM4OHB5
DM4OHB5 DN US9181182, 47
DM4OHB5 HS Patented
DM4OHB5 SN SCHEMBL566158; CHEMBL3944892; KVXIWHRSUIQTTC-UHFFFAOYSA-N; BDBM190520; US9181182, 47; 2-Amino-2-((4-(5-(3,4-dipropylphenyl)-1,2,4-oxadiazol-3-yl)indolin-1-yl)methyl)propane-1,3-diol
DM4OHB5 DT Small molecular drug
DM4OHB5 PC 46195606
DM4OHB5 MW 450.6
DM4OHB5 FM C26H34N4O3
DM4OHB5 IC InChI=1S/C26H34N4O3/c1-3-6-18-10-11-20(14-19(18)7-4-2)25-28-24(29-33-25)22-8-5-9-23-21(22)12-13-30(23)15-26(27,16-31)17-32/h5,8-11,14,31-32H,3-4,6-7,12-13,15-17,27H2,1-2H3
DM4OHB5 CS CCCC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCN(C4=CC=C3)CC(CO)(CO)N)CCC
DM4OHB5 IK KVXIWHRSUIQTTC-UHFFFAOYSA-N
DM4OHB5 IU 2-amino-2-[[4-[5-(3,4-dipropylphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydroindol-1-yl]methyl]propane-1,3-diol
DMVFBHD ID DMVFBHD
DMVFBHD DN US9187437, 24
DMVFBHD HS Patented
DMVFBHD SN SCHEMBL876114; CHEMBL3909228; BDBM192144; US9187437, 24
DMVFBHD DT Small molecular drug
DMVFBHD PC 56949017
DMVFBHD MW 481.4
DMVFBHD FM C26H26Cl2N4O
DMVFBHD IC InChI=1S/C26H26Cl2N4O/c27-23-24(28)32(18-29-23)17-19-8-7-9-20(16-19)25-30-22(33-31-25)12-15-26(13-5-2-6-14-26)21-10-3-1-4-11-21/h1,3-4,7-11,16,18H,2,5-6,12-15,17H2
DMVFBHD CS C1CCC(CC1)(CCC2=NC(=NO2)C3=CC=CC(=C3)CN4C=NC(=C4Cl)Cl)C5=CC=CC=C5
DMVFBHD IK TVHRMMKSOSXQRC-UHFFFAOYSA-N
DMVFBHD IU 3-[3-[(4,5-dichloroimidazol-1-yl)methyl]phenyl]-5-[2-(1-phenylcyclohexyl)ethyl]-1,2,4-oxadiazole
DM2ULB8 ID DM2ULB8
DM2ULB8 DN US9187437, 38
DM2ULB8 HS Patented
DM2ULB8 SN SCHEMBL876090; CHEMBL3906369; BDBM192146; US9187437, 38
DM2ULB8 DT Small molecular drug
DM2ULB8 PC 56949269
DM2ULB8 MW 333.4
DM2ULB8 FM C21H23N3O
DM2ULB8 IC InChI=1S/C21H23N3O/c1-3-9-18(10-4-1)21(12-5-2-6-13-21)14-11-19-23-20(24-25-19)17-8-7-15-22-16-17/h1,3-4,7-10,15-16H,2,5-6,11-14H2
DM2ULB8 CS C1CCC(CC1)(CCC2=NC(=NO2)C3=CN=CC=C3)C4=CC=CC=C4
DM2ULB8 IK UAUQCABEJBRLRC-UHFFFAOYSA-N
DM2ULB8 IU 5-[2-(1-phenylcyclohexyl)ethyl]-3-pyridin-3-yl-1,2,4-oxadiazole
DMEHSR7 ID DMEHSR7
DMEHSR7 DN US9187437, 8
DMEHSR7 HS Patented
DMEHSR7 SN SCHEMBL877139; CHEMBL3911469; BDBM192127; US9187437, 8
DMEHSR7 DT Small molecular drug
DMEHSR7 PC 56948777
DMEHSR7 MW 400.4
DMEHSR7 FM C23H23F3N2O
DMEHSR7 IC InChI=1S/C23H23F3N2O/c24-23(25,26)19-11-7-8-17(16-19)21-27-20(29-28-21)12-15-22(13-5-2-6-14-22)18-9-3-1-4-10-18/h1,3-4,7-11,16H,2,5-6,12-15H2
DMEHSR7 CS C1CCC(CC1)(CCC2=NC(=NO2)C3=CC(=CC=C3)C(F)(F)F)C4=CC=CC=C4
DMEHSR7 IK QEEBNTVAPQWKOQ-UHFFFAOYSA-N
DMEHSR7 IU 5-[2-(1-phenylcyclohexyl)ethyl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
DMCLHX5 ID DMCLHX5
DMCLHX5 DN US9200020, Table 3 compound 8
DMCLHX5 HS Patented
DMCLHX5 SN BDBM194499; US9200020, Table 3 compound 8
DMCLHX5 DT Small molecular drug
DMCLHX5 PC 72671667
DMCLHX5 MW 374.29
DMCLHX5 FM C12H19N6O6P
DMCLHX5 IC InChI=1S/C12H19N6O6P/c13-12-15-10-9(11(21)16-12)14-7-18(10)4-3-17(2-1-8(19)20)5-6-25(22,23)24/h7,9H,1-6H2,(H,19,20)(H2,13,16,21)(H2,22,23,24)
DMCLHX5 CS C1=NC2C(=NC(=NC2=O)N)N1CCN(CCC(=O)O)CCP(=O)(O)O
DMCLHX5 IK LUBVDKAUBOMGNH-UHFFFAOYSA-N
DMCLHX5 IU 3-[2-(2-amino-6-oxo-5H-purin-9-yl)ethyl-(2-phosphonoethyl)amino]propanoic acid
DMEARS2 ID DMEARS2
DMEARS2 DN US9200020, Table 3, Compound 1B
DMEARS2 HS Patented
DMEARS2 SN BDBM60886; US9200020, Table 3, Compound 1B
DMEARS2 DT Small molecular drug
DMEARS2 PC 72672374
DMEARS2 MW 373.3
DMEARS2 FM C13H20N5O6P
DMEARS2 IC InChI=1S/C13H20N5O6P/c1-2-24-10(19)7-17(5-6-25(21,22)23)3-4-18-9-16-11-12(18)14-8-15-13(11)20/h8-9,11H,2-7H2,1H3,(H2,21,22,23)
DMEARS2 CS CCOC(=O)CN(CCN1C=NC2C1=NC=NC2=O)CCP(=O)(O)O
DMEARS2 IK ISSPDMWVBYSPCQ-UHFFFAOYSA-N
DMEARS2 IU 2-[(2-ethoxy-2-oxoethyl)-[2-(6-oxo-5H-purin-9-yl)ethyl]amino]ethylphosphonic acid
DMXFB5Z ID DMXFB5Z
DMXFB5Z DN US9200020, Table 3, Compound 2B
DMXFB5Z HS Patented
DMXFB5Z SN BDBM60887; US9200020, Table 3, Compound 2B
DMXFB5Z DT Small molecular drug
DMXFB5Z PC 72671666
DMXFB5Z MW 373.3
DMXFB5Z FM C13H20N5O6P
DMXFB5Z IC InChI=1S/C13H20N5O6P/c1-24-10(19)2-3-17(6-7-25(21,22)23)4-5-18-9-16-11-12(18)14-8-15-13(11)20/h8-9,11H,2-7H2,1H3,(H2,21,22,23)
DMXFB5Z CS COC(=O)CCN(CCN1C=NC2C1=NC=NC2=O)CCP(=O)(O)O
DMXFB5Z IK VXLAMFCNIGSKKO-UHFFFAOYSA-N
DMXFB5Z IU 2-[(3-methoxy-3-oxopropyl)-[2-(6-oxo-5H-purin-9-yl)ethyl]amino]ethylphosphonic acid
DM3NE8J ID DM3NE8J
DM3NE8J DN US9206139, 4
DM3NE8J HS Patented
DM3NE8J SN CHEMBL3955404; SCHEMBL15692527; BDBM194645; US9206139, 4
DM3NE8J DT Small molecular drug
DM3NE8J PC 74221131
DM3NE8J MW 411.4
DM3NE8J FM C20H24F3N3O3
DM3NE8J IC InChI=1S/C20H24F3N3O3/c1-11(2)15(9-12-3-5-14(6-4-12)20(21,22)23)16(27)24-10-19(13-7-8-13)17(28)25-18(29)26-19/h3-6,11,13,15H,7-10H2,1-2H3,(H,24,27)(H2,25,26,28,29)/t15-,19-/m0/s1
DM3NE8J CS CC(C)[C@H](CC1=CC=C(C=C1)C(F)(F)F)C(=O)NC[C@@]2(C(=O)NC(=O)N2)C3CC3
DM3NE8J IK VXXYNKXMRXANKX-KXBFYZLASA-N
DM3NE8J IU (2S)-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-3-methyl-2-[[4-(trifluoromethyl)phenyl]methyl]butanamide
DMB4JS7 ID DMB4JS7
DMB4JS7 DN US9206139, 5
DMB4JS7 HS Patented
DMB4JS7 SN SCHEMBL15692518; CHEMBL3972836; BDBM194646; US9206139, 5
DMB4JS7 DT Small molecular drug
DMB4JS7 PC 74221070
DMB4JS7 MW 397.4
DMB4JS7 FM C19H22F3N3O3
DMB4JS7 IC InChI=1S/C19H22F3N3O3/c1-17(2,9-11-3-5-13(6-4-11)19(20,21)22)14(26)23-10-18(12-7-8-12)15(27)24-16(28)25-18/h3-6,12H,7-10H2,1-2H3,(H,23,26)(H2,24,25,27,28)/t18-/m0/s1
DMB4JS7 CS CC(C)(CC1=CC=C(C=C1)C(F)(F)F)C(=O)NC[C@@]2(C(=O)NC(=O)N2)C3CC3
DMB4JS7 IK FJEJHTFPLBTMLO-SFHVURJKSA-N
DMB4JS7 IU N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2,2-dimethyl-3-[4-(trifluoromethyl)phenyl]propanamide
DMD803F ID DMD803F
DMD803F DN US9216972, 132
DMD803F HS Patented
DMD803F SN SCHEMBL1807765; CHEMBL3909064; XVGCLGONKUIZED-UHFFFAOYSA-N; BDBM197672; US9216972, 132; N-(1-cyanocyclopropyl)-2-hydroxy-2-(3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)acetamide
DMD803F DT Small molecular drug
DMD803F PC 67168742
DMD803F MW 520.5
DMD803F FM C27H19F3N4O4
DMD803F IC InChI=1S/C27H19F3N4O4/c28-27(29,30)19-21(34-37-23(19)14-4-2-1-3-5-14)24-18-9-6-15-12-16(7-8-17(15)20(18)33-38-24)22(35)25(36)32-26(13-31)10-11-26/h1-5,7-8,12,22,35H,6,9-11H2,(H,32,36)
DMD803F CS C1CC2=C(ON=C2C3=C1C=C(C=C3)C(C(=O)NC4(CC4)C#N)O)C5=NOC(=C5C(F)(F)F)C6=CC=CC=C6
DMD803F IK XVGCLGONKUIZED-UHFFFAOYSA-N
DMD803F IU N-(1-cyanocyclopropyl)-2-hydroxy-2-[3-[5-phenyl-4-(trifluoromethyl)-1,2-oxazol-3-yl]-4,5-dihydrobenzo[g][2,1]benzoxazol-7-yl]acetamide
DM7AHQE ID DM7AHQE
DM7AHQE DN US9216972, 61
DM7AHQE HS Patented
DM7AHQE SN SCHEMBL1806497; CHEMBL3908750; BDBM197666; US9216972, 61
DM7AHQE DT Small molecular drug
DM7AHQE PC 67168136
DM7AHQE MW 497.4
DM7AHQE FM C25H18F3N3O5
DM7AHQE IC InChI=1S/C25H18F3N3O5/c26-25(27,28)19-20(14-4-2-1-3-5-14)29-36-23(19)22-17-12-34-18-8-13(6-7-16(18)21(17)30-35-22)9-31-10-15(11-31)24(32)33/h1-8,15H,9-12H2,(H,32,33)
DM7AHQE CS C1C(CN1CC2=CC3=C(C=C2)C4=NOC(=C4CO3)C5=C(C(=NO5)C6=CC=CC=C6)C(F)(F)F)C(=O)O
DM7AHQE IK QUYMGOJIHUGBPQ-UHFFFAOYSA-N
DM7AHQE IU 1-[[3-[3-phenyl-4-(trifluoromethyl)-1,2-oxazol-5-yl]-4H-chromeno[4,3-c][1,2]oxazol-7-yl]methyl]azetidine-3-carboxylic acid
DMXR5SZ ID DMXR5SZ
DMXR5SZ DN US9216972, 67
DMXR5SZ HS Patented
DMXR5SZ SN SCHEMBL1810811; CHEMBL3900885; BDBM197667; US9216972, 67
DMXR5SZ DT Small molecular drug
DMXR5SZ PC 67170110
DMXR5SZ MW 499.4
DMXR5SZ FM C25H17F4N3O4
DMXR5SZ IC InChI=1S/C25H17F4N3O4/c26-17-9-16-13(8-18(17)32-10-14(11-32)24(33)34)6-7-15-21(16)31-35-22(15)23-19(25(27,28)29)20(30-36-23)12-4-2-1-3-5-12/h1-5,8-9,14H,6-7,10-11H2,(H,33,34)
DMXR5SZ CS C1CC2=C(ON=C2C3=CC(=C(C=C31)N4CC(C4)C(=O)O)F)C5=C(C(=NO5)C6=CC=CC=C6)C(F)(F)F
DMXR5SZ IK TTXDTJUDJNHFLR-UHFFFAOYSA-N
DMXR5SZ IU 1-[8-fluoro-3-[3-phenyl-4-(trifluoromethyl)-1,2-oxazol-5-yl]-4,5-dihydrobenzo[g][2,1]benzoxazol-7-yl]azetidine-3-carboxylic acid
DMKLCZF ID DMKLCZF
DMKLCZF DN US9216972, 94
DMKLCZF HS Patented
DMKLCZF SN SCHEMBL1815648; CHEMBL3893505; HJNGPEXUUTVSJW-UHFFFAOYSA-N; BDBM197671; US9216972, 94; 2-amino-2-methyl-4-(3-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-4,5-dihydronaphtho[1,2-c]isoxazol-7-yl)butanoic acid
DMKLCZF DT Small molecular drug
DMKLCZF PC 67172159
DMKLCZF MW 497.5
DMKLCZF FM C26H22F3N3O4
DMKLCZF IC InChI=1S/C26H22F3N3O4/c1-25(30,24(33)34)12-11-14-7-9-17-16(13-14)8-10-18-20(17)31-36-23(18)21-19(26(27,28)29)22(35-32-21)15-5-3-2-4-6-15/h2-7,9,13H,8,10-12,30H2,1H3,(H,33,34)
DMKLCZF CS CC(CCC1=CC2=C(C=C1)C3=NOC(=C3CC2)C4=NOC(=C4C(F)(F)F)C5=CC=CC=C5)(C(=O)O)N
DMKLCZF IK HJNGPEXUUTVSJW-UHFFFAOYSA-N
DMKLCZF IU 2-amino-2-methyl-4-[3-[5-phenyl-4-(trifluoromethyl)-1,2-oxazol-3-yl]-4,5-dihydrobenzo[g][2,1]benzoxazol-7-yl]butanoic acid
DMSXG78 ID DMSXG78
DMSXG78 DN US9217012, 10
DMSXG78 HS Patented
DMSXG78 SN SCHEMBL19222783; CHEMBL3969776; BDBM199180; US9217012, 10
DMSXG78 DT Small molecular drug
DMSXG78 PC 122198705
DMSXG78 MW 898
DMSXG78 FM C46H62F2N5O9P
DMSXG78 IC InChI=1S/C46H62F2N5O9P/c1-5-31-15-19-34(20-16-31)43(56)50-24-10-9-13-37(42(49)55)52-45(58)39(27-33-17-21-35(22-18-33)46(47,48)63(59,60)61)53-44(57)38(26-32-11-7-6-8-12-32)51-41(54)28-62-40-25-30(4)14-23-36(40)29(2)3/h6-8,11-12,15-22,29-30,36-40H,5,9-10,13-14,23-28H2,1-4H3,(H2,49,55)(H,50,56)(H,51,54)(H,52,58)(H,53,57)(H2,59,60,61)
DMSXG78 CS CCC1=CC=C(C=C1)C(=O)NCCCCC(C(=O)N)NC(=O)C(CC2=CC=C(C=C2)C(F)(F)P(=O)(O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)COC4CC(CCC4C(C)C)C
DMSXG78 IK DZZMIHDOJVEPRL-UHFFFAOYSA-N
DMSXG78 IU [[4-[3-[[1-amino-6-[(4-ethylbenzoyl)amino]-1-oxohexan-2-yl]amino]-2-[[2-[[2-(5-methyl-2-propan-2-ylcyclohexyl)oxyacetyl]amino]-3-phenylpropanoyl]amino]-3-oxopropyl]phenyl]-difluoromethyl]phosphonic acid
DM8GW54 ID DM8GW54
DM8GW54 DN US9241942, 32-12
DM8GW54 HS Patented
DM8GW54 SN CHEMBL3917195; SCHEMBL12674880; BDBM202540; US9241942, 32-12
DM8GW54 DT Small molecular drug
DM8GW54 PC 88947020
DM8GW54 MW 364.4
DM8GW54 FM C21H20N2O4
DM8GW54 IC InChI=1S/C21H20N2O4/c1-22-8-10-23(11-9-22)21(26)20-7-6-19(27-20)15-2-4-16-14(12-15)3-5-18(25)17(16)13-24/h2-7,12-13,25H,8-11H2,1H3
DM8GW54 CS CN1CCN(CC1)C(=O)C2=CC=C(O2)C3=CC4=C(C=C3)C(=C(C=C4)O)C=O
DM8GW54 IK XYOMDLUIYINLEM-UHFFFAOYSA-N
DM8GW54 IU 2-hydroxy-6-[5-(4-methylpiperazine-1-carbonyl)furan-2-yl]naphthalene-1-carbaldehyde
DMYUDCE ID DMYUDCE
DMYUDCE DN US9266828, B
DMYUDCE HS Patented
DMYUDCE SN SCHEMBL15289220; CHEMBL3902107; BDBM207839; US9266828, B
DMYUDCE DT Small molecular drug
DMYUDCE PC 71735825
DMYUDCE MW 668.8
DMYUDCE FM C31H45FN12O4
DMYUDCE IC InChI=1S/C31H45FN12O4/c1-16(2)25(44-28(47)23(41-17(3)45)5-4-12-39-30(35)36)29(48)43-24(14-18-6-9-20(10-7-18)42-31(37)38)27(46)40-15-19-8-11-21(26(33)34)22(32)13-19/h6-11,13,16,23-25H,4-5,12,14-15H2,1-3H3,(H3,33,34)(H,40,46)(H,41,45)(H,43,48)(H,44,47)(H4,35,36,39)(H4,37,38,42)/t23-,24-,25-/m0/s1
DMYUDCE CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)N=C(N)N)C(=O)NCC2=CC(=C(C=C2)C(=N)N)F)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMYUDCE IK STWIQLJAZUCKRU-SDHOMARFSA-N
DMYUDCE IU (2S)-2-acetamido-N-[(2S)-1-[[(2S)-1-[(4-carbamimidoyl-3-fluorophenyl)methylamino]-3-[4-(diaminomethylideneamino)phenyl]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMQEL1W ID DMQEL1W
DMQEL1W DN US9266828, C
DMQEL1W HS Patented
DMQEL1W SN CHEMBL3951979; SCHEMBL15289221; BDBM207840; US9266828, C
DMQEL1W DT Small molecular drug
DMQEL1W PC 71735826
DMQEL1W MW 668.8
DMQEL1W FM C31H45FN12O4
DMQEL1W IC InChI=1S/C31H45FN12O4/c1-16(2)25(44-28(47)23(41-17(3)45)5-4-12-39-30(35)36)29(48)43-24(13-18-6-10-21(11-7-18)42-31(37)38)27(46)40-15-20-9-8-19(26(33)34)14-22(20)32/h6-11,14,16,23-25H,4-5,12-13,15H2,1-3H3,(H3,33,34)(H,40,46)(H,41,45)(H,43,48)(H,44,47)(H4,35,36,39)(H4,37,38,42)/t23-,24-,25-/m0/s1
DMQEL1W CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)N=C(N)N)C(=O)NCC2=C(C=C(C=C2)C(=N)N)F)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMQEL1W IK HYFZTDZJLMLSBP-SDHOMARFSA-N
DMQEL1W IU (2S)-2-acetamido-N-[(2S)-1-[[(2S)-1-[(4-carbamimidoyl-2-fluorophenyl)methylamino]-3-[4-(diaminomethylideneamino)phenyl]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMYUL2X ID DMYUL2X
DMYUL2X DN US9266828, E
DMYUL2X HS Patented
DMYUL2X SN SCHEMBL15289761; CHEMBL3936612; BDBM207842; US9266828, E
DMYUL2X DT Small molecular drug
DMYUL2X PC 71722448
DMYUL2X MW 600.7
DMYUL2X FM C27H40N10O4S
DMYUL2X IC InChI=1S/C27H40N10O4S/c1-16(2)22(37-42(40,41)15-18-7-11-20(12-8-18)24(30)31)26(39)36-21(4-3-13-34-27(32)33)25(38)35-14-17-5-9-19(10-6-17)23(28)29/h5-12,16,21-22,37H,3-4,13-15H2,1-2H3,(H3,28,29)(H3,30,31)(H,35,38)(H,36,39)(H4,32,33,34)/t21-,22-/m0/s1
DMYUL2X CS CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC1=CC=C(C=C1)C(=N)N)NS(=O)(=O)CC2=CC=C(C=C2)C(=N)N
DMYUL2X IK PRSVXIFOXDFBKT-VXKWHMMOSA-N
DMYUL2X IU (2S)-N-[(4-carbamimidoylphenyl)methyl]-2-[[(2S)-2-[(4-carbamimidoylphenyl)methylsulfonylamino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DM0GOCZ ID DM0GOCZ
DM0GOCZ DN US9340511, 2
DM0GOCZ HS Patented
DM0GOCZ SN SCHEMBL522741; CHEMBL3962368; ZLDYCVXVGXUSBB-UHFFFAOYSA-N; BDBM227554; US9340511, 2; 2-(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carboxamido)acetic acid
DM0GOCZ DT Small molecular drug
DM0GOCZ PC 11462288
DM0GOCZ MW 352.3
DM0GOCZ FM C19H16N2O5
DM0GOCZ IC InChI=1S/C19H16N2O5/c1-11-14-8-7-13(26-12-5-3-2-4-6-12)9-15(14)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
DM0GOCZ CS CC1=C2C=CC(=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
DM0GOCZ IK ZLDYCVXVGXUSBB-UHFFFAOYSA-N
DM0GOCZ IU 2-[(4-hydroxy-1-methyl-6-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
DMFQERG ID DMFQERG
DMFQERG DN US9340511, 5
DMFQERG HS Patented
DMFQERG SN SCHEMBL523724; CHEMBL3970151; JPXYINYXIDIDQY-UHFFFAOYSA-N; BDBM227556; US9340511, 5; 2-[4-hydroxy-1-methyl-7-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid
DMFQERG DT Small molecular drug
DMFQERG PC 11440448
DMFQERG MW 382.4
DMFQERG FM C20H18N2O6
DMFQERG IC InChI=1S/C20H18N2O6/c1-11-16-9-14(28-13-5-3-12(27-2)4-6-13)7-8-15(16)19(25)18(22-11)20(26)21-10-17(23)24/h3-9,25H,10H2,1-2H3,(H,21,26)(H,23,24)
DMFQERG CS CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=C(C=C3)OC
DMFQERG IK JPXYINYXIDIDQY-UHFFFAOYSA-N
DMFQERG IU 2-[[4-hydroxy-7-(4-methoxyphenoxy)-1-methylisoquinoline-3-carbonyl]amino]acetic acid
DMRL0WA ID DMRL0WA
DMRL0WA DN US9340511, 6
DMRL0WA HS Patented
DMRL0WA SN SCHEMBL522900; CHEMBL3902458; MHMUTVWPLKKCIN-UHFFFAOYSA-N; BDBM227557; US9340511, 6; 2-[4-hydroxy-1-methyl-6-(4-methoxy-phenoxy)-isoquinoline-3-carboxamido]acetic acid
DMRL0WA DT Small molecular drug
DMRL0WA PC 57423255
DMRL0WA MW 382.4
DMRL0WA FM C20H18N2O6
DMRL0WA IC InChI=1S/C20H18N2O6/c1-11-15-8-7-14(28-13-5-3-12(27-2)4-6-13)9-16(15)19(25)18(22-11)20(26)21-10-17(23)24/h3-9,25H,10H2,1-2H3,(H,21,26)(H,23,24)
DMRL0WA CS CC1=C2C=CC(=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=C(C=C3)OC
DMRL0WA IK MHMUTVWPLKKCIN-UHFFFAOYSA-N
DMRL0WA IU 2-[[4-hydroxy-6-(4-methoxyphenoxy)-1-methylisoquinoline-3-carbonyl]amino]acetic acid
DMC0PUI ID DMC0PUI
DMC0PUI DN US9340511, 7
DMC0PUI HS Patented
DMC0PUI SN SCHEMBL522957; CHEMBL3960288; AWHJVFRHVNXXDF-UHFFFAOYSA-N; BDBM227558; US9340511, 7; 2-[4-hydroxy-1-methyl-7-(3,5-difluoro-phenoxy)-isoquinoline-3-carboxamido]acetic acid
DMC0PUI DT Small molecular drug
DMC0PUI PC 11176709
DMC0PUI MW 388.3
DMC0PUI FM C19H14F2N2O5
DMC0PUI IC InChI=1S/C19H14F2N2O5/c1-9-15-7-12(28-13-5-10(20)4-11(21)6-13)2-3-14(15)18(26)17(23-9)19(27)22-8-16(24)25/h2-7,26H,8H2,1H3,(H,22,27)(H,24,25)
DMC0PUI CS CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC(=CC(=C3)F)F
DMC0PUI IK AWHJVFRHVNXXDF-UHFFFAOYSA-N
DMC0PUI IU 2-[[7-(3,5-difluorophenoxy)-4-hydroxy-1-methylisoquinoline-3-carbonyl]amino]acetic acid
DM5E9RH ID DM5E9RH
DM5E9RH DN US9340574, 7
DM5E9RH HS Patented
DM5E9RH SN CHEMBL3978384; BDBM231167; US9340574, 7
DM5E9RH DT Small molecular drug
DM5E9RH PC 71494947
DM5E9RH MW 1085.6
DM5E9RH FM C42H45BrF2IN6O11P
DM5E9RH IC InChI=1S/C42H45BrF2IN6O11P/c1-23-8-12-27(21-30(23)43)39(57)51-32(17-24-9-13-28(14-10-24)42(44,45)64(60,61)62)41(59)50-31(7-4-16-48-38(56)26-5-3-6-29(46)20-26)40(58)52-33(37(47)55)22-49-36(54)19-25-11-15-34(53)35(18-25)63-2/h3,5-6,8-15,18,20-21,31-33,53H,4,7,16-17,19,22H2,1-2H3,(H2,47,55)(H,48,56)(H,49,54)(H,50,59)(H,51,57)(H,52,58)(H2,60,61,62)
DM5E9RH CS CC1=C(C=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)C(F)(F)P(=O)(O)O)C(=O)NC(CCCNC(=O)C3=CC(=CC=C3)I)C(=O)NC(CNC(=O)CC4=CC(=C(C=C4)O)OC)C(=O)N)Br
DM5E9RH IK PXNYEUGGRMYQLD-UHFFFAOYSA-N
DM5E9RH IU [[4-[3-[[1-[[1-amino-3-[[2-(4-hydroxy-3-methoxyphenyl)acetyl]amino]-1-oxopropan-2-yl]amino]-5-[(3-iodobenzoyl)amino]-1-oxopentan-2-yl]amino]-2-[(3-bromo-4-methylbenzoyl)amino]-3-oxopropyl]phenyl]-difluoromethyl]phosphonic acid
DMSLBT3 ID DMSLBT3
DMSLBT3 DN US9346821, A-20
DMSLBT3 HS Patented
DMSLBT3 SN CHEMBL3891228; SCHEMBL17770900; BDBM234241; US9346821, A-20
DMSLBT3 DT Small molecular drug
DMSLBT3 PC 71491786
DMSLBT3 MW 432.4
DMSLBT3 FM C19H20N4O8
DMSLBT3 IC InChI=1S/C19H20N4O8/c1-23(19(29)22-13(17(26)27)8-15(24)25)9-12-6-7-14(30-12)18(28)31-11-4-2-10(3-5-11)16(20)21/h2-7,13H,8-9H2,1H3,(H3,20,21)(H,22,29)(H,24,25)(H,26,27)/t13-/m0/s1
DMSLBT3 CS CN(CC1=CC=C(O1)C(=O)OC2=CC=C(C=C2)C(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMSLBT3 IK IPAMUZPOGLKECI-ZDUSSCGKSA-N
DMSLBT3 IU (2S)-2-[[[5-(4-carbamimidoylphenoxy)carbonylfuran-2-yl]methyl-methylcarbamoyl]amino]butanedioic acid
DMR6P8T ID DMR6P8T
DMR6P8T DN US9346821, B-13
DMR6P8T HS Patented
DMR6P8T SN CHEMBL3890156; SCHEMBL17771462; BDBM234246; US9346821, B-13
DMR6P8T DT Small molecular drug
DMR6P8T PC 71491842
DMR6P8T MW 506.5
DMR6P8T FM C22H23FN4O7S
DMR6P8T IC InChI=1S/C22H23FN4O7S/c23-13-8-11(19(24)25)3-5-16(13)34-22(33)17-6-4-12(35-17)10-27-7-1-2-15(27)20(30)26-14(21(31)32)9-18(28)29/h3-6,8,14-15H,1-2,7,9-10H2,(H3,24,25)(H,26,30)(H,28,29)(H,31,32)/t14-,15+/m0/s1
DMR6P8T CS C1C[C@@H](N(C1)CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F)C(=O)N[C@@H](CC(=O)O)C(=O)O
DMR6P8T IK CEBSLTBKCPYKRD-LSDHHAIUSA-N
DMR6P8T IU (2S)-2-[[(2R)-1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]pyrrolidine-2-carbonyl]amino]butanedioic acid
DMQ1LGV ID DMQ1LGV
DMQ1LGV DN US9346821, B-42
DMQ1LGV HS Patented
DMQ1LGV SN SCHEMBL17770908; CHEMBL3897108; BDBM234261; US9346821, B-42
DMQ1LGV DT Small molecular drug
DMQ1LGV PC 71491117
DMQ1LGV MW 387.4
DMQ1LGV FM C18H14FN3O4S
DMQ1LGV IC InChI=1S/C18H14FN3O4S/c19-12-8-10(16(20)21)3-5-14(12)26-18(25)15-6-4-11(27-15)9-22-7-1-2-13(22)17(23)24/h1-8H,9H2,(H3,20,21)(H,23,24)
DMQ1LGV CS C1=CN(C(=C1)C(=O)O)CC2=CC=C(S2)C(=O)OC3=C(C=C(C=C3)C(=N)N)F
DMQ1LGV IK FIQOBFTVRYSLKW-UHFFFAOYSA-N
DMQ1LGV IU 1-[[5-(4-carbamimidoyl-2-fluorophenoxy)carbonylthiophen-2-yl]methyl]pyrrole-2-carboxylic acid
DMWG98Z ID DMWG98Z
DMWG98Z DN US9353089, 135
DMWG98Z HS Patented
DMWG98Z SN CHEMBL2011974; SCHEMBL4232691; BDBM234502; BDBM50379890; US9353089, 135
DMWG98Z DT Small molecular drug
DMWG98Z PC 11359820
DMWG98Z MW 342.4
DMWG98Z FM C21H18N4O
DMWG98Z IC InChI=1S/C21H18N4O/c1-25-19(26)21(24-20(25)22,17-9-3-2-4-10-17)18-11-5-7-15(13-18)16-8-6-12-23-14-16/h2-14H,1H3,(H2,22,24)
DMWG98Z CS CN1C(=O)C(N=C1N)(C2=CC=CC=C2)C3=CC=CC(=C3)C4=CN=CC=C4
DMWG98Z IK PNSQCPQDRVOKMA-UHFFFAOYSA-N
DMWG98Z IU 2-amino-3-methyl-5-phenyl-5-(3-pyridin-3-ylphenyl)imidazol-4-one
DMB4MJ0 ID DMB4MJ0
DMB4MJ0 DN US9353089, 327
DMB4MJ0 HS Patented
DMB4MJ0 SN CHEMBL2011967; SCHEMBL7536669; SCHEMBL8237937; BDBM234554; BDBM50379882; US9353089, 327
DMB4MJ0 DT Small molecular drug
DMB4MJ0 PC 11581511
DMB4MJ0 MW 371.4
DMB4MJ0 FM C23H21N3O2
DMB4MJ0 IC InChI=1S/C23H21N3O2/c1-26-21(27)23(25-22(26)24,18-10-4-3-5-11-18)19-12-6-8-16(14-19)17-9-7-13-20(15-17)28-2/h3-15H,1-2H3,(H2,24,25)
DMB4MJ0 CS CN1C(=O)C(N=C1N)(C2=CC=CC=C2)C3=CC=CC(=C3)C4=CC(=CC=C4)OC
DMB4MJ0 IK LRYKHTDVFXMHEH-UHFFFAOYSA-N
DMB4MJ0 IU 2-amino-5-[3-(3-methoxyphenyl)phenyl]-3-methyl-5-phenylimidazol-4-one
DMK02LS ID DMK02LS
DMK02LS DN US9353089, 330
DMK02LS HS Patented
DMK02LS SN CHEMBL2012001; SCHEMBL7539510; BDBM234557; BDBM50379880; US9353089, 330
DMK02LS DT Small molecular drug
DMK02LS PC 59262421
DMK02LS MW 335.4
DMK02LS FM C20H21N3O2
DMK02LS IC InChI=1S/C20H21N3O2/c1-23-18(24)20(15-9-10-15,22-19(23)21)16-7-3-5-13(11-16)14-6-4-8-17(12-14)25-2/h3-8,11-12,15H,9-10H2,1-2H3,(H2,21,22)
DMK02LS CS CN1C(=O)C(N=C1N)(C2CC2)C3=CC=CC(=C3)C4=CC(=CC=C4)OC
DMK02LS IK NCNMSGOJBLVCOM-UHFFFAOYSA-N
DMK02LS IU 2-amino-5-cyclopropyl-5-[3-(3-methoxyphenyl)phenyl]-3-methylimidazol-4-one
DMA3OI4 ID DMA3OI4
DMA3OI4 DN US9359293, TA
DMA3OI4 HS Patented
DMA3OI4 SN SCHEMBL18103200; CHEMBL3892393; BDBM234205; US9359293, TA
DMA3OI4 DT Small molecular drug
DMA3OI4 PC 122580129
DMA3OI4 MW 399.5
DMA3OI4 FM C21H25N3O3S
DMA3OI4 IC InChI=1S/C21H25N3O3S/c1-16(28)22-15-9-8-14-19(20(25)23-17-10-4-2-5-11-17)24-21(26)27-18-12-6-3-7-13-18/h2-7,10-13,19H,8-9,14-15H2,1H3,(H,22,28)(H,23,25)(H,24,26)
DMA3OI4 CS CC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OC2=CC=CC=C2
DMA3OI4 IK KPDAUKDFHIWNQM-UHFFFAOYSA-N
DMA3OI4 IU phenyl N-[1-anilino-6-(ethanethioylamino)-1-oxohexan-2-yl]carbamate
DMRQ2G4 ID DMRQ2G4
DMRQ2G4 DN US9359293, TB
DMRQ2G4 HS Patented
DMRQ2G4 SN SCHEMBL18103198; CHEMBL3968962; BDBM234206; US9359293, TB
DMRQ2G4 DT Small molecular drug
DMRQ2G4 PC 122580127
DMRQ2G4 MW 427.6
DMRQ2G4 FM C23H29N3O3S
DMRQ2G4 IC InChI=1S/C23H29N3O3S/c1-2-11-21(30)24-17-10-9-16-20(22(27)25-18-12-5-3-6-13-18)26-23(28)29-19-14-7-4-8-15-19/h3-8,12-15,20H,2,9-11,16-17H2,1H3,(H,24,30)(H,25,27)(H,26,28)
DMRQ2G4 CS CCCC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OC2=CC=CC=C2
DMRQ2G4 IK WGKXXIZEWYTERA-UHFFFAOYSA-N
DMRQ2G4 IU phenyl N-[1-anilino-6-(butanethioylamino)-1-oxohexan-2-yl]carbamate
DM0NIB5 ID DM0NIB5
DM0NIB5 DN US9359293, TM
DM0NIB5 HS Patented
DM0NIB5 SN SCHEMBL18103197; CHEMBL3940508; BDBM234208; US9359293, TM
DM0NIB5 DT Small molecular drug
DM0NIB5 PC 71533676
DM0NIB5 MW 567.8
DM0NIB5 FM C33H49N3O3S
DM0NIB5 IC InChI=1S/C33H49N3O3S/c1-2-3-4-5-6-7-8-9-10-11-18-26-31(40)34-27-20-19-25-30(32(37)35-28-21-14-12-15-22-28)36-33(38)39-29-23-16-13-17-24-29/h12-17,21-24,30H,2-11,18-20,25-27H2,1H3,(H,34,40)(H,35,37)(H,36,38)
DM0NIB5 CS CCCCCCCCCCCCCC(=S)NCCCCC(C(=O)NC1=CC=CC=C1)NC(=O)OC2=CC=CC=C2
DM0NIB5 IK KNGBKXOOWUXHDK-UHFFFAOYSA-N
DM0NIB5 IU phenyl N-[1-anilino-1-oxo-6-(tetradecanethioylamino)hexan-2-yl]carbamate
DMSA86Y ID DMSA86Y
DMSA86Y DN US9365572, 5
DMSA86Y HS Patented
DMSA86Y SN BDBM236557; US9365572, 5
DMSA86Y DT Small molecular drug
DMSA86Y PC 129012341
DMSA86Y MW 460.5
DMSA86Y FM C22H23F3N6O2
DMSA86Y IC InChI=1S/C22H23F3N6O2/c23-22(24,25)12-2-1-3-13(8-12)31-19-14(20(32)30-21(31)33)10-27-16-6-5-15(29-18(16)19)11-4-7-17(26)28-9-11/h1-4,7-9,14-16,18-19,27,29H,5-6,10H2,(H2,26,28)(H,30,32,33)
DMSA86Y CS C1CC(NC2C1NCC3C2N(C(=O)NC3=O)C4=CC=CC(=C4)C(F)(F)F)C5=CN=C(C=C5)N
DMSA86Y IK PPLLDCXSMMXDPV-UHFFFAOYSA-N
DMSA86Y IU 9-(6-aminopyridin-3-yl)-1-[3-(trifluoromethyl)phenyl]-4a,5,6,6a,7,8,9,10,10a,10b-decahydropyrimido[5,4-c][1,5]naphthyridine-2,4-dione
DMVL57U ID DMVL57U
DMVL57U DN US9388139, 12
DMVL57U HS Patented
DMVL57U SN SCHEMBL12493454; CHEMBL3899621; BDBM236643; US9388139, 12
DMVL57U DT Small molecular drug
DMVL57U PC 60194756
DMVL57U MW 391.3
DMVL57U FM C20H20Cl2N2O2
DMVL57U IC InChI=1S/C20H20Cl2N2O2/c1-20(2,3)18-11-17(15-9-6-13(21)10-16(15)22)24(23-18)14-7-4-12(5-8-14)19(25)26/h4-10,17H,11H2,1-3H3,(H,25,26)
DMVL57U CS CC(C)(C)C1=NN(C(C1)C2=C(C=C(C=C2)Cl)Cl)C3=CC=C(C=C3)C(=O)O
DMVL57U IK DIZHQHRVPINGBC-UHFFFAOYSA-N
DMVL57U IU 4-[5-tert-butyl-3-(2,4-dichlorophenyl)-3,4-dihydropyrazol-2-yl]benzoic acid
DMMFC0V ID DMMFC0V
DMMFC0V DN US9409892, 136
DMMFC0V HS Patented
DMMFC0V SN SCHEMBL15268512; CHEMBL3893046; WTLXLQBMAJRSSQ-UHFFFAOYSA-N; BDBM241041; US9409892, 136; 3-{[1-(5-Fluoro-pyridin-3-yl)-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl]amino}-2,2-dimethyl-propionic acid
DMMFC0V DT Small molecular drug
DMMFC0V PC 71735619
DMMFC0V MW 475.5
DMMFC0V FM C26H22FN3O5
DMMFC0V IC InChI=1S/C26H22FN3O5/c1-26(2,25(33)34)14-29-24(32)22-23(31)19-9-8-18(35-17-6-4-3-5-7-17)11-20(19)21(30-22)15-10-16(27)13-28-12-15/h3-13,31H,14H2,1-2H3,(H,29,32)(H,33,34)
DMMFC0V CS CC(C)(CNC(=O)C1=C(C2=C(C=C(C=C2)OC3=CC=CC=C3)C(=N1)C4=CC(=CN=C4)F)O)C(=O)O
DMMFC0V IK WTLXLQBMAJRSSQ-UHFFFAOYSA-N
DMMFC0V IU 3-[[1-(5-fluoropyridin-3-yl)-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl]amino]-2,2-dimethylpropanoic acid
DMZJTSP ID DMZJTSP
DMZJTSP DN US9409892, 148
DMZJTSP HS Patented
DMZJTSP SN CHEMBL3893184; SCHEMBL15268628; BDBM241053; US9409892, 148
DMZJTSP DT Small molecular drug
DMZJTSP PC 71736440
DMZJTSP MW 368.4
DMZJTSP FM C20H17FN2O4
DMZJTSP IC InChI=1S/C20H17FN2O4/c21-15-6-3-12(4-7-15)13-5-8-16-14(10-13)11-23-18(19(16)26)20(27)22-9-1-2-17(24)25/h3-8,10-11,26H,1-2,9H2,(H,22,27)(H,24,25)
DMZJTSP CS C1=CC(=CC=C1C2=CC3=CN=C(C(=C3C=C2)O)C(=O)NCCCC(=O)O)F
DMZJTSP IK ZCPXHSRUGVQBOS-UHFFFAOYSA-N
DMZJTSP IU 4-[[7-(4-fluorophenyl)-4-hydroxyisoquinoline-3-carbonyl]amino]butanoic acid
DMHF2OX ID DMHF2OX
DMHF2OX DN US9409892, 19
DMHF2OX HS Patented
DMHF2OX SN SCHEMBL15268580; CHEMBL3889830; JSYWJICQZNCWHF-UHFFFAOYSA-N; BDBM240924; US9409892, 19; 1-{[(1-Cyano-4-hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-methyl}-cyclopentanecarboxylic acid
DMHF2OX DT Small molecular drug
DMHF2OX PC 89812932
DMHF2OX MW 431.4
DMHF2OX FM C24H21N3O5
DMHF2OX IC InChI=1S/C24H21N3O5/c25-13-19-18-12-16(32-15-6-2-1-3-7-15)8-9-17(18)21(28)20(27-19)22(29)26-14-24(23(30)31)10-4-5-11-24/h1-3,6-9,12,28H,4-5,10-11,14H2,(H,26,29)(H,30,31)
DMHF2OX CS C1CCC(C1)(CNC(=O)C2=C(C3=C(C=C(C=C3)OC4=CC=CC=C4)C(=N2)C#N)O)C(=O)O
DMHF2OX IK JSYWJICQZNCWHF-UHFFFAOYSA-N
DMHF2OX IU 1-[[(1-cyano-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]methyl]cyclopentane-1-carboxylic acid
DMWAL5Q ID DMWAL5Q
DMWAL5Q DN US9409892, 59
DMWAL5Q HS Patented
DMWAL5Q SN SCHEMBL15268697; CHEMBL3893917; QBSUFMQXFVGWJT-UHFFFAOYSA-N; BDBM240964; US9409892, 59; 3-{[1-Cyano-4-hydroxy-7-(naphthalen-2-yloxy)-isoquinoline-3-carbonyl]-amino}-2,2-dimethyl-propionic acid
DMWAL5Q DT Small molecular drug
DMWAL5Q PC 89813011
DMWAL5Q MW 455.5
DMWAL5Q FM C26H21N3O5
DMWAL5Q IC InChI=1S/C26H21N3O5/c1-26(2,25(32)33)14-28-24(31)22-23(30)19-10-9-18(12-20(19)21(13-27)29-22)34-17-8-7-15-5-3-4-6-16(15)11-17/h3-12,30H,14H2,1-2H3,(H,28,31)(H,32,33)
DMWAL5Q CS CC(C)(CNC(=O)C1=C(C2=C(C=C(C=C2)OC3=CC4=CC=CC=C4C=C3)C(=N1)C#N)O)C(=O)O
DMWAL5Q IK QBSUFMQXFVGWJT-UHFFFAOYSA-N
DMWAL5Q IU 3-[(1-cyano-4-hydroxy-7-naphthalen-2-yloxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropanoic acid
DMV4AHL ID DMV4AHL
DMV4AHL DN US9422240, 1-282
DMV4AHL HS Patented
DMV4AHL SN SCHEMBL16762172; CHEMBL3896281; BDBM242546; US9422240, 1-282
DMV4AHL DT Small molecular drug
DMV4AHL PC 73053164
DMV4AHL MW 414.4
DMV4AHL FM C21H19FN2O6
DMV4AHL IC InChI=1S/C21H19FN2O6/c22-15-3-1-2-4-17(15)30-14-7-5-13(6-8-14)12-24-10-9-16(25)19(21(24)29)20(28)23-11-18(26)27/h1-8,25H,9-12H2,(H,23,28)(H,26,27)
DMV4AHL CS C1CN(C(=O)C(=C1O)C(=O)NCC(=O)O)CC2=CC=C(C=C2)OC3=CC=CC=C3F
DMV4AHL IK FFAFLVNMXIWUFY-UHFFFAOYSA-N
DMV4AHL IU 2-[[1-[[4-(2-fluorophenoxy)phenyl]methyl]-4-hydroxy-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid
DM0S2UK ID DM0S2UK
DM0S2UK DN US9422240, 1-286
DM0S2UK HS Patented
DM0S2UK SN CHEMBL3899803; SCHEMBL16761915; BDBM242550; US9422240, 1-286
DM0S2UK DT Small molecular drug
DM0S2UK PC 73053305
DM0S2UK MW 426.4
DM0S2UK FM C22H22N2O7
DM0S2UK IC InChI=1S/C22H22N2O7/c1-30-16-3-2-4-17(11-16)31-15-7-5-14(6-8-15)13-24-10-9-18(25)20(22(24)29)21(28)23-12-19(26)27/h2-8,11,25H,9-10,12-13H2,1H3,(H,23,28)(H,26,27)
DM0S2UK CS COC1=CC(=CC=C1)OC2=CC=C(C=C2)CN3CCC(=C(C3=O)C(=O)NCC(=O)O)O
DM0S2UK IK ZKPWKTAYUOZETR-UHFFFAOYSA-N
DM0S2UK IU 2-[[4-hydroxy-1-[[4-(3-methoxyphenoxy)phenyl]methyl]-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid
DMST6IF ID DMST6IF
DMST6IF DN US9422240, 1-297
DMST6IF HS Patented
DMST6IF SN SCHEMBL16761684; CHEMBL3900473; BDBM242555; US9422240, 1-297
DMST6IF DT Small molecular drug
DMST6IF PC 73050968
DMST6IF MW 411.4
DMST6IF FM C21H21N3O6
DMST6IF IC InChI=1S/C21H21N3O6/c1-13-2-7-17(22-10-13)30-15-5-3-14(4-6-15)12-24-9-8-16(25)19(21(24)29)20(28)23-11-18(26)27/h2-7,10,25H,8-9,11-12H2,1H3,(H,23,28)(H,26,27)
DMST6IF CS CC1=CN=C(C=C1)OC2=CC=C(C=C2)CN3CCC(=C(C3=O)C(=O)NCC(=O)O)O
DMST6IF IK FHMUUXWOUSOEJQ-UHFFFAOYSA-N
DMST6IF IU 2-[[4-hydroxy-1-[[4-(5-methylpyridin-2-yl)oxyphenyl]methyl]-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid
DMH7DL5 ID DMH7DL5
DMH7DL5 DN US9422240, 1-298
DMH7DL5 HS Patented
DMH7DL5 SN SCHEMBL16761969; CHEMBL3899583; BDBM242556; US9422240, 1-298
DMH7DL5 DT Small molecular drug
DMH7DL5 PC 73050969
DMH7DL5 MW 465.4
DMH7DL5 FM C21H18F3N3O6
DMH7DL5 IC InChI=1S/C21H18F3N3O6/c22-21(23,24)13-3-6-16(25-9-13)33-14-4-1-12(2-5-14)11-27-8-7-15(28)18(20(27)32)19(31)26-10-17(29)30/h1-6,9,28H,7-8,10-11H2,(H,26,31)(H,29,30)
DMH7DL5 CS C1CN(C(=O)C(=C1O)C(=O)NCC(=O)O)CC2=CC=C(C=C2)OC3=NC=C(C=C3)C(F)(F)F
DMH7DL5 IK OAYSSFWXQZDVKQ-UHFFFAOYSA-N
DMH7DL5 IU 2-[[4-hydroxy-6-oxo-1-[[4-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]-2,3-dihydropyridine-5-carbonyl]amino]acetic acid
DMS842X ID DMS842X
DMS842X DN US9434725, 113
DMS842X HS Patented
DMS842X SN SCHEMBL15401435; CHEMBL3890745; AWEQRQAMCRCOJY-INIZCTEOSA-N; BDBM248882; US9434725, 113; (S)-1-(6-(3-methylpiperazin-1-yl)pyridin-2-yl)-6-(5-(oxetan-3-yl)pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridine
DMS842X DT Small molecular drug
DMS842X PC 72715135
DMS842X MW 427.5
DMS842X FM C24H25N7O
DMS842X IC InChI=1S/C24H25N7O/c1-16-13-30(6-5-26-16)23-3-2-4-24(29-23)31-22-8-21(27-11-19(22)12-28-31)18-7-17(9-25-10-18)20-14-32-15-20/h2-4,7-12,16,20,26H,5-6,13-15H2,1H3/t16-/m0/s1
DMS842X CS C[C@H]1CN(CCN1)C2=CC=CC(=N2)N3C4=CC(=NC=C4C=N3)C5=CC(=CN=C5)C6COC6
DMS842X IK AWEQRQAMCRCOJY-INIZCTEOSA-N
DMS842X IU 1-[6-[(3S)-3-methylpiperazin-1-yl]pyridin-2-yl]-6-[5-(oxetan-3-yl)pyridin-3-yl]pyrazolo[4,3-c]pyridine
DM6Z01B ID DM6Z01B
DM6Z01B DN US9434725, 285
DM6Z01B HS Patented
DM6Z01B SN SCHEMBL15400185; CHEMBL3891387; BDBM249054; US9434725, 285
DM6Z01B DT Small molecular drug
DM6Z01B PC 89914090
DM6Z01B MW 401.5
DM6Z01B FM C21H23N9
DM6Z01B IC InChI=1S/C21H23N9/c1-2-24-19-14-23-13-17(27-19)16-10-18-15(11-25-16)12-26-30(18)21-5-3-4-20(28-21)29-8-6-22-7-9-29/h3-5,10-14,22H,2,6-9H2,1H3,(H,24,27)
DM6Z01B CS CCNC1=NC(=CN=C1)C2=NC=C3C=NN(C3=C2)C4=NC(=CC=C4)N5CCNCC5
DM6Z01B IK XXIAOEADCPRWAT-UHFFFAOYSA-N
DM6Z01B IU N-ethyl-6-[1-(6-piperazin-1-ylpyridin-2-yl)pyrazolo[4,3-c]pyridin-6-yl]pyrazin-2-amine
DM316FB ID DM316FB
DM316FB DN US9434725, 315
DM316FB HS Patented
DM316FB SN SCHEMBL15400195; CHEMBL3890953; BDBM249084; US9434725, 315
DM316FB DT Small molecular drug
DM316FB PC 89914096
DM316FB MW 382.4
DM316FB FM C21H18N8
DM316FB IC InChI=1S/C21H18N8/c1-2-16-13-23-14-18(26-16)17-10-19-15(11-24-17)12-25-29(19)21-5-3-4-20(27-21)28-8-6-22-7-9-28/h1,3-5,10-14,22H,6-9H2
DM316FB CS C#CC1=CN=CC(=N1)C2=NC=C3C=NN(C3=C2)C4=NC(=CC=C4)N5CCNCC5
DM316FB IK LBSWUVMKCABART-UHFFFAOYSA-N
DM316FB IU 6-(6-ethynylpyrazin-2-yl)-1-(6-piperazin-1-ylpyridin-2-yl)pyrazolo[4,3-c]pyridine
DMIT0H3 ID DMIT0H3
DMIT0H3 DN US9434727, 120
DMIT0H3 HS Patented
DMIT0H3 SN SCHEMBL17222950; CHEMBL3890586; BDBM249522; US9434727, 120
DMIT0H3 DT Small molecular drug
DMIT0H3 PC 118483425
DMIT0H3 MW 439.4
DMIT0H3 FM C20H18F5N5O
DMIT0H3 IC InChI=1S/C20H18F5N5O/c21-14-2-1-12(16(17(14)22)20(23,24)25)11-3-7-30(8-4-11)19(31)18-13-5-6-29(10-26)9-15(13)27-28-18/h1-2,11H,3-9H2,(H,27,28)
DMIT0H3 CS C1CN(CCC1C2=C(C(=C(C=C2)F)F)C(F)(F)F)C(=O)C3=NNC4=C3CCN(C4)C#N
DMIT0H3 IK TXJTYIKCTGYLBH-UHFFFAOYSA-N
DMIT0H3 IU 3-[4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carbonitrile
DMC812I ID DMC812I
DMC812I DN US9434727, 153
DMC812I HS Patented
DMC812I SN SCHEMBL17223023; CHEMBL3892497; BDBM249555; US9434727, 153
DMC812I DT Small molecular drug
DMC812I PC 118483501
DMC812I MW 488.4
DMC812I FM C22H22F6N4O2
DMC812I IC InChI=1S/C22H22F6N4O2/c1-12(33)32-7-4-17-18(11-32)29-30-19(17)20(34)31-5-2-13(3-6-31)14-8-15(21(23,24)25)10-16(9-14)22(26,27)28/h8-10,13H,2-7,11H2,1H3,(H,29,30)
DMC812I CS CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMC812I IK UYJQGBUMNGFPIF-UHFFFAOYSA-N
DMC812I IU 1-[3-[4-[3,5-bis(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]ethanone
DMLPWK3 ID DMLPWK3
DMLPWK3 DN US9434727, 40
DMLPWK3 HS Patented
DMLPWK3 SN SCHEMBL17229884; CHEMBL3981399; BDBM249462; US9434727, 40
DMLPWK3 DT Small molecular drug
DMLPWK3 PC 118483372
DMLPWK3 MW 362.8
DMLPWK3 FM C18H20ClFN4O
DMLPWK3 IC InChI=1S/C18H20ClFN4O/c19-16-12(2-1-3-14(16)20)11-5-8-24(9-6-11)18(25)17-13-4-7-21-10-15(13)22-23-17/h1-3,11,21H,4-10H2,(H,22,23)
DMLPWK3 CS C1CN(CCC1C2=C(C(=CC=C2)F)Cl)C(=O)C3=NNC4=C3CCNC4
DMLPWK3 IK PJUXIWWOLCCJBG-UHFFFAOYSA-N
DMLPWK3 IU [4-(2-chloro-3-fluorophenyl)piperidin-1-yl]-(4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl)methanone
DM9HQXC ID DM9HQXC
DM9HQXC DN US9434727, 63
DM9HQXC HS Patented
DM9HQXC SN CHEMBL3892353; SCHEMBL17223067; BDBM249464; US9434727, 63
DM9HQXC DT Small molecular drug
DM9HQXC PC 118483546
DM9HQXC MW 438.4
DM9HQXC FM C21H22F4N4O2
DM9HQXC IC InChI=1S/C21H22F4N4O2/c1-12(30)29-10-7-15-17(11-29)26-27-19(15)20(31)28-8-5-13(6-9-28)14-3-2-4-16(22)18(14)21(23,24)25/h2-4,13H,5-11H2,1H3,(H,26,27)
DM9HQXC CS CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=C(C(=CC=C4)F)C(F)(F)F
DM9HQXC IK VICXOPXLVAUSNR-UHFFFAOYSA-N
DM9HQXC IU 1-[3-[4-[3-fluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl]-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-yl]ethanone
DMCJG8Z ID DMCJG8Z
DMCJG8Z DN US9434727, 93
DMCJG8Z HS Patented
DMCJG8Z SN SCHEMBL17222937; CHEMBL3890367; BDBM249495; US9434727, 93
DMCJG8Z DT Small molecular drug
DMCJG8Z PC 118483410
DMCJG8Z MW 510.4
DMCJG8Z FM C22H22F8N4O
DMCJG8Z IC InChI=1S/C22H22F8N4O/c23-15-2-1-13(17(18(15)24)22(28,29)30)12-3-8-34(9-4-12)20(35)19-14-11-33(10-6-21(25,26)27)7-5-16(14)31-32-19/h1-2,12H,3-11H2,(H,31,32)
DMCJG8Z CS C1CN(CCC1C2=C(C(=C(C=C2)F)F)C(F)(F)F)C(=O)C3=NNC4=C3CN(CC4)CCC(F)(F)F
DMCJG8Z IK GUCHXVVEHJYGON-UHFFFAOYSA-N
DMCJG8Z IU [4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]-[5-(3,3,3-trifluoropropyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-3-yl]methanone
DMVQ3IX ID DMVQ3IX
DMVQ3IX DN US9453017, 1
DMVQ3IX HS Patented
DMVQ3IX SN CHEMBL3925090; BDBM247409; US9453017, 1
DMVQ3IX DT Small molecular drug
DMVQ3IX PC 131635533
DMVQ3IX MW 446.5
DMVQ3IX FM C26H27FN4O2
DMVQ3IX IC InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-25(33)29-18-26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)
DMVQ3IX CS C1CN(CCC12CNC(=O)N2C3=CC(=CC=C3)F)CCNC(=O)C4=CC5=CC=CC=C5C=C4
DMVQ3IX IK BYFCBILNFVVIKQ-UHFFFAOYSA-N
DMVQ3IX IU N-[2-[1-(3-fluorophenyl)-2-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]ethyl]naphthalene-2-carboxamide
DMPH05Y ID DMPH05Y
DMPH05Y DN US9453017, 2
DMPH05Y HS Patented
DMPH05Y SN SCHEMBL14833317; CHEMBL3947795; BDBM247410; US9453017, 2
DMPH05Y DT Small molecular drug
DMPH05Y PC 74763829
DMPH05Y MW 497.4
DMPH05Y FM C25H29BrN4O2
DMPH05Y IC InChI=1S/C25H29BrN4O2/c1-16(27-24(31)21-14-20(21)17-5-3-2-4-6-17)15-29-11-9-19(10-12-29)30-23-8-7-18(26)13-22(23)28-25(30)32/h2-8,13,16,19-21H,9-12,14-15H2,1H3,(H,27,31)(H,28,32)/t16-,20+,21+/m0/s1
DMPH05Y CS C[C@@H](CN1CCC(CC1)N2C3=C(C=C(C=C3)Br)NC2=O)NC(=O)[C@@H]4C[C@@H]4C5=CC=CC=C5
DMPH05Y IK JSVNNLRZCJAYTQ-ZLGUVYLKSA-N
DMPH05Y IU (1R,2S)-N-[(2S)-1-[4-(5-bromo-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propan-2-yl]-2-phenylcyclopropane-1-carboxamide
DMGPDEF ID DMGPDEF
DMGPDEF DN US9475795, 19
DMGPDEF HS Patented
DMGPDEF SN CHEMBL3891428; SCHEMBL15549092; UOPFZPMEKNDBSU-UHFFFAOYSA-N; BDBM250540; US9475795, 19; 4-Phenoxy-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]piperidine
DMGPDEF DT Small molecular drug
DMGPDEF PC 72549319
DMGPDEF MW 349.4
DMGPDEF FM C17H23N3O3S
DMGPDEF IC InChI=1S/C17H23N3O3S/c1-13-17(14(2)19(3)18-13)24(21,22)20-11-9-16(10-12-20)23-15-7-5-4-6-8-15/h4-8,16H,9-12H2,1-3H3
DMGPDEF CS CC1=C(C(=NN1C)C)S(=O)(=O)N2CCC(CC2)OC3=CC=CC=C3
DMGPDEF IK UOPFZPMEKNDBSU-UHFFFAOYSA-N
DMGPDEF IU 4-phenoxy-1-(1,3,5-trimethylpyrazol-4-yl)sulfonylpiperidine
DM0ZDL3 ID DM0ZDL3
DM0ZDL3 DN US9475795, 80
DM0ZDL3 HS Patented
DM0ZDL3 SN SCHEMBL15548679; CHEMBL3891242; RXIULEDXXPGKEE-UHFFFAOYSA-N; BDBM250601; US9475795, 80; 4-(4-Chloro-2-fluorobenzyl)-1-((3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl)-4-fluoropiperidine
DM0ZDL3 DT Small molecular drug
DM0ZDL3 PC 72550891
DM0ZDL3 MW 403.9
DM0ZDL3 FM C17H20ClF2N3O2S
DM0ZDL3 IC InChI=1S/C17H20ClF2N3O2S/c1-11-16(12(2)22-21-11)26(24,25)23-7-5-17(20,6-8-23)10-13-3-4-14(18)9-15(13)19/h3-4,9H,5-8,10H2,1-2H3,(H,21,22)
DM0ZDL3 CS CC1=C(C(=NN1)C)S(=O)(=O)N2CCC(CC2)(CC3=C(C=C(C=C3)Cl)F)F
DM0ZDL3 IK RXIULEDXXPGKEE-UHFFFAOYSA-N
DM0ZDL3 IU 4-[(4-chloro-2-fluorophenyl)methyl]-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-fluoropiperidine
DMR6ODL ID DMR6ODL
DMR6ODL DN US9475795, 89
DMR6ODL HS Patented
DMR6ODL SN CHEMBL3889563; SCHEMBL15549096; JDTHPTFPMSSAJL-UHFFFAOYSA-N; BDBM250610; US9475795, 89; 4-(4-Chloro-2-methoxybenzyl)-1-((3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl)piperidin-4-ol
DMR6ODL DT Small molecular drug
DMR6ODL PC 72551112
DMR6ODL MW 413.9
DMR6ODL FM C18H24ClN3O4S
DMR6ODL IC InChI=1S/C18H24ClN3O4S/c1-12-17(13(2)21-20-12)27(24,25)22-8-6-18(23,7-9-22)11-14-4-5-15(19)10-16(14)26-3/h4-5,10,23H,6-9,11H2,1-3H3,(H,20,21)
DMR6ODL CS CC1=C(C(=NN1)C)S(=O)(=O)N2CCC(CC2)(CC3=C(C=C(C=C3)Cl)OC)O
DMR6ODL IK JDTHPTFPMSSAJL-UHFFFAOYSA-N
DMR6ODL IU 4-[(4-chloro-2-methoxyphenyl)methyl]-1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]piperidin-4-ol
DM4MJ3U ID DM4MJ3U
DM4MJ3U DN US9493447, 1001
DM4MJ3U HS Patented
DM4MJ3U SN SCHEMBL2388915; CHEMBL3964627; BDBM253042; US9493447, 1001
DM4MJ3U DT Small molecular drug
DM4MJ3U PC 53378118
DM4MJ3U MW 499
DM4MJ3U FM C25H23ClN2O5S
DM4MJ3U IC InChI=1S/C25H23ClN2O5S/c1-5-32-24(15-6-8-16(9-7-15)25-28-27-14(2)34-25)23(29)19-11-10-18(33-19)17-12-20(30-3)22(26)21(13-17)31-4/h6-13,24H,5H2,1-4H3
DM4MJ3U CS CCOC(C1=CC=C(C=C1)C2=NN=C(S2)C)C(=O)C3=CC=C(O3)C4=CC(=C(C(=C4)OC)Cl)OC
DM4MJ3U IK QQHJRLKSCSRMEM-UHFFFAOYSA-N
DM4MJ3U IU 1-[5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl]-2-ethoxy-2-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]ethanone
DMC1YR5 ID DMC1YR5
DMC1YR5 DN US9493490, C
DMC1YR5 HS Patented
DMC1YR5 SN US9493490, Example 3; BDBM258594; US9493490, C; US9493490, 6-(4-(1-aminoethyl)-2-fluorophenoxy)benzo[c][1,2]oxaborol-1(3H)-ol
DMC1YR5 DT Small molecular drug
DMC1YR5 PC 90646682
DMC1YR5 MW 287.1
DMC1YR5 FM C15H15BFNO3
DMC1YR5 IC InChI=1S/C15H15BFNO3/c1-9(18)10-3-5-15(14(17)6-10)21-12-4-2-11-8-20-16(19)13(11)7-12/h2-7,9,19H,8,18H2,1H3
DMC1YR5 CS B1(C2=C(CO1)C=CC(=C2)OC3=C(C=C(C=C3)C(C)N)F)O
DMC1YR5 IK AKFFDQJZYBSJJA-UHFFFAOYSA-N
DMC1YR5 IU 1-[3-fluoro-4-[(1-hydroxy-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]ethanamine
DMUVC25 ID DMUVC25
DMUVC25 DN US9493490, D
DMUVC25 HS Patented
DMUVC25 SN US9493490, Example 4; BDBM258595; US9493490, D; US9493490, 6-(4-(aminomethyl)-2-fluorophenoxy)-7-methylbenzo[c][1,2]oxaborol-1(3H)-ol
DMUVC25 DT Small molecular drug
DMUVC25 PC 90646684
DMUVC25 MW 287.1
DMUVC25 FM C15H15BFNO3
DMUVC25 IC InChI=1S/C15H15BFNO3/c1-9-13(5-3-11-8-20-16(19)15(9)11)21-14-4-2-10(7-18)6-12(14)17/h2-6,19H,7-8,18H2,1H3
DMUVC25 CS B1(C2=C(CO1)C=CC(=C2C)OC3=C(C=C(C=C3)CN)F)O
DMUVC25 IK ZCITXZXBLWIHHP-UHFFFAOYSA-N
DMUVC25 IU [3-fluoro-4-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]methanamine
DMFCIGE ID DMFCIGE
DMFCIGE DN US9493490, E
DMFCIGE HS Patented
DMFCIGE SN US9493490, Example 5; BDBM258596; US9493490, E; US9493490, 6-(4-(1-aminoethyl)-2-fluorophenoxy)-7-methylbenzo[c][1,2]oxaborol-1(3H)-ol
DMFCIGE DT Small molecular drug
DMFCIGE PC 87056186
DMFCIGE MW 301.1
DMFCIGE FM C16H17BFNO3
DMFCIGE IC InChI=1S/C16H17BFNO3/c1-9-14(5-4-12-8-21-17(20)16(9)12)22-15-6-3-11(10(2)19)7-13(15)18/h3-7,10,20H,8,19H2,1-2H3
DMFCIGE CS B1(C2=C(CO1)C=CC(=C2C)OC3=C(C=C(C=C3)C(C)N)F)O
DMFCIGE IK LKHWQSZVOZRQIZ-UHFFFAOYSA-N
DMFCIGE IU 1-[3-fluoro-4-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]ethanamine
DMJDTSN ID DMJDTSN
DMJDTSN DN US9493490, L
DMJDTSN HS Patented
DMJDTSN SN US9493490, Example 11; BDBM258599; US9493490, L; US9493490, tert-butyl 2-fluoro-3-(1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yloxy)benzylcarbamate
DMJDTSN DT Small molecular drug
DMJDTSN PC 90646685
DMJDTSN MW 387.2
DMJDTSN FM C20H23BFNO5
DMJDTSN IC InChI=1S/C20H23BFNO5/c1-12-15(9-8-14-11-26-21(25)17(12)14)27-16-7-5-6-13(18(16)22)10-23-19(24)28-20(2,3)4/h5-9,25H,10-11H2,1-4H3,(H,23,24)
DMJDTSN CS B1(C2=C(CO1)C=CC(=C2C)OC3=CC=CC(=C3F)CNC(=O)OC(C)(C)C)O
DMJDTSN IK LHNSCZROXVKHFK-UHFFFAOYSA-N
DMJDTSN IU tert-butyl N-[[2-fluoro-3-[(1-hydroxy-7-methyl-3H-2,1-benzoxaborol-6-yl)oxy]phenyl]methyl]carbamate
DMR1Z3I ID DMR1Z3I
DMR1Z3I DN US9522888, 412
DMR1Z3I HS Patented
DMR1Z3I SN SCHEMBL17511423; BDBM65041; XFNWLBLKUWRFPE-SQGPQFPESA-N; US9522888, 412; ((1R,3S)-1-amino-3-((R)-2-((pentyloxy)methyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)cyclopentyl)methyl dihydrogen phosphate
DMR1Z3I DT Small molecular drug
DMR1Z3I PC 118877302
DMR1Z3I MW 429.4
DMR1Z3I FM C20H32NO7P
DMR1Z3I IC InChI=1S/C20H32NO7P/c1-2-3-4-9-25-12-17-13-26-19-10-15(5-6-18(19)28-17)16-7-8-20(21,11-16)14-27-29(22,23)24/h5-6,10,16-17H,2-4,7-9,11-14,21H2,1H3,(H2,22,23,24)/t16-,17+,20+/m0/s1
DMR1Z3I CS CCCCCOC[C@@H]1COC2=C(O1)C=CC(=C2)[C@H]3CC[C@@](C3)(COP(=O)(O)O)N
DMR1Z3I IK XFNWLBLKUWRFPE-SQGPQFPESA-N
DMR1Z3I IU [(1R,3S)-1-amino-3-[(2R)-2-(pentoxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]cyclopentyl]methyl dihydrogen phosphate
DM6UXZK ID DM6UXZK
DM6UXZK DN US9522888, 575
DM6UXZK HS Patented
DM6UXZK SN SCHEMBL15953589; BDBM65249; US9522888, 575
DM6UXZK DT Small molecular drug
DM6UXZK PC 90342772
DM6UXZK MW 409.5
DM6UXZK FM C22H36NO4P
DM6UXZK IC InChI=1S/C22H36NO4P/c1-2-3-4-5-6-17-7-8-19-14-20(10-9-18(19)13-17)21-11-12-22(23,15-21)16-27-28(24,25)26/h9-10,14,17,21H,2-8,11-13,15-16,23H2,1H3,(H2,24,25,26)/t17-,21-,22+/m1/s1
DM6UXZK CS CCCCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@@H]3CC[C@](C3)(COP(=O)(O)O)N
DM6UXZK IK BWKSEIHXZRSETR-YHYVQYDKSA-N
DM6UXZK IU [(1S,3R)-1-amino-3-[(6R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate
DMG0QZ1 ID DMG0QZ1
DMG0QZ1 DN US9522888, 618
DMG0QZ1 HS Patented
DMG0QZ1 SN SCHEMBL17511478; BDBM65302; US9522888, 618
DMG0QZ1 DT Small molecular drug
DMG0QZ1 PC 118877354
DMG0QZ1 MW 479.5
DMG0QZ1 FM C23H30NO6PS
DMG0QZ1 IC InChI=1S/C23H30NO6PS/c24-23(16-30-31(25,26)27)11-10-21(14-23)20-9-8-18-12-17(6-7-19(18)13-20)15-32(28,29)22-4-2-1-3-5-22/h1-5,8-9,13,17,21H,6-7,10-12,14-16,24H2,(H2,25,26,27)/t17-,21-,23+/m0/s1
DMG0QZ1 CS C1CC2=C(C[C@H]1CS(=O)(=O)C3=CC=CC=C3)C=CC(=C2)[C@H]4CC[C@@](C4)(COP(=O)(O)O)N
DMG0QZ1 IK UIXJBOOFWQSQAS-JWNTYJGQSA-N
DMG0QZ1 IU [(1R,3S)-1-amino-3-[(6S)-6-(benzenesulfonylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate
DMTRZI7 ID DMTRZI7
DMTRZI7 DN US9522888, 695
DMTRZI7 HS Patented
DMTRZI7 SN SCHEMBL17511431; BDBM258469; US9522888, 695
DMTRZI7 DT Small molecular drug
DMTRZI7 PC 118877309
DMTRZI7 MW 411.5
DMTRZI7 FM C21H34NO5P
DMTRZI7 IC InChI=1S/C21H34NO5P/c1-2-26-11-3-4-16-5-6-18-13-19(8-7-17(18)12-16)20-9-10-21(22,14-20)15-27-28(23,24)25/h7-8,13,16,20H,2-6,9-12,14-15,22H2,1H3,(H2,23,24,25)/t16-,20+,21-/m1/s1
DMTRZI7 CS CCOCCC[C@@H]1CCC2=C(C1)C=CC(=C2)[C@H]3CC[C@@](C3)(COP(=O)(O)O)N
DMTRZI7 IK VHKORLDZIRFKDI-TYCQWZJGSA-N
DMTRZI7 IU [(1R,3S)-1-amino-3-[(6S)-6-(3-ethoxypropyl)-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate
DM81MV6 ID DM81MV6
DM81MV6 DN US9567304, Compound F-54
DM81MV6 HS Patented
DM81MV6 SN SCHEMBL16529160; ASAFNJMZLYOBFG-OAHLLOKOSA-N; BDBM286586; US9567304, Compound F-54; 7-[[(3R)-3-aminopiperidin-1-yl]methyl]-8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione; 7-((R)-3-Amino-piperidin-1-ylmethyl)-8-chloro-3-(5-chloro-2-ethanesulfonyl-benzyl)-6-trifluoromethyl-1H-quinazoline-2,4-dione
DM81MV6 DT Small molecular drug
DM81MV6 PC 72195492
DM81MV6 MW 593.4
DM81MV6 FM C24H25Cl2F3N4O4S
DM81MV6 IC InChI=1S/C24H25Cl2F3N4O4S/c1-2-38(36,37)19-6-5-14(25)8-13(19)10-33-22(34)16-9-18(24(27,28)29)17(20(26)21(16)31-23(33)35)12-32-7-3-4-15(30)11-32/h5-6,8-9,15H,2-4,7,10-12,30H2,1H3,(H,31,35)/t15-/m1/s1
DM81MV6 CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(=C3NC2=O)Cl)CN4CCC[C@H](C4)N)C(F)(F)F
DM81MV6 IK ASAFNJMZLYOBFG-OAHLLOKOSA-N
DM81MV6 IU 7-[[(3R)-3-aminopiperidin-1-yl]methyl]-8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione
DMCGUNB ID DMCGUNB
DMCGUNB DN US9567304, Compound N-9
DMCGUNB HS Patented
DMCGUNB SN 8-Chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-7-[[(3S)-3-(2-hydroxyethylamino)piperidin-1-yl]methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione; SCHEMBL15363305; YWUVDJQWNVIFHU-KRWDZBQOSA-N; US9567304, Compound N-9; BDBM286969
DMCGUNB DT Small molecular drug
DMCGUNB PC 72195490
DMCGUNB MW 637.5
DMCGUNB FM C26H29Cl2F3N4O5S
DMCGUNB IC InChI=1S/C26H29Cl2F3N4O5S/c1-2-41(39,40)21-6-5-16(27)10-15(21)12-35-24(37)18-11-20(26(29,30)31)19(22(28)23(18)33-25(35)38)14-34-8-3-4-17(13-34)32-7-9-36/h5-6,10-11,17,32,36H,2-4,7-9,12-14H2,1H3,(H,33,38)/t17-/m0/s1
DMCGUNB CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(=C3NC2=O)Cl)CN4CCC[C@@H](C4)NCCO)C(F)(F)F
DMCGUNB IK YWUVDJQWNVIFHU-KRWDZBQOSA-N
DMCGUNB IU 8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-7-[[(3S)-3-(2-hydroxyethylamino)piperidin-1-yl]methyl]-6-(trifluoromethyl)-1H-quinazoline-2,4-dione
DMJ76RC ID DMJ76RC
DMJ76RC DN US9580418, Example 11
DMJ76RC HS Patented
DMJ76RC SN N-{4-[(3R,4R,5S)-3-Amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl}-7-(tetrahydro-2H-pyran-4-yl)quinoline-2-carboxamide; SCHEMBL17420248; ZCIAXCLJCAUHGJ-CQSIOLINSA-N; US9580418, Example 11; BDBM291190
DMJ76RC DT Small molecular drug
DMJ76RC PC 118646830
DMJ76RC MW 461.6
DMJ76RC FM C26H31N5O3
DMJ76RC IC InChI=1S/C26H31N5O3/c1-16-14-31(15-20(27)25(16)32)24-6-9-28-13-23(24)30-26(33)21-5-4-18-2-3-19(12-22(18)29-21)17-7-10-34-11-8-17/h2-6,9,12-13,16-17,20,25,32H,7-8,10-11,14-15,27H2,1H3,(H,30,33)/t16-,20+,25+/m0/s1
DMJ76RC CS C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC4=C(C=CC(=C4)C5CCOCC5)C=C3
DMJ76RC IK ZCIAXCLJCAUHGJ-CQSIOLINSA-N
DMJ76RC IU N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-7-(oxan-4-yl)quinoline-2-carboxamide
DMGH9B3 ID DMGH9B3
DMGH9B3 DN US9580418, Example 8
DMGH9B3 HS Patented
DMGH9B3 SN N-{4-[(3R,4R,5S)-3-Amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl}-7-morpholin-4-yl-1,5-naphthyridine-2-carboxamide; SCHEMBL17420252; US9580418, Example 8; SSNIKHVUFVVWIH-XSSDXNQZSA-N; BDBM291186
DMGH9B3 DT Small molecular drug
DMGH9B3 PC 118646834
DMGH9B3 MW 463.5
DMGH9B3 FM C24H29N7O3
DMGH9B3 IC InChI=1S/C24H29N7O3/c1-15-13-31(14-17(25)23(15)32)22-4-5-26-12-21(22)29-24(33)19-3-2-18-20(28-19)10-16(11-27-18)30-6-8-34-9-7-30/h2-5,10-12,15,17,23,32H,6-9,13-14,25H2,1H3,(H,29,33)/t15-,17+,23+/m0/s1
DMGH9B3 CS C[C@H]1CN(C[C@H]([C@@H]1O)N)C2=C(C=NC=C2)NC(=O)C3=NC4=C(C=C3)N=CC(=C4)N5CCOCC5
DMGH9B3 IK SSNIKHVUFVVWIH-XSSDXNQZSA-N
DMGH9B3 IU N-[4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]pyridin-3-yl]-7-morpholin-4-yl-1,5-naphthyridine-2-carboxamide
DMERWUQ ID DMERWUQ
DMERWUQ DN US9586942, 16
DMERWUQ HS Patented
DMERWUQ SN SCHEMBL16651983; BDBM294242; US9586942, 16; N-(1-((7S,8R)-8-benzyl-7-(3-azabicyclo[3.1.0]hexan-3-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-methyl-1H-1,2,3-triazole-4-sulfonamide
DMERWUQ DT Small molecular drug
DMERWUQ PC 118022753
DMERWUQ MW 518.7
DMERWUQ FM C28H34N6O2S
DMERWUQ IC InChI=1S/C28H34N6O2S/c1-32-18-28(29-31-32)37(35,36)30-23-16-33(17-23)24-9-7-20-8-10-27(34-14-21-12-22(21)15-34)26(25(20)13-24)11-19-5-3-2-4-6-19/h2-7,9,13,18,21-23,26-27,30H,8,10-12,14-17H2,1H3/t21?,22?,26-,27+/m1/s1
DMERWUQ CS CN1C=C(N=N1)S(=O)(=O)NC2CN(C2)C3=CC4=C(CC[C@@H]([C@@H]4CC5=CC=CC=C5)N6CC7CC7C6)C=C3
DMERWUQ IK RWNRNSRLIFLPBC-PGJSQRTPSA-N
DMERWUQ IU N-[1-[(7S,8R)-7-(3-azabicyclo[3.1.0]hexan-3-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]azetidin-3-yl]-1-methyltriazole-4-sulfonamide
DMZ745J ID DMZ745J
DMZ745J DN US9586942, 2
DMZ745J HS Patented
DMZ745J SN SCHEMBL16652919; OLRHCKCMIVFULU-FTJBHMTQSA-N; BDBM294228; BDBM294227; US9586942, 2; US9586942, 1; N-(1-((7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-methyl-1H-imidazole-4-sulfonamide; N-(1-((7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)azetidin-3-yl)-1-methyl-1H-pyrazole-4-sulfonamide
DMZ745J DT Small molecular drug
DMZ745J PC 91754447
DMZ745J MW 491.6
DMZ745J FM C27H33N5O2S
DMZ745J IC InChI=1S/C27H33N5O2S/c1-30-18-27(28-19-30)35(33,34)29-22-16-32(17-22)23-10-8-21-9-11-26(31-12-5-13-31)25(24(21)15-23)14-20-6-3-2-4-7-20/h2-4,6-8,10,15,18-19,22,25-26,29H,5,9,11-14,16-17H2,1H3/t25-,26+/m1/s1
DMZ745J CS CN1C=C(N=C1)S(=O)(=O)NC2CN(C2)C3=CC4=C(CC[C@@H]([C@@H]4CC5=CC=CC=C5)N6CCC6)C=C3
DMZ745J IK OLRHCKCMIVFULU-FTJBHMTQSA-N
DMZ745J IU N-[1-[(7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]azetidin-3-yl]-1-methylimidazole-4-sulfonamide
DMRXCYF ID DMRXCYF
DMRXCYF DN US9586942, 3*
DMRXCYF HS Patented
DMRXCYF SN SCHEMBL16651324; BDBM294229; US9586942, 3*
DMRXCYF DT Small molecular drug
DMRXCYF PC 118022168
DMRXCYF MW 425.6
DMRXCYF FM C24H31N3O2S
DMRXCYF IC InChI=1S/C24H31N3O2S/c1-30(28,29)25-20-16-27(17-20)21-10-8-19-9-11-24(26-12-5-13-26)23(22(19)15-21)14-18-6-3-2-4-7-18/h2-4,6-8,10,15,20,23-25H,5,9,11-14,16-17H2,1H3/t23-,24+/m1/s1
DMRXCYF CS CS(=O)(=O)NC1CN(C1)C2=CC3=C(CC[C@@H]([C@@H]3CC4=CC=CC=C4)N5CCC5)C=C2
DMRXCYF IK DTCYWONIILSWPE-RPWUZVMVSA-N
DMRXCYF IU N-[1-[(7S,8R)-7-(azetidin-1-yl)-8-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl]azetidin-3-yl]methanesulfonamide
DM2RE91 ID DM2RE91
DM2RE91 DN US9586945, 1
DM2RE91 HS Patented
DM2RE91 SN SCHEMBL16652550; BDBM294244; US9586945, 1; N-[1-[3-(azetidin-1-yl)-4-benzyl-chroman-6-yl]azetidin-3-yl]-1-methyl-imidazole-4-sulfonamide
DM2RE91 DT Small molecular drug
DM2RE91 PC 91754453
DM2RE91 MW 493.6
DM2RE91 FM C26H31N5O3S
DM2RE91 IC InChI=1S/C26H31N5O3S/c1-29-16-26(27-18-29)35(32,33)28-20-14-31(15-20)21-8-9-25-23(13-21)22(12-19-6-3-2-4-7-19)24(17-34-25)30-10-5-11-30/h2-4,6-9,13,16,18,20,22,24,28H,5,10-12,14-15,17H2,1H3
DM2RE91 CS CN1C=C(N=C1)S(=O)(=O)NC2CN(C2)C3=CC4=C(C=C3)OCC(C4CC5=CC=CC=C5)N6CCC6
DM2RE91 IK LMBGMNQXZDWDDD-UHFFFAOYSA-N
DM2RE91 IU N-[1-[3-(azetidin-1-yl)-4-benzyl-3,4-dihydro-2H-chromen-6-yl]azetidin-3-yl]-1-methylimidazole-4-sulfonamide
DMKZC4V ID DMKZC4V
DMKZC4V DN US9586945, 19a
DMKZC4V HS Patented
DMKZC4V SN SCHEMBL16651999; BDBM294267; US9586945, 19a; Cis-N-(1-(4-benzyl-7-fluoro-3-(methylamino)chroman-6-yl)azetidin-3-yl)-1-cyclopropylmethanesulfonamide
DMKZC4V DT Small molecular drug
DMKZC4V PC 118022766
DMKZC4V MW 459.6
DMKZC4V FM C24H30FN3O3S
DMKZC4V IC InChI=1S/C24H30FN3O3S/c1-26-22-14-31-24-11-21(25)23(10-20(24)19(22)9-16-5-3-2-4-6-16)28-12-18(13-28)27-32(29,30)15-17-7-8-17/h2-6,10-11,17-19,22,26-27H,7-9,12-15H2,1H3/t19-,22+/m0/s1
DMKZC4V CS CN[C@@H]1COC2=CC(=C(C=C2[C@@H]1CC3=CC=CC=C3)N4CC(C4)NS(=O)(=O)CC5CC5)F
DMKZC4V IK BOABKZGNZKTRFI-SIKLNZKXSA-N
DMKZC4V IU N-[1-[(3S,4S)-4-benzyl-7-fluoro-3-(methylamino)-3,4-dihydro-2H-chromen-6-yl]azetidin-3-yl]-1-cyclopropylmethanesulfonamide
DM6A8XJ ID DM6A8XJ
DM6A8XJ DN US9586945, 5
DM6A8XJ HS Patented
DM6A8XJ SN SCHEMBL16651786; BDBM294248; US9586945, 5; Cis-N-(1-(3-(azetidin-1-yl)-4-benzylchroman-6-yl)azetidin-3-yl)-1-methyl-1H-pyrazole-4-sulfonamide
DM6A8XJ DT Small molecular drug
DM6A8XJ PC 118022572
DM6A8XJ MW 493.6
DM6A8XJ FM C26H31N5O3S
DM6A8XJ IC InChI=1S/C26H31N5O3S/c1-29-17-22(14-27-29)35(32,33)28-20-15-31(16-20)21-8-9-26-24(13-21)23(12-19-6-3-2-4-7-19)25(18-34-26)30-10-5-11-30/h2-4,6-9,13-14,17,20,23,25,28H,5,10-12,15-16,18H2,1H3
DM6A8XJ CS CN1C=C(C=N1)S(=O)(=O)NC2CN(C2)C3=CC4=C(C=C3)OCC(C4CC5=CC=CC=C5)N6CCC6
DM6A8XJ IK WCDMIBGCPCYAHS-UHFFFAOYSA-N
DM6A8XJ IU N-[1-[3-(azetidin-1-yl)-4-benzyl-3,4-dihydro-2H-chromen-6-yl]azetidin-3-yl]-1-methylpyrazole-4-sulfonamide
DMRVQ5Z ID DMRVQ5Z
DMRVQ5Z DN US9598431, 1
DMRVQ5Z HS Patented
DMRVQ5Z SN SCHEMBL18579631; BDBM302858; US9598431, 1; (S)-N-((5-(ETHYLSULFONYL)PYRIDIN-2-YL)METHYL)-5'-METHYL-1-((R)-1-(2-(TRIFLUOROMETHYL)PYRIMIDIN-5-YL)ETHYL)-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN]-2'-CARBOXAMIDE; N-{[5-(Ethylsulfonyl)pyridine-2-yl]methyl}-5'-methyl-1-{1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-4',5'-dihydrospiro[piperidine-4,7'thieno[2,3-C]pyran]-2'-carboxamide
DMRVQ5Z DT Small molecular drug
DMRVQ5Z PC 126644142
DMRVQ5Z MW 623.7
DMRVQ5Z FM C28H32F3N5O4S2
DMRVQ5Z IC InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)
DMRVQ5Z CS CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)C(C)C5=CN=C(N=C5)C(F)(F)F)OC(C3)C
DMRVQ5Z IK ILXLMNLDODDHOQ-UHFFFAOYSA-N
DMRVQ5Z IU N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide
DMILY1P ID DMILY1P
DMILY1P DN US9598431, 2
DMILY1P HS Patented
DMILY1P SN SCHEMBL18609672; BDBM302859; US9598431, 2; (5S') inverted question markN-{[5-(Ethylsulfonyl)pyridine-2-yl]methyl}-5'-methyl-1-{(1S)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-4',5'-dihydrospiro[piperidine-4,7'thieno[2,3-C]pyran]-2'-carboxamide
DMILY1P DT Small molecular drug
DMILY1P PC 126669595
DMILY1P MW 623.7
DMILY1P FM C28H32F3N5O4S2
DMILY1P IC InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)/t17-,18-/m0/s1
DMILY1P CS CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)[C@@H](C)C5=CN=C(N=C5)C(F)(F)F)O[C@H](C3)C
DMILY1P IK ILXLMNLDODDHOQ-ROUUACIJSA-N
DMILY1P IU (5S)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[(1S)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide
DMRC4O7 ID DMRC4O7
DMRC4O7 DN US9598431, 3
DMRC4O7 HS Patented
DMRC4O7 SN SCHEMBL18580158; BDBM302860; (2S)-1-(3-Thienyl)propan-2-ol; US9598431, 3
DMRC4O7 DT Small molecular drug
DMRC4O7 PC 126644564
DMRC4O7 MW 623.7
DMRC4O7 FM C28H32F3N5O4S2
DMRC4O7 IC InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)/t17-,18+/m0/s1
DMRC4O7 CS CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)[C@H](C)C5=CN=C(N=C5)C(F)(F)F)O[C@H](C3)C
DMRC4O7 IK ILXLMNLDODDHOQ-ZWKOTPCHSA-N
DMRC4O7 IU (5S)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide
DMXGF56 ID DMXGF56
DMXGF56 DN US9598431, 5
DMXGF56 HS Patented
DMXGF56 SN SCHEMBL18609480; BDBM302861; BDBM302862; US9598431, 5; US9598431, 4; (5'S)-5-Methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]; tert-Butyl (5'S)-5'-methyl-4',5'-dihydro-1H-spiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-carboxylate
DMXGF56 DT Small molecular drug
DMXGF56 PC 126669412
DMXGF56 MW 623.7
DMXGF56 FM C28H32F3N5O4S2
DMXGF56 IC InChI=1S/C28H32F3N5O4S2/c1-4-42(38,39)22-6-5-21(32-16-22)15-33-25(37)23-12-19-11-17(2)40-27(24(19)41-23)7-9-36(10-8-27)18(3)20-13-34-26(35-14-20)28(29,30)31/h5-6,12-14,16-18H,4,7-11,15H2,1-3H3,(H,33,37)/t17-,18?/m1/s1
DMXGF56 CS CCS(=O)(=O)C1=CN=C(C=C1)CNC(=O)C2=CC3=C(S2)C4(CCN(CC4)C(C)C5=CN=C(N=C5)C(F)(F)F)O[C@@H](C3)C
DMXGF56 IK ILXLMNLDODDHOQ-QNSVNVJESA-N
DMXGF56 IU (5R)-N-[(5-ethylsulfonylpyridin-2-yl)methyl]-5-methyl-1'-[1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]spiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-2-carboxamide
DMSD354 ID DMSD354
DMSD354 DN US9611221, Example 9
DMSD354 HS Patented
DMSD354 SN 3-[(biphenyl-4-ylmethyl)amino]pyridine-4-carboxylic acid; US9611221, Example 9; SCHEMBL15286753; RNBCOBWQQCESLL-UHFFFAOYSA-N; BDBM314105
DMSD354 DT Small molecular drug
DMSD354 PC 71766727
DMSD354 MW 304.3
DMSD354 FM C19H16N2O2
DMSD354 IC InChI=1S/C19H16N2O2/c22-19(23)17-10-11-20-13-18(17)21-12-14-6-8-16(9-7-14)15-4-2-1-3-5-15/h1-11,13,21H,12H2,(H,22,23)
DMSD354 CS C1=CC=C(C=C1)C2=CC=C(C=C2)CNC3=C(C=CN=C3)C(=O)O
DMSD354 IK RNBCOBWQQCESLL-UHFFFAOYSA-N
DMSD354 IU 3-[(4-phenylphenyl)methylamino]pyridine-4-carboxylic acid
DM89LKQ ID DM89LKQ
DM89LKQ DN US9617250, Example 1 Example 204 of D1
DM89LKQ HS Patented
DM89LKQ SN CHEMBL3124957; BDBM50165434; SCHEMBL3214485; BDBM317453; US9617250, Example 1 Example 204 of D1
DM89LKQ DT Small molecular drug
DM89LKQ PC 25031140
DM89LKQ MW 496.6
DM89LKQ FM C27H36N4O5
DM89LKQ IC InChI=1S/C27H36N4O5/c1-6-18(7-2)23-12-21(10-17(5)29-23)27-30-26(31-36-27)20-9-16(4)25(19(8-3)11-20)35-15-22(33)13-28-24(34)14-32/h9-12,18,22,32-33H,6-8,13-15H2,1-5H3,(H,28,34)/t22-/m0/s1
DM89LKQ CS CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)C)C(CC)CC)C)OC[C@H](CNC(=O)CO)O
DM89LKQ IK CHIUPZSZKBJIHD-QFIPXVFZSA-N
DM89LKQ IU N-[(2S)-3-[2-ethyl-6-methyl-4-[5-(2-methyl-6-pentan-3-ylpyridin-4-yl)-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide
DM6F7M2 ID DM6F7M2
DM6F7M2 DN US9623028, Compound 101
DM6F7M2 HS Patented
DM6F7M2 SN SCHEMBL15880506; CHEMBL4099734; BDBM317468; US9623028, Compound 101; 4-(4-(cyclopentyloxy)-5-(2- methylbenzo[d]oxazol-6-yl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-N-(2-hydroxyethyl)-3- methoxybenzamide
DM6F7M2 DT Small molecular drug
DM6F7M2 PC 90285039
DM6F7M2 MW 542.6
DM6F7M2 FM C29H30N6O5
DM6F7M2 IC InChI=1S/C29H30N6O5/c1-16-32-22-9-7-17(13-24(22)39-16)20-15-31-26-25(20)28(40-19-5-3-4-6-19)35-29(34-26)33-21-10-8-18(14-23(21)38-2)27(37)30-11-12-36/h7-10,13-15,19,36H,3-6,11-12H2,1-2H3,(H,30,37)(H2,31,33,34,35)
DM6F7M2 CS CC1=NC2=C(O1)C=C(C=C2)C3=CNC4=C3C(=NC(=N4)NC5=C(C=C(C=C5)C(=O)NCCO)OC)OC6CCCC6
DM6F7M2 IK DUZMKFLMNMTYDM-UHFFFAOYSA-N
DM6F7M2 IU 4-[[4-cyclopentyloxy-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-N-(2-hydroxyethyl)-3-methoxybenzamide
DMMSHX4 ID DMMSHX4
DMMSHX4 DN US9623028, Compound 79
DMMSHX4 HS Patented
DMMSHX4 SN SCHEMBL15882853; CHEMBL4093026; US9623028, Compound 79; BDBM317465; 4-(4-(cyclopentyloxy)-5-(4- (methylcarbamoyl)phenyl)-7H- pyrrolo[2,3-d]pyrimidin-2- ylamino)-3-methoxy-N- methylbenzamide
DMMSHX4 DT Small molecular drug
DMMSHX4 PC 77846902
DMMSHX4 MW 514.6
DMMSHX4 FM C28H30N6O4
DMMSHX4 IC InChI=1S/C28H30N6O4/c1-29-25(35)17-10-8-16(9-11-17)20-15-31-24-23(20)27(38-19-6-4-5-7-19)34-28(33-24)32-21-13-12-18(26(36)30-2)14-22(21)37-3/h8-15,19H,4-7H2,1-3H3,(H,29,35)(H,30,36)(H2,31,32,33,34)
DMMSHX4 CS CNC(=O)C1=CC=C(C=C1)C2=CNC3=C2C(=NC(=N3)NC4=C(C=C(C=C4)C(=O)NC)OC)OC5CCCC5
DMMSHX4 IK YMYOREROCXXANC-UHFFFAOYSA-N
DMMSHX4 IU 4-[[4-cyclopentyloxy-5-[4-(methylcarbamoyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-N-methylbenzamide
DMR3Z49 ID DMR3Z49
DMR3Z49 DN US9650366, 12
DMR3Z49 HS Patented
DMR3Z49 SN SCHEMBL17669987; BDBM308061; US9650366, 12
DMR3Z49 DT Small molecular drug
DMR3Z49 PC 121268883
DMR3Z49 MW 525.5
DMR3Z49 FM C25H19F4N7O2
DMR3Z49 IC InChI=1S/C25H19F4N7O2/c26-21-9-6-19(25(27,28)29)13-22(21)32-24(38)31-20-7-4-16(5-8-20)2-3-17-12-18(15-30-14-17)23-33-35-36(34-23)10-1-11-37/h4-9,12-15,37H,1,10-11H2,(H2,31,32,38)
DMR3Z49 CS C1=CC(=CC=C1C#CC2=CC(=CN=C2)C3=NN(N=N3)CCCO)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F
DMR3Z49 IK LOBSULBGQKFHGX-UHFFFAOYSA-N
DMR3Z49 IU 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[4-[2-[5-[2-(3-hydroxypropyl)tetrazol-5-yl]pyridin-3-yl]ethynyl]phenyl]urea
DM9HZ03 ID DM9HZ03
DM9HZ03 DN US9650366, 2
DM9HZ03 HS Patented
DM9HZ03 SN SCHEMBL17669993; LHUVPYZTQHNXRU-UHFFFAOYSA-N; BDBM308050; US9650366, 2; 1-{2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothien-5-yl}-3-[4-chloro-3-(trifluoromethyl)phenyl]urea; 1-(2-(2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl)benzo[b]thiophen-5-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea
DM9HZ03 DT Small molecular drug
DM9HZ03 PC 121268887
DM9HZ03 MW 530.9
DM9HZ03 FM C22H14ClF3N8OS
DM9HZ03 IC InChI=1S/C22H14ClF3N8OS/c23-16-3-1-13(8-15(16)22(24,25)26)30-21(35)29-12-2-4-17-10(5-12)7-18(36-17)14-6-11(9-28-19(14)27)20-31-33-34-32-20/h1-9H,(H2,27,28)(H2,29,30,35)(H,31,32,33,34)
DM9HZ03 CS C1=CC2=C(C=C1NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)C=C(S2)C4=C(N=CC(=C4)C5=NNN=N5)N
DM9HZ03 IK LHUVPYZTQHNXRU-UHFFFAOYSA-N
DM9HZ03 IU 1-[2-[2-amino-5-(2H-tetrazol-5-yl)pyridin-3-yl]-1-benzothiophen-5-yl]-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
DMUCIPE ID DMUCIPE
DMUCIPE DN US9650366, 9
DMUCIPE HS Patented
DMUCIPE SN SCHEMBL17670002; OGVARLFWIBVKET-UHFFFAOYSA-N; BDBM308058; US9650366, 9; N-[3-({5-[2-(3-hydroxypropyl)-2H-tetrazol-5-yl]pyridin-3-yl}ethynyl)phenyl]-3-methyl-2-furamide
DMUCIPE DT Small molecular drug
DMUCIPE PC 121268893
DMUCIPE MW 428.4
DMUCIPE FM C23H20N6O3
DMUCIPE IC InChI=1S/C23H20N6O3/c1-16-8-11-32-21(16)23(31)25-20-5-2-4-17(13-20)6-7-18-12-19(15-24-14-18)22-26-28-29(27-22)9-3-10-30/h2,4-5,8,11-15,30H,3,9-10H2,1H3,(H,25,31)
DMUCIPE CS CC1=C(OC=C1)C(=O)NC2=CC=CC(=C2)C#CC3=CC(=CN=C3)C4=NN(N=N4)CCCO
DMUCIPE IK OGVARLFWIBVKET-UHFFFAOYSA-N
DMUCIPE IU N-[3-[2-[5-[2-(3-hydroxypropyl)tetrazol-5-yl]pyridin-3-yl]ethynyl]phenyl]-3-methylfuran-2-carboxamide
DMXU8DI ID DMXU8DI
DMXU8DI DN US9656955, Example 351
DMXU8DI HS Patented
DMXU8DI SN SCHEMBL16032164; BDBM308837; US9656955, Example 351; N-{(3R,4S)-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-yl}-6-(trifluoromethyl)pyridin-2-amine
DMXU8DI DT Small molecular drug
DMXU8DI PC 86295652
DMXU8DI MW 469.5
DMXU8DI FM C20H19F4N5O2S
DMXU8DI IC InChI=1S/C20H19F4N5O2S/c1-28-11-19(25-12-28)32(30,31)29-9-15(13-5-7-14(21)8-6-13)16(10-29)26-18-4-2-3-17(27-18)20(22,23)24/h2-8,11-12,15-16H,9-10H2,1H3,(H,26,27)/t15-,16+/m1/s1
DMXU8DI CS CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]([C@H](C2)NC3=CC=CC(=N3)C(F)(F)F)C4=CC=C(C=C4)F
DMXU8DI IK QHPPCJNRRPMMDC-CVEARBPZSA-N
DMXU8DI IU N-[(3R,4S)-4-(4-fluorophenyl)-1-(1-methylimidazol-4-yl)sulfonylpyrrolidin-3-yl]-6-(trifluoromethyl)pyridin-2-amine
DMC3Q9O ID DMC3Q9O
DMC3Q9O DN US9656955, Example 540
DMC3Q9O HS Patented
DMC3Q9O SN SCHEMBL16032646; BDBM309019; US9656955, Example 540; (3R,4S)-N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine
DMC3Q9O DT Small molecular drug
DMC3Q9O PC 86295651
DMC3Q9O MW 502.9
DMC3Q9O FM C21H19ClF4N4O2S
DMC3Q9O IC InChI=1S/C21H19ClF4N4O2S/c1-29-11-20(27-12-29)33(31,32)30-9-16(13-2-4-14(23)5-3-13)19(10-30)28-15-6-7-18(22)17(8-15)21(24,25)26/h2-8,11-12,16,19,28H,9-10H2,1H3/t16-,19+/m1/s1
DMC3Q9O CS CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]([C@H](C2)NC3=CC(=C(C=C3)Cl)C(F)(F)F)C4=CC=C(C=C4)F
DMC3Q9O IK VSJNRQGUSYDZJE-APWZRJJASA-N
DMC3Q9O IU (3R,4S)-N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-1-(1-methylimidazol-4-yl)sulfonylpyrrolidin-3-amine
DMKS7D9 ID DMKS7D9
DMKS7D9 DN US9656955, Example 652
DMKS7D9 HS Patented
DMKS7D9 SN SCHEMBL16031609; BDBM309130; US9656955, Example 652; (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]pyrrolidin-3-amine
DMKS7D9 DT Small molecular drug
DMKS7D9 PC 86295441
DMKS7D9 MW 486.5
DMKS7D9 FM C21H19F5N4O2S
DMKS7D9 IC InChI=1S/C21H19F5N4O2S/c1-29-11-20(27-12-29)33(31,32)30-9-16(13-2-4-14(22)5-3-13)19(10-30)28-15-6-7-18(23)17(8-15)21(24,25)26/h2-8,11-12,16,19,28H,9-10H2,1H3/t16-,19+/m1/s1
DMKS7D9 CS CN1C=C(N=C1)S(=O)(=O)N2C[C@@H]([C@H](C2)NC3=CC(=C(C=C3)F)C(F)(F)F)C4=CC=C(C=C4)F
DMKS7D9 IK QHYIYIVWHBQJLT-APWZRJJASA-N
DMKS7D9 IU (3R,4S)-4-(4-fluorophenyl)-N-[4-fluoro-3-(trifluoromethyl)phenyl]-1-(1-methylimidazol-4-yl)sulfonylpyrrolidin-3-amine
DM9JCL2 ID DM9JCL2
DM9JCL2 DN US9670220, 33
DM9JCL2 HS Patented
DM9JCL2 SN SCHEMBL322452; BDBM195889; US9670220, 33
DM9JCL2 DT Small molecular drug
DM9JCL2 PC 56597913
DM9JCL2 MW 395.4
DM9JCL2 FM C23H22FNO4
DM9JCL2 IC InChI=1S/C23H22FNO4/c24-20-4-2-1-3-17(20)15-28-19-7-5-16(6-8-19)22-13-18-14-25(12-10-23(26)27)11-9-21(18)29-22/h1-8,13H,9-12,14-15H2,(H,26,27)
DM9JCL2 CS C1CN(CC2=C1OC(=C2)C3=CC=C(C=C3)OCC4=CC=CC=C4F)CCC(=O)O
DM9JCL2 IK TUHBOROWRALEDS-UHFFFAOYSA-N
DM9JCL2 IU 3-[2-[4-[(2-fluorophenyl)methoxy]phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridin-5-yl]propanoic acid
DMNZD8T ID DMNZD8T
DMNZD8T DN US9670220, 76
DMNZD8T HS Patented
DMNZD8T SN SCHEMBL321039; BDBM195896; US9670220, 76
DMNZD8T DT Small molecular drug
DMNZD8T PC 56598044
DMNZD8T MW 391.5
DMNZD8T FM C24H25NO4
DMNZD8T IC InChI=1S/C24H25NO4/c1-17(13-24(26)27)25-12-11-22-20(15-25)14-23(29-22)19-7-9-21(10-8-19)28-16-18-5-3-2-4-6-18/h2-10,14,17H,11-13,15-16H2,1H3,(H,26,27)
DMNZD8T CS CC(CC(=O)O)N1CCC2=C(C1)C=C(O2)C3=CC=C(C=C3)OCC4=CC=CC=C4
DMNZD8T IK OBUYLWCGRDYKEQ-UHFFFAOYSA-N
DMNZD8T IU 3-[2-(4-phenylmethoxyphenyl)-6,7-dihydro-4H-furo[3,2-c]pyridin-5-yl]butanoic acid
DMZG1HO ID DMZG1HO
DMZG1HO DN US9670220, 77
DMZG1HO HS Patented
DMZG1HO SN SCHEMBL320491; BDBM195897; US9670220, 77
DMZG1HO DT Small molecular drug
DMZG1HO PC 56598043
DMZG1HO MW 425.9
DMZG1HO FM C24H24ClNO4
DMZG1HO IC InChI=1S/C24H24ClNO4/c1-16(24(27)28)13-26-11-10-22-19(14-26)12-23(30-22)18-4-8-21(9-5-18)29-15-17-2-6-20(25)7-3-17/h2-9,12,16H,10-11,13-15H2,1H3,(H,27,28)
DMZG1HO CS CC(CN1CCC2=C(C1)C=C(O2)C3=CC=C(C=C3)OCC4=CC=C(C=C4)Cl)C(=O)O
DMZG1HO IK YVXSDYLDIVRURS-UHFFFAOYSA-N
DMZG1HO IU 3-[2-[4-[(4-chlorophenyl)methoxy]phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridin-5-yl]-2-methylpropanoic acid
DM6EQVT ID DM6EQVT
DM6EQVT DN US9682983, 1
DM6EQVT HS Patented
DM6EQVT SN SCHEMBL16112697; YTUZELSDHUVEFM-UHFFFAOYSA-N; BDBM111122; US9682983, 1; US9682983, 17; 4-(6-(6-(piperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline
DM6EQVT DT Small molecular drug
DM6EQVT PC 86275005
DM6EQVT MW 407.5
DM6EQVT FM C24H21N7
DM6EQVT IC InChI=1S/C24H21N7/c1-2-4-22-20(3-1)19(7-8-26-22)21-15-29-31-16-18(14-28-24(21)31)17-5-6-23(27-13-17)30-11-9-25-10-12-30/h1-8,13-16,25H,9-12H2
DM6EQVT CS C1CN(CCN1)C2=NC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
DM6EQVT IK YTUZELSDHUVEFM-UHFFFAOYSA-N
DM6EQVT IU 4-[6-(6-piperazin-1-ylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
DM6R1YP ID DM6R1YP
DM6R1YP DN US9682983, 33
DM6R1YP HS Patented
DM6R1YP SN SCHEMBL16134982; BDBM148372; US9682983, 33
DM6R1YP DT Small molecular drug
DM6R1YP PC 86275006
DM6R1YP MW 435.5
DM6R1YP FM C26H25N7
DM6R1YP IC InChI=1S/C26H25N7/c1-17-11-27-12-18(2)33(17)25-8-7-19(13-29-25)20-14-30-26-23(15-31-32(26)16-20)21-9-10-28-24-6-4-3-5-22(21)24/h3-10,13-18,27H,11-12H2,1-2H3/t17-,18+
DM6R1YP CS C[C@@H]1CNC[C@@H](N1C2=NC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3)C
DM6R1YP IK OVXMCCQKIOSDGE-HDICACEKSA-N
DM6R1YP IU 4-[6-[6-[(2S,6R)-2,6-dimethylpiperazin-1-yl]pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
DMVGQXK ID DMVGQXK
DMVGQXK DN US9682991, 2
DMVGQXK HS Patented
DMVGQXK SN SCHEMBL12498787; BDBM161938; US9682991, 2
DMVGQXK DT Small molecular drug
DMVGQXK PC 53311212
DMVGQXK MW 463.5
DMVGQXK FM C21H24F3N7O2
DMVGQXK IC InChI=1S/C21H24F3N7O2/c1-29-8-6-14(7-9-29)25-18-16-17(32-11-10-30(16)2)20-27-26-19(31(20)28-18)13-4-3-5-15(12-13)33-21(22,23)24/h3-5,12,14H,6-11H2,1-2H3,(H,25,28)
DMVGQXK CS CN1CCC(CC1)NC2=NN3C(=NN=C3C4=C2N(CCO4)C)C5=CC(=CC=C5)OC(F)(F)F
DMVGQXK IK OIOYUXMGVUEQPH-UHFFFAOYSA-N
DMVGQXK IU 10-methyl-N-(1-methylpiperidin-4-yl)-5-[3-(trifluoromethoxy)phenyl]-13-oxa-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-8-amine
DMGTIP6 ID DMGTIP6
DMGTIP6 DN US9682991, 23
DMGTIP6 HS Patented
DMGTIP6 SN SCHEMBL2177395; BDBM161974; US9682991, 23
DMGTIP6 DT Small molecular drug
DMGTIP6 PC 53252518
DMGTIP6 MW 450.4
DMGTIP6 FM C20H21F3N6O3
DMGTIP6 IC InChI=1S/C20H21F3N6O3/c1-28-7-10-31-16-15(28)17(24-13-5-8-30-9-6-13)27-29-18(25-26-19(16)29)12-3-2-4-14(11-12)32-20(21,22)23/h2-4,11,13H,5-10H2,1H3,(H,24,27)
DMGTIP6 CS CN1CCOC2=C1C(=NN3C2=NN=C3C4=CC(=CC=C4)OC(F)(F)F)NC5CCOCC5
DMGTIP6 IK DKFWOQOORFAKNT-UHFFFAOYSA-N
DMGTIP6 IU 10-methyl-N-(oxan-4-yl)-5-[3-(trifluoromethoxy)phenyl]-13-oxa-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-8-amine
DM7SQKD ID DM7SQKD
DM7SQKD DN US9682991, 7
DM7SQKD HS Patented
DM7SQKD SN SCHEMBL2222299; BDBM161946; US9682991, 7
DM7SQKD DT Small molecular drug
DM7SQKD PC 53311131
DM7SQKD MW 420.4
DM7SQKD FM C19H19F3N6O2
DM7SQKD IC InChI=1S/C19H19F3N6O2/c1-27-7-8-29-15-14(27)16(23-10-11-5-6-11)26-28-17(24-25-18(15)28)12-3-2-4-13(9-12)30-19(20,21)22/h2-4,9,11H,5-8,10H2,1H3,(H,23,26)
DM7SQKD CS CN1CCOC2=C1C(=NN3C2=NN=C3C4=CC(=CC=C4)OC(F)(F)F)NCC5CC5
DM7SQKD IK RTBZFULAXSZFTC-UHFFFAOYSA-N
DM7SQKD IU N-(cyclopropylmethyl)-10-methyl-5-[3-(trifluoromethoxy)phenyl]-13-oxa-3,4,6,7,10-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-8-amine
DMMCNVO ID DMMCNVO
DMMCNVO DN US9694002, 129
DMMCNVO HS Patented
DMMCNVO SN SCHEMBL15535910; BDBM70974; US9694002, 129
DMMCNVO DT Small molecular drug
DMMCNVO PC 90015925
DMMCNVO MW 482.5
DMMCNVO FM C21H23FN2O6S2
DMMCNVO IC InChI=1S/C21H23FN2O6S2/c1-31(26,27)23-21(25)18-9-17(15-7-8-15)20(10-19(18)22)30-13-14-11-24(12-14)32(28,29)16-5-3-2-4-6-16/h2-6,9-10,14-15H,7-8,11-13H2,1H3,(H,23,25)
DMMCNVO CS CS(=O)(=O)NC(=O)C1=C(C=C(C(=C1)C2CC2)OCC3CN(C3)S(=O)(=O)C4=CC=CC=C4)F
DMMCNVO IK SPEKXWKFVSKSOS-UHFFFAOYSA-N
DMMCNVO IU 4-[[1-(benzenesulfonyl)azetidin-3-yl]methoxy]-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide
DMV1OR0 ID DMV1OR0
DMV1OR0 DN US9694002, 495
DMV1OR0 HS Patented
DMV1OR0 SN SCHEMBL16770932; BDBM71464; US9694002, 495
DMV1OR0 DT Small molecular drug
DMV1OR0 PC 91799679
DMV1OR0 MW 569.5
DMV1OR0 FM C27H31Cl2FN2O4S
DMV1OR0 IC InChI=1S/C27H31Cl2FN2O4S/c1-27(2,17-10-18(28)12-19(29)11-17)32-9-3-4-20(15-32)36-25-14-24(30)23(13-22(25)16-5-6-16)26(33)31-37(34,35)21-7-8-21/h10-14,16,20-21H,3-9,15H2,1-2H3,(H,31,33)/t20-/m1/s1
DMV1OR0 CS CC(C)(C1=CC(=CC(=C1)Cl)Cl)N2CCC[C@H](C2)OC3=CC(=C(C=C3C4CC4)C(=O)NS(=O)(=O)C5CC5)F
DMV1OR0 IK OCNOGKDYKRVBCZ-HXUWFJFHSA-N
DMV1OR0 IU 5-cyclopropyl-N-cyclopropylsulfonyl-4-[(3R)-1-[2-(3,5-dichlorophenyl)propan-2-yl]piperidin-3-yl]oxy-2-fluorobenzamide
DM804T5 ID DM804T5
DM804T5 DN US9694002, 59
DM804T5 HS Patented
DM804T5 SN SCHEMBL15535893; BDBM70886; YUDSOPSBYJDZMS-UHFFFAOYSA-N; US9694002, 59; 4-((1-benzhydrylazetidin-3-yl)methoxy)-5-chloro-2-fluoro-N-(methylsulfonyl)benzamide
DM804T5 DT Small molecular drug
DM804T5 PC 86703776
DM804T5 MW 503
DM804T5 FM C25H24ClFN2O4S
DM804T5 IC InChI=1S/C25H24ClFN2O4S/c1-34(31,32)28-25(30)20-12-21(26)23(13-22(20)27)33-16-17-14-29(15-17)24(18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-13,17,24H,14-16H2,1H3,(H,28,30)
DM804T5 CS CS(=O)(=O)NC(=O)C1=CC(=C(C=C1F)OCC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)Cl
DM804T5 IK YUDSOPSBYJDZMS-UHFFFAOYSA-N
DM804T5 IU 4-[(1-benzhydrylazetidin-3-yl)methoxy]-5-chloro-2-fluoro-N-methylsulfonylbenzamide
DMZF3AQ ID DMZF3AQ
DMZF3AQ DN US9695118, 4
DMZF3AQ HS Patented
DMZF3AQ SN SCHEMBL16528736; BDBM77146; US9695118, 4; US9695118, 13
DMZF3AQ DT Small molecular drug
DMZF3AQ PC 72195070
DMZF3AQ MW 484.7
DMZF3AQ FM C17H14BrClF3NO3S
DMZF3AQ IC InChI=1S/C17H14BrClF3NO3S/c1-2-27(25,26)15-4-3-14(19)7-11(15)9-23-16(24)10-5-12(17(20,21)22)8-13(18)6-10/h3-8H,2,9H2,1H3,(H,23,24)
DMZF3AQ CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CNC(=O)C2=CC(=CC(=C2)Br)C(F)(F)F
DMZF3AQ IK ZJRYMLPPVADAGI-UHFFFAOYSA-N
DMZF3AQ IU 3-bromo-N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-5-(trifluoromethyl)benzamide
DMAD3VL ID DMAD3VL
DMAD3VL DN US9695118, 8
DMAD3VL HS Patented
DMAD3VL SN SCHEMBL16528302; BDBM77168; YHSRDHPSFFNXQB-UHFFFAOYSA-N; US9695118, 8; N-(5-Chloro-2-ethanesulfonyl-benzyl)-3-trifluoromethyl-benzamide
DMAD3VL DT Small molecular drug
DMAD3VL PC 72195071
DMAD3VL MW 405.8
DMAD3VL FM C17H15ClF3NO3S
DMAD3VL IC InChI=1S/C17H15ClF3NO3S/c1-2-26(24,25)15-7-6-14(18)9-12(15)10-22-16(23)11-4-3-5-13(8-11)17(19,20)21/h3-9H,2,10H2,1H3,(H,22,23)
DMAD3VL CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CNC(=O)C2=CC(=CC=C2)C(F)(F)F
DMAD3VL IK YHSRDHPSFFNXQB-UHFFFAOYSA-N
DMAD3VL IU N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-3-(trifluoromethyl)benzamide
DMSI09Y ID DMSI09Y
DMSI09Y DN US9707205, 40
DMSI09Y HS Patented
DMSI09Y SN SCHEMBL176871; BDBM255789; US9707205, 40; 2-amino-2-(5-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)benzofuran-2-yl)propane-1,3-diol
DMSI09Y DT Small molecular drug
DMSI09Y PC 45255647
DMSI09Y MW 439.5
DMSI09Y FM C23H25N3O6
DMSI09Y IC InChI=1S/C23H25N3O6/c1-3-29-18-8-6-15(10-19(18)30-4-2)22-25-21(26-32-22)14-5-7-17-16(9-14)11-20(31-17)23(24,12-27)13-28/h5-11,27-28H,3-4,12-13,24H2,1-2H3
DMSI09Y CS CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC4=C(C=C3)OC(=C4)C(CO)(CO)N)OCC
DMSI09Y IK YPBZKICXUPGWLN-UHFFFAOYSA-N
DMSI09Y IU 2-amino-2-[5-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-1-benzofuran-2-yl]propane-1,3-diol
DMEB59T ID DMEB59T
DMEB59T DN US9714230, 12
DMEB59T HS Patented
DMEB59T SN SCHEMBL15778399; LKBZHRSAENXIOI-UHFFFAOYSA-N; BDBM263942; US9714230, 12; 2-(5-p-tolyl-1H-pyrazol-1- yl)isonicotinic acid; 2-(5-p-tolyl-1H-pyrazol-1-yl)isonicotinic acid
DMEB59T DT Small molecular drug
DMEB59T PC 76901247
DMEB59T MW 279.29
DMEB59T FM C16H13N3O2
DMEB59T IC InChI=1S/C16H13N3O2/c1-11-2-4-12(5-3-11)14-7-9-18-19(14)15-10-13(16(20)21)6-8-17-15/h2-10H,1H3,(H,20,21)
DMEB59T CS CC1=CC=C(C=C1)C2=CC=NN2C3=NC=CC(=C3)C(=O)O
DMEB59T IK LKBZHRSAENXIOI-UHFFFAOYSA-N
DMEB59T IU 2-[5-(4-methylphenyl)pyrazol-1-yl]pyridine-4-carboxylic acid
DMPZS16 ID DMPZS16
DMPZS16 DN US9714230, 46
DMPZS16 HS Patented
DMPZS16 SN SCHEMBL15778753; MITOFELVTHNBGA-UHFFFAOYSA-N; BDBM263981; US9714230, 46; 2-(5-(4-bromophenyl)-1H-pyrazol- 1-yl)isonicotinic acid; 2-[5-(4-bromophenyl)-1H-pyrazol-1-yl]pyridine-4-carboxylic acid
DMPZS16 DT Small molecular drug
DMPZS16 PC 86725517
DMPZS16 MW 344.16
DMPZS16 FM C15H10BrN3O2
DMPZS16 IC InChI=1S/C15H10BrN3O2/c16-12-3-1-10(2-4-12)13-6-8-18-19(13)14-9-11(15(20)21)5-7-17-14/h1-9H,(H,20,21)
DMPZS16 CS C1=CC(=CC=C1C2=CC=NN2C3=NC=CC(=C3)C(=O)O)Br
DMPZS16 IK MITOFELVTHNBGA-UHFFFAOYSA-N
DMPZS16 IU 2-[5-(4-bromophenyl)pyrazol-1-yl]pyridine-4-carboxylic acid
DMOVEZF ID DMOVEZF
DMOVEZF DN VAPBGCRAUJRZPO-UHFFFAOYSA-N
DMOVEZF HS Patented
DMOVEZF SN CHEMBL3422020; SCHEMBL16528756; VAPBGCRAUJRZPO-UHFFFAOYSA-N; BDBM50080409; N-(5-Chloro-2-ethanesulfonyl-benzyl)-4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-benzamide
DMOVEZF DT Small molecular drug
DMOVEZF PC 71768628
DMOVEZF MW 518
DMOVEZF FM C23H27ClF3N3O3S
DMOVEZF IC InChI=1S/C23H27ClF3N3O3S/c1-3-34(32,33)21-7-6-19(24)12-18(21)14-28-22(31)16-4-5-17(20(13-16)23(25,26)27)15-30-10-8-29(2)9-11-30/h4-7,12-13H,3,8-11,14-15H2,1-2H3,(H,28,31)
DMOVEZF CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CNC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F
DMOVEZF IK VAPBGCRAUJRZPO-UHFFFAOYSA-N
DMOVEZF IU N-[(5-chloro-2-ethylsulfonylphenyl)methyl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide
DMH9ION ID DMH9ION
DMH9ION DN VFEDEOUBYBLDKN-AAFJCEBUSA-N
DMH9ION HS Patented
DMH9ION SN CHEMBL1922120; SCHEMBL3853662; VFEDEOUBYBLDKN-AAFJCEBUSA-N; BDBM50358221; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-hexan-3-ol; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-hexan-3-ol
DMH9ION DT Small molecular drug
DMH9ION PC 12111409
DMH9ION MW 383.5
DMH9ION FM C20H29N7O
DMH9ION IC InChI=1S/C20H29N7O/c1-5-15(16(28)6-2)24-20-25-18(22-11-14-8-7-9-21-10-14)17-19(26-20)27(12-23-17)13(3)4/h7-10,12-13,15-16,28H,5-6,11H2,1-4H3,(H2,22,24,25,26)/t15-,16?/m1/s1
DMH9ION CS CC[C@H](C(CC)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=CC=C3
DMH9ION IK VFEDEOUBYBLDKN-AAFJCEBUSA-N
DMH9ION IU (4R)-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol
DMTMFNK ID DMTMFNK
DMTMFNK DN Vinyl sulfone derivative 1
DMTMFNK HS Patented
DMTMFNK SN PMID28454500-Compound-20
DMTMFNK CP KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
DMTMFNK DT Small molecular drug
DMTMFNK PC 73053707
DMTMFNK MW 308.8
DMTMFNK FM C15H13ClO3S
DMTMFNK IC InChI=1S/C15H13ClO3S/c1-19-14-8-4-5-9-15(14)20(17,18)11-10-12-6-2-3-7-13(12)16/h2-11H,1H3/b11-10+
DMTMFNK CS COC1=CC=CC=C1S(=O)(=O)/C=C/C2=CC=CC=C2Cl
DMTMFNK IK KVDYSDOWSIXKPB-ZHACJKMWSA-N
DMTMFNK IU 1-chloro-2-[(E)-2-(2-methoxyphenyl)sulfonylethenyl]benzene
DML32R8 ID DML32R8
DML32R8 DN VX-148
DML32R8 HS Patented
DML32R8 SN VX-148; SCHEMBL12343182; BDBM248095; VX-148 (3)
DML32R8 DT Small molecular drug
DML32R8 PC 56603796
DML32R8 MW 435.5
DML32R8 FM C23H25N5O4
DML32R8 IC InChI=1S/C23H25N5O4/c1-4-20(10-11-24)32-23(30)26-15(2)16-6-5-7-18(12-16)27-22(29)28-19-9-8-17(14-25)21(13-19)31-3/h5-9,12-13,15,20H,4,10H2,1-3H3,(H,26,30)(H2,27,28,29)/t15-,20?/m0/s1
DML32R8 CS CCC(CC#N)OC(=O)N[C@@H](C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C#N)OC
DML32R8 IK PJFQWSNOXLEDDZ-OOJLDXBWSA-N
DML32R8 IU 1-cyanobutan-2-yl N-[(1S)-1-[3-[(4-cyano-3-methoxyphenyl)carbamoylamino]phenyl]ethyl]carbamate
DML32R8 DE Psoriasis vulgaris
DMIULVJ ID DMIULVJ
DMIULVJ DN Xanthine derivative 1
DMIULVJ HS Patented
DMIULVJ SN PMID25482888-Compound-57
DMIULVJ DT Small molecular drug
DMNXJ8G ID DMNXJ8G
DMNXJ8G DN Xanthine/amino piperidine compound 1
DMNXJ8G HS Patented
DMNXJ8G SN PMID25482888-Compound-53
DMNXJ8G CP MERCK SHARP & DOHME CORP. BURNETT, Duane, A. ZHAO, Zhiqiang COLE, David JOSIEN, Hubert PISSARNITSKI, Dmitri, A. SASIKUMAR, Thavalakulamgar WU, Wen-Lian DOMALSKI, Martin
DMNXJ8G DT Small molecular drug
DMNXJ8G PC 57378228
DMNXJ8G MW 483.6
DMNXJ8G FM C26H29N9O
DMNXJ8G IC InChI=1S/C26H29N9O/c1-3-4-13-33-22-23(31-26(33)32-12-7-8-18(27)15-32)34-14-11-28-25(34)35(24(22)36)16-21-29-17(2)19-9-5-6-10-20(19)30-21/h5-6,9-10,18H,7-8,11-16,27H2,1-2H3/t18-/m1/s1
DMNXJ8G CS CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N4CCN=C4N(C2=O)CC5=NC6=CC=CC=C6C(=N5)C
DMNXJ8G IK WDWDEKNARRTAAI-GOSISDBHSA-N
DMNXJ8G IU 2-[(3R)-3-aminopiperidin-1-yl]-3-but-2-ynyl-5-[(4-methylquinazolin-2-yl)methyl]-7,8-dihydroimidazo[2,1-b]purin-4-one
DM5Q93Y ID DM5Q93Y
DM5Q93Y DN XHPNYYOUZWOWNT-PYUWXLGESA-N
DM5Q93Y HS Patented
DM5Q93Y SN CHEMBL1922122; SCHEMBL3855548; XHPNYYOUZWOWNT-PYUWXLGESA-N; BDBM50358223; US8846696, (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol; (3RS,4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol; (3RS, 4R)-4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol
DM5Q93Y DT Small molecular drug
DM5Q93Y PC 12111413
DM5Q93Y MW 411.5
DM5Q93Y FM C22H33N7O
DM5Q93Y IC InChI=1S/C22H33N7O/c1-7-16(18(30)22(4,5)6)26-21-27-19(24-12-15-9-8-10-23-11-15)17-20(28-21)29(13-25-17)14(2)3/h8-11,13-14,16,18,30H,7,12H2,1-6H3,(H2,24,26,27,28)/t16-,18?/m1/s1
DM5Q93Y CS CC[C@H](C(C(C)(C)C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=CC=C3
DM5Q93Y IK XHPNYYOUZWOWNT-PYUWXLGESA-N
DM5Q93Y IU (4R)-2,2-dimethyl-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol
DMHAVYS ID DMHAVYS
DMHAVYS DN Y-9680
DMHAVYS HS Patented
DMHAVYS SN isopropyl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate; 350997-33-0; ISOPROPYL 2-AMINO-4-(3,4-DIMETHOXYPHENYL)-THIOPHENE-3-CARBOXYLATE; propan-2-yl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate; AC1LI5BZ; CBMicro_031058; MixCom6_001362; Oprea1_764229; SCHEMBL12632700; CHEMBL2393423; CTK6J7310; US8889672, PKCzI-diMeO; ZINC442750; BDBM139464; ZX-AN001734; ALBB-001750; MFCD01923453; STK348738; BBL016154; AKOS000304253; MCULE-6167327602; BIM-0031131.P001; TR-051961; Y-9680; SR-01000228616; SR-01000228616-1
DMHAVYS DT Small molecular drug
DMHAVYS PC 874670
DMHAVYS MW 321.4
DMHAVYS FM C16H19NO4S
DMHAVYS IC InChI=1S/C16H19NO4S/c1-9(2)21-16(18)14-11(8-22-15(14)17)10-5-6-12(19-3)13(7-10)20-4/h5-9H,17H2,1-4H3
DMHAVYS CS CC(C)OC(=O)C1=C(SC=C1C2=CC(=C(C=C2)OC)OC)N
DMHAVYS IK WEHPOCNINSGWET-UHFFFAOYSA-N
DMHAVYS IU propan-2-yl 2-amino-4-(3,4-dimethoxyphenyl)thiophene-3-carboxylate
DMA91FM ID DMA91FM
DMA91FM DN YYDJCLCSBYCSCO-UHFFFAOYSA-N
DMA91FM HS Patented
DMA91FM SN CHEMBL1080382; 6-[cyclohexyl(cyclopropylmethyl)amino]-N-(6-methyl-1H-indazol-5-yl)pyrimidine-4-carboxamide; 6-(cyclohexyl(cyclopropylmethyl)amino)-N-(6-methyl-1H-indazol-5-yl)pyrimidine-4-carboxamide; SCHEMBL3025879; YYDJCLCSBYCSCO-UHFFFAOYSA-N; BDBM50313353
DMA91FM DT Small molecular drug
DMA91FM PC 25182901
DMA91FM MW 404.5
DMA91FM FM C23H28N6O
DMA91FM IC InChI=1S/C23H28N6O/c1-15-9-20-17(12-26-28-20)10-19(15)27-23(30)21-11-22(25-14-24-21)29(13-16-7-8-16)18-5-3-2-4-6-18/h9-12,14,16,18H,2-8,13H2,1H3,(H,26,28)(H,27,30)
DMA91FM CS CC1=CC2=C(C=C1NC(=O)C3=CC(=NC=N3)N(CC4CC4)C5CCCCC5)C=NN2
DMA91FM IK YYDJCLCSBYCSCO-UHFFFAOYSA-N
DMA91FM IU 6-[cyclohexyl(cyclopropylmethyl)amino]-N-(6-methyl-1H-indazol-5-yl)pyrimidine-4-carboxamide
DMUOZEJ ID DMUOZEJ
DMUOZEJ DN Z223457004
DMUOZEJ HS Patented
DMUOZEJ SN SCHEMBL18352896; BDBM113297; ZINC12619614; AKOS033814184; MCULE-3787435099; US9695194, 14; Z223457004; 5-(2-methanesulfonylphenyl)-6,11,14-trioxa-4-azatricyclo[8.4.0.0^{3,8}]tetradeca-1,3(8),4,9-tetraen-7-one; 1000928-10-8
DMUOZEJ DT Small molecular drug
DMUOZEJ PC 25400536
DMUOZEJ MW 359.4
DMUOZEJ FM C17H13NO6S
DMUOZEJ IC InChI=1S/C17H13NO6S/c1-25(20,21)15-5-3-2-4-10(15)16-18-12-9-14-13(22-6-7-23-14)8-11(12)17(19)24-16/h2-5,8-9H,6-7H2,1H3
DMUOZEJ CS CS(=O)(=O)C1=CC=CC=C1C2=NC3=CC4=C(C=C3C(=O)O2)OCCO4
DMUOZEJ IK NYGGGQOBPHOCIJ-UHFFFAOYSA-N
DMUOZEJ IU 2-(2-methylsulfonylphenyl)-7,8-dihydro-[1,4]dioxino[2,3-g][3,1]benzoxazin-4-one
DMRBFUA ID DMRBFUA
DMRBFUA DN Z90308237
DMRBFUA HS Patented
DMRBFUA SN SCHEMBL18352966; BDBM113300; ZINC12619607; AKOS034677493; MCULE-1271453362; US9695194, 16; Z90308237; 1000928-01-7; 5-(2-chlorophenyl)-6,11,14-trioxa-4-azatricyclo[8.4.0.0^{3,8}]tetradeca-1,3(8),4,9-tetraen-7-one
DMRBFUA DT Small molecular drug
DMRBFUA PC 25400532
DMRBFUA MW 315.71
DMRBFUA FM C16H10ClNO4
DMRBFUA IC InChI=1S/C16H10ClNO4/c17-11-4-2-1-3-9(11)15-18-12-8-14-13(20-5-6-21-14)7-10(12)16(19)22-15/h1-4,7-8H,5-6H2
DMRBFUA CS C1COC2=C(O1)C=C3C(=C2)N=C(OC3=O)C4=CC=CC=C4Cl
DMRBFUA IK RMEUFAVEIHZTRM-UHFFFAOYSA-N
DMRBFUA IU 2-(2-chlorophenyl)-7,8-dihydro-[1,4]dioxino[2,3-g][3,1]benzoxazin-4-one
DMLZDAK ID DMLZDAK
DMLZDAK DN ZINC19658740
DMLZDAK HS Patented
DMLZDAK SN SCHEMBL15548184; CHEMBL3448261; LSJGWMPNBWLCRK-UHFFFAOYSA-N; BDBM250597; ZINC19658740; AKOS030474436; US9475795, 76; 1-((3,5-Dimethyl-1H-pyrazol-4-yl)sulfonyl)-4-(2-fluorophenoxyl)piperidine; 1-((3,5-Dimethyl-1H-pyrazol-4-yl)sulfonyl)-4-(2-fluorophenoxy)piperidine
DMLZDAK DT Small molecular drug
DMLZDAK PC 46981204
DMLZDAK MW 353.4
DMLZDAK FM C16H20FN3O3S
DMLZDAK IC InChI=1S/C16H20FN3O3S/c1-11-16(12(2)19-18-11)24(21,22)20-9-7-13(8-10-20)23-15-6-4-3-5-14(15)17/h3-6,13H,7-10H2,1-2H3,(H,18,19)
DMLZDAK CS CC1=C(C(=NN1)C)S(=O)(=O)N2CCC(CC2)OC3=CC=CC=C3F
DMLZDAK IK LSJGWMPNBWLCRK-UHFFFAOYSA-N
DMLZDAK IU 1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(2-fluorophenoxy)piperidine
DMYCH0G ID DMYCH0G
DMYCH0G DN ZINC584606052
DMYCH0G HS Patented
DMYCH0G SN SCHEMBL17492363; YDADFGXXCHDXFC-UHFFFAOYSA-N; US10077269, Example 5; BDBM285532; ZINC584606052; 3-(6-cyanopyridin-3-yl)-N-cyclopropylimidazo[1,2-b]pyridazine-2-carboxamide; 3-(6-Cyanopyridin-3-yl)-N-cyclopropylimidazo[1,2-b]pyridazine-2-carboxamide (5)
DMYCH0G DT Small molecular drug
DMYCH0G PC 118863059
DMYCH0G MW 304.31
DMYCH0G FM C16H12N6O
DMYCH0G IC InChI=1S/C16H12N6O/c17-8-12-4-3-10(9-18-12)15-14(16(23)20-11-5-6-11)21-13-2-1-7-19-22(13)15/h1-4,7,9,11H,5-6H2,(H,20,23)
DMYCH0G CS C1CC1NC(=O)C2=C(N3C(=N2)C=CC=N3)C4=CN=C(C=C4)C#N
DMYCH0G IK YDADFGXXCHDXFC-UHFFFAOYSA-N
DMYCH0G IU 3-(6-cyanopyridin-3-yl)-N-cyclopropylimidazo[1,2-b]pyridazine-2-carboxamide
DMW9P6U ID DMW9P6U
DMW9P6U DN ZINC915379
DMW9P6U HS Patented
DMW9P6U SN CHEMBL2315467; BAS 02073268; SCHEMBL16409978; ZINC915379; BDBM50424850; AKOS000586084; MCULE-1228568202; 3-Benzylsulfanyl-5-phenoxymethyl-4-phenyl-4H-[1,2,4]triazole
DMW9P6U DT Small molecular drug
DMW9P6U PC 1162727
DMW9P6U MW 373.5
DMW9P6U FM C22H19N3OS
DMW9P6U IC InChI=1S/C22H19N3OS/c1-4-10-18(11-5-1)17-27-22-24-23-21(16-26-20-14-8-3-9-15-20)25(22)19-12-6-2-7-13-19/h1-15H,16-17H2
DMW9P6U CS C1=CC=C(C=C1)CSC2=NN=C(N2C3=CC=CC=C3)COC4=CC=CC=C4
DMW9P6U IK SSZGXGUFAAHHAF-UHFFFAOYSA-N
DMW9P6U IU 3-benzylsulfanyl-5-(phenoxymethyl)-4-phenyl-1,2,4-triazole
DMR0F4H ID DMR0F4H
DMR0F4H DN ZINC959121
DMR0F4H HS Patented
DMR0F4H SN SCHEMBL18538657; ZINC959121; BDBM101826; AKOS001379122; MCULE-5667109528; US9695160, 40
DMR0F4H DT Small molecular drug
DMR0F4H PC 1194266
DMR0F4H MW 369.4
DMR0F4H FM C17H18F3N3OS
DMR0F4H IC InChI=1S/C17H18F3N3OS/c1-22-6-8-23(9-7-22)14-5-4-12(17(18,19)20)11-13(14)21-16(24)15-3-2-10-25-15/h2-5,10-11H,6-9H2,1H3,(H,21,24)
DMR0F4H CS CN1CCN(CC1)C2=C(C=C(C=C2)C(F)(F)F)NC(=O)C3=CC=CS3
DMR0F4H IK ZMQGTVWBYJXOLY-UHFFFAOYSA-N
DMR0F4H IU N-[2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]thiophene-2-carboxamide
DM3OPBR ID DM3OPBR
DM3OPBR DN ZNFTXQFGUIKQQE-UHFFFAOYSA-N
DM3OPBR HS Patented
DM3OPBR SN CHEMBL1076708; 6-[cyclohexyl(ethyl)amino]-N-(4-hydroxy-2-methylphenyl)pyrimidine-4-carboxamide; 6-(cyclohexyl(ethyl)amino)-N-(4-hydroxy-2-methylphenyl)pyrimidine-4-carboxamide; SCHEMBL3029985; ZNFTXQFGUIKQQE-UHFFFAOYSA-N; BDBM50313322
DM3OPBR DT Small molecular drug
DM3OPBR PC 25182763
DM3OPBR MW 354.4
DM3OPBR FM C20H26N4O2
DM3OPBR IC InChI=1S/C20H26N4O2/c1-3-24(15-7-5-4-6-8-15)19-12-18(21-13-22-19)20(26)23-17-10-9-16(25)11-14(17)2/h9-13,15,25H,3-8H2,1-2H3,(H,23,26)
DM3OPBR CS CCN(C1CCCCC1)C2=NC=NC(=C2)C(=O)NC3=C(C=C(C=C3)O)C
DM3OPBR IK ZNFTXQFGUIKQQE-UHFFFAOYSA-N
DM3OPBR IU 6-[cyclohexyl(ethyl)amino]-N-(4-hydroxy-2-methylphenyl)pyrimidine-4-carboxamide
DMXYA5K ID DMXYA5K
DMXYA5K DN Agomelatine
DMXYA5K HS Withdrawn from market
DMXYA5K SN Thymanax; Valdoxan; Agomelatine [INN]; AGO 178; AGO178; S 20098; S20098; AGO-178; Agomelatine(INN); S-20098; Valdoxan (TN); Valdoxan, Melitor, Thymanax, Agomelatine; N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide; N-(2-(7-Methoxy-1-naphthalenyl)ethyl)acetamide; N-(2-(7-Methoxynaphth-1-yl)ethyl)acetamide; N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide
DMXYA5K CP Servier
DMXYA5K DT Small molecular drug
DMXYA5K PC 82148
DMXYA5K MW 243.3
DMXYA5K FM C15H17NO2
DMXYA5K IC InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
DMXYA5K CS CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC
DMXYA5K IK YJYPHIXNFHFHND-UHFFFAOYSA-N
DMXYA5K IU N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
DMXYA5K CA CAS 138112-76-2
DMXYA5K CB CHEBI:134990
DMXYA5K DE Major depressive disorder
DMYJ8Z3 ID DMYJ8Z3
DMYJ8Z3 DN Alprenolol
DMYJ8Z3 HS Withdrawn from market
DMYJ8Z3 SN Alfeprol; Alpheprol; Alprenololum; Yobir; Alfeprol [Russian]; Alprenolol (INN); Alprenolol [INN:BAN]; Alprenololum [INN-Latin]; Apllobal (TN); Aptine (TN); Aptol (TN); Duriles (TN); Gubernal (TN); Regletin (TN); Yobir (TN); H-56-28; 1-(2-Allylphenoxy)-3-isopropylamino-2-propanol; 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol; 1-(o-Allylphenoxy)-3-isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol; 1-[2-(propen-2-ylphenoxy)]-3-(isopropylamino)propan-2-ol
DMYJ8Z3 CP AstraZeneca
DMYJ8Z3 TC Antiarrhythmic Agents
DMYJ8Z3 DT Small molecular drug
DMYJ8Z3 PC 2119
DMYJ8Z3 MW 249.35
DMYJ8Z3 FM C15H23NO2
DMYJ8Z3 IC InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
DMYJ8Z3 CS CC(C)NCC(COC1=CC=CC=C1CC=C)O
DMYJ8Z3 IK PAZJSJFMUHDSTF-UHFFFAOYSA-N
DMYJ8Z3 IU 1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol
DMYJ8Z3 CA CAS 13655-52-2
DMYJ8Z3 CB CHEBI:51211
DMYJ8Z3 DE Hypertension
DMGVNJ7 ID DMGVNJ7
DMGVNJ7 DN Amineptine
DMGVNJ7 HS Withdrawn from market
DMGVNJ7 SN Amineptin; Amineptino; Amineptinum; Amineptine [INN]; S 1694; Amineptine (INN); Amineptino [INN-Spanish]; Amineptinum [INN-Latin]; Survector (TN); 10,11-dihydrodibenzo(a,d)cyclohept-5-enyl-7-aminoheptanoic acid; 7-((10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid; 7-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)heptanoic acid
DMGVNJ7 CP Roche
DMGVNJ7 DT Small molecular drug
DMGVNJ7 PC 34870
DMGVNJ7 MW 337.5
DMGVNJ7 FM C22H27NO2
DMGVNJ7 IC InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)
DMGVNJ7 CS C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O
DMGVNJ7 IK ONNOFKFOZAJDHT-UHFFFAOYSA-N
DMGVNJ7 IU 7-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylamino)heptanoic acid
DMGVNJ7 CA CAS 57574-09-1
DMGVNJ7 CB CHEBI:32499
DMGVNJ7 DE Major depressive disorder
DMQ9RBV ID DMQ9RBV
DMQ9RBV DN Aminopterin
DMQ9RBV HS Withdrawn from market
DMQ9RBV SN APGA; Aminopteridine; Aminopterine; Aminopterinum; Aminotrexate; Pteramina; Pteramina [Czech]; A 1784; A-7170;A-Ninopterin; ENT-26079; Kyselina 4-aminolistova; Kyselina 4-aminolistova [Czech]; Kyselina 4-aminopteroylglutamova; Kyselina 4-aminopteroylglutamova [Czech]; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]; N-(1-((2,4-Diamino-6-pteridinylmethyl)amino)benzoyl)glutaminsaeure; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}phenyl)carbonyl]glutamic acid; N-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid; Kyselina N-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-L(+)-glutamova; Kyselina N-(p-((2,4-diamino-6-pteridinyl)methyl)benzoyl)-L(+)-glutamova [Czech]; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-L(+)-glutamova; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)amino)benzoyl)-L(+)-glutamova [Czech]; N-(4-(((2,4-Diamino-6-pteridyl)-methyl)amino)benzoyl)-L-glutamic acid; (2R)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid; 4'-Amino-folsaeure; 4'-Desoxy-4'-aminofolsaeure; 4-Amino pteroylglutamic acid; 4-Amino-4-deoxypteroylglutamate; 4-Amino-4-desoxy-pteroylglutaminsaeure; 4-Amino-PGA; 4-Aminofolic acid; 4-Aminopteroyl-glutamic acid; 4-Aminopteroyl-L-glutamic acid; 4-Aminopteroyl-glutamic acid; 4-Aminopteroylglutamic acid
DMQ9RBV CP Lederle Laboratories
DMQ9RBV TC Anticancer Agents
DMQ9RBV DT Small molecular drug
DMQ9RBV PC 169371
DMQ9RBV MW 440.4
DMQ9RBV FM C19H20N8O5
DMQ9RBV IC InChI=1S/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)/t12-/m0/s1
DMQ9RBV CS C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N
DMQ9RBV IK TVZGACDUOSZQKY-LBPRGKRZSA-N
DMQ9RBV IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMQ9RBV CA CAS 54-62-6
DMQ9RBV CB CHEBI:22526
DMQ9RBV DE leukaemia
DM2HN6Q ID DM2HN6Q
DM2HN6Q DN Astemizole
DM2HN6Q HS Withdrawn from market
DM2HN6Q SN Alermizol; Astemina; Astemisan; Astemisol; Astemison; Astemizol; Astemizolum; Astesen; Emdar; Esmacen; Fustermizol; Hestazol; Hismanal; Histamen; Histaminos; Histazol; Hubermizol; Kelp; Laridal; Metodih; Metodik; Paralergin; Retolen; Rifedot; Rimbol; Romadin; Simprox; Urdrim; Wareezol; Waruzol; AlacanBrand of Astemizole; Alonga Brand of Astemizole; Astemizol Alonga; Astemizol [German]; Astemizol ratiopharm; Astemizole Alacan Brand; Astemizole Alonga Brand; Astemizole Byk Brand; Astemizole Diba Brand; Astemizole Elfar Brand; Astemizole Esteve Brand; Astemizole Fustery Brand; Astemizole ICN Brand; Astemizole Janssen Brand; Astemizole Lesvi Brand; Astemizole McNeil Brand; Astemizole Medinsa Brand; Astemizole Merck Brand; Astemizole Senosiain Brand; Astemizole Septa Brand; Astemizole Smaller Brand; Astemizole Urbion Brand; Astemizole Vita Brand; Astemizole ratiopharm Brand; Byk Brand of Astemizole; Diba Brand of Astemizole; Elfar Brand of Astemizole; Esteve Brand of Astemizole; Fustery Brand of Astemizole; ICN Brand of Astemizole; Janssen Brand of Astemizole; Lesvi Brand of Astemizole; McNeil Brand of Astemizole; Medinsa Brand of Astemizole; Merck Brand of Astemizole; Ratiopharm Brand of Astemizole; Reig Jofre Brand of Astemizole; Senosiain Brand of Astemizole; Septa Brand of Astemizole; Smaller Brand of Astemizole; Urbion Brand of Astemizole; Vita Brand of Astemizole; R 42512; [3H]Astemizole; Alonga, Astemizol; Astemizol [INN-Spanish]; Astemizolum [INN-Latin]; HISMANAL (TN); Hismanal (TN); MJD-30; Nono-Nastizol A; Novo-mastizol A; Ratiopharm, Astemizol; Astemizole [USAN:BAN:INN]; GNF-PF-2461; Astemizole (JAN/USP/INN); Hestazol, Kelp, Laridal, Retolen, Wareezol, HSBD 6799, BRN 4830190; 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole
DM2HN6Q CP Janssen Pharmaceutica
DM2HN6Q TC Antiallergic Agents
DM2HN6Q DT Small molecular drug
DM2HN6Q PC 2247
DM2HN6Q MW 458.6
DM2HN6Q FM C28H31FN4O
DM2HN6Q IC InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)
DM2HN6Q CS COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
DM2HN6Q IK GXDALQBWZGODGZ-UHFFFAOYSA-N
DM2HN6Q IU 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]benzimidazol-2-amine
DM2HN6Q CA CAS 68844-77-9
DM2HN6Q CB CHEBI:2896
DM2HN6Q DE Allergic rhinitis
DM0J92L ID DM0J92L
DM0J92L DN Benactyzine
DM0J92L HS Withdrawn from market
DM0J92L SN BENACTYZINE; Benactyzin; Benzactyzine; 302-40-9; Diethylaminoethyl benzilate; Benactizina; Benactizina [DCIT]; Benactizina [Italian]; 2-(Diethylamino)ethyl benzilate; Benactyzine [INN:BAN]; Benactyzinum [INN-Latin]; Benacticina [INN-Spanish]; 2-Diethylaminoethyl benzilate; UNII-595EG71R3F; 2-(Diethylamino)ethyl diphenylglycolate; HSDB 3292; Benzilic acid, 2-(diethylamino)ethyl ester; EINECS 206-123-8; Diphenylglycolic acid 2-(diethylamino)ethyl ester; BRN 2156821; Benzilic acid beta-diethylaminoethyl ester; CHEMBL70352
DM0J92L DT Small molecular drug
DM0J92L PC 9330
DM0J92L MW 327.4
DM0J92L FM C20H25NO3
DM0J92L IC InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3
DM0J92L CS CCN(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O
DM0J92L IK IVQOFBKHQCTVQV-UHFFFAOYSA-N
DM0J92L IU 2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate
DM0J92L CA CAS 302-40-9
DM0J92L CB CHEBI:94775
DM0J92L DE Depression
DM5ZOX8 ID DM5ZOX8
DM5ZOX8 DN Benoxaprofen
DM5ZOX8 HS Withdrawn from market
DM5ZOX8 SN Benoxaprofene; Benoxaprofeno; Benoxaprofenum; Coxigon; Inflamid; Opren; Oraflex; Uniprofen; LRCL3794; Lilly 90459; Benoxaprofene [INN-French]; Benoxaprofeno [INN-Spanish]; Benoxaprofenum [INN-Latin]; Dl-Benoxaprofen; Oraflex (TN); Benoxaprofen (USAN/INN); Benoxaprofen [USAN:INN:BAN]; (+-)-2-(p-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; (-)-2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; (-)-Benoxaprofen; (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid; 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid; 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid; 2-(p-Chlorophenyl)-.alpha.-methyl-5-benzoxazoleacetic acid; 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
DM5ZOX8 CP Eli Lilly
DM5ZOX8 DT Small molecular drug
DM5ZOX8 PC 39941
DM5ZOX8 MW 301.72
DM5ZOX8 FM C16H12ClNO3
DM5ZOX8 IC InChI=1S/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)
DM5ZOX8 CS CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O
DM5ZOX8 IK MITFXPHMIHQXPI-UHFFFAOYSA-N
DM5ZOX8 IU 2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
DM5ZOX8 CA CAS 51234-28-7
DM5ZOX8 CB CHEBI:76114
DM5ZOX8 DE Inflammation
DMJMHNL ID DMJMHNL
DMJMHNL DN Bethanidine
DMJMHNL HS Withdrawn from market
DMJMHNL SN Betanidina; Betanidine; Betanidinum; Betanidole; Bethanid; Esbatal; Regulin; Tenathan; Bethanidine hemisulfate; Bethanidinesulfate; BW 467C60; BW467C60; Betanidina [INN-Spanish]; Betanidine [INN:BAN]; Betanidinum [INN-Latin]; Esbatal (TN); Regulin (TN); Tenathan (TN); Bethanidine Sulfate (2:1); Ulfate (2:1); BW-467-C-60;Bethanidine Sulfate (2:1) (USAN); Bethanidine, Sulfate (2:1); Guanidine, 1-benzyl-2,3-dimethyl-(8CI); Guanidine, 1-benzyl-2,3-dimethyl-, s; N-Benzyl-N',N''-dimethylguanidine sulfate; N,N'-dimethyl-N''-(phenylmethyl)-guanidine; Sulfuric acid compound with N''-benzyl-N,N'-dimethylguanidine (1:1); Guanidine, N, N'-dimethyl-N''-(phenylmethyl)-, sulfate (2:1); 1,2-dimethyl-3-(phenylmethyl)guanidine; 1-BENZYL-2,3-DIMETHYLGUANIDINE; 1-Benzyl-2,3-dimethylguanidine sulfate; 1-Benzyl-2,3-dimethylguanidine sulfate (1:1/2); 1-Benzyl-2,3-dimethylguanidinium sulfate; 2-Benzyl-1,3-dimethylguanidine
DMJMHNL TC Antihypertensive Agents
DMJMHNL DT Small molecular drug
DMJMHNL PC 2368
DMJMHNL MW 177.25
DMJMHNL FM C10H15N3
DMJMHNL IC InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)
DMJMHNL CS CNC(=NC)NCC1=CC=CC=C1
DMJMHNL IK NIVZHWNOUVJHKV-UHFFFAOYSA-N
DMJMHNL IU 1-benzyl-2,3-dimethylguanidine
DMJMHNL CA CAS 55-73-2
DMJMHNL CB CHEBI:37937
DMJMHNL DE Heart arrhythmia
DMPJKRL ID DMPJKRL
DMPJKRL DN Bithionol
DMPJKRL HS Withdrawn from market
DMPJKRL SN bithionol; 97-18-7; Actamer; Bithin; 2,2'-Thiobis(4,6-dichlorophenol); Lorothidol; Bitionol; Bithionol sulfide; Bisoxyphen; Bidiphen; Lorothiodol; Bitin; Nobacter; Bithionolate; Neopellis; Vancide BL; Usaf B-22; Bithional; Bithionolum; 2-Hydroxy-3,5-dichlorophenyl sulfide; TKhsd; Bis(2-hydroxy-3,5-dichlorophenyl) sulfide; Bis(3,5-dichloro-2-hydroxyphenyl) sulfide; 2,2'-sulfanediylbis(4,6-dichlorophenol); Caswell No. 852; Bitionol [INN-Spanish]; XL 7; Bithionolum [INN-Latin]; 2,2'-Dihydroxy-3,3',5,5'-tetrachlorodiphenyl sulfide
DMPJKRL DT Small molecular drug
DMPJKRL PC 2406
DMPJKRL MW 356
DMPJKRL FM C12H6Cl4O2S
DMPJKRL IC InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H
DMPJKRL CS C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl
DMPJKRL IK JFIOVJDNOJYLKP-UHFFFAOYSA-N
DMPJKRL IU 2,4-dichloro-6-(3,5-dichloro-2-hydroxyphenyl)sulfanylphenol
DMPJKRL CA CAS 97-18-7
DMPJKRL CB CHEBI:3131
DMPJKRL DE Trematode infection
DMBQYO0 ID DMBQYO0
DMBQYO0 DN Casopitant
DMBQYO0 HS Withdrawn from market
DMBQYO0 SN Rezonic; Zunrisa; GW 679769; GW679769
DMBQYO0 CP GlaxoSmithKline
DMBQYO0 DT Small molecular drug
DMBQYO0 PC 9917021
DMBQYO0 MW 616.6
DMBQYO0 FM C30H35F7N4O2
DMBQYO0 IC InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25+,27-/m1/s1
DMBQYO0 CS CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
DMBQYO0 IK XGGTZCKQRWXCHW-WMTVXVAQSA-N
DMBQYO0 IU (2R,4S)-4-(4-acetylpiperazin-1-yl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide
DMBQYO0 CA CAS 414910-27-3
DMBQYO0 CB CHEBI:135967
DMBQYO0 DE Chemotherapy-induced nausea
DM4Y95F ID DM4Y95F
DM4Y95F DN Cephaloridine
DM4Y95F HS Withdrawn from market
DM4Y95F SN cephaloridine; cefaloridine; Cefaloridin; Cephaloridin; Cephaloridinum; Cepaloridin; Cefalorizin; Cephalomycine; Cefaloridinum; Cepalorin; Cefaloridina; Loridine; Ceflorin; 50-59-9; Kefloridin; Glaxoridin; Ceporin; Vioviantine; Intrasporin; Sefacin; Keflordin; Deflorin; Cilifor; Ceporan; Sasperin; Faredina; Ceporine; Keflodin; Verolgin; Lloncefal; Kefspor; Ampligram; Betaine cephaloridine; CHEBI:3537; UNII-LVZ1VC61HB; Cefaloridinum [INN-Latin]; Cefaloridina [INN-Spanish]; N-(7-(2'-Thienylacetamidoceph-3-ylmethyl))-pyridinium-2-carboxylate; SCH
DM4Y95F DT Small molecular drug
DM4Y95F PC 5773
DM4Y95F MW 415.5
DM4Y95F FM C19H17N3O4S2
DM4Y95F IC InChI=1S/C19H17N3O4S2/c23-14(9-13-5-4-8-27-13)20-15-17(24)22-16(19(25)26)12(11-28-18(15)22)10-21-6-2-1-3-7-21/h1-8,15,18H,9-11H2,(H-,20,23,25,26)/t15-,18-/m1/s1
DM4Y95F CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)[O-])C[N+]4=CC=CC=C4
DM4Y95F IK CZTQZXZIADLWOZ-CRAIPNDOSA-N
DM4Y95F IU (6R,7R)-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM4Y95F CA CAS 50-59-9
DM4Y95F CB CHEBI:3537
DM4Y95F DE Gram-positive bacterial infection
DMSV2WZ ID DMSV2WZ
DMSV2WZ DN Chlorotrianisene
DMSV2WZ HS Withdrawn from market
DMSV2WZ SN Anisene; Chloortrianisestrol; Chlorestrolo; Chlorotrianisenum; Chlorotrianisestrol; Chlorotrianisine; Chlorotrianizen; Chlorotrisin; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Chlortrianizen; Clorestrolo; Clorotrianisene; Clorotrianiseno; Clorotrisin; Hormonisene; Khlortrianizen; Merbentul; Metace; Rianil; TACE; Triagen; Trianisestrol; Chlorotrianisene [Nonsteroidal oestrogens]; Clorotrianisene [DCIT]; Chlorotrianisene (INN); Chlorotrianisene [BAN:INN]; Chlorotrianisene [INN:BAN]; Chlorotrianisenum [INN-Latin]; Clorotrianiseno [INN-Spanish]; TACE (TN); Tace (pharmaceutical); Tace-fn; Chlorotris(p-methoxyphenyl)ethylene; Tri-p-anisylchloroethylene; Tris(p-methoxyphenyl)chloroethylene; 1,1',1''-(1-Chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene); 1,1',1''-(2-chloroethene-1,1,2-triyl)tris[4-(methyloxy)benzene]; 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
DMSV2WZ TC Anticancer Agents
DMSV2WZ DT Small molecular drug
DMSV2WZ PC 11289
DMSV2WZ MW 380.9
DMSV2WZ FM C23H21ClO3
DMSV2WZ IC InChI=1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3
DMSV2WZ CS COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)Cl)C3=CC=C(C=C3)OC
DMSV2WZ IK BFPSDSIWYFKGBC-UHFFFAOYSA-N
DMSV2WZ IU 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
DMSV2WZ CA CAS 569-57-3
DMSV2WZ CB CHEBI:3641
DMSV2WZ DE Menopause symptom
DM746BZ ID DM746BZ
DM746BZ DN Clioquinol
DM746BZ HS Withdrawn from market
DM746BZ SN clioquinol; 130-26-7; 5-Chloro-7-iodoquinolin-8-ol; Iodochlorhydroxyquin; Chinoform; Chloroiodoquin; Chloroiodoquine; 5-Chloro-8-hydroxy-7-iodoquinoline; Iodochloroxyquinoline; Cliquinol; Vioform; Iodochlorohydroxyquinoline; Chlorojodochin; Iodochloroxine; Iodochloroquine; Enteroquinol; Iodoenterol; 7-Iodo-5-chloroxine; Entero-Vioform; 5-Chloro-7-iodo-8-quinolinol; Iodochlorhydroxyquinoline; Iodoxyquinoline; Rheaform; Quinoform; Quinambicide; Lekosept; Dioquinol; Dermaform; Iodenterol; Entrokin; Enteroseptol; Domeform; Barquinol
DM746BZ DT Small molecular drug
DM746BZ PC 2788
DM746BZ MW 305.5
DM746BZ FM C9H5ClINO
DM746BZ IC InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
DM746BZ CS C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1
DM746BZ IK QCDFBFJGMNKBDO-UHFFFAOYSA-N
DM746BZ IU 5-chloro-7-iodoquinolin-8-ol
DM746BZ CA CAS 130-26-7
DM746BZ CB CHEBI:74460
DMJ7YDS ID DMJ7YDS
DMJ7YDS DN Dexfenfluramine
DMJ7YDS HS Withdrawn from market
DMJ7YDS SN DEXFENFLURAN; Dexfenfluramine (INN); Redux (TN); (2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine; (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMJ7YDS CP Wyeth Pharmaceuticals
DMJ7YDS TC Appetite Depressants
DMJ7YDS DT Small molecular drug
DMJ7YDS PC 66265
DMJ7YDS MW 231.26
DMJ7YDS FM C12H16F3N
DMJ7YDS IC InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m0/s1
DMJ7YDS CS CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
DMJ7YDS IK DBGIVFWFUFKIQN-VIFPVBQESA-N
DMJ7YDS IU (2S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMJ7YDS CA CAS 3239-44-9
DMJ7YDS CB CHEBI:439329
DMJ7YDS DE Obesity
DMRZ5D7 ID DMRZ5D7
DMRZ5D7 DN Droxicam
DMRZ5D7 HS Withdrawn from market
DMRZ5D7 SN Dobenam; Drogelon; Droxar; Ferpan; Ombolan; Precam; E-3128; E-318
DMRZ5D7 CP Esteve
DMRZ5D7 DT Small molecular drug
DMRZ5D7 PC 65679
DMRZ5D7 MW 357.3
DMRZ5D7 FM C16H11N3O5S
DMRZ5D7 IC InChI=1S/C16H11N3O5S/c1-18-13-14(10-6-2-3-7-11(10)25(18,22)23)24-16(21)19(15(13)20)12-8-4-5-9-17-12/h2-9H,1H3
DMRZ5D7 CS CN1C2=C(C3=CC=CC=C3S1(=O)=O)OC(=O)N(C2=O)C4=CC=CC=N4
DMRZ5D7 IK OEHFRZLKGRKFAS-UHFFFAOYSA-N
DMRZ5D7 IU 5-methyl-6,6-dioxo-3-pyridin-2-yl-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4-dione
DMRZ5D7 CA CAS 90101-16-9
DMRZ5D7 CB CHEBI:76133
DMRZ5D7 DE Inflammation
DMV5KR3 ID DMV5KR3
DMV5KR3 DN Ebrotidine
DMV5KR3 HS Withdrawn from market
DMV5KR3 SN Ebrocit; FI-3542
DMV5KR3 CP Ferrer Internacional SA
DMV5KR3 DT Small molecular drug
DMV5KR3 PC 65869
DMV5KR3 MW 477.4
DMV5KR3 FM C14H17BrN6O2S3
DMV5KR3 IC InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21)
DMV5KR3 CS C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br
DMV5KR3 IK ZQHFZHPUZXNPMF-UHFFFAOYSA-N
DMV5KR3 IU N-(4-bromophenyl)sulfonyl-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide
DMV5KR3 CA CAS 100981-43-9
DMV5KR3 CB CHEBI:135774
DMV5KR3 DE Duodenal ulcer
DMK0GHV ID DMK0GHV
DMK0GHV DN Encainide
DMK0GHV HS Withdrawn from market
DMK0GHV SN Encainida; Encainidum; Enkaid; Encainida [Spanish]; Encainide [French]; Encainidum [Latin]; No stereochem; MJ 9067; Encainide (INN); Encainide [INN:BAN]; MJ-9067; MJ-9067-1; Encainide Hydrochloride, (+-)-Isomer; (+-)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilide; (+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; (+/-)-4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide; 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide; 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide; 4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide
DMK0GHV TC Antiarrhythmic Agents
DMK0GHV DT Small molecular drug
DMK0GHV PC 48041
DMK0GHV MW 352.5
DMK0GHV FM C22H28N2O2
DMK0GHV IC InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
DMK0GHV CS CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
DMK0GHV IK PJWPNDMDCLXCOM-UHFFFAOYSA-N
DMK0GHV IU 4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide
DMK0GHV CA CAS 66778-36-7
DMK0GHV CB CHEBI:4788
DMK0GHV DE Heart arrhythmia
DM67PWD ID DM67PWD
DM67PWD DN Etilefrine
DM67PWD HS Withdrawn from market
DM67PWD SN etilefrine hydrochloride; 943-17-9; Etilefrine HCl; Circupon; Kertasin; Effontil; 534-87-2; 3-[2-(ethylamino)-1-hydroxyethyl]phenol hydrochloride; Effortilvet; Phetasin; Updormin; Pulsamin; Apocretin; Phetanol; Funasol; Ethyl adrianol; Tonus-Forte; Etilefrin Hydrochloride; Eti-Puren; 3-(2-(Ethylamino)-1-hydroxyethyl)phenol hydrochloride; 2-Ethylamino-1-(3-hydroxyphenyl)ethanol Hydrochloride; Etilefrine hydrochloride (TN); dl-Effortil hydrochloride; Ethylephrine hydrochloride; dl-Etilefrin hydrochloride; dl-N-Ethylnorphenylephrine h
DM67PWD DT Small molecular drug
DM67PWD PC 3306
DM67PWD MW 181.23
DM67PWD FM C10H15NO2
DM67PWD IC InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
DM67PWD CS CCNCC(C1=CC(=CC=C1)O)O
DM67PWD IK SQVIAVUSQAWMKL-UHFFFAOYSA-N
DM67PWD IU 3-[2-(ethylamino)-1-hydroxyethyl]phenol
DM67PWD CA CAS 709-55-7
DM67PWD CB CHEBI:91518
DM67PWD DE Cardiovascular disease
DMVG9YN ID DMVG9YN
DMVG9YN DN Fencamfamine
DMVG9YN HS Withdrawn from market
DMVG9YN SN Euvitol; Fenacamfamin; Fencamfamin; Fencamfamina; Fencamfaminum; Fencanfamina; Reactivan; Fencamfamina [DCIT]; Fencamfamin (INN); Fencamfamin [INN:BAN]; Fencamfamine [INN-French]; Fencamfaminum [INN-Latin]; Fencanfamina [INN-Spanish]; Glucoenergan (TN); Reactivan (TN); N-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine; N-ethyl-3-phenylbicyclo(2.2.1)heptan-2-amine; 2-Ethylamino-3-phenylnorbornane; 2-Phenyl-3-ethylaminobicyclo(2.2.1)heptane; 2-ethylamino-3-phenylnorcamphane; 3-Phenyl-N-ethyl-2-norbornanamine
DMVG9YN TC Central Nervous System Stimulants
DMVG9YN DT Small molecular drug
DMVG9YN PC 14584
DMVG9YN MW 215.33
DMVG9YN FM C15H21N
DMVG9YN IC InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3
DMVG9YN CS CCNC1C2CCC(C2)C1C3=CC=CC=C3
DMVG9YN IK IKFBPFGUINLYQI-UHFFFAOYSA-N
DMVG9YN IU N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
DMVG9YN CA CAS 1209-98-9
DMVG9YN CB CHEBI:134895
DMVG9YN DE Depressive fatigue
DMH6NG5 ID DMH6NG5
DMH6NG5 DN Fendiline
DMH6NG5 HS Withdrawn from market
DMH6NG5 SN fendiline; Fendilin; 13042-18-7; Fendilinum; Fendilinum [INN-Latin]; Fendilina [INN-Spanish]; Fendiline [INN]; EINECS 235-915-6; CHEMBL254832; Fendiline (INN); Benzenepropanamine, gamma-phenyl-N-(1-phenylethyl)-; Benzenepropanamine, .gamma.-phenyl-N-(1-phenylethyl)-; 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine; Phendilin; Fendilina; Senzit; NCGC00018223-06; SPBio_001131; Spectrum_000443; AC1L1FPB; Spectrum5_001302; Spectrum2_001006; Prestwick1_000270; Spectrum4_000417; Prestwick3_000270; Spectrum3_001436; Prestwick2_000270
DMH6NG5 DT Small molecular drug
DMH6NG5 PC 3336
DMH6NG5 MW 315.5
DMH6NG5 FM C23H25N
DMH6NG5 IC InChI=1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3
DMH6NG5 CS CC(C1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DMH6NG5 IK NMKSAYKQLCHXDK-UHFFFAOYSA-N
DMH6NG5 IU 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine
DMH6NG5 CA CAS 13042-18-7
DMH6NG5 CB CHEBI:94434
DMH6NG5 DE Coronary artery disease
DMY9P37 ID DMY9P37
DMY9P37 DN Flupenthixol
DMY9P37 HS Withdrawn from market
DMY9P37 SN Depixol; Emergil; Fluanxol; Fluxanxol; Siplaril; Siplarol; LC 44; N 7009; ALPHA-FLUPENTHIXOL; Cis(Z)Flupenthixol; Cis-Flupenthixol; Cis-Flupentixol; Depixol (TN); Fluanxol (TN); Flupentixol (INN); Flupentixol [INN:DCF]; Flupentixolum [INN-Latin]; Cis-(Z)-Flupenthixol; (Z)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; (Z)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethanol; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-(9CI); 2-Trifluoromethyl-9-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propylidene)thioxanthene; 2-Trifluoromethyl-9-(3-(4-(beta-hydroxyethyl)-1-piperazinyl)propylidene)thioxanthene; 2-[4-[(3Z)-3-[2-(Trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol; 4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 4-(3-(2-(Trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol
DMY9P37 CP Lundbeck Inc
DMY9P37 TC Antipsychotic Agents
DMY9P37 DT Small molecular drug
DMY9P37 PC 5281881
DMY9P37 MW 434.5
DMY9P37 FM C23H25F3N2OS
DMY9P37 IC InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
DMY9P37 CS C1CN(CCN1CC/C=C\\2/C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMY9P37 IK NJMYODHXAKYRHW-DVZOWYKESA-N
DMY9P37 IU 2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DMY9P37 CA CAS 53772-82-0
DMY9P37 CB CHEBI:10454
DMY9P37 DE Schizophrenia
DMWIDJK ID DMWIDJK
DMWIDJK DN FORMESTANE
DMWIDJK HS Withdrawn from market
DMWIDJK SN formestane; 566-48-3; 4-Hydroxyandrost-4-ene-3,17-dione; 4-Hydroxyandrostenedione; Lentaron; CGP-32349; Lentaron(R); 4-OH-A; B, Aromatase inhibitor; 4-Hydroxy-4-androstene-3,17-dione; NSC 282175; 17-dione; 4-OHA; CGP 32349; Formestane [INN:BAN]; UNII-PUB9T8T355; CCRIS 7483; ANDROST-4-ENE-3,17-DIONE, 4-HYDROXY-; 4-Hydroxy-delta(sub 4)-androstenedione; BRN 1889793; MLS002153359; MLS000028826; PUB9T8T355; CHEBI:75172
DMWIDJK DT Small molecular drug
DMWIDJK PC 11273
DMWIDJK MW 302.4
DMWIDJK FM C19H26O3
DMWIDJK IC InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
DMWIDJK CS C[C@]12CCC(=O)C(=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMWIDJK IK OSVMTWJCGUFAOD-KZQROQTASA-N
DMWIDJK IU (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMWIDJK CA CAS 566-48-3
DMWIDJK CB CHEBI:75172
DMWIDJK DE Breast cancer
DM9AGWQ ID DM9AGWQ
DM9AGWQ DN HEXESTROL
DM9AGWQ HS Withdrawn from market
DM9AGWQ SN hexestrol; Dihydrodiethylstilbestrol; Vitestrol; Hexoestrolum; Exestrol; 5635-50-7; Stilbestrol, dihydro-; 4,4'-(1,2-Diethylethylene)diphenol; 4,4'-(hexane-3,4-diyl)diphenol; Synoestrolum; Hexanestrol; Cycloestrol; Esestrolo [DCIT]; Phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-; Hexestrolum [INN-Latin]; Hexane, 3,4-bis(4-hydroxyphenyl)-; EINECS 227-082-2; 3,4-Bis(p-hydroxyphenyl)hexane; Hormoestrol; Syntrogene; Synthovo; Phenol, 4,4'-(1,2-diethylethylene)di-; CHEBI:31669; PBBGSZCBWVPOOL-UHFFFAOYSA-N; Hexestrol [INN]
DM9AGWQ DT Small molecular drug
DM9AGWQ PC 3606
DM9AGWQ MW 270.4
DM9AGWQ FM C18H22O2
DM9AGWQ IC InChI=1S/C18H22O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,17-20H,3-4H2,1-2H3
DM9AGWQ CS CCC(C1=CC=C(C=C1)O)C(CC)C2=CC=C(C=C2)O
DM9AGWQ IK PBBGSZCBWVPOOL-UHFFFAOYSA-N
DM9AGWQ IU 4-[4-(4-hydroxyphenyl)hexan-3-yl]phenol
DM9AGWQ CA CAS 5635-50-7
DM9AGWQ CB CHEBI:31669
DM9AGWQ DE Irregularities
DMSO2T9 ID DMSO2T9
DMSO2T9 DN Ibuproxam
DMSO2T9 HS Withdrawn from market
DMSO2T9 SN Ibuproxam; Ibudros; Ibuproxamum; 53648-05-8; Ibuproxam [INN]; n-hydroxy-2-(4-isobutylphenyl)propanamide; G-277; BRN 2267673; CHEMBL292707; CHEBI:76160; D,L-2-(4-Isobutylphenyl)propiohydroxamic acid; p-Isobutylhydratropohydroxamic acid; Ibuproxam (INN); D,L-N-Hydroxy-alpha-methyl-4-(2-methylpropyl)benzeneacetamide; N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide; Propionohydroxamic acid, 2-(p-isobutylphenyl)-, D,L-; Deflogon; Ibuproxamum [INN-Latin]; (S)-Ibuproxam; 73826-33-2; Ibudros (TN); EINECS 258-683-8; NSC 305528
DMSO2T9 DT Small molecular drug
DMSO2T9 PC 68704
DMSO2T9 MW 221.29
DMSO2T9 FM C13H19NO2
DMSO2T9 IC InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)
DMSO2T9 CS CC(C)CC1=CC=C(C=C1)C(C)C(=O)NO
DMSO2T9 IK BYPIURIATSUHDW-UHFFFAOYSA-N
DMSO2T9 IU N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide
DMSO2T9 CA CAS 53648-05-8
DMSO2T9 CB CHEBI:76160
DMSO2T9 DE Respiratory disease
DM5QSKN ID DM5QSKN
DM5QSKN DN INDOPROFEN
DM5QSKN HS Withdrawn from market
DM5QSKN SN Dexindoprofen; UNII-004T8726AU; 53086-13-8; 004T8726AU; (+)-indoprofen; Dexindoprofenum; Dexindoprofene; Dexindoprofeno; Dexindoprofen [INN]; Dexindoprofenum [INN-Latin]; Dexindoprofene [INN-French]; Dexindoprofeno [INN-Spanish]; Indoprofen (+)-; EINECS 258-351-2; AC1Q5QZO; AC1L2A9M; ZINC391; SCHEMBL286896; (+)-(S)-4-(1-Oxo-2-isoindolinyl)hydratropasaeure; CHEMBL2106252; AJ-07888; (+)-(S)-p-(1-Oxo-2-isoindolinyl)hydratropic acid; UNII-CPE46ZU14N component RJMIEHBSYVWVIN-NSHDSACASA-N
DM5QSKN DT Small molecular drug
DM5QSKN PC 3718
DM5QSKN MW 281.3
DM5QSKN FM C17H15NO3
DM5QSKN IC InChI=1S/C17H15NO3/c1-11(17(20)21)12-6-8-14(9-7-12)18-10-13-4-2-3-5-15(13)16(18)19/h2-9,11H,10H2,1H3,(H,20,21)
DM5QSKN CS CC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O
DM5QSKN IK RJMIEHBSYVWVIN-UHFFFAOYSA-N
DM5QSKN IU 2-[4-(3-oxo-1H-isoindol-2-yl)phenyl]propanoic acid
DM5QSKN CA CAS 31842-01-0
DM5QSKN CB CHEBI:76162
DM5QSKN DE Gout
DMNSJFD ID DMNSJFD
DMNSJFD DN Indoramin
DMNSJFD HS Withdrawn from market
DMNSJFD SN INDORAMIN; Indoramine; 26844-12-2; Indoramina; Wy-21901; Indoraminum [INN-Latin]; Indoramine [INN-French]; Indoramina [INN-Spanish]; UNII-0Z802HMY7H; Baratol; EINECS 248-041-5; BRN 0494035; WY 21901; 0Z802HMY7H; CHEMBL279516; C22H25N3O; Benzamide, N-(1-(2-(1H-indol-3-yl)ethyl)-4-piperidinyl)-; 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole; JXZZEXZZKAWDSP-UHFFFAOYSA-N; N-(1-(2-Indol-3-ylethyl)-4-piperidyl)benzamide; N-(1-(2-(1H-Indol-3-yl)ethyl)-4-piperidinyl)benzamide; Benzamide, N-(1-(2-indol-3-ylethyl)-4-piperidyl)-; Benzamide, N
DMNSJFD DT Small molecular drug
DMNSJFD PC 33625
DMNSJFD MW 347.5
DMNSJFD FM C22H25N3O
DMNSJFD IC InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
DMNSJFD CS C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43
DMNSJFD IK JXZZEXZZKAWDSP-UHFFFAOYSA-N
DMNSJFD IU N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide
DMNSJFD CA CAS 26844-12-2
DMNSJFD CB CHEBI:135470
DMNSJFD DE Hypertension
DMGTBC7 ID DMGTBC7
DMGTBC7 DN ISIS 2922
DMGTBC7 HS Withdrawn from market
DMGTBC7 SN Formivirsen sodium; 5'-d[G*C*G*T*T*T*G*C*T*C*T*T*C*T*T*C*T*T*G*C*G*]-3'; 5-SpG SpC SpG SpT spT SpT spG spC spT spC spT spT spC spT spT spC spT spT spG spC spG-3'
DMGTBC7 CP Isis Pharmaceuticals
DMGTBC7 DT Antisense drug
DMGTBC7 SQ GCGTTTGCTCTTCTTCTTGCG
DMGTBC7 DE Cytomegalovirus infection
DMMS2J5 ID DMMS2J5
DMMS2J5 DN Isoxicam
DMMS2J5 HS Withdrawn from market
DMMS2J5 SN isoxicam; 34552-84-6; Maxicam; Isoxicamo; Isoxicamum; UNII-8XU734C4NG; Pacyl (antiinflammatory); Isoxicamum [INN-Latin]; Isoxicamo [INN-Spanish]; EINECS 252-084-5; W 8495; BRN 0577221; 8XU734C4NG; CHEBI:76163; C14H13N3O5S; NCGC00016829-05; CAS-34552-84-6; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide; DSSTox_CID_25462; DSSTox_RID_80893; DSSTox_GSID_45462
DMMS2J5 DT Small molecular drug
DMMS2J5 PC 54677972
DMMS2J5 MW 335.34
DMMS2J5 FM C14H13N3O5S
DMMS2J5 IC InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)
DMMS2J5 CS CC1=CC(=NO1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
DMMS2J5 IK YYUAYBYLJSNDCX-UHFFFAOYSA-N
DMMS2J5 IU 4-hydroxy-2-methyl-N-(5-methyl-1,2-oxazol-3-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
DMMS2J5 CA CAS 34552-84-6
DMMS2J5 CB CHEBI:76163
DMMS2J5 DE Osteoarthritis
DMACMLO ID DMACMLO
DMACMLO DN LYSERGIC ACID DIETHYLAMIDE
DMACMLO HS Withdrawn from market
DMACMLO SN Lysergide; D-Lysergic acid diethylamide; Delysid; D-Lsd; N,N-Diethyllysergamide; Lysergamid; 50-37-3; Lysergsaeurediaethylamid; Cubes; Pearly gates; Heavenly Blue; Lysergaure diethylamid; Royal blue; N,N-Diethyl-D-lysergamide; LSD (alkaloid); Lysergidum; Wedding bells; Lysergsauerediaethylamid; Lysergic acid diethylamide-25; LSD 25; Lysergidum [INN-Latin]; LSD-25; Lisergide [DCIT]; Lysergamide, N,N-diethyl-; Ubergluben; Clearlight; Sunshine; Cupcakes; Greenies; Barrels; Yellows; Trippers; Microdots; Spoonies
DMACMLO DT Small molecular drug
DMACMLO PC 5761
DMACMLO MW 323.4
DMACMLO FM C20H25N3O
DMACMLO IC InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1
DMACMLO CS CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMACMLO IK VAYOSLLFUXYJDT-RDTXWAMCSA-N
DMACMLO IU (6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMACMLO CA CAS 50-37-3
DMACMLO CB CHEBI:6605
DMACMLO DE Addictive disorder
DM79GRO ID DM79GRO
DM79GRO DN Metamizole
DM79GRO HS Withdrawn from market
DM79GRO SN Dipyrone; dipyrone; Analgin; Metamizole sodium; Methampyrone; Novalgin; sulpyrine; 68-89-3; Neomelurbrin; Methylmelubrin; Algocalmin; Optalgin; Novalgetol; Sulpyrin; Pyralgin; Narone; Novaminsulfone; Novamidazophen; Nevralgina; Pharmalgine; Algopyrine; Farmolisina; Pyretin; Keypyrone; Analgine; Noveltex; Fevonil; Diprofarn; Dimethone; Alginodia; Pyrojec; Paralgin; Metilon; Metapyrin; Gifaril; Bonpyrin; Sulpin; Conmel; Barone; Neo-melubrine; Di-podil; Aminopyrine sodium sulfonate; Novaminsulfonum; Novaminsulfon; Metamizolum natricum
DM79GRO CP Aventis SA
DM79GRO DT Small molecular drug
DM79GRO PC 3111
DM79GRO MW 311.36
DM79GRO FM C13H17N3O4S
DM79GRO IC InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20)
DM79GRO CS CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O
DM79GRO IK LVWZTYCIRDMTEY-UHFFFAOYSA-N
DM79GRO IU [(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonic acid
DM79GRO CA CAS 50567-35-6
DM79GRO CB CHEBI:62088
DM79GRO DE Pain; Fever
DMW9NY0 ID DMW9NY0
DMW9NY0 DN Methaqualone
DMW9NY0 HS Withdrawn from market
DMW9NY0 SN Methaqualone hydrochloride; Melsedin; Somnofac; Optimil; Parest; Mequal; Melsed HCl; MTQ hydrochloride; Sopor hydrochloride; Somnafac; Quaalude hydrochloride; Methaqualone HCl; Hyminal monohydrochloride; TR 495 monohydrochloride; Mozambin hydrochloride; Methylquinazolone hydrochloride; UNII-RJQ4G25ZRH; 340-56-7; EINECS 206-431-2; NSC 75892; RJQ4G25ZRH; 2-Methyl-3-(o-tolyl)-4-quinazolone hydrochloride; CHI 38; 4(3H)-Quinazolinone, 2-methyl-3-(2-methylphenyl)-, monohydrochloride; 2-Methyl-3-tolylchinazolon-4 hydrochloride [German]
DMW9NY0 DT Small molecular drug
DMW9NY0 PC 6292
DMW9NY0 MW 250.29
DMW9NY0 FM C16H14N2O
DMW9NY0 IC InChI=1S/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3
DMW9NY0 CS CC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C
DMW9NY0 IK JEYCTXHKTXCGPB-UHFFFAOYSA-N
DMW9NY0 IU 2-methyl-3-(2-methylphenyl)quinazolin-4-one
DMW9NY0 CA CAS 72-44-6
DMW9NY0 CB CHEBI:6821
DMW9NY0 DE Insomnia
DMCP2TS ID DMCP2TS
DMCP2TS DN Nomifensine
DMCP2TS HS Withdrawn from market
DMCP2TS SN Linamiphen; Nomifenison; Nomifensin; Nomifensina; Nomifensinum; Nomiphensine; Nomifensina [INN-Spanish]; Nomifensine [INN:BAN]; Nomifensine maleate(USAN); Nomifensinum [INN-Latin]; D,L-nomifensine; Nomifensine Maleate (1:1); R/S-nomifensine; (+)-Nomifensine; (+)-Nomiphensine; (+-)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; (+-)-Nomifensin; (+-)-Nomifensine; (R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine 2-butenedioate; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine; 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine; 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline maleate (1:1); 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-(9CI)
DMCP2TS CP Uihlein
DMCP2TS DT Small molecular drug
DMCP2TS PC 4528
DMCP2TS MW 238.33
DMCP2TS FM C16H18N2
DMCP2TS IC InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3
DMCP2TS CS CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3
DMCP2TS IK XXPANQJNYNUNES-UHFFFAOYSA-N
DMCP2TS IU 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine
DMCP2TS CA CAS 24526-64-5
DMCP2TS CB CHEBI:116225
DMCP2TS DE Breast cancer
DMDKXYC ID DMDKXYC
DMDKXYC DN Parabis
DMDKXYC HS Withdrawn from market
DMDKXYC SN Dichlorophen; dichlorophene; Dichlorofen; Dichlorphen; 2,2'-Methylenebis(4-chlorophenol); Didroxane; Didroxan; Trivex; Difentan; Dicestal; Antiphen; Vermithana; Teniatol; Prevental; Teniotol; Embephen; Anthiphen; Teniathane; Taeniatol; Panacide; Cordocel; Palacel; Halenol; Parabis; Korium; Hyosan; Antifen; Dichlorophen B; Dichlorophene 10; Dichloorfeen; Gingivit; Wespuril; Gefir; Fungicide M; Plath-Lyse; DDDM; Bis(5-chloro-2-hydroxyphenyl)methane; Preventol GD; Fungicide GM; Preventol GDC; Diphenthane 70; Sandocide; Super mosstox
DMDKXYC PC 3037
DMDKXYC MW 269.12
DMDKXYC FM C13H10Cl2O2
DMDKXYC IC InChI=1S/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2
DMDKXYC CS C1=CC(=C(C=C1Cl)CC2=C(C=CC(=C2)Cl)O)O
DMDKXYC IK MDNWOSOZYLHTCG-UHFFFAOYSA-N
DMDKXYC IU 4-chloro-2-[(5-chloro-2-hydroxyphenyl)methyl]phenol
DMDKXYC CA CAS 97-23-4
DMDKXYC CB CHEBI:34689
DMDKXYC DE Tapeworm infestation
DMRQAM0 ID DMRQAM0
DMRQAM0 DN Phenacetin
DMRQAM0 HS Withdrawn from market
DMRQAM0 SN phenacetin; 62-44-2; Acetophenetidin; N-(4-Ethoxyphenyl)acetamide; Acetphenetidin; Acetophenetidine; Acetophenetin; Phenacetine; p-Acetophenetidide; Contradouleur; Commotional; Achrocidin; Phenazetin; Contradol; Codempiral; 4'-Ethoxyacetanilide; 4-Ethoxyacetanilide; Acetamide, N-(4-ethoxyphenyl)-; p-Acetophenetidine; Fenacetina; Phenidin; Pyraphen; Phenacitin; Phenacetinum; Fenidina; Phenedina; Phenacet; Pertonal; Fenina; Phenin; Kalmin; p-Acetphenetidin; p-Acetophenetide; Phenazetina; Tetracydin; p-Ethoxyacetanilide; Stellacyl; Phenodyne; Imidazo[4,5-e][1,4]diazapine nucleotide (I)
DMRQAM0 DT Small molecular drug
DMRQAM0 PC 4754
DMRQAM0 MW 179.22
DMRQAM0 FM C10H13NO2
DMRQAM0 IC InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)
DMRQAM0 CS CCOC1=CC=C(C=C1)NC(=O)C
DMRQAM0 IK CPJSUEIXXCENMM-UHFFFAOYSA-N
DMRQAM0 IU N-(4-ethoxyphenyl)acetamide
DMRQAM0 CA CAS 62-44-2
DMRQAM0 CB CHEBI:8050
DMRQAM0 DE Analgesia
DMQ52JG ID DMQ52JG
DMQ52JG DN Phenformin
DMQ52JG HS Withdrawn from market
DMQ52JG SN Azucaps; Cronoformin; DBI; Debeone; Debinyl; Diabis; Dibein; Dibiraf; Dibotin; Dipar; Feguanide; Fenfoduron; Fenformin; Fenformina; Fenormin; Glukopostin; Glyphen; Insoral; Lentobetic; Meltrol; Normoglucina; Pedg; Phenethyldiguanide; Phenformine; Phenforminum; Phenformix; Phenylethylbiguanide; Retardo; D Bretard; DB Comb; DBI monohydrochloride; Phenformine HCl; Phenoformine hydrochloride; W 32; Beta-PEBG; Beta-Phenethybiguanide; Beta-Phenethylbiguanide; Db-retard; Debeone (TN); Fenformina [INN-Spanish]; Meltrol-50; N-Phenethylbiguanide hydrochloride; Phenformin (BAN); Phenformin [INN:BAN]; Phenformine [INN-French]; Phenforminum [INN-Latin]; N'-beta-Fenetilformamidiniliminourea; N'-beta-Fenetilformamidiniliminourea [Italian]; N'-beta-Phenethylformamidinylliminourea; N-(2-Phenylethyl)imidodicarbonimidic diamide; PHENFORMIN (SEE ALSO PHENFORMIN HYDROCHLORIDE 834-28-6); 1-(diaminomethylidene)-2-phenethylguanidine; 1-Phenethylbiguanide
DMQ52JG CP Eli Lilly
DMQ52JG TC Hypoglycemic Agents
DMQ52JG DT Small molecular drug
DMQ52JG PC 8249
DMQ52JG MW 205.26
DMQ52JG FM C10H15N5
DMQ52JG IC InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)
DMQ52JG CS C1=CC=C(C=C1)CCN=C(N)N=C(N)N
DMQ52JG IK ICFJFFQQTFMIBG-UHFFFAOYSA-N
DMQ52JG IU 1-(diaminomethylidene)-2-(2-phenylethyl)guanidine
DMQ52JG CA CAS 114-86-3
DMQ52JG CB CHEBI:8064
DMQ52JG DE Diabetic complication
DM5SICT ID DM5SICT
DM5SICT DN Phenolphthalein
DM5SICT HS Withdrawn from market
DM5SICT SN phenolphthalein; 77-09-8; Phthalimetten; Phthalin; Euchessina; Phenolax; Purgophen; Espotabs; Koprol; Trilax; Laxogen; Purga; Lilo; Spulmako-lax; Feen-A-Mint Gum; Chocolax; Purgen; 3,3-Bis(4-hydroxyphenyl)phthalide; Ex-Lax; Fenolftalein; Correctol; Alophen; Medilax; Doxidan; Colax; Laxin; FemiLax; Dihydroxyphthalophenone; Phillips Gelcaps; 3,3-Bis(4-hydroxyphenyl)-1(3H)-isobenzofuranone; Lax-Pills; Evac-Q-Tabs; Evac-Q-Kwik; Evac-U-Gen; Evac-Q-Kit; 1(3H)-Isobenzofuranone, 3,3-bis(4-hydroxyphenyl)-; Phenolphtaleine; Fenolftaleina; Phenophthalein
DM5SICT DT Small molecular drug
DM5SICT PC 4764
DM5SICT MW 318.3
DM5SICT FM C20H14O4
DM5SICT IC InChI=1S/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H
DM5SICT CS C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DM5SICT IK KJFMBFZCATUALV-UHFFFAOYSA-N
DM5SICT IU 3,3-bis(4-hydroxyphenyl)-2-benzofuran-1-one
DM5SICT CA CAS 77-09-8
DM5SICT CB CHEBI:34914
DM5SICT DE Constipation
DMTFK3O ID DMTFK3O
DMTFK3O DN Phenylpropanolamine
DMTFK3O HS Withdrawn from market
DMTFK3O SN Norephedrine; phenylpropanolamine; Rhindecon; dl-Norephedrine; (+)-Norephedrine; Propagest; Dexatrim; Mucron; d-Norephedrine; Propadrine; 1r,2s-phenylpropylamine; Super Odrinex; 14838-15-4; (1S,2R)-2-amino-1-phenylpropan-1-ol; Fenilpropanolamina; dl-1-Phenyl-2-aminopropanol-1; UNII-7875H6443P; Phenylpropanolaminum; (+-)-Norephedrin; dl-Phenylpropanolamine; dl-2-Amino-1-hydroxy-1-phenylpropane; CHEBI:36; Naldecon; Cathinum [INN-Latin]; (+-)-Phenylpropanolamine; NSC9920; DLNKOYKMWOXYQA-VXNVDRBHSA-N; 37577-28-9; Cathina [INN-Spanish]; Acutrim; Cathina; Cathine; Cathinum; Codimal; Conex; Contuss; Despec; Exponcit; Fansia; Fugoa; Gentab; Guaipax; Katine; Minusine; Mydriatin; Myminic; Nolex; Norpseudoephedrine; Partuss; Phenoxine; Phenyldrine; Phenylfenesin; Phenylpropanolamina; Pseudonorephedrine; Rhymed; Snaplets; ULR; Vanex; Cathine [INN]; Fugoa Depot; Ami-Tex; D-Norpseudoephedrine; Dl-Norephedrine; Dura-Vent; Fansia (TN); L-Norephedrine; Proin (TN); Propalin (TN); Psi-Norephedrine; TAVIST-D; USAF CS-6; D-Nor-psi-ephedrine; L-Nor-psi-ephedrin; L-Nor-psi-ephedrine; D-(+)-Norephedrine; L-(-)-Norephedrine; (+-)-Norephedrine; (+/-)-Norephedrin; (+/-)-Norephedrine; (-)-Norephedrin; (-)-Norephedrine; (1R,2S)-Norephedrine
DMTFK3O CP Cipla phamaceuticals
DMTFK3O TC Appetite Depressants
DMTFK3O DT Small molecular drug
DMTFK3O PC 26934
DMTFK3O MW 151.21
DMTFK3O FM C9H13NO
DMTFK3O IC InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1
DMTFK3O CS C[C@H]([C@H](C1=CC=CC=C1)O)N
DMTFK3O IK DLNKOYKMWOXYQA-VXNVDRBHSA-N
DMTFK3O IU (1S,2R)-2-amino-1-phenylpropan-1-ol
DMTFK3O CA CAS 37577-28-9
DMTFK3O CB CHEBI:36
DMTFK3O DE Obesity
DMGQF3R ID DMGQF3R
DMGQF3R DN Remoxipride
DMGQF3R HS Withdrawn from market
DMGQF3R SN Remoxiprida; Remoxipridum; Romoxipride; A 33547; FLA 731; A-33547; FLA-731; Remoxiprida [INN-Spanish]; Remoxipride (USAN); Remoxipridum [INN-Latin]; Remoxipride [USAN:BAN:INN]; (-)-(S)-3-Brom-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamid; (-)-(S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; (-)-n-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine; (S)-3-Bromo-2,6-dimethoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-3-Bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide; 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
DMGQF3R TC Antipsychotic Agents
DMGQF3R DT Small molecular drug
DMGQF3R PC 54477
DMGQF3R MW 371.27
DMGQF3R FM C16H23BrN2O3
DMGQF3R IC InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1
DMGQF3R CS CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC
DMGQF3R IK GUJRSXAPGDDABA-NSHDSACASA-N
DMGQF3R IU 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
DMGQF3R CA CAS 80125-14-0
DMGQF3R CB CHEBI:92948
DMGQF3R DE Schizophrenia
DMVMIK2 ID DMVMIK2
DMVMIK2 DN Roxithromycin
DMVMIK2 HS Withdrawn from market
DMVMIK2 SN Assoral; Overall; RXM; Rossitrol; Roxithromycine; Roxithromycinum; Roxitromicina; Rulid; Rulide; Surlid; Roxithromycine [French]; Roxithromycinum [Latin]; Roxitromicina [Spanish]; RC2952; RU 28965; RU 965; Biaxsig (TN); Coroxin (TN); RU-28965; RU-965; Roxar (TN); Roximycin (TN); Roxithromycin & Tumor Necrosis Factor; Roxo (TN); Rulide (TN); Surlid (TN); Tirabicin (TN); Roxithromycin [USAN:INN:JAN]; Roxl-150 (TN); Roxithromycin (JP15/USAN/INN); Erythromycin 9-(-O-[2-methoxyethoxy]methyloxime);Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime); Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime); 9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin; 9-[O-(2-methoxyethoxymethyl)-oxime] of erythromycin
DMVMIK2 CP Sanofi-Aventis
DMVMIK2 TC Antibiotics
DMVMIK2 DT Small molecular drug
DMVMIK2 PC 6915744
DMVMIK2 MW 837
DMVMIK2 FM C41H76N2O15
DMVMIK2 IC InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1
DMVMIK2 CS CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
DMVMIK2 IK RXZBMPWDPOLZGW-XMRMVWPWSA-N
DMVMIK2 IU (3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
DMVMIK2 CA CAS 80214-83-1
DMVMIK2 CB CHEBI:48935
DMVMIK2 DE Bacterial infection
DMMP65N ID DMMP65N
DMMP65N DN Sertindole
DMMP65N HS Withdrawn from market
DMMP65N SN SerLect; Serdolect; Sertindol; Sertindolum; Sertindole hydrochloride; Lu 23-174; S-1991; SerLect (TN); Serdolect (TN); Serlect (TN); Sertindol [INN-Spanish]; Sertindole [USAN:INN]; Sertindolum [INN-Latin]; Lu-23-174; Sertindole (USAN/INN); 1-(2-(4-(5-Chloro-1-(4-fluorophenyl)-1H-indole-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-(4-(5-Chloro-1-(p-fluorophenyl)indol-3-yl)piperidino)ethyl)-2-imidazolidinone; 1-(2-(4-(5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinyl)ethyl)-2-imidazolidinone; 1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one; 1-[2-[4-[5-Chloro-1-(p-fluorophenyl)indol-3-yl]piperidino]ethyl]-2-imidazolidinone; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one; 1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one
DMMP65N TC Antipsychotic Agents
DMMP65N DT Small molecular drug
DMMP65N PC 60149
DMMP65N MW 440.9
DMMP65N FM C24H26ClFN4O
DMMP65N IC InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)
DMMP65N CS C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
DMMP65N IK GZKLJWGUPQBVJQ-UHFFFAOYSA-N
DMMP65N IU 1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one
DMMP65N CA CAS 106516-24-9
DMMP65N CB CHEBI:9122
DMMP65N DE Schizophrenia
DMKM5HB ID DMKM5HB
DMKM5HB DN Sitaxsentan
DMKM5HB HS Withdrawn from market
DMKM5HB SN Sitaxentan; IPI 1040; TBC 11251; TBC11251; Sitaxentan (INN); TBC-11251; N-(4-Chloro-3-methyl-5-isoxazolyl)-2-((2-methyl-4,5-methylenedioxyphenyl)acetyl)thiophene-3-sulfonamide; N-(4-Chloro-3-methyl-5-isoxazolyl)-2-((3,4-(methylenedioxy)-6-methylphenyl)acetyl)-3-thiophenesulfonamide; N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
DMKM5HB CP Encysive
DMKM5HB DT Small molecular drug
DMKM5HB PC 216235
DMKM5HB MW 454.9
DMKM5HB FM C18H15ClN2O6S2
DMKM5HB IC InChI=1S/C18H15ClN2O6S2/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h3-5,7,21H,6,8H2,1-2H3
DMKM5HB CS CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2
DMKM5HB IK PHWXUGHIIBDVKD-UHFFFAOYSA-N
DMKM5HB IU N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
DMKM5HB CA CAS 184036-34-8
DMKM5HB CB CHEBI:135736
DMKM5HB DE Pulmonary arterial hypertension
DMBCK2S ID DMBCK2S
DMBCK2S DN Sulfametopyrazine
DMBCK2S HS Withdrawn from market
DMBCK2S SN Dalysep; Kelfizin; Kelfizina; Kelfizine; Longum; Polycidal; SMP; SULFALENE; Solfametopirazina; Sulfalen; Sulfaleno; Sulfalenum; Sulfamethopyrazine; Sulfamethoxypyrazine; Sulfamethoxysuccinate; Sulfametoxypyridazin; Sulfapyrazinemethoxine; Sulfapyrazinemethoxyine; Sulfapyrazinemethoxyne; Sulfapyrazinmethoxine; Sulphalene; Sulphametopyrazine; Kelfizine W; Solfametopirazina [DCIT]; AS 18908; CBMicro_013257; FI 5978; WR 4629; Farmitalia 204/122; Kelfizina (TN); Sulfalene (USAN); Sulfalene [USAN:INN]; Sulfaleno [INN-Spanish]; Sulfalenum [INN-Latin]; Sulfamethopyrazine (JAN); N1-(3-Methoxypyrazinyl)sulfanilamide; N(sup 1)-(3-Methoxypyrazinyl)sulfanilamide; N(sup1)-(3-Methoxypyrazinyl)sulfanilamide; N(sup 1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; N(sup1)-(3-Methoxy-2-pyrazinyl)sulfanilamide; Sulfanilamide, N1-(3-methoxypyrazinyl)-(8CI); 2-(p-Aminobenzenesulfanamide)-3-methoxypyrazine; 2-(p-Aminobenzenesulfonamido)-3-methoxypyrazine; 2-Methoxy-3-sulfanilamidopyrazine; 2-Sulfanilamide 3-methoxy-pyrazine; 2-Sulfanilamido-3-methoxypyrazine; 3-Methoxy-2-sulfanilamidopyrazine; 3-Methoxy-2-sulfapyrazine; 3-Methoxypyrazine sulfanilamide; 4-Amino-N-(3-methoxy-pyrazin-2-yl)-benzenesulfonamide; 4-Amino-N-(3-methoxypyrazinyl)-benzenesulfonamide; 4-Amino-N-(3-methoxypyrazinyl)benzenesulfonamide; 4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide
DMBCK2S TC Antiinfective Agents
DMBCK2S DT Small molecular drug
DMBCK2S PC 9047
DMBCK2S MW 280.31
DMBCK2S FM C11H12N4O3S
DMBCK2S IC InChI=1S/C11H12N4O3S/c1-18-11-10(13-6-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)
DMBCK2S CS COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)N
DMBCK2S IK KXRZBTAEDBELFD-UHFFFAOYSA-N
DMBCK2S IU 4-amino-N-(3-methoxypyrazin-2-yl)benzenesulfonamide
DMBCK2S CA CAS 152-47-6
DMBCK2S CB CHEBI:32162
DMBCK2S DE Urinary tract infection
DMFR79T ID DMFR79T
DMFR79T DN TBC 11251 (TBC)
DMFR79T HS Withdrawn from market
DMFR79T DT Small molecular drug
DMFR79T PC 9867934
DMFR79T MW 441.5
DMFR79T FM C24H31N3O5
DMFR79T IC InChI=1S/C20H27N3O.C4H4O4/c1-3-24-19-10-7-13-21-20(19)22(2)18-11-14-23(15-12-18)16-17-8-5-4-6-9-17;5-3(6)1-2-4(7)8/h4-10,13,18H,3,11-12,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMFR79T CS CCOC1=C(N=CC=C1)N(C)C2CCN(CC2)CC3=CC=CC=C3.C(=C\\C(=O)O)\\C(=O)O
DMFR79T IK ADAMULBLHXHVFN-BTJKTKAUSA-N
DMFR79T IU N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine;(Z)-but-2-enedioic acid
DMFR79T DE Pulmonary arterial hypertension
DM3TON2 ID DM3TON2
DM3TON2 DN Temafloxacin
DM3TON2 HS Withdrawn from market
DM3TON2 SN Omniflox; Temabiotic; Temac; Temadie; Temaflox; Temafloxacin hydrochloride; A-62254; A-63004; T-30036; TA-167
DM3TON2 CP Abbott Laboratories
DM3TON2 DT Small molecular drug
DM3TON2 PC 60021
DM3TON2 MW 417.4
DM3TON2 FM C21H18F3N3O3
DM3TON2 IC InChI=1S/C21H18F3N3O3/c1-11-9-26(5-4-25-11)19-8-18-13(7-16(19)24)20(28)14(21(29)30)10-27(18)17-3-2-12(22)6-15(17)23/h2-3,6-8,10-11,25H,4-5,9H2,1H3,(H,29,30)
DM3TON2 CS CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F
DM3TON2 IK QKDHBVNJCZBTMR-UHFFFAOYSA-N
DM3TON2 IU 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM3TON2 CA CAS 108319-06-8
DM3TON2 CB CHEBI:77796
DM3TON2 DE Bacterial infection
DM4KLPT ID DM4KLPT
DM4KLPT DN Terfenadine
DM4KLPT HS Withdrawn from market
DM4KLPT SN Aldaban; Allerplus; Cyater; Hisfedin; Rapidal; Seldane; Teldane; Teldanex; Terdin; Terfedura; Terfemundin; Terfen; Terfenadina; Terfenadinum; Terfenidine; Terfex; Ternadin; Triludan; Aliud Brand of Terfenadine; Balkis Saft Spezial; Bial Brand of Terfenadine; Cantabria Brand of Terfenadine; Ct Arzneimittel Brand of Terfenadine; Dolorgiet Brand of Terfenadine; Heumann Brand of Terfenadine; Hoechst Brand of Terfenadine; Merck dura Brand of Terfenadine; Mundipharma Brand of Terfenadine; Ratiopharm Brand of Terfenadine; Sigma Tau Brand of Terfenadine; Stadapharm Brand of Terfenadine; Terfenadin AL; Terfenadin Heumann; Terfenadin Stada; Terfenadin von ct; Wolff Brand of Terfenadine; MDL 9918; RMI 9918; RMI9918; T 9652; Ct-Arzneimittel Brand of Terfenadine; MDL-9918; RMI-9918; Seldane (TN); Sigma-Tau Brand of Terfenadine; Teldane (TN); Terfenadin-ratiopharm; Terfenadina [INN-Spanish]; Terfenadinum [INN-Latin]; Triludan (TN); Terfenadine (JAN/USAN/INN); Terfenadine [USAN:BAN:INN:JAN]; Alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; 1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol
DM4KLPT CP Marion Merrell. Dow, Inc.
DM4KLPT TC Antihistamines
DM4KLPT DT Small molecular drug
DM4KLPT PC 5405
DM4KLPT MW 471.7
DM4KLPT FM C32H41NO2
DM4KLPT IC InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3
DM4KLPT CS CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
DM4KLPT IK GUGOEEXESWIERI-UHFFFAOYSA-N
DM4KLPT IU 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol
DM4KLPT CA CAS 50679-08-8
DM4KLPT CB CHEBI:9453
DM4KLPT DE Allergy
DMLFSTR ID DMLFSTR
DMLFSTR DN Ticrynafen
DMLFSTR HS Withdrawn from market
DMLFSTR SN Ticrynafen; Tienilic acid; 40180-04-9; Thienylic acid; Selacryn; Diflurex; Ticrex; Acido tienilico; Acide tienilique; Acidum tienilicum; Tienilico acido; Tienilico acido [Spanish]; Ticrynafen [USAN]; Acido tienilico [INN-Spanish]; Acide tienilique [INN-French]; Acidum tienilicum [INN-Latin]; ANP 3624; C13H8Cl2O4S; SKF 62698; UNII-HC95205SY4; 2-(2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid; (2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid; CCRIS 5489; 4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid
DMLFSTR DT Small molecular drug
DMLFSTR PC 38409
DMLFSTR MW 331.2
DMLFSTR FM C13H8Cl2O4S
DMLFSTR IC InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)
DMLFSTR CS C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl
DMLFSTR IK AGHANLSBXUWXTB-UHFFFAOYSA-N
DMLFSTR IU 2-[2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy]acetic acid
DMLFSTR CA CAS 40180-04-9
DMLFSTR CB CHEBI:9590
DMLFSTR DE Congestive heart failure
DMABRJL ID DMABRJL
DMABRJL DN Ximelagatran
DMABRJL HS Withdrawn from market
DMABRJL SN Exanta; Exarta; H 376/95; Ximelagatran [USAN:INN]; 192939-46-1; H 376-95; H 37695; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; NCGC00183598-01; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; H 376 95; Exanta (TN); Exarta (TN); Xi-melagatran; H-376/95; Ximelagatran (JAN/USAN/INN); Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; H376/95
DMABRJL CP AstraZeneca
DMABRJL TC Anticoagulants
DMABRJL DT Small molecular drug
DMABRJL PC 9574101
DMABRJL MW 473.6
DMABRJL FM C24H35N5O5
DMABRJL IC InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
DMABRJL CS CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)/C(=N/O)/N
DMABRJL IK ZXIBCJHYVWYIKI-PZJWPPBQSA-N
DMABRJL IU ethyl 2-[[(1R)-1-cyclohexyl-2-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxoethyl]amino]acetate
DMABRJL CA CAS 192939-46-1
DMABRJL CB CHEBI:136702
DMABRJL DE Coagulation defect
DMNI3U2 ID DMNI3U2
DMNI3U2 DN ZIMELIDINE
DMNI3U2 HS Withdrawn from market
DMNI3U2 SN Prestwick0_000092; Prestwick1_000092; 56775-88-3; AC1L26VA; NCIStruc1_001846; NCIStruc2_001359; SPBio_001983; 2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-; CTK1F3832; OYPPVKRFBIWMSX-UHFFFAOYSA-N; DB04832; NCI60_002580; FT-0675907; N,N-dimethyl-3-(4-bromophenyl)-3-(pyrid-3-yl)allylamine; N,N-dimethyl-3-(4-bromophenyl)-3-(3-pyridyl)-allylamine; (Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
DMNI3U2 DT Small molecular drug
DMNI3U2 PC 5365247
DMNI3U2 MW 317.22
DMNI3U2 FM C16H17BrN2
DMNI3U2 IC InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
DMNI3U2 CS CN(C)C/C=C(/C1=CC=C(C=C1)Br)\\C2=CN=CC=C2
DMNI3U2 IK OYPPVKRFBIWMSX-SXGWCWSVSA-N
DMNI3U2 IU (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
DMNI3U2 CA CAS 56775-88-3
DMNI3U2 CB CHEBI:92824
DMNI3U2 DE Major depressive disorder; Depression
DM7APNJ ID DM7APNJ
DM7APNJ DN Zomepirac
DM7APNJ HS Withdrawn from market
DM7APNJ SN ZOMEPIRAC SODIUM; Zomepirac sodium [USAN:USP]; UNII-Y0185WZ209; McN-2783-21-98; Y0185WZ209; 64092-49-5; Zomepirac sodium dihydrate; 1H-Pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-, sodium salt, dihydrate; Zomepirac sodium (USAN); CHEMBL3989403; DTXSID60214282; ZJXLSCXDGPDZOL-UHFFFAOYSA-M; D06382; Sodium 5-(p-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetate dihydrate; Sodium 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetate Dihydrate
DM7APNJ DT Small molecular drug
DM7APNJ PC 5733
DM7APNJ MW 291.73
DM7APNJ FM C15H14ClNO3
DM7APNJ IC InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)
DM7APNJ CS CC1=C(N(C(=C1)CC(=O)O)C)C(=O)C2=CC=C(C=C2)Cl
DM7APNJ IK ZXVNMYWKKDOREA-UHFFFAOYSA-N
DM7APNJ IU 2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid
DM7APNJ CA CAS 33369-31-2
DM7APNJ CB CHEBI:35859
DM7APNJ DE Pain
DMEQ3IW ID DMEQ3IW
DMEQ3IW DN (S)-amisulpride
DMEQ3IW HS Discontinued in Phase 4
DMEQ3IW SN UNII-ES3TWM82E8; ES3TWM82E8; 71675-92-8; Amisulpride, (S)-; AC1MHORM; SCHEMBL675545; NTJOBXMMWNYJFB-LBPRGKRZSA-N; ZINC1846088; Benzamide, 4-amino-N-(((2S)-1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-; LS-25533; UNII-8110R61I4U component NTJOBXMMWNYJFB-LBPRGKRZSA-N; 4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMEQ3IW CP Sanofi-Aventis
DMEQ3IW DT Small molecular drug
DMEQ3IW PC 3055076
DMEQ3IW MW 369.5
DMEQ3IW FM C17H27N3O4S
DMEQ3IW IC InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)/t12-/m0/s1
DMEQ3IW CS CCN1CCC[C@H]1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
DMEQ3IW IK NTJOBXMMWNYJFB-LBPRGKRZSA-N
DMEQ3IW IU 4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide
DMEQ3IW CA CAS 71675-92-8
DMEQ3IW DE Schizophrenia
DMPL2KM ID DMPL2KM
DMPL2KM DN GW-501516
DMPL2KM HS Discontinued in Phase 4
DMPL2KM SN 317318-70-0; GW501516; GW 501516; Endurobol; GW-501516; GSK-516; UNII-7I2HA1NU22; GW1516; GW 1516; 2-(2-Methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid; GW-516; GW-1516; CHEMBL38943; 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid; 2-(4-((2-(4-(Trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid; 7I2HA1NU22
DMPL2KM DT Small molecular drug
DMPL2KM PC 9803963
DMPL2KM MW 453.5
DMPL2KM FM C21H18F3NO3S2
DMPL2KM IC InChI=1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)
DMPL2KM CS CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O
DMPL2KM IK YDBLKRPLXZNVNB-UHFFFAOYSA-N
DMPL2KM IU 2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
DMPL2KM CA CAS 317318-70-0
DMPL2KM CB CHEBI:73726
DMPL2KM DE Type-1 diabetes
DMTF9YV ID DMTF9YV
DMTF9YV DN AE-0047
DMTF9YV HS Discontinued in Preregistration
DMTF9YV SN Calbren; Vatanidipine; Watanidipine hydrochloride; GJ-0956; (R)-(-)-AE 0047; (S)-(+)-AE 0047
DMTF9YV CP Mitsubishi Pharma Corp
DMTF9YV DT Small molecular drug
DMTF9YV PC 101588922
DMTF9YV MW 686.8
DMTF9YV FM C41H42N4O6
DMTF9YV IC InChI=1S/C41H42N4O6/c1-28-36(40(46)50-3)38(33-15-10-16-35(27-33)45(48)49)37(29(2)42-28)41(47)51-26-21-30-17-19-34(20-18-30)43-22-24-44(25-23-43)39(31-11-6-4-7-12-31)32-13-8-5-9-14-32/h4-20,27,38-39,46H,21-26H2,1-3H3
DMTF9YV CS CC1=C(C(C(=C([O-])OC)C(=N1)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCC3=CC=C(C=C3)[NH+]4CCN(CC4)C(C5=CC=CC=C5)C6=CC=CC=C6
DMTF9YV IK VPQACPHDDSSGPL-UHFFFAOYSA-N
DMTF9YV IU [5-[2-[4-(4-benzhydrylpiperazin-1-ium-1-yl)phenyl]ethoxycarbonyl]-2,6-dimethyl-4-(3-nitrophenyl)-4H-pyridin-3-ylidene]-methoxymethanolate
DMTF9YV DE Hypertension
DM7BN1A ID DM7BN1A
DM7BN1A DN Bermoprofen
DM7BN1A HS Discontinued in Preregistration
DM7BN1A SN Dibenon; Bermoprofen potasium salt; AD-1590; AJ-1590
DM7BN1A CP Dainippon Pharmaceutical Co Ltd
DM7BN1A DT Small molecular drug
DM7BN1A PC 54204
DM7BN1A MW 296.3
DM7BN1A FM C18H16O4
DM7BN1A IC InChI=1S/C18H16O4/c1-10-3-5-16-13(7-10)9-15(19)14-8-12(11(2)18(20)21)4-6-17(14)22-16/h3-8,11H,9H2,1-2H3,(H,20,21)
DM7BN1A CS CC1=CC2=C(C=C1)OC3=C(C=C(C=C3)C(C)C(=O)O)C(=O)C2
DM7BN1A IK REHLODZXMGOGQP-UHFFFAOYSA-N
DM7BN1A IU 2-(8-methyl-5-oxo-6H-benzo[b][1]benzoxepin-3-yl)propanoic acid
DM7BN1A CA CAS 78499-27-1
DM7BN1A CB CHEBI:135248
DM7BN1A DE Inflammation
DM6E5VA ID DM6E5VA
DM6E5VA DN Clinprost
DM6E5VA HS Discontinued in Preregistration
DM6E5VA SN Arteon; Isocarbacyclin methyl ester; TEI-9090; TTC-909; Clinprost (liposomal), Taisho; Clinprost (liposomal), Teijin
DM6E5VA CP Teijin Ltd
DM6E5VA DT Small molecular drug
DM6E5VA PC 6436040
DM6E5VA MW 364.5
DM6E5VA FM C22H36O4
DM6E5VA IC InChI=1S/C22H36O4/c1-3-4-5-9-18(23)11-12-19-20-14-16(13-17(20)15-21(19)24)8-6-7-10-22(25)26-2/h11-13,17-21,23-24H,3-10,14-15H2,1-2H3/b12-11+/t17-,18-,19+,20-,21+/m0/s1
DM6E5VA CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=C2)CCCCC(=O)OC)O)O
DM6E5VA IK QIGRQPVOWVHYBT-KABTVRTISA-N
DM6E5VA IU methyl 5-[(3aS,5R,6R,6aS)-5-hydroxy-6-[(E,3S)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoate
DM6E5VA CA CAS 88931-51-5
DM6E5VA DE Asthma
DM3OUWC ID DM3OUWC
DM3OUWC DN Domitroban
DM3OUWC HS Discontinued in Preregistration
DM3OUWC SN S-145; UNII-742F5K270Q; 5,7-(3-Phenylsulfonylamino(221)bicyclohept-2-yl)heptenoic acid; Calcium 5,7-(3-phenylsulfonylaminobicyclo(221)hept-2-yl)-5-heptenoate hydrate; 742F5K270Q; 112966-96-8; S-1452; (+)-S-145; (+)-(Z)-7-((1R,2S,3S,4S)-3-Benzenesulfonamido-2-norbornyl)-5-heptenoic acid; 5-Heptenoic acid, 7-(3-((phenylsulfonyl)amino)bicyclo(221)hept-2-yl)-, (1R-(1alpha,2alpha(Z),3beta,4alpha))-; Domitroban [INN]; 5-Heptenoic acid, 7-((1R,2S,3S,4S)-3-((phenylsulfonyl)amino)bicyclo(221)hept-2-yl)-,; Amboxan; Anboxan; [3H]S-145
DM3OUWC CP Shionogi & Co Ltd
DM3OUWC DT Small molecular drug
DM3OUWC PC 5312138
DM3OUWC MW 377.5
DM3OUWC FM C20H27NO4S
DM3OUWC IC InChI=1S/C20H27NO4S/c22-19(23)11-7-2-1-6-10-18-15-12-13-16(14-15)20(18)21-26(24,25)17-8-4-3-5-9-17/h1,3-6,8-9,15-16,18,20-21H,2,7,10-14H2,(H,22,23)/b6-1-/t15-,16+,18+,20+/m1/s1
DM3OUWC CS C1C[C@H]2C[C@@H]1[C@@H]([C@H]2NS(=O)(=O)C3=CC=CC=C3)C/C=C\\CCCC(=O)O
DM3OUWC IK PWTCIBWRMQFJBC-ZEMKZVSASA-N
DM3OUWC IU (Z)-7-[(1R,2S,3S,4S)-3-(benzenesulfonamido)-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid
DM3OUWC CA CAS 112966-96-8
DM3OUWC CB CHEBI:135586
DM3OUWC DE Thrombosis
DMFOEVQ ID DMFOEVQ
DMFOEVQ DN Ecabapide
DMFOEVQ HS Discontinued in Preregistration
DMFOEVQ SN Ecabamide; Muralis; DQ-2511
DMFOEVQ CP Daiichi Seiyaku Co Ltd
DMFOEVQ DT Small molecular drug
DMFOEVQ PC 65885
DMFOEVQ MW 371.4
DMFOEVQ FM C20H25N3O4
DMFOEVQ IC InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)
DMFOEVQ CS CNC(=O)C1=CC(=CC=C1)NCC(=O)NCCC2=CC(=C(C=C2)OC)OC
DMFOEVQ IK JTAGHJPZEDNHHA-UHFFFAOYSA-N
DMFOEVQ IU 3-[[2-[2-(3,4-dimethoxyphenyl)ethylamino]-2-oxoethyl]amino]-N-methylbenzamide
DMFOEVQ CA CAS 104775-36-2
DMFOEVQ DE Peptic ulcer
DMKQI7S ID DMKQI7S
DMKQI7S DN EMITEFUR
DMKQI7S HS Discontinued in Preregistration
DMKQI7S SN BOF-A2; Emitefur; Last-F (Otsuka, JP, US, US, US); 3-[3-(6-Benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil
DMKQI7S DT Small molecular drug
DMKQI7S PC 65910
DMKQI7S MW 558.5
DMKQI7S FM C28H19FN4O8
DMKQI7S IC InChI=1S/C28H19FN4O8/c1-2-39-16-32-15-21(29)25(35)33(28(32)38)24(34)18-9-6-10-19(13-18)27(37)41-23-20(14-30)11-12-22(31-23)40-26(36)17-7-4-3-5-8-17/h3-13,15H,2,16H2,1H3
DMKQI7S CS CCOCN1C=C(C(=O)N(C1=O)C(=O)C2=CC(=CC=C2)C(=O)OC3=C(C=CC(=N3)OC(=O)C4=CC=CC=C4)C#N)F
DMKQI7S IK WTSKMKRYHATLLL-UHFFFAOYSA-N
DMKQI7S IU (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate
DMKQI7S CA CAS 110690-43-2
DMKQI7S DE Solid tumour/cancer
DML1Y49 ID DML1Y49
DML1Y49 DN Epanolol
DML1Y49 HS Discontinued in Preregistration
DML1Y49 SN Visacor; TS-704
DML1Y49 CP Imperial Chemical Industries Plc
DML1Y49 DT Small molecular drug
DML1Y49 PC 72014
DML1Y49 MW 369.4
DML1Y49 FM C20H23N3O4
DML1Y49 IC InChI=1S/C20H23N3O4/c21-12-16-3-1-2-4-19(16)27-14-18(25)13-22-9-10-23-20(26)11-15-5-7-17(24)8-6-15/h1-8,18,22,24-25H,9-11,13-14H2,(H,23,26)
DML1Y49 CS C1=CC=C(C(=C1)C#N)OCC(CNCCNC(=O)CC2=CC=C(C=C2)O)O
DML1Y49 IK YARKMNAWFIMDKV-UHFFFAOYSA-N
DML1Y49 IU N-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-2-(4-hydroxyphenyl)acetamide
DML1Y49 CA CAS 86880-51-5
DML1Y49 CB CHEBI:4800
DML1Y49 DE Angina pectoris
DM05MCO ID DM05MCO
DM05MCO DN Inaperisone
DM05MCO HS Discontinued in Preregistration
DM05MCO SN Inapen; Inapene; Rilan; Riran; Inaperison HCl; Inaperisone hydrochloride; HN-770; HSR-770; HY-770; YM-170; YM-18170; 118230-97-]]]
DM05MCO CP Hokuriku Seiyaku KK
DM05MCO DT Small molecular drug
DM05MCO PC 65860
DM05MCO MW 245.36
DM05MCO FM C16H23NO
DM05MCO IC InChI=1S/C16H23NO/c1-3-14-6-8-15(9-7-14)16(18)13(2)12-17-10-4-5-11-17/h6-9,13H,3-5,10-12H2,1-2H3
DM05MCO CS CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCC2
DM05MCO IK VNFAARJCGSAROU-UHFFFAOYSA-N
DM05MCO IU 1-(4-ethylphenyl)-2-methyl-3-pyrrolidin-1-ylpropan-1-one
DM05MCO CA CAS 99323-21-4
DM05MCO CB CHEBI:134999
DM05MCO DE Pollakiuria
DM1B8NU ID DM1B8NU
DM1B8NU DN Isbogrel
DM1B8NU HS Discontinued in Preregistration
DM1B8NU SN Antexan; A-66900; CV-4151
DM1B8NU CP Takeda Pharmaceutical Co Ltd
DM1B8NU DT Small molecular drug
DM1B8NU PC 5284442
DM1B8NU MW 281.3
DM1B8NU FM C18H19NO2
DM1B8NU IC InChI=1S/C18H19NO2/c20-18(21)12-6-2-5-11-17(15-8-3-1-4-9-15)16-10-7-13-19-14-16/h1,3-4,7-11,13-14H,2,5-6,12H2,(H,20,21)/b17-11+
DM1B8NU CS C1=CC=C(C=C1)/C(=C\\CCCCC(=O)O)/C2=CN=CC=C2
DM1B8NU IK UWPBQLKEHGGKKD-GZTJUZNOSA-N
DM1B8NU IU (E)-7-phenyl-7-pyridin-3-ylhept-6-enoic acid
DM1B8NU CA CAS 89667-40-3
DM1B8NU DE Angina pectoris
DMXZ4BK ID DMXZ4BK
DMXZ4BK DN LAS-41001
DMXZ4BK HS Discontinued in Preregistration
DMXZ4BK SN Anti-inflammatory doxycycline derivative (rosacea), Almirall
DMXZ4BK CP Almirall Prodesfarma SA
DMXZ4BK DE Rosacea
DMBKNJT ID DMBKNJT
DMBKNJT DN LEMINOPRAZOLE
DMBKNJT HS Discontinued in Preregistration
DMBKNJT SN Leminon; Leminoprazole; NC-1300-O-3; Rac-2-[2-(N-Isobutyl-N-methylamino)benzylsulfinyl]benzimidazole
DMBKNJT DT Small molecular drug
DMBKNJT PC 65881
DMBKNJT MW 341.5
DMBKNJT FM C19H23N3OS
DMBKNJT IC InChI=1S/C19H23N3OS/c1-14(2)12-22(3)18-11-7-4-8-15(18)13-24(23)19-20-16-9-5-6-10-17(16)21-19/h4-11,14H,12-13H2,1-3H3,(H,20,21)
DMBKNJT CS CC(C)CN(C)C1=CC=CC=C1CS(=O)C2=NC3=CC=CC=C3N2
DMBKNJT IK PSIREIZGKQBEEO-UHFFFAOYSA-N
DMBKNJT IU 2-(1H-benzimidazol-2-ylsulfinylmethyl)-N-methyl-N-(2-methylpropyl)aniline
DMBKNJT CA CAS 104340-86-5
DMBKNJT DE Ulcerative colitis
DMNS4TK ID DMNS4TK
DMNS4TK DN Levcromakalim
DMNS4TK HS Discontinued in Preregistration
DMNS4TK SN Levcromakalim; Lemakalim; Cromakalim; (-)-Cromakalim; 94535-50-9; Levcromakelim; BRL 38227; BRL-38227; UNII-RW7PN4BLDJ; RW7PN4BLDJ; CHEMBL100; BRN 3622889; MLS000069770; CHEBI:6436; Cromakalime [French]; Cromakalimum [Latin]; Cromakalim, (3S-trans)-Isomer; SMR000058880; (3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile; DSSTox_RID_81051; DSSTox_CID_25677; DSSTox_GSID_45677; 94470-67-4; Cromakalimum; Cromakalime; BRL-34915; BRL 34915; 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-o
DMNS4TK DT Small molecular drug
DMNS4TK PC 93504
DMNS4TK MW 286.33
DMNS4TK FM C16H18N2O3
DMNS4TK IC InChI=1S/C16H18N2O3/c1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h5-6,8,14-15,20H,3-4,7H2,1-2H3/t14-,15+/m1/s1
DMNS4TK CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C
DMNS4TK IK TVZCRIROJQEVOT-CABCVRRESA-N
DMNS4TK IU (3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydrochromene-6-carbonitrile
DMNS4TK CA CAS 94535-50-9
DMNS4TK CB CHEBI:6436
DMNS4TK DE Chronic obstructive pulmonary disease
DMFGMD9 ID DMFGMD9
DMFGMD9 DN LUBELUZOLE
DMFGMD9 HS Discontinued in Preregistration
DMFGMD9 SN Lubeluzole; Prosynap; 144665-07-6; UNII-V2SIB71583; CHEMBL281724; V2SIB71583; R 87926; R-87926; (2S)-1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol; (+)-(S)-4-(2-Benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-1-piperidineethanol; 1-Piperidineethanol, 4-(2-benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-, (S)-; Lubeluzol; Lubeluzole [USAN:INN:BAN]; C22H25F2N3O2S; Prosynap (TN); R-91154; AC1Q4ONU; Lubeluzole (USAN/INN); SCHEMBL159725; Lubeluzole [USAN:B
DMFGMD9 DT Small molecular drug
DMFGMD9 PC 65998
DMFGMD9 MW 433.5
DMFGMD9 FM C22H25F2N3O2S
DMFGMD9 IC InChI=1S/C22H25F2N3O2S/c1-26(22-25-20-4-2-3-5-21(20)30-22)15-8-10-27(11-9-15)13-16(28)14-29-17-6-7-18(23)19(24)12-17/h2-7,12,15-16,28H,8-11,13-14H2,1H3/t16-/m0/s1
DMFGMD9 CS CN(C1CCN(CC1)C[C@@H](COC2=CC(=C(C=C2)F)F)O)C3=NC4=CC=CC=C4S3
DMFGMD9 IK OZFSWVOEXHGDES-INIZCTEOSA-N
DMFGMD9 IU (2S)-1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol
DMFGMD9 CA CAS 144665-07-6
DMFGMD9 CB CHEBI:135703
DMFGMD9 DE Neurological disorder
DMEQDHP ID DMEQDHP
DMEQDHP DN Meluadrine
DMEQDHP HS Discontinued in Preregistration
DMEQDHP SN Meluadrine tartrate; HSR-81
DMEQDHP CP Hokuriku Seiyaku KK
DMEQDHP DT Small molecular drug
DMEQDHP PC 3045414
DMEQDHP MW 243.73
DMEQDHP FM C12H18ClNO2
DMEQDHP IC InChI=1S/C12H18ClNO2/c1-12(2,3)14-7-11(16)9-5-4-8(15)6-10(9)13/h4-6,11,14-16H,7H2,1-3H3/t11-/m0/s1
DMEQDHP CS CC(C)(C)NC[C@@H](C1=C(C=C(C=C1)O)Cl)O
DMEQDHP IK LIXBJWRFCNRAPA-NSHDSACASA-N
DMEQDHP IU 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol
DMEQDHP CA CAS 134865-33-1
DMEQDHP DE Premature ejaculation
DM9ADLQ ID DM9ADLQ
DM9ADLQ DN Monatepil maleate
DM9ADLQ HS Discontinued in Preregistration
DM9ADLQ SN AD-2615; AJ-2615
DM9ADLQ CP Dainippon Pharmaceutical Co Ltd
DM9ADLQ DT Small molecular drug
DM9ADLQ PC 5282401
DM9ADLQ MW 591.7
DM9ADLQ FM C32H34FN3O5S
DM9ADLQ IC InChI=1S/C28H30FN3OS.C4H4O4/c29-22-11-13-23(14-12-22)32-18-16-31(17-19-32)15-5-10-27(33)30-28-24-7-2-1-6-21(24)20-34-26-9-4-3-8-25(26)28;5-3(6)1-2-4(7)8/h1-4,6-9,11-14,28H,5,10,15-20H2,(H,30,33);1-2H,(H,5,6)(H,7,8)/b;2-1-
DM9ADLQ CS C1CN(CCN1CCCC(=O)NC2C3=CC=CC=C3CSC4=CC=CC=C24)C5=CC=C(C=C5)F.C(=C\\C(=O)O)\\C(=O)O
DM9ADLQ IK ZDZXCYHMVFLGMT-BTJKTKAUSA-N
DM9ADLQ IU (Z)-but-2-enedioic acid;N-(6,11-dihydrobenzo[c][1]benzothiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide
DM9ADLQ CA CAS 103379-03-9
DM9ADLQ CB CHEBI:31862
DM9ADLQ DE Angina pectoris
DM31OGZ ID DM31OGZ
DM31OGZ DN MONTIRELIN TETRAHYDRATE
DM31OGZ HS Discontinued in Preregistration
DM31OGZ SN NS-3; Montirelin tetrahydrate; Remnos (Nippon Shinyaku, JP); (2R,5R)-N-(2-Methyl-3-oxothiomorpholin-5-ylcarbonyl)-L-histidyl-L-prolinamide tetrahydrate
DM31OGZ DT Small molecular drug
DM31OGZ PC 53297483
DM31OGZ MW 480.5
DM31OGZ FM C17H32N6O8S
DM31OGZ IC InChI=1S/C17H24N6O4S.4H2O/c1-9-15(25)22-12(7-28-9)16(26)21-11(5-10-6-19-8-20-10)17(27)23-4-2-3-13(23)14(18)24;;;;/h6,8-9,11-13H,2-5,7H2,1H3,(H2,18,24)(H,19,20)(H,21,26)(H,22,25);4*1H2/t9-,11+,12+,13+;;;;/m1..../s1
DM31OGZ CS C[C@@H]1C(=O)N[C@@H](CS1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N.O.O.O.O
DM31OGZ IK LYTHVCBIYIODIA-UVZXXTSMSA-N
DM31OGZ IU (3R,6R)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-6-methyl-5-oxothiomorpholine-3-carboxamide;tetrahydrate
DM31OGZ DE Pain
DMXF0NS ID DMXF0NS
DMXF0NS DN Norastemizole
DMXF0NS HS Discontinued in Preregistration
DMXF0NS SN Tecastemizole; Soltara; UNII-W5DCO14M05; 75970-99-9; CHEMBL61301; W5DCO14M05; T 1348; 1-((4-Flurophenyl)methyl)-N-4-piperidinyl-1H-benzimidazol-2-amine; 1-(-Fluorobenzyl)-N-(piperidin-4-yl)-1H-benzimidazol-2-amine; 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl-; Tecastemizole[USAN]; 75970-64-8; Tecastemizole [USAN:INN]; 1-(4-fluorobenzyl)-n-(piperidin-4-yl)-1h-benzimidazol-2-amine; AC1Q4NSA; AC1L3WZJ; Tecastemizole (USAN/INN); SCHEMBL18200; ZINC2303; DTXSID30226877
DMXF0NS DT Small molecular drug
DMXF0NS PC 123618
DMXF0NS MW 324.4
DMXF0NS FM C19H21FN4
DMXF0NS IC InChI=1S/C19H21FN4/c20-15-7-5-14(6-8-15)13-24-18-4-2-1-3-17(18)23-19(24)22-16-9-11-21-12-10-16/h1-8,16,21H,9-13H2,(H,22,23)
DMXF0NS CS C1CNCCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
DMXF0NS IK SFOVDSLXFUGAIV-UHFFFAOYSA-N
DMXF0NS IU 1-[(4-fluorophenyl)methyl]-N-piperidin-4-ylbenzimidazol-2-amine
DMXF0NS CA CAS 75970-99-9
DMUH0KO ID DMUH0KO
DMUH0KO DN Palonidipine hydrochloride
DMUH0KO HS Discontinued in Preregistration
DMUH0KO SN Palonidipine; TC-81
DMUH0KO CP Teijin Ltd
DMUH0KO DT Small molecular drug
DMUH0KO PC 119153
DMUH0KO MW 576.1
DMUH0KO FM C29H35ClFN3O6
DMUH0KO IC InChI=1S/C29H34FN3O6.ClH/c1-18-24(27(34)38-6)26(22-14-21(33(36)37)12-13-23(22)30)25(19(2)31-18)28(35)39-17-29(3,4)16-32(5)15-20-10-8-7-9-11-20;/h7-14,26,31H,15-17H2,1-6H3;1H
DMUH0KO CS CC1=C(C(C(=C(N1)C)C(=O)OCC(C)(C)CN(C)CC2=CC=CC=C2)C3=C(C=CC(=C3)[N+](=O)[O-])F)C(=O)OC.Cl
DMUH0KO IK OQHXRVQARZHYGQ-UHFFFAOYSA-N
DMUH0KO IU 5-O-[3-[benzyl(methyl)amino]-2,2-dimethylpropyl] 3-O-methyl 4-(2-fluoro-5-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMUH0KO CA CAS 96515-74-1
DMUH0KO DE Hypertension
DMP6BG4 ID DMP6BG4
DMP6BG4 DN Pirazolac
DMP6BG4 HS Discontinued in Preregistration
DMP6BG4 SN MY-309; ZK-76604
DMP6BG4 CP Bayer Schering Pharma AG
DMP6BG4 DT Small molecular drug
DMP6BG4 PC 51222
DMP6BG4 MW 330.7
DMP6BG4 FM C17H12ClFN2O2
DMP6BG4 IC InChI=1S/C17H12ClFN2O2/c18-12-3-1-11(2-4-12)15-10-21(20-16(15)9-17(22)23)14-7-5-13(19)6-8-14/h1-8,10H,9H2,(H,22,23)
DMP6BG4 CS C1=CC(=CC=C1C2=CN(N=C2CC(=O)O)C3=CC=C(C=C3)F)Cl
DMP6BG4 IK YAMFWQIVVMITPG-UHFFFAOYSA-N
DMP6BG4 IU 2-[4-(4-chlorophenyl)-1-(4-fluorophenyl)pyrazol-3-yl]acetic acid
DMP6BG4 CA CAS 71002-09-0
DMP6BG4 DE Inflammation
DMD8K3B ID DMD8K3B
DMD8K3B DN PW-2101
DMD8K3B HS Discontinued in Preregistration
DMD8K3B SN Antihypertensive (oral once-daily, TIMERx), Penwest
DMD8K3B CP Penwest Pharmaceuticals
DMD8K3B DE Angina pectoris
DM4LSJ2 ID DM4LSJ2
DM4LSJ2 DN Satigrel
DM4LSJ2 HS Discontinued in Preregistration
DM4LSJ2 SN E-5510
DM4LSJ2 CP Eisai Co Ltd
DM4LSJ2 DT Small molecular drug
DM4LSJ2 PC 65913
DM4LSJ2 MW 337.4
DM4LSJ2 FM C20H19NO4
DM4LSJ2 IC InChI=1S/C20H19NO4/c1-24-17-8-3-14(4-9-17)20(16(13-21)7-12-19(22)23)15-5-10-18(25-2)11-6-15/h3-6,8-11H,7,12H2,1-2H3,(H,22,23)
DM4LSJ2 CS COC1=CC=C(C=C1)C(=C(CCC(=O)O)C#N)C2=CC=C(C=C2)OC
DM4LSJ2 IK GRVCTHTXJDYIHB-UHFFFAOYSA-N
DM4LSJ2 IU 4-cyano-5,5-bis(4-methoxyphenyl)pent-4-enoic acid
DM4LSJ2 CA CAS 111753-73-2
DM4LSJ2 DE Thrombosis
DMYBPJ1 ID DMYBPJ1
DMYBPJ1 DN Semotiadil
DMYBPJ1 HS Discontinued in Preregistration
DMYBPJ1 SN Semotiadil fumarate; Sesamodil fumarate; DQ-4823; DS-4823; SD-3211
DMYBPJ1 CP Santen Pharmaceutical Co Ltd
DMYBPJ1 DT Small molecular drug
DMYBPJ1 PC 65929
DMYBPJ1 MW 536.6
DMYBPJ1 FM C29H32N2O6S
DMYBPJ1 IC InChI=1S/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m1/s1
DMYBPJ1 CS CN1C2=CC=CC=C2S[C@@H](C1=O)C3=C(C=CC(=C3)OC)OCCCN(C)CCOC4=CC5=C(C=C4)OCO5
DMYBPJ1 IK RKXVEXUAWGRFNP-MUUNZHRXSA-N
DMYBPJ1 IU (2R)-2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-1,4-benzothiazin-3-one
DMYBPJ1 CA CAS 116476-13-2
DMYBPJ1 DE Hypertension
DMC14HL ID DMC14HL
DMC14HL DN Suriclone
DMC14HL HS Discontinued in Preregistration
DMC14HL SN Suril; RP-31264
DMC14HL CP Rhone-Poulenc SA
DMC14HL DT Small molecular drug
DMC14HL PC 40903
DMC14HL MW 478
DMC14HL FM C20H20ClN5O3S2
DMC14HL IC InChI=1S/C20H20ClN5O3S2/c1-24-6-8-25(9-7-24)20(28)29-19-16-15(30-10-11-31-16)18(27)26(19)14-5-3-12-2-4-13(21)22-17(12)23-14/h2-5,19H,6-11H2,1H3
DMC14HL CS CN1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3
DMC14HL IK RMXOUBDDDQUBKD-UHFFFAOYSA-N
DMC14HL IU [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate
DMC14HL CA CAS 53813-83-5
DMC14HL DE Anxiety disorder
DM6PVWS ID DM6PVWS
DM6PVWS DN Telenzepine
DM6PVWS HS Discontinued in Preregistration
DM6PVWS SN Telenzepine [INN]; Telenzepinum [Latin]; Telenzepino [Spanish]; 80880-90-6; UNII-0990EG3K10; 0990EG3K10; NCGC00015987-05; DSSTox_RID_80752; DSSTox_CID_25209; 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one; DSSTox_GSID_45209; 4,9-Dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10H-thieno(3,4-b)(1,5)benzodiazepin-10-one; Telenzepine hydrochloride; Telenzepine dihydrochloide; C19H22N4O2S; Telenzepino; Telenzepinum; Telenzepine dihydrochloride hydrate; BY-802; [3H](+)telenzepine
DM6PVWS CP ALTANA Pharma AG
DM6PVWS DT Small molecular drug
DM6PVWS PC 5387
DM6PVWS MW 370.5
DM6PVWS FM C19H22N4O2S
DM6PVWS IC InChI=1S/C19H22N4O2S/c1-13-18-14(12-26-13)19(25)20-15-5-3-4-6-16(15)23(18)17(24)11-22-9-7-21(2)8-10-22/h3-6,12H,7-11H2,1-2H3,(H,20,25)
DM6PVWS CS CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)C
DM6PVWS IK VSWPGAIWKHPTKX-UHFFFAOYSA-N
DM6PVWS IU 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one
DM6PVWS CA CAS 80880-90-6
DM6PVWS CB CHEBI:92110
DM6PVWS DE Chronic obstructive pulmonary disease
DMUM3CP ID DMUM3CP
DMUM3CP DN 15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon
DMUM3CP HS Discontinued in Phase 3
DMUM3CP SN PROCALYX; 15(S)-HETE; 15(S)-Hydroxyeicosatetraenoic acid
DMUM3CP CP Alcon Inc
DMUM3CP DT Small molecular drug
DMUM3CP PC 5280724
DMUM3CP MW 320.5
DMUM3CP FM C20H32O3
DMUM3CP IC InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14+/t19-/m0/s1
DMUM3CP CS CCCCC[C@@H](/C=C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O)O
DMUM3CP IK JSFATNQSLKRBCI-VAEKSGALSA-N
DMUM3CP IU (5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoic acid
DMUM3CP CA CAS 54845-95-3
DMUM3CP CB CHEBI:15558
DMUM3CP DE Ocular disease
DM0GMJ6 ID DM0GMJ6
DM0GMJ6 DN 2085-P
DM0GMJ6 HS Discontinued in Phase 3
DM0GMJ6 SN VD-2085
DM0GMJ6 CP LEO Pharma A/S
DM0GMJ6 DT Small molecular drug
DM0GMJ6 PC 6917705
DM0GMJ6 MW 743.7
DM0GMJ6 FM C30H39BrN4O9S2
DM0GMJ6 IC InChI=1S/C22H29N3O6S.C8H10BrNO3S/c1-21(2,3)20(29)31-11-30-19(28)15-22(4,5)32-18-14(17(27)25(15)18)24-16(26)13(23)12-9-7-6-8-10-12;1-8(2)4(7(12)13)10-5(11)3(9)6(10)14-8/h6-10,13-15,18H,11,23H2,1-5H3,(H,24,26);3-4,6H,1-2H3,(H,12,13)/t13-,14+,15-,18+;3-,4+,6-/m01/s1
DM0GMJ6 CS CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)Br)C(=O)[O-])C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@H](C3=CC=CC=C3)[NH3+])C(=O)OCOC(=O)C(C)(C)C)C
DM0GMJ6 IK NSZOIZOWOWUYKG-VKICDOHCSA-N
DM0GMJ6 IU (2S,5R,6R)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;[(1S)-2-[[(2S,5R,6R)-2-(2,2-dimethylpropanoyloxymethoxycarbonyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl]amino]-2-oxo-1-phenylethyl]azanium
DM0GMJ6 DE Otitis media
DM09GSW ID DM09GSW
DM09GSW DN Abafungin
DM09GSW HS Discontinued in Phase 3
DM09GSW SN Abasol; W-634; YP-006; YP-007; Abafungin (gel formulation), York Pharma; Abafungin (cream, dermatomycosis), York Pharma; Abafungin (gel formulation, onychomycosis), York Pharma; Abafungin (pessary, vaginal candidiasis), York Pharma
DM09GSW CP York Pharma
DM09GSW DT Small molecular drug
DM09GSW PC 159326
DM09GSW MW 378.5
DM09GSW FM C21H22N4OS
DM09GSW IC InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)
DM09GSW CS CC1=CC(=C(C=C1)OC2=CC=CC=C2C3=CSC(=N3)NC4=NCCCN4)C
DM09GSW IK TYBHXIFFPVFXQW-UHFFFAOYSA-N
DM09GSW IU 4-[2-(2,4-dimethylphenoxy)phenyl]-N-(1,4,5,6-tetrahydropyrimidin-2-yl)-1,3-thiazol-2-amine
DM09GSW CA CAS 129639-79-8
DM09GSW CB CHEBI:76005
DM09GSW DE Fungal infection
DMAENDF ID DMAENDF
DMAENDF DN Abetimus sodium
DMAENDF HS Discontinued in Phase 3
DMAENDF SN Abetimus sodium (USAN); Riquent (TN)
DMAENDF CP La Jolla Pharmaceutical
DMAENDF DE Lupus
DMNKZ61 ID DMNKZ61
DMNKZ61 DN Ablukast
DMNKZ61 HS Discontinued in Phase 3
DMNKZ61 SN Ablukast sodium; RO-23-3544
DMNKZ61 CP Roche Holding AG
DMNKZ61 DT Small molecular drug
DMNKZ61 PC 57109
DMNKZ61 MW 498.6
DMNKZ61 FM C28H34O8
DMNKZ61 IC InChI=1S/C28H34O8/c1-4-8-21-23(12-10-20(17(2)29)27(21)31)34-13-6-5-7-14-35-26-16-25-19(15-22(26)18(3)30)9-11-24(36-25)28(32)33/h10,12,15-16,24,31H,4-9,11,13-14H2,1-3H3,(H,32,33)
DMNKZ61 CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCCOC2=C(C=C3CCC(OC3=C2)C(=O)O)C(=O)C
DMNKZ61 IK FGGYJWZYDAROFF-UHFFFAOYSA-N
DMNKZ61 IU 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
DMNKZ61 CA CAS 96566-25-5
DMNKZ61 DE Asthma
DMKM543 ID DMKM543
DMKM543 DN Acecainide
DMKM543 HS Discontinued in Phase 3
DMKM543 SN N-Acetylprocainamide; Acekainid; 32795-44-1; Acecainida; Acecainidum; NAPA; N-Acetyloprokainamid; Acecainide [INN]; Acekainid [Polish]; 4'-((2-(Diethylamino)ethyl)carbamoyl)acetanilide; Acecainidum [INN-Latin]; Acecainida [INN-Spanish]; N-Acetyloprokainamid [Polish]; UNII-910Q707V6F; CHEBI:60728; Benzamide, 4-(acetylamino)-N-(2-(diethylamino)ethyl)-; BRN 2868559; CHEMBL1097; MLS000069490; KEECCEWTUVWFCV-UHFFFAOYSA-N; 4-acetamido-N-[2-(diethylamino)ethyl]benzamide; 910Q707V6F; SMR000059070; ACETANILIDE,; NAPA; Acecainide hydrochloride; ASL-601; Acetylprocainamide
DMKM543 CP King Pharmaceuticals R&D Inc
DMKM543 DT Small molecular drug
DMKM543 PC 4342
DMKM543 MW 277.36
DMKM543 FM C15H23N3O2
DMKM543 IC InChI=1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)
DMKM543 CS CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C
DMKM543 IK KEECCEWTUVWFCV-UHFFFAOYSA-N
DMKM543 IU 4-acetamido-N-[2-(diethylamino)ethyl]benzamide
DMKM543 CA CAS 32795-44-1
DMKM543 CB CHEBI:60728
DMKM543 DE Solid tumour/cancer
DMPQZ80 ID DMPQZ80
DMPQZ80 DN Acivicin
DMPQZ80 HS Discontinued in Phase 3
DMPQZ80 SN acivicin; 42228-92-2; Antibiotic AT 125; Acivicinum; Acivicino; Acivicine; AT-125; AT 125; NSC-163501; NSC 163501; NSC163501; UNII-O0X60K76I6; ACIA; U 42126; CHEBI:74545; O0X60K76I6; U-42,126; Acivicin [USAN:INN]; (alphaS,5S)-alpha-Amino-3-chloro-2-isoxazoline-5-acetic acid; Acivicinum [INN-Latin]; Acivicine [INN-French]; Acivicino [INN-Spanish]; (alpha-S,5S)-alpha-Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid; C5H7ClN2O3; (2S)-2-Amino-2-[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]acetic acid; U-42126
DMPQZ80 DT Small molecular drug
DMPQZ80 PC 294641
DMPQZ80 MW 178.57
DMPQZ80 FM C5H7ClN2O3
DMPQZ80 IC InChI=1S/C5H7ClN2O3/c6-3-1-2(11-8-3)4(7)5(9)10/h2,4H,1,7H2,(H,9,10)/t2-,4-/m0/s1
DMPQZ80 CS C1[C@H](ON=C1Cl)[C@@H](C(=O)O)N
DMPQZ80 IK QAWIHIJWNYOLBE-OKKQSCSOSA-N
DMPQZ80 IU (2S)-2-amino-2-[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]acetic acid
DMPQZ80 CA CAS 42228-92-2
DMPQZ80 CB CHEBI:74545
DMTG18I ID DMTG18I
DMTG18I DN Aleglitazar
DMTG18I HS Discontinued in Phase 3
DMTG18I SN RO7; Aleglitazar (USAN); 2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzothiophen-7-yl]propanoic Acid
DMTG18I CP Roche
DMTG18I DT Small molecular drug
DMTG18I PC 10274777
DMTG18I MW 437.5
DMTG18I FM C24H23NO5S
DMTG18I IC InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1
DMTG18I CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)C[C@@H](C(=O)O)OC
DMTG18I IK DAYKLWSKQJBGCS-NRFANRHFSA-N
DMTG18I IU (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid
DMTG18I CA CAS 475479-34-6
DMTG18I DE Type-2 diabetes
DMV2Y6L ID DMV2Y6L
DMV2Y6L DN Alinidine
DMV2Y6L HS Discontinued in Phase 3
DMV2Y6L SN ST-567
DMV2Y6L CP Boehringer Ingelheim Corp
DMV2Y6L DT Small molecular drug
DMV2Y6L PC 36354
DMV2Y6L MW 270.15
DMV2Y6L FM C12H13Cl2N3
DMV2Y6L IC InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16)
DMV2Y6L CS C=CCN(C1=C(C=CC=C1Cl)Cl)C2=NCCN2
DMV2Y6L IK OXTYVEUAQHPPMV-UHFFFAOYSA-N
DMV2Y6L IU N-(2,6-dichlorophenyl)-N-prop-2-enyl-4,5-dihydro-1H-imidazol-2-amine
DMV2Y6L CA CAS 33178-86-8
DMV2Y6L DE Angina pectoris
DMV3PEA ID DMV3PEA
DMV3PEA DN Almokalant
DMV3PEA HS Discontinued in Phase 3
DMV3PEA SN Almokalant; 123955-10-2; Almokalantum; CHEMBL362103; Almokalant [INN]; 4-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile; Almokalantum [INN-Latin]; Almoklant; Benzonitrile, 4-(3-(ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)-; (+-)-p-(3-(Ethyl(3-(propylsulfinyl)propyl)amino)-2-hydroxypropoxy)benzonitrile; AC1MHWND; SCHEMBL247121; H 234-09; ZMHOBBKJBYLXFR-UHFFFAOYSA-N; BDBM50151869; LS-38713; HY-106855; CS-0026741; 4-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]-benzonitrile
DMV3PEA DT Small molecular drug
DMV3PEA PC 3033962
DMV3PEA MW 352.5
DMV3PEA FM C18H28N2O3S
DMV3PEA IC InChI=1S/C18H28N2O3S/c1-3-11-24(22)12-5-10-20(4-2)14-17(21)15-23-18-8-6-16(13-19)7-9-18/h6-9,17,21H,3-5,10-12,14-15H2,1-2H3
DMV3PEA CS CCCS(=O)CCCN(CC)CC(COC1=CC=C(C=C1)C#N)O
DMV3PEA IK ZMHOBBKJBYLXFR-UHFFFAOYSA-N
DMV3PEA IU 4-[3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile
DMV3PEA CA CAS 123955-10-2
DMV3PEA DE Cardiac arrhythmias
DMFE3CT ID DMFE3CT
DMFE3CT DN Alniditan
DMFE3CT HS Discontinued in Phase 3
DMFE3CT SN UNII-B57Z82EOGE; B57Z82EOGE; 152317-89-0; [3H]alniditan; Alniditan [INN:BAN]; N-[[(2R)-chroman-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine; AC1Q4UFC; AC1L24EQ; GTPL117; GTPL120; SCHEMBL717887; CHEMBL88240; ZINC1536693; PDSP2_001383; PDSP1_001399; BDBM50403503; CS-6739; HY-101698; 2-((3-(((R)-2-Chromanylmethyl)amino)propyl)amino)-1,4,5,6-tetrahydropyrimidine; Pasmigren; R-091274
DMFE3CT CP Janssen-Cilag Ltd
DMFE3CT DT Small molecular drug
DMFE3CT PC 66004
DMFE3CT MW 302.4
DMFE3CT FM C17H26N4O
DMFE3CT IC InChI=1S/C17H26N4O/c1-2-6-16-14(5-1)7-8-15(22-16)13-18-9-3-10-19-17-20-11-4-12-21-17/h1-2,5-6,15,18H,3-4,7-13H2,(H2,19,20,21)/t15-/m1/s1
DMFE3CT CS C1CNC(=NC1)NCCCNC[C@H]2CCC3=CC=CC=C3O2
DMFE3CT IK QVSXOXCYXPQXMF-OAHLLOKOSA-N
DMFE3CT IU N-[[(2R)-3,4-dihydro-2H-chromen-2-yl]methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine
DMFE3CT CA CAS 152317-89-0
DMFE3CT DE Migraine
DMGW07M ID DMGW07M
DMGW07M DN Aloxistatin
DMGW07M HS Discontinued in Phase 3
DMGW07M SN NSC694281; AC1L95AQ; SCHEMBL254426; CHEMBL1978255; CTK8C9289; ethyl(2s,3s)-3-[[1-(isopentylcarbamoyl)-3-methyl-butyl]carbamoyl]oxirane-2-carboxylate; NSC-694281; VC30685; NCI60_033765; ethyl (2S,3S)-3-[[4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate; 2-Oxiranecarboxylicacid,3-[[[(1S)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-,ethyl ester, (2S,3S)-
DMGW07M DT Small molecular drug
DMGW07M PC 65663
DMGW07M MW 342.4
DMGW07M FM C17H30N2O5
DMGW07M IC InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
DMGW07M CS CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C
DMGW07M IK SRVFFFJZQVENJC-IHRRRGAJSA-N
DMGW07M IU ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
DMGW07M CA CAS 88321-09-9
DMGW07M CB CHEBI:101381
DMGW07M DE Neurological disorder; Coronavirus infection
DMPS14M ID DMPS14M
DMPS14M DN Amibegron
DMPS14M HS Discontinued in Phase 3
DMPS14M SN SR 58611; Amibegron (USAN/INN); Ethyl 2-[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate
DMPS14M CP Sanofi-Aventis; Eli Lilly
DMPS14M DT Small molecular drug
DMPS14M PC 3035442
DMPS14M MW 403.9
DMPS14M FM C22H26ClNO4
DMPS14M IC InChI=1S/C22H26ClNO4/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3/t19-,21-/m0/s1
DMPS14M CS CCOC(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=CC=C3)Cl)O)C=C1
DMPS14M IK RDJQCOBTKKAQAH-FPOVZHCZSA-N
DMPS14M IU ethyl 2-[[(7S)-7-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate
DMPS14M CA CAS 121524-08-1
DMPS14M DE Type-2 diabetes; Obesity; Major depressive disorder; Mood disorder
DMNEM2C ID DMNEM2C
DMNEM2C DN Anipamil
DMNEM2C HS Discontinued in Phase 3
DMNEM2C SN LU-42668
DMNEM2C CP Knoll GmbH
DMNEM2C DT Small molecular drug
DMNEM2C PC 54966
DMNEM2C MW 520.799
DMNEM2C FM C34H52N2O2
DMNEM2C IC InChI=1S/C34H52N2O2/c1-5-6-7-8-9-10-11-12-13-14-23-34(29-35,31-19-16-21-33(28-31)38-4)24-17-25-36(2)26-22-30-18-15-20-32(27-30)37-3/h15-16,18-21,27-28H,5-14,17,22-26H2,1-4H3
DMNEM2C CS CCCCCCCCCCCCC(CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=CC=C2)OC
DMNEM2C IK PHFDAOXXIZOUIX-UHFFFAOYSA-N
DMNEM2C IU 2-(3-methoxyphenyl)-2-[3-[2-(3-methoxyphenyl)ethyl-methylamino]propyl]tetradecanenitrile
DMNEM2C CA CAS 83200-10-6
DMNEM2C DE Hypertension
DM8XO3B ID DM8XO3B
DM8XO3B DN ARANOSE
DM8XO3B HS Discontinued in Phase 3
DM8XO3B SN Aranoza; CRC-0510375; 3-(alpha-L-Arabinopyranosyl)-1-methyl-1-nitrosourea
DM8XO3B DT Small molecular drug
DM8XO3B PC 208900
DM8XO3B MW 235.19
DM8XO3B FM C7H13N3O6
DM8XO3B IC InChI=1S/C7H13N3O6/c1-10(9-15)7(14)8-6-5(13)4(12)3(11)2-16-6/h3-6,11-13H,2H2,1H3,(H,8,14)/t3-,4-,5+,6+/m0/s1
DM8XO3B CS CN(C(=O)N[C@H]1[C@@H]([C@H]([C@H](CO1)O)O)O)N=O
DM8XO3B IK BADMGRJDJPQBLS-UNTFVMJOSA-N
DM8XO3B IU 1-methyl-1-nitroso-3-[(2R,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]urea
DM8XO3B CA CAS 167396-23-8
DM8XO3B DE Solid tumour/cancer
DM4BV2W ID DM4BV2W
DM4BV2W DN Asoprisnil
DM4BV2W HS Discontinued in Phase 3
DM4BV2W SN J867; J-867; Asoprisnil (USAN/INN); 11beta-(4-((E)-(Hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one
DM4BV2W CP Bayer
DM4BV2W DT Small molecular drug
DM4BV2W PC 9577221
DM4BV2W MW 449.6
DM4BV2W FM C28H35NO4
DM4BV2W IC InChI=1S/C28H35NO4/c1-27-15-24(19-6-4-18(5-7-19)16-29-31)26-22-11-9-21(30)14-20(22)8-10-23(26)25(27)12-13-28(27,33-3)17-32-2/h4-7,14,16,23-25,31H,8-13,15,17H2,1-3H3/b29-16+/t23-,24+,25-,27-,28+/m0/s1
DM4BV2W CS C[C@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(COC)OC)C5=CC=C(C=C5)/C=N/O
DM4BV2W IK GJMNAFGEUJBOCE-MEQIQULJSA-N
DM4BV2W IU (8S,11R,13S,14S,17S)-11-[4-[(E)-hydroxyiminomethyl]phenyl]-17-methoxy-17-(methoxymethyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
DM4BV2W CA CAS 199396-76-4
DM4BV2W DE Endometriosis
DMPTG39 ID DMPTG39
DMPTG39 DN Ataprost
DMPTG39 HS Discontinued in Phase 3
DMPTG39 SN ONO-41483; OP-41483
DMPTG39 CP Ono Pharmaceutical Co Ltd
DMPTG39 DT Small molecular drug
DMPTG39 PC 6436122
DMPTG39 MW 348.5
DMPTG39 FM C21H32O4
DMPTG39 IC InChI=1S/C21H32O4/c22-19(15-6-2-3-7-15)10-9-17-18-12-14(5-1-4-8-21(24)25)11-16(18)13-20(17)23/h5,9-10,15-20,22-23H,1-4,6-8,11-13H2,(H,24,25)/b10-9+,14-5+/t16-,17+,18-,19+,20+/m0/s1
DMPTG39 CS C1CCC(C1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C/C(=C/CCCC(=O)O)/C3)O)O
DMPTG39 IK DKLGLHQHLFISGJ-YLBFUXKPSA-N
DMPTG39 IU (5E)-5-[(3aS,4R,5R,6aS)-4-[(E,3S)-3-cyclopentyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMPTG39 CA CAS 83997-19-7
DMPTG39 DE Asthma
DMFG4OM ID DMFG4OM
DMFG4OM DN Avasimibe
DMFG4OM HS Discontinued in Phase 3
DMFG4OM SN Avasimibe; 166518-60-1; CI-1011; Avasimibe(CI-1011); UNII-28LQ20T5RC; CI 1011; Avasimibe (CI-1011); PD 148515; CHEMBL101309; 28LQ20T5RC; 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate; 2,6-diisopropylphenyl 2-(2,4,6-triisopropylphenyl)acetylsulfamate; 2,6-Diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate; 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)-acetyl)sulfamate; ((2,4,6-Tris(1-methylethyl)phenyl)acetyl)sulfamic acid 2,6-bis(1-methylethyl)phenyl ester
DMFG4OM DT Small molecular drug
DMFG4OM PC 166558
DMFG4OM MW 501.7
DMFG4OM FM C29H43NO4S
DMFG4OM IC InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)
DMFG4OM CS CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C
DMFG4OM IK PTQXTEKSNBVPQJ-UHFFFAOYSA-N
DMFG4OM IU [2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate
DMFG4OM CA CAS 166518-60-1
DMFG4OM DE Peripheral vascular disease
DM3SE2N ID DM3SE2N
DM3SE2N DN Avitriptan
DM3SE2N HS Discontinued in Phase 3
DM3SE2N SN Avitriptan fumarate; BMS-180048
DM3SE2N CP Bristol-Myers Squibb Co
DM3SE2N DT Small molecular drug
DM3SE2N PC 133081
DM3SE2N MW 458.6
DM3SE2N FM C22H30N6O3S
DM3SE2N IC InChI=1S/C22H30N6O3S/c1-23-32(29,30)15-17-5-6-20-19(12-17)18(13-25-20)4-3-7-27-8-10-28(11-9-27)22-21(31-2)14-24-16-26-22/h5-6,12-14,16,23,25H,3-4,7-11,15H2,1-2H3
DM3SE2N CS CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCCN3CCN(CC3)C4=NC=NC=C4OC
DM3SE2N IK WRZVGHXUPBWIOO-UHFFFAOYSA-N
DM3SE2N IU 1-[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DM3SE2N CA CAS 151140-96-4
DM3SE2N DE Migraine
DMT5O8I ID DMT5O8I
DMT5O8I DN Axokine
DMT5O8I HS Discontinued in Phase 3
DMT5O8I DE Obesity
DM7G8T0 ID DM7G8T0
DM7G8T0 DN Azithromycin/chloroquine
DM7G8T0 HS Discontinued in Phase 3
DM7G8T0 SN Chloroquine (TN)
DM7G8T0 CP Pfizer
DM7G8T0 DE Bacterial infection
DMAMFXC ID DMAMFXC
DMAMFXC DN BCG65-E7
DMAMFXC HS Discontinued in Phase 3
DMAMFXC CP Nventa BioPharma
DMAMFXC DE Human papillomavirus infection; Anal intraepithelial neoplasia
DMRQV8I ID DMRQV8I
DMRQV8I DN Becatecarin
DMRQV8I HS Discontinued in Phase 3
DMRQV8I SN BMS-181176; Becatecarin < USAN; DEAE-Rebeccamycin; XL-119; BMY-27557-01 (HCl); BMY-27557-14 (tartrate); 1,11-Dichloro-6-[2-(diethylamino)ethyl]-12-(4-O-methyl-beta-D-glucopyranosyl)-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DMRQV8I CP Exelixis
DMRQV8I DT Small molecular drug
DMRQV8I PC 101524
DMRQV8I MW 669.5
DMRQV8I FM C33H34Cl2N4O7
DMRQV8I IC InChI=1S/C33H34Cl2N4O7/c1-4-37(5-2)12-13-38-31(43)22-20-15-8-6-10-17(34)24(15)36-25(20)27-21(23(22)32(38)44)16-9-7-11-18(35)26(16)39(27)33-29(42)28(41)30(45-3)19(14-40)46-33/h6-11,19,28-30,33,36,40-42H,4-5,12-14H2,1-3H3/t19-,28-,29-,30-,33-/m1/s1
DMRQV8I CS CCN(CC)CCN1C(=O)C2=C3C4=C(C(=CC=C4)Cl)NC3=C5C(=C2C1=O)C6=C(N5[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)OC)O)O)C(=CC=C6)Cl
DMRQV8I IK JSKFWUPVIZYJMR-UDOAKELVSA-N
DMRQV8I IU 5,21-dichloro-13-[2-(diethylamino)ethyl]-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DMRQV8I CA CAS 119673-08-4
DMRQV8I DE Solid tumour/cancer
DMZIV6D ID DMZIV6D
DMZIV6D DN Befloxatone
DMZIV6D HS Discontinued in Phase 3
DMZIV6D SN MD-370503
DMZIV6D CP Sanofi-Synthelabo
DMZIV6D DT Small molecular drug
DMZIV6D PC 60824
DMZIV6D MW 349.3
DMZIV6D FM C15H18F3NO5
DMZIV6D IC InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m1/s1
DMZIV6D CS COC[C@H]1CN(C(=O)O1)C2=CC=C(C=C2)OCC[C@H](C(F)(F)F)O
DMZIV6D IK IALVDLPLCLFBCF-CHWSQXEVSA-N
DMZIV6D IU (5R)-5-(methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-1,3-oxazolidin-2-one
DMZIV6D CA CAS 134564-82-2
DMZIV6D DE Major depressive disorder
DMSPJX9 ID DMSPJX9
DMSPJX9 DN BEMESETRON
DMSPJX9 HS Discontinued in Phase 3
DMSPJX9 SN 3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo
DMSPJX9 DT Small molecular drug
DMSPJX9 PC 671690
DMSPJX9 MW 314.2
DMSPJX9 FM C15H17Cl2NO2
DMSPJX9 IC InChI=1S/C15H17Cl2NO2/c1-18-12-2-3-13(18)8-14(7-12)20-15(19)9-4-10(16)6-11(17)5-9/h4-6,12-14H,2-3,7-8H2,1H3/t12-,13+,14?
DMSPJX9 CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CC(=CC(=C3)Cl)Cl
DMSPJX9 IK MNJNPLVXBISNSX-PBWFPOADSA-N
DMSPJX9 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3,5-dichlorobenzoate
DMSPJX9 CA CAS 40796-97-2
DMIEB8Y ID DMIEB8Y
DMIEB8Y DN Bevasiranib
DMIEB8Y HS Discontinued in Phase 3
DMIEB8Y CP Opko Health
DMIEB8Y TC siRNA
DMIEB8Y DT siRNA drug
DMIEB8Y DE Exudative age-related macular degeneration
DM47ZHW ID DM47ZHW
DM47ZHW DN Bidisomide
DM47ZHW HS Discontinued in Phase 3
DM47ZHW SN Butanamide; SC-40230
DM47ZHW CP GD Searle & Co
DM47ZHW DT Small molecular drug
DM47ZHW PC 59798
DM47ZHW MW 408
DM47ZHW FM C22H34ClN3O2
DM47ZHW IC InChI=1S/C22H34ClN3O2/c1-17(2)26(18(3)27)16-12-22(21(24)28,19-9-5-6-10-20(19)23)11-15-25-13-7-4-8-14-25/h5-6,9-10,17H,4,7-8,11-16H2,1-3H3,(H2,24,28)
DM47ZHW CS CC(C)N(CCC(CCN1CCCCC1)(C2=CC=CC=C2Cl)C(=O)N)C(=O)C
DM47ZHW IK GTEPPJFJSNSNIH-UHFFFAOYSA-N
DM47ZHW IU 2-[2-[acetyl(propan-2-yl)amino]ethyl]-2-(2-chlorophenyl)-4-piperidin-1-ylbutanamide
DM47ZHW CA CAS 116078-65-0
DM47ZHW CB CHEBI:135658
DM47ZHW DE Heart arrhythmia
DMOQIMS ID DMOQIMS
DMOQIMS DN Bifeprunox
DMOQIMS HS Discontinued in Phase 3
DMOQIMS SN Bifeprunoxum; Bifeprunox [INN]; DU 127090; DU127090; Bifeprunoxum [INN-Latin]; Bifeprunox (USAN/INN); 7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one; 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DMOQIMS CP Solvay
DMOQIMS DT Small molecular drug
DMOQIMS PC 208951
DMOQIMS MW 385.5
DMOQIMS FM C24H23N3O2
DMOQIMS IC InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
DMOQIMS CS C1CN(CCN1CC2=CC(=CC=C2)C3=CC=CC=C3)C4=CC=CC5=C4OC(=O)N5
DMOQIMS IK CYGODHVAJQTCBG-UHFFFAOYSA-N
DMOQIMS IU 7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3H-1,3-benzoxazol-2-one
DMOQIMS CA CAS 350992-10-8
DMOQIMS DE Schizophrenia
DMLXHZR ID DMLXHZR
DMLXHZR DN BL-1832
DMLXHZR HS Discontinued in Phase 3
DMLXHZR CP Bioglan Labs Ltd
DMLXHZR DE Pain
DMKSFPE ID DMKSFPE
DMKSFPE DN BMS 275291
DMKSFPE HS Discontinued in Phase 3
DMKSFPE SN D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
DMKSFPE CP Bristol Myers Squibb; Celltech Group
DMKSFPE TC Anticancer Agents
DMKSFPE DT Small molecular drug
DMKSFPE PC 148203
DMKSFPE MW 499.7
DMKSFPE FM C23H41N5O5S
DMKSFPE IC InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-19(31)16(24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,24,34H,10-12H2,1-9H3,(H,25,30)(H,26,29,31)/t14-,15-,16+/m0/s1
DMKSFPE CS CC(C)C[C@@H](C(=O)NC(=O)[C@H](C(C)(C)C)NC)NC(=O)[C@H](CCN1C(=O)C(N(C1=O)C)(C)C)S
DMKSFPE IK BWLOJMZLTBBDHA-HRCADAONSA-N
DMKSFPE IU (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
DMKSFPE DE Kaposi sarcoma; Prostate cancer; Non-small-cell lung cancer
DM0HR5W ID DM0HR5W
DM0HR5W DN BMS-181100
DM0HR5W HS Discontinued in Phase 3
DM0HR5W SN BMY-14786; BMY-14802; BMY-14802 hydrochloride; MJ-14676; MJ-14786; MJ-14802; BMY-14802, Skybridge; BMY-14802-1; BMY-14802 (dyskinesia), Skybridge; 5-HT 1a receptor agonist (dyskinesia), Skybridge
DM0HR5W CP Bristol-Myers Squibb Co; Skybridge Pharmaceuticals Inc
DM0HR5W DT Small molecular drug
DM0HR5W PC 108046
DM0HR5W MW 348.4
DM0HR5W FM C18H22F2N4O
DM0HR5W IC InChI=1S/C18H22F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13,17,25H,1-2,7-11H2
DM0HR5W CS C1CN(CCN1CCCC(C2=CC=C(C=C2)F)O)C3=NC=C(C=N3)F
DM0HR5W IK ZXUYYZPJUGQHLQ-UHFFFAOYSA-N
DM0HR5W IU 1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-ol
DM0HR5W CA CAS 105565-56-8
DM0HR5W CB CHEBI:91549
DM0HR5W DE Psychotic disorder
DMFZNLH ID DMFZNLH
DMFZNLH DN BMS-204352
DMFZNLH HS Discontinued in Phase 3
DMFZNLH SN Flindokalner; MaxiPost; BMS-204352; 187523-35-9; Flindokalner [USAN:INN]; UNII-J57O328W4W; (3S)-3-(5-Chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2H-indol-2-one; BMS 204352; J57O328W4W; 2H-Indol-2-one, 3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-, (3S)-; Maxipost (TN); (s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)indolin-2-one; (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1H-indol-2-one; Bms204352; Flindokalner (USAN/INN); AC1Q4JQL; AC1L4WO7
DMFZNLH DT Small molecular drug
DMFZNLH PC 214350
DMFZNLH MW 359.7
DMFZNLH FM C16H10ClF4NO2
DMFZNLH IC InChI=1S/C16H10ClF4NO2/c1-24-13-5-3-9(17)7-11(13)15(18)10-4-2-8(16(19,20)21)6-12(10)22-14(15)23/h2-7H,1H3,(H,22,23)/t15-/m0/s1
DMFZNLH CS COC1=C(C=C(C=C1)Cl)[C@]2(C3=C(C=C(C=C3)C(F)(F)F)NC2=O)F
DMFZNLH IK ULYONBAOIMCNEH-HNNXBMFYSA-N
DMFZNLH IU (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1H-indol-2-one
DMFZNLH CA CAS 187523-35-9
DMFZNLH DE Nerve injury
DMZK70E ID DMZK70E
DMZK70E DN BN 50730
DMZK70E HS Discontinued in Phase 3
DMZK70E SN Rocepafant; BN 50730; UNII-4KGX1STY2N; BN-50730; 4KGX1STY2N; 132579-32-9; BN50730; 132418-36-1; 6-(2-Chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 4H-Pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-; Rocepafant [INN]; LAU8080; LAU-8080; LAU 8080; AC1MHWNG; C27H25ClN6OS; SCHEMBL1065775; CHEMBL2105298; ZINC1481916; LS-172840
DMZK70E DT Small molecular drug
DMZK70E PC 3033963
DMZK70E MW 535.1
DMZK70E FM C26H23ClN6OS2
DMZK70E IC InChI=1S/C26H23ClN6OS2/c1-15-30-31-22-13-28-24(18-5-3-4-6-20(18)27)23-19-11-12-32(14-21(19)36-25(23)33(15)22)26(35)29-16-7-9-17(34-2)10-8-16/h3-10H,11-14H2,1-2H3,(H,29,35)
DMZK70E CS CC1=NN=C2N1C3=C(C4=C(S3)CN(CC4)C(=S)NC5=CC=C(C=C5)OC)C(=NC2)C6=CC=CC=C6Cl
DMZK70E IK WBGAFGNZNGJVNW-UHFFFAOYSA-N
DMZK70E IU 9-(2-chlorophenyl)-N-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carbothioamide
DMZK70E CA CAS 132579-32-9
DMZK70E DE Asthma
DMMT1YQ ID DMMT1YQ
DMMT1YQ DN Bropirimine
DMMT1YQ HS Discontinued in Phase 3
DMMT1YQ SN 56741-95-8; 2-Amino-5-bromo-4-hydroxy-6-phenylpyrimidine; ABPP; 2-AMINO-5-BROMO-6-PHENYLPYRIMIDIN-4-OL; Bropiriminum [Latin]; 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidinone; 2-amino-5-bromo-6-phenylpyrimidin-4(3H)-one; U-54461; Bropirimina [Spanish]; UNII-J57CTF25XJ; C10H8BrN3O; CCRIS 3730; 2-amino-5-bromo-6-phenyl-1H-pyrimidin-4-one; 2-Amino-5-bromo-6-phenyl-4(1H)-pyrimidinone; 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-phenyl-; BRN 0651807; J57CTF25XJ; 5-Bromo-6-phenylisocytosine; CHEBI:31307; 2-Amino-5-Bromo-6-Phenylpyrimidin-4-Ol
DMMT1YQ CP Pharmacia & Upjohn Inc
DMMT1YQ DT Small molecular drug
DMMT1YQ PC 135413497
DMMT1YQ MW 266.09
DMMT1YQ FM C10H8BrN3O
DMMT1YQ IC InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
DMMT1YQ CS C1=CC=C(C=C1)C2=C(C(=O)NC(=N2)N)Br
DMMT1YQ IK CIUUIPMOFZIWIZ-UHFFFAOYSA-N
DMMT1YQ IU 2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one
DMMT1YQ CA CAS 56741-95-8
DMMT1YQ CB CHEBI:31307
DMMT1YQ DE Virus infection
DMRA6H5 ID DMRA6H5
DMRA6H5 DN Broxaterol
DMRA6H5 HS Discontinued in Phase 3
DMRA6H5 SN Summair; Z-1170
DMRA6H5 CP Zambon Co SpA
DMRA6H5 DT Small molecular drug
DMRA6H5 PC 71149
DMRA6H5 MW 263.13
DMRA6H5 FM C9H15BrN2O2
DMRA6H5 IC InChI=1S/C9H15BrN2O2/c1-9(2,3)11-5-6(13)7-4-8(10)12-14-7/h4,6,11,13H,5H2,1-3H3
DMRA6H5 CS CC(C)(C)NCC(C1=CC(=NO1)Br)O
DMRA6H5 IK JBRBWHCVRGURBA-UHFFFAOYSA-N
DMRA6H5 IU 1-(3-bromo-1,2-oxazol-5-yl)-2-(tert-butylamino)ethanol
DMRA6H5 CA CAS 76596-57-1
DMRA6H5 DE Asthma
DM4HGMX ID DM4HGMX
DM4HGMX DN CDP571
DM4HGMX HS Discontinued in Phase 3
DM4HGMX DE Crohn disease
DMANMXZ ID DMANMXZ
DMANMXZ DN CEFCANEL DALOXATE HYDROCHLORIDE
DMANMXZ HS Discontinued in Phase 3
DMANMXZ SN Loride; Onohydrochloride; Enylethyl ester monohydrochloride; KY-109; Cefcanel daloxate hydrochloride; (5-Methyl-1,3-dioxolen-2-on-4-ylmethyl) 7-[D-O-(L-alanyl)mandelamido]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-3-cephem-4-carboxylate hydrochloride; (5-Methyl-2-oxo-1,3-dioxo-4-yl)methyl (6R,7R)-7-[(R)-2-[(S)-alanyloxy]-2-phenylacetamido]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thiomethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydroch; (6R,7R)-7beta-[2(R)-(S-Alanyloxy)-2-phenylacetamido]-3-(5-methyl-1,3,4-thiadiazol-2-ylthiomethyl)-3-cephem-4-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; L-Alanine [6R-[6alpha,7beta(R*)]]-2-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxo-1-ph; 2,3-Dihydroxy-2-butenyl (6R,7R)-7-[(R)-mandelamido]-3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate,cyclic-2,3-carbonate,ester with L-alanine m
DMANMXZ DT Small molecular drug
DMANMXZ PC 179696
DMANMXZ MW 698.2
DMANMXZ FM C27H28ClN5O9S3
DMANMXZ IC InChI=1S/C27H27N5O9S3.ClH/c1-12(28)24(35)41-20(15-7-5-4-6-8-15)21(33)29-18-22(34)32-19(25(36)38-9-17-13(2)39-27(37)40-17)16(10-42-23(18)32)11-43-26-31-30-14(3)44-26;/h4-8,12,18,20,23H,9-11,28H2,1-3H3,(H,29,33);1H/t12-,18+,20+,23+;/m0./s1
DMANMXZ CS CC1=C(OC(=O)O1)COC(=O)C2=C(CS[C@H]3N2C(=O)[C@H]3NC(=O)[C@@H](C4=CC=CC=C4)OC(=O)[C@H](C)N)CSC5=NN=C(S5)C.Cl
DMANMXZ IK HFVATKYQUGKLGL-PCQLZLFJSA-N
DMANMXZ IU (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (6R,7R)-7-[[(2R)-2-[(2S)-2-aminopropanoyl]oxy-2-phenylacetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrochloride
DMANMXZ CA CAS 92602-21-6
DMANMXZ DE Bacterial infection
DMEMUQP ID DMEMUQP
DMEMUQP DN CEFETECOL
DMEMUQP HS Discontinued in Phase 3
DMEMUQP SN Cefetecol < Rec INN; GR-69153; GR-69153E (diNa salt); GR-69153X (as tetrahydrate); (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 7(2)-(Z)-[O-[(S)-alpha-carboxy-3,4-dihydroxybenzyl]oxime]; (6R,7R,2'Z,S)-7beta-[2-(2-Aminothiazol-4-yl)-2-[(carboxy)(3,4-dihydroxyphenyl)methoxyimino]acetamido]-3-cephem-4-carboxylic acid
DMEMUQP DT Small molecular drug
DMEMUQP PC 71719688
DMEMUQP MW 535.5
DMEMUQP FM C20H17N5O9S2
DMEMUQP IC InChI=1S/C20H17N5O9S2/c21-20-22-8(6-36-20)12(24-34-14(19(32)33)7-1-2-10(26)11(27)5-7)15(28)23-13-16(29)25-9(18(30)31)3-4-35-17(13)25/h1-3,5-6,13-14,17,26-27H,4H2,(H2,21,22)(H,23,28)(H,30,31)(H,32,33)/b24-12+/t13-,14+,17-/m1/s1
DMEMUQP CS C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N/O[C@@H](C3=CC(=C(C=C3)O)O)C(=O)O)/C4=CSC(=N4)N)C(=O)O
DMEMUQP IK ILZCDOYRDFDUPN-UITOYEBDSA-N
DMEMUQP IU (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-[(S)-carboxy-(3,4-dihydroxyphenyl)methoxy]iminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMEMUQP CA CAS 117211-03-7
DMEMUQP DE Bacterial infection
DMRYC08 ID DMRYC08
DMRYC08 DN CGP71683A
DMRYC08 HS Discontinued in Phase 3
DMRYC08 SN CGP-71683A; N-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide
DMRYC08 CP Servier
DMRYC08 DT Small molecular drug
DMRYC08 PC 9849276
DMRYC08 MW 512.1
DMRYC08 FM C26H30ClN5O2S
DMRYC08 IC InChI=1S/C26H29N5O2S.ClH/c27-25-22-9-3-4-10-23(22)30-26(31-25)28-16-18-12-14-19(15-13-18)17-29-34(32,33)24-11-5-7-20-6-1-2-8-21(20)24;/h1-11,18-19,29H,12-17H2,(H3,27,28,30,31);1H
DMRYC08 CS C1CC(CCC1CNC2=NC3=CC=CC=C3C(=N2)N)CNS(=O)(=O)C4=CC=CC5=CC=CC=C54.Cl
DMRYC08 IK DIQDKUNCSVFGHH-UHFFFAOYSA-N
DMRYC08 IU N-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride
DMRYC08 CA CAS 192322-50-2
DMRYC08 DE Obesity
DMHSM7I ID DMHSM7I
DMHSM7I DN Cilomilast
DMHSM7I HS Discontinued in Phase 3
DMHSM7I SN Ariflo; CIO; SB 207499; SB207499; Ariflo (TN); Cilomilast [USAN:INN]; SB-207499; Ariflo, SB-207499,Cilomilast; Cilomilast (JAN/USAN/INN); CIS-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANECARBOXYLIC ACID; Cis-4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-Cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)cyclohexanecarboxylic acid; Cis-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-4-cyanocyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1-carboxylic acid; 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
DMHSM7I CP GlaxoSmithKline
DMHSM7I DT Small molecular drug
DMHSM7I PC 151170
DMHSM7I MW 343.4
DMHSM7I FM C20H25NO4
DMHSM7I IC InChI=1S/C20H25NO4/c1-24-17-7-6-15(12-18(17)25-16-4-2-3-5-16)20(13-21)10-8-14(9-11-20)19(22)23/h6-7,12,14,16H,2-5,8-11H2,1H3,(H,22,23)
DMHSM7I CS COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3
DMHSM7I IK CFBUZOUXXHZCFB-UHFFFAOYSA-N
DMHSM7I IU 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid
DMHSM7I CA CAS 153259-65-5
DMHSM7I CB CHEBI:94683
DMHSM7I DE Chronic obstructive pulmonary disease; Bronchitis; Emphysema
DMOU173 ID DMOU173
DMOU173 DN CP-945598
DMOU173 HS Discontinued in Phase 3
DMOU173 SN Otenabant; Otenabant hydrochloride; CP 945598; Otenabant hydrochloride (USAN); CP-945,598; Otenabant (USAN/INN); 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide monohydrochloride; 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-ethylamino-piperidine-4-carboxamide
DMOU173 CP Pfizer
DMOU173 DT Small molecular drug
DMOU173 PC 10052040
DMOU173 MW 510.4
DMOU173 FM C25H25Cl2N7O
DMOU173 IC InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)
DMOU173 CS CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N
DMOU173 IK UNAZAADNBYXMIV-UHFFFAOYSA-N
DMOU173 IU 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide
DMOU173 CA CAS 686344-29-6
DMOU173 DE Obesity
DM753RT ID DM753RT
DM753RT DN CVT-124
DM753RT HS Discontinued in Phase 3
DM753RT SN Adentri; Naxifylline; ENX cpd; BG 9719; BG9719; CVT 124; BG-9719; 1,3-ENX; 1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine; 8-((2S,5,6-Exo)-5,6-epoxy-2-norbonyl)-1,3-dipropylxanthine
DM753RT CP CV Therapeutics
DM753RT DT Small molecular drug
DM753RT PC 9841075
DM753RT MW 344.4
DM753RT FM C18H24N4O3
DM753RT IC InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11+,13-,14+/m1/s1
DM753RT CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3C[C@H]4C[C@@H]3[C@H]5[C@@H]4O5
DM753RT IK OQCJPFYWFGUHIN-GJKBLCTNSA-N
DM753RT IU 8-[(1S,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7H-purine-2,6-dione
DM753RT CA CAS 166374-49-8
DM753RT DE Autoimmune diabetes
DMHSLVO ID DMHSLVO
DMHSLVO DN DA-7101
DMHSLVO HS Discontinued in Phase 3
DMHSLVO CP Dong-A
DMHSLVO DE Gram-positive bacterial infection
DMNQIKV ID DMNQIKV
DMNQIKV DN DALTROBAN
DMNQIKV HS Discontinued in Phase 3
DMNQIKV SN 79094-20-5; BM-13505; Daltrobanum; SKF 96148; BM 13505; UNII-S25VDY08ZC; BM 13.505; C16H16ClNO4S; SKF-96148; F 96148; S25VDY08ZC; CHEMBL71685; 4-(2-(4-Chlorophenylsulfonylamino)ethyl)phenylacetic acid; 4-(2-(4-Chlorobenzenesulfonylamino)ethyl)benzeneacetic acid; F-96148; NCGC00165787-02; 2-(4-(2-(4-chlorophenylsulfonamido)ethyl)phenyl)acetic acid; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid; DSSTox_RID_81670; DSSTox_CID_26501; DSSTox_GSID_46501; 105218-03-9; Benzeneacetic acid, 4-(2-((
DMNQIKV DT Small molecular drug
DMNQIKV PC 54343
DMNQIKV MW 353.8
DMNQIKV FM C16H16ClNO4S
DMNQIKV IC InChI=1S/C16H16ClNO4S/c17-14-5-7-15(8-6-14)23(21,22)18-10-9-12-1-3-13(4-2-12)11-16(19)20/h1-8,18H,9-11H2,(H,19,20)
DMNQIKV CS C1=CC(=CC=C1CCNS(=O)(=O)C2=CC=C(C=C2)Cl)CC(=O)O
DMNQIKV IK IULOBWFWYDMECP-UHFFFAOYSA-N
DMNQIKV IU 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid
DMNQIKV CA CAS 79094-20-5
DMZ38EN ID DMZ38EN
DMZ38EN DN Dalvastatin
DMZ38EN HS Discontinued in Phase 3
DMZ38EN SN RG-12561
DMZ38EN CP Rhone-Poulenc SA
DMZ38EN DT Small molecular drug
DMZ38EN PC 6436002
DMZ38EN MW 386.5
DMZ38EN FM C24H31FO3
DMZ38EN IC InChI=1S/C24H31FO3/c1-15-10-16(6-9-21(15)25)19-13-23(2,3)14-24(4,5)20(19)8-7-18-11-17(26)12-22(27)28-18/h6-10,17-18,26H,11-14H2,1-5H3/b8-7+/t17-,18-/m0/s1
DMZ38EN CS CC1=C(C=CC(=C1)C2=C(C(CC(C2)(C)C)(C)C)/C=C/[C@H]3C[C@@H](CC(=O)O3)O)F
DMZ38EN IK VDSBXXDKCUBMQC-VUOWKATKSA-N
DMZ38EN IU (4S,6R)-6-[(E)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one
DMZ38EN DE Hyperlipidaemia
DMSWLA3 ID DMSWLA3
DMSWLA3 DN Darapladib
DMSWLA3 HS Discontinued in Phase 3
DMSWLA3 SN SB 480848; Darapladib (USAN)
DMSWLA3 CP GlaxoSmithKline
DMSWLA3 DT Small molecular drug
DMSWLA3 PC 9939609
DMSWLA3 MW 666.8
DMSWLA3 FM C36H38F4N4O2S
DMSWLA3 IC InChI=1S/C36H38F4N4O2S/c1-3-42(4-2)20-21-43(22-25-8-12-27(13-9-25)28-14-16-29(17-15-28)36(38,39)40)33(45)23-44-32-7-5-6-31(32)34(46)41-35(44)47-24-26-10-18-30(37)19-11-26/h8-19H,3-7,20-24H2,1-2H3
DMSWLA3 CS CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F
DMSWLA3 IK WDPFJWLDPVQCAJ-UHFFFAOYSA-N
DMSWLA3 IU N-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DMSWLA3 CA CAS 356057-34-6
DMSWLA3 DE Arteriosclerosis
DMC40SD ID DMC40SD
DMC40SD DN Darexaban maleate
DMC40SD HS Discontinued in Phase 3
DMC40SD SN Darexaban maleate; UNII-03RTP2436R; 365462-24-4; 03RTP2436R; YM150; Darexaban maleate (JAN); SCHEMBL5406349; CHEMBL1922345; D09817; N-[2-[[4-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-3-hydroxyphenyl]-4-methoxybenzamide (2Z)-2-Butenedioate
DMC40SD CP Astellas Pharma
DMC40SD DT Small molecular drug
DMC40SD PC 49843900
DMC40SD MW 590.6
DMC40SD FM C31H34N4O8
DMC40SD IC InChI=1S/C27H30N4O4.C4H4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20;5-3(6)1-2-4(7)8/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34);1-2H,(H,5,6)(H,7,8)/b;2-1-
DMC40SD CS CN1CCCN(CC1)C2=CC=C(C=C2)C(=O)NC3=C(C=CC=C3O)NC(=O)C4=CC=C(C=C4)OC.C(=C\\C(=O)O)\\C(=O)O
DMC40SD IK WHMPMUVISXATBH-BTJKTKAUSA-N
DMC40SD IU (Z)-but-2-enedioic acid;N-[2-hydroxy-6-[(4-methoxybenzoyl)amino]phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
DMC40SD CA CAS 365462-24-4
DMC40SD DE Acute coronary syndrome
DMEMF60 ID DMEMF60
DMEMF60 DN Delequamine hydrochloride
DMEMF60 HS Discontinued in Phase 3
DMEMF60 SN Delquamine; RS-15385-197; RS-15385-FP; RS-15385-FPh
DMEMF60 CP Roche Bioscience
DMEMF60 DT Small molecular drug
DMEMF60 PC 168898
DMEMF60 MW 386.9
DMEMF60 FM C18H27ClN2O3S
DMEMF60 IC InChI=1S/C18H26N2O3S.ClH/c1-23-15-5-6-16-13(10-15)7-9-19-12-14-4-3-8-20(24(2,21)22)17(14)11-18(16)19;/h5-6,10,14,17-18H,3-4,7-9,11-12H2,1-2H3;1H/t14-,17+,18+;/m1./s1
DMEMF60 CS COC1=CC2=C(C=C1)[C@@H]3C[C@H]4[C@H](CCCN4S(=O)(=O)C)CN3CC2.Cl
DMEMF60 IK ITJOISLXCMAIOC-CVLULELNSA-N
DMEMF60 IU (8aR,12aS,13aS)-3-methoxy-12-methylsulfonyl-5,6,8,8a,9,10,11,12a,13,13a-decahydroisoquinolino[2,1-g][1,6]naphthyridine;hydrochloride
DMEMF60 CA CAS 119942-75-5
DMEMF60 DE Male sexual disorder
DMXKWAL ID DMXKWAL
DMXKWAL DN Deligoparin sodium
DMXKWAL HS Discontinued in Phase 3
DMXKWAL SN Ultra low molecular weight heparin
DMXKWAL CP Aeolus Pharmaceuticals
DMXKWAL DE Ulcerative colitis
DM8DUZT ID DM8DUZT
DM8DUZT DN Deramciclane
DM8DUZT HS Discontinued in Phase 3
DM8DUZT SN EGIS-3886; EGIS-7056; EGYT-3886
DM8DUZT CP EGIS Gyogyszergyar RT
DM8DUZT DT Small molecular drug
DM8DUZT PC 119590
DM8DUZT MW 301.5
DM8DUZT FM C20H31NO
DM8DUZT IC InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1
DM8DUZT CS C[C@@]12CC[C@@H](C1(C)C)C[C@@]2(C3=CC=CC=C3)OCCN(C)C
DM8DUZT IK QOBGWWQAMAPULA-RLLQIKCJSA-N
DM8DUZT IU N,N-dimethyl-2-[[(1R,2S,4R)-1,7,7-trimethyl-2-phenyl-2-bicyclo[2.2.1]heptanyl]oxy]ethanamine
DM8DUZT CA CAS 120444-71-5
DM8DUZT DE Anxiety disorder
DMO3AJS ID DMO3AJS
DMO3AJS DN DG031
DMO3AJS HS Discontinued in Phase 3
DMO3AJS SN Veliflapon; 128253-31-6; Bay-x-1005; Bay X 1005; DG-031; Bayx-1005; Bay X1005; UNII-JXH6X663L0; Bay-X1005; BAY 1005; DG 031; CHEMBL88712; JXH6X663L0; 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; Benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (R)-; C23H23NO3; BAY-X 1005; (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid; Veliflapon [USAN:INN]; Velifapon; Veliflapon (USAN/INN); AC1L3X6M; MLS006010705; Benzeneacetic acid, a-cyclopentyl-4-(2-quinolinylmethoxy)-,(aR)-; GTPL5148
DMO3AJS CP DeCODE genetics
DMO3AJS DT Small molecular drug
DMO3AJS PC 123723
DMO3AJS MW 361.4
DMO3AJS FM C23H23NO3
DMO3AJS IC InChI=1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1
DMO3AJS CS C1CCC(C1)[C@H](C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O
DMO3AJS IK ZEYYDOLCHFETHQ-JOCHJYFZSA-N
DMO3AJS IU (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid
DMO3AJS CA CAS 128253-31-6
DMO3AJS DE Asthma
DMX2SHT ID DMX2SHT
DMX2SHT DN Dianicline
DMX2SHT HS Discontinued in Phase 3
DMX2SHT SN SSR591813; SSR591813L; 5a,6,9,10-Tetrahydro-7H,11H-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine
DMX2SHT CP Sanofi-Aventis
DMX2SHT DT Small molecular drug
DMX2SHT PC 10176764
DMX2SHT MW 216.28
DMX2SHT FM C13H16N2O
DMX2SHT IC InChI=1S/C13H16N2O/c1-2-11-10(14-5-1)8-13-4-7-15(9-13)6-3-12(13)16-11/h1-2,5,12H,3-4,6-9H2/t12-,13+/m0/s1
DMX2SHT CS C1CN2CC[C@@]3(C2)[C@H]1OC4=C(C3)N=CC=C4
DMX2SHT IK SUPRUPHAEXPGPF-QWHCGFSZSA-N
DMX2SHT IU (1R,10S)-9-oxa-4,13-diazatetracyclo[11.2.1.01,10.03,8]hexadeca-3(8),4,6-triene
DMX2SHT CA CAS 292634-27-6
DMX2SHT DE Tobacco dependence
DMWMHU7 ID DMWMHU7
DMWMHU7 DN Dofequidar fumarate
DMWMHU7 HS Discontinued in Phase 3
DMWMHU7 SN MS-209; Dofequidar fumarate; 1-(Diphenylacetyl)-4-[(2RS)-2-hydroxy-3-(5-quinolyloxy)propyl]piperazine sesquifumarate; 1-[4-(2,2-Diphenylacetyl)piperazin-1-yl]-3-(quinoliln-5-yloxy)-2-propanol sesquifumarate; 5-[3-[4-(2,2-Diphenylacetyl)piperazin-1-yl]-2-hydroxypropoxy]quinoline sesquifumarate
DMWMHU7 DT Small molecular drug
DMWMHU7 PC 9960287
DMWMHU7 MW 597.7
DMWMHU7 FM C34H35N3O7
DMWMHU7 IC InChI=1S/C30H31N3O3.C4H4O4/c34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24;5-3(6)1-2-4(7)8/h1-16,25,29,34H,17-22H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMWMHU7 CS C1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5.C(=C/C(=O)O)\\C(=O)O
DMWMHU7 IK QIAVTDQTRFYXSD-WLHGVMLRSA-N
DMWMHU7 IU (E)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone
DMWMHU7 DE Solid tumour/cancer
DMJOM31 ID DMJOM31
DMJOM31 DN ELGODIPINE HYDROCHLORIDE
DMJOM31 HS Discontinued in Phase 3
DMJOM31 SN IQB-875; Elgodipine hydrochloride; Rac-2,6-Dimethyl-4-(2,3-methylenedioxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-isopropyl 5-[2-[N-(4-fluorobenzyl)-N-methylamino]ethyl] diester monohydrochloride
DMJOM31 DT Small molecular drug
DMJOM31 PC 3078492
DMJOM31 MW 561
DMJOM31 FM C29H34ClFN2O6
DMJOM31 IC InChI=1S/C29H33FN2O6.ClH/c1-17(2)38-29(34)25-19(4)31-18(3)24(26(25)22-7-6-8-23-27(22)37-16-36-23)28(33)35-14-13-32(5)15-20-9-11-21(30)12-10-20;/h6-12,17,26,31H,13-16H2,1-5H3;1H
DMJOM31 CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=C3C(=CC=C2)OCO3)C(=O)OCCN(C)CC4=CC=C(C=C4)F.Cl
DMJOM31 IK JBKDMKOYLBVOOR-UHFFFAOYSA-N
DMJOM31 IU 3-O-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-O-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMJOM31 CA CAS 121489-04-1
DMJOM31 DE Angina pectoris
DM38CIV ID DM38CIV
DM38CIV DN ELTANOLONE
DM38CIV HS Discontinued in Phase 3
DM38CIV SN Pregnanolone; 3alpha-Hydroxy-5beta-pregnan-20-one; 128-20-1; Pregnanolone II; Pregnan-3alpha-ol-20-one; Eltanolona; Eltanolonum; 5beta-Pregnan-3alpha-ol-20-one; Eltanolone [INN]; SKF 6455; NSC 82867; UNII-BXO86P3XXW; Eltanolonum [INN-Latin]; Eltanolona [INN-Spanish]; Allopregnan-3 beta-ol-20-one; (3alpha,5beta)-3-hydroxypregnan-20-one; 3alpha-Hydroxy-5beta-tetrahydroprogesterone; 3alpha,5beta-Epimeric pregnanolone; Pregnanolone, (3alpha,5beta)-isomer; BXO86P3XXW
DM38CIV DT Small molecular drug
DM38CIV PC 31402
DM38CIV MW 318.5
DM38CIV FM C21H34O2
DM38CIV IC InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+,17-,18+,19+,20+,21-/m1/s1
DM38CIV CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C
DM38CIV IK AURFZBICLPNKBZ-YZRLXODZSA-N
DM38CIV IU 1-[(3R,5R,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DM38CIV CA CAS 128-20-1
DM38CIV CB CHEBI:1712
DM38CIV DE Premenstrual syndrome
DM5JUW0 ID DM5JUW0
DM5JUW0 DN EM-800
DM5JUW0 HS Discontinued in Phase 3
DM5JUW0 SN EM-800; UNII-XCR716LECP; XCR716LECP; 182167-03-9; Em 800; SCH 57050; BIDD:ER0061; SCHEMBL1821303; CHEMBL308234; 189021-25-8; (s)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-meth-yl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2h-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate
DM5JUW0 DT Small molecular drug
DM5JUW0 PC 9873952
DM5JUW0 MW 625.8
DM5JUW0 FM C39H47NO6
DM5JUW0 IC InChI=1S/C39H47NO6/c1-26-32-20-19-31(45-37(42)39(5,6)7)25-33(32)46-35(34(26)27-11-17-30(18-12-27)44-36(41)38(2,3)4)28-13-15-29(16-14-28)43-24-23-40-21-9-8-10-22-40/h11-20,25,35H,8-10,21-24H2,1-7H3/t35-/m0/s1
DM5JUW0 CS CC1=C([C@@H](OC2=C1C=CC(=C2)OC(=O)C(C)(C)C)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)OC(=O)C(C)(C)C
DM5JUW0 IK OEKMGABCSLYWOP-DHUJRADRSA-N
DM5JUW0 IU [4-[(2S)-7-(2,2-dimethylpropanoyloxy)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-3-yl]phenyl] 2,2-dimethylpropanoate
DM5JUW0 CA CAS 182167-03-9
DM5JUW0 DE Estrogen deficiency
DMCU1WO ID DMCU1WO
DMCU1WO DN Eperezolid
DMCU1WO HS Discontinued in Phase 3
DMCU1WO SN PNU-100592; U-100592
DMCU1WO CP Pharmacia & Upjohn Co
DMCU1WO DT Small molecular drug
DMCU1WO PC 73214
DMCU1WO MW 394.4
DMCU1WO FM C18H23FN4O5
DMCU1WO IC InChI=1S/C18H23FN4O5/c1-12(25)20-9-14-10-23(18(27)28-14)13-2-3-16(15(19)8-13)21-4-6-22(7-5-21)17(26)11-24/h2-3,8,14,24H,4-7,9-11H2,1H3,(H,20,25)/t14-/m0/s1
DMCU1WO CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)C(=O)CO)F
DMCU1WO IK SIMWTRCFFSTNMG-AWEZNQCLSA-N
DMCU1WO IU N-[[(5S)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMCU1WO CA CAS 165800-04-4
DMCU1WO DE Bacterial infection
DMM5ZX6 ID DMM5ZX6
DMM5ZX6 DN Epothilone B
DMM5ZX6 HS Discontinued in Phase 3
DMM5ZX6 SN Epothilone B; Patupilone; 152044-54-7; (-)-Epothilone B; Epo B; EpoB; EPO906; EPO 906; UNII-UEC0H0URSE; EPO 906A; GNF-PF-193; CHEBI:31550; UEC0H0URSE; AK163080; Epothilone B (EPO906, Patupilone); 7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[1-METHYL-2-(2-METHYL-THIAZOL-4-YL)VINYL]-4,17-DIOXABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE; Epothilon B; Patupilone [INN]; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMM5ZX6 DT Small molecular drug
DMM5ZX6 PC 448013
DMM5ZX6 MW 507.7
DMM5ZX6 FM C27H41NO6S
DMM5ZX6 IC InChI=1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1
DMM5ZX6 CS C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C
DMM5ZX6 IK QXRSDHAAWVKZLJ-PVYNADRNSA-N
DMM5ZX6 IU (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMM5ZX6 CA CAS 152044-54-7
DMM5ZX6 CB CHEBI:31550
DMM5ZX6 DE Solid tumour/cancer
DM3OUT0 ID DM3OUT0
DM3OUT0 DN Etarotene
DM3OUT0 HS Discontinued in Phase 3
DM3OUT0 SN Ro-15-1570; Ro-15-1570/000
DM3OUT0 CP Roche Holding AG
DM3OUT0 DT Small molecular drug
DM3OUT0 PC 6435463
DM3OUT0 MW 396.6
DM3OUT0 FM C25H32O2S
DM3OUT0 IC InChI=1S/C25H32O2S/c1-7-28(26,27)21-11-8-19(9-12-21)16-18(2)20-10-13-22-23(17-20)25(5,6)15-14-24(22,3)4/h8-13,16-17H,7,14-15H2,1-6H3/b18-16+
DM3OUT0 CS CCS(=O)(=O)C1=CC=C(C=C1)/C=C(\\C)/C2=CC3=C(C=C2)C(CCC3(C)C)(C)C
DM3OUT0 IK UDAZCXVIYSIEFX-FBMGVBCBSA-N
DM3OUT0 IU 6-[(E)-1-(4-ethylsulfonylphenyl)prop-1-en-2-yl]-1,1,4,4-tetramethyl-2,3-dihydronaphthalene
DM3OUT0 CA CAS 87719-32-2
DM3OUT0 DE Psoriasis vulgaris
DMF93U1 ID DMF93U1
DMF93U1 DN Etilevodopa
DMF93U1 HS Discontinued in Phase 3
DMF93U1 SN LDEE; ND-0601; TV-1203; Levodopa-ethyl-ester; Levodopa prodrug (transdermal, Parkinson's disease); Levodopa prodrug (transdermal, Parkinson's disease), NeuroDerm; L-DOPA prodrug (transdermal, Parkinson's disease), NeuroDerm; Levodopa ester, (transdermal, Parkinson's disease), NeuroDerm
DMF93U1 CP Hebrew University of Jerusalem; NeuroDerm Ltd
DMF93U1 DT Small molecular drug
DMF93U1 PC 170345
DMF93U1 MW 225.24
DMF93U1 FM C11H15NO4
DMF93U1 IC InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1
DMF93U1 CS CCOC(=O)[C@H](CC1=CC(=C(C=C1)O)O)N
DMF93U1 IK NULMGOSOSZBEQL-QMMMGPOBSA-N
DMF93U1 IU ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
DMF93U1 CA CAS 37178-37-3
DMF93U1 CB CHEBI:135971
DMF93U1 DE Parkinson disease
DM159U2 ID DM159U2
DM159U2 DN Evernimicin
DM159U2 HS Discontinued in Phase 3
DM159U2 SN Everninomicin; Everninomycin; Everninomycins; Ziracin; Evernimicin [USAN:INN]; Sch-27899; Antibiotic 13-384-1
DM159U2 CP Schering-Plough
DM159U2 DT Small molecular drug
DM159U2 PC 6917933
DM159U2 MW 1631.4
DM159U2 FM C70H97Cl2NO38
DM159U2 IC InChI=1S/C70H97Cl2NO38/c1-24-15-31(74)16-32(75)40(24)61(82)100-36-22-94-70(60-53(36)92-23-93-60)108-37-21-91-63(46(79)52(37)109-70)106-65-56(89-13)45(78)51(35(101-65)20-86-10)104-64-47(80)55(50(87-11)27(4)97-64)105-66-57(81)68(9)59(30(7)98-66)110-69(111-68)18-33(76)48(28(5)107-69)102-38-17-34(99-39-19-67(8,73(84)85)58(90-14)29(6)96-39)49(26(3)95-38)103-62(83)41-25(2)42(71)44(77)43(72)54(41)88-12/h15-16,26-30,33-39,45-53,55-60,63-66,74-81H,17-23H2,1-14H3/t26-,27-,28-,29+,30-,33-,34-,35-,36-,37+,38+,39+,45+,46-,47-,48-,49-,50+,51-,52-,53+,55-,56+,57-,58+,59-,60-,63+,64+,65+,66+,67+,68-,69-,70-/m1/s1
DM159U2 CS C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@]3(C[C@H]2O)O[C@@H]4[C@H](O[C@H]([C@H]([C@]4(O3)C)O)O[C@@H]5[C@H]([C@@H](O[C@@H]([C@@H]5OC)C)O[C@@H]6[C@H](O[C@H]([C@H]([C@H]6O)OC)O[C@H]7[C@@H]([C@H]8[C@H](CO7)O[C@@]9(O8)[C@H]1[C@H]([C@@H](CO9)OC(=O)C2=C(C=C(C=C2C)O)O)OCO1)O)COC)O)C)C)O[C@H]1C[C@]([C@H]([C@@H](O1)C)OC)(C)[N+](=O)[O-])OC(=O)C1=C(C(=C(C(=C1OC)Cl)O)Cl)C
DM159U2 IK UPADRKHAIMTUCC-OWALTSPQSA-N
DM159U2 IU [(2R,3R,4R,6S)-6-[(2R,2'R,3'S,3aR,4R,4'R,6S,7S,7aR)-6-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4S,5S,6S)-6-[(3aR,3'aS,4R,6'S,7R,7'R,7aS,7'aS)-7-(2,4-dihydroxy-6-methylbenzoyl)oxy-7'-hydroxyspiro[3a,6,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4,2'-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran]-6'-yl]oxy-4-hydroxy-5-methoxy-2-(methoxymethyl)oxan-3-yl]oxy-3-hydroxy-5-methoxy-6-methyloxan-4-yl]oxy-4',7-dihydroxy-2',4,7a-trimethylspiro[3a,4,6,7-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2,6'-oxane]-3'-yl]oxy-4-[(2S,4S,5R,6S)-5-methoxy-4,6-dimethyl-4-nitrooxan-2-yl]oxy-2-methyloxan-3-yl] 3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoate
DM159U2 CA CAS 109545-84-8
DM159U2 DE Bacterial infection
DMOIP7R ID DMOIP7R
DMOIP7R DN Flesinoxan
DMOIP7R HS Discontinued in Phase 3
DMOIP7R SN Flesinoxan hydrochloride; DU-29373
DMOIP7R CP Solvay Pharmaceuticals BV
DMOIP7R DT Small molecular drug
DMOIP7R PC 57347
DMOIP7R MW 415.5
DMOIP7R FM C22H26FN3O4
DMOIP7R IC InChI=1S/C22H26FN3O4/c23-17-6-4-16(5-7-17)22(28)24-8-9-25-10-12-26(13-11-25)19-2-1-3-20-21(19)29-15-18(14-27)30-20/h1-7,18,27H,8-15H2,(H,24,28)/t18-/m0/s1
DMOIP7R CS C1CN(CCN1CCNC(=O)C2=CC=C(C=C2)F)C3=C4C(=CC=C3)O[C@H](CO4)CO
DMOIP7R IK NYSDRDDQELAVKP-SFHVURJKSA-N
DMOIP7R IU 4-fluoro-N-[2-[4-[(2S)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl]ethyl]benzamide
DMOIP7R CA CAS 98206-10-1
DMOIP7R DE Anxiety disorder
DMN1O7E ID DMN1O7E
DMN1O7E DN FLUPAROXAN
DMN1O7E HS Discontinued in Phase 3
DMN1O7E SN Fluparoxan < Rec INN; GR-50360A (HCl); (3aS,9aS)-5-Fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]benzodioxino[2,3-c]pyrrole
DMN1O7E DT Small molecular drug
DMN1O7E PC 72036
DMN1O7E MW 195.19
DMN1O7E FM C10H10FNO2
DMN1O7E IC InChI=1S/C10H10FNO2/c11-6-2-1-3-7-10(6)14-9-5-12-4-8(9)13-7/h1-3,8-9,12H,4-5H2/t8-,9-/m0/s1
DMN1O7E CS C1[C@H]2[C@H](CN1)OC3=C(O2)C=CC=C3F
DMN1O7E IK XSOUHEXVEOQRKJ-IUCAKERBSA-N
DMN1O7E IU (3aS,9aS)-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]benzodioxino[2,3-c]pyrrole
DMN1O7E CA CAS 105182-45-4
DMN1O7E DE Depression
DML1DGP ID DML1DGP
DML1DGP DN FOROPAFANT
DML1DGP HS Discontinued in Phase 3
DML1DGP SN SR-27417; Foropafant; 2-[N-[2-(Dimethylamino)ethyl]-N-(3-pyridylmethyl)amino]-4-(2,4,6-triisopropylphenyl)thiazole
DML1DGP DT Small molecular drug
DML1DGP PC 119368
DML1DGP MW 464.7
DML1DGP FM C28H40N4S
DML1DGP IC InChI=1S/C28H40N4S/c1-19(2)23-14-24(20(3)4)27(25(15-23)21(5)6)26-18-33-28(30-26)32(13-12-31(7)8)17-22-10-9-11-29-16-22/h9-11,14-16,18-21H,12-13,17H2,1-8H3
DML1DGP CS CC(C)C1=CC(=C(C(=C1)C(C)C)C2=CSC(=N2)N(CCN(C)C)CC3=CN=CC=C3)C(C)C
DML1DGP IK VVBFISAUNSXQGZ-UHFFFAOYSA-N
DML1DGP IU N,N-dimethyl-N'-(pyridin-3-ylmethyl)-N'-[4-[2,4,6-tri(propan-2-yl)phenyl]-1,3-thiazol-2-yl]ethane-1,2-diamine
DML1DGP CA CAS 136468-36-5
DML1DGP DE Asthma
DME94QF ID DME94QF
DME94QF DN Furnidipine
DME94QF HS Discontinued in Phase 3
DME94QF SN Furaldipine; CRE-319
DME94QF CP Cermol SA
DME94QF DT Small molecular drug
DME94QF PC 65988
DME94QF MW 416.4
DME94QF FM C21H24N2O7
DME94QF IC InChI=1S/C21H24N2O7/c1-12-17(20(24)28-3)19(15-8-4-5-9-16(15)23(26)27)18(13(2)22-12)21(25)30-11-14-7-6-10-29-14/h4-5,8-9,14,19,22H,6-7,10-11H2,1-3H3
DME94QF CS CC1=C(C(C(=C(N1)C)C(=O)OCC2CCCO2)C3=CC=CC=C3[N+](=O)[O-])C(=O)OC
DME94QF IK GGVUNNUOJDGCBK-UHFFFAOYSA-N
DME94QF IU 3-O-methyl 5-O-(oxolan-2-ylmethyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DME94QF CA CAS 138661-03-7
DME94QF DE Nerve injury
DMNSE2I ID DMNSE2I
DMNSE2I DN Galocitabine
DMNSE2I HS Discontinued in Phase 3
DMNSE2I SN Galocitabine; Ro-09-1390; N-[1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydro-4-pyrimidinyl]-3,4,5-trimethoxybenzamide; 5'-Deoxy-5-fluoro-N4-(3,4,5-trimethoxybenzoyl)cytidine
DMNSE2I DT Small molecular drug
DMNSE2I PC 65950
DMNSE2I MW 439.4
DMNSE2I FM C19H22FN3O8
DMNSE2I IC InChI=1S/C19H22FN3O8/c1-8-13(24)14(25)18(31-8)23-7-10(20)16(22-19(23)27)21-17(26)9-5-11(28-2)15(30-4)12(6-9)29-3/h5-8,13-14,18,24-25H,1-4H3,(H,21,22,26,27)/t8-,13-,14-,18-/m1/s1
DMNSE2I CS C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=NC2=O)NC(=O)C3=CC(=C(C(=C3)OC)OC)OC)F)O)O
DMNSE2I IK TVYPSLDUBVTDIS-FUOMVGGVSA-N
DMNSE2I IU N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide
DMNSE2I CA CAS 124012-42-6
DMNSE2I DE Solid tumour/cancer
DMJ4KQS ID DMJ4KQS
DMJ4KQS DN GW-406381
DMJ4KQS HS Discontinued in Phase 3
DMJ4KQS SN GW 406381; GW406381; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene
DMJ4KQS CP GlaxoSmithKline
DMJ4KQS TC Analgesics
DMJ4KQS DT Small molecular drug
DMJ4KQS PC 9832687
DMJ4KQS MW 393.5
DMJ4KQS FM C21H19N3O3S
DMJ4KQS IC InChI=1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3
DMJ4KQS CS CCOC1=CC=C(C=C1)C2=NN3C(=C2C4=CC=C(C=C4)S(=O)(=O)C)C=CC=N3
DMJ4KQS IK NXMZBNYLCVTRGB-UHFFFAOYSA-N
DMJ4KQS IU 2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)pyrazolo[1,5-b]pyridazine
DMJ4KQS CA CAS 221148-46-5
DMJ4KQS DE Neuropathic pain; Osteoarthritis
DMG6TS2 ID DMG6TS2
DMG6TS2 DN GW873140
DMG6TS2 HS Discontinued in Phase 3
DMG6TS2 SN Aplaviroc; Aplaviroc HCl; Aplaviroc hydrochloride; AK 602; AK602; GSK873140; GW 873140; ONO 4128; AK-602; Aplaviroc hydrochloride (USAN); GW-873140; ONO-4128; Benzoic acid, 4-[4-[[1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]-& Soluble CD4; 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid; 4-[4-[[(9R)-11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid hydrochloride; 873140 Compound
DMG6TS2 CP GlaxoSmithKline
DMG6TS2 DT Small molecular drug
DMG6TS2 PC 3001322
DMG6TS2 MW 577.7
DMG6TS2 FM C33H43N3O6
DMG6TS2 IC InChI=1S/C33H43N3O6/c1-2-3-19-36-30(38)28(29(37)24-7-5-4-6-8-24)34-32(41)33(36)17-20-35(21-18-33)22-23-9-13-26(14-10-23)42-27-15-11-25(12-16-27)31(39)40/h9-16,24,28-29,37H,2-8,17-22H2,1H3,(H,34,41)(H,39,40)/t28-,29-/m1/s1
DMG6TS2 CS CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O
DMG6TS2 IK GWNOTCOIYUNTQP-FQLXRVMXSA-N
DMG6TS2 IU 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid
DMG6TS2 CA CAS 461443-59-4
DMG6TS2 DE Human immunodeficiency virus-1 infection
DMWB23S ID DMWB23S
DMWB23S DN H1N1 influenza vaccine
DMWB23S HS Discontinued in Phase 3
DMWB23S SN GC-1116; Greenflu-S Plus; H1N1 influenza vaccine (MF59-adjuvanted); H1N1 influenza vaccine (MF59-adjuvanted), Korea Green Cross
DMWB23S CP Green Cross Corp
DMWB23S DT Vaccine
DMWB23S DE Influenza virus infection
DMX3IRE ID DMX3IRE
DMX3IRE DN HBP-347
DMX3IRE HS Discontinued in Phase 3
DMX3IRE SN HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University
DMX3IRE CP Weizmann Institute of Science
DMX3IRE DE Autoimmune diabetes
DMGYKDN ID DMGYKDN
DMGYKDN DN Hemoximer
DMGYKDN HS Discontinued in Phase 3
DMGYKDN SN PHP-CT; PHP-HT; PHP-OC; Pyridoxalated hemoglobin polyoxyethylene-CT; Pyridoxalated hemoglobin polyoxyethylene-HT; Pyridoxalated hemoglobin polyoxyethylene-OC; VTR-PHP
DMGYKDN CP Ajinomoto Co Inc
DMGYKDN DE Hypotension
DMRXUY7 ID DMRXUY7
DMRXUY7 DN Idoxifene
DMRXUY7 HS Discontinued in Phase 3
DMRXUY7 SN CB-7432; SB-223030
DMRXUY7 CP Institute of Cancer Research UK
DMRXUY7 DT Small molecular drug
DMRXUY7 PC 3034011
DMRXUY7 MW 523.4
DMRXUY7 FM C28H30INO
DMRXUY7 IC InChI=1S/C28H30INO/c1-2-27(22-8-4-3-5-9-22)28(23-10-14-25(29)15-11-23)24-12-16-26(17-13-24)31-21-20-30-18-6-7-19-30/h3-5,8-17H,2,6-7,18-21H2,1H3/b28-27-
DMRXUY7 CS CC/C(=C(/C1=CC=C(C=C1)OCCN2CCCC2)\\C3=CC=C(C=C3)I)/C4=CC=CC=C4
DMRXUY7 IK JJKOTMDDZAJTGQ-DQSJHHFOSA-N
DMRXUY7 IU 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine
DMRXUY7 CA CAS 116057-75-1
DMRXUY7 DE Breast cancer
DM3SKAC ID DM3SKAC
DM3SKAC DN Idraparinux
DM3SKAC HS Discontinued in Phase 3
DM3SKAC SN SR 34006; SR-34006
DM3SKAC CP Sanofi-Aventis
DM3SKAC DT Small molecular drug
DM3SKAC PC 3083445
DM3SKAC MW 1529.4
DM3SKAC FM C38H64O49S7
DM3SKAC IC InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-/m1/s1
DM3SKAC CS CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OC)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O
DM3SKAC IK AJBMORBNKXNZSF-COSHMZDQSA-N
DM3SKAC IU (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
DM3SKAC CA CAS 162610-17-5
DM3SKAC DE Thrombosis
DMDEL2W ID DMDEL2W
DMDEL2W DN Iferanserin-Ventrus
DMDEL2W HS Discontinued in Phase 3
DMDEL2W SN VEN 309; VEN-309
DMDEL2W CP Ventrus Biosciences
DMDEL2W DE Hemorrhoids
DM8KSMX ID DM8KSMX
DM8KSMX DN IMIRESTAT
DM8KSMX HS Discontinued in Phase 3
DM8KSMX SN Imirestat; 89391-50-4; Imirestat [INN]; Alcon 1576; HOE 843; Imirestatum [INN-Latin]; Hoe-843; UNII-0PM69S95UQ; AL 1576; C15H8F2N2O2; AL-1576; 0PM69S95UQ; CHEMBL269455; 2,7-Difluorospiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione; Imirestatum; 2,7-Difluorospiro(fluorene-9,4'-imidazolidine)-2',5'-dione; Spiro[9H-fluorene-9,4'-imidazolidine]-2',5'-dione, 2,7-difluoro-; Spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione, 2,7-difluoro-; AL-theta-1576; ALO1576; AL1576; SCHEMBL49034; ZINC3724; AC1L23Q8; DTXSID80237635
DM8KSMX DT Small molecular drug
DM8KSMX PC 65673
DM8KSMX MW 286.23
DM8KSMX FM C15H8F2N2O2
DM8KSMX IC InChI=1S/C15H8F2N2O2/c16-7-1-3-9-10-4-2-8(17)6-12(10)15(11(9)5-7)13(20)18-14(21)19-15/h1-6H,(H2,18,19,20,21)
DM8KSMX CS C1=CC2=C(C=C1F)C3(C4=C2C=CC(=C4)F)C(=O)NC(=O)N3
DM8KSMX IK QCCHBHSAIQIQGO-UHFFFAOYSA-N
DM8KSMX IU 2,7-difluorospiro[fluorene-9,5'-imidazolidine]-2',4'-dione
DM8KSMX CA CAS 89391-50-4
DM8KSMX DE Diabetic complication
DMTHMEI ID DMTHMEI
DMTHMEI DN INS 316
DMTHMEI HS Discontinued in Phase 3
DMTHMEI SN Uridine 5'-triphosphate; uridine 5'-triphosphate; uridine triphosphate; 63-39-8; Uteplex; UTP; Uridine 5'-(tetrahydrogen triphosphate); 5'-UTP; Uridine 5'-triphosphoric acid; H4utp; UNII-UT0S826Z60; BRN 0071520; INS316; EINECS 200-558-7; uridine-5'-triphosphate; CHEMBL336296; CHEBI:15713; UT0S826Z60; Uridine5'-(tetrahydrogen triphosphate); [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate; uridine5'-triphosphate; uridintriphosphat; uridine tetrahydrogen
DMTHMEI CP Inspire Pharmaceuticals
DMTHMEI DT Small molecular drug
DMTHMEI PC 6133
DMTHMEI MW 484.14
DMTHMEI FM C9H15N2O15P3
DMTHMEI IC InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMTHMEI CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMTHMEI IK PGAVKCOVUIYSFO-XVFCMESISA-N
DMTHMEI IU [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMTHMEI CA CAS 63-39-8
DMTHMEI CB CHEBI:15713
DMTHMEI DE Lung cancer
DMVL8PB ID DMVL8PB
DMVL8PB DN IoGen
DMVL8PB HS Discontinued in Phase 3
DMVL8PB SN Oral iodine-based therapy (fibrocystic breast disease), Symbollon; Oral iodine-based therapy (fibrocystic breast disease), Symbollon/Gardant
DMVL8PB CP Symbollon Pharmaceuticals
DMVL8PB DE Pain
DM7SA9J ID DM7SA9J
DM7SA9J DN IR-103
DM7SA9J HS Discontinued in Phase 3
DM7SA9J SN HIV vaccine + Amplivax, IRC; HIV vaccine + Amplivax, Immune Response Corp; HIV vaccine + HYB-2055, IRC; HIV vaccine + HYB-2055, Immune Response Corp; Vaccine (HIV) + Amplivax, IRC; Vaccine (HIV) + Amplivax, Immune Response Corp; Vaccine (HIV) + HYB-2055, IRC; Vaccine (HIV) + HYB-2055, Immune Response Corp
DM7SA9J CP Immune Response BioPharma Inc
DM7SA9J DT Vaccine
DM7SA9J DE Human immunodeficiency virus infection
DMUYQH8 ID DMUYQH8
DMUYQH8 DN IRX-4310
DMUYQH8 HS Discontinued in Phase 3
DMUYQH8 SN AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310; RARa antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics; Retinoic acid receptor alpha antagonist (oral, chemotherapy-induced neutropenia), Io Therapeutics
DMUYQH8 CP Io Therapeutics Inc
DMUYQH8 DE Psoriasis vulgaris
DM1AFPW ID DM1AFPW
DM1AFPW DN KC-764
DM1AFPW HS Discontinued in Phase 3
DM1AFPW SN (2-Methylpyrazolo[1,5-a]pyridin-3-yl)(1,4,5,6-tetrahydro-3-pyridyl)methanone; 2-Methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine; 2-Methyl-3-(1,4,5,6-tetrahydropyridin-3-ylcarbonyl)pyrazolo[1,5-a]pyridine; 94457-09-7
DM1AFPW DT Small molecular drug
DM1AFPW PC 146826
DM1AFPW MW 241.29
DM1AFPW FM C14H15N3O
DM1AFPW IC InChI=1S/C14H15N3O/c1-10-13(12-6-2-3-8-17(12)16-10)14(18)11-5-4-7-15-9-11/h2-3,6,8-9,15H,4-5,7H2,1H3
DM1AFPW CS CC1=NN2C=CC=CC2=C1C(=O)C3=CNCCC3
DM1AFPW IK SLMUMPSLUWOXAO-UHFFFAOYSA-N
DM1AFPW IU (2-methylpyrazolo[1,5-a]pyridin-3-yl)-(1,2,3,4-tetrahydropyridin-5-yl)methanone
DM1AFPW CA CAS 94457-09-7
DM1AFPW DE Platelet aggregation disorder
DMZMFX6 ID DMZMFX6
DMZMFX6 DN KU-1257
DMZMFX6 HS Discontinued in Phase 3
DMZMFX6 SN Dalcotidine; 120958-90-9; UNII-9968S2UKFJ; KU-1257; KU 1257; 9968S2UKFJ; NCGC00182982-01; Dalcotidine [INN]; Dalcotidine (JAN/INN); AC1L2VE9; DSSTox_RID_83001; DSSTox_CID_28732; DSSTox_GSID_48806; CHEMBL311206; SCHEMBL1815082; N-Ethyl-N'-(3-(3-(piperidinomethyl)phenoxy)propyl)urea; DTXSID4048806; CHEBI:31454; 1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]urea; ZINC1889603; Tox21_113283; BDBM50406670; CAS-120958-90-9; D01698; L002431; A1-04840; 1-Ethyl-3-(3-((alpha-piperidino-m-tolyl)oxy)propyl)urea; Urea, N-ethyl-N'-(3-(3-(1-p
DMZMFX6 CP Kyorin Pharmaceutical Co Ltd
DMZMFX6 DT Small molecular drug
DMZMFX6 PC 129319
DMZMFX6 MW 319.4
DMZMFX6 FM C18H29N3O2
DMZMFX6 IC InChI=1S/C18H29N3O2/c1-2-19-18(22)20-10-7-13-23-17-9-6-8-16(14-17)15-21-11-4-3-5-12-21/h6,8-9,14H,2-5,7,10-13,15H2,1H3,(H2,19,20,22)
DMZMFX6 CS CCNC(=O)NCCCOC1=CC=CC(=C1)CN2CCCCC2
DMZMFX6 IK SVCQBXMFONNZHX-UHFFFAOYSA-N
DMZMFX6 IU 1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]urea
DMZMFX6 CA CAS 120958-90-9
DMZMFX6 CB CHEBI:31454
DMZMFX6 DE Duodenal ulcer
DMQZ6SE ID DMQZ6SE
DMQZ6SE DN KW-2149
DMQZ6SE HS Discontinued in Phase 3
DMQZ6SE SN KT-6149; E-90/007; Mitomycin C derivatives (cancer), Kyowa
DMQZ6SE CP Kyowa Hakko Kogyo Co Ltd
DMQZ6SE DT Small molecular drug
DMQZ6SE PC 108151
DMQZ6SE MW 598.7
DMQZ6SE FM C24H34N6O8S2
DMQZ6SE IC InChI=1S/C24H34N6O8S2/c1-11-17(28-6-8-40-39-7-5-27-15(31)4-3-13(25)22(34)35)20(33)16-12(10-38-23(26)36)24(37-2)21-14(29-21)9-30(24)18(16)19(11)32/h12-14,21,28-29H,3-10,25H2,1-2H3,(H2,26,36)(H,27,31)(H,34,35)/t12-,13+,14+,21+,24-/m1/s1
DMQZ6SE CS CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)NCCSSCCNC(=O)CC[C@@H](C(=O)O)N
DMQZ6SE IK BIOSTZMAOGCGSC-CYUGEGSCSA-N
DMQZ6SE IU (2S)-2-amino-5-[2-[2-[[(4S,6S,7R,8S)-8-(carbamoyloxymethyl)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-11-yl]amino]ethyldisulfanyl]ethylamino]-5-oxopentanoic acid
DMQZ6SE CA CAS 118359-59-4
DMQZ6SE DE Solid tumour/cancer
DMXWRGF ID DMXWRGF
DMXWRGF DN L-759274
DMXWRGF HS Discontinued in Phase 3
DMXWRGF CP Merck
DMXWRGF DE Depression; Mood disorder
DM7RGFW ID DM7RGFW
DM7RGFW DN Lamectacin
DM7RGFW HS Discontinued in Phase 3
DM7RGFW CP AstraZeneca & NewBiotics
DM7RGFW DT Small molecular drug
DM7RGFW PC 9873954
DM7RGFW MW 625.9
DM7RGFW FM C26H19Cl3N2O6S2
DM7RGFW IC InChI=1S/C26H19Cl3N2O6S2/c27-14-3-5-18(17(29)8-14)37-19-6-4-15(28)9-20(19)36-11-13-12-39-25-22(24(33)31(25)23(13)26(34)35)30-21(32)10-16-2-1-7-38-16/h1-9,22,25H,10-12H2,(H,30,32)(H,34,35)/t22-,25-/m1/s1
DM7RGFW CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)O)COC4=C(C=CC(=C4)Cl)OC5=C(C=C(C=C5)Cl)Cl
DM7RGFW IK XKYWDADJBIQZBT-RCZVLFRGSA-N
DM7RGFW IU (6R,7R)-3-[[5-chloro-2-(2,4-dichlorophenoxy)phenoxy]methyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM7RGFW DE Bacterial infection
DMHR1A7 ID DMHR1A7
DMHR1A7 DN LAMIFIBAN
DMHR1A7 HS Discontinued in Phase 3
DMHR1A7 SN Lamifiban; UNII-9XOE28082S; Ro-44-9883; CHEMBL108111; 144412-49-7; 9XOE28082S; Lamifiban [USAN:INN]; Ro 44-9883/000; Lamstat; AC1MI4XF; SCHEMBL4683; ((1-(N-(p-Amidinobenzoyl)-L-tyrosyl)-4-piperidyl)oxy)acetic acid; FPKOGTAFKSLZLD-FQEVSTJZSA-N; 2-[1-[2-[(4-carbamimidoylbenzoyl)amino]-3-(4-hydroxyphenyl)propanoyl]piperidin-4-yl]oxyacetic acid; Acetic acid, ((1-(2-((4-(aminoiminomethyl)benzoyl)amino)-3-(4-hydroxyphenyl)-1-oxopropyl)-4-piperidinyl)oxy)-, (S)-; Acetic acid, ((1-(2-((4-aminoiminomethyl)benzoyl)amino)-3-(4-hydro
DMHR1A7 DT Small molecular drug
DMHR1A7 PC 3038484
DMHR1A7 MW 468.5
DMHR1A7 FM C24H28N4O6
DMHR1A7 IC InChI=1S/C24H28N4O6/c25-22(26)16-3-5-17(6-4-16)23(32)27-20(13-15-1-7-18(29)8-2-15)24(33)28-11-9-19(10-12-28)34-14-21(30)31/h1-8,19-20,29H,9-14H2,(H3,25,26)(H,27,32)(H,30,31)/t20-/m0/s1
DMHR1A7 CS C1CN(CCC1OCC(=O)O)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C3=CC=C(C=C3)C(=N)N
DMHR1A7 IK FPKOGTAFKSLZLD-FQEVSTJZSA-N
DMHR1A7 IU 2-[1-[(2S)-2-[(4-carbamimidoylbenzoyl)amino]-3-(4-hydroxyphenyl)propanoyl]piperidin-4-yl]oxyacetic acid
DMHR1A7 CA CAS 144412-49-7
DMHR1A7 DE Angina pectoris
DMJY9CW ID DMJY9CW
DMJY9CW DN Lapaquistat acetate
DMJY9CW HS Discontinued in Phase 3
DMJY9CW SN Lapaquistat acetate (USAN); TAK-475; 1-((1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid
DMJY9CW CP Takeda Chemical Industries
DMJY9CW DT Small molecular drug
DMJY9CW PC 9874248
DMJY9CW MW 645.1
DMJY9CW FM C33H41ClN2O9
DMJY9CW IC InChI=1S/C33H41ClN2O9/c1-20(37)44-19-33(2,3)18-36-25-10-9-22(34)16-24(25)30(23-7-6-8-26(42-4)31(23)43-5)45-27(32(36)41)17-28(38)35-13-11-21(12-14-35)15-29(39)40/h6-10,16,21,27,30H,11-15,17-19H2,1-5H3,(H,39,40)/t27-,30-/m1/s1
DMJY9CW CS CC(=O)OCC(C)(C)CN1C2=C(C=C(C=C2)Cl)[C@H](O[C@@H](C1=O)CC(=O)N3CCC(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC
DMJY9CW IK CMLUGNQVANVZHY-POURPWNDSA-N
DMJY9CW IU 2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid
DMJY9CW CA CAS 189060-13-7
DMJY9CW DE Hyperlipidaemia
DM8CEDR ID DM8CEDR
DM8CEDR DN Laropiprant+niacin
DM8CEDR HS Discontinued in Phase 3
DM8CEDR SN Tredaptive (TN)
DM8CEDR CP Merck
DM8CEDR DT Small molecular drug
DM8CEDR PC 11948701
DM8CEDR MW 559
DM8CEDR FM C27H24ClFN2O6S
DM8CEDR IC InChI=1S/C21H19ClFNO4S.C6H5NO2/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12;8-6(9)5-2-1-3-7-4-5/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26);1-4H,(H,8,9)/t13-;/m1./s1
DM8CEDR CS CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F.C1=CC(=CN=C1)C(=O)O
DM8CEDR IK ZZRFQBQNZLFESZ-BTQNPOSSSA-N
DM8CEDR IU 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid;pyridine-3-carboxylic acid
DM8CEDR CA CAS 1046050-73-0
DM8CEDR DE Dyslipidemia
DMCM239 ID DMCM239
DMCM239 DN Larotaxel
DMCM239 HS Discontinued in Phase 3
DMCM239 SN Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
DMCM239 CP Sanofi-Aventis
DMCM239 DT Small molecular drug
DMCM239 PC 6918260
DMCM239 MW 831.9
DMCM239 FM C45H53NO14
DMCM239 IC InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1
DMCM239 CS CC1=C2[C@H](C(=O)[C@]34C[C@H]3C[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=CC=CC=C6)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)OC(=O)C
DMCM239 IK DXOJIXGRFSHVKA-BZVZGCBYSA-N
DMCM239 IU [(1S,2S,3R,4S,7R,9S,11R,13R,16S)-4,13-diacetyloxy-1-hydroxy-16-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-15,18,18-trimethyl-12-oxo-6-oxapentacyclo[12.3.1.03,11.04,7.09,11]octadec-14-en-2-yl] benzoate
DMCM239 CA CAS 156294-36-9
DMCM239 DE Bladder cancer; Pancreatic cancer
DMKMTR7 ID DMKMTR7
DMKMTR7 DN LDI-200
DMKMTR7 HS Discontinued in Phase 3
DMKMTR7 SN Chorionic gonadotropin, Milkhaus; HCG, Milkhaus; Oncology therapeutics, Milkhaus
DMKMTR7 CP Milkhaus Laboratory Inc
DMKMTR7 DE leukaemia
DMN9KJ2 ID DMN9KJ2
DMN9KJ2 DN Lenercept
DMN9KJ2 HS Discontinued in Phase 3
DMN9KJ2 SN Tenefuse; RsTNFR-IgG1; Ro-45-2081; TNF receptor-Ig, Roche; TNFR-IgG1 fusion protein, Roche
DMN9KJ2 CP Roche Holding AG
DMN9KJ2 DE Asthma
DMWUS8N ID DMWUS8N
DMWUS8N DN Licarbazepine
DMWUS8N HS Discontinued in Phase 3
DMWUS8N SN GP 47779; GP-47779; (-)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxycarbamazepine; 10-HYDROXY-CARBAMAZEPINE; 10-Hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide; 10-Hydroxy-10,11-dihydrocarbamazepine; 10-Hydroxycarbamazepine; 10-Hydroxycarbazepine; 10-OH-Carbazepine; 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMWUS8N CP Novartis
DMWUS8N DT Small molecular drug
DMWUS8N PC 114709
DMWUS8N MW 254.28
DMWUS8N FM C15H14N2O2
DMWUS8N IC InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
DMWUS8N CS C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
DMWUS8N IK BMPDWHIDQYTSHX-UHFFFAOYSA-N
DMWUS8N IU 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
DMWUS8N CA CAS 29331-92-8
DMWUS8N CB CHEBI:701
DMWUS8N DE Bipolar disorder
DM8OMI6 ID DM8OMI6
DM8OMI6 DN Lobucavir
DM8OMI6 HS Discontinued in Phase 3
DM8OMI6 SN LOBUCAVIR; 127759-89-1; Cyclobut-G; C-Oxetanocin-G; C-Oxt-G; BMS-180194; Cygalovir; (+)-Cyclobut G; 2-Amino-9-((1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl)-1H-purin-6(9H)-one; Lobucavir [USAN:INN]; SQ 33054; UNII-8U5PYQ1R2E; SQ 34,514; DRG-0235; 126062-18-8; 8U5PYQ1R2E; SQ-34514; Bms 180194; 9-((1R,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutyl)guanine; C11H15N5O3; Carbocyclic oxetanocin G; A-69992; 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one
DM8OMI6 CP Bristol-Myers Squibb
DM8OMI6 DT Small molecular drug
DM8OMI6 PC 135413519
DM8OMI6 MW 265.27
DM8OMI6 FM C11H15N5O3
DM8OMI6 IC InChI=1S/C11H15N5O3/c12-11-14-9-8(10(19)15-11)13-4-16(9)7-1-5(2-17)6(7)3-18/h4-7,17-18H,1-3H2,(H3,12,14,15,19)/t5-,6-,7-/m1/s1
DM8OMI6 CS C1[C@@H]([C@H]([C@@H]1N2C=NC3=C2N=C(NC3=O)N)CO)CO
DM8OMI6 IK GWFOVSGRNGAGDL-FSDSQADBSA-N
DM8OMI6 IU 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1H-purin-6-one
DM8OMI6 CA CAS 127759-89-1
DM8OMI6 DE Virus infection
DMHE804 ID DMHE804
DMHE804 DN LOTRAFIBAN
DMHE804 HS Discontinued in Phase 3
DMHE804 SN Lotrafiban; SB 214857; UNII-KLQ306I83X; 171049-14-2; SB-214857; CHEMBL356301; KLQ306I83X; DSSTox_CID_31391; R-Lotrafiban; Lotrafiban [INN]; AC1L2Z4G; DSSTox_RID_97278; DSSTox_RID_97279; DSSTox_GSID_57602; DSSTox_GSID_57603; SCHEMBL29596; CAS-NOCAS_57603; DTXSID7057602; ZINC3812598; Tox21_113990; Tox21_113989; BDBM50054825; SB-214857A; NCGC00319023-02; NCGC00319023-01; (2S)-7-((4,4'-Bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; KB-80491; SB-214134; CAS-171049-14-2
DMHE804 DT Small molecular drug
DMHE804 PC 80274
DMHE804 MW 428.5
DMHE804 FM C23H32N4O4
DMHE804 IC InChI=1S/C23H32N4O4/c1-26-14-18-12-17(2-3-19(18)25-20(23(26)31)13-21(28)29)22(30)27-10-6-16(7-11-27)15-4-8-24-9-5-15/h2-3,12,15-16,20,24-25H,4-11,13-14H2,1H3,(H,28,29)/t20-/m0/s1
DMHE804 CS CN1CC2=C(C=CC(=C2)C(=O)N3CCC(CC3)C4CCNCC4)N[C@H](C1=O)CC(=O)O
DMHE804 IK PYZOVVQJTLOHDG-FQEVSTJZSA-N
DMHE804 IU 2-[(2S)-4-methyl-3-oxo-7-(4-piperidin-4-ylpiperidine-1-carbonyl)-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid
DMHE804 CA CAS 171049-14-2
DMHE804 DE Cardiovascular disease
DM2KITF ID DM2KITF
DM2KITF DN LY335979
DM2KITF HS Discontinued in Phase 3
DM2KITF SN Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride
DM2KITF CP Eli Lilly
DM2KITF TC Anticancer Agents
DM2KITF DT Small molecular drug
DM2KITF PC 153997
DM2KITF MW 637
DM2KITF FM C32H34Cl3F2N3O2
DM2KITF IC InChI=1S/C32H31F2N3O2.3ClH/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27;;;/h1-14,21,29-31,38H,15-20H2;3*1H/t21-,29-,30+,31?;;;/m1.../s1
DM2KITF CS C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47.Cl.Cl.Cl
DM2KITF IK ZPFVQKPWGDRLHL-ZLYBXYBFSA-N
DM2KITF IU (2R)-1-[4-[(2R,4S)-3,3-difluoro-11-tetracyclo[10.4.0.02,4.05,10]hexadeca-1(16),5,7,9,12,14-hexaenyl]piperazin-1-yl]-3-quinolin-5-yloxypropan-2-ol;trihydrochloride
DM2KITF CA CAS 167465-36-3
DM2KITF DE Acute myeloid leukaemia
DMSC4K1 ID DMSC4K1
DMSC4K1 DN LY-544344
DMSC4K1 HS Discontinued in Phase 3
DMSC4K1 CP Eli Lilly
DMSC4K1 TC Psychiatric
DMSC4K1 DT Small molecular drug
DMSC4K1 PC 9857256
DMSC4K1 MW 256.25
DMSC4K1 FM C11H16N2O5
DMSC4K1 IC InChI=1S/C11H16N2O5/c1-4(12)8(14)13-11(10(17)18)3-2-5-6(7(5)11)9(15)16/h4-7H,2-3,12H2,1H3,(H,13,14)(H,15,16)(H,17,18)/t4-,5-,6-,7-,11-/m0/s1
DMSC4K1 CS C[C@@H](C(=O)N[C@]1(CC[C@@H]2[C@H]1[C@H]2C(=O)O)C(=O)O)N
DMSC4K1 IK UPSXYNJDCKOCFD-QIMCWZKGSA-N
DMSC4K1 IU (1S,2S,5R,6S)-2-[[(2S)-2-aminopropanoyl]amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMSC4K1 CA CAS 441765-98-6
DMSC4K1 DE Anxiety disorder
DMUR3VP ID DMUR3VP
DMUR3VP DN MDL-11939
DMUR3VP HS Discontinued in Phase 3
DMUR3VP SN Glemanserin; 107703-78-6; alpha-Phenyl-1-(2-phenylethyl)-4-piperidinemethanol; MDL 11,939; Mdl 11939; Mdl-11,939; MDL-11939; Glemanserin [USAN:INN]; CHEMBL18972; 132553-86-7; 4-Piperidinemethanol, alpha-phenyl-1-(2-phenylethyl)-; 4-Piperidinemethanol, alpha-phenyl-1-(2-phenylethyl)-, (+-)-; (+-)-1-Phenethyl-alpha-phenyl-4-piperidinemethanol; AC1L2GSP; Glemanserin (USAN/INN); ( inverted exclamation markA)-1-phenethyl-a-phenyl-4-piperidinemethanol; GTPL186; SCHEMBL120012; AC1Q771C; DTXSID4042624; CTK8D3348; CHEBI:91790
DMUR3VP DT Small molecular drug
DMUR3VP PC 71781
DMUR3VP MW 295.4
DMUR3VP FM C20H25NO
DMUR3VP IC InChI=1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2
DMUR3VP CS C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMUR3VP IK AXNGJCOYCMDPQG-UHFFFAOYSA-N
DMUR3VP IU phenyl-[1-(2-phenylethyl)piperidin-4-yl]methanol
DMUR3VP CA CAS 107703-78-6
DMUR3VP CB CHEBI:91790
DMUR3VP DE Anxiety disorder
DMAZ28C ID DMAZ28C
DMAZ28C DN Metazosin
DMAZ28C HS Discontinued in Phase 3
DMAZ28C SN Metazosin; Kenosin; VUFB15111; 116728-65-5; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)piperazine; (+-)-4-Amino-2-(4-(2-methoxypropionyl)piperazino)-6,7-dimethoxyquinazoline; (+-)-1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxypropionyl)piperazine; 95549-92-1; 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-methoxypropan-1-one; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-methoxy-1-oxopropyl)-
DMAZ28C DT Small molecular drug
DMAZ28C PC 93514
DMAZ28C MW 375.4
DMAZ28C FM C18H25N5O4
DMAZ28C IC InChI=1S/C18H25N5O4/c1-11(25-2)17(24)22-5-7-23(8-6-22)18-20-13-10-15(27-4)14(26-3)9-12(13)16(19)21-18/h9-11H,5-8H2,1-4H3,(H2,19,20,21)
DMAZ28C CS CC(C(=O)N1CCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC)OC
DMAZ28C IK YEOTYALSMRNXLJ-UHFFFAOYSA-N
DMAZ28C IU 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-methoxypropan-1-one
DMAZ28C CA CAS 95549-92-1
DMAZ28C DE Cardiac disease
DM9FJ7N ID DM9FJ7N
DM9FJ7N DN Midafotel
DM9FJ7N HS Discontinued in Phase 3
DM9FJ7N SN EAA-494
DM9FJ7N CP BTG plc
DM9FJ7N DT Small molecular drug
DM9FJ7N PC 6435801
DM9FJ7N MW 250.19
DM9FJ7N FM C8H15N2O5P
DM9FJ7N IC InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+/t7-/m1/s1
DM9FJ7N CS C1CN(C[C@@H](N1)C(=O)O)C/C=C/P(=O)(O)O
DM9FJ7N IK VZXMZMJSGLFKQI-ABVWVHJUSA-N
DM9FJ7N IU (2R)-4-[(E)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
DM9FJ7N CA CAS 117414-74-1
DM9FJ7N DE Cognitive impairment
DMPCY8K ID DMPCY8K
DMPCY8K DN Milameline
DMPCY8K HS Discontinued in Phase 3
DMPCY8K SN Miramelin; Mirameline; Milameline hydrochloride; PD-129409; RU-35926
DMPCY8K CP Pfizer Inc
DMPCY8K DT Small molecular drug
DMPCY8K PC 9571002
DMPCY8K MW 154.21
DMPCY8K FM C8H14N2O
DMPCY8K IC InChI=1S/C8H14N2O/c1-10-5-3-4-8(7-10)6-9-11-2/h4,6H,3,5,7H2,1-2H3/b9-6+
DMPCY8K CS CN1CCC=C(C1)/C=N/OC
DMPCY8K IK YMMXHEYLRHNXAB-RMKNXTFCSA-N
DMPCY8K IU (E)-N-methoxy-1-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)methanimine
DMPCY8K CA CAS 139886-32-1
DMPCY8K DE Cognitive impairment
DM86XJG ID DM86XJG
DM86XJG DN MINALRESTAT
DM86XJG HS Discontinued in Phase 3
DM86XJG SN Minalrestat; WAY-ARI-509; 129688-50-2; Minalrestat [USAN:INN]; Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone, 2-((4-bromo-2-fluorophenyl)-methyl)-6-fluoro-;; 2-(4-Bromo-2-fluorobenzyl)-6-fluorospiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone; Spiro(isoquinoline-4(1H),3'-pyrrolidine)-1,2',3,5'(2H)-tetrone, 2-((4-Bromo-2-fluorophenyl)methyl)-6-fluoro-; Bffipt; Minalrestat (2); AC1L4RBZ; Minalrestat (USAN/INN); SCHEMBL49649; CHEMBL273910; BDBM228819; AKOS022180622; SB19712; API0013644
DM86XJG DT Small molecular drug
DM86XJG PC 190816
DM86XJG MW 449.2
DM86XJG FM C19H11BrF2N2O4
DM86XJG IC InChI=1S/C19H11BrF2N2O4/c20-10-2-1-9(14(22)5-10)8-24-16(26)12-4-3-11(21)6-13(12)19(18(24)28)7-15(25)23-17(19)27/h1-6H,7-8H2,(H,23,25,27)
DM86XJG CS C1C(=O)NC(=O)C12C3=C(C=CC(=C3)F)C(=O)N(C2=O)CC4=C(C=C(C=C4)Br)F
DM86XJG IK BMHZAHGTGIZZCT-UHFFFAOYSA-N
DM86XJG IU 2-[(4-bromo-2-fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4,3'-pyrrolidine]-1,2',3,5'-tetrone
DM86XJG CA CAS 129688-50-2
DM86XJG DE Diabetic complication
DMMZO8X ID DMMZO8X
DMMZO8X DN Miproxifene
DMMZO8X HS Discontinued in Phase 3
DMMZO8X SN Miproxifene phosphate; TAT-59
DMMZO8X CP Taiho Pharmaceutical Co Ltd
DMMZO8X DT Small molecular drug
DMMZO8X PC 3037015
DMMZO8X MW 429.6
DMMZO8X FM C29H35NO2
DMMZO8X IC InChI=1S/C29H35NO2/c1-6-28(23-9-7-22(8-10-23)21(2)3)29(24-11-15-26(31)16-12-24)25-13-17-27(18-14-25)32-20-19-30(4)5/h7-18,21,31H,6,19-20H2,1-5H3/b29-28-
DMMZO8X CS CC/C(=C(\\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=C(C=C3)C(C)C
DMMZO8X IK FVVPWVFWOOMXEZ-ZIADKAODSA-N
DMMZO8X IU 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4-propan-2-ylphenyl)but-1-enyl]phenol
DMMZO8X CA CAS 129612-87-9
DMMZO8X DE Solid tumour/cancer
DMXT36M ID DMXT36M
DMXT36M DN Mivazerol
DMXT36M HS Discontinued in Phase 3
DMXT36M SN 125472-02-8; Mivazerol [INN]; UNII-W5P1SSA8KD; Mivazerolum [INN-Latin]; alpha-Imidazol-4-yl-2,3-cresotamide; 2-HYDROXY-3-(1H-IMIDAZOL-4-YLMETHYL)-BENZAMIDE; W5P1SSA8KD; 3-((1H-Imidazol-4-yl)methyl)-2-hydroxybenzamide; Benzamide,2-hydroxy-3-(1H-imidazol-5-ylmethyl)-; Mivazerolum; ucb 22073; mivazerol[inn]; ACMC-20mrix; AC1L1TX2; 2-hydroxy-3-(1H-imidazol-5-ylmethyl)benzamide; SCHEMBL593707; SCHEMBL8097939; AC1Q5D40; CHEMBL2105189; CTK4B4380; DTXSID30154782; ZINC4674535; 3-((1H-imidazol-4-yl)methyl)-2-hydroxybenzamide; Closantel 6
DMXT36M DT Small molecular drug
DMXT36M PC 60784
DMXT36M MW 217.22
DMXT36M FM C11H11N3O2
DMXT36M IC InChI=1S/C11H11N3O2/c12-11(16)9-3-1-2-7(10(9)15)4-8-5-13-6-14-8/h1-3,5-6,15H,4H2,(H2,12,16)(H,13,14)
DMXT36M CS C1=CC(=C(C(=C1)C(=O)N)O)CC2=CN=CN2
DMXT36M IK RLHGFJMGWQXPBW-UHFFFAOYSA-N
DMXT36M IU 2-hydroxy-3-(1H-imidazol-5-ylmethyl)benzamide
DMXT36M CA CAS 125472-02-8
DMXT36M DE Angina pectoris
DMJ59A4 ID DMJ59A4
DMJ59A4 DN MOFEGILINE
DMJ59A4 HS Discontinued in Phase 3
DMJ59A4 SN Mofegiline; Mofegiline (free base); UNII-1FMJ6D8Y1B; MDL 72974; 119386-96-8; MDL-72,974; 1FMJ6D8Y1B; CHEMBL489079; C11H13F2N; (E)-2-(Fluoromethylene)-4-(p-fluorophenyl)butylamine; Benzenebutanamine, 4-fluoro-beta-(fluoromethylene)-, (E)-; (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine; Mofegiline [INN]; AC1O5OIU; 4-fluoro-beta-(fluoromethylene)benzenebutanamine; SCHEMBL1295041; GTPL9754; VXLBSYHAEKDUSU-JXMROGBWSA-N; ZINC1542534; Mofegiline Hydrochloride (free base); MDL-72974; BDBM50246766; AKOS006271451; LS-172413
DMJ59A4 DT Small molecular drug
DMJ59A4 PC 6437850
DMJ59A4 MW 197.22
DMJ59A4 FM C11H13F2N
DMJ59A4 IC InChI=1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
DMJ59A4 CS C1=CC(=CC=C1CC/C(=C\\F)/CN)F
DMJ59A4 IK VXLBSYHAEKDUSU-JXMROGBWSA-N
DMJ59A4 IU (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
DMJ59A4 CA CAS 119386-96-8
DMJ59A4 DE Cognitive impairment
DMZAL8C ID DMZAL8C
DMZAL8C DN Motesanib
DMZAL8C HS Discontinued in Phase 3
DMZAL8C SN N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
DMZAL8C CP Amgen
DMZAL8C DT Small molecular drug
DMZAL8C PC 11667893
DMZAL8C MW 373.5
DMZAL8C FM C22H23N5O
DMZAL8C IC InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
DMZAL8C CS CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C
DMZAL8C IK RAHBGWKEPAQNFF-UHFFFAOYSA-N
DMZAL8C IU N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
DMZAL8C CA CAS 453562-69-1
DMZAL8C CB CHEBI:51098
DMZAL8C DE Non-small-cell lung cancer
DMYQZBT ID DMYQZBT
DMYQZBT DN MR-889
DMYQZBT HS Discontinued in Phase 3
DMYQZBT SN Midesteine; Midesteine [INN]; Midesteinum [INN-Latin]; Midesteina [INN-Spanish]; MR-889; 94149-41-4; MR 889; CHEMBL1808549; 2-(Thiophen-2-ylcarbonylthio)-N-(2-oxo-2,3,4,5-tetrahydrothiophen-3-yl)propionamide; 2-Thiophenecarbothioic acid, S-(1-methyl-2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl) ester; C12H13NO3S3; Midesteinum; Midesteina; 2-Thiophenecarbothioic acid, S-ester with (+-)-2-mercapto-N-(tetrahydro-2-oxo-3-thienyl)propionamide; SCHEMBL724755; AC1L242H; CTK3I7550; MR889; BDBM50349435; SB19618; LS-152918
DMYQZBT DT Small molecular drug
DMYQZBT PC 65837
DMYQZBT MW 315.4
DMYQZBT FM C12H13NO3S3
DMYQZBT IC InChI=1S/C12H13NO3S3/c1-7(19-12(16)9-3-2-5-17-9)10(14)13-8-4-6-18-11(8)15/h2-3,5,7-8H,4,6H2,1H3,(H,13,14)
DMYQZBT CS CC(C(=O)NC1CCSC1=O)SC(=O)C2=CC=CS2
DMYQZBT IK MKTVMEMIKNBVHI-UHFFFAOYSA-N
DMYQZBT IU S-[1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl] thiophene-2-carbothioate
DMYQZBT CA CAS 94149-41-4
DMYQZBT DE Phlegmy cough
DMNX0JH ID DMNX0JH
DMNX0JH DN N-0861
DMNX0JH HS Discontinued in Phase 3
DMNX0JH SN WRC-0006; WRC-0007
DMNX0JH CP Aderis Pharmaceuticals Inc
DMNX0JH DT Small molecular drug
DMNX0JH PC 126615
DMNX0JH MW 243.31
DMNX0JH FM C13H17N5
DMNX0JH IC InChI=1S/C13H17N5/c1-18-7-16-11-12(14-6-15-13(11)18)17-10-5-8-2-3-9(10)4-8/h6-10H,2-5H2,1H3,(H,14,15,17)/t8-,9+,10-/m1/s1
DMNX0JH CS CN1C=NC2=C(N=CN=C21)N[C@@H]3C[C@@H]4CC[C@H]3C4
DMNX0JH IK MTQYIGCUBBMQCJ-KXUCPTDWSA-N
DMNX0JH IU N-[(1S,2R,4R)-2-bicyclo[2.2.1]heptanyl]-9-methylpurin-6-amine
DMNX0JH CA CAS 141696-90-4
DMNX0JH DE Cardiac disease
DMXHWK6 ID DMXHWK6
DMXHWK6 DN Neutralase
DMXHWK6 HS Discontinued in Phase 3
DMXHWK6 SN Heparinase I, IBEX
DMXHWK6 CP IBEX Technologies Inc
DMXHWK6 DE Angiogenesis disorder
DMJL5TR ID DMJL5TR
DMJL5TR DN NOLOMIROLE HYDROCHLORIDE
DMJL5TR HS Discontinued in Phase 3
DMJL5TR SN CHF-1035; Nolomirole hydrochloride; Rac-5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalene hydrochloride
DMJL5TR DT Small molecular drug
DMJL5TR PC 219049
DMJL5TR MW 369.9
DMJL5TR FM C19H28ClNO4
DMJL5TR IC InChI=1S/C19H27NO4.ClH/c1-11(2)18(21)23-16-9-6-13-10-14(20-5)7-8-15(13)17(16)24-19(22)12(3)4;/h6,9,11-12,14,20H,7-8,10H2,1-5H3;1H
DMJL5TR CS CC(C)C(=O)OC1=C(C2=C(CC(CC2)NC)C=C1)OC(=O)C(C)C.Cl
DMJL5TR IK TWTMQRXNAZGSCE-UHFFFAOYSA-N
DMJL5TR IU [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;hydrochloride
DMJL5TR CA CAS 138531-51-8
DMJL5TR DE Heart failure
DMMDY27 ID DMMDY27
DMMDY27 DN Nuleusin
DMMDY27 HS Discontinued in Phase 3
DMMDY27 SN IL-2 (subcutaneous formulation, RCC/MM), 3SBio
DMMDY27 CP 3SBio Inc
DMMDY27 DE Melanoma
DMQN3JX ID DMQN3JX
DMQN3JX DN Ocinaplon
DMQN3JX HS Discontinued in Phase 3
DMQN3JX SN CL 273547; Ocinaplon [USAN:INN]; Ocinaplon (USAN/INN); Pyridin-2-yl-(7-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)methanone; Methanone, 2-pyri(dinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl); 2-Pyridinyl(7-(4-pyridinyl)pyrazolo(1,5-a)pyrimidin-3-yl)methanone; 2-Pyridyl 7-(4-pyridyl)pyrazolo(1,5-a)pyrimidin-3-yl ketone
DMQN3JX CP Dov Pharmaceutical
DMQN3JX TC Psychiatric
DMQN3JX DT Small molecular drug
DMQN3JX PC 216456
DMQN3JX MW 301.3
DMQN3JX FM C17H11N5O
DMQN3JX IC InChI=1S/C17H11N5O/c23-16(14-3-1-2-7-19-14)13-11-21-22-15(6-10-20-17(13)22)12-4-8-18-9-5-12/h1-11H
DMQN3JX CS C1=CC=NC(=C1)C(=O)C2=C3N=CC=C(N3N=C2)C4=CC=NC=C4
DMQN3JX IK OQJFBUOFGHPMSR-UHFFFAOYSA-N
DMQN3JX IU pyridin-2-yl-(7-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)methanone
DMQN3JX CA CAS 96604-21-6
DMQN3JX DE Generalized anxiety disorder
DM0O2HP ID DM0O2HP
DM0O2HP DN OLAMUFLOXACIN MESILATE
DM0O2HP HS Discontinued in Phase 3
DM0O2HP SN HSR-903; Olamufloxacin mesilate; (-)-5-Amino-7-[7(S)-amino-5-azaspiro[2.4]hept-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid methanesulfonate
DM0O2HP DT Small molecular drug
DM0O2HP PC 9826542
DM0O2HP MW 482.5
DM0O2HP FM C21H27FN4O6S
DM0O2HP IC InChI=1S/C20H23FN4O3.CH4O3S/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20;1-5(2,3)4/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28);1H3,(H,2,3,4)/t12-;/m1./s1
DM0O2HP CS CC1=C2C(=C(C(=C1N3C[C@H](C4(C3)CC4)N)F)N)C(=O)C(=CN2C5CC5)C(=O)O.CS(=O)(=O)O
DM0O2HP IK QCRMQMNCFYYEFX-UTONKHPSSA-N
DM0O2HP IU 5-amino-7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid
DM0O2HP CA CAS 167888-07-5
DM0O2HP DE Bacterial infection
DM1RKWV ID DM1RKWV
DM1RKWV DN ONO-3805
DM1RKWV HS Discontinued in Phase 3
DM1RKWV SN ONO-3805; CHEMBL24470; BDBM50057482; 4-(2-{4-[1-(4-Isobutyl-phenyl)-ethoxy]-2,3-dimethyl-benzoylamino}-phenoxy)-butyric acid; 4-(2-{4-[(S)-1-(4-Isobutyl-phenyl)-ethoxy]-2,3-dimethyl-benzoylamino}-phenoxy)-butyric acid
DM1RKWV DT Small molecular drug
DM1RKWV PC 11504627
DM1RKWV MW 503.6
DM1RKWV FM C31H37NO5
DM1RKWV IC InChI=1S/C31H37NO5/c1-20(2)19-24-12-14-25(15-13-24)23(5)37-28-17-16-26(21(3)22(28)4)31(35)32-27-9-6-7-10-29(27)36-18-8-11-30(33)34/h6-7,9-10,12-17,20,23H,8,11,18-19H2,1-5H3,(H,32,35)(H,33,34)/t23-/m0/s1
DM1RKWV CS CC1=C(C=CC(=C1C)O[C@@H](C)C2=CC=C(C=C2)CC(C)C)C(=O)NC3=CC=CC=C3OCCCC(=O)O
DM1RKWV IK XWNSOVPLENXWNU-QHCPKHFHSA-N
DM1RKWV IU 4-[2-[[2,3-dimethyl-4-[(1S)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl]amino]phenoxy]butanoic acid
DM1RKWV DE Prostate disease
DMEDLXJ ID DMEDLXJ
DMEDLXJ DN ORBOFIBAN
DMEDLXJ HS Discontinued in Phase 3
DMEDLXJ SN Orbofiban; UNII-FGJ53JS7PT; 163250-90-6; FGJ53JS7PT; CHEMBL64706; SC-57099B; Orbofiban [INN]; AC1L435J; SCHEMBL7854981; DTXSID20167543; ZINC3951736; BDBM50092109; AKOS022181223; AJ-47472; ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate; 3-{(S)-3-[1-(4-Carbamimidoyl-phenyl)-2-oxo-pyrrolidin-3-yl]-ureido}-propionic acid ethyl ester; beta-Alanine, N-((((3S)-1-(4-(aminoiminomethyl)phenyl)-2-oxo-3- pyrrolidinyl)amino)carbonyl)-, ethyl ester
DMEDLXJ DT Small molecular drug
DMEDLXJ PC 178080
DMEDLXJ MW 361.4
DMEDLXJ FM C17H23N5O4
DMEDLXJ IC InChI=1S/C17H23N5O4/c1-2-26-14(23)7-9-20-17(25)21-13-8-10-22(16(13)24)12-5-3-11(4-6-12)15(18)19/h3-6,13H,2,7-10H2,1H3,(H3,18,19)(H2,20,21,25)/t13-/m0/s1
DMEDLXJ CS CCOC(=O)CCNC(=O)N[C@H]1CCN(C1=O)C2=CC=C(C=C2)C(=N)N
DMEDLXJ IK VJDOPFARMOLELX-ZDUSSCGKSA-N
DMEDLXJ IU ethyl 3-[[(3S)-1-(4-carbamimidoylphenyl)-2-oxopyrrolidin-3-yl]carbamoylamino]propanoate
DMEDLXJ CA CAS 163250-90-6
DMEDLXJ DE Angina pectoris; Cardiovascular disease
DMVRA8N ID DMVRA8N
DMVRA8N DN Org-2766
DMVRA8N HS Discontinued in Phase 3
DMVRA8N SN Org-2766; H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH; UNII-OP1H5I4TBQ; OP1H5I4TBQ; 50913-82-1; AC1OCEIT; (4S)-5-[[(2S)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(2S)-1-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid
DMVRA8N CP Organon BioSciences
DMVRA8N DT Small molecular drug
DMVRA8N PC 6917685
DMVRA8N MW 870
DMVRA8N FM C40H55N9O11S
DMVRA8N IC InChI=1S/C40H55N9O11S/c1-61(59,60)19-17-28(42)35(52)45-30(15-16-34(50)51)37(54)48-32(22-27-23-43-24-44-27)39(56)47-31(20-25-10-4-2-5-11-25)38(55)46-29(14-8-9-18-41)36(53)49-33(40(57)58)21-26-12-6-3-7-13-26/h2-7,10-13,23-24,28-33H,8-9,14-22,41-42H2,1H3,(H,43,44)(H,45,52)(H,46,55)(H,47,56)(H,48,54)(H,49,53)(H,50,51)(H,57,58)/t28-,29+,30-,31-,32-,33-/m0/s1
DMVRA8N CS CS(=O)(=O)CC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N
DMVRA8N IK QUCFVNGGGFLOES-ACQYNFKHSA-N
DMVRA8N IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid
DMVRA8N CA CAS 50913-82-1
DMVRA8N DE Cognitive impairment
DMN7TL8 ID DMN7TL8
DMN7TL8 DN Osutidine
DMN7TL8 HS Discontinued in Phase 3
DMN7TL8 SN T-593
DMN7TL8 CP Toyama Chemical Co Ltd
DMN7TL8 DT Small molecular drug
DMN7TL8 PC 132303
DMN7TL8 MW 456.6
DMN7TL8 FM C19H28N4O5S2
DMN7TL8 IC InChI=1S/C19H28N4O5S2/c1-20-11-16-7-8-17(28-16)13-29-10-9-21-19(23-30(2,26)27)22-12-18(25)14-3-5-15(24)6-4-14/h3-8,18,20,24-25H,9-13H2,1-2H3,(H2,21,22,23)
DMN7TL8 CS CNCC1=CC=C(O1)CSCCNC(=NCC(C2=CC=C(C=C2)O)O)NS(=O)(=O)C
DMN7TL8 IK GZPOYVTZKHVRHE-UHFFFAOYSA-N
DMN7TL8 IU 2-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-1-[2-[[5-(methylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-3-methylsulfonylguanidine
DMN7TL8 CA CAS 140695-21-2
DMN7TL8 DE Duodenal ulcer
DMGOPMK ID DMGOPMK
DMGOPMK DN Otamixaban
DMGOPMK HS Discontinued in Phase 3
DMGOPMK SN Methyl 2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-4-yl)benzoyl]amino]butanoate; Methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate; 2-(3-Carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester
DMGOPMK CP Sanofi-Aventis
DMGOPMK DT Small molecular drug
DMGOPMK PC 5496659
DMGOPMK MW 446.5
DMGOPMK FM C25H26N4O4
DMGOPMK IC InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
DMGOPMK CS C[C@H]([C@@H](CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
DMGOPMK IK PFGVNLZDWRZPJW-OPAMFIHVSA-N
DMGOPMK IU methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
DMGOPMK CA CAS 193153-04-7
DMGOPMK DE Angina pectoris
DMWPT8J ID DMWPT8J
DMWPT8J DN Oxibendazole
DMWPT8J HS Discontinued in Phase 3
DMWPT8J SN Oxibendazole, GlaxoSmithKline
DMWPT8J CP GlaxoSmithKline
DMWPT8J DT Small molecular drug
DMWPT8J PC 4622
DMWPT8J MW 249.27
DMWPT8J FM C12H15N3O3
DMWPT8J IC InChI=1S/C12H15N3O3/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
DMWPT8J CS CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
DMWPT8J IK RAOCRURYZCVHMG-UHFFFAOYSA-N
DMWPT8J IU methyl N-(6-propoxy-1H-benzimidazol-2-yl)carbamate
DMWPT8J CA CAS 20559-55-1
DMWPT8J CB CHEBI:92907
DMWPT8J DE Pediatric cancer
DMPEHBJ ID DMPEHBJ
DMPEHBJ DN OX-NLA
DMPEHBJ HS Discontinued in Phase 3
DMPEHBJ SN NLA; BLX-NLA; NCX-1510; NO-donating therapeutics, Biolipox; Anti-allergy drug, NicOx/Biolipox; NO-donating allergy therapeutics, Biolipox/Nicox; NO-donating respiratory therapeutics, NicOx/Biolipox; NO-donating therapeutics, Biolipox/Nicox; Liposomal nitric oxide-donating cetirizine derivative (nasal, rhinitis), Biolipox; Nitric oxide-donating cetirizine derivative (liposomal, intranasal, rhinitis), Orexo; OX-NLA (nasal/liposomal formulation, allergic rhinitis/rhinitis); OX-NLA (nasal/liposomal formulation, allergic rhinitis/rhinitis), Meda
DMPEHBJ CP NicOx SA
DMPEHBJ DT Small molecular drug
DMPEHBJ PC 55182
DMPEHBJ MW 461.8
DMPEHBJ FM C21H27Cl3N2O3
DMPEHBJ IC InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H
DMPEHBJ CS C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
DMPEHBJ IK PGLIUCLTXOYQMV-UHFFFAOYSA-N
DMPEHBJ IU 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
DMPEHBJ CA CAS 83881-52-1
DMPEHBJ CB CHEBI:3562
DMPEHBJ DE Allergic rhinitis
DMFNLDY ID DMFNLDY
DMFNLDY DN P-1
DMFNLDY HS Discontinued in Phase 3
DMFNLDY SN Zemaphyte; Zemaphyte (P1)
DMFNLDY CP Phytopharm plc
DMFNLDY DT Small molecular drug
DMFNLDY PC 200882
DMFNLDY MW 287.78
DMFNLDY FM C14H22ClNO3
DMFNLDY IC InChI=1S/C14H21NO3.ClH/c1-3-15(4-2)8-9-16-12-6-5-7-13-14(12)18-11-10-17-13;/h5-7H,3-4,8-11H2,1-2H3;1H
DMFNLDY CS CCN(CC)CCOC1=CC=CC2=C1OCCO2.Cl
DMFNLDY IK ACLBTXLOASZGRX-UHFFFAOYSA-N
DMFNLDY IU 2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-N,N-diethylethanamine;hydrochloride
DMFNLDY CA CAS 2906-73-2
DMFNLDY DE Atopic dermatitis
DM1FST8 ID DM1FST8
DM1FST8 DN Pazinaclone
DM1FST8 HS Discontinued in Phase 3
DM1FST8 SN A-77000; DN-2327; Pazinaclone < Rec INN; Rac-8-[[2-(7-Chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-1,4-dioxa-8-azaspiro[4.5]decane
DM1FST8 DT Small molecular drug
DM1FST8 PC 59743
DM1FST8 MW 478.9
DM1FST8 FM C25H23ClN4O4
DM1FST8 IC InChI=1S/C25H23ClN4O4/c26-20-7-5-16-6-8-21(28-23(16)27-20)30-19(17-3-1-2-4-18(17)24(30)32)15-22(31)29-11-9-25(10-12-29)33-13-14-34-25/h1-8,19H,9-15H2
DM1FST8 CS C1CN(CCC12OCCO2)C(=O)CC3C4=CC=CC=C4C(=O)N3C5=NC6=C(C=C5)C=CC(=N6)Cl
DM1FST8 IK DPGKFACWOCLTCA-UHFFFAOYSA-N
DM1FST8 IU 2-(7-chloro-1,8-naphthyridin-2-yl)-3-[2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3H-isoindol-1-one
DM1FST8 CA CAS 103255-66-9
DM1FST8 DE Anxiety disorder
DM4IM0G ID DM4IM0G
DM4IM0G DN Pexelizumab
DM4IM0G HS Discontinued in Phase 3
DM4IM0G CP Alexion Pharmaceuticals
DM4IM0G DT Antibody
DM4IM0G SQ h5g1.1 scFv: MADIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIKRTGGGGSGGGGSGGGGSQVQLVQSGAEVEKPGASVKKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYAQKFQGRVTMTADTSTSTAYMELSSLRSEDTAVYYCARYFFGSSPNYWYFDVWGQGTLVTVSS >h5g1.1VHC + F | Heavy Chain Variable RegionQVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYAQKFQGRVTMTADTSTSTAYMELSSLRSEDTAVYYCARYFFGSSPNWYFVWGQGT >h5g1.1VHC + F | Light Chain Variable RegionDIQMTQSPSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
DM4IM0G DE Cardiovascular disease
DMXEU14 ID DMXEU14
DMXEU14 DN PF-1913539
DMXEU14 HS Discontinued in Phase 3
DMXEU14 SN Sch-58261; Sch 58261; 160098-96-4; Sch58261; 2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; UNII-4309023MAH; CHEMBL17127; 4309023MAH; 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine; [3H]SCH 58261; SCH58261
DMXEU14 CP Pfizer
DMXEU14 DT Small molecular drug
DMXEU14 PC 176408
DMXEU14 MW 345.4
DMXEU14 FM C18H15N7O
DMXEU14 IC InChI=1S/C18H15N7O/c19-18-22-16-13(11-20-24(16)9-8-12-5-2-1-3-6-12)17-21-15(23-25(17)18)14-7-4-10-26-14/h1-7,10-11H,8-9H2,(H2,19,22)
DMXEU14 CS C1=CC=C(C=C1)CCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
DMXEU14 IK UTLPKQYUXOEJIL-UHFFFAOYSA-N
DMXEU14 IU 4-(furan-2-yl)-10-(2-phenylethyl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
DMXEU14 CA CAS 160098-96-4
DMXEU14 CB CHEBI:93424
DMXEU14 DE Alzheimer disease
DMXSTRM ID DMXSTRM
DMXSTRM DN Pibutidine
DMXSTRM HS Discontinued in Phase 3
DMXSTRM SN Alex; Pibutidine hydrochloride; IT-066
DMXSTRM CP Ikeda Mohando Co Ltd
DMXSTRM DT Small molecular drug
DMXSTRM PC 5282450
DMXSTRM MW 356.4
DMXSTRM FM C19H24N4O3
DMXSTRM IC InChI=1S/C19H24N4O3/c20-16-17(19(25)18(16)24)22-7-2-5-11-26-15-12-14(6-8-21-15)13-23-9-3-1-4-10-23/h2,5-6,8,12,22H,1,3-4,7,9-11,13,20H2/b5-2-
DMXSTRM CS C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\\CNC3=C(C(=O)C3=O)N
DMXSTRM IK XMDYZASWLGWIPL-DJWKRKHSSA-N
DMXSTRM IU 3-amino-4-[[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]amino]cyclobut-3-ene-1,2-dione
DMXSTRM CA CAS 103922-33-4
DMXSTRM CB CHEBI:145662
DMXSTRM DE Ulcerative colitis
DMQXJDM ID DMQXJDM
DMQXJDM DN Piroximone
DMQXJDM HS Discontinued in Phase 3
DMQXJDM SN MDL-19205
DMQXJDM CP Hoechst Marion Roussel Inc
DMQXJDM DT Small molecular drug
DMQXJDM PC 55263
DMQXJDM MW 217.22
DMQXJDM FM C11H11N3O2
DMQXJDM IC InChI=1S/C11H11N3O2/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7/h3-6H,2H2,1H3,(H2,13,14,16)
DMQXJDM CS CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2
DMQXJDM IK OQGWJZOWLHWFME-UHFFFAOYSA-N
DMQXJDM IU 4-ethyl-5-(pyridine-4-carbonyl)-1,3-dihydroimidazol-2-one
DMQXJDM CA CAS 84490-12-0
DMQXJDM DE Cardiac failure
DMDZBIQ ID DMDZBIQ
DMDZBIQ DN PMI-001
DMDZBIQ HS Discontinued in Phase 3
DMDZBIQ CP Phytomedics
DMDZBIQ DE Lupus
DM04ZUW ID DM04ZUW
DM04ZUW DN Ponalrestat
DM04ZUW HS Discontinued in Phase 3
DM04ZUW SN PONALRESTAT; statil; 72702-95-5; Ponalrestatum [Latin]; UNII-2CV0A5G64E; ICI-128436; ICI 128,436; CHEMBL7679; C17H12BrFN2O3; 2CV0A5G64E; 2-(3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid; NCGC00024824-01; 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid; 1-Phthalazineaceticacid, 3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-; Ponalrestatum; 1-Phthalazineacetic acid, 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-; Prodiax; Ponalrestat [USAN:BAN:INN]; ISIS-5GLT2rx
DM04ZUW DT Small molecular drug
DM04ZUW PC 5278
DM04ZUW MW 391.2
DM04ZUW FM C17H12BrFN2O3
DM04ZUW IC InChI=1S/C17H12BrFN2O3/c18-11-6-5-10(14(19)7-11)9-21-17(24)13-4-2-1-3-12(13)15(20-21)8-16(22)23/h1-7H,8-9H2,(H,22,23)
DM04ZUW CS C1=CC=C2C(=C1)C(=NN(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DM04ZUW IK LKBFFDOJUKLQNY-UHFFFAOYSA-N
DM04ZUW IU 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid
DM04ZUW CA CAS 72702-95-5
DM04ZUW CB CHEBI:93199
DM04ZUW DE Gout; Diabetic complication
DML6EWH ID DML6EWH
DML6EWH DN Posatirelin
DML6EWH HS Discontinued in Phase 3
DML6EWH SN Esotirelin; Pyladox; RGH-2202
DML6EWH CP Gedeon Richter Ltd
DML6EWH DT Small molecular drug
DML6EWH PC 71230
DML6EWH MW 352.4
DML6EWH FM C17H28N4O4
DML6EWH IC InChI=1S/C17H28N4O4/c1-10(2)9-12(17(25)21-8-4-6-13(21)15(18)23)20-16(24)11-5-3-7-14(22)19-11/h10-13H,3-9H2,1-2H3,(H2,18,23)(H,19,22)(H,20,24)/t11-,12-,13-/m0/s1
DML6EWH CS CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@@H]2CCCC(=O)N2
DML6EWH IK DPNGIIPSQYKWQA-AVGNSLFASA-N
DML6EWH IU (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]-6-oxopiperidine-2-carboxamide
DML6EWH CA CAS 78664-73-0
DML6EWH CB CHEBI:135486
DML6EWH DE Neurodegenerative disorder
DMI02PF ID DMI02PF
DMI02PF DN PRINOMIDE TROMETHAMINE
DMI02PF HS Discontinued in Phase 3
DMI02PF SN 3-(1-Methylpyrrol-2-yl)-3-oxo-2-(N-phenylcarbamoyl)propionitrile tromethamine salt
DMI02PF DT Small molecular drug
DMI02PF PC 3033812
DMI02PF MW 388.4
DMI02PF FM C19H24N4O5
DMI02PF IC InChI=1S/C15H13N3O2.C4H11NO3/c1-18-9-5-8-13(18)14(19)12(10-16)15(20)17-11-6-3-2-4-7-11;5-4(1-6,2-7)3-8/h2-9,12H,1H3,(H,17,20);6-8H,1-3,5H2
DMI02PF CS CN1C=CC=C1C(=O)C(C#N)C(=O)NC2=CC=CC=C2.C(C(CO)(CO)N)O
DMI02PF IK CPUJDORGQAJDCT-UHFFFAOYSA-N
DMI02PF IU 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-cyano-3-(1-methylpyrrol-2-yl)-3-oxo-N-phenylpropanamide
DMI02PF CA CAS 109636-76-2
DMI02PF DE Inflammation
DMW9H7M ID DMW9H7M
DMW9H7M DN Propiram fumarate
DMW9H7M HS Discontinued in Phase 3
DMW9H7M SN Algeril; Diramax; Dirame; Diramine; Diratab; Propiram; FBA-4503
DMW9H7M CP Bayer AG
DMW9H7M DT Small molecular drug
DMW9H7M PC 6433584
DMW9H7M MW 391.5
DMW9H7M FM C20H29N3O5
DMW9H7M IC InChI=1S/C16H25N3O.C4H4O4/c1-3-16(20)19(15-9-5-6-10-17-15)14(2)13-18-11-7-4-8-12-18;5-3(6)1-2-4(7)8/h5-6,9-10,14H,3-4,7-8,11-13H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMW9H7M CS CCC(=O)N(C1=CC=CC=N1)C(C)CN2CCCCC2.C(=C/C(=O)O)\\C(=O)O
DMW9H7M IK WQTLOZFMTGYQDX-WLHGVMLRSA-N
DMW9H7M IU (E)-but-2-enedioic acid;N-(1-piperidin-1-ylpropan-2-yl)-N-pyridin-2-ylpropanamide
DMW9H7M CA CAS 13717-04-9
DMW9H7M DE Cancer related pain
DMB069L ID DMB069L
DMB069L DN PUMAPRAZOLE
DMB069L HS Discontinued in Phase 3
DMB069L SN BY-841; Pumaprazole; N-[2-(2,3-Dimethylimidazol[1,2-a]pyridin-8-ylaminomethyl)-3-methylphenyl]carbamic acid methyl ester
DMB069L DT Small molecular drug
DMB069L PC 3052764
DMB069L MW 338.4
DMB069L FM C19H22N4O2
DMB069L IC InChI=1S/C19H22N4O2/c1-12-7-5-8-16(22-19(24)25-4)15(12)11-20-17-9-6-10-23-14(3)13(2)21-18(17)23/h5-10,20H,11H2,1-4H3,(H,22,24)
DMB069L CS CC1=C(C(=CC=C1)NC(=O)OC)CNC2=CC=CN3C2=NC(=C3C)C
DMB069L IK NZQTVUWEPPDOKK-UHFFFAOYSA-N
DMB069L IU methyl N-[2-[[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)amino]methyl]-3-methylphenyl]carbamate
DMB069L CA CAS 158364-59-1
DMB069L DE Duodenal ulcer
DMO9XTJ ID DMO9XTJ
DMO9XTJ DN Quinelorane
DMO9XTJ HS Discontinued in Phase 3
DMO9XTJ SN Quinelorane; Quinelorane [INN:BAN]; Quineloranum [INN-Latin]; UNII-Z0X4VT3Y1Q; Quinelorano [INN-Spanish]; 97466-90-5; Z0X4VT3Y1Q; LY 163502; LY 137157; LY 175877; CHEMBL155731; (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine; (5aR-trans)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido(2,3-g)quinazolin-2-amine; Pyrido(2,3-g)quinazolin-2-amine, 5,5a,6,7,8,9,9a,10-octahydro-6-propyl-, (5aR-trans)-; DSSTox_RID_81533; DSSTox_CID_26315; DSSTox_GSID_46315; Quineloranum; Quinelorano; CAS-97466-90-5
DMO9XTJ DT Small molecular drug
DMO9XTJ PC 57242
DMO9XTJ MW 246.35
DMO9XTJ FM C14H22N4
DMO9XTJ IC InChI=1S/C14H22N4/c1-2-5-18-6-3-4-10-7-12-11(8-13(10)18)9-16-14(15)17-12/h9-10,13H,2-8H2,1H3,(H2,15,16,17)/t10-,13-/m1/s1
DMO9XTJ CS CCCN1CCC[C@H]2[C@H]1CC3=CN=C(N=C3C2)N
DMO9XTJ IK TUFADSGTJUOBEH-ZWNOBZJWSA-N
DMO9XTJ IU (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine
DMO9XTJ CA CAS 97466-90-5
DMO9XTJ CB CHEBI:92230
DMO9XTJ DE Male sexual disorder
DMNTURD ID DMNTURD
DMNTURD DN Ranagengliotucel-T
DMNTURD HS Discontinued in Phase 3
DMNTURD SN Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx
DMNTURD CP NovaRx Corp
DMNTURD DT Vaccine
DMNTURD DE Brain cancer
DMAINU1 ID DMAINU1
DMAINU1 DN RB-006
DMAINU1 HS Discontinued in Phase 3
DMAINU1 CP Regado Biosci
DMAINU1 PC 86278324
DMAINU1 MW 551.5
DMAINU1 FM C20H39N3NaO11P
DMAINU1 IC InChI=1S/C20H40N3O11P.Na/c1-30-13-15-32-19(25)22-11-7-5-9-17(23-20(26)33-16-14-31-2)18(24)21-10-6-3-4-8-12-34-35(27,28)29;/h17H,3-16H2,1-2H3,(H,21,24)(H,22,25)(H,23,26)(H2,27,28,29);/q;+1/p-1
DMAINU1 CS COCCOC(=O)NCCCCC(C(=O)NCCCCCCOP(=O)(O)[O-])NC(=O)OCCOC.[Na+]
DMAINU1 IK AYPFBAOWSFOSKF-UHFFFAOYSA-M
DMAINU1 IU sodium;6-[2,6-bis(2-methoxyethoxycarbonylamino)hexanoylamino]hexyl hydrogen phosphate
DMAINU1 CA CAS 959716-32-6
DMAINU1 DE Vascular disease; Coronary artery disease; Thrombosis
DMXV28I ID DMXV28I
DMXV28I DN RG-12915
DMXV28I HS Discontinued in Phase 3
DMXV28I SN RG 12915; CHEMBL171393; RG-12915; (5aS-(4(R*),5aalpha,9aalpha))-N-1-Azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-4-dibenzofurancarboxamide; 4-dibenzofurancarboxamide, N-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-, (5aS,9aS)-; N-(1-Azabicyclo(2.2.2)octan-3-yl)-2-chloro-5a,6,7,8,9,9a-hexahydrodibenzofuran-4-carboxamide; 4-Dibenzofurancarboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-, (5aS-(4(R*),5aalpha,9aalpha))-; UNII-533O919MKO; 533O919MKO
DMXV28I CP Rhone-Poulenc SA
DMXV28I DT Small molecular drug
DMXV28I PC 130427
DMXV28I MW 360.9
DMXV28I FM C20H25ClN2O2
DMXV28I IC InChI=1S/C20H25ClN2O2/c21-13-9-15-14-3-1-2-4-18(14)25-19(15)16(10-13)20(24)22-17-11-23-7-5-12(17)6-8-23/h9-10,12,14,17-18H,1-8,11H2,(H,22,24)
DMXV28I CS C1CCC2C(C1)C3=C(O2)C(=CC(=C3)Cl)C(=O)NC4CN5CCC4CC5
DMXV28I IK LDYMIBZOCSHLBG-UHFFFAOYSA-N
DMXV28I IU N-(1-azabicyclo[2.2.2]octan-3-yl)-2-chloro-5a,6,7,8,9,9a-hexahydrodibenzofuran-4-carboxamide
DMXV28I CA CAS 125363-06-6
DMXV28I DE Nausea
DMCV0BZ ID DMCV0BZ
DMCV0BZ DN RhTPO
DMCV0BZ HS Discontinued in Phase 3
DMCV0BZ SN TPIAO (TN)
DMCV0BZ CP Pharmacia; Pfizer
DMCV0BZ DE Idiopathic thrombocytopenic purpura
DMBKN4P ID DMBKN4P
DMBKN4P DN Riferminogene pecaplasmid
DMBKN4P HS Discontinued in Phase 3
DMBKN4P SN Temusi (TN)
DMBKN4P CP Sanofi-aventis
DMBKN4P DE Critical limb ischemia
DM0X36Y ID DM0X36Y
DM0X36Y DN Ritanserin
DM0X36Y HS Discontinued in Phase 3
DM0X36Y SN ritanserin; 87051-43-2; Tiserton; Ritanserine; Ritanserinum; Ritanserina; R-55667; Ritanserinum [Latin]; Ritanserine [French]; Ritanserina [Spanish]; UNII-145TFV465S; C27H25F2N3OS; R 55,667; 6-(2-(4-(bis(4-fluorophenyl)methylene)piperidin-1-yl)ethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; MLS000069360; CHEMBL267777; 6-(2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl)-7-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one; N,N-dialkyl-dipeptidylamines
DM0X36Y DT Small molecular drug
DM0X36Y PC 5074
DM0X36Y MW 477.6
DM0X36Y FM C27H25F2N3OS
DM0X36Y IC InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3
DM0X36Y CS CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3
DM0X36Y IK JUQLTPCYUFPYKE-UHFFFAOYSA-N
DM0X36Y IU 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one
DM0X36Y CA CAS 87051-43-2
DM0X36Y CB CHEBI:64195
DM0X36Y DE Anxiety disorder
DM8M1X0 ID DM8M1X0
DM8M1X0 DN Ro-16-6028
DM8M1X0 HS Discontinued in Phase 3
DM8M1X0 SN Bretazenil; 84379-13-5; Ro 16-6028; UNII-OSZ0E9DGOJ; Bretazenil [USAN:INN]; 1-Bretazenil; Bretazenilum [INN-Latin]; Ro-16-6028; OSZ0E9DGOJ; BRN 4765855; C19H20BrN3O3; CHEMBL366947; NCGC00160640-01; DSSTox_RID_81493; DSSTox_CID_26266; DSSTox_GSID_46266; tert-Butyl (S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylate; Bretazenilum; 9H-Imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid; 9H-Imidazo(1,5-a)pyrrolo(2,1-c)(1,4)benzodiazepine-1-carboxylic acid, 8-bro
DM8M1X0 DT Small molecular drug
DM8M1X0 PC 107926
DM8M1X0 MW 418.3
DM8M1X0 FM C19H20BrN3O3
DM8M1X0 IC InChI=1S/C19H20BrN3O3/c1-19(2,3)26-18(25)15-16-13-8-5-9-22(13)17(24)14-11(20)6-4-7-12(14)23(16)10-21-15/h4,6-7,10,13H,5,8-9H2,1-3H3/t13-/m0/s1
DM8M1X0 CS CC(C)(C)OC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=C(N2C=N1)C=CC=C4Br
DM8M1X0 IK LWUDDYHYYNNIQI-ZDUSSCGKSA-N
DM8M1X0 IU tert-butyl (7S)-14-bromo-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DM8M1X0 CA CAS 84379-13-5
DM8M1X0 DE Anxiety disorder
DMOVJ60 ID DMOVJ60
DMOVJ60 DN RPAF-AH
DMOVJ60 HS Discontinued in Phase 3
DMOVJ60 CP ICOS Corp
DMOVJ60 DE Sepsis
DMPUED3 ID DMPUED3
DMPUED3 DN S-12968
DMPUED3 HS Discontinued in Phase 3
DMPUED3 SN Olradipine; Pranedipine; (-)-S 12968
DMPUED3 CP Servier
DMPUED3 DT Small molecular drug
DMPUED3 PC 6918192
DMPUED3 MW 637.5
DMPUED3 FM C26H34Cl2N2O12
DMPUED3 IC InChI=1S/C22H28Cl2N2O6.C4H6O6/c1-4-32-22(28)19-16(12-31-11-10-30-9-8-25)26-13(2)17(21(27)29-3)18(19)14-6-5-7-15(23)20(14)24;5-1(3(7)8)2(6)4(9)10/h5-7,18,26H,4,8-12,25H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DMPUED3 CS CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)COCCOCCN.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMPUED3 IK LKFLYCNXQSCXIV-LREBCSMRSA-N
DMPUED3 IU (2R,3R)-2,3-dihydroxybutanedioic acid;3-O-ethyl 5-O-methyl 2-[2-(2-aminoethoxy)ethoxymethyl]-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMPUED3 DE Hypertension
DMSW051 ID DMSW051
DMSW051 DN Sabeluzole
DMSW051 HS Discontinued in Phase 3
DMSW051 SN Arbetuzole; R-58735
DMSW051 CP Janssen Pharmaceutica NV
DMSW051 DT Small molecular drug
DMSW051 PC 59823
DMSW051 MW 415.5
DMSW051 FM C22H26FN3O2S
DMSW051 IC InChI=1S/C22H26FN3O2S/c1-25(22-24-20-4-2-3-5-21(20)29-22)17-10-12-26(13-11-17)14-18(27)15-28-19-8-6-16(23)7-9-19/h2-9,17-18,27H,10-15H2,1H3
DMSW051 CS CN(C1CCN(CC1)CC(COC2=CC=C(C=C2)F)O)C3=NC4=CC=CC=C4S3
DMSW051 IK IGMKTIJBFUMVIN-UHFFFAOYSA-N
DMSW051 IU 1-[4-[1,3-benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(4-fluorophenoxy)propan-2-ol
DMSW051 CA CAS 104383-17-7
DMSW051 DE Cerebrovascular ischaemia
DM3KC81 ID DM3KC81
DM3KC81 DN Sanfetrinem
DM3KC81 HS Discontinued in Phase 3
DM3KC81 SN Sanfetrinem sodium; GV-104326; GV-104326B; GV-104326X; GV-326; LK-176
DM3KC81 CP Glaxo Wellcome plc
DM3KC81 DT Small molecular drug
DM3KC81 PC 71452
DM3KC81 MW 281.3
DM3KC81 FM C14H19NO5
DM3KC81 IC InChI=1S/C14H19NO5/c1-6(16)9-11-7-4-3-5-8(20-2)10(7)12(14(18)19)15(11)13(9)17/h6-9,11,16H,3-5H2,1-2H3,(H,18,19)/t6-,7+,8+,9-,11-/m1/s1
DM3KC81 CS C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(N2C1=O)C(=O)O)OC)O
DM3KC81 IK ICFDDEJRXZSWTA-KJFVXYAMSA-N
DM3KC81 IU (1S,5S,8aS,8bR)-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-5,6,7,8,8a,8b-hexahydro-1H-azeto[1,2-b]isoindole-4-carboxylic acid
DM3KC81 CA CAS 156769-21-0
DM3KC81 DE Bacterial infection
DMSRJY3 ID DMSRJY3
DMSRJY3 DN Saredutant
DMSRJY3 HS Discontinued in Phase 3
DMSRJY3 SN SR-48968; 142001-63-6; SR 48968; SR48968; UNII-720U2QK8I5; (S)-N-Methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide; CHEMBL308148; SR48968C; 720U2QK8I5; N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide; N-((S)-beta-(2-(4-Acetamido-4-phenylpiperidino)ethyl)-3,4-dichlorophenethyl)-N-methylbenzamide; [3H]saredutant; SR 48968C; Benzamide, N-((2S)-4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-N-methyl-; SR 48965; SR-48965; SR-489686; SR-48968C
DMSRJY3 CP Sanofi-aventis
DMSRJY3 DT Small molecular drug
DMSRJY3 PC 104974
DMSRJY3 MW 552.5
DMSRJY3 FM C31H35Cl2N3O2
DMSRJY3 IC InChI=1S/C31H35Cl2N3O2/c1-23(37)34-31(27-11-7-4-8-12-27)16-19-36(20-17-31)18-15-26(25-13-14-28(32)29(33)21-25)22-35(2)30(38)24-9-5-3-6-10-24/h3-14,21,26H,15-20,22H2,1-2H3,(H,34,37)/t26-/m1/s1
DMSRJY3 CS CC(=O)NC1(CCN(CC1)CC[C@H](CN(C)C(=O)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4
DMSRJY3 IK PGKXDIMONUAMFR-AREMUKBSSA-N
DMSRJY3 IU N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide
DMSRJY3 CA CAS 142001-63-6
DMSRJY3 DE Anxiety disorder; Depression
DMCJLD1 ID DMCJLD1
DMCJLD1 DN SCH 727965
DMCJLD1 HS Discontinued in Phase 3
DMCJLD1 SN Dinaciclib; SCH-727965
DMCJLD1 CP Schering-Plough
DMCJLD1 DT Small molecular drug
DMCJLD1 PC 46926350
DMCJLD1 MW 396.5
DMCJLD1 FM C21H28N6O2
DMCJLD1 IC InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
DMCJLD1 CS CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO
DMCJLD1 IK PIMQWRZWLQKKBJ-SFHVURJKSA-N
DMCJLD1 IU 2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
DMCJLD1 CA CAS 779353-01-4
DMCJLD1 CB CHEBI:95060
DMCJLD1 DE Acute lymphoblastic leukaemia
DMIHQZ8 ID DMIHQZ8
DMIHQZ8 DN Segard
DMIHQZ8 HS Discontinued in Phase 3
DMIHQZ8 SN Afelimomab
DMIHQZ8 CP Abbott Laboratories
DMIHQZ8 DT Antibody
DMIHQZ8 DE Sepsis
DM3IJMN ID DM3IJMN
DM3IJMN DN Seletracetam
DM3IJMN HS Discontinued in Phase 3
DM3IJMN SN UCB 44212; UCB-44212; 2-[4-(2,2-difluoroethenyl)-2-oxo-pyrrolidin-1-yl]butanamide
DM3IJMN CP UCB Pharma
DM3IJMN DT Small molecular drug
DM3IJMN PC 9942725
DM3IJMN MW 232.23
DM3IJMN FM C10H14F2N2O2
DM3IJMN IC InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1
DM3IJMN CS CC[C@@H](C(=O)N)N1C[C@@H](CC1=O)C=C(F)F
DM3IJMN IK ANWPENAPCIFDSZ-RQJHMYQMSA-N
DM3IJMN IU (2S)-2-[(4S)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide
DM3IJMN CA CAS 357336-74-4
DM3IJMN DE Epilepsy
DM3FLIX ID DM3FLIX
DM3FLIX DN Selfotel
DM3FLIX HS Discontinued in Phase 3
DM3FLIX SN Selfotel; 110347-85-8; CGS 19755; CGS-19755; Selfotel [USAN:INN]; CPDD 0027; (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid; UNII-N0905W44Y3; H-4-Pal-OH.2HCl; cis-4-(Phosphonomethyl)pipecolic acid; CHEMBL39664; 2-Piperidinecarboxylic acid, 4-(phosphonomethyl)-, cis-; CIS-4-[PHOSPHONOMETHYL]-PIPERIDINE-2-CARBOXYLIC ACID; CHEBI:34973; 2-Piperidinecarboxylic acid, 4-(phosphonomethyl)-, (2S,4R)-; N0905W44Y3; 113229-62-2; cis-4-(phosphonomethyl)piperidine-2-carboxylic acid; Selfotel, (+)-
DM3FLIX DT Small molecular drug
DM3FLIX PC 68736
DM3FLIX MW 223.16
DM3FLIX FM C7H14NO5P
DM3FLIX IC InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1
DM3FLIX CS C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O
DM3FLIX IK LPMRCCNDNGONCD-RITPCOANSA-N
DM3FLIX IU (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid
DM3FLIX CA CAS 110347-85-8
DM3FLIX CB CHEBI:34973
DM3FLIX DE Cerebrovascular ischaemia
DMRBYH8 ID DMRBYH8
DMRBYH8 DN Sepimostat mesylate
DMRBYH8 HS Discontinued in Phase 3
DMRBYH8 SN Renofuthan; FUT-187; TO-187
DMRBYH8 CP Taiho Pharmaceutical Co Ltd
DMRBYH8 DT Small molecular drug
DMRBYH8 PC 108040
DMRBYH8 MW 469.5
DMRBYH8 FM C22H23N5O5S
DMRBYH8 IC InChI=1S/C21H19N5O2.CH4O3S/c22-19(23)16-2-1-15-12-18(8-5-14(15)11-16)28-20(27)13-3-6-17(7-4-13)26-21-24-9-10-25-21;1-5(2,3)4/h1-8,11-12H,9-10H2,(H3,22,23)(H2,24,25,26);1H3,(H,2,3,4)
DMRBYH8 CS CS(=O)(=O)O.C1CN=C(N1)NC2=CC=C(C=C2)C(=O)OC3=CC4=C(C=C3)C=C(C=C4)C(=N)N
DMRBYH8 IK NAMGRNXMZHEICS-UHFFFAOYSA-N
DMRBYH8 IU (6-carbamimidoylnaphthalen-2-yl) 4-(4,5-dihydro-1H-imidazol-2-ylamino)benzoate;methanesulfonic acid
DMRBYH8 CA CAS 103926-82-5
DMRBYH8 DE Solid tumour/cancer
DMPNTDL ID DMPNTDL
DMPNTDL DN Seratrodast
DMPNTDL HS Discontinued in Phase 3
DMPNTDL SN Bronica; A 73001; AA 2414; ABT 001; Abbott 73001; A-73001; AA-2414; ABT-001; Abbott-73001; Bronica (TN); Seratrodast [USAN:INN]; Seratrodast (JAN/USAN/INN); (+-)-2,4,5-Trimethyl-3,6-dioxo-zeta-phenyl-1,4-cyclohexadiene-1-heptanoic acid; (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
DMPNTDL CP Takeda Pharma
DMPNTDL DT Small molecular drug
DMPNTDL PC 2449
DMPNTDL MW 354.4
DMPNTDL FM C22H26O4
DMPNTDL IC InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
DMPNTDL CS CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C
DMPNTDL IK ZBVKEHDGYSLCCC-UHFFFAOYSA-N
DMPNTDL IU 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
DMPNTDL CA CAS 112665-43-7
DMPNTDL CB CHEBI:32126
DMPNTDL DE Allergic asthma
DMYQT2V ID DMYQT2V
DMYQT2V DN Sibenadet
DMYQT2V HS Discontinued in Phase 3
DMYQT2V SN UNII-N32934RHGW; 154189-40-9; CHEMBL82663; N32934RHGW; Sibenadet [INN:BAN]; AC1L4DOB; SCHEMBL48983; DTXSID50165552; AR-C 68397XX; ZINC36268680; ARC-68397; BDBM50128690; AR-C 68397; 4-Hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-1,3-benzothiazol-2(3H)-one; SB-07499; 2(3H)-Benzothiazolone, 4-hydroxy-7-(2-((2-((3-(2-phenylethoxy)propyl)sulfonyl)ethyl)amino)ethyl)-; FT-0674579; L001485; 4-Hydroxy-7-{2-[2-(3-phenethyloxy-propane-1-sulfonyl)-ethylamino]-ethyl}-3H-benzothiazol-2-one
DMYQT2V CP AstraZeneca
DMYQT2V DT Small molecular drug
DMYQT2V PC 183812
DMYQT2V MW 464.6
DMYQT2V FM C22H28N2O5S2
DMYQT2V IC InChI=1S/C22H28N2O5S2/c25-19-8-7-18(21-20(19)24-22(26)30-21)9-11-23-12-16-31(27,28)15-4-13-29-14-10-17-5-2-1-3-6-17/h1-3,5-8,23,25H,4,9-16H2,(H,24,26)
DMYQT2V CS C1=CC=C(C=C1)CCOCCCS(=O)(=O)CCNCCC2=C3C(=C(C=C2)O)NC(=O)S3
DMYQT2V IK DBCKRBGYGMVSTI-UHFFFAOYSA-N
DMYQT2V IU 4-hydroxy-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]ethylamino]ethyl]-3H-1,3-benzothiazol-2-one
DMYQT2V CA CAS 154189-40-9
DMYQT2V DE Chronic obstructive pulmonary disease
DMZU1TV ID DMZU1TV
DMZU1TV DN SIBRAFIBAN
DMZU1TV HS Discontinued in Phase 3
DMZU1TV SN Sibrafiban; UNII-YUE443B0NF; Sibrafiban [USAN:INN:BAN]; YUE443B0NF; Ro 48-3657; 172927-65-0; Ro 48-3657/001; Ethyl (Z)-((1-(N-((p-hydroxyamidino)benzoyl)-L-alanyl)-4-piperidyl)oxy)acetate; Ro-48-3657; ((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid ethyl ester; Sibrafiban [INN]; Acetic acid, ((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)-, ethyl ester, (S-(Z))-; Sibrafiban [USAN]; Sibrafiban [MART.]; Sibrafiban [WHO-DD]; Xubix
DMZU1TV DT Small molecular drug
DMZU1TV PC 5491394
DMZU1TV MW 420.5
DMZU1TV FM C20H28N4O6
DMZU1TV IC InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1
DMZU1TV CS CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)C2=CC=C(C=C2)/C(=N\\O)/N
DMZU1TV IK WBNUCLPUOSXSNJ-ZDUSSCGKSA-N
DMZU1TV IU ethyl 2-[1-[(2S)-2-[[4-[(E)-N'-hydroxycarbamimidoyl]benzoyl]amino]propanoyl]piperidin-4-yl]oxyacetate
DMZU1TV CA CAS 170094-62-9
DMZU1TV DE Angina pectoris; Cardiovascular disease
DM0T2QV ID DM0T2QV
DM0T2QV DN Sitimagene ceradenovec
DM0T2QV HS Discontinued in Phase 3
DM0T2QV SN Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark
DM0T2QV CP Ark Therapeutics
DM0T2QV DE Brain cancer
DMXW1Y3 ID DMXW1Y3
DMXW1Y3 DN SKF-96067
DMXW1Y3 HS Discontinued in Phase 3
DMXW1Y3 SN 115607-61-9; Skf-96067; F-96067; SKF96067; 3-Butyryl-4-(2-methylphenylamino)-8-methoxyquinoline; CHEMBL327717; SK-96067; 1-Butanone,1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-; 1-Butanone, 1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-; 1-Butanone, 1-(8-methoxy-4-((2-methylphenyl)amino)-3-quinolinyl)-; MAVJDLHBPIXVJL-UHFFFAOYSA-N; AC1MIWAF; ACMC-1BTM4; SCHEMBL451221; ZINC3665; CTK4A9399; DTXSID40151146; BDBM50001254; HY-U00042; 1-[8-METHOXY-4-[(2-METHYLPHENYL)AMINO]-3-QUINOLINYL]-1-BUTANONE
DMXW1Y3 CP SmithKline Beecham plc
DMXW1Y3 DT Small molecular drug
DMXW1Y3 PC 3081087
DMXW1Y3 MW 334.4
DMXW1Y3 FM C21H22N2O2
DMXW1Y3 IC InChI=1S/C21H22N2O2/c1-4-8-18(24)16-13-22-21-15(10-7-12-19(21)25-3)20(16)23-17-11-6-5-9-14(17)2/h5-7,9-13H,4,8H2,1-3H3,(H,22,23)
DMXW1Y3 CS CCCC(=O)C1=CN=C2C(=C1NC3=CC=CC=C3C)C=CC=C2OC
DMXW1Y3 IK MAVJDLHBPIXVJL-UHFFFAOYSA-N
DMXW1Y3 IU 1-[8-methoxy-4-(2-methylanilino)quinolin-3-yl]butan-1-one
DMXW1Y3 CA CAS 115607-61-9
DMXW1Y3 DE Peptic ulcer
DMMG47P ID DMMG47P
DMMG47P DN SUN-09
DMMG47P HS Discontinued in Phase 3
DMMG47P SN SUN-B09; Prodrug (muscle spasticity), Sun Pharmaceutical
DMMG47P CP Sun pharma advanced research
DMMG47P DE Hypertonia
DM6M8ZX ID DM6M8ZX
DM6M8ZX DN Sunepitron
DM6M8ZX HS Discontinued in Phase 3
DM6M8ZX SN Sunepitron hydrochloride; SUNEPITRON HYDROCHLORIDE; (7S,9aS)-7-(2,5-Dioxopyrrolidin-1-ylmethyl)-2-(2-pyrimidinyl)octahydro-1H-pyrido[1,2-a]pyrazine hydrochloride; (7S,9aS)-1-[2-(2-Pyrimidinyl)perhydropyrido[1,2-a]pyrazin-7-ylmethyl]pyrrolidine-2,5-dione hydrochloride; Sunepitron hydrochloride; CP-93393 (free base); CP-93393-1; 131831-03-3
DM6M8ZX DT Small molecular drug
DM6M8ZX PC 183092
DM6M8ZX MW 329.4
DM6M8ZX FM C17H23N5O2
DM6M8ZX IC InChI=1S/C17H23N5O2/c23-15-4-5-16(24)22(15)11-13-2-3-14-12-21(9-8-20(14)10-13)17-18-6-1-7-19-17/h1,6-7,13-14H,2-5,8-12H2/t13-,14-/m0/s1
DM6M8ZX CS C1C[C@H]2CN(CCN2C[C@H]1CN3C(=O)CCC3=O)C4=NC=CC=N4
DM6M8ZX IK UXWBIYCPUVWKHP-KBPBESRZSA-N
DM6M8ZX IU 1-[[(7S,9aS)-2-pyrimidin-2-yl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-yl]methyl]pyrrolidine-2,5-dione
DM6M8ZX CA CAS 131831-03-3
DMVB9XC ID DMVB9XC
DMVB9XC DN Tanomastat
DMVB9XC HS Discontinued in Phase 3
DMVB9XC SN Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
DMVB9XC CP Bayer
DMVB9XC TC Anticancer Agents
DMVB9XC DT Small molecular drug
DMVB9XC PC 6918336
DMVB9XC MW 410.9
DMVB9XC FM C23H19ClO3S
DMVB9XC IC InChI=1S/C23H19ClO3S/c24-20-12-10-17(11-13-20)16-6-8-18(9-7-16)22(25)14-19(23(26)27)15-28-21-4-2-1-3-5-21/h1-13,19H,14-15H2,(H,26,27)/t19-/m1/s1
DMVB9XC CS C1=CC=C(C=C1)SC[C@@H](CC(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)Cl)C(=O)O
DMVB9XC IK JXAGDPXECXQWBC-LJQANCHMSA-N
DMVB9XC IU (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
DMVB9XC CA CAS 179545-77-8
DMVB9XC DE Osteoarthritis; Ovarian cancer; Lung cancer; Pancreatic cancer
DMA4WY5 ID DMA4WY5
DMA4WY5 DN Taprostene
DMA4WY5 HS Discontinued in Phase 3
DMA4WY5 SN CG-4203
DMA4WY5 CP Grunenthal GmbH
DMA4WY5 DT Small molecular drug
DMA4WY5 PC 5311243
DMA4WY5 MW 398.5
DMA4WY5 FM C24H30O5
DMA4WY5 IC InChI=1S/C24H30O5/c25-21(16-6-2-1-3-7-16)10-9-19-20-13-18(29-23(20)14-22(19)26)12-15-5-4-8-17(11-15)24(27)28/h4-5,8-12,16,19-23,25-26H,1-3,6-7,13-14H2,(H,27,28)/b10-9+,18-12-/t19-,20-,21-,22-,23+/m1/s1
DMA4WY5 CS C1CCC(CC1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C/C(=C/C4=CC(=CC=C4)C(=O)O)/O3)O)O
DMA4WY5 IK ZLJOKYGJNOQXDP-OZUBPDBUSA-N
DMA4WY5 IU 3-[(Z)-[(3aR,4R,5R,6aS)-4-[(E,3S)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid
DMA4WY5 CA CAS 108945-35-3
DMA4WY5 DE Thrombosis
DM5G9W0 ID DM5G9W0
DM5G9W0 DN Taranabant
DM5G9W0 HS Discontinued in Phase 3
DM5G9W0 SN Taranabant [USAN]; MK 0364; MK0364; MK-0364; MK-0634; Taranabant (INN/USAN); L]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropy; N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide; N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
DM5G9W0 CP Merck
DM5G9W0 DT Small molecular drug
DM5G9W0 PC 11226090
DM5G9W0 MW 516
DM5G9W0 FM C27H25ClF3N3O2
DM5G9W0 IC InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
DM5G9W0 CS C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F
DM5G9W0 IK QLYKJCMUNUWAGO-GAJHUEQPSA-N
DM5G9W0 IU N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide
DM5G9W0 CA CAS 701977-09-5
DM5G9W0 DE Obesity
DM9T6MS ID DM9T6MS
DM9T6MS DN Tecadenoson
DM9T6MS HS Discontinued in Phase 3
DM9T6MS SN CVT-510; 204512-90-3; UNII-GZ1X96601Z; CHEMBL392149; GZ1X96601Z; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol; BDBM50224766; Tecadenoson [USAN:INN]; Tecadenoson (USAN/INN); AC1L4KMO; SCHEMBL246787; GTPL5592; CHEMBL356254; DTXSID80174415; BDBM50138530; DB04954; N6-[3-(R)-tetrahydrofuranyl]adenosine; HY-19661; Adenosine, N-(3R)-tetrahydro-3-furanyl-; LS-190860; Adenosine, N-(3R)-tetrahydro-3-furanyl)-; CS-0016174; D06019; CVT-510; N-(3-Tetrahydrofuranyl)-6-aminopurine riboside; Selenocompounds
DM9T6MS CP CV Therapeutics
DM9T6MS DT Small molecular drug
DM9T6MS PC 158795
DM9T6MS MW 337.33
DM9T6MS FM C14H19N5O5
DM9T6MS IC InChI=1S/C14H19N5O5/c20-3-8-10(21)11(22)14(24-8)19-6-17-9-12(15-5-16-13(9)19)18-7-1-2-23-4-7/h5-8,10-11,14,20-22H,1-4H2,(H,15,16,18)/t7-,8-,10-,11-,14-/m1/s1
DM9T6MS CS C1COC[C@@H]1NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM9T6MS IK OESBDSFYJMDRJY-BAYCTPFLSA-N
DM9T6MS IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol
DM9T6MS CA CAS 204512-90-3
DM9T6MS DE Cardiac arrhythmias; Atrial fibrillation
DMYF1DN ID DMYF1DN
DMYF1DN DN Terutroban sodium
DMYF1DN HS Discontinued in Phase 3
DMYF1DN SN S-18886; Terutroban sodium salt; 609340-89-8; 1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl-, monosodium salt,
DMYF1DN CP Servier
DMYF1DN DT Small molecular drug
DMYF1DN PC 23674098
DMYF1DN MW 429.9
DMYF1DN FM C20H21ClNNaO4S
DMYF1DN IC InChI=1S/C20H22ClNO4S.Na/c1-13-2-3-14-12-16(6-9-19(14)18(13)10-11-20(23)24)22-27(25,26)17-7-4-15(21)5-8-17;/h2-5,7-8,16,22H,6,9-12H2,1H3,(H,23,24);/q;+1/p-1/t16-;/m1./s1
DMYF1DN CS CC1=C(C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1)CCC(=O)[O-].[Na+]
DMYF1DN IK BQMSKINGUUUIHE-PKLMIRHRSA-M
DMYF1DN IU sodium;3-[(6R)-6-[(4-chlorophenyl)sulfonylamino]-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoate
DMYF1DN CA CAS 609340-89-8
DMYF1DN DE Thrombosis
DMWNXES ID DMWNXES
DMWNXES DN Thrombomodulin
DMWNXES HS Discontinued in Phase 3
DMWNXES SN THRODULIN Inj; MB-015; MR-33; Thrombomodulin, Mochida/JCR
DMWNXES CP Mochida Pharmaceutical Co Ltd
DMWNXES DE Disseminated intravascular coagulation
DME5QDP ID DME5QDP
DME5QDP DN TIOSPIRONE
DME5QDP HS Discontinued in Phase 3
DME5QDP SN TIOSPIRONE; tiaspirone; Tiospirone [INN]; Tiospironum [Latin]; Tiospirona [Spanish]; 87691-91-6; UNII-35C6UMO5SR; 35C6UMO5SR; CHEMBL35057; BMY-13859; Tiospironum; Tiospirona; 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-Azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-; BMY-13859-1; tiospyrone; TIOSPERONE; AC1L1JPQ; 8-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-8-azaspiro(4.5)decane-7,9-dione hydrochloride; SCHEMBL78696; GTPL101
DME5QDP DT Small molecular drug
DME5QDP PC 55752
DME5QDP MW 440.6
DME5QDP FM C24H32N4O2S
DME5QDP IC InChI=1S/C24H32N4O2S/c29-21-17-24(9-3-4-10-24)18-22(30)28(21)12-6-5-11-26-13-15-27(16-14-26)23-19-7-1-2-8-20(19)31-25-23/h1-2,7-8H,3-6,9-18H2
DME5QDP CS C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54
DME5QDP IK ZFZPJDFBJFHYIV-UHFFFAOYSA-N
DME5QDP IU 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione
DME5QDP CA CAS 87691-91-6
DM7RNPJ ID DM7RNPJ
DM7RNPJ DN Trenonacog alfa
DM7RNPJ HS Discontinued in Phase 3
DM7RNPJ SN IB-1001; IXinity; Nonacog-alfa biosimilar - Emergent BioSolutions; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - Emergent BioSolutions; Recombinant factor IX biosimilar - Inspiration
DM7RNPJ DE Discovery agent
DMOVBSF ID DMOVBSF
DMOVBSF DN Tresperimus
DMOVBSF HS Discontinued in Phase 3
DMOVBSF SN LF-08-0299
DMOVBSF CP Fournier Pharma
DMOVBSF DT Small molecular drug
DMOVBSF PC 3086680
DMOVBSF MW 387.5
DMOVBSF FM C17H37N7O3
DMOVBSF IC InChI=1S/C17H37N7O3/c18-8-7-10-21-9-5-6-13-24-17(26)27-14-15(25)22-11-3-1-2-4-12-23-16(19)20/h21H,1-14,18H2,(H,22,25)(H,24,26)(H4,19,20,23)
DMOVBSF CS C(CCCN=C(N)N)CCNC(=O)COC(=O)NCCCCNCCCN
DMOVBSF IK LVBMFPUTQOHXQE-UHFFFAOYSA-N
DMOVBSF IU [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] N-[4-(3-aminopropylamino)butyl]carbamate
DMOVBSF CA CAS 160677-67-8
DMOVBSF DE Autoimmune diabetes
DMXRU9M ID DMXRU9M
DMXRU9M DN Valspodar
DMXRU9M HS Discontinued in Phase 3
DMXRU9M CP Novartis
DMXRU9M DT Small molecular drug
DMXRU9M PC 5281884
DMXRU9M MW 1214.6
DMXRU9M FM C63H111N11O12
DMXRU9M IC InChI=1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1
DMXRU9M CS C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C
DMXRU9M IK YJDYDFNKCBANTM-QCWCSKBGSA-N
DMXRU9M IU (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(E,2R)-2-methylhex-4-enoyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMXRU9M CA CAS 121584-18-7
DMXRU9M CB CHEBI:8985
DMXRU9M DE Acute myeloid leukaemia
DMUB0EC ID DMUB0EC
DMUB0EC DN VELNACRINE
DMUB0EC HS Discontinued in Phase 3
DMUB0EC SN Velnacrine; 124027-47-0; 1-hydroxytacrine; 9-amino-1,2,3,4-tetrahydroacridin-1-ol; Velnacrine [INN:BAN]; Velnacrinum [INN-Latin]; Velnacrina [INN-Spanish]; 1-Acridinol,9-amino-1,2,3,4-tetrahydro-; 104675-29-8; 1-Acridinol, 9-amino-1,2,3,4-tetrahydro-; UNII-JFN3Z63E2C; UNII-OQL6V4U301; JFN3Z63E2C; CHEMBL51934; OQL6V4U301; HLVVITIHAZBPKB-UHFFFAOYSA-N; AK160411; Velnacrinum; Velnacrina; 112964-98-4; Velnacrine, (+)-; 9-ATHCO; 1-hydroxy-tacrine; 1-Hydroxy Tacrine; 121445-17-8; ACMC-20ddjc; Velnacrine, (-)-; Spectrum_000073; AC1Q7AWG
DMUB0EC DT Small molecular drug
DMUB0EC PC 3655
DMUB0EC MW 214.26
DMUB0EC FM C13H14N2O
DMUB0EC IC InChI=1S/C13H14N2O/c14-13-8-4-1-2-5-9(8)15-10-6-3-7-11(16)12(10)13/h1-2,4-5,11,16H,3,6-7H2,(H2,14,15)
DMUB0EC CS C1CC(C2=C(C3=CC=CC=C3N=C2C1)N)O
DMUB0EC IK HLVVITIHAZBPKB-UHFFFAOYSA-N
DMUB0EC IU 9-amino-1,2,3,4-tetrahydroacridin-1-ol
DMUB0EC CA CAS 124027-47-0
DMUB0EC CB CHEBI:91990
DMUB0EC DE Cognitive impairment
DMFJORV ID DMFJORV
DMFJORV DN Verpasep caltespen
DMFJORV HS Discontinued in Phase 3
DMFJORV CP Akela Pharma
DMFJORV DT Vaccine
DMFJORV DE Cervical Intraepithelial neoplasia
DMBRYT8 ID DMBRYT8
DMBRYT8 DN XEMILOFIBAN
DMBRYT8 HS Discontinued in Phase 3
DMBRYT8 SN Xemilofiban; Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate
DMBRYT8 DT Small molecular drug
DMBRYT8 PC 60957
DMBRYT8 MW 358.4
DMBRYT8 FM C18H22N4O4
DMBRYT8 IC InChI=1S/C18H22N4O4/c1-3-13(11-17(25)26-4-2)21-15(23)9-10-16(24)22-14-7-5-12(6-8-14)18(19)20/h1,5-8,13H,4,9-11H2,2H3,(H3,19,20)(H,21,23)(H,22,24)/t13-/m1/s1
DMBRYT8 CS CCOC(=O)C[C@@H](C#C)NC(=O)CCC(=O)NC1=CC=C(C=C1)C(=N)N
DMBRYT8 IK ZHCINJQZDFCSEL-CYBMUJFWSA-N
DMBRYT8 IU ethyl (3S)-3-[[4-(4-carbamimidoylanilino)-4-oxobutanoyl]amino]pent-4-ynoate
DMBRYT8 CA CAS 149820-74-6
DMBRYT8 DE Peripheral vascular disease; Cardiovascular disease
DM3EZ68 ID DM3EZ68
DM3EZ68 DN Y-23684
DM3EZ68 HS Discontinued in Phase 3
DM3EZ68 SN 2-(4-Chlorophenyl)-2,3,5,6-tetrahydro[1]benzothiepino[5,4-c]pyridazin-3-one 7-oxide
DM3EZ68 DT Small molecular drug
DM3EZ68 PC 195253
DM3EZ68 MW 356.8
DM3EZ68 FM C18H13ClN2O2S
DM3EZ68 IC InChI=1S/C18H13ClN2O2S/c19-13-5-7-14(8-6-13)21-17(22)11-12-9-10-24(23)16-4-2-1-3-15(16)18(12)20-21/h1-8,11H,9-10H2
DM3EZ68 CS C1CS(=O)C2=CC=CC=C2C3=NN(C(=O)C=C31)C4=CC=C(C=C4)Cl
DM3EZ68 IK WHMCSFWQVGJBGM-UHFFFAOYSA-N
DM3EZ68 IU 2-(4-chlorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one
DM3EZ68 CA CAS 118288-67-8
DM3EZ68 CB CHEBI:79404
DM3EZ68 DE Anxiety disorder
DMFEN6T ID DMFEN6T
DMFEN6T DN YM533
DMFEN6T HS Discontinued in Phase 3
DMFEN6T SN Beraprost sodium
DMFEN6T CP Astellas
DMFEN6T DT Small molecular drug
DMFEN6T PC 23676207
DMFEN6T MW 420.5
DMFEN6T FM C24H29NaO5
DMFEN6T IC InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;
DMFEN6T CS CC#CCC(C)C(/C=C/C1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+]
DMFEN6T IK YTCZZXIRLARSET-UEIGIMKUSA-M
DMFEN6T IU sodium;4-[2-hydroxy-1-[(E)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
DMFEN6T CA CAS 88475-69-8
DMFEN6T DE Chronic renal failure
DM51FVE ID DM51FVE
DM51FVE DN Zamifenacin
DM51FVE HS Discontinued in Phase 3
DM51FVE SN Zamifenacin; 127308-82-1; UNII-Y88Q418Y7M; Y88Q418Y7M; Zamifenacin [INN]; 127263-13-2; AC1MJ6I5; DSSTox_RID_82215; DSSTox_CID_27257; DSSTox_GSID_47257; SCHEMBL311829; CHEMBL27507; DTXSID9047257; UK-766542 [As Fumarate]; CHEBI:93417; ZINC3802222; BCP28100; Tox21_300210; AKOS022182209; SB19711; API0007427; UK-76654-2 [AS FUMARATE]; NCGC00247932-01; NCGC00254011-01; AJ-45652; CAS-127308-82-1; BRD-K80451230-051-01-8; (R)-3-(Diphenylmethoxy)-1-(3,4-(methylenedioxy)phenetyl)piperidene
DM51FVE DT Small molecular drug
DM51FVE PC 3086618
DM51FVE MW 415.5
DM51FVE FM C27H29NO3
DM51FVE IC InChI=1S/C27H29NO3/c1-3-8-22(9-4-1)27(23-10-5-2-6-11-23)31-24-12-7-16-28(19-24)17-15-21-13-14-25-26(18-21)30-20-29-25/h1-6,8-11,13-14,18,24,27H,7,12,15-17,19-20H2/t24-/m1/s1
DM51FVE CS C1C[C@H](CN(C1)CCC2=CC3=C(C=C2)OCO3)OC(C4=CC=CC=C4)C5=CC=CC=C5
DM51FVE IK BDNFQGRSKSQXRI-XMMPIXPASA-N
DM51FVE IU (3R)-3-benzhydryloxy-1-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine
DM51FVE CA CAS 127308-82-1
DM51FVE CB CHEBI:93417
DM51FVE DE Urinary incontinence
DMTCP8H ID DMTCP8H
DMTCP8H DN Zanapezil
DMTCP8H HS Discontinued in Phase 3
DMTCP8H SN TAK-147
DMTCP8H CP Takeda Pharmaceutical Co Ltd
DMTCP8H DT Small molecular drug
DMTCP8H PC 198752
DMTCP8H MW 376.5
DMTCP8H FM C25H32N2O
DMTCP8H IC InChI=1S/C25H32N2O/c28-25(23-11-10-22-8-4-5-15-26-24(22)18-23)12-9-20-13-16-27(17-14-20)19-21-6-2-1-3-7-21/h1-3,6-7,10-11,18,20,26H,4-5,8-9,12-17,19H2
DMTCP8H CS C1CCNC2=C(C1)C=CC(=C2)C(=O)CCC3CCN(CC3)CC4=CC=CC=C4
DMTCP8H IK PMBLXLOXUGVTGB-UHFFFAOYSA-N
DMTCP8H IU 3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propan-1-one
DMTCP8H CA CAS 142852-50-4
DMTCP8H DE Alzheimer disease
DMIK6C9 ID DMIK6C9
DMIK6C9 DN Zibotentan
DMIK6C9 HS Discontinued in Phase 3
DMIK6C9 SN ZD4054; ZD-4054; ZD4054, Zibotentan; Zibotentan (JAN/INN); Trans,trans-2(4-methoxyphenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)pyrrolidine-3-carboxylic acid; N-(3-methoxy-5-methyl-pyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
DMIK6C9 CP AstraZeneca
DMIK6C9 DT Small molecular drug
DMIK6C9 PC 9910224
DMIK6C9 MW 424.4
DMIK6C9 FM C19H16N6O4S
DMIK6C9 IC InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25)
DMIK6C9 CS CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4
DMIK6C9 IK FJHHZXWJVIEFGJ-UHFFFAOYSA-N
DMIK6C9 IU N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
DMIK6C9 CA CAS 186497-07-4
DMIK6C9 CB CHEBI:94573
DMIK6C9 DE Prostate cancer
DM6R3WC ID DM6R3WC
DM6R3WC DN BAY 86-6150
DM6R3WC HS Discontinued in Phase 2/3
DM6R3WC SN Peg rFVIIa
DM6R3WC CP Bayer HealthCare Pharmaceuticals
DM6R3WC DE Hemophilia
DMTR50E ID DMTR50E
DMTR50E DN Ilepatril
DMTR50E HS Discontinued in Phase 2/3
DMTR50E CP Sanofi-Aventis
DMTR50E PC 9824131
DMTR50E MW 432.5
DMTR50E FM C22H28N2O5S
DMTR50E IC InChI=1S/C22H28N2O5S/c1-12(2)19(30-13(3)25)20(26)23-16-11-14-7-4-5-8-15(14)17-9-6-10-18(22(28)29)24(17)21(16)27/h4-5,7-8,12,16-19H,6,9-11H2,1-3H3,(H,23,26)(H,28,29)/t16-,17+,18-,19-/m0/s1
DMTR50E CS CC(C)[C@@H](C(=O)N[C@H]1CC2=CC=CC=C2[C@H]3CCC[C@H](N3C1=O)C(=O)O)SC(=O)C
DMTR50E IK FXKFFTMLFPWYFH-RDGPPVDQSA-N
DMTR50E IU (4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-methylbutanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
DMTR50E CA CAS 473289-62-2
DMTR50E DE Diabetic nephropathy; Heart failure; Renal failure; Hypertension
DMMT4PB ID DMMT4PB
DMMT4PB DN Osanetant
DMMT4PB HS Discontinued in Phase 2b
DMMT4PB SN Osanetant [INN]; SR-142801; UNII-K7G81N94DT; SB-236984; SR-142806; SR142801; SR-14280; K7G81N94DT; CHEMBL346178; 160492-56-8; SR 142801; N-(1-(3-((R)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-N-methylacetamide; n-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide; N-(1-(3-((3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-N-methylacetamide; [3H]osanetant; Osanetant [INN]; N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide; N-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide
DMMT4PB CP Sanofi-aventis
DMMT4PB DT Small molecular drug
DMMT4PB PC 219077
DMMT4PB MW 606.6
DMMT4PB FM C35H41Cl2N3O2
DMMT4PB IC InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
DMMT4PB CS CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
DMMT4PB IK DZOJBGLFWINFBF-UMSFTDKQSA-N
DMMT4PB IU N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide
DMMT4PB CA CAS 160492-56-8
DMMT4PB DE Schizoaffective disorder; Schizophrenia; Depression
DMLQVTJ ID DMLQVTJ
DMLQVTJ DN Octopamine
DMLQVTJ HS Discontinued in Phase 2a
DMLQVTJ SN Analet; Norden; Norfen; Norphen; Norsympathol; Norsympatol; Norsynephrine; Octapamine; Octopamin; Octopamina; Octopaminum; Octopamina [Spanish]; Octopamine [INN]; Octopamine hydrochloride; Octopaminum [Latin]; Paraoxyphenyl aminoethanol; ND 50; TBB066518; WIN 5512; WV 569; Beta-hydroxytyramine; Octopamina [INN-Spanish]; Octopaminum [INN-Latin]; P-Hydroxyphenylethanolamine; P-Norsynephrin; P-Octopamine; Para-Octopamine; Alpha-Aminoethyl-4-hydroxybenzylalkohol; Alpha-(Aminoethyl)-4-hydroxybenzenemethanol; Alpha-(Aminoethyl)-p-hydroxybenzyl alcohol; Alpha-(Aminomethyl)-p-hydroxybenzyl alcohol; Alpha-(aminomethyl)-4-hydroxybenzenemethanol; 1-(p-Hydroxyphenyl)-2-aminoethanol; 4-(2-Amino-1-hydroxyethyl)phenol; 4-Octopamine
DMLQVTJ CP Sanofi-aventis
DMLQVTJ DT Small molecular drug
DMLQVTJ PC 4581
DMLQVTJ MW 153.18
DMLQVTJ FM C8H11NO2
DMLQVTJ IC InChI=1S/C8H11NO2/c9-5-8(11)6-1-3-7(10)4-2-6/h1-4,8,10-11H,5,9H2
DMLQVTJ CS C1=CC(=CC=C1C(CN)O)O
DMLQVTJ IK QHGUCRYDKWKLMG-UHFFFAOYSA-N
DMLQVTJ IU 4-(2-amino-1-hydroxyethyl)phenol
DMLQVTJ CA CAS 104-14-3
DMLQVTJ CB CHEBI:17134
DMLQVTJ DE Thrombosis
DMQV4C3 ID DMQV4C3
DMQV4C3 DN 4030W92
DMQV4C3 HS Discontinued in Phase 2
DMQV4C3 SN BW-4030W92; 5-(2,3-Dichlorophenyl)-6-(fluoromethyl)pyrimidine-2,4-diamine
DMQV4C3 DT Small molecular drug
DMQV4C3 PC 9860692
DMQV4C3 MW 287.12
DMQV4C3 FM C11H9Cl2FN4
DMQV4C3 IC InChI=1S/C11H9Cl2FN4/c12-6-3-1-2-5(9(6)13)8-7(4-14)17-11(16)18-10(8)15/h1-3H,4H2,(H4,15,16,17,18)
DMQV4C3 CS C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=C2N)N)CF
DMQV4C3 IK GKBLWFDYSYTVEA-UHFFFAOYSA-N
DMQV4C3 IU 5-(2,3-dichlorophenyl)-6-(fluoromethyl)pyrimidine-2,4-diamine
DMQV4C3 CA CAS 130801-33-1
DMQV4C3 DE Pain
DMUXMGN ID DMUXMGN
DMUXMGN DN 4991W93
DMUXMGN HS Discontinued in Phase 2
DMUXMGN SN UNII-EP9X802T0C; EP9X802T0C; 171549-56-7; SCHEMBL7838123; SCHEMBL7838126; 2-Oxazolidinone, 4-((3-(trans-3-(dimethylamino)cyclobutyl)-1H-indol-5-yl)methyl)-, (4S)-; LS-192216; 4991-W-93
DMUXMGN CP Glaxo Wellcome plc
DMUXMGN DT Small molecular drug
DMUXMGN PC 9818279
DMUXMGN MW 313.4
DMUXMGN FM C18H23N3O2
DMUXMGN IC InChI=1S/C18H23N3O2/c1-21(2)14-7-12(8-14)16-9-19-17-4-3-11(6-15(16)17)5-13-10-23-18(22)20-13/h3-4,6,9,12-14,19H,5,7-8,10H2,1-2H3,(H,20,22)/t12?,13-,14?/m0/s1
DMUXMGN CS CN(C)C1CC(C1)C2=CNC3=C2C=C(C=C3)C[C@H]4COC(=O)N4
DMUXMGN IK JLDUTSKKXXJGGG-MOKVOYLWSA-N
DMUXMGN IU (4S)-4-[[3-[3-(dimethylamino)cyclobutyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
DMUXMGN CA CAS 171549-56-7
DMUXMGN DE Migraine
DMYOG98 ID DMYOG98
DMYOG98 DN 534U87
DMYOG98 HS Discontinued in Phase 2
DMYOG98 SN Anticonvulsant, Glaxo Wellcome; BW-534U87
DMYOG98 CP Burroughs Wellcome Inc
DMYOG98 PC 22149400
DMYOG98 MW 297.69
DMYOG98 FM C12H10ClF2N5
DMYOG98 IC InChI=1S/C12H9F2N5.ClH/c13-8-2-1-3-9(14)7(8)6-19-10-4-5-16-12(15)11(10)17-18-19;/h1-5H,6H2,(H2,15,16);1H
DMYOG98 CS C1=CC(=C(C(=C1)F)CN2C3=C(C(=NC=C3)N)N=N2)F.Cl
DMYOG98 IK JKXUBXRPDZPXOD-UHFFFAOYSA-N
DMYOG98 IU 1-[(2,6-difluorophenyl)methyl]triazolo[4,5-c]pyridin-4-amine;hydrochloride
DMYOG98 CA CAS 143153-93-9
DMYOG98 DE Epileptic seizures
DMG0I6L ID DMG0I6L
DMG0I6L DN 97-139
DMG0I6L HS Discontinued in Phase 2
DMG0I6L SN S-0139; SB-737004; 737004; [4aS-(4abeta,6aalpha,6bbeta,12abeta,14bbeta]-6a-[3-[2-(3-Carboxy-2(E)-propenamido)-5-hydroxyphenyl]-2(E)-propenoyloxymethyl]-2,2,6b,9,9.12a-hexamethyl-10-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a
DMG0I6L DE Cerebrovascular disease
DMSGY5M ID DMSGY5M
DMSGY5M DN 99mTc-ciprofloxacin
DMSGY5M HS Discontinued in Phase 2
DMSGY5M SN INFECTON; Technetium-99m-ciprofloxacin; 99mTc-ciprofloxacin
DMSGY5M CP Draxis
DMSGY5M DE Infectious disease
DMEG240 ID DMEG240
DMEG240 DN A-437203
DMEG240 HS Discontinued in Phase 2
DMEG240 SN ABT-925 anhydrous free base; A-437203; 220519-06-2; UNII-E6CKI5C54O; E6CKI5C54O; CHEMBL439338; 2-((3-(4-(2-(tert-Butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)propyl)thio)pyrimidin-4(3H)-one; ABT-925 free base; SCHEMBL1043144; DTXSID70176529; BDBM50177354; HY-U00185; AKOS027334456; CS-7258; LU-201640; LU 201640; A 37203; A-37203; L018707; 4(3H)-Pyrimidinone, 2-((3-(4-(2-(1,1-dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl)-1-piperazinyl)propyl)thio)-
DMEG240 DT Small molecular drug
DMEG240 PC 9916104
DMEG240 MW 456.5
DMEG240 FM C20H27F3N6OS
DMEG240 IC InChI=1S/C20H27F3N6OS/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30)
DMEG240 CS CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCSC3=NC=CC(=O)N3)C(F)(F)F
DMEG240 IK KXVAICSRMHXLJN-UHFFFAOYSA-N
DMEG240 IU 2-[3-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]propylsulfanyl]-1H-pyrimidin-6-one
DMEG240 CA CAS 220519-06-2
DMEG240 DE Psychotic disorder
DMX56G4 ID DMX56G4
DMX56G4 DN A-5021
DMX56G4 HS Discontinued in Phase 2
DMX56G4 SN (-)-9-[1(S),2(R)-Bis(hydroxymethyl)cyclopropan-1-ylmethyl]guanine; 145512-85-2
DMX56G4 DT Small molecular drug
DMX56G4 PC 484557
DMX56G4 DE Virus infection
DMF4MRD ID DMF4MRD
DMF4MRD DN A-75925
DMF4MRD HS Discontinued in Phase 2
DMF4MRD SN A-74704; A-76928; A-77003; Protease inhibitors, Abbott
DMF4MRD CP Abbott Laboratories
DMF4MRD DT Small molecular drug
DMF4MRD PC 72290
DMF4MRD MW 766.9
DMF4MRD FM C44H54N4O8
DMF4MRD IC InChI=1S/C44H54N4O8/c1-29(2)37(47-43(53)55-27-33-21-13-7-14-22-33)41(51)45-35(25-31-17-9-5-10-18-31)39(49)40(50)36(26-32-19-11-6-12-20-32)46-42(52)38(30(3)4)48-44(54)56-28-34-23-15-8-16-24-34/h5-24,29-30,35-40,49-50H,25-28H2,1-4H3,(H,45,51)(H,46,52)(H,47,53)(H,48,54)/t35-,36-,37-,38-,39+,40+/m0/s1
DMF4MRD CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H]([C@@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)OCC3=CC=CC=C3)O)O)NC(=O)OCC4=CC=CC=C4
DMF4MRD IK TZRRVSCDIPHXHN-RRUVMKMCSA-N
DMF4MRD IU benzyl N-[(2S)-1-[[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMF4MRD CA CAS 129467-48-7
DMF4MRD DE Virus infection
DM7VSBH ID DM7VSBH
DM7VSBH DN A-86719.1
DM7VSBH HS Discontinued in Phase 2
DM7VSBH SN ABT-719; AC1OCF8N; A-86719.1; 8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid hydrate hydrochloride
DM7VSBH CP Abbott Laboratories
DM7VSBH DT Small molecular drug
DM7VSBH PC 6918280
DM7VSBH MW 399.8
DM7VSBH FM C18H23ClFN3O4
DM7VSBH IC InChI=1S/C18H20FN3O3.ClH.H2O/c1-9-15-12(10-2-3-10)6-13(18(24)25)17(23)22(15)8-14(19)16(9)21-5-4-11(20)7-21;;/h6,8,10-11H,2-5,7,20H2,1H3,(H,24,25);1H;1H2/t11-;;/m0../s1
DM7VSBH CS CC1=C(C(=CN2C1=C(C=C(C2=O)C(=O)O)C3CC3)F)N4CC[C@@H](C4)N.O.Cl
DM7VSBH IK HOXFHPNUPIUHBB-IDMXKUIJSA-N
DM7VSBH IU 8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid;hydrate;hydrochloride
DM7VSBH DE Bacterial infection
DMB5TH3 ID DMB5TH3
DMB5TH3 DN AA-193
DMB5TH3 HS Discontinued in Phase 2
DMB5TH3 SN AA-193; 107804-48-8; Furo[2,3-g]-1,2-benzisoxazole-7-carboxylicacid, 5-chloro-7,8-dihydro-3-phenyl-; AC1OCEWV; ACMC-20mb6x; CHEMBL93997; SCHEMBL10512834; CTK0H6407; AKOS030601198; 5-chloro-3-phenyl-7,8-dihydrofuro[2,3-g][1,2]benzoxazole-7-carboxylic acid
DMB5TH3 CP Chugai Pharmaceutical Co Ltd
DMB5TH3 DT Small molecular drug
DMB5TH3 PC 6918012
DMB5TH3 MW 315.71
DMB5TH3 FM C16H10ClNO4
DMB5TH3 IC InChI=1S/C16H10ClNO4/c17-11-6-9-13(8-4-2-1-3-5-8)18-22-14(9)10-7-12(16(19)20)21-15(10)11/h1-6,12H,7H2,(H,19,20)
DMB5TH3 CS C1C(OC2=C(C=C3C(=C21)ON=C3C4=CC=CC=C4)Cl)C(=O)O
DMB5TH3 IK RVKIPRIYUGLRFF-UHFFFAOYSA-N
DMB5TH3 IU 5-chloro-3-phenyl-7,8-dihydrofuro[2,3-g][1,2]benzoxazole-7-carboxylic acid
DMB5TH3 DE Hyperuricaemia
DM78623 ID DM78623
DM78623 DN AA-2379
DM78623 HS Discontinued in Phase 2
DM78623 SN 7-Butyl-3-(methylamino)-4,6-dioxo-5-propyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidine-2-carboxylic acid methyl ester
DM78623 DT Small molecular drug
DM78623 PC 128390
DM78623 MW 337.37
DM78623 FM C15H23N5O4
DM78623 IC InChI=1S/C15H23N5O4/c1-5-7-9-18-12-10(13(21)19(8-6-2)14(18)22)11(16-3)20(17-12)15(23)24-4/h16H,5-9H2,1-4H3
DM78623 CS CCCCN1C2=NN(C(=C2C(=O)N(C1=O)CCC)NC)C(=O)OC
DM78623 IK AKJPAUXGPOUISG-UHFFFAOYSA-N
DM78623 IU methyl 7-butyl-3-(methylamino)-4,6-dioxo-5-propylpyrazolo[3,4-d]pyrimidine-2-carboxylate
DM78623 CA CAS 103446-98-6
DM78623 DE Inflammation
DM8DT7U ID DM8DT7U
DM8DT7U DN ABT-089
DM8DT7U HS Discontinued in Phase 2
DM8DT7U SN Pozanicline; A 94224; ABT 089; Pozanicline (USAN); (R)-2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine; 2-Methyl-3-(2-pyrrolidinylmethoxy)pyridine; 2-Methyl-3-(2S-pyrrolidinylmethoxy)pyridine; 2-methyl-3-[[(2R)-pyrrolidin-2-yl]methoxy]pyridine; 2-methyl-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine
DM8DT7U CP Abbott Laboratories
DM8DT7U DT Small molecular drug
DM8DT7U PC 178052
DM8DT7U MW 192.26
DM8DT7U FM C11H16N2O
DM8DT7U IC InChI=1S/C11H16N2O/c1-9-11(5-3-6-12-9)14-8-10-4-2-7-13-10/h3,5-6,10,13H,2,4,7-8H2,1H3/t10-/m0/s1
DM8DT7U CS CC1=C(C=CC=N1)OC[C@@H]2CCCN2
DM8DT7U IK YRVIKLBSVVNSHF-JTQLQIEISA-N
DM8DT7U IU 2-methyl-3-[[(2S)-pyrrolidin-2-yl]methoxy]pyridine
DM8DT7U CA CAS 161417-03-4
DM8DT7U DE Dementia; Anxiety disorder; Schizophrenia; Attention deficit hyperactivity disorder
DMNP72I ID DMNP72I
DMNP72I DN ABT-418
DMNP72I HS Discontinued in Phase 2
DMNP72I SN Abt-418; Abt 418; 147402-53-7; 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; CHEMBL274525; (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; (S)-3-methyl-5-(1-methylpyrrolidin-2-yl)isoxazole; C9H14N2O; Isoxazole, 3-methyl-5-((2S)-1-methyl-2-pyrrolidinyl)-; Isoxazole, 3-methyl-5-(1-methyl-2-pyrrolidinyl)-, (S)-; Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-; 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole; AC1L3OPH; SCHEMBL194161; DTXSID10163711; ILLGYRJAYAAAEW-QMMMGPOBSA-N; ZINC3786099; BDBM50035398
DMNP72I DT Small molecular drug
DMNP72I PC 119380
DMNP72I MW 166.22
DMNP72I FM C9H14N2O
DMNP72I IC InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1
DMNP72I CS CC1=NOC(=C1)[C@@H]2CCCN2C
DMNP72I IK ILLGYRJAYAAAEW-QMMMGPOBSA-N
DMNP72I IU 3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
DMNP72I CA CAS 147402-53-7
DMNP72I DE Alzheimer disease
DMGMBCW ID DMGMBCW
DMGMBCW DN ABT-594
DMGMBCW HS Discontinued in Phase 2
DMGMBCW SN Tebanicline; ABT-594; 198283-73-7; Tebanicline [INN]; UNII-9KX8NKV538; CHEMBL430497; ABT594; 9KX8NKV538; (R)-5-(2-Azetidnylmethoxy)-2-chloropyridine; 5-((2R)-Azetidinylmethoxy)-2-chloropyridine; Pyridine, 5-(2-azetidnylmethoxy)-2-chloro-, (R)-; (R)-5-(azetidin-2-ylmethoxy)-2-chloropyridine; 5-[[(2R)-azetidin-2-yl]methoxy]-2-chloropyridine; Ebanicline; TEBENICILINE; AC1MIP4S; Tebanicline(ABT-594); SCHEMBL120178; GTPL3989; DTXSID90173555; MolPort-044-727-781; MKTAGSRKQIGEBH-SSDOTTSWSA-N; EX-A2483; BCP19181; ZINC3959783; BDBM50062641
DMGMBCW DT Small molecular drug
DMGMBCW PC 3075702
DMGMBCW MW 198.65
DMGMBCW FM C9H11ClN2O
DMGMBCW IC InChI=1S/C9H11ClN2O/c10-9-2-1-8(5-12-9)13-6-7-3-4-11-7/h1-2,5,7,11H,3-4,6H2/t7-/m1/s1
DMGMBCW CS C1CN[C@H]1COC2=CN=C(C=C2)Cl
DMGMBCW IK MKTAGSRKQIGEBH-SSDOTTSWSA-N
DMGMBCW IU 5-[[(2R)-azetidin-2-yl]methoxy]-2-chloropyridine
DMGMBCW CA CAS 198283-73-7
DMDQVY4 ID DMDQVY4
DMDQVY4 DN ABT-724
DMDQVY4 HS Discontinued in Phase 2
DMDQVY4 SN 2-[4-(2-Pyridyl)piperazin-1-ylmethyl]-1H-benzimidazole maleate
DMDQVY4 DT Small molecular drug
DMDQVY4 PC 5025739
DMDQVY4 MW 293.4
DMDQVY4 FM C17H19N5
DMDQVY4 IC InChI=1S/C17H19N5/c1-2-6-15-14(5-1)19-16(20-15)13-21-9-11-22(12-10-21)17-7-3-4-8-18-17/h1-8H,9-13H2,(H,19,20)
DMDQVY4 CS C1CN(CCN1CC2=NC3=CC=CC=C3N2)C4=CC=CC=N4
DMDQVY4 IK FRPJGTNLZNXQEX-UHFFFAOYSA-N
DMDQVY4 IU 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole
DMDQVY4 CA CAS 70006-24-5
DMDQVY4 CB CHEBI:104134
DMDQVY4 DE Erectile dysfunction
DMM02XV ID DMM02XV
DMM02XV DN AD-5467
DMM02XV HS Discontinued in Phase 2
DMM02XV SN Rac-2,8-Bis(1-methylethyl)-3-thioxo-2,3-dihydro-4H-1,4-benzoxazine-4-acetic acid
DMM02XV DT Small molecular drug
DMM02XV PC 197383
DMM02XV MW 307.4
DMM02XV FM C16H21NO3S
DMM02XV IC InChI=1S/C16H21NO3S/c1-9(2)11-6-5-7-12-15(11)20-14(10(3)4)16(21)17(12)8-13(18)19/h5-7,9-10,14H,8H2,1-4H3,(H,18,19)
DMM02XV CS CC(C)C1C(=S)N(C2=CC=CC(=C2O1)C(C)C)CC(=O)O
DMM02XV IK CLDJCRWXLDLJLO-UHFFFAOYSA-N
DMM02XV IU 2-[2,8-di(propan-2-yl)-3-sulfanylidene-1,4-benzoxazin-4-yl]acetic acid
DMM02XV CA CAS 112808-22-7
DMM02XV DE Diabetic complication
DMTOCV7 ID DMTOCV7
DMTOCV7 DN Adaprolol maleate-SME
DMTOCV7 HS Discontinued in Phase 2
DMTOCV7 SN Adaprolol; Adaprolol maleate; CDDD-2803; HGP-2; Submicron Emulsion, Pharmos; Adaprolol maleate-SME, Pharmos
DMTOCV7 CP Pharmos Corp
DMTOCV7 DE Glaucoma/ocular hypertension
DMMKFUP ID DMMKFUP
DMMKFUP DN Adatanserin
DMMKFUP HS Discontinued in Phase 2
DMMKFUP SN Adatanserin [INN]; WY 50324; N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
DMMKFUP CP Wyeth
DMMKFUP DT Small molecular drug
DMMKFUP PC 130918
DMMKFUP MW 369.5
DMMKFUP FM C21H31N5O
DMMKFUP IC InChI=1S/C21H31N5O/c27-19(21-13-16-10-17(14-21)12-18(11-16)15-21)22-4-5-25-6-8-26(9-7-25)20-23-2-1-3-24-20/h1-3,16-18H,4-15H2,(H,22,27)
DMMKFUP CS C1CN(CCN1CCNC(=O)C23CC4CC(C2)CC(C4)C3)C5=NC=CC=N5
DMMKFUP IK HPFLVTSWRFCPCV-UHFFFAOYSA-N
DMMKFUP IU N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
DMMKFUP CA CAS 127266-56-2
DMMKFUP DE Mood disorder
DMPFQLX ID DMPFQLX
DMPFQLX DN ADL 10-0101
DMPFQLX HS Discontinued in Phase 2
DMPFQLX CP Adolor
DMPFQLX DE Pain
DMQM54P ID DMQM54P
DMQM54P DN ADL-5945
DMQM54P HS Discontinued in Phase 2
DMQM54P SN OpRA III
DMQM54P CP Eli Lilly & Co
DMQM54P DE Constipation
DMJ8ZFR ID DMJ8ZFR
DMJ8ZFR DN ADOZELESIN
DMJ8ZFR HS Discontinued in Phase 2
DMJ8ZFR SN Adosar; Adozelesin < Rec INN; U-73975; (7bR,8aS)-N-[2-[(1,2,4,5,8,8a-Hexahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2-yl)carbonyl]-1H-indol-5-yl]-2-benzofurancarboxamide
DMJ8ZFR DT Small molecular drug
DMJ8ZFR PC 6917987
DMJ8ZFR MW 502.5
DMJ8ZFR FM C30H22N4O4
DMJ8ZFR IC InChI=1S/C30H22N4O4/c1-15-13-31-27-22(35)11-25-30(26(15)27)12-18(30)14-34(25)29(37)21-9-17-8-19(6-7-20(17)33-21)32-28(36)24-10-16-4-2-3-5-23(16)38-24/h2-11,13,18,31,33H,12,14H2,1H3,(H,32,36)/t18-,30+/m1/s1
DMJ8ZFR CS CC1=CNC2=C1[C@@]34C[C@@H]3CN(C4=CC2=O)C(=O)C5=CC6=C(N5)C=CC(=C6)NC(=O)C7=CC8=CC=CC=C8O7
DMJ8ZFR IK BYRVKDUQDLJUBX-JJCDCTGGSA-N
DMJ8ZFR IU N-[2-[(1R,12S)-3-methyl-7-oxo-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),3,8-triene-10-carbonyl]-1H-indol-5-yl]-1-benzofuran-2-carboxamide
DMJ8ZFR CA CAS 110314-48-2
DMJ8ZFR DE Solid tumour/cancer
DMS8JIU ID DMS8JIU
DMS8JIU DN ADROGOLIDE HYDROCHLORIDE
DMS8JIU HS Discontinued in Phase 2
DMS8JIU SN ABT-431; Adrogolide hydrochloride < USAN; DAS-431; A-93431.1; 9,10-Diacetoxy-2-propyl-4,5,5a(R),6,7,11b(S)-hexahydrobenzo[f]thieno[2,3-c]quinoline hydrochloride
DMS8JIU DT Small molecular drug
DMS8JIU PC 6918298
DMS8JIU MW 436
DMS8JIU FM C22H26ClNO4S
DMS8JIU IC InChI=1S/C22H25NO4S.ClH/c1-4-5-15-9-17-21(28-15)11-23-18-7-6-14-8-19(26-12(2)24)20(27-13(3)25)10-16(14)22(17)18;/h8-10,18,22-23H,4-7,11H2,1-3H3;1H/t18-,22+;/m1./s1
DMS8JIU CS CCCC1=CC2=C(S1)CN[C@H]3[C@H]2C4=CC(=C(C=C4CC3)OC(=O)C)OC(=O)C.Cl
DMS8JIU IK NPEZSCRKHFTLPE-MYXGOWFTSA-N
DMS8JIU IU [(1S,10R)-4-acetyloxy-15-propyl-14-thia-11-azatetracyclo[8.7.0.02,7.013,17]heptadeca-2,4,6,13(17),15-pentaen-5-yl] acetate;hydrochloride
DMS8JIU CA CAS 166591-11-3
DMS8JIU DE Cognitive impairment
DMZS2M4 ID DMZS2M4
DMZS2M4 DN ADX-10061
DMZS2M4 HS Discontinued in Phase 2
DMZS2M4 SN CEE-310; NNC-687; NO-687; CEE-03-310; NNC-01-0687; NNC-01-687
DMZS2M4 CP Addex Pharmaceuticals; Novo Nordisk A/S
DMZS2M4 DE Psychotic disorder
DMZ7WKN ID DMZ7WKN
DMZ7WKN DN Adyvia
DMZ7WKN HS Discontinued in Phase 2
DMZ7WKN SN ID 1101
DMZ7WKN CP Innodia
DMZ7WKN DT Small molecular drug
DMZ7WKN PC 6918732
DMZ7WKN MW 147.17
DMZ7WKN FM C6H13NO3
DMZ7WKN IC InChI=1S/C6H13NO3/c1-3(4(2)8)5(7)6(9)10/h3-5,8H,7H2,1-2H3,(H,9,10)/t3-,4-,5-/m0/s1
DMZ7WKN CS C[C@@H]([C@H](C)O)[C@@H](C(=O)O)N
DMZ7WKN IK OSCCDBFHNMXNME-YUPRTTJUSA-N
DMZ7WKN IU (2S,3R,4S)-2-amino-4-hydroxy-3-methylpentanoic acid
DMZ7WKN CA CAS 55399-93-4
DMZ7WKN CB CHEBI:78247
DMZ7WKN DE Type-2 diabetes
DMRWSKX ID DMRWSKX
DMRWSKX DN Afegostat
DMRWSKX HS Discontinued in Phase 2
DMRWSKX SN Isofagomine; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL; 169105-89-9; iso-Fagomine; D-Isofagomine; UNII-G23AP190YS; 5-HYDROXYMETHYL-3,4-DIHYDROXYPIPERIDINE; CHEMBL206468; G23AP190YS; IFM; 5-Hydroxymethyl-3,4-piperidinediol; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL HYDROCHLORIDE; Afegostat [USAN:INN]; 1oif; Afegostat (USAN/INN); SCHEMBL581577; GTPL7410; 3,4-piperidinediol, 5-(hydroxymethyl)-, (3R,4R,5R)-; DTXSID20168651; 5-Hydroxymethylpiperidine-3,4-diol; ZINC3813668; BDBM50182801; AKOS006348872; DB04545; HY-14829; CS-0003581; D09576; Q21396373; (3R,4R,5R)-5-(Hydroxymethyl)piperidine-3,4-diol, 8; Afegostat; isofagomine; (3R,4R,5R)-5-(HYDROXYMETHYL)PIPERIDINE-3,4-DIOL
DMRWSKX CP Amicus Therapeutics
DMRWSKX DT Small molecular drug
DMRWSKX PC 447607
DMRWSKX MW 147.17
DMRWSKX FM C6H13NO3
DMRWSKX IC InChI=1S/C6H13NO3/c8-3-4-1-7-2-5(9)6(4)10/h4-10H,1-3H2/t4-,5-,6-/m1/s1
DMRWSKX CS C1[C@@H]([C@H]([C@@H](CN1)O)O)CO
DMRWSKX IK QPYJXFZUIJOGNX-HSUXUTPPSA-N
DMRWSKX IU (3R,4R,5R)-5-(hydroxymethyl)piperidine-3,4-diol
DMRWSKX CA CAS 169105-89-9
DMRWSKX DE Gaucher disease
DMSF5VK ID DMSF5VK
DMSF5VK DN Affitope AD-02
DMSF5VK HS Discontinued in Phase 2
DMSF5VK SN Alzheimer's disease vaccine 2 (AFFITOPE), AFFiRiS; Alzheimer's disease vaccine 2 (AFFITOPE), GlaxoSmithKline Biologicals
DMSF5VK CP AFFiRiS AG
DMSF5VK DT Vaccine
DMSF5VK DE Alzheimer disease
DM497SK ID DM497SK
DM497SK DN Agatolimod
DM497SK HS Discontinued in Phase 2
DM497SK CP Pfizer
DM497SK DE Lung cancer
DMZRW5E ID DMZRW5E
DMZRW5E DN AGN211745
DMZRW5E HS Discontinued in Phase 2
DMZRW5E CP Allergan
DMZRW5E TC siRNA
DMZRW5E DT siRNA drug
DMZRW5E DE Choroidal neovascularization
DME6OXB ID DME6OXB
DME6OXB DN AKL-0707
DME6OXB HS Discontinued in Phase 2
DME6OXB SN Akela GHRH; LAB GHRH; GHRH analog, Akela; Malnutrition therapy, LAB International
DME6OXB CP Akela Pharma Inc
DME6OXB DE Lipodystrophy
DM6IPWN ID DM6IPWN
DM6IPWN DN AKP-020
DM6IPWN HS Discontinued in Phase 2
DM6IPWN SN BEOV; Bis(ethylmaltolato)oxovanadium IV; Insulin enhancer (oral, type 2 diabetes), Akesis Pharmaceuticals
DM6IPWN CP Akesis Pharmaceuticals
DM6IPWN DE Type-2 diabetes
DMT5KBF ID DMT5KBF
DMT5KBF DN ALNESPIRONE
DMT5KBF HS Discontinued in Phase 2
DMT5KBF SN S-20499; Alnespirone; (+)-(S)-N-[4-[(5-Methoxy-3-chromanyl)propylamino]butyl]-1,1-cyclopentanediacetimide; (S)-(+)-8-[4-[N-(5-Methoxy-3,4-dihydro-2H-benzo[b]pyran-3-yl)-N-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione
DMT5KBF DT Small molecular drug
DMT5KBF PC 178132
DMT5KBF MW 442.6
DMT5KBF FM C26H38N2O4
DMT5KBF IC InChI=1S/C26H38N2O4/c1-3-13-27(20-16-21-22(31-2)9-8-10-23(21)32-19-20)14-6-7-15-28-24(29)17-26(18-25(28)30)11-4-5-12-26/h8-10,20H,3-7,11-19H2,1-2H3/t20-/m0/s1
DMT5KBF CS CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@H]3CC4=C(C=CC=C4OC)OC3
DMT5KBF IK DLLULNTXJPATBC-FQEVSTJZSA-N
DMT5KBF IU 8-[4-[[(3S)-5-methoxy-3,4-dihydro-2H-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione
DMT5KBF CA CAS 138298-79-0
DMT5KBF DE Anxiety disorder
DMIKLRN ID DMIKLRN
DMIKLRN DN ALPRENOXIME HYDROCHLORIDE
DMIKLRN HS Discontinued in Phase 2
DMIKLRN SN CDDD-1815; HGP-5; Alprenoxime hydrochloride; 1-(2-Allylphenoxy)-3-(isopropylamino)-2-propanone oxime monohydrochloride; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-2-propanone oxime monohydrochloride
DMIKLRN DT Small molecular drug
DMIKLRN PC 60729
DMIKLRN MW 298.81
DMIKLRN FM C15H23ClN2O2
DMIKLRN IC InChI=1S/C15H22N2O2.ClH/c1-4-7-13-8-5-6-9-15(13)19-11-14(17-18)10-16-12(2)3;/h4-6,8-9,12,16,18H,1,7,10-11H2,2-3H3;1H
DMIKLRN CS CC(C)NCC(=NO)COC1=CC=CC=C1CC=C.Cl
DMIKLRN IK ZFLRDGZJSCQDSR-UHFFFAOYSA-N
DMIKLRN IU N-[1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ylidene]hydroxylamine;hydrochloride
DMIKLRN CA CAS 121009-30-1
DMIKLRN DE Glaucoma/ocular hypertension
DMIAXCZ ID DMIAXCZ
DMIAXCZ DN Alrestatin
DMIAXCZ HS Discontinued in Phase 2
DMIAXCZ SN alrestatin; 51411-04-2; Alrestatine; Alrestatin [INN]; Alrestatinum [INN-Latin]; Alrestatine [INN-French]; Alrestatino [INN-Spanish]; UNII-515DHK15LG; Spectrum_001449; Tocris-0485; (1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-acetic acid; (1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetic acid; NSC 299132; BRN 0244370; AY 22284; CHEMBL63055; 515DHK15LG; NSC299132; 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-acetic acid; 1H-Benz[de]isoquinoline-2(3H)-aceticacid, 1,3-dioxo-; NCGC00024613-01
DMIAXCZ DT Small molecular drug
DMIAXCZ PC 2120
DMIAXCZ MW 255.22
DMIAXCZ FM C14H9NO4
DMIAXCZ IC InChI=1S/C14H9NO4/c16-11(17)7-15-13(18)9-5-1-3-8-4-2-6-10(12(8)9)14(15)19/h1-6H,7H2,(H,16,17)
DMIAXCZ CS C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CC(=O)O
DMIAXCZ IK GCUCIFQCGJIRNT-UHFFFAOYSA-N
DMIAXCZ IU 2-(1,3-dioxobenzo[de]isoquinolin-2-yl)acetic acid
DMIAXCZ CA CAS 51411-04-2
DMEKHX0 ID DMEKHX0
DMEKHX0 DN ALS 2-0426
DMEKHX0 HS Discontinued in Phase 2
DMEKHX0 CP Alantos Pharmaceuticals
DMEKHX0 DE Type-2 diabetes
DMAQNBW ID DMAQNBW
DMAQNBW DN AM103
DMAQNBW HS Discontinued in Phase 2
DMAQNBW CP Amira Pharma.
DMAQNBW DT Small molecular drug
DMAQNBW PC 56603665
DMAQNBW DE Cardiovascular disease
DMF8KH7 ID DMF8KH7
DMF8KH7 DN AM336
DMF8KH7 HS Discontinued in Phase 2
DMF8KH7 SN Leconotide; Leconotide [INN]; Omega conotoxin CVID; Omega-conopeptide CVID; UNII-2P1P5JB93S; 2P1P5JB93S; 247207-64-3; 247207-83-6
DMF8KH7 TC Analgesics
DMF8KH7 DT Small molecular drug
DMF8KH7 PC 16132255
DMF8KH7 MW 2756.3
DMF8KH7 FM C107H179N35O36S7
DMF8KH7 IC InChI=1S/C107H179N35O36S7/c1-51(2)33-64(129-91(163)62(20-11-15-30-111)127-100(172)71(44-147)135-103(175)73(47-181)137-93(165)60(18-9-13-28-109)124-85(157)53(5)121-77(150)36-117-87(159)58(17-8-12-27-108)126-99(171)70(43-146)134-92(164)61(19-10-14-29-110)125-86(158)57(112)45-179)95(167)128-63(26-32-185-7)94(166)130-65(34-55-22-24-56(149)25-23-55)96(168)131-66(35-81(154)155)97(169)138-76(50-184)104(176)140-75(49-183)102(174)133-67(40-143)88(160)118-37-79(152)123-69(42-145)98(170)139-74(48-182)101(173)132-68(41-144)89(161)119-39-80(153)141-83(54(6)148)106(178)142-82(52(3)4)105(177)120-38-78(151)122-59(21-16-31-116-107(114)115)90(162)136-72(46-180)84(113)156/h22-25,46,48-49,51-54,57-76,82-83,143-149,179,181,184H,8-21,26-45,47,50,108-112H2,1-7H3,(H2,113,156)(H,117,159)(H,118,160)(H,119,161)(H,120,177)(H,121,150)(H,122,151)(H,123,152)(H,124,157)(H,125,158)(H,126,171)(H,127,172)(H,128,167)(H,129,163)(H,130,166)(H,131,168)(H,132,173)(H,133,174)(H,134,164)(H,135,175)(H,136,162)(H,137,165)(H,138,169)(H,139,170)(H,140,176)(H,141,153)(H,142,178)(H,154,155)(H4,114,115,116)/t53-,54+,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-,83-/m0/s1
DMF8KH7 CS C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C=S)C(=O)N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C=S)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C=S)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)O
DMF8KH7 IK HBMCYCKNGADUQP-CFIKXUEXSA-N
DMF8KH7 IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[2-[[(2S,3R)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylidenepropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylidenepropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylidenepropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-oxobutanoic acid
DMF8KH7 CA CAS 247207-64-3
DMF8KH7 DE Pain
DMA57O4 ID DMA57O4
DMA57O4 DN Ambasilide
DMA57O4 HS Discontinued in Phase 2
DMA57O4 SN LU-47110
DMA57O4 CP BASF AG
DMA57O4 DT Small molecular drug
DMA57O4 PC 71270
DMA57O4 MW 335.4
DMA57O4 FM C21H25N3O
DMA57O4 IC InChI=1S/C21H25N3O/c22-20-8-6-19(7-9-20)21(25)24-14-17-10-18(15-24)13-23(12-17)11-16-4-2-1-3-5-16/h1-9,17-18H,10-15,22H2
DMA57O4 CS C1C2CN(CC1CN(C2)C(=O)C3=CC=C(C=C3)N)CC4=CC=CC=C4
DMA57O4 IK DLNAKYFPFYUBDR-UHFFFAOYSA-N
DMA57O4 IU (4-aminophenyl)-(7-benzyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone
DMA57O4 CA CAS 83991-25-7
DMA57O4 DE Cardiac arrhythmias
DMRY9V8 ID DMRY9V8
DMRY9V8 DN AMESERGIDE
DMRY9V8 HS Discontinued in Phase 2
DMRY9V8 SN Amesergide < Rec INN; LY-237733; N-Cyclohexyl-1-isopropyl-6-methylergoline-8beta-carboxamide; N-Cyclohexyl-4-isopropyl-7-methyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[4,3-fg]quinoline-9beta-carboxamide
DMRY9V8 DT Small molecular drug
DMRY9V8 PC 9821951
DMRY9V8 MW 393.6
DMRY9V8 FM C25H35N3O
DMRY9V8 IC InChI=1S/C25H35N3O/c1-16(2)28-15-17-13-23-21(20-10-7-11-22(28)24(17)20)12-18(14-27(23)3)25(29)26-19-8-5-4-6-9-19/h7,10-11,15-16,18-19,21,23H,4-6,8-9,12-14H2,1-3H3,(H,26,29)/t18-,21-,23-/m1/s1
DMRY9V8 CS CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)NC4CCCCC4)C5=C2C1=CC=C5
DMRY9V8 IK KEMOOQHMCGCZKH-JMUQELJHSA-N
DMRY9V8 IU (6aR,9R,10aR)-N-cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
DMRY9V8 CA CAS 121588-75-8
DMRY9V8 DE Mood disorder
DMMUS8X ID DMMUS8X
DMMUS8X DN AMG 108
DMMUS8X HS Discontinued in Phase 2
DMMUS8X CP Amgen
DMMUS8X DT Small molecular drug
DMMUS8X PC 444499
DMMUS8X DE Rheumatoid arthritis
DM4RFT8 ID DM4RFT8
DM4RFT8 DN Amifloxacin
DM4RFT8 HS Discontinued in Phase 2
DM4RFT8 SN AMIFLOXACIN; 86393-37-5; UNII-5TU5227KYQ; Win49375; WIN-49375; 5TU5227KYQ; 6-Fluoro-1,4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; Amifloxacino; Amifloxacine; Amifloxacinum; Win-493753; Amifloxacinum [Latin]; Amifloxacine [French]; Amifloxacino [Spanish]; Amifloxacin [USAN:INN:BAN]; Win 49375; EINECS 289-231-8; Amifloxacin (USAN/INN); CHEMBL6231; SCHEMBL48001; ZINC917; AC1L1J77; CTK3E8601; DTXSID20235519; Win 49,375; RUXPNBWPIRDVTH-UHFFFAOYSA-N; HY-U00221; AKOS030530713; CS-7366; FT-0711169
DM4RFT8 DT Small molecular drug
DM4RFT8 PC 55492
DM4RFT8 MW 334.35
DM4RFT8 FM C16H19FN4O3
DM4RFT8 IC InChI=1S/C16H19FN4O3/c1-18-21-9-11(16(23)24)15(22)10-7-12(17)14(8-13(10)21)20-5-3-19(2)4-6-20/h7-9,18H,3-6H2,1-2H3,(H,23,24)
DM4RFT8 CS CNN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
DM4RFT8 IK RUXPNBWPIRDVTH-UHFFFAOYSA-N
DM4RFT8 IU 6-fluoro-1-(methylamino)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
DM4RFT8 CA CAS 86393-37-5
DMGL0Q2 ID DMGL0Q2
DMGL0Q2 DN AN-9
DMGL0Q2 HS Discontinued in Phase 2
DMGL0Q2 SN Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE
DMGL0Q2 CP Anacor Pharma.
DMGL0Q2 DT Small molecular drug
DMGL0Q2 PC 60748
DMGL0Q2 MW 202.25
DMGL0Q2 FM C10H18O4
DMGL0Q2 IC InChI=1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3
DMGL0Q2 CS CCCC(=O)OCOC(=O)C(C)(C)C
DMGL0Q2 IK GYKLFBYWXZYSOW-UHFFFAOYSA-N
DMGL0Q2 IU butanoyloxymethyl 2,2-dimethylpropanoate
DMGL0Q2 CA CAS 122110-53-6
DMGL0Q2 DE Melanoma
DMBQLS5 ID DMBQLS5
DMBQLS5 DN Angiozyme
DMBQLS5 HS Discontinued in Phase 2
DMBQLS5 SN RPI-4610; Ribozyme (VEGFr), Ribozyme/Chiron; Ribozyme (VEGFr), Sirna/Chiron
DMBQLS5 CP Sirna Therapeutics Inc
DMBQLS5 DE Solid tumour/cancer
DMEO6PR ID DMEO6PR
DMEO6PR DN Antide
DMEO6PR HS Discontinued in Phase 2
DMEO6PR SN GnRH antagonist, Serono; GnRHA, Serono; Iturelix nanospheres, Serono; ORF-23541; Iturelix (nanospheres encapsulated), Serono; Nal-Lys-GnRH
DMEO6PR CP Merck Serono SA
DMEO6PR DT Small molecular drug
DMEO6PR PC 16130938
DMEO6PR MW 1591.3
DMEO6PR FM C82H108ClN17O14
DMEO6PR IC InChI=1S/C82H108ClN17O14/c1-50(2)41-65(76(108)95-64(26-11-12-37-88-51(3)4)82(114)100-40-18-27-70(100)81(113)91-52(5)71(84)103)96-75(107)63(25-10-14-39-90-73(105)60-23-17-36-87-48-60)93-74(106)62(24-9-13-38-89-72(104)59-22-16-35-86-47-59)94-80(112)69(49-101)99-79(111)68(45-56-19-15-34-85-46-56)98-78(110)67(43-54-29-32-61(83)33-30-54)97-77(109)66(92-53(6)102)44-55-28-31-57-20-7-8-21-58(57)42-55/h7-8,15-17,19-23,28-36,42,46-48,50-52,62-70,88,101H,9-14,18,24-27,37-41,43-45,49H2,1-6H3,(H2,84,103)(H,89,104)(H,90,105)(H,91,113)(H,92,102)(H,93,106)(H,94,112)(H,95,108)(H,96,107)(H,97,109)(H,98,110)(H,99,111)/t52-,62+,63-,64+,65+,66-,67-,68-,69+,70+/m1/s1
DMEO6PR CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)C2=CN=CC=C2)NC(=O)[C@H](CCCCNC(=O)C3=CN=CC=C3)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMEO6PR IK QRYFGTULTGLGHU-NBERXCRTSA-N
DMEO6PR IU N-[(5R)-5-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-(pyridine-3-carbonylamino)hexanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-6-oxohexyl]pyridine-3-carboxamide
DMEO6PR CA CAS 112568-12-4
DMEO6PR DE Prostate hyperplasia
DMGDPSI ID DMGDPSI
DMGDPSI DN AOD-9604
DMGDPSI HS Discontinued in Phase 2
DMGDPSI SN AOD 9604; AOD9604; Human GH (hGH) lipolytic fragment; Tyr-somatostatin (177-191)
DMGDPSI CP Monash University/Metabolic Pharmaceuticals
DMGDPSI DT Small molecular drug
DMGDPSI PC 16131447
DMGDPSI MW 1817.1
DMGDPSI FM C78H125N23O23S2
DMGDPSI IC InChI=1S/C78H125N23O23S2/c1-9-41(8)62(101-68(115)47(18-14-28-86-78(83)84)91-63(110)45(79)29-38(2)3)75(122)100-61(40(6)7)74(121)94-49(23-25-56(80)105)67(114)98-55(37-126)72(119)92-46(17-13-27-85-77(81)82)66(113)96-53(35-103)71(118)99-60(39(4)5)73(120)93-48(24-26-59(108)109)64(111)87-33-58(107)90-52(34-102)70(117)97-54(36-125)65(112)88-32-57(106)89-50(30-42-15-11-10-12-16-42)69(116)95-51(76(123)124)31-43-19-21-44(104)22-20-43/h10-12,15-16,19-22,38-41,45-55,60-62,102-104,125-126H,9,13-14,17-18,23-37,79H2,1-8H3,(H2,80,105)(H,87,111)(H,88,112)(H,89,106)(H,90,107)(H,91,110)(H,92,119)(H,93,120)(H,94,121)(H,95,116)(H,96,113)(H,97,117)(H,98,114)(H,99,118)(H,100,122)(H,101,115)(H,108,109)(H,123,124)(H4,81,82,85)(H4,83,84,86)/t41-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-,61-,62-/m0/s1
DMGDPSI CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)N
DMGDPSI IK GNOVCDMBTHSXBH-BPXGDYAESA-N
DMGDPSI IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-5-[[2-[[(2S)-1-[[(2R)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid
DMGDPSI DE Obesity
DMWDCG7 ID DMWDCG7
DMWDCG7 DN AP-521
DMWDCG7 HS Discontinued in Phase 2
DMWDCG7 SN N-(1,3-Benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro[1]benzothieno[2,3-c]pyridine-3(R)-carboxamide hydrochloride
DMWDCG7 DE Anxiety disorder
DMWKJCB ID DMWKJCB
DMWKJCB DN AP-5346
DMWKJCB HS Discontinued in Phase 2
DMWKJCB SN ProLindac; AP-5286; DACH polymer platinate, Access; DACH-Pt; DACH-Pt prodrug
DMWKJCB CP Access Pharmaceuticals Inc
DMWKJCB DE Head and neck cancer
DM8IB6K ID DM8IB6K
DM8IB6K DN APC-2059
DM8IB6K HS Discontinued in Phase 2
DM8IB6K SN BAY-44-3965
DM8IB6K CP Celera South San Francisco
DM8IB6K DE Inflammatory bowel disease
DM02DNQ ID DM02DNQ
DM02DNQ DN APC-366
DM02DNQ HS Discontinued in Phase 2
DM02DNQ SN APC-366; UNII-TGP1HP0WBC; TGP1HP0WBC; APC 366; 178925-65-0; apc366; N-(1-Hydroxy-2-naphthoyl)-L-arginyl-L-prolinamide hydrochloride; APC-366 hydrochloride; AC1L42OQ; SCHEMBL15659721; APC-366-C; APC-366-A; APC-366-R; L-Prolinamide, N2-((1-hydroxy-2-naphthalenyl)carbonyl)-L-arginyl-, monohydrochloride; (2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide hydrochloride
DM02DNQ DT Small molecular drug
DM02DNQ PC 177339
DM02DNQ MW 477
DM02DNQ FM C22H29ClN6O4
DM02DNQ IC InChI=1S/C22H28N6O4.ClH/c23-19(30)17-8-4-12-28(17)21(32)16(7-3-11-26-22(24)25)27-20(31)15-10-9-13-5-1-2-6-14(13)18(15)29;/h1-2,5-6,9-10,16-17,29H,3-4,7-8,11-12H2,(H2,23,30)(H,27,31)(H4,24,25,26);1H/t16-,17-;/m0./s1
DM02DNQ CS C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)C2=C(C3=CC=CC=C3C=C2)O)C(=O)N.Cl
DM02DNQ IK IZLPTTJTHFFFJF-QJHJCNPRSA-N
DM02DNQ IU (2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[(1-hydroxynaphthalene-2-carbonyl)amino]pentanoyl]pyrrolidine-2-carboxamide;hydrochloride
DM02DNQ CA CAS 178925-65-0
DM02DNQ DE Asthma
DMR3Q82 ID DMR3Q82
DMR3Q82 DN Apricoxib
DMR3Q82 HS Discontinued in Phase 2
DMR3Q82 SN TG01
DMR3Q82 CP Tragara Pharmaceuticals
DMR3Q82 DT Small molecular drug
DMR3Q82 PC 9820073
DMR3Q82 MW 356.4
DMR3Q82 FM C19H20N2O3S
DMR3Q82 IC InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)
DMR3Q82 CS CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
DMR3Q82 IK JTMITOKKUMVWRT-UHFFFAOYSA-N
DMR3Q82 IU 4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide
DMR3Q82 CA CAS 197904-84-0
DMR3Q82 DE Rheumatoid arthritis; Pancreatic cancer; Non-small-cell lung cancer
DMML5WB ID DMML5WB
DMML5WB DN AR-D-111421
DMML5WB HS Discontinued in Phase 2
DMML5WB CP AstraZeneca plc
DMML5WB DE Asthma
DMBTG8J ID DMBTG8J
DMBTG8J DN AR-H047108
DMBTG8J HS Discontinued in Phase 2
DMBTG8J SN RAPID, AstraZeneca; Reversible acid pump inhibitor, AstraZeneca
DMBTG8J CP AstraZeneca plc
DMBTG8J PC 9864291
DMBTG8J MW 336.4
DMBTG8J FM C20H24N4O
DMBTG8J IC InChI=1S/C20H24N4O/c1-5-15-8-6-7-12(2)17(15)10-22-18-9-16(19(21)25)11-24-14(4)13(3)23-20(18)24/h6-9,11,22H,5,10H2,1-4H3,(H2,21,25)
DMBTG8J CS CCC1=CC=CC(=C1CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N)C
DMBTG8J IK IDSZXCFCCNVXER-UHFFFAOYSA-N
DMBTG8J IU 8-[(2-ethyl-6-methylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide
DMBTG8J CA CAS 248281-68-7
DMBTG8J DE Duodenal ulcer
DMNGQM0 ID DMNGQM0
DMNGQM0 DN Arm036
DMNGQM0 HS Discontinued in Phase 2
DMNGQM0 SN ALADORIAN; UNII-PJ5KSA836G; PJ5KSA836G; 865433-00-7; ARM036; Aladorian [USAN:INN]; Aladorian (USAN/INN); S44121-1; SCHEMBL3423110; CHEMBL2104951; DTXSID40235657; FPWBHFYYVSNIFZ-UHFFFAOYSA-N; s44121; D10304; (7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)oxoacetic acid; 1,4-Benzothiazepine-4(5H)-acetic acid, 2,3-dihydro-7-methoxy-alpha-oxo-; 2-(7-Methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)-2-oxoacetic acid
DMNGQM0 CP Armgo pharma
DMNGQM0 DT Small molecular drug
DMNGQM0 PC 11161474
DMNGQM0 MW 267.3
DMNGQM0 FM C12H13NO4S
DMNGQM0 IC InChI=1S/C12H13NO4S/c1-17-9-2-3-10-8(6-9)7-13(4-5-18-10)11(14)12(15)16/h2-3,6H,4-5,7H2,1H3,(H,15,16)
DMNGQM0 CS COC1=CC2=C(C=C1)SCCN(C2)C(=O)C(=O)O
DMNGQM0 IK FPWBHFYYVSNIFZ-UHFFFAOYSA-N
DMNGQM0 IU 2-(7-methoxy-3,5-dihydro-2H-1,4-benzothiazepin-4-yl)-2-oxoacetic acid
DMNGQM0 CA CAS 865433-00-7
DMNGQM0 DE Heart failure
DMS0LCZ ID DMS0LCZ
DMS0LCZ DN ARX-201
DMS0LCZ HS Discontinued in Phase 2
DMS0LCZ SN PEG-ahGH; PEG-hGH variants (growth disorders), Ambrx; PEG-human growth hormone variants (ReCODE, growth disorders), Ambrx; 30KPEG-N1-pAFhGH; 30PEG-N4-pAFhGH
DMS0LCZ CP Ambrx Inc
DMS0LCZ DE Growth failure
DMC2WI7 ID DMC2WI7
DMC2WI7 DN AS-35
DMC2WI7 HS Discontinued in Phase 2
DMC2WI7 SN AS-35; AS 35; 108427-72-1; 9-((4-Acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one; C21H20N6O4; 4H-Pyrido[1,2-a]pyrimidin-4-one,9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)-; 4H-Pyrido(1,2-a)pyrimidin-4-one, 9-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)-3-(1H-tetrazol-5-yl)-; RVRGDCZGEKSIRW-UHFFFAOYSA-N; ACMC-20mbio; as35; AC1L2WU8; SCHEMBL159227; CTK4A6033; DTXSID90148546; CS-7624; LS-134160; HY-101946; L003846
DMC2WI7 CP Mitsubishi-Tokyo Pharmaceuticals Inc
DMC2WI7 DT Small molecular drug
DMC2WI7 PC 130135
DMC2WI7 MW 420.4
DMC2WI7 FM C21H20N6O4
DMC2WI7 IC InChI=1S/C21H20N6O4/c1-3-5-15-17(8-7-14(12(2)28)18(15)29)31-11-13-6-4-9-27-20(13)22-10-16(21(27)30)19-23-25-26-24-19/h4,6-10,29H,3,5,11H2,1-2H3,(H,23,24,25,26)
DMC2WI7 CS CCCC1=C(C=CC(=C1O)C(=O)C)OCC2=CC=CN3C2=NC=C(C3=O)C4=NNN=N4
DMC2WI7 IK RVRGDCZGEKSIRW-UHFFFAOYSA-N
DMC2WI7 IU 9-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
DMC2WI7 CA CAS 108427-72-1
DMC2WI7 DE Asthma
DM10XWU ID DM10XWU
DM10XWU DN Atipamezole
DM10XWU HS Discontinued in Phase 2
DM10XWU SN Atipamezole; 104054-27-5; Antisedan; MPV-1248; MPV 1248; 4-(2-Ethyl-2-indanyl)imidazole; 4-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; Atipamezolum [Latin]; Atipamezol [Spanish]; UNII-03N9U5JAF6; 1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-; 03N9U5JAF6; 5-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole; NCGC00182707-01; Zeolite, type: ZSM-5; DSSTox_CID_29061; DSSTox_RID_83274; DSSTox_GSID_49135; 5-(2-ethyl-1,3-dihydroinden-2-yl)-1H-imidazole; antipamezole; Atipamezolum; Atipamezol; C14H16N2
DM10XWU DT Small molecular drug
DM10XWU PC 71310
DM10XWU MW 212.29
DM10XWU FM C14H16N2
DM10XWU IC InChI=1S/C14H16N2/c1-2-14(13-9-15-10-16-13)7-11-5-3-4-6-12(11)8-14/h3-6,9-10H,2,7-8H2,1H3,(H,15,16)
DM10XWU CS CCC1(CC2=CC=CC=C2C1)C3=CN=CN3
DM10XWU IK HSWPZIDYAHLZDD-UHFFFAOYSA-N
DM10XWU IU 5-(2-ethyl-1,3-dihydroinden-2-yl)-1H-imidazole
DM10XWU CA CAS 104054-27-5
DM10XWU DE Male sexual disorder
DMZEMG6 ID DMZEMG6
DMZEMG6 DN Atiratecan
DMZEMG6 HS Discontinued in Phase 2
DMZEMG6 SN CH-0793011; CH-0793076; CH-4556300; TP-300
DMZEMG6 CP Chugai Pharmaceutical Co Ltd
DMZEMG6 DT Small molecular drug
DMZEMG6 PC 11592352
DMZEMG6 MW 586.6
DMZEMG6 FM C31H34N6O6
DMZEMG6 IC InChI=1S/C31H34N6O6/c1-4-6-7-11-36-17-33-21-9-8-10-22-26(21)28(36)18-14-37-23(27(18)34-22)12-20-19(29(37)40)16-42-30(41)31(20,5-2)43-25(39)15-35(3)24(38)13-32/h8-10,12,17H,4-7,11,13-16,32H2,1-3H3/t31-/m0/s1
DMZEMG6 CS CCCCCN1C=NC2=CC=CC3=C2C1=C4CN5C(=CC6=C(C5=O)COC(=O)[C@@]6(CC)OC(=O)CN(C)C(=O)CN)C4=N3
DMZEMG6 IK CWJSAEZZZABNRI-HKBQPEDESA-N
DMZEMG6 IU [(10S)-10-ethyl-5,9-dioxo-23-pentyl-8-oxa-4,15,21,23-tetrazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16(24),17,19,21-octaen-10-yl] 2-[(2-aminoacetyl)-methylamino]acetate
DMZEMG6 CA CAS 867063-97-6
DMZEMG6 DE Colorectal cancer
DM7OE9F ID DM7OE9F
DM7OE9F DN Atocalcitol
DM7OE9F HS Discontinued in Phase 2
DM7OE9F SN KH-1650
DM7OE9F CP LEO Pharma A/S
DM7OE9F DT Small molecular drug
DM7OE9F PC 6445225
DM7OE9F MW 494.7
DM7OE9F FM C32H46O4
DM7OE9F IC InChI=1S/C32H46O4/c1-21(19-36-20-23-8-6-10-26(16-23)31(3,4)35)28-13-14-29-24(9-7-15-32(28,29)5)11-12-25-17-27(33)18-30(34)22(25)2/h6,8,10-12,16,21,27-30,33-35H,2,7,9,13-15,17-20H2,1,3-5H3/b24-11+,25-12-/t21-,27+,28+,29-,30-,32+/m0/s1
DM7OE9F CS C[C@@H](COCC1=CC(=CC=C1)C(C)(C)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DM7OE9F IK CFIFSLBCJAXYTC-FJLAUVHZSA-N
DM7OE9F IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-1-[[3-(2-hydroxypropan-2-yl)phenyl]methoxy]propan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM7OE9F CA CAS 302904-82-1
DM7OE9F DE Psoriasis vulgaris
DMWJ245 ID DMWJ245
DMWJ245 DN ATX-201
DMWJ245 HS Discontinued in Phase 2
DMWJ245 CP Kythera Biopharmaceuticals
DMWJ245 DE Actinic keratosis
DMWA957 ID DMWA957
DMWA957 DN Avarofloxacin
DMWA957 HS Discontinued in Phase 2
DMWA957 SN JNJ-Q2
DMWA957 CP Furiex pharmaceuticals
DMWA957 DT Small molecular drug
DMWA957 PC 11546234
DMWA957 MW 419.4
DMWA957 FM C21H23F2N3O4
DMWA957 IC InChI=1S/C21H23F2N3O4/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29)/b16-11+
DMWA957 CS COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O
DMWA957 IK VMKVDAAFMQKZJS-LFIBNONCSA-N
DMWA957 IU 7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMWA957 CA CAS 878592-87-1
DMWA957 DE Bacterial pneumonia
DMRYK1C ID DMRYK1C
DMRYK1C DN AVE-0847
DMRYK1C HS Discontinued in Phase 2
DMRYK1C SN PPAR alpha/gamma agonists (diabetes/dyslipidemia), Genfit; PPAR alpha/gamma agonists (diabetes/dyslipidemia), aventis; PPAR alpha/gamma agonists (diabetes/dyslipidemia), sanofi-aventis
DMRYK1C CP Genfit SA
DMRYK1C DE Hyperlipidaemia
DMXNK0J ID DMXNK0J
DMXNK0J DN AVE1625
DMXNK0J HS Discontinued in Phase 2
DMXNK0J SN Drinabant; 358970-97-5; AVE-1625; AVE1625; UNII-61S98RLL5I; 61S98RLL5I; Drinabant [INN]; SCHEMBL684143; C23H20Cl2F2N2O2S; CHEMBL3545166; CTK8E8263; DTXSID50189455; MolPort-009-019-211; ZINC59299699; 1745AH; RT-011348; 970D975; Methanesulfonamide, N-(1-(bis(4-chlorophenyl)methyl)-3-azetidinyl)-N-(3,5-difluorophenyl)-
DMXNK0J CP Sanofi-Aventis
DMXNK0J DT Small molecular drug
DMXNK0J PC 10278470
DMXNK0J MW 497.4
DMXNK0J FM C23H20Cl2F2N2O2S
DMXNK0J IC InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3
DMXNK0J CS CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F
DMXNK0J IK IQQBRKLVEALROM-UHFFFAOYSA-N
DMXNK0J IU N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
DMXNK0J CA CAS 358970-97-5
DMXNK0J DE Psychotic disorder
DMUQ6IL ID DMUQ6IL
DMUQ6IL DN AVE-1642
DMUQ6IL HS Discontinued in Phase 2
DMUQ6IL SN EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis
DMUQ6IL CP ImmunoGen Inc
DMUQ6IL DT Antibody
DMUQ6IL DE Breast cancer
DMCX6MD ID DMCX6MD
DMCX6MD DN AVE-8134
DMCX6MD HS Discontinued in Phase 2
DMCX6MD SN PPAR alpha agonist, Genfit
DMCX6MD CP Genfit SA
DMCX6MD PC 11625114
DMCX6MD MW 381.4
DMCX6MD FM C22H23NO5
DMCX6MD IC InChI=1S/C22H23NO5/c1-16-7-5-10-18(20(16)22(24)25)13-26-11-6-12-27-14-19-15-28-21(23-19)17-8-3-2-4-9-17/h2-5,7-10,15H,6,11-14H2,1H3,(H,24,25)
DMCX6MD CS CC1=C(C(=CC=C1)COCCCOCC2=COC(=N2)C3=CC=CC=C3)C(=O)O
DMCX6MD IK WLHOBCUVPMOXAT-UHFFFAOYSA-N
DMCX6MD IU 2-methyl-6-[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]propoxymethyl]benzoic acid
DMCX6MD CA CAS 304025-09-0
DMCX6MD DE Heart failure
DMFCOZL ID DMFCOZL
DMFCOZL DN AVN 397
DMFCOZL HS Discontinued in Phase 2
DMFCOZL CP Avineuro Pharmaceuticals
DMFCOZL DE Anxiety disorder; Alzheimer disease
DM2I8NT ID DM2I8NT
DM2I8NT DN Avosentan
DM2I8NT HS Discontinued in Phase 2
DM2I8NT SN SPP 301; SPP301; Ro 67-0565; N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-5-methyl-pyridine-2-sulfonamide; 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide
DM2I8NT CP Speedel
DM2I8NT DT Small molecular drug
DM2I8NT PC 9912992
DM2I8NT MW 479.5
DM2I8NT FM C23H21N5O5S
DM2I8NT IC InChI=1S/C23H21N5O5S/c1-15-8-9-19(25-14-15)34(29,30)28-22-20(33-18-7-5-4-6-17(18)31-2)23(32-3)27-21(26-22)16-10-12-24-13-11-16/h4-14H,1-3H3,(H,26,27,28)
DM2I8NT CS CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=NC=C3)OC)OC4=CC=CC=C4OC
DM2I8NT IK YBWLTKFZAOSWSM-UHFFFAOYSA-N
DM2I8NT IU N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
DM2I8NT CA CAS 290815-26-8
DM2I8NT DE Diabetic nephropathy
DM8NA4M ID DM8NA4M
DM8NA4M DN AVT-02 UE
DM8NA4M HS Discontinued in Phase 2
DM8NA4M CP Avontec GmbH
DM8NA4M DE Skin infection
DMV1ES3 ID DMV1ES3
DMV1ES3 DN AZALANSTAT
DMV1ES3 HS Discontinued in Phase 2
DMV1ES3 SN Azalanstat; RS-21607; UNII-2NL79NI1WS; 143393-27-5; 2NL79NI1WS; CHEMBL70611; 1-(((2S,4S)-4-(((p-Aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole; 4-[[(2S,4S)-2-[2-(4-chlorophenyl)ethyl]-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]aniline; Azalanstat [INN]; RS-21607197; RS 21607; AC1Q3NQV; AC1L1U3F; SCHEMBL1230519; GTPL8799; 4-{2-[2-(4-Chloro-phenyl)-ethyl]-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethylsulfanyl}-phenylamine; BDBM50044424; compound 1 [PMID: 8340925]; Benzenamine, 4
DMV1ES3 DT Small molecular drug
DMV1ES3 PC 60876
DMV1ES3 MW 430
DMV1ES3 FM C22H24ClN3O2S
DMV1ES3 IC InChI=1S/C22H24ClN3O2S/c23-18-3-1-17(2-4-18)9-10-22(15-26-12-11-25-16-26)27-13-20(28-22)14-29-21-7-5-19(24)6-8-21/h1-8,11-12,16,20H,9-10,13-15,24H2/t20-,22-/m0/s1
DMV1ES3 CS C1[C@H](O[C@@](O1)(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)CSC4=CC=C(C=C4)N
DMV1ES3 IK VYNIUBZKEWJOJP-UNMCSNQZSA-N
DMV1ES3 IU 4-[[(2S,4S)-2-[2-(4-chlorophenyl)ethyl]-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]aniline
DMV1ES3 CA CAS 143393-27-5
DMV1ES3 DE Hyperlipidaemia
DM4B7CM ID DM4B7CM
DM4B7CM DN AZD0328
DM4B7CM HS Discontinued in Phase 2
DM4B7CM SN AR-R23465XX; AZD-0328; Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]
DM4B7CM CP AstraZeneca
DM4B7CM DT Small molecular drug
DM4B7CM PC 9794392
DM4B7CM MW 216.28
DM4B7CM FM C13H16N2O
DM4B7CM IC InChI=1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1
DM4B7CM CS C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC=C4
DM4B7CM IK OCKIPDMKGPYYJS-ZDUSSCGKSA-N
DM4B7CM IU (3R)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
DM4B7CM CA CAS 220099-91-2
DM4B7CM DE Alzheimer disease
DMA9Q2V ID DMA9Q2V
DMA9Q2V DN AZD0837
DMA9Q2V HS Discontinued in Phase 2
DMA9Q2V SN Atecegatran metoxil; Atecegatran fexenetil; UNII-4GU1D587JV; 4GU1D587JV; AZD0837; AZD 0837; 433937-93-0; Atecegatran metoxil [INN]; Atecegatran fexenetil [INN]; SCHEMBL9914214; DB12507; 2-Azetidinecarboxamide, 1-((2R)-(3-chloro-5- (difluoromethoxy)phenyl)hydroxyacetyl)-N-((4-(imino(methoxyamino)methyl)phenyl)methyl)-, (2S)-
DMA9Q2V CP AstraZeneca
DMA9Q2V DT Small molecular drug
DMA9Q2V PC 9961205
DMA9Q2V MW 496.9
DMA9Q2V FM C22H23ClF2N4O5
DMA9Q2V IC InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31)/t17-,18+/m0/s1
DMA9Q2V CS CO/N=C(/C1=CC=C(C=C1)CNC(=O)[C@@H]2CCN2C(=O)[C@@H](C3=CC(=CC(=C3)Cl)OC(F)F)O)\\N
DMA9Q2V IK XSNMGLZVFNDDPW-ZWKOTPCHSA-N
DMA9Q2V IU (2S)-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide
DMA9Q2V CA CAS 433937-93-0
DMA9Q2V DE Thrombosis; Nonvalvular atrial fibrillation
DML3RSF ID DML3RSF
DML3RSF DN AZD1236
DML3RSF HS Discontinued in Phase 2
DML3RSF SN (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD1236; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)
DML3RSF CP AstraZeneca
DML3RSF DT Small molecular drug
DML3RSF PC 24751752
DML3RSF MW 402.9
DML3RSF FM C15H19ClN4O5S
DML3RSF IC InChI=1S/C15H19ClN4O5S/c1-15(13(21)18-14(22)19-15)9-26(23,24)20-6-4-11(5-7-20)25-12-3-2-10(16)8-17-12/h2-3,8,11H,4-7,9H2,1H3,(H2,18,19,21,22)/t15-/m1/s1
DML3RSF CS C[C@]1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=NC=C(C=C3)Cl
DML3RSF IK SFJFBTPHDHUUPU-OAHLLOKOSA-N
DML3RSF IU (5S)-5-[[4-(5-chloropyridin-2-yl)oxypiperidin-1-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione
DML3RSF CA CAS 459814-89-2
DML3RSF DE Chronic obstructive pulmonary disease
DMFAG8W ID DMFAG8W
DMFAG8W DN AZD1386
DMFAG8W HS Discontinued in Phase 2
DMFAG8W SN azd1386; 946080-23-5; AZD-1386; KB-270807; AZD 1386; SCHEMBL4257077; GTPL7820; CHEMBL3545039; AZ12457709
DMFAG8W CP AstraZeneca
DMFAG8W TC Analgesics
DMFAG8W DT Small molecular drug
DMFAG8W PC 24752296
DMFAG8W MW 423.8
DMFAG8W FM C19H13ClF3N3O3
DMFAG8W IC InChI=1S/C19H13ClF3N3O3/c1-9-5-12(20)7-13-14(9)26(16(28)18(13)15(27)24-17(29)25-18)8-10-3-2-4-11(6-10)19(21,22)23/h2-7H,8H2,1H3,(H2,24,25,27,29)
DMFAG8W CS CC1=CC(=CC2=C1N(C(=O)C23C(=O)NC(=O)N3)CC4=CC(=CC=C4)C(F)(F)F)Cl
DMFAG8W IK DXDVSYALLVVBOV-UHFFFAOYSA-N
DMFAG8W IU 5'-chloro-7'-methyl-1'-[[3-(trifluoromethyl)phenyl]methyl]spiro[imidazolidine-5,3'-indole]-2,2',4-trione
DMFAG8W DE Gastroesophageal reflux disease; Esophagus sensitivity
DMHP6OY ID DMHP6OY
DMHP6OY DN AZD2066
DMHP6OY HS Discontinued in Phase 2
DMHP6OY SN AZD-2066; UNII-MQ908Y1ZB2; MQ908Y1ZB2; 934282-55-0; AZD 2066; AZD2066; SXWHYTICXCLKDG-GFCCVEGCSA-N; SCHEMBL1848325; CHEMBL3545164; MolPort-042-624-538; ZINC34885049; AKOS027470229; DB12644; Pyridine, 4-(5-((1R)-1-(5-(3-chlorophenyl)-3-isoxazolyl)ethoxy)-4-methyl-4H-1,2,4-triazol-3-yl)-; J3.560.339E; 5-(3-chlorophenyl)-3-[(1r)-1-[[4-methyl-5-(4-pyridyl)-1,2,4-triazol-3-yl]oxy]ethyl]isoxazole; 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine
DMHP6OY CP AstraZeneca
DMHP6OY TC Analgesics
DMHP6OY DT Small molecular drug
DMHP6OY PC 16041426
DMHP6OY MW 381.8
DMHP6OY FM C19H16ClN5O2
DMHP6OY IC InChI=1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1
DMHP6OY CS C[C@H](C1=NOC(=C1)C2=CC(=CC=C2)Cl)OC3=NN=C(N3C)C4=CC=NC=C4
DMHP6OY IK SXWHYTICXCLKDG-GFCCVEGCSA-N
DMHP6OY IU 5-(3-chlorophenyl)-3-[(1R)-1-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)oxy]ethyl]-1,2-oxazole
DMHP6OY CA CAS 934282-55-0
DMHP6OY DE Chronic neuropathic pain; Gastroesophageal reflux disease; Major depressive disorder
DM1TDWI ID DM1TDWI
DM1TDWI DN AZD2207
DM1TDWI HS Discontinued in Phase 2
DM1TDWI SN AC1O4QIO; CHEMBL3545289
DM1TDWI CP AstraZeneca
DM1TDWI DT Small molecular drug
DM1TDWI PC 6398473
DM1TDWI MW 499.3
DM1TDWI FM C22H22Cl2F2N4O3+2
DM1TDWI IC InChI=1S/C22H20Cl2F2N4O3/c1-14(15-5-4-6-16(23)11-15)28-21(31)12-18-17(24)8-9-20(30(18)33)27-13-22(25,26)19-7-2-3-10-29(19)32/h2-11,14,33H,12-13H2,1H3,(H-,28,31,32)/p+2/t14-/m1/s1
DM1TDWI CS C[C@H](C1=CC(=CC=C1)Cl)NC(=O)CC2=C(C=CC(=[N+]2O)NCC(C3=CC=CC=[N+]3O)(F)F)Cl
DM1TDWI IK GNYWBETUYIZBHL-CQSZACIVSA-P
DM1TDWI IU 2-[3-chloro-6-[[2,2-difluoro-2-(1-hydroxypyridin-1-ium-2-yl)ethyl]amino]-1-hydroxypyridin-1-ium-2-yl]-N-[(1R)-1-(3-chlorophenyl)ethyl]acetamide
DM1TDWI DE Obesity; Diabetic complication
DM9OPDE ID DM9OPDE
DM9OPDE DN AZD2516
DM9OPDE HS Discontinued in Phase 2
DM9OPDE CP AstraZeneca
DM9OPDE TC Analgesics
DM9OPDE DE Chronic neuropathic pain
DMT5ZK3 ID DMT5ZK3
DMT5ZK3 DN AZD3355
DMT5ZK3 HS Discontinued in Phase 2
DMT5ZK3 CP AstraZeneca
DMT5ZK3 DT Small molecular drug
DMT5ZK3 PC 9833984
DMT5ZK3 MW 140.07
DMT5ZK3 FM C3H8FNO2P+
DMT5ZK3 IC InChI=1S/C3H7FNO2P/c4-3(1-5)2-8(6)7/h3H,1-2,5H2/p+1/t3-/m1/s1
DMT5ZK3 CS C([C@H](C[P+](=O)O)F)N
DMT5ZK3 IK WVTGPBOMAQLPCP-GSVOUGTGSA-O
DMT5ZK3 IU [(2R)-3-amino-2-fluoropropyl]-hydroxy-oxophosphanium
DMT5ZK3 CA CAS 344413-67-8
DMT5ZK3 DE Gastroesophageal reflux disease
DM4K085 ID DM4K085
DM4K085 DN AZD-3778
DM4K085 HS Discontinued in Phase 2
DM4K085 SN AZD-3778; CHEMBL2158814; SCHEMBL5418656; GTPL7679; AZD3778; QVLZVRFIGXNZMN-UHFFFAOYSA-N; AZD 3778; BDBM50394155; N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide
DM4K085 CP AstraZeneca plc
DM4K085 DT Small molecular drug
DM4K085 PC 11753159
DM4K085 MW 526.5
DM4K085 FM C24H29Cl2N3O4S
DM4K085 IC InChI=1S/C24H29Cl2N3O4S/c1-17-2-5-21(6-3-17)34(31,32)27-24(30)29-12-8-18(9-13-29)28-14-10-19(11-15-28)33-20-4-7-22(25)23(26)16-20/h2-7,16,18-19H,8-15H2,1H3,(H,27,30)
DM4K085 CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
DM4K085 IK QVLZVRFIGXNZMN-UHFFFAOYSA-N
DM4K085 IU 4-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-N-(4-methylphenyl)sulfonylpiperidine-1-carboxamide
DM4K085 DE Asthma
DM3VFKM ID DM3VFKM
DM3VFKM DN AZD4818
DM3VFKM HS Discontinued in Phase 2
DM3VFKM SN 18-HYDROXYASCOMYCIN; AC1L9IBR; SCHEMBL14434002
DM3VFKM CP AstraZeneca
DM3VFKM DT Small molecular drug
DM3VFKM DE Chronic obstructive pulmonary disease
DME8KQW ID DME8KQW
DME8KQW DN AZD-5423
DME8KQW HS Discontinued in Phase 2
DME8KQW SN AZD-5423; 1034148-04-3; UNII-641H0Q518W; 641H0Q518W; 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide; 2,2,2-Tris(Fluoranyl)-~{n}-[(1~{r},2~{s})-1-[1-(4-Fluorophenyl)indazol-5-Yl]oxy-1-(3-Methoxyphenyl)propan-2-Yl]ethanamide; Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-;Acetamide, 2,2,2-trifluoro-N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(3-methoxyphenyl)-1-methylethyl]-
DME8KQW CP AstraZeneca plc
DME8KQW DT Small molecular drug
DME8KQW PC 24825740
DME8KQW MW 487.4
DME8KQW FM C25H21F4N3O3
DME8KQW IC InChI=1S/C25H21F4N3O3/c1-15(31-24(33)25(27,28)29)23(16-4-3-5-20(12-16)34-2)35-21-10-11-22-17(13-21)14-30-32(22)19-8-6-18(26)7-9-19/h3-15,23H,1-2H3,(H,31,33)/t15-,23-/m0/s1
DME8KQW CS C[C@@H]([C@@H](C1=CC(=CC=C1)OC)OC2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)NC(=O)C(F)(F)F
DME8KQW IK FCNQMDSJHADDFT-WNSKOXEYSA-N
DME8KQW IU 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-(3-methoxyphenyl)propan-2-yl]acetamide
DME8KQW CA CAS 1034148-04-3
DME8KQW DE Chronic obstructive pulmonary disease
DMVZSRG ID DMVZSRG
DMVZSRG DN AZD6370
DMVZSRG HS Discontinued in Phase 2
DMVZSRG CP AstraZeneca
DMVZSRG DE Type-2 diabetes
DMHZ3DE ID DMHZ3DE
DMHZ3DE DN AZD6765
DMHZ3DE HS Discontinued in Phase 2
DMHZ3DE SN Lanicemine; 153322-05-5; AZD6765; UNII-9TMU325RK3; AR-R15896AR; ARL 15896; 9TMU325RK3; AZD-6765; (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-amine; Lanicemine [INN]; FPL 15896; AR-R 15896; GTPL7681; CHEMBL467084; SCHEMBL1422817; ZINC6163; AR-R-15896AR; MolPort-030-004-688; AKOS026744074; DB11889; AJ-08269; (1S)-1-phenyl-2-pyridin-2-ylethanamine; (+)-2-((S)-beta-Aminophenethyl)pyridine; ( )-2-(S)-beta-Aminophenethyl-pyridine.; Z2286637868
DMHZ3DE CP AstraZeneca
DMHZ3DE DT Small molecular drug
DMHZ3DE PC 9794203
DMHZ3DE MW 198.26
DMHZ3DE FM C13H14N2
DMHZ3DE IC InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1
DMHZ3DE CS C1=CC=C(C=C1)[C@H](CC2=CC=CC=N2)N
DMHZ3DE IK FWUQWDCOOWEXRY-ZDUSSCGKSA-N
DMHZ3DE IU (1S)-1-phenyl-2-pyridin-2-ylethanamine
DMHZ3DE CA CAS 153322-05-5
DMHZ3DE DE Major depressive disorder
DMEQ2N1 ID DMEQ2N1
DMEQ2N1 DN AZD8529
DMEQ2N1 HS Discontinued in Phase 2
DMEQ2N1 SN AZD-8529; UNII-6H81G454I7; CHEMBL3937907; 6H81G454I7; AZD8529; 7-Methyl-5-(3-piperazin-1-ylmethyl-(1,2,4)oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; 7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one; GTPL7678; SCHEMBL2124540; AZD 8529; ZINC43201296; BDBM50194618; HY-107457; CS-0028525; 1092453-15-0; 7-methyl-5-[3-(piperazin-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-3H-isoindol-1-one
DMEQ2N1 CP AstraZeneca
DMEQ2N1 DT Small molecular drug
DMEQ2N1 PC 25125217
DMEQ2N1 MW 487.5
DMEQ2N1 FM C24H24F3N5O3
DMEQ2N1 IC InChI=1S/C24H24F3N5O3/c1-15-10-17(22-29-20(30-35-22)14-31-8-6-28-7-9-31)11-18-13-32(23(33)21(15)18)12-16-2-4-19(5-3-16)34-24(25,26)27/h2-5,10-11,28H,6-9,12-14H2,1H3
DMEQ2N1 CS CC1=CC(=CC2=C1C(=O)N(C2)CC3=CC=C(C=C3)OC(F)(F)F)C4=NC(=NO4)CN5CCNCC5
DMEQ2N1 IK IPCYZQQFECEHLI-UHFFFAOYSA-N
DMEQ2N1 IU 7-methyl-5-[3-(piperazin-1-ylmethyl)-1,2,4-oxadiazol-5-yl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-3H-isoindol-1-one
DMEQ2N1 CA CAS 1092453-15-0
DMEQ2N1 DE Schizophrenia
DMHA5ME ID DMHA5ME
DMHA5ME DN AZD-9684
DMHA5ME HS Discontinued in Phase 2
DMHA5ME SN Laudanosine; DL-Laudanosine; 1699-51-0; (+-)-Laudanosine; Laudanosine (R,S); (R,S)-Laudanosine; EINECS 216-923-9; NSC 94267; AI3-61890; 20412-65-1; NSC35045; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; (+-)-1,2,3,4-Tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinoline; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-VERATRYL-, (+-)-
DMHA5ME CP AstraZeneca
DMHA5ME DT Small molecular drug
DMHA5ME PC 87609775
DMHA5ME MW 226.3
DMHA5ME FM C10H14N2O2S
DMHA5ME IC InChI=1S/C10H14N2O2S/c1-6(15)8(10(13)14)4-7-2-3-9(11)12-5-7/h2-3,5-6,8,15H,4H2,1H3,(H2,11,12)(H,13,14)/t6-,8-/m1/s1
DMHA5ME CS C[C@H]([C@@H](CC1=CN=C(C=C1)N)C(=O)O)S
DMHA5ME IK GYIYAOUGKJSCCG-HTRCEHHLSA-N
DMHA5ME IU (2S,3R)-2-[(6-aminopyridin-3-yl)methyl]-3-sulfanylbutanoic acid
DMHA5ME DE Thrombosis
DM04CIK ID DM04CIK
DM04CIK DN AZT-P-DDI
DM04CIK HS Discontinued in Phase 2
DM04CIK SN Scriptene; IVX-E-59; 3'-Azido-3'-deoxythymidylyl-(5',5')-2',3'-dideoxy-5'-inosinic acid; 3'-Azido-3'-deoxythymidylyl-(5'-5')-2',3'-dideoxyinosine
DM04CIK DT Small molecular drug
DM04CIK PC 135462914
DM04CIK MW 565.4
DM04CIK FM C20H24N9O9P
DM04CIK IC InChI=1S/C20H24N9O9P/c1-10-5-28(20(32)25-18(10)30)15-4-12(26-27-21)13(38-15)7-36-39(33,34)35-6-11-2-3-14(37-11)29-9-24-16-17(29)22-8-23-19(16)31/h5,8-9,11-15H,2-4,6-7H2,1H3,(H,33,34)(H,22,23,31)(H,25,30,32)/t11-,12-,13+,14+,15+/m0/s1
DM04CIK CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OC[C@@H]3CC[C@@H](O3)N4C=NC5=C4N=CNC5=O)N=[N+]=[N-]
DM04CIK IK XURFYCWNUGWGDL-VQJWOFKYSA-N
DM04CIK IU [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [(2S,5R)-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl hydrogen phosphate
DM04CIK CA CAS 121135-53-3
DM04CIK DE Human immunodeficiency virus infection
DM06JTL ID DM06JTL
DM06JTL DN Balicatib
DM06JTL HS Discontinued in Phase 2
DM06JTL SN N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
DM06JTL CP Novartis
DM06JTL DT Small molecular drug
DM06JTL PC 10201696
DM06JTL MW 411.5
DM06JTL FM C23H33N5O2
DM06JTL IC InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
DM06JTL CS CCCN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3(CCCCC3)C(=O)NCC#N
DM06JTL IK LLCRBOWRJOUJAE-UHFFFAOYSA-N
DM06JTL IU N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(4-propylpiperazin-1-yl)benzamide
DM06JTL CA CAS 354813-19-7
DM06JTL DE Osteoporosis
DMPMKUF ID DMPMKUF
DMPMKUF DN BAM-1110
DMPMKUF HS Discontinued in Phase 2
DMPMKUF SN (6aR,9R,10aR)-7-Methyl-9-(1,2,4-triazol-1-ylmethyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolinemaleate
DMPMKUF DT Small molecular drug
DMPMKUF PC 3064755
DMPMKUF MW 307.4
DMPMKUF FM C18H21N5
DMPMKUF IC InChI=1S/C18H21N5/c1-22-8-12(9-23-11-19-10-21-23)5-15-14-3-2-4-16-18(14)13(7-20-16)6-17(15)22/h2-4,7,10-12,15,17,20H,5-6,8-9H2,1H3/t12-,15?,17-/m1/s1
DMPMKUF CS CN1C[C@@H](CC2[C@H]1CC3=CNC4=CC=CC2=C34)CN5C=NC=N5
DMPMKUF IK AIBHLZVVPXCTKY-XURPUJGUSA-N
DMPMKUF IU (6aR,9R)-7-methyl-9-(1,2,4-triazol-1-ylmethyl)-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DMPMKUF CA CAS 105579-47-3
DMPMKUF DE Parkinson disease
DMV2DIW ID DMV2DIW
DMV2DIW DN BAY 10-00394
DMV2DIW HS Discontinued in Phase 2
DMV2DIW SN roniciclib; BAY 1000394; BAY 10-00394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874
DMV2DIW CP Bayer healthcare pharmaceuticals
DMV2DIW DT Small molecular drug
DMV2DIW PC 45380979
DMV2DIW MW 430.4
DMV2DIW FM C18H21F3N4O3S
DMV2DIW IC InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29?/m1/s1
DMV2DIW CS C[C@H]([C@@H](C)OC1=NC(=NC=C1C(F)(F)F)NC2=CC=C(C=C2)S(=N)(=O)C3CC3)O
DMV2DIW IK UELYDGOOJPRWGF-MFOHZAOFSA-N
DMV2DIW IU (2R,3R)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol
DMV2DIW DE Small-cell lung cancer
DMCZKG0 ID DMCZKG0
DMCZKG0 DN BAY-Y-3118
DMCZKG0 HS Discontinued in Phase 2
DMCZKG0 SN UNII-08VLU38WTI; BAY-Y-3118 free base; Bay-Y 3118; 08VLU38WTI; 151213-16-0; 144194-96-7; AC1L3OP2; SCHEMBL7502039; CHEMBL107544; DTXSID40164736; VRXORHRXNRJZCQ-ZUZCIYMTSA-N; BAY-Y-3118; HY-U00092; CS-7127; LS-194353; 8-Chloro-1-cyclopropyl-7-[(S,S)-2,8- diazobicyclo(4.3.0)-non-8-yl]-6-fluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acid, hydrochloride; 8-Chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[[(4aalpha,7aalpha)-octahydro-1H-pyrrolo[3,4-b]pyridin]-6-yl]quinoline-3-carboxylic acid
DMCZKG0 CP Bayer AG
DMCZKG0 DT Small molecular drug
DMCZKG0 PC 119375
DMCZKG0 MW 405.8
DMCZKG0 FM C20H21ClFN3O3
DMCZKG0 IC InChI=1S/C20H21ClFN3O3/c21-16-17-12(19(26)13(20(27)28)8-25(17)11-3-4-11)6-14(22)18(16)24-7-10-2-1-5-23-15(10)9-24/h6,8,10-11,15,23H,1-5,7,9H2,(H,27,28)/t10-,15+/m0/s1
DMCZKG0 CS C1C[C@H]2CN(C[C@H]2NC1)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5)F
DMCZKG0 IK VRXORHRXNRJZCQ-ZUZCIYMTSA-N
DMCZKG0 IU 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMCZKG0 CA CAS 151213-51-3
DMCZKG0 DE Bacterial infection
DMR569L ID DMR569L
DMR569L DN BBR-3438
DMR569L HS Discontinued in Phase 2
DMR569L SN Nortopixantrone; UNII-PH2639TAB4; BBR-3438; PH2639TAB4; Nortopixantrone [INN:BAN]; AC1MI4ZO; CHEMBL150303; SCHEMBL7804438
DMR569L CP Roche Holding AG
DMR569L DT Small molecular drug
DMR569L PC 3038512
DMR569L MW 380.4
DMR569L FM C20H24N6O2
DMR569L IC InChI=1S/C20H24N6O2/c1-21-6-7-24-15-2-3-16-18-17(15)20(28)13-4-5-23-12-14(13)19(18)25-26(16)10-8-22-9-11-27/h2-5,12,21-22,24,27H,6-11H2,1H3
DMR569L CS CNCCNC1=C2C3=C(C=C1)N(N=C3C4=C(C2=O)C=CN=C4)CCNCCO
DMR569L IK PMGQHDIXCJMHRO-UHFFFAOYSA-N
DMR569L IU 14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(methylamino)ethylamino]-4,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one
DMR569L CA CAS 156090-17-4
DMR569L DE Gastric adenocarcinoma
DM6ANFC ID DM6ANFC
DM6ANFC DN BCH-2687
DM6ANFC HS Discontinued in Phase 2
DM6ANFC CP Shire BioChem Inc
DM6ANFC DE Pain
DMPIJE7 ID DMPIJE7
DMPIJE7 DN Becampanel
DMPIJE7 HS Discontinued in Phase 2
DMPIJE7 SN AMP397; AMP-397; AMP-397A; [(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylamino]methylphosphonic acid
DMPIJE7 CP Novartis
DMPIJE7 DT Small molecular drug
DMPIJE7 PC 5491960
DMPIJE7 MW 330.19
DMPIJE7 FM C10H11N4O7P
DMPIJE7 IC InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)
DMPIJE7 CS C1=C(C=C2C(=C1CNCP(=O)(O)O)NC(=O)C(=O)N2)[N+](=O)[O-]
DMPIJE7 IK ABFMMCZFKUIJGQ-UHFFFAOYSA-N
DMPIJE7 IU [(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylamino]methylphosphonic acid
DMPIJE7 CA CAS 188696-80-2
DMPIJE7 DE Epilepsy
DMEQL9U ID DMEQL9U
DMEQL9U DN Benzydamine
DMEQL9U HS Discontinued in Phase 2
DMEQL9U SN Bencidamina; Benzidamina; Benzidamine; Benzindamine; Benzydaminum; Benzidamina [DCIT]; Benzydamine Monohydrochoride; C 1523; Apo-Benzydamine; Bencidamina [INN-Spanish]; Benzydamine (INN); Benzydamine [INN:BAN]; Benzydaminum [INN-Latin]; Apo-Benzydamine (TN); {3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine; 1-Benzyl-3-(3-(dimethylamino)propoxy)-1H-indazole; 3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine; 3-[(1-benzyl-1H-indazol-3-yl)oxy]-N,N-dimethylpropan-1-amine
DMEQL9U CP Camurus
DMEQL9U TC Analgesics
DMEQL9U DT Small molecular drug
DMEQL9U PC 12555
DMEQL9U MW 309.4
DMEQL9U FM C19H23N3O
DMEQL9U IC InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3
DMEQL9U CS CN(C)CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3
DMEQL9U IK CNBGNNVCVSKAQZ-UHFFFAOYSA-N
DMEQL9U IU 3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine
DMEQL9U CA CAS 642-72-8
DMEQL9U CB CHEBI:94563
DMEQL9U DE Chemotherapy or radiotherapy-induced mucositis
DMEK6J0 ID DMEK6J0
DMEK6J0 DN Bervastatin
DMEK6J0 HS Discontinued in Phase 2
DMEK6J0 SN LS-2904
DMEK6J0 CP Merck Sante SA
DMEK6J0 DT Small molecular drug
DMEK6J0 PC 6436003
DMEK6J0 MW 466.5
DMEK6J0 FM C28H31FO5
DMEK6J0 IC InChI=1S/C28H31FO5/c1-2-33-26(32)18-22(31)17-21(30)13-14-24-27(19-9-11-20(29)12-10-19)23-7-3-4-8-25(23)34-28(24)15-5-6-16-28/h3-4,7-14,21-22,30-31H,2,5-6,15-18H2,1H3/b14-13+/t21-,22-/m0/s1
DMEK6J0 CS CCOC(=O)C[C@H](C[C@H](/C=C/C1=C(C2=CC=CC=C2OC13CCCC3)C4=CC=C(C=C4)F)O)O
DMEK6J0 IK ZADJRRFMOOACHL-WQICJITCSA-N
DMEK6J0 IU ethyl (E,3S,5R)-7-[4-(4-fluorophenyl)spiro[chromene-2,1'-cyclopentane]-3-yl]-3,5-dihydroxyhept-6-enoate
DMEK6J0 CA CAS 132017-01-7
DMEK6J0 DE Thrombosis
DMTE3UV ID DMTE3UV
DMTE3UV DN BI 1467335
DMTE3UV HS Discontinued in Phase 2
DMTE3UV SN PXS-4728A; 1478364-68-9; BI-1467335 HCl; UNII-6W2049SJPH; 6W2049SJPH; PXS 4728A; 1478364-68-9 (HCl); (E)-4-((2-(Aminomethyl)-3-fluoroallyl)oxy)-N-(tert-butyl)benzamide hydrochloride; PXS 4728 HCl; BI-1467335 hydrochloride; CHEMBL3897599; SCHEMBL16766775; EX-A4639; AC-31510; Benzamide, 4-(((2E)-2-(aminomethyl)-3-fluoro-2-propen-1-yl)oxy)-N-(1,1-dimethylethyl)-, hydrochloride (1:1); HY-112726; CS-0062985; Q27265609; (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride
DMTE3UV CP Boehringer Ingelheim
DMTE3UV DT Small molecular drug
DMTE3UV PC 71812246
DMTE3UV MW 316.8
DMTE3UV FM C15H22ClFN2O2
DMTE3UV IC InChI=1S/C15H21FN2O2.ClH/c1-15(2,3)18-14(19)12-4-6-13(7-5-12)20-10-11(8-16)9-17;/h4-8H,9-10,17H2,1-3H3,(H,18,19);1H/b11-8+;
DMTE3UV CS CC(C)(C)NC(=O)C1=CC=C(C=C1)OC/C(=C/F)/CN.Cl
DMTE3UV IK AEMZEDNMNLIDSL-YGCVIUNWSA-N
DMTE3UV IU 4-[(E)-2-(aminomethyl)-3-fluoroprop-2-enoxy]-N-tert-butylbenzamide;hydrochloride
DMTE3UV CA CAS 1478364-68-9
DMTE3UV DE Diabetic retinopathy
DMGWFZJ ID DMGWFZJ
DMGWFZJ DN BIBR-363
DMGWFZJ HS Discontinued in Phase 2
DMGWFZJ SN BIBR 363 CL2
DMGWFZJ CP Boehringer Ingelheim Corp
DMGWFZJ DE Hypertension
DMIZ59O ID DMIZ59O
DMIZ59O DN BIM-23268
DMIZ59O HS Discontinued in Phase 2
DMIZ59O SN BIM-23268D; L-Cysteinyl-L-phenylalanyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-L-cysteinamide cyclic-(1-8)-disulfide
DMIZ59O DT Small molecular drug
DMIZ59O PC 5311026
DMIZ59O MW 1078.3
DMIZ59O FM C54H67N11O9S2
DMIZ59O IC InChI=1S/C54H67N11O9S2/c1-32(66)46-54(74)63-43(27-35-19-9-4-10-20-35)52(72)64-45(47(57)67)31-76-75-30-38(56)48(68)60-41(25-33-15-5-2-6-16-33)50(70)61-42(26-34-17-7-3-8-18-34)51(71)62-44(28-36-29-58-39-22-12-11-21-37(36)39)53(73)59-40(49(69)65-46)23-13-14-24-55/h2-12,15-22,29,32,38,40-46,58,66H,13-14,23-28,30-31,55-56H2,1H3,(H2,57,67)(H,59,73)(H,60,68)(H,61,70)(H,62,71)(H,63,74)(H,64,72)(H,65,69)/t32-,38+,40+,41+,42+,43+,44-,45+,46+/m1/s1
DMIZ59O CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)N)CC6=CC=CC=C6)O
DMIZ59O IK JNMPZUZCPFIJGJ-OCZUONHDSA-N
DMIZ59O IU (4R,7S,10S,13S,16R,19S,22S,25R)-25-amino-13-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24-heptaoxo-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carboxamide
DMIZ59O DE Acromegaly
DMOP95G ID DMOP95G
DMOP95G DN Bimoclomol
DMOP95G HS Discontinued in Phase 2
DMOP95G SN ABT-822; BRLP-42; BRX-211
DMOP95G CP CytRx; Biorex Research and Development Co
DMOP95G DT Small molecular drug
DMOP95G PC 9576891
DMOP95G MW 297.78
DMOP95G FM C14H20ClN3O2
DMOP95G IC InChI=1S/C14H20ClN3O2/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18/h4-6,9,13,19H,1-3,7-8,10-11H2/b17-14-
DMOP95G CS C1CCN(CC1)CC(CO/N=C(/C2=CN=CC=C2)\\Cl)O
DMOP95G IK NMOVJBAGBXIKCG-VKAVYKQESA-N
DMOP95G IU (3Z)-N-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidoyl chloride
DMOP95G CA CAS 130493-03-7
DMOP95G DE Diabetic complication
DM65JCM ID DM65JCM
DM65JCM DN Biricodar
DM65JCM HS Discontinued in Phase 2
DM65JCM SN Incel; Biricodar [INN]; Vx 710; Incel (TN); 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
DM65JCM CP Vertex Pharmaceuticals
DM65JCM TC Anticancer Agents
DM65JCM DT Small molecular drug
DM65JCM PC 3037617
DM65JCM MW 603.7
DM65JCM FM C34H41N3O7
DM65JCM IC InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1
DM65JCM CS COC1=CC(=CC(=C1OC)OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCC3=CN=CC=C3)CCCC4=CN=CC=C4
DM65JCM IK CGVWPQOFHSAKRR-NDEPHWFRSA-N
DM65JCM IU 1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
DM65JCM CA CAS 159997-94-1
DM65JCM CB CHEBI:135847
DM65JCM DE Ovarian cancer
DMBIQL2 ID DMBIQL2
DMBIQL2 DN BISNAFIDE MESILATE
DMBIQL2 HS Discontinued in Phase 2
DMBIQL2 SN DMP-840; Bisnafide mesilate; Bisnafide mesylate; (R,R)-2,2'-(Ethane-1,2-diyl)bis[imino(1-methylethane-2,1-diyl)]bis(5-nitro-2,3-dihydro-1H-benzo[de]isoquinoline-1,3-dione) dimethanesulfonate; (R,R)-2,2'-(Ethylenediimino)bis(1-methyl-2,1-ethanediyl)bis(5-nitro-2,3-dihydro-1H-benzo[de]isoquinoline-1,3-dione) dimethanesulfonate
DMBIQL2 DT Small molecular drug
DMBIQL2 PC 60916
DMBIQL2 MW 816.8
DMBIQL2 FM C34H36N6O14S2
DMBIQL2 IC InChI=1S/C32H28N6O8.2CH4O3S/c1-17(35-29(39)23-7-3-5-19-11-21(37(43)44)13-25(27(19)23)31(35)41)15-33-9-10-34-16-18(2)36-30(40)24-8-4-6-20-12-22(38(45)46)14-26(28(20)24)32(36)42;2*1-5(2,3)4/h3-8,11-14,17-18,33-34H,9-10,15-16H2,1-2H3;2*1H3,(H,2,3,4)/t17-,18-;;/m1../s1
DMBIQL2 CS C[C@H](CNCCNC[C@@H](C)N1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)[N+](=O)[O-])N4C(=O)C5=CC=CC6=CC(=CC(=C65)C4=O)[N+](=O)[O-].CS(=O)(=O)O.CS(=O)(=O)O
DMBIQL2 IK KPQJSSLKKBKWEW-RKDOVGOJSA-N
DMBIQL2 IU methanesulfonic acid;5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione
DMBIQL2 CA CAS 145124-30-7
DMBIQL2 DE Solid tumour/cancer
DMQ6CYE ID DMQ6CYE
DMQ6CYE DN BIWB-1
DMQ6CYE HS Discontinued in Phase 2
DMQ6CYE SN Melanoma vaccine (autologous), Boehringer Ingelheim/Bender; IL-2 gene therapy (autologous), Boehringer Ingelheim/Bender
DMQ6CYE CP Boehringer Ingelheim Corp
DMQ6CYE DT Vaccine
DMQ6CYE DE Melanoma
DM7ZI8A ID DM7ZI8A
DM7ZI8A DN BM-17.0744
DM7ZI8A HS Discontinued in Phase 2
DM7ZI8A SN K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid
DM7ZI8A DT Small molecular drug
DM7ZI8A PC 9929731
DM7ZI8A MW 379.7
DM7ZI8A FM C18H25Cl3O2
DM7ZI8A IC InChI=1S/C18H25Cl3O2/c19-16-12-10-15(11-13-16)9-7-5-3-1-2-4-6-8-14-18(20,21)17(22)23/h10-13H,1-9,14H2,(H,22,23)
DM7ZI8A CS C1=CC(=CC=C1CCCCCCCCCCC(C(=O)O)(Cl)Cl)Cl
DM7ZI8A IK GPCJDSXBRMKASP-UHFFFAOYSA-N
DM7ZI8A IU 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
DM7ZI8A CA CAS 221564-97-2
DM7ZI8A DE Type-1 diabetes
DMVBGIT ID DMVBGIT
DMVBGIT DN BMS-180448
DMVBGIT HS Discontinued in Phase 2
DMVBGIT SN C20H18ClN5O2; BMS 180448; CHEMBL11802; 144264-47-1; BMS-180448; trans-N-(4-Chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)guanidine; Guanidine, N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-, trans-; Bms 180426; AC1L3TUP; DTXSID90162661; BDBM50409908; BMS-180426; LS-173206; 1-(4-chlorophenyl)-3-cyano-2-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]guanidine
DMVBGIT CP Bristol-Myers Squibb Co
DMVBGIT DT Small molecular drug
DMVBGIT PC 60880
DMVBGIT MW 395.8
DMVBGIT FM C20H18ClN5O2
DMVBGIT IC InChI=1S/C20H18ClN5O2/c1-20(2)18(27)17(15-9-12(10-22)3-8-16(15)28-20)26-19(24-11-23)25-14-6-4-13(21)5-7-14/h3-9,17-18,27H,1-2H3,(H2,24,25,26)/t17-,18+/m1/s1
DMVBGIT CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N=C(NC#N)NC3=CC=C(C=C3)Cl)O)C
DMVBGIT IK VLICJSLDCJXZBG-MSOLQXFVSA-N
DMVBGIT IU 1-(4-chlorophenyl)-3-cyano-2-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]guanidine
DMVBGIT CA CAS 144301-94-0
DMVBGIT DE Angina pectoris
DMT4VSE ID DMT4VSE
DMT4VSE DN BMS-181101
DMT4VSE HS Discontinued in Phase 2
DMT4VSE SN 1H-Indole
DMT4VSE CP Bristol-Myers Squibb Co
DMT4VSE DT Small molecular drug
DMT4VSE PC 177836
DMT4VSE MW 369.4
DMT4VSE FM C20H24FN5O
DMT4VSE IC InChI=1S/C20H24FN5O/c1-27-19-13-22-14-24-20(19)26-9-7-25(8-10-26)6-2-3-15-12-23-18-5-4-16(21)11-17(15)18/h4-5,11-14,23H,2-3,6-10H2,1H3
DMT4VSE CS COC1=CN=CN=C1N2CCN(CC2)CCCC3=CNC4=C3C=C(C=C4)F
DMT4VSE IK NRLXAYBZNVHRFL-UHFFFAOYSA-N
DMT4VSE IU 5-fluoro-3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indole
DMT4VSE CA CAS 141071-67-2
DMT4VSE DE Mood disorder
DMGPHTJ ID DMGPHTJ
DMGPHTJ DN BMS-181168
DMGPHTJ HS Discontinued in Phase 2
DMGPHTJ SN BMY-21502
DMGPHTJ CP Bristol-Myers Squibb Co
DMGPHTJ DT Small molecular drug
DMGPHTJ PC 129930
DMGPHTJ MW 328.33
DMGPHTJ FM C15H19F3N4O
DMGPHTJ IC InChI=1S/C15H19F3N4O/c16-15(17,18)14-19-6-3-12(20-14)21-8-4-11(5-9-21)10-22-7-1-2-13(22)23/h3,6,11H,1-2,4-5,7-10H2
DMGPHTJ CS C1CC(=O)N(C1)CC2CCN(CC2)C3=NC(=NC=C3)C(F)(F)F
DMGPHTJ IK KEWFMWJJMGQBAN-UHFFFAOYSA-N
DMGPHTJ IU 1-[[1-[2-(trifluoromethyl)pyrimidin-4-yl]piperidin-4-yl]methyl]pyrrolidin-2-one
DMGPHTJ CA CAS 123259-91-6
DMGPHTJ DE Cognitive impairment
DMP8SIV ID DMP8SIV
DMP8SIV DN BMS-187745
DMP8SIV HS Discontinued in Phase 2
DMP8SIV SN 157124-84-0; CHEMBL351151
DMP8SIV DT Small molecular drug
DMP8SIV PC 153978
DMP8SIV MW 386.4
DMP8SIV FM C16H19O7PS
DMP8SIV IC InChI=1S/C16H19O7PS/c17-24(18,19)16(25(20,21)22)11-5-7-13-6-4-10-15(12-13)23-14-8-2-1-3-9-14/h1-4,6,8-10,12,16H,5,7,11H2,(H2,17,18,19)(H,20,21,22)/t16-/m0/s1
DMP8SIV CS C1=CC=C(C=C1)OC2=CC=CC(=C2)CCC[C@@H](P(=O)(O)O)S(=O)(=O)O
DMP8SIV IK RCGCZPXSRLLKCK-INIZCTEOSA-N
DMP8SIV IU (1S)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid
DMP8SIV CA CAS 157126-18-6
DMP8SIV DE Hyperlipidaemia
DMODK2J ID DMODK2J
DMODK2J DN BMS-193884
DMODK2J HS Discontinued in Phase 2
DMODK2J SN BMS-193884; UNII-7ON53PV45J; CHEMBL24461; 7ON53PV45J; 176960-47-7; SCHEMBL4204130; BDBM50091105; (1,1'-Biphenyl)-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-; LS-44539; L001532; 4''-Oxazol-2-yl-biphenyl-2-sulfonicacid(3,4-dimethyl-isoxazol-5-yl)-amide; 4''-Oxazol-2-yl-biphenyl-2-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide; 4''''-Oxazol-2-yl-biphenyl-2-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide
DMODK2J DT Small molecular drug
DMODK2J PC 9843631
DMODK2J MW 395.4
DMODK2J FM C20H17N3O4S
DMODK2J IC InChI=1S/C20H17N3O4S/c1-13-14(2)22-27-19(13)23-28(24,25)18-6-4-3-5-17(18)15-7-9-16(10-8-15)20-21-11-12-26-20/h3-12,23H,1-2H3
DMODK2J CS CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC=C2C3=CC=C(C=C3)C4=NC=CO4
DMODK2J IK LJGUZUROJOJEMI-UHFFFAOYSA-N
DMODK2J IU N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide
DMODK2J CA CAS 176960-47-7
DMODK2J DE Pulmonary arterial hypertension
DMRPU10 ID DMRPU10
DMRPU10 DN BMS-488043
DMRPU10 HS Discontinued in Phase 2
DMRPU10 SN AIDS171276; BMS043; BMS488043; BMS-043; 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
DMRPU10 CP Bristol-Myers Squibb
DMRPU10 DT Small molecular drug
DMRPU10 PC 507806
DMRPU10 MW 422.4
DMRPU10 FM C22H22N4O5
DMRPU10 IC InChI=1S/C22H22N4O5/c1-30-16-13-24-20(31-2)18-17(16)15(12-23-18)19(27)22(29)26-10-8-25(9-11-26)21(28)14-6-4-3-5-7-14/h3-7,12-13,23H,8-11H2,1-2H3
DMRPU10 CS COC1=CN=C(C2=C1C(=CN2)C(=O)C(=O)N3CCN(CC3)C(=O)C4=CC=CC=C4)OC
DMRPU10 IK DBPMWRYLTBNCCE-UHFFFAOYSA-N
DMRPU10 IU 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
DMRPU10 CA CAS 452296-83-2
DMRPU10 DE Human immunodeficiency virus infection
DMS2IC9 ID DMS2IC9
DMS2IC9 DN BMS-587101
DMS2IC9 HS Discontinued in Phase 2
DMS2IC9 SN BMS-688521
DMS2IC9 CP Bristol Myers Squibb
DMS2IC9 PC 11635371
DMS2IC9 MW 555.4
DMS2IC9 FM C26H20Cl2N4O4S
DMS2IC9 IC InChI=1S/C26H20Cl2N4O4S/c1-30-25(36)32(20-8-18(27)7-19(28)9-20)24(35)26(30)14-31(11-21-6-17(13-37-21)23(33)34)12-22(26)16-4-2-15(10-29)3-5-16/h2-9,13,22H,11-12,14H2,1H3,(H,33,34)/t22-,26+/m0/s1
DMS2IC9 CS CN1C(=O)N(C(=O)[C@]12CN(C[C@H]2C3=CC=C(C=C3)C#N)CC4=CC(=CS4)C(=O)O)C5=CC(=CC(=C5)Cl)Cl
DMS2IC9 IK NXNKJLOEGWSJGI-BKMJKUGQSA-N
DMS2IC9 IU 5-[[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]methyl]thiophene-3-carboxylic acid
DMS2IC9 CA CAS 509083-77-6
DMS2IC9 DE Psoriasis vulgaris
DM2NBXR ID DM2NBXR
DM2NBXR DN BMY-21950
DM2NBXR HS Discontinued in Phase 2
DM2NBXR SN Rac-erythro-9,9-Bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyl-1H-tetrazol-5-yl)-6,8-nonadienoic acid sodium salt
DM2NBXR DT Small molecular drug
DM2NBXR PC 23665941
DM2NBXR MW 478.4
DM2NBXR FM C23H21F2N4NaO4
DM2NBXR IC InChI=1S/C23H22F2N4O4.Na/c1-29-23(26-27-28-29)20(11-10-18(30)12-19(31)13-21(32)33)22(14-2-6-16(24)7-3-14)15-4-8-17(25)9-5-15;/h2-11,18-19,30-31H,12-13H2,1H3,(H,32,33);/q;+1/p-1/b11-10+;/t18-,19-;/m0./s1
DM2NBXR CS CN1C(=NN=N1)C(=C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O.[Na+]
DM2NBXR IK NTDIRNUKAZNMSW-IYVGUKHKSA-M
DM2NBXR IU sodium;(3S,5R,6E)-9,9-bis(4-fluorophenyl)-3,5-dihydroxy-8-(1-methyltetrazol-5-yl)nona-6,8-dienoate
DM2NBXR CA CAS 131177-45-2
DM2NBXR DE Hyperlipidaemia
DMMJDYI ID DMMJDYI
DMMJDYI DN BMY-30123
DMMJDYI HS Discontinued in Phase 2
DMMJDYI SN Retinoic acid 4-acetamidophenyl ester; 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2(E),4(E),6(E),8(E)-nonatetraenoic acid 4-acetamidophenyl ester
DMMJDYI DT Small molecular drug
DMMJDYI PC 6505275
DMMJDYI MW 433.6
DMMJDYI FM C28H35NO3
DMMJDYI IC InChI=1S/C28H35NO3/c1-20(12-17-26-22(3)11-8-18-28(26,5)6)9-7-10-21(2)19-27(31)32-25-15-13-24(14-16-25)29-23(4)30/h7,9-10,12-17,19H,8,11,18H2,1-6H3,(H,29,30)/b10-7+,17-12+,20-9+,21-19+
DMMJDYI CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)OC2=CC=C(C=C2)NC(=O)C)/C)/C
DMMJDYI IK LQBHPDDJEMOJQA-ABRSJASVSA-N
DMMJDYI IU (4-acetamidophenyl) (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
DMMJDYI CA CAS 1959588-74-9
DMMJDYI DE Acne vulgaris
DMA4UCP ID DMA4UCP
DMA4UCP DN BMY-30129
DMA4UCP HS Discontinued in Phase 2
DMA4UCP SN BMS-181162; 4-(3-Carboxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2(Z),4(E),6(E),8(E)-nonatetraenoicacid
DMA4UCP DE Pruritus
DMC35T1 ID DMC35T1
DMC35T1 DN BN50727
DMC35T1 HS Discontinued in Phase 2
DMC35T1 SN Setipafant; Setipafant [INN]; UNII-UFN2Q54HS6; UFN2Q54HS6; 132418-35-0; BN 50727; 6-(o-Chlorophenyl)-7,10-dihydro-1-methyl-4H-pyrido(4',3':4,5)thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine-9(8H)-carbox-p-anisidide; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carboxamide, 7,10-dihydro-6-(2-chlorophenyl)-N-(4-methoxyphenyl)-1-methyl-; BN50727; AC1L24CK; AC1Q3P7H; SCHEMBL2110462; CHEMBL2107078; DTXSID90157552; ZINC1481922; CS-6678; BN-50727; LS-134347; HY-101675
DMC35T1 DT Small molecular drug
DMC35T1 PC 65968
DMC35T1 MW 519
DMC35T1 FM C26H23ClN6O2S
DMC35T1 IC InChI=1S/C26H23ClN6O2S/c1-15-30-31-22-13-28-24(18-5-3-4-6-20(18)27)23-19-11-12-32(14-21(19)36-25(23)33(15)22)26(34)29-16-7-9-17(35-2)10-8-16/h3-10H,11-14H2,1-2H3,(H,29,34)
DMC35T1 CS CC1=NN=C2N1C3=C(C4=C(S3)CN(CC4)C(=O)NC5=CC=C(C=C5)OC)C(=NC2)C6=CC=CC=C6Cl
DMC35T1 IK DDJKTQDAEYPACV-UHFFFAOYSA-N
DMC35T1 IU 9-(2-chlorophenyl)-N-(4-methoxyphenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene-14-carboxamide
DMC35T1 CA CAS 132418-35-0
DMC35T1 DE Inflammatory bowel disease
DMK0PVC ID DMK0PVC
DMK0PVC DN BOF-4272
DMK0PVC HS Discontinued in Phase 2
DMK0PVC SN Rac-8-[3-Methoxy-4-(phenylsulfinyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazin-4-ol sodium salt hydrate
DMK0PVC DT Small molecular drug
DMK0PVC PC 23698229
DMK0PVC MW 388.4
DMK0PVC FM C18H13N4NaO3S
DMK0PVC IC InChI=1S/C18H14N4O3S.Na/c1-25-15-9-12(14-10-21-22-17(14)19-11-20-18(22)23)7-8-16(15)26(24)13-5-3-2-4-6-13;/h2-11H,1H3,(H,19,20,21,23);/q;+1/p-1
DMK0PVC CS COC1=C(C=CC(=C1)C2=C3[N-]C=NC(=O)N3N=C2)S(=O)C4=CC=CC=C4.[Na+]
DMK0PVC IK FRSOALVXQKHLLF-UHFFFAOYSA-M
DMK0PVC IU sodium;7-[4-(benzenesulfinyl)-3-methoxyphenyl]-1,3,9-triaza-5-azanidabicyclo[4.3.0]nona-3,6,8-trien-2-one
DMK0PVC CA CAS 142181-44-0
DMK0PVC DE Gout
DMI3T64 ID DMI3T64
DMI3T64 DN BP-2.94
DMI3T64 HS Discontinued in Phase 2
DMI3T64 SN FUB-94; (-)-2-[1-[2-(4-Imidazolyl)-1(R)-methylethylimino]-1-phenylmethyl]phenol
DMI3T64 DT Small molecular drug
DMI3T64 PC 5487462
DMI3T64 DE Pain
DMAQ6DS ID DMAQ6DS
DMAQ6DS DN BP-897
DMAQ6DS HS Discontinued in Phase 2
DMAQ6DS SN BP 897; BP-897; BP897; UNII-2FVL90IM8I; 2FVL90IM8I; CHEMBL25236; 314776-92-6; N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide; N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide; BP-897 free base; SPBio_002558; SR-01000075725; DO-687; Prestwick-07H10; Prestwick3_000559; Prestwick2_000559; Prestwick1_000559; Prestwick0_000559; Lopac-B-9308; 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-; AC1MI4Y9; Lopac0_000165; BSPBio_000637; SCHEMBL2125882; GTPL7625; BPBio1_000701
DMAQ6DS DT Small molecular drug
DMAQ6DS PC 3038495
DMAQ6DS MW 417.5
DMAQ6DS FM C26H31N3O2
DMAQ6DS IC InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)
DMAQ6DS CS COC1=CC=CC=C1N2CCN(CC2)CCCCNC(=O)C3=CC4=CC=CC=C4C=C3
DMAQ6DS IK MNHDKMDLOJSCGN-UHFFFAOYSA-N
DMAQ6DS IU N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide
DMAQ6DS CA CAS 192384-87-5
DMAQ6DS CB CHEBI:92310
DMAQ6DS DE Cocaine addiction
DMFN1WI ID DMFN1WI
DMFN1WI DN BR3-Fc
DMFN1WI HS Discontinued in Phase 2
DMFN1WI CP Genentech; Biogen Idec
DMFN1WI DE Idiopathic thrombocytopenic purpura; Rheumatoid arthritis
DMRVH2S ID DMRVH2S
DMRVH2S DN Brecanavir
DMRVH2S HS Discontinued in Phase 2
DMRVH2S SN Brecanavir; 313682-08-5; UNII-E367I8C7FI; GW64085X; GW640385; E367I8C7FI; CHEMBL206031; VX-385; GW0385; (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL [(1S,2R)-3-[(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO]-2-HYDROXY-1-{4-[(2-METHYL-1,3-THIAZOL-4-YL)METHOXY]BENZYL}PROPYL]CARBAMATE; [3H]GW0385; Brecanavir [USAN:INN]; Proteinase inhibitor 640385; 2fde; 2fdd; Brecanavir (USAN); GSK 640385; GW 0385; AC1NX470; SCHEMBL1533991; BDBM4685; DTXSID10185296; JORVRJNILJXMMG-OLNQLETPSA-N; ZINC3994828; VX 385; AKOS005145761; DB04887; D03253
DMRVH2S DT Small molecular drug
DMRVH2S PC 5743186
DMRVH2S MW 703.8
DMRVH2S FM C33H41N3O10S2
DMRVH2S IC InChI=1S/C33H41N3O10S2/c1-20(2)14-36(48(39,40)25-8-9-29-30(13-25)45-19-44-29)15-28(37)27(35-33(38)46-31-17-43-32-26(31)10-11-41-32)12-22-4-6-24(7-5-22)42-16-23-18-47-21(3)34-23/h4-9,13,18,20,26-28,31-32,37H,10-12,14-17,19H2,1-3H3,(H,35,38)/t26-,27-,28+,31-,32+/m0/s1
DMRVH2S CS CC1=NC(=CS1)COC2=CC=C(C=C2)C[C@@H]([C@@H](CN(CC(C)C)S(=O)(=O)C3=CC4=C(C=C3)OCO4)O)NC(=O)O[C@H]5CO[C@@H]6[C@H]5CCO6
DMRVH2S IK JORVRJNILJXMMG-OLNQLETPSA-N
DMRVH2S IU [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[1,3-benzodioxol-5-ylsulfonyl(2-methylpropyl)amino]-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
DMRVH2S CA CAS 313682-08-5
DMRVH2S DE Human immunodeficiency virus infection
DMRKBIU ID DMRKBIU
DMRKBIU DN BRL-32872A
DMRKBIU HS Discontinued in Phase 2
DMRKBIU SN BRL-32872 (free base); N-(3,4-Dimethoxyphenyl)-N-[3-[N'-methyl-N'-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride
DMRKBIU DT Small molecular drug
DMRKBIU PC 656770
DMRKBIU MW 574.1
DMRKBIU FM C29H36ClN3O7
DMRKBIU IC InChI=1S/C29H35N3O7.ClH/c1-30(18-15-21-7-13-25(36-2)27(19-21)38-4)16-6-17-31(24-12-14-26(37-3)28(20-24)39-5)29(33)22-8-10-23(11-9-22)32(34)35;/h7-14,19-20H,6,15-18H2,1-5H3;1H
DMRKBIU CS CN(CCCN(C1=CC(=C(C=C1)OC)OC)C(=O)C2=CC=C(C=C2)[N+](=O)[O-])CCC3=CC(=C(C=C3)OC)OC.Cl
DMRKBIU IK CMKVOHIRMCFVBJ-UHFFFAOYSA-N
DMRKBIU IU N-(3,4-dimethoxyphenyl)-N-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-4-nitrobenzamide;hydrochloride
DMRKBIU CA CAS 113241-47-7
DMRKBIU CB CHEBI:34551
DMRKBIU DE Cardiac arrhythmias
DMIHSOG ID DMIHSOG
DMIHSOG DN BRL-46470
DMIHSOG HS Discontinued in Phase 2
DMIHSOG SN CHEMBL285999; BRL-46470; SCHEMBL634827; BDBM50060257; BC600835; N-(8-Methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3,3-dimethyl-1H-indole-1-carboxamide; 3,3-Dimethyl-2,3-dihydro-indole-1-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide; endo-N-(8-methyl-8-azabicyclo [3.2.1]oct-3-yl)2,3-dihydro-3,3 dimethyl-indole-1-carboxamide
DMIHSOG DT Small molecular drug
DMIHSOG PC 71785
DMIHSOG MW 313.4
DMIHSOG FM C19H27N3O
DMIHSOG IC InChI=1S/C19H27N3O/c1-19(2)12-22(17-7-5-4-6-16(17)19)18(23)20-13-10-14-8-9-15(11-13)21(14)3/h4-7,13-15H,8-12H2,1-3H3,(H,20,23)/t13?,14-,15+
DMIHSOG CS CC1(CN(C2=CC=CC=C21)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C
DMIHSOG IK ILXWRFDRNAKTDD-GOOCMWNKSA-N
DMIHSOG IU 3,3-dimethyl-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2H-indole-1-carboxamide
DMIHSOG CA CAS 117086-68-7
DMIHSOG DE Anxiety disorder
DM0WG4U ID DM0WG4U
DM0WG4U DN BRL-55834
DM0WG4U HS Discontinued in Phase 2
DM0WG4U SN Brl-55834; Brl 55834; 131899-25-7; brl55834; SCHEMBL6369898; AC1L2Z70; DTXSID80157243; 3,4-Dihydro-2,2-dimethyl-4-(oxopiperidin-1-yl)-6-pentafluoroethyl-2H-1-benzopyran-3-ol; 2-Piperidinone, 1-(3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(pentafluoroethyl)-2H-1-benzopyran-4-yl)-, (3S-trans)-
DM0WG4U CP SmithKline Beecham plc
DM0WG4U DT Small molecular drug
DM0WG4U PC 131442
DM0WG4U MW 393.3
DM0WG4U FM C18H20F5NO3
DM0WG4U IC InChI=1S/C18H20F5NO3/c1-16(2)15(26)14(24-8-4-3-5-13(24)25)11-9-10(6-7-12(11)27-16)17(19,20)18(21,22)23/h6-7,9,14-15,26H,3-5,8H2,1-2H3/t14-,15+/m1/s1
DM0WG4U CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C(C(F)(F)F)(F)F)N3CCCCC3=O)O)C
DM0WG4U IK ZSUFQZNGDIXQAD-CABCVRRESA-N
DM0WG4U IU 1-[(3S,4R)-3-hydroxy-2,2-dimethyl-6-(1,1,2,2,2-pentafluoroethyl)-3,4-dihydrochromen-4-yl]piperidin-2-one
DM0WG4U CA CAS 131899-25-7
DM0WG4U DE Chronic obstructive pulmonary disease
DMV3Y8R ID DMV3Y8R
DMV3Y8R DN BRL-61063
DMV3Y8R HS Discontinued in Phase 2
DMV3Y8R SN Cipamfylline; 132210-43-6; UNII-AFP56R140L; AFP56R140L; CHEMBL356323; Cipamfylline [USAN:INN]; Cipamfyllinum; AC1Q6LCD; 8-Amino-1,3-bis(cyclopropylmethyl)xanthine; Cipamfylline (USAN/INN); AC1L2G0B; SCHEMBL26990; MLS006010682; SCHEMBL8327157; Brl 61063; 8-amino-1,3-bis(cyclopropylmethyl)-7H-purine-2,6-dione; DTXSID50157437; Cipamfylline, > KSPYMJJKQMWWNB-UHFFFAOYSA-N; ZINC3781835; BDBM50040348; 1,3-dicyclopropylmethyl-8-amino xanthine; SMR004701664; 8-Amino-1,3-di(cyclopropylmethyl)xanthine; D03516
DMV3Y8R DT Small molecular drug
DMV3Y8R PC 71356
DMV3Y8R MW 275.31
DMV3Y8R FM C13H17N5O2
DMV3Y8R IC InChI=1S/C13H17N5O2/c14-12-15-9-10(16-12)17(5-7-1-2-7)13(20)18(11(9)19)6-8-3-4-8/h7-8H,1-6H2,(H3,14,15,16)
DMV3Y8R CS C1CC1CN2C3=C(C(=O)N(C2=O)CC4CC4)NC(=N3)N
DMV3Y8R IK KSPYMJJKQMWWNB-UHFFFAOYSA-N
DMV3Y8R IU 8-amino-1,3-bis(cyclopropylmethyl)-7H-purine-2,6-dione
DMV3Y8R CA CAS 132210-43-6
DMV3Y8R DE Allergy
DMTEQ0G ID DMTEQ0G
DMTEQ0G DN Brofaromine
DMTEQ0G HS Discontinued in Phase 2
DMTEQ0G SN Brofaremine; Consonar; Consonev; Brofaromine hydrochloride; CGP-11305A
DMTEQ0G CP Novartis AG
DMTEQ0G DT Small molecular drug
DMTEQ0G PC 44571
DMTEQ0G MW 310.19
DMTEQ0G FM C14H16BrNO2
DMTEQ0G IC InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3
DMTEQ0G CS COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br
DMTEQ0G IK WZXHSWVDAYOFPE-UHFFFAOYSA-N
DMTEQ0G IU 4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine
DMTEQ0G CA CAS 63638-91-5
DMTEQ0G DE Anxiety disorder
DM54K2P ID DM54K2P
DM54K2P DN BTS-67582
DM54K2P HS Discontinued in Phase 2
DM54K2P SN 1,1-Dimethyl-2-(2-morpholinophenyl)guanidine fumarate
DM54K2P PC 9885406
DM54K2P MW 364.4
DM54K2P FM C17H24N4O5
DM54K2P IC InChI=1S/C13H20N4O.C4H4O4/c1-16(2)13(14)15-11-5-3-4-6-12(11)17-7-9-18-10-8-17;5-3(6)1-2-4(7)8/h3-6H,7-10H2,1-2H3,(H2,14,15);1-2H,(H,5,6)(H,7,8)/b;2-1+
DM54K2P CS CN(C)C(=NC1=CC=CC=C1N2CCOCC2)N.C(=C/C(=O)O)\\C(=O)O
DM54K2P IK FFEKJBVVAJTQST-WLHGVMLRSA-N
DM54K2P IU (E)-but-2-enedioic acid;1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine
DM54K2P CA CAS 161748-40-9
DM54K2P DE Diabetic complication
DM43JK0 ID DM43JK0
DM43JK0 DN BVT-115959
DM43JK0 HS Discontinued in Phase 2
DM43JK0 SN Adenosine A2a agonists, Biovitrum; CBT-1008; Pain therapy, Cambridge Biotechnology
DM43JK0 CP Biovitrum
DM43JK0 DE Pain
DMI2LFG ID DMI2LFG
DMI2LFG DN BW-773U82
DMI2LFG HS Discontinued in Phase 2
DMI2LFG SN BW-A773U; 2-(3-Fluoranthenylmethylamino)-2-methyl-1,3-propanediol hydrochloride; 3-[2-Hydroxy-1-(hydroxymethyl)-1-methylethylaminomethyl]fluoranthene hydrochloride; 773U82.HCl
DMI2LFG DT Small molecular drug
DMI2LFG PC 3024572
DMI2LFG MW 355.9
DMI2LFG FM C21H22ClNO2
DMI2LFG IC InChI=1S/C21H21NO2.ClH/c1-21(12-23,13-24)22-11-14-9-10-19-17-6-3-2-5-16(17)18-8-4-7-15(14)20(18)19;/h2-10,22-24H,11-13H2,1H3;1H
DMI2LFG CS CC(CO)(CO)NCC1=C2C=CC=C3C2=C(C=C1)C4=CC=CC=C43.Cl
DMI2LFG IK XPSPHVAGYMFPFA-UHFFFAOYSA-N
DMI2LFG IU 2-(fluoranthen-3-ylmethylamino)-2-methylpropane-1,3-diol;hydrochloride
DMI2LFG CA CAS 96404-51-2
DMI2LFG DE Solid tumour/cancer
DM8ZFS3 ID DM8ZFS3
DM8ZFS3 DN BY-1949
DM8ZFS3 HS Discontinued in Phase 2
DM8ZFS3 SN BY-1949; 90158-59-1; 3-Methoxy-11-methyldibenz(b,f)oxazepine-8-carboxylate; AC1L3SM5; SCHEMBL194184; DTXSID60238049; JTZGDJSJVQONAV-UHFFFAOYSA-N; 11-methyl-3-methoxydibenz[b,f][1,4]oxazepine-8-carboxylic acid; Dibenz(b,f)(1,4)oxazepine-8-carboxylic acid, 3-methoxy-11-methyl-; 9-methoxy-6-methylbenzo[b][1,4]benzoxazepine-3-carboxylic acid; 3-methoxy-11-methyldibenzo[b,f][1,4]oxazepin-8-carboxylic acid
DM8ZFS3 CP Chugai Pharmaceutical Co Ltd
DM8ZFS3 DT Small molecular drug
DM8ZFS3 PC 146138
DM8ZFS3 MW 283.28
DM8ZFS3 FM C16H13NO4
DM8ZFS3 IC InChI=1S/C16H13NO4/c1-9-12-5-4-11(20-2)8-15(12)21-14-6-3-10(16(18)19)7-13(14)17-9/h3-8H,1-2H3,(H,18,19)
DM8ZFS3 CS CC1=NC2=C(C=CC(=C2)C(=O)O)OC3=C1C=CC(=C3)OC
DM8ZFS3 IK JTZGDJSJVQONAV-UHFFFAOYSA-N
DM8ZFS3 IU 9-methoxy-6-methylbenzo[b][1,4]benzoxazepine-3-carboxylic acid
DM8ZFS3 CA CAS 90158-59-1
DM8ZFS3 DE Cognitive impairment
DMHJ3SN ID DMHJ3SN
DMHJ3SN DN Cadrofloxacin
DMHJ3SN HS Discontinued in Phase 2
DMHJ3SN SN Caderofloxacin; CS-940
DMHJ3SN CP Sankyo Co Ltd
DMHJ3SN DT Small molecular drug
DMHJ3SN PC 189912
DMHJ3SN MW 411.4
DMHJ3SN FM C19H20F3N3O4
DMHJ3SN IC InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1
DMHJ3SN CS C[C@H]1CN(CCN1)C2=C(C=C3C(=C2OC(F)F)N(C=C(C3=O)C(=O)O)C4CC4)F
DMHJ3SN IK QBDBUKJBJJWZMG-VIFPVBQESA-N
DMHJ3SN IU 1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-[(3S)-3-methylpiperazin-1-yl]-4-oxoquinoline-3-carboxylic acid
DMHJ3SN CA CAS 153808-85-6
DMHJ3SN DE Bacterial infection
DMS3ECJ ID DMS3ECJ
DMS3ECJ DN Camobucol
DMS3ECJ HS Discontinued in Phase 2
DMS3ECJ SN AGIX-4207; AGIX-4207 IV; V-protectant (rheumatoid arthritis), AtheroGenics
DMS3ECJ CP AtheroGenics Inc
DMS3ECJ DT Small molecular drug
DMS3ECJ PC 9875498
DMS3ECJ MW 574.9
DMS3ECJ FM C33H50O4S2
DMS3ECJ IC InChI=1S/C33H50O4S2/c1-29(2,3)22-15-20(16-23(27(22)36)30(4,5)6)38-33(13,14)39-21-17-24(31(7,8)9)28(37-19-26(34)35)25(18-21)32(10,11)12/h15-18,36H,19H2,1-14H3,(H,34,35)
DMS3ECJ CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OCC(=O)O)C(C)(C)C
DMS3ECJ IK FGBGXESDYFKUFX-UHFFFAOYSA-N
DMS3ECJ IU 2-[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]acetic acid
DMS3ECJ CA CAS 216167-92-9
DMS3ECJ DE Rheumatoid arthritis
DMNOLHT ID DMNOLHT
DMNOLHT DN Caracemide
DMNOLHT HS Discontinued in Phase 2
DMNOLHT SN NSC-253272
DMNOLHT CP Hoechst Marion Roussel Inc
DMNOLHT DT Small molecular drug
DMNOLHT PC 54747
DMNOLHT MW 189.17
DMNOLHT FM C6H11N3O4
DMNOLHT IC InChI=1S/C6H11N3O4/c1-4(10)9(5(11)7-2)13-6(12)8-3/h1-3H3,(H,7,11)(H,8,12)
DMNOLHT CS CC(=O)N(C(=O)NC)OC(=O)NC
DMNOLHT IK JURAJLFHWXNPHG-UHFFFAOYSA-N
DMNOLHT IU [acetyl(methylcarbamoyl)amino] N-methylcarbamate
DMNOLHT CA CAS 81424-67-1
DMNOLHT DE Solid tumour/cancer
DMV2DY3 ID DMV2DY3
DMV2DY3 DN CARIPORIDE
DMV2DY3 HS Discontinued in Phase 2
DMV2DY3 SN Cariporide mesylate; UNII-0543W2JFRZ; 159138-81-5; Cariporide mesylate [USAN]; CHEMBL462831; 0543W2JFRZ; Cariporide mesylate (USAN); Cariporide mesilate; N-(4-Isopropyl-3-methanesulfonyl-benzoyl)-guanidine; DSSTox_RID_82284; DSSTox_CID_27344; DSSTox_GSID_47344; SCHEMBL221094; DTXSID3047344; AC1L4343; Tox21_300231; NCGC00254230-01; CAS-159138-81-5; D03406; (4-isopropyl-3-methanesulfonyl-benzoyl) guanidine methanesulfonate; Benzamide, N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)-, monomethanesulfonate
DMV2DY3 DT Small molecular drug
DMV2DY3 PC 151172
DMV2DY3 MW 283.35
DMV2DY3 FM C12H17N3O3S
DMV2DY3 IC InChI=1S/C12H17N3O3S/c1-7(2)9-5-4-8(11(16)15-12(13)14)6-10(9)19(3,17)18/h4-7H,1-3H3,(H4,13,14,15,16)
DMV2DY3 CS CC(C)C1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C
DMV2DY3 IK IWXNYAIICFKCTM-UHFFFAOYSA-N
DMV2DY3 IU N-(diaminomethylidene)-3-methylsulfonyl-4-propan-2-ylbenzamide
DMV2DY3 CA CAS 159138-80-4
DMV2DY3 DE Angina pectoris
DM5DI1G ID DM5DI1G
DM5DI1G DN CARZELESIN
DM5DI1G HS Discontinued in Phase 2
DM5DI1G SN Carzelesin < Rec INN; U-80244; (S)-N-[2-[1-(Chloromethyl)-8-methyl-5-(N-phenylcarbamoyloxy)-1,2,3,6-tetrahydrobenzo[1,2-b:4,3-b']dipyrrol-3-ylcarbonyl]-1H-indol-5-yl]-6-(diethylamino)benzofuran-2-carboxamide
DM5DI1G DT Small molecular drug
DM5DI1G PC 3034013
DM5DI1G MW 729.2
DM5DI1G FM C41H37ClN6O5
DM5DI1G IC InChI=1S/C41H37ClN6O5/c1-4-47(5-2)29-13-11-24-17-35(52-33(24)18-29)39(49)44-28-12-14-30-25(15-28)16-31(46-30)40(50)48-22-26(20-42)37-32(48)19-34(38-36(37)23(3)21-43-38)53-41(51)45-27-9-7-6-8-10-27/h6-19,21,26,43,46H,4-5,20,22H2,1-3H3,(H,44,49)(H,45,51)/t26-/m1/s1
DM5DI1G CS CCN(CC)C1=CC2=C(C=C1)C=C(O2)C(=O)NC3=CC4=C(C=C3)NC(=C4)C(=O)N5C[C@H](C6=C7C(=CNC7=C(C=C65)OC(=O)NC8=CC=CC=C8)C)CCl
DM5DI1G IK BBZDXMBRAFTCAA-AREMUKBSSA-N
DM5DI1G IU [(8S)-8-(chloromethyl)-6-[5-[[6-(diethylamino)-1-benzofuran-2-carbonyl]amino]-1H-indole-2-carbonyl]-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indol-4-yl] N-phenylcarbamate
DM5DI1G CA CAS 119813-10-4
DM5DI1G DE Solid tumour/cancer
DMPZFDE ID DMPZFDE
DMPZFDE DN CASTANOSPERMINE
DMPZFDE HS Discontinued in Phase 2
DMPZFDE SN MDL-26190; (1S,6S,7R,8R,8aR)-1,6,7,8-Tetrahydroxyoctahydroindolizine
DMPZFDE DT Small molecular drug
DMPZFDE PC 54445
DMPZFDE MW 189.21
DMPZFDE FM C8H15NO4
DMPZFDE IC InChI=1S/C8H15NO4/c10-4-1-2-9-3-5(11)7(12)8(13)6(4)9/h4-8,10-13H,1-3H2/t4-,5-,6+,7+,8+/m0/s1
DMPZFDE CS C1CN2C[C@@H]([C@H]([C@@H]([C@H]2[C@H]1O)O)O)O
DMPZFDE IK JDVVGAQPNNXQDW-TVNFTVLESA-N
DMPZFDE IU (1S,6S,7R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,6,7,8-tetrol
DMPZFDE CA CAS 79831-76-8
DMPZFDE CB CHEBI:27860
DMPZFDE DE Diabetic complication
DMVP4YK ID DMVP4YK
DMVP4YK DN CB1954
DMVP4YK HS Discontinued in Phase 2
DMVP4YK SN Tretazicar; CB 1954; 21919-05-1; CB1954; 5-(1-Aziridinyl)-2,4-dinitrobenzamide; 5-Aziridino-2,4-dinitrobenzamide; CB-1954; 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE; 5-Aziridinyl-2,4-dinitrobenzamide; Tretazicar [INN]; 2,4-Dinitroethyleneiminobenzamide; 2,4-Dinitro-5-ethyleneiminobenzamide; CHEMBL23330; CCRIS 1631; UNII-7865D5D01M; NSC 115829; 7865D5D01M; BRN 5825582; Benzamide,5-(1-aziridinyl)-2,4-dinitro-; Benzamide, 5-(1-aziridinyl)-2,4-dinitro-; CB1; C9H8N4O5; SMR000326847; aziridine dinitrobenzamide; CB1954(Tretazicar); AC1Q1YAR
DMVP4YK DT Small molecular drug
DMVP4YK PC 89105
DMVP4YK MW 252.18
DMVP4YK FM C9H8N4O5
DMVP4YK IC InChI=1S/C9H8N4O5/c10-9(14)5-3-7(11-1-2-11)8(13(17)18)4-6(5)12(15)16/h3-4H,1-2H2,(H2,10,14)
DMVP4YK CS C1CN1C2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-]
DMVP4YK IK WOCXQMCIOTUMJV-UHFFFAOYSA-N
DMVP4YK IU 5-(aziridin-1-yl)-2,4-dinitrobenzamide
DMVP4YK CA CAS 21919-05-1
DMVP4YK DE Solid tumour/cancer
DM2FAH0 ID DM2FAH0
DM2FAH0 DN CBF-BS2
DM2FAH0 HS Discontinued in Phase 2
DM2FAH0 SN KSB-302
DM2FAH0 CP KS Biomedix Ltd
DM2FAH0 DE Rheumatoid arthritis
DM9P7Z2 ID DM9P7Z2
DM9P7Z2 DN CD-349
DM9P7Z2 HS Discontinued in Phase 2
DM9P7Z2 SN CD-349; CD 349; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(nitrooxy)propyl 3-(nitrooxy)propyl ester; 2-Nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; AC1L3OLK; SCHEMBL7376581; AC1Q63B2; 2-(nitrooxy)propyl 3-(nitrooxy)propyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; LS-186864; LS-187520; 5-O-(2-nitrooxypropyl) 3-O-(3-nitrooxypropyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM9P7Z2 CP Taisho Pharmaceutical Co Ltd
DM9P7Z2 DT Small molecular drug
DM9P7Z2 PC 119325
DM9P7Z2 MW 524.4
DM9P7Z2 FM C21H24N4O12
DM9P7Z2 IC InChI=1S/C21H24N4O12/c1-12(37-25(32)33)11-35-21(27)18-14(3)22-13(2)17(20(26)34-8-5-9-36-24(30)31)19(18)15-6-4-7-16(10-15)23(28)29/h4,6-7,10,12,19,22H,5,8-9,11H2,1-3H3
DM9P7Z2 CS CC1=C(C(C(=C(N1)C)C(=O)OCC(C)O[N+](=O)[O-])C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCCO[N+](=O)[O-]
DM9P7Z2 IK QSTCLWROWBZZLA-UHFFFAOYSA-N
DM9P7Z2 IU 5-O-(2-nitrooxypropyl) 3-O-(3-nitrooxypropyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM9P7Z2 CA CAS 88594-08-5
DM9P7Z2 DE Hypertension
DMUPJW4 ID DMUPJW4
DMUPJW4 DN CDP840
DMUPJW4 HS Discontinued in Phase 2
DMUPJW4 SN Cdp-840; Cdp 840; CDP840; CHEMBL32442; 4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; (R)-4-(2-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)pyridine; 4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine; Pyridine, 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)-, (R)-; 162542-90-7; AC1L2SW5; SCHEMBL84490; 4-[2-(3-Cyclopentyloxy-4-methoxy-phenyl)-2-phenyl-ethyl]-pyridine; GTPL9330; UTUUPXBCDMQYRR-HSZRJFAPSA-N; ZINC599006; PDSP2_001272; BDBM50064858; PDSP1_001288
DMUPJW4 DT Small molecular drug
DMUPJW4 PC 127928
DMUPJW4 MW 373.5
DMUPJW4 FM C25H27NO2
DMUPJW4 IC InChI=1S/C25H27NO2/c1-27-24-12-11-21(18-25(24)28-22-9-5-6-10-22)23(20-7-3-2-4-8-20)17-19-13-15-26-16-14-19/h2-4,7-8,11-16,18,22-23H,5-6,9-10,17H2,1H3/t23-/m1/s1
DMUPJW4 CS COC1=C(C=C(C=C1)[C@H](CC2=CC=NC=C2)C3=CC=CC=C3)OC4CCCC4
DMUPJW4 IK UTUUPXBCDMQYRR-HSZRJFAPSA-N
DMUPJW4 IU 4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine
DMUPJW4 CA CAS 162542-90-7
DMUPJW4 DE Chronic obstructive pulmonary disease
DMWHQM3 ID DMWHQM3
DMWHQM3 DN CDP-850
DMWHQM3 HS Discontinued in Phase 2
DMWHQM3 SN VLA-4, Celltech; Anti-E-selectin antibody, Celltech
DMWHQM3 CP UCB Celltech
DMWHQM3 DT Antibody
DMWHQM3 DE Solid tumour/cancer
DMEI0LJ ID DMEI0LJ
DMEI0LJ DN CDP-860
DMEI0LJ HS Discontinued in Phase 2
DMEI0LJ SN MAb, PDGFr, Celltech
DMEI0LJ CP ZymoGenetics Inc
DMEI0LJ DE Solid tumour/cancer
DM746L8 ID DM746L8
DM746L8 DN CE-1037
DM746L8 HS Discontinued in Phase 2
DM746L8 SN SPWHS19WTL; UNII-SPWHS19WTL; CHEMBL56605; Mdl 201404YA; Mdl 201,404YA; CE 1037; 150493-09-7; ce1037; SCHEMBL8974527; BDBM50058491; Bis(4-(2'-(carboxy-2'-methylpropylsulfonyl)phenyl)2,2'-(1,4-phenylene))diisobutyrate; 3-{4-[2-(4-{1-[4-(2-Carboxy-2-methyl-propane-1-sulfonyl)-phenoxycarbonyl]-1-methyl-ethyl}-phenyl)-2-methyl-propionyloxy]-benzenesulfonyl}-2,2-dimethyl-propionic acid(CE-1037)
DM746L8 DT Small molecular drug
DM746L8 PC 131801066
DM746L8 MW 774.8
DM746L8 FM C36H40Na2O12S2
DM746L8 IC InChI=1S/C36H42O12S2.2Na/c1-33(2,29(37)38)21-49(43,44)27-17-13-25(14-18-27)47-31(41)35(5,6)23-9-11-24(12-10-23)36(7,8)32(42)48-26-15-19-28(20-16-26)50(45,46)22-34(3,4)30(39)40;;/h9-20H,21-22H2,1-8H3,(H,37,38)(H,39,40);;/q;2*+1/p-2
DM746L8 CS CC(C)(CS(=O)(=O)C1=CC=C(C=C1)OC(=O)C(C)(C)C2=CC=C(C=C2)C(C)(C)C(=O)OC3=CC=C(C=C3)S(=O)(=O)CC(C)(C)C(=O)[O-])C(=O)[O-].[Na+].[Na+]
DM746L8 IK HTARXGMNANKUGQ-UHFFFAOYSA-L
DM746L8 IU disodium;3-[4-[2-[4-[1-[4-(2-carboxylato-2-methylpropyl)sulfonylphenoxy]-2-methyl-1-oxopropan-2-yl]phenyl]-2-methylpropanoyl]oxyphenyl]sulfonyl-2,2-dimethylpropanoate
DM746L8 CA CAS 155947-72-1
DM746L8 DE Chronic obstructive pulmonary disease
DMXO49B ID DMXO49B
DMXO49B DN CE-326597
DMXO49B HS Discontinued in Phase 2
DMXO49B SN CE-326597; UNII-1FGZ6L9SF2; 1FGZ6L9SF2; CHEMBL1269258; CE 326597; CE-326,597; GTPL9055; BDBM50329179; DB12694; compound 4a [PMID: 20851601]; 6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (-)-; 6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine-6-acetamide, 4,5-dihydro-4-(1H-indol-3-ylmethyl)-N-(1-methylethyl)-5-oxo-1-phenyl-N-(phenylmethyl)-, (S)-; J3.552.307C
DMXO49B CP Pfizer Inc
DMXO49B DT Small molecular drug
DMXO49B PC 52949124
DMXO49B MW 594.7
DMXO49B FM C37H34N6O2
DMXO49B IC InChI=1S/C37H34N6O2/c1-25(2)41(23-26-13-5-3-6-14-26)34(44)24-42-32-19-11-12-20-33(32)43-35(27-15-7-4-8-16-27)39-40-36(43)30(37(42)45)21-28-22-38-31-18-10-9-17-29(28)31/h3-20,22,25,30,38H,21,23-24H2,1-2H3/t30-/m0/s1
DMXO49B CS CC(C)N(CC1=CC=CC=C1)C(=O)CN2C3=CC=CC=C3N4C(=NN=C4C5=CC=CC=C5)[C@@H](C2=O)CC6=CNC7=CC=CC=C76
DMXO49B IK UBNMGTSDHSQBEL-PMERELPUSA-N
DMXO49B IU N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4H-[1,2,4]triazolo[3,4-d][1,5]benzodiazepin-6-yl]-N-propan-2-ylacetamide
DMXO49B CA CAS 870615-40-0
DMXO49B DE Obesity
DMIR4FB ID DMIR4FB
DMIR4FB DN CEMADOTIN HYDROCHLORIDE
DMIR4FB HS Discontinued in Phase 2
DMIR4FB SN LU-103793; Cemadotin hydrochloride; N,N-Dimethyl-L-valyl-L-valyl-L-(N-methyl)-valyl-L-prolyl-L-proline benzylamide hydrochloride
DMIR4FB DT Small molecular drug
DMIR4FB PC 21143092
DMIR4FB MW 677.3
DMIR4FB FM C35H57ClN6O5
DMIR4FB IC InChI=1S/C35H56N6O5.ClH/c1-22(2)28(37-32(43)29(23(3)4)38(7)8)34(45)39(9)30(24(5)6)35(46)41-20-14-18-27(41)33(44)40-19-13-17-26(40)31(42)36-21-25-15-11-10-12-16-25;/h10-12,15-16,22-24,26-30H,13-14,17-21H2,1-9H3,(H,36,42)(H,37,43);1H/t26-,27-,28-,29-,30-;/m0./s1
DMIR4FB CS CC(C)[C@@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N(C)C.Cl
DMIR4FB IK MRJQTLJSMQOFTP-JGTKTWDESA-N
DMIR4FB IU (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride
DMIR4FB CA CAS 172837-41-1
DMIR4FB DE Solid tumour/cancer
DMG62H1 ID DMG62H1
DMG62H1 DN CereCRIB
DMG62H1 HS Discontinued in Phase 2
DMG62H1 SN ACTID; Drug implant (analgesic), CytoTherapeutics; Bovine cell impant (pain, ECT), CytoTherapeutics; Bovine cell implant (pain, CRIB), CytoTherapeutics; Bovine cell impant (pain, ECT), CytoTherapeutics, AstraZeneca; Bovine cell implant (pain, CRIB), CytoTherapeutics, AstraZeneca
DMG62H1 CP StemCells Inc
DMG62H1 DT Small molecular drug
DMG62H1 PC 16129718
DMG62H1 MW 3305.8
DMG62H1 FM C150H230N44O39S
DMG62H1 IC InChI=1S/C150H230N44O39S/c1-80(2)120(190-139(224)112-40-26-62-192(112)144(229)101(35-17-21-58-154)173-115(200)75-168-125(210)106(69-87-72-166-93-31-13-12-30-91(87)93)184-129(214)98(37-23-60-164-149(158)159)177-134(219)105(66-84-28-10-9-11-29-84)183-136(221)107(70-88-73-162-79-170-88)185-130(215)99(50-52-117(202)203)178-131(216)100(54-65-234-8)179-137(222)110(78-196)188-135(220)104(182-124(209)92(155)77-195)67-85-42-46-89(197)47-43-85)141(226)169-76-114(199)172-94(32-14-18-55-151)126(211)175-95(33-15-19-56-152)127(212)176-97(36-22-59-163-148(156)157)128(213)181-102(38-24-61-165-150(160)161)145(230)193-63-27-41-113(193)140(225)191-122(82(5)6)142(227)180-96(34-16-20-57-153)132(217)189-121(81(3)4)143(228)187-109(68-86-44-48-90(198)49-45-86)146(231)194-64-25-39-111(194)138(223)186-108(71-119(206)207)133(218)171-83(7)123(208)167-74-116(201)174-103(147(232)233)51-53-118(204)205/h9-13,28-31,42-49,72-73,79-83,92,94-113,120-122,166,195-198H,14-27,32-41,50-71,74-78,151-155H2,1-8H3,(H,162,170)(H,167,208)(H,168,210)(H,169,226)(H,171,218)(H,172,199)(H,173,200)(H,174,201)(H,175,211)(H,176,212)(H,177,219)(H,178,216)(H,179,222)(H,180,227)(H,181,213)(H,182,209)(H,183,221)(H,184,214)(H,185,215)(H,186,223)(H,187,228)(H,188,220)(H,189,217)(H,190,224)(H,191,225)(H,202,203)(H,204,205)(H,206,207)(H,232,233)(H4,156,157,163)(H4,158,159,164)(H4,160,161,165)/t83-,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,120-,121-,122-/m0/s1
DMG62H1 CS C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CO)N
DMG62H1 IK VDBFSWDFTQMVDA-GDNBNFDOSA-N
DMG62H1 IU (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]acetyl]amino]pentanedioic acid
DMG62H1 DE Pain
DMFBNI6 ID DMFBNI6
DMFBNI6 DN Ceronapril
DMFBNI6 HS Discontinued in Phase 2
DMFBNI6 SN Ceranapril; SQ-29852
DMFBNI6 CP Bristol-Myers Squibb Co
DMFBNI6 DT Small molecular drug
DMFBNI6 PC 189729
DMFBNI6 MW 440.5
DMFBNI6 FM C21H33N2O6P
DMFBNI6 IC InChI=1S/C21H33N2O6P/c22-14-6-4-13-19(20(24)23-15-8-12-18(23)21(25)26)29-30(27,28)16-7-5-11-17-9-2-1-3-10-17/h1-3,9-10,18-19H,4-8,11-16,22H2,(H,25,26)(H,27,28)/t18-,19-/m0/s1
DMFBNI6 CS C1C[C@H](N(C1)C(=O)[C@H](CCCCN)OP(=O)(CCCCC2=CC=CC=C2)O)C(=O)O
DMFBNI6 IK IFYLTXNCFVRALQ-OALUTQOASA-N
DMFBNI6 IU (2S)-1-[(2S)-6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid
DMFBNI6 CA CAS 111223-26-8
DMFBNI6 DE Major depressive disorder
DMUG5OB ID DMUG5OB
DMUG5OB DN CETi-1
DMUG5OB HS Discontinued in Phase 2
DMUG5OB SN Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences
DMUG5OB CP Celldex Therapeutics Inc
DMUG5OB DT Vaccine
DMUG5OB DE Arteriosclerosis
DMHK8IM ID DMHK8IM
DMHK8IM DN CFC-222
DMHK8IM HS Discontinued in Phase 2
DMHK8IM SN Ecenofloxacin
DMHK8IM CP CJ Corp
DMHK8IM DT Small molecular drug
DMHK8IM PC 178065
DMHK8IM MW 408.9
DMHK8IM FM C19H22ClFN4O3
DMHK8IM IC InChI=1S/C19H21FN4O3.ClH/c1-19-5-14(21)12(19)7-23(8-19)17-13(20)4-10-15(25)11(18(26)27)6-24(9-2-3-9)16(10)22-17;/h4,6,9,12,14H,2-3,5,7-8,21H2,1H3,(H,26,27);1H/t12-,14-,19-;/m0./s1
DMHK8IM CS C[C@@]12C[C@@H]([C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F)N.Cl
DMHK8IM IK OTJVJUVCWOCNQA-ZJKXRWPCSA-N
DMHK8IM IU 7-[(1R,5S,6S)-6-amino-1-methyl-3-azabicyclo[3.2.0]heptan-3-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;hydrochloride
DMHK8IM CA CAS 162424-67-1
DMHK8IM DE Bacterial infection
DMBJQU6 ID DMBJQU6
DMBJQU6 DN CGP-49823
DMBJQU6 HS Discontinued in Phase 2
DMBJQU6 SN CGP-49823; CHEMBL290364; cgp49823; SCHEMBL6904655; BDBM50287397; {(R)-2-Benzyl-4-[(quinolin-4-ylmethyl)-amino]-piperidin-1-yl}-(3,5-dimethyl-phenyl)-methanone
DMBJQU6 CP Novartis AG
DMBJQU6 DT Small molecular drug
DMBJQU6 PC 9869033
DMBJQU6 MW 463.6
DMBJQU6 FM C31H33N3O
DMBJQU6 IC InChI=1S/C31H33N3O/c1-22-16-23(2)18-26(17-22)31(35)34-15-13-27(20-28(34)19-24-8-4-3-5-9-24)33-21-25-12-14-32-30-11-7-6-10-29(25)30/h3-12,14,16-18,27-28,33H,13,15,19-21H2,1-2H3/t27-,28+/m0/s1
DMBJQU6 CS CC1=CC(=CC(=C1)C(=O)N2CC[C@@H](C[C@H]2CC3=CC=CC=C3)NCC4=CC=NC5=CC=CC=C45)C
DMBJQU6 IK WQZUOBIIPDZRJP-WUFINQPMSA-N
DMBJQU6 IU [(2R,4S)-2-benzyl-4-(quinolin-4-ylmethylamino)piperidin-1-yl]-(3,5-dimethylphenyl)methanone
DMBJQU6 CA CAS 150705-88-7
DMBJQU6 DE Pain
DMCRPKS ID DMCRPKS
DMCRPKS DN CGRP
DMCRPKS HS Discontinued in Phase 2
DMCRPKS SN Calcitonin gene related peptide; LAB CGRP; CGRP (inhaled, asthma); CGRP (inhaled, asthma), Akela Pharma; Calcitonin gene-related peptide (inhaled, asthma), LAB International
DMCRPKS CP Akela Pharma
DMCRPKS DT Small molecular drug
DMCRPKS PC 44134599
DMCRPKS MW 3795.4
DMCRPKS FM C163H273N51O49S2
DMCRPKS IC InChI=1S/C163H273N51O49S2/c1-73(2)52-97(186-116(226)65-179-131(233)82(18)183-139(241)98(53-74(3)4)193-137(239)94(44-35-49-176-162(171)172)188-142(244)101(57-91-62-175-72-182-91)199-159(261)128(88(24)221)213-156(258)123(79(13)14)207-151(253)110(71-265)204-160(262)126(86(22)219)210-133(235)84(20)185-157(259)125(85(21)218)211-147(249)105(61-119(229)230)198-150(252)109(70-264)203-130(232)81(17)166)140(242)194-99(54-75(5)6)141(243)202-108(69-217)149(251)190-95(45-36-50-177-163(173)174)138(240)201-106(67-215)134(236)180-63-115(225)178-64-118(228)205-121(77(9)10)155(257)208-122(78(11)12)154(256)191-93(43-32-34-48-165)136(238)196-102(58-112(167)222)144(246)197-103(59-113(168)223)143(245)195-100(56-90-40-29-26-30-41-90)145(247)209-124(80(15)16)161(263)214-51-37-46-111(214)152(254)212-127(87(23)220)158(260)200-104(60-114(169)224)146(248)206-120(76(7)8)153(255)181-66-117(227)187-107(68-216)148(250)189-92(42-31-33-47-164)135(237)184-83(19)132(234)192-96(129(170)231)55-89-38-27-25-28-39-89/h25-30,38-41,73-88,91-111,120-128,175,182,215-221,264-265H,31-37,42-72,164-166H2,1-24H3,(H2,167,222)(H2,168,223)(H2,169,224)(H2,170,231)(H,178,225)(H,179,233)(H,180,236)(H,181,255)(H,183,241)(H,184,237)(H,185,259)(H,186,226)(H,187,227)(H,188,244)(H,189,250)(H,190,251)(H,191,256)(H,192,234)(H,193,239)(H,194,242)(H,195,245)(H,196,238)(H,197,246)(H,198,252)(H,199,261)(H,200,260)(H,201,240)(H,202,243)(H,203,232)(H,204,262)(H,205,228)(H,206,248)(H,207,253)(H,208,257)(H,209,247)(H,210,235)(H,211,249)(H,212,254)(H,213,258)(H,229,230)(H4,171,172,176)(H4,173,174,177)
DMCRPKS CS CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CO)C(=O)NCC(=O)NCC(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(CC3=CC=CC=C3)C(=O)N)NC(=O)CNC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC4CNCN4)NC(=O)C(C(C)O)NC(=O)C(C(C)C)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(CS)NC(=O)C(C)N
DMCRPKS IK JAPBQZADVRUIIO-UHFFFAOYSA-N
DMCRPKS IU 4-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[2-[[1-[[1-[[1-[[1-[[1-[[2-[[2-[[1-[[1-[[6-amino-1-[[4-amino-1-[[4-amino-1-[[1-[[1-[2-[[1-[[4-amino-1-[[1-[[2-[[1-[[6-amino-1-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-imidazolidin-4-yl-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-[[2-(2-aminopropanoylamino)-3-sulfanylpropanoyl]amino]-4-oxobutanoic acid
DMCRPKS DE Asthma
DM2OWCV ID DM2OWCV
DM2OWCV DN CGS-25462
DM2OWCV HS Discontinued in Phase 2
DM2OWCV SN Cgs-25462; UNII-UP2R15WBF4; UP2R15WBF4; Cgs 25462; 147862-03-1; AC1L31LU; SCHEMBL7312208; CHEMBL147342; JTQWXNZXTRVPHN-LJAQVGFWSA-N; beta-Alanine, N-(3-(1,1'-biphenyl)-4-yl-N-((diphenoxyphosphinyl)methyl)-L-alanyl)-; 3-(N-(2-(((Diphenylphosphono)methyl)amino)-3-(4-biphenylyl)propionyl)amino)propionic acid; (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)-propionyl]-3-aminopropionic acid; (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)propionyl]-3-aminopropionic acid
DM2OWCV CP Novartis AG
DM2OWCV DT Small molecular drug
DM2OWCV PC 132812
DM2OWCV MW 558.6
DM2OWCV FM C31H31N2O6P
DM2OWCV IC InChI=1S/C31H31N2O6P/c34-30(35)20-21-32-31(36)29(22-24-16-18-26(19-17-24)25-10-4-1-5-11-25)33-23-40(37,38-27-12-6-2-7-13-27)39-28-14-8-3-9-15-28/h1-19,29,33H,20-23H2,(H,32,36)(H,34,35)/t29-/m0/s1
DM2OWCV CS C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C(=O)NCCC(=O)O)NCP(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4
DM2OWCV IK JTQWXNZXTRVPHN-LJAQVGFWSA-N
DM2OWCV IU 3-[[(2S)-2-(diphenoxyphosphorylmethylamino)-3-(4-phenylphenyl)propanoyl]amino]propanoic acid
DM2OWCV CA CAS 147862-03-1
DM2OWCV DE Hypertension
DM03XVA ID DM03XVA
DM03XVA DN CI-1018
DM03XVA HS Discontinued in Phase 2
DM03XVA SN CI-1018; UNII-Y4O6325SYW; Y4O6325SYW; CHEMBL111925; DSSTox_CID_27248; DSSTox_RID_82208; DSSTox_GSID_47248; SCHEMBL185627; CAS-NOCAS_47248; DTXSID0047248; NOCAS_47248; Tox21_300203; BDBM50217550; NCGC00254191-01; NCGC00247925-01; 179024-48-7; PD-168787; (+)-CI-1018; CI-1018, (+)-; UNII-05127JZ9KQ component KYFWUBJMTHVBIF-QFIPXVFZSA-N; 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; 4-Pyridinecarboxamide, N-((3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrol
DM03XVA DT Small molecular drug
DM03XVA PC 9865514
DM03XVA MW 396.4
DM03XVA FM C24H20N4O2
DM03XVA IC InChI=1S/C24H20N4O2/c1-15-13-18-9-12-28-21(18)19(14-15)20(16-5-3-2-4-6-16)26-22(24(28)30)27-23(29)17-7-10-25-11-8-17/h2-8,10-11,13-14,22H,9,12H2,1H3,(H,27,29)/t22-/m0/s1
DM03XVA CS CC1=CC2=C3C(=C1)C(=N[C@H](C(=O)N3CC2)NC(=O)C4=CC=NC=C4)C5=CC=CC=C5
DM03XVA IK KYFWUBJMTHVBIF-QFIPXVFZSA-N
DM03XVA IU N-[(11R)-6-methyl-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]pyridine-4-carboxamide
DM03XVA CA CAS 179024-48-7
DM03XVA DE Asthma
DMADPQX ID DMADPQX
DMADPQX DN CI-930
DMADPQX HS Discontinued in Phase 2
DMADPQX SN CI-930; CI 930; 86798-59-6; 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone; 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-5-methyl-; AC1MIBTH; CHEMBL440593; SCHEMBL6052113; CTK5F7194; BDBM14362; AEZZPAQOEUQNBB-UHFFFAOYSA-N; 90791-23-4 (hydrochloride); BDBM50225945; LS-187480; LS-186812; 6-[4-(1-Imidazolyl)phenyl]-5-methyl-3-oxo-2,3,4,5-tetrahydropyridazine; 3-(4-imidazol-1-ylphenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DMADPQX DT Small molecular drug
DMADPQX PC 3021729
DMADPQX MW 254.29
DMADPQX FM C14H14N4O
DMADPQX IC InChI=1S/C14H14N4O/c1-10-8-13(19)16-17-14(10)11-2-4-12(5-3-11)18-7-6-15-9-18/h2-7,9-10H,8H2,1H3,(H,16,19)
DMADPQX CS CC1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3
DMADPQX IK AEZZPAQOEUQNBB-UHFFFAOYSA-N
DMADPQX IU 3-(4-imidazol-1-ylphenyl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DMADPQX CA CAS 86798-59-6
DMN4QSW ID DMN4QSW
DMN4QSW DN CI-949
DMN4QSW HS Discontinued in Phase 2
DMN4QSW SN CI 949; UNII-EM1J51043X; EM1J51043X; L-Arginine, compd. with 5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide (1:1); OHOCQQJBKBVAFF-VWMHFEHESA-N; AC1L4M1L; AC1Q5G9U; 121530-58-3; SCHEMBL17041896; n5-(diaminomethylidene)-l-ornithine- 5-methoxy-1-phenyl-3-(propan-2-yloxy)-n-(2h-tetrazol-5-yl)-1h-indole-2-carboxamide(1:1); LS-21607; 5-Methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide L-arginate salt; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
DMN4QSW CP Dura Pharmaceuticals Inc
DMN4QSW DT Small molecular drug
DMN4QSW PC 159563
DMN4QSW MW 392.4
DMN4QSW FM C20H20N6O3
DMN4QSW IC InChI=1S/C20H20N6O3/c1-12(2)29-18-15-11-14(28-3)9-10-16(15)26(13-7-5-4-6-8-13)17(18)19(27)21-20-22-24-25-23-20/h4-12H,1-3H3,(H2,21,22,23,24,25,27)
DMN4QSW CS CC(C)OC1=C(N(C2=C1C=C(C=C2)OC)C3=CC=CC=C3)C(=O)NC4=NNN=N4
DMN4QSW IK JPTSIWRGXIZEOO-UHFFFAOYSA-N
DMN4QSW IU 5-methoxy-1-phenyl-3-propan-2-yloxy-N-(2H-tetrazol-5-yl)indole-2-carboxamide
DMN4QSW CA CAS 104961-19-5
DMN4QSW DE Asthma
DMBO28J ID DMBO28J
DMBO28J DN CI-976
DMBO28J HS Discontinued in Phase 2
DMBO28J SN CI 976; 114289-47-3; 2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide; CI-976; PD 128042; BRN 5831010; CHEMBL22373; UNII-8653IQ20EA; 8653IQ20EA; Dodecanamide,2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-; Dodecanamide, 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-; 2,2-Dimethyl-dodecanoic acid (2,4,6-trimethoxy-phenyl)-amide; C23H39NO4; ACMC-1CUXF; AC1L3UE4; SCHEMBL691688; CTK4A8660; CHEBI:95040; DTXSID00150690; MolPort-002-018-232; HMS3268D10; HMS3262L19; ZINC8022586; Tox21_500859; BN0150; BDBM50005944; AKOS022180044; LP00859; CCG-222163
DMBO28J DT Small molecular drug
DMBO28J PC 122327
DMBO28J MW 393.6
DMBO28J FM C23H39NO4
DMBO28J IC InChI=1S/C23H39NO4/c1-7-8-9-10-11-12-13-14-15-23(2,3)22(25)24-21-19(27-5)16-18(26-4)17-20(21)28-6/h16-17H,7-15H2,1-6H3,(H,24,25)
DMBO28J CS CCCCCCCCCCC(C)(C)C(=O)NC1=C(C=C(C=C1OC)OC)OC
DMBO28J IK WAFNZAURAWBNDZ-UHFFFAOYSA-N
DMBO28J IU 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide
DMBO28J CA CAS 114289-47-3
DMBO28J CB CHEBI:95040
DMBO28J DE Hyperlipidaemia
DMTAKNF ID DMTAKNF
DMTAKNF DN Cipralisant
DMTAKNF HS Discontinued in Phase 2
DMTAKNF SN Cipralisant [INN]; 5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole
DMTAKNF CP Gliatech
DMTAKNF DT Small molecular drug
DMTAKNF PC 6450823
DMTAKNF MW 216.32
DMTAKNF FM C14H20N2
DMTAKNF IC InChI=1S/C14H20N2/c1-14(2,3)7-5-4-6-11-8-12(11)13-9-15-10-16-13/h9-12H,5,7-8H2,1-3H3,(H,15,16)/t11-,12-/m1/s1
DMTAKNF CS CC(C)(C)CCC#C[C@@H]1C[C@H]1C2=CN=CN2
DMTAKNF IK CVKJAXCQPFOAIN-VXGBXAGGSA-N
DMTAKNF IU 5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole
DMTAKNF CA CAS 213027-19-1
DMTAKNF DE Attention deficit hyperactivity disorder
DM1CDNS ID DM1CDNS
DM1CDNS DN CJ-13610
DM1CDNS HS Discontinued in Phase 2
DM1CDNS SN CJ 13610; CJ-13,610
DM1CDNS CP Pfizer
DM1CDNS DT Small molecular drug
DM1CDNS PC 9821945
DM1CDNS MW 393.5
DM1CDNS FM C22H23N3O2S
DM1CDNS IC InChI=1S/C22H23N3O2S/c1-16-24-11-12-25(16)18-5-7-19(8-6-18)28-20-4-2-3-17(15-20)22(21(23)26)9-13-27-14-10-22/h2-8,11-12,15H,9-10,13-14H2,1H3,(H2,23,26)
DM1CDNS CS CC1=NC=CN1C2=CC=C(C=C2)SC3=CC=CC(=C3)C4(CCOCC4)C(=O)N
DM1CDNS IK VPTONMHDLLMOOV-UHFFFAOYSA-N
DM1CDNS IU 4-[3-[4-(2-methylimidazol-1-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide
DM1CDNS CA CAS 179420-17-8
DM1CDNS DE Asthma
DMQD2LS ID DMQD2LS
DMQD2LS DN CJC-1131
DMQD2LS HS Discontinued in Phase 2
DMQD2LS SN CJC-1131-albumin bioconjugate; DAC:GLP-1; Glucagon-like peptide 1, ConjuChem
DMQD2LS CP ConjuChem Biotechnologies Inc
DMQD2LS DT Small molecular drug
DMQD2LS PC 72941834
DMQD2LS MW 3722
DMQD2LS FM C168H254N44O52
DMQD2LS IC InChI=1S/C168H254N44O52/c1-17-89(10)137(165(260)188-93(14)144(239)197-118(72-99-75-180-104-38-25-24-37-102(99)104)155(250)199-114(68-86(4)5)156(251)208-135(87(6)7)163(258)196-106(40-26-29-58-169)146(241)181-77-125(221)189-107(42-32-61-179-168(174)175)150(245)191-105(140(173)235)39-28-31-60-177-128(224)83-264-66-65-263-64-62-178-124(220)57-63-212-129(225)52-53-130(212)226)210-157(252)116(69-96-33-20-18-21-34-96)200-152(247)112(50-56-133(231)232)195-151(246)108(41-27-30-59-170)192-142(237)91(12)185-141(236)90(11)187-149(244)111(47-51-123(172)219)190-126(222)78-182-148(243)110(49-55-132(229)230)194-153(248)113(67-85(2)3)198-154(249)115(71-98-43-45-101(218)46-44-98)201-160(255)120(80-213)204-162(257)122(82-215)205-164(259)136(88(8)9)209-159(254)119(74-134(233)234)202-161(256)121(81-214)206-167(262)139(95(16)217)211-158(253)117(70-97-35-22-19-23-36-97)203-166(261)138(94(15)216)207-127(223)79-183-147(242)109(48-54-131(227)228)193-143(238)92(13)186-145(240)103(171)73-100-76-176-84-184-100/h18-25,33-38,43-46,52-53,75-76,84-95,103,105-122,135-139,180,213-218H,17,26-32,39-42,47-51,54-74,77-83,169-171H2,1-16H3,(H2,172,219)(H2,173,235)(H,176,184)(H,177,224)(H,178,220)(H,181,241)(H,182,243)(H,183,242)(H,185,236)(H,186,240)(H,187,244)(H,188,260)(H,189,221)(H,190,222)(H,191,245)(H,192,237)(H,193,238)(H,194,248)(H,195,246)(H,196,258)(H,197,239)(H,198,249)(H,199,250)(H,200,247)(H,201,255)(H,202,256)(H,203,261)(H,204,257)(H,205,259)(H,206,262)(H,207,223)(H,208,251)(H,209,254)(H,210,252)(H,211,253)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H4,174,175,179)/t89-,90-,91-,92+,93-,94+,95+,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,135-,136-,137-,138-,139-/m0/s1
DMQD2LS CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC7=CNC=N7)N
DMQD2LS IK AIWAEWBZDJARBJ-PXUUZXDZSA-N
DMQD2LS IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[[(2S)-1-amino-6-[[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]acetyl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMQD2LS CA CAS 532951-64-7
DMQD2LS DE Type-1 diabetes
DM7LIDT ID DM7LIDT
DM7LIDT DN CL-283796
DM7LIDT HS Discontinued in Phase 2
DM7LIDT SN ACB-796; N-(4-Chloro-2,6-dimethylphenyl)-N'-heptyl-N'-[4-(3-methylbutyl)benzyl]urea
DM7LIDT PC 9955733
DM7LIDT MW 457.1
DM7LIDT FM C28H41ClN2O
DM7LIDT IC InChI=1S/C28H41ClN2O/c1-6-7-8-9-10-17-31(20-25-15-13-24(14-16-25)12-11-21(2)3)28(32)30-27-22(4)18-26(29)19-23(27)5/h13-16,18-19,21H,6-12,17,20H2,1-5H3,(H,30,32)
DM7LIDT CS CCCCCCCN(CC1=CC=C(C=C1)CCC(C)C)C(=O)NC2=C(C=C(C=C2C)Cl)C
DM7LIDT IK YQFGILAFZYCULR-UHFFFAOYSA-N
DM7LIDT IU 3-(4-chloro-2,6-dimethylphenyl)-1-heptyl-1-[[4-(3-methylbutyl)phenyl]methyl]urea
DM7LIDT DE Hyperlipidaemia
DMKFMYR ID DMKFMYR
DMKFMYR DN CLOTURIN
DMKFMYR HS Discontinued in Phase 2
DMKFMYR SN VUFB-15686; N-(2-Chloroethyl)thiocarbamic acid 6-purinyl ester; (2-Chloroethyl)carbamothioic acid S-1H-purin-6-yl ester; 6-[N-(2-Chloroethyl)carbamoyl]thiopurine
DMKFMYR DT Small molecular drug
DMKFMYR PC 128676
DMKFMYR MW 257.7
DMKFMYR FM C8H8ClN5OS
DMKFMYR IC InChI=1S/C8H8ClN5OS/c9-1-2-10-8(15)16-7-5-6(12-3-11-5)13-4-14-7/h3-4H,1-2H2,(H,10,15)(H,11,12,13,14)
DMKFMYR CS C1=NC2=C(N1)C(=NC=N2)SC(=O)NCCCl
DMKFMYR IK OQBORDVFGPUGDV-UHFFFAOYSA-N
DMKFMYR IU S-(7H-purin-6-yl) N-(2-chloroethyl)carbamothioate
DMKFMYR CA CAS 104789-46-0
DMKFMYR DE Solid tumour/cancer
DMRVJ1A ID DMRVJ1A
DMRVJ1A DN Corus 1030
DMRVJ1A HS Discontinued in Phase 2
DMRVJ1A SN Inhaled Lidocaine
DMRVJ1A CP Gilead Sciences
DMRVJ1A DE Asthma
DMNJD9H ID DMNJD9H
DMNJD9H DN CP-118
DMNJD9H HS Discontinued in Phase 2
DMNJD9H SN Antihistamine combination
DMNJD9H CP Collegium Pharmaceuticals
DMNJD9H DE Allergic rhinitis
DM3OJP0 ID DM3OJP0
DM3OJP0 DN CP-122288
DM3OJP0 HS Discontinued in Phase 2
DM3OJP0 SN N-Methyl-3-[1-methylpyrrolidin-2(R)-ylmethyl]-1H-indol-5-ylmethylsulfonamide; 5-(Methylaminosulfonylmethyl)-3-[1-methylpyrrolidin-2(R)-ylmethyl]-1H-indole
DM3OJP0 DT Small molecular drug
DM3OJP0 PC 132552
DM3OJP0 MW 321.4
DM3OJP0 FM C16H23N3O2S
DM3OJP0 IC InChI=1S/C16H23N3O2S/c1-17-22(20,21)11-12-5-6-16-15(8-12)13(10-18-16)9-14-4-3-7-19(14)2/h5-6,8,10,14,17-18H,3-4,7,9,11H2,1-2H3/t14-/m1/s1
DM3OJP0 CS CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2C[C@H]3CCCN3C
DM3OJP0 IK BWQZTHPHLITOOZ-CQSZACIVSA-N
DM3OJP0 IU N-methyl-1-[3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indol-5-yl]methanesulfonamide
DM3OJP0 CA CAS 143321-74-8
DM3OJP0 DE Migraine
DM1OSUR ID DM1OSUR
DM1OSUR DN CP-195543
DM1OSUR HS Discontinued in Phase 2
DM1OSUR SN LB4 antagonist (RA), Pfizer; LB4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (inflammation), Pfizer; Leukotriene B4 antagonist (rheumatoid arthritis), Pfizer
DM1OSUR CP Pfizer Inc
DM1OSUR DT Small molecular drug
DM1OSUR PC 9823886
DM1OSUR MW 428.4
DM1OSUR FM C24H19F3O4
DM1OSUR IC InChI=1S/C24H19F3O4/c25-24(26,27)17-7-9-18(23(29)30)20(12-17)15-6-8-19-21(11-15)31-13-16(22(19)28)10-14-4-2-1-3-5-14/h1-9,11-12,16,22,28H,10,13H2,(H,29,30)/t16-,22+/m0/s1
DM1OSUR CS C1[C@@H]([C@H](C2=C(O1)C=C(C=C2)C3=C(C=CC(=C3)C(F)(F)F)C(=O)O)O)CC4=CC=CC=C4
DM1OSUR IK NZQDWKCNBOELAI-KSFYIVLOSA-N
DM1OSUR IU 2-[(3S,4R)-3-benzyl-4-hydroxy-3,4-dihydro-2H-chromen-7-yl]-4-(trifluoromethyl)benzoic acid
DM1OSUR CA CAS 204981-48-6
DM1OSUR DE Rheumatoid arthritis
DMZ76EM ID DMZ76EM
DMZ76EM DN CP-316,311
DMZ76EM HS Discontinued in Phase 2
DMZ76EM SN CP-316311
DMZ76EM CP Pfizer
DMZ76EM DT Small molecular drug
DMZ76EM PC 9818802
DMZ76EM MW 327.5
DMZ76EM FM C21H29NO2
DMZ76EM IC InChI=1S/C21H29NO2/c1-8-18(9-2)23-19-12-16(6)22-21(17(19)7)24-20-14(4)10-13(3)11-15(20)5/h10-12,18H,8-9H2,1-7H3
DMZ76EM CS CCC(CC)OC1=C(C(=NC(=C1)C)OC2=C(C=C(C=C2C)C)C)C
DMZ76EM IK ZSEJGVQTBLJRCQ-UHFFFAOYSA-N
DMZ76EM IU 3,6-dimethyl-4-pentan-3-yloxy-2-(2,4,6-trimethylphenoxy)pyridine
DMZ76EM CA CAS 175139-41-0
DMZ76EM DE Mood disorder; Major depressive disorder
DMH5LKS ID DMH5LKS
DMH5LKS DN CPA-926
DMH5LKS HS Discontinued in Phase 2
DMH5LKS SN 6-(2-Acetamido-2-deoxy-beta-D-glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one
DMH5LKS PC 9800054
DMH5LKS MW 381.3
DMH5LKS FM C17H19NO9
DMH5LKS IC InChI=1S/C17H19NO9/c1-7(20)18-14-16(24)15(23)12(6-19)27-17(14)26-11-4-8-2-3-13(22)25-10(8)5-9(11)21/h2-5,12,14-17,19,21,23-24H,6H2,1H3,(H,18,20)/t12-,14-,15-,16-,17-/m1/s1
DMH5LKS CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C(C=C3C(=C2)C=CC(=O)O3)O)CO)O)O
DMH5LKS IK OTXAWKXSJDFGID-LMHBHQSJSA-N
DMH5LKS IU N-[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(7-hydroxy-2-oxochromen-6-yl)oxyoxan-3-yl]acetamide
DMH5LKS DE Arthritis
DMVU4A5 ID DMVU4A5
DMVU4A5 DN CRD-5
DMVU4A5 HS Discontinued in Phase 2
DMVU4A5 SN Charge-regulating drugs (dyslipidemia/heart disease), Liponex
DMVU4A5 CP Liponex Inc
DMVU4A5 DE Hyperlipidaemia
DMZLIUQ ID DMZLIUQ
DMZLIUQ DN Cromafiban
DMZLIUQ HS Discontinued in Phase 2
DMZLIUQ CP Millennium Pharmaceuticals
DMZLIUQ DE Coronary artery disease
DMB9QSJ ID DMB9QSJ
DMB9QSJ DN CRx-191
DMB9QSJ HS Discontinued in Phase 2
DMB9QSJ CP CombinatoRx
DMB9QSJ DE Psoriatic disorder
DM39N7W ID DM39N7W
DM39N7W DN CRx-401
DM39N7W HS Discontinued in Phase 2
DM39N7W CP CombinatoRx
DM39N7W DE Type-2 diabetes
DM73C4K ID DM73C4K
DM73C4K DN Cryptophycin
DM73C4K HS Discontinued in Phase 2
DM73C4K SN Cryptophycin 1; cryptophycin; UNII-XO974V2M5T; 124689-65-2; XO974V2M5T; 10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone; CRYPTOPHYCIN A; 1,4-Dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-((3-chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-; C35H43ClN2O8; AC1O5PMQ; CHEMBL441018; SCHEMBL1346966; PSNOPSMXOBPNNV-VVCTWANISA-N; LS-172597; C16877
DM73C4K DT Small molecular drug
DM73C4K PC 6438401
DM73C4K MW 655.2
DM73C4K FM C35H43ClN2O8
DM73C4K IC InChI=1S/C35H43ClN2O8/c1-20(2)16-29-35(42)44-27(22(4)31-32(46-31)24-10-7-6-8-11-24)12-9-13-30(39)38-26(33(40)37-19-21(3)34(41)45-29)18-23-14-15-28(43-5)25(36)17-23/h6-11,13-15,17,20-22,26-27,29,31-32H,12,16,18-19H2,1-5H3,(H,37,40)(H,38,39)/b13-9+/t21-,22+,26-,27+,29+,31-,32-/m1/s1
DM73C4K CS C[C@@H]1CNC(=O)[C@H](NC(=O)/C=C/C[C@H](OC(=O)[C@@H](OC1=O)CC(C)C)[C@H](C)[C@@H]2[C@H](O2)C3=CC=CC=C3)CC4=CC(=C(C=C4)OC)Cl
DM73C4K IK PSNOPSMXOBPNNV-VVCTWANISA-N
DM73C4K IU (3S,6R,10R,13E,16S)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[(1S)-1-[(2R,3R)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
DM73C4K CA CAS 124689-65-2
DM1AEVT ID DM1AEVT
DM1AEVT DN CS-003
DM1AEVT HS Discontinued in Phase 2
DM1AEVT CP Sankyo
DM1AEVT DT Small molecular drug
DM1AEVT PC 9831640
DM1AEVT MW 710.1
DM1AEVT FM C34H39Cl3N2O6S
DM1AEVT IC InChI=1S/C34H38Cl2N2O6S.ClH/c1-41-29-18-24(19-30(42-2)31(29)43-3)32(39)38-16-17-44-33(22-38,25-8-9-27(35)28(36)20-25)10-13-37-14-11-34(12-15-37)26-7-5-4-6-23(26)21-45(34)40;/h4-9,18-20H,10-17,21-22H2,1-3H3;1H/t33-,45-;/m0./s1
DM1AEVT CS COC1=CC(=CC(=C1OC)OC)C(=O)N2CCO[C@](C2)(CCN3CCC4(CC3)C5=CC=CC=C5C[S@@]4=O)C6=CC(=C(C=C6)Cl)Cl.Cl
DM1AEVT IK IHDDYKNRVLPVEV-FFKPOUSOSA-N
DM1AEVT IU [(2R)-2-(3,4-dichlorophenyl)-2-[2-[(2S)-2-oxospiro[1H-2-benzothiophene-3,4'-piperidine]-1'-yl]ethyl]morpholin-4-yl]-(3,4,5-trimethoxyphenyl)methanone;hydrochloride
DM1AEVT DE Chronic obstructive pulmonary disease
DMGYXA4 ID DMGYXA4
DMGYXA4 DN CS-722
DMGYXA4 HS Discontinued in Phase 2
DMGYXA4 SN RS-722
DMGYXA4 CP Sankyo Co Ltd
DMGYXA4 DT Small molecular drug
DMGYXA4 PC 132659
DMGYXA4 MW 375.2
DMGYXA4 FM C16H20Cl2N2O4
DMGYXA4 IC InChI=1S/C16H19ClN2O4.ClH/c17-14-15(12-4-2-1-3-5-12)23-19(16(14)21)11-13(20)10-18-6-8-22-9-7-18;/h1-5,13,20H,6-11H2;1H/t13-;/m1./s1
DMGYXA4 CS C1COCCN1C[C@H](CN2C(=O)C(=C(O2)C3=CC=CC=C3)Cl)O.Cl
DMGYXA4 IK KIWUOCZHZROUNT-BTQNPOSSSA-N
DMGYXA4 IU 4-chloro-2-[(2R)-2-hydroxy-3-morpholin-4-ylpropyl]-5-phenyl-1,2-oxazol-3-one;hydrochloride
DMGYXA4 CA CAS 144886-17-9
DMGYXA4 DE Epilepsy
DM17I8O ID DM17I8O
DM17I8O DN CS-891B
DM17I8O HS Discontinued in Phase 2
DM17I8O CP Sankyo Co Ltd
DM17I8O DE Alopecia
DM09CUO ID DM09CUO
DM09CUO DN CTL-102-GDEPT
DM09CUO HS Discontinued in Phase 2
DM09CUO SN CTL-102; NTR-GDEPT; GDEPT (CTL-102), ML Laboratories; Gene directed chemotherapy (CTL-102), ML Laboratories; Ad-NTR + CB-1954 GDEPT, ML Labs; Human adenovirus (hAdV5) GDEPT (E coli nitroreductase (NTR)/CB-1954, aseptic prosthetic implant loosening), Broadvector
DM09CUO CP Cobra Biomanufacturing plc
DM09CUO DE Head and neck cancer
DMG3HX2 ID DMG3HX2
DMG3HX2 DN CV-6504
DMG3HX2 HS Discontinued in Phase 2
DMG3HX2 SN CV-6504; 117574-40-0; CV 6504; 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone; 2,5-Cyclohexadiene-1,4-dione,2,3,5-trimethyl-6-(3-pyridinylmethyl)-; ACMC-20mn9v; AC1L3QEW; ZINC4541; SCHEMBL2715544; CTK4B0337; DTXSID80151827; IPGAFOVEIIWXFR-UHFFFAOYSA-N; EX-A2681; 6-(3-pyridylmethyl)-2,3,5-trimethyl-1,4-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5-trimethyl-6-(3-pyridinylmethyl)-
DMG3HX2 DT Small molecular drug
DMG3HX2 PC 93543
DMG3HX2 MW 241.28
DMG3HX2 FM C15H15NO2
DMG3HX2 IC InChI=1S/C15H15NO2/c1-9-10(2)15(18)13(11(3)14(9)17)7-12-5-4-6-16-8-12/h4-6,8H,7H2,1-3H3
DMG3HX2 CS CC1=C(C(=O)C(=C(C1=O)C)CC2=CN=CC=C2)C
DMG3HX2 IK IPGAFOVEIIWXFR-UHFFFAOYSA-N
DMG3HX2 IU 2,3,5-trimethyl-6-(pyridin-3-ylmethyl)cyclohexa-2,5-diene-1,4-dione
DMG3HX2 CA CAS 117574-40-0
DMP8TKA ID DMP8TKA
DMP8TKA DN CY-208243
DMP8TKA HS Discontinued in Phase 2
DMP8TKA SN Indolophenanthridine; CY 208-243; 100999-26-6; CY-208-243; 4,6,6a,7,8,12b-Hexahydro-7-methylindolo(4,3-ab)-phenanthridine; Indolo(4,3-ab)phenanthridine, 4,6,6a,7,8,12b-hexahydro-7-methyl-, trans-(-)-; (6aR,12bR)-7-methyl-4,6,6a,7,8,12b-hexahydroindolo[4,3-ab]phenanthridine; Tocris-1249; AC1L1ODE; Biomol-NT_000032; AC1Q1IN1; CHEMBL313737; BPBio1_001225; SCHEMBL9364562; DTXSID9042598; CHEBI:93399; MolPort-003-983-825; HMS3267H13; ZINC26501186; AKOS024456489; API0009347; NCGC00025078-01; NCGC00025078-02; LS-183405
DMP8TKA CP Novartis AG
DMP8TKA DT Small molecular drug
DMP8TKA PC 58144
DMP8TKA MW 274.4
DMP8TKA FM C19H18N2
DMP8TKA IC InChI=1S/C19H18N2/c1-21-11-12-5-2-3-6-14(12)19-15-7-4-8-16-18(15)13(10-20-16)9-17(19)21/h2-8,10,17,19-20H,9,11H2,1H3/t17-,19-/m1/s1
DMP8TKA CS CN1CC2=CC=CC=C2[C@H]3[C@H]1CC4=CNC5=CC=CC3=C45
DMP8TKA IK WRNKIDLXXXIELU-IEBWSBKVSA-N
DMP8TKA IU (2R,11R)-10-methyl-10,15-diazapentacyclo[11.6.1.02,11.03,8.016,20]icosa-1(20),3,5,7,13,16,18-heptaene
DMP8TKA CA CAS 100999-26-6
DMP8TKA CB CHEBI:93399
DMP8TKA DE Pain
DMO9HWU ID DMO9HWU
DMO9HWU DN D-7193
DMO9HWU HS Discontinued in Phase 2
DMO9HWU SN D-7042
DMO9HWU CP Astra AB
DMO9HWU DE Immune System disease
DM48ECA ID DM48ECA
DM48ECA DN DA-5018
DM48ECA HS Discontinued in Phase 2
DM48ECA SN Capsavanil; Davasaicin; Da 5018; KR-25018; Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide hydrochloride
DM48ECA CP Dong-A
DM48ECA DT Small molecular drug
DM48ECA PC 177286
DM48ECA MW 406.9
DM48ECA FM C22H31ClN2O3
DM48ECA IC InChI=1S/C22H30N2O3.ClH/c1-16-6-7-18(13-17(16)2)5-4-11-24-22(25)15-19-8-9-20(27-12-10-23)21(14-19)26-3;/h6-9,13-14H,4-5,10-12,15,23H2,1-3H3,(H,24,25);1H
DM48ECA CS CC1=C(C=C(C=C1)CCCNC(=O)CC2=CC(=C(C=C2)OCCN)OC)C.Cl
DM48ECA IK OUEKLNJUMVZULZ-UHFFFAOYSA-N
DM48ECA IU 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide;hydrochloride
DM48ECA CA CAS 174661-97-3
DM48ECA DE Postherpetic neuralgia; Diabetic neuropathy
DMDQH5E ID DMDQH5E
DMDQH5E DN Dabuzalgron
DMDQH5E HS Discontinued in Phase 2
DMDQH5E SN R-450; Alpha-1 adrenoceptor agonist, Roche; Ro-115-1240
DMDQH5E CP Roche
DMDQH5E DT Small molecular drug
DMDQH5E PC 216249
DMDQH5E MW 317.79
DMDQH5E FM C12H16ClN3O3S
DMDQH5E IC InChI=1S/C12H16ClN3O3S/c1-8-10(19-7-11-14-5-6-15-11)4-3-9(13)12(8)16-20(2,17)18/h3-4,16H,5-7H2,1-2H3,(H,14,15)
DMDQH5E CS CC1=C(C=CC(=C1NS(=O)(=O)C)Cl)OCC2=NCCN2
DMDQH5E IK FOYWMEJSRSBQGB-UHFFFAOYSA-N
DMDQH5E IU N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl]methanesulfonamide
DMDQH5E CA CAS 219311-44-1
DMDQH5E CB CHEBI:142452
DMDQH5E DE Urinary incontinence
DMF3E51 ID DMF3E51
DMF3E51 DN DANOFLOXACIN
DMF3E51 HS Discontinued in Phase 2
DMF3E51 SN CP-76136; Danofloxacin < Rec INN; CP-76136-27 (mesylate); 1-Cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DMF3E51 DT Small molecular drug
DMF3E51 PC 71335
DMF3E51 MW 357.4
DMF3E51 FM C19H20FN3O3
DMF3E51 IC InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1
DMF3E51 CS CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F
DMF3E51 IK QMLVECGLEOSESV-RYUDHWBXSA-N
DMF3E51 IU 1-cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxoquinoline-3-carboxylic acid
DMF3E51 CA CAS 112398-08-0
DMF3E51 DE Bacterial infection
DMJ4WR6 ID DMJ4WR6
DMJ4WR6 DN Darotropium
DMJ4WR6 HS Discontinued in Phase 2
DMJ4WR6 CP GSK
DMJ4WR6 PC 25195533
DMJ4WR6 MW 345.5
DMJ4WR6 FM C24H29N2+
DMJ4WR6 IC InChI=1S/C24H29N2/c1-26(2)22-13-14-23(26)16-19(15-22)17-24(18-25,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,19,22-23H,13-17H2,1-2H3/q+1/t19?,22-,23+
DMJ4WR6 CS C[N+]1([C@@H]2CC[C@H]1CC(C2)CC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4)C
DMJ4WR6 IK BKLAJZNVMHLXAP-VKGMXUHCSA-N
DMJ4WR6 IU 3-[(1S,5R)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile
DMJ4WR6 CA CAS 850689-51-9
DMJ4WR6 DE Chronic obstructive pulmonary disease
DMOWIGC ID DMOWIGC
DMOWIGC DN DASANTAFIL
DMOWIGC HS Discontinued in Phase 2
DMOWIGC SN Dasantafil < USAN; SCH-446132; 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[2(R)-hydroxycyclopent-1(R)-ylamino]-3-(2-hydroxyethyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 7-(3-Bromo-4-methoxybenzyl)-1-ethyl-8-[2(R)-hydroxycyclopent-1(R)-ylamino]-3-(2-hydroxyethyl)xanthine
DMOWIGC DT Small molecular drug
DMOWIGC PC 9871410
DMOWIGC MW 522.4
DMOWIGC FM C22H28BrN5O5
DMOWIGC IC InChI=1S/C22H28BrN5O5/c1-3-26-20(31)18-19(27(9-10-29)22(26)32)25-21(24-15-5-4-6-16(15)30)28(18)12-13-7-8-17(33-2)14(23)11-13/h7-8,11,15-16,29-30H,3-6,9-10,12H2,1-2H3,(H,24,25)/t15-,16-/m1/s1
DMOWIGC CS CCN1C(=O)C2=C(N=C(N2CC3=CC(=C(C=C3)OC)Br)N[C@@H]4CCC[C@H]4O)N(C1=O)CCO
DMOWIGC IK RCJYGWGQCPDYSL-HZPDHXFCSA-N
DMOWIGC IU 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1R,2R)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione
DMOWIGC CA CAS 569351-91-3
DMOWIGC DE Erectile dysfunction
DMY3M0J ID DMY3M0J
DMY3M0J DN DAT-582
DMY3M0J HS Discontinued in Phase 2
DMY3M0J SN AS-5820
DMY3M0J CP Dainippon Pharmaceutical Co Ltd
DMY3M0J DT Small molecular drug
DMY3M0J PC 132326
DMY3M0J MW 450.4
DMY3M0J FM C22H29Cl2N5O
DMY3M0J IC InChI=1S/C22H27N5O.2ClH/c1-16-6-5-7-17(12-16)13-27-11-10-26(2)14-18(15-27)23-22(28)21-19-8-3-4-9-20(19)24-25-21;;/h3-9,12,18H,10-11,13-15H2,1-2H3,(H,23,28)(H,24,25);2*1H/t18-;;/m1../s1
DMY3M0J CS CC1=CC(=CC=C1)CN2CCN(C[C@H](C2)NC(=O)C3=NNC4=CC=CC=C43)C.Cl.Cl
DMY3M0J IK BDHAPQXDDJQQBI-JPKZNVRTSA-N
DMY3M0J IU N-[(6R)-1-methyl-4-[(3-methylphenyl)methyl]-1,4-diazepan-6-yl]-1H-indazole-3-carboxamide;dihydrochloride
DMY3M0J CA CAS 141034-42-6
DMY3M0J DE Nausea
DM9S3R8 ID DM9S3R8
DM9S3R8 DN Davalintide
DM9S3R8 HS Discontinued in Phase 2
DM9S3R8 SN Davalintide acetate; Second-generation amylinomimetics (obesity), Amylin
DM9S3R8 CP Amylin Pharmaceuticals Inc
DM9S3R8 PC 71587842
DM9S3R8 MW 3624
DM9S3R8 FM C152H248N50O49S2
DM9S3R8 IC InChI=1S/C152H248N50O49S2/c1-66(2)48-91(189-143(245)113(70(9)10)195-140(242)103-64-253-252-63-102(193-122(224)83(154)24-18-19-43-153)139(241)188-97(56-108(158)216)135(237)200-115(73(13)206)144(246)174-71(11)121(223)196-116(74(14)207)148(250)194-103)123(225)171-59-110(218)175-84(25-20-44-168-150(161)162)124(226)183-94(51-69(7)8)132(234)192-101(62-204)138(240)180-87(37-40-105(155)213)126(228)178-89(39-42-112(220)221)127(229)185-93(50-68(5)6)131(233)186-95(54-80-58-167-65-173-80)133(235)177-85(26-21-45-169-151(163)164)125(227)184-92(49-67(3)4)130(232)179-88(38-41-106(156)214)129(231)199-119(77(17)210)147(249)191-99(53-79-31-35-82(212)36-32-79)149(251)202-47-23-28-104(202)141(243)181-86(27-22-46-170-152(165)166)128(230)198-118(76(16)209)146(248)190-98(57-109(159)217)136(238)197-114(72(12)205)142(244)172-60-111(219)176-100(61-203)137(239)187-96(55-107(157)215)134(236)201-117(75(15)208)145(247)182-90(120(160)222)52-78-29-33-81(211)34-30-78/h29-36,58,65-77,83-104,113-119,203-212H,18-28,37-57,59-64,153-154H2,1-17H3,(H2,155,213)(H2,156,214)(H2,157,215)(H2,158,216)(H2,159,217)(H2,160,222)(H,167,173)(H,171,225)(H,172,244)(H,174,246)(H,175,218)(H,176,219)(H,177,235)(H,178,228)(H,179,232)(H,180,240)(H,181,243)(H,182,247)(H,183,226)(H,184,227)(H,185,229)(H,186,233)(H,187,239)(H,188,241)(H,189,245)(H,190,248)(H,191,249)(H,192,234)(H,193,224)(H,194,250)(H,195,242)(H,196,223)(H,197,238)(H,198,230)(H,199,231)(H,200,237)(H,201,236)(H,220,221)(H4,161,162,168)(H4,163,164,169)(H4,165,166,170)/t71-,72+,73+,74+,75+,76+,77+,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,113-,114-,115-,116-,117-,118-,119-/m0/s1
DM9S3R8 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N)[C@@H](C)O
DM9S3R8 IK SLYFITHISHUGLZ-QPMCIWSFSA-N
DM9S3R8 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-16-(2-amino-2-oxoethyl)-19-[[(2S)-2,6-diaminohexanoyl]amino]-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoic acid
DM9S3R8 CA CAS 863919-85-1
DM9S3R8 DE Obesity
DMXO9BQ ID DMXO9BQ
DMXO9BQ DN Daxalipram
DMXO9BQ HS Discontinued in Phase 2
DMXO9BQ SN PDE 4 inhibitor (multiple sclerosis), Schering AG
DMXO9BQ CP Bayer Schering Pharma AG
DMXO9BQ PC 449190
DMXO9BQ MW 265.3
DMXO9BQ FM C14H19NO4
DMXO9BQ IC InChI=1S/C14H19NO4/c1-4-7-18-12-8-10(5-6-11(12)17-3)14(2)9-15-13(16)19-14/h5-6,8H,4,7,9H2,1-3H3,(H,15,16)/t14-/m0/s1
DMXO9BQ CS CCCOC1=C(C=CC(=C1)[C@@]2(CNC(=O)O2)C)OC
DMXO9BQ IK PCCPERGCFKIYIS-AWEZNQCLSA-N
DMXO9BQ IU (5R)-5-(4-methoxy-3-propoxyphenyl)-5-methyl-1,3-oxazolidin-2-one
DMXO9BQ CA CAS 189940-24-7
DMXO9BQ DE Multiple sclerosis
DMGM2HY ID DMGM2HY
DMGM2HY DN DCDT-2980S
DMGM2HY HS Discontinued in Phase 2
DMGM2HY CP Genentech
DMGM2HY DT Antibody
DMGM2HY DE Diffuse large B-cell lymphoma; Non-hodgkin lymphoma
DMMV6RK ID DMMV6RK
DMMV6RK DN DDP-200
DMMV6RK HS Discontinued in Phase 2
DMMV6RK SN Overactive bladder therapeutics, Dynogen
DMMV6RK CP Dynogen
DMMV6RK DE Urinary incontinence
DM3AVO1 ID DM3AVO1
DM3AVO1 DN DE-081
DM3AVO1 HS Discontinued in Phase 2
DM3AVO1 SN Apafant; 105219-56-5; WEB-2086; Web 2086; Apafant [USAN:INN]; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; WEB 2086BS; WEB2086; UNII-J613NI05SV; WEB 2086 BS; BRN 4302553; C22H22ClN5O2S; J613NI05SV; CHEMBL280164; NCGC00092377-03; NCGC00092377-02; Apafantum; Apafanto; DSSTox_CID_28900; DSSTox_RID_83168; DSSTox_GSID_48974; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; [3H]apafant; Morpholine; Apafant (ophthalmic formulation), Santen
DM3AVO1 CP Santen Pharmaceutical Co Ltd
DM3AVO1 DT Small molecular drug
DM3AVO1 PC 65889
DM3AVO1 MW 456
DM3AVO1 FM C22H22ClN5O2S
DM3AVO1 IC InChI=1S/C22H22ClN5O2S/c1-14-25-26-19-13-24-21(16-4-2-3-5-18(16)23)17-12-15(31-22(17)28(14)19)6-7-20(29)27-8-10-30-11-9-27/h2-5,12H,6-11,13H2,1H3
DM3AVO1 CS CC1=NN=C2N1C3=C(C=C(S3)CCC(=O)N4CCOCC4)C(=NC2)C5=CC=CC=C5Cl
DM3AVO1 IK JGPJQFOROWSRRS-UHFFFAOYSA-N
DM3AVO1 IU 3-[7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-4-yl]-1-morpholin-4-ylpropan-1-one
DM3AVO1 CA CAS 105219-56-5
DM3AVO1 CB CHEBI:92490
DM3AVO1 DE Conjunctivitis; Ocular allergy
DM5QFT4 ID DM5QFT4
DM5QFT4 DN Declopramide
DM5QFT4 HS Discontinued in Phase 2
DM5QFT4 SN IBD therapy, Active Biotech; Inflammatory bowel disease therapy, Active Biotech; OXi-104; IMO-B project, Active Biotech; 3-CPA; 3-chloroprocainamide
DM5QFT4 CP OXiGENE Inc
DM5QFT4 DT Small molecular drug
DM5QFT4 PC 70177
DM5QFT4 MW 269.77
DM5QFT4 FM C13H20ClN3O
DM5QFT4 IC InChI=1S/C13H20ClN3O/c1-3-17(4-2)8-7-16-13(18)10-5-6-12(15)11(14)9-10/h5-6,9H,3-4,7-8,15H2,1-2H3,(H,16,18)
DM5QFT4 CS CCN(CC)CCNC(=O)C1=CC(=C(C=C1)N)Cl
DM5QFT4 IK YEYAKZXEBSVURO-UHFFFAOYSA-N
DM5QFT4 IU 4-amino-3-chloro-N-[2-(diethylamino)ethyl]benzamide
DM5QFT4 CA CAS 891-60-1
DM5QFT4 DE Inflammatory bowel disease
DMYJ28R ID DMYJ28R
DMYJ28R DN Deriglidole
DMYJ28R HS Discontinued in Phase 2
DMYJ28R SN SL-84.0418; SL-84.0714; SL-84.0715
DMYJ28R CP Synthelabo
DMYJ28R DT Small molecular drug
DMYJ28R PC 65945
DMYJ28R MW 255.36
DMYJ28R FM C16H21N3
DMYJ28R IC InChI=1S/C16H21N3/c1-2-7-16(15-17-8-9-18-15)11-13-5-3-4-12-6-10-19(16)14(12)13/h3-5H,2,6-11H2,1H3,(H,17,18)
DMYJ28R CS CCCC1(CC2=CC=CC3=C2N1CC3)C4=NCCN4
DMYJ28R IK BADQRNHAZHSOKC-UHFFFAOYSA-N
DMYJ28R IU 3-(4,5-dihydro-1H-imidazol-2-yl)-3-propyl-4-azatricyclo[5.3.1.04,11]undeca-1(10),7(11),8-triene
DMYJ28R CA CAS 122830-14-2
DMYJ28R DE Diabetic complication
DM6WSU2 ID DM6WSU2
DM6WSU2 DN Dermolastin
DM6WSU2 HS Discontinued in Phase 2
DM6WSU2 SN Dermolastin
DM6WSU2 CP Arriva Pharma
DM6WSU2 DT Small molecular drug
DM6WSU2 PC 188403
DM6WSU2 MW 449.7
DM6WSU2 FM C27H31NOS2
DM6WSU2 IC InChI=1S/C27H31NOS2/c1-5-28(14-8-6-7-13-27(2,3)4)18-22-10-9-11-25(16-22)29-19-26-17-24(21-31-26)23-12-15-30-20-23/h6,8-12,15-17,20-21H,5,14,18-19H2,1-4H3
DM6WSU2 CS CCN(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)OCC2=CC(=CS2)C3=CSC=C3
DM6WSU2 IK KIRGLCXNEVICOG-UHFFFAOYSA-N
DM6WSU2 IU N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine
DM6WSU2 DE Atopic dermatitis
DMLZIT2 ID DMLZIT2
DMLZIT2 DN Dexniguldipine
DMLZIT2 HS Discontinued in Phase 2
DMLZIT2 SN Dexniguldipine hydrochloride; BY-935; B-8509-035; B-859-35
DMLZIT2 CP ALTANA Pharma AG
DMLZIT2 DT Small molecular drug
DMLZIT2 PC 6918097
DMLZIT2 MW 609.7
DMLZIT2 FM C36H39N3O6
DMLZIT2 IC InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m1/s1
DMLZIT2 CS CC1=C([C@H](C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMLZIT2 IK SVJMLYUFVDMUHP-MGBGTMOVSA-N
DMLZIT2 IU 5-O-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMLZIT2 CA CAS 120054-86-6
DMLZIT2 CB CHEBI:103932
DMLZIT2 DE Solid tumour/cancer
DMJT8Q0 ID DMJT8Q0
DMJT8Q0 DN Dezinamide
DMJT8Q0 HS Discontinued in Phase 2
DMJT8Q0 SN ADD-94057; ADDR-84116; AHR-11748; AN-051
DMJT8Q0 CP A H Robins Co Inc
DMJT8Q0 DT Small molecular drug
DMJT8Q0 PC 146291
DMJT8Q0 MW 260.209
DMJT8Q0 FM C11H11F3N2O2
DMJT8Q0 IC InChI=1S/C11H11F3N2O2/c12-11(13,14)7-2-1-3-8(4-7)18-9-5-16(6-9)10(15)17/h1-4,9H,5-6H2,(H2,15,17)
DMJT8Q0 CS C1C(CN1C(=O)N)OC2=CC=CC(=C2)C(F)(F)F
DMJT8Q0 IK LIAILJLSVRAGSM-UHFFFAOYSA-N
DMJT8Q0 IU 3-[3-(trifluoromethyl)phenoxy]azetidine-1-carboxamide
DMJT8Q0 CA CAS 91077-32-6
DMJT8Q0 DE Epileptic seizures
DMVO9WM ID DMVO9WM
DMVO9WM DN DG041
DMVO9WM HS Discontinued in Phase 2
DMVO9WM SN DTSI; D-000151746; DG-041
DMVO9WM CP DeCODE genetics
DMVO9WM DT Small molecular drug
DMVO9WM PC 11296282
DMVO9WM MW 592.3
DMVO9WM FM C23H15Cl4FN2O3S2
DMVO9WM IC InChI=1S/C23H15Cl4FN2O3S2/c1-12-10-30(11-14-2-4-15(24)7-18(14)25)22-13(6-16(28)8-17(12)22)3-5-20(31)29-35(32,33)21-9-19(26)23(27)34-21/h2-10H,11H2,1H3,(H,29,31)/b5-3+
DMVO9WM CS CC1=CN(C2=C(C=C(C=C12)F)/C=C/C(=O)NS(=O)(=O)C3=CC(=C(S3)Cl)Cl)CC4=C(C=C(C=C4)Cl)Cl
DMVO9WM IK BFBTVZNKWXWKNZ-HWKANZROSA-N
DMVO9WM IU (E)-3-[1-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methylindol-7-yl]-N-(4,5-dichlorothiophen-2-yl)sulfonylprop-2-enamide
DMVO9WM CA CAS 861238-35-9
DMVO9WM DE Peripheral vascular disease
DM3I0GS ID DM3I0GS
DM3I0GS DN DG051
DM3I0GS HS Discontinued in Phase 2
DM3I0GS SN 929916-05-2; DG-051; (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid; CHEMBL565789; 4-[(2s)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}pyrrolidin-1-Yl]butanoate; compound 20 [PMID: 19950900]; SCHEMBL989668; GTPL6548; PVCTYSQBVIGZRU-KRWDZBQOSA-N; BDBM50303649; ZINC34884331; AKOS030525381; 4-[(2S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl]butanoic acid; 4-{(S)-2-[4-(4-Chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}-butyric Acid
DM3I0GS CP DeCODE genetics
DM3I0GS DT Small molecular drug
DM3I0GS PC 44818987
DM3I0GS MW 426.3
DM3I0GS FM C21H25Cl2NO4
DM3I0GS IC InChI=1S/C21H24ClNO4.ClH/c22-16-5-7-19(8-6-16)27-20-11-9-18(10-12-20)26-15-17-3-1-13-23(17)14-2-4-21(24)25;/h5-12,17H,1-4,13-15H2,(H,24,25);1H/t17-;/m0./s1
DM3I0GS CS C1C[C@H](N(C1)CCCC(=O)O)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl.Cl
DM3I0GS IK UCPVOTSNNAVKNE-LMOVPXPDSA-N
DM3I0GS IU 4-[(2S)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanoic acid;hydrochloride
DM3I0GS CA CAS 929915-58-2
DM3I0GS DE Myocardial infarction
DM64CAS ID DM64CAS
DM64CAS DN Didox
DM64CAS HS Discontinued in Phase 2
DM64CAS SN 69839-83-4; N,3,4-Trihydroxybenzamide; 3,4-Dihydroxybenzohydroxamic acid; NSC-324360; Benzamide, N,3,4-trihydroxy-; 3,4-Dihydroxyphenylhydroxamic acid; UNII-L106XFV0RQ; VF 147; NSC 324360; DIDO; CCRIS 7909; BRN 2096682; L106XFV0RQ; C7H7NO4; NSC324360; AC1L1F1T; Benzamide,3,4-trihydroxy-; AC1Q5DI9; N-3,4-Tridhydroxybenzamide; SCHEMBL171446; CHEMBL367788; SCHEMBL18732059; Didox, > SCHEMBL18346609; CTK8F9165; DTXSID90220134; QJMCKEPOKRERLN-UHFFFAOYSA-N; MolPort-009-019-216; KS-00001DF2; BCP16846; ZINC3872288; 1716AH
DM64CAS DT Small molecular drug
DM64CAS PC 3045
DM64CAS MW 169.13
DM64CAS FM C7H7NO4
DM64CAS IC InChI=1S/C7H7NO4/c9-5-2-1-4(3-6(5)10)7(11)8-12/h1-3,9-10,12H,(H,8,11)
DM64CAS CS C1=CC(=C(C=C1C(=O)NO)O)O
DM64CAS IK QJMCKEPOKRERLN-UHFFFAOYSA-N
DM64CAS IU N,3,4-trihydroxybenzamide
DM64CAS CA CAS 69839-83-4
DM64CAS DE Solid tumour/cancer
DMIP3EC ID DMIP3EC
DMIP3EC DN DM-83
DMIP3EC HS Discontinued in Phase 2
DMIP3EC CP DiaMedica Inc
DMIP3EC DE Type-2 diabetes
DMCNEOZ ID DMCNEOZ
DMCNEOZ DN DMP-543
DMCNEOZ HS Discontinued in Phase 2
DMCNEOZ SN XR-543
DMCNEOZ CP Bristol-Myers Squibb Pharma Co
DMCNEOZ DT Small molecular drug
DMCNEOZ PC 9887884
DMCNEOZ MW 412.4
DMCNEOZ FM C26H18F2N2O
DMCNEOZ IC InChI=1S/C26H18F2N2O/c27-23-13-17(9-11-29-23)15-26(16-18-10-12-30-24(28)14-18)21-7-3-1-5-19(21)25(31)20-6-2-4-8-22(20)26/h1-14H,15-16H2
DMCNEOZ CS C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2(CC4=CC(=NC=C4)F)CC5=CC(=NC=C5)F
DMCNEOZ IK MUJBUUDUXGDXLW-UHFFFAOYSA-N
DMCNEOZ IU 10,10-bis[(2-fluoropyridin-4-yl)methyl]anthracen-9-one
DMCNEOZ CA CAS 160588-45-4
DMCNEOZ CB CHEBI:93560
DMCNEOZ DE Parkinson disease
DMI5XKC ID DMI5XKC
DMI5XKC DN DMP-961
DMI5XKC HS Discontinued in Phase 2
DMI5XKC SN DPC-961; (-)-6-Chloro-4(S)-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one
DMI5XKC DT Small molecular drug
DMI5XKC PC 474120
DMI5XKC MW 314.69
DMI5XKC FM C14H10ClF3N2O
DMI5XKC IC InChI=1S/C14H10ClF3N2O/c15-9-3-4-11-10(7-9)13(14(16,17)18,20-12(21)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H2,19,20,21)/t13-/m0/s1
DMI5XKC CS C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)N2)C(F)(F)F
DMI5XKC IK JJWJSIAJLBEMEN-ZDUSSCGKSA-N
DMI5XKC IU (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
DMI5XKC CA CAS 214287-88-4
DMI5XKC DE Human immunodeficiency virus infection
DM4ZO01 ID DM4ZO01
DM4ZO01 DN DNK-333
DM4ZO01 HS Discontinued in Phase 2
DM4ZO01 SN DNK 333; DNK333; N-((R,R)-(E)-1-(3,4-Dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide
DM4ZO01 CP Novartis
DM4ZO01 DT Small molecular drug
DM4ZO01 PC 9939040
DM4ZO01 MW 624.4
DM4ZO01 FM C27H25Cl2F6N3O3
DM4ZO01 IC InChI=1S/C27H25Cl2F6N3O3/c1-38(25(41)16-12-17(26(30,31)32)14-18(13-16)27(33,34)35)19(10-15-5-7-20(28)21(29)11-15)6-8-23(39)37-22-4-2-3-9-36-24(22)40/h5-8,11-14,19,22H,2-4,9-10H2,1H3,(H,36,40)(H,37,39)/b8-6+/t19-,22+/m0/s1
DM4ZO01 CS CN([C@H](CC1=CC(=C(C=C1)Cl)Cl)/C=C/C(=O)N[C@@H]2CCCCNC2=O)C(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DM4ZO01 IK BHCJHYIMNHXLOM-WVDRJWPYSA-N
DM4ZO01 IU N-[(E,2R)-1-(3,4-dichlorophenyl)-5-oxo-5-[[(3R)-2-oxoazepan-3-yl]amino]pent-3-en-2-yl]-N-methyl-3,5-bis(trifluoromethyl)benzamide
DM4ZO01 CA CAS 398507-81-8
DM4ZO01 DE Irritable bowel syndrome
DMMC6H7 ID DMMC6H7
DMMC6H7 DN Dopropidil
DMMC6H7 HS Discontinued in Phase 2
DMMC6H7 SN CERM-4205
DMMC6H7 CP Riom Laboratories
DMMC6H7 DT Small molecular drug
DMMC6H7 PC 71236
DMMC6H7 MW 321.5
DMMC6H7 FM C20H35NO2
DMMC6H7 IC InChI=1S/C20H35NO2/c1-4-10-20(11-6-5-7-12-20)23-17-19(16-22-15-18(2)3)21-13-8-9-14-21/h18-19H,5-9,11-17H2,1-3H3
DMMC6H7 CS CC#CC1(CCCCC1)OCC(COCC(C)C)N2CCCC2
DMMC6H7 IK FITWYAUFKJXWPL-UHFFFAOYSA-N
DMMC6H7 IU 1-[1-(2-methylpropoxy)-3-(1-prop-1-ynylcyclohexyl)oxypropan-2-yl]pyrrolidine
DMMC6H7 CA CAS 79700-61-1
DMMC6H7 DE Angina pectoris
DMTE14H ID DMTE14H
DMTE14H DN DOV-216303
DMTE14H HS Discontinued in Phase 2
DMTE14H SN 66504-40-3; CHEMBL528995; 3-Azabicyclo[3.1.0]hexane, 1-(3,4-dichlorophenyl)-; SCHEMBL79279; SCHEMBL9604846; CTK1J4675; MolPort-035-942-269; BSMNRYCSBFHEMQ-UHFFFAOYSA-N; DOV-2947; BDBM50243895; AKOS025396236; FCH1601649; SB10890; KB-50426; AS-51627; AK173863; CS-0052898; KS-00000461
DMTE14H CP DOV
DMTE14H DT Small molecular drug
DMTE14H PC 9795276
DMTE14H MW 228.11
DMTE14H FM C11H11Cl2N
DMTE14H IC InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2
DMTE14H CS C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
DMTE14H IK BSMNRYCSBFHEMQ-UHFFFAOYSA-N
DMTE14H IU 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
DMTE14H DE Mood disorder
DMKGXT2 ID DMKGXT2
DMKGXT2 DN DPI-3290
DMKGXT2 HS Discontinued in Phase 2
DMKGXT2 SN DPI-3290W93; (+)-3-[1(R)-[4-Allyl-2(S),5(R)-dimethylpiperazin-1-yl]-1-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide; 3290W93
DMKGXT2 CP Enhance Biotech
DMKGXT2 DT Small molecular drug
DMKGXT2 PC 9826770
DMKGXT2 MW 487.6
DMKGXT2 FM C30H34FN3O2
DMKGXT2 IC InChI=1S/C30H34FN3O2/c1-5-15-33-19-22(3)34(20-21(33)2)29(24-10-7-14-28(35)17-24)23-9-6-11-25(16-23)30(36)32(4)27-13-8-12-26(31)18-27/h5-14,16-18,21-22,29,35H,1,15,19-20H2,2-4H3/t21-,22+,29-/m1/s1
DMKGXT2 CS C[C@H]1CN([C@@H](CN1[C@H](C2=CC(=CC=C2)C(=O)N(C)C3=CC(=CC=C3)F)C4=CC(=CC=C4)O)C)CC=C
DMKGXT2 IK LZXRQLIIMYJZDA-UETOGOEVSA-N
DMKGXT2 IU 3-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide
DMKGXT2 CA CAS 182417-73-8
DMKGXT2 DE Pain
DMCZ75T ID DMCZ75T
DMCZ75T DN DRAFLAZINE
DMCZ75T HS Discontinued in Phase 2
DMCZ75T SN Draflazine < Rec INN; R-70380; R-75231; Rac-N-(4-Amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-2-carbamoylpiperazine-1-acetamide; Rac-2-(Aminocarbonyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4-fluorophenyl)pentyl]-1-piperazineacetamide; Rac-4'-Amino-4-[5,5-bis(p-fluorophenyl)pentyl]-2-carbamoyl-2',6'-dichloro-1-piperazineacetanilide
DMCZ75T DT Small molecular drug
DMCZ75T PC 60849
DMCZ75T MW 604.5
DMCZ75T FM C30H33Cl2F2N5O2
DMCZ75T IC InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)
DMCZ75T CS C1CN(C(CN1CCCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)N)CC(=O)NC4=C(C=C(C=C4Cl)N)Cl
DMCZ75T IK IWMYIWLIESDFRZ-UHFFFAOYSA-N
DMCZ75T IU 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide
DMCZ75T CA CAS 120770-34-5
DMCZ75T DE Cardiac arrhythmias
DM9JPUD ID DM9JPUD
DM9JPUD DN Droloxifene
DM9JPUD HS Discontinued in Phase 2
DM9JPUD SN E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen
DM9JPUD CP Klinge Pharma GmbH
DM9JPUD DT Small molecular drug
DM9JPUD PC 3033767
DM9JPUD MW 387.5
DM9JPUD FM C26H29NO2
DM9JPUD IC InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+
DM9JPUD CS CC/C(=C(/C1=CC=C(C=C1)OCCN(C)C)\\C2=CC(=CC=C2)O)/C3=CC=CC=C3
DM9JPUD IK ZQZFYGIXNQKOAV-OCEACIFDSA-N
DM9JPUD IU 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DM9JPUD CA CAS 82413-20-5
DM9JPUD CB CHEBI:34731
DM9JPUD DE Breast cancer
DM8GZWC ID DM8GZWC
DM8GZWC DN DS-4574
DM8GZWC HS Discontinued in Phase 2
DM8GZWC SN DS 4574; DS-4574; 118314-35-5; 6-(2-Cyclohexylethyl)-(1,3,4)thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one; (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(1H)-one, 6-(2-cyclohexylethyl)-; [1,3,4]Thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one,6-(2-cyclohexylethyl)-; AC1L4LXR; ACMC-20c9t1; AC1Q6E9S; SCHEMBL156066; CTK4B0638; DTXSID80152096; AKOS030534249; 6-(2-cyclohexylethyl)[1,3,4]thiadiazolo[3,2-a][1,2,3]triazolo[4,5-d]pyrimidin-9(2h)-one; LS-150402
DM8GZWC CP Daiichi Seiyaku Co Ltd
DM8GZWC DT Small molecular drug
DM8GZWC PC 159491
DM8GZWC MW 304.37
DM8GZWC FM C13H16N6OS
DM8GZWC IC InChI=1S/C13H16N6OS/c20-12-10-11(16-18-15-10)14-13-19(12)17-9(21-13)7-6-8-4-2-1-3-5-8/h8H,1-7H2,(H,15,16,18)
DM8GZWC CS C1CCC(CC1)CCC2=NN3C(=O)C4=NNN=C4N=C3S2
DM8GZWC IK ASIFEXZWAKYMRM-UHFFFAOYSA-N
DM8GZWC IU 11-(2-cyclohexylethyl)-10-thia-1,4,5,6,8,12-hexazatricyclo[7.3.0.03,7]dodeca-3,6,8,11-tetraen-2-one
DM8GZWC CA CAS 118314-35-5
DM8GZWC DE Asthma
DM63UA9 ID DM63UA9
DM63UA9 DN DU 125530
DM63UA9 HS Discontinued in Phase 2
DM63UA9 SN DU 125530; UNII-ZB05V621UD; CHEMBL79261; DU-125530; ZB05V621UD; 161611-99-0; DU125530; SCHEMBL1082516; BDBM85079; DTXSID00167208; MolPort-044-830-638; PDSP1_000932; PDSP2_000918; 1,2-Benzisothiazol-3(2H)-one, 2-(4-(4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl)butyl)-, 1,1-dioxide; L001571; 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]-butyl]-1,2-benzisothiazol-3(2h)-one-1,1-dioxide; 2-[4-[4-[(7-Chloro-2,3-dihydro-1,4-benzodioxin)-5-yl]-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,
DM63UA9 DT Small molecular drug
DM63UA9 PC 9848499
DM63UA9 MW 492
DM63UA9 FM C23H26ClN3O5S
DM63UA9 IC InChI=1S/C23H26ClN3O5S/c24-17-15-19(22-20(16-17)31-13-14-32-22)26-11-9-25(10-12-26)7-3-4-8-27-23(28)18-5-1-2-6-21(18)33(27,29)30/h1-2,5-6,15-16H,3-4,7-14H2
DM63UA9 CS C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=C5C(=CC(=C4)Cl)OCCO5
DM63UA9 IK LYXKFNHUJJDTIA-UHFFFAOYSA-N
DM63UA9 IU 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,1-dioxo-1,2-benzothiazol-3-one
DM63UA9 CA CAS 161611-99-0
DM63UA9 DE Mood disorder
DMQ9IO0 ID DMQ9IO0
DMQ9IO0 DN DuP-654
DMQ9IO0 HS Discontinued in Phase 2
DMQ9IO0 SN DUP-654; 2-benzylnaphthalen-1-ol; 2-Benzyl-1-naphthol; Dup 654; 36441-32-4; DuP654; 2-(phenylmethyl)-1-naphthol; UNII-96251IH9OJ; 2-Benzyl-1-hydroxynaphthalene; 2-(Phenylmethyl)-1-naphthalenol; BRN 1965326; CHEMBL85000; 96251IH9OJ; 1-Naphthalenol, 2-(phenylmethyl)-; AC1L4NCB; AC1Q7AVK; 2-phenylmethyl1-naphthol; 2-phenylmethyl-1-naphthol; 2-Benzyl-naphthalen-1-ol; 4-06-00-04990 (Beilstein Handbook Reference); SCHEMBL664782; DTXSID00189965; CZTSOXCSVFEFIK-UHFFFAOYSA-N; ZINC1485058; BDBM50004679; 2-Benzyl-naphthalen-1-ol(DuP 654)
DMQ9IO0 CP Bristol-Myers Squibb Pharma Co
DMQ9IO0 DT Small molecular drug
DMQ9IO0 PC 160268
DMQ9IO0 MW 234.29
DMQ9IO0 FM C17H14O
DMQ9IO0 IC InChI=1S/C17H14O/c18-17-15(12-13-6-2-1-3-7-13)11-10-14-8-4-5-9-16(14)17/h1-11,18H,12H2
DMQ9IO0 CS C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3C=C2)O
DMQ9IO0 IK CZTSOXCSVFEFIK-UHFFFAOYSA-N
DMQ9IO0 IU 2-benzylnaphthalen-1-ol
DMQ9IO0 CA CAS 36441-32-4
DMQ9IO0 DE Pruritus
DMSTA5L ID DMSTA5L
DMSTA5L DN DX-619
DMSTA5L HS Discontinued in Phase 2
DMSTA5L SN Quinolone derivative (injectable, bacterial infection), Daiichi Sankyo
DMSTA5L CP Daiichi Seiyaku Co Ltd
DMSTA5L DT Small molecular drug
DMSTA5L PC 9865774
DMSTA5L MW 401.4
DMSTA5L FM C21H24FN3O4
DMSTA5L IC InChI=1S/C21H24FN3O4/c1-29-19-15(24-7-4-11(9-24)21(23)5-6-21)3-2-12-17(19)25(16-8-14(16)22)10-13(18(12)26)20(27)28/h2-3,10-11,14,16H,4-9,23H2,1H3,(H,27,28)/t11-,14+,16-/m1/s1
DMSTA5L CS COC1=C(C=CC2=C1N(C=C(C2=O)C(=O)O)[C@@H]3C[C@@H]3F)N4CC[C@H](C4)C5(CC5)N
DMSTA5L IK ZLICIITZJTYKAQ-DIOULYMOSA-N
DMSTA5L IU 7-[(3R)-3-(1-aminocyclopropyl)pyrrolidin-1-yl]-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid
DMSTA5L CA CAS 431058-65-0
DMSTA5L DE Bacterial infection
DMEQLC4 ID DMEQLC4
DMEQLC4 DN DX-9065
DMEQLC4 HS Discontinued in Phase 2
DMEQLC4 SN DX-9065 (enteric-coated tablet)
DMEQLC4 CP Daiichi Sankyo Co Ltd
DMEQLC4 DE Coagulation defect
DMIXUMZ ID DMIXUMZ
DMIXUMZ DN DX-9065a
DMIXUMZ HS Discontinued in Phase 2
DMIXUMZ SN dx-9065a; QXQVEPEVI2; UNII-QXQVEPEVI2; 155204-81-2; 2-(4-((1-Acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphthyl)propanoic acid hydrocloride pentahydrate; DX 9065a; (S-(R*,R*))-7-(Aminoiminomethyl)-alpha-(4-((1-(1-iminoethyl)-3-pyrrolidinyl)oxy)phenyl)-2-naphthalenepropanoic acid monohydrochloride, pentahydrate; 2-Naphthalenepropanoic acid, 7-(aminoiminomethyl)-alpha-(4-((1-(1-iminoethyl)-3-pyrrolidinyl)oxy)phenyl)-, monohydrochloride, pentahydrate, (S-(R*,R*))-; AC1L3U17; X-9065a; C26H28N4O3.5H2O.HCl
DMIXUMZ DT Small molecular drug
DMIXUMZ PC 122128
DMIXUMZ MW 571.1
DMIXUMZ FM C26H39ClN4O8
DMIXUMZ IC InChI=1S/C26H28N4O3.ClH.5H2O/c1-16(27)30-11-10-23(15-30)33-22-8-6-19(7-9-22)24(26(31)32)13-17-2-3-18-4-5-20(25(28)29)14-21(18)12-17;;;;;;/h2-9,12,14,23-24,27H,10-11,13,15H2,1H3,(H3,28,29)(H,31,32);1H;5*1H2/t23-,24-;;;;;;/m0....../s1
DMIXUMZ CS CC(=N)N1CC[C@@H](C1)OC2=CC=C(C=C2)[C@H](CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)C(=O)O.O.O.O.O.O.Cl
DMIXUMZ IK LJCBAPRMNYSDOP-LVCYMWGESA-N
DMIXUMZ IU (2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3S)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;pentahydrate;hydrochloride
DMIXUMZ CA CAS 155204-81-2
DMIXUMZ DE Angina pectoris
DMT2WVP ID DMT2WVP
DMT2WVP DN Dynorphin A
DMT2WVP HS Discontinued in Phase 2
DMT2WVP SN Dynorphin A; 80448-90-4; Dynorphin A porcine; Dynorphin-(1-17); UNII-9M18T0TD14; 9M18T0TD14; MFCD00076351; Dynorphin A1-17; Dynorphin A (swine); Dynorphin acetate; Dynorphin A (1-17), porcine; JMNJYGMAUMANNW-FIXZTSJVSA-N; BDBM50096785; AKOS024457469; Dynorphin A porcine, > NCGC00167144-01
DMT2WVP DT Small molecular drug
DMT2WVP PC 16133805
DMT2WVP MW 2147.5
DMT2WVP FM C99H155N31O23
DMT2WVP IC InChI=1S/C99H155N31O23/c1-7-55(6)81(129-86(142)66(28-18-40-112-98(107)108)118-83(139)65(27-17-39-111-97(105)106)120-88(144)70(44-54(4)5)125-89(145)71(46-56-21-9-8-10-22-56)117-79(135)52-115-78(134)51-116-82(138)61(102)45-57-31-33-59(131)34-32-57)94(150)122-67(29-19-41-113-99(109)110)95(151)130-42-20-30-75(130)93(149)121-64(26-14-16-38-101)85(141)124-69(43-53(2)3)87(143)119-63(25-13-15-37-100)84(140)126-72(47-58-50-114-62-24-12-11-23-60(58)62)90(146)128-74(49-80(136)137)92(148)127-73(48-77(104)133)91(147)123-68(96(152)153)35-36-76(103)132/h8-12,21-24,31-34,50,53-55,61,63-75,81,114,131H,7,13-20,25-30,35-49,51-52,100-102H2,1-6H3,(H2,103,132)(H2,104,133)(H,115,134)(H,116,138)(H,117,135)(H,118,139)(H,119,143)(H,120,144)(H,121,149)(H,122,150)(H,123,147)(H,124,141)(H,125,145)(H,126,140)(H,127,148)(H,128,146)(H,129,142)(H,136,137)(H,152,153)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113)/t55-,61-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,81-/m0/s1
DMT2WVP CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)CNC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMT2WVP IK JMNJYGMAUMANNW-FIXZTSJVSA-N
DMT2WVP IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMT2WVP CA CAS 80448-90-4
DMHEW40 ID DMHEW40
DMHEW40 DN E-2078
DMHEW40 HS Discontinued in Phase 2
DMHEW40 SN 66A-078
DMHEW40 CP Eisai Co Ltd
DMHEW40 DT Small molecular drug
DMHEW40 PC 122220
DMHEW40 MW 1036.3
DMHEW40 FM C50H81N15O9
DMHEW40 IC InChI=1S/C50H81N15O9/c1-8-56-44(70)37(24-30(2)3)64-47(73)40(17-13-23-58-50(53)54)65(7)48(74)35(16-12-22-57-49(51)52)62-45(71)38(25-31(4)5)63-46(72)39(27-32-14-10-9-11-15-32)61-42(68)29-59-41(67)28-60-43(69)36(55-6)26-33-18-20-34(66)21-19-33/h9-11,14-15,18-21,30-31,35-40,55,66H,8,12-13,16-17,22-29H2,1-7H3,(H,56,70)(H,59,67)(H,60,69)(H,61,68)(H,62,71)(H,63,72)(H,64,73)(H4,51,52,57)(H4,53,54,58)/t35-,36-,37+,38-,39-,40-/m0/s1
DMHEW40 CS CCNC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC
DMHEW40 IK JENWDDCMEATQSR-ONSKYXJOSA-N
DMHEW40 IU (2R)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-3-(4-hydroxyphenyl)-2-(methylamino)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]-methylamino]pentanoyl]amino]-N-ethyl-4-methylpentanamide
DMHEW40 CA CAS 103613-84-9
DMHEW40 DE Pain
DM35KZG ID DM35KZG
DM35KZG DN E-3040
DM35KZG HS Discontinued in Phase 2
DM35KZG SN E-3040; E 3040; CHEMBL105139; 145096-30-6; E3040; AC1L9EDQ; CHEBI:4732; 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole; SCHEMBL6009376; DTXSID80162877; CHEBI:271098; 5,7-Dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-6-benzothiazolol; BDBM50037037; 6-Benzothiazolol, 5,7-dimethyl-2-(methylamino)-4-(3-pyridinylmethyl)-; C11593; L001447; 5,7-Dimethyl-2-methylamino-4-pyridin-3-ylmethyl-benzothiazol-6-ol; 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole
DM35KZG CP Eisai Co Ltd
DM35KZG DT Small molecular drug
DM35KZG PC 443292
DM35KZG MW 299.4
DM35KZG FM C16H17N3OS
DM35KZG IC InChI=1S/C16H17N3OS/c1-9-12(7-11-5-4-6-18-8-11)13-15(10(2)14(9)20)21-16(17-3)19-13/h4-6,8,20H,7H2,1-3H3,(H,17,19)
DM35KZG CS CC1=C(C2=C(C(=C1O)C)SC(=N2)NC)CC3=CN=CC=C3
DM35KZG IK IONAQTGMWFXHIX-UHFFFAOYSA-N
DM35KZG IU 5,7-dimethyl-2-(methylamino)-4-(pyridin-3-ylmethyl)-1,3-benzothiazol-6-ol
DM35KZG CA CAS 145096-30-6
DM35KZG CB CHEBI:4732
DM35KZG DE Thrombosis
DMWF95G ID DMWF95G
DMWF95G DN E-3620
DMWF95G HS Discontinued in Phase 2
DMWF95G CP Eisai Co Ltd
DMWF95G PC 11281359
DMWF95G MW 412.3
DMWF95G FM C20H27Cl2N3O2
DMWF95G IC InChI=1S/C20H26ClN3O2.ClH/c1-4-5-12(2)26-19-11-18(22)17(21)10-16(19)20(25)23-13-8-14-6-7-15(9-13)24(14)3;/h10-15H,6-9,22H2,1-3H3,(H,23,25);1H/t12-,13?,14-,15+;/m0./s1
DMWF95G CS CC#C[C@H](C)OC1=CC(=C(C=C1C(=O)NC2C[C@H]3CC[C@@H](C2)N3C)Cl)N.Cl
DMWF95G IK GMHMNKHDLXRRGF-LZMJSSQSSA-N
DMWF95G IU 4-amino-5-chloro-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-[(2S)-pent-3-yn-2-yl]oxybenzamide;hydrochloride
DMWF95G CA CAS 151213-86-4
DMWF95G DE Gastric motility disorder
DMWIA56 ID DMWIA56
DMWIA56 DN E-4021
DMWIA56 HS Discontinued in Phase 2
DMWIA56 SN E-4021; CHEMBL25616; E4021
DMWIA56 CP Eisai Co Ltd
DMWIA56 DT Small molecular drug
DMWIA56 PC 23665864
DMWIA56 MW 462.9
DMWIA56 FM C22H20ClN4NaO4
DMWIA56 IC InChI=1S/C22H21ClN4O4.Na/c23-15-2-3-17-16(10-15)20(24-11-13-1-4-18-19(9-13)31-12-30-18)26-22(25-17)27-7-5-14(6-8-27)21(28)29;/h1-4,9-10,14H,5-8,11-12H2,(H,28,29)(H,24,25,26);/q;+1/p-1
DMWIA56 CS C1CN(CCC1C(=O)[O-])C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=CC5=C(C=C4)OCO5.[Na+]
DMWIA56 IK LDYABEHPDDRNAF-UHFFFAOYSA-M
DMWIA56 IU sodium;1-[4-(1,3-benzodioxol-5-ylmethylamino)-6-chloroquinazolin-2-yl]piperidine-4-carboxylate
DMWIA56 DE Cardiovascular disease
DMU872N ID DMU872N
DMU872N DN E-4031
DMU872N HS Discontinued in Phase 2
DMU872N SN E-4031; E 4031; 113558-89-7; CHEMBL327980; CHEBI:34732; 2-Methyl-6-(2-(4-(4-methylsulfonylamino)benzoylpiperidin-1-yl)ethyl)pyridine; Methanesulfonamide, N-(4-((1-(2-(6-methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)-; N-(4-((1-(2-(6-Methyl-2-pyridinyl)ethyl)-4-piperidinyl)carbonyl)phenyl)methanesulfonamide; N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide; E4031; N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide; Tocris-1808; AC1Q6VTV
DMU872N DT Small molecular drug
DMU872N PC 3087190
DMU872N MW 474.4
DMU872N FM C21H29Cl2N3O3S
DMU872N IC InChI=1S/C21H27N3O3S.2ClH/c1-16-4-3-5-19(22-16)12-15-24-13-10-18(11-14-24)21(25)17-6-8-20(9-7-17)23-28(2,26)27;;/h3-9,18,23H,10-15H2,1-2H3;2*1H
DMU872N CS CC1=NC(=CC=C1)CCN2CCC(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C.Cl.Cl
DMU872N IK ZQBNWMFBOSOOLX-UHFFFAOYSA-N
DMU872N IU N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dihydrochloride
DMU872N CA CAS 113559-13-0
DMU872N DE Cardiac arrhythmias
DM2G7IP ID DM2G7IP
DM2G7IP DN E-4177
DM2G7IP HS Discontinued in Phase 2
DM2G7IP SN E-4177; 135070-05-2; CHEMBL71162; 2-[4-[(8-cyclopropyl-5-methyl-2,7,9-triazabicyclo[4.3.0]nona-1,3,5,7-tetraen-9-yl)methyl]phenyl]benzoic acid; E4177; VWWMGPCUZVOLLK-UHFFFAOYSA-N; ACMC-20mvn4; AC1L2ZXE; E 4177; SCHEMBL685515; CTK0I0030; DTXSID50159239; BDBM50049212; 3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine; L004970; 4''-(2-Cyclopropyl-7-methyl-imidazo[4,5-b]pyridin-3-ylmethyl)-biphenyl-2-carboxylic acid
DM2G7IP CP Eisai Co Ltd
DM2G7IP DT Small molecular drug
DM2G7IP PC 131857
DM2G7IP MW 383.4
DM2G7IP FM C24H21N3O2
DM2G7IP IC InChI=1S/C24H21N3O2/c1-15-12-13-25-23-21(15)26-22(18-10-11-18)27(23)14-16-6-8-17(9-7-16)19-4-2-3-5-20(19)24(28)29/h2-9,12-13,18H,10-11,14H2,1H3,(H,28,29)
DM2G7IP CS CC1=C2C(=NC=C1)N(C(=N2)C3CC3)CC4=CC=C(C=C4)C5=CC=CC=C5C(=O)O
DM2G7IP IK VWWMGPCUZVOLLK-UHFFFAOYSA-N
DM2G7IP IU 2-[4-[(2-cyclopropyl-7-methylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]benzoic acid
DM2G7IP CA CAS 135070-05-2
DM2G7IP DE Hypertension
DM562BM ID DM562BM
DM562BM DN E-5324
DM562BM HS Discontinued in Phase 2
DM562BM SN E-5324; 141799-76-0; CHEMBL47095; E 5324; E5324; AC1L30VJ; SCHEMBL692563; DTXSID20161824; BDBM50047557; n-Butyl-N'-(2-(3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy)-6-methylphenyl)urea; HY-19183; CS-0014924; Urea, N-butyl-N'-(2-(3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy)-6-methylphenyl)-; 1-butyl-3-[2-[3-(5-ethyl-4-phenylimidazol-1-yl)propoxy]-6-methylphenyl]urea
DM562BM CP Eisai Co Ltd
DM562BM DT Small molecular drug
DM562BM PC 132377
DM562BM MW 434.6
DM562BM FM C26H34N4O2
DM562BM IC InChI=1S/C26H34N4O2/c1-4-6-16-27-26(31)29-24-20(3)12-10-15-23(24)32-18-11-17-30-19-28-25(22(30)5-2)21-13-8-7-9-14-21/h7-10,12-15,19H,4-6,11,16-18H2,1-3H3,(H2,27,29,31)
DM562BM CS CCCCNC(=O)NC1=C(C=CC=C1OCCCN2C=NC(=C2CC)C3=CC=CC=C3)C
DM562BM IK NQZTZGNLFLQHKG-UHFFFAOYSA-N
DM562BM IU 1-butyl-3-[2-[3-(5-ethyl-4-phenylimidazol-1-yl)propoxy]-6-methylphenyl]urea
DM562BM CA CAS 141799-76-0
DM562BM DE Hyperlipidaemia
DMBFYWU ID DMBFYWU
DMBFYWU DN E-5531
DMBFYWU HS Discontinued in Phase 2
DMBFYWU SN E-1-O-phosphate; 2-Deoxy-6-O-[2-deoxy-3-O-[3(R)-[5(Z)-dodecenoyloxy]decyl]-6-O-methyl-2-(3-oxotetradecanamido)-4-O-phosphono-beta-D-glucopyranosyl]-3-O-[3(R)-hydroxydecyl]-2-(3-oxotetradecanamido)-alpha-D-glucopyranos
DMBFYWU PC 6442269
DMBFYWU MW 1455.8
DMBFYWU FM C73H136N2O22P2
DMBFYWU IC InChI=1S/C73H136N2O22P2/c1-7-12-17-22-25-28-31-36-40-45-58(77)53-63(79)74-66-70(90-51-49-57(76)44-39-34-20-15-10-4)68(82)61(94-73(66)97-99(86,87)88)56-92-72-67(75-64(80)54-59(78)46-41-37-32-29-26-23-18-13-8-2)71(69(96-98(83,84)85)62(95-72)55-89-6)91-52-50-60(47-42-35-21-16-11-5)93-65(81)48-43-38-33-30-27-24-19-14-9-3/h30,33,57,60-62,66-73,76,82H,7-29,31-32,34-56H2,1-6H3,(H,74,79)(H,75,80)(H2,83,84,85)(H2,86,87,88)/b33-30-/t57-,60-,61-,62-,66-,67-,68-,69-,70-,71-,72-,73-/m1/s1
DMBFYWU CS CCCCCCCCCCCC(=O)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC)OP(=O)(O)O)OCC[C@@H](CCCCCCC)OC(=O)CCC/C=C\\CCCCCC)NC(=O)CC(=O)CCCCCCCCCCC)O)OCC[C@@H](CCCCCCC)O
DMBFYWU IK GDODKYPBSZCPOO-XFMGTHRKSA-N
DMBFYWU IU [(3R)-1-[(2R,3R,4R,5S,6R)-2-[[(2R,3S,4R,5R,6R)-3-hydroxy-4-[(3R)-3-hydroxydecoxy]-5-(3-oxotetradecanoylamino)-6-phosphonooxyoxan-2-yl]methoxy]-6-(methoxymethyl)-3-(3-oxotetradecanoylamino)-5-phosphonooxyoxan-4-yl]oxydecan-3-yl] (Z)-dodec-5-enoate
DMBFYWU CA CAS 162679-36-9
DMBFYWU DE Sepsis
DM296V7 ID DM296V7
DM296V7 DN E-6080
DM296V7 HS Discontinued in Phase 2
DM296V7 SN E-6080; E 6080; 120164-49-0; E6080; AC1L2UXT; SCHEMBL3053845; DTXSID10152706; 6-Hydroxy-2-(4-sulfamoylbenzylamine)-4,5,7-trimethylbenzothiazole hcl; 6-hydroxy-2-(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride; Benzenesulfonamide, 4-(((6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino)methyl)-, monohydrochloride; 4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide hydrochloride
DM296V7 CP Eisai Co Ltd
DM296V7 DT Small molecular drug
DM296V7 PC 129064
DM296V7 MW 413.9
DM296V7 FM C17H20ClN3O3S2
DM296V7 IC InChI=1S/C17H19N3O3S2.ClH/c1-9-10(2)15(21)11(3)16-14(9)20-17(24-16)19-8-12-4-6-13(7-5-12)25(18,22)23;/h4-7,21H,8H2,1-3H3,(H,19,20)(H2,18,22,23);1H
DM296V7 CS CC1=C(C(=C(C2=C1N=C(S2)NCC3=CC=C(C=C3)S(=O)(=O)N)C)O)C.Cl
DM296V7 IK WLODMDLNSQYBMG-UHFFFAOYSA-N
DM296V7 IU 4-[[(6-hydroxy-4,5,7-trimethyl-1,3-benzothiazol-2-yl)amino]methyl]benzenesulfonamide;hydrochloride
DM296V7 CA CAS 120164-49-0
DM296V7 DE Asthma
DMUW6QX ID DMUW6QX
DMUW6QX DN E-6123
DMUW6QX HS Discontinued in Phase 2
DMUW6QX SN E 6123; 131614-02-3; E-6123; BRN 4280434; E- 6123; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolol(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-7,8,9,10-tetrahydro-1,4-dimethyl-, (S)-; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 7,8,9,10-tetrahydro-6-(2-chlorophenyl)-9-(cyclopropylcarbonyl)-1,4-dimethyl-, (S)-; AC1MHYY4; CHEMBL114014; DTXSID20157146; API0009208; HY-10164; LS-134356
DMUW6QX DT Small molecular drug
DMUW6QX PC 3035214
DMUW6QX MW 452
DMUW6QX FM C23H22ClN5OS
DMUW6QX IC InChI=1S/C23H22ClN5OS/c1-12-21-27-26-13(2)29(21)23-19(20(25-12)15-5-3-4-6-17(15)24)16-9-10-28(11-18(16)31-23)22(30)14-7-8-14/h3-6,12,14H,7-11H2,1-2H3/t12-/m0/s1
DMUW6QX CS C[C@H]1C2=NN=C(N2C3=C(C4=C(S3)CN(CC4)C(=O)C5CC5)C(=N1)C6=CC=CC=C6Cl)C
DMUW6QX IK JEQVYSUCZLYBRQ-LBPRGKRZSA-N
DMUW6QX IU [(7S)-9-(2-chlorophenyl)-3,7-dimethyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaen-14-yl]-cyclopropylmethanone
DMUW6QX CA CAS 131614-02-3
DMUW6QX DE Asthma
DMC28Y4 ID DMC28Y4
DMC28Y4 DN EAA-090
DMC28Y4 HS Discontinued in Phase 2
DMC28Y4 SN Perzinfotel; EAA 090; Way 126090; WAY-126090; Perzinfotel (USAN/INN); 2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-6-yl)ethylphosphonic acid
DMC28Y4 CP Wyeth
DMC28Y4 DT Small molecular drug
DMC28Y4 PC 6918236
DMC28Y4 MW 260.18
DMC28Y4 FM C9H13N2O5P
DMC28Y4 IC InChI=1S/C9H13N2O5P/c12-8-6-7(9(8)13)11(3-1-2-10-6)4-5-17(14,15)16/h10H,1-5H2,(H2,14,15,16)
DMC28Y4 CS C1CNC2=C(C(=O)C2=O)N(C1)CCP(=O)(O)O
DMC28Y4 IK BDABGOLMYNHHTR-UHFFFAOYSA-N
DMC28Y4 IU 2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethylphosphonic acid
DMC28Y4 CA CAS 144912-63-0
DMC28Y4 DE Diabetic neuropathy
DMJ2ZFV ID DMJ2ZFV
DMJ2ZFV DN EB-1053
DMJ2ZFV HS Discontinued in Phase 2
DMJ2ZFV SN EB 1053; 125946-92-1; Disodium 1-hydroxy-3-(1-pyrrolidinyl)propylidene-1,1-bisphosphonate; AC1L2Y2V; SCHEMBL3067217; DTXSID20154998; Phosphonic acid, (1-hydroxy-3-(1-pyrrolidinyl)propylidene)bis-, disodium salt; disodium (1-hydroxy-1-phosphonato-3-pyrrolidin-1-ylpropyl)phosphonic acid
DMJ2ZFV CP LEO Pharma A/S
DMJ2ZFV DT Small molecular drug
DMJ2ZFV PC 130822
DMJ2ZFV MW 289.16
DMJ2ZFV FM C7H17NO7P2
DMJ2ZFV IC InChI=1S/C7H17NO7P2/c9-7(16(10,11)12,17(13,14)15)3-6-8-4-1-2-5-8/h9H,1-6H2,(H2,10,11,12)(H2,13,14,15)
DMJ2ZFV CS C1CCN(C1)CCC(O)(P(=O)(O)O)P(=O)(O)O
DMJ2ZFV IK PMXAPNNYCFBALB-UHFFFAOYSA-N
DMJ2ZFV IU (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid
DMJ2ZFV CA CAS 125946-92-1
DMJ2ZFV DE Osteoporosis
DMRPUEC ID DMRPUEC
DMRPUEC DN EDONENTAN HYDRATE
DMRPUEC HS Discontinued in Phase 2
DMRPUEC SN Edonentan hydrate < USAN; BMS-207940 (anhydrous); BMS-207940-02; N-[2'-(4,5-Dimethylisoxazol-3-ylsulfamoyl)-4-(2-oxazolyl)biphenyl-2-ylmethyl]-N,3,3-trimethylbutyramide hydrate
DMRPUEC PC 156689
DMRPUEC MW 554.7
DMRPUEC FM C28H34N4O6S
DMRPUEC IC InChI=1S/C28H32N4O5S.H2O/c1-18-19(2)37-30-26(18)31-38(34,35)24-10-8-7-9-23(24)22-12-11-20(27-29-13-14-36-27)15-21(22)17-32(6)25(33)16-28(3,4)5;/h7-15H,16-17H2,1-6H3,(H,30,31);1H2
DMRPUEC CS CC1=C(ON=C1NS(=O)(=O)C2=CC=CC=C2C3=C(C=C(C=C3)C4=NC=CO4)CN(C)C(=O)CC(C)(C)C)C.O
DMRPUEC IK VRUJTPHFVRXEPB-UHFFFAOYSA-N
DMRPUEC IU N-[[2-[2-[(4,5-dimethyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]-5-(1,3-oxazol-2-yl)phenyl]methyl]-N,3,3-trimethylbutanamide;hydrate
DMRPUEC CA CAS 264609-13-4
DMRPUEC DE Pulmonary arterial hypertension
DMZXRF2 ID DMZXRF2
DMZXRF2 DN Eflucimibe
DMZXRF2 HS Discontinued in Phase 2
DMZXRF2 SN F-12511
DMZXRF2 CP Pierre Fabre SA
DMZXRF2 DT Small molecular drug
DMZXRF2 PC 9804740
DMZXRF2 MW 469.7
DMZXRF2 FM C29H43NO2S
DMZXRF2 IC InChI=1S/C29H43NO2S/c1-5-6-7-8-9-10-11-12-13-17-20-33-28(25-18-15-14-16-19-25)29(32)30-26-21-22(2)27(31)24(4)23(26)3/h14-16,18-19,21,28,31H,5-13,17,20H2,1-4H3,(H,30,32)/t28-/m0/s1
DMZXRF2 CS CCCCCCCCCCCCS[C@@H](C1=CC=CC=C1)C(=O)NC2=C(C(=C(C(=C2)C)O)C)C
DMZXRF2 IK ZXEIEKDGPVTZLD-NDEPHWFRSA-N
DMZXRF2 IU (2S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide
DMZXRF2 CA CAS 202340-45-2
DMZXRF2 DE Hyperlipidaemia
DM7TM91 ID DM7TM91
DM7TM91 DN ELAROFIBAN
DM7TM91 HS Discontinued in Phase 2
DM7TM91 SN Elarofiban; RWJ-53308; UNII-T9YH5NSL8U; T9YH5NSL8U; 198958-88-2; CHEMBL87728; (3s)-3-[({(3r)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]-3-(pyridin-3-yl)propanoic acid; Elarofiban [INN]; AC1L50BO; AC1Q5T2G; SCHEMBL1650115; CTK4E2665; BDBM50104600; AKOS027326865; (S)-beta-((R)-1-(3-(4-Piperidyl)propionyl)nipecotamido)-3-pyridinepropionic acid; (S)-3-{[(R)-1-(3-Piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-3-pyridin-3-yl-propionic acid
DM7TM91 DT Small molecular drug
DM7TM91 PC 216230
DM7TM91 MW 416.5
DM7TM91 FM C22H32N4O4
DM7TM91 IC InChI=1S/C22H32N4O4/c27-20(6-5-16-7-10-23-11-8-16)26-12-2-4-18(15-26)22(30)25-19(13-21(28)29)17-3-1-9-24-14-17/h1,3,9,14,16,18-19,23H,2,4-8,10-13,15H2,(H,25,30)(H,28,29)/t18-,19+/m1/s1
DM7TM91 CS C1C[C@H](CN(C1)C(=O)CCC2CCNCC2)C(=O)N[C@@H](CC(=O)O)C3=CN=CC=C3
DM7TM91 IK ABNXKGFLZFSILK-MOPGFXCFSA-N
DM7TM91 IU (3S)-3-[[(3R)-1-(3-piperidin-4-ylpropanoyl)piperidine-3-carbonyl]amino]-3-pyridin-3-ylpropanoic acid
DM7TM91 CA CAS 198958-88-2
DM7TM91 DE Thrombosis
DM0B23J ID DM0B23J
DM0B23J DN ELB-139
DM0B23J HS Discontinued in Phase 2
DM0B23J CP Elbion AG; 4AZA Bioscience
DM0B23J TC Psychiatric
DM0B23J DT Small molecular drug
DM0B23J PC 11277418
DM0B23J MW 277.75
DM0B23J FM C14H16ClN3O
DM0B23J IC InChI=1S/C14H16ClN3O/c15-11-4-6-12(7-5-11)18-10-13(16-14(18)19)17-8-2-1-3-9-17/h4-7H,1-3,8-10H2
DM0B23J CS C1CCN(CC1)C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl
DM0B23J IK YGXIELIREXEJQN-UHFFFAOYSA-N
DM0B23J IU 3-(4-chlorophenyl)-5-piperidin-1-yl-4H-imidazol-2-one
DM0B23J CA CAS 188116-08-7
DM0B23J DE Anxiety disorder
DMBCYRG ID DMBCYRG
DMBCYRG DN ELINAFIDE MESILATE
DMBCYRG HS Discontinued in Phase 2
DMBCYRG SN LU-79553; Elinafide mesilate; 2,2'-Propane-1,3-diylbis(iminoethylene)bis(2,3-dihydro-1H-benz[de]isoquinoline-1,3-dione)dimethanesulfonate
DMBCYRG DE Solid tumour/cancer
DM0XF8J ID DM0XF8J
DM0XF8J DN Elisartan potassium
DM0XF8J HS Discontinued in Phase 2
DM0XF8J SN HN-65021
DM0XF8J CP GE Healthcare
DM0XF8J DT Small molecular drug
DM0XF8J PC 23663417
DM0XF8J MW 591.1
DM0XF8J FM C27H28ClKN6O5
DM0XF8J IC InChI=1S/C27H28ClN6O5.K/c1-4-6-11-22-29-24(28)23(26(35)38-17(3)39-27(36)37-5-2)34(22)16-18-12-14-19(15-13-18)20-9-7-8-10-21(20)25-30-32-33-31-25;/h7-10,12-15,17H,4-6,11,16H2,1-3H3;/q-1;+1
DM0XF8J CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)C(=O)OC(C)OC(=O)OCC)Cl.[K+]
DM0XF8J IK LWBGIHXLGBYBNG-UHFFFAOYSA-N
DM0XF8J IU potassium;1-ethoxycarbonyloxyethyl 2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
DM0XF8J CA CAS 154568-18-0
DM0XF8J DE Hypertension
DMM5WQL ID DMM5WQL
DMM5WQL DN Elvucitabine
DMM5WQL HS Discontinued in Phase 2
DMM5WQL SN Elvucitabine; beta-L-Fd4C; 181785-84-2; UNII-M09BUF90C0; L-F-D4C; L-D4FC; ACH-126443; ACH-126,443; M09BUF90C0; 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one; ACH 126443; 4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1h)-one; L-Fd4C; Elvucitabine [USAN:INN]; 4-amino-5-fluoro-1-((2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-one; ACH 126,443; AC1LAJSF; AC1Q4HKY; Elvucitabine (USAN/INN); CHEMBL38700; ZINC7048; SCHEMBL1649928; CTK4D7977
DMM5WQL DT Small molecular drug
DMM5WQL PC 469717
DMM5WQL MW 227.19
DMM5WQL FM C9H10FN3O3
DMM5WQL IC InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1
DMM5WQL CS C1=C[C@H](O[C@H]1CO)N2C=C(C(=NC2=O)N)F
DMM5WQL IK HSBKFSPNDWWPSL-VDTYLAMSSA-N
DMM5WQL IU 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
DMM5WQL CA CAS 181785-84-2
DMM5WQL DE Human immunodeficiency virus infection
DM1EOC3 ID DM1EOC3
DM1EOC3 DN Elzasonan hydrochloride
DM1EOC3 HS Discontinued in Phase 2
DM1EOC3 SN Elzasonan HCl; CP 448187-01; Elzasonan hydrochloride (USAN); (2E)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride; (2Z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one hydrochloride
DM1EOC3 CP Pfizer
DM1EOC3 DT Small molecular drug
DM1EOC3 PC 6506051
DM1EOC3 MW 484.9
DM1EOC3 FM C22H24Cl3N3OS
DM1EOC3 IC InChI=1S/C22H23Cl2N3OS.ClH/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17;/h2-7,14-15H,8-13H2,1H3;1H/b21-14-;
DM1EOC3 CS CN1CCN(CC1)C2=CC=CC=C2/C=C\\3/C(=O)N(CCS3)C4=CC(=C(C=C4)Cl)Cl.Cl
DM1EOC3 IK NMTRXBJYASHMND-UXTSPRGOSA-N
DM1EOC3 IU (2Z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one;hydrochloride
DM1EOC3 CA CAS 220322-05-4
DM1EOC3 DE Mood disorder
DM0RXCK ID DM0RXCK
DM0RXCK DN Emapunil
DM0RXCK HS Discontinued in Phase 2
DM0RXCK SN Emapunil; 226954-04-7; AC-5216; AC 5216; UNII-OG837L732J; XBD173; CHEMBL513922; XBD-173; OG837L732J; N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7H-purin-9(8H)-yl)acetamide; AC5216; Emapunil [INN]; N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide; N-Benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9H-purin-9-yl)acetamide; Emapunil(AC-5216); AC1O5FL9; GTPL8704; SCHEMBL4757030; CTK4E9959; SYN5155; DTXSID40177220; AOB3568; MolPort-005-943-292; NBMBIEOUVBHEBM-UHFFFAOYSA-N; ZINC602486; EX-A1040; BCP14398; BDBM50266889
DM0RXCK CP Dainippon; Novartis
DM0RXCK DT Small molecular drug
DM0RXCK PC 6433109
DM0RXCK MW 401.5
DM0RXCK FM C23H23N5O2
DM0RXCK IC InChI=1S/C23H23N5O2/c1-3-27(15-17-10-6-4-7-11-17)20(29)16-28-22-19(26(2)23(28)30)14-24-21(25-22)18-12-8-5-9-13-18/h4-14H,3,15-16H2,1-2H3
DM0RXCK CS CCN(CC1=CC=CC=C1)C(=O)CN2C3=NC(=NC=C3N(C2=O)C)C4=CC=CC=C4
DM0RXCK IK NBMBIEOUVBHEBM-UHFFFAOYSA-N
DM0RXCK IU N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide
DM0RXCK CA CAS 226954-04-7
DM0RXCK DE Anxiety disorder
DMML2PX ID DMML2PX
DMML2PX DN EML-336
DMML2PX HS Discontinued in Phase 2
DMML2PX SN CRE-16336; EML-16336; ONO-5816
DMML2PX CP Merck Sante SA
DMML2PX DE Type-2 diabetes
DMIQRJW ID DMIQRJW
DMIQRJW DN EMR-62203
DMIQRJW HS Discontinued in Phase 2
DMIQRJW SN EMR-6203; PDE 5 inhibitor, Merck KGaA
DMIQRJW CP Merck KGaA
DMIQRJW DE Erectile dysfunction
DMDAS5B ID DMDAS5B
DMDAS5B DN Enalkiren
DMDAS5B HS Discontinued in Phase 2
DMDAS5B SN ENALKIREN; Enalquireno; 113082-98-7; Abbott-64662; Enalkirenum [INN-Latin]; Enalkirene [INN-French]; Enalquireno [INN-Spanish]; Abbott 64662; Enalkiren [USAN:INN]; UNII-0U7YZ42Z47; A-64662; CHEMBL300337; CHEBI:4787; 0U7YZ42Z47; A 64662; (alphaS)-alpha-((alphaS)-alpha-(3-Amino-3-methylbutyramido)-p-methoxyhydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)imidazole-4-propionamide; Enalkirenum; Enalkirene
DMDAS5B DT Small molecular drug
DMDAS5B PC 60594
DMDAS5B MW 656.9
DMDAS5B FM C35H56N6O6
DMDAS5B IC InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)/t27-,28-,29-,30-,32+/m0/s1
DMDAS5B CS CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=C(C=C3)OC)NC(=O)CC(C)(C)N)O)O
DMDAS5B IK KQXVERRYBYGQJZ-WRPDIKACSA-N
DMDAS5B IU 3-amino-N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-methylbutanamide
DMDAS5B CA CAS 113082-98-7
DMDAS5B CB CHEBI:4787
DMDAS5B DE Glaucoma/ocular hypertension
DME7OCX ID DME7OCX
DME7OCX DN ENIPORIDE
DME7OCX HS Discontinued in Phase 2
DME7OCX SN Eniporide; 176644-21-6; N-(diaminomethylene)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; N-Carbamimidoyl-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide; EMD-96785; UNII-7IGF9182QU; CHEMBL64360; 7IGF9182QU; Eniporide [INN]; C14H16N4O3S; N-(Diaminomethylene); AC1O5FJV; Eniporide(EMD96785); SCHEMBL6619621; CTK8C4436; UADMBZFZZOBWBB-UHFFFAOYSA-N; MolPort-035-675-643; KS-00000IZ2; EX-A1476; CZC25146; BCP09780; BDBM50058715; ANW-71932; 9260AA; ZINC13555902; AKOS024262733; AKOS016007503; DS-16493; AK-61121; AJ-64172
DME7OCX DT Small molecular drug
DME7OCX PC 6433092
DME7OCX MW 320.37
DME7OCX FM C14H16N4O3S
DME7OCX IC InChI=1S/C14H16N4O3S/c1-9-7-11(18-5-3-4-6-18)12(22(2,20)21)8-10(9)13(19)17-14(15)16/h3-8H,1-2H3,(H4,15,16,17,19)
DME7OCX CS CC1=CC(=C(C=C1C(=O)N=C(N)N)S(=O)(=O)C)N2C=CC=C2
DME7OCX IK UADMBZFZZOBWBB-UHFFFAOYSA-N
DME7OCX IU N-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-pyrrol-1-ylbenzamide
DME7OCX CA CAS 176644-21-6
DME7OCX DE Cardiac arrhythmias
DM05F1Z ID DM05F1Z
DM05F1Z DN ENRASENTAN
DM05F1Z HS Discontinued in Phase 2
DM05F1Z SN SB-217242; Enrasentan; (+)-(1S,2R,3S)-3-[2-(2-Hydroxyethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid
DM05F1Z CP GlaxoSmithKline
DM05F1Z DT Small molecular drug
DM05F1Z PC 178103
DM05F1Z MW 506.5
DM05F1Z FM C29H30O8
DM05F1Z IC InChI=1S/C29H30O8/c1-3-11-34-19-6-7-20-22(14-19)27(21-8-5-18(33-2)15-24(21)35-12-10-30)28(29(31)32)26(20)17-4-9-23-25(13-17)37-16-36-23/h4-9,13-15,26-28,30H,3,10-12,16H2,1-2H3,(H,31,32)/t26-,27+,28+/m0/s1
DM05F1Z CS CCCOC1=CC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=C(C=C(C=C3)OC)OCCO)C(=O)O)C4=CC5=C(C=C4)OCO5
DM05F1Z IK GLCKXJLCYIJMRB-UPRLRBBYSA-N
DM05F1Z IU (1S,2R,3S)-1-(1,3-benzodioxol-5-yl)-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-5-propoxy-2,3-dihydro-1H-indene-2-carboxylic acid
DM05F1Z CA CAS 167256-08-8
DM05F1Z CB CHEBI:156258
DM05F1Z DE Pulmonary arterial hypertension
DMG3R14 ID DMG3R14
DMG3R14 DN EP-2104R
DMG3R14 HS Discontinued in Phase 2
DMG3R14 SN Gadolinium labeled fibrin-binding peptide, EPIX Medical
DMG3R14 CP Epix Pharmaceutical
DMG3R14 DE Cardiovascular disease
DMZKBU9 ID DMZKBU9
DMZKBU9 DN EPC-K1
DMZKBU9 HS Discontinued in Phase 2
DMZKBU9 SN CHX-3107; Phosphoric acid 2-L-ascorbyl D,L-alpha-tocopheryl diester potassium salt; 2-O-[Hydroxy[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydro-2H-1-benzopyran-6-yloxy]phosphoryl]-L-ascorbic acid potassium salt
DMZKBU9 DT Small molecular drug
DMZKBU9 PC 54715165
DMZKBU9 MW 706.9
DMZKBU9 FM C35H56KO10P
DMZKBU9 IC InChI=1S/C35H57O10P.K/c1-21(2)12-9-13-22(3)14-10-15-23(4)16-11-18-35(8)19-17-27-26(7)30(24(5)25(6)31(27)43-35)44-46(40,41)45-33-29(38)32(28(37)20-36)42-34(33)39;/h21-23,28,32,36-38H,9-20H2,1-8H3,(H,40,41);/q;+1/p-1/t22-,23-,28+,32-,35-;/m1./s1
DMZKBU9 CS CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OP(=O)([O-])OC3=C([C@H](OC3=O)[C@H](CO)O)O)C.[K+]
DMZKBU9 IK VIHIKSJKXIMMLV-FZTHFCCHSA-M
DMZKBU9 IU potassium;[(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-yl] [(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate
DMZKBU9 CA CAS 127061-56-7
DMZKBU9 DE Nerve injury
DMJ52FZ ID DMJ52FZ
DMJ52FZ DN EPI-2010
DMJ52FZ HS Discontinued in Phase 2
DMJ52FZ TC Antisense
DMJ52FZ DT Antisense drug
DMJ52FZ DE Asthma
DM1WGUT ID DM1WGUT
DM1WGUT DN Epothilone D
DM1WGUT HS Discontinued in Phase 2
DM1WGUT SN Epothilone D; Desoxyepothilone b; (-)-Desoxyepothilone B; 189453-10-9; KOS-862; 12,13-Desoxyepothilone B; KOS 862; UNII-T0358E0YUF; (-)-Epothilone D; NSC-703147; T0358E0YUF; CHEBI:29579; 12,13-Deoxyepothilone B; NSC 703147; Epo D; EPD; (4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)oxacyclohexadec-13-ene-2,6-dione; (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methylthiazol-4-yl)vinyl]-1-oxacyclohexadec-13-ene-2,6-dione; dEpoB
DM1WGUT DT Small molecular drug
DM1WGUT PC 447865
DM1WGUT MW 491.7
DM1WGUT FM C27H41NO5S
DM1WGUT IC InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1
DM1WGUT CS C[C@H]1CCC/C(=C\\C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C2=CSC(=N2)C)/C)/C
DM1WGUT IK XOZIUKBZLSUILX-GIQCAXHBSA-N
DM1WGUT IU (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
DM1WGUT CA CAS 189453-10-9
DM1WGUT CB CHEBI:29579
DM1WGUT DE Breast cancer
DM6NTAS ID DM6NTAS
DM6NTAS DN ERA-923
DM6NTAS HS Discontinued in Phase 2
DM6NTAS SN Pipendoxifene; UNII-TPC5Q8496G; 198480-55-6; CHEMBL44426; TPC5Q8496G; Pipendoxifene [INN]; ERA 923; AC1O5FKF; SCHEMBL134583; JICOGKJOQXTAIP-UHFFFAOYSA-N; ZINC602799; BDBM50099587; AKOS030631784; DB05414; 2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol; US8815934, No 97; US8815934, No 107; 2-(p-Hydroxyphenyl)-3-methyl-1-(p-(2-piperidinoethoxy)benzyl)indol-5-ol; 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
DM6NTAS CP Wyeth
DM6NTAS DT Small molecular drug
DM6NTAS PC 6433099
DM6NTAS MW 456.6
DM6NTAS FM C29H32N2O3
DM6NTAS IC InChI=1S/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3
DM6NTAS CS CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
DM6NTAS IK JICOGKJOQXTAIP-UHFFFAOYSA-N
DM6NTAS IU 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol
DM6NTAS CA CAS 198480-55-6
DM6NTAS DE Breast cancer
DM03I7V ID DM03I7V
DM03I7V DN ERBULOZOLE
DM03I7V HS Discontinued in Phase 2
DM03I7V SN Erbulozole < Rec INN; R-55104; Ethyl rac-cis-p-[[[2-(Imidazol-1-ylmethyl)-2-(p-methoxyphenyl)-1,3-dioxolan-4-yl]methyl]thio]carbanilate; Rac-cis-[4-[[2-((1H-Imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylthio]phenyl]carbamic acid ethyl ester
DM03I7V DT Small molecular drug
DM03I7V PC 9934372
DM03I7V MW 469.6
DM03I7V FM C24H27N3O5S
DM03I7V IC InChI=1S/C24H27N3O5S/c1-3-30-23(28)26-19-6-10-22(11-7-19)33-15-21-14-31-24(32-21,16-27-13-12-25-17-27)18-4-8-20(29-2)9-5-18/h4-13,17,21H,3,14-16H2,1-2H3,(H,26,28)/t21-,24+/m1/s1
DM03I7V CS CCOC(=O)NC1=CC=C(C=C1)SC[C@H]2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC
DM03I7V IK KLEPCGBEXOCIGS-QPPBQGQZSA-N
DM03I7V IU ethyl N-[4-[[(2R,4R)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate
DM03I7V CA CAS 124784-31-2
DM03I7V DE Solid tumour/cancer
DMYR5OX ID DMYR5OX
DMYR5OX DN EREMOMYCIN
DMYR5OX HS Discontinued in Phase 2
DMYR5OX SN Hexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid; (4"R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-19-dechlorovancomycin; Etrahydroxy-6-(N2-methylleucylamido)-2,5,24,38,39-pentaoxo-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tetradecahydro-1H,22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno[1,6,9]oxadiazacyclo; 22-(3-Amino-2,3,6-trideoxy-3-C-methyl-L-arabinohexopyranosyloxy)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-L-arabinohexopyranosyl)-beta-D-glucopyranosyloxy]-3-(carbamoylmethyl)-10-chloro-7,28,30,32-t; 3-(Carbamoylmethyl)-10-chloro-7,28,30,32-tetrahydroxy-6-(N2-methylleucylamido)-2,5,24,38,39-pentaoxo-22-(4-epi-vancosaminyloxy)-44-[2-O-(4-epi-vancosaminyl)-beta-D-glucopyranosyloxy]-2,3,4,5,6,7,23,24; 35-dimetheno[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid
DMYR5OX PC 122131
DMYR5OX MW 1558
DMYR5OX FM C73H89ClN10O26
DMYR5OX IC InChI=1S/C73H89ClN10O26/c1-27(2)16-39(78-7)64(95)83-54-56(90)32-11-15-43(38(74)18-32)106-45-20-33-19-44(60(45)110-71-61(58(92)57(91)46(26-85)107-71)109-49-25-73(6,77)63(94)29(4)104-49)105-35-12-8-30(9-13-35)59(108-48-24-72(5,76)62(93)28(3)103-48)55-69(100)82-53(70(101)102)37-21-34(86)22-42(88)50(37)36-17-31(10-14-41(36)87)51(66(97)84-55)81-67(98)52(33)80-65(96)40(23-47(75)89)79-68(54)99/h8-15,17-22,27-29,39-40,46,48-49,51-59,61-63,71,78,85-88,90-94H,16,23-26,76-77H2,1-7H3,(H2,75,89)(H,79,99)(H,80,96)(H,81,98)(H,82,100)(H,83,95)(H,84,97)(H,101,102)/t28-,29-,39+,40-,46+,48-,49-,51+,52+,53-,54+,55-,56+,57+,58-,59+,61+,62-,63-,71-,72-,73-/m0/s1
DMYR5OX CS C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC=C(O4)C=C1)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)N)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
DMYR5OX IK UECIPBUIMXSXEI-BNSVOVDNSA-N
DMYR5OX IU (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-48-[(2S,3R,4S,5S,6R)-3-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-15-chloro-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3(50),4,6(49),8(48),9,11,14,16,29(45),30,32,34(39),35,37,46-pentadecaene-40-carboxylic acid
DMYR5OX CA CAS 110865-90-2
DMYR5OX DE Bacterial infection
DMTUHWM ID DMTUHWM
DMTUHWM DN Esreboxetine
DMTUHWM HS Discontinued in Phase 2
DMTUHWM SN (S,S)-reboxetine; 98819-76-2; UNII-L8S50ZY490; PNU-165442G; L8S50ZY490; Norebox; Davedax; Solvex; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine; Prolift; Esreboxetine [USAN:INN]; Esreboxetine (USAN/INN); (S,S)-( )-Reboxetine; S-Reboxetine; PNU 165442g; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; Tocris-1982; NCGC00025335-01; SCHEMBL34534; Reboxetine mesylate; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (S,S)-Reboxetine
DMTUHWM CP Pfizer
DMTUHWM DT Small molecular drug
DMTUHWM PC 65856
DMTUHWM MW 313.4
DMTUHWM FM C19H23NO3
DMTUHWM IC InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
DMTUHWM CS CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
DMTUHWM IK CBQGYUDMJHNJBX-OALUTQOASA-N
DMTUHWM IU (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
DMTUHWM CA CAS 98819-76-2
DMTUHWM CB CHEBI:125535
DMTUHWM DE Fibromyalgia
DM1DHOT ID DM1DHOT
DM1DHOT DN Esuprone
DM1DHOT HS Discontinued in Phase 2
DM1DHOT SN LU-43839; Esuprone; 7-Hydroxy-3,4-dimethyl-2H-1-benzopyran-2-one ethanesulfonate; 7-Hydroxy-3,4-dimethylcoumarin ethanesulfonate
DM1DHOT DT Small molecular drug
DM1DHOT PC 65827
DM1DHOT MW 282.31
DM1DHOT FM C13H14O5S
DM1DHOT IC InChI=1S/C13H14O5S/c1-4-19(15,16)18-10-5-6-11-8(2)9(3)13(14)17-12(11)7-10/h5-7H,4H2,1-3H3
DM1DHOT CS CCS(=O)(=O)OC1=CC2=C(C=C1)C(=C(C(=O)O2)C)C
DM1DHOT IK CHDGAVDQRSPBTA-UHFFFAOYSA-N
DM1DHOT IU (3,4-dimethyl-2-oxochromen-7-yl) ethanesulfonate
DM1DHOT CA CAS 91406-11-0
DM1DHOT DE Major depressive disorder
DMEGMA2 ID DMEGMA2
DMEGMA2 DN ETH615
DMEGMA2 HS Discontinued in Phase 2
DMEGMA2 SN Eth 615; Eth-615; 133430-69-0; CHEMBL310584; AC1L2ZIP; SCHEMBL7749388; DTXSID50158106; BDBM50006807; 4-({(3-Fluoro-benzyl)-[4-(quinolin-2-ylmethoxy)-phenyl]-amino}-methyl)-benzoic acid; Benzoic acid, 4-((((3-fluorophenyl)methyl)(4-(2-quinolinylmethoxy)phenyl)amino)methyl)-; 4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid
DMEGMA2 DT Small molecular drug
DMEGMA2 PC 131627
DMEGMA2 MW 492.5
DMEGMA2 FM C31H25FN2O3
DMEGMA2 IC InChI=1S/C31H25FN2O3/c32-26-6-3-4-23(18-26)20-34(19-22-8-10-25(11-9-22)31(35)36)28-14-16-29(17-15-28)37-21-27-13-12-24-5-1-2-7-30(24)33-27/h1-18H,19-21H2,(H,35,36)
DMEGMA2 CS C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=C(C=C3)N(CC4=CC=C(C=C4)C(=O)O)CC5=CC(=CC=C5)F
DMEGMA2 IK KRCUWCAUDKTMPB-UHFFFAOYSA-N
DMEGMA2 IU 4-[[N-[(3-fluorophenyl)methyl]-4-(quinolin-2-ylmethoxy)anilino]methyl]benzoic acid
DMEGMA2 CA CAS 133430-69-0
DMEGMA2 DE Dermatitis
DMRB23N ID DMRB23N
DMRB23N DN ETRX-101
DMRB23N HS Discontinued in Phase 2
DMRB23N SN MARstem; Angiotensin analog, Essential; Angiotensin analog, Maret
DMRB23N CP Maret Pharmaceuticals Inc
DMRB23N DE Anemia
DMOYMGV ID DMOYMGV
DMOYMGV DN EVT-101
DMOYMGV HS Discontinued in Phase 2
DMOYMGV SN EVT-101; UNII-B55T45AA8F; B55T45AA8F; CHEMBL3545349
DMOYMGV CP Roche
DMOYMGV TC Neurodegenerative
DMOYMGV DT Small molecular drug
DMOYMGV PC 72941990
DMOYMGV MW 391.2
DMOYMGV FM C16H15Cl2F3N4
DMOYMGV IC InChI=1S/C16H13F3N4.2ClH/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19;;/h2-8,16H,9H2,1H3;2*1H
DMOYMGV CS CC1=NC=CN1CC2=NN=CC(=C2)C3=CC(=C(C=C3)F)C(F)F.Cl.Cl
DMOYMGV IK OJBLXSPBJMGZDN-UHFFFAOYSA-N
DMOYMGV IU 5-[3-(difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine;dihydrochloride
DMOYMGV CA CAS 1189088-41-2
DMOYMGV DE Neuropathic pain
DMGJMQH ID DMGJMQH
DMGJMQH DN Examorelin
DMGJMQH HS Discontinued in Phase 2
DMGJMQH SN Hexarelin; EP-23905; MF-6003
DMGJMQH CP Mediolanum Farmaceutici SpA
DMGJMQH DT Small molecular drug
DMGJMQH PC 6918297
DMGJMQH MW 887
DMGJMQH FM C47H58N12O6
DMGJMQH IC InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1
DMGJMQH CS CC1=C(C2=CC=CC=C2N1)C[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC6=CN=CN6)N
DMGJMQH IK RVWNMGKSNGWLOL-GIIHNPQRSA-N
DMGJMQH IU (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
DMGJMQH CA CAS 140703-51-1
DMGJMQH DE Growth hormone deficiency
DMTUPZ2 ID DMTUPZ2
DMTUPZ2 DN Ezlopitant
DMTUPZ2 HS Discontinued in Phase 2
DMTUPZ2 SN UNII-3L098A8MPY; 147116-64-1; CJ-11974; CHEMBL515966; 3L098A8MPY; Ezlopitant [USAN:INN]; Ezlopitant (USAN/INN); (2s,3s)-2-(diphenylmethyl)-n-(5-isopropyl-2-methoxybenzyl)quinuclidin-3-amine; AC1L4NQ6; SCHEMBL383011; AC1Q573W; SCHEMBL9069731; GTPL5751; BDBM50262567; CJ11974; (2S,3S)-2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[222]octan-3-amine; CJ 11974; CJ-11, 974; D04122; 2beta-(Diphenylmethyl)-3beta-(2-methoxy-5-isopropylbenzylamino)-1beta,4beta-ethanopiperidine; Ezlopitant (USAN/INN); 2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[222]octan-3-amine; CJ 11,974-01
DMTUPZ2 CP Pfizer
DMTUPZ2 DT Small molecular drug
DMTUPZ2 PC 188927
DMTUPZ2 MW 454.6
DMTUPZ2 FM C31H38N2O
DMTUPZ2 IC InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1
DMTUPZ2 CS CC(C)C1=CC(=C(C=C1)OC)CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
DMTUPZ2 IK XPNMCDYOYIKVGB-CONSDPRKSA-N
DMTUPZ2 IU (2S,3S)-2-benzhydryl-N-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DMTUPZ2 CA CAS 147116-64-1
DMTUPZ2 DE Irritable bowel syndrome; Vomiting; Pain
DMMSFK0 ID DMMSFK0
DMMSFK0 DN Fabesetron
DMMSFK0 HS Discontinued in Phase 2
DMMSFK0 SN FK-1052
DMMSFK0 CP Fujisawa Pharmaceutical Co Ltd
DMMSFK0 DT Small molecular drug
DMMSFK0 PC 208947
DMMSFK0 MW 293.4
DMMSFK0 FM C18H19N3O
DMMSFK0 IC InChI=1S/C18H19N3O/c1-11-14-5-3-4-6-17(14)21-16(11)8-7-13(18(21)22)9-15-12(2)19-10-20-15/h3-6,10,13H,7-9H2,1-2H3,(H,19,20)/t13-/m1/s1
DMMSFK0 CS CC1=C2CC[C@@H](C(=O)N2C3=CC=CC=C13)CC4=C(NC=N4)C
DMMSFK0 IK AEKQMJRJRAHOAP-CYBMUJFWSA-N
DMMSFK0 IU (7R)-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]-8,9-dihydro-7H-pyrido[1,2-a]indol-6-one
DMMSFK0 CA CAS 129300-27-2
DMMSFK0 CB CHEBI:31588
DMMSFK0 DE Irritable bowel syndrome
DM8UC0K ID DM8UC0K
DM8UC0K DN FANDOFLOXACIN HYDROCHLORIDE
DM8UC0K HS Discontinued in Phase 2
DM8UC0K SN DW-116; Fandofloxacin hydrochloride; 6-Fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
DM8UC0K DT Small molecular drug
DM8UC0K PC 178086
DM8UC0K MW 436.8
DM8UC0K FM C20H19ClF2N4O3
DM8UC0K IC InChI=1S/C20H18F2N4O3.ClH/c1-24-4-6-25(7-5-24)17-9-16-13(8-15(17)22)19(27)14(20(28)29)11-26(16)18-3-2-12(21)10-23-18;/h2-3,8-11H,4-7H2,1H3,(H,28,29);1H
DM8UC0K CS CN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=NC=C(C=C4)F)F.Cl
DM8UC0K IK UPCHGBDAUCFDMW-UHFFFAOYSA-N
DM8UC0K IU 6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride
DM8UC0K CA CAS 164150-85-0
DM8UC0K DE Bacterial infection
DMRU1KT ID DMRU1KT
DMRU1KT DN Fasidotril
DMRU1KT HS Discontinued in Phase 2
DMRU1KT SN Fasidotril; Alatriopril; 135038-57-2; AC1NSKG8; SCHEMBL49006; GTPL6501; CHEMBL325695; ZINC1545064; BP-1137; BP1.137; phenylmethyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate; benzyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate
DMRU1KT DT Small molecular drug
DMRU1KT PC 5311337
DMRU1KT MW 443.5
DMRU1KT FM C23H25NO6S
DMRU1KT IC InChI=1S/C23H25NO6S/c1-15(23(27)28-12-17-6-4-3-5-7-17)24-22(26)19(13-31-16(2)25)10-18-8-9-20-21(11-18)30-14-29-20/h3-9,11,15,19H,10,12-14H2,1-2H3,(H,24,26)/t15-,19+/m0/s1
DMRU1KT CS C[C@@H](C(=O)OCC1=CC=CC=C1)NC(=O)[C@H](CC2=CC3=C(C=C2)OCO3)CSC(=O)C
DMRU1KT IK KKBIUAUSZKGNOA-HNAYVOBHSA-N
DMRU1KT IU benzyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate
DMRU1KT CA CAS 135038-57-2
DMRU1KT DE Hypotension
DMT2Z1L ID DMT2Z1L
DMT2Z1L DN FCE-22716
DMT2Z1L HS Discontinued in Phase 2
DMT2Z1L SN 1-(6-Methylergolin-8beta-yl)hydantoin; 1-[[(8beta)-6-Methylergolin-8-yl]methyl]-2,4-imidazolidinedione; 7beta-(2,4,-Dioxo-1-imidazolidinylmethyl)-9-methyl-2,5balpha,6,7,8,9,9abeta,10-octahydroindolo[4,3a,3-f,g]quinoline; 8beta-(2,4-Dioxo-1-imidazolidinylmethyl)-6-methylergoline
DMT2Z1L DT Small molecular drug
DMT2Z1L PC 125720
DMT2Z1L MW 338.4
DMT2Z1L FM C19H22N4O2
DMT2Z1L IC InChI=1S/C19H22N4O2/c1-22-8-11(9-23-10-17(24)21-19(23)25)5-14-13-3-2-4-15-18(13)12(7-20-15)6-16(14)22/h2-4,7,11,14,16,20H,5-6,8-10H2,1H3,(H,21,24,25)/t11-,14-,16-/m1/s1
DMT2Z1L CS CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC5=O
DMT2Z1L IK VXIHQTMCLKWCBN-DJSGYFEHSA-N
DMT2Z1L IU 1-[[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]methyl]imidazolidine-2,4-dione
DMT2Z1L CA CAS 95688-34-9
DMT2Z1L DE Hypertension
DMTQLIJ ID DMTQLIJ
DMTQLIJ DN FCP-3P1
DMTQLIJ HS Discontinued in Phase 2
DMTQLIJ SN CardioRex; Antihyperlipidemic, Forbes Medi-Tech
DMTQLIJ CP Forbes Medi-Tech Inc
DMTQLIJ DT Small molecular drug
DMTQLIJ PC 60496
DMTQLIJ MW 567.1
DMTQLIJ FM C26H31ClN2O8S
DMTQLIJ IC InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
DMTQLIJ CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O
DMTQLIJ IK ZPBWCRDSRKPIDG-UHFFFAOYSA-N
DMTQLIJ IU benzenesulfonic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DMTQLIJ CA CAS 111470-99-6
DMTQLIJ CB CHEBI:2669
DMTQLIJ DE Arteriosclerosis
DMJRF5G ID DMJRF5G
DMJRF5G DN FIDUXOSIN HYDROCHLORIDE
DMJRF5G HS Discontinued in Phase 2
DMJRF5G SN ABT-980; Fiduxosin hydrochloride < USAN; A-185980.1; (3aR,9bR)-cis-3-[4-(9-Methoxy-1,2,3,3a,4,9b-hexahydro-[1]benzopyrano[3,4-c]pyrrol-2-yl)butyl]-8-phenylpyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione hydrochloride
DMJRF5G DT Small molecular drug
DMJRF5G PC 172306
DMJRF5G MW 592.1
DMJRF5G FM C30H30ClN5O4S
DMJRF5G IC InChI=1S/C30H29N5O4S.ClH/c1-38-22-10-7-11-23-24(22)20-16-34(15-19(20)17-39-23)12-5-6-13-35-29(36)27-25(33-30(35)37)26-28(40-27)31-14-21(32-26)18-8-3-2-4-9-18;/h2-4,7-11,14,19-20H,5-6,12-13,15-17H2,1H3,(H,33,37);1H/t19-,20-;/m1./s1
DMJRF5G CS COC1=CC=CC2=C1[C@@H]3CN(C[C@@H]3CO2)CCCCN4C(=O)C5=C(C6=NC(=CN=C6S5)C7=CC=CC=C7)NC4=O.Cl
DMJRF5G IK OFPMGRPQOZABPO-GZJHNZOKSA-N
DMJRF5G IU 5-[4-[(3aR,9bR)-9-methoxy-3,3a,4,9b-tetrahydro-1H-chromeno[3,4-c]pyrrol-2-yl]butyl]-12-phenyl-8-thia-3,5,10,13-tetrazatricyclo[7.4.0.02,7]trideca-1(13),2(7),9,11-tetraene-4,6-dione;hydrochloride
DMJRF5G CA CAS 208992-74-9
DMJRF5G DE Prostate disease
DMGD5QN ID DMGD5QN
DMGD5QN DN Filaminast
DMGD5QN HS Discontinued in Phase 2
DMGD5QN SN FILAMINAST; Way-pda-641; UNII-CDD69JC61J; 141184-34-1; CDD69JC61J; (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONE O-(AMINOCARBONYL)OXIME; FIL; Filaminast [USAN:INN]; Filaminast (USAN/INN); SCHEMBL73844; SCHEMBL73843; CHEMBL590754; BDBM14771; 1-(3-(Cyclopentyloxy)-4-methoxyphenyl)ethanone-(E)-O-(aminocarbonyl)oxime; DB02660; D04185; 3'-(Cyclopentyloxy)-4'-methoxyacetophenone (E)-O-carbamoyloxime; [1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino] carbamate; (E)-{1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethylidene}amino
DMGD5QN DT Small molecular drug
DMGD5QN PC 9578243
DMGD5QN MW 292.33
DMGD5QN FM C15H20N2O4
DMGD5QN IC InChI=1S/C15H20N2O4/c1-10(17-21-15(16)18)11-7-8-13(19-2)14(9-11)20-12-5-3-4-6-12/h7-9,12H,3-6H2,1-2H3,(H2,16,18)/b17-10+
DMGD5QN CS C/C(=N\\OC(=O)N)/C1=CC(=C(C=C1)OC)OC2CCCC2
DMGD5QN IK STTRYQAGHGJXJJ-LICLKQGHSA-N
DMGD5QN IU [(E)-1-(3-cyclopentyloxy-4-methoxyphenyl)ethylideneamino] carbamate
DMGD5QN CA CAS 141184-34-1
DMGD5QN DE Chronic obstructive pulmonary disease
DM06SC9 ID DM06SC9
DM06SC9 DN FINROZOLE
DM06SC9 HS Discontinued in Phase 2
DM06SC9 SN MPV-2213ad; Finrozole; Rac-(R*,S*)-4-[3-(4-Fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile
DM06SC9 DT Small molecular drug
DM06SC9 PC 6918277
DM06SC9 MW 322.3
DM06SC9 FM C18H15FN4O
DM06SC9 IC InChI=1S/C18H15FN4O/c19-16-7-3-13(4-8-16)9-17(24)18(23-12-21-11-22-23)15-5-1-14(10-20)2-6-15/h1-8,11-12,17-18,24H,9H2/t17-,18+/m0/s1
DM06SC9 CS C1=CC(=CC=C1C[C@@H]([C@@H](C2=CC=C(C=C2)C#N)N3C=NC=N3)O)F
DM06SC9 IK SLJZVZKQYSKYNV-ZWKOTPCHSA-N
DM06SC9 IU 4-[(1R,2S)-3-(4-fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile
DM06SC9 CA CAS 160146-17-8
DM06SC9 DE Prostate disease
DMCINOE ID DMCINOE
DMCINOE DN FK-011
DMCINOE HS Discontinued in Phase 2
DMCINOE CP Fujisawa Pharmaceutical Co Ltd
DMCINOE DE Asthma
DM1JUS0 ID DM1JUS0
DM1JUS0 DN FK-224
DM1JUS0 HS Discontinued in Phase 2
DM1JUS0 SN FR-115224
DM1JUS0 CP Fujisawa Pharmaceutical Co Ltd
DM1JUS0 DT Small molecular drug
DM1JUS0 PC 6437864
DM1JUS0 MW 1041.2
DM1JUS0 FM C54H72N8O13
DM1JUS0 IC InChI=1S/C54H72N8O13/c1-7-8-10-17-36-18-13-14-19-37(36)22-25-45(67)60-47-33(5)75-54(74)42(30-63)59-49(69)41(29-44(55)66)58-52(72)46(32(4)64)61-50(70)40(27-34-15-11-9-12-16-34)56-48(68)39(26-31(2)3)57-51(71)43(62(6)53(47)73)28-35-20-23-38(65)24-21-35/h9,11-16,18-21,23-24,28,31-33,39-42,46-47,63-65H,7-8,10,17,22,25-27,29-30H2,1-6H3,(H2,55,66)(H,56,68)(H,57,71)(H,58,72)(H,59,69)(H,60,67)(H,61,70)/b43-28-
DM1JUS0 CS CCCCCC1=CC=CC=C1CCC(=O)NC2C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)/C(=C/C3=CC=C(C=C3)O)/N(C2=O)C)CC(C)C)CC4=CC=CC=C4)C(C)O)CC(=O)N)CO)C
DM1JUS0 IK BEWCDVTWUFJSSM-MBMPTNJISA-N
DM1JUS0 IU N-[(18Z)-6-(2-amino-2-oxoethyl)-12-benzyl-9-(1-hydroxyethyl)-3-(hydroxymethyl)-18-[(4-hydroxyphenyl)methylidene]-19,22-dimethyl-15-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1-oxa-4,7,10,13,16,19-hexazacyclodocos-21-yl]-3-(2-pentylphenyl)propanamide
DM1JUS0 CA CAS 125787-94-2
DM1JUS0 DE Asthma
DMHIUGT ID DMHIUGT
DMHIUGT DN FK-352
DMHIUGT HS Discontinued in Phase 2
DMHIUGT SN FK-325B; FK-352B
DMHIUGT CP Fujisawa Pharmaceutical Co Ltd
DMHIUGT DT Small molecular drug
DMHIUGT PC 6442241
DMHIUGT MW 389.4
DMHIUGT FM C23H23N3O3
DMHIUGT IC InChI=1S/C23H23N3O3/c27-21(25-14-6-4-10-18(25)16-22(28)29)13-12-19-20-11-5-7-15-26(20)24-23(19)17-8-2-1-3-9-17/h1-3,5,7-9,11-13,15,18H,4,6,10,14,16H2,(H,28,29)/b13-12+/t18-/m1/s1
DMHIUGT CS C1CCN([C@H](C1)CC(=O)O)C(=O)/C=C/C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMHIUGT IK UWTYIJJJSYDUQM-QFQMRYFISA-N
DMHIUGT IU 2-[(2R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-enoyl]piperidin-2-yl]acetic acid
DMHIUGT CA CAS 143881-08-7
DMHIUGT DE Hypertension
DMH3DXY ID DMH3DXY
DMH3DXY DN FK-453
DMH3DXY HS Discontinued in Phase 2
DMH3DXY SN FK-453; FK 453; CHEMBL440115; 121524-18-3; (+)-(R)-((E)-3-(2-Phenylpyrazolo(1,5-a)pyridin-3-yl)acryloyl)-2-piperidineethanol; (R-(E))-1-(1-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-2-propenyl)-2-piperidineethanol; C23H25N3O2; 2-Piperidineethanol, 1-(1-oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-2-propenyl)-, (R-(E))-; (E)-1-[(2R)-2-(2-hydroxyethyl)piperidin-1-yl]-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-en-1-one; AC1O5QYH; SCHEMBL2826910; GTPL5606; SCHEMBL3074643; FK453; ZINC1486608; FR-453; BDBM50079652; FR113453
DMH3DXY DT Small molecular drug
DMH3DXY PC 6439091
DMH3DXY MW 375.5
DMH3DXY FM C23H25N3O2
DMH3DXY IC InChI=1S/C23H25N3O2/c27-17-14-19-10-4-6-15-25(19)22(28)13-12-20-21-11-5-7-16-26(21)24-23(20)18-8-2-1-3-9-18/h1-3,5,7-9,11-13,16,19,27H,4,6,10,14-15,17H2/b13-12+/t19-/m1/s1
DMH3DXY CS C1CCN([C@H](C1)CCO)C(=O)/C=C/C2=C3C=CC=CN3N=C2C4=CC=CC=C4
DMH3DXY IK OPLOPFHUHFGKMJ-JXOMPUQVSA-N
DMH3DXY IU (E)-1-[(2R)-2-(2-hydroxyethyl)piperidin-1-yl]-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)prop-2-en-1-one
DMH3DXY CA CAS 121524-18-3
DMH3DXY DE Renal failure
DMR2FPO ID DMR2FPO
DMR2FPO DN FK-584
DMR2FPO HS Discontinued in Phase 2
DMR2FPO SN 4,4-Diphenylcyclopentenylamine hydrochloride; 2-Cyclopenten-1-amine, 4,4-diphenyl-, hydrochloride; 4,4-diphenyl-2-cyclopentenylamine; FK 584; 56740-43-3; AC1L57OZ; LS-58284; 4,4-diphenylcyclopent-2-en-1-amine hydrochloride
DMR2FPO CP Fujisawa Pharmaceutical Co Ltd
DMR2FPO DT Small molecular drug
DMR2FPO PC 9947991
DMR2FPO MW 291.4
DMR2FPO FM C21H25N
DMR2FPO IC InChI=1S/C21H25N/c1-20(2,3)22-19-14-15-21(16-19,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-15,19,22H,16H2,1-3H3/t19-/m1/s1
DMR2FPO CS CC(C)(C)N[C@H]1CC(C=C1)(C2=CC=CC=C2)C3=CC=CC=C3
DMR2FPO IK QMTVTICJRCJOFZ-LJQANCHMSA-N
DMR2FPO IU (1S)-N-tert-butyl-4,4-diphenylcyclopent-2-en-1-amine
DMR2FPO DE Central and peripheral nervous disease
DMQ3O4C ID DMQ3O4C
DMQ3O4C DN FK-633
DMQ3O4C HS Discontinued in Phase 2
DMQ3O4C SN FK-633; Dryofragin; ((4-(4-Amidinophenoxy)butanoyl)aspartyl)valine; 147865-49-4; CHEMBL34901; FK 633; AC1L31M0; SCHEMBL1710973; DTXSID00163821; ZINC3918297; BDBM50092111; LS-161294; FR-144633; 4-(4-amidinophenoxy)butanoyl-aspartyl-valine; 2-{2-[4-(4-Carbamimidoyl-phenoxy)-butyrylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (FK633); (2S)-2-[[(2S)-2-[4-(4-carbamimidoylphenoxy)butanoylamino]-4-hydroxy-4-oxobutanoyl]amino]-3-methylbutanoic acid
DMQ3O4C DT Small molecular drug
DMQ3O4C PC 132814
DMQ3O4C MW 436.5
DMQ3O4C FM C20H28N4O7
DMQ3O4C IC InChI=1S/C20H28N4O7/c1-11(2)17(20(29)30)24-19(28)14(10-16(26)27)23-15(25)4-3-9-31-13-7-5-12(6-8-13)18(21)22/h5-8,11,14,17H,3-4,9-10H2,1-2H3,(H3,21,22)(H,23,25)(H,24,28)(H,26,27)(H,29,30)/t14-,17-/m0/s1
DMQ3O4C CS CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCOC1=CC=C(C=C1)C(=N)N
DMQ3O4C IK JFCXCBBSUORTNS-YOEHRIQHSA-N
DMQ3O4C IU (2S)-2-[[(2S)-2-[4-(4-carbamimidoylphenoxy)butanoylamino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
DMQ3O4C CA CAS 147865-49-4
DMQ3O4C DE Artery stenosis
DMFGJNW ID DMFGJNW
DMFGJNW DN FK-664
DMFGJNW HS Discontinued in Phase 2
DMFGJNW SN 1-Ethyl-6-(3,4-dimethoxyphenyl)-3-methyl-4-(2,4,6-trimethylphenylimino)-1,2,3,4-tetrahydropyrimidin-2-one
DMFGJNW DT Small molecular drug
DMFGJNW PC 146868
DMFGJNW MW 407.5
DMFGJNW FM C24H29N3O3
DMFGJNW IC InChI=1S/C24H29N3O3/c1-8-27-19(18-9-10-20(29-6)21(13-18)30-7)14-22(26(5)24(27)28)25-23-16(3)11-15(2)12-17(23)4/h9-14H,8H2,1-7H3
DMFGJNW CS CCN1C(=CC(=NC2=C(C=C(C=C2C)C)C)N(C1=O)C)C3=CC(=C(C=C3)OC)OC
DMFGJNW IK OYGHXRNCHYRYRR-UHFFFAOYSA-N
DMFGJNW IU 6-(3,4-dimethoxyphenyl)-1-ethyl-3-methyl-4-(2,4,6-trimethylphenyl)iminopyrimidin-2-one
DMFGJNW CA CAS 94936-90-0
DMFGJNW DE Cardiac disease
DM524J3 ID DM524J3
DM524J3 DN FK-706
DM524J3 HS Discontinued in Phase 2
DM524J3 DT Small molecular drug
DM524J3 PC 23690296
DM524J3 MW 592.5
DM524J3 FM C26H32F3N4NaO7
DM524J3 IC InChI=1S/C26H33F3N4O7.Na/c1-13(2)19(21(36)26(27,28)29)31-24(39)17-6-5-11-33(17)25(40)20(14(3)4)32-23(38)16-9-7-15(8-10-16)22(37)30-12-18(34)35;/h7-10,13-14,17,19-20H,5-6,11-12H2,1-4H3,(H,30,37)(H,31,39)(H,32,38)(H,34,35);/q;+1/p-1/t17-,19?,20-;/m0./s1
DM524J3 CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NCC(=O)[O-].[Na+]
DM524J3 IK DNTYCMNNMGACPR-JSAITXCESA-M
DM524J3 IU sodium;2-[[4-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamoyl]benzoyl]amino]acetate
DM524J3 DE Pulmonary emphysema
DM7TLF6 ID DM7TLF6
DM7TLF6 DN FK-739
DM7TLF6 HS Discontinued in Phase 2
DM7TLF6 SN FR-130739
DM7TLF6 CP Fujisawa Pharmaceutical Co Ltd
DM7TLF6 DT Small molecular drug
DM7TLF6 PC 23668568
DM7TLF6 MW 431.5
DM7TLF6 FM C24H22N7Na
DM7TLF6 IC InChI=1S/C24H22N7.Na/c1-2-3-10-22-26-21-9-6-15-25-24(21)31(22)16-17-11-13-18(14-12-17)19-7-4-5-8-20(19)23-27-29-30-28-23;/h4-9,11-15H,2-3,10,16H2,1H3;/q-1;+1
DM7TLF6 CS CCCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=N[N-]5)N=CC=C2.[Na+]
DM7TLF6 IK YFABTKCYNBWJHS-UHFFFAOYSA-N
DM7TLF6 IU sodium;2-butyl-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
DM7TLF6 CA CAS 136042-19-8
DM7TLF6 DE Hypertension
DMH6QAI ID DMH6QAI
DMH6QAI DN FK778
DMH6QAI HS Discontinued in Phase 2
DMH6QAI SN Manitimus; FK 778; HMR 1715; MNA 715; Malononitrilamide 715; X 920715; FK-778; HMR-1715; MNA-715; MNA-X 920715; Malononitrilamide-715; X-920715; (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxohept-6-ynenitrile; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid
DMH6QAI CP Astellas
DMH6QAI DT Small molecular drug
DMH6QAI PC 70683056
DMH6QAI MW 309.24
DMH6QAI FM C14H10F3N3O2
DMH6QAI IC InChI=1S/C14H10F3N3O2/c15-14(16,17)9-3-5-10(6-4-9)20-13(22)11(8-19)12(21)2-1-7-18/h3-6,21H,1-2H2,(H,20,22)/b12-11-
DMH6QAI CS C1=CC(=CC=C1C(F)(F)F)NC(=O)/C(=C(/CCC#N)\\O)/C#N
DMH6QAI IK OQUXVPJVBSENGK-QXMHVHEDSA-N
DMH6QAI IU (Z)-2,5-dicyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]pent-2-enamide
DMH6QAI DE Kidney/heart transplant rejection
DMS87T9 ID DMS87T9
DMS87T9 DN FK-838
DMS87T9 HS Discontinued in Phase 2
DMS87T9 SN FK-838; FK 838; 131185-37-0; CHEMBL292917; 6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazinebutyric acid; 6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazineboutanoic acid; C21H18N4O3; 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-; 1(6H)-Pyridazinebutanoicacid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-; FKJPZJACCBMNKZ-UHFFFAOYSA-N; AC1MHZMV; ACMC-20mtz5; SCHEMBL2641189; CTK0H8748; DTXSID60156936; BDBM50079654; AKOS030617923; LS-172794; L004106
DMS87T9 DT Small molecular drug
DMS87T9 PC 3035594
DMS87T9 MW 374.4
DMS87T9 FM C21H18N4O3
DMS87T9 IC InChI=1S/C21H18N4O3/c26-18-12-11-16(22-25(18)14-6-10-19(27)28)20-17-9-4-5-13-24(17)23-21(20)15-7-2-1-3-8-15/h1-5,7-9,11-13H,6,10,14H2,(H,27,28)
DMS87T9 CS C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=NN(C(=O)C=C4)CCCC(=O)O
DMS87T9 IK FKJPZJACCBMNKZ-UHFFFAOYSA-N
DMS87T9 IU 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]butanoic acid
DMS87T9 CA CAS 131185-37-0
DMS87T9 DE Hypertension
DM457B1 ID DM457B1
DM457B1 DN FK-888
DM457B1 HS Discontinued in Phase 2
DM457B1 SN FK 888; FK-888; 138449-07-7; FK888; N(2)-(4-Hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-prolyl)-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L-alaninamide; SCHEMBL8079679; GTPL2114; AC1L332N; CHEMBL1416993; CHEBI:93463; DTXSID70160680; MolPort-023-276-412; HMS3269A13; ZINC3926844; PDSP2_000648; AKOS024457076; NCGC00159560-01; L-Alaninamide, trans-4-hydroxy-1-((1-methyl-1H-indol-3-yl)carbonyl)-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-; LS-193299; BRD-K83508485-001-01-9
DM457B1 CP Fujisawa Pharmaceutical Co Ltd
DM457B1 DT Small molecular drug
DM457B1 PC 107967
DM457B1 MW 588.7
DM457B1 FM C36H36N4O4
DM457B1 IC InChI=1S/C36H36N4O4/c1-38-23-30(29-14-8-9-15-32(29)38)35(43)40-22-28(41)20-33(40)34(42)37-31(36(44)39(2)21-24-10-4-3-5-11-24)19-25-16-17-26-12-6-7-13-27(26)18-25/h3-18,23,28,31,33,41H,19-22H2,1-2H3,(H,37,42)/t28-,31+,33+/m1/s1
DM457B1 CS CN1C=C(C2=CC=CC=C21)C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N(C)CC6=CC=CC=C6)O
DM457B1 IK BFNKQTIJVFGCKQ-PDJGWCFMSA-N
DM457B1 IU (2S,4R)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-4-hydroxy-1-(1-methylindole-3-carbonyl)pyrrolidine-2-carboxamide
DM457B1 CA CAS 138449-07-7
DM457B1 CB CHEBI:93463
DM457B1 DE Migraine
DMTEW80 ID DMTEW80
DMTEW80 DN FK-906
DMTEW80 HS Discontinued in Phase 2
DMTEW80 SN FR-115906
DMTEW80 CP Fujisawa Pharmaceutical Co Ltd
DMTEW80 DT Small molecular drug
DMTEW80 PC 6918227
DMTEW80 MW 790.4
DMTEW80 FM C40H64ClN7O7
DMTEW80 IC InChI=1S/C40H63N7O7.ClH/c1-29(2)16-17-35(48)33(24-30-12-8-6-9-13-30)43-37(49)34(26-32-27-41-28-42-32)46(5)38(50)36(25-31-14-10-7-11-15-31)54-40(52)45(4)19-18-44(3)39(51)47-20-22-53-23-21-47;/h7,10-11,14-15,27-30,33-36,48H,6,8-9,12-13,16-26H2,1-5H3,(H,41,42)(H,43,49);1H/t33-,34-,35-,36-;/m0./s1
DMTEW80 CS CC(C)CC[C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CN=CN2)N(C)C(=O)[C@H](CC3=CC=CC=C3)OC(=O)N(C)CCN(C)C(=O)N4CCOCC4)O.Cl
DMTEW80 IK MBTHCNKHNNGZGE-GIOOZNHKSA-N
DMTEW80 IU [(2S)-1-[[(2S)-1-[[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl] N-methyl-N-[2-[methyl(morpholine-4-carbonyl)amino]ethyl]carbamate;hydrochloride
DMTEW80 DE Hypertension
DMPD8O2 ID DMPD8O2
DMPD8O2 DN FK-960
DMPD8O2 HS Discontinued in Phase 2
DMPD8O2 SN UNII-2GB92V6H2O; 2GB92V6H2O; FK-960; FK-960 hydrate; FK-960 monohydrate; AC1OCFBG; SCHEMBL3089403; FR-59960; LS-25245; N-(4-acetylpiperazin-1-yl)-4-fluorobenzamide hydrate; Benzamide, N-(4-acetyl-1-piperazinyl)-4-fluoro-, hydrate (1:1)
DMPD8O2 CP Fujisawa Pharmaceutical Co Ltd
DMPD8O2 DT Small molecular drug
DMPD8O2 PC 181428
DMPD8O2 MW 265.28
DMPD8O2 FM C13H16FN3O2
DMPD8O2 IC InChI=1S/C13H16FN3O2/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11/h2-5H,6-9H2,1H3,(H,15,19)
DMPD8O2 CS CC(=O)N1CCN(CC1)NC(=O)C2=CC=C(C=C2)F
DMPD8O2 IK XTOKQKWTUYYVAO-UHFFFAOYSA-N
DMPD8O2 IU N-(4-acetylpiperazin-1-yl)-4-fluorobenzamide
DMPD8O2 CA CAS 133920-70-4
DMPD8O2 DE Cognitive impairment
DMUQN83 ID DMUQN83
DMUQN83 DN FL-386
DMUQN83 HS Discontinued in Phase 2
DMUQN83 SN Benzene sulfonic acid 2-(trans-4-isobutylcyclohexyl)-2-oxoethyl ester
DMUQN83 DT Small molecular drug
DMUQN83 PC 134847
DMUQN83 MW 338.5
DMUQN83 FM C18H26O4S
DMUQN83 IC InChI=1S/C18H26O4S/c1-14(2)12-15-8-10-16(11-9-15)18(19)13-22-23(20,21)17-6-4-3-5-7-17/h3-7,14-16H,8-13H2,1-2H3
DMUQN83 CS CC(C)CC1CCC(CC1)C(=O)COS(=O)(=O)C2=CC=CC=C2
DMUQN83 IK RLVLLBHWAQWLKL-UHFFFAOYSA-N
DMUQN83 IU [2-[4-(2-methylpropyl)cyclohexyl]-2-oxoethyl] benzenesulfonate
DMUQN83 CA CAS 84856-18-8
DMUQN83 DE Hyperlipidaemia
DMOCMXH ID DMOCMXH
DMOCMXH DN FLOSATIDIL
DMOCMXH HS Discontinued in Phase 2
DMOCMXH SN Flosatidil; SL-85.1016-08; N-[2-(Dimethylamino)ethyl]-N-[2-[N-[2-(methylthio)phenyl]-N-(3-trifluoromethylbenzyl)amino]-2-oxoethyl]carbamic acid 2-methylpropyl ester
DMOCMXH DT Small molecular drug
DMOCMXH PC 216223
DMOCMXH MW 525.6
DMOCMXH FM C26H34F3N3O3S
DMOCMXH IC InChI=1S/C26H34F3N3O3S/c1-19(2)18-35-25(34)31(14-13-30(3)4)17-24(33)32(22-11-6-7-12-23(22)36-5)16-20-9-8-10-21(15-20)26(27,28)29/h6-12,15,19H,13-14,16-18H2,1-5H3
DMOCMXH CS CC(C)COC(=O)N(CCN(C)C)CC(=O)N(CC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC=C2SC
DMOCMXH IK MJOGWNMYQLVUOU-UHFFFAOYSA-N
DMOCMXH IU 2-methylpropyl N-[2-(dimethylamino)ethyl]-N-[2-[2-methylsulfanyl-N-[[3-(trifluoromethyl)phenyl]methyl]anilino]-2-oxoethyl]carbamate
DMOCMXH CA CAS 113593-34-3
DMOCMXH DE Angina pectoris
DM3PXLZ ID DM3PXLZ
DM3PXLZ DN FO-152
DM3PXLZ HS Discontinued in Phase 2
DM3PXLZ SN AC1OCEZ1; FO-152; [(2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate hydrochloride
DM3PXLZ CP Daiichi Fine Chemicals Co Ltd
DM3PXLZ DT Small molecular drug
DM3PXLZ PC 6918058
DM3PXLZ MW 397.78
DM3PXLZ FM C14H21ClFN3O7
DM3PXLZ IC InChI=1S/C14H20FN3O7.ClH/c1-5(2)8(16)13(22)24-4-7-9(19)10(20)12(25-7)18-3-6(15)11(21)17-14(18)23;/h3,5,7-10,12,19-20H,4,16H2,1-2H3,(H,17,21,23);1H/t7-,8+,9-,10-,12-;/m1./s1
DM3PXLZ CS CC(C)[C@@H](C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O)N.Cl
DM3PXLZ IK HMYHLEZOXXVLBU-LNKDGEPZSA-N
DM3PXLZ IU [(2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM3PXLZ DE Solid tumour/cancer
DM15LAP ID DM15LAP
DM15LAP DN Fonsartan
DM15LAP HS Discontinued in Phase 2
DM15LAP SN HR-720; Hoe-720
DM15LAP CP Hoechst Marion Roussel Inc; Hoechst AG
DM15LAP PC 11585346
DM15LAP MW 620.9
DM15LAP FM C26H30K2N4O5S2
DM15LAP IC InChI=1S/C26H32N4O5S2.2K/c1-4-6-11-22-28-24(36-3)23(25(31)32)30(22)17-18-12-14-19(15-13-18)20-9-7-8-10-21(20)37(34,35)29-26(33)27-16-5-2;;/h7-10,12-15H,4-6,11,16-17H2,1-3H3,(H,31,32)(H2,27,29,33);;/q;2*+1/p-2
DM15LAP CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=NCCC)[O-])C(=O)[O-])SC.[K+].[K+]
DM15LAP IK WGZNJDWXOFLZKQ-UHFFFAOYSA-L
DM15LAP IU dipotassium;2-butyl-5-methylsulfanyl-3-[[4-[2-[(C-oxido-N-propylcarbonimidoyl)sulfamoyl]phenyl]phenyl]methyl]imidazole-4-carboxylate
DM15LAP DE Hypertension
DMEH6LV ID DMEH6LV
DMEH6LV DN Fontolizumab
DMEH6LV HS Discontinued in Phase 2
DMEH6LV SN Fontolizumab (USAN/INN)
DMEH6LV CP PDL Biopharma
DMEH6LV DT Antibody
DMEH6LV DE Rheumatoid arthritis; Inflammatory bowel disease
DMTYHK4 ID DMTYHK4
DMTYHK4 DN FOSOPAMINE
DMTYHK4 HS Discontinued in Phase 2
DMTYHK4 SN S-2055; SIM-2055; Fosopamine; N-Methyldopamine 4-O-phosphate; 4-[2-(Methylamino)ethyl]-1,2-benzenediol 1-(dihydrogen phosphate)
DMTYHK4 DT Small molecular drug
DMTYHK4 PC 65878
DMTYHK4 MW 247.18
DMTYHK4 FM C9H14NO5P
DMTYHK4 IC InChI=1S/C9H14NO5P/c1-10-5-4-7-2-3-9(8(11)6-7)15-16(12,13)14/h2-3,6,10-11H,4-5H2,1H3,(H2,12,13,14)
DMTYHK4 CS CNCCC1=CC(=C(C=C1)OP(=O)(O)O)O
DMTYHK4 IK WHEGQKBWPSOMHG-UHFFFAOYSA-N
DMTYHK4 IU [2-hydroxy-4-[2-(methylamino)ethyl]phenyl] dihydrogen phosphate
DMTYHK4 CA CAS 103878-96-2
DMTYHK4 DE Hypertension
DMUD0IN ID DMUD0IN
DMUD0IN DN FOZIVUDINE TIDOXIL
DMUD0IN HS Discontinued in Phase 2
DMUD0IN SN HDP-990002; BM-21.1290; Fozivudine tidoxil; 3'-Azido-3'-deoxy-5'-O-[2-decyloxy-3-(dodecylthio)propoxy-hydroxyphosphoryl]thymidine
DMUD0IN DT Small molecular drug
DMUD0IN PC 64140
DMUD0IN MW 746
DMUD0IN FM C35H64N5O8PS
DMUD0IN IC InChI=1S/C35H64N5O8PS/c1-4-6-8-10-12-14-15-17-19-21-23-50-28-30(45-22-20-18-16-13-11-9-7-5-2)26-46-49(43,44)47-27-32-31(38-39-36)24-33(48-32)40-25-29(3)34(41)37-35(40)42/h25,30-33H,4-24,26-28H2,1-3H3,(H,43,44)(H,37,41,42)/t30?,31-,32+,33+/m0/s1
DMUD0IN CS CCCCCCCCCCCCSCC(COP(=O)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OCCCCCCCCCC
DMUD0IN IK IBHARWXWOCPXCR-WELGVCPWSA-N
DMUD0IN IU [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate
DMUD0IN CA CAS 141790-23-0
DMUD0IN DE Human immunodeficiency virus infection
DML6MVP ID DML6MVP
DML6MVP DN FPL-64170
DML6MVP HS Discontinued in Phase 2
DML6MVP CP Fisons plc
DML6MVP DE Psoriasis vulgaris
DMTRBU4 ID DMTRBU4
DMTRBU4 DN Frakefamide
DMTRBU4 HS Discontinued in Phase 2
DMTRBU4 SN BCH-3963; LEF-553; LEF-576; SPD-759; LEF, AstraZeneca/BioChem Pharma
DMTRBU4 CP Shire plc
DMTRBU4 DT Small molecular drug
DMTRBU4 PC 9829352
DMTRBU4 MW 563.6
DMTRBU4 FM C30H34FN5O5
DMTRBU4 IC InChI=1S/C30H34FN5O5/c1-18(34-29(40)24(32)15-20-9-13-23(37)14-10-20)28(39)36-26(17-21-7-11-22(31)12-8-21)30(41)35-25(27(33)38)16-19-5-3-2-4-6-19/h2-14,18,24-26,37H,15-17,32H2,1H3,(H2,33,38)(H,34,40)(H,35,41)(H,36,39)/t18-,24+,25+,26+/m1/s1
DMTRBU4 CS C[C@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMTRBU4 IK GTPHQORJKFJIRB-JTQLPTLWSA-N
DMTRBU4 IU (2S)-2-amino-N-[(2R)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMTRBU4 CA CAS 188196-22-7
DMTRBU4 DE Pain
DMJLEV7 ID DMJLEV7
DMJLEV7 DN FS-205-397
DMJLEV7 HS Discontinued in Phase 2
DMJLEV7 SN 6-Ethoxy-3,3-dimethyl-2,3-dihydro-1H-indole methanesulfonate; 6-Ethoxy-3,3-dimethylindoline methanesulfonate
DMJLEV7 DT Small molecular drug
DMJLEV7 PC 164014
DMJLEV7 MW 287.38
DMJLEV7 FM C13H21NO4S
DMJLEV7 IC InChI=1S/C12H17NO.CH4O3S/c1-4-14-9-5-6-10-11(7-9)13-8-12(10,2)3;1-5(2,3)4/h5-7,13H,4,8H2,1-3H3;1H3,(H,2,3,4)
DMJLEV7 CS CCOC1=CC2=C(C=C1)C(CN2)(C)C.CS(=O)(=O)O
DMJLEV7 IK QZTLHRAONHZQNK-UHFFFAOYSA-N
DMJLEV7 IU 6-ethoxy-3,3-dimethyl-1,2-dihydroindole;methanesulfonic acid
DMJLEV7 CA CAS 116861-51-9
DMJLEV7 DE Pain
DMHOMFK ID DMHOMFK
DMHOMFK DN G-1128
DMHOMFK HS Discontinued in Phase 2
DMHOMFK SN MATAGEN oligonucleotides; Antisense [cancer], Genta/Chugai; Anti-bcr-abl, Genta/Chugai
DMHOMFK CP Genta Inc
DMHOMFK DT Antisense drug
DMHOMFK DE Chronic myelogenous leukaemia
DMTNYSF ID DMTNYSF
DMTNYSF DN Galarubicin
DMTNYSF HS Discontinued in Phase 2
DMTNYSF SN DA-125; Metalloprotease inhibitors (cancer), Dong-A
DMTNYSF CP Dong-A Pharmaceutical Co Ltd
DMTNYSF DT Small molecular drug
DMTNYSF PC 114759
DMTNYSF MW 633.6
DMTNYSF FM C30H32FNO13
DMTNYSF IC InChI=1S/C30H32FNO13/c1-11-23(35)28(40)22(31)29(44-11)45-15-9-30(41,16(33)10-43-17(34)6-7-32)8-13-19(15)27(39)21-20(25(13)37)24(36)12-4-3-5-14(42-2)18(12)26(21)38/h3-5,11,15,22-23,28-29,35,37,39-41H,6-10,32H2,1-2H3/t11-,15-,22+,23+,28-,29-,30-/m0/s1
DMTNYSF CS C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCN)O)F)O)O
DMTNYSF IK CKXIPXAIFMTQCS-LRDUUELOSA-N
DMTNYSF IU [2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate
DMTNYSF CA CAS 195612-80-7
DMTNYSF DE Solid tumour/cancer
DMX0Z51 ID DMX0Z51
DMX0Z51 DN Gallium maltolate
DMX0Z51 HS Discontinued in Phase 2
DMX0Z51 SN GaM
DMX0Z51 CP Titan Pharmaceuticals; Geomed Inc
DMX0Z51 DT Small molecular drug
DMX0Z51 PC 9846339
DMX0Z51 MW 445
DMX0Z51 FM C18H15GaO9
DMX0Z51 IC InChI=1S/3C6H6O3.Ga/c3*1-4-6(8)5(7)2-3-9-4;/h3*2-3,8H,1H3;/q;;;+3/p-3
DMX0Z51 CS CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].CC1=C(C(=O)C=CO1)[O-].[Ga+3]
DMX0Z51 IK ASYYOZSDALANRF-UHFFFAOYSA-K
DMX0Z51 IU gallium;2-methyl-4-oxopyran-3-olate
DMX0Z51 CA CAS 108560-70-9
DMX0Z51 DE Human immunodeficiency virus infection
DMHAM2J ID DMHAM2J
DMHAM2J DN Gantofiban
DMHAM2J HS Discontinued in Phase 2
DMHAM2J SN Gantofiban; CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester
DMHAM2J DT Small molecular drug
DMHAM2J PC 135565976
DMHAM2J MW 447.5
DMHAM2J FM C21H29N5O6
DMHAM2J IC InChI=1S/C21H29N5O6/c1-3-31-18(27)14-25-10-8-24(9-11-25)12-17-13-26(21(29)32-17)16-6-4-15(5-7-16)19(22)23-20(28)30-2/h4-7,17H,3,8-14H2,1-2H3,(H2,22,23,28)/t17-/m1/s1
DMHAM2J CS CCOC(=O)CN1CCN(CC1)C[C@@H]2CN(C(=O)O2)C3=CC=C(C=C3)C(=N)NC(=O)OC
DMHAM2J IK YNBHAPKHWDNTMZ-QGZVFWFLSA-N
DMHAM2J IU ethyl 2-[4-[[(5R)-3-[4-(N-methoxycarbonylcarbamimidoyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]piperazin-1-yl]acetate
DMHAM2J CA CAS 183547-57-1
DMHAM2J DE Arteriosclerosis
DM8IL1U ID DM8IL1U
DM8IL1U DN Gavestinel
DM8IL1U HS Discontinued in Phase 2
DM8IL1U SN UNII-318X4QY113; 153436-22-7; GV 150526X; GV-150526X; 318X4QY113; 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-(3-oxo-3-(phenylamino)-1-propenyl)-, (E)-; 4,6-Dichloro-3-((E)-2-(phenylcarbamoyl)vinyl)indole-2-carboxylic acid; 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-((1E)-3-oxo-3-(phenylamino)-1-propenyl)-; (E)-4,6-Dichloro-3-(3-oxo-3-(phenylamino)-1-propenyl)-1H-indole-2-carboxylic acid; GV 150526; Gavestinel (USAN/INN); AC1O51WR; Gavestinel [USAN:INN:BAN]; CHEMBL44793; SCHEMBL678632; SCHEMBL1721070
DM8IL1U DT Small molecular drug
DM8IL1U PC 6450546
DM8IL1U MW 375.2
DM8IL1U FM C18H12Cl2N2O3
DM8IL1U IC InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+
DM8IL1U CS C1=CC=C(C=C1)NC(=O)/C=C/C2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O
DM8IL1U IK WZBNEZWCNKUOSM-VOTSOKGWSA-N
DM8IL1U IU 3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylic acid
DM8IL1U CA CAS 153436-22-7
DM8IL1U CB CHEBI:92867
DM8IL1U DE Nerve injury
DMS7TC5 ID DMS7TC5
DMS7TC5 DN Geldanamycin
DMS7TC5 HS Discontinued in Phase 2
DMS7TC5 SN GDM; GMY; Geldanamicin; Geldanomycin; Geldaramycin; Antibiotic U 29135; BODIPY-labeled Geldanamycin; Geldanamycin (9CI); Geldanamycin, Streptomyces hygroscopicus; U-29135; Antibiotic (U-29,135); [(8E,12E,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8E,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(8Z,12Z,14Z)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10R,11R)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,10S,11S)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10R,11S,12Z,14E)-6-Hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10R,11R,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; [(3S,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate; (6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl) carbamate; [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-9-[(Aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione; 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI); 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv.
DMS7TC5 CP Fermentek
DMS7TC5 DT Small molecular drug
DMS7TC5 PC 5288382
DMS7TC5 MW 560.6
DMS7TC5 FM C29H40N2O9
DMS7TC5 IC InChI=1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)/b10-8-,16-9+,18-13+/t15-,17+,22+,23+,24-,26+/m1/s1
DMS7TC5 CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)/C)OC)OC(=O)N)\\C)C)O)OC
DMS7TC5 IK QTQAWLPCGQOSGP-KSRBKZBZSA-N
DMS7TC5 IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMS7TC5 CA CAS 30562-34-6
DMS7TC5 CB CHEBI:5292
DMS7TC5 DE Peripheral nerve damage; Kidney cancer
DMLMT5O ID DMLMT5O
DMLMT5O DN Gemopatrilat
DMLMT5O HS Discontinued in Phase 2
DMLMT5O SN AC1L58XI; 2-[(6S)-2,2-dimethyl-7-oxo-6-[(3-phenyl-2-sulfanylpropanoyl)amino]azepan-1-yl]acetic acid
DMLMT5O DT Small molecular drug
DMLMT5O PC 9886079
DMLMT5O MW 378.5
DMLMT5O FM C19H26N2O4S
DMLMT5O IC InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1
DMLMT5O CS CC1(CCC[C@@H](C(=O)N1CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S)C
DMLMT5O IK YRSVDSQRGBYVIY-GJZGRUSLSA-N
DMLMT5O IU 2-[(6S)-2,2-dimethyl-7-oxo-6-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]azepan-1-yl]acetic acid
DMLMT5O CA CAS 160135-92-2
DMLMT5O DE Hypotension
DMIUFS4 ID DMIUFS4
DMIUFS4 DN GI 181771
DMIUFS4 HS Discontinued in Phase 2
DMIUFS4 SN GI 181771; GI-181771X; UNII-6YF0SHR37T; 305366-98-7; 6YF0SHR37T; CHEMBL1269257; GSKI181771X; GSKI 181771X; DTXSID60184613; BDBM50329178; DB12309; SB18866; HY-11076; GI-181771; CS-0003036; J3.552.309J; (S)-3-(3-(1-(2-(isopropyl(phenyl)amino)-2-oxoethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid; 782482-04-6
DMIUFS4 CP GlaxoSmithKline
DMIUFS4 DT Small molecular drug
DMIUFS4 PC 51353551
DMIUFS4 MW 605.6
DMIUFS4 FM C34H31N5O6
DMIUFS4 IC InChI=1S/C34H31N5O6/c1-22(2)38(25-14-5-3-6-15-25)29(40)21-37-27-18-9-10-19-28(27)39(26-16-7-4-8-17-26)32(42)30(31(37)41)36-34(45)35-24-13-11-12-23(20-24)33(43)44/h3-20,22,30H,21H2,1-2H3,(H,43,44)(H2,35,36,45)/t30-/m0/s1
DMIUFS4 CS CC(C)N(C1=CC=CC=C1)C(=O)CN2C3=CC=CC=C3N(C(=O)[C@H](C2=O)NC(=O)NC4=CC=CC(=C4)C(=O)O)C5=CC=CC=C5
DMIUFS4 IK CABBMMXFOOZVMS-PMERELPUSA-N
DMIUFS4 IU 3-[[(3S)-2,4-dioxo-1-[2-oxo-2-(N-propan-2-ylanilino)ethyl]-5-phenyl-1,5-benzodiazepin-3-yl]carbamoylamino]benzoic acid
DMIUFS4 CA CAS 305366-98-7
DMIUFS4 DE Obesity
DM10CBF ID DM10CBF
DM10CBF DN GL-331
DM10CBF HS Discontinued in Phase 2
DM10CBF SN GL-331; UNII-0I81858VSZ; 127882-73-9; 0I81858VSZ; NSC628672; NSC 628672; AC1L3WEV; CHEMBL283631; SCHEMBL5953587; DTXSID40155689; ZINC8652994; 5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-nitrophenyl)amino)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta))-; (5R-(5alpha,5abeta,8aalpha,9beta))-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-nitrophenyl)amino)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one
DM10CBF CP University of North Carolina
DM10CBF DT Small molecular drug
DM10CBF PC 148091
DM10CBF MW 520.5
DM10CBF FM C27H24N2O9
DM10CBF IC InChI=1S/C27H24N2O9/c1-34-21-7-13(8-22(35-2)26(21)30)23-16-9-19-20(38-12-37-19)10-17(16)25(18-11-36-27(31)24(18)23)28-14-3-5-15(6-4-14)29(32)33/h3-10,18,23-25,28,30H,11-12H2,1-2H3/t18-,23+,24-,25+/m0/s1
DM10CBF CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)NC6=CC=C(C=C6)[N+](=O)[O-]
DM10CBF IK DLROLUIVVKTFPW-LVEBQJTPSA-N
DM10CBF IU (5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-(4-nitroanilino)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DM10CBF CA CAS 127882-73-9
DM10CBF DE Colorectal cancer
DMT1LQS ID DMT1LQS
DMT1LQS DN GLENVASTATIN
DMT1LQS HS Discontinued in Phase 2
DMT1LQS SN HR-780; Glenvastatin; [4(R),6(S),(E)]-6-[2-[4-(4-Fluorophenyl)-2-isopropyl-6-phenyl-3-pyridyl]vinyl]-4-hydroxytetrahydropyran-2-one
DMT1LQS DT Small molecular drug
DMT1LQS PC 5281970
DMT1LQS MW 431.5
DMT1LQS FM C27H26FNO3
DMT1LQS IC InChI=1S/C27H26FNO3/c1-17(2)27-23(13-12-22-14-21(30)15-26(31)32-22)24(18-8-10-20(28)11-9-18)16-25(29-27)19-6-4-3-5-7-19/h3-13,16-17,21-22,30H,14-15H2,1-2H3/b13-12+/t21-,22-/m1/s1
DMT1LQS CS CC(C)C1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC=C(C=C3)F)/C=C/[C@@H]4C[C@H](CC(=O)O4)O
DMT1LQS IK LJIZUXQINHXGAO-ITWZMISCSA-N
DMT1LQS IU (4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one
DMT1LQS CA CAS 122254-45-9
DMT1LQS CB CHEBI:5597
DMT1LQS DE Hyperlipidaemia
DMC87DR ID DMC87DR
DMC87DR DN GLPG-0259
DMC87DR HS Discontinued in Phase 2
DMC87DR SN G-13919, GT-146, GT-1498, GT-1704, GT-314, GT-416, GT-514, GT-562
DMC87DR CP Johnson&Johnson
DMC87DR PC 44462738
DMC87DR MW 458.5
DMC87DR FM C24H26N8O2
DMC87DR IC InChI=1S/C24H26N8O2/c1-14(2)30-10-19-8-18(30)11-31(19)17-5-3-16(4-6-17)29-23-24-27-13-28-32(24)20(9-26-23)15-7-21(22(25)33)34-12-15/h3-7,9,12-14,18-19H,8,10-11H2,1-2H3,(H2,25,33)(H,26,29)/t18-,19-/m0/s1
DMC87DR CS CC(C)N1C[C@@H]2C[C@H]1CN2C3=CC=C(C=C3)NC4=NC=C(N5C4=NC=N5)C6=COC(=C6)C(=O)N
DMC87DR IK YBFGSJUVEOYPIS-OALUTQOASA-N
DMC87DR IU 4-[8-[4-[(1S,4S)-5-propan-2-yl-2,5-diazabicyclo[2.2.1]heptan-2-yl]anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide
DMC87DR CA CAS 1195065-29-2
DMC87DR DE Rheumatoid arthritis
DM5JKCL ID DM5JKCL
DM5JKCL DN GlycoPEGylated erythropoietin
DM5JKCL HS Discontinued in Phase 2
DM5JKCL SN GlycoPEGylated EPO, Neose; GlycoPEGylated erythropoietin, Neose; GlycoPeg-EPO; NE-180
DM5JKCL CP Neose Technologies
DM5JKCL DE Solid tumour/cancer
DM07VBW ID DM07VBW
DM07VBW DN Glypromate
DM07VBW HS Discontinued in Phase 2
DM07VBW SN Glycine-proline-glutamate (neuroprotectant), Neuren
DM07VBW CP Neuren Pharmaceuticals
DM07VBW DE Neurological disorder
DM7V9CT ID DM7V9CT
DM7V9CT DN GM6001
DM7V9CT HS Discontinued in Phase 2
DM7V9CT SN Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup; ILOMASTAT
DM7V9CT DT Small molecular drug
DM7V9CT PC 132519
DM7V9CT MW 388.5
DM7V9CT FM C20H28N4O4
DM7V9CT IC InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1
DM7V9CT CS CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NC
DM7V9CT IK NITYDPDXAAFEIT-DYVFJYSZSA-N
DM7V9CT IU (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
DM7V9CT CA CAS 142880-36-2
DM7V9CT CB CHEBI:137236
DM7V9CT DE Corneal ulcer
DM9MEAY ID DM9MEAY
DM9MEAY DN Gonadimmune
DM9MEAY HS Discontinued in Phase 2
DM9MEAY SN GnRH pharmaccine, Aphton/GlaxoSmithKline
DM9MEAY CP Aphton
DM9MEAY DE Prostate cancer
DMCXLIK ID DMCXLIK
DMCXLIK DN GR-213487
DMCXLIK HS Discontinued in Phase 2
DMCXLIK SN GR-213487B; MB-121; Gene therapy (CFTR), GW; Gene therapy (CFTR), Valentis; MB-121:CFTR
DMCXLIK CP Glaxo Wellcome plc
DMCXLIK DE Cystic fibrosis
DMSV6KP ID DMSV6KP
DMSV6KP DN GSK 679769
DMSV6KP HS Discontinued in Phase 2
DMSV6KP CP GlaxoSmithKline
DMSV6KP DE Major depressive disorder; Chemotherapy-induced nausea; Anxiety disorder; Incontinence
DMTZBXQ ID DMTZBXQ
DMTZBXQ DN GSK-159797
DMTZBXQ HS Discontinued in Phase 2
DMTZBXQ SN Milveterol hydrochloride; UNII-1D1MD355SJ; 1D1MD355SJ; 804518-03-4; Milveterol hydrochloride [USAN]; Milveterol hydrochloride (USAN); GSK159797C; Milveterol HCl; SCHEMBL2014099; CHEMBL2107356; DTXSID50230335; QQPHRRSYJMOQOC-DKIIUIKKSA-N; D08945; N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; 2-5A-anti-hTR
DMTZBXQ CP GlaxoSmithKline
DMTZBXQ DT Small molecular drug
DMTZBXQ PC 11225217
DMTZBXQ MW 472
DMTZBXQ FM C25H30ClN3O4
DMTZBXQ IC InChI=1S/C25H29N3O4.ClH/c29-17-28-22-14-20(8-11-23(22)30)24(31)15-26-13-12-18-6-9-21(10-7-18)27-16-25(32)19-4-2-1-3-5-19;/h1-11,14,17,24-27,30-32H,12-13,15-16H2,(H,28,29);1H/t24-,25-;/m0./s1
DMTZBXQ CS C1=CC=C(C=C1)[C@H](CNC2=CC=C(C=C2)CCNC[C@@H](C3=CC(=C(C=C3)O)NC=O)O)O.Cl
DMTZBXQ IK QQPHRRSYJMOQOC-DKIIUIKKSA-N
DMTZBXQ IU N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide;hydrochloride
DMTZBXQ CA CAS 804518-03-4
DMTZBXQ DE Chronic obstructive pulmonary disease
DM8J2AV ID DM8J2AV
DM8J2AV DN GSK159802
DM8J2AV HS Discontinued in Phase 2
DM8J2AV CP GSK
DM8J2AV DE Asthma
DMX7DVH ID DMX7DVH
DMX7DVH DN GSK163090
DMX7DVH HS Discontinued in Phase 2
DMX7DVH SN 844903-58-8; GSK-163090; UNII-7XI927X82B; CHEMBL1631540; 7XI927X82B; 1-(3-(2-(4-(2-Methyl-5-quinolinyl)-1-piperazinyl)ethyl)phenyl)-2-imidazolidinone; 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone; 1-[3-[2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl]-2-imidazolidinone; ANGUXJDGJCHGOG-UHFFFAOYSA-N; GSK 163090; SCHEMBL2881345; DTXSID30233480; EX-A1027; BCP16941; ZINC34451922; BDBM50333015; AKOS030526918; CS-5315; HY-14348
DMX7DVH CP GSK
DMX7DVH DT Small molecular drug
DMX7DVH PC 11292933
DMX7DVH MW 415.5
DMX7DVH FM C25H29N5O
DMX7DVH IC InChI=1S/C25H29N5O/c1-19-8-9-22-23(27-19)6-3-7-24(22)29-16-14-28(15-17-29)12-10-20-4-2-5-21(18-20)30-13-11-26-25(30)31/h2-9,18H,10-17H2,1H3,(H,26,31)
DMX7DVH CS CC1=NC2=C(C=C1)C(=CC=C2)N3CCN(CC3)CCC4=CC(=CC=C4)N5CCNC5=O
DMX7DVH IK ANGUXJDGJCHGOG-UHFFFAOYSA-N
DMX7DVH IU 1-[3-[2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl]phenyl]imidazolidin-2-one
DMX7DVH CA CAS 844903-58-8
DMX7DVH DE Anxiety disorder; Episode; Major depressive disorder
DMMIR1K ID DMMIR1K
DMMIR1K DN GSK184072
DMMIR1K HS Discontinued in Phase 2
DMMIR1K SN Flutimide; 162666-34-4; AC1O5YLM; AKOS027326745; (5Z)-1-hydroxy-3-isobutyl-5-(2-methylpropylidene)pyrazine-2,6-dione; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (Z)-; 2,6-(1H,3H)-Pyrazinedione, 1-hydroxy-5-(2-methylpropyl)-3-(2-methylpropylidene)-, (3Z)-; (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione
DMMIR1K CP GSK
DMMIR1K DT Small molecular drug
DMMIR1K PC 6443207
DMMIR1K MW 238.28
DMMIR1K FM C12H18N2O3
DMMIR1K IC InChI=1S/C12H18N2O3/c1-7(2)5-9-11(15)14(17)12(16)10(13-9)6-8(3)4/h5,7-8,17H,6H2,1-4H3/b9-5-
DMMIR1K CS CC(C)CC1=N/C(=C\\C(C)C)/C(=O)N(C1=O)O
DMMIR1K IK SIXHCCPAJIVTOY-UITAMQMPSA-N
DMMIR1K IU (5Z)-1-hydroxy-3-(2-methylpropyl)-5-(2-methylpropylidene)pyrazine-2,6-dione
DMMIR1K CA CAS 162666-34-4
DMMIR1K DE Type-2 diabetes; Hematologic tumour; Colon cancer
DMHZQ0T ID DMHZQ0T
DMHZQ0T DN GSK2190914
DMHZQ0T HS Discontinued in Phase 2
DMHZQ0T CP GlaxoSmithKline
DMHZQ0T DE Asthma
DM89AV2 ID DM89AV2
DM89AV2 DN GSK2190915
DM89AV2 HS Discontinued in Phase 2
DM89AV2 SN 1093403-33-8; sirtuin modulator; SRT 2104; SRT2104 (GSK2245840); SRT2104; SRT-2104; UNII-4521NR0J09; 4521NR0J09; 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)-; C26H24N6O2S2; 4-Methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide; 4-methyl-n-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide
DM89AV2 CP GSK
DM89AV2 DT Small molecular drug
DM89AV2 PC 44473151
DM89AV2 MW 637.8
DM89AV2 FM C38H43N3O4S
DM89AV2 IC InChI=1S/C38H43N3O4S/c1-8-44-34-18-14-28(22-40-34)27-12-10-26(11-13-27)23-41-32-17-16-30(45-24-29-15-9-25(2)21-39-29)19-31(32)35(46-37(3,4)5)33(41)20-38(6,7)36(42)43/h9-19,21-22H,8,20,23-24H2,1-7H3,(H,42,43)
DM89AV2 CS CCOC1=NC=C(C=C1)C2=CC=C(C=C2)CN3C4=C(C=C(C=C4)OCC5=NC=C(C=C5)C)C(=C3CC(C)(C)C(=O)O)SC(C)(C)C
DM89AV2 IK DFQGDHBGRSTTHX-UHFFFAOYSA-N
DM89AV2 IU 3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoic acid
DM89AV2 CA CAS 936350-00-4
DM89AV2 DE Asthma
DMBYQJH ID DMBYQJH
DMBYQJH DN GSK256066
DMBYQJH HS Discontinued in Phase 2
DMBYQJH SN GSK-256066
DMBYQJH CP GSK
DMBYQJH DT Small molecular drug
DMBYQJH PC 9827968
DMBYQJH MW 518.6
DMBYQJH FM C27H26N4O5S
DMBYQJH IC InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)
DMBYQJH CS CC1=CC(=CC2=C(C(=CN=C12)C(=O)N)NC3=CC(=CC=C3)OC)S(=O)(=O)C4=CC=CC(=C4)C(=O)N(C)C
DMBYQJH IK JFHROPTYMMSOLG-UHFFFAOYSA-N
DMBYQJH IU 6-[3-(dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide
DMBYQJH CA CAS 13122-87-7
DMBYQJH DE Asthma
DMUC9OS ID DMUC9OS
DMUC9OS DN GSK-644784
DMUC9OS HS Discontinued in Phase 2
DMUC9OS SN AC1NQWGT
DMUC9OS CP GlaxoSmithKline
DMUC9OS TC Analgesics
DMUC9OS DT Small molecular drug
DMUC9OS PC 5280119
DMUC9OS MW 563.6
DMUC9OS FM C24H36F3N5O7
DMUC9OS IC InChI=1S/C14H12F3N3O5.C10H24N2O2/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11;1-3-9(7-13)11-5-6-12-10(4-2)8-14/h1-4,6,11H,5,7-8H2;9-14H,3-8H2,1-2H3/t11-;9-,10-/m00/s1
DMUC9OS CS CC[C@@H](CO)NCCN[C@@H](CC)CO.C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
DMUC9OS IK CSKKOIQIXPTXLB-MZEPSHEKSA-N
DMUC9OS IU (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol;(6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
DMUC9OS DE Neuropathic pain
DM5WRJX ID DM5WRJX
DM5WRJX DN GSK-677954
DM5WRJX HS Discontinued in Phase 2
DM5WRJX SN SCHEMBL2065429
DM5WRJX CP GSK
DM5WRJX DT Small molecular drug
DM5WRJX PC 56603715
DM5WRJX MW 671.8
DM5WRJX FM C34H36F3N3O4S2
DM5WRJX IC InChI=1S/C34H36F3N3O4S2/c1-4-33(5-2,32(41)42)44-27-14-16-28(17-15-27)45-22-29-30(38-31(46-29)23-6-8-24(9-7-23)34(35,36)37)40-20-18-39(19-21-40)25-10-12-26(43-3)13-11-25/h6-17H,4-5,18-22H2,1-3H3,(H,41,42)
DM5WRJX CS CCC(CC)(C(=O)O)OC1=CC=C(C=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)N4CCN(CC4)C5=CC=C(C=C5)OC
DM5WRJX IK COHCTXOFKQXTRQ-UHFFFAOYSA-N
DM5WRJX IU 2-ethyl-2-[4-[[4-[4-(4-methoxyphenyl)piperazin-1-yl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]butanoic acid
DM5WRJX DE Non-alcoholic fatty liver disease
DMJ0ZB6 ID DMJ0ZB6
DMJ0ZB6 DN GSK-732461
DMJ0ZB6 HS Discontinued in Phase 2
DMJ0ZB6 SN HIV vaccine (gag, pol, nef), GSK; HIV vaccine (gag, pol, nef), GlaxoSmithKline; 732461; 732462
DMJ0ZB6 CP GlaxoSmithKline plc
DMJ0ZB6 DT Vaccine
DMJ0ZB6 DE Human immunodeficiency virus infection
DMRNJPY ID DMRNJPY
DMRNJPY DN GSK835726
DMRNJPY HS Discontinued in Phase 2
DMRNJPY SN Galnon trifluoroacetate salt; Galnon trifluoroacetate salt, > 7-((9-Fluorenylmethoxycarbonyl)cyclohexylalanyllysyl) amino-4-methylcoumarin trifluoroacetate salt
DMRNJPY CP GSK
DMRNJPY DT Small molecular drug
DMRNJPY PC 16219413
DMRNJPY MW 792.8
DMRNJPY FM C42H47F3N4O8
DMRNJPY IC InChI=1S/C40H46N4O6.C2HF3O2/c1-25-21-37(45)50-36-23-27(18-19-28(25)36)42-38(46)34(17-9-10-20-41)43-39(47)35(22-26-11-3-2-4-12-26)44-40(48)49-24-33-31-15-7-5-13-29(31)30-14-6-8-16-32(30)33;3-2(4,5)1(6)7/h5-8,13-16,18-19,21,23,26,33-35H,2-4,9-12,17,20,22,24,41H2,1H3,(H,42,46)(H,43,47)(H,44,48);(H,6,7)/t34-,35-;/m0./s1
DMRNJPY CS CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3CCCCC3)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46.C(=O)(C(F)(F)F)O
DMRNJPY IK NLKOPSMADZXEPE-WDAFUDAASA-N
DMRNJPY IU 9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate;2,2,2-trifluoroacetic acid
DMRNJPY DE Allergic rhinitis
DM8J30W ID DM8J30W
DM8J30W DN GSK870086
DM8J30W HS Discontinued in Phase 2
DM8J30W CP GlaxoSmithKline
DM8J30W DE Asthma
DMLFCNY ID DMLFCNY
DMLFCNY DN GT-389255
DMLFCNY HS Discontinued in Phase 2
DMLFCNY CP Peptimmune
DMLFCNY DE Obesity
DMZD023 ID DMZD023
DMZD023 DN GV-150013
DMZD023 HS Discontinued in Phase 2
DMZD023 SN WSFVPEEMNO; UNII-WSFVPEEMNO; CHEBI:79615; gv 150013; GV 150013X; GV-150013; CHEMBL329305; 167355-22-8; GV150013; 1-[(3R)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea; AC1NSK32; GTPL3503; BDBM50214395; C15096; N-(1-(Adamantyl-1-methyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-N'-phenylurea,(R)-(-); Urea, N-phenyl-N'-(2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl)-, (R)-; Urea, N-phenyl-N'-((3R)-2,3,4,5-tetrahydr
DMZD023 DT Small molecular drug
DMZD023 PC 5311147
DMZD023 MW 534.6
DMZD023 FM C33H34N4O3
DMZD023 IC InChI=1S/C33H34N4O3/c38-30-29(35-32(40)34-25-9-3-1-4-10-25)31(39)37(26-11-5-2-6-12-26)28-14-8-7-13-27(28)36(30)21-33-18-22-15-23(19-33)17-24(16-22)20-33/h1-14,22-24,29H,15-21H2,(H2,34,35,40)/t22?,23?,24?,29-,33?/m1/s1
DMZD023 CS C1C2CC3CC1CC(C2)(C3)CN4C5=CC=CC=C5N(C(=O)[C@@H](C4=O)NC(=O)NC6=CC=CC=C6)C7=CC=CC=C7
DMZD023 IK RZERRLOTRSJIAW-NEPGVILWSA-N
DMZD023 IU 1-[(3R)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea
DMZD023 CA CAS 167355-22-8
DMZD023 CB CHEBI:79615
DMZD023 DE Anxiety disorder
DMFN21T ID DMFN21T
DMFN21T DN GV-196771
DMFN21T HS Discontinued in Phase 2
DMFN21T SN GR-196771; GV-196771A
DMFN21T CP Glaxo Wellcome plc
DMFN21T DT Small molecular drug
DMFN21T PC 6913185
DMFN21T MW 401.2
DMFN21T FM C20H14Cl2N2O3
DMFN21T IC InChI=1S/C20H14Cl2N2O3/c21-12-9-15(22)17-14(18(20(26)27)23-16(17)10-12)8-11-6-7-24(19(11)25)13-4-2-1-3-5-13/h1-5,8-10,23H,6-7H2,(H,26,27)/b11-8+
DMFN21T CS C\\1CN(C(=O)/C1=C/C2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O)C4=CC=CC=C4
DMFN21T IK VDIRQCDDCGAGET-DHZHZOJOSA-N
DMFN21T IU 4,6-dichloro-3-[(E)-(2-oxo-1-phenylpyrrolidin-3-ylidene)methyl]-1H-indole-2-carboxylic acid
DMFN21T CA CAS 166974-22-7
DMFN21T DE Migraine
DMQ92WF ID DMQ92WF
DMQ92WF DN GW 468816
DMQ92WF HS Discontinued in Phase 2
DMQ92WF SN GW468816; SCHEMBL5750612; CHEMBL1207366; (4e)-7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid
DMQ92WF CP GlaxoSmithKline
DMQ92WF DT Small molecular drug
DMQ92WF PC 10303232
DMQ92WF MW 368.8
DMQ92WF FM C20H17ClN2O3
DMQ92WF IC InChI=1S/C20H17ClN2O3/c21-12-6-7-14-16(11-18(20(25)26)22-17(14)10-12)15-8-9-23(19(15)24)13-4-2-1-3-5-13/h1-7,10,18,22H,8-9,11H2,(H,25,26)/b16-15+
DMQ92WF CS C\\1CN(C(=O)/C1=C/2\\CC(NC3=C2C=CC(=C3)Cl)C(=O)O)C4=CC=CC=C4
DMQ92WF IK XDKRVNKVAKCFGW-FOCLMDBBSA-N
DMQ92WF IU (4E)-7-chloro-4-(2-oxo-1-phenylpyrrolidin-3-ylidene)-2,3-dihydro-1H-quinoline-2-carboxylic acid
DMQ92WF DE Tobacco dependence
DMOIL29 ID DMOIL29
DMOIL29 DN GW-275919
DMOIL29 HS Discontinued in Phase 2
DMOIL29 CP Glaxo Wellcome plc
DMOIL29 DE Pain
DMZ2OBD ID DMZ2OBD
DMZ2OBD DN GW-493838
DMZ2OBD HS Discontinued in Phase 2
DMZ2OBD CP GlaxoSmithKline
DMZ2OBD TC Analgesics
DMZ2OBD DT Small molecular drug
DMZ2OBD PC 9810927
DMZ2OBD MW 489.9
DMZ2OBD FM C21H21ClFN7O4
DMZ2OBD IC InChI=1S/C21H21ClFN7O4/c1-21(2,3)20-29-28-18(34-20)15-13(31)14(32)19(33-15)30-8-26-12-16(24-7-25-17(12)30)27-11-5-4-9(22)6-10(11)23/h4-8,13-15,19,31-32H,1-3H3,(H,24,25,27)/t13-,14+,15-,19+/m0/s1
DMZ2OBD CS CC(C)(C)C1=NN=C(O1)[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)NC5=C(C=C(C=C5)Cl)F)O)O
DMZ2OBD IK ZQYJPMPXQLNTPQ-QCUYGVNKSA-N
DMZ2OBD IU (2S,3S,4R,5R)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluoroanilino)purin-9-yl]oxolane-3,4-diol
DMZ2OBD CA CAS 253124-46-8
DMZ2OBD DE Neuropathic pain
DM1FIN9 ID DM1FIN9
DM1FIN9 DN GW-559090
DM1FIN9 HS Discontinued in Phase 2
DM1FIN9 SN Alpha-4 integrin antagonist (inhaled), GlaxoSmithKline
DM1FIN9 CP GlaxoSmithKline plc
DM1FIN9 PC 9809516
DM1FIN9 MW 596.7
DM1FIN9 FM C31H40N4O8
DM1FIN9 IC InChI=1S/C31H40N4O8/c1-19(2)16-24(33-27(36)18-42-26-7-5-4-6-20(26)3)29(38)34-25(30(39)40)17-21-8-10-23(11-9-21)43-31(41)35-14-12-22(13-15-35)28(32)37/h4-11,19,22,24-25H,12-18H2,1-3H3,(H2,32,37)(H,33,36)(H,34,38)(H,39,40)/t24-,25-/m0/s1
DM1FIN9 CS CC1=CC=CC=C1OCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)OC(=O)N3CCC(CC3)C(=O)N)C(=O)O
DM1FIN9 IK RZMCXMNNXGCFQG-DQEYMECFSA-N
DM1FIN9 IU (2S)-3-[4-(4-carbamoylpiperidine-1-carbonyl)oxyphenyl]-2-[[(2S)-4-methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl]amino]propanoic acid
DM1FIN9 CA CAS 278598-52-0
DM1FIN9 DE Allergic rhinitis
DMKC0J5 ID DMKC0J5
DMKC0J5 DN GW-766994
DMKC0J5 HS Discontinued in Phase 2
DMKC0J5 SN CCR3 antagonists, GSK; CCR3 antagonists, GlaxoSmithKline; Chemokine receptor 3 antagonist, GlaxoSmithKline; GW-633647; GW-633647X; GW-701877; GW-701897; GW-701897X; GW-782415X; SB-297006; SB-328437
DMKC0J5 CP GlaxoSmithKline plc
DMKC0J5 DT Small molecular drug
DMKC0J5 PC 10218765
DMKC0J5 MW 451.3
DMKC0J5 FM C21H24Cl2N4O3
DMKC0J5 IC InChI=1S/C21H24Cl2N4O3/c22-18-6-3-15(9-19(18)23)12-27-7-8-30-17(13-27)11-26-21(29)25-10-14-1-4-16(5-2-14)20(24)28/h1-6,9,17H,7-8,10-13H2,(H2,24,28)(H2,25,26,29)/t17-/m0/s1
DMKC0J5 CS C1CO[C@H](CN1CC2=CC(=C(C=C2)Cl)Cl)CNC(=O)NCC3=CC=C(C=C3)C(=O)N
DMKC0J5 IK GPLUUMAKBFSDIE-KRWDZBQOSA-N
DMKC0J5 IU 4-[[[(2S)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylcarbamoylamino]methyl]benzamide
DMKC0J5 CA CAS 408303-43-5
DMKC0J5 DE Asthma
DMLC154 ID DMLC154
DMLC154 DN GW842470X
DMLC154 HS Discontinued in Phase 2
DMLC154 CP GSK; Elbion
DMLC154 DE Atopic dermatitis
DMAXRBI ID DMAXRBI
DMAXRBI DN GW876008
DMAXRBI HS Discontinued in Phase 2
DMAXRBI SN GW-876008
DMAXRBI CP GSK
DMAXRBI DT Small molecular drug
DMAXRBI PC 11223423
DMAXRBI MW 404.5
DMAXRBI FM C22H24N6O2
DMAXRBI IC InChI=1S/C22H24N6O2/c1-14-12-16(30-3)4-5-18(14)26-9-6-17-19(13-15(2)24-21(17)26)28-10-7-20(25-28)27-11-8-23-22(27)29/h4-5,7,10,12-13H,6,8-9,11H2,1-3H3,(H,23,29)
DMAXRBI CS CC1=CC(=C2CCN(C2=N1)C3=C(C=C(C=C3)OC)C)N4C=CC(=N4)N5CCNC5=O
DMAXRBI IK JFHJGXQFESYQGY-UHFFFAOYSA-N
DMAXRBI IU 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]imidazolidin-2-one
DMAXRBI CA CAS 786701-13-1
DMAXRBI DE Irritable bowel syndrome
DMMZQVS ID DMMZQVS
DMMZQVS DN GYKI-16084
DMMZQVS HS Discontinued in Phase 2
DMMZQVS SN Uroflux; IDR-16084; (+)-(R)-2-[3-(Benzo-1,4-dioxan-2-ylmethylamino)propyl]pyridazin-3(2H)-one hydrochloride
DMMZQVS DT Small molecular drug
DMMZQVS PC 154069
DMMZQVS MW 301.34
DMMZQVS FM C16H19N3O3
DMMZQVS IC InChI=1S/C16H19N3O3/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13/h1-3,5-7,9,13,17H,4,8,10-12H2/t13-/m1/s1
DMMZQVS CS C1[C@H](OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3
DMMZQVS IK FJNRJBQUOQLUNQ-CYBMUJFWSA-N
DMMZQVS IU 2-[3-[[(3R)-2,3-dihydro-1,4-benzodioxin-3-yl]methylamino]propyl]pyridazin-3-one
DMMZQVS CA CAS 185739-21-3
DMMZQVS DE Prostate disease
DMYJ9CF ID DMYJ9CF
DMYJ9CF DN H-409/22
DMYJ9CF HS Discontinued in Phase 2
DMYJ9CF SN Y1 receptor antagonist 1; AC1NSKN0; H-409/22; H 409-22; SCHEMBL1593464; CS-7270; HY-101704
DMYJ9CF CP AstraZeneca plc
DMYJ9CF DT Small molecular drug
DMYJ9CF PC 5311439
DMYJ9CF MW 487.6
DMYJ9CF FM C28H33N5O3
DMYJ9CF IC InChI=1S/C28H33N5O3/c1-19(20-14-16-23(34)17-15-20)32-26(35)24(13-8-18-31-28(29)30)33-27(36)25(21-9-4-2-5-10-21)22-11-6-3-7-12-22/h2-7,9-12,14-17,19,24-25,34H,8,13,18H2,1H3,(H,32,35)(H,33,36)(H4,29,30,31)/t19-,24-/m1/s1
DMYJ9CF CS C[C@H](C1=CC=C(C=C1)O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3
DMYJ9CF IK AOUQZUZEYSDMEZ-NTKDMRAZSA-N
DMYJ9CF IU (2R)-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]-N-[(1R)-1-(4-hydroxyphenyl)ethyl]pentanamide
DMYJ9CF DE Cardiovascular disease
DMPQSE4 ID DMPQSE4
DMPQSE4 DN HCV-796
DMPQSE4 HS Discontinued in Phase 2
DMPQSE4 SN Nesbuvir; Nesbuvir (USAN); 79Z
DMPQSE4 CP ViroPharma; Wyeth
DMPQSE4 DT Small molecular drug
DMPQSE4 PC 11561383
DMPQSE4 MW 446.5
DMPQSE4 FM C22H23FN2O5S
DMPQSE4 IC InChI=1S/C22H23FN2O5S/c1-24-22(27)20-17-11-16(13-3-4-13)18(25(9-10-26)31(2,28)29)12-19(17)30-21(20)14-5-7-15(23)8-6-14/h5-8,11-13,26H,3-4,9-10H2,1-2H3,(H,24,27)
DMPQSE4 CS CNC(=O)C1=C(OC2=CC(=C(C=C21)C3CC3)N(CCO)S(=O)(=O)C)C4=CC=C(C=C4)F
DMPQSE4 IK WTDWVLJJJOTABN-UHFFFAOYSA-N
DMPQSE4 IU 5-cyclopropyl-2-(4-fluorophenyl)-6-[2-hydroxyethyl(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide
DMPQSE4 CA CAS 691852-58-1
DMPQSE4 DE Hepatitis C virus infection
DMWH4CY ID DMWH4CY
DMWH4CY DN HE-2000
DMWH4CY HS Discontinued in Phase 2
DMWH4CY SN Immunitin; Inactivin; Bromoepiandrosterone, Hollis-Eden; DHEA analogs, Hollis-Eden; Dehydroepiandrosterone, Hollis-Eden
DMWH4CY CP Colthurst Ltd
DMWH4CY DT Small molecular drug
DMWH4CY PC 71613
DMWH4CY MW 369.3
DMWH4CY FM C19H29BrO2
DMWH4CY IC InChI=1S/C19H29BrO2/c1-18-7-5-12(21)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(20)17(19)22/h11-16,21H,3-10H2,1-2H3/t11-,12-,13+,14-,15-,16+,18-,19-/m0/s1
DMWH4CY CS C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)Br)C)O
DMWH4CY IK CWVMWSZEMZOUPC-JUAXIXHSSA-N
DMWH4CY IU (3S,5S,8R,9S,10S,13S,14S,16R)-16-bromo-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMWH4CY CA CAS 28507-02-0
DMWH4CY DE Cystic fibrosis
DM5JZW2 ID DM5JZW2
DM5JZW2 DN Her-2-Bi-armed ATC
DM5JZW2 HS Discontinued in Phase 2
DM5JZW2 SN Her-2Bi-armed ATC (cancer), Roger Williams Medical Center; Anti-CD3 + anti-Her2/neu bispecific antibody armed T-cells (cancer), Roger Williams Medical Center; T-cells plus anti-CD3 + anti-Her2/neu antibody (cancer), Roger Williams Medical Center
DM5JZW2 CP Roger Williams Medical Center
DM5JZW2 DT Antibody
DM5JZW2 DE Breast cancer
DMIJSB3 ID DMIJSB3
DMIJSB3 DN HMR-1426
DMIJSB3 HS Discontinued in Phase 2
DMIJSB3 SN 6-Chloro-2-phenyl-8,8a-dihydro-3aH-indeno[1,2-d]thiazol-3a-ol
DMIJSB3 DE Obesity
DMYJ1ZB ID DMYJ1ZB
DMYJ1ZB DN HN-10200
DMYJ1ZB HS Discontinued in Phase 2
DMYJ1ZB CP Nycomed AS
DMYJ1ZB PC 101656410
DMYJ1ZB MW 293.4
DMYJ1ZB FM C12H11N3O2S2
DMYJ1ZB IC InChI=1S/C12H11N3O2S2/c1-17-9-8(19(2)16)6-18-10(9)12-14-7-4-3-5-13-11(7)15-12/h3-6H,1-2H3,(H,13,14,15)
DMYJ1ZB CS COC1=C(SC=C1S(=O)C)C2=NC3=C(N2)C=CC=N3
DMYJ1ZB IK WUXLGRPRVSOZPL-UHFFFAOYSA-N
DMYJ1ZB IU 2-(3-methoxy-4-methylsulfinylthiophen-2-yl)-1H-imidazo[4,5-b]pyridine
DMYJ1ZB DE Cardiac failure
DMUMGCY ID DMUMGCY
DMUMGCY DN HP-290
DMUMGCY HS Discontinued in Phase 2
DMUMGCY SN Quilostigmine; NXX-066; UNII-2L1YNO4SQJ; 2L1YNO4SQJ; 139314-01-5; CHEMBL1243298; Quilostigmine [USAN:INN]; NXX 066; HP 290; AC1L30LY; Quilostigmine (USAN/INN); SCHEMBL28872; IIFRKALDATVOJE-GGAORHGYSA-N; BDBM50326265; (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate; D03823; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-; NXX-066; QUILOSTIGMINE
DMUMGCY CP Astra AB; Hoechst AG
DMUMGCY DT Small molecular drug
DMUMGCY PC 132228
DMUMGCY MW 377.5
DMUMGCY FM C23H27N3O2
DMUMGCY IC InChI=1S/C23H27N3O2/c1-23-11-13-24(2)21(23)25(3)20-9-8-18(14-19(20)23)28-22(27)26-12-10-16-6-4-5-7-17(16)15-26/h4-9,14,21H,10-13,15H2,1-3H3/t21-,23+/m1/s1
DMUMGCY CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)N4CCC5=CC=CC=C5C4)C)C
DMUMGCY IK IIFRKALDATVOJE-GGAORHGYSA-N
DMUMGCY IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] 3,4-dihydro-1H-isoquinoline-2-carboxylate
DMUMGCY CA CAS 139314-01-5
DMUMGCY DE Parkinson disease
DM51GZS ID DM51GZS
DM51GZS DN HR325
DM51GZS HS Discontinued in Phase 2
DM51GZS DT Small molecular drug
DM51GZS PC 66583751
DM51GZS MW 310.27
DM51GZS FM C15H13F3N2O2
DM51GZS IC InChI=1S/C15H13F3N2O2/c1-8-6-10(4-5-12(8)15(16,17)18)20-14(22)11(7-19)13(21)9-2-3-9/h4-6,9,21H,2-3H2,1H3,(H,20,22)
DM51GZS CS CC1=C(C=CC(=C1)NC(=O)C(=C(C2CC2)O)C#N)C(F)(F)F
DM51GZS IK GDHFOVCRYCPOTK-UHFFFAOYSA-N
DM51GZS IU 2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]prop-2-enamide
DM51GZS DE Rheumatoid arthritis
DM1PJ0V ID DM1PJ0V
DM1PJ0V DN HSR-609
DM1PJ0V HS Discontinued in Phase 2
DM1PJ0V SN FY-609; 3-[4-(8-Fluoro-5,11-dihydrobenz[b]oxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propionic acid dihydrate
DM1PJ0V DT Small molecular drug
DM1PJ0V PC 3081352
DM1PJ0V MW 404.4
DM1PJ0V FM C21H25FN2O5
DM1PJ0V IC InChI=1S/C21H21FN2O3.2H2O/c22-16-3-4-17-18(12-16)27-13-15-2-1-8-23-21(15)20(17)14-5-9-24(10-6-14)11-7-19(25)26;;/h1-4,8,12H,5-7,9-11,13H2,(H,25,26);2*1H2
DM1PJ0V CS C1CN(CCC1=C2C3=C(C=C(C=C3)F)OCC4=C2N=CC=C4)CCC(=O)O.O.O
DM1PJ0V IK CWNCDQYLHMXURI-UHFFFAOYSA-N
DM1PJ0V IU 3-[4-(8-fluoro-5H-[1]benzoxepino[4,3-b]pyridin-11-ylidene)piperidin-1-yl]propanoic acid;dihydrate
DM1PJ0V CA CAS 188199-97-5
DM1PJ0V DE Rhinitis
DM1LVRP ID DM1LVRP
DM1LVRP DN IC-747
DM1LVRP HS Discontinued in Phase 2
DM1LVRP SN LFA-1 antagonists, ICOS/Biogen
DM1LVRP CP ICOS Corp
DM1LVRP DE Psoriasis vulgaris
DMKUVZO ID DMKUVZO
DMKUVZO DN ICI-170809
DMKUVZO HS Discontinued in Phase 2
DMKUVZO SN ZM-170809
DMKUVZO CP Zeneca Group plc
DMKUVZO DT Small molecular drug
DMKUVZO PC 9885848
DMKUVZO MW 373
DMKUVZO FM C21H25ClN2S
DMKUVZO IC InChI=1S/C21H24N2S.ClH/c1-21(2,23(3)4)15-24-20-18(16-10-6-5-7-11-16)14-17-12-8-9-13-19(17)22-20;/h5-14H,15H2,1-4H3;1H
DMKUVZO CS CC(C)(CSC1=NC2=CC=CC=C2C=C1C3=CC=CC=C3)N(C)C.Cl
DMKUVZO IK HVIXPSLXHVWFAU-UHFFFAOYSA-N
DMKUVZO IU N,N,2-trimethyl-1-(3-phenylquinolin-2-yl)sulfanylpropan-2-amine;hydrochloride
DMKUVZO CA CAS 85275-49-6
DMKUVZO DE Anxiety disorder
DMY8X6Q ID DMY8X6Q
DMY8X6Q DN ICI-192605
DMY8X6Q HS Discontinued in Phase 2
DMY8X6Q SN ICI 192,605; SCHEMBL2939361; SCHEMBL3103318; GTPL6072; 6-[2beta-(2-Chlorophenyl)-6beta-(2-hydroxyphenyl)-1,3-dioxan-5beta-yl]-4-hexenoic acid; (E)-6-[(2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid
DMY8X6Q CP Zeneca Group plc
DMY8X6Q DT Small molecular drug
DMY8X6Q PC 6438399
DMY8X6Q MW 402.9
DMY8X6Q FM C22H23ClO5
DMY8X6Q IC InChI=1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1
DMY8X6Q CS C1[C@@H]([C@@H](O[C@@H](O1)C2=CC=CC=C2Cl)C3=CC=CC=C3O)C/C=C\\CCC(=O)O
DMY8X6Q IK WHUIENZXNGAHQI-YGPRPMEGSA-N
DMY8X6Q IU (Z)-6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid
DMY8X6Q CA CAS 117621-64-4
DMY8X6Q DE Thrombosis
DM3R8TX ID DM3R8TX
DM3R8TX DN ICI-D-8731
DM3R8TX HS Discontinued in Phase 2
DM3R8TX SN D-8731; ZD-8731
DM3R8TX CP Zeneca Group plc
DM3R8TX PC 132562
DM3R8TX MW 407.5
DM3R8TX FM C25H21N5O
DM3R8TX IC InChI=1S/C25H21N5O/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25/h3-15H,2,16H2,1H3,(H,27,28,29,30)
DM3R8TX CS CCC1=NC2=CC=CC=C2C(=C1)OCC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DM3R8TX IK FSJCYXPMWQPVOS-UHFFFAOYSA-N
DM3R8TX IU 2-ethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]quinoline
DM3R8TX CA CAS 143494-72-8
DM3R8TX DE Hypertension
DM5WUK9 ID DM5WUK9
DM5WUK9 DN Icopezil maleate
DM5WUK9 HS Discontinued in Phase 2
DM5WUK9 DT Small molecular drug
DM5WUK9 PC 135462830
DM5WUK9 MW 491.5
DM5WUK9 FM C27H29N3O6
DM5WUK9 IC InChI=1S/C23H25N3O2.C4H4O4/c27-23-13-18-12-19-20(25-28-22(19)14-21(18)24-23)7-6-16-8-10-26(11-9-16)15-17-4-2-1-3-5-17;5-3(6)1-2-4(7)8/h1-5,12,14,16H,6-11,13,15H2,(H,24,27);1-2H,(H,5,6)(H,7,8)/b;2-1-
DM5WUK9 CS C1CN(CCC1CCC2=NOC3=C2C=C4CC(=O)NC4=C3)CC5=CC=CC=C5.C(=C\\C(=O)O)\\C(=O)O
DM5WUK9 IK CTYSKGVFLJLGGX-BTJKTKAUSA-N
DM5WUK9 IU 3-[2-(1-benzylpiperidin-4-yl)ethyl]-5,7-dihydropyrrolo[3,2-f][1,2]benzoxazol-6-one;(Z)-but-2-enedioic acid
DM5WUK9 CA CAS 145815-98-1
DM5WUK9 DE Cognitive impairment
DMILUHA ID DMILUHA
DMILUHA DN IDEC-151
DMILUHA HS Discontinued in Phase 2
DMILUHA SN Clenoliximab
DMILUHA CP Biogen Idec
DMILUHA DT Antibody
DMILUHA DE Rheumatoid arthritis
DM7O0UR ID DM7O0UR
DM7O0UR DN Idrapril
DM7O0UR HS Discontinued in Phase 2
DM7O0UR SN LG-32001
DM7O0UR CP Laboratorio Guidotti SpA
DM7O0UR DT Small molecular drug
DM7O0UR PC 65960
DM7O0UR MW 258.269
DM7O0UR FM C11H18N2O5
DM7O0UR IC InChI=1S/C11H18N2O5/c1-13(6-9(14)12-18)10(15)7-4-2-3-5-8(7)11(16)17/h7-8,18H,2-6H2,1H3,(H,12,14)(H,16,17)/t7-,8+/m1/s1
DM7O0UR CS CN(CC(=O)NO)C(=O)[C@@H]1CCCC[C@@H]1C(=O)O
DM7O0UR IK QKIVRALZQSUWHH-SFYZADRCSA-N
DM7O0UR IU (1S,2R)-2-[[2-(hydroxyamino)-2-oxoethyl]-methylcarbamoyl]cyclohexane-1-carboxylic acid
DM7O0UR CA CAS 127420-24-0
DM7O0UR DE Hypertension
DMRPBJW ID DMRPBJW
DMRPBJW DN IDX375
DMRPBJW HS Discontinued in Phase 2
DMRPBJW CP Idenix
DMRPBJW PC 135566716
DMRPBJW MW 540.6
DMRPBJW FM C24H37N4O6PS
DMRPBJW IC InChI=1S/C24H37N4O6PS/c1-9-34-35(31)17-14-15(27-36(8,32)33)10-11-16(17)25-21(26-35)18-19(29)20(24(5,6)7)28(22(18)30)13-12-23(2,3)4/h10-11,14,20,27,29H,9,12-13H2,1-8H3,(H,25,26,31)/t20-,35+/m1/s1
DMRPBJW CS CCO[P@@]1(=O)C2=C(C=CC(=C2)NS(=O)(=O)C)NC(=N1)C3=C([C@@H](N(C3=O)CCC(C)(C)C)C(C)(C)C)O
DMRPBJW IK FKLYVKZFUGOUQH-GOKJBEJGSA-N
DMRPBJW IU N-[(1S)-3-[(2S)-2-tert-butyl-1-(3,3-dimethylbutyl)-3-hydroxy-5-oxo-2H-pyrrol-4-yl]-1-ethoxy-1-oxo-4H-2,4,1lambda5-benzodiazaphosphinin-7-yl]methanesulfonamide
DMRPBJW DE Hepatitis C virus infection
DMOG1LX ID DMOG1LX
DMOG1LX DN IGN-101
DMOG1LX HS Discontinued in Phase 2
DMOG1LX SN Cancer vaccine, Igeneon; Anti-EpCam murine monoclonal antibody 17-A carcinoma vaccine; Aluminum-adsorbed murine monoclonal antibody 17-1A (edrecolomab) vaccine antigen (cancer), Igeneon
DMOG1LX CP Igeneon GmbH
DMOG1LX DT Vaccine
DMOG1LX DE Colorectal cancer
DMU4N1O ID DMU4N1O
DMU4N1O DN IGN-2098
DMU4N1O HS Discontinued in Phase 2
DMU4N1O CP Ikeda Mohando Co Ltd
DMU4N1O DT Small molecular drug
DMU4N1O PC 135483992
DMU4N1O MW 455.4
DMU4N1O FM C22H32Cl2N4O2
DMU4N1O IC InChI=1S/C22H30N4O2.2ClH/c1-17-18(2)24-22(25-21(17)27)23-11-4-7-14-28-20-10-8-9-19(15-20)16-26-12-5-3-6-13-26;;/h4,7-10,15H,3,5-6,11-14,16H2,1-2H3,(H2,23,24,25,27);2*1H/b7-4-;;
DMU4N1O CS CC1=C(N=C(NC1=O)NC/C=C\\COC2=CC=CC(=C2)CN3CCCCC3)C.Cl.Cl
DMU4N1O IK NTLKFRQIRDDXCH-XIFWRFGDSA-N
DMU4N1O IU 4,5-dimethyl-2-[[(Z)-4-[3-(piperidin-1-ylmethyl)phenoxy]but-2-enyl]amino]-1H-pyrimidin-6-one;dihydrochloride
DMU4N1O CA CAS 126869-04-3
DMU4N1O DE Duodenal ulcer
DMQ2ULV ID DMQ2ULV
DMQ2ULV DN Imitrodast
DMQ2ULV HS Discontinued in Phase 2
DMQ2ULV SN Logran; CS-518; RS-5186
DMQ2ULV CP Sankyo Co Ltd
DMQ2ULV DT Small molecular drug
DMQ2ULV PC 65922
DMQ2ULV MW 260.31
DMQ2ULV FM C13H12N2O2S
DMQ2ULV IC InChI=1S/C13H12N2O2S/c16-13(17)10-2-1-9-5-11(18-12(9)6-10)7-15-4-3-14-8-15/h3-6,8H,1-2,7H2,(H,16,17)
DMQ2ULV CS C1CC2=C(C=C1C(=O)O)SC(=C2)CN3C=CN=C3
DMQ2ULV IK KRBSZXUPPSXPAN-UHFFFAOYSA-N
DMQ2ULV IU 2-(imidazol-1-ylmethyl)-4,5-dihydro-1-benzothiophene-6-carboxylic acid
DMQ2ULV CA CAS 114686-12-3
DMQ2ULV DE Asthma
DMRHZBD ID DMRHZBD
DMRHZBD DN INCB19602
DMRHZBD HS Discontinued in Phase 2
DMRHZBD CP Incyte
DMRHZBD DE Type-2 diabetes
DMNRQA9 ID DMNRQA9
DMNRQA9 DN INCB47986
DMNRQA9 HS Discontinued in Phase 2
DMNRQA9 CP Incyte
DMNRQA9 DE Rheumatoid arthritis
DMS56UD ID DMS56UD
DMS56UD DN Indeglitazar
DMS56UD HS Discontinued in Phase 2
DMS56UD SN PLX-204
DMS56UD CP Plexxikon
DMS56UD DT Small molecular drug
DMS56UD PC 11395145
DMS56UD MW 389.4
DMS56UD FM C19H19NO6S
DMS56UD IC InChI=1S/C19H19NO6S/c1-25-14-4-7-16(8-5-14)27(23,24)20-12-13(3-10-19(21)22)17-11-15(26-2)6-9-18(17)20/h4-9,11-12H,3,10H2,1-2H3,(H,21,22)
DMS56UD CS COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O
DMS56UD IK YMPALHOKRBVHOJ-UHFFFAOYSA-N
DMS56UD IU 3-[5-methoxy-1-(4-methoxyphenyl)sulfonylindol-3-yl]propanoic acid
DMS56UD CA CAS 835619-41-5
DMS56UD DE Type-2 diabetes
DMJM38Q ID DMJM38Q
DMJM38Q DN INGN-234
DMJM38Q HS Discontinued in Phase 2
DMJM38Q SN P53 tumor suppressor (topical formulation), Introgen
DMJM38Q CP Introgen Therapeutics Inc
DMJM38Q DE Oral cancer
DM6HDO3 ID DM6HDO3
DM6HDO3 DN INOGATRAN
DM6HDO3 HS Discontinued in Phase 2
DM6HDO3 SN Inogatran; Inogatran [INN]; UNII-428409I84L; CHEMBL114715; 155415-08-0; INOGATRAN (ASTRA-ZENECA); {[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID; 428409I84L; N-((1R)-2-Cyclohexyl-1-(((2S)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine; 2-[[(2R)-3-cyclohexyl-1-[(2S)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid; IGN; AC1Q5JWR; AC1L24ET; SCHEMBL22745; SCHEMBL22747
DM6HDO3 DT Small molecular drug
DM6HDO3 PC 66005
DM6HDO3 MW 438.6
DM6HDO3 FM C21H38N6O4
DM6HDO3 IC InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)/t16-,17+/m1/s1
DM6HDO3 CS C1CCC(CC1)C[C@H](C(=O)N2CCCC[C@H]2C(=O)NCCCN=C(N)N)NCC(=O)O
DM6HDO3 IK CDPROXZBMHOBTQ-SJORKVTESA-N
DM6HDO3 IU 2-[[(2R)-3-cyclohexyl-1-[(2S)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid
DM6HDO3 CA CAS 155415-08-0
DM6HDO3 DE Myocardial infarction
DMSATO0 ID DMSATO0
DMSATO0 DN IO-21
DMSATO0 HS Discontinued in Phase 2
DMSATO0 CP Nissin Foods Holdings Co Ltd
DMSATO0 DE Ulcer
DM4WJDK ID DM4WJDK
DM4WJDK DN IPENOXAZONE
DM4WJDK HS Discontinued in Phase 2
DM4WJDK SN MLV-6976; NC-1200; Ipenoxazone; (+)-(4S,5R)-4-(2-Methylpropyl)-3-[3-(perhydroazepin-1-yl)propyl]-5-phenyl-1,3-oxazolidin-2-one
DM4WJDK DT Small molecular drug
DM4WJDK PC 65882
DM4WJDK MW 358.5
DM4WJDK FM C22H34N2O2
DM4WJDK IC InChI=1S/C22H34N2O2/c1-18(2)17-20-21(19-11-6-5-7-12-19)26-22(25)24(20)16-10-15-23-13-8-3-4-9-14-23/h5-7,11-12,18,20-21H,3-4,8-10,13-17H2,1-2H3/t20-,21+/m0/s1
DM4WJDK CS CC(C)C[C@H]1[C@H](OC(=O)N1CCCN2CCCCCC2)C3=CC=CC=C3
DM4WJDK IK DQNMZSIJHFEYTM-LEWJYISDSA-N
DM4WJDK IU (4S,5R)-3-[3-(azepan-1-yl)propyl]-4-(2-methylpropyl)-5-phenyl-1,3-oxazolidin-2-one
DM4WJDK CA CAS 104454-71-9
DM4WJDK DE Alzheimer disease
DMLQWFA ID DMLQWFA
DMLQWFA DN IS-159
DMLQWFA HS Discontinued in Phase 2
DMLQWFA SN 133790-13-3; 2-(3-(2-aminoethyl)-1h-indol-5-yloxy)acetyl-l-tyrosyl-glycinamide; 2-[3-(2-aminoethyl)-1h-indol-5-yloxy]acetyl-l-tyrosyl-glycinamide; SCHEMBL6905927; AC1L52G2; CTK4B8797; Glycinamide,N-[[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-L-tyrosyl- (9CI); AKOS030608101
DMLQWFA CP Immunotech SA
DMLQWFA DT Small molecular drug
DMLQWFA PC 154730670
DMLQWFA DE Migraine
DMURWPH ID DMURWPH
DMURWPH DN ISIS 104838
DMURWPH HS Discontinued in Phase 2
DMURWPH CP Isis Pharmaceuticals
DMURWPH TC Antisense
DMURWPH DT Antisense drug
DMURWPH DE Rheumatoid arthritis; Crohn disease
DMGZV7U ID DMGZV7U
DMGZV7U DN ISIS 14803
DMGZV7U HS Discontinued in Phase 2
DMGZV7U CP Isis Pharmaceuticals
DMGZV7U TC Antisense
DMGZV7U DT Antisense drug
DMGZV7U DE Hepatitis C virus infection
DMR2STB ID DMR2STB
DMR2STB DN ISIS 2105
DMR2STB HS Discontinued in Phase 2
DMR2STB SN UNII-7EL4K2K27P; Afovirsen sodium; 7EL4K2K27P; ISIS 2105; Afovirsen sodium [USAN]; IP 2105; I 2105; 138330-98-0; ISIS-2105; IP-2105; I-2105; Thymidine, 2'-deoxy-P-thiocytidylyl-(5'-3')-P-thiothymidylyl-(5'-3')-2'-deoxy-P-thioguanylyl-(5'-3')-2'-deoxy-P-thiocytidylyl-(5'-3')-P-thiothymidylyl-(5'-3')-2'-deoxy-P-thiocytidylyl-(5'-3')-2'-deoxy-P-thiocytidy
DMR2STB CP Isis Pharmaceuticals
DMR2STB DT Antisense drug
DMR2STB SQ TTGCTTCCATCTTCCTCGTC
DMR2STB PC 71587499
DMR2STB MW 6684
DMR2STB FM C192H231N57Na19O107P19S19
DMR2STB IC InChI=1S/C192H250N57O107P19S19.19Na/c1-79-46-238(184(271)221-163(79)252)144-27-89(108(55-250)318-144)338-358(281,377)300-64-117-98(36-146(327-117)240-48-81(3)165(254)223-186(240)273)353-372(295,391)317-74-127-106(44-154(337-127)248-77-207-157-161(248)217-174(202)219-172(157)261)355-373(296,392)307-63-116-94(32-141(326-116)235-23-15-133(198)214-181(235)268)343-363(286,382)310-68-121-104(42-152(331-121)246-54-87(9)171(260)229-192(246)279)352-371(294,390)312-70-123-101(39-149(333-123)243-51-84(6)168(257)226-189(243)276)349-368(291,387)304-60-113-91(29-138(323-113)232-20-12-130(195)211-178(232)265)340-360(283,379)302-58-111-95(33-142(321-111)236-24-16-134(199)215-182(236)269)344-364(287,383)315-72-125-105(43-153(335-125)247-76-206-156-159(201)204-75-205-160(156)247)354-374(297,393)313-71-124-102(40-150(334-124)244-52-85(7)169(258)227-190(244)277)350-369(292,388)305-61-114-93(31-140(324-114)234-22-14-132(197)213-180(234)267)342-362(285,381)309-67-120-103(41-151(330-120)245-53-86(8)170(259)228-191(245)278)351-370(293,389)311-69-122-100(38-148(332-122)242-50-83(5)167(256)225-188(242)275)348-367(290,386)303-59-112-90(28-137(322-112)231-19-11-129(194)210-177(231)264)339-359(282,378)301-57-110-92(30-139(320-110)233-21-13-131(196)212-179(233)266)341-361(284,380)308-66-119-99(37-147(329-119)241-49-82(4)166(255)224-187(241)274)347-366(289,385)306-62-115-96(34-143(325-115)237-25-17-135(200)216-183(237)270)345-365(288,384)316-73-126-107(45-155(336-126)249-78-208-158-162(249)218-175(203)220-173(158)262)356-375(298,394)314-65-118-97(35-145(328-118)239-47-80(2)164(253)222-185(239)272)346-357(280,376)299-56-109-88(251)26-136(319-109)230-18-10-128(193)209-176(230)263;;;;;;;;;;;;;;;;;;;/h10-25,46-54,75-78,88-127,136-155,250-251H,26-45,55-74H2,1-9H3,(H,280,376)(H,281,377)(H,282,378)(H,283,379)(H,284,380)(H,285,381)(H,286,382)(H,287,383)(H,288,384)(H,289,385)(H,290,386)(H,291,387)(H,292,388)(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H2,193,209,263)(H2,194,210,264)(H2,195,211,265)(H2,196,212,266)(H2,197,213,267)(H2,198,214,268)(H2,199,215,269)(H2,200,216,270)(H2,201,204,205)(H,221,252,271)(H,222,253,272)(H,223,254,273)(H,224,255,274)(H,225,256,275)(H,226,257,276)(H,227,258,277)(H,228,259,278)(H,229,260,279)(H3,202,217,219,261)(H3,203,218,220,262);;;;;;;;;;;;;;;;;;;/q;19*+1/p-19/t88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,357?,358?,359?,360?,361?,362?,363?,364?,365?,366?,367?,368?,369?,370?,371?,372?,373?,374?,375?;;;;;;;;;;;;;;;;;;;/m0.................../s1
DMR2STB CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OP(=S)([O-])OC[C@@H]3[C@H](C[C@@H](O3)N4C=C(C(=O)NC4=O)C)OP(=S)([O-])OC[C@@H]5[C@H](C[C@@H](O5)N6C=NC7=C6N=C(NC7=O)N)OP(=S)([O-])OC[C@@H]8[C@H](C[C@@H](O8)N9C=CC(=NC9=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(OC[C@@H]1[C@H](C[C@@H](O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N1C=CC(=NC1=O)N)O)[S-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMR2STB IK ZWXNIBJNMPZZKZ-JILWZBBZSA-A
DMR2STB IU nonadecasodium;1-[(2R,4S,5R)-4-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3S,5R)-3-[[(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-sulfidophosphoryl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxyoxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphinothioyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR2STB CA CAS 138330-98-0
DMR2STB DE Human papillomavirus infection
DMEMKIS ID DMEMKIS
DMEMKIS DN ISIS 2503
DMEMKIS HS Discontinued in Phase 2
DMEMKIS DT Antisense drug
DMEMKIS SQ TCCGTCATCGCTCCTCAGGG
DMZFS69 ID DMZFS69
DMZFS69 DN ISIS 3521
DMZFS69 HS Discontinued in Phase 2
DMZFS69 TC Antisense
DMZFS69 DT Antisense drug
DMZFS69 SQ AAAACGTCAGCCATGGTCCC
DMKY2UE ID DMKY2UE
DMKY2UE DN Ispronicline
DMKY2UE HS Discontinued in Phase 2
DMKY2UE SN RJR 1734; TC 01734; AZD-3480; RJR-1734; Ispronicline (INN/USAN); (E)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine
DMKY2UE CP AstraZeneca
DMKY2UE DT Small molecular drug
DMKY2UE PC 9824145
DMKY2UE MW 234.34
DMKY2UE FM C14H22N2O
DMKY2UE IC InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1
DMKY2UE CS C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
DMKY2UE IK RPCVIAXDAUMJJP-PZBABLGHSA-N
DMKY2UE IU (E,2S)-N-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine
DMKY2UE CA CAS 252870-53-4
DMKY2UE DE Alzheimer disease; Schizophrenia
DMWN09H ID DMWN09H
DMWN09H DN Istaroxime
DMWN09H HS Discontinued in Phase 2
DMWN09H SN Debio-0614; PST-2107; PST-2744; PST-2915; ST-2744; Digitalis-like compounds, Sigma-Tau; Sodium/potassium-ATPase inhibitors (infusion, cardiac failure), Sigma-Tau/Debiopharm; Na(+)-/K(+)-ATPase inhibitors (cardiac failure), Sigma-Tau; Na(+)-/K(+)-ATPase inhibitors (infusion, cardiac failure), Sigma-Tau/ Debiopharm
DMWN09H CP Sigma-Tau Pharmaceuticals
DMWN09H DT Small molecular drug
DMWN09H PC 9841834
DMWN09H MW 360.5
DMWN09H FM C21H32N2O3
DMWN09H IC InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3/b23-13+/t14-,15-,16-,17+,20+,21-/m0/s1
DMWN09H CS C[C@]12CC/C(=N\\OCCN)/C[C@@H]1C(=O)C[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C
DMWN09H IK MPYLDWFDPHRTEG-PAAYLBSLSA-N
DMWN09H IU (3E,5S,8R,9S,10R,13S,14S)-3-(2-aminoethoxyimino)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-6,17-dione
DMWN09H CA CAS 203737-93-3
DMWN09H DE Cardiac disease
DM4TE8R ID DM4TE8R
DM4TE8R DN IX207-887
DM4TE8R HS Discontinued in Phase 2
DM4TE8R CP Sandoz AG
DM4TE8R PC 6509858
DM4TE8R MW 284.3
DM4TE8R FM C16H12O3S
DM4TE8R IC InChI=1S/C16H12O3S/c1-19-14-8-10-4-2-3-5-11(10)13(9-15(17)18)12-6-7-20-16(12)14/h2-9H,1H3,(H,17,18)/b13-9-
DM4TE8R CS COC1=CC2=CC=CC=C2/C(=C/C(=O)O)/C3=C1SC=C3
DM4TE8R IK XIKRQPKFOKKGGW-LCYFTJDESA-N
DM4TE8R IU (2Z)-2-(8-methoxy-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,8,10,12-hexaen-2-ylidene)acetic acid
DM4TE8R DE Rheumatoid arthritis
DM5E6MK ID DM5E6MK
DM5E6MK DN J-104132
DM5E6MK HS Discontinued in Phase 2
DM5E6MK SN L-753037; (5S,6R,7R)-2-Butyl-7-[2-[2(S)-carboxypropyl]-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid
DM5E6MK DT Small molecular drug
DM5E6MK PC 186002
DM5E6MK MW 531.6
DM5E6MK FM C31H33NO7
DM5E6MK IC InChI=1S/C31H33NO7/c1-4-5-6-20-8-10-23-26(18-7-12-24-25(15-18)39-16-38-24)28(31(35)36)27(29(23)32-20)22-11-9-21(37-3)14-19(22)13-17(2)30(33)34/h7-12,14-15,17,26-28H,4-6,13,16H2,1-3H3,(H,33,34)(H,35,36)/t17-,26-,27-,28+/m0/s1
DM5E6MK CS CCCCC1=NC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=C(C=C(C=C3)OC)C[C@H](C)C(=O)O)C(=O)O)C4=CC5=C(C=C4)OCO5
DM5E6MK IK IUHMIOAKWHUFKU-YINIXLNUSA-N
DM5E6MK IU (5S,6R,7R)-5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2-[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid
DM5E6MK CA CAS 198279-45-7
DM5E6MK DE Pulmonary arterial hypertension
DMV3UN4 ID DMV3UN4
DMV3UN4 DN JTC-801
DMV3UN4 HS Discontinued in Phase 2
DMV3UN4 SN UNII-BXU45ZH6LI; BXU45ZH6LI; 244218-93-7; CHEMBL140979; N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide; N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide; JTC-801 free base; AC1NSKGH; SCHEMBL4916443; GTPL1692; CHEBI:92314; MolPort-021-804-962; ZINC602902; BCPP000197; BDBM50094634; N-(4-amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]Benzamide; Benzamide, N-(4-amino-2-methyl-6-quinolinyl)-2-((4-ethylphenoxy)methyl)-; SB19531; BCP9000806; NCGC00161418-01; NCGC00161418-02
DMV3UN4 TC Analgesics
DMV3UN4 DT Small molecular drug
DMV3UN4 PC 5311339
DMV3UN4 MW 448
DMV3UN4 FM C26H26ClN3O2
DMV3UN4 IC InChI=1S/C26H25N3O2.ClH/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25;/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30);1H
DMV3UN4 CS CCC1=CC=C(C=C1)OCC2=CC=CC=C2C(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N.Cl
DMV3UN4 IK NQLIYKXNAXKMBL-UHFFFAOYSA-N
DMV3UN4 IU N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide;hydrochloride
DMV3UN4 CA CAS 244218-51-7
DMV3UN4 DE Pain
DM1BQFY ID DM1BQFY
DM1BQFY DN JTE-607
DM1BQFY HS Discontinued in Phase 2
DM1BQFY SN UNII-2B68H6BWCX; JTE-607; 2B68H6BWCX; 188791-09-5; JTE 607; JTE 607 dihydrochloride; (-)-ethyl N-(3,5-dichloro-2-hydroxy-4-(2-(4-methylpiperazin-1-yl))ethoxybenzoyl)-L-phenylamine dihydrochloride; SCHEMBL5961033; MolPort-039-052-197; AKOS025293489; L-Phenylalanine, N-(3,5-dichloro-2-hydroxy-4-(2-(4-methyl-1-piperazinyl)ethoxy)benzoyl)-, ethyl ester, dihydrochloride; L-Phenylalanine, N-(3,5-dichloro-2-hydroxy-4-(2-(4-methyl-1-piperazinyl)ethoxy)benzoyl)-, ethyl ester, hydrochloride (1:2)
DM1BQFY CP Japan Tobacco Inc
DM1BQFY DT Small molecular drug
DM1BQFY PC 9938544
DM1BQFY MW 597.4
DM1BQFY FM C25H33Cl4N3O5
DM1BQFY IC InChI=1S/C25H31Cl2N3O5.2ClH/c1-3-34-25(33)20(15-17-7-5-4-6-8-17)28-24(32)18-16-19(26)23(21(27)22(18)31)35-14-13-30-11-9-29(2)10-12-30;;/h4-8,16,20,31H,3,9-15H2,1-2H3,(H,28,32);2*1H/t20-;;/m0../s1
DM1BQFY CS CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C(C(=C2O)Cl)OCCN3CCN(CC3)C)Cl.Cl.Cl
DM1BQFY IK JUJAUEQJEWIWCQ-FJSYBICCSA-N
DM1BQFY IU ethyl (2S)-2-[[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]amino]-3-phenylpropanoate;dihydrochloride
DM1BQFY CA CAS 188791-09-5
DM1BQFY DE Sepsis
DMQRKH4 ID DMQRKH4
DMQRKH4 DN JTH-601
DMQRKH4 HS Discontinued in Phase 2
DMQRKH4 SN JTH-601-G-1
DMQRKH4 CP Japan Tobacco Inc
DMQRKH4 DT Small molecular drug
DMQRKH4 PC 119026061
DMQRKH4 MW 633.7
DMQRKH4 FM C32H43NO12
DMQRKH4 IC InChI=1S/C24H35NO4.2C4H4O4/c1-14(2)19-12-21(26)15(3)11-22(19)29-10-9-25(7)13-20-18(6)23(27)16(4)17(5)24(20)28-8;2*5-3(6)1-2-4(7)8/h11-12,14,26-27H,9-10,13H2,1-8H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+
DMQRKH4 CS CC1=CC(=C(C=C1O)C(C)C)OCCN(CC2=C(C(=C(C(=C2C)O)C)C)OC)C.C(=C/C(=O)O)\\C(=O)O.C(=C/C(=O)O)\\C(=O)O
DMQRKH4 IK SZSMNSNVWDKMMN-LVEZLNDCSA-N
DMQRKH4 IU (E)-but-2-enedioic acid;3-[[2-(4-hydroxy-5-methyl-2-propan-2-ylphenoxy)ethyl-methylamino]methyl]-4-methoxy-2,5,6-trimethylphenol
DMQRKH4 CA CAS 171277-07-9
DMQRKH4 DE Prostate disease
DMB0V5Y ID DMB0V5Y
DMB0V5Y DN JTK-003
DMB0V5Y HS Discontinued in Phase 2
DMB0V5Y CP Japan Tobacco Inc
DMB0V5Y DE Hepatitis C virus infection
DM29C6S ID DM29C6S
DM29C6S DN JTP-2942
DM29C6S HS Discontinued in Phase 2
DM29C6S SN Jtp-2942; Jtp 2942; AC1L2RRV; 148152-77-6; SCHEMBL194880; N(alpha)-(2-Methyl-4-oxocyclopentanecarbonyl)-L-histidyl-L-prolinamide; L-Prolinamide, N-((2-methyl-4-oxocyclopentyl)carbonyl)-L-histidyl-, (1S-cis)-; L-Prolinamide, N-((-methyl-4-oxocyclopentyl)carbonyl)-L-histidyl-, (1S-cis)-
DM29C6S CP Japan Tobacco Inc
DM29C6S DT Small molecular drug
DM29C6S PC 127299
DM29C6S MW 375.4
DM29C6S FM C18H25N5O4
DM29C6S IC InChI=1S/C18H25N5O4/c1-10-5-12(24)7-13(10)17(26)22-14(6-11-8-20-9-21-11)18(27)23-4-2-3-15(23)16(19)25/h8-10,13-15H,2-7H2,1H3,(H2,19,25)(H,20,21)(H,22,26)/t10-,13+,14+,15+/m1/s1
DM29C6S CS C[C@@H]1CC(=O)C[C@@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N
DM29C6S IK MVRLGJKFVUDFCR-KJEVXHAQSA-N
DM29C6S IU (2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(1S,2R)-2-methyl-4-oxocyclopentanecarbonyl]amino]propanoyl]pyrrolidine-2-carboxamide
DM29C6S CA CAS 148152-77-6
DM29C6S DE Cognitive impairment
DMI0UJS ID DMI0UJS
DMI0UJS DN JTP-4819
DMI0UJS HS Discontinued in Phase 2
DMI0UJS SN JTP-3399
DMI0UJS CP Japan Tobacco Inc
DMI0UJS DT Small molecular drug
DMI0UJS PC 178060
DMI0UJS MW 359.4
DMI0UJS FM C19H25N3O4
DMI0UJS IC InChI=1S/C19H25N3O4/c23-13-17(24)15-8-4-10-21(15)18(25)16-9-5-11-22(16)19(26)20-12-14-6-2-1-3-7-14/h1-3,6-7,15-16,23H,4-5,8-13H2,(H,20,26)/t15-,16-/m0/s1
DMI0UJS CS C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)NCC3=CC=CC=C3)C(=O)CO
DMI0UJS IK ICULFJDHZQTNRB-HOTGVXAUSA-N
DMI0UJS IU (2S)-N-benzyl-2-[(2S)-2-(2-hydroxyacetyl)pyrrolidine-1-carbonyl]pyrrolidine-1-carboxamide
DMI0UJS CA CAS 162203-65-8
DMI0UJS DE Cognitive impairment
DM35CQ4 ID DM35CQ4
DM35CQ4 DN JTS-653
DM35CQ4 HS Discontinued in Phase 2
DM35CQ4 CP Japan Tobacco
DM35CQ4 DE Pain; Overactive bladder
DMJ1ZTB ID DMJ1ZTB
DMJ1ZTB DN JTT-811
DMJ1ZTB HS Discontinued in Phase 2
DMJ1ZTB CP Japan Tobacco Inc
DMJ1ZTB DE Diabetic complication
DMM8UNL ID DMM8UNL
DMM8UNL DN JTV-506
DMM8UNL HS Discontinued in Phase 2
DMM8UNL CP Japan Tobacco Inc
DMM8UNL DT Small molecular drug
DMM8UNL DE Angina pectoris
DM7IP8U ID DM7IP8U
DM7IP8U DN KB-5492
DM7IP8U HS Discontinued in Phase 2
DM7IP8U SN KB 5492; AC1O5RCN; 1-((4-Methoxyphenoxy)carbonylmethyl)-4-(3,4,5-trimethoxybenzyl)piperazine difumarate hydrate; (4-methoxyphenyl) 2-[4-[(3,4,5-trimethoxyphenyl)methyl]piperazin-1-yl]acetate; 1-Piperazineacetic acid, 4-((3,4,5-trimethoxyphenyl)methyl)-, 4-methoxyphenyl ester, (E)-2-butenedioate, hydrate (1:2:1); LS-110141; 1-(3,4,5-Trimethoxybenzyl)-4-((4-methoxyphenyl)oxycarbonylmethyl)piperazine; 4-Methoxyphenyl 4-((3,4,5-trimethoxyphenyl)methyl)-1-piperazineacetate (E)-2-butened
DM7IP8U CP Kanebo KK
DM7IP8U DT Small molecular drug
DM7IP8U PC 6439276
DM7IP8U MW 546.6
DM7IP8U FM C27H34N2O10
DM7IP8U IC InChI=1S/C23H30N2O6.C4H4O4/c1-27-18-5-7-19(8-6-18)31-22(26)16-25-11-9-24(10-12-25)15-17-13-20(28-2)23(30-4)21(14-17)29-3;5-3(6)1-2-4(7)8/h5-8,13-14H,9-12,15-16H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DM7IP8U CS COC1=CC=C(C=C1)OC(=O)CN2CCN(CC2)CC3=CC(=C(C(=C3)OC)OC)OC.C(=C/C(=O)O)\\C(=O)O
DM7IP8U IK JUOYRBCKLAPYBI-WLHGVMLRSA-N
DM7IP8U IU (E)-but-2-enedioic acid;(4-methoxyphenyl) 2-[4-[(3,4,5-trimethoxyphenyl)methyl]piperazin-1-yl]acetate
DM7IP8U CA CAS 129200-10-8
DM7IP8U DE Peptic ulcer
DMOITN2 ID DMOITN2
DMOITN2 DN KC-11458
DMOITN2 HS Discontinued in Phase 2
DMOITN2 CP Solvay SA
DMOITN2 DE Gastric motility disorder
DMBX6C7 ID DMBX6C7
DMBX6C7 DN KC706
DMBX6C7 HS Discontinued in Phase 2
DMBX6C7 CP Kemia
DMBX6C7 DE Psoriasis vulgaris; Cardiovascular disease; Rheumatoid arthritis; Inflammatory bowel disease
DMC30N4 ID DMC30N4
DMC30N4 DN KCO-912
DMC30N4 HS Discontinued in Phase 2
DMC30N4 CP Novartis AG
DMC30N4 DE Chronic obstructive pulmonary disease
DMX9M53 ID DMX9M53
DMX9M53 DN KDS-2000
DMX9M53 HS Discontinued in Phase 2
DMX9M53 CP Kadmus Pharmaceuticals
DMX9M53 DE Postherpetic neuralgia
DMN4BIA ID DMN4BIA
DMN4BIA DN KN-38-7271
DMN4BIA HS Discontinued in Phase 2
DMN4BIA SN Cannabinoid 1/2 receptor agonists (cerebrovascular ischemia/pain), Bayer; Cannabinoid 1/2 receptor agonists (traumatic brain injury/stroke), KeyNeurotek
DMN4BIA CP Bayer AG
DMN4BIA DE Ischemia
DMM1SLF ID DMM1SLF
DMM1SLF DN KP-736
DMM1SLF HS Discontinued in Phase 2
DMM1SLF SN E-2-carboxylic acid disodium salt; [6R-[6alpha,7beta(Z)]-7-[[(2-Amino-4-thiazolyl)[[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-en; (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2(Z)-(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-ylmethoxyimino)acetamido]-3-(1,2,3-thiadiazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid disodium salt
DMM1SLF DT Small molecular drug
DMM1SLF PC 9690114
DMM1SLF MW 682.6
DMM1SLF FM C21H16N8Na2O8S4
DMM1SLF IC InChI=1S/C21H18N8O8S4.2Na/c22-21-24-10(7-40-21)14(26-37-4-9-1-11(30)12(31)3-28(9)36)17(32)25-15-18(33)29-16(20(34)35)8(6-39-19(15)29)5-38-13-2-23-27-41-13;;/h1-3,7,15,19,31,36H,4-6H2,(H2,22,24)(H,25,32)(H,34,35);;/q;2*+1/p-2/b26-14-;;/t15-,19-;;/m1../s1
DMM1SLF CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N\\OCC3=CC(=O)C(=CN3O)[O-])/C4=CSC(=N4)N)C(=O)[O-])CSC5=CN=NS5.[Na+].[Na+]
DMM1SLF IK RNPRGWFDYQHVDK-PUZJMABTSA-L
DMM1SLF IU disodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-hydroxy-5-oxido-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-8-oxo-3-(thiadiazol-5-ylsulfanylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMM1SLF DE Bacterial infection
DMIJ6FX ID DMIJ6FX
DMIJ6FX DN KRH-594
DMIJ6FX HS Discontinued in Phase 2
DMIJ6FX SN KRG-594; WK-1492; WK-1492-2K
DMIJ6FX CP Wakunaga Pharmaceutical Co Ltd
DMIJ6FX DT Small molecular drug
DMIJ6FX PC 23703120
DMIJ6FX MW 539.7
DMIJ6FX FM C25H22KN7O3S
DMIJ6FX IC InChI=1S/C25H23N7O3S.K/c1-2-21-29-32(25(36-21)26-23(33)19-8-5-9-20(19)24(34)35)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-30-31-28-22;/h3-4,6-7,10-13H,2,5,8-9,14H2,1H3,(H,34,35)(H,27,28,30,31);/q;+1/p-1
DMIJ6FX CS CCC1=NN(C(=NC(=O)C2=C(CCC2)C(=O)[O-])S1)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5.[K+]
DMIJ6FX IK IYBVDYGNSNOZHQ-UHFFFAOYSA-M
DMIJ6FX IU potassium;2-[[5-ethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-thiadiazol-2-ylidene]carbamoyl]cyclopentene-1-carboxylate
DMIJ6FX DE Hypertension
DMZ1SEW ID DMZ1SEW
DMZ1SEW DN KRN-2391
DMZ1SEW HS Discontinued in Phase 2
DMZ1SEW SN Ki-3315
DMZ1SEW CP Kirin Brewery Co Ltd
DMZ1SEW DT Small molecular drug
DMZ1SEW PC 123957
DMZ1SEW MW 331.31
DMZ1SEW FM C10H13N5O6S
DMZ1SEW IC InChI=1S/C9H9N5O3.CH4O3S/c10-7-13-9(8-2-1-3-11-6-8)12-4-5-17-14(15)16;1-5(2,3)4/h1-3,6H,4-5H2,(H,12,13);1H3,(H,2,3,4)
DMZ1SEW CS CS(=O)(=O)O.C1=CC(=CN=C1)C(=NCCO[N+](=O)[O-])NC#N
DMZ1SEW IK BIBJJSCMCXFMML-UHFFFAOYSA-N
DMZ1SEW IU 2-[[(cyanoamino)-pyridin-3-ylmethylidene]amino]ethyl nitrate;methanesulfonic acid
DMZ1SEW CA CAS 134431-49-5
DMZ1SEW DE Angina pectoris
DMBU9O4 ID DMBU9O4
DMBU9O4 DN KRP-101
DMBU9O4 HS Discontinued in Phase 2
DMBU9O4 SN PPAR alpha agonist (hyperlipidemia), Kyorin
DMBU9O4 CP Kyorin Pharmaceutical Co Ltd
DMBU9O4 PC 9825046
DMBU9O4 MW 451.5
DMBU9O4 FM C26H26FNO5
DMBU9O4 IC InChI=1S/C26H26FNO5/c1-3-19(26(30)31)14-18-6-13-24(32-2)23(15-18)25(29)28-16-17-4-9-21(10-5-17)33-22-11-7-20(27)8-12-22/h4-13,15,19H,3,14,16H2,1-2H3,(H,28,29)(H,30,31)/t19-/m0/s1
DMBU9O4 CS CC[C@@H](CC1=CC(=C(C=C1)OC)C(=O)NCC2=CC=C(C=C2)OC3=CC=C(C=C3)F)C(=O)O
DMBU9O4 IK VRHOBXXCNBZJRX-IBGZPJMESA-N
DMBU9O4 IU (2S)-2-[[3-[[4-(4-fluorophenoxy)phenyl]methylcarbamoyl]-4-methoxyphenyl]methyl]butanoic acid
DMBU9O4 CA CAS 311770-26-0
DMBU9O4 DE Hyperlipidaemia
DM9VHZC ID DM9VHZC
DM9VHZC DN KRP-297
DM9VHZC HS Discontinued in Phase 2
DM9VHZC SN KRP-297; MK 767; MK-767; KRP297; KRP 297; 213252-19-8; L410198; L 410198; 5-((2,4-Dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; Benzamide, 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)-; 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide; NFFXEUUOMTXWCX-UHFFFAOYSA-N; SCHEMBL3922; AC1L45TL; MLS006010319; GTPL2677; CTK4E6495; MolPort-018-657-358; AKOS005067111; NCGC00263123-01; SMR004701384
DM9VHZC CP Merck
DM9VHZC DT Small molecular drug
DM9VHZC PC 151183
DM9VHZC MW 438.4
DM9VHZC FM C20H17F3N2O4S
DM9VHZC IC InChI=1S/C20H17F3N2O4S/c1-29-15-7-4-12(9-16-18(27)25-19(28)30-16)8-14(15)17(26)24-10-11-2-5-13(6-3-11)20(21,22)23/h2-8,16H,9-10H2,1H3,(H,24,26)(H,25,27,28)
DM9VHZC CS COC1=C(C=C(C=C1)CC2C(=O)NC(=O)S2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F
DM9VHZC IK NFFXEUUOMTXWCX-UHFFFAOYSA-N
DM9VHZC IU 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
DM9VHZC CA CAS 213252-19-8
DM9VHZC DE Type-2 diabetes; Hyperlipidaemia
DM5YHJ2 ID DM5YHJ2
DM5YHJ2 DN KW-2170
DM5YHJ2 HS Discontinued in Phase 2
DM5YHJ2 CP Kyowa Hakko Kogyo Co Ltd
DM5YHJ2 DT Small molecular drug
DM5YHJ2 PC 3075774
DM5YHJ2 MW 470.3
DM5YHJ2 FM C20H25Cl2N5O4
DM5YHJ2 IC InChI=1S/C20H23N5O4.2ClH/c21-6-1-7-23-12-3-2-11-13(10-22-8-9-26)24-25-18(11)16(12)20(29)17-14(27)4-5-15(28)19(17)25;;/h2-5,22-23,26,28-29H,1,6-10,21H2;2*1H
DM5YHJ2 CS C1=CC(=C2C3=C1C(=NN3C4=C(C=CC(=O)C4=C2O)O)CNCCO)NCCCN.Cl.Cl
DM5YHJ2 IK FSJDQJHSJAGEJV-UHFFFAOYSA-N
DM5YHJ2 IU 10-(3-aminopropylamino)-3,8-dihydroxy-14-[(2-hydroxyethylamino)methyl]-1,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-2,4,7,9,11,13(16),14-heptaen-6-one;dihydrochloride
DM5YHJ2 CA CAS 207862-44-0
DM5YHJ2 DE Breast cancer
DMSWDKX ID DMSWDKX
DMSWDKX DN KW-4490
DMSWDKX HS Discontinued in Phase 2
DMSWDKX CP Kyowa Hakko Kogyo Co Ltd
DMSWDKX PC 9883436
DMSWDKX MW 317.34
DMSWDKX FM C17H19NO5
DMSWDKX IC InChI=1S/C17H19NO5/c1-21-13-3-2-12(14-15(13)23-9-8-22-14)17(10-18)6-4-11(5-7-17)16(19)20/h2-3,11H,4-9H2,1H3,(H,19,20)
DMSWDKX CS COC1=C2C(=C(C=C1)C3(CCC(CC3)C(=O)O)C#N)OCCO2
DMSWDKX IK SBCKAEJLDHJBNZ-UHFFFAOYSA-N
DMSWDKX IU 4-cyano-4-(5-methoxy-2,3-dihydro-1,4-benzodioxin-8-yl)cyclohexane-1-carboxylic acid
DMSWDKX DE Asthma
DMLOKXI ID DMLOKXI
DMLOKXI DN KW-5139
DMLOKXI HS Discontinued in Phase 2
DMLOKXI SN KW-1539; [Leu13]-motilin
DMLOKXI CP Kyowa Hakko Kogyo Co Ltd
DMLOKXI PC 16130985
DMLOKXI MW 2681
DMLOKXI FM C121H190N34O35
DMLOKXI IC InChI=1S/C121H190N34O35/c1-10-65(8)98(153-115(185)87-32-23-53-155(87)118(188)97(64(6)7)152-100(170)71(124)56-67-24-13-11-14-25-67)116(186)151-85(57-68-26-15-12-16-27-68)114(184)154-99(66(9)156)117(187)150-84(58-69-33-35-70(157)36-34-69)102(172)136-60-92(162)137-76(40-46-94(164)165)106(176)148-83(55-63(4)5)112(182)145-77(37-43-88(125)158)107(177)141-74(30-21-51-133-120(129)130)104(174)147-82(54-62(2)3)111(181)146-78(38-44-89(126)159)108(178)144-80(42-48-96(168)169)109(179)140-73(29-18-20-50-123)103(173)143-79(41-47-95(166)167)110(180)142-75(31-22-52-134-121(131)132)105(175)149-86(59-91(128)161)113(183)139-72(28-17-19-49-122)101(171)135-61-93(163)138-81(119(189)190)39-45-90(127)160/h11-16,24-27,33-36,62-66,71-87,97-99,156-157H,10,17-23,28-32,37-61,122-124H2,1-9H3,(H2,125,158)(H2,126,159)(H2,127,160)(H2,128,161)(H,135,171)(H,136,172)(H,137,162)(H,138,163)(H,139,183)(H,140,179)(H,141,177)(H,142,180)(H,143,173)(H,144,178)(H,145,182)(H,146,181)(H,147,174)(H,148,176)(H,149,175)(H,150,187)(H,151,186)(H,152,170)(H,153,185)(H,154,184)(H,164,165)(H,166,167)(H,168,169)(H,189,190)(H4,129,130,133)(H4,131,132,134)/t65-,66+,71-,72-,73-,74-,75+,76-,77-,78-,79-,80-,81+,82-,83-,84-,85-,86+,87-,97-,98-,99-/m0/s1
DMLOKXI CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMLOKXI IK GFOZQXMKARUPQI-DFIBRNPJSA-N
DMLOKXI IU (2R)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2R)-4-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMLOKXI CA CAS 59530-69-7
DMLOKXI DE Pain
DMJNSML ID DMJNSML
DMJNSML DN KW-7158
DMJNSML HS Discontinued in Phase 2
DMJNSML SN Non-cholinergic tricyclic (irritable bowel syndrome), Kyowa Hakko Kirin
DMJNSML CP Kyowa Hakko
DMJNSML DT Small molecular drug
DMJNSML PC 9844981
DMJNSML MW 419.4
DMJNSML FM C16H12F3NO5S2
DMJNSML IC InChI=1S/C16H12F3NO5S2/c1-15(23,16(17,18)19)14(22)20-9-3-2-4-10-11(9)12(21)13-8(5-6-26-13)7-27(10,24)25/h2-6,23H,7H2,1H3,(H,20,22)/t15-/m0/s1
DMJNSML CS C[C@](C(=O)NC1=C2C(=CC=C1)S(=O)(=O)CC3=C(C2=O)SC=C3)(C(F)(F)F)O
DMJNSML IK NAFSYPCVPLWHFY-HNNXBMFYSA-N
DMJNSML IU (2S)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4H-thieno[3,2-c][1]benzothiepin-9-yl)propanamide
DMJNSML CA CAS 214764-26-8
DMJNSML DE Urinary incontinence
DMKSEIY ID DMKSEIY
DMKSEIY DN L-158282
DMKSEIY HS Discontinued in Phase 2
DMKSEIY DT Small molecular drug
DMKSEIY PC 133031
DMKSEIY MW 524.6
DMKSEIY FM C30H28N4O3S
DMKSEIY IC InChI=1S/C30H28N4O3S/c1-4-27-32-28-20(2)18-21(3)31-29(28)34(27)19-22-14-16-23(17-15-22)25-12-8-9-13-26(25)38(36,37)33-30(35)24-10-6-5-7-11-24/h5-18H,4,19H2,1-3H3,(H,33,35)
DMKSEIY CS CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC(=O)C5=CC=CC=C5)N=C(C=C2C)C
DMKSEIY IK LIUNMFCWFYFUGQ-UHFFFAOYSA-N
DMKSEIY IU N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenyl]sulfonylbenzamide
DMKSEIY CA CAS 157263-00-8
DMT13ZR ID DMT13ZR
DMT13ZR DN L-365260
DMT13ZR HS Discontinued in Phase 2
DMT13ZR SN 1-(1-Methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; CHEMBL289498; 1-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; L 365260; L365260; AC1L2XQK; [3H]L365260; [3H]L-365,260; GTPL879; GTPL3477; SCHEMBL1650330; KDFQABSFVYLGPM-UHFFFAOYSA-N; BDBM50452555; (R)-L 365260; L000333; 1-Methyl-3-[3-(3-methylphenyl)ureido]-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
DMT13ZR DT Small molecular drug
DMT13ZR PC 5311201
DMT13ZR MW 398.5
DMT13ZR FM C24H22N4O2
DMT13ZR IC InChI=1S/C24H22N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h3-15,22H,1-2H3,(H2,25,27,30)/t22-/m0/s1
DMT13ZR CS CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)C
DMT13ZR IK KDFQABSFVYLGPM-QFIPXVFZSA-N
DMT13ZR IU 1-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMT13ZR CA CAS 118101-09-0
DMT13ZR CB CHEBI:79548
DMT13ZR DE Anxiety disorder
DM7JZ53 ID DM7JZ53
DM7JZ53 DN L-4-OXALYSINE
DM7JZ53 HS Discontinued in Phase 2
DM7JZ53 SN I-677; Oxalysine-L; O-(2-Aminoethyl)-L-serine
DM7JZ53 DT Small molecular drug
DM7JZ53 PC 160555
DM7JZ53 MW 148.16
DM7JZ53 FM C5H12N2O3
DM7JZ53 IC InChI=1S/C5H12N2O3/c6-1-2-10-3-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1
DM7JZ53 CS C(COC[C@@H](C(=O)O)N)N
DM7JZ53 IK SLTGLTLBIVDQKE-BYPYZUCNSA-N
DM7JZ53 IU (2S)-2-amino-3-(2-aminoethoxy)propanoic acid
DM7JZ53 CA CAS 15219-97-3
DM7JZ53 CB CHEBI:72341
DM7JZ53 DE Solid tumour/cancer
DMG5VJF ID DMG5VJF
DMG5VJF DN L-660771
DMG5VJF HS Discontinued in Phase 2
DMG5VJF SN MK-571
DMG5VJF DT Small molecular drug
DMG5VJF PC 16760063
DMG5VJF MW 514.1
DMG5VJF FM C26H26ClN2O3S2-
DMG5VJF IC InChI=1S/C26H27ClN2O3S2/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32)/p-1/b10-6+
DMG5VJF CS CN(C)C(=O)CCSC(C1=CC=CC(=C1)/C=C/C2=NC3=C(C=CC(=C3)Cl)C=C2)SCCC(=O)[O-]
DMG5VJF IK AXUZQJFHDNNPFG-UXBLZVDNSA-M
DMG5VJF IU 3-[[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoate
DM54I8A ID DM54I8A
DM54I8A DN L-696229
DM54I8A HS Discontinued in Phase 2
DM54I8A SN 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridine-2(1H)-one
DM54I8A DT Small molecular drug
DM54I8A PC 72352
DM54I8A MW 282.34
DM54I8A FM C17H18N2O2
DM54I8A IC InChI=1S/C17H18N2O2/c1-3-12-10-13(17(20)18-11(12)2)8-9-16-19-14-6-4-5-7-15(14)21-16/h4-7,10H,3,8-9H2,1-2H3,(H,18,20)
DM54I8A CS CCC1=C(NC(=O)C(=C1)CCC2=NC3=CC=CC=C3O2)C
DM54I8A IK MHUVLRNBDLFMHQ-UHFFFAOYSA-N
DM54I8A IU 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-1H-pyridin-2-one
DM54I8A CA CAS 135525-71-2
DM54I8A DE Human immunodeficiency virus infection
DMW8NOH ID DMW8NOH
DMW8NOH DN L-771688
DMW8NOH HS Discontinued in Phase 2
DMW8NOH SN L-771688; IW9MH6LGKH; UNII-IW9MH6LGKH; CHEMBL182998; SCHEMBL6735535; HY-U00237; BDBM50160148; CS-7401; 200050-59-5; L 771688; Methyl (4S)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-3-(3-(4-(2-pyridyl)-1-piperidyl)propylcarbamoyl)-1,4-dihydropyrimidine-5-carboxylate; 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-4-(methoxymethyl)-2-oxo-1-(((3-(4-(2-pyridinyl)-1-piperidinyl)propyl)amino)carbonyl)-, methyl ester, (6S)-
DMW8NOH DT Small molecular drug
DMW8NOH PC 9874983
DMW8NOH MW 557.6
DMW8NOH FM C28H33F2N5O5
DMW8NOH IC InChI=1S/C28H33F2N5O5/c1-39-17-23-24(26(36)40-2)25(19-7-8-20(29)21(30)16-19)35(28(38)33-23)27(37)32-12-5-13-34-14-9-18(10-15-34)22-6-3-4-11-31-22/h3-4,6-8,11,16,18,25H,5,9-10,12-15,17H2,1-2H3,(H,32,37)(H,33,38)/t25-/m0/s1
DMW8NOH CS COCC1=C([C@@H](N(C(=O)N1)C(=O)NCCCN2CCC(CC2)C3=CC=CC=N3)C4=CC(=C(C=C4)F)F)C(=O)OC
DMW8NOH IK FFXFCSQUTLDLAR-VWLOTQADSA-N
DMW8NOH IU methyl (4S)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-3-[3-(4-pyridin-2-ylpiperidin-1-yl)propylcarbamoyl]-1,4-dihydropyrimidine-5-carboxylate
DMW8NOH CA CAS 200050-59-5
DMW8NOH DE Prostate disease
DMSFL76 ID DMSFL76
DMSFL76 DN Labradimil
DMSFL76 HS Discontinued in Phase 2
DMSFL76 SN Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide
DMSFL76 CP Alkermes
DMSFL76 TC Anticancer Agents
DMSFL76 DT Small molecular drug
DMSFL76 PC 6918284
DMSFL76 MW 1098.3
DMSFL76 FM C49H75N15O12S
DMSFL76 IC InChI=1S/C49H75N15O12S/c1-76-31-14-12-28(13-15-31)21-29(24-57-34(47(74)75)9-3-17-56-49(53)54)59-43(70)37-10-4-18-62(37)45(72)36(27-65)61-41(68)35(23-32-7-6-20-77-32)60-40(67)25-58-42(69)39-22-30(66)26-64(39)46(73)38-11-5-19-63(38)44(71)33(50)8-2-16-55-48(51)52/h6-7,12-15,20,29-30,33-39,57,65-66H,2-5,8-11,16-19,21-27,50H2,1H3,(H,58,69)(H,59,70)(H,60,67)(H,61,68)(H,74,75)(H4,51,52,55)(H4,53,54,56)/t29-,30+,33-,34-,35-,36-,37-,38-,39-/m0/s1
DMSFL76 CS COC1=CC=C(C=C1)C[C@@H](CN[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)N)O
DMSFL76 IK IDXCXSCCZNCXCL-XMADEQCMSA-N
DMSFL76 IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-methoxyphenyl)propyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMSFL76 CA CAS 159768-75-9
DMSFL76 DE Brain cancer
DM3YABD ID DM3YABD
DM3YABD DN LANIQUIDAR
DM3YABD HS Discontinued in Phase 2
DM3YABD SN R-101933; Laniquidar; 11-[1-[2-[4-(2-Quinolylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylic acid methyl ester
DM3YABD DT Small molecular drug
DM3YABD PC 6450806
DM3YABD MW 584.7
DM3YABD FM C37H36N4O3
DM3YABD IC InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
DM3YABD CS COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6
DM3YABD IK TULGGJGJQXESOO-UHFFFAOYSA-N
DM3YABD IU methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
DM3YABD CA CAS 197509-46-9
DM3YABD DE Solid tumour/cancer
DM9J6BX ID DM9J6BX
DM9J6BX DN LAS-37779
DM9J6BX HS Discontinued in Phase 2
DM9J6BX CP Almirall Prodesfarma SA
DM9J6BX DE Psoriasis vulgaris
DMTY5VE ID DMTY5VE
DMTY5VE DN Lavoltidine
DMTY5VE HS Discontinued in Phase 2
DMTY5VE SN Loxtidine; AH-234844; GSK-1023911a; GSK-1040323b; Histamine H2 receptor antagonist (GERD), GlaxoSmithKline; Histamine H2 receptor antagonist (gastroesophageal reflux disorder), GlaxoSmithKline
DMTY5VE CP GlaxoSmithKline plc
DMTY5VE DT Small molecular drug
DMTY5VE PC 55473
DMTY5VE MW 359.5
DMTY5VE FM C19H29N5O2
DMTY5VE IC InChI=1S/C19H29N5O2/c1-23-19(21-18(15-25)22-23)20-9-6-12-26-17-8-5-7-16(13-17)14-24-10-3-2-4-11-24/h5,7-8,13,25H,2-4,6,9-12,14-15H2,1H3,(H,20,21,22)
DMTY5VE CS CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3
DMTY5VE IK VTLNPNNUIJHJQB-UHFFFAOYSA-N
DMTY5VE IU [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
DMTY5VE CA CAS 76956-02-0
DMTY5VE CB CHEBI:6550
DMTY5VE DE Gastroesophageal reflux disease
DMGQJ2U ID DMGQJ2U
DMGQJ2U DN LESOPITRON DIHYDROCHLORIDE
DMGQJ2U HS Discontinued in Phase 2
DMGQJ2U SN Lesopitran; Lesopitran); E-4424; Lesopitron dihydrochloride; 2-[4-[4-(4-Chloropyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine dihydrochloride
DMGQJ2U CP Esteve Group
DMGQJ2U DT Small molecular drug
DMGQJ2U PC 60812
DMGQJ2U MW 393.7
DMGQJ2U FM C15H23Cl3N6
DMGQJ2U IC InChI=1S/C15H21ClN6.2ClH/c16-14-12-19-22(13-14)7-2-1-6-20-8-10-21(11-9-20)15-17-4-3-5-18-15;;/h3-5,12-13H,1-2,6-11H2;2*1H
DMGQJ2U CS C1CN(CCN1CCCCN2C=C(C=N2)Cl)C3=NC=CC=N3.Cl.Cl
DMGQJ2U IK RGDLQJUAYQRGBC-UHFFFAOYSA-N
DMGQJ2U IU 2-[4-[4-(4-chloropyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine;dihydrochloride
DMGQJ2U CA CAS 132449-89-9
DMGQJ2U DE Mood disorder
DMKSY2R ID DMKSY2R
DMKSY2R DN Levosemotiadil
DMKSY2R HS Discontinued in Phase 2
DMKSY2R SN DS-4824; SA-3212; SD-3212
DMKSY2R CP Santen Pharmaceutical Co Ltd
DMKSY2R DT Small molecular drug
DMKSY2R PC 9852564
DMKSY2R MW 536.6
DMKSY2R FM C29H32N2O6S
DMKSY2R IC InChI=1S/C29H32N2O6S/c1-30(14-16-34-21-10-12-25-26(18-21)37-19-36-25)13-6-15-35-24-11-9-20(33-3)17-22(24)28-29(32)31(2)23-7-4-5-8-27(23)38-28/h4-5,7-12,17-18,28H,6,13-16,19H2,1-3H3/t28-/m0/s1
DMKSY2R CS CN1C2=CC=CC=C2S[C@H](C1=O)C3=C(C=CC(=C3)OC)OCCCN(C)CCOC4=CC5=C(C=C4)OCO5
DMKSY2R IK RKXVEXUAWGRFNP-NDEPHWFRSA-N
DMKSY2R IU (2S)-2-[2-[3-[2-(1,3-benzodioxol-5-yloxy)ethyl-methylamino]propoxy]-5-methoxyphenyl]-4-methyl-1,4-benzothiazin-3-one
DMKSY2R CA CAS 116476-16-5
DMKSY2R DE Cardiac arrhythmias
DMJ3ZT8 ID DMJ3ZT8
DMJ3ZT8 DN Lexacalcitol
DMJ3ZT8 HS Discontinued in Phase 2
DMJ3ZT8 SN KH-106; KH-1060; MC-1357; Vitamin D3 agonist, Leo
DMJ3ZT8 CP LEO Pharma A/S
DMJ3ZT8 DT Small molecular drug
DMJ3ZT8 PC 5288670
DMJ3ZT8 MW 460.7
DMJ3ZT8 FM C29H48O4
DMJ3ZT8 IC InChI=1S/C29H48O4/c1-6-29(32,7-2)16-9-17-33-21(4)25-13-14-26-22(10-8-15-28(25,26)5)11-12-23-18-24(30)19-27(31)20(23)3/h11-12,21,24-27,30-32H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,28-/m1/s1
DMJ3ZT8 CS CCC(CC)(CCCO[C@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C)O
DMJ3ZT8 IK KLZOTDOJMRMLDX-YBBVPDDNSA-N
DMJ3ZT8 IU (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMJ3ZT8 CA CAS 131875-08-6
DMJ3ZT8 DE Solid tumour/cancer
DM8W31H ID DM8W31H
DM8W31H DN LG-1550
DM8W31H HS Discontinued in Phase 2
DM8W31H SN ALRT-1550; ALRT-550; LGD-1550; Pre-Registered; (2E,4E,6E)-7-(3,5-Di-tert-butylphenyl)-3-methylocta-2,4,6-trienoic acid
DM8W31H CP Ligand Pharmaceuticals
DM8W31H DT Small molecular drug
DM8W31H PC 5287705
DM8W31H MW 340.5
DM8W31H FM C23H32O2
DM8W31H IC InChI=1S/C23H32O2/c1-16(12-21(24)25)10-9-11-17(2)18-13-19(22(3,4)5)15-20(14-18)23(6,7)8/h9-15H,1-8H3,(H,24,25)/b10-9+,16-12+,17-11+
DM8W31H CS C/C(=C\\C(=O)O)/C=C/C=C(\\C)/C1=CC(=CC(=C1)C(C)(C)C)C(C)(C)C
DM8W31H IK JMPZTWDLOGTBPM-OUQSKUGOSA-N
DM8W31H IU (2E,4E,6E)-7-(3,5-ditert-butylphenyl)-3-methylocta-2,4,6-trienoic acid
DM8W31H CA CAS 178600-20-9
DM8W31H DE Solid tumour/cancer
DM3R8TI ID DM3R8TI
DM3R8TI DN Lifarizine
DM3R8TI HS Discontinued in Phase 2
DM3R8TI SN BANM; Lifarizine hydrochloride < Rec INNM; RS-87476; 1-(Diphenylmethyl)-4-[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-ylmethyl]piperazine trihydrochloride
DM3R8TI DT Small molecular drug
DM3R8TI PC 71336
DM3R8TI MW 436.6
DM3R8TI FM C29H32N4
DM3R8TI IC InChI=1S/C29H32N4/c1-22-13-15-26(16-14-22)29-30-23(2)27(31-29)21-32-17-19-33(20-18-32)28(24-9-5-3-6-10-24)25-11-7-4-8-12-25/h3-16,28H,17-21H2,1-2H3,(H,30,31)
DM3R8TI CS CC1=CC=C(C=C1)C2=NC(=C(N2)C)CN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM3R8TI IK HTDFEXRUDGWNHA-UHFFFAOYSA-N
DM3R8TI IU 1-benzhydryl-4-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]piperazine
DM3R8TI CA 119514-66-8
DM3R8TI DE Nerve injury
DMF8B62 ID DMF8B62
DMF8B62 DN Linetastine
DMF8B62 HS Discontinued in Phase 2
DMF8B62 SN Tmk688; UNII-7U248Z56LA; 110501-66-1; TMK-688; 159776-68-8; 7U248Z56LA; Linetastine [INN]; Tmk 688; Linazolast; CCRIS 6902; Linazolast (JAN); YM-257; AC1O5R98; CHEMBL314338; SCHEMBL1614484; [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate; Carbonic acid, 4-(5-((2-(4-(diphenylmethoxy)-1-piperidinyl)ethyl)amino)-5-oxo-1,3-pentadienyl)-2-methoxyphenyl ethyl ester; D09850; Linazolast; Molecule 26
DMF8B62 CP Sankyo
DMF8B62 DT Small molecular drug
DMF8B62 PC 6439232
DMF8B62 MW 584.7
DMF8B62 FM C35H40N2O6
DMF8B62 IC InChI=1S/C35H40N2O6/c1-3-41-35(39)43-31-19-18-27(26-32(31)40-2)12-10-11-17-33(38)36-22-25-37-23-20-30(21-24-37)42-34(28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-19,26,30,34H,3,20-25H2,1-2H3,(H,36,38)/b12-10+,17-11+
DMF8B62 CS CCOC(=O)OC1=C(C=C(C=C1)/C=C/C=C/C(=O)NCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4)OC
DMF8B62 IK LUOUCHOLMUUZBO-SVSXJNCISA-N
DMF8B62 IU [4-[(1E,3E)-5-[2-(4-benzhydryloxypiperidin-1-yl)ethylamino]-5-oxopenta-1,3-dienyl]-2-methoxyphenyl] ethyl carbonate
DMF8B62 CA CAS 110501-66-1
DMF8B62 DE Rhinitis
DM32JL5 ID DM32JL5
DM32JL5 DN Linotroban
DM32JL5 HS Discontinued in Phase 2
DM32JL5 SN CL-871502; HN-11500
DM32JL5 CP Nycomed AS
DM32JL5 DT Small molecular drug
DM32JL5 PC 65940
DM32JL5 MW 341.4
DM32JL5 FM C14H15NO5S2
DM32JL5 IC InChI=1S/C14H15NO5S2/c16-13(17)10-20-14-7-6-11(21-14)8-9-15-22(18,19)12-4-2-1-3-5-12/h1-7,15H,8-10H2,(H,16,17)
DM32JL5 CS C1=CC=C(C=C1)S(=O)(=O)NCCC2=CC=C(S2)OCC(=O)O
DM32JL5 IK ISSKMEQROMFEHL-UHFFFAOYSA-N
DM32JL5 IU 2-[5-[2-(benzenesulfonamido)ethyl]thiophen-2-yl]oxyacetic acid
DM32JL5 CA CAS 120824-08-0
DM32JL5 DE Thrombosis
DMS5X94 ID DMS5X94
DMS5X94 DN Lintitript
DMS5X94 HS Discontinued in Phase 2
DMS5X94 SN SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
DMS5X94 CP Sanofi-aventis
DMS5X94 TC Anticancer Agents
DMS5X94 DT Small molecular drug
DMS5X94 PC 122077
DMS5X94 MW 411.9
DMS5X94 FM C20H14ClN3O3S
DMS5X94 IC InChI=1S/C20H14ClN3O3S/c21-14-7-3-2-6-13(14)15-11-28-20(22-15)23-19(27)17-9-12-5-1-4-8-16(12)24(17)10-18(25)26/h1-9,11H,10H2,(H,25,26)(H,22,23,27)
DMS5X94 CS C1=CC=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=CS3)C4=CC=CC=C4Cl
DMS5X94 IK ILNRQFBVVQUOLP-UHFFFAOYSA-N
DMS5X94 IU 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
DMS5X94 CA CAS 136381-85-6
DMS5X94 CB CHEBI:92624
DMS5X94 DE Obesity; Pancreatic cancer
DMD39G4 ID DMD39G4
DMD39G4 DN Lintuzumab
DMD39G4 HS Discontinued in Phase 2
DMD39G4 SN Zamyl; HuM195; HuM195, PDL; Humanized M195, PDL; KB-195; SGN-33; SMART M195, PDL; M195 (humanized), Protein Design Labs; Anti-CD33 mAb (leukemia), Seattle Genetics
DMD39G4 CP PDL BioPharma Inc; Seattle Genetics
DMD39G4 DT Antibody
DMD39G4 DE leukaemia
DM5ENKG ID DM5ENKG
DM5ENKG DN Lirequinil
DM5ENKG HS Discontinued in Phase 2
DM5ENKG SN Ro-41-3696
DM5ENKG CP Roche Holding AG
DM5ENKG DT Small molecular drug
DM5ENKG PC 3045375
DM5ENKG MW 448.9
DM5ENKG FM C26H25ClN2O3
DM5ENKG IC InChI=1S/C26H25ClN2O3/c1-2-32-20-11-12-28(16-20)25(30)23-15-22(17-6-4-3-5-7-17)26(31)29-13-10-18-8-9-19(27)14-21(18)24(23)29/h3-9,14-15,20H,2,10-13,16H2,1H3/t20-/m0/s1
DM5ENKG CS CCO[C@H]1CCN(C1)C(=O)C2=C3C4=C(CCN3C(=O)C(=C2)C5=CC=CC=C5)C=CC(=C4)Cl
DM5ENKG IK CBSWRAUYCIIUEI-FQEVSTJZSA-N
DM5ENKG IU 10-chloro-1-[(3S)-3-ethoxypyrrolidine-1-carbonyl]-3-phenyl-6,7-dihydrobenzo[a]quinolizin-4-one
DM5ENKG CA CAS 143943-73-1
DM5ENKG DE Anxiety disorder
DMGZ3BF ID DMGZ3BF
DMGZ3BF DN Lodenosine
DMGZ3BF HS Discontinued in Phase 2
DMGZ3BF SN FddA; FddI; F-ddN; Fdd analogs, NIH/US Bioscience
DMGZ3BF CP National Cancer Institute
DMGZ3BF DT Small molecular drug
DMGZ3BF PC 72180
DMGZ3BF MW 253.23
DMGZ3BF FM C10H12FN5O2
DMGZ3BF IC InChI=1S/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)/t5-,6-,10+/m0/s1
DMGZ3BF CS C1[C@H](O[C@H]([C@H]1F)N2C=NC3=C(N=CN=C32)N)CO
DMGZ3BF IK KBEMFSMODRNJHE-JFWOZONXSA-N
DMGZ3BF IU [(2S,4S,5R)-5-(6-aminopurin-9-yl)-4-fluorooxolan-2-yl]methanol
DMGZ3BF CA CAS 110143-10-7
DMGZ3BF DE Human immunodeficiency virus infection
DMW9MOK ID DMW9MOK
DMW9MOK DN Lomeguatrib
DMW9MOK HS Discontinued in Phase 2
DMW9MOK SN Patrin; AZD-5896; Patrin-2; O6-(4-bromothenylguanine), Cancer Research UK/KuDOS; 4-BTG (cancer), Paterson/Trinity/CRC/KuDOS/AstraZeneca
DMW9MOK CP Cancer Research Campaign
DMW9MOK DT Small molecular drug
DMW9MOK PC 3025944
DMW9MOK MW 326.17
DMW9MOK FM C10H8BrN5OS
DMW9MOK IC InChI=1S/C10H8BrN5OS/c11-5-1-6(18-3-5)2-17-9-7-8(14-4-13-7)15-10(12)16-9/h1,3-4H,2H2,(H3,12,13,14,15,16)
DMW9MOK CS C1=C(SC=C1Br)COC2=NC(=NC3=C2NC=N3)N
DMW9MOK IK JUJPKFNFCWJBCX-UHFFFAOYSA-N
DMW9MOK IU 6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine
DMW9MOK CA CAS 192441-08-0
DMW9MOK DE Solid tumour/cancer
DMCZI62 ID DMCZI62
DMCZI62 DN LORECLEZOLE
DMCZI62 HS Discontinued in Phase 2
DMCZI62 SN Loreclezole < Rec INN; R-72063; (Z)-1-(alpha,2,4-Trichlorostyryl)-1H-1,2,4-triazole; (Z)-1-[2-Chloro-2-(2,4-dichlorophenyl)vinyl]-1H-1,2,4-triazole
DMCZI62 DT Small molecular drug
DMCZI62 PC 3034012
DMCZI62 MW 274.5
DMCZI62 FM C10H6Cl3N3
DMCZI62 IC InChI=1S/C10H6Cl3N3/c11-7-1-2-8(9(12)3-7)10(13)4-16-6-14-5-15-16/h1-6H/b10-4-
DMCZI62 CS C1=CC(=C(C=C1Cl)Cl)/C(=C/N2C=NC=N2)/Cl
DMCZI62 IK XGLHZTBDUXXHOM-WMZJFQQLSA-N
DMCZI62 IU 1-[(Z)-2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole
DMCZI62 CA CAS 117857-45-1
DMCZI62 CB CHEBI:92491
DMCZI62 DE Epileptic seizures
DMM843E ID DMM843E
DMM843E DN LOSOXANTRONE
DMM843E HS Discontinued in Phase 2
DMM843E SN Losoxantrone; 88303-60-0; Losoxantrone [INN:BAN]; Bis-alkylamino anthrapyrazole; UNII-47KPH00809; CHEMBL83520; 47KPH00809; CI-941; bianthrazole; C22H27N5O4; DuP-941; DUP 941; Anthra(1,9-cd)pyrazol-6(2H)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)-; AC1Q6OLU; AC1L2HG1; SCHEMBL61319; DTXSID60236949; ZINC1583637; BDBM50240660; NCI60_003246; LS-178051; 33933-EP2311453A1; 33933-EP2308855A1; 33933-EP2275420A1; 33933-EP2270008A1; 33933-EP2298765A1; 33933-EP2298764A1; 33933-EP2292617A1
DMM843E DT Small molecular drug
DMM843E PC 72116
DMM843E MW 425.5
DMM843E FM C22H27N5O4
DMM843E IC InChI=1S/C22H27N5O4/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29/h1-5,23-25,28-30H,6-13H2
DMM843E CS C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC4=C3C2=NN4CCNCCO)NCCNCCO
DMM843E IK YROQEQPFUCPDCP-UHFFFAOYSA-N
DMM843E IU 6-hydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(2-hydroxyethylamino)ethylamino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one
DMM843E CA CAS 88303-60-0
DMM843E DE Breast cancer
DMD16VS ID DMD16VS
DMD16VS DN Loviride
DMD16VS HS Discontinued in Phase 2
DMD16VS SN R-089439; R-89439
DMD16VS CP Janssen Pharmaceutica NV
DMD16VS DT Small molecular drug
DMD16VS PC 3963
DMD16VS MW 351.2
DMD16VS FM C17H16Cl2N2O2
DMD16VS IC InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)
DMD16VS CS CC1=CC(=C(C=C1)C(=O)C)NC(C2=C(C=CC=C2Cl)Cl)C(=O)N
DMD16VS IK CJPLEFFCVDQQFZ-UHFFFAOYSA-N
DMD16VS IU 2-(2-acetyl-5-methylanilino)-2-(2,6-dichlorophenyl)acetamide
DMD16VS CA CAS 147362-57-0
DMD16VS DE Human immunodeficiency virus infection
DM6G0PN ID DM6G0PN
DM6G0PN DN LTB 019
DM6G0PN HS Discontinued in Phase 2
DM6G0PN CP Novartis
DM6G0PN DT Small molecular drug
DM6G0PN PC 9959759
DM6G0PN MW 571.7
DM6G0PN FM C30H41N3O8
DM6G0PN IC InChI=1S/C26H37N3O4.C4H4O4/c1-18(2)29(19(3)4)26(30)21-11-14-23(24(17-21)31-5)33-16-8-6-7-15-32-22-12-9-20(10-13-22)25(27)28;5-3(6)1-2-4(7)8/h9-14,17-19H,6-8,15-16H2,1-5H3,(H3,27,28);1-2H,(H,5,6)(H,7,8)/b;2-1-
DM6G0PN CS CC(C)N(C(C)C)C(=O)C1=CC(=C(C=C1)OCCCCCOC2=CC=C(C=C2)C(=N)N)OC.C(=C\\C(=O)O)\\C(=O)O
DM6G0PN IK BUMMZWFWCNQFPS-BTJKTKAUSA-N
DM6G0PN IU (Z)-but-2-enedioic acid;4-[5-(4-carbamimidoylphenoxy)pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide
DM6G0PN CA CAS 147398-01-4
DM6G0PN DE Asthma
DMQ7A35 ID DMQ7A35
DMQ7A35 DN Lu-35138
DMQ7A35 HS Discontinued in Phase 2
DMQ7A35 CP H Lundbeck A/S
DMQ7A35 DE Psychotic disorder
DMYR2U3 ID DMYR2U3
DMYR2U3 DN Lurosetron
DMYR2U3 HS Discontinued in Phase 2
DMYR2U3 SN Lurosetron mesylate; GR-87442; GR-87442N
DMYR2U3 CP Glaxo Wellcome plc
DMYR2U3 DT Small molecular drug
DMYR2U3 PC 172999
DMYR2U3 MW 312.34
DMYR2U3 FM C17H17FN4O
DMYR2U3 IC InChI=1S/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20)
DMYR2U3 CS CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=C(N3C)C(=CC=C4)F
DMYR2U3 IK NUMKWGDDRWJQMY-UHFFFAOYSA-N
DMYR2U3 IU 6-fluoro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one
DMYR2U3 CA CAS 128486-54-4
DMYR2U3 DE Vomiting
DMF1RTW ID DMF1RTW
DMF1RTW DN Lurtotecan
DMF1RTW HS Discontinued in Phase 2
DMF1RTW SN OSI-211; Lurtotecan [INN]; 149882-10-0; UNII-4J1L80T08I; OSI 211; NX 211; GG 211; Gi 147211; 4J1L80T08I; C28H30N4O6; CHEMBL341028; 11H-1,4-Dioxino(2,3-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-9,12(8H,14H)-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-((4-methyl-1-piperazinyl)methyl)-, (8S)-; GI-147211C; lurtotecan liposome; AC1L1U8C; SCHEMBL19208; CHEMBL305666; DTXSID30164422; GG-211; ZINC22010625; NX-211; GW-211; BDBM50036130; DB12222; LS-173358; Lurtotecan dihydrochloride; GI 147211C; GG-147211C; GI-147211; GI-147211A; GL-147211C; Liposomal lurtotecan
DMF1RTW CP Glaxo Inc
DMF1RTW DT Small molecular drug
DMF1RTW PC 60956
DMF1RTW MW 518.6
DMF1RTW FM C28H30N4O6
DMF1RTW IC InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
DMF1RTW CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OCCO6)CN7CCN(CC7)C)O
DMF1RTW IK RVFGKBWWUQOIOU-NDEPHWFRSA-N
DMF1RTW IU (18S)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.03,12.05,10.015,24.017,22]pentacosa-1,3,5(10),11,13,15,17(22)-heptaene-19,23-dione
DMF1RTW CA CAS 149882-10-0
DMF1RTW DE Lung cancer; Ovarian cancer
DMWB7DO ID DMWB7DO
DMWB7DO DN LY-223982
DMWB7DO HS Discontinued in Phase 2
DMWB7DO SN CGS-23131; LY-223980; LY-255253; SKF-107324
DMWB7DO CP Eli Lilly & Co
DMWB7DO DT Small molecular drug
DMWB7DO PC 6444688
DMWB7DO MW 502.6
DMWB7DO FM C30H30O7
DMWB7DO IC InChI=1S/C30H30O7/c1-36-26-14-10-21(11-15-26)7-4-2-3-5-18-37-27-16-12-24(19-22(27)13-17-28(31)32)29(33)23-8-6-9-25(20-23)30(34)35/h4,6-12,14-16,19-20H,2-3,5,13,17-18H2,1H3,(H,31,32)(H,34,35)/b7-4+
DMWB7DO CS COC1=CC=C(C=C1)/C=C/CCCCOC2=C(C=C(C=C2)C(=O)C3=CC(=CC=C3)C(=O)O)CCC(=O)O
DMWB7DO IK SYZSSLLFRVDRHL-QPJJXVBHSA-N
DMWB7DO IU 3-[3-(2-carboxyethyl)-4-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]benzoyl]benzoic acid
DMWB7DO CA CAS 117423-74-2
DMWB7DO DE Asthma
DMTS1X5 ID DMTS1X5
DMTS1X5 DN LY-2300559
DMTS1X5 HS Discontinued in Phase 2
DMTS1X5 SN MGlu2 Pot/Cys (migraine prevention), Eli Lilly; Metabotropic glutamate 2 receptor potentiator/cysteinyl leukotriene receptor 1 antagonist (migraine), Eli Lilly; Mglu2 potentiator/CysLT1 antagonist (migraine prevention), Eli Lilly
DMTS1X5 CP Eli Lilly & Co
DMTS1X5 PC 11611800
DMTS1X5 MW 434.5
DMTS1X5 FM C26H26O6
DMTS1X5 IC InChI=1S/C26H26O6/c1-3-5-22-23(13-12-21(16(2)27)25(22)29)32-15-17-8-10-18(11-9-17)24(28)19-6-4-7-20(14-19)26(30)31/h4,6-14,24,28-29H,3,5,15H2,1-2H3,(H,30,31)/t24-/m0/s1
DMTS1X5 CS CCCC1=C(C=CC(=C1O)C(=O)C)OCC2=CC=C(C=C2)[C@@H](C3=CC(=CC=C3)C(=O)O)O
DMTS1X5 IK DWQVYDLTPMGYNE-DEOSSOPVSA-N
DMTS1X5 IU 3-[(S)-[4-[(4-acetyl-3-hydroxy-2-propylphenoxy)methyl]phenyl]-hydroxymethyl]benzoic acid
DMTS1X5 CA CAS 889116-06-7
DMTS1X5 DE Migraine
DMGE9OA ID DMGE9OA
DMGE9OA DN LY-2523199
DMGE9OA HS Discontinued in Phase 2
DMGE9OA SN 11-beta hydroxysteroid dehydrogenase type 1 inhibitor (diabetes), Eli Lilly; 11-beta-HSD-1 inhibitor (type 2 diabetes), Eli Lilly
DMGE9OA CP Eli Lilly & Co
DMGE9OA DE Type-2 diabetes
DM03FHA ID DM03FHA
DM03FHA DN LY293111
DM03FHA HS Discontinued in Phase 2
DM03FHA SN Etalocib; LY293111; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny
DM03FHA CP Sawyer & Brooks
DM03FHA TC Anticancer Agents
DM03FHA DT Small molecular drug
DM03FHA PC 177941
DM03FHA MW 544.6
DM03FHA FM C33H33FO6
DM03FHA IC InChI=1S/C33H33FO6/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37)
DM03FHA CS CCCC1=C(C=CC=C1OC2=CC=CC=C2C(=O)O)OCCCOC3=CC(=C(C=C3CC)C4=CC=C(C=C4)F)O
DM03FHA IK YFIZRWPXUYFCSN-UHFFFAOYSA-N
DM03FHA IU 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid
DM03FHA CA CAS 161172-51-6
DM03FHA DE Pancreatic cancer
DMIS7DW ID DMIS7DW
DMIS7DW DN LY-307161
DMIS7DW HS Discontinued in Phase 2
DMIS7DW CP Eli Lilly & Co
DMIS7DW DE Type-2 diabetes
DM08BIZ ID DM08BIZ
DM08BIZ DN LY354740
DM08BIZ HS Discontinued in Phase 2
DM08BIZ SN Eglumetad; Eglumegad; 176199-48-7; (1S,2S,5R,6S)-2-aminobicyclo[310]hexane-2,6-dicarboxylic acid; Eglumegad [INN]; UNII-ONU5A67T2S; LY-354740; LY 354740; ONU5A67T2S; CHEMBL8759; Eglumegad (INN); (1S,2S,5R,6S)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; (1R,4S,5S,6S)-4-aminobicyclo[310]hexane-4,6-dicarboxylic acid; (1S,2S,5R,6S)-2-Amino-bicyclo[310]hexane-2,6-dicarboxylic acid; [3H]Eglumegad; LY366563; Eglumetad [USAN:INN]; (+)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; 40F; PubChem18158; Eglumegad; Eglumegad [USAN]; Eglumegad hydrate; Eglumetad hydrate; LY 314582; LY 366563; LY314582; Eglumegad (USAN); LY-314582; LY-354740 monohydrate; LY-366563; Eglumetad (INN/USAN); (1R,4S,5S,6S)-4-aminobicyclo[310]hexane-4,6-dicarboxylic acid hydrate; (1S,2S,5R,6S)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid monohydrate; 2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; 4-aminobicyclo[310]hexane-4,6-dicarboxylic acid; [3H]eglumegad
DM08BIZ CP Eli Lilly
DM08BIZ DT Small molecular drug
DM08BIZ PC 213056
DM08BIZ MW 185.18
DM08BIZ FM C8H11NO4
DM08BIZ IC InChI=1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1
DM08BIZ CS C1C[C@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(C(=O)O)N
DM08BIZ IK VTAARTQTOOYTES-RGDLXGNYSA-N
DM08BIZ IU (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DM08BIZ CA CAS 176199-48-7
DM08BIZ DE Anxiety disorder
DMQ1LWU ID DMQ1LWU
DMQ1LWU DN M-100240
DMQ1LWU HS Discontinued in Phase 2
DMQ1LWU SN Mdl 100240; M100,240; MDL-100240; Mdl 100,142; Mdl 100,240; (4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
DMQ1LWU CP Aventis Pharma
DMQ1LWU DT Small molecular drug
DMQ1LWU PC 133985
DMQ1LWU MW 480.6
DMQ1LWU FM C26H28N2O5S
DMQ1LWU IC InChI=1S/C26H28N2O5S/c1-16(29)34-23(14-17-8-3-2-4-9-17)24(30)27-20-15-18-10-5-6-11-19(18)21-12-7-13-22(26(32)33)28(21)25(20)31/h2-6,8-11,20-23H,7,12-15H2,1H3,(H,27,30)(H,32,33)/t20-,21+,22-,23-/m0/s1
DMQ1LWU CS CC(=O)S[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]2CC3=CC=CC=C3[C@H]4CCC[C@H](N4C2=O)C(=O)O
DMQ1LWU IK AIEZUMPHACQOGT-BJESRGMDSA-N
DMQ1LWU IU (4S,7S,12bR)-7-[[(2S)-2-acetylsulfanyl-3-phenylpropanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1H-pyrido[2,1-a][2]benzazepine-4-carboxylic acid
DMQ1LWU CA CAS 142695-08-7
DMQ1LWU DE Hypotension
DMRN7GC ID DMRN7GC
DMRN7GC DN Manifaxine
DMRN7GC HS Discontinued in Phase 2
DMRN7GC SN BW-1555U88; GW-320659; GW-320659A
DMRN7GC CP Glaxo Wellcome plc
DMRN7GC DT Small molecular drug
DMRN7GC PC 60829
DMRN7GC MW 243.25
DMRN7GC FM C12H15F2NO2
DMRN7GC IC InChI=1S/C12H15F2NO2/c1-7-6-17-12(16,8(2)15-7)9-3-10(13)5-11(14)4-9/h3-5,7-8,15-16H,6H2,1-2H3/t7-,8+,12-/m1/s1
DMRN7GC CS C[C@@H]1CO[C@]([C@@H](N1)C)(C2=CC(=CC(=C2)F)F)O
DMRN7GC IK OZGPVYJHWWPEFT-RGNHYFCHSA-N
DMRN7GC IU (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
DMRN7GC CA CAS 135306-39-7
DMRN7GC DE Major depressive disorder
DM1LM7D ID DM1LM7D
DM1LM7D DN Mannose phosphate
DM1LM7D HS Discontinued in Phase 2
DM1LM7D SN MANNOSE PHOSPHATE; SCHEMBL285569; SB17274
DM1LM7D CP Santa Cruz Biotechnology
DM1LM7D DT Small molecular drug
DM1LM7D PC 73014169
DM1LM7D MW 278.15
DM1LM7D FM C6H15O10P
DM1LM7D IC InChI=1S/C6H12O6.H3O4P/c7-1-3(9)5(11)6(12)4(10)2-8;1-5(2,3)4/h1,3-6,8-12H,2H2;(H3,1,2,3,4)/t3-,4-,5-,6-;/m1./s1
DM1LM7D CS C([C@H]([C@H]([C@@H]([C@@H](C=O)O)O)O)O)O.OP(=O)(O)O
DM1LM7D IK NDVRKEKNSBMTAX-MVNLRXSJSA-N
DM1LM7D IU (2S,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid
DM1LM7D DE Lesion
DMRHYAU ID DMRHYAU
DMRHYAU DN MAZAPERTINE
DMRHYAU HS Discontinued in Phase 2
DMRHYAU SN Mazapertine; UNII-N0X1XW704P; CHEMBL10085; N0X1XW704P; 134208-17-6; RWJ-377796; Mazapertine [INN]; AC1L1TZN; AC1Q5K4U; SCHEMBL636631; DTXSID40158594; ZKZFPRUSWCYSGT-UHFFFAOYSA-N; BDBM50029257; L001470; Piperidino[3-[[4-(2-isopropoxyphenyl)piperazino]methyl]phenyl] ketone; 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine; {3-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-phenyl}-piperidin-1-yl-methanone; piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMRHYAU DT Small molecular drug
DMRHYAU PC 60820
DMRHYAU MW 421.6
DMRHYAU FM C26H35N3O2
DMRHYAU IC InChI=1S/C26H35N3O2/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3
DMRHYAU CS CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC(=CC=C3)C(=O)N4CCCCC4
DMRHYAU IK ZKZFPRUSWCYSGT-UHFFFAOYSA-N
DMRHYAU IU piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone
DMRHYAU CA CAS 134208-17-6
DMIG5W8 ID DMIG5W8
DMIG5W8 DN MCPP
DMIG5W8 HS Discontinued in Phase 2
DMIG5W8 SN 1-(3-Chlorophenyl)piperazine
DMIG5W8 DT Small molecular drug
DMIG5W8 PC 7153
DMIG5W8 MW 214.64
DMIG5W8 FM C10H11ClO3
DMIG5W8 IC InChI=1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)
DMIG5W8 CS CC1=C(C=CC(=C1)Cl)OC(C)C(=O)O
DMIG5W8 IK WNTGYJSOUMFZEP-UHFFFAOYSA-N
DMIG5W8 IU 2-(4-chloro-2-methylphenoxy)propanoic acid
DMIG5W8 CA CAS 93-65-2
DMIG5W8 CB CHEBI:75704
DMIG5W8 DE Mood disorder
DMKEYSX ID DMKEYSX
DMKEYSX DN MDL 101,731
DMKEYSX HS Discontinued in Phase 2
DMKEYSX SN Tezacitabine; Fmdc cpd; 130306-02-4; Mdl 101,731; UNII-7607Y95N9S; Mdl 101731; (E)-2'-Deoxy-2'-(fluoromethylene) cytidine; MDL-101731; 2'-Deoxy-2'-(fluoromethylene)cytidine; 7607Y95N9S; Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-; (E)-2'-Deoxy-2'-(fluoromethylene)cytidine; Tezacitabine [INN]; tezaciabine; Tezacitabine, anhydrous; AC1O5KIG; SCHEMBL18724; SCHEMBL18725; Tezacitabine, anhydrous [INN]; CHEMBL2105467; C10H12FN3O4; DTXSID10156446; GFFXZLZWLOBBLO-ASKVSEFXSA-N; ZINC3777826; KW-2331
DMKEYSX DT Small molecular drug
DMKEYSX PC 6435808
DMKEYSX MW 257.22
DMKEYSX FM C10H12FN3O4
DMKEYSX IC InChI=1S/C10H12FN3O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-3,6,8-9,15-16H,4H2,(H2,12,13,17)/b5-3+/t6-,8+,9-/m1/s1
DMKEYSX CS C1=CN(C(=O)N=C1N)[C@H]2/C(=C/F)/[C@@H]([C@H](O2)CO)O
DMKEYSX IK GFFXZLZWLOBBLO-ASKVSEFXSA-N
DMKEYSX IU 4-amino-1-[(2R,3E,4S,5R)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMKEYSX CA CAS 130306-02-4
DMKEYSX DE Gastric adenocarcinoma
DM9ZEGT ID DM9ZEGT
DM9ZEGT DN MDX-070
DM9ZEGT HS Discontinued in Phase 2
DM9ZEGT CP Medarex
DM9ZEGT DT Antibody
DM9ZEGT DE Prostate cancer
DM3HIQY ID DM3HIQY
DM3HIQY DN Melanoma vaccine (ALVAC)
DM3HIQY HS Discontinued in Phase 2
DM3HIQY SN Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur
DM3HIQY CP Sanofi Pasteur
DM3HIQY DT Vaccine
DM3HIQY DE Melanoma
DM2DK4A ID DM2DK4A
DM2DK4A DN Mequitamium iodide
DM2DK4A HS Discontinued in Phase 2
DM2DK4A SN LG-30435
DM2DK4A CP Laboratorio Guidotti SpA
DM2DK4A DT Small molecular drug
DM2DK4A PC 72028
DM2DK4A MW 464.4
DM2DK4A FM C21H25IN2S
DM2DK4A IC InChI=1S/C21H25N2S.HI/c1-23-12-10-16(11-13-23)17(15-23)14-22-18-6-2-4-8-20(18)24-21-9-5-3-7-19(21)22;/h2-9,16-17H,10-15H2,1H3;1H/q+1;/p-1
DM2DK4A CS C[N+]12CCC(CC1)C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53.[I-]
DM2DK4A IK SWVANDLDSRKJFI-UHFFFAOYSA-M
DM2DK4A IU 10-[(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)methyl]phenothiazine;iodide
DM2DK4A CA CAS 101396-42-3
DM2DK4A DE Asthma
DMMZ4E9 ID DMMZ4E9
DMMZ4E9 DN Merbarone
DMMZ4E9 HS Discontinued in Phase 2
DMMZ4E9 SN NSC-336628
DMMZ4E9 CP Uniroyal Chemical Co Inc
DMMZ4E9 DT Small molecular drug
DMMZ4E9 PC 4990817
DMMZ4E9 MW 263.27
DMMZ4E9 FM C11H9N3O3S
DMMZ4E9 IC InChI=1S/C11H9N3O3S/c15-8(12-6-4-2-1-3-5-6)7-9(16)13-11(18)14-10(7)17/h1-5,7H,(H,12,15)(H2,13,14,16,17,18)
DMMZ4E9 CS C1=CC=C(C=C1)NC(=O)C2C(=O)NC(=S)NC2=O
DMMZ4E9 IK JARCFMKMOFFIGZ-UHFFFAOYSA-N
DMMZ4E9 IU 4,6-dioxo-N-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide
DMMZ4E9 CA CAS 97534-21-9
DMMZ4E9 DE Pancreatic cancer
DM90SHY ID DM90SHY
DM90SHY DN METIAPRIL
DM90SHY HS Discontinued in Phase 2
DM90SHY SN Methiopril; Cis-1-[3-(Acetylsulfanyl)propionyl]-6-methylpiperidine-2-carboxylic acid
DM90SHY PC 788183
DM90SHY MW 273.35
DM90SHY FM C12H19NO4S
DM90SHY IC InChI=1S/C12H19NO4S/c1-8-4-3-5-10(12(16)17)13(8)11(15)6-7-18-9(2)14/h8,10H,3-7H2,1-2H3,(H,16,17)/t8-,10-/m0/s1
DM90SHY CS C[C@H]1CCC[C@H](N1C(=O)CCSC(=O)C)C(=O)O
DM90SHY IK JHFOAISYWJRTIM-WPRPVWTQSA-N
DM90SHY IU (2S,6S)-1-(3-acetylsulfanylpropanoyl)-6-methylpiperidine-2-carboxylic acid
DM90SHY DE Hypotension
DMJLNUD ID DMJLNUD
DMJLNUD DN MILACAINIDE TARTRATE
DMJLNUD HS Discontinued in Phase 2
DMJLNUD SN (R)-RO-22-9194.tartrate; 2(R)-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate
DMJLNUD PC 15298297
DMJLNUD MW 461.5
DMJLNUD FM C23H31N3O7
DMJLNUD IC InChI=1S/C19H25N3O.C4H6O6/c1-14-7-4-8-15(2)18(14)22(19(23)16(3)20)12-6-10-17-9-5-11-21-13-17;5-1(3(7)8)2(6)4(9)10/h4-5,7-9,11,13,16H,6,10,12,20H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t16-;1-,2-/m10/s1
DMJLNUD CS CC1=C(C(=CC=C1)C)N(CCCC2=CN=CC=C2)C(=O)[C@@H](C)N.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O
DMJLNUD IK UKFWRCBTXJZERY-ZKBHHEPKSA-N
DMJLNUD IU (2R)-2-amino-N-(2,6-dimethylphenyl)-N-(3-pyridin-3-ylpropyl)propanamide;(2S,3S)-2,3-dihydroxybutanedioic acid
DMJLNUD CA CAS 141725-10-2
DMJLNUD DE Cardiac arrhythmias
DMTX97J ID DMTX97J
DMTX97J DN MILFASARTAN
DMTX97J HS Discontinued in Phase 2
DMTX97J SN Tienartan; Arwin (Knoll); LR-B/081; Milfasartan; 2-[4-Butyl-2-methyl-6-oxo-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1,6-dihydropyrimidin-1-ylmethyl]thiophene-3-carboxylic acid methyl ester; 4-Butyl-1-[3-(methoxycarbonyl)thien-2-ylmethyl]-2-methyl-5-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl-1,6-dihydropyrimidin-6-one
DMTX97J DT Small molecular drug
DMTX97J PC 3047757
DMTX97J MW 554.7
DMTX97J FM C30H30N6O3S
DMTX97J IC InChI=1S/C30H30N6O3S/c1-4-5-10-26-25(29(37)36(19(2)31-26)18-27-24(15-16-40-27)30(38)39-3)17-20-11-13-21(14-12-20)22-8-6-7-9-23(22)28-32-34-35-33-28/h6-9,11-16H,4-5,10,17-18H2,1-3H3,(H,32,33,34,35)
DMTX97J CS CCCCC1=C(C(=O)N(C(=N1)C)CC2=C(C=CS2)C(=O)OC)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMTX97J IK QVFVAKQHELFATN-UHFFFAOYSA-N
DMTX97J IU methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-1-yl]methyl]thiophene-3-carboxylate
DMTX97J CA CAS 148564-47-0
DMTX97J DE Hypertension
DMF1IH5 ID DMF1IH5
DMF1IH5 DN Milveterol
DMF1IH5 HS Discontinued in Phase 2
DMF1IH5 SN UNII-LGY1VQ9622; LGY1VQ9622; 652990-07-3; Milveterol [INN]; SCHEMBL265694; CHEMBL1940832; DTXSID30215640; BMKINZUHKYLSKI-DQEYMECFSA-N; BDBM50419652
DMF1IH5 CP GSK
DMF1IH5 DT Small molecular drug
DMF1IH5 PC 9892481
DMF1IH5 MW 435.5
DMF1IH5 FM C25H29N3O4
DMF1IH5 IC InChI=1S/C25H29N3O4/c29-17-28-22-14-20(8-11-23(22)30)24(31)15-26-13-12-18-6-9-21(10-7-18)27-16-25(32)19-4-2-1-3-5-19/h1-11,14,17,24-27,30-32H,12-13,15-16H2,(H,28,29)/t24-,25-/m0/s1
DMF1IH5 CS C1=CC=C(C=C1)[C@H](CNC2=CC=C(C=C2)CCNC[C@@H](C3=CC(=C(C=C3)O)NC=O)O)O
DMF1IH5 IK BMKINZUHKYLSKI-DQEYMECFSA-N
DMF1IH5 IU N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide
DMF1IH5 CA CAS 652990-07-3
DMF1IH5 DE Asthma
DMP8CVD ID DMP8CVD
DMP8CVD DN Milveterol+Fluticasone
DMP8CVD HS Discontinued in Phase 2
DMP8CVD SN S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate; 90566-53-3; S-(fluoromethyl) (6a,8x,11b,16a,17a)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate; AC1Q68ZV; AC1L1Y1V; AN-15808; s-(fluoromethyl)(6; A,8; I,11
DMP8CVD CP GlaxoSmithKline
DMP8CVD DT Small molecular drug
DMP8CVD PC 62924
DMP8CVD MW 444.5
DMP8CVD FM C22H27F3O4S
DMP8CVD IC InChI=1S/C22H27F3O4S/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)30-10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13+,14?,16+,17+,19+,20+,21+,22+/m1/s1
DMP8CVD CS C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)O)C)O)F)C)F
DMP8CVD IK MGNNYOODZCAHBA-AZYZPMHWSA-N
DMP8CVD IU S-(fluoromethyl) (6S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
DMP8CVD DE Chronic obstructive pulmonary disease
DMVF2R1 ID DMVF2R1
DMVF2R1 DN Minopafant
DMVF2R1 HS Discontinued in Phase 2
DMVF2R1 SN E-5880
DMVF2R1 CP Eisai Co Ltd
DMVF2R1 DT Small molecular drug
DMVF2R1 PC 130990
DMVF2R1 MW 861.5
DMVF2R1 FM C46H73ClN4O9
DMVF2R1 IC InChI=1S/C46H72N4O9.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4;/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3;1H/t40-;/m1./s1
DMVF2R1 CS CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=CC=CC=[N+]2CC)C(=O)C3=CC=CC=C3OC)OC.[Cl-]
DMVF2R1 IK IXRMFSBOHHRXSS-YPMTVOEDSA-N
DMVF2R1 IU [(2R)-3-[(1-ethylpyridin-1-ium-2-yl)methyl-(2-methoxybenzoyl)carbamoyl]oxy-2-methoxypropyl] 4-(octadecylcarbamoyloxy)piperidine-1-carboxylate;chloride
DMVF2R1 CA CAS 128420-61-1
DMVF2R1 DE Sepsis
DMT6IUR ID DMT6IUR
DMT6IUR DN MIRFENTANIL HYDROCHLORIDE
DMT6IUR HS Discontinued in Phase 2
DMT6IUR SN A-3508 hydrochloride; ANQ-3508 HCl; Mirfentanil hydrochloride < Rec INNM; OHM-10579 (free base); N-(1-Phenethyl-4-piperidinyl)-N-(2-pyrazinyl)furan-2-carboxamide hydrochloride
DMT6IUR DT Small molecular drug
DMT6IUR PC 60697
DMT6IUR MW 412.9
DMT6IUR FM C22H25ClN4O2
DMT6IUR IC InChI=1S/C22H24N4O2.ClH/c27-22(20-7-4-16-28-20)26(21-17-23-11-12-24-21)19-9-14-25(15-10-19)13-8-18-5-2-1-3-6-18;/h1-7,11-12,16-17,19H,8-10,13-15H2;1H
DMT6IUR CS C1CN(CCC1N(C2=NC=CN=C2)C(=O)C3=CC=CO3)CCC4=CC=CC=C4.Cl
DMT6IUR IK KVCOVXMNIYUKBS-UHFFFAOYSA-N
DMT6IUR IU N-[1-(2-phenylethyl)piperidin-4-yl]-N-pyrazin-2-ylfuran-2-carboxamide;hydrochloride
DMT6IUR CA CAS 119413-53-5
DMT6IUR DE Pain
DMW59FE ID DMW59FE
DMW59FE DN Mitonafide
DMW59FE HS Discontinued in Phase 2
DMW59FE SN Mitonafide; N-[2-(Dimethylamino)ethyl]-3-nitronaphthalimide; 2-[2-(Dimethylamino)ethyl]-5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione
DMW59FE DT Small molecular drug
DMW59FE PC 327044
DMW59FE MW 313.31
DMW59FE FM C16H15N3O4
DMW59FE IC InChI=1S/C16H15N3O4/c1-17(2)6-7-18-15(20)12-5-3-4-10-8-11(19(22)23)9-13(14(10)12)16(18)21/h3-5,8-9H,6-7H2,1-2H3
DMW59FE CS CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)[N+](=O)[O-]
DMW59FE IK XXVLKDRPHSFIIB-UHFFFAOYSA-N
DMW59FE IU 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione
DMW59FE CA CAS 54824-17-8
DMW59FE DE Solid tumour/cancer
DMCAKPG ID DMCAKPG
DMCAKPG DN MK-287
DMCAKPG HS Discontinued in Phase 2
DMCAKPG SN L-680573; (-)-(S,S)-2-[3-(2-Hydroxyethylsulfonyl)-5-methoxy-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran
DMCAKPG DT Small molecular drug
DMCAKPG PC 131925
DMCAKPG MW 510.6
DMCAKPG FM C25H34O9S
DMCAKPG IC InChI=1S/C25H34O9S/c1-6-10-33-25-22(31-4)14-17(15-23(25)35(27,28)11-9-26)19-8-7-18(34-19)16-12-20(29-2)24(32-5)21(13-16)30-3/h12-15,18-19,26H,6-11H2,1-5H3/t18-,19-/m0/s1
DMCAKPG CS CCCOC1=C(C=C(C=C1S(=O)(=O)CCO)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC
DMCAKPG IK WXIDMVGKJBAEFP-OALUTQOASA-N
DMCAKPG IU 2-[3-methoxy-2-propoxy-5-[(2S,5S)-5-(3,4,5-trimethoxyphenyl)oxolan-2-yl]phenyl]sulfonylethanol
DMCAKPG CA CAS 135947-75-0
DMCAKPG DE Sepsis
DM48ELZ ID DM48ELZ
DM48ELZ DN MK-386
DM48ELZ HS Discontinued in Phase 2
DM48ELZ SN CHEMBL25448; MK-386
DM48ELZ DT Small molecular drug
DM48ELZ PC 9888107
DM48ELZ MW 415.7
DM48ELZ FM C28H49NO
DM48ELZ IC InChI=1S/C28H49NO/c1-18(2)9-8-10-19(3)21-11-12-22-26-20(4)17-24-28(6,16-14-25(30)29(24)7)23(26)13-15-27(21,22)5/h18-24,26H,8-17H2,1-7H3/t19-,20+,21-,22+,23+,24-,26+,27-,28-/m1/s1
DM48ELZ CS C[C@H]1C[C@@H]2[C@](CCC(=O)N2C)([C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)[C@H](C)CCCC(C)C)C
DM48ELZ IK XUTZDXHKQDPUMA-MVJJLJOTSA-N
DM48ELZ IU (1R,3aS,3bS,4S,5aR,9aR,9bS,11aR)-4,6,9a,11a-tetramethyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinolin-7-one
DM48ELZ CA CAS 158493-17-5
DM48ELZ DE Acne vulgaris
DMVEGW6 ID DMVEGW6
DMVEGW6 DN MK-499
DMVEGW6 HS Discontinued in Phase 2
DMVEGW6 SN MK-499; MK 499; L-706000; L 706000; L-706,000; SCHEMBL4706649; CHEMBL477015; GTPL2607; BDBM24064; MK499; [35S]-MK499; N-[[3,4-Dihydro-4beta-hydroxy-1'-[[(R)-6-cyano-1,2,3,4-tetrahydronaphthalen]-2-yl]spiro[2H-1-benzopyran-2,4'-piperidin]]-6-yl]methanesulfonamide; N-[(4R)-1''-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-3,4-dihydrospiro[1-benzopyran-2,4''-piperidine]-4-ol]methanesulfonamide
DMVEGW6 DT Small molecular drug
DMVEGW6 PC 9934294
DMVEGW6 MW 467.6
DMVEGW6 FM C25H29N3O4S
DMVEGW6 IC InChI=1S/C25H29N3O4S/c1-33(30,31)27-20-5-7-24-22(14-20)23(29)15-25(32-24)8-10-28(11-9-25)21-6-4-18-12-17(16-26)2-3-19(18)13-21/h2-3,5,7,12,14,21,23,27,29H,4,6,8-11,13,15H2,1H3/t21-,23-/m1/s1
DMVEGW6 CS CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)[C@@H]4CCC5=C(C4)C=CC(=C5)C#N)C[C@H]2O
DMVEGW6 IK NIYGLRKUBPNXQS-FYYLOGMGSA-N
DMVEGW6 IU N-[(4R)-1'-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide
DMVEGW6 CA CAS 150481-98-4
DMVEGW6 DE Cardiac arrhythmias
DMVXTZG ID DMVXTZG
DMVXTZG DN MK-591
DMVXTZG HS Discontinued in Phase 2
DMVXTZG SN Quiflapon; Quiflapon [INN]; L 686708; MK 0591; MK 591; L-686708; MK-0591; L-686,708; 3-(1-(4-chlorobenzyl-3-(t-butylthio)-5-(quinolin-2-ylmethoxy)indol-2-yl))-2,2-dimethyl propanoic acid; 3-(tert-Butylthio)-1-(p-chlorobenzyl)-alpha,alpha-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-(tert-butylthio)-1-(p-chlorobenzyl)-a,a-dimethyl-5-(2-quinolylmethoxy)indole-2-propionic acid; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid
DMVXTZG CP Merck
DMVXTZG DT Small molecular drug
DMVXTZG PC 23672584
DMVXTZG MW 609.2
DMVXTZG FM C34H34ClN2NaO3S
DMVXTZG IC InChI=1S/C34H35ClN2O3S.Na/c1-33(2,3)41-31-27-18-26(40-21-25-15-12-23-8-6-7-9-28(23)36-25)16-17-29(27)37(20-22-10-13-24(35)14-11-22)30(31)19-34(4,5)32(38)39;/h6-18H,19-21H2,1-5H3,(H,38,39);/q;+1/p-1
DMVXTZG CS CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)[O-].[Na+]
DMVXTZG IK YPURUCMVRRNPHJ-UHFFFAOYSA-M
DMVXTZG IU sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate
DMVXTZG CA CAS 147030-01-1
DMVXTZG DE Asthma
DMBJLZG ID DMBJLZG
DMBJLZG DN MK-852
DMBJLZG HS Discontinued in Phase 2
DMBJLZG SN MK-852; CHEMBL331559; BDBM50092127; 8-Acetylamino-22-(4-aminomethyl-benzyl)-5-carbamoylmethyl-16-carboxymethyl-1,1-dimethyl-4,7,15,18,21,24-hexaoxo-icosahydro-2,10,11-trithia-3a,6,14,17,20,23-hexaaza-cyclopentacyclotricosene-13-carboxylic acid (MK-0852)
DMBJLZG DT Small molecular drug
DMBJLZG PC 44344173
DMBJLZG MW 870
DMBJLZG FM C34H47N9O12S3
DMBJLZG IC InChI=1S/C34H47N9O12S3/c1-16(44)38-22-13-57-58-14-23(33(54)55)42-29(50)20(10-26(47)48)39-25(46)12-37-28(49)19(8-17-4-6-18(11-35)7-5-17)40-31(52)27-34(2,3)56-15-43(27)32(53)21(9-24(36)45)41-30(22)51/h4-7,19-23,27H,8-15,35H2,1-3H3,(H2,36,45)(H,37,49)(H,38,44)(H,39,46)(H,40,52)(H,41,51)(H,42,50)(H,47,48)(H,54,55)/t19?,20-,21-,22+,23+,27-/m0/s1
DMBJLZG CS CC(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)C(NC(=O)[C@H]2C(SCN2C(=O)[C@@H](NC1=O)CC(=O)N)(C)C)CC3=CC=C(C=C3)CN)CC(=O)O)C(=O)O
DMBJLZG IK IHTQUFFCUYSOIH-JUXWROAHSA-N
DMBJLZG IU (3S,6S,11S,14S,23S)-6-acetamido-20-[[4-(aminomethyl)phenyl]methyl]-3-(2-amino-2-oxoethyl)-14-(carboxymethyl)-24,24-dimethyl-2,5,13,16,19,22-hexaoxo-8,9,25-trithia-1,4,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxylic acid
DMBJLZG DE Thrombosis
DMT0O7H ID DMT0O7H
DMT0O7H DN MK-886
DMT0O7H HS Discontinued in Phase 2
DMT0O7H SN MK-886; 118414-82-7; MK 886; MK886; 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid; UNII-080626SQ8C; QAOAOVKBIIKRNL-UHFFFAOYSA-N; L-663,536; CHEMBL29097; CHEBI:75390; L 663536; MK-886 (L-663,536); 080626SQ8C; 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid; 1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS]; L-663536; SMR000466278
DMT0O7H DT Small molecular drug
DMT0O7H PC 3651377
DMT0O7H MW 472.1
DMT0O7H FM C27H34ClNO2S
DMT0O7H IC InChI=1S/C27H34ClNO2S/c1-17(2)19-10-13-22-21(14-19)24(32-26(3,4)5)23(15-27(6,7)25(30)31)29(22)16-18-8-11-20(28)12-9-18/h8-14,17H,15-16H2,1-7H3,(H,30,31)
DMT0O7H CS CC(C)C1=CC2=C(C=C1)N(C(=C2SC(C)(C)C)CC(C)(C)C(=O)O)CC3=CC=C(C=C3)Cl
DMT0O7H IK QAOAOVKBIIKRNL-UHFFFAOYSA-N
DMT0O7H IU 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid
DMT0O7H CA CAS 118414-82-7
DMT0O7H CB CHEBI:75390
DMT0O7H DE Asthma
DMMNUZC ID DMMNUZC
DMMNUZC DN MK-912
DMMNUZC HS Discontinued in Phase 2
DMMNUZC SN MK-912; L 657743; MK 912; L-657,743; L-657,743-002W; L 657,743; 1',3'-Dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2H-benzo(b)furo(2,3-a)quinolizine)-2,4'-pyrimidin-2'-one; AC1L3X3J; Lopac0_000760; CHEMBL1256985; BDBM81811; Spiro(2H-benzofuro(2,3-a)quinolizine-2,4'(1'H)-pyrimidin)-2'(3'H)-one, 1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethyl-, (2S-trans)-; PDSP2_001636; PDSP1_001652; NSC_123679; CCG-204845; CAS_123679; NCGC00015699-02; NCGC00162243-01; NCGC00015699-03; LS-187521; LS-186865; L023963
DMMNUZC DT Small molecular drug
DMMNUZC PC 189711
DMMNUZC MW 339.4
DMMNUZC FM C20H25N3O2
DMMNUZC IC InChI=1S/C20H25N3O2/c1-21-11-8-20(22(2)19(21)24)9-12-23-10-7-15-14-5-3-4-6-17(14)25-18(15)16(23)13-20/h3-6,16H,7-13H2,1-2H3/t16-,20+/m0/s1
DMMNUZC CS CN1CC[C@]2(CCN3CCC4=C([C@@H]3C2)OC5=CC=CC=C45)N(C1=O)C
DMMNUZC IK JRDUBBHIPPPSLP-OXJNMPFZSA-N
DMMNUZC IU (2S,12bS)-1',3'-dimethylspiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one
DMMNUZC CA CAS 111466-41-2
DMOZUPB ID DMOZUPB
DMOZUPB DN MK-944a
DMOZUPB HS Discontinued in Phase 2
DMOZUPB SN L-756423
DMOZUPB CP Merck & Co Inc
DMOZUPB DT Small molecular drug
DMOZUPB PC 5481481
DMOZUPB MW 652.8
DMOZUPB FM C39H48N4O5
DMOZUPB IC InChI=1S/C39H48N4O5/c1-39(2,3)41-38(47)33-25-42(24-31-21-28-14-8-10-16-35(28)48-31)17-18-43(33)23-30(44)20-29(19-26-11-5-4-6-12-26)37(46)40-36-32-15-9-7-13-27(32)22-34(36)45/h4-16,21,29-30,33-34,36,44-45H,17-20,22-25H2,1-3H3,(H,40,46)(H,41,47)/t29-,30+,33+,34-,36+/m1/s1
DMOZUPB CS CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CC6=CC=CC=C6O5
DMOZUPB IK AOMZDQMIOCTPQP-QHQMVRJISA-N
DMOZUPB IU (2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide
DMOZUPB CA CAS 216863-66-0
DMOZUPB DE Human immunodeficiency virus infection
DMRA3EZ ID DMRA3EZ
DMRA3EZ DN MLN3897
DMRA3EZ HS Discontinued in Phase 2
DMRA3EZ CP Millenium Pharmacenticals; Sanofi Aventis
DMRA3EZ DE Rheumatoid arthritis
DMTWLG8 ID DMTWLG8
DMTWLG8 DN MLN-977
DMTWLG8 HS Discontinued in Phase 2
DMTWLG8 SN CHEMBL73148; CMI977; LDP-977; SCHEMBL16932371; LDP 977; CMI 977; HY-U00260; BDBM50144621; CS-7474; 175212-04-1; UNII-VNR0T3Q498 component YANONWCPCKIWEC-CABCVRRESA-N; N-(4-{(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydrofuran-2-yl}but-3-ynyl)-N-hydroxyurea; Urea, N-(4-((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydro-2-furanyl)-3-butyn-1-yl)-N-hydroxy-
DMTWLG8 CP PharmaEngine
DMTWLG8 DT Small molecular drug
DMTWLG8 PC 9905233
DMTWLG8 MW 322.33
DMTWLG8 FM C16H19FN2O4
DMTWLG8 IC InChI=1S/C16H19FN2O4/c17-12-4-6-13(7-5-12)22-11-15-9-8-14(23-15)3-1-2-10-19(21)16(18)20/h4-7,14-15,21H,2,8-11H2,(H2,18,20)/t14-,15+/m1/s1
DMTWLG8 CS C1C[C@H](O[C@@H]1COC2=CC=C(C=C2)F)C#CCCN(C(=O)N)O
DMTWLG8 IK YANONWCPCKIWEC-CABCVRRESA-N
DMTWLG8 IU 1-[4-[(2S,5S)-5-[(4-fluorophenoxy)methyl]oxolan-2-yl]but-3-ynyl]-1-hydroxyurea
DMTWLG8 CA CAS 175212-04-1
DMTWLG8 DE Chronic obstructive pulmonary disease
DMLG7QB ID DMLG7QB
DMLG7QB DN Mozenavir
DMLG7QB HS Discontinued in Phase 2
DMLG7QB SN DMP-450; Mozenavir mesilate; XM-412 (free base); (4R,5S,6S,7R)-1,3-Bis(3-aminobenzyl)-4,7-dibenzyl-5,6-dihydroxyhexahydro-1,3-diazepin-2-one dimethanesulfonate
DMLG7QB CP Bristol-Myers Squibb
DMLG7QB DT Small molecular drug
DMLG7QB PC 154044
DMLG7QB MW 536.7
DMLG7QB FM C33H36N4O3
DMLG7QB IC InChI=1S/C33H36N4O3/c34-27-15-7-13-25(17-27)21-36-29(19-23-9-3-1-4-10-23)31(38)32(39)30(20-24-11-5-2-6-12-24)37(33(36)40)22-26-14-8-16-28(35)18-26/h1-18,29-32,38-39H,19-22,34-35H2/t29-,30-,31+,32+/m1/s1
DMLG7QB CS C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC(=CC=C3)N)CC4=CC(=CC=C4)N)CC5=CC=CC=C5)O)O
DMLG7QB IK KYRSNWPSSXSNEP-ZRTHHSRSSA-N
DMLG7QB IU (4R,5S,6S,7R)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one
DMLG7QB CA 174391-92-5
DMLG7QB DE Human immunodeficiency virus infection
DMMKHGN ID DMMKHGN
DMMKHGN DN MP-435
DMMKHGN HS Discontinued in Phase 2
DMMKHGN SN C5a antagonist (rheumatoid arthritis), Mitsubishi Tanabe
DMMKHGN CP Mitsubishi Tanabe Pharma Corp
DMMKHGN DE Rheumatoid arthritis
DMKF3TD ID DMKF3TD
DMKF3TD DN Nafagrel
DMKF3TD HS Discontinued in Phase 2
DMKF3TD SN Nafagrel hydrochloride; DP-1904; SR-96325
DMKF3TD CP Daiichi Seiyaku Co Ltd
DMKF3TD DT Small molecular drug
DMKF3TD PC 65851
DMKF3TD MW 256.3
DMKF3TD FM C15H16N2O2
DMKF3TD IC InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)
DMKF3TD CS C1CC2=C(CC1CN3C=CN=C3)C=CC(=C2)C(=O)O
DMKF3TD IK VJJHOPPXRPHVCA-UHFFFAOYSA-N
DMKF3TD IU 6-(imidazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
DMKF3TD CA CAS 97901-21-8
DMKF3TD DE Asthma
DMF9Y57 ID DMF9Y57
DMF9Y57 DN Napitane mesilate
DMF9Y57 HS Discontinued in Phase 2
DMF9Y57 SN A-75200; ABT-200; Napitane mesilate < Prop INNM; Rac-1-[5,6-(Methylenedioxy)-1,2,3,4-tetrahydronaphth-1(R*)-ylmethyl]-3(R*)-phenylpyrrolidine methanesulfonate; Rac-3(R*)-Phenyl-1-[6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6(R*)-ylmethyl]pyrrolidine methanesulfonate
DMF9Y57 DT Small molecular drug
DMF9Y57 PC 60932
DMF9Y57 MW 335.4
DMF9Y57 FM C22H25NO2
DMF9Y57 IC InChI=1S/C22H25NO2/c1-2-5-16(6-3-1)17-11-12-23(13-17)14-18-7-4-8-20-19(18)9-10-21-22(20)25-15-24-21/h1-3,5-6,9-10,17-18H,4,7-8,11-15H2
DMF9Y57 CS C1CC(C2=C(C1)C3=C(C=C2)OCO3)CN4CCC(C4)C5=CC=CC=C5
DMF9Y57 IK HAEPGZUGYMHCJE-UHFFFAOYSA-N
DMF9Y57 IU 3-phenyl-1-(6,7,8,9-tetrahydrobenzo[g][1,3]benzodioxol-6-ylmethyl)pyrrolidine
DMF9Y57 DE Major depressive disorder
DM8L4Z0 ID DM8L4Z0
DM8L4Z0 DN Napsagatran
DM8L4Z0 HS Discontinued in Phase 2
DM8L4Z0 SN Ro-46-6240
DM8L4Z0 CP Roche Holding AG
DM8L4Z0 DT Small molecular drug
DM8L4Z0 PC 6918278
DM8L4Z0 MW 558.7
DM8L4Z0 FM C26H34N6O6S
DM8L4Z0 IC InChI=1S/C26H34N6O6S/c27-26(28)31-11-3-4-17(15-31)14-29-23(33)13-22(25(36)32(16-24(34)35)20-8-9-20)30-39(37,38)21-10-7-18-5-1-2-6-19(18)12-21/h1-2,5-7,10,12,17,20,22,30H,3-4,8-9,11,13-16H2,(H3,27,28)(H,29,33)(H,34,35)/t17-,22-/m0/s1
DM8L4Z0 CS C1C[C@H](CN(C1)C(=N)N)CNC(=O)C[C@@H](C(=O)N(CC(=O)O)C2CC2)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DM8L4Z0 IK BYDKEYCXCIVOOV-JTSKRJEESA-N
DM8L4Z0 IU 2-[[(2S)-4-[[(3S)-1-carbamimidoylpiperidin-3-yl]methylamino]-2-(naphthalen-2-ylsulfonylamino)-4-oxobutanoyl]-cyclopropylamino]acetic acid
DM8L4Z0 CA CAS 154397-77-0
DM8L4Z0 DE Myocardial infarction
DM8BHL6 ID DM8BHL6
DM8BHL6 DN Naronapride
DM8BHL6 HS Discontinued in Phase 2
DM8BHL6 SN Naronapride dihydrochloride; ATI-7500; ATI-7505; Cisapride analog, ARYx Therapeutics; ATI-7000 series, ARYx Therapeutics; Cisapride analog, Procter & Gamble; ATI-7000 series, Procter & Gamble; 5-HT 4 receptor agonist (oral, gastroesophageal reflux/irritable bowel syndrome/gastric motilitydisorder/constipation/dyspepsia), ARYx Therapeutics/Procter & Gamble Pharmaceuticals Inc
DM8BHL6 CP ARYx Therapeutics
DM8BHL6 DT Small molecular drug
DM8BHL6 PC 11237985
DM8BHL6 MW 537.1
DM8BHL6 FM C27H41ClN4O5
DM8BHL6 IC InChI=1S/C27H41ClN4O5/c1-35-23-15-21(29)20(28)14-19(23)27(34)30-22-9-13-31(17-25(22)36-2)10-5-3-4-6-26(33)37-24-16-32-11-7-18(24)8-12-32/h14-15,18,22,24-25H,3-13,16-17,29H2,1-2H3,(H,30,34)/t22-,24+,25+/m1/s1
DM8BHL6 CS CO[C@H]1CN(CC[C@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCCCC(=O)O[C@H]3CN4CCC3CC4
DM8BHL6 IK VGDDOIZXGFJDRC-VJTSUQJLSA-N
DM8BHL6 IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] 6-[(3S,4R)-4-[(4-amino-5-chloro-2-methoxybenzoyl)amino]-3-methoxypiperidin-1-yl]hexanoate
DM8BHL6 CA CAS 860174-12-5
DM8BHL6 DE Gastroesophageal reflux disease
DM9K2IO ID DM9K2IO
DM9K2IO DN Naxagolide
DM9K2IO HS Discontinued in Phase 2
DM9K2IO SN Dopazinol; Nazagolide; PHNO; Naxagolide hydrochloride; L-647339; MK-458; (+)-PHNO
DM9K2IO CP Merck & Co Inc
DM9K2IO DT Small molecular drug
DM9K2IO PC 57533
DM9K2IO MW 247.33
DM9K2IO FM C15H21NO2
DM9K2IO IC InChI=1S/C15H21NO2/c1-2-7-16-8-9-18-15-13-10-12(17)5-3-11(13)4-6-14(15)16/h3,5,10,14-15,17H,2,4,6-9H2,1H3/t14-,15-/m1/s1
DM9K2IO CS CCCN1CCO[C@H]2[C@H]1CCC3=C2C=C(C=C3)O
DM9K2IO IK JCSREICEMHWFAY-HUUCEWRRSA-N
DM9K2IO IU (4aR,10bR)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-ol
DM9K2IO CA CAS 88058-88-2
DM9K2IO DE Parkinson disease
DMGVYXB ID DMGVYXB
DMGVYXB DN NB-506
DMGVYXB HS Discontinued in Phase 2
DMGVYXB SN J-107185; L-753000; N-[12-(beta-D-Glucopyranosyl)-1,11-dihydroxy-5,7-dioxo-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl]formamide; 6-(Formamido)-12-(beta-D-glucopyranosyl)-1,11-dihydroxy-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione
DMGVYXB PC 9915861
DMGVYXB MW 562.5
DMGVYXB FM C27H22N4O10
DMGVYXB IC InChI=1S/C27H22N4O10/c32-7-13-22(36)23(37)24(38)27(41-13)30-20-10(4-2-6-12(20)35)15-17-16(25(39)31(26(17)40)28-8-33)14-9-3-1-5-11(34)18(9)29-19(14)21(15)30/h1-6,8,13,22-24,27,29,32,34-38H,7H2,(H,28,33)/t13-,22-,23+,24-,27-/m1/s1
DMGVYXB CS C1=CC2=C(C(=C1)O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC=O)C6=C(N4[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C(=CC=C6)O
DMGVYXB IK WHTCLLAVOBBKHK-ISCYQWKGSA-N
DMGVYXB IU N-[5,21-dihydroxy-12,14-dioxo-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]formamide
DMGVYXB CA CAS 151069-12-4
DMGVYXB DE Solid tumour/cancer
DMTRMBL ID DMTRMBL
DMTRMBL DN NBI-6024
DMTRMBL HS Discontinued in Phase 2
DMTRMBL SN Diabetes therapeutics, Neurocrine/Taisho; APL (diabetes), Neurocrine/Taisho; Applied Peptide Ligand(diabetes), Neurocrine/Taisho; Insulin B9-23 peptide analog, Taisho/Neurocrine
DMTRMBL CP Neurocrine Biosciences
DMTRMBL DE Type-1 diabetes
DMGEBUQ ID DMGEBUQ
DMGEBUQ DN NC-190
DMGEBUQ HS Discontinued in Phase 2
DMGEBUQ SN NCU-190Na
DMGEBUQ CP Taisho Pharmaceutical Co Ltd
DMGEBUQ DT Small molecular drug
DMGEBUQ PC 135413513
DMGEBUQ MW 456.4
DMGEBUQ FM C23H21N4NaO5
DMGEBUQ IC InChI=1S/C23H22N4O5.Na/c1-27(2)9-8-24-22(29)18-20-19(12-6-4-5-7-13(12)21(18)28)25-16-11-17(32-3)14(23(30)31)10-15(16)26-20;/h4-7,10-11,28H,8-9H2,1-3H3,(H,24,29)(H,30,31);/q;+1/p-1
DMGEBUQ CS CN(C)CCNC(=O)C1=C(C2=CC=CC=C2C3=NC4=C(C=C(C(=C4)OC)C(=O)[O-])N=C13)O.[Na+]
DMGEBUQ IK GHPJVVCCBMRQAR-UHFFFAOYSA-M
DMGEBUQ IU sodium;6-[2-(dimethylamino)ethylcarbamoyl]-5-hydroxy-10-methoxybenzo[a]phenazine-9-carboxylate
DMGEBUQ CA CAS 120602-99-5
DMGEBUQ DE Solid tumour/cancer
DMWROJ5 ID DMWROJ5
DMWROJ5 DN NCX-701
DMWROJ5 HS Discontinued in Phase 2
DMWROJ5 SN Nitroparacetamol; NO-acetaminophen, NicOx; NO-paracetamol, NicOx
DMWROJ5 CP NicOx SA
DMWROJ5 DT Small molecular drug
DMWROJ5 PC 6918532
DMWROJ5 MW 282.25
DMWROJ5 FM C12H14N2O6
DMWROJ5 IC InChI=1S/C12H14N2O6/c1-9(15)13-10-4-6-11(7-5-10)20-12(16)3-2-8-19-14(17)18/h4-7H,2-3,8H2,1H3,(H,13,15)
DMWROJ5 CS CC(=O)NC1=CC=C(C=C1)OC(=O)CCCO[N+](=O)[O-]
DMWROJ5 IK XTMOQAKCOFLCRZ-UHFFFAOYSA-N
DMWROJ5 IU (4-acetamidophenyl) 4-nitrooxybutanoate
DMWROJ5 CA CAS 326850-30-0
DMWROJ5 DE Pain
DM6VP9U ID DM6VP9U
DM6VP9U DN Nemifitide
DM6VP9U HS Discontinued in Phase 2
DM6VP9U SN SCHEMBL678511; AC1L42N3
DM6VP9U CP Tetragenex Pharmaceuticals
DM6VP9U DT Small molecular drug
DM6VP9U PC 6918348
DM6VP9U MW 694.8
DM6VP9U FM C33H43FN10O6
DM6VP9U IC InChI=1S/C33H43FN10O6/c34-20-9-7-18(8-10-20)12-23(35)32(50)44-17-21(45)14-27(44)31(49)43-25(6-3-11-39-33(37)38)30(48)41-16-28(46)42-26(29(36)47)13-19-15-40-24-5-2-1-4-22(19)24/h1-2,4-5,7-10,15,21,23,25-27,40,45H,3,6,11-14,16-17,35H2,(H2,36,47)(H,41,48)(H,42,46)(H,43,49)(H4,37,38,39)/t21-,23+,25+,26+,27+/m1/s1
DM6VP9U CS C1[C@H](CN([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)C(=O)[C@H](CC4=CC=C(C=C4)F)N)O
DM6VP9U IK SGXPTOACEHQGHL-RCNLLYRESA-N
DM6VP9U IU (2S,4R)-1-[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]-N-[(2S)-1-[[2-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide
DM6VP9U CA CAS 173240-15-8
DM6VP9U DE Major depressive disorder
DMDAUCR ID DMDAUCR
DMDAUCR DN NGD 91-3
DMDAUCR HS Discontinued in Phase 2
DMDAUCR CP Neurogen Corporation
DMDAUCR DE Anxiety disorder
DMOWLVF ID DMOWLVF
DMOWLVF DN NGD-8243
DMOWLVF HS Discontinued in Phase 2
DMOWLVF SN SCHEMBL17320582
DMOWLVF CP Neurogen Corp
DMOWLVF TC Analgesics
DMOWLVF DT Small molecular drug
DMOWLVF PC 11247522
DMOWLVF MW 434.3
DMOWLVF FM C21H12F6N4
DMOWLVF IC InChI=1S/C21H12F6N4/c22-20(23,24)13-4-6-14(7-5-13)31-19-15-8-3-12(10-17(15)29-11-30-19)18-16(21(25,26)27)2-1-9-28-18/h1-11H,(H,29,30,31)
DMOWLVF CS C1=CC(=C(N=C1)C2=CC3=C(C=C2)C(=NC=N3)NC4=CC=C(C=C4)C(F)(F)F)C(F)(F)F
DMOWLVF IK VTANGSDRFFLTSQ-UHFFFAOYSA-N
DMOWLVF IU N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-amine
DMOWLVF CA CAS 573678-04-3
DMOWLVF DE Acute or chronic pain
DMSJYEX ID DMSJYEX
DMSJYEX DN Nitecapone
DMSJYEX HS Discontinued in Phase 2
DMSJYEX SN OR-462
DMSJYEX CP Orion Corp
DMSJYEX DT Small molecular drug
DMSJYEX PC 5464105
DMSJYEX MW 265.22
DMSJYEX FM C12H11NO6
DMSJYEX IC InChI=1S/C12H11NO6/c1-6(14)9(7(2)15)3-8-4-10(13(18)19)12(17)11(16)5-8/h3-5,16-17H,1-2H3
DMSJYEX CS CC(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C(=O)C
DMSJYEX IK UPMRZALMHVUCIN-UHFFFAOYSA-N
DMSJYEX IU 3-[(3,4-dihydroxy-5-nitrophenyl)methylidene]pentane-2,4-dione
DMSJYEX CA CAS 116313-94-1
DMSJYEX CB CHEBI:166596
DMSJYEX DE Pain
DMZMQDN ID DMZMQDN
DMZMQDN DN NK-1001
DMZMQDN HS Discontinued in Phase 2
DMZMQDN SN NNYK-1001; NYK-1001
DMZMQDN CP Nyken BV
DMZMQDN DT Small molecular drug
DMZMQDN PC 3040841
DMZMQDN MW 485.5
DMZMQDN FM C18H35N3O12
DMZMQDN IC InChI=1S/C18H35N3O12/c19-2-6-8(23)10(25)12(27)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)11(26)9(24)7(3-22)31-18/h4-18,22-29H,1-3,19-21H2/t4-,5+,6-,7-,8-,9-,10+,11+,12-,13-,14-,15+,16-,17-,18-/m1/s1
DMZMQDN CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
DMZMQDN IK NZCOZAMBHLSNDW-GUKOCFKPSA-N
DMZMQDN IU (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1S,2R,3R,4S,6R)-4,6-diamino-2-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl]oxyoxane-3,4,5-triol
DMZMQDN CA CAS 53025-93-7
DMZMQDN DE Atrial fibrillation
DM5OVGH ID DM5OVGH
DM5OVGH DN NK-611
DM5OVGH HS Discontinued in Phase 2
DM5OVGH SN 2''-Deoxy-2''-(dimethylamino)etoposide
DM5OVGH DT Small molecular drug
DM5OVGH PC 159302
DM5OVGH MW 652.1
DM5OVGH FM C31H38ClNO12
DM5OVGH IC InChI=1S/C31H37NO12.ClH/c1-13-38-11-22-29(42-13)27(34)25(32(2)3)31(43-22)44-28-16-9-19-18(40-12-41-19)8-15(16)23(24-17(28)10-39-30(24)35)14-6-20(36-4)26(33)21(7-14)37-5;/h6-9,13,17,22-25,27-29,31,33-34H,10-12H2,1-5H3;1H
DM5OVGH CS CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)N(C)C)O.Cl
DM5OVGH IK PYLTTZZOZBYUEI-UHFFFAOYSA-N
DM5OVGH IU 5-[[7-(dimethylamino)-8-hydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;hydrochloride
DM5OVGH CA CAS 105760-98-3
DM5OVGH DE Solid tumour/cancer
DMV5FN1 ID DMV5FN1
DMV5FN1 DN NKS-01
DMV5FN1 HS Discontinued in Phase 2
DMV5FN1 SN 14alpha-Hydroxy-4-androstene-3,6,17-trione
DMV5FN1 DT Small molecular drug
DMV5FN1 PC 6918079
DMV5FN1 MW 316.4
DMV5FN1 FM C19H24O4
DMV5FN1 IC InChI=1S/C19H24O4/c1-17-6-3-11(20)9-14(17)15(21)10-13-12(17)4-7-18(2)16(22)5-8-19(13,18)23/h9,12-13,23H,3-8,10H2,1-2H3/t12-,13+,17+,18+,19+/m0/s1
DMV5FN1 CS C[C@]12CCC(=O)C=C1C(=O)C[C@@H]3[C@@H]2CC[C@]4([C@]3(CCC4=O)O)C
DMV5FN1 IK UKVVNEHFNYKGMX-KIVPVIKRSA-N
DMV5FN1 IU (8R,9S,10R,13S,14R)-14-hydroxy-10,13-dimethyl-2,7,8,9,11,12,15,16-octahydro-1H-cyclopenta[a]phenanthrene-3,6,17-trione
DMV5FN1 CA CAS 120051-39-0
DMV5FN1 DE Bladder cancer
DM6NPUJ ID DM6NPUJ
DM6NPUJ DN NLX-P101
DM6NPUJ HS Discontinued in Phase 2
DM6NPUJ SN RAAV-GAD; STN AAV-GAD gene therapy, Neurologix; Subthalamic nucleus AAV-glutamic acid decarboxylase gene therapy, Neurologix; NLX gene therapy (Parkinson's), Neurologix
DM6NPUJ CP Neurologix Inc
DM6NPUJ DE Parkinson disease
DMVH3I7 ID DMVH3I7
DMVH3I7 DN NM-135
DMVH3I7 HS Discontinued in Phase 2
DMVH3I7 SN Glucocorticoid, Nissin Food
DMVH3I7 CP Nissin Foods Holdings Co Ltd
DMVH3I7 PC 9963271
DMVH3I7 MW 1029.099
DMVH3I7 FM C60H62F2O13
DMVH3I7 IC InChI=1S/C60H62F2O13/c1-32-8-16-37(17-9-32)53(66)70-31-47-50(73-54(67)38-18-10-33(2)11-19-38)51(74-55(68)39-20-12-34(3)13-21-39)52(75-56(69)40-22-14-35(4)15-23-40)57(72-47)71-30-46(64)49-36(5)26-42-43-28-45(61)44-27-41(63)24-25-59(44,7)60(43,62)48(65)29-58(42,49)6/h8-25,27,36,42-43,45,47-52,57,65H,26,28-31H2,1-7H3/t36-,42+,43+,45+,47-,48+,49-,50-,51+,52-,57-,58+,59+,60+/m1/s1
DMVH3I7 CS C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COC(=O)C6=CC=C(C=C6)C)OC(=O)C7=CC=C(C=C7)C)OC(=O)C8=CC=C(C=C8)C)OC(=O)C9=CC=C(C=C9)C)C)O)F)C)F
DMVH3I7 IK BVEAZFTXNPWHMR-QBKHVOGRSA-N
DMVH3I7 IU [(2R,3R,4S,5R,6R)-6-[2-[(6S,8S,9R,10S,11S,13S,14S,16R,17S)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-3,4,5-tris[(4-methylbenzoyl)oxy]oxan-2-yl]methyl 4-methylbenzoate
DMVH3I7 DE Dermatitis
DMU596F ID DMU596F
DMU596F DN NMI-870
DMU596F HS Discontinued in Phase 2
DMU596F CP NitroMed
DMU596F DE Sexual dysfunction
DM2TDE7 ID DM2TDE7
DM2TDE7 DN NN8209
DM2TDE7 HS Discontinued in Phase 2
DM2TDE7 CP Novo Nordisk
DM2TDE7 DE Rheumatoid arthritis
DMK5WLZ ID DMK5WLZ
DMK5WLZ DN Nolpitantium besilate
DMK5WLZ HS Discontinued in Phase 2
DMK5WLZ SN SR-140333; SR-140333B
DMK5WLZ CP Sanofi-Synthelabo; Sanofi-aventis
DMK5WLZ DT Small molecular drug
DMK5WLZ PC 3047794
DMK5WLZ MW 777.8
DMK5WLZ FM C43H50Cl2N2O5S
DMK5WLZ IC InChI=1S/C37H45Cl2N2O2.C6H6O3S/c1-28(2)43-32-11-6-8-29(24-32)25-35(42)40-19-7-14-37(27-40,31-12-13-33(38)34(39)26-31)18-23-41-20-15-36(16-21-41,17-22-41)30-9-4-3-5-10-30;7-10(8,9)6-4-2-1-3-5-6/h3-6,8-13,24,26,28H,7,14-23,25,27H2,1-2H3;1-5H,(H,7,8,9)/q+1;/p-1/t36?,37-,41?;/m1./s1
DMK5WLZ CS CC(C)OC1=CC=CC(=C1)CC(=O)N2CCC[C@](C2)(CC[N+]34CCC(CC3)(CC4)C5=CC=CC=C5)C6=CC(=C(C=C6)Cl)Cl.C1=CC=C(C=C1)S(=O)(=O)[O-]
DMK5WLZ IK PQRLQZNKDQQMBC-LSYPWIJNSA-M
DMK5WLZ IU benzenesulfonate;1-[(3S)-3-(3,4-dichlorophenyl)-3-[2-(4-phenyl-1-azoniabicyclo[2.2.2]octan-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone
DMK5WLZ CA CAS 155418-06-7
DMK5WLZ DE Asthma
DMJSKUI ID DMJSKUI
DMJSKUI DN Norcisapride
DMJSKUI HS Discontinued in Phase 2
DMJSKUI SN Norcisapride; 84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176
DMJSKUI DT Small molecular drug
DMJSKUI PC 3019427
DMJSKUI MW 313.78
DMJSKUI FM C14H20ClN3O3
DMJSKUI IC InChI=1S/C14H20ClN3O3/c1-20-12-6-10(16)9(15)5-8(12)14(19)18-11-3-4-17-7-13(11)21-2/h5-6,11,13,17H,3-4,7,16H2,1-2H3,(H,18,19)
DMJSKUI CS COC1CNCCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl
DMJSKUI IK OMLDMGPCWMBPAN-UHFFFAOYSA-N
DMJSKUI IU 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide
DMJSKUI CA CAS 84946-16-7
DMJSKUI DE Gastroesophageal reflux disease
DMYCLZR ID DMYCLZR
DMYCLZR DN Norelin
DMYCLZR HS Discontinued in Phase 2
DMYCLZR CP YM Biosciences
DMYCLZR DE Prostate cancer
DM8A64W ID DM8A64W
DM8A64W DN NP-118809
DM8A64W HS Discontinued in Phase 2
DM8A64W SN 41332-24-5; NP118809; Z-160; 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone; UNII-TX3R141LEP; TX3R141LEP; CHEMBL604710; Piperazine, 1-(diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)-; 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one; AC1NLRM8; GTPL7765; SCHEMBL4180792; CTK1D3910; DTXSID70407284; VCPMZDWBEWTGNW-UHFFFAOYSA-N; MolPort-001-545-055; EX-A2422; BCP08259; KS-00000T6R; ZINC20509316; 3934AH; STK411255; AKOS003297641; MK-6721; DB12743; MCULE-3294187169; CS-1361; API0014038; ACM41332245
DM8A64W TC Analgesics
DM8A64W DT Small molecular drug
DM8A64W PC 4988454
DM8A64W MW 460.6
DM8A64W FM C32H32N2O
DM8A64W IC InChI=1S/C32H32N2O/c35-31(25-30(26-13-5-1-6-14-26)27-15-7-2-8-16-27)33-21-23-34(24-22-33)32(28-17-9-3-10-18-28)29-19-11-4-12-20-29/h1-20,30,32H,21-25H2
DM8A64W CS C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5
DM8A64W IK VCPMZDWBEWTGNW-UHFFFAOYSA-N
DM8A64W IU 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one
DM8A64W CA CAS 41332-24-5
DM8A64W DE Pain
DMPMR2I ID DMPMR2I
DMPMR2I DN NP-50301
DMPMR2I HS Discontinued in Phase 2
DMPMR2I SN IDESTRIN; Estrogen ester (eyedrop, dry eye syndrome), Nascent
DMPMR2I CP Nascent Pharmaceuticals
DMPMR2I DE Eye disorder
DM50PZH ID DM50PZH
DM50PZH DN NP-619
DM50PZH HS Discontinued in Phase 2
DM50PZH CP Biophysica Inc
DM50PZH DE Alopecia
DMAVZ1F ID DMAVZ1F
DMAVZ1F DN NPC-567
DMAVZ1F HS Discontinued in Phase 2
DMAVZ1F SN Npc-567; Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-
DMAVZ1F DT Small molecular drug
DMAVZ1F PC 119343
DMAVZ1F MW 1282.5
DMAVZ1F FM C60H87N19O13
DMAVZ1F IC InChI=1S/C60H87N19O13/c61-39(20-10-24-68-58(62)63)49(83)73-40(21-11-25-69-59(64)65)55(89)78-27-13-23-46(78)56(90)79-33-38(81)31-47(79)54(88)71-32-48(82)72-42(28-35-14-4-1-5-15-35)50(84)77-45(34-80)53(87)76-44(30-37-18-8-3-9-19-37)52(86)75-43(29-36-16-6-2-7-17-36)51(85)74-41(57(91)92)22-12-26-70-60(66)67/h1-9,14-19,38-47,80-81H,10-13,20-34,61H2,(H,71,88)(H,72,82)(H,73,83)(H,74,85)(H,75,86)(H,76,87)(H,77,84)(H,91,92)(H4,62,63,68)(H4,64,65,69)(H4,66,67,70)/t38-,39-,40+,41+,42+,43+,44-,45+,46+,47+/m1/s1
DMAVZ1F CS C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2C[C@@H](C[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)O
DMAVZ1F IK RBIXVHPHNGXTCI-QJTYZATASA-N
DMAVZ1F IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMAVZ1F CA CAS 109333-26-8
DMAVZ1F CB CHEBI:73294
DMAVZ1F DE Rhinitis
DM0CF3B ID DM0CF3B
DM0CF3B DN NPS 1776
DM0CF3B HS Discontinued in Phase 2
DM0CF3B SN Isovaleramide
DM0CF3B CP NPS Pharmaceuticals
DM0CF3B DT Small molecular drug
DM0CF3B PC 10930
DM0CF3B MW 101.15
DM0CF3B FM C5H11NO
DM0CF3B IC InChI=1S/C5H11NO/c1-4(2)3-5(6)7/h4H,3H2,1-2H3,(H2,6,7)
DM0CF3B CS CC(C)CC(=O)N
DM0CF3B IK SANOUVWGPVYVAV-UHFFFAOYSA-N
DM0CF3B IU 3-methylbutanamide
DM0CF3B CA CAS 541-46-8
DM0CF3B DE Epilepsy
DMQPXLF ID DMQPXLF
DMQPXLF DN NPS-2143
DMQPXLF HS Discontinued in Phase 2
DMQPXLF SN NPS-2143; 284035-33-2; NPS 2143; NPS2143; UNII-Z25PJ77W7V; SB-262470; Z25PJ77W7V; CHEMBL180672; 2-CHLORO-6-[(2R)-3-[[1,1-DIMETHYL-2-(2-NAPHTHALENYL)ETHYL]AMINO]-2-HYDROXYPROPOXY]BENZONITRILE; C24H25ClN2O2; 2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile; (R)-2-chloro-6-(2-hydroxy-3-((2-methyl-1-(naphthalen-2-yl)propan-2-yl)amino)propoxy)benzonitrile; SB-262470A; (+)-NPS-2143; AC1OCFG2; GTPL716; SCHEMBL13597018; EX-A017; DTXSID10426075; MolPort-021-805-006; BCPP000077; ZINC3975668
DMQPXLF CP NPS Pharmaceuticals
DMQPXLF DT Small molecular drug
DMQPXLF PC 6918446
DMQPXLF MW 408.9
DMQPXLF FM C24H25ClN2O2
DMQPXLF IC InChI=1S/C24H25ClN2O2/c1-24(2,13-17-10-11-18-6-3-4-7-19(18)12-17)27-15-20(28)16-29-23-9-5-8-22(25)21(23)14-26/h3-12,20,27-28H,13,15-16H2,1-2H3/t20-/m1/s1
DMQPXLF CS CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=C(C(=CC=C3)Cl)C#N)O
DMQPXLF IK PZUJQWHTIRWCID-HXUWFJFHSA-N
DMQPXLF IU 2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile
DMQPXLF CA CAS 284035-33-2
DMQPXLF DE Osteoporosis
DMQ82T5 ID DMQ82T5
DMQ82T5 DN NS-220
DMQ82T5 HS Discontinued in Phase 2
DMQ82T5 SN R-1593; Cis-2-Methyl-5-[4-[5-methyl-2-(4-methylphenyl)oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid
DMQ82T5 DT Small molecular drug
DMQ82T5 PC 9947731
DMQ82T5 MW 373.4
DMQ82T5 FM C21H27NO5
DMQ82T5 IC InChI=1S/C21H27NO5/c1-14-8-10-17(11-9-14)19-22-18(15(2)27-19)7-5-4-6-16-12-25-21(3,20(23)24)26-13-16/h8-11,16H,4-7,12-13H2,1-3H3,(H,23,24)
DMQ82T5 CS CC1=CC=C(C=C1)C2=NC(=C(O2)C)CCCCC3COC(OC3)(C)C(=O)O
DMQ82T5 IK IMYPSTHZBIWMNA-UHFFFAOYSA-N
DMQ82T5 IU 2-methyl-5-[4-[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]butyl]-1,3-dioxane-2-carboxylic acid
DMQ82T5 DE Hyperlipidaemia
DMVRJ8D ID DMVRJ8D
DMVRJ8D DN NS-2389
DMVRJ8D HS Discontinued in Phase 2
DMVRJ8D SN GW-650250; GW-650250A; NS-2347
DMVRJ8D CP NeuroSearch A/S
DMVRJ8D DE Major depressive disorder
DMQ8P4U ID DMQ8P4U
DMQ8P4U DN NS-49
DMQ8P4U HS Discontinued in Phase 2
DMQ8P4U SN Garomefrine hydrochloride; ABT-232; PNO-49B
DMQ8P4U CP Nippon Shinyaku Co Ltd
DMQ8P4U DT Small molecular drug
DMQ8P4U PC 9838763
DMQ8P4U MW 248.28
DMQ8P4U FM C9H13FN2O3S
DMQ8P4U IC InChI=1S/C9H13FN2O3S/c1-16(14,15)12-6-2-3-8(10)7(4-6)9(13)5-11/h2-4,9,12-13H,5,11H2,1H3/t9-/m0/s1
DMQ8P4U CS CS(=O)(=O)NC1=CC(=C(C=C1)F)[C@H](CN)O
DMQ8P4U IK XYLJNMCMDOOJRW-VIFPVBQESA-N
DMQ8P4U IU N-[3-[(1R)-2-amino-1-hydroxyethyl]-4-fluorophenyl]methanesulfonamide
DMQ8P4U CA CAS 137431-02-8
DMQ8P4U DE Urinary incontinence
DMH2QBM ID DMH2QBM
DMH2QBM DN NSP-805
DMH2QBM HS Discontinued in Phase 2
DMH2QBM SN TZN-01; 5-Methyl-6-[4-(2-methyl-3-oxo-1-cyclopentenylamino)phenyl]-2,3,4,5-tetrahydropyridazin-3-one
DMH2QBM DT Small molecular drug
DMH2QBM PC 130349
DMH2QBM MW 297.35
DMH2QBM FM C17H19N3O2
DMH2QBM IC InChI=1S/C17H19N3O2/c1-10-9-16(22)19-20-17(10)12-3-5-13(6-4-12)18-14-7-8-15(21)11(14)2/h3-6,10,18H,7-9H2,1-2H3,(H,19,22)
DMH2QBM CS CC1CC(=O)NN=C1C2=CC=C(C=C2)NC3=C(C(=O)CC3)C
DMH2QBM IK DSRIICXPBQXOKK-UHFFFAOYSA-N
DMH2QBM IU 4-methyl-3-[4-[(2-methyl-3-oxocyclopenten-1-yl)amino]phenyl]-4,5-dihydro-1H-pyridazin-6-one
DMH2QBM CA CAS 125068-54-4
DMH2QBM DE Heart failure
DMGZ3DR ID DMGZ3DR
DMGZ3DR DN NT-3
DMGZ3DR HS Discontinued in Phase 2
DMGZ3DR SN Neurotrophin-3; NT-3, Amgen-Regeneron Partners; NT-3, Amgen/ Regeneron; Neurotrophin-3, Amgen-Regeneron Partners; Neurotrophin-3, Amgen/ Regeneron
DMGZ3DR CP Takeda Pharmaceutical Co Ltd
DMGZ3DR DE Constipation
DMX9KYW ID DMX9KYW
DMX9KYW DN NTx-488
DMX9KYW HS Discontinued in Phase 2
DMX9KYW SN Prolactin-containing multiple sclerosis therapy, Stem Cell Therapeutics
DMX9KYW CP Stem Cell Therapeutics Corp
DMX9KYW DE Multiple sclerosis
DMPM58S ID DMPM58S
DMPM58S DN Nuvanil
DMPM58S HS Discontinued in Phase 2
DMPM58S SN NE-21610
DMPM58S CP Procter & Gamble Pharmaceuticals Inc
DMPM58S DE Pain
DM9HKOM ID DM9HKOM
DM9HKOM DN NVP-DPP728
DM9HKOM HS Discontinued in Phase 2
DM9HKOM SN NVP-DPP728; HCX5M1YIOM; UNII-HCX5M1YIOM; CHEMBL77538; NVP-DPP-728; NVP-728; 247016-69-9; dpp-728; BMCL15687 Compound 2; cyanopyrrolidine derivative 2; SCHEMBL160102; BDBM11113; cyano-(S)-pyrrolidine deriv. 1; ZINC26396245; AKOS030529265; LS-137333; (2S)-1-(2-((2-((5-Cyano-2-pyridyl)amino)ethyl)amino)acetyl)pyrrolidine-2-carbonitrile; 1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(s)-pyrroli-dine; (S)-6-((2-((2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)amino)ethyl)amino)nicotinonitrile; 3-Pyridinecarbonitrile, 6-((2
DM9HKOM DT Small molecular drug
DM9HKOM PC 9796290
DM9HKOM MW 298.34
DM9HKOM FM C15H18N6O
DM9HKOM IC InChI=1S/C15H18N6O/c16-8-12-3-4-14(20-10-12)19-6-5-18-11-15(22)21-7-1-2-13(21)9-17/h3-4,10,13,18H,1-2,5-7,11H2,(H,19,20)/t13-/m0/s1
DM9HKOM CS C1C[C@H](N(C1)C(=O)CNCCNC2=NC=C(C=C2)C#N)C#N
DM9HKOM IK VFFZWMWTUSXDCB-ZDUSSCGKSA-N
DM9HKOM IU 6-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile
DM9HKOM CA CAS 247016-69-9
DM9HKOM DE Type-2 diabetes
DMO8PN9 ID DMO8PN9
DMO8PN9 DN OBERADILOL MONOETHYL MALEATE
DMO8PN9 HS Discontinued in Phase 2
DMO8PN9 SN TZC-5665; Oberadilol monoethyl maleate; Rac-6-[4-[2-[3-(5-Chloro-2-cyanophenoxy)-2-hydroxypropylamino]-2-methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H)-pyridazinone monoethylmaleate; Rac-6-[4-[2-[3-(5-Chloro-2-cyanophenoxy)-2-hydroxy-propylamino]-2-methylpropylamino]phenyl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one maleic acid monoethyl ester; Rac-4-Chloro-2-[3-[[1,1-dimethyl-2-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]amino]ethyl]amino]-2-hydroxypropoxy]benzonitrile mono[ethyl 2(Z)-butenedioate]
DMO8PN9 DT Small molecular drug
DMO8PN9 PC 3047798
DMO8PN9 MW 484
DMO8PN9 FM C25H30ClN5O3
DMO8PN9 IC InChI=1S/C25H30ClN5O3/c1-16-10-23(33)30-31-24(16)17-5-8-20(9-6-17)28-15-25(2,3)29-13-21(32)14-34-22-11-19(26)7-4-18(22)12-27/h4-9,11,16,21,28-29,32H,10,13-15H2,1-3H3,(H,30,33)
DMO8PN9 CS CC1CC(=O)NN=C1C2=CC=C(C=C2)NCC(C)(C)NCC(COC3=C(C=CC(=C3)Cl)C#N)O
DMO8PN9 IK SHAJOALCPZUGLR-UHFFFAOYSA-N
DMO8PN9 IU 4-chloro-2-[2-hydroxy-3-[[2-methyl-1-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)anilino]propan-2-yl]amino]propoxy]benzonitrile
DMO8PN9 CA CAS 114856-44-9
DMO8PN9 DE Hypertension
DMX6GFR ID DMX6GFR
DMX6GFR DN Omega interferon
DMX6GFR HS Discontinued in Phase 2
DMX6GFR CP Intarcia Therapeutics
DMX6GFR DE Hepatitis C virus infection
DMIZXFJ ID DMIZXFJ
DMIZXFJ DN ONO-4007
DMIZXFJ HS Discontinued in Phase 2
DMIZXFJ SN Ono-4007
DMIZXFJ CP Ono Pharmaceutical Co Ltd
DMIZXFJ DT Small molecular drug
DMIZXFJ PC 23663416
DMIZXFJ MW 940.2
DMIZXFJ FM C50H78NNaO12S
DMIZXFJ IC InChI=1S/C50H79NO12S.Na/c1-2-3-4-5-6-7-8-15-26-35-42(60-45(54)36-27-16-11-9-13-20-29-40-31-22-18-23-32-40)38-44(53)51-47-49(48(63-64(57,58)59)43(39-52)61-50(47)56)62-46(55)37-28-17-12-10-14-21-30-41-33-24-19-25-34-41;/h18-19,22-25,31-34,42-43,47-50,52,56H,2-17,20-21,26-30,35-39H2,1H3,(H,51,53)(H,57,58,59);/q;+1/p-1/t42-,43+,47+,48+,49+,50?;/m0./s1
DMIZXFJ CS CCCCCCCCCCC[C@@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)OS(=O)(=O)[O-])OC(=O)CCCCCCCCC2=CC=CC=C2)OC(=O)CCCCCCCCC3=CC=CC=C3.[Na+]
DMIZXFJ IK KSLCVWMGAOQHEA-TZBBHZOSSA-M
DMIZXFJ IU sodium;[(2R,3S,4R,5R)-6-hydroxy-2-(hydroxymethyl)-4-(9-phenylnonanoyloxy)-5-[[(3S)-3-(9-phenylnonanoyloxy)tetradecanoyl]amino]oxan-3-yl] sulfate
DMIZXFJ DE Immune System disease
DMNEA78 ID DMNEA78
DMNEA78 DN ONO-4057
DMNEA78 HS Discontinued in Phase 2
DMNEA78 SN Ono-LB-457; 5-[2-(2-Carboxyethyl)-3-[6-(4-methoxyphenyl)-5(E)-hexenyloxy]phenoxy]pentanoic acid
DMNEA78 DT Small molecular drug
DMNEA78 PC 6438358
DMNEA78 MW 470.6
DMNEA78 FM C27H34O7
DMNEA78 IC InChI=1S/C27H34O7/c1-32-22-15-13-21(14-16-22)9-4-2-3-6-19-33-24-10-8-11-25(23(24)17-18-27(30)31)34-20-7-5-12-26(28)29/h4,8-11,13-16H,2-3,5-7,12,17-20H2,1H3,(H,28,29)(H,30,31)/b9-4+
DMNEA78 CS COC1=CC=C(C=C1)/C=C/CCCCOC2=C(C(=CC=C2)OCCCCC(=O)O)CCC(=O)O
DMNEA78 IK JOPSSWGWLCLPPF-RUDMXATFSA-N
DMNEA78 IU 5-[2-(2-carboxyethyl)-3-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid
DMNEA78 CA CAS 134578-96-4
DMNEA78 DE Inflammatory bowel disease
DMSVQK2 ID DMSVQK2
DMSVQK2 DN ONO-4819
DMSVQK2 HS Discontinued in Phase 2
DMSVQK2 SN Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734
DMSVQK2 CP Novartis
DMSVQK2 DT Small molecular drug
DMSVQK2 PC 9803828
DMSVQK2 MW 450.6
DMSVQK2 FM C24H34O6S
DMSVQK2 IC InChI=1S/C24H34O6S/c1-29-16-18-6-3-5-17(13-18)14-19(25)8-9-20-21(23(27)15-22(20)26)10-12-31-11-4-7-24(28)30-2/h3,5-6,8-9,13,19-22,25-26H,4,7,10-12,14-16H2,1-2H3/b9-8+/t19-,20-,21-,22-/m1/s1
DMSVQK2 CS COCC1=CC=CC(=C1)C[C@@H](/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCSCCCC(=O)OC)O)O
DMSVQK2 IK FBQUXLIJKPWCAO-AZIFJQEOSA-N
DMSVQK2 IU methyl 4-[2-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl]-5-oxocyclopentyl]ethylsulfanyl]butanoate
DMSVQK2 CA CAS 256382-08-8
DMSVQK2 DE Fracture
DMWS7C2 ID DMWS7C2
DMWS7C2 DN ONO-5334
DMWS7C2 HS Discontinued in Phase 2
DMWS7C2 SN Bone resorption inhibitor (tablet/oral, osteoporosis/osteopenia), Ono; Cathepsin K inhibitor (tablet/oral formulation, osteoporosis/osteopenia), Ono
DMWS7C2 CP Ono Pharmaceutical Co Ltd
DMWS7C2 PC 11582982
DMWS7C2 MW 438.6
DMWS7C2 FM C21H34N4O4S
DMWS7C2 IC InChI=1S/C21H34N4O4S/c1-14-13-30-21(25(14)2)24-23-20(28)18(26)17(15-9-11-29-12-10-15)22-19(27)16-7-5-3-4-6-8-16/h14-17H,3-13H2,1-2H3,(H,22,27)(H,23,28)/b24-21-/t14-,17+/m1/s1
DMWS7C2 CS C[C@@H]1CS/C(=N\\NC(=O)C(=O)[C@H](C2CCOCC2)NC(=O)C3CCCCCC3)/N1C
DMWS7C2 IK BTZCSXIUAFVRTE-CHGLIHOBSA-N
DMWS7C2 IU N-[(1S)-3-[(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazinyl]-1-(oxan-4-yl)-2,3-dioxopropyl]cycloheptanecarboxamide
DMWS7C2 CA CAS 868273-90-9
DMWS7C2 DE Osteoporosis
DMQM4OV ID DMQM4OV
DMQM4OV DN OP-2507
DMQM4OV HS Discontinued in Phase 2
DMQM4OV SN OP-2507; AC1OCEV0; op2507; methyl 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-3-(4-propylcyclohexyl)prop-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-yl]pentanoate
DMQM4OV CP Ono Pharmaceutical Co Ltd
DMQM4OV DT Small molecular drug
DMQM4OV PC 6917967
DMQM4OV MW 419.6
DMQM4OV FM C25H41NO4
DMQM4OV IC InChI=1S/C25H41NO4/c1-3-6-17-9-11-18(12-10-17)23(27)14-13-20-21-15-19(26-22(21)16-24(20)28)7-4-5-8-25(29)30-2/h13-14,17-18,20-24,27-28H,3-12,15-16H2,1-2H3/b14-13+/t17?,18?,20-,21-,22+,23-,24-/m1/s1
DMQM4OV CS CCCC1CCC(CC1)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2CC(=N3)CCCCC(=O)OC)O)O
DMQM4OV IK UQEOPLABKYFAJH-FPNSLHOUSA-N
DMQM4OV IU methyl 5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-3-(4-propylcyclohexyl)prop-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-yl]pentanoate
DMQM4OV DE Hypertension
DMP0ARJ ID DMP0ARJ
DMP0ARJ DN Opaviraline
DMP0ARJ HS Discontinued in Phase 2
DMP0ARJ SN Opaviraline; GW420867X; UNII-Q3A8EU2NMU; 178040-94-3; Q3A8EU2NMU; GW-420867X; Isopropyl (2s)-2-Ethyl-7-Fluoro-3-Oxo-3,4-Dihydroquinoxaline-1(2h)-Carboxylate; isopropyl (2S)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate; Opaviraline [INN]; HBQ; AC1L4BLF; SCHEMBL464732; Opaviraline (GW 420867); CHEMBL301370; BDBM2955; GW 867X; HBY1293; DTXSID60170415; GW867; HBY1293/GW867; ZINC3916138; HBY-1293; GW-867; AKOS027326866; DB07884; 1(2H)-Quinoxalinecarboxylic acid,2-ethyl-7-fluoro-3,4-dihydro-3-oxo-,1-methylethyl ester,(2S)-
DMP0ARJ DT Small molecular drug
DMP0ARJ PC 154048
DMP0ARJ MW 280.29
DMP0ARJ FM C14H17FN2O3
DMP0ARJ IC InChI=1S/C14H17FN2O3/c1-4-11-13(18)16-10-6-5-9(15)7-12(10)17(11)14(19)20-8(2)3/h5-8,11H,4H2,1-3H3,(H,16,18)/t11-/m0/s1
DMP0ARJ CS CC[C@H]1C(=O)NC2=C(N1C(=O)OC(C)C)C=C(C=C2)F
DMP0ARJ IK KELNNWMENBUHNS-NSHDSACASA-N
DMP0ARJ IU propan-2-yl (2S)-2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate
DMP0ARJ CA CAS 178040-94-3
DMP0ARJ DE Human immunodeficiency virus infection
DM7OVMH ID DM7OVMH
DM7OVMH DN OPC-21268
DM7OVMH HS Discontinued in Phase 2
DM7OVMH SN Acetamide, N-(3-(4-((4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-piperidinyl)carbonyl)phenoxy)propyl)-; Opc 21268; 131631-89-5; Fuscoside; 1-(1-(4-(3-Acetylaminopropoxy)benzoyl)-4-piperidyl)-3,4-dihydro-2(1H)-quinolinone; CHEMBL296908; OPC-1268; N-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide; N-(3-(4-(4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carbonyl)phenoxy)propyl)acetamide; ACMC-20mu6h; AC1L3G6H; SCHEMBL3504368; GTPL2196; CTK0H6673; EX-A593
DM7OVMH DT Small molecular drug
DM7OVMH PC 114904
DM7OVMH MW 449.5
DM7OVMH FM C26H31N3O4
DM7OVMH IC InChI=1S/C26H31N3O4/c1-19(30)27-15-4-18-33-23-10-7-21(8-11-23)26(32)28-16-13-22(14-17-28)29-24-6-3-2-5-20(24)9-12-25(29)31/h2-3,5-8,10-11,22H,4,9,12-18H2,1H3,(H,27,30)
DM7OVMH CS CC(=O)NCCCOC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3C(=O)CCC4=CC=CC=C43
DM7OVMH IK KSNUCNRMDYJBKT-UHFFFAOYSA-N
DM7OVMH IU N-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide
DM7OVMH CA CAS 131631-89-5
DM7OVMH DE Cardiac disease
DMYM8OG ID DMYM8OG
DMYM8OG DN OPC-28326
DMYM8OG HS Discontinued in Phase 2
DMYM8OG SN N-[2,6-Dimethyl-4-[4-[N-methyl-N-(2-phenylethyl)amino]piperidin-1-ylcarbonyl]phenyl]propionamide hydrochloride monohydrate
DMYM8OG CP Otsuka America Pharmaceutical
DMYM8OG DT Small molecular drug
DMYM8OG PC 219020
DMYM8OG MW 421.6
DMYM8OG FM C26H35N3O2
DMYM8OG IC InChI=1S/C26H35N3O2/c1-5-24(30)27-25-19(2)17-22(18-20(25)3)26(31)29-15-12-23(13-16-29)28(4)14-11-21-9-7-6-8-10-21/h6-10,17-18,23H,5,11-16H2,1-4H3,(H,27,30)
DMYM8OG CS CCC(=O)NC1=C(C=C(C=C1C)C(=O)N2CCC(CC2)N(C)CCC3=CC=CC=C3)C
DMYM8OG IK BESKMDLUOAVUJF-UHFFFAOYSA-N
DMYM8OG IU N-[2,6-dimethyl-4-[4-[methyl(2-phenylethyl)amino]piperidine-1-carbonyl]phenyl]propanamide
DMYM8OG DE Peripheral vascular disease
DM9ORUL ID DM9ORUL
DM9ORUL DN OPC-8490
DM9ORUL HS Discontinued in Phase 2
DM9ORUL SN Opc 8490; Opc-8490; 123941-50-4; 6-[4-(4-oxo-4-phenyl-butyl)piperazine-1-carbonyl]-3,4-dihydro-1H-quinolin-2-one; ACMC-20mqub; AC1MI0AB; SCHEMBL8212456; CTK0I0428; DTXSID40154152; 3,4-Dihydro-6-(4-(4-oxo-4-phenylbutyl)-1-piperazinylcarbonyl)-2(1H)-quinolinone; Piperazine, 1-(4-oxo-4-phenylbutyl)-4-((1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)carbonyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
DM9ORUL CP Otsuka Pharmaceutical Co Ltd
DM9ORUL DT Small molecular drug
DM9ORUL PC 3035953
DM9ORUL MW 597.6
DM9ORUL FM C30H35N3O10
DM9ORUL IC InChI=1S/C24H27N3O3.C6H8O7/c28-22(18-5-2-1-3-6-18)7-4-12-26-13-15-27(16-14-26)24(30)20-8-10-21-19(17-20)9-11-23(29)25-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-3,5-6,8,10,17H,4,7,9,11-16H2,(H,25,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DM9ORUL CS C1CC(=O)NC2=C1C=C(C=C2)C(=O)N3CCN(CC3)CCCC(=O)C4=CC=CC=C4.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM9ORUL IK ONELTIQETCJUSG-UHFFFAOYSA-N
DM9ORUL IU 2-hydroxypropane-1,2,3-tricarboxylic acid;6-[4-(4-oxo-4-phenylbutyl)piperazine-1-carbonyl]-3,4-dihydro-1H-quinolin-2-one
DM9ORUL CA CAS 123941-50-4
DM9ORUL DE Cardiovascular disease
DMVM4NE ID DMVM4NE
DMVM4NE DN OPM-3023
DMVM4NE HS Discontinued in Phase 2
DMVM4NE SN OPM-3023; Bone metabolism modulator (periodontitis), Bionetworks; Bone metabolism modulator (periodontitis), Onepharm; OPM-3023 (local extended release formulation, peridontitis), OnePharm; OPM-3023 (oral, peridontitis), OnePharm
DMVM4NE CP Bionetworks GmbH
DMVM4NE DE Inflammation
DMWZXF7 ID DMWZXF7
DMWZXF7 DN ORG-33628
DMWZXF7 HS Discontinued in Phase 2
DMWZXF7 SN 11beta-(4-Acetylphenyl)-3'-methylenespiro[estra-4,9-dien-17(R),2'-tetrahydrofuran]-3-one
DMWZXF7 DT Small molecular drug
DMWZXF7 PC 9846209
DMWZXF7 MW 442.6
DMWZXF7 FM C30H34O3
DMWZXF7 IC InChI=1S/C30H34O3/c1-18-13-15-33-30(18)14-12-27-25-10-8-22-16-23(32)9-11-24(22)28(25)26(17-29(27,30)3)21-6-4-20(5-7-21)19(2)31/h4-7,16,25-27H,1,8-15,17H2,2-3H3/t25-,26+,27-,29-,30+/m0/s1
DMWZXF7 CS CC(=O)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@@]34C(=C)CCO4)[C@H]5C2=C6CCC(=O)C=C6CC5)C
DMWZXF7 IK YNWTZVKFWBTFFE-ONBAZCQBSA-N
DMWZXF7 IU (8S,11R,13S,14S,17R)-11-(4-acetylphenyl)-13-methyl-3'-methylidenespiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one
DMWZXF7 CA CAS 155768-17-5
DMWZXF7 DE Contraception
DMU5PFD ID DMU5PFD
DMU5PFD DN Org-7797
DMU5PFD HS Discontinued in Phase 2
DMU5PFD SN org7797; 80177-51-1; Org 7797; SCHEMBL11227348; EINECS 279-413-5; AKOS030532756; (3,16alpha-Dihydroxyestra-1,3,5(10)-trien-17beta-yl)(methyl)ammonium hydrogen maleate; Estra-1,3,5(10)-triene-3,16-diol, 17-(methylamino)-, (16alpha,17beta)-, (Z)-2-butenedioate (1:1) (salt)
DMU5PFD CP Organon BioSciences
DMU5PFD DT Small molecular drug
DMU5PFD PC 9866662
DMU5PFD MW 417.5
DMU5PFD FM C23H31NO6
DMU5PFD IC InChI=1S/C19H27NO2.C4H4O4/c1-19-8-7-14-13-6-4-12(21)9-11(13)3-5-15(14)16(19)10-17(22)18(19)20-2;5-3(6)1-2-4(7)8/h4,6,9,14-18,20-22H,3,5,7-8,10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-,16+,17-,18+,19+;/m1./s1
DMU5PFD CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2NC)O)CCC4=C3C=CC(=C4)O.C(=C\\C(=O)O)\\C(=O)O
DMU5PFD IK UDCGSEPMGRJOAG-IQQQYFTASA-N
DMU5PFD IU (Z)-but-2-enedioic acid;(8R,9S,13S,14S,16R,17R)-13-methyl-17-(methylamino)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16-diol
DMU5PFD CA CAS 80177-51-1
DMU5PFD DE Cardiac arrhythmias
DMW1FT0 ID DMW1FT0
DMW1FT0 DN ORG-9273
DMW1FT0 HS Discontinued in Phase 2
DMW1FT0 SN 1-[(2beta,3alpha,5alpha,16beta,17beta)-17-Acetoxy-3-hydroxy-2-morpholinoandrostan-16-yl]-1-methylpiperidinium bromide; 17beta-Acetoxy-3alpha-hydroxy-16beta-(1-methylhexahydropyridinio-1-yl)-2beta-morpholino-5alpha-androstane bromide
DMW1FT0 DT Small molecular drug
DMW1FT0 PC 131901
DMW1FT0 MW 517.799
DMW1FT0 FM C31H53N2O4+
DMW1FT0 IC InChI=1S/C31H53N2O4/c1-21(34)37-29-27(33(4)14-6-5-7-15-33)19-25-23-9-8-22-18-28(35)26(32-12-16-36-17-13-32)20-31(22,3)24(23)10-11-30(25,29)2/h22-29,35H,5-20H2,1-4H3/q+1/t22-,23?,24?,25?,26-,27-,28-,29-,30-,31-/m0/s1
DMW1FT0 CS CC(=O)O[C@H]1[C@H](CC2[C@@]1(CCC3C2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCCC6)C
DMW1FT0 IK DHYOZTTVCWLBTR-JHKQNVCFSA-N
DMW1FT0 IU [(2S,3S,5S,10S,13S,16S,17R)-3-hydroxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-morpholin-4-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
DMW1FT0 CA CAS 135644-85-8
DMW1FT0 DE Paralysis
DMZEV63 ID DMZEV63
DMZEV63 DN Org-9731
DMZEV63 HS Discontinued in Phase 2
DMZEV63 SN IDDB3777
DMZEV63 CP Organon BioSciences
DMZEV63 DE Heart failure
DMRXHAC ID DMRXHAC
DMRXHAC DN Otenzepad
DMRXHAC HS Discontinued in Phase 2
DMRXHAC SN Otenzepad; AF-DX 116; 102394-31-0; AF-DX-116; 11-(2-(2-((Diethylamino)methyl)piperidin-1-yl)acetyl)-5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11H)-one; UNII-WW6A9TFL2C; UNII-SX2WTG9R3Z; WW6A9TFL2C; SX2WTG9R3Z; 11-[[2-[(DIETHYLAMINO)METHYL]-1-PIPERIDINYL]ACETYL]-5,11-DIHYDRO-6H-PYRIDO[2,3-B][1,4]BENZODIAZEPIN-6-ONE; BRN 4212983; CHEMBL17045; NSC664529; 100158-38-1; NCGC00025002-02; DSSTox_RID_81048; DSSTox_CID_25674; DSSTox_GSID_45674; 6H-Pyrido(2,3-b)(1,4)benzodiazepin-6-one, 11-((2-((diethylamino)methyl)-1-piperidinyl)acetyl)
DMRXHAC DT Small molecular drug
DMRXHAC PC 107867
DMRXHAC MW 421.5
DMRXHAC FM C24H31N5O2
DMRXHAC IC InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)
DMRXHAC CS CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMRXHAC IK UBRKDAVQCKZSPO-UHFFFAOYSA-N
DMRXHAC IU 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMRXHAC CA CAS 102394-31-0
DMRXHAC CB CHEBI:111174
DMRXHAC DE Heart failure
DMHFOIX ID DMHFOIX
DMHFOIX DN OxycoDex
DMHFOIX HS Discontinued in Phase 2
DMHFOIX SN Oxycodone/dextromethorphan
DMHFOIX CP Endo Pharmaceuticals
DMHFOIX DE Pain
DM02ANM ID DM02ANM
DM02ANM DN P-1075
DM02ANM HS Discontinued in Phase 2
DM02ANM SN 60559-98-0; P1075; N-Cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridylguanidine; P-1075; BRN 0480738; 2-Cyano-1-tert-pentyl-3-(3-pyridyl)guanidine; CHEMBL11458; Guanidine, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinyl-; N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine; P 1075; GUANIDINE, 2-CYANO-1-tert-PENTYL-3-(3-PYRIDYL)-; Guanidine, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinyl- [CAS]; SMR000466288; Tocris-1355; AC1L29NR; MLS000758317; MLS001424147; SCHEMBL2129487; SCHEMBL8747731; BDBM86250; CTK8J5792; CTK2F3712
DM02ANM CP LEO Pharma A/S
DM02ANM DT Small molecular drug
DM02ANM PC 43345
DM02ANM MW 231.3
DM02ANM FM C12H17N5
DM02ANM IC InChI=1S/C12H17N5/c1-4-12(2,3)17-11(15-9-13)16-10-6-5-7-14-8-10/h5-8H,4H2,1-3H3,(H2,15,16,17)
DM02ANM CS CCC(C)(C)N=C(NC#N)NC1=CN=CC=C1
DM02ANM IK HKZNADVVGXKQDL-UHFFFAOYSA-N
DM02ANM IU 1-cyano-2-(2-methylbutan-2-yl)-3-pyridin-3-ylguanidine
DM02ANM CA CAS 60559-98-0
DM02ANM CB CHEBI:92004
DM02ANM DE Hypertension
DMWCAQD ID DMWCAQD
DMWCAQD DN P1A
DMWCAQD HS Discontinued in Phase 2
DMWCAQD SN IPSAT P1A; P1A, Ipsat Therapies
DMWCAQD CP Ipsat Therapies Oy
DMWCAQD DT Small molecular drug
DMWCAQD PC 115127
DMWCAQD MW 464.6
DMWCAQD FM C27H44O6
DMWCAQD IC InChI=1S/C27H44O6/c1-15(2)6-7-23(31)26(5,32)22-9-11-27(33)17-12-19(28)18-13-20(29)21(30)14-24(18,3)16(17)8-10-25(22,27)4/h12,15-16,18,20-23,29-33H,6-11,13-14H2,1-5H3/t16-,18-,20+,21-,22-,23+,24+,25+,26+,27+/m0/s1
DMWCAQD CS CC(C)CC[C@H]([C@@](C)([C@H]1CC[C@@]2([C@@]1(CC[C@H]3C2=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)C)O)O)O
DMWCAQD IK PJYYBCXMCWDUAZ-JJJZTNILSA-N
DMWCAQD IU (2S,3R,5R,9R,10R,13R,14S,17S)-17-[(2R,3R)-2,3-dihydroxy-6-methylheptan-2-yl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one
DMWCAQD CA CAS 13408-56-5
DMWCAQD CB CHEBI:28135
DMWCAQD DE Toxicity
DM4ZNKX ID DM4ZNKX
DM4ZNKX DN PA-1806
DM4ZNKX HS Discontinued in Phase 2
DM4ZNKX SN BMS-180680; SQ-32633; SQ-33110; BMS-180680-01
DM4ZNKX CP Bristol-Myers Squibb Co
DM4ZNKX PC 135462917
DM4ZNKX MW 567.5
DM4ZNKX FM C19H17N7O10S2
DM4ZNKX IC InChI=1S/C19H17N7O10S2/c1-6-13(17(30)26(6)38(33,34)35)24-16(29)14(10-5-37-19(20)23-10)25-36-4-9-15(18(31)32)22-8-3-12(28)11(27)2-7(8)21-9/h2-3,5-6,13,27-28H,4H2,1H3,(H2,20,23)(H,24,29)(H,31,32)(H,33,34,35)/b25-14-/t6-,13+/m1/s1
DM4ZNKX CS C[C@@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\\OCC2=NC3=CC(=C(C=C3N=C2C(=O)O)O)O)/C4=CSC(=N4)N
DM4ZNKX IK FAUHVXXXXAHABE-VHLYPECSSA-N
DM4ZNKX IU 3-[[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2R,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxymethyl]-6,7-dihydroxyquinoxaline-2-carboxylic acid
DM4ZNKX DE Bacterial infection
DMRSMW8 ID DMRSMW8
DMRSMW8 DN PAI-2
DMRSMW8 HS Discontinued in Phase 2
DMRSMW8 SN N-Butyryl-DL-homoserine lactone; N-butanoyl-lhomoserine lactone; N-(2-oxooxolan-3-yl)butanamide; N-(2-oxotetrahydrofuran-3-yl)butanamide; N-Butyrylhomoserine lactone; 98426-48-3; N-(2-Oxotetrahydro-3-furanyl)butanamide; AC1L9ENE; SCHEMBL787006; Homoserine lactone, N-butanoyl-; N-Butanoyl-DL-homoserine lactone; VFFNZZXXTGXBOG-UHFFFAOYSA-N; LMFA08030002; AN-38291; N-Butyryl-DL-homoserine lactone, >
DMRSMW8 DT Small molecular drug
DMRSMW8 PC 443433
DMRSMW8 MW 171.19
DMRSMW8 FM C8H13NO3
DMRSMW8 IC InChI=1S/C8H13NO3/c1-2-3-7(10)9-6-4-5-12-8(6)11/h6H,2-5H2,1H3,(H,9,10)
DMRSMW8 CS CCCC(=O)NC1CCOC1=O
DMRSMW8 IK VFFNZZXXTGXBOG-UHFFFAOYSA-N
DMRSMW8 IU N-(2-oxooxolan-3-yl)butanamide
DMWCLZ6 ID DMWCLZ6
DMWCLZ6 DN PALOSURAN
DMWCLZ6 HS Discontinued in Phase 2
DMWCLZ6 SN Palosuran; 540769-28-6; ACT-058362; UNII-ULD9ZKE457; 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea; ULD9ZKE457; ACT 058362; Palosuran; CHEMBL567303; Palosuran [INN]; 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea; ACT 058362; ACT058362 (Palosuran); GTPL3516; SCHEMBL1363480; DTXSID00202406; WYJCYXOCHXWTHG-UHFFFAOYSA-N; BCP15786; BDBM50302272; ZINC34375693; AKOS026750332; 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl-3-(2-methylquinolin-4-yl)urea; CS-1722; NCGC00408890-01
DMWCLZ6 DT Small molecular drug
DMWCLZ6 PC 10173280
DMWCLZ6 MW 418.5
DMWCLZ6 FM C25H30N4O2
DMWCLZ6 IC InChI=1S/C25H30N4O2/c1-19-17-23(21-9-5-6-10-22(21)27-19)28-24(30)26-13-16-29-14-11-25(31,12-15-29)18-20-7-3-2-4-8-20/h2-10,17,31H,11-16,18H2,1H3,(H2,26,27,28,30)
DMWCLZ6 CS CC1=NC2=CC=CC=C2C(=C1)NC(=O)NCCN3CCC(CC3)(CC4=CC=CC=C4)O
DMWCLZ6 IK WYJCYXOCHXWTHG-UHFFFAOYSA-N
DMWCLZ6 IU 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea
DMWCLZ6 CA CAS 540769-28-6
DMWCLZ6 DE Renal failure
DM9SYUT ID DM9SYUT
DM9SYUT DN PAMAPIMOD
DM9SYUT HS Discontinued in Phase 2
DM9SYUT SN Pamapimod; 449811-01-2; RO 4402257; UNII-8S2C9V11K4; Pamapimod (R-1503, Ro4402257); CHEMBL1090089; CHEBI:90685; 8S2C9V11K4; Ro4402257; Ro-4402257; R1503; R 1503; R-1503; 6-(2,4-Difluorophenoxy)-2-{[3-Hydroxy-1-(2-Hydroxyethyl)propyl]amino}-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; Pamapimod [USAN:INN]; 6-(2,4-Difluorophenoxy)-2-((3-hydroxy-1-(2-hydroxyethyl)propyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,4-Difluorophenoxy)-2-[[3-hydroxy-1-(2-hydroxyethyl)propyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
DM9SYUT DT Small molecular drug
DM9SYUT PC 16220188
DM9SYUT MW 406.4
DM9SYUT FM C19H20F2N4O4
DM9SYUT IC InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24)
DM9SYUT CS CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC(CCO)CCO
DM9SYUT IK JYYLVUFNAHSSFE-UHFFFAOYSA-N
DM9SYUT IU 6-(2,4-difluorophenoxy)-2-(1,5-dihydroxypentan-3-ylamino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DM9SYUT CA CAS 449811-01-2
DM9SYUT CB CHEBI:90685
DM9SYUT DE Rheumatoid arthritis
DM6TPCJ ID DM6TPCJ
DM6TPCJ DN Panamesine
DM6TPCJ HS Discontinued in Phase 2
DM6TPCJ SN EMD-57445; EMD-59983
DM6TPCJ CP Merck KGaA
DM6TPCJ DT Small molecular drug
DM6TPCJ PC 3047810
DM6TPCJ MW 426.5
DM6TPCJ FM C23H26N2O6
DM6TPCJ IC InChI=1S/C23H26N2O6/c1-28-18-5-3-17(4-6-18)25-14-19(31-22(25)26)13-24-10-8-23(27,9-11-24)16-2-7-20-21(12-16)30-15-29-20/h2-7,12,19,27H,8-11,13-15H2,1H3/t19-/m0/s1
DM6TPCJ CS COC1=CC=C(C=C1)N2C[C@@H](OC2=O)CN3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O
DM6TPCJ IK NINYZUDVKTUKIA-IBGZPJMESA-N
DM6TPCJ IU (5S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxypiperidin-1-yl]methyl]-3-(4-methoxyphenyl)-1,3-oxazolidin-2-one
DM6TPCJ CA CAS 139225-22-2
DM6TPCJ DE Psychotic disorder
DME4RSI ID DME4RSI
DME4RSI DN Panomifene
DME4RSI HS Discontinued in Phase 2
DME4RSI SN Panomifine; EGIS-5650
DME4RSI CP EGIS Gyogyszergyar RT
DME4RSI DT Small molecular drug
DME4RSI PC 3033654
DME4RSI MW 427.5
DME4RSI FM C25H24F3NO2
DME4RSI IC InChI=1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+
DME4RSI CS C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO
DME4RSI IK MHXVDXXARZCVRK-WCWDXBQESA-N
DME4RSI IU 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol
DME4RSI CA CAS 77599-17-8
DME4RSI DE Solid tumour/cancer
DM80UNM ID DM80UNM
DM80UNM DN PD-134308
DM80UNM HS Discontinued in Phase 2
DM80UNM SN CI-988; 130332-27-3; CI 988; PD-134308; UNII-2637PDX9SI; 2637PDX9SI; CHEMBL287735; CHEMBL2062154; PD 134308; 4-(((R)-2-((R)-2-(((Adamantan-2-yloxy)carbonyl)amino)-3-(1H-indol-3-yl)-2-methylpropanamido)-1-phenylethyl)amino)-4-oxobutanoic acid; 4-[[(1R)-2-[[(2R)-3-(1H-Indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo[3.3.1.13,7]dec-2-yloxy)carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic Acid
DM80UNM DT Small molecular drug
DM80UNM PC 108187
DM80UNM MW 614.7
DM80UNM FM C35H42N4O6
DM80UNM IC InChI=1S/C35H42N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-10,19,21-22,24-25,29,32,36H,11-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/t21?,22?,24?,25?,29-,32?,35+/m0/s1
DM80UNM CS C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)NC[C@@H](C3=CC=CC=C3)NC(=O)CCC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DM80UNM IK FVQSSYMRZKLFDR-ZABPBAJSSA-N
DM80UNM IU 4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid
DM80UNM CA CAS 130332-27-3
DM80UNM DE Anxiety disorder
DMMYNKH ID DMMYNKH
DMMYNKH DN PD-348292
DMMYNKH HS Discontinued in Phase 2
DMMYNKH SN Eribaxaban; PD 0348292; PD 348292; PD0348292; Eribaxaban (USAN); PD-0348292; N-(4-Chlorophenyl)-N-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidiine-1,2-dicarboxamide
DMMYNKH CP Pfizer
DMMYNKH DT Small molecular drug
DMMYNKH PC 11634458
DMMYNKH MW 484.9
DMMYNKH FM C24H22ClFN4O4
DMMYNKH IC InChI=1S/C24H22ClFN4O4/c1-34-18-13-21(30(14-18)24(33)27-16-7-5-15(25)6-8-16)23(32)28-20-10-9-17(12-19(20)26)29-11-3-2-4-22(29)31/h2-12,18,21H,13-14H2,1H3,(H,27,33)(H,28,32)/t18-,21-/m1/s1
DMMYNKH CS CO[C@@H]1C[C@@H](N(C1)C(=O)NC2=CC=C(C=C2)Cl)C(=O)NC3=C(C=C(C=C3)N4C=CC=CC4=O)F
DMMYNKH IK QQBKAVAGLMGMHI-WIYYLYMNSA-N
DMMYNKH IU (2R,4R)-1-N-(4-chlorophenyl)-2-N-[2-fluoro-4-(2-oxopyridin-1-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide
DMMYNKH CA CAS 536748-46-6
DMMYNKH CB CHEBI:140420
DMMYNKH DE Thrombosis
DMGD20T ID DMGD20T
DMGD20T DN PEG-Infergen
DMGD20T HS Discontinued in Phase 2
DMGD20T SN PEG-Alfacon; PEGylated interferon alpha, Intermune; PEG-Infergen, InterMune; PEG-Interferon alfacon-1, InterMune
DMGD20T CP InterMune
DMGD20T DE Hepatitis virus infection
DMTGBPW ID DMTGBPW
DMTGBPW DN Pentisomide
DMTGBPW HS Discontinued in Phase 2
DMTGBPW SN Penticainide; Propisomide; ME 3202; CM-7857
DMTGBPW CP Sanofi
DMTGBPW DT Small molecular drug
DMTGBPW PC 65847
DMTGBPW MW 319.5
DMTGBPW FM C19H33N3O
DMTGBPW IC InChI=1S/C19H33N3O/c1-14(2)13-19(18(20)23,17-9-7-8-11-21-17)10-12-22(15(3)4)16(5)6/h7-9,11,14-16H,10,12-13H2,1-6H3,(H2,20,23)
DMTGBPW CS CC(C)CC(CCN(C(C)C)C(C)C)(C1=CC=CC=N1)C(=O)N
DMTGBPW IK ZZOZYGHXNQPIPS-UHFFFAOYSA-N
DMTGBPW IU 2-[2-[di(propan-2-yl)amino]ethyl]-4-methyl-2-pyridin-2-ylpentanamide
DMTGBPW CA CAS 78833-03-1
DMTGBPW DE Heart arrhythmia
DMFWC3O ID DMFWC3O
DMFWC3O DN Perillyl alcohol
DMFWC3O HS Discontinued in Phase 2
DMFWC3O SN Monoterpenes, University of Wisconsin; Perillyl alcohol, University of Wisconsin; Perillyl alcohol, WARF
DMFWC3O CP University of Wisconsin-Madison
DMFWC3O DT Small molecular drug
DMFWC3O PC 10819
DMFWC3O MW 152.23
DMFWC3O FM C10H16O
DMFWC3O IC InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3
DMFWC3O CS CC(=C)C1CCC(=CC1)CO
DMFWC3O IK NDTYTMIUWGWIMO-UHFFFAOYSA-N
DMFWC3O IU (4-prop-1-en-2-ylcyclohexen-1-yl)methanol
DMFWC3O CA CAS 536-59-4
DMFWC3O CB CHEBI:15420
DMFWC3O DE Solid tumour/cancer
DMBDPN2 ID DMBDPN2
DMBDPN2 DN PF-217830
DMBDPN2 HS Discontinued in Phase 2
DMBDPN2 SN PF-00217830; 7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DMBDPN2 CP Pfizer
DMBDPN2 DT Small molecular drug
DMBDPN2 PC 11697676
DMBDPN2 MW 430.5
DMBDPN2 FM C26H30N4O2
DMBDPN2 IC InChI=1S/C26H30N4O2/c31-24-12-10-21-11-13-25(28-26(21)27-24)32-19-4-3-14-29-15-17-30(18-16-29)23-9-5-7-20-6-1-2-8-22(20)23/h1-2,5-9,11,13H,3-4,10,12,14-19H2,(H,27,28,31)
DMBDPN2 CS C1CC(=O)NC2=C1C=CC(=N2)OCCCCN3CCN(CC3)C4=CC=CC5=CC=CC=C54
DMBDPN2 IK QGNOXTFZOLDODX-UHFFFAOYSA-N
DMBDPN2 IU 7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one
DMBDPN2 CA CAS 846032-02-8
DMBDPN2 DE Schizophrenia; Bipolar disorder
DMWYJHC ID DMWYJHC
DMWYJHC DN PF-4480682
DMWYJHC HS Discontinued in Phase 2
DMWYJHC CP Pfizer Inc
DMWYJHC DE Neuropathic pain
DM6XEQA ID DM6XEQA
DM6XEQA DN PF-610355
DM6XEQA HS Discontinued in Phase 2
DM6XEQA SN PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer
DM6XEQA CP Pfizer Inc
DM6XEQA PC 11505444
DM6XEQA MW 617.8
DM6XEQA FM C34H39N3O6S
DM6XEQA IC InChI=1S/C34H39N3O6S/c1-34(2,36-22-32(40)28-12-15-31(39)30(19-28)37-44(3,42)43)20-24-7-4-6-23(16-24)18-33(41)35-21-25-8-5-9-27(17-25)26-10-13-29(38)14-11-26/h4-17,19,32,36-40H,18,20-22H2,1-3H3,(H,35,41)/t32-/m0/s1
DM6XEQA CS CC(C)(CC1=CC=CC(=C1)CC(=O)NCC2=CC(=CC=C2)C3=CC=C(C=C3)O)NC[C@@H](C4=CC(=C(C=C4)O)NS(=O)(=O)C)O
DM6XEQA IK YPHDIMUXXABSSO-YTTGMZPUSA-N
DM6XEQA IU 2-[3-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(methanesulfonamido)phenyl]ethyl]amino]-2-methylpropyl]phenyl]-N-[[3-(4-hydroxyphenyl)phenyl]methyl]acetamide
DM6XEQA CA CAS 862541-45-5
DM6XEQA DE Chronic obstructive pulmonary disease
DMELXBQ ID DMELXBQ
DMELXBQ DN PG-530742
DMELXBQ HS Discontinued in Phase 2
DMELXBQ SN PG 116800; PG 530742; PGE 530742; PGE 7113313; PG-116800
DMELXBQ CP Pharmagenesis
DMELXBQ DT Small molecular drug
DMELXBQ PC 9848869
DMELXBQ MW 501.6
DMELXBQ FM C24H27N3O7S
DMELXBQ IC InChI=1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)
DMELXBQ CS COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(=O)O
DMELXBQ IK JAYVKNDQKXUNOJ-UHFFFAOYSA-N
DMELXBQ IU 2-[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonylamino]-6-morpholin-4-ylhex-4-ynoic acid
DMELXBQ CA CAS 291533-11-4
DMELXBQ DE Myocardial infarction; Osteoarthritis
DM2N0TO ID DM2N0TO
DM2N0TO DN Physostigmine
DM2N0TO HS Discontinued in Phase 2
DM2N0TO SN Xalieve; Acetylcholinesterase inhibitor (dry mouth), Calabar; Physostigmine (local acting gel, xerostomia); Physostigmine (buccal, xerostomia), Calabar; Physostigmine (local acting gel, xerostomia), Calabar
DM2N0TO CP Calabar AB
DM2N0TO DT Small molecular drug
DM2N0TO PC 5983
DM2N0TO MW 275.35
DM2N0TO FM C15H21N3O2
DM2N0TO IC InChI=1S/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1
DM2N0TO CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
DM2N0TO IK PIJVFDBKTWXHHD-HIFRSBDPSA-N
DM2N0TO IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate
DM2N0TO CA CAS 57-47-6
DM2N0TO CB CHEBI:27953
DM2N0TO DE Xerostomia
DMJKN0B ID DMJKN0B
DMJKN0B DN PIBROZELESIN HYDROCHLORIDE
DMJKN0B HS Discontinued in Phase 2
DMJKN0B SN KW-2189; Pibrozelesin hydrochloride < Prop INNM; 8(S)-(Bromomethyl)-2-methyl-4-(4-methylpiperazin-1-ylcarbonyloxy)-6-(5,6,7-trimethoxyindol-2-ylcarbonyl)-3,6,7,8-tetrahydrobenzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid methyl ester hydrochloride
DMJKN0B DT Small molecular drug
DMJKN0B PC 6918188
DMJKN0B MW 735
DMJKN0B FM C32H37BrClN5O8
DMJKN0B IC InChI=1S/C32H36BrN5O8.ClH/c1-16-23(31(40)45-6)25-24-18(14-33)15-38(20(24)13-21(27(25)34-16)46-32(41)37-9-7-36(2)8-10-37)30(39)19-11-17-12-22(42-3)28(43-4)29(44-5)26(17)35-19;/h11-13,18,34-35H,7-10,14-15H2,1-6H3;1H/t18-;/m1./s1
DMJKN0B CS CC1=C(C2=C3[C@@H](CN(C3=CC(=C2N1)OC(=O)N4CCN(CC4)C)C(=O)C5=CC6=CC(=C(C(=C6N5)OC)OC)OC)CBr)C(=O)OC.Cl
DMJKN0B IK LXRTZQKDZOKJRQ-GMUIIQOCSA-N
DMJKN0B IU methyl (8S)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-1-carboxylate;hydrochloride
DMJKN0B DE Solid tumour/cancer
DMA13WI ID DMA13WI
DMA13WI DN Picumeterol
DMA13WI HS Discontinued in Phase 2
DMA13WI SN Levopicumeterol; Picumeterol fumarate; GX 63411; GR-114297; GR-114297A; GR-114297X; GR-63411
DMA13WI CP Glaxo Wellcome plc
DMA13WI DT Small molecular drug
DMA13WI PC 131251
DMA13WI MW 426.4
DMA13WI FM C21H29Cl2N3O2
DMA13WI IC InChI=1S/C21H29Cl2N3O2/c22-18-13-16(14-19(23)21(18)24)20(27)15-25-9-4-1-2-6-11-28-12-8-17-7-3-5-10-26-17/h3,5,7,10,13-14,20,25,27H,1-2,4,6,8-9,11-12,15,24H2/t20-/m0/s1
DMA13WI CS C1=CC=NC(=C1)CCOCCCCCCNC[C@@H](C2=CC(=C(C(=C2)Cl)N)Cl)O
DMA13WI IK NUBLQEKABJXICM-FQEVSTJZSA-N
DMA13WI IU (1R)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol
DMA13WI CA CAS 130641-36-0
DMA13WI DE Asthma
DM3ISKB ID DM3ISKB
DM3ISKB DN PIRODAVIR
DM3ISKB HS Discontinued in Phase 2
DM3ISKB SN Pirodavir < Rec INN; R-77975; 4-[2-[1-(6-Methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]benzoic acid ethyl ester
DM3ISKB DT Small molecular drug
DM3ISKB PC 71345
DM3ISKB MW 369.5
DM3ISKB FM C21H27N3O3
DM3ISKB IC InChI=1S/C21H27N3O3/c1-3-26-21(25)18-5-7-19(8-6-18)27-15-12-17-10-13-24(14-11-17)20-9-4-16(2)22-23-20/h4-9,17H,3,10-15H2,1-2H3
DM3ISKB CS CCOC(=O)C1=CC=C(C=C1)OCCC2CCN(CC2)C3=NN=C(C=C3)C
DM3ISKB IK KCHIOGFOPPOUJC-UHFFFAOYSA-N
DM3ISKB IU ethyl 4-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]benzoate
DM3ISKB CA CAS 124436-59-5
DM3ISKB DE Virus infection
DMSQ794 ID DMSQ794
DMSQ794 DN PKI166
DMSQ794 HS Discontinued in Phase 2
DMSQ794 SN PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, > 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol
DMSQ794 DT Small molecular drug
DMSQ794 PC 6918403
DMSQ794 MW 330.4
DMSQ794 FM C20H18N4O
DMSQ794 IC InChI=1S/C20H18N4O/c1-13(14-5-3-2-4-6-14)23-19-17-11-18(24-20(17)22-12-21-19)15-7-9-16(25)10-8-15/h2-13,25H,1H3,(H2,21,22,23,24)/t13-/m1/s1
DMSQ794 CS C[C@H](C1=CC=CC=C1)NC2=NC=NC3=C2C=C(N3)C4=CC=C(C=C4)O
DMSQ794 IK XRYJULCDUUATMC-CYBMUJFWSA-N
DMSQ794 IU 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol
DMSQ794 DE Esophageal cancer
DMLK5IM ID DMLK5IM
DMLK5IM DN PNU-142633
DMLK5IM HS Discontinued in Phase 2
DMLK5IM SN PNU 142633; PNU-142633; 187665-65-2; UNII-B54P1BQ73L; B54P1BQ73L; CHEMBL441095; PNU-142633F; SCHEMBL6871704; CTK8E8481; DTXSID00431734; MolPort-023-276-296; ZINC13587959; BDBM50136471; AKOS024456892; NCGC00378553-01; 1H-2-Benzopyran-6-carboxamide, 1-(2-(4-(4-(aminocarbonyl)phenyl)-1-piperazinyl)ethyl)-3,4-dihydro-N-methyl-, (1S)-; (1S)-1-[2-[4-[4-(AMINOCARBONYL)PHENYL]-1-PIPERAZINYL]ETHYL]-3,4-DIHYDRO-N-METHYL-1H-2-BENZOPYRAN-6-CARBOXAMIDE; RT-015081; KB-275102; B6906; J-012076
DMLK5IM CP Pharmacia & Upjohn Inc
DMLK5IM DT Small molecular drug
DMLK5IM PC 9845148
DMLK5IM MW 422.5
DMLK5IM FM C24H30N4O3
DMLK5IM IC InChI=1S/C24H30N4O3/c1-26-24(30)19-4-7-21-18(16-19)9-15-31-22(21)8-10-27-11-13-28(14-12-27)20-5-2-17(3-6-20)23(25)29/h2-7,16,22H,8-15H2,1H3,(H2,25,29)(H,26,30)/t22-/m0/s1
DMLK5IM CS CNC(=O)C1=CC2=C(C=C1)[C@@H](OCC2)CCN3CCN(CC3)C4=CC=C(C=C4)C(=O)N
DMLK5IM IK PNTVCCRNJOGKGA-QFIPXVFZSA-N
DMLK5IM IU (1S)-1-[2-[4-(4-carbamoylphenyl)piperazin-1-yl]ethyl]-N-methyl-3,4-dihydro-1H-isochromene-6-carboxamide
DMLK5IM CA CAS 187665-65-2
DMLK5IM DE Migraine
DMP43IR ID DMP43IR
DMP43IR DN Pranazepide
DMP43IR HS Discontinued in Phase 2
DMP43IR SN Pranazepide; UNII-10TO0RP68C; FK 480; FK-480; 150408-73-4; FR-120480; FR 120480; CHEMBL300072; 10TO0RP68C; Panazepide; Pranazepide [INN:JAN]; NCGC00183009-01; NCGC00183006-01; Panazepide (JAN); AC1L31TI; DSSTox_RID_82980; DSSTox_CID_28711; DSSTox_GSID_48785; GTPL874; SCHEMBL2110207; DTXSID8048785; CHEBI:32039; ZINC3798924; Tox21_113262; PDSP2_000866; BDBM50290400; PDSP1_000880; N-(1-(2-Fluorophenyl)-3,4,6,7-tetrahydro-4-oxo-pyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-1H-indole-2-carboxamide; CAS-150408-73-4; D01858
DMP43IR DT Small molecular drug
DMP43IR PC 132916
DMP43IR MW 438.5
DMP43IR FM C26H19FN4O2
DMP43IR IC InChI=1S/C26H19FN4O2/c27-19-10-3-2-8-17(19)22-18-9-5-7-15-12-13-31(23(15)18)26(33)24(29-22)30-25(32)21-14-16-6-1-4-11-20(16)28-21/h1-11,14,24,28H,12-13H2,(H,30,32)/t24-/m1/s1
DMP43IR CS C1CN2C(=O)[C@H](N=C(C3=CC=CC1=C32)C4=CC=CC=C4F)NC(=O)C5=CC6=CC=CC=C6N5
DMP43IR IK WKJDXKWFGJWGAS-XMMPIXPASA-N
DMP43IR IU N-[(11S)-9-(2-fluorophenyl)-12-oxo-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]-1H-indole-2-carboxamide
DMP43IR CA CAS 150408-73-4
DMP43IR CB CHEBI:32039
DMP43IR DE Pancreatic malfunction
DM082ZW ID DM082ZW
DM082ZW DN Prednisolone sodium metazoate
DM082ZW HS Discontinued in Phase 2
DM082ZW SN Prednisolone metasulfobenzoate; Prednisolone sodium metasulfobenzoate; ATL-2502; ATL-2505; COLAL-PRED; Prednisolone sodium metazoate (COLAL); Program AZM-110; Prednisolone sodium metasulfobenzoate (COLAL), Alizyme; Prednisolone sodium metazoate (COLAL), Alizyme; Prednisolone (colonic delivery, COLAL, ulcerative colitis), Alizyme; Prednisolone (colonic delivery, COLAL, ulcerative colitis), Prometheus/TSD Japan
DM082ZW CP Alizyme
DM082ZW TC Anticancer Agents
DM082ZW DT Small molecular drug
DM082ZW PC 23675004
DM082ZW MW 566.6
DM082ZW FM C28H31NaO9S
DM082ZW IC InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1/t20-,21-,22-,24+,26-,27-,28-;/m0./s1
DM082ZW CS C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)C4=CC(=CC=C4)S(=O)(=O)[O-])O)CCC5=CC(=O)C=C[C@]35C)O.[Na+]
DM082ZW IK RWFZSORKWFPGNE-VDYYWZOJSA-M
DM082ZW IU sodium;3-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]carbonylbenzenesulfonate
DM082ZW CA CAS 630-67-1
DM082ZW DE Inflammatory bowel disease
DMLOGR3 ID DMLOGR3
DMLOGR3 DN Pro 542
DMLOGR3 HS Discontinued in Phase 2
DMLOGR3 CP Progenics
DMLOGR3 DE Human immunodeficiency virus infection
DM8U3R6 ID DM8U3R6
DM8U3R6 DN PROXODOLOL
DM8U3R6 HS Discontinued in Phase 2
DM8U3R6 SN Rac-5-[2-(3-tert-Butylamino-2-hydroxypropoxy)phenoxymethyl]-3-methyl-1,2,4-oxadiazole hydrochloride
DM8U3R6 DT Small molecular drug
DM8U3R6 PC 133046
DM8U3R6 MW 387.9
DM8U3R6 FM C17H26ClN3O5
DM8U3R6 IC InChI=1S/C17H25N3O5.ClH/c1-17(2,3)18-9-12(21)10-23-13-7-5-6-8-14(13)24-11-15-19-16(22-4)20-25-15;/h5-8,12,18,21H,9-11H2,1-4H3;1H
DM8U3R6 CS CC(C)(C)NCC(COC1=CC=CC=C1OCC2=NC(=NO2)OC)O.Cl
DM8U3R6 IK IQEOUWNTUSFDSZ-UHFFFAOYSA-N
DM8U3R6 IU 1-(tert-butylamino)-3-[2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy]propan-2-ol;hydrochloride
DM8U3R6 CA CAS 158446-41-4
DM8U3R6 DE Glaucoma/ocular hypertension
DMHDP9R ID DMHDP9R
DMHDP9R DN PRS-211375 iv
DMHDP9R HS Discontinued in Phase 2
DMHDP9R SN Cannabinor; Bicyclic cannabinoids, Pharmos; HU-308; PRS-211058; PRS-211096; PRS-211335; PRS-211359; PRS-211375; CB2-selective cannabinoid platform, Pharmos; Oral Cannabinor (pain), Pharmos; PRS-211375 (oral, pain), Pharmos; PRS-211375 (iv, inflammation/autoimmune disease), Pharmos
DMHDP9R CP Pharmos
DMHDP9R DT Small molecular drug
DMHDP9R PC 9844711
DMHDP9R MW 414.6
DMHDP9R FM C27H42O3
DMHDP9R IC InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20-,21-,22+/m0/s1
DMHDP9R CS CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)[C@H]2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
DMHDP9R IK CFMRIVODIXTERW-FDFHNCONSA-N
DMHDP9R IU [(1R,4S,5R)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl]methanol
DMHDP9R DE Pain
DMN4RV0 ID DMN4RV0
DMN4RV0 DN PRX-00023
DMN4RV0 HS Discontinued in Phase 2
DMN4RV0 SN Naluzotan; 740873-06-7; PRX-00023; UNII-LQ54E5B4EW; LQ54E5B4EW; CHEMBL209821; Naluzotan [USAN:INN]; PRX 00023; Naluzotan (USAN/INN); SCHEMBL678016; ZINC3963096; BCP20177; BDBM50187377; CS-6740; SB16847; N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide; HY-14848; AN-27536; D09358; L001689; 833C676; Acetamide, N-(3-(4-(4-(((cyclohexylmethyl)sulfonyl)amino)butyl)-1-piperazinyl)phenyl)-; N-(3-[4-(4-Cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl)acetamide
DMN4RV0 CP Epix
DMN4RV0 DT Small molecular drug
DMN4RV0 PC 11430856
DMN4RV0 MW 450.6
DMN4RV0 FM C23H38N4O3S
DMN4RV0 IC InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
DMN4RV0 CS CC(=O)NC1=CC(=CC=C1)N2CCN(CC2)CCCCNS(=O)(=O)CC3CCCCC3
DMN4RV0 IK SPWZXWDPAWDKQE-UHFFFAOYSA-N
DMN4RV0 IU N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide
DMN4RV0 CA CAS 740873-06-7
DMN4RV0 DE Mood disorder
DMT0KB1 ID DMT0KB1
DMT0KB1 DN PSD-506
DMT0KB1 HS Discontinued in Phase 2
DMT0KB1 SN Muscarinic M2 antagonists, Roche; Ro-320-2904; M2/M3 muscarinic antagonists (benign prostate hyperplasia), Roche/Plethora; M2/M3 muscarinic antagonists (overactive bladder), Roche/Plethora; M2/M3 muscarinic antagonists (urge incontinence), Roche/Plethora; M2/M3 muscarinic antagonists (urological disorders), Roche/Plethora
DMT0KB1 CP Roche Bioscience
DMT0KB1 DE Overactive bladder
DMR1OJM ID DMR1OJM
DMR1OJM DN PSD-508
DMR1OJM HS Discontinued in Phase 2
DMR1OJM SN M-5003; Dysmenorrhea therapy (intravaginal), Metris/Plethora; Intravaginal NSAID (dysmenorrhea), Plethora Solutions/Metris
DMR1OJM CP Metris Therapeutics Ltd
DMR1OJM DE Dysmenorrhea
DMDOFE7 ID DMDOFE7
DMDOFE7 DN PSN357
DMDOFE7 HS Discontinued in Phase 2
DMDOFE7 SN SCHEMBL2607197
DMDOFE7 CP OSI Pharma
DMDOFE7 DT Small molecular drug
DMDOFE7 PC 56603686
DMDOFE7 MW 501
DMDOFE7 FM C25H30ClFN6O2
DMDOFE7 IC InChI=1S/C25H30ClFN6O2/c1-31(2)7-8-32-9-11-33(12-10-32)25(35)21(13-17-3-5-19(27)6-4-17)30-24(34)20-14-18-15-23(26)28-16-22(18)29-20/h3-6,14-16,21,29H,7-13H2,1-2H3,(H,30,34)/t21-/m0/s1
DMDOFE7 CS CN(C)CCN1CCN(CC1)C(=O)[C@H](CC2=CC=C(C=C2)F)NC(=O)C3=CC4=CC(=NC=C4N3)Cl
DMDOFE7 IK RDFYSUFNGGYNSK-NRFANRHFSA-N
DMDOFE7 IU 5-chloro-N-[(2S)-1-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-3-(4-fluorophenyl)-1-oxopropan-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
DMDOFE7 DE Type-2 diabetes
DMMF9RS ID DMMF9RS
DMMF9RS DN PSN-9301
DMMF9RS HS Discontinued in Phase 2
DMMF9RS SN P93/01; DPP-IV inhibitor (type 2 diabetes), Probiodrug; Dipeptidyl peptidase IV inhibitor (type 2 diabetes), (OSI) Prosidion; DPP-IV inhibitor (type 2 diabetes), (OSI) Prosidion
DMMF9RS CP OSI Pharmaceuticals
DMMF9RS DE Diabetic complication
DMYM9JL ID DMYM9JL
DMYM9JL DN PT-14
DMYM9JL HS Discontinued in Phase 2
DMYM9JL SN Erectide; PT-14 (transmucosal); PT-14 (transmucosal), Palatin/TheraTech
DMYM9JL CP Competitive Technologies Inc
DMYM9JL PC 6875
DMYM9JL MW 248.32
DMYM9JL FM C14H20N2O2
DMYM9JL IC InChI=1S/C14H20N2O2/c15-13-7-2-1-6-12(13)14(17)18-10-8-11-5-3-4-9-16-11/h1-2,6-7,11,16H,3-5,8-10,15H2
DMYM9JL CS C1CCNC(C1)CCOC(=O)C2=CC=CC=C2N
DMYM9JL IK BMIJYAZXNZEMLI-UHFFFAOYSA-N
DMYM9JL IU 2-piperidin-2-ylethyl 2-aminobenzoate
DMYM9JL CA CAS 87-21-8
DMYM9JL CB CHEBI:135011
DMYM9JL DE Erectile dysfunction
DMGO2AV ID DMGO2AV
DMGO2AV DN PTI-701
DMGO2AV HS Discontinued in Phase 2
DMGO2AV SN Hydrocodone + acetaminophen + naltrexone
DMGO2AV CP Pain Therapeutics
DMGO2AV DE Pain
DMI8T41 ID DMI8T41
DMI8T41 DN Pumafentrine
DMI8T41 HS Discontinued in Phase 2
DMI8T41 SN Pumafentrin; BY-343; BYK-33043
DMI8T41 CP ALTANA Pharma AG
DMI8T41 DT Small molecular drug
DMI8T41 PC 3052763
DMI8T41 MW 477.6
DMI8T41 FM C29H39N3O3
DMI8T41 IC InChI=1S/C29H39N3O3/c1-8-35-27-15-22-23(16-26(27)34-7)28(30-25-13-14-31(6)17-24(22)25)20-9-11-21(12-10-20)29(33)32(18(2)3)19(4)5/h9-12,15-16,18-19,24-25H,8,13-14,17H2,1-7H3/t24-,25-/m1/s1
DMI8T41 CS CCOC1=C(C=C2C(=C1)[C@H]3CN(CC[C@H]3N=C2C4=CC=C(C=C4)C(=O)N(C(C)C)C(C)C)C)OC
DMI8T41 IK CVDXFPBVOIERBH-JWQCQUIFSA-N
DMI8T41 IU 4-[(4aR,10bS)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-yl]-N,N-di(propan-2-yl)benzamide
DMI8T41 CA CAS 207993-12-2
DMI8T41 DE Asthma
DMWE6V1 ID DMWE6V1
DMWE6V1 DN Putrescine
DMWE6V1 HS Discontinued in Phase 2
DMWE6V1 SN putrescine; 1,4-diaminobutane; 1,4-butanediamine; butane-1,4-diamine; 110-60-1; tetramethylenediamine; Butylenediamine; Putrescin; 1,4-Butylenediamine; Tetramethyldiamine; 1,4-Tetramethylenediamine; putrescina; Putreszin; Tetramethylendiamin; UNII-V10TVZ52E4; NSC 60545; BRN 0605282; H2N(CH2)4NH2; CCRIS 6751; AI3-25444; 1,4-Diamino-n-butane; EINECS 203-782-3; 1,4-Diaminobutane, 99%; CHEMBL46257; V10TVZ52E4; CHEBI:17148; KIDHWZJUCRJVML-UHFFFAOYSA-N; MFCD00008235; 1,4-butanediammonium; Diaminobutane dihydrochloride; PUT; HSDB 7865
DMWE6V1 DT Small molecular drug
DMWE6V1 PC 1045
DMWE6V1 MW 88.15
DMWE6V1 FM C4H12N2
DMWE6V1 IC InChI=1S/C4H12N2/c5-3-1-2-4-6/h1-6H2
DMWE6V1 CS C(CCN)CN
DMWE6V1 IK KIDHWZJUCRJVML-UHFFFAOYSA-N
DMWE6V1 IU butane-1,4-diamine
DMWE6V1 CA CAS 110-60-1
DMWE6V1 CB CHEBI:17148
DMWE6V1 DE Burn and burn infection
DMRODZS ID DMRODZS
DMRODZS DN PV-707
DMRODZS HS Discontinued in Phase 2
DMRODZS CP Novozymes GroPep Limited
DMRODZS DE Skin burns
DMD308S ID DMD308S
DMD308S DN Pyrazinoylguanidine
DMD308S HS Discontinued in Phase 2
DMD308S SN PZG
DMD308S CP Sparta Pharmaceuticals Inc
DMD308S PC 124704
DMD308S MW 165.15
DMD308S FM C6H7N5O
DMD308S IC InChI=1S/C6H7N5O/c7-6(8)11-5(12)4-3-9-1-2-10-4/h1-3H,(H4,7,8,11,12)
DMD308S CS C1=CN=C(C=N1)C(=O)N=C(N)N
DMD308S IK WNBSDCKJFDZMHT-UHFFFAOYSA-N
DMD308S IU N-(diaminomethylidene)pyrazine-2-carboxamide
DMD308S CA CAS 60398-24-5
DMD308S DE Diabetic complication
DMTGFV6 ID DMTGFV6
DMTGFV6 DN PYY3-36
DMTGFV6 HS Discontinued in Phase 2
DMTGFV6 CP Nastech; Merck
DMTGFV6 DE Obesity
DM2Q5IS ID DM2Q5IS
DM2Q5IS DN R-1438
DM2Q5IS HS Discontinued in Phase 2
DM2Q5IS CP Roche
DM2Q5IS DE Type-2 diabetes
DMAPRGQ ID DMAPRGQ
DMAPRGQ DN R-1578
DMAPRGQ HS Discontinued in Phase 2
DMAPRGQ SN MGluR2 antagonist (depression), Roche; MGluR2 antagonist (Alzheimer's disease/depression), Roche
DMAPRGQ CP Abiocode; Hoffmann-La Roche AG
DMAPRGQ DE Mood disorder
DMGVRQ2 ID DMGVRQ2
DMGVRQ2 DN R-18893
DMGVRQ2 HS Discontinued in Phase 2
DMGVRQ2 CP Janssen Pharmaceutica NV
DMGVRQ2 PC 486457
DMGVRQ2 MW 340.2
DMGVRQ2 FM C14H11Cl2N3O3
DMGVRQ2 IC InChI=1S/C14H11Cl2N3O3/c15-8-4-3-5-9(16)12(8)13(14(17)20)18-10-6-1-2-7-11(10)19(21)22/h1-7,13,18H,(H2,17,20)
DMGVRQ2 CS C1=CC=C(C(=C1)NC(C2=C(C=CC=C2Cl)Cl)C(=O)N)[N+](=O)[O-]
DMGVRQ2 IK BSFPWNBIKBSHRL-UHFFFAOYSA-N
DMGVRQ2 IU 2-(2,6-dichlorophenyl)-2-(2-nitroanilino)acetamide
DMGVRQ2 DE Human immunodeficiency virus infection
DMEJNM1 ID DMEJNM1
DMEJNM1 DN R-343
DMEJNM1 HS Discontinued in Phase 2
DMEJNM1 SN R-921303; Syk tyrosine kinase inhibitor (allergic asthma), Rigel/Pfizer
DMEJNM1 CP Rigel Pharmaceuticals Inc
DMEJNM1 DT Small molecular drug
DMEJNM1 PC 10344820
DMEJNM1 MW 474.4
DMEJNM1 FM C21H17F3N6O4
DMEJNM1 IC InChI=1S/C21H17F3N6O4/c1-25-17(31)10-33-13-4-2-3-11(7-13)28-20-26-9-14(22)18(30-20)27-12-5-6-16-15(8-12)29-19(32)21(23,24)34-16/h2-9H,10H2,1H3,(H,25,31)(H,29,32)(H2,26,27,28,30)
DMEJNM1 CS CNC(=O)COC1=CC=CC(=C1)NC2=NC=C(C(=N2)NC3=CC4=C(C=C3)OC(C(=O)N4)(F)F)F
DMEJNM1 IK MOXXQFNQDDSJHT-UHFFFAOYSA-N
DMEJNM1 IU 2-[3-[[4-[(2,2-difluoro-3-oxo-4H-1,4-benzoxazin-6-yl)amino]-5-fluoropyrimidin-2-yl]amino]phenoxy]-N-methylacetamide
DMEJNM1 DE Asthma
DM5NWPD ID DM5NWPD
DM5NWPD DN R-568
DM5NWPD HS Discontinued in Phase 2
DM5NWPD SN Tecalcet; Tecalcet [INN]; NPS-R-568; UNII-8I16YLE4US; R 568; NPS R 568; NPS R-568; 148717-54-8; 8I16YLE4US; CHEMBL292376; (R)-2-Chloro-N-(1-(3-methoxyphenyl)ethyl)benzenepropanamine; Benzenepropanamine, 2-chloro-N-(1-(3-methoxyphenyl)ethyl)-, (R)-; 3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine; AC1L4KMU; GTPL718; SCHEMBL311950; NPS R568; DTXSID90164084; ZVQUCWXZCKWZBP-CQSZACIVSA-N; ZINC1538900; BDBM50432960; BDBM50299670; NCGC00344508-01; LS-31029; KB-80823
DM5NWPD DT Small molecular drug
DM5NWPD PC 158796
DM5NWPD MW 340.3
DM5NWPD FM C18H23Cl2NO
DM5NWPD IC InChI=1S/C18H22ClNO.ClH/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19;/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3;1H/t14-;/m1./s1
DM5NWPD CS C[C@H](C1=CC(=CC=C1)OC)NCCCC2=CC=CC=C2Cl.Cl
DM5NWPD IK YJXUXANREVNZLH-PFEQFJNWSA-N
DM5NWPD IU 3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine;hydrochloride
DM5NWPD CA CAS 177172-49-5
DMJTOP8 ID DMJTOP8
DMJTOP8 DN R-61837
DMJTOP8 HS Discontinued in Phase 2
DMJTOP8 SN 3-Methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine
DMJTOP8 DT Small molecular drug
DMJTOP8 PC 127504
DMJTOP8 MW 284.36
DMJTOP8 FM C16H20N4O
DMJTOP8 IC InChI=1S/C16H20N4O/c1-13-4-3-5-14(12-13)19-8-10-20(11-9-19)15-6-7-16(21-2)18-17-15/h3-7,12H,8-11H2,1-2H3
DMJTOP8 CS CC1=CC(=CC=C1)N2CCN(CC2)C3=NN=C(C=C3)OC
DMJTOP8 IK DDOAUTHWSCUHQA-UHFFFAOYSA-N
DMJTOP8 IU 3-methoxy-6-[4-(3-methylphenyl)piperazin-1-yl]pyridazine
DMJTOP8 CA CAS 100241-46-1
DMJTOP8 DE Virus infection
DM2NTJY ID DM2NTJY
DM2NTJY DN R-68151
DM2NTJY HS Discontinued in Phase 2
DM2NTJY SN 1-Ethyl-3-{4-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-phenyl}-5,5-dimethyl-2-thioxo-imidazolidin-4-one; 5-Lipoxygenase-In-1; R 68151; CHEMBL85599; 138331-04-1; AC1L30HG; SCHEMBL13696698; DTXSID10160583; BDBM50006793; HY-U00308; CS-7300; (1-Ethyl-3(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-dimethyl)-2-thioxo-4-imidazolidinone; 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one; M55551
DM2NTJY DT Small molecular drug
DM2NTJY PC 132150
DM2NTJY MW 424.6
DM2NTJY FM C23H28N4O2S
DM2NTJY IC InChI=1S/C23H28N4O2S/c1-4-26-22(30)27(21(29)23(26,2)3)19-7-5-17(6-8-19)24-13-15-25(16-14-24)18-9-11-20(28)12-10-18/h5-12,28H,4,13-16H2,1-3H3
DM2NTJY CS CCN1C(=S)N(C(=O)C1(C)C)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)O
DM2NTJY IK AHWDHLCCXRVAIC-UHFFFAOYSA-N
DM2NTJY IU 1-ethyl-3-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]-5,5-dimethyl-2-sulfanylideneimidazolidin-4-one
DM2NTJY CA CAS 138331-04-1
DM2NTJY DE Psoriasis vulgaris
DM9BI3Y ID DM9BI3Y
DM9BI3Y DN R7128
DM9BI3Y HS Discontinued in Phase 2
DM9BI3Y SN R-4048; R-7128; RG-7128; RO-5024048
DM9BI3Y CP Roche
DM9BI3Y DT Small molecular drug
DM9BI3Y PC 16122663
DM9BI3Y MW 399.4
DM9BI3Y FM C18H26FN3O6
DM9BI3Y IC InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1
DM9BI3Y CS CC(C)C(=O)OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C
DM9BI3Y IK MLESJYFEMSJZLZ-MAAOGQSESA-N
DM9BI3Y IU [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
DM9BI3Y CA CAS 940908-79-2
DM9BI3Y DE Hepatitis C virus infection
DM4O7KA ID DM4O7KA
DM4O7KA DN R-84760
DM4O7KA HS Discontinued in Phase 2
DM4O7KA SN R-84760; R-84761; R-86436; R 86428; R 84761; R-86428; R 86436; R 84760; 3-(1-Pyrrolidinylmethyl)-4-(5,6-dichloro-1-indancarbonyl)-tetrahydro-1,4-thiazine hydrochloride; Thiomorpholine, 4-((5,6-dichloro-2,3-dihydro-1H-inden-1-yl)carbonyl)-3-(1-pyrrolidinylmethyl)-, monohydrochloride, (R-(R*,S*))-; C19H24Cl2N2OS.HCl; 157824-23-2; AC1L3220; LS-173526; [(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]-[(3R)-3-(pyrrolidin-1-ylmethyl)thiomorpholin-4-yl]methanone hydrochloride
DM4O7KA CP Sankyo Co Ltd
DM4O7KA DT Small molecular drug
DM4O7KA PC 133035
DM4O7KA MW 435.8
DM4O7KA FM C19H25Cl3N2OS
DM4O7KA IC InChI=1S/C19H24Cl2N2OS.ClH/c20-17-9-13-3-4-15(16(13)10-18(17)21)19(24)23-7-8-25-12-14(23)11-22-5-1-2-6-22;/h9-10,14-15H,1-8,11-12H2;1H/t14-,15+;/m1./s1
DM4O7KA CS C1CCN(C1)C[C@@H]2CSCCN2C(=O)[C@H]3CCC4=CC(=C(C=C34)Cl)Cl.Cl
DM4O7KA IK KSUNRZWFIKXTKO-LIOBNPLQSA-N
DM4O7KA IU [(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]-[(3R)-3-(pyrrolidin-1-ylmethyl)thiomorpholin-4-yl]methanone;hydrochloride
DM4O7KA CA CAS 157824-23-2
DM4O7KA DE Pain
DMDOETQ ID DMDOETQ
DMDOETQ DN R-873
DMDOETQ HS Discontinued in Phase 2
DMDOETQ CP Roche Holding AG
DMDOETQ DE Erectile dysfunction
DMRZI3C ID DMRZI3C
DMRZI3C DN R-87366
DMRZI3C HS Discontinued in Phase 2
DMRZI3C SN Quinoxalin-2-ylcarbonyl-L-asparaginyl-[3(S)-amino-2(S)-hydroxy-4-phenylbutyryl]-L-proline tert-butylamide
DMRZI3C DT Small molecular drug
DMRZI3C PC 464206
DMRZI3C MW 617.7
DMRZI3C FM C32H39N7O6
DMRZI3C IC InChI=1S/C32H39N7O6/c1-32(2,3)38-30(44)25-14-9-15-39(25)31(45)27(41)22(16-19-10-5-4-6-11-19)36-28(42)23(17-26(33)40)37-29(43)24-18-34-20-12-7-8-13-21(20)35-24/h4-8,10-13,18,22-23,25,27,41H,9,14-17H2,1-3H3,(H2,33,40)(H,36,42)(H,37,43)(H,38,44)/t22-,23-,25-,27-/m0/s1
DMRZI3C CS CC(C)(C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)C3=NC4=CC=CC=C4N=C3)O
DMRZI3C IK UYZMZENNYRSFDS-QNWDWTFCSA-N
DMRZI3C IU (2S)-N-[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]-2-(quinoxaline-2-carbonylamino)butanediamide
DMRZI3C CA CAS 144779-91-9
DMRZI3C DE Human immunodeficiency virus infection
DMARQE0 ID DMARQE0
DMARQE0 DN Radafaxine
DMARQE0 HS Discontinued in Phase 2
DMARQE0 SN Hydroxybupropion
DMARQE0 CP GlaxoSmithKline
DMARQE0 DT Small molecular drug
DMARQE0 PC 9795056
DMARQE0 MW 255.74
DMARQE0 FM C13H18ClNO2
DMARQE0 IC InChI=1S/C13H18ClNO2/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3/t9-,13+/m0/s1
DMARQE0 CS C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O
DMARQE0 IK RCOBKSKAZMVBHT-TVQRCGJNSA-N
DMARQE0 IU (2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
DMARQE0 CA CAS 192374-14-4
DMARQE0 DE Major depressive disorder
DMI1SXB ID DMI1SXB
DMI1SXB DN Rafabegron
DMI1SXB HS Discontinued in Phase 2
DMI1SXB SN AD-9677; AJ-9677; TAK-677
DMI1SXB CP Dainippon Pharmaceutical Co Ltd
DMI1SXB DT Small molecular drug
DMI1SXB PC 5493324
DMI1SXB MW 402.9
DMI1SXB FM C21H23ClN2O4
DMI1SXB IC InChI=1S/C21H23ClN2O4/c1-13(23-11-18(25)14-4-2-5-16(22)9-14)8-15-10-24-21-17(15)6-3-7-19(21)28-12-20(26)27/h2-7,9-10,13,18,23-25H,8,11-12H2,1H3,(H,26,27)/t13-,18+/m1/s1
DMI1SXB CS C[C@H](CC1=CNC2=C1C=CC=C2OCC(=O)O)NC[C@@H](C3=CC(=CC=C3)Cl)O
DMI1SXB IK FHEYFIGWYQJVDR-ACJLOTCBSA-N
DMI1SXB IU 2-[[3-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yl]oxy]acetic acid
DMI1SXB CA CAS 244081-42-3
DMI1SXB DE Type-2 diabetes
DMYSADI ID DMYSADI
DMYSADI DN RBx10558
DMYSADI HS Discontinued in Phase 2
DMYSADI CP PPD Wilmington
DMYSADI DE Hyperlipidaemia
DM7OD3J ID DM7OD3J
DM7OD3J DN RBx-2258
DM7OD3J HS Discontinued in Phase 2
DM7OD3J SN Pamirosin; Parvosin; SPM-969
DM7OD3J CP Ranbaxy Laboratories Ltd
DM7OD3J DE Prostate hyperplasia
DMIEFH0 ID DMIEFH0
DMIEFH0 DN REC-15/3079
DMIEFH0 HS Discontinued in Phase 2
DMIEFH0 SN REC-3079; 5 HT1A antagonist, Recordati
DMIEFH0 CP Recordati SpA
DMIEFH0 DT Small molecular drug
DMIEFH0 PC 9847377
DMIEFH0 MW 466.6
DMIEFH0 FM C26H34N4O4
DMIEFH0 IC InChI=1S/C26H34N4O4/c1-34-25-14-8-7-13-24(25)28-18-15-27(16-19-28)17-20-29(26(31)21-9-3-2-4-10-21)22-11-5-6-12-23(22)30(32)33/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3
DMIEFH0 CS COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=C3[N+](=O)[O-])C(=O)C4CCCCC4
DMIEFH0 IK HVMKWKIPLGPYAR-UHFFFAOYSA-N
DMIEFH0 IU N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-nitrophenyl)cyclohexanecarboxamide
DMIEFH0 DE Urinary incontinence
DMX4ZWK ID DMX4ZWK
DMX4ZWK DN REC-15-2739
DMX4ZWK HS Discontinued in Phase 2
DMX4ZWK SN Upidosin; UPIDOSIN; Rec-15-2739; 152735-23-4; UNII-TXG28R7G4Y; TXG28R7G4Y; CHEMBL278865; 4H-1-Benzopyran-8-carboxamide,N-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]-3-methyl-4-oxo-2-phenyl-; Upidosin [INN]; N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide; SB 216469-S; Rec 15-2739; ACMC-20n6iu; AC1L3XX2; GTPL496; SCHEMBL6638869; CTK4C7558; DTXSID70165115; Rec 15/2739; ZINC3796141; BDBM50057465; AKOS030553705; SB 216469; L000508; SB-216469; REC-15-2869; REC-15-3011; REC-22/009
DMX4ZWK CP Recordati SpA
DMX4ZWK DT Small molecular drug
DMX4ZWK PC 148842
DMX4ZWK MW 511.6
DMX4ZWK FM C31H33N3O4
DMX4ZWK IC InChI=1S/C31H33N3O4/c1-22-28(35)24-12-8-13-25(30(24)38-29(22)23-10-4-3-5-11-23)31(36)32-16-9-17-33-18-20-34(21-19-33)26-14-6-7-15-27(26)37-2/h3-8,10-15H,9,16-21H2,1-2H3,(H,32,36)
DMX4ZWK CS CC1=C(OC2=C(C1=O)C=CC=C2C(=O)NCCCN3CCN(CC3)C4=CC=CC=C4OC)C5=CC=CC=C5
DMX4ZWK IK DUCNHKDCVVSJLG-UHFFFAOYSA-N
DMX4ZWK IU N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide
DMX4ZWK CA CAS 152735-23-4
DMX4ZWK DE Prostate disease
DMIN73Y ID DMIN73Y
DMIN73Y DN Reglixane
DMIN73Y HS Discontinued in Phase 2
DMIN73Y CP Pfizer
DMIN73Y DE Diabetic complication
DMLJEFH ID DMLJEFH
DMLJEFH DN Relacatib
DMLJEFH HS Discontinued in Phase 2
DMLJEFH SN GSK-462795; SB-462795; Azepan-3-one compound 10; Relacatib (USAN/INN); N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
DMLJEFH CP GlaxoSmithKline
DMLJEFH DT Small molecular drug
DMLJEFH PC 6918602
DMLJEFH MW 540.6
DMLJEFH FM C27H32N4O6S
DMLJEFH IC InChI=1S/C27H32N4O6S/c1-17(2)14-21(30-27(34)24-15-19-8-4-5-9-23(19)37-24)26(33)29-20-12-11-18(3)31(16-22(20)32)38(35,36)25-10-6-7-13-28-25/h4-10,13,15,17-18,20-21H,11-12,14,16H2,1-3H3,(H,29,33)(H,30,34)/t18-,20+,21+/m1/s1
DMLJEFH CS C[C@@H]1CC[C@@H](C(=O)CN1S(=O)(=O)C2=CC=CC=N2)NC(=O)[C@H](CC(C)C)NC(=O)C3=CC4=CC=CC=C4O3
DMLJEFH IK BWYBBMQLUKXECQ-GIVPXCGWSA-N
DMLJEFH IU N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
DMLJEFH CA CAS 362505-84-8
DMLJEFH DE Osteoporosis; Bone metastases
DMHCBQS ID DMHCBQS
DMHCBQS DN ReN-1869
DMHCBQS HS Discontinued in Phase 2
DMHCBQS SN Neurin project, ReNeuron; ReN-0189; NNC-05-1869; NNC-47-0189
DMHCBQS CP Novo Nordisk Pharmaceuticals Ltd
DMHCBQS PC 9799039
DMHCBQS MW 361.5
DMHCBQS FM C24H27NO2
DMHCBQS IC InChI=1S/C24H27NO2/c26-24(27)20-9-5-15-25(17-20)16-6-12-23-21-10-3-1-7-18(21)13-14-19-8-2-4-11-22(19)23/h1-4,7-8,10-12,20H,5-6,9,13-17H2,(H,26,27)/t20-/m1/s1
DMHCBQS CS C1C[C@H](CN(C1)CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42)C(=O)O
DMHCBQS IK RXWDEUWOJGGNHU-HXUWFJFHSA-N
DMHCBQS IU (3R)-1-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propyl]piperidine-3-carboxylic acid
DMHCBQS DE Pain
DMSOALX ID DMSOALX
DMSOALX DN Repifermin
DMSOALX HS Discontinued in Phase 2
DMSOALX SN FGF 10; FGF-10, HGS; Fibroblast growth factor-10, HGS; KGF-2, HGS; KGF-2D33, HGS; Keratinocyte growth factor-2, HGS; S69-S208, HGS
DMSOALX CP Human Genome Sciences Inc
DMSOALX DE Oral mucositis
DM3EAYN ID DM3EAYN
DM3EAYN DN RESEQUINIL
DM3EAYN HS Discontinued in Phase 2
DM3EAYN SN AVE-3933; SX-3933; Resequinil; 5-(3-Methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one
DM3EAYN DT Small molecular drug
DM3EAYN PC 135418404
DM3EAYN MW 334.3
DM3EAYN FM C18H14N4O3
DM3EAYN IC InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23)
DM3EAYN CS CC1=NC(=NO1)C2=CC3=C(C=CN=C3C4=CC(=CC=C4)OC)NC2=O
DM3EAYN IK JQOFKKWHXGQABB-UHFFFAOYSA-N
DM3EAYN IU 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1H-1,6-naphthyridin-2-one
DM3EAYN CA CAS 219846-31-8
DM3EAYN DE Epilepsy
DM3TU7D ID DM3TU7D
DM3TU7D DN RG1578
DM3TU7D HS Discontinued in Phase 2
DM3TU7D CP Roche
DM3TU7D DE Major depressive disorder
DM5KJGB ID DM5KJGB
DM5KJGB DN RG7160
DM5KJGB HS Discontinued in Phase 2
DM5KJGB CP Roche
DM5KJGB DE Metastatic colorectal cancer
DMCQRS2 ID DMCQRS2
DMCQRS2 DN RG7414
DMCQRS2 HS Discontinued in Phase 2
DMCQRS2 CP Genentech
DMCQRS2 DE Non-small-cell lung cancer; Colorectal cancer
DM32IV4 ID DM32IV4
DM32IV4 DN RG7593
DM32IV4 HS Discontinued in Phase 2
DM32IV4 CP Seattle Genetics; Roche
DM32IV4 DE Haematological malignancy
DMPQC18 ID DMPQC18
DMPQC18 DN RG7685
DMPQC18 HS Discontinued in Phase 2
DMPQC18 CP Roche
DMPQC18 DE Type-2 diabetes
DMI1XQ9 ID DMI1XQ9
DMI1XQ9 DN RG7697
DMI1XQ9 HS Discontinued in Phase 2
DMI1XQ9 CP Roche
DMI1XQ9 DE Type-2 diabetes
DMQ4IKZ ID DMQ4IKZ
DMQ4IKZ DN RHIZOXIN
DMQ4IKZ HS Discontinued in Phase 2
DMQ4IKZ SN 90996-54-6; Rhizoxin from Rhizopus sp.
DMQ4IKZ DT Small molecular drug
DMQ4IKZ PC 6437358
DMQ4IKZ MW 625.7
DMQ4IKZ FM C35H47NO9
DMQ4IKZ IC InChI=1S/C35H47NO9/c1-19(13-25-18-41-23(5)36-25)9-8-10-21(3)32(40-7)22(4)27-17-29(37)35(6)30(45-35)12-11-20(2)26-14-24(16-31(38)42-26)15-28-33(43-28)34(39)44-27/h8-13,18,20,22,24,26-30,32-33,37H,14-17H2,1-7H3/b9-8+,12-11+,19-13+,21-10+/t20-,22+,24+,26-,27+,28+,29+,30-,32+,33-,35-/m1/s1
DMQ4IKZ CS C[C@@H]1/C=C/[C@@H]2[C@](O2)([C@H](C[C@H](OC(=O)[C@H]3[C@@H](O3)C[C@@H]4C[C@H]1OC(=O)C4)[C@H](C)[C@H](/C(=C/C=C/C(=C/C5=COC(=N5)C)/C)/C)OC)O)C
DMQ4IKZ IK OWPCHSCAPHNHAV-QIPOKPRISA-N
DMQ4IKZ IU (1S,3S,5R,8S,10S,11R,13R,14E,16R,17R)-10-hydroxy-8-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-11,16-dimethyl-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-ene-6,19-dione
DMQ4IKZ CA CAS 90996-54-6
DMQ4IKZ CB CHEBI:72590
DMQ4IKZ DE Breast cancer
DMD8ZSW ID DMD8ZSW
DMD8ZSW DN Rilotumumab
DMD8ZSW HS Discontinued in Phase 2
DMD8ZSW CP Amgen
DMD8ZSW DT Antibody
DMD8ZSW DE Grade IV malignant glioma
DME5MGP ID DME5MGP
DME5MGP DN RIPISARTAN
DME5MGP HS Discontinued in Phase 2
DME5MGP SN Ripisartan; UP-269-6; 5-Methyl-7-propyl-8-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1,2,4-triazolo[1,5-c]pyrimidin-2(3H)-one
DME5MGP DT Small molecular drug
DME5MGP PC 132840
DME5MGP MW 426.5
DME5MGP FM C23H22N8O
DME5MGP IC InChI=1S/C23H22N8O/c1-3-6-20-19(22-25-23(32)28-31(22)14(2)24-20)13-15-9-11-16(12-10-15)17-7-4-5-8-18(17)21-26-29-30-27-21/h4-5,7-12H,3,6,13H2,1-2H3,(H,28,32)(H,26,27,29,30)
DME5MGP CS CCCC1=C(C2=NC(=O)NN2C(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DME5MGP IK OLJAPHMBAMBVKL-UHFFFAOYSA-N
DME5MGP IU 5-methyl-7-propyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-[1,2,4]triazolo[1,5-c]pyrimidin-2-one
DME5MGP CA CAS 148504-51-2
DME5MGP DE Hypertension
DMNRGB7 ID DMNRGB7
DMNRGB7 DN Risotilide
DMNRGB7 HS Discontinued in Phase 2
DMNRGB7 SN Risotilide hydrochloride; WY-48986
DMNRGB7 CP Wyeth
DMNRGB7 DT Small molecular drug
DMNRGB7 PC 60667
DMNRGB7 MW 377.5
DMNRGB7 FM C15H27N3O4S2
DMNRGB7 IC InChI=1S/C15H27N3O4S2/c1-12(2)16-10-11-18(13(3)4)24(21,22)15-8-6-14(7-9-15)17-23(5,19)20/h6-9,12-13,16-17H,10-11H2,1-5H3
DMNRGB7 CS CC(C)NCCN(C(C)C)S(=O)(=O)C1=CC=C(C=C1)NS(=O)(=O)C
DMNRGB7 IK GLIRXHQYWRYQDV-UHFFFAOYSA-N
DMNRGB7 IU 4-(methanesulfonamido)-N-propan-2-yl-N-[2-(propan-2-ylamino)ethyl]benzenesulfonamide
DMNRGB7 CA CAS 120688-08-6
DMNRGB7 DE Heart arrhythmia
DMVHT6F ID DMVHT6F
DMVHT6F DN Rispenzepine
DMVHT6F HS Discontinued in Phase 2
DMVHT6F SN Nuvenzepine; DF-545
DMVHT6F CP Merck & Co Inc
DMVHT6F DT Small molecular drug
DMVHT6F PC 129505
DMVHT6F MW 336.4
DMVHT6F FM C19H20N4O2
DMVHT6F IC InChI=1S/C19H20N4O2/c1-22-11-5-6-13(12-22)19(25)23-16-9-3-2-8-15(16)21-18(24)14-7-4-10-20-17(14)23/h2-4,7-10,13H,5-6,11-12H2,1H3,(H,21,24)
DMVHT6F CS CN1CCCC(C1)C(=O)N2C3=CC=CC=C3NC(=O)C4=C2N=CC=C4
DMVHT6F IK LPLNSPKKMWHFAU-UHFFFAOYSA-N
DMVHT6F IU 11-(1-methylpiperidine-3-carbonyl)-6H-pyrido[3,2-c][1,5]benzodiazepin-5-one
DMVHT6F CA CAS 96449-05-7
DMVHT6F DE Chronic obstructive pulmonary disease
DMOZEN6 ID DMOZEN6
DMOZEN6 DN RJR-2403
DMOZEN6 HS Discontinued in Phase 2
DMOZEN6 SN Metanicotine; Rivanicline; RJR-2403; Trans-metanicotine; 15585-43-0; Rivanicline [INN]; 538-79-4; (E)-Metanicotine; UNII-6H35LF645A; NSC 66331; 3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-; TC-2403; AI3-18211; CHEMBL132966; 6H35LF645A; (3E)-N-Methyl-4-(pyridin-3-yl)but-3-en-1-amine; But-3-en-1-amine, N-methyl-4-(pyridin-3-yl)-, (E)-; Pyridine, 3-(4-(methylamino)-1-butenyl)-; (E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine; (3E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine
DMOZEN6 DT Small molecular drug
DMOZEN6 PC 5310967
DMOZEN6 MW 162.23
DMOZEN6 FM C10H14N2
DMOZEN6 IC InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3/b5-2+
DMOZEN6 CS CNCC/C=C/C1=CN=CC=C1
DMOZEN6 IK JUOSGGQXEBBCJB-GORDUTHDSA-N
DMOZEN6 IU (E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine
DMOZEN6 CA CAS 15585-43-0
DMOZEN6 DE Cognitive impairment
DMHSUQ1 ID DMHSUQ1
DMHSUQ1 DN R-ketoprofen
DMHSUQ1 HS Discontinued in Phase 2
DMHSUQ1 SN (R)-Ketoprofen; 56105-81-8; (R)-Ketoprophen; UNII-S03709D0TH; (R)-(-)-Ketoprofen; (R)-2-(3-benzoylphenyl)propanoic acid; CHEMBL372052; S03709D0TH; (R)-2-(3-Benzoylphenyl)propionic acid; Benzeneacetic acid,3-benzoyl-a-methyl-, (aR)-; Ketoprofen, (R)-; NCGC00016757-01; CAS-22071-15-4; (2R)-2-(3-benzoylphenyl)propanoic acid; Lopac-K-1751; SCHEMBL195303; ZINC2272; AC1L47D6; CTK5A4646; DTXSID50204652; DKYWVDODHFEZIM-LLVKDONJSA-N; BDBM50169048; AKOS022182275
DMHSUQ1 DT Small molecular drug
DMHSUQ1 PC 180540
DMHSUQ1 MW 254.28
DMHSUQ1 FM C16H14O3
DMHSUQ1 IC InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m1/s1
DMHSUQ1 CS C[C@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
DMHSUQ1 IK DKYWVDODHFEZIM-LLVKDONJSA-N
DMHSUQ1 IU (2R)-2-(3-benzoylphenyl)propanoic acid
DMHSUQ1 CA CAS 56105-81-8
DM5P1KQ ID DM5P1KQ
DM5P1KQ DN RN6G
DM5P1KQ HS Discontinued in Phase 2
DM5P1KQ SN PF-04382923; PF-4382923
DM5P1KQ CP Pfizer
DM5P1KQ DE Age-related macular degeneration
DME9V0I ID DME9V0I
DME9V0I DN RNAPc2
DME9V0I HS Discontinued in Phase 2
DME9V0I SN RAcAPc2; Recombinant nematode anticoagulant protein, Dendreon; Recombinant nematode anticoagulant protein, Nuvelo
DME9V0I CP Dendreon San Diego LLC
DME9V0I DE Colorectal cancer
DM4YA63 ID DM4YA63
DM4YA63 DN Ro-23-9424
DM4YA63 HS Discontinued in Phase 2
DM4YA63 SN Ro-23-9424
DM4YA63 CP Roche
DM4YA63 DT Small molecular drug
DM4YA63 PC 6918090
DM4YA63 MW 764.8
DM4YA63 FM C31H31F3N8O8S2
DM4YA63 IC InChI=1S/C31H31F3N8O8S2/c1-39-5-7-40(8-6-39)24-17(33)9-15-23(19(24)34)41(4-3-32)10-16(25(15)43)30(48)50-11-14-12-51-28-21(27(45)42(28)22(14)29(46)47)37-26(44)20(38-49-2)18-13-52-31(35)36-18/h9-10,13,21,28H,3-8,11-12H2,1-2H3,(H2,35,36)(H,37,44)(H,46,47)/b38-20+/t21-,28-/m1/s1
DM4YA63 CS CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)OCC4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N/OC)/C6=CSC(=N6)N)SC4)C(=O)O)CCF)F
DM4YA63 IK IKYGJSBKPPIKJK-YZURVANNSA-N
DM4YA63 IU (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyl]oxymethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM4YA63 DE Bacterial infection
DM01MRZ ID DM01MRZ
DM01MRZ DN Ro-24-4736
DM01MRZ HS Discontinued in Phase 2
DM01MRZ SN Ro-24-4736; Ro 24-4736; UNII-I2MJ13SOFO; I2MJ13SOFO; 125030-71-9; CHEMBL277650; 5-(3-(4-(2-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-2-yl)-2-propynyl)phenanthridin-6(5H)-one; AC1L1TWB; AC1Q3P7I; SCHEMBL7528667; DTXSID80154550; ro24-4736; ZINC1550948; BDBM50011638; CS-6683; HY-19097; 5-{3-[4-(2-Chloro-phenyl)-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-5H-phenanthridin-6-one; 6(5H)-Phenanthridinone, 5-(3-(4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triaz
DM01MRZ CP Roche Holding AG
DM01MRZ DT Small molecular drug
DM01MRZ PC 60775
DM01MRZ MW 546
DM01MRZ FM C31H20ClN5OS
DM01MRZ IC InChI=1S/C31H20ClN5OS/c1-19-34-35-28-18-33-29(24-13-4-6-14-26(24)32)25-17-20(39-31(25)37(19)28)9-8-16-36-27-15-7-5-11-22(27)21-10-2-3-12-23(21)30(36)38/h2-7,10-15,17H,16,18H2,1H3
DM01MRZ CS CC1=NN=C2N1C3=C(C=C(S3)C#CCN4C5=CC=CC=C5C6=CC=CC=C6C4=O)C(=NC2)C7=CC=CC=C7Cl
DM01MRZ IK MPMZSZMDCRPSRF-UHFFFAOYSA-N
DM01MRZ IU 5-[3-[7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-4-yl]prop-2-ynyl]phenanthridin-6-one
DM01MRZ CA CAS 125030-71-9
DM01MRZ DE Sepsis
DMPB80O ID DMPB80O
DMPB80O DN RO-26-9228
DMPB80O HS Discontinued in Phase 2
DMPB80O SN Elocalcitol; BXL628; BXL-628; (23E)-1alpha-Fluoro-25-hydroxy-16,17,23,24-tetradehydro-26,27-bishomo-20-epicholecalciferol
DMPB80O CP BioXell
DMPB80O DT Small molecular drug
DMPB80O PC 11396600
DMPB80O MW 442.6
DMPB80O FM C29H43FO2
DMPB80O IC InChI=1S/C29H43FO2/c1-6-29(32,7-2)17-8-10-20(3)25-14-15-26-22(11-9-16-28(25,26)5)12-13-23-18-24(31)19-27(30)21(23)4/h8,12-14,17,20,24,26-27,31-32H,4,6-7,9-11,15-16,18-19H2,1-3,5H3/b17-8+,22-12+,23-13-/t20-,24+,26-,27-,28+/m0/s1
DMPB80O CS CCC(CC)(/C=C/C[C@H](C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)F)O)C)O
DMPB80O IK LRLWXBHFPGSUOX-GJQYOBCGSA-N
DMPB80O IU (1R,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(E,2S)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol
DMPB80O CA CAS 199798-84-0
DMPB80O DE Urinary incontinence
DMH912O ID DMH912O
DMH912O DN RO-48-6791
DMH912O HS Discontinued in Phase 2
DMH912O SN 3-[5-(Dipropylaminomethyl)-1,2,4-oxadiazol-3-yl]-8-fluoro-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMH912O DT Small molecular drug
DMH912O PC 9953485
DMH912O MW 412.5
DMH912O FM C21H25FN6O2
DMH912O IC InChI=1S/C21H25FN6O2/c1-4-8-27(9-5-2)12-18-24-20(25-30-18)19-17-11-26(3)21(29)15-10-14(22)6-7-16(15)28(17)13-23-19/h6-7,10,13H,4-5,8-9,11-12H2,1-3H3
DMH912O CS CCCN(CCC)CC1=NC(=NO1)C2=C3CN(C(=O)C4=C(N3C=N2)C=CC(=C4)F)C
DMH912O IK NOQIYRGMEFBZTI-UHFFFAOYSA-N
DMH912O IU 3-[5-[(dipropylamino)methyl]-1,2,4-oxadiazol-3-yl]-8-fluoro-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMH912O CA CAS 172407-17-9
DMH912O DE Anxiety disorder
DMZAISC ID DMZAISC
DMZAISC DN Robalzotan
DMZAISC HS Discontinued in Phase 2
DMZAISC SN Robalzotan; 169758-66-1; NAD-299; UNII-I18M56OGME; I18M56OGME; AZD-7371; (R)-3-(Dicyclobutylamino)-8-fluoro-5-chromancarboxamide; (R)-3-(Dicyclobutylamino)-8-fluorochroman-5-carboxamide; Robalzotan [INN]; Robalzotan [INN:BAN]; (3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide; AC1MHOZC; GTPL72; SCHEMBL115079; NAD299; CHEMBL1628569; DTXSID30168743; ZINC3811952; AKOS022180489; VC30713; NCGC00370859-01; AJ-45676; LS-182403; (R)-3-(dicyclobutylamino)-8-fluorochromane-5-carboxamide
DMZAISC DT Small molecular drug
DMZAISC PC 3055171
DMZAISC MW 318.4
DMZAISC FM C18H23FN2O2
DMZAISC IC InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1
DMZAISC CS C1CC(C1)N([C@@H]2CC3=C(C=CC(=C3OC2)F)C(=O)N)C4CCC4
DMZAISC IK MQTUXRKNJYPMCG-CYBMUJFWSA-N
DMZAISC IU (3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide
DMZAISC CA CAS 169758-66-1
DMZAISC DE Anxiety disorder
DM6OSPQ ID DM6OSPQ
DM6OSPQ DN Rofleponide
DM6OSPQ HS Discontinued in Phase 2
DM6OSPQ SN RPL; RPNS; Rofleponide palmitate; D-5522; Rofleponide 21-palmitate
DM6OSPQ CP AstraZeneca plc
DM6OSPQ DT Small molecular drug
DM6OSPQ PC 3055174
DM6OSPQ MW 468.5
DM6OSPQ FM C25H34F2O6
DM6OSPQ IC InChI=1S/C25H34F2O6/c1-4-5-21-32-20-10-14-15-9-17(26)16-8-13(29)6-7-22(16,2)24(15,27)18(30)11-23(14,3)25(20,33-21)19(31)12-28/h8,14-15,17-18,20-21,28,30H,4-7,9-12H2,1-3H3/t14-,15-,17-,18-,20+,21+,22-,23-,24-,25+/m0/s1
DM6OSPQ CS CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@@H](C5=CC(=O)CC[C@@]5([C@]4([C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)F)C)F
DM6OSPQ IK IXTCZMJQGGONPY-XJAYAHQCSA-N
DM6OSPQ IU (1S,2S,4R,6R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DM6OSPQ CA CAS 144459-70-1
DM6OSPQ DE Allergic rhinitis
DM8Q7XV ID DM8Q7XV
DM8Q7XV DN Rolafagrel
DM8Q7XV HS Discontinued in Phase 2
DM8Q7XV SN FCE-22178
DM8Q7XV CP Pharmacia & Upjohn AB
DM8Q7XV DT Small molecular drug
DM8Q7XV PC 56009
DM8Q7XV MW 240.26
DM8Q7XV FM C14H12N2O2
DM8Q7XV IC InChI=1S/C14H12N2O2/c17-14(18)11-2-1-10-3-4-13(8-12(10)7-11)16-6-5-15-9-16/h1-2,5-9H,3-4H2,(H,17,18)
DM8Q7XV CS C1CC(=CC2=C1C=CC(=C2)C(=O)O)N3C=CN=C3
DM8Q7XV IK DQEDSIVMYUUZCK-UHFFFAOYSA-N
DM8Q7XV IU 7-imidazol-1-yl-5,6-dihydronaphthalene-2-carboxylic acid
DM8Q7XV CA CAS 89781-55-5
DM8Q7XV DE Nephritis
DMYDWHN ID DMYDWHN
DMYDWHN DN Romergoline
DMYDWHN HS Discontinued in Phase 2
DMYDWHN SN FCE-23884
DMYDWHN CP Pharmacia & Upjohn AB
DMYDWHN DT Small molecular drug
DMYDWHN PC 65898
DMYDWHN MW 350.4
DMYDWHN FM C20H22N4O2
DMYDWHN IC InChI=1S/C20H22N4O2/c1-23-8-12(9-24-10-18(25)22-19(26)11-24)5-15-14-3-2-4-16-20(14)13(7-21-16)6-17(15)23/h2-5,7,12,17,21H,6,8-11H2,1H3,(H,22,25,26)/t12-,17-/m1/s1
DMYDWHN CS CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)CN5CC(=O)NC(=O)C5
DMYDWHN IK RJCXNCSJGRUWRW-SJKOYZFVSA-N
DMYDWHN IU 4-[[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]methyl]piperazine-2,6-dione
DMYDWHN CA CAS 107052-56-2
DMYDWHN DE Anxiety disorder
DM10ZJP ID DM10ZJP
DM10ZJP DN Ronacaleret
DM10ZJP HS Discontinued in Phase 2
DM10ZJP SN Ronacaleret; UNII-DIH95YP7J3; DIH95YP7J3; CHEMBL1198855; 753449-67-1; SB-751689; Ronacaleret [INN]; SCHEMBL3737849; GTPL9473; BDBM50346036; AKOS030261487; DB05255; SB16763; SB 751689; 3-[3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]-4,5-difluorophenyl]propanoic acid; 3-[3-[[(2R)-3-[[2-(2,3-Dihydro-1H-indene-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropyl]oxy]-4,5-difluorophenyl]propionic acid
DM10ZJP CP GSK
DM10ZJP DT Small molecular drug
DM10ZJP PC 10345214
DM10ZJP MW 447.5
DM10ZJP FM C25H31F2NO4
DM10ZJP IC InChI=1S/C25H31F2NO4/c1-25(2,13-17-9-18-5-3-4-6-19(18)10-17)28-14-20(29)15-32-22-12-16(7-8-23(30)31)11-21(26)24(22)27/h3-6,11-12,17,20,28-29H,7-10,13-15H2,1-2H3,(H,30,31)/t20-/m1/s1
DM10ZJP CS CC(C)(CC1CC2=CC=CC=C2C1)NC[C@H](COC3=C(C(=CC(=C3)CCC(=O)O)F)F)O
DM10ZJP IK FQJISUPNMFRIFZ-HXUWFJFHSA-N
DM10ZJP IU 3-[3-[(2R)-3-[[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]-4,5-difluorophenyl]propanoic acid
DM10ZJP CA CAS 753449-67-1
DM10ZJP DE Osteoporosis
DMNBUS7 ID DMNBUS7
DMNBUS7 DN Rozrolimupab
DMNBUS7 HS Discontinued in Phase 2
DMNBUS7 SN SYM-001; Symphoglobulin-D; Recombinant human polyclonal antibodies (rhesus D), Symphogen/Biovitrum; Recombinant polyclonal antibodies (idiopathic thrombocytopenic purpura), Symphogen/Biovitrum; Symphobodies (hemolytic disease of the newborn), Symphogen/Biovitrum; Anti-RhD (trombocytopeni, anti-D-profylax), Symphogen/Biovitrum
DMNBUS7 CP Symphogen A/S
DMNBUS7 DT Antibody
DMNBUS7 DE Anemia
DMTQ3BS ID DMTQ3BS
DMTQ3BS DN RP-64477
DMTQ3BS HS Discontinued in Phase 2
DMTQ3BS CP Rhone-Poulenc SA
DMTQ3BS PC 9870538
DMTQ3BS MW 498.7
DMTQ3BS FM C29H42N2O3S
DMTQ3BS IC InChI=1S/C29H42N2O3S/c1-4-6-8-9-10-11-12-13-21-34-25-17-14-23(15-18-25)29(33)31-26-22-24(16-19-27(26)35-3)28(32)30-20-7-5-2/h14-19,22H,4-13,20-21H2,1-3H3,(H,30,32)(H,31,33)
DMTQ3BS CS CCCCCCCCCCOC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C(=O)NCCCC)SC
DMTQ3BS IK OZMWNRSILHTVFV-UHFFFAOYSA-N
DMTQ3BS IU N-butyl-3-[(4-decoxybenzoyl)amino]-4-methylsulfanylbenzamide
DMTQ3BS CA CAS 135239-65-5
DMTQ3BS DE Hyperlipidaemia
DMRGC5B ID DMRGC5B
DMRGC5B DN RPR-106541
DMRGC5B HS Discontinued in Phase 2
DMRGC5B CP Aventis Pharma AG
DMRGC5B PC 9846880
DMRGC5B MW 456.6
DMRGC5B FM C24H34F2O4S
DMRGC5B IC InChI=1S/C24H34F2O4S/c1-5-6-20-29-19-11-14-15-10-17(25)16-9-13(27)7-8-21(16,2)23(15,26)18(28)12-22(14,3)24(19,30-20)31-4/h9,14-15,17-20,28H,5-8,10-12H2,1-4H3/t14-,15-,17-,18-,19+,20+,21-,22-,23-,24-/m0/s1
DMRGC5B CS CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4C[C@@H](C5=CC(=O)CC[C@@]5([C@]4([C@H](C[C@@]3([C@@]2(O1)SC)C)O)F)C)F
DMRGC5B IK QGBIFMJAQARMNQ-QISPFCDLSA-N
DMRGC5B IU (1S,2S,4R,6R,8R,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-8-methylsulfanyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
DMRGC5B CA CAS 159001-35-1
DMRGC5B DE Asthma
DM4GVZ9 ID DM4GVZ9
DM4GVZ9 DN RQ-00317076
DM4GVZ9 HS Discontinued in Phase 2
DM4GVZ9 SN COX-2 inhibitor (oral, pain), RaQualia
DM4GVZ9 CP RaQualia Pharma Inc
DM4GVZ9 DE Pain
DMOTANY ID DMOTANY
DMOTANY DN RS-130830
DMOTANY HS Discontinued in Phase 2
DMOTANY SN CTS-1027; 193022-04-7; RS-130830; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690
DMOTANY DT Small molecular drug
DMOTANY PC 3342298
DMOTANY MW 425.9
DMOTANY FM C19H20ClNO6S
DMOTANY IC InChI=1S/C19H20ClNO6S/c20-14-1-3-15(4-2-14)27-16-5-7-17(8-6-16)28(24,25)13-19(18(22)21-23)9-11-26-12-10-19/h1-8,23H,9-13H2,(H,21,22)
DMOTANY CS C1COCCC1(CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C(=O)NO
DMOTANY IK ROSNVSQTEGHUKU-UHFFFAOYSA-N
DMOTANY IU 4-[[4-(4-chlorophenoxy)phenyl]sulfonylmethyl]-N-hydroxyoxane-4-carboxamide
DMOTANY CA CAS 193022-04-7
DMOTANY DE Hepatitis C virus infection
DMERM0K ID DMERM0K
DMERM0K DN RS-8359
DMERM0K HS Discontinued in Phase 2
DMERM0K SN CS-8359; TUK-9261; TUK-9262; TUK-9508
DMERM0K CP Sankyo Co Ltd
DMERM0K DT Small molecular drug
DMERM0K PC 164116
DMERM0K MW 252.27
DMERM0K FM C14H12N4O
DMERM0K IC InChI=1S/C14H12N4O/c15-7-9-1-3-10(4-2-9)18-14-11-5-6-12(19)13(11)16-8-17-14/h1-4,8,12,19H,5-6H2,(H,16,17,18)
DMERM0K CS C1CC2=C(C1O)N=CN=C2NC3=CC=C(C=C3)C#N
DMERM0K IK YKTSVZRWKHWINV-UHFFFAOYSA-N
DMERM0K IU 4-[(7-hydroxy-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]benzonitrile
DMERM0K CA CAS 105365-76-2
DMERM0K DE Major depressive disorder
DMIKUXN ID DMIKUXN
DMIKUXN DN RSD-921
DMIKUXN HS Discontinued in Phase 2
DMIKUXN SN PD 123497
DMIKUXN CP University of British Columbia
DMIKUXN DT Small molecular drug
DMIKUXN PC 122115
DMIKUXN MW 356.5
DMIKUXN FM C21H28N2OS
DMIKUXN IC InChI=1S/C21H28N2OS/c1-22(18-8-2-3-9-19(18)23-12-4-5-13-23)21(24)15-16-7-6-10-20-17(16)11-14-25-20/h6-7,10-11,14,18-19H,2-5,8-9,12-13,15H2,1H3/t18-,19-/m1/s1
DMIKUXN CS CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)CC3=C4C=CSC4=CC=C3
DMIKUXN IK SYHJZCCNQDFHJQ-RTBURBONSA-N
DMIKUXN IU 2-(1-benzothiophen-4-yl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide
DMIKUXN CA CAS 111728-01-9
DMIKUXN DE Anaesthesia
DMPAH74 ID DMPAH74
DMPAH74 DN R-sibutramine metabolite
DMPAH74 HS Discontinued in Phase 2
DMPAH74 CP Sepracor
DMPAH74 DE Attention deficit hyperactivity disorder; Depression
DMR0K85 ID DMR0K85
DMR0K85 DN RX-77368
DMR0K85 HS Discontinued in Phase 2
DMR0K85 SN TRH analog, Reckitt & Colman
DMR0K85 CP Reckitt; Colman plc
DMR0K85 DT Small molecular drug
DMR0K85 PC 107823
DMR0K85 MW 390.4
DMR0K85 FM C18H26N6O4
DMR0K85 IC InChI=1S/C18H26N6O4/c1-18(2)5-6-24(14(18)15(19)26)17(28)12(7-10-8-20-9-21-10)23-16(27)11-3-4-13(25)22-11/h8-9,11-12,14H,3-7H2,1-2H3,(H2,19,26)(H,20,21)(H,22,25)(H,23,27)/t11-,12-,14+/m0/s1
DMR0K85 CS CC1(CCN([C@@H]1C(=O)N)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C
DMR0K85 IK ZEQAPQNFHVYDEL-SGMGOOAPSA-N
DMR0K85 IU (2S)-1-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]-3,3-dimethylpyrrolidine-2-carboxamide
DMR0K85 CA CAS 76820-40-1
DMR0K85 DE Dementia
DMS6NAK ID DMS6NAK
DMS6NAK DN S-12363
DMS6NAK HS Discontinued in Phase 2
DMS6NAK SN S-12363 (liposomal, cancer); S-12363 (liposomal, cancer), Servier
DMS6NAK CP Servier
DMS6NAK PC 6918169
DMS6NAK MW 1044.2
DMS6NAK FM C51H74N5O14PS
DMS6NAK IC InChI=1S/C51H72N5O10P.H2O4S/c1-10-47(60)27-32-28-50(46(59)64-9,40-34(19-23-55(29-32)30-47)33-17-14-15-18-37(33)52-40)36-25-35-38(26-39(36)63-8)54(7)43-49(35)21-24-56-22-16-20-48(11-2,42(49)56)44(57)51(43,61)45(58)53-41(31(5)6)67(62,65-12-3)66-13-4;1-5(2,3)4/h14-18,20,25-26,31-32,41-44,52,57,60-61H,10-13,19,21-24,27-30H2,1-9H3,(H,53,58);(H2,1,2,3,4)/t32-,41+,42+,43-,44-,47+,48-,49-,50+,51+;/m1./s1
DMS6NAK CS CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N[C@H](C(C)C)P(=O)(OCC)OCC)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O
DMS6NAK IK BZUUMJJIORUJAU-XFLWUYJZSA-N
DMS6NAK IU methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-[[(1S)-1-diethoxyphosphoryl-2-methylpropyl]carbamoyl]-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate;sulfuric acid
DMS6NAK DE Solid tumour/cancer
DMLCYX8 ID DMLCYX8
DMLCYX8 DN S-15261
DMLCYX8 HS Discontinued in Phase 2
DMLCYX8 SN L-4-[2-[2-(9-Fluorenyl)acetamido]ethyl]benzoic acid 2-[2-methoxy-2-[3-(trifluoromethyl)phenyl]ethylamino]ethyl ester
DMLCYX8 DT Small molecular drug
DMLCYX8 PC 3074609
DMLCYX8 MW 616.7
DMLCYX8 FM C36H35F3N2O4
DMLCYX8 IC InChI=1S/C36H35F3N2O4/c1-44-33(26-7-6-8-27(21-26)36(37,38)39)23-40-19-20-45-35(43)25-15-13-24(14-16-25)17-18-41-34(42)22-32-30-11-4-2-9-28(30)29-10-3-5-12-31(29)32/h2-16,21,32-33,40H,17-20,22-23H2,1H3,(H,41,42)
DMLCYX8 CS COC(CNCCOC(=O)C1=CC=C(C=C1)CCNC(=O)CC2C3=CC=CC=C3C4=CC=CC=C24)C5=CC(=CC=C5)C(F)(F)F
DMLCYX8 IK ASWYZRRXMGAWGN-UHFFFAOYSA-N
DMLCYX8 IU 2-[[2-methoxy-2-[3-(trifluoromethyl)phenyl]ethyl]amino]ethyl 4-[2-[[2-(9H-fluoren-9-yl)acetyl]amino]ethyl]benzoate
DMLCYX8 CA CAS 159978-02-6
DMLCYX8 DE Diabetic complication
DM51WJN ID DM51WJN
DM51WJN DN S-16020-2
DM51WJN HS Discontinued in Phase 2
DM51WJN SN N-[2-(Dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide dihydrochloride
DM51WJN DT Small molecular drug
DM51WJN PC 177329
DM51WJN MW 449.4
DM51WJN FM C22H26Cl2N4O2
DM51WJN IC InChI=1S/C22H24N4O2.2ClH/c1-13-15-7-8-23-20(22(28)24-9-10-25(2)3)17(15)12-18-16-11-14(27)5-6-19(16)26(4)21(13)18;;/h5-8,11-12,27H,9-10H2,1-4H3,(H,24,28);2*1H
DM51WJN CS CC1=C2C=CN=C(C2=CC3=C1N(C4=C3C=C(C=C4)O)C)C(=O)NCCN(C)C.Cl.Cl
DM51WJN IK DSJBVXJNKBKZSB-UHFFFAOYSA-N
DM51WJN IU N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethylpyrido[4,3-b]carbazole-1-carboxamide;dihydrochloride
DM51WJN CA CAS 178169-99-8
DM51WJN DE Solid tumour/cancer
DMA01BV ID DMA01BV
DMA01BV DN S-18986
DMA01BV HS Discontinued in Phase 2
DMA01BV SN S 18986; S-18986; UNII-IA262432Y9; 175340-20-2; S18986; IA262432Y9; MNTIJYGEITVWHU-SNVBAGLBSA-N; AC1LCV4Z; S18986-1; SCHEMBL6622911; S 18986-1; GTPL4304; CHEMBL320642; EX-A818; MolPort-023-276-986; (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide; ZINC3827020; AKOS024457867; (S)-2,3-dihydro-(3,4)cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide; B5493; (3aS)-5,5Dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine
DMA01BV CP Shionogi
DMA01BV TC Neurodegenerative
DMA01BV DT Small molecular drug
DMA01BV PC 637863
DMA01BV MW 224.28
DMA01BV FM C10H12N2O2S
DMA01BV IC InChI=1S/C10H12N2O2S/c13-15(14)9-5-2-1-4-8(9)12-7-3-6-10(12)11-15/h1-2,4-5,10-11H,3,6-7H2/t10-/m1/s1
DMA01BV CS C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1
DMA01BV IK MNTIJYGEITVWHU-SNVBAGLBSA-N
DMA01BV IU (3aS)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide
DMA01BV CA CAS 175340-20-2
DMA01BV DE Alzheimer disease
DMMSZ1A ID DMMSZ1A
DMMSZ1A DN S-2474
DMMSZ1A HS Discontinued in Phase 2
DMMSZ1A SN 158089-95-3; CTK4C9584; DTXSID20724630; PHENOL, 2,6-BIS(1,1-DIMETHYLETHYL)-4-[(E)-(2-ETHYL-1,1-DIOXIDO-5-ISOTHIAZOLIDINYLIDENE)METHYL]-
DMMSZ1A CP Shionogi & Co Ltd
DMMSZ1A DT Small molecular drug
DMMSZ1A PC 57370228
DMMSZ1A MW 365.5
DMMSZ1A FM C20H31NO3S
DMMSZ1A IC InChI=1S/C20H31NO3S/c1-8-21-10-9-15(25(21,23)24)11-14-12-16(19(2,3)4)18(22)17(13-14)20(5,6)7/h11-13,22H,8-10H2,1-7H3
DMMSZ1A CS CCN1CCC(=CC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C)S1(=O)=O
DMMSZ1A IK HFWZBWTWCKQUCB-UHFFFAOYSA-N
DMMSZ1A IU 2,6-ditert-butyl-4-[(2-ethyl-1,1-dioxo-1,2-thiazolidin-5-ylidene)methyl]phenol
DMMSZ1A CA CAS 158089-95-3
DMMSZ1A DE Rheumatoid arthritis
DMQ2RDZ ID DMQ2RDZ
DMQ2RDZ DN S-312-d
DMQ2RDZ HS Discontinued in Phase 2
DMQ2RDZ SN S-312; S-830312
DMQ2RDZ CP Shionogi & Co Ltd
DMQ2RDZ DT Small molecular drug
DMQ2RDZ PC 189723
DMQ2RDZ MW 386.5
DMQ2RDZ FM C20H22N2O4S
DMQ2RDZ IC InChI=1S/C20H22N2O4S/c1-11(2)8-14-10-27-19-18(14)17(16(12(3)21-19)20(23)26-4)13-6-5-7-15(9-13)22(24)25/h5-7,9-11,17,21H,8H2,1-4H3/t17-/m0/s1
DMQ2RDZ CS CC1=C([C@@H](C2=C(N1)SC=C2CC(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMQ2RDZ IK UTLPUICHKZBRCI-KRWDZBQOSA-N
DMQ2RDZ IU methyl (4S)-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate
DMQ2RDZ CA CAS 120056-57-7
DMQ2RDZ DE Epilepsy
DM2X6ME ID DM2X6ME
DM2X6ME DN S-5751
DM2X6ME HS Discontinued in Phase 2
DM2X6ME SN S-5751; AC1NSK82; GTPL1898; S5751; (Z)-7-[(1R,2R,3R,5S)-2-[(5-hydroxy1-benzothiophene-3-carbonyl)amino]-7,7-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid; (Z)-7-[(1S,3R,4R,5R)-4-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM2X6ME DT Small molecular drug
DM2X6ME PC 9867949
DM2X6ME MW 441.6
DM2X6ME FM C25H31NO4S
DM2X6ME IC InChI=1S/C25H31NO4S/c1-25(2)16-11-15(7-5-3-4-6-8-22(28)29)23(20(25)12-16)26-24(30)19-14-31-21-10-9-17(27)13-18(19)21/h3,5,9-10,13-16,20,23,27H,4,6-8,11-12H2,1-2H3,(H,26,30)(H,28,29)/b5-3-/t15-,16-,20-,23+/m0/s1
DM2X6ME CS CC1([C@H]2C[C@@H]([C@H]([C@@H]1C2)NC(=O)C3=CSC4=C3C=C(C=C4)O)C/C=C\\CCCC(=O)O)C
DM2X6ME IK ZXBHFWFKSIYJEK-MFJOXFORSA-N
DM2X6ME IU (Z)-7-[(1R,2R,3S,5S)-2-[(5-hydroxy-1-benzothiophene-3-carbonyl)amino]-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM2X6ME CA CAS 209268-36-0
DM2X6ME DE Rhinitis
DM9BEDL ID DM9BEDL
DM9BEDL DN S-8510
DM9BEDL HS Discontinued in Phase 2
DM9BEDL DT Small molecular drug
DM9BEDL PC 135409387
DM9BEDL MW 242.23
DM9BEDL FM C12H10N4O2
DM9BEDL IC InChI=1S/C12H10N4O2/c1-3-17-6-7-8(1)13-5-10-11(7)15-12(14-10)9-2-4-18-16-9/h2,4-5H,1,3,6H2,(H,14,15)
DM9BEDL CS C1COCC2=C3C(=CN=C21)NC(=N3)C4=NOC=C4
DM9BEDL IK ITPFSYAYHHPKRT-UHFFFAOYSA-N
DM9BEDL IU 4-(1,2-oxazol-3-yl)-12-oxa-3,5,8-triazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraene
DM9BEDL DE Cognitive impairment
DMER3I9 ID DMER3I9
DMER3I9 DN S-9788
DMER3I9 HS Discontinued in Phase 2
DMER3I9 SN S-9788; S9788; S 9788; CHEMBL85156; 140945-01-3; 6-(4-(2,2-di(4-Fluorophenyl)ethylamino)-1-piperidinyl)-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine; 1,3,5-Triazine-2,4-diamine, 6-(4-((2,2-bis(4-fluorophenyl)ethyl)amino)-1-piperidinyl)-N,N'-di-2-propenyl-; AC1L32YH; SCHEMBL1527824; DTXSID80161502; GERNFWKTMKWULM-UHFFFAOYSA-N; BDBM50053888; LS-187603; LS-186957; N,N''-Diallyl-6-{4-[2,2-bis-(4-fluoro-phenyl)-ethylamino]-piperidin-1-yl}-[1,3,5]triazine-2,4-diamine; H2O
DMER3I9 CP Servier
DMER3I9 DT Small molecular drug
DMER3I9 PC 107903
DMER3I9 MW 505.6
DMER3I9 FM C28H33F2N7
DMER3I9 IC InChI=1S/C28H33F2N7/c1-3-15-31-26-34-27(32-16-4-2)36-28(35-26)37-17-13-24(14-18-37)33-19-25(20-5-9-22(29)10-6-20)21-7-11-23(30)12-8-21/h3-12,24-25,33H,1-2,13-19H2,(H2,31,32,34,35,36)
DMER3I9 CS C=CCNC1=NC(=NC(=N1)N2CCC(CC2)NCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C
DMER3I9 IK GERNFWKTMKWULM-UHFFFAOYSA-N
DMER3I9 IU 6-[4-[2,2-bis(4-fluorophenyl)ethylamino]piperidin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
DMER3I9 CA CAS 140945-01-3
DMER3I9 DE Solid tumour/cancer
DMEO6A5 ID DMEO6A5
DMEO6A5 DN S-9977
DMEO6A5 HS Discontinued in Phase 2
DMEO6A5 SN S-9977-2
DMEO6A5 CP Servier
DMEO6A5 DT Small molecular drug
DMEO6A5 PC 132156
DMEO6A5 MW 456
DMEO6A5 FM C20H34ClN7O3
DMEO6A5 IC InChI=1S/C20H33N7O3.ClH/c1-6-26(7-2)20(30)27-13-11-25(12-14-27)10-8-9-15-21-17-16(22(15)3)18(28)24(5)19(29)23(17)4;/h6-14H2,1-5H3;1H
DMEO6A5 CS CCN(CC)C(=O)N1CCN(CC1)CCCC2=NC3=C(N2C)C(=O)N(C(=O)N3C)C.Cl
DMEO6A5 IK GVHZRDKDUVIRNY-UHFFFAOYSA-N
DMEO6A5 IU N,N-diethyl-4-[3-(1,3,7-trimethyl-2,6-dioxopurin-8-yl)propyl]piperazine-1-carboxamide;hydrochloride
DMEO6A5 CA CAS 138472-18-1
DMEO6A5 DE Cognitive impairment
DMC57JU ID DMC57JU
DMC57JU DN Saperconazole
DMC57JU HS Discontinued in Phase 2
DMC57JU SN R-66905
DMC57JU CP Janssen Pharmaceutica NV
DMC57JU DT Small molecular drug
DMC57JU PC 9809993
DMC57JU MW 672.7
DMC57JU FM C35H38F2N8O4
DMC57JU IC InChI=1S/C35H38F2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3
DMC57JU CS CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F
DMC57JU IK HUADITLKOCMHSB-UHFFFAOYSA-N
DMC57JU IU 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
DMC57JU DE Fungal infection
DMQMA17 ID DMQMA17
DMQMA17 DN SAVOXEPIN MESYLATE
DMQMA17 HS Discontinued in Phase 2
DMQMA17 SN CIPA; Cipazoxapine; CGP-19486A; Savoxepin mesylate; 3-(Cyclopentylmethyl)-2,3,4,5-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-d]azepine-7-carbonitrile methanesulfonate
DMQMA17 DT Small molecular drug
DMQMA17 PC 71587288
DMQMA17 MW 466.6
DMQMA17 FM C26H30N2O4S
DMQMA17 IC InChI=1S/C25H26N2O.CH4O3S/c26-16-19-9-10-25-23(15-19)21-12-14-27(17-18-5-1-2-6-18)13-11-20(21)22-7-3-4-8-24(22)28-25;1-5(2,3)4/h3-4,7-10,15,18H,1-2,5-6,11-14,17H2;1H3,(H,2,3,4)
DMQMA17 CS CS(=O)(=O)O.C1CCC(C1)CN2CCC3=C(CC2)C4=C(C=CC(=C4)C#N)OC5=CC=CC=C35
DMQMA17 IK PDYLRPIUJQGVNY-UHFFFAOYSA-N
DMQMA17 IU 18-(cyclopentylmethyl)-8-oxa-18-azatetracyclo[13.5.0.02,7.09,14]icosa-1(15),2(7),3,5,9,11,13-heptaene-4-carbonitrile;methanesulfonic acid
DMQMA17 CA CAS 79262-47-8
DMQMA17 DE Psychotic disorder
DMIF4VJ ID DMIF4VJ
DMIF4VJ DN SB-201993
DMIF4VJ HS Discontinued in Phase 2
DMIF4VJ SN SB-201993; UNII-4TWC061LPM; 4TWC061LPM; CHEMBL422598; SB 201993; AC1O5KJ7; SCHEMBL1893839; SCHEMBL1893835; sb201993; BDBM50037385; (E)-3-((((6-(2-Carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid; L009321; 3-[[6-[(E)-3-hydroxy-3-oxoprop-1-enyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid; 3-{6-((E)-2-Carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid; Benzoic acid, 3-((((6-(2-carboxyethenyl)-5-((8-(4-m
DMIF4VJ DT Small molecular drug
DMIF4VJ PC 6435820
DMIF4VJ MW 563.7
DMIF4VJ FM C32H37NO6S
DMIF4VJ IC InChI=1S/C32H37NO6S/c1-38-28-15-12-24(13-16-28)9-6-4-2-3-5-7-20-39-30-18-14-27(33-29(30)17-19-31(34)35)23-40-22-25-10-8-11-26(21-25)32(36)37/h8,10-19,21H,2-7,9,20,22-23H2,1H3,(H,34,35)(H,36,37)/b19-17+
DMIF4VJ CS COC1=CC=C(C=C1)CCCCCCCCOC2=C(N=C(C=C2)CSCC3=CC(=CC=C3)C(=O)O)/C=C/C(=O)O
DMIF4VJ IK QQUXZUFSDIOIFJ-HTXNQAPBSA-N
DMIF4VJ IU 3-[[6-[(E)-2-carboxyethenyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid
DMIF4VJ CA CAS 150399-22-7
DMIF4VJ DE Psoriasis vulgaris
DMJYW80 ID DMJYW80
DMJYW80 DN SB-209670
DMJYW80 HS Discontinued in Phase 2
DMJYW80 SN SKF-66861; (+/-)-SB 209670
DMJYW80 CP SmithKline Beecham plc
DMJYW80 DT Small molecular drug
DMJYW80 PC 108002
DMJYW80 MW 520.5
DMJYW80 FM C29H28O9
DMJYW80 IC InChI=1S/C29H28O9/c1-3-10-35-18-6-7-19-21(12-18)27(20-8-5-17(34-2)13-23(20)36-14-25(30)31)28(29(32)33)26(19)16-4-9-22-24(11-16)38-15-37-22/h4-9,11-13,26-28H,3,10,14-15H2,1-2H3,(H,30,31)(H,32,33)/t26-,27+,28+/m0/s1
DMJYW80 CS CCCOC1=CC2=C(C=C1)[C@@H]([C@H]([C@@H]2C3=C(C=C(C=C3)OC)OCC(=O)O)C(=O)O)C4=CC5=C(C=C4)OCO5
DMJYW80 IK UUAVCCWBNUITBB-UPRLRBBYSA-N
DMJYW80 IU (1S,2R,3S)-1-(1,3-benzodioxol-5-yl)-3-[2-(carboxymethoxy)-4-methoxyphenyl]-5-propoxy-2,3-dihydro-1H-indene-2-carboxylic acid
DMJYW80 CA CAS 157659-79-5
DMJYW80 DE Arrhythmia
DMXFQS1 ID DMXFQS1
DMXFQS1 DN SB-756050
DMXFQS1 HS Discontinued in Phase 2
DMXFQS1 CP GlaxoSmithKline
DMXFQS1 PC 1520267
DMXFQS1 MW 500.6
DMXFQS1 FM C21H28N2O8S2
DMXFQS1 IC InChI=1S/C21H28N2O8S2/c1-28-18-8-6-16(14-20(18)30-3)32(24,25)22-10-5-11-23(13-12-22)33(26,27)17-7-9-19(29-2)21(15-17)31-4/h6-9,14-15H,5,10-13H2,1-4H3
DMXFQS1 CS COC1=C(C=C(C=C1)S(=O)(=O)N2CCCN(CC2)S(=O)(=O)C3=CC(=C(C=C3)OC)OC)OC
DMXFQS1 IK GJUFPAZNBPFNRI-UHFFFAOYSA-N
DMXFQS1 IU 1,4-bis[(3,4-dimethoxyphenyl)sulfonyl]-1,4-diazepane
DMXFQS1 DE Type-2 diabetes
DMTZ7E4 ID DMTZ7E4
DMTZ7E4 DN SC-106
DMTZ7E4 HS Discontinued in Phase 2
DMTZ7E4 SN SC-106; AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid
DMTZ7E4 CP Scotia Holdings plc
DMTZ7E4 DT Small molecular drug
DMTZ7E4 PC 492984
DMTZ7E4 MW 331.33
DMTZ7E4 FM C15H17N5O4
DMTZ7E4 IC InChI=1S/C15H17N5O4/c1-2-10(7-13(22)23)19-12(21)8-18-14(24)9-4-3-5-11(6-9)20-15(16)17/h1,3-6,10H,7-8H2,(H,18,24)(H,19,21)(H,22,23)(H4,16,17,20)/t10-/m0/s1
DMTZ7E4 CS C#C[C@@H](CC(=O)O)NC(=O)CNC(=O)C1=CC(=CC=C1)N=C(N)N
DMTZ7E4 IK IABCGGIFHPDBCJ-JTQLQIEISA-N
DMTZ7E4 IU (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid
DMTZ7E4 DE Rheumatoid arthritis
DMQ0T6L ID DMQ0T6L
DMQ0T6L DN SC-45662
DMQ0T6L HS Discontinued in Phase 2
DMQ0T6L SN CHEMBL84566; SC-45662; UNII-TPG7IO601I component ADVNUIUADIXWMI-QWHCGFSZSA-N; 2-[[(1S,2R)-2-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylpropyl]oxy]acetic acid
DMQ0T6L CP GD Searle & Co
DMQ0T6L DT Small molecular drug
DMQ0T6L PC 5487420
DMQ0T6L MW 368.5
DMQ0T6L FM C20H32O4S
DMQ0T6L IC InChI=1S/C20H32O4S/c1-12(24-11-17(21)22)13(2)25-14-9-15(19(3,4)5)18(23)16(10-14)20(6,7)8/h9-10,12-13,23H,11H2,1-8H3,(H,21,22)/t12-,13+/m1/s1
DMQ0T6L CS C[C@H]([C@H](C)SC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)OCC(=O)O
DMQ0T6L IK ADVNUIUADIXWMI-OLZOCXBDSA-N
DMQ0T6L IU 2-[(2R,3S)-3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylbutan-2-yl]oxyacetic acid
DMQ0T6L CA CAS 135133-84-5
DMQ0T6L DE Asthma
DMAGBM2 ID DMAGBM2
DMAGBM2 DN SCH-32615
DMAGBM2 HS Discontinued in Phase 2
DMAGBM2 SN (S)-N-[N-(1-Carboxy-2-phenylethyl)-L-phenylalanyl]-beta-alanine; 83861-02-3
DMAGBM2 DT Small molecular drug
DMAGBM2 PC 5486715
DMAGBM2 MW 384.4
DMAGBM2 FM C21H24N2O5
DMAGBM2 IC InChI=1S/C21H24N2O5/c24-19(25)11-12-22-20(26)17(13-15-7-3-1-4-8-15)23-18(21(27)28)14-16-9-5-2-6-10-16/h1-10,17-18,23H,11-14H2,(H,22,26)(H,24,25)(H,27,28)/t17-,18-/m0/s1
DMAGBM2 CS C1=CC=C(C=C1)C[C@@H](C(=O)NCCC(=O)O)N[C@@H](CC2=CC=CC=C2)C(=O)O
DMAGBM2 IK WOVRTBFSWOVRST-ROUUACIJSA-N
DMAGBM2 IU (2S)-2-[[(2S)-1-(2-carboxyethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoic acid
DMAGBM2 CA CAS 83861-02-3
DMAGBM2 DE Pain
DMZR6GI ID DMZR6GI
DMZR6GI DN Sch-34826
DMZR6GI HS Discontinued in Phase 2
DMZR6GI SN Sch-34826; Sch 34826; 105262-04-2; N-(N-(1-(((2,2-Dimethyl-1,3-dioxolan-4-yl) methoxy)carbonyl)-2-phenylethyl)phenylalanine)alanine; beta-Alanine, N-(N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-oxo-1-(phenylmethyl)ethyl)-L-phenylalanyl)-; SCHEMBL489561; AC1L3U54; LS-186875; LS-187530; 3-[[(2S)-2-[[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoyl]amino]propanoic acid
DMZR6GI CP Schering-Plough Corp
DMZR6GI DT Small molecular drug
DMZR6GI PC 122184
DMZR6GI MW 498.6
DMZR6GI FM C27H34N2O7
DMZR6GI IC InChI=1S/C27H34N2O7/c1-27(2)35-18-21(36-27)17-34-26(33)23(16-20-11-7-4-8-12-20)29-22(15-19-9-5-3-6-10-19)25(32)28-14-13-24(30)31/h3-12,21-23,29H,13-18H2,1-2H3,(H,28,32)(H,30,31)/t21?,22-,23?/m0/s1
DMZR6GI CS CC1(OCC(O1)COC(=O)C(CC2=CC=CC=C2)N[C@@H](CC3=CC=CC=C3)C(=O)NCCC(=O)O)C
DMZR6GI IK GWLFRMJMKXSMSR-KOENEWCDSA-N
DMZR6GI IU 3-[[(2S)-2-[[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl]amino]-3-phenylpropanoyl]amino]propanoic acid
DMZR6GI CA CAS 105262-04-2
DMZR6GI DE Hypertension
DM2RH51 ID DM2RH51
DM2RH51 DN SCH-42495
DM2RH51 HS Discontinued in Phase 2
DM2RH51 SN N-[2(S)-(Acetylsulfanylmethyl)-3-(2-methylphenyl)propionyl]-L-methionine ethyl ester
DM2RH51 DT Small molecular drug
DM2RH51 PC 131965
DM2RH51 MW 411.6
DM2RH51 FM C20H29NO4S2
DM2RH51 IC InChI=1S/C20H29NO4S2/c1-5-25-20(24)18(10-11-26-4)21-19(23)17(13-27-15(3)22)12-16-9-7-6-8-14(16)2/h6-9,17-18H,5,10-13H2,1-4H3,(H,21,23)/t17-,18+/m1/s1
DM2RH51 CS CCOC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=CC=C1C)CSC(=O)C
DM2RH51 IK ZVQXPUMRSJGLSF-MSOLQXFVSA-N
DM2RH51 IU ethyl (2S)-2-[[(2S)-2-(acetylsulfanylmethyl)-3-(2-methylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate
DM2RH51 CA CAS 136511-43-8
DM2RH51 DE Hypotension
DM28AFU ID DM28AFU
DM28AFU DN SCH-48461
DM28AFU HS Discontinued in Phase 2
DM28AFU SN (-)-(3R,4S)-1,4-Bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one; 148260-92-8
DM28AFU DT Small molecular drug
DM28AFU PC 132832
DM28AFU MW 401.5
DM28AFU FM C26H27NO3
DM28AFU IC InChI=1S/C26H27NO3/c1-29-22-15-11-20(12-16-22)25-24(10-6-9-19-7-4-3-5-8-19)26(28)27(25)21-13-17-23(30-2)18-14-21/h3-5,7-8,11-18,24-25H,6,9-10H2,1-2H3/t24-,25-/m1/s1
DM28AFU CS COC1=CC=C(C=C1)[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)OC)CCCC4=CC=CC=C4
DM28AFU IK IMNTVVOUWFPRSB-JWQCQUIFSA-N
DM28AFU IU (3R,4S)-1,4-bis(4-methoxyphenyl)-3-(3-phenylpropyl)azetidin-2-one
DM28AFU CA CAS 148260-92-8
DM28AFU DE Hyperlipidaemia
DMX4938 ID DMX4938
DMX4938 DN SDZ-LAP-977
DMX4938 HS Discontinued in Phase 2
DMX4938 SN SDZ-281-977
DMX4938 CP Novartis AG
DMX4938 PC 9818362
DMX4938 MW 316.3
DMX4938 FM C18H20O5
DMX4938 IC InChI=1S/C18H20O5/c1-21-14-7-9-17(22-2)13(11-14)6-4-12-5-8-16(19)15(10-12)18(20)23-3/h5,7-11,19H,4,6H2,1-3H3
DMX4938 CS COC1=CC(=C(C=C1)OC)CCC2=CC(=C(C=C2)O)C(=O)OC
DMX4938 IK GZOFTOHENYHNMS-UHFFFAOYSA-N
DMX4938 IU methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate
DMX4938 CA CAS 150779-71-8
DMX4938 DE Psoriasis vulgaris
DMXZVPH ID DMXZVPH
DMXZVPH DN SEGLITIDE
DMXZVPH HS Discontinued in Phase 2
DMXZVPH SN L-363586; MK-678; Seglitide; Cyclic (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe)
DMXZVPH DT Small molecular drug
DMXZVPH PC 5311430
DMXZVPH MW 809
DMXZVPH FM C44H56N8O7
DMXZVPH IC InChI=1S/C44H56N8O7/c1-26(2)38-43(58)50-37(23-28-12-6-5-7-13-28)44(59)52(4)27(3)39(54)48-35(22-29-17-19-31(53)20-18-29)41(56)49-36(24-30-25-46-33-15-9-8-14-32(30)33)42(57)47-34(40(55)51-38)16-10-11-21-45/h5-9,12-15,17-20,25-27,34-38,46,53H,10-11,16,21-24,45H2,1-4H3,(H,47,57)(H,48,54)(H,49,56)(H,50,58)(H,51,55)/t27-,34-,35-,36+,37-,38-/m0/s1
DMXZVPH CS C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1C)CC2=CC=CC=C2)C(C)C)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=C(C=C5)O
DMXZVPH IK NPJIOCBFOAHEDO-AVWFULIKSA-N
DMXZVPH IU (3S,6S,9S,12R,15S,18S)-9-(4-aminobutyl)-3-benzyl-15-[(4-hydroxyphenyl)methyl]-12-(1H-indol-3-ylmethyl)-1,18-dimethyl-6-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone
DMXZVPH CA CAS 81377-02-8
DMXZVPH DE Pain
DMLK605 ID DMLK605
DMLK605 DN Semparatide
DMLK605 HS Discontinued in Phase 2
DMLK605 SN RS-66271
DMLK605 CP Roche Bioscience
DMLK605 PC 16131055
DMLK605 MW 4005
DMLK605 FM C175H300N56O51
DMLK605 IC InChI=1S/C175H300N56O51/c1-24-93(20)138(230-169(279)127(80-233)227-143(253)101(37-26-30-56-177)201-130(237)78-196-142(252)100(36-25-29-55-176)202-165(275)124(73-135(246)247)226-164(274)122(71-98-76-191-82-198-98)223-162(272)120(69-91(16)17)220-160(270)117(66-88(10)11)216-151(261)107(43-49-128(181)235)209-163(273)121(70-97-75-190-81-197-97)222-154(264)112(48-54-134(244)245)212-168(278)126(79-232)228-170(280)137(92(18)19)229-141(251)94(21)180)171(281)213-108(44-50-129(182)236)152(262)225-125(74-136(248)249)166(276)221-113(62-84(2)3)155(265)207-106(42-35-61-195-175(188)189)145(255)205-104(40-33-59-193-173(184)185)144(254)206-105(41-34-60-194-174(186)187)146(256)208-111(47-53-133(242)243)153(263)217-118(67-89(12)13)159(269)219-115(64-86(6)7)157(267)211-109(45-51-131(238)239)149(259)203-102(38-27-31-57-178)147(257)214-116(65-87(8)9)158(268)218-114(63-85(4)5)156(266)210-110(46-52-132(240)241)150(260)204-103(39-28-32-58-179)148(258)215-119(68-90(14)15)161(271)224-123(72-99-77-192-83-199-99)167(277)231-139(96(23)234)172(282)200-95(22)140(183)250/h75-77,81-96,100-127,137-139,232-234H,24-74,78-80,176-180H2,1-23H3,(H2,181,235)(H2,182,236)(H2,183,250)(H,190,197)(H,191,198)(H,192,199)(H,196,252)(H,200,282)(H,201,237)(H,202,275)(H,203,259)(H,204,260)(H,205,255)(H,206,254)(H,207,265)(H,208,256)(H,209,273)(H,210,266)(H,211,267)(H,212,278)(H,213,281)(H,214,257)(H,215,258)(H,216,261)(H,217,263)(H,218,268)(H,219,269)(H,220,270)(H,221,276)(H,222,264)(H,223,272)(H,224,271)(H,225,262)(H,226,274)(H,227,253)(H,228,280)(H,229,251)(H,230,279)(H,231,277)(H,238,239)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,137-,138-,139-/m0/s1
DMLK605 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMLK605 IK BLQSIKSVAXFNRH-ZMWZJJJDSA-N
DMLK605 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMLK605 CA CAS 154906-40-8
DMLK605 DE Osteoporosis
DM75ZO0 ID DM75ZO0
DM75ZO0 DN SERAZAPINE HYDROCHLORIDE
DM75ZO0 HS Discontinued in Phase 2
DM75ZO0 SN CGS-15040A; Serazapine hydrochloride < Rec INNM; Rac-2-Methyl-1,3,4,16b-tetrahydro-2H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4]benzodiazepine-16-carboxylic acid methyl ester monohydrochloride
DM75ZO0 DT Small molecular drug
DM75ZO0 PC 60676
DM75ZO0 MW 397.9
DM75ZO0 FM C22H24ClN3O2
DM75ZO0 IC InChI=1S/C22H23N3O2.ClH/c1-23-11-12-24-17-9-5-3-7-15(17)13-25-18-10-6-4-8-16(18)20(22(26)27-2)21(25)19(24)14-23;/h3-10,19H,11-14H2,1-2H3;1H
DM75ZO0 CS CN1CCN2C(C1)C3=C(C4=CC=CC=C4N3CC5=CC=CC=C52)C(=O)OC.Cl
DM75ZO0 IK YEITZTKANLXOTH-UHFFFAOYSA-N
DM75ZO0 IU methyl 4-methyl-4,7,15-triazapentacyclo[13.7.0.02,7.08,13.016,21]docosa-1(22),8,10,12,16,18,20-heptaene-22-carboxylate;hydrochloride
DM75ZO0 CA CAS 117581-05-2
DM75ZO0 DE Anxiety disorder
DM9KB8A ID DM9KB8A
DM9KB8A DN SERGOLEXOLE MALEATE
DM9KB8A HS Discontinued in Phase 2
DM9KB8A SN LY-281067; Sergolexole maleate < Rec INNM; [trans-(8beta)]-1-Isopropyl-6-methylergoline-8-carboxylic acid 4-methoxycyclohexyl ester maleate; (9S)-4-Isopropyl-7-methyl-4,6,6abeta,7,8,9,10,10aalpha-octahydroindolo[3,4-fg]quinoline-9beta-carboxylic acid trans-4-methoxycyclohexyl ester maleate
DM9KB8A DT Small molecular drug
DM9KB8A PC 6435752
DM9KB8A MW 540.6
DM9KB8A FM C30H40N2O7
DM9KB8A IC InChI=1S/C26H36N2O3.C4H4O4/c1-16(2)28-15-17-13-24-22(21-6-5-7-23(28)25(17)21)12-18(14-27(24)3)26(29)31-20-10-8-19(30-4)9-11-20;5-3(6)1-2-4(7)8/h5-7,15-16,18-20,22,24H,8-14H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t18-,19?,20?,22-,24-;/m1./s1
DM9KB8A CS CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)OC4CCC(CC4)OC)C5=C2C1=CC=C5.C(=C\\C(=O)O)\\C(=O)O
DM9KB8A IK AWRYUNKJBYLYFR-VRUJKGOYSA-N
DM9KB8A IU (Z)-but-2-enedioic acid;(4-methoxycyclohexyl) (6aR,9R,10aR)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate
DM9KB8A CA CAS 108674-87-9
DM9KB8A DE Migraine
DMSLP2O ID DMSLP2O
DMSLP2O DN SERM-3339
DMSLP2O HS Discontinued in Phase 2
DMSLP2O SN HMR-3339; SERM compound, Aventis; 3339
DMSLP2O CP Hoechst Marion Roussel Inc
DMSLP2O DE Osteoporosis
DMBG6LP ID DMBG6LP
DMBG6LP DN SGB-1534
DMBG6LP HS Discontinued in Phase 2
DMBG6LP SN Sgb-1534; 3-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}quinazoline-2,4(1h,3h)-dione hydrochloride(1:1); SGB 1534; AC1Q3ELH; AC1L3TWP; SCHEMBL3624263; CTK8D4853; AKOS030540550; 88068-72-8; 3-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-(1H,3H)-quinazoline-2,4-dione hcl; 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1H-quinazoline-2,4-dione hydrochloride; 2,4(1H,3H)-Quinazolinedione,3-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-, monohydrochloride
DMBG6LP CP Chugai Pharmaceutical Co Ltd
DMBG6LP DT Small molecular drug
DMBG6LP PC 122064
DMBG6LP MW 416.9
DMBG6LP FM C21H25ClN4O3
DMBG6LP IC InChI=1S/C21H24N4O3.ClH/c1-28-19-9-5-4-8-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-6-2-3-7-17(16)22-21(25)27;/h2-9H,10-15H2,1H3,(H,22,27);1H
DMBG6LP CS COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)C4=CC=CC=C4NC3=O.Cl
DMBG6LP IK NPNDIKQZGVCHMQ-UHFFFAOYSA-N
DMBG6LP IU 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1H-quinazoline-2,4-dione;hydrochloride
DMBG6LP CA CAS 88068-72-8
DMBG6LP DE Hypotension
DM6XJ9D ID DM6XJ9D
DM6XJ9D DN SGS-111
DM6XJ9D HS Discontinued in Phase 2
DM6XJ9D SN Noopept; DVD-111; GVS-111
DM6XJ9D CP Russian Academy of Sciences
DM6XJ9D DE Cognitive impairment
DM7XC0U ID DM7XC0U
DM7XC0U DN SIB-1553A
DM7XC0U HS Discontinued in Phase 2
DM7XC0U SN 191611-89-9; SIB 1553A hydrochloride; SIB 1553A Hyrdrochloride; SIB 1553A HCl; SCHEMBL6333252; SIB 1553A; MolPort-035-765-827; AKOS024458336; LS-104963; J-012387; (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride; (+-)-4-((2-(1-Methyl-2-pyrrolidinyl)ethyl)thio)phenol hydrochloride; Phenol, 4-((2-(1-methyl-2-pyrrolidinyl)ethyl)thio)-, hydrochloride
DM7XC0U DT Small molecular drug
DM7XC0U PC 5310968
DM7XC0U MW 237.36
DM7XC0U FM C13H19NOS
DM7XC0U IC InChI=1S/C13H19NOS/c1-14-9-2-3-11(14)8-10-16-13-6-4-12(15)5-7-13/h4-7,11,15H,2-3,8-10H2,1H3
DM7XC0U CS CN1CCCC1CCSC2=CC=C(C=C2)O
DM7XC0U IK NVZGJSVPOOILDI-UHFFFAOYSA-N
DM7XC0U IU 4-[2-(1-methylpyrrolidin-2-yl)ethylsulfanyl]phenol
DM7XC0U CA CAS 191611-76-4
DM7XC0U CB CHEBI:125446
DM7XC0U DE Alzheimer disease
DMY30G2 ID DMY30G2
DMY30G2 DN SILPERISONE HYDROCHLORIDE
DMY30G2 HS Discontinued in Phase 2
DMY30G2 SN RGH-5002; SILA-336; Silperisone hydrochloride; 1-[(4-Fluorobenzyl)dimethylsilylmethyl]piperidine hydrochloride
DMY30G2 DT Small molecular drug
DMY30G2 PC 178567
DMY30G2 MW 301.9
DMY30G2 FM C15H25ClFNSi
DMY30G2 IC InChI=1S/C15H24FNSi.ClH/c1-18(2,13-17-10-4-3-5-11-17)12-14-6-8-15(16)9-7-14;/h6-9H,3-5,10-13H2,1-2H3;1H
DMY30G2 CS C[Si](C)(CC1=CC=C(C=C1)F)CN2CCCCC2.Cl
DMY30G2 IK VGKGHWXDGBFJTP-UHFFFAOYSA-N
DMY30G2 IU (4-fluorophenyl)methyl-dimethyl-(piperidin-1-ylmethyl)silane;hydrochloride
DMY30G2 CA CAS 140944-30-5
DMY30G2 DE Spasm
DMMZ2JT ID DMMZ2JT
DMMZ2JT DN SINITRODIL
DMMZ2JT HS Discontinued in Phase 2
DMMZ2JT SN ITF-296; Sinitrodil; 3-[2-(Nitrooxy)ethyl]-2H-1,3-benzoxazin-4(3H)-one
DMMZ2JT DT Small molecular drug
DMMZ2JT PC 121985
DMMZ2JT MW 238.2
DMMZ2JT FM C10H10N2O5
DMMZ2JT IC InChI=1S/C10H10N2O5/c13-10-8-3-1-2-4-9(8)16-7-11(10)5-6-17-12(14)15/h1-4H,5-7H2
DMMZ2JT CS C1N(C(=O)C2=CC=CC=C2O1)CCO[N+](=O)[O-]
DMMZ2JT IK POVFCWQCRHXYAB-UHFFFAOYSA-N
DMMZ2JT IU 2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethyl nitrate
DMMZ2JT CA CAS 143248-63-9
DMMZ2JT DE Angina pectoris
DMYP3KI ID DMYP3KI
DMYP3KI DN SINOMENINE
DMYP3KI HS Discontinued in Phase 2
DMYP3KI SN Cucoline; Kukoline; (9alpha,13alpha,14alpha)-4-Hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one
DMYP3KI DT Small molecular drug
DMYP3KI PC 5459308
DMYP3KI MW 329.4
DMYP3KI FM C19H23NO4
DMYP3KI IC InChI=1S/C19H23NO4/c1-20-7-6-19-10-14(21)16(24-3)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19/h4-5,9,12-13,22H,6-8,10H2,1-3H3/t12-,13+,19-/m1/s1
DMYP3KI CS CN1CC[C@@]23CC(=O)C(=C[C@@H]2[C@@H]1CC4=C3C(=C(C=C4)OC)O)OC
DMYP3KI IK INYYVPJSBIVGPH-QHRIQVFBSA-N
DMYP3KI IU (1R,9S,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one
DMYP3KI CA CAS 115-53-7
DMYP3KI CB CHEBI:9163
DMYP3KI DE Arthritis
DMMQ4GC ID DMMQ4GC
DMMQ4GC DN Sipatrigine
DMMQ4GC HS Discontinued in Phase 2
DMMQ4GC SN Sipatrigine; 130800-90-7; Sipatrigine [INN:BAN]; 619C89; 2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine; UNII-OON9AVW1T3; BW619C89; BW-619C89; BW 619C89; OON9AVW1T3; CHEMBL28854; CHEBI:34977; 2-(4-Methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine; 4-Amino-2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)pyrimidine; 4-Pyrimidinamine, 2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-; AC1Q3LMC; AC1L1TYB; MLS006010764; SCHEMBL135888; C16H17Cl3N4; DTXSID20156750; MolPort-023-277-047
DMMQ4GC DT Small molecular drug
DMMQ4GC PC 60803
DMMQ4GC MW 372.7
DMMQ4GC FM C15H16Cl3N5
DMMQ4GC IC InChI=1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21)
DMMQ4GC CS CN1CCN(CC1)C2=NC=C(C(=N2)N)C3=C(C(=CC(=C3)Cl)Cl)Cl
DMMQ4GC IK PDOCBJADCWMDGL-UHFFFAOYSA-N
DMMQ4GC IU 2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine
DMMQ4GC CA CAS 130800-90-7
DMMQ4GC CB CHEBI:34977
DMMQ4GC DE Neurological disorder
DM2BDAW ID DM2BDAW
DM2BDAW DN SK&F-S-106203
DM2BDAW HS Discontinued in Phase 2
DM2BDAW SN SK&F-106203; (S)-beta-[(2-Carboxyethyl)thio]-2-(8-phenyloctyl)benzenepropanoic acid; 3(S)-[2-(Carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propionic acid
DM2BDAW PC 3035514
DM2BDAW MW 442.6
DM2BDAW FM C26H34O4S
DM2BDAW IC InChI=1S/C26H34O4S/c27-25(28)17-18-31-24(20-26(29)30)23-16-10-15-22(19-23)14-7-4-2-1-3-6-11-21-12-8-5-9-13-21/h5,8-10,12-13,15-16,19,24H,1-4,6-7,11,14,17-18,20H2,(H,27,28)(H,29,30)/t24-/m0/s1
DM2BDAW CS C1=CC=C(C=C1)CCCCCCCCC2=CC(=CC=C2)[C@H](CC(=O)O)SCCC(=O)O
DM2BDAW IK IEOUXQMKLRALNJ-DEOSSOPVSA-N
DM2BDAW IU (3S)-3-(2-carboxyethylsulfanyl)-3-[3-(8-phenyloctyl)phenyl]propanoic acid
DM2BDAW CA CAS 129047-98-9
DM2BDAW DE Asthma
DM40HTZ ID DM40HTZ
DM40HTZ DN SKF-97426
DM40HTZ HS Discontinued in Phase 2
DM40HTZ SN SKF-97426A
DM40HTZ CP SmithKline Beecham plc
DM40HTZ DE Hyperlipidaemia
DME1JYP ID DME1JYP
DME1JYP DN SL-25.1039
DME1JYP HS Discontinued in Phase 2
DME1JYP CP Sanofi-Synthelabo
DME1JYP DE Urinary incontinence
DMAM9BD ID DMAM9BD
DMAM9BD DN SL65.0155
DMAM9BD HS Discontinued in Phase 2
DMAM9BD SN capeserod; 769901-96-4; 5-(8-Amino-7-chloro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-(1-phenethylpiperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one; SL65.0155; UNII-8163770L8P; 8163770L8P; 5-(8-AMINO-7-CHLORO-2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-3-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]-1,3,4-OXADIAZOL-2(3H)-ONE; Capeserod [INN]; GTPL29; SCHEMBL4707724; CHEMBL2027925; BDBM86038; ZINC603773; PDSP2_001247; PDSP1_001263; 2009AC; AKOS016011606; SL650155; AJ-23687; DB-030409; KB-243722; FT-0735661
DMAM9BD DT Small molecular drug
DMAM9BD PC 9805719
DMAM9BD MW 456.9
DMAM9BD FM C23H25ClN4O4
DMAM9BD IC InChI=1S/C23H25ClN4O4/c24-18-14-17(20-21(19(18)25)31-13-12-30-20)22-26-28(23(29)32-22)16-7-10-27(11-8-16)9-6-15-4-2-1-3-5-15/h1-5,14,16H,6-13,25H2
DMAM9BD CS C1CN(CCC1N2C(=O)OC(=N2)C3=CC(=C(C4=C3OCCO4)N)Cl)CCC5=CC=CC=C5
DMAM9BD IK MDBNTXARNGRHEV-UHFFFAOYSA-N
DMAM9BD IU 5-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2-one
DMAM9BD CA CAS 769901-96-4
DMAM9BD DE Parkinson disease
DMU5RKC ID DMU5RKC
DMU5RKC DN SL65.0472
DMU5RKC HS Discontinued in Phase 2
DMU5RKC DT Small molecular drug
DMU5RKC PC 9869105
DMU5RKC MW 465.5
DMU5RKC FM C24H24FN5O2S
DMU5RKC IC InChI=1S/C24H24FN5O2S/c25-17-1-2-18-16(13-23(32)30(15-22(26)31)20(18)14-17)4-7-28-8-10-29(11-9-28)24-19-5-12-33-21(19)3-6-27-24/h1-3,5-6,12-14H,4,7-11,15H2,(H2,26,31)
DMU5RKC CS C1CN(CCN1CCC2=CC(=O)N(C3=C2C=CC(=C3)F)CC(=O)N)C4=NC=CC5=C4C=CS5
DMU5RKC IK JDLYOFUDIKMYBL-UHFFFAOYSA-N
DMU5RKC IU 2-[7-fluoro-2-oxo-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]quinolin-1-yl]acetamide
DMU5RKC CA CAS 189003-92-7
DMU5RKC DE Cardiovascular disease
DMS8AHE ID DMS8AHE
DMS8AHE DN SL-65.1498
DMS8AHE HS Discontinued in Phase 2
DMS8AHE SN SL-651498; 6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one
DMS8AHE DE Anxiety disorder
DMOXUEP ID DMOXUEP
DMOXUEP DN SL-89.0591
DMOXUEP HS Discontinued in Phase 2
DMOXUEP CP Synthelabo
DMOXUEP DE Prostate disease
DMBZM0D ID DMBZM0D
DMBZM0D DN SLV-305
DMBZM0D HS Discontinued in Phase 2
DMBZM0D CP Solvay SA
DMBZM0D DE Gastric motility disorder
DM71WGZ ID DM71WGZ
DM71WGZ DN SLV-310
DM71WGZ HS Discontinued in Phase 2
DM71WGZ SN L001635; 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione
DM71WGZ CP Solvay Pharma
DM71WGZ DT Small molecular drug
DM71WGZ PC 9888211
DM71WGZ MW 417.5
DM71WGZ FM C25H24FN3O2
DM71WGZ IC InChI=1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2
DM71WGZ CS C1CN(CC=C1C2=CNC3=C2C=C(C=C3)F)CCCCN4C(=O)C5=CC=CC=C5C4=O
DM71WGZ IK NECJNLXOJRDELU-UHFFFAOYSA-N
DM71WGZ IU 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]isoindole-1,3-dione
DM71WGZ CA CAS 264869-71-8
DM71WGZ DE Schizophrenia
DM0GKHX ID DM0GKHX
DM0GKHX DN SLV319
DM0GKHX HS Discontinued in Phase 2
DM0GKHX CP Solvay Pharmaceuticals
DM0GKHX DT Small molecular drug
DM0GKHX PC 11179267
DM0GKHX MW 487.4
DM0GKHX FM C23H20Cl2N4O2S
DM0GKHX IC InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)
DM0GKHX CS CN=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
DM0GKHX IK AXJQVVLKUYCICH-UHFFFAOYSA-N
DM0GKHX IU 5-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide
DM0GKHX CA CAS 362519-49-1
DM0GKHX DE Obesity
DM1J0YB ID DM1J0YB
DM1J0YB DN SLX-2101
DM1J0YB HS Discontinued in Phase 2
DM1J0YB CP Kadmon Pharmaceuticals; Nano Terra
DM1J0YB DE Raynaud disease; Hypertension; Erectile dysfunction
DMZYGW0 ID DMZYGW0
DMZYGW0 DN SM-10661
DMZYGW0 HS Discontinued in Phase 2
DMZYGW0 SN SM-12502; SM-10661 (racemate); Rac-cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride; (+)-cis-(2R,5S)-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride
DMZYGW0 DT Small molecular drug
DMZYGW0 PC 178014
DMZYGW0 MW 244.74
DMZYGW0 FM C10H13ClN2OS
DMZYGW0 IC InChI=1S/C10H12N2OS.ClH/c1-7-9(13)12(2)10(14-7)8-4-3-5-11-6-8;/h3-7,10H,1-2H3;1H/t7-,10+;/m0./s1
DMZYGW0 CS C[C@H]1C(=O)N([C@H](S1)C2=CN=CC=C2)C.Cl
DMZYGW0 IK CXHDSLQCNYLQND-XQRIHRDZSA-N
DMZYGW0 IU (2R,5S)-3,5-dimethyl-2-pyridin-3-yl-1,3-thiazolidin-4-one;hydrochloride
DMZYGW0 CA CAS 158511-47-8
DMZYGW0 DE Sepsis
DMBUH7E ID DMBUH7E
DMBUH7E DN SM-10888
DMBUH7E HS Discontinued in Phase 2
DMBUH7E SN AC1L52EB; 2,4-Methanoacridin-9-amine, 8-fluoro-1,2,3,4-tetrahydro-, 2-hydroxy-1,2,3-propanetricarboxylate (3:2)
DMBUH7E CP Sumitomo Pharmaceuticals Co Ltd
DMBUH7E PC 6918149
DMBUH7E MW 420.4
DMBUH7E FM C20H21FN2O7
DMBUH7E IC InChI=1S/C14H13FN2.C6H8O7/c15-10-2-1-3-11-12(10)13(16)9-6-7-4-8(5-7)14(9)17-11;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-3,7-8H,4-6H2,(H2,16,17);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMBUH7E CS C1C2CC1C3=NC4=C(C(=CC=C4)F)C(=C3C2)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMBUH7E IK ZCELBELLETVSEJ-UHFFFAOYSA-N
DMBUH7E IU 8-fluoro-3-azatetracyclo[11.1.1.02,11.04,9]pentadeca-2,4(9),5,7,10-pentaen-10-amine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMBUH7E DE Cognitive impairment
DMJ816F ID DMJ816F
DMJ816F DN Sodelglitazar
DMJ816F HS Discontinued in Phase 2
DMJ816F SN Sodelglitazar; 447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac
DMJ816F CP GlaxoSmithKline
DMJ816F DT Small molecular drug
DMJ816F PC 9805950
DMJ816F MW 499.5
DMJ816F FM C23H21F4NO3S2
DMJ816F IC InChI=1S/C23H21F4NO3S2/c1-12-9-15(6-8-18(12)31-22(3,4)21(29)30)32-11-19-13(2)28-20(33-19)16-7-5-14(10-17(16)24)23(25,26)27/h5-10H,11H2,1-4H3,(H,29,30)
DMJ816F CS CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=C(C=C(C=C3)C(F)(F)F)F)C)OC(C)(C)C(=O)O
DMJ816F IK ZUGQWAYOWCBWGM-UHFFFAOYSA-N
DMJ816F IU 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid
DMJ816F CA CAS 447406-78-2
DMJ816F DE Hyperlipidaemia
DMHITR4 ID DMHITR4
DMHITR4 DN SOLPECAINOL HYDROCHLORIDE
DMHITR4 HS Discontinued in Phase 2
DMHITR4 SN EGYT-2936; Solpecainol hydrochloride; Rac-threo-2-(1-Methyl-2-phenoxyethylamino)-1-phenyl-1,3-propanediol hydrochloride; Rac-[1R*,2S*(S*)]-2-[(1-Methyl-2-phenoxyethyl)amino]-1-phenyl-1,3-propanediol hydrochloride
DMHITR4 DT Small molecular drug
DMHITR4 PC 6918180
DMHITR4 MW 337.8
DMHITR4 FM C18H24ClNO3
DMHITR4 IC InChI=1S/C18H23NO3.ClH/c1-14(13-22-16-10-6-3-7-11-16)19-17(12-20)18(21)15-8-4-2-5-9-15;/h2-11,14,17-21H,12-13H2,1H3;1H/t14-,17-,18+;/m0./s1
DMHITR4 CS C[C@@H](COC1=CC=CC=C1)N[C@@H](CO)[C@@H](C2=CC=CC=C2)O.Cl
DMHITR4 IK ZERZMJPMHWGYET-QSCFYETBSA-N
DMHITR4 IU (1R,2S)-2-[[(2S)-1-phenoxypropan-2-yl]amino]-1-phenylpropane-1,3-diol;hydrochloride
DMHITR4 DE Cardiac arrhythmias
DMCS8FM ID DMCS8FM
DMCS8FM DN SORAPRAZAN
DMCS8FM HS Discontinued in Phase 2
DMCS8FM SN BY-359; Soraprazan; 2,3-Dimethyl-7(R)-(2-methoxyethoxy)-9(R)-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8(R)-ol
DMCS8FM DT Small molecular drug
DMCS8FM PC 213054
DMCS8FM MW 367.4
DMCS8FM FM C21H25N3O3
DMCS8FM IC InChI=1S/C21H25N3O3/c1-13-14(2)24-10-9-16-18(21(24)22-13)23-17(15-7-5-4-6-8-15)19(25)20(16)27-12-11-26-3/h4-10,17,19-20,23,25H,11-12H2,1-3H3/t17-,19-,20-/m1/s1
DMCS8FM CS CC1=C(N2C=CC3=C(C2=N1)N[C@@H]([C@H]([C@@H]3OCCOC)O)C4=CC=CC=C4)C
DMCS8FM IK PWILYDZRJORZDR-MISYRCLQSA-N
DMCS8FM IU (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol
DMCS8FM CA CAS 261944-46-1
DMCS8FM DE Peptic ulcer
DMPAEK5 ID DMPAEK5
DMPAEK5 DN SOU-001
DMPAEK5 HS Discontinued in Phase 2
DMPAEK5 SN AA-10020; DRP-001
DMPAEK5 CP Arachnova Therapeutics Ltd
DMPAEK5 DE Urinary incontinence
DMTJNRL ID DMTJNRL
DMTJNRL DN SPD-473
DMTJNRL HS Discontinued in Phase 2
DMTJNRL SN BTS-74398
DMTJNRL CP Shire Pharmaceuticals; Knoll Pharmaceuticals Co
DMTJNRL DE Mood disorder
DMTC4VY ID DMTC4VY
DMTC4VY DN SQ-30741
DMTC4VY HS Discontinued in Phase 2
DMTC4VY SN [1S-(1beta,2alpha(5Z),3alpha,4beta)]-7-[3-[[[[(1-Oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid
DMTC4VY DT Small molecular drug
DMTC4VY PC 5311394
DMTC4VY MW 422.6
DMTC4VY FM C23H38N2O5
DMTC4VY IC InChI=1S/C23H38N2O5/c1-2-3-4-8-11-21(26)25-16-22(27)24-15-18-17(19-13-14-20(18)30-19)10-7-5-6-9-12-23(28)29/h5,7,17-20H,2-4,6,8-16H2,1H3,(H,24,27)(H,25,26)(H,28,29)/b7-5-/t17-,18+,19+,20-/m1/s1
DMTC4VY CS CCCCCCC(=O)NCC(=O)NC[C@@H]1[C@H]2CC[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O2
DMTC4VY IK OPZODFCEYJMBAM-OXVBEWKXSA-N
DMTC4VY IU (Z)-7-[(1S,2R,3R,4R)-3-[[[2-(heptanoylamino)acetyl]amino]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMTC4VY CA CAS 107332-47-8
DMTC4VY DE Thrombosis
DMSQRXW ID DMSQRXW
DMSQRXW DN SQ-32709
DMSQRXW HS Discontinued in Phase 2
DMSQRXW SN farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330
DMSQRXW CP Bristol-Myers Squibb Co
DMSQRXW DT Small molecular drug
DMSQRXW PC 445713
DMSQRXW MW 382.33
DMSQRXW FM C15H28O7P2
DMSQRXW IC InChI=1S/C15H28O7P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-21-24(19,20)22-23(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+
DMSQRXW CS CC(=CCC/C(=C/CC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)/C)C
DMSQRXW IK VWFJDQUYCIWHTN-YFVJMOTDSA-N
DMSQRXW IU phosphono [(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl] hydrogen phosphate
DMSQRXW CA CAS 372-97-4
DMSQRXW CB CHEBI:17407
DMSQRXW DE Arteriosclerosis
DMCEQKG ID DMCEQKG
DMCEQKG DN SR-121787
DMCEQKG HS Discontinued in Phase 2
DMCEQKG SN SR-121566; SR-121566a
DMCEQKG CP Sanofi-Synthelabo
DMCEQKG DT Small molecular drug
DMCEQKG PC 9833004
DMCEQKG MW 559.7
DMCEQKG FM C27H37N5O6S
DMCEQKG IC InChI=1S/C27H37N5O6S/c1-4-36-23(33)13-16-32(21-11-14-31(15-12-21)17-24(34)37-5-2)26-29-22(18-39-26)19-7-9-20(10-8-19)25(28)30-27(35)38-6-3/h7-10,18,21H,4-6,11-17H2,1-3H3,(H2,28,30,35)
DMCEQKG CS CCOC(=O)CCN(C1CCN(CC1)CC(=O)OCC)C2=NC(=CS2)C3=CC=C(C=C3)/C(=N/C(=O)OCC)/N
DMCEQKG IK WJMRSKGCJGOLKV-UHFFFAOYSA-N
DMCEQKG IU ethyl 3-[[4-[4-[(Z)-N'-ethoxycarbonylcarbamimidoyl]phenyl]-1,3-thiazol-2-yl]-[1-(2-ethoxy-2-oxoethyl)piperidin-4-yl]amino]propanoate
DMCEQKG DE Thrombosis
DMV4FT2 ID DMV4FT2
DMV4FT2 DN SR-57227
DMV4FT2 HS Discontinued in Phase 2
DMV4FT2 SN SR-57227A
DMV4FT2 CP Sanofi
DMV4FT2 DT Small molecular drug
DMV4FT2 PC 131747
DMV4FT2 MW 211.69
DMV4FT2 FM C10H14ClN3
DMV4FT2 IC InChI=1S/C10H14ClN3/c11-9-2-1-3-10(13-9)14-6-4-8(12)5-7-14/h1-3,8H,4-7,12H2
DMV4FT2 CS C1CN(CCC1N)C2=NC(=CC=C2)Cl
DMV4FT2 IK WPVVMKYQOMJPIN-UHFFFAOYSA-N
DMV4FT2 IU 1-(6-chloropyridin-2-yl)piperidin-4-amine
DMV4FT2 CA CAS 77145-51-8
DMV4FT2 CB CHEBI:92163
DMV4FT2 DE Major depressive disorder
DMROKDM ID DMROKDM
DMROKDM DN SR-90067
DMROKDM HS Discontinued in Phase 2
DMROKDM SN Estradiol spray (menopausis), Sanofi-Synthelabo
DMROKDM CP Sanofi-Synthelabo
DMROKDM DE Hormone deficiency
DMRKE9G ID DMRKE9G
DMRKE9G DN SRI-62-834
DMRKE9G HS Discontinued in Phase 2
DMRKE9G SN CRC-8605; Rac-2-[Hydroxy[2-(octadecyloxymethyl)tetrahydrofuran-2-ylmethoxy]phosphinyloxy]-N,N,N-trimethylethylamminium hydroxyde,inner salt P-oxide
DMRKE9G DT Small molecular drug
DMRKE9G PC 130724
DMRKE9G MW 549.8
DMRKE9G FM C29H60NO6P
DMRKE9G IC InChI=1S/C29H60NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-33-27-29(22-21-25-34-29)28-36-37(31,32)35-26-23-30(2,3)4/h5-28H2,1-4H3
DMRKE9G CS CCCCCCCCCCCCCCCCCCOCC1(CCCO1)COP(=O)([O-])OCC[N+](C)(C)C
DMRKE9G IK OEWZGBLJCYAMEG-UHFFFAOYSA-N
DMRKE9G IU [2-(octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate
DMRKE9G CA CAS 113201-37-9
DMRKE9G DE Solid tumour/cancer
DMN7BM3 ID DMN7BM3
DMN7BM3 DN SSR-182289
DMN7BM3 HS Discontinued in Phase 2
DMN7BM3 SN SSR-182289A; N-[3-[N-[4-(5-Aminopyridin-2-yl)-1(S)-[4-(difluoromethylene)piperidin-1-ylcarbonyl]butyl]sulfamoyl]biphenyl-2-yl]acetamide hydrochloride
DMN7BM3 DE Myocardial infarction
DMNRW68 ID DMNRW68
DMNRW68 DN SU-14813
DMNRW68 HS Discontinued in Phase 2
DMNRW68 SN SU 14813; SU14813; 5-((5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
DMNRW68 CP Pfizer
DMNRW68 TC Anticancer Agents
DMNRW68 DT Small molecular drug
DMNRW68 PC 73755145
DMNRW68 MW 442.5
DMNRW68 FM C23H27FN4O4
DMNRW68 IC InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9-10,16,21,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30)/b18-10-/t16-,21?/m0/s1
DMNRW68 CS CC1=C(N=C(C1C(=O)NC[C@@H](CN2CCOCC2)O)C)/C=C\\3/C4=C(C=CC(=C4)F)NC3=O
DMNRW68 IK XWPFYHDOZULRTD-ROUJOJKSSA-N
DMNRW68 IU 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-3H-pyrrole-3-carboxamide
DMNRW68 DE Breast cancer
DMBSLZV ID DMBSLZV
DMBSLZV DN Sulukast
DMBSLZV HS Discontinued in Phase 2
DMBSLZV SN LY-170680
DMBSLZV CP Eli Lilly & Co
DMBSLZV DT Small molecular drug
DMBSLZV PC 6436123
DMBSLZV MW 472.6
DMBSLZV FM C25H36N4O3S
DMBSLZV IC InChI=1S/C25H36N4O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16-22(33-18-17-23(30)31)24(32)20-14-13-15-21(19-20)25-26-28-29-27-25/h10-16,19,22,24,32H,2-9,17-18H2,1H3,(H,30,31)(H,26,27,28,29)/b11-10-,16-12+/t22-,24+/m1/s1
DMBSLZV CS CCCCCCCCC/C=C\\C=C\\[C@H]([C@H](C1=CC=CC(=C1)C2=NNN=N2)O)SCCC(=O)O
DMBSLZV IK YPHOSUPSOWQQCB-AFOLHBCXSA-N
DMBSLZV IU 3-[(1S,2R,3E,5Z)-1-hydroxy-1-[3-(2H-tetrazol-5-yl)phenyl]pentadeca-3,5-dien-2-yl]sulfanylpropanoic acid
DMBSLZV CA CAS 98116-53-1
DMBSLZV DE Asthma
DMWTLQ4 ID DMWTLQ4
DMWTLQ4 DN SUN-1334H
DMWTLQ4 HS Discontinued in Phase 2
DMWTLQ4 SN Histamine H1 receptor antagonist (oral, allergy) Sun Pharmaceutical
DMWTLQ4 CP Sun Pharmaceutical Industries Ltd
DMWTLQ4 PC 69509032
DMWTLQ4 MW 489.4
DMWTLQ4 FM C23H28Cl2F2N2O3
DMWTLQ4 IC InChI=1S/C23H26F2N2O3.2ClH/c24-20-7-3-18(4-8-20)23(19-5-9-21(25)10-6-19)27-14-12-26(13-15-27)11-1-2-16-30-17-22(28)29;;/h1-10,23H,11-17H2,(H,28,29);2*1H/b2-1+;;
DMWTLQ4 CS C1CN(CCN1C/C=C/COCC(=O)O)C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F.Cl.Cl
DMWTLQ4 IK KAQMKGKFTBFMGE-SEPHDYHBSA-N
DMWTLQ4 IU 2-[(E)-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]but-2-enoxy]acetic acid;dihydrochloride
DMWTLQ4 DE Allergic rhinitis
DMZ8VI0 ID DMZ8VI0
DMZ8VI0 DN SUN-C5174
DMZ8VI0 HS Discontinued in Phase 2
DMZ8VI0 SN 5-[3-[4-(4-Fluorophenyl)piperazin-1-yl]propyl]-8(S)-hydroxy-1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepin-4-one
DMZ8VI0 DE Peripheral vascular disease
DM19Y0T ID DM19Y0T
DM19Y0T DN SUPER-LEU-DOX
DM19Y0T HS Discontinued in Phase 2
DM19Y0T SN CPI-0004; CPI-0004Na; CPI-004Na; DTS-201; TAP-doxorubicin; TSP-doxorubicin; Phthacene-5,12-dione sodium salt; N-[N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl]daunorubicin sodium salt; (8S,10S)-10-[3-[N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy]-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrona
DM19Y0T CP Diatos SA
DM19Y0T DE Solid tumour/cancer
DMDZ7AY ID DMDZ7AY
DMDZ7AY DN Suritozole
DMDZ7AY HS Discontinued in Phase 2
DMDZ7AY SN MDL-26479
DMDZ7AY CP Hoechst Marion Roussel Inc
DMDZ7AY DT Small molecular drug
DMDZ7AY PC 25431
DMDZ7AY MW 223.27
DMDZ7AY FM C10H10FN3S
DMDZ7AY IC InChI=1S/C10H10FN3S/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6H,1-2H3
DMDZ7AY CS CN1C(=NN(C1=S)C)C2=CC(=CC=C2)F
DMDZ7AY IK IWDUZEHNLHFBRZ-UHFFFAOYSA-N
DMDZ7AY IU 5-(3-fluorophenyl)-2,4-dimethyl-1,2,4-triazole-3-thione
DMDZ7AY CA CAS 110623-33-1
DMDZ7AY DE Major depressive disorder
DMGFS51 ID DMGFS51
DMGFS51 DN T-1095
DMGFS51 HS Discontinued in Phase 2
DMGFS51 SN RWJ-394718; T-0687; T-1095A; SGLT-2 inhibitors (diabetes), Tanabe/Johnson & Johnson
DMGFS51 CP Tanabe Seiyaku Co Ltd
DMGFS51 DT Small molecular drug
DMGFS51 PC 6918410
DMGFS51 MW 516.5
DMGFS51 FM C26H28O11
DMGFS51 IC InChI=1S/C26H28O11/c1-13-9-17(28)21(16(27)5-3-14-4-6-18-15(11-14)7-8-34-18)19(10-13)36-25-24(31)23(30)22(29)20(37-25)12-35-26(32)33-2/h4,6-11,20,22-25,28-31H,3,5,12H2,1-2H3/t20-,22-,23+,24-,25-/m1/s1
DMGFS51 CS CC1=CC(=C(C(=C1)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)OC)O)O)O)C(=O)CCC3=CC4=C(C=C3)OC=C4)O
DMGFS51 IK BXNCIERBDJYIQT-PRDVQWLOSA-N
DMGFS51 IU [(2R,3S,4S,5R,6S)-6-[2-[3-(1-benzofuran-5-yl)propanoyl]-3-hydroxy-5-methylphenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl methyl carbonate
DMGFS51 CA CAS 209746-59-8
DMGFS51 DE Diabetic complication
DMZTL7H ID DMZTL7H
DMZTL7H DN T487
DMZTL7H HS Discontinued in Phase 2
DMZTL7H SN AC1MVK5U; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methyl-ethanamine; 2-(2,4-diethyloctoxy)-N-[2-(2,4-diethyloctoxy)ethyl]-N-methylethanamine
DMZTL7H CP Amgen
DMZTL7H DT Small molecular drug
DMZTL7H PC 12896
DMZTL7H MW 242.23
DMZTL7H FM C12H10N4O2
DMZTL7H IC InChI=1S/C12H10N4O2/c13-9-1-3-10(4-2-9)14-15-11-5-7-12(8-6-11)16(17)18/h1-8H,13H2
DMZTL7H CS C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)[N+](=O)[O-]
DMZTL7H IK UNBOSJFEZZJZLR-UHFFFAOYSA-N
DMZTL7H IU 4-[(4-nitrophenyl)diazenyl]aniline
DMZTL7H CA CAS 730-40-5
DMZTL7H CB CHEBI:75648
DMZTL7H DE Inflammation; Psoriatic disorder
DM7XGJY ID DM7XGJY
DM7XGJY DN T-506
DM7XGJY HS Discontinued in Phase 2
DM7XGJY SN 2'-Deoxy-5-fluoro-3'-oleoyluridine 5'-[2-(trimethylammonio)ethyl]phosphate hydrate
DM7XGJY DT Small molecular drug
DM7XGJY PC 6441168
DM7XGJY MW 675.8
DM7XGJY FM C32H55FN3O9P
DM7XGJY IC InChI=1S/C32H55FN3O9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-30(37)45-27-23-29(35-24-26(33)31(38)34-32(35)39)44-28(27)25-43-46(40,41)42-22-21-36(2,3)4/h12-13,24,27-29H,5-11,14-23,25H2,1-4H3,(H-,34,38,39,40,41)/b13-12+
DM7XGJY CS CCCCCCCC/C=C/CCCCCCCC(=O)OC1CC(OC1COP(=O)([O-])OCC[N+](C)(C)C)N2C=C(C(=O)NC2=O)F
DM7XGJY IK JLGWAGKPIWGUEH-OUKQBFOZSA-N
DM7XGJY IU [5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-[(E)-octadec-9-enoyl]oxyoxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate
DM7XGJY CA CAS 104884-43-7
DM7XGJY DE Solid tumour/cancer
DMD3CUJ ID DMD3CUJ
DMD3CUJ DN T-5224
DMD3CUJ HS Discontinued in Phase 2
DMD3CUJ SN AKOS003047196; T5224
DMD3CUJ CP Toyama Chemical
DMD3CUJ DT Small molecular drug
DMD3CUJ PC 23626877
DMD3CUJ MW 517.5
DMD3CUJ FM C29H27NO8
DMD3CUJ IC InChI=1S/C29H27NO8/c31-24-15-21(37-20-3-1-2-4-20)8-10-22(24)28(34)19-6-11-25(18(14-19)7-12-27(32)33)36-16-17-5-9-23-26(13-17)38-30-29(23)35/h5-6,8-11,13-15,20,31H,1-4,7,12,16H2,(H,30,35)(H,32,33)
DMD3CUJ CS C1CCC(C1)OC2=CC(=C(C=C2)C(=O)C3=CC(=C(C=C3)OCC4=CC5=C(C=C4)C(=O)NO5)CCC(=O)O)O
DMD3CUJ IK DALCQQSLNPLQFZ-UHFFFAOYSA-N
DMD3CUJ IU 3-[5-(4-cyclopentyloxy-2-hydroxybenzoyl)-2-[(3-oxo-1,2-benzoxazol-6-yl)methoxy]phenyl]propanoic acid
DMD3CUJ DE Rheumatoid arthritis
DM3M5TU ID DM3M5TU
DM3M5TU DN T-588
DM3M5TU HS Discontinued in Phase 2
DM3M5TU SN (-)-(R)-1-(Benzothiophen-5-yl)-2-[2-(diethylamino)ethoxy]ethanol hydrochloride; 131965-06-5
DM3M5TU DT Small molecular drug
DM3M5TU PC 132522
DM3M5TU MW 329.9
DM3M5TU FM C16H24ClNO2S
DM3M5TU IC InChI=1S/C16H23NO2S.ClH/c1-3-17(4-2)8-9-19-12-15(18)13-5-6-16-14(11-13)7-10-20-16;/h5-7,10-11,15,18H,3-4,8-9,12H2,1-2H3;1H/t15-;/m0./s1
DM3M5TU CS CCN(CC)CCOC[C@@H](C1=CC2=C(C=C1)SC=C2)O.Cl
DM3M5TU IK BKMCUGFGPQNYHG-RSAXXLAASA-N
DM3M5TU IU (1R)-1-(1-benzothiophen-5-yl)-2-[2-(diethylamino)ethoxy]ethanol;hydrochloride
DM3M5TU CA CAS 142935-03-3
DM3M5TU DE Amyotrophic lateral sclerosis
DMDN3TV ID DMDN3TV
DMDN3TV DN T611
DMDN3TV HS Discontinued in Phase 2
DMDN3TV SN T-0902611; T-611; T-902611; T-902611); 4-[4-(1H-Imidazol-1-yl)-6-methyl-5-nitropyrimidin-2-yl]-3(S)-methylmorpholine benzenesulfonate
DMDN3TV CP Amgen
DMDN3TV PC 135465071
DMDN3TV MW 416.4
DMDN3TV FM C20H13N2NaO5S
DMDN3TV IC InChI=1S/C20H14N2O5S.Na/c23-17-11-18(28(25,26)27)14-7-3-4-8-15(14)19(17)22-21-16-10-9-12-5-1-2-6-13(12)20(16)24;/h1-11,23-24H,(H,25,26,27);/q;+1/p-1
DMDN3TV CS C1=CC=C2C(=C1)C=CC(=C2O)N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)[O-])O.[Na+]
DMDN3TV IK HOWITLLZNKSJOJ-UHFFFAOYSA-M
DMDN3TV IU sodium;3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]naphthalene-1-sulfonate
DMDN3TV CA CAS 3564-14-5
DMDN3TV DE Virus infection
DMBZG2Y ID DMBZG2Y
DMBZG2Y DN TA-5538
DMBZG2Y HS Discontinued in Phase 2
DMBZG2Y SN IDDBCP232835
DMBZG2Y CP Tanabe Seiyaku Co Ltd
DMBZG2Y DE Overactive bladder
DMB3W20 ID DMB3W20
DMB3W20 DN TA-6666
DMB3W20 HS Discontinued in Phase 2
DMB3W20 SN T-6666; 815541
DMB3W20 CP GlaxoSmithKline plc
DMB3W20 DE Type-2 diabetes
DM1Z74X ID DM1Z74X
DM1Z74X DN Tacedinaline
DM1Z74X HS Discontinued in Phase 2
DM1Z74X SN Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide
DM1Z74X CP National Cancer Institute (NCI)
DM1Z74X DT Small molecular drug
DM1Z74X PC 2746
DM1Z74X MW 269.3
DM1Z74X FM C15H15N3O2
DM1Z74X IC InChI=1S/C15H15N3O2/c1-10(19)17-12-8-6-11(7-9-12)15(20)18-14-5-3-2-4-13(14)16/h2-9H,16H2,1H3,(H,17,19)(H,18,20)
DM1Z74X CS CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
DM1Z74X IK VAZAPHZUAVEOMC-UHFFFAOYSA-N
DM1Z74X IU 4-acetamido-N-(2-aminophenyl)benzamide
DM1Z74X CA CAS 112522-64-2
DM1Z74X CB CHEBI:90195
DM1Z74X DE Solid tumour/cancer
DM0TDZI ID DM0TDZI
DM0TDZI DN TAK-013
DM0TDZI HS Discontinued in Phase 2
DM0TDZI SN Sufugolix; TAK-013; 308831-61-0; UNII-56S17Z6X9M; CHEMBL22055; 56S17Z6X9M; TAK 013; Sufugolix [INN:BAN]; Sufugolix(TAK-013); SCHEMBL209021; GTPL1185; AC1MI503; DTXSID40184893; UCQSBGOFELXYIN-UHFFFAOYSA-N; MolPort-046-033-569; ZINC3842924; BDBM50122654; AKOS030629545; CS-6434; AS-35342; HY-100209; L001648; N-(4-(5-((benzyl(methyl)amino)methyl)-1-(2,6-difluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
DM0TDZI DT Small molecular drug
DM0TDZI PC 3038517
DM0TDZI MW 667.7
DM0TDZI FM C36H31F2N5O4S
DM0TDZI IC InChI=1S/C36H31F2N5O4S/c1-41(20-23-10-5-3-6-11-23)21-28-31-33(44)43(26-12-7-4-8-13-26)36(46)42(22-27-29(37)14-9-15-30(27)38)34(31)48-32(28)24-16-18-25(19-17-24)39-35(45)40-47-2/h3-19H,20-22H2,1-2H3,(H2,39,40,45)
DM0TDZI CS CN(CC1=CC=CC=C1)CC2=C(SC3=C2C(=O)N(C(=O)N3CC4=C(C=CC=C4F)F)C5=CC=CC=C5)C6=CC=C(C=C6)NC(=O)NOC
DM0TDZI IK UCQSBGOFELXYIN-UHFFFAOYSA-N
DM0TDZI IU 1-[4-[5-[[benzyl(methyl)amino]methyl]-1-[(2,6-difluorophenyl)methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
DM0TDZI CA CAS 308831-61-0
DM0TDZI DE Uterine fibroids
DMBQ87R ID DMBQ87R
DMBQ87R DN TAK-044
DMBQ87R HS Discontinued in Phase 2
DMBQ87R SN TAK 044; 2-[(2R,5S,8S,11S,14S,17R)-8-(carboxymethyl)-17-(1H-indol-3-ylmethyl)-14-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-5-[2-oxo-2-(4-phenylpiperidin-1-yl)ethyl]-11-thiophen-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetic acid; AC1NSKOX; TAK044
DMBQ87R CP Takeda Pharmaceutical Co Ltd
DMBQ87R DT Small molecular drug
DMBQ87R PC 123882
DMBQ87R MW 972
DMBQ87R FM C45H51N9Na2O11S
DMBQ87R IC InChI=1S/C45H53N9O11S.2Na/c1-25(2)19-30-40(60)47-31(20-26-24-46-29-12-7-6-11-28(26)29)41(61)49-33(22-37(56)57)43(63)48-32(21-36(55)54-16-14-53(15-17-54)27-9-4-3-5-10-27)42(62)50-34(23-38(58)59)44(64)52-39(45(65)51-30)35-13-8-18-66-35;;/h3-13,18,24-25,30-34,39,46H,14-17,19-23H2,1-2H3,(H,47,60)(H,48,63)(H,49,61)(H,50,62)(H,51,65)(H,52,64)(H,56,57)(H,58,59);;/q;2*+1/p-2/t30-,31+,32-,33+,34-,39+;;/m0../s1
DMBQ87R CS CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)C2=CC=CS2)CC(=O)[O-])CC(=O)N3CCN(CC3)C4=CC=CC=C4)CC(=O)[O-])CC5=CNC6=CC=CC=C65.[Na+].[Na+]
DMBQ87R IK UWHBIISPHYTOGL-PFSAEEMXSA-L
DMBQ87R IU disodium;2-[(2R,5S,8S,11S,14S,17R)-8-(carboxylatomethyl)-17-(1H-indol-3-ylmethyl)-14-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-11-thiophen-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetate
DMBQ87R CA CAS 157380-72-8
DMBQ87R DE Renal failure
DM8S173 ID DM8S173
DM8S173 DN TAK-201
DM8S173 HS Discontinued in Phase 2
DM8S173 SN TAC-201; MT-201, Meiji
DM8S173 CP Meiji Dairies Corp
DM8S173 DE Allergy
DM7S69Q ID DM7S69Q
DM7S69Q DN TAK-218
DM7S69Q HS Discontinued in Phase 2
DM7S69Q CP TAP Pharmaceuticals Inc
DM7S69Q DE Neurological disorder
DMG4RFO ID DMG4RFO
DMG4RFO DN TAK-442
DMG4RFO HS Discontinued in Phase 2
DMG4RFO SN Letaxaban; TAK-442; 870262-90-1; UNII-Y3WB03966W; TAK 442; CHEMBL1095032; Y3WB03966W; 1-(1-{(2S)-3-[(6-Chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}piperidin-4-yl)tetrahydropyrimidin-2(1H)-one; 2(1H)-Pyrimidinone,1-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]tetrahydro-; Letaxaban [USAN:INN]; 1-[1-[(2S)-3-[(6-Chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl]piperidin-4-yl]tetrahydropyrimidin-2(1H)-one; 3kl6; Letaxaban (USAN/INN); SCHEMBL766143; GEHAEMCVKDPMKO-HXUWFJFHSA-N
DMG4RFO CP Takeda
DMG4RFO DT Small molecular drug
DMG4RFO PC 11641515
DMG4RFO MW 480
DMG4RFO FM C22H26ClN3O5S
DMG4RFO IC InChI=1S/C22H26ClN3O5S/c23-17-4-2-16-13-19(5-3-15(16)12-17)32(30,31)14-20(27)21(28)25-10-6-18(7-11-25)26-9-1-8-24-22(26)29/h2-5,12-13,18,20,27H,1,6-11,14H2,(H,24,29)/t20-/m1/s1
DMG4RFO CS C1CNC(=O)N(C1)C2CCN(CC2)C(=O)[C@@H](CS(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)Cl)O
DMG4RFO IK GEHAEMCVKDPMKO-HXUWFJFHSA-N
DMG4RFO IU 1-[1-[(2S)-3-(6-chloronaphthalen-2-yl)sulfonyl-2-hydroxypropanoyl]piperidin-4-yl]-1,3-diazinan-2-one
DMG4RFO CA CAS 870262-90-1
DMG4RFO DE Thrombosis
DMN1YHP ID DMN1YHP
DMN1YHP DN TAK-603
DMN1YHP HS Discontinued in Phase 2
DMN1YHP CP Takeda Pharmaceutical Co Ltd
DMN1YHP PC 153980
DMN1YHP MW 478.5
DMN1YHP FM C25H26N4O6
DMN1YHP IC InChI=1S/C25H26N4O6/c1-6-35-25(30)24-18(12-29-14-26-13-27-29)28-17-11-22(34-5)21(33-4)10-16(17)23(24)15-7-8-19(31-2)20(9-15)32-3/h7-11,13-14H,6,12H2,1-5H3
DMN1YHP CS CCOC(=O)C1=C(C2=CC(=C(C=C2N=C1CN3C=NC=N3)OC)OC)C4=CC(=C(C=C4)OC)OC
DMN1YHP IK CLQRMSBSMHXMMC-UHFFFAOYSA-N
DMN1YHP IU ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate
DMN1YHP CA CAS 158146-85-1
DMN1YHP DE Inflammatory bowel disease
DMDVJKW ID DMDVJKW
DMDVJKW DN TAK-637
DMDVJKW HS Discontinued in Phase 2
DMDVJKW SN TAK-637; UNII-QRT7W0TL6X; QRT7W0TL6X; CHEMBL339486; SCHEMBL122948; TAK637; GTPL9329; TAK 637; BDBM50081420; compound (aR,9R)-8b [PMID: 10508446]; 7H-(1,4)Diazocino(2,1-g)(1,7)naphthyridine-6,13-dione, 7-((3,5-bis(trifluoromethyl)phenyl)methyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)-; (Ar,9R)-7-(3,5-bis(trifluoromethyl)benzyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-(1,4)diazocino(2,1-g)(1,7)naphthyridine-6,13-dione
DMDVJKW CP Takeda
DMDVJKW DT Small molecular drug
DMDVJKW PC 9894349
DMDVJKW MW 573.5
DMDVJKW FM C30H25F6N3O2
DMDVJKW IC InChI=1S/C30H25F6N3O2/c1-17-5-7-20(8-6-17)24-23-4-3-10-37-25(23)27(40)39-11-9-18(2)15-38(28(41)26(24)39)16-19-12-21(29(31,32)33)14-22(13-19)30(34,35)36/h3-8,10,12-14,18H,9,11,15-16H2,1-2H3/t18-/m1/s1
DMDVJKW CS C[C@@H]1CCN2C(=C(C3=C(C2=O)N=CC=C3)C4=CC=C(C=C4)C)C(=O)N(C1)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F
DMDVJKW IK LDXQLWNPGRANTO-GOSISDBHSA-N
DMDVJKW IU (9R)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione
DMDVJKW CA CAS 183549-93-1
DMDVJKW DE Depression
DMHNZ31 ID DMHNZ31
DMHNZ31 DN TAK-802
DMHNZ31 HS Discontinued in Phase 2
DMHNZ31 CP Takeda Pharmaceutical Co Ltd
DMHNZ31 PC 9888392
DMHNZ31 MW 420.5
DMHNZ31 FM C26H29FN2O2
DMHNZ31 IC InChI=1S/C26H29FN2O2/c27-23-3-1-2-19(14-23)17-28-11-8-18(9-12-28)4-6-24(30)22-15-20-5-7-25(31)29-13-10-21(16-22)26(20)29/h1-3,14-16,18H,4-13,17H2
DMHNZ31 CS C1CN(CCC1CCC(=O)C2=CC3=C4C(=C2)CCN4C(=O)CC3)CC5=CC(=CC=C5)F
DMHNZ31 IK RAYMNBAAUXRZHA-UHFFFAOYSA-N
DMHNZ31 IU 6-[3-[1-[(3-fluorophenyl)methyl]piperidin-4-yl]propanoyl]-1-azatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-trien-11-one
DMHNZ31 DE Urinary dysfunction
DMWVPEU ID DMWVPEU
DMWVPEU DN Tallimustine
DMWVPEU HS Discontinued in Phase 2
DMWVPEU SN Tallimustine; Tallimustine [INN]; UNII-71193OXG6S; 115308-98-0; 71193OXG6S; N'-(2-Amidinoethyl)-4-(p-(bis(2-chloroethyl)amino)benzamido)-1,1',1'-trimethyl-N,4':N',4'-ter(pyrrole-2-carboxamide); 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1- methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-; 1H-Pyrrole-2-carboxamide, N-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1H-pyrrol-3-yl)-4-(((4-((4-(bis(2-chloroethy
DMWVPEU DT Small molecular drug
DMWVPEU PC 65924
DMWVPEU MW 697.6
DMWVPEU FM C32H38Cl2N10O4
DMWVPEU IC InChI=1S/C32H38Cl2N10O4/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47)
DMWVPEU CS CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl
DMWVPEU IK ARKYUICTMUZVEW-UHFFFAOYSA-N
DMWVPEU IU N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide
DMWVPEU CA CAS 115308-98-0
DMWVPEU DE Solid tumour/cancer
DM2KH9Y ID DM2KH9Y
DM2KH9Y DN Talsaclidine fumarate
DM2KH9Y HS Discontinued in Phase 2
DM2KH9Y SN Wal 2014 FU; Talsaclidine fumarate (USAN); 1-Azabicyclo(2.2.2)octane, 3-(2-propynyloxy)-, (R)-, (E)-2-butenedioate (1:1); 3-(2-Propynyloxy)-1-azabicyclo(2.2.2)octane 2-butenedioate; 3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane
DM2KH9Y CP Boehringer
DM2KH9Y DT Small molecular drug
DM2KH9Y PC 6918244
DM2KH9Y MW 281.3
DM2KH9Y FM C14H19NO5
DM2KH9Y IC InChI=1S/C10H15NO.C4H4O4/c1-2-7-12-10-8-11-5-3-9(10)4-6-11;5-3(6)1-2-4(7)8/h1,9-10H,3-8H2;1-2H,(H,5,6)(H,7,8)/b;2-1+/t10-;/m0./s1
DM2KH9Y CS C#CCO[C@H]1CN2CCC1CC2.C(=C/C(=O)O)\\C(=O)O
DM2KH9Y IK SBCXBWBXWKVIFK-PBBCPHEYSA-N
DM2KH9Y IU (E)-but-2-enedioic acid;(3R)-3-prop-2-ynoxy-1-azabicyclo[2.2.2]octane
DM2KH9Y CA CAS 147025-54-5
DM2KH9Y DE Alzheimer disease
DM1L5UX ID DM1L5UX
DM1L5UX DN TAMOLARIZINE HYDROCHLORIDE
DM1L5UX HS Discontinued in Phase 2
DM1L5UX SN NC-1100; Tamolarizine hydrochloride; Rac-alpha-(3,4-Dimethoxyphenyl)-4-(diphenylmethyl)-1-piperazineethanol dihydrochloride; Rac-1-(3,4-Dimethoxyphenyl)-2-(4-diphenylmethyl-1-piperazinyl)ethanol dihydrochloride
DM1L5UX DT Small molecular drug
DM1L5UX PC 146395
DM1L5UX MW 505.5
DM1L5UX FM C27H34Cl2N2O3
DM1L5UX IC InChI=1S/C27H32N2O3.2ClH/c1-31-25-14-13-23(19-26(25)32-2)24(30)20-28-15-17-29(18-16-28)27(21-9-5-3-6-10-21)22-11-7-4-8-12-22;;/h3-14,19,24,27,30H,15-18,20H2,1-2H3;2*1H
DM1L5UX CS COC1=C(C=C(C=C1)C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O)OC.Cl.Cl
DM1L5UX IK ZIGNSXDSBVYYFD-UHFFFAOYSA-N
DM1L5UX IU 2-(4-benzhydrylpiperazin-1-yl)-1-(3,4-dimethoxyphenyl)ethanol;dihydrochloride
DM1L5UX CA CAS 93035-33-7
DM1L5UX DE Cognitive impairment
DMNU2MH ID DMNU2MH
DMNU2MH DN Tandutinib
DMNU2MH HS Discontinued in Phase 2
DMNU2MH SN CT 53518; CT53518; MLN 518; CT-53518; MLN-0518; MLN-518; MLN518, CT53518; Tandutinib (USAN/INN); (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide; 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide; 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
DMNU2MH CP Millenium; Takeda
DMNU2MH TC Anticancer Agents
DMNU2MH DT Small molecular drug
DMNU2MH PC 3038522
DMNU2MH MW 562.7
DMNU2MH FM C31H42N6O4
DMNU2MH IC InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)
DMNU2MH CS CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCCC5
DMNU2MH IK UXXQOJXBIDBUAC-UHFFFAOYSA-N
DMNU2MH IU 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
DMNU2MH CA CAS 387867-13-2
DMNU2MH CB CHEBI:90237
DMNU2MH DE Anaplastic mixed oligoastrocytoma
DMF1VY4 ID DMF1VY4
DMF1VY4 DN Taprizosin
DMF1VY4 HS Discontinued in Phase 2
DMF1VY4 SN UK-338003
DMF1VY4 CP Pfizer Inc
DMF1VY4 DT Small molecular drug
DMF1VY4 PC 6433102
DMF1VY4 MW 506.6
DMF1VY4 FM C25H26N6O4S
DMF1VY4 IC InChI=1S/C25H26N6O4S/c1-34-20-13-19-22(21(23(20)35-2)18-8-4-5-11-27-18)24(26)29-25(28-19)31-12-10-16-15(14-31)7-6-9-17(16)30-36(3,32)33/h4-9,11,13,30H,10,12,14H2,1-3H3,(H2,26,28,29)
DMF1VY4 CS COC1=C(C(=C2C(=C1)N=C(N=C2N)N3CCC4=C(C3)C=CC=C4NS(=O)(=O)C)C5=CC=CC=N5)OC
DMF1VY4 IK OLYXPBZBZBVRGD-UHFFFAOYSA-N
DMF1VY4 IU N-[2-(4-amino-6,7-dimethoxy-5-pyridin-2-ylquinazolin-2-yl)-3,4-dihydro-1H-isoquinolin-5-yl]methanesulfonamide
DMF1VY4 CA CAS 210538-44-6
DMF1VY4 DE Prostate hyperplasia
DMX6ZYE ID DMX6ZYE
DMX6ZYE DN Tarazepide
DMX6ZYE HS Discontinued in Phase 2
DMX6ZYE SN Tarazepide (INN)
DMX6ZYE CP Solvay Pharma
DMX6ZYE DT Small molecular drug
DMX6ZYE PC 10343641
DMX6ZYE MW 448.5
DMX6ZYE FM C28H24N4O2
DMX6ZYE IC InChI=1S/C28H24N4O2/c1-31-22-15-6-5-14-21(22)24(18-9-3-2-4-10-18)29-26(28(31)34)30-27(33)23-17-20-12-7-11-19-13-8-16-32(23)25(19)20/h2-7,9-12,14-15,17,26H,8,13,16H2,1H3,(H,30,33)/t26-/m1/s1
DMX6ZYE CS CN1C2=CC=CC=C2C(=N[C@@H](C1=O)NC(=O)C3=CC4=C5N3CCCC5=CC=C4)C6=CC=CC=C6
DMX6ZYE IK CZPILLBHPRAPCB-AREMUKBSSA-N
DMX6ZYE IU N-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraene-2-carboxamide
DMX6ZYE CA CAS 141374-81-4
DMX6ZYE DE Gastrointestinal disease
DMJG7VP ID DMJG7VP
DMJG7VP DN Tariquidar
DMJG7VP HS Discontinued in Phase 2
DMJG7VP SN Tariquidarth; XR 9576; XR9576; Tariquidar (USAN/INN); N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide; N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide
DMJG7VP CP Xenova Group Ltd.
DMJG7VP DT Small molecular drug
DMJG7VP PC 148201
DMJG7VP MW 646.7
DMJG7VP FM C38H38N4O6
DMJG7VP IC InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)
DMJG7VP CS COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
DMJG7VP IK LGGHDPFKSSRQNS-UHFFFAOYSA-N
DMJG7VP IU N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
DMJG7VP CA CAS 206873-63-4
DMJG7VP DE Adrenocortical carcinoma
DMP1A4S ID DMP1A4S
DMP1A4S DN TC-2696
DMP1A4S HS Discontinued in Phase 2
DMP1A4S SN Neuronal nicotinic receptor alpha4beta2 agonist (pain), Targacept
DMP1A4S CP Targacept
DMP1A4S DE Pain
DM3VZ87 ID DM3VZ87
DM3VZ87 DN TCV-309
DM3VZ87 HS Discontinued in Phase 2
DM3VZ87 SN AC1L3GRQ; LS-184311; 2-[3-(N-(2-bromo-1-propylpyridin-1-ium-4-carbonyl)anilino)propanoylamino]ethyl 3,4-dihydro-1H-isoquinoline-2-carboxylate nitrate
DM3VZ87 DT Small molecular drug
DM3VZ87 PC 6918166
DM3VZ87 MW 656.5
DM3VZ87 FM C30H34BrN5O7
DM3VZ87 IC InChI=1S/C30H33BrN4O4.NO3/c1-2-15-33-20-25(19-26(31)22-33)29(37)35(27-10-4-3-5-11-27)17-13-28(36)32-14-18-39-30(38)34-16-12-23-8-6-7-9-24(23)21-34;2-1(3)4/h3-11,19-20,22H,2,12-18,21H2,1H3;/q;-1/p+1
DM3VZ87 CS CCC[N+]1=CC(=CC(=C1)Br)C(=O)N(CCC(=O)NCCOC(=O)N2CCC3=CC=CC=C3C2)C4=CC=CC=C4.[N+](=O)([O-])[O-]
DM3VZ87 IK DVGLBKDNVHDMTD-UHFFFAOYSA-O
DM3VZ87 IU 2-[3-(N-(5-bromo-1-propylpyridin-1-ium-3-carbonyl)anilino)propanoylamino]ethyl 3,4-dihydro-1H-isoquinoline-2-carboxylate;nitrate
DM3VZ87 CA CAS 131311-25-6
DM3VZ87 DE Sepsis
DMMUE8P ID DMMUE8P
DMMUE8P DN TEBUFELONE
DMMUE8P HS Discontinued in Phase 2
DMMUE8P SN Tebufelone; 112018-00-5; Tebufelone [USAN:INN]; Tebufelonum [INN-Latin]; Tebufelona [INN-Spanish]; UNII-O048K9ZFHO; O048K9ZFHO; NE 11740; CHEMBL13878; 3',5'-Di-tert-butyl-4'-hydroxy-5-hexynophenone; NE-11740; 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; 1-(3,5-di-tert-butyl-4-hydroxyphenyl)hex-5-yn-1-one; Tebufelonum; Tebufelona; 5-Hexyn-1-one, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-; 5-Hexyn-1-one, 1-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-; Tebufelone (USAN/INN); AC1Q5DB7; AC1L1TG2; SCHEMBL43674
DMMUE8P DT Small molecular drug
DMMUE8P PC 60542
DMMUE8P MW 300.4
DMMUE8P FM C20H28O2
DMMUE8P IC InChI=1S/C20H28O2/c1-8-9-10-11-17(21)14-12-15(19(2,3)4)18(22)16(13-14)20(5,6)7/h1,12-13,22H,9-11H2,2-7H3
DMMUE8P CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C(=O)CCCC#C
DMMUE8P IK ZHXUEUKVDMWSKV-UHFFFAOYSA-N
DMMUE8P IU 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one
DMMUE8P CA CAS 112018-00-5
DMMUE8P DE Pain
DMPCRUT ID DMPCRUT
DMPCRUT DN Teglicar
DMPCRUT HS Discontinued in Phase 2
DMPCRUT SN Reversible palmitoyltransferase inhibitor; ST-1326
DMPCRUT CP Sigma-Tau SpA
DMPCRUT DT Small molecular drug
DMPCRUT PC 9843897
DMPCRUT MW 399.6
DMPCRUT FM C22H45N3O3
DMPCRUT IC InChI=1S/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)/t20-/m1/s1
DMPCRUT CS CCCCCCCCCCCCCCNC(=O)N[C@H](CC(=O)[O-])C[N+](C)(C)C
DMPCRUT IK BMZYTDRMCBZVNH-HXUWFJFHSA-N
DMPCRUT IU (3R)-3-(tetradecylcarbamoylamino)-4-(trimethylazaniumyl)butanoate
DMPCRUT CA CAS 250694-07-6
DMPCRUT DE Diabetic complication
DM3F5E0 ID DM3F5E0
DM3F5E0 DN TEI-6122
DM3F5E0 HS Discontinued in Phase 2
DM3F5E0 SN TFC-612
DM3F5E0 CP Teijin Ltd
DM3F5E0 DT Small molecular drug
DM3F5E0 PC 6439638
DM3F5E0 MW 414.6
DM3F5E0 FM C22H38O5S
DM3F5E0 IC InChI=1S/C22H38O5S/c1-4-5-9-16(2)14-17(23)11-12-18-19(24)15-20(25)22(18)28-13-8-6-7-10-21(26)27-3/h11-12,16-19,22-24H,4-10,13-15H2,1-3H3/b12-11+/t16-,17?,18+,19-,22-/m1/s1
DM3F5E0 CS CCCC[C@@H](C)CC(/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1SCCCCCC(=O)OC)O)O
DM3F5E0 IK KMYUINCCFSNYPC-VPTZPLTNSA-N
DM3F5E0 IU methyl 6-[(1R,2S,3R)-3-hydroxy-2-[(E,5R)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]sulfanylhexanoate
DM3F5E0 CA CAS 83058-69-9
DM3F5E0 DE Diabetic complication
DMIDGZU ID DMIDGZU
DMIDGZU DN Telbermin
DMIDGZU HS Discontinued in Phase 2
DMIDGZU SN Telbermin (USAN/INN)
DMIDGZU CP Genentech
DMIDGZU DE Diabetic foot ulcer
DM8OWID ID DM8OWID
DM8OWID DN Telinavir
DM8OWID HS Discontinued in Phase 2
DM8OWID SN SC-52151
DM8OWID CP GD Searle & Co
DM8OWID DT Small molecular drug
DM8OWID PC 382974
DM8OWID MW 604.7
DM8OWID FM C33H44N6O5
DM8OWID IC InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1
DM8OWID CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)N)NC(=O)C2=NC3=CC=CC=C3C=C2)O)C(=O)NC(C)(C)C
DM8OWID IK ZILOOGIOHVCEKS-HZFUHODCSA-N
DM8OWID IU (2S)-N-[(2S,3R)-4-[tert-butylcarbamoyl(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
DM8OWID CA CAS 143224-34-4
DM8OWID DE Human immunodeficiency virus infection
DM4K3P9 ID DM4K3P9
DM4K3P9 DN Terflavoxate
DM4K3P9 HS Discontinued in Phase 2
DM4K3P9 SN ND-907; Rec-15-2053
DM4K3P9 CP Recordati SpA
DM4K3P9 DT Small molecular drug
DM4K3P9 PC 135750
DM4K3P9 MW 419.5
DM4K3P9 FM C26H29NO4
DM4K3P9 IC InChI=1S/C26H29NO4/c1-18-22(28)20-13-10-14-21(24(20)30-23(18)19-11-6-4-7-12-19)25(29)31-26(2,3)17-27-15-8-5-9-16-27/h4,6-7,10-14H,5,8-9,15-17H2,1-3H3
DM4K3P9 CS CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OC(C)(C)CN3CCCCC3)C4=CC=CC=C4
DM4K3P9 IK VQTYZZPDAFGNCK-UHFFFAOYSA-N
DM4K3P9 IU (2-methyl-1-piperidin-1-ylpropan-2-yl) 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
DM4K3P9 CA CAS 86433-40-1
DM4K3P9 DE Urinary incontinence
DMPB36I ID DMPB36I
DMPB36I DN Tesmilifene
DMPB36I HS Discontinued in Phase 2
DMPB36I SN DPPE; DPPE hydrocloride; Tesmilifene hydrochloride; BMS 217380-01; BMS-217380; BMY-33419; DPPE, BMS; YMB-1002; Anticancer, BMS/Manitoba Univ/MTCR
DMPB36I CP YM Biosciences
DMPB36I DT Small molecular drug
DMPB36I PC 108092
DMPB36I MW 283.4
DMPB36I FM C19H25NO
DMPB36I IC InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17/h5-13H,3-4,14-16H2,1-2H3
DMPB36I CS CCN(CC)CCOC1=CC=C(C=C1)CC2=CC=CC=C2
DMPB36I IK NFIXBCVWIPOYCD-UHFFFAOYSA-N
DMPB36I IU 2-(4-benzylphenoxy)-N,N-diethylethanamine
DMPB36I CA CAS 98774-23-3
DMPB36I CB CHEBI:93414
DMPB36I DE Breast cancer
DM5O6HM ID DM5O6HM
DM5O6HM DN Testosterone glucoside
DM5O6HM HS Discontinued in Phase 2
DM5O6HM SN S-403-G
DM5O6HM CP Strakan Group plc
DM5O6HM DE Hypogonadism
DMC0WNB ID DMC0WNB
DMC0WNB DN Tetramethylpyrazine
DMC0WNB HS Discontinued in Phase 2
DMC0WNB SN Ligustizine; Ligustrazine; 2,3,5,6-Tetramethylpyrazine
DMC0WNB DT Small molecular drug
DMC0WNB PC 14296
DMC0WNB MW 136.19
DMC0WNB FM C8H12N2
DMC0WNB IC InChI=1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3
DMC0WNB CS CC1=C(N=C(C(=N1)C)C)C
DMC0WNB IK FINHMKGKINIASC-UHFFFAOYSA-N
DMC0WNB IU 2,3,5,6-tetramethylpyrazine
DMC0WNB CA CAS 1124-11-4
DMC0WNB CB CHEBI:133246
DMC0WNB DE Neurological disorder
DMS4BUK ID DMS4BUK
DMS4BUK DN TG-1042
DMS4BUK HS Discontinued in Phase 2
DMS4BUK SN TG-1041; Adv-IFN-gamma; Adenovirus-interferon gamma based therapy (basal cell carcinoma), Virax; Adenovirus-interferon gamma based therapy (cancer), Transgene; Ad-IFN-gamma (basal cell carcinoma), Virax; Ad-IFN-gamma (lymphoma), Transgene
DMS4BUK CP Transgene SA
DMS4BUK DE B-cell lymphoma
DMQSNV8 ID DMQSNV8
DMQSNV8 DN TgAAV-CFTR
DMQSNV8 HS Discontinued in Phase 2
DMQSNV8 SN TgAAV-CF; Gene therapy (CFTR), Targeted Genetics; Gene therapy (CFTR), Targeted Genetics/Celltech
DMQSNV8 CP Targeted Genetics Corp
DMQSNV8 DE Cystic fibrosis
DMYN6G0 ID DMYN6G0
DMYN6G0 DN TGP-580
DMYN6G0 HS Discontinued in Phase 2
DMYN6G0 SN CS-23; HbFGF, Takeda
DMYN6G0 CP Takeda Pharmaceutical Co Ltd
DMYN6G0 DE Neurodegenerative disorder
DMGR7Y3 ID DMGR7Y3
DMGR7Y3 DN Theradigm-HBV
DMGR7Y3 HS Discontinued in Phase 2
DMGR7Y3 SN CY-1899; Theradigm-hepatitis B virus
DMGR7Y3 CP Genencor International Inc
DMGR7Y3 DE Virus infection
DMYH2PU ID DMYH2PU
DMYH2PU DN TIBENELAST
DMYH2PU HS Discontinued in Phase 2
DMYH2PU SN LY-186655 (sodium salt); Tibenelast; 5,6-Diethoxybenzothiophene-2-carboxylic acid
DMYH2PU DT Small molecular drug
DMYH2PU PC 59913
DMYH2PU MW 266.31
DMYH2PU FM C13H14O4S
DMYH2PU IC InChI=1S/C13H14O4S/c1-3-16-9-5-8-6-12(13(14)15)18-11(8)7-10(9)17-4-2/h5-7H,3-4H2,1-2H3,(H,14,15)
DMYH2PU CS CCOC1=C(C=C2C(=C1)C=C(S2)C(=O)O)OCC
DMYH2PU IK PDUXMHXBBXXJFQ-UHFFFAOYSA-N
DMYH2PU IU 5,6-diethoxy-1-benzothiophene-2-carboxylic acid
DMYH2PU CA CAS 97852-72-7
DMYH2PU DE Asthma
DMLWBYO ID DMLWBYO
DMLWBYO DN Tienoxolol
DMLWBYO HS Discontinued in Phase 2
DMLWBYO SN UP-788-42
DMLWBYO CP Laboratories UPSA
DMLWBYO DT Small molecular drug
DMLWBYO PC 65678
DMLWBYO MW 420.5
DMLWBYO FM C21H28N2O5S
DMLWBYO IC InChI=1S/C21H28N2O5S/c1-5-27-20(26)16-11-14(23-19(25)18-7-6-10-29-18)8-9-17(16)28-13-15(24)12-22-21(2,3)4/h6-11,15,22,24H,5,12-13H2,1-4H3,(H,23,25)
DMLWBYO CS CCOC(=O)C1=C(C=CC(=C1)NC(=O)C2=CC=CS2)OCC(CNC(C)(C)C)O
DMLWBYO IK PHMRLCQEIQGCHH-UHFFFAOYSA-N
DMLWBYO IU ethyl 2-[3-(tert-butylamino)-2-hydroxypropoxy]-5-(thiophene-2-carbonylamino)benzoate
DMLWBYO CA CAS 90055-97-3
DMLWBYO DE Hypertension
DMPWSRA ID DMPWSRA
DMPWSRA DN Tilmacoxib
DMPWSRA HS Discontinued in Phase 2
DMPWSRA SN Tilmacoxib; JTE-522; 180200-68-4; RWJ-57504; JTP-19605; UNII-G6VI5P84SX; 4-(4-Cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro-; G6VI5P84SX; CHEMBL34913; JTE522; 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo(4,5)imidazo(1,2a)pyridine-4-N-(2-fluorophenyl)carboxamide; CHEBI:73041; 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide; 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide
DMPWSRA DT Small molecular drug
DMPWSRA PC 159271
DMPWSRA MW 338.4
DMPWSRA FM C16H19FN2O3S
DMPWSRA IC InChI=1S/C16H19FN2O3S/c1-10-19-15(11-5-3-2-4-6-11)16(22-10)12-7-8-14(13(17)9-12)23(18,20)21/h7-9,11H,2-6H2,1H3,(H2,18,20,21)
DMPWSRA CS CC1=NC(=C(O1)C2=CC(=C(C=C2)S(=O)(=O)N)F)C3CCCCC3
DMPWSRA IK MIMJSJSRRDZIPW-UHFFFAOYSA-N
DMPWSRA IU 4-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide
DMPWSRA CA CAS 180200-68-4
DMPWSRA CB CHEBI:73041
DMPWSRA DE Colon polyp
DMUJ2X6 ID DMUJ2X6
DMUJ2X6 DN Tiqueside
DMUJ2X6 HS Discontinued in Phase 2
DMUJ2X6 SN Tigogenin cellobioside; CP-88818
DMUJ2X6 CP Pfizer Inc
DMUJ2X6 DT Small molecular drug
DMUJ2X6 PC 9896801
DMUJ2X6 MW 740.9
DMUJ2X6 FM C39H64O13
DMUJ2X6 IC InChI=1S/C39H64O13/c1-18-7-12-39(47-17-18)19(2)28-25(52-39)14-24-22-6-5-20-13-21(8-10-37(20,3)23(22)9-11-38(24,28)4)48-35-33(46)31(44)34(27(16-41)50-35)51-36-32(45)30(43)29(42)26(15-40)49-36/h18-36,40-46H,5-17H2,1-4H3/t18-,19+,20+,21+,22-,23+,24+,25+,26-,27-,28+,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-/m1/s1
DMUJ2X6 CS C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1
DMUJ2X6 IK GUSVHVVOABZHAH-OPZWKQDFSA-N
DMUJ2X6 IU (2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(1R,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMUJ2X6 CA CAS 99759-19-0
DMUJ2X6 DE Hyperlipidaemia
DMGF35T ID DMGF35T
DMGF35T DN Tisocalcitate
DMGF35T HS Discontinued in Phase 2
DMGF35T SN SH-597; ZK-156942; Calcitriol analog (topical formulation), Schering AG
DMGF35T CP Bayer Schering Pharma AG
DMGF35T DT Small molecular drug
DMGF35T PC 9913924
DMGF35T MW 500.7
DMGF35T FM C31H48O5
DMGF35T IC InChI=1S/C31H48O5/c1-19(2)36-29(35)30(5,6)28(34)15-10-20(3)25-13-14-26-22(9-8-16-31(25,26)7)11-12-23-17-24(32)18-27(33)21(23)4/h10-12,15,19-20,24-28,32-34H,4,8-9,13-14,16-18H2,1-3,5-7H3/b15-10+,22-11+,23-12-/t20-,24-,25-,26+,27+,28-,31-/m1/s1
DMGF35T CS C[C@H](/C=C/[C@H](C(C)(C)C(=O)OC(C)C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)C
DMGF35T IK AUMBXYDXKLLKEK-BGMQPCSBSA-N
DMGF35T IU propan-2-yl (E,3R,6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-3-hydroxy-2,2-dimethylhept-4-enoate
DMGF35T CA CAS 156965-06-9
DMGF35T DE Psoriasis vulgaris
DMXNQLU ID DMXNQLU
DMXNQLU DN TM30338
DMXNQLU HS Discontinued in Phase 2
DMXNQLU CP 7TMPharma.
DMXNQLU DE Obesity
DMW7LQT ID DMW7LQT
DMW7LQT DN TM30339
DMW7LQT HS Discontinued in Phase 2
DMW7LQT CP 7TMPharma.
DMW7LQT DT Small molecular drug
DMW7LQT PC 56603693
DMW7LQT MW 4231
DMW7LQT FM C185H286N52O58S2
DMW7LQT IC InChI=1S/C185H286N52O58S2/c1-20-92(10)144(172(282)222-122(83-136(189)246)161(271)213-115(64-75-297-19)158(268)218-120(78-90(6)7)163(273)229-146(99(17)239)181(292)295-231-117(33-24-68-202-185(197)198)175(285)236-72-27-36-131(236)167(277)214-110(32-23-67-201-184(195)196)154(264)224-126(178(288)289)81-102-43-51-106(242)52-44-102)227-164(274)121(79-100-39-47-104(240)48-40-100)220-153(263)109(31-22-66-200-183(193)194)209-152(262)108(30-21-65-199-182(191)192)210-159(269)118(76-88(2)3)219-162(272)123(85-141(253)254)217-148(258)94(12)204-150(260)97(15)230-293-179(290)127(82-103-45-53-107(243)54-46-103)225-157(267)111(55-59-134(187)244)208-147(257)95(13)205-151(261)114(63-74-296-18)212-155(265)112(56-60-135(188)245)211-156(266)113(57-61-139(249)250)215-168(278)132-37-29-73-237(132)177(287)145(98(16)238)228-149(259)96(14)206-165(275)124(84-137(190)247)232-294-180(291)128(86-142(255)256)207-138(248)87-203-166(276)129-34-25-70-234(129)176(286)125(80-101-41-49-105(241)50-42-101)223-171(281)143(91(8)9)226-170(280)133-38-28-71-235(133)174(284)116(58-62-140(251)252)216-160(270)119(77-89(4)5)221-169(279)130-35-26-69-233(130)173(283)93(11)186/h39-54,88-99,108-133,143-146,230-232,238-243H,20-38,55-87,186H2,1-19H3,(H2,187,244)(H2,188,245)(H2,189,246)(H2,190,247)(H,203,276)(H,204,260)(H,205,261)(H,206,275)(H,207,248)(H,208,257)(H,209,262)(H,210,269)(H,211,266)(H,212,265)(H,213,271)(H,214,277)(H,215,278)(H,216,270)(H,217,258)(H,218,268)(H,219,272)(H,220,263)(H,221,279)(H,222,282)(H,223,281)(H,224,264)(H,225,267)(H,226,280)(H,227,274)(H,228,259)(H,229,273)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,288,289)(H4,191,192,199)(H4,193,194,200)(H4,195,196,201)(H4,197,198,202)
DMW7LQT CS CCC(C)C(C(=O)NC(CC(=O)N)C(=O)NC(CCSC)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)ONC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(C)NOC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C5CCCN5C(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(CC(=O)N)NOC(=O)C(CC(=O)O)NC(=O)CNC(=O)C6CCCN6C(=O)C(CC7=CC=C(C=C7)O)NC(=O)C(C(C)C)NC(=O)C8CCCN8C(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C9CCCN9C(=O)C(C)N
DMW7LQT IK ZECLZCGVVAIWHI-UHFFFAOYSA-N
DMW7LQT IU 5-[[5-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[4-amino-1-[[1-[[1-[[1-[[5-carbamimidamido-1-[2-[[5-carbamimidamido-1-[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]oxy-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]oxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-[[1-[2-[2-[[4-amino-2-[[2-[[2-[[1-[2-[[2-[[1-[2-[[2-[[1-(2-aminopropanoyl)pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-carboxypropanoyl]oxyamino]-4-oxobutanoyl]amino]propanoylamino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid
DMW7LQT DE Schizophrenia
DMW05DS ID DMW05DS
DMW05DS DN TNP-351
DMW05DS HS Discontinued in Phase 2
DMW05DS SN N-[4-[3-(2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid
DMW05DS DT Small molecular drug
DMW05DS PC 5487322
DMW05DS MW 440.5
DMW05DS FM C21H24N6O5
DMW05DS IC InChI=1S/C21H24N6O5/c22-17-16-13(10-24-18(16)27-21(23)26-17)3-1-2-11-4-6-12(7-5-11)19(30)25-14(20(31)32)8-9-15(28)29/h4-7,10,14H,1-3,8-9H2,(H,25,30)(H,28,29)(H,31,32)(H5,22,23,24,26,27)/t14-/m0/s1
DMW05DS CS C1=CC(=CC=C1CCCC2=CNC3=NC(=NC(=C23)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMW05DS IK WLGCEMWNUHSIIS-AWEZNQCLSA-N
DMW05DS IU (2S)-2-[[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]pentanedioic acid
DMW05DS CA CAS 125991-51-7
DMW05DS DE Solid tumour/cancer
DMT0QK8 ID DMT0QK8
DMT0QK8 DN TNP-470
DMT0QK8 HS Discontinued in Phase 2
DMT0QK8 SN tnp 470; CCRIS 8049; C19H28ClNO6; O-chloroacetylcarbamoyl fumagillol; MSHZHSPISPJWHW-HUTWWKRSSA-N; Carbamic acid, (chloroacetyl)-, 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester, (3R-(3alpha,4alpha(2R*,3R*),5beta,6beta))-
DMT0QK8 DT Small molecular drug
DMT0QK8 PC 369976
DMT0QK8 MW 401.9
DMT0QK8 FM C19H28ClNO6
DMT0QK8 IC InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1
DMT0QK8 CS CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)NC(=O)CCl)OC)C
DMT0QK8 IK MSHZHSPISPJWHW-PVDLLORBSA-N
DMT0QK8 IU [(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate
DMT0QK8 CA CAS 129298-91-5
DMT0QK8 CB CHEBI:90748
DMT0QK8 DE Solid tumour/cancer
DMEROU4 ID DMEROU4
DMEROU4 DN Tolafentrine
DMEROU4 HS Discontinued in Phase 2
DMEROU4 SN BY-4070
DMEROU4 CP ALTANA Pharma AG
DMEROU4 DT Small molecular drug
DMEROU4 PC 65990
DMEROU4 MW 505.6
DMEROU4 FM C28H31N3O4S
DMEROU4 IC InChI=1S/C28H31N3O4S/c1-18-5-11-21(12-6-18)36(32,33)30-20-9-7-19(8-10-20)28-23-16-27(35-4)26(34-3)15-22(23)24-17-31(2)14-13-25(24)29-28/h5-12,15-16,24-25,30H,13-14,17H2,1-4H3/t24-,25-/m0/s1
DMEROU4 CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C3=N[C@H]4CCN(C[C@H]4C5=CC(=C(C=C53)OC)OC)C
DMEROU4 IK FVZJIAUYFDQQKJ-DQEYMECFSA-N
DMEROU4 IU N-[4-[(4aS,10bR)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-yl]phenyl]-4-methylbenzenesulfonamide
DMEROU4 CA CAS 139308-65-9
DMEROU4 DE Chronic obstructive pulmonary disease
DMY40KZ ID DMY40KZ
DMY40KZ DN Tomeglovir
DMY40KZ HS Discontinued in Phase 2
DMY40KZ SN BAY-38-4766; BAY-40-1007; BAY-43-9695
DMY40KZ CP Bayer AG
DMY40KZ DT Small molecular drug
DMY40KZ PC 475330
DMY40KZ MW 441.5
DMY40KZ FM C23H27N3O4S
DMY40KZ IC InChI=1S/C23H27N3O4S/c1-23(2,15-27)22(28)24-16-11-13-17(14-12-16)25-31(29,30)21-10-6-7-18-19(21)8-5-9-20(18)26(3)4/h5-14,25,27H,15H2,1-4H3,(H,24,28)
DMY40KZ CS CC(C)(CO)C(=O)NC1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C
DMY40KZ IK OSQAKHSYTKBSPB-UHFFFAOYSA-N
DMY40KZ IU N-[4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]phenyl]-3-hydroxy-2,2-dimethylpropanamide
DMY40KZ CA CAS 233254-24-5
DMY40KZ DE Virus infection
DM1YXPL ID DM1YXPL
DM1YXPL DN Tomopenem
DM1YXPL HS Discontinued in Phase 2
DM1YXPL SN R 115685; CS-023; R-1558; RO-4908463
DM1YXPL CP Sankyo Co Ltd
DM1YXPL DT Small molecular drug
DM1YXPL PC 9809656
DM1YXPL MW 537.6
DM1YXPL FM C23H35N7O6S
DM1YXPL IC InChI=1S/C23H35N7O6S/c1-10-17-16(11(2)31)21(34)30(17)18(22(35)36)19(10)37-13-6-14(28(3)9-13)20(33)29-5-4-12(8-29)27-15(32)7-26-23(24)25/h10-14,16-17,31H,4-9H2,1-3H3,(H,27,32)(H,35,36)(H4,24,25,26)/t10-,11-,12+,13+,14+,16-,17-/m1/s1
DM1YXPL CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](N(C3)C)C(=O)N4CC[C@@H](C4)NC(=O)CN=C(N)N)C(=O)O)[C@@H](C)O
DM1YXPL IK KEDAXBWZURNCHS-GPODMPQUSA-N
DM1YXPL IU (4R,5S,6S)-3-[(3S,5S)-5-[(3S)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM1YXPL CA CAS 222400-20-6
DM1YXPL DE Bacterial infection
DMZA06U ID DMZA06U
DMZA06U DN TOPIXANTRONE HYDROCHLORIDE
DMZA06U HS Discontinued in Phase 2
DMZA06U SN Topixantrone hydrochloride; SCHEMBL1418986; Topixantrone hydrochloride < Prop INNM; BBR-3409 (dimaleate); 5-[2-(Dimethylamino)ethylamino]-2-[2-(2-hydroxyethylamino)ethyl]indazolo[4,3-gh]isoquinolin-6(2H)-one dihydrochloride
DMZA06U DT Small molecular drug
DMZA06U PC 6918273
DMZA06U MW 467.4
DMZA06U FM C21H28Cl2N6O2
DMZA06U IC InChI=1S/C21H26N6O2.2ClH/c1-26(2)10-8-24-16-3-4-17-19-18(16)21(29)14-5-6-23-13-15(14)20(19)25-27(17)11-7-22-9-12-28;;/h3-6,13,22,24,28H,7-12H2,1-2H3;2*1H
DMZA06U CS CN(C)CCNC1=C2C3=C(C=C1)N(N=C3C4=C(C2=O)C=CN=C4)CCNCCO.Cl.Cl
DMZA06U IK CQZQVNJGECUKMB-UHFFFAOYSA-N
DMZA06U IU 10-[2-(dimethylamino)ethylamino]-14-[2-(2-hydroxyethylamino)ethyl]-4,14,15-triazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2(7),3,5,9,11,13(16)-heptaen-8-one;dihydrochloride
DMZA06U DE Gastric adenocarcinoma
DMDHYM7 ID DMDHYM7
DMDHYM7 DN Torcetrapib
DMDHYM7 HS Discontinued in Phase 2
DMDHYM7 SN Torcetrapib [USAN]; CP 529414; CP-529414; CP-529,414; Torcetrapib (USAN/INN); Ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate; Ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
DMDHYM7 CP Pfizer
DMDHYM7 DT Small molecular drug
DMDHYM7 PC 159325
DMDHYM7 MW 600.5
DMDHYM7 FM C26H25F9N2O4
DMDHYM7 IC InChI=1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
DMDHYM7 CS CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC
DMDHYM7 IK CMSGWTNRGKRWGS-NQIIRXRSSA-N
DMDHYM7 IU ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate
DMDHYM7 CA CAS 262352-17-0
DMDHYM7 CB CHEBI:49203
DMDHYM7 DE Hyperlipidaemia; Peripheral vascular disease
DMX32RC ID DMX32RC
DMX32RC DN Transdur-sufentanil
DMX32RC HS Discontinued in Phase 2
DMX32RC SN Sufentanil transdermal patch
DMX32RC CP Durect
DMX32RC DT Small molecular drug
DMX32RC PC 65494
DMX32RC MW 578.7
DMX32RC FM C28H38N2O9S
DMX32RC IC InChI=1S/C22H30N2O2S.C6H8O7/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,17H,3,11-16,18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMX32RC CS CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMX32RC IK OJCZPLDERGDQRJ-UHFFFAOYSA-N
DMX32RC IU 2-hydroxypropane-1,2,3-tricarboxylic acid;N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMX32RC CA CAS 60561-17-3
DMX32RC CB CHEBI:9317
DMX32RC DE Pain
DME85Z9 ID DME85Z9
DME85Z9 DN TREFENTANIL HYDROCHLORIDE
DME85Z9 HS Discontinued in Phase 2
DME85Z9 SN A-3665; ANQ-3665; Trefentanil hydrochloride < Rec INNM; N-[1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-N-(2-fluorophenyl)propionamide hydrochloride; 1-[2-(4-Ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[N-(2-fluorophenyl)propionamido]-4-phenylpiperidine hydrochloride
DME85Z9 DT Small molecular drug
DME85Z9 PC 60727
DME85Z9 MW 503
DME85Z9 FM C25H32ClFN6O2
DME85Z9 IC InChI=1S/C25H31FN6O2.ClH/c1-3-23(33)32(22-13-9-8-12-21(22)26)25(20-10-6-5-7-11-20)14-16-29(17-15-25)18-19-31-24(34)30(4-2)27-28-31;/h5-13H,3-4,14-19H2,1-2H3;1H
DME85Z9 CS CCC(=O)N(C1=CC=CC=C1F)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)C4=CC=CC=C4.Cl
DME85Z9 IK YMRJQYDWCFOMRR-UHFFFAOYSA-N
DME85Z9 IU N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-N-(2-fluorophenyl)propanamide;hydrochloride
DME85Z9 CA CAS 120656-93-1
DME85Z9 DE Pain
DMUZNF0 ID DMUZNF0
DMUZNF0 DN Tridolgosir
DMUZNF0 HS Discontinued in Phase 2
DMUZNF0 SN Swainsonine; Swainsonine hydrochloride; Tridolgosir hydrochloride; Carbohydrate processing inhibitors, GLYCODesign; GD-0039; Transforming growth factor beta inhibitors, GLYCODesign; GD-0039 analogs, GlycoDESIGN
DMUZNF0 CP GLYCODesign Inc
DMUZNF0 DT Small molecular drug
DMUZNF0 PC 51683
DMUZNF0 MW 173.21
DMUZNF0 FM C8H15NO3
DMUZNF0 IC InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1
DMUZNF0 CS C1C[C@H]([C@@H]2[C@@H]([C@@H](CN2C1)O)O)O
DMUZNF0 IK FXUAIOOAOAVCGD-WCTZXXKLSA-N
DMUZNF0 IU (1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol
DMUZNF0 CA CAS 72741-87-8
DMUZNF0 CB CHEBI:9367
DMUZNF0 DE Solid tumour/cancer
DMZ98Y4 ID DMZ98Y4
DMZ98Y4 DN TRO-40303
DMZ98Y4 HS Discontinued in Phase 2
DMZ98Y4 SN Ischemia-reperfusion injury agent, Trophos; Neuroprotectant (motor neuron disease), Trophos
DMZ98Y4 CP Trophos SA
DMZ98Y4 DT Small molecular drug
DMZ98Y4 PC 16734938
DMZ98Y4 MW 405.7
DMZ98Y4 FM C26H47NO2
DMZ98Y4 IC InChI=1S/C26H47NO2/c1-18(2)8-6-9-19(3)21-11-12-22-20-10-13-24(27-29)26(5,15-7-17-28)23(20)14-16-25(21,22)4/h18-23,28-29H,6-17H2,1-5H3/b27-24-/t19-,20+,21-,22+,23+,25-,26-/m1/s1
DMZ98Y4 CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC/C(=N/O)/[C@]3(C)CCCO)C
DMZ98Y4 IK OBKBVSFXEIFOMS-GHCPFUIOSA-N
DMZ98Y4 IU 3-[(3R,3aR,5aS,6R,7Z,9aS,9bS)-7-hydroxyimino-3a,6-dimethyl-3-[(2R)-6-methylheptan-2-yl]-1,2,3,4,5,5a,8,9,9a,9b-decahydrocyclopenta[a]naphthalen-6-yl]propan-1-ol
DMZ98Y4 DE Lateral sclerosis
DM6032E ID DM6032E
DM6032E DN Trombodipine
DM6032E HS Discontinued in Phase 2
DM6032E SN Thrombodipine; PCA-4230
DM6032E CP Alter SA
DM6032E DT Small molecular drug
DM6032E PC 124236
DM6032E MW 448.5
DM6032E FM C21H24N2O7S
DM6032E IC InChI=1S/C21H24N2O7S/c1-5-29-20(25)17-12(2)18(14(4)22-13(17)3)21(26)30-11-10-23-19(24)15-8-6-7-9-16(15)31(23,27)28/h6-9,12,22H,5,10-11H2,1-4H3
DM6032E CS CCOC(=O)C1=C(NC(=C(C1C)C(=O)OCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C)C
DM6032E IK MCNAAGLIGWJLQX-UHFFFAOYSA-N
DM6032E IU 3-O-ethyl 5-O-[2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)ethyl] 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM6032E CA CAS 113658-85-8
DM6032E DE Platelet aggregation disorder
DMALIFO ID DMALIFO
DMALIFO DN TS-033
DMALIFO HS Discontinued in Phase 2
DMALIFO SN SGL-0010; SGLT-2 inhibitor (diabetes), Taisho; Sodium-dependent glucose transporter-2 inhibitor (diabetes), Taisho
DMALIFO CP Taisho Pharmaceutical Co Ltd
DMALIFO DE Diabetic complication
DMWXOJN ID DMWXOJN
DMWXOJN DN TT-62
DMWXOJN HS Discontinued in Phase 2
DMWXOJN SN TEI-6170 (free acid); 2'-Deoxy-5-fluoro-5'-uridylic acid monotetradecyl ester sodium salt; 5-Fluoro-2'-deoxyuridine 5'-myristylphosphate sodium salt; 5-Fluoro-2'-deoxyuridine 5'-tetradecylphosphate sodium salt
DMWXOJN DT Small molecular drug
DMWXOJN PC 23663410
DMWXOJN MW 544.5
DMWXOJN FM C23H39FN2NaO8P
DMWXOJN IC InChI=1S/C23H40FN2O8P.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-32-35(30,31)33-17-20-19(27)15-21(34-20)26-16-18(24)22(28)25-23(26)29;/h16,19-21,27H,2-15,17H2,1H3,(H,30,31)(H,25,28,29);/q;+1/p-1/t19-,20+,21+;/m0./s1
DMWXOJN CS CCCCCCCCCCCCCCOP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)F)O.[Na+]
DMWXOJN IK YUGLAGAQPWTRTP-HWAJWLCKSA-M
DMWXOJN IU sodium;[(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl tetradecyl phosphate
DMWXOJN DE Virus infection
DMCEGN4 ID DMCEGN4
DMCEGN4 DN TTP-355
DMCEGN4 HS Discontinued in Phase 2
DMCEGN4 SN Glucokinase activator (type 2 diabetes), TransTech Pharma
DMCEGN4 CP TransTech Pharma Inc
DMCEGN4 DE Diabetic complication
DM81XLA ID DM81XLA
DM81XLA DN TV-4710
DM81XLA HS Discontinued in Phase 2
DM81XLA CP Teva
DM81XLA PC 16214485
DM81XLA MW 2309.5
DM81XLA FM C111H149N27O28
DM81XLA IC InChI=1S/C111H149N27O28/c1-5-59(3)94(107(163)123-57-93(150)151)135-103(159)82(49-64-53-119-72-22-11-8-19-69(64)72)131-99(155)77(38-41-92(148)149)127-98(154)76(37-40-91(146)147)125-89(144)55-121-96(152)74(24-13-14-42-112)124-90(145)56-122-106(162)85-26-16-44-137(85)110(166)86-27-17-45-138(86)109(165)78(36-39-87(114)142)129-97(153)75(25-15-43-117-111(115)116)128-108(164)95(60(4)6-2)136-104(160)83(50-65-54-120-73-23-12-9-20-70(65)73)133-105(161)84(58-139)134-102(158)81(48-63-52-118-71-21-10-7-18-68(63)71)132-101(157)80(47-62-30-34-67(141)35-31-62)130-100(156)79(126-88(143)51-113)46-61-28-32-66(140)33-29-61/h7-12,18-23,28-35,52-54,59-60,74-86,94-95,118-120,139-141H,5-6,13-17,24-27,36-51,55-58,112-113H2,1-4H3,(H2,114,142)(H,121,152)(H,122,162)(H,123,163)(H,124,145)(H,125,144)(H,126,143)(H,127,154)(H,128,164)(H,129,153)(H,130,156)(H,131,155)(H,132,157)(H,133,161)(H,134,158)(H,135,159)(H,136,160)(H,146,147)(H,148,149)(H,150,151)(H4,115,116,117)/t59-,60-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,94-,95-/m0/s1
DM81XLA CS CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN
DM81XLA IK VXXZQHUWZSRPAM-CDJUQFLLSA-N
DM81XLA IU (4S)-4-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]hexanoyl]amino]acetyl]amino]-5-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S,3S)-1-(carboxymethylamino)-3-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM81XLA CA CAS 433922-67-9
DM81XLA DE Systemic lupus erythematosus
DMQWA2R ID DMQWA2R
DMQWA2R DN TY-11345
DMQWA2R HS Discontinued in Phase 2
DMQWA2R SN TY 11345; (+-)-2-((4-Methoxy-6,7,8,9-tetrahydro-5H-cyclohepta(b)pyridin-9-yl)sulfinyl)-1H-benzimidazole sodium salt; 5H-Cyclohepta(b)pyridine, 9-(1H-benzimidazol-2-ylsulfinyl)-6,7,8,9-tetrahydro-4-methoxy-, sodium salt
DMQWA2R CP Toa Eiyo KK
DMQWA2R DT Small molecular drug
DMQWA2R PC 23689269
DMQWA2R MW 365.4
DMQWA2R FM C18H20N3NaO2S
DMQWA2R IC InChI=1S/C18H20N3O2S.Na/c1-23-15-10-11-19-17-12(15)6-2-5-9-16(17)24(22)18-20-13-7-3-4-8-14(13)21-18;/h3-4,7-8,10,16H,2,5-6,9,11H2,1H3,(H,20,21);/q-1;+1
DMQWA2R CS COC1=CC[N-]C2=C1CCCCC2S(=O)C3=NC4=CC=CC=C4N3.[Na+]
DMQWA2R IK IPAJARTUAXFVLF-UHFFFAOYSA-N
DMQWA2R IU sodium;9-(1H-benzimidazol-2-ylsulfinyl)-4-methoxy-2,5,6,7,8,9-hexahydrocyclohepta[b]pyridin-1-ide
DMQWA2R CA CAS 137927-14-1
DMQWA2R DE Peptic ulcer
DM4FZWP ID DM4FZWP
DM4FZWP DN UK-279,276
DM4FZWP HS Discontinued in Phase 2
DM4FZWP CP Corvas
DM4FZWP DE Stroke
DMAD1S5 ID DMAD1S5
DMAD1S5 DN UK-74505
DMAD1S5 HS Discontinued in Phase 2
DMAD1S5 SN rac-Modipafant; UK-74505; Modipafant racemate; 122956-68-7; UK 74505; 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-(4-(2-methyl-1H-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-((2-pyridinylamino)carbonyl)-, ethyl ester; UK 80067; Modipafant (racemate); AC1L2W8B; C34H29ClN6O3; SCHEMBL6995473; AN-3660; LS-172547; KB-276046; FT-0672447; ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(2-pyridylcarbamoyl)-1,4-dihydropyridine-3-carboxylate; ethyl 4-(2-chlorophenyl)-6-methyl-2
DMAD1S5 CP Pfizer Ltd
DMAD1S5 DT Small molecular drug
DMAD1S5 PC 129796
DMAD1S5 MW 605.1
DMAD1S5 FM C34H29ClN6O3
DMAD1S5 IC InChI=1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)
DMAD1S5 CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)NC3=CC=CC=N3)C)C4=CC=C(C=C4)N5C(=NC6=C5C=CN=C6)C
DMAD1S5 IK ODRYSCQFUGFOSU-UHFFFAOYSA-N
DMAD1S5 IU ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate
DMAD1S5 CA CAS 122956-68-7
DMAD1S5 DE Sepsis
DMRDXYV ID DMRDXYV
DMRDXYV DN Ultramorph
DMRDXYV HS Discontinued in Phase 2
DMRDXYV CP Innovata plc
DMRDXYV DE Pain
DMBJ8KG ID DMBJ8KG
DMBJ8KG DN Urtoxazumab
DMBJ8KG HS Discontinued in Phase 2
DMBJ8KG SN TMA-15; Anti shiga-like toxin 2 humanized MAb, Teijin; HuVTm1.1.1; Anti-SLT-2 humanized MAb (E coli infection), Teijin
DMBJ8KG CP Teijin Ltd
DMBJ8KG DT Antibody
DMBJ8KG DE Escherichia coli infection
DMOB2K5 ID DMOB2K5
DMOB2K5 DN UTIBAPRIL
DMOB2K5 HS Discontinued in Phase 2
DMOB2K5 SN FPL-63547; Utibapril < Rec INN; (S)-2-tert-Butyl-4-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]-DELTA2-1,3,4-thiadiazoline-5-carboxylic acid 4-ethyl ester; 5-tert-Butyl-3-[N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-2,3-dihydro-1,3,4-thiadiazole-2(S)-carboxylic acid
DMOB2K5 DT Small molecular drug
DMOB2K5 PC 9803778
DMOB2K5 MW 449.6
DMOB2K5 FM C22H31N3O5S
DMOB2K5 IC InChI=1S/C22H31N3O5S/c1-6-30-20(29)16(13-12-15-10-8-7-9-11-15)23-14(2)17(26)25-18(19(27)28)31-21(24-25)22(3,4)5/h7-11,14,16,18,23H,6,12-13H2,1-5H3,(H,27,28)/t14-,16-,18-/m0/s1
DMOB2K5 CS CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](SC(=N2)C(C)(C)C)C(=O)O
DMOB2K5 IK FTYVYAGWBXTWTN-ZVZYQTTQSA-N
DMOB2K5 IU (2S)-5-tert-butyl-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2H-1,3,4-thiadiazole-2-carboxylic acid
DMOB2K5 CA CAS 109683-61-6
DMOB2K5 DE Hypertension
DMEV1H5 ID DMEV1H5
DMEV1H5 DN V-11294A
DMEV1H5 HS Discontinued in Phase 2
DMEV1H5 SN Rolipram derivatives, Napp
DMEV1H5 CP Napp Pharmaceutical Group Ltd
DMEV1H5 PC 135430158
DMEV1H5 MW 409.5
DMEV1H5 FM C23H31N5O2
DMEV1H5 IC InChI=1S/C23H31N5O2/c1-5-24-22-20-23(27-21(26-20)15(2)3)28(14-25-22)13-16-10-11-18(29-4)19(12-16)30-17-8-6-7-9-17/h10-12,14-15,17H,5-9,13H2,1-4H3,(H,26,27)
DMEV1H5 CS CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4
DMEV1H5 IK KLPQJJKXRIDASJ-UHFFFAOYSA-N
DMEV1H5 IU 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine
DMEV1H5 DE Asthma
DMXQCBU ID DMXQCBU
DMXQCBU DN Valtorcitabine
DMXQCBU HS Discontinued in Phase 2
DMXQCBU SN Epcitabine; Torcitabine; LDC-300; NV-02C; L-2-deoxycytidine; Val-L-dC; Beta-L-2`-deoxycytidine; L-dC prodrug, Idenix/Novartis; L-dC, Idenix/Novartis
DMXQCBU CP Idenix Pharmaceuticals
DMXQCBU DT Small molecular drug
DMXQCBU PC 9927346
DMXQCBU MW 326.35
DMXQCBU FM C14H22N4O5
DMXQCBU IC InChI=1S/C14H22N4O5/c1-7(2)12(16)13(20)23-8-5-11(22-9(8)6-19)18-4-3-10(15)17-14(18)21/h3-4,7-9,11-12,19H,5-6,16H2,1-2H3,(H2,15,17,21)/t8-,9+,11+,12+/m1/s1
DMXQCBU CS CC(C)[C@@H](C(=O)O[C@@H]1C[C@H](O[C@H]1CO)N2C=CC(=NC2=O)N)N
DMXQCBU IK VFCYZPOEGWLYRM-QCZKYFFMSA-N
DMXQCBU IU [(2S,3R,5S)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] (2S)-2-amino-3-methylbutanoate
DMXQCBU CA CAS 380886-95-3
DMXQCBU DE Hepatitis virus infection
DMHCOFM ID DMHCOFM
DMHCOFM DN Vasoflux
DMHCOFM HS Discontinued in Phase 2
DMHCOFM CP Vascular Therapeutics Inc
DMHCOFM DE Myocardial infarction
DMROSHN ID DMROSHN
DMROSHN DN Velneperit
DMROSHN HS Discontinued in Phase 2
DMROSHN SN Velneperit; 342577-38-2; S-2367; UNII-09BQ2KJ22J; 09BQ2KJ22J; Velneperit [USAN:INN]; Velneperit (USAN/INN); SCHEMBL2806595; SCHEMBL13204979; SCHEMBL10114559; CHEMBL2016681; SCHEMBL10134095; BCP16623; BDBM50380914; AKOS027338754; ZINC257354192; DB12889; CS-5388; KB-81432; HY-14423; BC282913; D08026; 577V382; S-2367;S2367;S 2367; trans-4-(((1,1-Dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)pyridin-2-yl)cyclohexanecarboxamide; Cyclohexanecarboxamide, 4-(((1,1-dimethylethyl)sulfonyl)amino)-N-(5-(trifluoromethyl)-2-pyridinyl)-, tr
DMROSHN CP Shionogi & Co Ltd
DMROSHN DT Small molecular drug
DMROSHN PC 20629114
DMROSHN MW 407.5
DMROSHN FM C17H24F3N3O3S
DMROSHN IC InChI=1S/C17H24F3N3O3S/c1-16(2,3)27(25,26)23-13-7-4-11(5-8-13)15(24)22-14-9-6-12(10-21-14)17(18,19)20/h6,9-11,13,23H,4-5,7-8H2,1-3H3,(H,21,22,24)
DMROSHN CS CC(C)(C)S(=O)(=O)NC1CCC(CC1)C(=O)NC2=NC=C(C=C2)C(F)(F)F
DMROSHN IK WGEWUYACXPEFPO-UHFFFAOYSA-N
DMROSHN IU 4-(tert-butylsulfonylamino)-N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexane-1-carboxamide
DMROSHN CA CAS 342577-38-2
DMROSHN DE Obesity
DMHCLVQ ID DMHCLVQ
DMHCLVQ DN Vitaxin
DMHCLVQ HS Discontinued in Phase 2
DMHCLVQ DE Solid tumour/cancer
DMOS6CM ID DMOS6CM
DMOS6CM DN VLTS-587
DMOS6CM HS Discontinued in Phase 2
DMOS6CM SN Gene therapy (IL-2, cLipid) iv, Valentis; Gene therapy (interleukin-2, cLipid) iv, Valentis
DMOS6CM CP Valentis Inc
DMOS6CM DE Lung cancer
DM32N5G ID DM32N5G
DM32N5G DN VOROZOLE
DM32N5G HS Discontinued in Phase 2
DM32N5G SN Vorozole; Rivizor; 129731-10-8; R-83842; UNII-1E2S9YXV2A; 1E2S9YXV2A; Vorozol [INN-Spanish]; Vorozolum [INN-Latin]; (+)-Vorozole; CCRIS 7482; Vorozolum; Vorozol; Rivizor (TN); 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole; Vorozole (USAN/INN); AC1OCF4T; (S)-VOROZOLE; SCHEMBL4554; Vorozole [USAN:INN:BAN]; CHEMBL224060; DTXSID20156230; (+)-(S)-6-(p-Chloro-alpha-1H-1,2,4-triazol-1-ylbenzyl)-1-methyl-1H-benzotriazole; CHEBI:135387; 1H-Benzotriazole, 6-((4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl
DM32N5G DT Small molecular drug
DM32N5G PC 6918191
DM32N5G MW 324.77
DM32N5G FM C16H13ClN6
DM32N5G IC InChI=1S/C16H13ClN6/c1-22-15-8-12(4-7-14(15)20-21-22)16(23-10-18-9-19-23)11-2-5-13(17)6-3-11/h2-10,16H,1H3/t16-/m0/s1
DM32N5G CS CN1C2=C(C=CC(=C2)[C@H](C3=CC=C(C=C3)Cl)N4C=NC=N4)N=N1
DM32N5G IK XLMPPFTZALNBFS-INIZCTEOSA-N
DM32N5G IU 6-[(S)-(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole
DM32N5G CA CAS 129731-10-8
DM32N5G CB CHEBI:135387
DMFYM61 ID DMFYM61
DMFYM61 DN VTP-201227
DMFYM61 HS Discontinued in Phase 2
DMFYM61 CP Vitae Pharmaceuticals
DMFYM61 DE Psoriatic disorder
DMLCTBP ID DMLCTBP
DMLCTBP DN VTX-2337
DMLCTBP HS Discontinued in Phase 2
DMLCTBP SN Motolimod; 926927-61-9; VTX-2337; Motolimod (VTX-2337); UNII-WP6PY72ZH3; VTX-378; VTX 2337; WP6PY72ZH3; AK171372; Motolimod [USAN:INN]; Motolimod (USAN/INN); SCHEMBL254984; GTPL9026; CHEMBL3301618; KS-00000SZB; DTXSID10239107; MolPort-039-136-930; EX-A1102; BCP16667; ZINC34946588; s7161; AKOS025289797; SB16930; DB12303; HY-13773; KB-146010; J3.657.311B; D10716; 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
DMLCTBP CP VentiRx Pharmaceuticals
DMLCTBP DT Small molecular drug
DMLCTBP PC 16049404
DMLCTBP MW 458.6
DMLCTBP FM C28H34N4O2
DMLCTBP IC InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)
DMLCTBP CS CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N
DMLCTBP IK QSPOQCXMGPDIHI-UHFFFAOYSA-N
DMLCTBP IU 2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
DMLCTBP CA CAS 926927-61-9
DMLCTBP DE Allergy
DMH4U87 ID DMH4U87
DMH4U87 DN VX-366
DMH4U87 HS Discontinued in Phase 2
DMH4U87 SN Isobutyramide; Isobutyramide, Vertex
DMH4U87 CP Vertex Pharmaceuticals Inc
DMH4U87 DE Constitutional neutropenia
DMPE5XM ID DMPE5XM
DMPE5XM DN WAY-123641
DMPE5XM HS Discontinued in Phase 2
DMPE5XM CP Wyeth-Ayerst Pharmaceuticals Inc
DMPE5XM DE Asthma
DMLA4DU ID DMLA4DU
DMLA4DU DN WC-3027
DMLA4DU HS Discontinued in Phase 2
DMLA4DU SN SEGRA, Warner Chilcott; SEGRA, Warner Chilcott/Schering AG; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott; Selective glucocorticoid receptor agonist (dermatitis), Warner Chilcott/Schering AG
DMLA4DU CP AstraZeneca
DMLA4DU DE Chronic obstructive pulmonary disease
DM7VCDZ ID DM7VCDZ
DM7VCDZ DN WY-47766
DM7VCDZ HS Discontinued in Phase 2
DM7VCDZ SN OST-766
DM7VCDZ CP Wyeth-Ayerst Pharmaceuticals Inc
DM7VCDZ PC 9882376
DM7VCDZ MW 287.34
DM7VCDZ FM C14H13N3O2S
DM7VCDZ IC InChI=1S/C14H13N3O2S/c1-19-11-4-2-3-10(7-11)9-20(18)14-16-12-5-6-15-8-13(12)17-14/h2-8H,9H2,1H3,(H,16,17)
DM7VCDZ CS COC1=CC=CC(=C1)CS(=O)C2=NC3=C(N2)C=NC=C3
DM7VCDZ IK SWPJMIZLPONDGF-UHFFFAOYSA-N
DM7VCDZ IU 2-[(3-methoxyphenyl)methylsulfinyl]-3H-imidazo[4,5-c]pyridine
DM7VCDZ CA CAS 134217-27-9
DM7VCDZ DE Osteoporosis
DMICR39 ID DMICR39
DMICR39 DN XL784
DMICR39 HS Discontinued in Phase 2
DMICR39 CP Exelixis
DMICR39 DE Diabetic nephropathy
DMO90RN ID DMO90RN
DMO90RN DN Y-27152
DMO90RN HS Discontinued in Phase 2
DMO90RN SN Y-27152; 127408-30-4; N-(Benzyloxy)-N-((3S,4R)-6-cyano-3-hydroxy-2,2-dimethylchroman-4-yl)acetamide; N-[(3S,4R)-6-Cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-(phenylmethoxy)acetamide; NCGC00092304-01; AC1OCF4F; SCHEMBL8864736; CHEMBL1476996; CHEBI:92752; CTK4B5603; MolPort-003-983-713; HMS3268J07; ZINC3789145; Acetamide,N-[(3S,4R)-6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl]-N-(phenylmethoxy)-; BN0549; AKOS022180527; AJ-45617; CC-31938; B6940; FT-0643069; C-35545; BRD-K42679050-001-01-3
DMO90RN CP Mitsubishi Pharma Corp
DMO90RN DT Small molecular drug
DMO90RN PC 6918184
DMO90RN MW 366.4
DMO90RN FM C21H22N2O4
DMO90RN IC InChI=1S/C21H22N2O4/c1-14(24)23(26-13-15-7-5-4-6-8-15)19-17-11-16(12-22)9-10-18(17)27-21(2,3)20(19)25/h4-11,19-20,25H,13H2,1-3H3/t19-,20+/m1/s1
DMO90RN CS CC(=O)N([C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O)OCC3=CC=CC=C3
DMO90RN IK RHFUXPCCELGMFC-UXHICEINSA-N
DMO90RN IU N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-phenylmethoxyacetamide
DMO90RN CA CAS 127408-30-4
DMO90RN CB CHEBI:92752
DMO90RN DE Angina pectoris
DMHFTD0 ID DMHFTD0
DMHFTD0 DN Y-700
DMHFTD0 HS Discontinued in Phase 2
DMHFTD0 SN niraxostat; Piraxostat; Y-700; UNII-246FR6022S; CHEMBL169526; 206884-98-2; 1-[3-CYANO-4-(NEOPENTYLOXY)PHENYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID; 246FR6022S; YSH; 1-(3-cyano-4-neopentyloxyphenyl) pyrazole-4-carboxylic acid; 1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1h-pyrazole-4-carboxylic acid; Niraxostat [INN]; Y 700; AC1L9MN7; MLS006010327; SCHEMBL440021; ZINC7343; DTXSID70174747; AETHRPHBGJAIBT-UHFFFAOYSA-N; MolPort-005-943-250; BDBM50098068; DB03841; NCGC00263135-01; ACM206884982; SMR004701391; FT-0728443
DMHFTD0 DT Small molecular drug
DMHFTD0 PC 449035
DMHFTD0 MW 299.32
DMHFTD0 FM C16H17N3O3
DMHFTD0 IC InChI=1S/C16H17N3O3/c1-16(2,3)10-22-14-5-4-13(6-11(14)7-17)19-9-12(8-18-19)15(20)21/h4-6,8-9H,10H2,1-3H3,(H,20,21)
DMHFTD0 CS CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(=O)O)C#N
DMHFTD0 IK AETHRPHBGJAIBT-UHFFFAOYSA-N
DMHFTD0 IU 1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]pyrazole-4-carboxylic acid
DMHFTD0 CA CAS 206884-98-2
DMHFTD0 DE Gout
DML2IXO ID DML2IXO
DML2IXO DN YM-114
DML2IXO HS Discontinued in Phase 2
DML2IXO SN KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride
DML2IXO DT Small molecular drug
DML2IXO PC 132963
DML2IXO MW 303.78
DML2IXO FM C16H18ClN3O
DML2IXO IC InChI=1S/C16H17N3O.ClH/c20-16(12-5-6-13-14(9-12)18-10-17-13)19-8-7-11-3-1-2-4-15(11)19;/h1-4,10,12H,5-9H2,(H,17,18);1H/t12-;/m1./s1
DML2IXO CS C1CC2=C(C[C@@H]1C(=O)N3CCC4=CC=CC=C43)NC=N2.Cl
DML2IXO IK GZXONPGTMHLBKQ-UTONKHPSSA-N
DML2IXO IU 2,3-dihydroindol-1-yl-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone;hydrochloride
DML2IXO CA CAS 153608-99-2
DML2IXO DE Nausea
DMIRSLV ID DMIRSLV
DMIRSLV DN YM-17K
DMIRSLV HS Discontinued in Phase 2
DMIRSLV SN MC-352
DMIRSLV CP Yamanouchi Pharmaceutical Co Ltd
DMIRSLV DE Bacterial infection
DMCZIGQ ID DMCZIGQ
DMCZIGQ DN YM-337
DMCZIGQ HS Discontinued in Phase 2
DMCZIGQ SN SMART anti-platelet; YM-387; Anti-gpIIb/IIIa (platelet) MAb, Yamanouchi
DMCZIGQ CP Yamanouchi Pharmaceutical Co Ltd
DMCZIGQ DE Angiogenesis disorder
DM7OHR6 ID DM7OHR6
DM7OHR6 DN YM-440
DM7OHR6 HS Discontinued in Phase 2
DM7OHR6 SN 2,2'-[2(Z)-Butene-1,4-diyl]dioxybis(1,4-phenylene)bis(methylene)bis[1,2,4-oxadiazole-3,5(2H,4H)-dione]
DM7OHR6 PC 9890786
DM7OHR6 MW 468.4
DM7OHR6 FM C22H20N4O8
DM7OHR6 IC InChI=1S/C22H20N4O8/c27-19-23-21(29)33-25(19)13-15-3-7-17(8-4-15)31-11-1-2-12-32-18-9-5-16(6-10-18)14-26-20(28)24-22(30)34-26/h1-10H,11-14H2,(H,23,27,29)(H,24,28,30)/b2-1-
DM7OHR6 CS C1=CC(=CC=C1CN2C(=O)NC(=O)O2)OC/C=C\\COC3=CC=C(C=C3)CN4C(=O)NC(=O)O4
DM7OHR6 IK LUACLLSCZRRTIH-UPHRSURJSA-N
DM7OHR6 IU 2-[[4-[(Z)-4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione
DM7OHR6 DE Type-1 diabetes
DM7WDAG ID DM7WDAG
DM7WDAG DN YM-511
DM7WDAG HS Discontinued in Phase 2
DM7WDAG SN YM 511; YM511 (pharmaceutical); 148869-05-0; YM-511; Benzonitrile,4-[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]-; 4-[[(4-BROMOPHENYL)METHYL]-4H-1,2,4-TRIAZOL-4-YLAMINO]BENZONITRILE; YM511; ACMC-20n5jr; SCHEMBL544997; CHEMBL108425; AC1L430I; CTK4C5946; BDBM10016; DTXSID50164121; GGPPBTSXFROGAE-UHFFFAOYSA-N; MolPort-023-276-728; ZINC598425; AKOS024457519; B5405; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole; 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile; Benzonitrile, 4-(((4-bromophenyl
DM7WDAG DT Small molecular drug
DM7WDAG PC 177865
DM7WDAG MW 354.2
DM7WDAG FM C16H12BrN5
DM7WDAG IC InChI=1S/C16H12BrN5/c17-15-5-1-14(2-6-15)10-22(21-11-19-20-12-21)16-7-3-13(9-18)4-8-16/h1-8,11-12H,10H2
DM7WDAG CS C1=CC(=CC=C1CN(C2=CC=C(C=C2)C#N)N3C=NN=C3)Br
DM7WDAG IK GGPPBTSXFROGAE-UHFFFAOYSA-N
DM7WDAG IU 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile
DM7WDAG CA CAS 148869-05-0
DM7WDAG DE Breast cancer
DMDXP3C ID DMDXP3C
DMDXP3C DN YM-796
DMDXP3C HS Discontinued in Phase 2
DMDXP3C SN (S)-(-)-2,8-Dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate monohydrate; 132041-81-7
DMDXP3C DT Small molecular drug
DMDXP3C PC 10313386
DMDXP3C MW 181.27
DMDXP3C FM C11H19NO
DMDXP3C IC InChI=1S/C11H19NO/c1-9-8-11(13-10(9)2)4-6-12(3)7-5-11/h10H,1,4-8H2,2-3H3/t10-/m1/s1
DMDXP3C CS C[C@@H]1C(=C)CC2(O1)CCN(CC2)C
DMDXP3C IK HDTOQYUZMCNTBZ-SNVBAGLBSA-N
DMDXP3C IU (2R)-2,8-dimethyl-3-methylidene-1-oxa-8-azaspiro[4.5]decane
DMDXP3C DE Cognitive impairment
DMWRT4L ID DMWRT4L
DMWRT4L DN YM-90K
DMWRT4L HS Discontinued in Phase 2
DMWRT4L SN 154164-30-4; YM 90K hydrochloride; YM 90K; YM-90K; UAEXCLWI0Q; YM-90K hydrochloride; UNII-UAEXCLWI0Q; 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione; 2,3-Quinoxalinedione, 1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-, monohydrochloride; 1,4-Dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride; 6-(1h-imidazol-1-yl)-7-nitro-2,3(1h,4h)-quinoxalinedione hydrochloride; YM-900; YM90K hydrochloride; AC1NUOLT; YM90KHYDROCHLORIDE; YM 90K HCl; YM-90K HCl; CHEMBL3400490; C11H7N5O4; EX-A113; DTXSID00165547
DMWRT4L DT Small molecular drug
DMWRT4L PC 5486547
DMWRT4L MW 309.66
DMWRT4L FM C11H8ClN5O4
DMWRT4L IC InChI=1S/C11H7N5O4.ClH/c17-10-11(18)14-7-4-9(16(19)20)8(3-6(7)13-10)15-2-1-12-5-15;/h1-5H,(H,13,17)(H,14,18);1H
DMWRT4L CS C1=CN(C=N1)C2=C(C=C3C(=C2)NC(=O)C(=O)N3)[N+](=O)[O-].Cl
DMWRT4L IK UMLFDVOHVJPDIZ-UHFFFAOYSA-N
DMWRT4L IU 6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;hydrochloride
DMWRT4L CA CAS 154164-30-4
DMWRT4L DE Convulsion
DM845NM ID DM845NM
DM845NM DN YM-992
DM845NM HS Discontinued in Phase 2
DM845NM SN Lubazodone HCl; Lubazodone hydrochloride; Lubazodone hydrochloride [USAN]; YM992; Lubazodone (TN); Lubazodone hydrochloride (USAN); SM-50C; YM-35992; (2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine hydrochloride; (S)-2-(((7-fluoro-4-indanyl)oxy)methyl)morpholine hydrochloride
DM845NM CP Yamanouchi
DM845NM TC Psychiatric
DM845NM DT Small molecular drug
DM845NM PC 157918
DM845NM MW 287.76
DM845NM FM C14H19ClFNO2
DM845NM IC InChI=1S/C14H18FNO2.ClH/c15-13-4-5-14(12-3-1-2-11(12)13)18-9-10-8-16-6-7-17-10;/h4-5,10,16H,1-3,6-9H2;1H/t10-;/m0./s1
DM845NM CS C1CC2=C(C=CC(=C2C1)F)OC[C@@H]3CNCCO3.Cl
DM845NM IK HWEMEKZYQCJVEZ-PPHPATTJSA-N
DM845NM IU (2S)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxymethyl]morpholine;hydrochloride
DM845NM CA CAS 161178-10-5
DM845NM DE Depression
DM2438J ID DM2438J
DM2438J DN Z-335
DM2438J HS Discontinued in Phase 2
DM2438J SN 2-[2-(4-Chlorophenylsulfonamidomethyl)indan-5-yl]acetic acid sodium salt
DM2438J DT Small molecular drug
DM2438J PC 23669776
DM2438J MW 401.8
DM2438J FM C18H17ClNNaO4S
DM2438J IC InChI=1S/C18H18ClNO4S.Na/c19-16-3-5-17(6-4-16)25(23,24)20-11-13-8-14-2-1-12(10-18(21)22)7-15(14)9-13;/h1-7,13,20H,8-11H2,(H,21,22);/q;+1/p-1
DM2438J CS C1C(CC2=C1C=CC(=C2)CC(=O)[O-])CNS(=O)(=O)C3=CC=C(C=C3)Cl.[Na+]
DM2438J IK UEPBEZPJELQKJV-UHFFFAOYSA-M
DM2438J IU sodium;2-[2-[[(4-chlorophenyl)sulfonylamino]methyl]-2,3-dihydro-1H-inden-5-yl]acetate
DM2438J CA CAS 146731-14-8
DM2438J DE Thrombosis
DMBSHJ6 ID DMBSHJ6
DMBSHJ6 DN Zabiciprilat
DMBSHJ6 HS Discontinued in Phase 2
DMBSHJ6 SN Zabicipril; S-10211; S-9650
DMBSHJ6 CP Servier
DMBSHJ6 DT Small molecular drug
DMBSHJ6 PC 65680
DMBSHJ6 MW 388.5
DMBSHJ6 FM C21H28N2O5
DMBSHJ6 IC InChI=1S/C21H28N2O5/c1-13(22-17(20(25)26)12-7-14-5-3-2-4-6-14)19(24)23-16-10-8-15(9-11-16)18(23)21(27)28/h2-6,13,15-18,22H,7-12H2,1H3,(H,25,26)(H,27,28)/t13-,15?,16?,17-,18-/m0/s1
DMBSHJ6 CS C[C@@H](C(=O)N1[C@@H](C2CCC1CC2)C(=O)O)N[C@@H](CCC3=CC=CC=C3)C(=O)O
DMBSHJ6 IK HBZJVGFXZTUXNI-XMQLQKOFSA-N
DMBSHJ6 IU (3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]-2-azabicyclo[2.2.2]octane-3-carboxylic acid
DMBSHJ6 CA CAS 90103-92-7
DMBSHJ6 DE Hypertension
DM9F650 ID DM9F650
DM9F650 DN ZANKIREN
DM9F650 HS Discontinued in Phase 2
DM9F650 SN Zankiren; UNII-I36B16A34Q; CHEMBL113841; I36B16A34Q; A-72517; Zankiren [INN]; 138742-43-5; A 72517; AC1MJ6K5; SCHEMBL180700; ZINC27084753; BDBM50046798; (S)-N-((1S,2R,3S)-1-(Cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-((alphaS)-alpha-(((4-methyl-1-piperazinyl)sulfonyl)methyl)hydrocinnamamido)-4-thiazolepropionamide; (1S-(1R*(R*(R*)),2S*,3R*))-N-(1-(Cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-((2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-4-thiazolepropanamide
DM9F650 DT Small molecular drug
DM9F650 PC 3086652
DM9F650 MW 706
DM9F650 FM C35H55N5O6S2
DM9F650 IC InChI=1S/C35H55N5O6S2/c1-25(2)18-32(41)33(42)30(20-27-12-8-5-9-13-27)37-35(44)31(21-29-22-47-24-36-29)38-34(43)28(19-26-10-6-4-7-11-26)23-48(45,46)40-16-14-39(3)15-17-40/h4,6-7,10-11,22,24-25,27-28,30-33,41-42H,5,8-9,12-21,23H2,1-3H3,(H,37,44)(H,38,43)/t28-,30+,31+,32+,33-/m1/s1
DM9F650 CS CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CSC=N2)NC(=O)[C@H](CC3=CC=CC=C3)CS(=O)(=O)N4CCN(CC4)C)O)O
DM9F650 IK YFDSDRDMDDGDFC-HOQQKOLYSA-N
DM9F650 IU (2S)-2-benzyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]-3-(4-methylpiperazin-1-yl)sulfonylpropanamide
DM9F650 CA CAS 138742-43-5
DM9F650 DE Hypertension
DMS95DX ID DMS95DX
DMS95DX DN ZD-0947
DMS95DX HS Discontinued in Phase 2
DMS95DX SN AZD-0947
DMS95DX CP AstraZeneca plc
DMS95DX DT Small molecular drug
DMS95DX PC 9818432
DMS95DX MW 318.29
DMS95DX FM C17H13F3N2O
DMS95DX IC InChI=1S/C17H13F3N2O/c18-17(19,20)15-8-12(11-4-1-3-10(7-11)9-21)16-13(22-15)5-2-6-14(16)23/h1,3-4,7-8,12,22H,2,5-6H2/t12-/m0/s1
DMS95DX CS C1CC2=C([C@@H](C=C(N2)C(F)(F)F)C3=CC=CC(=C3)C#N)C(=O)C1
DMS95DX IK RUVMMEREJMHLOS-LBPRGKRZSA-N
DMS95DX IU 3-[(4S)-5-oxo-2-(trifluoromethyl)-4,6,7,8-tetrahydro-1H-quinolin-4-yl]benzonitrile
DMS95DX CA CAS 172649-40-0
DMS95DX DE Overactive bladder
DMVFCX7 ID DMVFCX7
DMVFCX7 DN ZD-2138
DMVFCX7 HS Discontinued in Phase 2
DMVFCX7 SN Ici D2138; 140841-32-3; ZD-2138; UNII-B6G6OX1ZH5; B6G6OX1ZH5; CHEMBL20403; 2(1H)-Quinolinone,6-[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-; Ici-D2138; 6-((3-fluoro-5-(4-methoxytetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinolin-2(1H)-one; ZD 2138; ACMC-20mzth; AC1L30RD; zd2138; 6-((3-Fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-1-methylquinol-2-one; SCHEMBL1083603; CTK4C2357; DTXSID90161477; BDBM50000829; AKOS025404954; ACN-048395
DMVFCX7 DT Small molecular drug
DMVFCX7 PC 132306
DMVFCX7 MW 397.4
DMVFCX7 FM C23H24FNO4
DMVFCX7 IC InChI=1S/C23H24FNO4/c1-25-21-5-3-16(11-17(21)4-6-22(25)26)15-29-20-13-18(12-19(24)14-20)23(27-2)7-9-28-10-8-23/h3-6,11-14H,7-10,15H2,1-2H3
DMVFCX7 CS CN1C2=C(C=CC1=O)C=C(C=C2)COC3=CC(=CC(=C3)C4(CCOCC4)OC)F
DMVFCX7 IK SLZBEPLWGGRZAY-UHFFFAOYSA-N
DMVFCX7 IU 6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]-1-methylquinolin-2-one
DMVFCX7 CA CAS 140841-32-3
DMVFCX7 DE Asthma
DMLFNMB ID DMLFNMB
DMLFNMB DN ZD-2486
DMLFNMB HS Discontinued in Phase 2
DMLFNMB SN ZD-2486; CHEMBL118090; SCHEMBL5144316; BDBM50092099; 3-Methyl-4-[4-(4-pyridin-4-yl-piperazin-1-yl)-phenoxy]-butyric acid (ZD 2486)
DMLFNMB DT Small molecular drug
DMLFNMB PC 9906649
DMLFNMB MW 355.4
DMLFNMB FM C20H25N3O3
DMLFNMB IC InChI=1S/C20H25N3O3/c1-16(14-20(24)25)15-26-19-4-2-17(3-5-19)22-10-12-23(13-11-22)18-6-8-21-9-7-18/h2-9,16H,10-15H2,1H3,(H,24,25)/t16-/m1/s1
DMLFNMB CS C[C@H](CC(=O)O)COC1=CC=C(C=C1)N2CCN(CC2)C3=CC=NC=C3
DMLFNMB IK RVVTUJLHUHZYOD-MRXNPFEDSA-N
DMLFNMB IU (3R)-3-methyl-4-[4-(4-pyridin-4-ylpiperazin-1-yl)phenoxy]butanoic acid
DMLFNMB DE Angina pectoris
DM5UCHW ID DM5UCHW
DM5UCHW DN ZD-4953
DM5UCHW HS Discontinued in Phase 2
DM5UCHW CP AstraZeneca plc
DM5UCHW DE Pain
DMVBL25 ID DMVBL25
DMVBL25 DN ZD-6169
DMVBL25 HS Discontinued in Phase 2
DMVBL25 SN ZD-6169; ZD 6169; UNII-H6UIO70F5E; H6UIO70F5E; Zeneca ZD 6169; LVEDGSIMCSQNNX-INIZCTEOSA-N; ZD6169; 147696-46-6; CHEMBL18861; SCHEMBL4261046; BDBM86249; AC1L4306; ZINC1535218; LS-119034; (2S)-N-(4-benzoylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
DMVBL25 CP AstraZeneca plc
DMVBL25 DT Small molecular drug
DMVBL25 PC 177852
DMVBL25 MW 337.29
DMVBL25 FM C17H14F3NO3
DMVBL25 IC InChI=1S/C17H14F3NO3/c1-16(24,17(18,19)20)15(23)21-13-9-7-12(8-10-13)14(22)11-5-3-2-4-6-11/h2-10,24H,1H3,(H,21,23)/t16-/m0/s1
DMVBL25 CS C[C@](C(=O)NC1=CC=C(C=C1)C(=O)C2=CC=CC=C2)(C(F)(F)F)O
DMVBL25 IK LVEDGSIMCSQNNX-INIZCTEOSA-N
DMVBL25 IU (2S)-N-(4-benzoylphenyl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
DMVBL25 CA CAS 147696-46-6
DMVBL25 DE Urinary incontinence
DM46JIR ID DM46JIR
DM46JIR DN ZD6416
DM46JIR HS Discontinued in Phase 2
DM46JIR DE Pain
DMBSXPJ ID DMBSXPJ
DMBSXPJ DN ZD-8321
DMBSXPJ HS Discontinued in Phase 2
DMBSXPJ PC 9910174
DMBSXPJ MW 423.4
DMBSXPJ FM C18H28F3N3O5
DMBSXPJ IC InChI=1S/C18H28F3N3O5/c1-9(2)12(14(25)18(19,20)21)22-15(26)11-7-6-8-24(11)16(27)13(10(3)4)23-17(28)29-5/h9-13H,6-8H2,1-5H3,(H,22,26)(H,23,28)/t11-,12-,13-/m0/s1
DMBSXPJ CS CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC
DMBSXPJ IK ZYLBZJKJNAYAFU-AVGNSLFASA-N
DMBSXPJ IU methyl N-[(2S)-3-methyl-1-oxo-1-[(2S)-2-[[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamate
DMBSXPJ CA CAS 182073-77-4
DMBSXPJ DE Acute lung injury
DM1QXPE ID DM1QXPE
DM1QXPE DN ZELANDOPAM HYDROCHLORIDE
DM1QXPE HS Discontinued in Phase 2
DM1QXPE SN MYD-37; YM-435; Zelandopam hydrochloride; (-)-(S)-4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol hydrochloride hydrate; (-)-(S)-4-(3,4-Dihydroxyphenyl)-7,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride hydrate
DM1QXPE DT Small molecular drug
DM1QXPE PC 3078104
DM1QXPE MW 309.74
DM1QXPE FM C15H16ClNO4
DM1QXPE IC InChI=1S/C15H15NO4.ClH/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20;/h1-5,10,16-20H,6-7H2;1H/t10-;/m0./s1
DM1QXPE CS C1[C@H](C2=C(CN1)C(=C(C=C2)O)O)C3=CC(=C(C=C3)O)O.Cl
DM1QXPE IK NHCWZEQEFHNLBQ-PPHPATTJSA-N
DM1QXPE IU (4S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol;hydrochloride
DM1QXPE CA CAS 138086-00-7
DM1QXPE DE Hypertension
DMC6H4Y ID DMC6H4Y
DMC6H4Y DN ZIFROSILONE
DMC6H4Y HS Discontinued in Phase 2
DMC6H4Y SN MDL-73745; Zifrosilone < Rec INN; 2,2,2-Trifluoro-1-[3-(trimethylsilyl)phenyl]ethanone
DMC6H4Y DT Small molecular drug
DMC6H4Y PC 60811
DMC6H4Y MW 246.3
DMC6H4Y FM C11H13F3OSi
DMC6H4Y IC InChI=1S/C11H13F3OSi/c1-16(2,3)9-6-4-5-8(7-9)10(15)11(12,13)14/h4-7H,1-3H3
DMC6H4Y CS C[Si](C)(C)C1=CC=CC(=C1)C(=O)C(F)(F)F
DMC6H4Y IK GAPOASFZXBWUGS-UHFFFAOYSA-N
DMC6H4Y IU 2,2,2-trifluoro-1-(3-trimethylsilylphenyl)ethanone
DMC6H4Y CA CAS 132236-18-1
DMC6H4Y DE Cognitive impairment
DM3IRES ID DM3IRES
DM3IRES DN Zilascorb (2H)
DM3IRES HS Discontinued in Phase 2
DM3IRES SN Zoxxoz
DM3IRES CP Pronova BioPharma ASA
DM3IRES DT Small molecular drug
DM3IRES PC 54679297
DM3IRES MW 265.24
DM3IRES FM C13H12O6
DM3IRES IC InChI=1S/C13H12O6/c14-9-10(15)12(16)19-11(9)8-6-17-13(18-8)7-4-2-1-3-5-7/h1-5,8,11,13-15H,6H2/t8-,11+,13?/m0/s1/i13D
DM3IRES CS [2H]C1(OC[C@H](O1)[C@@H]2C(=C(C(=O)O2)O)O)C3=CC=CC=C3
DM3IRES IK SWTGJCNCBUCXSS-GUFVNPKRSA-N
DM3IRES IU (2R)-2-[(4S)-2-deuterio-2-phenyl-1,3-dioxolan-4-yl]-3,4-dihydroxy-2H-furan-5-one
DM3IRES CA CAS 122431-96-3
DM3IRES DE Solid tumour/cancer
DM9FQI0 ID DM9FQI0
DM9FQI0 DN Zolasartan
DM9FQI0 HS Discontinued in Phase 2
DM9FQI0 SN GR-117289
DM9FQI0 CP Glaxo Wellcome plc
DM9FQI0 DT Small molecular drug
DM9FQI0 PC 72168
DM9FQI0 MW 555.8
DM9FQI0 FM C24H20BrClN6O3
DM9FQI0 IC InChI=1S/C24H20BrClN6O3/c1-2-3-8-18-27-22(26)20(24(33)34)32(18)12-13-9-10-17-16(11-13)19(25)21(35-17)14-6-4-5-7-15(14)23-28-30-31-29-23/h4-7,9-11H,2-3,8,12H2,1H3,(H,33,34)(H,28,29,30,31)
DM9FQI0 CS CCCCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4C5=NNN=N5)C(=O)O)Cl
DM9FQI0 IK FIKYECRHLXONOX-UHFFFAOYSA-N
DM9FQI0 IU 3-[[3-bromo-2-[2-(2H-tetrazol-5-yl)phenyl]-1-benzofuran-5-yl]methyl]-2-butyl-5-chloroimidazole-4-carboxylic acid
DM9FQI0 CA CAS 145781-32-4
DM9FQI0 CB CHEBI:149761
DM9FQI0 DE Hypotension
DMWOT92 ID DMWOT92
DMWOT92 DN ZOPOLRESTAT
DMWOT92 HS Discontinued in Phase 2
DMWOT92 SN ZOPOLRESTAT; 110703-94-1; Xedia; Alond; CP-73850; Zopolrestatum [INN-Latin]; UNII-1PV3S9WP3D; C19H12F3N3O3S; CP 73850; 1PV3S9WP3D; CHEMBL10372; 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid; 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid; 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid; 3,4-Dihydro-4-oxo-3-((5-(trifluoromethyl)-2-benzothiazolyl)methyl)-1-phthalazineacetic acid; Zopolrestatum
DMWOT92 DT Small molecular drug
DMWOT92 PC 1613
DMWOT92 MW 419.4
DMWOT92 FM C19H12F3N3O3S
DMWOT92 IC InChI=1S/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)
DMWOT92 CS C1=CC=C2C(=C1)C(=NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F)CC(=O)O
DMWOT92 IK BCSVCWVQNOXFGL-UHFFFAOYSA-N
DMWOT92 IU 2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid
DMWOT92 CA CAS 110703-94-1
DMWOT92 DE Diabetic complication
DMB8XJM ID DMB8XJM
DMB8XJM DN AD-121
DMB8XJM HS Discontinued in Phase 1/2
DMB8XJM SN PW-9101; Rheumatoid arthritis therapeutic (oral controlled release, Syncrodose), Arakis/Penwest; Rheumatoid arthritis therapeutic (oral controlled release, TIMERx), Arakis/Penwest
DMB8XJM CP Sosei R&D Ltd
DMB8XJM DE Rheumatoid arthritis
DMR8XEN ID DMR8XEN
DMR8XEN DN AME-527
DMR8XEN HS Discontinued in Phase 1/2
DMR8XEN CP Applied Molecular Evoltion
DMR8XEN DT Antibody
DMR8XEN DE Rheumatoid arthritis
DM3P84V ID DM3P84V
DM3P84V DN AVE-5883
DM3P84V HS Discontinued in Phase 1/2
DM3P84V CP Aventis SA
DM3P84V DE Asthma
DMGEDAY ID DMGEDAY
DMGEDAY DN AVI-4065
DMGEDAY HS Discontinued in Phase 1/2
DMGEDAY CP AVI BioPharma
DMGEDAY TC Antisense
DMGEDAY DT Antisense drug
DMGEDAY DE Hepatitis virus infection
DM7L8SG ID DM7L8SG
DM7L8SG DN AZD8055
DM7L8SG HS Discontinued in Phase 1/2
DM7L8SG SN AZD8055; 1009298-09-2; AZD-8055; AZD 8055; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; (5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; UNII-970JJ37FPW; 970JJ37FPW; CHEMBL1801204; AK109550; (5-(2,4-Bis((S)-3-methylmorpholino)pyrido-[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol; (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
DM7L8SG CP AstraZeneca
DM7L8SG DT Small molecular drug
DM7L8SG PC 25262965
DM7L8SG MW 465.5
DM7L8SG FM C25H31N5O4
DM7L8SG IC InChI=1S/C25H31N5O4/c1-16-14-33-10-8-29(16)24-20-5-6-21(18-4-7-22(32-3)19(12-18)13-31)26-23(20)27-25(28-24)30-9-11-34-15-17(30)2/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17-/m0/s1
DM7L8SG CS C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOC[C@@H]5C
DM7L8SG IK KVLFRAWTRWDEDF-IRXDYDNUSA-N
DM7L8SG IU [5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol
DM7L8SG CA CAS 1009298-09-2
DM7L8SG CB CHEBI:91329
DM7L8SG DE Solid tumour/cancer
DMJTB4E ID DMJTB4E
DMJTB4E DN CDP-484
DMJTB4E HS Discontinued in Phase 1/2
DMJTB4E SN Anti-IL-1 beta FAb-PEG, Celltech
DMJTB4E CP UCB Celltech
DMJTB4E DE Immune System disease
DMMZ79C ID DMMZ79C
DMMZ79C DN CER-227185
DMMZ79C HS Discontinued in Phase 1/2
DMMZ79C SN TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis
DMMZ79C CP Cerenis
DMMZ79C DE Acute myeloid leukaemia
DMH40I3 ID DMH40I3
DMH40I3 DN CM-GLP-1
DMH40I3 HS Discontinued in Phase 1/2
DMH40I3 SN CellBead Neuro; GLP-1-expressing stem cell therapy (drug eluting bead, neurological trauma/neurodegeneration); CM-1-expressing stem cell therapy (drug eluting bead, neurological trauma/neurodegeneration), CellMed; GLP-1-expressing stem cell therapy (drug eluting bead, neurological trauma/neurodegeneration), CellMed
DMH40I3 CP CellMed AG
DMH40I3 DE Brain injury
DMKFIBH ID DMKFIBH
DMKFIBH DN CYT-007-TNFQb
DMKFIBH HS Discontinued in Phase 1/2
DMKFIBH CP Cytos Biotechnology
DMKFIBH DE Allergic rhinitis
DMCWRYS ID DMCWRYS
DMCWRYS DN CYT-009-GhrQb
DMCWRYS HS Discontinued in Phase 1/2
DMCWRYS CP Cytos Biotechnology
DMCWRYS DT Small molecular drug
DMCWRYS PC 9963889
DMCWRYS MW 1410.9
DMCWRYS FM C42H59N14O31P5
DMCWRYS IC InChI=1S/C21H30N7O17P3.C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32;22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35);1,3-4,7-8,10-11,13-16,20-21,29-32H,2,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t2*10-,11-,13-,14-,15-,16-,20-,21-/m11/s1
DMCWRYS CS C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O.C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O
DMCWRYS IK HDXXPHUBUBEPGJ-JJVDBIKMSA-N
DMCWRYS IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMCWRYS DE Obesity
DM17GMN ID DM17GMN
DM17GMN DN EG-011
DM17GMN HS Discontinued in Phase 1/2
DM17GMN SN Ad-VEGF D; Trinam-variants (refractory angina), Ark Therpeutics Group; Adenoviral short-form VEGF D gene therapy (angina/peripheral vascular disease), Ark Therapeutics; Short form VEGF-D gene therapy (refractory angina/peripheral vascular disease), Ark Therapeutics Group
DM17GMN CP Ark Therapeutics Group plc
DM17GMN DE Angina pectoris
DM7JMVR ID DM7JMVR
DM7JMVR DN EG-016
DM7JMVR HS Discontinued in Phase 1/2
DM7JMVR CP Ark Therapeutics Group plc
DM7JMVR DE Peripheral vascular disease
DMB35UN ID DMB35UN
DMB35UN DN FGF-21
DMB35UN HS Discontinued in Phase 1/2
DMB35UN SN Fibroblast growth factor 21, Lilly; LP-10152; FGF-21, Lilly
DMB35UN CP Eli Lilly & Co
DMB35UN DE Type-2 diabetes
DMYR7LO ID DMYR7LO
DMYR7LO DN GPG
DMYR7LO HS Discontinued in Phase 1/2
DMYR7LO SN AlfaHGA
DMYR7LO CP Tripep
DMYR7LO DT Small molecular drug
DMYR7LO PC 145459100
DMYR7LO MW 624.5
DMYR7LO FM C22H29N10O10P
DMYR7LO IC InChI=1S/C22H29N10O10P/c23-21-27-17-11(19(37)29-21)25-5-31(17)9-2-8(13(34)14(9)35)4-41-43(39,40)42-16-7(3-33)1-10(15(16)36)32-6-26-12-18(32)28-22(24)30-20(12)38/h5-10,13-16,33-36H,1-4H2,(H,39,40)(H3,23,27,29,37)(H3,24,28,30,38)/t7-,8-,9-,10-,13-,14+,15+,16-/m1/s1
DMYR7LO CS C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C2N=C(NC3=O)N)O)OP(=O)(O)OC[C@H]4C[C@H]([C@@H]([C@@H]4O)O)N5C=NC6=C5N=C(NC6=O)N)CO
DMYR7LO IK WGYAYVXBDYHRBW-QPVXRGBGSA-N
DMYR7LO IU [(1R,2R,3S,4R)-4-(2-amino-6-oxo-1H-purin-9-yl)-2,3-dihydroxycyclopentyl]methyl [(1R,2S,3R,5R)-3-(2-amino-6-oxo-1H-purin-9-yl)-2-hydroxy-5-(hydroxymethyl)cyclopentyl] hydrogen phosphate
DMYR7LO CB CHEBI:165826
DMYR7LO DE Human immunodeficiency virus infection
DM7R126 ID DM7R126
DM7R126 DN GS-9005
DM7R126 HS Discontinued in Phase 1/2
DM7R126 SN GS-224338; GS-4338
DM7R126 CP Gilead Sciences Inc
DM7R126 PC 6539952
DM7R126 MW 482.6
DM7R126 FM C29H34N6O
DM7R126 IC InChI=1S/C29H34N6O/c1-33-15-17-34(18-16-33)22-9-11-23(12-10-22)35-19-26(27-28(30)31-20-32-29(27)35)21-7-13-25(14-8-21)36-24-5-3-2-4-6-24/h2-8,13-14,19-20,22-23H,9-12,15-18H2,1H3,(H2,30,31,32)
DM7R126 CS CN1CCN(CC1)C2CCC(CC2)N3C=C(C4=C(N=CN=C43)N)C5=CC=C(C=C5)OC6=CC=CC=C6
DM7R126 IK FDVSOQRNTAPCHB-UHFFFAOYSA-N
DM7R126 IU 7-[4-(4-methylpiperazin-1-yl)cyclohexyl]-5-(4-phenoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DM7R126 DE Human immunodeficiency virus infection
DMXB4T9 ID DMXB4T9
DMXB4T9 DN GS-9132
DMXB4T9 HS Discontinued in Phase 1/2
DMXB4T9 SN ACH-806; HCV replication inhibitors, Achillion/Gilead Sciences; Hepatitis C virus replication inhibitors, Achillion/Gilead
DMXB4T9 CP Achillion Pharmaceuticals Inc
DMXB4T9 DT Small molecular drug
DMXB4T9 PC 11640186
DMXB4T9 MW 411.4
DMXB4T9 FM C19H20F3N3O2S
DMXB4T9 IC InChI=1S/C19H20F3N3O2S/c1-2-3-4-10-27-16-8-7-14(11-15(16)19(20,21)22)24-18(28)25-17(26)13-6-5-9-23-12-13/h5-9,11-12H,2-4,10H2,1H3,(H2,24,25,26,28)
DMXB4T9 CS CCCCCOC1=C(C=C(C=C1)NC(=S)NC(=O)C2=CN=CC=C2)C(F)(F)F
DMXB4T9 IK WJSGOXONRXFGRY-UHFFFAOYSA-N
DMXB4T9 IU N-[[4-pentoxy-3-(trifluoromethyl)phenyl]carbamothioyl]pyridine-3-carboxamide
DMXB4T9 CA CAS 870142-71-5
DMXB4T9 DE Hepatitis C virus infection
DM9AOJT ID DM9AOJT
DM9AOJT DN HuM-195-Bi-213
DM9AOJT HS Discontinued in Phase 1/2
DM9AOJT SN SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195
DM9AOJT CP PDL BioPharma Inc
DM9AOJT DE Acute myeloid leukaemia
DMAYLS3 ID DMAYLS3
DMAYLS3 DN IDX-320
DMAYLS3 HS Discontinued in Phase 1/2
DMAYLS3 SN Hepatitis C virus NS3/4A protease inhibitor (oral/tablet formulation), Idenix Pharmaceuticals; Hepatitis C virus replication inhibitor (oral/tablet formulation, HCV infection), Idenix Pharmaceuticals
DMAYLS3 CP Idenix Pharmaceuticals Inc
DMAYLS3 DT Small molecular drug
DMAYLS3 PC 71768520
DMAYLS3 MW 804.9
DMAYLS3 FM C37H43F3N6O7S2
DMAYLS3 IC InChI=1S/C37H43F3N6O7S2/c1-21-27(52-4)11-10-24-28(18-25(41-30(21)24)32-42-29(20-54-32)37(38,39)40)53-23-12-16-46-26(17-23)31(47)43-36(33(48)44-55(50,51)35(2)13-14-35)19-22(36)9-7-5-6-8-15-45(3)34(46)49/h7,9-11,18,20,22-23,26H,5-6,8,12-17,19H2,1-4H3,(H,43,47)(H,44,48)/b9-7+/t22-,23+,26+,36-/m1/s1
DMAYLS3 CS CC1=C(C=CC2=C1N=C(C=C2O[C@H]3CCN4[C@@H](C3)C(=O)N[C@@]5(C[C@H]5/C=C/CCCCN(C4=O)C)C(=O)NS(=O)(=O)C6(CC6)C)C7=NC(=CS7)C(F)(F)F)OC
DMAYLS3 IK YEPBUHWNLNKZBW-FDVAVYTKSA-N
DMAYLS3 IU (1S,4R,6S,7E,18S)-18-[7-methoxy-8-methyl-2-[4-(trifluoromethyl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy-13-methyl-N-(1-methylcyclopropyl)sulfonyl-2,14-dioxo-3,13,15-triazatricyclo[13.4.0.04,6]nonadec-7-ene-4-carboxamide
DMAYLS3 CA CAS 1251165-81-7
DMAYLS3 DE Hepatitis C virus infection
DMEF9JW ID DMEF9JW
DMEF9JW DN IM0-8400
DMEF9JW HS Discontinued in Phase 1/2
DMEF9JW CP Idera pharmaceuticals
DMEF9JW DE Diffuse large B-cell lymphoma
DMMJC4Q ID DMMJC4Q
DMMJC4Q DN KSB-303
DMMJC4Q HS Discontinued in Phase 1/2
DMMJC4Q SN YMB-1003 Mab
DMMJC4Q CP YM Biosciences
DMMJC4Q DT Antibody
DMMJC4Q DE Colorectal cancer
DM7QGSX ID DM7QGSX
DM7QGSX DN KW-2450
DM7QGSX HS Discontinued in Phase 1/2
DM7QGSX CP Kyowa Hakko Kirin Pharma
DM7QGSX PC 56847547
DM7QGSX MW 687.8
DM7QGSX FM C35H37N5O6S2
DM7QGSX IC InChI=1S/C28H29N5O3S.C7H8O3S/c1-19-10-15-37-27(19)28(36)29-25-16-20(17-32-11-13-33(14-12-32)26(35)18-34)6-7-21(25)8-9-24-22-4-2-3-5-23(22)30-31-24;1-6-2-4-7(5-3-6)11(8,9)10/h2-10,15-16,34H,11-14,17-18H2,1H3,(H,29,36)(H,30,31);2-5H,1H3,(H,8,9,10)/b9-8+;
DM7QGSX CS CC1=CC=C(C=C1)S(=O)(=O)O.CC1=C(SC=C1)C(=O)NC2=C(C=CC(=C2)CN3CCN(CC3)C(=O)CO)/C=C/C4=NNC5=CC=CC=C54
DM7QGSX IK SIJKXSMUXNJNQM-HRNDJLQDSA-N
DM7QGSX IU N-[5-[[4-(2-hydroxyacetyl)piperazin-1-yl]methyl]-2-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-3-methylthiophene-2-carboxamide;4-methylbenzenesulfonic acid
DM7QGSX CA CAS 1360433-93-7
DM7QGSX DE Breast cancer
DMXB20Y ID DMXB20Y
DMXB20Y DN MDX-214
DMXB20Y HS Discontinued in Phase 1/2
DMXB20Y SN CD89 monoclonal antibody (cancer, autoimmune disease), Medarex
DMXB20Y CP Medarex Inc
DMXB20Y DT Antibody
DMXB20Y DE Autoimmune diabetes
DMNXCFZ ID DMNXCFZ
DMNXCFZ DN NCX 950
DMNXCFZ HS Discontinued in Phase 1/2
DMNXCFZ CP NicOx SA
DMNXCFZ DE Asthma
DMO34NQ ID DMO34NQ
DMO34NQ DN PD-151832
DMO34NQ HS Discontinued in Phase 1/2
DMO34NQ SN PD-142505 (racemate); (-)-(R)-(Z)-3-[3-(3-Methoxyphenyl)-2-propynyloxyimino]-1-azabicyclo[2.2.1]heptane
DMO34NQ DT Small molecular drug
DMO34NQ PC 9795428
DMO34NQ MW 270.33
DMO34NQ FM C16H18N2O2
DMO34NQ IC InChI=1S/C16H18N2O2/c1-19-15-6-2-4-13(10-15)5-3-9-20-17-16-12-18-8-7-14(16)11-18/h2,4,6,10,14H,7-9,11-12H2,1H3/b17-16+/t14-/m1/s1
DMO34NQ CS COC1=CC=CC(=C1)C#CCO/N=C/2\\CN3CC[C@@H]2C3
DMO34NQ IK FXBXWJPMXQHOGD-UVTIVQHFSA-N
DMO34NQ IU (Z,4R)-N-[3-(3-methoxyphenyl)prop-2-ynoxy]-1-azabicyclo[2.2.1]heptan-3-imine
DMO34NQ CA CAS 149929-39-5
DMO34NQ DE Parkinson disease
DMRQPOD ID DMRQPOD
DMRQPOD DN R-803
DMRQPOD HS Discontinued in Phase 1/2
DMRQPOD SN R-111706; R-940803
DMRQPOD CP Rigel Pharmaceuticals Inc
DMRQPOD DT Small molecular drug
DMRQPOD PC 37801
DMRQPOD MW 266.29
DMRQPOD FM C17H14O3
DMRQPOD IC InChI=1S/C17H14O3/c1-11(17(18)19)13-8-5-9-14-15(10-20-16(13)14)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
DMRQPOD CS CC(C1=CC=CC2=C1OC=C2C3=CC=CC=C3)C(=O)O
DMRQPOD IK ODZUWQAFWMLWCF-UHFFFAOYSA-N
DMRQPOD IU 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid
DMRQPOD CA CAS 67700-30-5
DMRQPOD DE Hepatitis C virus infection
DMIAZJ9 ID DMIAZJ9
DMIAZJ9 DN RhApo2L/TRAIL
DMIAZJ9 HS Discontinued in Phase 1/2
DMIAZJ9 CP Amgen
DMIAZJ9 DE Solid tumour/cancer
DMHXRZF ID DMHXRZF
DMHXRZF DN UK-369003
DMHXRZF HS Discontinued in Phase 1/2
DMHXRZF CP Pfizer
DMHXRZF DT Small molecular drug
DMHXRZF PC 135536943
DMHXRZF MW 519.6
DMHXRZF FM C23H33N7O5S
DMHXRZF IC InChI=1S/C23H33N7O5S/c1-5-18-19-20(27-30(18)12-13-34-4)22(31)26-21(25-19)17-14-16(15-24-23(17)35-7-3)36(32,33)29-10-8-28(6-2)9-11-29/h14-15H,5-13H2,1-4H3,(H,25,26,31)
DMHXRZF CS CCC1=C2C(=NN1CCOC)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC
DMHXRZF IK YPFZMBHKIVDSNR-UHFFFAOYSA-N
DMHXRZF IU 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-6H-pyrazolo[4,3-d]pyrimidin-7-one
DMHXRZF CA CAS 334826-98-1
DMHXRZF DE Erectile dysfunction
DM8Q2ZR ID DM8Q2ZR
DM8Q2ZR DN WX-UK1
DM8Q2ZR HS Discontinued in Phase 1/2
DM8Q2ZR SN UKI-1; UNII-00LOF6890B; CHEMBL107955; WX-UK1; 00LOF6890B; 220355-63-5; Wx-uk1 free base; compound 2r-L; GTPL6498; BDBM23891; 3-amidinophenylalanine deriv., 35; ZINC4426028; AKOS030526723; CS-5726; HY-100415; 1-Piperazinecarboxylic acid, 4-((2S)-3-(3-(aminoiminomethyl)phenyl)-1-oxo-2-(((2,4,6-tris(1-methylethyl)phenyl)sulfonyl)amino)propyl)-, ethyl ester; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate; ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-{[2,4,6
DM8Q2ZR CP Wilex
DM8Q2ZR DT Small molecular drug
DM8Q2ZR PC 9895194
DM8Q2ZR MW 613.8
DM8Q2ZR FM C32H47N5O5S
DM8Q2ZR IC InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)
DM8Q2ZR CS CCOC(=O)N1CCN(CC1)C(=O)C(CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C
DM8Q2ZR IK ISJSHQTWOHGCMM-UHFFFAOYSA-N
DM8Q2ZR IU ethyl 4-[3-(3-carbamimidoylphenyl)-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate
DM8Q2ZR DE Solid tumour/cancer
DMC7M3K ID DMC7M3K
DMC7M3K DN 447C88
DMC7M3K HS Discontinued in Phase 1
DMC7M3K SN BW-447C88
DMC7M3K CP GlaxoSmithKline Inc
DMC7M3K PC 9889686
DMC7M3K MW 444.6
DMC7M3K FM C27H38F2N2O
DMC7M3K IC InChI=1S/C27H38F2N2O/c1-5-6-7-8-9-16-30-26(32)31-25-22(17-23(28)18-24(25)29)15-14-20-10-12-21(13-11-20)19-27(2,3)4/h10-13,17-18H,5-9,14-16,19H2,1-4H3,(H2,30,31,32)
DMC7M3K CS CCCCCCCNC(=O)NC1=C(C=C(C=C1F)F)CCC2=CC=C(C=C2)CC(C)(C)C
DMC7M3K IK XWWXRQIQZOTQGF-UHFFFAOYSA-N
DMC7M3K IU 1-[2-[2-[4-(2,2-dimethylpropyl)phenyl]ethyl]-4,6-difluorophenyl]-3-heptylurea
DMC7M3K DE Hyperlipidaemia
DMHT84I ID DMHT84I
DMHT84I DN A-216546
DMHT84I HS Discontinued in Phase 1
DMHT84I SN ABT-546; (2S,3R,4S)-1-[2-(Dibutylamino)-2-oxoethyl]-2-(2,2-dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)tetrahydro-1H-pyrrole-3-carboxylic acid
DMHT84I DT Small molecular drug
DMHT84I PC 71587660
DMHT84I MW 569.2
DMHT84I FM C30H49ClN2O6
DMHT84I IC InChI=1S/C30H48N2O6.ClH/c1-7-10-13-31(14-11-8-2)26(33)19-32-18-22(21-15-24(36-6)28-25(16-21)37-20-38-28)27(29(34)35)23(32)17-30(4,5)12-9-3;/h15-16,22-23,27H,7-14,17-20H2,1-6H3,(H,34,35);1H/t22-,23+,27-;/m1./s1
DMHT84I CS CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1CC(C)(C)CCC)C(=O)O)C2=CC3=C(C(=C2)OC)OCO3.Cl
DMHT84I IK KMKKFZCVBRAWNX-KQQHTNMISA-N
DMHT84I IU (2S,3R,4S)-1-[2-(dibutylamino)-2-oxoethyl]-2-(2,2-dimethylpentyl)-4-(7-methoxy-1,3-benzodioxol-5-yl)pyrrolidine-3-carboxylic acid;hydrochloride
DMHT84I CA CAS 223756-43-2
DMHT84I DE Solid tumour/cancer
DM0DLC1 ID DM0DLC1
DM0DLC1 DN A-75998
DM0DLC1 HS Discontinued in Phase 1
DM0DLC1 SN CHEMBL263839
DM0DLC1 CP Abbott Laboratories
DM0DLC1 PC 44383749
DM0DLC1 MW 1535.2
DM0DLC1 FM C80H104ClN15O14
DM0DLC1 IC InChI=1S/C80H104ClN15O14/c1-46(2)38-63(73(103)90-62(20-10-17-59(82)47(3)4)80(110)96-37-13-21-68(96)77(107)87-48(5)71(84)101)91-72(102)61(19-11-18-60(83)70(100)55-32-35-85-36-33-55)89-78(108)69(43-51-25-30-58(99)31-26-51)95(7)79(109)67(45-97)94-76(106)66(42-53-14-12-34-86-44-53)93-75(105)65(40-50-23-28-57(81)29-24-50)92-74(104)64(88-49(6)98)41-52-22-27-54-15-8-9-16-56(54)39-52/h8-9,12,14-16,22-36,39,44,46-48,59-69,97,99H,10-11,13,17-21,37-38,40-43,45,82-83H2,1-7H3,(H2,84,101)(H,87,107)(H,88,98)(H,89,108)(H,90,103)(H,91,102)(H,92,104)(H,93,105)(H,94,106)/t48-,59?,60?,61-,62-,63-,64-,65-,66-,67-,68+,69-/m0/s1
DM0DLC1 CS C[C@@H](C(=O)N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CCCC(C(C)C)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCC(C(=O)C2=CC=NC=C2)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N(C)C(=O)[C@H](CO)NC(=O)[C@H](CC4=CN=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM0DLC1 IK WGWPBHBZVYAVTQ-HQDLIPOVSA-N
DM0DLC1 IU (2R)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-amino-7-oxo-7-pyridin-4-ylheptanoyl]amino]-4-methylpentanoyl]amino]-6-amino-7-methyloctanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM0DLC1 DE Hormone deficiency
DMGEWQ7 ID DMGEWQ7
DMGEWQ7 DN A-80987
DMGEWQ7 HS Discontinued in Phase 1
DMGEWQ7 SN ABT-987
DMGEWQ7 CP Abbott Laboratories
DMGEWQ7 DT Small molecular drug
DMGEWQ7 PC 461207
DMGEWQ7 MW 653.8
DMGEWQ7 FM C37H43N5O6
DMGEWQ7 IC InChI=1S/C37H43N5O6/c1-26(2)34(42-37(46)48-25-30-17-9-10-19-39-30)35(44)41-32(21-28-14-7-4-8-15-28)33(43)22-31(20-27-12-5-3-6-13-27)40-36(45)47-24-29-16-11-18-38-23-29/h3-19,23,26,31-34,43H,20-22,24-25H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)/t31-,32-,33-,34-/m0/s1
DMGEWQ7 CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CC=C3)O)NC(=O)OCC4=CC=CC=N4
DMGEWQ7 IK SSIBMWPFXYSVEK-CUPIEXAXSA-N
DMGEWQ7 IU pyridin-2-ylmethyl N-[(2S)-1-[[(2S,3S,5S)-3-hydroxy-1,6-diphenyl-5-(pyridin-3-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMGEWQ7 CA CAS 144141-97-9
DMGEWQ7 CB CHEBI:80009
DMGEWQ7 DE Human immunodeficiency virus infection
DMJTIUP ID DMJTIUP
DMJTIUP DN ABJ-879
DMJTIUP HS Discontinued in Phase 1
DMJTIUP CP Novartis AG
DMJTIUP PC 9871979
DMJTIUP MW 539.8
DMJTIUP FM C27H41NO6S2
DMJTIUP IC InChI=1S/C27H41NO6S2/c1-15-9-8-10-27(6)21(34-27)12-19(16(2)11-18-14-36-25(28-18)35-7)33-22(30)13-20(29)26(4,5)24(32)17(3)23(15)31/h11,14-15,17,19-21,23,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17+,19-,20-,21-,23-,27+/m0/s1
DMJTIUP CS C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)SC)/C)C
DMJTIUP IK FODFUEDBIXOGNY-AKXQMUJXSA-N
DMJTIUP IU (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methylsulfanyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMJTIUP CA CAS 252981-48-9
DMJTIUP DE Solid tumour/cancer
DMADKHB ID DMADKHB
DMADKHB DN ABN-912
DMADKHB HS Discontinued in Phase 1
DMADKHB SN Anti-CD46 mAb, Novartis; Anti-MCP1 monoclonal antibody, Novartis
DMADKHB CP Novartis AG
DMADKHB DT Antibody
DMADKHB DE Asthma
DMTYWE9 ID DMTYWE9
DMTYWE9 DN ABT-080
DMTYWE9 HS Discontinued in Phase 1
DMTYWE9 SN VML-530; 4,4-Bis[4-(quinolin-2-ylmethoxy)phenyl]pentanoic acid sodium salt
DMTYWE9 DE Asthma
DMPCYV6 ID DMPCYV6
DMPCYV6 DN ABT-107
DMPCYV6 HS Discontinued in Phase 1
DMPCYV6 SN Alpha 7 NNR (CNS diseases, schizophrenia, ADHD), Abbott; Alpha 7 NNR (CNS diseases, schizophrenia, ADHD), NeuroSearch; Alpha 7 neuronal nicotinic receptors (central nervous system diseases, schizophrenia, ADHD), Abbott; Alpha 7 neuronal nicotinic receptors (central nervous system diseases, schizophrenia, ADHD), NeuroSearch; NAChR alpha 7 (CNS diseases, schizophrenia, ADHD), Abbott; NAChR alpha 7 (CNS diseases, schizophrenia, ADHD), NeuroSearch; Nicotinic acetylcholine receptor alpha 7 (central nervous system diseases, schizophrenia, ADHD), Abbott; Nicotinic acetylcholine receptor alpha 7 (central nervous system diseases, schizophrenia, ADHD), NeuroSearch
DMPCYV6 CP NeuroSearch A/S
DMPCYV6 DT Small molecular drug
DMPCYV6 PC 11151363
DMPCYV6 MW 320.4
DMPCYV6 FM C19H20N4O
DMPCYV6 IC InChI=1S/C19H20N4O/c1-2-16-15(5-8-20-16)11-14(1)17-3-4-19(22-21-17)24-18-12-23-9-6-13(18)7-10-23/h1-5,8,11,13,18,20H,6-7,9-10,12H2/t18-/m0/s1
DMPCYV6 CS C1CN2CCC1[C@H](C2)OC3=NN=C(C=C3)C4=CC5=C(C=C4)NC=C5
DMPCYV6 IK LUKNJAQKVPBDSC-SFHVURJKSA-N
DMPCYV6 IU 5-[6-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole
DMPCYV6 CA CAS 855291-54-2
DMPCYV6 DE Attention deficit hyperactivity disorder
DMG9Y80 ID DMG9Y80
DMG9Y80 DN ABT-202
DMG9Y80 HS Discontinued in Phase 1
DMG9Y80 SN A-429202
DMG9Y80 CP NeuroSearch A/S
DMG9Y80 DT Small molecular drug
DMG9Y80 PC 17928441
DMG9Y80 MW 163.22
DMG9Y80 FM C9H13N3
DMG9Y80 IC InChI=1S/C9H13N3/c10-8-3-5-12(7-8)9-2-1-4-11-6-9/h1-2,4,6,8H,3,5,7,10H2
DMG9Y80 CS C1CN(CC1N)C2=CN=CC=C2
DMG9Y80 IK LVGMMVAWLISWJD-UHFFFAOYSA-N
DMG9Y80 IU 1-pyridin-3-ylpyrrolidin-3-amine
DMG9Y80 DE Pain
DMWVFDH ID DMWVFDH
DMWVFDH DN ABT-279
DMWVFDH HS Discontinued in Phase 1
DMWVFDH SN LS-193221
DMWVFDH CP Abbott Lab
DMWVFDH DT Small molecular drug
DMWVFDH PC 16049769
DMWVFDH MW 395.5
DMWVFDH FM C21H25N5O3
DMWVFDH IC InChI=1S/C21H25N5O3/c1-3-16-4-5-17(13-22)26(16)19(27)14-24-21(2)7-10-25(11-8-21)18-12-15(20(28)29)6-9-23-18/h1,6,9,12,16-17,24H,4-5,7-8,10-11,14H2,2H3,(H,28,29)/t16-,17-/m0/s1
DMWVFDH CS CC1(CCN(CC1)C2=NC=CC(=C2)C(=O)O)NCC(=O)N3[C@H](CC[C@H]3C#N)C#C
DMWVFDH IK FIMRNLAKAARHPD-IRXDYDNUSA-N
DMWVFDH IU 2-[4-[[2-[(2S,5R)-2-cyano-5-ethynylpyrrolidin-1-yl]-2-oxoethyl]amino]-4-methylpiperidin-1-yl]pyridine-4-carboxylic acid
DMWVFDH CA CAS 676559-83-4
DMWVFDH DE Type-2 diabetes
DM8GZAS ID DM8GZAS
DM8GZAS DN ABT-299
DM8GZAS HS Discontinued in Phase 1
DM8GZAS SN A-85783
DM8GZAS CP Abbott Laboratories
DM8GZAS DT Small molecular drug
DM8GZAS PC 9830503
DM8GZAS MW 619.1
DM8GZAS FM C32H28ClFN4O4S
DM8GZAS IC InChI=1S/C32H28FN4O4S.ClH/c1-20(38)41-19-35-13-4-5-23(16-35)31-36-14-12-26(29(36)18-42-31)30(39)27-17-37(32(40)34(2)3)28-15-22(8-11-25(27)28)21-6-9-24(33)10-7-21;/h4-17,31H,18-19H2,1-3H3;1H/q+1;/p-1/t31-;/m1./s1
DM8GZAS CS CC(=O)OC[N+]1=CC=CC(=C1)[C@@H]2N3C=CC(=C3CS2)C(=O)C4=CN(C5=C4C=CC(=C5)C6=CC=C(C=C6)F)C(=O)N(C)C.[Cl-]
DM8GZAS IK NKIONDJYXPXFFL-JSSVAETHSA-M
DM8GZAS IU [3-[(3R)-7-[1-(dimethylcarbamoyl)-6-(4-fluorophenyl)indole-3-carbonyl]-1,3-dihydropyrrolo[1,2-c][1,3]thiazol-3-yl]pyridin-1-ium-1-yl]methyl acetate;chloride
DM8GZAS CA CAS 161395-35-3
DM8GZAS DE Sepsis
DMA2RM3 ID DMA2RM3
DMA2RM3 DN ABT-518
DMA2RM3 HS Discontinued in Phase 1
DMA2RM3 SN N-[1(S)-[2,2-Dimethyl-1,3-dioxolan-4(S)-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenylsulfonyl]ethyl]-N-hydroxyformamide
DMA2RM3 DT Small molecular drug
DMA2RM3 PC 9827497
DMA2RM3 MW 505.5
DMA2RM3 FM C21H22F3NO8S
DMA2RM3 IC InChI=1S/C21H22F3NO8S/c1-20(2)30-11-19(33-20)18(25(27)13-26)12-34(28,29)17-9-7-15(8-10-17)31-14-3-5-16(6-4-14)32-21(22,23)24/h3-10,13,18-19,27H,11-12H2,1-2H3/t18-,19-/m1/s1
DMA2RM3 CS CC1(OC[C@@H](O1)[C@@H](CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)OC(F)(F)F)N(C=O)O)C
DMA2RM3 IK IVPPTWCRAFCOFJ-RTBURBONSA-N
DMA2RM3 IU N-[(1S)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonylethyl]-N-hydroxyformamide
DMA2RM3 CA CAS 286845-00-9
DMA2RM3 DE Solid tumour/cancer
DMZYVPB ID DMZYVPB
DMZYVPB DN ABX-MA1
DMZYVPB HS Discontinued in Phase 1
DMZYVPB SN Anti-MUC18 MAb, Abgenix
DMZYVPB CP Abgenix Inc
DMZYVPB DT Antibody
DMZYVPB DE Melanoma
DME98LV ID DME98LV
DME98LV DN AC-162352
DME98LV HS Discontinued in Phase 1
DME98LV CP Amylin
DME98LV DE Obesity
DM704HO ID DM704HO
DM704HO DN AC-253
DM704HO HS Discontinued in Phase 1
DM704HO SN Antam; Amylin antagonist, Amylin; Amylin antagonist, Glaxo; GG-747
DM704HO CP Amylin Pharmaceuticals Inc
DM704HO DE Hypertension
DM54W9A ID DM54W9A
DM54W9A DN AC3056
DM54W9A HS Discontinued in Phase 1
DM54W9A CP Amylin Pharmaceuticals
DM54W9A DE Arteriosclerosis
DMIJB68 ID DMIJB68
DMIJB68 DN AC-625
DMIJB68 HS Discontinued in Phase 1
DMIJB68 CP Amylin Pharmaceuticals Inc
DMIJB68 DE Hypertension
DMSPW3N ID DMSPW3N
DMSPW3N DN ACH-2928
DMSPW3N HS Discontinued in Phase 1
DMSPW3N CP Achillion Pharmaceuticals Inc
DMSPW3N DE Hepatitis C virus infection
DML1AUZ ID DML1AUZ
DML1AUZ DN ADL-7445
DML1AUZ HS Discontinued in Phase 1
DML1AUZ SN Mu-opioid antagonists (opioid-induced bowel disorder), Adolor; 14-beta-aminonaltrexone
DML1AUZ CP Adolor Corp
DML1AUZ DE Constipation
DMRSEZD ID DMRSEZD
DMRSEZD DN AE-3763
DMRSEZD HS Discontinued in Phase 1
DMRSEZD DT Small molecular drug
DMRSEZD PC 9807572
DMRSEZD MW 549.5
DMRSEZD FM C23H34F3N5O7
DMRSEZD IC InChI=1S/C23H34F3N5O7/c1-12(2)17(19(35)23(24,25)26)28-20(36)14-6-5-7-31(14)21(37)18(13(3)4)27-15(32)10-29-8-9-30(22(29)38)11-16(33)34/h12-14,17-18H,5-11H2,1-4H3,(H,27,32)(H,28,36)(H,33,34)/t14-,17-,18-/m0/s1
DMRSEZD CS CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)CN2CCN(C2=O)CC(=O)O
DMRSEZD IK DHQQXRRWRZFGDW-WBAXXEDZSA-N
DMRSEZD IU 2-[3-[2-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]amino]-2-oxoethyl]-2-oxoimidazolidin-1-yl]acetic acid
DMRSEZD DE Chronic obstructive pulmonary disease
DM1TYM4 ID DM1TYM4
DM1TYM4 DN AG-021541
DM1TYM4 HS Discontinued in Phase 1
DM1TYM4 SN SCHEMBL5880778
DM1TYM4 CP Agouron; Pfizer
DM1TYM4 DT Small molecular drug
DM1TYM4 PC 54684477
DM1TYM4 MW 559.1
DM1TYM4 FM C27H31ClN4O5S
DM1TYM4 IC InChI=1S/C27H31ClN4O5S/c1-15-11-16(2)32-25(29-15)30-26(31-32)38-23-20(33)14-27(37-24(23)34,18-7-5-6-8-18)10-9-17-12-19(28)22(36-4)13-21(17)35-3/h11-13,18,33H,5-10,14H2,1-4H3
DM1TYM4 CS CC1=CC(=NC2=NC(=NN12)SC3=C(CC(OC3=O)(CCC4=CC(=C(C=C4OC)OC)Cl)C5CCCC5)O)C
DM1TYM4 IK MKOFABQFNUCNTD-UHFFFAOYSA-N
DM1TYM4 IU 2-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-4-hydroxy-3H-pyran-6-one
DM1TYM4 DE Hepatitis C virus infection
DMCEM0L ID DMCEM0L
DMCEM0L DN AG-331
DMCEM0L HS Discontinued in Phase 1
DMCEM0L SN Metesind glucuronate
DMCEM0L CP Agouron Pharmaceuticals Inc
DMCEM0L DT Small molecular drug
DMCEM0L PC 3047716
DMCEM0L MW 436.5
DMCEM0L FM C23H24N4O3S
DMCEM0L IC InChI=1S/C23H24N4O3S/c1-26(21-10-9-20-22-18(21)3-2-4-19(22)23(24)25-20)15-16-5-7-17(8-6-16)31(28,29)27-11-13-30-14-12-27/h2-10H,11-15H2,1H3,(H2,24,25)
DMCEM0L CS CN(CC1=CC=C(C=C1)S(=O)(=O)N2CCOCC2)C3=C4C=CC=C5C4=C(C=C3)N=C5N
DMCEM0L IK CVEGTZWWWRJCFK-UHFFFAOYSA-N
DMCEM0L IU 6-N-methyl-6-N-[(4-morpholin-4-ylsulfonylphenyl)methyl]benzo[cd]indole-2,6-diamine
DMCEM0L CA CAS 138384-68-6
DMCEM0L DE Solid tumour/cancer
DM8XODL ID DM8XODL
DM8XODL DN AGN-191743
DM8XODL HS Discontinued in Phase 1
DM8XODL CP Roche Holding AG
DM8XODL DE Allergy
DMGAERX ID DMGAERX
DMGAERX DN AIR-Epinephrine
DMGAERX HS Discontinued in Phase 1
DMGAERX CP Alkermes
DMGAERX DE Allergy
DMVBKLO ID DMVBKLO
DMVBKLO DN ALBIFYLLINE
DMVBKLO HS Discontinued in Phase 1
DMVBKLO SN HWA-138; Albifylline; 1-(5-Hydroxy-5-methylhexyl)-3-methylxanthine
DMVBKLO DT Small molecular drug
DMVBKLO PC 115359
DMVBKLO MW 280.32
DMVBKLO FM C13H20N4O3
DMVBKLO IC InChI=1S/C13H20N4O3/c1-13(2,20)6-4-5-7-17-11(18)9-10(15-8-14-9)16(3)12(17)19/h8,20H,4-7H2,1-3H3,(H,14,15)
DMVBKLO CS CC(C)(CCCCN1C(=O)C2=C(N=CN2)N(C1=O)C)O
DMVBKLO IK NWXULHNEYYFVMF-UHFFFAOYSA-N
DMVBKLO IU 1-(5-hydroxy-5-methylhexyl)-3-methyl-7H-purine-2,6-dione
DMVBKLO CA CAS 107767-55-5
DMVBKLO DE Sepsis
DM2QMKJ ID DM2QMKJ
DM2QMKJ DN ALS-00T2-0501
DM2QMKJ HS Discontinued in Phase 1
DM2QMKJ SN TNF Blocker (Intradel, psoriasis), Apollo Life Sciences; TNF Blocker (TransD, psoriasis), Apollo Life Sciences; TNF Blocker (transdermal cream, psoriasis), Apollo Life Sciences; TNF receptor antagonist (Intradel, psoriasis), Apollo Life Sciences; TNF receptor antagonist (TransD, psoriasis), Apollo Life Sciences; TNF receptor antagonist (transdermal cream, psoriasis), Apollo Life Sciences
DM2QMKJ CP Apollo Life Sciences Pty Ltd
DM2QMKJ DE Psoriasis vulgaris
DMS5C06 ID DMS5C06
DMS5C06 DN ALTU-237
DMS5C06 HS Discontinued in Phase 1
DMS5C06 SN Oxalate oxidase (oral crystalline, kidney stones), Altus
DMS5C06 CP Altus Pharmaceuticals Inc
DMS5C06 DE Hyperoxaluria
DMNOZAI ID DMNOZAI
DMNOZAI DN ALX-0646
DMNOZAI HS Discontinued in Phase 1
DMNOZAI SN ALC-2527XX; ALC-900XX; ALC-901XX; ALC-902XX; ALC-905XX; ALC-907XX; ALC-913; ALC-918; ALC-918XX; ALC-947XX; ALC-948XX; ALC-962XX; ALC-963XX; ALC-973XX; ALC-974XX; ALX-2324; ALX-2325; ALX-2326; ALX-2354XX; ALX-2355XX; ALX-2356XX; ALX-2357XX; ALX-2436XX; ALX-2437XX; ALX-2458XX; ALX-2459XX; ALX-2476XX; ALX-2477XX; ALX-2503XX; ALX-2504XX; ALX-2581; ALX-2582; ALX-2592; ALX-646CL; ALX-912
DMNOZAI CP NPS Allelix Corp
DMNOZAI DT Small molecular drug
DMNOZAI PC 9860595
DMNOZAI MW 283.4
DMNOZAI FM C18H25N3
DMNOZAI IC InChI=1S/C18H25N3/c1-20(2)9-6-16-13-19-18-5-4-15(12-17(16)18)14-7-10-21(3)11-8-14/h4-5,7,12-13,19H,6,8-11H2,1-3H3
DMNOZAI CS CN1CCC(=CC1)C2=CC3=C(C=C2)NC=C3CCN(C)C
DMNOZAI IK RQTZMTMTBWAQAI-UHFFFAOYSA-N
DMNOZAI IU N,N-dimethyl-2-[5-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-1H-indol-3-yl]ethanamine
DMNOZAI CA CAS 208464-67-9
DMNOZAI DE Migraine
DMO7920 ID DMO7920
DMO7920 DN AM-831
DMO7920 HS Discontinued in Phase 1
DMO7920 SN 199330-66-0; METHYL 4-AMINOTETRAHYDRO-2H-PYRAN-4-CARBOXYLATE HYDROCHLORIDE; methyl 4-aminooxane-4-carboxylate hydrochloride; METHYL 4-AMINOTETRAHYDROPYRAN-4-CARBOXYLATE HCL; methyl 4-aminotetrahydropyran-4-carboxylate hydrochloride; 2H-Pyran-4-carboxylic acid, 4-aminotetrahydro-, methyl ester, hydrochloride (1:1); SCHEMBL1818830; MolPort-009-013-807; VNPBPEQYIQVYDP-UHFFFAOYSA-N; AM831; KS-000008CU; SBB091929; AKOS025147281; PB10899; AS-36521; DB-065487; CS-0049053; FT-0768000; Q-1506; methyl 4-aminooxane-4-carboxylate,hydroch
DMO7920 CP ACADIA Pharmaceuticals
DMO7920 DT Small molecular drug
DMO7920 PC 43811077
DMO7920 MW 195.64
DMO7920 FM C7H14ClNO3
DMO7920 IC InChI=1S/C7H13NO3.ClH/c1-10-6(9)7(8)2-4-11-5-3-7;/h2-5,8H2,1H3;1H
DMO7920 CS COC(=O)C1(CCOCC1)N.Cl
DMO7920 IK VNPBPEQYIQVYDP-UHFFFAOYSA-N
DMO7920 IU methyl 4-aminooxane-4-carboxylate;hydrochloride
DMO7920 DE Schizophrenia
DMALVX2 ID DMALVX2
DMALVX2 DN AMELTOLIDE
DMALVX2 HS Discontinued in Phase 1
DMALVX2 SN ADD-75073; Ameltolide < Prop INN; LY-201116; 4-Amino-N-(2,6-dimethylphenyl)benzamide
DMALVX2 DT Small molecular drug
DMALVX2 PC 13086
DMALVX2 MW 240.3
DMALVX2 FM C15H16N2O
DMALVX2 IC InChI=1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)
DMALVX2 CS CC1=C(C(=CC=C1)C)NC(=O)C2=CC=C(C=C2)N
DMALVX2 IK HZIWGOAXOBPQGY-UHFFFAOYSA-N
DMALVX2 IU 4-amino-N-(2,6-dimethylphenyl)benzamide
DMALVX2 CA CAS 787-93-9
DMALVX2 CB CHEBI:6342
DMALVX2 DE Epileptic seizures
DMIKQ40 ID DMIKQ40
DMIKQ40 DN AMG 076
DMIKQ40 HS Discontinued in Phase 1
DMIKQ40 SN AMG-076 free base; UNII-HX4T7JEV3D; HX4T7JEV3D; CHEMBL2032049; 693823-79-9; SCHEMBL2742722; DTXSID70219485; BDBM50383522; Cyclohexanecarboxylic acid, 1-(2-((4aR,11R,11aS)-1,3,4,4a,5,6,11,11a-octahydro-11-methyl-9-(trifluoromethyl)-2H-pyrido(4,3-b)carbazol-2-yl)ethyl)-; (4aR)-2-[2-(1-Carboxycyclohexyl)ethyl]-2,3,4,4abeta,5,6,11,11aalpha-octahydro-9-(trifluoromethyl)-11alpha-methyl-1H-pyrido[4,3-b]carbazole
DMIKQ40 CP Amgen
DMIKQ40 DT Small molecular drug
DMIKQ40 PC 23642854
DMIKQ40 MW 620.7
DMIKQ40 FM C32H39F3N2O5S
DMIKQ40 IC InChI=1S/C26H33F3N2O2.C6H6O3S/c1-16-20-15-31(12-10-25(24(32)33)8-3-2-4-9-25)11-7-17(20)13-22-23(16)19-14-18(26(27,28)29)5-6-21(19)30-22;7-10(8,9)6-4-2-1-3-5-6/h5-6,14,16-17,20,30H,2-4,7-13,15H2,1H3,(H,32,33);1-5H,(H,7,8,9)/t16-,17-,20-;/m1./s1
DMIKQ40 CS C[C@@H]1[C@H]2CN(CC[C@@H]2CC3=C1C4=C(N3)C=CC(=C4)C(F)(F)F)CCC5(CCCCC5)C(=O)O.C1=CC=C(C=C1)S(=O)(=O)O
DMIKQ40 IK IBDOVKSLMMFQPJ-IUPOGUASSA-N
DMIKQ40 IU 1-[2-[(4aR,11R,11aS)-11-methyl-9-(trifluoromethyl)-1,3,4,4a,5,6,11,11a-octahydropyrido[4,3-b]carbazol-2-yl]ethyl]cyclohexane-1-carboxylic acid;benzenesulfonic acid
DMIKQ40 CA CAS 1001438-96-5
DMIKQ40 DE Obesity
DMUO3T2 ID DMUO3T2
DMUO3T2 DN AMG 317
DMUO3T2 HS Discontinued in Phase 1
DMUO3T2 CP Amgen
DMUO3T2 DE Asthma
DMFCKJ1 ID DMFCKJ1
DMFCKJ1 DN AMG-221
DMFCKJ1 HS Discontinued in Phase 1
DMFCKJ1 DT Small molecular drug
DMFCKJ1 PC 135565424
DMFCKJ1 MW 266.4
DMFCKJ1 FM C14H22N2OS
DMFCKJ1 IC InChI=1S/C14H22N2OS/c1-8(2)14(3)12(17)16-13(18-14)15-11-7-9-4-5-10(11)6-9/h8-11H,4-7H2,1-3H3,(H,15,16,17)/t9-,10+,11+,14+/m1/s1
DMFCKJ1 CS CC(C)[C@]1(C(=O)NC(=N[C@H]2C[C@@H]3CC[C@H]2C3)S1)C
DMFCKJ1 IK YCNCXQNUXCHRRX-ZHPDPMBESA-N
DMFCKJ1 IU (5S)-2-[[(1S,2S,4R)-2-bicyclo[2.2.1]heptanyl]imino]-5-methyl-5-propan-2-yl-1,3-thiazolidin-4-one
DMFCKJ1 CA CAS 1095565-81-3
DMFCKJ1 DE Metabolic disorder
DM3HB06 ID DM3HB06
DM3HB06 DN AMG-517
DM3HB06 HS Discontinued in Phase 1
DM3HB06 SN AMG 517; BD-0082
DM3HB06 CP Amgen
DM3HB06 TC Analgesics
DM3HB06 DT Small molecular drug
DM3HB06 PC 16007367
DM3HB06 MW 430.4
DM3HB06 FM C20H13F3N4O2S
DM3HB06 IC InChI=1S/C20H13F3N4O2S/c1-11(28)26-19-27-18-15(3-2-4-16(18)30-19)29-17-9-14(24-10-25-17)12-5-7-13(8-6-12)20(21,22)23/h2-10H,1H3,(H,26,27,28)
DM3HB06 CS CC(=O)NC1=NC2=C(C=CC=C2S1)OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)F
DM3HB06 IK YUTIXVXZQIQWGY-UHFFFAOYSA-N
DM3HB06 IU N-[4-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide
DM3HB06 CA CAS 659730-32-2
DM3HB06 DE Chronic pain
DMFR3PD ID DMFR3PD
DMFR3PD DN ANA-975
DMFR3PD HS Discontinued in Phase 1
DMFR3PD SN Isatoribine prodrug, Anadys; ANA-245 prodrug, Anadys; ANA-97X program, Anadys
DMFR3PD CP Anadys Pharmaceuticals Inc
DMFR3PD DE Immune System disease
DMRQFIE ID DMRQFIE
DMRQFIE DN ANQ-9040
DMRQFIE HS Discontinued in Phase 1
DMRQFIE SN 3alpha-Acetoxy-3beta-(hexahydroazepinomethyl)-17a,17a-dimethyl-17-homo-17a-azonia-5alpha-androstane benzenesulfonate
DMRQFIE PC 9939141
DMRQFIE MW 630.9
DMRQFIE FM C36H58N2O5S
DMRQFIE IC InChI=1S/C30H53N2O2.C6H6O3S/c1-23(33)34-30(22-31-18-8-6-7-9-19-31)17-16-28(2)24(21-30)12-13-25-26(28)14-15-29(3)27(25)11-10-20-32(29,4)5;7-10(8,9)6-4-2-1-3-5-6/h24-27H,6-22H2,1-5H3;1-5H,(H,7,8,9)/q+1;/p-1/t24-,25+,26-,27-,28-,29-,30+;/m0./s1
DMRQFIE CS CC(=O)O[C@@]1(CC[C@]2([C@H](C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC[N+]4(C)C)C)C)CN5CCCCCC5.C1=CC=C(C=C1)S(=O)(=O)[O-]
DMRQFIE IK MUVZCNJMKMCHMD-IBSDALFFSA-M
DMRQFIE IU [(4aS,4bR,6aS,8R,10aS,10bS,12aS)-8-(azepan-1-ylmethyl)-1,1,10a,12a-tetramethyl-2,3,4,4a,4b,5,6,6a,7,9,10,10b,11,12-tetradecahydronaphtho[2,1-f]quinolin-1-ium-8-yl] acetate;benzenesulfonate
DMRQFIE CA CAS 142021-80-5
DMRQFIE DE Paralysis
DM9GSWY ID DM9GSWY
DM9GSWY DN Anthrax vaccine
DM9GSWY HS Discontinued in Phase 1
DM9GSWY SN Anthrax vaccine, DynPort/AVANT; Injectable anthrax vaccine, DynPort/AVANT; Anthrax vaccine (injectable), DynPort/AVANT
DM9GSWY CP Celldex Therapeutics Inc
DM9GSWY DT Vaccine
DM9GSWY DE Bacillus anthracis infection
DMN8R2U ID DMN8R2U
DMN8R2U DN APD668
DMN8R2U HS Discontinued in Phase 1
DMN8R2U SN 832714-46-2; APD-668; CHEMBL1775179; Isopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylate; isopropyl 4-(1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)piperidine-1-carboxylate; 1-Piperidinecarboxylic acid,4-[[1-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]-, 1-methylethyl ester; SCHEMBL389323; AOB6271; XTRUQJBVQBUKSQ-UHFFFAOYSA-N; MolPort-039-331-631; EX-A1795; BCP10207; BDBM50343442; ZINC68266967
DMN8R2U CP Arena Pharma.
DMN8R2U DT Small molecular drug
DMN8R2U PC 11705608
DMN8R2U MW 477.5
DMN8R2U FM C21H24FN5O5S
DMN8R2U IC InChI=1S/C21H24FN5O5S/c1-13(2)31-21(28)26-8-6-14(7-9-26)32-20-16-11-25-27(19(16)23-12-24-20)18-5-4-15(10-17(18)22)33(3,29)30/h4-5,10-14H,6-9H2,1-3H3
DMN8R2U CS CC(C)OC(=O)N1CCC(CC1)OC2=NC=NC3=C2C=NN3C4=C(C=C(C=C4)S(=O)(=O)C)F
DMN8R2U IK XTRUQJBVQBUKSQ-UHFFFAOYSA-N
DMN8R2U IU propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate
DMN8R2U DE Type-2 diabetes
DM71C6D ID DM71C6D
DM71C6D DN Aphidicolin
DM71C6D HS Discontinued in Phase 1
DM71C6D SN bis(hydroxymethyl)-dimethyl-[ ]diol; AC1LA8KN; 8,11a-Methano-11aH-cyclohepta[a]naphthalene-4,9-dimethanol, tetradecahydro-3,9-dihydroxy-4,11b-dimethyl-, (3R,4R,9R,11bS)-
DM71C6D DT Small molecular drug
DM71C6D PC 457964
DM71C6D MW 338.5
DM71C6D FM C20H34O4
DM71C6D IC InChI=1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1
DM71C6D CS C[C@]12CC[C@H]([C@@]([C@@H]1CC[C@@H]3[C@@]24CC[C@@]([C@H](C3)C4)(CO)O)(C)CO)O
DM71C6D IK NOFOAYPPHIUXJR-APNQCZIXSA-N
DM71C6D IU (1S,2S,5R,6R,7R,10S,12R,13R)-6,13-bis(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.01,10.02,7]hexadecane-5,13-diol
DM71C6D CA CAS 38966-21-1
DM71C6D CB CHEBI:2766
DM5L9I2 ID DM5L9I2
DM5L9I2 DN APP-018
DM5L9I2 HS Discontinued in Phase 1
DM5L9I2 SN D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis
DM5L9I2 CP Bruin Pharma Inc
DM5L9I2 PC 72941823
DM5L9I2 MW 2310.6
DM5L9I2 FM C114H156N24O28
DM5L9I2 IC InChI=1S/C114H156N24O28/c1-64(2)96(114(166)123-67(5)98(150)125-83(48-50-93(143)144)105(157)126-80(41-23-27-53-117)104(156)133-86(57-71-33-15-9-16-34-71)107(159)128-79(40-22-26-52-116)103(155)130-82(47-49-92(141)142)102(154)122-65(3)99(151)131-84(97(119)149)55-69-29-11-7-12-30-69)138-106(158)81(42-24-28-54-118)129-113(165)91(62-95(147)148)137-110(162)88(59-73-43-45-75(140)46-44-73)134-109(161)85(56-70-31-13-8-14-32-70)132-100(152)66(4)121-101(153)78(39-21-25-51-115)127-108(160)87(58-72-35-17-10-18-36-72)135-111(163)89(60-74-63-120-77-38-20-19-37-76(74)77)136-112(164)90(61-94(145)146)124-68(6)139/h7-20,29-38,43-46,63-67,78-91,96,120,140H,21-28,39-42,47-62,115-118H2,1-6H3,(H2,119,149)(H,121,153)(H,122,154)(H,123,166)(H,124,139)(H,125,150)(H,126,157)(H,127,160)(H,128,159)(H,129,165)(H,130,155)(H,131,151)(H,132,152)(H,133,156)(H,134,161)(H,135,163)(H,136,164)(H,137,162)(H,138,158)(H,141,142)(H,143,144)(H,145,146)(H,147,148)/t65-,66-,67-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,96-/m1/s1
DM5L9I2 CS C[C@H](C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@H](CC2=CC=C(C=C2)O)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)[C@@H](CC6=CNC7=CC=CC=C76)NC(=O)[C@@H](CC(=O)O)NC(=O)C
DM5L9I2 IK ZKKBZMXTFBAQLP-INNXVHPBSA-N
DM5L9I2 IU (4R)-4-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-carboxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-6-aminohexanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-[[(2R)-6-amino-1-[[(2R)-1-[[(2R)-6-amino-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DM5L9I2 CA CAS 452782-06-8
DM5L9I2 DE Arteriosclerosis
DMRLHNW ID DMRLHNW
DMRLHNW DN Aprosulate sodium
DMRLHNW HS Discontinued in Phase 1
DMRLHNW SN Aprosulate; LW-10082; MW-2388
DMRLHNW CP Luitpold Pharma GmbH
DMRLHNW PC 72125
DMRLHNW MW 2387.4
DMRLHNW FM C27H34N2Na16O70S16
DMRLHNW IC InChI=1S/C27H50N2O70S16.16Na/c30-24(20(96-112(68,69)70)16(92-108(56,57)58)12(10(88-104(44,45)46)6-82-102(38,39)40)86-26-22(98-114(74,75)76)18(94-110(62,63)64)14(90-106(50,51)52)8(84-26)4-80-100(32,33)34)28-2-1-3-29-25(31)21(97-113(71,72)73)17(93-109(59,60)61)13(11(89-105(47,48)49)7-83-103(41,42)43)87-27-23(99-115(77,78)79)19(95-111(65,66)67)15(91-107(53,54)55)9(85-27)5-81-101(35,36)37;;;;;;;;;;;;;;;;/h8-23,26-27H,1-7H2,(H,28,30)(H,29,31)(H,32,33,34)(H,35,36,37)(H,38,39,40)(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)(H,77,78,79);;;;;;;;;;;;;;;;/q;16*+1/p-16/t8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18+,19+,20-,21-,22-,23-,26+,27+;;;;;;;;;;;;;;;;/m1................/s1
DMRLHNW CS C(CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMRLHNW IK CXKOATPJKFZCEL-HPXJARCXSA-A
DMRLHNW IU hexadecasodium;[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R)-6-oxo-1,2,4,5-tetrasulfonatooxy-6-[3-[[(2R,3S,4R,5R)-2,3,5,6-tetrasulfonatooxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxyhexanoyl]amino]propylamino]hexan-3-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate
DMRLHNW CA CAS 123072-45-7
DMRLHNW DE Coagulation defect
DMKLCRI ID DMKLCRI
DMKLCRI DN ARC-183
DMKLCRI HS Discontinued in Phase 1
DMKLCRI SN Anti-thrombin aptamer (CABG surgery), Archemix/Nuvelo
DMKLCRI CP Archemix; Archemix Corp
DMKLCRI DT Aptamer
DMKLCRI DE Blood forming organ disorder
DMHZN42 ID DMHZN42
DMHZN42 DN AR-H049020
DMHZN42 HS Discontinued in Phase 1
DMHZN42 CP AstraZeneca plc
DMHZN42 DE Type-1 diabetes
DMXD93K ID DMXD93K
DMXD93K DN ARRY-614
DMXD93K HS Discontinued in Phase 1
DMXD93K SN Pexmetinib; 945614-12-0; ARRY-614; Pexmetinib (ARRY-614); UNII-3750D0U8B5; 3750D0U8B5; Pexmetinib [INN]; Pexmetinib;ARRY-614; Pexmetinib(ARRY-614); ARRY614; SCHEMBL379035; GTPL9917; MolPort-039-193-822; LNMRSSIMGCDUTP-UHFFFAOYSA-N; BCP28410; EX-A1421; s7799; ZINC41747181; AKOS032945154; SB16914; Urea, N-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-((5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)phenyl)methyl)-
DMXD93K CP Array BioPharma
DMXD93K DT Small molecular drug
DMXD93K PC 24765037
DMXD93K MW 556.6
DMXD93K FM C31H33FN6O3
DMXD93K IC InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)
DMXD93K CS CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NCC3=C(C=CC(=C3)F)OC4=CC5=C(C=C4)N(N=C5)CCO
DMXD93K IK LNMRSSIMGCDUTP-UHFFFAOYSA-N
DMXD93K IU 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea
DMXD93K CA CAS 945614-12-0
DMXD93K DE Myelodysplastic syndrome; Arthritis
DMJDYBX ID DMJDYBX
DMJDYBX DN Artilide
DMJDYBX HS Discontinued in Phase 1
DMJDYBX SN Artilide fumarate; U-88943E
DMJDYBX CP Pharmacia & Upjohn Co
DMJDYBX DT Small molecular drug
DMJDYBX PC 131606
DMJDYBX MW 370.6
DMJDYBX FM C19H34N2O3S
DMJDYBX IC InChI=1S/C19H34N2O3S/c1-4-6-14-21(15-7-5-2)16-8-9-19(22)17-10-12-18(13-11-17)20-25(3,23)24/h10-13,19-20,22H,4-9,14-16H2,1-3H3/t19-/m1/s1
DMJDYBX CS CCCCN(CCCC)CCC[C@H](C1=CC=C(C=C1)NS(=O)(=O)C)O
DMJDYBX IK UAARDOOBGJGDJV-LJQANCHMSA-N
DMJDYBX IU N-[4-[(1R)-4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide
DMJDYBX CA CAS 133267-19-3
DMJDYBX DE Cardiac arrhythmias
DMINF80 ID DMINF80
DMINF80 DN AS-601811
DMINF80 HS Discontinued in Phase 1
DMINF80 SN 4,8-Dimethyl-2,3,5,6-tetrahydro-1H-benzo[c]quinolizin-3-one
DMINF80 DT Small molecular drug
DMINF80 PC 10220187
DMINF80 MW 227.3
DMINF80 FM C15H17NO
DMINF80 IC InChI=1S/C15H17NO/c1-10-3-5-14-12(9-10)4-6-13-11(2)15(17)7-8-16(13)14/h3,5,9H,4,6-8H2,1-2H3
DMINF80 CS CC1=CC2=C(C=C1)N3CCC(=O)C(=C3CC2)C
DMINF80 IK SNEPAAKJPPNOQM-UHFFFAOYSA-N
DMINF80 IU 4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
DMINF80 CA CAS 194979-95-8
DMINF80 DE Acne vulgaris
DMKXDOI ID DMKXDOI
DMKXDOI DN AS602868
DMKXDOI HS Discontinued in Phase 1
DMKXDOI SN Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin; Isopsoralen
DMKXDOI CP Merck
DMKXDOI DT Small molecular drug
DMKXDOI PC 9820526
DMKXDOI MW 366.4
DMKXDOI FM C18H14N4O3S
DMKXDOI IC InChI=1S/C18H14N4O3S/c1-10-9-14(23)22(18(10)24)21-17-15-11(5-3-6-12(15)25-2)19-16(20-17)13-7-4-8-26-13/h3-9H,1-2H3,(H,19,20,21)
DMKXDOI CS CC1=CC(=O)N(C1=O)NC2=NC(=NC3=C2C(=CC=C3)OC)C4=CC=CS4
DMKXDOI IK GZGLPBNOIFLLRE-UHFFFAOYSA-N
DMKXDOI IU 1-[(5-methoxy-2-thiophen-2-ylquinazolin-4-yl)amino]-3-methylpyrrole-2,5-dione
DMKXDOI CA CAS 219773-55-4
DMKXDOI DE Multiple myeloma
DMMPBZF ID DMMPBZF
DMMPBZF DN AVE-3247
DMMPBZF HS Discontinued in Phase 1
DMMPBZF CP Sanofi-Aventis
DMMPBZF DE Thrombosis
DM5FDX2 ID DM5FDX2
DM5FDX2 DN AVE-5997EF
DM5FDX2 HS Discontinued in Phase 1
DM5FDX2 SN UNII-7E6G867INX; 7E6G867INX; SCHEMBL5667413; L001680; 1-p-Tolyl-3-(4-(4-(6-trifluoromethylbenzo(b)thien-3-yl)piperazin-1-yl)butyl)urea; Urea, N-(4-methylphenyl)-N'-(4-(4-(6-(trifluoromethyl)benzo(b)thien-3-yl)-1-piperazinyl)butyl)-
DM5FDX2 CP Sanofi-Aventis
DM5FDX2 DT Small molecular drug
DM5FDX2 PC 9891761
DM5FDX2 MW 490.6
DM5FDX2 FM C25H29F3N4OS
DM5FDX2 IC InChI=1S/C25H29F3N4OS/c1-18-4-7-20(8-5-18)30-24(33)29-10-2-3-11-31-12-14-32(15-13-31)22-17-34-23-16-19(25(26,27)28)6-9-21(22)23/h4-9,16-17H,2-3,10-15H2,1H3,(H2,29,30,33)
DM5FDX2 CS CC1=CC=C(C=C1)NC(=O)NCCCCN2CCN(CC2)C3=CSC4=C3C=CC(=C4)C(F)(F)F
DM5FDX2 IK XVFIYMFVLGFALY-UHFFFAOYSA-N
DM5FDX2 IU 1-(4-methylphenyl)-3-[4-[4-[6-(trifluoromethyl)-1-benzothiophen-3-yl]piperazin-1-yl]butyl]urea
DM5FDX2 CA CAS 452917-21-4
DM5FDX2 DE Psychotic disorder; Schizophrenia
DMIB3AT ID DMIB3AT
DMIB3AT DN AVE-9940
DMIB3AT HS Discontinued in Phase 1
DMIB3AT CP Aventis SA
DMIB3AT DE Rheumatoid arthritis
DMTG9EZ ID DMTG9EZ
DMTG9EZ DN AWD-140-190
DMTG9EZ HS Discontinued in Phase 1
DMTG9EZ SN AWD-12-151
DMTG9EZ CP ASTA Medica AG
DMTG9EZ DE Epileptic seizures
DM1JN6A ID DM1JN6A
DM1JN6A DN Axovan-3
DM1JN6A HS Discontinued in Phase 1
DM1JN6A CP Axovan AG
DM1JN6A DE Obesity; Eating disorder
DMIM9N1 ID DMIM9N1
DMIM9N1 DN AZD-1080
DMIM9N1 HS Discontinued in Phase 1
DMIM9N1 CP AstraZeneca plc
DMIM9N1 DT Small molecular drug
DMIM9N1 PC 135564570
DMIM9N1 MW 334.4
DMIM9N1 FM C19H18N4O2
DMIM9N1 IC InChI=1S/C19H18N4O2/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23/h1-4,9,11,22,24H,5-8,12H2
DMIM9N1 CS C1COCCN1CC2=CN=C(C=C2)C3=C(NC4=C3C=C(C=C4)C#N)O
DMIM9N1 IK BLTVBQXJFVRPFK-UHFFFAOYSA-N
DMIM9N1 IU 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile
DMIM9N1 CA CAS 612487-72-6
DMIM9N1 DE Alzheimer disease
DM65MUI ID DM65MUI
DM65MUI DN AZD1175
DM65MUI HS Discontinued in Phase 1
DM65MUI CP AstraZeneca
DM65MUI PC 11250433
DM65MUI MW 605.5
DM65MUI FM C25H25Cl2F3N4O4S
DM65MUI IC InChI=1S/C25H25Cl2F3N4O4S/c1-16-22(24(35)32-33-12-3-2-4-13-33)31-34(21-10-7-18(26)15-20(21)27)23(16)17-5-8-19(9-6-17)38-39(36,37)14-11-25(28,29)30/h5-10,15H,2-4,11-14H2,1H3,(H,32,35)
DM65MUI CS CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OS(=O)(=O)CCC(F)(F)F
DM65MUI IK AUAVZPQYSXVTLQ-UHFFFAOYSA-N
DM65MUI IU [4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)pyrazol-3-yl]phenyl] 3,3,3-trifluoropropane-1-sulfonate
DM65MUI CA CAS 863639-43-4
DM65MUI DE Obesity; Diabetic complication; Hypertension
DMVE4P3 ID DMVE4P3
DMVE4P3 DN AZD1704
DMVE4P3 HS Discontinued in Phase 1
DMVE4P3 CP AstraZeneca
DMVE4P3 DE Pain
DMCOMG5 ID DMCOMG5
DMCOMG5 DN AZD-1744
DMCOMG5 HS Discontinued in Phase 1
DMCOMG5 SN Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca
DMCOMG5 CP AstraZeneca plc
DMCOMG5 DE Asthma
DMUCQPB ID DMUCQPB
DMUCQPB DN AZD-3342
DMUCQPB HS Discontinued in Phase 1
DMUCQPB CP AstraZeneca plc
DMUCQPB DE Chronic obstructive pulmonary disease
DM7XQTM ID DM7XQTM
DM7XQTM DN AZD-4407
DM7XQTM HS Discontinued in Phase 1
DM7XQTM SN ZD-4407
DM7XQTM CP AstraZeneca plc
DM7XQTM DE Chronic obstructive pulmonary disease
DMQ2VYT ID DMQ2VYT
DMQ2VYT DN AZD-4750
DMQ2VYT HS Discontinued in Phase 1
DMQ2VYT CP AstraZeneca plc
DMQ2VYT DE Multiple sclerosis
DMA3OWI ID DMA3OWI
DMA3OWI DN AZD4769
DMA3OWI HS Discontinued in Phase 1
DMA3OWI SN Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic
DMA3OWI CP AstraZeneca
DMA3OWI DT Small molecular drug
DMA3OWI PC 124437
DMA3OWI MW 457.6
DMA3OWI FM C28H27NO3S
DMA3OWI IC InChI=1S/C28H27NO3S/c30-28(31)20-33-27(12-6-9-21-7-2-1-3-8-21)23-14-17-25(18-15-23)32-19-24-16-13-22-10-4-5-11-26(22)29-24/h1-5,7-8,10-11,13-18,27H,6,9,12,19-20H2,(H,30,31)
DMA3OWI CS C1=CC=C(C=C1)CCCC(C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)SCC(=O)O
DMA3OWI IK JOIXGLLMSDPZDN-UHFFFAOYSA-N
DMA3OWI IU 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic acid
DMA3OWI CA CAS 127481-29-2
DMA3OWI DE Solid tumour/cancer
DMWKYV7 ID DMWKYV7
DMWKYV7 DN AZD-5099
DMWKYV7 HS Discontinued in Phase 1
DMWKYV7 SN Gyrase B inhibitor (serious infection), AstraZeneca
DMWKYV7 CP AstraZeneca plc
DMWKYV7 PC 11995990
DMWKYV7 MW 548.4
DMWKYV7 FM C21H27Cl2N5O6S
DMWKYV7 IC InChI=1S/C21H27Cl2N5O6S/c1-9(8-33-3)24-19(30)16-17(20(31)32)35-21(27-16)28-6-5-11(12(7-28)34-4)26-18(29)15-14(23)13(22)10(2)25-15/h9,11-12,25H,5-8H2,1-4H3,(H,24,30)(H,26,29)(H,31,32)/t9-,11+,12-/m0/s1
DMWKYV7 CS CC1=C(C(=C(N1)C(=O)N[C@@H]2CCN(C[C@@H]2OC)C3=NC(=C(S3)C(=O)O)C(=O)N[C@@H](C)COC)Cl)Cl
DMWKYV7 IK KGZHRAVDXGQUQM-WCQGTBRESA-N
DMWKYV7 IU 2-[(3S,4R)-4-[(3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl)amino]-3-methoxypiperidin-1-yl]-4-[[(2S)-1-methoxypropan-2-yl]carbamoyl]-1,3-thiazole-5-carboxylic acid
DMWKYV7 CA CAS 907543-25-3
DMWKYV7 DE Infectious disease
DM8SCON ID DM8SCON
DM8SCON DN AZD5904
DM8SCON HS Discontinued in Phase 1
DM8SCON SN AZD5904; UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-
DM8SCON CP AstraZeneca
DM8SCON DT Small molecular drug
DM8SCON PC 10264211
DM8SCON MW 252.3
DM8SCON FM C10H12N4O2S
DM8SCON IC InChI=1S/C10H12N4O2S/c15-9-7-8(12-5-11-7)14(10(17)13-9)4-6-2-1-3-16-6/h5-6H,1-4H2,(H,11,12)(H,13,15,17)/t6-/m1/s1
DM8SCON CS C1C[C@@H](OC1)CN2C3=C(C(=O)NC2=S)NC=N3
DM8SCON IK RSPDBEVKURKEII-ZCFIWIBFSA-N
DM8SCON IU 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one
DM8SCON CA CAS 618913-30-7
DM8SCON DE Multiple sclerosis; Chronic obstructive pulmonary disease
DMCAKMV ID DMCAKMV
DMCAKMV DN AZD5985
DMCAKMV HS Discontinued in Phase 1
DMCAKMV CP AstraZeneca
DMCAKMV DT Small molecular drug
DMCAKMV PC 9811072
DMCAKMV MW 808.8
DMCAKMV FM C38H43Cl2N9O5S
DMCAKMV IC InChI=1S/C22H28N6O3S.C16H15Cl2N3O2/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-8,13-15,24-26H,9-12H2,1-3H3;4-6,19H,3,7H2,1-2H3,(H,20,22)
DMCAKMV CS CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)Cl)Cl)C.CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C
DMCAKMV IK XOJHGEHJHFRZRW-UHFFFAOYSA-N
DMCAKMV IU 3-[(4,7-dichloro-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one;N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
DMCAKMV DE Chronic obstructive pulmonary disease
DMFAZLU ID DMFAZLU
DMFAZLU DN AZD6280
DMFAZLU HS Discontinued in Phase 1
DMFAZLU CP AstraZeneca
DMFAZLU DT Small molecular drug
DMFAZLU PC 23630026
DMFAZLU MW 366.4
DMFAZLU FM C20H22N4O3
DMFAZLU IC InChI=1S/C20H22N4O3/c1-4-10-22-20(25)19-17(21)14-7-5-6-13(18(14)23-24-19)15-11-12(26-2)8-9-16(15)27-3/h5-9,11H,4,10H2,1-3H3,(H2,21,23)(H,22,25)
DMFAZLU CS CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC(=C3)OC)OC
DMFAZLU IK NVWCZRPXYVDQEE-UHFFFAOYSA-N
DMFAZLU IU 4-amino-8-(2,5-dimethoxyphenyl)-N-propylcinnoline-3-carboxamide
DMFAZLU CA CAS 942436-93-3
DMFAZLU DE Schizophrenia; Anxiety disorder
DMQZCET ID DMQZCET
DMQZCET DN AZD-6553
DMQZCET HS Discontinued in Phase 1
DMQZCET SN Neutrophil elastase inhibitor (oral, COPD), AstraZeneca/Quintiles
DMQZCET CP AstraZeneca plc
DMQZCET DE Chronic obstructive pulmonary disease
DM9KLD3 ID DM9KLD3
DM9KLD3 DN AZD-6703
DM9KLD3 HS Discontinued in Phase 1
DM9KLD3 SN P38 MAP kinase inhibitors (rheumatoid arthritis), AstraZeneca
DM9KLD3 CP AstraZeneca plc
DM9KLD3 DT Small molecular drug
DM9KLD3 PC 11373432
DM9KLD3 MW 417.5
DM9KLD3 FM C24H27N5O2
DM9KLD3 IC InChI=1S/C24H27N5O2/c1-16-3-4-17(23(30)26-18-5-6-18)13-22(16)29-15-25-21-8-7-19(14-20(21)24(29)31)28-11-9-27(2)10-12-28/h3-4,7-8,13-15,18H,5-6,9-12H2,1-2H3,(H,26,30)
DM9KLD3 CS CC1=C(C=C(C=C1)C(=O)NC2CC2)N3C=NC4=C(C3=O)C=C(C=C4)N5CCN(CC5)C
DM9KLD3 IK ZMAZXHICVRYLQN-UHFFFAOYSA-N
DM9KLD3 IU N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3-yl]benzamide
DM9KLD3 CA CAS 851845-37-9
DM9KLD3 DE Rheumatoid arthritis
DMHV3IW ID DMHV3IW
DMHV3IW DN AZD-6714
DMHV3IW HS Discontinued in Phase 1
DMHV3IW CP Astra zeneca
DMHV3IW DE Type-2 diabetes
DM2QHVW ID DM2QHVW
DM2QHVW DN AZD6918
DM2QHVW HS Discontinued in Phase 1
DM2QHVW CP AstraZeneca
DM2QHVW DE Advanced solid tumour
DMX63W1 ID DMX63W1
DMX63W1 DN AZD-7140
DMX63W1 HS Discontinued in Phase 1
DMX63W1 CP AstraZeneca plc
DMX63W1 DE Rheumatoid arthritis; Chronic obstructive pulmonary disease
DMKF9U3 ID DMKF9U3
DMKF9U3 DN AZD8075
DMKF9U3 HS Discontinued in Phase 1
DMKF9U3 CP AstraZeneca
DMKF9U3 DE Chronic obstructive pulmonary disease
DMW6IUB ID DMW6IUB
DMW6IUB DN AZD-8309
DMW6IUB HS Discontinued in Phase 1
DMW6IUB CP AstraZeneca plc
DMW6IUB DE Rheumatoid arthritis; Chronic obstructive pulmonary disease
DMUKNQ5 ID DMUKNQ5
DMUKNQ5 DN AZD8330
DMUKNQ5 HS Discontinued in Phase 1
DMUKNQ5 SN AZD8330; 869357-68-6; AZD-8330; ARRY-424704; ARRY-704; UNII-G4990BOZ66; AZD 8330; 2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; G4990BOZ66; C16H17FIN3O4; 2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; RWEVIPRMPFNTLO-UHFFFAOYSA-N
DMUKNQ5 CP AstraZeneca
DMUKNQ5 DT Small molecular drug
DMUKNQ5 PC 16666708
DMUKNQ5 MW 461.23
DMUKNQ5 FM C16H17FIN3O4
DMUKNQ5 IC InChI=1S/C16H17FIN3O4/c1-9-7-11(15(23)20-25-6-5-22)14(21(2)16(9)24)19-13-4-3-10(18)8-12(13)17/h3-4,7-8,19,22H,5-6H2,1-2H3,(H,20,23)
DMUKNQ5 CS CC1=CC(=C(N(C1=O)C)NC2=C(C=C(C=C2)I)F)C(=O)NOCCO
DMUKNQ5 IK RWEVIPRMPFNTLO-UHFFFAOYSA-N
DMUKNQ5 IU 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide
DMUKNQ5 CA CAS 869357-68-6
DMUKNQ5 CB CHEBI:91424
DMUKNQ5 DE Solid tumour/cancer
DMIYEZG ID DMIYEZG
DMIYEZG DN AZD8566
DMIYEZG HS Discontinued in Phase 1
DMIYEZG CP AstraZeneca
DMIYEZG DE Rheumatoid arthritis; Chronic obstructive pulmonary disease
DMYSBN3 ID DMYSBN3
DMYSBN3 DN AZD-9272
DMYSBN3 HS Discontinued in Phase 1
DMYSBN3 SN AZD 9272; 327056-26-8; UNII-54SQ9B412I; AZD9272; 54SQ9B412I; 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile; CHEMBL2164550; 3-Fluoro-5-(3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl)benzonitrile; RBSPCALDSNXWEP-UHFFFAOYSA-N; SCHEMBL2027395; GTPL6439; CHEMBL2164551; MolPort-039-338-067; ZINC33980255; BDBM50395923; AKOS027470228; HY-110254; AZD9272, > CS-0033119; J3.560.338G; 3-Fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]benzonitrile
DMYSBN3 CP AstraZeneca
DMYSBN3 TC Analgesics
DMYSBN3 DT Small molecular drug
DMYSBN3 PC 9838729
DMYSBN3 MW 284.22
DMYSBN3 FM C14H6F2N4O
DMYSBN3 IC InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H
DMYSBN3 CS C1=CC(=NC=C1F)C2=NOC(=N2)C3=CC(=CC(=C3)C#N)F
DMYSBN3 IK RBSPCALDSNXWEP-UHFFFAOYSA-N
DMYSBN3 IU 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile
DMYSBN3 CA CAS 327056-26-8
DMYSBN3 DE Neuropathic pain
DM1ZVO3 ID DM1ZVO3
DM1ZVO3 DN AZD-9343
DM1ZVO3 HS Discontinued in Phase 1
DM1ZVO3 CP AstraZeneca plc
DM1ZVO3 DE Gastroesophageal reflux disease
DMK5I07 ID DMK5I07
DMK5I07 DN Banoxantrone
DMK5I07 HS Discontinued in Phase 1
DMK5I07 SN AQ4M; AQ4N; AZD-1689; AQ4N, AstraZeneca/Novacea
DMK5I07 CP KuDOS Pharmaceuticals; Novacea
DMK5I07 DT Small molecular drug
DMK5I07 PC 9955116
DMK5I07 MW 444.5
DMK5I07 FM C22H28N4O6
DMK5I07 IC InChI=1S/C22H28N4O6/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30/h5-8,23-24,27-28H,9-12H2,1-4H3
DMK5I07 CS C[N+](C)(CCNC1=C2C(=C(C=C1)NCC[N+](C)(C)[O-])C(=O)C3=C(C=CC(=C3C2=O)O)O)[O-]
DMK5I07 IK YZBAXVICWUUHGG-UHFFFAOYSA-N
DMK5I07 IU 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-N,N-dimethylethanamine oxide
DMK5I07 CA CAS 136470-65-0
DMK5I07 DE Acute lymphoblastic leukaemia
DMGDSCK ID DMGDSCK
DMGDSCK DN BAY-27-9955
DMGDSCK HS Discontinued in Phase 1
DMGDSCK SN Glucagon antagonists, Bayer
DMGDSCK CP Bayer AG
DMGDSCK DT Small molecular drug
DMGDSCK PC 5311277
DMGDSCK MW 342.5
DMGDSCK FM C23H31FO
DMGDSCK IC InChI=1S/C23H31FO/c1-7-8-19-20(14(2)3)13-21(15(4)5)22(16(6)25)23(19)17-9-11-18(24)12-10-17/h9-16,25H,7-8H2,1-6H3
DMGDSCK CS CCCC1=C(C(=C(C=C1C(C)C)C(C)C)C(C)O)C2=CC=C(C=C2)F
DMGDSCK IK VDTWKXAPIQBOMO-UHFFFAOYSA-N
DMGDSCK IU 1-[2-(4-fluorophenyl)-4,6-di(propan-2-yl)-3-propylphenyl]ethanol
DMGDSCK CA CAS 202855-56-9
DMGDSCK DE Type-2 diabetes
DMKJ3IA ID DMKJ3IA
DMKJ3IA DN BAY-73-7977
DMKJ3IA HS Discontinued in Phase 1
DMKJ3IA SN Dual-acting GLP modulator/ glucagon antagonist (diabetes), Bayer; Dual-acting glucagon-like peptide modulator/ glucagon antagonist (diabetes), Bayer
DMKJ3IA CP Bayer AG
DMKJ3IA DE Diabetic complication
DM0UEKF ID DM0UEKF
DM0UEKF DN BAY-Y-1015
DM0UEKF HS Discontinued in Phase 1
DM0UEKF CP Bayer AG
DM0UEKF PC 9825810
DM0UEKF MW 466.6
DM0UEKF FM C26H30N2O4S
DM0UEKF IC InChI=1S/C26H30N2O4S/c1-33(30,31)28-26(29)25(20-9-4-2-3-5-10-20)21-13-16-23(17-14-21)32-18-22-15-12-19-8-6-7-11-24(19)27-22/h6-8,11-17,20,25H,2-5,9-10,18H2,1H3,(H,28,29)/t25-/m1/s1
DM0UEKF CS CS(=O)(=O)NC(=O)[C@H](C1CCCCCC1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3
DM0UEKF IK YAWBFCPZMALJCE-RUZDIDTESA-N
DM0UEKF IU (2R)-2-cycloheptyl-N-methylsulfonyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetamide
DM0UEKF CA CAS 133012-05-2
DM0UEKF DE Inflammation
DMYK8OG ID DMYK8OG
DMYK8OG DN BB-2983
DMYK8OG HS Discontinued in Phase 1
DMYK8OG SN GI-245402
DMYK8OG CP Vernalis plc
DMYK8OG DE Inflammatory bowel disease
DMN2XR7 ID DMN2XR7
DMN2XR7 DN BCX-1470
DMN2XR7 HS Discontinued in Phase 1
DMN2XR7 SN BCX 1470; 217099-43-9; CHEMBL2220483; 2-(Aminoiminomethyl)benzo[b]thiophen-6-yl ester-2-Thiophenecarboxylic acid; SCHEMBL7614663; DTXSID30431348; ZINC95558579; BDBM50201566; AKOS030526719; 2-(Aminoiminomethyl)benzo[b]thiophen-6-yl ester 2-thiophenecarboxylic acid; CS-0313; RL02657; KB-74872; HY-50874; W-5553; 099A439; J-506195; 2-Thiophenecarboxylic acid 2-(aminoiminomethyl)benzo[b]thiophene-6-yl ester
DMN2XR7 CP BioCryst Pharmaceuticals Inc
DMN2XR7 DT Small molecular drug
DMN2XR7 PC 9822205
DMN2XR7 MW 302.4
DMN2XR7 FM C14H10N2O2S2
DMN2XR7 IC InChI=1S/C14H10N2O2S2/c15-13(16)12-6-8-3-4-9(7-11(8)20-12)18-14(17)10-2-1-5-19-10/h1-7H,(H3,15,16)
DMN2XR7 CS C1=CSC(=C1)C(=O)OC2=CC3=C(C=C2)C=C(S3)C(=N)N
DMN2XR7 IK OTGQTQBPQCRNRG-UHFFFAOYSA-N
DMN2XR7 IU (2-carbamimidoyl-1-benzothiophen-6-yl) thiophene-2-carboxylate
DMN2XR7 DE Bleeding disorder
DMCOKFY ID DMCOKFY
DMCOKFY DN Beloxepin
DMCOKFY HS Discontinued in Phase 1
DMCOKFY SN ADL-6906; Beloxepin (oral, pain); Beloxepin (oral, depression), Organon; Beloxepin (oral, pain), Adolor
DMCOKFY CP Adolor Corp; Organon BioSciences
DMCOKFY PC 166560
DMCOKFY MW 295.4
DMCOKFY FM C19H21NO2
DMCOKFY IC InChI=1S/C19H21NO2/c1-13-6-5-7-14-16-12-20(2)11-10-19(16,21)15-8-3-4-9-17(15)22-18(13)14/h3-9,16,21H,10-12H2,1-2H3/t16-,19-/m0/s1
DMCOKFY CS CC1=C2C(=CC=C1)[C@@H]3CN(CC[C@@]3(C4=CC=CC=C4O2)O)C
DMCOKFY IK RPMDQAYGQBREBS-LPHOPBHVSA-N
DMCOKFY IU (2R,7R)-4,16-dimethyl-14-oxa-4-azatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaen-7-ol
DMCOKFY CA CAS 135928-30-2
DMCOKFY DE Depression
DMQI2F4 ID DMQI2F4
DMQI2F4 DN BEPH
DMQI2F4 HS Discontinued in Phase 1
DMQI2F4 SN MDL-28314; N,N'-Bis[3-(ethylamino)propyl]-1,7-heptanediamine
DMQI2F4 DT Small molecular drug
DMQI2F4 PC 60826
DMQI2F4 MW 300.5
DMQI2F4 FM C17H40N4
DMQI2F4 IC InChI=1S/C17H40N4/c1-3-18-14-10-16-20-12-8-6-5-7-9-13-21-17-11-15-19-4-2/h18-21H,3-17H2,1-2H3
DMQI2F4 CS CCNCCCNCCCCCCCNCCCNCC
DMQI2F4 IK WIOJAQYPAPCEMC-UHFFFAOYSA-N
DMQI2F4 IU N,N'-bis[3-(ethylamino)propyl]heptane-1,7-diamine
DMQI2F4 CA CAS 132004-62-7
DMQI2F4 DE Solid tumour/cancer
DMU1YON ID DMU1YON
DMU1YON DN Berupipam
DMU1YON HS Discontinued in Phase 1
DMU1YON SN NNC-22-0010
DMU1YON CP Novo Nordisk A/S
DMU1YON DT Small molecular drug
DMU1YON PC 66002
DMU1YON MW 408.7
DMU1YON FM C19H19BrClNO2
DMU1YON IC InChI=1S/C19H19BrClNO2/c1-22-4-2-11-7-17(21)18(23)9-14(11)16(10-22)15-8-13(20)6-12-3-5-24-19(12)15/h6-9,16,23H,2-5,10H2,1H3/t16-/m0/s1
DMU1YON CS CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC(=CC4=C3OCC4)Br)O)Cl
DMU1YON IK DIKLCFJDIZFAOM-INIZCTEOSA-N
DMU1YON IU (5S)-5-(5-bromo-2,3-dihydro-1-benzofuran-7-yl)-8-chloro-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DMU1YON CA CAS 150490-85-0
DMU1YON DE Psychotic disorder
DMMAFQP ID DMMAFQP
DMMAFQP DN Besonprodil
DMMAFQP HS Discontinued in Phase 1
DMMAFQP SN Co 200461; PD 0196860; PD 196860; PD196860; Besonprodil (USAN); 2(3H)-Benzoxazolone, 6-((2-(4-((4-fluorophenyl)methyl)-1-piperidinyl)ethyl)sulfinyl); 6-(2-(4-(4-Fluorobenzyl)-piperidin-1-yl)-ethanesulfinyl)-3H-benzoxazol-2-one; 6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3H-1,3-benzoxazol-2-one
DMMAFQP TC Neurodegenerative
DMMAFQP DT Small molecular drug
DMMAFQP PC 156328
DMMAFQP MW 402.5
DMMAFQP FM C21H23FN2O3S
DMMAFQP IC InChI=1S/C21H23FN2O3S/c22-17-3-1-15(2-4-17)13-16-7-9-24(10-8-16)11-12-28(26)18-5-6-19-20(14-18)27-21(25)23-19/h1-6,14,16H,7-13H2,(H,23,25)
DMMAFQP CS C1CN(CCC1CC2=CC=C(C=C2)F)CCS(=O)C3=CC4=C(C=C3)NC(=O)O4
DMMAFQP IK FCBQJNCAKZSIAH-UHFFFAOYSA-N
DMMAFQP IU 6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3H-1,3-benzoxazol-2-one
DMMAFQP CA CAS 253450-09-8
DMMAFQP DE Parkinson disease
DM9F4LP ID DM9F4LP
DM9F4LP DN BIM-26226
DM9F4LP HS Discontinued in Phase 1
DM9F4LP SN D-Pentafluorophenylalanyl-L-glutaminyl-L-tryptophyl-L-alanyl-L-valyl-D-alanyl-L-histidyl-L-leucine methyl ester; (D-Pentafluorophenylalanyl6,D-alanyl11)bombesin (6-13) methyl ester
DM9F4LP PC 9833285
DM9F4LP MW 1075.1
DM9F4LP FM C49H63F5N12O10
DM9F4LP IC InChI=1S/C49H63F5N12O10/c1-21(2)14-34(49(75)76-7)65-47(73)33(16-26-19-57-20-59-26)63-42(68)23(5)61-48(74)41(22(3)4)66-43(69)24(6)60-46(72)32(15-25-18-58-30-11-9-8-10-27(25)30)64-45(71)31(12-13-35(56)67)62-44(70)29(55)17-28-36(50)38(52)40(54)39(53)37(28)51/h8-11,18-24,29,31-34,41,58H,12-17,55H2,1-7H3,(H2,56,67)(H,57,59)(H,60,72)(H,61,74)(H,62,70)(H,63,68)(H,64,71)(H,65,73)(H,66,69)/t23-,24+,29-,31+,32+,33+,34+,41+/m1/s1
DM9F4LP CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)OC)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](CC4=C(C(=C(C(=C4F)F)F)F)F)N
DM9F4LP IK ZCTCXFYZJYFGAQ-ZZXDJSGYSA-N
DM9F4LP IU methyl (2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2R)-2-amino-3-(2,3,4,5,6-pentafluorophenyl)propanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoate
DM9F4LP DE Solid tumour/cancer
DM3HRQI ID DM3HRQI
DM3HRQI DN BINOSPIRONE MESYLATE
DM3HRQI HS Discontinued in Phase 1
DM3HRQI SN Binospirone mesylate < Rec INNM; MDL-73005EF; Rac-N-[2-[(1,4-Benzodioxan-2-ylmethyl)amino]ethyl]-1,1-cyclopentanediazetimide methanesulfonate; Rac-N-[4-(1,4-Benzodioxan-2-ylmethylamino)ethyl]-3,3-tetramethyleneglutarimide methanesulfonate; Rac-8-[2-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methylamino]ethyl]-8-azaspiro[4.5]decane-7,9-dione methanesulfonate
DM3HRQI DT Small molecular drug
DM3HRQI PC 71346
DM3HRQI MW 454.5
DM3HRQI FM C21H30N2O7S
DM3HRQI IC InChI=1S/C20H26N2O4.CH4O3S/c23-18-11-20(7-3-4-8-20)12-19(24)22(18)10-9-21-13-15-14-25-16-5-1-2-6-17(16)26-15;1-5(2,3)4/h1-2,5-6,15,21H,3-4,7-14H2;1H3,(H,2,3,4)
DM3HRQI CS CS(=O)(=O)O.C1CCC2(C1)CC(=O)N(C(=O)C2)CCNCC3COC4=CC=CC=C4O3
DM3HRQI IK JXBLEDCYKVWLJI-UHFFFAOYSA-N
DM3HRQI IU 8-[2-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione;methanesulfonic acid
DM3HRQI CA CAS 124756-23-6
DM3HRQI DE Anxiety disorder
DMJWLBU ID DMJWLBU
DMJWLBU DN BL-1827
DMJWLBU HS Discontinued in Phase 1
DMJWLBU CP Bioglan Pharmaceuticals Co
DMJWLBU DE Cancer related pain
DMR7WYX ID DMR7WYX
DMR7WYX DN BLX-883
DMR7WYX HS Discontinued in Phase 1
DMR7WYX SN A Form of Alfa Interferon
DMR7WYX CP Biolex
DMR7WYX DE Hepatitis C virus infection
DMKFXTD ID DMKFXTD
DMKFXTD DN BMS-191095
DMKFXTD HS Discontinued in Phase 1
DMKFXTD SN BMS-199080
DMKFXTD CP Bristol-Myers Squibb Co
DMKFXTD DT Small molecular drug
DMKFXTD PC 9822753
DMKFXTD MW 408.9
DMKFXTD FM C22H21ClN4O2
DMKFXTD IC InChI=1S/C22H21ClN4O2/c1-22(2)21(28)20(17-11-14(12-24)3-8-18(17)29-22)27(13-19-25-9-10-26-19)16-6-4-15(23)5-7-16/h3-11,20-21,28H,13H2,1-2H3,(H,25,26)/t20-,21+/m0/s1
DMKFXTD CS CC1([C@@H]([C@H](C2=C(O1)C=CC(=C2)C#N)N(CC3=NC=CN3)C4=CC=C(C=C4)Cl)O)C
DMKFXTD IK SMIKIPXIDLITMP-LEWJYISDSA-N
DMKFXTD IU (3R,4S)-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
DMKFXTD DE Angina pectoris
DMIX9O0 ID DMIX9O0
DMIX9O0 DN BRL-44154
DMIX9O0 HS Discontinued in Phase 1
DMIX9O0 SN 6beta-[2-(2-Aminothiazol-4-yl)-2(Z)-(cyclopentyloxyimino)acetamido]penicillanic acid sodium salt
DMIX9O0 PC 145705961
DMIX9O0 MW 489.5
DMIX9O0 FM C19H24N5NaO5S2
DMIX9O0 IC InChI=1S/C19H25N5O5S2.Na/c1-19(2)14(17(27)28)24-12(25)7-10(16(24)31-19)21-15(26)13(11-8-30-18(20)22-11)23-29-9-5-3-4-6-9;/h8-10,14,16H,3-7H2,1-2H3,(H2,20,22)(H,21,26)(H,27,28);/q;+1/p-1/t10?,14?,16-;/m0./s1
DMIX9O0 CS CC1(C(N2[C@@H](S1)C(CC2=O)NC(=O)C(=NOC3CCCC3)C4=CSC(=N4)N)C(=O)[O-])C.[Na+]
DMIX9O0 IK YNLKSESNCYDAMV-UNXXQQGRSA-M
DMIX9O0 IU sodium;(7aS)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-cyclopentyloxyiminoacetyl]amino]-2,2-dimethyl-5-oxo-3,6,7,7a-tetrahydropyrrolo[2,1-b][1,3]thiazole-3-carboxylate
DMIX9O0 DE Bacterial infection
DMGVEJ6 ID DMGVEJ6
DMGVEJ6 DN BTS-73947
DMGVEJ6 HS Discontinued in Phase 1
DMGVEJ6 SN BTS-72428 (HBr salt); (+)-1-[1-(2-Chlorophenyl)cyclopropyl]-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline
DMGVEJ6 DE Psychotic disorder
DM296HE ID DM296HE
DM296HE DN BW-1370U87
DM296HE HS Discontinued in Phase 1
DM296HE SN 1-Ethylphenoxathiin-10,10-dioxide
DM296HE DT Small molecular drug
DM296HE PC 126111
DM296HE MW 260.31
DM296HE FM C14H12O3S
DM296HE IC InChI=1S/C14H12O3S/c1-2-10-6-5-8-12-14(10)18(15,16)13-9-4-3-7-11(13)17-12/h3-9H,2H2,1H3
DM296HE CS CCC1=C2C(=CC=C1)OC3=CC=CC=C3S2(=O)=O
DM296HE IK HQSRQKBSOOZLHH-UHFFFAOYSA-N
DM296HE IU 1-ethylphenoxathiine 10,10-dioxide
DM296HE CA CAS 134476-36-1
DM296HE DE Major depressive disorder
DMUD6IK ID DMUD6IK
DMUD6IK DN BXL-746
DMUD6IK HS Discontinued in Phase 1
DMUD6IK SN VD3 analogs (inflammation), BioXell; VD3 analogs (inflammation), Roche; Vitamin D3 analogs (inflammation), BioXell; Vitamin D3 analogs (inflammation), Roche; Deuterated Gemini, (inflammation), BioXell
DMUD6IK CP Roche Holding AG
DMUD6IK DE Inflammation
DMSTN6W ID DMSTN6W
DMSTN6W DN CA9-ADC
DMSTN6W HS Discontinued in Phase 1
DMSTN6W SN MN-IC; CA IX inhibitor (solid tumor, ADC, HuCAL), MorphoSys/Bayer Schering Pharma; Carbonic anhydrase IX inhibitor (solid tumor, antibody-drug conjugate, HuCAL), MorphoSys/Bayer Schering Pharma
DMSTN6W CP MorphoSys AG
DMSTN6W DT Antibody
DMSTN6W DE Solid tumour/cancer
DMQ4HUA ID DMQ4HUA
DMQ4HUA DN CAB-2
DMQ4HUA HS Discontinued in Phase 1
DMQ4HUA SN MLN2222
DMQ4HUA CP Millennium Pharmaceuticals
DMQ4HUA DE Coronary artery disease
DMQIWZL ID DMQIWZL
DMQIWZL DN Candoxatrilat
DMQIWZL HS Discontinued in Phase 1
DMQIWZL SN Candoxatrilat < Rec INN; UK-69578; UK-73967; Cis-4-[[[1-[2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid; (+)-cis-4-[1-[(S)-2-Carboxy-3-(2-methoxyethoxy)propyl]cyclopentylcarbonylamino]cyclohexanecarboxylic acid; 3-[1-(4-cis-Carboxycyclohexylcarbamoyl)cyclopentyl]-2(R,S)-(2-methoxyethoxymethyl)propanoic acid
DMQIWZL DT Small molecular drug
DMQIWZL PC 443380
DMQIWZL MW 399.5
DMQIWZL FM C20H33NO7
DMQIWZL IC InChI=1S/C20H33NO7/c1-27-10-11-28-13-15(18(24)25)12-20(8-2-3-9-20)19(26)21-16-6-4-14(5-7-16)17(22)23/h14-16H,2-13H2,1H3,(H,21,26)(H,22,23)(H,24,25)/t14?,15-,16?/m0/s1
DMQIWZL CS COCCOC[C@H](CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)O
DMQIWZL IK ACZWIDANLCXHBM-PCKAHOCUSA-N
DMQIWZL IU 4-[[1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
DMQIWZL CA CAS 123122-54-3
DMQIWZL CB CHEBI:3354
DMQIWZL DE Heart failure
DMYCPF9 ID DMYCPF9
DMYCPF9 DN CB-182804
DMYCPF9 HS Discontinued in Phase 1
DMYCPF9 SN Polymyxin B analog (iv antibiotic, multidrug-resistant Gram negative bacterial infection), Cubist/BioSource
DMYCPF9 CP Cubist Pharmaceuticals Inc
DMYCPF9 PC 52918383
DMYCPF9 MW 1216.8
DMYCPF9 FM C54H86ClN17O13
DMYCPF9 IC InChI=1S/C54H86ClN17O13/c1-28(2)26-40-50(81)64-34(14-20-56)44(75)63-37(17-23-59)48(79)71-42(29(3)73)52(83)61-25-19-39(47(78)62-35(15-21-57)46(77)68-41(51(82)67-40)27-31-10-6-5-7-11-31)65-45(76)36(16-22-58)66-53(84)43(30(4)74)72-49(80)38(18-24-60)70-54(85)69-33-13-9-8-12-32(33)55/h5-13,28-30,34-43,73-74H,14-27,56-60H2,1-4H3,(H,61,83)(H,62,78)(H,63,75)(H,64,81)(H,65,76)(H,66,84)(H,67,82)(H,68,77)(H,71,79)(H,72,80)(H2,69,70,85)/t29-,30-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+/m1/s1
DMYCPF9 CS C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCN)CCN)CC(C)C)CC2=CC=CC=C2)CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)NC3=CC=CC=C3Cl)O
DMYCPF9 IK OINMSSZOBLWDTB-SHGLBBHXSA-N
DMYCPF9 IU (2S,3R)-2-[[(2S)-4-amino-2-[(2-chlorophenyl)carbamoylamino]butanoyl]amino]-N-[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15S,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]-3-hydroxybutanamide
DMYCPF9 DE Bacterial infection
DM3G4JD ID DM3G4JD
DM3G4JD DN CBD cannabis derivative
DM3G4JD HS Discontinued in Phase 1
DM3G4JD SN AC1L5AAH; (6,6-dimethyl-3-nonan-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl) 5-(diethylamino)pentanoate
DM3G4JD CP GW Pharmaceuticals
DM3G4JD DT Small molecular drug
DM3G4JD PC 173616
DM3G4JD MW 511.8
DM3G4JD FM C33H53NO3
DM3G4JD IC InChI=1S/C33H53NO3/c1-7-10-11-12-13-18-25(4)26-23-29(36-31(35)21-16-17-22-34(8-2)9-3)32-27-19-14-15-20-28(27)33(5,6)37-30(32)24-26/h23-25H,7-22H2,1-6H3
DM3G4JD CS CCCCCCCC(C)C1=CC2=C(C3=C(CCCC3)C(O2)(C)C)C(=C1)OC(=O)CCCCN(CC)CC
DM3G4JD IK LKZQTNSAWVCNMU-UHFFFAOYSA-N
DM3G4JD IU (6,6-dimethyl-3-nonan-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-1-yl) 5-(diethylamino)pentanoate
DM3G4JD DE Schizophrenia
DMMEC1W ID DMMEC1W
DMMEC1W DN CCD-3693
DMMEC1W HS Discontinued in Phase 1
DMMEC1W SN CCD 3000 series, CoCensys; CCD-3393; Epalon series member (3693), CoCensys; Insomnia therapy, CoCensys/Searle
DMMEC1W CP Purdue Neuroscience Corp
DMMEC1W DT Small molecular drug
DMMEC1W PC 192705
DMMEC1W MW 386.5
DMMEC1W FM C22H33F3O2
DMMEC1W IC InChI=1S/C22H33F3O2/c1-13(26)16-6-7-17-15-5-4-14-12-21(27,22(23,24)25)11-10-19(14,2)18(15)8-9-20(16,17)3/h14-18,27H,4-12H2,1-3H3/t14-,15-,16+,17-,18-,19-,20+,21-/m0/s1
DMMEC1W CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@](C4)(C(F)(F)F)O)C)C
DMMEC1W IK BLMOPJSSNJGYSZ-PECKBWEZSA-N
DMMEC1W IU 1-[(3S,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-3-(trifluoromethyl)-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMMEC1W CA CAS 177080-77-2
DMMEC1W DE Anxiety disorder
DMD8QHV ID DMD8QHV
DMD8QHV DN CCX-832
DMD8QHV HS Discontinued in Phase 1
DMD8QHV SN ChemR2 receptor antagonist (inflammation), ChemoCentryx/GlaxoSmithKline
DMD8QHV CP ChemoCentryx Inc
DMD8QHV DE Psoriasis vulgaris
DMHMST3 ID DMHMST3
DMHMST3 DN CCX915
DMHMST3 HS Discontinued in Phase 1
DMHMST3 SN Meglitinide; 54870-28-9; Meglitinide [INN]; Meglitinidum [INN-Latin]; Meglitinido [INN-Spanish]; HB 699; UNII-8V6OK1I088; BRN 2817215; 8V6OK1I088; 4-(2-((5-Chloro-2-methoxybenzoyl)amino)ethyl)benzoic acid; 4-(2-(5-Chlor-2-methoxy-benzamido)-aethyl)benzoasaeure [German]; p-(2-(5-Chloro-o-anisamido)ethyl)benzoic acid; C17H16ClNO4; 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid; Meglitinido; Meglitinidum; Benzoic acid, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-
DMHMST3 CP ChemoCentryx
DMHMST3 DT Small molecular drug
DMHMST3 PC 41214
DMHMST3 MW 333.8
DMHMST3 FM C17H16ClNO4
DMHMST3 IC InChI=1S/C17H16ClNO4/c1-23-15-7-6-13(18)10-14(15)16(20)19-9-8-11-2-4-12(5-3-11)17(21)22/h2-7,10H,8-9H2,1H3,(H,19,20)(H,21,22)
DMHMST3 CS COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)C(=O)O
DMHMST3 IK SWLAMJPTOQZTAE-UHFFFAOYSA-N
DMHMST3 IU 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid
DMHMST3 CA CAS 54870-28-9
DMHMST3 DE Multiple sclerosis
DMOCBQW ID DMOCBQW
DMOCBQW DN CD-581
DMOCBQW HS Discontinued in Phase 1
DMOCBQW SN 1-(Eicosa-5,8,11-triynoyl)-4-(2-hydroxyethyl)piperazine; 4-(1-Oxo-5,8,11-eicosatriynyl)-1-piprazineethanol
DMOCBQW DE Atopic dermatitis
DM5BG4P ID DM5BG4P
DM5BG4P DN CDP-1050
DM5BG4P HS Discontinued in Phase 1
DM5BG4P SN Ryanodine receptor modulators (heart failure), Cordex; Ryanodine receptor modulators (heart failure), Duke University; Ryanodine receptor modulators (heart failure), Duska Therapeutics
DM5BG4P CP Duke University
DM5BG4P DE Heart failure
DMJVZ9O ID DMJVZ9O
DMJVZ9O DN Cefdaloxime pentexil tosilate
DMJVZ9O HS Discontinued in Phase 1
DMJVZ9O SN HR-916B; HRT-916K; Cefdaloxime Pentexil Tosilate; HR-916J (1'R,6R, 7R);HR-916K (1'S,6R,7R); (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(pivaloyloxy)ethyl ester 7(2)-(Z)-oxime tosylate; (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylic acid 1-(2,2-dimethylpropanoyloxy)ethyl ester tosylate
DMJVZ9O DE Bacterial infection
DMO075K ID DMO075K
DMO075K DN CEFTRAZONAL BOPENTIL
DMO075K HS Discontinued in Phase 1
DMO075K SN Ro-41-3399; (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2(Z)-(methoxyimino)acetamido]-3-(azidomethyl)-3-cephem-4-carboxylic acid 2-(isobutoxycarbonyl)-2(E)-pentenyl ester
DMO075K DT Small molecular drug
DMO075K PC 9577440
DMO075K MW 606.7
DMO075K FM C24H30N8O7S2
DMO075K IC InChI=1S/C24H30N8O7S2/c1-5-6-13(22(35)38-8-12(2)3)9-39-23(36)18-14(7-27-31-26)10-40-21-17(20(34)32(18)21)29-19(33)16(30-37-4)15-11-41-24(25)28-15/h6,11-12,17,21H,5,7-10H2,1-4H3,(H2,25,28)(H,29,33)/b13-6-,30-16+/t17-,21-/m1/s1
DMO075K CS CC/C=C(/COC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N/OC)/C3=CSC(=N3)N)CN=[N+]=[N-])\\C(=O)OCC(C)C
DMO075K IK FHPWLEQQFDSPCU-SVEZEBCVSA-N
DMO075K IU [(Z)-2-(2-methylpropoxycarbonyl)pent-2-enyl] (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(azidomethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DMO075K CA CAS 124084-44-2
DMO075K DE Bacterial infection
DMH1PQ0 ID DMH1PQ0
DMH1PQ0 DN CEP-2563
DMH1PQ0 HS Discontinued in Phase 1
DMH1PQ0 SN KT-8391; L-Lysyl-beta-alanine 9(S),12(R)-Epoxy-10(S)-methoxy-9-methyl-1-oxo-2,3,9,10,11,12-hexahydro-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-ylmethyl ester dihydrochloride
DMH1PQ0 DE Solid tumour/cancer
DMK93VQ ID DMK93VQ
DMK93VQ DN CEREBROCRAST
DMK93VQ HS Discontinued in Phase 1
DMK93VQ SN IOS-1.1212; 4-[2-(Difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid di(2-propoxyethyl) diester
DMK93VQ DT Small molecular drug
DMK93VQ PC 159556
DMK93VQ MW 511.6
DMK93VQ FM C26H35F2NO7
DMK93VQ IC InChI=1S/C26H35F2NO7/c1-5-11-32-13-15-34-24(30)21-17(3)29-18(4)22(25(31)35-16-14-33-12-6-2)23(21)19-9-7-8-10-20(19)36-26(27)28/h7-10,23,26,29H,5-6,11-16H2,1-4H3
DMK93VQ CS CCCOCCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2OC(F)F)C(=O)OCCOCCC)C)C
DMK93VQ IK ASCWBYZMMHUZMQ-UHFFFAOYSA-N
DMK93VQ IU bis(2-propoxyethyl) 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DMK93VQ CA CAS 118790-71-9
DMK93VQ DE Nerve injury
DMQKRWO ID DMQKRWO
DMQKRWO DN CERM-11956
DMQKRWO HS Discontinued in Phase 1
DMQKRWO SN N-(1,3-Benzodioxolan-5-yl)-N-phenylmethyl-beta-[(2-methylpropoxy)methyl]-1-pyrrolidinylethanamine fumarate; 2-(N-Pyrrolidino)-3-isobutoxy-N-(3,4-methylenedioxyphenyl)-N-benzylpropylamine fumarate
DMQKRWO DT Small molecular drug
DMQKRWO PC 6438764
DMQKRWO MW 526.6
DMQKRWO FM C29H38N2O7
DMQKRWO IC InChI=1S/C25H34N2O3.C4H4O4/c1-3-20(2)28-18-23(26-13-7-8-14-26)17-27(16-21-9-5-4-6-10-21)22-11-12-24-25(15-22)30-19-29-24;5-3(6)1-2-4(7)8/h4-6,9-12,15,20,23H,3,7-8,13-14,16-19H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMQKRWO CS CCC(C)OCC(CN(CC1=CC=CC=C1)C2=CC3=C(C=C2)OCO3)N4CCCC4.C(=C/C(=O)O)\\C(=O)O
DMQKRWO IK RDZJRZMQCVQTSK-WLHGVMLRSA-N
DMQKRWO IU N-benzyl-N-(3-butan-2-yloxy-2-pyrrolidin-1-ylpropyl)-1,3-benzodioxol-5-amine;(E)-but-2-enedioic acid
DMQKRWO CA CAS 97631-49-7
DMQKRWO DE Angina pectoris
DM85SYL ID DM85SYL
DM85SYL DN Cetefloxacin
DM85SYL HS Discontinued in Phase 1
DM85SYL SN E-4868
DM85SYL CP Esteve
DM85SYL DT Small molecular drug
DM85SYL PC 65995
DM85SYL MW 403.4
DM85SYL FM C20H16F3N3O3
DM85SYL IC InChI=1S/C20H16F3N3O3/c1-9-15(24)8-25(9)18-6-17-11(5-14(18)23)19(27)12(20(28)29)7-26(17)16-3-2-10(21)4-13(16)22/h2-7,9,15H,8,24H2,1H3,(H,28,29)/t9-,15+/m0/s1
DM85SYL CS C[C@H]1[C@@H](CN1C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F)N
DM85SYL IK LTDOHCZUKCZDEQ-BJOHPYRUSA-N
DM85SYL IU 7-[(2S,3R)-3-amino-2-methylazetidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM85SYL CA CAS 141725-88-4
DM85SYL DE Bacterial infection
DMOULQ4 ID DMOULQ4
DMOULQ4 DN CGP-37849
DMOULQ4 HS Discontinued in Phase 1
DMOULQ4 SN CGP-39551; CGP-40116; CGP-43487; Ethyl ester of CGP-37849; 4-methyl-APPA
DMOULQ4 CP Novartis AG
DMOULQ4 DT Small molecular drug
DMOULQ4 PC 5950212
DMOULQ4 MW 209.14
DMOULQ4 FM C6H12NO5P
DMOULQ4 IC InChI=1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+
DMOULQ4 CS C/C(=C\\C(C(=O)O)N)/CP(=O)(O)O
DMOULQ4 IK BDYHNCZIGYIOGJ-DUXPYHPUSA-N
DMOULQ4 IU (E)-2-amino-4-methyl-5-phosphonopent-3-enoic acid
DMOULQ4 CA CAS 127910-31-0
DMOULQ4 DE Neurological disorder
DMY8KO4 ID DMY8KO4
DMY8KO4 DN CGP-48369
DMY8KO4 HS Discontinued in Phase 1
DMY8KO4 SN CGS-48369
DMY8KO4 CP Novartis AG
DMY8KO4 DT Small molecular drug
DMY8KO4 PC 135423125
DMY8KO4 MW 442.6
DMY8KO4 FM C26H30N6O
DMY8KO4 IC InChI=1S/C26H30N6O/c1-3-5-11-23-22(26(33)28-24(27-23)12-6-4-2)17-18-13-15-19(16-14-18)20-9-7-8-10-21(20)25-29-31-32-30-25/h7-10,13-16H,3-6,11-12,17H2,1-2H3,(H,27,28,33)(H,29,30,31,32)
DMY8KO4 CS CCCCC1=C(C(=O)NC(=N1)CCCC)CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMY8KO4 IK UKEZYWUWLICNPR-UHFFFAOYSA-N
DMY8KO4 IU 2,4-dibutyl-5-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1H-pyrimidin-6-one
DMY8KO4 CA CAS 135689-23-5
DMY8KO4 DE Hypertension
DMF0O2H ID DMF0O2H
DMF0O2H DN CGP-53437
DMF0O2H HS Discontinued in Phase 1
DMF0O2H SN CGP-58707
DMF0O2H CP Novartis AG
DMF0O2H DT Small molecular drug
DMF0O2H PC 5480679
DMF0O2H MW 728.9
DMF0O2H FM C42H56N4O7
DMF0O2H IC InChI=1S/C42H56N4O7/c1-29(2)37(39(49)43-35(27-32-19-13-8-14-20-32)40(50)46-21-23-52-24-22-46)45-38(48)33(25-30-15-9-6-10-16-30)28-36(47)34(26-31-17-11-7-12-18-31)44-41(51)53-42(3,4)5/h6-20,29,33-37,47H,21-28H2,1-5H3,(H,43,49)(H,44,51)(H,45,48)/t33-,34+,35+,36+,37+/m1/s1
DMF0O2H CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCOCC2)NC(=O)[C@H](CC3=CC=CC=C3)C[C@@H]([C@H](CC4=CC=CC=C4)NC(=O)OC(C)(C)C)O
DMF0O2H IK NAJDZKGRZBLNON-RKGCBODKSA-N
DMF0O2H IU tert-butyl N-[(2S,3S,5R)-5-benzyl-3-hydroxy-6-[[(2S)-3-methyl-1-[[(2S)-1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxobutan-2-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate
DMF0O2H DE Human immunodeficiency virus infection
DMF05DL ID DMF05DL
DMF05DL DN CGS-22652
DMF05DL HS Discontinued in Phase 1
DMF05DL SN Cgs 22652; CGS-22652; CHEMBL65414; (+-)-gamma-(4-(((4-Chlorophenyl)sulfonyl)amino)butyl)-3-pyridineheptanoic acid; (R,S)-8-((4-Chlorophenylsulfonyl)amino)-4-(3-(3-pyridinyl)propyl)octanoic acid; 3-Pyridineheptanoic acid, gamma-(4-(((4-chlorophenyl)sulfonyl)amino)butyl)-, (+-)-; C22H29ClN2O4S; AC1L2ZNZ; 8-CSAPOA; SCHEMBL9710116; 8-(4-Chloro-benzenesulfonylamino)-4-(3-pyridin-3-yl-propyl)-octanoic acid; ISMHAZMNDUAHLK-UHFFFAOYSA-N; BDBM50003776; 134235-78-2; LS-131625; L004635
DMF05DL DT Small molecular drug
DMF05DL PC 131717
DMF05DL MW 453
DMF05DL FM C22H29ClN2O4S
DMF05DL IC InChI=1S/C22H29ClN2O4S/c23-20-10-12-21(13-11-20)30(28,29)25-16-2-1-5-18(9-14-22(26)27)6-3-7-19-8-4-15-24-17-19/h4,8,10-13,15,17-18,25H,1-3,5-7,9,14,16H2,(H,26,27)
DMF05DL CS C1=CC(=CN=C1)CCCC(CCCCNS(=O)(=O)C2=CC=C(C=C2)Cl)CCC(=O)O
DMF05DL IK ISMHAZMNDUAHLK-UHFFFAOYSA-N
DMF05DL IU 8-[(4-chlorophenyl)sulfonylamino]-4-(3-pyridin-3-ylpropyl)octanoic acid
DMF05DL CA CAS 134235-78-2
DMF05DL DE Angina pectoris
DM0JUAL ID DM0JUAL
DM0JUAL DN ChelASE
DM0JUAL HS Discontinued in Phase 1
DM0JUAL SN VitrenASE; VIT-100
DM0JUAL CP Immusol
DM0JUAL DE Retina disorder
DMJ5UYL ID DMJ5UYL
DMJ5UYL DN Chpmpc
DMJ5UYL HS Discontinued in Phase 1
DMJ5UYL SN Cyclic HPMPC; Cyclic cidofovir; Cidofovir prodrug, Gilead; GS-504 analog; GS-930
DMJ5UYL CP Gilead Sciences Inc
DMJ5UYL DT Small molecular drug
DMJ5UYL PC 122873
DMJ5UYL MW 261.17
DMJ5UYL FM C8H12N3O5P
DMJ5UYL IC InChI=1S/C8H12N3O5P/c9-7-1-2-11(8(12)10-7)3-6-4-16-17(13,14)5-15-6/h1-2,6H,3-5H2,(H,13,14)(H2,9,10,12)/t6-/m0/s1
DMJ5UYL CS C1[C@@H](OCP(=O)(O1)O)CN2C=CC(=NC2=O)N
DMJ5UYL IK YXQUGSXUDFTPLL-LURJTMIESA-N
DMJ5UYL IU 4-amino-1-[[(5S)-2-hydroxy-2-oxo-1,4,2lambda5-dioxaphosphinan-5-yl]methyl]pyrimidin-2-one
DMJ5UYL CA CAS 127757-45-3
DMJ5UYL DE Virus infection
DM9ZBO0 ID DM9ZBO0
DM9ZBO0 DN CI-972
DM9ZBO0 HS Discontinued in Phase 1
DM9ZBO0 DT Small molecular drug
DM9ZBO0 PC 135418360
DM9ZBO0 MW 297.76
DM9ZBO0 FM C11H12ClN5OS
DM9ZBO0 IC InChI=1S/C11H11N5OS.ClH/c12-9-6(3-5-1-2-18-4-5)7-8(14-9)10(17)16-11(13)15-7;/h1-2,4,14H,3,12H2,(H3,13,15,16,17);1H
DM9ZBO0 CS C1=CSC=C1CC2=C(NC3=C2N=C(NC3=O)N)N.Cl
DM9ZBO0 IK SLNICZJKQXPOJA-UHFFFAOYSA-N
DM9ZBO0 IU 2,6-diamino-7-(thiophen-3-ylmethyl)-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one;hydrochloride
DM9ZBO0 CA CAS 115787-68-3
DM9ZBO0 DE Rheumatoid arthritis
DM3Q8UW ID DM3Q8UW
DM3Q8UW DN CJC-1004
DM3Q8UW HS Discontinued in Phase 1
DM3Q8UW SN CCI-1004; DAC-TI; DAC-Thrombin Inhibitor; Thrombin inhibitor, Conjuchem
DM3Q8UW CP ConjuChem Biotechnologies Inc
DM3Q8UW DE Thrombosis
DMSB7WV ID DMSB7WV
DMSB7WV DN CL-277082
DMSB7WV HS Discontinued in Phase 1
DMSB7WV SN CL-277082; UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea
DMSB7WV CP Lederle Laboratories
DMSB7WV DT Small molecular drug
DMSB7WV PC 125893
DMSB7WV MW 430.6
DMSB7WV FM C26H36F2N2O
DMSB7WV IC InChI=1S/C26H36F2N2O/c1-5-6-7-8-9-16-30(25(31)29-24-15-14-22(27)17-23(24)28)19-21-12-10-20(11-13-21)18-26(2,3)4/h10-15,17H,5-9,16,18-19H2,1-4H3,(H,29,31)
DMSB7WV CS CCCCCCCN(CC1=CC=C(C=C1)CC(C)(C)C)C(=O)NC2=C(C=C(C=C2)F)F
DMSB7WV IK QKJLDOBXDUVGEE-UHFFFAOYSA-N
DMSB7WV IU 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea
DMSB7WV CA CAS 96224-26-9
DMSB7WV DE Arteriosclerosis
DMYPFLR ID DMYPFLR
DMYPFLR DN Clomet
DMYPFLR HS Discontinued in Phase 1
DMYPFLR SN DMPEN (cancer), Xanthus Pharmaceuticals; Demethylpenclomedine (cancer), Xanthus Pharmaceuticals
DMYPFLR CP Xanthus Life Sciences
DMYPFLR DE Solid tumour/cancer
DM1C4IN ID DM1C4IN
DM1C4IN DN CP-105696
DM1C4IN HS Discontinued in Phase 1
DM1C4IN SN CP-105696; UNII-Z7354TW4BM; CP 105696; CP-105,696; CP105696; CHEMBL51770; Z7354TW4BM; 158081-99-3; Pfizer 105696; 1-(3-(4-phenylbenzyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid; DSSTox_RID_82258; DSSTox_CID_27308; DSSTox_GSID_47308; Cyclopentanecarboxylic acid, 1-((3S,4R)-3-((1,1'-biphenyl)-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl)-; SCHEMBL1898224; GTPL3368; DTXSID7047308; Tox21_300468; BDBM50037218; 1-[(3S,4R)-4-hydroxy-3-[(4-phenylphenyl)methyl]chroman-7-yl]cyclopentane-1-carboxylic Acid
DM1C4IN DT Small molecular drug
DM1C4IN PC 9867257
DM1C4IN MW 428.5
DM1C4IN FM C28H28O4
DM1C4IN IC InChI=1S/C28H28O4/c29-26-22(16-19-8-10-21(11-9-19)20-6-2-1-3-7-20)18-32-25-17-23(12-13-24(25)26)28(27(30)31)14-4-5-15-28/h1-3,6-13,17,22,26,29H,4-5,14-16,18H2,(H,30,31)/t22-,26+/m0/s1
DM1C4IN CS C1CCC(C1)(C2=CC3=C(C=C2)[C@@H]([C@H](CO3)CC4=CC=C(C=C4)C5=CC=CC=C5)O)C(=O)O
DM1C4IN IK KMNLXCBYBKHKSK-BKMJKUGQSA-N
DM1C4IN IU 1-[(3S,4R)-4-hydroxy-3-[(4-phenylphenyl)methyl]-3,4-dihydro-2H-chromen-7-yl]cyclopentane-1-carboxylic acid
DM1C4IN CA CAS 158081-99-3
DM1C4IN DE Inflammatory bowel disease
DMTM0UI ID DMTM0UI
DMTM0UI DN CP-66948
DMTM0UI HS Discontinued in Phase 1
DMTM0UI SN N1-[4-(2-Methyl-1H-imidazol-4-yl)-2-thiazolyl]-N3-pentylguanidine; 4-(2-Methylimidazol-4-yl)-2-(N-pentyldiaminomethyleneamino)thiazole
DMTM0UI DT Small molecular drug
DMTM0UI PC 127772
DMTM0UI MW 292.41
DMTM0UI FM C13H20N6S
DMTM0UI IC InChI=1S/C13H20N6S/c1-3-4-5-6-15-12(14)19-13-18-11(8-20-13)10-7-16-9(2)17-10/h7-8H,3-6H2,1-2H3,(H,16,17)(H3,14,15,18,19)
DMTM0UI CS CCCCCN=C(N)NC1=NC(=CS1)C2=CN=C(N2)C
DMTM0UI IK OZSXWXGDJLBJQO-UHFFFAOYSA-N
DMTM0UI IU 1-[4-(2-methyl-1H-imidazol-5-yl)-1,3-thiazol-2-yl]-2-pentylguanidine
DMTM0UI CA CAS 101189-47-3
DMTM0UI DE Gastric ulcer
DMZ0YU7 ID DMZ0YU7
DMZ0YU7 DN CP-800569
DMZ0YU7 HS Discontinued in Phase 1
DMZ0YU7 SN (2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol
DMZ0YU7 CP Pfizer
DMZ0YU7 DT Small molecular drug
DMZ0YU7 PC 6918520
DMZ0YU7 MW 565.9
DMZ0YU7 FM C26H23ClF7NO3
DMZ0YU7 IC InChI=1S/C26H23ClF7NO3/c1-2-17-12-20(9-10-22(17)27)37-19-7-4-6-18(13-19)35(15-23(36)25(30,31)32)14-16-5-3-8-21(11-16)38-26(33,34)24(28)29/h3-13,23-24,36H,2,14-15H2,1H3/t23-/m1/s1
DMZ0YU7 CS CCC1=C(C=CC(=C1)OC2=CC=CC(=C2)N(CC3=CC(=CC=C3)OC(C(F)F)(F)F)C[C@H](C(F)(F)F)O)Cl
DMZ0YU7 IK VHSPKQAESIGBIC-HSZRJFAPSA-N
DMZ0YU7 IU (2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol
DMZ0YU7 DE Arteriosclerosis
DMWVBGD ID DMWVBGD
DMWVBGD DN CR-2093
DMWVBGD HS Discontinued in Phase 1
DMWVBGD SN CR-2093; CR 2093; 136374-73-7; AC1L303W; 4-(3-Chlorobenzamido)-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; (R)-4-(3-Chlorobenzoylamino)-5-oxo-5-(3,3-dimethylbutylamino)valeric acid; (4R)-4-[(3-chlorobenzoyl)amino]-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3-chlorobenzoyl)amino)-5-((3,3-dimethylbutyl)amino)-5-oxo-, (R)-
DMWVBGD CP Rotta Research Lab SpA
DMWVBGD DT Small molecular drug
DMWVBGD PC 131954
DMWVBGD MW 368.9
DMWVBGD FM C18H25ClN2O4
DMWVBGD IC InChI=1S/C18H25ClN2O4/c1-18(2,3)9-10-20-17(25)14(7-8-15(22)23)21-16(24)12-5-4-6-13(19)11-12/h4-6,11,14H,7-10H2,1-3H3,(H,20,25)(H,21,24)(H,22,23)/t14-/m1/s1
DMWVBGD CS CC(C)(C)CCNC(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=CC=C1)Cl
DMWVBGD IK VUYSXYHJEIPUTG-CQSZACIVSA-N
DMWVBGD IU (4R)-4-[(3-chlorobenzoyl)amino]-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid
DMWVBGD CA CAS 136374-73-7
DMWVBGD DE Intestine cancer
DMVDLT4 ID DMVDLT4
DMVDLT4 DN CS-4771
DMVDLT4 HS Discontinued in Phase 1
DMVDLT4 CP Daiichi Sankyo
DMVDLT4 PC 288
DMVDLT4 MW 161.2
DMVDLT4 FM C7H15NO3
DMVDLT4 IC InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3
DMVDLT4 CS C[N+](C)(C)CC(CC(=O)[O-])O
DMVDLT4 IK PHIQHXFUZVPYII-UHFFFAOYSA-N
DMVDLT4 IU 3-hydroxy-4-(trimethylazaniumyl)butanoate
DMVDLT4 CA CAS 406-76-8
DMVDLT4 CB CHEBI:17126
DMVDLT4 DE Sepsis
DMXKB8V ID DMXKB8V
DMXKB8V DN CS-526
DMXKB8V HS Discontinued in Phase 1
DMXKB8V SN AKU-517; R-105266
DMXKB8V CP Sankyo Co Ltd
DMXKB8V PC 9833312
DMXKB8V MW 339.4
DMXKB8V FM C20H22FN3O
DMXKB8V IC InChI=1S/C20H22FN3O/c1-12-8-16(12)10-24-14(3)13(2)18-9-22-23-20(19(18)24)25-11-15-4-6-17(21)7-5-15/h4-7,9,12,16H,8,10-11H2,1-3H3/t12-,16+/m0/s1
DMXKB8V CS C[C@H]1C[C@@H]1CN2C(=C(C3=CN=NC(=C32)OCC4=CC=C(C=C4)F)C)C
DMXKB8V IK NXPLYKRKIFPEOA-BLLLJJGKSA-N
DMXKB8V IU 7-[(4-fluorophenyl)methoxy]-2,3-dimethyl-1-[[(1S,2S)-2-methylcyclopropyl]methyl]pyrrolo[2,3-d]pyridazine
DMXKB8V DE Gastroesophageal reflux disease
DMXY43L ID DMXY43L
DMXY43L DN CTP-354
DMXY43L HS Discontinued in Phase 1
DMXY43L CP Concert pharmaceuticals
DMXY43L PC 46183193
DMXY43L MW 408.5
DMXY43L FM C19H19F2N7O
DMXY43L IC InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3/i1D3,2D3,3D3
DMXY43L CS [2H]C([2H])([2H])C(C1=CC2=NN=C(N2N=C1OCC3=NC=NN3C)C4=C(C=CC(=C4)F)F)(C([2H])([2H])[2H])C([2H])([2H])[2H]
DMXY43L IK BQDUNOMMYOKHEP-GQALSZNTSA-N
DMXY43L IU 3-(2,5-difluorophenyl)-7-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
DMXY43L DE Pain
DMDRFZV ID DMDRFZV
DMDRFZV DN CVS-1123
DMDRFZV HS Discontinued in Phase 1
DMDRFZV SN Corthrombin oral
DMDRFZV CP Dendreon San Diego LLC
DMDRFZV PC 9806376
DMDRFZV MW 510.6
DMDRFZV FM C24H42N6O6
DMDRFZV IC InChI=1S/C24H42N6O6/c1-4-8-16(9-5-2)21(33)29-18(14-20(32)36-3)23(35)30-13-7-11-19(30)22(34)28-17(15-31)10-6-12-27-24(25)26/h15-19H,4-14H2,1-3H3,(H,28,34)(H,29,33)(H4,25,26,27)/t17-,18-,19-/m0/s1
DMDRFZV CS CCCC(CCC)C(=O)N[C@@H](CC(=O)OC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C=O
DMDRFZV IK ICMSWQUELAGTTR-FHWLQOOXSA-N
DMDRFZV IU methyl (3S)-4-[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-(2-propylpentanoylamino)butanoate
DMDRFZV DE Myocardial infarction
DMWY2NT ID DMWY2NT
DMWY2NT DN CY-1787
DMWY2NT HS Discontinued in Phase 1
DMWY2NT CP Epimmune Inc
DMWY2NT DE Allergy
DM1I7UO ID DM1I7UO
DM1I7UO DN Cyclocreatine
DM1I7UO HS Discontinued in Phase 1
DM1I7UO SN Cyclocreatinine; AM-285
DM1I7UO CP Repligen Corp
DM1I7UO DT Small molecular drug
DM1I7UO PC 2896
DM1I7UO MW 143.14
DM1I7UO FM C5H9N3O2
DM1I7UO IC InChI=1S/C5H9N3O2/c6-5-7-1-2-8(5)3-4(9)10/h1-3H2,(H2,6,7)(H,9,10)
DM1I7UO CS C1CN(C(=N1)N)CC(=O)O
DM1I7UO IK AMHZIUVRYRVYBA-UHFFFAOYSA-N
DM1I7UO IU 2-(2-amino-4,5-dihydroimidazol-1-yl)acetic acid
DM1I7UO CA CAS 35404-50-3
DM1I7UO DE Virus infection
DMB24V7 ID DMB24V7
DMB24V7 DN D-1367
DMB24V7 HS Discontinued in Phase 1
DMB24V7 SN 167692-94-6; 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; D-1367; SCHEMBL15923700; DTXSID80570615; ZINC196470483; SC-92964; 2-(3,3-dimethylbutyl)-4,4,5,5,-tetramethyl-1,3,2-d; 1,3,2-Dioxaborolane, 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-
DMB24V7 CP UCB Celltech
DMB24V7 DT Small molecular drug
DMB24V7 PC 15259989
DMB24V7 MW 212.14
DMB24V7 FM C12H25BO2
DMB24V7 IC InChI=1S/C12H25BO2/c1-10(2,3)8-9-13-14-11(4,5)12(6,7)15-13/h8-9H2,1-7H3
DMB24V7 CS B1(OC(C(O1)(C)C)(C)C)CCC(C)(C)C
DMB24V7 IK JAHKBUBFJVAEDA-UHFFFAOYSA-N
DMB24V7 IU 2-(3,3-dimethylbutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
DMB24V7 CA CAS 167692-94-6
DMB24V7 DE Arthritis
DM5D8JW ID DM5D8JW
DM5D8JW DN D-1927
DM5D8JW HS Discontinued in Phase 1
DM5D8JW CP Chiroscience R&D Ltd
DM5D8JW DE Solid tumour/cancer
DMUPEJK ID DMUPEJK
DMUPEJK DN D-4418
DMUPEJK HS Discontinued in Phase 1
DMUPEJK SN UNII-24A61J8R9E; D-4418; 257892-34-5; 24A61J8R9E; SCHEMBL450642; 5-Quinolinecarboxamide, N-(2,5-dichloro-3-pyridinyl)-8-methoxy-
DMUPEJK CP Chiroscience R&D Ltd
DMUPEJK DT Small molecular drug
DMUPEJK PC 9928260
DMUPEJK MW 348.2
DMUPEJK FM C16H11Cl2N3O2
DMUPEJK IC InChI=1S/C16H11Cl2N3O2/c1-23-13-5-4-11(10-3-2-6-19-14(10)13)16(22)21-12-7-9(17)8-20-15(12)18/h2-8H,1H3,(H,21,22)
DMUPEJK CS COC1=C2C(=C(C=C1)C(=O)NC3=C(N=CC(=C3)Cl)Cl)C=CC=N2
DMUPEJK IK FSDOTMQXIKBFKJ-UHFFFAOYSA-N
DMUPEJK IU N-(2,5-dichloropyridin-3-yl)-8-methoxyquinoline-5-carboxamide
DMUPEJK CA CAS 257892-34-5
DMUPEJK DE Cutaneous T-cell lymphoma
DMDUZ5W ID DMDUZ5W
DMDUZ5W DN DACOPAFANT
DMDUZ5W HS Discontinued in Phase 1
DMDUZ5W SN RP-55778; Dacopafant; (+)-3(R)-(3-Pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide
DMDUZ5W DT Small molecular drug
DMDUZ5W PC 205955
DMDUZ5W MW 245.3
DMDUZ5W FM C12H11N3OS
DMDUZ5W IC InChI=1S/C12H11N3OS/c13-11(16)9-3-5-15-10(9)7-17-12(15)8-2-1-4-14-6-8/h1-6,12H,7H2,(H2,13,16)/t12-/m1/s1
DMDUZ5W CS C1C2=C(C=CN2[C@H](S1)C3=CN=CC=C3)C(=O)N
DMDUZ5W IK ARFOASMERCHFBY-GFCCVEGCSA-N
DMDUZ5W IU (3R)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide
DMDUZ5W CA CAS 125372-33-0
DMDUZ5W DE Sepsis
DMAOZH3 ID DMAOZH3
DMAOZH3 DN DE-310
DMAOZH3 HS Discontinued in Phase 1
DMAOZH3 SN Exatecan prodrug, Daiichi
DMAOZH3 CP Daiichi Seiyaku Co Ltd
DMAOZH3 DE Solid tumour/cancer
DMFUCZQ ID DMFUCZQ
DMFUCZQ DN Delucemine
DMFUCZQ HS Discontinued in Phase 1
DMFUCZQ SN Delucemine hydrochloride; NPS-1506
DMFUCZQ CP NPS Pharmaceuticals Inc
DMFUCZQ DT Small molecular drug
DMFUCZQ PC 156421
DMFUCZQ MW 261.31
DMFUCZQ FM C16H17F2N
DMFUCZQ IC InChI=1S/C16H17F2N/c1-19-9-8-16(12-4-2-6-14(17)10-12)13-5-3-7-15(18)11-13/h2-7,10-11,16,19H,8-9H2,1H3
DMFUCZQ CS CNCCC(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
DMFUCZQ IK MUGNLPWYHGOJEG-UHFFFAOYSA-N
DMFUCZQ IU 3,3-bis(3-fluorophenyl)-N-methylpropan-1-amine
DMFUCZQ CA CAS 186495-49-8
DMFUCZQ DE Depression
DM5G43H ID DM5G43H
DM5G43H DN Denibulin
DM5G43H HS Discontinued in Phase 1
DM5G43H SN Denibulin hydrochloride; ANG-600 series; ANG-615; MN-029; Second generation VTAs, Angiogene Pharmaceuticals; Second generation VTAs, MediciNova; Vascular targeting agents (benzimidazole carbamates), Angiogene Pharmaceuticals; Vascular targeting agents (benzimidazole carbamates), MediciNova
DM5G43H CP Angiogene Pharmaceuticals Ltd
DM5G43H DT Small molecular drug
DM5G43H PC 11661758
DM5G43H MW 385.4
DM5G43H FM C18H19N5O3S
DM5G43H IC InChI=1S/C18H19N5O3S/c1-10(19)16(24)20-11-3-5-12(6-4-11)27-13-7-8-14-15(9-13)22-17(21-14)23-18(25)26-2/h3-10H,19H2,1-2H3,(H,20,24)(H2,21,22,23,25)/t10-/m0/s1
DM5G43H CS C[C@@H](C(=O)NC1=CC=C(C=C1)SC2=CC3=C(C=C2)N=C(N3)NC(=O)OC)N
DM5G43H IK GAOHLWCIAJNSEE-JTQLQIEISA-N
DM5G43H IU methyl N-[6-[4-[[(2S)-2-aminopropanoyl]amino]phenyl]sulfanyl-1H-benzimidazol-2-yl]carbamate
DM5G43H CA CAS 284019-34-7
DM5G43H DE Solid tumour/cancer
DMZYVFH ID DMZYVFH
DMZYVFH DN DF-1111301
DMZYVFH HS Discontinued in Phase 1
DMZYVFH SN 2-[2-(Dimethylamino)ethyl]-1-(2-ethoxyethyl)benzimidazole dihydrochloride
DMZYVFH DE Allergy
DMAR068 ID DMAR068
DMAR068 DN Discodermolide
DMAR068 HS Discontinued in Phase 1
DMAR068 SN Discodermolide, Novartis; XAA-296
DMAR068 CP Harbor Branch Oceanographic Institute Inc
DMAR068 DT Small molecular drug
DMAR068 PC 643668
DMAR068 MW 593.8
DMAR068 FM C33H55NO8
DMAR068 IC InChI=1S/C33H55NO8/c1-10-11-12-20(4)31(42-33(34)40)24(8)29(37)22(6)16-18(2)15-21(5)28(36)19(3)13-14-26(35)17-27-23(7)30(38)25(9)32(39)41-27/h10-15,19-31,35-38H,1,16-17H2,2-9H3,(H2,34,40)/b12-11-,14-13-,18-15-/t19-,20-,21-,22-,23-,24-,25+,26+,27-,28-,29+,30-,31-/m0/s1
DMAR068 CS C[C@H]1[C@@H](OC(=O)[C@@H]([C@H]1O)C)C[C@@H](/C=C\\[C@H](C)[C@@H]([C@@H](C)/C=C(/C)\\C[C@H](C)[C@H]([C@H](C)[C@H]([C@@H](C)/C=C\\C=C)OC(=O)N)O)O)O
DMAR068 IK AADVCYNFEREWOS-OBRABYBLSA-N
DMAR068 IU [(3Z,5S,6S,7S,8R,9S,11Z,13S,14S,15S,16Z,18S)-8,14,18-trihydroxy-19-[(2S,3R,4S,5R)-4-hydroxy-3,5-dimethyl-6-oxooxan-2-yl]-5,7,9,11,13,15-hexamethylnonadeca-1,3,11,16-tetraen-6-yl] carbamate
DMAR068 CA CAS 127943-53-7
DMAR068 CB CHEBI:80700
DMAR068 DE Immune System disease
DME5PXL ID DME5PXL
DME5PXL DN DK-507k
DME5PXL HS Discontinued in Phase 1
DME5PXL CP Daiichi Seiyaku Co Ltd
DME5PXL DT Small molecular drug
DME5PXL PC 5271826
DME5PXL MW 405.4
DME5PXL FM C20H21F2N3O4
DME5PXL IC InChI=1S/C20H21F2N3O4/c1-29-18-15-9(17(26)10(19(27)28)6-25(15)13-5-11(13)21)4-12(22)16(18)24-7-14(23)20(8-24)2-3-20/h4,6,11,13-14H,2-3,5,7-8,23H2,1H3,(H,27,28)/t11-,13+,14+/m0/s1
DME5PXL CS COC1=C2C(=CC(=C1N3C[C@H](C4(C3)CC4)N)F)C(=O)C(=CN2[C@@H]5C[C@@H]5F)C(=O)O
DME5PXL IK JYRHGXXQSIPDDP-IACUBPJLSA-N
DME5PXL IU 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid
DME5PXL CA CAS 364069-14-7
DME5PXL DE Bacterial infection
DMCK7LM ID DMCK7LM
DMCK7LM DN DMP-728
DMCK7LM HS Discontinued in Phase 1
DMCK7LM SN CHEMBL114946; BDBM50369582
DMCK7LM DT Small molecular drug
DMCK7LM PC 9831047
DMCK7LM MW 656.7
DMCK7LM FM C26H40N8O10S
DMCK7LM IC InChI=1S/C25H36N8O7.CH4O3S/c1-3-16-24(40)33(2)18(8-5-9-28-25(26)27)23(39)30-13-19(34)31-17(11-20(35)36)22(38)29-12-14-6-4-7-15(10-14)21(37)32-16;1-5(2,3)4/h4,6-7,10,16-18H,3,5,8-9,11-13H2,1-2H3,(H,29,38)(H,30,39)(H,31,34)(H,32,37)(H,35,36)(H4,26,27,28);1H3,(H,2,3,4)/t16-,17+,18+;/m1./s1
DMCK7LM CS CC[C@@H]1C(=O)N([C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC2=CC(=CC=C2)C(=O)N1)CC(=O)O)CCCN=C(N)N)C.CS(=O)(=O)O
DMCK7LM IK CSRWGJAILKTYLJ-PWGAQZMISA-N
DMCK7LM IU 2-[(5S,11S,14R)-11-[3-(diaminomethylideneamino)propyl]-14-ethyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid;methanesulfonic acid
DMCK7LM CA CAS 155158-97-7
DMCK7LM DE Thrombosis
DMDK6HP ID DMDK6HP
DMDK6HP DN DMP-802
DMDK6HP HS Discontinued in Phase 1
DMDK6HP SN CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid
DMDK6HP DT Small molecular drug
DMDK6HP PC 9812185
DMDK6HP MW 492.5
DMDK6HP FM C20H24N6O7S
DMDK6HP IC InChI=1S/C20H24N6O7S/c1-10-18(11(2)32-24-10)34(30,31)26-16(20(28)29)9-23-17(27)8-14-7-15(25-33-14)12-3-5-13(6-4-12)19(21)22/h3-6,14,16,26H,7-9H2,1-2H3,(H3,21,22)(H,23,27)(H,28,29)/t14-,16+/m1/s1
DMDK6HP CS CC1=C(C(=NO1)C)S(=O)(=O)N[C@@H](CNC(=O)C[C@H]2CC(=NO2)C3=CC=C(C=C3)C(=N)N)C(=O)O
DMDK6HP IK XKFYFSNOQRUIAO-ZBFHGGJFSA-N
DMDK6HP IU (2S)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]-2-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonylamino]propanoic acid
DM412S9 ID DM412S9
DM412S9 DN DMP-851
DM412S9 HS Discontinued in Phase 1
DM412S9 SN XQ-443; (4R,5S,6S,7R)-1-(3-Amino-1H-indazol-5-ylmethyl)-4,7-dibenzyl-3-butyl-5,6-dihydroxyperhydro-1,3-diazepin-2-one
DM412S9 DT Small molecular drug
DM412S9 PC 470551
DM412S9 MW 527.7
DM412S9 FM C31H37N5O3
DM412S9 IC InChI=1S/C31H37N5O3/c1-2-3-16-35-26(18-21-10-6-4-7-11-21)28(37)29(38)27(19-22-12-8-5-9-13-22)36(31(35)39)20-23-14-15-25-24(17-23)30(32)34-33-25/h4-15,17,26-29,37-38H,2-3,16,18-20H2,1H3,(H3,32,33,34)/t26-,27-,28+,29+/m1/s1
DM412S9 CS CCCCN1[C@@H]([C@@H]([C@H]([C@H](N(C1=O)CC2=CC3=C(C=C2)NN=C3N)CC4=CC=CC=C4)O)O)CC5=CC=CC=C5
DM412S9 IK CGEJBZXGNPASAG-GKQHHHCTSA-N
DM412S9 IU (4R,5S,6S,7R)-1-[(3-amino-1H-indazol-5-yl)methyl]-4,7-dibenzyl-3-butyl-5,6-dihydroxy-1,3-diazepan-2-one
DM412S9 CA CAS 188978-02-1
DM412S9 DE Human immunodeficiency virus infection
DMR6INY ID DMR6INY
DMR6INY DN DPC 423
DMR6INY HS Discontinued in Phase 1
DMR6INY SN DPC602; 228258-45-5; DPC-423; 209957-47-1; SCHEMBL3052253; CHEMBL176140; BDBM12657; ZINC1490578; 1H-Pyrazole-5-carboxamide,1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-; KB-65316; KB-76718; 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide; 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2-(methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
DMR6INY DT Small molecular drug
DMR6INY PC 9895762
DMR6INY MW 532.5
DMR6INY FM C25H20F4N4O3S
DMR6INY IC InChI=1S/C25H20F4N4O3S/c1-37(35,36)22-8-3-2-7-18(22)16-9-10-20(19(26)12-16)31-24(34)21-13-23(25(27,28)29)32-33(21)17-6-4-5-15(11-17)14-30/h2-13H,14,30H2,1H3,(H,31,34)
DMR6INY CS CS(=O)(=O)C1=CC=CC=C1C2=CC(=C(C=C2)NC(=O)C3=CC(=NN3C4=CC=CC(=C4)CN)C(F)(F)F)F
DMR6INY IK ZLUOAFAJSUPHOG-UHFFFAOYSA-N
DMR6INY IU 2-[3-(aminomethyl)phenyl]-N-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
DMR6INY DE Thrombosis
DMSOHR6 ID DMSOHR6
DMSOHR6 DN DPC-082
DMSOHR6 HS Discontinued in Phase 1
DMSOHR6 SN (E)-4(S)-(2-Cyclopropylvinyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one; 214287-98-6
DMSOHR6 DT Small molecular drug
DMSOHR6 PC 6451134
DMSOHR6 MW 318.24
DMSOHR6 FM C14H11F5N2O
DMSOHR6 IC InChI=1S/C14H11F5N2O/c15-8-3-4-9-10(11(8)16)13(14(17,18)19,21-12(22)20-9)6-5-7-1-2-7/h3-7H,1-2H2,(H2,20,21,22)/b6-5+/t13-/m0/s1
DMSOHR6 CS C1CC1/C=C/[C@]2(C3=C(C=CC(=C3F)F)NC(=O)N2)C(F)(F)F
DMSOHR6 IK JUCDJPCFPITYRP-GFUIURDCSA-N
DMSOHR6 IU (4S)-4-[(E)-2-cyclopropylethenyl]-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
DMSOHR6 CA CAS 214287-98-6
DMSOHR6 DE Human immunodeficiency virus infection
DMA7DH0 ID DMA7DH0
DMA7DH0 DN DPC-168
DMA7DH0 HS Discontinued in Phase 1
DMA7DH0 CP Bristol-Myers Squibb Pharma Co
DMA7DH0 PC 129734673
DMA7DH0 MW 465.6
DMA7DH0 FM C28H36FN3O2
DMA7DH0 IC InChI=1S/C28H36FN3O2/c1-20(33)23-8-4-9-26(17-23)30-28(34)31-27-10-3-2-7-24(27)19-32-15-5-6-22(18-32)16-21-11-13-25(29)14-12-21/h4,8-9,11-14,17,22,24,27H,2-3,5-7,10,15-16,18-19H2,1H3,(H2,30,31,34)/t22-,24?,27+/m0/s1
DMA7DH0 CS CC(=O)C1=CC(=CC=C1)NC(=O)N[C@@H]2CCCCC2CN3CCC[C@H](C3)CC4=CC=C(C=C4)F
DMA7DH0 IK ASRDPULQBHFPGU-RJCBHOSBSA-N
DMA7DH0 IU 1-(3-acetylphenyl)-3-[(1R)-2-[[(3S)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea
DMA7DH0 DE Allergic rhinitis
DM5HAG0 ID DM5HAG0
DM5HAG0 DN DPC-681
DM5HAG0 HS Discontinued in Phase 1
DM5HAG0 SN N-(3-Fluorobenzyl)glycyl-N-[3-[N-(3-aminophenylsulfonyl)-N-isobutylamino]-1(S)-benzyl-2(R)-hydroxypropyl]-3-methyl-L-valinamide mesylate
DM5HAG0 DT Small molecular drug
DM5HAG0 PC 456215
DM5HAG0 MW 669.9
DM5HAG0 FM C35H48FN5O5S
DM5HAG0 IC InChI=1S/C35H48FN5O5S/c1-24(2)22-41(47(45,46)29-16-10-15-28(37)19-29)23-31(42)30(18-25-11-7-6-8-12-25)39-34(44)33(35(3,4)5)40-32(43)21-38-20-26-13-9-14-27(36)17-26/h6-17,19,24,30-31,33,38,42H,18,20-23,37H2,1-5H3,(H,39,44)(H,40,43)/t30-,31+,33+/m0/s1
DM5HAG0 CS CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNCC2=CC(=CC=C2)F)O)S(=O)(=O)C3=CC=CC(=C3)N
DM5HAG0 IK PNIFFZXGBAYVMQ-RKKDRKJOSA-N
DM5HAG0 IU (2S)-N-[(2S,3R)-4-[(3-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide
DM5HAG0 CA CAS 367281-49-0
DM5HAG0 DE Human immunodeficiency virus infection
DMS19VG ID DMS19VG
DMS19VG DN DPC-684
DMS19VG HS Discontinued in Phase 1
DMS19VG SN N-(3-Fluorobenzyl)glycyl-N-[3-[N-(4-aminophenylsulfonyl)-N-isobutylamino]-1(S)-benzyl-2(R)-hydroxypropyl]-3-methyl-L-valinamide
DMS19VG DT Small molecular drug
DMS19VG PC 101143534
DMS19VG MW 669.9
DMS19VG FM C35H48FN5O5S
DMS19VG IC InChI=1S/C35H48FN5O5S/c1-24(2)22-41(47(45,46)29-16-14-28(37)15-17-29)23-31(42)30(19-25-10-7-6-8-11-25)39-34(44)33(35(3,4)5)40-32(43)21-38-20-26-12-9-13-27(36)18-26/h6-18,24,30-31,33,38,42H,19-23,37H2,1-5H3,(H,39,44)(H,40,43)/t30-,31-,33+/m0/s1
DMS19VG CS CC(C)CN(C[C@@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNCC2=CC(=CC=C2)F)O)S(=O)(=O)C3=CC=C(C=C3)N
DMS19VG IK IXZYCIFRVZKVRJ-MZSJJGOWSA-N
DMS19VG IU (2S)-N-[(2S,3S)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-2-[[2-[(3-fluorophenyl)methylamino]acetyl]amino]-3,3-dimethylbutanamide
DMS19VG DE Human immunodeficiency virus infection
DMOPM7L ID DMOPM7L
DMOPM7L DN DRF 10945
DMOPM7L HS Discontinued in Phase 1
DMOPM7L CP Dr. Reddy's Laboratories
DMOPM7L DE Hyperlipidaemia
DMS4IBW ID DMS4IBW
DMS4IBW DN DS-1442
DMS4IBW HS Discontinued in Phase 1
DMS4IBW CP Daiichi Sankyo
DMS4IBW PC 260936
DMS4IBW MW 173.17
DMS4IBW FM C10H7NO2
DMS4IBW IC InChI=1S/C10H7NO2/c12-10(13)9-3-1-2-7-6-11-5-4-8(7)9/h1-6H,(H,12,13)
DMS4IBW CS C1=CC2=C(C=CN=C2)C(=C1)C(=O)O
DMS4IBW IK ZIPLFLRGHZAXSJ-UHFFFAOYSA-N
DMS4IBW IU isoquinoline-5-carboxylic acid
DMS4IBW CA CAS 27810-64-6
DMS4IBW DE Dyslipidemia
DMDAO8E ID DMDAO8E
DMDAO8E DN DS-6930
DMDAO8E HS Discontinued in Phase 1
DMDAO8E CP Daiichi Sankyo
DMDAO8E DE Diabetic complication
DMQK53O ID DMQK53O
DMQK53O DN DS-7250
DMQK53O HS Discontinued in Phase 1
DMQK53O CP Daiichi Sankyo
DMQK53O PC 18464794
DMQK53O MW 225.71
DMQK53O FM C12H16ClNO
DMQK53O IC InChI=1S/C12H16ClNO/c13-11-3-1-10(2-4-11)12(6-8-15)5-7-14-9-12/h1-4,14-15H,5-9H2
DMQK53O CS C1CNCC1(CCO)C2=CC=C(C=C2)Cl
DMQK53O IK ILTULPUUFNFODT-UHFFFAOYSA-N
DMQK53O IU 2-[3-(4-chlorophenyl)pyrrolidin-3-yl]ethanol
DMQK53O CA CAS 52423-70-8
DMQK53O DE Diabetic complication
DMN9KXU ID DMN9KXU
DMN9KXU DN DU-29894
DMN9KXU HS Discontinued in Phase 1
DMN9KXU CP Solvay Pharmaceuticals BV
DMN9KXU PC 208917
DMN9KXU MW 375.4
DMN9KXU FM C23H22FN3O
DMN9KXU IC InChI=1S/C23H22FN3O/c24-19-6-4-17(5-7-19)21-9-8-20(25-21)16-26-11-13-27(14-12-26)22-3-1-2-18-10-15-28-23(18)22/h1-10,15,25H,11-14,16H2
DMN9KXU CS C1CN(CCN1CC2=CC=C(N2)C3=CC=C(C=C3)F)C4=CC=CC5=C4OC=C5
DMN9KXU IK PGNHBJGIQAEIHD-UHFFFAOYSA-N
DMN9KXU IU 1-(1-benzofuran-7-yl)-4-[[5-(4-fluorophenyl)-1H-pyrrol-2-yl]methyl]piperazine
DMN9KXU CA CAS 115464-77-2
DMN9KXU DE Psychotic disorder
DM9S51Q ID DM9S51Q
DM9S51Q DN DU-6681
DM9S51Q HS Discontinued in Phase 1
DM9S51Q SN DU-6681a (Na salt); (1R,5S,6S)-2-[6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-6(S)-ylsulfanyl]-6-[1(R)-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid
DM9S51Q PC 100935628
DM9S51Q MW 349.4
DM9S51Q FM C16H19N3O4S
DM9S51Q IC InChI=1S/C16H19N3O4S/c1-7-12-11(8(2)20)15(21)19(12)13(16(22)23)14(7)24-9-5-10-17-3-4-18(10)6-9/h3-4,7-9,11-12,20H,5-6H2,1-2H3,(H,22,23)/t7-,8-,9+,11-,12+/m1/s1
DM9S51Q CS C[C@@H]1[C@H]2[C@H](C(=O)N2C(=C1S[C@H]3CC4=NC=CN4C3)C(=O)O)[C@@H](C)O
DM9S51Q IK SYFIHQJVKJGGGB-VZSYODPGSA-N
DM9S51Q IU (4R,5R,6S)-3-[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
DM9S51Q DE Bacterial infection
DMUMAHC ID DMUMAHC
DMUMAHC DN DUP 697
DMUMAHC HS Discontinued in Phase 1
DMUMAHC SN Dup 697; dup-697; 88149-94-4; MRWLZPOFPA; UNII-MRWLZPOFPA; CHEMBL42485; CHEBI:4720; 5-Bromo-2-(4-fluorophenyl)-3-(4-methysulfonylphenyl)thiophene; 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene; CPD000466299; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-; Thiophene, 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- [CAS]; 5-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]thiophene; 5-Bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)thiophene; SMR000466299
DMUMAHC TC Analgesics
DMUMAHC DT Small molecular drug
DMUMAHC PC 3177
DMUMAHC MW 411.3
DMUMAHC FM C17H12BrFO2S2
DMUMAHC IC InChI=1S/C17H12BrFO2S2/c1-23(20,21)14-8-4-11(5-9-14)15-10-16(18)22-17(15)12-2-6-13(19)7-3-12/h2-10H,1H3
DMUMAHC CS CS(=O)(=O)C1=CC=C(C=C1)C2=C(SC(=C2)Br)C3=CC=C(C=C3)F
DMUMAHC IK AJFTZWGGHJXZOB-UHFFFAOYSA-N
DMUMAHC IU 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)thiophene
DMUMAHC CA CAS 88149-94-4
DMUMAHC CB CHEBI:4720
DMUMAHC DE Pain
DM59WQ7 ID DM59WQ7
DM59WQ7 DN DuP-532
DM59WQ7 HS Discontinued in Phase 1
DM59WQ7 SN Dup-532; Dup 532; 124750-95-4; CHEMBL443269; 1H-Imidazole-5-carboxylicacid,4-(1,1,2,2,2-pentafluoroethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; dup532; ACMC-20mr6i; SCHEMBL62; AC1L1TVZ; AC1Q4ICA; CTK4B4065; BDBM82428; DTXSID00154476; PDSP2_000123; PDSP1_000124; PDSP1_000123; BDBM50230908; 2-Propyl-4-pentafluoroethyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazole-5-carboxylic acid; CAS_124750-95-4; CB91356279; L002873; 1H-Imidazole-5-carboxylic acid, 4-(pentafluoroethyl)-2-propyl-1-((2'-(1H-te
DM59WQ7 CP Bristol-Myers Squibb Pharma Co
DM59WQ7 DT Small molecular drug
DM59WQ7 PC 60770
DM59WQ7 MW 506.4
DM59WQ7 FM C23H19F5N6O2
DM59WQ7 IC InChI=1S/C23H19F5N6O2/c1-2-5-17-29-19(22(24,25)23(26,27)28)18(21(35)36)34(17)12-13-8-10-14(11-9-13)15-6-3-4-7-16(15)20-30-32-33-31-20/h3-4,6-11H,2,5,12H2,1H3,(H,35,36)(H,30,31,32,33)
DM59WQ7 CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C(F)(F)F)(F)F
DM59WQ7 IK RQGDXPDTZWGCQI-UHFFFAOYSA-N
DM59WQ7 IU 5-(1,1,2,2,2-pentafluoroethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
DM59WQ7 CA CAS 124750-95-4
DM59WQ7 DE Hypertension
DMI5EPB ID DMI5EPB
DMI5EPB DN DUP-734
DMI5EPB HS Discontinued in Phase 1
DMI5EPB SN 1-(Cyclopropylmethyl)-4-[2-(4-fluorophenyl)-2-oxoethyl]piperidine hydrobromide
DMI5EPB DT Small molecular drug
DMI5EPB PC 121967
DMI5EPB MW 356.3
DMI5EPB FM C17H23BrFNO
DMI5EPB IC InChI=1S/C17H22FNO.BrH/c18-16-5-3-15(4-6-16)17(20)11-13-7-9-19(10-8-13)12-14-1-2-14;/h3-6,13-14H,1-2,7-12H2;1H
DMI5EPB CS C1CC1CN2CCC(CC2)CC(=O)C3=CC=C(C=C3)F.Br
DMI5EPB IK QLZIAKMYJFJBKA-UHFFFAOYSA-N
DMI5EPB IU 2-[1-(cyclopropylmethyl)piperidin-4-yl]-1-(4-fluorophenyl)ethanone;hydrobromide
DMI5EPB CA CAS 135135-87-4
DMI5EPB DE Psychotic disorder
DMDC4BA ID DMDC4BA
DMDC4BA DN DV-7751A
DMDC4BA HS Discontinued in Phase 1
DMDC4BA SN 10-[8(S)-Amino-6-azaspiro[3.4]octan-6-yl]-9-fluoro-3(S)-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid hemihydrate
DMDC4BA DT Small molecular drug
DMDC4BA PC 122823
DMDC4BA MW 387.4
DMDC4BA FM C20H22FN3O4
DMDC4BA IC InChI=1S/C20H22FN3O4/c1-10-8-28-18-15-11(17(25)12(19(26)27)6-24(10)15)5-13(21)16(18)23-7-14(22)20(9-23)3-2-4-20/h5-6,10,14H,2-4,7-9,22H2,1H3,(H,26,27)/t10-,14+/m0/s1
DMDC4BA CS C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4C[C@H](C5(C4)CCC5)N)F)C(=O)O
DMDC4BA IK UGGPRXAHUOKTKV-IINYFYTJSA-N
DMDC4BA IU (2S)-6-[(8S)-8-amino-6-azaspiro[3.4]octan-6-yl]-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
DMDC4BA CA CAS 129321-78-4
DMDC4BA DE Bacterial infection
DMXJ54Z ID DMXJ54Z
DMXJ54Z DN DW-908e
DMXJ54Z HS Discontinued in Phase 1
DMXJ54Z SN Allergy therapeutics, Daiichi; Asthma therapeutics, Daiichi; PS-181895; PS-460644; PS-489655; PS-969819; Asthma/allergy therapeutics, Daiichi
DMXJ54Z CP Pharmacopeia Inc
DMXJ54Z PC 23704320
DMXJ54Z MW 638.5
DMXJ54Z FM C31H34Cl2N3NaO6
DMXJ54Z IC InChI=1S/C31H35Cl2N3O6.Na/c1-35-16-24(23-5-3-4-6-28(23)35)30(38)34-27-14-25(32)19(11-26(27)33)12-29(37)36-15-22(41-2)13-20(36)17-42-21-9-7-18(8-10-21)31(39)40;/h3-6,11,14,16,18,20-22H,7-10,12-13,15,17H2,1-2H3,(H,34,38)(H,39,40);/q;+1/p-1/t18?,20-,21?,22-;/m0./s1
DMXJ54Z CS CN1C=C(C2=CC=CC=C21)C(=O)NC3=C(C=C(C(=C3)Cl)CC(=O)N4C[C@H](C[C@H]4COC5CCC(CC5)C(=O)[O-])OC)Cl.[Na+]
DMXJ54Z IK YWWOTADRIASLGN-VMAKYHEJSA-M
DMXJ54Z IU sodium;4-[[(2S,4S)-1-[2-[2,5-dichloro-4-[(1-methylindole-3-carbonyl)amino]phenyl]acetyl]-4-methoxypyrrolidin-2-yl]methoxy]cyclohexane-1-carboxylate
DMXJ54Z DE Allergy
DMI9NZ3 ID DMI9NZ3
DMI9NZ3 DN E2101
DMI9NZ3 HS Discontinued in Phase 1
DMI9NZ3 SN UNII-7X2U66KMP7; 7X2U66KMP7; E2101; SCHEMBL4081913; L001631; 1H-Indole-6-acetamide, 1-(1-(2-(2-fluorophenyl)ethyl)-4-piperidinyl)-N-methyl-; 1-(1-(2-(2-Fluorophenyl)ethyl)-4-piperidinyl)-N-methyl-1H-indole-6-acetamide
DMI9NZ3 CP Eisai Co. Ltd.
DMI9NZ3 DT Small molecular drug
DMI9NZ3 PC 9908587
DMI9NZ3 MW 393.5
DMI9NZ3 FM C24H28FN3O
DMI9NZ3 IC InChI=1S/C24H28FN3O/c1-26-24(29)17-18-6-7-20-9-15-28(23(20)16-18)21-10-13-27(14-11-21)12-8-19-4-2-3-5-22(19)25/h2-7,9,15-16,21H,8,10-14,17H2,1H3,(H,26,29)
DMI9NZ3 CS CNC(=O)CC1=CC2=C(C=C1)C=CN2C3CCN(CC3)CCC4=CC=CC=C4F
DMI9NZ3 IK CQEOXWCXSBFJMB-UHFFFAOYSA-N
DMI9NZ3 IU 2-[1-[1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl]indol-6-yl]-N-methylacetamide
DMI9NZ3 CA CAS 265667-22-9
DMI9NZ3 DE Spasm; Cervical dystonia
DMJWR1I ID DMJWR1I
DMJWR1I DN E-3030
DMJWR1I HS Discontinued in Phase 1
DMJWR1I SN Dual PPAR alpha/gamma agonists, Eisai
DMJWR1I CP Eisai Co Ltd
DMJWR1I PC 11949481
DMJWR1I MW 909.8
DMJWR1I FM C44H44CaCl2F2N2O10
DMJWR1I IC InChI=1S/2C22H23ClFNO5.Ca/c2*1-14(2)30-21(22(26)27)9-15-4-3-5-19(8-15)28-12-18(24)13-29-20-7-6-17(23)10-16(20)11-25;/h2*3-8,10,14,18,21H,9,12-13H2,1-2H3,(H,26,27);/q;;+2/p-2/t2*18-,21-;/m00./s1
DMJWR1I CS CC(C)O[C@@H](CC1=CC(=CC=C1)OC[C@@H](COC2=C(C=C(C=C2)Cl)C#N)F)C(=O)[O-].CC(C)O[C@@H](CC1=CC(=CC=C1)OC[C@@H](COC2=C(C=C(C=C2)Cl)C#N)F)C(=O)[O-].[Ca+2]
DMJWR1I IK QBPOEQDRFVFZRI-ATAMATRTSA-L
DMJWR1I IU calcium;(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-propan-2-yloxypropanoate
DMJWR1I CA CAS 913722-93-7
DMJWR1I DE Hyperlipidaemia
DM79MI4 ID DM79MI4
DM79MI4 DN E-6087
DM79MI4 HS Discontinued in Phase 1
DM79MI4 SN E-6231 ((R)-(+)-isomer); E-6232 ((S)-(-)-isomer); Rac-4-[5-(2,4-Difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl]benzenesulfonamide
DM79MI4 PC 9953093
DM79MI4 MW 405.3
DM79MI4 FM C16H12F5N3O2S
DM79MI4 IC InChI=1S/C16H12F5N3O2S/c17-9-1-6-12(13(18)7-9)14-8-15(16(19,20)21)23-24(14)10-2-4-11(5-3-10)27(22,25)26/h1-7,14H,8H2,(H2,22,25,26)
DM79MI4 CS C1C(N(N=C1C(F)(F)F)C2=CC=C(C=C2)S(=O)(=O)N)C3=C(C=C(C=C3)F)F
DM79MI4 IK ZZMJXWXXMAAPLI-UHFFFAOYSA-N
DM79MI4 IU 4-[3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide
DM79MI4 CA CAS 251442-94-1
DM79MI4 DE Pain
DMSOH09 ID DMSOH09
DMSOH09 DN Ebalzotan
DMSOH09 HS Discontinued in Phase 1
DMSOH09 SN NAE-086
DMSOH09 CP Astra AB
DMSOH09 DT Small molecular drug
DMSOH09 PC 9797080
DMSOH09 MW 318.5
DMSOH09 FM C19H30N2O2
DMSOH09 IC InChI=1S/C19H30N2O2/c1-6-10-21(14(4)5)15-11-17-16(19(22)20-13(2)3)8-7-9-18(17)23-12-15/h7-9,13-15H,6,10-12H2,1-5H3,(H,20,22)/t15-/m1/s1
DMSOH09 CS CCCN([C@@H]1CC2=C(C=CC=C2OC1)C(=O)NC(C)C)C(C)C
DMSOH09 IK UEAKCKJAKUFIQP-OAHLLOKOSA-N
DMSOH09 IU (3R)-N-propan-2-yl-3-[propan-2-yl(propyl)amino]-3,4-dihydro-2H-chromene-5-carboxamide
DMSOH09 CA CAS 149494-37-1
DMSOH09 DE Anxiety disorder
DMURVE8 ID DMURVE8
DMURVE8 DN Elacridar
DMURVE8 HS Discontinued in Phase 1
DMURVE8 SN Elacridar hydrochloride; 143851-98-3; Elacridar HCl; Elacridar (hydrochloride); gf 120918a; UNII-NX2BHH1A5B; NX2BHH1A5B; Elacridar hydrochloride [USAN]; GF-120918A; Elacridar hydrochloride (USAN); GF 120918; AC1Q3EOG; AC1L55DX; C34H34ClN3O5; SCHEMBL15847793; CHEMBL2074730; AOB5938; MolPort-023-332-877; BCP14056; 7066AA; AKOS016005297; CS-1113; ACN-041487; 4CA-0489; HY-50880; AC-30266; FT-0696337; W-5457; D03968; N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro
DMURVE8 DT Small molecular drug
DMURVE8 PC 119373
DMURVE8 MW 563.6
DMURVE8 FM C34H33N3O5
DMURVE8 IC InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)
DMURVE8 CS COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC
DMURVE8 IK OSFCMRGOZNQUSW-UHFFFAOYSA-N
DMURVE8 IU N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide
DMURVE8 CA CAS 143664-11-3
DMURVE8 DE Solid tumour/cancer
DMWRQG7 ID DMWRQG7
DMWRQG7 DN Eltenac
DMWRQG7 HS Discontinued in Phase 1
DMWRQG7 SN BY-820; B-788-20
DMWRQG7 CP ALTANA Pharma AG
DMWRQG7 DT Small molecular drug
DMWRQG7 PC 51717
DMWRQG7 MW 302.2
DMWRQG7 FM C12H9Cl2NO2S
DMWRQG7 IC InChI=1S/C12H9Cl2NO2S/c13-8-2-1-3-9(14)12(8)15-10-6-18-5-7(10)4-11(16)17/h1-3,5-6,15H,4H2,(H,16,17)
DMWRQG7 CS C1=CC(=C(C(=C1)Cl)NC2=CSC=C2CC(=O)O)Cl
DMWRQG7 IK AELILMBZWCGOSB-UHFFFAOYSA-N
DMWRQG7 IU 2-[4-(2,6-dichloroanilino)thiophen-3-yl]acetic acid
DMWRQG7 CA CAS 72895-88-6
DMWRQG7 DE Arthritis
DM2V5XP ID DM2V5XP
DM2V5XP DN Emakalim
DM2V5XP HS Discontinued in Phase 1
DM2V5XP SN EMD-56431
DM2V5XP CP Merck KGaA
DM2V5XP DT Small molecular drug
DM2V5XP PC 9839143
DM2V5XP MW 296.32
DM2V5XP FM C17H16N2O3
DM2V5XP IC InChI=1S/C17H16N2O3/c1-17(2)16(21)15(19-8-4-3-5-14(19)20)12-9-11(10-18)6-7-13(12)22-17/h3-9,15-16,21H,1-2H3/t15-,16+/m1/s1
DM2V5XP CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3C=CC=CC3=O)O)C
DM2V5XP IK MMSFHQSHXRMPLJ-CVEARBPZSA-N
DM2V5XP IU (3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyridin-1-yl)-3,4-dihydrochromene-6-carbonitrile
DM2V5XP CA CAS 129729-66-4
DM2V5XP DE Angina pectoris
DMQH8L2 ID DMQH8L2
DMQH8L2 DN EMD-503982
DMQH8L2 HS Discontinued in Phase 1
DMQH8L2 SN EMD-495235; Factor Xa inhibitors, Merck KGaA
DMQH8L2 CP Merck KGaA
DMQH8L2 PC 9912033
DMQH8L2 MW 458.9
DMQH8L2 FM C22H23ClN4O5
DMQH8L2 IC InChI=1S/C22H23ClN4O5/c23-14-1-3-16(4-2-14)25-22(31)27-12-18(28)11-19(27)21(30)24-15-5-7-17(8-6-15)26-9-10-32-13-20(26)29/h1-8,18-19,28H,9-13H2,(H,24,30)(H,25,31)/t18-,19-/m1/s1
DMQH8L2 CS C1COCC(=O)N1C2=CC=C(C=C2)NC(=O)[C@H]3C[C@H](CN3C(=O)NC4=CC=C(C=C4)Cl)O
DMQH8L2 IK DMYZJLOWGSRVKP-RTBURBONSA-N
DMQH8L2 IU (2R,4R)-1-N-(4-chlorophenyl)-4-hydroxy-2-N-[4-(3-oxomorpholin-4-yl)phenyl]pyrrolidine-1,2-dicarboxamide
DMQH8L2 DE Thrombosis
DMVS8IE ID DMVS8IE
DMVS8IE DN EMD-53998
DMVS8IE HS Discontinued in Phase 1
DMVS8IE SN 5-[1-(3,4-Dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl]-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazin-2-one
DMVS8IE DT Small molecular drug
DMVS8IE PC 187079
DMVS8IE MW 425.5
DMVS8IE FM C22H23N3O4S
DMVS8IE IC InChI=1S/C22H23N3O4S/c1-13-20(23-24-22(27)30-13)15-6-8-17-14(11-15)5-4-10-25(17)21(26)16-7-9-18(28-2)19(12-16)29-3/h6-9,11-13H,4-5,10H2,1-3H3,(H,24,27)
DMVS8IE CS CC1C(=NNC(=O)S1)C2=CC3=C(C=C2)N(CCC3)C(=O)C4=CC(=C(C=C4)OC)OC
DMVS8IE IK IZLRMTJLQCLMKF-UHFFFAOYSA-N
DMVS8IE IU 5-[1-(3,4-dimethoxybenzoyl)-3,4-dihydro-2H-quinolin-6-yl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-one
DMVS8IE CA CAS 120223-04-3
DMVS8IE DE Cardiovascular disease
DMFGTMR ID DMFGTMR
DMFGTMR DN Eptapirone
DMFGTMR HS Discontinued in Phase 1
DMFGTMR SN F-11440
DMFGTMR CP Pierre Fabre SA
DMFGTMR DT Small molecular drug
DMFGTMR PC 208928
DMFGTMR MW 345.4
DMFGTMR FM C16H23N7O2
DMFGTMR IC InChI=1S/C16H23N7O2/c1-20-14(24)13-19-23(16(20)25)8-3-2-7-21-9-11-22(12-10-21)15-17-5-4-6-18-15/h4-6,13H,2-3,7-12H2,1H3
DMFGTMR CS CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=NC=CC=N3
DMFGTMR IK NMYAHEULKSYAPP-UHFFFAOYSA-N
DMFGTMR IU 4-methyl-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2,4-triazine-3,5-dione
DMFGTMR CA CAS 179756-85-5
DMFGTMR DE Anxiety disorder
DM3LKAR ID DM3LKAR
DM3LKAR DN ER-35786
DM3LKAR HS Discontinued in Phase 1
DM3LKAR SN E-1010; (1R,5S,6S)-6-[1(R)-Hydroxymethyl]-2-[2(S)-[1(R)-hydroxy-1-[pyrrolidin-3(R)-yl]methyl]pyrrolidin-4(S)-ylsulfanyl]-1-methyl-1-carba-2-penem-3-carboxylic acid monohydrochloride
DM3LKAR DT Small molecular drug
DM3LKAR PC 6918311
DM3LKAR MW 448
DM3LKAR FM C19H30ClN3O5S
DM3LKAR IC InChI=1S/C19H29N3O5S.ClH/c1-8-14-13(9(2)23)18(25)22(14)15(19(26)27)17(8)28-11-5-12(21-7-11)16(24)10-3-4-20-6-10;/h8-14,16,20-21,23-24H,3-7H2,1-2H3,(H,26,27);1H/t8-,9-,10-,11+,12+,13-,14-,16-;/m1./s1
DM3LKAR CS C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)[C@@H]([C@@H]4CCNC4)O)C(=O)O)[C@@H](C)O.Cl
DM3LKAR IK WRVJTXDJDKITNK-XNGFCKKMSA-N
DM3LKAR IU (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(3S,5S)-5-[(R)-hydroxy-[(3R)-pyrrolidin-3-yl]methyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;hydrochloride
DM3LKAR CA CAS 186319-97-1
DM3LKAR DE Bacterial infection
DMGX08C ID DMGX08C
DMGX08C DN ERB-196
DMGX08C HS Discontinued in Phase 1
DMGX08C SN WAY-196; WAY-202196; Estrogen receptor beta agonist (oral, inflammation/sepsis), Wyeth
DMGX08C CP Wyeth
DMGX08C PC 6102691
DMGX08C MW 279.26
DMGX08C FM C17H10FNO2
DMGX08C IC InChI=1S/C17H10FNO2/c18-16-7-10(2-4-17(16)21)12-5-11-1-3-14(20)8-15(11)13(6-12)9-19/h1-8,20-21H
DMGX08C CS C1=CC(=CC2=C(C=C(C=C21)C3=CC(=C(C=C3)O)F)C#N)O
DMGX08C IK NSSOSHDCWCMNDM-UHFFFAOYSA-N
DMGX08C IU 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile
DMGX08C CA CAS 550997-55-2
DMGX08C DE Inflammatory bowel disease
DMW9LHG ID DMW9LHG
DMW9LHG DN ES-285
DMW9LHG HS Discontinued in Phase 1
DMW9LHG SN Spisulosine-285
DMW9LHG CP PharmaMar SA
DMW9LHG PC 9925886
DMW9LHG MW 285.5
DMW9LHG FM C18H39NO
DMW9LHG IC InChI=1S/C18H39NO/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20)17(2)19/h17-18,20H,3-16,19H2,1-2H3/t17-,18+/m0/s1
DMW9LHG CS CCCCCCCCCCCCCCC[C@H]([C@H](C)N)O
DMW9LHG IK YRYJJIXWWQLGGV-ZWKOTPCHSA-N
DMW9LHG IU (2S,3R)-2-aminooctadecan-3-ol
DMW9LHG CA CAS 196497-48-0
DMW9LHG CB CHEBI:67106
DMW9LHG DE Solid tumour/cancer
DM9450Z ID DM9450Z
DM9450Z DN EVT-103
DM9450Z HS Discontinued in Phase 1
DM9450Z SN ENS-103
DM9450Z CP Roche Holding AG
DM9450Z DE Major depressive disorder
DMCZ8SF ID DMCZ8SF
DMCZ8SF DN EVT-301
DMCZ8SF HS Discontinued in Phase 1
DMCZ8SF SN MAO B inhibitors (Alzheimer's disease), Evotec/Roche; Monoamineoxidase B inhibitors (Alzheimer's disease),Evotec/Roche
DMCZ8SF CP Roche Holding AG
DMCZ8SF DE Alzheimer disease
DMLRF7U ID DMLRF7U
DMLRF7U DN F-11105
DMLRF7U HS Discontinued in Phase 1
DMLRF7U CP Pierre Fabre SA
DMLRF7U DE Asthma
DMPC9K3 ID DMPC9K3
DMPC9K3 DN F-1394
DMPC9K3 HS Discontinued in Phase 1
DMPC9K3 SN AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
DMPC9K3 CP Fujirebio KK
DMPC9K3 DT Small molecular drug
DMPC9K3 PC 6918210
DMPC9K3 MW 595.9
DMPC9K3 FM C33H61N3O6
DMPC9K3 IC InChI=1S/C33H61N3O6/c1-9-10-11-12-13-14-17-22-36(23-31(2,3)4)30(39)35-25-18-15-16-19-26(25)41-27(37)20-21-34-29(38)28-32(5,6)24-40-33(7,8)42-28/h25-26,28H,9-24H2,1-8H3,(H,34,38)(H,35,39)/t25-,26-,28?/m0/s1
DMPC9K3 CS CCCCCCCCCN(CC(C)(C)C)C(=O)N[C@H]1CCCC[C@@H]1OC(=O)CCNC(=O)C2C(COC(O2)(C)C)(C)C
DMPC9K3 IK NWLFOBZKYXKBOF-QIELNMHASA-N
DMPC9K3 IU [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
DMPC9K3 DE Arteriosclerosis
DMMG6W5 ID DMMG6W5
DMMG6W5 DN F-50040
DMMG6W5 HS Discontinued in Phase 1
DMMG6W5 SN Metastatic melanoma vaccine, Pierre Fabre; P40-ELA; Metastatic melanoma vaccine, BioMerieux-Pierre Fabre; Vaccine (melanoma), Pierre Fabre; Vaccine (melanoma), BioMerieux-Pierre Fabre
DMMG6W5 CP Pierre Fabre SA
DMMG6W5 DE Melanoma
DM76GRQ ID DM76GRQ
DM76GRQ DN Farampator
DM76GRQ HS Discontinued in Phase 1
DM76GRQ SN CX 691; CX-691; Farampator (USAN/INN); 1-(Benzofurazan-5-ylcarbonyl)piperidine; 2,1,3-benzoxadiazol-5-yl(piperidin-1-yl)methanone
DM76GRQ CP Cortex Pharmaceuticals
DM76GRQ DT Small molecular drug
DM76GRQ PC 4118151
DM76GRQ MW 231.25
DM76GRQ FM C12H13N3O2
DM76GRQ IC InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2
DM76GRQ CS C1CCN(CC1)C(=O)C2=CC3=NON=C3C=C2
DM76GRQ IK XFVRBYKKGGDPAJ-UHFFFAOYSA-N
DM76GRQ IU 2,1,3-benzoxadiazol-5-yl(piperidin-1-yl)methanone
DM76GRQ CA CAS 211735-76-1
DM76GRQ DE Schizophrenia; Major depressive disorder
DMEX12T ID DMEX12T
DMEX12T DN FC EPO
DMEX12T HS Discontinued in Phase 1
DMEX12T SN Long acting erythropoietin (anemia), Merck Serono
DMEX12T CP Merck Serono SA
DMEX12T DE Anemia
DMSFA7L ID DMSFA7L
DMSFA7L DN FCE-28161
DMSFA7L HS Discontinued in Phase 1
DMSFA7L SN PNU-166945; Lodeca[3,4]benz[1,2-b]oxet-5-one; Copolymer of N-(2-hydroxypropyl)methacrylamide,methacryloylglycine 2-hydroxypropylamide and [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-6,12b-diacetoxy-9-[3-benza; Mido-2-(methacryloyl-glycyl-L-phenylalanyl-L-leucyl-glycyloxy)-3-phenylpropionyloxy]-12-benzoyloxy-4,11-dihydroxy-4a,8,13,13-tetramethyl-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyc
DMSFA7L DE Solid tumour/cancer
DMC3DVB ID DMC3DVB
DMC3DVB DN Figitumumab
DMC3DVB HS Discontinued in Phase 1
DMC3DVB SN AC1OCENC; (2R)-3-[(4S,6R,7R,10S)-4-[(E,2R)-4-[(2S,2'S,4R,4aS,6R,8aR)-4-hydroxy-2-[(1S,3S)-1-hydroxy-3-[(6S,9R,10S)-9-methyl-5,11-dioxaspiro[5.5]undecan-10-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-7-hydroxy-2-methyl-5,11-dioxaspiro[5.5]undec-1-en-10-yl]-2-hydroxy-2-methylpropanoic acid
DMC3DVB CP Pfizer
DMC3DVB DT Monoclonal antibody
DMC3DVB DE Malignant adrenal gland cancer
DMVL5RC ID DMVL5RC
DMVL5RC DN FK-041
DMVL5RC HS Discontinued in Phase 1
DMVL5RC CP Fujisawa Pharmaceutical Co Ltd
DMVL5RC PC 102315666
DMVL5RC MW 481.5
DMVL5RC FM C16H15N7O5S3
DMVL5RC IC InChI=1S/C16H15N7O5S3/c17-16-20-7(4-31-16)9(22-28)12(24)21-10-13(25)23-11(15(26)27)8(5-30-14(10)23)29-3-6-1-18-19-2-6/h1-2,4,10,14,28H,3,5H2,(H2,17,20)(H,18,19)(H,21,24)(H,26,27)/b22-9+/t10-,14-/m1/s1
DMVL5RC CS C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=N/O)/C3=CSC(=N3)N)C(=O)O)SCC4=CNN=C4
DMVL5RC IK RNWMKMFWVBYAMX-KXDGEKGBSA-N
DMVL5RC IU (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-(1H-pyrazol-4-ylmethylsulfanyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMVL5RC DE Bacterial infection
DMB5HMS ID DMB5HMS
DMB5HMS DN FK-973
DMB5HMS HS Discontinued in Phase 1
DMB5HMS SN FK-973
DMB5HMS CP Fujisawa Pharmaceutical Co Ltd
DMB5HMS DT Small molecular drug
DMB5HMS PC 6917966
DMB5HMS MW 447.4
DMB5HMS FM C20H21N3O9
DMB5HMS IC InChI=1S/C20H21N3O9/c1-9(25)23-15-6-22-14-4-12(7-24)5-16(30-10(2)26)17(14)13(8-29-19(21)28)20(32-22,18(15)23)31-11(3)27/h4-5,7,13,15,18H,6,8H2,1-3H3,(H2,21,28)/t13-,15-,18-,20?,23?/m0/s1
DMB5HMS CS CC(=O)N1[C@@H]2[C@H]1C3([C@H](C4=C(C=C(C=C4OC(=O)C)C=O)N(C2)O3)COC(=O)N)OC(=O)C
DMB5HMS IK FBXPCVIKIBWXAE-GFUNNECNSA-N
DMB5HMS IU [(8R,10S,12S)-11-acetyl-9-acetyloxy-8-(carbamoyloxymethyl)-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-6-yl] acetate
DMB5HMS DE Solid tumour/cancer
DMKWTPX ID DMKWTPX
DMKWTPX DN FLM-5011
DMKWTPX HS Discontinued in Phase 1
DMKWTPX SN 1-(2-Hydroxy-5-methylphenyl)-1-dodecanone oxime; 2-Hydroxy-5-methylaurophenone oxime
DMKWTPX DT Small molecular drug
DMKWTPX PC 136029274
DMKWTPX MW 305.5
DMKWTPX FM C19H31NO2
DMKWTPX IC InChI=1S/C19H31NO2/c1-3-4-5-6-7-8-9-10-11-12-18(20-22)17-15-16(2)13-14-19(17)21/h13-15,21-22H,3-12H2,1-2H3/b20-18-
DMKWTPX CS CCCCCCCCCCC/C(=N/O)/C1=C(C=CC(=C1)C)O
DMKWTPX IK OOXQDZTUGOJLHK-ZZEZOPTASA-N
DMKWTPX IU 2-[(Z)-N-hydroxy-C-undecylcarbonimidoyl]-4-methylphenol
DMKWTPX CA CAS 105634-48-8
DMKWTPX DE Inflammation
DM5FW8Y ID DM5FW8Y
DM5FW8Y DN FR-158999
DM5FW8Y HS Discontinued in Phase 1
DM5FW8Y SN 4-[4-(4-Amidinophenoxy)butyryl-L-aspartyl-L-valyl]thiomorpholine S,S-dioxide
DM5FW8Y DT Small molecular drug
DM5FW8Y PC 178035
DM5FW8Y MW 553.6
DM5FW8Y FM C24H35N5O8S
DM5FW8Y IC InChI=1S/C24H35N5O8S/c1-15(2)21(24(34)29-9-12-38(35,36)13-10-29)28-23(33)18(14-20(31)32)27-19(30)4-3-11-37-17-7-5-16(6-8-17)22(25)26/h5-8,15,18,21H,3-4,9-14H2,1-2H3,(H3,25,26)(H,27,30)(H,28,33)(H,31,32)/t18-,21-/m0/s1
DM5FW8Y CS CC(C)[C@@H](C(=O)N1CCS(=O)(=O)CC1)NC(=O)[C@H](CC(=O)O)NC(=O)CCCOC2=CC=C(C=C2)C(=N)N
DM5FW8Y IK FPOQHPVEVPIFME-RXVVDRJESA-N
DM5FW8Y IU (3S)-3-[4-(4-carbamimidoylphenoxy)butanoylamino]-4-[[(2S)-1-(1,1-dioxo-1,4-thiazinan-4-yl)-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM5FW8Y CA CAS 160138-41-0
DM5FW8Y DE Thrombosis
DM69OR8 ID DM69OR8
DM69OR8 DN FR167653
DM69OR8 HS Discontinued in Phase 1
DM69OR8 SN HMPQTEPEMQZWQH-ROUUACIJSA-N; 2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE; AC1NR9VL; SCHEMBL15034365; 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-N-[(1S,2S)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-hydroxy-3-methylbutan-2-yl]acetamide; ONO-6818
DM69OR8 DT Small molecular drug
DM69OR8 PC 135484078
DM69OR8 MW 525.5
DM69OR8 FM C24H20FN5O6S
DM69OR8 IC InChI=1S/C24H18FN5O2.H2O4S/c25-19-8-6-17(7-9-19)21-20(16-10-12-26-13-11-16)23-28-30(15-14-29(23)27-21)24(32)22(31)18-4-2-1-3-5-18;1-5(2,3)4/h1-13,28H,14-15H2;(H2,1,2,3,4)
DM69OR8 CS C1CN(NC2=C(C(=NN21)C3=CC=C(C=C3)F)C4=CC=NC=C4)C(=O)C(=O)C5=CC=CC=C5.OS(=O)(=O)O
DM69OR8 IK KCPHXRBKBLJJJJ-UHFFFAOYSA-N
DM69OR8 IU 1-[7-(4-fluorophenyl)-8-pyridin-4-yl-3,4-dihydro-1H-pyrazolo[5,1-c][1,2,4]triazin-2-yl]-2-phenylethane-1,2-dione;sulfuric acid
DM69OR8 CA CAS 158876-66-5
DM69OR8 DE Chronic obstructive pulmonary disease
DMDW64X ID DMDW64X
DMDW64X DN FT-105
DMDW64X HS Discontinued in Phase 1
DMDW64X SN FT-105 (long-acting, Medusa), Flamel
DMDW64X CP Flamel Technologies SA
DMDW64X DE Diabetic complication
DMCZAJW ID DMCZAJW
DMCZAJW DN Garnocestim
DMCZAJW HS Discontinued in Phase 1
DMCZAJW SN SB-251353
DMCZAJW CP SmithKline Beecham plc
DMCZAJW DE Bone marrow transplantation
DM041IZ ID DM041IZ
DM041IZ DN GED-aPC
DM041IZ HS Discontinued in Phase 1
DM041IZ SN LY458202; LY-458202
DM041IZ CP Eli Lilly
DM041IZ DE Cardiovascular disease
DMNFWR1 ID DMNFWR1
DMNFWR1 DN Gedocarnil
DMNFWR1 HS Discontinued in Phase 1
DMNFWR1 SN SH-530
DMNFWR1 CP Bayer Schering Pharma AG
DMNFWR1 DT Small molecular drug
DMNFWR1 PC 219095
DMNFWR1 MW 424.9
DMNFWR1 FM C23H21ClN2O4
DMNFWR1 IC InChI=1S/C23H21ClN2O4/c1-13(2)29-23(27)22-16(12-28-3)20-18(11-25-22)26-17-5-4-6-19(21(17)20)30-15-9-7-14(24)8-10-15/h4-11,13,26H,12H2,1-3H3
DMNFWR1 CS CC(C)OC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC=C3OC4=CC=C(C=C4)Cl
DMNFWR1 IK SLYDYLLJUXFULK-UHFFFAOYSA-N
DMNFWR1 IU propan-2-yl 5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylate
DMNFWR1 CA CAS 109623-97-4
DMNFWR1 DE Anxiety disorder
DM4ZDVY ID DM4ZDVY
DM4ZDVY DN Gem 92
DM4ZDVY HS Discontinued in Phase 1
DM4ZDVY CP Idera Pharmaceuticals
DM4ZDVY TC Antisense
DM4ZDVY DT Antisense drug
DM4ZDVY DE Human immunodeficiency virus-1 infection
DM520D8 ID DM520D8
DM520D8 DN Gevotroline
DM520D8 HS Discontinued in Phase 1
DM520D8 SN Carvotroline; Carvotroline hydrochloride; Gevotroline hydrochloride; WY-47384; WY-47791; Wy-46320
DM520D8 CP Wyeth; Wyeth-Ayerst Pharmaceuticals Inc
DM520D8 DT Small molecular drug
DM520D8 PC 60547
DM520D8 MW 309.4
DM520D8 FM C19H20FN3
DM520D8 IC InChI=1S/C19H20FN3/c20-15-5-6-18-16(11-15)17-13-23(10-7-19(17)22-18)9-2-4-14-3-1-8-21-12-14/h1,3,5-6,8,11-12,22H,2,4,7,9-10,13H2
DM520D8 CS C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCCC4=CN=CC=C4
DM520D8 IK RZXHTPCHKSYGIB-UHFFFAOYSA-N
DM520D8 IU 8-fluoro-2-(3-pyridin-3-ylpropyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole
DM520D8 CA CAS 107266-06-8
DM520D8 CB CHEBI:142391
DM520D8 DE Psychotic disorder
DMSGUY9 ID DMSGUY9
DMSGUY9 DN Goxalapladib
DMSGUY9 HS Discontinued in Phase 1
DMSGUY9 SN Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide; 677116
DMSGUY9 DT Small molecular drug
DMSGUY9 PC 11686305
DMSGUY9 MW 718.8
DMSGUY9 FM C40H39F5N4O3
DMSGUY9 IC InChI=1S/C40H39F5N4O3/c1-52-23-22-47-20-17-32(18-21-47)48(25-27-7-9-28(10-8-27)29-11-14-31(15-12-29)40(43,44)45)37(51)26-49-33(16-13-30-4-2-6-35(41)38(30)42)24-36(50)34-5-3-19-46-39(34)49/h2-12,14-15,19,24,32H,13,16-18,20-23,25-26H2,1H3
DMSGUY9 CS COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C(=CC(=O)C5=C4N=CC=C5)CCC6=C(C(=CC=C6)F)F
DMSGUY9 IK OBJKLVFDRLAGJI-UHFFFAOYSA-N
DMSGUY9 IU 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DMSGUY9 CA CAS 412950-27-7
DMSGUY9 DE Arteriosclerosis
DMRNI6K ID DMRNI6K
DMRNI6K DN GR-127607
DMRNI6K HS Discontinued in Phase 1
DMRNI6K CP Glaxo Group Research Ltd
DMRNI6K DE Migraine
DMWY2F6 ID DMWY2F6
DMWY2F6 DN GR-253035
DMWY2F6 HS Discontinued in Phase 1
DMWY2F6 CP Glaxo Wellcome plc
DMWY2F6 DE Alzheimer disease
DMUANK9 ID DMUANK9
DMUANK9 DN GR-328713
DMUANK9 HS Discontinued in Phase 1
DMUANK9 SN GW-320449X; GW-328713X
DMUANK9 CP Glaxo Wellcome plc
DMUANK9 DE Arteriosclerosis
DM13GK8 ID DM13GK8
DM13GK8 DN GR-63799X
DM13GK8 HS Discontinued in Phase 1
DM13GK8 SN (-)-[1(R)-[1alpha(Z),2beta(R*),3alpha]-7-[3-Hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]-4-heptenoic acid 4-(benzoylamino)phenyl ester; (Z)-4,5-Didehydro-13-oxa-16-phenoxy-13,14-dihydro-17,18,19,20-tetranor-PGE1 4-(benzoylamino)phenyl ester; 119906-28-4
DM13GK8 DT Small molecular drug
DM13GK8 PC 6439068
DM13GK8 MW 587.7
DM13GK8 FM C34H37NO8
DM13GK8 IC InChI=1S/C34H37NO8/c36-26(22-41-27-13-7-4-8-14-27)23-42-33-29(30(37)21-31(33)38)15-9-1-2-10-16-32(39)43-28-19-17-25(18-20-28)35-34(40)24-11-5-3-6-12-24/h1-8,11-14,17-20,26,29,31,33,36,38H,9-10,15-16,21-23H2,(H,35,40)/b2-1-/t26?,29-,31+,33+/m0/s1
DM13GK8 CS C1[C@H]([C@@H]([C@H](C1=O)CC/C=C\\CCC(=O)OC2=CC=C(C=C2)NC(=O)C3=CC=CC=C3)OCC(COC4=CC=CC=C4)O)O
DM13GK8 IK QQTQLHVRUZWVQZ-WYFSZTNASA-N
DM13GK8 IU (4-benzamidophenyl) (Z)-7-[(1R,2R,3R)-3-hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl]hept-4-enoate
DM13GK8 CA CAS 106342-69-2
DM13GK8 DE Asthma
DM9C1LQ ID DM9C1LQ
DM9C1LQ DN GR-79236
DM9C1LQ HS Discontinued in Phase 1
DM9C1LQ SN GR79236; 124555-18-6; GR-79236; GR 79236; UNII-Q4H682B2VZ; GR 79236X; N-((1S,trans)-2-Hydroxycyclopentyl)adenosine; Q4H682B2VZ; CHEMBL2163568; N-((1S,2S)-2-Hydroxycyclopentyl)adenosine; N-[(1S, trans)-2-Hydroxycyclopentyl]adenosine; N-[(1S,2S)-2-Hydroxycyclopentyl]adenosine; N-[(1S,trans)-2-hydroxycyclopentyl]adenosine; Adenosine, N-(2-hydroxycyclopentyl)-, (1S-trans)-; gr79236x; SCHEMBL2779184; GTPL3288; CHEBI:92714; DTXSID10154427; MolPort-023-276-288; GYWXTRVEUURNEW-TVDBPQCTSA-N; HMS3268O08; ZINC3794575; MFCD00884605
DM9C1LQ CP Glaxo Group Research Ltd
DM9C1LQ DT Small molecular drug
DM9C1LQ PC 9884817
DM9C1LQ MW 351.36
DM9C1LQ FM C15H21N5O5
DM9C1LQ IC InChI=1S/C15H21N5O5/c21-4-9-11(23)12(24)15(25-9)20-6-18-10-13(16-5-17-14(10)20)19-7-2-1-3-8(7)22/h5-9,11-12,15,21-24H,1-4H2,(H,16,17,19)/t7-,8-,9+,11+,12+,15+/m0/s1
DM9C1LQ CS C1C[C@@H]([C@H](C1)O)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM9C1LQ IK GYWXTRVEUURNEW-TVDBPQCTSA-N
DM9C1LQ IU (2R,3R,4S,5R)-2-[6-[[(1S,2S)-2-hydroxycyclopentyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM9C1LQ CA CAS 124555-18-6
DM9C1LQ CB CHEBI:92714
DM9C1LQ DE Diabetic complication
DMEC6RD ID DMEC6RD
DMEC6RD DN GSK1004723
DMEC6RD HS Discontinued in Phase 1
DMEC6RD SN CHEMBL1767168; SCHEMBL2819051
DMEC6RD CP GSK
DMEC6RD DT Small molecular drug
DMEC6RD PC 17747460
DMEC6RD MW 641.3
DMEC6RD FM C39H49ClN4O2
DMEC6RD IC InChI=1S/C39H49ClN4O2/c40-33-19-15-32(16-20-33)29-38-36-13-3-4-14-37(36)39(45)44(41-38)30-34-12-9-27-43(34)26-8-5-11-31-17-21-35(22-18-31)46-28-10-25-42-23-6-1-2-7-24-42/h3-4,13-22,34H,1-2,5-12,23-30H2/t34-/m1/s1
DMEC6RD CS C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
DMEC6RD IK YANGEESWIGIKOP-UUWRZZSWSA-N
DMEC6RD IU 2-[[(2R)-1-[4-[4-[3-(azepan-1-yl)propoxy]phenyl]butyl]pyrrolidin-2-yl]methyl]-4-[(4-chlorophenyl)methyl]phthalazin-1-one
DMEC6RD CA CAS 955359-72-5
DMEC6RD DE Allergic rhinitis
DM7ACJ4 ID DM7ACJ4
DM7ACJ4 DN GSK1018921
DM7ACJ4 HS Discontinued in Phase 1
DM7ACJ4 CP GSK
DM7ACJ4 DE Schizophrenia
DMI6KQM ID DMI6KQM
DMI6KQM DN GSK1059615
DMI6KQM HS Discontinued in Phase 1
DMI6KQM SN KS-00001CUQ; CTK8F0346; HMS3654N17; BCP02498; AKOS026750445; NCGC00346509-01; FT-0669060
DMI6KQM CP GlaxoSmithKline
DMI6KQM DT Small molecular drug
DMI6KQM PC 23582824
DMI6KQM MW 333.4
DMI6KQM FM C18H11N3O2S
DMI6KQM IC InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)/b16-10-
DMI6KQM CS C1=CC2=NC=CC(=C2C=C1/C=C\\3/C(=O)NC(=O)S3)C4=CC=NC=C4
DMI6KQM IK QDITZBLZQQZVEE-YBEGLDIGSA-N
DMI6KQM IU (5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione
DMI6KQM CA CAS 958852-01-2
DMI6KQM CB CHEBI:71955
DMI6KQM DE Lymphoma; Endometrial cancer; Breast cancer
DMBXYKG ID DMBXYKG
DMBXYKG DN GSK-1362885
DMBXYKG HS Discontinued in Phase 1
DMBXYKG SN 1362885
DMBXYKG CP GlaxoSmithKline plc
DMBXYKG DE Type-2 diabetes
DMM7Q3L ID DMM7Q3L
DMM7Q3L DN GSK2849466
DMM7Q3L HS Discontinued in Phase 1
DMM7Q3L CP Glaxosmithkline
DMM7Q3L DE Heart failure
DM6E84O ID DM6E84O
DM6E84O DN GSK568859
DM6E84O HS Discontinued in Phase 1
DM6E84O CP GlaxoSmithKline
DM6E84O DE Arteriosclerosis
DMRTPY6 ID DMRTPY6
DMRTPY6 DN GSK729327
DMRTPY6 HS Discontinued in Phase 1
DMRTPY6 CP GSK
DMRTPY6 DE Schizophrenia
DM2AP64 ID DM2AP64
DM2AP64 DN GSK945237
DM2AP64 HS Discontinued in Phase 1
DM2AP64 CP GSK
DM2AP64 DE Bacterial infection
DMWJZAP ID DMWJZAP
DMWJZAP DN GW-250495
DMWJZAP HS Discontinued in Phase 1
DMWJZAP SN GR-250495; GR-250495X; GW-250495X
DMWJZAP CP Glaxo Wellcome plc
DMWJZAP DE Asthma
DM62T1C ID DM62T1C
DM62T1C DN GW-311616
DM62T1C HS Discontinued in Phase 1
DM62T1C SN XVDWNSFFSMWXJJ-BDRHRQAXSA-N; UNII-HN0T99OO4V component XVDWNSFFSMWXJJ-BDRHRQAXSA-N; N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl) ethyl]amino]methyl]phenyl]-2E-2-propenamide D-(-)-lactate salt; n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide d-(-)-lactate salt
DM62T1C DT Small molecular drug
DM62T1C PC 9800961
DM62T1C MW 397.5
DM62T1C FM C19H31N3O4S
DM62T1C IC InChI=1S/C19H31N3O4S/c1-14(2)17-18-15(22(19(17)24)27(3,25)26)9-13-21(18)16(23)8-7-12-20-10-5-4-6-11-20/h7-8,14-15,17-18H,4-6,9-13H2,1-3H3/b8-7+/t15-,17+,18-/m1/s1
DM62T1C CS CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)/C=C/CN3CCCCC3)N(C1=O)S(=O)(=O)C
DM62T1C IK NDNKNUMSTIMSHQ-URZKGLGPSA-N
DM62T1C IU (3aR,6S,6aS)-4-methylsulfonyl-1-[(E)-4-piperidin-1-ylbut-2-enoyl]-6-propan-2-yl-3,3a,6,6a-tetrahydro-2H-pyrrolo[3,2-b]pyrrol-5-one
DM62T1C CA CAS 198062-54-3
DMRQVI9 ID DMRQVI9
DMRQVI9 DN GW-473178
DMRQVI9 HS Discontinued in Phase 1
DMRQVI9 SN 473178
DMRQVI9 CP Glaxo Wellcome plc
DMRQVI9 DE Heart arrhythmia
DMQNX02 ID DMQNX02
DMQNX02 DN GYKI-12743
DMQNX02 HS Discontinued in Phase 1
DMQNX02 SN GYKI-12743; Gyki 12743; GKYI-12743; 110714-10-8; 2-(3-(Benzo(1,4)dioxan-2-ylmethylamino)-1-propyl)-3(2H)-pyridazinone hydrochloride; 2-{3-[(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)amino]propyl}pyridazin-3(2h)-one hydrochloride(1:1); 133983-22-9; 3(2H)-Pyridazinone, 2-[3-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]propyl]-, hydrochloride (1:1); 3(2H)-Pyridazinone, 2-(3-(((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)amino)propyl)-, monohydrochloride; AC1Q3EJF; AC1L4TO4; SCHEMBL7284667; CTK4B8909; LS-129872
DMQNX02 CP Gedeon Richter Ltd
DMQNX02 DT Small molecular drug
DMQNX02 PC 163825
DMQNX02 MW 337.8
DMQNX02 FM C16H20ClN3O3
DMQNX02 IC InChI=1S/C16H19N3O3.ClH/c20-16-7-3-9-18-19(16)10-4-8-17-11-13-12-21-14-5-1-2-6-15(14)22-13;/h1-3,5-7,9,13,17H,4,8,10-12H2;1H
DMQNX02 CS C1C(OC2=CC=CC=C2O1)CNCCCN3C(=O)C=CC=N3.Cl
DMQNX02 IK WJDFSAOMSJHHCG-UHFFFAOYSA-N
DMQNX02 IU 2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]pyridazin-3-one;hydrochloride
DMQNX02 CA CAS 110714-10-8
DMQNX02 DE Hypertension
DM2RF06 ID DM2RF06
DM2RF06 DN HCV-086
DM2RF06 HS Discontinued in Phase 1
DM2RF06 SN VP-18344
DM2RF06 CP ViroPharma; ViroPharma Inc
DM2RF06 DT Small molecular drug
DM2RF06 PC 10409873
DM2RF06 MW 420.5
DM2RF06 FM C20H21FN2O5S
DM2RF06 IC InChI=1S/C20H21FN2O5S/c1-11(2)27-17-9-14-16(10-15(17)23-29(4,25)26)28-19(18(14)20(24)22-3)12-5-7-13(21)8-6-12/h5-11,23H,1-4H3,(H,22,24)
DM2RF06 CS CC(C)OC1=C(C=C2C(=C1)C(=C(O2)C3=CC=C(C=C3)F)C(=O)NC)NS(=O)(=O)C
DM2RF06 IK VBRUONUESYTIDA-UHFFFAOYSA-N
DM2RF06 IU 2-(4-fluorophenyl)-6-(methanesulfonamido)-N-methyl-5-propan-2-yloxy-1-benzofuran-3-carboxamide
DM2RF06 DE Hepatitis virus infection
DMCP2KH ID DMCP2KH
DMCP2KH DN HE2100
DMCP2KH HS Discontinued in Phase 1
DMCP2KH SN Androstenediol; Hermaphrodiol; 5-Androstenediol; Androst-5-enediol; 521-17-5; Androst-5-ene-3beta,17beta-diol; Neumune; 3beta,17beta-Dihydroxyandrost-5-ene; delta(sup 5)-Androstenediol; Androstenediol [JAN]; UNII-95PS51EMXY; Androst-5-enediol (VAN); (3beta,17beta)-androst-5-ene-3,17-diol; 5-AED; 3beta,17beta-Dihydroxy-5-androstene; androst-5-en-3beta,17beta-diol; EINECS 208-306-8; NSC 12163; 95PS51EMXY; ANDROST-5-ENE-3-beta,17-beta-DIOL; CHEMBL440283; CHEBI:2710; (3-beta,17-beta)-Androst-5-ene-3,17-diol; delta(sup; ANDROSTENEDIOL
DMCP2KH CP Hollis-Eden Pharmaceuticals
DMCP2KH DT Small molecular drug
DMCP2KH PC 10634
DMCP2KH MW 290.4
DMCP2KH FM C19H30O2
DMCP2KH IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
DMCP2KH CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC=C4[C@@]3(CC[C@@H](C4)O)C
DMCP2KH IK QADHLRWLCPCEKT-LOVVWNRFSA-N
DMCP2KH IU (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
DMCP2KH CA CAS 521-17-5
DMCP2KH CB CHEBI:2710
DMCP2KH DE Thrombocytopenia
DM0W2TA ID DM0W2TA
DM0W2TA DN HGS-TR2J
DM0W2TA HS Discontinued in Phase 1
DM0W2TA SN KMTR2; Trail-R2 human antibody; TRAIL-R2 mAbs, HGS/Kirin; TRAIL-R2 monoclonal antibody (cancer), Human Genome Sciences/Kirin; TRAIL-R2 monoclonal antibody (cancer), Human Genome Sciences/Kyowa Hakko Kirin
DM0W2TA CP Kirin Brewery Co Ltd
DM0W2TA DT Antibody
DM0W2TA DE Solid tumour/cancer
DMH4ANG ID DMH4ANG
DMH4ANG DN HMN-214
DMH4ANG HS Discontinued in Phase 1
DMH4ANG SN N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
DMH4ANG CP Nippon Shinyaku
DMH4ANG TC Anticancer Agents
DMH4ANG DT Small molecular drug
DMH4ANG PC 9888590
DMH4ANG MW 424.5
DMH4ANG FM C22H20N2O5S
DMH4ANG IC InChI=1S/C22H20N2O5S/c1-17(25)24(30(27,28)21-11-9-20(29-2)10-12-21)22-6-4-3-5-19(22)8-7-18-13-15-23(26)16-14-18/h3-16H,1-2H3/b8-7+
DMH4ANG CS CC(=O)N(C1=CC=CC=C1/C=C/C2=CC=[N+](C=C2)[O-])S(=O)(=O)C3=CC=C(C=C3)OC
DMH4ANG IK OCKHRKSTDPOHEN-BQYQJAHWSA-N
DMH4ANG IU N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide
DMH4ANG CA CAS 173529-46-9
DMH4ANG CB CHEBI:91440
DMH4ANG DE Prostate cancer; Pancreatic cancer
DMKA612 ID DMKA612
DMKA612 DN HMR-3562
DMKA612 HS Discontinued in Phase 1
DMKA612 SN 11-Deoxy-3-des(hexopyranosyloxy)-2-fluoro-11-[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butylamino]-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate
DMKA612 DT Small molecular drug
DMKA612 PC 6918484
DMKA612 MW 830
DMKA612 FM C43H64FN5O10
DMKA612 IC InChI=1S/C43H64FN5O10/c1-12-32-43(8)35(49(40(54)59-43)19-14-13-18-48-23-30(46-24-48)29-16-15-17-45-22-29)27(4)33(50)25(2)21-41(6,55-11)37(28(5)36(52)42(7,44)39(53)57-32)58-38-34(51)31(47(9)10)20-26(3)56-38/h15-17,22-28,31-32,34-35,37-38,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
DMKA612 CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
DMKA612 IK RSIQCUSPSFSWMQ-XXTFOGKVSA-N
DMKA612 IU (1S,2R,5S,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMKA612 DE Bacterial infection
DMQOW8H ID DMQOW8H
DMQOW8H DN HO-221
DMQOW8H HS Discontinued in Phase 1
DMQOW8H SN N-(2-Nitrobenzoyl)-N'-[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]urea; N-[4-(5-Bromo-2-pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoyl)urea
DMQOW8H DT Small molecular drug
DMQOW8H PC 128803
DMQOW8H MW 492.7
DMQOW8H FM C18H11BrClN5O5
DMQOW8H IC InChI=1S/C18H11BrClN5O5/c19-10-8-21-18(22-9-10)30-15-6-5-11(7-13(15)20)23-17(27)24-16(26)12-3-1-2-4-14(12)25(28)29/h1-9H,(H2,23,24,26,27)
DMQOW8H CS C1=CC=C(C(=C1)C(=O)NC(=O)NC2=CC(=C(C=C2)OC3=NC=C(C=N3)Br)Cl)[N+](=O)[O-]
DMQOW8H IK WKXWMGOTZJGIIK-UHFFFAOYSA-N
DMQOW8H IU N-[[4-(5-bromopyrimidin-2-yl)oxy-3-chlorophenyl]carbamoyl]-2-nitrobenzamide
DMQOW8H CA CAS 105128-93-6
DMQOW8H DE Virus infection
DMNC1A3 ID DMNC1A3
DMNC1A3 DN HOE-065
DMNC1A3 HS Discontinued in Phase 1
DMNC1A3 SN 2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid n-octyl ester maleate
DMNC1A3 DT Small molecular drug
DMNC1A3 PC 6444220
DMNC1A3 MW 644.8
DMNC1A3 FM C35H52N2O9
DMNC1A3 IC InChI=1S/C31H48N2O5.C4H4O4/c1-4-6-7-8-9-13-21-38-31(36)28-22-25-17-14-18-27(25)33(28)29(34)23(3)32-26(30(35)37-5-2)20-19-24-15-11-10-12-16-24;5-3(6)1-2-4(7)8/h10-12,15-16,23,25-28,32H,4-9,13-14,17-22H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-,25-,26-,27-,28-;/m0./s1
DMNC1A3 CS CCCCCCCCOC(=O)[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC.C(=C/C(=O)O)\\C(=O)O
DMNC1A3 IK RCEDCOCCCMIKCY-ZVCJTHDASA-N
DMNC1A3 IU (E)-but-2-enedioic acid;octyl (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylate
DMNC1A3 CA CAS 123060-44-6
DMNC1A3 DE Cognitive impairment
DMH32LM ID DMH32LM
DMH32LM DN HRC-302
DMH32LM HS Discontinued in Phase 1
DMH32LM SN HML-115; XL-2; Cell therapy, X-Cell Biotech; GDT-CML, Hemosol; Stem cells, X-Cell Biotech; Gamma delta T-cells (selectively expanded), Hemosol; GDT-CML (HRC-302-expanded), Hemosol
DMH32LM CP Ontario Inc
DMH32LM DE Chronic myelogenous leukaemia
DMQYWAH ID DMQYWAH
DMQYWAH DN HRT
DMQYWAH HS Discontinued in Phase 1
DMQYWAH SN HRT (oral); IP-1162; IP-1163; IP-1164; HRT (oral), Shire
DMQYWAH CP Shire Pharmaceutical Development Ltd
DMQYWAH DE Estrogen deficiency
DMCS06R ID DMCS06R
DMCS06R DN HSR-6071
DMCS06R HS Discontinued in Phase 1
DMCS06R SN PTPC; 6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazine-2-carboxamide
DMCS06R DT Small molecular drug
DMCS06R PC 159466
DMCS06R MW 260.26
DMCS06R FM C10H12N8O
DMCS06R IC InChI=1S/C10H12N8O/c19-9(13-10-14-16-17-15-10)7-5-11-6-8(12-7)18-3-1-2-4-18/h5-6H,1-4H2,(H2,13,14,15,16,17,19)
DMCS06R CS C1CCN(C1)C2=NC(=CN=C2)C(=O)NC3=NNN=N3
DMCS06R IK LUJDHCXCWJFNOJ-UHFFFAOYSA-N
DMCS06R IU 6-pyrrolidin-1-yl-N-(2H-tetrazol-5-yl)pyrazine-2-carboxamide
DMCS06R CA CAS 111374-21-1
DMCS06R DE Asthma
DMUPOIG ID DMUPOIG
DMUPOIG DN HT-1067
DMUPOIG HS Discontinued in Phase 1
DMUPOIG SN MOA-B inhibitor (memory impairement) Helicon; MOA-B inhibitor (cognitive disorder/Parkinson's Disease) Helicon
DMUPOIG CP Dart neuroscience
DMUPOIG DE Parkinson disease
DM9LY4Q ID DM9LY4Q
DM9LY4Q DN HuMV833
DM9LY4Q HS Discontinued in Phase 1
DM9LY4Q SN Anti-VEGF antibody, Toagosei; MAb (cancer), Toagosei; SMART anti-VEGF MAb, Protein Design Labs; SMART anti-VEGF, Toagosei/PDL
DM9LY4Q CP Toagosei Co Ltd
DM9LY4Q DT Antibody
DM9LY4Q DE Solid tumour/cancer
DMZYA9E ID DMZYA9E
DMZYA9E DN ICI-D-6888
DMZYA9E HS Discontinued in Phase 1
DMZYA9E SN ZD-6888
DMZYA9E CP Zeneca Group plc
DMZYA9E PC 19935771
DMZYA9E MW 448
DMZYA9E FM C25H26ClN5O
DMZYA9E IC InChI=1S/C25H25N5O.ClH/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25;/h3-4,7-8,11-15H,2,5-6,9-10,16H2,1H3,(H,27,28,29,30);1H
DMZYA9E CS CCC1=CC(=C2CCCCC2=N1)OCC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5.Cl
DMZYA9E IK RPRNBLHRKYAXSM-UHFFFAOYSA-N
DMZYA9E IU 2-ethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]-5,6,7,8-tetrahydroquinoline;hydrochloride
DMZYA9E CA CAS 138620-17-4
DMZYA9E DE Hypertension
DMAU79Q ID DMAU79Q
DMAU79Q DN IDEC-131
DMAU79Q HS Discontinued in Phase 1
DMAU79Q CP Biogen Idec
DMAU79Q DT Antibody
DMAU79Q DE Thrombocytopenia
DMP8MBW ID DMP8MBW
DMP8MBW DN IGANIDIPINE HYDROCHLORIDE
DMP8MBW HS Discontinued in Phase 1
DMP8MBW SN NKY-722; Iganidipine hydrochloride; Rac-2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl] 5-methyl diester dihydrochloride
DMP8MBW DT Small molecular drug
DMP8MBW PC 164031
DMP8MBW MW 599.5
DMP8MBW FM C28H40Cl2N4O6
DMP8MBW IC InChI=1S/C28H38N4O6.2ClH/c1-7-11-30-12-14-31(15-13-30)17-28(4,5)18-38-27(34)24-20(3)29-19(2)23(26(33)37-6)25(24)21-9-8-10-22(16-21)32(35)36;;/h7-10,16,25,29H,1,11-15,17-18H2,2-6H3;2*1H
DMP8MBW CS CC1=C(C(C(=C(N1)C)C(=O)OCC(C)(C)CN2CCN(CC2)CC=C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC.Cl.Cl
DMP8MBW IK PJGTYHKZUAHNHC-UHFFFAOYSA-N
DMP8MBW IU 5-O-[2,2-dimethyl-3-(4-prop-2-enylpiperazin-1-yl)propyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;dihydrochloride
DMP8MBW CA CAS 117241-46-0
DMP8MBW DE Glaucoma/ocular hypertension
DMRSJ49 ID DMRSJ49
DMRSJ49 DN IL-18BP
DMRSJ49 HS Discontinued in Phase 1
DMRSJ49 CP Yeda; Merck Serono
DMRSJ49 DE Rheumatoid arthritis; B-cell non-hodgkin lymphoma
DMQIXD2 ID DMQIXD2
DMQIXD2 DN IMC-1C11
DMQIXD2 HS Discontinued in Phase 1
DMQIXD2 DT Antibody
DMQIXD2 DE Solid tumour/cancer
DM8OYZB ID DM8OYZB
DM8OYZB DN Imepitoin
DM8OYZB HS Discontinued in Phase 1
DM8OYZB SN ADD-233089; AWD-131-138
DM8OYZB CP ASTA Medica AG
DM8OYZB DT Small molecular drug
DM8OYZB PC 3083511
DM8OYZB MW 279.72
DM8OYZB FM C13H14ClN3O2
DM8OYZB IC InChI=1S/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4H,5-9H2
DM8OYZB CS C1COCCN1C2=NC(=O)N(C2)C3=CC=C(C=C3)Cl
DM8OYZB IK IQHYCZKIFIHTAI-UHFFFAOYSA-N
DM8OYZB IU 3-(4-chlorophenyl)-5-morpholin-4-yl-4H-imidazol-2-one
DM8OYZB CA CAS 188116-07-6
DM8OYZB DE Convulsion
DMFACQU ID DMFACQU
DMFACQU DN IMS
DMFACQU HS Discontinued in Phase 1
DMFACQU SN INO-2002
DMFACQU CP Inotek Pharmaceuticals
DMFACQU DT Small molecular drug
DMFACQU PC 13551
DMFACQU MW 138.19
DMFACQU FM C4H10O3S
DMFACQU IC InChI=1S/C4H10O3S/c1-4(2)7-8(3,5)6/h4H,1-3H3
DMFACQU CS CC(C)OS(=O)(=O)C
DMFACQU IK SWWHCQCMVCPLEQ-UHFFFAOYSA-N
DMFACQU IU propan-2-yl methanesulfonate
DMFACQU CA CAS 926-06-7
DMFACQU DE Inflammatory bowel disease
DM8PTUC ID DM8PTUC
DM8PTUC DN INCB8696
DM8PTUC HS Discontinued in Phase 1
DM8PTUC CP Incyte
DM8PTUC DE Multiple sclerosis
DMGCUTI ID DMGCUTI
DMGCUTI DN INOC-002
DMGCUTI HS Discontinued in Phase 1
DMGCUTI SN Chemotherapy potentiator (colon cancer), Innovate Oncology
DMGCUTI CP Targent Inc
DMGCUTI DE Solid tumour/cancer
DMCF0XK ID DMCF0XK
DMCF0XK DN IPI-493
DMCF0XK HS Discontinued in Phase 1
DMCF0XK SN [(3R,5R,6S,7R,8E,10R,11R,12Z,14E)-21-amino-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; AC1NS08X; SCHEMBL16226496; SCHEMBL16225851
DMCF0XK CP AstraZeneca
DMCF0XK DT Small molecular drug
DMCF0XK PC 9893658
DMCF0XK MW 545.6
DMCF0XK FM C28H39N3O8
DMCF0XK IC InChI=1S/C28H39N3O8/c1-14-10-18-23(29)20(32)13-19(25(18)34)31-27(35)15(2)8-7-9-21(37-5)26(39-28(30)36)17(4)12-16(3)24(33)22(11-14)38-6/h7-9,12-14,16,21-22,24,26,33H,10-11,29H2,1-6H3,(H2,30,36)(H,31,35)/b9-7-,15-8+,17-12+/t14-,16+,21+,22+,24-,26+/m1/s1
DMCF0XK CS C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=O)C(=C(C1)C2=O)N)/C)OC)OC(=O)N)\\C)C)O)OC
DMCF0XK IK XYFFWTYOFPSZRM-TWNAANEASA-N
DMCF0XK IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-amino-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
DMCF0XK CA CAS 64202-81-9
DMCF0XK DE Gastric adenocarcinoma
DM8139E ID DM8139E
DM8139E DN ITAMELINE
DM8139E HS Discontinued in Phase 1
DM8139E SN RU-47213; Itameline; (E)-3-[(Methoxyimino)methyl]-1,2,5,6-tetrahydropyridine-1-carboxylic acid 4-chlorophenyl ester
DM8139E DT Small molecular drug
DM8139E PC 9571042
DM8139E MW 294.73
DM8139E FM C14H15ClN2O3
DM8139E IC InChI=1S/C14H15ClN2O3/c1-19-16-9-11-3-2-8-17(10-11)14(18)20-13-6-4-12(15)5-7-13/h3-7,9H,2,8,10H2,1H3/b16-9+
DM8139E CS CO/N=C/C1=CCCN(C1)C(=O)OC2=CC=C(C=C2)Cl
DM8139E IK CTVQNEVLCGSTKL-CXUHLZMHSA-N
DM8139E IU (4-chlorophenyl) 5-[(E)-methoxyiminomethyl]-3,6-dihydro-2H-pyridine-1-carboxylate
DM8139E CA CAS 121750-57-0
DM8139E DE Cognitive impairment
DMUNYR7 ID DMUNYR7
DMUNYR7 DN JTK-109
DMUNYR7 HS Discontinued in Phase 1
DMUNYR7 SN CHEMBL379677; 2-[4-(benzyloxy)phenyl]-1-cyclohexyl-1h-benzimidazole-5-carboxylic acid; AC1LAMB2; SCHEMBL791364; CTK7I8521; GWCTUYUNVJTNJR-UHFFFAOYSA-N; MolPort-039-347-685; BDBM50181950; ZINC28572342; AKOS027470656; 2-(4-benzyloxyphenyl)-1-cyclohexyl-benzimidazole-5-carboxylic acid; 1-cyclohexyl-2-(4-phenylmethoxyphenyl)benzimidazole-5-carboxylic acid; 2-(4-(benzyloxy)phenyl)-1-cyclohexyl-1H-benzo[d]imidazole-5-carboxylic acid; 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-
DMUNYR7 CP Japan Tobacco Inc
DMUNYR7 DT Small molecular drug
DMUNYR7 PC 491098
DMUNYR7 MW 426.5
DMUNYR7 FM C27H26N2O3
DMUNYR7 IC InChI=1S/C27H26N2O3/c30-27(31)21-13-16-25-24(17-21)28-26(29(25)22-9-5-2-6-10-22)20-11-14-23(15-12-20)32-18-19-7-3-1-4-8-19/h1,3-4,7-8,11-17,22H,2,5-6,9-10,18H2,(H,30,31)
DMUNYR7 CS C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)O)N=C2C4=CC=C(C=C4)OCC5=CC=CC=C5
DMUNYR7 IK GWCTUYUNVJTNJR-UHFFFAOYSA-N
DMUNYR7 IU 1-cyclohexyl-2-(4-phenylmethoxyphenyl)benzimidazole-5-carboxylic acid
DMUNYR7 DE Hepatitis C virus infection
DMZFEY1 ID DMZFEY1
DMZFEY1 DN JTK-652
DMZFEY1 HS Discontinued in Phase 1
DMZFEY1 SN HCV NS5B polymerase inhibitors (JTK-109 derivatives), Japan Tobacco; JTK-109 derivatives (HCV), Japan Tobacco
DMZFEY1 CP Japan Tobacco Inc
DMZFEY1 DE Hepatitis C virus infection
DMEADBG ID DMEADBG
DMEADBG DN JTK-656
DMEADBG HS Discontinued in Phase 1
DMEADBG CP Japan Tobacco Inc
DMEADBG DE Human immunodeficiency virus infection
DM64FX9 ID DM64FX9
DM64FX9 DN JTK-853
DM64FX9 HS Discontinued in Phase 1
DM64FX9 SN JTK-853; UNII-WDX8QQD13B; WDX8QQD13B; 954389-09-4; (2r)-4-(5-Cyclopropyl[1,3]thiazolo[4,5-D]pyrimidin-2-Yl)-N-[3-Fluoro-4-(Trifluoromethoxy)benzyl]-1-{[4-(Trifluoromethyl)phenyl]sulfonyl}piperazine-2-Carboxamide; 3vqs; JTK 853; SCHEMBL2440999; DTXSID60241836; JQLOVYLALGSISI-HXUWFJFHSA-N; DB13095; HY-19921; 2-Piperazinecarboxamide, 4-(5-cyclopropylthiazolo(4,5-d)pyrimidin-2-yl)-n-((3-fluoro-4-(trifluoromethoxy)phenyl)methyl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)-, (2R)-; CS-0016935; JT1
DM64FX9 CP Japan Tobacco Inc
DM64FX9 DT Small molecular drug
DM64FX9 PC 57519700
DM64FX9 MW 704.6
DM64FX9 FM C28H23F7N6O4S2
DM64FX9 IC InChI=1S/C28H23F7N6O4S2/c29-19-11-15(1-8-21(19)45-28(33,34)35)12-37-25(42)20-14-40(26-39-24-22(46-26)13-36-23(38-24)16-2-3-16)9-10-41(20)47(43,44)18-6-4-17(5-7-18)27(30,31)32/h1,4-8,11,13,16,20H,2-3,9-10,12,14H2,(H,37,42)/t20-/m1/s1
DM64FX9 CS C1CC1C2=NC=C3C(=N2)N=C(S3)N4CCN([C@H](C4)C(=O)NCC5=CC(=C(C=C5)OC(F)(F)F)F)S(=O)(=O)C6=CC=C(C=C6)C(F)(F)F
DM64FX9 IK JQLOVYLALGSISI-HXUWFJFHSA-N
DM64FX9 IU (2R)-4-(5-cyclopropyl-[1,3]thiazolo[4,5-d]pyrimidin-2-yl)-N-[[3-fluoro-4-(trifluoromethoxy)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]sulfonylpiperazine-2-carboxamide
DM64FX9 CA CAS 954389-09-4
DM64FX9 DE Hepatitis C virus infection
DMI7Z1Y ID DMI7Z1Y
DMI7Z1Y DN JTT-553
DMI7Z1Y HS Discontinued in Phase 1
DMI7Z1Y SN DGAT1 inhibitor (oral, obesity) Japan Tobacco
DMI7Z1Y CP Japan Tobacco Inc
DMI7Z1Y PC 10435589
DMI7Z1Y MW 488.5
DMI7Z1Y FM C25H27F3N4O3
DMI7Z1Y IC InChI=1S/C25H27F3N4O3/c1-23(2)19(30-18-20(29)31-22(25(26,27)28)32-21(18)35-23)15-3-4-16-14(12-15)7-10-24(16)8-5-13(6-9-24)11-17(33)34/h3-4,12-13H,5-11H2,1-2H3,(H,33,34)(H2,29,31,32)
DMI7Z1Y CS CC1(C(=NC2=C(N=C(N=C2O1)C(F)(F)F)N)C3=CC4=C(C=C3)C5(CCC(CC5)CC(=O)O)CC4)C
DMI7Z1Y IK YFJNLPDVCDNOMJ-UHFFFAOYSA-N
DMI7Z1Y IU 2-[6-[4-amino-7,7-dimethyl-2-(trifluoromethyl)pyrimido[4,5-b][1,4]oxazin-6-yl]spiro[1,2-dihydroindene-3,4'-cyclohexane]-1'-yl]acetic acid
DMI7Z1Y CA CAS 701232-94-2
DMI7Z1Y DE Obesity
DMGP42Q ID DMGP42Q
DMGP42Q DN JTT-651
DMGP42Q HS Discontinued in Phase 1
DMGP42Q SN Glycogen phosphorylase inhibitor (oral, diabetes) Japan Tobacco
DMGP42Q CP Japan Tobacco Inc
DMGP42Q DE Type-2 diabetes
DMXUH6W ID DMXUH6W
DMXUH6W DN JTV-803
DMXUH6W HS Discontinued in Phase 1
DMXUH6W SN UNII-7PT6AGF1ST; JTV 803; 7PT6AGF1ST; 247131-79-9; JTV-803; SCHEMBL6191062; NOBZETMXGVAWIM-UHFFFAOYSA-N; 4-Piperidinecarboxylic acid, 4-(((2-(aminoiminomethyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)oxy)methyl)-1-(4-pyridinyl)-, monomethanesulfonate; 4-Piperidinecarboxylic acid, 4-(((2-(aminoiminomethyl)-1,2,3,4-tetrahydro-7-isoquinolinyl)oxy)methyl)-1-(4-pyridinyl)-, methanesulfonate (1:1); KB-78007; 4-(2-amidino-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)-1-(pyridin-4-yl)piperidine-4-carboxylic acid methanesulfonate
DMXUH6W CP Japan Tobacco Inc
DMXUH6W DT Small molecular drug
DMXUH6W PC 11432124
DMXUH6W MW 505.6
DMXUH6W FM C23H31N5O6S
DMXUH6W IC InChI=1S/C22H27N5O3.CH4O3S/c23-21(24)27-10-5-16-1-2-19(13-17(16)14-27)30-15-22(20(28)29)6-11-26(12-7-22)18-3-8-25-9-4-18;1-5(2,3)4/h1-4,8-9,13H,5-7,10-12,14-15H2,(H3,23,24)(H,28,29);1H3,(H,2,3,4)
DMXUH6W CS CS(=O)(=O)O.C1CN(CC2=C1C=CC(=C2)OCC3(CCN(CC3)C4=CC=NC=C4)C(=O)O)C(=N)N
DMXUH6W IK NOBZETMXGVAWIM-UHFFFAOYSA-N
DMXUH6W IU 4-[(2-carbamimidoyl-3,4-dihydro-1H-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid;methanesulfonic acid
DMXUH6W CA CAS 247131-79-9
DMXUH6W DE Thrombosis
DM37IH5 ID DM37IH5
DM37IH5 DN KN-203
DM37IH5 HS Discontinued in Phase 1
DM37IH5 SN Mu-opioid recceptor agonist (urinary incontinence), Grunenthal/KeyNeurotek
DM37IH5 CP Grunenthal GmbH
DM37IH5 DE Urinary incontinence
DM6LTRC ID DM6LTRC
DM6LTRC DN KNI-764
DM6LTRC HS Discontinued in Phase 1
DM6LTRC SN KNI-764; JE-2147; AG1776; 186538-00-1; AG 1776; JE-2147, AG1776, KNI-764; JE2; (4r)-3-{(2s,3s)-2-Hydroxy-3-[(3-Hydroxy-2-Methylbenzoyl)amino]-4-Phenylbutanoyl}-5,5-Dimethyl-N-(2-Methylbenzyl)-1,3-Thiazolidine-4-Carboxamide; 1msn; 2anl; 1kzk; 1msm; 4-Thiazolidinecarboxamide, 3-((2S,3S)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-1-oxo-4-phenylbutyl)-5,5-dimethyl-N-((2-methylphenyl)methyl)-, (4R)-; 4-Thiazolidinecarboxamide, 3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-1-oxo-4-phenylbutyl]-5,5-dimethyl-N-[
DM6LTRC DT Small molecular drug
DM6LTRC PC 446837
DM6LTRC MW 575.7
DM6LTRC FM C32H37N3O5S
DM6LTRC IC InChI=1S/C32H37N3O5S/c1-20-11-8-9-14-23(20)18-33-30(39)28-32(3,4)41-19-35(28)31(40)27(37)25(17-22-12-6-5-7-13-22)34-29(38)24-15-10-16-26(36)21(24)2/h5-16,25,27-28,36-37H,17-19H2,1-4H3,(H,33,39)(H,34,38)/t25-,27-,28+/m0/s1
DM6LTRC CS CC1=CC=CC=C1CNC(=O)[C@@H]2C(SCN2C(=O)[C@H]([C@H](CC3=CC=CC=C3)NC(=O)C4=C(C(=CC=C4)O)C)O)(C)C
DM6LTRC IK CUFQBQOBLVLKRF-RZDMPUFOSA-N
DM6LTRC IU (4R)-3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl]-5,5-dimethyl-N-[(2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide
DM6LTRC CA CAS 186538-00-1
DM6LTRC DE Human immunodeficiency virus infection
DMICLMR ID DMICLMR
DMICLMR DN KP106
DMICLMR HS Discontinued in Phase 1
DMICLMR CP KemPharm
DMICLMR DE Attention deficit hyperactivity disorder
DMMD6LR ID DMMD6LR
DMMD6LR DN KR-30450
DMMD6LR HS Discontinued in Phase 1
DMMD6LR SN SKP-450; 1-[2(R)-(1,3-Dioxolan-2-yl)-2-methyl-6-nitro-2H-1-benzopyran-4-yl]pyrrolidin-2-one
DMMD6LR PC 9906213
DMMD6LR MW 346.3
DMMD6LR FM C17H18N2O6
DMMD6LR IC InChI=1S/C17H18N2O6/c1-17(16-23-7-8-24-16)10-13(18-6-2-3-15(18)20)12-9-11(19(21)22)4-5-14(12)25-17/h4-5,9-10,16H,2-3,6-8H2,1H3/t17-/m1/s1
DMMD6LR CS C[C@@]1(C=C(C2=C(O1)C=CC(=C2)[N+](=O)[O-])N3CCCC3=O)C4OCCO4
DMMD6LR IK NJJPKIPOZSWUHV-QGZVFWFLSA-N
DMMD6LR IU 1-[(2R)-2-(1,3-dioxolan-2-yl)-2-methyl-6-nitrochromen-4-yl]pyrrolidin-2-one
DMMD6LR CA CAS 172489-10-0
DMMD6LR DE Hypertension
DMBH5G3 ID DMBH5G3
DMBH5G3 DN KT2-962
DMBH5G3 HS Discontinued in Phase 1
DMBH5G3 SN 3-[4-(4-Chlorophenylsulfonamido)butyl]-6-isopropylazulene-1-sulfonic acid sodium salt
DMBH5G3 DT Small molecular drug
DMBH5G3 PC 23661969
DMBH5G3 MW 518
DMBH5G3 FM C23H25ClNNaO5S2
DMBH5G3 IC InChI=1S/C23H26ClNO5S2.Na/c1-16(2)17-6-12-21-18(15-23(32(28,29)30)22(21)13-7-17)5-3-4-14-25-31(26,27)20-10-8-19(24)9-11-20;/h6-13,15-16,25H,3-5,14H2,1-2H3,(H,28,29,30);/q;+1/p-1
DMBH5G3 CS CC(C)C1=CC=C2C(=C(C=C2S(=O)(=O)[O-])CCCCNS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1.[Na+]
DMBH5G3 IK QIBQVFYOTMPEIP-UHFFFAOYSA-M
DMBH5G3 IU sodium;3-[4-[(4-chlorophenyl)sulfonylamino]butyl]-6-propan-2-ylazulene-1-sulfonate
DMBH5G3 CA CAS 129648-96-0
DMBH5G3 DE Thrombosis
DM74BK8 ID DM74BK8
DM74BK8 DN KT-362
DM74BK8 HS Discontinued in Phase 1
DM74BK8 SN 3-[2-(3,4-dimethoxyphenyl)ethylamino]-1-(2-thia-6-azabicyclo[5.4.0]undeca-7,9,11-trien-6-yl)propan-1-one; ACMC-20m87t
DM74BK8 CP Kotobuki Pharmaceutical Co Ltd
DM74BK8 DT Small molecular drug
DM74BK8 PC 6438134
DM74BK8 MW 516.6
DM74BK8 FM C26H32N2O7S
DM74BK8 IC InChI=1S/C22H28N2O3S.C4H4O4/c1-26-19-9-8-17(16-20(19)27-2)10-12-23-13-11-22(25)24-14-5-15-28-21-7-4-3-6-18(21)24;5-3(6)1-2-4(7)8/h3-4,6-9,16,23H,5,10-15H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DM74BK8 CS COC1=C(C=C(C=C1)CCNCCC(=O)N2CCCSC3=CC=CC=C32)OC.C(=C/C(=O)O)\\C(=O)O
DM74BK8 IK YIVXAQUBENUHJC-WLHGVMLRSA-N
DM74BK8 IU (E)-but-2-enedioic acid;1-(3,4-dihydro-2H-1,5-benzothiazepin-5-yl)-3-[2-(3,4-dimethoxyphenyl)ethylamino]propan-1-one
DM74BK8 CA CAS 105394-80-7
DM74BK8 DE Heart arrhythmia
DMG068H ID DMG068H
DMG068H DN KW-3635
DMG068H HS Discontinued in Phase 1
DMG068H SN KW-3635; GTPL1977; KW3635
DMG068H CP Kyowa Hakko Kogyo Co Ltd
DMG068H DT Small molecular drug
DMG068H PC 23673318
DMG068H MW 432.4
DMG068H FM C26H21N2NaO3
DMG068H IC InChI=1S/C26H22N2O3.Na/c1-16-11-23-24(12-17(16)2)28(15-27-23)10-9-21-20-6-4-3-5-19(20)14-31-25-8-7-18(26(29)30)13-22(21)25;/h3-9,11-13,15H,10,14H2,1-2H3,(H,29,30);/q;+1/p-1/b21-9+;
DMG068H CS CC1=CC2=C(C=C1C)N(C=N2)C/C=C/3\\C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)[O-].[Na+]
DMG068H IK KWELWDMCBFWKQN-CSFJJMQLSA-M
DMG068H IU sodium;(11E)-11-[2-(5,6-dimethylbenzimidazol-1-yl)ethylidene]-6H-benzo[c][1]benzoxepine-2-carboxylate
DMG068H CA CAS 127166-41-0
DMG068H DE Thrombosis
DM76O23 ID DM76O23
DM76O23 DN KW-6055
DM76O23 HS Discontinued in Phase 1
DM76O23 SN N-[3-Nitro-4-(2-pyridinylmethyl)phenyl]butanamide; 2-[4-(Butyrylamino)-2-nitrobenzyl]pyridine
DM76O23 DT Small molecular drug
DM76O23 PC 3047323
DM76O23 MW 299.32
DM76O23 FM C16H17N3O3
DM76O23 IC InChI=1S/C16H17N3O3/c1-2-5-16(20)18-14-8-7-12(15(11-14)19(21)22)10-13-6-3-4-9-17-13/h3-4,6-9,11H,2,5,10H2,1H3,(H,18,20)
DM76O23 CS CCCC(=O)NC1=CC(=C(C=C1)CC2=CC=CC=N2)[N+](=O)[O-]
DM76O23 IK CZKQVCYQBJJAGG-UHFFFAOYSA-N
DM76O23 IU N-[3-nitro-4-(pyridin-2-ylmethyl)phenyl]butanamide
DM76O23 CA CAS 63233-46-5
DM76O23 DE Inflammation
DM5LRKC ID DM5LRKC
DM5LRKC DN L-368899
DM5LRKC HS Discontinued in Phase 1
DM5LRKC SN UNII-ER33G946JT; L-368899; ER33G946JT; CHEMBL1253853; L 368,899; L 368899; 148927-60-0; (S)-2-amino-N-((1S,2S,4R)-7,7-dimethyl-1-((4-o-tolylpiperazin-1-ylsulfonyl)methyl)bicyclo[2.2.1]heptan-2-yl)-4-(methylsulfonyl)butanamide; GTPL2249; SCHEMBL17423276; ZINC3923061; BDBM50326719; NCGC00485193-01; 1-(((7,7-Dimethyl-2-(2-amino-4-(methylsulfonyl)butyramido)bicyclo(2.2.1)heptan-1-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine; Butanamide, 2-amino-N-(7,7-dimethyl-1-(((4-(2-methylphenyl)-1-piperazinyl)sulfonyl)methyl)bicyclo
DM5LRKC CP Merck & Co Inc
DM5LRKC DT Small molecular drug
DM5LRKC PC 9872389
DM5LRKC MW 554.8
DM5LRKC FM C26H42N4O5S2
DM5LRKC IC InChI=1S/C26H42N4O5S2/c1-19-7-5-6-8-22(19)29-12-14-30(15-13-29)37(34,35)18-26-11-9-20(25(26,2)3)17-23(26)28-24(31)21(27)10-16-36(4,32)33/h5-8,20-21,23H,9-18,27H2,1-4H3,(H,28,31)/t20-,21+,23+,26-/m1/s1
DM5LRKC CS CC1=CC=CC=C1N2CCN(CC2)S(=O)(=O)C[C@@]34CC[C@@H](C3(C)C)C[C@@H]4NC(=O)[C@H](CCS(=O)(=O)C)N
DM5LRKC IK MWIASLNTAGRGGA-ZJPWWDJASA-N
DM5LRKC IU (2S)-2-amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[4-(2-methylphenyl)piperazin-1-yl]sulfonylmethyl]-2-bicyclo[2.2.1]heptanyl]-4-methylsulfonylbutanamide
DM5LRKC CA CAS 148927-60-0
DM5LRKC DE Miscarriage
DMLHE5A ID DMLHE5A
DMLHE5A DN L-692429
DMLHE5A HS Discontinued in Phase 1
DMLHE5A SN 3-Amino-3-methyl-N-[2-oxo-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2,3,4,5-tetrahydro-1H-1-benzazepin-3(R)-yl]butyramide
DMLHE5A DT Small molecular drug
DMLHE5A PC 121879
DMLHE5A MW 509.6
DMLHE5A FM C29H31N7O2
DMLHE5A IC InChI=1S/C29H31N7O2/c1-29(2,30)17-26(37)31-24-16-15-21-7-3-6-10-25(21)36(28(24)38)18-19-11-13-20(14-12-19)22-8-4-5-9-23(22)27-32-34-35-33-27/h3-14,24H,15-18,30H2,1-2H3,(H,31,37)(H,32,33,34,35)/t24-/m1/s1
DMLHE5A CS CC(C)(CC(=O)N[C@@H]1CCC2=CC=CC=C2N(C1=O)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N
DMLHE5A IK SBJLJOFPWOYATP-XMMPIXPASA-N
DMLHE5A IU 3-amino-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide
DMLHE5A CA CAS 145455-23-8
DMLHE5A DE Growth hormone deficiency
DMBIR5P ID DMBIR5P
DMBIR5P DN L-697639
DMBIR5P HS Discontinued in Phase 1
DMBIR5P SN HND0YP0TJG; 135525-77-8; UNII-HND0YP0TJG; L 697639; L-697,639; L-697639; 3-[(4,7-dimethyl-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone,3-[[(4,7-dimethyl-2-benzoxazolyl) methyl]amino]-5-ethyl-6-methyl-; DRG-0101; ACMC-20mvsl; 3benzoxazolMeNH deriv.; AC1L1U0H; CHEMBL37803; SCHEMBL6367001; BDBM1314; AC1Q69B1; CTK4B9862; DTXSID50159456; VDZJXIOFISBBLT-UHFFFAOYSA-N; 3-(((4,7-Dimethyl-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one
DMBIR5P CP Merck & Co Inc
DMBIR5P DT Small molecular drug
DMBIR5P PC 60832
DMBIR5P MW 311.4
DMBIR5P FM C18H21N3O2
DMBIR5P IC InChI=1S/C18H21N3O2/c1-5-13-8-14(18(22)20-12(13)4)19-9-15-21-16-10(2)6-7-11(3)17(16)23-15/h6-8,19H,5,9H2,1-4H3,(H,20,22)
DMBIR5P CS CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)C)C)C
DMBIR5P IK VDZJXIOFISBBLT-UHFFFAOYSA-N
DMBIR5P IU 3-[(4,7-dimethyl-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one
DMBIR5P CA CAS 135525-77-8
DMBIR5P DE Human immunodeficiency virus infection
DMSB0J8 ID DMSB0J8
DMSB0J8 DN L-734217
DMSB0J8 HS Discontinued in Phase 1
DMSB0J8 SN L-734217; UNII-3JRV8H947H; CHEMBL48371; 3JRV8H947H; 146144-48-1; AC1L42ZO; L 734217; SCHEMBL6886518; L-734,217; CTK4C4832; Butanoic acid,3-[[2-[(3R)-2-oxo-3-[2-(4-piperidinyl)ethyl]-1-piperidinyl]acetyl]amino]-,(3R)-; BDBM50033030; AKOS030571127; 3-{2-[2-Oxo-3-(2-piperidin-4-yl-ethyl)-piperidin-1-yl]-acetylamino}-butyric acid (L-734217); (R)-3-{2-[(R)-2-Oxo-3-(2-piperidin-4-yl-ethyl)-piperidin-1-yl]-acetylamino}-butyric acid; (3R)-3-[[2-[(3R)-2-oxo-3-(2-piperidin-4-ylethyl)piperidin-1-yl]acetyl]amino]butanoic acid
DMSB0J8 DT Small molecular drug
DMSB0J8 PC 177831
DMSB0J8 MW 353.5
DMSB0J8 FM C18H31N3O4
DMSB0J8 IC InChI=1S/C18H31N3O4/c1-13(11-17(23)24)20-16(22)12-21-10-2-3-15(18(21)25)5-4-14-6-8-19-9-7-14/h13-15,19H,2-12H2,1H3,(H,20,22)(H,23,24)/t13-,15+/m1/s1
DMSB0J8 CS C[C@H](CC(=O)O)NC(=O)CN1CCC[C@H](C1=O)CCC2CCNCC2
DMSB0J8 IK SFFMYDBKYYBJRY-HIFRSBDPSA-N
DMSB0J8 IU (3R)-3-[[2-[(3R)-2-oxo-3-(2-piperidin-4-ylethyl)piperidin-1-yl]acetyl]amino]butanoic acid
DMSB0J8 CA CAS 146144-48-1
DMSB0J8 DE Thrombosis
DMHEKIN ID DMHEKIN
DMHEKIN DN LASINAVIR
DMHEKIN HS Discontinued in Phase 1
DMHEKIN SN BMS-234475; CGP-61755; Lasinavir; N-[5(S)-(tert-Butoxycarbonylamino)-4(S)-hydroxy-6-phenyl-2(R)-(2,3,4-trimethoxybenzyl)hexanoyl]-L-valine 2-methoxyethylamide
DMHEKIN DT Small molecular drug
DMHEKIN PC 464372
DMHEKIN MW 659.8
DMHEKIN FM C35H53N3O9
DMHEKIN IC InChI=1S/C35H53N3O9/c1-22(2)29(33(41)36-17-18-43-6)38-32(40)25(20-24-15-16-28(44-7)31(46-9)30(24)45-8)21-27(39)26(19-23-13-11-10-12-14-23)37-34(42)47-35(3,4)5/h10-16,22,25-27,29,39H,17-21H2,1-9H3,(H,36,41)(H,37,42)(H,38,40)/t25-,26+,27+,29+/m1/s1
DMHEKIN CS CC(C)[C@@H](C(=O)NCCOC)NC(=O)[C@H](CC1=C(C(=C(C=C1)OC)OC)OC)C[C@@H]([C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O
DMHEKIN IK BEUUJDAEPJZWHM-COROXYKFSA-N
DMHEKIN IU tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(2S)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate
DMHEKIN CA CAS 175385-62-3
DMHEKIN DE Human immunodeficiency virus infection
DMSRD5U ID DMSRD5U
DMSRD5U DN LBY-135
DMSRD5U HS Discontinued in Phase 1
DMSRD5U SN LCR-211; Anti-DR5 agonist chimerics mAb (cancer), Novartis; Anti-death receptor5 agonist chimeric monoclonal antibody (cancer), Novartis
DMSRD5U CP Novartis AG
DMSRD5U DT Antibody
DMSRD5U DE Solid tumour/cancer
DM41RK2 ID DM41RK2
DM41RK2 DN LG100268
DM41RK2 HS Discontinued in Phase 1
DM41RK2 SN AmbkkkkK580; LG 100268; LG2; LG-100268; 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)nicotinic acid; 6-[1-(3,5,5,8,8-PENTAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)CYCLOPROPYL]PYRIDINE-3-CARBOXYLIC ACID; 6-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-nicotinic acid; 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
DM41RK2 CP Ligand Pharmaceuticals
DM41RK2 DT Small molecular drug
DM41RK2 PC 3922
DM41RK2 MW 363.5
DM41RK2 FM C24H29NO2
DM41RK2 IC InChI=1S/C24H29NO2/c1-15-12-18-19(23(4,5)9-8-22(18,2)3)13-17(15)24(10-11-24)20-7-6-16(14-25-20)21(26)27/h6-7,12-14H,8-11H2,1-5H3,(H,26,27)
DM41RK2 CS CC1=CC2=C(C=C1C3(CC3)C4=NC=C(C=C4)C(=O)O)C(CCC2(C)C)(C)C
DM41RK2 IK SLXTWXQUEZSSTJ-UHFFFAOYSA-N
DM41RK2 IU 6-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]pyridine-3-carboxylic acid
DM41RK2 CA CAS 153559-76-3
DM41RK2 DE Acquired immune deficiency syndrome
DM0PXGU ID DM0PXGU
DM0PXGU DN LG-101280
DM0PXGU HS Discontinued in Phase 1
DM0PXGU SN LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly
DM0PXGU CP Ligand Pharmaceuticals Inc
DM0PXGU DE Arteriosclerosis
DM9LEGU ID DM9LEGU
DM9LEGU DN LGD2941
DM9LEGU HS Discontinued in Phase 1
DM9LEGU SN LGD2941; CHEMBL467888; SCHEMBL3015188; BDBM18522; DB05234; 6-(1-Pyrrolidine)quinolin-2(1H)-one, 6a
DM9LEGU CP Ligand Pharmaceuticals
DM9LEGU DT Small molecular drug
DM9LEGU PC 16750192
DM9LEGU MW 394.31
DM9LEGU FM C17H16F6N2O2
DM9LEGU IC InChI=1S/C17H16F6N2O2/c1-8-2-5-13(15(27)17(21,22)23)25(8)9-3-4-12-10(6-9)11(16(18,19)20)7-14(26)24-12/h3-4,6-8,13,15,27H,2,5H2,1H3,(H,24,26)/t8-,13-,15-/m1/s1
DM9LEGU CS C[C@@H]1CC[C@@H](N1C2=CC3=C(C=C2)NC(=O)C=C3C(F)(F)F)[C@H](C(F)(F)F)O
DM9LEGU IK HWLLYFXDDGGHOE-BCSUUIJWSA-N
DM9LEGU IU 6-[(2R,5R)-2-methyl-5-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-4-(trifluoromethyl)-1H-quinolin-2-one
DM9LEGU DE Osteoporosis
DM7HLFD ID DM7HLFD
DM7HLFD DN Licofelone
DM7HLFD HS Discontinued in Phase 1
DM7HLFD SN LCF; Licofelone [INN]; ML 3000; ML-3000; [6-(4-CHLOROPHENYL)-2,2-DIMETHYL-7-PHENYL-2,3-DIHYDRO-1H-PYRROLIZIN-5-YL]ACETIC ACID; (2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)acetic acid; (6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid; 2,2-Dimethyl-6-(4-chlorophenyl-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl)acetic acid; 2,3-Dihydro-6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid; 2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid; 6-(4-Chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizine-5-acetic acid
DM7HLFD CP Merckle GmbH
DM7HLFD DT Small molecular drug
DM7HLFD PC 133021
DM7HLFD MW 379.9
DM7HLFD FM C23H22ClNO2
DM7HLFD IC InChI=1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)
DM7HLFD CS CC1(CC2=C(C(=C(N2C1)CC(=O)O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4)C
DM7HLFD IK UAWXGRJVZSAUSZ-UHFFFAOYSA-N
DM7HLFD IU 2-[2-(4-chlorophenyl)-6,6-dimethyl-1-phenyl-5,7-dihydropyrrolizin-3-yl]acetic acid
DM7HLFD CA CAS 156897-06-2
DM7HLFD DE Osteoarthritis
DMMWCU3 ID DMMWCU3
DMMWCU3 DN Licostinel
DMMWCU3 HS Discontinued in Phase 1
DMMWCU3 SN Licostinel; 153504-81-5; ACEA 1021; ACEA-1021; UNII-3Z3037LJTC; 6,7-Dichloro-5-nitro-2,3-quinoxalinedione; 5-Nitro-6,7-dichloro-2,3-quinoxalinedione; 5-Nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione; 6,7-Dichloro-1,4-dihydro-5-nitro-2,3-quinoxalinedione; CHEMBL289832; 3Z3037LJTC; 6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione; 6,7-DICHLORO-5-NITROQUINOXALINE-2,3(1H,4H)-DIONE; 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro-5-nitro-; Licostinel [USAN]; Licostinel [USAN:INN]; C8H3Cl2N3O4; AC1NUOFE; Licostinel (USAN/
DMMWCU3 DT Small molecular drug
DMMWCU3 PC 5486198
DMMWCU3 MW 276.03
DMMWCU3 FM C8H3Cl2N3O4
DMMWCU3 IC InChI=1S/C8H3Cl2N3O4/c9-2-1-3-5(6(4(2)10)13(16)17)12-8(15)7(14)11-3/h1H,(H,11,14)(H,12,15)
DMMWCU3 CS C1=C2C(=C(C(=C1Cl)Cl)[N+](=O)[O-])NC(=O)C(=O)N2
DMMWCU3 IK CHFSOFHQIZKQCR-UHFFFAOYSA-N
DMMWCU3 IU 6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMMWCU3 CA CAS 153504-81-5
DMMWCU3 DE Neurological disorder
DM9WEP5 ID DM9WEP5
DM9WEP5 DN LJP-1082
DM9WEP5 HS Discontinued in Phase 1
DM9WEP5 SN Quinacrine azide; 3-Azido-9-((4-(diethylamino)-1-methylbutyl)amino)-7-methoxyacridine; AC1MI36Z; 73332-88-4; 1,4-Pentanediamine, N4-(6-azido-2-methoxy-9-acridinyl)-N1,N1-diethyl-
DM9WEP5 CP La Jolla Pharmaceutical
DM9WEP5 DT Small molecular drug
DM9WEP5 PC 3037609
DM9WEP5 MW 406.5
DM9WEP5 FM C23H30N6O
DM9WEP5 IC InChI=1S/C23H30N6O/c1-5-29(6-2)13-7-8-16(3)25-23-19-11-9-17(27-28-24)14-22(19)26-21-12-10-18(30-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)
DM9WEP5 CS CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)N=[N+]=[N-])OC
DM9WEP5 IK OJZRYFDOXJOKNZ-UHFFFAOYSA-N
DM9WEP5 IU 4-N-(6-azido-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine
DM9WEP5 CA CAS 73332-88-4
DM9WEP5 DE Hughes syndrome
DMSL0Y5 ID DMSL0Y5
DMSL0Y5 DN LOR-2501
DMSL0Y5 HS Discontinued in Phase 1
DMSL0Y5 SN GTI-2501; R1 ribonucleotide reductase mRNA antisense oligo, Lorus; Antisense oligonucleotide (cancer), Lorus; U-sense technology, Lorus
DMSL0Y5 CP Lorus Therapeutics Inc
DMSL0Y5 DT Antisense drug
DMSL0Y5 DE Solid tumour/cancer
DMGUX5Y ID DMGUX5Y
DMGUX5Y DN Lu-AA38466
DMGUX5Y HS Discontinued in Phase 1
DMGUX5Y SN Ion channel modulator (neurological disease), H Lundbeck
DMGUX5Y CP H Lundbeck A/S
DMGUX5Y DE Neurological disorder
DMH0AMG ID DMH0AMG
DMH0AMG DN Lu-AA44608
DMH0AMG HS Discontinued in Phase 1
DMH0AMG CP H. Lundbeck A/S
DMH0AMG DE Mood disorder
DML86MJ ID DML86MJ
DML86MJ DN Lu-AA47070
DML86MJ HS Discontinued in Phase 1
DML86MJ SN Adenosine A2a antagonists (Parkinson's disease), Lundbeck
DML86MJ CP H. Lundbeck A/S
DML86MJ DE Parkinson disease
DMKMIQ6 ID DMKMIQ6
DMKMIQ6 DN LY-315902
DMKMIQ6 HS Discontinued in Phase 1
DMKMIQ6 CP Eli Lilly & Co
DMKMIQ6 DE Type-2 diabetes
DMNPJL3 ID DMNPJL3
DMNPJL3 DN LY-444711
DMNPJL3 HS Discontinued in Phase 1
DMNPJL3 SN 2(R)-(2-Amino-2-methylpropanamido)-N-[1-[1(R)-(4-methoxyphenyl)-1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]-5-phenylpentanamide dihydrochloride
DMNPJL3 PC 9872936
DMNPJL3 MW 574.7
DMNPJL3 FM C32H42N6O4
DMNPJL3 IC InChI=1S/C32H42N6O4/c1-31(2,33)29(40)35-26(14-10-13-23-11-6-5-7-12-23)28(39)36-27-21-38(22-34-27)32(3,30(41)37-19-8-9-20-37)24-15-17-25(42-4)18-16-24/h5-7,11-12,15-18,21-22,26H,8-10,13-14,19-20,33H2,1-4H3,(H,35,40)(H,36,39)/t26-,32-/m1/s1
DMNPJL3 CS C[C@@](C1=CC=C(C=C1)OC)(C(=O)N2CCCC2)N3C=C(N=C3)NC(=O)[C@@H](CCCC4=CC=CC=C4)NC(=O)C(C)(C)N
DMNPJL3 IK MJUQKUGRKDKGBY-HVIPQOSHSA-N
DMNPJL3 IU (2R)-2-[(2-amino-2-methylpropanoyl)amino]-N-[1-[(2R)-2-(4-methoxyphenyl)-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]imidazol-4-yl]-5-phenylpentanamide
DMNPJL3 DE Growth hormone deficiency
DMB1OAR ID DMB1OAR
DMB1OAR DN LY-73497
DMB1OAR HS Discontinued in Phase 1
DMB1OAR SN LY73497; Thiourea, N-(2-phenylethyl)-N'-2-thiazolyl-; LY 73497; 149485-30-3; LY-73497; CHEMBL33981; AC1MHDK1; MLS001243522; SCHEMBL1520344; BDBM1894; DTXSID90164286; HMS3338J14; HMS2211G04; 1-Phenethyl-3-thiazol-2-yl-thiourea; AKOS030011215; NCGC00247398-01; SMR000841574; Phenylethylthiazolylthiourea (PETT) Analog; N-(2-phenethyl)-N -(2-thiazolyl)thiourea; 1-phenethyl-3-(1,3-thiazol-2-yl)thiourea
DMB1OAR DT Small molecular drug
DMB1OAR PC 3001082
DMB1OAR MW 263.4
DMB1OAR FM C12H13N3S2
DMB1OAR IC InChI=1S/C12H13N3S2/c16-11(15-12-14-8-9-17-12)13-7-6-10-4-2-1-3-5-10/h1-5,8-9H,6-7H2,(H2,13,14,15,16)
DMB1OAR CS C1=CC=C(C=C1)CCNC(=S)NC2=NC=CS2
DMB1OAR IK ANUSGJXVCFPWMQ-UHFFFAOYSA-N
DMB1OAR IU 1-(2-phenylethyl)-3-(1,3-thiazol-2-yl)thiourea
DMB1OAR CA CAS 149485-30-3
DMVYG5X ID DMVYG5X
DMVYG5X DN LY-929
DMVYG5X HS Discontinued in Phase 1
DMVYG5X SN LY-510929; Dual PPAR-alpha/PPAR-gamma agonists
DMVYG5X CP Ligand Pharmaceuticals Inc
DMVYG5X DT Small molecular drug
DMVYG5X PC 9890585
DMVYG5X MW 463.5
DMVYG5X FM C26H25NO5S
DMVYG5X IC InChI=1S/C26H25NO5S/c1-18-22(27-24(31-18)23-9-6-16-33-23)14-15-30-20-12-10-19(11-13-20)17-26(2,25(28)29)32-21-7-4-3-5-8-21/h3-13,16H,14-15,17H2,1-2H3,(H,28,29)/t26-/m0/s1
DMVYG5X CS CC1=C(N=C(O1)C2=CC=CS2)CCOC3=CC=C(C=C3)C[C@@](C)(C(=O)O)OC4=CC=CC=C4
DMVYG5X IK KWSPYUOBNIMILB-SANMLTNESA-N
DMVYG5X IU (2S)-2-methyl-3-[4-[2-(5-methyl-2-thiophen-2-yl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-phenoxypropanoic acid
DMVYG5X DE Lipid metabolism disorder
DMDUM0Z ID DMDUM0Z
DMDUM0Z DN LymphoRad-131
DMDUM0Z HS Discontinued in Phase 1
DMDUM0Z SN Ardenermin; LymphoRad; LR-131; Radiolabeled BLyS protein, HGS; Radiolabeled ardenermine, HGS
DMDUM0Z CP Human Genome Sciences Inc
DMDUM0Z DE Lymphoma
DMP19KT ID DMP19KT
DMP19KT DN MBI 1121
DMP19KT HS Discontinued in Phase 1
DMP19KT CP Migenix
DMP19KT TC Antisense
DMP19KT DT Antisense drug
DMP19KT DE Solid tumour/cancer
DMRIK2Y ID DMRIK2Y
DMRIK2Y DN MC-02,479
DMRIK2Y HS Discontinued in Phase 1
DMRIK2Y SN RWJ-54428; (6R,7R)-7-[2-(2-Amino-5-chlorothiazol-4-yl)-2(Z)-(hydroxyimino)acetamido]-3-[3-(2-aminoethylsulfanylmethyl)pyridin-4-ylsulfanyl]-3-cephem-4-carboxylic acid methanesulfonate
DMRIK2Y DE Bacterial infection
DMUMSFR ID DMUMSFR
DMUMSFR DN ME-3277
DMUMSFR HS Discontinued in Phase 1
DMUMSFR SN 4-[2-(4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-2-ylcarboxamido)acetyl]phenylene-1,2-dioxybis(acetic acid)
DMUMSFR PC 9955286
DMUMSFR MW 448.4
DMUMSFR FM C20H20N2O8S
DMUMSFR IC InChI=1S/C20H20N2O8S/c23-13(8-22-20(28)17-6-12-7-21-4-3-16(12)31-17)11-1-2-14(29-9-18(24)25)15(5-11)30-10-19(26)27/h1-2,5-6,21H,3-4,7-10H2,(H,22,28)(H,24,25)(H,26,27)
DMUMSFR CS C1CNCC2=C1SC(=C2)C(=O)NCC(=O)C3=CC(=C(C=C3)OCC(=O)O)OCC(=O)O
DMUMSFR IK NCPUFPHVKAPNOO-UHFFFAOYSA-N
DMUMSFR IU 2-[2-(carboxymethoxy)-4-[2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-carbonylamino)acetyl]phenoxy]acetic acid
DMUMSFR DE Thrombosis
DMC2V5J ID DMC2V5J
DMC2V5J DN Mirisetron maleate
DMC2V5J HS Discontinued in Phase 1
DMC2V5J SN SEC-579; WAY-100579; WAY-SEC-579
DMC2V5J CP Wyeth
DMC2V5J DT Small molecular drug
DMC2V5J PC 6435818
DMC2V5J MW 509.6
DMC2V5J FM C28H35N3O6
DMC2V5J IC InChI=1S/C24H31N3O2.C4H4O4/c1-26-18-11-12-19(26)14-16(13-18)25-24(29)21-15-27(17-7-3-2-4-8-17)22-10-6-5-9-20(22)23(21)28;5-3(6)1-2-4(7)8/h5-6,9-10,15-19H,2-4,7-8,11-14H2,1H3,(H,25,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t16?,18-,19+;
DMC2V5J CS CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)C3=CN(C4=CC=CC=C4C3=O)C5CCCCC5.C(=C\\C(=O)O)\\C(=O)O
DMC2V5J IK OQIHDZMOAKTHKW-WPJOOPQGSA-N
DMC2V5J IU (Z)-but-2-enedioic acid;1-cyclohexyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-4-oxoquinoline-3-carboxamide
DMC2V5J CA CAS 148611-75-0
DMC2V5J DE Anxiety disorder
DM23KBM ID DM23KBM
DM23KBM DN MIV-701
DM23KBM HS Discontinued in Phase 1
DM23KBM CP Medivir
DM23KBM DE Osteoporosis
DMNAJGK ID DMNAJGK
DMNAJGK DN MK-0963
DMNAJGK HS Discontinued in Phase 1
DMNAJGK SN L-654066; MK-963; (5alpha)-23-Methyl-4-aza-21-norchol-1-ene-3,20-dione; 23-Methyl-21-nor-4-aza-5alpha-chol-1-ene-3,20-dione
DMNAJGK DT Small molecular drug
DMNAJGK PC 6918127
DMNAJGK MW 357.5
DMNAJGK FM C23H35NO2
DMNAJGK IC InChI=1S/C23H35NO2/c1-14(2)13-19(25)18-7-6-16-15-5-8-20-23(4,12-10-21(26)24-20)17(15)9-11-22(16,18)3/h10,12,14-18,20H,5-9,11,13H2,1-4H3,(H,24,26)/t15-,16-,17-,18+,20+,22-,23+/m0/s1
DMNAJGK CS CC(C)CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C=CC(=O)N4)C)C
DMNAJGK IK RDPJISLOFXUIDK-RLAPWRJVSA-N
DMNAJGK IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-9a,11a-dimethyl-1-(3-methylbutanoyl)-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one
DMNAJGK CA CAS 103497-68-3
DMNAJGK DE Prostate disease
DMERKWM ID DMERKWM
DMERKWM DN MK-434
DMERKWM HS Discontinued in Phase 1
DMERKWM SN 17beta-Benzoyl-4-aza-5alpha-androst-1-en-3-one
DMERKWM DT Small molecular drug
DMERKWM PC 131705
DMERKWM MW 377.5
DMERKWM FM C25H31NO2
DMERKWM IC InChI=1S/C25H31NO2/c1-24-14-12-19-17(8-11-21-25(19,2)15-13-22(27)26-21)18(24)9-10-20(24)23(28)16-6-4-3-5-7-16/h3-7,13,15,17-21H,8-12,14H2,1-2H3,(H,26,27)/t17-,18-,19-,20+,21+,24-,25+/m0/s1
DMERKWM CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)C4=CC=CC=C4)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
DMERKWM IK ZYTQEOWFSVTRLX-QKONGSNMSA-N
DMERKWM IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-1-benzoyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one
DMERKWM CA CAS 134067-56-4
DMERKWM DE Prostate disease
DMB5NOI ID DMB5NOI
DMB5NOI DN MK-6592
DMB5NOI HS Discontinued in Phase 1
DMB5NOI SN VX-667
DMB5NOI CP Vertex Pharmaceuticals Inc
DMB5NOI PC 16731225
DMB5NOI MW 530
DMB5NOI FM C25H26ClF2N7O2
DMB5NOI IC InChI=1S/C25H26ClF2N7O2/c1-14-8-21(33-32-14)29-20-10-22(35-12-25(28,13-35)15-2-3-15)31-24(30-20)37-17-6-7-34(11-17)23(36)18-9-16(26)4-5-19(18)27/h4-5,8-10,15,17H,2-3,6-7,11-13H2,1H3,(H2,29,30,31,32,33)/t17-/m0/s1
DMB5NOI CS CC1=CC(=NN1)NC2=CC(=NC(=N2)O[C@H]3CCN(C3)C(=O)C4=C(C=CC(=C4)Cl)F)N5CC(C5)(C6CC6)F
DMB5NOI IK SLUHYAXFRJQTGB-KRWDZBQOSA-N
DMB5NOI IU (5-chloro-2-fluorophenyl)-[(3S)-3-[4-(3-cyclopropyl-3-fluoroazetidin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]oxypyrrolidin-1-yl]methanone
DMB5NOI DE Solid tumour/cancer
DMG72VK ID DMG72VK
DMG72VK DN MLN0415
DMG72VK HS Discontinued in Phase 1
DMG72VK SN SCHEMBL3805703
DMG72VK CP Takeda
DMG72VK DT Small molecular drug
DMG72VK PC 86630595
DMG72VK MW 610.1
DMG72VK FM C27H36ClN5O7S
DMG72VK IC InChI=1S/C26H32ClN5O4.CH4O3S/c1-15-10-31(11-16(2)36-15)23(33)12-32-14-26(3,4)35-13-22(32)25(34)30-20-8-17(27)7-19-18-5-6-28-9-21(18)29-24(19)20;1-5(2,3)4/h5-9,15-16,22,29H,10-14H2,1-4H3,(H,30,34);1H3,(H,2,3,4)/t15-,16+,22-;/m0./s1
DMG72VK CS C[C@@H]1CN(C[C@@H](O1)C)C(=O)CN2CC(OC[C@H]2C(=O)NC3=CC(=CC4=C3NC5=C4C=CN=C5)Cl)(C)C.CS(=O)(=O)O
DMG72VK IK VCONVNPAMVXEOA-ZOPSOCCDSA-N
DMG72VK IU (3S)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-oxoethyl]-6,6-dimethylmorpholine-3-carboxamide;methanesulfonic acid
DMG72VK DE Arthritis
DMQA5JW ID DMQA5JW
DMQA5JW DN MLN-2201
DMQA5JW HS Discontinued in Phase 1
DMQA5JW SN LDP-01; MLN-01; Anti-beta2-integrin MAb, LeukoSite
DMQA5JW CP LeukoSite Inc
DMQA5JW DT Antibody
DMQA5JW DE Cerebrovascular ischaemia
DM2PUYI ID DM2PUYI
DM2PUYI DN MN-246
DM2PUYI HS Discontinued in Phase 1
DM2PUYI SN Incontinence therapy, MediciNova; TT-138; Beta 3 adrenoceptor agonist (incontinence), MediciNova
DM2PUYI CP Mitsubishi Pharma Corp
DM2PUYI DE Urinary incontinence
DMKHEQL ID DMKHEQL
DMKHEQL DN Mofarotene
DMKHEQL HS Discontinued in Phase 1
DMKHEQL SN Ro-40-8757
DMKHEQL CP Roche Holding AG
DMKHEQL DT Small molecular drug
DMKHEQL PC 5467732
DMKHEQL MW 433.6
DMKHEQL FM C29H39NO2
DMKHEQL IC InChI=1S/C29H39NO2/c1-22(24-8-11-26-27(21-24)29(4,5)13-12-28(26,2)3)20-23-6-9-25(10-7-23)32-19-16-30-14-17-31-18-15-30/h6-11,20-21H,12-19H2,1-5H3/b22-20+
DMKHEQL CS C/C(=C\\C1=CC=C(C=C1)OCCN2CCOCC2)/C3=CC4=C(C=C3)C(CCC4(C)C)(C)C
DMKHEQL IK OUQPTBCOEKUHBH-LSDHQDQOSA-N
DMKHEQL IU 4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine
DMKHEQL CA CAS 125533-88-2
DMKHEQL DE Solid tumour/cancer
DMK91WR ID DMK91WR
DMK91WR DN MP-136
DMK91WR HS Discontinued in Phase 1
DMK91WR CP Mitsubishi Tanabe Pharma
DMK91WR DE Lipid metabolism disorder
DMMVG34 ID DMMVG34
DMMVG34 DN MPC-0920
DMMVG34 HS Discontinued in Phase 1
DMMVG34 CP Myriad Genetics
DMMVG34 DE Thrombosis
DMCMNKV ID DMCMNKV
DMCMNKV DN MPC-9055
DMCMNKV HS Discontinued in Phase 1
DMCMNKV SN Vivecon
DMCMNKV CP Myriad Genetics
DMCMNKV DE Human immunodeficiency virus infection
DMCJ1B2 ID DMCJ1B2
DMCJ1B2 DN MT-500
DMCJ1B2 HS Discontinued in Phase 1
DMCJ1B2 SN 199864-87-4; RS-127445; 4-(4-fluoronaphthalen-1-yl)-6-isopropylpyrimidin-2-amine; RS 127445; UNII-0JAU3P8OBM; MT 500; 0JAU3P8OBM; CHEMBL473186; C17H16FN3; RS-127445 HCl; 2-Amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine; RS127445; 2-Pyrimidinamine, 4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-; RS-127,445; 4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine; AC1L52MZ; GTPL188; RS 127445 hydrochloride/; SCHEMBL375979; MolPort-021-804-999; ZZZQXCUPAJFVBN-UHFFFAOYSA-N; HMS3651H11; BCPP000085; BCP02714; ZINC3961115
DMCJ1B2 DT Small molecular drug
DMCJ1B2 PC 196968
DMCJ1B2 MW 281.33
DMCJ1B2 FM C17H16FN3
DMCJ1B2 IC InChI=1S/C17H16FN3/c1-10(2)15-9-16(21-17(19)20-15)13-7-8-14(18)12-6-4-3-5-11(12)13/h3-10H,1-2H3,(H2,19,20,21)
DMCJ1B2 CS CC(C)C1=NC(=NC(=C1)C2=CC=C(C3=CC=CC=C32)F)N
DMCJ1B2 IK ZZZQXCUPAJFVBN-UHFFFAOYSA-N
DMCJ1B2 IU 4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine
DMCJ1B2 CA CAS 199864-87-4
DMCJ1B2 DE Migraine
DMC4RK7 ID DMC4RK7
DMC4RK7 DN MX-4509
DMC4RK7 HS Discontinued in Phase 1
DMC4RK7 SN 17alpha-Estradiol; 57-91-0; Alfatradiol; Epiestradiol; 17-alpha-Estradiol; 3,17-Dihydroxyestratriene; 17a-estradiol; Estradiol-17alpha; Epiestrol; 17-Epiestradiol; Estra-1,3,5(10)-triene-3,17alpha-diol; 17alpha estradiol; NSC 20293; UNII-3VQ38D63M7; Alfatradiol [INN]; Oestradiol-17alpha; 17alpha-Oestradiol; Estradiol, 17alpha-; CHEBI:17160; VOXZDWNPVJITMN-SFFUCWETSA-N; 3VQ38D63M7; 17-epi-Estradiol; Alfatradiol (INN); Oestradiol-17-alpha; MITO-4509; Parkinsons therapeutics, MitoKor; Drug screening (Parkinsons), MitoKor; Estrogen analogs (Parkinsons), Mitokor
DMC4RK7 CP MitoKor; Migenix
DMC4RK7 DT Small molecular drug
DMC4RK7 PC 68570
DMC4RK7 MW 272.4
DMC4RK7 FM C18H24O2
DMC4RK7 IC InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17-,18+/m1/s1
DMC4RK7 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@H]2O)CCC4=C3C=CC(=C4)O
DMC4RK7 IK VOXZDWNPVJITMN-SFFUCWETSA-N
DMC4RK7 IU (8R,9S,13S,14S,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMC4RK7 CA CAS 57-91-0
DMC4RK7 CB CHEBI:17160
DMC4RK7 DE Neurological disorder
DM4MTPU ID DM4MTPU
DM4MTPU DN NBI-42902
DM4MTPU HS Discontinued in Phase 1
DM4MTPU SN 352290-60-9; UNII-3FWQ4MD98O; 3FWQ4MD98O; CHEMBL179691; NBI42902; GTPL1187; GTPL1178; SCHEMBL5758034; ZINC6716969; BDBM50162007; NBI 42902; API0005260; 2,4(1H,3H)-Pyrimidinedione, 3-((2R)-2-amino-2-phenylethyl)-1-((2,6-difluorophenyl)methyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyl-; KB-138000; FT-0771447; 3-[(2R)-2-amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4-dione
DM4MTPU DT Small molecular drug
DM4MTPU PC 11167850
DM4MTPU MW 495.5
DM4MTPU FM C27H24F3N3O3
DM4MTPU IC InChI=1S/C27H24F3N3O3/c1-16-24(18-10-6-13-23(36-2)25(18)30)26(34)33(15-22(31)17-8-4-3-5-9-17)27(35)32(16)14-19-20(28)11-7-12-21(19)29/h3-13,22H,14-15,31H2,1-2H3/t22-/m0/s1
DM4MTPU CS CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)F)C[C@@H](C3=CC=CC=C3)N)C4=C(C(=CC=C4)OC)F
DM4MTPU IK CJUWBZDJMYYRDG-QFIPXVFZSA-N
DM4MTPU IU 3-[(2R)-2-amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4-dione
DM4MTPU CA CAS 352290-60-9
DM4MTPU DE Prostate cancer
DMMLESX ID DMMLESX
DMMLESX DN ND1251
DMMLESX HS Discontinued in Phase 1
DMMLESX SN JLFMYEAXZNPWBK-REWPJTCUSA-N; Ro64-6198; Ro-64-6198; CHEMBL2088034; Ro-646198; Ro 64-6198; GTPL1684; SCHEMBL2240259; ZINC3963671; BDBM50420802; Ro646198; (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[45]decan-4-one
DMMLESX CP Neuro3d
DMMLESX DT Small molecular drug
DMMLESX PC 9844019
DMMLESX MW 401.5
DMMLESX FM C26H31N3O
DMMLESX IC InChI=1S/C26H31N3O/c30-25-26(29(18-27-25)21-9-2-1-3-10-21)14-16-28(17-15-26)23-13-12-20-7-4-6-19-8-5-11-22(23)24(19)20/h1-3,5,8-11,20,23H,4,6-7,12-18H2,(H,27,30)/t20-,23-/m0/s1
DMMLESX CS C1C[C@H]2CC[C@@H](C3=CC=CC(=C23)C1)N4CCC5(CC4)C(=O)NCN5C6=CC=CC=C6
DMMLESX IK JLFMYEAXZNPWBK-REWPJTCUSA-N
DMMLESX IU 8-[(1S,3aS)-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMMLESX CA CAS 280783-56-4
DMMLESX DE Depression
DMK5VB2 ID DMK5VB2
DMK5VB2 DN Nerisopam
DMK5VB2 HS Discontinued in Phase 1
DMK5VB2 SN EGIS-6775
DMK5VB2 CP EGIS Gyogyszergyar RT
DMK5VB2 DT Small molecular drug
DMK5VB2 PC 65875
DMK5VB2 MW 309.4
DMK5VB2 FM C18H19N3O2
DMK5VB2 IC InChI=1S/C18H19N3O2/c1-11-8-13-9-16(22-2)17(23-3)10-15(13)18(21-20-11)12-4-6-14(19)7-5-12/h4-7,9-10H,8,19H2,1-3H3
DMK5VB2 CS CC1=NN=C(C2=CC(=C(C=C2C1)OC)OC)C3=CC=C(C=C3)N
DMK5VB2 IK WWQDEXGFYVSTCX-UHFFFAOYSA-N
DMK5VB2 IU 4-(7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)aniline
DMK5VB2 CA CAS 102771-12-0
DMK5VB2 DE Anxiety disorder
DMXDLUH ID DMXDLUH
DMXDLUH DN NGD-4715
DMXDLUH HS Discontinued in Phase 1
DMXDLUH SN NGD-4715; 476322-70-0; 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine; SCHEMBL4712990; DTXSID10432090; VAKYVNYLCIABRV-UHFFFAOYSA-N; HY-100318
DMXDLUH CP Neurogen Corp
DMXDLUH DT Small molecular drug
DMXDLUH PC 9866893
DMXDLUH MW 422.3
DMXDLUH FM C19H24BrN3O3
DMXDLUH IC InChI=1S/C19H24BrN3O3/c1-24-16-6-4-14(12-17(16)25-2)13-22-8-10-23(11-9-22)18-7-5-15(20)19(21-18)26-3/h4-7,12H,8-11,13H2,1-3H3
DMXDLUH CS COC1=C(C=C(C=C1)CN2CCN(CC2)C3=NC(=C(C=C3)Br)OC)OC
DMXDLUH IK VAKYVNYLCIABRV-UHFFFAOYSA-N
DMXDLUH IU 1-(5-bromo-6-methoxypyridin-2-yl)-4-[(3,4-dimethoxyphenyl)methyl]piperazine
DMXDLUH CA CAS 476322-70-0
DMXDLUH DE Obesity
DMZ9WLO ID DMZ9WLO
DMZ9WLO DN NGD-94-4
DMZ9WLO HS Discontinued in Phase 1
DMZ9WLO CP Neurogen Corp
DMZ9WLO DE Schizophrenia
DMMT7BC ID DMMT7BC
DMMT7BC DN NIP-520
DMMT7BC HS Discontinued in Phase 1
DMMT7BC SN NIP-502
DMMT7BC CP Nissan Chemical Industries Ltd
DMMT7BC DE Asthma
DM95NDT ID DM95NDT
DM95NDT DN NN-2501
DM95NDT HS Discontinued in Phase 1
DM95NDT CP Novo Nordisk A/S
DM95NDT DE Type-2 diabetes
DM8Z5VH ID DM8Z5VH
DM8Z5VH DN NN8210
DM8Z5VH HS Discontinued in Phase 1
DM8Z5VH CP Novo Nordisk
DM8Z5VH DE Rheumatoid arthritis
DMWDE8K ID DMWDE8K
DMWDE8K DN NOStentin
DMWDE8K HS Discontinued in Phase 1
DMWDE8K SN Gene therapy (restenosis); Gene therapy (iNOS), Cardion; Gene therapy (restenosis), Cardion
DMWDE8K CP Stanford University
DMWDE8K DE Artery stenosis
DMT8IGE ID DMT8IGE
DMT8IGE DN NP-252
DMT8IGE HS Discontinued in Phase 1
DMT8IGE SN 3-(Cyclopropylcarbonyl)-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-5-carboxylic acid octyl ester
DMT8IGE DT Small molecular drug
DMT8IGE PC 131462
DMT8IGE MW 469.6
DMT8IGE FM C26H35N3O5
DMT8IGE IC InChI=1S/C26H35N3O5/c1-4-5-6-7-8-11-16-34-26(31)23-18(3)27-17(2)22(25(30)28-19-14-15-19)24(23)20-12-9-10-13-21(20)29(32)33/h9-10,12-13,19,24,27H,4-8,11,14-16H2,1-3H3,(H,28,30)
DMT8IGE CS CCCCCCCCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2[N+](=O)[O-])C(=O)NC3CC3)C)C
DMT8IGE IK IAWVGADTHVEXRD-UHFFFAOYSA-N
DMT8IGE IU octyl 5-(cyclopropylcarbamoyl)-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DMT8IGE CA CAS 132031-81-3
DMT8IGE DE Hypertension
DMXI5YW ID DMXI5YW
DMXI5YW DN NP-61
DMXI5YW HS Discontinued in Phase 1
DMXI5YW SN Dual binding site acetylcholinesterase inhibitor, Neuropharma; NP-00361; NP-0361; AChE inhibitor (Alzheimer's) Neuropharma (Zeltia); AChE inhibitor/beta amyloid secretion inhibitor (oral formulation, Alzheimer's disease), Noscira
DMXI5YW CP Noscira SA
DMXI5YW DE Alzheimer disease
DMOMVW9 ID DMOMVW9
DMOMVW9 DN NPC-15669
DMOMVW9 HS Discontinued in Phase 1
DMOMVW9 SN Npc-15669; Npc 15669; UNII-K6JBN2T3Z4; K6JBN2T3Z4; N-(9H-(2,7-Dimethylfluoren-9-ylmethoxy)carbonyl)leucine; N-(((2,7-Dimethyl-9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine; L-Leucine, N-(((2,7-dimethyl-9H-fluoren-9-yl)methoxy)carbonyl)-; AC1L3OOH; 132684-62-9; CHEMBL42385; SCHEMBL8066678; LS-187592; LS-186942; (2S)-2-[(2,7-dimethyl-9H-fluoren-9-yl)methoxycarbonylamino]-4-methylpentanoic acid
DMOMVW9 CP Scios Inc
DMOMVW9 DT Small molecular drug
DMOMVW9 PC 119365
DMOMVW9 MW 381.5
DMOMVW9 FM C23H27NO4
DMOMVW9 IC InChI=1S/C23H27NO4/c1-13(2)9-21(22(25)26)24-23(27)28-12-20-18-10-14(3)5-7-16(18)17-8-6-15(4)11-19(17)20/h5-8,10-11,13,20-21H,9,12H2,1-4H3,(H,24,27)(H,25,26)/t21-/m0/s1
DMOMVW9 CS CC1=CC2=C(C=C1)C3=C(C2COC(=O)N[C@@H](CC(C)C)C(=O)O)C=C(C=C3)C
DMOMVW9 IK SEHPSBSPFWAVPK-NRFANRHFSA-N
DMOMVW9 IU (2S)-2-[(2,7-dimethyl-9H-fluoren-9-yl)methoxycarbonylamino]-4-methylpentanoic acid
DMOMVW9 CA CAS 132684-62-9
DMOMVW9 DE Inflammation
DMNL9DS ID DMNL9DS
DMNL9DS DN NSD-644
DMNL9DS HS Discontinued in Phase 1
DMNL9DS SN Serotonin/noradrenaline/dopamine activator (pain, depression, CNS disorder), NeuroSearch
DMNL9DS CP NeuroSearch A/S
DMNL9DS DE Neurological disorder
DM1QZKS ID DM1QZKS
DM1QZKS DN NTC-801
DM1QZKS HS Discontinued in Phase 1
DM1QZKS CP Bristol-Myers Squibb; Nissan Chemical; Teijin Pharma
DM1QZKS DE Atrial flutter; Atrial fibrillation
DMXJO5F ID DMXJO5F
DMXJO5F DN NZ-107
DMXJO5F HS Discontinued in Phase 1
DMXJO5F SN 4-Bromo-5-(3-ethoxy-4-methoxybenzylamino)pyridazin-3(2H)-one
DMXJO5F DT Small molecular drug
DMXJO5F PC 129496
DMXJO5F MW 354.2
DMXJO5F FM C14H16BrN3O3
DMXJO5F IC InChI=1S/C14H16BrN3O3/c1-3-21-12-6-9(4-5-11(12)20-2)7-16-10-8-17-18-14(19)13(10)15/h4-6,8H,3,7H2,1-2H3,(H2,16,18,19)
DMXJO5F CS CCOC1=C(C=CC(=C1)CNC2=C(C(=O)NN=C2)Br)OC
DMXJO5F IK KNIKAZNCSPYOED-UHFFFAOYSA-N
DMXJO5F IU 5-bromo-4-[(3-ethoxy-4-methoxyphenyl)methylamino]-1H-pyridazin-6-one
DMXJO5F CA CAS 107186-52-7
DMXJO5F DE Asthma
DMZN6F3 ID DMZN6F3
DMZN6F3 DN Odapipam
DMZN6F3 HS Discontinued in Phase 1
DMZN6F3 SN NNC 0756; NNC-756; NNC-01-0756
DMZN6F3 CP Novo Nordisk A/S
DMZN6F3 DT Small molecular drug
DMZN6F3 PC 132421
DMZN6F3 MW 329.8
DMZN6F3 FM C19H20ClNO2
DMZN6F3 IC InChI=1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
DMZN6F3 CS CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)Cl
DMZN6F3 IK SKMVRXPBCSTNKE-MRXNPFEDSA-N
DMZN6F3 IU (5S)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DMZN6F3 CA CAS 131796-63-9
DMZN6F3 DE Psychotic disorder
DM47ELH ID DM47ELH
DM47ELH DN Oncolysin M
DM47ELH HS Discontinued in Phase 1
DM47ELH SN Anti-CD33-bR; Anti-My9-bR
DM47ELH CP Dana-Farber Cancer Institute Inc
DM47ELH DE leukaemia
DML7Q56 ID DML7Q56
DML7Q56 DN ONO-1714
DML7Q56 HS Discontinued in Phase 1
DML7Q56 SN CHEMBL1800346; CHEMBL105792; SCHEMBL2717045; BDBM50386178
DML7Q56 DT Small molecular drug
DML7Q56 PC 9815538
DML7Q56 MW 195.09
DML7Q56 FM C7H12Cl2N2
DML7Q56 IC InChI=1S/C7H11ClN2.ClH/c1-3-2-4(9)10-7-5(3)6(7)8;/h3,5-7H,2H2,1H3,(H2,9,10);1H/t3-,5-,6+,7-;/m0./s1
DML7Q56 CS C[C@H]1CC(=N[C@H]2[C@@H]1[C@H]2Cl)N.Cl
DML7Q56 IK IZIZKGZAEABSET-IEUZAGAGSA-N
DML7Q56 IU (1S,5S,6R,7R)-7-chloro-5-methyl-2-azabicyclo[4.1.0]hept-2-en-3-amine;hydrochloride
DML7Q56 DE Sepsis
DM8KN2M ID DM8KN2M
DM8KN2M DN ONO-2231
DM8KN2M HS Discontinued in Phase 1
DM8KN2M SN ONO-1924H; PARP inhibitor (intravenous, stroke), ONO; Poly ADP ribose polymerase inhibitors (intravenous formulation, stroke), ONO
DM8KN2M CP Ono Pharmaceutical Co Ltd
DM8KN2M DE Cerebrovascular ischaemia
DMUSKY0 ID DMUSKY0
DMUSKY0 DN ONO-4127
DMUSKY0 HS Discontinued in Phase 1
DMUSKY0 SN Allergic rhinitis agent, Ono
DMUSKY0 CP Ono Pharmaceutical Co Ltd
DMUSKY0 DE Allergic rhinitis
DMKRVUN ID DMKRVUN
DMKRVUN DN ONO-4817
DMKRVUN HS Discontinued in Phase 1
DMKRVUN SN ONO-MI1-335
DMKRVUN CP Ono Pharmaceutical Co Ltd
DMKRVUN DT Small molecular drug
DMKRVUN PC 9888141
DMKRVUN MW 416.5
DMKRVUN FM C22H28N2O6
DMKRVUN IC InChI=1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)/t16-,18-/m0/s1
DMKRVUN CS CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)C1=CC=C(C=C1)OC2=CC=CC=C2
DMKRVUN IK HDWWQELUBWGQGA-WMZOPIPTSA-N
DMKRVUN IU N-[(2S,4S)-1-(ethoxymethoxy)-5-(hydroxyamino)-4-methyl-5-oxopentan-2-yl]-4-phenoxybenzamide
DMKRVUN DE Inflammatory bowel disease
DMB8T5U ID DMB8T5U
DMB8T5U DN ONT-093
DMB8T5U HS Discontinued in Phase 1
DMB8T5U SN MDR inhibitors, Ontogen; OC-144-093
DMB8T5U CP Ontogen Corp
DMB8T5U DT Small molecular drug
DMB8T5U PC 6450807
DMB8T5U MW 494.7
DMB8T5U FM C32H38N4O
DMB8T5U IC InChI=1S/C32H38N4O/c1-6-37-21-7-8-24-9-11-27(12-10-24)32-35-30(25-13-17-28(18-14-25)33-22(2)3)31(36-32)26-15-19-29(20-16-26)34-23(4)5/h7-20,22-23,33-34H,6,21H2,1-5H3,(H,35,36)/b8-7+
DMB8T5U CS CCOC/C=C/C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=C(C=C3)NC(C)C)C4=CC=C(C=C4)NC(C)C
DMB8T5U IK RSJCLODJSVZNQA-BQYQJAHWSA-N
DMB8T5U IU 4-[2-[4-[(E)-3-ethoxyprop-1-enyl]phenyl]-4-[4-(propan-2-ylamino)phenyl]-1H-imidazol-5-yl]-N-propan-2-ylaniline
DMB8T5U CA CAS 216227-54-2
DMB8T5U DE Solid tumour/cancer
DMDCOSP ID DMDCOSP
DMDCOSP DN OPC-51803
DMDCOSP HS Discontinued in Phase 1
DMDCOSP SN SOU-003; 2-[1-[2-Chloro-4-(1-pyrrolidinyl)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepin-5(R)-yl]-N-isopropylacetamide
DMDCOSP CP Otsuka America Pharmaceutical; Sosei
DMDCOSP DT Small molecular drug
DMDCOSP PC 3038506
DMDCOSP MW 454
DMDCOSP FM C26H32ClN3O2
DMDCOSP IC InChI=1S/C26H32ClN3O2/c1-18(2)28-25(31)16-19-8-7-15-30(24-10-4-3-9-21(19)24)26(32)22-12-11-20(17-23(22)27)29-13-5-6-14-29/h3-4,9-12,17-19H,5-8,13-16H2,1-2H3,(H,28,31)/t19-/m1/s1
DMDCOSP CS CC(C)NC(=O)C[C@H]1CCCN(C2=CC=CC=C12)C(=O)C3=C(C=C(C=C3)N4CCCC4)Cl
DMDCOSP IK INGXCNVWWKKWOO-LJQANCHMSA-N
DMDCOSP IU 2-[(5R)-1-(2-chloro-4-pyrrolidin-1-ylbenzoyl)-2,3,4,5-tetrahydro-1-benzazepin-5-yl]-N-propan-2-ylacetamide
DMDCOSP CA CAS 192514-54-8
DMDCOSP DE Urinary incontinence
DMPDJC8 ID DMPDJC8
DMPDJC8 DN Opterone
DMPDJC8 HS Discontinued in Phase 1
DMPDJC8 SN SEPA testosterone cream
DMPDJC8 CP MacroChem Corporation
DMPDJC8 DE Hormone deficiency
DMB5TL9 ID DMB5TL9
DMB5TL9 DN Orazipone
DMB5TL9 HS Discontinued in Phase 1
DMB5TL9 SN OR-1384
DMB5TL9 CP Orion Corp
DMB5TL9 DT Small molecular drug
DMB5TL9 PC 178387
DMB5TL9 MW 266.31
DMB5TL9 FM C13H14O4S
DMB5TL9 IC InChI=1S/C13H14O4S/c1-9(14)13(10(2)15)8-11-4-6-12(7-5-11)18(3,16)17/h4-8H,1-3H3
DMB5TL9 CS CC(=O)C(=CC1=CC=C(C=C1)S(=O)(=O)C)C(=O)C
DMB5TL9 IK CAWYWWPWSAMGBV-UHFFFAOYSA-N
DMB5TL9 IU 3-[(4-methylsulfonylphenyl)methylidene]pentane-2,4-dione
DMB5TL9 CA CAS 137109-78-5
DMB5TL9 DE Inflammatory bowel disease
DMQBURK ID DMQBURK
DMQBURK DN Ordopidine
DMQBURK HS Discontinued in Phase 1
DMQBURK SN ACR-321; ACR-325
DMQBURK CP A Carlsson Research AB
DMQBURK DT Small molecular drug
DMQBURK PC 11701939
DMQBURK MW 285.38
DMQBURK FM C14H20FNO2S
DMQBURK IC InChI=1S/C14H20FNO2S/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18/h4-6,11H,3,7-10H2,1-2H3
DMQBURK CS CCN1CCC(CC1)C2=C(C(=CC=C2)S(=O)(=O)C)F
DMQBURK IK UKUPJASJNQDHPH-UHFFFAOYSA-N
DMQBURK IU 1-ethyl-4-(2-fluoro-3-methylsulfonylphenyl)piperidine
DMQBURK CA CAS 871351-60-9
DMQBURK DE Psychotic disorder
DMMYI9U ID DMMYI9U
DMMYI9U DN Org-21465
DMMYI9U HS Discontinued in Phase 1
DMMYI9U SN SCHEMBL8751071; Org 21465
DMMYI9U CP Organon BioSciences
DMMYI9U DT Small molecular drug
DMMYI9U PC 9803583
DMMYI9U MW 445.6
DMMYI9U FM C27H43NO4
DMMYI9U IC InChI=1S/C27H43NO4/c1-16(29)19-8-9-20-18-7-6-17-12-22(30)21(28-10-11-32-25(2,3)15-28)13-26(17,4)24(18)23(31)14-27(19,20)5/h17-22,24,30H,6-15H2,1-5H3/t17-,18-,19+,20-,21-,22-,24+,26-,27+/m0/s1
DMMYI9U CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOC(C5)(C)C)C)C
DMMYI9U IK HQEJMKVZYCQIIH-JJLPOIBOSA-N
DMMYI9U IU (2S,3S,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-2-(2,2-dimethylmorpholin-4-yl)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
DMMYI9U CA CAS 167946-96-5
DMMYI9U DE Anaesthesia
DMZKTU5 ID DMZKTU5
DMZKTU5 DN Org-31710
DMZKTU5 HS Discontinued in Phase 1
DMZKTU5 SN Org-31806
DMZKTU5 CP Organon BioSciences
DMZKTU5 DT Small molecular drug
DMZKTU5 PC 164090
DMZKTU5 MW 445.6
DMZKTU5 FM C30H39NO2
DMZKTU5 IC InChI=1S/C30H39NO2/c1-19-16-25-27-12-14-30(13-5-15-33-30)29(27,2)18-26(20-6-8-21(9-7-20)31(3)4)28(25)23-11-10-22(32)17-24(19)23/h6-9,17,19,25-27H,5,10-16,18H2,1-4H3/t19-,25+,26-,27+,29+,30+/m1/s1
DMZKTU5 CS C[C@@H]1C[C@H]2[C@@H]3CC[C@]4([C@]3(C[C@@H](C2=C5C1=CC(=O)CC5)C6=CC=C(C=C6)N(C)C)C)CCCO4
DMZKTU5 IK HFDGABTZPISMDD-IEVXGSBISA-N
DMZKTU5 IU (6R,8S,11R,13S,14S,17R)-11-[4-(dimethylamino)phenyl]-6,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one
DMZKTU5 CA CAS 118968-41-5
DMZKTU5 DE Contraception
DM5UYI7 ID DM5UYI7
DM5UYI7 DN OX 19
DM5UYI7 HS Discontinued in Phase 1
DM5UYI7 SN Sublingual desmopressin
DM5UYI7 CP Orexo
DM5UYI7 DE Urinary incontinence
DMF4KPM ID DMF4KPM
DMF4KPM DN PA-1050040
DMF4KPM HS Discontinued in Phase 1
DMF4KPM SN PA-040
DMF4KPM CP Panacos
DMF4KPM DE Human immunodeficiency virus infection
DM6LQGO ID DM6LQGO
DM6LQGO DN Pafenolol
DM6LQGO HS Discontinued in Phase 1
DM6LQGO SN H-138/03; Pafenolol; Rac-N-[2-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]ethyl]-N'-isopropylurea
DM6LQGO DT Small molecular drug
DM6LQGO PC 71144
DM6LQGO MW 337.5
DM6LQGO FM C18H31N3O3
DM6LQGO IC InChI=1S/C18H31N3O3/c1-13(2)20-11-16(22)12-24-17-7-5-15(6-8-17)9-10-19-18(23)21-14(3)4/h5-8,13-14,16,20,22H,9-12H2,1-4H3,(H2,19,21,23)
DM6LQGO CS CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)NC(C)C)O
DM6LQGO IK PKWZWSXSCKVUJB-UHFFFAOYSA-N
DM6LQGO IU 1-[2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethyl]-3-propan-2-ylurea
DM6LQGO CA CAS 75949-61-0
DM6LQGO DE Hypertension
DMVFGWM ID DMVFGWM
DMVFGWM DN PD-131112
DMVFGWM HS Discontinued in Phase 1
DMVFGWM SN 7-[(3S)-3-Aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 7-[(3S)-3-amino-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid; 127967-03-7; 7-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid; ci-990; 1,8-Naphthyridine-3-carboxylic acid, 7-((3S)-3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-; CI-990 (Hydrochloride); AC1L2I3J; CHEMBL51678; PD131628; CI-990; [S-(R*,R*)]-7-[3-(2-Aminopropanamido)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; (S,S)-7-[3-(Alanylamino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 122536-20-3; PD-131628
DMVFGWM DT Small molecular drug
DMVFGWM PC 9953002
DMVFGWM MW 403.4
DMVFGWM FM C19H22FN5O4
DMVFGWM IC InChI=1S/C19H22FN5O4/c1-9(21)18(27)22-10-4-5-24(7-10)17-14(20)6-12-15(26)13(19(28)29)8-25(11-2-3-11)16(12)23-17/h6,8-11H,2-5,7,21H2,1H3,(H,22,27)(H,28,29)/t9-,10-/m0/s1
DMVFGWM CS C[C@@H](C(=O)N[C@H]1CCN(C1)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F)N
DMVFGWM IK ZVZRDFTXNAZBOX-UWVGGRQHSA-N
DMVFGWM IU 7-[(3S)-3-[[(2S)-2-aminopropanoyl]amino]pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DMVFGWM DE Bacterial infection
DM7KJTI ID DM7KJTI
DM7KJTI DN PD-153035
DM7KJTI HS Discontinued in Phase 1
DM7KJTI SN 183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo
DM7KJTI DT Small molecular drug
DM7KJTI PC 4705
DM7KJTI MW 360.2
DM7KJTI FM C16H14BrN3O2
DM7KJTI IC InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)
DM7KJTI CS COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br)OC
DM7KJTI IK LSPANGZZENHZNJ-UHFFFAOYSA-N
DM7KJTI IU N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine
DM7KJTI CA CAS 153436-54-5
DM7KJTI CB CHEBI:91076
DM7KJTI DE Psoriasis vulgaris
DMO4S6T ID DMO4S6T
DMO4S6T DN PF-03814735
DMO4S6T HS Discontinued in Phase 1
DMO4S6T SN PF-03814735; 942490-07-5; PF 03814735; PF-3814735; PF03814735; Kinome_1769; MLS006010949; CHEMBL1983111; SB19308; NCGC00389594-01; KB-74441; SMR004703046; BCP0726000114; J3.628.238J; N-(2-(6-((4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-1,2,3,4-tetrahydro-1,4-epiminonaphthalen-9-yl)-2-oxoethyl)acetamide; N-[2-(4-{[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-11-azatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-11-yl)-2-oxoethyl]acetamide
DMO4S6T CP Pfizer
DMO4S6T DT Small molecular drug
DMO4S6T PC 51346455
DMO4S6T MW 474.5
DMO4S6T FM C23H25F3N6O2
DMO4S6T IC InChI=1S/C23H25F3N6O2/c1-12(33)27-11-20(34)32-18-7-8-19(32)16-9-14(5-6-15(16)18)30-22-28-10-17(23(24,25)26)21(31-22)29-13-3-2-4-13/h5-6,9-10,13,18-19H,2-4,7-8,11H2,1H3,(H,27,33)(H2,28,29,30,31)/t18-,19+/m0/s1
DMO4S6T CS CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1C3=C2C=CC(=C3)NC4=NC=C(C(=N4)NC5CCC5)C(F)(F)F
DMO4S6T IK RYYNGWLOYLRZLK-RBUKOAKNSA-N
DMO4S6T IU N-[2-[(1R,8S)-4-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-11-yl]-2-oxoethyl]acetamide
DMO4S6T CA CAS 942487-16-3
DMO4S6T DE Advanced solid tumour
DMD83VY ID DMD83VY
DMD83VY DN PF-05212372
DMD83VY HS Discontinued in Phase 1
DMD83VY SN PLA-950; Asthma therapy (inhaled, asthma), Pfizer; Asthma therapy (inhaled, asthma), Wyeth
DMD83VY CP Wyeth
DMD83VY DE Asthma
DM68PYA ID DM68PYA
DM68PYA DN PF-05236812
DM68PYA HS Discontinued in Phase 1
DM68PYA SN AAB-003
DM68PYA CP Wyeth
DM68PYA DE Alzheimer disease
DMSE3WP ID DMSE3WP
DMSE3WP DN PF-06260414
DMSE3WP HS Discontinued in Phase 1
DMSE3WP SN PF-14
DMSE3WP CP PharmacoFore Inc
DMSE3WP PC 76071881
DMSE3WP MW 302.35
DMSE3WP FM C14H14N4O2S
DMSE3WP IC InChI=1S/C14H14N4O2S/c1-10-8-17-21(19,20)18(9-10)12-2-3-13-11(6-12)4-5-16-14(13)7-15/h2-6,10,17H,8-9H2,1H3/t10-/m1/s1
DMSE3WP CS C[C@@H]1CNS(=O)(=O)N(C1)C2=CC3=C(C=C2)C(=NC=C3)C#N
DMSE3WP IK ZKAVFOXYJCREBQ-SNVBAGLBSA-N
DMSE3WP IU 6-[(4R)-4-methyl-1,1-dioxo-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
DMSE3WP CA CAS 1612755-71-1
DMSE3WP DE Cachexia; Pain
DM5R2MG ID DM5R2MG
DM5R2MG DN PF-2393296
DM5R2MG HS Discontinued in Phase 1
DM5R2MG SN IDDBCP185108
DM5R2MG CP Pfizer Inc
DM5R2MG DE Neuropathic pain
DM2V7WH ID DM2V7WH
DM2V7WH DN PF-251802
DM2V7WH HS Discontinued in Phase 1
DM2V7WH SN PF-00251802; Selective glucocorticoid receptor agonist (1), Pfizer
DM2V7WH CP Pfizer Inc
DM2V7WH DE Rheumatoid arthritis
DMOQZIW ID DMOQZIW
DMOQZIW DN PF-3052334
DMOQZIW HS Discontinued in Phase 1
DMOQZIW SN PF-3052334; SCHEMBL3959323
DMOQZIW DT Small molecular drug
DMOQZIW PC 24742042
DMOQZIW MW 533.6
DMOQZIW FM C28H33FN3NaO5
DMOQZIW IC InChI=1S/C28H34FN3O5.Na/c1-17(2)26-24(13-12-22(33)14-23(34)15-25(35)36)32(21-10-8-20(29)9-11-21)31-27(26)28(37)30-16-19-6-4-18(3)5-7-19;/h4-11,17,22-23,33-34H,12-16H2,1-3H3,(H,30,37)(H,35,36);/q;+1/p-1/t22-,23-;/m1./s1
DMOQZIW CS CC1=CC=C(C=C1)CNC(=O)C2=NN(C(=C2C(C)C)CC[C@H](C[C@H](CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+]
DMOQZIW IK VEGKDAAILHTMLD-OHIDFYLOSA-M
DMOQZIW IU sodium;(3R,5R)-7-[2-(4-fluorophenyl)-5-[(4-methylphenyl)methylcarbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate
DMOQZIW DE Arteriosclerosis
DMCFYZM ID DMCFYZM
DMCFYZM DN PF-3185043
DMCFYZM HS Discontinued in Phase 1
DMCFYZM CP Pfizer
DMCFYZM DE Arteriosclerosis
DMD42MN ID DMD42MN
DMD42MN DN PF-3274167
DMD42MN HS Discontinued in Phase 1
DMD42MN SN PF-3274167; Cligosiban; 900510-03-4; UNII-D361S17AIF; D361S17AIF; CHEMBL594828; 5-(3-(3-(2-chloro-4-fluorophenoxy)azetidin-1-yl)-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl)-2-methoxypyridine; Cligosiban [INN]; 5-{3-[3-(2-chloro-4-fluorophenoxy)azetidin-1-yl]-5-(methoxymethyl)-4H-1,2,4-triazol-4-yl}-2-methoxypyridine; SCHEMBL4126605; EX-A297; MolPort-044-567-557; BCP08878; ZINC38239529; BDBM50305506; AKOS030526977; CS-5337; HY-15023; PF3274167; B5924; PF 3274167; J-690387; Pyridine, 5-(3-(3-(2-chloro-4-fluorophenoxy)-1-azetidinyl)-5
DMD42MN DT Small molecular drug
DMD42MN PC 11683187
DMD42MN MW 419.8
DMD42MN FM C19H19ClFN5O3
DMD42MN IC InChI=1S/C19H19ClFN5O3/c1-27-11-17-23-24-19(26(17)13-4-6-18(28-2)22-8-13)25-9-14(10-25)29-16-5-3-12(21)7-15(16)20/h3-8,14H,9-11H2,1-2H3
DMD42MN CS COCC1=NN=C(N1C2=CN=C(C=C2)OC)N3CC(C3)OC4=C(C=C(C=C4)F)Cl
DMD42MN IK HNIFCPBQMKPRCX-UHFFFAOYSA-N
DMD42MN IU 5-[3-[3-(2-chloro-4-fluorophenoxy)azetidin-1-yl]-5-(methoxymethyl)-1,2,4-triazol-4-yl]-2-methoxypyridine
DMD42MN CA CAS 900510-03-4
DMD42MN DE Female sexual arousal dysfunction
DMMU1W3 ID DMMU1W3
DMMU1W3 DN PF-3526299
DMMU1W3 HS Discontinued in Phase 1
DMMU1W3 CP Pfizer Inc
DMMU1W3 DE Asthma
DMITYCN ID DMITYCN
DMITYCN DN PF-3557156
DMITYCN HS Discontinued in Phase 1
DMITYCN SN PDE 7 inhibitor (pain), Pfizer; Phosphodiesterase 7 inhibitor (pain), Pfizer
DMITYCN CP Pfizer Inc
DMITYCN DE Pain
DMNLAU7 ID DMNLAU7
DMNLAU7 DN PF-4629991
DMNLAU7 HS Discontinued in Phase 1
DMNLAU7 SN PF-991; S1P1 receptor agonist (autoimmune disease), Pfizer
DMNLAU7 CP Pfizer Inc
DMNLAU7 DE Rheumatoid arthritis
DMDOTW0 ID DMDOTW0
DMDOTW0 DN PF-477736
DMDOTW0 HS Discontinued in Phase 1
DMDOTW0 CP Pfizer
DMDOTW0 DT Small molecular drug
DMDOTW0 PC 135565545
DMDOTW0 MW 419.5
DMDOTW0 FM C22H25N7O2
DMDOTW0 IC InChI=1S/C22H25N7O2/c1-29-11-13(9-25-29)20-16-10-24-28-21(30)15-7-14(8-17(27-20)18(15)16)26-22(31)19(23)12-5-3-2-4-6-12/h7-12,19,27H,2-6,23H2,1H3,(H,26,31)(H,28,30)/t19-/m1/s1
DMDOTW0 CS CN1C=C(C=N1)C2=C3C=NNC(=O)C4=C3C(=CC(=C4)NC(=O)[C@@H](C5CCCCC5)N)N2
DMDOTW0 IK NDEXUOWTGYUVGA-LJQANCHMSA-N
DMDOTW0 IU (2R)-2-amino-2-cyclohexyl-N-[2-(1-methylpyrazol-4-yl)-9-oxo-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-6-yl]acetamide
DMDOTW0 CA CAS 952021-60-2
DMDOTW0 CB CHEBI:91385
DMDOTW0 DE Advanced solid tumour
DMS7M0U ID DMS7M0U
DMS7M0U DN PF-514273
DMS7M0U HS Discontinued in Phase 1
DMS7M0U SN PF 514273; 2-(2-CHLOROPHENYL)-3-(4-CHLOROPHENYL)-7-(2,2-DIFLUOROPROPYL)-6,7-DIHYDRO-2H-PYRAZOLO[3,4-F][1,4]OXAZEPIN-8(5H)-ONE; FJMQJSUOOGOWBD-UHFFFAOYSA-N; SCHEMBL1315434; CHEMBL484929; BDBM29075; DTXSID80462142; MolPort-023-276-895; ZINC40939374; AKOS024457743; API0006251; NCGC00370822-01; PF-0514273; FT-0673651; PF-514273, >
DMS7M0U CP Pfizer Inc
DMS7M0U DT Small molecular drug
DMS7M0U PC 11316919
DMS7M0U MW 452.3
DMS7M0U FM C21H17Cl2F2N3O2
DMS7M0U IC InChI=1S/C21H17Cl2F2N3O2/c1-21(24,25)12-27-10-11-30-19-17(20(27)29)26-28(16-5-3-2-4-15(16)23)18(19)13-6-8-14(22)9-7-13/h2-9H,10-12H2,1H3
DMS7M0U CS CC(CN1CCOC2=C(N(N=C2C1=O)C3=CC=CC=C3Cl)C4=CC=C(C=C4)Cl)(F)F
DMS7M0U IK FJMQJSUOOGOWBD-UHFFFAOYSA-N
DMS7M0U IU 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one
DMS7M0U CA CAS 851728-60-4
DMS7M0U DE Obesity
DMB7EIN ID DMB7EIN
DMB7EIN DN PF-915275
DMB7EIN HS Discontinued in Phase 1
DMB7EIN SN PF-915275; 857290-04-1; PF 915275; UNII-388927163B; N-(6-aminopyridin-2-yl)-4'-cyanobiphenyl-4-sulfonamide; 388927163B; ZESFDAKNYJQYKO-UHFFFAOYSA-N; SCHEMBL4384483; CHEMBL495841; CTK5F5674; BDBM29864; DTXSID00235037; MolPort-023-276-737; KS-00001D9U; BCP28049; ZINC40955326; AKOS024457530; CS-5559; N-(Pyridin-2-yl) arylsulfonamide, 26; NCGC00370811-01; HY-18056; RT-015014; KB-274983; B7346; N-(6-Aminopyridin-2-yl)4'-cyanobiphenyl-4-sulfonamide; N-(6-Amino-2-pyridinyl)-4'-cyano-[1,1'-biphenyl]-4-sulfonamide
DMB7EIN DT Small molecular drug
DMB7EIN PC 23725123
DMB7EIN MW 350.4
DMB7EIN FM C18H14N4O2S
DMB7EIN IC InChI=1S/C18H14N4O2S/c19-12-13-4-6-14(7-5-13)15-8-10-16(11-9-15)25(23,24)22-18-3-1-2-17(20)21-18/h1-11H,(H3,20,21,22)
DMB7EIN CS C1=CC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C#N)N
DMB7EIN IK ZESFDAKNYJQYKO-UHFFFAOYSA-N
DMB7EIN IU N-(6-aminopyridin-2-yl)-4-(4-cyanophenyl)benzenesulfonamide
DMB7EIN CA CAS 857290-04-1
DMB7EIN DE Non-insulin dependent diabetes
DMAPD6M ID DMAPD6M
DMAPD6M DN PLD-147
DMAPD6M HS Discontinued in Phase 1
DMAPD6M SN LA-12; (OC-6-43)Bis(acetato-kappaO)amminedichloro(adamant-1-ylamine)platinum
DMAPD6M DT Small molecular drug
DMAPD6M PC 10007773
DMAPD6M MW 552.4
DMAPD6M FM C14H26Cl2N2O4Pt
DMAPD6M IC InChI=1S/C10H17N.2C2H4O2.2ClH.H3N.Pt/c11-10-4-7-1-8(5-10)3-9(2-7)6-10;2*1-2(3)4;;;;/h7-9H,1-6,11H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
DMAPD6M CS CC(=O)[O-].CC(=O)[O-].C1C2CC3CC1CC(C2)(C3)N.N.[Cl-].[Cl-].[Pt+4]
DMAPD6M IK RGCIZXNKLJAKIS-UHFFFAOYSA-J
DMAPD6M IU adamantan-1-amine;azane;platinum(4+);diacetate;dichloride
DMAPD6M CA CAS 250611-20-2
DMAPD6M DE Solid tumour/cancer
DMFKC7L ID DMFKC7L
DMFKC7L DN PN-355
DMFKC7L HS Discontinued in Phase 1
DMFKC7L SN AndroVir; Tyrosine kinase inhibitors (HIV infection), Paracelsian
DMFKC7L CP Paracelsian Inc
DMFKC7L DE Human immunodeficiency virus-1 infection
DMPWG2K ID DMPWG2K
DMPWG2K DN PNU-142721
DMPWG2K HS Discontinued in Phase 1
DMPWG2K SN PNU-109866; PNU-142721E
DMPWG2K CP Pharmacia & Upjohn Inc
DMPWG2K DT Small molecular drug
DMPWG2K PC 446309
DMPWG2K MW 306.77
DMPWG2K FM C13H11ClN4OS
DMPWG2K IC InChI=1S/C13H11ClN4OS/c1-7(20-13-17-11(14)5-12(15)18-13)9-4-8-2-3-19-10(8)6-16-9/h2-7H,1H3,(H2,15,17,18)/t7-/m0/s1
DMPWG2K CS C[C@@H](C1=NC=C2C(=C1)C=CO2)SC3=NC(=CC(=N3)Cl)N
DMPWG2K IK ATCRIOJPQXDFNY-ZETCQYMHSA-N
DMPWG2K IU 6-chloro-2-[(1S)-1-furo[2,3-c]pyridin-5-ylethyl]sulfanylpyrimidin-4-amine
DMPWG2K CA CAS 185220-03-5
DMPWG2K DE Human immunodeficiency virus infection
DMG2WAX ID DMG2WAX
DMG2WAX DN Prostate cancer vaccine
DMG2WAX HS Discontinued in Phase 1
DMG2WAX SN Prostate cancer vaccine, United Biomedical; SUIS-LHRH; UBITh LHRH peptide, UBI; Peptide (prostate cancer), UBI; UBITh LHRH immunotherapeutics (prostate cancer), United Biomedical
DMG2WAX CP United Biomedical Inc
DMG2WAX DT Vaccine
DMG2WAX DE Prostate cancer
DM4LNBQ ID DM4LNBQ
DM4LNBQ DN Pyroxamide
DM4LNBQ HS Discontinued in Phase 1
DM4LNBQ SN POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide
DM4LNBQ CP National Cancer Institute (NCI)
DM4LNBQ DT Small molecular drug
DM4LNBQ PC 4996
DM4LNBQ MW 265.31
DM4LNBQ FM C13H19N3O3
DM4LNBQ IC InChI=1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)
DM4LNBQ CS C1=CC(=CN=C1)NC(=O)CCCCCCC(=O)NO
DM4LNBQ IK PTJGLFIIZFVFJV-UHFFFAOYSA-N
DM4LNBQ IU N'-hydroxy-N-pyridin-3-yloctanediamide
DM4LNBQ CA CAS 382180-17-8
DM4LNBQ CB CHEBI:93953
DM4LNBQ DE Solid tumour/cancer
DMU93JL ID DMU93JL
DMU93JL DN R 80122
DMU93JL HS Discontinued in Phase 1
DMU93JL DT Small molecular drug
DMU93JL PC 135544124
DMU93JL MW 459.5
DMU93JL FM C26H29N5O3
DMU93JL IC InChI=1S/C26H29N5O3/c1-30(21-10-6-3-7-11-21)24(33)17-34-29-25(18-8-4-2-5-9-18)19-12-13-22-20(14-19)15-31-16-23(32)28-26(31)27-22/h2,4-5,8-9,12-14,21H,3,6-7,10-11,15-17H2,1H3,(H,27,28,32)/b29-25+
DMU93JL CS CN(C1CCCCC1)C(=O)CO/N=C(\\C2=CC=CC=C2)/C3=CC4=C(C=C3)N=C5NC(=O)CN5C4
DMU93JL IK VHDUUXNHZLBGHQ-XLVZBRSZSA-N
DMU93JL IU N-cyclohexyl-N-methyl-2-[(E)-[(2-oxo-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-7-yl)-phenylmethylidene]amino]oxyacetamide
DMU93JL CA CAS 133718-29-3
DMU93JL DE Cardiovascular disease
DMHPV1D ID DMHPV1D
DMHPV1D DN R-1065
DMHPV1D HS Discontinued in Phase 1
DMHPV1D SN VR-1065; Ro-60-0332
DMHPV1D CP Vernalis Group plc
DMHPV1D DE Obesity
DML7M3S ID DML7M3S
DML7M3S DN R-1068
DML7M3S HS Discontinued in Phase 1
DML7M3S CP Roche Holding AG
DML7M3S DE Vomiting
DMRHF97 ID DMRHF97
DMRHF97 DN R1204
DMRHF97 HS Discontinued in Phase 1
DMRHF97 CP Roche
DMRHF97 PC 15461
DMRHF97 MW 162.23
DMRHF97 FM C11H14O
DMRHF97 IC InChI=1S/C11H14O/c1-7-5-8(2)11(10(4)12)9(3)6-7/h5-6H,1-4H3
DMRHF97 CS CC1=CC(=C(C(=C1)C)C(=O)C)C
DMRHF97 IK XWCIICLTKWRWCI-UHFFFAOYSA-N
DMRHF97 IU 1-(2,4,6-trimethylphenyl)ethanone
DMRHF97 CA CAS 1667-01-2
DMRHF97 DE Depression
DMT8V9G ID DMT8V9G
DMT8V9G DN R1295
DMT8V9G HS Discontinued in Phase 1
DMT8V9G SN CHEMBL2146615
DMT8V9G CP Roche
DMT8V9G DT Small molecular drug
DMT8V9G PC 70329
DMT8V9G MW 166.17
DMT8V9G FM C9H10O3
DMT8V9G IC InChI=1S/C9H10O3/c1-7-2-4-8(5-3-7)12-6-9(10)11/h2-5H,6H2,1H3,(H,10,11)
DMT8V9G CS CC1=CC=C(C=C1)OCC(=O)O
DMT8V9G IK SFTDDFBJWUWKMN-UHFFFAOYSA-N
DMT8V9G IU 2-(4-methylphenoxy)acetic acid
DMT8V9G CA CAS 940-64-7
DMT8V9G DE Rheumatoid arthritis
DM9C6LN ID DM9C6LN
DM9C6LN DN R-1479
DM9C6LN HS Discontinued in Phase 1
DM9C6LN SN 4-Azidocytidine
DM9C6LN CP Roche Holding AG
DM9C6LN DT Small molecular drug
DM9C6LN PC 457388
DM9C6LN MW 284.23
DM9C6LN FM C9H12N6O5
DM9C6LN IC InChI=1S/C9H12N6O5/c10-4-1-2-15(8(19)12-4)7-5(17)6(18)9(3-16,20-7)13-14-11/h1-2,5-7,16-18H,3H2,(H2,10,12,19)/t5-,6+,7-,9-/m1/s1
DM9C6LN CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@](O2)(CO)N=[N+]=[N-])O)O
DM9C6LN IK ODLGMSQBFONGNG-JVZYCSMKSA-N
DM9C6LN IU 4-amino-1-[(2R,3R,4S,5R)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DM9C6LN CA CAS 478182-28-4
DM9C6LN DE Hepatitis C virus infection
DM7WPI0 ID DM7WPI0
DM7WPI0 DN R-1487
DM7WPI0 HS Discontinued in Phase 1
DM7WPI0 SN 449811-92-1; 6-(2,4-difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; UNII-IO0DCY55NQ; R-1487; IO0DCY55NQ; CHEMBL1230122; 6-(2,4-difluorophenoxy)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2h-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8h)-one; Kinome_3762; SCHEMBL5120612; KKKRKRMVJRHDMG-UHFFFAOYSA-N; HMS3401C13; BDBM50341342; ZINC58633224; AKOS027420928; NCGC00262195-02; KB-80224; ACM449811921
DM7WPI0 CP Roche Holding AG
DM7WPI0 DT Small molecular drug
DM7WPI0 PC 11406590
DM7WPI0 MW 388.4
DM7WPI0 FM C19H18F2N4O3
DM7WPI0 IC InChI=1S/C19H18F2N4O3/c1-25-17-11(10-22-19(24-17)23-13-4-6-27-7-5-13)8-16(18(25)26)28-15-3-2-12(20)9-14(15)21/h2-3,8-10,13H,4-7H2,1H3,(H,22,23,24)
DM7WPI0 CS CN1C2=NC(=NC=C2C=C(C1=O)OC3=C(C=C(C=C3)F)F)NC4CCOCC4
DM7WPI0 IK KKKRKRMVJRHDMG-UHFFFAOYSA-N
DM7WPI0 IU 6-(2,4-difluorophenoxy)-8-methyl-2-(oxan-4-ylamino)pyrido[2,3-d]pyrimidin-7-one
DM7WPI0 CA CAS 449811-92-1
DM7WPI0 DE Rheumatoid arthritis
DM2J5AO ID DM2J5AO
DM2J5AO DN R-1518
DM2J5AO HS Discontinued in Phase 1
DM2J5AO SN Levovirin prodrug, Roche
DM2J5AO CP Roche Holding AG
DM2J5AO PC 10249157
DM2J5AO MW 379.8
DM2J5AO FM C13H22ClN5O6
DM2J5AO IC InChI=1S/C13H21N5O6.ClH/c1-5(2)7(14)13(22)23-3-6-8(19)9(20)12(24-6)18-4-16-11(17-18)10(15)21;/h4-9,12,19-20H,3,14H2,1-2H3,(H2,15,21);1H/t6-,7-,8-,9-,12-;/m0./s1
DM2J5AO CS CC(C)[C@@H](C(=O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC(=N2)C(=O)N)O)O)N.Cl
DM2J5AO IK BZAMJGAXDMZZKX-JSNLFJDGSA-N
DM2J5AO IU [(2S,3R,4S,5S)-5-(3-carbamoyl-1,2,4-triazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate;hydrochloride
DM2J5AO CA CAS 705930-02-5
DM2J5AO DE Hepatitis C virus infection
DMK25FU ID DMK25FU
DMK25FU DN R547
DMK25FU HS Discontinued in Phase 1
DMK25FU SN LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone
DMK25FU CP Hoffmann CLa Roche
DMK25FU DT Small molecular drug
DMK25FU PC 6918852
DMK25FU MW 441.5
DMK25FU FM C18H21F2N5O4S
DMK25FU IC InChI=1S/C18H21F2N5O4S/c1-29-13-4-3-12(19)15(20)14(13)16(26)11-9-22-18(24-17(11)21)23-10-5-7-25(8-6-10)30(2,27)28/h3-4,9-10H,5-8H2,1-2H3,(H3,21,22,23,24)
DMK25FU CS COC1=C(C(=C(C=C1)F)F)C(=O)C2=CN=C(N=C2N)NC3CCN(CC3)S(=O)(=O)C
DMK25FU IK JRNJNYBQQYBCLE-UHFFFAOYSA-N
DMK25FU IU [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone
DMK25FU CA CAS 741713-40-6
DMK25FU DE Advanced solid tumour
DMF3A6H ID DMF3A6H
DMF3A6H DN R-701
DMF3A6H HS Discontinued in Phase 1
DMF3A6H CP Roche Holding AG
DMF3A6H DE Overactive bladder
DMETAP8 ID DMETAP8
DMETAP8 DN R7232
DMETAP8 HS Discontinued in Phase 1
DMETAP8 CP Roche
DMETAP8 PC 13637622
DMETAP8 MW 172.61
DMETAP8 FM C7H9ClN2O
DMETAP8 IC InChI=1S/C7H9ClN2O/c1-4-6(7(8)11)5(2)10(3)9-4/h1-3H3
DMETAP8 CS CC1=C(C(=NN1C)C)C(=O)Cl
DMETAP8 IK UFNVZQRBSDFSPY-UHFFFAOYSA-N
DMETAP8 IU 1,3,5-trimethylpyrazole-4-carbonyl chloride
DMETAP8 CA CAS 98298-63-6
DMETAP8 DE Dyslipidemia
DMTK3DR ID DMTK3DR
DMTK3DR DN R-82150
DMTK3DR HS Discontinued in Phase 1
DMTK3DR SN R 82150; R82150; NSC633810; 126320-77-2; CHEMBL46961; methyl(3-methylbut-2-enyl)[ ]thione; NSC-633810; AC1MHD28; SCHEMBL599870; BDBM1433; TIBO R82150; TIBO-R82150; DTXSID60155141; 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione; (5R)-5beta-Methyl-6-(3-methyl-2-butenyl)-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione; (+)-S-4,6,7-Tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione
DMTK3DR DT Small molecular drug
DMTK3DR PC 3000236
DMTK3DR MW 287.4
DMTK3DR FM C16H21N3S
DMTK3DR IC InChI=1S/C16H21N3S/c1-11(2)7-8-18-10-13-5-4-6-14-15(13)19(9-12(18)3)16(20)17-14/h4-7,12H,8-10H2,1-3H3,(H,17,20)/t12-/m0/s1
DMTK3DR CS C[C@H]1CN2C3=C(CN1CC=C(C)C)C=CC=C3NC2=S
DMTK3DR IK WTTIBCHOELPGFK-LBPRGKRZSA-N
DMTK3DR IU (11S)-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-thione
DMTK3DR CA CAS 126320-77-2
DMTK3DR DE Human immunodeficiency virus infection
DM4WJHY ID DM4WJHY
DM4WJHY DN R-82913
DM4WJHY HS Discontinued in Phase 1
DM4WJHY SN 9-Cl-Tibo; R-82913; 9-Cmbib; r82913; R 82913; UNII-4FOI87E52P; 4-CHLORO-8-METHYL-7-(3-METHYL-BUT-2-ENYL)-6,7,8,9-TETRAHYDRO-2H-2,7,9A-TRIAZA-BENZO[CD]AZULENE-1-THIONE; NSC 637653; CHEMBL293498; 4FOI87E52P; 126347-69-1; 9-Chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4,5,1-jk)(1,4)benzodiazepine-2-(1H)-thione; 4,5,6,7-Tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4,5,1-jk)(1,4)benzodiazepin-2-(1H)-thione; TB9; Imidazo(4,5,1-jk)(1,4)benzodiazepine-2(1H)-thione, 9-chloro-4,5,6,7-tetrahydro-5-
DM4WJHY DT Small molecular drug
DM4WJHY PC 3000237
DM4WJHY MW 321.9
DM4WJHY FM C16H20ClN3S
DM4WJHY IC InChI=1S/C16H20ClN3S/c1-10(2)4-5-19-9-12-6-13(17)7-14-15(12)20(8-11(19)3)16(21)18-14/h4,6-7,11H,5,8-9H2,1-3H3,(H,18,21)/t11-/m0/s1
DM4WJHY CS C[C@H]1CN2C3=C(CN1CC=C(C)C)C=C(C=C3NC2=S)Cl
DM4WJHY IK RCSLUNOLLUVOOG-NSHDSACASA-N
DM4WJHY IU (11S)-6-chloro-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-thione
DM4WJHY CA CAS 126347-69-1
DM4WJHY DE Human immunodeficiency virus infection
DMJ2ZVW ID DMJ2ZVW
DMJ2ZVW DN R-944
DMJ2ZVW HS Discontinued in Phase 1
DMJ2ZVW SN HIV protease inhibitors, Roche; Ro-332910
DMJ2ZVW CP Roche Products Ltd
DMJ2ZVW DE Human immunodeficiency virus infection
DMVID8E ID DMVID8E
DMVID8E DN Ramorelix
DMVID8E HS Discontinued in Phase 1
DMVID8E SN Hoe-013
DMVID8E CP Aventis Pharma AG
DMVID8E PC 25077455
DMVID8E MW 1532.1
DMVID8E FM C74H95ClN16O18
DMVID8E IC InChI=1S/C74H95ClN16O18/c1-38(2)29-52(63(98)82-51(15-9-27-79-73(76)77)71(106)91-28-10-16-59(91)70(105)89-90-74(78)107)83-69(104)58(37-108-72-62(97)61(96)60(95)39(3)109-72)88-66(101)55(32-42-20-25-48(94)26-21-42)85-68(103)57(36-92)87-67(102)56(34-46-35-80-50-14-8-7-13-49(46)50)86-65(100)54(31-41-18-23-47(75)24-19-41)84-64(99)53(81-40(4)93)33-43-17-22-44-11-5-6-12-45(44)30-43/h5-8,11-14,17-26,30,35,38-39,51-62,72,80,92,94-97H,9-10,15-16,27-29,31-34,36-37H2,1-4H3,(H,81,93)(H,82,98)(H,83,104)(H,84,99)(H,85,103)(H,86,100)(H,87,102)(H,88,101)(H,89,105)(H4,76,77,79)(H3,78,90,107)/t39-,51-,52-,53+,54+,55-,56+,57-,58+,59-,60-,61+,62+,72+/m0/s1
DMVID8E CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2CCC[C@H]2C(=O)NNC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C)O)O)O
DMVID8E IK WDYSQADGBBEGRQ-APSDYLPASA-N
DMVID8E IU (2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]-N-[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-methylpentanamide
DMVID8E CA CAS 127932-90-5
DMVID8E DE Esophageal cancer
DM3V5O2 ID DM3V5O2
DM3V5O2 DN RB-6145
DM3V5O2 HS Discontinued in Phase 1
DM3V5O2 SN PD-144872
DM3V5O2 CP BTG plc
DM3V5O2 DT Small molecular drug
DM3V5O2 PC 125377
DM3V5O2 MW 374.03
DM3V5O2 FM C8H14Br2N4O3
DM3V5O2 IC InChI=1S/C8H13BrN4O3.BrH/c9-1-2-10-5-7(14)6-12-4-3-11-8(12)13(15)16;/h3-4,7,10,14H,1-2,5-6H2;1H
DM3V5O2 CS C1=CN(C(=N1)[N+](=O)[O-])CC(CNCCBr)O.Br
DM3V5O2 IK XPBJPGMCFKYBBV-UHFFFAOYSA-N
DM3V5O2 IU 1-(2-bromoethylamino)-3-(2-nitroimidazol-1-yl)propan-2-ol;hydrobromide
DM3V5O2 CA CAS 129448-97-1
DM3V5O2 DE Solid tumour/cancer
DMR6QMJ ID DMR6QMJ
DMR6QMJ DN RC-8800
DMR6QMJ HS Discontinued in Phase 1
DMR6QMJ SN 24-hydroxylase inhibitor (prostate cancer), Rejuvenon; 24-hydroxylase inhibitor (prostate cancer), Sapphire
DMR6QMJ CP Novo Nordisk A/S
DMR6QMJ DE Solid tumour/cancer
DM0ILRU ID DM0ILRU
DM0ILRU DN RDEA-436
DM0ILRU HS Discontinued in Phase 1
DM0ILRU SN MEK inhibitor, Ardea; MEK inhibitor (cancer), Bayer; MEK inhibitor 200 series (cancer), Bayer HealthCare; MEK inhibitor 200 series (inflammation), Ardea; Mitogen-activated ERK kinase inhibitor (inflammation), Ardea; RDEA-436 (cancer), Bayer HealthCare; RDEA-436 (cancer/inflammation), Ardea
DM0ILRU CP Ardea Biosciences Inc
DM0ILRU DE Solid tumour/cancer
DMW08TD ID DMW08TD
DMW08TD DN REGN 3048
DMW08TD HS Discontinue in Phase 1 Trial
DMW08TD TC Antiviral Agents
DMW08TD DT Monoclonal antibody
DMW08TD DE Middle East Respiratory Syndrome (MERS)
DMLH28J ID DMLH28J
DMLH28J DN REGN 3051
DMLH28J HS Discontinue in Phase 1 Trial
DMLH28J TC Antiviral Agents
DMLH28J DT Monoclonal antibody
DMLH28J DE Middle East Respiratory Syndrome (MERS)
DMT5VXF ID DMT5VXF
DMT5VXF DN Revatropate
DMT5VXF HS Discontinued in Phase 1
DMT5VXF SN UK-112166; UK-112,166; UK-112166-04; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-methylsulfinyl-2-phenylbutanoate; (3R-(3R*(S*(R*))))-1-Azabicyclo(2.2.2)oct-3-yl alpha-(hydroxymethyl)-alpha-(2-(methylsulfinyl)ethyl)benzenacetate
DMT5VXF CP Pfizer
DMT5VXF DT Small molecular drug
DMT5VXF PC 9690123
DMT5VXF MW 365.5
DMT5VXF FM C19H27NO4S
DMT5VXF IC InChI=1S/C19H27NO4S/c1-25(23)12-9-19(14-21,16-5-3-2-4-6-16)18(22)24-17-13-20-10-7-15(17)8-11-20/h2-6,15,17,21H,7-14H2,1H3/t17-,19-,25-/m0/s1
DMT5VXF CS C[S@](=O)CC[C@](CO)(C1=CC=CC=C1)C(=O)O[C@H]2CN3CCC2CC3
DMT5VXF IK VGXACJMXDYPFDB-KMEZTADASA-N
DMT5VXF IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-(hydroxymethyl)-4-[(S)-methylsulfinyl]-2-phenylbutanoate
DMT5VXF DE Chronic obstructive pulmonary disease
DMW4G68 ID DMW4G68
DMW4G68 DN RG-201
DMW4G68 HS Discontinued in Phase 1
DMW4G68 CP Questcor Pharmaceuticals Inc
DMW4G68 DE Acquired immune deficiency syndrome
DMOI037 ID DMOI037
DMOI037 DN RG-4934
DMOI037 HS Discontinued in Phase 1
DMOI037 SN IL-17 huMAb (psoriatic arthritis), Roche
DMOI037 CP Roche Holding AG
DMOI037 DT Antibody
DMOI037 DE Arthritis
DMG9U8D ID DMG9U8D
DMG9U8D DN RG-7152
DMG9U8D HS Discontinued in Phase 1
DMG9U8D SN 5-[3-[3-(2-Quinolinylmethoxy)phenoxy]propyl]-1H-tetrazole
DMG9U8D DT Small molecular drug
DMG9U8D PC 129968
DMG9U8D MW 361.4
DMG9U8D FM C20H19N5O2
DMG9U8D IC InChI=1S/C20H19N5O2/c1-2-8-19-15(5-1)10-11-16(21-19)14-27-18-7-3-6-17(13-18)26-12-4-9-20-22-24-25-23-20/h1-3,5-8,10-11,13H,4,9,12,14H2,(H,22,23,24,25)
DMG9U8D CS C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)OCCCC4=NNN=N4
DMG9U8D IK XDPLTERFGJAMRU-UHFFFAOYSA-N
DMG9U8D IU 2-[[3-[3-(2H-tetrazol-5-yl)propoxy]phenoxy]methyl]quinoline
DMG9U8D CA CAS 107813-63-8
DMG9U8D DE Asthma
DMKLPMW ID DMKLPMW
DMKLPMW DN RG-7166
DMKLPMW HS Discontinued in Phase 1
DMKLPMW SN Triple reuptake inhibitors (depression), Roche; Serotonin/norephineprine/dopamine reuptake inhibitors (depression), Roche
DMKLPMW CP Roche Holding AG
DMKLPMW DE Major depressive disorder
DMGLRK0 ID DMGLRK0
DMGLRK0 DN RG-7167
DMGLRK0 HS Discontinued in Phase 1
DMGLRK0 SN CIF; R-7167; CIF (solid tumors), Chugai/Roche; MEK inhibitor (oral, solid tumors), Roche/Chugai
DMGLRK0 CP Chugai Pharmaceutical Co Ltd
DMGLRK0 DE Solid tumour/cancer
DM12VHC ID DM12VHC
DM12VHC DN RG-7185
DM12VHC HS Discontinued in Phase 1
DM12VHC SN CRTH2 antagonist (asthma), Roche
DM12VHC CP Roche Holding AG
DM12VHC DE Asthma
DMDPWCM ID DMDPWCM
DMDPWCM DN RG-7236
DMDPWCM HS Discontinued in Phase 1
DMDPWCM SN RG7236
DMDPWCM CP Hoffmann-La Roche
DMDPWCM DE Cardiovascular disease
DM0LXBW ID DM0LXBW
DM0LXBW DN RG-7256
DM0LXBW HS Discontinued in Phase 1
DM0LXBW SN B-raf inhibitor (melanoma), Roche/Plexxikon
DM0LXBW CP Roche Holding AG
DM0LXBW DE Melanoma
DMXMQAT ID DMXMQAT
DMXMQAT DN RG-7273
DMXMQAT HS Discontinued in Phase 1
DMXMQAT SN RG 7273; RG7273
DMXMQAT CP Hoffmann-La Roche
DMXMQAT DE Lipid metabolism disorder
DMUR6OV ID DMUR6OV
DMUR6OV DN RG-7356
DMUR6OV HS Discontinued in Phase 1
DMUR6OV SN RO-5429083; AR-001 series, ARIUS; ARH460-16-2; ChARH460-16-2; H460-16-2; MuARH460-16-2; Anti-CD44 antibody (cancer), ARIUS; Anti-CD44 mAb (cancer), Roche; Chimeric ARH460-16-2-IgG1; Chimeric ARH460-16-2-IgG2; (ch)ARH460-16-2-IgG1; (ch)ARH460-16-2-IgG2
DMUR6OV CP ARIUS Research Inc
DMUR6OV DT Antibody
DMUR6OV DE Haematological malignancy
DMXRHDL ID DMXRHDL
DMXRHDL DN RG7418
DMXRHDL HS Discontinued in Phase 1
DMXRHDL SN BI204
DMXRHDL CP BioInvent; Genentech
DMXRHDL DE Arteriosclerosis
DMSUV3B ID DMSUV3B
DMSUV3B DN RG-7432
DMSUV3B HS Discontinued in Phase 1
DMSUV3B CP Roche Holding AG
DMSUV3B DE Hepatitis C virus infection
DMW87YE ID DMW87YE
DMW87YE DN RG7458
DMW87YE HS Discontinued in Phase 1
DMW87YE CP Genentech
DMW87YE DT Antibody
DMW87YE DE Ovarian cancer
DMXJAFC ID DMXJAFC
DMXJAFC DN RG7602
DMXJAFC HS Discontinued in Phase 1
DMXJAFC CP Array BioPharma; Roche
DMXJAFC DE Lymphoma
DMQAK6T ID DMQAK6T
DMQAK6T DN Rhodamine-123
DMQAK6T HS Discontinued in Phase 1
DMQAK6T SN RH 123; Rhodamine 123; Rh-123, Huntington; Rhodamine-123 (intravenous infusion); Rhodamine-123 (intravenous infusion), Huntington Medical Research Institutes
DMQAK6T CP Huntington Medical Research Institutes
DMQAK6T DT Small molecular drug
DMQAK6T PC 9929799
DMQAK6T MW 380.8
DMQAK6T FM C21H17ClN2O3
DMQAK6T IC InChI=1S/C21H16N2O3.ClH/c1-25-21(24)15-5-3-2-4-14(15)20-16-8-6-12(22)10-18(16)26-19-11-13(23)7-9-17(19)20;/h2-11,22H,23H2,1H3;1H
DMQAK6T CS COC(=O)C1=CC=CC=C1C2=C3C=CC(=N)C=C3OC4=C2C=CC(=C4)N.Cl
DMQAK6T IK MYFATKRONKHHQL-UHFFFAOYSA-N
DMQAK6T IU methyl 2-(3-amino-6-iminoxanthen-9-yl)benzoate;hydrochloride
DMQAK6T CA CAS 62669-70-9
DMQAK6T CB CHEBI:8828
DMQAK6T DE Prostate cancer
DMLQD6F ID DMLQD6F
DMLQD6F DN RIG-200
DMLQD6F HS Discontinued in Phase 1
DMLQD6F SN 1,3,4,6-Tetra-O-acetyl-2-[2(S)-(acetylamino)-3-methyl-3-(nitrososulfanyl)butyramido]-2-deoxy-beta-D-glucopyranose
DMLQD6F DT Small molecular drug
DMLQD6F PC 6918441
DMLQD6F MW 549.6
DMLQD6F FM C21H31N3O12S
DMLQD6F IC InChI=1S/C21H31N3O12S/c1-9(25)22-18(21(6,7)37-24-31)19(30)23-15-17(34-12(4)28)16(33-11(3)27)14(8-32-10(2)26)36-20(15)35-13(5)29/h14-18,20H,8H2,1-7H3,(H,22,25)(H,23,30)/t14-,15-,16-,17-,18+,20-/m1/s1
DMLQD6F CS CC(=O)N[C@@H](C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C)C(C)(C)SN=O
DMLQD6F IK VISYVRBZWPNIOD-GFJCLWMYSA-N
DMLQD6F IU [(2R,3S,4R,5R,6S)-5-[[(2S)-2-acetamido-3-methyl-3-nitrososulfanylbutanoyl]amino]-3,4,6-triacetyloxyoxan-2-yl]methyl acetate
DMLQD6F DE Hypertension
DMBQZTO ID DMBQZTO
DMBQZTO DN Rilmakalim
DMBQZTO HS Discontinued in Phase 1
DMBQZTO SN Hoe-234
DMBQZTO CP Hoechst AG
DMBQZTO DT Small molecular drug
DMBQZTO PC 65966
DMBQZTO MW 401.5
DMBQZTO FM C21H23NO5S
DMBQZTO IC InChI=1S/C21H23NO5S/c1-21(2)20(24)19(22-12-6-9-18(22)23)16-13-15(10-11-17(16)27-21)28(25,26)14-7-4-3-5-8-14/h3-5,7-8,10-11,13,19-20,24H,6,9,12H2,1-2H3/t19-,20+/m1/s1
DMBQZTO CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)S(=O)(=O)C3=CC=CC=C3)N4CCCC4=O)O)C
DMBQZTO IK LKAQWOWWTKFLNX-UXHICEINSA-N
DMBQZTO IU 1-[(3S,4R)-6-(benzenesulfonyl)-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]pyrrolidin-2-one
DMBQZTO CA CAS 132014-21-2
DMBQZTO DE Chronic obstructive pulmonary disease
DMOVZDY ID DMOVZDY
DMOVZDY DN RO-16-8714
DMOVZDY HS Discontinued in Phase 1
DMOVZDY SN P-[(R)-3-[Bis-[(R)-beta-hydroxyphenethyl]amino]butyl]benzamide
DMOVZDY DT Small molecular drug
DMOVZDY PC 146200
DMOVZDY MW 432.6
DMOVZDY FM C27H32N2O3
DMOVZDY IC InChI=1S/C27H32N2O3/c1-20(12-13-21-14-16-24(17-15-21)27(28)32)29(18-25(30)22-8-4-2-5-9-22)19-26(31)23-10-6-3-7-11-23/h2-11,14-17,20,25-26,30-31H,12-13,18-19H2,1H3,(H2,28,32)
DMOVZDY CS CC(CCC1=CC=C(C=C1)C(=O)N)N(CC(C2=CC=CC=C2)O)CC(C3=CC=CC=C3)O
DMOVZDY IK OPPQEWZOPDBGAS-UHFFFAOYSA-N
DMOVZDY IU 4-[3-[bis(2-hydroxy-2-phenylethyl)amino]butyl]benzamide
DMOVZDY CA CAS 90505-66-1
DMOVZDY DE Diabetic complication
DMAJDPN ID DMAJDPN
DMAJDPN DN Ro-31-6930
DMAJDPN HS Discontinued in Phase 1
DMAJDPN SN Ro-31-6930; 120280-37-7; 2H-1-Benzopyran-6-carbonitrile,2,2-dimethyl-4-(1-oxido-2-pyridinyl)-; Ro 31-6930; ACMC-20motq; AC1MI1CT; CHEMBL97196; SCHEMBL6369348; CTK4B1782; DTXSID70152787; PQVILGHAVGQHRP-UHFFFAOYSA-N; 2-(6-cyano-2,2-dimethyl-2H1-benzopyran-4-yl)pyridine N-oxide; 2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)chromene-6-carbonitrile; 2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)pyridine 1-oxide; 2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)pyridine N-oxide
DMAJDPN CP Roche Holding AG
DMAJDPN DT Small molecular drug
DMAJDPN PC 3036546
DMAJDPN MW 278.3
DMAJDPN FM C17H14N2O2
DMAJDPN IC InChI=1S/C17H14N2O2/c1-17(2)10-14(15-5-3-4-8-19(15)20)13-9-12(11-18)6-7-16(13)21-17/h3-10H,1-2H3
DMAJDPN CS CC1(C=C(C2=C(O1)C=CC(=C2)C#N)C3=CC=CC=[N+]3[O-])C
DMAJDPN IK PQVILGHAVGQHRP-UHFFFAOYSA-N
DMAJDPN IU 2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)chromene-6-carbonitrile
DMAJDPN CA CAS 120280-37-7
DMAJDPN DE Hypertension
DMOX8AD ID DMOX8AD
DMOX8AD DN RO-48-8684
DMOX8AD HS Discontinued in Phase 1
DMOX8AD SN 3-[5-(Dipropylaminomethyl)oxazol-2-yl]-8-fluoro-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMOX8AD PC 9866317
DMOX8AD MW 411.5
DMOX8AD FM C22H26FN5O2
DMOX8AD IC InChI=1S/C22H26FN5O2/c1-4-8-27(9-5-2)12-16-11-24-21(30-16)20-19-13-26(3)22(29)17-10-15(23)6-7-18(17)28(19)14-25-20/h6-7,10-11,14H,4-5,8-9,12-13H2,1-3H3
DMOX8AD CS CCCN(CCC)CC1=CN=C(O1)C2=C3CN(C(=O)C4=C(N3C=N2)C=CC(=C4)F)C
DMOX8AD IK YKKLHEHNUYCLQQ-UHFFFAOYSA-N
DMOX8AD IU 3-[5-[(dipropylamino)methyl]-1,3-oxazol-2-yl]-8-fluoro-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMOX8AD DE Anxiety disorder
DMMF0OP ID DMMF0OP
DMMF0OP DN RO-4987655
DMMF0OP HS Discontinued in Phase 1
DMMF0OP SN CH-4987655; RO-04927350; MEK inhibitors (solid tumor), Roche
DMMF0OP CP F Hoffmann-La Roche Ltd
DMMF0OP DT Small molecular drug
DMMF0OP PC 11548630
DMMF0OP MW 565.3
DMMF0OP FM C20H19F3IN3O5
DMMF0OP IC InChI=1S/C20H19F3IN3O5/c21-14-9-12(24)3-4-15(14)25-19-13(20(30)26-31-7-5-28)8-11(17(22)18(19)23)10-27-16(29)2-1-6-32-27/h3-4,8-9,25,28H,1-2,5-7,10H2,(H,26,30)
DMMF0OP CS C1CC(=O)N(OC1)CC2=CC(=C(C(=C2F)F)NC3=C(C=C(C=C3)I)F)C(=O)NOCCO
DMMF0OP IK FIMYFEGKMOCQKT-UHFFFAOYSA-N
DMMF0OP IU 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide
DMMF0OP CA CAS 874101-00-5
DMMF0OP DE Solid tumour/cancer
DMP0YNU ID DMP0YNU
DMP0YNU DN RO7040547
DMP0YNU HS Discontinued in Phase 1
DMP0YNU SN BITS7201A; RG7990
DMP0YNU CP Roche
DMP0YNU DT Antibody
DMP0YNU DE Asthma
DMMK42O ID DMMK42O
DMMK42O DN Roquinimex
DMMK42O HS Discontinued in Phase 1
DMMK42O SN Linomide
DMMK42O CP Pharmacia & Upjohn AB
DMMK42O DT Small molecular drug
DMMK42O PC 54676478
DMMK42O MW 308.3
DMMK42O FM C18H16N2O3
DMMK42O IC InChI=1S/C18H16N2O3/c1-19(12-8-4-3-5-9-12)17(22)15-16(21)13-10-6-7-11-14(13)20(2)18(15)23/h3-11,21H,1-2H3
DMMK42O CS CN1C2=CC=CC=C2C(=C(C1=O)C(=O)N(C)C3=CC=CC=C3)O
DMMK42O IK SGOOQMRIPALTEL-UHFFFAOYSA-N
DMMK42O IU 4-hydroxy-N,1-dimethyl-2-oxo-N-phenylquinoline-3-carboxamide
DMMK42O CA CAS 84088-42-6
DMMK42O CB CHEBI:92056
DMMK42O DE Rheumatoid arthritis
DM94R8B ID DM94R8B
DM94R8B DN RS-100975
DM94R8B HS Discontinued in Phase 1
DM94R8B SN RS-97078; Ro-70-0004
DM94R8B CP Roche Bioscience
DM94R8B DT Small molecular drug
DM94R8B PC 9872515
DM94R8B MW 444.4
DM94R8B FM C20H24F4N4O3
DM94R8B IC InChI=1S/C20H24F4N4O3/c1-14-12-25-19(30)28(18(14)29)6-2-5-26-7-9-27(10-8-26)16-4-3-15(21)11-17(16)31-13-20(22,23)24/h3-4,11-12H,2,5-10,13H2,1H3,(H,25,30)
DM94R8B CS CC1=CNC(=O)N(C1=O)CCCN2CCN(CC2)C3=C(C=C(C=C3)F)OCC(F)(F)F
DM94R8B IK WEZFJPKJUIGDPS-UHFFFAOYSA-N
DM94R8B IU 3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-1H-pyrimidine-2,4-dione
DM94R8B CA CAS 186386-21-0
DM94R8B DE Prostate disease
DM4P5WO ID DM4P5WO
DM4P5WO DN RS-8891
DM4P5WO HS Discontinued in Phase 1
DM4P5WO CP Sankyo Co Ltd
DM4P5WO DE Hypertension
DMMEAZ2 ID DMMEAZ2
DMMEAZ2 DN RU-58841
DMMEAZ2 HS Discontinued in Phase 1
DMMEAZ2 SN 154992-24-2; RU 58841; RU58841; 4-(3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile; ARBYGDBJECGMGA-UHFFFAOYSA-N; UNII-0D8FJQ0ADW; 0D8FJQ0ADW; CHEMBL9337; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile; AK-64424; 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile; Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)-
DMMEAZ2 DT Small molecular drug
DMMEAZ2 PC 132981
DMMEAZ2 MW 369.34
DMMEAZ2 FM C17H18F3N3O3
DMMEAZ2 IC InChI=1S/C17H18F3N3O3/c1-16(2)14(25)23(15(26)22(16)7-3-4-8-24)12-6-5-11(10-21)13(9-12)17(18,19)20/h5-6,9,24H,3-4,7-8H2,1-2H3
DMMEAZ2 CS CC1(C(=O)N(C(=O)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMMEAZ2 IK ARBYGDBJECGMGA-UHFFFAOYSA-N
DMMEAZ2 IU 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
DMMEAZ2 CA CAS 154992-24-2
DMMEAZ2 DE Acne vulgaris
DMSHYAP ID DMSHYAP
DMSHYAP DN RUS 3108
DMSHYAP HS Discontinued in Phase 1
DMSHYAP CP Dr. Reddy's Laboratories
DMSHYAP DE Arteriosclerosis
DM6BIHE ID DM6BIHE
DM6BIHE DN RWJ-56423
DM6BIHE HS Discontinued in Phase 1
DM6BIHE SN RWJ-56423; CHEMBL256892; CHEMBL124571; (2S,4R)-1-ACETYL-N-[(1S)-4-[(AMINOIMINOMETHYL)AMINO]-1-(2-BENZOTHIAZOLYLCARBONYL)BUTYL]-4-HYDROXY-2-PYRROLIDINECARBOXAMIDE; (2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide; AC1NR9Y0; SCHEMBL4314345; GTPL9333; VXDAVYUFYPFGDX-SNPRPXQTSA-N; BDBM50228764; BDBM50131977; DB02812; (2S)-6; (4R)-1-acetyl-N-[(1S)-1-(1,3-benzothiazol-2-ylcarbonyl)-4-carbamimidamidobutyl]-4-hydroxy-L-prolinamide
DM6BIHE DT Small molecular drug
DM6BIHE PC 5287596
DM6BIHE MW 446.5
DM6BIHE FM C20H26N6O4S
DM6BIHE IC InChI=1S/C20H26N6O4S/c1-11(27)26-10-12(28)9-15(26)18(30)24-14(6-4-8-23-20(21)22)17(29)19-25-13-5-2-3-7-16(13)31-19/h2-3,5,7,12,14-15,28H,4,6,8-10H2,1H3,(H,24,30)(H4,21,22,23)/t12-,14+,15+/m1/s1
DM6BIHE CS CC(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)C2=NC3=CC=CC=C3S2)O
DM6BIHE IK VXDAVYUFYPFGDX-SNPRPXQTSA-N
DM6BIHE IU (2S,4R)-1-acetyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-4-hydroxypyrrolidine-2-carboxamide
DM6BIHE DE Asthma
DMRXB8F ID DMRXB8F
DMRXB8F DN S-1746
DMRXB8F HS Discontinued in Phase 1
DMRXB8F CP Shionogi & Co Ltd
DMRXB8F DE Cerebrovascular ischaemia
DMX59E8 ID DMX59E8
DMX59E8 DN S-18326
DMX59E8 HS Discontinued in Phase 1
DMX59E8 SN Acetyl-D-phenylalanyl-N-(cyclopentyl)-glycyl-L-1-boroarginine
DMX59E8 PC 9891654
DMX59E8 MW 488.4
DMX59E8 FM C23H37BN6O5
DMX59E8 IC InChI=1S/C23H37BN6O5/c1-16(31)28-19(14-17-8-3-2-4-9-17)22(33)30(18-10-5-6-11-18)15-21(32)29-20(24(34)35)12-7-13-27-23(25)26/h2-4,8-9,18-20,34-35H,5-7,10-15H2,1H3,(H,28,31)(H,29,32)(H4,25,26,27)/t19-,20+/m1/s1
DMX59E8 CS B([C@H](CCCN=C(N)N)NC(=O)CN(C1CCCC1)C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMX59E8 IK XSHCQGJMSFRKKN-UXHICEINSA-N
DMX59E8 IU [(1R)-1-[[2-[[(2R)-2-acetamido-3-phenylpropanoyl]-cyclopentylamino]acetyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid
DMX59E8 DE Myocardial infarction
DML6A8X ID DML6A8X
DML6A8X DN S-18327
DML6A8X HS Discontinued in Phase 1
DML6A8X CP Servier
DML6A8X PC 9953269
DML6A8X MW 408.5
DML6A8X FM C23H25FN4O2
DML6A8X IC InChI=1S/C23H25FN4O2/c24-18-6-7-20-21(16-18)30-25-22(20)17-8-10-26(11-9-17)12-13-27-14-15-28(23(27)29)19-4-2-1-3-5-19/h1-7,16-17H,8-15H2
DML6A8X CS C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCN4CCN(C4=O)C5=CC=CC=C5
DML6A8X IK ULCAXFRFGIKHRG-UHFFFAOYSA-N
DML6A8X IU 1-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3-phenylimidazolidin-2-one
DML6A8X CA CAS 200398-40-9
DML6A8X DE Psychotic disorder
DM80P4U ID DM80P4U
DM80P4U DN S-234462
DM80P4U HS Discontinued in Phase 1
DM80P4U CP Shionogi & Co Ltd
DM80P4U DE Obesity
DM6SON1 ID DM6SON1
DM6SON1 DN S-23906-1
DM6SON1 HS Discontinued in Phase 1
DM6SON1 SN S-23906; Rac-cis-1,2-Bis(acetoxy)-6-methoxy-3,3,14-trimethyl-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridin-7-one
DM6SON1 PC 20684516
DM6SON1 MW 489.5
DM6SON1 FM C28H27NO7
DM6SON1 IC InChI=1S/C28H27NO7/c1-14(30)34-26-23-21(36-28(3,4)27(26)35-15(2)31)13-20(33-6)22-24(23)29(5)19-12-17-10-8-7-9-16(17)11-18(19)25(22)32/h7-13,26-27H,1-6H3/t26-,27-/m0/s1
DM6SON1 CS CC(=O)O[C@@H]1[C@@H](C(OC2=CC(=C3C(=C12)N(C4=CC5=CC=CC=C5C=C4C3=O)C)OC)(C)C)OC(=O)C
DM6SON1 IK OASYWNFOHKQIGI-SVBPBHIXSA-N
DM6SON1 IU [(5S,6S)-6-acetyloxy-11-methoxy-2,7,7-trimethyl-13-oxo-8-oxa-2-azapentacyclo[12.8.0.03,12.04,9.016,21]docosa-1(22),3,9,11,14,16,18,20-octaen-5-yl] acetate
DM6SON1 DE Solid tumour/cancer
DM1R8Z7 ID DM1R8Z7
DM1R8Z7 DN S-33138
DM1R8Z7 HS Discontinued in Phase 1
DM1R8Z7 SN N-[4-[2-[(3aS,9bR)-8-Cyano-1,2,3,3a,4,9b-hexahydro[1]benzopyrano[3,4-c]pyrrol-2-yl]ethyl]phenyl]acetamide
DM1R8Z7 DT Small molecular drug
DM1R8Z7 PC 9841864
DM1R8Z7 MW 361.4
DM1R8Z7 FM C22H23N3O2
DM1R8Z7 IC InChI=1S/C22H23N3O2/c1-15(26)24-19-5-2-16(3-6-19)8-9-25-12-18-14-27-22-7-4-17(11-23)10-20(22)21(18)13-25/h2-7,10,18,21H,8-9,12-14H2,1H3,(H,24,26)/t18-,21+/m0/s1
DM1R8Z7 CS CC(=O)NC1=CC=C(C=C1)CCN2C[C@H]3COC4=C([C@@H]3C2)C=C(C=C4)C#N
DM1R8Z7 IK ZDZWIQDJFWTDAM-GHTZIAJQSA-N
DM1R8Z7 IU N-[4-[2-[(3aS,9bR)-8-cyano-3,3a,4,9b-tetrahydro-1H-chromeno[3,4-c]pyrrol-2-yl]ethyl]phenyl]acetamide
DM1R8Z7 DE Psychotic disorder
DMZYRI3 ID DMZYRI3
DMZYRI3 DN S-3536
DMZYRI3 HS Discontinued in Phase 1
DMZYRI3 CP Shionogi & Co Ltd
DMZYRI3 PC 11040978
DMZYRI3 MW 159.18
DMZYRI3 FM C10H9NO
DMZYRI3 IC InChI=1S/C10H9NO/c1-12-10-3-2-9-7-11-5-4-8(9)6-10/h2-7H,1H3
DMZYRI3 CS COC1=CC2=C(C=C1)C=NC=C2
DMZYRI3 IK XZNUJESLPUNSNO-UHFFFAOYSA-N
DMZYRI3 IU 6-methoxyisoquinoline
DMZYRI3 CA CAS 52986-70-6
DMZYRI3 DE Osteoarthritis
DMCEOAJ ID DMCEOAJ
DMCEOAJ DN Sabcomeline
DMCEOAJ HS Discontinued in Phase 1
DMCEOAJ SN Sabcomeline; 159912-53-5; UNII-P8P92V596C; SB-202026; CHEMBL134641; P8P92V596C; Sabcomeline [INN:BAN]; SCHEMBL3838658; sb202026; CHEBI:134846; BDBM50061705; AKOS022181195; AKOS006331527; AN-31122; 912S535; (3Z,3R)-N-methoxyquinuclidine-3-carboximidoyl cyanide
DMCEOAJ DT Small molecular drug
DMCEOAJ PC 9577995
DMCEOAJ MW 193.25
DMCEOAJ FM C10H15N3O
DMCEOAJ IC InChI=1S/C10H15N3O/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13/h8-9H,2-5,7H2,1H3/b12-10+/t9-/m0/s1
DMCEOAJ CS CO/N=C(\\C#N)/[C@H]1CN2CCC1CC2
DMCEOAJ IK IQWCBYSUUOFOMF-QTLFRQQHSA-N
DMCEOAJ IU (3Z,3R)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl cyanide
DMCEOAJ CA CAS 159912-53-5
DMCEOAJ CB CHEBI:134846
DMIZ7Q4 ID DMIZ7Q4
DMIZ7Q4 DN SAR101099
DMIZ7Q4 HS Discontinued in Phase 1
DMIZ7Q4 CP Sanofi
DMIZ7Q4 DE Diabetic nephropathy
DM7OR48 ID DM7OR48
DM7OR48 DN SAR-152954
DM7OR48 HS Discontinued in Phase 1
DM7OR48 SN Histamine H3 antagonist (sleep disorder), Sanofi-aventis
DM7OR48 CP Sanofi
DM7OR48 DE Sleep-wake disorder
DMNH8XU ID DMNH8XU
DMNH8XU DN SB 235699
DMNH8XU HS Discontinued in Phase 1
DMNH8XU SN 4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; VK-19911; CHEMBL279416; UNII-NP7J08ZRYY; NP7J08ZRYY; 180869-32-3; SCHEMBL140202; HEP 689; sb235699; BDBM50099331; SB-235699; 4-(5-(4-Fluorophenyl)-3-(4-piperidyl)imidazol-4-yl)pyridine; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine; Pyridine, 4-(4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl)-
DMNH8XU DT Small molecular drug
DMNH8XU PC 9797240
DMNH8XU MW 322.4
DMNH8XU FM C19H19FN4
DMNH8XU IC InChI=1S/C19H19FN4/c20-16-3-1-14(2-4-16)18-19(15-5-9-21-10-6-15)24(13-23-18)17-7-11-22-12-8-17/h1-6,9-10,13,17,22H,7-8,11-12H2
DMNH8XU CS C1CNCCC1N2C=NC(=C2C3=CC=NC=C3)C4=CC=C(C=C4)F
DMNH8XU IK QBACMJFLMUCPNA-UHFFFAOYSA-N
DMNH8XU IU 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]pyridine
DMNH8XU CA CAS 180869-32-3
DMNH8XU DE Psoriasis vulgaris
DM2C0LN ID DM2C0LN
DM2C0LN DN SB 249417
DM2C0LN HS Discontinued in Phase 1
DM2C0LN CP GlaxoSmithKline
DM2C0LN DT Antibody
DM2C0LN DE Sepsis
DMGHDTB ID DMGHDTB
DMGHDTB DN SB 418790
DMGHDTB HS Discontinued in Phase 1
DMGHDTB CP Asahi Kasei Pharma
DMGHDTB DE Type-2 diabetes
DMX7PNY ID DMX7PNY
DMX7PNY DN SB-234551
DMX7PNY HS Discontinued in Phase 1
DMX7PNY SN 2-[2-[1-Butyl-4-[2-carboxy-3-(6-methoxy-1,3-benzodioxol-5-yl)-1(E)-propenyl]pyrazol-5-yl]-5-methoxyphenoxymethyl]benzoic acid
DMX7PNY DT Small molecular drug
DMX7PNY PC 5311425
DMX7PNY MW 614.6
DMX7PNY FM C34H34N2O9
DMX7PNY IC InChI=1S/C34H34N2O9/c1-4-5-12-36-32(27-11-10-25(41-2)16-29(27)43-19-21-8-6-7-9-26(21)34(39)40)24(18-35-36)14-23(33(37)38)13-22-15-30-31(45-20-44-30)17-28(22)42-3/h6-11,14-18H,4-5,12-13,19-20H2,1-3H3,(H,37,38)(H,39,40)/b23-14+
DMX7PNY CS CCCCN1C(=C(C=N1)/C=C(\\CC2=CC3=C(C=C2OC)OCO3)/C(=O)O)C4=C(C=C(C=C4)OC)OCC5=CC=CC=C5C(=O)O
DMX7PNY IK MCHCGWZNXSZKJY-OEAKJJBVSA-N
DMX7PNY IU 2-[[2-[2-butyl-4-[(E)-2-carboxy-3-(6-methoxy-1,3-benzodioxol-5-yl)prop-1-enyl]pyrazol-3-yl]-5-methoxyphenoxy]methyl]benzoic acid
DMX7PNY DE Nerve injury
DMKSFL0 ID DMKSFL0
DMKSFL0 DN SB-242235
DMKSFL0 HS Discontinued in Phase 1
DMKSFL0 SN 193746-75-7; SB-242235; SB242235; SB 242235; 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; CHEMBL95692; 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine; Kinome_3169; SCHEMBL2267209; BDBM15458; SYN1076; PDTYLGXVBIWRIM-UHFFFAOYSA-N; MolPort-028-720-427; HMS3244I18; HMS3244J17; HMS3244I17; EX-A1881; BCP05992; ZINC1487129; 3254AH; RS0056; AKOS027323444; CS-2097; NCGC00345831-01; NCGC00345831-03
DMKSFL0 DT Small molecular drug
DMKSFL0 PC 9863367
DMKSFL0 MW 353.4
DMKSFL0 FM C19H20FN5O
DMKSFL0 IC InChI=1S/C19H20FN5O/c1-26-19-22-11-8-16(24-19)18-17(13-2-4-14(20)5-3-13)23-12-25(18)15-6-9-21-10-7-15/h2-5,8,11-12,15,21H,6-7,9-10H2,1H3
DMKSFL0 CS COC1=NC=CC(=N1)C2=C(N=CN2C3CCNCC3)C4=CC=C(C=C4)F
DMKSFL0 IK PDTYLGXVBIWRIM-UHFFFAOYSA-N
DMKSFL0 IU 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine
DMKSFL0 DE Arthritis
DMOVLDT ID DMOVLDT
DMOVLDT DN SB-247853
DMOVLDT HS Discontinued in Phase 1
DMOVLDT SN 5-Methyl-N-[6-(2-pyridylmethoxy)pyridin-3-yl]-6-(trifluoromethyl)indoline-1-carboxamide
DMOVLDT PC 9888804
DMOVLDT MW 428.4
DMOVLDT FM C22H19F3N4O2
DMOVLDT IC InChI=1S/C22H19F3N4O2/c1-14-10-15-7-9-29(19(15)11-18(14)22(23,24)25)21(30)28-16-5-6-20(27-12-16)31-13-17-4-2-3-8-26-17/h2-6,8,10-12H,7,9,13H2,1H3,(H,28,30)
DMOVLDT CS CC1=CC2=C(C=C1C(F)(F)F)N(CC2)C(=O)NC3=CN=C(C=C3)OCC4=CC=CC=N4
DMOVLDT IK KLAHZRONIHBPPB-UHFFFAOYSA-N
DMOVLDT IU 5-methyl-N-[6-(pyridin-2-ylmethoxy)pyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
DMOVLDT DE Anxiety disorder
DMIBFAV ID DMIBFAV
DMIBFAV DN SB-267268
DMIBFAV HS Discontinued in Phase 1
DMIBFAV SN 2-[3-Oxo-8-[3-(2-pyridylamino)propoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepin-4(S)-yl]acetic acid
DMIBFAV DT Small molecular drug
DMIBFAV PC 9955461
DMIBFAV MW 451.4
DMIBFAV FM C22H24F3N3O4
DMIBFAV IC InChI=1S/C22H24F3N3O4/c23-22(24,25)14-28-13-17-11-18(32-9-3-8-27-19-4-1-2-7-26-19)6-5-15(17)10-16(21(28)31)12-20(29)30/h1-2,4-7,11,16H,3,8-10,12-14H2,(H,26,27)(H,29,30)/t16-/m0/s1
DMIBFAV CS C1[C@H](C(=O)N(CC2=C1C=CC(=C2)OCCCNC3=CC=CC=N3)CC(F)(F)F)CC(=O)O
DMIBFAV IK PVDGZHKJXXVONO-INIZCTEOSA-N
DMIBFAV IU 2-[(4S)-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-2-benzazepin-4-yl]acetic acid
DMIBFAV DE Osteoporosis
DMV7M1H ID DMV7M1H
DMV7M1H DN SB-273005
DMV7M1H HS Discontinued in Phase 1
DMV7M1H SN SB-267597
DMV7M1H CP SmithKline Beecham plc
DMV7M1H PC 9868426
DMV7M1H MW 451.4
DMV7M1H FM C22H24F3N3O4
DMV7M1H IC InChI=1S/C22H24F3N3O4/c1-26-19-4-2-3-17(27-19)7-8-32-18-6-5-14-9-15(11-20(29)30)21(31)28(12-16(14)10-18)13-22(23,24)25/h2-6,10,15H,7-9,11-13H2,1H3,(H,26,27)(H,29,30)/t15-/m0/s1
DMV7M1H CS CNC1=CC=CC(=N1)CCOC2=CC3=C(C[C@H](C(=O)N(C3)CC(F)(F)F)CC(=O)O)C=C2
DMV7M1H IK KSSPHFGIOASRDE-HNNXBMFYSA-N
DMV7M1H IU 2-[(4S)-8-[2-[6-(methylamino)pyridin-2-yl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-2-benzazepin-4-yl]acetic acid
DMV7M1H CA CAS 205678-31-5
DMV7M1H DE Osteoporosis
DMYTAJW ID DMYTAJW
DMYTAJW DN SB-281832
DMYTAJW HS Discontinued in Phase 1
DMYTAJW CP GlaxoSmithKline plc
DMYTAJW DE Asthma
DM57HZW ID DM57HZW
DM57HZW DN SB-332235
DM57HZW HS Discontinued in Phase 1
DM57HZW SN 1-(4-Chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; 276702-15-9; SB 332235; UNII-5HLP8UVL8M; 5HLP8UVL8M; CHEMBL3819292; WTLRWOHEKQGKDS-UHFFFAOYSA-N; SCHEMBL1535901; sb332235; MolPort-042-624-550; ZINC3990011; BDBM50182254; 1-(4-chloro-2-hydroxy-3-sulfamoyl-phenyl)-3-(2,3-dichlorophenyl)urea; AKOS027470251; N-(4-Chloro-2hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) urea; n-(4-chloro-2-hydroxy-3-aminosulfonylphenyl)-n'-(2,3-dichlorophenyl)urea; N-(4-Chloro-2-hydroxy-3-aminosulfonylphenyl)-N'-(2,3-dichlorophenyl) Urea; N-(3-(aminosulfonyl)-4-chloro-2-hydroxyphenyl)-N'-(2,3-dichlorophenyl) urea
DM57HZW CP GlaxoSmithKline
DM57HZW DT Small molecular drug
DM57HZW PC 9887803
DM57HZW MW 410.7
DM57HZW FM C13H10Cl3N3O4S
DM57HZW IC InChI=1S/C13H10Cl3N3O4S/c14-6-2-1-3-8(10(6)16)18-13(21)19-9-5-4-7(15)12(11(9)20)24(17,22)23/h1-5,20H,(H2,17,22,23)(H2,18,19,21)
DM57HZW CS C1=CC(=C(C(=C1)Cl)Cl)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)N)O
DM57HZW IK WTLRWOHEKQGKDS-UHFFFAOYSA-N
DM57HZW IU 1-(4-chloro-2-hydroxy-3-sulfamoylphenyl)-3-(2,3-dichlorophenyl)urea
DM57HZW CA CAS 276702-15-9
DM57HZW DE Chronic obstructive pulmonary disease
DM92BXN ID DM92BXN
DM92BXN DN SB-435495
DM92BXN HS Discontinued in Phase 1
DM92BXN CP GlaxoSmithKline plc
DM92BXN PC 10417440
DM92BXN MW 720.8
DM92BXN FM C38H40F4N6O2S
DM92BXN IC InChI=1S/C38H40F4N6O2S/c1-4-46(5-2)18-19-47(23-27-6-10-30(11-7-27)31-12-14-33(15-13-31)38(40,41)42)35(49)25-48-24-32(20-29-21-43-45(3)22-29)36(50)44-37(48)51-26-28-8-16-34(39)17-9-28/h6-17,21-22,24H,4-5,18-20,23,25-26H2,1-3H3
DM92BXN CS CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C=C(C(=O)N=C3SCC4=CC=C(C=C4)F)CC5=CN(N=C5)C
DM92BXN IK VGIQUSQBXZXBGW-UHFFFAOYSA-N
DM92BXN IU N-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-5-[(1-methylpyrazol-4-yl)methyl]-4-oxopyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
DM92BXN CA CAS 304694-39-1
DM92BXN DE Arteriosclerosis
DMFC19E ID DMFC19E
DMFC19E DN SC-52012
DMFC19E HS Discontinued in Phase 1
DMFC19E SN N-[5-(4-Amidinophenyl)-1-oxopentyl]-L-aspartyl-L-phenylalanine
DMFC19E DT Small molecular drug
DMFC19E PC 9805266
DMFC19E MW 482.5
DMFC19E FM C25H30N4O6
DMFC19E IC InChI=1S/C25H30N4O6/c26-23(27)18-12-10-16(11-13-18)6-4-5-9-21(30)28-19(15-22(31)32)24(33)29-20(25(34)35)14-17-7-2-1-3-8-17/h1-3,7-8,10-13,19-20H,4-6,9,14-15H2,(H3,26,27)(H,28,30)(H,29,33)(H,31,32)(H,34,35)/t19-,20-/m0/s1
DMFC19E CS C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCC2=CC=C(C=C2)C(=N)N
DMFC19E IK VUUBSMRWDWDDPT-PMACEKPBSA-N
DMFC19E IU (3S)-3-[5-(4-carbamimidoylphenyl)pentanoylamino]-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid
DMFC19E DE Thrombosis
DMIVRWS ID DMIVRWS
DMIVRWS DN SC-57666
DMIVRWS HS Discontinued in Phase 1
DMIVRWS SN SC-57666; CHEMBL274893; AC1L9EJK; SC57666; CHEBI:8982; 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene; SureCN213008; SCHEMBL213008; ZINC18527; GJGZQTGPOKPFES-UHFFFAOYSA-N; HY-U00129; BDBM50029614; DNC003789; CS-7166; C11706; 1-[2(4-Flurophenyl)-1-cyclopentyl]4-methylsulfonylbenzene; 1-[2-(4-fluorophenyl)cyclopenten-1-yl]-4-(methylsulfonyl)benzene; 1-[2-(4-fluorophenyl) cyclopenten-1-yl]-4- (methylsulfonyl)benzene; 1-fluoro-4-[2-(4-methylsulfonylphenyl)-1-cyclopentenyl]benzene
DMIVRWS DT Small molecular drug
DMIVRWS PC 443373
DMIVRWS MW 316.4
DMIVRWS FM C18H17FO2S
DMIVRWS IC InChI=1S/C18H17FO2S/c1-22(20,21)16-11-7-14(8-12-16)18-4-2-3-17(18)13-5-9-15(19)10-6-13/h5-12H,2-4H2,1H3
DMIVRWS CS CS(=O)(=O)C1=CC=C(C=C1)C2=C(CCC2)C3=CC=C(C=C3)F
DMIVRWS IK GJGZQTGPOKPFES-UHFFFAOYSA-N
DMIVRWS IU 1-fluoro-4-[2-(4-methylsulfonylphenyl)cyclopenten-1-yl]benzene
DMIVRWS CB CHEBI:8982
DMIVRWS DE Rheumatoid arthritis
DM92E0W ID DM92E0W
DM92E0W DN SCH-211803
DM92E0W HS Discontinued in Phase 1
DM92E0W SN SCH-211803; UNII-61GSP3D46U; CHEMBL12098; 61GSP3D46U; Sch211803; SCHEMBL12124213; ZINC3994912; BDBM50111346; L001654; (2-Amino-3-methylphenyl)(4-((4-((3-chlorophenyl)sulfonyl)phenyl)methyl)(1,4'-bipiperidin)-1'-yl)methanone; Piperidine, 1-(1-(3-methyl-2-aminophenyl)carbonylpiperidin-4-yl)-4-((3-chlorophenypsulphonylphenyl-4)methyl-); (2-Amino-3-methyl-phenyl)-{4-[4-(3-chloro-benzenesulfonyl)-benzyl]-[1,4'']bipiperidinyl-1''-yl}-methanone; Methanone, (2-amino-3-methylphenyl)(4-((4-((3-chlorophenyl)sulfonyl)phenyl)methyl
DM92E0W DT Small molecular drug
DM92E0W PC 9894173
DM92E0W MW 566.2
DM92E0W FM C31H36ClN3O3S
DM92E0W IC InChI=1S/C31H36ClN3O3S/c1-22-4-2-7-29(30(22)33)31(36)35-18-14-26(15-19-35)34-16-12-24(13-17-34)20-23-8-10-27(11-9-23)39(37,38)28-6-3-5-25(32)21-28/h2-11,21,24,26H,12-20,33H2,1H3
DM92E0W CS CC1=C(C(=CC=C1)C(=O)N2CCC(CC2)N3CCC(CC3)CC4=CC=C(C=C4)S(=O)(=O)C5=CC(=CC=C5)Cl)N
DM92E0W IK VMJKUCKTXMESQR-UHFFFAOYSA-N
DM92E0W IU (2-amino-3-methylphenyl)-[4-[4-[[4-(3-chlorophenyl)sulfonylphenyl]methyl]piperidin-1-yl]piperidin-1-yl]methanone
DM92E0W CA CAS 331765-50-5
DM92E0W DE Parkinson disease
DMK40VO ID DMK40VO
DMK40VO DN SCH-351591
DMK40VO HS Discontinued in Phase 1
DMK40VO SN SCH-351591; SCH 351591; UNII-G6EF7V146S; CHEMBL250546; G6EF7V146S; CHEBI:77774; N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide; 444659-43-2; N-(3,5-dichloro-1-oxidopyridin-4-yl)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide; SCH351591; SCHEMBL157018; DTXSID8044125; NOCAS_44125; BDBM50219270; D 4396; 8-methoxy-2-trifluoromethyl-quinoline-5-carboxylic acid (3,5-dichloro-1-oxy-pyridin-4-yl)-amide; 5-Quinolinecarboxamide, N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- (
DMK40VO DT Small molecular drug
DMK40VO PC 9802841
DMK40VO MW 432.2
DMK40VO FM C17H10Cl2F3N3O3
DMK40VO IC InChI=1S/C17H10Cl2F3N3O3/c1-28-12-4-2-9(8-3-5-13(17(20,21)22)23-14(8)12)16(26)24-15-10(18)6-25(27)7-11(15)19/h2-7,27H,1H3
DMK40VO CS COC1=C2C(=C(C=C1)C(=O)N=C3C(=CN(C=C3Cl)O)Cl)C=CC(=N2)C(F)(F)F
DMK40VO IK NPGREARFJMFTDF-UHFFFAOYSA-N
DMK40VO IU N-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide
DMK40VO CA CAS 444659-43-2
DMK40VO CB CHEBI:77774
DMK40VO DE Chronic obstructive pulmonary disease
DM8J9SF ID DM8J9SF
DM8J9SF DN SCH-C
DM8J9SF HS Discontinued in Phase 1
DM8J9SF SN Ancriviroc; SCH-C & AOP-RANTES; SCH 351125 & SCH 351125 (non-stereospecific); SCH 351125; CHEMBL78535; 305792-46-5; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide & Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-pipiperidin)-4-yl)-, O-ethyloxime, N1-oxide; 1'-[(2,4-Dimethyl-1-oxidopyridin-3-yl)carbonyl]-4'-methyl-1,4'-bipiperidine; Methanone,; Ancriviroc; SCH C; SCH351125; SC-351125; SCH 351125 AOP-RANTES; SCH-351125; SCH-C cpd; AK671/SCH-C; SCH 351125 & AOP-RANTES; SCH-C & PA14; SCH-C AOP-RANTES; SCH-C & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & PRO 140 (Anti-CCR5 monoclonal antibody); Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide AOP-RANTES; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; (2,4-Dimethyl-1-oxy-pyridin-3-yl)-(4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone; 4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide; [3H]ancriviroc
DM8J9SF CP Schering-Plough
DM8J9SF DT Small molecular drug
DM8J9SF PC 9574343
DM8J9SF MW 557.5
DM8J9SF FM C28H37BrN4O3
DM8J9SF IC InChI=1S/C28H37BrN4O3/c1-5-36-30-26(22-6-8-24(29)9-7-22)23-11-15-32(16-12-23)28(4)13-18-31(19-14-28)27(34)25-20(2)10-17-33(35)21(25)3/h6-10,17,23H,5,11-16,18-19H2,1-4H3/b30-26+
DM8J9SF CS CCO/N=C(/C1CCN(CC1)C2(CCN(CC2)C(=O)C3=C(C=C[N+](=C3C)[O-])C)C)\\C4=CC=C(C=C4)Br
DM8J9SF IK ZGDKVKUWTCGYOA-URGPHPNLSA-N
DM8J9SF IU [4-[4-[(Z)-C-(4-bromophenyl)-N-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone
DM8J9SF CA CAS 305792-46-5
DM8J9SF DE Human immunodeficiency virus infection
DM8BIV4 ID DM8BIV4
DM8BIV4 DN SDZ-210-086
DM8BIV4 HS Discontinued in Phase 1
DM8BIV4 SN SDZ-BOP-086
DM8BIV4 CP Novartis AG
DM8BIV4 PC 9860700
DM8BIV4 MW 171.24
DM8BIV4 FM C9H17NO2
DM8BIV4 IC InChI=1S/C9H17NO2/c1-8-11-7-9(12-8)3-5-10(2)6-4-9/h8H,3-7H2,1-2H3/t8-/m0/s1
DM8BIV4 CS C[C@H]1OCC2(O1)CCN(CC2)C
DM8BIV4 IK VHBBMEXIWWKUNY-QMMMGPOBSA-N
DM8BIV4 IU (2S)-2,8-dimethyl-1,3-dioxa-8-azaspiro[4.5]decane
DM8BIV4 DE Cognitive impairment
DMU3TQJ ID DMU3TQJ
DMU3TQJ DN SDZ-62-434
DMU3TQJ HS Discontinued in Phase 1
DMU3TQJ SN 5-[4-(Piperidinomethyl)phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline dihydrochloride
DMU3TQJ DT Small molecular drug
DMU3TQJ PC 130786
DMU3TQJ MW 402.4
DMU3TQJ FM C22H25Cl2N3
DMU3TQJ IC InChI=1S/C22H23N3.2ClH/c1-4-13-24(14-5-1)19-10-8-17(9-11-19)21-16-18-6-2-3-7-20(18)22-23-12-15-25(21)22;;/h2-3,6-11,16H,1,4-5,12-15H2;2*1H
DMU3TQJ CS C1CCN(CC1)C2=CC=C(C=C2)C3=CC4=CC=CC=C4C5=NCCN35.Cl.Cl
DMU3TQJ IK BKOQATFPPHQOQH-UHFFFAOYSA-N
DMU3TQJ IU 5-(4-piperidin-1-ylphenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline;dihydrochloride
DMU3TQJ CA CAS 115621-95-9
DMU3TQJ DE Solid tumour/cancer
DM70MJQ ID DM70MJQ
DM70MJQ DN SDZ-CPI-975
DM70MJQ HS Discontinued in Phase 1
DM70MJQ SN CPT inhibitors, Sandoz; Carnitine palmitoyl transferase I inhbitors, Sandoz; SDZ-267-894
DM70MJQ CP Sandoz Research Institute
DM70MJQ DT Small molecular drug
DM70MJQ PC 9954767
DM70MJQ MW 437.6
DM70MJQ FM C21H44NO6P
DM70MJQ IC InChI=1S/C21H44NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-27-29(25,26)28-20(18-21(23)24)19-22(2,3)4/h20H,5-19H2,1-4H3,(H-,23,24,25,26)/t20-/m1/s1
DM70MJQ CS CCCCCCCCCCCCCCOP(=O)([O-])O[C@H](CC(=O)O)C[N+](C)(C)C
DM70MJQ IK HSNUXANXVHLGQT-HXUWFJFHSA-N
DM70MJQ IU [(2R)-1-carboxy-3-(trimethylazaniumyl)propan-2-yl] tetradecyl phosphate
DM70MJQ CA CAS 157244-53-6
DM70MJQ DE Diabetic complication
DM1C0K4 ID DM1C0K4
DM1C0K4 DN SDZ-GLC-756
DM1C0K4 HS Discontinued in Phase 1
DM1C0K4 SN GLC-756; SDZ GLC 756; SCHEMBL14392424; BDBM85047; PDSP1_000850
DM1C0K4 CP Novartis AG
DM1C0K4 DT Small molecular drug
DM1C0K4 PC 101061738
DM1C0K4 MW 324.5
DM1C0K4 FM C20H24N2S
DM1C0K4 IC InChI=1S/C20H24N2S/c1-22-13-15(14-23-20-8-4-5-9-21-20)10-18-11-16-6-2-3-7-17(16)12-19(18)22/h2-9,15,18-19H,10-14H2,1H3/t15-,18-,19-/m1/s1
DM1C0K4 CS CN1C[C@@H](C[C@H]2[C@H]1CC3=CC=CC=C3C2)CSC4=CC=CC=N4
DM1C0K4 IK JVCCQRRESBKGJS-ATZDWAIDSA-N
DM1C0K4 IU (3R,4aR,10aR)-1-methyl-3-(pyridin-2-ylsulfanylmethyl)-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
DM1C0K4 DE Glaucoma/ocular hypertension
DM8C3G5 ID DM8C3G5
DM8C3G5 DN SDZ-NKT-343
DM8C3G5 HS Discontinued in Phase 1
DM8C3G5 SN NKT-343; SDZ-250343
DM8C3G5 CP Novartis AG
DM8C3G5 DT Small molecular drug
DM8C3G5 PC 9851211
DM8C3G5 MW 579.6
DM8C3G5 FM C33H33N5O5
DM8C3G5 IC InChI=1S/C33H33N5O5/c1-36(22-23-10-3-2-4-11-23)32(40)28(21-24-17-18-25-12-5-6-13-26(25)20-24)34-31(39)30-16-9-19-37(30)33(41)35-27-14-7-8-15-29(27)38(42)43/h2-8,10-15,17-18,20,28,30H,9,16,19,21-22H2,1H3,(H,34,39)(H,35,41)/t28-,30-/m0/s1
DM8C3G5 CS CN(CC1=CC=CC=C1)C(=O)[C@H](CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@@H]4CCCN4C(=O)NC5=CC=CC=C5[N+](=O)[O-]
DM8C3G5 IK PCVSIMQAFWRUEC-JDXGNMNLSA-N
DM8C3G5 IU (2S)-2-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-N-(2-nitrophenyl)pyrrolidine-1,2-dicarboxamide
DM8C3G5 CA CAS 180046-99-5
DM8C3G5 DE Pain
DMTOH03 ID DMTOH03
DMTOH03 DN SDZ-NVI-085
DMTOH03 HS Discontinued in Phase 1
DMTOH03 SN Sdz-nvi-085; Sdz nvi-085; 104195-17-7; Sdz nvi 085; 2H-Naphth[2,3-b]-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4aR,10aR)-;2H-Naphth[2,3-b]-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4aR,10aR)-; SLMAGYSTRWJTMF-TZMCWYRMSA-N; sdznvi-085; AC1L2TWR; SCHEMBL194836; CHEMBL337879; DTXSID60146337; 3,4,4a,5,10,10a-Hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth(2,3-b)-1,4-oxazine
DMTOH03 CP Novartis AG
DMTOH03 DT Small molecular drug
DMTOH03 PC 128503
DMTOH03 MW 279.4
DMTOH03 FM C15H21NO2S
DMTOH03 IC InChI=1S/C15H21NO2S/c1-16-6-7-18-14-9-11-10(8-12(14)16)13(17-2)4-5-15(11)19-3/h4-5,12,14H,6-9H2,1-3H3/t12-,14-/m1/s1
DMTOH03 CS CN1CCO[C@H]2[C@H]1CC3=C(C=CC(=C3C2)SC)OC
DMTOH03 IK SLMAGYSTRWJTMF-TZMCWYRMSA-N
DMTOH03 IU (4aR,10aR)-6-methoxy-4-methyl-9-methylsulfanyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazine
DMTOH03 CA CAS 104195-17-7
DMTOH03 DE Major depressive disorder
DMZHOYM ID DMZHOYM
DMZHOYM DN SDZ-PCO-400
DMZHOYM HS Discontinued in Phase 1
DMZHOYM SN PCO-400
DMZHOYM CP Novartis AG
DMZHOYM DT Small molecular drug
DMZHOYM PC 129348
DMZHOYM MW 299.32
DMZHOYM FM C17H17NO4
DMZHOYM IC InChI=1S/C17H17NO4/c1-17(2)16(20)15(21-12-5-4-11(19)8-12)13-7-10(9-18)3-6-14(13)22-17/h3,6-8,15-16,20H,4-5H2,1-2H3/t15-,16+/m1/s1
DMZHOYM CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)OC3=CC(=O)CC3)O)C
DMZHOYM IK WJBHHTPFTVKZCV-CVEARBPZSA-N
DMZHOYM IU (3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile
DMZHOYM CA CAS 121055-10-5
DMZHOYM CB CHEBI:92920
DMZHOYM DE Asthma
DMFLOT4 ID DMFLOT4
DMFLOT4 DN SDZ-WAG-994
DMFLOT4 HS Discontinued in Phase 1
DMFLOT4 SN WAG-994
DMFLOT4 CP Novartis AG
DMFLOT4 DT Small molecular drug
DMFLOT4 PC 164305
DMFLOT4 MW 363.4
DMFLOT4 FM C17H25N5O4
DMFLOT4 IC InChI=1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1
DMFLOT4 CS CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)NC4CCCCC4)CO)O
DMFLOT4 IK JAKAFSGZUXCHLF-LSCFUAHRSA-N
DMFLOT4 IU (2R,3R,4R,5R)-5-[6-(cyclohexylamino)purin-9-yl]-2-(hydroxymethyl)-4-methoxyoxolan-3-ol
DMFLOT4 CA CAS 130714-47-5
DMFLOT4 DE Hypertension
DMCQI25 ID DMCQI25
DMCQI25 DN SEP-226332
DMCQI25 HS Discontinued in Phase 1
DMCQI25 SN SEP-0226332; 5-HT3 receptor antagonist (sleep apnea), Sepracor
DMCQI25 CP Sunovion Pharmaceuticals Inc
DMCQI25 DE Obstructive sleep apnea
DMTGCSX ID DMTGCSX
DMTGCSX DN SIM-916
DMTGCSX HS Discontinued in Phase 1
DMTGCSX SN Womens health therapeutics, ArQule/Wyeth; Rheumatoid arthritis therapeutics (1), ArQule/Wyeth
DMTGCSX CP ArQule Inc
DMTGCSX DE Gynecological disease
DM1XEUV ID DM1XEUV
DM1XEUV DN SKF-97574
DM1XEUV HS Discontinued in Phase 1
DM1XEUV SN 3-Butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline; SCHEMBL9264291; FOYCAZSJGNVMMS-UHFFFAOYSA-N; SKF 97574; F-97574; 3-butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline hydrochloride; 1-(8-(2-Hydroxyethoxy)-4-((2-methylphenyl)amino)-3-quinolinyl)-1-butanone monohydrochloride; 1-Butanone, 1-(8-(2-hydroxyethoxy)-4-((2-methylphenyl)amino)-3-quinolinyl)-, monohydrochloride
DM1XEUV CP SmithKline Beecham plc
DM1XEUV DT Small molecular drug
DM1XEUV PC 9887258
DM1XEUV MW 364.4
DM1XEUV FM C22H24N2O3
DM1XEUV IC InChI=1S/C22H24N2O3/c1-3-7-19(26)17-14-23-22-16(9-6-11-20(22)27-13-12-25)21(17)24-18-10-5-4-8-15(18)2/h4-6,8-11,14,25H,3,7,12-13H2,1-2H3,(H,23,24)
DM1XEUV CS CCCC(=O)C1=CN=C2C(=C1NC3=CC=CC=C3C)C=CC=C2OCCO
DM1XEUV IK BMCBJKLELCZGBF-UHFFFAOYSA-N
DM1XEUV IU 1-[8-(2-hydroxyethoxy)-4-(2-methylanilino)quinolin-3-yl]butan-1-one
DM1XEUV DE Peptic ulcer
DMP0DLW ID DMP0DLW
DMP0DLW DN SL-25.1188
DMP0DLW HS Discontinued in Phase 1
DMP0DLW CP Sanofi-Synthelabo
DMP0DLW DE Alzheimer disease
DMFUTHB ID DMFUTHB
DMFUTHB DN SL-90.0571
DMFUTHB HS Discontinued in Phase 1
DMFUTHB CP Synthelabo
DMFUTHB DE Epilepsy
DM5TJIY ID DM5TJIY
DM5TJIY DN SLV-311
DM5TJIY HS Discontinued in Phase 1
DM5TJIY CP Solvay SA
DM5TJIY DE Gastrointestinal disease
DMJFWB7 ID DMJFWB7
DMJFWB7 DN SLV-313
DMJFWB7 HS Discontinued in Phase 1
DMJFWB7 SN L001624
DMJFWB7 CP Solvay Pharma
DMJFWB7 DT Small molecular drug
DMJFWB7 PC 9887537
DMJFWB7 MW 405.5
DMJFWB7 FM C24H24FN3O2
DMJFWB7 IC InChI=1S/C24H24FN3O2/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23/h1-7,14-16H,8-13,17H2
DMJFWB7 CS C1CN(CCN1CC2=CC(=CN=C2)C3=CC=C(C=C3)F)C4=C5C(=CC=C4)OCCO5
DMJFWB7 IK IUVSEUFHPNITEQ-UHFFFAOYSA-N
DMJFWB7 IU 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine
DMJFWB7 CA CAS 222551-17-9
DMJFWB7 DE Schizophrenia
DMHRYX6 ID DMHRYX6
DMHRYX6 DN SLV-323
DMHRYX6 HS Discontinued in Phase 1
DMHRYX6 CP Solvay
DMHRYX6 DE Gastric motility disorder; Chemotherapy-induced nausea; Irritable bowel syndrome
DM6CLX9 ID DM6CLX9
DM6CLX9 DN SM-6586
DM6CLX9 HS Discontinued in Phase 1
DM6CLX9 CP Sumitomo Pharmaceuticals Co Ltd
DM6CLX9 DT Small molecular drug
DM6CLX9 PC 128443
DM6CLX9 MW 489.5
DM6CLX9 FM C26H27N5O5
DM6CLX9 IC InChI=1S/C26H27N5O5/c1-16-22(25-28-21(29-36-25)15-30(3)14-18-9-6-5-7-10-18)24(23(17(2)27-16)26(32)35-4)19-11-8-12-20(13-19)31(33)34/h5-13,24,27H,14-15H2,1-4H3
DM6CLX9 CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C3=NC(=NO3)CN(C)CC4=CC=CC=C4
DM6CLX9 IK HHVCXSOKQHQGFB-UHFFFAOYSA-N
DM6CLX9 IU methyl 5-[3-[[benzyl(methyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DM6CLX9 CA CAS 103898-38-0
DM6CLX9 DE Hypertension
DMC49KO ID DMC49KO
DMC49KO DN SMART anti-E/P selectin
DMC49KO HS Discontinued in Phase 1
DMC49KO SN HuEP5C7; Bispecific anti-E/P selectin, PDL; SMART anti-E/P selectin, PDL; SMART anti-E/P selectin, Protein Design Labs; Anti-E/P selectin (humanized), PDL
DMC49KO CP PDL BioPharma Inc
DMC49KO DE Asthma
DMQSGOD ID DMQSGOD
DMQSGOD DN SMP-028
DMQSGOD HS Discontinued in Phase 1
DMQSGOD CP Dainippon Sumitomo Pharma Co Ltd
DMQSGOD PC 11949660
DMQSGOD MW 455.6
DMQSGOD FM C23H26FN5O2S
DMQSGOD IC InChI=1S/C23H26FN5O2S/c1-25-22(30)26-9-10-29-21(16-32-23(29)27-19-4-2-3-18(24)15-19)17-5-7-20(8-6-17)28-11-13-31-14-12-28/h2-8,15-16H,9-14H2,1H3,(H2,25,26,30)
DMQSGOD CS CNC(=O)NCCN1C(=CSC1=NC2=CC(=CC=C2)F)C3=CC=C(C=C3)N4CCOCC4
DMQSGOD IK NBGPMRBRSOZDOV-UHFFFAOYSA-N
DMQSGOD IU 1-[2-[2-(3-fluorophenyl)imino-4-(4-morpholin-4-ylphenyl)-1,3-thiazol-3-yl]ethyl]-3-methylurea
DMQSGOD CA CAS 914389-14-3
DMQSGOD DE Asthma
DMKGL2I ID DMKGL2I
DMKGL2I DN SPI-256
DMKGL2I HS Discontinued in Phase 1
DMKGL2I SN HIV protease inhibitors (Resistant-Repellent), Sequoia
DMKGL2I CP Sequoia Pharmaceuticals Inc
DMKGL2I DE Human immunodeficiency virus infection
DMWQKEN ID DMWQKEN
DMWQKEN DN SPP-1148
DMWQKEN HS Discontinued in Phase 1
DMWQKEN SN SPP-1100; SPP-1193; Renin inhibitors (hypertension), Novartis; Renin inhibitors (hypertension), Speedel
DMWQKEN CP Speedel Holding AG
DMWQKEN DE Hypertension
DMKEHGT ID DMKEHGT
DMKEHGT DN SPP-676
DMKEHGT HS Discontinued in Phase 1
DMKEHGT CP Speedel Holding AG
DMKEHGT DE Hypertension
DMK4XT8 ID DMK4XT8
DMK4XT8 DN SR 144190
DMK4XT8 HS Discontinued in Phase 1
DMK4XT8 SN SR-144190; 3-(1-(2-(4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl)ethyl)-4-phenylpiperidin-4-yl)-1-dimethylurea
DMK4XT8 CP Sanofi-aventis
DMK4XT8 TC Analgesics
DMK4XT8 DT Small molecular drug
DMK4XT8 PC 9810217
DMK4XT8 MW 576.7
DMK4XT8 FM C33H38F2N4O3
DMK4XT8 IC InChI=1S/C33H38F2N4O3/c1-37(2)31(41)36-32(26-11-7-4-8-12-26)15-18-38(19-16-32)20-17-33(27-13-14-28(34)29(35)23-27)24-39(21-22-42-33)30(40)25-9-5-3-6-10-25/h3-14,23H,15-22,24H2,1-2H3,(H,36,41)
DMK4XT8 CS CN(C)C(=O)NC1(CCN(CC1)CCC2(CN(CCO2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)F)F)C5=CC=CC=C5
DMK4XT8 IK QNLIUVLFRVYNCV-UHFFFAOYSA-N
DMK4XT8 IU 3-[1-[2-[4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea
DMK4XT8 DE Urinary incontinence; Anxiety disorder; Acute or chronic pain; Depression
DML7KCO ID DML7KCO
DML7KCO DN SR-146131
DML7KCO HS Discontinued in Phase 1
DML7KCO SN SR 146131; SR-146131; SR146131; 221671-61-0; NFDFTMICKVDYLQ-UHFFFAOYSA-N; GTPL868; SCHEMBL1008694; DTXSID5047370; CHEMBL3302616; NCGC00247967-01; HY-11077; CS-0003037; L000574; 2-(4- (4-Chloro-2,5-dimethoxyphenyl)-5-cyclohexylethyl-2-thiazolylcarbamoyl)-5,7-dimethyl-1-indoleacetic acid; 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid
DML7KCO CP Sanofi-Synthelabo
DML7KCO DT Small molecular drug
DML7KCO PC 9852833
DML7KCO MW 610.2
DML7KCO FM C32H36ClN3O5S
DML7KCO IC InChI=1S/C32H36ClN3O5S/c1-18-12-19(2)30-21(13-18)14-24(36(30)17-28(37)38)31(39)35-32-34-29(22-15-26(41-4)23(33)16-25(22)40-3)27(42-32)11-10-20-8-6-5-7-9-20/h12-16,20H,5-11,17H2,1-4H3,(H,37,38)(H,34,35,39)
DML7KCO CS CC1=CC(=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=C(S3)CCC4CCCCC4)C5=CC(=C(C=C5OC)Cl)OC)C
DML7KCO IK NFDFTMICKVDYLQ-UHFFFAOYSA-N
DML7KCO IU 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid
DML7KCO CA CAS 221671-61-0
DML7KCO DE Obesity
DM6X9M8 ID DM6X9M8
DM6X9M8 DN SR-271425
DM6X9M8 HS Discontinued in Phase 1
DM6X9M8 SN BCN-326862; SW-71425; WIN-71425; 1-[2-(Diethylamino)ethylamino]-4-(formamidomethyl)-7-methoxy-9H-thioxanthen-9-one
DM6X9M8 DT Small molecular drug
DM6X9M8 PC 9909677
DM6X9M8 MW 413.5
DM6X9M8 FM C22H27N3O3S
DM6X9M8 IC InChI=1S/C22H27N3O3S/c1-4-25(5-2)11-10-24-18-8-6-15(13-23-14-26)22-20(18)21(27)17-12-16(28-3)7-9-19(17)29-22/h6-9,12,14,24H,4-5,10-11,13H2,1-3H3,(H,23,26)
DM6X9M8 CS CCN(CC)CCNC1=C2C(=C(C=C1)CNC=O)SC3=C(C2=O)C=C(C=C3)OC
DM6X9M8 IK GWLFIMOOGVXSMZ-UHFFFAOYSA-N
DM6X9M8 IU N-[[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide
DM6X9M8 CA CAS 155990-20-8
DM6X9M8 DE Solid tumour/cancer
DM471IG ID DM471IG
DM471IG DN SR-33805
DM471IG HS Discontinued in Phase 1
DM471IG SN SR 33805; 121345-64-0; AC1L2VL6; SCHEMBL7268066; CHEMBL287679; DTXSID40153241; 3,4-Dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phenoxy)propyl)benzeneethanamine; N-[3-[4-[(1-Methyl-2-isopropyl-1H-indol-3-yl)sulfonyl]phenoxy]propyl]-N-methyl-3,4-dimethoxyphenethylamine; N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-2-propan-2-ylindol-3-yl)sulfonylphenoxy]propan-1-amine; Benzeneethanamine, 3,4-dimethoxy-N-methyl-N(3-(4-((1-methyl-2-(1-methylethyl)-1H-indol-3-yl)sulfonyl)phen
DM471IG CP Sanofi
DM471IG DT Small molecular drug
DM471IG PC 9850876
DM471IG MW 564.7
DM471IG FM C32H40N2O5S
DM471IG IC InChI=1S/C32H40N2O5S/c1-23(2)31-27-10-7-8-11-28(27)34(4)32(31)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6/h7-8,10-17,22-23H,9,18-21H2,1-6H3
DM471IG CS CC(C)C1=C(N(C2=CC=CC=C21)C)S(=O)(=O)C3=CC=C(C=C3)OCCCN(C)CCC4=CC(=C(C=C4)OC)OC
DM471IG IK GCVFQRRBTCHIPK-UHFFFAOYSA-N
DM471IG IU N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[4-(1-methyl-3-propan-2-ylindol-2-yl)sulfonylphenoxy]propan-1-amine
DM471IG DE Angina pectoris
DMAICVN ID DMAICVN
DMAICVN DN SR-47063
DMAICVN HS Discontinued in Phase 1
DMAICVN SN SR-47063; SR 47063; 135809-60-8; SCHEMBL3694183; SCHEMBL9205867; sr47063; AC1L3015; 4-(2-Cyanimino-1,2-dihydropyrid-1-yl)-2,2-dimethyl-6-nitrochromene; (1-(2,2-Dimethyl-6-nitro-2H-1-benzopyran-4-yl)-2(1H)-pyridinylidene)cyanamide; [1-(2,2-dimethyl-6-nitrochromen-4-yl)pyridin-2-ylidene]cyanamide; Cyanamide, (1-(2,2-dimethyl-6-nitro-2H-1-benzopyran-4-yl)-2(1H)-pyridinylidene)-
DMAICVN CP Sanofi
DMAICVN DT Small molecular drug
DMAICVN PC 131912
DMAICVN MW 322.32
DMAICVN FM C17H14N4O3
DMAICVN IC InChI=1S/C17H14N4O3/c1-17(2)10-14(20-8-4-3-5-16(20)19-11-18)13-9-12(21(22)23)6-7-15(13)24-17/h3-10H,1-2H3
DMAICVN CS CC1(C=C(C2=C(O1)C=CC(=C2)[N+](=O)[O-])N3C=CC=CC3=NC#N)C
DMAICVN IK ZOHLDHMGABPLCB-UHFFFAOYSA-N
DMAICVN IU [1-(2,2-dimethyl-6-nitrochromen-4-yl)pyridin-2-ylidene]cyanamide
DMAICVN CA CAS 135809-60-8
DMAICVN DE Cardiac arrhythmias
DM3O4ST ID DM3O4ST
DM3O4ST DN SS1(dsFv)-PE38
DM3O4ST HS Discontinued in Phase 1
DM3O4ST SN CAT-5001; SS (dsFv) PE38 immunotoxin); SS1-PE38; SS (dsFv) PE38 immunotoxin, NCI; SS1P, Enzon/NCI
DM3O4ST CP National Cancer Institute
DM3O4ST DT Antibody
DM3O4ST DE Solid tumour/cancer
DMSOBW2 ID DMSOBW2
DMSOBW2 DN SSR-125180
DMSOBW2 HS Discontinued in Phase 1
DMSOBW2 CP Sanofi-Synthelabo
DMSOBW2 DE Obesity
DMR9JA8 ID DMR9JA8
DMR9JA8 DN SSR-146977
DMR9JA8 HS Discontinued in Phase 1
DMR9JA8 SN N-[1-[3-[1-Benzoyl-3(R)-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N',N'-dimethylurea
DMR9JA8 DT Small molecular drug
DMR9JA8 PC 9938990
DMR9JA8 MW 621.6
DMR9JA8 FM C35H42Cl2N4O2
DMR9JA8 IC InChI=1S/C35H42Cl2N4O2/c1-39(2)33(43)38-35(28-13-7-4-8-14-28)19-23-40(24-20-35)21-9-17-34(29-15-16-30(36)31(37)25-29)18-10-22-41(26-34)32(42)27-11-5-3-6-12-27/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3,(H,38,43)/t34-/m0/s1
DMR9JA8 CS CN(C)C(=O)NC1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
DMR9JA8 IK XWPBINGFFFZAOZ-UMSFTDKQSA-N
DMR9JA8 IU 3-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea
DMR9JA8 CA CAS 264618-44-2
DMR9JA8 DE Psychotic disorder
DMI3K2D ID DMI3K2D
DMI3K2D DN SSR-162369
DMI3K2D HS Discontinued in Phase 1
DMI3K2D CP Sanofi-Aventis
DMI3K2D DT Small molecular drug
DMI3K2D PC 56603733
DMI3K2D MW 459.6
DMI3K2D FM C27H33N5O2
DMI3K2D IC InChI=1S/C27H33N5O2/c1-17(2)13-15-31-24-26(29-25(31)21-10-11-22-20(21)12-14-28-22)30(4)18(3)32(27(24)34)16-23(33)19-8-6-5-7-9-19/h5-9,13,20-22,28H,3,10-12,14-16H2,1-2,4H3/t20-,21?,22+/m0/s1
DMI3K2D CS CC(=CCN1C(=NC2=C1C(=O)N(C(=C)N2C)CC(=O)C3=CC=CC=C3)C4CC[C@@H]5[C@H]4CCN5)C
DMI3K2D IK PBLJWGCWKPKYPH-JAFNVKOHSA-N
DMI3K2D IU 8-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrol-4-yl]-3-methyl-7-(3-methylbut-2-enyl)-2-methylidene-1-phenacylpurin-6-one
DMI3K2D DE Type-2 diabetes
DMBCQFH ID DMBCQFH
DMBCQFH DN SUN-8399
DMBCQFH HS Discontinued in Phase 1
DMBCQFH SN Sun-8399; Sun 8399; 131112-58-8; SCHEMBL9370364; AC1L2Z10; DTXSID50156900; 4-(4-(4-(2-Pyrimidyl)-1-piperazinyl)butyl)-1,4-benzoxazepine-3,5(2H,4H)-dione; 4-(4-(4-(2-Pyrimidinyl)piperazin-1-yl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione; L004090; 4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,4-benzoxazepine-3,5-dione; 1,4-Benzoxazepine-3,5(2H,4H)-dione, 4-(4-(4-(2-pyrimidyl)-1-piperazinyl)butyl)-
DMBCQFH CP Suntory Ltd
DMBCQFH DT Small molecular drug
DMBCQFH PC 131339
DMBCQFH MW 395.5
DMBCQFH FM C21H25N5O3
DMBCQFH IC InChI=1S/C21H25N5O3/c27-19-16-29-18-7-2-1-6-17(18)20(28)26(19)11-4-3-10-24-12-14-25(15-13-24)21-22-8-5-9-23-21/h1-2,5-9H,3-4,10-16H2
DMBCQFH CS C1CN(CCN1CCCCN2C(=O)COC3=CC=CC=C3C2=O)C4=NC=CC=N4
DMBCQFH IK ITTHDTFPCPHJOU-UHFFFAOYSA-N
DMBCQFH IU 4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,4-benzoxazepine-3,5-dione
DMBCQFH CA CAS 131112-58-8
DMBCQFH DE Anxiety disorder
DM6BO7R ID DM6BO7R
DM6BO7R DN SUN-9221
DM6BO7R HS Discontinued in Phase 1
DM6BO7R CP Suntory Ltd
DM6BO7R DE Hypertension
DM1Z42H ID DM1Z42H
DM1Z42H DN SURADISTA
DM1Z42H HS Discontinued in Phase 1
DM1Z42H SN PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt
DM1Z42H DE Solid tumour/cancer
DMY3FES ID DMY3FES
DMY3FES DN SW-33377
DMY3FES HS Discontinued in Phase 1
DMY3FES SN SR-233377; Win-33377; N-[1-[2-(Diethylamino)ethylamino]-9-oxothioxanthen-4-ylmethyl]methanesulfonamide; 1-[2-(Diethylamino)ethylamino]-4-(methanesulfonamidomethyl)thioxanthen-9-one
DMY3FES DT Small molecular drug
DMY3FES PC 3035776
DMY3FES MW 433.6
DMY3FES FM C21H27N3O3S2
DMY3FES IC InChI=1S/C21H27N3O3S2/c1-4-24(5-2)13-12-22-17-11-10-15(14-23-29(3,26)27)21-19(17)20(25)16-8-6-7-9-18(16)28-21/h6-11,22-23H,4-5,12-14H2,1-3H3
DMY3FES CS CCN(CC)CCNC1=C2C(=C(C=C1)CNS(=O)(=O)C)SC3=CC=CC=C3C2=O
DMY3FES IK NAMOLZVVTPNNTE-UHFFFAOYSA-N
DMY3FES IU N-[[1-[2-(diethylamino)ethylamino]-9-oxothioxanthen-4-yl]methyl]methanesulfonamide
DMY3FES CA CAS 146537-07-7
DMY3FES DE Solid tumour/cancer
DMSPBJ9 ID DMSPBJ9
DMSPBJ9 DN Symakalim
DMSPBJ9 HS Discontinued in Phase 1
DMSPBJ9 SN EMD-57283
DMSPBJ9 CP Merck KGaA
DMSPBJ9 PC 9840338
DMSPBJ9 MW 327.33
DMSPBJ9 FM C17H17N3O4
DMSPBJ9 IC InChI=1S/C17H17N3O4/c1-17(2)16(22)15(23-13-6-7-14(21)20(3)19-13)11-8-10(9-18)4-5-12(11)24-17/h4-8,15-16,22H,1-3H3
DMSPBJ9 CS CC1(C(C(C2=C(O1)C=CC(=C2)C#N)OC3=NN(C(=O)C=C3)C)O)C
DMSPBJ9 IK RIBYSHCVSQIIJE-UHFFFAOYSA-N
DMSPBJ9 IU 3-hydroxy-2,2-dimethyl-4-(1-methyl-6-oxopyridazin-3-yl)oxy-3,4-dihydrochromene-6-carbonitrile
DMSPBJ9 DE Hypertension
DM4JPLM ID DM4JPLM
DM4JPLM DN SYN-114
DM4JPLM HS Discontinued in Phase 1
DM4JPLM SN 5-HT 6 receptor antagonists (cognitive disorders), Synosia/Roche
DM4JPLM CP Roche Holding AG
DM4JPLM DE Cognitive impairment
DML4M5K ID DML4M5K
DML4M5K DN T-0632
DML4M5K HS Discontinued in Phase 1
DML4M5K SN Z-203; (S)-1-(2-Fluorophenyl)-3-(3-isoquinolinylcarboxamido)-6-methoxy-2-oxo-1H-indole-3-propionic acid sodium salt
DML4M5K DT Small molecular drug
DML4M5K PC 127948
DML4M5K MW 502.5
DML4M5K FM C29H27FN2O5
DML4M5K IC InChI=1S/C29H27FN2O5/c1-37-21-12-13-22-25(17-21)32(24-9-5-4-8-23(24)30)28(36)29(22,15-14-26(33)34)31-27(35)20-11-10-18-6-2-3-7-19(18)16-20/h2-9,12-13,17,20H,10-11,14-16H2,1H3,(H,31,35)(H,33,34)/t20?,29-/m0/s1
DML4M5K CS COC1=CC2=C(C=C1)[C@](C(=O)N2C3=CC=CC=C3F)(CCC(=O)O)NC(=O)C4CCC5=CC=CC=C5C4
DML4M5K IK RORYEMYJJAIHBK-PRTIIRGTSA-N
DML4M5K IU 3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid
DML4M5K DE Pancreatic malfunction
DMQVLZH ID DMQVLZH
DMQVLZH DN T-62
DMQVLZH HS Discontinued in Phase 1
DMQVLZH SN 40312-34-3; T-62; T62; UNII-9Q765ZIF8L; CHEMBL57997; 9Q765ZIF8L; 3-(4-chlorobenzoyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-amine; (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone; 2-Amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophene; (2-amino-4,5,6,7-tetrahydro-1-benzothien-3-yl)(4-chlorophenyl)methanone; (2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-(4-chloro-phenyl)-methanone; BAS 01842965; AC1Q50OD; AC1LH2S9; Oprea1_104969; Oprea1_077736; SCHEMBL135569; CTK6G9061; DTXSID20193322
DMQVLZH CP King Pharmaceuticals
DMQVLZH TC Analgesics
DMQVLZH DT Small molecular drug
DMQVLZH PC 855908
DMQVLZH MW 291.8
DMQVLZH FM C15H14ClNOS
DMQVLZH IC InChI=1S/C15H14ClNOS/c16-10-7-5-9(6-8-10)14(18)13-11-3-1-2-4-12(11)19-15(13)17/h5-8H,1-4,17H2
DMQVLZH CS C1CCC2=C(C1)C(=C(S2)N)C(=O)C3=CC=C(C=C3)Cl
DMQVLZH IK OTZVBZFYMFTYKH-UHFFFAOYSA-N
DMQVLZH IU (2-amino-4,5,6,7-tetrahydro-1-benzothiophen-3-yl)-(4-chlorophenyl)methanone
DMQVLZH CA CAS 40312-34-3
DMQVLZH DE Neuropathic pain
DMFES2K ID DMFES2K
DMFES2K DN TA-5493
DMFES2K HS Discontinued in Phase 1
DMFES2K SN P38 inhibitor (rheumatoid arthritis/ psoriasis), Mitsubishi Tanabe
DMFES2K CP Tanabe Seiyaku Co Ltd
DMFES2K DE Inflammation
DMI52NT ID DMI52NT
DMI52NT DN TAFA-93
DMI52NT HS Discontinued in Phase 1
DMI52NT SN MTOR inhibitor, Isotechnika; Rapamycin prodrug, Isotechnika; Transplant rejection therapy, Isotechnika
DMI52NT CP Isotechnika Pharma Inc; Isotechnika
DMI52NT DT Small molecular drug
DMI52NT PC 54601137
DMI52NT MW 1095.4
DMI52NT FM C56H90N2O17S
DMI52NT IC InChI=1S/C55H86N2O14.CH4O3S/c1-33-18-14-13-15-19-34(2)45(66-10)30-41-23-21-39(7)55(65,71-41)52(62)53(63)57-25-17-16-20-42(57)54(64)69-46(36(4)28-40-22-24-43(58)47(29-40)67-11)31-44(59)35(3)27-38(6)50(70-48(60)32-56(8)9)51(68-12)49(61)37(5)26-33;1-5(2,3)4/h13-15,18-19,27,33,35-37,39-43,45-47,50-51,58,65H,16-17,20-26,28-32H2,1-12H3;1H3,(H,2,3,4)/b15-13+,18-14+,34-19-,38-27?;/t33?,35?,36?,37?,39?,40?,41?,42?,43?,45?,46?,47?,50?,51?,55-;/m0./s1
DMI52NT CS CC1CCC2CC(/C(=C\\C=C\\C=C\\C(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)[C@]1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)OC(=O)CN(C)C)OC)C)C)/C)OC.CS(=O)(=O)O
DMI52NT IK XVNMRKHCSMPLOF-CPNVPWJOSA-N
DMI52NT IU [(1S,24E,26E,28Z)-1-hydroxy-12-[1-(4-hydroxy-3-methoxycyclohexyl)propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-18-yl] 2-(dimethylamino)acetate;methanesulfonic acid
DMI52NT DE Transplant rejection
DMN02XD ID DMN02XD
DMN02XD DN TAK-029
DMN02XD HS Discontinued in Phase 1
DMN02XD CP Takeda Pharmaceutical Co Ltd
DMN02XD PC 9824171
DMN02XD MW 433.4
DMN02XD FM C19H23N5O7
DMN02XD IC InChI=1S/C19H23N5O7/c1-31-16(28)8-13-19(30)23(10-15(26)27)6-7-24(13)14(25)9-22-18(29)12-4-2-11(3-5-12)17(20)21/h2-5,13H,6-10H2,1H3,(H3,20,21)(H,22,29)(H,26,27)/t13-/m0/s1
DMN02XD CS COC(=O)C[C@H]1C(=O)N(CCN1C(=O)CNC(=O)C2=CC=C(C=C2)C(=N)N)CC(=O)O
DMN02XD IK CRFQJHNXTNBRQR-ZDUSSCGKSA-N
DMN02XD IU 2-[(3S)-4-[2-[(4-carbamimidoylbenzoyl)amino]acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazin-1-yl]acetic acid
DMN02XD CA CAS 176655-58-6
DMN02XD DE Thrombosis
DMH16ND ID DMH16ND
DMH16ND DN TAK-100
DMH16ND HS Discontinued in Phase 1
DMH16ND SN CHEMBL1672127
DMH16ND CP Takeda
DMH16ND DT Small molecular drug
DMH16ND PC 11996845
DMH16ND MW 354.5
DMH16ND FM C22H30N2O2
DMH16ND IC InChI=1S/C22H30N2O2/c1-6-18-16(11-20(25)26)21(15-9-7-14(2)8-10-15)17(13-23)19(24-18)12-22(3,4)5/h7-10H,6,11-13,23H2,1-5H3,(H,25,26)
DMH16ND CS CCC1=C(C(=C(C(=N1)CC(C)(C)C)CN)C2=CC=C(C=C2)C)CC(=O)O
DMH16ND IK HQVOROHHYWZJLD-UHFFFAOYSA-N
DMH16ND IU 2-[5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)pyridin-3-yl]acetic acid
DMH16ND DE Diabetic complication
DMBE5OF ID DMBE5OF
DMBE5OF DN TAK165
DMBE5OF HS Discontinued in Phase 1
DMBE5OF SN Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole
DMBE5OF CP Takeda Pharmaceuticals
DMBE5OF TC Anticancer Agents
DMBE5OF DT Small molecular drug
DMBE5OF PC 6444692
DMBE5OF MW 468.5
DMBE5OF FM C25H23F3N4O2
DMBE5OF IC InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
DMBE5OF CS C1=CC(=CC=C1CCCCN2C=CN=N2)OCC3=COC(=N3)/C=C/C4=CC=C(C=C4)C(F)(F)F
DMBE5OF IK ZTFBIUXIQYRUNT-MDWZMJQESA-N
DMBE5OF IU 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole
DMBE5OF CA CAS 366017-09-6
DMBE5OF DE Solid tumour/cancer
DM25DB4 ID DM25DB4
DM25DB4 DN TAK-591
DM25DB4 HS Discontinued in Phase 1
DM25DB4 CP Takeda
DM25DB4 DE Hypertension
DMRD8HK ID DMRD8HK
DMRD8HK DN TAK-683
DMRD8HK HS Discontinued in Phase 1
DMRD8HK SN (5S)-6-[6-[(1E,3R,5Z)-3-Hydroxyundeca-1,5-dienyl]pyridin-2-yl]hexane-1,5-diol; U 75302; U-75302; 119477-85-9; (5S)-6-[6-[(1E,3R,5Z)-3-hydroxyundeca-1,5-dienyl]pyridin-2-yl]hexane-1,5-diol; 6-(6-(3-Hydroxy-1,5-undecadien-1-yl)-2-pyridinyl)-1,5-hexanediol; U75302; AC1O6A9C; SCHEMBL1894359; GTPL3325; ZINC4489632; SR-01000946976; SR-01000946976-1; 1,5-Hexanediol, 6-(6-(3-hydroxy-1,5-undecadienyl)-2-pyridinyl)-,
DMRD8HK CP Takeda
DMRD8HK DT Small molecular drug
DMRD8HK PC 49787129
DMRD8HK MW 1298.4
DMRD8HK FM C64H83N17O13
DMRD8HK IC InChI=1S/C64H83N17O13/c1-34(2)26-48(57(88)73-46(20-13-25-69-63(67)68-5)56(87)74-47(55(66)86)29-39-32-70-44-18-11-9-16-42(39)44)78-64(94)81-80-61(92)50(27-37-14-7-6-8-15-37)77-62(93)54(35(3)82)79-60(91)52(31-53(65)85)76-59(90)51(30-40-33-71-45-19-12-10-17-43(40)45)75-58(89)49(72-36(4)83)28-38-21-23-41(84)24-22-38/h6-12,14-19,21-24,32-35,46-52,54,70-71,82,84H,13,20,25-31H2,1-5H3,(H2,65,85)(H2,66,86)(H,72,83)(H,73,88)(H,74,87)(H,75,89)(H,76,90)(H,77,93)(H,79,91)(H,80,92)(H3,67,68,69)(H2,78,81,94)/t35-,46+,47+,48+,49-,50+,51-,52+,54+/m1/s1
DMRD8HK CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=NC)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@@H](CC6=CC=C(C=C6)O)NC(=O)C)O
DMRD8HK IK BDPDXFSIFWZPCE-PHOVXGMNSA-N
DMRD8HK IU (2S)-2-[[(2R)-2-[[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
DMRD8HK DE Allergy; Prostate cancer
DMCFOSG ID DMCFOSG
DMCFOSG DN TAK-810
DMCFOSG HS Discontinued in Phase 1
DMCFOSG SN N-[4-[3-(N-Benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-5-isobutyryl-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-2-yl]phenyl]-1-hydroxycyclopropanecarboxamide
DMCFOSG PC 9939511
DMCFOSG MW 655.8
DMCFOSG FM C37H35F2N3O4S
DMCFOSG IC InChI=1S/C37H35F2N3O4S/c1-22(2)32(43)28-21-42(20-26-29(38)10-7-11-30(26)39)35-31(33(28)44)27(19-41(3)18-23-8-5-4-6-9-23)34(47-35)24-12-14-25(15-13-24)40-36(45)37(46)16-17-37/h4-15,21-22,46H,16-20H2,1-3H3,(H,40,45)
DMCFOSG CS CC(C)C(=O)C1=CN(C2=C(C1=O)C(=C(S2)C3=CC=C(C=C3)NC(=O)C4(CC4)O)CN(C)CC5=CC=CC=C5)CC6=C(C=CC=C6F)F
DMCFOSG IK NWNSIURBDQNMCZ-UHFFFAOYSA-N
DMCFOSG IU N-[4-[3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-5-(2-methylpropanoyl)-4-oxothieno[2,3-b]pyridin-2-yl]phenyl]-1-hydroxycyclopropane-1-carboxamide
DMCFOSG DE Prostate cancer
DM13YN0 ID DM13YN0
DM13YN0 DN TAK-937
DM13YN0 HS Discontinued in Phase 1
DM13YN0 SN Cerebroprotectant (acute stroke, injection), Takeda; CB1/CB2 receptor agonist (acute stroke, injection), Takeda
DM13YN0 CP Takeda Pharmaceutical Co Ltd
DM13YN0 DE Cerebrovascular ischaemia
DM1ZYCA ID DM1ZYCA
DM1ZYCA DN TALTOBULIN
DM1ZYCA HS Discontinued in Phase 1
DM1ZYCA SN HTI-286; SPA-110 (trifluoroacetate salt); Taltobulin; N,3,3-Trimethyl-L-phenylalanyl-N1-[3-carboxy-1(S)-isopropyl-2(E)-butenyl]-N1,3-dimethyl-L-valinamide
DM1ZYCA DT Small molecular drug
DM1ZYCA PC 6918637
DM1ZYCA MW 473.6
DM1ZYCA FM C27H43N3O4
DM1ZYCA IC InChI=1S/C27H43N3O4/c1-17(2)20(16-18(3)25(33)34)30(10)24(32)22(26(4,5)6)29-23(31)21(28-9)27(7,8)19-14-12-11-13-15-19/h11-17,20-22,28H,1-10H3,(H,29,31)(H,33,34)/b18-16+/t20-,21-,22-/m1/s1
DM1ZYCA CS CC(C)[C@@H](/C=C(\\C)/C(=O)O)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C(C)(C)C1=CC=CC=C1)NC
DM1ZYCA IK CNTMOLDWXSVYKD-PSRNMDMQSA-N
DM1ZYCA IU (E,4S)-4-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
DM1ZYCA CA CAS 228266-40-8
DM1ZYCA DE Solid tumour/cancer
DM5PZ60 ID DM5PZ60
DM5PZ60 DN TAZOMELINE
DM5PZ60 HS Discontinued in Phase 1
DM5PZ60 SN Hexylthio-TZTP; LY-287041; Tazomeline < Prop INN; NNC-11-0309; 3-[3-(Hexylthio)-1,2,5-thiadiazol-4-yl]-1-methyl-1,2,5,6-tetrahydropyridine
DM5PZ60 DT Small molecular drug
DM5PZ60 PC 131460
DM5PZ60 MW 297.5
DM5PZ60 FM C14H23N3S2
DM5PZ60 IC InChI=1S/C14H23N3S2/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3
DM5PZ60 CS CCCCCCSC1=NSN=C1C2=CCCN(C2)C
DM5PZ60 IK XUHMGFKQBWZWPO-UHFFFAOYSA-N
DM5PZ60 IU 3-hexylsulfanyl-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DM5PZ60 CA CAS 131987-54-7
DM5PZ60 DE Cognitive impairment
DMCA97F ID DMCA97F
DMCA97F DN TD-2749
DMCA97F HS Discontinued in Phase 1
DMCA97F CP Theravance
DMCA97F PC 11225102
DMCA97F MW 466.6
DMCA97F FM C26H38N6O2
DMCA97F IC InChI=1S/C26H38N6O2/c1-18(2)32-24-7-5-4-6-23(24)25(28-32)26(34)27-20-16-21-8-9-22(17-20)31(21)15-12-29-10-13-30(14-11-29)19(3)33/h4-7,18,20-22H,8-17H2,1-3H3,(H,27,34)/t20?,21-,22+
DMCA97F CS CC(C)N1C2=CC=CC=C2C(=N1)C(=O)NC3C[C@H]4CC[C@@H](C3)N4CCN5CCN(CC5)C(=O)C
DMCA97F IK ZQMXTDPQEHZTBG-FRIKZZABSA-N
DMCA97F IU N-[(1R,5S)-8-[2-(4-acetylpiperazin-1-yl)ethyl]-8-azabicyclo[3.2.1]octan-3-yl]-1-propan-2-ylindazole-3-carboxamide
DMCA97F CA CAS 863248-59-3
DMCA97F DE Gastrointestinal disease
DMDT5HZ ID DMDT5HZ
DMDT5HZ DN Teloxantrone
DMDT5HZ HS Discontinued in Phase 1
DMDT5HZ SN Moxantrazole; Teloxantrone hydrochloride; Teloxantrone hydrochloride hydrate; DuP-937; PD-113309
DMDT5HZ CP Parke-Davis & Co
DMDT5HZ DT Small molecular drug
DMDT5HZ PC 124644
DMDT5HZ MW 411.5
DMDT5HZ FM C21H25N5O4
DMDT5HZ IC InChI=1S/C21H25N5O4/c1-22-6-7-24-12-2-3-13-17-16(12)21(30)19-15(29)5-4-14(28)18(19)20(17)25-26(13)10-8-23-9-11-27/h2-5,22-23,25,27,29-30H,6-11H2,1H3
DMDT5HZ CS CNCCN=C1C=CC2=C3C1=C(C4=C(C=CC(=O)C4=C3NN2CCNCCO)O)O
DMDT5HZ IK WOPAVGQTOMNFGS-UHFFFAOYSA-N
DMDT5HZ IU 6,8-dihydroxy-14-[2-(2-hydroxyethylamino)ethyl]-10-[2-(methylamino)ethylimino]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1,4,6,8,11,13(16)-hexaen-3-one
DMDT5HZ CA CAS 91441-48-4
DMDT5HZ DE Solid tumour/cancer
DM9KYVQ ID DM9KYVQ
DM9KYVQ DN TG-1024
DM9KYVQ HS Discontinued in Phase 1
DM9KYVQ SN Ad-IL-2, Transgene; Adenoviral-IL-2, Transgene
DM9KYVQ CP Transgene SA; Transgene
DM9KYVQ DE Solid tumour/cancer
DMELNA8 ID DMELNA8
DMELNA8 DN TGN-1412
DMELNA8 HS Discontinued in Phase 1
DMELNA8 SN SuperMAB; CD28-SuperMAB; Superagonistic monoclonal antibodies, TeGenero
DMELNA8 CP TeGenero ImmunoTherapeutics AG
DMELNA8 DT Antibody
DMELNA8 DE Autoimmune diabetes
DMTC4LP ID DMTC4LP
DMTC4LP DN Tidembersat
DMTC4LP HS Discontinued in Phase 1
DMTC4LP SN SB-218842
DMTC4LP CP SmithKline Beecham plc
DMTC4LP DT Small molecular drug
DMTC4LP PC 170378
DMTC4LP MW 375.4
DMTC4LP FM C20H19F2NO4
DMTC4LP IC InChI=1S/C20H19F2NO4/c1-10(24)11-4-5-16-15(8-11)17(18(25)20(2,3)27-16)23-19(26)12-6-13(21)9-14(22)7-12/h4-9,17-18,25H,1-3H3,(H,23,26)/t17-,18+/m0/s1
DMTC4LP CS CC(=O)C1=CC2=C(C=C1)OC([C@@H]([C@H]2NC(=O)C3=CC(=CC(=C3)F)F)O)(C)C
DMTC4LP IK NWHCDESSIHFNIJ-ZWKOTPCHSA-N
DMTC4LP IU N-[(3R,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3,5-difluorobenzamide
DMTC4LP CA CAS 175013-73-7
DMTC4LP DE Migraine
DMI0Q8Y ID DMI0Q8Y
DMI0Q8Y DN TOP-53
DMI0Q8Y HS Discontinued in Phase 1
DMI0Q8Y SN Top 53; (5R,5aR,8aR,9S)-9-[2-[2-dimethylaminoethyl(methyl)amino]ethyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one dihydrochloride
DMI0Q8Y CP Taiho Pharmaceutical Co Ltd
DMI0Q8Y DT Small molecular drug
DMI0Q8Y PC 177859
DMI0Q8Y MW 512.6
DMI0Q8Y FM C28H36N2O7
DMI0Q8Y IC InChI=1S/C28H36N2O7/c1-29(2)8-9-30(3)7-6-17-18-12-21-22(37-15-36-21)13-19(18)25(26-20(17)14-35-28(26)32)16-10-23(33-4)27(31)24(11-16)34-5/h10-13,17,20,25-26,31H,6-9,14-15H2,1-5H3/t17-,20-,25-,26+/m1/s1
DMI0Q8Y CS CN(C)CCN(C)CC[C@H]1[C@H]2COC(=O)[C@@H]2[C@@H](C3=CC4=C(C=C13)OCO4)C5=CC(=C(C(=C5)OC)O)OC
DMI0Q8Y IK KLCCMMSKRMSMKI-QVNMXXJYSA-N
DMI0Q8Y IU (5R,5aR,8aR,9S)-9-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-6-one
DMI0Q8Y CA CAS 148262-19-5
DMI0Q8Y CB CHEBI:134547
DMI0Q8Y DE Metastatic lung cancer
DM6SUDC ID DM6SUDC
DM6SUDC DN Totrombopag
DM6SUDC HS Discontinued in Phase 1
DM6SUDC SN Totrombopag; SB-559448; 376592-42-6; Totrombopag [INN]; 5-(3'-((2Z)-2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxybiphenyl-3-yl)tetrazol-1-ide; 1H-Pyrazole-4,5-dione,1-(3,4-dimethylphenyl)-3-methyl-,4-((2-hydroxy-3'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-3-yl)hydrazone), ion(1-), (4Z)-
DM6SUDC CP GSK
DM6SUDC DT Small molecular drug
DM6SUDC PC 135871124
DM6SUDC MW 466.5
DM6SUDC FM C25H22N8O2
DM6SUDC IC InChI=1S/C25H22N8O2/c1-14-10-11-19(12-15(14)2)33-25(35)22(16(3)30-33)27-26-21-9-5-8-20(23(21)34)17-6-4-7-18(13-17)24-28-31-32-29-24/h4-13,22,34H,1-3H3,(H,28,29,31,32)
DM6SUDC CS CC1=C(C=C(C=C1)N2C(=O)C(C(=N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C5=NNN=N5)C
DM6SUDC IK KWJKFQSAMABKBG-UHFFFAOYSA-N
DM6SUDC IU 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3-[3-(2H-tetrazol-5-yl)phenyl]phenyl]diazenyl]-5-methyl-4H-pyrazol-3-one
DM6SUDC DE Thrombocytopenia
DMCV2KQ ID DMCV2KQ
DMCV2KQ DN TP-9201
DMCV2KQ HS Discontinued in Phase 1
DMCV2KQ SN Acetyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-arginyl-glycyl-L-aspartyl-L-(4-O-methyl)-tyrosyl-L-arginyl-L-cysteinamide cyclic 1-9-disulfide
DMCV2KQ DT Small molecular drug
DMCV2KQ PC 6918252
DMCV2KQ MW 1136.3
DMCV2KQ FM C45H69N17O14S2
DMCV2KQ IC InChI=1S/C45H69N17O14S2/c1-22(63)55-31-21-78-77-20-30(36(47)68)61-38(70)26(7-4-14-53-45(50)51)57-39(71)27(16-23-9-11-24(76-2)12-10-23)59-40(72)28(18-35(66)67)56-34(65)19-54-37(69)25(6-3-13-52-44(48)49)58-42(74)32-8-5-15-62(32)43(75)29(17-33(46)64)60-41(31)73/h9-12,25-32H,3-8,13-21H2,1-2H3,(H2,46,64)(H2,47,68)(H,54,69)(H,55,63)(H,56,65)(H,57,71)(H,58,74)(H,59,72)(H,60,73)(H,61,70)(H,66,67)(H4,48,49,52)(H4,50,51,53)/t25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
DMCV2KQ CS CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC1=O)CC(=O)N)CCCN=C(N)N)CC(=O)O)CC3=CC=C(C=C3)OC)CCCN=C(N)N)C(=O)N
DMCV2KQ IK RRPUNOOJZOAZNU-ALERXTORSA-N
DMCV2KQ IU 2-[(3S,6R,11R,14S,17S,20S,26S,29S)-6-acetamido-3-(2-amino-2-oxoethyl)-11-carbamoyl-14,26-bis[3-(diaminomethylideneamino)propyl]-17-[(4-methoxyphenyl)methyl]-2,5,13,16,19,22,25,28-octaoxo-8,9-dithia-1,4,12,15,18,21,24,27-octazabicyclo[27.3.0]dotriacontan-20-yl]acetic acid
DMCV2KQ CA CAS 138297-15-1
DMCV2KQ DE Thrombosis
DMWD39E ID DMWD39E
DMWD39E DN Tr-14035
DMWD39E HS Discontinued in Phase 1
DMWD39E SN 232271-19-1; TR-14035; (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid; CHEMBL91485; N-(2,6-DICHLOROBENZOYL)-4-(2,6-DIMETHOXYPHENYL)-L-PHENYLALANINE; C24H21Cl2NO5; DRSJLVGDSNWQBI-SFHVURJKSA-N; TR 14035; SCHEMBL1222491; BDBM16801; CTK8C1530; MolPort-023-334-229; ZINC1490484; ANW-66841; N-Acyl-4-arylphenylalanine analogue.; AKOS016008162; CS-1812; CS-W000631; MP-2027; NCGC00390619-01; SB683698; HY-15770; AK-95353; AJ-26339; KB-210922; TC-155586; AB0077984; AX8237663; ST24020804; Z4458
DMWD39E DT Small molecular drug
DMWD39E PC 9912743
DMWD39E MW 474.3
DMWD39E FM C24H21Cl2NO5
DMWD39E IC InChI=1S/C24H21Cl2NO5/c1-31-19-7-4-8-20(32-2)21(19)15-11-9-14(10-12-15)13-18(24(29)30)27-23(28)22-16(25)5-3-6-17(22)26/h3-12,18H,13H2,1-2H3,(H,27,28)(H,29,30)/t18-/m0/s1
DMWD39E CS COC1=C(C(=CC=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3Cl)Cl
DMWD39E IK DRSJLVGDSNWQBI-SFHVURJKSA-N
DMWD39E IU (2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-(2,6-dimethoxyphenyl)phenyl]propanoic acid
DMWD39E CA CAS 232271-19-1
DMWD39E DE Multiple sclerosis
DMH5SA6 ID DMH5SA6
DMH5SA6 DN TR-14531
DMH5SA6 HS Discontinued in Phase 1
DMH5SA6 SN IDDB25065
DMH5SA6 CP Tanabe Seiyaku Co Ltd
DMH5SA6 DE Asthma
DMZ5RA7 ID DMZ5RA7
DMZ5RA7 DN TRK-851
DMZ5RA7 HS Discontinued in Phase 1
DMZ5RA7 SN (4bS,8R,8aS,16bR)-7-(Cyclopropylmethyl)-11-fluoro-5,6,7,8,9,14,15,16b-octahydro-4,8-methano-8aH,13H-[1]benzofuro[2,3-a]dipyrido[4,3-b:3',2',1'-jk]carbazole-1,8a-diol; 189015-25-6
DMZ5RA7 DE Cough
DMSFV9T ID DMSFV9T
DMSFV9T DN TRM-115
DMSFV9T HS Discontinued in Phase 1
DMSFV9T SN TRM-15
DMSFV9T CP Terumo Corp
DMSFV9T DT Small molecular drug
DMSFV9T PC 6918243
DMSFV9T MW 512.7
DMSFV9T FM C27H36N4O4S
DMSFV9T IC InChI=1S/C27H36N4O4S/c32-26(9-5-12-29-27(36)30-22-10-11-24-25(18-22)35-20-34-24)28-13-6-16-33-23-8-4-7-21(17-23)19-31-14-2-1-3-15-31/h4,7-8,10-11,17-18H,1-3,5-6,9,12-16,19-20H2,(H,28,32)(H2,29,30,36)
DMSFV9T CS C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CCCNC(=S)NC3=CC4=C(C=C3)OCO4
DMSFV9T IK DZSMTMGGLVZZLW-UHFFFAOYSA-N
DMSFV9T IU 4-(1,3-benzodioxol-5-ylcarbamothioylamino)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]butanamide
DMSFV9T DE Gastric ulcer
DMOHEYU ID DMOHEYU
DMOHEYU DN TS-032
DMOHEYU HS Discontinued in Phase 1
DMOHEYU SN PF-04802540; PF-4802540; MGluR agonists (schizophrenia), Taisho; Metabotropic glutamate receptor agonists (schizophrenia), Taisho; MGluR agonists (schizophrenia), Taisho/Pfizer; Metabotropic glutamate receptor agonists (schizophrenia), Taisho/Pfizer
DMOHEYU CP Taisho Pharmaceutical Co Ltd
DMOHEYU DE Schizophrenia
DMHJXL6 ID DMHJXL6
DMHJXL6 DN TT-235
DMHJXL6 HS Discontinued in Phase 1
DMHJXL6 SN [beta,beta-(3-Thiapentamethylene)-beta-sulfanylpropionic acid,D-Trp2,Pen6,Arg8]-oxytocin acetate
DMHJXL6 DE Miscarriage
DMTVC3W ID DMTVC3W
DMTVC3W DN U-103017
DMTVC3W HS Discontinued in Phase 1
DMTVC3W SN Pnu-103017; Pnu 103017; U-103017; 166335-18-8; PNU-103264; AC1Q4RFB; AC1L1KS2; SCHEMBL7352941; CHEMBL2062136; 4-cyano-n-{3-[cyclopropyl(2-hydroxy-4-oxo-5,6,7,8,9,10-hexahydro-4h-cycloocta[b]pyran-3-yl)methyl]phenyl}benzenesulfonamide; HY-19236; 4-Cyano-N-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2H-cycloocta(b)pyran-3-yl)methyl )phenyl)benzenesulfonamide; 4-Cyano-N-(3-(cyclopropyl(5,6,7,8,9,10-hexahydro-4-hydroxy-2-oxo-2H-cycloocta(b)pyran-3-yl)methyl)phenyl)benzenesulfonamide; CS-0014977; U103017
DMTVC3W CP Upjohn Co Ltd
DMTVC3W DT Small molecular drug
DMTVC3W PC 54692909
DMTVC3W MW 504.6
DMTVC3W FM C28H28N2O5S
DMTVC3W IC InChI=1S/C28H28N2O5S/c29-17-18-10-14-22(15-11-18)36(33,34)30-21-7-5-6-20(16-21)25(19-12-13-19)26-27(31)23-8-3-1-2-4-9-24(23)35-28(26)32/h5-7,10-11,14-16,19,25,30-31H,1-4,8-9,12-13H2
DMTVC3W CS C1CCCC2=C(CC1)C(=C(C(=O)O2)C(C3CC3)C4=CC(=CC=C4)NS(=O)(=O)C5=CC=C(C=C5)C#N)O
DMTVC3W IK VCYQENLVFRTJIC-UHFFFAOYSA-N
DMTVC3W IU 4-cyano-N-[3-[cyclopropyl-(4-hydroxy-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyran-3-yl)methyl]phenyl]benzenesulfonamide
DMTVC3W CA CAS 166335-18-8
DMTVC3W DE Human immunodeficiency virus infection
DMC94D2 ID DMC94D2
DMC94D2 DN U-104067F
DMC94D2 HS Discontinued in Phase 1
DMC94D2 SN U-104067 (anhydrous free base); 9-[2-(4-Morpholinyl)ethyl]-2,4-bis(pyrrolidin-1-yl]-9H-pyrimido[4,5-b]indole monohydrochloride hemihydrate
DMC94D2 DT Small molecular drug
DMC94D2 PC 9890309
DMC94D2 MW 457
DMC94D2 FM C24H33ClN6O
DMC94D2 IC InChI=1S/C24H32N6O.ClH/c1-2-8-20-19(7-1)21-22(28-9-3-4-10-28)25-24(29-11-5-6-12-29)26-23(21)30(20)14-13-27-15-17-31-18-16-27;/h1-2,7-8H,3-6,9-18H2;1H
DMC94D2 CS C1CCN(C1)C2=NC(=NC3=C2C4=CC=CC=C4N3CCN5CCOCC5)N6CCCC6.Cl
DMC94D2 IK OTTSSGXCAVAVKV-UHFFFAOYSA-N
DMC94D2 IU 4-[2-(2,4-dipyrrolidin-1-ylpyrimido[4,5-b]indol-9-yl)ethyl]morpholine;hydrochloride
DMC94D2 CA CAS 172035-75-5
DMC94D2 DE Neurological disorder
DM2WOPX ID DM2WOPX
DM2WOPX DN U-78875
DM2WOPX HS Discontinued in Phase 1
DM2WOPX SN PANADIPLON; 124423-84-3; U-78875; UNII-V4PW0S7ZP7; V4PW0S7ZP7; FG-10571; CHEMBL279867; Panadiplonum; Panadiplone; AC1MHWDJ; Panadiplon (USAN/INN); Panadiplon (U-78875); SCHEMBL123304; ZINC4220; DTXSID40869698; BDBM50048837; AKOS015904452; RL01109; API0007797; ZB000564; D05346; J-523865; 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one; 3-(5-Cyclopropyl-[1,2,4]oxadiazol-3-yl)-5-isopropyl-5H-imidazo[1,5-a]quinoxalin-4-one
DM2WOPX DT Small molecular drug
DM2WOPX PC 3033821
DM2WOPX MW 335.4
DM2WOPX FM C18H17N5O2
DM2WOPX IC InChI=1S/C18H17N5O2/c1-10(2)23-13-6-4-3-5-12(13)22-9-19-14(15(22)18(23)24)16-20-17(25-21-16)11-7-8-11/h3-6,9-11H,7-8H2,1-2H3
DM2WOPX CS CC(C)N1C2=CC=CC=C2N3C=NC(=C3C1=O)C4=NOC(=N4)C5CC5
DM2WOPX IK ZGEGOFCLSWVVKG-UHFFFAOYSA-N
DM2WOPX IU 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one
DM2WOPX CA CAS 124423-84-3
DM2WOPX DE Anxiety disorder
DMMSWJ3 ID DMMSWJ3
DMMSWJ3 DN U-93385
DMMSWJ3 HS Discontinued in Phase 1
DMMSWJ3 SN (-)-cis-3-Propyl-2,3,3a(R),4,5,9b-hexahydro-1H-benz[e]indole-9-carboxamide
DMMSWJ3 DT Small molecular drug
DMMSWJ3 PC 132792
DMMSWJ3 MW 258.36
DMMSWJ3 FM C16H22N2O
DMMSWJ3 IC InChI=1S/C16H22N2O/c1-2-9-18-10-8-12-14(18)7-6-11-4-3-5-13(15(11)12)16(17)19/h3-5,12,14H,2,6-10H2,1H3,(H2,17,19)/t12-,14-/m1/s1
DMMSWJ3 CS CCCN1CC[C@@H]2[C@H]1CCC3=C2C(=CC=C3)C(=O)N
DMMSWJ3 IK JSZBRMZCAIJCKB-TZMCWYRMSA-N
DMMSWJ3 IU (3aR,9bS)-3-propyl-1,2,3a,4,5,9b-hexahydrobenzo[e]indole-9-carboxamide
DMMSWJ3 CA CAS 147145-16-2
DMMSWJ3 DE Anxiety disorder
DML73BR ID DML73BR
DML73BR DN U-96988
DML73BR HS Discontinued in Phase 1
DML73BR SN U-96988; CHEMBL22164; PNU-96988; AC1LA3LC; BDBM770; SCHEMBL6173602; 149394-65-0; U96988; 6-(1-benzylpropyl)-4-hydroxy-3-(1-phenylpropyl)pyran-2-one; 2-hydroxy-6-(1-phenylbutan-2-yl)-3-(1-phenylpropyl)pyran-4-one
DML73BR CP Pharmacia & Upjohn Co
DML73BR DT Small molecular drug
DML73BR PC 54686718
DML73BR MW 362.5
DML73BR FM C24H26O3
DML73BR IC InChI=1S/C24H26O3/c1-3-18(15-17-11-7-5-8-12-17)22-16-21(25)23(24(26)27-22)20(4-2)19-13-9-6-10-14-19/h5-14,16,18,20,25H,3-4,15H2,1-2H3
DML73BR CS CCC(CC1=CC=CC=C1)C2=CC(=C(C(=O)O2)C(CC)C3=CC=CC=C3)O
DML73BR IK HALPINAQGOXQAN-UHFFFAOYSA-N
DML73BR IU 4-hydroxy-6-(1-phenylbutan-2-yl)-3-(1-phenylpropyl)pyran-2-one
DML73BR DE Human immunodeficiency virus infection
DML51D0 ID DML51D0
DML51D0 DN UCL-2000; butabindide
DML51D0 HS Discontinued in Phase 1
DML51D0 CP University College London
DML51D0 DE Obesity
DMGFPIY ID DMGFPIY
DMGFPIY DN UK-156406
DMGFPIY HS Discontinued in Phase 1
DMGFPIY SN 1-[3-(3-Amidinophenyl)-2(S)-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ylsulfonamido)propionyl]-4-methyl-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid; 1-[3-Amidino-N-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ylsulfonyl)-L-phenylalanyl]-4-methyl-1,2,3,6-tetrahydropyridine-2(R)-carboxylic acid
DMGFPIY DT Small molecular drug
DMGFPIY PC 44342278
DMGFPIY MW 539.6
DMGFPIY FM C27H33N5O5S
DMGFPIY IC InChI=1S/C27H33N5O5S/c1-17-9-12-32(24(13-17)27(34)35)26(33)23(14-18-3-5-20(6-4-18)25(28)29)30-38(36,37)22-8-7-19-10-11-31(2)16-21(19)15-22/h3-9,15,23-24,30H,10-14,16H2,1-2H3,(H3,28,29)(H,34,35)/t23-,24+/m0/s1
DMGFPIY CS CC1=CCN([C@H](C1)C(=O)O)C(=O)[C@H](CC2=CC=C(C=C2)C(=N)N)NS(=O)(=O)C3=CC4=C(CCN(C4)C)C=C3
DMGFPIY IK ZDHBBBQAVLNJBL-BJKOFHAPSA-N
DMGFPIY IU (2R)-1-[(2S)-3-(4-carbamimidoylphenyl)-2-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)sulfonylamino]propanoyl]-4-methyl-3,6-dihydro-2H-pyridine-2-carboxylic acid
DMGFPIY DE Myocardial infarction
DMDTRJB ID DMDTRJB
DMDTRJB DN UK-224671
DMDTRJB HS Discontinued in Phase 1
DMDTRJB SN UK-369202; UK-416960
DMDTRJB CP Pfizer Inc
DMDTRJB DT Small molecular drug
DMDTRJB PC 9915372
DMDTRJB MW 544.5
DMDTRJB FM C24H35Cl2N5O3S
DMDTRJB IC InChI=1S/C24H35Cl2N5O3S/c25-21-4-3-19(13-22(21)26)24(6-5-23(32)30(17-24)14-18-1-2-18)7-8-28-15-20(16-28)29-9-11-31(12-10-29)35(27,33)34/h3-4,13,18,20H,1-2,5-12,14-17H2,(H2,27,33,34)/t24-/m1/s1
DMDTRJB CS C1CC1CN2C[C@@](CCC2=O)(CCN3CC(C3)N4CCN(CC4)S(=O)(=O)N)C5=CC(=C(C=C5)Cl)Cl
DMDTRJB IK OQXJUJDDCWHRLA-XMMPIXPASA-N
DMDTRJB IU 4-[1-[2-[(3S)-1-(cyclopropylmethyl)-3-(3,4-dichlorophenyl)-6-oxopiperidin-3-yl]ethyl]azetidin-3-yl]piperazine-1-sulfonamide
DMDTRJB DE Urinary incontinence
DMXN9Z5 ID DMXN9Z5
DMXN9Z5 DN UR-7198
DMXN9Z5 HS Discontinued in Phase 1
DMXN9Z5 SN UR-7247; UR-7280; Angiotensin II AT-1 antagonists, Uriach; UR-7280 analogs, Uriach
DMXN9Z5 CP Grupo Uriach
DMXN9Z5 DE Hypertension
DMR2EUV ID DMR2EUV
DMR2EUV DN V-102862
DMR2EUV HS Discontinued in Phase 1
DMR2EUV SN CO 102862; UNII-0KN11H90GF; 181144-66-1; V-102862; CHEMBL287833; 0KN11H90GF; 4-(4-fluorophenoxy)benzaldehyde semicarbazone; (E)-2-(4-(4-fluorophenoxy)benz-ylidene)hydrazinecarboxamide; V102862; 2-(4-(4-Fluorophenoxy)benzylidene)hydrazinecarboxamide; 2-((4-(4-Fluorophenoxy)phenyl)methylene)hydrazinecarboxamide; CO-102862; 2-[[4-(4-Fluorophenoxy)phenyl]methylene]hydrazinecarboxamide; Hydrazinecarboxamide, 2-((4-(4-fluorophenoxy)phenyl)methylene)-; CHEBI:92156; MolPort-022-863-701; BDBM50141073; AKOS016004881; NCGC00167807-01
DMR2EUV DT Small molecular drug
DMR2EUV PC 9816959
DMR2EUV MW 273.26
DMR2EUV FM C14H12FN3O2
DMR2EUV IC InChI=1S/C14H12FN3O2/c15-11-3-7-13(8-4-11)20-12-5-1-10(2-6-12)9-17-18-14(16)19/h1-9H,(H3,16,18,19)/b17-9+
DMR2EUV CS C1=CC(=CC=C1/C=N/NC(=O)N)OC2=CC=C(C=C2)F
DMR2EUV IK MHUUDVZSPFRUSK-RQZCQDPDSA-N
DMR2EUV IU [(E)-[4-(4-fluorophenoxy)phenyl]methylideneamino]urea
DMR2EUV CA CAS 181144-66-1
DMR2EUV CB CHEBI:92156
DMLFMSY ID DMLFMSY
DMLFMSY DN V85546
DMLFMSY HS Discontinued in Phase 1
DMLFMSY CP Vernalis
DMLFMSY TC Antiinflammatory Agents
DMLFMSY DE Inflammation
DMBQPA5 ID DMBQPA5
DMBQPA5 DN Vanoxerine
DMBQPA5 HS Discontinued in Phase 1
DMBQPA5 SN Vanoxerina; Vanoxerinum; Vanoxerine [INN]; D-052; Vanoxerina [INN-Spanish]; Vanoxerinum [INN-Latin]; Piperazine, 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)-, dihydrochloride; 1-(2 (Bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine di-hcl; 1-(2-(Bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine; 1-(2-bis-[4-FLUOROPHENYL]-METHOXYETHYL)-4-(3-PHENYL-2-PROPYL)PIPERAZINE; 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
DMBQPA5 CP National Institute on Drug Abuse
DMBQPA5 DT Small molecular drug
DMBQPA5 PC 3455
DMBQPA5 MW 450.6
DMBQPA5 FM C28H32F2N2O
DMBQPA5 IC InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2
DMBQPA5 CS C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMBQPA5 IK NAUWTFJOPJWYOT-UHFFFAOYSA-N
DMBQPA5 IU 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
DMBQPA5 CA CAS 67469-69-6
DMBQPA5 CB CHEBI:64089
DMBQPA5 DE Cocaine addiction
DMKRG0I ID DMKRG0I
DMKRG0I DN VNA-932
DMKRG0I HS Discontinued in Phase 1
DMKRG0I SN WAY-VNA-932; [2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)phenyl](10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-10-y-)methanone; 10-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine
DMKRG0I DT Small molecular drug
DMKRG0I PC 5311500
DMKRG0I MW 402.9
DMKRG0I FM C23H19ClN4O
DMKRG0I IC InChI=1S/C23H19ClN4O/c1-16-10-12-28(25-16)18-8-9-20(21(24)13-18)23(29)27-15-19-6-4-11-26(19)14-17-5-2-3-7-22(17)27/h2-13H,14-15H2,1H3
DMKRG0I CS CC1=NN(C=C1)C2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
DMKRG0I IK JXKQHDZUZGKDGO-UHFFFAOYSA-N
DMKRG0I IU [2-chloro-4-(3-methylpyrazol-1-yl)phenyl]-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepin-5-yl)methanone
DMKRG0I CA CAS 220460-92-4
DMKRG0I DE Urinary incontinence
DMATEL0 ID DMATEL0
DMATEL0 DN Vorsetuzumab mafodotin
DMATEL0 HS Discontinued in Phase 1
DMATEL0 CP Seattle Genetics
DMATEL0 DT Antibody
DMATEL0 DE Renal cell carcinoma
DMXK8FQ ID DMXK8FQ
DMXK8FQ DN VP004
DMXK8FQ HS Discontinued in Phase 1
DMXK8FQ CP Indevus Pharmaceuticals
DMXK8FQ DT Antibody
DMXK8FQ DE Substance use disorder
DM0HZBU ID DM0HZBU
DM0HZBU DN VP-025
DM0HZBU HS Discontinued in Phase 1
DM0HZBU SN Inflammation therapeutics, Vasogen; VP-015
DM0HZBU CP Vasogen
DM0HZBU DE Alzheimer disease
DMFQWNI ID DMFQWNI
DMFQWNI DN VR-776
DMFQWNI HS Discontinued in Phase 1
DMFQWNI SN Premature ejaculation therapy (inhaled, PowerHale), Vectura
DMFQWNI CP Vectura Group plc
DMFQWNI DT Small molecular drug
DMFQWNI PC 68539
DMFQWNI MW 351.3
DMFQWNI FM C19H24Cl2N2
DMFQWNI IC InChI=1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22;/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3;1H
DMFQWNI CS CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl
DMFQWNI IK WIMWMKZEIBHDTH-UHFFFAOYSA-N
DMFQWNI IU 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride
DMFQWNI CA CAS 17321-77-6
DMFQWNI CB CHEBI:3755
DMFQWNI DE Premature ejaculation
DM3GD7V ID DM3GD7V
DM3GD7V DN WAY-100289
DM3GD7V HS Discontinued in Phase 1
DM3GD7V SN Endo-2-(Cyclopropylmethoxy)-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-ylcarbamoyl)benzamide maleate; Endo-1-[2-(Cyclopropylmethoxy)benzoyl]-3-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)urea maleate
DM3GD7V DT Small molecular drug
DM3GD7V PC 6918186
DM3GD7V MW 357.4
DM3GD7V FM C20H27N3O3
DM3GD7V IC InChI=1S/C20H27N3O3/c1-23-15-8-9-16(23)11-14(10-15)21-20(25)22-19(24)17-4-2-3-5-18(17)26-12-13-6-7-13/h2-5,13-16H,6-12H2,1H3,(H2,21,22,24,25)/t14?,15-,16+
DM3GD7V CS CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)NC(=O)C3=CC=CC=C3OCC4CC4
DM3GD7V IK VFRIHPWRNNTKEX-MQVJKMGUSA-N
DM3GD7V IU 2-(cyclopropylmethoxy)-N-[[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]carbamoyl]benzamide
DM3GD7V CA CAS 136013-69-9
DM3GD7V DE Anxiety disorder
DM8SVHI ID DM8SVHI
DM8SVHI DN WAY-181187
DM8SVHI HS Discontinued in Phase 1
DM8SVHI SN WAY-181187; 554403-49-5; UNII-WXE3H7W295; WXE3H7W295; WAY-181,187; WAY 181187; SCHEMBL801436; WAY181187 HCl; GTPL3240; CHEMBL392760; BDBM21358; SAX-187; DTXSID50204011; EX-A799; MolPort-005-933-335; ZINC3816551; AKOS028111927; WAY-181187(SAX-187); KB-81479; FT-0700331; WAY181187.HCl pound WAY-181 187 pound(c); J-690323; N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine; 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-1H-indole-3-ethanamine
DM8SVHI DT Small molecular drug
DM8SVHI PC 10150497
DM8SVHI MW 380.9
DM8SVHI FM C15H13ClN4O2S2
DM8SVHI IC InChI=1S/C15H13ClN4O2S2/c16-13-14(19-7-8-23-15(19)18-13)24(21,22)20-9-10(5-6-17)11-3-1-2-4-12(11)20/h1-4,7-9H,5-6,17H2
DM8SVHI CS C1=CC=C2C(=C1)C(=CN2S(=O)(=O)C3=C(N=C4N3C=CS4)Cl)CCN
DM8SVHI IK RYBOXBBYCVOYNO-UHFFFAOYSA-N
DM8SVHI IU 2-[1-(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonylindol-3-yl]ethanamine
DM8SVHI CA CAS 554403-49-5
DM8SVHI DE Anxiety disorder
DMSZJ5H ID DMSZJ5H
DMSZJ5H DN Wetimicin
DMSZJ5H HS Discontinued in Phase 1
DMSZJ5H SN Aminoglycoside antibiotic (infection), Jiangsu Institute of Microbiology
DMSZJ5H CP Jiangsu Institute of Microbiology
DMSZJ5H DE Infectious disease
DMHTG38 ID DMHTG38
DMHTG38 DN XL844
DMHTG38 HS Discontinued in Phase 1
DMHTG38 SN SCHEMBL14517914; XL-844
DMHTG38 CP Exelixis
DMHTG38 TC Anticancer Agents
DMHTG38 DT Small molecular drug
DMHTG38 PC 10016910
DMHTG38 MW 287.32
DMHTG38 FM C14H17N5O2
DMHTG38 IC InChI=1S/C14H17N5O2/c15-6-3-9-21-12-5-2-1-4-11(12)18-14(20)19-13-10-16-7-8-17-13/h1-2,4-5,7-8,10H,3,6,9,15H2,(H2,17,18,19,20)
DMHTG38 CS C1=CC=C(C(=C1)NC(=O)NC2=NC=CN=C2)OCCCN
DMHTG38 IK UVSSZSQSZGKMAL-UHFFFAOYSA-N
DMHTG38 IU 1-[2-(3-aminopropoxy)phenyl]-3-pyrazin-2-ylurea
DMHTG38 DE Solid tumour/cancer
DMQKH07 ID DMQKH07
DMQKH07 DN XM-323
DMQKH07 HS Discontinued in Phase 1
DMQKH07 SN DM-323; DMP-323; JCR-424
DMQKH07 CP Bristol-Myers Squibb Pharma Co
DMQKH07 DT Small molecular drug
DMQKH07 PC 72404
DMQKH07 MW 566.7
DMQKH07 FM C35H38N2O5
DMQKH07 IC InChI=1S/C35H38N2O5/c38-23-29-15-11-27(12-16-29)21-36-31(19-25-7-3-1-4-8-25)33(40)34(41)32(20-26-9-5-2-6-10-26)37(35(36)42)22-28-13-17-30(24-39)18-14-28/h1-18,31-34,38-41H,19-24H2/t31-,32-,33+,34+/m1/s1
DMQKH07 CS C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC=C(C=C3)CO)CC4=CC=C(C=C4)CO)CC5=CC=CC=C5)O)O
DMQKH07 IK XCVGQMUMMDXKCY-WZJLIZBTSA-N
DMQKH07 IU (4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[[4-(hydroxymethyl)phenyl]methyl]-1,3-diazepan-2-one
DMQKH07 CA CAS 151867-81-1
DMQKH07 CB CHEBI:42082
DMQKH07 DE Human immunodeficiency virus infection
DMCK210 ID DMCK210
DMCK210 DN XR-9051
DMCK210 HS Discontinued in Phase 1
DMCK210 SN Multidrug resistance inhibitor, Xenova
DMCK210 CP Xenova Ltd
DMCK210 DT Small molecular drug
DMCK210 PC 9917447
DMCK210 MW 642.7
DMCK210 FM C39H38N4O5
DMCK210 IC InChI=1S/C39H38N4O5/c1-42-34(22-27-8-5-4-6-9-27)38(45)41-33(39(42)46)21-28-10-7-11-30(20-28)37(44)40-32-14-12-26(13-15-32)16-18-43-19-17-29-23-35(47-2)36(48-3)24-31(29)25-43/h4-15,20-24H,16-19,25H2,1-3H3,(H,40,44)(H,41,45)/b33-21-,34-22-
DMCK210 CS CN1/C(=C\\C2=CC=CC=C2)/C(=O)N/C(=C\\C3=CC(=CC=C3)C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC)/C1=O
DMCK210 IK RTIZZWMBGKGLFO-YWQXDYITSA-N
DMCK210 IU 3-[(Z)-[(5Z)-5-benzylidene-4-methyl-3,6-dioxopiperazin-2-ylidene]methyl]-N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]benzamide
DMCK210 DE Solid tumour/cancer
DM3Y6M7 ID DM3Y6M7
DM3Y6M7 DN XTL-2125
DM3Y6M7 HS Discontinued in Phase 1
DM3Y6M7 CP XTL Biopharmaceutical
DM3Y6M7 DE Hepatitis C virus infection
DM0FSA9 ID DM0FSA9
DM0FSA9 DN YM-17E
DM0FSA9 HS Discontinued in Phase 1
DM0FSA9 SN YM-17E; YM17E; 124884-99-7; AC1L46WN; SCHEMBL6340546; DTXSID80154515; 1-cycloheptyl-1-[[3-[[cycloheptyl-[(4-dimethylaminophenyl)carbamoyl]amino]methyl]phenyl]methyl]-3-(4-dimethylaminophenyl)urea dihydrochloride
DM0FSA9 CP Yamanouchi Pharmaceutical Co Ltd
DM0FSA9 DT Small molecular drug
DM0FSA9 PC 180288
DM0FSA9 MW 725.8
DM0FSA9 FM C40H58Cl2N6O2
DM0FSA9 IC InChI=1S/C40H56N6O2.2ClH/c1-43(2)35-24-20-33(21-25-35)41-39(47)45(37-16-9-5-6-10-17-37)29-31-14-13-15-32(28-31)30-46(38-18-11-7-8-12-19-38)40(48)42-34-22-26-36(27-23-34)44(3)4;;/h13-15,20-28,37-38H,5-12,16-19,29-30H2,1-4H3,(H,41,47)(H,42,48);2*1H
DM0FSA9 CS CN(C)C1=CC=C(C=C1)NC(=O)N(CC2=CC(=CC=C2)CN(C3CCCCCC3)C(=O)NC4=CC=C(C=C4)N(C)C)C5CCCCCC5.Cl.Cl
DM0FSA9 IK AKJWTZIUYIFCCS-UHFFFAOYSA-N
DM0FSA9 IU 1-cycloheptyl-1-[[3-[[cycloheptyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]phenyl]methyl]-3-[4-(dimethylamino)phenyl]urea;dihydrochloride
DM0FSA9 CA CAS 124884-99-7
DM0FSA9 DE Hyperlipidaemia
DMLD2R0 ID DMLD2R0
DMLD2R0 DN YM-750
DMLD2R0 HS Discontinued in Phase 1
DMLD2R0 SN ACAT inhibitors, Yamanouchi
DMLD2R0 CP Yamanouchi Pharmaceutical Co Ltd
DMLD2R0 DT Small molecular drug
DMLD2R0 PC 9911716
DMLD2R0 MW 452.6
DMLD2R0 FM C31H36N2O
DMLD2R0 IC InChI=1S/C31H36N2O/c1-21-16-22(2)30(23(3)17-21)32-31(34)33(27-11-6-4-5-7-12-27)20-24-14-15-29-26(18-24)19-25-10-8-9-13-28(25)29/h8-10,13-18,27H,4-7,11-12,19-20H2,1-3H3,(H,32,34)
DMLD2R0 CS CC1=CC(=C(C(=C1)C)NC(=O)N(CC2=CC3=C(C=C2)C4=CC=CC=C4C3)C5CCCCCC5)C
DMLD2R0 IK FMLJREWZCZHGGW-UHFFFAOYSA-N
DMLD2R0 IU 1-cycloheptyl-1-(9H-fluoren-2-ylmethyl)-3-(2,4,6-trimethylphenyl)urea
DMLD2R0 CA CAS 138046-43-2
DMLD2R0 DE Hyperlipidaemia
DMDJ2O5 ID DMDJ2O5
DMDJ2O5 DN YM-75466
DMDJ2O5 HS Discontinued in Phase 1
DMDJ2O5 SN YM-466 (free base); YM-60828 (free base); 2-[N-(7-Amidinonaphthalen-2-ylmethyl)-N-[4-[1-(1-iminoethyl)piperidin-4-yloxy]phenyl]sulfamoyl]acetic acid methanesulfonate
DMDJ2O5 PC 9874074
DMDJ2O5 MW 633.7
DMDJ2O5 FM C28H35N5O8S2
DMDJ2O5 IC InChI=1S/C27H31N5O5S.CH4O3S/c1-18(28)31-12-10-25(11-13-31)37-24-8-6-23(7-9-24)32(38(35,36)17-26(33)34)16-19-2-3-20-4-5-21(27(29)30)15-22(20)14-19;1-5(2,3)4/h2-9,14-15,25,28H,10-13,16-17H2,1H3,(H3,29,30)(H,33,34);1H3,(H,2,3,4)
DMDJ2O5 CS CC(=N)N1CCC(CC1)OC2=CC=C(C=C2)N(CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)S(=O)(=O)CC(=O)O.CS(=O)(=O)O
DMDJ2O5 IK YRIFGKTUAWTSFP-UHFFFAOYSA-N
DMDJ2O5 IU 2-[(7-carbamimidoylnaphthalen-2-yl)methyl-[4-(1-ethanimidoylpiperidin-4-yl)oxyphenyl]sulfamoyl]acetic acid;methanesulfonic acid
DMDJ2O5 DE Thrombosis
DMCDK6S ID DMCDK6S
DMCDK6S DN YM-976
DMCDK6S HS Discontinued in Phase 1
DMCDK6S SN 4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one
DMCDK6S DT Small molecular drug
DMCDK6S PC 6604918
DMCDK6S MW 313.8
DMCDK6S FM C17H16ClN3O
DMCDK6S IC InChI=1S/C17H16ClN3O/c1-3-13-8-9-14-15(11-6-5-7-12(18)10-11)20-17(22)21(4-2)16(14)19-13/h5-10H,3-4H2,1-2H3
DMCDK6S CS CCC1=NC2=C(C=C1)C(=NC(=O)N2CC)C3=CC(=CC=C3)Cl
DMCDK6S IK MNHXYNNKDDXKNP-UHFFFAOYSA-N
DMCDK6S IU 4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2-one
DMCDK6S CA CAS 191219-80-4
DMCDK6S CB CHEBI:92225
DMCDK6S DE Asthma
DMA412G ID DMA412G
DMA412G DN Z-300
DMA412G HS Discontinued in Phase 1
DMA412G SN 2-(2-Hydroxyethylsulfanyl)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide 2-(4-hydroxybenzoyl)benzoate
DMA412G DT Small molecular drug
DMA412G PC 124488
DMA412G MW 366.5
DMA412G FM C19H30N2O3S
DMA412G IC InChI=1S/C19H30N2O3S/c22-11-13-25-16-19(23)20-8-5-12-24-18-7-4-6-17(14-18)15-21-9-2-1-3-10-21/h4,6-7,14,22H,1-3,5,8-13,15-16H2,(H,20,23)
DMA412G CS C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CSCCO
DMA412G IK ZRVDLLKTYZXNAD-UHFFFAOYSA-N
DMA412G IU 2-(2-hydroxyethylsulfanyl)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
DMA412G CA CAS 127966-78-3
DMA412G DE Gastric ulcer
DMLO2QY ID DMLO2QY
DMLO2QY DN Z-321
DMLO2QY HS Discontinued in Phase 1
DMLO2QY SN 1-[3-(2-Indanylacetyl)thiazolidin-4(R)-ylcarbonyl]pyrrolidine; 1-[N-(2-Indanylacetyl)-4-thia-L-prolyl]pyrrolidine
DMLO2QY DT Small molecular drug
DMLO2QY PC 9798234
DMLO2QY MW 344.5
DMLO2QY FM C19H24N2O2S
DMLO2QY IC InChI=1S/C19H24N2O2S/c22-18(11-14-9-15-5-1-2-6-16(15)10-14)21-13-24-12-17(21)19(23)20-7-3-4-8-20/h1-2,5-6,14,17H,3-4,7-13H2/t17-/m0/s1
DMLO2QY CS C1CCN(C1)C(=O)[C@@H]2CSCN2C(=O)CC3CC4=CC=CC=C4C3
DMLO2QY IK GDOVFSONSLOIAK-KRWDZBQOSA-N
DMLO2QY IU 2-(2,3-dihydro-1H-inden-2-yl)-1-[(4R)-4-(pyrrolidine-1-carbonyl)-1,3-thiazolidin-3-yl]ethanone
DMLO2QY CA CAS 130849-58-0
DMLO2QY DE Parkinson disease
DM82V1D ID DM82V1D
DM82V1D DN ZD-0892
DM82V1D HS Discontinued in Phase 1
DM82V1D SN CHEMBL55210; SCHEMBL7363455; CTK4D4091; BDBM50058391; HY-19254; 171964-73-1; CS-0014993; L-Prolinamide,N-(4-methoxybenzoyl)-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-; (S)-1-[(S)-2-(4-Methoxy-benzoylamino)-3-methyl-butyryl]-pyrrolidine-2-carboxylic acid
DM82V1D DT Small molecular drug
DM82V1D PC 9892148
DM82V1D MW 499.5
DM82V1D FM C24H32F3N3O5
DM82V1D IC InChI=1S/C24H32F3N3O5/c1-13(2)18(20(31)24(25,26)27)28-22(33)17-7-6-12-30(17)23(34)19(14(3)4)29-21(32)15-8-10-16(35-5)11-9-15/h8-11,13-14,17-19H,6-7,12H2,1-5H3,(H,28,33)(H,29,32)/t17-,18-,19-/m0/s1
DM82V1D CS CC(C)[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)C2=CC=C(C=C2)OC
DM82V1D IK PNILZVBINXNWHW-FHWLQOOXSA-N
DM82V1D IU (2S)-1-[(2S)-2-[(4-methoxybenzoyl)amino]-3-methylbutanoyl]-N-[(3S)-1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl]pyrrolidine-2-carboxamide
DM82V1D DE Chronic obstructive pulmonary disease
DMUDLFM ID DMUDLFM
DMUDLFM DN ZD-1611
DMUDLFM HS Discontinued in Phase 1
DMUDLFM SN Endothelin antagonist, Zeneca
DMUDLFM CP AstraZeneca plc
DMUDLFM PC 9933752
DMUDLFM MW 456.5
DMUDLFM FM C22H24N4O5S
DMUDLFM IC InChI=1S/C22H24N4O5S/c1-14-13-24-19(20(25-14)31-4)26-32(29,30)17-6-5-11-23-18(17)16-9-7-15(8-10-16)12-22(2,3)21(27)28/h5-11,13H,12H2,1-4H3,(H,24,26)(H,27,28)
DMUDLFM CS CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)CC(C)(C)C(=O)O
DMUDLFM IK CDBNTQYPMBJKQZ-UHFFFAOYSA-N
DMUDLFM IU 3-[4-[3-[(3-methoxy-5-methylpyrazin-2-yl)sulfamoyl]pyridin-2-yl]phenyl]-2,2-dimethylpropanoic acid
DMUDLFM DE Hypotension
DM7JUCI ID DM7JUCI
DM7JUCI DN ZD-2767
DM7JUCI HS Discontinued in Phase 1
DM7JUCI SN Colorectal cancer therapy (ADEPT), AstraZeneca/CRCT; Colorectal cancer therapy (ADEPT), Zeneca/CRCT
DM7JUCI CP AstraZeneca plc
DM7JUCI DE Solid tumour/cancer
DMQDNU1 ID DMQDNU1
DMQDNU1 DN ZD-4927
DMQDNU1 HS Discontinued in Phase 1
DMQDNU1 CP AstraZeneca plc
DMQDNU1 DE Thrombosis
DM1EB6H ID DM1EB6H
DM1EB6H DN ZD-7349
DM1EB6H HS Discontinued in Phase 1
DM1EB6H SN VLA-4 antagonists, Zeneca
DM1EB6H CP Zeneca Group plc
DM1EB6H DE Multiple sclerosis
DMJ9R4A ID DMJ9R4A
DMJ9R4A DN ZK 304709
DMJ9R4A HS Discontinued in Phase 1
DMJ9R4A SN ZK 304709; 1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701
DMJ9R4A CP Schering AG
DMJ9R4A DT Small molecular drug
DMJ9R4A PC 59733314
DMJ9R4A MW 445
DMJ9R4A FM C22H29ClN6O2
DMJ9R4A IC InChI=1S/C22H29ClN6O2/c1-28-7-9-29(10-8-28)18-12-15(11-16(23)13-18)21(30)26-19-14-24-27-20(19)22(31)25-17-5-3-2-4-6-17/h11-14,17H,2-10H2,1H3,(H,24,27)(H,25,31)(H,26,30)
DMJ9R4A CS CN1CCN(CC1)C2=CC(=CC(=C2)C(=O)NC3=C(NN=C3)C(=O)NC4CCCCC4)Cl
DMJ9R4A IK OALDDSAHYZPJQM-UHFFFAOYSA-N
DMJ9R4A IU 4-[[3-chloro-5-(4-methylpiperazin-1-yl)benzoyl]amino]-N-cyclohexyl-1H-pyrazole-5-carboxamide
DMJ9R4A CA CAS 1010440-84-2
DMJ9R4A DE Advanced solid tumour
DMHXVN1 ID DMHXVN1
DMHXVN1 DN DFD-11
DMHXVN1 HS Application submitted
DMHXVN1 CP Promius Pharma Princeton, NJ
DMHXVN1 DE Head and body lice
DMCA7LN ID DMCA7LN
DMCA7LN DN Oxycodone hydrochloride
DMCA7LN HS Application submitted
DMCA7LN SN oxycodone ER
DMCA7LN CP Intellipharmaceutics International Toronto, Canada
DMCA7LN PC 5462350
DMCA7LN MW 351.8
DMCA7LN FM C18H22ClNO4
DMCA7LN IC InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1
DMCA7LN CS CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O.Cl
DMCA7LN IK MUZQPDBAOYKNLO-RKXJKUSZSA-N
DMCA7LN IU (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
DMCA7LN CA CAS 124-90-3
DMCA7LN CB CHEBI:7859
DMCA7LN DE Chronic pain
DMC7EQT ID DMC7EQT
DMC7EQT DN AAB-002
DMC7EQT HS Phase 0
DMC7EQT CP Janssen Alzheimer Immunotherapy; Pfizer
DMC7EQT DE Alzheimer disease
DM3V8JN ID DM3V8JN
DM3V8JN DN Anti-CD19 CAR T cells
DM3V8JN HS Phase 0
DM3V8JN CP University of Pennsylvania
DM3V8JN DT CAR T Cell Therapy
DM3V8JN DE Hodgkin lymphoma
DMYZ3O9 ID DMYZ3O9
DMYZ3O9 DN Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
DMYZ3O9 HS Phase 0
DMYZ3O9 CP University of Pennsylvania
DMYZ3O9 DT CAR T Cell Therapy
DMYZ3O9 DE Acute myeloid leukaemia
DMFRA38 ID DMFRA38
DMFRA38 DN CART19 cells
DMFRA38 HS Phase 0
DMFRA38 CP University of Pennsylvania
DMFRA38 DT CAR T Cell Therapy
DMFRA38 DE Hodgkin lymphoma
DMA85ND ID DMA85ND
DMA85ND DN ET-1
DMA85ND HS Phase 0
DMA85ND SN Endothelin-1
DMA85ND PC 16212950
DMA85ND MW 2491.9
DMA85ND FM C109H159N25O32S5
DMA85ND IC InChI=1S/C109H159N25O32S5/c1-12-56(9)87(107(163)125-76(109(165)166)39-60-43-113-65-24-18-17-23-63(60)65)134-108(164)88(57(10)13-2)133-99(155)75(42-85(143)144)123-94(150)70(36-54(5)6)118-97(153)73(40-61-44-112-52-114-61)121-103(159)80-49-169-168-48-64(111)89(145)126-77(45-135)102(158)131-81-50-170-171-51-82(105(161)132-86(55(7)8)106(162)124-72(38-59-26-28-62(138)29-27-59)95(151)120-71(96(152)130-80)37-58-21-15-14-16-22-58)129-91(147)67(30-31-83(139)140)116-90(146)66(25-19-20-33-110)115-98(154)74(41-84(141)142)122-92(148)68(32-34-167-11)117-93(149)69(35-53(3)4)119-100(156)78(46-136)127-101(157)79(47-137)128-104(81)160/h14-18,21-24,26-29,43-44,52-57,64,66-82,86-88,113,135-138H,12-13,19-20,25,30-42,45-51,110-111H2,1-11H3,(H,112,114)(H,115,154)(H,116,146)(H,117,149)(H,118,153)(H,119,156)(H,120,151)(H,121,159)(H,122,148)(H,123,150)(H,124,162)(H,125,163)(H,126,145)(H,127,157)(H,128,160)(H,129,147)(H,130,152)(H,131,158)(H,132,161)(H,133,155)(H,134,164)(H,139,140)(H,141,142)(H,143,144)(H,165,166)/t56-,57-,64-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,86-,87-,88-/m0/s1
DMA85ND CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC5=O)CO)CO)CC(C)C)CCSC)CC(=O)O)CCCCN)CCC(=O)O)CO)N
DMA85ND IK ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N
DMA85ND IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-7-(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-19,22,28-tris(hydroxymethyl)-42-[(4-hydroxyphenyl)methyl]-16-(2-methylpropyl)-13-(2-methylsulfanylethyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-45-propan-2-yl-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMA85ND CA CAS 123626-67-5
DMIUZEX ID DMIUZEX
DMIUZEX DN (R)-PFI-2
DMIUZEX HS Preclinical
DMIUZEX SN PFI-2; 1627676-59-8; (R)-PFI-2; CHEMBL3414622; PFI-2 HCl; 8-Fluoro-N-{(2r)-1-Oxo-1-(Pyrrolidin-1-Yl)-3-[3-(Trifluoromethyl)phenyl]propan-2-Yl}-1,2,3,4-Tetrahydroisoquinoline-6-Sulfonamide; 1L8; GTPL8235; C23H25F4N3O3S; MolPort-035-789-712; EX-A1603; s7294; ZINC95920703; BDBM50075073; 2648AH; AKOS030526617; CS-4177; NCGC00351479-01; HY-18627; BC600610; (R)-8-Fluoro-N-(1-oxo-1-(pyrrolidin-1-yl)-3-(3-(trifluoromethyl)phenyl)propan-2-yl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
DMIUZEX DT Small molecular drug
DMIUZEX PC 71300326
DMIUZEX MW 499.5
DMIUZEX FM C23H25F4N3O3S
DMIUZEX IC InChI=1S/C23H25F4N3O3S/c24-20-13-18(12-16-6-7-28-14-19(16)20)34(32,33)29-21(22(31)30-8-1-2-9-30)11-15-4-3-5-17(10-15)23(25,26)27/h3-5,10,12-13,21,28-29H,1-2,6-9,11,14H2/t21-/m1/s1
DMIUZEX CS C1CCN(C1)C(=O)[C@@H](CC2=CC(=CC=C2)C(F)(F)F)NS(=O)(=O)C3=CC4=C(CNCC4)C(=C3)F
DMIUZEX IK JCKGSPAAPQRPBW-OAQYLSRUSA-N
DMIUZEX IU 8-fluoro-N-[(2R)-1-oxo-1-pyrrolidin-1-yl-3-[3-(trifluoromethyl)phenyl]propan-2-yl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
DMIUZEX DE Breast cancer
DMXWD08 ID DMXWD08
DMXWD08 DN (R)-Xamoterol
DMXWD08 HS Preclinical
DMXWD08 PC 155774
DMXWD08 FM C16H25N3O5
DMXWD08 IC InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)
DMXWD08 CS C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O
DMXWD08 IK DXPOSRCHIDYWHW-UHFFFAOYSA-N
DMXWD08 IU N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide
DMXWD08 CA CAS 81801-12-9
DMXWD08 CB CHEBI:10055
DMXWD08 DE Heart failure
DMEJYV4 ID DMEJYV4
DMEJYV4 DN (S)-4-(Ethylsulfonyl)benzoylalanine
DMEJYV4 HS Preclinical
DMEJYV4 SN S-ESBA
DMEJYV4 DT Small molecular drug
DMEJYV4 DE Cognitive impairment; Schizophrenia
DM1ZQ5G ID DM1ZQ5G
DM1ZQ5G DN (S)-Xamoterol
DM1ZQ5G HS Preclinical
DM1ZQ5G SN UNII-ZIB581LRDV; ZIB581LRDV; (S)-Xamoterol; Xamoterol, (S)-; 69630-22-4; SCHEMBL11533496; ZINC1532365; UNII-7HE0JQL703 component DXPOSRCHIDYWHW-AWEZNQCLSA-N; 4-Morpholinecarboxamide, N-(2-(((2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-
DM1ZQ5G PC 12681891
DM1ZQ5G MW 339.39
DM1ZQ5G FM C16H25N3O5
DM1ZQ5G IC InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)/t14-/m0/s1
DM1ZQ5G CS C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O
DM1ZQ5G IK DXPOSRCHIDYWHW-AWEZNQCLSA-N
DM1ZQ5G IU N-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide
DM1ZQ5G CA CAS 69630-22-4
DM1ZQ5G DE Heart failure
DM9TQDE ID DM9TQDE
DM9TQDE DN 111In-hEGF
DM9TQDE HS Preclinical
DM9TQDE SN Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto
DM9TQDE CP University of Toronto
DM9TQDE DE Breast cancer
DM5IUN8 ID DM5IUN8
DM5IUN8 DN 12B9m
DM5IUN8 HS Preclinical
DM5IUN8 CP Amgen
DM5IUN8 DT Antibody
DM5IUN8 DE Anaemia
DM503DN ID DM503DN
DM503DN DN 1954U89
DM503DN HS Preclinical
DM503DN CP Glaxo Wellcome plc
DM503DN PC 177894
DM503DN MW 283.37
DM503DN FM C16H21N5
DM503DN IC InChI=1S/C16H21N5/c1-4-10(5-2)21-9(3)8-11-13(21)7-6-12-14(11)15(17)20-16(18)19-12/h6-8,10H,4-5H2,1-3H3,(H4,17,18,19,20)
DM503DN CS CCC(CC)N1C(=CC2=C1C=CC3=C2C(=NC(=N3)N)N)C
DM503DN IK YBHNZQJIFKDDHM-UHFFFAOYSA-N
DM503DN IU 8-methyl-7-pentan-3-ylpyrrolo[3,2-f]quinazoline-1,3-diamine
DM503DN CA CAS 150057-49-1
DM503DN DE Solid tumour/cancer
DMT8SFV ID DMT8SFV
DMT8SFV DN 1-methyl-L-tryptophan
DMT8SFV HS Preclinical
DMT8SFV SN 1-L-MT; 1-LMT
DMT8SFV DT Small molecular drug
DMT8SFV PC 676159
DMT8SFV MW 218.25
DMT8SFV FM C12H14N2O2
DMT8SFV IC InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m0/s1
DMT8SFV CS CN1C=C(C2=CC=CC=C21)C[C@@H](C(=O)O)N
DMT8SFV IK ZADWXFSZEAPBJS-JTQLQIEISA-N
DMT8SFV IU (2S)-2-amino-3-(1-methylindol-3-yl)propanoic acid
DMT8SFV CA CAS 21339-55-9
DMT8SFV DE Solid tumour/cancer
DMIS1G7 ID DMIS1G7
DMIS1G7 DN 2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester
DMIS1G7 HS Preclinical
DMIS1G7 DT Small molecular drug
DMIS1G7 DE Glioma
DMLVADH ID DMLVADH
DMLVADH DN 212Pb-labelled aCD37
DMLVADH HS Preclinical
DMLVADH SN 212PB-NNV003
DMLVADH CP OranoMed/NordicNanovector
DMLVADH DT Radiopharmaceutical therapy agent
DMLVADH DE leukaemia
DM1O2C3 ID DM1O2C3
DM1O2C3 DN 227Th-labelled HER2-TTC
DM1O2C3 HS Preclinical
DM1O2C3 CP Bayer
DM1O2C3 DT Radiopharmaceutical therapy agent
DM1O2C3 DE Solid tumour/cancer
DM1R3VC ID DM1R3VC
DM1R3VC DN 2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid
DM1R3VC HS Preclinical
DM1R3VC DT Small molecular drug
DM1R3VC DE Breast cancer
DMRDQPT ID DMRDQPT
DMRDQPT DN 2-D08
DMRDQPT HS Preclinical
DMRDQPT SN 144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE
DMRDQPT DT Small molecular drug
DMRDQPT PC 22507438
DMRDQPT MW 270.24
DMRDQPT FM C15H10O5
DMRDQPT IC InChI=1S/C15H10O5/c16-10-6-5-9(14(18)15(10)19)13-7-11(17)8-3-1-2-4-12(8)20-13/h1-7,16,18-19H
DMRDQPT CS C1=CC=C2C(=C1)C(=O)C=C(O2)C3=C(C(=C(C=C3)O)O)O
DMRDQPT IK JJAXTFSPCLZPIW-UHFFFAOYSA-N
DMRDQPT IU 2-(2,3,4-trihydroxyphenyl)chromen-4-one
DMRDQPT DE Acute myeloid leukaemia
DM4NURZ ID DM4NURZ
DM4NURZ DN 2E9IgA1
DM4NURZ HS Preclinical
DM4NURZ DT Antibody
DM4NURZ DE Mycobacterium infection
DMAM4FE ID DMAM4FE
DMAM4FE DN 2-Ethoxypropanoic acid
DMAM4FE HS Preclinical
DMAM4FE SN 2-ethoxypropanoic acid; 53103-75-6; 2-ethoxypropionic acid; MFCD09940775; Propanoic acid, 2-ethoxy-; SCHEMBL142064; DTXSID00570733; 2-Ethoxypropanoic acid, AldrichCPR; STL508457; AKOS000184266; AKOS016903919; MCULE-2185795311; SY040144; DB-104575; EN300-39488; Y-6023
DMAM4FE DT Small molecular drug
DMAM4FE PC 15268841
DMAM4FE MW 118.13
DMAM4FE FM C5H10O3
DMAM4FE IC InChI=1S/C5H10O3/c1-3-8-4(2)5(6)7/h4H,3H2,1-2H3,(H,6,7)
DMAM4FE CS CCOC(C)C(=O)O
DMAM4FE IK XBHQOMRKOUANQQ-UHFFFAOYSA-N
DMAM4FE IU 2-ethoxypropanoic acid
DMAM4FE CA CAS 53103-75-6
DMAM4FE DE Breast cancer
DM5CVBM ID DM5CVBM
DM5CVBM DN 3-Oxo-C12-(2-amino-cyclohexanone)
DM5CVBM HS Preclinical
DM5CVBM DT Small molecular drug
DM5CVBM DE Pseudomonas infection
DM57GL1 ID DM57GL1
DM57GL1 DN 4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine
DM57GL1 HS Preclinical
DM57GL1 SN CHEMBL4166624; BDBM50321330
DM57GL1 CP Genentech
DM57GL1 DT Small molecular drug
DM57GL1 PC 145952699
DM57GL1 MW 168.13
DM57GL1 FM C6H5FN4O
DM57GL1 IC InChI=1S/C6H5FN4O/c7-4-1-9-11(3-4)5-2-10-12-6(5)8/h1-3H,8H2
DM57GL1 CS C1=C(C=NN1C2=C(ON=C2)N)F
DM57GL1 IK YCBKZPFCIBXKIG-UHFFFAOYSA-N
DM57GL1 IU 4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine
DM57GL1 DE Solid tumour/cancer
DMXFC3W ID DMXFC3W
DMXFC3W DN 4SC-202
DMXFC3W HS Preclinical
DMXFC3W CP 4SC AG
DMXFC3W DT Small molecular drug
DMXFC3W PC 44217246
DMXFC3W MW 619.7
DMXFC3W FM C30H29N5O6S2
DMXFC3W IC InChI=1S/C23H21N5O3S.C7H8O3S/c1-27-16-19(14-25-27)18-7-9-20(10-8-18)32(30,31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24;1-6-2-4-7(5-3-6)11(8,9)10/h2-16H,24H2,1H3,(H,26,29);2-5H,1H3,(H,8,9,10)/b11-6+;
DMXFC3W CS CC1=CC=C(C=C1)S(=O)(=O)O.CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N
DMXFC3W IK IAVXAZDVNICKFJ-ICSBZGNSSA-N
DMXFC3W IU (E)-N-(2-aminophenyl)-3-[1-[4-(1-methylpyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]prop-2-enamide;4-methylbenzenesulfonic acid
DMXFC3W CA CAS 1186222-89-8
DMXFC3W DE Solid tumour/cancer
DMAJWLD ID DMAJWLD
DMAJWLD DN 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one
DMAJWLD HS Preclinical
DMAJWLD DT Small molecular drug
DMAJWLD DE Pompe disease
DMC4IUQ ID DMC4IUQ
DMC4IUQ DN 5-(N,N-hexamethylene)-amiloride
DMC4IUQ HS Preclinical
DMC4IUQ SN 5-(N,N-Hexamethylene)amiloride; Hexamethyleneamiloride; 1428-95-1; Hexamethylene amiloride; HMA-5; HMA; C12H18ClN7O; 3-Amino-6-chloro-5-(1-homopiperidyl)-N-(diaminomethylene)pyrazinecarboxamide; N,N-HEXAMETHYLENEAMILORIDE; CHEBI:76400; 3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylene)pyrazine-2-carboxamide; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)pyrazinecarboxamide; Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)-; 5-HMA; Spectrum_001596
DMC4IUQ DT Small molecular drug
DMC4IUQ PC 1794
DMC4IUQ MW 311.77
DMC4IUQ FM C12H18ClN7O
DMC4IUQ IC InChI=1S/C12H18ClN7O/c13-8-10(20-5-3-1-2-4-6-20)18-9(14)7(17-8)11(21)19-12(15)16/h1-6H2,(H2,14,18)(H4,15,16,19,21)
DMC4IUQ CS C1CCCN(CC1)C2=NC(=C(N=C2Cl)C(=O)N=C(N)N)N
DMC4IUQ IK RQQJJXVETXFINY-UHFFFAOYSA-N
DMC4IUQ IU 3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMC4IUQ CA CAS 1428-95-1
DMC4IUQ CB CHEBI:76400
DMC4IUQ DE Coronavirus infection
DM7RHOC ID DM7RHOC
DM7RHOC DN 5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin
DM7RHOC HS Preclinical
DM7RHOC DT Small molecular drug
DM7RHOC DE GM1 gangliosidosis
DMCDTIG ID DMCDTIG
DMCDTIG DN 680C91
DMCDTIG HS Preclinical
DMCDTIG SN 163239-22-3; CHEMBL355606; 6-Fluoro-3-((E)-2-pyridin-3-yl-vinyl)-1H-indole; 6-fluoro-3-[(E)-2-pyridin-3-ylethenyl]-1H-indole; SCHEMBL3262721; SCHEMBL3262726; ZINC19965; CHEBI:131851; EX-A4573; BDBM50289137; s8997; AKOS024458137; 680C91, >=98% (HPLC); 680C-91; (e)-6-fluoro-3-[2-(3-pyridyl)vinyl]-1h-indole; (E)-6-Fluoro-3-(2-(pyridin-3-yl)vinyl)-1H-indole; 6-fluoro-3-[(E)-2-(pyridin-3-yl)vinyl]-1H-indole; Q27225279; 6-Fluoro-3-[(1E)-2-(3-pyridinyl)ethenyl]-1H-indole; 1H-Indole, 6-fluoro-3-[(1E)-2-(3-pyridinyl)ethenyl]-
DMCDTIG CP Glaxo Wellcome
DMCDTIG DT Small molecular drug
DMCDTIG PC 10014426
DMCDTIG MW 238.26
DMCDTIG FM C15H11FN2
DMCDTIG IC InChI=1S/C15H11FN2/c16-13-5-6-14-12(10-18-15(14)8-13)4-3-11-2-1-7-17-9-11/h1-10,18H/b4-3+
DMCDTIG CS C1=CC(=CN=C1)/C=C/C2=CNC3=C2C=CC(=C3)F
DMCDTIG IK YBSDQTBCNYWBMX-ONEGZZNKSA-N
DMCDTIG IU 6-fluoro-3-[(E)-2-pyridin-3-ylethenyl]-1H-indole
DMCDTIG CA CAS 163239-22-3
DMCDTIG CB CHEBI:131851
DMCDTIG DE Solid tumour/cancer
DMEKMV0 ID DMEKMV0
DMEKMV0 DN 9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0 HS Preclinical
DMEKMV0 SN HY50737A; 924296-19-5; 9-(ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile; USP8-IN-22e; (9E)-9-ethoxyiminoindeno[1,2-b]pyrazine-2,3-dicarbonitrile; SCHEMBL1512635; 9-ethoxyiminoindeno[1,2-b]pyrazine-2,3-dicarbonitrile; 9-ethyloxyimino-9h-indeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0 CP Hybrigenics
DMEKMV0 DT Small molecular drug
DMEKMV0 PC 73230796
DMEKMV0 MW 275.26
DMEKMV0 FM C15H9N5O
DMEKMV0 IC InChI=1S/C15H9N5O/c1-2-21-20-14-10-6-4-3-5-9(10)13-15(14)19-12(8-17)11(7-16)18-13/h3-6H,2H2,1H3
DMEKMV0 CS CCON=C1C2=CC=CC=C2C3=NC(=C(N=C31)C#N)C#N
DMEKMV0 IK VKVAJBRQGBRHIK-UHFFFAOYSA-N
DMEKMV0 IU 9-ethoxyiminoindeno[1,2-b]pyrazine-2,3-dicarbonitrile
DMEKMV0 DE Solid tumour/cancer
DMFP316 ID DMFP316
DMFP316 DN A-196
DMFP316 HS Preclinical
DMFP316 SN 1982372-88-2; 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine; A 196; SGC A-196; Cyclopentyl-(6,7-dichloro-4-pyridin-4-yl-phthalazin-1-yl)-amine; GTPL8949; CHEMBL4521971; SCHEMBL17968181; BDBM223981; EX-A4473; s7983; AKOS032945052; ZINC521836458; CCG-268144; CS-5613; NCGC00387310-01; AK685671; BS-15880; HY-100201; A-196, >=98% (HPLC); A-196 (3); Q27074057; 6,7-Dichloro-N-cyclopentyl-4-(4-pyridinyl)-1-phthalazinamine; ClC=1C=C2C(=NN=C(C2=CC=1Cl)NC1CCCC1)C1=CC=NC=C1
DMFP316 DT Small molecular drug
DMFP316 PC 117072548
DMFP316 MW 359.2
DMFP316 FM C18H16Cl2N4
DMFP316 IC InChI=1S/C18H16Cl2N4/c19-15-9-13-14(10-16(15)20)18(22-12-3-1-2-4-12)24-23-17(13)11-5-7-21-8-6-11/h5-10,12H,1-4H2,(H,22,24)
DMFP316 CS C1CCC(C1)NC2=NN=C(C3=CC(=C(C=C32)Cl)Cl)C4=CC=NC=C4
DMFP316 IK ABGOSOMRWSYAOB-UHFFFAOYSA-N
DMFP316 IU 6,7-dichloro-N-cyclopentyl-4-pyridin-4-ylphthalazin-1-amine
DMFP316 DE Discovery agent
DM1H45U ID DM1H45U
DM1H45U DN A-366
DM1H45U HS Preclinical
DM1H45U SN A 366; A366
DM1H45U DT Small molecular drug
DM1H45U PC 76285486
DM1H45U MW 329.4
DM1H45U FM C19H27N3O2
DM1H45U IC InChI=1S/C19H27N3O2/c1-23-16-12-14-15(21-18(20)19(14)6-4-7-19)13-17(16)24-11-5-10-22-8-2-3-9-22/h12-13H,2-11H2,1H3,(H2,20,21)
DM1H45U CS COC1=C(C=C2C(=C1)C3(CCC3)C(=N2)N)OCCCN4CCCC4
DM1H45U IK BKCDJTRMYWSXMC-UHFFFAOYSA-N
DM1H45U IU 5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine
DM1H45U DE Solid tumour/cancer
DML5SO1 ID DML5SO1
DML5SO1 DN A-366833
DML5SO1 HS Preclinical
DML5SO1 SN 5-[(1R,5S)-3,6-Diazabicyclo[3.2.0]hept-6-yl]pyridine-3-carbonitrile
DML5SO1 DT Small molecular drug
DML5SO1 PC 9942427
DML5SO1 MW 200.24
DML5SO1 FM C11H12N4
DML5SO1 IC InChI=1S/C11H12N4/c12-2-8-1-10(5-13-3-8)15-7-9-4-14-6-11(9)15/h1,3,5,9,11,14H,4,6-7H2/t9-,11-/m1/s1
DML5SO1 CS C1[C@@H]2CN([C@@H]2CN1)C3=CN=CC(=C3)C#N
DML5SO1 IK GPXAWLDGWSBLKM-MWLCHTKSSA-N
DML5SO1 IU 5-[(1R,5S)-3,6-diazabicyclo[3.2.0]heptan-6-yl]pyridine-3-carbonitrile
DML5SO1 CA CAS 370882-41-0
DML5SO1 DE Pain
DMECV6L ID DMECV6L
DMECV6L DN A-425619
DMECV6L HS Preclinical
DMECV6L SN AC1OYT5J; T5512318; LS-192912; 1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea; 1-isoquinolin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea
DMECV6L CP Abbott
DMECV6L TC Analgesics
DMECV6L DT Small molecular drug
DMECV6L PC 8068410
DMECV6L MW 345.3
DMECV6L FM C18H14F3N3O
DMECV6L IC InChI=1S/C18H14F3N3O/c19-18(20,21)14-6-4-12(5-7-14)10-23-17(25)24-16-3-1-2-13-11-22-9-8-15(13)16/h1-9,11H,10H2,(H2,23,24,25)
DMECV6L CS C1=CC2=C(C=CN=C2)C(=C1)NC(=O)NCC3=CC=C(C=C3)C(F)(F)F
DMECV6L IK SJGVXVZUSQLLJB-UHFFFAOYSA-N
DMECV6L IU 1-isoquinolin-5-yl-3-[[4-(trifluoromethyl)phenyl]methyl]urea
DMECV6L CA CAS 581809-67-8
DMECV6L DE Pain
DMZ4HMP ID DMZ4HMP
DMZ4HMP DN A-71378
DMZ4HMP HS Preclinical
DMZ4HMP SN A 71378; Desamino-tyr(SO3H)-nle-gly-trp-nle-(N-methyl)asp-phe-NH2; (3S)-4-[[(2R)-1-[2-[[(2S)-2-[[1H-indol-3-ylmethyl-[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]carbamoyl]amino]hexanoyl]carbamoyl]phenyl]propan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]-methylamino]-4-oxobutanoic acid
DMZ4HMP CP Abbott
DMZ4HMP DT Small molecular drug
DMZ4HMP PC 5489450
DMZ4HMP MW 991.1
DMZ4HMP FM C48H62N8O13S
DMZ4HMP IC InChI=1S/C48H62N8O13S/c1-5-7-16-38(53-41(57)24-21-31-19-22-34(23-20-31)69-70(66,67)68)45(62)51-28-42(58)56(29-33-27-50-37-18-12-11-14-35(33)37)48(65)54-39(17-8-6-2)46(63)55-44(61)36-15-10-9-13-32(36)25-30(3)52-47(64)40(49-4)26-43(59)60/h9-15,18-20,22-23,27,30,38-40,49-50H,5-8,16-17,21,24-26,28-29H2,1-4H3,(H,51,62)(H,52,64)(H,53,57)(H,54,65)(H,59,60)(H,55,61,63)(H,66,67,68)/t30-,38+,39+,40+/m1/s1
DMZ4HMP CS CCCC[C@@H](C(=O)NCC(=O)N(CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)NC(=O)C3=CC=CC=C3C[C@@H](C)NC(=O)[C@H](CC(=O)O)NC)NC(=O)CCC4=CC=C(C=C4)OS(=O)(=O)O
DMZ4HMP IK DLOJBPLQFCFYKX-QQYYTUMTSA-N
DMZ4HMP IU (3S)-4-[[(2R)-1-[2-[[(2S)-2-[[1H-indol-3-ylmethyl-[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]carbamoyl]amino]hexanoyl]carbamoyl]phenyl]propan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid
DMZ4HMP CA CAS 127902-33-4
DMZ4HMP DE Obesity
DMAK6H3 ID DMAK6H3
DMAK6H3 DN A-74498
DMAK6H3 HS Preclinical
DMAK6H3 CP Abbott
DMAK6H3 PC 9962628
DMAK6H3 MW 841
DMAK6H3 FM C44H56N8O9
DMAK6H3 IC InChI=1S/C44H56N8O9/c1-27-15-9-11-19-31(27)50-42(59)46-22-14-13-21-33(41(58)52(5)36(25-37(53)54)40(57)49-34(38(45)55)23-28-16-7-6-8-17-28)48-39(56)35(51-43(60)61-44(2,3)4)24-29-26-47-32-20-12-10-18-30(29)32/h6-12,15-20,26,33-36,47H,13-14,21-25H2,1-5H3,(H2,45,55)(H,48,56)(H,49,57)(H,51,60)(H,53,54)(H2,46,50,59)/t33-,34-,35-,36-/m0/s1
DMAK6H3 CS CC1=CC=CC=C1NC(=O)NCCCC[C@@H](C(=O)N(C)[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)OC(C)(C)C
DMAK6H3 IK KONMZUWCOVKBMG-ZYADHFCISA-N
DMAK6H3 IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]-methylamino]-4-oxobutanoic acid
DMAK6H3 DE Obesity
DMSO8IE ID DMSO8IE
DMSO8IE DN A-841720
DMSO8IE HS Preclinical
DMSO8IE SN 869802-58-4; A-841720; A 841720; UNII-U8C5C9D65S; U8C5C9D65S; CHEMBL386565; SCHEMBL8237949; GTPL3953; CTK5F7481; DTXSID10236030; MolPort-023-276-650; ZINC13676140; BDBM50177080; AKOS024457407; 3-(azepan-1-yl)-9-(dimethylamino)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one; NCGC00371083-02; Pyrido(3',2':4,5)thieno(3,2-d)pyrimidin-4(3H)-one, 9-(dimethylamino)-3-(hexahydro-1H-azepin-1-yl)-; RT-011135; KB-270514; A-440; B7258; 3-(azepan-1-yl)-9-(dimethylamino)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one
DMSO8IE CP Abbott Laboratories
DMSO8IE DT Small molecular drug
DMSO8IE PC 11559235
DMSO8IE MW 343.4
DMSO8IE FM C17H21N5OS
DMSO8IE IC InChI=1S/C17H21N5OS/c1-20(2)12-7-8-18-16-13(12)14-15(24-16)17(23)22(11-19-14)21-9-5-3-4-6-10-21/h7-8,11H,3-6,9-10H2,1-2H3
DMSO8IE CS CN(C)C1=C2C3=C(C(=O)N(C=N3)N4CCCCCC4)SC2=NC=C1
DMSO8IE IK GYWGXEGOXODOQU-UHFFFAOYSA-N
DMSO8IE IU 5-(azepan-1-yl)-13-(dimethylamino)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMSO8IE CA CAS 869802-58-4
DMSO8IE DE Pain
DM8XHJG ID DM8XHJG
DM8XHJG DN A-893
DM8XHJG HS Preclinical
DM8XHJG SN 1868232-32-9; (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide; CHEMBL3590526; N-Cyclohexyl-N~3~-[2-(3,4-Dichlorophenyl)ethyl]-N-(2-{[(2r)-2-Hydroxy-2-(3-Oxo-3,4-Dihydro-2h-1,4-Benzoxazin-8-Yl)ethyl]amino}ethyl)-Beta-Alaninamide; SCHEMBL17476248; EX-A2769; BDBM50095537; AKOS030235552; ZINC230499113; ACN-037539; AC-29886; HY-19563; CS-0015655; Q27454706; 4GQ; N-Cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide
DM8XHJG DT Small molecular drug
DM8XHJG PC 91757965
DM8XHJG MW 577.5
DM8XHJG FM C29H38Cl2N4O4
DM8XHJG IC InChI=1S/C29H38Cl2N4O4/c30-23-10-9-20(17-24(23)31)11-13-32-14-12-28(38)35(21-5-2-1-3-6-21)16-15-33-18-26(36)22-7-4-8-25-29(22)39-19-27(37)34-25/h4,7-10,17,21,26,32-33,36H,1-3,5-6,11-16,18-19H2,(H,34,37)/t26-/m0/s1
DM8XHJG CS C1CCC(CC1)N(CCNC[C@@H](C2=C3C(=CC=C2)NC(=O)CO3)O)C(=O)CCNCCC4=CC(=C(C=C4)Cl)Cl
DM8XHJG IK WVRBXBROEPXZHF-SANMLTNESA-N
DM8XHJG IU N-cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[[(2R)-2-hydroxy-2-(3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]propanamide
DM8XHJG DE Lung cancer
DMRSATG ID DMRSATG
DMRSATG DN Abamectin B1A
DMRSATG HS Preclinical
DMRSATG SN AVERMECTIN B1A; abamectin component B1a; Avermectin B(1)a; Abamectine [French]; Abamectinum [Latin]; Abamectina [Spanish]; Caswell No. 063AB; Antibiotic C 076B1a; Abamectin komponente B1a; 5-O-Demethylavermectin A1a; UNII-K54ZMM929K; Avermectin; Avermectin A1a, 5-O-demethyl-; EINECS 265-610-3; Antibiotic C 076A1a, 5-O-demethyl-; K54ZMM929K; CHEBI:29534; Avermectin A(sub 1a), 5-O-demethyl-; DSSTox_CID_3892; DSSTox_RID_77221; DSSTox_GSID_23892; Abamectina; Abamectine; C48H72O14; Abamectin B1a
DMRSATG PC 6434889
DMRSATG MW 873.1
DMRSATG FM C48H72O14
DMRSATG IC InChI=1S/C48H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,17-19,25-26,28,30-31,33-45,49-50,52H,11,16,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
DMRSATG CS CCC(C)C1C(C=CC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C
DMRSATG IK RRZXIRBKKLTSOM-XPNPUAGNSA-N
DMRSATG IU (1'R,2R,3S,4'S,6S,8'R,10'E,12'S,13'S,14'E,16'E,20'R,21'R,24'S)-2-[(2S)-butan-2-yl]-21',24'-dihydroxy-12'-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one
DMRSATG CA CAS 65195-55-3
DMRSATG CB CHEBI:29534
DMRSATG DE Parasitic worm infestations
DMQ0NU1 ID DMQ0NU1
DMQ0NU1 DN ABI-013
DMQ0NU1 HS Preclinical
DMQ0NU1 SN Nab-CY196; Nab-ABI-139; Nanoparticle albumin-bound ABI-139 (injectable, cancer), Abraxis; Nanoparticle albumin-bound ABI-139 (injectable, cancer), Celgene
DMQ0NU1 CP Abraxis BioScience Inc
DMQ0NU1 DT Antibody
DMQ0NU1 DE Solid tumour/cancer
DMKUPW0 ID DMKUPW0
DMKUPW0 DN ABX-0401
DMKUPW0 HS Preclinical
DMKUPW0 SN ALX-0071; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Pfizer; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Wyeth
DMKUPW0 CP Ablynx NV
DMKUPW0 DE Inflammatory bowel disease
DMBI1H2 ID DMBI1H2
DMBI1H2 DN AD-529
DMBI1H2 HS Preclinical
DMBI1H2 CP Sosei R&D Ltd
DMBI1H2 DE Neuropathic pain
DM19R28 ID DM19R28
DM19R28 DN ADC-01
DM19R28 HS Preclinical
DM19R28 CP Almac Discovery
DM19R28 DT Small molecular drug
DM19R28 DE Solid tumour/cancer
DM21I35 ID DM21I35
DM21I35 DN ADC-03
DM21I35 HS Preclinical
DM21I35 CP Almac Discovery
DM21I35 DT Small molecular drug
DM21I35 DE Solid tumour/cancer
DM2WKDN ID DM2WKDN
DM2WKDN DN ADX-2 series
DM2WKDN HS Preclinical
DM2WKDN CP Addex
DM2WKDN DT Small molecular drug
DM2WKDN PC 9821813
DM2WKDN MW 391.3
DM2WKDN FM C20H27BrN2O
DM2WKDN IC InChI=1S/C20H26N2O.BrH/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19;/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3;1H
DM2WKDN CS CCC1CC2CC3C1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC.Br
DM2WKDN IK NVBHPBGGYJRLTF-UHFFFAOYSA-N
DM2WKDN IU 17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene;hydrobromide
DM2WKDN DE Schizophrenia
DMEWFOL ID DMEWFOL
DMEWFOL DN ADX-71943
DMEWFOL HS Preclinical
DMEWFOL CP Addex Pharmaceuticals SA
DMEWFOL DE Gastroesophageal reflux disease
DM13YRT ID DM13YRT
DM13YRT DN AEOL-10150
DM13YRT HS Preclinical
DM13YRT SN AEOL-10112; AEOL-10113; AEOL-10113); AEOL-10123
DM13YRT CP Aeolus Pharmaceuticals; Aeolus Pharmaceuticals Inc
DM13YRT PC 42609702
DM13YRT MW 1033.2
DM13YRT FM C48H56Cl5MnN12
DM13YRT IC InChI=1S/C48H56N12.5ClH.Mn/c1-9-53-25-26-54(10-2)45(53)41-33-17-19-35(49-33)42(46-55(11-3)27-28-56(46)12-4)37-21-23-39(51-37)44(48-59(15-7)31-32-60(48)16-8)40-24-22-38(52-40)43(36-20-18-34(41)50-36)47-57(13-5)29-30-58(47)14-6;;;;;;/h17-32H,9-16H2,1-8H3;5*1H;/q+2;;;;;;+3/p-5
DM13YRT CS CCN1C=C[N+](=C1C2=C3C=CC(=C(C4=NC(=C(C5=CC=C([N-]5)C(=C6C=CC2=N6)C7=[N+](C=CN7CC)CC)C8=[N+](C=CN8CC)CC)C=C4)C9=[N+](C=CN9CC)CC)[N-]3)CC.[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3]
DM13YRT IK XMYHQLIAYLLEKT-UHFFFAOYSA-I
DM13YRT IU manganese(3+);5,10,15,20-tetrakis(1,3-diethylimidazol-1-ium-2-yl)porphyrin-22,24-diide;pentachloride
DM13YRT DE Multiple sclerosis
DMYIK5D ID DMYIK5D
DMYIK5D DN AEZS-123
DMYIK5D HS Preclinical
DMYIK5D CP Aeterna Zentaris Inc.
DMYIK5D DE Alcohol dependence
DM648KQ ID DM648KQ
DM648KQ DN ALN-FLU01
DM648KQ HS Preclinical
DM648KQ SN RNAi therapeutic (influenza), Alnylam/Novartis; NP/NA gene-silencing siRNA (influenza infection), Alnylam/Novartis
DM648KQ CP Alnylam Pharmaceuticals Inc
DM648KQ DT siRNA drug
DM648KQ DE Influenza virus infection
DM8T6H7 ID DM8T6H7
DM8T6H7 DN ALN-HTT
DM8T6H7 HS Preclinical
DM8T6H7 CP Alnylam Pharmaceuticals
DM8T6H7 DT RNAi therapeutics
DM8T6H7 DE Huntington disease
DMCJMOS ID DMCJMOS
DMCJMOS DN ALN-PCS
DMCJMOS HS Preclinical
DMCJMOS CP Alnylam Pharmaceuticals
DMCJMOS DT RNAi therapeutics
DMCJMOS DE Hypercholesterolaemia
DMW7XEU ID DMW7XEU
DMW7XEU DN ALN-TMP
DMW7XEU HS Preclinical
DMW7XEU CP Alnylam Pharmaceuticals
DMW7XEU DT Small interfering RNA
DMW7XEU DE Beta thalassemia
DMATQB7 ID DMATQB7
DMATQB7 DN Alpha-Helical lipopeptides FFS
DMATQB7 HS Preclinical
DMATQB7 SN FFS
DMATQB7 TC Antiviral Agents
DMATQB7 DT Protein/peptide drug
DMATQB7 SQ FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKK-A-K(C16)
DMATQB7 DE Middle East Respiratory Syndrome (MERS)
DMVSKQF ID DMVSKQF
DMVSKQF DN Alpha-Helical lipopeptides IIK
DMVSKQF HS Preclinical
DMVSKQF SN IIK
DMVSKQF TC Antiviral Agents
DMVSKQF DT Protein/peptide drug
DMVSKQF SQ IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKK-A-K(C16)
DMVSKQF DE Middle East Respiratory Syndrome (MERS)
DM1MGBX ID DM1MGBX
DM1MGBX DN Alpha-Helical lipopeptides IIS
DM1MGBX HS Preclinical
DM1MGBX SN IIS
DM1MGBX TC Antiviral Agents
DM1MGBX DT Protein/peptide drug
DM1MGBX SQ IEEISKKIEEISKKIEEISKKIEEISKKIEEISKK-A-K(C16)
DM1MGBX DE Middle East Respiratory Syndrome (MERS)
DM3WVM4 ID DM3WVM4
DM3WVM4 DN Alpha-Helical lipopeptides LLS
DM3WVM4 HS Preclinical
DM3WVM4 SN LLS
DM3WVM4 TC Antiviral Agents
DM3WVM4 DT Protein/peptide drug
DM3WVM4 SQ LEELSKKLEELSKKLEELSKKLEELSKKLEELSKK-A-K(C16)
DM3WVM4 DE Middle East Respiratory Syndrome (MERS)
DMQMAWK ID DMQMAWK
DMQMAWK DN Alpha-Zearalenol
DMQMAWK HS Preclinical
DMQMAWK SN alpha-Zearalenol; trans-Zearalenol; cis-Zearalenol; alpha zearalenol; UNII-59D4EVJ5KC; Zearalenol; 59D4EVJ5KC; CHEMBL371463; CHEBI:35065; A-ZEARALENOL; (3S,7R,11E)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-1-one; .alpha.-Zearalenol; (-)-; A-Zearalenol; (2E,7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-13-one; 36J; AC1NR4TQ; SCHEMBL343610; SCHEMBL109175; BIDD:ER0100; SGCUT00105; DTXSID8022402; FPQFYIAXQDXNOR-QDKLYSGJSA-N
DMQMAWK PC 5284645
DMQMAWK MW 320.4
DMQMAWK FM C18H24O5
DMQMAWK IC InChI=1S/C18H24O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h3,7,10-12,14,19-21H,2,4-6,8-9H2,1H3/b7-3+/t12-,14+/m0/s1
DMQMAWK CS CC1CCCC(CCCC=CC2=C(C(=CC(=C2)O)O)C(=O)O1)O
DMQMAWK IK FPQFYIAXQDXNOR-QDKLYSGJSA-N
DMQMAWK IU (4S,8R,12E)-8,16,18-trihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),12,15,17-tetraen-2-one
DMQMAWK CA CAS 36455-71-7
DMQMAWK CB CHEBI:35065
DMQMAWK DE Cardiovascular disease
DM2U16Z ID DM2U16Z
DM2U16Z DN ANAVEX 1007
DM2U16Z HS Preclinical
DM2U16Z CP Anavex
DM2U16Z DE Pancreatic cancer; Prostate cancer; Melanoma
DM1MQON ID DM1MQON
DM1MQON DN ANAVEX 1-41
DM1MQON HS Preclinical
DM1MQON CP Anavex
DM1MQON PC 10446473
DM1MQON MW 281.4
DM1MQON FM C19H23NO
DM1MQON IC InChI=1S/C19H23NO/c1-20(2)14-16-13-19(21-15-16,17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,16H,13-15H2,1-2H3
DM1MQON CS CN(C)CC1CC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3
DM1MQON IK AMVCMSPVJGQNFF-UHFFFAOYSA-N
DM1MQON IU 1-(5,5-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
DM1MQON DE Alzheimer disease
DM61TDB ID DM61TDB
DM61TDB DN ARI-809
DM61TDB HS Preclinical
DM61TDB SN Aldose reductase inhibitors (diabetes); CP-744809; Aldose reductase inhibitors (diabetes), Pfizer
DM61TDB CP Pfizer Inc
DM61TDB DT Small molecular drug
DM61TDB PC 6420118
DM61TDB MW 324.74
DM61TDB FM C13H9ClN2O4S
DM61TDB IC InChI=1S/C13H9ClN2O4S/c1-7-9-6-8(14)2-3-10(9)20-13(7)21(18,19)12-5-4-11(17)15-16-12/h2-6H,1H3,(H,15,17)
DM61TDB CS CC1=C(OC2=C1C=C(C=C2)Cl)S(=O)(=O)C3=NNC(=O)C=C3
DM61TDB IK FXFPQPNUMWQRAO-UHFFFAOYSA-N
DM61TDB IU 3-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]-1H-pyridazin-6-one
DM61TDB CA CAS 463976-07-0
DM61TDB DE Diabetic complication
DMMD8VY ID DMMD8VY
DMMD8VY DN AR-R-1589
DMMD8VY HS Preclinical
DMMD8VY CP Fisons; AstraZeneca
DMMD8VY DE Eating disorder; Obesity
DMRPX4W ID DMRPX4W
DMRPX4W DN ASP8497
DMRPX4W HS Preclinical
DMRPX4W CP Astellas Pharma
DMRPX4W DE Type-2 diabetes
DM34FEA ID DM34FEA
DM34FEA DN ATA2431
DM34FEA HS Preclinical
DM34FEA CP Atara Biotherapeutics
DM34FEA DT CAR T Cell Therapy
DM34FEA DE B-cell lymphoma
DMJTYH3 ID DMJTYH3
DMJTYH3 DN ATA3219
DMJTYH3 HS Preclinical
DMJTYH3 CP Atara Biotherapeutics
DMJTYH3 DT CAR T Cell Therapy
DMJTYH3 DE B-cell lymphoma
DMXQVBT ID DMXQVBT
DMXQVBT DN ATA3271
DMXQVBT HS Preclinical
DMXQVBT CP Atara Biotherapeutics
DMXQVBT DT CAR T Cell Therapy
DMXQVBT DE Solid tumour/cancer; Mesothelioma
DMZJVR5 ID DMZJVR5
DMZJVR5 DN ATI-17000
DMZJVR5 HS Preclinical
DMZJVR5 SN CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one,
DMZJVR5 CP ARY x Therapeutics
DMZJVR5 DT Small molecular drug
DMZJVR5 PC 5311194
DMZJVR5 MW 399.6
DMZJVR5 FM C24H37N3O2
DMZJVR5 IC InChI=1S/C24H37N3O2/c1-2-26-22-12-8-9-13-23(22)27(24(26)29)21-14-15-25(17-20(21)18-28)16-19-10-6-4-3-5-7-11-19/h8-9,12-13,19-21,28H,2-7,10-11,14-18H2,1H3/t20-,21+/m0/s1
DMZJVR5 CS CCN1C2=CC=CC=C2N(C1=O)[C@@H]3CCN(C[C@H]3CO)CC4CCCCCCC4
DMZJVR5 IK MBGVUMXBUGIIBQ-LEWJYISDSA-N
DMZJVR5 IU 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one
DMZJVR5 CA CAS 256640-45-6
DMZJVR5 DE Irritable bowel syndrome
DM4XZU2 ID DM4XZU2
DM4XZU2 DN ATL-1101
DM4XZU2 HS Preclinical
DM4XZU2 CP Antisense Therapeutics
DM4XZU2 DT Antisense drug
DM4XZU2 DE Psoriatic disorder
DM0KM6F ID DM0KM6F
DM0KM6F DN AUNP-12
DM0KM6F HS Preclinical
DM0KM6F SN Aurigene NP-12; Aurigene-012; Aur-012; GTPL10117; MolPort-044-830-666; s8549; compound #8 [WO2011161699A3]
DM0KM6F CP Aurigene/Curis
DM0KM6F DT Peptide
DM0KM6F PC 131709240
DM0KM6F MW 3261.6
DM0KM6F FM C142H226N40O48
DM0KM6F IC InChI=1S/C142H226N40O48/c1-12-71(6)110(176-124(213)83(36-22-25-51-143)158-125(214)89(180-152)45-50-108(201)202)137(226)163-85(41-46-102(146)193)118(207)156-73(8)116(205)165-90(38-23-26-52-144)141(230)182-55-29-40-101(182)135(224)155-72(7)114(203)115(204)91(56-69(2)3)166-120(209)86(42-47-103(147)194)164-138(227)113(76(11)192)179-136(225)109(70(4)5)175-123(212)84(39-28-53-153-142(150)151)160-127(216)92(57-77-30-16-13-17-31-77)168-119(208)82(159-128(217)93(58-78-32-18-14-19-33-78)169-133(222)98(66-187)171-121(210)87(43-48-106(197)198)162-132(221)99(67-188)174-140(229)112(75(10)191)177-129(218)95(61-105(149)196)167-117(206)81(145)64-185)37-24-27-54-154-181-96(59-79-34-20-15-21-35-79)130(219)173-97(65-186)131(220)161-88(44-49-107(199)200)122(211)172-100(68-189)134(223)178-111(74(9)190)139(228)170-94(60-104(148)195)126(215)157-80(62-183)63-184/h13-21,30-35,62,69-76,80-101,109-113,154,180-181,184-192H,12,22-29,36-61,63-68,143-145,152H2,1-11H3,(H2,146,193)(H2,147,194)(H2,148,195)(H2,149,196)(H,155,224)(H,156,207)(H,157,215)(H,158,214)(H,159,217)(H,160,216)(H,161,220)(H,162,221)(H,163,226)(H,164,227)(H,165,205)(H,166,209)(H,167,206)(H,168,208)(H,169,222)(H,170,228)(H,171,210)(H,172,211)(H,173,219)(H,174,229)(H,175,212)(H,176,213)(H,177,218)(H,178,223)(H,179,225)(H,197,198)(H,199,200)(H,201,202)(H4,150,151,153)/t71-,72-,73-,74+,75+,76+,80-,81+,82?,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,109+,110+,111+,112+,113+/m1/s1
DM0KM6F CS CC[C@@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)C(CCCCNN[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NN
DM0KM6F IK YQYGGOPUTPQHAY-KIQLFZLRSA-N
DM0KM6F IU (4S)-4-[[(2S)-2-[[(2S)-2-[2-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(4S,7R)-7-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-4-carboxy-2-hydrazinylbutanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-5,6-dioxooctan-4-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]hydrazinyl]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-hydroxy-3-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKQ20J ID DMKQ20J
DMKQ20J DN AZ505
DMKQ20J HS Preclinical
DMKQ20J SN AZ 505; AZ-505
DMKQ20J DT Small molecular drug
DMKQ20J PC 24961094
DMKQ20J MW 577.5
DMKQ20J FM C29H38Cl2N4O4
DMKQ20J IC InChI=1S/C29H38Cl2N4O4/c30-23-8-6-20(18-24(23)31)10-13-32-15-12-27(38)35(22-4-2-1-3-5-22)17-16-33-14-11-21-7-9-25(36)28-29(21)39-19-26(37)34-28/h6-9,18,22,32-33,36H,1-5,10-17,19H2,(H,34,37)
DMKQ20J CS C1CCC(CC1)N(CCNCCC2=C3C(=C(C=C2)O)NC(=O)CO3)C(=O)CCNCCC4=CC(=C(C=C4)Cl)Cl
DMKQ20J IK LIBVHXXKHSODII-UHFFFAOYSA-N
DMKQ20J IU N-cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethylamino]ethyl]propanamide
DMKQ20J DE Solid tumour/cancer
DMY7R3X ID DMY7R3X
DMY7R3X DN AZD-1678
DMY7R3X HS Preclinical
DMY7R3X SN CCR4 antagonist (asthma), AstraZeneca
DMY7R3X CP AstraZeneca plc
DMY7R3X PC 23585443
DMY7R3X MW 352.2
DMY7R3X FM C11H8Cl2FN3O3S
DMY7R3X IC InChI=1S/C11H8Cl2FN3O3S/c1-20-11-10(15-5-8(14)16-11)17-21(18,19)7-4-2-3-6(12)9(7)13/h2-5H,1H3,(H,15,17)
DMY7R3X CS COC1=NC(=CN=C1NS(=O)(=O)C2=C(C(=CC=C2)Cl)Cl)F
DMY7R3X IK NWSUDJQTTGDPIR-UHFFFAOYSA-N
DMY7R3X IU 2,3-dichloro-N-(5-fluoro-3-methoxypyrazin-2-yl)benzenesulfonamide
DMY7R3X DE Asthma
DM3FLMR ID DM3FLMR
DM3FLMR DN Azidothymidine monophosphate
DM3FLMR HS Preclinical
DM3FLMR SN azidothymidine monophosphate; SCHEMBL17515060
DM3FLMR PC 118879755
DM3FLMR MW 363.223
DM3FLMR FM C10H14N5O8P
DM3FLMR IC InChI=1S/C10H14N5O8P/c1-5-3-15(9(18)12-8(5)17)10(13-14-11)2-6(16)7(23-10)4-22-24(19,20)21/h3,6-7,16H,2,4H2,1H3,(H,12,17,18)(H2,19,20,21)/t6-,7+,10-/m0/s1
DM3FLMR CS CC1=CN(C(=O)NC1=O)C2(CC(C(O2)COP(=O)(O)O)O)N=[N+]=[N-]
DM3FLMR IK VUEHGFOETMXHKA-PJKMHFRUSA-N
DM3FLMR IU [(2R,3S,5R)-5-azido-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DM3FLMR DE Cancer
DMOW07D ID DMOW07D
DMOW07D DN BAP-15
DMOW07D HS Preclinical
DMOW07D DT Small molecular drug
DMOW07D DE Solid tumour/cancer
DMTJZIL ID DMTJZIL
DMTJZIL DN Barasertib-hQPA
DMTJZIL HS Preclinical
DMTJZIL SN AZD1152-HQPA; Barasertib (AZD1152-HQPA); AZD-1152HQPA; barasertib-hQPA; UNII-29P8LWS24N; INH 34; AZD1152 HPQA; 29P8LWS24N; CHEMBL215152; 2-[5-(7-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propoxy}-quinazolin-4-ylamino)-2H-pyrazol-3-yl]-N-(3-fluoro-phenyl)-acetamide; 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide; 5-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-3-acetamide; AZD 1152
DMTJZIL PC 16007391
DMTJZIL MW 507.6
DMTJZIL FM C26H30FN7O3
DMTJZIL IC InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)
DMTJZIL CS CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO
DMTJZIL IK QYZOGCMHVIGURT-UHFFFAOYSA-N
DMTJZIL IU 2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide
DMTJZIL CA CAS 722544-51-6
DMTJZIL CB CHEBI:91367
DMTJZIL DE Cancer
DM92VRP ID DM92VRP
DM92VRP DN Batimastat
DM92VRP HS Preclinical
DM92VRP SN batimastat; 130370-60-4; BB-94; Batimastat (BB-94); BB 94; UNII-BK349F52C9; BB94; Batimastat(BB-94); C23H31N3O4S2; CHEMBL279786; BK349F52C9; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-; 4-(N-HYDROXYAMINO)-2R-ISOBUTYL-2S-(2-THIENYLTHIOMETHYL)SUCCINYL-L-PHENYLALANINE-N-METHYLAMIDE; (2S,3R)-5-Methyl-3-(((alphaS)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid
DM92VRP CP Pfizer
DM92VRP DT Small molecular drug
DM92VRP PC 5362422
DM92VRP MW 477.6
DM92VRP FM C23H31N3O4S2
DM92VRP IC InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1
DM92VRP CS CC(C)C[C@H]([C@H](CSC1=CC=CS1)C(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC
DM92VRP IK XFILPEOLDIKJHX-QYZOEREBSA-N
DM92VRP IU (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide
DM92VRP CA CAS 130370-60-4
DM92VRP DE Idiopathic pulmonary fibrosis
DMWH19X ID DMWH19X
DMWH19X DN BAY 598
DMWH19X HS Preclinical
DMWH19X SN BAY-598; 1906919-67-2; CHEMBL3818617; 1906919-67-2 (S-isomer); (S,E)-N-(1-(N'-cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; BAY 598 - Bio-X; BAY598; GTPL8953; EX-A1835; BDBM50180955; ZINC504786915; AC-31567; BS-16389; HY-19546; CS-0015642; J3.601.000B; Q27074893; (S)-N-(1-(N'-Cyano-N-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,E)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; (S,Z)-N-(1-(N-cyano-N'-(3-(difluoromethoxy)phenyl)carbamimidoyl)-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl)-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Cyanoamino)[[3-(difluoromethoxy)phenyl]imino]methyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide; N-[(4S)-1-[(Z)-N'-cyano-N-[3-(difluoromethoxy)phenyl]carbamimidoyl]-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide
DMWH19X DT Small molecular drug
DMWH19X PC 117072551
DMWH19X MW 525.3
DMWH19X FM C22H20Cl2F2N6O3
DMWH19X IC InChI=1S/C22H20Cl2F2N6O3/c1-2-31(19(34)11-33)18-10-32(30-20(18)13-6-7-16(23)17(24)8-13)22(28-12-27)29-14-4-3-5-15(9-14)35-21(25)26/h3-9,18,21,33H,2,10-11H2,1H3,(H,28,29)/t18-/m0/s1
DMWH19X CS CCN([C@H]1CN(N=C1C2=CC(=C(C=C2)Cl)Cl)C(=NC3=CC(=CC=C3)OC(F)F)NC#N)C(=O)CO
DMWH19X IK OTTJIRVZJJGFTK-SFHVURJKSA-N
DMWH19X IU N-[(4S)-2-[N-cyano-N'-[3-(difluoromethoxy)phenyl]carbamimidoyl]-5-(3,4-dichlorophenyl)-3,4-dihydropyrazol-4-yl]-N-ethyl-2-hydroxyacetamide
DMWH19X DE Discovery agent
DMTEJV1 ID DMTEJV1
DMTEJV1 DN BAY 60-6583
DMTEJV1 HS Preclinical
DMTEJV1 SN BAY-60-6583; BAY60-6583
DMTEJV1 DT Small molecular drug
DMTEJV1 PC 11717831
DMTEJV1 MW 379.4
DMTEJV1 FM C19H17N5O2S
DMTEJV1 IC InChI=1S/C19H17N5O2S/c20-7-14-17(12-3-5-13(6-4-12)26-9-11-1-2-11)15(8-21)19(24-18(14)23)27-10-16(22)25/h3-6,11H,1-2,9-10H2,(H2,22,25)(H2,23,24)
DMTEJV1 CS C1CC1COC2=CC=C(C=C2)C3=C(C(=NC(=C3C#N)SCC(=O)N)N)C#N
DMTEJV1 IK ZTYHZMAZUWOXNC-UHFFFAOYSA-N
DMTEJV1 IU 2-[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl]sulfanylacetamide
DMTEJV1 CA CAS 910487-58-0
DMTEJV1 CB CHEBI:131358
DMTEJV1 DE Myocardial ischemia
DMVESTF ID DMVESTF
DMVESTF DN BAY-38-1315
DMVESTF HS Preclinical
DMVESTF SN BAY-19-4789
DMVESTF CP Bayer AG
DMVESTF DT Small molecular drug
DMVESTF PC 46880878
DMVESTF MW 501.5
DMVESTF FM C29H28F5NO
DMVESTF IC InChI=1S/C29H28F5NO/c1-16(2)27-25(26(31)18-4-8-19(9-5-18)29(32,33)34)23(17-6-10-20(30)11-7-17)24-21(35-27)14-28(12-3-13-28)15-22(24)36/h4-11,16,22,26,36H,3,12-15H2,1-2H3/t22-,26-/m0/s1
DMVESTF CS CC(C)C1=NC2=C([C@H](CC3(C2)CCC3)O)C(=C1[C@H](C4=CC=C(C=C4)C(F)(F)F)F)C5=CC=C(C=C5)F
DMVESTF IK HNPNOKPKJPAVPV-NVQXNPDNSA-N
DMVESTF IU (5S)-4-(4-fluorophenyl)-3-[(S)-fluoro-[4-(trifluoromethyl)phenyl]methyl]-2-propan-2-ylspiro[6,8-dihydro-5H-quinoline-7,1'-cyclobutane]-5-ol
DMVESTF DE Arteriosclerosis
DM3EUBA ID DM3EUBA
DM3EUBA DN BC-1215
DM3EUBA HS Preclinical
DM3EUBA SN 1507370-20-8; N1,N2-Bis(4-(pyridin-2-yl)benzyl)ethane-1,2-diamine; C26H26N4; N1,N2-Bis[4-(2-pyridinyl)benzyl]-1,2-ethanediamine; CHEMBL4549895; SCHEMBL16781356; AOB4428; SYN5093; EX-A4964; MFCD28118991; ZINC205895150; AS-16457; HY-117937; CS-0068629; N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine
DM3EUBA DT Small molecular drug
DM3EUBA PC 72201045
DM3EUBA MW 394.5
DM3EUBA FM C26H26N4
DM3EUBA IC InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2
DM3EUBA CS C1=CC=NC(=C1)C2=CC=C(C=C2)CNCCNCC3=CC=C(C=C3)C4=CC=CC=N4
DM3EUBA IK IXEPQJQQSLMESJ-UHFFFAOYSA-N
DM3EUBA IU N,N'-bis[(4-pyridin-2-ylphenyl)methyl]ethane-1,2-diamine
DM3EUBA DE Inflammation
DMSJ2I6 ID DMSJ2I6
DMSJ2I6 DN Beta-aminopropionitrile
DMSJ2I6 HS Preclinical
DMSJ2I6 SN 3-aminopropionitrile; 3-Aminopropanenitrile; 151-18-8; 2-Cyanoethylamine; Aminopropionitrile; BETA-AMINOPROPIONITRILE; Propanenitrile, 3-amino-; BAPN; 3-Aminopropiononitrile; beta-Cyanoethylamine; beta-Alaninenitrile; Propionitrile, 3-amino-; beta-Aminoethyl cyanide; beta-Alaminenitrile; UNII-38D5LJ4KH2; NSC 40641; 3-amino-propionitrile; beta-Alaninenitrile; CHEBI:27413; beta-Cyanoethylamine; beta-Aminopropionitrile; H2NCH2CH2CN; MFCD00014820; 38D5LJ4KH2; CHEMBL1618272; 3-Aminopropionitrile, 98%, stabilized; 3-Aminopropionitrile; Aminopropionitrile; BAPN; N-(2-Cyanoethyl)amine; NSC 40641; HSDB 2897; EINECS 205-786-0; BRN 1698848; cyanoethylamine; aminoethylcyanide; b-Alaminenitrile; b-Alaninenitrile; CCRIS 8134; b-Cyanoethylamine; 3-Aminopropanitrile; EINECS 268-598-8; b-Aminoethyl cyanide; 3-aminopropanonitrile; Propanenitrile, 3-amino-, N-C11-13-isoalkyl derivs.; n-(2-cyanoethyl)amine; PubChem19134; beta-amino propionitrile; beta-amino-propionitrile; (C12-C18)Alkyl alkoxyethyleneaminonitrile; Lopac-A-3134; beta-Aminoethyl cyanide; (C11-C13)Branched alkyl aminoethylenenitrile; WLN: Z2CN; ACMC-1B8B9; Lopac0_000055; 68130-65-4; 68130-66-5; C(#N)CC[N]; DTXSID6048418; AGSPXMVUFBBBMO-UHFFFAOYSA-; 3-amino-propionitrile, AldrichCPR; SODIUMBITARTRATE,MONOHYDRATE; CS-D1507; HY-Y1750; NSC40641; STR02529; ZINC1530259; ANW-43145; BBL101609; BDBM50232678; NSC-40641; Propanenitrile, 3-amino-, N-(3-(C12-18-alkyloxy)propyl) derivs.; STL555405; AKOS000121388; NCGC00015048-01; NCGC00015048-02; NCGC00015048-03; NCGC00015048-05; NCGC00162054-01; 3-Aminopropionitrile stabilized with K2CO3; A0408; FT-0615060; C05670; 97104-EP2298731A1; 97104-EP2305660A1; Q3614347; W-109080
DMSJ2I6 DT Small molecular drug
DMSJ2I6 PC 1647
DMSJ2I6 MW 70.09
DMSJ2I6 FM C3H6N2
DMSJ2I6 IC InChI=1S/C3H6N2/c4-2-1-3-5/h1-2,4H2
DMSJ2I6 CS C(CN)C#N
DMSJ2I6 IK AGSPXMVUFBBBMO-UHFFFAOYSA-N
DMSJ2I6 IU 3-aminopropanenitrile
DMSJ2I6 CA CAS 151-18-8
DMSJ2I6 CB CHEBI:27413
DMSJ2I6 DE Cardiac arrest
DM6BGJ9 ID DM6BGJ9
DM6BGJ9 DN BFF-122
DM6BGJ9 HS Preclinical
DM6BGJ9 DT Small molecular drug
DM6BGJ9 PC 102425126
DM6BGJ9 MW 364.4
DM6BGJ9 FM C17H21FN4O4
DM6BGJ9 IC InChI=1S/C17H21FN4O4/c1-9-8-26-16-13-10(15(23)11(17(24)25)7-22(9)13)6-12(18)14(16)20-2-4-21(19)5-3-20/h6,9,11H,2-5,7-8,19H2,1H3,(H,24,25)/t9-,11?/m0/s1
DM6BGJ9 CS C[C@H]1COC2=C3N1CC(C(=O)C3=CC(=C2N4CCN(CC4)N)F)C(=O)O
DM6BGJ9 IK SBYIJFJAUBGBOA-FTNKSUMCSA-N
DM6BGJ9 IU (2S)-6-(4-aminopiperazin-1-yl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8-triene-11-carboxylic acid
DM6BGJ9 DE Cognitive impairment; Schizophrenia
DMK3SAF ID DMK3SAF
DMK3SAF DN BI-D1870
DMK3SAF HS Preclinical
DMK3SAF SN 501437-28-1; 2-((3,5-difluoro-4-hydroxyphenyl)amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; 2-(3,5-difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one; C19H23F2N5O2; 2-(3,5-difluoro-4-hydroxyphenylamino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-one; BI-D 1870; CHEMBL573107; GTPL8038; SCHEMBL13881333; CTK8I8998; BDBM25017; DTXSID40648506; BID1870; MolPort-008-266-821; HMS3244D11; HMS3244C12; HMS3244C11; BCPP000343; HMS3651D17; BCP01977; EX-A2471; NSC747342
DMK3SAF DT Small molecular drug
DMK3SAF PC 25023738
DMK3SAF MW 391.4
DMK3SAF FM C19H23F2N5O2
DMK3SAF IC InChI=1S/C19H23F2N5O2/c1-10(2)5-6-26-11(3)18(28)25(4)15-9-22-19(24-17(15)26)23-12-7-13(20)16(27)14(21)8-12/h7-11,27H,5-6H2,1-4H3,(H,22,23,24)
DMK3SAF CS CC1C(=O)N(C2=CN=C(N=C2N1CCC(C)C)NC3=CC(=C(C(=C3)F)O)F)C
DMK3SAF IK DTEKTGDVSARYDS-UHFFFAOYSA-N
DMK3SAF IU 2-(3,5-difluoro-4-hydroxyanilino)-5,7-dimethyl-8-(3-methylbutyl)-7H-pteridin-6-one
DMK3SAF CA CAS 501437-28-1
DMK3SAF DE Chronic lymphocytic leukaemia
DM2JOXF ID DM2JOXF
DM2JOXF DN BIIR-777
DM2JOXF HS Preclinical
DM2JOXF SN AMPA receptor modulator (memory/neurological disorders); AMPA receptor modulator (memory/neurological disorders), Boehringer Ingelheim
DM2JOXF CP Boehringer Ingelheim Corp
DM2JOXF DE Neurological disorder
DMPUBK8 ID DMPUBK8
DMPUBK8 DN BIO-306
DMPUBK8 HS Preclinical
DMPUBK8 SN AC1L1H3K; CTK6E1327; CCG-204816; NCGC00162232-03; NCGC00162232-02; NCGC00162232-01; AB00513961; AB00513961_07; 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoate
DMPUBK8 CP Enhance Biotech
DMPUBK8 DT Small molecular drug
DMPUBK8 PC 3959
DMPUBK8 MW 458.4
DMPUBK8 FM C22H31Cl2N2O4-
DMPUBK8 IC InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)/p-1
DMPUBK8 CS CCCCCN(CCCCC)C(=O)C(CCC(=O)[O-])NC(=O)C1=CC(=C(C=C1)Cl)Cl
DMPUBK8 IK IEKOTSCYBBDIJC-UHFFFAOYSA-M
DMPUBK8 IU 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoate
DMPUBK8 DE Migraine
DM5CBNY ID DM5CBNY
DM5CBNY DN BIX-01294
DM5CBNY HS Preclinical
DM5CBNY SN BIX01294; BIX 01294
DM5CBNY DT Small molecular drug
DM5CBNY PC 25150857
DM5CBNY MW 490.6
DM5CBNY FM C28H38N6O2
DM5CBNY IC InChI=1S/C28H38N6O2/c1-32-12-7-13-34(17-16-32)28-30-24-19-26(36-3)25(35-2)18-23(24)27(31-28)29-22-10-14-33(15-11-22)20-21-8-5-4-6-9-21/h4-6,8-9,18-19,22H,7,10-17,20H2,1-3H3,(H,29,30,31)
DM5CBNY CS CN1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)NC4CCN(CC4)CC5=CC=CC=C5)OC)OC
DM5CBNY IK OSXFATOLZGZLSK-UHFFFAOYSA-N
DM5CBNY IU N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine
DM5CBNY CA CAS 935693-62-2
DM5CBNY CB CHEBI:93986
DM5CBNY DE Breast cancer
DMDJH2L ID DMDJH2L
DMDJH2L DN BMS 536924
DMDJH2L HS Preclinical
DMDJH2L SN BMS-536924; BMS 536924; BMS536924; UNII-40E3AZG1MX; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone; 40E3AZG1MX; CHEMBL401930; CS-0117; HY-10262; MLS006011171; SCHEMBL4132577; SCHEMBL15974144; BDBM27879; BCP02116; ZINC6718468; 2278AH; s1012; ABP000159; ZINC140935730; AKOS024458339; AKOS025149514; SB19378; RL03740; KIN0000061; NCGC00346460-05; NCGC00346460-02; SMR004702940; BMS-536924/BMS536924; A2238; X5078; SW218124-2; S-7752
DMDJH2L PC 135440466
DMDJH2L MW 479.965
DMDJH2L FM C25H26ClN5O3
DMDJH2L IC InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1
DMDJH2L CS CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5
DMDJH2L IK ZWVZORIKUNOTCS-OAQYLSRUSA-N
DMDJH2L IU 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one
DMDJH2L CA CAS 468740-43-4
DMDJH2L CB CHEBI:91454
DMDJH2L DE Cancer
DMHAWBR ID DMHAWBR
DMHAWBR DN BMS-192548
DMHAWBR HS Preclinical
DMHAWBR CP BMS
DMHAWBR PC 9887988
DMHAWBR MW 414.4
DMHAWBR FM C21H18O9
DMHAWBR IC InChI=1S/C21H18O9/c1-8(22)14-13(24)7-20(28)6-10-3-9-4-11(30-2)5-12(23)15(9)17(25)16(10)19(27)21(20,29)18(14)26/h3-5,23,25-26,28-29H,6-7H2,1-2H3
DMHAWBR CS CC(=O)C1=C(C2(C(=O)C3=C(C4=C(C=C(C=C4C=C3CC2(CC1=O)O)OC)O)O)O)O
DMHAWBR IK GEIAHRUFSQGALU-UHFFFAOYSA-N
DMHAWBR IU 3-acetyl-4,4a,6,7,12a-pentahydroxy-9-methoxy-1,12-dihydrotetracene-2,5-dione
DMHAWBR CB CHEBI:133806
DMHAWBR DE Obesity
DMCWIBU ID DMCWIBU
DMCWIBU DN BMS-3870032
DMCWIBU HS Preclinical
DMCWIBU SN SNS-032; BMS-387032; SNS 032; BMS 387032; N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide; SNS-032 (BMS-387032); N-(5-(((5-(tert-Butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide; N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide; UNII-9979I93686; N-(5-(((5-(1,1-Dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide; CHEMBL296468; SNS032; C17H24N4O2S2; BMS387032
DMCWIBU PC 3025986
DMCWIBU MW 380.5
DMCWIBU FM C17H24N4O2S2
DMCWIBU IC InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)
DMCWIBU CS CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3
DMCWIBU IK OUSFTKFNBAZUKL-UHFFFAOYSA-N
DMCWIBU IU N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide
DMCWIBU CA CAS 345627-80-7
DMCWIBU CB CHEBI:91399
DMCWIBU DE Cancer
DMQG39T ID DMQG39T
DMQG39T DN BMS-695735
DMQG39T HS Preclinical
DMQG39T DT Small molecular drug
DMQG39T PC 135441202
DMQG39T MW 512
DMQG39T FM C26H31ClFN7O
DMQG39T IC InChI=1S/C26H31ClFN7O/c1-17-13-19(18-4-10-34(11-5-18)9-2-6-28)14-22-24(17)33-25(32-22)23-21(3-7-30-26(23)36)29-8-12-35-16-20(27)15-31-35/h3,7,13-16,18H,2,4-6,8-12H2,1H3,(H,32,33)(H2,29,30,36)
DMQG39T CS CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCCN4C=C(C=N4)Cl)C5CCN(CC5)CCCF
DMQG39T IK VWELCPLMPPEKOL-UHFFFAOYSA-N
DMQG39T IU 4-[2-(4-chloropyrazol-1-yl)ethylamino]-3-[6-[1-(3-fluoropropyl)piperidin-4-yl]-4-methyl-1H-benzimidazol-2-yl]-1H-pyridin-2-one
DMQG39T CA CAS 1054315-48-8
DMQG39T DE Solid tumour/cancer
DM4BZEJ ID DM4BZEJ
DM4BZEJ DN BMS-986118
DM4BZEJ HS Preclinical
DM4BZEJ SN CHEMBL4080226; 1610562-74-7; 2-((4S,5S)-1-(4-(((3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-5-yl)acetic acid; SCHEMBL15710831; BDBM50243975; 2-[(3S,4S)-2-[4-[(3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl]oxyphenyl]-4-methyl-5-(trifluoromethyl)-3,4-dihydropyrazol-3-yl]acetic acid
DM4BZEJ DT Small molecular drug
DM4BZEJ PC 76900387
DM4BZEJ MW 541
DM4BZEJ FM C25H28ClF3N4O4
DM4BZEJ IC InChI=1S/C25H28ClF3N4O4/c1-14-13-32(20-10-22(36-3)30-12-18(20)26)9-8-21(14)37-17-6-4-16(5-7-17)33-19(11-23(34)35)15(2)24(31-33)25(27,28)29/h4-7,10,12,14-15,19,21H,8-9,11,13H2,1-3H3,(H,34,35)/t14-,15+,19+,21-/m1/s1
DM4BZEJ CS C[C@@H]1CN(CC[C@H]1OC2=CC=C(C=C2)N3[C@H]([C@@H](C(=N3)C(F)(F)F)C)CC(=O)O)C4=CC(=NC=C4Cl)OC
DM4BZEJ IK GKIUHMMLGAMMOO-OITFXXTJSA-N
DM4BZEJ IU 2-[(3S,4S)-2-[4-[(3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl]oxyphenyl]-4-methyl-5-(trifluoromethyl)-3,4-dihydropyrazol-3-yl]acetic acid
DM4BZEJ DE Type 2 diabetes
DM8TAI9 ID DM8TAI9
DM8TAI9 DN BMS-986202
DM8TAI9 HS Preclinical
DM8TAI9 SN AM-095; AM-966; LPA1 antagonists (fibrotic disease), Amira; Lysophosphatidic acid antagonists (fibrotic disease), Amira
DM8TAI9 CP Bristol-myers squibb; Amira Pharmaceuticals Inc
DM8TAI9 DT Small molecular drug
DM8TAI9 PC 49838688
DM8TAI9 MW 482.5
DM8TAI9 FM C29H26N2O5
DM8TAI9 IC InChI=1S/C29H26N2O5/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33)/t19-/m0/s1
DM8TAI9 CS CC1=NOC(=C1NC(=O)O[C@@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O
DM8TAI9 IK GQBRZBHEPUQRPL-IBGZPJMESA-N
DM8TAI9 IU 1-[4-[4-[3-methyl-4-[[(1S)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
DM8TAI9 DE Idiopathic pulmonary fibrosis
DMRCMEK ID DMRCMEK
DMRCMEK DN BMS-PCSK9
DMRCMEK HS Preclinical
DMRCMEK CP ISIS Pharm; Bristol-Myers Squibb
DMRCMEK DT Antisense drug
DMRCMEK DE Coronary artery disease
DMCPQJ9 ID DMCPQJ9
DMCPQJ9 DN BN-AA-003-NY
DMCPQJ9 HS Preclinical
DMCPQJ9 SN Selective estrogen receptor modulators (menopause symptoms); Selective estrogen receptor modulators (menopause symptoms), Bionovo
DMCPQJ9 CP Bionovo Inc
DMCPQJ9 DE Estrogen deficiency
DMVMY4X ID DMVMY4X
DMVMY4X DN BN-AO-014
DMVMY4X HS Preclinical
DMVMY4X SN Selective estrogen receptor modulators (genitourinary atrophy); Selective estrogen receptor modulators (genitourinary atrophy), Bionovo
DMVMY4X CP Bionovo Inc
DMVMY4X DE Atrophy
DMM1O0P ID DMM1O0P
DMM1O0P DN BNC-102
DMM1O0P HS Preclinical
DMM1O0P CP Bionomics
DMM1O0P DT Antibody
DMM1O0P DE Solid tumour/cancer
DMBPTDC ID DMBPTDC
DMBPTDC DN BN-CB-045
DMBPTDC HS Preclinical
DMBPTDC SN Selective estrogen receptor modulators (female sexual dysfunction); BN-ES-022; Selective estrogen receptor modulators (female sexual dysfunction), Bionovo
DMBPTDC CP Bionovo Inc
DMBPTDC DE Female sexual arousal dysfunction
DMFNLE6 ID DMFNLE6
DMFNLE6 DN BN-DF-037
DMFNLE6 HS Preclinical
DMFNLE6 SN Selective estrogen receptor modulators (osteoporosis); BN-EU-036; Selective estrogen receptor modulators (osteoporosis), Bionovo; BN-AM-008-XG; BN-PC-049-BK
DMFNLE6 CP Bionovo Inc
DMFNLE6 DE Osteoporosis
DM0PJU9 ID DM0PJU9
DM0PJU9 DN BN-GU-005-DHP
DM0PJU9 HS Preclinical
DM0PJU9 SN Selective estrogen receptor modulators (arthralgia); Selective estrogen receptor modulators (arthralgia), Bionovo
DM0PJU9 CP Bionovo Inc
DM0PJU9 DE Arthralgia
DM8WDAL ID DM8WDAL
DM8WDAL DN BN-OD-026
DM8WDAL HS Preclinical
DM8WDAL SN Selective estrogen receptor modulators (colon/breast cancer); BN-RP-006-OHA; Selective estrogen receptor modulators (colon/breast cancer), Bionovo
DM8WDAL CP Bionovo Inc
DM8WDAL DE Solid tumour/cancer
DM5O3HC ID DM5O3HC
DM5O3HC DN Bouvardin
DM5O3HC HS Preclinical
DM5O3HC SN Bouvardin; MLS002703036; NSC259968; NSC 259968; NSC-259968; AC1L8NRS; Neuro_000123; SCHEMBL8739404; SMR001566844; From fraction F049 of Bouvardia ternifolia; Cyclic(D-alanyl-L-alanyl-N, cyclic(54.fwdarw.63)-ether, (S)-; 17,24-dihydroxy-10-(4-methoxybenzyl)-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexaazatetracyclo[14.12.2.2~18,21~.1~23,27~]tritriaconta-18,20,23(31),24,26,32-hexaene-2,5,8,11,14,30-hexone
DM5O3HC PC 429598
DM5O3HC MW 772.8
DM5O3HC FM C40H48N6O10
DM5O3HC IC InChI=1S/C40H48N6O10/c1-21-35(49)42-22(2)38(52)44(4)29(18-24-8-13-27(55-7)14-9-24)37(51)43-23(3)39(53)46(6)33-34(48)26-11-15-28(16-12-26)56-32-20-25(10-17-31(32)47)19-30(36(50)41-21)45(5)40(33)54/h8-17,20-23,29-30,33-34,47-48H,18-19H2,1-7H3,(H,41,50)(H,42,49)(H,43,51)
DM5O3HC CS CC1C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)N(C2C(C3=CC=C(C=C3)OC4=C(C=CC(=C4)CC(C(=O)N1)N(C2=O)C)O)O)C)C)CC5=CC=C(C=C5)OC)C)C
DM5O3HC IK TWOWSRSKGJSZHZ-UHFFFAOYSA-N
DM5O3HC IU 17,24-dihydroxy-10-[(4-methoxyphenyl)methyl]-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexazatetracyclo[14.12.2.218,21.123,27]tritriaconta-18,20,23,25,27(31),32-hexaene-2,5,8,11,14,30-hexone
DM5O3HC CA CAS 64755-14-2
DM5O3HC DE Cancer
DMT2C78 ID DMT2C78
DMT2C78 DN Brensocatib
DMT2C78 HS Preclinical
DMT2C78 SN AZD7986; AZD-7986; UNII-25CG88L0BB; 25CG88L0BB; INS1007; INS-1007; AZD 7986
DMT2C78 TC Antiviral Agents
DMT2C78 DT Small molecular drug
DMT2C78 PC 118253852
DMT2C78 MW 420.5
DMT2C78 FM C23H24N4O4
DMT2C78 IC InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1
DMT2C78 CS CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
DMT2C78 IK AEXFXNFMSAAELR-RXVVDRJESA-N
DMT2C78 IU (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
DMT2C78 CA CAS 1802148-05-5
DMT2C78 DE Coronavirus Disease 2019 (COVID-19)
DMO15TX ID DMO15TX
DMO15TX DN BSF-78438
DMO15TX HS Preclinical
DMO15TX CP Abbott
DMO15TX DE Schizophrenia
DM3WHB2 ID DM3WHB2
DM3WHB2 DN BST-1005
DM3WHB2 HS Preclinical
DM3WHB2 SN BST-1004; Anti-laminin gamma2 mAbs (cancer), BioStratum; Anti-laminin gamma2 monoclonal antibodies (cancer), BioStratum
DM3WHB2 CP BioStratum Inc
DM3WHB2 DT Antibody
DM3WHB2 DE Solid tumour/cancer
DMT4532 ID DMT4532
DMT4532 DN Bunitrolol
DMT4532 HS Preclinical
DMT4532 SN Bunitrolol; 2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; Bunitrolol [INN]; Stresson; Bunitrololum [INN-Latin]; KO-1366; Bunitrolol HCl; BRN 2374567; 2-Nitrilo-N-tert-butylphenoxypropanolamine; Koe 1366; o-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitrile; 2-Propanol, 3-(tert-butylamino)-1-(m-cyanophenoxy)-; (RS)-2-(3-(tert-Butylamino)-2-hydroxypropoxy)benzonitril; 2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile; Bunitrololum; BENZONITRILE, o-(3-(tert-BUTYLAMINO)-2-HYDROXYPROPOXY)-
DMT4532 PC 2473
DMT4532 MW 248.32
DMT4532 FM C14H20N2O2
DMT4532 IC InChI=1S/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
DMT4532 CS CC(C)(C)NCC(COC1=CC=CC=C1C#N)O
DMT4532 IK VCVQSRCYSKKPBA-UHFFFAOYSA-N
DMT4532 IU 2-[3-(tert-butylamino)-2-hydroxypropoxy]benzonitrile
DMT4532 CA CAS 34915-68-9
DMT4532 CB CHEBI:135012
DMDSX58 ID DMDSX58
DMDSX58 DN BVT-A
DMDSX58 HS Preclinical
DMDSX58 CP BioVitrum
DMDSX58 DE Acromegaly
DMY9F1M ID DMY9F1M
DMY9F1M DN C30
DMY9F1M HS Preclinical
DMY9F1M DT Small molecular drug
DMY9F1M PC 134820957
DMY9F1M MW 795.9
DMY9F1M FM C38H71NO12P2-6
DMY9F1M IC InChI=1S/C38H71NO12P2/c1-27(2)14-9-15-28(3)16-10-17-29(4)18-11-19-30(5)20-12-21-31(6)22-13-23-32(7)24-25-48-52(44,45)51-53(46,47)50-38-35(39-33(8)41)37(43)36(42)34(26-40)49-38/h14,16,18,20,22,24,27-32,34-38,40,42-43H,9-13,15,17,19,21,23,25-26H2,1-8H3,(H,39,41)(H,44,45)(H,46,47)/q-6/t28?,29?,30?,31?,32?,34-,35-,36-,37-,38-/m1/s1
DMY9F1M CS CC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]CCC(C)[CH-]COP(=O)(O)OP(=O)(O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C
DMY9F1M IK CREFDRPJYMJUQD-PVHPPTMHSA-N
DMY9F1M IU [(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] [3,7,11,15,19,23-hexamethyltetracosoxy(hydroxy)phosphoryl] hydrogen phosphate
DMY9F1M DE Pseudomonas infection
DMVN3FU ID DMVN3FU
DMVN3FU DN CA-074Me
DMVN3FU HS Preclinical
DMVN3FU SN 147859-80-1; Cathepsin B Inhibitor IV; CA-074 methyl ester; CA-074 Me; Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate; CA-074-Me; MFCD03452890; methyl N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-prolinate; CA 074 methyl ester; CA 074Me; CA074Me; CA inhibitor 6; (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate; PrNH-tES-Ile-Pro-OMe; epoxysuccinyl derivative 6; KBioGR_000234; KBioSS_000234; CHEMBL262103; SCHEMBL1974424; BDBM16503; KBio2_000234; KBio2_002802; KBio2_005370; KBio3_000467; KBio3_000468; DTXSID50881386; Bio2_000234; Bio2_000714; HMS1361L16; HMS3886D15; EX-A1196; ZINC4899858; s7420; CCG-268623; CS-6086; DB07223; CA-074 methyl ester (CA-074 Me); IDI1_033984; NCGC00163431-01; AC-32670; methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate; methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate; QC-10413; HY-100350; 859C801; Q27096448; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA074ME; N-(L-3-TRANS-PROPYLCARBAMOYLOXIRANE-2-CARBONYL)-L-ISOLEUCYL-L-PROLINE METHYL ESTER
DMVN3FU DT Small molecular drug
DMVN3FU PC 6610318
DMVN3FU MW 397.5
DMVN3FU FM C19H31N3O6
DMVN3FU IC InChI=1S/C19H31N3O6/c1-5-9-20-16(23)14-15(28-14)17(24)21-13(11(3)6-2)18(25)22-10-7-8-12(22)19(26)27-4/h11-15H,5-10H2,1-4H3,(H,20,23)(H,21,24)/t11-,12-,13-,14-,15-/m0/s1
DMVN3FU CS CCCNC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)OC
DMVN3FU IK XGWSRLSPWIEMLQ-YTFOTSKYSA-N
DMVN3FU IU methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate
DMVN3FU CA CAS 147859-80-1
DMVN3FU DE Cardiac arrest; Pulmonary fibrosis; Cystic fibrosis
DM9HG6S ID DM9HG6S
DM9HG6S DN CAR-T cells targeting CD117
DM9HG6S HS Preclinical
DM9HG6S CP Zhujiang Hospital
DM9HG6S DT CAR T Cell Therapy
DM9HG6S DE Acute myeloid leukaemia
DMSZNQE ID DMSZNQE
DMSZNQE DN CAR-T cells targeting CD123
DMSZNQE HS Preclinical
DMSZNQE CP Zhujiang Hospital
DMSZNQE DT CAR T Cell Therapy
DMSZNQE DE Acute myeloid leukaemia
DMYOR5T ID DMYOR5T
DMYOR5T DN CAR-T cells targeting CD133
DMYOR5T HS Preclinical
DMYOR5T CP Zhujiang Hospital
DMYOR5T DT CAR T Cell Therapy
DMYOR5T DE Acute myeloid leukaemia
DMH7BT9 ID DMH7BT9
DMH7BT9 DN CAR-T cells targeting CD33
DMH7BT9 HS Preclinical
DMH7BT9 CP Zhujiang Hospital
DMH7BT9 DT CAR T Cell Therapy
DMH7BT9 DE Acute myeloid leukaemia
DM3G0OP ID DM3G0OP
DM3G0OP DN CAR-T cells targeting CD34
DM3G0OP HS Preclinical
DM3G0OP CP Zhujiang Hospital
DM3G0OP DT CAR T Cell Therapy
DM3G0OP DE Acute myeloid leukaemia
DMA1BLC ID DMA1BLC
DMA1BLC DN CAR-T cells targeting Mucl
DMA1BLC HS Preclinical
DMA1BLC CP Zhujiang Hospital
DMA1BLC DT CAR T Cell Therapy
DMA1BLC DE Acute myeloid leukaemia
DMDUKMR ID DMDUKMR
DMDUKMR DN CAT4001
DMDUKMR HS Preclinical
DMDUKMR CP Catabasis
DMDUKMR DT Small molecular drug
DMDUKMR DE Alpha-1 antitrypsin deficiency; Friedreich's ataxia
DMKFAG3 ID DMKFAG3
DMKFAG3 DN CB-01-16
DMKFAG3 HS Preclinical
DMKFAG3 SN Opioid antagonist (MMX, opioid-induced constipation), Cosmo
DMKFAG3 CP Cosmo Pharmaceuticals SpA
DMKFAG3 DE Constipation
DM53JW0 ID DM53JW0
DM53JW0 DN CB1 antagonist, Bayer
DM53JW0 HS Preclinical
DM53JW0 SN 2-[(2,6-dichloro-3-methylphenyl)amino]benzoate; CHEMBL876; CL-583.NA SALT; meclofenamic acid(1-); UPCMLD-DP012; AC1L1H9Q; UPCMLD-DP012:001; CTK5I4915; CHEBI:76230; BDBM50012896; MCULE-3600081195; CCG-204812; NCGC00023217-05; NCGC00023217-04; NCGC00023217-03; NCGC00023217-06; ZB000384; 2-(2,6-dichloro-3-methylanilino)benzoate; AB00053494; AB00053494_19; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate; 2-(2,6-dichloro-3-methyl-phenylamino)-benzoate(Fenamate series)
DM53JW0 CP Bayer
DM53JW0 DT Small molecular drug
DM53JW0 PC 4036
DM53JW0 MW 295.1
DM53JW0 FM C14H10Cl2NO2-
DM53JW0 IC InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)/p-1
DM53JW0 CS CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl
DM53JW0 IK SBDNJUWAMKYJOX-UHFFFAOYSA-M
DM53JW0 IU 2-(2,6-dichloro-3-methylanilino)benzoate
DM53JW0 CB CHEBI:76230
DM53JW0 DE Obesity
DMJUQ6E ID DMJUQ6E
DMJUQ6E DN CB7993113
DMJUQ6E HS Preclinical
DMJUQ6E DT Small molecular drug
DMJUQ6E DE Solid tumour/cancer
DMCFEUG ID DMCFEUG
DMCFEUG DN CCG-208408
DMCFEUG HS Preclinical
DMCFEUG SN Narirutin; Naringenin 7-rutinoside; Naringenin-7-O-rutinoside; (S)-7-[[6-O-(6-deoxy-a-L-mannopyranosyl)-ss-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AK554011; CCG-208408; CHEMBL3185240; NCGC00163600-01
DMCFEUG PC 85704
DMCFEUG MW 580.5
DMCFEUG FM C27H32O14
DMCFEUG IC HXTFHSYLYXVTHC-UHFFFAOYSA-N
DMCFEUG CS CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)O)O)O)O)O)O
DMCFEUG IK 1S/C27H32O14/c1-10-20(31)22(33)24(35)26(38-10)37-9-18-21(32)23(34)25(36)27(41-18)39-13-6-14(29)19-15(30)8-16(40-17(19)7-13)11-2-4-12(28)5-3-11/h2-7,10,16,18,20-29,31-36H,8-9H2,1H3
DMCFEUG IU 5-hydroxy-2-(4-hydroxyphenyl)-7-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
DMCFEUG CA CAS 14259-46-2
DMCFEUG DE Depression
DM065ZH ID DM065ZH
DM065ZH DN CCT-018159
DM065ZH HS Preclinical
DM065ZH SN CCT 018159; CCT018159; (6Z)-6-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1,2-dihydropyrazol-3-ylidene]-4-ethyl-3-hydroxycyclohexa-2,4-dien-1-one; 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol
DM065ZH CP Vernalis; Novartis
DM065ZH TC Anticancer Agents
DM065ZH DT Small molecular drug
DM065ZH PC 984170
DM065ZH MW 352.4
DM065ZH FM C20H20N2O4
DM065ZH IC InChI=1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22)
DM065ZH CS CCC1=CC(=C(C=C1O)O)C2=NNC(=C2C3=CC4=C(C=C3)OCCO4)C
DM065ZH IK OWPMENVYXDJDOW-UHFFFAOYSA-N
DM065ZH IU 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethylbenzene-1,3-diol
DM065ZH CA CAS 171009-07-7
DM065ZH CB CHEBI:41656
DM065ZH DE Solid tumour/cancer
DMNA9KW ID DMNA9KW
DMNA9KW DN CCT251545
DMNA9KW HS Preclinical
DMNA9KW SN 1661839-45-7; 8-(3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one; CHEMBL3408213; 8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one; CCT-251545; 8-{3-Chloro-5-[4-(1-Methyl-1h-Pyrazol-4-Yl)phenyl]pyridin-4-Yl}-2,8-Diazaspiro[4.5]decan-1-One; GTPL8945; SCHEMBL17113515; CHEBI:143114; AMY16654; BCP17378; EX-A2539; BDBM50073190; NSC784591; s7981; ZINC212373586; CCT 251545; CS-5359; NSC-784591; AC-31717; HY-12681; DB-119021; CCT 251545;CCT-251545; CCT-251545;CCT 251545; Q27075796; 2,8-Diazaspiro[4.5]decan-1-one, 8-[3-chloro-5-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-4-pyridinyl]-; 4TV; 8-[3-Chloro-5-[4-(1-methyl-1H-pyrazole-4-yl)phenyl]-4-pyridyl]-2,8-diazaspiro[4.5]decane-1-one
DMNA9KW CP Merck
DMNA9KW DT Small molecular drug
DMNA9KW PC 77050682
DMNA9KW MW 421.9
DMNA9KW FM C23H24ClN5O
DMNA9KW IC InChI=1S/C23H24ClN5O/c1-28-15-18(12-27-28)16-2-4-17(5-3-16)19-13-25-14-20(24)21(19)29-10-7-23(8-11-29)6-9-26-22(23)30/h2-5,12-15H,6-11H2,1H3,(H,26,30)
DMNA9KW CS CN1C=C(C=N1)C2=CC=C(C=C2)C3=CN=CC(=C3N4CCC5(CCNC5=O)CC4)Cl
DMNA9KW IK LBFYQISQYCGDDW-UHFFFAOYSA-N
DMNA9KW IU 8-[3-chloro-5-[4-(1-methylpyrazol-4-yl)phenyl]pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one
DMNA9KW CB CHEBI:143114
DMNA9KW DE Colorectal cancer
DMWQIJX ID DMWQIJX
DMWQIJX DN Celastrol
DMWQIJX HS Preclinical
DMWQIJX SN Tripterin; Tripterine; Celastrol, Celastrus scandens; (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid; (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid; 3-Hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic Acid
DMWQIJX CP Schering-Plough
DMWQIJX DT Small molecular drug
DMWQIJX PC 122724
DMWQIJX MW 450.6
DMWQIJX FM C29H38O4
DMWQIJX IC InChI=1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1
DMWQIJX CS CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CC[C@@]4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O
DMWQIJX IK KQJSQWZMSAGSHN-JJWQIEBTSA-N
DMWQIJX IU (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
DMWQIJX CA CAS 34157-83-0
DMWQIJX CB CHEBI:63959
DMWQIJX DE Motor neurone disease
DM1ZFCS ID DM1ZFCS
DM1ZFCS DN Cephaeline
DM1ZFCS HS Preclinical
DM1ZFCS SN Cephaeline; Cephaelin; 483-17-0; 7',10,11-Trimethoxyemetan-6'-ol; UNII-QA971541A1; Desmethylemetine; QA971541A1; Dihydropsychotrine; Cepheline; GNF-Pf-307; (1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol; NSC32944; Cephaelinel; (-)-Cephaeline; EINECS 207-591-6; Prestwick2_000428; Prestwick3_000428; Prestwick1_000428; Prestwick0_000428; AC1L9CF2; BSPBio_000416; SCHEMBL181711; SPBio_002355; CHEMBL255708
DM1ZFCS PC 442195
DM1ZFCS MW 466.6
DM1ZFCS FM C28H38N2O4
DM1ZFCS IC InChI=1S/C28H38N2O4/c1-5-17-16-30-9-7-19-13-27(33-3)28(34-4)15-22(19)24(30)11-20(17)10-23-21-14-26(32-2)25(31)12-18(21)6-8-29-23/h12-15,17,20,23-24,29,31H,5-11,16H2,1-4H3/t17-,20-,23+,24-/m0/s1
DM1ZFCS CS CCC1CN2CCC3=CC(=C(C=C3C2CC1CC4C5=CC(=C(C=C5CCN4)O)OC)OC)OC
DM1ZFCS IK DTGZHCFJNDAHEN-OZEXIGSWSA-N
DM1ZFCS IU (1R)-1-[[(2S,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol
DM1ZFCS CA CAS 483-17-0
DM1ZFCS CB CHEBI:3533
DM1ZFCS DE Accidental poisoning
DMQSJ20 ID DMQSJ20
DMQSJ20 DN CF502
DMQSJ20 HS Preclinical
DMQSJ20 SN CHEMBL175543; MRS-3558; CF502; GTPL5601; MRS3558; MRS-5358; MRS 3558; BDBM50163020; (1S,2R,3S,4R,5S)-4-[2-Chloro-6-(3-chloro-benzylamino)-purin-9-yl]-2,3-dihydroxy-bicyclo[3.1.0]hexane-1-carboxylic acid methylamide; (1S,2R,3S,4R,5S)-4-(6-(3-chlorobenzylamino)-2-chloro-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide; 1N-methyl-4-[2-chloro-6-(3-chlorobenzylamino)-9H-9-purinyl]-2,3-dihydroxy-(1S,2R,3S,4R,5S)-bicyclo[3.1.0]hexane-1-carboxamide
DMQSJ20 CP Can-Fite BioPharm
DMQSJ20 DT Small molecular drug
DMQSJ20 PC 11248240
DMQSJ20 MW 463.3
DMQSJ20 FM C20H20Cl2N6O3
DMQSJ20 IC InChI=1S/C20H20Cl2N6O3/c1-23-18(31)20-6-11(20)13(14(29)15(20)30)28-8-25-12-16(26-19(22)27-17(12)28)24-7-9-3-2-4-10(21)5-9/h2-5,8,11,13-15,29-30H,6-7H2,1H3,(H,23,31)(H,24,26,27)/t11-,13-,14+,15+,20+/m1/s1
DMQSJ20 CS CNC(=O)[C@@]12C[C@@H]1[C@H]([C@@H]([C@@H]2O)O)N3C=NC4=C(N=C(N=C43)Cl)NCC5=CC(=CC=C5)Cl
DMQSJ20 IK GAYWHRPOIWFKIF-DDDALXFXSA-N
DMQSJ20 IU (1S,2R,3S,4R,5S)-4-[2-chloro-6-[(3-chlorophenyl)methylamino]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide
DMQSJ20 DE Inflammation
DM0ULO2 ID DM0ULO2
DM0ULO2 DN CF602
DM0ULO2 HS Preclinical
DM0ULO2 SN UNII-QXA2220N3T; CF-602; 1116652-18-6; QXA2220N3T; SCHEMBL196780; CHEMBL472925; GTPL9447; DTXSID60149702; Cyclohexanecarboxamide, N-(2-((3,4-dichlorophenyl)amino)-4-quinolinyl)-; SB17193
DM0ULO2 CP Can-Fite BioPharm
DM0ULO2 DT Small molecular drug
DM0ULO2 PC 25191023
DM0ULO2 MW 414.3
DM0ULO2 FM C22H21Cl2N3O
DM0ULO2 IC InChI=1S/C22H21Cl2N3O/c23-17-11-10-15(12-18(17)24)25-21-13-20(16-8-4-5-9-19(16)26-21)27-22(28)14-6-2-1-3-7-14/h4-5,8-14H,1-3,6-7H2,(H2,25,26,27,28)
DM0ULO2 CS C1CCC(CC1)C(=O)NC2=CC(=NC3=CC=CC=C32)NC4=CC(=C(C=C4)Cl)Cl
DM0ULO2 IK UWEIQVQNNLVOEI-UHFFFAOYSA-N
DM0ULO2 IU N-[2-(3,4-dichloroanilino)quinolin-4-yl]cyclohexanecarboxamide
DM0ULO2 CA CAS 1116652-18-6
DM0ULO2 DE Inflammation
DMYGITU ID DMYGITU
DMYGITU DN CHDI-340246
DMYGITU HS Preclinical
DMYGITU DT Small molecular drug
DMYGITU DE Huntington disease
DM89DQP ID DM89DQP
DM89DQP DN Chlamydocin
DM89DQP HS Preclinical
DM89DQP SN HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone
DM89DQP TC Anticancer Agents
DM89DQP DT Small molecular drug
DM89DQP PC 124134
DM89DQP MW 526.6
DM89DQP FM C28H38N4O6
DM89DQP IC InChI=1S/C28H38N4O6/c1-28(2)27(37)30-20(16-18-10-5-3-6-11-18)26(36)32-15-9-13-21(32)25(35)29-19(24(34)31-28)12-7-4-8-14-22(33)23-17-38-23/h3,5-6,10-11,19-21,23H,4,7-9,12-17H2,1-2H3,(H,29,35)(H,30,37)(H,31,34)/t19-,20-,21+,23-/m0/s1
DM89DQP CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCC(=O)[C@@H]3CO3)CC4=CC=CC=C4)C
DM89DQP IK SGYJGGKDGBXCNY-QXUYBEEESA-N
DM89DQP IU (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM89DQP CA CAS 53342-16-8
DM89DQP DE Solid tumour/cancer
DMAPO0T ID DMAPO0T
DMAPO0T DN Ciglitazone
DMAPO0T HS Preclinical
DMAPO0T SN ciglitazone; 74772-77-3; Ciglitizone; ADD-3878; Ciglitazonum; Ciglitazona; Ciglitazonum [Latin]; Ciglitazona [Spanish]; Ciglitazone [USAN:INN]; ADD 3878; CHEBI:64227; U-63287; (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione; C18H23NO3S; 5-(4-((1-methylcyclohexyl)methoxy)benzyl)thiazolidine-2,4-dione; YZFWTZACSRHJQD-UHFFFAOYSA-N; (+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione; U 63287; 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione; NCGC00164446-01
DMAPO0T DT Small molecular drug
DMAPO0T PC 2750
DMAPO0T MW 333.4
DMAPO0T FM C18H23NO3S
DMAPO0T IC InChI=1S/C18H23NO3S/c1-18(9-3-2-4-10-18)12-22-14-7-5-13(6-8-14)11-15-16(20)19-17(21)23-15/h5-8,15H,2-4,9-12H2,1H3,(H,19,20,21)
DMAPO0T CS CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
DMAPO0T IK YZFWTZACSRHJQD-UHFFFAOYSA-N
DMAPO0T IU 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMAPO0T CA CAS 74772-77-3
DMAPO0T CB CHEBI:64227
DMAPO0T DE Pulmonary fibrosis
DM37NYK ID DM37NYK
DM37NYK DN Citrate
DM37NYK HS Preclinical
DM37NYK PC 311
DM37NYK MW 192.123
DM37NYK FM C6H8O7
DM37NYK IC InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DM37NYK CS C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM37NYK IK KRKNYBCHXYNGOX-UHFFFAOYSA-N
DM37NYK IU 2-hydroxypropane-1,2,3-tricarboxylic acid
DM37NYK CA CAS 77-92-9
DM37NYK CB CHEBI:30769
DM37NYK DE Acute kidney injury
DMV0RFU ID DMV0RFU
DMV0RFU DN CKI-7
DMV0RFU HS Preclinical
DMV0RFU SN 120615-25-0; N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide; CKI 7; N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide; CKI-7 (free base); UNII-3IE84W82O5; CHEBI:47322; 3IE84W82O5; 8-Isoquinolinesulfonamide,N-(2-aminoethyl)-5-chloro-; 8-Isoquinolinesulfonamide, N-(2-aminoethyl)-5-chloro-; 2csn; CKI; ACMC-20efrf; CHEMBL489157; Isoquinolinesulfonamide, CKI-7; SCHEMBL3491587; BDBM92674; DTXSID20152934; ZINC6415144; MFCD00269886; AKOS027446743; DB03693; NCGC00165762-01; DB-082055; HY-133028; B4936; CS-0109499; FT-0661792; Y7241; W-205095; N-(2-aminoethyl)-5-chloro-isoquinoline-8-sulfonamide; Q27094604; 5-Chloro-isoquinoline-8-sulfonic acid, (2-amino-ethyl)-amide
DMV0RFU DT Small molecular drug
DMV0RFU PC 129236
DMV0RFU MW 285.75
DMV0RFU FM C11H12ClN3O2S
DMV0RFU IC InChI=1S/C11H12ClN3O2S/c12-10-1-2-11(18(16,17)15-6-4-13)9-7-14-5-3-8(9)10/h1-3,5,7,15H,4,6,13H2
DMV0RFU CS C1=CC(=C2C=CN=CC2=C1S(=O)(=O)NCCN)Cl
DMV0RFU IK OGKYMFFYOWUTKV-UHFFFAOYSA-N
DMV0RFU IU N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide
DMV0RFU CA CAS 120615-25-0
DMV0RFU CB CHEBI:47322
DMV0RFU DE Mood disorder
DM6HADZ ID DM6HADZ
DM6HADZ DN CL-314698
DM6HADZ HS Preclinical
DM6HADZ CP Cyanamid
DM6HADZ DE Type-2 diabetes; Obesity
DM0BHL8 ID DM0BHL8
DM0BHL8 DN CLIK-148
DM0BHL8 HS Preclinical
DM0BHL8 SN SCHEMBL7207304
DM0BHL8 DT Small molecular drug
DM0BHL8 PC 9801663
DM0BHL8 MW 410.5
DM0BHL8 FM C22H26N4O4
DM0BHL8 IC InChI=1S/C22H26N4O4/c1-26(2)22(29)17(14-15-8-4-3-5-9-15)25-21(28)19-18(30-19)20(27)24-13-11-16-10-6-7-12-23-16/h3-10,12,17-19H,11,13-14H2,1-2H3,(H,24,27)(H,25,28)/t17-,18-,19-/m0/s1
DM0BHL8 CS CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2[C@H](O2)C(=O)NCCC3=CC=CC=N3
DM0BHL8 IK SXMRSAGDCJGMTG-FHWLQOOXSA-N
DM0BHL8 IU (2S,3S)-2-N-[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]-3-N-(2-pyridin-2-ylethyl)oxirane-2,3-dicarboxamide
DM0BHL8 DE Rheumatoid arthritis
DMXKN6R ID DMXKN6R
DMXKN6R DN CLIK-181
DMXKN6R HS Preclinical
DMXKN6R SN J3.633.044I
DMXKN6R DT Small molecular drug
DMXKN6R PC 132504749
DMXKN6R MW 466.5
DMXKN6R FM C25H30N4O5
DMXKN6R IC InChI=1S/C25H30N4O5/c1-16(30)27-19-11-9-17(10-12-19)13-14-26-23(31)21-22(34-21)24(32)28-20(25(33)29(2)3)15-18-7-5-4-6-8-18/h4-12,20-22H,13-15H2,1-3H3,(H,26,31)(H,27,30)(H,28,32)/t20-,21-,22+/m0/s1
DMXKN6R CS CC(=O)NC1=CC=C(C=C1)CCNC(=O)[C@@H]2[C@@H](O2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N(C)C
DMXKN6R IK BULLLJQHDGSHOZ-FDFHNCONSA-N
DMXKN6R IU (2R,3S)-3-N-[2-(4-acetamidophenyl)ethyl]-2-N-[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]oxirane-2,3-dicarboxamide
DMXKN6R DE Rheumatoid arthritis
DMP9EJ7 ID DMP9EJ7
DMP9EJ7 DN CM-2236
DMP9EJ7 HS Preclinical
DMP9EJ7 SN Psychomodulator (post-traumatic stress disorder), Cenomed BioSciences
DMP9EJ7 CP Cenomed BioSciences LLC
DMP9EJ7 DE Post-traumatic stress disorder
DMHAI0M ID DMHAI0M
DMHAI0M DN CNSB-004
DMHAI0M HS Preclinical
DMHAI0M SN Drug combination (intractable severe pain), CNSbio
DMHAI0M CP Relevare Pharmaceuticals Ltd
DMHAI0M DE Pain
DM1H8D6 ID DM1H8D6
DM1H8D6 DN CNX-011-67
DM1H8D6 HS Preclinical
DM1H8D6 DT Small molecular drug
DM1H8D6 DE Type 2 diabetes
DMG3BE1 ID DMG3BE1
DMG3BE1 DN Coelenterazine
DMG3BE1 HS Preclinical
DMG3BE1 SN coelenterazine; Coelenteramine; Oplophorus luciferin; UNII-3O1CB88RRD; CLZN; 8-benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one; coelenterate luciferin; Coelenterazine, native; 3O1CB88RRD; MFCD00467176; C-7001; C-7002; 8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]-7H-imidazo[1,2-a]pyrazin-3-one; 8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo-[1,2a]pyrazin-3(7H)-one; 2-(p-Hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazin-3-(7H)-one
DMG3BE1 PC 135445694
DMG3BE1 MW 423.472
DMG3BE1 FM C26H21N3O3
DMG3BE1 IC InChI=1S/C26H21N3O3/c30-20-10-6-18(7-11-20)15-23-26(32)29-16-24(19-8-12-21(31)13-9-19)27-22(25(29)28-23)14-17-4-2-1-3-5-17/h1-13,16,30-32H,14-15H2
DMG3BE1 CS C1=CC=C(C=C1)CC2=NC(=CN3C2=NC(=C3O)CC4=CC=C(C=C4)O)C5=CC=C(C=C5)O
DMG3BE1 IK LNCOEGVEEQDKGX-UHFFFAOYSA-N
DMG3BE1 IU 8-benzyl-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]imidazo[1,2-a]pyrazin-3-ol
DMG3BE1 CA CAS 55779-48-1
DMG3BE1 CB CHEBI:2311
DMG3BE1 DE Inflammatory bowel disease
DMN0GTR ID DMN0GTR
DMN0GTR DN COR100140
DMN0GTR HS Preclinical
DMN0GTR CP Cortical
DMN0GTR DT Small molecular drug
DMN0GTR PC 9853902
DMN0GTR DE Inflammation
DMLXMCB ID DMLXMCB
DMLXMCB DN COR-D
DMLXMCB HS Preclinical
DMLXMCB DT Small molecular drug
DMLXMCB DE T-cell leukaemia
DMATUKO ID DMATUKO
DMATUKO DN CP-114271
DMATUKO HS Preclinical
DMATUKO CP Pfizer
DMATUKO PC 9953045
DMATUKO MW 404.4
DMATUKO FM C17H19F3N2O4S
DMATUKO IC InChI=1S/C17H19F3N2O4S/c1-10(6-11-2-4-12(5-3-11)26-8-15(24)25)21-7-14(23)13-9-27-16(22-13)17(18,19)20/h2-5,9-10,14,21,23H,6-8H2,1H3,(H,24,25)/t10-,14+/m1/s1
DMATUKO CS C[C@H](CC1=CC=C(C=C1)OCC(=O)O)NC[C@@H](C2=CSC(=N2)C(F)(F)F)O
DMATUKO IK YVIXXPCJZAUQHJ-YGRLFVJLSA-N
DMATUKO IU 2-[4-[(2R)-2-[[(2S)-2-hydroxy-2-[2-(trifluoromethyl)-1,3-thiazol-4-yl]ethyl]amino]propyl]phenoxy]acetic acid
DMATUKO CA CAS 162326-86-5
DMATUKO DE Obesity
DMQGRC8 ID DMQGRC8
DMQGRC8 DN CPH-102
DMQGRC8 HS Preclinical
DMQGRC8 SN IABP; INH2BP, Crimson Pharmaceutical; INH2BP, Octamer; PARP inhibitors, Crimson Pharmaceutical; PARP inhibitors, Octamer; CPH-101, Crimson Pharma
DMQGRC8 CP Octamer Inc
DMQGRC8 DE Solid tumour/cancer
DMWMBIV ID DMWMBIV
DMWMBIV DN CRA1000
DMWMBIV HS Preclinical
DMWMBIV SN CRA-1000; CRA1000; UNII-3899V9A17F; 3899V9A17F; CRA 1000; 226948-11-4; 2-Pyrimidinamine, N-ethyl-4-(4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl)-6-methyl-N-(4-(1-methylethyl)-2-(methylthio)phenyl)-; 2-(N-(2-methylthio-4-isopropylphenyl)-N-ethylamino)-4-(4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridin-1-yl)-6-methylpyrimidine; CHEMBL297986; SCHEMBL6171730; GTPL3498; PDSP2_001710; PDSP1_001727
DMWMBIV DT Small molecular drug
DMWMBIV PC 9849313
DMWMBIV MW 476.7
DMWMBIV FM C28H33FN4S
DMWMBIV IC InChI=1S/C28H33FN4S/c1-6-33(25-11-10-22(19(2)3)18-26(25)34-5)28-30-20(4)16-27(31-28)32-14-12-21(13-15-32)23-8-7-9-24(29)17-23/h7-12,16-19H,6,13-15H2,1-5H3
DMWMBIV CS CCN(C1=C(C=C(C=C1)C(C)C)SC)C2=NC(=CC(=N2)N3CCC(=CC3)C4=CC(=CC=C4)F)C
DMWMBIV IK DDSMCPASYQDKFS-UHFFFAOYSA-N
DMWMBIV IU N-ethyl-4-[4-(3-fluorophenyl)-3,6-dihydro-2H-pyridin-1-yl]-6-methyl-N-(2-methylsulfanyl-4-propan-2-ylphenyl)pyrimidin-2-amine
DMWMBIV CA CAS 226948-11-4
DMWMBIV DE Anxiety disorder
DM8AR0E ID DM8AR0E
DM8AR0E DN Cruentaren
DM8AR0E HS Preclinical
DM8AR0E TC Antifungal Agents
DM8AR0E DE Fungal infection
DMB4FWX ID DMB4FWX
DMB4FWX DN CS-00028
DMB4FWX HS Preclinical
DMB4FWX SN CS-028; HDAC antagonist (cancer), Shenzhen Chipscreen Biosciences
DMB4FWX CP Shenzhen Chipscreen Biosciences Ltd
DMB4FWX DE Solid tumour/cancer
DMK230A ID DMK230A
DMK230A DN CS-3030
DMK230A HS Preclinical
DMK230A SN R-142086; Factor Xa inhibitor (DVT/ pulmonary embolism), Daiichi Sankyo; Factor Xa inhibitor (DVT/ pulmonary embolism), Sankyo; Factor Xa inhibitor (deep vein thrombosis/ pulmonary embolism), Daiichi Sankyo; Factor Xa inhibitor (deep vein thrombosis/ pulmonary embolism), Sankyo
DMK230A CP Daiichi-Sankyo
DMK230A DE Thrombosis
DMKVW25 ID DMKVW25
DMKVW25 DN Cu-anti-hAXL
DMKVW25 HS Preclinical
DMKVW25 DT Antibody
DMKVW25 DE Breast cancer
DMB1ET0 ID DMB1ET0
DMB1ET0 DN Cutamesine
DMB1ET0 HS Preclinical
DMB1ET0 SN AGY-94806; Msc-1; SA-4502; SA-4503; Sigma opioid receptor agonist, Santen
DMB1ET0 CP Santen Pharmaceutical Co Ltd
DMB1ET0 DT Small molecular drug
DMB1ET0 PC 9907323
DMB1ET0 MW 368.5
DMB1ET0 FM C23H32N2O2
DMB1ET0 IC InChI=1S/C23H32N2O2/c1-26-22-11-10-21(19-23(22)27-2)12-14-25-17-15-24(16-18-25)13-6-9-20-7-4-3-5-8-20/h3-5,7-8,10-11,19H,6,9,12-18H2,1-2H3
DMB1ET0 CS COC1=C(C=C(C=C1)CCN2CCN(CC2)CCCC3=CC=CC=C3)OC
DMB1ET0 IK UVSWWUWQVAQPJR-UHFFFAOYSA-N
DMB1ET0 IU 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine
DMB1ET0 CA CAS 165377-43-5
DMB1ET0 DE Major depressive disorder
DM8YUJT ID DM8YUJT
DM8YUJT DN CWHM-12
DM8YUJT HS Preclinical
DM8YUJT SN cwhm-12; CWHM12; 1564286-55-0; (3S)-3-(3-bromo-5-(tert-butyl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid; CHEMBL3319237; CWHM 12; SCHEMBL15475283; GTPL10495; AOB2397; EX-A850; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid; BDBM50497716; MFCD28385850; AKOS027423695; CS-3537; NCGC00390566-03; AS-16717; HY-18644; J-690209; (3S)-3-(3-bromo-5-tert-butylphenyl)-3-(2-(3-hydroxy-5-(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-ylamino)benzamido)acetamido)propanoic acid
DM8YUJT DT Small molecular drug
DM8YUJT PC 72949858
DM8YUJT MW 590.5
DM8YUJT FM C26H32BrN5O6
DM8YUJT IC InChI=1S/C26H32BrN5O6/c1-26(2,3)16-4-14(5-17(27)8-16)21(10-23(36)37)32-22(35)13-28-24(38)15-6-18(9-19(33)7-15)31-25-29-11-20(34)12-30-25/h4-9,20-21,33-34H,10-13H2,1-3H3,(H,28,38)(H,32,35)(H,36,37)(H2,29,30,31)/t21-/m0/s1
DM8YUJT CS CC(C)(C)C1=CC(=CC(=C1)[C@H](CC(=O)O)NC(=O)CNC(=O)C2=CC(=CC(=C2)O)NC3=NCC(CN3)O)Br
DM8YUJT IK YDHAGPCZRFQPOI-NRFANRHFSA-N
DM8YUJT IU (3S)-3-(3-bromo-5-tert-butylphenyl)-3-[[2-[[3-hydroxy-5-[(5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino]benzoyl]amino]acetyl]amino]propanoic acid
DM8YUJT DE Hepatic fibrosis; Pulmonary fibrosis
DMKZCBE ID DMKZCBE
DMKZCBE DN CX-1501
DMKZCBE HS Preclinical
DMKZCBE SN AMPA receptor modulators (ADHD, AD, sleep disorders), Cortex Pharmaceuticals
DMKZCBE CP Cortex Pharmaceuticals Inc
DMKZCBE DE Alzheimer disease
DMA1MK5 ID DMA1MK5
DMA1MK5 DN CYC-800
DMA1MK5 HS Preclinical
DMA1MK5 CP Cyclacel
DMA1MK5 TC Anticancer Agents
DMA1MK5 DT Small molecular drug
DMA1MK5 PC 24759764
DMA1MK5 MW 424.4
DMA1MK5 FM C21H25FO8
DMA1MK5 IC InChI=1S/C15H13FO2.C6H12O6/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11;7-1-2(8)4(10)6(12)5(11)3(1)9/h2-10H,1H3,(H,17,18);1-12H/t10-;/m1./s1
DMA1MK5 CS C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O.C1(C(C(C(C(C1O)O)O)O)O)O
DMA1MK5 IK XXWQLQXGYRVJNJ-HNCPQSOCSA-N
DMA1MK5 IU cyclohexane-1,2,3,4,5,6-hexol;(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
DMA1MK5 DE Solid tumour/cancer
DMV8APG ID DMV8APG
DMV8APG DN Cytolin
DMV8APG HS Preclinical
DMV8APG CP CytoDyn
DMV8APG DT Antibody
DMV8APG DE Human immunodeficiency virus infection
DMHD3R8 ID DMHD3R8
DMHD3R8 DN D-4476
DMHD3R8 HS Preclinical
DMHD3R8 SN CK1 inhibitor; D 4476
DMHD3R8 DT Small molecular drug
DMHD3R8 PC 6419753
DMHD3R8 MW 398.4
DMHD3R8 FM C23H18N4O3
DMHD3R8 IC InChI=1S/C23H18N4O3/c24-22(28)14-4-6-15(7-5-14)23-26-20(21(27-23)17-3-1-2-10-25-17)16-8-9-18-19(13-16)30-12-11-29-18/h1-10,13H,11-12H2,(H2,24,28)(H,26,27)
DMHD3R8 CS C1COC2=C(O1)C=CC(=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
DMHD3R8 IK DPDZHVCKYBCJHW-UHFFFAOYSA-N
DMHD3R8 IU 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
DMHD3R8 CA CAS 301836-43-1
DMHD3R8 CB CHEBI:91448
DMHD3R8 DE Chronic lymphocytic leukaemia
DMUWRIF ID DMUWRIF
DMUWRIF DN DAP-81
DMUWRIF HS Preclinical
DMUWRIF CP RottaPharma
DMUWRIF TC Anticancer Agents
DMUWRIF PC 9548005
DMUWRIF MW 468.5
DMUWRIF FM C25H20N6O4
DMUWRIF IC InChI=1S/C25H20N6O4/c1-16(32)27-18-11-13-19(14-12-18)28-25-26-15-22(31(34)35)24(30-25)29-21-10-6-5-9-20(21)23(33)17-7-3-2-4-8-17/h2-15H,1H3,(H,27,32)(H2,26,28,29,30)
DMUWRIF CS CC(=O)NC1=CC=C(C=C1)NC2=NC=C(C(=N2)NC3=CC=CC=C3C(=O)C4=CC=CC=C4)[N+](=O)[O-]
DMUWRIF IK LOMJSEHTDFISSP-UHFFFAOYSA-N
DMUWRIF IU N-[4-[[4-(2-benzoylanilino)-5-nitropyrimidin-2-yl]amino]phenyl]acetamide
DMUWRIF DE Solid tumour/cancer
DM8WTAZ ID DM8WTAZ
DM8WTAZ DN Debio1453
DM8WTAZ HS Preclinical
DM8WTAZ CP Debiopharm
DM8WTAZ DT Small molecular drug
DM8WTAZ DE Neisseria gonorrhoeae infection
DMAUILH ID DMAUILH
DMAUILH DN DecRVKRCMK
DMAUILH HS Preclinical
DMAUILH DT Small molecular drug
DMAUILH DE Coronavirus infection
DMJKQFT ID DMJKQFT
DMJKQFT DN Dec-RVKR-CMK
DMJKQFT HS Preclinical
DMJKQFT SN AKOS024457645; DECANOYL-ARG-VAL-LYS-ARG-CHLOROMETHYLKETONE; Decanoyl-Arg-Val-Lys-Arg-chloromethylketone trifluoroacetate salt; ZINC98052548; decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone
DMJKQFT TC Antiviral Agents
DMJKQFT DT Protein/peptide drug
DMJKQFT PC 9962075
DMJKQFT MW 744.4
DMJKQFT FM C34H66ClN11O5
DMJKQFT IC InChI=1S/C34H66ClN11O5/c1-4-5-6-7-8-9-10-18-28(48)43-25(17-14-21-42-34(39)40)31(50)46-29(23(2)3)32(51)45-26(15-11-12-19-36)30(49)44-24(27(47)22-35)16-13-20-41-33(37)38/h23-26,29H,4-22,36H2,1-3H3,(H,43,48)(H,44,49)(H,45,51)(H,46,50)(H4,37,38,41)(H4,39,40,42)/t24-,25-,26-,29-/m0/s1
DMJKQFT CS CCCCCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl
DMJKQFT IK NHBJTTGFHCHQHS-VZTVMPNDSA-N
DMJKQFT IU N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(3S)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]decanamide
DMJKQFT DE Middle East Respiratory Syndrome (MERS)
DMD0T1U ID DMD0T1U
DMD0T1U DN Depudecin
DMD0T1U HS Preclinical
DMD0T1U SN (1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9
DMD0T1U DT Small molecular drug
DMD0T1U PC 16219259
DMD0T1U MW 212.24
DMD0T1U FM C11H16O4
DMD0T1U IC InChI=1S/C11H16O4/c1-3-7(13)11-9(15-11)5-4-8-10(14-8)6(2)12/h3-13H,1H2,2H3/b5-4+/t6-,7-,8+,9+,10+,11+/m1/s1
DMD0T1U CS C[C@H]([C@H]1[C@@H](O1)/C=C/[C@H]2[C@@H](O2)[C@@H](C=C)O)O
DMD0T1U IK DLVJMFOLJOOWFS-INMLLLKOSA-N
DMD0T1U IU (1R)-1-[(2S,3S)-3-[(E)-2-[(2S,3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol
DMD0T1U CA CAS 139508-73-9
DMD0T1U CB CHEBI:64143
DMD0T1U DE Solid tumour/cancer
DM2I76R ID DM2I76R
DM2I76R DN Desmethylsertraline
DM2I76R HS Preclinical
DM2I76R SN Desmethylsertraline; Norsertraline; (1s,4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; UNII-CJJ71O9BE8; CJJ71O9BE8; CHEMBL40733; (1S,4S)-4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydronaphthalen-1-amine; CHEMBL1743864; N-Demethylsertraline; N-Desmethylsertraline; Demethylsertraline; CP 62508; CP-53261; AC1L3FVW; AC1Q3O5M; SCHEMBL145234; NAP005; CTK8E0157; DTXSID60236666; SRPXSILJHWNFMK-ZBEGNZNMSA-N; ZINC6117444; PDSP2_001789; BDBM50367182; MFCD00871799; BDBM50028066; AKOS027382323
DM2I76R PC 114743
DM2I76R MW 292.2
DM2I76R FM C16H15Cl2N
DM2I76R IC InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16-/m0/s1
DM2I76R CS C1CC(C2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)N
DM2I76R IK SRPXSILJHWNFMK-ZBEGNZNMSA-N
DM2I76R IU (1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
DM2I76R CA CAS 87857-41-8
DM2I76R DE Major depressive disorder
DM5H2W9 ID DM5H2W9
DM5H2W9 DN Dioscin
DM5H2W9 HS Preclinical
DM5H2W9 SN Dioscin; 19057-60-4; Collettiside III; Dioscine; CHEBI:74023; CCRIS 4123; UNII-3B95U4OLWV; 3-O-(Rhaalpha1-4(Rhaalpha1-2)Glcbeta)-(25R)-spirost-5-en-3beta-ol; 3-O-[alpha-L-Rha-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Glc]-diosgenin; 3-O-[alpha-L-Rhap-(1->4)-[alpha-L-Rhap-(1->2)]-beta-D-Glcp]-diosgenin; (25R)-spirost-5-en-3beta-yl alpha-L-rhamnopyranosyl-(1->2)-[alpha-L-mannopyranosyl-(1->4)]-beta-D-glucopyranoside; 3B95U4OLWV; AC1L3OGN; Dioscin(Collettiside III); Dioscin (Collettiside III); GTPL840
DM5H2W9 DT Small molecular drug
DM5H2W9 PC 119245
DM5H2W9 MW 869
DM5H2W9 FM C45H72O16
DM5H2W9 IC InChI=1S/C45H72O16/c1-19-9-14-45(54-18-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(52)34(50)32(48)22(4)56-41)37(53)38(29(17-46)58-42)59-40-35(51)33(49)31(47)21(3)55-40/h7,19-22,24-42,46-53H,8-18H2,1-6H3/t19-,20+,21+,22+,24+,25-,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36-,37+,38-,39-,40+,41+,42-,43+,44+,45-/m1/s1
DM5H2W9 CS C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1
DM5H2W9 IK VNONINPVFQTJOC-ZGXDEBHDSA-N
DM5H2W9 IU (2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
DM5H2W9 CA CAS 19057-60-4
DM5H2W9 CB CHEBI:74023
DM5H2W9 DE Hepatic fibrosis
DMA2K7C ID DMA2K7C
DMA2K7C DN Donitriptan
DMA2K7C HS Preclinical
DMA2K7C SN Donitriptan mesylate; F-11356; F-12640; Migraine therapy, Pierre Fabre; 5-HT1D agonist, Pierre Fabre
DMA2K7C CP Pierre Fabre SA
DMA2K7C DT Small molecular drug
DMA2K7C PC 197706
DMA2K7C MW 403.5
DMA2K7C FM C23H25N5O2
DMA2K7C IC InChI=1S/C23H25N5O2/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19/h1-6,13,15,26H,7-12,16,24H2
DMA2K7C CS C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN
DMA2K7C IK SOHCKWZVTCTQBG-UHFFFAOYSA-N
DMA2K7C IU 4-[4-[2-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]piperazin-1-yl]benzonitrile
DMA2K7C CA CAS 170912-52-4
DMA2K7C DE Migraine
DMYH3VR ID DMYH3VR
DMYH3VR DN DP-3975
DMYH3VR HS Preclinical
DMYH3VR CP Deciphera Pharmaceuticals
DMYH3VR DT Small molecular drug
DMYH3VR DE Mesothelioma
DMMI2EY ID DMMI2EY
DMMI2EY DN DS-1558
DMMI2EY HS Preclinical
DMMI2EY SN 1202575-67-4; CHEMBL3427712; (S)-3-ethoxy-3-(4-(((R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)propanoic acid; SCHEMBL1508316; BDBM50085568; SB18922; (3S)-3-ethoxy-3-[4-[[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]propanoic acid; (3S)-3-Ethoxy-3-[4-[[(R)-4-(trifluoromethyl)-2,3-dihydro-1H-indene-1alpha-yl]oxy]phenyl]propanoic acid
DMMI2EY DT Small molecular drug
DMMI2EY PC 45107312
DMMI2EY MW 394.4
DMMI2EY FM C21H21F3O4
DMMI2EY IC InChI=1S/C21H21F3O4/c1-2-27-19(12-20(25)26)13-6-8-14(9-7-13)28-18-11-10-15-16(18)4-3-5-17(15)21(22,23)24/h3-9,18-19H,2,10-12H2,1H3,(H,25,26)/t18-,19+/m1/s1
DMMI2EY CS CCO[C@@H](CC(=O)O)C1=CC=C(C=C1)O[C@@H]2CCC3=C2C=CC=C3C(F)(F)F
DMMI2EY IK YHLQVQKZDZYMIP-MOPGFXCFSA-N
DMMI2EY IU (3S)-3-ethoxy-3-[4-[[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy]phenyl]propanoic acid
DMMI2EY DE Type 2 diabetes
DM8YSW7 ID DM8YSW7
DM8YSW7 DN DX-2802
DM8YSW7 HS Preclinical
DM8YSW7 CP Dyax Corp
DM8YSW7 DT Antibody
DM8YSW7 DE Solid tumour/cancer
DMCVXBE ID DMCVXBE
DMCVXBE DN E-64D
DMCVXBE HS Preclinical
DMCVXBE SN E64D; E64d; Aloxistatin; Aloxistatin [INN]; Aloxistatina; Aloxistatina [Spanish]; Aloxistatine; Aloxistatine [French]; Aloxistatinum; Aloxistatinum [Latin]; BRN 5354546; C17H30N2O5; CCRIS 1934; CHEMBL63440; E 64c ethyl ester; E 64d; EP 453; EST; EST (pharmaceutical); L5W337AOUR; Loxistatin; MLS000028372; NSC 694281; SMR000058552; UNII-L5W337AOUR
DMCVXBE TC Antiviral Agents
DMCVXBE DT Small molecular drug
DMCVXBE PC 65663
DMCVXBE MW 342.4
DMCVXBE FM C17H30N2O5
DMCVXBE IC InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
DMCVXBE CS CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C
DMCVXBE IK SRVFFFJZQVENJC-IHRRRGAJSA-N
DMCVXBE IU ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
DMCVXBE CA CAS 88321-09-9
DMCVXBE CB CHEBI:101381
DMCVXBE DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMG4DHX ID DMG4DHX
DMG4DHX DN ED-1812
DMG4DHX HS Preclinical
DMG4DHX CP Sosei R&D Ltd
DMG4DHX DE Pain
DMELPJM ID DMELPJM
DMELPJM DN EDD7H9
DMELPJM HS Preclinical
DMELPJM SN Anti S1P3 antibody (breast cancer), Expression Drug Designs; Anti-GPCR Abs (cancer), Expression Drug Designs; G-protein-coupled receptor inhibitor antibodies (breast cancer), Expression Drug Designs
DMELPJM CP Expression Drug Designs
DMELPJM DT Antibody
DMELPJM DE Breast cancer
DMZ3YP6 ID DMZ3YP6
DMZ3YP6 DN EGFR/IGFR tandem adnectin
DMZ3YP6 HS Preclinical
DMZ3YP6 SN BMS-964210
DMZ3YP6 CP Bristol-Myers Squibb
DMZ3YP6 DE Solid tumour/cancer
DMK6WIO ID DMK6WIO
DMK6WIO DN Enrofloxacin
DMK6WIO HS Preclinical
DMK6WIO SN Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacinum; Enrofloxacino; endrofloxicin; BAY VP 2674; Bay-Vp-2674; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; UNII-3DX3XEK1BN; N-Ethylciprofloxacin; Baytril (TN); ERFX; Enrofloxacin [USAN:BAN:INN]; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; HSDB 6952; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3DX3XEK1BN; Enrofloxacin (USAN/INN)
DMK6WIO PC 71188
DMK6WIO MW 359.4
DMK6WIO FM C19H22FN3O3
DMK6WIO IC InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
DMK6WIO CS CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
DMK6WIO IK SPFYMRJSYKOXGV-UHFFFAOYSA-N
DMK6WIO IU 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid
DMK6WIO CA CAS 93106-60-6
DMK6WIO CB CHEBI:35720
DMK6WIO DE Bacterial infections
DM2K51E ID DM2K51E
DM2K51E DN EP-01492
DM2K51E HS Preclinical
DM2K51E CP Ardana
DM2K51E DT Small molecular drug
DM2K51E PC 56603735
DM2K51E MW 514.7
DM2K51E FM C31H38N4O3
DM2K51E IC InChI=1S/C31H38N4O3/c1-31(2,32)19-11-16-27(36)34(4)26(21-22-17-18-23-12-9-10-15-25(23)20-22)30(38)35(5)28(29(37)33-3)24-13-7-6-8-14-24/h6-18,20,26,28H,19,21,32H2,1-5H3,(H,33,37)/b16-11+/t26-,28-/m1/s1
DM2K51E CS CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)[C@H](C3=CC=CC=C3)C(=O)NC)N
DM2K51E IK DPTDDSCCZNKDBZ-JABCAPRSSA-N
DM2K51E IU (E)-5-amino-N,5-dimethyl-N-[(2R)-1-[methyl-[(1R)-2-(methylamino)-2-oxo-1-phenylethyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide
DM2K51E DE Obesity
DMJEKQM ID DMJEKQM
DMJEKQM DN EP-128504
DMJEKQM HS Preclinical
DMJEKQM SN MX-116839; MX-126374; MX-126911; MX-128504; MX-74420; MX-77356; IGF modulator (cancer), Maxim; IGF-2 receptor modulators (cancer); IGF-2 receptor modulators (cancer), EpiCept; IGF-2 receptor modulators (cancer), Maxim; Insulin-like growth factor modulator (cancer), Maxim
DMJEKQM CP Maxim Pharmaceuticals Inc
DMJEKQM DE Solid tumour/cancer
DMERKYO ID DMERKYO
DMERKYO DN EP-2167
DMERKYO HS Preclinical
DMERKYO SN MX-2167; Transferrin modulating apoptosis inducers (cancer); Transferrin modulating apoptosis inducers (cancer), EpiCept;Transferrin modulating apoptosis inducers (cancer), Maxim
DMERKYO CP Maxim Pharmaceuticals Inc
DMERKYO DE Solid tumour/cancer
DMVNR20 ID DMVNR20
DMVNR20 DN Epipodophyllotoxins
DMVNR20 HS Preclinical
DMVNR20 SN (-)-epipodophyllotoxin; 137513-EP2272827A1; 137513-EP2292088A1; AC1L2Y2E; AJ-42064; BRN 0099162; C22H22O8; CHEMBL282256; Epipodophyllotoxin; Etopside; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5-alpha,5a-beta,8a-alpha,9-beta))-; LS-70861; SCHEMBL5792464; VP16; ZINC2572657
DMVNR20 TC Anticancer Agents
DMVNR20 DT Small molecular drug
DMVNR20 PC 105111
DMVNR20 MW 414.41
DMVNR20 FM C22H22O8
DMVNR20 IC InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20+/m0/s1
DMVNR20 CS COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O
DMVNR20 IK YJGVMLPVUAXIQN-LGWHJFRWSA-N
DMVNR20 IU (5S,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMVNR20 CA CAS 4375-07-9
DMVNR20 DE External genital and perianal warts; Molluscum contagiosum infection
DM5K17C ID DM5K17C
DM5K17C DN EPL-1410
DM5K17C HS Preclinical
DM5K17C CP Emcure Pharmaceuticals
DM5K17C DT Small molecular drug
DM5K17C DE Solid tumour/cancer
DMX2FZS ID DMX2FZS
DMX2FZS DN Epothilone A
DMX2FZS HS Preclinical
DMX2FZS SN Epothilone A; (-)-Epothilone A; Epo A; epothile; Epothilone-A; UNII-51E07YBX96; Epoa; 51E07YBX96; EP; Epothilones; Epothilon A; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,(1S,3S,7S,10R,11S,12S,16R)-
DMX2FZS PC 448799
DMX2FZS MW 493.7
DMX2FZS FM C26H39NO6S
DMX2FZS IC InChI=1S/C26H39NO6S/c1-14-8-7-9-19-21(32-19)11-20(15(2)10-18-13-34-17(4)27-18)33-23(29)12-22(28)26(5,6)25(31)16(3)24(14)30/h10,13-14,16,19-22,24,28,30H,7-9,11-12H2,1-6H3/b15-10+/t14-,16+,19+,20-,21-,22-,24-/m0/s1
DMX2FZS CS CC1CCCC2C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C
DMX2FZS IK HESCAJZNRMSMJG-KKQRBIROSA-N
DMX2FZS IU (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMX2FZS CA CAS 152044-53-6
DMX2FZS CB CHEBI:31549
DMX2FZS DE Cancer
DM2TESM ID DM2TESM
DM2TESM DN EPZ028862
DM2TESM HS Preclinical
DM2TESM DT Small molecular drug
DM2TESM DE Solid tumour/cancer
DM8UKL0 ID DM8UKL0
DM8UKL0 DN EPZ031686
DM8UKL0 HS Preclinical
DM8UKL0 SN 1808011-22-4; 6-chloro-2-oxo-N-((1R,3r,5S)-8-(((1-(4,4,4-trifluorobutyl)piperidin-4-yl)methyl)sulfonyl)-8-azabicyclo[3.2.1]octan-3-yl)indoline-5-carboxamide; EPZ-031686; CHEMBL3798741; SCHEMBL17591794; SCHEMBL17591795; SCHEMBL21490167; BDBM378462; EX-A1613; NSC804862; US10266526, Compound 595; ZINC521836533; CS-5775; NSC-804862; HY-19324; A16375
DM8UKL0 DT Small molecular drug
DM8UKL0 PC 118946372
DM8UKL0 MW 591.1
DM8UKL0 FM C26H34ClF3N4O4S
DM8UKL0 IC InChI=1S/C26H34ClF3N4O4S/c27-22-14-23-17(11-24(35)32-23)10-21(22)25(36)31-18-12-19-2-3-20(13-18)34(19)39(37,38)15-16-4-8-33(9-5-16)7-1-6-26(28,29)30/h10,14,16,18-20H,1-9,11-13,15H2,(H,31,36)(H,32,35)/t18?,19-,20+
DM8UKL0 CS C1C[C@H]2CC(C[C@@H]1N2S(=O)(=O)CC3CCN(CC3)CCCC(F)(F)F)NC(=O)C4=C(C=C5C(=C4)CC(=O)N5)Cl
DM8UKL0 IK OTEIUEJPHNOGBG-IHWFROFDSA-N
DM8UKL0 IU 6-chloro-2-oxo-N-[(1S,5R)-8-[[1-(4,4,4-trifluorobutyl)piperidin-4-yl]methylsulfonyl]-8-azabicyclo[3.2.1]octan-3-yl]-1,3-dihydroindole-5-carboxamide
DM8UKL0 DE Solid tumour/cancer
DMHU742 ID DMHU742
DMHU742 DN EPZ032597
DMHU742 HS Preclinical
DMHU742 DT Small molecular drug
DMHU742 DE Solid tumour/cancer
DMUKVYL ID DMUKVYL
DMUKVYL DN EPZ0330456
DMUKVYL HS Preclinical
DMUKVYL DT Small molecular drug
DMUKVYL DE Colon cancer
DMDO6NZ ID DMDO6NZ
DMDO6NZ DN EPZ033294
DMDO6NZ HS Preclinical
DMDO6NZ DT Small molecular drug
DMDO6NZ DE Solid tumour/cancer
DMBINP0 ID DMBINP0
DMBINP0 DN ER-319711-15
DMBINP0 HS Preclinical
DMBINP0 CP Eisai Co Ltd
DMBINP0 DE Type-2 diabetes
DMUFP05 ID DMUFP05
DMUFP05 DN F-15063
DMUFP05 HS Preclinical
DMUFP05 SN D2/D3 antagonists (psychosis/schizophrenia), Pierre Fabre
DMUFP05 CP Centre de Recherche Pierre Fabre
DMUFP05 DT Small molecular drug
DMUFP05 PC 10248159
DMUFP05 MW 363.5
DMUFP05 FM C24H29NO2
DMUFP05 IC InChI=1S/C24H29NO2/c1-24(2)16-21-11-6-12-22(23(21)27-24)26-14-13-25-17-18-7-5-10-20(15-18)19-8-3-4-9-19/h5-8,10-12,15,25H,3-4,9,13-14,16-17H2,1-2H3
DMUFP05 CS CC1(CC2=C(O1)C(=CC=C2)OCCNCC3=CC(=CC=C3)C4=CCCC4)C
DMUFP05 IK RAIDOKRWKAIHOH-UHFFFAOYSA-N
DMUFP05 IU N-[[3-(cyclopenten-1-yl)phenyl]methyl]-2-[(2,2-dimethyl-3H-1-benzofuran-7-yl)oxy]ethanamine
DMUFP05 CA CAS 680203-70-7
DMUFP05 DE Schizophrenia
DM29M4R ID DM29M4R
DM29M4R DN F24F2
DM29M4R HS Preclinical
DM29M4R DT Antibody
DM29M4R DE Anthrax
DM2GEHA ID DM2GEHA
DM2GEHA DN F26G3
DM2GEHA HS Preclinical
DM2GEHA DT Antibody
DM2GEHA DE Anthrax
DMAVQ2X ID DMAVQ2X
DMAVQ2X DN F26G4
DMAVQ2X HS Preclinical
DMAVQ2X DT Antibody
DMAVQ2X DE Anthrax
DMTHLB8 ID DMTHLB8
DMTHLB8 DN FA-613
DMTHLB8 HS Preclinical
DMTHLB8 SN 6-bromo-2-(4-ethoxyphenyl)-4-quinolinecarboxylic acid
DMTHLB8 TC Antiviral Agents
DMTHLB8 DT Small molecular drug
DMTHLB8 DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMYFVZ3 ID DMYFVZ3
DMYFVZ3 DN FAP5-DM1
DMYFVZ3 HS Preclinical
DMYFVZ3 DT Antibody
DMYFVZ3 DE Solid tumour/cancer
DMAX2EW ID DMAX2EW
DMAX2EW DN FAS1
DMAX2EW HS Preclinical
DMAX2EW TC Antifungal Agents
DMAX2EW DE Fungal infection
DMBZVYG ID DMBZVYG
DMBZVYG DN FOXO4-DRI
DMBZVYG HS Preclinical
DMBZVYG DT Peptide
DMBZVYG DE Hypogonadism
DMUHVEA ID DMUHVEA
DMUHVEA DN FPL-14294
DMUHVEA HS Preclinical
DMUHVEA SN Fpl 14294; Hpa(SO3H)-met-gly-trp-met-asp-mephe-NH2NH3; (3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-4-methylsulfanyl-2-[[2-(4-sulfooxyphenyl)acetyl]amino]butanoyl]amino]acetyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid; 4-(Sulfoxy)-phenylacetyl(mephe6)cck-6; 4-(Sulfoxy)phenylacetyl-methionyl-glycyl-trptophyl-methionyl-aspartyl-methylphenylalaninehydrazide
DMUHVEA CP Fisons
DMUHVEA DT Small molecular drug
DMUHVEA PC 132969
DMUHVEA MW 1013.2
DMUHVEA FM C45H56N8O13S3
DMUHVEA IC InChI=1S/C45H56N8O13S3/c1-46-35(21-27-9-5-4-6-10-27)43(60)53-45(62)37(24-40(56)57)52-42(59)34(18-20-68-3)51-44(61)36(23-29-25-47-32-12-8-7-11-31(29)32)50-39(55)26-48-41(58)33(17-19-67-2)49-38(54)22-28-13-15-30(16-14-28)66-69(63,64)65/h4-16,25,33-37,46-47H,17-24,26H2,1-3H3,(H,48,58)(H,49,54)(H,50,55)(H,51,61)(H,52,59)(H,56,57)(H,53,60,62)(H,63,64,65)/t33-,34-,35-,36-,37-/m0/s1
DMUHVEA CS CN[C@@H](CC1=CC=CC=C1)C(=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)CC4=CC=C(C=C4)OS(=O)(=O)O
DMUHVEA IK PKMRCHBERGHHNY-LTLCPEALSA-N
DMUHVEA IU (3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-4-methylsulfanyl-2-[[2-(4-sulfooxyphenyl)acetyl]amino]butanoyl]amino]acetyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMUHVEA CA CAS 154132-95-3
DMUHVEA DE Obesity
DMF53Z7 ID DMF53Z7
DMF53Z7 DN FR167356
DMF53Z7 HS Preclinical
DMF53Z7 PC 10068207
DMF53Z7 MW 378.2
DMF53Z7 FM C19H17Cl2NO3
DMF53Z7 IC InChI=1S/C19H17Cl2NO3/c1-10-16(19(2,3)24)11-6-4-9-14(17(11)25-10)22-18(23)15-12(20)7-5-8-13(15)21/h4-9,24H,1-3H3,(H,22,23)
DMF53Z7 CS CC1=C(C2=C(O1)C(=CC=C2)NC(=O)C3=C(C=CC=C3Cl)Cl)C(C)(C)O
DMF53Z7 IK GCAOVMKRBUCSET-UHFFFAOYSA-N
DMF53Z7 IU 2,6-dichloro-N-[3-(2-hydroxypropan-2-yl)-2-methyl-1-benzofuran-7-yl]benzamide
DMF53Z7 CA CAS 174185-16-1
DMF53Z7 DE Osteoporosis
DMXR287 ID DMXR287
DMXR287 DN FR-79620
DMXR287 HS Preclinical
DMXR287 SN 3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
DMXR287 CP Fujisawa
DMXR287 DT Small molecular drug
DMXR287 PC 10421577
DMXR287 MW 235.28
DMXR287 FM C15H13N3
DMXR287 IC InChI=1S/C15H13N3/c1-11-14(13-8-5-9-16-10-13)18-15(17-11)12-6-3-2-4-7-12/h2-10H,1H3,(H,17,18)
DMXR287 CS CC1=C(N=C(N1)C2=CC=CC=C2)C3=CN=CC=C3
DMXR287 IK CAQAIFUDUGDPFB-UHFFFAOYSA-N
DMXR287 IU 3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
DMXR287 DE Diabetic complication; Obesity; Eating disorder
DMLNRCI ID DMLNRCI
DMLNRCI DN FSA2
DMLNRCI HS Preclinical
DMLNRCI TC Antifungal Agents
DMLNRCI DE Fungal infection
DMXE6ML ID DMXE6ML
DMXE6ML DN FX-007
DMXE6ML HS Preclinical
DMXE6ML CP Flexion Therapeutics
DMXE6ML DE Pain
DM7UJ1I ID DM7UJ1I
DM7UJ1I DN FX-107
DM7UJ1I HS Preclinical
DM7UJ1I SN FX-06; FX-06); FX-06HS; FX-06MRI; FX-108; FX-201; IK-600X program; Bbeta(15-42); FX-06 analogs (transplantation), Fibrex Medical; FX-06 analogs (transplantation), Ikaria; Peptide leukocyte migration inhibitor (reperfusion injury/hemorrhagic shock), Ikaria; Peptide leukocyte migration inhibitor (reperfusion injury/hemorrhagic shock), FIBREX Medical R&D; FX-06 analogs (sepsis, septic shock, Dengue), Fibrex Medical
DM7UJ1I CP Fibrex Medical R&D GmbH
DM7UJ1I DE Dengue fever
DMR1CLY ID DMR1CLY
DMR1CLY DN GC376
DMR1CLY HS Preclinical
DMR1CLY SN CS-6923; HY-100721; CHEMBL2315036
DMR1CLY TC Antiviral Agents
DMR1CLY DT Small molecular drug
DMR1CLY PC 71481119
DMR1CLY MW 507.5
DMR1CLY FM C21H30N3NaO8S
DMR1CLY IC InChI=1S/C21H31N3O8S.Na/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25;/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31);/q;+1/p-1/t15?,16-,17-,20?;/m0./s1
DMR1CLY CS CC(C)C[C@@H](C(=O)N[C@@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2=CC=CC=C2.[Na+]
DMR1CLY IK BSPJDKCMFIPBAW-JPBGFCRCSA-M
DMR1CLY IU sodium;(2S)-1-hydroxy-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate
DMR1CLY CA CAS 1416992-39-6
DMR1CLY DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM7PBJC ID DM7PBJC
DM7PBJC DN GC813
DM7PBJC HS Preclinical
DM7PBJC SN GC813 compound
DM7PBJC TC Antiviral Agents
DM7PBJC DT Small molecular drug
DM7PBJC DE Middle East Respiratory Syndrome (MERS)
DMFW0H9 ID DMFW0H9
DMFW0H9 DN GCR-1087
DMFW0H9 HS Preclinical
DMFW0H9 CP Glenmark
DMFW0H9 DE Type-2 diabetes; Obesity
DMFQI38 ID DMFQI38
DMFQI38 DN GG-8573
DMFQI38 HS Preclinical
DMFQI38 CP GSK
DMFQI38 DE Obesity
DM25N8B ID DM25N8B
DM25N8B DN GI-264879A
DM25N8B HS Preclinical
DM25N8B SN gi264879a
DM25N8B CP GSK
DM25N8B DT Small molecular drug
DM25N8B PC 9875299
DM25N8B MW 743.8
DM25N8B FM C41H44F3N5O5
DM25N8B IC InChI=1S/C39H43N5O3.C2HF3O2/c1-47-26-30(24-27-12-3-2-4-13-27)43-38(46)36(22-11-23-42-39(40)41)44-37(45)25-35(33-20-9-16-28-14-5-7-18-31(28)33)34-21-10-17-29-15-6-8-19-32(29)34;3-2(4,5)1(6)7/h2-10,12-21,30,35-36H,11,22-26H2,1H3,(H,43,46)(H,44,45)(H4,40,41,42);(H,6,7)/t30-,36+;/m0./s1
DM25N8B CS COC[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CC(C2=CC=CC3=CC=CC=C32)C4=CC=CC5=CC=CC=C54.C(=O)(C(F)(F)F)O
DM25N8B IK NZGALICACGXBQM-HOBHVFGFSA-N
DM25N8B IU (2R)-5-(diaminomethylideneamino)-2-(3,3-dinaphthalen-1-ylpropanoylamino)-N-[(2S)-1-methoxy-3-phenylpropan-2-yl]pentanamide;2,2,2-trifluoroacetic acid
DM25N8B DE Obesity
DMZC91G ID DMZC91G
DMZC91G DN GL21.T
DMZC91G HS Preclinical
DMZC91G DT Oligonucleotide
DMZC91G DE Non-small-cell lung cancer
DMSW07R ID DMSW07R
DMSW07R DN GLPG-0492
DMSW07R HS Preclinical
DMSW07R SN G-100192; Selective androgen receptor modulators, Galapagos; Selective androgen receptor modulators, ProSkelia; Selective androgen receptor modulators, ProStrakan; SARMs (osteoporosis), ProSkelia; SARMs (osteoporosis), ProStraken; SARMs (osteoporosis/cachexia), Galapagos
DMSW07R CP ProSkelia Pharmaceuticals SAS
DMSW07R PC 59317190
DMSW07R MW 389.3
DMSW07R FM C19H14F3N3O3
DMSW07R IC InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1
DMSW07R CS CN1C(=O)N(C(=O)[C@@]1(CO)C2=CC=CC=C2)C3=CC(=C(C=C3)C#N)C(F)(F)F
DMSW07R IK VAJGULUVTFDTAS-GOSISDBHSA-N
DMSW07R IU 4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
DMSW07R CA CAS 1215085-92-9
DMSW07R DE Cachexia
DMXVHOQ ID DMXVHOQ
DMXVHOQ DN GNE684
DMXVHOQ HS Preclinical
DMXVHOQ SN (5S)-N-[(3S)-7-methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[3,4-b]azepin-3-yl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide; HY-128585; CS-0095948; (s)-N-((s)-7-methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1h-pyrido[3,4-b]azepin-3-yl)-5-phenyl-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide; 2438637-64-8; L8D; rel-(S)-N-((S)-7-Methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[3,4-b]azepin-3-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide
DMXVHOQ CP Genentech
DMXVHOQ DT Small molecular drug
DMXVHOQ PC 138377384
DMXVHOQ MW 432.5
DMXVHOQ FM C23H24N6O3
DMXVHOQ IC InChI=1S/C23H24N6O3/c1-28-18-13-24-20(32-2)12-15(18)8-9-16(23(28)31)25-22(30)21-26-19-11-10-17(29(19)27-21)14-6-4-3-5-7-14/h3-7,12-13,16-17H,8-11H2,1-2H3,(H,25,30)/t16-,17-/m0/s1
DMXVHOQ CS CN1C2=CN=C(C=C2CC[C@@H](C1=O)NC(=O)C3=NN4[C@@H](CCC4=N3)C5=CC=CC=C5)OC
DMXVHOQ IK JXFYROJRZJPKTQ-IRXDYDNUSA-N
DMXVHOQ IU (5S)-N-[(3S)-7-methoxy-1-methyl-2-oxo-4,5-dihydro-3H-pyrido[3,4-b]azepin-3-yl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide
DMXVHOQ DE Inflammation
DMTJRLU ID DMTJRLU
DMTJRLU DN GNTI
DMTJRLU HS Preclinical
DMTJRLU SN G 3416; GNTI di-trifluoroacetate; Guanidinyl-naltrindole di-trifluoroacetate; 5'-Guanidinonaltrindole di(trifluoroacetate) salt hydrate; 5'-Guanidinylnaltrindole dihydrochloride
DMTJRLU CP University of Minneapolis
DMTJRLU DT Small molecular drug
DMTJRLU PC 9826034
DMTJRLU MW 471.5
DMTJRLU FM C27H29N5O3
DMTJRLU IC InChI=1S/C27H29N5O3/c28-25(29)30-15-4-5-18-16(10-15)17-11-27(34)20-9-14-3-6-19(33)23-21(14)26(27,24(35-23)22(17)31-18)7-8-32(20)12-13-1-2-13/h3-6,10,13,20,24,31,33-34H,1-2,7-9,11-12H2,(H4,28,29,30)/t20-,24+,26+,27-/m1/s1
DMTJRLU CS C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)C=CC(=C8)N=C(N)N
DMTJRLU IK VLNHDKDBGWXJEE-GYHUNEDQSA-N
DMTJRLU IU 2-[(1S,2S,13R,21R)-22-(cyclopropylmethyl)-2,16-dihydroxy-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5(10),6,8,15,17,19(25)-heptaen-7-yl]guanidine
DMTJRLU DE Obesity
DMNZA4L ID DMNZA4L
DMNZA4L DN Griffithsin
DMNZA4L HS Preclinical
DMNZA4L SN GRFT
DMNZA4L TC Antiviral Agents
DMNZA4L DT Protein/peptide drug
DMNZA4L SQ SLTHRKFGGSGGSPFSGLSSIAVRSGSYLDAIIIDGVHHGGSGGNLSPTFTFGSGEYISNMTIRSGDYINISFETNMGRRFGPTYGGSGGSANTLSNVKVIQINGSAGDYLDSLDIYYEQY
DMNZA4L DE Severe acute respiratory syndrome (SARS)
DM19T2V ID DM19T2V
DM19T2V DN GRL001
DM19T2V HS Preclinical
DM19T2V DT Small molecular drug
DM19T2V DE Coronavirus infection
DMVB1PD ID DMVB1PD
DMVB1PD DN GRL-001
DMVB1PD HS Preclinical
DMVB1PD SN CE-5
DMVB1PD TC Antiviral Agents
DMVB1PD DT Small molecular drug
DMVB1PD DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMX9AGF ID DMX9AGF
DMX9AGF DN GRL0617
DMX9AGF HS Preclinical
DMX9AGF SN 5-Amino-2-Methyl-N-[(1r)-1-Naphthalen-1-Ylethyl]benzamide; GRL-0617; 5-Amino-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide; 5-Amino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide; 5-Amino-2-methyl-N-(1R-naphthalen-1-yl-ethyl)-benzamide; CHEMBL549695; SCHEMBL1319181; BDBM31524; GTPL11078; CHEBI:167176; 5-amino-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide; EX-A4032; GRL 0617; s6845; ZINC43012570; AKOS015840255; AKOS015924263; DB08656; compound 25 [PMID: 19645480]; NCGC00188640-01; Naphthalene and Benzamide Derivative, 25; HY-117043; CS-0063568; Q27097846
DMX9AGF DT Small molecular drug
DMX9AGF PC 24941262
DMX9AGF MW 304.4
DMX9AGF FM C20H20N2O
DMX9AGF IC InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1
DMX9AGF CS CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32
DMX9AGF IK UVERBUNNCOKGNZ-CQSZACIVSA-N
DMX9AGF IU 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
DMX9AGF CB CHEBI:167176
DMX9AGF DE Coronavirus infection
DMNU3SI ID DMNU3SI
DMNU3SI DN GSK180
DMNU3SI HS Preclinical
DMNU3SI SN 1799725-26-0; CHEMBL4092205; 3-(5,6-dichloro-2-oxo-1,3-benzoxazol-3-yl)propanoic acid; 3-(5,6-Dichloro-2-Oxobenzo[d]oxazol-3(2h)-Yl)propanoic Acid; JHY; GTPL9007; SCHEMBL16836556; GSK-180; BCP33987; EX-A4035; GSK 180; GSK-180; BDBM50266036; SB19707; inhibitor A1 [PMID: 28604669]; HY-112179; CS-0043620; ClC=1C(=CC2=C(N(C(O2)=O)CCC(=O)O)C1)Cl; Q27077878
DMNU3SI CP GlaxoSmithKline
DMNU3SI DT Small molecular drug
DMNU3SI PC 105539874
DMNU3SI MW 276.07
DMNU3SI FM C10H7Cl2NO4
DMNU3SI IC InChI=1S/C10H7Cl2NO4/c11-5-3-7-8(4-6(5)12)17-10(16)13(7)2-1-9(14)15/h3-4H,1-2H2,(H,14,15)
DMNU3SI CS C1=C2C(=CC(=C1Cl)Cl)OC(=O)N2CCC(=O)O
DMNU3SI IK MIGAKMWKMLYGJX-UHFFFAOYSA-N
DMNU3SI IU 3-(5,6-dichloro-2-oxo-1,3-benzoxazol-3-yl)propanoic acid
DMNU3SI DE Neurodegenerative disorder; Pancreatitis
DM5AOI3 ID DM5AOI3
DM5AOI3 DN GSK2643943A
DM5AOI3 HS Preclinical
DM5AOI3 SN 2449301-27-1; EX-A4538; s6878; HY-111458; CS-0041056
DM5AOI3 CP GlaxoSmithKline
DM5AOI3 DT Small molecular drug
DM5AOI3 PC 137319705
DM5AOI3 MW 277.29
DM5AOI3 FM C17H12FN3
DM5AOI3 IC InChI=1S/C17H12FN3/c18-13-3-1-2-11(8-13)4-5-12-6-7-14-15(10-19)17(20)21-16(14)9-12/h1-9,21H,20H2/b5-4+
DM5AOI3 CS C1=CC(=CC(=C1)F)/C=C/C2=CC3=C(C=C2)C(=C(N3)N)C#N
DM5AOI3 IK CGXBPMZRTMXEIA-SNAWJCMRSA-N
DM5AOI3 IU 2-amino-6-[(E)-2-(3-fluorophenyl)ethenyl]-1H-indole-3-carbonitrile
DM5AOI3 DE Solid tumour/cancer
DMAZROV ID DMAZROV
DMAZROV DN GSK2807
DMAZROV HS Preclinical
DMAZROV SN GSK-2807 free base; 5'-{[(3s)-3-Amino-3-Carboxypropyl][3-(Dimethylamino)propyl]amino}-5'-Deoxyadenosine; 2245255-65-4 (free base); (S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(dimethylamino)propyl)amino)butanoic acid; 2245255-65-4; SCHEMBL19586501; EX-A2734; GSK-2807; Q27456186; 62X
DMAZROV DT Small molecular drug
DMAZROV PC 118797898
DMAZROV MW 452.5
DMAZROV FM C19H32N8O5
DMAZROV IC InChI=1S/C19H32N8O5/c1-25(2)5-3-6-26(7-4-11(20)19(30)31)8-12-14(28)15(29)18(32-12)27-10-24-13-16(21)22-9-23-17(13)27/h9-12,14-15,18,28-29H,3-8,20H2,1-2H3,(H,30,31)(H2,21,22,23)/t11-,12+,14+,15+,18+/m0/s1
DMAZROV CS CN(C)CCCN(CC[C@@H](C(=O)O)N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMAZROV IK FYXRZDCUJHGULY-URQYDQELSA-N
DMAZROV IU (2S)-2-amino-4-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-[3-(dimethylamino)propyl]amino]butanoic acid
DMAZROV DE Solid tumour/cancer
DMFJ0ZA ID DMFJ0ZA
DMFJ0ZA DN GSK-326416
DMFJ0ZA HS Preclinical
DMFJ0ZA CP GlaxoSmithKline
DMFJ0ZA DE Gastroparesis
DM04UGQ ID DM04UGQ
DM04UGQ DN GSK366
DM04UGQ HS Preclinical
DM04UGQ SN CHEMBL4081917; GSK 366; 1953157-39-5; (R)-3-(5-Chloro-6-(1-(6-methylpyridazin-3-yl)ethoxy)benzo[d]isoxazol-3-yl)propanoic acid; 3-[5-Chloranyl-6-[(1~{r})-1-(6-Methylpyridazin-3-Yl)ethoxy]-1,2-Benzoxazol-3-Yl]propanoic Acid; SCHEMBL17844503; EX-A4734; BDBM50266002; HY-119171; CS-0069358; ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)O[C@H](C)C=1N=NC(=CC=1)C; 8RB
DM04UGQ CP GlaxoSmithKline
DM04UGQ DT Small molecular drug
DM04UGQ PC 121415048
DM04UGQ MW 361.8
DM04UGQ FM C17H16ClN3O4
DM04UGQ IC InChI=1S/C17H16ClN3O4/c1-9-3-4-13(20-19-9)10(2)24-16-8-15-11(7-12(16)18)14(21-25-15)5-6-17(22)23/h3-4,7-8,10H,5-6H2,1-2H3,(H,22,23)/t10-/m1/s1
DM04UGQ CS CC1=NN=C(C=C1)[C@@H](C)OC2=C(C=C3C(=C2)ON=C3CCC(=O)O)Cl
DM04UGQ IK YWASLAPMFGBZQP-SNVBAGLBSA-N
DM04UGQ IU 3-[5-chloro-6-[(1R)-1-(6-methylpyridazin-3-yl)ethoxy]-1,2-benzoxazol-3-yl]propanoic acid
DM04UGQ DE Pancreatitis
DM1S5UO ID DM1S5UO
DM1S5UO DN GSK4112
DM1S5UO HS Preclinical
DM1S5UO SN SR6452; GSK-4112
DM1S5UO DT Small molecular drug
DM1S5UO PC 50905018
DM1S5UO MW 396.9
DM1S5UO FM C18H21ClN2O4S
DM1S5UO IC InChI=1S/C18H21ClN2O4S/c1-18(2,3)25-17(22)12-20(10-13-4-6-14(19)7-5-13)11-15-8-9-16(26-15)21(23)24/h4-9H,10-12H2,1-3H3
DM1S5UO CS CC(C)(C)OC(=O)CN(CC1=CC=C(C=C1)Cl)CC2=CC=C(S2)[N+](=O)[O-]
DM1S5UO IK WYSLOKHVFKLWOU-UHFFFAOYSA-N
DM1S5UO IU tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate
DM1S5UO DE Inflammation
DMNAT5V ID DMNAT5V
DMNAT5V DN GW-2592X
DMNAT5V HS Preclinical
DMNAT5V SN Azepanone inhibitors, GlaxoSmithKline; Cathepsin K inhibitors (bone disorder); Cathepsin K inhibitors, SmithKline Beecham; GW-2637X; GW-2934X; GW-9696X; SB-237632; SB-244875; SB-267320; SB-271194; SB-327537; SB-331750; SB-357114; SB-432238; SB-553484; Cathepsin K inhibitors (bone disorder), GlaxoSmithKline
DMNAT5V CP SmithKline Beecham Pharmaceuticals
DMNAT5V DE Bone disease; Osteoporosis
DM3PMAZ ID DM3PMAZ
DM3PMAZ DN GW-3333
DM3PMAZ HS Preclinical
DM3PMAZ SN SMZPWUUYPYYHIV-HNJRGHQBSA-N; GW3333; CHEMBL514958; UNII-54J77T5T74; 54J77T5T74; 212609-68-2; AC1Q5NWC; AC1L50QR; BIDD:PXR0031; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; SCHEMBL2875070; BDBM50247805; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide; GW3333; Gw 3333; N2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; 5-carboxymethylthio-3-(3'-chlorophenyl)-1,2,4-oxadiazol
DM3PMAZ CP GlaxoSmithKline
DM3PMAZ DT Small molecular drug
DM3PMAZ PC 216470
DM3PMAZ MW 420.5
DM3PMAZ FM C22H36N4O4
DM3PMAZ IC InChI=1S/C22H36N4O4/c1-7-16(6)19(22(29)24-18-10-8-9-11-23-18)25-21(28)17(12-14(2)3)20(15(4)5)26(30)13-27/h8-11,13-17,19-20,30H,7,12H2,1-6H3,(H,25,28)(H,23,24,29)/t16-,17+,19-,20-/m0/s1
DM3PMAZ CS CC[C@H](C)[C@@H](C(=O)NC1=CC=CC=N1)NC(=O)[C@H](CC(C)C)[C@H](C(C)C)N(C=O)O
DM3PMAZ IK SMZPWUUYPYYHIV-HNJRGHQBSA-N
DM3PMAZ IU (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide
DM3PMAZ CA CAS 212609-68-2
DM3PMAZ DE Chronic obstructive pulmonary disease
DMHUD27 ID DMHUD27
DMHUD27 DN GW-594884A
DMHUD27 HS Preclinical
DMHUD27 CP GSK
DMHUD27 DE Obesity
DM97RV4 ID DM97RV4
DM97RV4 DN GYKI-47261
DM97RV4 HS Preclinical
DM97RV4 SN GYKI 47261
DM97RV4 DT Small molecular drug
DM97RV4 PC 9927197
DM97RV4 MW 322.8
DM97RV4 FM C18H15ClN4
DM97RV4 IC InChI=1S/C18H15ClN4/c1-11-10-23-17(21-11)8-13-2-5-14(19)9-16(13)18(22-23)12-3-6-15(20)7-4-12/h2-7,9-10H,8,20H2,1H3
DM97RV4 CS CC1=CN2C(=N1)CC3=C(C=C(C=C3)Cl)C(=N2)C4=CC=C(C=C4)N
DM97RV4 IK FPXVCCSOTAQPIV-UHFFFAOYSA-N
DM97RV4 IU 4-(8-chloro-2-methyl-11H-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline
DM97RV4 CA CAS 220445-20-5
DM97RV4 DE Parkinson disease
DM6GSI1 ID DM6GSI1
DM6GSI1 DN HBX19818
DM6GSI1 HS Preclinical
DM6GSI1 SN HBX 19818; 1426944-49-1; CHEMBL2398213; 9-Chloro-5,6,7,8-tetrahydro-N-[3-[methyl(phenylmethyl)amino]propyl]-2-acridinecarboxamide; N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide; SCHEMBL20007093; BDBM50436150; HBX-19818; NCGC00378705-01; HY-17540; J3.502.626F
DM6GSI1 CP Hybrigenics
DM6GSI1 DT Small molecular drug
DM6GSI1 PC 73349008
DM6GSI1 MW 422
DM6GSI1 FM C25H28ClN3O
DM6GSI1 IC InChI=1S/C25H28ClN3O/c1-29(17-18-8-3-2-4-9-18)15-7-14-27-25(30)19-12-13-23-21(16-19)24(26)20-10-5-6-11-22(20)28-23/h2-4,8-9,12-13,16H,5-7,10-11,14-15,17H2,1H3,(H,27,30)
DM6GSI1 CS CN(CCCNC(=O)C1=CC2=C(C=C1)N=C3CCCCC3=C2Cl)CC4=CC=CC=C4
DM6GSI1 IK ZCALMLVWZSQGGR-UHFFFAOYSA-N
DM6GSI1 IU N-[3-[benzyl(methyl)amino]propyl]-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide
DM6GSI1 DE Solid tumour/cancer
DMPLZ7E ID DMPLZ7E
DMPLZ7E DN HC-Toxin
DMPLZ7E HS Preclinical
DMPLZ7E SN HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMPLZ7E TC Anticancer Agents
DMPLZ7E DT Small molecular drug
DMPLZ7E PC 107864
DMPLZ7E MW 436.5
DMPLZ7E FM C21H32N4O6
DMPLZ7E IC InChI=1S/C21H32N4O6/c1-12-18(27)22-13(2)19(28)24-14(7-4-3-5-9-16(26)17-11-31-17)21(30)25-10-6-8-15(25)20(29)23-12/h12-15,17H,3-11H2,1-2H3,(H,22,27)(H,23,29)(H,24,28)/t12-,13+,14-,15+,17?/m0/s1
DMPLZ7E CS C[C@@H]1C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)C)CCCCCC(=O)C3CO3
DMPLZ7E IK GNYCTMYOHGBSBI-KVUCBBCISA-N
DMPLZ7E IU (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMPLZ7E CB CHEBI:48028
DMPLZ7E DE Solid tumour/cancer
DMLZ5TQ ID DMLZ5TQ
DMLZ5TQ DN Hexamethylene amiloride
DMLZ5TQ HS Preclinical
DMLZ5TQ SN 5-(N,N-Hexamethylene)amiloride; 5-HMA; BIDD; BSPBio_003443; C12H18ClN7O; DivK1c_006875; HMA; HMA-5; Hexamethyleneamiloride; KBioGR_001206; KBioSS_002076; Lopac-A-9561; Lopac0_000104; MLS002153208; N,N-HEXAMETHYLENEAMILORIDE; SPECTRUM1504215; SpecPlus_000779; Spectrum2_001669; Spectrum3_001662; Spectrum4_000623; Spectrum5_001388; Spectrum_001596
DMLZ5TQ TC Antiviral Agents
DMLZ5TQ DT Small molecular drug
DMLZ5TQ PC 1794
DMLZ5TQ MW 311.77
DMLZ5TQ FM C12H18ClN7O
DMLZ5TQ IC InChI=1S/C12H18ClN7O/c13-8-10(20-5-3-1-2-4-6-20)18-9(14)7(17-8)11(21)19-12(15)16/h1-6H2,(H2,14,18)(H4,15,16,19,21)
DMLZ5TQ CS C1CCCN(CC1)C2=NC(=C(N=C2Cl)C(=O)N=C(N)N)N
DMLZ5TQ IK RQQJJXVETXFINY-UHFFFAOYSA-N
DMLZ5TQ IU 3-amino-5-(azepan-1-yl)-6-chloro-N-(diaminomethylidene)pyrazine-2-carboxamide
DMLZ5TQ CA CAS 1428-95-1
DMLZ5TQ CB CHEBI:76400
DMLZ5TQ DE Severe acute respiratory syndrome (SARS)
DMRE52S ID DMRE52S
DMRE52S DN HL-004
DMRE52S HS Preclinical
DMRE52S SN TS-962
DMRE52S CP Taisho Pharmaceutical Co Ltd
DMRE52S PC 6426883
DMRE52S MW 447.8
DMRE52S FM C28H49NOS
DMRE52S IC InChI=1S/C28H49NOS/c1-6-7-8-9-10-11-12-13-14-15-16-17-21-31-22-27(30)29-28-25(23(2)3)19-18-20-26(28)24(4)5/h18-20,23-24H,6-17,21-22H2,1-5H3,(H,29,30)
DMRE52S CS CCCCCCCCCCCCCCSCC(=O)NC1=C(C=CC=C1C(C)C)C(C)C
DMRE52S IK KRMKZDOWCOBWNU-UHFFFAOYSA-N
DMRE52S IU N-[2,6-di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide
DMRE52S DE Arteriosclerosis
DMBQDA3 ID DMBQDA3
DMBQDA3 DN Homocamptothecin
DMBQDA3 HS Preclinical
DMBQDA3 SN homocamptothecin; UNII-5B3LFU8GLM; 5B3LFU8GLM; E-Homocamptothecin; E-Homocamptothecine; (20R)-Homocamptothecin; E-Homocamptothecin, (R)-; CHEMBL74190; SCHEMBL5860320; PAEZRCINULFAGO-OAQYLSRUSA-N; ZINC840834; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5R)-; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (R)-
DMBQDA3 PC 10666346
DMBQDA3 MW 362.4
DMBQDA3 FM C21H18N2O4
DMBQDA3 IC InChI=1S/C21H18N2O4/c1-2-21(26)9-18(24)27-11-14-15(21)8-17-19-13(10-23(17)20(14)25)7-12-5-3-4-6-16(12)22-19/h3-8,26H,2,9-11H2,1H3/t21-/m1/s1
DMBQDA3 CS CCC1(CC(=O)OCC2=C1C=C3C4=NC5=CC=CC=C5C=C4CN3C2=O)O
DMBQDA3 IK PAEZRCINULFAGO-OAQYLSRUSA-N
DMBQDA3 IU (20R)-20-ethyl-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4,6,8,10,15(21)-heptaene-14,18-dione
DMBQDA3 CA CAS 186669-19-2
DMBQDA3 DE Cancer
DM69UZG ID DM69UZG
DM69UZG DN HPP-851
DM69UZG HS Preclinical
DM69UZG SN 11-beta HSD-1 (metabolic disorders), High Point; 11-beta HSD-1 (metabolic disorders), TransTech Pharma; 11-beta hydroxysteroid dehydrogenase-1 inhibitors (metabolic disorders), Novo Nordisk; 11-beta hydroxysteroid dehydrogenase-1 inhibitors (metabolic disorders), TransTech Pharma
DM69UZG CP Novo Nordisk A/S
DM69UZG DE Metabolic disorder
DMNF9P5 ID DMNF9P5
DMNF9P5 DN HR1P peptide
DMNF9P5 HS Preclinical
DMNF9P5 SN HR1P
DMNF9P5 TC Antiviral Agents
DMNF9P5 DT Protein/peptide drug
DMNF9P5 SQ ANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASE
DMNF9P5 DE Middle East Respiratory Syndrome (MERS)
DM6WC1Q ID DM6WC1Q
DM6WC1Q DN HR2P peptide
DM6WC1Q HS Preclinical
DM6WC1Q SN HR2P
DM6WC1Q TC Antiviral Agents
DM6WC1Q DT Protein/peptide drug
DM6WC1Q SQ SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL
DM6WC1Q DE Middle East Respiratory Syndrome (MERS)
DMSR96X ID DMSR96X
DMSR96X DN HR2P-M1 peptide
DMSR96X HS Preclinical
DMSR96X SN HR2P-M1
DMSR96X TC Antiviral Agents
DMSR96X DT Protein/peptide drug
DMSR96X SQ SLTQINTTLLDLEYEMRSLQQVVKALNESYIDLKEL
DMSR96X DE Middle East Respiratory Syndrome (MERS)
DM7X4SV ID DM7X4SV
DM7X4SV DN HR2P-M2 peptide
DM7X4SV HS Preclinical
DM7X4SV SN HR2P-M2
DM7X4SV TC Antiviral Agents
DM7X4SV DT Protein/peptide drug
DM7X4SV SQ SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL
DM7X4SV DE Middle East Respiratory Syndrome (MERS)
DMR8VJA ID DMR8VJA
DMR8VJA DN HSDB-41
DMR8VJA HS Preclinical
DMR8VJA SN Aceton; Aceton [German, Dutch, Polish]; Acetone (natural); Acetone; Acetone [NF]; Chevron acetone; Dimethyl formaldehyde; Dimethyl ketone; Dimethylformaldehyde; Dimethylketal; Ketone propane; Ketone, dimethyl; Ketone, dimethyl-; Methyl ketone; Pyroacetic acid; Pyroacetic ether; RCRA waste number U002; UN1090; acetone; beta-Ketopropane; dimethylketone; propan-2-one; propanone; .beta.-Ketopropane; 2-propanone; 67-64-1; CCRIS 5953; Caswell No. 004; EINECS 200-662-2; FEMA No. 3326; HSDB 41; MFCD00008765; NSC 135802; UNII-1364PS73AF
DMR8VJA PC 180
DMR8VJA MW 58.08
DMR8VJA FM C3H6O
DMR8VJA IC CSCPPACGZOOCGX-UHFFFAOYSA-N
DMR8VJA CS CC(=O)C
DMR8VJA IK 1S/C3H6O/c1-3(2)4/h1-2H3
DMR8VJA IU propan-2-one
DMR8VJA CA CAS 67-64-1
DMR8VJA CB CHEBI:15347
DMR8VJA DE Epilepsy
DMUAPNF ID DMUAPNF
DMUAPNF DN humanin
DMUAPNF HS Preclinical
DMUAPNF SN formyl humanin
DMUAPNF DT Small molecular drug
DMUAPNF PC 16131438
DMUAPNF MW 2687.2
DMUAPNF FM C119H204N34O32S2
DMUAPNF IC InChI=1S/C119H204N34O32S2/c1-19-65(14)92(112(180)144-81(54-90(160)161)104(172)145-82(52-63(10)11)115(183)153-46-29-37-87(153)110(178)149-91(64(12)13)111(179)139-72(32-23-24-41-120)97(165)136-74(35-27-44-130-119(126)127)98(166)135-73(34-26-43-129-118(124)125)96(164)133-67(16)116(184)185)150-99(167)75(38-39-89(158)159)137-106(174)84(57-155)147-113(181)93(68(17)156)151-105(173)79(51-62(8)9)142-101(169)77(49-60(4)5)140-100(168)76(48-59(2)3)141-102(170)78(50-61(6)7)143-108(176)85(58-186)148-107(175)83(56-154)146-103(171)80(53-69-30-21-20-22-31-69)134-88(157)55-131-95(163)71(33-25-42-128-117(122)123)138-109(177)86-36-28-45-152(86)114(182)66(15)132-94(162)70(121)40-47-187-18/h20-22,30-31,59-68,70-87,91-93,154-156,186H,19,23-29,32-58,120-121H2,1-18H3,(H,131,163)(H,132,162)(H,133,164)(H,134,157)(H,135,166)(H,136,165)(H,137,174)(H,138,177)(H,139,179)(H,140,168)(H,141,170)(H,142,169)(H,143,176)(H,144,180)(H,145,172)(H,146,171)(H,147,181)(H,148,175)(H,149,178)(H,150,167)(H,151,173)(H,158,159)(H,160,161)(H,184,185)(H4,122,123,128)(H4,124,125,129)(H4,126,127,130)/t65-,66-,67-,68+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,91-,92-,93-/m0/s1
DMUAPNF CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](CCSC)N
DMUAPNF IK DPEUWKZJZIPZKE-OFANTOPUSA-N
DMUAPNF IU (4S)-5-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-1-carboxyethyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMUAPNF CA CAS 330936-69-1
DMUAPNF DE Alzheimer disease
DM3NP4I ID DM3NP4I
DM3NP4I DN Huntingtin gene antisense
DM3NP4I HS Preclinical
DM3NP4I CP Alnylam Pharmaceuticals & Medtronic, Inc.
DM3NP4I TC Antisense
DM3NP4I DT Antisense drug
DM3NP4I DE Huntington disease
DM349AM ID DM349AM
DM349AM DN HY-N0040
DM349AM HS Preclinical
DM349AM SN Ginsenoside C; Ginsenoside Rb2; Ginsenoside-Rb2; (20S)-ginsenoside Rb2; 11021-13-9; 20-[(6-O-a-L-arabinopyranosyl-ss-D-glucopyranosyl)oxy]-12ss-hydroxydammar-24-en-3ss-yl 2-O-ss-D-glucopyranosyl-ss-D-glucopyranoside; CHEBI:77152; CHEMBL449303; EINECS 234-251-4; HY-N0040; N219O0L31C; NSC 308878; UNII-N219O0L31C; beta-D-Glucopyranoside, (3-beta,12-beta)-20-((6-O-alpha-L-arabinopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-
DM349AM PC 6917976
DM349AM MW 1079.3
DM349AM FM C53H90O22
DM349AM IC NODILNFGTFIURN-GZPRDHCNSA-N
DM349AM CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(CO8)O)O)O)O)O)O)C
DM349AM IK 1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-69-45-41(65)34(58)26(57)21-68-45)24-11-16-52(7)33(24)25(56)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)36(60)28(20-55)71-48)74-46-42(66)38(62)35(59)27(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26-,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-,46-,47-,48-,50-,51+,52+,53-/m0/s1
DM349AM IU (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM349AM CA CAS 11021-13-9
DM349AM CB CHEBI:77152
DM349AM DE Rotavirus gastroenteritis
DML4IAX ID DML4IAX
DML4IAX DN HY-N2258
DML4IAX HS Preclinical
DML4IAX SN Citrifolioside; Poncirin; Poncirin, analytical standard; SCHEMBL123069; SureCN123069; ZINC8234320; (2S)-poncirin; 14941-08-3; 8MUY4P95B4; AKOS037514792; CHEBI:66773; CHEMBL451050; CP0093; DTXSID00933642; EINECS 239-020-1; HY-N2258; Isosakuranetin 7-O-neohesperidoside; NLAWPKPYBMEWIR-SKYQDXIQSA-N; Isosakuranetin-7-O-beta-D-neohesperidoside; Isosakuranetin-7-O-neohesperidoside; NCGC00163611-01; UNII-8MUY4P95B4; s9165
DML4IAX PC 442456
DML4IAX MW 594.6
DML4IAX FM C28H34O14
DML4IAX IC NLAWPKPYBMEWIR-SKYQDXIQSA-N
DML4IAX CS CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)OC)O)CO)O)O)O)O)O
DML4IAX IK 1S/C28H34O14/c1-11-21(32)23(34)25(36)27(38-11)42-26-24(35)22(33)19(10-29)41-28(26)39-14-7-15(30)20-16(31)9-17(40-18(20)8-14)12-3-5-13(37-2)6-4-12/h3-8,11,17,19,21-30,32-36H,9-10H2,1-2H3/t11-,17-,19+,21-,22+,23+,24-,25+,26+,27-,28+/m0/s1
DML4IAX IU (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DML4IAX CA CAS 14941-08-3
DML4IAX CB CHEBI:66773
DML4IAX DE Anaesthesia
DMXB95R ID DMXB95R
DMXB95R DN IC261
DMXB95R HS Preclinical
DMXB95R SN IC-261; IC 261
DMXB95R DT Small molecular drug
DMXB95R PC 5288600
DMXB95R MW 311.3
DMXB95R FM C18H17NO4
DMXB95R IC InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)/b13-10+
DMXB95R CS COC1=CC(=C(C(=C1)OC)/C=C/2\\C3=CC=CC=C3NC2=O)OC
DMXB95R IK JBJYTZXCZDNOJW-JLHYYAGUSA-N
DMXB95R IU (3E)-3-[(2,4,6-trimethoxyphenyl)methylidene]-1H-indol-2-one
DMXB95R DE Pancreatic cancer
DM1RZVI ID DM1RZVI
DM1RZVI DN ICA-69673
DM1RZVI HS Preclinical
DM1RZVI SN ICA-069673; Ion channel modulators (epilepsy), ICAgen; Ion channel modulators, ICAgen/ArQule
DM1RZVI CP Icagen Inc
DM1RZVI PC 10149311
DM1RZVI MW 269.63
DM1RZVI FM C11H6ClF2N3O
DM1RZVI IC InChI=1S/C11H6ClF2N3O/c12-11-15-4-7(5-16-11)17-10(18)6-1-2-8(13)9(14)3-6/h1-5H,(H,17,18)
DM1RZVI CS C1=CC(=C(C=C1C(=O)NC2=CN=C(N=C2)Cl)F)F
DM1RZVI IK IIBSHMFXVWTQSJ-UHFFFAOYSA-N
DM1RZVI IU N-(2-chloropyrimidin-5-yl)-3,4-difluorobenzamide
DM1RZVI CA CAS 582323-16-8
DM1RZVI DE Pain
DMIYSD4 ID DMIYSD4
DMIYSD4 DN IDDB-41331
DMIYSD4 HS Preclinical
DMIYSD4 CP Amgen
DMIYSD4 DE Obesity
DMQ3BXV ID DMQ3BXV
DMQ3BXV DN IDDBCP-150101
DMQ3BXV HS Preclinical
DMQ3BXV CP Amgen
DMQ3BXV DE Sexual dysfunction; Obesity
DMRIMZL ID DMRIMZL
DMRIMZL DN IDX136
DMRIMZL HS Preclinical
DMRIMZL CP Idenix
DMRIMZL DE Hepatitis C virus infection
DMXN2ZQ ID DMXN2ZQ
DMXN2ZQ DN IMO-2134
DMXN2ZQ HS Preclinical
DMXN2ZQ CP Idera Pharmaceuticals
DMXN2ZQ DE Allergy; Asthma
DMV5KSA ID DMV5KSA
DMV5KSA DN IMX-942
DMV5KSA HS Preclinical
DMV5KSA SN IDR-1; IMX-001; IMX-502; IMX-502001; IMX-503; IMX-602; IMX-602001; IMX-606; IMX-606001; IMX-735; IMX-775; Innate immune system upregulators, Inimex; Innate defense-regulatory peptides (infection), Ininmex
DMV5KSA CP Inimex Pharmaceuticals Inc
DMV5KSA DE Mucositis
DMXJO20 ID DMXJO20
DMXJO20 DN Indol-3-carbinol
DMXJO20 HS Preclinical
DMXJO20 SN Pinusolide; 31685-80-0; CHEBI:69237; 1-Naphthalenecarboxylicacid,5-[2-(2,5-dihydro-2-oxo-3-furanyl)ethyl]decahydro-1,4a-dimethyl-6-methylene-,methyl ester, (1S,4aR,5S,8aR)-; AC1L4PYK; CHEMBL425068; CTK4G7584; MolPort-039-052-550; ZINC6067611; AKOS032948704; methyl (1S,4aR,5S,8aR)-1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylate; 1-Naphthalenecarboxylic acid, 5-(2-(2,5-dihydro-2-oxo-3-furanyl)ethyl)decahydro-1,4a-dimethyl-6-methylene-, methyl ester,
DMXJO20 TC Antifungal Agents
DMXJO20 DT Small molecular drug
DMXJO20 PC 161721
DMXJO20 MW 346.5
DMXJO20 FM C21H30O4
DMXJO20 IC InChI=1S/C21H30O4/c1-14-6-9-17-20(2,11-5-12-21(17,3)19(23)24-4)16(14)8-7-15-10-13-25-18(15)22/h10,16-17H,1,5-9,11-13H2,2-4H3/t16-,17+,20+,21-/m0/s1
DMXJO20 CS C[C@]12CCC[C@]([C@@H]1CCC(=C)[C@@H]2CCC3=CCOC3=O)(C)C(=O)OC
DMXJO20 IK WTKBZJAWPZXKJU-NLEAXPPASA-N
DMXJO20 IU methyl (1S,4aR,5S,8aR)-1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylate
DMXJO20 CA CAS 31685-80-0
DMXJO20 CB CHEBI:69237
DMXJO20 DE Fungal infection
DMBQGZ9 ID DMBQGZ9
DMBQGZ9 DN INOC-005
DMBQGZ9 HS Preclinical
DMBQGZ9 SN Capridine beta (prostate cancer), Prostagenics
DMBQGZ9 CP Prostagenics LLC
DMBQGZ9 DE Solid tumour/cancer
DMRJ9P4 ID DMRJ9P4
DMRJ9P4 DN INT-767
DMRJ9P4 HS Preclinical
DMRJ9P4 SN INT-767 sodium; 1000403-03-1 (sodium); 1000403-03-1; sodium (R)-3-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)butyl sulfate; CS-5007; HY-12434; Sulfuric acid sodium 3alpha,7alpha-dihydroxy-6alpha-ethyl-24-nor-5beta-cholane-23-yl ester salt
DMRJ9P4 CP Intercept
DMRJ9P4 DT Small molecular drug
DMRJ9P4 PC 23712772
DMRJ9P4 MW 494.7
DMRJ9P4 FM C25H43NaO6S
DMRJ9P4 IC InChI=1S/C25H44O6S.Na/c1-5-17-21-14-16(26)8-11-25(21,4)20-9-12-24(3)18(6-7-19(24)22(20)23(17)27)15(2)10-13-31-32(28,29)30;/h15-23,26-27H,5-14H2,1-4H3,(H,28,29,30);/q;+1/p-1/t15-,16-,17-,18-,19+,20+,21+,22+,23-,24-,25-;/m1./s1
DMRJ9P4 CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCOS(=O)(=O)[O-])C)C)O.[Na+]
DMRJ9P4 IK TXIWHUPIUUZFFK-PMWRKVJASA-M
DMRJ9P4 IU sodium;[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl] sulfate
DMRJ9P4 DE Hepatic fibrosis
DMMUVAF ID DMMUVAF
DMMUVAF DN IRX-4
DMMUVAF HS Preclinical
DMMUVAF SN IRX-2 + tumor-specific antigen (cancer), IRx Therapeutics
DMMUVAF CP IRX Therapeutics Inc
DMMUVAF DE Prostate cancer
DMJ0A2R ID DMJ0A2R
DMJ0A2R DN IU1
DMJ0A2R HS Preclinical
DMJ0A2R SN 314245-33-5; 1-[1-(4-Fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(1-pyrrolidinyl)ethanone; 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one; IU-1; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethanone; CHEMBL1410015; MFCD01917473; 1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(pyrrolidin-1-yl)ethan-1-one; 1-[1-(4-Fluoro-phenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-pyrrolidin-1-yl-ethanone; Usp14 inhibitor; MLS001032847; GTPL8880; SCHEMBL6923146; ZINC38235; DTXSID80350196; HMS1726C11; HMS2742M13; HMS3653I09; HMS3743A07; AMY24153; BCP12722; EX-A2079; 2486AH; BDBM50437694; s7134; AKOS000811299; IU1, >=98% (HPLC); CCG-190730; CS-7546; MCULE-9620933012; NE48827; QC-8208; SB19054; NCGC00249377-01; NCGC00249377-04; NCGC00249377-08; AC-32694; DA-33458; HY-13817; SMR000363441; ST054127; AB0097167; FT-0716455; MLS001032847-02; SW219677-1; EN300-72884; SR-01000010584; J-018415; SR-01000010584-1; Z55133506; F1142-1244; 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidinylethan-1-one; 1-[1-(4-FLUOROPHENYL)-2,5-DIMETHYLPYRROL-3-YL]-2-(PYRROLIDIN-1-YL)ETHANONE
DMJ0A2R CP Proteostasis Therapeutics
DMJ0A2R DT Small molecular drug
DMJ0A2R PC 675434
DMJ0A2R MW 300.4
DMJ0A2R FM C18H21FN2O
DMJ0A2R IC InChI=1S/C18H21FN2O/c1-13-11-17(18(22)12-20-9-3-4-10-20)14(2)21(13)16-7-5-15(19)6-8-16/h5-8,11H,3-4,9-10,12H2,1-2H3
DMJ0A2R CS CC1=CC(=C(N1C2=CC=C(C=C2)F)C)C(=O)CN3CCCC3
DMJ0A2R IK JUWDSDKJBMFLHE-UHFFFAOYSA-N
DMJ0A2R IU 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone
DMJ0A2R CA CAS 314245-33-5
DMJ0A2R DE Neurodegenerative disorder
DMTGI64 ID DMTGI64
DMTGI64 DN JD-5037
DMTGI64 HS Preclinical
DMTGI64 CP Jenrin Discovery Inc.
DMTGI64 PC 66553204
DMTGI64 MW 572.5
DMTGI64 FM C27H27Cl2N5O3S
DMTGI64 IC InChI=1S/C27H27Cl2N5O3S/c1-17(2)24(26(30)35)31-27(33-38(36,37)22-14-12-21(29)13-15-22)34-16-23(18-6-4-3-5-7-18)25(32-34)19-8-10-20(28)11-9-19/h3-15,17,23-24H,16H2,1-2H3,(H2,30,35)(H,31,33)/t23-,24+/m1/s1
DMTGI64 CS CC(C)[C@@H](C(=O)N)N=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
DMTGI64 IK GTCSIQFTNPTSLO-RPWUZVMVSA-N
DMTGI64 IU (2S)-2-[[[(4S)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-[(4-chlorophenyl)sulfonylamino]methylidene]amino]-3-methylbutanamide
DMTGI64 CA CAS 1392116-14-1
DMTGI64 DE Diabetic complication; Obesity
DMSXOPE ID DMSXOPE
DMSXOPE DN JNJ-26070109
DMSXOPE HS Preclinical
DMSXOPE SN CCK2 receptor antagonists, (oral, cancer); CCK2 receptor antagonists, (oral, cancer),Johnson & Johnson Pharmaceutical Research & Development
DMSXOPE CP Johnson & Johnson Pharmaceutical Research & Development LLC
DMSXOPE DT Small molecular drug
DMSXOPE PC 11307323
DMSXOPE MW 547.4
DMSXOPE FM C23H17BrF2N4O3S
DMSXOPE IC InChI=1S/C23H17BrF2N4O3S/c1-13(16-8-6-15(25)12-18(16)26)29-23(31)17-7-5-14(24)11-20(17)30-34(32,33)21-4-2-3-19-22(21)28-10-9-27-19/h2-13,30H,1H3,(H,29,31)/t13-/m1/s1
DMSXOPE CS C[C@H](C1=C(C=C(C=C1)F)F)NC(=O)C2=C(C=C(C=C2)Br)NS(=O)(=O)C3=CC=CC4=NC=CN=C43
DMSXOPE IK TZKCPFFVWLRNRZ-CYBMUJFWSA-N
DMSXOPE IU 4-bromo-N-[(1R)-1-(2,4-difluorophenyl)ethyl]-2-(quinoxalin-5-ylsulfonylamino)benzamide
DMSXOPE DE Gastroesophageal reflux disease
DMCNBHY ID DMCNBHY
DMCNBHY DN JNJ-42905343
DMCNBHY HS Preclinical
DMCNBHY CP Janssen
DMCNBHY DT Small molecular drug
DMCNBHY DE Anaemia; Iron deficiency
DMHBWOP ID DMHBWOP
DMHBWOP DN JT07
DMHBWOP HS Preclinical
DMHBWOP CP Jyant Technologies
DMHBWOP DT Antibody
DMHBWOP DE Solid tumour/cancer
DM8OAZ6 ID DM8OAZ6
DM8OAZ6 DN JT08
DM8OAZ6 HS Preclinical
DM8OAZ6 CP Jyant Technologies
DM8OAZ6 DT Antibody
DM8OAZ6 DE Solid tumour/cancer
DM86YBK ID DM86YBK
DM86YBK DN K11777
DM86YBK HS Preclinical
DM86YBK SN N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl
DM86YBK TC Antiviral Agents
DM86YBK DT Small molecular drug
DM86YBK DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMIQXEP ID DMIQXEP
DMIQXEP DN KD-3020
DMIQXEP HS Preclinical
DMIQXEP CP Kalypsys
DMIQXEP DE Non-alcoholic fatty liver disease
DML93TN ID DML93TN
DML93TN DN Kestose
DML93TN HS Preclinical
DML93TN SN Kestose; Kestose, 6-; Q27133478; (Fruf)2 (Glc)1; 562-68-5; 6-Kestose; 6-kestotriose; AAE9A8CC-2223-4E2E-84C7-100A261F8834; Beta-D-Fructofuranosyl-(2->6)-Beta-D-Fructofuranosyl Alpha-D-Glucopyranoside; CHEBI:64833; EINECS 209-232-9; G7AZF7CGY8; O-beta-D-Fructofuranosyl-(2.6)-beta-D-fructofuranosyl-alpha-D-glucopyranoside; UNII-19B0LEI158 component ODEHMIGXGLNAKK-OESPXIITSA-N; UNII-G7AZF7CGY8; UNII-YUH1C99228 component ODEHMIGXGLNAKK-OESPXIITSA-N
DML93TN PC 9914062
DML93TN MW 504.4
DML93TN FM C18H32O16
DML93TN IC ODEHMIGXGLNAKK-OESPXIITSA-N
DML93TN CS C(C1C(C(C(C(O1)OC2(C(C(C(O2)COC3(C(C(C(O3)CO)O)O)CO)O)O)CO)O)O)O)O
DML93TN IK 1S/C18H32O16/c19-1-6-9(23)12(26)13(27)16(31-6)34-18(5-22)15(29)11(25)8(33-18)3-30-17(4-21)14(28)10(24)7(2-20)32-17/h6-16,19-29H,1-5H2/t6-,7-,8-,9-,10-,11-,12+,13-,14+,15+,16-,17-,18+/m1/s1
DML93TN IU (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-5-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DML93TN CA CAS 562-68-5
DML93TN CB CHEBI:64833
DML93TN DE Atopic dermatitis
DMHX1LA ID DMHX1LA
DMHX1LA DN KL001
DMHX1LA HS Preclinical
DMHX1LA SN 309928-48-1; N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; SMR000106264; MLS000110334; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; KL-001; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-[(furan-2-yl)methyl]methanesulfonamide; N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(furan-2-ylmethyl)methanesulfonamide; CBMicro_005790; ChemDiv2_003790; Oprea1_152161; Oprea1_419357; MLS002540427; MLS006011739; CHEMBL1498001; SCHEMBL15380452; BDBM56256; cid_2888648; HMS1379M06; HMS2371E17; SMSF0015860; STK839587; AKOS000581142; AKOS016386481; CB08282; MCULE-8116422943; IDI1_002505; NCGC00079434-02; NCGC00079434-03; NCGC00079434-06; BIM-0006034.P001; KL001(KL-001;KL 001); EU-0005302; ST50257205; 10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; doi:10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; SR-01000436091; SR-01000436091-1; BRD-A94580299-001-08-8; F1345-0456; (3-carbazol-9-yl-2-hydroxypropyl)(2-furylmethyl)(methylsulfonyl)amine; N-(3-carbazol-9-yl-2-hydroxy-propyl)-N-(2-furfuryl)methanesulfonamide; N-[3-(9-carbazolyl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-oxidanyl-propyl)-N-(furan-2-ylmethyl)methanesulfonamide
DMHX1LA DT Small molecular drug
DMHX1LA PC 2888648
DMHX1LA MW 398.5
DMHX1LA FM C21H22N2O4S
DMHX1LA IC InChI=1S/C21H22N2O4S/c1-28(25,26)22(15-17-7-6-12-27-17)13-16(24)14-23-20-10-4-2-8-18(20)19-9-3-5-11-21(19)23/h2-12,16,24H,13-15H2,1H3
DMHX1LA CS CS(=O)(=O)N(CC1=CC=CO1)CC(CN2C3=CC=CC=C3C4=CC=CC=C42)O
DMHX1LA IK OQAFDLPAPSSOHY-UHFFFAOYSA-N
DMHX1LA IU N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide
DMHX1LA DE Glioblastoma of brain
DMFLIC0 ID DMFLIC0
DMFLIC0 DN KOS-1803
DMFLIC0 HS Preclinical
DMFLIC0 SN Isoxazole-fludelone; SK-10105; Third generation epothilone (cancer), Bristol-Myers Squibb; Third generation epothilone (cancer),Kosan/Roche; 9,10-didehydro-26-trifluoro-isoazole-epothilone D
DMFLIC0 CP Memorial Sloan-Kettering Cancer Center
DMFLIC0 PC 10436928
DMFLIC0 MW 527.6
DMFLIC0 FM C27H36F3NO6
DMFLIC0 IC InChI=1S/C27H36F3NO6/c1-15-8-7-9-19(27(28,29)30)10-11-21(16(2)12-20-13-17(3)37-31-20)36-23(33)14-22(32)26(5,6)25(35)18(4)24(15)34/h7-8,10,12-13,15,18,21-22,24,32,34H,9,11,14H2,1-6H3/b8-7+,16-12+,19-10+/t15-,18+,21-,22-,24-/m0/s1
DMFLIC0 CS C[C@H]1/C=C/C/C(=C\\C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C2=NOC(=C2)C)/C)/C(F)(F)F
DMFLIC0 IK DNCHSYUWCVTLJJ-PHNYORQKSA-N
DMFLIC0 IU (4S,7R,8S,9S,10E,13E,16S)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(E)-1-(5-methyl-1,2-oxazol-3-yl)prop-1-en-2-yl]-13-(trifluoromethyl)-1-oxacyclohexadeca-10,13-diene-2,6-dione
DMFLIC0 DE Solid tumour/cancer
DMCGFY6 ID DMCGFY6
DMCGFY6 DN KOS-1815
DMCGFY6 HS Preclinical
DMCGFY6 SN CRM1 and nuclear export inhibitors (cancer); KOS-2385; KOS-2464; CRM1 and nuclear export inhibitors (cancer), Kosan
DMCGFY6 CP Kosan Biosciences Inc
DMCGFY6 DE Solid tumour/cancer
DMXY81K ID DMXY81K
DMXY81K DN KOS-2484
DMXY81K HS Preclinical
DMXY81K SN KOS-2539; KOS-2540; HSP90 inhibitors (cancer), Kosan
DMXY81K CP Kosan Biosciences Inc
DMXY81K DE Solid tumour/cancer
DMZCW3J ID DMZCW3J
DMZCW3J DN KP3
DMZCW3J HS Preclinical
DMZCW3J DT Antibody
DMZCW3J DE Pneumonia due to Klebsiella pneumoniae
DMMEH12 ID DMMEH12
DMMEH12 DN L-006235-1
DMMEH12 HS Preclinical
DMMEH12 SN 294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; L-006235-1; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235
DMMEH12 DT Small molecular drug
DMMEH12 PC 9912381
DMMEH12 MW 466.6
DMMEH12 FM C24H30N6O2S
DMMEH12 IC InChI=1S/C24H30N6O2S/c1-29-13-15-30(16-14-29)23-27-20(17-33-23)18-5-7-19(8-6-18)21(31)28-24(9-3-2-4-10-24)22(32)26-12-11-25/h5-8,17H,2-4,9-10,12-16H2,1H3,(H,26,32)(H,28,31)
DMMEH12 CS CN1CCN(CC1)C2=NC(=CS2)C3=CC=C(C=C3)C(=O)NC4(CCCCC4)C(=O)NCC#N
DMMEH12 IK FIVYCSWOCXEWSE-UHFFFAOYSA-N
DMMEH12 IU N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzamide
DMMEH12 CA CAS 294623-49-7
DMMEH12 DE Osteoarthritis
DMK3TXY ID DMK3TXY
DMK3TXY DN L-742791
DMK3TXY HS Preclinical
DMK3TXY SN CHEMBL276257; SCHEMBL289708; L-742791; GTPL3467; compound 3 [PMID:9873496]; BDBM50070152; L742791; L 742791; L-742,791; N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide
DMK3TXY CP Merck
DMK3TXY DT Small molecular drug
DMK3TXY PC 16118894
DMK3TXY MW 568.4
DMK3TXY FM C23H25IN2O5S
DMK3TXY IC InChI=1S/C23H25IN2O5S/c24-18-3-11-23(12-4-18)32(29,30)26-19-5-1-17(2-6-19)13-14-25-15-21(28)16-31-22-9-7-20(27)8-10-22/h1-12,21,25-28H,13-16H2/t21-/m0/s1
DMK3TXY CS C1=CC(=CC=C1CCNC[C@@H](COC2=CC=C(C=C2)O)O)NS(=O)(=O)C3=CC=C(C=C3)I
DMK3TXY IK ZNTDIRUBXSTBGJ-NRFANRHFSA-N
DMK3TXY IU N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide
DMK3TXY DE Obesity
DMOERXK ID DMOERXK
DMOERXK DN L-751250
DMOERXK HS Preclinical
DMOERXK SN Purvalanol B; 212844-54-7; PURVALANOL; Purvalanol B(NG-95); (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG 95; NG-95; C20H25ClN6O3; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; J-502183; PVB
DMOERXK CP Merck
DMOERXK DT Small molecular drug
DMOERXK PC 448991
DMOERXK MW 432.9
DMOERXK FM C20H25ClN6O3
DMOERXK IC InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)/t15-/m0/s1
DMOERXK CS CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=C(C=C3)C(=O)O)Cl
DMOERXK IK ZKDXRFMOHZVXSG-HNNXBMFYSA-N
DMOERXK IU 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid
DMOERXK CA CAS 212844-54-7
DMOERXK CB CHEBI:49840
DMOERXK DE Obesity
DMFBMXD ID DMFBMXD
DMFBMXD DN LAS-101057
DMFBMXD HS Preclinical
DMFBMXD SN LAS-38096; Adenosine A2b receptor antagonists (inflammation), Almirall
DMFBMXD CP Almirall Prodesfarma SA
DMFBMXD DT Small molecular drug
DMFBMXD PC 11716665
DMFBMXD MW 316.32
DMFBMXD FM C17H12N6O
DMFBMXD IC InChI=1S/C17H12N6O/c1-3-12(9-18-6-1)22-17-20-10-13(14-5-7-19-11-21-14)16(23-17)15-4-2-8-24-15/h1-11H,(H,20,22,23)
DMFBMXD CS C1=CC(=CN=C1)NC2=NC=C(C(=N2)C3=CC=CO3)C4=NC=NC=C4
DMFBMXD IK YRPIMMMBNUUYLG-UHFFFAOYSA-N
DMFBMXD IU 4-(furan-2-yl)-N-pyridin-3-yl-5-pyrimidin-4-ylpyrimidin-2-amine
DMFBMXD CA CAS 851371-22-7
DMFBMXD DE Asthma
DM1982I ID DM1982I
DM1982I DN LDN-57444
DM1982I HS Preclinical
DM1982I SN 668467-91-2; CHEMBL3407553; LDN 57444; (Z)-3-(acetoxyimino)-5-chloro-1-(2,5-dichlorobenzyl)indolin-2-one; C17H11Cl3N2O3; LDN57444; Ubiquitin Thiolesterase L1 Inhibitor; Ubiquitin C-Terminal Esterase L1 Inhibitor; Ubiquitin C-Terminal Hydrolase L1 Inhibitor; SCHEMBL16249746; BDBM65518; AOB1095; EX-A700; 5-Chloro-1-[(2,5-dichlorophenyl)methyl]-1H-indole-2,3-dione 3-(O-acetyloxime); 2511AH; BDBM50514120; MFCD09037562; ZINC83434034; AKOS025295611; CS-3923; 3-(O-acetyloxime), 5-chloro-1-[(2,5-dichlorophenyl)methyl]-1H-Indole-2,3-dione; NCGC00247668-01; AC-32696; AS-56100; HY-18637; SW219408-1; LDN-57444, >=98% (HPLC); [(E)-[5-Chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate
DM1982I CP Brigham and Women's Hospital
DM1982I DT Small molecular drug
DM1982I PC 16760696
DM1982I MW 397.6
DM1982I FM C17H11Cl3N2O3
DM1982I IC InChI=1S/C17H11Cl3N2O3/c1-9(23)25-21-16-13-7-12(19)3-5-15(13)22(17(16)24)8-10-6-11(18)2-4-14(10)20/h2-7H,8H2,1H3/b21-16-
DM1982I CS CC(=O)O/N=C\\1/C2=C(C=CC(=C2)Cl)N(C1=O)CC3=C(C=CC(=C3)Cl)Cl
DM1982I IK OPQRFPHLZZPCCH-PGMHBOJBSA-N
DM1982I IU [(Z)-[5-chloro-1-[(2,5-dichlorophenyl)methyl]-2-oxoindol-3-ylidene]amino] acetate
DM1982I DE Solid tumour/cancer
DMGJL16 ID DMGJL16
DMGJL16 DN LE-300
DMGJL16 HS Preclinical
DMGJL16 SN L 8401; LE 300; 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine
DMGJL16 CP Sanofi-Aventis
DMGJL16 DT Small molecular drug
DMGJL16 PC 4350931
DMGJL16 MW 290.4
DMGJL16 FM C20H22N2
DMGJL16 IC InChI=1S/C20H22N2/c1-22-12-10-15-6-2-3-7-16(15)14-20-18(11-13-22)17-8-4-5-9-19(17)21-20/h2-9,21H,10-14H2,1H3
DMGJL16 CS CN1CCC2=CC=CC=C2CC3=C(CC1)C4=CC=CC=C4N3
DMGJL16 IK YEWGIGCYIAMFMA-UHFFFAOYSA-N
DMGJL16 IU 11-methyl-11,21-diazatetracyclo[12.7.0.03,8.015,20]henicosa-1(14),3,5,7,15,17,19-heptaene
DMGJL16 CA CAS 274694-98-3
DMGJL16 CB CHEBI:92030
DMGJL16 DE Schizophrenia
DMJXZIS ID DMJXZIS
DMJXZIS DN LH846
DMJXZIS HS Preclinical
DMJXZIS SN 639052-78-1; LH-846; LH 846; N-(5-chloro-6-methyl-1,3-benzothiazol-2-yl)-2-phenylacetamide; N-(5-Chloro-6-methyl-2-benzothiazolyl)benzeneacetamide; Benzeneacetamide, N-(5-chloro-6-methyl-2-benzothiazolyl)-; N-(5-chloro-6-methylbenzo[d]thiazol-2-yl)-2-phenylacetamide; N-(5-Chloro-6-methyl-benzothiazol-2-yl)-2-phenyl-acetamide; Oprea1_693221; CHEMBL4303305; SCHEMBL18921565; AOB3510; ZINC386312; BCP09669; EX-A2092; 3782AH; MFCD03786038; STK241276; AKOS000461714; CCG-357108; CS-1810; MCULE-4592612500; NCGC00371143-05; AK205552; AS-55880; DA-33437; HY-15704; FT-0768032; ST51028673; AP-970/41681903; N-(5-chloro-6-methylbenzothiazol-2-yl)-2-phenylacetamide
DMJXZIS DT Small molecular drug
DMJXZIS PC 851474
DMJXZIS MW 316.8
DMJXZIS FM C16H13ClN2OS
DMJXZIS IC InChI=1S/C16H13ClN2OS/c1-10-7-14-13(9-12(10)17)18-16(21-14)19-15(20)8-11-5-3-2-4-6-11/h2-7,9H,8H2,1H3,(H,18,19,20)
DMJXZIS CS CC1=CC2=C(C=C1Cl)N=C(S2)NC(=O)CC3=CC=CC=C3
DMJXZIS IK DYHAMRNAHTWYKY-UHFFFAOYSA-N
DMJXZIS IU N-(5-chloro-6-methyl-1,3-benzothiazol-2-yl)-2-phenylacetamide
DMJXZIS DE Mood disorder
DMNOE1M ID DMNOE1M
DMNOE1M DN LLY-507
DMNOE1M HS Preclinical
DMNOE1M SN LLY-507; 1793053-37-8; LLY507; CHEMBL3414623; 5-Cyano-2'-{4-[2-(3-Methyl-1h-Indol-1-Yl)ethyl]piperazin-1-Yl}-N-[3-(Pyrrolidin-1-Yl)propyl]biphenyl-3-Carboxamide; 3-cyano-5-(2-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}phenyl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide; 3-Cyano-5-[2-[4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide; GTPL8239; SCHEMBL19760400; EX-A899; LLY 507; MolPort-042-624-530; BCP17114; s7575; BDBM50075102; ZINC231558920; AKOS027470175; CS-5126
DMNOE1M DT Small molecular drug
DMNOE1M PC 91623361
DMNOE1M MW 574.8
DMNOE1M FM C36H42N6O
DMNOE1M IC InChI=1S/C36H42N6O/c1-28-27-42(34-11-4-2-9-32(28)34)22-19-40-17-20-41(21-18-40)35-12-5-3-10-33(35)30-23-29(26-37)24-31(25-30)36(43)38-13-8-16-39-14-6-7-15-39/h2-5,9-12,23-25,27H,6-8,13-22H2,1H3,(H,38,43)
DMNOE1M CS CC1=CN(C2=CC=CC=C12)CCN3CCN(CC3)C4=CC=CC=C4C5=CC(=CC(=C5)C#N)C(=O)NCCCN6CCCC6
DMNOE1M IK PNYRDVBFYVDJJI-UHFFFAOYSA-N
DMNOE1M IU 3-cyano-5-[2-[4-[2-(3-methylindol-1-yl)ethyl]piperazin-1-yl]phenyl]-N-(3-pyrrolidin-1-ylpropyl)benzamide
DMNOE1M DE Solid tumour/cancer
DMXYDMP ID DMXYDMP
DMXYDMP DN LM10
DMXYDMP HS Preclinical
DMXYDMP SN 1316695-35-8; (E)-3-(2-(1H-TETRAZOL-5-YL)VINYL)-6-FLUORO-1H-INDOLE; CHEMBL1812545; LM-10; 6-fluoro-3-[(E)-2-(1H-1,2,3,4-tetrazol-5-yl)ethenyl]-1H-indole; 6-Fluoro-3-[(1E)-2-(2H-tetrazol-5-yl)ethenyl]-1H-indole; 1H-Indole, 6-fluoro-3-[(1E)-2-(2H-tetrazol-5-yl)ethenyl]-; LM 10; GTPL9016; SCHEMBL16820602; SCHEMBL16820603; BDBM311862; CS-D0342; BDBM50350248; MFCD26097257; s8368; US10155972, Compound LM10; ZINC72108665; AKOS024464444; CCG-266788; AS-30527; Q27081058
DMXYDMP DT Small molecular drug
DMXYDMP PC 135743630
DMXYDMP MW 229.21
DMXYDMP FM C11H8FN5
DMXYDMP IC InChI=1S/C11H8FN5/c12-8-2-3-9-7(6-13-10(9)5-8)1-4-11-14-16-17-15-11/h1-6,13H,(H,14,15,16,17)/b4-1+
DMXYDMP CS C1=CC2=C(C=C1F)NC=C2/C=C/C3=NNN=N3
DMXYDMP IK JDBSZVDIUIRSDG-DAFODLJHSA-N
DMXYDMP IU 6-fluoro-3-[(E)-2-(2H-tetrazol-5-yl)ethenyl]-1H-indole
DMXYDMP DE Solid tumour/cancer
DMNIWF5 ID DMNIWF5
DMNIWF5 DN Lopinavir
DMNIWF5 HS Preclinical
DMNIWF5 SN AIDS032937; Aluvia (TN); Aluviran; Kaletra (TN); Koletra; LPV; Lopinavir (JAN/USAN/INN); Lopinavir [USAN:INN:BAN]; RS-346; A 157378; A 157378.0; A-157378-0; A-157378.0; ABT 157378; ABT 378; ABT-378; ABT-378
DMNIWF5 CP Abbott Laboratories
DMNIWF5 TC Antiviral Agents
DMNIWF5 DT Small molecular drug
DMNIWF5 PC 92727
DMNIWF5 MW 628.8
DMNIWF5 FM C37H48N4O5
DMNIWF5 IC InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
DMNIWF5 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
DMNIWF5 IK KJHKTHWMRKYKJE-SUGCFTRWSA-N
DMNIWF5 IU (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
DMNIWF5 CA CAS 192725-17-0
DMNIWF5 CB CHEBI:31781
DMNIWF5 DE Human immunodeficiency virus infection; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM0URLP ID DM0URLP
DM0URLP DN Lopinavir + ritonavir + interferon alpha
DM0URLP HS Preclinical
DM0URLP SN Aluviran + norvir + interferon apha
DM0URLP TC Antiviral Agents
DM0URLP DT Combination drug
DM0URLP DE Coronavirus Disease 2019 (COVID-19)
DMV1A25 ID DMV1A25
DMV1A25 DN LpxC-1
DMV1A25 HS Preclinical
DMV1A25 DT Small molecular drug
DMV1A25 DE Acinetobacter baumannii infection
DM7XPDB ID DM7XPDB
DM7XPDB DN LY-2463665
DM7XPDB HS Preclinical
DM7XPDB CP Eli Lilly
DM7XPDB DE Type-2 diabetes
DM2N637 ID DM2N637
DM2N637 DN LY-25582
DM2N637 HS Preclinical
DM2N637 SN 3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; LY-255582; LY255582; CHEMBL300662; 119193-09-8; LY 255582; SCHEMBL2740453; AOB5354; (3R,4R)3-[1-(3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; ZINC3783617; BDBM50045775; NCGC00408804-01; AS-16869; LY255582, > 3-[(3R,4R)-1-((S)-3-Cyclohexyl-3-hydroxy-propyl)-3,4-dimethyl-piperidin-4-yl]-phenol; 3-((3R,4R)-1-((S)-3-cyclohexyl-3-hydroxypropyl)-3,4-dimethylpiperidin-4-yl)phenol; 1-Piperidinepropanol,
DM2N637 CP Eli Lilly
DM2N637 DT Small molecular drug
DM2N637 PC 9906198
DM2N637 MW 345.5
DM2N637 FM C22H35NO2
DM2N637 IC InChI=1S/C22H35NO2/c1-17-16-23(13-11-21(25)18-7-4-3-5-8-18)14-12-22(17,2)19-9-6-10-20(24)15-19/h6,9-10,15,17-18,21,24-25H,3-5,7-8,11-14,16H2,1-2H3/t17-,21-,22+/m0/s1
DM2N637 CS C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)CC[C@@H](C3CCCCC3)O
DM2N637 IK LVVHEFJXPXAUDD-BULFRSBZSA-N
DM2N637 IU 3-[(3R,4R)-1-[(3S)-3-cyclohexyl-3-hydroxypropyl]-3,4-dimethylpiperidin-4-yl]phenol
DM2N637 CA CAS 119193-09-8
DM2N637 DE Obesity
DMUFIO9 ID DMUFIO9
DMUFIO9 DN M102
DMUFIO9 HS Preclinical
DMUFIO9 CP Aclipse Therapeutics
DMUFIO9 DE Amyotrophic lateral sclerosis
DM7HUVB ID DM7HUVB
DM7HUVB DN m337
DM7HUVB HS Preclinical
DM7HUVB DT Antibody
DM7HUVB DE Coronavirus infection
DM32XJS ID DM32XJS
DM32XJS DN M64
DM32XJS HS Preclinical
DM32XJS DT Small molecular drug
DM32XJS DE Pseudomonas infection
DM5IMAU ID DM5IMAU
DM5IMAU DN MAb173
DM5IMAU HS Preclinical
DM5IMAU DT Antibody
DM5IMAU DE Kaposi sarcoma
DMNO20J ID DMNO20J
DMNO20J DN mAb926
DMNO20J HS Preclinical
DMNO20J DT Antibody
DMNO20J DE Urinary tract infection
DMZHT39 ID DMZHT39
DMZHT39 DN Macrolactin A
DMZHT39 HS Preclinical
DMZHT39 SN 7-O-succinyl macrolactin A; 7-O-Succinyl Macrolactin F; CHEMBL528105; CHEMBL485779
DMZHT39 PC 10601542
DMZHT39 MW 502.6
DMZHT39 FM C28H38O8
DMZHT39 IC QPJULYYJHQTWML-GIDLKBJSSA-N
DMZHT39 CS CC1CCCC=CC=CC(CC(CC=CC=CC(CC=CC=CC(=O)O1)OC(=O)CCC(=O)O)O)O
DMZHT39 IK 1S/C28H38O8/c1-22-13-7-3-2-4-8-14-23(29)21-24(30)15-9-5-10-16-25(36-28(34)20-19-26(31)32)17-11-6-12-18-27(33)35-22/h2,4-6,8-12,14,16,18,22-25,29-30H,3,7,13,15,17,19-21H2,1H3,(H,31,32)/b4-2+,9-5-,11-6+,14-8+,16-10+,18-12-/t22-,23+,24+,25-/m1/s1
DMZHT39 IU 4-[[(3Z,5E,8S,9E,11Z,14S,16R,17E,19E,24R)-14,16-dihydroxy-24-methyl-2-oxo-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-8-yl]oxy]-4-oxobutanoic acid
DMZHT39 DE Colon cancer
DM1XYGF ID DM1XYGF
DM1XYGF DN MAX-10129
DM1XYGF HS Preclinical
DM1XYGF CP Guangzhou Maxinovel Pharmaceuticals
DM1XYGF DT Small molecule immunotherapy
DMBT2RJ ID DMBT2RJ
DMBT2RJ DN MC-2001
DMBT2RJ HS Preclinical
DMBT2RJ SN MC-2002; MC-2006; Multiple selective kinase inhibitors (leukemia); Dual Flt3/ABL inhibitors, MaxoCore; Multiple selective kinase inhibitors (leukemia), Maxocore
DMBT2RJ CP MaxoCore Pharmaceuticals Inc
DMBT2RJ DE leukaemia
DMLK2D0 ID DMLK2D0
DMLK2D0 DN MC-3001
DMLK2D0 HS Preclinical
DMLK2D0 SN MC-3004; PPAR-alpha agonists, MaxoCore
DMLK2D0 CP MaxoCore Pharmaceuticals Inc
DMLK2D0 DE Lipid metabolism disorder
DM7UGY9 ID DM7UGY9
DM7UGY9 DN MC-3002
DM7UGY9 HS Preclinical
DM7UGY9 SN PPAR dual agonists, MaxoCore
DM7UGY9 CP MaxoCore Pharmaceuticals Inc
DM7UGY9 DE Metabolic disorder
DMHJLPS ID DMHJLPS
DMHJLPS DN M-carboxycinnamic acid bishydroxamide
DMHJLPS HS Preclinical
DMHJLPS SN Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide
DMHJLPS DT Small molecular drug
DMHJLPS PC 5353484
DMHJLPS MW 222.2
DMHJLPS FM C10H10N2O4
DMHJLPS IC InChI=1S/C10H10N2O4/c13-9(11-15)5-4-7-2-1-3-8(6-7)10(14)12-16/h1-6,15-16H,(H,11,13)(H,12,14)/b5-4+
DMHJLPS CS C1=CC(=CC(=C1)C(=O)NO)/C=C/C(=O)NO
DMHJLPS IK OYKBQNOPCSXWBL-SNAWJCMRSA-N
DMHJLPS IU N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide
DMHJLPS CA CAS 174664-65-4
DMHJLPS DE Solid tumour/cancer
DMYEFKH ID DMYEFKH
DMYEFKH DN MCP-1
DMYEFKH HS Preclinical
DMYEFKH CP Pfizer
DMYEFKH DE Rheumatoid arthritis
DM7Q1PF ID DM7Q1PF
DM7Q1PF DN MEDI-543
DM7Q1PF HS Preclinical
DM7Q1PF SN MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune
DM7Q1PF CP Cerus Corp
DM7Q1PF DT Vaccine
DM7Q1PF DE Solid tumour/cancer
DMYK8MV ID DMYK8MV
DMYK8MV DN Melanotetan II
DMYK8MV HS Preclinical
DMYK8MV SN Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor
DMYK8MV CP Clinuvel Pharmaceuticals
DMYK8MV DT Small molecular drug
DMYK8MV DE Type-2 diabetes; Obesity; Sexual dysfunction
DMX4IS3 ID DMX4IS3
DMX4IS3 DN Mephenoxalone
DMX4IS3 HS Preclinical
DMX4IS3 SN 5-((2-Methoxyphenoxy)methyl)oxazolidin-2-one; 5-(o-Methoxyphenoxymethyl)-2-oxazolidinone; 5-(o-Methoxyphenoxymethyl)-2-oxazolidone; AHR 233; Alkapol peg-400; CL 27,319; Control-OM; Dorsiflex; Dorsilon; EINECS 200-723-3; Ekilan; Lenetran; Lenetran TAB; Lenetranat; MEPHENOXALONE; Mefenoxalona; Mefenoxalona [INN-Spanish]; Mefenoxalone; Mephenoxalone [INN:DCF]; Mephenoxalonum [INN-Latin]; Methoxadone; Methoxydon; Methoxydon(E); Methoxydone; Metoxadone; Moderamin; Placidex; Riself; Transpoise; Trepidone; Valanas; Xerene
DMX4IS3 TC Anxiolytic Agents
DMX4IS3 DT Small molecular drug
DMX4IS3 PC 6257
DMX4IS3 MW 223.228
DMX4IS3 FM C11H13NO4
DMX4IS3 IC InChI=1S/C11H13NO4/c1-14-9-4-2-3-5-10(9)15-7-8-6-12-11(13)16-8/h2-5,8H,6-7H2,1H3,(H,12,13)
DMX4IS3 CS COC1=CC=CC=C1OCC2CNC(=O)O2
DMX4IS3 IK ZMNSRFNUONFLSP-UHFFFAOYSA-N
DMX4IS3 IU 5-[(2-methoxyphenoxy)methyl]-1,3-oxazolidin-2-one
DMX4IS3 CA CAS 70-07-5
DMX4IS3 CB CHEBI:134916
DMX4IS3 DE Anxiety
DMTQXS7 ID DMTQXS7
DMTQXS7 DN Mercaptopurine
DMTQXS7 HS Preclinical
DMTQXS7 SN 6-mercaptopurine; Ismipur; Leukerin; Leupurin; Mercaleukim; Mercaleukin; Mercaptopurin; Mercaptopurina; Mercaptopurinum; Mercapurin; Merkaptopuryna; Mern; Purimethol; Purinethiol; Purinethol; Thiopurine; Leupu rin; Mercaptopurin [German]; Mercaptopurina Wellcome; Mercaptopurine anhydrous; Merkaptopuryna [Polish]; Puri Nethol; BW 57 323H; Glaxo Wellcome Brand of 6 Mercaptopurine; GlaxoSmithKline Brand of 6 Mercaptopurine; M0063; NCIMech_000025; PM6; Wellcome Brand of 6 Mercaptopurine; Glaxo Wellcome Brand of 6-Mercaptopurine; GlaxoSmithKline Brand of 6-Mercaptopurine; Mercaptopurina [INN-Spanish]; Mercaptopurine (INN); Mercaptopurine (VAN); Mercaptopurine (anhydrous); Mercaptopurinum [INN-Latin]; Puri-Nethol; Purineantimetabolite: inhibits nucleic acid replication; Purinethol (TN); U-4748; Wellcome Brand of 6-Mercaptopurine; AG-670/31547064; Purine-6-thiol; Leukerin, 99%-Carc; Purine-6(1H)-thione; Purinethol, 6-mercaptopurine, 6-MP, Mercaptopurine; 6 MP; 6 Mercaptopurine Monohydrate; 6 Thiohypoxanthine; 6 Thiopurine; 6-MERCAPTOPURINE MONOHYDRATE; 6-MP; 6-Mercaptopurin; 6-Merkaptopurin; 6-Merkaptopurin [Czech]; 6-Purinethiol; 6-Thiohypoxanthine; 6-Thiopurine; 6-Thioxopurine; Mercaptopurine (Purine analog)
DMTQXS7 CP Novopharm
DMTQXS7 TC Antiviral Agents
DMTQXS7 DT Small molecular drug
DMTQXS7 PC 667490
DMTQXS7 MW 152.18
DMTQXS7 FM C5H4N4S
DMTQXS7 IC InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMTQXS7 CS C1=NC2=C(N1)C(=S)N=CN2
DMTQXS7 IK GLVAUDGFNGKCSF-UHFFFAOYSA-N
DMTQXS7 IU 3,7-dihydropurine-6-thione
DMTQXS7 CA CAS 50-44-2
DMTQXS7 CB CHEBI:2208
DMTQXS7 DE Acute lymphoblastic leukaemia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMVGIB4 ID DMVGIB4
DMVGIB4 DN MERS-27
DMVGIB4 HS Preclinical
DMVGIB4 DT Antibody
DMVGIB4 DE Coronavirus infection
DMS6KT8 ID DMS6KT8
DMS6KT8 DN MERS-4
DMS6KT8 HS Preclinical
DMS6KT8 DT Antibody
DMS6KT8 DE Coronavirus infection
DMG5YRP ID DMG5YRP
DMG5YRP DN MERS-five-helix bundle
DMG5YRP HS Preclinical
DMG5YRP SN MERS-5HB
DMG5YRP TC Antiviral Agents
DMG5YRP DT Protein/peptide drug
DMG5YRP SQ GITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLESGGRGGSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYGGSGGSGGGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLESGGRGGSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYGGSGGSGGGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLE
DMG5YRP DE Middle East Respiratory Syndrome (MERS)
DMQW5MH ID DMQW5MH
DMQW5MH DN Metampicillin
DMQW5MH HS Preclinical
DMQW5MH SN (2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-(methylideneamino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6beta-[(2R)-2-(methylideneamino)-2-phenylacetamido]penicillanic acid; Blomopen; Bonopen; CHEBI:52060; Celinmicina; Elatocilline; G0H6U7VSTK; METHAMPICILLIN; Magnipen; Metampicilina; Metampicillina; Metampicilline; Metampicillinum; Micinovo; Pangocilin; Probiotic; Relyothenate; Ruticina; Rutizina; Sedomycin; Suvipen; UNII-G0H6U7VSTK; Viderpen; Viderpin; Vioplex; metampicillin; metampilene
DMQW5MH TC Anti-Bacterial Agents
DMQW5MH DT Small molecular drug
DMQW5MH PC 6713928
DMQW5MH MW 361.416
DMQW5MH FM C17H19N3O4S
DMQW5MH IC InChI=1S/C17H19N3O4S/c1-17(2)12(16(23)24)20-14(22)11(15(20)25-17)19-13(21)10(18-3)9-7-5-4-6-8-9/h4-8,10-12,15H,3H2,1-2H3,(H,19,21)(H,23,24)/t10-,11-,12+,15-/m1/s1
DMQW5MH CS CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N=C)C(=O)O)C
DMQW5MH IK FZECHKJQHUVANE-MCYUEQNJSA-N
DMQW5MH IU (2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-(methylideneamino)-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMQW5MH CA CAS 6489-97-0
DMQW5MH CB CHEBI:52060
DMQW5MH DE Bacterial infections
DMDPV82 ID DMDPV82
DMDPV82 DN Metildigoxin
DMDPV82 HS Preclinical
DMDPV82 SN 4'''-Methyldigoxin; 4'''-O-Methyldigoxin; Betamethyl digoxin; Digoxin, 4'''-O-methyl-; Lanirapid; Lanitop; MEDIGOXIN; Medigossina; Medigossina [DCIT]; Medigoxina; Medigoxina [Spanish]; Methyldigoxin; Metildigoxin; Metildigoxin [INN:BAN:JAN]; Metildigoxina; Metildigoxina [INN-Spanish]; Metildigoxine; Metildigoxine [INN-French]; Metildigoxinum; Metildigoxinum [INN-Latin]; beta-Methyl Digoxin; beta-Methyldigoxin; beta-Metildigoxina; beta-Metildigoxina [Spanish]
DMDPV82 DT Small molecular drug
DMDPV82 PC 443946
DMDPV82 MW 794.976
DMDPV82 FM C42H66O14
DMDPV82 IC InChI=1S/C42H66O14/c1-20-37(49-6)29(43)16-35(51-20)55-39-22(3)53-36(18-31(39)45)56-38-21(2)52-34(17-30(38)44)54-25-9-11-40(4)24(14-25)7-8-27-28(40)15-32(46)41(5)26(10-12-42(27,41)48)23-13-33(47)50-19-23/h13,20-22,24-32,34-39,43-46,48H,7-12,14-19H2,1-6H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m1/s1
DMDPV82 CS CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)OC
DMDPV82 IK IYJMSDVSVHDVGT-PEQKVOOWSA-N
DMDPV82 IU 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMDPV82 CA CAS 30685-43-9
DMDPV82 CB ChEBI:135885
DMDPV82 DE Cardiac arrhythmias; Congestive heart failure
DMDU8KC ID DMDU8KC
DMDU8KC DN Metkephamid
DMDU8KC HS Preclinical
DMDU8KC SN METKEFAMIDE; UNII-MNL20FXH9Y; MNL20FXH9Y; Metkephamid; Metkephamide; Metkefamida; Metkefamidum; L-Methioninamide, L-tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-; Metkefamidum [INN-Latin]; Metkefamida [INN-Spanish]; L-Tyrosyl-D-alanylglycyl-L-phenylalanyl-N2-methyl-L-methioninamide; Metkefamide [INN]; AC1NUZ1B; SCHEMBL329997; CHEMBL2220405; CTK2F4766
DMDU8KC PC 5464184
DMDU8KC MW 600.7
DMDU8KC FM C29H40N6O6S
DMDU8KC IC InChI=1S/C29H40N6O6S/c1-18(33-28(40)22(30)15-20-9-11-21(36)12-10-20)27(39)32-17-25(37)34-23(16-19-7-5-4-6-8-19)29(41)35(2)24(26(31)38)13-14-42-3/h4-12,18,22-24,36H,13-17,30H2,1-3H3,(H2,31,38)(H,32,39)(H,33,40)(H,34,37)/t18-,22+,23+,24+/m1/s1
DMDU8KC CS CC(C(=O)NCC(=O)NC(CC1=CC=CC=C1)C(=O)N(C)C(CCSC)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N
DMDU8KC IK FWDIKROEWJOQIQ-JMBSJVKXSA-N
DMDU8KC IU (2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-methylamino]-4-methylsulfanylbutanamide
DMDU8KC CA CAS 66960-34-7
DMDU8KC DE Pain
DMKA2YS ID DMKA2YS
DMKA2YS DN MG-132
DMKA2YS HS Preclinical
DMKA2YS SN MG-132; Z-Leu-leu-leu-al; MG132; Zlllal; MG 132; Z-LLL-CHO; Zlll-cho; Z-Leu-leu-leucinal; Z-Leu-Leu-Leu-H; Z-Leu-Leu-Leu-CHO; Carbobenzoxy-leucyl-leucyl-leucinal; UNII-RF1P63GW3K; Benzyloxycarbonyl-leu-leu-leu-aldehyde; Benzyloxycarbonyl-leucyl-leucyl-leucinal; Lll cpd; Carbobenzoxyl-leucinyl-leucinyl-leucinal-H; Cbz-Leu-Leu-Leu-H; Benzyloxycarbonylleucyl-leucyl-leucine aldehyde; benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate; RF1P63GW3K
DMKA2YS PC 462382
DMKA2YS MW 475.6
DMKA2YS FM C26H41N3O5
DMKA2YS IC InChI=1S/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1
DMKA2YS CS CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1
DMKA2YS IK TZYWCYJVHRLUCT-VABKMULXSA-N
DMKA2YS IU benzyl N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMKA2YS CA CAS 133407-82-6
DMKA2YS CB CHEBI:75142
DMKA2YS DE Cancer
DMI3E0Y ID DMI3E0Y
DMI3E0Y DN MK6-83
DMI3E0Y HS Preclinical
DMI3E0Y SN 1062271-24-2; UNII-RE9JUR6NT4; RE9JUR6NT4; 5-Methyl-N-[2-(1-piperidinyl)phenyl]-2-thiophenesulfonamide; C16H20N2O2S2; 5-methyl-N-(2-(piperidin-1-yl)phenyl)thiophene-2-sulfonamide; 5-methyl-N-(2-piperidin-1-ylphenyl)thiophene-2-sulfonamide; 5-Methyl-N-(2-(1-piperidinyl)phenyl)-2-thiophenesulfonamide; GTPL9783; AOB6422; SYN5108; ZINC69572886; AKOS025147398; NCGC00402264-02; NCGC00402264-04; AS-16472; CID 18191179; HY-110238; CS-0033102; 2-Thiophenesulfonamide, 5-methyl-N-(2-(1-piperidinyl)phenyl)-
DMI3E0Y DT Small molecular drug
DMI3E0Y PC 18191179
DMI3E0Y MW 336.5
DMI3E0Y FM C16H20N2O2S2
DMI3E0Y IC InChI=1S/C16H20N2O2S2/c1-13-9-10-16(21-13)22(19,20)17-14-7-3-4-8-15(14)18-11-5-2-6-12-18/h3-4,7-10,17H,2,5-6,11-12H2,1H3
DMI3E0Y CS CC1=CC=C(S1)S(=O)(=O)NC2=CC=CC=C2N3CCCCC3
DMI3E0Y IK IRGYSXZCDAWOOC-UHFFFAOYSA-N
DMI3E0Y IU 5-methyl-N-(2-piperidin-1-ylphenyl)thiophene-2-sulfonamide
DMI3E0Y CA CAS 1062271-24-2
DMI3E0Y DE Discovery agent
DMV2F84 ID DMV2F84
DMV2F84 DN ML209
DMV2F84 HS Preclinical
DMV2F84 SN CHEMBL2326408; 3-(1,3-Benzodioxol-5-yl)-1-(cis-3,5-dimethyl-1-piperidinyl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-propanone; NCGC00238427-01; SCHEMBL14826293; BDBM50426366; AKOS032947172; NCGC00238427-02; 1-[(3S)-3beta,5beta-Dimethylpiperidino]-3-(1,3-benzodioxole-5-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-propanone
DMV2F84 DT Small molecular drug
DMV2F84 PC 53385590
DMV2F84 MW 441.5
DMV2F84 FM C25H31NO6
DMV2F84 IC InChI=1S/C25H31NO6/c1-15-7-16(2)13-26(12-15)24(28)11-19(17-5-6-21-22(8-17)32-14-31-21)25-20(27)9-18(29-3)10-23(25)30-4/h5-6,8-10,15-16,19,27H,7,11-14H2,1-4H3/t15-,16+,19?
DMV2F84 CS C[C@@H]1C[C@@H](CN(C1)C(=O)CC(C2=CC3=C(C=C2)OCO3)C4=C(C=C(C=C4OC)OC)O)C
DMV2F84 IK YEKVAIMYYCZDLI-MCPYQZEQSA-N
DMV2F84 IU 3-(1,3-benzodioxol-5-yl)-1-[(3S,5R)-3,5-dimethylpiperidin-1-yl]-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one
DMV2F84 DE Autoimmune disease
DMY91A3 ID DMY91A3
DMY91A3 DN ML323
DMY91A3 HS Preclinical
DMY91A3 SN ML 323; ML-323
DMY91A3 DT Small molecular drug
DMY91A3 PC 60167849
DMY91A3 MW 384.5
DMY91A3 FM C23H24N6
DMY91A3 IC InChI=1S/C23H24N6/c1-16(2)20-6-4-5-7-21(20)23-24-14-17(3)22(27-23)25-15-18-8-10-19(11-9-18)29-13-12-26-28-29/h4-14,16H,15H2,1-3H3,(H,24,25,27)
DMY91A3 CS CC1=CN=C(N=C1NCC2=CC=C(C=C2)N3C=CN=N3)C4=CC=CC=C4C(C)C
DMY91A3 IK VUIRVWPJNKZOSS-UHFFFAOYSA-N
DMY91A3 IU 5-methyl-2-(2-propan-2-ylphenyl)-N-[[4-(triazol-1-yl)phenyl]methyl]pyrimidin-4-amine
DMY91A3 DE Solid tumour/cancer
DM6RFLE ID DM6RFLE
DM6RFLE DN ML364
DM6RFLE HS Preclinical
DM6RFLE SN 1991986-30-1; 2-[(4-methylphenyl)sulfonylamino]-n-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide; NCGC00262995-02; CHEMBL3392741; SCHEMBL20782884; BCP20769; EX-A4472; ML-364; s6748; AKOS032944928; ZINC169341604; CS-6197; NCGC00262995-01; AS-55828; HY-100900; 2-((4-methylphenyl)sulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide; 2-(4-Methylphenylsulfonamido)-N-(4-phenylthiazol-2-yl)-4-(trifluoromethyl)benzamide
DM6RFLE CP National Institutes of Health
DM6RFLE DT Small molecular drug
DM6RFLE PC 70789348
DM6RFLE MW 517.5
DM6RFLE FM C24H18F3N3O3S2
DM6RFLE IC InChI=1S/C24H18F3N3O3S2/c1-15-7-10-18(11-8-15)35(32,33)30-20-13-17(24(25,26)27)9-12-19(20)22(31)29-23-28-21(14-34-23)16-5-3-2-4-6-16/h2-14,30H,1H3,(H,28,29,31)
DM6RFLE CS CC1=CC=C(C=C1)S(=O)(=O)NC2=C(C=CC(=C2)C(F)(F)F)C(=O)NC3=NC(=CS3)C4=CC=CC=C4
DM6RFLE IK QZUGMNXETPARLI-UHFFFAOYSA-N
DM6RFLE IU 2-[(4-methylphenyl)sulfonylamino]-N-(4-phenyl-1,3-thiazol-2-yl)-4-(trifluoromethyl)benzamide
DM6RFLE DE Inflammation
DMEK78T ID DMEK78T
DMEK78T DN MNLP-18
DMEK78T HS Preclinical
DMEK78T SN MNLP-41; Glycosidase inhibitors (HCV Infection/Influenza); Imino sugar (antiviral), MNLpharma; Glycosidase inhibitors (HCV Infection/Influenza), MNLPharma
DMEK78T CP MNLpharma Ltd
DMEK78T DE Virus infection
DMG2UJS ID DMG2UJS
DMG2UJS DN Monomethyl-auristatin-E
DMG2UJS HS Preclinical
DMG2UJS SN Monomethyl auristatin E; UNII-V7I58RC5EJ; MMAE; V7I58RC5EJ; N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide; Monomethyl auristatin E (MMAE); Monomethylauristatin E; 4Q5; monomethyl-auristatin-e-mmae; MMAE, monomethyl auristatin E; SCHEMBL5402144; CHEMBL2103835; AOB5196; DASWEROEPLKSEI-UIJRFTGLSA-N; C39H67N5O7; MFCD22124498; ZINC85537145; s7721; CS-0837
DMG2UJS PC 11542188
DMG2UJS MW 718
DMG2UJS FM C39H67N5O7
DMG2UJS IC InChI=1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t25-,26+,27+,29-,30+,32-,33-,34-,35+,36+/m0/s1
DMG2UJS CS CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC
DMG2UJS IK DASWEROEPLKSEI-UIJRFTGLSA-N
DMG2UJS IU (2S)-N-[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamide
DMG2UJS CA CAS 474645-27-7
DMG2UJS DE Cancer
DM5AMFV ID DM5AMFV
DM5AMFV DN MS012
DM5AMFV HS Preclinical
DM5AMFV SN CHEMBL4086403; 2089617-83-2 (free base); N2-hexyl-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine; BDBM50501525; N~2~-hexyl-6,7-dimethoxy-N~4~-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
DM5AMFV DT Small molecular drug
DM5AMFV PC 137348638
DM5AMFV MW 401.5
DM5AMFV FM C22H35N5O2
DM5AMFV IC InChI=1S/C22H35N5O2/c1-5-6-7-8-11-23-22-25-18-15-20(29-4)19(28-3)14-17(18)21(26-22)24-16-9-12-27(2)13-10-16/h14-16H,5-13H2,1-4H3,(H2,23,24,25,26)
DM5AMFV CS CCCCCCNC1=NC2=CC(=C(C=C2C(=N1)NC3CCN(CC3)C)OC)OC
DM5AMFV IK ZYNUWSFRZCRKSN-UHFFFAOYSA-N
DM5AMFV IU 2-N-hexyl-6,7-dimethoxy-4-N-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine
DM5AMFV DE Inflammation
DMDEJBQ ID DMDEJBQ
DMDEJBQ DN MS2177
DMDEJBQ HS Preclinical
DMDEJBQ DT Small molecular drug
DMDEJBQ DE Solid tumour/cancer
DMCZW4Q ID DMCZW4Q
DMCZW4Q DN Mteron-F1
DMCZW4Q HS Preclinical
DMCZW4Q CP Dompe
DMCZW4Q DE Mucositis
DMC3NSK ID DMC3NSK
DMC3NSK DN MUT-056399
DMC3NSK HS Preclinical
DMC3NSK SN Fab-001; MUT-1; MUT-2; MUT-3; MUT-37307; MUT-4; FabI inhibitors (antibacterial), Mutabilis; FabI inhibitors (bacterial infection), FAB Pharma
DMC3NSK CP Mutabilis SA
DMC3NSK PC 44208849
DMC3NSK MW 293.26
DMC3NSK FM C15H13F2NO3
DMC3NSK IC InChI=1S/C15H13F2NO3/c1-2-8-6-12(19)14(7-10(8)16)21-13-4-3-9(15(18)20)5-11(13)17/h3-7,19H,2H2,1H3,(H2,18,20)
DMC3NSK CS CCC1=CC(=C(C=C1F)OC2=C(C=C(C=C2)C(=O)N)F)O
DMC3NSK IK QUHARGDBJJUOEB-UHFFFAOYSA-N
DMC3NSK IU 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide
DMC3NSK CA CAS 1269055-85-7
DMC3NSK DE Methicillin-resistant staphylococci infection
DMDE7OR ID DMDE7OR
DMDE7OR DN NA-808
DMDE7OR HS Preclinical
DMDE7OR SN HCV replication inhibitors, Chugai; Hepatitis C virus replication inhibitors, Chugai; NA-255; SPT inhibitor (injection, HCV infection), Roche/Chugai; SPT inhibitor (injection, hepatitis C virus infection), Roche/Chugai; Serine palmitoyltransferase inhibitor (injection, HCV infection), Roche/Chugai; Serine palmitoyltransferase inhibitor (injection, hepatitis C virus infection), Roche/Chugai
DMDE7OR CP Chugai Pharmaceutical Co Ltd
DMDE7OR PC 101837495
DMDE7OR MW 600.7
DMDE7OR FM C34H48O9
DMDE7OR IC InChI=1S/C34H48O9/c1-3-5-7-10-13-16-27(35)17-14-11-8-9-12-15-18-30(34(42,33(40)41)25-31(36)37)29(32(38)39)24-26-19-21-28(22-20-26)43-23-6-4-2/h15,18-22,29-30,42H,3,5,7-14,16-17,23-25H2,1-2H3,(H,36,37)(H,38,39)(H,40,41)/b18-15+/t29-,30-,34-/m0/s1
DMDE7OR CS CCCCCCCC(=O)CCCCCC/C=C/[C@@H]([C@H](CC1=CC=C(C=C1)OCC#CC)C(=O)O)[C@@](CC(=O)O)(C(=O)O)O
DMDE7OR IK XQPJMZTYCIBZTB-UIWDEBCHSA-N
DMDE7OR IU (2S,3S,4S)-5-(4-but-2-ynoxyphenyl)-2-hydroxy-3-[(E)-9-oxohexadec-1-enyl]pentane-1,2,4-tricarboxylic acid
DMDE7OR DE Hepatitis C virus infection
DMEHO9G ID DMEHO9G
DMEHO9G DN NC043
DMEHO9G HS Preclinical
DMEHO9G SN 15-oxospiramilactone; 1053172-87-4; Q35479640
DMEHO9G CP Chinese Academy of Sciences
DMEHO9G DT Small molecular drug
DMEHO9G PC 139033589
DMEHO9G MW 358.5
DMEHO9G FM C22H30O4
DMEHO9G IC InChI=1S/C22H30O4/c1-13-14-4-7-22(19(13)25)16(10-14)21-6-3-5-20(2,15(21)11-17(22)23)8-9-26-12-18(21)24/h14-17,23H,1,3-12H2,2H3/t14-,15+,16-,17+,20-,21-,22+/m0/s1
DMEHO9G CS C[C@@]12CCC[C@@]3([C@@H]1C[C@H]([C@]45[C@H]3C[C@H](CC4)C(=C)C5=O)O)C(=O)COCC2
DMEHO9G IK RCPPZYXWUAJXMA-KGYWYPJXSA-N
DMEHO9G IU (1S,2S,4S,7R,8R,10R,11S)-8-hydroxy-11-methyl-5-methylidene-14-oxapentacyclo[9.5.3.24,7.01,10.02,7]henicosane-6,16-dione
DMEHO9G DE Neurodegenerative disorder
DMXG0O1 ID DMXG0O1
DMXG0O1 DN NCGC607
DMXG0O1 HS Preclinical
DMXG0O1 SN 1462267-07-7; MLS003874050; KUC107647N; KUC107647N-02; SMR002530685; 2-[2-(4-iodoanilino)-2-oxoethoxy]-N-[2-(N-methylanilino)-2-oxoethyl]benzamide; 2-(2-((4-iodophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide; ksc-22-92-D69; SCHEMBL16534468; GTPL10697; EX-A4846; NCGC00241607; NCGC00241607-01; KSC-242-13-2; 2-[2-[(4-Iodophenyl)amino]-2-oxoethoxy]-N-[2-(methylphenylamino)-2-oxoethyl]-benzamide
DMXG0O1 DT Small molecular drug
DMXG0O1 PC 46943210
DMXG0O1 MW 543.4
DMXG0O1 FM C24H22IN3O4
DMXG0O1 IC InChI=1S/C24H22IN3O4/c1-28(19-7-3-2-4-8-19)23(30)15-26-24(31)20-9-5-6-10-21(20)32-16-22(29)27-18-13-11-17(25)12-14-18/h2-14H,15-16H2,1H3,(H,26,31)(H,27,29)
DMXG0O1 CS CN(C1=CC=CC=C1)C(=O)CNC(=O)C2=CC=CC=C2OCC(=O)NC3=CC=C(C=C3)I
DMXG0O1 IK HFVDMJQQAKLUSN-UHFFFAOYSA-N
DMXG0O1 IU 2-[2-(4-iodoanilino)-2-oxoethoxy]-N-[2-(N-methylanilino)-2-oxoethyl]benzamide
DMXG0O1 DE Gaucher disease
DM5ATJ0 ID DM5ATJ0
DM5ATJ0 DN N-desethyl sunitinib
DM5ATJ0 HS Preclinical
DM5ATJ0 SN N-Desethyl Sunitinib; N-DesethylSunitinib; UNII-42LJ35612R; 42LJ35612R; C20H23FN4O2; N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; SCHEMBL2115189; CHEMBL3542344; DTXSID10437828
DM5ATJ0 PC 10292573
DM5ATJ0 MW 370.4
DM5ATJ0 FM C20H23FN4O2
DM5ATJ0 IC InChI=1S/C20H23FN4O2/c1-4-22-7-8-23-20(27)18-11(2)17(24-12(18)3)10-15-14-9-13(21)5-6-16(14)25-19(15)26/h5-6,9-10,22,24H,4,7-8H2,1-3H3,(H,23,27)(H,25,26)/b15-10-
DM5ATJ0 CS CCNCCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
DM5ATJ0 IK LIZNIAKSBJKPQC-GDNBJRDFSA-N
DM5ATJ0 IU N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
DM5ATJ0 CA CAS 356068-97-8
DM5ATJ0 DE Cancer
DMX7Q3H ID DMX7Q3H
DMX7Q3H DN Nemorubicin
DMX7Q3H HS Preclinical
DMX7Q3H SN Nemorubicinol; FCE-23762; PNU-152243; PNU-156685; PNU-156686; PNU-159682
DMX7Q3H CP Pharmacia & Upjohn AB
DMX7Q3H DT Small molecular drug
DMX7Q3H PC 65907
DMX7Q3H MW 643.6
DMX7Q3H FM C32H37NO13
DMX7Q3H IC InChI=1S/C32H37NO13/c1-14-27(36)17(33-7-8-44-22(12-33)43-3)9-21(45-14)46-19-11-32(41,20(35)13-34)10-16-24(19)31(40)26-25(29(16)38)28(37)15-5-4-6-18(42-2)23(15)30(26)39/h4-6,14,17,19,21-22,27,34,36,38,40-41H,7-13H2,1-3H3/t14-,17-,19-,21-,22-,27+,32-/m0/s1
DMX7Q3H CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N6CCO[C@@H](C6)OC)O
DMX7Q3H IK CTMCWCONSULRHO-UHQPFXKFSA-N
DMX7Q3H IU (7S,9S)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2R,4S,5S,6S)-5-hydroxy-4-[(2S)-2-methoxymorpholin-4-yl]-6-methyloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
DMX7Q3H CA CAS 108852-90-0
DMX7Q3H CB CHEBI:42053
DMX7Q3H DE Solid tumour/cancer
DMW1LKP ID DMW1LKP
DMW1LKP DN Nicotinamide mononucleotide
DMW1LKP HS Preclinical
DMW1LKP SN Beta-NMN; Beta-Nicotinamide mononucleotide; Beta-Nicotinamide ribonucleotide; Nicotinamide D-ribonucleotide; Nicotinamide mononucleotide; Nicotinamide nucleotide; Nicotinamide ribonucleotide; Nicotinamide ribotide
DMW1LKP TC Bone Density Conservation Agents
DMW1LKP DT Small molecular drug
DMW1LKP PC 14180
DMW1LKP MW 334.221
DMW1LKP FM C11H15N2O8P
DMW1LKP IC InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/t7-,8-,9-,11-/m1/s1
DMW1LKP CS C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)(O)[O-])O)O)C(=O)N
DMW1LKP IK DAYLJWODMCOQEW-TURQNECASA-N
DMW1LKP IU [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMW1LKP CA CAS 1094-61-7
DMW1LKP CB CHEBI:16171
DMW1LKP DE Dietary shortage
DMK8UD0 ID DMK8UD0
DMK8UD0 DN NKP-46
DMK8UD0 HS Preclinical
DMK8UD0 SN FFC-11; KP-46
DMK8UD0 CP University of Vienna
DMK8UD0 DT Antibody
DMK8UD0 DE Solid tumour/cancer
DMVUKEW ID DMVUKEW
DMVUKEW DN N-methylpyridinium
DMVUKEW HS Preclinical
DMVUKEW SN 1-Methyl-Pyridinium; 1-Methylpyridin-1-ium; 1-Methylpyridinium; N-Methylpyridinium; Pyridinium, 1-methyl-
DMVUKEW TC Anticancer Agents
DMVUKEW DT Small molecular drug
DMVUKEW PC 13597
DMVUKEW MW 94.137
DMVUKEW FM C6H8N+
DMVUKEW IC InChI=1S/C6H8N/c1-7-5-3-2-4-6-7/h2-6H,1H3/q+1
DMVUKEW CS C[N+]1=CC=CC=C1
DMVUKEW IK PQBAWAQIRZIWIV-UHFFFAOYSA-N
DMVUKEW IU 1-methylpyridin-1-ium
DMVUKEW CB ChEBI:15761
DMVUKEW DE Colon cancer
DMLNYGX ID DMLNYGX
DMLNYGX DN NN-818
DMLNYGX HS Preclinical
DMLNYGX SN Beta-amyloid precursor protein modulator (CNS disorders), NewNeural
DMLNYGX CP University of Illinois
DMLNYGX DE Brain injury
DM7R3B6 ID DM7R3B6
DM7R3B6 DN Nobiletin
DM7R3B6 HS Preclinical
DM7R3B6 SN 478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)
DM7R3B6 DT Small molecular drug
DM7R3B6 PC 72344
DM7R3B6 MW 402.4
DM7R3B6 FM C21H22O8
DM7R3B6 IC InChI=1S/C21H22O8/c1-23-13-8-7-11(9-15(13)24-2)14-10-12(22)16-17(25-3)19(26-4)21(28-6)20(27-5)18(16)29-14/h7-10H,1-6H3
DM7R3B6 CS COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC
DM7R3B6 IK MRIAQLRQZPPODS-UHFFFAOYSA-N
DM7R3B6 IU 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one
DM7R3B6 CA CAS 478-01-3
DM7R3B6 CB CHEBI:7602
DM7R3B6 DE Atherosclerosis
DMTQ2UD ID DMTQ2UD
DMTQ2UD DN N-Octyl-4-epi-beta-valienamine
DMTQ2UD HS Preclinical
DMTQ2UD SN CHEMBL1922581; (1s,2s,3s,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol; CHEMBL1922579; N-Octyl-4-epi-beta-Valienamine; BDBM50358321; Q27463709
DMTQ2UD DT Small molecular drug
DMTQ2UD PC 10039700
DMTQ2UD MW 287.39
DMTQ2UD FM C15H29NO4
DMTQ2UD IC InChI=1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13+,14+,15+/m1/s1
DMTQ2UD CS CCCCCCCCN[C@@H]1C=C([C@@H]([C@@H]([C@H]1O)O)O)CO
DMTQ2UD IK UPZUHYMBTUUPML-QPSCCSFWSA-N
DMTQ2UD IU (1S,2S,3S,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
DMTQ2UD DE GM1 gangliosidosis
DM39C47 ID DM39C47
DM39C47 DN N-Octyl-beta-valienamine
DM39C47 HS Preclinical
DM39C47 SN (1s,2s,3r,6r)-4-(Hydroxymethyl)-6-(Octylamino)cyclohex-4-Ene-1,2,3-Triol; CHEMBL1922580; N-Octylvalienamine; CHEMBL1234952; SCHEMBL21067585; BDBM50358322; DB08321; Q27097540; OEV
DM39C47 DT Small molecular drug
DM39C47 PC 9817381
DM39C47 MW 287.39
DM39C47 FM C15H29NO4
DM39C47 IC InChI=1S/C15H29NO4/c1-2-3-4-5-6-7-8-16-12-9-11(10-17)13(18)15(20)14(12)19/h9,12-20H,2-8,10H2,1H3/t12-,13-,14+,15+/m1/s1
DM39C47 CS CCCCCCCCN[C@@H]1C=C([C@H]([C@@H]([C@H]1O)O)O)CO
DM39C47 IK UPZUHYMBTUUPML-KBXIAJHMSA-N
DM39C47 IU (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
DM39C47 DE Gaucher disease
DMKF2H0 ID DMKF2H0
DMKF2H0 DN Nonactin
DMKF2H0 HS Preclinical
DMKF2H0 SN nonactin; Werramycin-A; Antibiotic from Actinomycete; Upjohn 170t (high melting); UPJOHN 170T, high melting; UNII-TTP24WX8P7; 5342 PFW 19; TA-25-M-I; EINECS 229-911-3; A 4426; NSC 56409; E-79-C; NSC 52141; N-329-A; BRN 0076434; TTP24WX8P7; CHEBI:7614; GNF-PF-1094; 3584-A; NSC52141; 4,13,22,31,37,38,39,40-Octaoxapentacyclo(32.2.1.1(sup 7,10).1(sup 16,19).1(sup 25,28))tetracontane-3,12,21,30-tetrone, 2,5,11,14,20,23,29,32-octamethyl-, (1R-(1R*,2R*,5R*,7R*,10S*,11S*,14S*,16S*,19R*,20R*,23R*,25R*,28S*,29S*,32S*,34S*))-
DMKF2H0 PC 72519
DMKF2H0 MW 736.9
DMKF2H0 FM C40H64O12
DMKF2H0 IC InChI=1S/C40H64O12/c1-21-17-29-9-13-34(49-29)26(6)38(42)46-23(3)19-31-11-15-36(51-31)28(8)40(44)48-24(4)20-32-12-16-35(52-32)27(7)39(43)47-22(2)18-30-10-14-33(50-30)25(5)37(41)45-21/h21-36H,9-20H2,1-8H3/t21-,22+,23+,24-,25-,26+,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-
DMKF2H0 CS CC1CC2CCC(O2)C(C(=O)OC(CC3CCC(O3)C(C(=O)OC(CC4CCC(O4)C(C(=O)OC(CC5CCC(O5)C(C(=O)O1)C)C)C)C)C)C)C
DMKF2H0 IK RMIXHJPMNBXMBU-QIIXEHPYSA-N
DMKF2H0 IU (1R,2R,5R,7R,10S,11S,14S,16S,19R,20R,23R,25R,28S,29S,32S,34S)-2,5,11,14,20,23,29,32-octamethyl-4,13,22,31,37,38,39,40-octaoxapentacyclo[32.2.1.17,10.116,19.125,28]tetracontane-3,12,21,30-tetrone
DMKF2H0 CA CAS 6833-84-7
DMKF2H0 CB CHEBI:7614
DMKF2H0 DE Cancer
DM83DSA ID DM83DSA
DM83DSA DN NOX-F37
DM83DSA HS Preclinical
DM83DSA DE Acute and chronic heart failure
DMOGRWB ID DMOGRWB
DMOGRWB DN NPS-1034
DMOGRWB HS Preclinical
DMOGRWB SN 1221713-92-3; CHEMBL3810063; 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide.; SCHEMBL1963111; BCP15998; NPS1034;NPS 1034; BDBM50172077; s7669; ZINC68204845; CCG-270007; NCGC00481564-01; AC-31427; AK685795; BS-14709; HY-100509; CS-0019643; N-(3-fluoro-4-((3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide; S4K
DMOGRWB CP NeoPharm
DMOGRWB DT Small molecular drug
DMOGRWB PC 46194178
DMOGRWB MW 551.5
DMOGRWB FM C31H23F2N5O3
DMOGRWB IC InChI=1S/C31H23F2N5O3/c1-18-27(31(40)38(37(18)2)22-11-8-20(32)9-12-22)30(39)36-21-10-13-25(24(33)16-21)41-26-14-15-34-29-28(26)23(17-35-29)19-6-4-3-5-7-19/h3-17H,1-2H3,(H,34,35)(H,36,39)
DMOGRWB CS CC1=C(C(=O)N(N1C)C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C5C(=CNC5=NC=C4)C6=CC=CC=C6)F
DMOGRWB IK RGAZVGZUBCFHRJ-UHFFFAOYSA-N
DMOGRWB IU 1-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dimethyl-5-oxopyrazole-4-carboxamide
DMOGRWB DE Solid tumour/cancer
DMMRY0Z ID DMMRY0Z
DMMRY0Z DN NPS-2390
DMMRY0Z HS Preclinical
DMMRY0Z SN N-(Adamantan-1-yl)quinoxaline-2-carboxamide; NPS 2390; 226878-01-9; NPS2390; N-(1-adamantyl)quinoxaline-2-carboxamide; CHEMBL399160; N-(adamantan-1-yl)quinoxaline-2-carboxamide; quinoxaline-2-carboxylic acid adamantan-1-ylamide; N-tricyclo[33113,7]dec-1-yl-2-quinoxalinecarboxamide; AC1OF2ZL; SCHEMBL659603; GTPL1384; NPS-239; DTXSID10427729; MolPort-003-351-281; ZKFVOZCCAXQXBU-UHFFFAOYSA-N; ZINC3966256; PDSP2_001301; BDBM50231744; PDSP1_001317; AKOS001304198; NPS-2390 solution, 30 mM in DMSO; N-(1-Adamantyl)-2-quinoxalinecarboxamide; Quinoxaline-2-carboxylic acid adamantan-1-ylamide
DMMRY0Z CP NPS Pharmaceuticals Inc
DMMRY0Z DT Small molecular drug
DMMRY0Z PC 7067728
DMMRY0Z MW 307.4
DMMRY0Z FM C19H21N3O
DMMRY0Z IC InChI=1S/C19H21N3O/c23-18(17-11-20-15-3-1-2-4-16(15)21-17)22-19-8-12-5-13(9-19)7-14(6-12)10-19/h1-4,11-14H,5-10H2,(H,22,23)
DMMRY0Z CS C1C2CC3CC1CC(C2)(C3)NC(=O)C4=NC5=CC=CC=C5N=C4
DMMRY0Z IK ZKFVOZCCAXQXBU-UHFFFAOYSA-N
DMMRY0Z IU N-(1-adamantyl)quinoxaline-2-carboxamide
DMMRY0Z CA CAS 226878-01-9
DMMRY0Z DE Cerebrovascular ischaemia
DMXUCSN ID DMXUCSN
DMXUCSN DN NPY5RA-972
DMXUCSN HS Preclinical
DMXUCSN SN NPY 5RA972; 439861-56-0; CHEMBL325226; N-[4-METHYL-9-(1-METHYLETHYL)-9H-CARBAZOL-3-YL]-4-MORPHOLINECARBOXAMIDE; SCHEMBL6826732; CTK8F0016; DTXSID30432395; MolPort-023-276-896; ZINC27101553; BDBM50116592; AKOS024457744; NCGC00370914-01; RT-014756; B7466; N-(4-Methyl-9-isopropyl-9H-carbazole-3-yl)morpholine-4-carboxamide; Morpholine-4-carboxylic acid (9-isopropyl-4-methyl-9H-carbazol-3-yl)-amide
DMXUCSN CP AstraZeneca
DMXUCSN DT Small molecular drug
DMXUCSN PC 9884833
DMXUCSN MW 351.4
DMXUCSN FM C21H25N3O2
DMXUCSN IC InChI=1S/C21H25N3O2/c1-14(2)24-18-7-5-4-6-16(18)20-15(3)17(8-9-19(20)24)22-21(25)23-10-12-26-13-11-23/h4-9,14H,10-13H2,1-3H3,(H,22,25)
DMXUCSN CS CC1=C(C=CC2=C1C3=CC=CC=C3N2C(C)C)NC(=O)N4CCOCC4
DMXUCSN IK ZNFMHLDBJPAFEQ-UHFFFAOYSA-N
DMXUCSN IU N-(4-methyl-9-propan-2-ylcarbazol-3-yl)morpholine-4-carboxamide
DMXUCSN CA CAS 439861-56-0
DMXUCSN DE Obesity
DMO5MUY ID DMO5MUY
DMO5MUY DN NSC-207895
DMO5MUY HS Preclinical
DMO5MUY SN 58131-57-0; NSC 207895; NSC207895; NSC 179940; MLS000756495; Benzofurazan, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 4-(4-Methyl-1-piperazinyl)-7-nitro-benzofurazan 3-oxide; BENZOFURAZAN, 7-(4-METHYL-1-PIPERAZINYL)-4-NITRO-, 1-OXIDE; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; SMR000528763; NSC 207895 (XI-006); NSC-207895 (XI-006); 4-(4-methyl-1-piperazinyl)-7-nitro-2,1,3-benzoxadiazole, 3-oxide; XI-006; WLN: T56 BNONJ BO FNW I- AT6N DNTJ D1; 7-(4-Methyl-1-piperazinyl)-4-nitrobenzofurazan 1-oxide; B2368; NCIStruc1_000831; NCIStruc2_001869; cc-262; cid_42640; MLS006011023; SCHEMBL8738959; CHEMBL1608727; BDBM51256; DTXSID50206858; HMS2861M23; XI006; ZINC5180959; NSC179940; s2678; BCP9000997; NCGC00246958-01; NCGC00246958-02; NCGC00246958-03; HY-14714; NCI60_001741; BCP0726000315; NSC-207895?XI-006?; A4209; CS-0003525; NSC-207895 - XI-006; NSC?207895?(XI-006); X7598; Z-3234; 7-(4-methylpiperazino)-4-nitro-1-oxido-benzofurazan-1-ium; 2,1,3-Benzoxadiazole, 4-(4-methyl-1-piperazinyl)-7-nitro-, 3-oxide; 2,1,3-benzoxadiazole, 7-(4-methyl-1-piperazinyl)-4-nitro-, 1-oxide; 4-(4-methyl-1-piperazinyl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium; 7-(4-methylpiperazin-1-yl)-4-nitrobenzo[c][1,2,5]oxadiazole 1-oxide; 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxidanidyl-2,1,3-benzoxadiazol-3-ium; 4-(hydroxy(oxido)amino)-7-(4-methyl-1-piperazinyl)-2,15,3-benzoxadiazol-1-ol
DMO5MUY DT Small molecular drug
DMO5MUY PC 42640
DMO5MUY MW 279.25
DMO5MUY FM C11H13N5O4
DMO5MUY IC InChI=1S/C11H13N5O4/c1-13-4-6-14(7-5-13)9-3-2-8(15(17)18)10-11(9)16(19)20-12-10/h2-3H,4-7H2,1H3
DMO5MUY CS CN1CCN(CC1)C2=CC=C(C3=NO[N+](=C23)[O-])[N+](=O)[O-]
DMO5MUY IK MWFZDJLPWDCQIL-UHFFFAOYSA-N
DMO5MUY IU 4-(4-methylpiperazin-1-yl)-7-nitro-3-oxido-2,1,3-benzoxadiazol-3-ium
DMO5MUY CA CAS 58131-57-0
DMO5MUY DE Solid tumour/cancer
DMQRZ4T ID DMQRZ4T
DMQRZ4T DN NSC632839
DMQRZ4T HS Preclinical
DMQRZ4T SN 157654-67-6; NSC 632839 hydrochloride; NSC-632839; Nsc 632839; NSC-632839 hydrochloride; 3,5-BIS[(4-METHYLPHENYL)METHYLENE]-4-PIPERIDONE HYDROCHLORIDE; 157654-67-6 (HCl); MLS002701647; C21H21NO.ClH; (3E,5E)-3,5-bis[(4-methylphenyl)methylidene]piperidin-4-one;hydrochloride; CHEMBL1990474; DTXSID10417701; AMY19345; BCP28077; EX-A4187; 2599AH; s4922; AKOS024457219; CS-6014; BS-15510; HY-100708; NSC 632839, >=98% (HPLC); J-009433; 3,5-bis((E)-4-methylbenzylidene)piperidin-4-one hydrochloride; 4-Piperidione,3,5-bis[(4-methylphenyl)methylene] hydrochloride; 4-Piperidinone,5-bis[(4-methylphenyl)methylene]-, hydrochloride; 4-Piperidinone, 3,5-bis[(4-methylphenyl)methylene]-, hydrochloride (1:1)
DMQRZ4T DT Small molecular drug
DMQRZ4T PC 5351362
DMQRZ4T MW 339.9
DMQRZ4T FM C21H22ClNO
DMQRZ4T IC InChI=1S/C21H21NO.ClH/c1-15-3-7-17(8-4-15)11-19-13-22-14-20(21(19)23)12-18-9-5-16(2)6-10-18;/h3-12,22H,13-14H2,1-2H3;1H/b19-11+,20-12+;
DMQRZ4T CS CC1=CC=C(C=C1)/C=C\\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl
DMQRZ4T IK ZOKZLTXPTLIWOJ-BYCVLTJGSA-N
DMQRZ4T IU (3E,5E)-3,5-bis[(4-methylphenyl)methylidene]piperidin-4-one;hydrochloride
DMQRZ4T CA CAS 157654-67-6
DMQRZ4T DE Solid tumour/cancer
DM65UZ2 ID DM65UZ2
DM65UZ2 DN NTU281
DM65UZ2 HS Preclinical
DM65UZ2 DT Small molecular drug
DM65UZ2 DE Renal fibrosis
DMO5EXL ID DMO5EXL
DMO5EXL DN NVP-2
DMO5EXL HS Preclinical
DMO5EXL SN NVP-2; SCHEMBL1192176; SCHEMBL1192177; GTPL8053; SCHEMBL12850532; CHEMBL3656841; BDBM126500; BDBM126547; Example 93 [US8778951]; HY-12214A; Compound 310 [US8778951]; CS-0015386; US8778951, 310; US8778951, 358; 4-({[6-(5-chloro-2-{[(1r,4r)-4-{[(2R)-1-methoxypropan-2-yl]amino}cyclohexyl]amino}pyridin-4-yl)pyridin-2-yl]amino}methyl)oxane-4-carbonitrile
DMO5EXL DT Small molecular drug
DMO5EXL PC 66937006
DMO5EXL MW 513.1
DMO5EXL FM C27H37ClN6O2
DMO5EXL IC InChI=1S/C27H37ClN6O2/c1-19(16-35-2)32-20-6-8-21(9-7-20)33-26-14-22(23(28)15-30-26)24-4-3-5-25(34-24)31-18-27(17-29)10-12-36-13-11-27/h3-5,14-15,19-21,32H,6-13,16,18H2,1-2H3,(H,30,33)(H,31,34)/t19-,20?,21?/m1/s1
DMO5EXL CS C[C@H](COC)NC1CCC(CC1)NC2=NC=C(C(=C2)C3=NC(=CC=C3)NCC4(CCOCC4)C#N)Cl
DMO5EXL IK XWQVQSXLXAXOPJ-QNGMFEMESA-N
DMO5EXL IU 4-[[[6-[5-chloro-2-[[4-[[(2R)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]pyridin-4-yl]pyridin-2-yl]amino]methyl]oxane-4-carbonitrile
DMO5EXL DE Solid tumour/cancer
DMEXLU5 ID DMEXLU5
DMEXLU5 DN ON-01135
DMEXLU5 HS Preclinical
DMEXLU5 SN Amerliorex; CDK1 inhibitors, Onconova; Novonex analogs, Onconova; ON-01060; ON-01130; ON-01220; ON-01250; ON-01300; ON-01330; ON-01370; ON-01500; ON-01560; ON-01590; ON-01620; Cell cycle checkpoint activators (cytoprotection), Onconova; ON-01060 derivatives, Onconova; ON-01500 series, Onconova; ON-01910 analogs, Onconova; Styryl benzyl sulfones (cell cycle checkpoint activators), Onconova
DMEXLU5 CP Onconova Therapeutics Inc
DMEXLU5 DE Solid tumour/cancer
DMMBIHO ID DMMBIHO
DMMBIHO DN ONO-1301
DMMBIHO HS Preclinical
DMMBIHO SN Ono-1301; 176391-41-6; AC1O6W2S; SCHEMBL3771841; CHEMBL188539; MFCD00936504; AKOS032954172; NCGC00165852-01; ONO-1301, > J-011185; 7,8-Dihydro-5-[(E)-[[alpha-(3-pyridyl)benzylidene]aminooxy]ethyl]-1-naphthyloxy]acetic acid; 2-[[5-[2-[(E)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid; [[7,8-Dihydro-5-[2-[[[phenyl(3-pyridinyl)methylene]amino]oxy]ethyl]naphthalene-1-yl]oxy]acetic acid
DMMBIHO CP Ono Pharmaceutical Co Ltd
DMMBIHO DT Small molecular drug
DMMBIHO PC 6536812
DMMBIHO MW 428.5
DMMBIHO FM C26H24N2O4
DMMBIHO IC InChI=1S/C26H24N2O4/c29-25(30)18-31-24-13-5-11-22-19(9-4-12-23(22)24)14-16-32-28-26(20-7-2-1-3-8-20)21-10-6-15-27-17-21/h1-3,5-11,13,15,17H,4,12,14,16,18H2,(H,29,30)/b28-26+
DMMBIHO CS C1CC2=C(C=CC=C2OCC(=O)O)C(=C1)CCO/N=C(\\C3=CC=CC=C3)/C4=CN=CC=C4
DMMBIHO IK WBBLIRPKRKYMTD-BYCLXTJYSA-N
DMMBIHO IU 2-[[5-[2-[(E)-[phenyl(pyridin-3-yl)methylidene]amino]oxyethyl]-7,8-dihydronaphthalen-1-yl]oxy]acetic acid
DMMBIHO DE Angina pectoris
DMHQUM2 ID DMHQUM2
DMHQUM2 DN Org-23366
DMHQUM2 HS Preclinical
DMHQUM2 SN SCHEMBL7887966; CHEMBL2078915
DMHQUM2 CP Akzo Nobel
DMHQUM2 DT Small molecular drug
DMHQUM2 PC 9804326
DMHQUM2 MW 424.5
DMHQUM2 FM C26H30F2N2O
DMHQUM2 IC InChI=1S/C26H30F2N2O/c27-23-9-5-20(6-10-23)26(21-7-11-24(28)12-8-21)22-13-18-29(19-14-22)15-3-4-25(31)30-16-1-2-17-30/h5-12H,1-4,13-19H2
DMHQUM2 CS C1CCN(C1)C(=O)CCCN2CCC(=C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)CC2
DMHQUM2 IK FZWURHPZIJCZOY-UHFFFAOYSA-N
DMHQUM2 IU 4-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]-1-pyrrolidin-1-ylbutan-1-one
DMHQUM2 DE Schizophrenia
DMCMS7V ID DMCMS7V
DMCMS7V DN Org-24461
DMCMS7V HS Preclinical
DMCMS7V SN ORG-24461
DMCMS7V CP Servier
DMCMS7V DT Small molecular drug
DMCMS7V PC 23670635
DMCMS7V MW 373.3
DMCMS7V FM C19H19F3LiNO3
DMCMS7V IC InChI=1S/C19H20F3NO3.Li/c1-23(13-18(24)25)12-11-17(14-5-3-2-4-6-14)26-16-9-7-15(8-10-16)19(20,21)22;/h2-10,17H,11-13H2,1H3,(H,24,25);/q;+1/p-1
DMCMS7V CS [Li+].CN(CCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F)CC(=O)[O-]
DMCMS7V IK VMQXVSNARQMSDL-UHFFFAOYSA-M
DMCMS7V IU lithium;2-[methyl-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]acetate
DMCMS7V CA CAS 722456-08-8
DMCMS7V DE Schizophrenia
DMERWUC ID DMERWUC
DMERWUC DN Organon
DMERWUC HS Preclinical
DMERWUC SN Allylestrenol; Allyloestrenol; Allyloestrenolum; Gestanin; Gestanol; Gestanon; Gestanyn; Orageston; Perselin; Turinal; Allilestrenolo [DCIT]; Alilestrenol [INN-Spanish]; Allylestrenol [INN:JAN]; Allylestrenol(jan); Allylestrenolum [INN-Latin]; Gestanon-r; Perselin (TN); Allylestrenol (JAN/INN); (17beta)-17-prop-2-en-1-ylestr-4-en-17-ol; (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; 17-(2-Propenyl)estr-4-en-17-ol; 17-Hydroxy-17-alpha-allyl-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-delta(sup 4)-estren; 17-alpha-Allyl-3-deoxy-19-nortestosterone; 17-alpha-Allyl-4-oestrene-17-beta-ol; 17-alpha-Allylestr-4-en-17-beta-ol; 17-alpha-Allylhydroxy-19-nor-4-androstene; 17.alpha.-Allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren; 17.alpha.-Allyl-17.beta.-hydroxy-4-estrene; 17.alpha.-Allyl-3-deoxy-19-nortestosterone; 17.alpha.-Allyl-4-destrene-17.beta.-ol; 17.alpha.-Allyl-4-estren-17.beta.-ol; 17.alpha.-Allyl-4-oestrene-17.beta.-ol; 17.alpha.-Allylestr-4-en-17.beta.-ol; 17.alpha.-Allylestrenol; 17alpha-Allyl-17beta-hydroxy-4-estrene; 17alpha-Allyl-19-nor-delta-4-androstene-17beta-ol; 17alpha-Allyl-3-deoxy-19-nortestosterone; 17alpha-Allyl-4-destrene-17beta-ol; 17alpha-Allyl-4-estren-17beta-ol; 17alpha-Allyl-4-oestrene-17beta-ol; 17alpha-Allylestr-4-en-17beta-ol; 17alpha-Allylestrenol; 21-Methylene-19-nor-17-alpha-preg-4-en-17-ol; 3-Deoxy-17-alpha-allyl-19-nortestosterone
DMERWUC CP Akzo Nobel
DMERWUC DT Small molecular drug
DMERWUC PC 235905
DMERWUC MW 300.5
DMERWUC FM C21H32O
DMERWUC IC InChI=1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
DMERWUC CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(CC=C)O)CCC4=CCCC[C@H]34
DMERWUC IK ATXHVCQZZJYMCF-XUDSTZEESA-N
DMERWUC IU (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
DMERWUC CA CAS 432-60-0
DMERWUC CB CHEBI:31189
DMERWUC DE Schizophrenia
DM46QXZ ID DM46QXZ
DM46QXZ DN Organon-2
DM46QXZ HS Preclinical
DM46QXZ CP Akzo Nobel
DM46QXZ DE Schizophrenia
DM07EU4 ID DM07EU4
DM07EU4 DN Organon-3
DM07EU4 HS Preclinical
DM07EU4 CP Akzo Nobel
DM07EU4 DE Schizophrenia
DMPUSM5 ID DMPUSM5
DMPUSM5 DN Otamixaban
DMPUSM5 HS Preclinical
DMPUSM5 SN XRP0673; FXV-673; XRP-0673; FXV673; UNII-S173RED00L
DMPUSM5 TC Antiviral Agents
DMPUSM5 DT Small molecular drug
DMPUSM5 PC 5496659
DMPUSM5 MW 446.5
DMPUSM5 FM C25H26N4O4
DMPUSM5 IC InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
DMPUSM5 CS C[C@H]([C@@H](CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
DMPUSM5 IK PFGVNLZDWRZPJW-OPAMFIHVSA-N
DMPUSM5 IU methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
DMPUSM5 CA CAS 193153-04-7
DMPUSM5 DE Coronavirus Disease 2019 (COVID-19)
DMYKG8R ID DMYKG8R
DMYKG8R DN Oxypertine
DMYKG8R HS Preclinical
DMYKG8R SN 1H-Indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-; 5,6-Dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indole; 5,6-Dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-1H-indole; 5JGL4G25R7; BRN 0899339; DO 180; EINECS 205-818-3; Equipertine; Forit; Opertil; Oxipertina [INN-Spanish]; Oxipertine; Oxipertinum; Oxypertine [USAN:INN:BAN:JAN]; Oxypertinum [INN-Latin]; UNII-5JGL4G25R7; WIN 18501-2; XCWPUUGSGHNIDZ-UHFFFAOYSA-N; oxypertine
DMYKG8R DT Small molecular drug
DMYKG8R PC 4640
DMYKG8R MW 379.504
DMYKG8R FM C23H29N3O2
DMYKG8R IC InChI=1S/C23H29N3O2/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18/h4-8,15-16,24H,9-14H2,1-3H3
DMYKG8R CS CC1=C(C2=CC(=C(C=C2N1)OC)OC)CCN3CCN(CC3)C4=CC=CC=C4
DMYKG8R IK XCWPUUGSGHNIDZ-UHFFFAOYSA-N
DMYKG8R IU 5,6-dimethoxy-2-methyl-3-[2-(4-phenylpiperazin-1-yl)ethyl]-1H-indole
DMYKG8R CA CAS 153-87-7
DMYKG8R CB CHEBI:31952
DMYKG8R DE Schizophrenia
DMD8JIC ID DMD8JIC
DMD8JIC DN P22077
DMD8JIC HS Preclinical
DMD8JIC SN 1247819-59-5; P 22077; 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159498; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone; 1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-22077; 1-(5-((2,4-Difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; 1-{5-[(2,4-Difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one; C12H7F2NO3S2; SCHEMBL2680945; DTXSID40677376; HMS3653G09; BCP07858; EX-A1445; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one; 2624AH; BDBM50393440; MFCD22580421; s7133; ZINC91696068; AKOS024458186; CCG-267643; CS-1860; QC-8199; AC-32695; AK313221; AS-55923; DA-46729; HY-13865; AB0003913; FT-0707469; SW219709-1; EC-000.2542; J3.502.624J; Z1646327284; 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-[(2,4-Difluorophenyl)thio]-4-nitro-2-thienyl]ethanon; 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone
DMD8JIC CP Progenra
DMD8JIC DT Small molecular drug
DMD8JIC PC 46931953
DMD8JIC MW 315.3
DMD8JIC FM C12H7F2NO3S2
DMD8JIC IC InChI=1S/C12H7F2NO3S2/c1-6(16)11-5-9(15(17)18)12(20-11)19-10-3-2-7(13)4-8(10)14/h2-5H,1H3
DMD8JIC CS CC(=O)C1=CC(=C(S1)SC2=C(C=C(C=C2)F)F)[N+](=O)[O-]
DMD8JIC IK RMAMGGNACJHXHO-UHFFFAOYSA-N
DMD8JIC IU 1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
DMD8JIC CA CAS 1247819-59-5
DMD8JIC DE Inflammation
DMGIR3F ID DMGIR3F
DMGIR3F DN P5091
DMGIR3F HS Preclinical
DMGIR3F SN 882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one
DMGIR3F CP Progenra
DMGIR3F DT Small molecular drug
DMGIR3F PC 2819993
DMGIR3F MW 348.2
DMGIR3F FM C12H7Cl2NO3S2
DMGIR3F IC InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3
DMGIR3F CS CC(=O)C1=CC(=C(S1)SC2=C(C(=CC=C2)Cl)Cl)[N+](=O)[O-]
DMGIR3F IK LKZLGMAAKNEGCH-UHFFFAOYSA-N
DMGIR3F IU 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
DMGIR3F CA CAS 882257-11-6
DMGIR3F DE Solid tumour/cancer
DM3YUGA ID DM3YUGA
DM3YUGA DN Pancratistatin
DM3YUGA HS Preclinical
DM3YUGA SN Pancratistatin; (+)-Pancratistatin; NSC349156; MLS002701837; AC1L9BE4; SCHEMBL93612; CHEMBL419335; VREZDOWOLGNDPW-ALTGWBOUSA-N; ZINC4097654; (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one; NSC-349156; SMP1_000217; NCI60_003105; B844009K070; C08535
DM3YUGA PC 441597
DM3YUGA MW 325.27
DM3YUGA FM C14H15NO8
DM3YUGA IC InChI=1S/C14H15NO8/c16-8-5-3-1-4-13(23-2-22-4)9(17)6(3)14(21)15-7(5)10(18)12(20)11(8)19/h1,5,7-8,10-12,16-20H,2H2,(H,15,21)/t5-,7-,8-,10+,11+,12+/m1/s1
DM3YUGA CS C1OC2=C(O1)C(=C3C(=C2)C4C(C(C(C(C4O)O)O)O)NC3=O)O
DM3YUGA IK VREZDOWOLGNDPW-ALTGWBOUSA-N
DM3YUGA IU (1R,2S,3S,4S,4aR,11bR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
DM3YUGA CA CAS 96203-70-2
DM3YUGA CB CHEBI:7906
DM3YUGA DE Cancer
DMNIM96 ID DMNIM96
DMNIM96 DN P-BCMA-ALL01
DMNIM96 HS Preclinical
DMNIM96 CP Poseida Therapeutics
DMNIM96 DT CAR T Cell Therapy
DMNIM96 DE Multiple myeloma
DMW3TGI ID DMW3TGI
DMW3TGI DN PCI-45292
DMW3TGI HS Preclinical
DMW3TGI SN Btk inhibitors (autoimmune disease); Btk inhibitors (autoimmune disease), Pharmacyclics; Bruton's tyrosine kinase inhibitors (autoimmune disease), Pharmacyclics
DMW3TGI CP Pharmacyclics Inc
DMW3TGI DE Autoimmune diabetes
DMTG730 ID DMTG730
DMTG730 DN PD-157533
DMTG730 HS Preclinical
DMTG730 CP Pfizer
DMTG730 DE Schizophrenia
DMDSR1X ID DMDSR1X
DMDSR1X DN PD-157695
DMDSR1X HS Preclinical
DMDSR1X CP Pfizer
DMDSR1X DT Small molecular drug
DMDSR1X PC 3854666
DMDSR1X MW 352.14
DMDSR1X FM C13H10BrN3O4
DMDSR1X IC InChI=1S/C13H10BrN3O4/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17(20)21)7-12(11)18/h1-7,18H,(H2,15,16,19)
DMDSR1X CS C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])O)Br
DMDSR1X IK MQBZVUNNWUIPMK-UHFFFAOYSA-N
DMDSR1X IU 1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
DMDSR1X CA CAS 182498-32-4
DMDSR1X CB CHEBI:93074
DMDSR1X DE Schizophrenia
DM682UV ID DM682UV
DM682UV DN PD-158771
DM682UV HS Preclinical
DM682UV SN PD 158771; N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine; Trans-N-(4-(2-(4-Phenyl-1-piperazinyl)ethyl)cyclohexyl)-2-pyrimidinamine
DM682UV CP Pfizer
DM682UV DT Small molecular drug
DM682UV PC 3075615
DM682UV MW 365.5
DM682UV FM C22H31N5
DM682UV IC InChI=1S/C22H31N5/c1-2-5-21(6-3-1)27-17-15-26(16-18-27)14-11-19-7-9-20(10-8-19)25-22-23-12-4-13-24-22/h1-6,12-13,19-20H,7-11,14-18H2,(H,23,24,25)
DM682UV CS C1CC(CCC1CCN2CCN(CC2)C3=CC=CC=C3)NC4=NC=CC=N4
DM682UV IK OUUMPVSFLSOGJZ-UHFFFAOYSA-N
DM682UV IU N-[4-[2-(4-phenylpiperazin-1-yl)ethyl]cyclohexyl]pyrimidin-2-amine
DM682UV CA CAS 189152-50-9
DM682UV DE Schizophrenia
DMB9Z4C ID DMB9Z4C
DMB9Z4C DN PD-160170
DMB9Z4C HS Preclinical
DMB9Z4C SN NCGC00092332-01; BRD-K12079898-001-01-8; 5-nitro-6-(2-propan-2-ylphenyl)sulfonyl-quinolin-8-amine
DMB9Z4C CP Parke CDavis
DMB9Z4C DT Small molecular drug
DMB9Z4C PC 9820766
DMB9Z4C MW 371.4
DMB9Z4C FM C18H17N3O4S
DMB9Z4C IC InChI=1S/C18H17N3O4S/c1-11(2)12-6-3-4-8-15(12)26(24,25)16-10-14(19)17-13(7-5-9-20-17)18(16)21(22)23/h3-11H,19H2,1-2H3
DMB9Z4C CS CC(C)C1=CC=CC=C1S(=O)(=O)C2=C(C3=C(C(=C2)N)N=CC=C3)[N+](=O)[O-]
DMB9Z4C IK YUVNGBZROXQYQH-UHFFFAOYSA-N
DMB9Z4C IU 5-nitro-6-(2-propan-2-ylphenyl)sulfonylquinolin-8-amine
DMB9Z4C CA CAS 181468-88-2
DMB9Z4C CB CHEBI:92206
DMB9Z4C DE Heart disease; Obesity; Hypertension
DMD0GB4 ID DMD0GB4
DMD0GB4 DN PD-165167
DMD0GB4 HS Preclinical
DMD0GB4 SN CHEMBL332154; SCHEMBL8169927; BDBM50080797; 7-[[(2-Anilinoethyl)amino]methyl]coumarin; L017812
DMD0GB4 CP Pfizer
DMD0GB4 DT Small molecular drug
DMD0GB4 PC 9926143
DMD0GB4 MW 294.3
DMD0GB4 FM C18H18N2O2
DMD0GB4 IC InChI=1S/C18H18N2O2/c21-18-9-8-15-7-6-14(12-17(15)22-18)13-19-10-11-20-16-4-2-1-3-5-16/h1-9,12,19-20H,10-11,13H2
DMD0GB4 CS C1=CC=C(C=C1)NCCNCC2=CC3=C(C=C2)C=CC(=O)O3
DMD0GB4 IK RNNKCHJUBXFBQB-UHFFFAOYSA-N
DMD0GB4 IU 7-[(2-anilinoethylamino)methyl]chromen-2-one
DMD0GB4 DE Schizophrenia
DMEOVDQ ID DMEOVDQ
DMEOVDQ DN PD-170292
DMEOVDQ HS Preclinical
DMEOVDQ SN PD-170292; CHEMBL14153
DMEOVDQ CP Pfizer
DMEOVDQ DT Small molecular drug
DMEOVDQ PC 44269000
DMEOVDQ MW 671.8
DMEOVDQ FM C38H49N5O6
DMEOVDQ IC InChI=1S/C38H49N5O6/c1-23-9-3-5-12-31(23)42-36(47)39-14-8-7-10-29(20-33(44)45)41-35(46)38(2,21-28-22-40-32-13-6-4-11-30(28)32)43-37(48)49-34-26-16-24-15-25(18-26)19-27(34)17-24/h3-6,9,11-13,22,24-27,29,34,40H,7-8,10,14-21H2,1-2H3,(H,41,46)(H,43,48)(H,44,45)(H2,39,42,47)/t24?,25?,26?,27?,29-,34?,38+/m0/s1
DMEOVDQ CS CC1=CC=CC=C1NC(=O)NCCCC[C@@H](CC(=O)O)NC(=O)[C@@](C)(CC2=CNC3=CC=CC=C32)NC(=O)OC4C5CC6CC(C5)CC4C6
DMEOVDQ IK LMIPXHAXVWAMTP-VUFPLIBQSA-N
DMEOVDQ IU (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-7-[(2-methylphenyl)carbamoylamino]heptanoic acid
DMEOVDQ DE Obesity
DMA5T3J ID DMA5T3J
DMA5T3J DN Pepticlere
DMA5T3J HS Preclinical
DMA5T3J SN DP-68; DP-74; Small peptide beta amyloid protein fibril formation inhibitors, Proteotech; Alzheimers disease therapy (nasal spray), ProteTech; Small peptide A-beta protein fibril formation inhibitors, Proteotech; Laminin alpha chain derivatives (Alzheimer's disease), Proteotech; 6-9 mer peptide analogs (Alzheimer's disease), Proteotech
DMA5T3J CP Proteotech
DMA5T3J DE Alzheimer disease
DMMWQTI ID DMMWQTI
DMMWQTI DN Peptide P21S10
DMMWQTI HS Preclinical
DMMWQTI SN P21S10
DMMWQTI TC Antiviral Agents
DMMWQTI DT Protein/peptide drug
DMMWQTI SQ LDLTYEM LSLQQVV K*LNE*Y
DMMWQTI DE Middle East Respiratory Syndrome (MERS)
DM3U2S5 ID DM3U2S5
DM3U2S5 DN PF-04859989
DM3U2S5 HS Preclinical
DM3U2S5 SN (3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one; (S)-3-Amino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one; CHEMBL2047851; 34783-48-7 (free base); 34783-48-7; (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one; GTPL9038; SCHEMBL2132616; ZINC6117343; BDBM50386292; AKOS006281463; compound 1 [PMID: 23466229]; NCGC00485082-01; Q27088318; (3s)-3-amino-1-hydroxy-3,4-dihydroquinolin-2(1h)-one; Z1601186413
DM3U2S5 CP Pfizer
DM3U2S5 DT Small molecular drug
DM3U2S5 PC 22868923
DM3U2S5 MW 178.19
DM3U2S5 FM C9H10N2O2
DM3U2S5 IC InChI=1S/C9H10N2O2/c10-7-5-6-3-1-2-4-8(6)11(13)9(7)12/h1-4,7,13H,5,10H2/t7-/m0/s1
DM3U2S5 CS C1[C@@H](C(=O)N(C2=CC=CC=C21)O)N
DM3U2S5 IK HYTRYTZFJVVZAF-ZETCQYMHSA-N
DM3U2S5 IU (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one
DM3U2S5 DE Cognitive impairment; Schizophrenia
DM8P9ST ID DM8P9ST
DM8P9ST DN PF-4800567
DM8P9ST HS Preclinical
DM8P9ST SN PF4800567; PF 4800567
DM8P9ST DT Small molecular drug
DM8P9ST PC 53472153
DM8P9ST MW 359.8
DM8P9ST FM C17H18ClN5O2
DM8P9ST IC InChI=1S/C17H18ClN5O2/c18-11-2-1-3-13(8-11)25-9-14-15-16(19)20-10-21-17(15)23(22-14)12-4-6-24-7-5-12/h1-3,8,10,12H,4-7,9H2,(H2,19,20,21)
DM8P9ST CS C1COCCC1N2C3=NC=NC(=C3C(=N2)COC4=CC(=CC=C4)Cl)N
DM8P9ST IK AUMDBEHGJRZSOO-UHFFFAOYSA-N
DM8P9ST IU 3-[(3-chlorophenoxy)methyl]-1-(oxan-4-yl)pyrazolo[3,4-d]pyrimidin-4-amine
DM8P9ST CA CAS 1188296-52-7
DM8P9ST CB CHEBI:87237
DM8P9ST DE Chronic lymphocytic leukaemia
DMTJBP9 ID DMTJBP9
DMTJBP9 DN PF-670462
DMTJBP9 HS Preclinical
DMTJBP9 SN 950912-80-8; PF 670462; PF670462; UNII-D68ANS5I8B; D68ANS5I8B; 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinamine Dihydrochloride; PF-670462 HCl; 950912-80-8 (HCl); 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-2-pyrimidinaminedihydrochloride; 4-[1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine dihydrochloride; 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride; 4-[3-Cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine dihydrochloride; 4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyrimidin-2-amine dihydrochloride; PF670462 dihydrochloride; cc-367; C19H20FN5.2ClH; C19H20FN5.2HCl; SCHEMBL18921552; CHEBI:87236; AOB3526; DTXSID50679609; BCP04305; EX-A2193; 3966AH; MFCD12828759; AKOS024457546; BCP9000015; CS-1015; QC-8952; 2-Pyrimidinamine, 4-(1-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-, hydrochloride (1:2); AC-32583; AK232229; AS-73728; HY-15490; BCP0726000078; FT-0673653; S6734; A11781; S-7816; PF670462/ PF-670462; J-514222; Q27159459; 4-[1-Cyclohexyl-4-(4-fluorophenyl)- 1H-imidazol-5-yl]-2-pyrimidinamine dihydrochloride; 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-aminedihydrochloride; 4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]pyrimidin-2-amine--hydrogen chloride (1/2)
DMTJBP9 DT Small molecular drug
DMTJBP9 PC 51049607
DMTJBP9 MW 410.3
DMTJBP9 FM C19H22Cl2FN5
DMTJBP9 IC InChI=1S/C19H20FN5.2ClH/c20-14-8-6-13(7-9-14)17-18(16-10-11-22-19(21)24-16)25(12-23-17)15-4-2-1-3-5-15;;/h6-12,15H,1-5H2,(H2,21,22,24);2*1H
DMTJBP9 CS C1CCC(CC1)N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F.Cl.Cl
DMTJBP9 IK PSNKGVAXBSAHCH-UHFFFAOYSA-N
DMTJBP9 IU 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]pyrimidin-2-amine;dihydrochloride
DMTJBP9 CA CAS 950912-80-8
DMTJBP9 CB CHEBI:87236
DMTJBP9 DE Chronic lymphocytic leukaemia
DMNZG8T ID DMNZG8T
DMNZG8T DN PF-821385
DMNZG8T HS Preclinical
DMNZG8T SN PF-348089; Gp120 inhibitor (HIV), Pfizer
DMNZG8T CP Pfizer Inc
DMNZG8T DE Human immunodeficiency virus infection
DM1A2UI ID DM1A2UI
DM1A2UI DN PGX-200097
DM1A2UI HS Preclinical
DM1A2UI SN COMT/dopamine D2 receptor inhibitors (schizophrenia), Psychiatric Genomics; Catechol-O-methyltransferase/dopamine D2 receptor inhibitors (schizophrenia), Psychiatric Genomics
DM1A2UI CP Psychiatric Genomics Inc
DM1A2UI DE Schizophrenia
DMM149N ID DMM149N
DMM149N DN PHA-568487
DMM149N HS Preclinical
DMM149N CP Pfizer Inc
DMM149N PC 9932000
DMM149N MW 288.34
DMM149N FM C16H20N2O3
DMM149N IC InChI=1S/C16H20N2O3/c19-16(17-13-10-18-5-3-11(13)4-6-18)12-1-2-14-15(9-12)21-8-7-20-14/h1-2,9,11,13H,3-8,10H2,(H,17,19)/t13-/m0/s1
DMM149N CS C1CN2CCC1[C@H](C2)NC(=O)C3=CC4=C(C=C3)OCCO4
DMM149N IK LUVXHMJTVXZFPD-ZDUSSCGKSA-N
DMM149N IU N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide
DMM149N CA CAS 527680-56-4
DMM149N DE Cognitive impairment
DMIGH6W ID DMIGH6W
DMIGH6W DN PHENSERINE TARTRATE
DMIGH6W HS Preclinical
DMIGH6W SN N-Phenylcarbamic acid (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl ester L-tartrate; (-)-5-O-(N-Phenylcarbamoyl)eseroline L-tartrate
DMIGH6W DT Small molecular drug
DMIGH6W PC 6918263
DMIGH6W MW 487.5
DMIGH6W FM C24H29N3O8
DMIGH6W IC InChI=1S/C20H23N3O2.C4H6O6/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14;5-1(3(7)8)2(6)4(9)10/h4-10,13,18H,11-12H2,1-3H3,(H,21,24);1-2,5-6H,(H,7,8)(H,9,10)/t18-,20+;1-,2-/m11/s1
DMIGH6W CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMIGH6W IK XKKPTCVQEJZDGT-PWUAAHBCSA-N
DMIGH6W IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate;(2R,3R)-2,3-dihydroxybutanedioic acid
DMIGH6W CA CAS 156910-61-1
DMIGH6W DE Parkinson disease
DM16W8F ID DM16W8F
DM16W8F DN Phenylisoserine derivatives SK80
DM16W8F HS Preclinical
DM16W8F SN SK80
DM16W8F TC Antiviral Agents
DM16W8F DT Small molecular drug
DM16W8F DE Severe acute respiratory syndrome (SARS)
DMIZCOE ID DMIZCOE
DMIZCOE DN Piperlongumine
DMIZCOE HS Preclinical
DMIZCOE SN Piplartine; 20069-09-4; Piperlongumin; UNII-SGD66V4SVJ; (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one; CHEBI:8241; SGD66V4SVJ; MFCD00075706; ST079382; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,2,5,6-tetrahydropyridin-2-one; 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-; 5,6-Dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-pyridinone; BRD2293; Piplartin; BRD-2293; PPLGM; (E)-1-[3-(3,4,5-Trimethoxyphenyl)acryloyl]-5,6-dihydropyridin-2(1H)-one; 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one; 5,6-Dihydro-1-(1-oxo-3-[3,4,5-trimethoxyphenyl]-trans-2-propenyl)-2[1H]-pyridinone; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-trans-2-propenyl]-2(1H)-pyridinone; Piplartine;PPLGM; Prestwick_399; FERROUSFLUOBORATE; Prestwick2_000604; Prestwick3_000604; Piperlongumine; Piplartine; BSPBio_000508; MLS002153903; SCHEMBL173092; SPECTRUM1505135; BPBio1_000560; CHEMBL465843; SCHEMBL2465593; 1-[3-(3,4,5-Trimethoxy-phenyl)-acryloyl]-5,6-dihydro-1H-pyridin-2-one; ACon1_001541; CHEBI:92424; HMS1569J10; HMS2096J10; HMS2234K24; Piperlongumine, >=97% (HPLC); ZINC899053; BCP13030; EX-A2925; HY-N2329; 2659AH; BDBM50462013; NSC794671; s7551; AKOS024284776; CCG-214375; NSC-794671; 2(1H)-Pyridinone, 5,6-dihydro-1-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, (E)-; NCGC00096028-01; NCGC00096028-02; NCGC00096028-03; NCGC00096028-04; NCGC00096028-14; AC-32683; AS-74140; BP-25401; LS-14579; SMR001233252; CS-0021113; P2361; A14124; C10166; SR-01000841248; A1-00162; J-012992; N-(3,4,5-Trimethoxycinnamoyl)-D3-piperidin-2-one; Q7197361; SR-01000841248-2; BRD-K24132293-001-05-3; BRD-K24132293-001-09-5; BRD-K24132293-001-16-0; 5,6-Dihydro-1-(3,4,5-trimethoxycinnamoyl)-2(1H)-pyridinone; 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone #; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,5,6-trihydropyridin-2-one; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone, 9CI; Prop-2-en-1-one, 3-(3,4,5-trimethoxyphenyl)-1-(2,3-dihydropyridin-6(1H)-one-1-yl)-; (2E)-1-(1,2,5,6-Tetrahydro-2-oxopyridine-1-yl)-3-(3,4,5-trimethoxyphenyl)-2-propene-1-one
DMIZCOE DT Small molecular drug
DMIZCOE PC 637858
DMIZCOE MW 317.34
DMIZCOE FM C17H19NO5
DMIZCOE IC InChI=1S/C17H19NO5/c1-21-13-10-12(11-14(22-2)17(13)23-3)7-8-16(20)18-9-5-4-6-15(18)19/h4,6-8,10-11H,5,9H2,1-3H3/b8-7+
DMIZCOE CS COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCC=CC2=O
DMIZCOE IK VABYUUZNAVQNPG-BQYQJAHWSA-N
DMIZCOE IU 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one
DMIZCOE CA CAS 20069-09-4
DMIZCOE CB CHEBI:8241
DMIZCOE DE Solid tumour/cancer
DM82Y75 ID DM82Y75
DM82Y75 DN PIRINIXIC ACID
DM82Y75 HS Preclinical
DM82Y75 SN Pirinixic acid; 50892-23-4; WY-14643; [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid; WY-14,643; WY14643; Wyeth 14,643; Wy 14643; Pirinixic acid [INN]; WY-14643 (Pirinixic Acid); (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid; UNII-86C4MRT55A; C14H14ClN3O2S; CCRIS 133; Acidum pirinixicum [INN-Latin]; Acide pirinixique [INN-French]; Acido pirinixico [INN-Spanish]; NSC310038; NSC-310038; NSC 310038; BRN 0759945; ((4-Chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid; Acetic acid, ((4-chloro-6-(
DM82Y75 DT Small molecular drug
DM82Y75 PC 5694
DM82Y75 MW 323.8
DM82Y75 FM C14H14ClN3O2S
DM82Y75 IC InChI=1S/C14H14ClN3O2S/c1-8-4-3-5-10(9(8)2)16-12-6-11(15)17-14(18-12)21-7-13(19)20/h3-6H,7H2,1-2H3,(H,19,20)(H,16,17,18)
DM82Y75 CS CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C
DM82Y75 IK SZRPDCCEHVWOJX-UHFFFAOYSA-N
DM82Y75 IU 2-[4-chloro-6-(2,3-dimethylanilino)pyrimidin-2-yl]sulfanylacetic acid
DM82Y75 CA CAS 50892-23-4
DM82Y75 CB CHEBI:32509
DM82Y75 DE Pulmonary fibrosis
DMXO6YH ID DMXO6YH
DMXO6YH DN PJ34
DMXO6YH HS Preclinical
DMXO6YH SN PJ34; 344458-19-1; pj-34; N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE; CHEMBL372303; P34; 2-(dimethylamino)-N-(6-oxo-5,6-dihydrophenanthridin-2-yl)acetamide; Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-; UYJZZVDLGDDTCL-UHFFFAOYSA-N; PJ34(free base); 1xk9; SCHEMBL422317; ZINC8960; AC1L1J45; BDBM27497; CTK1B7701; MolPort-035-395-737; Ibrutinib (PCI32765 pound(c); HMS3651B06; BCP07990; HY-13688A; 2662AH; AKOS030229047; SB19292; DB08348; CS-1463; NCGC00370866-10; DA-42692; BC600341
DMXO6YH DT Small molecular drug
DMXO6YH PC 4858
DMXO6YH MW 295.34
DMXO6YH FM C17H17N3O2
DMXO6YH IC InChI=1S/C17H17N3O2/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22)
DMXO6YH CS CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32
DMXO6YH IK UYJZZVDLGDDTCL-UHFFFAOYSA-N
DMXO6YH IU 2-(dimethylamino)-N-(6-oxo-5H-phenanthridin-2-yl)acetamide
DMXO6YH DE Coronavirus infection
DM94ZOI ID DM94ZOI
DM94ZOI DN PMID21925774-compound-5e
DM94ZOI HS Preclinical
DM94ZOI SN PMID21925774-C-5e
DM94ZOI TC Antiviral Agents
DM94ZOI DT Small molecular drug
DM94ZOI DE Severe acute respiratory syndrome (SARS)
DMOHPX4 ID DMOHPX4
DMOHPX4 DN PMID25197057-Compound6e
DMOHPX4 HS Preclinical
DMOHPX4 DT Small molecular drug
DMOHPX4 DE Staphylococcus infection
DMFNS7U ID DMFNS7U
DMFNS7U DN PMID26048809-compound2
DMFNS7U HS Preclinical
DMFNS7U SN PMID26048809-C2
DMFNS7U TC Antiviral Agents
DMFNS7U DT Small molecular drug
DMFNS7U DE Middle East Respiratory Syndrome (MERS)
DMZMYU5 ID DMZMYU5
DMZMYU5 DN PMID26868298-compound-5705213
DMZMYU5 HS Preclinical
DMZMYU5 SN PMID26868298-C-5705213
DMZMYU5 TC Antiviral Agents
DMZMYU5 DT Small molecular drug
DMZMYU5 DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMQFUCD ID DMQFUCD
DMQFUCD DN PMID26868298-compound-N3
DMQFUCD HS Preclinical
DMQFUCD SN PMID26868298-C-N3
DMQFUCD TC Antiviral Agents
DMQFUCD DT Small molecular drug
DMQFUCD DE Coronavirus Disease 2019 (COVID-19); Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMUH012 ID DMUH012
DMUH012 DN PMID26911565-peptide-P9
DMUH012 HS Preclinical
DMUH012 SN PMID26911565-P9
DMUH012 TC Antiviral Agents
DMUH012 DT Protein/peptide drug
DMUH012 SQ NGAICWGPCPTAFRQIGNCGHFKVRCCKIR
DMUH012 DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMPC29W ID DMPC29W
DMPC29W DN PMID27240464-compound-3f
DMPC29W HS Preclinical
DMPC29W SN PMID27240464-C-3f
DMPC29W TC Antiviral Agents
DMPC29W DT Small molecular drug
DMPC29W DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMPWUFT ID DMPWUFT
DMPWUFT DN PMID28216367-compound-6d
DMPWUFT HS Preclinical
DMPWUFT SN PMID28216367-C-6d
DMPWUFT TC Antiviral Agents
DMPWUFT DT Small molecular drug
DMPWUFT DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMYNCWK ID DMYNCWK
DMYNCWK DN PMID28624700-compound-3-31
DMYNCWK HS Preclinical
DMYNCWK SN Unsymmetrical aromatic disulfides 3-31
DMYNCWK TC Antiviral Agents
DMYNCWK DT Small molecular drug
DMYNCWK DE Severe acute respiratory syndrome (SARS)
DMVB0P3 ID DMVB0P3
DMVB0P3 DN PMID30784880-compound-6-5
DMVB0P3 HS Preclinical
DMVB0P3 SN PMID30784880-C-6-5
DMVB0P3 TC Antiviral Agents
DMVB0P3 DT Small molecular drug
DMVB0P3 DE Severe acute respiratory syndrome (SARS)
DMXCKL9 ID DMXCKL9
DMXCKL9 DN PMID30940566-compound-6
DMXCKL9 HS Preclinical
DMXCKL9 SN PMID30940566-C-6
DMXCKL9 TC Antiviral Agents
DMXCKL9 DT Small molecular drug
DMXCKL9 DE Middle East Respiratory Syndrome (MERS)
DMZJWON ID DMZJWON
DMZJWON DN PMID31244113-compound-2c
DMZJWON HS Preclinical
DMZJWON SN PMID31244113-C-2c
DMZJWON TC Antiviral Agents
DMZJWON DT Small molecular drug
DMZJWON DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM9LS0R ID DM9LS0R
DM9LS0R DN PMID31955138-compound-16
DM9LS0R HS Preclinical
DM9LS0R SN PMID31955138-C-16
DM9LS0R TC Antiviral Agents
DM9LS0R DT Small molecular drug
DM9LS0R DE Middle East Respiratory Syndrome (MERS)
DMMXR3L ID DMMXR3L
DMMXR3L DN PMX205
DMMXR3L HS Preclinical
DMMXR3L SN PMX 205; 514814-49-4; PMX-205; UNII-DC25O3L7KZ; Hydrocinnamate-(orn-Pro-dcha-Trp-Arg); DC25O3L7KZ; Cyclic hexapeptide complement C5a antagonist; N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide; HC-[OP(D-Cha)WR]; SCHEMBL12971708; CHEBI:144869; LP-16; ZINC95627847; HY-110136; CS-0032991; A16946; hydrocinnamate-cyclo(ornithyl-prolyl-D-cyclohexylalanyl-tryptophyl-arginyl); (5->1)-lactam-N(2)-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine; N-[(3R,6S,9S,15S,20aS)-9-(3-carbamimidamidopropyl)-3-(cyclohexylmethyl)-6-(1H-indol-3-ylmethyl)-1,4,7,10,16-pentaoxoicosahydropyrrolo[1,2-a][1,4,7,10,13]pentaazacyclooctadecin-15-yl]-3-phenylpropanamide
DMMXR3L DT Small molecular drug
DMMXR3L PC 6918845
DMMXR3L MW 839
DMMXR3L FM C45H62N10O6
DMMXR3L IC InChI=1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2,5-6,9-11,14-15,18-27H2,(H,48,57)(H,51,56)(H,52,59)(H,53,58)(H,54,60)(H4,46,47,49)/t34-,35-,36+,37-,38-/m0/s1
DMMXR3L CS C1CCC(CC1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC[C@@H](C(=O)N3CCC[C@H]3C(=O)N2)NC(=O)CCC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65
DMMXR3L IK VATFHFJULBPYLM-ILOBPARPSA-N
DMMXR3L IU N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide
DMMXR3L CA CAS 514814-49-4
DMMXR3L CB CHEBI:144869
DMMXR3L DE Central nervous system disease
DM9SY8E ID DM9SY8E
DM9SY8E DN PT630
DM9SY8E HS Preclinical
DM9SY8E DT Peptide
DM9SY8E DE Lung cancer; Colon cancer
DMDKLB5 ID DMDKLB5
DMDKLB5 DN Puromycin
DMDKLB5 HS Preclinical
DMDKLB5 SN puromycin; Stylomycin; Puromycinum; Puromycine; Puromicina; UNII-4A6ZS6Q2CL; P-638; Stillomycin; CL 13900; 3123L; 4A6ZS6Q2CL; 3'-(L-alpha-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine; (S)-3'-((2-Amino-3-(4-methoxyphenyl)-1-oxopropyl)amino)-3'-deoxy-N,N-dimethyladenosine; GNF-PF-2016; Puromycinum [INN-Latin]; Puromycine [INN-French]; Puromicina [INN-Spanish]; 9-{3-deoxy-3-[(O-methyl-L-tyrosyl)amino]-beta-D-xylofuranosyl}-N,N-dimethyl-9H-purin-6-amine; Bacterenomycin
DMDKLB5 PC 439530
DMDKLB5 MW 471.5
DMDKLB5 FM C22H29N7O5
DMDKLB5 IC InChI=1S/C22H29N7O5/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32)/t14-,15+,16+,18+,22+/m0/s1
DMDKLB5 CS CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O
DMDKLB5 IK RXWNCPJZOCPEPQ-NVWDDTSBSA-N
DMDKLB5 IU (2S)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide
DMDKLB5 CA CAS 53-79-2
DMDKLB5 CB CHEBI:17939
DMDKLB5 DE Bacterial infections
DMLBFC0 ID DMLBFC0
DMLBFC0 DN Q-44287045
DMLBFC0 HS Preclinical
DMLBFC0 SN Macrolactin A; Macrolactin-A; (-)-Macrolactin A; (3Z,5E,8R,9E,11Z,14S,16S,17E,19E,24R)-8,14,16-trihydroxy-24-methyl-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one; 122540-27-6; Oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one, 8,14,16-trihydroxy-24-methyl-, (3Z,5E,8S,9E,11Z,14S,16R,17E,19E,24R)-
DMLBFC0 PC 6451096
DMLBFC0 MW 402.5
DMLBFC0 FM C24H34O5
DMLBFC0 IC XXDIJWSZFWZBRM-QCEWEWFLSA-N
DMLBFC0 CS CC1CCCC=CC=CC(CC(CC=CC=CC(CC=CC=CC(=O)O1)O)O)O
DMLBFC0 IK 1S/C24H34O5/c1-20-13-7-3-2-4-8-16-22(26)19-23(27)17-11-5-9-14-21(25)15-10-6-12-18-24(28)29-20/h2,4-6,8-12,14,16,18,20-23,25-27H,3,7,13,15,17,19H2,1H3/b4-2+,10-6+,11-5-,14-9+,16-8+,18-12-/t20-,21+,22-,23+/m1/s1
DMLBFC0 IU (3Z,5E,8R,9E,11Z,14S,16S,17E,19E,24R)-8,14,16-trihydroxy-24-methyl-1-oxacyclotetracosa-3,5,9,11,17,19-hexaen-2-one
DMLBFC0 CA CAS 122540-27-6
DMLBFC0 DE Colon cancer
DMASVOD ID DMASVOD
DMASVOD DN QSP
DMASVOD HS Preclinical
DMASVOD DE Acetabular fracture
DMRZBM7 ID DMRZBM7
DMRZBM7 DN RANBEZOLID HYDROCHLORIDE
DMRZBM7 HS Preclinical
DMRZBM7 SN RBx-7644; N-[3-[3-Fluoro-4-[4-(5-nitrofuran-2-ylmethyl)piperazin-1-yl]phenyl]-2-oxooxazolidin-5(S)-ylmethyl]acetamide monohydrochloride
DMRZBM7 DT Small molecular drug
DMRZBM7 PC 6918631
DMRZBM7 MW 497.9
DMRZBM7 FM C21H25ClFN5O6
DMRZBM7 IC InChI=1S/C21H24FN5O6.ClH/c1-14(28)23-11-17-13-26(21(29)33-17)15-2-4-19(18(22)10-15)25-8-6-24(7-9-25)12-16-3-5-20(32-16)27(30)31;/h2-5,10,17H,6-9,11-13H2,1H3,(H,23,28);1H/t17-;/m0./s1
DMRZBM7 CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)CC4=CC=C(O4)[N+](=O)[O-])F.Cl
DMRZBM7 IK XYGNKPXLGBABKJ-LMOVPXPDSA-N
DMRZBM7 IU N-[[(5S)-3-[3-fluoro-4-[4-[(5-nitrofuran-2-yl)methyl]piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide;hydrochloride
DMRZBM7 DE Bacterial infection
DM7JH0K ID DM7JH0K
DM7JH0K DN RG70099
DM7JH0K HS Preclinical
DM7JH0K CP Roche
DM7JH0K DT Small molecular drug
DM7JH0K DE Solid tumour/cancer
DMJGQD2 ID DMJGQD2
DMJGQD2 DN RMG-40083
DMJGQD2 HS Preclinical
DMJGQD2 CP Remergent
DMJGQD2 DE Schizophrenia
DMWAR1T ID DMWAR1T
DMWAR1T DN Ro 61-8048
DMWAR1T HS Preclinical
DMWAR1T SN 199666-03-0; Ro61-8048; 3,4-dimethoxy-N-(4-(3-nitrophenyl)thiazol-2-yl)benzenesulfonamide; Ro-61-8048; 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide; CHEMBL134915; 3,4-Dimethoxy-N-[4-(3-nitro-phenyl)-thiazol-2-yl]-benzenesulfonamide; CHEBI:34953; C14126; MFCD11040807; 3,4-Dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide; C17H15N3O6S2; Benzenesulfonamide, 3,4-dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-; AC1NQZWG; 7ZR; SCHEMBL424256; AOB1234; DTXSID20415218; EX-A805; SYN5225; HMS3886F06; BCP07470; ZINC1546077; 4013AH; BDBM50061916; s8172; AKOS024457509; CCG-222062; CS-3332; NE62855; SB19626; NCGC00370730-07; NCGC00370730-09; NCGC00370730-13; AC-32906; AK312615; AS-16581; DA-43342; HY-12347; B7334; FT-0700256; EC-000.2437; Ro 61-8048, >=98% (HPLC); J-012900; Q27116332; 3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-benzenesulfonamide; 3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]benzenesulfonamide; 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzene-1-sulfonamide
DMWAR1T CP Roche
DMWAR1T DT Small molecular drug
DMWAR1T PC 5282337
DMWAR1T MW 421.5
DMWAR1T FM C17H15N3O6S2
DMWAR1T IC InChI=1S/C17H15N3O6S2/c1-25-15-7-6-13(9-16(15)26-2)28(23,24)19-17-18-14(10-27-17)11-4-3-5-12(8-11)20(21)22/h3-10H,1-2H3,(H,18,19)
DMWAR1T CS COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=CS2)C3=CC(=CC=C3)[N+](=O)[O-])OC
DMWAR1T IK NDPBMCKQJOZAQX-UHFFFAOYSA-N
DMWAR1T IU 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide
DMWAR1T CA CAS 199666-03-0
DMWAR1T CB CHEBI:34953
DMWAR1T DE Neurodegenerative disorder
DM3ZE5A ID DM3ZE5A
DM3ZE5A DN RO-26-2853
DM3ZE5A HS Preclinical
DM3ZE5A CP Roche
DM3ZE5A DE Solid tumour/cancer
DMF3YQZ ID DMF3YQZ
DMF3YQZ DN Ro-27-3225
DMF3YQZ HS Preclinical
DMF3YQZ CP Roche; Millenium
DMF3YQZ DT Small molecular drug
DMF3YQZ PC 56603736
DMF3YQZ MW 782.9
DMF3YQZ FM C41H54N10O6
DMF3YQZ IC InChI=1S/C41H54N10O6/c1-3-12-36(53)47-32(21-27-15-7-8-16-27)38(55)49-33(22-26-13-5-4-6-14-26)39(56)48-31(19-11-20-45-41(43)44)37(54)50-34(40(57)51(2)25-35(42)52)23-28-24-46-30-18-10-9-17-29(28)30/h4-10,13-15,17-18,31-34H,3,11-12,16,19-25H2,1-2H3,(H2,42,52)(H,47,53)(H,48,56)(H,49,55)(H,50,54)(H4,43,44,45)/t31-,32-,33?,34?/m0/s1
DMF3YQZ CS CCCC(=O)N[C@@H](CC1=CC=CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC(CC3=C4C=CC=CC4=NC3)C(=O)N(C)CC(=O)N
DMF3YQZ IK IRCWGIYPMAYZQR-URRMOVRVSA-N
DMF3YQZ IU (2S)-N-[1-[(2-amino-2-oxoethyl)-methylamino]-3-(2H-indol-3-yl)-1-oxopropan-2-yl]-2-[[2-[[(2S)-2-(butanoylamino)-3-cyclopenta-1,3-dien-1-ylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMF3YQZ DE Obesity
DMRT3FK ID DMRT3FK
DMRT3FK DN RO5461111
DMRT3FK HS Preclinical
DMRT3FK CP Roche
DMRT3FK DE Systemic lupus erythematosus
DMZOUX4 ID DMZOUX4
DMZOUX4 DN Romazarit
DMZOUX4 HS Preclinical
DMZOUX4 SN ORE-5007; Metabolic modulator (obesity/hyperlipidemia), Ore Pharmaceuticals
DMZOUX4 CP Roche Holding AG
DMZOUX4 DT Small molecular drug
DMZOUX4 PC 71321
DMZOUX4 MW 309.74
DMZOUX4 FM C15H16ClNO4
DMZOUX4 IC InChI=1S/C15H16ClNO4/c1-9-12(8-20-15(2,3)14(18)19)21-13(17-9)10-4-6-11(16)7-5-10/h4-7H,8H2,1-3H3,(H,18,19)
DMZOUX4 CS CC1=C(OC(=N1)C2=CC=C(C=C2)Cl)COC(C)(C)C(=O)O
DMZOUX4 IK LNXXSBRGLBOASF-UHFFFAOYSA-N
DMZOUX4 IU 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid
DMZOUX4 CA CAS 109543-76-2
DMZOUX4 DE Rheumatoid arthritis
DMOQ63E ID DMOQ63E
DMOQ63E DN Rottlerin
DMOQ63E HS Preclinical
DMOQ63E SN Kamalin; Mallotoxin; R 5648; BMK1-F10; (E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one; (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one; 1-[6-(3-Acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-2H-chromen-8-yl]-3-phenyl-propenone; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one; 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
DMOQ63E DT Small molecular drug
DMOQ63E PC 5281847
DMOQ63E MW 516.5
DMOQ63E FM C30H28O8
DMOQ63E IC InChI=1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+
DMOQ63E CS CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C(=C3C(=C2O)C=CC(O3)(C)C)C(=O)/C=C/C4=CC=CC=C4)O)O
DMOQ63E IK DEZFNHCVIZBHBI-ZHACJKMWSA-N
DMOQ63E IU (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethylchromen-8-yl]-3-phenylprop-2-en-1-one
DMOQ63E CA CAS 82-08-6
DMOQ63E CB CHEBI:8899
DMOQ63E DE Parkinson disease
DM89VIO ID DM89VIO
DM89VIO DN RS2-1G9
DM89VIO HS Preclinical
DM89VIO DT Antibody
DM89VIO DE Pseudomonas infection
DMB9IPR ID DMB9IPR
DMB9IPR DN RS-504393
DMB9IPR HS Preclinical
DMB9IPR SN 300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS-504393; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463
DMB9IPR CP Roche
DMB9IPR DT Small molecular drug
DMB9IPR PC 9953769
DMB9IPR MW 417.5
DMB9IPR FM C25H27N3O3
DMB9IPR IC InChI=1S/C25H27N3O3/c1-17-8-9-22-20(16-17)25(31-24(29)27-22)11-14-28(15-12-25)13-10-21-18(2)30-23(26-21)19-6-4-3-5-7-19/h3-9,16H,10-15H2,1-2H3,(H,27,29)
DMB9IPR CS CC1=CC2=C(C=C1)NC(=O)OC23CCN(CC3)CCC4=C(OC(=N4)C5=CC=CC=C5)C
DMB9IPR IK ODNICNWASXKNNQ-UHFFFAOYSA-N
DMB9IPR IU 6-methyl-1'-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one
DMB9IPR CA CAS 300816-15-3
DMB9IPR CB CHEBI:93525
DMB9IPR DE Chronic obstructive pulmonary disease
DMH1FRY ID DMH1FRY
DMH1FRY DN RWJ-416457
DMH1FRY HS Preclinical
DMH1FRY SN JNJ-10283104; JNJ-10391849; Oxazolidinones, RW Johnson; RJW-334181; RWJ-302377; RWJ-306490; RWJ-334181; RWJ-337813; RWJ-400294; RWJ-417174; RWJ-445158
DMH1FRY CP RW Johnson Pharmaceutical Research Institute
DMH1FRY DT Small molecular drug
DMH1FRY PC 15984076
DMH1FRY MW 373.4
DMH1FRY FM C18H20FN5O3
DMH1FRY IC InChI=1S/C18H20FN5O3/c1-11(25)20-6-14-9-24(18(26)27-14)13-3-4-17(15(19)5-13)23-8-12-7-22(2)21-16(12)10-23/h3-5,7,14H,6,8-10H2,1-2H3,(H,20,25)/t14-/m0/s1
DMH1FRY CS CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4=CN(N=C4C3)C)F
DMH1FRY IK UCBHICFFJKDMMR-AWEZNQCLSA-N
DMH1FRY IU N-[[(5S)-3-[3-fluoro-4-(2-methyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
DMH1FRY CA CAS 474016-05-2
DMH1FRY DE Bacterial infection
DMMVS07 ID DMMVS07
DMMVS07 DN RWJ-51204
DMMVS07 HS Preclinical
DMMVS07 SN 5-(Ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-3-oxo-1,2,3,5-tetrahydropyrido[1,2-a]benzimidazole-4-carboxamide
DMMVS07 DT Small molecular drug
DMMVS07 PC 9822240
DMMVS07 MW 399.4
DMMVS07 FM C21H19F2N3O3
DMMVS07 IC InChI=1S/C21H19F2N3O3/c1-2-29-12-26-17-11-13(22)7-8-16(17)25-10-9-18(27)19(21(25)26)20(28)24-15-6-4-3-5-14(15)23/h3-8,11H,2,9-10,12H2,1H3,(H,24,28)
DMMVS07 CS CCOCN1C2=C(C=CC(=C2)F)N3C1=C(C(=O)CC3)C(=O)NC4=CC=CC=C4F
DMMVS07 IK VQOQDABVGWLROX-UHFFFAOYSA-N
DMMVS07 IU 5-(ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-3-oxo-1,2-dihydropyrido[1,2-a]benzimidazole-4-carboxamide
DMMVS07 CA CAS 205701-85-5
DMMVS07 DE Anxiety disorder
DM3AIQO ID DM3AIQO
DM3AIQO DN RX-01-423
DM3AIQO HS Preclinical
DM3AIQO SN RX-01 series; RX-01-413; RX-01-445; Non-macrolide antibiotics, Rib-X; Translation inhibitor (50s ribosome subunit), Rib-X
DM3AIQO CP Rib-X Pharmaceuticals Inc
DM3AIQO DE Bacterial infection
DMXM2BZ ID DMXM2BZ
DMXM2BZ DN Rycals
DMXM2BZ HS Preclinical
DMXM2BZ SN Rycals (cardiac disease/muscle disorders); Calcium release channel stabilizers (cardiac disease/muscle disorders), Armgo; Rycals (cardiac disease/muscle disorders), Armgo
DMXM2BZ CP Columbia University
DMXM2BZ DE Heart failure
DM9Y05C ID DM9Y05C
DM9Y05C DN S-(2-Aminophenyl)-L-cysteine S,S-dioxide
DM9Y05C HS Preclinical
DM9Y05C SN SCHEMBL9065263
DM9Y05C DT Small molecular drug
DM9Y05C PC 10263849
DM9Y05C MW 244.27
DM9Y05C FM C9H12N2O4S
DM9Y05C IC InChI=1S/C9H12N2O4S/c10-6-3-1-2-4-8(6)16(14,15)5-7(11)9(12)13/h1-4,7H,5,10-11H2,(H,12,13)/t7-/m0/s1
DM9Y05C CS C1=CC=C(C(=C1)N)S(=O)(=O)C[C@@H](C(=O)O)N
DM9Y05C IK JJUXYMMPJKOKBD-ZETCQYMHSA-N
DM9Y05C IU (2R)-2-amino-3-(2-aminophenyl)sulfonylpropanoic acid
DM9Y05C DE Bacterial infection
DM4V8ZD ID DM4V8ZD
DM4V8ZD DN S32504
DM4V8ZD HS Preclinical
DM4V8ZD SN CHEMBL484599; SCHEMBL3831115; BDBM86473; LS-192133; S32504 (+); (+/-)-trans-3,4,4a,5,6,10b-hexahydro-9-carbamoyl-4-propyl-2h-naphth[1,2-b]-1,4-oxazine
DM4V8ZD CP Shionogi
DM4V8ZD DT Small molecular drug
DM4V8ZD PC 15389743
DM4V8ZD MW 274.36
DM4V8ZD FM C16H22N2O2
DM4V8ZD IC InChI=1S/C16H22N2O2/c1-2-7-18-8-9-20-15-13-10-12(16(17)19)4-3-11(13)5-6-14(15)18/h3-4,10,14-15H,2,5-9H2,1H3,(H2,17,19)/t14-,15-/m1/s1
DM4V8ZD CS CCCN1CCO[C@H]2[C@H]1CCC3=C2C=C(C=C3)C(=O)N
DM4V8ZD IK XKTRZPQOQOCNJU-HUUCEWRRSA-N
DM4V8ZD IU (4aR,10bR)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazine-9-carboxamide
DM4V8ZD DE Parkinson disease; Major depressive disorder
DMWQ3TH ID DMWQ3TH
DMWQ3TH DN S-33084
DMWQ3TH HS Preclinical
DMWQ3TH SN Benzopyrano[3,4-c]pyrrole derivs, Servier
DMWQ3TH CP Servier
DMWQ3TH DT Small molecular drug
DMWQ3TH PC 9868452
DMWQ3TH MW 451.6
DMWQ3TH FM C29H29N3O2
DMWQ3TH IC InChI=1S/C29H29N3O2/c30-17-21-8-13-28-26(16-21)27-19-32(18-25(27)20-34-28)15-5-4-14-31-29(33)24-11-9-23(10-12-24)22-6-2-1-3-7-22/h1-3,6-13,16,25,27H,4-5,14-15,18-20H2,(H,31,33)/t25-,27+/m1/s1
DMWQ3TH CS C1[C@@H]2COC3=C([C@H]2CN1CCCCNC(=O)C4=CC=C(C=C4)C5=CC=CC=C5)C=C(C=C3)C#N
DMWQ3TH IK QQJHRQZZCNYDMX-VPUSJEBWSA-N
DMWQ3TH IU N-[4-[(3aR,9bS)-8-cyano-3,3a,4,9b-tetrahydro-1H-chromeno[3,4-c]pyrrol-2-yl]butyl]-4-phenylbenzamide
DMWQ3TH CA CAS 273203-30-8
DMWQ3TH DE Psychotic disorder
DMGXVRZ ID DMGXVRZ
DMGXVRZ DN Salicylihalamide A
DMGXVRZ HS Preclinical
DMGXVRZ SN SCHEMBL2401788
DMGXVRZ DT Small molecular drug
DMGXVRZ PC 643725
DMGXVRZ MW 439.5
DMGXVRZ FM C26H33NO5
DMGXVRZ IC InChI=1S/C26H33NO5/c1-3-4-5-6-16-24(30)27-17-10-14-21-18-23(29)19(2)11-7-8-12-20-13-9-15-22(28)25(20)26(31)32-21/h4-10,13,15-17,19,21,23,28-29H,3,11-12,14,18H2,1-2H3,(H,27,30)/b5-4-,8-7+,16-6-,17-10+/t19-,21-,23+/m0/s1
DMGXVRZ CS CC/C=C\\C=C/C(=O)N/C=C/C[C@H]1C[C@H]([C@H](C/C=C/CC2=C(C(=CC=C2)O)C(=O)O1)C)O
DMGXVRZ IK VFCUJHFLFHQCRD-PFIOQAQVSA-N
DMGXVRZ IU (2Z,4Z)-N-[(E)-3-[(4S,6R,7S,9E)-6,16-dihydroxy-7-methyl-2-oxo-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-4-yl]prop-1-enyl]hepta-2,4-dienamide
DMGXVRZ CA CAS 198481-99-1
DMGXVRZ DE Solid tumour/cancer
DMLMRGH ID DMLMRGH
DMLMRGH DN Saliphenylhalamide
DMLMRGH HS Preclinical
DMLMRGH SN RTA-203; Saliphenylhalamide (cancer); Saliphenylhalamide (cancer), Reata; V-ATPase inhibitor (cancer), Reata; Vacuolar H+-ATPase inhibitors (anticancer), Reata
DMLMRGH CP Reata Pharmaceuticals Inc
DMLMRGH DT Small molecular drug
DMLMRGH PC 11271117
DMLMRGH MW 459.5
DMLMRGH FM C28H29NO5
DMLMRGH IC InChI=1S/C28H29NO5/c1-20-9-5-6-12-22-13-7-15-24(30)27(22)28(33)34-23(19-25(20)31)14-8-18-29-26(32)17-16-21-10-3-2-4-11-21/h2-8,10-11,13,15,18,20,23,25,30-31H,9,12,14,19H2,1H3,(H,29,32)/b6-5+,18-8+/t20-,23-,25+/m0/s1
DMLMRGH CS C[C@H]1C/C=C/CC2=C(C(=CC=C2)O)C(=O)O[C@H](C[C@H]1O)C/C=C/NC(=O)C#CC3=CC=CC=C3
DMLMRGH IK FTBLSENPBXIDKK-ZZHCZQHNSA-N
DMLMRGH IU N-[(E)-3-[(4S,6R,7S,9E)-6,16-dihydroxy-7-methyl-2-oxo-3-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraen-4-yl]prop-1-enyl]-3-phenylprop-2-ynamide
DMLMRGH DE Solid tumour/cancer
DM7E324 ID DM7E324
DM7E324 DN SAND-5
DM7E324 HS Preclinical
DM7E324 SN Mubodina; Complement C5 minibody (hemolytic uremic syndrome/hemolytic uremic syndrome), ADIENNE
DM7E324 CP ADIENNE Pharma & Biotech
DM7E324 DE Glomerulonephritis
DM7NS1L ID DM7NS1L
DM7NS1L DN Savirin
DM7NS1L HS Preclinical
DM7NS1L SN 3-(4-propan-2-ylphenyl)sulfonyl-1H-triazolo[1,5-a]quinazolin-5-one; 866350-26-7; 3-[(4-isopropylphenyl)sulfonyl][1,2,3]triazolo[1,5-a]quinazolin-5(4H)-one; 3-[4-(propan-2-yl)benzenesulfonyl]-4H,5H-[1,2,3]triazolo[1,5-a]quinazolin-5-one; SMR000016143; MLS000103489; MLS000044860; CHEMBL1494499; CHEBI:107601; HMS2494G18; ZINC8762827; CCG-27345; HTS003632; MFCD05899664; STL094729; AKOS005723252; BS-6686; MCULE-8359721687; UNM000011043901; SR-01000104752; SR-01000104752-1; Q27185926; 3-{[4-(propan-2-yl)phenyl]sulfonyl}[1,2,3]triazolo[1,5-a]quinazolin-5(4H)-one
DM7NS1L DT Small molecular drug
DM7NS1L PC 3243271
DM7NS1L MW 368.4
DM7NS1L FM C18H16N4O3S
DM7NS1L IC InChI=1S/C18H16N4O3S/c1-11(2)12-7-9-13(10-8-12)26(24,25)18-16-19-17(23)14-5-3-4-6-15(14)22(16)21-20-18/h3-11,21H,1-2H3
DM7NS1L CS CC(C)C1=CC=C(C=C1)S(=O)(=O)C2=NNN3C2=NC(=O)C4=CC=CC=C43
DM7NS1L IK GIFXGSITUBUVGH-UHFFFAOYSA-N
DM7NS1L IU 3-(4-propan-2-ylphenyl)sulfonyl-1H-triazolo[1,5-a]quinazolin-5-one
DM7NS1L CB CHEBI:107601
DM7NS1L DE Staphylococcus infection
DMFXJDL ID DMFXJDL
DMFXJDL DN SB 242784
DMFXJDL HS Preclinical
DMFXJDL CP SmithKline Beecham Biologicals
DMFXJDL DT Small molecular drug
DMFXJDL DE Arterial calcification
DM6X0PZ ID DM6X0PZ
DM6X0PZ DN SB222200
DM6X0PZ HS Preclinical
DM6X0PZ SN S 5192; SB 222200; SB-222200; N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide; (S)-3-Methyl-2-phenyl-N-(1-phenylpropyl)-4-quinolinecarboxamide; 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DM6X0PZ CP GlaxoSmithKline
DM6X0PZ DT Small molecular drug
DM6X0PZ PC 6604009
DM6X0PZ MW 380.5
DM6X0PZ FM C26H24N2O
DM6X0PZ IC InChI=1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1
DM6X0PZ CS CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)C
DM6X0PZ IK MQNYRKWJSMQECI-QFIPXVFZSA-N
DM6X0PZ IU 3-methyl-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
DM6X0PZ CA CAS 174635-69-9
DM6X0PZ CB CHEBI:92079
DM6X0PZ DE Schizoaffective disorder; Schizophrenia
DM0YOXQ ID DM0YOXQ
DM0YOXQ DN SB-431542
DM0YOXQ HS Preclinical
DM0YOXQ SN 301836-41-9; SB-431542; SB 431542; 4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide; SB431542; UNII-E1557V1V0N; CHEMBL440084; E1557V1V0N; 4-[4-(1,3-BENZODIOXOL-5-YL)-5-(2-PYRIDINYL)-1H-IMIDAZOL-2-YL]BENZAMIDE; 4-(4-(1,3-Benzodioxole-5-yl)-5-(2-pyridyl)-1H-imidazole-2-yl)benzamide; SB 431542 hydrate; C22H16N4O3; 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide; 4-(4-Benzo[1,3]dioxol-5-yl-5-pyridin-2-yl-1H-imidazol-2-yl)-benzamide
DM0YOXQ DT Small molecular drug
DM0YOXQ PC 4521392
DM0YOXQ MW 384.4
DM0YOXQ FM C22H16N4O3
DM0YOXQ IC InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)
DM0YOXQ CS C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
DM0YOXQ IK FHYUGAJXYORMHI-UHFFFAOYSA-N
DM0YOXQ IU 4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
DM0YOXQ CA CAS 301836-41-9
DM0YOXQ CB CHEBI:91108
DM0YOXQ DE Pulmonary fibrosis
DMXN4UC ID DMXN4UC
DMXN4UC DN SBX-101
DMXN4UC HS Preclinical
DMXN4UC CP Symberix
DMXN4UC DE Intestinal toxicities from therapy
DMLG682 ID DMLG682
DMLG682 DN SCH-1359113
DMLG682 HS Preclinical
DMLG682 SN SCH-1341030; SCH-1682496; SCH-745966; SCH-747123; SCH-785532; BACE-1 inhibitors (Alzheimer's disease); BACE-1 inhibitors (Alzheimer's disease), Merck & Co; BACE-1 inhibitors (Alzheimer's disease), Schering-Plough; Beta-secretase inhibitors (Alzheimer's disease), Schering-Plough
DMLG682 CP Schering-Plough Corp
DMLG682 DT Small molecular drug
DMLG682 PC 23627211
DMLG682 MW 338.4
DMLG682 FM C18H18N4OS
DMLG682 IC InChI=1S/C18H18N4OS/c1-4-5-12-6-13(10-20-9-12)14-7-15(24-11-14)18(2)8-16(23)22(3)17(19)21-18/h6-7,9-11H,8H2,1-3H3,(H2,19,21)/t18-/m0/s1
DMLG682 CS CC#CC1=CC(=CN=C1)C2=CSC(=C2)[C@@]3(CC(=O)N(C(=N3)N)C)C
DMLG682 IK IKFZEHQGULJMKI-SFHVURJKSA-N
DMLG682 IU (6S)-2-amino-3,6-dimethyl-6-[4-(5-prop-1-ynylpyridin-3-yl)thiophen-2-yl]-5H-pyrimidin-4-one
DMLG682 CA CAS 1613380-81-6
DMLG682 DE Alzheimer disease
DM9JZ21 ID DM9JZ21
DM9JZ21 DN Scriptaid
DM9JZ21 HS Preclinical
DM9JZ21 SN CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
DM9JZ21 CP Alexis Biochemicals
DM9JZ21 DT Small molecular drug
DM9JZ21 PC 5186
DM9JZ21 MW 326.3
DM9JZ21 FM C18H18N2O4
DM9JZ21 IC InChI=1S/C18H18N2O4/c21-15(19-24)10-2-1-3-11-20-17(22)13-8-4-6-12-7-5-9-14(16(12)13)18(20)23/h4-9,24H,1-3,10-11H2,(H,19,21)
DM9JZ21 CS C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO
DM9JZ21 IK JTDYUFSDZATMKU-UHFFFAOYSA-N
DM9JZ21 IU 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
DM9JZ21 CA CAS 287383-59-9
DM9JZ21 CB CHEBI:92401
DM9JZ21 DE Solid tumour/cancer
DMJT1E5 ID DMJT1E5
DMJT1E5 DN Scutellarin
DMJT1E5 HS Preclinical
DMJT1E5 SN Scutellarin; Breviscapin; Scutellarein-7-glucuronide; Scutellarin B; Breviscapine; Scutellarein-7beta-D-glucuronide; Scutellarein 7-beta-D-glucuronide; Scutellarein-7beta-D-glucuronoside; Scutellarein-7-O-beta-D-glucuronide; UNII-16IGP0ML9A; Scutellarein 7-b-D-glucuronide; Scutellarein 7-O-beta-D-glucuronide; 16IGP0ML9A; SCUTELLAREIN 7-O-GLUCURONIDE; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl
DMJT1E5 PC 185617
DMJT1E5 MW 462.4
DMJT1E5 FM C21H18O12
DMJT1E5 IC InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1
DMJT1E5 CS C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O
DMJT1E5 IK DJSISFGPUUYILV-ZFORQUDYSA-N
DMJT1E5 IU (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMJT1E5 CA CAS 27740-01-8
DMJT1E5 CB CHEBI:61278
DMJT1E5 DE Cerebrovascular ischaemia
DMELFBU ID DMELFBU
DMELFBU DN SCY-641
DMELFBU HS Preclinical
DMELFBU CP SCYNEXIS
DMELFBU DE Ocular inflammation
DMLAF6C ID DMLAF6C
DMLAF6C DN SD1002
DMLAF6C HS Preclinical
DMLAF6C DT Small molecular drug
DMLAF6C DE Alzheimer disease
DM29BW1 ID DM29BW1
DM29BW1 DN SD1003
DM29BW1 HS Preclinical
DM29BW1 DT Small molecular drug
DM29BW1 DE Alzheimer disease
DM5LU3N ID DM5LU3N
DM5LU3N DN Selamectin
DM5LU3N HS Preclinical
DM5LU3N SN selamectin; UNII-A2669OWX9N; A2669OWX9N; UK-124,114; 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 monosaccharide; Stronghold; Revolution; 220119-17-5; 25-Cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin A1a
DM5LU3N PC 9578507
DM5LU3N MW 770
DM5LU3N FM C43H63NO11
DM5LU3N IC InChI=1S/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26,28-29,31-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3/b11-10+,25-15+,30-14+,44-36-/t24-,26-,28-,31+,32-,33-,34-,35-,37-,38-,39-,40+,42+,43+/m0/s1
DM5LU3N CS CC1CCC2(CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5=NO)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)O)OC)C)OC1C7CCCCC7
DM5LU3N IK AFJYYKSVHJGXSN-XHKIUTQPSA-N
DM5LU3N IU (1R,4S,5'S,6R,6'S,8R,10E,12S,13S,14E,16E,20R,21Z,24S)-6'-cyclohexyl-24-hydroxy-21-hydroxyimino-12-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
DM5LU3N CA CAS 165108-07-6
DM5LU3N DE Infections disease
DMH1WNI ID DMH1WNI
DMH1WNI DN SGN-19A
DMH1WNI HS Preclinical
DMH1WNI CP Seattle Genetics
DMH1WNI DT Antibody
DMH1WNI DE Haematological malignancy
DMHAONP ID DMHAONP
DMHAONP DN SHP-627
DMHAONP HS Preclinical
DMHAONP SN FT011; 1001288-58-9; FT-011; UNII-C6V7ZU2NPR; C6V7ZU2NPR; 2-(3-Methoxy-4-propargyloxycinnamoyl)aminobenzoic acid; 2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid; Benzoic acid, 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)-; Benzoic acid, 2-[[(2E)-3-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]-1-oxo-2-propen-1-yl]amino]-; SCHEMBL1590608; SCHEMBL1590611; CHEMBL1075834; FT 011; ZINC49050436; CS-5842; SB16798; HY-100495; (E)-2-[[3-(3-methoxy-4-(prop-2-ynyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid; (E)-2-[[3-(3-methoxy-4-propargyloxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid; 2-(((2E)-3-(3-Methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid
DMHAONP DT Small molecular drug
DMHAONP PC 23648966
DMHAONP MW 351.4
DMHAONP FM C20H17NO5
DMHAONP IC InChI=1S/C20H17NO5/c1-3-12-26-17-10-8-14(13-18(17)25-2)9-11-19(22)21-16-7-5-4-6-15(16)20(23)24/h1,4-11,13H,12H2,2H3,(H,21,22)(H,23,24)/b11-9+
DMHAONP CS COC1=C(C=CC(=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OCC#C
DMHAONP IK UIWZIDIJCUEOMT-PKNBQFBNSA-N
DMHAONP IU 2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid
DMHAONP CA CAS 1001288-58-9
DMHAONP DE Cardiac arrest
DM8DYJQ ID DM8DYJQ
DM8DYJQ DN SHP656
DM8DYJQ HS Preclinical
DM8DYJQ DT Small molecular drug
DM8DYJQ DE Glioblastoma of brain
DMWBCTA ID DMWBCTA
DMWBCTA DN SIS-3
DMWBCTA HS Preclinical
DMWBCTA SN SIS3 free base; Smad3 Inhibitor, SIS3; 1009104-85-1; Specific Inhibitor of Smad3; SIS3 (free base); (E)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 521985-36-4; Smad3 inhibitor SIS3; (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; SCHEMBL6479525; SCHEMBL6479530; CHEMBL4303604; CHEBI:87589; 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; ZINC34299760; NCGC00387473-03; 6,7-Dimethyl-2-((2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-prop-2-enoyl))-1,2,3,4-tetrahydroisoquinoline; HY-100444; CS-0019029; J3.550.832E; J-000258; Q27159754; (2E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one; 2-Propen-1-one, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-
DMWBCTA DT Small molecular drug
DMWBCTA PC 10138988
DMWBCTA MW 453.5
DMWBCTA FM C28H27N3O3
DMWBCTA IC InChI=1S/C28H27N3O3/c1-30-27(19-8-5-4-6-9-19)22(23-10-7-14-29-28(23)30)11-12-26(32)31-15-13-20-16-24(33-2)25(34-3)17-21(20)18-31/h4-12,14,16-17H,13,15,18H2,1-3H3/b12-11+
DMWBCTA CS CN1C(=C(C2=C1N=CC=C2)/C=C/C(=O)N3CCC4=CC(=C(C=C4C3)OC)OC)C5=CC=CC=C5
DMWBCTA IK IJYPHMXWKKKHGT-VAWYXSNFSA-N
DMWBCTA IU (E)-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one
DMWBCTA CA CAS 1009104-85-1
DMWBCTA CB CHEBI:87589
DMWBCTA DE Renal fibrosis
DM7DNOG ID DM7DNOG
DM7DNOG DN SK-7041
DM7DNOG HS Preclinical
DM7DNOG SN IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
DM7DNOG DT Small molecular drug
DM7DNOG PC 6918714
DM7DNOG MW 339.4
DM7DNOG FM C19H21N3O3
DM7DNOG IC InChI=1S/C19H21N3O3/c1-22(2)17-10-8-16(9-11-17)19(24)20-13-15-5-3-14(4-6-15)7-12-18(23)21-25/h3-12,25H,13H2,1-2H3,(H,20,24)(H,21,23)/b12-7+
DM7DNOG CS CN(C)C1=CC=C(C=C1)C(=O)NCC2=CC=C(C=C2)/C=C/C(=O)NO
DM7DNOG IK WWMASNYTEATYTC-KPKJPENVSA-N
DM7DNOG IU 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
DM7DNOG DE Solid tumour/cancer
DMCI371 ID DMCI371
DMCI371 DN SK-7068
DMCI371 HS Preclinical
DMCI371 SN N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide
DMCI371 DT Small molecular drug
DMCI371 PC 9799221
DMCI371 MW 365.4
DMCI371 FM C21H23N3O3
DMCI371 IC InChI=1S/C21H23N3O3/c25-20(23-27)12-7-16-3-5-17(6-4-16)15-22-21(26)18-8-10-19(11-9-18)24-13-1-2-14-24/h3-12,27H,1-2,13-15H2,(H,22,26)(H,23,25)/b12-7+
DMCI371 CS C1CCN(C1)C2=CC=C(C=C2)C(=O)NCC3=CC=C(C=C3)/C=C/C(=O)NO
DMCI371 IK JKVNVKOVLBVYHQ-KPKJPENVSA-N
DMCI371 IU N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]-4-pyrrolidin-1-ylbenzamide
DMCI371 DE Solid tumour/cancer
DMY9DA3 ID DMY9DA3
DMY9DA3 DN SLV-332
DMY9DA3 HS Preclinical
DMY9DA3 SN AC1MHEA6; Isoxyl &
DMY9DA3 CP Solvay
DMY9DA3 DT Small molecular drug
DMY9DA3 PC 3002337
DMY9DA3 MW 553.7
DMY9DA3 FM C30H39N3O5S
DMY9DA3 IC InChI=1S/C23H32N2O2S.C7H7NO3/c1-17(2)13-15-26-21-9-5-19(6-10-21)24-23(28)25-20-7-11-22(12-8-20)27-16-14-18(3)4;8-4-1-2-5(7(10)11)6(9)3-4/h5-12,17-18H,13-16H2,1-4H3,(H2,24,25,28);1-3,9H,8H2,(H,10,11)
DMY9DA3 CS CC(C)CCOC1=CC=C(C=C1)NC(=S)NC2=CC=C(C=C2)OCCC(C)C.C1=CC(=C(C=C1N)O)C(=O)O
DMY9DA3 IK HHBOLVQEBVCBNA-UHFFFAOYSA-N
DMY9DA3 IU 4-amino-2-hydroxybenzoic acid;1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
DMY9DA3 DE Irritable bowel syndrome
DM3X4JL ID DM3X4JL
DM3X4JL DN SMITB14
DM3X4JL HS Preclinical
DM3X4JL DT Antibody
DM3X4JL DE Mycobacterium infection
DM5KE4R ID DM5KE4R
DM5KE4R DN SNAP-7941
DM5KE4R HS Preclinical
DM5KE4R SN Snap7941
DM5KE4R CP Synaptic
DM5KE4R DT Small molecular drug
DM5KE4R PC 11520239
DM5KE4R MW 613.7
DM5KE4R FM C31H37F2N5O6
DM5KE4R IC InChI=1S/C31H37F2N5O6/c1-19(39)35-23-7-4-6-21(16-23)20-10-14-37(15-11-20)13-5-12-34-30(41)38-28(22-8-9-24(32)25(33)17-22)27(29(40)44-3)26(18-43-2)36-31(38)42/h4,6-9,16-17,20,28H,5,10-15,18H2,1-3H3,(H,34,41)(H,35,39)(H,36,42)/t28-/m0/s1
DM5KE4R CS CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCNC(=O)N3[C@H](C(=C(NC3=O)COC)C(=O)OC)C4=CC(=C(C=C4)F)F
DM5KE4R IK FWMHZWMPUWAUPL-NDEPHWFRSA-N
DM5KE4R IU methyl (4S)-3-[3-[4-(3-acetamidophenyl)piperidin-1-yl]propylcarbamoyl]-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,4-dihydropyrimidine-5-carboxylate
DM5KE4R DE Depression; Anxiety disorder; Obesity
DMSNX4O ID DMSNX4O
DMSNX4O DN SoRI-9409
DMSNX4O HS Preclinical
DMSNX4O SN SoRI-9409; CHEMBL610261
DMSNX4O CP Southern Research Institute
DMSNX4O DT Small molecular drug
DMSNX4O PC 9805452
DMSNX4O MW 487
DMSNX4O FM C29H27ClN2O3
DMSNX4O IC InChI=1S/C29H27ClN2O3/c30-21-6-3-17(4-7-21)20-11-19-13-29(34)23-12-18-5-8-22(33)26-24(18)28(29,27(35-26)25(19)31-14-20)9-10-32(23)15-16-1-2-16/h3-8,11,14,16,23,27,33-34H,1-2,9-10,12-13,15H2/t23-,27+,28+,29-/m1/s1
DMSNX4O CS C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C=C(C=N6)C8=CC=C(C=C8)Cl
DMSNX4O IK WRVDUHKCIPYGNZ-FQYQUSJJSA-N
DMSNX4O IU (1S,2S,10R,18R)-6-(4-chlorophenyl)-19-(cyclopropylmethyl)-11-oxa-8,19-diazahexacyclo[10.9.1.01,10.02,18.04,9.016,22]docosa-4(9),5,7,12,14,16(22)-hexaene-2,13-diol
DMSNX4O DE Alcohol dependence
DMJHWYP ID DMJHWYP
DMJHWYP DN Spautin 1
DMJHWYP HS Preclinical
DMJHWYP SN Spautin-1; 1262888-28-7; 6-Fluoro-N-(4-fluorobenzyl)quinazolin-4-amine; 6-fluoro-N-[(4-fluorophenyl)methyl]quinazolin-4-amine; CHEMBL2391504; 6-Fluoro-N-[(4-Fluorophenyl)methyl]-4-quinazolinamine; 4-Quinazolinamine, 6-fluoro-N-[(4-fluorophenyl)methyl]-; Spautin-1 analogue; MBCQ derivative C43; MLS006010730; SCHEMBL1068401; AOB5088; EX-A668; HMS3750O05; HMS3871D13; Spautin-1, >=98% (HPLC); BCP15695; BCP16463; BDBM50069761; MFCD16962292; s7888; ZINC41470892; AKOS016367939; CCG-267171; CS-4616; MCULE-4088585655; SB19056; NCGC00263555-02; NCGC00263555-05; NCGC00263555-07; AK161228; AS-69827; HY-12990; SMR004701692; DS-017062; B5873; FT-0700152; J-690113; Spautin 1 analogue;Spautin1 analogue;N-(4-chlorobenzyl)-6-fluoroquinazoline-4-amine; C43
DMJHWYP CP Shanghai Institute of Organic Chemistry; Harvard Medical School
DMJHWYP DT Small molecular drug
DMJHWYP PC 51037431
DMJHWYP MW 271.26
DMJHWYP FM C15H11F2N3
DMJHWYP IC InChI=1S/C15H11F2N3/c16-11-3-1-10(2-4-11)8-18-15-13-7-12(17)5-6-14(13)19-9-20-15/h1-7,9H,8H2,(H,18,19,20)
DMJHWYP CS C1=CC(=CC=C1CNC2=NC=NC3=C2C=C(C=C3)F)F
DMJHWYP IK AWIVHRPYFSSVOG-UHFFFAOYSA-N
DMJHWYP IU 6-fluoro-N-[(4-fluorophenyl)methyl]quinazolin-4-amine
DMJHWYP CA CAS 1262888-28-7
DMJHWYP DE Inflammation
DMMA2ZW ID DMMA2ZW
DMMA2ZW DN SPH-1285
DMMA2ZW HS Preclinical
DMMA2ZW SN Galantamine derivatives, Sanochemia; SPH-1286; SPH-1359
DMMA2ZW CP Sanochemia Pharmazeutika AG
DMMA2ZW DE Alzheimer disease
DM32NMB ID DM32NMB
DM32NMB DN S-Phenyl-L-cysteine sulfoxide
DM32NMB HS Preclinical
DM32NMB SN S-phenyl-l-cysteine sulfoxide; 3-(Phenylsulfinyl)-L-alanine; SCHEMBL17894423; (2R)-2-Amino-3-(phenylsulfinyl)propanoic acid; 103000-63-1
DM32NMB DT Small molecular drug
DM32NMB PC 101712556
DM32NMB MW 213.26
DM32NMB FM C9H11NO3S
DM32NMB IC InChI=1S/C9H11NO3S/c10-8(9(11)12)6-14(13)7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-,14?/m0/s1
DM32NMB CS C1=CC=C(C=C1)S(=O)C[C@@H](C(=O)O)N
DM32NMB IK YIYUCMJLQCHZLS-BVVIDWAXSA-N
DM32NMB IU (2R)-2-amino-3-(benzenesulfinyl)propanoic acid
DM32NMB DE Bacterial infection
DMYZQKC ID DMYZQKC
DMYZQKC DN SPHINX31
DMYZQKC HS Preclinical
DMYZQKC SN 1818389-84-2; N-(2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-5-(trifluoromethyl)phenyl)-5-(pyridin-4-yl)furan-2-carboxamide; 5-(4-pyridinyl)-N-[2-[4-(2-pyridinylmethyl)-1-piperazinyl]-5-(trifluoromethyl)phenyl]-2-furancarboxamide; SPHINX 31;SPHINX-31; SCHEMBL17196904; BDBM221074; AMY11306; BCP30381; EX-A2804; s8810; BS-16147; HY-117661; CS-0066777; US9695160, 12; RXZ
DMYZQKC CP Exonate
DMYZQKC DT Small molecular drug
DMYZQKC PC 91972002
DMYZQKC MW 507.5
DMYZQKC FM C27H24F3N5O2
DMYZQKC IC InChI=1S/C27H24F3N5O2/c28-27(29,30)20-4-5-23(35-15-13-34(14-16-35)18-21-3-1-2-10-32-21)22(17-20)33-26(36)25-7-6-24(37-25)19-8-11-31-12-9-19/h1-12,17H,13-16,18H2,(H,33,36)
DMYZQKC CS C1CN(CCN1CC2=CC=CC=N2)C3=C(C=C(C=C3)C(F)(F)F)NC(=O)C4=CC=C(O4)C5=CC=NC=C5
DMYZQKC IK VURLRACCOCGFDB-UHFFFAOYSA-N
DMYZQKC IU 5-pyridin-4-yl-N-[2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]-5-(trifluoromethyl)phenyl]furan-2-carboxamide
DMYZQKC DE Wet age-related macular degeneration
DMC1WAJ ID DMC1WAJ
DMC1WAJ DN SPI-376
DMC1WAJ HS Preclinical
DMC1WAJ SN NEO 376; SCHEMBL1253420; CQSQHUPRBBCQRE-UHFFFAOYSA-N; CS-6790; HY-101583; L001673; 1-{2-[4-(3-Chlorophenyl)piperazin-1-yl]ethyl}-1,5,6,7-tetrahydroindol 4-one; 1-{2-[4-(3-Chlorophenyl)piperazin-1-yl]ethyl}-1,5,6,7-tetrahydroindol-4-one; 1-{2-[4-(3-Chloro-phenyl)-piperazin-1-yl]-ethyl}-1,5,6,7-tetrahydro-indol 4-one
DMC1WAJ CP Spectrum Pharmaceuticals
DMC1WAJ DT Small molecular drug
DMC1WAJ PC 9906770
DMC1WAJ MW 357.9
DMC1WAJ FM C20H24ClN3O
DMC1WAJ IC InChI=1S/C20H24ClN3O/c21-16-3-1-4-17(15-16)23-12-9-22(10-13-23)11-14-24-8-7-18-19(24)5-2-6-20(18)25/h1,3-4,7-8,15H,2,5-6,9-14H2
DMC1WAJ CS C1CC2=C(C=CN2CCN3CCN(CC3)C4=CC(=CC=C4)Cl)C(=O)C1
DMC1WAJ IK CQSQHUPRBBCQRE-UHFFFAOYSA-N
DMC1WAJ IU 1-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]-6,7-dihydro-5H-indol-4-one
DMC1WAJ DE Schizophrenia
DMO2UKI ID DMO2UKI
DMO2UKI DN SP-MET-1
DMO2UKI HS Preclinical
DMO2UKI SN S1004A receptor antagonist (cancer), Supratek; SP-MET-X1; Antimetastatic agent (oral, cancer), Supratek; S1004A receptor antagonist (oral, melanoma/breast/colorectal cancer), Supratek
DMO2UKI CP Supratek Pharma Inc
DMO2UKI DE Breast cancer
DM7MDZE ID DM7MDZE
DM7MDZE DN SR1078
DM7MDZE HS Preclinical
DM7MDZE SN 1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2
DM7MDZE DT Small molecular drug
DM7MDZE PC 17980288
DM7MDZE MW 431.25
DM7MDZE FM C17H10F9NO2
DM7MDZE IC InChI=1S/C17H10F9NO2/c18-15(19,20)11-3-1-9(2-4-11)13(28)27-12-7-5-10(6-8-12)14(29,16(21,22)23)17(24,25)26/h1-8,29H,(H,27,28)
DM7MDZE CS C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)C(F)(F)F
DM7MDZE IK DUXWIYXHHGNUJU-UHFFFAOYSA-N
DM7MDZE IU N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide
DM7MDZE CA CAS 1246525-60-9
DM7MDZE DE Liver cancer
DMZV9JX ID DMZV9JX
DMZV9JX DN SR1555
DMZV9JX HS Preclinical
DMZV9JX SN CHEMBL3218917; SR-1555; 1386439-51-5; 1-(4-((4'-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1'-biphenyl]-4-yl)methyl)piperazin-1-yl)ethan-1-one; 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone; SCHEMBL13974905; GTPL10145; BDBM50044227; ZINC95537675
DMZV9JX DT Small molecular drug
DMZV9JX PC 71470549
DMZV9JX MW 460.4
DMZV9JX FM C22H22F6N2O2
DMZV9JX IC InChI=1S/C22H22F6N2O2/c1-15(31)30-12-10-29(11-13-30)14-16-2-4-17(5-3-16)18-6-8-19(9-7-18)20(32,21(23,24)25)22(26,27)28/h2-9,32H,10-14H2,1H3
DMZV9JX CS CC(=O)N1CCN(CC1)CC2=CC=C(C=C2)C3=CC=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O
DMZV9JX IK LTFVNEZXOPUABB-UHFFFAOYSA-N
DMZV9JX IU 1-[4-[[4-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]phenyl]methyl]piperazin-1-yl]ethanone
DMZV9JX DE Rheumatoid arthritis
DMWCBG8 ID DMWCBG8
DMWCBG8 DN SR2211
DMWCBG8 HS Preclinical
DMWCBG8 SN 1359164-11-6; sr-2211; SR 2211; CHEMBL2137199; 1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol; 1,1,1,3,3,3-hexafluoro-2-[2-fluoro-4'-({4-[(pyridin-4-yl)methyl]piperazin-1-yl}methyl)[1,1'-biphenyl]-4-yl]propan-2-ol; 2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-; A,; A-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; 2-fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-aa-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; MLS004256334; SCHEMBL13974431; C26H24F7N3O; GTPL10144; AOB1053; SYN5040; ML310; BDBM50005410; ZINC95571083; AKOS024458387; NCGC00379220-06; AS-16406; HY-16998; SMR003081219; B5743; CS-0013508; J3.525.407B; SR-03000002211; SR-03000002211-1; 1,1,1,3,3,3-hexafluoro-2-(2-fluoro-4'-((4-(pyridin-4-ylmethyl)piperazin-1-yl)methyl)-[1,1'-biphenyl]-4-yl)propan-2-ol; 2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-?,?-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; 2-Fluoro-4'-[[4-(4-pyridinylmethyl)-1-piperazinyl]methyl]-a,a-bis(trifluoromethyl)-[1,1'-biphenyl]-4-methanol; 2-Fluoro-4'-[[4-(4-pyridinylMethyl)-1-piperazinyl]Methyl]-alpha,alpha-bis(trifluoroMethyl)-[1,1'-biphenyl]-4-Methanol; L7P
DMWCBG8 DT Small molecular drug
DMWCBG8 PC 51035449
DMWCBG8 MW 527.5
DMWCBG8 FM C26H24F7N3O
DMWCBG8 IC InChI=1S/C26H24F7N3O/c27-23-15-21(24(37,25(28,29)30)26(31,32)33)5-6-22(23)20-3-1-18(2-4-20)16-35-11-13-36(14-12-35)17-19-7-9-34-10-8-19/h1-10,15,37H,11-14,16-17H2
DMWCBG8 CS C1CN(CCN1CC2=CC=C(C=C2)C3=C(C=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O)F)CC4=CC=NC=C4
DMWCBG8 IK KVHKWAZUPPBMLL-UHFFFAOYSA-N
DMWCBG8 IU 1,1,1,3,3,3-hexafluoro-2-[3-fluoro-4-[4-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]phenyl]propan-2-ol
DMWCBG8 DE Autoimmune disease
DM96IUW ID DM96IUW
DM96IUW DN SR3335
DM96IUW HS Preclinical
DM96IUW SN 293753-05-6; SR-3335; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]thiophene-2-sulfonamide; 2-Thiophenesulfonamide, N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-thiophenesulfonamide; N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-2-thiophenesulfonamide; N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)thiophene-2-sulfonamide; MLS003126319; C13H9F6NO3S2; CHEMBL3218916; SCHEMBL12334063; CHEBI:92371; DTXSID70368245; HMS3740K07; ML176; BCP13177; ZINC3243391; 4064AH; CS-1044; NCGC00378899-02; NCGC00378899-03; AC-32811; AK547718; AS-74314; HY-14413; SMR001835204; W-5295; SR-06000113335-2; Q27164113; ML-176;SR 3335;SR-3335;ML176;ML 176; SR-3335;SR 3335; ML 176; ML-176; ML176; N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}thiophene-2-sulfonamide
DM96IUW DT Small molecular drug
DM96IUW PC 2360837
DM96IUW MW 405.3
DM96IUW FM C13H9F6NO3S2
DM96IUW IC InChI=1S/C13H9F6NO3S2/c14-12(15,16)11(21,13(17,18)19)8-3-5-9(6-4-8)20-25(22,23)10-2-1-7-24-10/h1-7,20-21H
DM96IUW CS C1=CSC(=C1)S(=O)(=O)NC2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
DM96IUW IK LZWUNZRMANFRAO-UHFFFAOYSA-N
DM96IUW IU N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]thiophene-2-sulfonamide
DM96IUW CA CAS 293753-05-6
DM96IUW CB CHEBI:92371
DM96IUW DE Type-2 diabetes
DMSK5N3 ID DMSK5N3
DMSK5N3 DN SR8278
DMSK5N3 HS Preclinical
DMSK5N3 SN SR 8278; SR-8278
DMSK5N3 DT Small molecular drug
DMSK5N3 PC 53393127
DMSK5N3 MW 361.5
DMSK5N3 FM C18H19NO3S2
DMSK5N3 IC InChI=1S/C18H19NO3S2/c1-3-22-18(21)14-10-12-6-4-5-7-13(12)11-19(14)17(20)15-8-9-16(23-2)24-15/h4-9,14H,3,10-11H2,1-2H3
DMSK5N3 CS CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C3=CC=C(S3)SC
DMSK5N3 IK UIEBLUZPSFAFOC-UHFFFAOYSA-N
DMSK5N3 IU ethyl 2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate
DMSK5N3 CA CAS 1254944-66-5
DMSK5N3 DE Myocardial disease
DM8SKU1 ID DM8SKU1
DM8SKU1 DN SR9009
DM8SKU1 HS Preclinical
DM8SKU1 SN 1379686-30-2; SR-9009; Stenabolic (SR9009); SR 9009; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate; CHEMBL1961796; 1-Pyrrolidinecarboxylic acid, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-, ethyl ester; 1-pyrrolidinecarboxylic acid, 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-, ethyl ester; GTPL8901; EX-A726; BCP16215; BDBM50366238; MFCD29472236; s8692; AKOS027470307; CCG-269102; CS-4669; DB14013; SB19006; NCGC00384202-01; AC-30219; AK547297; AS-55859; HY-16989; J-690150; Q15410184; N'-[(1E)-1-(5-Chloro-2-hydroxyphenyl)ethylidene]-3-(4-morpholinylsulfonyl)benzohydrazide; ethyl 3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate; ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitro-2-thienyl)methyl]amino]methyl]pyrrolidine-1-carboxylate; Ethyl 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-1-pyrrolidinecarboxylate
DM8SKU1 DT Small molecular drug
DM8SKU1 PC 57394020
DM8SKU1 MW 437.9
DM8SKU1 FM C20H24ClN3O4S
DM8SKU1 IC InChI=1S/C20H24ClN3O4S/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17(21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16H,2,9-14H2,1H3
DM8SKU1 CS CCOC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]
DM8SKU1 IK MMJJNHOIVCGAAP-UHFFFAOYSA-N
DM8SKU1 IU ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
DM8SKU1 CA CAS 1379686-30-2
DM8SKU1 DE Solid tumour/cancer
DMZ9BO8 ID DMZ9BO8
DMZ9BO8 DN SR9011
DMZ9BO8 HS Preclinical
DMZ9BO8 SN SR-9011; 1379686-29-9; CHEMBL1961797; 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide; 1-Pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl-; GTPL8900; BDBM50366239; CS-4668; DB14014; SB19005; SR 9011; NCGC00347956-01; AK547296; AS-55867; HY-16988; Q15410183
DMZ9BO8 DT Small molecular drug
DMZ9BO8 PC 57394021
DMZ9BO8 MW 479
DMZ9BO8 FM C23H31ClN4O3S
DMZ9BO8 IC InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29)
DMZ9BO8 CS CCCCCNC(=O)N1CCC(C1)CN(CC2=CC=C(C=C2)Cl)CC3=CC=C(S3)[N+](=O)[O-]
DMZ9BO8 IK PPUYOYQTTWJTIU-UHFFFAOYSA-N
DMZ9BO8 IU 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide
DMZ9BO8 CA CAS 1379686-29-9
DMZ9BO8 DE Solid tumour/cancer
DM84EOW ID DM84EOW
DM84EOW DN SSR-103800
DM84EOW HS Preclinical
DM84EOW CP Sanofi-Aventis
DM84EOW DE Schizophrenia
DMQTR4I ID DMQTR4I
DMQTR4I DN SSR-504734
DMQTR4I HS Preclinical
DMQTR4I SN 2-chloro-N-[(R)-phenyl-(2-piperidyl)methyl]-3-(trifluoromethyl)benzamide Hydrochloride
DMQTR4I CP Sanofi-Aventis
DMQTR4I DT Small molecular drug
DMQTR4I PC 9954540
DMQTR4I MW 396.8
DMQTR4I FM C20H20ClF3N2O
DMQTR4I IC InChI=1S/C20H20ClF3N2O/c21-17-14(9-6-10-15(17)20(22,23)24)19(27)26-18(13-7-2-1-3-8-13)16-11-4-5-12-25-16/h1-3,6-10,16,18,25H,4-5,11-12H2,(H,26,27)/t16-,18-/m0/s1
DMQTR4I CS C1CCN[C@@H](C1)[C@H](C2=CC=CC=C2)NC(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl
DMQTR4I IK MEZRZVWPLXVLSO-WMZOPIPTSA-N
DMQTR4I IU 2-chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide
DMQTR4I CA CAS 742693-38-5
DMQTR4I DE Schizophrenia
DM0NPIO ID DM0NPIO
DM0NPIO DN SSYA10-001
DM0NPIO HS Preclinical
DM0NPIO SN 3-[(2-Nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
DM0NPIO TC Antiviral Agents
DM0NPIO DT Small molecular drug
DM0NPIO DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMXZ08K ID DMXZ08K
DMXZ08K DN SSYA10-001
DMXZ08K HS Preclinical
DMXZ08K SN 3-[(2-nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione; MLS001181552; DSHS00884; SMR000567368; 675104-49-1; CHEMBL1595621; SCHEMBL15398584; BDBM61876; cid_2807230; HMS2884A17; CCG-45281; ZINC15923400; MCULE-1412768678; HY-113794; CS-0065749; SR-01000635060-1; 4-allyl-3-[[(2-nitrophenyl)thio]methyl]-1H-1,2,4-triazole-5-thione; 3-[(2-nitrophenyl)sulphanylmethyl]-4prop-2-enyl-1h-1,2,4-triazole-5-thione; 3-[[(2-nitrophenyl)thio]methyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
DMXZ08K DT Small molecular drug
DMXZ08K PC 2807230
DMXZ08K MW 308.4
DMXZ08K FM C12H12N4O2S2
DMXZ08K IC InChI=1S/C12H12N4O2S2/c1-2-7-15-11(13-14-12(15)19)8-20-10-6-4-3-5-9(10)16(17)18/h2-6H,1,7-8H2,(H,14,19)
DMXZ08K CS C=CCN1C(=NNC1=S)CSC2=CC=CC=C2[N+](=O)[O-]
DMXZ08K IK VWFIHGWHMXSTAO-UHFFFAOYSA-N
DMXZ08K IU 3-[(2-nitrophenyl)sulfanylmethyl]-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
DMXZ08K DE Coronavirus infection
DM7Y4GT ID DM7Y4GT
DM7Y4GT DN T-226293
DM7Y4GT HS Preclinical
DM7Y4GT SN Triparanol; TRIPARANOL; Metasqualene; MER 29; 78-41-1; triparanolum; valip; Metasclene; Clotrox; Triparanolo [DCIT]; Hipocolestina; Acosterina; Drenaren; Diticyl; Triparanol [INN:BAN]; Triparanolum [INN-Latin]; EINECS 201-115-0; NSC 65345; BRN 2064866; 1-(4-(2-Diethylaminoethoxy)phenyl)-1-p-tolyl-2-(4-chlorophenyl)ethanol; CHEMBL187709; 2-p-Chlorophenyl-1-(p-(2-diethylaminoethoxy)phenyl)-1-p-tolylethanol; 1-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(p-tolyl)-2-(p-chlorophenyl)ethanol; NCGC00165907-02
DM7Y4GT CP Schering Plough
DM7Y4GT DT Small molecular drug
DM7Y4GT PC 6536
DM7Y4GT MW 438
DM7Y4GT FM C27H32ClNO2
DM7Y4GT IC InChI=1S/C27H32ClNO2/c1-4-29(5-2)18-19-31-26-16-12-24(13-17-26)27(30,23-10-6-21(3)7-11-23)20-22-8-14-25(28)15-9-22/h6-17,30H,4-5,18-20H2,1-3H3
DM7Y4GT CS CCN(CC)CCOC1=CC=C(C=C1)C(CC2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)C)O
DM7Y4GT IK SYHDSBBKRLVLFF-UHFFFAOYSA-N
DM7Y4GT IU 2-(4-chlorophenyl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-1-(4-methylphenyl)ethanol
DM7Y4GT CA CAS 78-41-1
DM7Y4GT CB CHEBI:135714
DM7Y4GT DE Obesity
DMJ6P9U ID DMJ6P9U
DMJ6P9U DN T-226296
DMJ6P9U HS Preclinical
DMJ6P9U SN N-[6-(Dimethylaminomethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide; T 226296; CHEMBL178707; 331758-35-1; 4'-Fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide; 4'-Fluoro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl)[1,1'-biphenyl]-4-carboxamide; PDSP1_000981; LS-44229; LS-193063; SCHEMBL5582818; GTPL1314; GXAQELJVODWLDD-UHFFFAOYSA-N; BDBM50150715; PDSP2_000965; KB-80782; T226296; 102690-EP2272841A1; 102690-EP2301936A1; N-[6-(dimethylaminomethyl)-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide; LS-193063; S-20951
DMJ6P9U CP Takeda
DMJ6P9U DT Small molecular drug
DMJ6P9U PC 9865843
DMJ6P9U MW 402.5
DMJ6P9U FM C26H27FN2O
DMJ6P9U IC InChI=1S/C26H27FN2O/c1-29(2)17-18-3-4-23-16-25(14-11-22(23)15-18)28-26(30)21-7-5-19(6-8-21)20-9-12-24(27)13-10-20/h5-14,16,18H,3-4,15,17H2,1-2H3,(H,28,30)
DMJ6P9U CS CN(C)CC1CCC2=C(C1)C=CC(=C2)NC(=O)C3=CC=C(C=C3)C4=CC=C(C=C4)F
DMJ6P9U IK GXAQELJVODWLDD-UHFFFAOYSA-N
DMJ6P9U IU N-[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydronaphthalen-2-yl]-4-(4-fluorophenyl)benzamide
DMJ6P9U DE Atrial fibrillation; Obesity
DMQJSF9 ID DMQJSF9
DMQJSF9 DN Taxifolin
DMQJSF9 HS Preclinical
DMQJSF9 SN TAXIFOLIN; (+)-Taxifolin; dihydroquercetin; Distylin; Taxifoliol; (2R,3R)-Dihydroquercetin; (+)-Dihydroquercetin; TAXIFOLIN-(+); Lavitol; Lariksin; taxifolin (dihydroquercetin); 3,5,7,3',4'-Pentahydroxyflavanone; UNII-9SOB9E3987; trans-Dihydroquercetin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; (+)-trans-Taxifolin; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone
DMQJSF9 PC 439533
DMQJSF9 MW 304.25
DMQJSF9 FM C15H12O7
DMQJSF9 IC InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1
DMQJSF9 CS C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O
DMQJSF9 IK CXQWRCVTCMQVQX-LSDHHAIUSA-N
DMQJSF9 IU (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one
DMQJSF9 CA CAS 480-18-2
DMQJSF9 CB CHEBI:17948
DMQJSF9 DE Ovarian cancer
DMY8QP5 ID DMY8QP5
DMY8QP5 DN TFM735
DMY8QP5 HS Preclinical
DMY8QP5 CP Mochida
DMY8QP5 DT Small molecular drug
DMY8QP5 DE Multiple sclerosis
DM1KTOC ID DM1KTOC
DM1KTOC DN TGX-6B4
DM1KTOC HS Preclinical
DM1KTOC SN Antiglycoprotein 1b monoclonal antibodies, CuraGen; GPIb-blocking MAb, Thromb-X; GPIb-blocking Fab fragment (thrombosis), Thromb-X
DM1KTOC CP ThromboGenics NV
DM1KTOC DT Antibody
DM1KTOC DE Thrombosis
DM4BDGW ID DM4BDGW
DM4BDGW DN TH301
DM4BDGW HS Preclinical
DM4BDGW DT Small molecular drug
DM4BDGW DE Glioblastoma of brain
DMDMQIE ID DMDMQIE
DMDMQIE DN THAPSIGARGIN
DMDMQIE HS Preclinical
DMDMQIE SN thapsigargin; 67526-95-8; UNII-Z96BQ26RZD; Z96BQ26RZD; CHEMBL96926; CHEBI:9516; OCTANOIC ACID [3S-[3ALPHA, 3ABETA, 4ALPHA, 6BETA, 6ABETA, 7BETA, 8ALPHA(Z), 9BALPHA]]-6-(ACETYLOXY)-2,3,-3A,4,5,6,6A,7,8,9B-DECAHYDRO-3,3A-DIHYDROXY-3,6,9-TRIMETHYL-8-[(2-METHYL-1-OXO-2-BUTENYL)OXY]-2-OXO-4-(1-OXOBUTOXY)-AZULENO[4,5-B]FURAN-7-YL ESTER
DMDMQIE DT Small molecular drug
DMDMQIE PC 446378
DMDMQIE MW 650.8
DMDMQIE FM C34H50O12
DMDMQIE IC InChI=1S/C34H50O12/c1-9-12-13-14-15-17-24(37)43-28-26-25(20(5)27(28)44-30(38)19(4)11-3)29-34(41,33(8,40)31(39)45-29)22(42-23(36)16-10-2)18-32(26,7)46-21(6)35/h11,22,26-29,40-41H,9-10,12-18H2,1-8H3/b19-11-/t22-,26+,27-,28-,29-,32-,33+,34+/m0/s1
DMDMQIE CS CCCCCCCC(=O)O[C@H]1[C@H]2C(=C([C@@H]1OC(=O)/C(=C\\C)/C)C)[C@H]3[C@]([C@H](C[C@]2(C)OC(=O)C)OC(=O)CCC)([C@](C(=O)O3)(C)O)O
DMDMQIE IK IXFPJGBNCFXKPI-FSIHEZPISA-N
DMDMQIE IU [(3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-acetyloxy-4-butanoyloxy-3,3a-dihydroxy-3,6,9-trimethyl-8-[(Z)-2-methylbut-2-enoyl]oxy-2-oxo-4,5,6a,7,8,9b-hexahydroazuleno[4,5-b]furan-7-yl] octanoate
DMDMQIE CA CAS 67526-95-8
DMDMQIE CB CHEBI:9516
DM7RMG9 ID DM7RMG9
DM7RMG9 DN Thioguanine
DM7RMG9 HS Preclinical
DM7RMG9 SN 6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog)
DM7RMG9 CP Glaxo Smith Kline Pharmaceuticals
DM7RMG9 TC Antiviral Agents
DM7RMG9 DT Small molecular drug
DM7RMG9 PC 2723601
DM7RMG9 MW 167.19
DM7RMG9 FM C5H5N5S
DM7RMG9 IC InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)
DM7RMG9 CS C1=NC2=C(N1)C(=S)N=C(N2)N
DM7RMG9 IK WYWHKKSPHMUBEB-UHFFFAOYSA-N
DM7RMG9 IU 2-amino-3,7-dihydropurine-6-thione
DM7RMG9 CA CAS 154-42-7
DM7RMG9 CB CHEBI:9555
DM7RMG9 DE Acute myeloid leukaemia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMDSJO8 ID DMDSJO8
DMDSJO8 DN TMC-353121
DMDSJO8 HS Preclinical
DMDSJO8 SN JNJ-2408068; R-170591; Viral fusion inhibitor (RSV infection), J&J; Viral fusion inhibitor (respiratory syncytial virus infection), J&J
DMDSJO8 CP Johnson & Johnson
DMDSJO8 DT Small molecular drug
DMDSJO8 PC 11249932
DMDSJO8 MW 558.7
DMDSJO8 FM C32H42N6O3
DMDSJO8 IC InChI=1S/C32H42N6O3/c1-23-6-9-26(5-3-16-39)28(19-23)34-21-25-8-10-27-30(20-25)38(22-29-31(40)11-7-24(2)35-29)32(36-27)33-12-4-13-37-14-17-41-18-15-37/h6-11,19-20,34,39-40H,3-5,12-18,21-22H2,1-2H3,(H,33,36)
DMDSJO8 CS CC1=CC(=C(C=C1)CCCO)NCC2=CC3=C(C=C2)N=C(N3CC4=C(C=CC(=N4)C)O)NCCCN5CCOCC5
DMDSJO8 IK DKORMNNYNRPTBJ-UHFFFAOYSA-N
DMDSJO8 IU 2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
DMDSJO8 CA CAS 857066-90-1
DMDSJO8 DE Respiratory syncytial virus infection
DMONGIR ID DMONGIR
DMONGIR DN Tosyl-l-arginine methyl ester
DMONGIR HS Preclinical
DMONGIR SN Tame; 901-47-3; Methyl P-toluenesulfonyl-L-argininate; Ts-Arg-OMe; tosyl-arginine methyl ester; UNII-1H7BKF44U1; p-toluenesulfonyl-L-arginine methyl ester; tosyl-L-arginine methyl ester; CHEMBL44752; methyl (2S)-5-(diaminomethylideneamino)-2-[(4-methylphenyl)sulfonylamino]pentanoate; 1H7BKF44U1; CHEBI:62167; methyl N(2)-(p-tosyl)-L-argininate; p-toluensulfonyl-L-arginine methyl ester; N(alpha)-p-tosyl-L-arginine methyl ester; (S)-methyl 5-guanidino-2-(4-methylphenylsulfonamido)pentanoate; methyl N(2)-(p-toluenenesulfonyl)-L-argininate; methyl N(2)-[(p-tolyl)sulphonyl]-L-argininate; N(2)-(p-tolylsulfonyl)-L-arginine methyl ester; methyl N(2)-[(4-methylphenyl)sulfonyl]-L-argininate; L-Arginine, N2-((4-methylphenyl)sulfonyl)-, methyl ester; TOSYLARGININE METHYL ESTER; TAME/; SCHEMBL324561; p-tosyl-l-arginine methyl ester; Nalpha-tosylarginine methyl ester; BCPP000052; ZINC1639578; ABP000326; BDBM50070707; s2225; AKOS030214485; CCG-264948; CS-0466; alpha-N-p-Tosyl-L-arginine methyl ester; NCGC00346615-01; HY-13255; SW219688-1; X7573; N-alpha-Toluenesulfonyl-L-arginine methyl ester; W-5260; AB01566842_01; p-TOLUENESULFONYL-L-ARGININE METHYL ESTER HCl; Q27131658; (S)-5-Guanidino-2-(toluene-4-sulfonylamino)-pentanoic acid methyl ester
DMONGIR DT Small molecular drug
DMONGIR PC 1550286
DMONGIR MW 342.42
DMONGIR FM C14H22N4O4S
DMONGIR IC InChI=1S/C14H22N4O4S/c1-10-5-7-11(8-6-10)23(20,21)18-12(13(19)22-2)4-3-9-17-14(15)16/h5-8,12,18H,3-4,9H2,1-2H3,(H4,15,16,17)/t12-/m0/s1
DMONGIR CS CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCN=C(N)N)C(=O)OC
DMONGIR IK FKMJXALNHKIDOD-LBPRGKRZSA-N
DMONGIR IU methyl (2S)-5-(diaminomethylideneamino)-2-[(4-methylphenyl)sulfonylamino]pentanoate
DMONGIR CA CAS 901-47-3
DMONGIR CB CHEBI:62167
DMONGIR DE Solid tumour/cancer
DM6W9YM ID DM6W9YM
DM6W9YM DN TP-023
DM6W9YM HS Preclinical
DM6W9YM TC Psychiatric
DM6W9YM DE Anxiety disorder
DM06BUL ID DM06BUL
DM06BUL DN TPT-43
DM06BUL HS Preclinical
DM06BUL TC Neurodegenerative
DM06BUL DE Alzheimer disease
DMY8GDA ID DMY8GDA
DMY8GDA DN Trimidox
DMY8GDA HS Preclinical
DMY8GDA SN 3,4,5-Trihydroxybenzamidoxime; CCRIS 7910; Benzenecarboximidamide, N,3,4,5-tetrahydroxy-; 95933-74-7; AC1NUZ8S; SCHEMBL4168968; CHEMBL1214553; CHEBI:94508; N,3,4,5-tetrahydroxybenzamidine; MolPort-044-561-997; N',3,4,5-Tetrahydroxybenzimidamide; 3,4,5-Trihydroxybenzamidoxamic acid; LS-29453; BRD-K11801786-003-01-7; T01312
DMY8GDA DT Small molecular drug
DMY8GDA PC 135409350
DMY8GDA MW 184.15
DMY8GDA FM C7H8N2O4
DMY8GDA IC InChI=1S/C7H8N2O4/c8-7(9-13)3-1-4(10)6(12)5(11)2-3/h1-2,10-13H,(H2,8,9)
DMY8GDA CS C1=C(C=C(C(=C1O)O)O)/C(=N/O)/N
DMY8GDA IK MSLJYSGFUMYUDX-UHFFFAOYSA-N
DMY8GDA IU N',3,4,5-tetrahydroxybenzenecarboximidamide
DMY8GDA CA CAS 95933-74-7
DMY8GDA CB CHEBI:94508
DMY8GDA DE Solid tumour/cancer
DMWZCIF ID DMWZCIF
DMWZCIF DN TTA-A8
DMWZCIF HS Preclinical
DMWZCIF SN TTA-A2; TTA-P2; T-type calcium channel antagonists, Merck & Co
DMWZCIF CP Merck & Co Inc
DMWZCIF DT Small molecular drug
DMWZCIF PC 42609962
DMWZCIF MW 430.4
DMWZCIF FM C22H21F3N4O2
DMWZCIF IC InChI=1S/C22H21F3N4O2/c1-14(19-8-7-18(12-28-19)31-13-22(23,24)25)29-20(30)11-16-3-5-17(6-4-16)21-15(2)26-9-10-27-21/h3-10,12,14H,11,13H2,1-2H3,(H,29,30)/t14-/m1/s1
DMWZCIF CS CC1=NC=CN=C1C2=CC=C(C=C2)CC(=O)N[C@H](C)C3=NC=C(C=C3)OCC(F)(F)F
DMWZCIF IK OURCOVUGQRXRTE-CQSZACIVSA-N
DMWZCIF IU 2-[4-(3-methylpyrazin-2-yl)phenyl]-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide
DMWZCIF DE Insomnia
DMB7WEY ID DMB7WEY
DMB7WEY DN TV-1390
DMB7WEY HS Preclinical
DMB7WEY SN Multiple sclerosis therapy, Teva Pharmaceuticals
DMB7WEY CP Aventis Behring LLC
DMB7WEY DE Multiple sclerosis
DMRGZQA ID DMRGZQA
DMRGZQA DN TZP-202
DMRGZQA HS Preclinical
DMRGZQA CP Tranzyme Pharma Inc
DMRGZQA DE Dyspepsia
DME8AL0 ID DME8AL0
DME8AL0 DN TZP-301
DME8AL0 HS Preclinical
DME8AL0 CP Tranzyme Pharma Inc
DME8AL0 DE Metabolic disorder
DMW87JR ID DMW87JR
DMW87JR DN U-99194A
DMW87JR HS Preclinical
DMW87JR SN U 99194A; (5,6-dimethoxyindan-2-yl)dipropylamine; 1H-Indan-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-, hydrochloride; 1H-Inden-2-amine, 2,3-dihydro-5,6-dimethoxy-N,N-dipropyl-, hydrochloride; 5,6-Dimethoxy-2-(dipropylamino)indan hydrochloride; 5,6-Dimethoxy-N,N-dipropyl-2,3-dihydro-1H-indan-2-amine; 5,6-Dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine hydrochloride; 5,6-dimethoxy-2-(di-n-propylamino)indan; 5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine hydrochloride(1:1)
DMW87JR CP Pfizer
DMW87JR DT Small molecular drug
DMW87JR PC 119195
DMW87JR MW 313.9
DMW87JR FM C17H28ClNO2
DMW87JR IC InChI=1S/C17H27NO2.ClH/c1-5-7-18(8-6-2)15-9-13-11-16(19-3)17(20-4)12-14(13)10-15;/h11-12,15H,5-10H2,1-4H3;1H
DMW87JR CS CCCN(CCC)C1CC2=CC(=C(C=C2C1)OC)OC.Cl
DMW87JR IK NMBUOXDBNWBGIM-UHFFFAOYSA-N
DMW87JR IU 5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine;hydrochloride
DMW87JR CA CAS 83598-46-3
DMW87JR DE Schizophrenia
DMOIWVC ID DMOIWVC
DMOIWVC DN U-99363E
DMOIWVC HS Preclinical
DMOIWVC SN U 99363; U 99363E; U-99363; N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine; 3-Ethoxy-N-methyl-N-(1-(phenylmethyl)-4-piperidinyl)-2-pyridinylamine
DMOIWVC CP Pfizer
DMOIWVC DT Small molecular drug
DMOIWVC PC 133107
DMOIWVC MW 325.4
DMOIWVC FM C20H27N3O
DMOIWVC IC InChI=1S/C20H27N3O/c1-3-24-19-10-7-13-21-20(19)22(2)18-11-14-23(15-12-18)16-17-8-5-4-6-9-17/h4-10,13,18H,3,11-12,14-16H2,1-2H3
DMOIWVC CS CCOC1=C(N=CC=C1)N(C)C2CCN(CC2)CC3=CC=CC=C3
DMOIWVC IK VNSBZWKWQFCKGO-UHFFFAOYSA-N
DMOIWVC IU N-(1-benzylpiperidin-4-yl)-3-ethoxy-N-methylpyridin-2-amine
DMOIWVC CA CAS 170856-57-2
DMOIWVC DE Schizophrenia
DMT06MI ID DMT06MI
DMT06MI DN UCART-CLL1
DMT06MI HS Preclinical
DMT06MI CP Cellectis
DMT06MI DT CAR T Cell Therapy
DMT06MI DE Multiple myeloma
DMD1E4J ID DMD1E4J
DMD1E4J DN UNC0379
DMD1E4J HS Preclinical
DMD1E4J SN 1620401-82-2; 6,7-Dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine; UNC-0379; CHEMBL3318285; UNC 0379; 6,7-Dimethoxy-2-pyrrolidin-1-yl-N-(5-pyrrolidin-1-ylpentyl)quinazolin-4-amine; C23H35N5O2; 4-Quinazolinamine, 6,7-dimethoxy-2-(1-pyrrolidinyl)-N-[5-(1-pyrrolidinyl)pentyl]-; CS-3345; HY-12335; SCHEMBL22568439; AOB6365; EX-A461; SYN5081; BCP10429; 3362AH; BDBM50051117; MFCD28167817; s7570; ZINC98214604; AKOS025404942; UNC 0379;UNC-0379; CCG-268809; SB19349; NCGC00384189-06; NCGC00384189-10; AK174945; AS-16447; DA-43617; B8009; FT-0699830; A14320; UNC0379 trifluoroacetate salt, >=98% (HPLC)
DMD1E4J DT Small molecular drug
DMD1E4J PC 78357767
DMD1E4J MW 413.6
DMD1E4J FM C23H35N5O2
DMD1E4J IC InChI=1S/C23H35N5O2/c1-29-20-16-18-19(17-21(20)30-2)25-23(28-14-8-9-15-28)26-22(18)24-10-4-3-5-11-27-12-6-7-13-27/h16-17H,3-15H2,1-2H3,(H,24,25,26)
DMD1E4J CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCCC3)NCCCCCN4CCCC4)OC
DMD1E4J IK WEXCGGWTIDNVNT-UHFFFAOYSA-N
DMD1E4J IU 6,7-dimethoxy-2-pyrrolidin-1-yl-N-(5-pyrrolidin-1-ylpentyl)quinazolin-4-amine
DMD1E4J DE Hepatocellular carcinoma
DMDVZQ8 ID DMDVZQ8
DMDVZQ8 DN UPF-648
DMDVZQ8 HS Preclinical
DMDVZQ8 SN 213400-34-1; (1s,2s)-2-(3,4-Dichlorobenzoyl)cyclopropanecarboxylic Acid; UPF 648; CHEMBL3407929; (1S,2S)-2-(3,4-DICHLOROBENZOYL)CYCLOPROPANE-1-CARBOXYLIC ACID; DBCC; SCHEMBL5310798; BDBM50072083; ZINC33994919; AKOS027470152; CS-3567; HY-15600; Q27452085; (1s,2s)-2-(3,4-dichlorobenzoyl)-cyclopropane-1-carboxylic acid; (1S,2S)-2-[(3,4-dichlorophenyl)carbonyl]cyclopropane-1-carboxylic acid; 1HR
DMDVZQ8 DT Small molecular drug
DMDVZQ8 PC 9859947
DMDVZQ8 MW 259.079
DMDVZQ8 FM C11H8Cl2O3
DMDVZQ8 IC InChI=1S/C11H8Cl2O3/c12-8-2-1-5(3-9(8)13)10(14)6-4-7(6)11(15)16/h1-3,6-7H,4H2,(H,15,16)/t6-,7-/m0/s1
DMDVZQ8 CS C1[C@@H]([C@H]1C(=O)O)C(=O)C2=CC(=C(C=C2)Cl)Cl
DMDVZQ8 IK ZBRKMOHDGFGXLN-BQBZGAKWSA-N
DMDVZQ8 IU (1S,2S)-2-(3,4-dichlorobenzoyl)cyclopropane-1-carboxylic acid
DMDVZQ8 DE Neurodegenerative disorder
DMUO6XC ID DMUO6XC
DMUO6XC DN VCB101
DMUO6XC HS Preclinical
DMUO6XC CP V ClinBio
DMUO6XC DT Small molecular drug
DMUO6XC DE Multiple sclerosis
DMR3XDH ID DMR3XDH
DMR3XDH DN VCB102
DMR3XDH HS Preclinical
DMR3XDH CP V ClinBio
DMR3XDH DT Small molecular drug
DMR3XDH DE Psoriasis vulgaris
DM95VQ6 ID DM95VQ6
DM95VQ6 DN vialinin A
DM95VQ6 HS Preclinical
DM95VQ6 SN ganbajunin C
DM95VQ6 DT Small molecular drug
DM95VQ6 PC 11563133
DM95VQ6 MW 562.6
DM95VQ6 FM C34H26O8
DM95VQ6 IC InChI=1S/C34H26O8/c35-25-15-11-23(12-16-25)29-31(39)32(40)30(24-13-17-26(36)18-14-24)34(42-28(38)20-22-9-5-2-6-10-22)33(29)41-27(37)19-21-7-3-1-4-8-21/h1-18,35-36,39-40H,19-20H2
DM95VQ6 CS C1=CC=C(C=C1)CC(=O)OC2=C(C(=C(C(=C2C3=CC=C(C=C3)O)O)O)C4=CC=C(C=C4)O)OC(=O)CC5=CC=CC=C5
DM95VQ6 IK NOJUKCRPSUMHQQ-UHFFFAOYSA-N
DM95VQ6 IU [3,4-dihydroxy-2,5-bis(4-hydroxyphenyl)-6-(2-phenylacetyl)oxyphenyl] 2-phenylacetate
DM95VQ6 CA CAS 858134-23-3
DM95VQ6 DE Inflammation
DMS5LPF ID DMS5LPF
DMS5LPF DN Viquidacin
DMS5LPF HS Preclinical
DMS5LPF SN AVE-4221; AVE-6971; NXL-101; Topoisomerase IV inhibitor antibacterials, Novexel
DMS5LPF CP Aventis Pharma AG
DMS5LPF DT Small molecular drug
DMS5LPF PC 11591505
DMS5LPF MW 504.6
DMS5LPF FM C25H29FN2O4S2
DMS5LPF IC InChI=1S/C25H29FN2O4S2/c1-32-17-5-6-21-18(13-17)24(20(26)14-27-21)22(29)7-4-16-8-9-28(15-19(16)25(30)31)10-12-34-23-3-2-11-33-23/h2-3,5-6,11,13-14,16,19,22,29H,4,7-10,12,15H2,1H3,(H,30,31)/t16-,19+,22+/m1/s1
DMS5LPF CS COC1=CC2=C(C(=CN=C2C=C1)F)[C@H](CC[C@@H]3CCN(C[C@@H]3C(=O)O)CCSC4=CC=CS4)O
DMS5LPF IK USGHRRVFKSLEJT-WVBUVRCRSA-N
DMS5LPF IU (3R,4R)-4-[(3S)-3-(3-fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl]-1-(2-thiophen-2-ylsulfanylethyl)piperidine-3-carboxylic acid
DMS5LPF CA CAS 904302-98-3
DMS5LPF DE Bacterial infection
DMQG2EY ID DMQG2EY
DMQG2EY DN Virstatin
DMQG2EY HS Preclinical
DMQG2EY SN 88909-96-0; Isodibut; 4-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-butyric acid; 4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butanoic acid; 4-NAPHTHALIMIDOBUTYRIC ACID; 4-(N-(1,8-naphthalimide))-n-butyric acid; 4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butanoic acid; UNII-24SR2Q1Y6M; 24SR2Q1Y6M; MFCD00181400; 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-butanoic acid; 1,3-dioxo-1H-Benz[de]isoquinoline-2(3H)-butanoic acid; 4-{2,4-dioxo-3-azatricyclo[7.3.1.0^{5,13}]trideca-1(13),5,7,9,11-pentaen-3-yl}butanoic acid; Izodibut; 1,3-Dioxo-1H-benz(de)isoquinoline-2(3H)-butyric acid; ACMC-209qxu; SpecPlus_000928; Spectrum2_000449; Spectrum3_001240; CBMicro_014897; CBKinase1_000229; CBKinase1_012629; BSPBio_002720; CBDivE_001858; CBDivE_003272; MLS001207259; DivK1c_007024; SPBio_000498; CHEMBL403272; SCHEMBL3134908; SCHEMBL3852274; KBio1_001968; KBio3_002220; 1H-Benz(de)isoquinoline-2(3H)-butanoic acid, 1,3-dioxo-; DTXSID10237406; ZINC3884670; ANW-39184; CCG-39963; KM2782; SBB043186; STK395003; AKOS000114634; DG-0077; MCULE-6695567974; NCGC00178507-01; SMR000504925; FT-0734904; ST50049126; X6840; EN300-00247; AB00053241-05; BRD-K60241851-001-02-8; BRD-K60241851-001-06-9; Z56891243; 1h,3H-benzo(de)isoquinoline-2-butyric acid-1,3-dione; F0303-0081; 4-{2,4-Dioxo-3-azatricyclo[7.3.1.0 {5,13}]trideca- 1(13),5,7,9,11-pentaen-3-yl}butanoic acid
DMQG2EY DT Small molecular drug
DMQG2EY PC 145949
DMQG2EY MW 283.28
DMQG2EY FM C16H13NO4
DMQG2EY IC InChI=1S/C16H13NO4/c18-13(19)8-3-9-17-15(20)11-6-1-4-10-5-2-7-12(14(10)11)16(17)21/h1-2,4-7H,3,8-9H2,(H,18,19)
DMQG2EY CS C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCC(=O)O
DMQG2EY IK ZHXRDXTYPCPBTI-UHFFFAOYSA-N
DMQG2EY IU 4-(1,3-dioxobenzo[de]isoquinolin-2-yl)butanoic acid
DMQG2EY CA CAS 88909-96-0
DMQG2EY DE Acinetobacter baumannii infection
DMJDT5O ID DMJDT5O
DMJDT5O DN VIS513
DMJDT5O HS Preclinical
DMJDT5O CP Visterra
DMJDT5O DT Antibody
DMJDT5O DE Dengue
DMZHAVG ID DMZHAVG
DMZHAVG DN VPM-4-001
DMZHAVG HS Preclinical
DMZHAVG SN Allogenic LNCaP cell vaccine (prostate tumor), Vakzine Projekt Management; Cell vaccine (prostate cancer), Vakzine Projekt Management; Allogenic LNCaP cells (IL-2, IFN-gamma), Vakzine Projekt Management
DMZHAVG CP Memorial Sloan-Kettering Cancer Center
DMZHAVG DT Vaccine
DMZHAVG DE Prostate cancer
DMOY15R ID DMOY15R
DMOY15R DN VT-111
DMOY15R HS Preclinical
DMOY15R CP Viron Therapeutics
DMOY15R DE Graft rejection in heart transplantation
DM7WFR0 ID DM7WFR0
DM7WFR0 DN VUFB-11502
DM7WFR0 HS Preclinical
DM7WFR0 SN Ciadox; Ciadox [INN]; Cyadox; Ciadoxum [INN-Latin]; SCHEMBL1817373; VUFB 11502; 2-formylquinoxaline-1,4-dioxide cyanoacetylhydrazone; 65884-46-0; ACETIC ACID, CYANO-, (2-QUINOXALINYLMETHYLENE)HYDRAZIDE, N,N-DIOXIDE; BRN 0826894; C12H8N5O3; Cyanoacetic acid (2-quinoxalinylmethylene)hydrazide, N(sup 1),N(sup 4)-dioxide; Cyanoacetylhydrazone 2-formylquinoxaline-1,4-dioxide; EINECS 265-963-3; N'-(2-Chinoxalinylmethylen)cyanacetohydrazid 1,4-dioxid; SCHEMBL10793569
DM7WFR0 PC 135412736
DM7WFR0 MW 271.23
DM7WFR0 FM C12H9N5O3
DM7WFR0 IC MBCZYLSVSCJJJQ-VGOFMYFVSA-N
DM7WFR0 CS C1=CC=C2C(=C1)[N+](=CC(=[N+]2[O-])C=NNC(=O)CC#N)[O-]
DM7WFR0 IK 1S/C12H9N5O3/c13-6-5-12(18)15-14-7-9-8-16(19)10-3-1-2-4-11(10)17(9)20/h1-4,7-8H,5H2,(H,15,18)/b14-7+
DM7WFR0 IU 2-cyano-N-[(E)-(1,4-dioxidoquinoxaline-1,4-diium-2-yl)methylideneamino]acetamide
DM7WFR0 CA CAS 65884-46-0
DM7WFR0 DE Amebiasis
DMZKY56 ID DMZKY56
DMZKY56 DN VX-166
DMZKY56 HS Preclinical
DMZKY56 SN 800408-39-3; (S)-3-((S)-2-(3-((methoxycarbonyl)amino)-2-oxopyridin-1(2H)-yl)butanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid; SCHEMBL473147; CHEMBL1935078; ZINC82158134; (3S)-3-[[(2S)-2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
DMZKY56 DT Small molecular drug
DMZKY56 PC 42602413
DMZKY56 MW 531.4
DMZKY56 FM C22H21F4N3O8
DMZKY56 IC InChI=1S/C22H21F4N3O8/c1-3-14(29-6-4-5-12(21(29)34)28-22(35)36-2)20(33)27-13(8-16(31)32)15(30)9-37-19-17(25)10(23)7-11(24)18(19)26/h4-7,13-14H,3,8-9H2,1-2H3,(H,27,33)(H,28,35)(H,31,32)/t13-,14-/m0/s1
DMZKY56 CS CC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)N2C=CC=C(C2=O)NC(=O)OC
DMZKY56 IK WQNDPVUOABHOHK-KBPBESRZSA-N
DMZKY56 IU (3S)-3-[[(2S)-2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
DMZKY56 DE Hepatic fibrosis
DM68HNR ID DM68HNR
DM68HNR DN W-201259
DM68HNR HS Preclinical
DM68HNR SN A-D-Mannopyranosyl-D-mannose; Mannobiose; BDH pure salt; GUBGYTABKSRVRQ-KWCWEWCRSA-N; SCHEMBL162205; beta-1,4-Mannobiose; 14417-51-7; 15548-43-3; 4-O-; 4-O-(b-D-Mannopyranosyl)-D-mannose; 4-O-(beta-D-Mannopyranosyl)-D-mannose; 4-O-beta-D-Mannopyranosyl-D-mannopyranose; C20861; CHEBI:25164; D-Mannopyranose, 4-O-beta-D-mannopyranosyl-; Mannopyranose, 4-O-beta-D-mannopyranosyl-; Mannopyranose, 4-O-beta-D-mannopyranosyl-, D-; O-MBI; beta-D-mannopyranosyl-(1->4)-D-mannopyranose; beta-D-mannopyranosyl-(1->4)-D-mannose
DM68HNR PC 152109
DM68HNR MW 342.3
DM68HNR FM C12H22O11
DM68HNR IC GUBGYTABKSRVRQ-KWCWEWCRSA-N
DM68HNR CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)O)CO)O)O)O)O
DM68HNR IK 1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8+,9+,10-,11?,12+/m1/s1
DM68HNR IU (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DM68HNR CA CAS 15548-43-3
DM68HNR CB CHEBI:25164
DM68HNR DE Salmonella infection
DMKE5QH ID DMKE5QH
DMKE5QH DN WZB-117
DMKE5QH HS Preclinical
DMKE5QH SN WZB117; 1223397-11-2; 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate); CHEMBL3092944; WZB 117; [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate; WBZ117; SCHEMBL19183300; AOB5670; BCP24665; EX-A1492; BDBM50444088; NSC750937; s7927; AKOS032945159; ZINC103244507; CCG-268262; NSC-750937; AC-32898; AK685810; BS-14666; HY-19331; WZB-117, >=98% (HPLC); CS-0015243; Bis(3-hydroxybenzoic acid)3-fluoro-1,2-phenylene ester; Benzoic acid, 3-hydroxy-, 1,1'-(3-fluoro-1,2-phenylene) ester
DMKE5QH DT Small molecular drug
DMKE5QH PC 46830365
DMKE5QH MW 368.3
DMKE5QH FM C20H13FO6
DMKE5QH IC InChI=1S/C20H13FO6/c21-16-8-3-9-17(26-19(24)12-4-1-6-14(22)10-12)18(16)27-20(25)13-5-2-7-15(23)11-13/h1-11,22-23H
DMKE5QH CS C1=CC(=CC(=C1)O)C(=O)OC2=C(C(=CC=C2)F)OC(=O)C3=CC(=CC=C3)O
DMKE5QH IK FRSWCCBXIHFKKY-UHFFFAOYSA-N
DMKE5QH IU [3-fluoro-2-(3-hydroxybenzoyl)oxyphenyl] 3-hydroxybenzoate
DMKE5QH DE Skin fibrosis
DMD8TNK ID DMD8TNK
DMD8TNK DN XL475
DMD8TNK HS Preclinical
DMD8TNK CP Exelixis
DMD8TNK DE Type-2 diabetes
DMINSA5 ID DMINSA5
DMINSA5 DN XL-499
DMINSA5 HS Preclinical
DMINSA5 SN PI3K delta inhibitor (cancer/inflammatory disease), Exelixis
DMINSA5 CP Exelixis Inc
DMINSA5 DE Solid tumour/cancer
DMU86XT ID DMU86XT
DMU86XT DN YM-201636
DMU86XT HS Preclinical
DMU86XT SN 371942-69-7; YM201636; YM 201636; 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide; 3-pyridinecarboxamide, 6-amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-; 6-amino-n-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide; 6-amino-N-[3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenyl]-3-pyridinecarboxamide; PubChem22459; cc-386; MLS006010997; SCHEMBL258416; CHEMBL2178735; CHEBI:91382; AOB1919; DTXSID90433303; EX-A037; QCR-257; BCPP000006; HMS3229J15; HMS3295C07; HMS3654F03; AMY23718; BCP01972; ABP000099; MFCD16038303; s1219; ZINC34048998; AKOS027250783; CCG-264866; CS-0592; NCGC00346683-01; NCGC00346683-09; 6-amino-N-[3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenyl]pyridine-3-carboxamide; AK175782; AS-16693; HY-13228; SMR004702795; AB0035851; FT-0756177; SW218129-2; Y0272; A19418; W-5608; 942Y697; J-518249; BRD-K48488978-001-01-2; Q27163245; YM-201636,CAS:371942-69-7; 6-Amino-N-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenyl]pyridine-3-carboxamide; 6-Amino-N-{3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl}pyridine-3-carboxamide
DMU86XT DT Small molecular drug
DMU86XT PC 9956222
DMU86XT MW 467.5
DMU86XT FM C25H21N7O3
DMU86XT IC InChI=1S/C25H21N7O3/c26-19-7-6-16(14-28-19)24(33)29-17-4-1-3-15(13-17)22-30-20-18-5-2-8-27-25(18)35-21(20)23(31-22)32-9-11-34-12-10-32/h1-8,13-14H,9-12H2,(H2,26,28)(H,29,33)
DMU86XT CS C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)NC(=O)C6=CN=C(C=C6)N
DMU86XT IK YBPIBGNBHHGLEB-UHFFFAOYSA-N
DMU86XT IU 6-amino-N-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenyl]pyridine-3-carboxamide
DMU86XT CA CAS 371942-69-7
DMU86XT CB CHEBI:91382
DMU86XT DE Discovery agent
DMMUYC2 ID DMMUYC2
DMMUYC2 DN YM-344031
DMMUYC2 HS Preclinical
DMMUYC2 CP Astellas
DMMUYC2 DT Small molecular drug
DMMUYC2 PC 56603737
DMMUYC2 MW 502.6
DMMUYC2 FM C29H31FN4O3
DMMUYC2 IC InChI=1S/C29H31FN4O3/c1-20-3-2-11-34(37)28(20)29(36)33-13-8-21(9-14-33)16-27(35)31-26-10-12-32(19-26)18-22-4-5-24-17-25(30)7-6-23(24)15-22/h2-7,11,15-17,26H,8-10,12-14,18-19H2,1H3,(H,31,35)
DMMUYC2 CS CC1=C([N+](=CC=C1)[O-])C(=O)N2CCC(=CC(=O)NC3CCN(C3)CC4=CC5=C(C=C4)C=C(C=C5)F)CC2
DMMUYC2 IK AINQBHMFEKHERT-UHFFFAOYSA-N
DMMUYC2 IU N-[1-[(6-fluoronaphthalen-2-yl)methyl]pyrrolidin-3-yl]-2-[1-(3-methyl-1-oxidopyridin-1-ium-2-carbonyl)piperidin-4-ylidene]acetamide
DMMUYC2 DE Asthma
DMTM1LK ID DMTM1LK
DMTM1LK DN YM-355179
DMTM1LK HS Preclinical
DMTM1LK SN YM-355179; GTPL793; SCHEMBL3808393
DMTM1LK CP Astellas
DMTM1LK DT Small molecular drug
DMTM1LK PC 11556309
DMTM1LK MW 502.6
DMTM1LK FM C29H31FN4O3
DMTM1LK IC InChI=1S/C29H31FN4O3/c1-19-12-26(35)28(31-16-19)29(37)34-10-6-20(7-11-34)14-27(36)32-25-8-9-33(18-25)17-21-2-3-23-15-24(30)5-4-22(23)13-21/h2-5,12-16,25,35H,6-11,17-18H2,1H3,(H,32,36)/t25-/m1/s1
DMTM1LK CS CC1=CC(=C(N=C1)C(=O)N2CCC(=CC(=O)N[C@@H]3CCN(C3)CC4=CC5=C(C=C4)C=C(C=C5)F)CC2)O
DMTM1LK IK LHTPHICFHRATTG-RUZDIDTESA-N
DMTM1LK IU N-[(3R)-1-[(6-fluoronaphthalen-2-yl)methyl]pyrrolidin-3-yl]-2-[1-(3-hydroxy-5-methylpyridine-2-carbonyl)piperidin-4-ylidene]acetamide
DMTM1LK DE Asthma
DMH0I9N ID DMH0I9N
DMH0I9N DN YW327.6S2
DMH0I9N HS Preclinical
DMH0I9N DT Antibody
DMH0I9N DE Non-small-cell lung cancer; Breast cancer
DMDRQIA ID DMDRQIA
DMDRQIA DN ZBzl-YAA5911
DMDRQIA HS Preclinical
DMDRQIA DT Peptide
DMDRQIA DE Enterococcus faecium infection
DMNG84V ID DMNG84V
DMNG84V DN ZK-thiazolidinone
DMNG84V HS Preclinical
DMNG84V SN Zoledronate trisodium; Zoledronate trisodium hydrate; UNII-ARL915IH66; Zoledronate trisodium [USAN]; ARL915IH66; 165800-08-8; Zoledronate trisodium (USAN); CGP-42446B; CGP 42446B; CHEMBL3989655; D06379; Trisodium hydrogen (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonate, hydrate (5:2); Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-, trisodium salt hydrate (5:2)
DMNG84V CP Bayer Schering Pharma.
DMNG84V TC Anticancer Agents
DMNG84V DT Small molecular drug
DMNG84V PC 73442801
DMNG84V MW 497.6
DMNG84V FM C23H30F3N5O2S
DMNG84V IC InChI=1S/C23H30F3N5O2S/c1-2-31-21(33)19(34-22(31)18(13-27)20(32)29-15-23(24,25)26)14-28-17-7-5-6-16(12-17)8-11-30-9-3-4-10-30/h5-7,12,18-19,22,28H,2-4,8-11,14-15H2,1H3,(H,29,32)
DMNG84V CS CCN1C(SC(C1=O)CNC2=CC=CC(=C2)CCN3CCCC3)C(C#N)C(=O)NCC(F)(F)F
DMNG84V IK WFZRONKPJVZNAO-UHFFFAOYSA-N
DMNG84V IU 2-cyano-2-[3-ethyl-4-oxo-5-[[3-(2-pyrrolidin-1-ylethyl)anilino]methyl]-1,3-thiazolidin-2-yl]-N-(2,2,2-trifluoroethyl)acetamide
DMNG84V DE Solid tumour/cancer
DMX23CZ ID DMX23CZ
DMX23CZ DN Z-Phe-Ala-diazomethylketone
DMX23CZ HS Preclinical
DMX23CZ SN Z-Phe-Ala-Diazomethylketone; 71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DMX23CZ DT Small molecular drug
DMX23CZ PC 155664
DMX23CZ MW 394.4
DMX23CZ FM C21H22N4O4
DMX23CZ IC InChI=1S/C21H22N4O4/c1-15(19(26)13-23-22)24-20(27)18(12-16-8-4-2-5-9-16)25-21(28)29-14-17-10-6-3-7-11-17/h2-11,13,15,18H,12,14H2,1H3,(H,24,27)(H,25,28)/t15-,18-/m0/s1
DMX23CZ CS C[C@@H](C(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
DMX23CZ IK QMPATRQNERZOMF-YJBOKZPZSA-N
DMX23CZ IU benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
DMX23CZ DE Alzheimer disease
DMTDG7L ID DMTDG7L
DMTDG7L DN Z-VAD-fmk
DMTDG7L HS Preclinical
DMTDG7L SN 187389-52-2; Z-VAD(OMe)-FMK; z-vad-FMK; Z-VAD (OMe)-FMK; Z-Val-Ala-Asp(OMe)-FMK; ZVAD-FMK; 5-Bromo-2 -deoxyuridine; Z-Val-Ala-Asp(OMe)-fluoromethyl ketone; Z-Val-Ala-Asp(OMe)-CH2F; C22H30FN3O7; Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone; Caspase-1 Inhibitor Z-Val-Ala-DL-Asp-fluoromethylketone; z-Val-Ala-Asp(OMe)-fluoromethylketone; Z-Val-Ala-Asp(OCH3)-fluoromethylketone; L-alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-; methyl 5-fluoro-3-[2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoylamino]-4-oxopentanoate; benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone; MFCD02684037; Bio2_000471; zVAD; pan-caspase inhibitor; Z-VAD-(OMe)-FMK; Probes1_000501; CBiol_001923; BSPBio_001262; KBioGR_000602; KBioSS_000602; CHEMBL1213366; SCHEMBL15012737; Z-Val-Ala-Asp(OCH3)-CH2F; KBio2_000602; KBio2_003170; KBio2_005738; KBio3_001063; KBio3_001064; AOB5976; DTXSID40420586; CHEBI:137045; Bio1_000209; Bio1_000698; Bio1_001187; Bio2_000951; HMS1362P03; HMS1792P03; HMS1990P03; HMS3403P03; EX-A2192; ZINC3875327; 2822AH; Z-L-Val-L-Ala-L-Asp(OMe)-CH2F; AKOS024456966; z-Val-Ala-Asp(OMe) fluoromethylketone; CCG-207882; CS-3153; IDI1_002226; z-Val-Ala-Asp(OMe)-fluoromethyl-ketone; Cbz-Val-Ala-Asp(OMe)-fluoromethylketone; NCGC00163487-01; NCGC00163487-02; AS-74918; Cbz-Val-Ala-Asp(OMe)-fluoromethyl ketone; HY-16658; Z-Val-Ala-Asp(OCH3)-fluoromethyl ketone; z-Val-Ala-Asp(O-methyl)-fluoromethylketone; S7023; SW219162-1; Caspase Inhibitor I - CAS 187389-52-2; A12373; Z-VAD(OMe)-FMK; Z-Val-Ala-Asp(OMe)-FMK; J-012061; benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone; benzyloxycarbonyl-Val-Ala-Asp(OMe)fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe)fluoromethylketone; benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe) fluoromethylketone; N-benzyloxycarbonyl-Val-Ala-Asp(OMe)fluoromethyl ketone; benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl) fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethyl ketone; N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone; L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]- (9CI); METHYL (3S)-3-[(2S)-2-[(2S)-2-{[(BENZYLOXY)CARBONYL]AMINO}-3-METHYLBUTANAMIDO]PROPANAMIDO]-5-FLUORO-4-OXOPENTANOATE; N-[(benzyloxy)carbonyl]-L-valyl-N-[(3S)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]-L-alaninamide; Methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate
DMTDG7L CP InvivoGen
DMTDG7L DT Small molecular drug
DMTDG7L PC 5497174
DMTDG7L MW 467.5
DMTDG7L FM C22H30FN3O7
DMTDG7L IC InChI=1S/C22H30FN3O7/c1-13(2)19(26-22(31)33-12-15-8-6-5-7-9-15)21(30)24-14(3)20(29)25-16(17(27)11-23)10-18(28)32-4/h5-9,13-14,16,19H,10-12H2,1-4H3,(H,24,30)(H,25,29)(H,26,31)/t14-,16-,19-/m0/s1
DMTDG7L CS C[C@@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1
DMTDG7L IK MIFGOLAMNLSLGH-QOKNQOGYSA-N
DMTDG7L IU methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate
DMTDG7L CA CAS 187389-52-2
DMTDG7L CB CHEBI:137045
DMTDG7L DE Pulmonary fibrosis
DMVO0LU ID DMVO0LU
DMVO0LU DN 131I-81C6
DMVO0LU HS Terminated
DMVO0LU SN Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6
DMVO0LU CP Duke University
DMVO0LU DT Antibody
DMVO0LU DE Brain cancer
DMTH52F ID DMTH52F
DMTH52F DN 21-AMINOEPOTHILONE B
DMTH52F HS Terminated
DMTH52F SN BMS-310705; (4S,7R,8S,9S,13R,14S,16S)-13,14-Epoxy-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2(E)-[2-(aminomethyl)thiazol-4-yl]vinyl]-1-oxacyclohexadecane-2,6-dione
DMTH52F DT Small molecular drug
DMTH52F PC 9828138
DMTH52F MW 522.7
DMTH52F FM C27H42N2O6S
DMTH52F IC InChI=1S/C27H42N2O6S/c1-15-8-7-9-27(6)21(35-27)11-19(16(2)10-18-14-36-22(13-28)29-18)34-23(31)12-20(30)26(4,5)25(33)17(3)24(15)32/h10,14-15,17,19-21,24,30,32H,7-9,11-13,28H2,1-6H3/b16-10+/t15-,17+,19-,20-,21-,24-,27+/m0/s1
DMTH52F CS C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)CN)/C)C
DMTH52F IK PFJFPBDHCFMQPN-RGJAOAFDSA-N
DMTH52F IU (1S,3S,7S,10R,11S,12S,16R)-3-[(E)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
DMTH52F CA CAS 280578-49-6
DMTH52F DE Solid tumour/cancer
DMO6BA0 ID DMO6BA0
DMO6BA0 DN 3-DEAZAADENOSINE
DMO6BA0 HS Terminated
DMO6BA0 SN Cc3Ado; BW-91Y78; 3DZA; 4-Amino-1-beta-D-ribofuranosyl-1H-imidazo[4,5-c]pyridine
DMO6BA0 DT Small molecular drug
DMO6BA0 PC 23190
DMO6BA0 MW 266.25
DMO6BA0 FM C11H14N4O4
DMO6BA0 IC InChI=1S/C11H14N4O4/c12-10-7-5(1-2-13-10)15(4-14-7)11-9(18)8(17)6(3-16)19-11/h1-2,4,6,8-9,11,16-18H,3H2,(H2,12,13)/t6-,8-,9-,11-/m1/s1
DMO6BA0 CS C1=CN=C(C2=C1N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMO6BA0 IK DBZQFUNLCALWDY-PNHWDRBUSA-N
DMO6BA0 IU (2R,3R,4S,5R)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMO6BA0 CA CAS 6736-58-9
DMO6BA0 DE Arthritis
DMQ4X7Y ID DMQ4X7Y
DMQ4X7Y DN 443C81
DMQ4X7Y HS Terminated
DMQ4X7Y SN BW 443C; BW-443C81
DMQ4X7Y CP Burroughs Wellcome Inc
DMQ4X7Y PC 101630908
DMQ4X7Y MW 682.7
DMQ4X7Y FM C31H42N10O8
DMQ4X7Y IC InChI=1S/C31H42N10O8/c32-22(15-18-7-11-21(42)12-8-18)28(45)39-23(3-1-13-36-31(34)35)29(46)37-17-26(43)38-24(16-19-5-9-20(10-6-19)41(48)49)30(47)40-14-2-4-25(40)27(33)44/h5-12,22-25H,1-4,13-17,32H2,(H10,33,34,35,36,37,38,39,42,43,44,45,46)/t22-,23+,24+,25+/m1/s1
DMQ4X7Y CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CNC(=O)[C@H](CCCN=C(N)[NH-])NC(=O)[C@@H](CC3=CC=C(C=C3)O)[NH3+])C(=O)N
DMQ4X7Y IK CQEKFKUITZRTPQ-ROHNOIKCSA-N
DMQ4X7Y IU [N'-[(4S)-4-[[(2R)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]-5-[[2-[[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(4-nitrophenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentyl]carbamimidoyl]azanide
DMQ4X7Y DE Asthma
DMM3UK5 ID DMM3UK5
DMM3UK5 DN 50-235
DMM3UK5 HS Terminated
DMM3UK5 SN Myriceric acid A
DMM3UK5 CP Shionogi & Co Ltd
DMM3UK5 DE Hypertension
DM5MVF9 ID DM5MVF9
DM5MVF9 DN 6-nitroquipazine
DM5MVF9 HS Terminated
DM5MVF9 SN 6-nitroquipazine; 77372-73-7; 6-nitro-2-(piperazin-1-yl)quinoline; 6-Nitro-2-piperazin-1-yl-quinoline; 6-Nitro,2-(1-piperazinyl)quinoline; DU-24565; DU 24565; UNII-28M0X094BH; Quinoline,6-nitro-2-(1-piperazinyl)-; Quinoline, 6-nitro-2-(1-piperazinyl)-; CHEMBL41140; 28M0X094BH; 6-nitro-2-piperazin-1-ylquinoline; 6-Nitro-2-(1-piperazinyl)quinoline maleate salt; Lopac-Q-109; Biomol-NT_000101; AC1L1JF0; AC1Q1XW4; Lopac0_001010; SCHEMBL401156; AC1Q21C2; BPBio1_001389; DTXSID7044001; CTK5E4324; GGDBEAVVGFNWIA-UHFFFAOYSA-N; CHEBI:104164
DM5MVF9 DT Small molecular drug
DM5MVF9 PC 5012
DM5MVF9 MW 258.279
DM5MVF9 FM C13H14N4O2
DM5MVF9 IC InChI=1S/C13H14N4O2/c18-17(19)11-2-3-12-10(9-11)1-4-13(15-12)16-7-5-14-6-8-16/h1-4,9,14H,5-8H2
DM5MVF9 CS C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)[N+](=O)[O-]
DM5MVF9 IK GGDBEAVVGFNWIA-UHFFFAOYSA-N
DM5MVF9 IU 6-nitro-2-piperazin-1-ylquinoline
DM5MVF9 CA CAS 77372-73-7
DM5MVF9 CB CHEBI:104164
DMX5K4C ID DMX5K4C
DMX5K4C DN 7-methoxytacrine
DMX5K4C HS Terminated
DMX5K4C SN 7-Methoxytacrine; 7-Meota; 7-methoxy-1,2,3,4-tetrahydroacridin-9-amine; TA-03; 5778-80-3; BRN 0477401; CHEMBL1256415; 1,2,3,4-Tetrahydro-7-methoxy-9-acridinamine; 9-Amino-7-methoxy-1,2,3,4-tetrahydroacridine; 9-Amino-7-methoxy-1,2,3,4-tetrahydroakridin [Czech]; Acridine, 1,2,3,4-tetrahydro-9-amino-7-methoxy-; 9-Amino-7-methoxy-1,2,3,4-tetrahydroakridin; AC1L3O4H; 9-Acridinamine, 1,2,3,4-tetrahydro-7-methoxy-; 5-22-12-00199 (Beilstein Handbook Reference); SCHEMBL195752; AC1Q582Q; CTK8D9577; MolPort-013-241-798; ZINC6018808
DMX5K4C DT Small molecular drug
DMX5K4C PC 119053
DMX5K4C MW 228.29
DMX5K4C FM C14H16N2O
DMX5K4C IC InChI=1S/C14H16N2O/c1-17-9-6-7-13-11(8-9)14(15)10-4-2-3-5-12(10)16-13/h6-8H,2-5H2,1H3,(H2,15,16)
DMX5K4C CS COC1=CC2=C(C=C1)N=C3CCCCC3=C2N
DMX5K4C IK APQPVVOYBLOJDY-UHFFFAOYSA-N
DMX5K4C IU 7-methoxy-1,2,3,4-tetrahydroacridin-9-amine
DMX5K4C CA CAS 5778-80-3
DM0NY6K ID DM0NY6K
DM0NY6K DN A 77636
DM0NY6K HS Terminated
DM0NY6K SN A77636; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.1(3,7))dec-1-yl-, hydrochloride, (1R-cis)-; UNII-WA6RGP1J4W; WA6RGP1J4W; 3-(1'-Adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride; C20H27NO3.HCl; 145307-34-2; AC1Q3F7L; AC1L21MK; LS-173243; (1R)-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol hydrochloride; (1r)-1-(aminomethyl)-3-(tricyclo[3.3.1.13,7]dec-1-yl)-3,4-dihydro-1h-isochromene-5,6-diol hydrochloride(1:1)
DM0NY6K DT Small molecular drug
DM0NY6K PC 6603703
DM0NY6K MW 329.4
DM0NY6K FM C20H27NO3
DM0NY6K IC InChI=1S/C20H27NO3/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20/h1-2,11-13,17-18,22-23H,3-10,21H2/t11?,12?,13?,17-,18-,20?/m0/s1
DM0NY6K CS C1[C@H](O[C@H](C2=C1C(=C(C=C2)O)O)CN)C34CC5CC(C3)CC(C5)C4
DM0NY6K IK QLJOSZATCBCBDR-DFKUFRTHSA-N
DM0NY6K IU (1R,3S)-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol
DM0NY6K CA CAS 778546-51-3
DM0NY6K CB CHEBI:64080
DM0NY6K DE Parkinson disease
DMZ5NQP ID DMZ5NQP
DMZ5NQP DN A-11259
DMZ5NQP HS Terminated
DMZ5NQP SN A-00000762; A-00000764; A-00026158; A-00026161; A-764; Shikimate kinase inhibitors (antibacterial); Shikimate kinase inhibitors (antibacterial), Arrow
DMZ5NQP CP Arrow Therapeutics Ltd
DMZ5NQP DE Bacterial infection
DM6CSRU ID DM6CSRU
DM6CSRU DN A-131701
DM6CSRU HS Terminated
DM6CSRU SN A-131701; CHEMBL40650; SCHEMBL7637490; BDBM50060965; 2-[2-(6-Methoxy-1,3,3a,4,5,9b-hexahydro-benzo[e]isoindol-2-yl)-ethyl]-4H-9-thia-2,4,5-triaza-fluorene-1,3-dione; 2-[2-((3aR,9bR)-6-Methoxy-1,3,3a,4,5,9b-hexahydro-benzo[e]isoindol-2-yl)-ethyl]-4H-9-thia-2,4,5-triaza-fluorene-1,3-dione
DM6CSRU DT Small molecular drug
DM6CSRU PC 10527469
DM6CSRU MW 448.5
DM6CSRU FM C24H24N4O3S
DM6CSRU IC InChI=1S/C24H24N4O3S/c1-31-18-5-2-4-15-16(18)8-7-14-12-27(13-17(14)15)10-11-28-23(29)22-21(26-24(28)30)20-19(32-22)6-3-9-25-20/h2-6,9,14,17H,7-8,10-13H2,1H3,(H,26,30)/t14-,17+/m0/s1
DM6CSRU CS COC1=CC=CC2=C1CC[C@@H]3[C@H]2CN(C3)CCN4C(=O)C5=C(C6=C(S5)C=CC=N6)NC4=O
DM6CSRU IK OLPQNRLJYOGSGV-WMLDXEAASA-N
DM6CSRU IU 5-[2-[(3aR,9bR)-6-methoxy-1,3,3a,4,5,9b-hexahydrobenzo[e]isoindol-2-yl]ethyl]-8-thia-3,5,13-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),10,12-tetraene-4,6-dione
DMRWDX5 ID DMRWDX5
DMRWDX5 DN A-134974
DMRWDX5 HS Terminated
DMRWDX5 SN a-134974; GTPL5130; CHEMBL1591918; ZINC3827162; SMP2_000021; NCGC00186045-01; A134974; A 134974
DMRWDX5 CP Abbott Laboratories
DMRWDX5 DT Small molecular drug
DMRWDX5 PC 9885936
DMRWDX5 MW 375.17
DMRWDX5 FM C11H14IN5O2
DMRWDX5 IC InChI=1S/C11H14IN5O2/c12-4-2-17(6-1-5(13)8(18)9(6)19)11-7(4)10(14)15-3-16-11/h2-3,5-6,8-9,18-19H,1,13H2,(H2,14,15,16)/t5-,6+,8+,9-/m0/s1
DMRWDX5 CS C1[C@@H]([C@H]([C@H]([C@@H]1N2C=C(C3=C(N=CN=C32)N)I)O)O)N
DMRWDX5 IK NSXJHIFQIZKLGF-LWIVVEGESA-N
DMRWDX5 IU (1S,2R,3S,5R)-3-amino-5-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
DMRWDX5 DE Epilepsy
DMPEJ4O ID DMPEJ4O
DMPEJ4O DN A-204176
DMPEJ4O HS Terminated
DMPEJ4O CP Abbott Laboratories
DMPEJ4O PC 9904117
DMPEJ4O MW 291.37
DMPEJ4O FM C14H17N3O2S
DMPEJ4O IC InChI=1S/C14H17N3O2S/c1-20(18,19)17-13-7-3-4-10-11(13)5-2-6-12(10)14-8-15-9-16-14/h3-4,7-9,12,17H,2,5-6H2,1H3,(H,15,16)
DMPEJ4O CS CS(=O)(=O)NC1=CC=CC2=C1CCCC2C3=CN=CN3
DMPEJ4O IK FTWWLMPVXHMPNP-UHFFFAOYSA-N
DMPEJ4O IU N-[5-(1H-imidazol-5-yl)-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide
DMPEJ4O DE Stress urinary incontinence
DMDTA36 ID DMDTA36
DMDTA36 DN A-252444.0
DMDTA36 HS Terminated
DMDTA36 SN A-155918; A-205804; A-241548
DMDTA36 CP Abbott Laboratories
DMDTA36 DE Inflammation
DMKL482 ID DMKL482
DMKL482 DN A-364
DMKL482 HS Terminated
DMKL482 SN A-358; Dehydroquinate synthase inhibitors (antibacterial); Dehydroquinate synthase inhibitors (antibacterial), Arrow
DMKL482 CP Arrow Therapeutics Ltd
DMKL482 DE Bacterial infection
DM4WT7Z ID DM4WT7Z
DM4WT7Z DN A-62176
DM4WT7Z HS Terminated
DM4WT7Z SN A-62176
DM4WT7Z DT Small molecular drug
DM4WT7Z PC 10474948
DM4WT7Z MW 381.4
DM4WT7Z FM C20H16FN3O4
DM4WT7Z IC InChI=1S/C20H16FN3O4/c21-13-7-11-16-19(17(13)23-6-5-10(22)8-23)28-15-4-2-1-3-14(15)24(16)9-12(18(11)25)20(26)27/h1-4,7,9-10H,5-6,8,22H2,(H,26,27)/t10-/m0/s1
DM4WT7Z CS C1CN(C[C@H]1N)C2=C(C=C3C4=C2OC5=CC=CC=C5N4C=C(C3=O)C(=O)O)F
DM4WT7Z IK OLNJLTFSGFZCKE-JTQLQIEISA-N
DM4WT7Z IU 10-[(3S)-3-aminopyrrolidin-1-yl]-11-fluoro-14-oxo-8-oxa-1-azatetracyclo[7.7.1.02,7.013,17]heptadeca-2,4,6,9(17),10,12,15-heptaene-15-carboxylic acid
DM1BDHY ID DM1BDHY
DM1BDHY DN A-68552
DM1BDHY HS Terminated
DM1BDHY SN IDDB2379
DM1BDHY CP Abbott Laboratories
DM1BDHY DT Small molecular drug
DM1BDHY PC 194986
DM1BDHY MW 991.1
DM1BDHY FM C48H62N8O13S
DM1BDHY IC InChI=1S/C48H62N8O13S/c1-4-6-16-36(52-41(57)24-21-30-19-22-33(23-20-30)69-70(66,67)68)44(61)51-29-42(58)53-39(26-32-28-50-35-18-12-11-15-34(32)35)47(64)54-37(17-7-5-2)45(62)55-40(27-43(59)60)48(65)56-46(63)38(49-3)25-31-13-9-8-10-14-31/h8-15,18-20,22-23,28,36-40,49-50H,4-7,16-17,21,24-27,29H2,1-3H3,(H,51,61)(H,52,57)(H,53,58)(H,54,64)(H,55,62)(H,59,60)(H,56,63,65)(H,66,67,68)/t36-,37-,38-,39-,40-/m0/s1
DM1BDHY CS CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)NC(=O)[C@H](CC3=CC=CC=C3)NC)NC(=O)CCC4=CC=C(C=C4)OS(=O)(=O)O
DM1BDHY IK HTISDDBHNNOAGK-HECCNADXSA-N
DM1BDHY IU (3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-[[(2S)-2-(methylamino)-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DM1BDHY CA CAS 112882-74-3
DM1BDHY DE Obesity
DMUJ94B ID DMUJ94B
DMUJ94B DN A-68930
DMUJ94B HS Terminated
DMUJ94B SN 5,6-Dihydroxy-3-phenyl-1-aminomethylisochroman; A-70108; A 68930; A70360; A70108; A68930; A 70360; A-70360; A 70108; UNII-B4NI77O5D4; CHEMBL86931; B4NI77O5D4; 1-(Aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran; 130465-45-1; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-phenyl-, (1R-cis)-; Tocris-1534; AC1L3UDV; GTPL6077; SCHEMBL10380334; CHEBI:103966; ZINC3787668; BDBM50007129; NCGC00025206-01; NCGC00025206-02; LS-172768; BRD-K33400588-003-01-2
DMUJ94B CP Abbott Laboratories
DMUJ94B DT Small molecular drug
DMUJ94B PC 122324
DMUJ94B MW 271.31
DMUJ94B FM C16H17NO3
DMUJ94B IC InChI=1S/C16H17NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h1-7,14-15,18-19H,8-9,17H2/t14-,15-/m0/s1
DMUJ94B CS C1[C@H](O[C@H](C2=C1C(=C(C=C2)O)O)CN)C3=CC=CC=C3
DMUJ94B IK SUHGRZPINGKYNV-GJZGRUSLSA-N
DMUJ94B IU (1R,3S)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-isochromene-5,6-diol
DMUJ94B CA CAS 130465-45-1
DMUJ94B CB CHEBI:103966
DMUJ94B DE Hypertension
DMPL1OV ID DMPL1OV
DMPL1OV DN A-69024
DMPL1OV HS Terminated
DMPL1OV SN A-69024; 58939-37-0; 7-Isoquinolinol, 1-((2-bromo-4,5-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-; A 69024; A-66359; A 66359; 1-[(2-bromo-4,5-dimethoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol; AC1L5ACF; 1-(2-Bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; Oprea1_293762; SCHEMBL462517; CTK1H3031
DMPL1OV CP Abbott Laboratories
DMPL1OV DT Small molecular drug
DMPL1OV PC 173657
DMPL1OV MW 422.3
DMPL1OV FM C20H24BrNO4
DMPL1OV IC InChI=1S/C20H24BrNO4/c1-22-6-5-12-8-18(24-2)17(23)10-14(12)16(22)7-13-9-19(25-3)20(26-4)11-15(13)21/h8-11,16,23H,5-7H2,1-4H3
DMPL1OV CS CN1CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3Br)OC)OC)O)OC
DMPL1OV IK YVBUTIYRCMQJHW-UHFFFAOYSA-N
DMPL1OV IU 1-[(2-bromo-4,5-dimethoxyphenyl)methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol
DMPL1OV CA CAS 58939-37-0
DMPL1OV DE Psychotic disorder
DM9KNFZ ID DM9KNFZ
DM9KNFZ DN A-70276
DM9KNFZ HS Terminated
DM9KNFZ SN A-71134
DM9KNFZ CP Abbott Laboratories
DM9KNFZ DE Gastrointestinal disease
DM9X24J ID DM9X24J
DM9X24J DN A-70826
DM9X24J HS Terminated
DM9X24J SN A-70826; AC1OCF5L; 7-[3-[[(2S)-2-[[(2S)-2-aminopentanoyl]amino]pentanoyl]amino]pyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride
DM9X24J CP Abbott Laboratories
DM9X24J DT Small molecular drug
DM9X24J PC 6918207
DM9X24J MW 639.1
DM9X24J FM C29H34ClF3N6O5
DM9X24J IC InChI=1S/C29H33F3N6O5.ClH/c1-3-5-21(33)27(40)35-22(6-4-2)28(41)34-16-9-10-37(13-16)26-20(32)12-17-24(39)18(29(42)43)14-38(25(17)36-26)23-8-7-15(30)11-19(23)31;/h7-8,11-12,14,16,21-22H,3-6,9-10,13,33H2,1-2H3,(H,34,41)(H,35,40)(H,42,43);1H/t16?,21-,22-;/m0./s1
DM9X24J CS CCC[C@@H](C(=O)N[C@@H](CCC)C(=O)NC1CCN(C1)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F)N.Cl
DM9X24J IK FTKPWZYQYLDWSN-KSNQKOBFSA-N
DM9X24J IU 7-[3-[[(2S)-2-[[(2S)-2-aminopentanoyl]amino]pentanoyl]amino]pyrrolidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;hydrochloride
DM9X24J DE Bacterial infection
DMKZNTY ID DMKZNTY
DMKZNTY DN A-71623
DMKZNTY HS Terminated
DMKZNTY SN A-71623; 130408-77-4; CHEMBL323521; A 71623; A71623; (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid; PDSP1_000879; AC1L3TQM; GTPL858; CHEMBL337366; ZINC95610808; PDSP2_000865; BDBM50003666; Boc-trp-lys(epsilon-N-2-methylphenylaminocarbonyl)-asp-(N-methyl)-phe-NH2; AKOS024457082; KB-270509; B7046; J-005804
DMKZNTY CP Abbott Laboratories
DMKZNTY DT Small molecular drug
DMKZNTY PC 121964
DMKZNTY MW 841
DMKZNTY FM C44H56N8O9
DMKZNTY IC InChI=1S/C44H56N8O9/c1-27-15-9-11-19-31(27)50-42(59)46-22-14-13-21-33(39(56)49-35(25-37(53)54)41(58)52(5)36(38(45)55)23-28-16-7-6-8-17-28)48-40(57)34(51-43(60)61-44(2,3)4)24-29-26-47-32-20-12-10-18-30(29)32/h6-12,15-20,26,33-36,47H,13-14,21-25H2,1-5H3,(H2,45,55)(H,48,57)(H,49,56)(H,51,60)(H,53,54)(H2,46,50,59)/t33-,34-,35-,36-/m0/s1
DMKZNTY CS CC1=CC=CC=C1NC(=O)NCCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N(C)[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)OC(C)(C)C
DMKZNTY IK KNHCBYMGWWTGSO-ZYADHFCISA-N
DMKZNTY IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid
DMKZNTY CA CAS 130408-77-4
DMKZNTY DE Obesity
DM7FI3S ID DM7FI3S
DM7FI3S DN A-72055
DM7FI3S HS Terminated
DM7FI3S CP Abbott Laboratories
DM7FI3S DE Alzheimer disease
DMBEIFL ID DMBEIFL
DMBEIFL DN A-74273
DMBEIFL HS Terminated
DMBEIFL SN A-74723
DMBEIFL CP Abbott Laboratories
DMBEIFL DT Small molecular drug
DMBEIFL PC 5483842
DMBEIFL MW 787.1
DMBEIFL FM C44H74N4O8
DMBEIFL IC InChI=1S/C44H74N4O8/c1-5-6-18-40(56-41(30-35-16-11-8-12-17-35)44(52)48-23-19-36(20-24-48)55-32-53-4)43(51)46-38(29-34-14-9-7-10-15-34)39(49)31-37(33(2)3)42(50)45-21-13-22-47-25-27-54-28-26-47/h8,11-12,16-17,33-34,36-41,49H,5-7,9-10,13-15,18-32H2,1-4H3,(H,45,50)(H,46,51)/t37?,38?,39?,40-,41-/m0/s1
DMBEIFL CS CCCC[C@@H](C(=O)NC(CC1CCCCC1)C(CC(C(C)C)C(=O)NCCCN2CCOCC2)O)O[C@@H](CC3=CC=CC=C3)C(=O)N4CCC(CC4)OCOC
DMBEIFL IK NVMVSIUABPBQIL-UOKFUGOKSA-N
DMBEIFL IU 6-cyclohexyl-4-hydroxy-5-[[(2S)-2-[(2S)-1-[4-(methoxymethoxy)piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]oxyhexanoyl]amino]-N-(3-morpholin-4-ylpropyl)-2-propan-2-ylhexanamide
DMBEIFL CA CAS 130316-95-9
DMBEIFL DE Hypertension
DMS3R15 ID DMS3R15
DMS3R15 DN A-74283
DMS3R15 HS Terminated
DMS3R15 CP Abbott Laboratories
DMS3R15 PC 9935515
DMS3R15 MW 458.6
DMS3R15 FM C29H34N2O3
DMS3R15 IC InChI=1S/C29H34N2O3/c1-34-24-6-4-5-17-7-8-18-15-30(16-23(18)25(17)24)13-2-3-14-31-28(32)26-21-11-12-22(27(26)29(31)33)20-10-9-19(20)21/h4-6,9-12,18-23,26-27H,2-3,7-8,13-16H2,1H3/t18-,19?,20?,21-,22+,23-,26?,27?/m1/s1
DMS3R15 CS COC1=CC=CC2=C1[C@@H]3CN(C[C@H]3CC2)CCCCN4C(=O)C5[C@@H]6C=C[C@H](C5C4=O)C7C6C=C7
DMS3R15 IK FIVMUTRIOVYDHZ-TZNWWNPGSA-N
DMS3R15 IU (1S,7R)-4-[4-[(3aS,9bR)-9-methoxy-1,3,3a,4,5,9b-hexahydrobenzo[e]isoindol-2-yl]butyl]-4-azatetracyclo[5.4.2.02,6.08,11]trideca-9,12-diene-3,5-dione
DMS3R15 DE Hypertension
DMNCGOP ID DMNCGOP
DMNCGOP DN A-74932
DMNCGOP HS Terminated
DMNCGOP SN A-74932; A 74932; 3H-Pyrido(3,2,1-kl)phenoxazine-2-carboxylic acid, 6-(2-((2-amino-1-oxopentyl)amino)-1-pyrrolidinyl)-5-fluoro-3-oxo-, monohydrochloride; 3H-Pyrido(3,2,1-k1)phenoxazine-2-carboxylic acid, 6-(2-((2-amino-1-oxopentyl)amino)-1-pyrrolidinyl)-5-fluoro-3-oxo-, monohydrochloride; AC1L31MU; 148201-60-9
DMNCGOP CP Abbott Laboratories
DMNCGOP DT Small molecular drug
DMNCGOP PC 132825
DMNCGOP MW 516.9
DMNCGOP FM C25H26ClFN4O5
DMNCGOP IC InChI=1S/C25H25FN4O5.ClH/c1-2-6-16(27)24(32)28-19-9-5-10-29(19)21-15(26)11-13-20-23(21)35-18-8-4-3-7-17(18)30(20)12-14(22(13)31)25(33)34;/h3-4,7-8,11-12,16,19H,2,5-6,9-10,27H2,1H3,(H,28,32)(H,33,34);1H
DMNCGOP CS CCCC(C(=O)NC1CCCN1C2=C(C=C3C4=C2OC5=CC=CC=C5N4C=C(C3=O)C(=O)O)F)N.Cl
DMNCGOP IK UFBYBJURMXBKFU-UHFFFAOYSA-N
DMNCGOP IU 10-[2-(2-aminopentanoylamino)pyrrolidin-1-yl]-11-fluoro-14-oxo-8-oxa-1-azatetracyclo[7.7.1.02,7.013,17]heptadeca-2,4,6,9(17),10,12,15-heptaene-15-carboxylic acid;hydrochloride
DMNCGOP CA CAS 148201-60-9
DMNCGOP DE Lung cancer
DMPX37E ID DMPX37E
DMPX37E DN A-75169
DMPX37E HS Terminated
DMPX37E SN A-74324; A-74325
DMPX37E CP Abbott Laboratories
DMPX37E PC 70208442
DMPX37E MW 331.9
DMPX37E FM C20H26ClNO
DMPX37E IC InChI=1S/C20H25NO.ClH/c1-21(13-12-16-6-3-2-4-7-16)15-18-9-5-8-17-14-19(22)10-11-20(17)18;/h2-4,6-7,10-11,14,18,22H,5,8-9,12-13,15H2,1H3;1H
DMPX37E CS CN(CCC1=CC=CC=C1)CC2CCCC3=C2C=CC(=C3)O.Cl
DMPX37E IK APKIWAWHUXJRIV-UHFFFAOYSA-N
DMPX37E IU 5-[[methyl(2-phenylethyl)amino]methyl]-5,6,7,8-tetrahydronaphthalen-2-ol;hydrochloride
DMPX37E DE Glaucoma/ocular hypertension
DMC3MH5 ID DMC3MH5
DMC3MH5 DN A-75729
DMC3MH5 HS Terminated
DMC3MH5 SN A-75290; A-75619
DMC3MH5 CP Abbott Laboratories
DMC3MH5 DE Bacterial infection
DMRHEWX ID DMRHEWX
DMRHEWX DN A-76202M
DMRHEWX HS Terminated
DMRHEWX SN A 76202
DMRHEWX CP Sankyo Co Ltd
DMRHEWX DE Acquired immune deficiency syndrome
DMTF6D9 ID DMTF6D9
DMTF6D9 DN A-76895
DMTF6D9 HS Terminated
DMTF6D9 SN IDDB2395
DMTF6D9 CP Abbott Laboratories
DMTF6D9 DE Epilepsy
DM4HRXI ID DM4HRXI
DM4HRXI DN A-78773
DM4HRXI HS Terminated
DM4HRXI SN 141579-67-1; A 78773; CHEMBL59598; N-Hydroxy-N-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea; N-(3-(5-(4-Fluorophenoxy)-2-furanyl)-1-methyl-2-propynyl)-N-hydroxyurea; 1-{4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl}-1-hydroxyurea; 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea; Urea,N-[3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propyn-1-yl]-N-hydroxy-; CCRIS 8531
DM4HRXI DT Small molecular drug
DM4HRXI PC 71460
DM4HRXI MW 304.27
DM4HRXI FM C15H13FN2O4
DM4HRXI IC InChI=1S/C15H13FN2O4/c1-10(18(20)15(17)19)2-5-12-8-9-14(21-12)22-13-6-3-11(16)4-7-13/h3-4,6-10,20H,1H3,(H2,17,19)
DM4HRXI CS CC(C#CC1=CC=C(O1)OC2=CC=C(C=C2)F)N(C(=O)N)O
DM4HRXI IK OLZHFFKRBCZHHT-UHFFFAOYSA-N
DM4HRXI IU 1-[4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DM4HRXI CA CAS 141579-67-1
DM4HRXI DE Asthma
DMT5ZFG ID DMT5ZFG
DMT5ZFG DN A-79175
DMT5ZFG HS Terminated
DMT5ZFG SN CHEMBL90552; UNII-25B75ID70W; 25B75ID70W; AC1L43J2; ZINC5333; SCHEMBL6438420; BDBM50369068; 141579-87-5; 1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DMT5ZFG DT Small molecular drug
DMT5ZFG PC 178577
DMT5ZFG MW 304.27
DMT5ZFG FM C15H13FN2O4
DMT5ZFG IC InChI=1S/C15H13FN2O4/c1-10(18(20)15(17)19)2-5-12-8-9-14(21-12)22-13-6-3-11(16)4-7-13/h3-4,6-10,20H,1H3,(H2,17,19)/t10-/m1/s1
DMT5ZFG CS C[C@H](C#CC1=CC=C(O1)OC2=CC=C(C=C2)F)N(C(=O)N)O
DMT5ZFG IK OLZHFFKRBCZHHT-SNVBAGLBSA-N
DMT5ZFG IU 1-[(2R)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea
DMT5ZFG CA CAS 141579-87-5
DMT5ZFG DE Asthma
DM3IYMF ID DM3IYMF
DM3IYMF DN A-79296
DM3IYMF HS Terminated
DM3IYMF CP Abbott Laboratories
DM3IYMF DE Herpes simplex virus infection
DMXWG6Z ID DMXWG6Z
DMXWG6Z DN A-798
DMXWG6Z HS Terminated
DMXWG6Z SN A-429; A-655; A-665798; A-748; A-761; A-780748; MCHR-1 antagonists (obesity); Melanin concentrating hormone-1 receptor antagonists, Abbott; MCH-1 antagonists (obesity), Abbott; MCHR-1 antagonists (obesity), Abbott
DMXWG6Z CP Abbott Laboratories
DMXWG6Z DE Obesity
DM89BGE ID DM89BGE
DM89BGE DN A-80263
DM89BGE HS Terminated
DM89BGE CP Abbott Laboratories
DM89BGE DE Inflammation
DMBC3DG ID DMBC3DG
DMBC3DG DN A-80426
DMBC3DG HS Terminated
DMBC3DG SN A-80426; CHEMBL268258; SCHEMBL647243; ZINC3810797; BDBM50057128; AKOS030558130; NCGC00378605-01
DMBC3DG DT Small molecular drug
DMBC3DG PC 9928332
DMBC3DG MW 349.5
DMBC3DG FM C23H27NO2
DMBC3DG IC InChI=1S/C23H27NO2/c1-24(13-11-17-9-10-18-12-14-26-23(18)15-17)16-19-5-3-7-21-20(19)6-4-8-22(21)25-2/h4,6,8-10,12,14-15,19H,3,5,7,11,13,16H2,1-2H3/t19-/m0/s1
DMBC3DG CS CN(CCC1=CC2=C(C=C1)C=CO2)C[C@@H]3CCCC4=C3C=CC=C4OC
DMBC3DG IK MHPMXTGKTXJIDI-IBGZPJMESA-N
DMBC3DG IU 2-(1-benzofuran-6-yl)-N-[[(1R)-5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]-N-methylethanamine
DMH6LCD ID DMH6LCD
DMH6LCD DN A-81282
DMH6LCD HS Terminated
DMH6LCD SN 141872-46-0; Abbott 81282; A-81282; CHEMBL333534; 4-[butyl([2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl)amino]-5-pyrimidinecarboxylic acid; 5-Pyrimidinecarboxylicacid, 4-[butyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-; Abbott-81282; ACMC-20cd64; AC1Q5UC5; AC1L4U4U; A 81282; Oprea1_016094; SCHEMBL7939345; CTK8G9360; CTK0I0417; DTXSID70161839; MolPort-039-032-861; ZINC1533713; BDBM50003155; AKOS027380884; 4-(butyl{[2'-(2h-tetrazol-5-yl)biphenyl-4-yl]methyl}amino)pyrimidine-5-carboxylic acid; CC-17571
DMH6LCD CP Abbott Laboratories
DMH6LCD DT Small molecular drug
DMH6LCD PC 192314
DMH6LCD MW 429.5
DMH6LCD FM C23H23N7O2
DMH6LCD IC InChI=1S/C23H23N7O2/c1-2-3-12-30(22-20(23(31)32)13-24-15-25-22)14-16-8-10-17(11-9-16)18-6-4-5-7-19(18)21-26-28-29-27-21/h4-11,13,15H,2-3,12,14H2,1H3,(H,31,32)(H,26,27,28,29)
DMH6LCD CS CCCCN(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C4=NC=NC=C4C(=O)O
DMH6LCD IK AHZXSVWCNDLJER-UHFFFAOYSA-N
DMH6LCD IU 4-[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyrimidine-5-carboxylic acid
DMH6LCD CA CAS 141872-46-0
DMH6LCD DE Hypertension
DM1GLIN ID DM1GLIN
DM1GLIN DN A-81988
DM1GLIN HS Terminated
DM1GLIN SN 2-[Propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid; 141887-34-5; A81988; A 81988; CHEMBL416477; Abbott-81988; 2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid; 3-Pyridinecarboxylicacid, 2-[propyl[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-; ACMC-20n0yv; [3H]A81988; [3H]-A81988; AC1L30WD; 2-(N-Propyl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)amino)pyridine-3-carboxylic acid; Oprea1_714523; SCHEMBL7048946; GTPL3938; CTK0H8555; DTXSID40161846; BDBM50003154; HY-U00188; CS-7281; L007227; Abbott-81988
DM1GLIN CP Abbott Laboratories
DM1GLIN DT Small molecular drug
DM1GLIN PC 132387
DM1GLIN MW 414.5
DM1GLIN FM C23H22N6O2
DM1GLIN IC InChI=1S/C23H22N6O2/c1-2-14-29(22-20(23(30)31)8-5-13-24-22)15-16-9-11-17(12-10-16)18-6-3-4-7-19(18)21-25-27-28-26-21/h3-13H,2,14-15H2,1H3,(H,30,31)(H,25,26,27,28)
DM1GLIN CS CCCN(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C4=C(C=CC=N4)C(=O)O
DM1GLIN IK DLMNZGAILMQDHA-UHFFFAOYSA-N
DM1GLIN IU 2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid
DM1GLIN CA CAS 141887-34-5
DM1GLIN DE Hypertension
DMUID46 ID DMUID46
DMUID46 DN A-87049
DMUID46 HS Terminated
DMUID46 SN A-87049; CHEMBL445618; BDBM50058945; (1S,2S,3S,4S)-3,4-Bis-[(4-phenoxy-benzyl)-propyl-carbamoyl]-cyclobutane-1,2-dicarboxylic acid
DMUID46 DT Small molecular drug
DMUID46 PC 9810076
DMUID46 MW 678.8
DMUID46 FM C40H42N2O8
DMUID46 IC InChI=1S/C40H42N2O8/c1-3-23-41(25-27-15-19-31(20-16-27)49-29-11-7-5-8-12-29)37(43)33-34(36(40(47)48)35(33)39(45)46)38(44)42(24-4-2)26-28-17-21-32(22-18-28)50-30-13-9-6-10-14-30/h5-22,33-36H,3-4,23-26H2,1-2H3,(H,45,46)(H,47,48)/t33-,34-,35-,36-/m0/s1
DMUID46 CS CCCN(CC1=CC=C(C=C1)OC2=CC=CC=C2)C(=O)[C@H]3[C@@H]([C@@H]([C@H]3C(=O)O)C(=O)O)C(=O)N(CCC)CC4=CC=C(C=C4)OC5=CC=CC=C5
DMUID46 IK PNOGMVDDWILAMR-ZYADHFCISA-N
DMUID46 IU (1S,2S,3S,4S)-3,4-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclobutane-1,2-dicarboxylic acid
DM1KBAY ID DM1KBAY
DM1KBAY DN A-93178
DM1KBAY HS Terminated
DM1KBAY SN A-93178.5
DM1KBAY CP Abbott Laboratories
DM1KBAY PC 101018054
DM1KBAY MW 432.5
DM1KBAY FM C26H28N2O4
DM1KBAY IC InChI=1S/C26H28N2O4/c1-18(26(29)30)28-32-25(20-8-3-2-4-9-20)21-12-15-23(16-13-21)31-17-22-14-11-19-7-5-6-10-24(19)27-22/h5-7,10-16,20,25H,2-4,8-9,17H2,1H3,(H,29,30)/b28-18-
DM1KBAY CS C/C(=N/OC(C1CCCCC1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)/C(=O)O
DM1KBAY IK USBHSZPRMPADOE-VEILYXNESA-N
DM1KBAY IU (2Z)-2-[cyclohexyl-[4-(quinolin-2-ylmethoxy)phenyl]methoxy]iminopropanoic acid
DM1KBAY DE Allergy
DMPEB0Z ID DMPEB0Z
DMPEB0Z DN AA-861
DMPEB0Z HS Terminated
DMPEB0Z SN aa-861; DOCEBENONE; 80809-81-0; Docebenonum; Docebenona; AA861; Docebenone [USAN:INN]; Docebenonum [INN-Latin]; Docebenona [INN-Spanish]; UNII-2XRX3BD53M; 2-(12-hydroxydodeca-5,10-diyn-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione; CHEBI:2340; A-61589; 2-(12-Hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone; 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone; 2XRX3BD53M; MLS000028467; A 61589; NCGC00015053-05; SMR000058412; 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone
DMPEB0Z DT Small molecular drug
DMPEB0Z PC 1967
DMPEB0Z MW 326.4
DMPEB0Z FM C21H26O3
DMPEB0Z IC InChI=1S/C21H26O3/c1-16-17(2)21(24)19(18(3)20(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h22H,5,7-10,12,14-15H2,1-3H3
DMPEB0Z CS CC1=C(C(=O)C(=C(C1=O)C)CCCCC#CCCCC#CCO)C
DMPEB0Z IK WDEABJKSGGRCQA-UHFFFAOYSA-N
DMPEB0Z IU 2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
DMPEB0Z CA CAS 80809-81-0
DMPEB0Z CB CHEBI:2340
DMPEB0Z DE Allergy
DMDOQCV ID DMDOQCV
DMDOQCV DN ABANOQUIL
DMDOQCV HS Terminated
DMDOQCV SN TCMDC-131968; UNII-MAX6HQS78D; MAX6HQS78D; UK 52046; UK 52046 mesylate; UK-52,046; UK 52046-27; Abanoquil mesilate; 118931-00-3; AC1Q6WCW; 4-Amino-6,7-dimethoxy-2-(1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)quinoline methanesulfonate; CHEMBL527515; AC1L4U62; SCHEMBL3672975; UK-52046-27; A807482; 4-Quinolinamine, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-, monomethanesulfonate; 2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-quinolin-4-amine
DMDOQCV DT Small molecular drug
DMDOQCV PC 164089
DMDOQCV MW 395.5
DMDOQCV FM C22H25N3O4
DMDOQCV IC InChI=1S/C22H25N3O4/c1-26-18-7-13-5-6-25(12-14(13)8-19(18)27-2)22-10-16(23)15-9-20(28-3)21(29-4)11-17(15)24-22/h7-11H,5-6,12H2,1-4H3,(H2,23,24)
DMDOQCV CS COC1=C(C=C2CN(CCC2=C1)C3=NC4=CC(=C(C=C4C(=C3)N)OC)OC)OC
DMDOQCV IK ANZIISNSHPKVRV-UHFFFAOYSA-N
DMDOQCV IU 2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxyquinolin-4-amine
DMDOQCV CA CAS 90402-40-7
DMALPDW ID DMALPDW
DMALPDW DN ABS-205
DMALPDW HS Terminated
DMALPDW SN ABS-205R; ABS-205S
DMALPDW CP American Biogenetic Sciences Inc
DMALPDW DE Neurodegenerative disorder
DMZ52P6 ID DMZ52P6
DMZ52P6 DN ABS-212
DMZ52P6 HS Terminated
DMZ52P6 SN Neurotensin derivative (pain), Argolyn
DMZ52P6 CP Argolyn Bioscience Inc
DMZ52P6 DE Pain
DMCW5DJ ID DMCW5DJ
DMCW5DJ DN ABS-301
DMCW5DJ HS Terminated
DMCW5DJ SN ABS-302; ABS-303; ABS-304; Tacrine analogs, ABS
DMCW5DJ CP American Biogenetic Sciences Inc
DMCW5DJ DE Alzheimer disease
DMPFLS5 ID DMPFLS5
DMPFLS5 DN ABT-100
DMPFLS5 HS Terminated
DMPFLS5 SN A-367074; A-409100; A-367074.1
DMPFLS5 CP Abbott Laboratories
DMPFLS5 DT Small molecular drug
DMPFLS5 PC 6451154
DMPFLS5 MW 504.5
DMPFLS5 FM C27H19F3N4O3
DMPFLS5 IC InChI=1S/C27H19F3N4O3/c1-34-17-33-15-25(34)26(35,21-7-2-18(13-31)3-8-21)16-36-24-11-4-19(14-32)12-23(24)20-5-9-22(10-6-20)37-27(28,29)30/h2-12,15,17,35H,16H2,1H3/t26-/m0/s1
DMPFLS5 CS CN1C=NC=C1[C@](COC2=C(C=C(C=C2)C#N)C3=CC=C(C=C3)OC(F)(F)F)(C4=CC=C(C=C4)C#N)O
DMPFLS5 IK HEUVRFNVTLGKMZ-SANMLTNESA-N
DMPFLS5 IU 4-[(2S)-2-(4-cyanophenyl)-2-hydroxy-2-(3-methylimidazol-4-yl)ethoxy]-3-[4-(trifluoromethoxy)phenyl]benzonitrile
DMPFLS5 CA CAS 450839-40-4
DMPFLS5 DE Solid tumour/cancer
DMYJMV9 ID DMYJMV9
DMYJMV9 DN ABT-702
DMYJMV9 HS Terminated
DMYJMV9 SN abt-702; Abt 702; ABT702; CHEMBL66089; UNII-2P206WS5B3; 2P206WS5B3; 5-(3-bromophenyl)-7-[6-(morpholin-4-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidin-4-amine; 5-(3-Bromo-phenyl)-7-(6-morpholin-4-yl-pyridin-3-yl)-pyrido[2,3-d]pyrimidin-4-ylamine; AC1L1CN5; SCHEMBL1914142; GTPL5131; CTK5I8409; MolPort-035-936-400; CHEBI:104129; ZINC21288919; BDBM50094703; AKOS030589605; SMP2_000264; NCGC00092381-03; NCGC00092381-02; LS-134028; BRD-K36021395-300-01-6; 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine
DMYJMV9 CP Abbott Laboratories
DMYJMV9 DT Small molecular drug
DMYJMV9 PC 1973
DMYJMV9 MW 463.3
DMYJMV9 FM C22H19BrN6O
DMYJMV9 IC InChI=1S/C22H19BrN6O/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29/h1-5,10-13H,6-9H2,(H2,24,26,27,28)
DMYJMV9 CS C1COCCN1C2=NC=C(C=C2)C3=NC4=NC=NC(=C4C(=C3)C5=CC(=CC=C5)Br)N
DMYJMV9 IK RQCXKDWOCUJWQZ-UHFFFAOYSA-N
DMYJMV9 IU 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine
DMYJMV9 CA CAS 214697-26-4
DMYJMV9 CB CHEBI:104129
DMYJMV9 DE Pain
DML0DBV ID DML0DBV
DML0DBV DN ABT-737
DML0DBV HS Terminated
DML0DBV SN ABT-737; 852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide
DML0DBV DT Small molecular drug
DML0DBV PC 11228183
DML0DBV MW 813.4
DML0DBV FM C42H45ClN6O5S2
DML0DBV IC InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1
DML0DBV CS CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
DML0DBV IK HPLNQCPCUACXLM-PGUFJCEWSA-N
DML0DBV IU 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide
DML0DBV CA CAS 852808-04-9
DM4UN9A ID DM4UN9A
DM4UN9A DN ABT-839
DM4UN9A HS Terminated
DM4UN9A SN ABT-839; CHEMBL29982; 216234-25-2; 2-{(5-{[BUTYL-(2-CYCLOHEXYL-ETHYL)-AMINO]-METHYL}-2'-METHYL-BIPHENYL-2-CARBONYL)-AMINO]-4-METHYLSULFANYL-BUTYRIC ACID; A 228839; AC1L9KPG; SCHEMBL629301; BDBM17325; 1n94; ZINC3973581; KB-74366; (2S)-2-[(4-{[butyl(2-cyclohexylethyl)amino]methyl}-2-(2-methylphenyl)phenyl)formamido]-4-(methylsulfanyl)butanoic acid; N-[(5-{[butyl(2-cyclohexylethyl)amino]methyl}-2'-methylbiphenyl-2-yl)carbonyl]-L-methionine
DM4UN9A DT Small molecular drug
DM4UN9A PC 447312
DM4UN9A MW 538.8
DM4UN9A FM C32H46N2O3S
DM4UN9A IC InChI=1S/C32H46N2O3S/c1-4-5-19-34(20-17-25-12-7-6-8-13-25)23-26-15-16-28(29(22-26)27-14-10-9-11-24(27)2)31(35)33-30(32(36)37)18-21-38-3/h9-11,14-16,22,25,30H,4-8,12-13,17-21,23H2,1-3H3,(H,33,35)(H,36,37)/t30-/m0/s1
DM4UN9A CS CCCCN(CCC1CCCCC1)CC2=CC(=C(C=C2)C(=O)N[C@@H](CCSC)C(=O)O)C3=CC=CC=C3C
DM4UN9A IK GAQHYZNOMLXSEA-PMERELPUSA-N
DM4UN9A IU (2S)-2-[[4-[[butyl(2-cyclohexylethyl)amino]methyl]-2-(2-methylphenyl)benzoyl]amino]-4-methylsulfanylbutanoic acid
DM4UN9A DE Non-small-cell lung cancer
DMDPUK6 ID DMDPUK6
DMDPUK6 DN ABX-PTH
DMDPUK6 HS Terminated
DMDPUK6 CP Amgen
DMDPUK6 DT Antibody
DMDPUK6 DE Parathyroid disease
DM5IDAQ ID DM5IDAQ
DM5IDAQ DN AC-187
DM5IDAQ HS Terminated
DM5IDAQ SN AC 187; 151804-77-2; AC187; salmon calcitonin (8-32) reduced; GTPL689; AKOS024457619
DM5IDAQ CP Amylin Pharmaceuticals Inc
DM5IDAQ DT Small molecular drug
DM5IDAQ PC 16133792
DM5IDAQ MW 2890.2
DM5IDAQ FM C127H205N37O40
DM5IDAQ IC InChI=1S/C127H205N37O40/c1-59(2)44-81(156-122(200)99(63(9)10)142-68(15)171)105(183)139-54-96(178)143-74(22-16-18-40-128)106(184)151-84(47-62(7)8)114(192)159-90(57-166)119(197)148-77(34-37-92(130)174)108(186)146-79(36-39-98(180)181)109(187)153-83(46-61(5)6)113(191)154-85(50-71-53-137-58-141-71)115(193)145-75(23-17-19-41-129)107(185)152-82(45-60(3)4)112(190)147-78(35-38-93(131)175)111(189)162-103(67(14)170)125(203)158-88(49-70-28-32-73(173)33-29-70)126(204)164-43-21-25-91(164)120(198)149-76(24-20-42-138-127(135)136)110(188)161-102(66(13)169)124(202)157-87(52-95(133)177)117(195)160-100(64(11)167)121(199)140-55-97(179)144-89(56-165)118(196)155-86(51-94(132)176)116(194)163-101(65(12)168)123(201)150-80(104(134)182)48-69-26-30-72(172)31-27-69/h26-33,53,58-67,74-91,99-103,165-170,172-173H,16-25,34-52,54-57,128-129H2,1-15H3,(H2,130,174)(H2,131,175)(H2,132,176)(H2,133,177)(H2,134,182)(H,137,141)(H,139,183)(H,140,199)(H,142,171)(H,143,178)(H,144,179)(H,145,193)(H,146,186)(H,147,190)(H,148,197)(H,149,198)(H,150,201)(H,151,184)(H,152,185)(H,153,187)(H,154,191)(H,155,196)(H,156,200)(H,157,202)(H,158,203)(H,159,192)(H,160,195)(H,161,188)(H,162,189)(H,163,194)(H,180,181)(H4,135,136,138)/t64-,65-,66-,67-,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,99+,100+,101+,102+,103+/m1/s1
DM5IDAQ CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)C)O
DM5IDAQ IK ZLFXHYNEZYAYPG-AABHONRUSA-N
DM5IDAQ IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM5IDAQ DE Type-2 diabetes
DMA93D8 ID DMA93D8
DMA93D8 DN AC-260584
DMA93D8 HS Terminated
DMA93D8 SN UNII-M4PN46N313; AC260584; AC-260584; CHEMBL2022960; M4PN46N313; 560083-42-3; 4-(3-(4-Butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one; 4-[3-(4-Butylpiperidin-1-yl)propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one; BWAKMLKESHKOHK-UHFFFAOYSA-N; GTPL334; SCHEMBL4069821; BDBM50382122; ZINC34033125; CS-6425; 2H-1,4-Benzoxazin-3(4H)-one, 4-(3-(4-butyl-1-piperidinyl)propyl)-7-fluoro-; AC 260584; HY-100336; 4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-1,4-benzoxazin-3-one
DMA93D8 DT Small molecular drug
DMA93D8 PC 9928284
DMA93D8 MW 348.5
DMA93D8 FM C20H29FN2O2
DMA93D8 IC InChI=1S/C20H29FN2O2/c1-2-3-5-16-8-12-22(13-9-16)10-4-11-23-18-7-6-17(21)14-19(18)25-15-20(23)24/h6-7,14,16H,2-5,8-13,15H2,1H3
DMA93D8 CS CCCCC1CCN(CC1)CCCN2C(=O)COC3=C2C=CC(=C3)F
DMA93D8 IK BWAKMLKESHKOHK-UHFFFAOYSA-N
DMA93D8 IU 4-[3-(4-butylpiperidin-1-yl)propyl]-7-fluoro-1,4-benzoxazin-3-one
DMA93D8 CA CAS 560083-42-3
DMA93D8 DE Schizophrenia
DMBY7AZ ID DMBY7AZ
DMBY7AZ DN ACEA-1011
DMBY7AZ HS Terminated
DMBY7AZ SN Glystatin series member (1011), CoCensys
DMBY7AZ CP Acea Pharmaceuticals Inc
DMBY7AZ DT Small molecular drug
DMBY7AZ PC 127872
DMBY7AZ MW 264.59
DMBY7AZ FM C9H4ClF3N2O2
DMBY7AZ IC InChI=1S/C9H4ClF3N2O2/c10-4-1-3(9(11,12)13)2-5-6(4)15-8(17)7(16)14-5/h1-2H,(H,14,16)(H,15,17)
DMBY7AZ CS C1=C(C=C(C2=C1NC(=O)C(=O)N2)Cl)C(F)(F)F
DMBY7AZ IK JDCKMCIQUXTYQI-UHFFFAOYSA-N
DMBY7AZ IU 5-chloro-7-(trifluoromethyl)-1,4-dihydroquinoxaline-2,3-dione
DMBY7AZ CA CAS 153504-72-4
DMBY7AZ DE Cerebral infarction
DMCWNVB ID DMCWNVB
DMCWNVB DN ACEA-1031
DMCWNVB HS Terminated
DMCWNVB SN Glystatin 1000 series member (1031), ACEA; Glystatin 1000 series member (1031), CoCensys
DMCWNVB CP Acea Pharmaceuticals Inc
DMCWNVB PC 9799201
DMCWNVB MW 364.93
DMCWNVB FM C8H3Br2N3O4
DMCWNVB IC InChI=1S/C8H3Br2N3O4/c9-2-1-3-5(6(4(2)10)13(16)17)12-8(15)7(14)11-3/h1H,(H,11,14)(H,12,15)
DMCWNVB CS C1=C2C(=C(C(=C1Br)Br)[N+](=O)[O-])NC(=O)C(=O)N2
DMCWNVB IK HPDZNXVZXICVSF-UHFFFAOYSA-N
DMCWNVB IU 6,7-dibromo-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMCWNVB DE Cerebrovascular ischaemia
DMEH9OY ID DMEH9OY
DMEH9OY DN ACEA-1328
DMEH9OY HS Terminated
DMEH9OY TC Analgesics
DMEH9OY PC 9816093
DMEH9OY MW 235.2
DMEH9OY FM C10H9N3O4
DMEH9OY IC InChI=1S/C10H9N3O4/c1-4-3-6-7(8(5(4)2)13(16)17)12-10(15)9(14)11-6/h3H,1-2H3,(H,11,14)(H,12,15)
DMEH9OY CS CC1=CC2=C(C(=C1C)[N+](=O)[O-])NC(=O)C(=O)N2
DMEH9OY IK CYJRVSOLVYLORV-UHFFFAOYSA-N
DMEH9OY IU 6,7-dimethyl-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMEH9OY DE Cancer related pain
DMRHSG4 ID DMRHSG4
DMRHSG4 DN ACEA-1416
DMRHSG4 HS Terminated
DMRHSG4 SN Glystatin series member (1416), CoCensys
DMRHSG4 CP Purdue Neuroscience Corp
DMRHSG4 PC 9816526
DMRHSG4 MW 255.61
DMRHSG4 FM C9H6ClN3O4
DMRHSG4 IC InChI=1S/C9H6ClN3O4/c1-3-4(10)2-5-6(7(3)13(16)17)12-9(15)8(14)11-5/h2H,1H3,(H,11,14)(H,12,15)
DMRHSG4 CS CC1=C(C=C2C(=C1[N+](=O)[O-])NC(=O)C(=O)N2)Cl
DMRHSG4 IK CODLITRXBIRDTG-UHFFFAOYSA-N
DMRHSG4 IU 7-chloro-6-methyl-5-nitro-1,4-dihydroquinoxaline-2,3-dione
DMRHSG4 DE Cerebrovascular ischaemia
DMXLB02 ID DMXLB02
DMXLB02 DN ACEA-2085
DMXLB02 HS Terminated
DMXLB02 SN AMPA/glycine antagonist, CoCensys
DMXLB02 CP Purdue Neuroscience Corp
DMXLB02 DE Pain
DM0YHKB ID DM0YHKB
DM0YHKB DN Acteoside
DM0YHKB HS Terminated
DM0YHKB SN TJC-160
DM0YHKB CP Tsumura & Co
DM0YHKB DT Small molecular drug
DM0YHKB PC 5281800
DM0YHKB MW 624.6
DM0YHKB FM C29H36O15
DM0YHKB IC InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
DM0YHKB CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
DM0YHKB IK FBSKJMQYURKNSU-ZLSOWSIRSA-N
DM0YHKB IU [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DM0YHKB CA CAS 61276-17-3
DM0YHKB CB CHEBI:9953
DM0YHKB DE Nephritis
DMT4P89 ID DMT4P89
DMT4P89 DN Actinonin
DMT4P89 HS Terminated
DMT4P89 SN actinonin; Actinonine; UNII-P18SPA8N0K; P18SPA8N0K; 13434-13-4; CHEMBL308333; Octanohydroxamic acid, 3-((1-((2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamoyl)-; 2-[(FORMYL-HYDROXY-AMINO)-METHYL]-HEPTANOIC ACID [1-(2-HYDROXYMETHYL-PYRROLIDINE-1-CARBONYL)-2-METHYL-PROPYL]-AMIDE; BB2; Butanediamide, N4-hydroxy-N1-(1-((2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)-2-pentyl-, stereoisomer; SR-01000075681; ( )-Actinonin; 4je7; 3pn4; 3m6p; 4dr9; 3m6q; 3m6r; 3g5k; Spectrum2_000628; Spectrum5_000728
DMT4P89 DT Small molecular drug
DMT4P89 PC 443600
DMT4P89 MW 385.5
DMT4P89 FM C19H35N3O5
DMT4P89 IC InChI=1S/C19H35N3O5/c1-4-5-6-8-14(11-16(24)21-27)18(25)20-17(13(2)3)19(26)22-10-7-9-15(22)12-23/h13-15,17,23,27H,4-12H2,1-3H3,(H,20,25)(H,21,24)/t14-,15+,17+/m1/s1
DMT4P89 CS CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO
DMT4P89 IK XJLATMLVMSFZBN-VYDXJSESSA-N
DMT4P89 IU (2R)-N'-hydroxy-N-[(2S)-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
DMT4P89 CA CAS 13434-13-4
DMJFY2I ID DMJFY2I
DMJFY2I DN AD 198
DMJFY2I HS Terminated
DMJFY2I SN N-Benzyladriamycin-14-valerate; AD 198; 98983-21-2; Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((phenylmethyl)amino)-alpha-L-lyxo-hexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester, (2S-cis)-; AC1L2RLY; AC1Q62MI; CTK8F7586; DTXSID40243893; 2-[(2s,4s)-4-{[3-(benzylamino)-2,3,6-trideoxy-; A-l-lyxo-hexopyranosyl]oxy}-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]-2-oxoethyl pentanoate; LS-101847
DMJFY2I DT Small molecular drug
DMJFY2I PC 117072592
DMJFY2I MW 717.8
DMJFY2I FM C39H43NO12
DMJFY2I IC InChI=1S/C39H43NO12/c1-4-5-14-28(41)49-19-29(42)51-22-15-24-32(39(47)34-33(37(24)45)36(44)23-12-9-13-26(48-3)31(23)38(34)46)27(16-22)52-30-17-25(35(43)20(2)50-30)40-18-21-10-7-6-8-11-21/h6-13,20,22,25,27,30,35,40,43,45,47H,4-5,14-19H2,1-3H3/t20-,22-,25-,27-,30-,35-/m0/s1
DMJFY2I CS CCCCC(=O)OCC(=O)O[C@@H]1C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O)NCC6=CC=CC=C6
DMJFY2I IK DFEZNIBKLJWMIQ-VEUGUUDJSA-N
DMJFY2I IU [2-[[(2S,4S)-4-[(2R,4S,5R,6S)-4-(benzylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-5,12-dihydroxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen-2-yl]oxy]-2-oxoethyl] pentanoate
DM1SLJ9 ID DM1SLJ9
DM1SLJ9 DN AD-5075
DM1SLJ9 HS Terminated
DM1SLJ9 SN 2,4-Thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-; AD 5075; 103788-05-2; 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 2,4-Thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-; YVQKIDLSVHRBGZ-UHFFFAOYSA-N; [3H]AD5075; [3H]-AD5075; ACMC-20m6lh; AC1L2TSO; CHEMBL88496; SCHEMBL131888; GTPL2702; GTPL2701; CTK4A2384; AD5075; 5-(4-(2-(5-Methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione; [3H]AD-5075
DM1SLJ9 CP Dainippon Pharmaceutical Co Ltd
DM1SLJ9 DT Small molecular drug
DM1SLJ9 PC 128440
DM1SLJ9 MW 424.5
DM1SLJ9 FM C22H20N2O5S
DM1SLJ9 IC InChI=1S/C22H20N2O5S/c1-13-19(23-21(29-13)15-5-3-2-4-6-15)17(25)12-28-16-9-7-14(8-10-16)11-18-20(26)24-22(27)30-18/h2-10,17-18,25H,11-12H2,1H3,(H,24,26,27)
DM1SLJ9 CS CC1=C(N=C(O1)C2=CC=CC=C2)C(COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)O
DM1SLJ9 IK YVQKIDLSVHRBGZ-UHFFFAOYSA-N
DM1SLJ9 IU 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM1SLJ9 CA CAS 103788-05-2
DM1SLJ9 DE Type-2 diabetes
DMQNFZE ID DMQNFZE
DMQNFZE DN Ad5-AC6
DMQNFZE HS Terminated
DMQNFZE SN Corgenic; AC6 gene therapy, Collateral/UCSD; Adenylyl cyclase gene therapy, Collateral/UCSD; CHF gene therapy, Collateral/UCSD; Gene therapy (CHF), Collateral/USCD; Gene therapy (adenylate cyclase), Collateral/USCD
DMQNFZE CP University of California San Diego
DMQNFZE DE Cardiac failure
DM61AV4 ID DM61AV4
DM61AV4 DN ADX415
DM61AV4 HS Terminated
DM61AV4 CP Shionogi
DM61AV4 DE Hypertension
DM625LN ID DM625LN
DM625LN DN AG-041R
DM625LN HS Terminated
DM625LN SN AG-041R; LS-83786; 199800-49-2; GTPL901; MLS006010838; AG041R; CTK8E8139; DTXSID40430968; AG 041R; MolPort-009-019-290; ZINC3930890; NCGC00263225-01; SMR004701765; RT-011212; FT-0773348; J-012912
DM625LN CP Chugai Pharmaceutical Co Ltd
DM625LN DT Small molecular drug
DM625LN PC 9807431
DM625LN MW 544.6
DM625LN FM C31H36N4O5
DM625LN IC InChI=1S/C31H36N4O5/c1-5-39-28(40-6-2)20-35-26-10-8-7-9-25(26)31(29(35)37,19-27(36)32-23-15-11-21(3)12-16-23)34-30(38)33-24-17-13-22(4)14-18-24/h7-18,28H,5-6,19-20H2,1-4H3,(H,32,36)(H2,33,34,38)/t31-/m1/s1
DM625LN CS CCOC(CN1C2=CC=CC=C2[C@@](C1=O)(CC(=O)NC3=CC=C(C=C3)C)NC(=O)NC4=CC=C(C=C4)C)OCC
DM625LN IK KOLPMNSDISYEBU-WJOKGBTCSA-N
DM625LN IU 2-[(3R)-1-(2,2-diethoxyethyl)-3-[(4-methylphenyl)carbamoylamino]-2-oxoindol-3-yl]-N-(4-methylphenyl)acetamide
DM625LN CA CAS 159883-95-1
DM625LN DE Ulcerative colitis
DMRI7YB ID DMRI7YB
DMRI7YB DN AG-1284
DMRI7YB HS Terminated
DMRI7YB SN Enantiomer of AG1284; 2-[4-[2-[(1-ethylcyclopentyl)-(2-hydroxyethyl)carbamoyl]phenyl]-2-hydroxy-butyl]-N-(2-hydroxyethyl)-5-methyl-N-(1-methyl-1-phenyl-ethyl)benzamide; N-(1-Ethylcyclopentyl)-N-(2-hydroxyethyl)-2-[3(R or S)-hydroxy-4-[2-[(2-hydroxyethyl)(1-methyl-1-phenylethyl)carbamoyl]-4-methylphenyl]butyl]benzamide; AG-1284; AC1LA3JC; Tertiary Amide deriv. 42cb; CHEMBL328435; BDBM9664; ag12-84; AG1284
DMRI7YB CP Agouron Pharmaceuticals Inc
DMRI7YB DT Small molecular drug
DMRI7YB PC 461066
DMRI7YB MW 628.8
DMRI7YB FM C39H52N2O5
DMRI7YB IC InChI=1S/C39H52N2O5/c1-5-39(21-11-12-22-39)41(24-26-43)36(45)34-16-10-9-13-30(34)19-20-33(44)28-31-18-17-29(2)27-35(31)37(46)40(23-25-42)38(3,4)32-14-7-6-8-15-32/h6-10,13-18,27,33,42-44H,5,11-12,19-26,28H2,1-4H3
DMRI7YB CS CCC1(CCCC1)N(CCO)C(=O)C2=CC=CC=C2CCC(CC3=C(C=C(C=C3)C)C(=O)N(CCO)C(C)(C)C4=CC=CC=C4)O
DMRI7YB IK MBNPLZRTGOAFGX-UHFFFAOYSA-N
DMRI7YB IU 2-[4-[2-[(1-ethylcyclopentyl)-(2-hydroxyethyl)carbamoyl]phenyl]-2-hydroxybutyl]-N-(2-hydroxyethyl)-5-methyl-N-(2-phenylpropan-2-yl)benzamide
DMRI7YB DE Human immunodeficiency virus infection
DMT10C2 ID DMT10C2
DMT10C2 DN AG1295
DMT10C2 HS Terminated
DMT10C2 SN 6,7-Dimethyl-2-phenylquinoxaline; 71897-07-9; ag1295; AG-1295; AG 1295; CHEMBL7724; TYRPHOSTIN AG 1295; BiomolKI_000019; Tyrphostin AG-1295; AC1Q4WCY; AC1L1CSX; ChemDiv2_000256; BiomolKI2_000029; AC1Q2O4Y; cid_2048; BMK1-C7; MLS001194710; SCHEMBL925674; IFLab1_005463; GTPL5914; AC1Q2E07; CHEBI:94668; BDBM33408; CTK2H8610; DTXSID10274351; MolPort-000-182-258; FQNCLVJEQCJWSU-UHFFFAOYSA-N; 2-Phenyl-6,7-dimethylquinoxaline; HMS1427I07; HMS3229M19; HMS2879L07; HMS1369L14; ZINC257983; HMS3428I13; API01003; 6,7-Dimethyl-2-phenyl-quinoxaline
DMT10C2 DT Small molecular drug
DMT10C2 PC 2048
DMT10C2 MW 234.29
DMT10C2 FM C16H14N2
DMT10C2 IC InChI=1S/C16H14N2/c1-11-8-14-15(9-12(11)2)18-16(10-17-14)13-6-4-3-5-7-13/h3-10H,1-2H3
DMT10C2 CS CC1=CC2=NC=C(N=C2C=C1C)C3=CC=CC=C3
DMT10C2 IK FQNCLVJEQCJWSU-UHFFFAOYSA-N
DMT10C2 IU 6,7-dimethyl-2-phenylquinoxaline
DMT10C2 CA CAS 71897-07-9
DMT10C2 CB CHEBI:94668
DMALV1W ID DMALV1W
DMALV1W DN AG-1350
DMALV1W HS Terminated
DMALV1W SN LY-316957; LY-316340 (free base); N-[3-[(3aR,6S,7aS)-6-(N-tert-Butylcarbamoyl)octahydrothieno[3,2-c]pyridin-5-yl)-2(R)-hydroxy-1(R)-(phenylsulfanylmethyl)propyl]-3-hydroxy-2-methylbenzamide methanesulfonate
DMALV1W DT Small molecular drug
DMALV1W PC 461244
DMALV1W MW 667.9
DMALV1W FM C31H45N3O7S3
DMALV1W IC InChI=1S/C30H41N3O4S2.CH4O3S/c1-19-22(11-8-12-25(19)34)28(36)31-23(18-39-21-9-6-5-7-10-21)26(35)17-33-16-20-13-14-38-27(20)15-24(33)29(37)32-30(2,3)4;1-5(2,3)4/h5-12,20,23-24,26-27,34-35H,13-18H2,1-4H3,(H,31,36)(H,32,37);1H3,(H,2,3,4)/t20-,23+,24+,26-,27+;/m1./s1
DMALV1W CS CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCS[C@H]4C[C@H]3C(=O)NC(C)(C)C)O.CS(=O)(=O)O
DMALV1W IK WYCLUAUPFCMDTI-KZMNDDLNSA-N
DMALV1W IU (3aR,6S,7aS)-N-tert-butyl-5-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,3a,4,6,7,7a-hexahydro-2H-thieno[3,2-c]pyridine-6-carboxamide;methanesulfonic acid
DMALV1W DE Human immunodeficiency virus infection
DMS7UPZ ID DMS7UPZ
DMS7UPZ DN AG-2024
DMS7UPZ HS Terminated
DMS7UPZ CP Agouron Pharmaceuticals Inc
DMS7UPZ DE Arthritis
DMF2ME4 ID DMF2ME4
DMF2ME4 DN AG-3296
DMF2ME4 HS Terminated
DMF2ME4 CP Agouron Pharmaceuticals Inc
DMF2ME4 DE Solid tumour/cancer
DM3WKO5 ID DM3WKO5
DM3WKO5 DN AG490
DM3WKO5 HS Terminated
DM3WKO5 SN (E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665
DM3WKO5 DT Small molecular drug
DM3WKO5 PC 5328779
DM3WKO5 MW 294.3
DM3WKO5 FM C17H14N2O3
DM3WKO5 IC InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+
DM3WKO5 CS C1=CC=C(C=C1)CNC(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N
DM3WKO5 IK TUCIOBMMDDOEMM-RIYZIHGNSA-N
DM3WKO5 IU (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
DM3WKO5 CA CAS 133550-30-8
DM3WKO5 CB CHEBI:131968
DM3WKO5 DE Multiple myeloma; Renal transplantation
DMVS6BN ID DMVS6BN
DMVS6BN DN AGN-193080
DMVS6BN HS Terminated
DMVS6BN SN AGN-193080; CHEMBL298936; SCHEMBL8348700; BDBM50052882; L012655
DMVS6BN DT Small molecular drug
DMVS6BN PC 9837551
DMVS6BN MW 232.28
DMVS6BN FM C12H16N4O
DMVS6BN IC InChI=1S/C12H16N4O/c1-8-9(16-12-14-4-5-15-12)2-3-10-11(8)13-6-7-17-10/h2-3,13H,4-7H2,1H3,(H2,14,15,16)
DMVS6BN CS CC1=C(C=CC2=C1NCCO2)NC3=NCCN3
DMVS6BN IK OSJZLDGTMVBIRV-UHFFFAOYSA-N
DMVS6BN IU N-(4,5-dihydro-1H-imidazol-2-yl)-5-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-amine
DMXY5AV ID DMXY5AV
DMXY5AV DN AH-9700
DMXY5AV HS Terminated
DMXY5AV SN UNII-2NG1J5TE78; 2NG1J5TE78; AH-9700; 337359-08-7; Pyrrolidine, 1-(2-(3,4-dihydro-6,7-dimethyl-2-naphthalenyl)ethyl)-, (2E)-2-butenedioate (1:1)
DMXY5AV CP Dainippon Pharmaceutical Co Ltd
DMXY5AV DT Small molecular drug
DMXY5AV PC 9842381
DMXY5AV MW 371.5
DMXY5AV FM C22H29NO4
DMXY5AV IC InChI=1S/C18H25N.C4H4O4/c1-14-11-17-6-5-16(13-18(17)12-15(14)2)7-10-19-8-3-4-9-19;5-3(6)1-2-4(7)8/h11-13H,3-10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DMXY5AV CS CC1=CC2=C(C=C1C)C=C(CC2)CCN3CCCC3.C(=C/C(=O)O)\\C(=O)O
DMXY5AV IK AYOYFVLAAQPHJT-WLHGVMLRSA-N
DMXY5AV IU (E)-but-2-enedioic acid;1-[2-(6,7-dimethyl-3,4-dihydronaphthalen-2-yl)ethyl]pyrrolidine
DMXY5AV CA CAS 337359-08-7
DMXY5AV DE Pollakiuria
DMJZ48W ID DMJZ48W
DMJZ48W DN AHR-16303B
DMJZ48W HS Terminated
DMJZ48W SN Ahr-16303B; Ahr 16303B; 117023-62-8; 1-(4-(3-(4-(Bis-(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)phenyl)-2-methyl-1-propanone ethanedioate; ACMC-20mmz9; AC1L4DL2; CTK0H5536; DTXSID80151685; 1-[4-[3-[4-[bis(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]propoxy]phenyl]-2-methylpropan-1-one; 1-Propanone, 1-(4-(3-(4-(bis(4-fluorophenyl)hydroxymethyl)-1-piperidinyl)propoxy)phenyl)-2-methyl-, ethanedioate (1:1) (salt)
DMJZ48W CP A H Robins Co Inc
DMJZ48W DT Small molecular drug
DMJZ48W PC 183770
DMJZ48W MW 597.6
DMJZ48W FM C33H37F2NO7
DMJZ48W IC InChI=1S/C31H35F2NO3.C2H2O4/c1-22(2)30(35)23-4-14-29(15-5-23)37-21-3-18-34-19-16-26(17-20-34)31(36,24-6-10-27(32)11-7-24)25-8-12-28(33)13-9-25;3-1(4)2(5)6/h4-15,22,26,36H,3,16-21H2,1-2H3;(H,3,4)(H,5,6)
DMJZ48W CS CC(C)C(=O)C1=CC=C(C=C1)OCCCN2CCC(CC2)C(C3=CC=C(C=C3)F)(C4=CC=C(C=C4)F)O.C(=O)(C(=O)O)O
DMJZ48W IK IJLRCTPQUZWJSL-UHFFFAOYSA-N
DMJZ48W IU 1-[4-[3-[4-[bis(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]propoxy]phenyl]-2-methylpropan-1-one;oxalic acid
DMJZ48W CA CAS 117023-62-8
DMJZ48W DE Hypertension
DMJ6BEO ID DMJ6BEO
DMJ6BEO DN AHR-16462B
DMJ6BEO HS Terminated
DMJ6BEO CP A H Robins Co Inc
DMJ6BEO DE Hypertension
DMOJTZV ID DMOJTZV
DMOJTZV DN AJ-3941
DMOJTZV HS Terminated
DMOJTZV SN AJ 3941; AC1O5RPK; Piperazine, 1-(3-fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)-, (E)-(+-)-, (Z)-2-butenedioate (1:2); 1-(3-Fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate; (+-)-(E)-1-(3-Fluoro-6,11-dihydrodibenz(b,e)oxepin-11-yl)-4-(3-phenyl-2-propenyl)piperazine dimaleate
DMOJTZV CP Dainippon Pharmaceutical Co Ltd
DMOJTZV DT Small molecular drug
DMOJTZV PC 154701484
DMOJTZV DE Cerebrovascular ischaemia
DM51NI0 ID DM51NI0
DM51NI0 DN AK-295
DM51NI0 HS Terminated
DM51NI0 SN Vasolex; AK-265; AK-275; CX-295; Calpain inhibitors (neuropathy); Calpain inhibitors (neuropathy), AxoTect; Calpain inhibitors, Cortex/Alkermes
DM51NI0 CP Alkermes Inc
DM51NI0 DT Small molecular drug
DM51NI0 PC 183798
DM51NI0 MW 504.6
DM51NI0 FM C26H40N4O6
DM51NI0 IC InChI=1S/C26H40N4O6/c1-4-21(23(31)25(33)27-11-8-12-30-13-15-35-16-14-30)28-24(32)22(17-19(2)3)29-26(34)36-18-20-9-6-5-7-10-20/h5-7,9-10,19,21-22H,4,8,11-18H2,1-3H3,(H,27,33)(H,28,32)(H,29,34)/t21?,22-/m0/s1
DM51NI0 CS CCC(C(=O)C(=O)NCCCN1CCOCC1)NC(=O)[C@H](CC(C)C)NC(=O)OCC2=CC=CC=C2
DM51NI0 IK TZVQRMYLYQNBOA-KEKNWZKVSA-N
DM51NI0 IU benzyl N-[(2S)-4-methyl-1-[[1-(3-morpholin-4-ylpropylamino)-1,2-dioxopentan-3-yl]amino]-1-oxopentan-2-yl]carbamate
DM51NI0 CA CAS 160399-35-9
DM51NI0 DE Cerebral infarction
DMMTZXV ID DMMTZXV
DMMTZXV DN AKP-320
DMMTZXV HS Terminated
DMMTZXV SN Bis(ethylmaltolato)oxovanadium (IV) + rosiglitazone (type 2 diabetes), Akesis
DMMTZXV CP Akesis Pharmaceuticals Inc
DMMTZXV DE Type-2 diabetes
DMRYJ40 ID DMRYJ40
DMRYJ40 DN AL-0671
DMRYJ40 HS Terminated
DMRYJ40 SN AL-0670
DMRYJ40 CP The Green Cross Corp
DMRYJ40 PC 57415651
DMRYJ40 MW 306.79
DMRYJ40 FM C14H19ClN6
DMRYJ40 IC InChI=1S/C14H18N6.ClH/c15-8-18-14(19-11-3-4-13(16)17-7-11)20-12-6-9-1-2-10(12)5-9;/h3-4,7,9-10,12H,1-2,5-6H2,(H2,16,17)(H2,18,19,20);1H/t9-,10+,12-;/m1./s1
DMRYJ40 CS C1C[C@H]2C[C@@H]1C[C@H]2N=C(NC#N)NC3=CN=C(C=C3)N.Cl
DMRYJ40 IK ZIVGNHQBUJFAOF-QQQUOLKDSA-N
DMRYJ40 IU 1-(6-aminopyridin-3-yl)-2-[(1S,2R,4R)-2-bicyclo[2.2.1]heptanyl]-3-cyanoguanidine;hydrochloride
DMRYJ40 DE Arteriosclerosis
DMWNMYS ID DMWNMYS
DMWNMYS DN ALB-127158(a)
DMWNMYS HS Terminated
DMWNMYS CP Albany Molecular Research Inc.
DMWNMYS PC 44193892
DMWNMYS MW 404.4
DMWNMYS FM C23H21FN4O2
DMWNMYS IC InChI=1S/C23H21FN4O2/c1-27-21-6-8-25-13-20(21)19-5-4-17(10-22(19)27)28-9-7-18(11-23(28)29)30-14-16-3-2-15(24)12-26-16/h2-5,7,9-12,25H,6,8,13-14H2,1H3
DMWNMYS CS CN1C2=C(CNCC2)C3=C1C=C(C=C3)N4C=CC(=CC4=O)OCC5=NC=C(C=C5)F
DMWNMYS IK VUUUHLIHQHVLLE-UHFFFAOYSA-N
DMWNMYS IU 4-[(5-fluoropyridin-2-yl)methoxy]-1-(5-methyl-1,2,3,4-tetrahydropyrido[4,3-b]indol-7-yl)pyridin-2-one
DMWNMYS DE Obesity
DMXK4CI ID DMXK4CI
DMXK4CI DN Albupoietin
DMXK4CI HS Terminated
DMXK4CI SN Long-acting erythropoietin, HGS; Long-acting erythropoietin, Human Genome Sciences; Long-acting erythropoietin, Teva Pharmaceutical
DMXK4CI CP Aventis Behring LLC
DMXK4CI DE Anemia
DMQALR5 ID DMQALR5
DMQALR5 DN Almorexant
DMQALR5 HS Terminated
DMQALR5 SN Almorexant [INN]; ACT-078573; (2R)-2-((1S)-6,7-dimethoxy-1-{2-(4-(trifluoromethyl)phenyl)ethyl}-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-2-phenylacetamide
DMQALR5 CP Actelion Pharma.
DMQALR5 DT Small molecular drug
DMQALR5 PC 23727689
DMQALR5 MW 512.6
DMQALR5 FM C29H31F3N2O3
DMQALR5 IC InChI=1S/C29H31F3N2O3/c1-33-28(35)27(20-7-5-4-6-8-20)34-16-15-21-17-25(36-2)26(37-3)18-23(21)24(34)14-11-19-9-12-22(13-10-19)29(30,31)32/h4-10,12-13,17-18,24,27H,11,14-16H2,1-3H3,(H,33,35)/t24-,27+/m0/s1
DMQALR5 CS CNC(=O)[C@@H](C1=CC=CC=C1)N2CCC3=CC(=C(C=C3[C@@H]2CCC4=CC=C(C=C4)C(F)(F)F)OC)OC
DMQALR5 IK DKMACHNQISHMDN-RPLLCQBOSA-N
DMQALR5 IU (2R)-2-[(1S)-6,7-dimethoxy-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-N-methyl-2-phenylacetamide
DMQALR5 CA CAS 871224-64-5
DMQALR5 DE Insomnia; Sleep-wake disorder
DMT584A ID DMT584A
DMT584A DN ALN-VEG01
DMT584A HS Terminated
DMT584A SN RNAi therapeutics (ocular disease), Alnylam; VEGF-silencing siRNAs, Alnylam; Vascular endothelial growth factor gene-silencing siRNAs, Alnylam; RNAi therapeutics (ocular disease), Alnylam/Merck; VEGF-silencing siRNAs, Alnylam/Merck; Vascular endothelial growth factor-silencing siRNAs, Alnylam/Merck
DMT584A CP Alnylam Pharmaceuticals Inc
DMT584A DT siRNA drug
DMT584A DE Macular degeneration
DM592WE ID DM592WE
DM592WE DN ALP-242
DM592WE HS Terminated
DM592WE SN Antileukoproteinases, Grunenthal
DM592WE CP Grunenthal GmbH
DM592WE DE Cystic fibrosis
DMGBT9Z ID DMGBT9Z
DMGBT9Z DN ALS-769
DMGBT9Z HS Terminated
DMGBT9Z SN ALS-1026; ALS-851; Betulinic acid derivative caspase inducers (cancer); Betulinic acid derivative caspase inducers (cancer), Advanced Life Sciences; Lupane triterpenoids (cancer), Advanced Life Sciences
DMGBT9Z CP Advanced Life Sciences Holdings Inc
DMGBT9Z DE Solid tumour/cancer
DMLN0Y5 ID DMLN0Y5
DMLN0Y5 DN Alvameline
DMLN0Y5 HS Terminated
DMLN0Y5 SN Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M
DMLN0Y5 CP H Lundbeck A/S
DMLN0Y5 DT Small molecular drug
DMLN0Y5 PC 178030
DMLN0Y5 MW 193.25
DMLN0Y5 FM C9H15N5
DMLN0Y5 IC InChI=1S/C9H15N5/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8/h5H,3-4,6-7H2,1-2H3
DMLN0Y5 CS CCN1N=C(N=N1)C2=CCCN(C2)C
DMLN0Y5 IK RNMOMKCRCIRYCZ-UHFFFAOYSA-N
DMLN0Y5 IU 5-(2-ethyltetrazol-5-yl)-1-methyl-3,6-dihydro-2H-pyridine
DMLN0Y5 CA CAS 120241-31-8
DMLN0Y5 DE Alzheimer disease
DMOIWFM ID DMOIWFM
DMOIWFM DN AM-577
DMOIWFM HS Terminated
DMOIWFM SN Pain therapeutic (cannabinoid), AMRAD
DMOIWFM CP Zenyth Therapeutics Ltd
DMOIWFM DE Pain
DMGBT63 ID DMGBT63
DMGBT63 DN AM-66
DMGBT63 HS Terminated
DMGBT63 SN Pain therapeutic (sodium channel blocker), AMRAD
DMGBT63 CP Zenyth Therapeutics Ltd
DMGBT63 DE Pain
DMMZNSC ID DMMZNSC
DMMZNSC DN AM-92016
DMMZNSC HS Terminated
DMMZNSC SN COMPOUND II; N-(4-(3-((2-(3,4-Dichlorophenyl)ethyl)methylamino)-2-hydroxypropoxy)phenyl)methanesulfonamide; AM-92016; Bio2_000288; AC1L1CZF; Msaph-2ClPhEA-2-propanol; CBiol_001738; KBioGR_000288; BSPBio_001568; KBioSS_000288; CHEMBL43527; AC1Q3O93; SCHEMBL9655059; KBio3_000575; CHEBI:91532; KBio3_000576; KBio2_002856; KBio2_005424; KBio2_000288; Bio1_000513; HMS1791O10; Bio1_001002; Bio1_000024; HMS1989O10; Bio2_000768; AC-115; IDI1_034038; NCGC00024837-04; NCGC00024837-03; NCGC00024837-02; BRD-A11813248-003-01-6; BRD-A11813248-001-02-8
DMMZNSC DT Small molecular drug
DMMZNSC PC 133104
DMMZNSC MW 569.5
DMMZNSC FM C26H30Cl2N2O6S
DMMZNSC IC InChI=1S/C19H24Cl2N2O4S.C7H6O2/c1-23(10-9-14-3-8-18(20)19(21)11-14)12-16(24)13-27-17-6-4-15(5-7-17)22-28(2,25)26;8-7(9)6-4-2-1-3-5-6/h3-8,11,16,22,24H,9-10,12-13H2,1-2H3;1-5H,(H,8,9)
DMMZNSC CS CN(CCC1=CC(=C(C=C1)Cl)Cl)CC(COC2=CC=C(C=C2)NS(=O)(=O)C)O.C1=CC=C(C=C1)C(=O)O
DMMZNSC IK KLXOTINBPRNEFS-UHFFFAOYSA-N
DMMZNSC IU benzoic acid;N-[4-[3-[2-(3,4-dichlorophenyl)ethyl-methylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide
DMMZNSC CA CAS 178894-81-0
DMYIPLH ID DMYIPLH
DMYIPLH DN AMG-548
DMYIPLH HS Terminated
DMYIPLH SN P38 MAP kinase inhibitor, Amgen
DMYIPLH CP Amgen Inc
DMYIPLH DT Small molecular drug
DMYIPLH PC 11167112
DMYIPLH MW 461.6
DMYIPLH FM C29H27N5O
DMYIPLH IC InChI=1S/C29H27N5O/c1-34-28(35)26(24-12-11-21-9-5-6-10-23(21)18-24)27(22-13-15-31-16-14-22)33-29(34)32-19-25(30)17-20-7-3-2-4-8-20/h2-16,18,25H,17,19,30H2,1H3,(H,32,33)/t25-/m0/s1
DMYIPLH CS CN1C(=O)C(=C(N=C1NC[C@H](CC2=CC=CC=C2)N)C3=CC=NC=C3)C4=CC5=CC=CC=C5C=C4
DMYIPLH IK RQVKVJIRFKVPBF-VWLOTQADSA-N
DMYIPLH IU 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-ylpyrimidin-4-one
DMYIPLH CA CAS 864249-60-5
DMYIPLH DE Inflammation
DMXRQS6 ID DMXRQS6
DMXRQS6 DN AMG-8562
DMXRQS6 HS Terminated
DMXRQS6 SN UNII-X2S52Z1DY9; X2S52Z1DY9; AMG-8562; AMG 8562; 1041478-78-7; SCHEMBL14993014; SCHEMBL14993018; 2-Propenamide, N-((2R)-2,3-dihydro-2-hydroxy-1H-inden-4-yl)-3-(2-(1-piperidinyl)-4-(trifluoromethyl)phenyl)-, (2E)-; (r,e)-n-(2-hydroxy-2,3-dihydro-1h-inden-4-yl)-3-(2-(piperidin-1-yl)-4 (trifluoromethyl)phenyl)acrylamide
DMXRQS6 CP Amgen
DMXRQS6 TC Analgesics
DMXRQS6 DT Small molecular drug
DMXRQS6 PC 56603667
DMXRQS6 MW 430.5
DMXRQS6 FM C24H25F3N2O2
DMXRQS6 IC InChI=1S/C24H25F3N2O2/c25-24(26,27)18-9-7-16(22(14-18)29-11-2-1-3-12-29)8-10-23(31)28-21-6-4-5-17-13-19(30)15-20(17)21/h4-10,14,19,30H,1-3,11-13,15H2,(H,28,31)/b10-8+/t19-/m1/s1
DMXRQS6 CS C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)/C=C/C(=O)NC3=CC=CC4=C3C[C@@H](C4)O
DMXRQS6 IK HAZYXDWNLMGLIS-LHUXKHBRSA-N
DMXRQS6 IU (E)-N-[(2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]-3-[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]prop-2-enamide
DMXRQS6 CA CAS 1041478-78-7
DMXRQS6 DE Pain
DM3D0WA ID DM3D0WA
DM3D0WA DN Amidox
DM3D0WA HS Terminated
DM3D0WA DT Small molecular drug
DM3D0WA PC 135413522
DM3D0WA MW 168.15
DM3D0WA FM C7H8N2O3
DM3D0WA IC InChI=1S/C7H8N2O3/c8-7(9-12)4-1-2-5(10)6(11)3-4/h1-3,10-12H,(H2,8,9)
DM3D0WA CS C1=CC(=C(C=C1/C(=N/O)/N)O)O
DM3D0WA IK JOAASNKBYBFGDN-UHFFFAOYSA-N
DM3D0WA IU N',3,4-trihydroxybenzenecarboximidamide
DM3D0WA CA CAS 95933-72-5
DM64YJW ID DM64YJW
DM64YJW DN Amitivir
DM64YJW HS Terminated
DM64YJW SN LY-217896
DM64YJW CP Eli Lilly & Co
DM64YJW DT Small molecular drug
DM64YJW PC 65912
DM64YJW MW 126.14
DM64YJW FM C3H2N4S
DM64YJW IC InChI=1S/C3H2N4S/c4-1-5-3-7-6-2-8-3/h2H,(H,5,7)
DM64YJW CS C1=NN=C(S1)NC#N
DM64YJW IK YUCHAYRHHXJNQK-UHFFFAOYSA-N
DM64YJW IU 1,3,4-thiadiazol-2-ylcyanamide
DM64YJW CA CAS 111393-84-1
DM64YJW DE Virus infection
DMDAMBW ID DMDAMBW
DMDAMBW DN AMPEROZIDE
DMDAMBW HS Terminated
DMDAMBW SN Amperozide; 75558-90-6; Amperozidum [INN-Latin]; Amperozida [INN-Spanish]; UNII-0M2W3TAG39; FG 5606; 0M2W3TAG39; CHEMBL1079935; 4-(4,4-Bis(p-fluorophenyl)butyl)-N-ethyl-1-piperazinecarboxamide; 4-(4,4-Bis(4-fluorphenyl)butyl)-N-ethyl-1-piperazinecarboxamid; Amperozidum; Amperozida; 4-[4,4-bis(4-fluorophenyl)butyl]-n-ethylpiperazine-1-carboxamide; 1-Piperazinecarboxamide, 4-(4,4-bis(p-fluorophenyl)butyl)-N-ethyl-; Amperozide [INN:BAN]; Amperozide [BAN:INN]; 4-(4,4-Bis(4-fluorophenyl)butyl)-N-ethylpiperazine-1-carboxamide
DMDAMBW DT Small molecular drug
DMDAMBW PC 73333
DMDAMBW MW 401.5
DMDAMBW FM C23H29F2N3O
DMDAMBW IC InChI=1S/C23H29F2N3O/c1-2-26-23(29)28-16-14-27(15-17-28)13-3-4-22(18-5-9-20(24)10-6-18)19-7-11-21(25)12-8-19/h5-12,22H,2-4,13-17H2,1H3,(H,26,29)
DMDAMBW CS CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DMDAMBW IK NNAIYOXJNVGUOM-UHFFFAOYSA-N
DMDAMBW IU 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethylpiperazine-1-carboxamide
DMDAMBW CA CAS 75558-90-6
DMDAMBW CB CHEBI:92913
DMDAMBW DE Alcohol dependence
DMW5RNZ ID DMW5RNZ
DMW5RNZ DN AMR-103
DMW5RNZ HS Terminated
DMW5RNZ CP Amarin Corp plc
DMW5RNZ DE Parkinson disease
DMD82LM ID DMD82LM
DMD82LM DN AMT-030
DMD82LM HS Terminated
DMD82LM SN AAV gene therapy (AGT, hyperoxaluria), AMT; Adeno-associated virus gene therapy (alanine:glyoxylate aminotransferase, hyperoxaluria), Amsterdam Molecular Therapeutics
DMD82LM CP Amsterdam Molecular Therapeutics BV
DMD82LM DE Hyperoxaluria
DMMKOCL ID DMMKOCL
DMMKOCL DN AMT-050
DMMKOCL HS Terminated
DMMKOCL SN ApoA1 deficiency gene therapy, Amsterdam Molecular Therapeutics
DMMKOCL CP Amsterdam Molecular Therapeutics BV
DMMKOCL DE Cholesterol metabolism disorder
DM50HB8 ID DM50HB8
DM50HB8 DN AN-10
DM50HB8 HS Terminated
DM50HB8 SN Novaheme
DM50HB8 CP Discovery Laboratories Inc
DM50HB8 DT Small molecular drug
DM50HB8 PC 55763
DM50HB8 MW 234.29
DM50HB8 FM C13H18N2O2
DM50HB8 IC InChI=1S/C13H18N2O2/c1-3-17-13(16)12-8-9(2)14-10-6-4-5-7-11(10)15-12/h4-7,9,12,14-15H,3,8H2,1-2H3
DM50HB8 CS CCOC(=O)C1CC(NC2=CC=CC=C2N1)C
DM50HB8 IK MGQPKIPVCPMXQF-UHFFFAOYSA-N
DM50HB8 IU ethyl 2-methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-4-carboxylate
DM50HB8 CA CAS 87896-36-4
DM50HB8 DE Alopecia
DMMLDG8 ID DMMLDG8
DMMLDG8 DN Anatumomab mafenatox
DMMLDG8 HS Terminated
DMMLDG8 SN ABR-214936; Fab5T4V13-SEAm9; PNU-214936; TTS-CD2; CD-2, Active Biotech
DMMLDG8 CP Pharmacia & Upjohn Inc
DMMLDG8 DT Antibody
DMMLDG8 DE Breast cancer
DM35LJC ID DM35LJC
DM35LJC DN Anpirtoline
DM35LJC HS Terminated
DM35LJC SN D-16949
DM35LJC CP ASTA Medica AG
DM35LJC DT Small molecular drug
DM35LJC PC 65854
DM35LJC MW 228.74
DM35LJC FM C10H13ClN2S
DM35LJC IC InChI=1S/C10H13ClN2S/c11-9-2-1-3-10(13-9)14-8-4-6-12-7-5-8/h1-3,8,12H,4-7H2
DM35LJC CS C1CNCCC1SC2=NC(=CC=C2)Cl
DM35LJC IK GGALEXMXDMUMDM-UHFFFAOYSA-N
DM35LJC IU 2-chloro-6-piperidin-4-ylsulfanylpyridine
DM35LJC CA CAS 98330-05-3
DM35LJC CB CHEBI:92968
DM35LJC DE Pain
DM2EKX5 ID DM2EKX5
DM2EKX5 DN Antalarmin
DM2EKX5 HS Terminated
DM2EKX5 SN Antalarmin; 157284-96-3; CHEMBL296641; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-; SCHEMBL466243; GTPL3489; AC1L433C; DTXSID50166241; CHEBI:139557; ZINC1539136; NSC715590; BDBM50074501; AKOS030559812; NSC-715590; NCGC00165732-01; NCI60_039940; LS-139513; N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine; N-butyl-N-ethyl-7-mesityl-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
DM2EKX5 DT Small molecular drug
DM2EKX5 PC 177990
DM2EKX5 MW 378.6
DM2EKX5 FM C24H34N4
DM2EKX5 IC InChI=1S/C24H34N4/c1-9-11-12-27(10-2)23-21-18(6)19(7)28(24(21)26-20(8)25-23)22-16(4)13-15(3)14-17(22)5/h13-14H,9-12H2,1-8H3
DM2EKX5 CS CCCCN(CC)C1=NC(=NC2=C1C(=C(N2C3=C(C=C(C=C3C)C)C)C)C)C
DM2EKX5 IK IXPROWGEHNVJOY-UHFFFAOYSA-N
DM2EKX5 IU N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DM2EKX5 CA CAS 157284-96-3
DM2EKX5 CB CHEBI:139557
DM2EKX5 DE Depression
DMXI185 ID DMXI185
DMXI185 DN Anti-IFN gamma
DMXI185 HS Terminated
DMXI185 SN AGT-1; Anti-IFN gamma (autoimmune diseases); Anti-cytokine antibodies, Advanced Biotherapy; Anti-cytokine therapy, Advanced Biotherapy; Anti-IFN gamma (autoimmune diseases), Advanced Biotherapy
DMXI185 CP Advanced Biotherapy Inc
DMXI185 DT Antibody
DMXI185 DE Alopecia
DMXKZDU ID DMXKZDU
DMXKZDU DN Antova
DMXKZDU HS Terminated
DMXKZDU SN Ruplizumab
DMXKZDU CP Biogen Idec
DMXKZDU DE Thrombocytopenia
DMOJP9E ID DMOJP9E
DMOJP9E DN ANX-201
DMOJP9E HS Terminated
DMOJP9E SN Thiophosphonoformic acid; TPFA; dihydroxyphosphinothioylformic acid; 99107-93-4; Thiofoscarnet; ANX-201; Thiovir (TM); AC1L9PNZ; SCHEMBL6244658; CTK5I0229
DMOJP9E DT Small molecular drug
DMOJP9E PC 451471
DMOJP9E MW 142.07
DMOJP9E FM CH3O4PS
DMOJP9E IC InChI=1S/CH3O4PS/c2-1(3)6(4,5)7/h(H,2,3)(H2,4,5,7)
DMOJP9E CS C(=O)(O)P(=S)(O)O
DMOJP9E IK OSIAURSWRZARKZ-UHFFFAOYSA-N
DMOJP9E IU dihydroxyphosphinothioylformic acid
DMOJP9E CA CAS 99107-93-4
DMOJP9E DE Cytomegalovirus infection
DM5B72D ID DM5B72D
DM5B72D DN AP22408
DM5B72D HS Terminated
DM5B72D SN UNII-3U3L5QR4KV; 3U3L5QR4KV; AP-22408; {4-[2-ACETYLAMINO-2-(3-CARBAMOYL-2-CYCLOHEXYLMETHOXY-6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTEN-5YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENYL}-PHOSPHONIC ACID; CC1; 268741-43-1; AP22408; AC1L9I7C; SCHEMBL7245569; DB01830; Phosphonic acid, (4-((2S)-2-(acetylamino)-3-(((5S)-3-(aminocarbonyl)-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)amino)-3-oxopropyl)-1,2-phenylene)bis-; Phosphonic acid, P,P'-(4-((2S)-2-(acetylamino)-3-(((5S)-3-(aminocarbonyl)-2-(cyclohexylmethoxy)-6
DM5B72D DT Small molecular drug
DM5B72D PC 445561
DM5B72D MW 665.6
DM5B72D FM C30H41N3O10P2
DM5B72D IC InChI=1S/C30H41N3O10P2/c1-18(34)32-25(13-20-11-12-27(44(37,38)39)28(14-20)45(40,41)42)30(36)33-24-10-6-5-9-21-15-26(23(29(31)35)16-22(21)24)43-17-19-7-3-2-4-8-19/h11-12,14-16,19,24-25H,2-10,13,17H2,1H3,(H2,31,35)(H,32,34)(H,33,36)(H2,37,38,39)(H2,40,41,42)/t24-,25-/m0/s1
DM5B72D CS CC(=O)N[C@@H](CC1=CC(=C(C=C1)P(=O)(O)O)P(=O)(O)O)C(=O)N[C@H]2CCCCC3=CC(=C(C=C23)C(=O)N)OCC4CCCCC4
DM5B72D IK SPSGYTWOIGAABK-DQEYMECFSA-N
DM5B72D IU [4-[(2S)-2-acetamido-3-[[(5S)-3-carbamoyl-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl]amino]-3-oxopropyl]-2-phosphonophenyl]phosphonic acid
DM5B72D CA CAS 268741-43-1
DM5B72D DE Osteoporosis
DM7LAXF ID DM7LAXF
DM7LAXF DN AP-227
DM7LAXF HS Terminated
DM7LAXF SN CHEMBL268477; AP227; AP-227; BDBM50095205; [6-(2-Benzhydryloxyimino-pentyl)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; (6-{2-[(E)-Benzhydryloxyimino]-pentyl}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid
DM7LAXF DT Small molecular drug
DM7LAXF PC 9847589
DM7LAXF MW 471.6
DM7LAXF FM C30H33NO4
DM7LAXF IC InChI=1S/C30H33NO4/c1-2-10-26(31-35-30(23-11-5-3-6-12-23)24-13-7-4-8-14-24)20-22-17-18-27-25(19-22)15-9-16-28(27)34-21-29(32)33/h3-9,11-16,22,30H,2,10,17-21H2,1H3,(H,32,33)/b31-26+
DM7LAXF CS CCC/C(=N\\OC(C1=CC=CC=C1)C2=CC=CC=C2)/CC3CCC4=C(C3)C=CC=C4OCC(=O)O
DM7LAXF IK XNRBBSJYERPMMB-GKPLWNPISA-N
DM7LAXF IU 2-[[6-[(2E)-2-benzhydryloxyiminopentyl]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetic acid
DMXLJBA ID DMXLJBA
DMXLJBA DN AP-23588
DMXLJBA HS Terminated
DMXLJBA SN AP-23485; AP-23485 analogs, ARIAD
DMXLJBA CP ARIAD Pharmaceuticals Inc
DMXLJBA DE Osteoporosis
DMBA4DK ID DMBA4DK
DMBA4DK DN APC-6336
DMBA4DK HS Terminated
DMBA4DK SN CRA-6336; HCV therapy, BMS/Arris; HCV therapy, BMS/Axys; Hepatitis C therapy, Axys/BMS; Protease inhibitors, BMS/Arris; Protease inhibitors, BMS/Axys
DMBA4DK CP Bristol-Myers Squibb Co
DMBA4DK DT Small molecular drug
DMBA4DK PC 72941786
DMBA4DK MW 500.4
DMBA4DK FM C21H21N6O7P
DMBA4DK IC InChI=1S/C21H21N6O7P/c1-27-16-7-11(20(29)26-15(21(30)31)9-35(32,33)34)3-5-13(16)25-18(27)8-17-23-12-4-2-10(19(22)28)6-14(12)24-17/h2-7,15H,8-9H2,1H3,(H2,22,28)(H,23,24)(H,26,29)(H,30,31)(H2,32,33,34)/t15-/m0/s1
DMBA4DK CS CN1C2=C(C=CC(=C2)C(=O)N[C@@H](CP(=O)(O)O)C(=O)O)N=C1CC3=NC4=C(N3)C=C(C=C4)C(=O)N
DMBA4DK IK PEXFKSJDXSBOLP-HNNXBMFYSA-N
DMBA4DK IU (2R)-2-[[2-[(6-carbamoyl-1H-benzimidazol-2-yl)methyl]-3-methylbenzimidazole-5-carbonyl]amino]-3-phosphonopropanoic acid
DMBA4DK CA CAS 263870-19-5
DMBA4DK DE Hepatitis C virus infection
DMYD04O ID DMYD04O
DMYD04O DN APF-580
DMYD04O HS Terminated
DMYD04O SN Opiate (controlled-release (Biochronomer), pain), AP Pharma
DMYD04O CP A P Pharma Inc
DMYD04O DE Pain
DMIYTPE ID DMIYTPE
DMIYTPE DN Apolipoprotein E
DMIYTPE HS Terminated
DMIYTPE SN Apolipoprotein E, Bio-Technology General; Apo-A4, Bio-Technology General; Apo-E, Bio-Technology General; Apolipoprotein-A4, Bio-Technology General
DMIYTPE CP Savient Pharmaceuticals Inc
DMIYTPE DE Glaucoma/ocular hypertension
DMPMW03 ID DMPMW03
DMPMW03 DN AQ-RA-741
DMPMW03 HS Terminated
DMPMW03 SN AQ-RA 741; 123548-16-3; AQ-RA-741; 11-[[4-[4-(DIETHYLAMINO)BUTYL]-1-PIPERIDINYL]ACETYL]-5,11-DIHYDRO-6H-PYRIDO[2,3-B][1,4]BENZODIAZEPIN-6-ONE; 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one,11-[2-[4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-; 11-(2-(4-(4-(Diethylamino)butyl)piperidin-1-yl)acetyl)-5H-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11H)-one; 11-((4-(4-(Diethylamino)butyl)-1-piperidinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; BCUGCHZRMKTPMU-UHFFFAOYSA-N; AC1L2WKT; ACMC-20ej93
DMPMW03 CP Dr Karl Thomae GmbH
DMPMW03 DT Small molecular drug
DMPMW03 PC 129989
DMPMW03 MW 463.6
DMPMW03 FM C27H37N5O2
DMPMW03 IC InChI=1S/C27H37N5O2/c1-3-30(4-2)17-8-7-10-21-14-18-31(19-15-21)20-25(33)32-24-13-6-5-11-22(24)27(34)29-23-12-9-16-28-26(23)32/h5-6,9,11-13,16,21H,3-4,7-8,10,14-15,17-20H2,1-2H3,(H,29,34)
DMPMW03 CS CCN(CC)CCCCC1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMPMW03 IK BCUGCHZRMKTPMU-UHFFFAOYSA-N
DMPMW03 IU 11-[2-[4-[4-(diethylamino)butyl]piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMPMW03 CA CAS 123548-16-3
DMPMW03 CB CHEBI:93432
DMPMW03 DE Cardiovascular disease
DMHU1E8 ID DMHU1E8
DMHU1E8 DN AR177
DMHU1E8 HS Terminated
DMHU1E8 SN Zintevir; AR177; T 30177; 171345-51-0; DNA, d(G-sp-T-G-G-T-G-G-G-T-G-G-G-T-G-G-G-sp-T); UNII-RR07N525H5; AR-177 free acid; GsGGTGGGTGGGTGGGsT; 163703-74-0; 5'-GsGGTGGGTGGGTGGGsT-3'; RR07N525H5; DNA, d(P-thio)(G-T-G-G-T-G-G-G-T-G-G-G-T-G-G-G-T); DBM-2245; Deoxyribonucleic acid, d(P-thio)(G-T-G-G-T-G-G-G-T-G-G-G-T-G-G-G-T)
DMHU1E8 DT Small molecular drug
DMHU1E8 PC 16130283
DMHU1E8 MW 5442
DMHU1E8 FM C170H210N70O103P16S2
DMHU1E8 IC InChI=1S/C170H210N70O103P16S2/c1-57-23-224(166(260)219-137(57)243)96-6-62(242)80(312-96)29-309-358(293,360)343-78-22-112(240-56-194-124-136(240)206-165(182)218-153(124)259)327-94(78)43-308-357(291,292)341-77-21-111(239-55-193-123-135(239)205-164(181)217-152(123)258)326-93(77)42-307-356(289,290)337-73-17-107(235-51-189-119-131(235)201-160(177)213-148(119)254)319-86(73)35-300-346(269,270)330-66-10-99(227-26-60(4)140(246)222-169(227)263)315-83(66)32-297-350(277,278)334-70-14-104(232-48-186-116-128(232)198-157(174)210-145(116)251)323-90(70)39-304-355(287,288)340-76-20-110(238-54-192-122-134(238)204-163(180)216-151(122)257)325-92(76)41-306-352(281,282)336-72-16-106(234-50-188-118-130(234)200-159(176)212-147(118)253)318-85(72)34-299-345(267,268)329-65-9-98(226-25-59(3)139(245)221-168(226)262)314-82(65)31-296-349(275,276)333-69-13-103(231-47-185-115-127(231)197-156(173)209-144(115)250)322-89(69)38-303-354(285,286)339-75-19-109(237-53-191-121-133(237)203-162(179)215-150(121)256)324-91(75)40-305-351(279,280)335-71-15-105(233-49-187-117-129(233)199-158(175)211-146(117)252)317-84(71)33-298-344(265,266)328-64-8-97(225-24-58(2)138(244)220-167(225)261)313-81(64)30-295-348(273,274)332-68-12-102(230-46-184-114-126(230)196-155(172)208-143(114)249)321-88(68)37-302-353(283,284)338-74-18-108(236-52-190-120-132(236)202-161(178)214-149(120)255)320-87(74)36-301-347(271,272)331-67-11-100(228-27-61(5)141(247)223-170(228)264)316-95(67)44-310-359(294,361)342-63-7-101(311-79(63)28-241)229-45-183-113-125(229)195-154(171)207-142(113)248/h23-27,45-56,62-112,241-242H,6-22,28-44H2,1-5H3,(H,265,266)(H,267,268)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,360)(H,294,361)(H,219,243,260)(H,220,244,261)(H,221,245,262)(H,222,246,263)(H,223,247,264)(H3,171,195,207,248)(H3,172,196,208,249)(H3,173,197,209,250)(H3,174,198,210,251)(H3,175,199,211,252)(H3,176,200,212,253)(H3,177,201,213,254)(H3,178,202,214,255)(H3,179,203,215,256)(H3,180,204,216,257)(H3,181,205,217,258)(H3,182,206,218,259)
DMHU1E8 CS CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=O)(O)OC4CC(OC4COP(=O)(O)OC5CC(OC5COP(=O)(O)OC6CC(OC6COP(=O)(O)OC7CC(OC7COP(=O)(O)OC8CC(OC8COP(=O)(O)OC9CC(OC9COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)S)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)O
DMHU1E8 IK FTRWNHBXCNPGCA-UHFFFAOYSA-N
DMHU1E8 IU [5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methyl [2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-sulfanylphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] hydrogen phosphate
DMHU1E8 DE Human immunodeficiency virus infection
DMUI81C ID DMUI81C
DMUI81C DN AR-709
DMUI81C HS Terminated
DMUI81C SN AR-103; AR-103 program, Arpida
DMUI81C CP Evolva Holding SA
DMUI81C DT Small molecular drug
DMUI81C PC 11226413
DMUI81C MW 535
DMUI81C FM C27H27ClN6O4
DMUI81C IC InChI=1S/C27H27ClN6O4/c1-34(2)26(35)22-19(18-9-15(28)5-6-20(18)32-22)11-16-10-17-13(7-14-12-31-27(30)33-25(14)29)8-21(36-3)24(37-4)23(17)38-16/h5-6,8-10,12,32H,7,11H2,1-4H3,(H4,29,30,31,33)
DMUI81C CS CN(C)C(=O)C1=C(C2=C(N1)C=CC(=C2)Cl)CC3=CC4=C(O3)C(=C(C=C4CC5=CN=C(N=C5N)N)OC)OC
DMUI81C IK ASSNCSVJAZEMQG-UHFFFAOYSA-N
DMUI81C IU 5-chloro-3-[[4-[(2,4-diaminopyrimidin-5-yl)methyl]-6,7-dimethoxy-1-benzofuran-2-yl]methyl]-N,N-dimethyl-1H-indole-2-carboxamide
DMUI81C CA CAS 663214-64-0
DMUI81C DE Bacterial infection
DMQ52JR ID DMQ52JR
DMQ52JR DN ARC239
DMQ52JR HS Terminated
DMQ52JR SN GTPL524; BDBM81772; NSC_122211; CAS_122211
DMQ52JR DT Small molecular drug
DMQ52JR PC 609483
DMQ52JR MW 407.5
DMQ52JR FM C24H29N3O3
DMQ52JR IC InChI=1S/C24H29N3O3/c1-24(2)19-9-5-4-8-18(19)22(28)27(23(24)29)17-14-25-12-15-26(16-13-25)20-10-6-7-11-21(20)30-3/h4-11H,12-17H2,1-3H3
DMQ52JR CS CC1(C2=CC=CC=C2C(=O)N(C1=O)CCN3CCN(CC3)C4=CC=CC=C4OC)C
DMQ52JR IK JFNKXGOEOQCXDM-UHFFFAOYSA-N
DMQ52JR IU 2-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethylisoquinoline-1,3-dione
DMQ52JR CA CAS 67339-62-2
DMQ52JR CB CHEBI:93630
DM9HZ8D ID DM9HZ8D
DM9HZ8D DN AR-C-89855
DM9HZ8D HS Terminated
DM9HZ8D SN AR-C68164AA; AR-C68475AA; AR-C69457AA; AR-C89855AA
DM9HZ8D CP AstraZeneca plc
DM9HZ8D PC 10206844
DM9HZ8D MW 493.6
DM9HZ8D FM C23H31N3O5S2
DM9HZ8D IC InChI=1S/C23H31N3O5S2/c1-17-3-5-18(6-4-17)10-14-31-15-13-25-33(29,30)16-2-11-24-12-9-19-7-8-20(27)21-22(19)32-23(28)26-21/h3-8,24-25,27H,2,9-16H2,1H3,(H,26,28)
DM9HZ8D CS CC1=CC=C(C=C1)CCOCCNS(=O)(=O)CCCNCCC2=C3C(=C(C=C2)O)NC(=O)S3
DM9HZ8D IK FIDWUJWRKJJJLL-UHFFFAOYSA-N
DM9HZ8D IU 3-[2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethylamino]-N-[2-[2-(4-methylphenyl)ethoxy]ethyl]propane-1-sulfonamide
DM9HZ8D CA CAS 189012-09-7
DM9HZ8D DE Chronic obstructive pulmonary disease
DMRXB74 ID DMRXB74
DMRXB74 DN ARISTEROMYCIN
DMRXB74 HS Terminated
DMRXB74 SN 19186-33-5; 3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol; NSC613806; NSC615828; NSC613807; NSC103526; Carbocyclic Lyxo-A; Carbocyclic Xylo-A; AC1Q4VH0; Cyclaradine Carbocyclic Ara A; SCHEMBL9820408; AC1L1D83; CTK4E0829; 3-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol; NSC-613807; NSC-613806; NSC-615828; NSC-103526; J-012404; 1,2-Cyclopentanediol,5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)-, (1S,2R,3R,5R)-
DMRXB74 DT Small molecular drug
DMRXB74 PC 65269
DMRXB74 MW 265.27
DMRXB74 FM C11H15N5O3
DMRXB74 IC InChI=1S/C11H15N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h3-6,8-9,17-19H,1-2H2,(H2,12,13,14)/t5-,6-,8-,9+/m1/s1
DMRXB74 CS C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO
DMRXB74 IK UGRNVLGKAGREKS-GCXDCGAKSA-N
DMRXB74 IU (1R,2S,3R,5R)-3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol
DMRXB74 CA CAS 19186-33-5
DMRYQBE ID DMRYQBE
DMRYQBE DN AS-1406
DMRYQBE HS Terminated
DMRYQBE SN Theranase; HuHMFG1-huRNase; Targeted apoptosis (RNase), Antisoma
DMRYQBE CP Antisoma plc
DMRYQBE DE Solid tumour/cancer
DMH78J6 ID DMH78J6
DMH78J6 DN AS-602305
DMH78J6 HS Terminated
DMH78J6 SN AS-603831; Oxytocin receptor antagonists (premature labor); Oxytocin receptor antagonists (premature labor), Merck Serono; Oxytocin receptor antagonists (premature labor), Serono
DMH78J6 CP Merck Serono SA
DMH78J6 DE Androgen deficiency
DMIFDPL ID DMIFDPL
DMIFDPL DN AS-8112
DMIFDPL HS Terminated
DMIFDPL CP Dainippon
DMIFDPL DE Vomiting
DMS2FB3 ID DMS2FB3
DMS2FB3 DN ATLIPROFEN METHYL ESTER
DMS2FB3 HS Terminated
DMS2FB3 SN IDPH-8261; Atliprofen methyl ester; 2-[4-(3-Thienyl)phenyl]propionic acid methyl ester
DMS2FB3 DT Small molecular drug
DMS2FB3 PC 130978
DMS2FB3 MW 246.33
DMS2FB3 FM C14H14O2S
DMS2FB3 IC InChI=1S/C14H14O2S/c1-10(14(15)16-2)11-3-5-12(6-4-11)13-7-8-17-9-13/h3-10H,1-2H3
DMS2FB3 CS CC(C1=CC=C(C=C1)C2=CSC=C2)C(=O)OC
DMS2FB3 IK WINXAKJYORVNHU-UHFFFAOYSA-N
DMS2FB3 IU methyl 2-(4-thiophen-3-ylphenyl)propanoate
DMS2FB3 CA CAS 108912-17-0
DMS2FB3 DE Inflammation
DM4UTXV ID DM4UTXV
DM4UTXV DN AVE0675
DM4UTXV HS Terminated
DM4UTXV CP Sanofi-Aventis
DM4UTXV DE Asthma
DMD8ZM1 ID DMD8ZM1
DMD8ZM1 DN AWD-23-111
DMD8ZM1 HS Terminated
DMD8ZM1 CP Elbion AG
DMD8ZM1 DE Heart arrhythmia
DMJH7IX ID DMJH7IX
DMJH7IX DN AZD-0275
DMJH7IX HS Terminated
DMJH7IX CP AstraZeneca plc
DMJH7IX DE Rheumatoid arthritis; Chronic obstructive pulmonary disease
DMS7INR ID DMS7INR
DMS7INR DN AZD-0902
DMS7INR HS Terminated
DMS7INR CP AstraZeneca plc
DMS7INR DE Rheumatoid arthritis; Chronic obstructive pulmonary disease
DMPCFRN ID DMPCFRN
DMPCFRN DN AZD-1134
DMPCFRN HS Terminated
DMPCFRN SN AZD-1134; CHEMBL602674; SCHEMBL4251105; CKBARMWSFIJZTL-UHFFFAOYSA-N; BDBM50306588; 6-Fluoro-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid [4-(4-propionyl-piperazin-1-yl)-phenyl]-amide
DMPCFRN CP AstraZeneca plc
DMPCFRN DT Small molecular drug
DMPCFRN PC 9830790
DMPCFRN MW 521.6
DMPCFRN FM C28H32FN5O4
DMPCFRN IC InChI=1S/C28H32FN5O4/c1-3-26(36)34-14-12-32(13-15-34)21-6-4-20(5-7-21)30-28(37)25-18-24(35)22-16-19(29)17-23(27(22)38-25)33-10-8-31(2)9-11-33/h4-7,16-18H,3,8-15H2,1-2H3,(H,30,37)
DMPCFRN CS CCC(=O)N1CCN(CC1)C2=CC=C(C=C2)NC(=O)C3=CC(=O)C4=C(O3)C(=CC(=C4)F)N5CCN(CC5)C
DMPCFRN IK CKBARMWSFIJZTL-UHFFFAOYSA-N
DMPCFRN IU 6-fluoro-8-(4-methylpiperazin-1-yl)-4-oxo-N-[4-(4-propanoylpiperazin-1-yl)phenyl]chromene-2-carboxamide
DMPCFRN DE Anxiety disorder
DM3WFB5 ID DM3WFB5
DM3WFB5 DN AZD3409
DM3WFB5 HS Terminated
DM3WFB5 SN GTPL8027; AZD 3409; propan-2-yl (2S)-2-[1-[2-(2-fluoroethyl)-5-[[(2S,5S)-5-(pyridine-3-carbonylsulfanyl)pyrrolidin-2-yl]methylamino]phenyl]ethenylamino]-4-methylsulfanylbutanoate
DM3WFB5 CP AstraZeneca
DM3WFB5 TC Anticancer Agents
DM3WFB5 DT Small molecular drug
DM3WFB5 PC 56603668
DM3WFB5 MW 574.8
DM3WFB5 FM C29H39FN4O3S2
DM3WFB5 IC InChI=1S/C29H39FN4O3S2/c1-19(2)37-28(35)26(12-15-38-4)33-20(3)25-16-23(8-7-21(25)11-13-30)32-18-24-9-10-27(34-24)39-29(36)22-6-5-14-31-17-22/h5-8,14,16-17,19,24,26-27,32-34H,3,9-13,15,18H2,1-2,4H3/t24-,26-,27-/m0/s1
DM3WFB5 CS CC(C)OC(=O)[C@H](CCSC)NC(=C)C1=C(C=CC(=C1)NC[C@@H]2CC[C@@H](N2)SC(=O)C3=CN=CC=C3)CCF
DM3WFB5 IK GIJNHMGFNKZBIR-URORMMCBSA-N
DM3WFB5 IU propan-2-yl (2S)-2-[1-[2-(2-fluoroethyl)-5-[[(2S,5S)-5-(pyridine-3-carbonylsulfanyl)pyrrolidin-2-yl]methylamino]phenyl]ethenylamino]-4-methylsulfanylbutanoate
DM3WFB5 DE Solid tumour/cancer
DMABY43 ID DMABY43
DMABY43 DN AZD-5106
DMABY43 HS Terminated
DMABY43 CP AstraZeneca plc
DMABY43 DE Urinary incontinence
DMQUX28 ID DMQUX28
DMQUX28 DN AZD5672
DMQUX28 HS Terminated
DMQUX28 SN CHEMBL1951914; SCHEMBL2767780; GTPL7686; QOSMEMHKXNNIGG-SSEXGKCCSA-N; AZD 5672; BDBM50364743; N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide
DMQUX28 CP AstraZeneca
DMQUX28 DT Small molecular drug
DMQUX28 PC 11614352
DMQUX28 MW 639.8
DMQUX28 FM C31H43F2N3O5S2
DMQUX28 IC InChI=1S/C31H43F2N3O5S2/c1-4-36(31(37)19-23-5-7-29(8-6-23)42(2,38)39)28-11-14-34(15-12-28)16-13-30(25-20-26(32)22-27(33)21-25)24-9-17-35(18-10-24)43(3,40)41/h5-8,20-22,24,28,30H,4,9-19H2,1-3H3/t30-/m1/s1
DMQUX28 CS CCN(C1CCN(CC1)CC[C@H](C2CCN(CC2)S(=O)(=O)C)C3=CC(=CC(=C3)F)F)C(=O)CC4=CC=C(C=C4)S(=O)(=O)C
DMQUX28 IK QOSMEMHKXNNIGG-SSEXGKCCSA-N
DMQUX28 IU N-[1-[(3R)-3-(3,5-difluorophenyl)-3-(1-methylsulfonylpiperidin-4-yl)propyl]piperidin-4-yl]-N-ethyl-2-(4-methylsulfonylphenyl)acetamide
DMQUX28 DE Rheumatoid arthritis
DMVP4E5 ID DMVP4E5
DMVP4E5 DN AZD6482
DMVP4E5 HS Terminated
DMVP4E5 SN AZD6482; 1173900-33-8; AZD 6482; (R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino)benzoic acid; 2-[[(1R)-1-[7-Methyl-2-(4-morpholinyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl]amino]benzoic acid; AZD-6482; CHEMBL2165191; UNII-78G6MP5PZ5; 78G6MP5PZ5; 2-({(1R)-1-[7-Methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid; 2-{[(1R)-1-[7-methyl-2-(morpholin-4-yl)-4-oxopyrido[1,2-a]pyrimidin-9-yl]ethyl]amino}benzoic acid
DMVP4E5 CP AstraZeneca
DMVP4E5 DT Small molecular drug
DMVP4E5 PC 44137675
DMVP4E5 MW 408.4
DMVP4E5 FM C22H24N4O4
DMVP4E5 IC InChI=1S/C22H24N4O4/c1-14-11-17(15(2)23-18-6-4-3-5-16(18)22(28)29)21-24-19(12-20(27)26(21)13-14)25-7-9-30-10-8-25/h3-6,11-13,15,23H,7-10H2,1-2H3,(H,28,29)/t15-/m1/s1
DMVP4E5 CS CC1=CN2C(=O)C=C(N=C2C(=C1)[C@@H](C)NC3=CC=CC=C3C(=O)O)N4CCOCC4
DMVP4E5 IK IRTDIKMSKMREGO-OAHLLOKOSA-N
DMVP4E5 IU 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid
DMVP4E5 CA CAS 1173900-33-8
DMVP4E5 CB CHEBI:91359
DMVP4E5 DE Thrombosis
DMZ90OV ID DMZ90OV
DMZ90OV DN AZD-6942
DMZ90OV HS Terminated
DMZ90OV SN CCR2b antagonists, AstraZeneca; CCR2b, AstraZeneca
DMZ90OV CP AstraZeneca plc
DMZ90OV DE Rheumatoid arthritis
DMU6L4I ID DMU6L4I
DMU6L4I DN AZD-7545
DMU6L4I HS Terminated
DMU6L4I SN AZD7545; 252017-04-2; 4-[(3-Chloro-4-{[(2r)-3,3,3-Trifluoro-2-Hydroxy-2-Methylpropanoyl]amino}phenyl)sulfonyl]-N,N-Dimethylbenzamide; 4-{3-chloro-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamido]benzenesulfonyl}-N,N-dimethylbenzamide; DTDZLJHKVNTQGZ-GOSISDBHSA-N; AZD-7545; AZD 7545; 2q8g; C19H18ClF3N2O5S; GTPL9362; SCHEMBL6350247; AOB6866; MolPort-035-395-876; ZINC1547088; EX-A1208; AZD-7547; BCP07524; KS-00000RM2; s7517; 2244AH; AZD 7545;AZD-7545; AKOS027326647; DB07403; CS-1740; NCGC00250391-07; NCGC00250391-01; HY-16082
DMU6L4I CP AstraZeneca plc
DMU6L4I DT Small molecular drug
DMU6L4I PC 16741245
DMU6L4I MW 478.9
DMU6L4I FM C19H18ClF3N2O5S
DMU6L4I IC InChI=1S/C19H18ClF3N2O5S/c1-18(28,19(21,22)23)17(27)24-15-9-8-13(10-14(15)20)31(29,30)12-6-4-11(5-7-12)16(26)25(2)3/h4-10,28H,1-3H3,(H,24,27)/t18-/m1/s1
DMU6L4I CS C[C@@](C(=O)NC1=C(C=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)C(=O)N(C)C)Cl)(C(F)(F)F)O
DMU6L4I IK DTDZLJHKVNTQGZ-GOSISDBHSA-N
DMU6L4I IU 4-[3-chloro-4-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino]phenyl]sulfonyl-N,N-dimethylbenzamide
DMU6L4I DE Diabetic complication
DMFE3CD ID DMFE3CD
DMFE3CD DN AZD-9935
DMFE3CD HS Terminated
DMFE3CD CP AstraZeneca plc
DMFE3CD DE Solid tumour/cancer
DMLCSRF ID DMLCSRF
DMLCSRF DN AZM-131
DMLCSRF HS Terminated
DMLCSRF CP Alizyme plc
DMLCSRF DE Obesity
DMIWC64 ID DMIWC64
DMIWC64 DN AZM-134
DMIWC64 HS Terminated
DMIWC64 SN AZM-133; GLP-1 mimetics, Alizyme; Glucagon-like peptide-1 mimetics, Alizyme
DMIWC64 CP Alizyme plc
DMIWC64 DE Type-2 diabetes
DME6OFU ID DME6OFU
DME6OFU DN B-428
DME6OFU HS Terminated
DME6OFU CP Eisai Co Ltd
DME6OFU PC 1747
DME6OFU MW 302.14
DME6OFU FM C9H7IN2S
DME6OFU IC InChI=1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)
DME6OFU CS C1=CC2=C(C=C(S2)C(=N)N)C(=C1)I
DME6OFU IK YERQOXAYAFWFEJ-UHFFFAOYSA-N
DME6OFU IU 4-iodo-1-benzothiophene-2-carboximidamide
DME6OFU CA CAS 154628-42-9
DME6OFU DE Solid tumour/cancer
DM8I5UF ID DM8I5UF
DM8I5UF DN B-5354a
DM8I5UF HS Terminated
DM8I5UF SN B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo
DM8I5UF CP Sankyo Co Ltd
DM8I5UF DE Arteriosclerosis
DM5EKPM ID DM5EKPM
DM5EKPM DN B-581
DM5EKPM HS Terminated
DM5EKPM SN 149759-96-6; B581; FTase Inhibitor I; B 581; B-581; CHEMBL91722; CHEBI:83620; N-[2(S)-(2(R)-2-Amino-3-mercaptopropylamino)-3-methylbutyl]-L-phenylalanyl-L-methionine trifluoroacetate salt; (S)-2-((S)-2-((S)-2-((R)-2-amino-3-mercaptopropylamino)-3-methylbutylamino)-3-phenylpropanamido)-4-(methylthio)butanoic acid; CBiol_001875; H-Cys-psi(CH2NH)Val-psi(CH2NH)Phe-Met-OH; AC1L31RF; BSPBio_001466; KBioSS_000186; KBioGR_000186; SCHEMBL2723960; KBio3_000372; KBio2_005322; KBio2_000186; KBio3_000371; KBio2_002754; CTK8E9094
DM5EKPM CP Eisai Co Ltd
DM5EKPM DT Small molecular drug
DM5EKPM PC 132887
DM5EKPM MW 470.7
DM5EKPM FM C22H38N4O3S2
DM5EKPM IC InChI=1S/C22H38N4O3S2/c1-15(2)20(24-12-17(23)14-30)13-25-19(11-16-7-5-4-6-8-16)21(27)26-18(22(28)29)9-10-31-3/h4-8,15,17-20,24-25,30H,9-14,23H2,1-3H3,(H,26,27)(H,28,29)/t17-,18+,19+,20-/m1/s1
DM5EKPM CS CC(C)[C@@H](CN[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)NC[C@H](CS)N
DM5EKPM IK QISLMXIYRQCLIR-FUMNGEBKSA-N
DM5EKPM IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylbutyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DM5EKPM CA CAS 149759-96-6
DM5EKPM CB CHEBI:83620
DM5EKPM DE Solid tumour/cancer
DM1IO9X ID DM1IO9X
DM1IO9X DN B-956
DM1IO9X HS Terminated
DM1IO9X SN B-1086; B-957
DM1IO9X CP Eisai Co Ltd
DM1IO9X PC 15379028
DM1IO9X MW 464.7
DM1IO9X FM C24H36N2O3S2
DM1IO9X IC InChI=1S/C24H36N2O3S2/c1-17(2)19(11-12-21(25)16-30)9-10-20(15-18-7-5-4-6-8-18)23(27)26-22(24(28)29)13-14-31-3/h4-12,17,19-22,30H,13-16,25H2,1-3H3,(H,26,27)(H,28,29)/b10-9+,12-11+/t19-,20+,21+,22-/m0/s1
DM1IO9X CS CC(C)[C@@H](/C=C/[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)/C=C/[C@H](CS)N
DM1IO9X IK IPRQDTJTDYDPBX-KPVQYLNHSA-N
DM1IO9X IU (2S)-2-[[(2S,3E,5S,6E,8R)-8-amino-2-benzyl-5-propan-2-yl-9-sulfanylnona-3,6-dienoyl]amino]-4-methylsulfanylbutanoic acid
DM1IO9X DE Solid tumour/cancer
DM8AGOE ID DM8AGOE
DM8AGOE DN BABIM
DM8AGOE HS Terminated
DM8AGOE SN BABIM; Bis(5-amidino-2-benzimidazolyl)methane; 74733-75-8; CHEMBL99951; 1H-Benzimidazole-5-carboximidamide, 2,2'-methylenebis-; 1xug; 1c1v; AC1L1DKB; SCHEMBL65730; AC1Q1U90; CTK5E0415; BDBM16127; DTXSID60225717; AIDS007118; ZINC3871731; AKOS028112598; Bis(5-amidino-1H-benzimidazole-2-yl)methane; 1H-Benzimidazole-6-carboximidamide,2,2'-methylenebis-; 2,2 -methanediylbis(1H-benzimidazole-6-carboximidamide); 2-[(5-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-1H-benzimidazole-5-carboxamidine
DM8AGOE DT Small molecular drug
DM8AGOE PC 2387
DM8AGOE MW 332.4
DM8AGOE FM C17H16N8
DM8AGOE IC InChI=1S/C17H16N8/c18-16(19)8-1-3-10-12(5-8)24-14(22-10)7-15-23-11-4-2-9(17(20)21)6-13(11)25-15/h1-6H,7H2,(H3,18,19)(H3,20,21)(H,22,24)(H,23,25)
DM8AGOE CS C1=CC2=C(C=C1C(=N)N)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)C(=N)N
DM8AGOE IK QZKOOEFIMWKZPK-UHFFFAOYSA-N
DM8AGOE IU 2-[(6-carbamimidoyl-1H-benzimidazol-2-yl)methyl]-3H-benzimidazole-5-carboximidamide
DM8AGOE CA CAS 74733-75-8
DM8AGOE DE Asthma
DMY1TLZ ID DMY1TLZ
DMY1TLZ DN Baicalin
DMY1TLZ HS Terminated
DMY1TLZ SN Baicalin; 21967-41-9; Baicalein 7-O-glucuronide; 7-D-Glucuronic acid-5,6-dihydroxyflavone; CHEBI:2981; CHEMBL485818; UNII-347Q89U4M5; 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; Baicalin hydrate; 347Q89U4M5; (2S,3S,4S,5R,6S)-6-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; 5,6,7-trihydroxyflavone 7-O-beta-D-glucuronide; BAICAILIN; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl; 31564-28-0
DMY1TLZ DT Small molecular drug
DMY1TLZ PC 64982
DMY1TLZ MW 446.4
DMY1TLZ FM C21H18O11
DMY1TLZ IC InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1
DMY1TLZ CS C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O
DMY1TLZ IK IKIIZLYTISPENI-ZFORQUDYSA-N
DMY1TLZ IU (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMY1TLZ CA CAS 21967-41-9
DMY1TLZ CB CHEBI:2981
DMY1TLZ DE Human immunodeficiency virus infection
DMDLN9E ID DMDLN9E
DMDLN9E DN BALANOL
DMDLN9E HS Terminated
DMDLN9E SN balanol; 63590-19-2; Azepinostatin; CHEMBL60254; Balanol, 1; 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid; BA1; (-)-Balanol; (3R-trans)-Balanol; AC1NRA6W; SCHEMBL62128; MEGxm0_000504; GTPL8142; BDBM3149; Acyclic Balanol Analog (-)-1; BDBM36607; ACon0_001438; ZINC3871640; MCULE-9310625171; 167937-47-5; FT-0662471; 33879-EP2275420A1; 33879-EP2295416A2; 33879-EP2295055A2; 33879-EP2311453A1; 33879-EP2305642A2; 33879-EP2298764A1; 33879-EP2298765A1; 33879-EP2298748A2
DMDLN9E DT Small molecular drug
DMDLN9E PC 5287736
DMDLN9E MW 550.5
DMDLN9E FM C28H26N2O10
DMDLN9E IC InChI=1S/C28H26N2O10/c31-16-8-6-14(7-9-16)26(36)30-18-13-29-10-2-5-22(18)40-28(39)15-11-20(33)24(21(34)12-15)25(35)23-17(27(37)38)3-1-4-19(23)32/h1,3-4,6-9,11-12,18,22,29,31-34H,2,5,10,13H2,(H,30,36)(H,37,38)/t18-,22-/m1/s1
DMDLN9E CS C1C[C@H]([C@@H](CNC1)NC(=O)C2=CC=C(C=C2)O)OC(=O)C3=CC(=C(C(=C3)O)C(=O)C4=C(C=CC=C4O)C(=O)O)O
DMDLN9E IK XYUFCXJZFZPEJD-XMSQKQJNSA-N
DMDLN9E IU 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid
DMDLN9E CA CAS 63590-19-2
DMTMS3L ID DMTMS3L
DMTMS3L DN Barucainide
DMTMS3L HS Terminated
DMTMS3L SN Barucainide; UNII-14NFL30YOH; 79784-22-8; 14NFL30YOH; Barucainidum; Barucainide [INN]; Barucainid; AC1Q1QCZ; AC1L3TX5; SCHEMBL2110723; CHEMBL2105905; DTXSID60229912; ZINC3643459; 4-Benzyl-1,3-dihydro-7-(4-(isopropylamino)butoxy)-6-methylfuro(3,4-c)pyridine; 4-[(4-benzyl-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl)oxy]-N-propan-2-ylbutan-1-amine
DMTMS3L CP BASF AG
DMTMS3L DT Small molecular drug
DMTMS3L PC 146795
DMTMS3L MW 354.5
DMTMS3L FM C22H30N2O2
DMTMS3L IC InChI=1S/C22H30N2O2/c1-16(2)23-11-7-8-12-26-22-17(3)24-21(19-14-25-15-20(19)22)13-18-9-5-4-6-10-18/h4-6,9-10,16,23H,7-8,11-15H2,1-3H3
DMTMS3L CS CC1=C(C2=C(COC2)C(=N1)CC3=CC=CC=C3)OCCCCNC(C)C
DMTMS3L IK KXSKBNFNSAMNEZ-UHFFFAOYSA-N
DMTMS3L IU 4-[(4-benzyl-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-yl)oxy]-N-propan-2-ylbutan-1-amine
DMTMS3L CA CAS 79784-22-8
DMTMS3L DE Heart arrhythmia
DM7LZFQ ID DM7LZFQ
DM7LZFQ DN BAY-17-1998
DM7LZFQ HS Terminated
DM7LZFQ SN BAY-35-8535
DM7LZFQ CP Arris Pharmaceutical Corp
DM7LZFQ DE Asthma
DMPUG18 ID DMPUG18
DMPUG18 DN BAY-39-9624
DMPUG18 HS Terminated
DMPUG18 CP Bayer AG
DMPUG18 DE Osteoporosis
DM40ORU ID DM40ORU
DM40ORU DN BAY-44-3428
DM40ORU HS Terminated
DM40ORU SN APC-1167
DM40ORU CP Celera South San Francisco
DM40ORU DE Asthma
DMAKXN3 ID DMAKXN3
DMAKXN3 DN BAY-50-9062
DMAKXN3 HS Terminated
DMAKXN3 SN Osteoporosis therapeutic (2), Bayer; 17beta-hydroxysteroid dehydrogenase inhibitor, Bayer
DMAKXN3 CP Bayer AG
DMAKXN3 DE Osteoporosis
DM69EHF ID DM69EHF
DM69EHF DN BAY-793
DM69EHF HS Terminated
DM69EHF SN Hoe-793
DM69EHF CP Bayer AG
DM69EHF DE Human immunodeficiency virus infection
DMZGFM6 ID DMZGFM6
DMZGFM6 DN BAY-Z-4305
DMZGFM6 HS Terminated
DMZGFM6 CP Bayer AG
DMZGFM6 DE Human immunodeficiency virus-1 infection
DM7GH5Z ID DM7GH5Z
DM7GH5Z DN BB-1101
DM7GH5Z HS Terminated
DM7GH5Z SN BB-1101; CHEMBL432079; SCHEMBL1844243; BDBM50070453
DM7GH5Z DT Small molecular drug
DM7GH5Z PC 9908389
DM7GH5Z MW 389.5
DM7GH5Z FM C21H31N3O4
DM7GH5Z IC InChI=1S/C21H31N3O4/c1-5-9-16(20(26)24-28)17(12-14(2)3)19(25)23-18(21(27)22-4)13-15-10-7-6-8-11-15/h5-8,10-11,14,16-18,28H,1,9,12-13H2,2-4H3,(H,22,27)(H,23,25)(H,24,26)/t16-,17+,18-/m0/s1
DM7GH5Z CS CC(C)C[C@H]([C@H](CC=C)C(=O)NO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC
DM7GH5Z IK GKHRDWHFKKUYAX-KSZLIROESA-N
DM7GH5Z IU (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide
DM7GH5Z DE Multiple sclerosis
DMWAKC8 ID DMWAKC8
DMWAKC8 DN BB-1433
DMWAKC8 HS Terminated
DMWAKC8 SN BB-2014; BB-2116; BB-2284; BB-2633; BB-3029; BB-3050; BB-3103; BB-3241
DMWAKC8 CP Vernalis plc
DMWAKC8 PC 101708593
DMWAKC8 MW 357.4
DMWAKC8 FM C17H31N3O5
DMWAKC8 IC InChI=1S/C17H31N3O5/c1-10(2)13(14(21)17(24)20-25)16(23)19-12(15(22)18-3)9-11-7-5-4-6-8-11/h10-14,21,25H,4-9H2,1-3H3,(H,18,22)(H,19,23)(H,20,24)/t12-,13+,14-/m0/s1
DMWAKC8 CS CC(C)[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC
DMWAKC8 IK OOYLWSYMDSXZMO-MJBXVCDLSA-N
DMWAKC8 IU (2R,3S)-N-[(2S)-3-cyclohexyl-1-(methylamino)-1-oxopropan-2-yl]-N',3-dihydroxy-2-propan-2-ylbutanediamide
DMWAKC8 DE Arthritis
DM6ETM8 ID DM6ETM8
DM6ETM8 DN BB-2275
DM6ETM8 HS Terminated
DM6ETM8 CP Vernalis plc
DM6ETM8 DE Human immunodeficiency virus infection
DM7YRFE ID DM7YRFE
DM7YRFE DN BB-3644
DM7YRFE HS Terminated
DM7YRFE SN SCHEMBL609641
DM7YRFE CP Vernalis
DM7YRFE TC Anticancer Agents
DM7YRFE DT Small molecular drug
DM7YRFE PC 9822724
DM7YRFE MW 408.5
DM7YRFE FM C20H32N4O5
DM7YRFE IC InChI=1S/C20H32N4O5/c1-12(2)11-13(15(29-6)18(26)24-28)17(25)23-16(20(3,4)5)19(27)22-14-9-7-8-10-21-14/h7-10,12-13,15-16,28H,11H2,1-6H3,(H,23,25)(H,24,26)(H,21,22,27)/t13-,15+,16-/m1/s1
DM7YRFE CS CC(C)C[C@H]([C@@H](C(=O)NO)OC)C(=O)N[C@H](C(=O)NC1=CC=CC=N1)C(C)(C)C
DM7YRFE IK WORSVFBVUCBRIP-VNQPRFMTSA-N
DM7YRFE IU (2R,3S)-N-[(2S)-3,3-dimethyl-1-oxo-1-(pyridin-2-ylamino)butan-2-yl]-N'-hydroxy-3-methoxy-2-(2-methylpropyl)butanediamide
DM7YRFE CA CAS 226072-63-5
DM7YRFE DE Solid tumour/cancer
DMITV4F ID DMITV4F
DMITV4F DN BBB-022
DMITV4F HS Terminated
DMITV4F CP Eisai Co Ltd
DMITV4F DE Cerebrovascular ischaemia
DMNH9A6 ID DMNH9A6
DMNH9A6 DN BCH-150
DMNH9A6 HS Terminated
DMNH9A6 CP Shire BioChem Inc
DMNH9A6 DE Gastrointestinal disease
DM3TP8X ID DM3TP8X
DM3TP8X DN BCH-2763
DM3TP8X HS Terminated
DM3TP8X SN UNII-2Y77S7IT1P; 2Y77S7IT1P; BCH 2763; 204641-27-0
DM3TP8X DT Small molecular drug
DM3TP8X PC 72941757
DM3TP8X MW 1272.5
DM3TP8X FM C64H93N11O16
DM3TP8X IC InChI=1S/C64H93N11O16/c1-5-40(4)55(71-59(85)48-24-17-33-73(48)61(87)44(28-29-53(78)79)69-56(82)45(37-42-21-10-7-11-22-42)70-57(83)46(38-54(80)81)68-51(76)26-12-14-30-65)63(89)74-34-18-25-49(74)62(88)75(50(64(90)91)35-39(2)3)52(77)27-13-15-31-67-58(84)47-23-16-32-72(47)60(86)43(66)36-41-19-8-6-9-20-41/h6-11,19-22,39-40,43-50,55H,5,12-18,23-38,65-66H2,1-4H3,(H,67,84)(H,68,76)(H,69,82)(H,70,83)(H,71,85)(H,78,79)(H,80,81)(H,90,91)/t40-,43+,44-,45-,46-,47-,48-,49-,50-,55-/m0/s1
DM3TP8X CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N([C@@H](CC(C)C)C(=O)O)C(=O)CCCCNC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC3=CC=CC=C3)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCN
DM3TP8X IK VKIPOMGKUAJAEY-GEPLSBMPSA-N
DM3TP8X IU (2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(5-aminopentanoylamino)-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]-[5-[[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-methylpentanoic acid
DM3TP8X CA CAS 204641-27-0
DM3TP8X DE Thrombosis
DMBJERO ID DMBJERO
DMBJERO DN BCX-140
DMBJERO HS Terminated
DMBJERO SN 4-(Acetylamino)-3-guanidinobenzoic acid; BANA-113; UNII-V02KF5948M; BANA 113; CHEMBL55440; 170447-93-5; V02KF5948M; Benzoic acid, 4-(acetylamino)-3-((aminoiminomethyl)amino)-; 4-acetamido-3-guanidino-benzoic acid; Benzoic acid, 4-(acetylamino)-3-[(aminoiminomethyl)amino]-; 1inf; AC1L9JI9; 4-acetamido-3-(diaminomethylideneamino)benzoic acid; SCHEMBL141675; BDBM4707; UDQJOWCVSMIZJP-UHFFFAOYSA-N; 4-Acetylamino-3-guanidino-benzoic acid; 3-carbamimidamido-4-acetamidobenzoic acid; 3-(2,2-diaminoimino)-4-methylcarboxamidobenzoate; BANA-113; BANA-153; BANA-205; BANA-206; Neuraminidase inhibitors, BioCryst; 4-(Acetylamino)-3-Guanidinobenzoic Acid
DMBJERO CP BioCryst Pharmaceuticals Inc
DMBJERO DT Small molecular drug
DMBJERO PC 446323
DMBJERO MW 236.23
DMBJERO FM C10H12N4O3
DMBJERO IC InChI=1S/C10H12N4O3/c1-5(15)13-7-3-2-6(9(16)17)4-8(7)14-10(11)12/h2-4H,1H3,(H,13,15)(H,16,17)(H4,11,12,14)
DMBJERO CS CC(=O)NC1=C(C=C(C=C1)C(=O)O)N=C(N)N
DMBJERO IK UDQJOWCVSMIZJP-UHFFFAOYSA-N
DMBJERO IU 4-acetamido-3-(diaminomethylideneamino)benzoic acid
DMBJERO CA CAS 170447-93-5
DMBJERO DE Influenza virus infection
DM4GEUF ID DM4GEUF
DM4GEUF DN BCX-25
DM4GEUF HS Terminated
DM4GEUF SN BCX-14
DM4GEUF CP BioCryst Pharmaceuticals Inc
DM4GEUF DE Arthritis
DMV5K0I ID DMV5K0I
DMV5K0I DN BDF-9148
DMV5K0I HS Terminated
DMV5K0I SN BDF-9167; BDF-9196
DMV5K0I CP Beiersdorf AG
DMV5K0I DT Small molecular drug
DMV5K0I PC 123765
DMV5K0I MW 453.5
DMV5K0I FM C28H27N3O3
DMV5K0I IC InChI=1S/C28H27N3O3/c29-15-22-14-25-26(30-22)12-7-13-27(25)34-19-23(32)18-33-24-16-31(17-24)28(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-14,23-24,28,30,32H,16-19H2
DMV5K0I CS C1C(CN1C(C2=CC=CC=C2)C3=CC=CC=C3)OCC(COC4=CC=CC5=C4C=C(N5)C#N)O
DMV5K0I IK KQQFGABYYXEKDM-UHFFFAOYSA-N
DMV5K0I IU 4-[3-(1-benzhydrylazetidin-3-yl)oxy-2-hydroxypropoxy]-1H-indole-2-carbonitrile
DMV5K0I CA CAS 120838-62-2
DMV5K0I DE Cardiac failure
DM6WQ8F ID DM6WQ8F
DM6WQ8F DN BE-13793C
DM6WQ8F HS Terminated
DM6WQ8F CP MSD Japan
DM6WQ8F DT Small molecular drug
DM6WQ8F PC 9928668
DM6WQ8F MW 357.3
DM6WQ8F FM C20H11N3O4
DM6WQ8F IC InChI=1S/C20H11N3O4/c24-9-5-1-3-7-11-13-14(20(27)23-19(13)26)12-8-4-2-6-10(25)16(8)22-18(12)17(11)21-15(7)9/h1-6,21-22,24-25H,(H,23,26,27)
DM6WQ8F CS C1=CC2=C(C(=C1)O)NC3=C4C(=C5C(=C23)C(=O)NC5=O)C6=C(N4)C(=CC=C6)O
DM6WQ8F IK FETFZHLVPOJEBR-UHFFFAOYSA-N
DM6WQ8F IU 5,21-dihydroxy-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
DM6WQ8F CA CAS 133805-03-5
DM6WQ8F DE Solid tumour/cancer
DM1SVQX ID DM1SVQX
DM1SVQX DN BE-16627B
DM1SVQX HS Terminated
DM1SVQX SN BE-16627B; 137530-61-1; be16627b; AC1L30CH; L-N-(N-Hydroxy-2-isobutylsuccinamoyl)seryl-L-valine; L-Valine, N-(N-(2-(2-(hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-seryl)-; (2S)-2-[[(2S)-3-hydroxy-2-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoic acid
DM1SVQX CP MSD Japan
DM1SVQX DT Small molecular drug
DM1SVQX PC 132070
DM1SVQX MW 375.42
DM1SVQX FM C16H29N3O7
DM1SVQX IC InChI=1S/C16H29N3O7/c1-8(2)5-10(6-12(21)19-26)14(22)17-11(7-20)15(23)18-13(9(3)4)16(24)25/h8-11,13,20,26H,5-7H2,1-4H3,(H,17,22)(H,18,23)(H,19,21)(H,24,25)/t10?,11-,13-/m0/s1
DM1SVQX CS CC(C)CC(CC(=O)NO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O
DM1SVQX IK ZTDAMCPLHAKWAY-KUNJKIHDSA-N
DM1SVQX IU (2S)-2-[[(2S)-3-hydroxy-2-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoic acid
DM1SVQX CA CAS 137530-61-1
DM1SVQX DE Inflammation
DM39SEK ID DM39SEK
DM39SEK DN BE-22179
DM39SEK HS Terminated
DM39SEK SN BE 22179; AC1L4UUG; AC1Q6NP2; SCHEMBL14221468; FD-179; n,n'-[(1r,7s,14r,20s)-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triacontane-7,20-diyl]bis(3-hydroxyquinoline-2-carboxamide); 3-hydroxy-N-[(1R,7S,14R,20S)-7-[(3-hydroxyquinoline-2-carbonyl)amino]-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-20-yl]quinoline-2-carboxamide
DM39SEK CP MSD Japan
DM39SEK PC 9941484
DM39SEK MW 1061.2
DM39SEK FM C46H48N10O12S4
DM39SEK IC InChI=1S/C46H48N10O12S4/c1-23-45(67)69-19-29(51-41(63)37-33(57)15-25-11-7-9-13-27(25)49-37)39(61)47-18-36(60)56(6)32-22-72-71-21-31(43(65)53(23)3)55(5)35(59)17-48-40(62)30(20-70-46(68)24(2)54(4)44(32)66)52-42(64)38-34(58)16-26-12-8-10-14-28(26)50-38/h7-16,29-32,57-58H,1-2,17-22H2,3-6H3,(H,47,61)(H,48,62)(H,51,63)(H,52,64)
DM39SEK CS CN1C2CSSCC(C(=O)N(C(=C)C(=O)SCC(C(=O)NCC1=O)NC(=O)C3=NC4=CC=CC=C4C=C3O)C)N(C(=O)CNC(=O)C(CSC(=O)C(=C)N(C2=O)C)NC(=O)C5=NC6=CC=CC=C6C=C5O)C
DM39SEK IK QLOZXPNJEDVFIH-UHFFFAOYSA-N
DM39SEK IU 3-hydroxy-N-[20-[(3-hydroxyquinoline-2-carbonyl)amino]-2,12,15,25-tetramethyl-11,24-dimethylidene-3,6,10,13,16,19,23,26-octaoxo-9,22,28,29-tetrathia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoline-2-carboxamide
DM39SEK DE leukaemia
DM6KRJW ID DM6KRJW
DM6KRJW DN BEA-005
DM6KRJW HS Terminated
DM6KRJW SN HMddC; BEA-005; 3'-Hydroxymethyl-ddC; UNII-C7BPP68MLT; C7BPP68MLT; 2',3'-Dideoxy-3'-hydroxymethyl cytidine; 132235-73-5; AC1L9PVF; SCHEMBL598443; DTXSID60157443; 1-(2',3'-Dideoxy-3'-C-(hydroxymethyl)-beta-D-erythro-pentofuranosyl)cytosine; 2',3'-dideoxy-3'-c-(hydroxymethyl)cytidine; 4-amino-1-[(2R,4R,5S)-4,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-.beta.-D-erythro-pentofuranosyl]cytosine
DM6KRJW CP Medivir AB
DM6KRJW DT Small molecular drug
DM6KRJW PC 451819
DM6KRJW MW 241.24
DM6KRJW FM C10H15N3O4
DM6KRJW IC InChI=1S/C10H15N3O4/c11-8-1-2-13(10(16)12-8)9-3-6(4-14)7(5-15)17-9/h1-2,6-7,9,14-15H,3-5H2,(H2,11,12,16)/t6-,7-,9-/m1/s1
DM6KRJW CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)CO
DM6KRJW IK WZGBNAXNHRMYLG-ZXFLCMHBSA-N
DM6KRJW IU 4-amino-1-[(2R,4R,5S)-4,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DM6KRJW CA CAS 132235-73-5
DM6KRJW DE Cytomegalovirus infection
DMGAPH1 ID DMGAPH1
DMGAPH1 DN Befiperide
DMGAPH1 HS Terminated
DMGAPH1 CP Solvay Pharmaceuticals BV
DMGAPH1 PC 182859
DMGAPH1 MW 405.5
DMGAPH1 FM C25H31N3O2
DMGAPH1 IC InChI=1S/C25H31N3O2/c1-19(2)20-7-9-22(10-8-20)25(29)26(3)12-13-27-14-16-28(17-15-27)23-6-4-5-21-11-18-30-24(21)23/h4-11,18-19H,12-17H2,1-3H3
DMGAPH1 CS CC(C)C1=CC=C(C=C1)C(=O)N(C)CCN2CCN(CC2)C3=CC=CC4=C3OC=C4
DMGAPH1 IK XZHMFCUWVDUYBV-UHFFFAOYSA-N
DMGAPH1 IU N-[2-[4-(1-benzofuran-7-yl)piperazin-1-yl]ethyl]-N-methyl-4-propan-2-ylbenzamide
DMGAPH1 CA CAS 100927-14-8
DMGAPH1 DE Anxiety disorder
DMM0ZIJ ID DMM0ZIJ
DMM0ZIJ DN Belaperidone
DMM0ZIJ HS Terminated
DMM0ZIJ SN Balaperidone; Belaperidone [INN]; LU 111995; LU-111995; 3-[2-[(1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[(1s,5r,6s)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl}quinazoline-2,4(1h,3h)-dione
DMM0ZIJ CP Abbott
DMM0ZIJ DT Small molecular drug
DMM0ZIJ PC 184841
DMM0ZIJ MW 379.4
DMM0ZIJ FM C22H22FN3O2
DMM0ZIJ IC InChI=1S/C22H22FN3O2/c23-16-7-5-14(6-8-16)18-11-15-12-25(13-19(15)18)9-10-26-21(27)17-3-1-2-4-20(17)24-22(26)28/h1-8,15,18-19H,9-13H2,(H,24,28)/t15-,18-,19+/m1/s1
DMM0ZIJ CS C1[C@@H]2CN(C[C@@H]2[C@H]1C3=CC=C(C=C3)F)CCN4C(=O)C5=CC=CC=C5NC4=O
DMM0ZIJ IK XLJWJFKYRFPJSD-LZQZEXGQSA-N
DMM0ZIJ IU 3-[2-[(1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]ethyl]-1H-quinazoline-2,4-dione
DMM0ZIJ CA CAS 208661-17-0
DMM0ZIJ DE Schizophrenia
DMXH3A2 ID DMXH3A2
DMXH3A2 DN Benafentrine dimaleate
DMXH3A2 HS Terminated
DMXH3A2 SN AH-21-132; Benafentrine dimaleate; Cis-6-(4-Acetamidophenyl)-8,9-dimethoxy-2-methyl-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridine bis(hydrogenmaleate); Cis-4'-(1,2,3,4,4a,10b-Hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl)acetanilide bis(hydrogenmaleate); Cis-N-[4-(1,2,3,4,4a,10b-Hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl)phenyl]acetamide (Z)-2-butenedioate (1:2)
DMXH3A2 DT Small molecular drug
DMXH3A2 PC 6438805
DMXH3A2 MW 625.6
DMXH3A2 FM C31H35N3O11
DMXH3A2 IC InChI=1S/C23H27N3O3.2C4H4O4/c1-14(27)24-16-7-5-15(6-8-16)23-18-12-22(29-4)21(28-3)11-17(18)19-13-26(2)10-9-20(19)25-23;2*5-3(6)1-2-4(7)8/h5-8,11-12,19-20H,9-10,13H2,1-4H3,(H,24,27);2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+/t19-,20-;;/m1../s1
DMXH3A2 CS CC(=O)NC1=CC=C(C=C1)C2=N[C@H]3[C@@H](C4=CC(=C(C=C24)OC)OC)CN(CC3)C.C(=C/C(=O)O)\\C(=O)O.C(=C/C(=O)O)\\C(=O)O
DMXH3A2 IK BWJFLHODOYZAML-GODXOYSCSA-N
DMXH3A2 IU N-[4-[(4aR,10bS)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-yl]phenyl]acetamide;(E)-but-2-enedioic acid
DMXH3A2 CA CAS 76166-55-7
DMXH3A2 DE Sepsis
DMVK78Q ID DMVK78Q
DMVK78Q DN Bepafant
DMVK78Q HS Terminated
DMVK78Q SN STY-2108; WEB-2170
DMVK78Q CP Boehringer Ingelheim Corp
DMVK78Q DT Small molecular drug
DMVK78Q PC 65923
DMVK78Q MW 468
DMVK78Q FM C23H22ClN5O2S
DMVK78Q IC InChI=1S/C23H22ClN5O2S/c1-13-26-27-19-12-25-21(15-4-2-3-5-17(15)24)20-16-10-14(11-18(16)32-23(20)29(13)19)22(30)28-6-8-31-9-7-28/h2-5,14H,6-12H2,1H3
DMVK78Q CS CC1=NN=C2N1C3=C(C4=C(S3)CC(C4)C(=O)N5CCOCC5)C(=NC2)C6=CC=CC=C6Cl
DMVK78Q IK FWYVRZOREBYLCY-UHFFFAOYSA-N
DMVK78Q IU [9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetrazatetracyclo[8.6.0.02,6.011,15]hexadeca-1(10),3,5,8,11(15)-pentaen-13-yl]-morpholin-4-ylmethanone
DMVK78Q CA CAS 114776-28-2
DMVK78Q DE Sepsis
DMXRTFM ID DMXRTFM
DMXRTFM DN Ber-H2/saporin
DMXRTFM HS Terminated
DMXRTFM DT Antibody
DMQA4JU ID DMQA4JU
DMQA4JU DN Berlafenone
DMQA4JU HS Terminated
DMQA4JU SN Bipranol; GK-23G
DMQA4JU CP Helopharm
DMQA4JU DT Small molecular drug
DMQA4JU PC 65691
DMQA4JU MW 299.4
DMQA4JU FM C19H25NO2
DMQA4JU IC InChI=1S/C19H25NO2/c1-19(2,3)20-13-16(21)14-22-18-12-8-7-11-17(18)15-9-5-4-6-10-15/h4-12,16,20-21H,13-14H2,1-3H3
DMQA4JU CS CC(C)(C)NCC(COC1=CC=CC=C1C2=CC=CC=C2)O
DMQA4JU IK DBHPVKNFKBKJCE-UHFFFAOYSA-N
DMQA4JU IU 1-(tert-butylamino)-3-(2-phenylphenoxy)propan-2-ol
DMQA4JU CA CAS 18965-97-4
DMQA4JU DE Heart arrhythmia
DM56WD3 ID DM56WD3
DM56WD3 DN Bertosamil
DM56WD3 HS Terminated
DM56WD3 SN Bertosamil; 126825-36-3; SCHEMBL379798; CHEMBL2104579; AOIVZQPSIHOHMP-HDICACEKSA-N
DM56WD3 CP Solvay Pharmaceuticals GmbH
DM56WD3 DT Small molecular drug
DM56WD3 PC 16092093
DM56WD3 MW 292.5
DM56WD3 FM C19H36N2
DM56WD3 IC InChI=1S/C19H36N2/c1-15(2)10-20-11-17-13-21(16(3)4)14-18(12-20)19(17)8-6-5-7-9-19/h15-18H,5-14H2,1-4H3/t17-,18-/m0/s1
DM56WD3 CS CC(C)CN1C[C@H]2CN(C[C@H](C1)C23CCCCC3)C(C)C
DM56WD3 IK AOIVZQPSIHOHMP-ROUUACIJSA-N
DM56WD3 IU (1S,5S)-3-(2-methylpropyl)-7-propan-2-ylspiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclohexane]
DM56WD3 CA CAS 126825-36-3
DM56WD3 DE Angina pectoris
DMH7YD4 ID DMH7YD4
DMH7YD4 DN Bexlosteride
DMH7YD4 HS Terminated
DMH7YD4 SN LY-191704
DMH7YD4 DT Small molecular drug
DMH7YD4 PC 166562
DMH7YD4 MW 249.73
DMH7YD4 FM C14H16ClNO
DMH7YD4 IC InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1
DMH7YD4 CS CN1[C@@H]2CCC3=C([C@H]2CCC1=O)C=CC(=C3)Cl
DMH7YD4 IK WQBIOEFDDDEARX-CHWSQXEVSA-N
DMH7YD4 IU (4aR,10bR)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin-3-one
DMH7YD4 CA CAS 148905-78-6
DM6QT9P ID DM6QT9P
DM6QT9P DN BIBB-515
DM6QT9P HS Terminated
DM6QT9P SN BIBB 515; BIBB-515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-
DM6QT9P CP Dr Karl Thomae GmbH
DM6QT9P DT Small molecular drug
DM6QT9P PC 501398
DM6QT9P MW 380.9
DM6QT9P FM C22H21ClN2O2
DM6QT9P IC InChI=1S/C22H21ClN2O2/c23-20-7-5-19(6-8-20)22(26)25-12-9-17(10-13-25)15-16-1-3-18(4-2-16)21-24-11-14-27-21/h1-8,15H,9-14H2
DM6QT9P CS C1CN(CCC1=CC2=CC=C(C=C2)C3=NCCO3)C(=O)C4=CC=C(C=C4)Cl
DM6QT9P IK JQNWPWUJMRAASQ-UHFFFAOYSA-N
DM6QT9P IU (4-chlorophenyl)-[4-[[4-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]methylidene]piperidin-1-yl]methanone
DM6QT9P CA CAS 156635-05-1
DM6QT9P DE Arteriosclerosis
DM019Y7 ID DM019Y7
DM019Y7 DN BIBN-140
DM019Y7 HS Terminated
DM019Y7 SN Bibn 140; 145301-79-7; SCHEMBL8879830; Pentanamide, N-(3-(1-(2-(10,11-dihydro-11-oxo-5H-dibenzo(b,e)(1,4)diazepin-5-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-
DM019Y7 CP Boehringer Ingelheim Corp
DM019Y7 DT Small molecular drug
DM019Y7 PC 10030021
DM019Y7 MW 532.7
DM019Y7 FM C32H44N4O3
DM019Y7 IC InChI=1S/C32H44N4O3/c1-5-19-32(3,4)31(39)35(6-2)20-11-12-24-17-21-34(22-18-24)23-29(37)36-27-15-9-7-13-25(27)30(38)33-26-14-8-10-16-28(26)36/h7-10,13-16,24H,5-6,11-12,17-23H2,1-4H3,(H,33,38)
DM019Y7 CS CCCC(C)(C)C(=O)N(CC)CCCC1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=CC=CC=C42
DM019Y7 IK LOAZWNRCWBWKAC-UHFFFAOYSA-N
DM019Y7 IU N-ethyl-2,2-dimethyl-N-[3-[1-[2-oxo-2-(6-oxo-5H-benzo[b][1,4]benzodiazepin-11-yl)ethyl]piperidin-4-yl]propyl]pentanamide
DM019Y7 CA CAS 145301-79-7
DM019Y7 DE Alzheimer disease
DMZTPCX ID DMZTPCX
DMZTPCX DN BIBN-99
DMZTPCX HS Terminated
DMZTPCX SN Bibn-99; Bibn 99; 145301-48-0; AC1L31GK; SCHEMBL194898; DTXSID00162975; N-(3-(1-(2-(8-Chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethylpentanamide; L008252; N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide; Pentanamide, N-(3-(1-(2-(8-chloro-5,6-dihydro-6-oxo-11H-pyrido(2,3-b)(1,4)benzodiazepin-11-yl)-2-oxoethyl)-4-piperidinyl)propyl)-N-ethyl-2,2-dimethyl-
DMZTPCX CP Boehringer Ingelheim Corp
DMZTPCX DT Small molecular drug
DMZTPCX PC 132712
DMZTPCX MW 568.1
DMZTPCX FM C31H42ClN5O3
DMZTPCX IC InChI=1S/C31H42ClN5O3/c1-5-15-31(3,4)30(40)36(6-2)17-8-9-22-13-18-35(19-14-22)21-27(38)37-26-12-11-23(32)20-24(26)29(39)34-25-10-7-16-33-28(25)37/h7,10-12,16,20,22H,5-6,8-9,13-15,17-19,21H2,1-4H3,(H,34,39)
DMZTPCX CS CCCC(C)(C)C(=O)N(CC)CCCC1CCN(CC1)CC(=O)N2C3=C(C=C(C=C3)Cl)C(=O)NC4=C2N=CC=C4
DMZTPCX IK LUPAFPUKESJDMZ-UHFFFAOYSA-N
DMZTPCX IU N-[3-[1-[2-(8-chloro-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)-2-oxoethyl]piperidin-4-yl]propyl]-N-ethyl-2,2-dimethylpentanamide
DMZTPCX CA CAS 145301-48-0
DMZTPCX DE Alzheimer disease
DMYBR9D ID DMYBR9D
DMYBR9D DN BIBP 3226
DMYBR9D HS Terminated
DMYBR9D SN KUWBXRGRMQZCSS-HSZRJFAPSA-N; BIBP3226; 159013-54-4; BIBP-3226; CHEMBL332347; N2-(Diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine amide; BIBP 3226 TRIFLUOROACETATE; [3H]BIBP3226; [3H]-BIBP3226; (2R)-5-(diaminomethylideneamino)-2-[[2,2-di(phenyl)acetyl]amino]-N-[(4-hydroxyphenyl)methyl]pentanamide; AC1NSJUK; SCHEMBL650331; GTPL3474; GTPL1485; DTXSID30415502; ZINC3811314; MFCD00938562; BDBM50060728; AKOS034831590; 102691-EP2301936A1; 102691-EP2272841A1; (R)-2-Diphenylacetylamino-5-guanidino-pentanoic acid 4-hydroxy-benzylamide
DMYBR9D DT Small molecular drug
DMYBR9D PC 5311023
DMYBR9D MW 473.6
DMYBR9D FM C27H31N5O3
DMYBR9D IC InChI=1S/C27H31N5O3/c28-27(29)30-17-7-12-23(25(34)31-18-19-13-15-22(33)16-14-19)32-26(35)24(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-6,8-11,13-16,23-24,33H,7,12,17-18H2,(H,31,34)(H,32,35)(H4,28,29,30)/t23-/m1/s1
DMYBR9D CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)O
DMYBR9D IK KUWBXRGRMQZCSS-HSZRJFAPSA-N
DMYBR9D IU (2R)-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]-N-[(4-hydroxyphenyl)methyl]pentanamide
DMYBR9D CA CAS 159013-54-4
DMYBR9D DE Hypertension
DM5107E ID DM5107E
DM5107E DN BIBS-222
DM5107E HS Terminated
DM5107E SN Benzoic acid,2-[[[4-[[2-butyl-6-[[(methylamino)carbonyl]pentylamino]-1H-benzimidazol-1-yl]methyl]phenyl]amino]carbonyl]-3,6-dichloro-; ACMC-20n14b
DM5107E CP Boehringer Ingelheim Corp
DM5107E DT Small molecular drug
DM5107E PC 132404
DM5107E MW 638.6
DM5107E FM C33H37Cl2N5O4
DM5107E IC InChI=1S/C33H37Cl2N5O4/c1-4-6-8-18-39(33(44)36-3)23-14-17-26-27(19-23)40(28(38-26)9-7-5-2)20-21-10-12-22(13-11-21)37-31(41)29-24(34)15-16-25(35)30(29)32(42)43/h10-17,19H,4-9,18,20H2,1-3H3,(H,36,44)(H,37,41)(H,42,43)
DM5107E CS CCCCCN(C1=CC2=C(C=C1)N=C(N2CC3=CC=C(C=C3)NC(=O)C4=C(C=CC(=C4C(=O)O)Cl)Cl)CCCC)C(=O)NC
DM5107E IK ZHWGRXBJGUEATA-UHFFFAOYSA-N
DM5107E IU 2-[[4-[[2-butyl-6-[methylcarbamoyl(pentyl)amino]benzimidazol-1-yl]methyl]phenyl]carbamoyl]-3,6-dichlorobenzoic acid
DM5107E CA CAS 142023-57-2
DM5107E DE Hypertension
DM098BL ID DM098BL
DM098BL DN BIBS-39
DM098BL HS Terminated
DM098BL SN Bibs 39; 133085-33-3; BIBS39; CHEMBL130896; 2-[4-[[2-butyl-6-(cyclohexylcarbamoylamino)benzimidazol-1-yl]methyl]phenyl]benzoic acid; AC1L2ZGG; SCHEMBL6567316; DTXSID60157943; BCP17735; BDBM50035429; ZINC11687040; AKOS030526411; CS-5552; HY-19732; 4'-((2-n-Butyl-6-cyclohexylaminocarbonylaminobenzimidazole-1-yl)methyl)biphenyl-2-carboxylic acid; KB-227067; FT-0700165; 4''-[2-Butyl-6-(3-cyclohexyl-ureido)-benzoimidazol-1-ylmethyl]-biphenyl-2-carboxylic acid; (1,1'-Biphenyl)-2-carboxylic acid, 4'-((2-butyl-6-(((cyclohexylamino)c
DM098BL CP Boehringer Ingelheim Corp
DM098BL DT Small molecular drug
DM098BL PC 131590
DM098BL MW 524.7
DM098BL FM C32H36N4O3
DM098BL IC InChI=1S/C32H36N4O3/c1-2-3-13-30-35-28-19-18-25(34-32(39)33-24-9-5-4-6-10-24)20-29(28)36(30)21-22-14-16-23(17-15-22)26-11-7-8-12-27(26)31(37)38/h7-8,11-12,14-20,24H,2-6,9-10,13,21H2,1H3,(H,37,38)(H2,33,34,39)
DM098BL CS CCCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2)NC(=O)NC5CCCCC5
DM098BL IK OLQFKFSAJNUOPT-UHFFFAOYSA-N
DM098BL IU 2-[4-[[2-butyl-6-(cyclohexylcarbamoylamino)benzimidazol-1-yl]methyl]phenyl]benzoic acid
DM098BL CA CAS 133085-33-3
DM098BL DE Hypertension
DMMNI5K ID DMMNI5K
DMMNI5K DN BIBU-251
DMMNI5K HS Terminated
DMMNI5K CP Boehringer Ingelheim Corp
DMMNI5K DE Thrombosis
DMXIH3Q ID DMXIH3Q
DMXIH3Q DN BIBW-22
DMXIH3Q HS Terminated
DMXIH3Q SN RMKP-22; BIBW-22-BS
DMXIH3Q CP Boehringer Ingelheim Corp
DMXIH3Q DT Small molecular drug
DMXIH3Q PC 132088
DMXIH3Q MW 565.7
DMXIH3Q FM C30H43N7O4
DMXIH3Q IC InChI=1S/C30H43N7O4/c1-19-14-36(15-20(2)40-19)27-24(23-10-8-7-9-11-23)31-25-26(32-27)33-29(37-16-21(3)41-22(4)17-37)34-28(25)35(12-13-38)18-30(5,6)39/h7-11,19-22,38-39H,12-18H2,1-6H3/t19-,20+,21-,22+
DMXIH3Q CS C[C@@H]1CN(C[C@@H](O1)C)C2=NC3=C(C(=NC(=N3)N4C[C@H](O[C@H](C4)C)C)N(CCO)CC(C)(C)O)N=C2C5=CC=CC=C5
DMXIH3Q IK JNHIGDFEPXMPAO-COPRSSIGSA-N
DMXIH3Q IU 1-[[2,7-bis[(2R,6S)-2,6-dimethylmorpholin-4-yl]-6-phenylpteridin-4-yl]-(2-hydroxyethyl)amino]-2-methylpropan-2-ol
DMXIH3Q CA CAS 137694-16-7
DMXIH3Q DE Solid tumour/cancer
DMRXWCO ID DMRXWCO
DMRXWCO DN BIBX-79
DMRXWCO HS Terminated
DMRXWCO SN 175033-26-8; BIBX-79; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide
DMRXWCO CP Boehringer Ingelheim Corp
DMRXWCO DT Small molecular drug
DMRXWCO PC 501396
DMRXWCO MW 384.9
DMRXWCO FM C23H29ClN2O
DMRXWCO IC InChI=1S/C23H29ClN2O/c1-25(2)16-17-4-6-18(7-5-17)19-10-14-22(15-11-19)26(3)23(27)20-8-12-21(24)13-9-20/h4-9,12-13,19,22H,10-11,14-16H2,1-3H3
DMRXWCO CS CN(C)CC1=CC=C(C=C1)C2CCC(CC2)N(C)C(=O)C3=CC=C(C=C3)Cl
DMRXWCO IK WBNUHWUTAHSPER-UHFFFAOYSA-N
DMRXWCO IU 4-chloro-N-[4-[4-[(dimethylamino)methyl]phenyl]cyclohexyl]-N-methylbenzamide
DMRXWCO DE Arteriosclerosis
DMU73F0 ID DMU73F0
DMU73F0 DN Bifemelane
DMU73F0 HS Terminated
DMU73F0 SN Alnert; Celeport; E-0687; MCI-2016; SON-216
DMU73F0 CP Mitsubishi-Tokyo Pharmaceuticals Inc
DMU73F0 DT Small molecular drug
DMU73F0 PC 2377
DMU73F0 MW 269.4
DMU73F0 FM C18H23NO
DMU73F0 IC InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3
DMU73F0 CS CNCCCCOC1=CC=CC=C1CC2=CC=CC=C2
DMU73F0 IK QSQQPMHPCBLLGX-UHFFFAOYSA-N
DMU73F0 IU 4-(2-benzylphenoxy)-N-methylbutan-1-amine
DMU73F0 CA CAS 90293-01-9
DMU73F0 CB CHEBI:92338
DMU73F0 DE Alzheimer disease
DMBR48G ID DMBR48G
DMBR48G DN BI-L-357
DMBR48G HS Terminated
DMBR48G SN BI-L-226
DMBR48G CP Boehringer Ingelheim Corp
DMBR48G DT Small molecular drug
DMBR48G PC 6440014
DMBR48G MW 330.4
DMBR48G FM C18H18O4S
DMBR48G IC InChI=1S/C18H18O4S/c1-12-10-14(5-6-15-4-3-9-23-15)11-13(2)18(12)22-17(21)8-7-16(19)20/h3-6,9-11H,7-8H2,1-2H3,(H,19,20)/b6-5+
DMBR48G CS CC1=CC(=CC(=C1OC(=O)CCC(=O)O)C)/C=C/C2=CC=CS2
DMBR48G IK OIDYLVFJAIPWBI-AATRIKPKSA-N
DMBR48G IU 4-[2,6-dimethyl-4-[(E)-2-thiophen-2-ylethenyl]phenoxy]-4-oxobutanoic acid
DMBR48G CA CAS 125722-33-0
DMBR48G DE Asthma
DMRV4UL ID DMRV4UL
DMRV4UL DN BILA-2157BS
DMRV4UL HS Terminated
DMRV4UL CP Boehringer Ingelheim Corp
DMRV4UL PC 10509124
DMRV4UL MW 727
DMRV4UL FM C39H62N6O5S
DMRV4UL IC InChI=1S/C39H62N6O5S/c1-27(2)20-34(46)37(49)33(21-28-12-6-4-7-13-28)43-38(50)30(22-32-26-51-39(40)42-32)23-35(47)45(24-29-14-8-5-9-15-29)25-36(48)44(3)19-17-31-16-10-11-18-41-31/h10-11,16,18,26-30,33-34,37,46,49H,4-9,12-15,17,19-25H2,1-3H3,(H2,40,42)(H,43,50)/t30-,33-,34-,37+/m0/s1
DMRV4UL CS CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@@H](CC2=CSC(=N2)N)CC(=O)N(CC3CCCCC3)CC(=O)N(C)CCC4=CC=CC=N4)O)O
DMRV4UL IK RTFZIRGGIOYLOO-KGVCAXOZSA-N
DMRV4UL IU (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N-[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]-N'-(cyclohexylmethyl)-N'-[2-[methyl(2-pyridin-2-ylethyl)amino]-2-oxoethyl]butanediamide
DMRV4UL DE Hypertension
DMUOPBF ID DMUOPBF
DMUOPBF DN BILD-1263
DMUOPBF HS Terminated
DMUOPBF CP Bio-Mega Research Division
DMUOPBF DT Small molecular drug
DMUOPBF PC 513004
DMUOPBF MW 917.2
DMUOPBF FM C51H76N6O9
DMUOPBF IC InChI=1S/C51H76N6O9/c1-33(2)40(56(9)47(64)36(28-34-20-12-10-13-21-34)29-35-22-14-11-15-23-35)44(61)54-41(50(6,7)8)45(62)53-38(30-39(59)57-26-18-19-27-57)43(60)55-42(51(48(65)66)24-16-17-25-51)46(63)52-37(32-58)31-49(3,4)5/h10-15,20-23,33,36-38,40-42,58H,16-19,24-32H2,1-9H3,(H,52,63)(H,53,62)(H,54,61)(H,55,60)(H,65,66)/t37-,38-,40-,41+,42+/m0/s1
DMUOPBF CS CC(C)[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)(C)C)CO)C2(CCCC2)C(=O)O)C(C)(C)C)N(C)C(=O)C(CC3=CC=CC=C3)CC4=CC=CC=C4
DMUOPBF IK ZEZGINAYPYMJJU-HOMVEOSBSA-N
DMUOPBF IU 1-[(1S)-1-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzyl-3-phenylpropanoyl)-methylamino]-3-methylbutanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[[(2S)-1-hydroxy-4,4-dimethylpentan-2-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMUOPBF DE Herpes simplex virus infection
DMR01WE ID DMR01WE
DMR01WE DN BILD-1351
DMR01WE HS Terminated
DMR01WE SN BILD-1351-SE
DMR01WE CP Bio-Mega Research Division
DMR01WE DT Small molecular drug
DMR01WE PC 5478827
DMR01WE MW 705
DMR01WE FM C39H68N4O7
DMR01WE IC InChI=1S/C39H68N4O7/c1-13-27(36(4,5)6)40-33(47)31(39(34(48)49)19-14-15-20-39)42-32(46)25(22-28(45)37(7,8)9)21-26(44)30(38(10,11)12)43-35(50)41-29-23(2)17-16-18-24(29)3/h23-25,27,29-31H,13-22H2,1-12H3,(H,40,47)(H,42,46)(H,48,49)(H2,41,43,50)/t23-,24+,25-,27+,29?,30+,31+/m0/s1
DMR01WE CS CC[C@H](C(C)(C)C)NC(=O)[C@H](C1(CCCC1)C(=O)O)NC(=O)[C@@H](CC(=O)[C@H](C(C)(C)C)NC(=O)NC2[C@@H](CCC[C@@H]2C)C)CC(=O)C(C)(C)C
DMR01WE IK BICMJCLCIQRONK-CVXWQFLKSA-N
DMR01WE IU 1-[(1S)-1-[[(2R,5S)-5-[[(2S,6R)-2,6-dimethylcyclohexyl]carbamoylamino]-2-(3,3-dimethyl-2-oxobutyl)-6,6-dimethyl-4-oxoheptanoyl]amino]-2-[[(3R)-2,2-dimethylpentan-3-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMR01WE DE Herpes simplex virus infection
DMZMUG2 ID DMZMUG2
DMZMUG2 DN BILD-1357
DMZMUG2 HS Terminated
DMZMUG2 SN BILD 1357; AC1LAKBO; 1-[[2-(2-{2-[(2-Benzyl-4-phenyl-butyryl)-methyl-amino]-3-methyl-butyrylamino}-3,3-dimethyl-butyrylamino)-4-oxo-4-pyrrolidin-1-yl-butyrylamino]-(1-ethyl-2,2-dimethyl-propylcarbamoyl)-methyl]-cyclopentanecarboxylic acid; 1-[(1S)-1-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzyl-4-phenylbutanoyl)-methylamino]-3-methylbutanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[[(3R)-2,2-dimethylpentan-3-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMZMUG2 CP Bio-Mega Research Division
DMZMUG2 DT Small molecular drug
DMZMUG2 PC 9832760
DMZMUG2 MW 901.2
DMZMUG2 FM C51H76N6O8
DMZMUG2 IC InChI=1S/C51H76N6O8/c1-11-38(49(4,5)6)53-46(62)42(51(48(64)65)26-18-19-27-51)55-43(59)37(32-39(58)57-28-20-21-29-57)52-45(61)41(50(7,8)9)54-44(60)40(33(2)3)56(10)47(63)36(30-34-22-14-12-15-23-34)31-35-24-16-13-17-25-35/h12-17,22-25,33,36-38,40-42H,11,18-21,26-32H2,1-10H3,(H,52,61)(H,53,62)(H,54,60)(H,55,59)(H,64,65)/t37-,38+,40-,41+,42+/m0/s1
DMZMUG2 CS CC[C@H](C(C)(C)C)NC(=O)[C@H](C1(CCCC1)C(=O)O)NC(=O)[C@H](CC(=O)N2CCCC2)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)C(CC3=CC=CC=C3)CC4=CC=CC=C4
DMZMUG2 IK QRACUPFHILQVKO-ZEIRWQBWSA-N
DMZMUG2 IU 1-[(1S)-1-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-benzyl-3-phenylpropanoyl)-methylamino]-3-methylbutanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[[(3R)-2,2-dimethylpentan-3-yl]amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMZMUG2 DE Herpes simplex virus infection
DMAU5WL ID DMAU5WL
DMAU5WL DN BILD-733
DMAU5WL HS Terminated
DMAU5WL CP Boehringer Ingelheim Corp
DMAU5WL DT Small molecular drug
DMAU5WL PC 101684726
DMAU5WL MW 827.1
DMAU5WL FM C44H70N6O9
DMAU5WL IC InChI=1S/C44H70N6O9/c1-28(2)34(49(9)32(52)20-19-29-17-11-10-12-18-29)38(55)47-35(43(6,7)8)39(56)46-31(25-33(53)50-23-15-16-24-50)37(54)48-36(44(41(58)59)21-13-14-22-44)40(57)45-30(27-51)26-42(3,4)5/h10-12,17-18,28,30-31,34-36,51H,13-16,19-27H2,1-9H3,(H,45,57)(H,46,56)(H,47,55)(H,48,54)(H,58,59)/t30?,31-,34-,35+,36+/m0/s1
DMAU5WL CS CC(C)[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)N1CCCC1)C(=O)N[C@H](C(=O)NC(CC(C)(C)C)CO)C2(CCCC2)C(=O)O)C(C)(C)C)N(C)C(=O)CCC3=CC=CC=C3
DMAU5WL IK KEQHTXSUCBEFIM-GSKLOGINSA-N
DMAU5WL IU 1-[(1S)-1-[[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-3-methyl-2-[methyl(3-phenylpropanoyl)amino]butanoyl]amino]butanoyl]amino]-4-oxo-4-pyrrolidin-1-ylbutanoyl]amino]-2-[(1-hydroxy-4,4-dimethylpentan-2-yl)amino]-2-oxoethyl]cyclopentane-1-carboxylic acid
DMAU5WL DE Herpes simplex virus infection
DM9X1DZ ID DM9X1DZ
DM9X1DZ DN BIMG80
DM9X1DZ HS Terminated
DM9X1DZ CP Boehringer Ingelheim Corp
DM9X1DZ PC 9866050
DM9X1DZ MW 406.5
DM9X1DZ FM C25H27FN2O2
DM9X1DZ IC InChI=1S/C25H27FN2O2/c1-30-22-10-11-24-23(15-22)20(16-27-24)14-18-4-2-12-28(17-18)13-3-5-25(29)19-6-8-21(26)9-7-19/h4,6-11,15-16,27H,2-3,5,12-14,17H2,1H3
DM9X1DZ CS COC1=CC2=C(C=C1)NC=C2CC3=CCCN(C3)CCCC(=O)C4=CC=C(C=C4)F
DM9X1DZ IK CIPFPNCFILKTBF-UHFFFAOYSA-N
DM9X1DZ IU 1-(4-fluorophenyl)-4-[5-[(5-methoxy-1H-indol-3-yl)methyl]-3,6-dihydro-2H-pyridin-1-yl]butan-1-one
DM9X1DZ DE Psychotic disorder
DMKNS10 ID DMKNS10
DMKNS10 DN BIPHALIN
DMKNS10 HS Terminated
DMKNS10 SN Biphalin; (Tyr-ala-gly-phe-NH2)2; D-Enk-O; Dala(2); D-ENK; Bis(tyr-ala-gly-phenh2)hydrazide; CHEMBL200199; 83916-01-2; (Tyrosyl-alanyl-glycyl-phenylalaninamide)dimer; Bis(tyrosyl-alanyl-glycyl-phenylalaninamide)hydrazide; L-Phenylalanine, N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-, 2-(N-(N-(N-L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)hydrazide; enkephalin dimer; AC1NUPQ3; BDBM21014; DTXSID80232802; ZINC150345473; LS-187519; LS-186863
DMKNS10 DT Small molecular drug
DMKNS10 PC 5487663
DMKNS10 MW 909
DMKNS10 FM C46H56N10O10
DMKNS10 IC InChI=1S/C46H56N10O10/c1-27(51-43(63)35(47)21-31-13-17-33(57)18-14-31)41(61)49-25-39(59)53-37(23-29-9-5-3-6-10-29)45(65)55-56-46(66)38(24-30-11-7-4-8-12-30)54-40(60)26-50-42(62)28(2)52-44(64)36(48)22-32-15-19-34(58)20-16-32/h3-20,27-28,35-38,57-58H,21-26,47-48H2,1-2H3,(H,49,61)(H,50,62)(H,51,63)(H,52,64)(H,53,59)(H,54,60)(H,55,65)(H,56,66)/t27-,28-,35+,36+,37+,38+/m1/s1
DMKNS10 CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMKNS10 IK DESSEGDLRYOPTJ-VRANXALZSA-N
DMKNS10 IU (2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMKNS10 CA CAS 83916-01-2
DMKRBL2 ID DMKRBL2
DMKRBL2 DN Bisbenzimide
DMKRBL2 HS Terminated
DMKRBL2 SN Hoechst 33342; 23491-52-3; Bisbenzimide; hoechst33342; UNII-99KZS6CNZX; Ho 342; 2'-(4-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-1H,1'H-2,5'-bibenzo[d]imidazole; EINECS 245-691-1; 99KZS6CNZX; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole; CHEMBL343002; CHEBI:51232; 2'-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole; 2'-(4'-Ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bis-1H-benzimidazole trihydrochloride trihydrate
DMKRBL2 DT Small molecular drug
DMKRBL2 PC 1464
DMKRBL2 MW 452.6
DMKRBL2 FM C27H28N6O
DMKRBL2 IC InChI=1S/C27H28N6O/c1-3-34-21-8-4-18(5-9-21)26-28-22-10-6-19(16-24(22)30-26)27-29-23-11-7-20(17-25(23)31-27)33-14-12-32(2)13-15-33/h4-11,16-17H,3,12-15H2,1-2H3,(H,28,30)(H,29,31)
DMKRBL2 CS CCOC1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C4=NC5=C(N4)C=C(C=C5)N6CCN(CC6)C
DMKRBL2 IK PRDFBSVERLRRMY-UHFFFAOYSA-N
DMKRBL2 IU 2-(4-ethoxyphenyl)-6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazole
DMKRBL2 CA CAS 23491-52-3
DMKRBL2 CB CHEBI:51232
DMKRBL2 DE Solid tumour/cancer
DM0DO4S ID DM0DO4S
DM0DO4S DN Bivatuzumab mertansine
DM0DO4S HS Terminated
DM0DO4S SN BIWI-1; Bivatuzumab-DM1
DM0DO4S CP Boehringer Ingelheim International GmbH
DM0DO4S DT Antibody
DM0DO4S DE Solid tumour/cancer
DM9IQR6 ID DM9IQR6
DM9IQR6 DN BK-218
DM9IQR6 HS Terminated
DM9IQR6 SN 7-[(3-Chloroisoxazol-5-yl)acetamido]-3-[[(1-methyl-1H-tetrazol-5-yl)thiomethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid sodium salt dihydrate; 7-[2-(3-Chloroisoxazol-5-yl)acetamido]-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid sodium salt dihydrate
DM9IQR6 DT Small molecular drug
DM9IQR6 PC 23666181
DM9IQR6 MW 493.9
DM9IQR6 FM C15H13ClN7NaO5S2
DM9IQR6 IC InChI=1S/C15H14ClN7O5S2.Na/c1-22-15(18-20-21-22)30-5-6-4-29-13-10(12(25)23(13)11(6)14(26)27)17-9(24)3-7-2-8(16)19-28-7;/h2,10,13H,3-5H2,1H3,(H,17,24)(H,26,27);/q;+1/p-1/t10-,13-;/m1./s1
DM9IQR6 CS CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CC4=CC(=NO4)Cl)SC2)C(=O)[O-].[Na+]
DM9IQR6 IK XQPMNRFOIDADDS-HTMVYDOJSA-M
DM9IQR6 IU sodium;(6R,7R)-7-[[2-(3-chloro-1,2-oxazol-5-yl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DM9IQR6 CA CAS 110008-56-5
DM9IQR6 DE Bacterial infection
DMGDTLX ID DMGDTLX
DMGDTLX DN BL-1872
DMGDTLX HS Terminated
DMGDTLX CP Bioglan Pharmaceuticals Co
DMGDTLX DE Pain
DMKITQN ID DMKITQN
DMKITQN DN BM-13677
DMKITQN HS Terminated
DMKITQN SN BM-13677; BM 13677; 129393-59-5; BM 13,677; 2-((3-Phenylpropoxy)imino)butanoic acid; Butanoic acid, 2-((3-phenylpropoxy)imino)-
DMKITQN CP Boehringer Mannheim GmbH
DMKITQN DT Small molecular drug
DMKITQN PC 5486935
DMKITQN MW 235.28
DMKITQN FM C13H17NO3
DMKITQN IC InChI=1S/C13H17NO3/c1-2-12(13(15)16)14-17-10-6-9-11-7-4-3-5-8-11/h3-5,7-8H,2,6,9-10H2,1H3,(H,15,16)/b14-12-
DMKITQN CS CC/C(=N/OCCCC1=CC=CC=C1)/C(=O)O
DMKITQN IK TVHDNHNLJMQXMI-OWBHPGMISA-N
DMKITQN IU (2Z)-2-(3-phenylpropoxyimino)butanoic acid
DMKITQN DE Diabetic complication
DMWDRI0 ID DMWDRI0
DMWDRI0 DN BMS-180560
DMWDRI0 HS Terminated
DMWDRI0 SN CHEMBL2021417
DMWDRI0 CP Bristol-Myers Squibb Co
DMWDRI0 DT Small molecular drug
DMWDRI0 PC 9891811
DMWDRI0 MW 475.9
DMWDRI0 FM C24H22ClN7O2
DMWDRI0 IC InChI=1S/C24H22ClN7O2/c1-2-3-11-20-26-22(25)21(24(33)34)32(20)14-15-7-6-10-18-16(15)12-13-31(18)19-9-5-4-8-17(19)23-27-29-30-28-23/h4-10,12-13H,2-3,11,14H2,1H3,(H,33,34)(H,27,28,29,30)
DMWDRI0 CS CCCCC1=NC(=C(N1CC2=C3C=CN(C3=CC=C2)C4=CC=CC=C4C5=NNN=N5)C(=O)O)Cl
DMWDRI0 IK AIGVXGCHRIOQNR-UHFFFAOYSA-N
DMWDRI0 IU 2-butyl-5-chloro-3-[[1-[2-(2H-tetrazol-5-yl)phenyl]indol-4-yl]methyl]imidazole-4-carboxylic acid
DMWDRI0 DE Hypertension
DM1Y75C ID DM1Y75C
DM1Y75C DN BMS-181184
DM1Y75C HS Terminated
DM1Y75C SN Pradimicin derivative; BMY 181184; BMY-28864
DM1Y75C CP Bristol-Myers Squibb Co
DM1Y75C DT Small molecular drug
DM1Y75C PC 122695
DM1Y75C MW 843.7
DM1Y75C FM C39H41NO20
DM1Y75C IC InChI=1S/C39H41NO20/c1-10-4-16-23(30(49)20(10)36(53)40-17(8-41)37(54)55)22-14(7-15-24(31(22)50)27(46)13-5-12(56-3)6-18(42)21(13)26(15)45)28(47)34(16)59-39-33(52)35(25(44)11(2)58-39)60-38-32(51)29(48)19(43)9-57-38/h4-7,11,17,19,25,28-29,32-35,38-39,41-44,47-52H,8-9H2,1-3H3,(H,40,53)(H,54,55)/t11?,17?,19?,25?,28?,29?,32?,33?,34-,35?,38?,39?/m0/s1
DM1Y75C CS CC1C(C(C(C(O1)O[C@@H]2C(C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(CO)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)OC7C(C(C(CO7)O)O)O)O
DM1Y75C IK AXPBRQZJFXIYTD-PWEAUJHISA-N
DM1Y75C IU 2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxypropanoic acid
DM1Y75C DE Fungal infection
DMYWI04 ID DMYWI04
DMYWI04 DN BMS-181885
DMYWI04 HS Terminated
DMYWI04 SN 3-[3-[3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-ylamino]-4-methyl-3-cyclobutene-1,2-dione
DMYWI04 PC 153988
DMYWI04 MW 460.5
DMYWI04 FM C25H28N6O3
DMYWI04 IC InChI=1S/C25H28N6O3/c1-16-22(24(33)23(16)32)29-18-5-6-20-19(12-18)17(13-27-20)4-3-7-30-8-10-31(11-9-30)25-21(34-2)14-26-15-28-25/h5-6,12-15,27,29H,3-4,7-11H2,1-2H3
DMYWI04 CS CC1=C(C(=O)C1=O)NC2=CC3=C(C=C2)NC=C3CCCN4CCN(CC4)C5=NC=NC=C5OC
DMYWI04 IK HCXROGVQIBVJTA-UHFFFAOYSA-N
DMYWI04 IU 3-[[3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indol-5-yl]amino]-4-methylcyclobut-3-ene-1,2-dione
DMYWI04 CA CAS 165250-47-5
DMYWI04 DE Migraine
DMEDLHG ID DMEDLHG
DMEDLHG DN BMS-182193
DMEDLHG HS Terminated
DMEDLHG CP Bristol-Myers Squibb Co
DMEDLHG PC 447617
DMEDLHG MW 543.7
DMEDLHG FM C30H45N3O6
DMEDLHG IC InChI=1S/C30H45N3O6/c1-29(2,3)38-27(36)32-23(17-21-13-9-7-10-14-21)25(34)19-31-20-26(35)24(18-22-15-11-8-12-16-22)33-28(37)39-30(4,5)6/h7-16,23-26,31,34-35H,17-20H2,1-6H3,(H,32,36)(H,33,37)/t23-,24-,25+,26+/m0/s1
DMEDLHG CS CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CNC[C@H]([C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)O)O
DMEDLHG IK KKRYDPVDJYCEER-QEGGNFSNSA-N
DMEDLHG IU tert-butyl N-[(2S,3R)-3-hydroxy-4-[[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutyl]amino]-1-phenylbutan-2-yl]carbamate
DMEDLHG CA CAS 161302-38-1
DMEDLHG DE Human immunodeficiency virus infection
DMO7C09 ID DMO7C09
DMO7C09 DN BMS-182566
DMO7C09 HS Terminated
DMO7C09 CP Bristol-Myers Squibb AG
DMO7C09 DE Solid tumour/cancer
DM0K4DZ ID DM0K4DZ
DM0K4DZ DN BMS-182657
DM0K4DZ HS Terminated
DM0K4DZ CP Bristol-Myers Squibb Co
DM0K4DZ PC 9801007
DM0K4DZ MW 398.5
DM0K4DZ FM C21H22N2O4S
DM0K4DZ IC InChI=1S/C21H22N2O4S/c24-19(25)13-23-17-9-5-4-8-15(17)10-11-16(21(23)27)22-20(26)18(28)12-14-6-2-1-3-7-14/h1-9,16,18,28H,10-13H2,(H,22,26)(H,24,25)/t16-,18-/m0/s1
DM0K4DZ CS C1CC2=CC=CC=C2N(C(=O)[C@H]1NC(=O)[C@H](CC3=CC=CC=C3)S)CC(=O)O
DM0K4DZ IK TYXFDFMUHPWCDX-WMZOPIPTSA-N
DM0K4DZ IU 2-[(3S)-2-oxo-3-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid
DM0K4DZ DE Cardiovascular disease
DM5PG6C ID DM5PG6C
DM5PG6C DN BMS-182874
DM5PG6C HS Terminated
DM5PG6C SN BMS-182874; Bms 182874; 5-Ddins; 153042-42-3; CHEMBL267458; 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide; 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-; Tocris-1441; AC1L3UAG; SCHEMBL802730; ZINC5803; CHEBI:92993; DTXSID60165205; BDBM50034435; NCGC00025164-01; LS-173440; L009159; BRD-K56509348-003-01-3; 5-Dimethylamino-naphthalene-1-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide; 5-Dimethylamino-naphthalene-1-sulfonic acid (3,4-dimethyl-2,3-dihydro-oxazol-5-yl)-amide
DM5PG6C DT Small molecular drug
DM5PG6C PC 122272
DM5PG6C MW 345.4
DM5PG6C FM C17H19N3O3S
DM5PG6C IC InChI=1S/C17H19N3O3S/c1-11-12(2)18-23-17(11)19-24(21,22)16-10-6-7-13-14(16)8-5-9-15(13)20(3)4/h5-10,19H,1-4H3
DM5PG6C CS CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC3=C2C=CC=C3N(C)C
DM5PG6C IK MJRGSRRZKSJHOE-UHFFFAOYSA-N
DM5PG6C IU 5-(dimethylamino)-N-(3,4-dimethyl-1,2-oxazol-5-yl)naphthalene-1-sulfonamide
DM5PG6C CA CAS 153042-42-3
DM5PG6C CB CHEBI:92993
DM5PG6C DE Hypertension
DMTA7O8 ID DMTA7O8
DMTA7O8 DN BMS-185857
DMTA7O8 HS Terminated
DMTA7O8 CP Bristol-Myers Squibb AG
DMTA7O8 DE Solid tumour/cancer
DMKZ3PW ID DMKZ3PW
DMKZ3PW DN BMS-186318
DMKZ3PW HS Terminated
DMKZ3PW SN BMS-186318; BMS 186318; 161302-40-5; 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3-((4-(2-(4-morpholinyl)-2-oxoethoxy)phenyl)methyl)-11-oxo-9-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S,4R,8R,9S)-; BMS-186318 analog 19; 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3-[[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-11-oxo-9-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S,4R,8R,9S)-; tert-butyl N-[(1S,2R)-1-benzyl-3-[[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4
DMKZ3PW CP Bristol-Myers Squibb Co
DMKZ3PW DT Small molecular drug
DMKZ3PW PC 65024
DMKZ3PW MW 686.8
DMKZ3PW FM C36H54N4O9
DMKZ3PW IC InChI=1S/C36H54N4O9/c1-35(2,3)48-33(44)38-28(20-25-10-8-7-9-11-25)30(41)22-37-23-31(42)29(39-34(45)49-36(4,5)6)21-26-12-14-27(15-13-26)47-24-32(43)40-16-18-46-19-17-40/h7-15,28-31,37,41-42H,16-24H2,1-6H3,(H,38,44)(H,39,45)/t28-,29-,30+,31+/m0/s1
DMKZ3PW CS CC(C)(C)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CNC[C@H]([C@H](CC2=CC=C(C=C2)OCC(=O)N3CCOCC3)NC(=O)OC(C)(C)C)O)O
DMKZ3PW IK OQHZMGOXOOOFEE-SYQUUIDJSA-N
DMKZ3PW IU tert-butyl N-[(2S,3R)-3-hydroxy-4-[[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[4-(2-morpholin-4-yl-2-oxoethoxy)phenyl]butyl]amino]-1-phenylbutan-2-yl]carbamate
DMKZ3PW CA CAS 161302-40-5
DMKZ3PW DE Human immunodeficiency virus-1 infection
DMV3B5Y ID DMV3B5Y
DMV3B5Y DN BMS-189664
DMV3B5Y HS Terminated
DMV3B5Y SN N-(1-Amidinopiperidin-4-ylmethyl)-1-[N-(methylsulfonyl)-D-phenylalanyl]-L-prolinamide
DMV3B5Y DT Small molecular drug
DMV3B5Y PC 9869699
DMV3B5Y MW 478.6
DMV3B5Y FM C22H34N6O4S
DMV3B5Y IC InChI=1S/C22H34N6O4S/c1-33(31,32)26-18(14-16-6-3-2-4-7-16)21(30)28-11-5-8-19(28)20(29)25-15-17-9-12-27(13-10-17)22(23)24/h2-4,6-7,17-19,26H,5,8-15H2,1H3,(H3,23,24)(H,25,29)/t18-,19+/m1/s1
DMV3B5Y CS CS(=O)(=O)N[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)NCC3CCN(CC3)C(=N)N
DMV3B5Y IK UCVAQBJLJIKTFJ-MOPGFXCFSA-N
DMV3B5Y IU (2S)-N-[(1-carbamimidoylpiperidin-4-yl)methyl]-1-[(2R)-2-(methanesulfonamido)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMV3B5Y CA CAS 162166-80-5
DMV3B5Y DE Myocardial infarction
DMMBTU6 ID DMMBTU6
DMMBTU6 DN BMS-210285
DMMBTU6 HS Terminated
DMMBTU6 SN UNII-WS7S13Q9RH; WS7S13Q9RH; CHEMBL60116; BMS-210285; 344607-69-8; SCHEMBL13550990; BDBM50073046; Methanesulfonamide, N-(5-((1R)-2-(((1R)-2-(3-chlorophenyl)-1-(4-(difluoromethoxy)phenyl)ethyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)-; N-(5-{(R)-2-[(R)-2-(3-Chloro-phenyl)-1-(4-difluoromethoxy-phenyl)-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methanesulfonamide
DMMBTU6 CP Bristol-Myers Squibb Co
DMMBTU6 DT Small molecular drug
DMMBTU6 PC 9828292
DMMBTU6 MW 527
DMMBTU6 FM C24H25ClF2N2O5S
DMMBTU6 IC InChI=1S/C24H25ClF2N2O5S/c1-35(32,33)29-21-13-17(7-10-22(21)30)23(31)14-28-20(12-15-3-2-4-18(25)11-15)16-5-8-19(9-6-16)34-24(26)27/h2-11,13,20,23-24,28-31H,12,14H2,1H3/t20-,23+/m1/s1
DMMBTU6 CS CS(=O)(=O)NC1=C(C=CC(=C1)[C@H](CN[C@H](CC2=CC(=CC=C2)Cl)C3=CC=C(C=C3)OC(F)F)O)O
DMMBTU6 IK DSEGFUSAJVUFLK-OFNKIYASSA-N
DMMBTU6 IU N-[5-[(1R)-2-[[(1R)-2-(3-chlorophenyl)-1-[4-(difluoromethoxy)phenyl]ethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide
DMMBTU6 CA CAS 344607-69-8
DMMBTU6 DE Type-2 diabetes
DME20VP ID DME20VP
DME20VP DN BMS-433771
DME20VP HS Terminated
DME20VP SN AIDS161903; Bms 433771; 1-cyclopropyl-3-[[1-(3-hydroxypropyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one; 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one
DME20VP CP Bristol-Myers Squibb
DME20VP DT Small molecular drug
DME20VP PC 6478034
DME20VP MW 377.4
DME20VP FM C21H23N5O2
DME20VP IC InChI=1S/C21H23N5O2/c27-12-4-3-11-24-17-6-2-1-5-16(17)23-20(24)14-25-19-13-22-10-9-18(19)26(21(25)28)15-7-8-15/h1-2,5-6,9-10,13,15,27H,3-4,7-8,11-12,14H2
DME20VP CS C1CC1N2C3=C(C=NC=C3)N(C2=O)CC4=NC5=CC=CC=C5N4CCCCO
DME20VP IK KSHJXDWYTZJUEI-UHFFFAOYSA-N
DME20VP IU 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one
DME20VP CA CAS 543700-68-1
DME20VP DE Respiratory syncytial virus infection
DMY7ZRA ID DMY7ZRA
DMY7ZRA DN BMS-605339
DMY7ZRA HS Terminated
DMY7ZRA SN NS3 protease inhibitor (hepatitis C virus infection), BMS
DMY7ZRA CP Bristol-Myers Squibb Co
DMY7ZRA PC 46862685
DMY7ZRA MW 713.8
DMY7ZRA FM C35H47N5O9S
DMY7ZRA IC InChI=1S/C35H47N5O9S/c1-9-21-18-35(21,31(43)39-50(45,46)24-11-12-24)38-28(41)26-17-23(48-29-25-13-10-22(47-8)16-20(25)14-15-36-29)19-40(26)30(42)27(33(2,3)4)37-32(44)49-34(5,6)7/h9-10,13-16,21,23-24,26-27H,1,11-12,17-19H2,2-8H3,(H,37,44)(H,38,41)(H,39,43)/t21-,23-,26+,27-,35-/m1/s1
DMY7ZRA CS CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=CC5=C4C=CC(=C5)OC)NC(=O)OC(C)(C)C
DMY7ZRA IK IYWRCNFZPNEADN-CXODAYGWSA-N
DMY7ZRA IU tert-butyl N-[(2S)-1-[(2S,4R)-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]-4-(6-methoxyisoquinolin-1-yl)oxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
DMY7ZRA CA CAS 630417-82-2
DMY7ZRA DE Hepatitis C virus infection
DMDPJ8M ID DMDPJ8M
DMDPJ8M DN BMY-20844
DMDPJ8M HS Terminated
DMDPJ8M SN Bmy-20844; 124886-01-7; UNII-ALR3F45M10; CHEMBL88583; ALR3F45M10; 1,3-Dihydro-7,8-dimethyl-2H-imidazo(4,5-b)quinolin-2-one; 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one; 2H-Imidazo[4,5-b]quinolin-2-one,1,3-dihydro-7,8-dimethyl-; 2H-Imidazo[4,5-b]quinolin-2-one, 1,3-dihydro-7,8-dimethyl-; 2H-Imidazo(4,5-b)quinolin-2-one, 1,3-dihydro-7,8-dimethyl-; AC1NUPC3; ACMC-1C2JD; SCHEMBL2457579; 7,8-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one; CTK4B4100; DTXSID40154516; ODCKPUDNMNCWMR-UHFFFAOYSA-N; BDBM50000925
DMDPJ8M DT Small molecular drug
DMDPJ8M PC 5487281
DMDPJ8M MW 213.23
DMDPJ8M FM C12H11N3O
DMDPJ8M IC InChI=1S/C12H11N3O/c1-6-3-4-9-8(7(6)2)5-10-11(13-9)15-12(16)14-10/h3-5H,1-2H3,(H2,13,14,15,16)
DMDPJ8M CS CC1=C(C2=CC3=C(NC(=O)N3)N=C2C=C1)C
DMDPJ8M IK ODCKPUDNMNCWMR-UHFFFAOYSA-N
DMDPJ8M IU 7,8-dimethyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMDPJ8M CA CAS 124886-01-7
DMZFTLK ID DMZFTLK
DMZFTLK DN BMY-22089
DMZFTLK HS Terminated
DMZFTLK SN (4R,6S)-6-[4,4-Bis(4-fluorophenyl)-3-(1-methyl-1H-tetrazol-5-yl)-1(E),3-butadienyl]-4-hydroxytetrahydropyran-2-one
DMZFTLK DT Small molecular drug
DMZFTLK PC 9932838
DMZFTLK MW 438.4
DMZFTLK FM C23H20F2N4O3
DMZFTLK IC InChI=1S/C23H20F2N4O3/c1-29-23(26-27-28-29)20(11-10-19-12-18(30)13-21(31)32-19)22(14-2-6-16(24)7-3-14)15-4-8-17(25)9-5-15/h2-11,18-19,30H,12-13H2,1H3/b11-10+/t18-,19-/m1/s1
DMZFTLK CS CN1C(=NN=N1)C(=C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)/C=C/[C@@H]4C[C@H](CC(=O)O4)O
DMZFTLK IK VIMMECPCYZXUCI-MMKWGKFASA-N
DMZFTLK IU (4R,6S)-6-[(1E)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one
DMZFTLK CA CAS 118845-59-3
DMZFTLK DE Hyperlipidaemia
DM2TF9P ID DM2TF9P
DM2TF9P DN BMY-40062
DM2TF9P HS Terminated
DM2TF9P SN 1-(tert-Butyl)-7-(1R,4R-2,5-diazabicyclo[2.2.1]hept-2-yl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
DM2TF9P DT Small molecular drug
DM2TF9P PC 163995
DM2TF9P MW 360.4
DM2TF9P FM C18H21FN4O3
DM2TF9P IC InChI=1S/C18H21FN4O3/c1-18(2,3)23-8-12(17(25)26)14(24)11-5-13(19)16(21-15(11)23)22-7-9-4-10(22)6-20-9/h5,8-10,20H,4,6-7H2,1-3H3,(H,25,26)/t9-,10-/m1/s1
DM2TF9P CS CC(C)(C)N1C=C(C(=O)C2=CC(=C(N=C21)N3C[C@H]4C[C@@H]3CN4)F)C(=O)O
DM2TF9P IK KNHLHFDFFDCJJR-NXEZZACHSA-N
DM2TF9P IU 1-tert-butyl-7-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
DM2TF9P CA CAS 116143-32-9
DM2TF9P DE Bacterial infection
DM8R3N0 ID DM8R3N0
DM8R3N0 DN BMY-44621
DM8R3N0 HS Terminated
DM8R3N0 SN CHEMBL304794; BDBM50290020; (S)-5-Guanidino-2-[[1-(phenylacetyl)-L-prolyl]amino]pentanal; (S)-1-Phenylacetyl-pyrrolidine-2-carboxylic acid ((S)-1-formyl-4-guanidino-butyl)-amide
DM8R3N0 DT Small molecular drug
DM8R3N0 PC 11740077
DM8R3N0 MW 373.4
DM8R3N0 FM C19H27N5O3
DM8R3N0 IC InChI=1S/C19H27N5O3/c20-19(21)22-10-4-8-15(13-25)23-18(27)16-9-5-11-24(16)17(26)12-14-6-2-1-3-7-14/h1-3,6-7,13,15-16H,4-5,8-12H2,(H,23,27)(H4,20,21,22)/t15-,16-/m0/s1
DM8R3N0 CS C1C[C@H](N(C1)C(=O)CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C=O
DM8R3N0 IK FWMLVCYBCSOEBZ-HOTGVXAUSA-N
DM8R3N0 IU (2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-(2-phenylacetyl)pyrrolidine-2-carboxamide
DMRHCEG ID DMRHCEG
DMRHCEG DN BMY-7378
DMRHCEG HS Terminated
DMRHCEG SN Bmy-7378; UNII-08EI0K81OL; CHEMBL13647; 08EI0K81OL; 8-(2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl)-8-azaspiro[4.5]decane-7,9-dione; BMY7378; 8-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-8-azaspiro(4.5)decane-7,9-dione; 21102-94-3; 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione; 8-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-8-azaspiro[4.5]decane-7,9-dione; 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione; 8-Azaspiro(4.5)decane-7,9-dione, 8-(2-(4-(2-methox
DMRHCEG DT Small molecular drug
DMRHCEG PC 2419
DMRHCEG MW 385.5
DMRHCEG FM C22H31N3O3
DMRHCEG IC InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3
DMRHCEG CS COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)CC4(CCCC4)CC3=O
DMRHCEG IK AYYCFGDXLUPJAQ-UHFFFAOYSA-N
DMRHCEG IU 8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione
DMRHCEG CA CAS 21102-94-3
DMRHCEG CB CHEBI:92539
DMTKJDS ID DMTKJDS
DMTKJDS DN BN-50726
DMTKJDS HS Terminated
DMTKJDS SN BN-50726; BN 50726; 127279-06-5; 4H-Pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine,6-(2-chlorophenyl)-9-(hexadecylsulfonyl)-7,8,9,10-tetrahydro-1-methyl-; ACMC-20c9sz; AC1L4UGJ; AC1Q6VN1; bn50726; CTK4B5547; DTXSID80155486; AKOS030566818
DMTKJDS CP Ipsen
DMTKJDS DT Small molecular drug
DMTKJDS PC 164238
DMTKJDS MW 658.4
DMTKJDS FM C34H48ClN5O2S2
DMTKJDS IC InChI=1S/C34H48ClN5O2S2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-23-44(41,42)39-22-21-28-30(25-39)43-34-32(28)33(27-19-16-17-20-29(27)35)36-24-31-38-37-26(2)40(31)34/h16-17,19-20H,3-15,18,21-25H2,1-2H3
DMTKJDS CS CCCCCCCCCCCCCCCCS(=O)(=O)N1CCC2=C(C1)SC3=C2C(=NCC4=NN=C(N43)C)C5=CC=CC=C5Cl
DMTKJDS IK XYNVFDKKFDLTPP-UHFFFAOYSA-N
DMTKJDS IU 9-(2-chlorophenyl)-14-hexadecylsulfonyl-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaene
DMTKJDS CA CAS 127279-06-5
DMTKJDS DE Nerve injury
DMU1TRQ ID DMU1TRQ
DMU1TRQ DN BN50739
DMU1TRQ HS Terminated
DMU1TRQ SN BN 50739; BN-50739; 128672-07-1; BN50739; Tetrahydro-4,7,8,10 methyl-(chloro-2-phenyl)-6-((3,4-dimethoxyphenyl)thio)methylthiocarbonyl-9-pyrido(4',3'-4,5)thieno(3,2-f)triazolo-1,2,4(4,3-a)diazepine-1,4; 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(2-((3,4-dimethoxyphenyl)thio)-1-thioxoethyl)-7,8,9,10-tetrahydro-1-methyl-; AC1L3GCW; GTPL1851; DTXSID60155969; LS-187569; LS-186919; L000670
DMU1TRQ DT Small molecular drug
DMU1TRQ PC 115002
DMU1TRQ MW 596.2
DMU1TRQ FM C28H26ClN5O2S3
DMU1TRQ IC InChI=1S/C28H26ClN5O2S3/c1-16-31-32-24-13-30-27(18-6-4-5-7-20(18)29)26-19-10-11-33(14-23(19)39-28(26)34(16)24)25(37)15-38-17-8-9-21(35-2)22(12-17)36-3/h4-9,12H,10-11,13-15H2,1-3H3
DMU1TRQ CS CC1=NN=C2N1C3=C(C4=C(S3)CN(CC4)C(=S)CSC5=CC(=C(C=C5)OC)OC)C(=NC2)C6=CC=CC=C6Cl
DMU1TRQ IK MRVWRDZEYURFSW-UHFFFAOYSA-N
DMU1TRQ IU 1-[9-(2-chlorophenyl)-3-methyl-17-thia-2,4,5,8,14-pentazatetracyclo[8.7.0.02,6.011,16]heptadeca-1(10),3,5,8,11(16)-pentaen-14-yl]-2-(3,4-dimethoxyphenyl)sulfanylethanethione
DMU1TRQ CA CAS 128672-07-1
DMU1TRQ DE Cerebral infarction
DMMZ9DY ID DMMZ9DY
DMMZ9DY DN BN-80245
DMMZ9DY HS Terminated
DMMZ9DY SN DU-1441; DU-1442
DMMZ9DY CP Institut Henri Beaufour
DMMZ9DY DT Small molecular drug
DMMZ9DY PC 9863779
DMMZ9DY MW 362.4
DMMZ9DY FM C21H18N2O4
DMMZ9DY IC InChI=1S/C21H18N2O4/c1-2-21(26)9-18(24)27-11-14-15(21)8-17-19-13(10-23(17)20(14)25)7-12-5-3-4-6-16(12)22-19/h3-8,26H,2,9-11H2,1H3
DMMZ9DY CS CCC1(CC(=O)OCC2=C1C=C3C4=NC5=CC=CC=C5C=C4CN3C2=O)O
DMMZ9DY IK PAEZRCINULFAGO-UHFFFAOYSA-N
DMMZ9DY IU 20-ethyl-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4,6,8,10,15(21)-heptaene-14,18-dione
DMMZ9DY CA CAS 186668-40-6
DMMZ9DY DE Solid tumour/cancer
DMN8FAG ID DMN8FAG
DMN8FAG DN BP4.879a
DMN8FAG HS Terminated
DMN8FAG CP Bioprojet
DMN8FAG DT Small molecular drug
DMN8FAG PC 5311254
DMN8FAG MW 298.4
DMN8FAG FM C17H22N4O
DMN8FAG IC InChI=1S/C17H22N4O/c1-20-12-7-8-13(20)10-11(9-12)18-17(22)16-14-5-3-4-6-15(14)21(2)19-16/h3-6,11-13H,7-10H2,1-2H3,(H,18,22)/t11?,12-,13+
DMN8FAG CS CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMN8FAG IK DDHAJFBBJWHSBR-YHWZYXNKSA-N
DMN8FAG IU 1-methyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]indazole-3-carboxamide
DMN8FAG DE Schizophrenia
DM3O4BG ID DM3O4BG
DM3O4BG DN BQ-518
DM3O4BG HS Terminated
DM3O4BG SN BQ 518; CHEBI:2967; CHEMBL2074702; BQ-518; AC1L9EDN; BQ518; BDBM50390984; 136554-29-5; C11589; 2-[(3R,6R,9S,12S,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-thiophen-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM3O4BG CP MSD Japan
DM3O4BG DT Small molecular drug
DM3O4BG PC 443291
DM3O4BG MW 650.7
DM3O4BG FM C32H38N6O7S
DM3O4BG IC InChI=1S/C32H38N6O7S/c1-17(2)13-21-28(41)34-22(14-18-16-33-20-8-4-3-7-19(18)20)29(42)36-23(15-26(39)40)32(45)38-11-5-9-24(38)30(43)37-27(31(44)35-21)25-10-6-12-46-25/h3-4,6-8,10,12,16-17,21-24,27,33H,5,9,11,13-15H2,1-2H3,(H,34,41)(H,35,44)(H,36,42)(H,37,43)(H,39,40)/t21-,22+,23+,24-,27+/m0/s1
DM3O4BG CS CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C3=CC=CS3)CC(=O)O)CC4=CNC5=CC=CC=C54
DM3O4BG IK KXUDUVUGZWJNHV-QEXRHJMMSA-N
DM3O4BG IU 2-[(3R,6R,9S,12S,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-thiophen-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
DM3O4BG CB CHEBI:2967
DM3O4BG DE Hypertension
DMPRNQL ID DMPRNQL
DMPRNQL DN BQ610
DMPRNQL HS Terminated
DMPRNQL SN BQ-610; 141595-53-1; BQ 610; AZEPANE-1-CARBONYL-LEU-D-TRP(FOR)-D-TRP-OH; BQ610; Hexahydroazepinocarbonyl-leu-D-trp(cho)-D-trp; Hexahydroazepinocarbonyl-leucyl-tryptophyl(cho)-tryptophan; AC1L3XIP; SCHEMBL2678706; CTK8F0466; DTXSID20161768; ZINC72190207; D-Tryptophan, N-(1-formyl-N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-; RT-011809; J-007520; (R)-2-((R)-2-((S)-2-(azepane-1-carboxamido)-4-methylpentanamido)-3-(1-formyl-1H-indol-3-yl)propanamido)-3-(1H-indol-3-yl)propanoic acid
DMPRNQL DT Small molecular drug
DMPRNQL PC 123905
DMPRNQL MW 656.8
DMPRNQL FM C36H44N6O6
DMPRNQL IC InChI=1S/C36H44N6O6/c1-23(2)17-29(40-36(48)41-15-9-3-4-10-16-41)33(44)38-30(19-25-21-42(22-43)32-14-8-6-12-27(25)32)34(45)39-31(35(46)47)18-24-20-37-28-13-7-5-11-26(24)28/h5-8,11-14,20-23,29-31,37H,3-4,9-10,15-19H2,1-2H3,(H,38,44)(H,39,45)(H,40,48)(H,46,47)/t29-,30+,31+/m0/s1
DMPRNQL CS CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C=O)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)N5CCCCCC5
DMPRNQL IK QHSRPPJQBFQWSC-OJDZSJEKSA-N
DMPRNQL IU (2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-formylindol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMPRNQL CA CAS 141595-53-1
DMGX0E1 ID DMGX0E1
DMGX0E1 DN BRL 26830A
DMGX0E1 HS Terminated
DMGX0E1 SN Brl 26830; BRL 26830A; Methyl 4-(2-((2-hydroxy-2-phenethyl)amino)propyl)benzoate-2-butanedioate; Brl-26830A; Benzoic acid, 4-(2-((2-hydroxy-2-phenylethyl)amino)propyl)-, methyl ester, (R*,R*)-(+-)-, (E)-2-butenedioate (2:1) (salt); 87857-42-9; AC1O5PHH; LS-186797; methyl 4-[(2S)-2-[[(2S)-2-hydroxy-2-phenylethyl]amino]propyl]benzoate; (E)-4-oxopent-2-enoic acid
DMGX0E1 DT Small molecular drug
DMGX0E1 PC 6438331
DMGX0E1 MW 427.5
DMGX0E1 FM C24H29NO6
DMGX0E1 IC InChI=1S/C19H23NO3.C5H6O3/c1-14(20-13-18(21)16-6-4-3-5-7-16)12-15-8-10-17(11-9-15)19(22)23-2;1-4(6)2-3-5(7)8/h3-11,14,18,20-21H,12-13H2,1-2H3;2-3H,1H3,(H,7,8)/b;3-2+/t14-,18+;/m0./s1
DMGX0E1 CS C[C@@H](CC1=CC=C(C=C1)C(=O)OC)NC[C@H](C2=CC=CC=C2)O.CC(=O)/C=C/C(=O)O
DMGX0E1 IK OIZISCUUSLPUEN-LMORPYAASA-N
DMGX0E1 IU methyl 4-[(2S)-2-[[(2S)-2-hydroxy-2-phenylethyl]amino]propyl]benzoate;(E)-4-oxopent-2-enoic acid
DMGX0E1 CA CAS 87857-42-9
DMGX0E1 DE Obesity
DMS4320 ID DMS4320
DMS4320 DN BRL 37344
DMS4320 HS Terminated
DMS4320 SN UNII-42FZ27IZLV; Brl-37344; 42FZ27IZLV; CHEMBL284782; BRL 37344; 2-(4-((2R)-2-(((2R)-2-(3-Chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)acetic acid; SB-206606; BRL37344; SB 206606; 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid; BRL-44092; GTPL567; 116049-78-6; SCHEMBL304308; CHEBI:131180; Acetic acid, (4-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-; ZINC3871771; BDBM50002133; Acetic acid, 2-(4-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)phenoxy)-
DMS4320 DT Small molecular drug
DMS4320 PC 9841972
DMS4320 MW 363.8
DMS4320 FM C19H22ClNO4
DMS4320 IC InChI=1S/C19H22ClNO4/c1-13(21-11-18(22)15-3-2-4-16(20)10-15)9-14-5-7-17(8-6-14)25-12-19(23)24/h2-8,10,13,18,21-22H,9,11-12H2,1H3,(H,23,24)/t13-,18+/m1/s1
DMS4320 CS C[C@H](CC1=CC=C(C=C1)OCC(=O)O)NC[C@@H](C2=CC(=CC=C2)Cl)O
DMS4320 IK ZGGNJJJYUVRADP-ACJLOTCBSA-N
DMS4320 IU 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid
DMS4320 CA CAS 116049-78-6
DMS4320 CB CHEBI:131180
DMBC12X ID DMBC12X
DMBC12X DN BRL-42715
DMBC12X HS Terminated
DMBC12X SN Brl 42715; Brl-42715; C6-(N1-Methyl-1,2,3-trazolylmethylene)penem; 4-Thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1-methyl-1H-1,2,3-triazol-4-yl)methylene)-7-oxo-, sodium salt, (R-(Z))-; 102209-75-6
DMBC12X CP SmithKline Beecham plc
DMBC12X DT Small molecular drug
DMBC12X PC 23705463
DMBC12X MW 286.24
DMBC12X FM C10H7N4NaO3S
DMBC12X IC InChI=1S/C10H8N4O3S.Na/c1-13-3-5(11-12-13)2-6-8(15)14-7(10(16)17)4-18-9(6)14;/h2-4,9H,1H3,(H,16,17);/q;+1/p-1/b6-2-;/t9-;/m1./s1
DMBC12X CS CN1C=C(N=N1)/C=C/2\\[C@@H]3N(C2=O)C(=CS3)C(=O)[O-].[Na+]
DMBC12X IK OMJBLZMKGVWHQP-VKVLVNHFSA-M
DMBC12X IU sodium;(5R,6Z)-6-[(1-methyltriazol-4-yl)methylidene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DMBC12X DE Bacterial infection
DMAH3Z9 ID DMAH3Z9
DMAH3Z9 DN BTS-79018
DMAH3Z9 HS Terminated
DMAH3Z9 SN CHEMBL418854; SCHEMBL6767394; BDBM50079939; L018296
DMAH3Z9 CP Abbott
DMAH3Z9 DT Small molecular drug
DMAH3Z9 PC 9909113
DMAH3Z9 MW 402.9
DMAH3Z9 FM C22H27ClN2O3
DMAH3Z9 IC InChI=1S/C22H27ClN2O3/c1-26-20-5-3-2-4-19(20)25-10-8-16(9-11-25)13-24-14-18-15-27-21-7-6-17(23)12-22(21)28-18/h2-7,12,16,18,24H,8-11,13-15H2,1H3/t18-/m0/s1
DMAH3Z9 CS COC1=CC=CC=C1N2CCC(CC2)CNC[C@H]3COC4=C(O3)C=C(C=C4)Cl
DMAH3Z9 IK QHLRKDSRGUZHSH-SFHVURJKSA-N
DMAH3Z9 IU N-[[(3S)-6-chloro-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]-1-[1-(2-methoxyphenyl)piperidin-4-yl]methanamine
DMAH3Z9 CA CAS 246517-66-8
DMAH3Z9 DE Schizophrenia
DMJDMTK ID DMJDMTK
DMJDMTK DN BU-4514N
DMJDMTK HS Terminated
DMJDMTK SN BU-4514N; BU 4514N; AC1Q6BPU; AC1L4UFU; SCHEMBL194669; 4-[(2-{2-[(5-amino-6-methyltetrahydro-2h-pyran-2-yl)oxy]propyl}-1,3,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)carbonyl]-5-hydroxy-1,2-dihydro-3h-pyrrol-3-one
DMJDMTK CP Bristol-Myers Squibb Co
DMJDMTK DT Small molecular drug
DMJDMTK PC 54704416
DMJDMTK MW 474.6
DMJDMTK FM C27H42N2O5
DMJDMTK IC InChI=1S/C27H42N2O5/c1-14-6-7-19-18(10-14)11-15(2)20(12-16(3)33-23-9-8-21(28)17(4)34-23)27(19,5)25(31)24-22(30)13-29-26(24)32/h11,14,16-21,23,31H,6-10,12-13,28H2,1-5H3,(H,29,32)/b25-24-
DMJDMTK CS CC1CCC2C(C1)C=C(C(C2(C)/C(=C/3\\C(=O)CNC3=O)/O)CC(C)OC4CCC(C(O4)C)N)C
DMJDMTK IK NKWRHFUPAYVQCE-IZHYLOQSSA-N
DMJDMTK IU (3Z)-3-[[2-[2-(5-amino-6-methyloxan-2-yl)oxypropyl]-1,3,6-trimethyl-4a,5,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]-hydroxymethylidene]pyrrolidine-2,4-dione
DMJDMTK CA CAS 151013-39-7
DMJDMTK DE Alzheimer disease
DM4OT0S ID DM4OT0S
DM4OT0S DN BU-4601A
DM4OT0S HS Terminated
DM4OT0S SN BU-4601B; BU-4601C
DM4OT0S CP Bristol-Myers Squibb Co
DM4OT0S DT Small molecular drug
DM4OT0S PC 192421
DM4OT0S MW 293.4
DM4OT0S FM C17H27NO3
DM4OT0S IC InChI=1S/C17H27NO3/c1-13(2)8-6-4-3-5-7-11-21-17(20)15-12-14(19)9-10-16(15)18/h9-10,12-13,19H,3-8,11,18H2,1-2H3
DM4OT0S CS CC(C)CCCCCCCOC(=O)C1=C(C=CC(=C1)O)N
DM4OT0S IK WQDDSULPVSBTBO-UHFFFAOYSA-N
DM4OT0S IU 8-methylnonyl 2-amino-5-hydroxybenzoate
DM4OT0S CA CAS 148915-76-8
DM4OT0S DE Asthma
DMIYPLU ID DMIYPLU
DMIYPLU DN BVT-142
DMIYPLU HS Terminated
DMIYPLU SN BVT-13; BVT-142 analogs, Biovitrum; Dual PPAR alpha/gamma agonists (type II diabetes); Dual PPAR alpha/gamma agonists (type II diabetes), Biovitrum
DMIYPLU CP Swedish Orphan Biovitrum AB
DMIYPLU DE Type-2 diabetes
DMHLUFN ID DMHLUFN
DMHLUFN DN BVT-24834
DMHLUFN HS Terminated
DMHLUFN SN BVT-1960; Fatty acid-binding protein 4 inhibitors, Biovitrum; FABP-4 inhibitors (obesity), Biovitrum
DMHLUFN CP Swedish Orphan Biovitrum AB
DMHLUFN DE Obesity
DMOZQHX ID DMOZQHX
DMOZQHX DN BVT-3498
DMOZQHX HS Terminated
DMOZQHX SN AMG-311
DMOZQHX CP Swedish Orphan Biovitrum AB
DMOZQHX PC 76849181
DMOZQHX MW 415.9
DMOZQHX FM C16H18ClN3O4S2
DMOZQHX IC InChI=1S/C16H18ClN3O4S2/c1-11-13(17)3-2-4-14(11)26(22,23)19-16-18-12(10-25-16)5-6-20-7-8-24-9-15(20)21/h2-4,10H,5-9H2,1H3,(H,18,19)
DMOZQHX CS CC1=C(C=CC=C1Cl)S(=O)(=O)NC2=NC(=CS2)CCN3CCOCC3=O
DMOZQHX IK WZFZJEPHYDDFCT-UHFFFAOYSA-N
DMOZQHX IU 3-chloro-2-methyl-N-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide
DMOZQHX CA CAS 376641-49-5
DMOZQHX DE Metabolic disorder
DMXFZWJ ID DMXFZWJ
DMXFZWJ DN BW 373U86
DMXFZWJ HS Terminated
DMXFZWJ SN BW 373U86; BW-373U86; SNC-86; CHEMBL25230; 155836-50-3; BW373U86; 4-((R)-((2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-hydroxyphenyl)methyl)-N,N-diethylbenzamide; 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide; LBLDMHBSVIVJPM-YZIHRLCOSA-N; 150428-54-9; Tocris-1663; AC1L3O2K; (+-)-4-((alpha-R*)-alpha-((2S*,5R*)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide; SCHEMBL232127; GTPL9002; CHEBI:114187; MolPort-023-276-182
DMXFZWJ DT Small molecular drug
DMXFZWJ PC 119029
DMXFZWJ MW 435.6
DMXFZWJ FM C27H37N3O2
DMXFZWJ IC InChI=1S/C27H37N3O2/c1-6-16-29-18-21(5)30(19-20(29)4)26(24-10-9-11-25(31)17-24)22-12-14-23(15-13-22)27(32)28(7-2)8-3/h6,9-15,17,20-21,26,31H,1,7-8,16,18-19H2,2-5H3/t20-,21+,26-/m1/s1
DMXFZWJ CS CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)O)N3C[C@H](N(C[C@@H]3C)CC=C)C
DMXFZWJ IK LBLDMHBSVIVJPM-YZIHRLCOSA-N
DMXFZWJ IU 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide
DMXFZWJ CA CAS 150428-54-9
DMXFZWJ CB CHEBI:114187
DMNUMDG ID DMNUMDG
DMNUMDG DN BW A4C
DMNUMDG HS Terminated
DMNUMDG SN BW4C; Bwa-4C; Bwa 4C; 106328-57-8; BW-A4C; BWA4C; CHEMBL314360; C17H17NO3; N-(E)-3-(3-Phenoxyphenyl)prop-2-enylacetohydroxamine acid; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-; N-[(E)-3-(3-Phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; Acetohydroxamine acid, N-(E)-3-(3-phenoxyphenyl)prop-2-enyl-; Acetamide, N-hydroxy-N-(3-(3-phenoxyphenyl)-2-propenyl)-, (E)-; BW-4AC; AC1O5PJ5; BW-A-4C; BW-A 4C; JMC515449 Compound 7; BDBM22334; ZINC5138195; MFCD00869694; N-(3-phenoxycinnamyl)-N-hydroxyacetamide
DMNUMDG DT Small molecular drug
DMNUMDG PC 6438354
DMNUMDG MW 283.32
DMNUMDG FM C17H17NO3
DMNUMDG IC InChI=1S/C17H17NO3/c1-14(19)18(20)12-6-8-15-7-5-11-17(13-15)21-16-9-3-2-4-10-16/h2-11,13,20H,12H2,1H3/b8-6+
DMNUMDG CS CC(=O)N(C/C=C/C1=CC(=CC=C1)OC2=CC=CC=C2)O
DMNUMDG IK CEUDWZXMLMKPNN-SOFGYWHQSA-N
DMNUMDG IU N-hydroxy-N-[(E)-3-(3-phenoxyphenyl)prop-2-enyl]acetamide
DMNUMDG CA CAS 106328-57-8
DMNUMDG DE Arthritis
DMTYCJ6 ID DMTYCJ6
DMTYCJ6 DN BW B70C
DMTYCJ6 HS Terminated
DMTYCJ6 SN BW B70C; BWB70C; BW-B 70C; 134470-38-5; BW-B70C; CHEMBL86676; CHEBI:75307; (E)-N-(3-(3-(4-Fluorophenoxy)phenyl)-1-(R,S)-methylprop-2-enyl)-N-hydroxyurea; 70C; N-[3-[3-4(-Fluorophenoxy)phenyl]-1-methyl-2-propenyl]-N-hydroxyurea; N-(3-(3-(4-Fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxyurea; Urea, N-(3-(3-(4-fluorophenoxy)phenyl)-1-methyl-2-propenyl)-N-hydroxy-; C17H17FN2O3; SR-01000075717; (e)-N-{3-[3-(4-fluorophenoxy)phenyl]-1-(r,s)-methylprop-2-enyl}-N-hydroxyurea; Lopac0_000202; BSPBio_001512; SCHEMBL2681955
DMTYCJ6 DT Small molecular drug
DMTYCJ6 PC 5353454
DMTYCJ6 MW 316.33
DMTYCJ6 FM C17H17FN2O3
DMTYCJ6 IC InChI=1S/C17H17FN2O3/c1-12(20(22)17(19)21)5-6-13-3-2-4-16(11-13)23-15-9-7-14(18)8-10-15/h2-12,22H,1H3,(H2,19,21)/b6-5+
DMTYCJ6 CS CC(/C=C/C1=CC(=CC=C1)OC2=CC=C(C=C2)F)N(C(=O)N)O
DMTYCJ6 IK UAIYNMRLUHHRMF-AATRIKPKSA-N
DMTYCJ6 IU 1-[(E)-4-[3-(4-fluorophenoxy)phenyl]but-3-en-2-yl]-1-hydroxyurea
DMTYCJ6 CA CAS 134470-38-5
DMTYCJ6 CB CHEBI:75307
DMTYCJ6 DE Asthma
DMEP9B6 ID DMEP9B6
DMEP9B6 DN BW-1003C87
DMEP9B6 HS Terminated
DMEP9B6 SN 144425-86-5; BW-1003C87; 5-(2,3,5-Trichlorophenyl)pyrimidine-2,4-diamine ethane sulfonate; Ethanesulfonic acid, compd. with 5-(2,3,5-trichlorophenyl)-2,4-pyrimidinediamine (1:1); BW 1003C87; ACMC-20n3z2; AC1L31BW; SCHEMBL15914195; CTK0H6679; DTXSID70162705; AKOS030595718; ethanesulfonic acid
DMEP9B6 CP Burroughs Wellcome Inc
DMEP9B6 DT Small molecular drug
DMEP9B6 PC 132630
DMEP9B6 MW 399.7
DMEP9B6 FM C12H13Cl3N4O3S
DMEP9B6 IC InChI=1S/C10H7Cl3N4.C2H6O3S/c11-4-1-5(8(13)7(12)2-4)6-3-16-10(15)17-9(6)14;1-2-6(3,4)5/h1-3H,(H4,14,15,16,17);2H2,1H3,(H,3,4,5)
DMEP9B6 CS CCS(=O)(=O)O.C1=C(C=C(C(=C1C2=CN=C(N=C2N)N)Cl)Cl)Cl
DMEP9B6 IK NVKJAOGJEDODFZ-UHFFFAOYSA-N
DMEP9B6 IU ethanesulfonic acid;5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine
DMEP9B6 CA CAS 144425-86-5
DMEP9B6 DE Cerebrovascular ischaemia
DMQM3P4 ID DMQM3P4
DMQM3P4 DN BW755C
DMQM3P4 HS Terminated
DMQM3P4 SN BW755C; 66000-40-6; BW-755C; UNII-6V6JF56BXO; 6V6JF56BXO; CHEMBL274642; 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; 1-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1H-pyrazol-3-amine; 1-(3-trifluoromethylphenyl)-4,5-dihydro-1H-pyrazol-3-amine; 1-(3-Trifluoromethyl-phenyl)-4,5-dihydro-1H-pyrazol-3-ylamine; 4,5-DIHYDRO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H-PYRAZOL-3-AMINE; 1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-3-amine; BW 755C; EINECS 266-051-8; AC1L2IRR; SCHEMBL2573191; CTK5C3353; DTXSID30216213
DMQM3P4 DT Small molecular drug
DMQM3P4 PC 47795
DMQM3P4 MW 229.2
DMQM3P4 FM C10H10F3N3
DMQM3P4 IC InChI=1S/C10H10F3N3/c11-10(12,13)7-2-1-3-8(6-7)16-5-4-9(14)15-16/h1-3,6H,4-5H2,(H2,14,15)
DMQM3P4 CS C1CN(N=C1N)C2=CC=CC(=C2)C(F)(F)F
DMQM3P4 IK CPXGGWXJNQSFEP-UHFFFAOYSA-N
DMQM3P4 IU 2-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-5-amine
DMQM3P4 CA CAS 66000-40-6
DMQM3P4 DE Inflammation
DMF6OY8 ID DMF6OY8
DMF6OY8 DN BW-A502U
DMF6OY8 HS Terminated
DMF6OY8 SN BW-502U83; 2-[10-(2-Hydroxyethoxy)-9-anthracenylmethylamino]-2-methyl-1,3-propanediol
DMF6OY8 DT Small molecular drug
DMF6OY8 PC 125301
DMF6OY8 MW 355.4
DMF6OY8 FM C21H25NO4
DMF6OY8 IC InChI=1S/C21H25NO4/c1-21(13-24,14-25)22-12-19-15-6-2-4-8-17(15)20(26-11-10-23)18-9-5-3-7-16(18)19/h2-9,22-25H,10-14H2,1H3
DMF6OY8 CS CC(CO)(CO)NCC1=C2C=CC=CC2=C(C3=CC=CC=C31)OCCO
DMF6OY8 IK JPCHHZXQVHSGGC-UHFFFAOYSA-N
DMF6OY8 IU 2-[[10-(2-hydroxyethoxy)anthracen-9-yl]methylamino]-2-methylpropane-1,3-diol
DMF6OY8 CA CAS 129026-48-8
DMF6OY8 DE Solid tumour/cancer
DM0P8CE ID DM0P8CE
DM0P8CE DN BX-044
DM0P8CE HS Terminated
DM0P8CE SN Plasminogen activator inhibitor inhibitors, Berlex; ZK-4044; PAI-1 inhibitors, Berlex
DM0P8CE CP Berlex Biosciences
DM0P8CE DE Thrombosis
DMPL0C9 ID DMPL0C9
DMPL0C9 DN C-202
DMPL0C9 HS Terminated
DMPL0C9 SN C-301
DMPL0C9 CP CepTor Corp
DMPL0C9 DE Epilepsy
DMJQ3WR ID DMJQ3WR
DMJQ3WR DN C-AFG
DMJQ3WR HS Terminated
DMJQ3WR SN GR-85478
DMJQ3WR CP Glaxo Wellcome plc
DMJQ3WR DE Virus infection
DM9X2D0 ID DM9X2D0
DM9X2D0 DN Calphostin C
DM9X2D0 HS Terminated
DM9X2D0 SN calphostin C; CHEMBL460433; UNII-I271P23G24; I271P23G24; CHEMBL1256495; Ucn 1028 C; UCN 1028C; BSPBio_001520; GTPL5156; SCHEMBL15185703; HSDB 7592; SRJYZPCBWDVSGO-NHCUHLMSSA-N; HMS1989L22; HMS3402L22; HMS1791L22; BDBM213748; Carbonic acid, 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxyphenyl ester; Carbonic acid, (1R)-2-(12-((2R)-2-(benzoyloxy)propyl)-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl)-1-methylethyl 4-hydroxy
DM9X2D0 DT Small molecular drug
DM9X2D0 PC 2533
DM9X2D0 MW 790.8
DM9X2D0 FM C44H38O14
DM9X2D0 IC InChI=1S/C44H38O14/c1-20(56-43(50)22-10-8-7-9-11-22)16-25-31-32-26(17-21(2)57-44(51)58-24-14-12-23(45)13-15-24)42(55-6)40(49)34-28(47)19-30(53-4)36(38(32)34)35-29(52-3)18-27(46)33(37(31)35)39(48)41(25)54-5/h7-15,18-21,45,48-49H,16-17H2,1-6H3
DM9X2D0 CS CC(CC1=C2C3=C(C(=C(C4=C3C(=C5C2=C(C(=O)C=C5OC)C(=C1OC)O)C(=CC4=O)OC)O)OC)CC(C)OC(=O)OC6=CC=C(C=C6)O)OC(=O)C7=CC=CC=C7
DM9X2D0 IK LSUTUUOITDQYNO-UHFFFAOYSA-N
DM9X2D0 IU 1-[3,10-dihydroxy-12-[2-(4-hydroxyphenoxy)carbonyloxypropyl]-2,6,7,11-tetramethoxy-4,9-dioxoperylen-1-yl]propan-2-yl benzoate
DM9X2D0 CA CAS 121263-19-2
DMZ3QHF ID DMZ3QHF
DMZ3QHF DN CB-102930
DMZ3QHF HS Terminated
DMZ3QHF SN Antimicrobials, Cubist; CB-193; CB-286; CB-432; CB-447; CB-454; CB-484; CB-545; CB-628; CB-629; TRNA synthetase inhibitors (antimicrobial); TRNA synthetase inhibitors (antimicrobial), Cubist
DMZ3QHF CP Cubist Pharmaceuticals Inc
DMZ3QHF DE Bacterial infection
DM75KBM ID DM75KBM
DM75KBM DN CB-1267
DM75KBM HS Terminated
DM75KBM CP LEO Pharma A/S
DM75KBM PC 7021558
DM75KBM MW 293.36
DM75KBM FM C16H23NO4
DM75KBM IC InChI=1S/C16H23NO4/c1-16(2,3)21-15(20)17-13(11-14(18)19)10-9-12-7-5-4-6-8-12/h4-8,13H,9-11H2,1-3H3,(H,17,20)(H,18,19)/t13-/m1/s1
DM75KBM CS CC(C)(C)OC(=O)N[C@H](CCC1=CC=CC=C1)CC(=O)O
DM75KBM IK MYWZFJXOLAXENE-CYBMUJFWSA-N
DM75KBM IU (3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoic acid
DM75KBM CA CAS 218608-83-4
DM75KBM DE Prostate cancer
DMJAGKY ID DMJAGKY
DMJAGKY DN CBR-2092
DMJAGKY HS Terminated
DMJAGKY CP Cumbre
DMJAGKY DT Small molecular drug
DMJAGKY PC 137253362
DMJAGKY MW 1205.4
DMJAGKY FM C65H81FN6O15
DMJAGKY IC InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(39-15-16-39)27-43(63(82)83)62(81)72(51)30-45(52)66/h12-14,20,26-28,30-31,33,35-36,39-41,46,53-54,58,74-78H,15-19,21-25,29H2,1-11H3,(H,68,80)(H,82,83)/b13-12+,26-20+,32-14-,67-28-/t31-,33+,35+,36+,40+,46-,53-,54+,58+,64-/m0/s1
DMJAGKY CS C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N\\N5CCC(CC5)N(C)C6(CC6)[C@@H]7CCN(C7)C8=C(C9=C(C=C(C(=O)N9C=C8F)C(=O)O)C1CC1)C)/C
DMJAGKY IK OPZFMLLAJBIKAN-OSKJXBEZSA-N
DMJAGKY IU 8-[(3R)-3-[1-[[1-[(Z)-[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-26-yl]methylideneamino]piperidin-4-yl]-methylamino]cyclopropyl]pyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid
DMJAGKY DE Bacterial infection
DMAZB1R ID DMAZB1R
DMAZB1R DN CCR5Qb
DMAZB1R HS Terminated
DMAZB1R SN HIV vaccine, Cytos Biotechnology; AlphaVaccine (HIV), Cytos; CCR5-targeting HIV vaccine, Cytos; Immunodrug vaccines (CCR5) (HIV infection), Cytos
DMAZB1R CP Cytos Biotechnology AG
DMAZB1R DT Vaccine
DMAZB1R DE Human immunodeficiency virus infection
DM5FEBQ ID DM5FEBQ
DM5FEBQ DN CD-832
DM5FEBQ HS Terminated
DM5FEBQ CP Taisho Pharmaceutical Co Ltd
DM5FEBQ DE Angina pectoris
DMGQ9WP ID DMGQ9WP
DMGQ9WP DN CDE-5110
DMGQ9WP HS Terminated
DMGQ9WP SN CDE-6963; ROCK I/II inhibitors (inflammation); ROCK I/II inhibitors (inflammation), Devgen
DMGQ9WP CP Devgen NV
DMGQ9WP DE Inflammation
DMVHTQI ID DMVHTQI
DMVHTQI DN CDE-5498
DMVHTQI HS Terminated
DMVHTQI SN Dev-0304; Dev-0305; Kv4.3 voltage-dependent potassium channel antagonists (arrhythmia); Kv4.3 voltage-dependent potassium channel antagonists (arrhythmia), Devgen
DMVHTQI CP Devgen NV
DMVHTQI DE Heart arrhythmia
DMA0DKI ID DMA0DKI
DMA0DKI DN CDE-6960
DMA0DKI HS Terminated
DMA0DKI SN Protein kinase C epsilon/theta inhibitors (inflammation); PKC epsilon/theta inhibitors (inflammation), Devgen; Protein kinase C epsilon/theta inhibitors (inflammation), Devgen
DMA0DKI CP Devgen NV
DMA0DKI DE Inflammation
DMGMS2D ID DMGMS2D
DMGMS2D DN CDP-845
DMGMS2D HS Terminated
DMGMS2D CP UCB Celltech
DMGMS2D DE Solid tumour/cancer
DMNJXRG ID DMNJXRG
DMNJXRG DN CEB-925
DMNJXRG HS Terminated
DMNJXRG SN ACAT inhibitor, AHP
DMNJXRG CP Wyeth
DMNJXRG DE Hypercholesterolaemia
DMGEFX7 ID DMGEFX7
DMGEFX7 DN CEE-03-320
DMGEFX7 HS Terminated
DMGEFX7 SN CEE-320; NNC-220215
DMGEFX7 CP Novo Nordisk A/S
DMGEFX7 DE Substance use disorder
DMZE0SJ ID DMZE0SJ
DMZE0SJ DN CEP-4186
DMZE0SJ HS Terminated
DMZE0SJ SN CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma
DMZE0SJ CP LEO Pharma A/S
DMZE0SJ DE Acute myeloid leukaemia
DMTI10C ID DMTI10C
DMTI10C DN CEP-427
DMTI10C HS Terminated
DMTI10C CP Cephalon Inc
DMTI10C DE Alzheimer disease
DMDH0AM ID DMDH0AM
DMDH0AM DN CEP-431
DMDH0AM HS Terminated
DMDH0AM SN Clipsin inhibitor, Cephalon
DMDH0AM CP Cephalon Inc
DMDH0AM DE Alzheimer disease
DMFRW0G ID DMFRW0G
DMFRW0G DN CEP-5214
DMFRW0G HS Terminated
DMFRW0G SN 12-(3-Hydroxypropyl)-9-(isopropoxymethyl)-6,7,12,13-tetrahydro-5H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-5-one
DMFRW0G DT Small molecular drug
DMFRW0G PC 10275001
DMFRW0G MW 440.5
DMFRW0G FM C28H28N2O3
DMFRW0G IC InChI=1S/C28H28N2O3/c1-16(2)33-15-17-8-9-23-20(12-17)25-22-14-29-28(32)26(22)24-19-7-4-3-6-18(19)13-21(24)27(25)30(23)10-5-11-31/h3-4,6-9,12,16,31H,5,10-11,13-15H2,1-2H3,(H,29,32)
DMFRW0G CS CC(C)OCC1=CC2=C(C=C1)N(C3=C2C4=C(C5=C3CC6=CC=CC=C65)C(=O)NC4)CCCO
DMFRW0G IK MLIFNJABMANKEU-UHFFFAOYSA-N
DMFRW0G IU 3-(3-hydroxypropyl)-7-(propan-2-yloxymethyl)-3,13-diazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-14-one
DMFRW0G DE Solid tumour/cancer
DM956N7 ID DM956N7
DM956N7 DN CEP-751
DM956N7 HS Terminated
DM956N7 DT Small molecular drug
DM956N7 PC 9868524
DM956N7 MW 453.5
DM956N7 FM C27H23N3O4
DM956N7 IC InChI=1S/C27H23N3O4/c1-26-27(13-31,33-2)11-19(34-26)29-17-9-5-3-7-14(17)21-22-16(12-28-25(22)32)20-15-8-4-6-10-18(15)30(26)24(20)23(21)29/h3-10,19,31H,11-13H2,1-2H3,(H,28,32)/t19?,26-,27-/m0/s1
DM956N7 CS C[C@@]12[C@](CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)OC
DM956N7 IK NMMGUHANGUWNBN-OGLOGDKOSA-N
DM956N7 IU (15S,16S)-16-(hydroxymethyl)-16-methoxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one
DM956N7 DE Neurodegenerative disorder
DMIDFLV ID DMIDFLV
DMIDFLV DN Cetamolol
DMIDFLV HS Terminated
DMIDFLV SN Betacor; Cetamolol hydrochloride; AI-27303; AY-27303
DMIDFLV CP Zeneca Group plc
DMIDFLV DT Small molecular drug
DMIDFLV PC 53698
DMIDFLV MW 310.39
DMIDFLV FM C16H26N2O4
DMIDFLV IC InChI=1S/C16H26N2O4/c1-16(2,3)18-9-12(19)10-21-13-7-5-6-8-14(13)22-11-15(20)17-4/h5-8,12,18-19H,9-11H2,1-4H3,(H,17,20)
DMIDFLV CS CC(C)(C)NCC(COC1=CC=CC=C1OCC(=O)NC)O
DMIDFLV IK UWCBNAVPISMFJZ-UHFFFAOYSA-N
DMIDFLV IU 2-[2-[3-(tert-butylamino)-2-hydroxypropoxy]phenoxy]-N-methylacetamide
DMIDFLV CA CAS 34919-98-7
DMIDFLV CB CHEBI:135322
DMIDFLV DE Angina pectoris
DM5ESZU ID DM5ESZU
DM5ESZU DN CGP-25454A
DM5ESZU HS Terminated
DM5ESZU CP Novartis AG
DM5ESZU PC 9819590
DM5ESZU MW 346.2
DM5ESZU FM C15H21Cl2N3O2
DM5ESZU IC InChI=1S/C15H20ClN3O2.ClH/c1-4-19(5-2)7-6-18-15(20)12-8-11(10-17)13(16)9-14(12)21-3;/h8-9H,4-7H2,1-3H3,(H,18,20);1H
DM5ESZU CS CCN(CC)CCNC(=O)C1=C(C=C(C(=C1)C#N)Cl)OC.Cl
DM5ESZU IK ZETCQNUMZFZSLJ-UHFFFAOYSA-N
DM5ESZU IU 4-chloro-5-cyano-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydrochloride
DM5ESZU DE Major depressive disorder
DMZM70X ID DMZM70X
DMZM70X DN CGP-35348
DMZM70X HS Terminated
DMZM70X SN Cgp 35348; Cgp-35348; 123690-79-9; UNII-87TI61875H; P-(3-Aminopropyl)-P-diethoxymethylphosphinic acid; CHEMBL40157; 3-aminopropyl(diethoxymethyl)phosphinic acid; Phosphinic acid, (3-aminopropyl)(diethoxymethyl)-; CGP35348; 87TI61875H; (S)-(3-Aminopropyl)(Diethoxymethyl)phosphinic Acid; CGP 35348 hydrate; (3-Aminopropyl)(diethoxymethyl)phosphinic acid hydrate; Tocris-1245; Biomol-NT_000237; AC1L32KY; C8H20NO4P; SCHEMBL195698; GTPL1069; BPBio1_000508; DTXSID70154064; QIIVUOWTHWIXFO-UHFFFAOYSA-N; MolPort-003-983-819; PDSP2_000408
DMZM70X DT Small molecular drug
DMZM70X PC 107699
DMZM70X MW 225.22
DMZM70X FM C8H20NO4P
DMZM70X IC InChI=1S/C8H20NO4P/c1-3-12-8(13-4-2)14(10,11)7-5-6-9/h8H,3-7,9H2,1-2H3,(H,10,11)
DMZM70X CS CCOC(OCC)P(=O)(CCCN)O
DMZM70X IK QIIVUOWTHWIXFO-UHFFFAOYSA-N
DMZM70X IU 3-aminopropyl(diethoxymethyl)phosphinic acid
DMZM70X CA CAS 123690-79-9
DMZM70X DE Epilepsy
DM69YWS ID DM69YWS
DM69YWS DN CGP-40215A
DM69YWS HS Terminated
DM69YWS SN Cgp-40215A; Cgp 40215A; Bis((3-(aminoiminomethyl)phenyl)methylene)carbonimidic dihydrazide trihydrochloride; Carbonimidic dihydrazide, bis((3-(aminoiminomethyl)phenyl)methylene)-, trihydrochloride
DM69YWS CP Novartis AG
DM69YWS DT Small molecular drug
DM69YWS PC 9576797
DM69YWS MW 458.8
DM69YWS FM C17H22Cl3N9
DM69YWS IC InChI=1S/C17H19N9.3ClH/c18-15(19)13-5-1-3-11(7-13)9-23-25-17(22)26-24-10-12-4-2-6-14(8-12)16(20)21;;;/h1-10H,(H3,18,19)(H3,20,21)(H3,22,25,26);3*1H/b23-9+,24-10+;;;
DM69YWS CS C1=CC(=CC(=C1)C(=N)N)/C=N/N/C(=N/N=C/C2=CC(=CC=C2)C(=N)N)/N.Cl.Cl.Cl
DM69YWS IK OTMBXWAKBWGKPN-VOTJPXFPSA-N
DM69YWS IU 3-[(E)-[[(E)-N'-[(E)-(3-carbamimidoylphenyl)methylideneamino]carbamimidoyl]hydrazinylidene]methyl]benzenecarboximidamide;trihydrochloride
DM69YWS CA CAS 126534-93-8
DM69YWS DE Pneumocystis pneumonia
DMIWUFC ID DMIWUFC
DMIWUFC DN CGP-52411
DMIWUFC HS Terminated
DMIWUFC SN DAPH
DMIWUFC CP Novartis AG
DMIWUFC DT Small molecular drug
DMIWUFC PC 1697
DMIWUFC MW 329.4
DMIWUFC FM C20H15N3O2
DMIWUFC IC InChI=1S/C20H15N3O2/c24-19-15-11-17(21-13-7-3-1-4-8-13)18(12-16(15)20(25)23-19)22-14-9-5-2-6-10-14/h1-12,21-22H,(H,23,24,25)
DMIWUFC CS C1=CC=C(C=C1)NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=CC=C4
DMIWUFC IK AAALVYBICLMAMA-UHFFFAOYSA-N
DMIWUFC IU 5,6-dianilinoisoindole-1,3-dione
DMIWUFC CA CAS 145915-58-8
DMIWUFC CB CHEBI:53110
DMIWUFC DE Solid tumour/cancer
DM9VDZP ID DM9VDZP
DM9VDZP DN CGP-53353
DM9VDZP HS Terminated
DM9VDZP SN 145915-60-2; CGP 53353; CGP-53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492
DM9VDZP DT Small molecular drug
DM9VDZP PC 6711154
DM9VDZP MW 365.3
DM9VDZP FM C20H13F2N3O2
DM9VDZP IC InChI=1S/C20H13F2N3O2/c21-11-1-5-13(6-2-11)23-17-9-15-16(20(27)25-19(15)26)10-18(17)24-14-7-3-12(22)4-8-14/h1-10,23-24H,(H,25,26,27)
DM9VDZP CS C1=CC(=CC=C1NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=C(C=C4)F)F
DM9VDZP IK RONQPWQYDRPRGG-UHFFFAOYSA-N
DM9VDZP IU 5,6-bis(4-fluoroanilino)isoindole-1,3-dione
DM9VDZP CA CAS 145915-60-2
DM9VDZP CB CHEBI:92560
DMJ325M ID DMJ325M
DMJ325M DN CGP-53716
DMJ325M HS Terminated
DMJ325M SN CGS-53716
DMJ325M CP Novartis AG
DMJ325M PC 9864718
DMJ325M MW 381.4
DMJ325M FM C23H19N5O
DMJ325M IC InChI=1S/C23H19N5O/c1-16-9-10-19(26-22(29)17-6-3-2-4-7-17)14-21(16)28-23-25-13-11-20(27-23)18-8-5-12-24-15-18/h2-15H,1H3,(H,26,29)(H,25,27,28)
DMJ325M CS CC1=C(C=C(C=C1)NC(=O)C2=CC=CC=C2)NC3=NC=CC(=N3)C4=CN=CC=C4
DMJ325M IK UOEJSOXEHKCNAE-UHFFFAOYSA-N
DMJ325M IU N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMJ325M DE Solid tumour/cancer
DM4TGY0 ID DM4TGY0
DM4TGY0 DN CGP-60474
DM4TGY0 HS Terminated
DM4TGY0 SN CGP60474; 164658-13-3; CGP-60474; UNII-16IP6G5MLC; CGP 60474; GNF-Pf-88; 16IP6G5MLC; 3-[[4-[2-[(3-Chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-1-propanol; MLS000911536; SMR000463552; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]-2-pyridyl]amino]propan-1-ol; 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol; 1-Propanol, 3-((4-(2-((3-chlorophenyl)amino)-4-pyrimidinyl)-2-pyridinyl)amino)-; 1-propanol, 3-[[4-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-; AC1LD8S6; MLS003105942
DM4TGY0 DT Small molecular drug
DM4TGY0 PC 644215
DM4TGY0 MW 355.8
DM4TGY0 FM C18H18ClN5O
DM4TGY0 IC InChI=1S/C18H18ClN5O/c19-14-3-1-4-15(12-14)23-18-22-9-6-16(24-18)13-5-8-21-17(11-13)20-7-2-10-25/h1,3-6,8-9,11-12,25H,2,7,10H2,(H,20,21)(H,22,23,24)
DM4TGY0 CS C1=CC(=CC(=C1)Cl)NC2=NC=CC(=N2)C3=CC(=NC=C3)NCCCO
DM4TGY0 IK IYNDTACKOAXKBJ-UHFFFAOYSA-N
DM4TGY0 IU 3-[[4-[2-(3-chloroanilino)pyrimidin-4-yl]pyridin-2-yl]amino]propan-1-ol
DM4TGY0 CA CAS 164658-13-3
DM4TGY0 CB CHEBI:91339
DM4TGY0 DE Solid tumour/cancer
DMRLXC3 ID DMRLXC3
DMRLXC3 DN CGP-70726
DMRLXC3 HS Terminated
DMRLXC3 CP Novartis AG
DMRLXC3 PC 469663
DMRLXC3 MW 689.8
DMRLXC3 FM C38H51N5O7
DMRLXC3 IC InChI=1S/C38H51N5O7/c1-25(2)32(40-36(47)49-6)34(45)39-30(22-26-14-10-8-11-15-26)31(44)24-43(42-35(46)33(38(3,4)5)41-37(48)50-7)23-27-18-20-29(21-19-27)28-16-12-9-13-17-28/h8-21,25,30-33,44H,22-24H2,1-7H3,(H,39,45)(H,40,47)(H,41,48)(H,42,46)/t30-,31-,32-,33+/m0/s1
DMRLXC3 CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=C3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC
DMRLXC3 IK BYEWWQZDUPJZHX-ZWDYZTTJSA-N
DMRLXC3 IU methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-phenylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMRLXC3 CA CAS 215312-87-1
DMRLXC3 DE Human immunodeficiency virus-1 infection
DMKUETX ID DMKUETX
DMKUETX DN CGS 8515
DMKUETX HS Terminated
DMKUETX SN 114832-13-2; CGS-8515; Methyl 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)benzoate; Benzoic acid,2-[(3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino]-, methyl ester; methyl 2-[(3,4-dioxonaphthalen-1-yl)amino]benzoate; AC1L4TWI; AC1Q5ZBK; cgs8515; ACMC-1C4N1; SCHEMBL3273068; CTK4A8934; DTXSID80150875; methyl 2-[(3,4-dioxo-3,4-dihydronaphthalen-1-yl)amino]benzoate; Benzoic acid, 2-((3,4-dihydro-3,4-dioxo-1-naphthalenyl)amino)-, methyl ester
DMKUETX DT Small molecular drug
DMKUETX PC 163944
DMKUETX MW 307.3
DMKUETX FM C18H13NO4
DMKUETX IC InChI=1S/C18H13NO4/c1-23-18(22)13-8-4-5-9-14(13)19-15-10-16(20)17(21)12-7-3-2-6-11(12)15/h2-10,19H,1H3
DMKUETX CS COC(=O)C1=CC=CC=C1NC2=CC(=O)C(=O)C3=CC=CC=C32
DMKUETX IK PEJZAKFAABRDEN-UHFFFAOYSA-N
DMKUETX IU methyl 2-[(3,4-dioxonaphthalen-1-yl)amino]benzoate
DMKUETX CA CAS 114832-13-2
DM6MEX4 ID DM6MEX4
DM6MEX4 DN CGS-12066B
DM6MEX4 HS Terminated
DM6MEX4 SN CGS 12066B; UNII-5TB4SXQ7HG; CGS 12066B-parent; Cgs 12066; CGS12066; 5TB4SXQ7HG; 109028-09-3; 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline; CHEMBL27403; CGS-12066B; CHEBI:64055; CGS-12066A; CGS-12066; CGS-12066A maleate salt; Pyrrolo[1,2-a]quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-; Pyrrolo(1,2-a)quinoxaline, 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-; NCGC00024701-01; Tocris-0638; 7-Trifluoromethyl-4-(4-methyl-1-piperazinyl)pyrrolo-[1,2-a]quinoxaline maleate salt
DM6MEX4 DT Small molecular drug
DM6MEX4 PC 9915956
DM6MEX4 MW 566.5
DM6MEX4 FM C25H25F3N4O8
DM6MEX4 IC InChI=1S/C17H17F3N4.2C4H4O4/c1-22-7-9-23(10-8-22)16-15-3-2-6-24(15)14-5-4-12(17(18,19)20)11-13(14)21-16;2*5-3(6)1-2-4(7)8/h2-6,11H,7-10H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
DM6MEX4 CS CN1CCN(CC1)C2=NC3=C(N4C2=CC=C4)C=CC(=C3)C(F)(F)F.C(=C\\C(=O)O)\\C(=O)O.C(=C\\C(=O)O)\\C(=O)O
DM6MEX4 IK HTEVMLYDEWVIQE-SPIKMXEPSA-N
DM6MEX4 IU (Z)-but-2-enedioic acid;4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline
DM6MEX4 CA CAS 109028-10-6
DM6MEX4 DE Anxiety disorder
DMUPKYO ID DMUPKYO
DMUPKYO DN CGS-13080
DMUPKYO HS Terminated
DMUPKYO SN PIRMAGREL; CGS-13080; Pirmagrelum [Latin]; Pirmgrel; Pirmagrel [USAN:INN]; UNII-9J5H2VA91V; CGS 13080; 85691-74-3; CHEMBL48092; 9J5H2VA91V; Imidazo(1,5-a)pyridine-5-hexanoic acid; Pirmagrelum; Imidazo[1,5-a]pyridine-5-hexanoic acid; Pirmagrel (USAN/INN); AC1L1IZ7; SCHEMBL636018; DTXSID80234982; LIFOFTJHFFTNRV-UHFFFAOYSA-N; ZINC2021333; BDBM50025953; imidazol(1,5-a)pyridine-5-hexanoic acid; LS-177888; 6-imidazo[1,5-a]pyridin-5-ylhexanoic acid; 5-(5-carboxypentyl)imidazo[1,5-a]pyridine; 5-(5-carboxypentyl)-imidazo[1,5-a]pyridine
DMUPKYO DT Small molecular drug
DMUPKYO PC 55390
DMUPKYO MW 232.28
DMUPKYO FM C13H16N2O2
DMUPKYO IC InChI=1S/C13H16N2O2/c16-13(17)8-3-1-2-5-11-6-4-7-12-9-14-10-15(11)12/h4,6-7,9-10H,1-3,5,8H2,(H,16,17)
DMUPKYO CS C1=CC2=CN=CN2C(=C1)CCCCCC(=O)O
DMUPKYO IK LIFOFTJHFFTNRV-UHFFFAOYSA-N
DMUPKYO IU 6-imidazo[1,5-a]pyridin-5-ylhexanoic acid
DMUPKYO CA CAS 85691-74-3
DMUPKYO DE Asthma
DMMZJY3 ID DMMZJY3
DMMZJY3 DN CGS-17867A
DMMZJY3 HS Terminated
DMMZJY3 SN Cgs-17867A; CHEMBL116842; 2-(4-Chloro-phenyl)-2,5,6,7,8,9-hexahydro-pyrazolo[4,3-c]quinolin-3-one; AC1L2T4E; SCHEMBL2287621; OJVURBSORBSWLX-UHFFFAOYSA-N; CGS-17867; BDBM50148320; 2-p-Tolyl-2,5,6,7,8,9-hexahydro-pyrazolo[4,3-c]quinolin-3-one; 2-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrazolo[4,3-c]quinolin-3-one
DMMZJY3 DT Small molecular drug
DMMZJY3 PC 128064
DMMZJY3 MW 299.75
DMMZJY3 FM C16H14ClN3O
DMMZJY3 IC InChI=1S/C16H14ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h5-9,19H,1-4H2
DMMZJY3 CS C1CCC2=NC=C3C(=C2C1)NN(C3=O)C4=CC=C(C=C4)Cl
DMMZJY3 IK NZEIZTTWQRQFFV-UHFFFAOYSA-N
DMMZJY3 IU 2-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrazolo[4,3-c]quinolin-3-one
DMMZJY3 DE Alcohol dependence
DM4W3MU ID DM4W3MU
DM4W3MU DN CGS-18102A
DM4W3MU HS Terminated
DM4W3MU SN CGP-50281; CGS-18102
DM4W3MU CP Novartis AG
DM4W3MU DT Small molecular drug
DM4W3MU PC 146963
DM4W3MU MW 297.82
DM4W3MU FM C16H24ClNO2
DM4W3MU IC InChI=1S/C16H23NO2.ClH/c1-3-9-17-10-5-6-12-13(17)11-19-15-8-4-7-14(18-2)16(12)15;/h4,7-8,12-13H,3,5-6,9-11H2,1-2H3;1H/t12-,13+;/m1./s1
DM4W3MU CS CCCN1CCC[C@@H]2[C@@H]1COC3=C2C(=CC=C3)OC.Cl
DM4W3MU IK IIARBXRSECAIPI-KZCZEQIWSA-N
DM4W3MU IU (4aR,10bS)-10-methoxy-4-propyl-1,2,3,4a,5,10b-hexahydrochromeno[3,4-b]pyridine;hydrochloride
DM4W3MU CA CAS 100746-36-9
DM4W3MU DE Anxiety disorder
DMFZM09 ID DMFZM09
DMFZM09 DN CGS-26303
DMFZM09 HS Terminated
DMFZM09 SN Cgs-26303; Cgs 26303; 154116-31-1; CHEMBL290698; (S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminomethyl phosphonic acid; cgs26303; SCHEMBL653011; AC1L31X6; CTK4C8115; DTXSID40165541; BDBM50064106; Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, (S)-; {[(S)-2-Biphenyl-4-yl-1-(2H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic acid; {[(S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic acid; {[(R)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic ac
DMFZM09 DT Small molecular drug
DMFZM09 PC 132968
DMFZM09 MW 359.32
DMFZM09 FM C16H18N5O3P
DMFZM09 IC InChI=1S/C16H18N5O3P/c22-25(23,24)11-17-15(16-18-20-21-19-16)10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-9,15,17H,10-11H2,(H2,22,23,24)(H,18,19,20,21)/t15-/m0/s1
DMFZM09 CS C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NCP(=O)(O)O
DMFZM09 IK UUMKQZVEZSXWBY-HNNXBMFYSA-N
DMFZM09 IU [[(1S)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethyl]amino]methylphosphonic acid
DMFZM09 CA CAS 154116-31-1
DM4U72A ID DM4U72A
DM4U72A DN CGS-26393
DM4U72A HS Terminated
DM4U72A SN Cgs 26393; Cgs-26393; 154116-34-4; AC1L2SSW; cgs26393; CHEMBL36795; SCHEMBL8921559; CTK4C8116; DTXSID00165542; 2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid; (S)-Diphenyl (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)phosphonate; (1S)-N-(diphenoxyphosphorylmethyl)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethanamine; Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, diphenyl ester, (S)-; Phosphonic acid,P-[[[(1S)-2-[1,1'-biphenyl]-4-yl-1-(2H-tetraz
DM4U72A CP Novartis AG
DM4U72A DT Small molecular drug
DM4U72A PC 127883
DM4U72A MW 511.5
DM4U72A FM C28H26N5O3P
DM4U72A IC InChI=1S/C28H26N5O3P/c34-37(35-25-12-6-2-7-13-25,36-26-14-8-3-9-15-26)21-29-27(28-30-32-33-31-28)20-22-16-18-24(19-17-22)23-10-4-1-5-11-23/h1-19,27,29H,20-21H2,(H,30,31,32,33)/t27-/m0/s1
DM4U72A CS C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NCP(=O)(OC4=CC=CC=C4)OC5=CC=CC=C5
DM4U72A IK AHIFMZUYRNPRJK-MHZLTWQESA-N
DM4U72A IU (1S)-N-(diphenoxyphosphorylmethyl)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethanamine
DM4U72A CA CAS 154116-34-4
DM4U72A DE Heart disease
DMJ4FGZ ID DMJ4FGZ
DMJ4FGZ DN CGS-26529
DMJ4FGZ HS Terminated
DMJ4FGZ SN CGS-265529
DMJ4FGZ CP Novartis AG
DMJ4FGZ PC 9803758
DMJ4FGZ MW 449.5
DMJ4FGZ FM C25H24FN3O4
DMJ4FGZ IC InChI=1S/C25H24FN3O4/c26-21-7-5-19(6-8-21)18-3-1-17(2-4-18)16-28-12-11-20-15-22(9-10-23(20)24(28)30)33-14-13-29(32)25(27)31/h1-10,15,32H,11-14,16H2,(H2,27,31)
DMJ4FGZ CS C1CN(C(=O)C2=C1C=C(C=C2)OCCN(C(=O)N)O)CC3=CC=C(C=C3)C4=CC=C(C=C4)F
DMJ4FGZ IK QFDRKYCYRMSXMS-UHFFFAOYSA-N
DMJ4FGZ IU 1-[2-[[2-[[4-(4-fluorophenyl)phenyl]methyl]-1-oxo-3,4-dihydroisoquinolin-6-yl]oxy]ethyl]-1-hydroxyurea
DMJ4FGZ DE Inflammation
DM8TLY3 ID DM8TLY3
DM8TLY3 DN CGS-27830
DM8TLY3 HS Terminated
DM8TLY3 SN Cgs-27830; Cgs 27830; AC1L4RBN; AC1Q5XDJ; cgs27830; (4r)-5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic(4s)-5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic anhydride; SCHEMBL9089580; 155485-56-6; meso-1,4-Dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine carboxylic acid anhydride; 5-O-[(4S)-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carbonyl] 3-O-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydr
DM8TLY3 DT Small molecular drug
DM8TLY3 PC 190809
DM8TLY3 MW 646.6
DM8TLY3 FM C32H30N4O11
DM8TLY3 IC InChI=1S/C32H30N4O11/c1-15-23(29(37)45-5)27(19-9-7-11-21(13-19)35(41)42)25(17(3)33-15)31(39)47-32(40)26-18(4)34-16(2)24(30(38)46-6)28(26)20-10-8-12-22(14-20)36(43)44/h7-14,27-28,33-34H,1-6H3/t27-,28+
DM8TLY3 CS CC1=C([C@H](C(=C(N1)C)C(=O)OC(=O)C2=C(NC(=C([C@@H]2C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC)C)C)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DM8TLY3 IK PZNZOWSLQRURNA-HNRBIFIRSA-N
DM8TLY3 IU 5-O-[(4R)-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carbonyl] 3-O-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM8TLY3 CA CAS 155485-56-6
DM94WIO ID DM94WIO
DM94WIO DN CGS-30440
DM94WIO HS Terminated
DM94WIO CP Ciba-Geigy Corp
DM94WIO PC 87992715
DM94WIO MW 464.6
DM94WIO FM C23H32N2O6S
DM94WIO IC InChI=1S/C23H32N2O6S/c1-14(2)19(32-15(3)26)20(27)25-23(11-5-6-12-23)22(30)24-18(21(28)29)13-16-7-9-17(31-4)10-8-16/h7-10,14,18-19H,5-6,11-13H2,1-4H3,(H,24,30)(H,25,27)(H,28,29)/t18-,19-/m0/s1
DM94WIO CS CC(C)[C@@H](C(=O)NC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(C=C2)OC)C(=O)O)SC(=O)C
DM94WIO IK POVJRTWSWOOUQR-OALUTQOASA-N
DM94WIO IU (2S)-2-[[1-[[(2S)-2-acetylsulfanyl-3-methylbutanoyl]amino]cyclopentanecarbonyl]amino]-3-(4-methoxyphenyl)propanoic acid
DM94WIO DE Hypertension
DM1VZ2I ID DM1VZ2I
DM1VZ2I DN CGS-32359
DM1VZ2I HS Terminated
DM1VZ2I SN C5aRAD
DM1VZ2I CP Novartis AG
DM1VZ2I DE Inflammation
DM39PQI ID DM39PQI
DM39PQI DN CGS-9896
DM39PQI HS Terminated
DM39PQI SN Cgs-9896; Cgs 9896; 77779-36-3; UNII-86PWQ4PVN0; 86PWQ4PVN0; AC1Q3J9C; AC1L337H; SCHEMBL7308514; AC1Q3T13; 2-(4-chlorophenyl)-1H-pyrazolo[4,3-c]quinolin-3-one; SCHEMBL17236324; CTK5E4889; BDBM84957; AOB4759; MolPort-009-714-150; CQINXWYVIOMBEI-UHFFFAOYSA-N; PDSP2_001748; 2-(4-chlorophenyl)-1,2-dihydro-3h-pyrazolo[4,3-c]quinolin-3-one; PDSP1_001765; ZINC100367629; AKOS021973584; MCULE-9708849911; A10022; 2-(p-chlorophenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one; F3406-4901; 2-(4-chlorophenyl)-1H-pyrazolo[4,5-c]quinolin-3-one
DM39PQI DT Small molecular drug
DM39PQI PC 108030
DM39PQI MW 295.72
DM39PQI FM C16H10ClN3O
DM39PQI IC InChI=1S/C16H10ClN3O/c17-10-5-7-11(8-6-10)20-16(21)13-9-18-14-4-2-1-3-12(14)15(13)19-20/h1-9,19H
DM39PQI CS C1=CC=C2C(=C1)C3=C(C=N2)C(=O)N(N3)C4=CC=C(C=C4)Cl
DM39PQI IK QCBUAKLOWCOUCR-UHFFFAOYSA-N
DM39PQI IU 2-(4-chlorophenyl)-1H-pyrazolo[4,3-c]quinolin-3-one
DM39PQI CA CAS 77779-36-3
DMADYF7 ID DMADYF7
DMADYF7 DN CGX-1160
DMADYF7 HS Terminated
DMADYF7 CP Cognetix
DMADYF7 TC Analgesics
DMADYF7 DT Small molecular drug
DMADYF7 PC 56603671
DMADYF7 MW 2038.2
DMADYF7 FM C89H144N20O34
DMADYF7 IC InChI=1S/C89H144N20O34/c1-41(2)29-57(89(140)141)106-86(137)69(42(3)4)94-34-49(30-46-16-18-50(115)19-17-46)98-85(136)60-15-12-28-109(60)88(139)55(14-9-11-27-91)104-79(130)51(13-8-10-26-90)103-87(138)70(44(6)142-61-31-48(38-111)73(125)76(71(61)97-45(7)114)143-62-32-47(37-110)72(124)75(127)74(62)126)108-77(128)43(5)96-82(133)56(33-63(92)116)105-83(134)58(39-112)100-66(119)36-93-65(118)35-95-78(129)52(21-24-67(120)121)101-81(132)54(22-25-68(122)123)102-84(135)59(40-113)107-80(131)53-20-23-64(117)99-53/h16-19,41-44,47-49,51-62,69-76,94,110-113,115,124-127H,8-15,20-40,90-91H2,1-7H3,(H2,92,116)(H,93,118)(H,95,129)(H,96,133)(H,97,114)(H,98,136)(H,99,117)(H,100,119)(H,101,132)(H,102,135)(H,103,138)(H,104,130)(H,105,134)(H,106,137)(H,107,131)(H,108,128)(H,120,121)(H,122,123)(H,140,141)/t43-,44-,47-,48?,49-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61?,62+,69-,70+,71?,72+,73?,74+,75+,76?/m0/s1
DMADYF7 CS C[C@@H]([C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)CN[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]3CCC(=O)N3)OC4CC(C(C(C4NC(=O)C)O[C@@H]5C[C@H]([C@H]([C@H]([C@@H]5O)O)O)CO)O)CO
DMADYF7 IK BDYYRSHYAJPHLA-CDMGOGEFSA-N
DMADYF7 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R,3S)-3-[2-acetamido-4-hydroxy-5-(hydroxymethyl)-3-[(1R,2S,3R,4R,5S)-2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl]oxycyclohexyl]oxy-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[2-[[2-[[(2S)-4-carboxy-2-[[(2S)-4-carboxy-2-[[(2S)-3-hydroxy-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]butanoyl]amino]butanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoic acid
DMADYF7 DE Acute or chronic pain
DMJ2P1Q ID DMJ2P1Q
DMJ2P1Q DN CI-1002
DMJ2P1Q HS Terminated
DMJ2P1Q SN PD-142676
DMJ2P1Q CP Parke-Davis & Co
DMJ2P1Q PC 9838284
DMJ2P1Q MW 269.17
DMJ2P1Q FM C13H14Cl2N2
DMJ2P1Q IC InChI=1S/C13H14Cl2N2/c14-9-6-11(15)10-8-17-5-3-1-2-4-13(17)16-12(10)7-9/h6-7H,1-5,8H2
DMJ2P1Q CS C1CCC2=NC3=C(CN2CC1)C(=CC(=C3)Cl)Cl
DMJ2P1Q IK WTPSHLVHJOJDIF-UHFFFAOYSA-N
DMJ2P1Q IU 1,3-dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazoline
DMJ2P1Q CA CAS 149028-28-4
DMJ2P1Q DE Alzheimer disease
DMUK9L4 ID DMUK9L4
DMUK9L4 DN CI-1021
DMUK9L4 HS Terminated
DMUK9L4 SN Methyl-GAG pamoate; NSC96016; 18186-55-5; NSC 96016; NSC-96016; 2-Naphthalencarboxylic acid, 4,4'-methylenebis(3-hydroxy-, compd. with 2,2'-(1-methyl-1, 2-ethanediylidene)bis(hydrazinecarboximideamide) (1:1); 2-Naphthoic acid, 4,4'methylenebis[3-hydroxy-, compd with 1, 1'-[(methylethanediyldene)dinitrilo]diguanidine (1:1); 1-[(E)-[(2E)-2-(carbamimidoylhydrazono)-1-methyl-ethylidene]amino]guanidine; 4-[(3-carboxy-2-hydroxy-1-naphthyl)methyl]-3-hydroxy-naphthalene-2-carboxylic acid; 2-Naphthalencarboxylic acid,4'-met
DMUK9L4 DT Small molecular drug
DMUK9L4 PC 9805809
DMUK9L4 MW 495.6
DMUK9L4 FM C30H29N3O4
DMUK9L4 IC InChI=1S/C30H29N3O4/c1-20(21-10-4-3-5-11-21)32-28(34)30(2,17-23-18-31-26-14-8-7-13-25(23)26)33-29(35)36-19-24-16-22-12-6-9-15-27(22)37-24/h3-16,18,20,31H,17,19H2,1-2H3,(H,32,34)(H,33,35)/t20-,30+/m0/s1
DMUK9L4 CS C[C@@H](C1=CC=CC=C1)NC(=O)[C@@](C)(CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC5=CC=CC=C5O4
DMUK9L4 IK IVIQHHCTWSXXCT-WENCNXQZSA-N
DMUK9L4 IU 1-benzofuran-2-ylmethyl N-[(2R)-3-(1H-indol-3-yl)-2-methyl-1-oxo-1-[[(1S)-1-phenylethyl]amino]propan-2-yl]carbamate
DMUK9L4 CA CAS 158991-23-2
DMI0TD8 ID DMI0TD8
DMI0TD8 DN CI-986
DMI0TD8 HS Terminated
DMI0TD8 SN CI-986; CI 986; 5-(3,5-Di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione; 5-(3,5-Bis(1,1-dimethylethyl)-4-(hydroxyphenyl))-1,3,4-thiadiazole-2(3H)-thione choline salt; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 5-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione (1:1); 130116-16-4; AC1MI25H; C16H22N2OS2.C5H14NO; LS-172752; 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate
DMI0TD8 CP Parke-Davis & Co
DMI0TD8 DT Small molecular drug
DMI0TD8 PC 3037017
DMI0TD8 MW 425.7
DMI0TD8 FM C21H35N3O2S2
DMI0TD8 IC InChI=1S/C16H22N2OS2.C5H14NO/c1-15(2,3)10-7-9(13-17-18-14(20)21-13)8-11(12(10)19)16(4,5)6;1-6(2,3)4-5-7/h7-8,19H,1-6H3,(H,18,20);7H,4-5H2,1-3H3/q;+1/p-1
DMI0TD8 CS CC(C)(C)C1=CC(=CC(=C1[O-])C(C)(C)C)C2=NNC(=S)S2.C[N+](C)(C)CCO
DMI0TD8 IK BIZSVVIRPJXFOI-UHFFFAOYSA-M
DMI0TD8 IU 2,6-ditert-butyl-4-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)phenolate;2-hydroxyethyl(trimethyl)azanium
DMI0TD8 CA CAS 130116-16-4
DMI0TD8 DE Rheumatoid arthritis
DMBHYIJ ID DMBHYIJ
DMBHYIJ DN CI-992
DMBHYIJ HS Terminated
DMBHYIJ SN CI-992; CHEMBL34894; 135704-06-2; CTK4B9950; N-[2-(2-Amino-thiazol-4-yl)-1-(1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-ethyl]-2-(morpholine-4-sulfonylamino)-3-phenyl-propionamide; L-Alaninamide,N-(4-morpholinylsulfonyl)-L-phenylalanyl-3-(2-amino-4-thiazolyl)-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-(9CI); BDBM50006844
DMBHYIJ DT Small molecular drug
DMBHYIJ PC 9875002
DMBHYIJ MW 708.9
DMBHYIJ FM C33H52N6O7S2
DMBHYIJ IC InChI=1S/C33H52N6O7S2/c1-22(2)17-29(40)30(41)26(18-23-9-5-3-6-10-23)36-31(42)27(20-25-21-47-33(34)35-25)37-32(43)28(19-24-11-7-4-8-12-24)38-48(44,45)39-13-15-46-16-14-39/h4,7-8,11-12,21-23,26-30,38,40-41H,3,5-6,9-10,13-20H2,1-2H3,(H2,34,35)(H,36,42)(H,37,43)/t26-,27-,28-,29-,30+/m0/s1
DMBHYIJ CS CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)[C@H](CC2=CSC(=N2)N)NC(=O)[C@H](CC3=CC=CC=C3)NS(=O)(=O)N4CCOCC4)O)O
DMBHYIJ IK QGJKHQRFJGLJLV-VFFRCKCKSA-N
DMBHYIJ IU (2S)-N-[(2S)-3-(2-amino-1,3-thiazol-4-yl)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-1-oxopropan-2-yl]-2-(morpholin-4-ylsulfonylamino)-3-phenylpropanamide
DMBHYIJ DE Hypertension
DMCJ7N1 ID DMCJ7N1
DMCJ7N1 DN CI-996
DMCJ7N1 HS Terminated
DMCJ7N1 CP Parke-Davis & Co
DMCJ7N1 PC 9828975
DMCJ7N1 MW 549.5
DMCJ7N1 FM C27H22F3N7O3
DMCJ7N1 IC InChI=1S/C27H22F3N7O3/c1-2-6-21-31-25(36-14-5-9-20(36)23(38)27(28,29)30)22(26(39)40)37(21)15-16-10-12-17(13-11-16)18-7-3-4-8-19(18)24-32-34-35-33-24/h3-5,7-14H,2,6,15H2,1H3,(H,39,40)(H,32,33,34,35)
DMCJ7N1 CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)N5C=CC=C5C(=O)C(F)(F)F
DMCJ7N1 IK MGSBGAVGFLLRDU-UHFFFAOYSA-N
DMCJ7N1 IU 2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5-[2-(2,2,2-trifluoroacetyl)pyrrol-1-yl]imidazole-4-carboxylic acid
DMCJ7N1 DE Hypertension
DMV1J0P ID DMV1J0P
DMV1J0P DN CI-999
DMV1J0P HS Terminated
DMV1J0P SN PD-138142-15
DMV1J0P CP Warner-Lambert Co
DMV1J0P PC 74083365
DMV1J0P MW 483.6
DMV1J0P FM C25H34NNaO5S
DMV1J0P IC InChI=1S/C25H35NO5S.Na/c1-15(2)19-11-9-12-20(16(3)4)23(19)30-25(27)26-32(28,29)31-24-21(17(5)6)13-10-14-22(24)18(7)8;/h9-18H,1-8H3,(H,26,27);/q;+1/p-1
DMV1J0P CS CC(C)C1=C(C(=CC=C1)C(C)C)OC(=NS(=O)(=O)OC2=C(C=CC=C2C(C)C)C(C)C)[O-].[Na+]
DMV1J0P IK XVUJDEGOJDKQDX-UHFFFAOYSA-M
DMV1J0P IU sodium;1-[2,6-di(propan-2-yl)phenoxy]-N-[2,6-di(propan-2-yl)phenoxy]sulfonylmethanimidate
DMV1J0P DE Arteriosclerosis
DMBNWM1 ID DMBNWM1
DMBNWM1 DN Cilofungin
DMBNWM1 HS Terminated
DMBNWM1 SN Cilofungina; Cilofunginum; L-646991; LY-121019; Cilofungin (USAN/INN); L-649,991; 1-[(4R,5R)-4,5-Dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]echinocandin B; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-[4-(octyloxy)benzoyl]-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}
DMBNWM1 CP Eli Lilly
DMBNWM1 DT Small molecular drug
DMBNWM1 PC 6918120
DMBNWM1 MW 1030.099
DMBNWM1 FM C49H71N7O17
DMBNWM1 IC InChI=1S/C49H71N7O17/c1-5-6-7-8-9-10-19-73-31-17-13-28(14-18-31)42(65)50-32-21-34(61)45(68)54-47(70)38-39(62)24(2)22-56(38)49(72)36(26(4)58)52-46(69)37(41(64)40(63)27-11-15-29(59)16-12-27)53-44(67)33-20-30(60)23-55(33)48(71)35(25(3)57)51-43(32)66/h11-18,24-26,30,32-41,45,57-64,68H,5-10,19-23H2,1-4H3,(H,50,65)(H,51,66)(H,52,69)(H,53,67)(H,54,70)/t24-,25+,26+,30+,32-,33-,34+,35-,36-,37-,38-,39-,40-,41-,45+/m0/s1
DMBNWM1 CS CCCCCCCCOC1=CC=C(C=C1)C(=O)N[C@H]2C[C@H]([C@H](NC(=O)[C@@H]3[C@H]([C@H](CN3C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](NC2=O)[C@@H](C)O)O)[C@@H]([C@H](C5=CC=C(C=C5)O)O)O)[C@@H](C)O)C)O)O)O
DMBNWM1 IK ZKZKCEAHVFVZDJ-MTUMARHDSA-N
DMBNWM1 IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-octoxybenzamide
DMBNWM1 CA CAS 79404-91-4
DMBNWM1 CB CHEBI:315019
DMBNWM1 DE Candidiasis
DM0NJMG ID DM0NJMG
DM0NJMG DN Ciprokiren
DM0NJMG HS Terminated
DM0NJMG SN Ro-44-9375
DM0NJMG CP F Hoffmann-La Roche Ltd
DM0NJMG DT Small molecular drug
DM0NJMG PC 5312136
DM0NJMG MW 729.9
DM0NJMG FM C37H55N5O8S
DM0NJMG IC InChI=1S/C37H55N5O8S/c1-37(2,36(47)42-15-17-50-18-16-42)51(48,49)23-28(19-25-9-5-3-6-10-25)34(45)41-31(21-29-22-38-24-39-29)35(46)40-30(20-26-11-7-4-8-12-26)33(44)32(43)27-13-14-27/h3,5-6,9-10,22,24,26-28,30-33,43-44H,4,7-8,11-21,23H2,1-2H3,(H,38,39)(H,40,46)(H,41,45)/t28-,30+,31+,32+,33-/m1/s1
DM0NJMG CS CC(C)(C(=O)N1CCOCC1)S(=O)(=O)C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC4CCCCC4)[C@H]([C@H](C5CC5)O)O
DM0NJMG IK PODHJNNUGIBMOP-HOQQKOLYSA-N
DM0NJMG IU (2S)-2-benzyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-3-(2-methyl-1-morpholin-4-yl-1-oxopropan-2-yl)sulfonylpropanamide
DM0NJMG CA CAS 143631-62-3
DM0NJMG DE Hypertension
DMJBGI1 ID DMJBGI1
DMJBGI1 DN CL-184005
DMJBGI1 HS Terminated
DMJBGI1 SN GF2IPH21J7; CL 184005; UNII-GF2IPH21J7; CL-184005; CHEMBL296973; 140466-18-8; CL-184,005; AC1L30Q7; DTXSID40161407; BDBM50001754; (2-methoxycarbonyl-3-tetradecoxyphenyl) [3-[(5-methyl-1,3-thiazol-3-ium-3-yl)methyl]phenyl] phosphate; ((CL 184005))3-{3-[Hydroxy-(2-methoxycarbonyl-3-tetradecyloxy-phenoxy)-phosphoryloxy]-benzyl}-5-methyl-thiazol-3-ium; 2-{Hydroxy-[3-(5-methyl-thiazol-3-ylmethyl)-phenoxy]-dihydrogen phosphate}-6-tetradecyloxy-benzoic acid methyl ester(CL 184005); Thiazolium, 3-((3-((hydroxy(2-(methoxycarbony
DMJBGI1 DT Small molecular drug
DMJBGI1 PC 132290
DMJBGI1 MW 631.8
DMJBGI1 FM C33H46NO7PS
DMJBGI1 IC InChI=1S/C33H46NO7PS/c1-4-5-6-7-8-9-10-11-12-13-14-15-22-39-30-20-17-21-31(32(30)33(35)38-3)41-42(36,37)40-29-19-16-18-28(23-29)25-34-24-27(2)43-26-34/h16-21,23-24,26H,4-15,22,25H2,1-3H3
DMJBGI1 CS CCCCCCCCCCCCCCOC1=C(C(=CC=C1)OP(=O)([O-])OC2=CC=CC(=C2)C[N+]3=CSC(=C3)C)C(=O)OC
DMJBGI1 IK VGVUQNMRGKNUJA-UHFFFAOYSA-N
DMJBGI1 IU (2-methoxycarbonyl-3-tetradecoxyphenyl) [3-[(5-methyl-1,3-thiazol-3-ium-3-yl)methyl]phenyl] phosphate
DMJBGI1 CA CAS 140466-18-8
DMJBGI1 DE Sepsis
DMYML2N ID DMYML2N
DMYML2N DN CL-186659
DMYML2N HS Terminated
DMYML2N SN IDDB8406
DMYML2N CP Lederle Laboratories
DMYML2N DE Bacterial infection
DMA4DNX ID DMA4DNX
DMA4DNX DN CL-387626
DMA4DNX HS Terminated
DMA4DNX SN RFI-641 (free acid); 4,4'-Bis[4,6-bis[3-[bis(3-amino-3-oxopropyl)aminosulfonyl]phenylamino]-1,3,5-triazin-2-ylamino][1,1'-biphenyl]-2,2'-disulfonic acid disodium salt
DMA4DNX PC 16134411
DMA4DNX MW 1795.8
DMA4DNX FM C66H76N24Na2O22S6
DMA4DNX IC InChI=1S/C66H78N24O22S6.2Na/c67-53(91)17-25-87(26-18-54(68)92)113(99,100)45-9-1-5-39(33-45)75-61-81-62(76-40-6-2-10-46(34-40)114(101,102)88(27-19-55(69)93)28-20-56(70)94)84-65(83-61)79-43-13-15-49(51(37-43)117(107,108)109)50-16-14-44(38-52(50)118(110,111)112)80-66-85-63(77-41-7-3-11-47(35-41)115(103,104)89(29-21-57(71)95)30-22-58(72)96)82-64(86-66)78-42-8-4-12-48(36-42)116(105,106)90(31-23-59(73)97)32-24-60(74)98;;/h1-16,33-38H,17-32H2,(H2,67,91)(H2,68,92)(H2,69,93)(H2,70,94)(H2,71,95)(H2,72,96)(H2,73,97)(H2,74,98)(H,107,108,109)(H,110,111,112)(H3,75,76,79,81,83,84)(H3,77,78,80,82,85,86);;/q;2*+1/p-2
DMA4DNX CS C1=CC(=CC(=C1)S(=O)(=O)N(CCC(=O)N)CCC(=O)N)NC2=NC(=NC(=N2)NC3=CC(=C(C=C3)C4=C(C=C(C=C4)NC5=NC(=NC(=N5)NC6=CC(=CC=C6)S(=O)(=O)N(CCC(=O)N)CCC(=O)N)NC7=CC(=CC=C7)S(=O)(=O)N(CCC(=O)N)CCC(=O)N)S(=O)(=O)[O-])S(=O)(=O)[O-])NC8=CC(=CC=C8)S(=O)(=O)N(CCC(=O)N)CCC(=O)N.[Na+].[Na+]
DMA4DNX IK RHYDQBKNSGARFE-UHFFFAOYSA-L
DMA4DNX IU disodium;5-[[4,6-bis[3-[bis(3-amino-3-oxopropyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-[4-[[4,6-bis[3-[bis(3-amino-3-oxopropyl)sulfamoyl]anilino]-1,3,5-triazin-2-yl]amino]-2-sulfonatophenyl]benzenesulfonate
DMA4DNX DE Virus infection
DM8TQC9 ID DM8TQC9
DM8TQC9 DN Clentiazem
DM8TQC9 HS Terminated
DM8TQC9 SN CLENTIAZEM; Clentiazem [INN]; Clentiazemum [INN-Latin]; UNII-40DK034DRC; 40DK034DRC; 96125-53-0; C22H25ClN2O4S; (+)-cis-2-(4-Methoxyphenyl)-3-acetoxy-5-(2-(N,N-dimethylamino)ethyl)-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; Clentiazemum; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (25-cis)-; 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-8-chloro-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S,3S)-; AC1L1M5S; SCHEMBL33909
DM8TQC9 DT Small molecular drug
DM8TQC9 PC 57026
DM8TQC9 MW 449
DM8TQC9 FM C22H25ClN2O4S
DM8TQC9 IC InChI=1S/C22H25ClN2O4S/c1-14(26)29-20-21(15-5-8-17(28-4)9-6-15)30-19-13-16(23)7-10-18(19)25(22(20)27)12-11-24(2)3/h5-10,13,20-21H,11-12H2,1-4H3/t20-,21+/m1/s1
DM8TQC9 CS CC(=O)O[C@@H]1[C@@H](SC2=C(C=CC(=C2)Cl)N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DM8TQC9 IK GYKFWCDBQAFCLJ-RTWAWAEBSA-N
DM8TQC9 IU [(2S,3S)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DM8TQC9 CA CAS 96125-53-0
DM8TQC9 DE Angina pectoris
DM6F8L5 ID DM6F8L5
DM6F8L5 DN Clinafloxacin
DM6F8L5 HS Terminated
DM6F8L5 SN Clinafloxacin hydrochloride; AM-1091; PD-127391
DM6F8L5 CP Parke-Davis & Co
DM6F8L5 DT Small molecular drug
DM6F8L5 PC 60063
DM6F8L5 MW 365.8
DM6F8L5 FM C17H17ClFN3O3
DM6F8L5 IC InChI=1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)
DM6F8L5 CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)Cl)N4CCC(C4)N)F)C(=O)O
DM6F8L5 IK QGPKADBNRMWEQR-UHFFFAOYSA-N
DM6F8L5 IU 7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
DM6F8L5 CA CAS 105956-97-6
DM6F8L5 CB CHEBI:94459
DM6F8L5 DE Pneumonia
DMVUL4P ID DMVUL4P
DMVUL4P DN CLX-0301
DMVUL4P HS Terminated
DMVUL4P CP Calyx Therapeutics Inc
DMVUL4P DE Diabetic complication
DMYPRS9 ID DMYPRS9
DMYPRS9 DN CLX-0900
DMYPRS9 HS Terminated
DMYPRS9 SN CLX-0900E
DMYPRS9 CP Calyx Therapeutics Inc
DMYPRS9 DE Hyperlipidaemia
DMEIW7K ID DMEIW7K
DMEIW7K DN CMI-206
DMEIW7K HS Terminated
DMEIW7K SN IDDB8444
DMEIW7K CP CytoMed Inc
DMEIW7K DE Inflammation
DMP3QAZ ID DMP3QAZ
DMP3QAZ DN CNS-1237
DMP3QAZ HS Terminated
DMP3QAZ CP CeNeS Pharmaceuticals Inc
DMP3QAZ PC 9907241
DMP3QAZ MW 367.4
DMP3QAZ FM C24H21N3O
DMP3QAZ IC InChI=1S/C24H21N3O/c1-28-22-14-13-20(17-6-2-3-7-18(17)22)26-24(25)27-21-12-11-16-10-9-15-5-4-8-19(21)23(15)16/h2-8,11-14H,9-10H2,1H3,(H3,25,26,27)
DMP3QAZ CS COC1=CC=C(C2=CC=CC=C21)NC(=NC3=CC=C4CCC5=C4C3=CC=C5)N
DMP3QAZ IK AZZRFSWIWLKNLQ-UHFFFAOYSA-N
DMP3QAZ IU 2-(1,2-dihydroacenaphthylen-5-yl)-1-(4-methoxynaphthalen-1-yl)guanidine
DMP3QAZ DE Cerebrovascular ischaemia
DM03LZB ID DM03LZB
DM03LZB DN CNS-1307
DM03LZB HS Terminated
DM03LZB CP CeNeS Pharmaceuticals Inc
DM03LZB DE Schizophrenia
DMZ5N2I ID DMZ5N2I
DMZ5N2I DN CNS-1531
DMZ5N2I HS Terminated
DMZ5N2I CP CeNeS Pharmaceuticals Inc
DMZ5N2I DE Nervous system disease
DMZY0SF ID DMZY0SF
DMZY0SF DN CNS-5788
DMZY0SF HS Terminated
DMZY0SF SN UNII-67M8W71RHJ; 67M8W71RHJ
DMZY0SF CP CeNeS Pharmaceuticals Inc
DMZY0SF DT Small molecular drug
DMZY0SF PC 9842186
DMZY0SF MW 367.9
DMZY0SF FM C16H18ClN3OS2
DMZY0SF IC InChI=1S/C16H18ClN3OS2/c1-20(11-5-4-6-13(9-11)23(3)21)16(18)19-15-10-12(22-2)7-8-14(15)17/h4-10H,1-3H3,(H2,18,19)
DMZY0SF CS CN(C1=CC(=CC=C1)S(=O)C)C(=NC2=C(C=CC(=C2)SC)Cl)N
DMZY0SF IK RODJWDCTFWIGQR-UHFFFAOYSA-N
DMZY0SF IU 2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfinylphenyl)guanidine
DMZY0SF CA CAS 342047-49-8
DMZY0SF DE Cerebrovascular ischaemia
DMU5TZD ID DMU5TZD
DMU5TZD DN Co-152791
DMU5TZD HS Terminated
DMU5TZD CP Purdue Neuroscience Corp
DMU5TZD PC 9825518
DMU5TZD MW 460.6
DMU5TZD FM C31H40O3
DMU5TZD IC InChI=1S/C31H40O3/c1-20(32)23-7-5-22(6-8-23)13-16-31(34)18-17-29(3)24(19-31)9-10-25-27-12-11-26(21(2)33)30(27,4)15-14-28(25)29/h5-8,24-28,34H,9-12,14-15,17-19H2,1-4H3/t24-,25-,26+,27-,28-,29-,30+,31+/m0/s1
DMU5TZD CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C#CC5=CC=C(C=C5)C(=O)C)O)C)C
DMU5TZD IK ZPPSBQVNGSDAFI-KWJNIICQSA-N
DMU5TZD IU 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-[2-(4-acetylphenyl)ethynyl]-3-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMU5TZD DE Epilepsy
DMGIZHX ID DMGIZHX
DMGIZHX DN Co-60549
DMGIZHX HS Terminated
DMGIZHX SN Epalon series member (60549), CoCensys
DMGIZHX CP Purdue Neuroscience Corp
DMGIZHX DE Anxiety disorder
DMQESM7 ID DMQESM7
DMQESM7 DN Cordil
DMQESM7 HS Terminated
DMQESM7 SN LND-796; LNF-209
DMQESM7 CP The Procter & Gamble Co
DMQESM7 PC 3081161
DMQESM7 MW 495.6
DMQESM7 FM C27H45NO7
DMQESM7 IC InChI=1S/C27H45NO7/c1-14-20(29)21(30)22(31)24(34-14)35-16-7-10-25(2)15(13-16)5-6-18-17(25)8-11-26(3)19(23(32)33-4)9-12-27(18,26)28/h14-22,24,29-31H,5-13,28H2,1-4H3/t14-,15+,16-,17-,18+,19+,20-,21+,22+,24-,25-,26+,27-/m0/s1
DMQESM7 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C(=O)OC)N)C)C)O)O)O
DMQESM7 IK HKWLCBGLVAWZRK-CBYCSKBWSA-N
DMQESM7 IU methyl (3S,5R,8R,9S,10S,13R,14S,17S)-14-amino-10,13-dimethyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-17-carboxylate
DMQESM7 CA CAS 118549-42-1
DMQESM7 DE Heart arrhythmia
DMO3486 ID DMO3486
DMO3486 DN COSALANE
DMO3486 HS Terminated
DMO3486 SN Cosalane; AC1L2I0J; CHEMBL300101; CTK6A7531; BDBM50036146; LS-187298; 5-[1-(3-carboxy-5-chloro-4-hydroxyphenyl)-4-[(3S,10S,13R,17R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-hydroxybenzoic acid; 5-{1-(3-carboxy-5-chloro-4-hydroxyphenyl-4-[1-(1,5-dimethylhexyl)-9a,11a-dimethylperhydrocyclopenta[a]phenanthren-7-yl]-1-butenyl}-3-chloro-2-hydroxy acetic acid (Cosalane)
DMO3486 DT Small molecular drug
DMO3486 PC 455040
DMO3486 MW 767.9
DMO3486 FM C45H60Cl2O6
DMO3486 IC InChI=1S/C45H60Cl2O6/c1-25(2)8-6-9-26(3)35-14-15-36-32-13-12-30-20-27(16-18-44(30,4)37(32)17-19-45(35,36)5)10-7-11-31(28-21-33(42(50)51)40(48)38(46)23-28)29-22-34(43(52)53)41(49)39(47)24-29/h11,21-27,30,32,35-37,48-49H,6-10,12-20H2,1-5H3,(H,50,51)(H,52,53)/t26-,27+,30+,32+,35-,36+,37+,44+,45-/m1/s1
DMO3486 CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@H](C4)CCC=C(C5=CC(=C(C(=C5)Cl)O)C(=O)O)C6=CC(=C(C(=C6)Cl)O)C(=O)O)C)C
DMO3486 IK VOJOOGPALCATLT-ZFQBPCNVSA-N
DMO3486 IU 5-[1-(3-carboxy-5-chloro-4-hydroxyphenyl)-4-[(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-hydroxybenzoic acid
DMO3486 CA CAS 154212-56-3
DMS23JX ID DMS23JX
DMS23JX DN CP-0597
DMS23JX HS Terminated
DMS23JX CP Cortech Inc
DMS23JX PC 9833644
DMS23JX MW 1292.5
DMS23JX FM C58H89N19O13S
DMS23JX IC InChI=1S/C58H89N19O13S/c59-38(16-6-20-66-56(60)61)48(82)72-39(17-7-21-67-57(62)63)51(85)74-23-9-19-43(74)53(87)77-30-36(79)26-44(77)50(84)69-28-46(80)71-41(27-37-15-10-24-91-37)49(83)73-42(32-78)52(86)76-29-34-12-5-4-11-33(34)25-45(76)54(88)75(35-13-2-1-3-14-35)31-47(81)70-40(55(89)90)18-8-22-68-58(64)65/h4-5,10-12,15,24,35-36,38-45,78-79H,1-3,6-9,13-14,16-23,25-32,59H2,(H,69,84)(H,70,81)(H,71,80)(H,72,82)(H,73,83)(H,89,90)(H4,60,61,66)(H4,62,63,67)(H4,64,65,68)/t36-,38-,39+,40+,41+,42+,43+,44+,45-/m1/s1
DMS23JX CS C1CCC(CC1)N(CC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C(=O)[C@H]2CC3=CC=CC=C3CN2C(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CS4)NC(=O)CNC(=O)[C@@H]5C[C@H](CN5C(=O)[C@@H]6CCCN6C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O
DMS23JX IK UZTHIUKOCVEJNZ-GWJNKJQQSA-N
DMS23JX IU (2S)-2-[[2-[[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-cyclohexylamino]acetyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMS23JX DE Asthma
DMDQBAL ID DMDQBAL
DMDQBAL DN CP-293019
DMDQBAL HS Terminated
DMDQBAL SN CP-293019; CHEMBL66227; GTPL977; SCHEMBL6844226; BDBM50069041; CP293019; CP 293019; 7-(4-Fluoro-phenoxymethyl)-2-(5-fluoro-pyrimidin-2-yl)-octahydro-pyrido[1,2-a]pyrazine (CP-293019); (7R,9aalpha)-2-(5-Fluoro-2-pyrimidinyl)-7alpha-(4-fluorophenoxymethyl)octahydro-6H-pyrido[1,2-a]pyrazine; (7R,9aS)-7-[(4-fluorophenoxy)methyl]-2-(5-fluoropyrimidin-2-yl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine
DMDQBAL DT Small molecular drug
DMDQBAL PC 9820261
DMDQBAL MW 360.4
DMDQBAL FM C19H22F2N4O
DMDQBAL IC InChI=1S/C19H22F2N4O/c20-15-2-5-18(6-3-15)26-13-14-1-4-17-12-25(8-7-24(17)11-14)19-22-9-16(21)10-23-19/h2-3,5-6,9-10,14,17H,1,4,7-8,11-13H2/t14-,17+/m1/s1
DMDQBAL CS C1C[C@H]2CN(CCN2C[C@@H]1COC3=CC=C(C=C3)F)C4=NC=C(C=N4)F
DMDQBAL IK QXWNESOGWFJDFR-PBHICJAKSA-N
DMDQBAL IU (7R,9aS)-7-[(4-fluorophenoxy)methyl]-2-(5-fluoropyrimidin-2-yl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine
DMCIXYR ID DMCIXYR
DMCIXYR DN CP-331
DMCIXYR HS Terminated
DMCIXYR CP Zeria Pharmaceutical Co Ltd
DMCIXYR DT Small molecular drug
DMCIXYR PC 130967
DMCIXYR MW 706.3
DMCIXYR FM C38H44ClN3O6S
DMCIXYR IC InChI=1S/C38H44ClN3O6S/c1-27-33(34-23-31(46-2)14-15-35(34)42(27)38(45)29-10-12-30(39)13-11-29)24-37(44)48-20-21-49-26-36(43)40-16-7-19-47-32-9-6-8-28(22-32)25-41-17-4-3-5-18-41/h6,8-15,22-23H,3-5,7,16-21,24-26H2,1-2H3,(H,40,43)
DMCIXYR CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCCSCC(=O)NCCCOC4=CC=CC(=C4)CN5CCCCC5
DMCIXYR IK SWFXMFDHMPMWMA-UHFFFAOYSA-N
DMCIXYR IU 2-[2-oxo-2-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]ethyl]sulfanylethyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate
DMCIXYR CA CAS 127966-70-5
DMCIXYR DE Pain
DMDEPKM ID DMDEPKM
DMDEPKM DN CP-471358
DMDEPKM HS Terminated
DMDEPKM CP Pfizer Inc
DMDEPKM PC 9869142
DMDEPKM MW 466.5
DMDEPKM FM C21H23FN2O7S
DMDEPKM IC InChI=1S/C21H23FN2O7S/c22-15-3-5-16(6-4-15)31-17-7-9-18(10-8-17)32(29,30)24(14-11-19(25)26)21(20(27)23-28)12-1-2-13-21/h3-10,28H,1-2,11-14H2,(H,23,27)(H,25,26)
DMDEPKM CS C1CCC(C1)(C(=O)NO)N(CCC(=O)O)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)F
DMDEPKM IK VHHGUBHZBLPTKL-UHFFFAOYSA-N
DMDEPKM IU 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclopentyl]amino]propanoic acid
DMDEPKM DE Solid tumour/cancer
DMIZMJD ID DMIZMJD
DMIZMJD DN CP-663427
DMIZMJD HS Terminated
DMIZMJD SN LNK-427; OSI-427
DMIZMJD CP Pfizer Inc
DMIZMJD DE Solid tumour/cancer
DMWFI4A ID DMWFI4A
DMWFI4A DN CP-67015
DMWFI4A HS Terminated
DMWFI4A SN 100325-51-7; CCRIS 2955; CP-67015; CP 67015; CP-67,015; 3-Quinolinecarboxylic acid, 1,4-dihydro-6,8-difluoro-1-ethyl-4-oxo-7-(4-pyridinyl)-; 3-Quinolinecarboxylicacid, 1-ethyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(4-pyridinyl)-; ACMC-20m3dd; AC1L2S7K; SCHEMBL9304919; CTK0H9319; DTXSID00143163; AKOS030543955; LS-141575; 1-ethyl-6,8-difluoro-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-4-oxo-7-(4-pyridinyl)-; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dih
DMWFI4A CP Pfizer Inc
DMWFI4A DT Small molecular drug
DMWFI4A PC 127557
DMWFI4A MW 330.28
DMWFI4A FM C17H12F2N2O3
DMWFI4A IC InChI=1S/C17H12F2N2O3/c1-2-21-8-11(17(23)24)16(22)10-7-12(18)13(14(19)15(10)21)9-3-5-20-6-4-9/h3-8H,2H2,1H3,(H,23,24)
DMWFI4A CS CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)C3=CC=NC=C3)F)C(=O)O
DMWFI4A IK AVTJRMCCKOBMQP-UHFFFAOYSA-N
DMWFI4A IU 1-ethyl-6,8-difluoro-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
DMWFI4A CA CAS 100325-51-7
DMWFI4A DE Bacterial infection
DMSOT07 ID DMSOT07
DMSOT07 DN CP-83101
DMSOT07 HS Terminated
DMSOT07 SN AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; CP-83101; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-
DMSOT07 CP Pfizer Inc
DMSOT07 DT Small molecular drug
DMSOT07 PC 6438614
DMSOT07 MW 352.4
DMSOT07 FM C22H24O4
DMSOT07 IC InChI=1S/C22H24O4/c1-26-22(25)16-20(24)15-19(23)13-8-14-21(17-9-4-2-5-10-17)18-11-6-3-7-12-18/h2-14,19-20,23-24H,15-16H2,1H3/b13-8+/t19-,20-/m1/s1
DMSOT07 CS COC(=O)C[C@@H](C[C@@H](/C=C/C=C(C1=CC=CC=C1)C2=CC=CC=C2)O)O
DMSOT07 IK NSZBOSJMBQKKKB-ZCBOBATRSA-N
DMSOT07 IU methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate
DMSOT07 CA CAS 130746-82-6
DMSOT07 DE Arteriosclerosis
DMEJBQY ID DMEJBQY
DMEJBQY DN CP-903397
DMEJBQY HS Terminated
DMEJBQY CP Pfizer Inc
DMEJBQY DE Schizophrenia
DM4HYWR ID DM4HYWR
DM4HYWR DN CP-96345
DM4HYWR HS Terminated
DM4HYWR SN CP 96345; CP-96345; 132746-60-2; UNII-W22ILA2I52; CP 96344; CP 96,345; CHEMBL16192; W22ILA2I52; 2-(Diphenylmethyl)-N-((2-methoxyphenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine; CP-96,345; (2S,3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine; (2S,3S)-2-benzhydryl-N-[(2-methoxyphenyl)methyl]quinuclidin-3-amine; (2S,3S)-N-(2-methoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo[2.2.2]octan-3-amine; 1-Azabicyclo(2.2.2)octan-3-amine, 2-(diphenylmethyl)-N-((2-methoxyphenyl)methyl)-, (2S-cis
DM4HYWR DT Small molecular drug
DM4HYWR PC 104943
DM4HYWR MW 412.6
DM4HYWR FM C28H32N2O
DM4HYWR IC InChI=1S/C28H32N2O/c1-31-25-15-9-8-14-24(25)20-29-27-23-16-18-30(19-17-23)28(27)26(21-10-4-2-5-11-21)22-12-6-3-7-13-22/h2-15,23,26-29H,16-20H2,1H3/t27-,28-/m0/s1
DM4HYWR CS COC1=CC=CC=C1CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM4HYWR IK FLNYLINBEZROPL-NSOVKSMOSA-N
DM4HYWR IU (2S,3S)-2-benzhydryl-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DM4HYWR CA CAS 132746-60-2
DM8NVZQ ID DM8NVZQ
DM8NVZQ DN CR-1795
DM8NVZQ HS Terminated
DM8NVZQ SN CHEMBL169466; BDBM50281699; 5-Dipentylcarbamoyl-5-[((R)-naphthalene-2-carbonyl)-amino]-pentanoic acid
DM8NVZQ DT Small molecular drug
DM8NVZQ PC 44381915
DM8NVZQ MW 454.6
DM8NVZQ FM C27H38N2O4
DM8NVZQ IC InChI=1S/C27H38N2O4/c1-3-5-9-18-29(19-10-6-4-2)27(33)24(14-11-15-25(30)31)28-26(32)23-17-16-21-12-7-8-13-22(21)20-23/h7-8,12-13,16-17,20,24H,3-6,9-11,14-15,18-19H2,1-2H3,(H,28,32)(H,30,31)/t24-/m1/s1
DM8NVZQ CS CCCCCN(CCCCC)C(=O)[C@@H](CCCC(=O)O)NC(=O)C1=CC2=CC=CC=C2C=C1
DM8NVZQ IK VHCOMPFCZPOZFX-XMMPIXPASA-N
DM8NVZQ IU (5R)-6-(dipentylamino)-5-(naphthalene-2-carbonylamino)-6-oxohexanoic acid
DM51XDU ID DM51XDU
DM51XDU DN CR-2991
DM51XDU HS Terminated
DM51XDU SN Quinazoline alpha1 adrenoceptor antagonist (hypertension, prostatic hyperplasia), Rottapharm
DM51XDU CP Rottapharm Madaus
DM51XDU DE Hypertension
DM1MBG9 ID DM1MBG9
DM1MBG9 DN CR-3124
DM1MBG9 HS Terminated
DM1MBG9 CP RottaPharma
DM1MBG9 DT Small molecular drug
DM1MBG9 PC 11738327
DM1MBG9 MW 306.4
DM1MBG9 FM C20H22N2O
DM1MBG9 IC InChI=1S/C20H22N2O/c1-21-15-8-9-16(21)11-17(10-15)22-12-14-7-6-13-4-2-3-5-18(13)19(14)20(22)23/h2-7,15-17H,8-12H2,1H3/t15-,16+,17?
DM1MBG9 CS CN1[C@@H]2CC[C@H]1CC(C2)N3CC4=C(C3=O)C5=CC=CC=C5C=C4
DM1MBG9 IK RCJGTDKFZCRBAH-SJPCQFCGSA-N
DM1MBG9 IU 2-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3H-benzo[g]isoindol-1-one
DM1MBG9 CA CAS 263896-41-9
DM1MBG9 DE Substance use disorder
DMTPDX7 ID DMTPDX7
DMTPDX7 DN CR-3834
DMTPDX7 HS Terminated
DMTPDX7 SN Angiotensin II antagonist (hypertension), Rottapharm
DMTPDX7 CP Rottapharm Madaus
DMTPDX7 DE Hypertension
DMRNB7V ID DMRNB7V
DMRNB7V DN CRA-028129
DMRNB7V HS Terminated
DMRNB7V CP Celera Genomics
DMRNB7V DE Psoriatic disorder
DM1E7H3 ID DM1E7H3
DM1E7H3 DN CS-204
DM1E7H3 HS Terminated
DM1E7H3 SN CS-00088; PPAR alpha/gamma/delta agonist (type 2 diabetes), Chipscreen Bioscience
DM1E7H3 CP Shenzhen Chipscreen Biosciences Ltd
DM1E7H3 DE Metabolic disorder
DMFJ4VT ID DMFJ4VT
DMFJ4VT DN CS-207
DMFJ4VT HS Terminated
DMFJ4VT SN CS-307; PPAR alpha agonists (cardiovascular disease associated with dyslipidemia); PPAR alpha agonists (cardiovascular disease associated with dyslipidemia), Chipscreen Biosciences
DMFJ4VT CP Shenzhen Chipscreen Biosciences Ltd
DMFJ4VT DE Cardiovascular disease
DM84KOY ID DM84KOY
DM84KOY DN CT-1746
DM84KOY HS Terminated
DM84KOY CP Celltech Therapeutics Ltd
DM84KOY PC 9930721
DM84KOY MW 397.9
DM84KOY FM C19H28ClN3O4
DM84KOY IC InChI=1S/C19H28ClN3O4/c1-19(2,3)16(17(21)25)22-18(26)13(11-15(24)23-27)6-4-5-12-7-9-14(20)10-8-12/h7-10,13,16,27H,4-6,11H2,1-3H3,(H2,21,25)(H,22,26)(H,23,24)/t13-,16-/m1/s1
DM84KOY CS CC(C)(C)[C@@H](C(=O)N)NC(=O)[C@H](CCCC1=CC=C(C=C1)Cl)CC(=O)NO
DM84KOY IK CZCIELLKWLGEFJ-CZUORRHYSA-N
DM84KOY IU (2R)-N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-2-[3-(4-chlorophenyl)propyl]-N'-hydroxybutanediamide
DM84KOY DE Colorectal cancer
DMQBULC ID DMQBULC
DMQBULC DN CV 6209
DMQBULC HS Terminated
DMQBULC SN CHEMBL274420; CV6209; GTPL1852; AC1L32P4; SCHEMBL8538219; CHEMBL1180101; PDSP1_000728; PDSP1_000727; PDSP2_000718; PDSP2_000717; BDBM50005232; 2-(2-Acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacosan-1-yl)-1-ethylpyridinium; 2-{[Acetyl-(2-methoxy-3-octadecylcarbamoyloxy-propoxycarbonyl)-amino]-methyl}-1-ethyl-pyridinium; [2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate
DMQBULC DT Small molecular drug
DMQBULC PC 107756
DMQBULC MW 642.3
DMQBULC FM C34H60ClN3O6
DMQBULC IC InChI=1S/C34H59N3O6.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-25-35-33(39)42-28-32(41-4)29-43-34(40)37(30(3)38)27-31-24-21-23-26-36(31)6-2;/h21,23-24,26,32H,5-20,22,25,27-29H2,1-4H3;1H
DMQBULC CS CCCCCCCCCCCCCCCCCCNC(=O)OCC(COC(=O)N(CC1=CC=CC=[N+]1CC)C(=O)C)OC.[Cl-]
DMQBULC IK APUCCVGQZPNXIO-UHFFFAOYSA-N
DMQBULC IU [2-methoxy-3-(octadecylcarbamoyloxy)propyl] N-acetyl-N-[(1-ethylpyridin-1-ium-2-yl)methyl]carbamate;chloride
DMQBULC CA CAS 100488-87-7
DMQBULC DE Asthma
DMMDO3X ID DMMDO3X
DMMDO3X DN CVS-995
DMMDO3X HS Terminated
DMMDO3X SN Corthrombin injectable
DMMDO3X CP Dendreon San Diego LLC
DMMDO3X DE Myocardial infarction
DMPWZCI ID DMPWZCI
DMPWZCI DN CVT-1
DMPWZCI HS Terminated
DMPWZCI CP Gilead Palo Alto Inc
DMPWZCI DE Hypercholesterolaemia
DM0X147 ID DM0X147
DM0X147 DN CY-1748
DM0X147 HS Terminated
DM0X147 CP Epimmune Inc
DM0X147 DE Deep vein thrombosis
DMPBCLA ID DMPBCLA
DMPBCLA DN CY-9652
DMPBCLA HS Terminated
DMPBCLA SN Integrin antagonists, Cytel
DMPBCLA CP Epimmune Inc
DMPBCLA DE Inflammation
DM17NYA ID DM17NYA
DM17NYA DN CYC-103
DM17NYA HS Terminated
DM17NYA SN Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel
DM17NYA CP Cyclacel Pharmaceuticals Inc
DM17NYA DE Solid tumour/cancer
DMF8TCI ID DMF8TCI
DMF8TCI DN CZ-112
DMF8TCI HS Terminated
DMF8TCI CP Stehlin Foundation For Cancer Research
DMF8TCI DE Solid tumour/cancer
DME07ML ID DME07ML
DME07ML DN D-21775
DME07ML HS Terminated
DME07ML CP ASTA Medica AG
DME07ML DE Solid tumour/cancer
DM7FTCV ID DM7FTCV
DM7FTCV DN D-22888
DM7FTCV HS Terminated
DM7FTCV SN AWD-12-232
DM7FTCV CP ASTA Medica AG
DM7FTCV DT Small molecular drug
DM7FTCV PC 197714
DM7FTCV MW 300.36
DM7FTCV FM C16H20N4O2
DM7FTCV IC InChI=1S/C16H20N4O2/c1-5-9-19-11-7-8-13(22-4)18-15(11)20-12(6-2)17-10(3)14(20)16(19)21/h7-8H,5-6,9H2,1-4H3
DM7FTCV CS CCCN1C2=C(N=C(C=C2)OC)N3C(=NC(=C3C1=O)C)CC
DM7FTCV IK PJRYVTGCPZXGEY-UHFFFAOYSA-N
DM7FTCV IU 3-ethyl-12-methoxy-5-methyl-8-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,10,12-pentaen-7-one
DM7FTCV CA CAS 182282-60-6
DM7FTCV DE Allergy
DMBJAUC ID DMBJAUC
DMBJAUC DN D-26344
DMBJAUC HS Terminated
DMBJAUC CP ASTA Medica AG
DMBJAUC DE Solid tumour/cancer
DM0YFZ6 ID DM0YFZ6
DM0YFZ6 DN D-43787
DM0YFZ6 HS Terminated
DM0YFZ6 SN D-43787; UNII-18SFZ71BQO; 198016-44-3; 18SFZ71BQO; CTK8E8581; DTXSID30173514; ZINC3960990; d43787; 1H-Indole-1-carboxylic acid, 2-(((2S)-2,3-dihydro-2-((((1S)-1-(methoxycarbonyl)-5-(((phenylmethoxy)carbonyl)amino)pentyl)amino)carbonyl)-1H-indol-1-yl)carbonyl)-2,3-dihydro-, 1,1-dimethylethyl ester, (2S)-; RT-012166; FT-0665439; J-012788; (2S)-2-[[(2S)-2,3-Dihydro-2-[[[(1S)-1-(methoxycarbonyl)-5-[[(phenylmethoxy)carbonyl]amino]pentyl]amino]carbonyl]-1H-indol-1-yl]carbonyl]-2,3-dihydro-1H-Indole-1-carboxylic Acid 1,1-Dime
DM0YFZ6 DT Small molecular drug
DM0YFZ6 PC 9961556
DM0YFZ6 MW 684.8
DM0YFZ6 FM C38H44N4O8
DM0YFZ6 IC InChI=1S/C38H44N4O8/c1-38(2,3)50-37(47)42-30-20-11-9-17-27(30)23-32(42)34(44)41-29-19-10-8-16-26(29)22-31(41)33(43)40-28(35(45)48-4)18-12-13-21-39-36(46)49-24-25-14-6-5-7-15-25/h5-11,14-17,19-20,28,31-32H,12-13,18,21-24H2,1-4H3,(H,39,46)(H,40,43)/t28-,31-,32-/m0/s1
DM0YFZ6 CS CC(C)(C)OC(=O)N1[C@@H](CC2=CC=CC=C21)C(=O)N3[C@@H](CC4=CC=CC=C43)C(=O)N[C@@H](CCCCNC(=O)OCC5=CC=CC=C5)C(=O)OC
DM0YFZ6 IK GKYGBJABPHBINI-MHDHXZMLSA-N
DM0YFZ6 IU tert-butyl (2S)-2-[(2S)-2-[[(2S)-1-methoxy-1-oxo-6-(phenylmethoxycarbonylamino)hexan-2-yl]carbamoyl]-2,3-dihydroindole-1-carbonyl]-2,3-dihydroindole-1-carboxylate
DM0YFZ6 CA CAS 198016-44-3
DM0YFZ6 DE Allergy
DMXHN6U ID DMXHN6U
DMXHN6U DN D-5410
DMXHN6U HS Terminated
DMXHN6U SN CH-138; CH-263
DMXHN6U CP UCB Celltech
DMXHN6U DE Rheumatoid arthritis
DMHNZ1P ID DMHNZ1P
DMHNZ1P DN D-9120
DMHNZ1P HS Terminated
DMHNZ1P CP UCB Celltech
DMHNZ1P DE Inflammatory bowel disease
DM3LJK5 ID DM3LJK5
DM3LJK5 DN DAA-1097
DM3LJK5 HS Terminated
DM3LJK5 SN DAA-1106
DM3LJK5 CP Taisho Pharmaceutical Co Ltd
DM3LJK5 DT Small molecular drug
DM3LJK5 PC 9844410
DM3LJK5 MW 409.9
DM3LJK5 FM C24H24ClNO3
DM3LJK5 IC InChI=1S/C24H24ClNO3/c1-17(2)28-23-12-8-7-9-19(23)16-26(18(3)27)22-14-13-20(25)15-24(22)29-21-10-5-4-6-11-21/h4-15,17H,16H2,1-3H3
DM3LJK5 CS CC(C)OC1=CC=CC=C1CN(C2=C(C=C(C=C2)Cl)OC3=CC=CC=C3)C(=O)C
DM3LJK5 IK CGUBOFYHGYNUDL-UHFFFAOYSA-N
DM3LJK5 IU N-(4-chloro-2-phenoxyphenyl)-N-[(2-propan-2-yloxyphenyl)methyl]acetamide
DM3LJK5 CA CAS 220551-79-1
DM3LJK5 DE Anxiety disorder
DMP3X6Q ID DMP3X6Q
DMP3X6Q DN Dacetuzumab
DMP3X6Q HS Terminated
DMP3X6Q SN SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789
DMP3X6Q CP Roche; Genentech
DMP3X6Q DT Monoclonal antibody
DMP3X6Q DE Non-hodgkin lymphoma; Diffuse large B-cell lymphoma
DMZ8OMT ID DMZ8OMT
DMZ8OMT DN DACTIMICIN
DMZ8OMT HS Terminated
DMZ8OMT SN SF-2052; 4-Amino-1,4-dideoxy-3-O-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranosyl)-1-[(N-formimidoylglycyl)methylamino]-6-O-methyl-L-chiro-inositol; 4-Amino-1,4-dideoxy-3-O-(2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranosyl)-1-[[[(iminomethyl)amino]acetyl]methylamino]-6-O-methyl-L-chiro-inositol
DMZ8OMT DT Small molecular drug
DMZ8OMT PC 107800
DMZ8OMT MW 432.5
DMZ8OMT FM C18H36N6O6
DMZ8OMT IC InChI=1S/C18H36N6O6/c1-8(20)10-5-4-9(21)18(29-10)30-16-12(22)14(26)17(28-3)13(15(16)27)24(2)11(25)6-23-7-19/h7-10,12-18,26-27H,4-6,20-22H2,1-3H3,(H2,19,23)
DMZ8OMT CS CC(C1CCC(C(O1)OC2C(C(C(C(C2O)N(C)C(=O)CN=CN)OC)O)N)N)N
DMZ8OMT IK VFBPKQSATYZKRX-UHFFFAOYSA-N
DMZ8OMT IU N-[4-amino-3-[3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2,5-dihydroxy-6-methoxycyclohexyl]-2-(aminomethylideneamino)-N-methylacetamide
DMZ8OMT CA CAS 73196-97-1
DMZ8OMT DE Bacterial infection
DMFCMPS ID DMFCMPS
DMFCMPS DN Daidzin
DMFCMPS HS Terminated
DMFCMPS SN AC1N4RYA; MLS000563445; SCHEMBL3423674; CHEMBL115316; KYQZWONCHDNPDP-UHFFFAOYSA-N; HMS3604G15; HMS3348J07; HMS2194K16; AKOS024284500; AC-6036; MCULE-3802707688; SMR000232339; ST077114; SR-01000721602; SR-01000721602-3; I06-0227; 3-(4-hydroxyphenyl)-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranosyloxy)-3-(4-hydroxyphenyl)-; 3-(4-hydroxyphenyl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one
DMFCMPS DT Small molecular drug
DMFCMPS PC 107971
DMFCMPS MW 416.4
DMFCMPS FM C21H20O9
DMFCMPS IC InChI=1S/C21H20O9/c22-8-16-18(25)19(26)20(27)21(30-16)29-12-5-6-13-15(7-12)28-9-14(17(13)24)10-1-3-11(23)4-2-10/h1-7,9,16,18-23,25-27H,8H2/t16-,18-,19+,20-,21-/m1/s1
DMFCMPS CS C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
DMFCMPS IK KYQZWONCHDNPDP-QNDFHXLGSA-N
DMFCMPS IU 3-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMFCMPS CA CAS 552-66-9
DMFCMPS CB CHEBI:42202
DMHJAD4 ID DMHJAD4
DMHJAD4 DN Daniplestim
DMHJAD4 HS Terminated
DMHJAD4 DE Osteoporosis
DM6IGRL ID DM6IGRL
DM6IGRL DN DARGLITAZONE
DM6IGRL HS Terminated
DM6IGRL SN CP-86325; Darglitazone < Rec INN; Rac-5-[4-[3-(5-Methyl-2-phenyloxazol-4-yl)propionyl]benzyl]thiazolidine-2,4-dione
DM6IGRL DT Small molecular drug
DM6IGRL PC 60870
DM6IGRL MW 420.5
DM6IGRL FM C23H20N2O4S
DM6IGRL IC InChI=1S/C23H20N2O4S/c1-14-18(24-22(29-14)17-5-3-2-4-6-17)11-12-19(26)16-9-7-15(8-10-16)13-20-21(27)25-23(28)30-20/h2-10,20H,11-13H2,1H3,(H,25,27,28)
DM6IGRL CS CC1=C(N=C(O1)C2=CC=CC=C2)CCC(=O)C3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DM6IGRL IK QQKNSPHAFATFNQ-UHFFFAOYSA-N
DM6IGRL IU 5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM6IGRL CA CAS 141200-24-0
DM6IGRL DE Diabetic complication
DM160FM ID DM160FM
DM160FM DN Darodipine
DM160FM HS Terminated
DM160FM SN Dazodipine; Plimo; PY-108-068
DM160FM CP Novartis AG
DM160FM DT Small molecular drug
DM160FM PC 51701
DM160FM MW 371.4
DM160FM FM C19H21N3O5
DM160FM IC InChI=1S/C19H21N3O5/c1-5-25-18(23)14-10(3)20-11(4)15(19(24)26-6-2)16(14)12-8-7-9-13-17(12)22-27-21-13/h7-9,16,20H,5-6H2,1-4H3
DM160FM CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC3=NON=C32)C(=O)OCC)C)C
DM160FM IK QERUYFVNIOLCHV-UHFFFAOYSA-N
DM160FM IU diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM160FM CA CAS 72803-02-2
DM160FM DE Cerebrovascular ischaemia
DMR80AL ID DMR80AL
DMR80AL DN Datelliptium chloride
DMR80AL HS Terminated
DMR80AL SN Datelliptinium; Detalliptinium; SR-95156B
DMR80AL CP Sanofi
DMR80AL DT Small molecular drug
DMR80AL PC 72034
DMR80AL MW 397.9
DMR80AL FM C23H28ClN3O
DMR80AL IC InChI=1S/C23H27N3O.ClH/c1-5-25(6-2)11-12-26-10-9-18-16(4)23-22(15(3)20(18)14-26)19-13-17(27)7-8-21(19)24-23;/h7-10,13-14,27H,5-6,11-12H2,1-4H3;1H
DMR80AL CS CCN(CC)CC[N+]1=CC2=C(C3=C(C(=C2C=C1)C)NC4=C3C=C(C=C4)O)C.[Cl-]
DMR80AL IK UCICRVXYPSKKJK-UHFFFAOYSA-N
DMR80AL IU 2-[2-(diethylamino)ethyl]-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;chloride
DMR80AL CA CAS 105118-14-7
DMR80AL DE Breast cancer
DMP9GFZ ID DMP9GFZ
DMP9GFZ DN DAU-6285
DMP9GFZ HS Terminated
DMP9GFZ SN Dau 6285; CHEMBL552854; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3H-benzimidazole-1-carboxylate; AC1L2WHB; GTPL246; SCHEMBL2945410; CHEMBL1194556; PDSP1_000035; BDBM50007863; PDSP2_000035; PDSP1_001680; PDSP2_001663; L000897; 6-Methoxy-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester
DMP9GFZ CP Boehringer Ingelheim Corp
DMP9GFZ DT Small molecular drug
DMP9GFZ PC 129927
DMP9GFZ MW 367.8
DMP9GFZ FM C17H22ClN3O4
DMP9GFZ IC InChI=1S/C17H21N3O4.ClH/c1-19-10-3-4-11(19)8-13(7-10)24-17(22)20-15-9-12(23-2)5-6-14(15)18-16(20)21;/h5-6,9-11,13H,3-4,7-8H2,1-2H3,(H,18,21);1H
DMP9GFZ CS CN1C2CCC1CC(C2)OC(=O)N3C4=C(C=CC(=C4)OC)NC3=O.Cl
DMP9GFZ IK MXZAMPPIKDHMOJ-UHFFFAOYSA-N
DMP9GFZ IU (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3H-benzimidazole-1-carboxylate;hydrochloride
DMP9GFZ CA CAS 123258-98-0
DMP9GFZ DE Vomiting
DMJUW8H ID DMJUW8H
DMJUW8H DN Dazoxiben
DMJUW8H HS Terminated
DMJUW8H SN DAZOXIBEN; 78218-09-4; Dazoxibene; Dazoxiben [INN-Spanish]; Dazoxibenum; Dazoxibenum [INN-Latin]; Dazoxibene [INN-French]; Dazoxiben [INN:BAN]; 4-(2-(1H-Imidazol-1-yl)ethoxy)benzoic acid; UNII-09ZFC7974Q; 4-(2-imidazol-1-ylethoxy)benzoic acid; UK 37248; Benzoic acid, 4-(2-(1H-imidazol-1-yl)ethoxy)-; p-(2-Imidazol-1-ylethoxy)benzoic acid; 4-(2-(1-Imidazolyl)ethoxy)benzoesaeure; UK-37248; CHEMBL267473; 103735-00-8; 4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid; 09ZFC7974Q; AH-P 719 (9CI); NCGC00018938-03
DMJUW8H DT Small molecular drug
DMJUW8H PC 53001
DMJUW8H MW 232.23
DMJUW8H FM C12H12N2O3
DMJUW8H IC InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)
DMJUW8H CS C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2
DMJUW8H IK XQGZSYKGWHUSDH-UHFFFAOYSA-N
DMJUW8H IU 4-(2-imidazol-1-ylethoxy)benzoic acid
DMJUW8H CA CAS 78218-09-4
DMTXPSB ID DMTXPSB
DMTXPSB DN DB-200
DMTXPSB HS Terminated
DMTXPSB SN DB-200 series (topical, psoriasis); CPT-1 inhibitor (topical, psoriasis), DARA; DB-200 series (topical, psoriasis), DARA BioSciences
DMTXPSB CP DARA BioSciences
DMTXPSB DE Psoriasis vulgaris
DM8GHT2 ID DM8GHT2
DM8GHT2 DN DBO-11
DM8GHT2 HS Terminated
DM8GHT2 SN 166374-49-8; Naxifylline (USAN/INN)
DM8GHT2 TC Analgesics
DM8GHT2 DT Small molecular drug
DM8GHT2 PC 23724971
DM8GHT2 MW 344.4
DM8GHT2 FM C18H24N4O3
DM8GHT2 IC InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10-,11-,13+,14-/m0/s1
DM8GHT2 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)[C@H]3C[C@@H]4C[C@@H]3[C@H]5[C@@H]4O5
DM8GHT2 IK OQCJPFYWFGUHIN-JZKMBYMZSA-N
DM8GHT2 IU 8-[(1R,2R,4S,5S,6S)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7H-purine-2,6-dione
DM8GHT2 DE Cancer related pain
DMFJ3UW ID DMFJ3UW
DMFJ3UW DN DBO-17
DMFJ3UW HS Terminated
DMFJ3UW TC Analgesics
DMFJ3UW PC 10042211
DMFJ3UW MW 329.4
DMFJ3UW FM C18H23N3O3
DMFJ3UW IC InChI=1S/C18H23N3O3/c1-2-18(22)19-12-16-9-10-17(13-19)20(16)11-3-4-14-5-7-15(8-6-14)21(23)24/h3-8,16-17H,2,9-13H2,1H3/b4-3+
DMFJ3UW CS CCC(=O)N1CC2CCC(C1)N2C/C=C/C3=CC=C(C=C3)[N+](=O)[O-]
DMFJ3UW IK VWJDGZDXFSHUPA-ONEGZZNKSA-N
DMFJ3UW IU 1-[8-[(E)-3-(4-nitrophenyl)prop-2-enyl]-3,8-diazabicyclo[3.2.1]octan-3-yl]propan-1-one
DMFJ3UW DE Cancer related pain
DM0JDCS ID DM0JDCS
DM0JDCS DN DBO-83
DM0JDCS HS Terminated
DM0JDCS SN DBO-83; EU-0100452; CHEMBL1527419; Tox21_500452; LP00452; CCG-221756; NCGC00261137-01; NCGC00093868-01; D 7938; SR-01000075832
DM0JDCS DT Small molecular drug
DM0JDCS PC 9926237
DM0JDCS MW 297.6
DM0JDCS FM C10H15Cl3N4
DM0JDCS IC InChI=1S/C10H13ClN4.2ClH/c11-9-3-4-10(14-13-9)15-5-7-1-2-8(6-15)12-7;;/h3-4,7-8,12H,1-2,5-6H2;2*1H
DM0JDCS CS C1CC2CN(CC1N2)C3=NN=C(C=C3)Cl.Cl.Cl
DM0JDCS IK FMBGHZXNKMHVDT-UHFFFAOYSA-N
DM0JDCS IU 3-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane;dihydrochloride
DM0JDCS CA CAS 195211-53-1
DMCDMWJ ID DMCDMWJ
DMCDMWJ DN DC-015
DMCDMWJ HS Terminated
DMCDMWJ DT Small molecular drug
DMCDMWJ PC 132891
DMCDMWJ MW 391.5
DMCDMWJ FM C22H25N5O2
DMCDMWJ IC InChI=1S/C22H25N5O2/c1-29-20-9-5-4-8-19(20)26-12-10-25(11-13-26)15-16-14-23-21-17-6-2-3-7-18(17)24-22(28)27(16)21/h2-9,16,23H,10-15H2,1H3
DMCDMWJ CS COC1=CC=CC=C1N2CCN(CC2)CC3CNC4=C5C=CC=CC5=NC(=O)N34
DMCDMWJ IK COCJIISORPXDPN-UHFFFAOYSA-N
DMCDMWJ IU 3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-one
DMCDMWJ CA CAS 149847-87-0
DM5VFR0 ID DM5VFR0
DM5VFR0 DN DHP-218
DM5VFR0 HS Terminated
DM5VFR0 SN Dhp-218; 102097-78-9; Dhp 218; 3-Pyridinecarboxylicacid,1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxido-1,3,2-dioxaphosphorinan-2-yl)-,methyl ester; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxido-1,3,2-dioxaphosphorinan-2-yl)-, methyl ester;3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxido-1,3,2-dioxaphosphorinan-2-yl)-, methyl ester; AC1O3SAA; ACMC-20m53m; SCHEMBL1356340; CTK4A0679; AKOS030566270; Methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,
DM5VFR0 CP Nippon Shinyaku Co Ltd
DM5VFR0 DT Small molecular drug
DM5VFR0 PC 6336069
DM5VFR0 MW 408.3
DM5VFR0 FM C18H21N2O7P
DM5VFR0 IC InChI=1S/C18H21N2O7P/c1-11-15(18(21)25-3)16(13-7-4-5-8-14(13)20(22)23)17(12(2)19-11)28(24)26-9-6-10-27-28/h4-5,7-8,16,19H,6,9-10H2,1-3H3
DM5VFR0 CS CC1=C(C(C(=C(N1)C)P2(=O)OCCCO2)C3=CC=CC=C3[N+](=O)[O-])C(=O)OC
DM5VFR0 IK GSWINTXYUFHJGW-UHFFFAOYSA-N
DM5VFR0 IU methyl 2,6-dimethyl-4-(2-nitrophenyl)-5-(2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl)-1,4-dihydropyridine-3-carboxylate
DM5VFR0 CA CAS 102097-78-9
DM5VFR0 DE Hypertension
DM6LP0R ID DM6LP0R
DM6LP0R DN Dianicline+rimonabant
DM6LP0R HS Terminated
DM6LP0R SN [3H]nemonapride; (2R,3R)-nemonapride; 75272-39-8; CHEBI:64219; C21H26ClN3O2; 93664-94-9
DM6LP0R CP Sanofi-Aventis
DM6LP0R DT Combination drug (Antibody)
DM6LP0R DE Tobacco dependence
DM61BWZ ID DM61BWZ
DM61BWZ DN Diaspirin crosslinked hemoglobin
DM61BWZ HS Terminated
DM61BWZ SN DCLHb; HemAssist; DCLHb, Baxter; Diaspirin crosslinked hemoglobin, Baxter
DM61BWZ CP Baxter Healthcare Ltd
DM61BWZ DE Cerebrovascular ischaemia
DMB74CM ID DMB74CM
DMB74CM DN DIAVERIDINE
DMB74CM HS Terminated
DMB74CM SN Diaveridine < Rec INN; EGIS-5645; 2,4-Diamino-5-(3',4'-dimethoxybenzyl)pyrimidine; 5-[(3,4-Dimethoxyphenyl)methyl]-2,4-pyrimidinediamine
DMB74CM DT Small molecular drug
DMB74CM PC 21453
DMB74CM MW 260.29
DMB74CM FM C13H16N4O2
DMB74CM IC InChI=1S/C13H16N4O2/c1-18-10-4-3-8(6-11(10)19-2)5-9-7-16-13(15)17-12(9)14/h3-4,6-7H,5H2,1-2H3,(H4,14,15,16,17)
DMB74CM CS COC1=C(C=C(C=C1)CC2=CN=C(N=C2N)N)OC
DMB74CM IK LDBTVAXGKYIFHO-UHFFFAOYSA-N
DMB74CM IU 5-[(3,4-dimethoxyphenyl)methyl]pyrimidine-2,4-diamine
DMB74CM CA CAS 5355-16-8
DMB74CM CB CHEBI:123115
DMB74CM DE Bacterial infection
DMAK3V7 ID DMAK3V7
DMAK3V7 DN DIO-901
DMAK3V7 HS Terminated
DMAK3V7 SN CAM-4044; VLD glucagon (diabetes), DiObex; Very low dose glucagon (diabetes), DiObex; VLD glucagon (FluidCrystal, diabetes), DiObex; VLD glucagon (extended-release, diabetes) DiObex
DMAK3V7 CP DiObex
DMAK3V7 DE Type-1 diabetes
DMO3XBP ID DMO3XBP
DMO3XBP DN Divaplon
DMO3XBP HS Terminated
DMO3XBP SN Divaplon; 90808-12-1; UNII-4AOV43246G; 4AOV43246G; Divaplonum; Divaplone; methanone,(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl-; Divaplon [INN]; Divaplonum [INN-Latin]; Divaplone [INN-French]; SCHEMBL678101; CHEMBL281164; ZINC1325; DTXSID40238269; AC1L2418; RU-32698; KB-274411; 6-Ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl phenyl ketone; (6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-phenylmethanone; Methanone, (6-ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl)phenyl-
DMO3XBP DT Small molecular drug
DMO3XBP PC 65822
DMO3XBP MW 295.34
DMO3XBP FM C17H17N3O2
DMO3XBP IC InChI=1S/C17H17N3O2/c1-4-13-11(2)20-10-14(18-17(20)19-16(13)22-3)15(21)12-8-6-5-7-9-12/h5-10H,4H2,1-3H3
DMO3XBP CS CCC1=C(N2C=C(N=C2N=C1OC)C(=O)C3=CC=CC=C3)C
DMO3XBP IK NRJVHCSYLGLURI-UHFFFAOYSA-N
DMO3XBP IU (6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-phenylmethanone
DMO3XBP CA CAS 90808-12-1
DMMGYXR ID DMMGYXR
DMMGYXR DN Dizocilpine
DMMGYXR HS Terminated
DMMGYXR SN DIZOCILPINE; 77086-21-6; MK-801 (Dizocilpine); UNII-7PY8KH681I; MK-801; Lopac-M-108; Lopac-M-107; MK 801; Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; Dizocilpine [INN]; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; Dizocilpinum; Dizocilpina; MK801; MK-801(Dizocilpine); HSDB 7641; (+)MK-801; (+)-MK-801; (+/-)-MK801; Prestwick2_000109; Prestwick3_000109; Prestwick1_000109; Biomol-NT_000210; SCHEMBL34528; Lopac0_000872; BSPBio_000098; SPBio_002037
DMMGYXR DT Small molecular drug
DMMGYXR PC 180081
DMMGYXR MW 221.3
DMMGYXR FM C16H15N
DMMGYXR IC InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3/t15-,16+/m1/s1
DMMGYXR CS C[C@@]12C3=CC=CC=C3C[C@@H](N1)C4=CC=CC=C24
DMMGYXR IK LBOJYSIDWZQNJS-CVEARBPZSA-N
DMMGYXR IU (1S,9R)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene
DMMGYXR CA CAS 77086-21-6
DMMGYXR CB CHEBI:34725
DMMGYXR DE Cerebrovascular ischaemia
DMNSDM1 ID DMNSDM1
DMNSDM1 DN DMP-696
DMNSDM1 HS Terminated
DMNSDM1 SN DMP 696; DMP-696; DMP696; CHEMBL44698; SCHEMBL2931046; GTPL3499; ZINC1489783; PDSP1_001296; PDSP2_001280; BDBM50084875; CS-6810; HY-12131; 8-(2,4-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine; [8-(2,4-Dichloro-phenyl)-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl]-(2-methoxy-1-methoxymethyl-ethyl)-amine; N-[1-(Methoxymethyl)-2-methoxyethyl]-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine-4-amine
DMNSDM1 DT Small molecular drug
DMNSDM1 PC 9909468
DMNSDM1 MW 410.3
DMNSDM1 FM C18H21Cl2N5O2
DMNSDM1 IC InChI=1S/C18H21Cl2N5O2/c1-10-16(14-6-5-12(19)7-15(14)20)17-21-11(2)22-18(25(17)24-10)23-13(8-26-3)9-27-4/h5-7,13H,8-9H2,1-4H3,(H,21,22,23)
DMNSDM1 CS CC1=NN2C(=C1C3=C(C=C(C=C3)Cl)Cl)N=C(N=C2NC(COC)COC)C
DMNSDM1 IK MDWRPTOUDPFXKK-UHFFFAOYSA-N
DMNSDM1 IU 8-(2,4-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMNSDM1 CA CAS 202578-52-7
DMNSDM1 DE Anxiety disorder
DMGNUXC ID DMGNUXC
DMGNUXC DN DMP-757
DMGNUXC HS Terminated
DMGNUXC SN CHEMBL65617; DMP-757; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid
DMGNUXC DT Small molecular drug
DMGNUXC PC 10031011
DMGNUXC MW 574.6
DMGNUXC FM C26H38N8O7
DMGNUXC IC InChI=1S/C26H38N8O7/c1-14(2)21-25(41)34(3)18(8-5-9-29-26(27)28)24(40)31-13-19(35)32-17(11-20(36)37)23(39)30-12-15-6-4-7-16(10-15)22(38)33-21/h4,6-7,10,14,17-18,21H,5,8-9,11-13H2,1-3H3,(H,30,39)(H,31,40)(H,32,35)(H,33,38)(H,36,37)(H4,27,28,29)/t17-,18-,21-/m0/s1
DMGNUXC CS CC(C)[C@H]1C(=O)N([C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC2=CC(=CC=C2)C(=O)N1)CC(=O)O)CCCN=C(N)N)C
DMGNUXC IK TZZMWRLTTWMKCL-WFXMLNOXSA-N
DMGNUXC IU 2-[(5S,11S,14S)-11-[3-(diaminomethylideneamino)propyl]-12-methyl-4,7,10,13,16-pentaoxo-14-propan-2-yl-3,6,9,12,15-pentazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid
DMO26E7 ID DMO26E7
DMO26E7 DN DMP-811
DMO26E7 HS Terminated
DMO26E7 SN L-708404
DMO26E7 CP Bristol-Myers Squibb Pharma Co
DMO26E7 DT Small molecular drug
DMO26E7 PC 3081289
DMO26E7 MW 416.5
DMO26E7 FM C23H24N6O2
DMO26E7 IC InChI=1S/C23H24N6O2/c1-3-7-20-24-19(4-2)21(23(30)31)29(20)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-25-27-28-26-22/h5-6,8-13H,3-4,7,14H2,1-2H3,(H,30,31)(H,25,26,27,28)
DMO26E7 CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)CC
DMO26E7 IK OFYWYKMCRWMPPQ-UHFFFAOYSA-N
DMO26E7 IU 5-ethyl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
DMO26E7 CA CAS 139964-19-5
DMO26E7 DE Hypertension
DMKU469 ID DMKU469
DMKU469 DN DMP-963
DMKU469 HS Terminated
DMKU469 SN DPC-963; 4(S)-(2-Cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-3,4-dihydro-1H-quinazolin-2-one
DMKU469 DT Small molecular drug
DMKU469 PC 474121
DMKU469 MW 316.23
DMKU469 FM C14H9F5N2O
DMKU469 IC InChI=1S/C14H9F5N2O/c15-8-3-4-9-10(11(8)16)13(14(17,18)19,21-12(22)20-9)6-5-7-1-2-7/h3-4,7H,1-2H2,(H2,20,21,22)/t13-/m0/s1
DMKU469 CS C1CC1C#C[C@]2(C3=C(C=CC(=C3F)F)NC(=O)N2)C(F)(F)F
DMKU469 IK QCNJQJJFXFJVCX-ZDUSSCGKSA-N
DMKU469 IU (4S)-4-(2-cyclopropylethynyl)-5,6-difluoro-4-(trifluoromethyl)-1,3-dihydroquinazolin-2-one
DMKU469 CA CAS 214287-90-8
DMKU469 DE Human immunodeficiency virus infection
DMLBS83 ID DMLBS83
DMLBS83 DN DMPDDF
DMLBS83 HS Terminated
DMLBS83 SN IDDB5773
DMLBS83 CP Glaxo Wellcome plc
DMLBS83 DE Solid tumour/cancer
DMXR3V1 ID DMXR3V1
DMXR3V1 DN DNP-004089
DMXR3V1 HS Terminated
DMXR3V1 SN BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo
DMXR3V1 CP De Novo Pharmaceuticals Ltd
DMXR3V1 DE Alzheimer disease
DM6Q05K ID DM6Q05K
DM6Q05K DN Dotarizine
DM6Q05K HS Terminated
DM6Q05K SN Dotarazine; FI-6020; FI-6026
DM6Q05K CP Ferrer Internacional SA
DM6Q05K DT Small molecular drug
DM6Q05K PC 55285
DM6Q05K MW 442.6
DM6Q05K FM C29H34N2O2
DM6Q05K IC InChI=1S/C29H34N2O2/c1-4-11-25(12-5-1)28(26-13-6-2-7-14-26)31-21-19-30(20-22-31)18-10-17-29(32-23-24-33-29)27-15-8-3-9-16-27/h1-9,11-16,28H,10,17-24H2
DM6Q05K CS C1CN(CCN1CCCC2(OCCO2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM6Q05K IK LRMJAFKKJLRDLE-UHFFFAOYSA-N
DM6Q05K IU 1-benzhydryl-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine
DM6Q05K CA CAS 84625-59-2
DM6Q05K CB CHEBI:138033
DM6Q05K DE Migraine
DM4BPFV ID DM4BPFV
DM4BPFV DN Doxorubicin-CEA conjugate
DM4BPFV HS Terminated
DM4BPFV SN DOX-CEA; Doxorubicin-CEA conjugate, Immunomedics
DM4BPFV CP Immunomedics Inc
DM4BPFV DE Breast cancer
DM4JBQD ID DM4JBQD
DM4JBQD DN DPC-333
DM4JBQD HS Terminated
DM4JBQD SN BMS-561392; UNII-2X066A8676; BMS 561392; CHEMBL489100; DPC-333; BMS561392; 2X066A8676; DPC 333; 611227-74-8; SCHEMBL6350418; GTPL6509; BDBM50247606; C476910000; (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide
DM4JBQD CP Bristol-Myers Squibb Pharma
DM4JBQD DT Small molecular drug
DM4JBQD PC 9847838
DM4JBQD MW 476.6
DM4JBQD FM C27H32N4O4
DM4JBQD IC InChI=1S/C27H32N4O4/c1-17(2)14-24(25(32)30-34)31-13-12-27(28,26(31)33)20-8-10-21(11-9-20)35-16-19-15-18(3)29-23-7-5-4-6-22(19)23/h4-11,15,17,24,34H,12-14,16,28H2,1-3H3,(H,30,32)/t24-,27-/m1/s1
DM4JBQD CS CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)[C@@]4(CCN(C4=O)[C@H](CC(C)C)C(=O)NO)N
DM4JBQD IK QVNZBDLTUKCPGJ-SHQCIBLASA-N
DM4JBQD IU (2R)-2-[(3R)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-N-hydroxy-4-methylpentanamide
DM4JBQD CA CAS 611227-74-8
DM4JBQD DE Rheumatoid arthritis; Inflammatory bowel disease
DM67VDK ID DM67VDK
DM67VDK DN DPC-A78277
DM67VDK HS Terminated
DM67VDK CP Bristol-Myers Squibb Pharma Co
DM67VDK DE Human immunodeficiency virus infection
DM1AQVE ID DM1AQVE
DM1AQVE DN DPI-201-106
DM1AQVE HS Terminated
DM1AQVE SN 4-{3-[4-(Diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; Dpi 201-106; 97730-95-5; SDZ-201106; CHEMBL314639; SDZ-201 106 (+/-); 4-{3-[4-(diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile; (+-)-4-(3-(4-(Diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile; 1H-Indole-2-carbonitrile, 4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy-, (+-)-; 4(3-(4-Diphenylmethylpiperazine-1-yl)-2-hydroxypropoxy)-1H-indol-2-carbonitrile; CBiol_001886; DPI-201106; 4-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-1H-indole-2-carbonitrile
DM1AQVE CP Novartis AG
DM1AQVE DT Small molecular drug
DM1AQVE PC 5190
DM1AQVE MW 466.6
DM1AQVE FM C29H30N4O2
DM1AQVE IC InChI=1S/C29H30N4O2/c30-19-24-18-26-27(31-24)12-7-13-28(26)35-21-25(34)20-32-14-16-33(17-15-32)29(22-8-3-1-4-9-22)23-10-5-2-6-11-23/h1-13,18,25,29,31,34H,14-17,20-21H2
DM1AQVE CS C1CN(CCN1CC(COC2=CC=CC3=C2C=C(N3)C#N)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM1AQVE IK BYBYHCOEAFHGJL-UHFFFAOYSA-N
DM1AQVE IU 4-[3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy]-1H-indole-2-carbonitrile
DM1AQVE CA CAS 97730-95-5
DM1AQVE CB CHEBI:110175
DM1AQVE DE Cardiovascular disease
DMX4KIT ID DMX4KIT
DMX4KIT DN Draculin
DMX4KIT HS Terminated
DMX4KIT CP Instituto Venezolano de Investigaciones Cientificas
DMX4KIT DE Thrombosis
DM6EJVF ID DM6EJVF
DM6EJVF DN Droxinavir hydrochloride
DM6EJVF HS Terminated
DM6EJVF SN SC-55389; SC-55389A
DM6EJVF CP GD Searle & Co
DM6EJVF PC 9937952
DM6EJVF MW 570.2
DM6EJVF FM C29H52ClN5O4
DM6EJVF IC InChI=1S/C29H51N5O4.ClH/c1-20(2)15-16-34(27(38)33-29(6,7)8)19-23(35)22(17-21-13-11-10-12-14-21)31-26(37)25(28(3,4)5)32-24(36)18-30-9;/h10-14,20,22-23,25,30,35H,15-19H2,1-9H3,(H,31,37)(H,32,36)(H,33,38);1H/t22-,23+,25+;/m0./s1
DM6EJVF CS CC(C)CCN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNC)O)C(=O)NC(C)(C)C.Cl
DM6EJVF IK IYKXRORSPVZSHP-ZELIPEIJSA-N
DM6EJVF IU (2S)-N-[(2S,3R)-4-[tert-butylcarbamoyl(3-methylbutyl)amino]-3-hydroxy-1-phenylbutan-2-yl]-3,3-dimethyl-2-[[2-(methylamino)acetyl]amino]butanamide;hydrochloride
DM6EJVF CA CAS 155662-50-3
DM6EJVF DE Human immunodeficiency virus infection
DMAE43P ID DMAE43P
DMAE43P DN DSP-7238
DMAE43P HS Terminated
DMAE43P CP Dianippen
DMAE43P DE Diabetic complication
DMX5SN8 ID DMX5SN8
DMX5SN8 DN Du-123015
DMX5SN8 HS Terminated
DMX5SN8 SN Benzopyran piperazine derivative (5HT modulator, neurological disorders), Solvay
DMX5SN8 CP Solvay SA
DMX5SN8 DE Anxiety disorder
DM87ZWP ID DM87ZWP
DM87ZWP DN DU-1777
DM87ZWP HS Terminated
DM87ZWP SN DU 1777; AC1MIWBL; du1777; 1-(N2-Nicotinoyl-L-lysyl-gamma-D-glutamyl)octahydro-1H-indole-2-carboxylic acid; 5-(2-Carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-(N2-(3-pyridinylcarbonyl)-L-lysyl)-D-norvaline (2S-(2alpha,3abeta,7abeta))-; (2S,3aS,7aS)-1-[(2R)-2-[[(2S)-6-amino-2-(pyridine-3-carbonylamino)hexanoyl]amino]-5-hydroxy-5-oxopentanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid; D-Norvaline, 5-(2-carboxyoctahydro-1H-indol-1-yl)-5-oxo-N-(N2-(3-pyridinylcarbonyl)-L-lysyl)-, (2S-(2alpha,3abeta,7abeta))-
DM87ZWP CP Dainippon Pharmaceutical Co Ltd
DM87ZWP DT Small molecular drug
DM87ZWP PC 3081108
DM87ZWP MW 531.6
DM87ZWP FM C26H37N5O7
DM87ZWP IC InChI=1S/C26H37N5O7/c27-12-4-3-8-18(29-23(34)17-7-5-13-28-15-17)24(35)30-19(10-11-22(32)33)25(36)31-20-9-2-1-6-16(20)14-21(31)26(37)38/h5,7,13,15-16,18-21H,1-4,6,8-12,14,27H2,(H,29,34)(H,30,35)(H,32,33)(H,37,38)/t16-,18-,19+,20-,21-/m0/s1
DM87ZWP CS C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)C3=CN=CC=C3)C(=O)O
DM87ZWP IK NDXIQTFRXMWLEQ-RQUKQETFSA-N
DM87ZWP IU (2S,3aS,7aS)-1-[(2R)-2-[[(2S)-6-amino-2-(pyridine-3-carbonylamino)hexanoyl]amino]-4-carboxybutanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
DM87ZWP CA CAS 116662-73-8
DM87ZWP DE Hypertension
DMZOCHT ID DMZOCHT
DMZOCHT DN DuP 714
DMZOCHT HS Terminated
DMZOCHT SN acetylphenylalanyl-prolyl-boroarginine; Dup-714; Dup 714; Ac-Phe-pro-boroarg-OH; AC-(D)PHE-PRO-BOROARG-OH; CHEMBL290376; 130982-43-3; L-Prolinamide, N-acetyl-D-phenylalanyl-N-(4-((aminoiminomethyl)amino)-1-boronobutyl)-, (S)-; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid; dup714; AC1L3UBV; SCHEMBL4454615; GTPL8760; CHEBI:42142; DTXSID70156826; BDBM50288406; BDBM50451005; LS-186929; LS-187579
DMZOCHT DT Small molecular drug
DMZOCHT PC 122296
DMZOCHT MW 460.3
DMZOCHT FM C21H33BN6O5
DMZOCHT IC InChI=1S/C21H33BN6O5/c1-14(29)26-16(13-15-7-3-2-4-8-15)20(31)28-12-6-9-17(28)19(30)27-18(22(32)33)10-5-11-25-21(23)24/h2-4,7-8,16-18,32-33H,5-6,9-13H2,1H3,(H,26,29)(H,27,30)(H4,23,24,25)/t16-,17+,18+/m1/s1
DMZOCHT CS B([C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMZOCHT IK FXFYPTZERULUBS-SQNIBIBYSA-N
DMZOCHT IU [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-(diaminomethylideneamino)butyl]boronic acid
DMZOCHT CA CAS 130982-43-3
DMZOCHT CB CHEBI:42142
DMZOCHT DE Thrombosis
DMJGCYO ID DMJGCYO
DMJGCYO DN DuP-129
DMJGCYO HS Terminated
DMJGCYO SN ACAT inhibitors, Du Pont
DMJGCYO CP Bristol-Myers Squibb Pharma Co
DMJGCYO DE Hypercholesterolaemia
DM7YORJ ID DM7YORJ
DM7YORJ DN DuP-630
DM7YORJ HS Terminated
DM7YORJ CP Bristol-Myers Squibb Pharma Co
DM7YORJ DE Dermatitis
DM872CU ID DM872CU
DM872CU DN DuP-983
DM872CU HS Terminated
DM872CU CP Bristol-Myers Squibb Pharma Co
DM872CU DE Pruritus
DMKNJM7 ID DMKNJM7
DMKNJM7 DN DV-7028
DMKNJM7 HS Terminated
DMKNJM7 SN 133364-63-3; DV 7028; AC1O5RHW; SCHEMBL9378376; 3-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl)-6,7,8,9-tetrahydro-2H-pyrido(1,2-a)-1,3,5-triazine-2,4(3H)dione maleate; 2H-Pyrido(1,2-a)-1,3,5-triazine-2,4(3H)-dione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-,(Z)-2-butenedioate (1:1)
DMKNJM7 DT Small molecular drug
DMKNJM7 PC 6439352
DMKNJM7 MW 516.5
DMKNJM7 FM C25H29FN4O7
DMKNJM7 IC InChI=1S/C21H25FN4O3.C4H4O4/c22-17-6-4-15(5-7-17)19(27)16-8-11-24(12-9-16)13-14-26-20(28)23-18-3-1-2-10-25(18)21(26)29;5-3(6)1-2-4(7)8/h4-7,16H,1-3,8-14H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMKNJM7 CS C1CCN2C(=NC(=O)N(C2=O)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F)C1.C(=C\\C(=O)O)\\C(=O)O
DMKNJM7 IK GVSYIVYQDRVBAL-BTJKTKAUSA-N
DMKNJM7 IU (Z)-but-2-enedioic acid;3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-6,7,8,9-tetrahydropyrido[1,2-a][1,3,5]triazine-2,4-dione
DMKNJM7 CA CAS 133364-63-3
DMKNJM7 DE Cardiovascular disease
DM3L0T1 ID DM3L0T1
DM3L0T1 DN DW-1350
DM3L0T1 HS Terminated
DM3L0T1 SN DW-1352; Osteoblast modulator (oral, osteoporosis), Dong Wha/ Teijin/ Procter & Gamble
DM3L0T1 CP Dong Wha Pharmaceutical Co Ltd
DM3L0T1 DT Small molecular drug
DM3L0T1 PC 10139005
DM3L0T1 MW 453.6
DM3L0T1 FM C25H31N3O3S
DM3L0T1 IC InChI=1S/C25H31N3O3S/c1-17(2)24-23(27-18(3)32-24)19-7-11-21(12-8-19)30-15-5-4-6-16-31-22-13-9-20(10-14-22)25(26)28-29/h7-14,17,29H,4-6,15-16H2,1-3H3,(H2,26,28)
DM3L0T1 CS CC1=NC(=C(S1)C(C)C)C2=CC=C(C=C2)OCCCCCOC3=CC=C(C=C3)/C(=N/O)/N
DM3L0T1 IK JDXVNCOKDAGOAM-UHFFFAOYSA-N
DM3L0T1 IU N'-hydroxy-4-[5-[4-(2-methyl-5-propan-2-yl-1,3-thiazol-4-yl)phenoxy]pentoxy]benzenecarboximidamide
DM3L0T1 CA CAS 491577-61-8
DM3L0T1 DE Osteoporosis
DM2PVMZ ID DM2PVMZ
DM2PVMZ DN E-0722
DM2PVMZ HS Terminated
DM2PVMZ SN Methosorbinil; E-79175; M-79175
DM2PVMZ CP Eisai Co Ltd
DM2PVMZ DT Small molecular drug
DM2PVMZ PC 175915
DM2PVMZ MW 250.23
DM2PVMZ FM C12H11FN2O3
DM2PVMZ IC InChI=1S/C12H11FN2O3/c1-6-5-12(10(16)14-11(17)15-12)8-4-7(13)2-3-9(8)18-6/h2-4,6H,5H2,1H3,(H2,14,15,16,17)/t6-,12+/m1/s1
DM2PVMZ CS C[C@@H]1C[C@]2(C3=C(O1)C=CC(=C3)F)C(=O)NC(=O)N2
DM2PVMZ IK SEAQTHCVAGBRFY-INWYIAFRSA-N
DM2PVMZ IU (2R,4S)-6-fluoro-2-methylspiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione
DM2PVMZ CA CAS 102916-95-0
DM2PVMZ DE Diabetic cataract
DMD4GQ8 ID DMD4GQ8
DMD4GQ8 DN E-2011
DMD4GQ8 HS Terminated
DMD4GQ8 CP Eisai Co Ltd
DMD4GQ8 DE Anxiety disorder
DMZWU8V ID DMZWU8V
DMZWU8V DN E-2040
DMZWU8V HS Terminated
DMZWU8V CP Eisai Co Ltd
DMZWU8V PC 74889592
DMZWU8V MW 290.17
DMZWU8V FM C15H23BN2O3
DMZWU8V IC InChI=1S/C15H23BN2O3/c1-6-19-12-9-13(17)18-10-11(12)7-8-16-20-14(2,3)15(4,5)21-16/h7-10H,6H2,1-5H3,(H2,17,18)/b8-7+
DMZWU8V CS B1(OC(C(O1)(C)C)(C)C)/C=C/C2=CN=C(C=C2OCC)N
DMZWU8V IK LHNZICNYYCFWCS-BQYQJAHWSA-N
DMZWU8V IU 4-ethoxy-5-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridin-2-amine
DMZWU8V DE Schizophrenia
DMQKEHA ID DMQKEHA
DMQKEHA DN E-2050
DMQKEHA HS Terminated
DMQKEHA CP Eisai
DMQKEHA TC Analgesics
DMQKEHA DE Cerebrovascular ischaemia
DMAU0FP ID DMAU0FP
DMAU0FP DN E-2070
DMAU0FP HS Terminated
DMAU0FP SN Bayer E-2070; 64050-66-4; ENT 22,742; Phosphoric acid, 2-chloroethyl 2,2-dichlorovinyl propyl ester; AC1Q3VAX; AC1L3IYS; 2-chloroethyl 2,2-dichlorovinyl propyl phosphate; 2-chloroethyl 2,2-dichloroethenyl propyl phosphate; CTK5C0574; ENT-22742; LS-107547; Phosphoric acid,2-chloroethyl 2,2-dichloroethenyl propyl ester
DMAU0FP CP Eisai Inc.
DMAU0FP TC Analgesics
DMAU0FP DT Small molecular drug
DMAU0FP PC 74788985
DMAU0FP MW 291.11
DMAU0FP FM C14H18BNO5
DMAU0FP IC InChI=1S/C14H18BNO5/c1-13(2)14(3,4)21-15(20-13)8-7-9-11(17)6-5-10(16-9)12(18)19/h5-8,17H,1-4H3,(H,18,19)/b8-7+
DMAU0FP CS B1(OC(C(O1)(C)C)(C)C)/C=C/C2=C(C=CC(=N2)C(=O)O)O
DMAU0FP IK WTOZVQHWGKJNCT-BQYQJAHWSA-N
DMAU0FP IU 5-hydroxy-6-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridine-2-carboxylic acid
DMAU0FP DE Neuropathic pain
DMZ1JKX ID DMZ1JKX
DMZ1JKX DN E-4080
DMZ1JKX HS Terminated
DMZ1JKX SN E 4080; AC1O5RBK; E4080; 127404-34-6; E-N-(3-((N'-(2-(3,5-Dimethoxyphenyl)ethyl)-N'-methyl)amino)propyl)-4-(4-(1H-imidazol-1-yl)phenyl)-3-butenamide dihydrochloride dihydrate; e-40-80; 3-Butenamide, N-(3-((2-(3,5-dimethoxyphenyl)ethyl)methylamino)propyl)-4-(4-(1H-imidazol-1-yl)phenyl)-, dihydrochloride, (E)-; (E)-N-[3-[2-(3,5-dimethoxyphenyl)ethyl-methylamino]propyl]-4-(4-imidazol-1-ylphenyl)but-3-enamide dihydrochloride
DMZ1JKX CP Eisai Co Ltd
DMZ1JKX DT Small molecular drug
DMZ1JKX PC 6439262
DMZ1JKX MW 535.5
DMZ1JKX FM C27H36Cl2N4O3
DMZ1JKX IC InChI=1S/C27H34N4O3.2ClH/c1-30(16-12-23-18-25(33-2)20-26(19-23)34-3)15-5-13-29-27(32)7-4-6-22-8-10-24(11-9-22)31-17-14-28-21-31;;/h4,6,8-11,14,17-21H,5,7,12-13,15-16H2,1-3H3,(H,29,32);2*1H/b6-4+;;
DMZ1JKX CS CN(CCCNC(=O)C/C=C/C1=CC=C(C=C1)N2C=CN=C2)CCC3=CC(=CC(=C3)OC)OC.Cl.Cl
DMZ1JKX IK KKUNFGOKUGASRQ-SLNOCBGISA-N
DMZ1JKX IU (E)-N-[3-[2-(3,5-dimethoxyphenyl)ethyl-methylamino]propyl]-4-(4-imidazol-1-ylphenyl)but-3-enamide;dihydrochloride
DMZ1JKX CA CAS 127404-34-6
DMZ1JKX DE Angina pectoris
DMR861Q ID DMR861Q
DMR861Q DN E-5110
DMR861Q HS Terminated
DMR861Q SN CHEMBL12594; E 5110; E-5110; N-Methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-pyrrolidone; 3-((3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-1-methoxy-2-pyrrolidinone; 2-Pyrrolidinone, 3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-1-methoxy-; 107746-52-1; AC1O5P5J; SCHEMBL5323330; BDBM50008954; LS-138638; 3-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-1-methoxy-pyrrolidin-2-one; N-methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-one
DMR861Q CP Eisai Co Ltd
DMR861Q DT Small molecular drug
DMR861Q PC 6438164
DMR861Q MW 331.4
DMR861Q FM C20H29NO3
DMR861Q IC InChI=1S/C20H29NO3/c1-19(2,3)15-11-13(12-16(17(15)22)20(4,5)6)10-14-8-9-21(24-7)18(14)23/h10-12,22H,8-9H2,1-7H3/b14-10+
DMR861Q CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C/2\\CCN(C2=O)OC
DMR861Q IK NJTQENWDJVHUOX-GXDHUFHOSA-N
DMR861Q IU (3E)-3-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1-methoxypyrrolidin-2-one
DMR861Q CA CAS 107746-52-1
DMR861Q DE Inflammation
DMV0QI1 ID DMV0QI1
DMV0QI1 DN E-5842
DMV0QI1 HS Terminated
DMV0QI1 SN E 5842; E5842; 4-(4-fluorophenil)-1,2,3,4-tetrahydro-1-(4-(1,2,4-triazol-1-il)butyl)pyridine citrate; 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2H-pyridine
DMV0QI1 CP Esteve
DMV0QI1 DT Small molecular drug
DMV0QI1 PC 6918385
DMV0QI1 MW 492.5
DMV0QI1 FM C23H29FN4O7
DMV0QI1 IC InChI=1S/C17H21FN4.C6H8O7/c18-17-5-3-15(4-6-17)16-7-11-21(12-8-16)9-1-2-10-22-14-19-13-20-22;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-7,13-14H,1-2,8-12H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DMV0QI1 CS C1CN(CC=C1C2=CC=C(C=C2)F)CCCCN3C=NC=N3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DMV0QI1 IK LTBKOSQVBVYJKW-UHFFFAOYSA-N
DMV0QI1 IU 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2H-pyridine;2-hydroxypropane-1,2,3-tricarboxylic acid
DMV0QI1 CA CAS 220120-14-9
DMV0QI1 DE Schizophrenia
DMTEY8W ID DMTEY8W
DMTEY8W DN E-6276
DMTEY8W HS Terminated
DMTEY8W SN 1-(2-Benzhydrylideneaminooxy-ethyl)-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid; UNII-BGU9MZ2G30; BGU9MZ2G30; CHEMBL473104; 159094-94-7; Tocris-1779; Lopac-N-142; Biomol-NT_000271; AC1L1IC7; Lopac0_000880; SCHEMBL5969062; GTPL4669; BPBio1_000948; CTK0H8642; CHEBI:92744; DTXSID30166582; ZINC1534967; BDBM50426075; BDBM50080344; AKOS030543350; CCG-204962; 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-; NCGC00015712-05; NCGC00015712-02; NCGC00025293-03; NCGC00025293-02; NCGC00015712-04; NCGC00025293-01; NCGC00015712-03; NCGC00015712-01; LS-187291
DMTEY8W CP Esteve
DMTEY8W DT Small molecular drug
DMTEY8W PC 4515
DMTEY8W MW 350.4
DMTEY8W FM C21H22N2O3
DMTEY8W IC InChI=1S/C21H22N2O3/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-6,8-12H,7,13-16H2,(H,24,25)
DMTEY8W CS C1CN(CC(=C1)C(=O)O)CCON=C(C2=CC=CC=C2)C3=CC=CC=C3
DMTEY8W IK NGNALWDRPKNJGR-UHFFFAOYSA-N
DMTEY8W IU 1-[2-(benzhydrylideneamino)oxyethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
DMTEY8W CA CAS 159094-94-7
DMTEY8W CB CHEBI:92744
DMTEY8W DE Schizophrenia
DM5ITJF ID DM5ITJF
DM5ITJF DN EC-154
DM5ITJF HS Terminated
DM5ITJF SN Heat shock protein 90 inhibitors (cancer), Biogen Idec; Hsp 90inhibitors (cancer), Biogen Idec
DM5ITJF CP Biogen Idec Inc
DM5ITJF DE Solid tumour/cancer
DMUR1FK ID DMUR1FK
DMUR1FK DN Ecalcidene
DMUR1FK HS Terminated
DMUR1FK SN Vitamin D3 derivative, Barrier
DMUR1FK CP Research Institute for Medicine & Chemistry Inc
DMUR1FK DT Small molecular drug
DMUR1FK PC 9955662
DMUR1FK MW 455.7
DMUR1FK FM C29H45NO3
DMUR1FK IC InChI=1S/C29H45NO3/c1-20(9-14-28(33)30-16-5-4-6-17-30)25-12-13-26-22(8-7-15-29(25,26)3)10-11-23-18-24(31)19-27(32)21(23)2/h10-11,20,24-27,31-32H,2,4-9,12-19H2,1,3H3/b22-10+,23-11-/t20-,24+,25+,26-,27-,29+/m0/s1
DMUR1FK CS C[C@@H](CCC(=O)N1CCCCC1)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DMUR1FK IK DXWZPQRKPXFQGC-QCUPEZPBSA-N
DMUR1FK IU (4S)-4-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-1-piperidin-1-ylpentan-1-one
DMUR1FK CA CAS 150337-94-3
DMUR1FK CB CHEBI:137136
DMUR1FK DE Acne vulgaris
DMJN7MY ID DMJN7MY
DMJN7MY DN ED-110
DMJN7MY HS Terminated
DMJN7MY CP MSD Japan
DMJN7MY DT Small molecular drug
DMJN7MY PC 135705573
DMJN7MY MW 519.5
DMJN7MY FM C26H21N3O9
DMJN7MY IC InChI=1S/C26H21N3O9/c30-6-15-22(34)23(35)24(36)25(38-15)9-3-8-12(4-13(9)32)28-21-17(8)18-11(5-27-26(18)37)16-10-1-7(31)2-14(33)19(10)29-20(16)21/h1,4-5,9,15,22-25,30-32,34-36H,2-3,6H2/t9?,15-,22-,23+,24-,25+/m1/s1
DMJN7MY CS C1C(C(=CC2=C1C3=C4C(=C5C6=C(C(=O)CC(=C6)O)N=C5C3=N2)C=NC4=O)O)[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O
DMJN7MY IK GEFUXTHVYBRRRD-FKKAOLSPSA-N
DMJN7MY IU 7,20-dihydroxy-19-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(23),2,4(9),7,10,12,15,17(22),20-nonaene-5,14-dione
DMJN7MY CA CAS 139112-73-5
DMJN7MY DE Solid tumour/cancer
DMIC460 ID DMIC460
DMIC460 DN Edaglitazone
DMIC460 HS Terminated
DMIC460 SN Edaglitazone sodium; BM-131258; BM-152054; R-483; Ro-205; BM-13.258; BM-15.2054; Ro-205-2349; Ro-2052349-602
DMIC460 CP Roche Holding AG
DMIC460 PC 9825701
DMIC460 MW 464.6
DMIC460 FM C24H20N2O4S2
DMIC460 IC InChI=1S/C24H20N2O4S2/c1-14-18(25-23(30-14)15-5-3-2-4-6-15)9-11-29-19-8-7-16(21-17(19)10-12-31-21)13-20-22(27)26-24(28)32-20/h2-8,10,12,20H,9,11,13H2,1H3,(H,26,27,28)
DMIC460 CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC5C(=O)NC(=O)S5
DMIC460 IK HAAXAFNSRADSMK-UHFFFAOYSA-N
DMIC460 IU 5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]methyl]-1,3-thiazolidine-2,4-dione
DMIC460 CA CAS 213411-83-7
DMIC460 DE Type-2 diabetes
DM7ROS1 ID DM7ROS1
DM7ROS1 DN Efegatran
DM7ROS1 HS Terminated
DM7ROS1 SN efegatran; Efegatran [INN]; UNII-VT0VK2474K; CHEMBL273196; VT0VK2474K; 105806-65-3; L-Prolinamide, N-methyl-D-phenylalanyl-N-(4-((aminoiminomethyl)amino)-1-formylbutyl)-, (S)-; Me-Phe-Pro-Arg-H; AC1L3UA7; Me-(D-Phe)-Pro-Arg-CHO; SCHEMBL635674; SCHEMBL635675; 126721-07-1 (sulfate); (S)-1-((R)-2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid ((S)-1-formyl-4-guanidino-butyl)-amide; D-methyl-phenylalanyl-prolyl-arginal; BDBM50228863; LS-171983
DM7ROS1 DT Small molecular drug
DM7ROS1 PC 122267
DM7ROS1 MW 416.5
DM7ROS1 FM C21H32N6O3
DM7ROS1 IC InChI=1S/C21H32N6O3/c1-24-17(13-15-7-3-2-4-8-15)20(30)27-12-6-10-18(27)19(29)26-16(14-28)9-5-11-25-21(22)23/h2-4,7-8,14,16-18,24H,5-6,9-13H2,1H3,(H,26,29)(H4,22,23,25)/t16-,17+,18-/m0/s1
DM7ROS1 CS CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O
DM7ROS1 IK KAGLWQUWUNBAOO-KSZLIROESA-N
DM7ROS1 IU (2S)-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DM7ROS1 CA CAS 105806-65-3
DMJ0A5U ID DMJ0A5U
DMJ0A5U DN EFIPLADIB
DMJ0A5U HS Terminated
DMJ0A5U SN Efipladib; 381683-94-9; UNII-S97YUG2A91; S97YUG2A91; CHEMBL272342; PLA-902; Efipladib [USAN:INN]; Efipladib (USAN); 4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)methylsulfonamido)ethyl)-1H-indol-3-yl)propyl)benzoic acid; SCHEMBL1500831; HIZOPJQOPKRKFM-UHFFFAOYSA-N; ZINC85536943; BDBM50226792; D06674; 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid
DMJ0A5U DT Small molecular drug
DMJ0A5U PC 9853499
DMJ0A5U MW 746.1
DMJ0A5U FM C40H35Cl3N2O4S
DMJ0A5U IC InChI=1S/C40H35Cl3N2O4S/c41-32-19-21-37-34(25-32)33(13-7-8-27-14-17-31(18-15-27)40(46)47)38(22-23-44-50(48,49)26-28-16-20-35(42)36(43)24-28)45(37)39(29-9-3-1-4-10-29)30-11-5-2-6-12-30/h1-6,9-12,14-21,24-25,39,44H,7-8,13,22-23,26H2,(H,46,47)
DMJ0A5U CS C1=CC=C(C=C1)C(C2=CC=CC=C2)N3C4=C(C=C(C=C4)Cl)C(=C3CCNS(=O)(=O)CC5=CC(=C(C=C5)Cl)Cl)CCCC6=CC=C(C=C6)C(=O)O
DMJ0A5U IK HIZOPJQOPKRKFM-UHFFFAOYSA-N
DMJ0A5U IU 4-[3-[1-benzhydryl-5-chloro-2-[2-[(3,4-dichlorophenyl)methylsulfonylamino]ethyl]indol-3-yl]propyl]benzoic acid
DMJ0A5U CA CAS 381683-94-9
DMJ0A5U DE Asthma
DMYAMP5 ID DMYAMP5
DMYAMP5 DN EHT-1864
DMYAMP5 HS Terminated
DMYAMP5 SN EHT-0101; EHT-0206; EHT-101; EHT-206; Rac1 inhibitor (Alzheimer's disease/cancer),Exonhit
DMYAMP5 CP Exonhit
DMYAMP5 DT Small molecular drug
DMYAMP5 PC 9938202
DMYAMP5 MW 581.5
DMYAMP5 FM C25H29Cl2F3N2O4S
DMYAMP5 IC InChI=1S/C25H27F3N2O4S.2ClH/c26-25(27,28)18-4-5-20-21(14-18)29-7-6-24(20)35-13-3-1-2-10-33-23-17-34-19(15-22(23)31)16-30-8-11-32-12-9-30;;/h4-7,14-15,17H,1-3,8-13,16H2;2*1H
DMYAMP5 CS C1COCCN1CC2=CC(=O)C(=CO2)OCCCCCSC3=C4C=CC(=CC4=NC=C3)C(F)(F)F.Cl.Cl
DMYAMP5 IK LSECOAJFCKFQJG-UHFFFAOYSA-N
DMYAMP5 IU 2-(morpholin-4-ylmethyl)-5-[5-[7-(trifluoromethyl)quinolin-4-yl]sulfanylpentoxy]pyran-4-one;dihydrochloride
DMYAMP5 CA CAS 754240-09-0
DMYAMP5 DE Alzheimer disease
DMIP8NB ID DMIP8NB
DMIP8NB DN EK-399
DMIP8NB HS Terminated
DMIP8NB SN ek-399; AC1L2RJX; AC1Q5SZK; Ekk-399; (2r)-n-(2-{[(2s)-1-(2-acetylhydrazinyl)-1-oxo-3-phenylpropan-2-yl](ethyl)amino}-2-oxoethyl)-2-{[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino}-4-(methylsulfinyl)butanamide acetate(1:1)(non-preferred name); Tyr-met(O)-gly-etphe-nhnhcoch3; 98849-86-6; Tyrosyl-methionyl(O)-glycyl-ethylphenylalanine-2-acetylhydrazide; L-Phenylalanine, L-tyrosyl-4-(methylsulfinyl)-D-2-aminobutanoylglycyl-N-ethyl-, 2-acetylhydrazide, monoacetate (salt)
DMIP8NB CP Takeda Pharmaceutical Co Ltd
DMIP8NB DT Small molecular drug
DMIP8NB PC 127164
DMIP8NB MW 676.8
DMIP8NB FM C31H44N6O9S
DMIP8NB IC InChI=1S/C29H40N6O7S.C2H4O2/c1-4-35(25(29(41)34-33-19(2)36)17-20-8-6-5-7-9-20)26(38)18-31-28(40)24(14-15-43(3)42)32-27(39)23(30)16-21-10-12-22(37)13-11-21;1-2(3)4/h5-13,23-25,37H,4,14-18,30H2,1-3H3,(H,31,40)(H,32,39)(H,33,36)(H,34,41);1H3,(H,3,4)/t23-,24+,25-,43?;/m0./s1
DMIP8NB CS CCN([C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)C)C(=O)CNC(=O)[C@@H](CCS(=O)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N.CC(=O)O
DMIP8NB IK NOOIAQHTLKMMAW-VQCKKKRLSA-N
DMIP8NB IU acetic acid;(2R)-N-[2-[[(2S)-1-(2-acetylhydrazinyl)-1-oxo-3-phenylpropan-2-yl]-ethylamino]-2-oxoethyl]-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfinylbutanamide
DMIP8NB CA CAS 98849-86-6
DMIP8NB DE Inflammation
DMG9R8E ID DMG9R8E
DMG9R8E DN EM-2487
DMG9R8E HS Terminated
DMG9R8E SN EM2487; AC1L9SS4; N-(2-amino-2-oxoethyl)-[2-[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]oxy-N-[hydroxy-[methyl(12-methyltridecyl)amino]oxyphosphoryl]phosphonamidic acid; N-(2-amino-2-oxo-ethyl)-[2-[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy]-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]oxy-N-[hydroxy-[methyl(12-methyltridecyl)amino]oxy-phosphoryl]phosphonamidic acid
DMG9R8E CP Eisai Co Ltd
DMG9R8E DT Small molecular drug
DMG9R8E PC 10440507
DMG9R8E MW 829.8
DMG9R8E FM C32H57N5O16P2
DMG9R8E IC InChI=1S/C32H57N5O16P2/c1-20(2)13-11-9-7-5-4-6-8-10-12-15-35(3)53-55(48,49)37(17-23(33)39)54(46,47)52-30-27(43)25(41)21(18-38)29(30)50-19-22-26(42)28(44)31(51-22)36-16-14-24(40)34-32(36)45/h14,16,20,22,25-28,30-31,38,41-44H,4-13,15,17-19H2,1-3H3,(H2,33,39)(H,46,47)(H,48,49)(H,34,40,45)
DMG9R8E CS CC(C)CCCCCCCCCCCN(C)OP(=O)(N(CC(=O)N)P(=O)(O)OC1C(C(C(=C1OCC2C(C(C(O2)N3C=CC(=O)NC3=O)O)O)CO)O)O)O
DMG9R8E IK MTKDUTOCKQTOED-UHFFFAOYSA-N
DMG9R8E IU N-(2-amino-2-oxoethyl)-[2-[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]oxy-N-[hydroxy-[methyl(12-methyltridecyl)amino]oxyphosphoryl]phosphonamidic acid
DMG9R8E DE Human immunodeficiency virus infection
DMFZO4Y ID DMFZO4Y
DMFZO4Y DN EMBELIN
DMFZO4Y HS Terminated
DMFZO4Y SN EMBELIN; 550-24-3; Embelic acid; Emberine; 2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione; 2,5-Dihydroxy-3-undecyl-1,4-benzoquinone; 2,5-Dihydroxy-3-undecyl-p-benzoquinone; 2,5-Dihydroxy-3-undecyl-2,5-cyclohexadiene-1,4-dione; UNII-SHC6U8F5ER; CHEBI:4778; Embelin, Embelia ribes; C17H26O4; NSC91874; XIAP inhibitor, Embelin; EINECS 208-979-8; NSC 91874; SHC6U8F5ER; BRN 1885786; Apoptosis Activator III, Embelin; AK115155; p-Benzoquinone, 2,5-dihydroxy-3-undecyl-; SR-01000597536; Spectrum_001513; Tocris-2156; SpecPlus_000501
DMFZO4Y DT Small molecular drug
DMFZO4Y PC 3218
DMFZO4Y MW 294.4
DMFZO4Y FM C17H26O4
DMFZO4Y IC InChI=1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h12,18,21H,2-11H2,1H3
DMFZO4Y CS CCCCCCCCCCCC1=C(C(=O)C=C(C1=O)O)O
DMFZO4Y IK IRSFLDGTOHBADP-UHFFFAOYSA-N
DMFZO4Y IU 2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
DMFZO4Y CA CAS 550-24-3
DMFZO4Y CB CHEBI:4778
DMAEDQG ID DMAEDQG
DMAEDQG DN EMODIN
DMAEDQG HS Terminated
DMAEDQG SN emodin; 518-82-1; Emodol; Schuttgelb; Frangula emodin; Rheum emodin; Frangulic acid; 3-Methyl-1,6,8-trihydroxyanthraquinone; Archin; 1,3,8-trihydroxy-6-methylanthracene-9,10-dione; Persian Berry Lake; 1,3,8-Trihydroxy-6-methyl-9,10-anthraquinone; 6-Methyl-1,3,8-trihydroxyanthraquinone; C.I. Natural Yellow 14; 9,10-Anthracenedione, 1,3,8-trihydroxy-6-methyl-; 1,3,8-Trihydroxy-6-methylanthraquinone; 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione; 4,5,7-Trihydroxy-2-methylanthraquinone; UNII-KA46RNI6HN; C.I. 75440; NSC 622947
DMAEDQG DT Small molecular drug
DMAEDQG PC 3220
DMAEDQG MW 270.24
DMAEDQG FM C15H10O5
DMAEDQG IC InChI=1S/C15H10O5/c1-6-2-8-12(10(17)3-6)15(20)13-9(14(8)19)4-7(16)5-11(13)18/h2-5,16-18H,1H3
DMAEDQG CS CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O
DMAEDQG IK RHMXXJGYXNZAPX-UHFFFAOYSA-N
DMAEDQG IU 1,3,8-trihydroxy-6-methylanthracene-9,10-dione
DMAEDQG CA CAS 518-82-1
DMAEDQG CB CHEBI:42223
DMW210B ID DMW210B
DMW210B DN Emopamil
DMW210B HS Terminated
DMW210B SN Levemopamil
DMW210B CP Knoll GmbH
DMW210B DT Small molecular drug
DMW210B PC 71225
DMW210B MW 334.5
DMW210B FM C23H30N2
DMW210B IC InChI=1S/C23H30N2/c1-20(2)23(19-24,22-13-8-5-9-14-22)16-10-17-25(3)18-15-21-11-6-4-7-12-21/h4-9,11-14,20H,10,15-18H2,1-3H3
DMW210B CS CC(C)C(CCCN(C)CCC1=CC=CC=C1)(C#N)C2=CC=CC=C2
DMW210B IK DWAWDSVKAUWFHC-UHFFFAOYSA-N
DMW210B IU 5-[methyl(2-phenylethyl)amino]-2-phenyl-2-propan-2-ylpentanenitrile
DMW210B CA CAS 78370-13-5
DMW210B CB CHEBI:34736
DMW210B DE Cerebrovascular ischaemia
DMJU39N ID DMJU39N
DMJU39N DN Endovion
DMJU39N HS Terminated
DMJU39N SN Angiogenesis inhibitor, NeuroSearch; Chloride channel antagonist, NeuroSearch; NS-1652; NS-3728
DMJU39N CP NeuroSearch A/S
DMJU39N DT Small molecular drug
DMJU39N PC 10005966
DMJU39N MW 495.18
DMJU39N FM C16H9BrF6N6O
DMJU39N IC InChI=1S/C16H9BrF6N6O/c17-9-1-2-12(11(6-9)13-26-28-29-27-13)25-14(30)24-10-4-7(15(18,19)20)3-8(5-10)16(21,22)23/h1-6H,(H2,24,25,30)(H,26,27,28,29)
DMJU39N CS C1=CC(=C(C=C1Br)C2=NNN=N2)NC(=O)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMJU39N IK AEFYFGMSRKDXHZ-UHFFFAOYSA-N
DMJU39N IU 1-[3,5-bis(trifluoromethyl)phenyl]-3-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]urea
DMJU39N CA CAS 265646-85-3
DMJU39N DE Solid tumour/cancer
DMZA5Q4 ID DMZA5Q4
DMZA5Q4 DN EP-2060
DMZA5Q4 HS Terminated
DMZA5Q4 SN Apoptosis inducers, EpiCept; MX-11697; Anticancer agents, Celera/EpiCept; Apoptosis inducers, Celera/EpiCept; Apoptosis inducers, Celera/Maxim; Anti-cancer agents, Celera/Maxim
DMZA5Q4 CP Celera South San Francisco
DMZA5Q4 DE Solid tumour/cancer
DM149HL ID DM149HL
DM149HL DN EPD-clofarabine
DM149HL HS Terminated
DM149HL SN Clofarabine (Enhanced Prodrug), Heidelberg Pharma; HDP-15-0001; HDP-15-0022
DM149HL CP Heidelberg Pharma Holding GmbH
DM149HL DE Solid tumour/cancer
DM6IY4M ID DM6IY4M
DM6IY4M DN Epiroprim
DM6IY4M HS Terminated
DM6IY4M SN Epiroprim; Epiroprim [INN]; TCMDC-137295; 73090-70-7; Epiroprimum [INN-Latin]; Epiroprime [INN-French]; Epiroprima [INN-Spanish]; Ro 11-8958; UNII-9G69D95443; BRN 4273487; CHEMBL280378; C19H23N5O2; Ro-11-8958; 9G69D95443; 5-((3,5-Diethoxy-4-(1H-pyrrol-1-yl)phenyl)methyl)-2,4-pyrimidinediamine; Epiroprime; Epiroprimum; Epiroprima; 2,4-Diamino-5-(3,5-diethoxy-4-pyrrol-1-ylbenzyl)pyrimidine; 2,4-Pyrimidinediamine, 5-((3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl)methyl)-; Epir; AC1L2APS; SCHEMBL75698; AC1Q563X; DTXSID20223355; ZINC598590
DM6IY4M DT Small molecular drug
DM6IY4M PC 68916
DM6IY4M MW 353.4
DM6IY4M FM C19H23N5O2
DM6IY4M IC InChI=1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23)
DM6IY4M CS CCOC1=CC(=CC(=C1N2C=CC=C2)OCC)CC3=CN=C(N=C3N)N
DM6IY4M IK NMARPFMJVCXSAV-UHFFFAOYSA-N
DM6IY4M IU 5-[(3,5-diethoxy-4-pyrrol-1-ylphenyl)methyl]pyrimidine-2,4-diamine
DM6IY4M CA CAS 73090-70-7
DM6IY4M DE Bacterial infection
DMWRSXK ID DMWRSXK
DMWRSXK DN Epocarbazolin-A
DMWRSXK HS Terminated
DMWRSXK SN Epocarbazolin-B
DMWRSXK CP Bristol-Myers Squibb Co
DMWRSXK DT Small molecular drug
DMWRSXK PC 192365
DMWRSXK MW 369.5
DMWRSXK FM C22H27NO4
DMWRSXK IC InChI=1S/C22H27NO4/c1-11(2)7-8-22(4)21(27-22)17-12(3)16(26)9-14-18-13(10-24)5-6-15(25)20(18)23-19(14)17/h5-6,9,11,21,23-26H,7-8,10H2,1-4H3
DMWRSXK CS CC1=C(C=C2C3=C(C=CC(=C3NC2=C1C4C(O4)(C)CCC(C)C)O)CO)O
DMWRSXK IK JFHJFCCMTNIENN-UHFFFAOYSA-N
DMWRSXK IU 4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylbutyl)oxiran-2-yl]-9H-carbazole-1,6-diol
DMWRSXK CA CAS 146935-39-9
DMWRSXK DE Asthma
DM2NHLW ID DM2NHLW
DM2NHLW DN EPTALOPROST
DM2NHLW HS Terminated
DM2NHLW SN Eptaprost; ZK-97959; Eptaloprost; (5E)-16(S)-13,14-Didehydro-1a,1b-dihomo-16,20-dimethyl-3-oxa-18,18,19,19-tetrahydro-6a-carbaprostaglandin-I2; 4-[2-[(2E,3aS,4S,5R,6aS)-5-Hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl]hexahydro-2(1H)-pentalenylidene]ethoxy]butyric acid
DM2NHLW DT Small molecular drug
DM2NHLW PC 6436047
DM2NHLW MW 402.5
DM2NHLW FM C24H34O5
DM2NHLW IC InChI=1S/C24H34O5/c1-3-4-5-7-17(2)22(25)10-9-20-21-15-18(14-19(21)16-23(20)26)11-13-29-12-6-8-24(27)28/h11,17,19-23,25-26H,3,6-8,12-16H2,1-2H3,(H,27,28)/b18-11+/t17-,19-,20+,21-,22+,23+/m0/s1
DM2NHLW CS CCC#CC[C@H](C)[C@@H](C#C[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/COCCCC(=O)O)/C2)O)O
DM2NHLW IK MAUUNYHAXGTMMQ-AMXXQSRZSA-N
DM2NHLW IU 4-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]butanoic acid
DM2NHLW CA CAS 90693-76-8
DM2NHLW DE Solid tumour/cancer
DMAZVUB ID DMAZVUB
DMAZVUB DN ER-34122
DMAZVUB HS Terminated
DMAZVUB SN ER-34122; UNII-72Y1B3J8FS; 72Y1B3J8FS; ER 34122; 179325-62-3; SCHEMBL8854202; 5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide; Benzamide, 5-((1,5-bis(4-methoxyphenyl)-1H-pyrazol-3-yl)dimethoxymethyl)-2-chloro-
DMAZVUB CP Eisai Co Ltd
DMAZVUB DT Small molecular drug
DMAZVUB PC 9892473
DMAZVUB MW 508
DMAZVUB FM C27H26ClN3O5
DMAZVUB IC InChI=1S/C27H26ClN3O5/c1-33-20-10-5-17(6-11-20)24-16-25(30-31(24)19-8-12-21(34-2)13-9-19)27(35-3,36-4)18-7-14-23(28)22(15-18)26(29)32/h5-16H,1-4H3,(H2,29,32)
DMAZVUB CS COC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)OC)C(C4=CC(=C(C=C4)Cl)C(=O)N)(OC)OC
DMAZVUB IK USJVSASRKOHVHQ-UHFFFAOYSA-N
DMAZVUB IU 5-[[1,5-bis(4-methoxyphenyl)pyrazol-3-yl]-dimethoxymethyl]-2-chlorobenzamide
DMAZVUB CA CAS 179325-62-3
DMAZVUB DE Inflammation
DMYSTAD ID DMYSTAD
DMYSTAD DN ER-37328
DMYSTAD HS Terminated
DMYSTAD SN ER-37328; SCHEMBL6623792; CHEMBL604052
DMYSTAD DT Small molecular drug
DMYSTAD PC 21849939
DMYSTAD MW 411.9
DMYSTAD FM C22H22ClN3O3
DMYSTAD IC InChI=1S/C22H21N3O3.ClH/c1-24(2)9-8-14-21(27)15-10-23-11-25-16-7-6-12-13(4-3-5-17(12)26)18(16)19(20(15)25)22(14)28;/h3,5,10-11,14H,4,6-9H2,1-2H3;1H
DMYSTAD CS CN(C)CCC1C(=O)C2=CN=CN3C2=C(C1=O)C4=C3CCC5=C4CC=CC5=O.Cl
DMYSTAD IK WTKWSQVGFMBOGJ-UHFFFAOYSA-N
DMYSTAD IU 18-[2-(dimethylamino)ethyl]-12,14-diazapentacyclo[10.7.1.02,11.03,8.016,20]icosa-1(20),2(11),3(8),5,13,15-hexaene-7,17,19-trione;hydrochloride
DM08XS2 ID DM08XS2
DM08XS2 DN ERIC-1
DM08XS2 HS Terminated
DM08XS2 SN UJ13A; NCAM antagonist, Imperial Cancer Research Technology; ERIC-1, ICRT; ERIC-1, Imperial CancerResearch Technology
DM08XS2 CP Imperial Cancer Research Technology Ltd
DM08XS2 DE Solid tumour/cancer
DMJXEV7 ID DMJXEV7
DMJXEV7 DN ERTIPROTAFIB
DMJXEV7 HS Terminated
DMJXEV7 SN Ertiprotafib; UNII-5TPM2EB426; PTP-112; CHEMBL184041; 5TPM2EB426; 251303-04-5; Ertiprotafib [USAN:INN]; ptp112; AC1L4HAB; Ertiprotafib (USAN/INN); SCHEMBL6703442; DTXSID30179814; FONCZICQWCUXEB-RUZDIDTESA-N; BDBM50209683; HY-19383; CS-0015482; D04050; (2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid; (2R)-2-(4-(9-bromo-2,3-dimethylnaphtho(2,3-b)thiophen-4-yl)-2,6-dimethylphenoxy)-3-phenylpropionic acid; Benzenepropanoic acid, alpha-(4-(9-bromo-2,3-dimethylnaphtho(2,3-
DMJXEV7 DT Small molecular drug
DMJXEV7 PC 157049
DMJXEV7 MW 559.5
DMJXEV7 FM C31H27BrO3S
DMJXEV7 IC InChI=1S/C31H27BrO3S/c1-17-14-22(15-18(2)29(17)35-25(31(33)34)16-21-10-6-5-7-11-21)27-23-12-8-9-13-24(23)28(32)30-26(27)19(3)20(4)36-30/h5-15,25H,16H2,1-4H3,(H,33,34)/t25-/m1/s1
DMJXEV7 CS CC1=CC(=CC(=C1O[C@H](CC2=CC=CC=C2)C(=O)O)C)C3=C4C(=C(SC4=C(C5=CC=CC=C53)Br)C)C
DMJXEV7 IK FONCZICQWCUXEB-RUZDIDTESA-N
DMJXEV7 IU (2R)-2-[4-(9-bromo-2,3-dimethylbenzo[f][1]benzothiol-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid
DMJXEV7 CA CAS 251303-04-5
DMJXEV7 DE Type-2 diabetes
DMRP7BX ID DMRP7BX
DMRP7BX DN ES-1005
DMRP7BX HS Terminated
DMRP7BX SN ES 1005; ES-1005; AC1MIZDF; Bis((1-naphthyl)methyl)acetyl-histidyl-statyl-leucyl-episilon-lysinol; 115404-79-0; 1H-Imidazole-4-propanamide, N-(4-((1-(((5-amino-6-hydroxyhexyl)amino)carbonyl)-3-methylbutyl)amino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl)-alpha-((3-(1-naphthalenyl)-2-(1-naphthalenylmethyl)-1-oxopropyl)amino)-, dihydrochloride, (1S-(1R*(R*),2R*,4(R*(R*))))-
DMRP7BX CP Sankyo Co Ltd
DMRP7BX DT Small molecular drug
DMRP7BX PC 3082723
DMRP7BX MW 935
DMRP7BX FM C50H69Cl2N7O6
DMRP7BX IC InChI=1S/C50H67N7O6.2ClH/c1-32(2)23-43(46(59)28-47(60)55-44(24-33(3)4)49(62)53-22-10-9-19-39(51)30-58)56-50(63)45(27-40-29-52-31-54-40)57-48(61)38(25-36-17-11-15-34-13-5-7-20-41(34)36)26-37-18-12-16-35-14-6-8-21-42(35)37;;/h5-8,11-18,20-21,29,31-33,38-39,43-46,58-59H,9-10,19,22-28,30,51H2,1-4H3,(H,52,54)(H,53,62)(H,55,60)(H,56,63)(H,57,61);2*1H/t39-,43?,44-,45?,46-;;/m0../s1
DMRP7BX CS CC(C)C[C@@H](C(=O)NCCCC[C@@H](CO)N)NC(=O)C[C@@H](C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC2=CC=CC3=CC=CC=C32)CC4=CC=CC5=CC=CC=C54)O.Cl.Cl
DMRP7BX IK IYZRFOAPEUBNQP-JPZLKUPGSA-N
DMRP7BX IU (3S)-N-[(2S)-1-[[(5S)-5-amino-6-hydroxyhexyl]amino]-4-methyl-1-oxopentan-2-yl]-3-hydroxy-4-[[3-(1H-imidazol-5-yl)-2-[[3-naphthalen-1-yl-2-(naphthalen-1-ylmethyl)propanoyl]amino]propanoyl]amino]-6-methylheptanamide;dihydrochloride
DMRP7BX CA CAS 115404-79-0
DMRP7BX DE Hypertension
DM3BHN1 ID DM3BHN1
DM3BHN1 DN Etomoxir
DM3BHN1 HS Terminated
DM3BHN1 SN ETOMOXIR; 82258-36-4; rac- Etomoxir; Etomoxirum [Latin]; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate; BRN 4496620; Oxiranecarboxylic acid, 2-(6-(4-chlorophenoxy)hexyl)-, ethyl ester; B 807-54; Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxiranecarboxylate; Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester- [CAS]; Etomoxirum; etomoxir[inn]; SMR000449321; Rac-Etomoxir Ethyl Ester; C17H23ClO4; ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate; etoxomir; AC1L3XCY; MLS001424024; MLS000758228; SCHEMBL681359
DM3BHN1 DT Small molecular drug
DM3BHN1 PC 9840324
DM3BHN1 MW 326.8
DM3BHN1 FM C17H23ClO4
DM3BHN1 IC InChI=1S/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3/t17-/m1/s1
DM3BHN1 CS CCOC(=O)[C@]1(CO1)CCCCCCOC2=CC=C(C=C2)Cl
DM3BHN1 IK DZLOHEOHWICNIL-QGZVFWFLSA-N
DM3BHN1 IU ethyl (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate
DM3BHN1 CA CAS 124083-20-1
DM3BHN1 CB CHEBI:95011
DM3BHN1 DE Heart failure
DMRQOXG ID DMRQOXG
DMRQOXG DN Etrabamine
DMRQOXG HS Terminated
DMRQOXG SN 14839-JL
DMRQOXG CP Chiesi SA
DMRQOXG DT Small molecular drug
DMRQOXG PC 68895
DMRQOXG MW 168.26
DMRQOXG FM C8H12N2S
DMRQOXG IC InChI=1S/C8H12N2S/c1-9-6-2-3-7-8(4-6)11-5-10-7/h5-6,9H,2-4H2,1H3
DMRQOXG CS CNC1CCC2=C(C1)SC=N2
DMRQOXG IK YDSVAKPJAOSZJA-UHFFFAOYSA-N
DMRQOXG IU N-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-6-amine
DMRQOXG CA CAS 70590-58-8
DMRQOXG DE Parkinson disease
DMLA3P1 ID DMLA3P1
DMLA3P1 DN EUK-207
DMLA3P1 HS Terminated
DMLA3P1 CP Eukarion Inc
DMLA3P1 DT Small molecular drug
DMLA3P1 PC 135469150
DMLA3P1 MW 414.5
DMLA3P1 FM C22H26N2O6
DMLA3P1 IC InChI=1S/C22H26N2O6/c25-21-17-3-1-5-19(21)29-13-11-27-9-10-28-12-14-30-20-6-2-4-18(22(20)26)16-24-8-7-23-15-17/h1-6,15-16,25-26H,7-14H2
DMLA3P1 CS C1CN=CC2=C(C(=CC=C2)OCCOCCOCCOC3=CC=CC(=C3O)C=N1)O
DMLA3P1 IK IJRRNMCPHVFFMW-UHFFFAOYSA-N
DMLA3P1 IU 13,16,19,22-tetraoxa-3,6-diazatricyclo[21.3.1.18,12]octacosa-1(27),2,6,8(28),9,11,23,25-octaene-27,28-diol
DMLA3P1 DE Neurodegenerative disorder
DM9P4ZN ID DM9P4ZN
DM9P4ZN DN EXP-6803
DM9P4ZN HS Terminated
DM9P4ZN SN 114773-44-3; 1H-Imidazole-5-aceticacid, 2-butyl-1-[[4-[(2-carboxybenzoyl)amino]phenyl]methyl]-4-chloro-, 5-methylester, sodium salt (1:1); Exp 6803; AC1Q1VXO; ACMC-20d225; CTK4A8893; sodium 2-(2-butyl-1-{4-[(2-carboxybenzoyl)amino]benzyl}-4-chloro-1h-imidazol-5-yl)propanoate; Methyl 2-n-butyl-1-(4-(2-carboxybenzamido)benzyl)-4-chloroimidazole-5-acetate; 1H-Imidazole-5-acetic acid, 2-butyl-1-((4-((2-carboxybenzoyl)amino)phenyl)methyl)-4-chloro-, alpha-methyl ester, monosodium salt
DM9P4ZN CP Bristol-Myers Squibb Pharma Co
DM9P4ZN DT Small molecular drug
DM9P4ZN PC 23695961
DM9P4ZN MW 505.9
DM9P4ZN FM C25H25ClN3NaO5
DM9P4ZN IC InChI=1S/C25H26ClN3O5.Na/c1-3-4-9-20-28-22(26)21(15(2)24(31)32)29(20)14-16-10-12-17(13-11-16)27-23(30)18-7-5-6-8-19(18)25(33)34;/h5-8,10-13,15H,3-4,9,14H2,1-2H3,(H,27,30)(H,31,32)(H,33,34);/q;+1/p-1
DM9P4ZN CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)NC(=O)C3=CC=CC=C3C(=O)O)C(C)C(=O)[O-])Cl.[Na+]
DM9P4ZN IK OSDQJFVHDVAJSD-UHFFFAOYSA-M
DM9P4ZN IU sodium;2-[2-butyl-3-[[4-[(2-carboxybenzoyl)amino]phenyl]methyl]-5-chloroimidazol-4-yl]propanoate
DM9P4ZN CA CAS 114773-44-3
DM9P4ZN DE Hypertension
DMR1X2U ID DMR1X2U
DMR1X2U DN F-0401
DMR1X2U HS Terminated
DMR1X2U SN F 0401; AC1O5R3Q; SCHEMBL7291536; SCHEMBL7291521; f04-01; ((+-)-(E)-3-(4-(1-Imidazolyl)methylphenyl)-2-propen-1-yl)methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; (E)-3-(4-(1H-Imidazol-1-ylmethyl)phenyl)-2-propenyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; 5-O-[(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-ni
DMR1X2U DT Small molecular drug
DMR1X2U PC 6439160
DMR1X2U MW 528.6
DMR1X2U FM C29H28N4O6
DMR1X2U IC InChI=1S/C29H28N4O6/c1-19-25(28(34)38-3)27(23-7-4-8-24(16-23)33(36)37)26(20(2)31-19)29(35)39-15-5-6-21-9-11-22(12-10-21)17-32-14-13-30-18-32/h4-14,16,18,27,31H,15,17H2,1-3H3/b6-5+
DMR1X2U CS CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=C(C=C2)CN3C=CN=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC
DMR1X2U IK CSBQPRGTYHAYKS-AATRIKPKSA-N
DMR1X2U IU 5-O-[(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMR1X2U CA CAS 123852-99-3
DM3786U ID DM3786U
DM3786U DN F-12509A
DM3786U HS Terminated
DM3786U CP Sankyo Co Ltd
DM3786U PC 9862964
DM3786U MW 344.4
DM3786U FM C21H28O4
DM3786U IC InChI=1S/C21H28O4/c1-12-6-7-17-20(2,3)8-5-9-21(17,4)14(12)10-13-18(24)15(22)11-16(23)19(13)25/h11,14,17,22,25H,1,5-10H2,2-4H3/t14-,17-,21+/m0/s1
DM3786U CS C[C@]12CCCC([C@@H]1CCC(=C)[C@@H]2CC3=C(C(=O)C=C(C3=O)O)O)(C)C
DM3786U IK KFAYECQGXSDHKU-XXHMAFKTSA-N
DM3786U IU 3-[[(1S,4aS,8aS)-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]methyl]-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
DM3786U DE Arteriosclerosis
DM23OHW ID DM23OHW
DM23OHW DN F-12682
DM23OHW HS Terminated
DM23OHW SN Antidepressant, Pierre Fabre; F-12318; 5-HT1B antagonists, Pierre Fabre
DM23OHW CP Pierre Fabre SA
DM23OHW DE Major depressive disorder
DMGH3QD ID DMGH3QD
DMGH3QD DN F-14413
DMGH3QD HS Terminated
DMGH3QD SN Alpha-2 adrenoceptor antagonist (Alzheimer's disease), Pierre Fabre
DMGH3QD CP Pierre Fabre SA
DMGH3QD DE Alzheimer disease
DMVWZN1 ID DMVWZN1
DMVWZN1 DN F-200
DMVWZN1 HS Terminated
DMVWZN1 SN Eos-200-F; Anti-alpha-5/beta-1 integrin Ab Fragment, PDL; Anti-alpha-5/beta-1 integrin Fab, PDL; Anti-alpha-5/beta-1 integrin Fab, Protein Design Labs
DMVWZN1 CP Eos Biotechnology Inc
DMVWZN1 DT Small molecular drug
DMVWZN1 PC 16660135
DMVWZN1 MW 371.4
DMVWZN1 FM C18H18FN5OS
DMVWZN1 IC InChI=1S/C18H18FN5OS/c1-11(2)22-16-8-14(20-10-21-16)15-9-26-18(23-15)24(3)17(25)12-4-6-13(19)7-5-12/h4-11H,1-3H3,(H,20,21,22)
DMVWZN1 CS CC(C)NC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)F
DMVWZN1 IK WIVGIKIKQHUFOD-UHFFFAOYSA-N
DMVWZN1 IU 4-fluoro-N-methyl-N-[4-[6-(propan-2-ylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]benzamide
DMVWZN1 DE Ocular disease
DMXB8SE ID DMXB8SE
DMXB8SE DN F-3796
DMXB8SE HS Terminated
DMXB8SE CP Pierre Fabre SA
DMXB8SE DE Alzheimer disease
DMJ3MAZ ID DMJ3MAZ
DMJ3MAZ DN F-992
DMJ3MAZ HS Terminated
DMJ3MAZ SN Pulmonary emphysema therapeutic, Fornix; F-992, Fornix
DMJ3MAZ CP Fornix BioSciences NV
DMJ3MAZ DE Urinary incontinence
DME694O ID DME694O
DME694O DN Fananserin
DME694O HS Terminated
DME694O SN 127625-29-0; RP 62203; Fananserin [USAN:INN]; RP-62203; UNII-38QJ762ET6; CHEMBL83894; C23H24FN3O2S; VGIGHGMPMUCLIQ-UHFFFAOYSA-N; 38QJ762ET6; NCGC00167808-01; DSSTox_RID_81871; DSSTox_CID_26743; 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide; 2H-Naphth(1,8-cd)isothiazole, 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-, 1,1-dioxide; DSSTox_GSID_46743; [3H]fananserin; CAS-127625-29-0; Fananserin (USAN/INN); [3H]RP62203; [3H]RP-62203; AC1L1TX5; RP 62203; 2-(3-(4-(4-fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide
DME694O CP Sanofi-Aventis
DME694O DT Small molecular drug
DME694O PC 60785
DME694O MW 425.5
DME694O FM C23H24FN3O2S
DME694O IC InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2
DME694O CS C1CN(CCN1CCCN2C3=CC=CC4=C3C(=CC=C4)S2(=O)=O)C5=CC=C(C=C5)F
DME694O IK VGIGHGMPMUCLIQ-UHFFFAOYSA-N
DME694O IU 3-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]-2lambda6-thia-3-azatricyclo[6.3.1.04,12]dodeca-1(11),4,6,8(12),9-pentaene 2,2-dioxide
DME694O CA CAS 127625-29-0
DME694O CB CHEBI:92159
DME694O DE Schizophrenia
DMR3ZWA ID DMR3ZWA
DMR3ZWA DN FCE-25876
DMR3ZWA HS Terminated
DMR3ZWA CP Pharmacia & Upjohn SpA
DMR3ZWA DE Major depressive disorder
DMJX1IB ID DMJX1IB
DMJX1IB DN Fedotozine
DMJX1IB HS Terminated
DMJX1IB SN AC1L1TVH; SCHEMBL1649900; AC1Q56G3; (2s)-n,n-dimethyl-2-phenyl-1-[(3,4,5-trimethoxybenzyl)oxy]butan-2-amine
DMJX1IB DT Small molecular drug
DMJX1IB PC 6918160
DMJX1IB MW 373.5
DMJX1IB FM C22H31NO4
DMJX1IB IC InChI=1S/C22H31NO4/c1-7-22(23(2)3,18-11-9-8-10-12-18)16-27-15-17-13-19(24-4)21(26-6)20(14-17)25-5/h8-14H,7,15-16H2,1-6H3/t22-/m0/s1
DMJX1IB CS CC[C@](COCC1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
DMJX1IB IK MVKIWCDXKCUDEH-QFIPXVFZSA-N
DMJX1IB IU (2R)-N,N-dimethyl-2-phenyl-1-[(3,4,5-trimethoxyphenyl)methoxy]butan-2-amine
DMJX1IB CA CAS 123618-00-8
DMJ35RC ID DMJ35RC
DMJ35RC DN FH-510
DMJ35RC HS Terminated
DMJ35RC SN Fh-510; CCRIS 6870; UNII-J02GJE6S84; FH 510; 139304-28-2; J02GJE6S84; 9H-Carbazole-4-ethanamine, 5,8-dimethyl-N,N-dipropyl-, monohydrochloride; AC1L36MK; SCHEMBL467264; DTXSID00161004; LS-189199; N-[2-(5,8-dimethyl-9H-carbazol-4-yl)ethyl]-N-propylpropan-1-amine hydrochloride
DMJ35RC CP Taisho Pharmaceutical Co Ltd
DMJ35RC DT Small molecular drug
DMJ35RC PC 135554
DMJ35RC MW 358.9
DMJ35RC FM C22H31ClN2
DMJ35RC IC InChI=1S/C22H30N2.ClH/c1-5-13-24(14-6-2)15-12-18-8-7-9-19-21(18)20-16(3)10-11-17(4)22(20)23-19;/h7-11,23H,5-6,12-15H2,1-4H3;1H
DMJ35RC CS CCCN(CCC)CCC1=C2C(=CC=C1)NC3=C(C=CC(=C23)C)C.Cl
DMJ35RC IK NSLYKDHGJLVNIJ-UHFFFAOYSA-N
DMJ35RC IU N-[2-(5,8-dimethyl-9H-carbazol-4-yl)ethyl]-N-propylpropan-1-amine;hydrochloride
DMJ35RC CA CAS 139304-28-2
DMJ35RC DE Psychotic disorder
DMIGXQF ID DMIGXQF
DMIGXQF DN FK-355
DMIGXQF HS Terminated
DMIGXQF SN NK1 antagonists, Fujisawa
DMIGXQF CP Fujisawa Pharmaceutical Co Ltd
DMIGXQF DE Asthma
DMDVAI5 ID DMDVAI5
DMDVAI5 DN Florifenine
DMDVAI5 HS Terminated
DMDVAI5 SN Florifenine; 83863-79-0; UNII-S7UT8VQG94; S7UT8VQG94; C23H22F3N3O2; Florifenine [INN]; SCHEMBL379372; AC1L50B0; CHEMBL2104893; ZINC537734; API0011459; FI-2522; M454; FT-0668560; 2-pyrrolidin-1-ylethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate; 2-(1-Pyrrolidinyl)ethyl N-(7-(trifluoromethyl)-4-quinolyl)anthranilate.; 2-(1-Pyrrolidinyl)ethyl N-(7-(trifluoromethyl)-4-quinolyl)anthranilate; 2-[[7-(Trifluoromethyl)-4-quinolinyl]amino]benzoic Acid 2-(1-Pyrrolidinyl)ethyl Ester
DMDVAI5 CP Ferrer Internacional SA
DMDVAI5 DT Small molecular drug
DMDVAI5 PC 216222
DMDVAI5 MW 429.4
DMDVAI5 FM C23H22F3N3O2
DMDVAI5 IC InChI=1S/C23H22F3N3O2/c24-23(25,26)16-7-8-17-20(9-10-27-21(17)15-16)28-19-6-2-1-5-18(19)22(30)31-14-13-29-11-3-4-12-29/h1-2,5-10,15H,3-4,11-14H2,(H,27,28)
DMDVAI5 CS C1CCN(C1)CCOC(=O)C2=CC=CC=C2NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F
DMDVAI5 IK DQOYUDHAZMAVLD-UHFFFAOYSA-N
DMDVAI5 IU 2-pyrrolidin-1-ylethyl 2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate
DMDVAI5 CA CAS 83863-79-0
DMDVAI5 DE Inflammation
DMY89KQ ID DMY89KQ
DMY89KQ DN Flosequinan
DMY89KQ HS Terminated
DMY89KQ SN Manoplax; BTS-49465; BTS-53554
DMY89KQ CP Knoll Pharmaceuticals Co
DMY89KQ DT Small molecular drug
DMY89KQ PC 4474062
DMY89KQ MW 239.27
DMY89KQ FM C11H10FNO2S
DMY89KQ IC InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3
DMY89KQ CS CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C
DMY89KQ IK UYGONJYYUKVHDD-UHFFFAOYSA-N
DMY89KQ IU 7-fluoro-1-methyl-3-methylsulfinylquinolin-4-one
DMY89KQ CA CAS 76568-02-0
DMY89KQ CB CHEBI:134972
DMY89KQ DE Cardiovascular disease
DM6OIJ1 ID DM6OIJ1
DM6OIJ1 DN Flosulide
DM6OIJ1 HS Terminated
DM6OIJ1 SN CGP-28238; CGP-28328; CGS-28238; SH-459; ZK-38997
DM6OIJ1 CP Novartis AG
DM6OIJ1 DT Small molecular drug
DM6OIJ1 PC 71246
DM6OIJ1 MW 353.3
DM6OIJ1 FM C16H13F2NO4S
DM6OIJ1 IC InChI=1S/C16H13F2NO4S/c1-24(21,22)19-13-6-9-2-4-14(20)11(9)8-16(13)23-15-5-3-10(17)7-12(15)18/h3,5-8,19H,2,4H2,1H3
DM6OIJ1 CS CS(=O)(=O)NC1=C(C=C2C(=C1)CCC2=O)OC3=C(C=C(C=C3)F)F
DM6OIJ1 IK CXJONBHNIJFARE-UHFFFAOYSA-N
DM6OIJ1 IU N-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide
DM6OIJ1 CA CAS 80937-31-1
DM6OIJ1 DE Pain
DM7JT3D ID DM7JT3D
DM7JT3D DN Fluoratec
DM7JT3D HS Terminated
DM7JT3D SN Technepine; DAT imaging agent, Alseres; DAT imaging agent, Boston life Sciences; DAT imaging agent, Harvard University; Dopamine transporter imaging agent, Alseres; Dopamine transporter imaging agent, Boston life Sciences; O-1505; O-1505T; O-1506; O-1730; O-1783; O-1794; O-861T; Dopamine transporter imaging agent, Harvard/MIT/Organix; 99mTc-O-1505; 99mTc-O-1505T
DM7JT3D CP Harvard University
DM7JT3D DE Attention deficit hyperactivity disorder
DMSYLIF ID DMSYLIF
DMSYLIF DN Fosfluridine tidoxil
DMSYLIF HS Terminated
DMSYLIF SN Fosfluridine; HDP-99-0006; 5-fluorouridine prodrug, Heidelberg Pharma
DMSYLIF CP Heidelberg Pharma Holding GmbH
DMSYLIF DT Small molecular drug
DMSYLIF PC 9875280
DMSYLIF MW 740.9
DMSYLIF FM C34H62FN2O10PS
DMSYLIF IC InChI=1S/C34H62FN2O10PS/c1-3-5-7-9-11-13-14-16-18-20-22-49-26-27(44-21-19-17-15-12-10-8-6-4-2)24-45-48(42,43)46-25-29-30(38)31(39)33(47-29)37-23-28(35)32(40)36-34(37)41/h23,27,29-31,33,38-39H,3-22,24-26H2,1-2H3,(H,42,43)(H,36,40,41)/t27?,29-,30-,31-,33-/m1/s1
DMSYLIF CS CCCCCCCCCCCCSCC(COP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O)OCCCCCCCCCC
DMSYLIF IK LBBDGLOPGRGFDO-FKJRLRTPSA-N
DMSYLIF IU (2-decoxy-3-dodecylsulfanylpropyl) [(2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DMSYLIF CA CAS 174638-15-4
DMSYLIF DE Keratosis
DMF1CDK ID DMF1CDK
DMF1CDK DN FPL-55712
DMF1CDK HS Terminated
DMF1CDK SN Fpl-55712; 40786-08-1; 7-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-carboxy late, sodium salt; CHEMBL267976; 7-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]- 4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid sodium salt; 4H-1-Benzopyran-2-carboxylic acid, 7-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy)-4-oxo-8-propyl-, monosodium salt; fpl55712; SCHEMBL1890293; AOB5208; ZDEVPOBNLIVGFA-UHFFFAOYSA-M; MFCD00068619; LS-186693; FT-0639668; FPL-55712, >
DMF1CDK CP Fisons plc
DMF1CDK DT Small molecular drug
DMF1CDK PC 23662025
DMF1CDK MW 520.5
DMF1CDK FM C27H29NaO9
DMF1CDK IC InChI=1S/C27H30O9.Na/c1-4-6-19-22(10-8-17(15(3)28)25(19)31)34-13-16(29)14-35-23-11-9-18-21(30)12-24(27(32)33)36-26(18)20(23)7-5-2;/h8-12,16,29,31H,4-7,13-14H2,1-3H3,(H,32,33);/q;+1/p-1
DMF1CDK CS CCCC1=C(C=CC(=C1O)C(=O)C)OCC(COC2=C(C3=C(C=C2)C(=O)C=C(O3)C(=O)[O-])CCC)O.[Na+]
DMF1CDK IK ZDEVPOBNLIVGFA-UHFFFAOYSA-M
DMF1CDK IU sodium;7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propylchromene-2-carboxylate
DMF1CDK CA CAS 40786-08-1
DMF1CDK DE Asthma
DMCAZPR ID DMCAZPR
DMCAZPR DN FR-113680
DMCAZPR HS Terminated
DMCAZPR SN FR 113680; 126088-92-4; Ac-Thr-trp(cho)-phe-N-mebzl; AC1L2Y4S; DTXSID70155076; fr113680; N(alpha)-(N(alpha)-(N(alpha)-Acetylthreonyl)-N(1)-formyltryptophyl)-N-methyl-N-(phenylmethyl)phenylalaninamide; L-Phenylalaninamide, N-acetyl-L-threonyl-1-formyl-D-tryptophyl-N-methyl-N-(phenylmethyl)-
DMCAZPR CP Fujisawa Pharmaceutical Co Ltd
DMCAZPR DT Small molecular drug
DMCAZPR PC 130848
DMCAZPR MW 625.7
DMCAZPR FM C35H39N5O6
DMCAZPR IC InChI=1S/C35H39N5O6/c1-23(42)32(37-24(2)43)35(46)40(33(44)29(36)19-27-21-39(22-41)30-17-11-10-16-28(27)30)34(45)31(18-25-12-6-4-7-13-25)38(3)20-26-14-8-5-9-15-26/h4-17,21-23,29,31-32,42H,18-20,36H2,1-3H3,(H,37,43)/t23-,29-,31+,32+/m1/s1
DMCAZPR CS C[C@H]([C@@H](C(=O)N(C(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C=O)N)C(=O)[C@H](CC3=CC=CC=C3)N(C)CC4=CC=CC=C4)NC(=O)C)O
DMCAZPR IK GUMFSDXELXANKA-KGLGFYCJSA-N
DMCAZPR IU (2S,3R)-2-acetamido-N-[(2R)-2-amino-3-(1-formylindol-3-yl)propanoyl]-N-[(2S)-2-[benzyl(methyl)amino]-3-phenylpropanoyl]-3-hydroxybutanamide
DMCAZPR CA CAS 126088-92-4
DMCAZPR DE Asthma
DMY2IB8 ID DMY2IB8
DMY2IB8 DN FR-115427
DMY2IB8 HS Terminated
DMY2IB8 SN FR-115427; 1-Methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline; (+)-1,2,3,4-Tetrahydro-1-methyl-1-phenylisoquinoline hydrochloride; Isoquinoline, 1,2,3,4-tetrahydro-1-methyl-1-phenyl-, hydrochloride, (+)-; FR115427; 126114-66-7; SCHEMBL6021932; AC1L2Y54; LS-172648; FR 115427; 1-methyl-1-phenyl-3,4-dihydro-2H-isoquinoline hydrochloride; (+)-1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride
DMY2IB8 CP Fujisawa Pharmaceutical Co Ltd
DMY2IB8 DT Small molecular drug
DMY2IB8 PC 130852
DMY2IB8 MW 259.769
DMY2IB8 FM C16H18ClN
DMY2IB8 IC InChI=1S/C16H17N.ClH/c1-16(14-8-3-2-4-9-14)15-10-6-5-7-13(15)11-12-17-16;/h2-10,17H,11-12H2,1H3;1H
DMY2IB8 CS CC1(C2=CC=CC=C2CCN1)C3=CC=CC=C3.Cl
DMY2IB8 IK LUSUZDOXGNAITA-UHFFFAOYSA-N
DMY2IB8 IU 1-methyl-1-phenyl-3,4-dihydro-2H-isoquinoline;hydrochloride
DMY2IB8 CA CAS 126114-66-7
DMY2IB8 DE Cerebrovascular ischaemia
DMNRUGA ID DMNRUGA
DMNRUGA DN FR-121196
DMNRUGA HS Terminated
DMNRUGA SN FR-121196; FR 121196; 133920-65-7; N-(4-Acetyl-1-piperazinyl)-4-fluorobenzenesulfonamide; PZQKOVUNWPDCCQ-UHFFFAOYSA-N; FR121196; ACMC-20mv5f; AC1L2ZLZ; SCHEMBL195526; CTK4B8875; DTXSID90158423; Piperazine, 1-acetyl-4-(((4-fluorophenyl)sulfonyl)amino)-
DMNRUGA CP Fujisawa Pharmaceutical Co Ltd
DMNRUGA DT Small molecular drug
DMNRUGA PC 131688
DMNRUGA MW 301.34
DMNRUGA FM C12H16FN3O3S
DMNRUGA IC InChI=1S/C12H16FN3O3S/c1-10(17)15-6-8-16(9-7-15)14-20(18,19)12-4-2-11(13)3-5-12/h2-5,14H,6-9H2,1H3
DMNRUGA CS CC(=O)N1CCN(CC1)NS(=O)(=O)C2=CC=C(C=C2)F
DMNRUGA IK PZQKOVUNWPDCCQ-UHFFFAOYSA-N
DMNRUGA IU N-(4-acetylpiperazin-1-yl)-4-fluorobenzenesulfonamide
DMNRUGA CA CAS 133920-65-7
DMNRUGA DE Alzheimer disease
DM0582D ID DM0582D
DM0582D DN FR-123826
DM0582D HS Terminated
DM0582D SN COX-2 inhibitor, Fujisawa
DM0582D CP Fujisawa Pharmaceutical Co Ltd
DM0582D PC 10042938
DM0582D MW 341.4
DM0582D FM C17H12FN3O2S
DM0582D IC InChI=1S/C17H12FN3O2S/c1-24(22,23)16-8-2-12(3-9-16)17-10-14(11-19)20-21(17)15-6-4-13(18)5-7-15/h2-10H,1H3
DM0582D CS CS(=O)(=O)C1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)F)C#N
DM0582D IK NKBRWXWNSUIHNI-UHFFFAOYSA-N
DM0582D IU 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile
DM0582D DE Rheumatoid arthritis
DMMOBHW ID DMMOBHW
DMMOBHW DN FR-128998
DMMOBHW HS Terminated
DMMOBHW CP Fujisawa Pharmaceutical Co Ltd
DMMOBHW DE Thrombocytopenia
DM9V6AU ID DM9V6AU
DM9V6AU DN FR-129169
DM9V6AU HS Terminated
DM9V6AU CP Fujisawa Pharmaceutical Co Ltd
DM9V6AU PC 9803486
DM9V6AU MW 443.6
DM9V6AU FM C30H37NO2
DM9V6AU IC InChI=1S/C30H37NO2/c1-2-3-4-5-6-15-22-33-29-21-14-13-20-27(29)24-30(32)31-28(26-18-11-8-12-19-26)23-25-16-9-7-10-17-25/h7-14,16-21,28H,2-6,15,22-24H2,1H3,(H,31,32)
DM9V6AU CS CCCCCCCCOC1=CC=CC=C1CC(=O)NC(CC2=CC=CC=C2)C3=CC=CC=C3
DM9V6AU IK XUCJTVYTRXSOJC-UHFFFAOYSA-N
DM9V6AU IU N-(1,2-diphenylethyl)-2-(2-octoxyphenyl)acetamide
DM9V6AU CA CAS 143895-84-5
DM9V6AU DE Arteriosclerosis
DMXWL0N ID DMXWL0N
DMXWL0N DN FR-133605
DMXWL0N HS Terminated
DMXWL0N CP Fujisawa Pharmaceutical Co Ltd
DMXWL0N DE Arthritis
DMHV43M ID DMHV43M
DMHV43M DN FR-145237
DMHV43M HS Terminated
DMHV43M CP Fujisawa Pharmaceutical Co Ltd
DMHV43M PC 9850056
DMHV43M MW 535
DMHV43M FM C30H22ClF3N2O2
DMHV43M IC InChI=1S/C30H22ClF3N2O2/c1-18-7-12-26-23(13-18)28(20-8-10-21(31)11-9-20)27(38-26)17-36(16-19-5-3-2-4-6-19)30(37)35-29-24(33)14-22(32)15-25(29)34/h2-15H,16-17H2,1H3,(H,35,37)
DMHV43M CS CC1=CC2=C(C=C1)OC(=C2C3=CC=C(C=C3)Cl)CN(CC4=CC=CC=C4)C(=O)NC5=C(C=C(C=C5F)F)F
DMHV43M IK GJRPAGNTTAPJCC-UHFFFAOYSA-N
DMHV43M IU 1-benzyl-1-[[3-(4-chlorophenyl)-5-methyl-1-benzofuran-2-yl]methyl]-3-(2,4,6-trifluorophenyl)urea
DMHV43M CA CAS 146011-65-6
DMHV43M DE Arteriosclerosis
DMBOFSQ ID DMBOFSQ
DMBOFSQ DN FR-149581
DMBOFSQ HS Terminated
DMBOFSQ SN Angiotensin II antagonist, Fujisawa
DMBOFSQ CP Fujisawa Pharmaceutical Co Ltd
DMBOFSQ DE Hypertension
DMOEYX2 ID DMOEYX2
DMOEYX2 DN FR-152558
DMOEYX2 HS Terminated
DMOEYX2 CP Fujisawa Pharmaceutical Co Ltd
DMOEYX2 DE Alzheimer disease
DMIQB9E ID DMIQB9E
DMIQB9E DN FR-171113
DMIQB9E HS Terminated
DMIQB9E SN CTK8E8568
DMIQB9E CP Fujisawa Pharmaceutical Corp
DMIQB9E DT Small molecular drug
DMIQB9E PC 25015749
DMIQB9E MW 469.7
DMIQB9E FM C19H11Cl3N2O4S
DMIQB9E IC InChI=1S/C19H11Cl3N2O4S/c1-28-16(25)9-15-18(27)24(12-5-2-10(20)3-6-12)19(29-15)23-17(26)13-7-4-11(21)8-14(13)22/h2-9H,1H3/b15-9+,23-19?
DMIQB9E CS COC(=O)/C=C/1\\C(=O)N(C(=NC(=O)C2=C(C=C(C=C2)Cl)Cl)S1)C3=CC=C(C=C3)Cl
DMIQB9E IK SDGLYCKTPKZBGI-DALCUZTNSA-N
DMIQB9E IU methyl (2E)-2-[3-(4-chlorophenyl)-2-(2,4-dichlorobenzoyl)imino-4-oxo-1,3-thiazolidin-5-ylidene]acetate
DMIQB9E DE Thrombosis
DMY1LRI ID DMY1LRI
DMY1LRI DN FR-172357
DMY1LRI HS Terminated
DMY1LRI CP Fujisawa Pharmaceutical Co Ltd
DMY1LRI DE Inflammation
DM37OS4 ID DM37OS4
DM37OS4 DN FR-173657
DM37OS4 HS Terminated
DM37OS4 SN FK-3657; FR-173657; FR173657; FR 173657; CHEMBL130517; XCKWRUGRUFVXGC-NTEUORMPSA-N; AC1NSK08; GTPL674; 167838-64-4; SCHEMBL1559539; SCHEMBL3718364; BDBM50067301; FK 3657; L015626; 3-(6-acetamidopyridin-3-yl)-N-(2-((2,4-dichloro-3-((2-methylquinolin-8-yloxy)methyl)phenyl)(methyl)amino)-2-oxoethyl)acrylamide; (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide
DM37OS4 DT Small molecular drug
DM37OS4 PC 5311108
DM37OS4 MW 592.5
DM37OS4 FM C30H27Cl2N5O4
DM37OS4 IC InChI=1S/C30H27Cl2N5O4/c1-18-7-10-21-5-4-6-25(30(21)35-18)41-17-22-23(31)11-12-24(29(22)32)37(3)28(40)16-34-27(39)14-9-20-8-13-26(33-15-20)36-19(2)38/h4-15H,16-17H2,1-3H3,(H,34,39)(H,33,36,38)/b14-9+
DM37OS4 CS CC1=NC2=C(C=CC=C2OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CN=C(C=C4)NC(=O)C)Cl)C=C1
DM37OS4 IK XCKWRUGRUFVXGC-NTEUORMPSA-N
DM37OS4 IU (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide
DM37OS4 CA CAS 167838-64-4
DMCQHG4 ID DMCQHG4
DMCQHG4 DN FR-183998
DMCQHG4 HS Terminated
DMCQHG4 SN FR-183998; AC1OCFC6; SCHEMBL6134503; 3-N-(diaminomethylidene)-5-(2,5-dichlorothiophen-3-yl)-1-N-(2-dimethylaminoethyl)benzene-1,3-dicarboxamide dihydrochloride; 3-(2,5-dichlorothiophen-3-yl)-N-[2-(dimethylamino)ethyl]-5-guanidinocarbonylbenzamide dihydrochloride
DMCQHG4 CP Fujisawa Pharmaceutical Co Ltd
DMCQHG4 DT Small molecular drug
DMCQHG4 PC 6918360
DMCQHG4 MW 501.3
DMCQHG4 FM C17H21Cl4N5O2S
DMCQHG4 IC InChI=1S/C17H19Cl2N5O2S.2ClH/c1-24(2)4-3-22-15(25)10-5-9(12-8-13(18)27-14(12)19)6-11(7-10)16(26)23-17(20)21;;/h5-8H,3-4H2,1-2H3,(H,22,25)(H4,20,21,23,26);2*1H
DMCQHG4 CS CN(C)CCNC(=O)C1=CC(=CC(=C1)C2=C(SC(=C2)Cl)Cl)C(=O)N=C(N)N.Cl.Cl
DMCQHG4 IK NPUVTFLPUFCAOB-UHFFFAOYSA-N
DMCQHG4 IU 3-N-(diaminomethylidene)-5-(2,5-dichlorothiophen-3-yl)-1-N-[2-(dimethylamino)ethyl]benzene-1,3-dicarboxamide;dihydrochloride
DMCQHG4 DE Hypertension
DMNACIV ID DMNACIV
DMNACIV DN FR-194738
DMNACIV HS Terminated
DMNACIV SN FR194738; FR-194738; CHEMBL537176; HY-100303A; CS-0006187; (e)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[2-methyl-2-(3-thienyl-methoxy)propyloxy]benzylamine hydrochloride
DMNACIV CP Fujisawa Pharmaceutical Co Ltd
DMNACIV DT Small molecular drug
DMNACIV PC 9869566
DMNACIV MW 476.1
DMNACIV FM C27H38ClNO2S
DMNACIV IC InChI=1S/C27H37NO2S.ClH/c1-7-28(16-10-8-9-15-26(2,3)4)19-23-12-11-13-25(18-23)29-22-27(5,6)30-20-24-14-17-31-21-24;/h8,10-14,17-18,21H,7,16,19-20,22H2,1-6H3;1H/b10-8+;
DMNACIV CS CCN(C/C=C/C#CC(C)(C)C)CC1=CC(=CC=C1)OCC(C)(C)OCC2=CSC=C2.Cl
DMNACIV IK XZCWZZDUAVANHV-VRTOBVRTSA-N
DMNACIV IU (E)-N-ethyl-6,6-dimethyl-N-[[3-[2-methyl-2-(thiophen-3-ylmethoxy)propoxy]phenyl]methyl]hept-2-en-4-yn-1-amine;hydrochloride
DMNACIV DE Hypercholesterolaemia
DMLG426 ID DMLG426
DMLG426 DN FR-208419
DMLG426 HS Terminated
DMLG426 SN IDDB16886
DMLG426 CP Fujisawa Pharmaceutical Co Ltd
DMLG426 DT Small molecular drug
DMLG426 PC 6918392
DMLG426 MW 474.6
DMLG426 FM C28H34N4O3
DMLG426 IC InChI=1S/C28H34N4O3/c1-4-23-22-15-9-11-19(3)25(22)32(17-24(33)20-12-6-5-7-13-20)27(34)26(30-23)31-28(35)29-21-14-8-10-18(2)16-21/h8-11,14-16,20,26H,4-7,12-13,17H2,1-3H3,(H2,29,31,35)/t26-/m0/s1
DMLG426 CS CCC1=N[C@H](C(=O)N(C2=C(C=CC=C12)C)CC(=O)C3CCCCC3)NC(=O)NC4=CC=CC(=C4)C
DMLG426 IK HEJSSPHGFQDYCH-SANMLTNESA-N
DMLG426 IU 1-[(3R)-1-(2-cyclohexyl-2-oxoethyl)-5-ethyl-9-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMLG426 DE Dyspepsia
DMT6R8I ID DMT6R8I
DMT6R8I DN FR-229934
DMT6R8I HS Terminated
DMT6R8I SN FR-2299340
DMT6R8I CP Fujisawa Pharmaceutical Co Ltd
DMT6R8I DT Small molecular drug
DMT6R8I PC 11259905
DMT6R8I MW 468.4
DMT6R8I FM C21H23Cl2N3O3S
DMT6R8I IC InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)16-7-9-19-20(12-16)26(14(2)24-19)13-15-6-8-17(22)18(23)11-15/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
DMT6R8I CS CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=CC(=C(C=C3)Cl)Cl)C
DMT6R8I IK QLXVZAXTUBLQJW-UHFFFAOYSA-N
DMT6R8I IU 3-[(3,4-dichlorophenyl)methyl]-2-methyl-N-pentylsulfonylbenzimidazole-5-carboxamide
DMT6R8I CA CAS 799841-02-4
DMT6R8I DE Erectile dysfunction
DMJS9YB ID DMJS9YB
DMJS9YB DN FR-62765
DMJS9YB HS Terminated
DMJS9YB SN FR-62765; 105346-34-7; FR 62765; ODHJHYPKZNTPCS-UHFFFAOYSA-N; AC1L2TN6; SCHEMBL5953715; Ethyl 2,5-dihydro-4-methoxy-5-oxo-3-phenyl-2-furanpropanoate; ethyl 3-(4-methoxy-5-oxo-3-phenyl-2H-furan-2-yl)propanoate; ethyl 3-(4-methoxy-5-oxo-3-phenyl-2,5-dihydro-2-furyl)propionate; 2-Furanpropanoic acid, 2,5-dihydro-4-methoxy-5-oxo-3-phenyl-, ethyl ester
DMJS9YB CP Fujisawa Pharmaceutical Co Ltd
DMJS9YB DT Small molecular drug
DMJS9YB PC 128354
DMJS9YB MW 290.31
DMJS9YB FM C16H18O5
DMJS9YB IC InChI=1S/C16H18O5/c1-3-20-13(17)10-9-12-14(11-7-5-4-6-8-11)15(19-2)16(18)21-12/h4-8,12H,3,9-10H2,1-2H3
DMJS9YB CS CCOC(=O)CCC1C(=C(C(=O)O1)OC)C2=CC=CC=C2
DMJS9YB IK ODHJHYPKZNTPCS-UHFFFAOYSA-N
DMJS9YB IU ethyl 3-(4-methoxy-5-oxo-3-phenyl-2H-furan-2-yl)propanoate
DMJS9YB CA CAS 105346-34-7
DMJS9YB DE Diabetic complication
DM7WGXS ID DM7WGXS
DM7WGXS DN FR-76830
DM7WGXS HS Terminated
DM7WGXS SN 113243-75-7; FR 76830; 3-Pyridinecarboxamide,2-methyl-N-[2-(4-morpholinyl)ethyl]-4-(3-nitrophenyl)-6-phenyl-; FR-76830; HNBRMVZTOLAZRW-UHFFFAOYSA-N; ACMC-20mhoq; AC1MIZ8R; SCHEMBL9601411; fr76830; CTK4A8167; DTXSID70150329; 2-Methyl-N-(2-(4-morpholinyl)ethyl)-4-(3-nitrophenyl)-6-phenylnicotinamide; AKOS030543198; 2-Methyl-N-(4-morpholinylethyl)-4-(3-nitrophenyl)-6-phenyl-3-pyridinecarboxamide; 3-(2-morpholinoethylcarbamoyl)-2-methyl-4-(3-nitrophenyl)-6-phenylpyridine
DM7WGXS CP Fujisawa Pharmaceutical Co Ltd
DM7WGXS DT Small molecular drug
DM7WGXS PC 3082657
DM7WGXS MW 446.5
DM7WGXS FM C25H26N4O4
DM7WGXS IC InChI=1S/C25H26N4O4/c1-18-24(25(30)26-10-11-28-12-14-33-15-13-28)22(20-8-5-9-21(16-20)29(31)32)17-23(27-18)19-6-3-2-4-7-19/h2-9,16-17H,10-15H2,1H3,(H,26,30)
DM7WGXS CS CC1=C(C(=CC(=N1)C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)NCCN4CCOCC4
DM7WGXS IK HNBRMVZTOLAZRW-UHFFFAOYSA-N
DM7WGXS IU 2-methyl-N-(2-morpholin-4-ylethyl)-4-(3-nitrophenyl)-6-phenylpyridine-3-carboxamide
DM7WGXS CA CAS 113243-75-7
DM7WGXS DE Angina pectoris
DM6PFVD ID DM6PFVD
DM6PFVD DN FR-901277
DM6PFVD HS Terminated
DM6PFVD SN CHEMBL437538; FR-901277; BDBM50080264
DM6PFVD DT Small molecular drug
DM6PFVD PC 44316902
DM6PFVD MW 962.1
DM6PFVD FM C47H63N9O13
DM6PFVD IC InChI=1S/C47H63N9O13/c1-8-28-40(61)51-30-16-17-36(59)56(44(30)65)33(19-26-13-10-9-11-14-26)45(66)55(7)32-20-27-21-34(57)35(58)22-31(27)52-47(68)48-18-12-15-29(50-39(60)24(4)5)41(62)54-38(43(64)49-28)25(6)69-46(67)37(23(2)3)53-42(32)63/h8-11,13-14,21-25,29-30,32-33,36-38,57-59H,12,15-20H2,1-7H3,(H,49,64)(H,50,60)(H,51,61)(H,53,63)(H,54,62)(H2,48,52,68)/b28-8-/t25-,29-,30-,32-,33-,36+,37-,38-/m0/s1
DM6PFVD CS C/C=C\\1/C(=O)N[C@H]2CC[C@H](N(C2=O)[C@H](C(=O)N([C@H]3CC4=CC(=C(C=C4NC(=O)NCCC[C@@H](C(=O)N[C@@H]([C@@H](OC(=O)[C@@H](NC3=O)C(C)C)C)C(=O)N1)NC(=O)C(C)C)O)O)C)CC5=CC=CC=C5)O
DM6PFVD IK MHMMGTGXNPFNAJ-MVPXUFHVSA-N
DM6PFVD IU N-[(1S,15S,18S,21Z,24S,27R,29S,34S,37S)-29-benzyl-21-ethylidene-5,6,27-trihydroxy-31,37-dimethyl-10,16,19,22,30,32,35,38-octaoxo-34-propan-2-yl-36-oxa-9,11,17,20,23,28,31,33-octazatetracyclo[16.13.6.124,28.03,8]octatriaconta-3,5,7-trien-15-yl]-2-methylpropanamide
DM2FNPO ID DM2FNPO
DM2FNPO DN FR-901451
DM2FNPO HS Terminated
DM2FNPO SN FR-901451; CHEMBL403896; fr901451
DM2FNPO PC 44445940
DM2FNPO MW 1284.4
DM2FNPO FM C61H81N13O18
DM2FNPO IC InChI=1S/C61H81N13O18/c1-30(2)23-39-53(81)65-37-17-10-11-21-63-46(76)27-43(61(89)90)71-55(83)41-28-48(78)91-29-44(72-57(85)45-18-12-22-74(45)60(88)42(70-51(37)79)24-33-13-6-5-7-14-33)56(84)66-38(19-20-47(77)92-32(4)50(59(87)69-39)73-58(86)49(62)31(3)75)52(80)67-40(54(82)68-41)26-35-25-34-15-8-9-16-36(34)64-35/h5-9,13-16,25,30-32,37-45,49-50,64,75H,10-12,17-24,26-29,62H2,1-4H3,(H,63,76)(H,65,81)(H,66,84)(H,67,80)(H,68,82)(H,69,87)(H,70,79)(H,71,83)(H,72,85)(H,73,86)(H,89,90)/t31-,32+,37+,38+,39+,40+,41+,42+,43+,44+,45+,49+,50+/m1/s1
DM2FNPO CS C[C@H]1[C@@H](C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)C[C@H](NC(=O)[C@@H]3CC(=O)OC[C@@H](C(=O)N[C@@H](CCC(=O)O1)C(=O)N[C@H](C(=O)N3)CC4=CC5=CC=CC=C5N4)NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC2=O)CC7=CC=CC=C7)C(=O)O)CC(C)C)NC(=O)[C@H]([C@@H](C)O)N
DM2FNPO IK OBJRDBYSSAEARM-WSFPPIIISA-N
DM2FNPO IU (1S,4S,7S,12S,13S,16S,19S,22S,28S,31S,38S)-13-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-22-benzyl-4-(1H-indol-2-ylmethyl)-12-methyl-16-(2-methylpropyl)-3,6,10,14,17,20,23,29,34,36,40,46-dodecaoxo-11,33-dioxa-2,5,15,18,21,24,30,37,41,47-decazatetracyclo[17.16.10.27,31.024,28]heptatetracontane-38-carboxylic acid
DMN4E5H ID DMN4E5H
DMN4E5H DN Fradafiban
DMN4E5H HS Terminated
DMN4E5H SN BIBL-12; BIBU-52; BIBV-52; BIBW-103; BIBW-98
DMN4E5H CP Boehringer Ingelheim Corp
DMN4E5H DT Small molecular drug
DMN4E5H PC 66000
DMN4E5H MW 367.4
DMN4E5H FM C20H21N3O4
DMN4E5H IC InChI=1S/C20H21N3O4/c21-19(22)14-3-1-12(2-4-14)13-5-7-17(8-6-13)27-11-16-9-15(10-18(24)25)20(26)23-16/h1-8,15-16H,9-11H2,(H3,21,22)(H,23,26)(H,24,25)/t15-,16-/m0/s1
DMN4E5H CS C1[C@H](C(=O)N[C@@H]1COC2=CC=C(C=C2)C3=CC=C(C=C3)C(=N)N)CC(=O)O
DMN4E5H IK IKZACQMAVUIGPY-HOTGVXAUSA-N
DMN4E5H IU 2-[(3S,5S)-5-[[4-(4-carbamimidoylphenyl)phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetic acid
DMN4E5H CA CAS 148396-36-5
DMN4E5H CB CHEBI:73266
DMN4E5H DE Thrombosis
DMC5O3X ID DMC5O3X
DMC5O3X DN FRG-8701
DMC5O3X HS Terminated
DMC5O3X SN FRG8701; 108498-50-6; Acetamide,2-[(2-furanylmethyl)sulfinyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-; Frg 8701; Frg-8701; ACMC-20mbjv; AC1L2WUW; SCHEMBL5083014; CTK4A6065; IWLUMUDDKHJJPB-UHFFFAOYSA-N; HY-U00238; AKOS030565773; N-(3-(3-(Piperidinylmethyl)phenoxy)propyl)-2-(furfurylsulfinyl)acetamide; CS-7405; L002080; N-{3-[3-(piperidinomethyl)phenoxy] propyl]-2-(furfurylsulfinyl) acetamide; Acetamide, 2-((2-furanylmethyl)sulfinyl)-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-
DMC5O3X CP Fujirebio KK
DMC5O3X DT Small molecular drug
DMC5O3X PC 130145
DMC5O3X MW 418.6
DMC5O3X FM C22H30N2O4S
DMC5O3X IC InChI=1S/C22H30N2O4S/c25-22(18-29(26)17-21-9-5-13-28-21)23-10-6-14-27-20-8-4-7-19(15-20)16-24-11-2-1-3-12-24/h4-5,7-9,13,15H,1-3,6,10-12,14,16-18H2,(H,23,25)
DMC5O3X CS C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC(=O)CS(=O)CC3=CC=CO3
DMC5O3X IK IWLUMUDDKHJJPB-UHFFFAOYSA-N
DMC5O3X IU 2-(furan-2-ylmethylsulfinyl)-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide
DMC5O3X CA CAS 108498-50-6
DMC5O3X DE Stomach ulcer
DMI1Y92 ID DMI1Y92
DMI1Y92 DN FUSIDIENOL
DMI1Y92 HS Terminated
DMI1Y92 SN Fusidienol; CHEMBL35732; 157173-61-0; AC1NUTDT; SCHEMBL9139208; DTXSID10166222; BDBM50059880; methyl 7-hydroxy-3-(hydroxymethyl)-6-oxooxepino[2,3-b]chromene-5-carboxylate; 1-Hydroxy-8-hydroxymethyl-11-oxo-11H-5,6-dioxa-cyclohepta[b]naphthalene-10-carboxylic acid methyl ester; 1-Hydroxy-8-hydroxymethyl-11-oxo-11H-5,6-dioxa-cyclohepta[b]naphthalene-10-carboxylic acid methyl ester(fusidienol)
DMI1Y92 DT Small molecular drug
DMI1Y92 PC 5492684
DMI1Y92 MW 316.26
DMI1Y92 FM C16H12O7
DMI1Y92 IC InChI=1S/C16H12O7/c1-21-15(20)9-5-8(6-17)7-22-16-12(9)14(19)13-10(18)3-2-4-11(13)23-16/h2-5,7,17-18H,6H2,1H3
DMI1Y92 CS COC(=O)C1=CC(=COC2=C1C(=O)C3=C(C=CC=C3O2)O)CO
DMI1Y92 IK LJNGMSGIOXTZLN-UHFFFAOYSA-N
DMI1Y92 IU methyl 7-hydroxy-3-(hydroxymethyl)-6-oxooxepino[2,3-b]chromene-5-carboxylate
DMI1Y92 CA CAS 157173-61-0
DMZXA0W ID DMZXA0W
DMZXA0W DN Garenoxacin
DMZXA0W HS Terminated
DMZXA0W SN T 3811; T-3811; T-3811MEa; BMS 284756 (*Mesylate salt*); BMS-284756 (*Mesylate salt*);1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-(1-methyl-2,3-dihydro-1H-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid
DMZXA0W CP Toyama Chemical
DMZXA0W DT Small molecular drug
DMZXA0W PC 124093
DMZXA0W MW 426.4
DMZXA0W FM C23H20F2N2O4
DMZXA0W IC InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
DMZXA0W CS C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F
DMZXA0W IK NJDRXTDGYFKORP-LLVKDONJSA-N
DMZXA0W IU 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid
DMZXA0W CA CAS 194804-75-6
DMZXA0W CB CHEBI:131716
DMZXA0W DE Endocarditis
DMOAURL ID DMOAURL
DMOAURL DN GDC-0834
DMOAURL HS Terminated
DMOAURL SN GDC-0834; 1133432-49-1; UNII-FM7JG3L4SR; FM7JG3L4SR; CHEMBL2057915; N-{3-[6-({4-[(2r)-1,4-Dimethyl-3-Oxopiperazin-2-Yl]phenyl}amino)-4-Methyl-5-Oxo-4,5-Dihydropyrazin-2-Yl]-2-Methylphenyl}-4,5,6,7-Tetrahydro-1-Benzothiophene-2-Carboxamide; GDC0834; CDOOFZZILLRUQH-GDLZYMKVSA-N; 2VL; GTPL9263; SCHEMBL1205333; GDC 0834; GDC 0834;GDC0834; ZINC59185874; BDBM50388183; AKOS030526267; SB18925; CS-3123; Benzo(b)thiophene-2-carboxamide, N-(3-(6-((4-((2R)-1,4-dimethyl-3-oxo-2-piperazinyl)phenyl)amino)-4,5-dihydro-4-methyl-5-oxo-2-pyraz
DMOAURL CP CGI Pharmaceuticals Inc
DMOAURL DT Small molecular drug
DMOAURL PC 25234918
DMOAURL MW 596.7
DMOAURL FM C33H36N6O3S
DMOAURL IC InChI=1S/C33H36N6O3S/c1-20-24(9-7-10-25(20)36-31(40)28-18-22-8-5-6-11-27(22)43-28)26-19-39(4)33(42)30(35-26)34-23-14-12-21(13-15-23)29-32(41)38(3)17-16-37(29)2/h7,9-10,12-15,18-19,29H,5-6,8,11,16-17H2,1-4H3,(H,34,35)(H,36,40)/t29-/m1/s1
DMOAURL CS CC1=C(C=CC=C1NC(=O)C2=CC3=C(S2)CCCC3)C4=CN(C(=O)C(=N4)NC5=CC=C(C=C5)[C@@H]6C(=O)N(CCN6C)C)C
DMOAURL IK CDOOFZZILLRUQH-GDLZYMKVSA-N
DMOAURL IU N-[3-[6-[4-[(2R)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide
DMOAURL CA CAS 1133432-49-1
DMOAURL DE Rheumatoid arthritis
DMGM3VP ID DMGM3VP
DMGM3VP DN GE-20372A
DMGM3VP HS Terminated
DMGM3VP SN GE-20372B; HIV protease inhibitors (II), HMR
DMGM3VP CP Biosearch Italia SpA
DMGM3VP PC 124019
DMGM3VP MW 611.7
DMGM3VP FM C30H41N7O7
DMGM3VP IC InChI=1S/C30H41N7O7/c1-18(2)25(27(41)34-21(17-38)15-19-7-4-3-5-8-19)37-26(40)23(9-6-14-33-29(31)32)35-30(44)36-24(28(42)43)16-20-10-12-22(39)13-11-20/h3-5,7-8,10-13,17-18,21,23-25,39H,6,9,14-16H2,1-2H3,(H,34,41)(H,37,40)(H,42,43)(H4,31,32,33)(H2,35,36,44)/t21-,23-,24-,25-/m0/s1
DMGM3VP CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O
DMGM3VP IK DYNPEHYVIZVLIF-LFBFJMOVSA-N
DMGM3VP IU (2S)-2-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]amino]-1-oxopentan-2-yl]carbamoylamino]-3-(4-hydroxyphenyl)propanoic acid
DMGM3VP CA CAS 163565-75-1
DMGM3VP DE Human immunodeficiency virus infection
DMZF9CY ID DMZF9CY
DMZF9CY DN GE-68
DMZF9CY HS Terminated
DMZF9CY SN GE-68; GE 68; 158358-22-6; CHEMBL93812; AC1L322R; SCHEMBL9738669; (+-)-3-(2-Phenylethyl)-alpha-((propylamino)methyl)-2-benzofuranmethanol; 1-(3-phenethyl-1-benzofuran-2-yl)-2-(propylamino)ethanol; 2-(Propylamino)-1-[3-(2-phenylethyl)benzofuran-2-yl]ethanol; 2-Benzofuranmethanol, 3-(2-phenylethyl)-alpha-((propylamino)methyl)-, (+-)-
DMZF9CY CP University of Vienna
DMZF9CY DT Small molecular drug
DMZF9CY PC 133044
DMZF9CY MW 323.4
DMZF9CY FM C21H25NO2
DMZF9CY IC InChI=1S/C21H25NO2/c1-2-14-22-15-19(23)21-18(13-12-16-8-4-3-5-9-16)17-10-6-7-11-20(17)24-21/h3-11,19,22-23H,2,12-15H2,1H3
DMZF9CY CS CCCNCC(C1=C(C2=CC=CC=C2O1)CCC3=CC=CC=C3)O
DMZF9CY IK XPEXCFSBFPOSQR-UHFFFAOYSA-N
DMZF9CY IU 1-[3-(2-phenylethyl)-1-benzofuran-2-yl]-2-(propylamino)ethanol
DMZF9CY CA CAS 158358-22-6
DMZF9CY DE Heart arrhythmia
DMVAM18 ID DMVAM18
DMVAM18 DN Gene therapy, IFN-alpha
DMVAM18 HS Terminated
DMVAM18 SN Gene therapy (IFN-alpha, PINC); Gene therapy (interferon alpha, PINC), Valentis/ Roche; Gene therapy (IFN-alpha, PINC), Valentis/ Roche
DMVAM18 CP Valentis Inc
DMVAM18 DE Head and neck cancer
DM6JNV3 ID DM6JNV3
DM6JNV3 DN Genevx
DM6JNV3 HS Terminated
DM6JNV3 SN Ad5-VEGF145; Restenosis therapy, Collateral; VEGF gene therapy, Collateral
DM6JNV3 CP Collateral Therapeutics Inc
DM6JNV3 DE Angina pectoris
DMGX5Q0 ID DMGX5Q0
DMGX5Q0 DN Gepirone
DMGX5Q0 HS Terminated
DMGX5Q0 SN 83928-76-1; 4,4-Dimethyl-1-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)piperidine-2,6-dione; Gepironum [Latin]; Gepirone [INN]; Gepirona [Spanish]; UNII-JW5Y7B8Z18; BMY-13805; JW5Y7B8Z18; CHEMBL284092; Gepironum; AK115965; Gepirona; Travivo; 2,6-Piperidinedione, 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-; BMY 13805; gepiron ER; MJ 13805-1; ORG-13011(Gepirone); AC1L1IK6; AC1Q6F8Q; 4,4-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-2,6-piperidinedione; 3,3-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]glutarimide; 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMGX5Q0 CP Fabre-Kramer; GSK
DMGX5Q0 DT Small molecular drug
DMGX5Q0 PC 55191
DMGX5Q0 MW 359.5
DMGX5Q0 FM C19H29N5O2
DMGX5Q0 IC InChI=1S/C19H29N5O2/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18/h5-7H,3-4,8-15H2,1-2H3
DMGX5Q0 CS CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C
DMGX5Q0 IK QOIGKGMMAGJZNZ-UHFFFAOYSA-N
DMGX5Q0 IU 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
DMGX5Q0 CA CAS 83928-76-1
DMGX5Q0 CB CHEBI:135990
DMGX5Q0 DE Depression
DM1CG0J ID DM1CG0J
DM1CG0J DN GGTI-298
DM1CG0J HS Terminated
DM1CG0J SN GGTI298; GGTI-298; Ggti 298; 180977-44-0; CHEMBL282748; N-4-[2(R)-Amino-3-mercaptopropyl]amino-2-naphthylbenzoyl-(L)-Leucine methyl ester, TFA; (S)-methyl 2-(4-((R)-2-amino-3-mercaptopropylamino)-2-(naphthalen-1-yl)benzamido)-4-methylpentanoate; SCHEMBL4283635; CHEBI:124997; EX-A2390; ZINC1488051; BCP24854; BDBM50076138; AKOS032945065; CS-6098; NCGC00165800-01; HY-100876; BRD-K19669037-019-01-3; 2-[4-((R)-2-Amino-3-mercapto-propylamino)-2-naphthalen-1-yl-benzoylamino]-4-methyl-pentanoic acid (S)-methyl ester
DM1CG0J DT Small molecular drug
DM1CG0J PC 9811606
DM1CG0J MW 479.6
DM1CG0J FM C27H33N3O3S
DM1CG0J IC InChI=1S/C27H33N3O3S/c1-17(2)13-25(27(32)33-3)30-26(31)23-12-11-20(29-15-19(28)16-34)14-24(23)22-10-6-8-18-7-4-5-9-21(18)22/h4-12,14,17,19,25,29,34H,13,15-16,28H2,1-3H3,(H,30,31)/t19-,25+/m1/s1
DM1CG0J CS CC(C)C[C@@H](C(=O)OC)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC3=CC=CC=C32
DM1CG0J IK XVWPFYDMUFBHBF-CLOONOSVSA-N
DM1CG0J IU methyl (2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-naphthalen-1-ylbenzoyl]amino]-4-methylpentanoate
DM1CG0J CA CAS 180977-44-0
DM1CG0J CB CHEBI:124997
DMXVP13 ID DMXVP13
DMXVP13 DN GI-129471
DMXVP13 HS Terminated
DMXVP13 SN GI-129471; GI 129471; CHEMBL114427; 130370-59-1; AC1NX8L8; SCHEMBL6838720; DTXSID60156496; gi129471; BDBM50069608; GW9471; GW-9471; (2R-(1(S*),2R*,3S*))-N4-Hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((phenylthio)methyl)butanediamide; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((phenylthio)methyl)-, (2R-(1(S*),2R*,3S*))-
DMXVP13 CP Glaxo Inc
DMXVP13 DT Small molecular drug
DMXVP13 PC 5748217
DMXVP13 MW 471.6
DMXVP13 FM C25H33N3O4S
DMXVP13 IC InChI=1S/C25H33N3O4S/c1-17(2)14-20(21(24(30)28-32)16-33-19-12-8-5-9-13-19)23(29)27-22(25(31)26-3)15-18-10-6-4-7-11-18/h4-13,17,20-22,32H,14-16H2,1-3H3,(H,26,31)(H,27,29)(H,28,30)/t20-,21+,22+/m1/s1
DMXVP13 CS CC(C)C[C@H]([C@H](CSC1=CC=CC=C1)C(=O)NO)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NC
DMXVP13 IK UBFGIEDUTRCMEQ-FSSWDIPSSA-N
DMXVP13 IU (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(phenylsulfanylmethyl)butanediamide
DMXVP13 CA CAS 130370-59-1
DMXVP13 DE Inflammation
DM6HZU1 ID DM6HZU1
DM6HZU1 DN GI-197111
DM6HZU1 HS Terminated
DM6HZU1 CP Glaxo Wellcome plc
DM6HZU1 DE Alopecia
DMT6J1E ID DMT6J1E
DMT6J1E DN GI-248573
DMT6J1E HS Terminated
DMT6J1E CP Glaxo Wellcome plc
DMT6J1E DE Bladder disease
DM3KN2Q ID DM3KN2Q
DM3KN2Q DN GI-270384X
DM3KN2Q HS Terminated
DM3KN2Q SN 270384
DM3KN2Q CP GlaxoSmithKline Inc
DM3KN2Q DE Inflammatory bowel disease
DMX0N9P ID DMX0N9P
DMX0N9P DN Ginkgolide B (GKB)
DMX0N9P HS Terminated
DMX0N9P SN SCHEMBL464783; MolPort-003-983-580; s1343; BN0224; NCGC00386140-01; BN 52021, 15291-77-7
DMX0N9P DT Small molecular drug
DMX0N9P PC 17751009
DMX0N9P MW 424.4
DMX0N9P FM C20H24O10
DMX0N9P IC InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9-,10+,11+,15+,17?,18?,19-,20-/m1/s1
DMX0N9P CS C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@@H]2O)C6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMX0N9P IK SQOJOAFXDQDRGF-RLAVLKHASA-N
DMX0N9P IU (1R,3R,6R,8S,10R,12S,13S,16S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMX0N9P CA CAS 15291-77-7
DMLIM7B ID DMLIM7B
DMLIM7B DN GINKOLIDE B
DMLIM7B HS Terminated
DMLIM7B SN Ginkolide B; Gingko lactone; C20H24O10; Ginkgolide B from Ginkgo biloba leaves; AK160212; Ginkgolide A, 1-hydroxy-, (1beta)-; BN 52051; SR-01000597598; lide B; 99796-69-7; AC1Q6PCU; CHEMBL266625; AC1L22W1; SCHEMBL14279903; KS-00000IWU; CTK8F0398; 1-Hydroxy-(1beta)-Ginkgolide A; MolPort-003-847-584; 9H-1,7a-(Epoxymethano)-1H,6aH-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4H)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b,11
DMLIM7B DT Small molecular drug
DMLIM7B PC 65243
DMLIM7B MW 424.4
DMLIM7B FM C20H24O10
DMLIM7B IC InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3
DMLIM7B CS CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O
DMLIM7B IK SQOJOAFXDQDRGF-UHFFFAOYSA-N
DMLIM7B IU 8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMLIM7B CA CAS 15291-77-7
DMLIM7B DE Sepsis
DMSVMF2 ID DMSVMF2
DMSVMF2 DN Girisopam
DMSVMF2 HS Terminated
DMSVMF2 SN EGIS-5810; GYKI-51189
DMSVMF2 CP EGIS Gyogyszergyar RT
DMSVMF2 DT Small molecular drug
DMSVMF2 PC 71257
DMSVMF2 MW 328.8
DMSVMF2 FM C18H17ClN2O2
DMSVMF2 IC InChI=1S/C18H17ClN2O2/c1-11-7-13-9-16(22-2)17(23-3)10-15(13)18(21-20-11)12-5-4-6-14(19)8-12/h4-6,8-10H,7H2,1-3H3
DMSVMF2 CS CC1=NN=C(C2=CC(=C(C=C2C1)OC)OC)C3=CC(=CC=C3)Cl
DMSVMF2 IK VQYLGVVODFDFNK-UHFFFAOYSA-N
DMSVMF2 IU 1-(3-chlorophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
DMSVMF2 CA CAS 82230-53-3
DMSVMF2 DE Anxiety disorder
DM4RKDU ID DM4RKDU
DM4RKDU DN GK-128
DM4RKDU HS Terminated
DM4RKDU CP Taisho Pharmaceutical Co Ltd
DM4RKDU PC 178063
DM4RKDU MW 342.8
DM4RKDU FM C18H15ClN2OS
DM4RKDU IC InChI=1S/C18H14N2OS.ClH/c1-12-19-8-9-20(12)10-14-11-22-16-7-6-13-4-2-3-5-15(13)17(16)18(14)21;/h2-9,11H,10H2,1H3;1H
DM4RKDU CS CC1=NC=CN1CC2=CSC3=C(C2=O)C4=CC=CC=C4C=C3.Cl
DM4RKDU IK DBXKJORICFHAQA-UHFFFAOYSA-N
DM4RKDU IU 2-[(2-methylimidazol-1-yl)methyl]benzo[f]thiochromen-1-one;hydrochloride
DM4RKDU CA CAS 162413-52-7
DM4RKDU DE Vomiting
DMONQYZ ID DMONQYZ
DMONQYZ DN Gliotoxin
DMONQYZ HS Terminated
DMONQYZ SN gliotoxin; 67-99-2; Aspergillin; UNII-5L648PH06K; CCRIS 4025; Gliotoxin from Gliocladium fimbriatum; NSC 102866; BRN 0050675; AI3-62383; CHEBI:5385; CHEMBL331627; S.N. 12870; Gliotoxin, Gladiocladium fimbriatum; 5L648PH06K; 10H-3,10a-Epidithiopyrazino(1,2-a)indole-1,4-dione, 2,3,5a,6-tetrahydro-6-hydroxy-3-(hydroxymethyl)-2-methyl-; Gliotoxins; 10H-3,10a-Epidithiopyrazino(1,2-a)indole-1,4-dione, 2,3,5a,6-hydroxy-3- (hydroxymethyl)-2-methyl-, (3R-(3-alpha,5a-beta,6-beta,10a-alpha))-
DMONQYZ DT Small molecular drug
DMONQYZ PC 6223
DMONQYZ MW 326.4
DMONQYZ FM C13H14N2O4S2
DMONQYZ IC InChI=1S/C13H14N2O4S2/c1-14-10(18)12-5-7-3-2-4-8(17)9(7)15(12)11(19)13(14,6-16)21-20-12/h2-4,8-9,16-17H,5-6H2,1H3/t8-,9-,12+,13+/m0/s1
DMONQYZ CS CN1C(=O)[C@]23CC4=CC=C[C@@H]([C@H]4N2C(=O)[C@]1(SS3)CO)O
DMONQYZ IK FIVPIPIDMRVLAY-RBJBARPLSA-N
DMONQYZ IU (1R,7S,8S,11R)-7-hydroxy-11-(hydroxymethyl)-15-methyl-12,13-dithia-9,15-diazatetracyclo[9.2.2.01,9.03,8]pentadeca-3,5-diene-10,14-dione
DMONQYZ CA CAS 67-99-2
DMONQYZ CB CHEBI:5385
DM0IKB4 ID DM0IKB4
DM0IKB4 DN GLY-515n
DM0IKB4 HS Terminated
DM0IKB4 CP GlycoForm Ltd
DM0IKB4 DE Cerebrovascular ischaemia
DMEVIP9 ID DMEVIP9
DMEVIP9 DN GM-7050
DMEVIP9 HS Terminated
DMEVIP9 CP Glycomed Inc
DMEVIP9 DE Inflammation
DMT1RH6 ID DMT1RH6
DMT1RH6 DN GMC-283
DMT1RH6 HS Terminated
DMT1RH6 SN CHEMBL430798; MolPort-042-665-651; GMC-2-83; ZINC14299682; BDBM50078062; Trifluoro-methanesulfonic acid 11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepin-2-yl ester
DMT1RH6 CP Merck KGaA
DMT1RH6 DT Small molecular drug
DMT1RH6 PC 10026300
DMT1RH6 MW 441.4
DMT1RH6 FM C19H18F3N3O4S
DMT1RH6 IC InChI=1S/C19H18F3N3O4S/c1-24-8-10-25(11-9-24)18-14-12-13(29-30(26,27)19(20,21)22)6-7-16(14)28-17-5-3-2-4-15(17)23-18/h2-7,12H,8-11H2,1H3
DMT1RH6 CS CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)OS(=O)(=O)C(F)(F)F
DMT1RH6 IK DQNCRNVCBHYBQP-UHFFFAOYSA-N
DMT1RH6 IU [6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepin-8-yl] trifluoromethanesulfonate
DMT1RH6 DE Schizophrenia
DMHXRN8 ID DMHXRN8
DMHXRN8 DN GNI-104
DMHXRN8 HS Terminated
DMHXRN8 SN Ed-004; Neutralizing monoclonal antibodies (HCV), Innogenetics
DMHXRN8 CP GENimmune NV
DMHXRN8 DT Antibody
DMHXRN8 DE Hepatitis C virus infection
DMPODL9 ID DMPODL9
DMPODL9 DN GP-683
DMPODL9 HS Terminated
DMPODL9 SN Analgesic-sparing agent, Univ Texas
DMPODL9 CP Metabasis Therapeutics Inc
DMPODL9 DT Small molecular drug
DMPODL9 PC 5311109
DMPODL9 MW 402.4
DMPODL9 FM C23H22N4O3
DMPODL9 IC InChI=1S/C23H22N4O3/c1-14-19(28)20(29)23(30-14)27-12-17(15-8-4-2-5-9-15)18-21(24-13-25-22(18)27)26-16-10-6-3-7-11-16/h2-14,19-20,23,28-29H,1H3,(H,24,25,26)/t14-,19-,20-,23-/m1/s1
DMPODL9 CS C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C3=C(N=CN=C32)NC4=CC=CC=C4)C5=CC=CC=C5)O)O
DMPODL9 IK YPWISWJHVQIXIL-DVHMWJAFSA-N
DMPODL9 IU (2R,3R,4S,5R)-2-(4-anilino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)-5-methyloxolane-3,4-diol
DMPODL9 DE Pain
DMD5WK4 ID DMD5WK4
DMD5WK4 DN Gpi-1046
DMD5WK4 HS Terminated
DMD5WK4 SN 186452-09-5; gpi-1046; (S)-3-(Pyridin-3-yl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate; CHEMBL6367; L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester; (2S)-[3-PYRIDYL-1-PROPYL]-1-[3,3-DIMETHYL-1,2-DIOXOPENTYL]-2-PYRROLIDINECARBOXYLATE; 3-pyridin-3-ylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate; 3-(pyridin-3-yl)propyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate; GPI; AC1L9I3R; SCHEMBL4766380; BDBM23334; CTK0I3903; DTXSID00332191
DMD5WK4 DT Small molecular drug
DMD5WK4 PC 445501
DMD5WK4 MW 360.4
DMD5WK4 FM C20H28N2O4
DMD5WK4 IC InChI=1S/C20H28N2O4/c1-4-20(2,3)17(23)18(24)22-12-6-10-16(22)19(25)26-13-7-9-15-8-5-11-21-14-15/h5,8,11,14,16H,4,6-7,9-10,12-13H2,1-3H3/t16-/m0/s1
DMD5WK4 CS CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCC2=CN=CC=C2
DMD5WK4 IK OQAHHWOPVDDWHD-INIZCTEOSA-N
DMD5WK4 IU 3-pyridin-3-ylpropyl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate
DMD5WK4 CA CAS 186452-09-5
DMD5WK4 DE Parkinson disease
DMBMAPH ID DMBMAPH
DMBMAPH DN GPI-3000
DMBMAPH HS Terminated
DMBMAPH SN NPC-17742
DMBMAPH CP Scios Inc
DMBMAPH DT Small molecular drug
DMBMAPH PC 108099
DMBMAPH MW 279.27
DMBMAPH FM C11H22NO5P
DMBMAPH IC InChI=1S/C11H22NO5P/c12-10(11(13)14)7-9-4-2-1-3-8(9)5-6-18(15,16)17/h8-10H,1-7,12H2,(H,13,14)(H2,15,16,17)
DMBMAPH CS C1CCC(C(C1)CCP(=O)(O)O)CC(C(=O)O)N
DMBMAPH IK DHJQWBSZKBDBFP-UHFFFAOYSA-N
DMBMAPH IU 2-amino-3-[2-(2-phosphonoethyl)cyclohexyl]propanoic acid
DMBMAPH CA CAS 117571-54-7
DMBMAPH DE Cerebrovascular ischaemia
DM01HLX ID DM01HLX
DM01HLX DN GR-127935
DM01HLX HS Terminated
DM01HLX SN 148672-13-3; GR 127935; GR-127935; N-(4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-carboxamide; GR127935; UNII-2LLH6CEB40; 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide; 2LLH6CEB40; CHEMBL15928; GR 127935 hydrochloride hydrate; N-[4-METHOXY-3-(4-METHYLPIPERAZIN-1-YL)-PHENYL]-4-[2-METHYL-4-(5-METHYL-1,2,4-OXADIAZOL-3-YL)PHENYL]BENZAMIDE; CHEBI:64114; GR 127935 HCl; C29H31N5O3
DM01HLX DT Small molecular drug
DM01HLX PC 107780
DM01HLX MW 497.6
DM01HLX FM C29H31N5O3
DM01HLX IC InChI=1S/C29H31N5O3/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34/h5-12,17-18H,13-16H2,1-4H3,(H,31,35)
DM01HLX CS CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C
DM01HLX IK YDBCEBYHYKAFRX-UHFFFAOYSA-N
DM01HLX IU N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]benzamide
DM01HLX CA CAS 148672-13-3
DM01HLX CB CHEBI:64114
DM01HLX DE Major depressive disorder
DMKAGLV ID DMKAGLV
DMKAGLV DN GR-131663
DMKAGLV HS Terminated
DMKAGLV SN AH-002; AH-017; GR-131665
DMKAGLV CP Glaxo Group Research Ltd
DMKAGLV DE Anxiety disorder
DMNRJA0 ID DMNRJA0
DMNRJA0 DN GR-133347
DMNRJA0 HS Terminated
DMNRJA0 SN AH-023
DMNRJA0 CP Glaxo Group Research Ltd
DMNRJA0 DE Anxiety disorder
DMN8TH1 ID DMN8TH1
DMN8TH1 DN GR-144053
DMN8TH1 HS Terminated
DMN8TH1 SN GR-144053; CHEMBL36326; GR-144053F; GR144053; 2-[4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl]acetic acid; {4-[4-(4-Carbamimidoyl-phenyl)-piperazin-1-yl]-piperidin-1-yl}-acetic acid; GR 144053; AC1L5AAD; GTPL6587; ZINC5719; SCHEMBL6839445; CHEBI:92207; BDBM50037970; BRD-K12120659-305-01-4; {4-[4-(4-Carbamimidoyl-phenyl)-piperazin-1-yl]-piperidin-1-yl}-acetic acid (GR 144053)
DMN8TH1 CP Glaxo Wellcome plc
DMN8TH1 DT Small molecular drug
DMN8TH1 PC 173614
DMN8TH1 MW 345.4
DMN8TH1 FM C18H27N5O2
DMN8TH1 IC InChI=1S/C18H27N5O2/c19-18(20)14-1-3-15(4-2-14)22-9-11-23(12-10-22)16-5-7-21(8-6-16)13-17(24)25/h1-4,16H,5-13H2,(H3,19,20)(H,24,25)
DMN8TH1 CS C1CN(CCC1N2CCN(CC2)C3=CC=C(C=C3)C(=N)N)CC(=O)O
DMN8TH1 IK QGEGSJUSWLLZLH-UHFFFAOYSA-N
DMN8TH1 IU 2-[4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl]acetic acid
DMN8TH1 CB CHEBI:92207
DMN8TH1 DE Thrombosis
DMLQ71Y ID DMLQ71Y
DMLQ71Y DN GR-159897
DMLQ71Y HS Terminated
DMLQ71Y SN CHEMBL2110370; GR 159897; 158848-32-9; 5-FLUORO-3-[2-[4-METHOXY-4-[[(R)-PHENYLSULPHINYL]METHYL]-1-PIPERIDINYL]ETHYL]-1H-INDOLE; GR-159897; GR-159,897; GTPL2115; CHEBI:92912; MolPort-023-276-059; ZINC7999073; BDBM50212987; AKOS025147300; AKOS024456505; NCGC00381706-02; KB-309739; SR-01000597395; SR-01000597395-1; 5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulfinyl]methyl]piperidin-1-yl]ethyl]-1H-indole; 5-Fluoro-3-[2-[4-methoxy-4-[[ -phenylsulphinyl]methyl]-1-piperidinyl]ethyl]-1H-indole
DMLQ71Y CP Glaxo Group Research Ltd
DMLQ71Y DT Small molecular drug
DMLQ71Y PC 9953599
DMLQ71Y MW 414.5
DMLQ71Y FM C23H27FN2O2S
DMLQ71Y IC InChI=1S/C23H27FN2O2S/c1-28-23(17-29(27)20-5-3-2-4-6-20)10-13-26(14-11-23)12-9-18-16-25-22-8-7-19(24)15-21(18)22/h2-8,15-16,25H,9-14,17H2,1H3/t29-/m1/s1
DMLQ71Y CS COC1(CCN(CC1)CCC2=CNC3=C2C=C(C=C3)F)C[S@@](=O)C4=CC=CC=C4
DMLQ71Y IK BANYJBHWTOJQDU-GDLZYMKVSA-N
DMLQ71Y IU 5-fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulfinyl]methyl]piperidin-1-yl]ethyl]-1H-indole
DMLQ71Y CA CAS 158848-32-9
DMLQ71Y CB CHEBI:92912
DMLQ71Y DE Anxiety disorder
DMOY8UA ID DMOY8UA
DMOY8UA DN GR-175737
DMOY8UA HS Terminated
DMOY8UA SN GR-175737; CHEMBL276798; GR 175737; SCHEMBL195040; GTPL1243; BDBM50070213; 3-[(4-chlorophenyl)methyl]-5-[2-(3H-imidazol-4-yl)ethyl]-1,2,4-oxadiazole; GR175737; L015003; 3-(4-Chloro-benzyl)-5-[2-(1H-imidazol-4-yl)-ethyl]-[1,2,4]oxadiazole; 1,2,4-Oxadiazole, 3-((4-chlorophenyl)methyl)-5-(2-(1H-imidazol-4-yl)ethyl)-; 203874-78-6
DMOY8UA DT Small molecular drug
DMOY8UA PC 9838905
DMOY8UA MW 288.73
DMOY8UA FM C14H13ClN4O
DMOY8UA IC InChI=1S/C14H13ClN4O/c15-11-3-1-10(2-4-11)7-13-18-14(20-19-13)6-5-12-8-16-9-17-12/h1-4,8-9H,5-7H2,(H,16,17)
DMOY8UA CS C1=CC(=CC=C1CC2=NOC(=N2)CCC3=CN=CN3)Cl
DMOY8UA IK CPOUJACQGWJJQB-UHFFFAOYSA-N
DMOY8UA IU 3-[(4-chlorophenyl)methyl]-5-[2-(1H-imidazol-5-yl)ethyl]-1,2,4-oxadiazole
DMOY8UA CA CAS 176860-26-7
DMA7FX1 ID DMA7FX1
DMA7FX1 DN GR-199114X
DMA7FX1 HS Terminated
DMA7FX1 SN GR-199114X; CHEMBL320141; SCHEMBL14520869
DMA7FX1 CP Glaxo Wellcome plc
DMA7FX1 DT Small molecular drug
DMA7FX1 PC 9914672
DMA7FX1 MW 521.6
DMA7FX1 FM C28H32FN5O4
DMA7FX1 IC InChI=1S/C28H32FN5O4/c29-19-12-14-20(15-13-19)30-28(38)31-25-26(36)33(18-24(35)32-16-6-7-17-32)22-10-4-5-11-23(22)34(27(25)37)21-8-2-1-3-9-21/h4-5,10-15,21,25H,1-3,6-9,16-18H2,(H2,30,31,38)/t25-/m0/s1
DMA7FX1 CS C1CCC(CC1)N2C3=CC=CC=C3N(C(=O)[C@@H](C2=O)NC(=O)NC4=CC=C(C=C4)F)CC(=O)N5CCCC5
DMA7FX1 IK URMOKEJAUAGZGV-VWLOTQADSA-N
DMA7FX1 IU 1-[(3S)-5-cyclohexyl-2,4-dioxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)-1,5-benzodiazepin-3-yl]-3-(4-fluorophenyl)urea
DMA7FX1 DE Stomach ulcer
DMIJCH1 ID DMIJCH1
DMIJCH1 DN GR-218231
DMIJCH1 HS Terminated
DMIJCH1 SN GR 218231; GR218231; CHEMBL131556; 175442-95-2; (+)-(2R)-1,2,3,4-Tetrahydro-6-[[(4-methoxyphenyl)sulfonyl]methyl]-N,N-dipropyl-2-naphthalenamine; (2R)-6-[(4-methoxyphenyl)sulfonylmethyl]-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine; AC1NSM1X; GR 218,231; GTPL70; SCHEMBL626977; DTXSID70415546; ZINC3824084; PDSP2_001398; PDSP1_001414; BDBM50214486; (3R)-N,N-Dipropyl-7-(4-methoxyphenylsulfonylmethyl)tetralin-3beta-amine
DMIJCH1 DT Small molecular drug
DMIJCH1 PC 24840389
DMIJCH1 MW 415.6
DMIJCH1 FM C24H33NO3S
DMIJCH1 IC InChI=1S/C24H33NO3S/c1-4-14-25(15-5-2)22-9-8-20-16-19(6-7-21(20)17-22)18-29(26,27)24-12-10-23(28-3)11-13-24/h6-7,10-13,16,22H,4-5,8-9,14-15,17-18H2,1-3H3
DMIJCH1 CS CCCN(CCC)C1CCC2=C(C1)C=CC(=C2)CS(=O)(=O)C3=CC=C(C=C3)OC
DMIJCH1 IK HUXFXXWYIRBVJR-UHFFFAOYSA-N
DMIJCH1 IU 6-[(4-methoxyphenyl)sulfonylmethyl]-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMHM0EU ID DMHM0EU
DMHM0EU DN GR-233548
DMHM0EU HS Terminated
DMHM0EU SN Fibrinogen antagonist, Glaxo Wellcome
DMHM0EU CP Glaxo Wellcome plc
DMHM0EU DE Thrombosis
DMRPE3D ID DMRPE3D
DMRPE3D DN GR-65630
DMRPE3D HS Terminated
DMRPE3D SN GR-65630A
DMRPE3D CP Glaxo Group Research Ltd
DMRPE3D DT Small molecular drug
DMRPE3D PC 124006
DMRPE3D MW 267.33
DMRPE3D FM C16H17N3O
DMRPE3D IC InChI=1S/C16H17N3O/c1-11-13(18-10-17-11)7-8-16(20)15-9-12-5-3-4-6-14(12)19(15)2/h3-6,9-10H,7-8H2,1-2H3,(H,17,18)
DMRPE3D CS CC1=C(N=CN1)CCC(=O)C2=CC3=CC=CC=C3N2C
DMRPE3D IK AQCBJPZFJDPIGL-UHFFFAOYSA-N
DMRPE3D IU 3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol-2-yl)propan-1-one
DMRPE3D CA CAS 117186-80-8
DMRPE3D DE Vomiting
DMR2TZK ID DMR2TZK
DMR2TZK DN GR-82334
DMR2TZK HS Terminated
DMR2TZK SN GR 82334; 129623-01-4; Physalaemin(1-11), D-pro(9)(spiro-gamma-lactam)leu(10)-trp(11)-; Physalemin, 9-deglycine-10-((5S)-6-oxo-L-alpha-(2-methylpropyl)-1,7-diazaspiro(4.4)nonane-7-acetic acid)-11-L-tryptophanamide-; SCHEMBL7945525; gr82334; DTXSID10156209; MFCD00214619; AKOS024456738; LS-184749; B5161; GR 82334, > pGlu-Ala-Asp-Pro-Asn-Lys-Phe-Tyr-Pro(spiro-; A-lactam-Leu-Trp-NH2
DMR2TZK CP Glaxo Group Research Ltd
DMR2TZK PC 16130972
DMR2TZK MW 1386.6
DMR2TZK FM C69H91N15O16
DMR2TZK IC InChI=1S/C69H91N15O16/c1-38(2)31-54(65(97)77-48(58(72)90)34-42-37-73-45-16-8-7-15-44(42)45)83-30-26-69(68(83)100)25-12-29-84(69)67(99)51(33-41-19-21-43(85)22-20-41)81-62(94)49(32-40-13-5-4-6-14-40)78-61(93)46(17-9-10-27-70)76-63(95)50(35-55(71)86)79-64(96)53-18-11-28-82(53)66(98)52(36-57(88)89)80-59(91)39(3)74-60(92)47-23-24-56(87)75-47/h4-8,13-16,19-22,37-39,46-54,73,85H,9-12,17-18,23-36,70H2,1-3H3,(H2,71,86)(H2,72,90)(H,74,92)(H,75,87)(H,76,95)(H,77,97)(H,78,93)(H,79,96)(H,80,91)(H,81,94)(H,88,89)/t39-,46-,47-,48-,49-,50-,51-,52-,53-,54-,69-/m0/s1
DMR2TZK CS C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@@]45CCN(C5=O)[C@@H](CC(C)C)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N)NC(=O)[C@@H]8CCC(=O)N8
DMR2TZK IK KWECNVXXONDEKG-JTCMYMKESA-N
DMR2TZK IU (3S)-4-[(2S)-2-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[(5S)-7-[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-6-oxo-1,7-diazaspiro[4.4]nonan-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-[[(2S)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]butanoic acid
DMR2TZK CA CAS 129623-01-4
DMR2TZK DE Vomiting
DMTGH8N ID DMTGH8N
DMTGH8N DN GR-89696
DMTGH8N HS Terminated
DMTGH8N SN GR-103545; 1-Piperazinecarboxylic acid, 4-[(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-, methyl ester
DMTGH8N CP Glaxo Group Research Ltd
DMTGH8N DT Small molecular drug
DMTGH8N PC 3505
DMTGH8N MW 414.3
DMTGH8N FM C19H25Cl2N3O3
DMTGH8N IC InChI=1S/C19H25Cl2N3O3/c1-27-19(26)23-8-9-24(15(13-23)12-22-6-2-3-7-22)18(25)11-14-4-5-16(20)17(21)10-14/h4-5,10,15H,2-3,6-9,11-13H2,1H3
DMTGH8N CS COC(=O)N1CCN(C(C1)CN2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DMTGH8N IK HJUAKZYKCANOOZ-UHFFFAOYSA-N
DMTGH8N IU methyl 4-[2-(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate
DMTGH8N CB CHEBI:91965
DMTGH8N DE Neurodegenerative disorder
DM96KF7 ID DM96KF7
DM96KF7 DN GR-94839
DM96KF7 HS Terminated
DM96KF7 SN GR-94839; 133407-20-2; 1-[4-acetyl-2-[(3-hydroxypyrrolidin-1-yl)methyl]piperazin-1-yl]-2-(3,4-dichlorophenyl)ethanone; GR 94839; ACMC-20muxb; AC1L2ZIM; SCHEMBL9650718; gr94839; CTK0I2209; 4-Acetyl-1-((3,4-dichlorophenyl)acetyl)-2-((3-hydroxy-1-pyrrolidinyl)methyl)piperazine; L004338; Piperazine, 4-acetyl-1-((3,4-dichlorophenyl)acetyl)-2-((3-hydroxy-1-pyrrolidinyl)methyl)-
DM96KF7 CP Glaxo Group Research Ltd
DM96KF7 DT Small molecular drug
DM96KF7 PC 131626
DM96KF7 MW 414.3
DM96KF7 FM C19H25Cl2N3O3
DM96KF7 IC InChI=1S/C19H25Cl2N3O3/c1-13(25)23-6-7-24(15(11-23)10-22-5-4-16(26)12-22)19(27)9-14-2-3-17(20)18(21)8-14/h2-3,8,15-16,26H,4-7,9-12H2,1H3
DM96KF7 CS CC(=O)N1CCN(C(C1)CN2CCC(C2)O)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DM96KF7 IK ZFWNCCCNZIYJAQ-UHFFFAOYSA-N
DM96KF7 IU 1-[4-acetyl-2-[(3-hydroxypyrrolidin-1-yl)methyl]piperazin-1-yl]-2-(3,4-dichlorophenyl)ethanone
DM96KF7 CA CAS 133407-20-2
DM96KF7 DE Pain
DMAHNF6 ID DMAHNF6
DMAHNF6 DN GR-95168
DMAHNF6 HS Terminated
DMAHNF6 SN GR-91568
DMAHNF6 CP Glaxo Group Research Ltd
DMAHNF6 DE Virus infection
DMPSZR0 ID DMPSZR0
DMPSZR0 DN GS-2992
DMPSZR0 HS Terminated
DMPSZR0 CP Gilead Sciences Inc
DMPSZR0 DE Human immunodeficiency virus infection
DMV7JC6 ID DMV7JC6
DMV7JC6 DN GS-3435
DMV7JC6 HS Terminated
DMV7JC6 CP Gilead Sciences Inc
DMV7JC6 PC 11150691
DMV7JC6 MW 298.77
DMV7JC6 FM C13H19ClN4O2
DMV7JC6 IC InChI=1S/C13H19ClN4O2/c1-13(2,3)20-12(19)18-8-6-17(7-9-18)11-10(14)15-4-5-16-11/h4-5H,6-9H2,1-3H3
DMV7JC6 CS CC(C)(C)OC(=O)N1CCN(CC1)C2=NC=CN=C2Cl
DMV7JC6 IK IJINSJSWDSHUBL-UHFFFAOYSA-N
DMV7JC6 IU tert-butyl 4-(3-chloropyrazin-2-yl)piperazine-1-carboxylate
DMV7JC6 CA CAS 313654-83-0
DMV7JC6 DE Influenza virus infection
DMT6S9B ID DMT6S9B
DMT6S9B DN GS-522
DMT6S9B HS Terminated
DMT6S9B CP Gilead Sciences Inc
DMT6S9B PC 9898337
DMT6S9B MW 1138.1
DMT6S9B FM C42H71N15O22
DMT6S9B IC InChI=1S/C42H71N15O22/c1-16(58)31(37(74)48-8-23(65)46-13-28(70)55-36(21(6)63)42(79)57-34(19(4)61)40(77)50-10-25(67)47-15-30(72)73)53-29(71)14-51-38(75)32(17(2)59)52-27(69)12-45-24(66)9-49-39(76)33(18(3)60)56-41(78)35(20(5)62)54-26(68)11-44-22(64)7-43/h16-21,31-36,58-63H,7-15,43H2,1-6H3,(H,44,64)(H,45,66)(H,46,65)(H,47,67)(H,48,74)(H,49,76)(H,50,77)(H,51,75)(H,52,69)(H,53,71)(H,54,68)(H,55,70)(H,56,78)(H,57,79)(H,72,73)/t16-,17-,18-,19-,20-,21-,31+,32+,33+,34+,35+,36+/m1/s1
DMT6S9B CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)CN)O
DMT6S9B IK QHRKUKVLFJBEQL-CPVSMZBNSA-N
DMT6S9B IU 2-[[2-[[(2S,3R)-2-[[(2S,3R)-2-[[2-[[2-[[(2S,3R)-2-[[2-[[(2S,3R)-2-[[2-[[2-[[(2S,3R)-2-[[(2S,3R)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetic acid
DMT6S9B DE Thrombosis
DMCYZL3 ID DMCYZL3
DMCYZL3 DN GS-9148
DMCYZL3 HS Terminated
DMCYZL3 SN GS-9131; Nucleoside reverse transcriptase inhibitor (HIV infection), Gilead Sciences; Mono-amidate prodrug of GS-9148 (HIV infection), Gilead
DMCYZL3 CP Gilead Sciences Inc
DMCYZL3 DT Small molecular drug
DMCYZL3 PC 15958718
DMCYZL3 MW 331.2
DMCYZL3 FM C10H11FN5O5P
DMCYZL3 IC InChI=1S/C10H11FN5O5P/c11-5-1-6(20-4-22(17,18)19)21-10(5)16-3-15-7-8(12)13-2-14-9(7)16/h1-3,6,10H,4H2,(H2,12,13,14)(H2,17,18,19)/t6-,10+/m0/s1
DMCYZL3 CS C1=C([C@@H](O[C@@H]1OCP(=O)(O)O)N2C=NC3=C(N=CN=C32)N)F
DMCYZL3 IK MPSGQQOHTJUJKB-QUBYGPBYSA-N
DMCYZL3 IU [(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethylphosphonic acid
DMCYZL3 CA CAS 875608-25-6
DMCYZL3 DE Human immunodeficiency virus infection
DMQSMB1 ID DMQSMB1
DMQSMB1 DN GS-9160
DMQSMB1 HS Terminated
DMQSMB1 SN GS-9160; GS9160; N-[7-(4-Fluorobenzyl)-9-Hydroxy-8-Oxo-7,8-Dihydro-6h-Pyrrolo[3,4-G]quinolin-5-Yl]-N-Methylmethanesulfonamide; N-(7-(4-fluorobenzyl)-9-hydroxy-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinolin-5-yl)-N-methylmethanesulfonamide; SCHEMBL4652222; CHEMBL513189; RJWBOLLTMJMYNV-UHFFFAOYSA-N; ZINC35078403; GS 9160; 915407-80-6; ZZV; N-[7-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6H-pyrrolo[3,4-g]quinolin-5-yl]-N-methyl-methanesulfonamide; Methanesulfonamide, N-(7-((4-fluorophenyl)methyl)-7,8-dihydro-9-hydroxy-8-oxo-6H
DMQSMB1 CP Gilead Sciences Inc
DMQSMB1 DT Small molecular drug
DMQSMB1 PC 16097721
DMQSMB1 MW 415.4
DMQSMB1 FM C20H18FN3O4S
DMQSMB1 IC InChI=1S/C20H18FN3O4S/c1-23(29(2,27)28)18-14-4-3-9-22-17(14)19(25)16-15(18)11-24(20(16)26)10-12-5-7-13(21)8-6-12/h3-9,25H,10-11H2,1-2H3
DMQSMB1 CS CN(C1=C2CN(C(=O)C2=C(C3=C1C=CC=N3)O)CC4=CC=C(C=C4)F)S(=O)(=O)C
DMQSMB1 IK RJWBOLLTMJMYNV-UHFFFAOYSA-N
DMQSMB1 IU N-[7-[(4-fluorophenyl)methyl]-9-hydroxy-8-oxo-6H-pyrrolo[3,4-g]quinolin-5-yl]-N-methylmethanesulfonamide
DMQSMB1 CA CAS 915407-80-6
DMQSMB1 DE Human immunodeficiency virus infection
DMOALVR ID DMOALVR
DMOALVR DN GSK-2485852
DMOALVR HS Terminated
DMOALVR SN GL-60667; GSK-2485852A; NVP-LDI133; HCV RNA polymerase inhibitors, Genelabs/Novartis; NS5b non-nucleoside inhibitors (HCV infection), GSK/Novartis; NS5b non-nucleoside inhibitors (HCV), Genelabs/Novartis
DMOALVR CP Genelabs Technologies Inc
DMOALVR PC 53354790
DMOALVR MW 554.4
DMOALVR FM C27H25BF2N2O6S
DMOALVR IC InChI=1S/C27H25BF2N2O6S/c1-31-27(33)25-20-12-19(16-4-5-16)23(13-24(20)38-26(25)17-6-8-18(29)9-7-17)32(39(2,36)37)14-15-3-10-21(28(34)35)22(30)11-15/h3,6-13,16,34-35H,4-5,14H2,1-2H3,(H,31,33)
DMOALVR CS B(C1=C(C=C(C=C1)CN(C2=C(C=C3C(=C2)OC(=C3C(=O)NC)C4=CC=C(C=C4)F)C5CC5)S(=O)(=O)C)F)(O)O
DMOALVR IK GDSKPIAEYNJODX-UHFFFAOYSA-N
DMOALVR IU [4-[[[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl]-methylsulfonylamino]methyl]-2-fluorophenyl]boronic acid
DMOALVR CA CAS 1331942-30-3
DMOALVR DE Hepatitis C virus infection
DMMYUWT ID DMMYUWT
DMMYUWT DN GSK-923295
DMMYUWT HS Terminated
DMMYUWT SN 1088965-37-0; GSK-923295; GSK923295; 3-Chloro-N-((S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-((S)-1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide; 3-Chloro-N-((S)-1-(2-(dimethylamino)acetamido)-3-(4-(8-((S)-1-hydroxyethyl)-imidazo[1,2-a]pyridin-2-yl)phenyl)propan-2-yl)-4-isopropoxybenzamide; GSK 923295; MLS006011170; SCHEMBL1492164; UNII-072702W9QD; CTK8C0600; DTXSID50677145; GSK-295; AOB5937; EX-A633; MolPort-023-332-816; GSK-923295A; BCP09858; ANW-64945; s7090; ZINC68151184; AKOS016005270
DMMYUWT CP GlaxoSmithKline
DMMYUWT TC Anticancer Agents
DMMYUWT DT Small molecular drug
DMMYUWT PC 46898058
DMMYUWT MW 592.1
DMMYUWT FM C32H38ClN5O4
DMMYUWT IC InChI=1S/C32H38ClN5O4/c1-20(2)42-29-13-12-24(16-27(29)33)32(41)35-25(17-34-30(40)19-37(4)5)15-22-8-10-23(11-9-22)28-18-38-14-6-7-26(21(3)39)31(38)36-28/h6-14,16,18,20-21,25,39H,15,17,19H2,1-5H3,(H,34,40)(H,35,41)/t21-,25-/m0/s1
DMMYUWT CS C[C@@H](C1=CC=CN2C1=NC(=C2)C3=CC=C(C=C3)C[C@@H](CNC(=O)CN(C)C)NC(=O)C4=CC(=C(C=C4)OC(C)C)Cl)O
DMMYUWT IK WHMXDBPHBVLYRC-OFVILXPXSA-N
DMMYUWT IU 3-chloro-N-[(2S)-1-[[2-(dimethylamino)acetyl]amino]-3-[4-[8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide
DMMYUWT CA CAS 1088965-37-0
DMMYUWT DE Solid tumour/cancer
DMA6RL2 ID DMA6RL2
DMA6RL2 DN GT-16-239
DMA6RL2 HS Terminated
DMA6RL2 CP GelTex Pharmaceuticals Inc
DMA6RL2 DE Arteriosclerosis
DM42XHS ID DM42XHS
DM42XHS DN GT-2016
DM42XHS HS Terminated
DM42XHS SN GT 2016; GT-2016; CHEMBL14812; 152241-24-2; SCHEMBL3395544; BDBM86490; MolPort-023-276-421; ZINC1537834; PDSP2_001477; PDSP1_001493; AKOS024457088; API0010299; NCGC00371075-01; LS-193753; L009653
DM42XHS DT Small molecular drug
DM42XHS PC 9839975
DM42XHS MW 317.5
DM42XHS FM C19H31N3O
DM42XHS IC InChI=1S/C19H31N3O/c23-19(9-5-4-8-16-6-2-1-3-7-16)22-12-10-17(11-13-22)18-14-20-15-21-18/h14-17H,1-13H2,(H,20,21)
DM42XHS CS C1CCC(CC1)CCCCC(=O)N2CCC(CC2)C3=CN=CN3
DM42XHS IK YTCGNPGLMAECND-UHFFFAOYSA-N
DM42XHS IU 5-cyclohexyl-1-[4-(1H-imidazol-5-yl)piperidin-1-yl]pentan-1-one
DM42XHS DE Alzheimer disease
DMJ4PNR ID DMJ4PNR
DMJ4PNR DN GT-2203
DMJ4PNR HS Terminated
DMJ4PNR SN GT-2144; GT-2204; GT-2223; GT-2328; GT-2396; GT-2397; GT-2431; H3 agonists, Gliatech
DMJ4PNR CP Gliatech Inc
DMJ4PNR PC 10103168
DMJ4PNR MW 123.16
DMJ4PNR FM C6H9N3
DMJ4PNR IC InChI=1S/C6H9N3/c7-5-1-4(5)6-2-8-3-9-6/h2-5H,1,7H2,(H,8,9)/t4-,5-/m1/s1
DMJ4PNR CS C1[C@H]([C@@H]1N)C2=CN=CN2
DMJ4PNR IK OWWNABDDYQLERE-RFZPGFLSSA-N
DMJ4PNR IU (1R,2R)-2-(1H-imidazol-5-yl)cyclopropan-1-amine
DMJ4PNR DE Anxiety disorder
DMGSN1V ID DMGSN1V
DMGSN1V DN GW-275175
DMGSN1V HS Terminated
DMGSN1V SN CMV therapy, Glaxo Wellcome; GW-275175X
DMGSN1V CP Glaxo Wellcome plc
DMGSN1V DE Virus infection
DMUG82P ID DMUG82P
DMUG82P DN GW-278884
DMUG82P HS Terminated
DMUG82P SN BW-668W95; 668W95
DMUG82P CP Glaxo Wellcome plc
DMUG82P DE Colorectal cancer
DMSZH0I ID DMSZH0I
DMSZH0I DN GW-3600
DMSZH0I HS Terminated
DMSZH0I SN Phosphodiesterase 4 inhibitor, Glaxo
DMSZH0I CP GlaxoSmithKline Inc
DMSZH0I PC 9842576
DMSZH0I MW 375.5
DMSZH0I FM C21H29NO5
DMSZH0I IC InChI=1S/C21H29NO5/c1-14(23)21(2)13-22(20(24)26-4)12-17(21)15-9-10-18(25-3)19(11-15)27-16-7-5-6-8-16/h9-11,16-17H,5-8,12-13H2,1-4H3/t17-,21-/m0/s1
DMSZH0I CS CC(=O)[C@@]1(CN(C[C@H]1C2=CC(=C(C=C2)OC)OC3CCCC3)C(=O)OC)C
DMSZH0I IK YTFBNFMILWHYAP-UWJYYQICSA-N
DMSZH0I IU methyl (3S,4S)-3-acetyl-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidine-1-carboxylate
DMSZH0I DE Asthma
DMG5A1Z ID DMG5A1Z
DMG5A1Z DN GW-660511
DMG5A1Z HS Terminated
DMG5A1Z SN GW-660511X; Z-13752A
DMG5A1Z CP Zambon Co SpA
DMG5A1Z DE Hypertension
DMPLYHU ID DMPLYHU
DMPLYHU DN GW-974
DMPLYHU HS Terminated
DMPLYHU SN GW-282974; GW-2974; GW-449; GW-734; GW-9263; Erb B-2 inhibitor, Glaxo Wellcome
DMPLYHU CP Glaxo Wellcome plc
DMPLYHU PC 6603857
DMPLYHU MW 395.5
DMPLYHU FM C23H21N7
DMPLYHU IC InChI=1S/C23H21N7/c1-29(2)22-11-19-20(13-24-22)25-15-26-23(19)28-18-8-9-21-17(10-18)12-27-30(21)14-16-6-4-3-5-7-16/h3-13,15H,14H2,1-2H3,(H,25,26,28)
DMPLYHU CS CN(C)C1=NC=C2C(=C1)C(=NC=N2)NC3=CC4=C(C=C3)N(N=C4)CC5=CC=CC=C5
DMPLYHU IK DYYZXRCFCVDSKD-UHFFFAOYSA-N
DMPLYHU IU 4-N-(1-benzylindazol-5-yl)-6-N,6-N-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine
DMPLYHU CA CAS 202272-68-2
DMPLYHU CB CHEBI:95273
DMPLYHU DE Breast cancer
DM3YG5P ID DM3YG5P
DM3YG5P DN GYKI-52466
DM3YG5P HS Terminated
DM3YG5P SN Gyki-52466; 102771-26-6; GYKI 52466; UNII-471V8NZ5X3; GYKI 52466 HCl; CHEMBL275006; CHEBI:79560; 471V8NZ5X3; 1-(p-Aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride; 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline; 4-(8-Methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)benzenamine; Benzenamine,4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-; Benzenamine, 4-(8-methyl-9H-1,3-dioxolo(4,5-h)(2,3)benzodiazepin-5-yl)-; C17H15N3O2
DM3YG5P DT Small molecular drug
DM3YG5P PC 3538
DM3YG5P MW 293.32
DM3YG5P FM C17H15N3O2
DM3YG5P IC InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3
DM3YG5P CS CC1=NN=C(C2=CC3=C(C=C2C1)OCO3)C4=CC=C(C=C4)N
DM3YG5P IK LFBZZHVSGAHQPP-UHFFFAOYSA-N
DM3YG5P IU 4-(8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline
DM3YG5P CA CAS 102771-26-6
DM3YG5P CB CHEBI:79560
DM3YG5P DE Alzheimer disease
DMC0JN8 ID DMC0JN8
DMC0JN8 DN GYKI-53655
DMC0JN8 HS Terminated
DMC0JN8 SN GYKI-53655; Gyki 53655; GYKI53655; 1-(4-AMINOPHENYL)-3-METHYLCARBAMOYL-4-METHYL-7,8-METHYLENEDIOXY-3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE; 143692-18-6; CHEMBL267450; LY 300168; SMGACXZFVXKEAX-UHFFFAOYSA-N; AC1L2QV0; GYKI-53655 free base; MLS006010331; SCHEMBL351325; GTPL4209; DTXSID30276296; MolPort-006-418-196; BCP27661; BDBM50048386; ABP000447; NCGC00263113-03; NCGC00263113-01; SMR004701394; LY300168; LY-300168; FT-0765288; LY 300168(GYKI 53655); LY-300168, (+/-)-; 7H-1,3-Dioxolo(4,5-H)(2,3)benzodiazepine-7-carboxamide, 5-(4-aminopheny
DMC0JN8 DT Small molecular drug
DMC0JN8 PC 126758
DMC0JN8 MW 352.4
DMC0JN8 FM C19H20N4O3
DMC0JN8 IC InChI=1S/C19H20N4O3/c1-11-7-13-8-16-17(26-10-25-16)9-15(13)18(22-23(11)19(24)21-2)12-3-5-14(20)6-4-12/h3-6,8-9,11H,7,10,20H2,1-2H3,(H,21,24)
DMC0JN8 CS CC1CC2=CC3=C(C=C2C(=NN1C(=O)NC)C4=CC=C(C=C4)N)OCO3
DMC0JN8 IK SMGACXZFVXKEAX-UHFFFAOYSA-N
DMC0JN8 IU 5-(4-aminophenyl)-N,8-dimethyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide
DMC0JN8 CA CAS 143692-18-6
DM904UQ ID DM904UQ
DM904UQ DN H-216/44
DM904UQ HS Terminated
DM904UQ SN 108495-27-8; 1-Piperidinecarboxamide,N-[2-[[3-[4-[2-[2-(cyclopropylmethoxy)ethoxy]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-4-hydroxy-; H 21644; ACMC-20mbju; AC1L2WUQ; H 216-44; H-216-44; H-216/44; CHEMBL151651; CTK4A6062; L002328; N-[2-[[3-[4-[2-[2-(cyclopropylmethoxy)ethoxy]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-4-hydroxypiperidine-1-carboxamide; 1-Piperidinecarboxamide, N-(2-((3-(4-(2-(2-(cyclopropylmethoxy)ethoxy)ethyl)phenoxy)-2-hydroxypropyl)amino)ethyl)-4-hydroxy-
DM904UQ CP Astra AB
DM904UQ DT Small molecular drug
DM904UQ PC 130141
DM904UQ MW 479.6
DM904UQ FM C25H41N3O6
DM904UQ IC InChI=1S/C25H41N3O6/c29-22-7-12-28(13-8-22)25(31)27-11-10-26-17-23(30)19-34-24-5-3-20(4-6-24)9-14-32-15-16-33-18-21-1-2-21/h3-6,21-23,26,29-30H,1-2,7-19H2,(H,27,31)
DM904UQ CS C1CC1COCCOCCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCC(CC3)O)O
DM904UQ IK IWACLEHDBMHXHC-UHFFFAOYSA-N
DM904UQ IU N-[2-[[3-[4-[2-[2-(cyclopropylmethoxy)ethoxy]ethyl]phenoxy]-2-hydroxypropyl]amino]ethyl]-4-hydroxypiperidine-1-carboxamide
DM904UQ CA CAS 108495-27-8
DM904UQ DE Glaucoma/ocular hypertension
DMMCI4H ID DMMCI4H
DMMCI4H DN HELENALIN
DMMCI4H HS Terminated
DMMCI4H SN HELENALIN; 6754-13-8; PF 56; Helenalin A; HSDB 3490; NSC85236; UNII-4GUY9L896T; NSC 85236; BRN 0028081; MLS000728512; CHEBI:5635; 4GUY9L896T; 6alpha,8beta-Dihydroxy-4-oxoambrosa-2,11(13)-dien-12-oic acid 12,8-lactone; SMR000445626; Ambrosa-2,11(13)-dien-12-oic acid, 6alpha,8beta-dihydroxy-4-oxo-, 12,8-lactone; (3aR,5R,5aR,8aR,9S,9aS)-9-hydroxy-5,8a-dimethyl-1-methylene-3a,4,5,5a,9,9a-hexahydroazuleno[6,7-b]furan-2,8-dione; Azuleno(6,5-b)furan-2,5-dione, 3,3a,4,4a,7a,8,9,9a-octahydro-4-hydroxy-4a,8-dimethyl-3-methylene-, (3
DMMCI4H DT Small molecular drug
DMMCI4H PC 23205
DMMCI4H MW 262.3
DMMCI4H FM C15H18O4
DMMCI4H IC InChI=1S/C15H18O4/c1-7-6-10-12(8(2)14(18)19-10)13(17)15(3)9(7)4-5-11(15)16/h4-5,7,9-10,12-13,17H,2,6H2,1,3H3/t7-,9+,10-,12-,13+,15+/m1/s1
DMMCI4H CS C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1C=CC3=O)C)O)C(=C)C(=O)O2
DMMCI4H IK ZVLOPMNVFLSSAA-XEPQRQSNSA-N
DMMCI4H IU (3aR,5R,5aR,8aR,9S,9aS)-9-hydroxy-5,8a-dimethyl-1-methylidene-3a,4,5,5a,9,9a-hexahydroazuleno[6,7-b]furan-2,8-dione
DMMCI4H CA CAS 6754-13-8
DMMCI4H CB CHEBI:5635
DM5HMZW ID DM5HMZW
DM5HMZW DN Hementin
DM5HMZW HS Terminated
DM5HMZW SN EMD-66777; Hementin, Biopharm
DM5HMZW CP Biopharm (UK) Ltd
DM5HMZW DE Thrombosis
DMMXG2I ID DMMXG2I
DMMXG2I DN Heparin-EGF-like factor
DMMXG2I HS Terminated
DMMXG2I SN HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova
DMMXG2I CP Scios Inc
DMMXG2I DE Gastrointestinal disease
DMGAKD8 ID DMGAKD8
DMGAKD8 DN HIMBACINE
DMGAKD8 HS Terminated
DMGAKD8 SN Himbacine; UNII-M17C7V122D; NSC 23969; HIMBAFCINE; CHEMBL277642; CHEBI:5720; (+)-himbacine; M17C7V122D; 6879-74-9; Naphtho(2,3-c)furan-1(3H)-one, decahydro-4-(2-(1,6-dimethyl-2-piperidinyl)ethenyl)-3-methyl-,(3S-(3-alpha,3a-alpha,4-beta(1E,2(2R*,6S*)),4a-beta,8a-alpha,9a-alpha))-; AC1O5LBZ; GTPL324; SCHEMBL194692; BDBM50076089; CCG-208219; NCGC00163249-01; LS-95329; SR-05000002338; SR-05000002338-2; 4-[2-(1,6-Dimethyl-piperidin-2-yl)-vinyl]-3-methyl-decahydro-naphtho[2,3-c]furan-1-one
DMGAKD8 DT Small molecular drug
DMGAKD8 PC 6436265
DMGAKD8 MW 345.5
DMGAKD8 FM C22H35NO2
DMGAKD8 IC InChI=1S/C22H35NO2/c1-14-7-6-9-17(23(14)3)11-12-19-18-10-5-4-8-16(18)13-20-21(19)15(2)25-22(20)24/h11-12,14-21H,4-10,13H2,1-3H3/b12-11+/t14-,15-,16+,17+,18-,19+,20-,21+/m0/s1
DMGAKD8 CS C[C@H]1CCC[C@@H](N1C)/C=C/[C@@H]2[C@H]3CCCC[C@@H]3C[C@H]4[C@@H]2[C@@H](OC4=O)C
DMGAKD8 IK FMPNFDSPHNUFOS-LPJDIUFZSA-N
DMGAKD8 IU (3S,3aR,4R,4aS,8aR,9aS)-4-[(E)-2-[(2R,6S)-1,6-dimethylpiperidin-2-yl]ethenyl]-3-methyl-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f][2]benzofuran-1-one
DMGAKD8 CA CAS 6879-74-9
DMGAKD8 CB CHEBI:5720
DM784QJ ID DM784QJ
DM784QJ DN Hirufaxin
DM784QJ HS Terminated
DM784QJ CP Savient Pharmaceuticals Inc
DM784QJ DE Thrombosis
DMCHFIT ID DMCHFIT
DMCHFIT DN HMR-3787
DMCHFIT HS Terminated
DMCHFIT SN 11-Deoxy-3-des(hexopyranosyloxy)-2-fluoro-11-[4-(3H-imidazo[4,5-b]pyridin-3-yl)butylamino]-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate
DMCHFIT DT Small molecular drug
DMCHFIT PC 6918384
DMCHFIT MW 804
DMCHFIT FM C41H62FN5O10
DMCHFIT IC InChI=1S/C41H62FN5O10/c1-12-29-41(8)32(47(38(52)57-41)19-14-13-18-46-22-44-27-16-15-17-43-35(27)46)25(4)30(48)23(2)21-39(6,53-11)34(26(5)33(50)40(7,42)37(51)55-29)56-36-31(49)28(45(9)10)20-24(3)54-36/h15-17,22-26,28-29,31-32,34,36,49H,12-14,18-21H2,1-11H3/t23-,24-,25+,26+,28+,29-,31-,32-,34-,36+,39-,40+,41-/m1/s1
DMCHFIT CS CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@](C(=O)O1)(C)F)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=NC5=C4N=CC=C5)C
DMCHFIT IK NRYQCCZBHGMXIN-SAWHFZNOSA-N
DMCHFIT IU (1S,2R,5S,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-15-(4-imidazo[4,5-b]pyridin-3-ylbutyl)-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone
DMCHFIT DE Bacterial infection
DML0B97 ID DML0B97
DML0B97 DN HOE-694
DML0B97 HS Terminated
DML0B97 SN 141923-47-9; 3-METHYLSULFONYL-4-PIPERIDIN-1-YLBENZOYL GUANIDINE; HOE694; AC1L3XEA; CHEMBL62231; SCHEMBL3906516; CTK4C2847; ZINC3915646; AKOS030541973; KB-236684; TX-016775; 3-methylsulphonyl-4-piperidinobenzoyl-guanidine
DML0B97 DT Small molecular drug
DML0B97 PC 123841
DML0B97 MW 324.4
DML0B97 FM C14H20N4O3S
DML0B97 IC InChI=1S/C14H20N4O3S/c1-22(20,21)12-9-10(13(19)17-14(15)16)5-6-11(12)18-7-3-2-4-8-18/h5-6,9H,2-4,7-8H2,1H3,(H4,15,16,17,19)
DML0B97 CS CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)N2CCCCC2
DML0B97 IK WITSYJHGEIZBQU-UHFFFAOYSA-N
DML0B97 IU N-(diaminomethylidene)-3-methylsulfonyl-4-piperidin-1-ylbenzamide
DML0B97 DE Heart arrhythmia
DMHP9WV ID DMHP9WV
DMHP9WV DN HOMOEPIBATIDINE
DMHP9WV HS Terminated
DMHP9WV SN homoepibatidine; CHEMBL94427; CHEMBL535389; BDBM50194073; BDBM50194070
DMHP9WV DT Small molecular drug
DMHP9WV PC 44327552
DMHP9WV MW 222.71
DMHP9WV FM C12H15ClN2
DMHP9WV IC InChI=1S/C12H15ClN2/c13-12-5-4-8(7-14-12)10-6-9-2-1-3-11(10)15-9/h4-5,7,9-11,15H,1-3,6H2
DMHP9WV CS C1CC2CC(C(C1)N2)C3=CN=C(C=C3)Cl
DMHP9WV IK GDSORCYTZJIZHU-UHFFFAOYSA-N
DMHP9WV IU 6-(6-chloropyridin-3-yl)-8-azabicyclo[3.2.1]octane
DMEZ5P2 ID DMEZ5P2
DMEZ5P2 DN HRC-101
DMEZ5P2 HS Terminated
DMEZ5P2 SN Oxygain; HML-109
DMEZ5P2 CP Ontario Inc
DMEZ5P2 DE Blood transfusion
DMJACXN ID DMJACXN
DMJACXN DN HRC-102
DMJACXN HS Terminated
DMJACXN SN Hemolox T; HML-110
DMJACXN CP Ontario Inc
DMJACXN DE Reperfusion injury
DM5A3GX ID DM5A3GX
DM5A3GX DN HRC-201
DM5A3GX HS Terminated
DM5A3GX SN Hemoglobin-imaging conjugate (HepSelect), Hemosol
DM5A3GX CP Ontario Inc
DM5A3GX DE Liver cancer
DMQINWF ID DMQINWF
DMQINWF DN HT-90B
DMQINWF HS Terminated
DMQINWF CP Chugai Pharmaceutical Co Ltd
DMQINWF PC 9886379
DMQINWF MW 384.5
DMQINWF FM C23H32N2O3
DMQINWF IC InChI=1S/C23H32N2O3/c1-15-3-2-4-20-21(15)28-19(14-27-20)13-24-5-6-25-22(26)23-10-16-7-17(11-23)9-18(8-16)12-23/h2-4,16-19,24H,5-14H2,1H3,(H,25,26)
DMQINWF CS CC1=C2C(=CC=C1)OCC(O2)CNCCNC(=O)C34CC5CC(C3)CC(C5)C4
DMQINWF IK QKQSDPQVNKEJPX-UHFFFAOYSA-N
DMQINWF IU N-[2-[(5-methyl-2,3-dihydro-1,4-benzodioxin-3-yl)methylamino]ethyl]adamantane-1-carboxamide
DMQINWF DE Anxiety disorder
DMK1VHF ID DMK1VHF
DMK1VHF DN Hu Dreg 55
DMK1VHF HS Terminated
DMK1VHF SN SMART Anti-L-Selectin
DMK1VHF CP PDL BioPharma
DMK1VHF DT Antibody
DMK1VHF DE Psoriasis vulgaris
DMTGCA6 ID DMTGCA6
DMTGCA6 DN HuCD40L
DMTGCA6 HS Terminated
DMTGCA6 SN Avrend; CD40 ligand, Celldex; CD40 ligand, Immunex; HuCD40L, Immunex
DMTGCA6 CP Amgen
DMTGCA6 DE Solid tumour/cancer
DMA7EFM ID DMA7EFM
DMA7EFM DN Human chorionic gonadotropin
DMA7EFM HS Terminated
DMA7EFM SN Human chorionic gonadotropin (heart disease); HCG (heart disease), Stem Cell Therapeutics; Human chorionic gonadotropin (heart disease), Stem Cell Therapeutics
DMA7EFM CP Stem Cell Therapeutics Corp
DMA7EFM SQ Alpha Chain: APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS >Beta ChainSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ
DMA7EFM DE Heart disease
DMFVB7Z ID DMFVB7Z
DMFVB7Z DN HuMax-HepC
DMFVB7Z HS Terminated
DMFVB7Z SN E2-hmAb; HCV-specific antibody, Genmab; Hepatitis C virus-specific antibody, Connex/INSERM
DMFVB7Z CP Genmab A/S
DMFVB7Z DT Antibody
DMFVB7Z DE Hepatitis C virus infection
DM8BSF3 ID DM8BSF3
DM8BSF3 DN HuMax-TAC
DM8BSF3 HS Terminated
DM8BSF3 SN Anti-IL-2R antibody, Genmab/Merck Serono
DM8BSF3 CP Genmab A/S
DM8BSF3 DT Antibody
DM8BSF3 DE Autoimmune diabetes
DM37KVY ID DM37KVY
DM37KVY DN HY-12638
DM37KVY HS Discontinued
DM37KVY SN Anthiphen; Dichlorophen; Antifen; Antiphen; Cordocel; Dicestal; Dichloorfeen; Dichlorofen; Dichlorophen B; Dichlorophene 10; Dichlorphen; Didroxan; Didroxane; Difentan; Diphenthane 70; Embephen; Fungicide GM; Fungicide M; Gingivit; Halenol; Hyosan; Korium; Palacel; Panacide; Parabis; Plath-Lyse; Prevental; Preventol GD; Preventol GDC; Sandocide; Super mosstox; Taeniatol; Teniathane; Teniatol; Teniotol; Trivex; Vermithana; Wespuril; dichlorophene; 2,2'-Methylenebis(4-chlorophenol); 97-23-4; Bis(5-chloro-2-hydroxyphenyl)methane; DDDM; Gefir
DM37KVY PC 3037
DM37KVY MW 269.12
DM37KVY FM C13H10Cl2O2
DM37KVY IC MDNWOSOZYLHTCG-UHFFFAOYSA-N
DM37KVY CS C1=CC(=C(C=C1Cl)CC2=C(C=CC(=C2)Cl)O)O
DM37KVY IK 1S/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2
DM37KVY IU 4-chloro-2-[(5-chloro-2-hydroxyphenyl)methyl]phenol
DM37KVY CA CAS 97-23-4
DM37KVY CB CHEBI:34689
DM37KVY DE Tapeworm infestation
DM4HA9C ID DM4HA9C
DM4HA9C DN HydrocoDex
DM4HA9C HS Terminated
DM4HA9C SN Acetaminophen/dextromethorphan
DM4HA9C CP Endo Pharmaceuticals
DM4HA9C DE Pain
DM1C4IG ID DM1C4IG
DM1C4IG DN ICA-1
DM1C4IG HS Terminated
DM1C4IG SN PKC-iota inhibitor (cancer), Inhibition therapeutics
DM1C4IG CP AlumiFuel Power Corp
DM1C4IG PC 71510744
DM1C4IG MW 336.24
DM1C4IG FM C10H17N4O7P
DM1C4IG IC InChI=1S/C10H17N4O7P/c11-9-6(10(12)17)13-3-14(9)5-1-4(7(15)8(5)16)2-21-22(18,19)20/h3-5,7-8,15-16H,1-2,11H2,(H2,12,17)(H2,18,19,20)/t4-,5-,7-,8+/m0/s1
DM1C4IG CS C1[C@H]([C@@H]([C@@H]([C@H]1N2C=NC(=C2N)C(=O)N)O)O)COP(=O)(O)O
DM1C4IG IK VFGPDCAAUMRRSL-BKMCOVHNSA-N
DM1C4IG IU [(1S,2S,3R,4S)-4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl]methyl dihydrogen phosphate
DM1C4IG DE Solid tumour/cancer
DMYN3WG ID DMYN3WG
DMYN3WG DN ICI-164384
DMYN3WG HS Terminated
DMYN3WG SN Ici 164384; ICI-164384; 98007-99-9; UNII-84LT43726C; ICI M164384; ICI 164,384; CHEMBL1222035; N-n-Butyl-N-methyl-11-(3,17beta-dihydroxyestra-1,3,5(10)-trien-7alpha-yl)undecanamide; 84LT43726C; N-BUTYL-11-[(7R,8R,9S,13S,14S,17S)-3,17-DIHYDROXY-13-METHYL-7,8,9,11,12,13,14,15,16,17-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-7-YL]-N-METHYLUNDECANAMIDE; Estra-1,3,5(10)-triene-7-undecanamide, N-butyl-3,17-dihydroxy-N-methyl-, (7alpha,17beta)-; AOE
DMYN3WG DT Small molecular drug
DMYN3WG PC 104772
DMYN3WG MW 525.8
DMYN3WG FM C34H55NO3
DMYN3WG IC InChI=1S/C34H55NO3/c1-4-5-22-35(3)32(38)15-13-11-9-7-6-8-10-12-14-25-23-26-24-27(36)16-17-28(26)29-20-21-34(2)30(33(25)29)18-19-31(34)37/h16-17,24-25,29-31,33,36-37H,4-15,18-23H2,1-3H3/t25-,29-,30+,31+,33-,34+/m1/s1
DMYN3WG CS CCCCN(C)C(=O)CCCCCCCCCC[C@@H]1CC2=C(C=CC(=C2)O)[C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)O
DMYN3WG IK BVVFOLSZMQVDKV-KXQIQQEYSA-N
DMYN3WG IU N-butyl-11-[(7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-yl]-N-methylundecanamide
DMYN3WG CA CAS 98007-99-9
DMYN3WG DE Breast cancer
DMQ0IOF ID DMQ0IOF
DMQ0IOF DN ICI-169369
DMQ0IOF HS Terminated
DMQ0IOF SN 2-Detpq; Ici 169369; 2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline; 85273-95-6; Ici-169,369; UNII-4CT4CS5BA7; ICI-169369; 4CT4CS5BA7; N,N-dimethyl-2-(3-phenylquinolin-2-yl)sulfanylethanamine; Ethanamine, N,N-dimethyl-2-((3-phenyl-2-quinolinyl)thio)-; Ethanamine, N,N-dimethyl-2-[(3-phenyl-2-quinolinyl)thio]-; AC1L3UA4; GTPL273; AC1Q7E25; SCHEMBL2640021; CHEMBL1191534; CTK2I4265; BDBM84945; DTXSID40234468; 85273-96-7 (hydrochloride); n,n-dimethyl-2-[(3-phenylquinolin-2-yl)sulfanyl]ethanamine; ZINC5140456; PDSP2_001405
DMQ0IOF CP Zeneca Group plc
DMQ0IOF DT Small molecular drug
DMQ0IOF PC 122265
DMQ0IOF MW 308.4
DMQ0IOF FM C19H20N2S
DMQ0IOF IC InChI=1S/C19H20N2S/c1-21(2)12-13-22-19-17(15-8-4-3-5-9-15)14-16-10-6-7-11-18(16)20-19/h3-11,14H,12-13H2,1-2H3
DMQ0IOF CS CN(C)CCSC1=NC2=CC=CC=C2C=C1C3=CC=CC=C3
DMQ0IOF IK HYOLQGVNMQNERE-UHFFFAOYSA-N
DMQ0IOF IU N,N-dimethyl-2-(3-phenylquinolin-2-yl)sulfanylethanamine
DMQ0IOF CA CAS 85273-95-6
DMQ0IOF DE Anxiety disorder
DM0XU4P ID DM0XU4P
DM0XU4P DN ICI-181037
DM0XU4P HS Terminated
DM0XU4P SN ZM-181037
DM0XU4P CP Zeneca Group plc
DM0XU4P DT Small molecular drug
DM0XU4P PC 5487455
DM0XU4P MW 414.5
DM0XU4P FM C24H34N2O4
DM0XU4P IC InChI=1S/C24H34N2O4/c1-16(26(5)6)24(28,18-10-8-9-11-21(18)30-15-22(25)27)19-14-17(23(2,3)4)12-13-20(19)29-7/h8-14,16,28H,15H2,1-7H3,(H2,25,27)/t16-,24-/m1/s1
DM0XU4P CS C[C@H]([C@@](C1=CC=CC=C1OCC(=O)N)(C2=C(C=CC(=C2)C(C)(C)C)OC)O)N(C)C
DM0XU4P IK DLGGQRFVOGBFAX-VOIUYBSRSA-N
DM0XU4P IU 2-[2-[(1R,2R)-1-(5-tert-butyl-2-methoxyphenyl)-2-(dimethylamino)-1-hydroxypropyl]phenoxy]acetamide
DM0XU4P CA CAS 138779-29-0
DM0XU4P DE Heart arrhythmia
DM0195G ID DM0195G
DM0195G DN ICI-198615
DM0195G HS Terminated
DM0195G SN Cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate; Ici 198615; 104448-53-5; CHEMBL22033; Ici-198,615; ZM 198615; ZM-198,615; cyclopentyl N-[1-({4-[(benzenesulfonyl)carbamoyl]-2-methoxyphenyl}methyl)-1H-indazol-6-yl]carbamate; [3H]ICI198615; [3H]-ICI198615; [3H]ICI-198615; [3H]ICI-198,615; AC1L3GQZ; (1-((2-Methoxy-4-(((phenylsulfonyl)amino)carbonyl)phenyl)methyl)-1H-indazol-6-yl)carbamic acid cyclopentyl ester; GTPL3414; GTPL3358; SCHEMBL9806720; DTXSID80146490; BDBM50009075; PDSP1_000520; PDSP2_000518; ICI198615
DM0195G CP Zeneca Group plc
DM0195G DT Small molecular drug
DM0195G PC 115219
DM0195G MW 548.6
DM0195G FM C28H28N4O6S
DM0195G IC InChI=1S/C28H28N4O6S/c1-37-26-15-19(27(33)31-39(35,36)24-9-3-2-4-10-24)11-12-21(26)18-32-25-16-22(14-13-20(25)17-29-32)30-28(34)38-23-7-5-6-8-23/h2-4,9-17,23H,5-8,18H2,1H3,(H,30,34)(H,31,33)
DM0195G CS COC1=C(C=CC(=C1)C(=O)NS(=O)(=O)C2=CC=CC=C2)CN3C4=C(C=CC(=C4)NC(=O)OC5CCCC5)C=N3
DM0195G IK YRCPIXCRSAKRGM-UHFFFAOYSA-N
DM0195G IU cyclopentyl N-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate
DM0195G CA CAS 104448-53-5
DM0195G DE Asthma
DMDBICR ID DMDBICR
DMDBICR DN ICM-3
DMDBICR HS Terminated
DMDBICR SN ICAM-3 antibodies, ICOS; ICAM-R antibodies, ICOS
DMDBICR CP ICOS Corp
DMDBICR DT Antibody
DMDBICR DE Graft-versus-host disease
DMG1FQW ID DMG1FQW
DMG1FQW DN IDRA-21
DMG1FQW HS Terminated
DMG1FQW SN IDRA-21 analogs; IDRA-5
DMG1FQW CP Fidia-Georgetown Institute for the Neurosciences
DMG1FQW DT Small molecular drug
DMG1FQW PC 3688
DMG1FQW MW 232.69
DMG1FQW FM C8H9ClN2O2S
DMG1FQW IC InChI=1S/C8H9ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-5,10-11H,1H3
DMG1FQW CS CC1NC2=C(C=C(C=C2)Cl)S(=O)(=O)N1
DMG1FQW IK VZRNTCHTJRLTMU-UHFFFAOYSA-N
DMG1FQW IU 7-chloro-3-methyl-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
DMG1FQW CA CAS 22503-72-6
DMG1FQW CB CHEBI:111162
DMG1FQW DE Alzheimer disease
DM16S98 ID DM16S98
DM16S98 DN IGE-026
DM16S98 HS Terminated
DM16S98 SN IgE inhibitors, Novartis; NVP-VAB-053; NVP-VAD-463
DM16S98 CP Novartis AG
DM16S98 DE Allergic rhinitis
DMBKZ4R ID DMBKZ4R
DMBKZ4R DN IGN-311
DMBKZ4R HS Terminated
DMBKZ4R SN HuABL-364; IGN-314; Anti-Lewis Y mAb (cancer), Igeneon
DMBKZ4R CP PDL BioPharma Inc
DMBKZ4R DT Antibody
DMBKZ4R DE Solid tumour/cancer
DMKS4Z9 ID DMKS4Z9
DMKS4Z9 DN IL1aQb
DMKS4Z9 HS Terminated
DMKS4Z9 SN IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos
DMKS4Z9 CP Cytos Biotechnology AG
DMKS4Z9 DT Vaccine
DMKS4Z9 DE Arteriosclerosis
DMWTFO3 ID DMWTFO3
DMWTFO3 DN IMAZODAN
DMWTFO3 HS Terminated
DMWTFO3 SN IMAZODAN HYDROCHLORIDE; Imazodan HCl; CI-914; UNII-5EP74J9Q34; Imazodan hydrochloride [USAN]; 89198-09-4; 4,5-Dihydro-6-(p-imidazol-1-ylphenyl)-3(2H)-pyridazinone monohydrochloride; 5EP74J9Q34; 4,5-Dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-3(2H)-pyridazinone hydrochloride; Imazodan hydrochloride (USAN); 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-(1H-imidazol-1-yl)phenyl)-, monohydrochloride; 3(2H)-Pyridazinone, 4,5-dihydro-6-(p-(1-imidazolyl)phenyl)-, monohydrochloride; ACMC-20livl; AC1Q3ES0; C13H12N4O.HCl; SCHEMBL124243; AC1L1K29
DMWTFO3 DT Small molecular drug
DMWTFO3 PC 55918
DMWTFO3 MW 240.26
DMWTFO3 FM C13H12N4O
DMWTFO3 IC InChI=1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)
DMWTFO3 CS C1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3
DMWTFO3 IK VXMYWVMXSWJFCV-UHFFFAOYSA-N
DMWTFO3 IU 3-(4-imidazol-1-ylphenyl)-4,5-dihydro-1H-pyridazin-6-one
DMWTFO3 CA CAS 84243-58-3
DMW39DV ID DMW39DV
DMW39DV DN INCB3344
DMW39DV HS Terminated
DMW39DV SN INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer
DMW39DV CP Incyte Corp
DMW39DV DT Small molecular drug
DMW39DV PC 10008367
DMW39DV MW 577.6
DMW39DV FM C29H34F3N3O6
DMW39DV IC InChI=1S/C29H34F3N3O6/c1-2-39-25-16-35(21-8-10-28(38,11-9-21)19-6-7-23-24(13-19)41-17-40-23)15-22(25)34-26(36)14-33-27(37)18-4-3-5-20(12-18)29(30,31)32/h3-7,12-13,21-22,25,38H,2,8-11,14-17H2,1H3,(H,33,37)(H,34,36)/t21?,22-,25-,28?/m0/s1
DMW39DV CS CCO[C@H]1CN(C[C@@H]1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)C3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O
DMW39DV IK MZEOSVPWMSEFPW-XYCDVDSTSA-N
DMW39DV IU N-[2-[[(3S,4S)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
DMW39DV DE Arteriosclerosis
DMODQW0 ID DMODQW0
DMODQW0 DN INXC-ICAM1
DMODQW0 HS Terminated
DMODQW0 SN Antisense ICAM-1-TCS, Inex; ICAM-1 antisense (inflammation), INEX; Transmembrane carrier system (antisense ICAM-1), Inex; Antisense (ICAM-1, inflammation), INEX
DMODQW0 CP Inex Pharmaceuticals Corp
DMODQW0 DT Antisense drug
DMODQW0 DE Transplant rejection
DMY3BMC ID DMY3BMC
DMY3BMC DN IPH-3102
DMY3BMC HS Terminated
DMY3BMC SN IPH-31XX; TLR-3 receptor agonist (cancer), Innate Pharma; Toll-like receptor 3 agonist (cancer),Innate Pharma
DMY3BMC CP Innate Pharma SA
DMY3BMC DE Solid tumour/cancer
DM7J8IO ID DM7J8IO
DM7J8IO DN IPH-3201
DM7J8IO HS Terminated
DM7J8IO SN IPH-32XX; TLR-7 modulators (cancer), Cancer Research Technology; TLR-7 modulators (cancer), Innate; Toll-like receptor 7 modulators (cancer), Innate
DM7J8IO CP Cancer Research Technology Ltd
DM7J8IO DE Solid tumour/cancer
DMRVZMX ID DMRVZMX
DMRVZMX DN IPH-4201
DMRVZMX HS Terminated
DMRVZMX SN MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM
DMRVZMX CP Universite de la Mediterranee
DMRVZMX DT Antibody
DMRVZMX DE Pancreatic cancer
DMEJU1L ID DMEJU1L
DMEJU1L DN Ipsapirone
DMEJU1L HS Terminated
DMEJU1L SN IPSAPIRONE; 95847-70-4; Ipsapironum [Latin]; Ipsapirona [Spanish]; Ipsapirone [INN:BAN]; UNII-6J9B11MN0K; C19H23N5O3S; 2-[4-[4-(2-PYRIMIDINYL)-1-PIPERAZINYL]BUTYL]-1,2-BENZISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE; BRN 5486134; CHEMBL8412; 6J9B11MN0K; NCGC00025315-01; DSSTox_CID_25688; 2-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide; DSSTox_RID_81060; DSSTox_GSID_45688; Ipsapironum; Ipsapirona; 1,1-dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one
DMEJU1L DT Small molecular drug
DMEJU1L PC 56971
DMEJU1L MW 401.5
DMEJU1L FM C19H23N5O3S
DMEJU1L IC InChI=1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2
DMEJU1L CS C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4
DMEJU1L IK TZJUVVIWVWFLCD-UHFFFAOYSA-N
DMEJU1L IU 1,1-dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one
DMEJU1L CA CAS 95847-70-4
DMEJU1L CB CHEBI:93578
DMEJU1L DE Anxiety disorder
DMYCPFU ID DMYCPFU
DMYCPFU DN IQM-95333
DMYCPFU HS Terminated
DMYCPFU SN IQM-95333; CHEMBL113718; IQM95333; AC1NSK6B; BDBM50060319; tert-butyl N-[(2S)-1-[[(4aS,5R)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate; [(S)-1-((4aS,5R)-2-Benzyl-1,3-dioxo-octahydro-pyrido[1,2-c]pyrimidin-5-ylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester
DMYCPFU DT Small molecular drug
DMYCPFU PC 5311188
DMYCPFU MW 559.7
DMYCPFU FM C31H37N5O5
DMYCPFU IC InChI=1S/C31H37N5O5/c1-31(2,3)41-29(39)34-25(16-21-18-32-23-13-8-7-12-22(21)23)28(38)33-24-14-9-15-35-26(24)17-27(37)36(30(35)40)19-20-10-5-4-6-11-20/h4-8,10-13,18,24-26,32H,9,14-17,19H2,1-3H3,(H,33,38)(H,34,39)/t24-,25+,26+/m1/s1
DMYCPFU CS CC(C)(C)OC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]3CCCN4[C@H]3CC(=O)N(C4=O)CC5=CC=CC=C5
DMYCPFU IK JRSRZYFBWXHHNX-ZNZIZOMTSA-N
DMYCPFU IU tert-butyl N-[(2S)-1-[[(4aS,5R)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamate
DMJ3ZUN ID DMJ3ZUN
DMJ3ZUN DN Irindalone
DMJ3ZUN HS Terminated
DMJ3ZUN SN Irindalone; 96478-43-2; UNII-4F39T8N10K; CHEMBL73461; 4F39T8N10K; Irindalonum; Irindalona; Irindalone [INN]; 1-[2-[4-[(1R,3S)-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one; Irindalonum [Latin]; Irindalona [Spanish]; SCHEMBL247221; DTXSID30242274; 1-(2-{4-[3-(4-Fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethyl)-imidazolidin-2-one; AC1L2435; ZINC22463226; BDBM50020232; CS-6668; HY-101632; (+)-(1R,3S)-1-(2-(4-(3-(p-Fluorophenyl)-1-indanyl)-1-piperazinyl)ethyl)-2-imidazolidinone
DMJ3ZUN DT Small molecular drug
DMJ3ZUN PC 65845
DMJ3ZUN MW 408.5
DMJ3ZUN FM C24H29FN4O
DMJ3ZUN IC InChI=1S/C24H29FN4O/c25-19-7-5-18(6-8-19)22-17-23(21-4-2-1-3-20(21)22)28-14-11-27(12-15-28)13-16-29-10-9-26-24(29)30/h1-8,22-23H,9-17H2,(H,26,30)/t22-,23+/m0/s1
DMJ3ZUN CS C1CN(C(=O)N1)CCN2CCN(CC2)[C@@H]3C[C@H](C4=CC=CC=C34)C5=CC=C(C=C5)F
DMJ3ZUN IK GHAMYXPEZSUOCU-XZOQPEGZSA-N
DMJ3ZUN IU 1-[2-[4-[(1R,3S)-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl]ethyl]imidazolidin-2-one
DMJ3ZUN CA CAS 96478-43-2
DMJ3ZUN DE Inflammation
DMH6K7N ID DMH6K7N
DMH6K7N DN IRL-2500
DMH6K7N HS Terminated
DMH6K7N SN IRL-2500; 169545-27-1; IRL2500; CHEMBL72410; (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-(4-phenylphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid; Tocris-1838; AC1NSK6K; SCHEMBL7444422; GTPL3887; CTK8E7373; DTXSID20415511; MolPort-003-983-837; IRL 2500; ZINC1891205; BDBM50071433; AKOS024456806; NCGC00025309-02; NCGC00025309-01; RT-013358; B6872; A-360; I-190; SR-01000597543; J-010557; SR-01000597543-1; N-3-[1,1'-Biphenyl]-4-yl-N-(3,5-dimethylbenzoyl)-N-methyl-D-alanyl-L-tryptophan
DMH6K7N DT Small molecular drug
DMH6K7N PC 5311192
DMH6K7N MW 573.7
DMH6K7N FM C36H35N3O4
DMH6K7N IC InChI=1S/C36H35N3O4/c1-23-17-24(2)19-28(18-23)35(41)39(3)33(20-25-13-15-27(16-14-25)26-9-5-4-6-10-26)34(40)38-32(36(42)43)21-29-22-37-31-12-8-7-11-30(29)31/h4-19,22,32-33,37H,20-21H2,1-3H3,(H,38,40)(H,42,43)/t32-,33+/m0/s1
DMH6K7N CS CC1=CC(=CC(=C1)C(=O)N(C)[C@H](CC2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)O)C
DMH6K7N IK UZDORQWMYRRLQV-JHOUSYSJSA-N
DMH6K7N IU (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-(4-phenylphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMH6K7N CA CAS 169545-27-1
DMD6SXO ID DMD6SXO
DMD6SXO DN ISIS-1082
DMD6SXO HS Terminated
DMD6SXO SN IP-1082
DMD6SXO CP Isis Pharmaceuticals Inc
DMD6SXO DE Virus infection
DM4YJ2W ID DM4YJ2W
DM4YJ2W DN Isomazole
DM4YJ2W HS Terminated
DM4YJ2W SN Isosulmazole; Isomazole fumarate; Isomazole hydrochloride; EMD-41064; EMD-47200; EMD-50250; EMD-52750; LY-175326
DM4YJ2W CP Merck KGaA
DM4YJ2W DT Small molecular drug
DM4YJ2W PC 55690
DM4YJ2W MW 287.34
DM4YJ2W FM C14H13N3O2S
DM4YJ2W IC InChI=1S/C14H13N3O2S/c1-19-13-7-9(20(2)18)3-4-10(13)14-16-11-5-6-15-8-12(11)17-14/h3-8H,1-2H3,(H,16,17)
DM4YJ2W CS COC1=C(C=CC(=C1)S(=O)C)C2=NC3=C(N2)C=NC=C3
DM4YJ2W IK JQUKCPUPFALELS-UHFFFAOYSA-N
DM4YJ2W IU 2-(2-methoxy-4-methylsulfinylphenyl)-3H-imidazo[4,5-c]pyridine
DM4YJ2W CA CAS 86315-52-8
DM4YJ2W CB CHEBI:91691
DM4YJ2W DE Asthma
DMU5TGC ID DMU5TGC
DMU5TGC DN JSM-10292
DMU5TGC HS Terminated
DMU5TGC SN Bradykinin B2 receptor antagonist (pain/inflammation), Jerini
DMU5TGC CP Jerini AG
DMU5TGC DT Small molecular drug
DMU5TGC PC 25019714
DMU5TGC MW 519.5
DMU5TGC FM C28H24F3N5O2
DMU5TGC IC InChI=1S/C28H24F3N5O2/c1-16-9-10-32-23(14-36-11-5-7-22(27(36)37)28(29,30)31)21(16)15-38-24-8-4-6-19-20(12-18(3)34-26(19)24)25-17(2)13-33-35-25/h4-13H,14-15H2,1-3H3,(H,33,35)
DMU5TGC CS CC1=C(C(=NC=C1)CN2C=CC=C(C2=O)C(F)(F)F)COC3=CC=CC4=C(C=C(N=C43)C)C5=C(C=NN5)C
DMU5TGC IK KFVOKCIYVVCZGF-UHFFFAOYSA-N
DMU5TGC IU 1-[[4-methyl-3-[[2-methyl-4-(4-methyl-1H-pyrazol-5-yl)quinolin-8-yl]oxymethyl]pyridin-2-yl]methyl]-3-(trifluoromethyl)pyridin-2-one
DMU5TGC CA CAS 1064674-16-3
DMU5TGC DE Pain
DMG7B61 ID DMG7B61
DMG7B61 DN JTP-2724
DMG7B61 HS Terminated
DMG7B61 SN JTP-3072; JTP-4129
DMG7B61 CP Japan Tobacco Inc
DMG7B61 DE Hypertension
DM6TXKR ID DM6TXKR
DM6TXKR DN JTP-4761
DM6TXKR HS Terminated
DM6TXKR SN JTV-505
DM6TXKR CP Japan Tobacco Inc
DM6TXKR DE Hypertension
DM48HVI ID DM48HVI
DM48HVI DN JTT-551
DM48HVI HS Terminated
DM48HVI CP Japan Tobacco Inc
DM48HVI PC 23080446
DM48HVI MW 605.9
DM48HVI FM C34H43N3O3S2
DM48HVI IC InChI=1S/C34H43N3O3S2/c1-6-8-25(9-7-2)26-14-16-28(17-15-26)40-22-24-10-12-27(13-11-24)29-23-41-32(36-29)20-37(21-33(38)39)19-31-35-18-30(42-31)34(3,4)5/h10-18,23,25H,6-9,19-22H2,1-5H3,(H,38,39)
DM48HVI CS CCCC(CCC)C1=CC=C(C=C1)OCC2=CC=C(C=C2)C3=CSC(=N3)CN(CC4=NC=C(S4)C(C)(C)C)CC(=O)O
DM48HVI IK FKGBFRNVTCFMGU-UHFFFAOYSA-N
DM48HVI IU 2-[(5-tert-butyl-1,3-thiazol-2-yl)methyl-[[4-[4-[(4-heptan-4-ylphenoxy)methyl]phenyl]-1,3-thiazol-2-yl]methyl]amino]acetic acid
DM48HVI DE Type-2 diabetes
DMZBNHC ID DMZBNHC
DMZBNHC DN JTT-608
DMZBNHC HS Terminated
DMZBNHC SN Trans-4-(4-Methylcyclohexyl)-4-oxobutanoic acid
DMZBNHC DT Small molecular drug
DMZBNHC PC 6919096
DMZBNHC MW 198.26
DMZBNHC FM C11H18O3
DMZBNHC IC InChI=1S/C11H18O3/c1-8-2-4-9(5-3-8)10(12)6-7-11(13)14/h8-9H,2-7H2,1H3,(H,13,14)
DMZBNHC CS CC1CCC(CC1)C(=O)CCC(=O)O
DMZBNHC IK JOWMTYWOBJALGB-UHFFFAOYSA-N
DMZBNHC IU 4-(4-methylcyclohexyl)-4-oxobutanoic acid
DMZBNHC CA CAS 195137-72-5
DMZBNHC DE Diabetic complication
DM89TXB ID DM89TXB
DM89TXB DN JTV-605
DM89TXB HS Terminated
DM89TXB SN CHEMBL430083; BDBM50137940; L001683; Biphenyl-2-carboxylic acid [2-[4-(4-dimethylamino-piperidin-1-yl)-4-oxo-butoxy]-4-(5,6,7,8-tetrahydro-thieno[3,2-b]azepine-4-carbonyl)-phenyl]-amide
DM89TXB DT Small molecular drug
DM89TXB PC 9939929
DM89TXB MW 664.9
DM89TXB FM C39H44N4O4S
DM89TXB IC InChI=1S/C39H44N4O4S/c1-41(2)30-19-23-42(24-20-30)37(44)16-10-25-47-35-27-29(39(46)43-22-9-8-15-36-34(43)21-26-48-36)17-18-33(35)40-38(45)32-14-7-6-13-31(32)28-11-4-3-5-12-28/h3-7,11-14,17-18,21,26-27,30H,8-10,15-16,19-20,22-25H2,1-2H3,(H,40,45)
DM89TXB CS CN(C)C1CCN(CC1)C(=O)CCCOC2=C(C=CC(=C2)C(=O)N3CCCCC4=C3C=CS4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6
DM89TXB IK LKUCMBNAHQWPJK-UHFFFAOYSA-N
DM89TXB IU N-[2-[4-[4-(dimethylamino)piperidin-1-yl]-4-oxobutoxy]-4-(5,6,7,8-tetrahydrothieno[3,2-b]azepine-4-carbonyl)phenyl]-2-phenylbenzamide
DM89TXB DE Dysmenorrhea
DM0MXWC ID DM0MXWC
DM0MXWC DN KA-398
DM0MXWC HS Terminated
DM0MXWC SN Scopinast; Scopinast, Wilmar Schwabe
DM0MXWC CP Dr Willmar Schwabe GmbH & Co
DM0MXWC DE Asthma
DM2LFYD ID DM2LFYD
DM2LFYD DN KB-5246
DM2LFYD HS Terminated
DM2LFYD SN 9,1-Epoxymethano-7-fluoro-8-(4-methyl-1-piperazinyl)-5-oxo-5H-thiazolo[3,2-a]quinoline-4-carboxylic acid hydrochloride
DM2LFYD DT Small molecular drug
DM2LFYD PC 6918093
DM2LFYD MW 425.9
DM2LFYD FM C18H17ClFN3O4S
DM2LFYD IC InChI=1S/C18H16FN3O4S.ClH/c1-20-2-4-21(5-3-20)14-11(19)6-10-13-16(14)26-7-9-8-27-17(22(9)13)12(15(10)23)18(24)25;/h6,8H,2-5,7H2,1H3,(H,24,25);1H
DM2LFYD CS CN1CCN(CC1)C2=C(C=C3C4=C2OCC5=CSC(=C(C3=O)C(=O)O)N54)F.Cl
DM2LFYD IK YNPLQSCXSPGFPU-UHFFFAOYSA-N
DM2LFYD IU 6-fluoro-5-(4-methylpiperazin-1-yl)-9-oxo-3-oxa-12-thia-14-azatetracyclo[6.5.2.04,15.011,14]pentadeca-1(13),4(15),5,7,10-pentaene-10-carboxylic acid;hydrochloride
DM2LFYD DE Bacterial infection
DMM7S3V ID DMM7S3V
DMM7S3V DN KB-5359
DMM7S3V HS Terminated
DMM7S3V SN KB-3495; Selective thyroid hormone agonists (TR STAD, dyslipidemia), Karo Bio
DMM7S3V CP Karo Bio AB
DMM7S3V DE Lipid metabolism disorder
DM3H90W ID DM3H90W
DM3H90W DN KC-11404
DM3H90W HS Terminated
DM3H90W CP Solvay Deutschland GmbH
DM3H90W DE Asthma
DMC295V ID DMC295V
DMC295V DN KC-11425
DMC295V HS Terminated
DMC295V CP Solvay Pharmaceuticals Inc
DMC295V DE Asthma
DMD0FNH ID DMD0FNH
DMD0FNH DN KC-399
DMD0FNH HS Terminated
DMD0FNH SN KC-399; 152661-13-7; 2H-1-Benzopyran-4-carbothioamide,N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-nitro-; LKUDLWNQCZSCQW-UHFFFAOYSA-N; ACMC-20n6i6; SCHEMBL8314846; CHEMBL291410; CTK4C7529
DMD0FNH CP Chugai Pharmaceutical Co Ltd
DMD0FNH DT Small molecular drug
DMD0FNH PC 9863361
DMD0FNH MW 353.3
DMD0FNH FM C15H13F2N3O3S
DMD0FNH IC InChI=1S/C15H13F2N3O3S/c16-8-15(9-17)7-12(14(24)19-5-1-4-18)11-6-10(20(21)22)2-3-13(11)23-15/h2-3,6-7H,1,5,8-9H2,(H,19,24)
DMD0FNH CS C1=CC2=C(C=C1[N+](=O)[O-])C(=CC(O2)(CF)CF)C(=S)NCCC#N
DMD0FNH IK LKUDLWNQCZSCQW-UHFFFAOYSA-N
DMD0FNH IU N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-nitrochromene-4-carbothioamide
DMD0FNH DE Alopecia
DMNZ1LR ID DMNZ1LR
DMNZ1LR DN KF-15766
DMNZ1LR HS Terminated
DMNZ1LR CP Kyowa Hakko Kogyo Co Ltd
DMNZ1LR DE Allergy
DMQXPJB ID DMQXPJB
DMQXPJB DN Ki-1769
DMQXPJB HS Terminated
DMQXPJB SN Ki-1769; Ki 1769; AC1L2ZHG; ki1769; SCHEMBL9214494; SCHEMBL6377119; CHEMBL310746; SUPZSNPDPSPMTK-UHFFFAOYSA-N; N-CYANO-N'-(2-PHENYLETHYL)-3-PYRIDINECARBOXIMIDAMIDE; N-cyano-N'-phenethylpyridine-3-carboximidamide; 3-Pyridinecarboximidamide, N-cyano-N'-(2-phenylethyl)-
DMQXPJB CP Kirin Brewery Co Ltd
DMQXPJB DT Small molecular drug
DMQXPJB PC 131608
DMQXPJB MW 250.3
DMQXPJB FM C15H14N4
DMQXPJB IC InChI=1S/C15H14N4/c16-12-19-15(14-7-4-9-17-11-14)18-10-8-13-5-2-1-3-6-13/h1-7,9,11H,8,10H2,(H,18,19)
DMQXPJB CS C1=CC=C(C=C1)CCN=C(C2=CN=CC=C2)NC#N
DMQXPJB IK SUPZSNPDPSPMTK-UHFFFAOYSA-N
DMQXPJB IU N-cyano-N'-(2-phenylethyl)pyridine-3-carboximidamide
DMQXPJB CA CAS 133300-00-2
DMQXPJB DE Hypertension
DMXZNB2 ID DMXZNB2
DMXZNB2 DN KNI-102
DMXZNB2 HS Terminated
DMXZNB2 SN Kni-102; Kni 102; 139694-65-8; Rpi 312; CHEBI:80005; AHPBA 1a; Z-Asn-apns-pro-NH-t-but; RPI-312; Cbz-Asn-Apns-Pro-NH-tBu; AC1Q5L2D; BDBM4215; AC1L22E8; SCHEMBL2771668; Z-Asparaginyl-allophenylnorstatinyl-t-butylproline amide; CHEMBL3349847; DTXSID70161152; 1-(3-(N-alpha-Benzyloxycarbonyl-L-asparaginyl)amino-2-hydroxy-4-phenylbutyryl)-N-tert-butyl-L-prolinamide; C15654; benzyl N-[(2S)-4-amino-1-[[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamate
DMXZNB2 CP Japan Energy Corp
DMXZNB2 DT Small molecular drug
DMXZNB2 PC 65004
DMXZNB2 MW 595.7
DMXZNB2 FM C31H41N5O7
DMXZNB2 IC InChI=1S/C31H41N5O7/c1-31(2,3)35-28(40)24-15-10-16-36(24)29(41)26(38)22(17-20-11-6-4-7-12-20)33-27(39)23(18-25(32)37)34-30(42)43-19-21-13-8-5-9-14-21/h4-9,11-14,22-24,26,38H,10,15-19H2,1-3H3,(H2,32,37)(H,33,39)(H,34,42)(H,35,40)/t22-,23-,24-,26-/m0/s1
DMXZNB2 CS CC(C)(C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)OCC3=CC=CC=C3)O
DMXZNB2 IK XCVUOCMQYKSJJR-IGRGDXOOSA-N
DMXZNB2 IU benzyl N-[(2S)-4-amino-1-[[(2S,3S)-4-[(2S)-2-(tert-butylcarbamoyl)pyrrolidin-1-yl]-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamate
DMXZNB2 CA CAS 139694-65-8
DMXZNB2 CB CHEBI:80005
DMXZNB2 DE Human immunodeficiency virus infection
DMXT2SL ID DMXT2SL
DMXT2SL DN KRG-3332
DMXT2SL HS Terminated
DMXT2SL SN Pivalic acid 3-[7-carbamoyl-5-[2(R)-[2-(2-ethoxyphenoxy)ethylamino]propyl]-1H-indol-1-yl]propyl ester hydrochloride
DMXT2SL DE Glaucoma/ocular hypertension
DM2L0VF ID DM2L0VF
DM2L0VF DN KRH-2731
DM2L0VF HS Terminated
DM2L0VF CP Kureha
DM2L0VF DE Human immunodeficiency virus infection
DM4QHNG ID DM4QHNG
DM4QHNG DN KRI-1314
DM4QHNG HS Terminated
DM4QHNG SN CHEMBL3350322; Kri-1314; CHEMBL91826; 4-Cyclohexyl-2-hydroxy-3-[3-(1H-imidazol-4-yl)-2-(4-morpholin-4-yl-2-naphthalen-1-ylmethyl-4-oxo-butyrylamino)-propionylamino]-butyric acid isopropyl ester; BDBM50012951; (2R,3S)-3-[N-[(2R)-3-(Morpholinocarbonyl)-2-[(naphthalen-1-yl)methyl]propionyl]-L-histidyl]amino-4-cyclohexyl-2-hydroxybutanoic acid isopropyl ester
DM4QHNG CP Kissei Pharmaceutical Co Ltd
DM4QHNG DT Small molecular drug
DM4QHNG PC 5492607
DM4QHNG MW 689.8
DM4QHNG FM C38H51N5O7
DM4QHNG IC InChI=1S/C38H51N5O7/c1-25(2)50-38(48)35(45)32(19-26-9-4-3-5-10-26)41-37(47)33(22-30-23-39-24-40-30)42-36(46)29(21-34(44)43-15-17-49-18-16-43)20-28-13-8-12-27-11-6-7-14-31(27)28/h6-8,11-14,23-26,29,32-33,35,45H,3-5,9-10,15-22H2,1-2H3,(H,39,40)(H,41,47)(H,42,46)/t29-,32?,33+,35?/m1/s1
DM4QHNG CS CC(C)OC(=O)C(C(CC1CCCCC1)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=CC4=CC=CC=C43)CC(=O)N5CCOCC5)O
DM4QHNG IK NQXSBCTYTMQGGJ-GBDGZKRDSA-N
DM4QHNG IU propan-2-yl 4-cyclohexyl-2-hydroxy-3-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2R)-4-morpholin-4-yl-2-(naphthalen-1-ylmethyl)-4-oxobutanoyl]amino]propanoyl]amino]butanoate
DM4QHNG CA CAS 128053-53-2
DM4QHNG DE Hypertension
DMVZSAM ID DMVZSAM
DMVZSAM DN KRP-105
DMVZSAM HS Terminated
DMVZSAM CP Kyorin Pharmaceutical Co Ltd
DMVZSAM DE Lipid metabolism disorder
DM8VMJ3 ID DM8VMJ3
DM8VMJ3 DN KT-95
DM8VMJ3 HS Terminated
DM8VMJ3 SN KT-90
DM8VMJ3 CP Toho Chemical Industry Co
DM8VMJ3 PC 102002354
DM8VMJ3 MW 439.5
DM8VMJ3 FM C24H25NO5S
DM8VMJ3 IC InChI=1S/C24H25NO5S/c1-12(26)29-17-7-5-15-19-22(17)30-23-18(31-13(2)27)8-6-16-20(21(15)28)25(11-14-3-4-14)10-9-24(16,19)23/h5-8,14,16,18,20,23H,3-4,9-11H2,1-2H3/t16-,18+,20-,23-,24-/m0/s1
DM8VMJ3 CS CC(=O)OC1=C2C3=C(C=C1)C(=O)[C@@H]4[C@H]5[C@]3(CCN4CC6CC6)[C@@H](O2)[C@@H](C=C5)SC(=O)C
DM8VMJ3 IK JALSXEHOWOEHCB-SDAQKBEVSA-N
DM8VMJ3 IU [(4S,4aR,7R,7aR,12bS)-7-acetylsulfanyl-3-(cyclopropylmethyl)-13-oxo-1,2,4,4a,7,7a-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl] acetate
DM8VMJ3 DE Inflammatory bowel disease
DMS2KEG ID DMS2KEG
DMS2KEG DN KW-3433
DMS2KEG HS Terminated
DMS2KEG SN CHEMBL433895; BDBM50049200
DMS2KEG CP Kyowa Hakko Kogyo Co Ltd
DMS2KEG DT Small molecular drug
DMS2KEG PC 44373246
DMS2KEG MW 435.5
DMS2KEG FM C26H25N7
DMS2KEG IC InChI=1S/C26H25N7/c1-4-24-28-25-15(2)11-16(3)27-26(25)33(24)14-17-9-10-20-18-7-5-6-8-19(18)22(21(20)12-17)13-23-29-31-32-30-23/h5-12,22H,4,13-14H2,1-3H3,(H,29,30,31,32)
DMS2KEG CS CCC1=NC2=C(N1CC3=CC4=C(C=C3)C5=CC=CC=C5C4CC6=NNN=N6)N=C(C=C2C)C
DMS2KEG IK DYYWUYUUDYPWON-UHFFFAOYSA-N
DMS2KEG IU 2-ethyl-5,7-dimethyl-3-[[9-(2H-tetrazol-5-ylmethyl)-9H-fluoren-2-yl]methyl]imidazo[4,5-b]pyridine
DMS2KEG DE Hypertension
DMQ4LDB ID DMQ4LDB
DMQ4LDB DN L-158809
DMQ4LDB HS Terminated
DMQ4LDB SN 2-Ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine; CHEMBL7550; 133240-46-7; 2-Ethyl-5,7-dimethyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)imidazo(4,5-b)pyridine; YFWXFHNZGKNDBC-UHFFFAOYSA-N; 2-ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine; [3H]L158809; [3H]-L158809; AC1L4CB2; [3H]L-158,809; SCHEMBL683357; GTPL3939; BDBM50009718; 3H-Imidazo(4,5-b)pyridine, 2-ethyl-5,7-dimethyl-3-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; LS-193980; L004397
DMQ4LDB DT Small molecular drug
DMQ4LDB PC 183134
DMQ4LDB MW 409.5
DMQ4LDB FM C24H23N7
DMQ4LDB IC InChI=1S/C24H23N7/c1-4-21-26-22-15(2)13-16(3)25-24(22)31(21)14-17-9-11-18(12-10-17)19-7-5-6-8-20(19)23-27-29-30-28-23/h5-13H,4,14H2,1-3H3,(H,27,28,29,30)
DMQ4LDB CS CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N=C(C=C2C)C
DMQ4LDB IK YFWXFHNZGKNDBC-UHFFFAOYSA-N
DMQ4LDB IU 2-ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
DMQ4LDB CA CAS 133240-46-7
DMQ4LDB DE Hypertension
DM9JE7Y ID DM9JE7Y
DM9JE7Y DN L-159689
DM9JE7Y HS Terminated
DM9JE7Y SN L-159689; CHEMBL302102; SCHEMBL8852212; BDBM82433; L-159,689
DM9JE7Y DT Small molecular drug
DM9JE7Y PC 9851889
DM9JE7Y MW 611.7
DM9JE7Y FM C37H37N7O2
DM9JE7Y IC InChI=1S/C37H37N7O2/c1-3-5-11-23-43(36(45)28-13-7-6-8-14-28)29-21-22-33-32(24-29)37(46)44(34(38-33)12-4-2)25-26-17-19-27(20-18-26)30-15-9-10-16-31(30)35-39-41-42-40-35/h6-10,13-22,24H,3-5,11-12,23,25H2,1-2H3,(H,39,40,41,42)
DM9JE7Y CS CCCCCN(C1=CC2=C(C=C1)N=C(N(C2=O)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)CCC)C(=O)C6=CC=CC=C6
DM9JE7Y IK JQXJNTQZCWEHKS-UHFFFAOYSA-N
DM9JE7Y IU N-[4-oxo-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]-N-pentylbenzamide
DM9JE7Y DE Hypertension
DMYSEBK ID DMYSEBK
DMYSEBK DN L-162234
DMYSEBK HS Terminated
DMYSEBK SN CHEMBL292150; L-162234; SCHEMBL9377635; IVFMKMCSJZZCKV-UHFFFAOYSA-N; BDBM50035451; L008869; 5-n-Butyl-4-[[2''-[N-(tert-butoxycarbonyl)sulfamoyl]biphenyl-4yl]methyl]-2-[2-trifluoromethyl-phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one; 4''-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid amide-N-carbonyoxylterbutyl; 4''-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid (2-tert-butoxycarbonyl)amide
DMYSEBK DT Small molecular drug
DMYSEBK PC 9830680
DMYSEBK MW 630.7
DMYSEBK FM C31H33F3N4O5S
DMYSEBK IC InChI=1S/C31H33F3N4O5S/c1-5-6-15-27-35-38(25-13-9-8-12-24(25)31(32,33)34)29(40)37(27)20-21-16-18-22(19-17-21)23-11-7-10-14-26(23)44(41,42)36-28(39)43-30(2,3)4/h7-14,16-19H,5-6,15,20H2,1-4H3,(H,36,39)
DMYSEBK CS CCCCC1=NN(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=O)OC(C)(C)C)C4=CC=CC=C4C(F)(F)F
DMYSEBK IK IVFMKMCSJZZCKV-UHFFFAOYSA-N
DMYSEBK IU tert-butyl N-[2-[4-[[3-butyl-5-oxo-1-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonylcarbamate
DMYB5RV ID DMYB5RV
DMYB5RV DN L-163017
DMYB5RV HS Terminated
DMYB5RV SN L-163017; CHEMBL160494; SCHEMBL6556686; BDBM50049203; L000330
DMYB5RV CP Merck & Co Inc
DMYB5RV DT Small molecular drug
DMYB5RV PC 9895877
DMYB5RV MW 653.8
DMYB5RV FM C36H39N5O5S
DMYB5RV IC InChI=1S/C36H39N5O5S/c1-5-11-32-39-33-25(4)30(38-35(42)28-12-7-6-8-13-28)22-37-34(33)41(32)23-26-16-18-27(19-17-26)29-14-9-10-15-31(29)47(44,45)40-36(43)46-21-20-24(2)3/h6-10,12-19,22,24H,5,11,20-21,23H2,1-4H3,(H,38,42)(H,40,43)
DMYB5RV CS CCCC1=NC2=C(C(=CN=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC(=O)OCCC(C)C)NC(=O)C5=CC=CC=C5)C
DMYB5RV IK WGFOETKPMPCUOG-UHFFFAOYSA-N
DMYB5RV IU 3-methylbutyl N-[2-[4-[(6-benzamido-7-methyl-2-propylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenyl]sulfonylcarbamate
DMYB5RV DE Hypertension
DMCRQTH ID DMCRQTH
DMCRQTH DN L-371257
DMCRQTH HS Terminated
DMCRQTH SN 162042-44-6; L-371257; L-371,257; CHEMBL24781; L 371257; 1-[1-[4-(1-acetylpiperidin-4-yl)oxy-2-methoxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one; AC1OCFAC; NCGC00159562-01; SCHEMBL4954712; GTPL2252; CTK8E8747; DTXSID30426072; MolPort-023-276-417; ZINC3824080; BDBM50029649; ABP001011; AKOS024457081; API0009977; KB-78045; 1-[4-[(1-ACETYL-4-PIPERIDINYL)OXY]-2-METHOXYBENZOYL]-4-(2-OXO-2H-3,1-BENZOXAZIN-1(4H)-YL)PIPERIDINE; RT-013479; B7045; L014161; L371,257
DMCRQTH DT Small molecular drug
DMCRQTH PC 6918320
DMCRQTH MW 507.6
DMCRQTH FM C28H33N3O6
DMCRQTH IC InChI=1S/C28H33N3O6/c1-19(32)29-15-11-22(12-16-29)37-23-7-8-24(26(17-23)35-2)27(33)30-13-9-21(10-14-30)31-25-6-4-3-5-20(25)18-36-28(31)34/h3-8,17,21-22H,9-16,18H2,1-2H3
DMCRQTH CS CC(=O)N1CCC(CC1)OC2=CC(=C(C=C2)C(=O)N3CCC(CC3)N4C5=CC=CC=C5COC4=O)OC
DMCRQTH IK WDERJSQJYIJOPD-UHFFFAOYSA-N
DMCRQTH IU 1-[1-[4-(1-acetylpiperidin-4-yl)oxy-2-methoxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one
DMCRQTH CA CAS 162042-44-6
DMOKZ2V ID DMOKZ2V
DMOKZ2V DN L-373890
DMOKZ2V HS Terminated
DMOKZ2V CP Merck & Co Inc
DMOKZ2V DE Thrombosis
DMK2QW0 ID DMK2QW0
DMK2QW0 DN L-374,087
DMK2QW0 HS Terminated
DMK2QW0 DE Thrombosis
DMTKCNJ ID DMTKCNJ
DMTKCNJ DN L-648051
DMTKCNJ HS Terminated
DMTKCNJ SN 4-Apsob; L-648051; L 648051; UNII-0LGZ40MB45; 0LGZ40MB45; 91541-18-3; 4-((3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxobenzenebutanoic acid; 4-(4-{[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]sulfonyl}phenyl)-4-oxobutanoic acid; Benzenebutanoic acid, 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma-oxo-; AC1Q5VP2; AC1L3TT7; SCHEMBL157166; CHEMBL282253; CTK8D5118; DTXSID50238619; ZAKKEARLDPTRLX-UHFFFAOYSA-N; AKOS030530731; LS-186850; LS-187510
DMTKCNJ CP Merck & Co Inc
DMTKCNJ DT Small molecular drug
DMTKCNJ PC 122010
DMTKCNJ MW 476.5
DMTKCNJ FM C24H28O8S
DMTKCNJ IC InChI=1S/C24H28O8S/c1-3-5-20-22(12-10-19(16(2)25)24(20)29)32-14-4-15-33(30,31)18-8-6-17(7-9-18)21(26)11-13-23(27)28/h6-10,12,29H,3-5,11,13-15H2,1-2H3,(H,27,28)
DMTKCNJ CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCS(=O)(=O)C2=CC=C(C=C2)C(=O)CCC(=O)O
DMTKCNJ IK ZAKKEARLDPTRLX-UHFFFAOYSA-N
DMTKCNJ IU 4-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl]phenyl]-4-oxobutanoic acid
DMTKCNJ CA CAS 91541-18-3
DMTKCNJ DE Asthma
DMGX3MK ID DMGX3MK
DMGX3MK DN L-655240
DMGX3MK HS Terminated
DMGX3MK SN L-655,240; 103253-15-2; L-655240; L 655240; CHEMBL362223; 3-[1-(4-Chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]-2,2-dimethyl propanoic acid; 1-((4-chlorophenyl)methyl)-5-fluoro-a,a-3-trimethyl-(1h)-indole-2-propanoic acid; SR-01000075967; JLPYLHLUHJOPNL-UHFFFAOYSA-N; Tocris-1698; Lopac-L-9539; AC1L3TX4; Lopac0_000670; SCHEMBL3252820; CHEBI:93563; CTK8E8278; MolPort-003-958-591; HMS3268O17; ZINC2526554; BDBM50168772; AKOS024456751; CCG-204756; 3-(1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl)-2,2-dimethylpropanoic acid
DMGX3MK DT Small molecular drug
DMGX3MK PC 122070
DMGX3MK MW 373.8
DMGX3MK FM C21H21ClFNO2
DMGX3MK IC InChI=1S/C21H21ClFNO2/c1-13-17-10-16(23)8-9-18(17)24(12-14-4-6-15(22)7-5-14)19(13)11-21(2,3)20(25)26/h4-10H,11-12H2,1-3H3,(H,25,26)
DMGX3MK CS CC1=C(N(C2=C1C=C(C=C2)F)CC3=CC=C(C=C3)Cl)CC(C)(C)C(=O)O
DMGX3MK IK JLPYLHLUHJOPNL-UHFFFAOYSA-N
DMGX3MK IU 3-[1-[(4-chlorophenyl)methyl]-5-fluoro-3-methylindol-2-yl]-2,2-dimethylpropanoic acid
DMGX3MK CA CAS 103253-15-2
DMGX3MK CB CHEBI:93563
DMOTY3G ID DMOTY3G
DMOTY3G DN L-657925
DMOTY3G HS Terminated
DMOTY3G SN L-657926
DMOTY3G DT Small molecular drug
DMOTY3G PC 129772
DMOTY3G MW 373.8
DMOTY3G FM C21H21ClFNO2
DMOTY3G IC InChI=1S/C21H21ClFNO2/c22-15-6-4-13(5-7-15)12-24-19-9-8-16(23)11-18(19)17-3-1-2-14(21(17)24)10-20(25)26/h4-9,11,14,17,21H,1-3,10,12H2,(H,25,26)
DMOTY3G CS C1CC(C2C(C1)C3=C(N2CC4=CC=C(C=C4)Cl)C=CC(=C3)F)CC(=O)O
DMOTY3G IK USFMJLOJQLMDAA-UHFFFAOYSA-N
DMOTY3G IU 2-[9-[(4-chlorophenyl)methyl]-6-fluoro-1,2,3,4,4a,9a-hexahydrocarbazol-1-yl]acetic acid
DMOTY3G CA CAS 122757-59-9
DMLENQ7 ID DMLENQ7
DMLENQ7 DN L-659989
DMLENQ7 HS Terminated
DMLENQ7 SN L-659989; 113787-28-3; L-659,989; L659989; L 659989; CHEMBL37781; SCHEMBL6154076; GTPL3426; DTXSID70433028; BDBM50002829; ZINC13650944; FT-0670693; L-662,418; L-659,989, (+); (2S,5S)-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane; (2R,5R)-rel-Tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan; trans-( inverted exclamation markA)-Tetrahydro-2-[3-methoxy-5-(methylsulfonyl)-4-propoxyphenyl]-5-(3,4,5-trimethoxyphenyl)furan
DMLENQ7 DT Small molecular drug
DMLENQ7 PC 9934870
DMLENQ7 MW 480.6
DMLENQ7 FM C24H32O8S
DMLENQ7 IC InChI=1S/C24H32O8S/c1-7-10-31-24-21(29-4)13-16(14-22(24)33(6,25)26)18-9-8-17(32-18)15-11-19(27-2)23(30-5)20(12-15)28-3/h11-14,17-18H,7-10H2,1-6H3/t17-,18-/m0/s1
DMLENQ7 CS CCCOC1=C(C=C(C=C1S(=O)(=O)C)[C@@H]2CC[C@H](O2)C3=CC(=C(C(=C3)OC)OC)OC)OC
DMLENQ7 IK NZWPFJNQOZFEDT-ROUUACIJSA-N
DMLENQ7 IU (2S,5S)-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)oxolane
DMLENQ7 CA CAS 113787-28-3
DM56VPY ID DM56VPY
DM56VPY DN L-687414
DM56VPY HS Terminated
DM56VPY SN (3R,4R)-3-Amino-1-hydroxy-4-methylpyrrolidin-2-one; 130931-65-6; L-687414; CHEMBL283819; 132619-43-3; cis-3-amino-1-hydroxy-4-methylpyrrolidin-2-one; SCHEMBL561932; DTXSID00437953; SKYSFPFYQBZGDC-QWWZWVQMSA-N; ZINC3805040; BDBM50038169; AKOS006239328; KB-78073; AJ-45657; 3-Amino-1-hydroxy-4-methyl-pyrrolidin-2-one; r(+)-cis-beta-methyl-3-amino-1-hydroxypyrrolid-2-one
DM56VPY DT Small molecular drug
DM56VPY PC 10313147
DM56VPY MW 130.15
DM56VPY FM C5H10N2O2
DM56VPY IC InChI=1S/C5H10N2O2/c1-3-2-7(9)5(8)4(3)6/h3-4,9H,2,6H2,1H3/t3-,4-/m1/s1
DM56VPY CS C[C@@H]1CN(C(=O)[C@@H]1N)O
DM56VPY IK SKYSFPFYQBZGDC-QWWZWVQMSA-N
DM56VPY IU (3R,4R)-3-amino-1-hydroxy-4-methylpyrrolidin-2-one
DM56VPY CA CAS 130931-65-6
DMCVY4U ID DMCVY4U
DMCVY4U DN L-689560
DMCVY4U HS Terminated
DMCVY4U SN trans-2-Carboxy-5,7-dichloro-4-(((phenylamino)carbonyl)amino)-1,2,3,4-tetrahydroquinoline; C17H15Cl2N3O3; L 689560; L-689,560; 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline; 139051-78-8; (2S,4R)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 2-Quinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-4-(((phenylamino)carbonyl)amino)-, trans-(+-)-; [3H]L689560; AC1L3TN7; SCHEMBL193615; GTPL4239; GTPL4086; ZINC2567729; compound 35
DMCVY4U CP Merck & Co Inc
DMCVY4U DT Small molecular drug
DMCVY4U PC 121918
DMCVY4U MW 380.2
DMCVY4U FM C17H15Cl2N3O3
DMCVY4U IC InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25)/t13-,14+/m1/s1
DMCVY4U CS C1[C@H](C2=C(C=C(C=C2Cl)Cl)N[C@@H]1C(=O)O)NC(=O)NC3=CC=CC=C3
DMCVY4U IK UCKHICKHGAOGAP-KGLIPLIRSA-N
DMCVY4U IU (2S,4R)-5,7-dichloro-4-(phenylcarbamoylamino)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
DMCVY4U CA CAS 139051-78-8
DMCVY4U DE Neurodegenerative disorder
DM2F4GT ID DM2F4GT
DM2F4GT DN L-694247
DM2F4GT HS Terminated
DM2F4GT SN 137403-12-4; L-694,247; N-(4-((5-(3-(2-Aminoethyl)-1H-indol-5-yl)-1,2,4-oxadiazol-3-yl)methyl)phenyl)methanesulfonamide; L-694247; L 694247; 2-[5-[3-(4-Methylsulfonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine; N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide; Methanesulfonamide,N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]-; Tocris-0781; Biomol-NT_000112; GTPL15; AC1L30BK
DM2F4GT CP Merck & Co Inc
DM2F4GT DT Small molecular drug
DM2F4GT PC 132059
DM2F4GT MW 411.5
DM2F4GT FM C20H21N5O3S
DM2F4GT IC InChI=1S/C20H21N5O3S/c1-29(26,27)25-16-5-2-13(3-6-16)10-19-23-20(28-24-19)14-4-7-18-17(11-14)15(8-9-21)12-22-18/h2-7,11-12,22,25H,8-10,21H2,1H3
DM2F4GT CS CS(=O)(=O)NC1=CC=C(C=C1)CC2=NOC(=N2)C3=CC4=C(C=C3)NC=C4CCN
DM2F4GT IK HKXMQLISPYELRD-UHFFFAOYSA-N
DM2F4GT IU N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide
DM2F4GT CA CAS 137403-12-4
DM2F4GT CB CHEBI:92341
DM2F4GT DE Migraine
DMT1DNS ID DMT1DNS
DMT1DNS DN L-695902
DMT1DNS HS Terminated
DMT1DNS SN L-695902; CHEMBL104297; SCHEMBL8018550; AKOS022507211; methyl 7-chloro-2,4-dihydroxy-3-quinolinecarboxylate; methyl 7-chloro-2,4-dihydroxyquinoline-3-carboxylate
DMT1DNS DT Small molecular drug
DMT1DNS PC 54695867
DMT1DNS MW 253.64
DMT1DNS FM C11H8ClNO4
DMT1DNS IC InChI=1S/C11H8ClNO4/c1-17-11(16)8-9(14)6-3-2-5(12)4-7(6)13-10(8)15/h2-4H,1H3,(H2,13,14,15)
DMT1DNS CS COC(=O)C1=C(C2=C(C=C(C=C2)Cl)NC1=O)O
DMT1DNS IK GEUWRNTWGHPTPU-UHFFFAOYSA-N
DMT1DNS IU methyl 7-chloro-4-hydroxy-2-oxo-1H-quinoline-3-carboxylate
DMV785R ID DMV785R
DMV785R DN L-696418
DMV785R HS Terminated
DMV785R SN CHEMBL8494; L-696418; BDBM50057083; (R)-2-[(S)-1-(3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid; (R)-2-((S)-1-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylamino)-1-oxo-4-phenylbutan-2-ylamino)propanoic acid; (R)-2-[(S)-1-((S)-3-Methyl-1-phenylcarbamoyl-butylcarbamoyl)-3-phenyl-propylamino]-propionic acid
DMV785R DT Small molecular drug
DMV785R PC 10478364
DMV785R MW 439.5
DMV785R FM C25H33N3O4
DMV785R IC InChI=1S/C25H33N3O4/c1-17(2)16-22(24(30)27-20-12-8-5-9-13-20)28-23(29)21(26-18(3)25(31)32)15-14-19-10-6-4-7-11-19/h4-13,17-18,21-22,26H,14-16H2,1-3H3,(H,27,30)(H,28,29)(H,31,32)/t18-,21+,22+/m1/s1
DMV785R CS C[C@H](C(=O)O)N[C@@H](CCC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)NC2=CC=CC=C2
DMV785R IK DLCYKLDSIUJNLE-COPCDDAFSA-N
DMV785R IU (2R)-2-[[(2S)-1-[[(2S)-1-anilino-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid
DMO9HM7 ID DMO9HM7
DMO9HM7 DN L-698532
DMO9HM7 HS Terminated
DMO9HM7 SN 28563-19-1; 3-Phenyl-4-hydroxy-7-chloroquinolin-2(1H)-one; L-698532; CHEMBL31661; 7-Chloro-4-hydroxy-3-phenyl-2(1H)-quinolone; 7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone; 7-Chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one; Mdl 104,653; ZINC5910; AC1MD767; SCHEMBL1612505; CTK4G1708; DTXSID80182777; RDXQSWLUXKUQSI-UHFFFAOYSA-N; BCP18252; BDBM50041467; AKOS032961557; 7-chloro-4-hydroxy-3-phenylquinolin-2(1H)-one; 7-chloro-2-hydroxy-3-phenyl-1H-quinolin-4-one; 3-phenyl-4-hydroxy-7-chloro-quinolin-2(1h)-one
DMO9HM7 DT Small molecular drug
DMO9HM7 PC 54697468
DMO9HM7 MW 271.7
DMO9HM7 FM C15H10ClNO2
DMO9HM7 IC InChI=1S/C15H10ClNO2/c16-10-6-7-11-12(8-10)17-15(19)13(14(11)18)9-4-2-1-3-5-9/h1-8H,(H2,17,18,19)
DMO9HM7 CS C1=CC=C(C=C1)C2=C(C3=C(C=C(C=C3)Cl)NC2=O)O
DMO9HM7 IK RDXQSWLUXKUQSI-UHFFFAOYSA-N
DMO9HM7 IU 7-chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMO9HM7 CA CAS 28563-19-1
DMO9HM7 DE Neurological disorder
DMLRBN1 ID DMLRBN1
DMLRBN1 DN L-698544
DMLRBN1 HS Terminated
DMLRBN1 SN 7-Chloro-3-nitro-3,4-dihydroquinolin-2(1H)-one; 147778-05-0; 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one; 7-CHLORO-3-NITRO-3,4-DIHYDROQUINOLIN-2(1H)-ONE; CHEMBL102574; 2(1H)-Quinolinone,7-chloro-3,4-dihydro-3-nitro-; ACMC-1C9KO; SCHEMBL8271408; CTK4C5567; DTXSID50436916; BDBM50038176; 3697AJ; AKOS024260378; AB06846; AK153524; DB-063735; AX8026622; FT-0703007; Z-7553; CNDQ; 7-Chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one
DMLRBN1 CP Merck & Co Inc
DMLRBN1 DT Small molecular drug
DMLRBN1 PC 10220180
DMLRBN1 MW 226.61
DMLRBN1 FM C9H7ClN2O3
DMLRBN1 IC InChI=1S/C9H7ClN2O3/c10-6-2-1-5-3-8(12(14)15)9(13)11-7(5)4-6/h1-2,4,8H,3H2,(H,11,13)
DMLRBN1 CS C1C(C(=O)NC2=C1C=CC(=C2)Cl)[N+](=O)[O-]
DMLRBN1 IK JXGOSNKBNBJAGV-UHFFFAOYSA-N
DMLRBN1 IU 7-chloro-3-nitro-3,4-dihydro-1H-quinolin-2-one
DMLRBN1 CA CAS 147778-05-0
DMLRBN1 DE Alzheimer disease
DMAIJSX ID DMAIJSX
DMAIJSX DN L-701324
DMAIJSX HS Terminated
DMAIJSX SN L-701324; 142326-59-8; L-701,324; L 701324; UNII-I9WY146163; C21H14ClNO3; L 701,324; CHEMBL31741; 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone; I9WY146163; 7-Chloro-4-hydroxy-3-(3-pheoxyphenyl)-2(1H)-quinolinone; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-pheoxyphenyl)-; SMR000326934; compund 13 [PMID: 8182696]; Tocris-0907; AC1L3GJN; Biomol-NT_000206; MLS002153302; MLS000860076; GTPL4240; SCHEMBL1998890; BPBio1_001264; CHEBI:92140; DTXSID00162016; EX-A587; MolPort-003-941-887; 2(1H)-Quinolinone, 7-chloro-4-hydroxy-3-(3-ph
DMAIJSX DT Small molecular drug
DMAIJSX PC 54682505
DMAIJSX MW 363.8
DMAIJSX FM C21H14ClNO3
DMAIJSX IC InChI=1S/C21H14ClNO3/c22-14-9-10-17-18(12-14)23-21(25)19(20(17)24)13-5-4-8-16(11-13)26-15-6-2-1-3-7-15/h1-12H,(H2,23,24,25)
DMAIJSX CS C1=CC=C(C=C1)OC2=CC=CC(=C2)C3=C(C4=C(C=C(C=C4)Cl)NC3=O)O
DMAIJSX IK FLVRDMUHUXVRET-UHFFFAOYSA-N
DMAIJSX IU 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one
DMAIJSX CA CAS 142326-59-8
DMAIJSX CB CHEBI:92140
DMAIJSX DE Cerebrovascular ischaemia
DMO7GWC ID DMO7GWC
DMO7GWC DN L-702958
DMO7GWC HS Terminated
DMO7GWC SN L 702958; 136078-58-5; L-702958; 150576-09-3; AC1L50NP; AC1Q3EU4; SCHEMBL9227313; L-702,958; DTXSID60159644; n-{1'-[(2r)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxo-3,4-dihydrospiro[chromene-2,4'-piperidin]-6-yl}methanesulfonamide hydrochloride(1:1); N-[1'-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxospiro[3H-chromene-2,4'-piperidine]-6-yl]methanesulfonamide hydrochloride; Methanesulfonamide, N-(1'-(6-cyano-1,2,3,4-tetrahydro-2-naphthalenyl)-3,4-dihydro-4-oxospiro(2H-1-benzopyran-2,4'-piperidin)-6-yl)-,
DMO7GWC CP Merck & Co Inc
DMO7GWC DT Small molecular drug
DMO7GWC PC 195821
DMO7GWC MW 502
DMO7GWC FM C25H28ClN3O4S
DMO7GWC IC InChI=1S/C25H27N3O4S.ClH/c1-33(30,31)27-20-5-7-24-22(14-20)23(29)15-25(32-24)8-10-28(11-9-25)21-6-4-18-12-17(16-26)2-3-19(18)13-21;/h2-3,5,7,12,14,21,27H,4,6,8-11,13,15H2,1H3;1H/t21-;/m1./s1
DMO7GWC CS CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)[C@@H]4CCC5=C(C4)C=CC(=C5)C#N)CC2=O.Cl
DMO7GWC IK BASAUWFNEPUJDQ-ZMBIFBSDSA-N
DMO7GWC IU N-[1'-[(2R)-6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl]-4-oxospiro[3H-chromene-2,4'-piperidine]-6-yl]methanesulfonamide;hydrochloride
DMO7GWC CA CAS 136078-58-5
DMO7GWC DE Cardiac arrhythmias
DM47MKE ID DM47MKE
DM47MKE DN L-703014
DM47MKE HS Terminated
DM47MKE SN CHEMBL325687; BDBM50092114; 4-(1H-Indol-3-yl)-2-[2-(4-piperidin-4-yl-butyrylamino)-acetylamino]-butyric acid (L-703014)
DM47MKE DT Small molecular drug
DM47MKE PC 44343739
DM47MKE MW 428.5
DM47MKE FM C23H32N4O4
DM47MKE IC InChI=1S/C23H32N4O4/c28-21(7-3-4-16-10-12-24-13-11-16)26-15-22(29)27-20(23(30)31)9-8-17-14-25-19-6-2-1-5-18(17)19/h1-2,5-6,14,16,20,24-25H,3-4,7-13,15H2,(H,26,28)(H,27,29)(H,30,31)/t20-/m1/s1
DM47MKE CS C1CNCCC1CCCC(=O)NCC(=O)N[C@H](CCC2=CNC3=CC=CC=C32)C(=O)O
DM47MKE IK WDRKDCBKBCRZSK-HXUWFJFHSA-N
DM47MKE IU (2R)-4-(1H-indol-3-yl)-2-[[2-(4-piperidin-4-ylbutanoylamino)acetyl]amino]butanoic acid
DM47MKE DE Thrombosis
DMQZW6D ID DMQZW6D
DMQZW6D DN L-709049
DMQZW6D HS Terminated
DMQZW6D SN Ac-Yvad-cho; L-709049; 143313-51-3; Acetyl-tyrosyl-valyl-alanyl-aspartal; Caspase-1 Inhibitor I; CHEMBL37630; Ac-Tyr-Val-Ala-Asp-H; IL-1beta Converting Enzyme (ICE) Inhibitor I; acetyl-Tyr-Val-Ala-Asp-aldehyde; N-acetyl-Tyr-Val-Ala-Asp-aldehyde; (3S)-3-[(2S)-2-[(2S)-2-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]-4-oxobutanoic acid; Ac-Tyr-Val-Ala-Asp-Aldehyde; AC1NSK2K; SCHEMBL4349143; BDBM10355; MolPort-016-580-695; N-acetyl-Tyr-Val-Ala-Asp aldehyde; ZINC3915255; 1600AH; NCGC00167338-01
DMQZW6D DT Small molecular drug
DMQZW6D PC 5311139
DMQZW6D MW 492.5
DMQZW6D FM C23H32N4O8
DMQZW6D IC InChI=1S/C23H32N4O8/c1-12(2)20(23(35)24-13(3)21(33)26-16(11-28)10-19(31)32)27-22(34)18(25-14(4)29)9-15-5-7-17(30)8-6-15/h5-8,11-13,16,18,20,30H,9-10H2,1-4H3,(H,24,35)(H,25,29)(H,26,33)(H,27,34)(H,31,32)/t13-,16-,18-,20-/m0/s1
DMQZW6D CS C[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)C
DMQZW6D IK LPIARALSGDVZEP-SJVNDZIOSA-N
DMQZW6D IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
DMB3ZTI ID DMB3ZTI
DMB3ZTI DN L-709780
DMB3ZTI HS Terminated
DMB3ZTI SN CHEMBL32960; L-709780; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid
DMB3ZTI DT Small molecular drug
DMB3ZTI PC 9885190
DMB3ZTI MW 359.4
DMB3ZTI FM C19H25N3O4
DMB3ZTI IC InChI=1S/C19H25N3O4/c23-17(24)5-9-21-18(25)14-1-2-15-12-22(19(26)16(15)11-14)10-6-13-3-7-20-8-4-13/h1-2,11,13,20H,3-10,12H2,(H,21,25)(H,23,24)
DMB3ZTI CS C1CNCCC1CCN2CC3=C(C2=O)C=C(C=C3)C(=O)NCCC(=O)O
DMB3ZTI IK YAAYYZAARZCUQN-UHFFFAOYSA-N
DMB3ZTI IU 3-[[3-oxo-2-(2-piperidin-4-ylethyl)-1H-isoindole-5-carbonyl]amino]propanoic acid
DM1XBKC ID DM1XBKC
DM1XBKC DN L-731735
DM1XBKC HS Terminated
DM1XBKC SN CHEMBL2052018; L-731735; SCHEMBL2723563
DM1XBKC DT Small molecular drug
DM1XBKC PC 54041632
DM1XBKC MW 420.6
DM1XBKC FM C19H40N4O4S
DM1XBKC IC InChI=1S/C19H40N4O4S/c1-5-12(3)16(21-9-14(20)11-28)10-22-17(13(4)6-2)18(25)23-15(7-8-24)19(26)27/h12-17,21-22,24,28H,5-11,20H2,1-4H3,(H,23,25)(H,26,27)/t12-,13-,14+,15-,16+,17-/m0/s1
DM1XBKC CS CC[C@H](C)[C@@H](CN[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCO)C(=O)O)NC[C@H](CS)N
DM1XBKC IK LMTIEVNRUFAFPM-NYXISSTPSA-N
DM1XBKC IU (2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentyl]amino]-3-methylpentanoyl]amino]-4-hydroxybutanoic acid
DM1XBKC DE Solid tumour/cancer
DMVXKMF ID DMVXKMF
DMVXKMF DN L-732138
DMVXKMF HS Terminated
DMVXKMF SN L-732,138; 148451-96-1; 3,5-Bis(tfm)Bz nactrp; L-732138; 3,5-Bis(trifluoromethyl)benzyl N-acetyltryptophan; N-Acetyltryptophan 3,5-bis(trifluoromethyl)benzyl ester; L 732138; CHEMBL22870; N-Acetyl-L-trp-3,5-bistrifluoromethylbenzyl ester; L732138; N-Acetyl-L-tryptophan-3,5-bistrifluoromethylbenzyl ester; N-Acetyl-L-tryptophan 3,5-bis(trifluoromethyl)benzyl ester; [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate; AC-TRP-3,5-BIS(TRIFLUOROMETHYL)BENZYL ESTER; L-Tryptophan, N-acetyl-, (3,5-
DMVXKMF DT Small molecular drug
DMVXKMF PC 132837
DMVXKMF MW 472.4
DMVXKMF FM C22H18F6N2O3
DMVXKMF IC InChI=1S/C22H18F6N2O3/c1-12(31)30-19(8-14-10-29-18-5-3-2-4-17(14)18)20(32)33-11-13-6-15(21(23,24)25)9-16(7-13)22(26,27)28/h2-7,9-10,19,29H,8,11H2,1H3,(H,30,31)/t19-/m0/s1
DMVXKMF CS CC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMVXKMF IK BYYQYXVAWXAYQC-IBGZPJMESA-N
DMVXKMF IU [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate
DMVXKMF CA CAS 148451-96-1
DMA1NJW ID DMA1NJW
DMA1NJW DN L-733060
DMA1NJW HS Terminated
DMA1NJW SN L-733060; L 733060; 148700-85-0; L-733,060 hydrochloride; L-733061; L 733061; L 733,061; L 733,060; L-733,061; CHEMBL27006; 3-((3,5-Bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine; L-733,060; (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine; Tocris-1145; AC1L31OI; Lopac0_000752; SCHEMBL1282817; CHEBI:92286; FCDRFVCGMLUYPG-ROUUACIJSA-N; ZINC3809445; BDBM50049468; AKOS030230939; CCG-204837; API0013970; NCGC00025030-02; NCGC00025030-01; KB-78050; l733060; LS-114326; BRD-K15791587-003-01-7
DMA1NJW DT Small molecular drug
DMA1NJW PC 132846
DMA1NJW MW 403.4
DMA1NJW FM C20H19F6NO
DMA1NJW IC InChI=1S/C20H19F6NO/c21-19(22,23)15-9-13(10-16(11-15)20(24,25)26)12-28-17-7-4-8-27-18(17)14-5-2-1-3-6-14/h1-3,5-6,9-11,17-18,27H,4,7-8,12H2/t17-,18-/m0/s1
DMA1NJW CS C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMA1NJW IK FCDRFVCGMLUYPG-ROUUACIJSA-N
DMA1NJW IU (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine
DMA1NJW CA CAS 148700-85-0
DMA1NJW CB CHEBI:92286
DMYZPJU ID DMYZPJU
DMYZPJU DN L-733560
DMYZPJU HS Terminated
DMYZPJU SN AC1L4318; L 733560; Pneumocandin B0, 1-((4R,5R)-5-(2-aminoethoxy)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)
DMYZPJU CP Merck & Co Inc
DMYZPJU PC 177900
DMYZPJU MW 1092.3
DMYZPJU FM C52H85N9O16
DMYZPJU IC InChI=1S/C52H85N9O16/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(68)55-34-26-38(67)50(77-23-21-54)59-49(74)43-37(66)19-22-60(43)52(76)41(36(65)18-20-53)57-48(73)42(45(70)44(69)31-14-16-32(63)17-15-31)58-47(72)35-25-33(64)27-61(35)51(75)40(30(4)62)56-46(34)71/h14-17,28-30,33-38,40-43,45,50,62-67,70H,5-13,18-27,53-54H2,1-4H3,(H,55,68)(H,56,71)(H,57,73)(H,58,72)(H,59,74)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40?,41+,42?,43+,45+,50+/m1/s1
DMYZPJU CS CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]3C[C@H](CN3C(=O)C(NC1=O)[C@@H](C)O)O)[C@@H](C(=O)C4=CC=C(C=C4)O)O)[C@@H](CCN)O)O)OCCN)O
DMYZPJU IK UWUVRFXWJQIKTQ-NQPUGUJXSA-N
DMYZPJU IU N-[(3S,9S,11R,18S,20R,21S,24S,25S)-21-(2-aminoethoxy)-3-[(1R)-3-amino-1-hydroxypropyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-6-[(1S)-1-hydroxy-2-(4-hydroxyphenyl)-2-oxoethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMYZPJU CA CAS 150283-06-0
DMYZPJU DE Aspergillosis
DMO69X8 ID DMO69X8
DMO69X8 DN L-738167
DMO69X8 HS Terminated
DMO69X8 SN L-738167; CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)
DMO69X8 DT Small molecular drug
DMO69X8 PC 153986
DMO69X8 MW 546.6
DMO69X8 FM C25H34N6O6S
DMO69X8 IC InChI=1S/C25H34N6O6S/c1-17-3-5-19(6-4-17)38(36,37)29-21(25(34)35)16-27-23(32)20-15-22-24(33)30(12-2-13-31(22)28-20)14-9-18-7-10-26-11-8-18/h3-6,15,18,21,26,29H,2,7-14,16H2,1H3,(H,27,32)(H,34,35)/t21-/m0/s1
DMO69X8 CS CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CNC(=O)C2=NN3CCCN(C(=O)C3=C2)CCC4CCNCC4)C(=O)O
DMO69X8 IK YLFFZEQHDMFOEC-NRFANRHFSA-N
DMO69X8 IU (2S)-2-[(4-methylphenyl)sulfonylamino]-3-[[4-oxo-5-(2-piperidin-4-ylethyl)-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepine-2-carbonyl]amino]propanoic acid
DMO69X8 CA CAS 163212-43-9
DMAUG0L ID DMAUG0L
DMAUG0L DN L-739749
DMAUG0L HS Terminated
DMAUG0L SN CHEMBL99645; BDBM50059867; (S)-2-{(S)-2-[(S)-2-((R)-2-Amino-3-mercapto-propylamino)-3-methyl-pentyloxy]-3-phenyl-propionylamino}-4-methanesulfonyl-butyric acid methyl ester; (S)-methyl 2-((S)-2-((2S,3R)-2-((R)-2-amino-3-mercaptopropylamino)-3-methylpentyloxy)-3-phenylpropanamido)-4-(methylsulfonyl)butanoate
DMAUG0L DT Small molecular drug
DMAUG0L PC 158357
DMAUG0L MW 531.7
DMAUG0L FM C24H41N3O6S2
DMAUG0L IC InChI=1S/C24H41N3O6S2/c1-5-17(2)21(26-14-19(25)16-34)15-33-22(13-18-9-7-6-8-10-18)23(28)27-20(24(29)32-3)11-12-35(4,30)31/h6-10,17,19-22,26,34H,5,11-16,25H2,1-4H3,(H,27,28)/t17-,19+,20-,21+,22-/m0/s1
DMAUG0L CS CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC)NC[C@H](CS)N
DMAUG0L IK XDPAYLCHZOZGMW-NDYOWHOSSA-N
DMAUG0L IU methyl (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoate
DMAUG0L CA CAS 156511-34-1
DMAUG0L DE Solid tumour/cancer
DMNSH0V ID DMNSH0V
DMNSH0V DN L-741604
DMNSH0V HS Terminated
DMNSH0V SN L-741604; CHEMBL296161; SCHEMBL6943364; IGNXHSPBUUSUHB-UHFFFAOYSA-N; BDBM50060426; L010084; N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine; Dimethyl-[2-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-ethyl]-amine
DMNSH0V DT Small molecular drug
DMNSH0V PC 9881526
DMNSH0V MW 255.32
DMNSH0V FM C14H17N5
DMNSH0V IC InChI=1S/C14H17N5/c1-18(2)6-5-11-8-15-14-4-3-12(7-13(11)14)19-9-16-17-10-19/h3-4,7-10,15H,5-6H2,1-2H3
DMNSH0V CS CN(C)CCC1=CNC2=C1C=C(C=C2)N3C=NN=C3
DMNSH0V IK IGNXHSPBUUSUHB-UHFFFAOYSA-N
DMNSH0V IU N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethanamine
DMRVXEQ ID DMRVXEQ
DMRVXEQ DN L-741671
DMRVXEQ HS Terminated
DMRVXEQ DT Small molecular drug
DMRVXEQ PC 135539114
DMRVXEQ MW 500.4
DMRVXEQ FM C23H22F6N4O2
DMRVXEQ IC InChI=1S/C23H22F6N4O2/c24-22(25,26)16-9-14(10-17(11-16)23(27,28)29)13-35-18-7-4-8-33(12-19-30-21(34)32-31-19)20(18)15-5-2-1-3-6-15/h1-3,5-6,9-11,18,20H,4,7-8,12-13H2,(H2,30,31,32,34)/t18-,20-/m0/s1
DMRVXEQ CS C1C[C@@H]([C@@H](N(C1)CC2=NNC(=O)N2)C3=CC=CC=C3)OCC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMRVXEQ IK ZUWHBRRBKKTMQO-ICSRJNTNSA-N
DMRVXEQ IU 3-[[(2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidin-1-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
DMRVXEQ CA CAS 187724-85-2
DMRVXEQ DE Vomiting
DMOQIWH ID DMOQIWH
DMOQIWH DN L-745337
DMOQIWH HS Terminated
DMOQIWH SN Thioflosulide; L-745337; CHEMBL287919; 158205-05-1; L 745337; L 745,337; L-745,337; SCHEMBL2464202; ZINC1887701; BDBM50029603; CS-6783; N-(6-((2,4-Difluorophenyl)thio)-2,3-dihydro-1-oxo-1H-inden-5-yl)methanesulfonamide; HY-19217; L745,337
DMOQIWH DT Small molecular drug
DMOQIWH PC 9799453
DMOQIWH MW 369.4
DMOQIWH FM C16H13F2NO3S2
DMOQIWH IC InChI=1S/C16H13F2NO3S2/c1-24(21,22)19-13-6-9-2-4-14(20)11(9)8-16(13)23-15-5-3-10(17)7-12(15)18/h3,5-8,19H,2,4H2,1H3
DMOQIWH CS CS(=O)(=O)NC1=C(C=C2C(=C1)CCC2=O)SC3=C(C=C(C=C3)F)F
DMOQIWH IK HDUWKQUHMUSICC-UHFFFAOYSA-N
DMOQIWH IU N-[6-(2,4-difluorophenyl)sulfanyl-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide
DMOQIWH CA CAS 158205-05-1
DMOQIWH DE Asthma
DM4UP7R ID DM4UP7R
DM4UP7R DN L-745631
DM4UP7R HS Terminated
DM4UP7R SN CHEMBL103575; L-745631; SCHEMBL16111943; BDBM50059846
DM4UP7R DT Small molecular drug
DM4UP7R PC 44332320
DM4UP7R MW 387.5
DM4UP7R FM C21H29N3O2S
DM4UP7R IC InChI=1S/C21H29N3O2S/c1-26-12-9-18-14-24(11-10-23(18)13-17(22)15-27)21(25)20-8-4-6-16-5-2-3-7-19(16)20/h2-8,17-18,27H,9-15,22H2,1H3/t17-,18+/m0/s1
DM4UP7R CS COCC[C@@H]1CN(CCN1C[C@@H](CS)N)C(=O)C2=CC=CC3=CC=CC=C32
DM4UP7R IK GKTZPBPAMFCBNI-ZWKOTPCHSA-N
DM4UP7R IU [(3R)-4-[(2S)-2-amino-3-sulfanylpropyl]-3-(2-methoxyethyl)piperazin-1-yl]-naphthalen-1-ylmethanone
DM4UP7R DE Solid tumour/cancer
DMPWBNU ID DMPWBNU
DMPWBNU DN L-755507
DMPWBNU HS Terminated
DMPWBNU SN 159182-43-1; L755507; L-755,507; CHEMBL12998; 4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE; L 755507; SCHEMBL5165122; GTPL3931; MolPort-003-983-607; ZINC3939153; EX-A2397; s7974; BDBM50070156; AKOS024456983; CP-0074; CS-7782; NCGC00092331-01; HY-19334; F10055; L755507, > J-009574; L-755 507; (S)-4-(3-hexylureido)-N-(4-(2-(1-hydroxy-2-(4-hydroxyphenoxy)ethylamino)ethyl)phenyl)benzenesulfonamide
DMPWBNU DT Small molecular drug
DMPWBNU PC 9829836
DMPWBNU MW 584.7
DMPWBNU FM C30H40N4O6S
DMPWBNU IC InChI=1S/C30H40N4O6S/c1-2-3-4-5-19-32-30(37)33-24-10-16-29(17-11-24)41(38,39)34-25-8-6-23(7-9-25)18-20-31-21-27(36)22-40-28-14-12-26(35)13-15-28/h6-17,27,31,34-36H,2-5,18-22H2,1H3,(H2,32,33,37)/t27-/m0/s1
DMPWBNU CS CCCCCCNC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CCNC[C@@H](COC3=CC=C(C=C3)O)O
DMPWBNU IK NYYJKMXNVNFOFQ-MHZLTWQESA-N
DMPWBNU IU 1-hexyl-3-[4-[[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]sulfamoyl]phenyl]urea
DMPWBNU CA CAS 159182-43-1
DM17S85 ID DM17S85
DM17S85 DN L-757464
DM17S85 HS Terminated
DM17S85 SN 5-Chloro-2-[4-[4-(2-oxo-2,3-dihydrobenzoxazol-3-yl)piperidin-1-yl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide
DM17S85 CP Merck & Co Inc
DM17S85 DE Prostate hyperplasia
DM7J6QH ID DM7J6QH
DM7J6QH DN L-768277
DM7J6QH HS Terminated
DM7J6QH SN L-766112
DM7J6QH CP Merck Sharp & Dohme Research Laboratories
DM7J6QH DE Hyperthermia
DMZ402C ID DMZ402C
DMZ402C DN L-768673
DMZ402C HS Terminated
DMZ402C SN L-768673; CHEMBL16900; SCHEMBL7207125; BDBM50061209; LS-28521; l-768,673
DMZ402C DT Small molecular drug
DMZ402C PC 9851380
DMZ402C MW 587.4
DMZ402C FM C27H18F9N3O2
DMZ402C IC InChI=1S/C27H18F9N3O2/c28-25(29,30)14-39-20-9-5-4-8-18(20)22(15-6-2-1-3-7-15)38-23(24(39)41)37-21(40)12-16-10-11-17(26(31,32)33)13-19(16)27(34,35)36/h1-11,13,23H,12,14H2,(H,37,40)/t23-/m1/s1
DMZ402C CS C1=CC=C(C=C1)C2=N[C@H](C(=O)N(C3=CC=CC=C32)CC(F)(F)F)NC(=O)CC4=C(C=C(C=C4)C(F)(F)F)C(F)(F)F
DMZ402C IK VVCYJFVTVHMTBV-HSZRJFAPSA-N
DMZ402C IU 2-[2,4-bis(trifluoromethyl)phenyl]-N-[(3R)-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepin-3-yl]acetamide
DMZ402C CA CAS 177954-68-6
DMJ37IX ID DMJ37IX
DMJ37IX DN L-775606
DMJ37IX HS Terminated
DMJ37IX SN L-775606; L-775,606; CHEMBL292779; 188400-51-3; 1-(3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl)-4-(2-(3-fluorophenyl)ethyl)piperazine; 3-[3-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]propyl]-5-(1,2,4-triazol-4-yl)-1H-indole; ZUTQCPBDRJBADG-UHFFFAOYSA-N; 1-[3-(5-(1,2,4-Triazol-4-yl)-1H-indol-3-yl)propyl]-4-[2-(3-fluorophenyl)ethyl]piperazine; 1-(3-[5-{1,2,4-triazol-4-yl}-1h-indol-3-yl]propyl)-4-(2-{3-fluorophenyl}ethyl)piperazine; AC1O52LD; GTPL114; L 775606; SCHEMBL7477108; BDBM50060437; L016148; 1H-Indole, 3-(3-(4-(2-
DMJ37IX DT Small molecular drug
DMJ37IX PC 6426760
DMJ37IX MW 432.5
DMJ37IX FM C25H29FN6
DMJ37IX IC InChI=1S/C25H29FN6/c26-22-5-1-3-20(15-22)8-10-31-13-11-30(12-14-31)9-2-4-21-17-27-25-7-6-23(16-24(21)25)32-18-28-29-19-32/h1,3,5-7,15-19,27H,2,4,8-14H2
DMJ37IX CS C1CN(CCN1CCCC2=CNC3=C2C=C(C=C3)N4C=NN=C4)CCC5=CC(=CC=C5)F
DMJ37IX IK ZUTQCPBDRJBADG-UHFFFAOYSA-N
DMJ37IX IU 3-[3-[4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]propyl]-5-(1,2,4-triazol-4-yl)-1H-indole
DMJ37IX CA CAS 188400-51-3
DM07S4N ID DM07S4N
DM07S4N DN LAS-30538
DM07S4N HS Terminated
DM07S4N SN Las 30538; Las-30538; 145067-04-5; AC1L31FQ; DTXSID60162875; 1-(2-(2,6-Dimethylphenoxy)ethyl)-alpha,alpha-bis-(p-fluorophenyl)-4-piperidine methanol; 4-Piperidinemethanol, 1-(2-(2,6-dimethylphenoxy)ethyl)-alpha,alpha-bis(4-fluorophenyl)-
DM07S4N CP Almirall Prodesfarma SA
DM07S4N DT Small molecular drug
DM07S4N PC 132693
DM07S4N MW 451.5
DM07S4N FM C28H31F2NO2
DM07S4N IC InChI=1S/C28H31F2NO2/c1-20-4-3-5-21(2)27(20)33-19-18-31-16-14-24(15-17-31)28(32,22-6-10-25(29)11-7-22)23-8-12-26(30)13-9-23/h3-13,24,32H,14-19H2,1-2H3
DM07S4N CS CC1=C(C(=CC=C1)C)OCCN2CCC(CC2)C(C3=CC=C(C=C3)F)(C4=CC=C(C=C4)F)O
DM07S4N IK BIZCZAJFIUSFDU-UHFFFAOYSA-N
DM07S4N IU [1-[2-(2,6-dimethylphenoxy)ethyl]piperidin-4-yl]-bis(4-fluorophenyl)methanol
DM07S4N CA CAS 145067-04-5
DM07S4N DE Hyperinsulinemia
DMW2K1L ID DMW2K1L
DMW2K1L DN LAS-31180
DMW2K1L HS Terminated
DMW2K1L SN LAS-31180; LAS 31180; 137338-43-3; AC1Q6VQ1; AC1L50OY; ZINC8845; SCHEMBL7287896; DTXSID70160140; n-(1-methyl-4-oxo-1,4-dihydroquinolin-3-yl)methanesulfonamide; CS-6714; HY-101811
DMW2K1L CP Almirall Prodesfarma SA
DMW2K1L DT Small molecular drug
DMW2K1L PC 195841
DMW2K1L MW 252.29
DMW2K1L FM C11H12N2O3S
DMW2K1L IC InChI=1S/C11H12N2O3S/c1-13-7-9(12-17(2,15)16)11(14)8-5-3-4-6-10(8)13/h3-7,12H,1-2H3
DMW2K1L CS CN1C=C(C(=O)C2=CC=CC=C21)NS(=O)(=O)C
DMW2K1L IK LSIYNVMXGMDGMG-UHFFFAOYSA-N
DMW2K1L IU N-(1-methyl-4-oxoquinolin-3-yl)methanesulfonamide
DMW2K1L CA CAS 137338-43-3
DMW2K1L DE Heart failure
DMYGJCL ID DMYGJCL
DMYGJCL DN LB30057
DMYGJCL HS Terminated
DMYGJCL DT Small molecular drug
DMYGJCL PC 9913629
DMYGJCL MW 493.6
DMYGJCL FM C26H31N5O3S
DMYGJCL IC InChI=1S/C26H31N5O3S/c1-31(22-8-4-5-9-22)26(32)24(16-18-10-12-20(13-11-18)25(27)29-28)30-35(33,34)23-15-14-19-6-2-3-7-21(19)17-23/h2-3,6-7,10-15,17,22,24,30H,4-5,8-9,16,28H2,1H3,(H2,27,29)/t24-/m0/s1
DMYGJCL CS CN(C1CCCC1)C(=O)[C@H](CC2=CC=C(C=C2)/C(=N/N)/N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DMYGJCL IK ZPDICRPCOSQEDS-DEOSSOPVSA-N
DMYGJCL IU (2S)-3-[4-[(Z)-C-aminocarbonohydrazonoyl]phenyl]-N-cyclopentyl-N-methyl-2-(naphthalen-2-ylsulfonylamino)propanamide
DMYGJCL CA CAS 184770-78-3
DMFEMTG ID DMFEMTG
DMFEMTG DN Lecimibide
DMFEMTG HS Terminated
DMFEMTG SN DuP-128
DMFEMTG CP Bristol-Myers Squibb Pharma Co
DMFEMTG DT Small molecular drug
DMFEMTG PC 71355
DMFEMTG MW 590.8
DMFEMTG FM C34H40F2N4OS
DMFEMTG IC InChI=1S/C34H40F2N4OS/c1-2-3-4-5-13-22-40(34(41)37-30-21-20-28(35)25-29(30)36)23-14-8-15-24-42-33-38-31(26-16-9-6-10-17-26)32(39-33)27-18-11-7-12-19-27/h6-7,9-12,16-21,25H,2-5,8,13-15,22-24H2,1H3,(H,37,41)(H,38,39)
DMFEMTG CS CCCCCCCN(CCCCCSC1=NC(=C(N1)C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NC4=C(C=C(C=C4)F)F
DMFEMTG IK TVXOXGBTADZYCZ-UHFFFAOYSA-N
DMFEMTG IU 3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea
DMFEMTG CA CAS 130804-35-2
DMFEMTG DE Hyperlipidaemia
DMIYMS2 ID DMIYMS2
DMIYMS2 DN LF-984
DMIYMS2 HS Terminated
DMIYMS2 CP Fournier Pharma
DMIYMS2 DE Fibrosis
DMNXKR2 ID DMNXKR2
DMNXKR2 DN LG-2293
DMNXKR2 HS Terminated
DMNXKR2 SN LG-121100
DMNXKR2 CP Ligand Pharmaceuticals Inc
DMNXKR2 DE Prostate cancer
DMF9XU4 ID DMF9XU4
DMF9XU4 DN LM-1376
DMF9XU4 HS Terminated
DMF9XU4 CP Laboratorios Menarini SA
DMF9XU4 PC 9891157
DMF9XU4 MW 476.5
DMF9XU4 FM C30H24N2O4
DMF9XU4 IC InChI=1S/C30H24N2O4/c33-29(31-16-15-20-5-7-23(8-6-20)30(34)35)24-10-9-21-12-14-27(18-25(21)17-24)36-19-26-13-11-22-3-1-2-4-28(22)32-26/h1-14,17-18H,15-16,19H2,(H,31,33)(H,34,35)
DMF9XU4 CS C1=CC=C2C(=C1)C=CC(=N2)COC3=CC4=C(C=CC(=C4)C(=O)NCCC5=CC=C(C=C5)C(=O)O)C=C3
DMF9XU4 IK IXSRNSVQRMOPTQ-UHFFFAOYSA-N
DMF9XU4 IU 4-[2-[[7-(quinolin-2-ylmethoxy)naphthalene-2-carbonyl]amino]ethyl]benzoic acid
DMF9XU4 DE Asthma
DM6Y49D ID DM6Y49D
DM6Y49D DN L-NIL
DM6Y49D HS Terminated
DM6Y49D SN L-NIL; N(6)-acetimidoyllysine; H-Lys(acetimidoyl)-OH; N~6~-[(1z)-Ethanimidoyl]-L-Lysine; N(6)-acetimidoyl-L-lysine; N(6)-ethanimidoyl-L-lysine; CHEMBL7889; L-N(6)-(1-iminoethyl)lysine; CHEBI:63971; L-N(omega)-(1-iminoethyl)lysine; 53774-63-3; N-(iminoethyl)-L-lysine; L-NIL;H-Lys(1-iminoethyl)-OH;N-(5-Amino-5-carboxypentyl)-acetamidine; L-N6-(1-Iminoethyl)lysine; Tocris-1139; NCGC00015566-01; N6-ethanimidoyl-L-lysine; Lopac-I-8021; AC1MBZ26; (L-N6-1-iminoethyl)lysine; SCHEMBL322091; L-Lysine,n6-(1-iminoethyl)-; DTXSID9041071
DM6Y49D DT Small molecular drug
DM6Y49D PC 2733506
DM6Y49D MW 187.24
DM6Y49D FM C8H17N3O2
DM6Y49D IC InChI=1S/C8H17N3O2/c1-6(9)11-5-3-2-4-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1
DM6Y49D CS CC(=NCCCC[C@@H](C(=O)O)N)N
DM6Y49D IK ONYFNWIHJBLQKE-ZETCQYMHSA-N
DM6Y49D IU (2S)-2-amino-6-(1-aminoethylideneamino)hexanoic acid
DM6Y49D CB CHEBI:63971
DM904B6 ID DM904B6
DM904B6 DN Lorglumide
DM904B6 HS Terminated
DM904B6 SN Lorglumide; 97964-56-2; Lorglumide [INN]; Lorglumidum [Latin]; Lorglumida [Spanish]; CR-1409; CCRIS 6857; CHEMBL24938; CHEBI:88307; CR 1409; D,L-4-(3,4-Dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoic acid; Lorglumida; Lorglumidum; (+-)-4-(3,4-Dichlorobenzamido)-N,N-dipentylglutaramic acid; 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-, (+-)-; C22H32Cl2N2O4; 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxopentanoic a
DM904B6 DT Small molecular drug
DM904B6 PC 3960
DM904B6 MW 459.4
DM904B6 FM C22H32Cl2N2O4
DM904B6 IC InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)
DM904B6 CS CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DM904B6 IK IEKOTSCYBBDIJC-UHFFFAOYSA-N
DM904B6 IU 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
DM904B6 CA CAS 97964-56-2
DM904B6 CB CHEBI:88307
DM904B6 DE Pancreatic malfunction
DMFJPYV ID DMFJPYV
DMFJPYV DN LSI-518P
DMFJPYV HS Terminated
DMFJPYV SN HDL mimetics (atherosclerosis), Lipid Sciences
DMFJPYV CP Lipid Sciences Inc
DMFJPYV DE Cardiovascular disease
DMDHLUC ID DMDHLUC
DMDHLUC DN LU-29252
DMDHLUC HS Terminated
DMDHLUC CP H Lundbeck A/S
DMDHLUC DE Anxiety disorder
DMXRJQV ID DMXRJQV
DMXRJQV DN Luzindole
DMXRJQV HS Terminated
DMXRJQV SN Luzindole, Interneuron
DMXRJQV CP Endo Pharmaceuticals Solutions Inc
DMXRJQV DT Small molecular drug
DMXRJQV PC 122162
DMXRJQV MW 292.4
DMXRJQV FM C19H20N2O
DMXRJQV IC InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)
DMXRJQV CS CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3
DMXRJQV IK WVVXBPKOIZGVNS-UHFFFAOYSA-N
DMXRJQV IU N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide
DMXRJQV CA CAS 117946-91-5
DMXRJQV CB CHEBI:93173
DMXRJQV DE Sleep-wake disorder
DMMRLPF ID DMMRLPF
DMMRLPF DN LX-2932
DMMRLPF HS Terminated
DMMRLPF SN S1P lyase inhibitor (autoimmune diseases), Lexicon; Sphingosine-1-phosphate lyase inhibitor (autoimmune diseases), Lexicon
DMMRLPF CP Lexicon Pharmaceuticals Inc
DMMRLPF DT Small molecular drug
DMMRLPF PC 135912123
DMMRLPF MW 255.23
DMMRLPF FM C10H13N3O5
DMMRLPF IC InChI=1S/C10H13N3O5/c14-4-7(15)9(17)8(16)6-3-11-10(12-6)5-1-2-18-13-5/h1-3,7-9,14-17H,4H2,(H,11,12)/t7-,8-,9-/m1/s1
DMMRLPF CS C1=CON=C1C2=NC=C(N2)[C@H]([C@@H]([C@@H](CO)O)O)O
DMMRLPF IK WGDPRIZUIYIENM-IWSPIJDZSA-N
DMMRLPF IU (1R,2S,3R)-1-[2-(1,2-oxazol-3-yl)-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
DMMRLPF CA CAS 1055027-48-9
DMMRLPF DE Autoimmune diabetes
DMXYDJR ID DMXYDJR
DMXYDJR DN LXR-015-2
DMXYDJR HS Terminated
DMXYDJR SN Elirex; LXR-1035
DMXYDJR CP LXR Biotechnology Inc
DMXYDJR DE Ischemia
DMUHG0F ID DMUHG0F
DMUHG0F DN LY-117018
DMUHG0F HS Terminated
DMUHG0F SN LY-117018; Lilly 117018; LY 117018; 63676-25-5; CHEBI:90187; LY 139478; [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}methanone; 6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl 4-(2-(1-pyrrolidinyl)ethoxy) phenyl ketone; Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-; PHENETHIPYLONE; 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-pyrrolidinyl)ethoxy] phenyl ketone; LY117018; AC1L2XRN; AC1Q5D9H; CHEMBL10030
DMUHG0F DT Small molecular drug
DMUHG0F PC 104946
DMUHG0F MW 459.6
DMUHG0F FM C27H25NO4S
DMUHG0F IC InChI=1S/C27H25NO4S/c29-20-7-3-19(4-8-20)27-25(23-12-9-21(30)17-24(23)33-27)26(31)18-5-10-22(11-6-18)32-16-15-28-13-1-2-14-28/h3-12,17,29-30H,1-2,13-16H2
DMUHG0F CS C1CCN(C1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DMUHG0F IK JLERVPBPJHKRBJ-UHFFFAOYSA-N
DMUHG0F IU [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone
DMUHG0F CA CAS 63676-25-5
DMUHG0F CB CHEBI:90187
DMUEB4P ID DMUEB4P
DMUEB4P DN LY-210073
DMUEB4P HS Terminated
DMUEB4P SN LY210073; LY-210073; 148291-65-0; CHEMBL49210; LY 210073; SCHEMBL9148299; AC1O515S; BDBM50045092; HY-U00263; AKOS030562935; CS-7479; L005236; 5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid; 7-Carboxy-3-[[(E)-6-(4-methoxyphenyl)-5-hexenyl]oxy]-9-oxo-9H-xanthene-4-propanoic acid; (E)-7-Carboxy-3-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid; 7-Carboxy-3-((6-(methoxyphenyl)-5(E)-hexenyl)oxy)-9-oxo-9H-xanthene-4-propanoic acid
DMUEB4P CP Eli Lilly & Co
DMUEB4P DT Small molecular drug
DMUEB4P PC 6450158
DMUEB4P MW 516.5
DMUEB4P FM C30H28O8
DMUEB4P IC InChI=1S/C30H28O8/c1-36-21-10-7-19(8-11-21)6-4-2-3-5-17-37-25-15-12-23-28(33)24-18-20(30(34)35)9-14-26(24)38-29(23)22(25)13-16-27(31)32/h4,6-12,14-15,18H,2-3,5,13,16-17H2,1H3,(H,31,32)(H,34,35)/b6-4+
DMUEB4P CS COC1=CC=C(C=C1)/C=C/CCCCOC2=C(C3=C(C=C2)C(=O)C4=C(O3)C=CC(=C4)C(=O)O)CCC(=O)O
DMUEB4P IK MTTBGOLFCYOWSV-GQCTYLIASA-N
DMUEB4P IU 5-(2-carboxyethyl)-6-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]-9-oxoxanthene-2-carboxylic acid
DMUEB4P CA CAS 148291-65-0
DMUEB4P DE Asthma
DMJ54E9 ID DMJ54E9
DMJ54E9 DN LY-221068
DMJ54E9 HS Terminated
DMJ54E9 SN LY 221068; LY-221068; 132392-39-3; AC1O5RGH; SCHEMBL2746042; ly221068; 5-((3,5-Bis(1,1,-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-(dimethylamino)-
DMJ54E9 CP Eli Lilly & Co
DMJ54E9 DT Small molecular drug
DMJ54E9 PC 6439333
DMJ54E9 MW 362.5
DMJ54E9 FM C20H30N2O2S
DMJ54E9 IC InChI=1S/C20H30N2O2S/c1-19(2,3)14-9-13(10-15(17(14)23)20(4,5)6)11-16-18(24)22(12-25-16)21(7)8/h9-11,23H,12H2,1-8H3/b16-11-
DMJ54E9 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N(CS2)N(C)C
DMJ54E9 IK DNXBQWAKVPAADQ-WJDWOHSUSA-N
DMJ54E9 IU (5Z)-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-3-(dimethylamino)-1,3-thiazolidin-4-one
DMJ54E9 CA CAS 132392-39-3
DMJ54E9 DE Arthritis
DMIDK36 ID DMIDK36
DMIDK36 DN LY-243062
DMIDK36 HS Terminated
DMIDK36 CP Eli Lilly & Co
DMIDK36 DE Inflammation
DMFIR0S ID DMFIR0S
DMFIR0S DN LY-255283
DMFIR0S HS Terminated
DMFIR0S SN GTPL3351; MolPort-009-018-745; HMS3649C08; ZINC27644044; SR-01000946596; SR-01000946596-1
DMFIR0S DT Small molecular drug
DMFIR0S PC 122023
DMFIR0S MW 360.5
DMFIR0S FM C19H28N4O3
DMFIR0S IC InChI=1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
DMFIR0S CS CCC1=CC(=C(C=C1OCCCCCC(C)(C)C2=NNN=N2)O)C(=O)C
DMFIR0S IK WCGXJPFHTHQNJL-UHFFFAOYSA-N
DMFIR0S IU 1-[5-ethyl-2-hydroxy-4-[6-methyl-6-(2H-tetrazol-5-yl)heptoxy]phenyl]ethanone
DMFIR0S CA CAS 117690-79-6
DMFIR0S CB CHEBI:93616
DMFIR0S DE Asthma
DMG79NT ID DMG79NT
DMG79NT DN LY-274614
DMG79NT HS Terminated
DMG79NT SN LY 235959; 137433-06-8; UNII-AR2BHC0C6P; LY-235959; AR2BHC0C6P; Decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; LY-274614; C11H20NO5P; LY 274614; 136109-04-1; Tocris-1019; LY274614; LY235959; Biomol-NT_000192; SCHEMBL195083; BPBio1_001216; AC1L302W; CHEMBL1448057; CTK0H8339; MolPort-023-275-977; 3-Isoquinolinecarboxylicacid, decahydro-6-(phosphonomethyl)-, (3S,4aR,6S,8aR)-; ZINC31424744; AKOS024456335; NCGC00024942-02
DMG79NT CP Eli Lilly & Co
DMG79NT DT Small molecular drug
DMG79NT PC 131938
DMG79NT MW 277.25
DMG79NT FM C11H20NO5P
DMG79NT IC InChI=1S/C11H20NO5P/c13-11(14)10-4-9-3-7(6-18(15,16)17)1-2-8(9)5-12-10/h7-10,12H,1-6H2,(H,13,14)(H2,15,16,17)/t7-,8-,9+,10-/m0/s1
DMG79NT CS C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CP(=O)(O)O)C(=O)O
DMG79NT IK STIRHCNEGQQBOY-QEYWKRMJSA-N
DMG79NT IU (3S,4aR,6S,8aR)-6-(phosphonomethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DMG79NT CA CAS 137433-06-8
DMG79NT DE Dementia
DMG8YE9 ID DMG8YE9
DMG8YE9 DN LY288513
DMG8YE9 HS Terminated
DMG8YE9 SN LY-288512; CHEMBL117281; (4R,5S)-N-(4-bromophenyl)-3-oxo-4,5-diphenylpyrazolidine-1-carboxamide; LY-262691; GTPL902; SCHEMBL8846984; ZINC538559; BDBM50092157; 3-Oxo-4,5-diphenyl-pyrazolidine-1-carboxylic acid (4-bromo-phenyl)-amide(LY288512); (4R,5S)-3-Oxo-4,5-diphenyl-pyrazolidine-1-carboxylic acid (4-bromo-phenyl)-amide
DMG8YE9 DT Small molecular drug
DMG8YE9 PC 132190
DMG8YE9 MW 436.3
DMG8YE9 FM C22H18BrN3O2
DMG8YE9 IC InChI=1S/C22H18BrN3O2/c23-17-11-13-18(14-12-17)24-22(28)26-20(16-9-5-2-6-10-16)19(21(27)25-26)15-7-3-1-4-8-15/h1-14,19-20H,(H,24,28)(H,25,27)
DMG8YE9 CS C1=CC=C(C=C1)C2C(N(NC2=O)C(=O)NC3=CC=C(C=C3)Br)C4=CC=CC=C4
DMG8YE9 IK LMUQHXHWJWQXSD-UHFFFAOYSA-N
DMG8YE9 IU N-(4-bromophenyl)-3-oxo-4,5-diphenylpyrazolidine-1-carboxamide
DMG8YE9 CA CAS 138932-35-1
DMG8YE9 DE Anxiety disorder
DMPZ7AO ID DMPZ7AO
DMPZ7AO DN LY-290154
DMPZ7AO HS Terminated
DMPZ7AO CP Eli Lilly & Co
DMPZ7AO DE Asthma
DMU24HR ID DMU24HR
DMU24HR DN LY-292728
DMU24HR HS Terminated
DMU24HR SN LY-292728; LY 292728; 153034-77-6; CHEMBL292782; 9H-Xanthene-4-propanoicacid,7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-; ACMC-20ddq7; AC1Q4NQC; AC1L4UN3; SCHEMBL13696764; CTK4C7669; DTXSID00165204; BDBM50029464; 9h-xanthene-4-propanoic acid, 7-carboxy-3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-9-oxo-; L011726; 5-(2-carboxyethyl)-6-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9-oxoxanthene-2-carboxylic acid
DMU24HR DT Small molecular drug
DMU24HR PC 192617
DMU24HR MW 600.6
DMU24HR FM C34H29FO9
DMU24HR IC InChI=1S/C34H29FO9/c1-2-19-16-25(20-4-7-22(35)8-5-20)27(36)18-30(19)43-15-3-14-42-28-12-9-24-32(39)26-17-21(34(40)41)6-11-29(26)44-33(24)23(28)10-13-31(37)38/h4-9,11-12,16-18,36H,2-3,10,13-15H2,1H3,(H,37,38)(H,40,41)
DMU24HR CS CCC1=CC(=C(C=C1OCCCOC2=C(C3=C(C=C2)C(=O)C4=C(O3)C=CC(=C4)C(=O)O)CCC(=O)O)O)C5=CC=C(C=C5)F
DMU24HR IK DCTKEJXAVFAMFK-UHFFFAOYSA-N
DMU24HR IU 5-(2-carboxyethyl)-6-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-9-oxoxanthene-2-carboxylic acid
DMU24HR CA CAS 153034-77-6
DMH21JG ID DMH21JG
DMH21JG DN LY-293284
DMH21JG HS Terminated
DMH21JG SN LY-293284; LY 293284; 141318-62-9; LY293284; 6-Acetyl-4-(di-n-propylamino)-1,3,4,5-tetrahydrobenz(c,d)indole; LY-293,284; 1-(4-Dipropylamino-1,3,4,5-tetrahydro-benzo[cd]indol-6-yl)-ethanone; Ethanone, 1-(4-(dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indol-6-yl)-, (R)-; GTPL19; AC1L30TM; SCHEMBL6902000; DTXSID70161692; LS-173111
DMH21JG CP Eli Lilly & Co
DMH21JG DT Small molecular drug
DMH21JG PC 132345
DMH21JG MW 298.4
DMH21JG FM C19H26N2O
DMH21JG IC InChI=1S/C19H26N2O/c1-4-8-21(9-5-2)15-10-14-12-20-18-7-6-16(13(3)22)17(11-15)19(14)18/h6-7,12,15,20H,4-5,8-11H2,1-3H3/t15-/m0/s1
DMH21JG CS CCCN(CCC)[C@H]1CC2=CNC3=C2C(=C(C=C3)C(=O)C)C1
DMH21JG IK CKYZLYQSDNLGPT-HNNXBMFYSA-N
DMH21JG IU 1-[(4R)-4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indol-6-yl]ethanone
DMH21JG CA CAS 141318-62-9
DMH21JG DE Anxiety disorder
DMM20PI ID DMM20PI
DMM20PI DN LY-317644
DMM20PI HS Terminated
DMM20PI SN LY-317644; CHEMBL294120; BDBM50285193
DMM20PI DT Small molecular drug
DMM20PI PC 15391529
DMM20PI MW 455.5
DMM20PI FM C27H25N3O4
DMM20PI IC InChI=1S/C27H25N3O4/c31-16-17-10-12-30-15-21(19-7-2-4-9-23(19)30)25-24(26(32)28-27(25)33)20-14-29(11-5-13-34-17)22-8-3-1-6-18(20)22/h1-4,6-9,14-15,17,31H,5,10-13,16H2,(H,28,32,33)
DMM20PI CS C1CN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCC(OC1)CO)C6=CC=CC=C65)C(=O)NC4=O
DMM20PI IK XIFXMAQLEGCDQV-UHFFFAOYSA-N
DMM20PI IU 17-(hydroxymethyl)-18-oxa-4,14,22-triazahexacyclo[20.6.1.17,14.02,6.08,13.023,28]triaconta-1(29),2(6),7(30),8,10,12,23,25,27-nonaene-3,5-dione
DMFVYID ID DMFVYID
DMFVYID DN LY-353433
DMFVYID HS Terminated
DMFVYID SN LY-343031; LY-343032; LY-314580 (oxalate); LY-350355 (maleate)
DMFVYID CP Eli Lilly & Co Ltd
DMFVYID PC 9826941
DMFVYID MW 491.7
DMFVYID FM C29H41N5O2
DMFVYID IC InChI=1S/C29H41N5O2/c1-19(2)34-25-6-4-3-5-24(25)26(32-34)27(35)30-9-12-33-10-7-23(8-11-33)31-28(36)29-16-20-13-21(17-29)15-22(14-20)18-29/h3-6,19-23H,7-18H2,1-2H3,(H,30,35)(H,31,36)
DMFVYID CS CC(C)N1C2=CC=CC=C2C(=N1)C(=O)NCCN3CCC(CC3)NC(=O)C45CC6CC(C4)CC(C6)C5
DMFVYID IK QEZYDSSGVBTNBH-UHFFFAOYSA-N
DMFVYID IU N-[2-[4-(adamantane-1-carbonylamino)piperidin-1-yl]ethyl]-1-propan-2-ylindazole-3-carboxamide
DMFVYID CA CAS 176390-32-2
DMFVYID DE Inflammatory bowel disease
DM98POQ ID DM98POQ
DM98POQ DN LY-367385
DM98POQ HS Terminated
DM98POQ SN Metabotropic mGluR1 agonists, Lilly; L-367385 analogs, Lilly
DM98POQ CP Lilly Research Centre Ltd
DM98POQ DT Small molecular drug
DM98POQ PC 5311261
DM98POQ MW 209.2
DM98POQ FM C10H11NO4
DM98POQ IC InChI=1S/C10H11NO4/c1-5-4-6(9(12)13)2-3-7(5)8(11)10(14)15/h2-4,8H,11H2,1H3,(H,12,13)(H,14,15)/t8-/m0/s1
DM98POQ CS CC1=C(C=CC(=C1)C(=O)O)[C@@H](C(=O)O)N
DM98POQ IK SGIKDIUCJAUSRD-QMMMGPOBSA-N
DM98POQ IU 4-[(S)-amino(carboxy)methyl]-3-methylbenzoic acid
DM98POQ CA CAS 198419-91-9
DM98POQ DE Neurological disorder
DM0TV9L ID DM0TV9L
DM0TV9L DN LY467711
DM0TV9L HS Terminated
DM0TV9L SN BDBM86756; LY 467711
DM0TV9L CP Eli Lilly
DM0TV9L TC Analgesics
DM0TV9L DT Small molecular drug
DM0TV9L PC 129715717
DM0TV9L MW 435.9
DM0TV9L FM C21H30ClN5O3
DM0TV9L IC InChI=1S/C21H29N5O3.ClH/c1-13(2)12-28-21(27)18-10-15-9-16(8-7-14(15)11-22-18)29-19-6-4-3-5-17(19)20-23-25-26-24-20;/h3-6,13-16,18,22H,7-12H2,1-2H3,(H,23,24,25,26);1H/t14-,15+,16+,18+;/m0./s1
DM0TV9L CS CC(C)COC(=O)[C@H]1C[C@H]2C[C@@H](CC[C@H]2CN1)OC3=CC=CC=C3C4=NNN=N4.Cl
DM0TV9L IK STJGUHHJXMUHAN-DYZVKEBGSA-N
DM0TV9L IU 2-methylpropyl (3R,4aS,6R,8aR)-6-[2-(2H-tetrazol-5-yl)phenoxy]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate;hydrochloride
DM0TV9L DE Migraine; Neuropathic pain
DMPNMAR ID DMPNMAR
DMPNMAR DN LY525327
DMPNMAR HS Terminated
DMPNMAR SN CHEMBL187941; BDBM86753; BDBM50168966; LY-525327; LY 525327; LS-193664; (3S,4aR,6S,8aR)-6-[2-(1H-Tetrazol-5-yl)-phenylamino]-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester
DMPNMAR CP Eli Lilly
DMPNMAR TC Analgesics
DMPNMAR DT Small molecular drug
DMPNMAR PC 11249042
DMPNMAR MW 426.6
DMPNMAR FM C23H34N6O2
DMPNMAR IC InChI=1S/C23H34N6O2/c1-3-15(4-2)14-31-23(30)21-12-17-11-18(10-9-16(17)13-24-21)25-20-8-6-5-7-19(20)22-26-28-29-27-22/h5-8,15-18,21,24-25H,3-4,9-14H2,1-2H3,(H,26,27,28,29)/t16-,17+,18-,21-/m0/s1
DMPNMAR CS CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@H](CC[C@H]2CN1)NC3=CC=CC=C3C4=NNN=N4
DMPNMAR IK KQDBQKHPLFHNIW-NYUBLWNDSA-N
DMPNMAR IU 2-ethylbutyl (3S,4aR,6S,8aR)-6-[2-(2H-tetrazol-5-yl)anilino]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate
DMPNMAR DE Migraine; Neuropathic pain
DMY71LJ ID DMY71LJ
DMY71LJ DN LY53857
DMY71LJ HS Terminated
DMY71LJ SN UNII-OK43YC00I7; OK43YC00I7; LY53857; LY 53857; LY-53857 free base; Biomol-NT_000165; AC1MHY97; Lopac0_000721; GTPL183; BPBio1_000595; CHEMBL1356280; CCG-204806; NCGC00163176-01; LY-53,857; LS-187317; Ergoline-8beta-carboxylic acid, 1-isopropyl-6-methyl-, 2-hydroxy-1-methylpropyl ester; 6-Methyl-1-isopropylergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester; 6-methyl-1-(1-methylethyl)ergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester; Ergoline-8-carboxylic acid, 6-methyl-1-(1-methylethyl)-, 2-hydroxy-1-m
DMY71LJ DT Small molecular drug
DMY71LJ PC 3034814
DMY71LJ MW 384.5
DMY71LJ FM C23H32N2O3
DMY71LJ IC InChI=1S/C23H32N2O3/c1-13(2)25-12-16-10-21-19(18-7-6-8-20(25)22(16)18)9-17(11-24(21)5)23(27)28-15(4)14(3)26/h6-8,12-15,17,19,21,26H,9-11H2,1-5H3/t14?,15?,17-,19-,21-/m1/s1
DMY71LJ CS CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)OC(C)C(C)O)C4=C2C1=CC=C4
DMY71LJ IK JQYLIGHHVGCTPR-LYRPIDSHSA-N
DMY71LJ IU 3-hydroxybutan-2-yl (6aR,9R,10aR)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate
DMY71LJ CA CAS 32896-53-0
DM679IY ID DM679IY
DM679IY DN LZ-8
DM679IY HS Terminated
DM679IY SN Lzip; FIP-gts; Ling Zhi-8; Protein adjuvant, Yeastern
DM679IY CP Meiji Institute of Health Science
DM679IY DE Autoimmune diabetes
DMUIGM3 ID DMUIGM3
DMUIGM3 DN M-216765
DMUIGM3 HS Terminated
DMUIGM3 SN IDDB3562
DMUIGM3 CP Zeneca Group plc
DMUIGM3 DE Hypertension
DMIY51U ID DMIY51U
DMIY51U DN M-241247
DMIY51U HS Terminated
DMIY51U SN M-244249; NMDA/glycine antagonists, Zeneca
DMIY51U CP Zeneca Group plc
DMIY51U DE Cerebrovascular ischaemia
DMBFCHW ID DMBFCHW
DMBFCHW DN M-40401
DMBFCHW HS Terminated
DMBFCHW CP Metaphore Pharmaceuticals Inc
DMBFCHW DE Cerebrovascular ischaemia
DM1SWOY ID DM1SWOY
DM1SWOY DN MANUMYCIN A
DM1SWOY HS Terminated
DM1SWOY SN manumycin; Manumycin A; Ucfi-C; UNII-OIQ298X4XD; AC1O5PHE; OIQ298X4XD; CHEBI:29623; C31H38N2O7; 52665-74-4; 2,4-Decadienamide, N-(5-hydroxy-5-(7-((2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino)-7-oxo-1,3,5-heptatrienyl)-2-oxo-7-oxabicyclo(4.1.0)hept-3-en-3-yl)-2,4,6-trimethyl-; (2E,4E,6R)-N-[(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-7-[(2-hydroxy-5-oxo-cyclopenten-1-yl)amino]-7-oxo-hepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyl-deca-2,4-dienamide; ( )-Manumycin A; BSPBio_001231; SCHEMBL12519093
DM1SWOY DT Small molecular drug
DM1SWOY PC 6438330
DM1SWOY MW 550.6
DM1SWOY FM C31H38N2O7
DM1SWOY IC InChI=1S/C31H38N2O7/c1-5-6-11-19(2)16-20(3)17-21(4)30(38)32-22-18-31(39,29-28(40-29)27(22)37)15-10-8-7-9-12-25(36)33-26-23(34)13-14-24(26)35/h7-10,12,15-19,28-29,34,39H,5-6,11,13-14H2,1-4H3,(H,32,38)(H,33,36)/b8-7+,12-9+,15-10+,20-16+,21-17+/t19-,28-,29-,31+/m1/s1
DM1SWOY CS CCCC[C@@H](C)/C=C(\\C)/C=C(\\C)/C(=O)NC1=C[C@]([C@H]2[C@@H](C1=O)O2)(/C=C/C=C/C=C/C(=O)NC3=C(CCC3=O)O)O
DM1SWOY IK TWWQHCKLTXDWBD-MVTGTTCWSA-N
DM1SWOY IU (2E,4E,6R)-N-[(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-7-[(2-hydroxy-5-oxocyclopenten-1-yl)amino]-7-oxohepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide
DM1SWOY CA CAS 52665-74-4
DM1SWOY CB CHEBI:29623
DM31WQC ID DM31WQC
DM31WQC DN Maxy-10
DM31WQC HS Terminated
DM31WQC SN Optimized interferon beta, Maxygen; Beta-interferon (optimized), Maxygen
DM31WQC CP Maxygen Inc
DM31WQC DE Autoimmune diabetes
DMXLCB6 ID DMXLCB6
DMXLCB6 DN MCI-826
DMXLCB6 HS Terminated
DMXLCB6 SN (E)-2,2-Diethyl-3'-[2-[2-(4-isopropyl)thiazolyl]ethenyl]succinanilic acid; (E)-2,2-Diethyl-N-[3-[2-(4-isopropylthiazol-2-yl)vinyl]phenyl]succinamic acid
DMXLCB6 DT Small molecular drug
DMXLCB6 PC 6439428
DMXLCB6 MW 400.5
DMXLCB6 FM C22H28N2O3S
DMXLCB6 IC InChI=1S/C22H28N2O3S/c1-5-22(6-2,21(26)27)13-19(25)23-17-9-7-8-16(12-17)10-11-20-24-18(14-28-20)15(3)4/h7-12,14-15H,5-6,13H2,1-4H3,(H,23,25)(H,26,27)/b11-10+
DMXLCB6 CS CCC(CC)(CC(=O)NC1=CC=CC(=C1)/C=C/C2=NC(=CS2)C(C)C)C(=O)O
DMXLCB6 IK PGLNVMJTDKEOBE-ZHACJKMWSA-N
DMXLCB6 IU 2,2-diethyl-4-oxo-4-[3-[(E)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]anilino]butanoic acid
DMXLCB6 CA CAS 140646-80-6
DMXLCB6 DE Asthma
DMRSOBG ID DMRSOBG
DMRSOBG DN Mdl 101,146
DMRSOBG HS Terminated
DMRSOBG SN UNII-2D08A509S3; CHEBI:45517; CHEMBL56852; 1-{3-METHYL-2-[4-(MORPHOLINE-4-CARBONYL)-BENZOYLAMINO]-BUTYRYL}-PYRROLIDINE-2-CARBOXYLIC ACID (3,3,4,4,4-PENTAFLUORO-1-ISOPROPYL-2-OXO-BUTYL)-AMIDE; 2D08A509S3; Mdl 101,146; N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide; N-{[4-(morpholin-4-ylcarbonyl)phenyl]carbonyl}-L-valyl-N-[(1S)-3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-L-prolinamide; MDL-101146, (S)-; AC1NRD4J; BDBM50058341; 163660-59-1
DMRSOBG DT Small molecular drug
DMRSOBG PC 46936357
DMRSOBG MW 632.6
DMRSOBG FM C29H37F5N4O6
DMRSOBG IC InChI=1S/C29H37F5N4O6/c1-16(2)21(23(39)28(30,31)29(32,33)34)35-25(41)20-6-5-11-38(20)27(43)22(17(3)4)36-24(40)18-7-9-19(10-8-18)26(42)37-12-14-44-15-13-37/h7-10,16-17,20-22H,5-6,11-15H2,1-4H3,(H,35,41)(H,36,40)/t20-,21-,22-/m1/s1
DMRSOBG CS CC(C)[C@H](C(=O)C(C(F)(F)F)(F)F)NC(=O)[C@H]1CCCN1C(=O)[C@@H](C(C)C)NC(=O)C2=CC=C(C=C2)C(=O)N3CCOCC3
DMRSOBG IK XQAMVCHQGHAELT-YPAWHYETSA-N
DMRSOBG IU (2R)-1-[(2R)-3-methyl-2-[[4-(morpholine-4-carbonyl)benzoyl]amino]butanoyl]-N-[(3R)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]pyrrolidine-2-carboxamide
DMRSOBG CA CAS 149859-17-6
DMRSOBG DE Inflammation
DMHUJCI ID DMHUJCI
DMHUJCI DN MDL-105519
DMHUJCI HS Terminated
DMHUJCI SN Mdl 105519; MDL 105,519; 161230-88-2; Lopac-M-216; AC1O7G4O; Lopac0_000805; C18H11Cl2NO4; SCHEMBL499902; CHEMBL180427; AOB5684; HMS3262B11; ZINC1540415; Tox21_500805; AKOS027324667; LP00805; CCG-204889; CS-3882; NCGC00015639-04; NCGC00015639-01; NCGC00094138-02; NCGC00015639-03; NCGC00261490-01; NCGC00015639-02; HY-15085; X6860; M-216; EU-0100805; SR-01000075460; SR-01000075460-1
DMHUJCI DT Small molecular drug
DMHUJCI PC 6603913
DMHUJCI MW 376.2
DMHUJCI FM C18H11Cl2NO4
DMHUJCI IC InChI=1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)/b11-8+
DMHUJCI CS C1=CC=C(C=C1)/C(=C\\C2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O)/C(=O)O
DMHUJCI IK LPWVUDLZUVBQGP-DHZHZOJOSA-N
DMHUJCI IU 3-[(E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid
DMMG1K3 ID DMMG1K3
DMMG1K3 DN MDL-201112
DMMG1K3 HS Terminated
DMMG1K3 SN Carbocyclic nucleoside, Hoechst; MDL-201449; MDL-201449A
DMMG1K3 CP Hoechst Marion Roussel Inc
DMMG1K3 DT Small molecular drug
DMMG1K3 PC 132408
DMMG1K3 MW 219.24
DMMG1K3 FM C10H13N5O
DMMG1K3 IC InChI=1S/C10H13N5O/c11-9-8-10(13-4-12-9)15(5-14-8)6-1-2-7(16)3-6/h4-7,16H,1-3H2,(H2,11,12,13)/t6-,7+/m0/s1
DMMG1K3 CS C1C[C@H](C[C@H]1N2C=NC3=C(N=CN=C32)N)O
DMMG1K3 IK UZNXSBPBWFLVDK-NKWVEPMBSA-N
DMMG1K3 IU (1R,3S)-3-(6-aminopurin-9-yl)cyclopentan-1-ol
DMMG1K3 CA CAS 142130-73-2
DMMG1K3 DE Colitis
DM6X4IT ID DM6X4IT
DM6X4IT DN MDL-28133A
DM6X4IT HS Terminated
DM6X4IT SN Mdl 28133A; 136861-96-6; N-[4-[1-[2-(4-fluorophenyl)-2-oxo-ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide hydrochloride; Mdl-28,133A; ACMC-20mwcf; AC1L307E; CTK0H5594; DTXSID60159987; 1-(4-Fluorophenyl)-2-(4-((4-methanosulfonamidophenyl)carbonyl)-1-piperidinyl)ethanone hydrochloride; N-[4-[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide hydrochloride; Methanesulfonamide, N-(4-((1-(2-(4-fluorophenyl)-2-oxoethyl)-4-piperidinyl)carbonyl)phenyl)-, monohydrochloride
DM6X4IT CP Hoechst Marion Roussel Inc
DM6X4IT DT Small molecular drug
DM6X4IT PC 132001
DM6X4IT MW 454.9
DM6X4IT FM C21H24ClFN2O4S
DM6X4IT IC InChI=1S/C21H23FN2O4S.ClH/c1-29(27,28)23-19-8-4-16(5-9-19)21(26)17-10-12-24(13-11-17)14-20(25)15-2-6-18(22)7-3-15;/h2-9,17,23H,10-14H2,1H3;1H
DM6X4IT CS CS(=O)(=O)NC1=CC=C(C=C1)C(=O)C2CCN(CC2)CC(=O)C3=CC=C(C=C3)F.Cl
DM6X4IT IK YVIOSUWCZDHHEI-UHFFFAOYSA-N
DM6X4IT IU N-[4-[1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;hydrochloride
DM6X4IT CA CAS 136861-96-6
DM6X4IT DE Thrombosis
DM8ZDU2 ID DM8ZDU2
DM8ZDU2 DN MDL-28161
DM8ZDU2 HS Terminated
DM8ZDU2 SN MDL-28161; CHEMBL344273; SCHEMBL9328582
DM8ZDU2 DT Small molecular drug
DM8ZDU2 PC 44363475
DM8ZDU2 MW 313.4
DM8ZDU2 FM C20H24FNO
DM8ZDU2 IC InChI=1S/C20H24FNO/c21-19-8-6-16(7-9-19)10-13-22-14-11-18(12-15-22)20(23)17-4-2-1-3-5-17/h1-9,18,20,23H,10-15H2
DM8ZDU2 CS C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=C(C=C3)F
DM8ZDU2 IK HRSUYEGDQAVTRC-UHFFFAOYSA-N
DM8ZDU2 IU [1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-phenylmethanol
DMYK31O ID DMYK31O
DMYK31O DN MDL-28170
DMYK31O HS Terminated
DMYK31O SN MDL-2170
DMYK31O DT Small molecular drug
DMYK31O PC 72430
DMYK31O MW 382.5
DMYK31O FM C22H26N2O4
DMYK31O IC InChI=1S/C22H26N2O4/c1-16(2)20(24-22(27)28-15-18-11-7-4-8-12-18)21(26)23-19(14-25)13-17-9-5-3-6-10-17/h3-12,14,16,19-20H,13,15H2,1-2H3,(H,23,26)(H,24,27)/t19-,20-/m0/s1
DMYK31O CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)OCC2=CC=CC=C2
DMYK31O IK NGBKFLTYGSREKK-PMACEKPBSA-N
DMYK31O IU benzyl N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate
DMYK31O CA CAS 88191-84-8
DMYK31O CB CHEBI:82818
DMYK31O DE Alzheimer disease
DMBIDQX ID DMBIDQX
DMBIDQX DN MDL-43291
DMBIDQX HS Terminated
DMBIDQX SN Mdl 43291; Mdl 43,291; AC1MI0EN; ((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; (4aalpha,7Z,8beta,8abeta)-((Octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)acetic acid; Acetic acid, ((octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio)-, (4aalpha,7Z,8beta,8abeta)-; 2-[[(2Z,4aS,8S,8aS)-2-(2-oxotetradecan-7-ylidene)-3,4,4a,5,6,7,8,8a-octahydrochromen-8-yl]sulfanyl]acetic acid
DMBIDQX CP Hoechst Marion Roussel Inc
DMBIDQX DT Small molecular drug
DMBIDQX PC 14430182
DMBIDQX MW 438.7
DMBIDQX FM C25H42O4S
DMBIDQX IC InChI=1S/C25H42O4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-21-16-15-20-17-18-23(28)29-24(20)25(21)30-19-22(26)27/h14,20,24-25H,2-13,15-19H2,1H3,(H,26,27)/b21-14+/t20-,24-,25-/m1/s1
DMBIDQX CS CCCCCCCCCCCCC/C=C/1\\CC[C@@H]2CCC(=O)O[C@H]2[C@@H]1SCC(=O)O
DMBIDQX IK GKTHCWOVKAXGOW-HTJMSZESSA-N
DMBIDQX IU 2-[[(4aR,7E,8R,8aR)-2-oxo-7-tetradecylidene-4,4a,5,6,8,8a-hexahydro-3H-chromen-8-yl]sulfanyl]acetic acid
DMBIDQX DE Asthma
DMHX6IC ID DMHX6IC
DMHX6IC DN ME-3221
DMHX6IC HS Terminated
DMHX6IC SN EF-2831
DMHX6IC CP Meiji Seika Kaisha Ltd
DMHX6IC DT Small molecular drug
DMHX6IC PC 178553
DMHX6IC MW 387.4
DMHX6IC FM C22H21N5O2
DMHX6IC IC InChI=1S/C22H21N5O2/c1-14-12-20(21(28-3)15(2)23-14)29-13-16-8-10-17(11-9-16)18-6-4-5-7-19(18)22-24-26-27-25-22/h4-12H,13H2,1-3H3,(H,24,25,26,27)
DMHX6IC CS CC1=CC(=C(C(=N1)C)OC)OCC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DMHX6IC IK FTDRSCZZEUAAIP-UHFFFAOYSA-N
DMHX6IC IU 3-methoxy-2,6-dimethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]pyridine
DMHX6IC CA CAS 139958-16-0
DMHX6IC DE Hypertension
DMT3B4G ID DMT3B4G
DMT3B4G DN MEDI-500
DMT3B4G HS Terminated
DMT3B4G SN T10B9; T10B9.1A31
DMT3B4G CP University of Kentucky
DMT3B4G DE Bone marrow transplantation
DM4G0D5 ID DM4G0D5
DM4G0D5 DN MEDI-542
DM4G0D5 HS Terminated
DM4G0D5 SN Ephrin a4-targeting monoclonal antibody (cancer), MedImmune
DM4G0D5 CP Medlmmune LLC
DM4G0D5 DT Antibody
DM4G0D5 DE Solid tumour/cancer
DM185DR ID DM185DR
DM185DR DN MEN-10207
DM185DR HS Terminated
DM185DR SN Men 10207; MEN-10207; 126050-12-2; 5-Tyr-6,8,9-trp-10-arg-nka (4-10); 5-Tyr-6,8,9-trp-10-arg-neurokinin A (4-10); DTXSID50155059; Neurokinin A (4-10), tyrosyl(5)-tryptophyl(6,8,9)-arginine(10)-; Neurokinin A (4-10), tyr(5)-trp(6,8,9)-arg(10)-; L-Argininamide, L-alpha-aspartyl-L-tyrosyl-D-tryptophyl-L-valyl-D-tryptophyl-D-tryptophyl-
DM185DR CP The Menarini Group
DM185DR PC 25079030
DM185DR MW 1109.2
DM185DR FM C57H68N14O10
DM185DR IC InChI=1S/C57H68N14O10/c1-30(2)49(71-55(80)47(25-34-29-65-42-15-8-5-12-38(34)42)69-52(77)44(22-31-17-19-35(72)20-18-31)67-51(76)39(58)26-48(73)74)56(81)70-46(24-33-28-64-41-14-7-4-11-37(33)41)54(79)68-45(23-32-27-63-40-13-6-3-10-36(32)40)53(78)66-43(50(59)75)16-9-21-62-57(60)61/h3-8,10-15,17-20,27-30,39,43-47,49,63-65,72H,9,16,21-26,58H2,1-2H3,(H2,59,75)(H,66,78)(H,67,76)(H,68,79)(H,69,77)(H,70,81)(H,71,80)(H,73,74)(H4,60,61,62)/t39-,43-,44-,45+,46+,47+,49-/m0/s1
DM185DR CS CC(C)[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)N
DM185DR IK RLHLZLAKTUPWES-PEURKWGASA-N
DM185DR IU (3S)-3-amino-4-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DM185DR CA CAS 126050-12-2
DM185DR DE Pain
DM35ABD ID DM35ABD
DM35ABD DN MEN-10627
DM35ABD HS Terminated
DM35ABD SN MEN10627; 157351-81-0; AC1NSKCE; GTPL3901; cyc(2beta-5beta)(Met-Asp-Trp-Phe-Dap-Leu); (1R,4S,7S,10R,13R,16S)-13-(1H-indol-3-ylmethyl)-4-(2-methylpropyl)-7-(2-methylsulfanylethyl)-16-(phenylmethyl)-3,6,9,12,15,18,20-heptazabicyclo[8.8.4]docosane-2,5,8,11,14,17,21-heptone
DM35ABD CP The Menarini Group
DM35ABD DT Small molecular drug
DM35ABD PC 10327792
DM35ABD MW 760.9
DM35ABD FM C38H48N8O7S
DM35ABD IC InChI=1S/C38H48N8O7S/c1-21(2)15-27-34(49)41-26(13-14-54-3)33(48)45-30-18-32(47)40-20-31(38(53)42-27)46-35(50)28(16-22-9-5-4-6-10-22)43-36(51)29(44-37(30)52)17-23-19-39-25-12-8-7-11-24(23)25/h4-12,19,21,26-31,39H,13-18,20H2,1-3H3,(H,40,47)(H,41,49)(H,42,53)(H,43,51)(H,44,52)(H,45,48)(H,46,50)/t26-,27-,28-,29-,30-,31-/m0/s1
DM35ABD CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CC(=O)NC[C@@H](C(=O)N1)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CCSC
DM35ABD IK CFDNUNSOUUFTQO-HPMAGDRPSA-N
DM35ABD IU (1S,4S,7S,10S,13S,16S)-4-benzyl-7-(1H-indol-3-ylmethyl)-16-(2-methylpropyl)-13-(2-methylsulfanylethyl)-2,5,8,11,14,17,20-heptazabicyclo[8.8.4]docosane-3,6,9,12,15,18,21-heptone
DM35ABD DE Asthma
DM57S3D ID DM57S3D
DM57S3D DN MEN-10690
DM57S3D HS Terminated
DM57S3D SN MEN 10690; AC1LA5QI; CHEMBL36080; 11-ethyl-6,8,9-trimethylpyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide; 11-ethyl-6,8,9-trimethyl-pyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide; 5-Ethyl-7,8,10-trimethyl-5,10-dihydro-11-thia-4,5,10-triaza-11H-dibenzo[a,d]cycloheptene 11,11-dioxide
DM57S3D CP The Menarini Group
DM57S3D DT Small molecular drug
DM57S3D PC 462253
DM57S3D MW 317.4
DM57S3D FM C16H19N3O2S
DM57S3D IC InChI=1S/C16H19N3O2S/c1-5-19-14-10-12(3)11(2)9-13(14)18(4)22(20,21)15-7-6-8-17-16(15)19/h6-10H,5H2,1-4H3
DM57S3D CS CCN1C2=C(C=C(C(=C2)C)C)N(S(=O)(=O)C3=C1N=CC=C3)C
DM57S3D IK WLQKTBMFEMJDPC-UHFFFAOYSA-N
DM57S3D IU 11-ethyl-6,8,9-trimethylpyrido[3,2-c][2,1,5]benzothiadiazepine 5,5-dioxide
DM57S3D DE Human immunodeficiency virus-1 infection
DMKS1W0 ID DMKS1W0
DMKS1W0 DN MEN-10880
DMKS1W0 HS Terminated
DMKS1W0 SN MEN 10880; AC1LA5Q9
DMKS1W0 CP The Menarini Group
DMKS1W0 DT Small molecular drug
DMKS1W0 PC 462250
DMKS1W0 MW 310.4
DMKS1W0 FM C16H14N4OS
DMKS1W0 IC InChI=1S/C16H14N4OS/c1-3-20-13-12-11(7-5-8-17-12)21-14(13)16(22)19(2)10-6-4-9-18-15(10)20/h4-9H,3H2,1-2H3
DMKS1W0 CS CCN1C2=C(C(=S)N(C3=C1N=CC=C3)C)OC4=C2N=CC=C4
DMKS1W0 IK SSUWZXRTDXAIQO-UHFFFAOYSA-N
DMKS1W0 IU 2-ethyl-9-methyl-12-oxa-2,4,9,17-tetrazatetracyclo[9.7.0.03,8.013,18]octadeca-1(11),3(8),4,6,13(18),14,16-heptaene-10-thione
DMKS1W0 DE Human immunodeficiency virus-1 infection
DM6UYN1 ID DM6UYN1
DM6UYN1 DN MEN-10979
DM6UYN1 HS Terminated
DM6UYN1 SN MEN 10979; AC1LA5PO
DM6UYN1 CP The Menarini Group
DM6UYN1 DT Small molecular drug
DM6UYN1 PC 462243
DM6UYN1 MW 326.4
DM6UYN1 FM C16H14N4S2
DM6UYN1 IC InChI=1S/C16H14N4S2/c1-3-20-13-12-11(7-5-8-17-12)22-14(13)16(21)19(2)10-6-4-9-18-15(10)20/h4-9H,3H2,1-2H3
DM6UYN1 CS CCN1C2=C(C(=S)N(C3=C1N=CC=C3)C)SC4=C2N=CC=C4
DM6UYN1 IK YRSMQXBXGMENSN-UHFFFAOYSA-N
DM6UYN1 IU 2-ethyl-9-methyl-12-thia-2,4,9,17-tetrazatetracyclo[9.7.0.03,8.013,18]octadeca-1(11),3(8),4,6,13(18),14,16-heptaene-10-thione
DM6UYN1 DE Human immunodeficiency virus-1 infection
DMEYNB0 ID DMEYNB0
DMEYNB0 DN MEN-11149
DMEYNB0 HS Terminated
DMEYNB0 CP The Menarini Group
DMEYNB0 PC 101940285
DMEYNB0 MW 600.7
DMEYNB0 FM C38H40N4O3
DMEYNB0 IC InChI=1S/C38H40N4O3/c1-25-15-17-26(18-16-25)23-36(43)42(2)35(22-27-19-20-28-9-3-4-10-29(28)21-27)41-37(44)31-12-6-8-14-34(31)40-38(45)32-24-39-33-13-7-5-11-30(32)33/h3-5,7,9-11,13,15-21,24,31,34-35,39H,6,8,12,14,22-23H2,1-2H3,(H,40,45)(H,41,44)/t31-,34+,35?/m1/s1
DMEYNB0 CS CC1=CC=C(C=C1)CC(=O)N(C)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)[C@@H]4CCCC[C@@H]4NC(=O)C5=CNC6=CC=CC=C65
DMEYNB0 IK DTPDRMYRFVVGJZ-SKZJHLMYSA-N
DMEYNB0 IU N-[(1S,2R)-2-[[1-[methyl-[2-(4-methylphenyl)acetyl]amino]-2-naphthalen-2-ylethyl]carbamoyl]cyclohexyl]-1H-indole-3-carboxamide
DMEYNB0 DE Asthma
DMNTIWC ID DMNTIWC
DMNTIWC DN MEN-11467
DMNTIWC HS Terminated
DMNTIWC CP The Menarini Group
DMNTIWC PC 9960352
DMNTIWC MW 600.7
DMNTIWC FM C38H40N4O3
DMNTIWC IC InChI=1S/C38H40N4O3/c1-25-15-17-26(18-16-25)23-36(43)42(2)35(22-27-19-20-28-9-3-4-10-29(28)21-27)38(45)41-34-14-8-7-13-33(34)40-37(44)31-24-39-32-12-6-5-11-30(31)32/h3-6,9-12,15-21,24,33-35,39H,7-8,13-14,22-23H2,1-2H3,(H,40,44)(H,41,45)/t33-,34+,35+/m0/s1
DMNTIWC CS CC1=CC=C(C=C1)CC(=O)N(C)[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H]4CCCC[C@@H]4NC(=O)C5=CNC6=CC=CC=C65
DMNTIWC IK JXDKAWGCUBTYFX-BMPTZRATSA-N
DMNTIWC IU N-[(1S,2R)-2-[[(2R)-2-[methyl-[2-(4-methylphenyl)acetyl]amino]-3-naphthalen-2-ylpropanoyl]amino]cyclohexyl]-1H-indole-3-carboxamide
DMNTIWC DE Respiratory tract inflammation
DMC8J6F ID DMC8J6F
DMC8J6F DN Methylthioadenosine
DMC8J6F HS Terminated
DMC8J6F SN 5'-Deoxy-5'-methylthioadenosine; 2457-80-9; Methylthioadenosine; 5'-S-methyl-5'-thioadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-DEOXY-5'-METHYLTHIOADENOSINE; (2R,3R,4S,5S)-2-(6-Amino-9H-purin-9-yl)-5-((methylthio)methyl)tetrahydrofuran-3,4-diol; Thiomethyladenosine; Vitamin L2; ADENOSINE, 5'-S-METHYL-5'-THIO-; 5'-S-Methylthioadenosine; MTA; S-methyl-5'-thioadenosine; Vitamin L(sub 2); UNII-634Z2VK3UQ; 5'-Deoxy(methylthio)adenosine; 5'-Deoxy-5'-Methylthioadenosine
DMC8J6F DT Small molecular drug
DMC8J6F PC 439176
DMC8J6F MW 297.34
DMC8J6F FM C11H15N5O3S
DMC8J6F IC InChI=1S/C11H15N5O3S/c1-20-2-5-7(17)8(18)11(19-5)16-4-15-6-9(12)13-3-14-10(6)16/h3-5,7-8,11,17-18H,2H2,1H3,(H2,12,13,14)/t5-,7-,8-,11-/m1/s1
DMC8J6F CS CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMC8J6F IK WUUGFSXJNOTRMR-IOSLPCCCSA-N
DMC8J6F IU (2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(methylsulfanylmethyl)oxolane-3,4-diol
DMC8J6F CA CAS 2457-80-9
DMC8J6F CB CHEBI:17509
DMC8J6F DE Multiple sclerosis
DMS5CZ4 ID DMS5CZ4
DMS5CZ4 DN METRIFUDIL
DMS5CZ4 HS Terminated
DMS5CZ4 SN Metrifudil; UNII-7K4GKQ4XSE; 7K4GKQ4XSE; 23707-33-7; CHEMBL331382; Y-341; N-[(2-Methylphenyl)methyl]adenosine; TH-322; Metrifudilum; Metrifudil [INN]; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(2-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol; Metrifudilum [INN-Latin]; Th 322; NCGC00015640-02; Adenosine analog, 16; Y 341; AC1L23SZ; DSSTox_RID_80718; DSSTox_CID_25168; DSSTox_GSID_45168; GTPL426; SCHEMBL472516; n6 -(2-methylbenzyl)adenosine; DTXSID1045168; OOEMZCZWZXHBKW-SCFUHWHPSA-N; ZINC4216929; Tox21_110187; BDBM50080390
DMS5CZ4 DT Small molecular drug
DMS5CZ4 PC 65710
DMS5CZ4 MW 371.4
DMS5CZ4 FM C18H21N5O4
DMS5CZ4 IC InChI=1S/C18H21N5O4/c1-10-4-2-3-5-11(10)6-19-16-13-17(21-8-20-16)23(9-22-13)18-15(26)14(25)12(7-24)27-18/h2-5,8-9,12,14-15,18,24-26H,6-7H2,1H3,(H,19,20,21)/t12-,14-,15-,18-/m1/s1
DMS5CZ4 CS CC1=CC=CC=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMS5CZ4 IK OOEMZCZWZXHBKW-SCFUHWHPSA-N
DMS5CZ4 IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(2-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol
DMS5CZ4 CA CAS 23707-33-7
DM1LGKP ID DM1LGKP
DM1LGKP DN Mevastatin
DM1LGKP HS Terminated
DM1LGKP SN Mevastatin; compactin; 73573-88-3; ML-236B; Mevastatinum; Mevastatine; Mevastatina; Mevastatinum [INN-Latin]; Antibiotic ML 236B; Mevastatin [INN]; CS 500; Compactin (penicillium); Mevastatine [INN-French]; UNII-1UQM1K0W9X; ML 236 B; Mevastatina [INN-Spanish]; CCRIS 4505; 1UQM1K0W9X; CHEMBL54440; CHEBI:34848; [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate; Mevastatin (Compactin); ML236B
DM1LGKP DT Small molecular drug
DM1LGKP PC 64715
DM1LGKP MW 390.5
DM1LGKP FM C23H34O5
DM1LGKP IC InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
DM1LGKP CS CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O
DM1LGKP IK AJLFOPYRIVGYMJ-INTXDZFKSA-N
DM1LGKP IU [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM1LGKP CA CAS 73573-88-3
DM1LGKP CB CHEBI:34848
DMHV5OD ID DMHV5OD
DMHV5OD DN MF268
DMHV5OD HS Terminated
DMHV5OD SN MF 268; 154619-51-9; 5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl {8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octyl}carbamate; Carbamic acid, (8-(2,6-dimethyl-4-morpholinyl)octyl)-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-(3a-alpha,5(2R*,6S*),8a-alpha))-; AC1MINCK; SCHEMBL2405111; CHEBI:43927; LS-49610; [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-[8-[(2S,6R)-2,6-dimet
DMHV5OD DT Small molecular drug
DMHV5OD PC 5288799
DMHV5OD MW 270.41
DMHV5OD FM C15H30N2O2
DMHV5OD IC InChI=1S/C15H30N2O2/c1-14-11-17(12-15(2)19-14)10-8-6-4-3-5-7-9-16-13-18/h13-15H,3-12H2,1-2H3,(H,16,18)/t14-,15+
DMHV5OD CS C[C@@H]1CN(C[C@@H](O1)C)CCCCCCCCNC=O
DMHV5OD IK UXVBAZRPAJEAHR-GASCZTMLSA-N
DMHV5OD IU N-[8-[(2S,6R)-2,6-dimethylmorpholin-4-yl]octyl]formamide
DMHV5OD DE Alzheimer disease
DM72MQP ID DM72MQP
DM72MQP DN MF-5137
DM72MQP HS Terminated
DM72MQP CP Mediolanum Farmaceutici SpA
DM72MQP PC 460150
DM72MQP MW 389.4
DM72MQP FM C23H23N3O3
DM72MQP IC InChI=1S/C23H23N3O3/c1-13-20-17(22(27)18(23(28)29)12-26(20)16-6-7-16)10-19(24)21(13)25-9-8-14-4-2-3-5-15(14)11-25/h2-5,10,12,16H,6-9,11,24H2,1H3,(H,28,29)
DM72MQP CS CC1=C2C(=CC(=C1N3CCC4=CC=CC=C4C3)N)C(=O)C(=CN2C5CC5)C(=O)O
DM72MQP IK LLVLMYRWABCVEU-UHFFFAOYSA-N
DM72MQP IU 6-amino-1-cyclopropyl-7-(3,4-dihydro-1H-isoquinolin-2-yl)-8-methyl-4-oxoquinoline-3-carboxylic acid
DM72MQP DE Staphylococcus infection
DM47WS2 ID DM47WS2
DM47WS2 DN MF-8615
DM47WS2 HS Terminated
DM47WS2 CP Mediolanum Farmaceutici SpA
DM47WS2 DE Alzheimer disease
DM9GOT6 ID DM9GOT6
DM9GOT6 DN MGBG
DM9GOT6 HS Terminated
DM9GOT6 SN MITOGUAZONE; Methyl-Gag; 459-86-9; Methylglyoxal bis(guanylhydrazone); Me-GAG; Methylglyoxal bis(amidinohydrazone); Methyl-G; C5H12N8; Pyruvaldehyde bis(amidinohydrazone); Mitoguazonum; Mitoguazona; CHEMBL216913; CHEBI:43996; Methyl GAG; Mitoguazone [INN:DCF]; Mitoguazonum [INN-Latin]; MGGH; Mitoguazona [INN-Spanish]; (2E,2'E)-2,2'-(1E,2E)-propane-1,2-diylidenedihydrazinecarboximidamide; BRN 1912590; 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
DM9GOT6 DT Small molecular drug
DM9GOT6 PC 5351154
DM9GOT6 MW 184.2
DM9GOT6 FM C5H12N8
DM9GOT6 IC InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
DM9GOT6 CS C/C(=N\\N=C(N)N)/C=N/N=C(N)N
DM9GOT6 IK MXWHMTNPTTVWDM-NXOFHUPFSA-N
DM9GOT6 IU 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
DM9GOT6 CA CAS 459-86-9
DM9GOT6 CB CHEBI:43996
DM9GOT6 DE Head and neck cancer
DM96WKA ID DM96WKA
DM96WKA DN Midaglizole
DM96WKA HS Terminated
DM96WKA SN Midaglizole hydrochloride; DG 5218; DG-5128; Pyridine, 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]-, monohydrochloride
DM96WKA CP Daiichi Seiyaku Co Ltd
DM96WKA DT Small molecular drug
DM96WKA PC 68864
DM96WKA MW 251.33
DM96WKA FM C16H17N3
DM96WKA IC InChI=1S/C16H17N3/c1-2-6-13(7-3-1)14(12-16-18-10-11-19-16)15-8-4-5-9-17-15/h1-9,14H,10-12H2,(H,18,19)
DM96WKA CS C1CN=C(N1)CC(C2=CC=CC=C2)C3=CC=CC=N3
DM96WKA IK TYZQFNOLWJGHRZ-UHFFFAOYSA-N
DM96WKA IU 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine
DM96WKA CA CAS 66529-17-7
DM96WKA DE Asthma
DMJTR0U ID DMJTR0U
DMJTR0U DN Milacemide
DMJTR0U HS Terminated
DMJTR0U SN Glyzac; Glyzan; Milacemide hydrochloride; CP-1552S
DMJTR0U CP GD Searle & Co
DMJTR0U DT Small molecular drug
DMJTR0U PC 53569
DMJTR0U MW 144.21
DMJTR0U FM C7H16N2O
DMJTR0U IC InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)
DMJTR0U CS CCCCCNCC(=O)N
DMJTR0U IK GJNNXIYZWIZFRH-UHFFFAOYSA-N
DMJTR0U IU 2-(pentylamino)acetamide
DMJTR0U CA CAS 76990-56-2
DMJTR0U DE Alzheimer disease
DMZNWAV ID DMZNWAV
DMZNWAV DN Miltirone
DMZNWAV HS Terminated
DMZNWAV SN Miltiron; Rosmariquinone
DMZNWAV CP Abbott Laboratories
DMZNWAV DT Small molecular drug
DMZNWAV PC 160142
DMZNWAV MW 282.4
DMZNWAV FM C19H22O2
DMZNWAV IC InChI=1S/C19H22O2/c1-11(2)14-10-12-7-8-15-13(6-5-9-19(15,3)4)16(12)18(21)17(14)20/h7-8,10-11H,5-6,9H2,1-4H3
DMZNWAV CS CC(C)C1=CC2=C(C3=C(C=C2)C(CCC3)(C)C)C(=O)C1=O
DMZNWAV IK FEFAIBOZOKSLJR-UHFFFAOYSA-N
DMZNWAV IU 8,8-dimethyl-2-propan-2-yl-6,7-dihydro-5H-phenanthrene-3,4-dione
DMZNWAV CA CAS 27210-57-7
DMZNWAV CB CHEBI:34851
DMZNWAV DE Anxiety disorder
DMQB8TW ID DMQB8TW
DMQB8TW DN Mimosine
DMQB8TW HS Terminated
DMQB8TW SN Mimosine; Leucenol; 10182-82-8; WZNJWVWKTVETCG-UHFFFAOYSA-N; NSC69188; NSC159548; 1(4H)-Pyridinealanine, 3-hydroxy-4-oxo-; beta-[N-(3-Hydroxy-4-pyridone)]-alpha-aminopropionic Acid; 1(4H)-Pyridinepropanoic acid, .alpha.-amino-3-hydroxy-4-oxo-, (.alpha.S)-; beta-(N-(3-Hydroxy-4-pyridone))-alpha-aminopropionic acid; Prestwick_830; Spectrum_000287; AC1L1GVQ; Spectrum4_000110; Prestwick0_000379; Mimosine, (+/-)-; Spectrum2_000656; Spectrum3_000722; Prestwick2_000379; Spectrum5_001484; Prestwick1_000379
DMQB8TW DT Small molecular drug
DMQB8TW PC 3862
DMQB8TW MW 198.18
DMQB8TW FM C8H10N2O4
DMQB8TW IC InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)
DMQB8TW CS C1=CN(C=C(C1=O)O)CC(C(=O)O)N
DMQB8TW IK WZNJWVWKTVETCG-UHFFFAOYSA-N
DMQB8TW IU 2-amino-3-(3-hydroxy-4-oxopyridin-1-yl)propanoic acid
DMQB8TW CA CAS 2116-55-4
DMQB8TW CB CHEBI:95190
DM7IXH3 ID DM7IXH3
DM7IXH3 DN MINAMESTANE
DM7IXH3 HS Terminated
DM7IXH3 SN FCE-24928; Minamestane; 4-Aminoandrosta-1,4,6-triene-3,17-dione
DM7IXH3 DT Small molecular drug
DM7IXH3 PC 65886
DM7IXH3 MW 297.4
DM7IXH3 FM C19H23NO2
DM7IXH3 IC InChI=1S/C19H23NO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h3-4,8,10-13H,5-7,9,20H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
DM7IXH3 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)C=CC4=C(C(=O)C=C[C@]34C)N
DM7IXH3 IK DAKHYLIFCYPHQW-KZQROQTASA-N
DM7IXH3 IU (8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione
DM7IXH3 CA CAS 105051-87-4
DM7IXH3 DE Bladder cancer
DMO06JV ID DMO06JV
DMO06JV DN Mitoflaxone
DMO06JV HS Terminated
DMO06JV SN Flavone acetic acid; flavone-8-acetic acid; 87626-55-9; LM-975; NSC-347512; Mitoflaxone [INN]; NSC 347512; Mitoflaxonum [INN-Latin]; Mitoflaxona [INN-Spanish]; 4H-1-BENZOPYRAN-8-ACETIC ACID, 4-OXO-2-PHENYL-; UNII-X230G6E63B; 2-Phenyl-8-(carboxymethyl)-benzopyran-4-one; NSC347512; 4-Oxo-2-phenyl-4H-1-benzopyran-8-acetic acid; BRN 4260339; MLS003171055; TZZNWMJZDWYJAZ-UHFFFAOYSA-N; X230G6E63B; Mitoflaxonum; Mitoflaxona; C17H12O4; Flavoneacetic acid; LM 975; Flavone-8- acetic acid; AC1L1JPE; NCIStruc2_000951; Flavone acetic acid; FAA, Merck; Flavone acetic acid, Merck; Flavone-8-acetic acid
DMO06JV CP Merck KGaA
DMO06JV DT Small molecular drug
DMO06JV PC 55748
DMO06JV MW 280.27
DMO06JV FM C17H12O4
DMO06JV IC InChI=1S/C17H12O4/c18-14-10-15(11-5-2-1-3-6-11)21-17-12(9-16(19)20)7-4-8-13(14)17/h1-8,10H,9H2,(H,19,20)
DMO06JV CS C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC(=C3O2)CC(=O)O
DMO06JV IK TZZNWMJZDWYJAZ-UHFFFAOYSA-N
DMO06JV IU 2-(4-oxo-2-phenylchromen-8-yl)acetic acid
DMO06JV CA CAS 87626-55-9
DMO06JV DE Solid tumour/cancer
DMT9QB5 ID DMT9QB5
DMT9QB5 DN MIV-170
DMT9QB5 HS Terminated
DMT9QB5 SN MIV-140; MSK-076; Non-nucleoside reverse transcriptase inhibitors, Medivir; HIV polymerase inhibitors, Medivir/Bristol-Myers Squibb; NNRTIs (HIV infection), Medivir/Bristol-Myers Squibb
DMT9QB5 CP Medivir AB
DMT9QB5 DT Small molecular drug
DMT9QB5 PC 71589251
DMT9QB5 MW 485.5
DMT9QB5 FM C24H21F2N3O4S
DMT9QB5 IC InChI=1S/C24H21F2N3O4S/c25-19-11-12-20(26)21-17(19)9-10-18-22(21)23(18)29-24(30)28-13-1-3-14(4-2-13)33-15-5-7-16(8-6-15)34(27,31)32/h1-8,11-12,18,22-23H,9-10H2,(H2,27,31,32)(H2,28,29,30)/t18-,22-,23-/m1/s1
DMT9QB5 CS C1CC2=C(C=CC(=C2[C@H]3[C@@H]1[C@H]3NC(=O)NC4=CC=C(C=C4)OC5=CC=C(C=C5)S(=O)(=O)N)F)F
DMT9QB5 IK FRIDRXJGZVLPIQ-SXSPYAJSSA-N
DMT9QB5 IU 1-[(1R,1aR,7bR)-4,7-difluoro-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalen-1-yl]-3-[4-(4-sulfamoylphenoxy)phenyl]urea
DMT9QB5 DE Human immunodeficiency virus infection
DMAITRL ID DMAITRL
DMAITRL DN MKC-1313
DMAITRL HS Terminated
DMAITRL SN HDAC inhibitors, EntreMed; HDAC inhibitors, Miikana; Histone deacetylase inhibitors (cancer); MKC-1192; MKC-1704; HDAC inhibitor (cancer), EntreMed; Histone deacetylase inhibitors (cancer), EntreMed; Histone deacetylase inhibitors (cancer), Miikana
DMAITRL CP Miikana Therapeutics Inc
DMAITRL DE Solid tumour/cancer
DMF27BS ID DMF27BS
DMF27BS DN MMV00/0053
DMF27BS HS Terminated
DMF27BS SN PfENR inhibitors, Jacobus; Plasmodium falciparum enoyl acyl carrier protein reductase inhibitors, Jacobus; FAS II inhibitors, Jacobus/MMV; Fatty acid biosynthesis II inhibitors, Jacobus/MMV
DMF27BS CP Jacobus Pharmaceutical Co Inc
DMF27BS DE Malaria
DM543VY ID DM543VY
DM543VY DN MOL-218
DM543VY HS Terminated
DM543VY SN MOL-254; MOL-268; MOL-294; NFkB inhibitors, Molecumetics
DM543VY CP Molecumetics Ltd
DM543VY DE Asthma
DMRCH1M ID DMRCH1M
DMRCH1M DN MOR-102
DMRCH1M HS Terminated
DMRCH1M SN MOR-101; MOR-101); ICAM-1 antibody (inflammation), MorphoSys
DMRCH1M CP MorphoSys AG
DMRCH1M DT Antibody
DMRCH1M DE Psoriasis vulgaris
DMO2S6T ID DMO2S6T
DMO2S6T DN MOXIFETIN HYDROGEN MALEATE
DMO2S6T HS Terminated
DMO2S6T SN VUFB-15468; 2-(3-Hydroxyphenylsulfanyl)-N,N-dimethylbenzylamine hydrogen maleate; 3-[2-(Dimethylaminomethyl)phenylsulfanyl]phenol hydrogen maleate
DMO2S6T DT Small molecular drug
DMO2S6T PC 6918142
DMO2S6T MW 375.4
DMO2S6T FM C19H21NO5S
DMO2S6T IC InChI=1S/C15H17NOS.C4H4O4/c1-16(2)11-12-6-3-4-9-15(12)18-14-8-5-7-13(17)10-14;5-3(6)1-2-4(7)8/h3-10,17H,11H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMO2S6T CS C[NH+](C)CC1=CC=CC=C1SC2=CC=CC(=C2)O.C(=C\\C(=O)[O-])\\C(=O)O
DMO2S6T IK YLZUWDVZEDYTBB-BTJKTKAUSA-N
DMO2S6T IU (Z)-4-hydroxy-4-oxobut-2-enoate;[2-(3-hydroxyphenyl)sulfanylphenyl]methyl-dimethylazanium
DMO2S6T DE Mood disorder
DMAVD4Q ID DMAVD4Q
DMAVD4Q DN MPI-461359
DMAVD4Q HS Terminated
DMAVD4Q SN MPI-0461359; Antiviral (HIV infection), Myrexis; Antiviral (HIV infection), Myriad
DMAVD4Q CP Myriad Genetics Inc
DMAVD4Q DE Human immunodeficiency virus infection
DM4A92X ID DM4A92X
DM4A92X DN MRL-953
DM4A92X HS Terminated
DM4A92X SN SDZ-MRL-953
DM4A92X CP Novartis AG
DM4A92X DE Immune System disease
DMXERCA ID DMXERCA
DMXERCA DN MS-377
DMXERCA HS Terminated
DMXERCA SN MS-377; SCHEMBL466934; DKVVPXLIRYCKCS-OAHLLOKOSA-N; AKOS003589066; (R)-1-(4-chlorophenyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)methyl-2-pyrrolidinone; (r)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]methyl-2-pyrrolidinone
DMXERCA CP Schering AG
DMXERCA DT Small molecular drug
DMXERCA PC 9892249
DMXERCA MW 351.9
DMXERCA FM C18H26ClN3O2
DMXERCA IC InChI=1S/C18H26ClN3O2/c1-24-13-12-20-8-10-21(11-9-20)14-15-6-7-22(18(15)23)17-4-2-16(19)3-5-17/h2-5,15H,6-14H2,1H3/t15-/m1/s1
DMXERCA CS COCCN1CCN(CC1)C[C@H]2CCN(C2=O)C3=CC=C(C=C3)Cl
DMXERCA IK DKVVPXLIRYCKCS-OAHLLOKOSA-N
DMXERCA IU (3R)-1-(4-chlorophenyl)-3-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]pyrrolidin-2-one
DMXERCA DE Schizophrenia
DMNYLEU ID DMNYLEU
DMNYLEU DN MSC-204
DMNYLEU HS Terminated
DMNYLEU SN MSC-206; PETT-2; PETT-4
DMNYLEU CP Medivir AB
DMNYLEU DT Small molecular drug
DMNYLEU PC 468178
DMNYLEU MW 422.2
DMNYLEU FM C18H17BrFN3O3
DMNYLEU IC InChI=1S/C18H17BrFN3O3/c1-2-14(24)10-4-5-12(20)16(17(10)25)11-7-13(11)22-18(26)23-15-6-3-9(19)8-21-15/h3-6,8,11,13,25H,2,7H2,1H3,(H2,21,22,23,26)/t11-,13+/m0/s1
DMNYLEU CS CCC(=O)C1=C(C(=C(C=C1)F)[C@H]2C[C@H]2NC(=O)NC3=NC=C(C=C3)Br)O
DMNYLEU IK VRAJWAGCJIXJHQ-WCQYABFASA-N
DMNYLEU IU 1-(5-bromopyridin-2-yl)-3-[(1R,2R)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
DMNYLEU DE Human immunodeficiency virus infection
DMXW67H ID DMXW67H
DMXW67H DN MX-6120
DMXW67H HS Terminated
DMXW67H SN Endothelin-1 antagonists (heart disease); ET-1 antagonists (heart disease), Maxia; Endothelin-1 antagonists (heart disease), Maxia
DMXW67H CP Maxia Pharmaceuticals Inc
DMXW67H DE Heart disease
DMP26BW ID DMP26BW
DMP26BW DN MX-7065
DMP26BW HS Terminated
DMP26BW SN Cdc25 phosphatase inhibitors, Maxia Pharmaceuticals; MX-7102; MX-7174; MX-7214; MX-7306
DMP26BW CP Maxia Pharmaceuticals Inc
DMP26BW DE Solid tumour/cancer
DMNZ356 ID DMNZ356
DMNZ356 DN MX-781
DMNZ356 HS Terminated
DMNZ356 CP Maxia Pharmaceuticals Inc
DMNZ356 DE Breast cancer
DM31CV2 ID DM31CV2
DM31CV2 DN NAFAZATROM
DM31CV2 HS Terminated
DM31CV2 SN NAFAZATROM; Bay-g-6575; Bay-g 6575; Nafazatromum [INN-Latin]; BAY g 6575; 59040-30-1; UNII-K94216221B; EINECS 261-571-1; BRN 0665222; K94216221B; 2,4-Dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl)-3H-pyrazol-3-one; 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl)-; 3-Methyl-1-(2-(2-naphthyloxy)ethyl)-2-pyrazolin-5-one; Nafazatromum; Nafazatrom [INN:BAN]; Nafazatrom [BAN:INN]; SCHEMBL93681; Oprea1_097893; AC1L28U1; ZINC1764; 5-methyl-2-(2-naphthalen-2-yloxyethyl)-4H-pyrazol-3-one; DTXSID00207794
DM31CV2 DT Small molecular drug
DM31CV2 PC 42923
DM31CV2 MW 268.31
DM31CV2 FM C16H16N2O2
DM31CV2 IC InChI=1S/C16H16N2O2/c1-12-10-16(19)18(17-12)8-9-20-15-7-6-13-4-2-3-5-14(13)11-15/h2-7,11H,8-10H2,1H3
DM31CV2 CS CC1=NN(C(=O)C1)CCOC2=CC3=CC=CC=C3C=C2
DM31CV2 IK ISBUYSPRIJRBKX-UHFFFAOYSA-N
DM31CV2 IU 5-methyl-2-(2-naphthalen-2-yloxyethyl)-4H-pyrazol-3-one
DM31CV2 CA CAS 59040-30-1
DM7T2FO ID DM7T2FO
DM7T2FO DN Naltiazem hydrochloride
DM7T2FO HS Terminated
DM7T2FO SN Ro-23-6152; Ro-23-6152/001; (+)-cis-3-Acetoxy-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-2,3,4,5-tetrahydronaphtho[1,2-b][1,4]thiazepin-4-one hydrochloride
DM7T2FO DT Small molecular drug
DM7T2FO PC 130121
DM7T2FO MW 501
DM7T2FO FM C26H29ClN2O4S
DM7T2FO IC InChI=1S/C26H28N2O4S.ClH/c1-17(29)32-23-24(19-9-12-20(31-4)13-10-19)33-25-21-8-6-5-7-18(21)11-14-22(25)28(26(23)30)16-15-27(2)3;/h5-14,23-24H,15-16H2,1-4H3;1H/t23-,24+;/m1./s1
DM7T2FO CS CC(=O)O[C@@H]1[C@@H](SC2=C(C=CC3=CC=CC=C32)N(C1=O)CCN(C)C)C4=CC=C(C=C4)OC.Cl
DM7T2FO IK SFTBZKFGODNAKF-ITNPDYSASA-N
DM7T2FO IU [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydrobenzo[i][1,5]benzothiazepin-3-yl] acetate;hydrochloride
DM7T2FO CA CAS 108383-96-6
DM7T2FO DE Angina pectoris
DMML3J4 ID DMML3J4
DMML3J4 DN NAN-190
DMML3J4 HS Terminated
DMML3J4 SN NAN-190; Nan 190; NAN190; SJDOMIRMMUGQQK-UHFFFAOYSA-N; CHEMBL8618; CHEBI:64131; 2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione; 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine; 2-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1H-isoindole-1,3(2H)-dione; 2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]isoindole-1,3-dione; 2-{4-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-butyl}-isoindole-1,3-dione; 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine
DMML3J4 DT Small molecular drug
DMML3J4 PC 4431
DMML3J4 MW 393.5
DMML3J4 FM C23H27N3O3
DMML3J4 IC InChI=1S/C23H27N3O3/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28/h2-5,8-11H,6-7,12-17H2,1H3
DMML3J4 CS COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)C4=CC=CC=C4C3=O
DMML3J4 IK SJDOMIRMMUGQQK-UHFFFAOYSA-N
DMML3J4 IU 2-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]isoindole-1,3-dione
DMML3J4 CA CAS 102392-05-2
DMML3J4 CB CHEBI:64131
DM8FB6E ID DM8FB6E
DM8FB6E DN Navuridine
DM8FB6E HS Terminated
DM8FB6E SN AZDU; Azidouridine; AVS-2353; CS-87
DM8FB6E CP Bayer Schering Pharma AG
DM8FB6E DT Small molecular drug
DM8FB6E PC 55262
DM8FB6E MW 253.22
DM8FB6E FM C9H11N5O4
DM8FB6E IC InChI=1S/C9H11N5O4/c10-13-12-5-3-8(18-6(5)4-15)14-2-1-7(16)11-9(14)17/h1-2,5-6,8,15H,3-4H2,(H,11,16,17)/t5-,6+,8+/m0/s1
DM8FB6E CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)N=[N+]=[N-]
DM8FB6E IK ZSNNBSPEFVIUDS-SHYZEUOFSA-N
DM8FB6E IU 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM8FB6E CA CAS 84472-85-5
DM8FB6E DE Human immunodeficiency virus infection
DMJVTQN ID DMJVTQN
DMJVTQN DN NB-598
DMJVTQN HS Terminated
DMJVTQN SN KIRGLCXNEVICOG-SOFGYWHQSA-N; 131060-14-5; NB 598; CHEMBL27885; (E)-3-[(3,3'-Bithiophen)-5-ylmethoxy]-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-ethylbenzylamine; (2E)-N-({3-[([3,3'-bithiophen]-5-yl)methoxy]phenyl}methyl)-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine; AC1O5YMV; SCHEMBL9454494; C27H31NOS2; GTPL3103; SCHEMBL9454490; (E)-N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine; ZINC2003883; BCP28146; EX-A1748; BDBM50032850; 3914AH; AKOS030526399; CS-1274; NCGC00165845-01
DMJVTQN DT Small molecular drug
DMJVTQN PC 6443223
DMJVTQN MW 449.7
DMJVTQN FM C27H31NOS2
DMJVTQN IC InChI=1S/C27H31NOS2/c1-5-28(14-8-6-7-13-27(2,3)4)18-22-10-9-11-25(16-22)29-19-26-17-24(21-31-26)23-12-15-30-20-23/h6,8-12,15-17,20-21H,5,14,18-19H2,1-4H3/b8-6+
DMJVTQN CS CCN(C/C=C/C#CC(C)(C)C)CC1=CC(=CC=C1)OCC2=CC(=CS2)C3=CSC=C3
DMJVTQN IK KIRGLCXNEVICOG-SOFGYWHQSA-N
DMJVTQN IU (E)-N-ethyl-6,6-dimethyl-N-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine
DMJVTQN CA CAS 131060-14-5
DM3JY2N ID DM3JY2N
DM3JY2N DN NBI-37582
DM3JY2N HS Terminated
DM3JY2N SN UNII-PL877312XZ; PL877312XZ; RO-23-9424 dihydrochloride; SCHEMBL9844164
DM3JY2N CP Neurocrine Biosci
DM3JY2N DT Small molecular drug
DM3JY2N PC 9690113
DM3JY2N MW 837.7
DM3JY2N FM C31H33Cl2F3N8O8S2
DM3JY2N IC InChI=1S/C31H31F3N8O8S2.2ClH/c1-39-5-7-40(8-6-39)24-17(33)9-15-23(19(24)34)41(4-3-32)10-16(25(15)43)30(48)50-11-14-12-51-28-21(27(45)42(28)22(14)29(46)47)37-26(44)20(38-49-2)18-13-52-31(35)36-18;;/h9-10,13,21,28H,3-8,11-12H2,1-2H3,(H2,35,36)(H,37,44)(H,46,47);2*1H/b38-20-;;/t21-,28-;;/m1../s1
DM3JY2N CS CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)OCC4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\OC)/C6=CSC(=N6)N)SC4)C(=O)O)CCF)F.Cl.Cl
DM3JY2N IK DSGXXSRGPIYUHF-ZVOUVGCISA-N
DM3JY2N IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyl]oxymethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;dihydrochloride
DM3JY2N CA CAS 139263-69-7
DM3JY2N DE Depression; Anxiety disorder
DMEH50J ID DMEH50J
DMEH50J DN NE-033
DMEH50J HS Terminated
DMEH50J SN IDDB7806
DMEH50J CP Taisho Pharmaceutical Co Ltd
DMEH50J DE Psychotic disorder
DMP4J7T ID DMP4J7T
DMP4J7T DN NE-100
DMP4J7T HS Terminated
DMP4J7T SN NE 100; N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride; N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride; Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride
DMP4J7T CP Taisho
DMP4J7T DT Small molecular drug
DMP4J7T PC 9952420
DMP4J7T MW 392
DMP4J7T FM C23H34ClNO2
DMP4J7T IC InChI=1S/C23H33NO2.ClH/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20;/h6-12,19H,4-5,13-18H2,1-3H3;1H
DMP4J7T CS CCCN(CCC)CCC1=CC(=C(C=C1)OC)OCCC2=CC=CC=C2.Cl
DMP4J7T IK ZHGMDXSHODHWHV-UHFFFAOYSA-N
DMP4J7T IU N-[2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl]-N-propylpropan-1-amine;hydrochloride
DMP4J7T CA CAS 149409-57-4
DMP4J7T DE Schizophrenia
DMHYQ8K ID DMHYQ8K
DMHYQ8K DN Nerve growth factor
DMHYQ8K HS Terminated
DMHYQ8K SN Neuleze; Nerve growth factor (recombinant); RhNGF, Genentech; NGF-beta, Genentech; Nerve growth factor (recombinant), Genentech; Nerve growth factor, Mitsubishi/Dompe/Fidia
DMHYQ8K CP Genentech Inc
DMHYQ8K DE Alzheimer disease
DMFA26E ID DMFA26E
DMFA26E DN NGD-93-1
DMFA26E HS Terminated
DMFA26E CP Neurogen Corp
DMFA26E DE Psychotic disorder
DMSPWMF ID DMSPWMF
DMSPWMF DN Niguldipine
DMSPWMF HS Terminated
DMSPWMF SN NIGULDIPINE; S(+)-niguldipine; UNII-Z81N45O25Z; S(+)-Niguldipine hydrochloride; 113165-32-5; Z81N45O25Z; (+)-NIGULDIPINE; Niguldipine [INN]; niguldipine[inn]; (S)-Niguldipine; Tocris-1123; Tocris-1124; AC1Q1ZUF; AC1L1TKT; S(+)-1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride; GTPL487; SCHEMBL245992; CHEMBL41929; CHEMBL405355; DTXSID60274008; CHEBI:103931; MFCD00873564; BDBM50034683; BDBM50453799; ZINC100001967; DB09239; NCGC00025015-01
DMSPWMF DT Small molecular drug
DMSPWMF PC 1236
DMSPWMF MW 609.7
DMSPWMF FM C36H39N3O6
DMSPWMF IC InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3
DMSPWMF CS CC1=C(C(C(=C(N1)C)C(=O)OCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC
DMSPWMF IK SVJMLYUFVDMUHP-UHFFFAOYSA-N
DMSPWMF IU 5-O-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMSPWMF CA CAS 102993-22-6
DMSPWMF CB CHEBI:7572
DM4U7XB ID DM4U7XB
DM4U7XB DN NIK-616
DM4U7XB HS Terminated
DM4U7XB CP Kowa Pharmaceutical Co Ltd
DM4U7XB DE Chronic obstructive pulmonary disease
DMR1NMD ID DMR1NMD
DMR1NMD DN Nimesulide
DMR1NMD HS Terminated
DMR1NMD SN nimesulide; 51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
DMR1NMD DT Small molecular drug
DMR1NMD PC 4495
DMR1NMD MW 308.31
DMR1NMD FM C13H12N2O5S
DMR1NMD IC InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
DMR1NMD CS CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2
DMR1NMD IK HYWYRSMBCFDLJT-UHFFFAOYSA-N
DMR1NMD IU N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
DMR1NMD CA CAS 51803-78-2
DMR1NMD CB CHEBI:44445
DMR1NMD DE Metastatic colorectal cancer; Non-small-cell lung cancer; Non-hodgkin lymphoma
DM5IFU9 ID DM5IFU9
DM5IFU9 DN NMI-1182
DM5IFU9 HS Terminated
DM5IFU9 SN Naproxen-related CINOD, NitroMed
DM5IFU9 CP NitroMed Inc
DM5IFU9 DT Small molecular drug
DM5IFU9 PC 10250021
DM5IFU9 MW 394.3
DM5IFU9 FM C17H18N2O9
DM5IFU9 IC InChI=1S/C17H18N2O9/c1-11(12-3-4-14-8-15(25-2)6-5-13(14)7-12)17(20)26-9-16(28-19(23)24)10-27-18(21)22/h3-8,11,16H,9-10H2,1-2H3/t11-,16+/m0/s1
DM5IFU9 CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OC[C@H](CO[N+](=O)[O-])O[N+](=O)[O-]
DM5IFU9 IK DHMLCNFGWGUOSW-MEDUHNTESA-N
DM5IFU9 IU [(2R)-2,3-dinitrooxypropyl] (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DM5IFU9 DE Inflammation
DMX6DNZ ID DMX6DNZ
DMX6DNZ DN NMI-150
DMX6DNZ HS Terminated
DMX6DNZ SN NO-COX-2 inhibitor, NitroMed/Merck & Co; Nitric oxide-enhancing COX-2 inhibitor, NitroMed/Merck & Co
DMX6DNZ CP NitroMed Inc
DMX6DNZ DE Pain
DMPZ1EC ID DMPZ1EC
DMPZ1EC DN NNC 05-2045
DMPZ1EC HS Terminated
DMGEHZ9 ID DMGEHZ9
DMGEHZ9 DN NNC-09-0026
DMGEHZ9 HS Terminated
DMGEHZ9 SN Nnc 09-0026; Nnc-09-0026; 141360-03-4; AC1L30TY; 1-Butyl-4-(4-dimethylaminophenyl)-3-(4-trifluoromethylphenoxymethyl)piperidine dihydrochloride; SCHEMBL7413433; DTXSID90161699; 4-(1-Butyl-3-((4-(trifluoromethyl)phenoxy)methyl)-4-piperidinyl)-N,N-dimethylbenzenamine dihydrochloride, trans-(-)-; Benzenamine, 4-(1-butyl-3-((4-(trifluoromethyl)phenoxy)methyl)-4-piperidinyl)-N,N-dimethyl-, dihydrochloride, trans-(-)-; 4-[(3R,4S)-1-butyl-3-[[4-(trifluoromethyl)phenoxy]methyl]piperidin-4-yl]-N,N-dimethylaniline dihydrochlo
DMGEHZ9 CP Novo Nordisk A/S
DMGEHZ9 DT Small molecular drug
DMGEHZ9 PC 132350
DMGEHZ9 MW 507.5
DMGEHZ9 FM C25H35Cl2F3N2O
DMGEHZ9 IC InChI=1S/C25H33F3N2O.2ClH/c1-4-5-15-30-16-14-24(19-6-10-22(11-7-19)29(2)3)20(17-30)18-31-23-12-8-21(9-13-23)25(26,27)28;;/h6-13,20,24H,4-5,14-18H2,1-3H3;2*1H/t20-,24-;;/m1../s1
DMGEHZ9 CS CCCCN1CC[C@@H]([C@H](C1)COC2=CC=C(C=C2)C(F)(F)F)C3=CC=C(C=C3)N(C)C.Cl.Cl
DMGEHZ9 IK VAJHWBBBDAHYRE-OYNPXDHBSA-N
DMGEHZ9 IU 4-[(3R,4S)-1-butyl-3-[[4-(trifluoromethyl)phenoxy]methyl]piperidin-4-yl]-N,N-dimethylaniline;dihydrochloride
DMGEHZ9 CA CAS 141360-03-4
DMGEHZ9 DE Cerebrovascular ischaemia
DMMOAN0 ID DMMOAN0
DMMOAN0 DN NNC-13-8119
DMMOAN0 HS Terminated
DMMOAN0 SN FG-8119
DMMOAN0 CP Novo Nordisk A/S
DMMOAN0 DE Anxiety disorder
DMK7BV9 ID DMK7BV9
DMK7BV9 DN NNC-22-0031
DMK7BV9 HS Terminated
DMK7BV9 SN Nnc 220031; 160436-12-4; Nnc 22-0031; AC1MIXSG; 4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-(3-(3,4-methylenedioxyphenylcarbamoyloxy)propyl)piperidine; DTXSID50166882; 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl N-(1,3-benzodioxol-5-yl)carbamate hydrochloride; Carbamic acid, 1,3-benzodioxol-5-yl-, 3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propyl ester, monohydrochloride
DMK7BV9 CP Novo Nordisk A/S
DMK7BV9 DT Small molecular drug
DMK7BV9 PC 3081915
DMK7BV9 MW 441.5
DMK7BV9 FM C23H24FN3O5
DMK7BV9 IC InChI=1S/C23H24FN3O5/c24-16-2-4-18-20(12-16)32-26-22(18)15-6-9-27(10-7-15)8-1-11-29-23(28)25-17-3-5-19-21(13-17)31-14-30-19/h2-5,12-13,15H,1,6-11,14H2,(H,25,28)
DMK7BV9 CS C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCCOC(=O)NC4=CC5=C(C=C4)OCO5
DMK7BV9 IK ZEMJDGPKDOUEEZ-UHFFFAOYSA-N
DMK7BV9 IU 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl N-(1,3-benzodioxol-5-yl)carbamate
DMK7BV9 DE Psychotic disorder
DM0BYU2 ID DM0BYU2
DM0BYU2 DN NNC-252504
DM0BYU2 HS Terminated
DM0BYU2 SN Glucagon antagonists, Agouron/Novo Nordisk; NNC-25-0926; NNC-25-2504; NNC-25-2648
DM0BYU2 CP Agouron Pharmaceuticals Inc
DM0BYU2 DE Type-2 diabetes
DMLTYFI ID DMLTYFI
DMLTYFI DN NNC-26-0762
DMLTYFI HS Terminated
DMLTYFI SN Growth hormone secretagogues, Novo Nordisk; NNC-26-0722
DMLTYFI CP Novo Nordisk A/S
DMLTYFI DE Growth hormone deficiency
DM1SXG9 ID DM1SXG9
DM1SXG9 DN NNC-90-0270
DM1SXG9 HS Terminated
DM1SXG9 SN Nicotinic ACh agonists, Novo Nordisk
DM1SXG9 CP Novo Nordisk A/S
DM1SXG9 DE Alzheimer disease
DMX24FM ID DMX24FM
DMX24FM DN Nomifensine
DMX24FM HS Discontinued
DMX24FM SN Alival; D,L-nomifensine; Linamiphen; Nomifensina; Nomifensina [INN-Spanish]; Nomifensine; Nomifensine [INN:BAN]; Nomifensinum; Nomifensinum [INN-Latin]; nomifensin; (+)-Nomifensine; (+)-Nomiphensine; (+-)-Nomifensin; (+-)-Nomifensine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine; 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine; 24526-64-5; 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-; BRN 6064059; CCRIS 9179
DMX24FM PC 4528
DMX24FM MW 238.33
DMX24FM FM C16H18N2
DMX24FM IC XXPANQJNYNUNES-UHFFFAOYSA-N
DMX24FM CS CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3
DMX24FM IK 1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3
DMX24FM IU 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine
DMX24FM CA CAS 24526-64-5
DMX24FM CB CHEBI:116225
DMX24FM DE Depression
DM78P4X ID DM78P4X
DM78P4X DN NOX-200
DM78P4X HS Terminated
DM78P4X SN 2-Amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; alpha-Methyl-DL-tryptophan; 153-91-3; 2-amino-3-(1H-indol-3-yl)-2-methylpropanoic acid; NSC9948; 13510-08-2; alpha-Methyl-L-tryptophan; M-5098; Tryptophan, alpha-methyl-; 16709-25-4; DL-alpha-Methyltryptophan; alpha-methyl-D,L-tryptophan; NSC-9948; NSC 9948; Tryptophan,a-methyl-; ACMC-1BNRO; alpha-Methyltryptophan; AC1L3UBI; AC1Q5S1L; (S)-alpha-Methyl pryptophan; SCHEMBL343309; CHEMBL559578; GTPL4693; CTK4C8033; ZTTWHZHBPDYSQB-UHFFFAOYSA-N; MolPort-003-958-850; KS-000001AA; ANW-21478
DM78P4X CP Medinox Inc
DM78P4X DT Small molecular drug
DM78P4X PC 95438
DM78P4X MW 218.25
DM78P4X FM C12H14N2O2
DM78P4X IC InChI=1S/C12H14N2O2/c1-12(13,11(15)16)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,14H,6,13H2,1H3,(H,15,16)
DM78P4X CS CC(CC1=CNC2=CC=CC=C21)(C(=O)O)N
DM78P4X IK ZTTWHZHBPDYSQB-UHFFFAOYSA-N
DM78P4X IU 2-amino-3-(1H-indol-3-yl)-2-methylpropanoic acid
DM78P4X CA CAS 153-91-3
DM78P4X DE Rheumatoid arthritis
DM4B1VF ID DM4B1VF
DM4B1VF DN NP-7557
DM4B1VF HS Terminated
DM4B1VF SN Alzheimers disease therapy, Nastech; AChEI therapy (intranasal), Nastech
DM4B1VF CP Marina Biotech Inc
DM4B1VF DE Alzheimer disease
DM35RTJ ID DM35RTJ
DM35RTJ DN NPC-16377
DM35RTJ HS Terminated
DM35RTJ SN Npc-16377; 139652-86-1; 6-(6-(4-hydroxypiperidinyl)hexyloxy)-3-methylflavone hydrochloride; Npc 16377; npc16377; SCHEMBL8787810; DTXSID40161144; 6-(6-(4-Hydroxypiperidinyl)hexyloxy)-3-methylflavone HCl; 4H-1-Benzopyran-4-one, 6-((6-(4-hydroxy-1-piperidinyl)hexyl)oxy)-3-methyl-2-phenyl-, hydrochloride
DM35RTJ CP Scios Inc
DM35RTJ DT Small molecular drug
DM35RTJ PC 9890958
DM35RTJ MW 472
DM35RTJ FM C27H34ClNO4
DM35RTJ IC InChI=1S/C27H33NO4.ClH/c1-20-26(30)24-19-23(11-12-25(24)32-27(20)21-9-5-4-6-10-21)31-18-8-3-2-7-15-28-16-13-22(29)14-17-28;/h4-6,9-12,19,22,29H,2-3,7-8,13-18H2,1H3;1H
DM35RTJ CS CC1=C(OC2=C(C1=O)C=C(C=C2)OCCCCCCN3CCC(CC3)O)C4=CC=CC=C4.Cl
DM35RTJ IK GWSBQIZSTCDSLE-UHFFFAOYSA-N
DM35RTJ IU 6-[6-(4-hydroxypiperidin-1-yl)hexoxy]-3-methyl-2-phenylchromen-4-one;hydrochloride
DM35RTJ CA CAS 139652-86-1
DM35RTJ DE Psychotic disorder
DMGVIZY ID DMGVIZY
DMGVIZY DN NPC-17731
DMGVIZY HS Terminated
DMGVIZY SN Bradykinin antagonists, Scios; NPC-16731; NPC-17761; NPC-18521; NPC-18688; NPC-18884
DMGVIZY CP Scios Inc
DMGVIZY DT Small molecular drug
DMGVIZY PC 3081308
DMGVIZY MW 1294.5
DMGVIZY FM C59H95N19O14
DMGVIZY IC InChI=1S/C59H95N19O14/c1-2-23-92-35-27-42(71-29-35)53(88)78(54(89)43-25-33-13-6-7-15-38(33)73-43)59(55(90)91,48(83)44(31-79)76-51(86)41(24-32-11-4-3-5-12-32)74-46(81)30-72-50(85)40-26-34(80)28-70-40)36(18-21-69-58(65)66)47(82)45-17-10-22-77(45)52(87)39(16-9-20-68-57(63)64)75-49(84)37(60)14-8-19-67-56(61)62/h3-5,11-12,33-45,70-71,73,79-80H,2,6-10,13-31,60H2,1H3,(H,72,85)(H,74,81)(H,75,84)(H,76,86)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,34?,35-,36?,37+,38-,39-,40-,41-,42+,43?,44-,45-,59-/m0/s1
DMGVIZY CS CCCO[C@H]1C[C@@H](NC1)C(=O)N(C(=O)C2C[C@@H]3CCCC[C@@H]3N2)[C@@](C(CCN=C(N)N)C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)(C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)[C@@H]6CC(CN6)O)C(=O)O
DMGVIZY IK WYWZCALINPVKJW-KOCZGPIPSA-N
DMGVIZY IU (2S,4S)-2-[[(3aS,7aS)-2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carbonyl]-[(2R,4S)-4-propoxypyrrolidine-2-carbonyl]amino]-2-[1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidin-2-yl]-4-(diaminomethylideneamino)-1-oxobutan-2-yl]-5-hydroxy-4-[[(2S)-2-[[2-[[(2S)-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-oxopentanoic acid
DMGVIZY CA CAS 147267-10-5
DMGVIZY DE Asthma
DMD01GK ID DMD01GK
DMD01GK DN NPC-17923
DMD01GK HS Terminated
DMD01GK SN 147960-65-4; N-(9H-(2,7-Dichlorofluorenyl)-9-ethoxycarbonyl)-4-aminobenzoic acid; Benzoic acid, 4-((3-((2,7-dichloro-9H-fluoren-9-yl)oxy)-1-oxopropyl)amino)-
DMD01GK CP Scios Inc
DMD01GK DT Small molecular drug
DMD01GK PC 9824607
DMD01GK MW 442.3
DMD01GK FM C23H17Cl2NO4
DMD01GK IC InChI=1S/C23H17Cl2NO4/c24-14-3-7-17-18-8-4-15(25)12-20(18)22(19(17)11-14)30-10-9-21(27)26-16-5-1-13(2-6-16)23(28)29/h1-8,11-12,22H,9-10H2,(H,26,27)(H,28,29)
DMD01GK CS C1=CC(=CC=C1C(=O)O)NC(=O)CCOC2C3=C(C=CC(=C3)Cl)C4=C2C=C(C=C4)Cl
DMD01GK IK JTYWUQLFBWFIEV-UHFFFAOYSA-N
DMD01GK IU 4-[3-[(2,7-dichloro-9H-fluoren-9-yl)oxy]propanoylamino]benzoic acid
DMD01GK CA CAS 147960-65-4
DMD01GK DE Rheumatoid arthritis
DMAIH90 ID DMAIH90
DMAIH90 DN NPC-18166
DMAIH90 HS Terminated
DMAIH90 SN IDDB8389
DMAIH90 CP Scios Inc
DMAIH90 DE Psychotic disorder
DMH1YL8 ID DMH1YL8
DMH1YL8 DN NPI-1999
DMH1YL8 HS Terminated
DMH1YL8 SN Serine protease inhibitors, NovoScience
DMH1YL8 CP NovoScience Pharma Inc
DMH1YL8 DE Thrombosis
DMTWXE3 ID DMTWXE3
DMTWXE3 DN NPS-1392
DMTWXE3 HS Terminated
DMTWXE3 CP NPS Pharmaceuticals Inc
DMTWXE3 PC 9860006
DMTWXE3 MW 261.31
DMTWXE3 FM C16H17F2N
DMTWXE3 IC InChI=1S/C16H17F2N/c1-11(10-19)16(12-4-2-6-14(17)8-12)13-5-3-7-15(18)9-13/h2-9,11,16H,10,19H2,1H3/t11-/m0/s1
DMTWXE3 CS C[C@@H](CN)C(C1=CC(=CC=C1)F)C2=CC(=CC=C2)F
DMTWXE3 IK WEEQOTXCUZRCLD-NSHDSACASA-N
DMTWXE3 IU (2R)-3,3-bis(3-fluorophenyl)-2-methylpropan-1-amine
DMTWXE3 DE Cerebrovascular ischaemia
DMNL1VM ID DMNL1VM
DMNL1VM DN NPS-846
DMNL1VM HS Terminated
DMNL1VM SN NPS 846.HCl
DMNL1VM CP NPS Pharmaceuticals Inc
DMNL1VM DE Cerebrovascular ischaemia
DMCHLJ4 ID DMCHLJ4
DMCHLJ4 DN NS-004
DMCHLJ4 HS Terminated
DMCHLJ4 SN NS004; NS-004; NS-O04; 1-(5-Chloro-2-hydroxyphenyl)-5-trifluoromethyl-1,3-dihydrobenzoimidazol-2-one; WYLYBVMNGZOYOH-UHFFFAOYSA-N; AC1NSKFZ; ZINC5663; SCHEMBL8911620; GTPL4271; CHEMBL375448; SCHEMBL3102522; KB-09311; 1-[2-hydroxy-5-chlorophenyl]-5-trifluoromethyl-2-benzimidazolone; 3-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-1H-benzimidazol-2-one; 2H-benzimidazol-2-one, 1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-5-(trifluoromethyl)-; 1,3-dihydro-1-(5-chloro-2-hydroxyphenyl)-5-trifluoromethyl-2H-benzimidazol-2-one
DMCHLJ4 CP NeuroSearch A/S
DMCHLJ4 DT Small molecular drug
DMCHLJ4 PC 5311330
DMCHLJ4 MW 328.67
DMCHLJ4 FM C14H8ClF3N2O2
DMCHLJ4 IC InChI=1S/C14H8ClF3N2O2/c15-8-2-4-12(21)11(6-8)20-10-3-1-7(14(16,17)18)5-9(10)19-13(20)22/h1-6,21H,(H,19,22)
DMCHLJ4 CS C1=CC2=C(C=C1C(F)(F)F)NC(=O)N2C3=C(C=CC(=C3)Cl)O
DMCHLJ4 IK WYLYBVMNGZOYOH-UHFFFAOYSA-N
DMCHLJ4 IU 3-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMCHLJ4 DE Hypertension
DM75DZ1 ID DM75DZ1
DM75DZ1 DN NS-1546
DM75DZ1 HS Terminated
DM75DZ1 CP NeuroSearch A/S
DM75DZ1 DE Major depressive disorder
DMYV9M1 ID DMYV9M1
DMYV9M1 DN NS-1608
DMYV9M1 HS Terminated
DMYV9M1 SN NS 1608; CHEMBL33891; NS-1608; Kinome_784; 160383-80-2; AC1L323R; CHEBI:34878; SureCN1463468; ns1608; SCHEMBL1463468; DTXSID80166870; N-(3-(Trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl)urea; BDBM50158564; AKOS029964740; C13835; 1-(5-chloro-2-hydroxyphenyl)-3-(3-trifluoromethylphenyl)urea; 1-(5-chloro-2-hydroxy-phenyl)-3-[3-(trifluoromethyl)phenyl]urea; 1-(5-Chloro-2-hydroxy-phenyl)-3-(3-trifluoromethyl-phenyl)-urea
DMYV9M1 CP NeuroSearch A/S
DMYV9M1 DT Small molecular drug
DMYV9M1 PC 133058
DMYV9M1 MW 330.69
DMYV9M1 FM C14H10ClF3N2O2
DMYV9M1 IC InChI=1S/C14H10ClF3N2O2/c15-9-4-5-12(21)11(7-9)20-13(22)19-10-3-1-2-8(6-10)14(16,17)18/h1-7,21H,(H2,19,20,22)
DMYV9M1 CS C1=CC(=CC(=C1)NC(=O)NC2=C(C=CC(=C2)Cl)O)C(F)(F)F
DMYV9M1 IK KRHJDJMOIKRPNN-UHFFFAOYSA-N
DMYV9M1 IU 1-(5-chloro-2-hydroxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea
DMYV9M1 CA CAS 160383-80-2
DMYV9M1 CB CHEBI:34878
DMYV9M1 DE Cerebrovascular ischaemia
DMES0OT ID DMES0OT
DMES0OT DN NS-1619
DMES0OT HS Terminated
DMES0OT SN NS-1619; 153587-01-0; NS 1619; 1-(2-hydroxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-2(3H)-one; NS1619; CHEMBL384903; 1,3-Dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one; CHEBI:34879; 1-(2'-Hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone; 1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-1,3-dihydro-2h-benzimidazol-2-one; 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMES0OT CP NeuroSearch A/S
DMES0OT DT Small molecular drug
DMES0OT PC 4552
DMES0OT MW 362.23
DMES0OT FM C15H8F6N2O2
DMES0OT IC InChI=1S/C15H8F6N2O2/c16-14(17,18)7-1-3-10-9(5-7)22-13(25)23(10)11-6-8(15(19,20)21)2-4-12(11)24/h1-6,24H,(H,22,25)
DMES0OT CS C1=CC2=C(C=C1C(F)(F)F)NC(=O)N2C3=C(C=CC(=C3)C(F)(F)F)O
DMES0OT IK YLFMCMWKHSDUCT-UHFFFAOYSA-N
DMES0OT IU 3-[2-hydroxy-5-(trifluoromethyl)phenyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one
DMES0OT CA CAS 153587-01-0
DMES0OT CB CHEBI:34879
DMES0OT DE Asthma
DM9F81Z ID DM9F81Z
DM9F81Z DN NS-257
DM9F81Z HS Terminated
DM9F81Z SN PD-144216
DM9F81Z CP NeuroSearch A/S
DM9F81Z PC 135484540
DM9F81Z MW 324.36
DM9F81Z FM C13H16N4O4S
DM9F81Z IC InChI=1S/C13H16N4O4S/c1-16(2)22(20,21)10-4-7-11(14-13(18)12(7)15-19)9-6-17(3)5-8(9)10/h4,14,18H,5-6H2,1-3H3
DM9F81Z CS CN1CC2=C(C=C3C(=C2C1)NC(=C3N=O)O)S(=O)(=O)N(C)C
DM9F81Z IK ZPJJGAUEQIVPRW-UHFFFAOYSA-N
DM9F81Z IU 2-hydroxy-N,N,7-trimethyl-3-nitroso-6,8-dihydro-1H-pyrrolo[3,4-g]indole-5-sulfonamide
DM9F81Z DE Cerebrovascular ischaemia
DM19OGY ID DM19OGY
DM19OGY DN NS-2979
DM19OGY HS Terminated
DM19OGY SN Short-acting anesthetics, NeuroSearch
DM19OGY CP NeuroSearch A/S
DM19OGY DE Pain
DM2MU98 ID DM2MU98
DM2MU98 DN NS-377
DM2MU98 HS Terminated
DM2MU98 CP NeuroSearch A/S
DM2MU98 PC 9860852
DM2MU98 MW 292.3
DM2MU98 FM C18H16N2O2
DM2MU98 IC InChI=1S/C18H16N2O2/c1-2-20-9-14-12(11-6-4-3-5-7-11)8-13-16(15(14)10-20)19-18(22)17(13)21/h3-8H,2,9-10H2,1H3,(H,19,21,22)
DM2MU98 CS CCN1CC2=C(C1)C3=C(C=C2C4=CC=CC=C4)C(=O)C(=O)N3
DM2MU98 IK IWRZGAAKMZJBHL-UHFFFAOYSA-N
DM2MU98 IU 7-ethyl-5-phenyl-6,8-dihydro-1H-pyrrolo[3,4-g]indole-2,3-dione
DM2MU98 DE Alzheimer disease
DMINUWH ID DMINUWH
DMINUWH DN NS398
DMINUWH HS Terminated
DMINUWH SN ns-398; 123653-11-2; NS398; NS 398; N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide; N-[2-(Cyclohexyloxy)-4-nitrophenyl]methanesulfonamide; CHEMBL7162; CHEBI:73458; Methanesulfonamide, N-(2-(cyclohexyloxy)-4-nitrophenyl)-; n-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide; N-(2-Cyclohexyloxy-4-nitro-phenyl)-methanesulfonamide; Taisho NS 398; SR-01000597479; N-[2-Cyclohexyloxy-4-nitrophenyl]methanesulfonamide; N-(2-(cyclohexyloxy)-4-nitrophenyl)methanesulfonamide; CCRIS 8523; KTDZCOWXCWUPEO-UHFFFAOYSA-N; Tocris-0942
DMINUWH TC Analgesics
DMINUWH DT Small molecular drug
DMINUWH PC 4553
DMINUWH MW 314.36
DMINUWH FM C13H18N2O5S
DMINUWH IC InChI=1S/C13H18N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h7-9,11,14H,2-6H2,1H3
DMINUWH CS CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2CCCCC2
DMINUWH IK KTDZCOWXCWUPEO-UHFFFAOYSA-N
DMINUWH IU N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
DMINUWH CA CAS 123653-11-2
DMINUWH CB CHEBI:73458
DMINUWH DE Endometriosis
DMPT74G ID DMPT74G
DMPT74G DN NS-638
DMPT74G HS Terminated
DMPT74G SN 150493-34-8; NS-638; NS638; 2-Amino-1-(4-chlorobenzyl)-5-trifluoromethylbenzimidazole; 1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)benzimidazol-2-amine; 1H-Benzimidazol-2-amine,1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)-; NS 638; GXQCVUZORDAARJ-UHFFFAOYSA-N; ACMC-20n5zm; AC1L2SIQ; SCHEMBL3083259; ZINC5752; CTK4C6667; DTXSID10164561; MolPort-046-033-572; BCP20747; AKOS032947353; 1-((4-Chlorophenyl)methyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine; CS-6337; KB-227320; HY-101428
DMPT74G CP NeuroSearch A/S
DMPT74G DT Small molecular drug
DMPT74G PC 127722
DMPT74G MW 325.71
DMPT74G FM C15H11ClF3N3
DMPT74G IC InChI=1S/C15H11ClF3N3/c16-11-4-1-9(2-5-11)8-22-13-6-3-10(15(17,18)19)7-12(13)21-14(22)20/h1-7H,8H2,(H2,20,21)
DMPT74G CS C1=CC(=CC=C1CN2C3=C(C=C(C=C3)C(F)(F)F)N=C2N)Cl
DMPT74G IK GXQCVUZORDAARJ-UHFFFAOYSA-N
DMPT74G IU 1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)benzimidazol-2-amine
DMPT74G CA CAS 150493-34-8
DMPT74G DE Cerebrovascular ischaemia
DMXKMRV ID DMXKMRV
DMXKMRV DN NS-649
DMXKMRV HS Terminated
DMXKMRV CP NeuroSearch A/S
DMXKMRV PC 9905818
DMXKMRV MW 337.3
DMXKMRV FM C16H14F3N3O2
DMXKMRV IC InChI=1S/C16H14F3N3O2/c1-23-10-4-6-14(24-2)13(8-10)22-12-5-3-9(16(17,18)19)7-11(12)21-15(22)20/h3-8H,1-2H3,(H2,20,21)
DMXKMRV CS COC1=CC(=C(C=C1)OC)N2C3=C(C=C(C=C3)C(F)(F)F)N=C2N
DMXKMRV IK RUTNWAGOFFGBCZ-UHFFFAOYSA-N
DMXKMRV IU 1-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)benzimidazol-2-amine
DMXKMRV DE Alzheimer disease
DMI46T3 ID DMI46T3
DMI46T3 DN NS-696
DMI46T3 HS Terminated
DMI46T3 CP NeuroSearch A/S
DMI46T3 DE Epilepsy
DMEYMHB ID DMEYMHB
DMEYMHB DN NSC-303812
DMEYMHB HS Discontinued
DMEYMHB SN Aphidicolin; (+)-Aphidicolin; (3R,4R,4aR,6aS,8R,9R,11aS,11bS)-4,9-bis(hydroxymethyl)-4,11b-dimethyltetradecahydro-8,11a-methanocyclohepta[a]naphthalene-3,9-diol; 192TJ6PP19; 38966-21-1; 9,15-Cyclo-C,18-dinor-14,15-secoandrostane-4,17-dimethanol, 3,17-dihydroxy-4-methyl-, (3alpha,4alpha,5alpha,17alpha)-; BRN 4689958; CCRIS 1783; CHEBI:2766; CHEMBL29711; ICI 69653; MLS000069677; NSC 234714; NSC-234714; NSC-351140; NSC234714; SMR000058538; UNII-192TJ6PP19
DMEYMHB PC 457964
DMEYMHB MW 338.5
DMEYMHB FM C20H34O4
DMEYMHB IC NOFOAYPPHIUXJR-APNQCZIXSA-N
DMEYMHB CS CC12CCC(C(C1CCC3C24CCC(C(C3)C4)(CO)O)(C)CO)O
DMEYMHB IK 1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1
DMEYMHB IU (1S,2S,5R,6R,7R,10S,12R,13R)-6,13-bis(hydroxymethyl)-2,6-dimethyltetracyclo[10.3.1.01,10.02,7]hexadecane-5,13-diol
DMEYMHB CA CAS 38966-21-1
DMEYMHB CB CHEBI:2766
DMEYMHB DE Hyperphosphatemia
DMDJT7U ID DMDJT7U
DMDJT7U DN NSC-661755
DMDJT7U HS Terminated
DMDJT7U DT Small molecular drug
DMDJT7U PC 3246731
DMDJT7U MW 816.9
DMDJT7U FM C48H52N2O10
DMDJT7U IC InChI=1S/C46H48N2O8.C2H4O2/c1-19-9-25-27(41-31-13-21(3)47-23(5)39(31)33(49)17-35(41)51)15-29(45(53)43(25)37(11-19)55-7)30-16-28(26-10-20(2)12-38(56-8)44(26)46(30)54)42-32-14-22(4)48-24(6)40(32)34(50)18-36(42)52;1-2(3)4/h9-12,15-18,21-24,47-54H,13-14H2,1-8H3;1H3,(H,3,4)/t21-,22-,23+,24+;/m0./s1
DMDJT7U CS C[C@H]1CC2=C(C(=CC(=C2[C@H](N1)C)O)O)C3=CC(=C(C4=C3C=C(C=C4OC)C)O)C5=C(C6=C(C=C(C=C6OC)C)C(=C5)C7=C8C[C@@H](N[C@@H](C8=C(C=C7O)O)C)C)O.CC(=O)O
DMDJT7U IK IHCBLDDSPLYUGN-ZODOTUICSA-N
DMDJT7U IU acetic acid;(1R,3S)-5-[3-[4-[(1R,3S)-6,8-dihydroxy-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-5-yl]-1-hydroxy-8-methoxy-6-methylnaphthalen-2-yl]-4-hydroxy-5-methoxy-7-methylnaphthalen-1-yl]-1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline-6,8-diol
DMF2XMA ID DMF2XMA
DMF2XMA DN NSD-721
DMF2XMA HS Terminated
DMF2XMA SN NS-11394; NS-2552; NS-2664; GABA-A receptor modulators, NeuroSearch; GABA-A receptor modulators, NeuroSearch/Meiji Seika
DMF2XMA CP NeuroSearch A/S
DMF2XMA DE Anxiety disorder
DMPG703 ID DMPG703
DMPG703 DN NSL-036
DMPG703 HS Terminated
DMPG703 SN Non-specific tachykinin antagonist (iv, pain), Sosei/NeuroSolutions
DMPG703 CP Sosei Group Corp
DMPG703 DE Neuropathic pain
DMU3D1K ID DMU3D1K
DMU3D1K DN NTE-122
DMU3D1K HS Terminated
DMU3D1K SN ACAT inhibitor, Nissin Food
DMU3D1K CP Nissin Foods Holdings Co Ltd
DMU3D1K PC 9830692
DMU3D1K MW 630.9
DMU3D1K FM C38H58N6O2
DMU3D1K IC InChI=1S/C38H58N6O2/c1-41(2)33-23-19-31(20-24-33)39-37(45)43(35-11-7-5-8-12-35)27-29-15-17-30(18-16-29)28-44(36-13-9-6-10-14-36)38(46)40-32-21-25-34(26-22-32)42(3)4/h19-26,29-30,35-36H,5-18,27-28H2,1-4H3,(H,39,45)(H,40,46)
DMU3D1K CS CN(C)C1=CC=C(C=C1)NC(=O)N(CC2CCC(CC2)CN(C3CCCCC3)C(=O)NC4=CC=C(C=C4)N(C)C)C5CCCCC5
DMU3D1K IK SIHFCVXQGXGQQO-UHFFFAOYSA-N
DMU3D1K IU 1-cyclohexyl-1-[[4-[[cyclohexyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]cyclohexyl]methyl]-3-[4-(dimethylamino)phenyl]urea
DMU3D1K DE Arteriosclerosis
DMPA8WO ID DMPA8WO
DMPA8WO DN NU1025
DMPA8WO HS Terminated
DMPA8WO DT Small molecular drug
DMPA8WO PC 135398517
DMPA8WO MW 176.17
DMPA8WO FM C9H8N2O2
DMPA8WO IC InChI=1S/C9H8N2O2/c1-5-10-8-6(9(13)11-5)3-2-4-7(8)12/h2-4,12H,1H3,(H,10,11,13)
DMPA8WO CS CC1=NC2=C(C=CC=C2O)C(=O)N1
DMPA8WO IK YJDAOHJWLUNFLX-UHFFFAOYSA-N
DMPA8WO IU 8-hydroxy-2-methyl-3H-quinazolin-4-one
DMPA8WO CA CAS 90417-38-2
DMPA8WO CB CHEBI:75399
DMINSRW ID DMINSRW
DMINSRW DN NZ-1002
DMINSRW HS Terminated
DMINSRW SN Mucopolysaccharidosis I (MPS I) therapy, Novazyme; Phosphorylated alpha-L-iduronidase, Novazyme
DMINSRW CP Novazyme Pharmaceuticals Inc
DMINSRW DE Lysosomal storage disease
DMNAFG1 ID DMNAFG1
DMNAFG1 DN Olomoucine
DMNAFG1 HS Terminated
DMNAFG1 SN olomoucine; 101622-51-9; 4erk; UNII-6A839B2HYS; 2-(2-Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6A839B2HYS; CHEMBL280074; 2-{[6-(benzylamino)-9-methyl-9h-purin-2-yl]amino}ethanol; 6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine; 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine; Ethanol,2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-; OLO; 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine; 6-Benylamino-2-(2-hydroxyethylamino)-9-methylpurine
DMNAFG1 DT Small molecular drug
DMNAFG1 PC 4592
DMNAFG1 MW 298.34
DMNAFG1 FM C15H18N6O
DMNAFG1 IC InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20)
DMNAFG1 CS CN1C=NC2=C(N=C(N=C21)NCCO)NCC3=CC=CC=C3
DMNAFG1 IK GTVPOLSIJWJJNY-UHFFFAOYSA-N
DMNAFG1 IU 2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol
DMNAFG1 CA CAS 101622-51-9
DMNAFG1 CB CHEBI:44661
DMAGUY0 ID DMAGUY0
DMAGUY0 DN Omapatrilat
DMAGUY0 HS Terminated
DMAGUY0 SN BMS-186716; Omapatrilat (JAN/USAN/INN); (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
DMAGUY0 CP Bristol-Myers Squibb
DMAGUY0 DT Small molecular drug
DMAGUY0 PC 656629
DMAGUY0 MW 408.5
DMAGUY0 FM C19H24N2O4S2
DMAGUY0 IC InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
DMAGUY0 CS C1C[C@H](N2[C@H](C1)SCC[C@@H](C2=O)NC(=O)[C@H](CC3=CC=CC=C3)S)C(=O)O
DMAGUY0 IK LVRLSYPNFFBYCZ-VGWMRTNUSA-N
DMAGUY0 IU (4S,7S,10aS)-5-oxo-4-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]-2,3,4,7,8,9,10,10a-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
DMAGUY0 CA CAS 167305-00-2
DMAGUY0 CB CHEBI:135660
DMAGUY0 DE Hypertension
DMSKAGP ID DMSKAGP
DMSKAGP DN Omniferon
DMSKAGP HS Terminated
DMSKAGP SN Alpha Leukoferon; Human alpha interferon, Viragen; Leukocyte-derived interferon; Alpha-IFN, Viragen; Topically enhanced Onmiferon (genital herpes), Viragen/Zonagen; BST-GEL (Omniferon), Viragen/Biosyntech
DMSKAGP CP Viragen Inc
DMSKAGP DE Solid tumour/cancer
DMMLXRG ID DMMLXRG
DMMLXRG DN ON-09300
DMMLXRG HS Terminated
DMMLXRG SN Oncoxib; ON-09310; COX2/lipoxygenase inhibitors (cancer), Onconova; ON-09 pyrazoline series (dual COX2/lipoxygenase inhibitors), Onconova
DMMLXRG CP Onconova Therapeutics Inc
DMMLXRG DE Solid tumour/cancer
DMTS6HB ID DMTS6HB
DMTS6HB DN ON-579
DMTS6HB HS Terminated
DMTS6HB SN 141286-14-8; ON-579; ON 579; 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid; Acetic acid,2-[4-[[2-[[(4-chlorophenyl)sulfonyl]amino]ethyl]thio]-2,6-difluorophenoxy]-; ACMC-20cvej; AC1Q6UCK; AC1L4U4O; {4-[(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)sulfanyl]-2,6-difluorophenoxy}acetic acid; CHEMBL312763; SCHEMBL2925987; CTK4C2555; DTXSID70161657; AKOS030574939; 4-(2-(4-Chlorophenylsulfonylamino)-ethylthio)-2,6-difluorophenoxyacetic acid; KB-227077
DMTS6HB CP Taisho Pharmaceutical Co Ltd
DMTS6HB DT Small molecular drug
DMTS6HB PC 192308
DMTS6HB MW 437.9
DMTS6HB FM C16H14ClF2NO5S2
DMTS6HB IC InChI=1S/C16H14ClF2NO5S2/c17-10-1-3-12(4-2-10)27(23,24)20-5-6-26-11-7-13(18)16(14(19)8-11)25-9-15(21)22/h1-4,7-8,20H,5-6,9H2,(H,21,22)
DMTS6HB CS C1=CC(=CC=C1S(=O)(=O)NCCSC2=CC(=C(C(=C2)F)OCC(=O)O)F)Cl
DMTS6HB IK FEYKNJZBWNIWJD-UHFFFAOYSA-N
DMTS6HB IU 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethylsulfanyl]-2,6-difluorophenoxy]acetic acid
DMTS6HB CA CAS 141286-14-8
DMTS6HB DE Asthma
DMBDCL4 ID DMBDCL4
DMBDCL4 DN ONO-8130
DMBDCL4 HS Terminated
DMBDCL4 SN Pollakiuria agent, Ono
DMBDCL4 CP Ono Pharmaceutical Co Ltd
DMBDCL4 PC 9827317
DMBDCL4 MW 500.6
DMBDCL4 FM C25H28N2O5S2
DMBDCL4 IC InChI=1S/C25H28N2O5S2/c1-16(2)13-27(34(30,31)25-26-17(3)15-33-25)22-11-20-5-4-6-21(20)12-23(22)32-14-18-7-9-19(10-8-18)24(28)29/h7-12,15-16H,4-6,13-14H2,1-3H3,(H,28,29)
DMBDCL4 CS CC1=CSC(=N1)S(=O)(=O)N(CC(C)C)C2=C(C=C3CCCC3=C2)OCC4=CC=C(C=C4)C(=O)O
DMBDCL4 IK IOXMDBQCUCDLAF-UHFFFAOYSA-N
DMBDCL4 IU 4-[[6-[2-methylpropyl-[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]-2,3-dihydro-1H-inden-5-yl]oxymethyl]benzoic acid
DMBDCL4 CA CAS 459841-96-4
DMBDCL4 DE Pollakiuria
DM2VRK7 ID DM2VRK7
DM2VRK7 DN ONO-8711
DM2VRK7 HS Terminated
DM2VRK7 SN 6-[(2R,3S)-3-(4-Chloro-2-methylphenylsulfonamidomethyl)bicyclo[2.2.2]oct-2-yl]-5(Z)-hexenoic acid
DM2VRK7 DT Small molecular drug
DM2VRK7 PC 9824507
DM2VRK7 MW 440
DM2VRK7 FM C22H30ClNO4S
DM2VRK7 IC InChI=1S/C22H30ClNO4S/c1-15-13-18(23)11-12-21(15)29(27,28)24-14-20-17-9-7-16(8-10-17)19(20)5-3-2-4-6-22(25)26/h3,5,11-13,16-17,19-20,24H,2,4,6-10,14H2,1H3,(H,25,26)/b5-3-/t16?,17?,19-,20-/m0/s1
DM2VRK7 CS CC1=C(C=CC(=C1)Cl)S(=O)(=O)NC[C@@H]2[C@H](C3CCC2CC3)/C=C\\CCCC(=O)O
DM2VRK7 IK VVEXPDRCGCQELD-CFDZEDGGSA-N
DM2VRK7 IU (Z)-6-[(2R,3S)-3-[[(4-chloro-2-methylphenyl)sulfonylamino]methyl]-2-bicyclo[2.2.2]octanyl]hex-5-enoic acid
DM2VRK7 CA CAS 216158-34-8
DM2VRK7 DE Pain
DM4CVEG ID DM4CVEG
DM4CVEG DN ONO-8815Ly
DM4CVEG HS Terminated
DM4CVEG SN ONO-8815Lyn; ONO-AE-1259
DM4CVEG CP Ono Pharmaceutical Co Ltd
DM4CVEG DT Small molecular drug
DM4CVEG PC 9807448
DM4CVEG MW 399
DM4CVEG FM C22H35ClO4
DM4CVEG IC InChI=1S/C22H35ClO4/c1-2-22(13-8-14-22)20(25)11-7-10-17-16(18(23)15-19(17)24)9-5-3-4-6-12-21(26)27/h3,5,7,10,16-20,24-25H,2,4,6,8-9,11-15H2,1H3,(H,26,27)/b5-3-,10-7+/t16-,17-,18-,19-,20+/m1/s1
DM4CVEG CS CCC1(CCC1)[C@H](C/C=C/[C@H]2[C@@H](C[C@H]([C@@H]2C/C=C\\CCCC(=O)O)Cl)O)O
DM4CVEG IK LBIPUBVVGYRBNA-VGUVCEGPSA-N
DM4CVEG IU (Z)-7-[(1R,2R,3R,5R)-5-chloro-2-[(E,4S)-4-(1-ethylcyclobutyl)-4-hydroxybut-1-enyl]-3-hydroxycyclopentyl]hept-5-enoic acid
DM4CVEG DE Miscarriage
DMW68CE ID DMW68CE
DMW68CE DN Oral insulin
DMW68CE HS Terminated
DMW68CE SN Oral insulin (type I diabetes)
DMW68CE CP Oshadi Drug Administration Ltd
DMW68CE DE Type-1 diabetes
DMUGC2X ID DMUGC2X
DMUGC2X DN Org-10490
DMUGC2X HS Terminated
DMUGC2X CP Organon BioSciences
DMUGC2X PC 3086163
DMUGC2X MW 253.34
DMUGC2X FM C17H19NO
DMUGC2X IC InChI=1S/C17H19NO/c1-18-12-10-14-6-2-4-8-16(14)19-17-9-5-3-7-15(17)11-13-18/h2-9H,10-13H2,1H3
DMUGC2X CS CN1CCC2=CC=CC=C2OC3=CC=CC=C3CC1
DMUGC2X IK NREYMNFZCFNECP-UHFFFAOYSA-N
DMUGC2X IU 11-methyl-2-oxa-11-azatricyclo[12.4.0.03,8]octadeca-1(18),3,5,7,14,16-hexaene
DMUGC2X CA CAS 83507-02-2
DMUGC2X DE Psychotic disorder
DMQU8AR ID DMQU8AR
DMQU8AR DN Org-20599
DMQU8AR HS Terminated
DMQU8AR SN Org-20549
DMQU8AR CP Organon BioSciences
DMQU8AR DT Small molecular drug
DMQU8AR PC 9850026
DMQU8AR MW 438
DMQU8AR FM C25H40ClNO3
DMQU8AR IC InChI=1S/C25H40ClNO3/c1-24-8-7-19-17(18(24)5-6-20(24)23(29)15-26)4-3-16-13-22(28)21(14-25(16,19)2)27-9-11-30-12-10-27/h16-22,28H,3-15H2,1-2H3/t16-,17-,18-,19-,20+,21-,22-,24-,25-/m0/s1
DMQU8AR CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CCl)CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C
DMQU8AR IK NZFNABGZEQPYBX-PMBZPZLSSA-N
DMQU8AR IU 2-chloro-1-[(2S,3S,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
DMQU8AR CA CAS 156685-94-8
DMQU8AR DE Anaesthesia
DM95QG2 ID DM95QG2
DM95QG2 DN Org-20781
DM95QG2 HS Terminated
DM95QG2 CP Organon BioSciences
DM95QG2 PC 9861772
DM95QG2 MW 317.4
DM95QG2 FM C19H27NO3
DM95QG2 IC InChI=1S/C19H27NO3/c1-19-6-5-11-12(14(19)9-17(23)18(19)20-2)4-3-10-7-15(21)16(22)8-13(10)11/h7-8,11-12,14,17-18,20-23H,3-6,9H2,1-2H3/t11-,12+,14-,17+,18-,19-/m0/s1
DM95QG2 CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2NC)O)CCC4=CC(=C(C=C34)O)O
DM95QG2 IK YVBSZXJRJYYVQR-AFKMTKAPSA-N
DM95QG2 IU (8R,9S,13S,14S,16R,17R)-13-methyl-17-(methylamino)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16-triol
DM95QG2 DE Heart arrhythmia
DMMA92L ID DMMA92L
DMMA92L DN Org-30035
DMMA92L HS Terminated
DMMA92L CP Organon BioSciences
DMMA92L DE Psychotic disorder
DM3VWZF ID DM3VWZF
DM3VWZF DN Org-34092
DM3VWZF HS Terminated
DM3VWZF SN IDDB19835
DM3VWZF CP Organon BioSciences
DM3VWZF DE Thrombosis
DMB0IQT ID DMB0IQT
DMB0IQT DN Org-34116
DMB0IQT HS Terminated
DMB0IQT CP Organon BioSciences
DMB0IQT DE Anxiety disorder
DMY3LXH ID DMY3LXH
DMY3LXH DN Org-37684
DMY3LXH HS Terminated
DMY3LXH SN Org-36262
DMY3LXH CP Organon BioSciences
DMY3LXH DT Small molecular drug
DMY3LXH PC 9794656
DMY3LXH MW 233.31
DMY3LXH FM C14H19NO2
DMY3LXH IC InChI=1S/C14H19NO2/c1-16-13-6-5-10-3-2-4-12(10)14(13)17-11-7-8-15-9-11/h5-6,11,15H,2-4,7-9H2,1H3/t11-/m0/s1
DMY3LXH CS COC1=C(C2=C(CCC2)C=C1)O[C@H]3CCNC3
DMY3LXH IK QDJAYXYEXHVXJV-NSHDSACASA-N
DMY3LXH IU (3S)-3-[(5-methoxy-2,3-dihydro-1H-inden-4-yl)oxy]pyrrolidine
DMY3LXH DE Anxiety disorder
DMRZCH4 ID DMRZCH4
DMRZCH4 DN Org-9935
DMRZCH4 HS Terminated
DMRZCH4 SN Org-935
DMRZCH4 CP Organon BioSciences
DMRZCH4 DT Small molecular drug
DMRZCH4 PC 131100
DMRZCH4 MW 304.4
DMRZCH4 FM C15H16N2O3S
DMRZCH4 IC InChI=1S/C15H16N2O3S/c1-8-4-14(18)16-17-15(8)13-6-9-5-10(19-2)11(20-3)7-12(9)21-13/h5-8H,4H2,1-3H3,(H,16,18)
DMRZCH4 CS CC1CC(=O)NN=C1C2=CC3=CC(=C(C=C3S2)OC)OC
DMRZCH4 IK KIYDKXDCNSPKQQ-UHFFFAOYSA-N
DMRZCH4 IU 3-(5,6-dimethoxy-1-benzothiophen-2-yl)-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DMRZCH4 CA CAS 129425-83-8
DMRZCH4 DE Asthma
DM9YOMX ID DM9YOMX
DM9YOMX DN OT-4003
DM9YOMX HS Terminated
DM9YOMX SN IDDB10966
DM9YOMX CP LEO Pharma A/S
DM9YOMX DE Asthma
DMESWV1 ID DMESWV1
DMESWV1 DN OX-23
DMESWV1 HS Terminated
DMESWV1 SN Analgesic (sublingual tablet), Orexo
DMESWV1 CP Orexo AB
DMESWV1 DT Antibody
DMESWV1 DE Pain
DMVPG1N ID DMVPG1N
DMVPG1N DN OX-30
DMVPG1N HS Terminated
DMVPG1N SN Opioid (oral controlled-release, pain), Orexo
DMVPG1N CP Orexo AB
DMVPG1N DT Antibody
DMVPG1N DE Pain
DM1TG3C ID DM1TG3C
DM1TG3C DN Oxamflatin
DM1TG3C HS Terminated
DM1TG3C SN NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3
DM1TG3C TC Anticancer Agents
DM1TG3C DT Small molecular drug
DM1TG3C PC 5353852
DM1TG3C MW 342.4
DM1TG3C FM C17H14N2O4S
DM1TG3C IC InChI=1S/C17H14N2O4S/c20-17(18-21)12-5-4-7-14-8-6-9-15(13-14)19-24(22,23)16-10-2-1-3-11-16/h1-3,5-6,8-13,19,21H,(H,18,20)/b12-5+
DM1TG3C CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)C#C/C=C/C(=O)NO
DM1TG3C IK QRPSQQUYPMFERG-LFYBBSHMSA-N
DM1TG3C IU (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide
DM1TG3C CA CAS 151720-43-3
DM1TG3C CB CHEBI:93779
DM1TG3C DE Solid tumour/cancer
DMLKQUR ID DMLKQUR
DMLKQUR DN Palinavir
DMLKQUR HS Terminated
DMLKQUR SN BILA-2011; BILA-2011 BS
DMLKQUR CP Bio-Mega Research Division
DMLKQUR DT Small molecular drug
DMLKQUR PC 72981
DMLKQUR MW 708.9
DMLKQUR FM C41H52N6O5
DMLKQUR IC InChI=1S/C41H52N6O5/c1-27(2)37(45-38(49)33-16-15-30-13-9-10-14-32(30)43-33)40(51)44-34(23-28-11-7-6-8-12-28)36(48)25-47-22-19-31(52-26-29-17-20-42-21-18-29)24-35(47)39(50)46-41(3,4)5/h6-18,20-21,27,31,34-37,48H,19,22-26H2,1-5H3,(H,44,51)(H,45,49)(H,46,50)/t31-,34+,35+,36-,37+/m1/s1
DMLKQUR CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CN2CC[C@H](C[C@H]2C(=O)NC(C)(C)C)OCC3=CC=NC=C3)O)NC(=O)C4=NC5=CC=CC=C5C=C4
DMLKQUR IK RXBWRFDZXRAEJT-SZNOJMITSA-N
DMLKQUR IU N-[(2S)-1-[[(2S,3R)-4-[(2S,4R)-2-(tert-butylcarbamoyl)-4-(pyridin-4-ylmethoxy)piperidin-1-yl]-3-hydroxy-1-phenylbutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]quinoline-2-carboxamide
DMLKQUR CA CAS 154612-39-2
DMLKQUR DE Human immunodeficiency virus infection
DM6HBQJ ID DM6HBQJ
DM6HBQJ DN Patamostat
DM6HBQJ HS Terminated
DM6HBQJ SN E-3123
DM6HBQJ CP Eisai Co Ltd
DM6HBQJ DT Small molecular drug
DM6HBQJ PC 65921
DM6HBQJ MW 412.5
DM6HBQJ FM C20H20N4O4S
DM6HBQJ IC InChI=1S/C20H20N4O4S/c21-20(22)23-14-3-1-13(2-4-14)19(27)28-15-5-7-16(8-6-15)29-12-11-24-17(25)9-10-18(24)26/h1-8H,9-12H2,(H4,21,22,23)
DM6HBQJ CS C1CC(=O)N(C1=O)CCSC2=CC=C(C=C2)OC(=O)C3=CC=C(C=C3)N=C(N)N
DM6HBQJ IK ILRQPCQIFIURTG-UHFFFAOYSA-N
DM6HBQJ IU [4-[2-(2,5-dioxopyrrolidin-1-yl)ethylsulfanyl]phenyl] 4-(diaminomethylideneamino)benzoate
DM6HBQJ CA CAS 114568-26-2
DM6HBQJ DE Hypotension
DMWD1RC ID DMWD1RC
DMWD1RC DN PBI-1101
DMWD1RC HS Terminated
DMWD1RC CP ProMetic Life Sciences Inc
DMWD1RC DE Inflammation
DMWYP86 ID DMWYP86
DMWYP86 DN PD-0183812
DMWYP86 HS Terminated
DMWYP86 SN PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813
DMWYP86 DT Small molecular drug
DMWYP86 PC 5330258
DMWYP86 MW 473.6
DMWYP86 FM C28H35N5O2
DMWYP86 IC InChI=1S/C28H35N5O2/c34-15-1-2-19-11-13-32(14-12-19)24-8-6-23(7-9-24)30-28-29-18-22-5-10-26(35)33(27(22)31-28)25-17-20-3-4-21(25)16-20/h5-10,18-21,25,34H,1-4,11-17H2,(H,29,30,31)
DMWYP86 CS C1CC2CC1CC2N3C(=O)C=CC4=CN=C(N=C43)NC5=CC=C(C=C5)N6CCC(CC6)CCCO
DMWYP86 IK PETCVZZPKYJZAU-UHFFFAOYSA-N
DMWYP86 IU 8-(2-bicyclo[2.2.1]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one
DMWYP86 DE Retinoblastoma
DMGKVPH ID DMGKVPH
DMGKVPH DN PD-0204318
DMGKVPH HS Terminated
DMGKVPH SN PD-0183764
DMGKVPH CP Parke-Davis & Co
DMGKVPH DE Pain
DMN1A70 ID DMN1A70
DMN1A70 DN PD-117596
DMN1A70 HS Terminated
DMN1A70 SN PD-117596-2
DMN1A70 CP Parke-Davis & Co
DMN1A70 DT Small molecular drug
DMN1A70 PC 122796
DMN1A70 MW 349.33
DMN1A70 FM C17H17F2N3O3
DMN1A70 IC InChI=1S/C17H17F2N3O3/c18-12-5-10-14(13(19)15(12)21-4-3-8(20)6-21)22(9-1-2-9)7-11(16(10)23)17(24)25/h5,7-9H,1-4,6,20H2,(H,24,25)
DMN1A70 CS C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)F)N4CCC(C4)N)F)C(=O)O
DMN1A70 IK UHBXZNXCIZHGFF-UHFFFAOYSA-N
DMN1A70 IU 7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
DMN1A70 CA CAS 99734-98-2
DMN1A70 DE Bacterial infection
DM92VUF ID DM92VUF
DM92VUF DN PD-123319
DM92VUF HS Terminated
DM92VUF SN PD123319; PD 123319; 130663-39-7; PD-123319; CHEBI:61014; C31H32N4O3; CHEMBL157946; (S)-1-(4-(dimethylamino)-3-methylbenzyl)-5-(2,2-diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid; (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid; AC1NSKGQ; Epitope ID:140138; GTPL597; SCHEMBL668525; CHEMBL321820; PD-123319 ditrifluoroacetate; MolPort-005-942-100; EX-A2290; BCP08027; s7098; 2633AH; ZINC22015557; BDBM50282396; AKOS030526087
DM92VUF DT Small molecular drug
DM92VUF PC 5311345
DM92VUF MW 508.6
DM92VUF FM C31H32N4O3
DM92VUF IC InChI=1S/C31H32N4O3/c1-21-16-22(14-15-26(21)33(2)3)18-34-20-32-25-19-35(28(31(37)38)17-27(25)34)30(36)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-16,20,28-29H,17-19H2,1-3H3,(H,37,38)/t28-/m0/s1
DM92VUF CS CC1=C(C=CC(=C1)CN2C=NC3=C2C[C@H](N(C3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)O)N(C)C
DM92VUF IK YSTVFDAKLDMYCR-NDEPHWFRSA-N
DM92VUF IU (6S)-1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
DM92VUF CA CAS 130663-39-7
DM92VUF CB CHEBI:61014
DM0YXRQ ID DM0YXRQ
DM0YXRQ DN PD-128483
DM0YXRQ HS Terminated
DM0YXRQ SN CCRIS 4394; PD-128483; PD 128483; 153260-23-2; 115688-97-6; C11H15N3S; 6-Methyl-4,5,5a,6,7,8-hexahydrothiazolo(4,5-f)quinolin-2-amine; 4,5,5a,6,7,8-Hexahydro-6-methylthiazolo(4,5-f)quinoline-2-amine; Thiazolo(4,5-f)quinolin-2-amine, 4,5,5a,6,7,8-hexahydro-6-methyl-, (+-)-; CCRIS 6698; 6-METHYL-4,5,5A,6,7,8-HEXAHYDROTHIAZOLO[4,5-F]QUINOLIN-2-AMINE; 4,5,5A,6,7,8-HEXAHYDRO-6-METHYLTHIAZOLO[4,5-F]QUINOLINE-2-AMINE; XFJSSDHKIXXJLM-UHFFFAOYSA-N; AC1L2Y0S; CHEMBL350920; SCHEMBL10665477; AKOS022654211; LS-172297; LS-190761
DM0YXRQ DT Small molecular drug
DM0YXRQ PC 130792
DM0YXRQ MW 221.32
DM0YXRQ FM C11H15N3S
DM0YXRQ IC InChI=1S/C11H15N3S/c1-14-6-2-3-7-8(14)4-5-9-10(7)13-11(12)15-9/h3,8H,2,4-6H2,1H3,(H2,12,13)
DM0YXRQ CS CN1CCC=C2C1CCC3=C2N=C(S3)N
DM0YXRQ IK XFJSSDHKIXXJLM-UHFFFAOYSA-N
DM0YXRQ IU 6-methyl-5,5a,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-f]quinolin-2-amine
DM0YXRQ CA CAS 115688-97-6
DMLEVNC ID DMLEVNC
DMLEVNC DN PD-135666
DMLEVNC HS Terminated
DMLEVNC SN PD-135666; CHEMBL138534; GTPL903; SCHEMBL6895794; CHEMBL2111312; PDSP2_000908; PDSP1_000922; BDBM50062005; PD135666; 134557-41-8; PD 135666; (S)-3-[(R)-2-(Adamantan-2-yloxycarbonylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-4-phenyl-butyric acid; 3-[2-(2-Adamantan-2-yl-acetylamino)-3-(1H-indol-3-yl)-2-methyl-propionylamino]-4-phenyl-butyric acid(PD 135666); (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMLEVNC DT Small molecular drug
DMLEVNC PC 9850711
DMLEVNC MW 557.7
DMLEVNC FM C33H39N3O5
DMLEVNC IC InChI=1S/C33H39N3O5/c1-33(18-25-19-34-28-10-6-5-9-27(25)28,31(39)35-26(17-29(37)38)16-20-7-3-2-4-8-20)36-32(40)41-30-23-12-21-11-22(14-23)15-24(30)13-21/h2-10,19,21-24,26,30,34H,11-18H2,1H3,(H,35,39)(H,36,40)(H,37,38)/t21?,22?,23?,24?,26-,30?,33+/m0/s1
DMLEVNC CS C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC=CC=C3)CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMLEVNC IK PGOLWKTUHWHYJS-SFMDGOMNSA-N
DMLEVNC IU (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-phenylbutanoic acid
DMD6L82 ID DMD6L82
DMD6L82 DN PD136450
DMD6L82 HS Terminated
DMD6L82 SN PD-136450; Cam 1189; PD 136450; CHEMBL341460; CHEMBL3351022; (E)-4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobut-2-enoic acid; PD136450; CAM-1189; AC1O5RMN; GTPL867; SCHEMBL6895211; BDBM50230677; BDBM50007439; PD-136,450; 2-Butenoic acid, 4-((2-((3-(1H-indol-3-yl)-2-methyl-1-oxo-2-(((tricyclo(3.3.1.1(3,7))dec-2-yloxy)carbonyl)amino)propyl)amino)-1-phenylethyl)amino)-4-oxo-, (R-(R*,R*))-
DMD6L82 DT Small molecular drug
DMD6L82 PC 6439414
DMD6L82 MW 612.7
DMD6L82 FM C35H40N4O6
DMD6L82 IC InChI=1S/C35H40N4O6/c1-35(18-26-19-36-28-10-6-5-9-27(26)28,39-34(44)45-32-24-14-21-13-22(16-24)17-25(32)15-21)33(43)37-20-29(23-7-3-2-4-8-23)38-30(40)11-12-31(41)42/h2-12,19,21-22,24-25,29,32,36H,13-18,20H2,1H3,(H,37,43)(H,38,40)(H,39,44)(H,41,42)/b12-11+/t21?,22?,24?,25?,29-,32?,35+/m0/s1
DMD6L82 CS C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)NC[C@@H](C3=CC=CC=C3)NC(=O)/C=C/C(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMD6L82 IK REMAMJQTIPBFTH-MYJPUEAFSA-N
DMD6L82 IU (E)-4-[[(1R)-2-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-1-phenylethyl]amino]-4-oxobut-2-enoic acid
DMD6L82 CA CAS 139067-52-0
DMFA27N ID DMFA27N
DMFA27N DN PD142893
DMFA27N HS Terminated
DMFA27N SN PD 142893; PD-142893; CHEMBL438194; 143037-36-9; Ac-Dip-leu-asp-ile-ile-trp; Acetyldiphenylalanyl-leucyl-aspartyl-isoleucyl-isoleucyl-tryptophan; AC1L3U2Y; DTXSID40162297; IFDNLSRYZKUGIR-KXXXQFFTSA-N; BDBM50001218; N-(N-(N-(N-(N-(N-Acetyl-3-(1,1'-biphenyl)-4-yl-D-alanyl)-L-leucyl)-L-alpha-aspartyl)-L-isoleucyl)-L-isoleucyl)-L-tryptophan; Ac-3-(1,1'-Biphenyl-4-yl)-D-Ala-L-Leu-L-Asp-L-Ile-L-Ile-L-Trp-OH; L-Tryptophan, N-(N-(N-(N-(N-(N-acetyl-3-(1,1'-biphenyl)-4-yl-D-alanyl)-L-leucyl)-L-alpha-aspartyl)-L-isoleucyl)-L-isol
DMFA27N DT Small molecular drug
DMFA27N PC 122149
DMFA27N MW 924.1
DMFA27N FM C50H65N7O10
DMFA27N IC InChI=1S/C50H65N7O10/c1-8-29(5)43(48(64)55-41(50(66)67)25-35-27-51-37-18-14-13-17-36(35)37)57-49(65)44(30(6)9-2)56-47(63)40(26-42(59)60)54-45(61)38(23-28(3)4)53-46(62)39(52-31(7)58)24-32-19-21-34(22-20-32)33-15-11-10-12-16-33/h10-22,27-30,38-41,43-44,51H,8-9,23-26H2,1-7H3,(H,52,58)(H,53,62)(H,54,61)(H,55,64)(H,56,63)(H,57,65)(H,59,60)(H,66,67)/t29-,30-,38-,39+,40-,41-,43-,44-/m0/s1
DMFA27N CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC3=CC=C(C=C3)C4=CC=CC=C4)NC(=O)C
DMFA27N IK IFDNLSRYZKUGIR-KXXXQFFTSA-N
DMFA27N IU (3S)-3-[[(2S)-2-[[(2R)-2-acetamido-3-(4-phenylphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMFA27N CA CAS 143037-36-9
DMHQSF8 ID DMHQSF8
DMHQSF8 DN PD-146176
DMHQSF8 HS Terminated
DMHQSF8 SN PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, > (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-
DMHQSF8 DT Small molecular drug
DMHQSF8 PC 297589
DMHQSF8 MW 237.32
DMHQSF8 FM C15H11NS
DMHQSF8 IC InChI=1S/C15H11NS/c1-3-7-13-10(5-1)12-9-17-14-8-4-2-6-11(14)15(12)16-13/h1-8,16H,9H2
DMHQSF8 CS C1C2=C(C3=CC=CC=C3S1)NC4=CC=CC=C24
DMHQSF8 IK ZGOOPZVQMLHPFM-UHFFFAOYSA-N
DMHQSF8 IU 6,11-dihydrothiochromeno[4,3-b]indole
DMHQSF8 CA CAS 4079-26-9
DMHQSF8 DE Arteriosclerosis
DMVEXID ID DMVEXID
DMVEXID DN PD-153103
DMVEXID HS Terminated
DMVEXID CP Parke-Davis & Co
DMVEXID DE Human immunodeficiency virus-1 infection
DMQCNWD ID DMQCNWD
DMQCNWD DN PD-155080
DMQCNWD HS Terminated
DMQCNWD SN CHEMBL274383; SCHEMBL8187314; BDBM50034256
DMQCNWD DT Small molecular drug
DMQCNWD PC 11742628
DMQCNWD MW 416.4
DMQCNWD FM C25H20O6
DMQCNWD IC InChI=1S/C25H20O6/c1-28-19-10-8-18(9-11-19)25(27)20(13-16-5-3-2-4-6-16)23(24(26)31-25)17-7-12-21-22(14-17)30-15-29-21/h2-12,14,27H,13,15H2,1H3
DMQCNWD CS COC1=CC=C(C=C1)C2(C(=C(C(=O)O2)C3=CC4=C(C=C3)OCO4)CC5=CC=CC=C5)O
DMQCNWD IK JZHLIUOZBXWYGJ-UHFFFAOYSA-N
DMQCNWD IU 3-(1,3-benzodioxol-5-yl)-4-benzyl-5-hydroxy-5-(4-methoxyphenyl)furan-2-one
DMQCNWD DE Hypertension
DMAVZEJ ID DMAVZEJ
DMAVZEJ DN PD156707
DMAVZEJ HS Terminated
DMAVZEJ SN PD-156707; 162412-70-6; CHEMBL25438; GTPL999; DTXSID80635455; HMS3263B04; Tox21_501201; CCG-222505; NCGC00261886-01; LS-34623; P-305; PD-156707, > Sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate.; Sodium (2Z)-2-(2H-1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate; sodium (Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate
DMAVZEJ DT Small molecular drug
DMAVZEJ PC 23670447
DMAVZEJ MW 528.5
DMAVZEJ FM C28H25NaO9
DMAVZEJ IC InChI=1S/C28H26O9.Na/c1-32-19-8-5-17(6-9-19)26(29)20(11-16-12-23(33-2)27(35-4)24(13-16)34-3)25(28(30)31)18-7-10-21-22(14-18)37-15-36-21;/h5-10,12-14H,11,15H2,1-4H3,(H,30,31);/q;+1/p-1/b25-20-;
DMAVZEJ CS COC1=CC=C(C=C1)C(=O)/C(=C(/C2=CC3=C(C=C2)OCO3)\\C(=O)[O-])/CC4=CC(=C(C(=C4)OC)OC)OC.[Na+]
DMAVZEJ IK ZLHQEGFYBMZQGM-RKVLWQGQSA-M
DMAVZEJ IU sodium;(Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate
DMAVZEJ CA CAS 162412-70-6
DM61NFD ID DM61NFD
DM61NFD DN PD-157667
DM61NFD HS Terminated
DM61NFD SN CHEMBL78017; PD-157667; SCHEMBL7307021; pd157667; BDBM50071611
DM61NFD DT Small molecular drug
DM61NFD PC 9956291
DM61NFD MW 468.7
DM61NFD FM C32H40N2O
DM61NFD IC InChI=1S/C32H40N2O/c35-32-29(25-33-20-9-1-2-10-21-33)18-17-28-24-34(23-19-31(28)32)22-11-16-30(26-12-5-3-6-13-26)27-14-7-4-8-15-27/h3-8,12-15,17-18,30,35H,1-2,9-11,16,19-25H2
DM61NFD CS C1CCCN(CC1)CC2=C(C3=C(CN(CC3)CCCC(C4=CC=CC=C4)C5=CC=CC=C5)C=C2)O
DM61NFD IK SBYWDPHGZJEZBN-UHFFFAOYSA-N
DM61NFD IU 6-(azepan-1-ylmethyl)-2-(4,4-diphenylbutyl)-3,4-dihydro-1H-isoquinolin-5-ol
DMS1XK5 ID DMS1XK5
DMS1XK5 DN PD-158473
DMS1XK5 HS Terminated
DMS1XK5 SN SCHEMBL838874; CHEMBL62030; ZINC1542005
DMS1XK5 CP Pfizer Inc
DMS1XK5 DT Small molecular drug
DMS1XK5 PC 9821483
DMS1XK5 MW 385.3
DMS1XK5 FM C20H20NO5P
DMS1XK5 IC InChI=1S/C20H20NO5P/c21-19(20(22)23)11-13-8-14(12-27(24,25)26)10-16(9-13)18-7-3-5-15-4-1-2-6-17(15)18/h1-10,19H,11-12,21H2,(H,22,23)(H2,24,25,26)/t19-/m0/s1
DMS1XK5 CS C1=CC=C2C(=C1)C=CC=C2C3=CC(=CC(=C3)CP(=O)(O)O)C[C@@H](C(=O)O)N
DMS1XK5 IK YFASPHLUVUCGGI-IBGZPJMESA-N
DMS1XK5 IU (2S)-2-amino-3-[3-naphthalen-1-yl-5-(phosphonomethyl)phenyl]propanoic acid
DMS1XK5 DE Cerebrovascular ischaemia
DMJ5STO ID DMJ5STO
DMJ5STO DN PD-159913
DMJ5STO HS Terminated
DMJ5STO SN PD-159913; CHEMBL60181; SCHEMBL8923309
DMJ5STO CP Pfizer Inc
DMJ5STO DT Small molecular drug
DMJ5STO PC 10430161
DMJ5STO MW 385.3
DMJ5STO FM C20H20NO5P
DMJ5STO IC InChI=1S/C20H20NO5P/c21-19(20(22)23)10-13-7-14(12-27(24,25)26)9-18(8-13)17-6-5-15-3-1-2-4-16(15)11-17/h1-9,11,19H,10,12,21H2,(H,22,23)(H2,24,25,26)/t19-/m0/s1
DMJ5STO CS C1=CC=C2C=C(C=CC2=C1)C3=CC(=CC(=C3)CP(=O)(O)O)C[C@@H](C(=O)O)N
DMJ5STO IK GOPXMKDIVJBBQF-IBGZPJMESA-N
DMJ5STO IU (2S)-2-amino-3-[3-naphthalen-2-yl-5-(phosphonomethyl)phenyl]propanoic acid
DMJ5STO DE Cerebrovascular ischaemia
DMAOHXY ID DMAOHXY
DMAOHXY DN PD166285
DMAOHXY HS Terminated
DMAOHXY SN PD0166285; 185039-89-8; TCMDC-140940; CHEMBL49120; PD-0166285; 6-(2,6-dichlorophenyl)-2-({4-[2-(diethylamino)ethoxy]phenyl}amino)-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-2-({4-[2-(Diethylamino)ethoxy]phenyl}amino)-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; IFPPYSWJNWHOLQ-UHFFFAOYSA-N; AC1NSKIX; Kinome_3263; SCHEMBL133914; BDBM3096; GTPL8183; MolPort-044-560-325; ZINC1486219; BCP20228; s8148; AKOS032945173; NCGC00242490-02; NCGC00242490-01; HY-13925; CS-0008610
DMAOHXY DT Small molecular drug
DMAOHXY PC 5311382
DMAOHXY MW 512.4
DMAOHXY FM C26H27Cl2N5O2
DMAOHXY IC InChI=1S/C26H27Cl2N5O2/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31)
DMAOHXY CS CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl
DMAOHXY IK IFPPYSWJNWHOLQ-UHFFFAOYSA-N
DMAOHXY IU 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one
DMQRHMT ID DMQRHMT
DMQRHMT DN PD-29361
DMQRHMT HS Terminated
DMQRHMT DT Small molecular drug
DMQRHMT PC 136180343
DMQRHMT MW 496.6
DMQRHMT FM C31H36N4O2
DMQRHMT IC InChI=1S/C31H36N4O2/c36-30-24(20-34-12-3-1-4-13-34)17-22(26-9-11-32-19-28(26)30)16-23-18-25(21-35-14-5-2-6-15-35)31(37)29-27(23)8-7-10-33-29/h7-11,17-19,36-37H,1-6,12-16,20-21H2
DMQRHMT CS C1CCN(CC1)CC2=C(C3=C(C=CC=N3)C(=C2)CC4=CC(=C(C5=C4C=CN=C5)O)CN6CCCCC6)O
DMQRHMT IK WJEZXIYONPULSN-UHFFFAOYSA-N
DMQRHMT IU 5-[[8-hydroxy-7-(piperidin-1-ylmethyl)isoquinolin-5-yl]methyl]-7-(piperidin-1-ylmethyl)quinolin-8-ol
DMNUKB4 ID DMNUKB4
DMNUKB4 DN PD-85639
DMNUKB4 HS Terminated
DMNUKB4 SN PD-85639; CHEMBL282833; 150034-24-5; CTK8E7452; BDBM50043993; RT-014971; J-008654; N-[3-(2,6-Dimethyl-piperidin-1-yl)-propyl]-2,2-diphenyl-acetamide
DMNUKB4 DT Small molecular drug
DMNUKB4 PC 9950970
DMNUKB4 MW 364.5
DMNUKB4 FM C24H32N2O
DMNUKB4 IC InChI=1S/C24H32N2O/c1-19-11-9-12-20(2)26(19)18-10-17-25-24(27)23(21-13-5-3-6-14-21)22-15-7-4-8-16-22/h3-8,13-16,19-20,23H,9-12,17-18H2,1-2H3,(H,25,27)
DMNUKB4 CS CC1CCCC(N1CCCNC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C
DMNUKB4 IK BPZBEIHSHWNWTE-UHFFFAOYSA-N
DMNUKB4 IU N-[3-(2,6-dimethylpiperidin-1-yl)propyl]-2,2-diphenylacetamide
DMT819N ID DMT819N
DMT819N DN Pegorgotein
DMT819N HS Terminated
DMT819N SN Dismutec; Conjugated bSOD, Oxis; SOD, Sanofi; Superoxide dismutase, Sanofi; PEG-SOD, Oxis; PEG-SOD, Sanofi; PEG-bSOD, Oxis; PEG-bSOD, Sanofi; PEG-superoxide dismutase, Enzon Inc
DMT819N CP OXIS International Inc
DMT819N DT Small molecular drug
DMT819N PC 3086673
DMT819N MW 175.18
DMT819N FM C7H13NO4
DMT819N IC InChI=1S/C7H13NO4/c1-11-4-5-12-7(10)3-2-6(8)9/h2-5H2,1H3,(H2,8,9)
DMT819N CS COCCOC(=O)CCC(=O)N
DMT819N IK VJDVWBDSMDTODO-UHFFFAOYSA-N
DMT819N IU 2-methoxyethyl 4-amino-4-oxobutanoate
DMT819N CA CAS 155773-57-2
DMT819N DE Head injury
DM9S1EA ID DM9S1EA
DM9S1EA DN Pepstatin
DM9S1EA HS Terminated
DM9S1EA SN AC1NUZ3J; L-Valinamide, N-(3-methyl-1-oxobutyl)-L-valyl-N-(4-((2-((1-(2-carboxy-1-hydroxyethyl)-3-methylbutyl)amino)-1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl)-, (1S-(1R*,2R*,4(R*(R*(R*)))))-; N-Isovaleryl-L-valyl-L-valyl-3-hydroxy-6-methyl-gamma-aminoheptanoyl-L-alanyl-3-hydroxy-6-methyl-gamma-aminoheptanoic acid
DM9S1EA DT Small molecular drug
DM9S1EA PC 5478883
DM9S1EA MW 685.9
DM9S1EA FM C34H63N5O9
DM9S1EA IC InChI=1S/C34H63N5O9/c1-17(2)12-23(37-33(47)31(21(9)10)39-34(48)30(20(7)8)38-27(42)14-19(5)6)25(40)15-28(43)35-22(11)32(46)36-24(13-18(3)4)26(41)16-29(44)45/h17-26,30-31,40-41H,12-16H2,1-11H3,(H,35,43)(H,36,46)(H,37,47)(H,38,42)(H,39,48)(H,44,45)/t22-,23-,24-,25-,26-,30-,31-/m0/s1
DM9S1EA CS C[C@@H](C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)NC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C)O
DM9S1EA IK FAXGPCHRFPCXOO-LXTPJMTPSA-N
DM9S1EA IU (3S,4S)-3-hydroxy-4-[[(2S)-2-[[(3S,4S)-3-hydroxy-6-methyl-4-[[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(3-methylbutanoylamino)butanoyl]amino]butanoyl]amino]heptanoyl]amino]propanoyl]amino]-6-methylheptanoic acid
DM9S1EA CA CAS 26305-03-3
DM9S1EA CB CHEBI:7989
DM9S1EA DE Malaria
DMOS9NZ ID DMOS9NZ
DMOS9NZ DN PF-03882845
DMOS9NZ HS Terminated
DMOS9NZ SN UNII-34ZKU73FU3; 34ZKU73FU3; CHEMBL1215331; 1023650-66-9; PF-3882845; (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; compound 2 [PMID: 24738581]; SCHEMBL552307; GTPL9061; DTXSID70144940; XNULRSOGWPFPBL-REWPJTCUSA-N; (+/-)-(3SR,3aRS)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid; BDBM50324210; ZINC58583489; DB11814; NCGC00485023-01; PF-03882845, >
DMOS9NZ CP Pfizer
DMOS9NZ DT Small molecular drug
DMOS9NZ PC 46871935
DMOS9NZ MW 419.9
DMOS9NZ FM C24H22ClN3O2
DMOS9NZ IC InChI=1S/C24H22ClN3O2/c25-21-12-18(8-5-17(21)13-26)28-23(14-3-1-2-4-14)20-10-6-15-11-16(24(29)30)7-9-19(15)22(20)27-28/h5,7-9,11-12,14,20,23H,1-4,6,10H2,(H,29,30)/t20-,23-/m0/s1
DMOS9NZ CS C1CCC(C1)[C@H]2[C@H]3CCC4=C(C3=NN2C5=CC(=C(C=C5)C#N)Cl)C=CC(=C4)C(=O)O
DMOS9NZ IK XNULRSOGWPFPBL-REWPJTCUSA-N
DMOS9NZ IU (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydrobenzo[g]indazole-7-carboxylic acid
DMOS9NZ CA CAS 1023650-66-9
DMOS9NZ DE Diabetic nephropathy
DMSNOH3 ID DMSNOH3
DMSNOH3 DN PF-04620110
DMSNOH3 HS Terminated
DMSNOH3 SN PF-04620110; 1109276-89-2; CHEMBL1835919; 2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid; PF-4620110; trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexaneacetic acid; 2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid; UNII-CQ4M18RLJW; CQ4M18RLJW; SCHEMBL1424362; SCHEMBL1425038; GTPL7829; SCHEMBL1424359; SCHEMBL13954265; DTXSID90677361; GEVVQZHMFVFGLN-HDJSIYSDSA-N
DMSNOH3 CP Pfizer
DMSNOH3 DT Small molecular drug
DMSNOH3 PC 46926360
DMSNOH3 MW 396.4
DMSNOH3 FM C21H24N4O4
DMSNOH3 IC InChI=1S/C21H24N4O4/c22-19-18-20(24-12-23-19)29-10-9-25(21(18)28)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-17(26)27/h5-8,12-14H,1-4,9-11H2,(H,26,27)(H2,22,23,24)
DMSNOH3 CS C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)N3CCOC4=NC=NC(=C4C3=O)N
DMSNOH3 IK GEVVQZHMFVFGLN-UHFFFAOYSA-N
DMSNOH3 IU 2-[4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid
DMSNOH3 CA CAS 1109276-89-2
DMSNOH3 DE Type-2 diabetes
DMZ8HW7 ID DMZ8HW7
DMZ8HW7 DN PF-572778
DMZ8HW7 HS Terminated
DMZ8HW7 SN PF-00572778
DMZ8HW7 CP Pfizer Inc
DMZ8HW7 DE Generalized anxiety disorder
DMAJ9ZD ID DMAJ9ZD
DMAJ9ZD DN Phosphonate
DMAJ9ZD HS Terminated
DMAJ9ZD SN Fitofosine; Antitumor, InflaZyme
DMAJ9ZD CP Inflazyme Pharmaceuticals
DMAJ9ZD DT Small molecular drug
DMAJ9ZD PC 6326969
DMAJ9ZD MW 78.972
DMAJ9ZD FM O3P-
DMAJ9ZD IC InChI=1S/HO3P/c1-4(2)3/h(H,1,2,3)/p-1
DMAJ9ZD CS [O-]P(=O)=O
DMAJ9ZD IK UEZVMMHDMIWARA-UHFFFAOYSA-M
DMAJ9ZD CA CAS 60118-28-7
DMAJ9ZD CB CHEBI:8154
DMAJ9ZD DE leukaemia
DM63OD7 ID DM63OD7
DM63OD7 DN Pifithrin-alpha
DM63OD7 HS Terminated
DM63OD7 SN P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta
DM63OD7 CP University of Illinois
DM63OD7 DT Small molecular drug
DM63OD7 PC 9929138
DM63OD7 MW 367.3
DM63OD7 FM C16H19BrN2OS
DM63OD7 IC InChI=1S/C16H18N2OS.BrH/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17;/h6-9,17H,2-5,10H2,1H3;1H
DM63OD7 CS CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N.Br
DM63OD7 IK HAGVCKULCLQGRF-UHFFFAOYSA-N
DM63OD7 IU 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone;hydrobromide
DM63OD7 CA CAS 63208-82-2
DM63OD7 DE Toxicity
DMR87MO ID DMR87MO
DMR87MO DN PIROXANTRONE
DMR87MO HS Terminated
DMR87MO DT Small molecular drug
DMR87MO PC 59916
DMR87MO MW 411.5
DMR87MO FM C21H25N5O4
DMR87MO IC InChI=1S/C21H25N5O4/c22-6-1-7-24-12-2-3-13-17-16(12)21(30)19-15(29)5-4-14(28)18(19)20(17)25-26(13)10-8-23-9-11-27/h2-5,23,25,27,29-30H,1,6-11,22H2
DMR87MO CS C1=CC(=NCCCN)C2=C(C3=C(C=CC(=O)C3=C4C2=C1N(N4)CCNCCO)O)O
DMR87MO IK UKNVCOILWOLTLJ-UHFFFAOYSA-N
DMR87MO IU 10-(3-aminopropylimino)-6,8-dihydroxy-14-[2-(2-hydroxyethylamino)ethyl]-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1,4,6,8,11,13(16)-hexaen-3-one
DMR87MO CA CAS 91441-23-5
DMR87MO DE Solid tumour/cancer
DMPHUBO ID DMPHUBO
DMPHUBO DN PLD-177
DMPHUBO HS Terminated
DMPHUBO SN PLR-13; PLR-2146; Inhaled steroids (asthma), PLIVA; PLD-177 (inhaled, Clickhaler), PLIVA/Innovata Biomed
DMPHUBO CP PLIVA dd
DMPHUBO DE Allergic rhinitis
DMT83V6 ID DMT83V6
DMT83V6 DN PNQX
DMT83V6 HS Terminated
DMT83V6 SN NS-409; PD-152247; PD-160359; PD-160725; PD-161384; PD-161989; PD-166732
DMT83V6 CP NeuroSearch A/S
DMT83V6 PC 9903685
DMT83V6 MW 276.25
DMT83V6 FM C12H12N4O4
DMT83V6 IC InChI=1S/C12H12N4O4/c1-15-3-2-6-7(5-15)10-8(4-9(6)16(19)20)13-11(17)12(18)14-10/h4H,2-3,5H2,1H3,(H,13,17)(H,14,18)
DMT83V6 CS CN1CCC2=C(C=C3C(=C2C1)NC(=O)C(=O)N3)[N+](=O)[O-]
DMT83V6 IK GDSGJOIKTYTOQG-UHFFFAOYSA-N
DMT83V6 IU 9-methyl-6-nitro-4,7,8,10-tetrahydro-1H-pyrido[3,4-f]quinoxaline-2,3-dione
DMT83V6 DE Cerebrovascular ischaemia
DMZNM2K ID DMZNM2K
DMZNM2K DN PNU-109291
DMZNM2K HS Terminated
DMZNM2K SN U-109291
DMZNM2K CP Pharmacia & Upjohn Inc
DMZNM2K DT Small molecular drug
DMZNM2K PC 9909448
DMZNM2K MW 409.5
DMZNM2K FM C24H31N3O3
DMZNM2K IC InChI=1S/C24H31N3O3/c1-25-24(28)19-3-8-22-18(17-19)10-16-30-23(22)9-11-26-12-14-27(15-13-26)20-4-6-21(29-2)7-5-20/h3-8,17,23H,9-16H2,1-2H3,(H,25,28)/t23-/m0/s1
DMZNM2K CS CNC(=O)C1=CC2=C(C=C1)[C@@H](OCC2)CCN3CCN(CC3)C4=CC=C(C=C4)OC
DMZNM2K IK UDLSEQDYARNKTL-QHCPKHFHSA-N
DMZNM2K IU (1S)-1-[2-[4-(4-methoxyphenyl)piperazin-1-yl]ethyl]-N-methyl-3,4-dihydro-1H-isochromene-6-carboxamide
DMZNM2K CA CAS 187665-60-7
DMZNM2K DE Migraine
DM23ZHN ID DM23ZHN
DM23ZHN DN PNU156804
DM23ZHN HS Terminated
DM23ZHN SN Hexylglutathione; 24425-56-7; UNII-M73SNN908F; S-Hexyl-L-glutathione; L-gamma-glutamyl-S-hexyl-L-cysteinylglycine; NSC 131114; CHEMBL345292; M73SNN908F; CHEBI:27704; Glycine, N-(N-L-gamma-glutamyl-S-hexyl-L-cysteinyl)-; C16H29N3O6S; 1ydk; AC1L3YPR; GTX; S-Hexyl-L-glutathione reduced; SCHEMBL1158164; CTK4F3647; HXJDWCWJDCOHDG-RYUDHWBXSA-N; 2c80; ZINC3874923; BDBM50095998; AKOS015893910; DB04132; LS-174055; Glycine, L-g-glutamyl-S-hexyl-L-cysteinyl-; FT-0770776; C02886; Glycine, L-.gamma.-glutamyl
DM23ZHN DT Small molecular drug
DM23ZHN PC 135484060
DM23ZHN MW 506.1
DM23ZHN FM C31H40ClN3O
DM23ZHN IC InChI=1S/C31H39N3O.ClH/c1-2-3-4-5-6-7-8-9-13-17-26-19-20-27(33-26)22-30-31(35-24-25-15-11-10-12-16-25)23-29(34-30)28-18-14-21-32-28;/h10-12,14-16,18-23,32-33H,2-9,13,17,24H2,1H3;1H/b30-22-;
DM23ZHN CS CCCCCCCCCCCC1=CC=C(N1)/C=C\\2/C(=CC(=N2)C3=CC=CN3)OCC4=CC=CC=C4.Cl
DM23ZHN IK ODJQLZRYBXCIPR-VDFJEELKSA-N
DM23ZHN IU (2Z)-3-phenylmethoxy-5-(1H-pyrrol-2-yl)-2-[(5-undecyl-1H-pyrrol-2-yl)methylidene]pyrrole;hydrochloride
DM23ZHN DE Renal transplantation
DMRT69H ID DMRT69H
DMRT69H DN PNU-177864
DMRT69H HS Terminated
DMRT69H CP Pfizer
DMRT69H PC 56972219
DMRT69H MW 438.9
DMRT69H FM C18H22ClF3N2O3S
DMRT69H IC InChI=1S/C18H21F3N2O3S.ClH/c1-2-12-22-13-11-14-3-5-15(6-4-14)23-27(24,25)17-9-7-16(8-10-17)26-18(19,20)21;/h3-10,22-23H,2,11-13H2,1H3;1H
DMRT69H CS CCCNCCC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F.Cl
DMRT69H IK UOMDLHQTLPWCCE-UHFFFAOYSA-N
DMRT69H IU N-[4-[2-(propylamino)ethyl]phenyl]-4-(trifluoromethoxy)benzenesulfonamide;hydrochloride
DMRT69H DE Schizophrenia
DMGDC36 ID DMGDC36
DMGDC36 DN PNU-282987
DMGDC36 HS Terminated
DMGDC36 SN Benzamide, N-(3R)-1-azabicyclo[222]oct-3-yl-4-chloro-; PNU282987; 123464-89-1; 711085-63-1; PNU 282987; UNII-27M563MU5U; N-(3R)-1-Azabicyclo[222]oct-3-yl-4-chlorobenzamide; CHEMBL177611; 27M563MU5U; Benzamide, N-(3R)-1-azabicyclo(222)oct-3-yl-4-chloro-; CHEMBL554984; PNU-282,987; PNU-282987 free base; SCHEMBL677422; PNU282987HCl; GTPL3988; CHEBI:92508; CTK2H4027; MolPort-023-219-197; MolPort-003-983-664; HMS3268J18; ZINC3990028; BDBM50161764; BDBM50161753; ABP000998; AKOS016339643; AKOS024457037; KS-1399; API0008100; N-((3R)-1-Azabicyclo(222)oct-3-yl)-4-chlorobenzamide hydrochloride; ISIS 25302
DMGDC36 CP Pfizer
DMGDC36 DT Small molecular drug
DMGDC36 PC 11243536
DMGDC36 MW 301.2
DMGDC36 FM C14H18Cl2N2O
DMGDC36 IC InChI=1S/C14H17ClN2O.ClH/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17;/h1-4,10,13H,5-9H2,(H,16,18);1H/t13-;/m0./s1
DMGDC36 CS C1CN2CCC1[C@H](C2)NC(=O)C3=CC=C(C=C3)Cl.Cl
DMGDC36 IK HSEQUIRZHDYOIX-ZOWNYOTGSA-N
DMGDC36 IU N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide;hydrochloride
DMGDC36 CA CAS 123464-89-1
DMGDC36 DE Schizophrenia
DMLMISK ID DMLMISK
DMLMISK DN PNU-96391A
DMLMISK HS Terminated
DMLMISK SN (-)-OSU-6162
DMLMISK CP University of Gothenburg
DMLMISK DT Small molecular drug
DMLMISK PC 9836644
DMLMISK MW 317.9
DMLMISK FM C15H24ClNO2S
DMLMISK IC InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1
DMLMISK CS CCCN1CCC[C@H](C1)C2=CC(=CC=C2)S(=O)(=O)C.Cl
DMLMISK IK LEMGVHZVBREXAD-PFEQFJNWSA-N
DMLMISK IU (3S)-3-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride
DMLMISK CA CAS 156907-84-5
DMLMISK DE Substance use disorder
DMLY2TN ID DMLY2TN
DMLY2TN DN PPACK
DMLY2TN HS Terminated
DMLY2TN SN AC1MI1QZ; SCHEMBL871144; LS-186049
DMLY2TN DT Small molecular drug
DMLY2TN PC 5311176
DMLY2TN MW 451
DMLY2TN FM C21H31ClN6O3
DMLY2TN IC InChI=1S/C21H31ClN6O3/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26)/t15-,16+,17+/m1/s1
DMLY2TN CS C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl
DMLY2TN IK KWPACVJPAFGBEQ-IKGGRYGDSA-N
DMLY2TN IU (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3S)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide
DMLY2TN CA CAS 71142-71-7
DMI2N9H ID DMI2N9H
DMI2N9H DN Pranidipine
DMI2N9H HS Terminated
DMI2N9H SN Acalas; OPC-13340; OPC-13463
DMI2N9H CP Otsuka Pharmaceutical Co Ltd
DMI2N9H DT Small molecular drug
DMI2N9H PC 6436048
DMI2N9H MW 448.5
DMI2N9H FM C25H24N2O6
DMI2N9H IC InChI=1S/C25H24N2O6/c1-16-21(24(28)32-3)23(19-12-7-13-20(15-19)27(30)31)22(17(2)26-16)25(29)33-14-8-11-18-9-5-4-6-10-18/h4-13,15,23,26H,14H2,1-3H3/b11-8+
DMI2N9H CS CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMI2N9H IK XTFPDGZNWTZCMF-DHZHZOJOSA-N
DMI2N9H IU 3-O-methyl 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMI2N9H CA CAS 99522-79-9
DMI2N9H DE Angina pectoris
DMDIYFH ID DMDIYFH
DMDIYFH DN PRE-084
DMDIYFH HS Terminated
DMDIYFH SN Pre-084; 138847-85-5; 2-Morpholinoethyl 1-Phenylcyclohexanecarboxylate; 2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate; CHEMBL305881; 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate; Cyclohexanecarboxylic acid, 1-phenyl-, 2-(4-morpholinyl)ethyl ester; Tocris-0589; Lopac-P-2607; AC1L2Q9Z; Lopac0_000927; PRE084; GTPL6678; SCHEMBL5564153; CHEBI:93007; DTXSID40160819; EX-A911; BCP25418; BDBM50039197; ZINC25756875; AKOS027439951; CCG-205008; NCGC00024669-03; NCGC00024669-02; NCGC00024669-01; NCGC00015808-04
DMDIYFH CP INSERM
DMDIYFH DT Small molecular drug
DMDIYFH PC 126402
DMDIYFH MW 317.4
DMDIYFH FM C19H27NO3
DMDIYFH IC InChI=1S/C19H27NO3/c21-18(23-16-13-20-11-14-22-15-12-20)19(9-5-2-6-10-19)17-7-3-1-4-8-17/h1,3-4,7-8H,2,5-6,9-16H2
DMDIYFH CS C1CCC(CC1)(C2=CC=CC=C2)C(=O)OCCN3CCOCC3
DMDIYFH IK RQHKZUBCUZVZEF-UHFFFAOYSA-N
DMDIYFH IU 2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate
DMDIYFH CA CAS 138847-85-5
DMDIYFH CB CHEBI:93007
DMDIYFH DE Aging skin
DMS4FG0 ID DMS4FG0
DMS4FG0 DN Promegapoietin
DMS4FG0 HS Terminated
DMS4FG0 SN IL-3/TPO agonist, Searle; IL-3/TPO agonist, University of Maryland
DMS4FG0 CP GD Searle & Co
DMS4FG0 DE Bone marrow transplantation
DM57YO8 ID DM57YO8
DM57YO8 DN Protosufloxacin
DM57YO8 HS Terminated
DM57YO8 SN A-71497
DM57YO8 CP Abbott Laboratories
DM57YO8 DE Bacterial infection
DMNK2I0 ID DMNK2I0
DMNK2I0 DN PRS-639058
DMNK2I0 HS Terminated
DMNK2I0 CP Pharmos Corp
DMNK2I0 DE Neuropathic pain
DM8P05S ID DM8P05S
DM8P05S DN PS-388023
DM8P05S HS Terminated
DM8P05S SN PS-680648; PS-780035; Angiogenesis inhibitors (ocular indications), Pharmacopeia/Allergan; Angiogenesis inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia; Dual integrin avb3/avb5 inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia; Dual integrin alpha-5/beta-3 + alpha-5/beta-5 inhibitors (inflammatory/ocular/oncological indications), Pharmacopeia
DM8P05S CP Pharmacopeia Inc
DM8P05S DE Ocular disease
DMI0WHC ID DMI0WHC
DMI0WHC DN PS-519
DMI0WHC HS Terminated
DMI0WHC PC 9877196
DMI0WHC MW 241.28
DMI0WHC FM C12H19NO4
DMI0WHC IC InChI=1S/C12H19NO4/c1-4-5-7-9-12(11(16)17-9,13-10(7)15)8(14)6(2)3/h6-9,14H,4-5H2,1-3H3,(H,13,15)/t7-,8+,9+,12-/m1/s1
DMI0WHC CS CCC[C@@H]1[C@H]2[C@](C(=O)O2)(NC1=O)[C@H](C(C)C)O
DMI0WHC IK KMXHEXRPYSXLRN-JDVQERKKSA-N
DMI0WHC IU (1R,4R,5S)-1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
DMI0WHC CB CHEBI:52724
DMI0WHC DE Ischemia-reperfusion injury
DMWUOA8 ID DMWUOA8
DMWUOA8 DN PSI-6130
DMWUOA8 HS Terminated
DMWUOA8 SN R-1656; RO-4995855; Hepatitis C virus therapy, Pharmasset/Roche; PSI-6130-DP; PSI-6130-MP; PSI-6130-TP
DMWUOA8 CP Pharmasset Inc
DMWUOA8 DT Small molecular drug
DMWUOA8 PC 6481236
DMWUOA8 MW 259.23
DMWUOA8 FM C10H14FN3O4
DMWUOA8 IC InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
DMWUOA8 CS C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)O)F
DMWUOA8 IK NYPIRLYMDJMKGW-VPCXQMTMSA-N
DMWUOA8 IU 4-amino-1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one
DMWUOA8 CA CAS 817204-33-4
DMWUOA8 DE Hepatitis C virus infection
DM579WS ID DM579WS
DM579WS DN PSI-661
DM579WS HS Terminated
DM579WS SN PSI-353661
DM579WS CP Pharmasset Inc
DM579WS DE Hepatitis C virus infection
DMGEWUS ID DMGEWUS
DMGEWUS DN PSN821
DMGEWUS HS Terminated
DMGEWUS CP Astellas Pharma Inc
DMGEWUS DE Type-2 diabetes
DMH3RPO ID DMH3RPO
DMH3RPO DN PT-630
DMH3RPO HS Terminated
DMH3RPO SN Non insulin dependent diabetes therapy, DARA BioSciences; Non insulin dependent diabetes therapy, Point Therapeutics
DMH3RPO CP DARA BioSciences Inc
DMH3RPO PC 11673176
DMH3RPO MW 244.06
DMH3RPO FM C9H17BN2O5
DMH3RPO IC InChI=1S/C9H17BN2O5/c11-6(3-4-8(13)14)9(15)12-5-1-2-7(12)10(16)17/h6-7,16-17H,1-5,11H2,(H,13,14)/t6-,7-/m0/s1
DMH3RPO CS B([C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)N)(O)O
DMH3RPO IK DMTPQYQQHYOTQM-BQBZGAKWSA-N
DMH3RPO IU (4S)-4-amino-5-[(2R)-2-boronopyrrolidin-1-yl]-5-oxopentanoic acid
DMH3RPO DE Type-2 diabetes
DM89RT7 ID DM89RT7
DM89RT7 DN PTX-007011
DM89RT7 HS Terminated
DM89RT7 SN PTX-040334; PTX-042695; Phosphopantethiene adenyltransferase inhibitors (antibacterial); Phosphopantethiene adenyltransferase inhibitors (antibacterial), PanTherix
DM89RT7 CP PanTherix Ltd
DM89RT7 DE Bacterial infection
DM84RHP ID DM84RHP
DM84RHP DN PTX-008313
DM84RHP HS Terminated
DM84RHP SN Chorismate synthase inhibitors (antibacterial); PTX-110130; Chorismate synthase inhibitors (antibacterial), PanTherix
DM84RHP CP PanTherix Ltd
DM84RHP DE Bacterial infection
DM63O4F ID DM63O4F
DM63O4F DN PURPUROGALLIN
DM63O4F HS Terminated
DM63O4F SN 3tiy; AC1NQYND; BIDD:ER0545
DM63O4F DT Small molecular drug
DM63O4F PC 135403797
DM63O4F MW 220.18
DM63O4F FM C11H8O5
DM63O4F IC InChI=1S/C11H8O5/c12-6-3-1-2-5-4-7(13)10(15)11(16)8(5)9(6)14/h1-4,13,15-16H,(H,12,14)
DM63O4F CS C1=CC2=CC(=C(C(=C2C(=O)C(=C1)O)O)O)O
DM63O4F IK WDGFFVCWBZVLCE-UHFFFAOYSA-N
DM63O4F IU 2,3,4,6-tetrahydroxybenzo[7]annulen-5-one
DM63O4F CA CAS 569-77-7
DM63O4F CB CHEBI:8647
DMCNE2G ID DMCNE2G
DMCNE2G DN PX-867
DMCNE2G HS Terminated
DMCNE2G SN PI-3-K inhibitor (cardiovascular disease), Oncothyreon; Phosphatidylinositol-3-kinase inhibitor (cardiovascular disease), Oncothyreon
DMCNE2G CP Oncothyreon Inc
DMCNE2G DT Small molecular drug
DMCNE2G PC 11191229
DMCNE2G MW 499.6
DMCNE2G FM C27H33NO8
DMCNE2G IC InChI=1S/C27H33NO8/c1-14(29)35-17-11-26(2)16(7-8-18(26)30)20-22(17)27(3)19(13-34-4)36-25(33)15(12-28-9-5-6-10-28)21(27)24(32)23(20)31/h12,16-17,19,32H,5-11,13H2,1-4H3/b15-12-/t16-,17+,19+,26-,27-/m0/s1
DMCNE2G CS CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C\\N5CCCC5)/C4=C(C3=O)O)COC)C)C
DMCNE2G IK JUSZLIOETSSZJM-WQVKNQJISA-N
DMCNE2G IU [(3aR,6Z,9S,9aR,10R,11aS)-5-hydroxy-9-(methoxymethyl)-9a,11a-dimethyl-1,4,7-trioxo-6-(pyrrolidin-1-ylmethylidene)-2,3,3a,9,10,11-hexahydroindeno[4,5-h]isochromen-10-yl] acetate
DMCNE2G DE Cardiovascular disease
DM1AXZ6 ID DM1AXZ6
DM1AXZ6 DN PXS-2076
DM1AXZ6 HS Terminated
DM1AXZ6 SN PXS-2000; PXS-2030; Cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis; TNFrelease inhibitor (rheumatoid arthritis), Pharmaxis
DM1AXZ6 CP Pharmaxis Ltd
DM1AXZ6 DE Rheumatoid arthritis
DM8RHST ID DM8RHST
DM8RHST DN QAP-642
DM8RHST HS Terminated
DM8RHST SN CCR3 antagonist (allergic rhinitis), Novartis
DM8RHST CP Novartis AG
DM8RHST DE Allergic rhinitis
DMAV2FM ID DMAV2FM
DMAV2FM DN QX-314
DMAV2FM HS Terminated
DMAV2FM SN QX 314; CHEBI:46937; 2-[(2,6-dimethylphenyl)amino]-N,N,N-triethyl-2-oxoethanaminium; 2-((2,6-Dimethylphenyl)amino)-N,N,N-triethyl-2-oxoethanaminium; Ethanaminium, 2-((2,6-dimethylphenyl)amino)-N,N,N-triethyl-2-oxo-; Tocris-1014; AC1Q5LWR; Lopac-L-5783; UPCMLD-DP014; AC1L1H0Q; SCHEMBL93854; Lopac0_000679; KBioGR_000191; BSPBio_001471; KBioSS_000191; GTPL2405; UPCMLD-DP014:001; CHEMBL1180496; C16H27N2O; KBio3_000382; KBio2_005327; KBio2_002759; KBio2_000191; KBio3_000381; QX314; Bio2_000671; Bio2_000191; ZINC2037285; CCG-204765
DMAV2FM TC Analgesics
DMAV2FM DT Small molecular drug
DMAV2FM PC 9884487
DMAV2FM MW 343.3
DMAV2FM FM C16H27BrN2O
DMAV2FM IC InChI=1S/C16H26N2O.BrH/c1-6-18(7-2,8-3)12-15(19)17-16-13(4)10-9-11-14(16)5;/h9-11H,6-8,12H2,1-5H3;1H
DMAV2FM CS CC[N+](CC)(CC)CC(=O)NC1=C(C=CC=C1C)C.[Br-]
DMAV2FM IK DLHMKHREUTXMCH-UHFFFAOYSA-N
DMAV2FM IU [2-(2,6-dimethylanilino)-2-oxoethyl]-triethylazanium;bromide
DMAV2FM CA CAS 24003-58-5
DMAV2FM DE Pain
DMA187T ID DMA187T
DMA187T DN R zileuton
DMA187T HS Terminated
DMA187T CP Cornerstone Therapeutics
DMA187T DE Asthma
DM46YHG ID DM46YHG
DM46YHG DN R-102444
DM46YHG HS Terminated
DM46YHG SN Dopamine D2 antagonists, Sankyo; 5-HT2 antagonists, Sankyo
DM46YHG CP Sankyo Co Ltd
DM46YHG PC 10256696
DM46YHG MW 537.8
DM46YHG FM C34H51NO4
DM46YHG IC InChI=1S/C34H51NO4/c1-4-5-6-7-8-9-10-11-12-20-34(36)39-32-26-30(35(2)27-32)23-24-38-33-19-14-13-17-29(33)22-21-28-16-15-18-31(25-28)37-3/h13-19,25,30,32H,4-12,20-24,26-27H2,1-3H3/t30-,32-/m1/s1
DM46YHG CS CCCCCCCCCCCC(=O)O[C@@H]1C[C@H](N(C1)C)CCOC2=CC=CC=C2CCC3=CC(=CC=C3)OC
DM46YHG IK ZVCROHONSVCKKH-XLJNKUFUSA-N
DM46YHG IU [(3R,5R)-5-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]-1-methylpyrrolidin-3-yl] dodecanoate
DM46YHG DE Pancreatitis
DMIBCZ5 ID DMIBCZ5
DMIBCZ5 DN R-1315
DMIBCZ5 HS Terminated
DMIBCZ5 CP Roche Holding AG
DMIBCZ5 DE Alzheimer disease
DMBU24I ID DMBU24I
DMBU24I DN R-1437
DMBU24I HS Terminated
DMBU24I CP Roche Holding AG
DMBU24I DE Prostate hyperplasia
DM8XBKG ID DM8XBKG
DM8XBKG DN R-1554
DM8XBKG HS Terminated
DM8XBKG CP Roche Holding AG
DM8XBKG DE Overactive bladder
DM12EYR ID DM12EYR
DM12EYR DN R348
DM12EYR HS Terminated
DM12EYR CP Rigel Pharmaceuticals
DM12EYR PC 68254
DM12EYR MW 121.18
DM12EYR FM C8H11N
DM12EYR IC InChI=1S/C8H11N/c1-3-8-6-9-5-4-7(8)2/h4-6H,3H2,1-2H3
DM12EYR CS CCC1=C(C=CN=C1)C
DM12EYR IK JDQNYWYMNFRKNQ-UHFFFAOYSA-N
DM12EYR IU 3-ethyl-4-methylpyridine
DM12EYR CA CAS 529-21-5
DM12EYR DE Psoriasis vulgaris
DMYTI3J ID DMYTI3J
DMYTI3J DN R-56865
DMYTI3J HS Terminated
DMYTI3J SN R-56865; UNII-8MUQ2U7UV6; 104606-13-5; R 56865; BRN 6616961; 8MUQ2U7UV6; CHEMBL137009; R56865; N-(1-(4-(4-Fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-2-benzothiazolamine; 2-Benzothiazolamine, N-(1-(4-(4-fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-; 2-Benzothiazolamine,N-[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-N-methyl-; ACMC-20m7dr; SCHEMBL933977; CTK4A3161; DTXSID40146613; AC1L3388; BDBM50067625; LS-40628; Benzothiazol-2-yl-{1-[4-(4-fluoro-phenoxy)-butyl]-piperidin-4-yl}-methyl-amine
DMYTI3J DT Small molecular drug
DMYTI3J PC 108043
DMYTI3J MW 413.6
DMYTI3J FM C23H28FN3OS
DMYTI3J IC InChI=1S/C23H28FN3OS/c1-26(23-25-21-6-2-3-7-22(21)29-23)19-12-15-27(16-13-19)14-4-5-17-28-20-10-8-18(24)9-11-20/h2-3,6-11,19H,4-5,12-17H2,1H3
DMYTI3J CS CN(C1CCN(CC1)CCCCOC2=CC=C(C=C2)F)C3=NC4=CC=CC=C4S3
DMYTI3J IK PZPXREFPAFDHNG-UHFFFAOYSA-N
DMYTI3J IU N-[1-[4-(4-fluorophenoxy)butyl]piperidin-4-yl]-N-methyl-1,3-benzothiazol-2-amine
DMYTI3J CA CAS 104606-13-5
DMYTI3J DE Angina pectoris
DM36JFP ID DM36JFP
DM36JFP DN R-59494
DM36JFP HS Terminated
DM36JFP SN R 59494; 136917-41-4; AC1L307W; DTXSID50160007; N-Methyl-N-(1-(4-phenoxybutyl)-3-pyrrolidinyl)-2-benzothiazolamine; N-methyl-N-[1-(4-phenoxybutyl)pyrrol-3-yl]-1,3-benzothiazol-2-amine; 2-Benzothiazolamine, N-methyl-N-(1-(4-phenoxybutyl)-1H-pyrrol-3-yl)-
DM36JFP CP Janssen Pharmaceutica NV
DM36JFP DT Small molecular drug
DM36JFP PC 132007
DM36JFP MW 377.5
DM36JFP FM C22H23N3OS
DM36JFP IC InChI=1S/C22H23N3OS/c1-24(22-23-20-11-5-6-12-21(20)27-22)18-13-15-25(17-18)14-7-8-16-26-19-9-3-2-4-10-19/h2-6,9-13,15,17H,7-8,14,16H2,1H3
DM36JFP CS CN(C1=CN(C=C1)CCCCOC2=CC=CC=C2)C3=NC4=CC=CC=C4S3
DM36JFP IK PFBZXLGUUGDBNI-UHFFFAOYSA-N
DM36JFP IU N-methyl-N-[1-(4-phenoxybutyl)pyrrol-3-yl]-1,3-benzothiazol-2-amine
DM36JFP CA CAS 136917-41-4
DM36JFP DE Ischemia
DMLAIZG ID DMLAIZG
DMLAIZG DN R-7025
DMLAIZG HS Terminated
DMLAIZG SN Maxy-24; Maxy-alpha; PEGylated IFN alpha, Maxygen/Roche; PEGylated interferonalpha, Maxygen/Roche
DMLAIZG CP Maxygen Inc
DMLAIZG DE Hepatitis B virus infection
DMZQJVN ID DMZQJVN
DMZQJVN DN R-85355
DMZQJVN HS Terminated
DMZQJVN SN SCHEMBL10277001
DMZQJVN DT Small molecular drug
DMZQJVN PC 56603786
DMZQJVN MW 427.9
DMZQJVN FM C21H22ClN5O3
DMZQJVN IC InChI=1S/C21H22ClN5O3/c1-15-23-26(14-20(29)16-2-4-17(22)5-3-16)21(30)27(15)25-12-10-24(11-13-25)18-6-8-19(28)9-7-18/h2-9,28H,10-14H2,1H3
DMZQJVN CS CC1=NN(C(=O)N1N2CCN(CC2)C3=CC=C(C=C3)O)CC(=O)C4=CC=C(C=C4)Cl
DMZQJVN IK VZSLWTZQSOCFIA-UHFFFAOYSA-N
DMZQJVN IU 2-[2-(4-chlorophenyl)-2-oxoethyl]-4-[4-(4-hydroxyphenyl)piperazin-1-yl]-5-methyl-1,2,4-triazol-3-one
DM7HAE9 ID DM7HAE9
DM7HAE9 DN Ralitoline
DM7HAE9 HS Terminated
DM7HAE9 SN GO-4942; Goe-4942; PD-117818
DM7HAE9 CP Parke-Davis & Co
DM7HAE9 DT Small molecular drug
DM7HAE9 PC 6436118
DM7HAE9 MW 296.77
DM7HAE9 FM C13H13ClN2O2S
DM7HAE9 IC InChI=1S/C13H13ClN2O2S/c1-8-4-3-5-9(14)13(8)15-10(17)6-12-16(2)11(18)7-19-12/h3-6H,7H2,1-2H3,(H,15,17)/b12-6-
DM7HAE9 CS CC1=C(C(=CC=C1)Cl)NC(=O)/C=C\\2/N(C(=O)CS2)C
DM7HAE9 IK YJXQTIXFPYPQFT-SDQBBNPISA-N
DM7HAE9 IU (2Z)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-4-oxo-1,3-thiazolidin-2-ylidene)acetamide
DM7HAE9 CA CAS 93738-40-0
DM7HAE9 DE Epilepsy
DM4FNWO ID DM4FNWO
DM4FNWO DN RC-01
DM4FNWO HS Terminated
DM4FNWO CP Recida Therapeutics
DM4FNWO DE Gram-negative bacterial infection
DM08BUV ID DM08BUV
DM08BUV DN RDEA-427
DM08BUV HS Terminated
DM08BUV SN Non-nucleoside reverse transcriptase inhibitors (HIV infection), Ardea Bioscience
DM08BUV CP Ardea Biosciences Inc
DM08BUV DE Human immunodeficiency virus infection
DM61RGQ ID DM61RGQ
DM61RGQ DN RDEA-640
DM61RGQ HS Terminated
DM61RGQ SN RDEA-800; RDEA-900; VRX-480773; VRX-840773; NNRTIs (HIV infection), Ardea; NNRTIs (HIV infection), Valeant; Non-nucleoside reverse transcriptase inhibitor 800 series (HIV infection), Ardea; Non-nucleoside reverse transcriptase inhibitor 900 series (HIV infection), Ardea; Non-nucleoside reverse transcriptase inhibitors (HIV infection), Ardea; Non-nucleoside reverse transcriptase inhibitors (HIV infection), Valeant
DM61RGQ CP Valeant Pharmaceuticals International Inc
DM61RGQ DE Human immunodeficiency virus infection
DMDC2E8 ID DMDC2E8
DMDC2E8 DN Recainam
DMDC2E8 HS Terminated
DMDC2E8 SN Vanorm; Recainam hydrochloride; Win-42362; Wy-42362
DMDC2E8 CP Wyeth
DMDC2E8 DT Small molecular drug
DMDC2E8 PC 53084
DMDC2E8 MW 263.38
DMDC2E8 FM C15H25N3O
DMDC2E8 IC InChI=1S/C15H25N3O/c1-11(2)16-9-6-10-17-15(19)18-14-12(3)7-5-8-13(14)4/h5,7-8,11,16H,6,9-10H2,1-4H3,(H2,17,18,19)
DMDC2E8 CS CC1=C(C(=CC=C1)C)NC(=O)NCCCNC(C)C
DMDC2E8 IK WHJSFPCTWYLZRC-UHFFFAOYSA-N
DMDC2E8 IU 1-(2,6-dimethylphenyl)-3-[3-(propan-2-ylamino)propyl]urea
DMDC2E8 CA CAS 74738-24-2
DMDC2E8 DE Heart arrhythmia
DMWIAUK ID DMWIAUK
DMWIAUK DN ReN-1820
DMWIAUK HS Terminated
DMWIAUK SN TrkAd5; HNGF, ReNeuron; Human nerve growth factor, ReNeuron; HNGF, Enact/University of Bristol; Human nerve growth factor, Enact/University of Bristol
DMWIAUK CP University of Bristol
DMWIAUK DE Cystitis
DMGY51F ID DMGY51F
DMGY51F DN ReN-1826
DMGY51F HS Terminated
DMGY51F SN Neurotrophin receptor program, Enact; Neurotrophin receptor program, ReNeuron
DMGY51F CP University of Bristol
DMGY51F DE Central nervous system disease
DM1XYJU ID DM1XYJU
DM1XYJU DN RES-701-1
DM1XYJU HS Terminated
DM1XYJU SN L-Tryptophan, glycyl-L-asparaginyl-L-tryptophyl-L-histidylglycyl-L-threonyl-L-alanyl-L-prolyl-L-alpha-aspartyl-L-tryptophyl-L-phenylalanyl-L-phenylalanyl-L-asparaginyl-L-tyrosyl-L-tyrosyl-, cyclic (9-1)-peptide
DM1XYJU PC 16131113
DM1XYJU MW 2043.2
DM1XYJU FM C103H115N23O23
DM1XYJU IC InChI=1S/C103H115N23O23/c1-54-102(147)126-35-15-26-83(126)100(145)123-81(46-85(131)110-51-87(133)114-72(90(105)135)45-86(132)115-77(40-60-47-107-69-23-12-9-20-66(60)69)96(141)121-79(43-63-50-106-53-112-63)91(136)111-52-88(134)125-89(55(2)127)101(146)113-54)99(144)120-78(41-61-48-108-70-24-13-10-21-67(61)70)97(142)118-73(36-56-16-5-3-6-17-56)92(137)116-74(37-57-18-7-4-8-19-57)94(139)122-80(44-84(104)130)98(143)119-75(38-58-27-31-64(128)32-28-58)93(138)117-76(39-59-29-33-65(129)34-30-59)95(140)124-82(103(148)149)42-62-49-109-71-25-14-11-22-68(62)71/h3-14,16-25,27-34,47-50,53-55,72-83,89,107-109,127-129H,15,26,35-46,51-52H2,1-2H3,(H2,104,130)(H2,105,135)(H,106,112)(H,110,131)(H,111,136)(H,113,146)(H,114,133)(H,115,132)(H,116,137)(H,117,138)(H,118,142)(H,119,143)(H,120,144)(H,121,141)(H,122,139)(H,123,145)(H,124,140)(H,125,134)(H,148,149)/t54-,55+,72?,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DM1XYJU CS C[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(=O)NCC(=O)NC(CC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1)[C@@H](C)O)CC3=CN=CN3)CC4=CNC5=CC=CC=C54)C(=O)N)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N[C@@H](CC9=CC=CC=C9)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O
DM1XYJU IK GKJHBAGJUMHZCI-WOMVBXCFSA-N
DM1XYJU IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S,6S,12S,15S,26S,29S)-19-carbamoyl-6-[(1R)-1-hydroxyethyl]-12-(1H-imidazol-5-ylmethyl)-15-(1H-indol-3-ylmethyl)-3-methyl-2,5,8,11,14,17,21,24,28-nonaoxo-1,4,7,10,13,16,20,23,27-nonazabicyclo[27.3.0]dotriacontane-26-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DM1XYJU CA CAS 151308-34-8
DMI94L1 ID DMI94L1
DMI94L1 DN REV-5901
DMI94L1 HS Terminated
DMI94L1 SN Rev 5901; REV-5901; 101910-24-1; RG 5901; PF 5901; alpha-Pentyl-3-(2-quinolinylmethoxy)benzenemethanol; 1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-ol; CHEMBL8747; MLS000069771; REV-901; PF-5901; SMR000058509; alpha-Pentyl-3-[2-quinolinylmethoxy]benzyl alcohol; Benzenemethanol, alpha-pentyl-3-(2-quinolinylmethoxy)-; 1-(3-(quinolin-2-ylmethoxy)phenyl)hexan-1-ol; SR-01000076105; ACMC-20d0wb; Opera_ID_512; WNW5RYD8MG; UNII-WNW5RYD8MG; AC1L1JIU; Lopac0_001042; CBiol_001910; KBioGR_000242; BSPBio_001522; KBioSS_000242; MLS001076522
DMI94L1 DT Small molecular drug
DMI94L1 PC 5059
DMI94L1 MW 335.4
DMI94L1 FM C22H25NO2
DMI94L1 IC InChI=1S/C22H25NO2/c1-2-3-4-12-22(24)18-9-7-10-20(15-18)25-16-19-14-13-17-8-5-6-11-21(17)23-19/h5-11,13-15,22,24H,2-4,12,16H2,1H3
DMI94L1 CS CCCCCC(C1=CC(=CC=C1)OCC2=NC3=CC=CC=C3C=C2)O
DMI94L1 IK JRLOEMCOOZSCQP-UHFFFAOYSA-N
DMI94L1 IU 1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-ol
DMI94L1 CA CAS 101910-24-1
DMI94L1 CB CHEBI:91821
DM314CZ ID DM314CZ
DM314CZ DN REV-598
DM314CZ HS Terminated
DM314CZ SN EV-598
DM314CZ CP Evolutec Group plc
DM314CZ DE Carcinoid syndrome
DMA971L ID DMA971L
DMA971L DN Reveromycin A
DMA971L HS Terminated
DMA971L DT Small molecular drug
DMA971L PC 9939559
DMA971L MW 660.8
DMA971L FM C36H52O11
DMA971L IC InChI=1S/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1
DMA971L CS CCCC[C@]1(CC[C@]2(CC[C@@H]([C@H](O2)C/C=C(\\C)/C=C/[C@@H]([C@@H](C)/C=C/C(=O)O)O)C)O[C@H]1/C=C/C(=C/C(=O)O)/C)OC(=O)CCC(=O)O
DMA971L IK ZESGNAJSBDILTB-OXVOKJAASA-N
DMA971L IU (2E,4S,5S,6E,8E)-10-[(2S,3R,6S,8R,9S)-3-butyl-2-[(1E,3E)-4-carboxy-3-methylbuta-1,3-dienyl]-3-(3-carboxypropanoyloxy)-9-methyl-1,7-dioxaspiro[5.5]undecan-8-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
DMRFYOS ID DMRFYOS
DMRFYOS DN RG-13022
DMRFYOS HS Terminated
DMRFYOS SN RG-13022; RG 13022; CHEMBL67027; NSC666257; (Z)-3-(3,4-Dimethoxy-phenyl)-2-pyridin-3-yl-acrylonitrile; 136831-48-6; DBGZNJVTHYFQJI-RIYZIHGNSA-N; 149286-90-8; Tyrphostin RG13022; AC1NV4OE; SCHEMBL241869; SCHEMBL1959494; CHEBI:93448; MolPort-009-019-306; BDBM50039091; ZINC37858694; HSCI1_000158; AKOS032947325; NSC-666257; NCGC00018297-02; NCGC00018297-01; J-006919; BRD-K82688027-001-01-5; 3-(3,4-Dimethoxyphenyl)-2-(3-pyridinyl)acrylonitrile; (Z)-3-(3,4-dimethoxyphenyl)-2-pyridin-3-ylprop-2-enenitrile
DMRFYOS DT Small molecular drug
DMRFYOS PC 5468216
DMRFYOS MW 266.29
DMRFYOS FM C16H14N2O2
DMRFYOS IC InChI=1S/C16H14N2O2/c1-19-15-6-5-12(9-16(15)20-2)8-14(10-17)13-4-3-7-18-11-13/h3-9,11H,1-2H3/b14-8+
DMRFYOS CS COC1=C(C=C(C=C1)/C=C(\\C#N)/C2=CN=CC=C2)OC
DMRFYOS IK DBGZNJVTHYFQJI-RIYZIHGNSA-N
DMRFYOS IU (Z)-3-(3,4-dimethoxyphenyl)-2-pyridin-3-ylprop-2-enenitrile
DMRFYOS CA CAS 136831-48-6
DMRFYOS CB CHEBI:93448
DMKFQC7 ID DMKFQC7
DMKFQC7 DN RG-14893
DMKFQC7 HS Terminated
DMKFQC7 SN RG-14893; RG 14893; 141835-49-6; CHEMBL328712; 2-Naphthalenecarboxylicacid, 4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-; ACMC-20n0x5; AC1L30VP; SCHEMBL1894401; rg14893; CTK0H7370; DTXSID30161835; BDBM50001609; 4-(2-(Methyl(2-phenylethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; 4-(2-(Methyl(2-phenethyl)amino)-2-oxoethyl)-8-(phenylmethoxy)-2-naphthalenecarboxylic acid; L006851; 8-Benzyloxy-4-[(methyl-phenethyl-carbamoyl)-methyl]-naphthalene-2-carboxylic acid
DMKFQC7 CP Rhone-Poulenc SA
DMKFQC7 DT Small molecular drug
DMKFQC7 PC 132379
DMKFQC7 MW 453.5
DMKFQC7 FM C29H27NO4
DMKFQC7 IC InChI=1S/C29H27NO4/c1-30(16-15-21-9-4-2-5-10-21)28(31)19-23-17-24(29(32)33)18-26-25(23)13-8-14-27(26)34-20-22-11-6-3-7-12-22/h2-14,17-18H,15-16,19-20H2,1H3,(H,32,33)
DMKFQC7 CS CN(CCC1=CC=CC=C1)C(=O)CC2=C3C=CC=C(C3=CC(=C2)C(=O)O)OCC4=CC=CC=C4
DMKFQC7 IK VPJQGXIZXVPFOC-UHFFFAOYSA-N
DMKFQC7 IU 4-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-8-phenylmethoxynaphthalene-2-carboxylic acid
DMKFQC7 CA CAS 141835-49-6
DMKFQC7 DE Asthma
DMI0CYV ID DMI0CYV
DMI0CYV DN RG-8803
DMI0CYV HS Terminated
DMI0CYV SN Angiogenesis inhibitors, Repligen; BFGF inhibitors, Repligen; RG-8803B11; RGEN-1009; VEGF inhibitors, Repligen; 8803B11
DMI0CYV CP Repligen Corp
DMI0CYV DE Diabetic retinopathy
DM8RIA6 ID DM8RIA6
DM8RIA6 DN RGH-1756
DM8RIA6 HS Terminated
DM8RIA6 SN NCGC00015909-01; Lopac-S-106; AC1L1JZN; Prestwick3_000443; Lopac0_001152; BSPBio_000486; BPBio1_000536; CHEBI:93632; CTK7A2978; BDBM50000687; ZINC100071375; CCG-205226; NCGC00015909-03; NCGC00162355-01; NCGC00016970-01; NCGC00015909-02; NCGC00015909-04; AB00513839; CAS-105538-73-6; BRD-K93280214-004-02-3; 6-amino-1-(3-carboxypropyl)-3-(4-methoxyphenyl)pyridazin-1-ium; 4-[6-amino-3-(4-methoxyphenyl)pyridazin-1-ium-1-yl]butanoic acid; 6-Amino-1-(3-carboxy-propyl)-3-(4-methoxy-phenyl)-pyridazin-1-ium
DM8RIA6 CP Gedeon Richter
DM8RIA6 DT Small molecular drug
DM8RIA6 PC 9868983
DM8RIA6 MW 462.6
DM8RIA6 FM C26H30N4O2S
DM8RIA6 IC InChI=1S/C26H30N4O2S/c1-31-25-7-3-2-6-24(25)29-15-13-28(14-16-29)12-4-5-18-32-22-10-8-21(9-11-22)23-20-30-17-19-33-26(30)27-23/h2-3,6-11,17,19-20H,4-5,12-16,18H2,1H3
DM8RIA6 CS COC1=CC=CC=C1N2CCN(CC2)CCCCOC3=CC=C(C=C3)C4=CN5C=CSC5=N4
DM8RIA6 IK XFCPMLXQURUUPM-UHFFFAOYSA-N
DM8RIA6 IU 6-[4-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]phenyl]imidazo[2,1-b][1,3]thiazole
DM8RIA6 CA CAS 207277-37-0
DM8RIA6 DE Schizophrenia
DMBCIPO ID DMBCIPO
DMBCIPO DN RGH-2721
DMBCIPO HS Terminated
DMBCIPO SN IDDB9322
DMBCIPO CP Gedeon Richter Ltd
DMBCIPO DE Psychotic disorder
DM7CY0T ID DM7CY0T
DM7CY0T DN RHb1.1
DM7CY0T HS Terminated
DM7CY0T SN Optro; Hemoglobin, Somatogen
DM7CY0T CP Somatogen Inc
DM7CY0T DE Anemia
DMW4UTB ID DMW4UTB
DMW4UTB DN RhuCD40L
DMW4UTB HS Terminated
DMKDS1C ID DMKDS1C
DMKDS1C DN Rimcazole
DMKDS1C HS Terminated
DMKDS1C SN Rimcazol; Rimcazolum; Rimcazole [INN]; BW 234U; BW-234U; Rimcazol [INN-Spanish]; Rimcazolum [INN-Latin]; Cis-9-(3-(3,5-dimethyl-1-piperazinyl)propyl)carbazole; 9-[3-(Cis-3,5-Dimethyl-1-Piperazinyl)Propyl]Carbazole Hydrochloride; 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride monohydrate; 9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole; 9-[3-[(3S,5R)-3,5-dimethylpiperazin-1-yl]propyl]carbazole
DMKDS1C CP GlaxoSmithKline
DMKDS1C DT Small molecular drug
DMKDS1C PC 53389
DMKDS1C MW 321.5
DMKDS1C FM C21H27N3
DMKDS1C IC InChI=1S/C21H27N3/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3/t16-,17+
DMKDS1C CS C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42
DMKDS1C IK GUDVQJXODNJRIJ-CALCHBBNSA-N
DMKDS1C IU 9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole
DMKDS1C CA CAS 75859-04-0
DMKDS1C CB CHEBI:94713
DMKDS1C DE Schizophrenia
DMHQ5ZE ID DMHQ5ZE
DMHQ5ZE DN RN-1005
DMHQ5ZE HS Terminated
DMHQ5ZE CP Renovo Group plc
DMHQ5ZE DE Sarcoidosis
DM0PSCF ID DM0PSCF
DM0PSCF DN Ro 20-1724
DM0PSCF HS Terminated
DM0PSCF SN 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; RO 20-1724; 29925-17-5; 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one; ro-20-1724; Ro 201724; CHEMBL18701; 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-; RO-201724; 2-Imidazolidinone, 4-((3-butoxy-4-methoxyphenyl)methyl)-, (+-)-; 4-(3-butoxy-4-methoxy-benzyl)imidazolidin-2-one; 34185-37-0; 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; SR-01000075647; keratan sulfate I; Keratan sulphate I; Naphthoquinone analogs
DM0PSCF DT Small molecular drug
DM0PSCF PC 5087
DM0PSCF MW 278.35
DM0PSCF FM C15H22N2O3
DM0PSCF IC InChI=1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)
DM0PSCF CS CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC
DM0PSCF IK PDMUULPVBYQBBK-UHFFFAOYSA-N
DM0PSCF IU 4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one
DM0PSCF CA CAS 29925-17-5
DM0PSCF CB CHEBI:111173
DM0PSCF DE Asthma
DMFRCM2 ID DMFRCM2
DMFRCM2 DN Ro-19-8022
DMFRCM2 HS Terminated
DMFRCM2 SN Ro 19-8022; 104604-66-2; 1-((10-Chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidine methanol; (R)-1-((10-Chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidinemethanol; 2-Pyrrolidinemethanol, 1-((10-chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-, (R)-; Ro-19-8022; (R)-1-[(10-chloro-4-oxo-3-phenyl-4H-benzo[a]quinolizin-1-yl)carbonyl]-2-pyrrolidinemethanol; AC1MHYOM; SCHEMBL9334361; CTK4A3158; DTXSID20146611; MAHSERINKSLHDX-LJQANCHMSA-N; ro19-8022
DMFRCM2 CP Roche Holding AG
DMFRCM2 DT Small molecular drug
DMFRCM2 PC 3035058
DMFRCM2 MW 432.9
DMFRCM2 FM C25H21ClN2O3
DMFRCM2 IC InChI=1S/C25H21ClN2O3/c26-18-9-8-17-10-12-28-23(20(17)13-18)22(25(31)27-11-4-7-19(27)15-29)14-21(24(28)30)16-5-2-1-3-6-16/h1-3,5-6,8-10,12-14,19,29H,4,7,11,15H2/t19-/m1/s1
DMFRCM2 CS C1C[C@@H](N(C1)C(=O)C2=C3C4=C(C=CC(=C4)Cl)C=CN3C(=O)C(=C2)C5=CC=CC=C5)CO
DMFRCM2 IK MAHSERINKSLHDX-LJQANCHMSA-N
DMFRCM2 IU 10-chloro-1-[(2R)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-3-phenylbenzo[a]quinolizin-4-one
DMFRCM2 CA CAS 104604-66-2
DMFRCM2 DE Anxiety disorder
DM7B2WH ID DM7B2WH
DM7B2WH DN Ro-23-7777
DM7B2WH HS Terminated
DM7B2WH SN IDDB4246
DM7B2WH CP Roche Holding AG
DM7B2WH DE Fungal infection
DMJQA0D ID DMJQA0D
DMJQA0D DN Ro-24-0238
DMJQA0D HS Terminated
DMJQA0D SN Ro-24-0238; UNII-7G3UI0W9Y5; CHEMBL277245; 7G3UI0W9Y5; 120555-31-9; Ro 24-0238; AC1O5QW5; SCHEMBL9120960; SCHEMBL9120974; 5-(4-Methoxy-phenyl)-deca-2,4-dienoic acid (1-methyl-4-pyridin-3-yl-butyl)-amide; BDBM50011671; 5-(4-Methoxyphenyl)-N-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide; CS-6684; (R-(E,E))-5-(4-Methoxyphenyl)-N-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide; HY-19084; 2,4-Decadienamide, 5-(4-methoxyphenyl)-N-(1-methyl-4-(3-pyridinyl)butyl)-, (R-(E,E))-
DMJQA0D DT Small molecular drug
DMJQA0D PC 6439060
DMJQA0D MW 420.6
DMJQA0D FM C27H36N2O2
DMJQA0D IC InChI=1S/C27H36N2O2/c1-4-5-6-13-24(25-16-18-26(31-3)19-17-25)14-8-15-27(30)29-22(2)10-7-11-23-12-9-20-28-21-23/h8-9,12,14-22H,4-7,10-11,13H2,1-3H3,(H,29,30)/b15-8+,24-14+/t22-/m1/s1
DMJQA0D CS CCCCC/C(=C\\C=C\\C(=O)N[C@H](C)CCCC1=CN=CC=C1)/C2=CC=C(C=C2)OC
DMJQA0D IK HLCHRSFXEXAMLU-YDQNRGGDSA-N
DMJQA0D IU (2E,4E)-5-(4-methoxyphenyl)-N-[(2R)-5-pyridin-3-ylpentan-2-yl]deca-2,4-dienamide
DMJQA0D CA CAS 120555-31-9
DMJQA0D DE Sepsis
DMVB0C3 ID DMVB0C3
DMVB0C3 DN Ro-25-4094
DMVB0C3 HS Terminated
DMVB0C3 SN Ro-25-4094; CHEMBL86900; 2-[(5-Carboxypentyl)oxy]-6-[6-[(3,4-dihydro-4-oxo-8-propyl-2H-1-benzopyran-7-yl)oxy]hexyl]benzenepropanoic Acid; 2-[(5-Carboxypentyl)oxy]-6-[6-[[3,4-dihydro-4-oxo-8-propyl-2H-1-benzopyran-7-yl)oxy]hexyl]benzenepropanoic Acid; SCHEMBL9121929; KLENIMLYAFNVOB-UHFFFAOYSA-N; BDBM50052025; Ro-0254094; L011960; 6-{2-(2-Carboxy-ethyl)-3-[6-(4-oxo-8-propyl-chroman-7-yloxy)-hexyl]-phenoxy}-hexanoic acid
DMVB0C3 CP Roche Holding AG
DMVB0C3 DT Small molecular drug
DMVB0C3 PC 9850974
DMVB0C3 MW 568.7
DMVB0C3 FM C33H44O8
DMVB0C3 IC InChI=1S/C33H44O8/c1-2-11-27-30(18-16-26-28(34)20-23-41-33(26)27)40-21-8-4-3-6-12-24-13-10-14-29(25(24)17-19-32(37)38)39-22-9-5-7-15-31(35)36/h10,13-14,16,18H,2-9,11-12,15,17,19-23H2,1H3,(H,35,36)(H,37,38)
DMVB0C3 CS CCCC1=C(C=CC2=C1OCCC2=O)OCCCCCCC3=C(C(=CC=C3)OCCCCCC(=O)O)CCC(=O)O
DMVB0C3 IK KLENIMLYAFNVOB-UHFFFAOYSA-N
DMVB0C3 IU 6-[2-(2-carboxyethyl)-3-[6-[(4-oxo-8-propyl-2,3-dihydrochromen-7-yl)oxy]hexyl]phenoxy]hexanoic acid
DMVB0C3 DE Inflammation
DM07ZSC ID DM07ZSC
DM07ZSC DN Ro-25-6833
DM07ZSC HS Terminated
DM07ZSC SN Ro-25-6833; 161672-76-0; Ro25-6833; RO 25-6833; CHEMBL53624; SCHEMBL7614481; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyimino)acetyl)amino)-8-oxo-((2-oxo-1-(2,2,2-trifluoroethyl)-3-pyrrolidinylidene)methyl)-, (6R-(3(E),6a,7b(Z)))-; 3-[[(3E)-1-(2,2,2-Trifluoroethyl)-2-oxopyrrolidin-3-ylidene]methyl]-7beta-[[[(Z)-hydroxyimino](2-aminothiazol-4-yl)acetyl]amino]cepham-3-ene-4-carboxylic acid
DM07ZSC CP F Hoffmann-La Roche Ltd
DM07ZSC DT Small molecular drug
DM07ZSC PC 9578062
DM07ZSC MW 546.5
DM07ZSC FM C19H17F3N6O6S2
DM07ZSC IC InChI=1S/C19H17F3N6O6S2/c20-19(21,22)6-27-2-1-7(14(27)30)3-8-4-35-16-11(15(31)28(16)12(8)17(32)33)25-13(29)10(26-34)9-5-36-18(23)24-9/h3,5,11,16,34H,1-2,4,6H2,(H2,23,24)(H,25,29)(H,32,33)/b7-3+,26-10-/t11-,16-/m1/s1
DM07ZSC CS C\\1CN(C(=O)/C1=C/C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\\O)/C4=CSC(=N4)N)SC2)C(=O)O)CC(F)(F)F
DM07ZSC IK NOAJGZYUGGBORE-SUVYSZLLSA-N
DM07ZSC IU (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-(2,2,2-trifluoroethyl)pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DM07ZSC CA CAS 161672-76-0
DM07ZSC DE Bacterial infection
DM3H921 ID DM3H921
DM3H921 DN RO-25-6981
DM3H921 HS Terminated
DM3H921 SN Ro 25-6981; Ro-25-6981; CHEMBL305195; ro25-6981; 169274-78-6; 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol; 4-((1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl)phenol; QEM; Tocris-1594; AC1O7H0A; Lopac0_001082; ZINC7042; SCHEMBL6159263; CHEBI:92897; HMS3268G13; EX-A1825; PDSP2_000361; BDBM50080029; CS-2011; CCG-205159; NCGC00025226-01; NCGC00025226-03; NCGC00025226-02; HY-13993; (AR,BS)-ALPHA-(4-HYDROXYPHENYL)-BETA-METHYL-4-(PHENYLMETHYL)-1-PIPERIDINEPROPANOL MALEATE; BRD-K51541829-001-01-3
DM3H921 TC Analgesics
DM3H921 DT Small molecular drug
DM3H921 PC 6604887
DM3H921 MW 339.5
DM3H921 FM C22H29NO2
DM3H921 IC InChI=1S/C22H29NO2/c1-17(22(25)20-7-9-21(24)10-8-20)16-23-13-11-19(12-14-23)15-18-5-3-2-4-6-18/h2-10,17,19,22,24-25H,11-16H2,1H3/t17-,22+/m0/s1
DM3H921 CS C[C@@H](CN1CCC(CC1)CC2=CC=CC=C2)[C@H](C3=CC=C(C=C3)O)O
DM3H921 IK WVZSEUPGUDIELE-HTAPYJJXSA-N
DM3H921 IU 4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol
DM3H921 CA CAS 169274-78-6
DM3H921 CB CHEBI:92897
DM3H921 DE Cancer related pain
DM8B9YT ID DM8B9YT
DM8B9YT DN Ro-31-4724
DM8B9YT HS Terminated
DM8B9YT SN Ro-31-4724; CHEMBL92608; [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER; RO4; 112105-54-1; Ro 314724; ro 31-4724; AC1NUPD6; ZINC3801503; ro-314724; BDBM50146631; DB08482; RO314724; (R)-N-(N-(2-(2-(Hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)-L-leucyl)-L-alanine ethyl ester; ethyl N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-L-leucyl-L-alaninate; ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate
DM8B9YT DT Small molecular drug
DM8B9YT PC 5487313
DM8B9YT MW 401.5
DM8B9YT FM C19H35N3O6
DM8B9YT IC InChI=1S/C19H35N3O6/c1-7-28-19(26)13(6)20-18(25)15(9-12(4)5)21-17(24)14(8-11(2)3)10-16(23)22-27/h11-15,27H,7-10H2,1-6H3,(H,20,25)(H,21,24)(H,22,23)/t13-,14+,15-/m0/s1
DM8B9YT CS CCOC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)CC(=O)NO
DM8B9YT IK XKRONJXEXGFBRZ-ZNMIVQPWSA-N
DM8B9YT IU ethyl (2S)-2-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoate
DM8B9YT CA CAS 112105-54-1
DM8B9YT DE Arthritis
DMTIW6K ID DMTIW6K
DMTIW6K DN Ro-31-8830
DMTIW6K HS Terminated
DMTIW6K SN Ro-31-8830; 131848-98-1; 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-{8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}-4-(1-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione; Bisindolylmaleimide deriv. 18b; ACMC-20caiw; Ro 31-8830; AC1L1JKR; AC1Q6PDZ; CHEMBL95925; SCHEMBL5036866; BDBM2705; CTK0H9238; HMS3401J16; HMS3401G14; HSCI1_000347; BIM 11; Bisindolylmaleimide XI, HCl; NCGC00163696-04; NCGC00163696-01; K00206
DMTIW6K CP Roche Holding AG
DMTIW6K DT Small molecular drug
DMTIW6K PC 5084
DMTIW6K MW 452.5
DMTIW6K FM C28H28N4O2
DMTIW6K IC InChI=1S/C28H28N4O2/c1-30(2)15-17-12-13-32-22-11-7-5-9-19(22)24(23(32)14-17)26-25(27(33)29-28(26)34)20-16-31(3)21-10-6-4-8-18(20)21/h4-11,16-17H,12-15H2,1-3H3,(H,29,33,34)
DMTIW6K CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C5CC(CCN5C6=CC=CC=C64)CN(C)C
DMTIW6K IK FXGHOAZJQNLNFD-UHFFFAOYSA-N
DMTIW6K IU 3-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione
DMTIW6K CA CAS 131848-98-1
DMTIW6K DE Inflammation
DML3NEU ID DML3NEU
DML3NEU DN RO-319790
DML3NEU HS Terminated
DML3NEU SN Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703
DML3NEU DT Small molecular drug
DML3NEU PC 9904965
DML3NEU MW 315.41
DML3NEU FM C15H29N3O4
DML3NEU IC InChI=1S/C15H29N3O4/c1-9(2)7-10(8-11(19)18-22)13(20)17-12(14(21)16-6)15(3,4)5/h9-10,12,22H,7-8H2,1-6H3,(H,16,21)(H,17,20)(H,18,19)/t10-,12-/m1/s1
DML3NEU CS CC(C)C[C@H](CC(=O)NO)C(=O)N[C@H](C(=O)NC)C(C)(C)C
DML3NEU IK QRXOZHSEEGNRFC-ZYHUDNBSSA-N
DML3NEU IU (2R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N'-hydroxy-2-(2-methylpropyl)butanediamide
DML3NEU DE Rheumatoid arthritis
DMFZ1YW ID DMFZ1YW
DMFZ1YW DN RO-320432
DMFZ1YW HS Terminated
DMFZ1YW SN ro 32-0432; Ro-32-0432; CHEMBL26501; (S)-3-(8-(Dimethylaminomethyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione hydrochloride; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrol-2,5-dione; (S)-3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 151342-35-7; 1H-Pyrrole-2,5-dione, 3-(8-((dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)in
DMFZ1YW DT Small molecular drug
DMFZ1YW PC 127757
DMFZ1YW MW 452.5
DMFZ1YW FM C28H28N4O2
DMFZ1YW IC InChI=1S/C28H28N4O2/c1-30(2)15-17-12-13-32-22-11-7-5-9-19(22)24(23(32)14-17)26-25(27(33)29-28(26)34)20-16-31(3)21-10-6-4-8-18(20)21/h4-11,16-17H,12-15H2,1-3H3,(H,29,33,34)/t17-/m0/s1
DMFZ1YW CS CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C5C[C@H](CCN5C6=CC=CC=C64)CN(C)C
DMFZ1YW IK FXGHOAZJQNLNFD-KRWDZBQOSA-N
DMFZ1YW IU 3-[(8S)-8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione
DMFZ1YW CA CAS 151342-35-7
DMPNHF0 ID DMPNHF0
DMPNHF0 DN Ro-43-5054
DMPNHF0 HS Terminated
DMPNHF0 SN Ro-43-5054; CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)
DMPNHF0 DT Small molecular drug
DMPNHF0 PC 44343754
DMPNHF0 MW 449.5
DMPNHF0 FM C20H27N5O7
DMPNHF0 IC InChI=1S/C20H27N5O7/c1-10(2)16(20(31)32)25-19(30)13(9-15(27)28)24-14(26)7-8-23-18(29)12-5-3-11(4-6-12)17(21)22/h3-6,10,13,16H,7-9H2,1-2H3,(H3,21,22)(H,23,29)(H,24,26)(H,25,30)(H,27,28)(H,31,32)/t13-,16-/m0/s1
DMPNHF0 CS CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCNC(=O)C1=CC=C(C=C1)C(=N)N
DMPNHF0 IK RRUJJOMANFUDEN-BBRMVZONSA-N
DMPNHF0 IU (2S)-2-[[(2S)-2-[3-[(4-carbamimidoylbenzoyl)amino]propanoylamino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
DM4VY8S ID DM4VY8S
DM4VY8S DN Ro-43-8857
DM4VY8S HS Terminated
DM4VY8S SN Ro-43-8857; CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid
DM4VY8S DT Small molecular drug
DM4VY8S PC 9933077
DM4VY8S MW 443.4
DM4VY8S FM C21H21N3O8
DM4VY8S IC InChI=1S/C21H21N3O8/c1-24(21(30)13-4-2-12(3-5-13)20(22)23)9-15(25)14-6-7-16(31-10-18(26)27)17(8-14)32-11-19(28)29/h2-8H,9-11H2,1H3,(H3,22,23)(H,26,27)(H,28,29)
DM4VY8S CS CN(CC(=O)C1=CC(=C(C=C1)OCC(=O)O)OCC(=O)O)C(=O)C2=CC=C(C=C2)C(=N)N
DM4VY8S IK ZCCMELPMDDSRHL-UHFFFAOYSA-N
DM4VY8S IU 2-[4-[2-[(4-carbamimidoylbenzoyl)-methylamino]acetyl]-2-(carboxymethoxy)phenoxy]acetic acid
DMRT6FV ID DMRT6FV
DMRT6FV DN Ro-46-2005
DMRT6FV HS Terminated
DMRT6FV SN 150725-87-4; Ro 46-2005; Ro-46-2005; RO462005; CHEMBL115951; ro46-2005; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide; Benzenesulfonamide,4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)-4-pyrimidinyl]-; 4-tert-butyl-N-{6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl}benzenesulfonamide; ZNXOKLWCOWOECF-UHFFFAOYSA-N; AC1L3TVG; ACMC-20n61p; SCHEMBL2678965; KS-00001DFD; CTK4C6747; DTXSID80164598; ZINC1535471; BCP17756; BDBM50105015; AKOS030526571; Ro 462005
DMRT6FV CP Roche Holding AG
DMRT6FV DT Small molecular drug
DMRT6FV PC 122044
DMRT6FV MW 473.5
DMRT6FV FM C23H27N3O6S
DMRT6FV IC InChI=1S/C23H27N3O6S/c1-23(2,3)16-8-10-19(11-9-16)33(28,29)26-21-20(22(25-15-24-21)31-13-12-27)32-18-7-5-6-17(14-18)30-4/h5-11,14-15,27H,12-13H2,1-4H3,(H,24,25,26)
DMRT6FV CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC=N2)OCCO)OC3=CC=CC(=C3)OC
DMRT6FV IK ZNXOKLWCOWOECF-UHFFFAOYSA-N
DMRT6FV IU 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxyphenoxy)pyrimidin-4-yl]benzenesulfonamide
DMRT6FV CA CAS 150725-87-4
DMRT6FV DE Hypertension
DMU9JAH ID DMU9JAH
DMU9JAH DN Ro-46-5934
DMU9JAH HS Terminated
DMU9JAH CP F Hoffmann-La Roche Ltd
DMU9JAH DE Alzheimer disease
DMXMP3D ID DMXMP3D
DMXMP3D DN Ro-48-1220
DMXMP3D HS Terminated
DMXMP3D CP Roche Holding AG
DMXMP3D DT Small molecular drug
DMXMP3D PC 10612083
DMXMP3D MW 270.26
DMXMP3D FM C10H10N2O5S
DMXMP3D IC InChI=1S/C10H10N2O5S/c1-10(3-2-4-11)8(9(14)15)12-6(13)5-7(12)18(10,16)17/h2-3,7-8H,5H2,1H3,(H,14,15)/b3-2+/t7-,8+,10+/m1/s1
DMXMP3D CS C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)/C=C/C#N
DMXMP3D IK JYGFUXUBGZBBAC-RCRIAUEHSA-N
DMXMP3D IU (2S,3S,5R)-3-[(E)-2-cyanoethenyl]-3-methyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DMXMP3D CA CAS 768335-49-5
DMXMP3D DE Bacterial infection
DM7AUF2 ID DM7AUF2
DM7AUF2 DN Ro-48-5545
DM7AUF2 HS Terminated
DM7AUF2 SN Bridged beta lactamase inhibitors, Roche; Ro-47-5325; Ro-48-1256; Ro-48-7953
DM7AUF2 CP F Hoffmann-La Roche Ltd
DM7AUF2 DE Bacterial infection
DM0RZEO ID DM0RZEO
DM0RZEO DN Ro-48-8724
DM0RZEO HS Terminated
DM0RZEO CP F Hoffmann-La Roche Ltd
DM0RZEO DE Multidrug resistant infection
DMZSQU8 ID DMZSQU8
DMZSQU8 DN Ro-60-0175
DMZSQU8 HS Terminated
DMZSQU8 SN Ro-600175
DMZSQU8 DT Small molecular drug
DMZSQU8 PC 3045227
DMZSQU8 MW 226.68
DMZSQU8 FM C11H12ClFN2
DMZSQU8 IC InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1
DMZSQU8 CS C[C@@H](CN1C=CC2=CC(=C(C=C21)Cl)F)N
DMZSQU8 IK XJJZQXUGLLXTHO-ZETCQYMHSA-N
DMZSQU8 IU (2S)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine
DMZSQU8 CB CHEBI:142183
DM6JO30 ID DM6JO30
DM6JO30 DN Rogletimide
DM6JO30 HS Terminated
DM6JO30 SN ROGLETIMIDE; Pyridoglutethimide; 92788-10-8; 3-PYG; (+-)-Pyridoglutethimide; Racemic-pyridoglutethimide; 2-Ethyl-2-(4-pyridyl)glutarimide; 121840-95-7; 3-Ethyl-3-(4-pyridyl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-ethyl-3-(4-pyridinyl)-; CHEMBL289116; 3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione; 3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione; (+/-) 3-Ethyl-3-(4-pyridinyl)-2,6-piperidinedione; 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione; Rogletimida; Rogletimidum; Rogletimidum [INN-Latin]; Rogletimida [INN-Spanish]
DM6JO30 DT Small molecular drug
DM6JO30 PC 56487
DM6JO30 MW 218.25
DM6JO30 FM C12H14N2O2
DM6JO30 IC InChI=1S/C12H14N2O2/c1-2-12(9-4-7-13-8-5-9)6-3-10(15)14-11(12)16/h4-5,7-8H,2-3,6H2,1H3,(H,14,15,16)
DM6JO30 CS CCC1(CCC(=O)NC1=O)C2=CC=NC=C2
DM6JO30 IK QXKJWHWUDVQATH-UHFFFAOYSA-N
DM6JO30 IU 3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione
DM6JO30 CA CAS 92788-10-8
DM6JO30 DE Breast cancer
DM4VCJI ID DM4VCJI
DM4VCJI DN Rovelizumab
DM4VCJI HS Terminated
DM4VCJI SN LeukArrest; Hu23F2G; Monoclonal antibody (MS), ICOS; 23F2G, ICOS
DM4VCJI CP ICOS Corp
DM4VCJI DT Antibody
DM4VCJI DE Cerebrovascular disease
DMQZ2JA ID DMQZ2JA
DMQZ2JA DN RP-58802B
DMQZ2JA HS Terminated
DMQZ2JA SN Imoxiterol; 88578-07-8; Imoxiterolum; Imoxiterol [INN]; Imoxiterolum [Latin]; AC1L23PZ; SCHEMBL249468; CHEMBL2104918; RP 58802B; CS-6651; 2-(3-(1-Benzimidazolyl)-1-methylpropylamino)-1-(4-hydroxy-3-methoxyphenyl)ethanol; RP-58802; HY-101585; L007875; alpha-(((3-(1-Benzimidazolyl)-1-methylpropyl)amino)methyl)vanillyl alcohol
DMQZ2JA CP Rhone-Poulenc SA
DMQZ2JA DT Small molecular drug
DMQZ2JA PC 65665
DMQZ2JA MW 355.4
DMQZ2JA FM C20H25N3O3
DMQZ2JA IC InChI=1S/C20H25N3O3/c1-14(9-10-23-13-22-16-5-3-4-6-17(16)23)21-12-19(25)15-7-8-18(24)20(11-15)26-2/h3-8,11,13-14,19,21,24-25H,9-10,12H2,1-2H3
DMQZ2JA CS CC(CCN1C=NC2=CC=CC=C21)NCC(C3=CC(=C(C=C3)O)OC)O
DMQZ2JA IK NKKPVWPMPWLEMY-UHFFFAOYSA-N
DMQZ2JA IU 4-[2-[4-(benzimidazol-1-yl)butan-2-ylamino]-1-hydroxyethyl]-2-methoxyphenol
DMQZ2JA CA CAS 88578-07-8
DMQZ2JA DE Asthma
DM09QLY ID DM09QLY
DM09QLY DN RP-66055
DM09QLY HS Terminated
DM09QLY SN CHEMBL405225
DM09QLY CP Rhone-Poulenc SA
DM09QLY DT Small molecular drug
DM09QLY PC 44277787
DM09QLY MW 355.5
DM09QLY FM C20H22FN3S
DM09QLY IC InChI=1S/C20H22FN3S/c21-17-7-5-15(6-8-17)16-9-11-23(12-10-16)13-14-24-18-3-1-2-4-19(18)25-20(24)22/h1-8,16,22H,9-14H2
DM09QLY CS C1CN(CCC1C2=CC=C(C=C2)F)CCN3C4=CC=CC=C4SC3=N
DM09QLY IK YIJMYOZUUPAERG-UHFFFAOYSA-N
DM09QLY IU 3-[2-[4-(4-fluorophenyl)piperidin-1-yl]ethyl]-1,3-benzothiazol-2-imine
DM09QLY DE Cerebral infarction
DMX4E75 ID DMX4E75
DMX4E75 DN RP-66153
DMX4E75 HS Terminated
DMX4E75 SN RP-66153; RP 66153; CHEMBL108415; 142422-79-5; AC1L30YM; SCHEMBL4355829; DTXSID80162034; 2,2-Dimethyl-7-(3-(3-phenylpropyl)-2-thienyl)heptanoic acid; BDBM50001162; 2-Thiopheneheptanoic acid, alpha,alpha-dimethyl-3-(3-phenylpropyl); 2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid; 2,2-Dimethyl-7-[3-(3-phenyl-propyl)-thiophen-2-yl]-heptanoic acid
DMX4E75 CP Rhone-Poulenc SA
DMX4E75 DT Small molecular drug
DMX4E75 PC 132425
DMX4E75 MW 358.5
DMX4E75 FM C22H30O2S
DMX4E75 IC InChI=1S/C22H30O2S/c1-22(2,21(23)24)16-8-4-7-14-20-19(15-17-25-20)13-9-12-18-10-5-3-6-11-18/h3,5-6,10-11,15,17H,4,7-9,12-14,16H2,1-2H3,(H,23,24)
DMX4E75 CS CC(C)(CCCCCC1=C(C=CS1)CCCC2=CC=CC=C2)C(=O)O
DMX4E75 IK QMXLXSYXJOJQSN-UHFFFAOYSA-N
DMX4E75 IU 2,2-dimethyl-7-[3-(3-phenylpropyl)thiophen-2-yl]heptanoic acid
DMX4E75 CA CAS 142422-79-5
DMX4E75 DE Asthma
DM6HJX7 ID DM6HJX7
DM6HJX7 DN RP-66364
DM6HJX7 HS Terminated
DM6HJX7 SN RP-60532; RP-69929
DM6HJX7 CP Rhone-Poulenc SA
DM6HJX7 DE Inflammation
DM2GV78 ID DM2GV78
DM2GV78 DN RP-66784
DM2GV78 HS Terminated
DM2GV78 SN IDDB5413
DM2GV78 CP Rhone-Poulenc SA
DM2GV78 DT Small molecular drug
DM2GV78 PC 9823280
DM2GV78 MW 417.6
DM2GV78 FM C21H27N3O2S2
DM2GV78 IC InChI=1S/C21H27N3O2S2/c1-22-20(27)21(18-9-7-14-23-16-18)13-6-5-8-17(21)12-15-24-28(25,26)19-10-3-2-4-11-19/h2-4,7,9-11,14,16-17,24H,5-6,8,12-13,15H2,1H3,(H,22,27)/t17-,21+/m1/s1
DM2GV78 CS CNC(=S)[C@]1(CCCC[C@@H]1CCNS(=O)(=O)C2=CC=CC=C2)C3=CN=CC=C3
DM2GV78 IK GLFXCUUHWBFHSB-UTKZUKDTSA-N
DM2GV78 IU (1S,2R)-2-[2-(benzenesulfonamido)ethyl]-N-methyl-1-pyridin-3-ylcyclohexane-1-carbothioamide
DM2GV78 DE Angina pectoris
DMDLW64 ID DMDLW64
DMDLW64 DN RP-67580
DMDLW64 HS Terminated
DMDLW64 SN RP-68651
DMDLW64 CP Rhone-Poulenc SA
DMDLW64 DT Small molecular drug
DMDLW64 PC 107686
DMDLW64 MW 438.6
DMDLW64 FM C29H30N2O2
DMDLW64 IC InChI=1S/C29H30N2O2/c1-33-27-15-9-8-10-21(27)18-28(30)31-19-24-25(20-31)29(17-16-26(24)32,22-11-4-2-5-12-22)23-13-6-3-7-14-23/h2-15,24-25,30H,16-20H2,1H3/t24-,25+/m0/s1
DMDLW64 CS COC1=CC=CC=C1CC(=N)N2C[C@H]3[C@@H](C2)C(CCC3=O)(C4=CC=CC=C4)C5=CC=CC=C5
DMDLW64 IK VWBOQFANCXZMAU-LOSJGSFVSA-N
DMDLW64 IU (3aR,7aR)-2-[2-(2-methoxyphenyl)ethanimidoyl]-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-4-one
DMDLW64 CA CAS 135911-02-3
DMDLW64 DE Pain
DM0BEM3 ID DM0BEM3
DM0BEM3 DN RP-68303
DM0BEM3 HS Terminated
DM0BEM3 SN 136701-68-3; RP-68303; CHEMBL274728; 1-(2-(4-((5-Fluoro-1H-indol-3-yl)methyl)-1-piperidinyl)ethyl)-5,6-dihydro-1H,4H-1,2,5-thiadiazolo(4,3,2-ij)quinoline 2,2-dioxide; 1-(Fim-PE)-dtqd; 1H,4H-[1,2,5]Thiadiazolo[4,3,2-ij]quinoline,1-[2-[4-[(5-fluoro-1H-indol-3-yl)methyl]-1-piperidinyl]ethyl]-5,6-dihydro-,2,2-dioxide; ACMC-20mw9l; AC1L4DLH; SCHEMBL9635292; CTK4C0419; DTXSID70159892; BDBM50047098; 1-{2-[4-(5-Fluoro-1H-indol-3-ylmethyl)-piperidin-1-yl]-ethyl}-4,5-dihydro-1H,3H-2-thia-1,2a-diaza-acenaphthylene 2,2-dioxide
DM0BEM3 DT Small molecular drug
DM0BEM3 PC 183775
DM0BEM3 MW 468.6
DM0BEM3 FM C25H29FN4O2S
DM0BEM3 IC InChI=1S/C25H29FN4O2S/c26-21-6-7-23-22(16-21)20(17-27-23)15-18-8-11-28(12-9-18)13-14-29-24-5-1-3-19-4-2-10-30(25(19)24)33(29,31)32/h1,3,5-7,16-18,27H,2,4,8-15H2
DM0BEM3 CS C1CC2=C3C(=CC=C2)N(S(=O)(=O)N3C1)CCN4CCC(CC4)CC5=CNC6=C5C=C(C=C6)F
DM0BEM3 IK NZUSTSFFNOEAHE-UHFFFAOYSA-N
DM0BEM3 IU 3-[2-[4-[(5-fluoro-1H-indol-3-yl)methyl]piperidin-1-yl]ethyl]-2lambda6-thia-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12)-triene 2,2-dioxide
DM0BEM3 CA CAS 136701-68-3
DMUY4FD ID DMUY4FD
DMUY4FD DN RP-69698
DMUY4FD HS Terminated
DMUY4FD SN CHEMBL95799; SCHEMBL8987246
DMUY4FD CP Rhone-Poulenc SA
DMUY4FD DT Small molecular drug
DMUY4FD PC 10452674
DMUY4FD MW 385.5
DMUY4FD FM C23H23N5O
DMUY4FD IC InChI=1S/C23H23N5O/c1-4-10-18(11-5-1)20-16-21(19-12-6-2-7-13-19)24-23(17-20)29-15-9-3-8-14-22-25-27-28-26-22/h1-2,4-7,10-13,16-17H,3,8-9,14-15H2,(H,25,26,27,28)
DMUY4FD CS C1=CC=C(C=C1)C2=CC(=NC(=C2)OCCCCCC3=NNN=N3)C4=CC=CC=C4
DMUY4FD IK MIZPMMYJEGMAHP-UHFFFAOYSA-N
DMUY4FD IU 2,4-diphenyl-6-[5-(2H-tetrazol-5-yl)pentoxy]pyridine
DMUY4FD DE Inflammation
DMHO5AG ID DMHO5AG
DMHO5AG DN RP-70676
DMHO5AG HS Terminated
DMHO5AG CP Rhone-Poulenc SA
DMHO5AG DE Hyperlipidaemia
DMO3FYI ID DMO3FYI
DMO3FYI DN RP-73163
DMO3FYI HS Terminated
DMO3FYI SN CHEMBL434418; BDBM50106700
DMO3FYI CP Rhone-Poulenc SA
DMO3FYI DT Small molecular drug
DMO3FYI PC 44356696
DMO3FYI MW 446.6
DMO3FYI FM C26H30N4OS
DMO3FYI IC InChI=1S/C26H30N4OS/c1-20-19-21(2)30(29-20)17-11-3-4-12-18-32(31)26-27-24(22-13-7-5-8-14-22)25(28-26)23-15-9-6-10-16-23/h5-10,13-16,19H,3-4,11-12,17-18H2,1-2H3,(H,27,28)
DMO3FYI CS CC1=CC(=NN1CCCCCCS(=O)C2=NC(=C(N2)C3=CC=CC=C3)C4=CC=CC=C4)C
DMO3FYI IK TVSPJKIQOPZAPE-UHFFFAOYSA-N
DMO3FYI IU 1-[6-[(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]hexyl]-3,5-dimethylpyrazole
DMO3FYI DE Arteriosclerosis
DMUCP8K ID DMUCP8K
DMUCP8K DN RPK-739
DMUCP8K HS Terminated
DMUCP8K SN KUN-CSF; KUN-GMCSF; Cancer vaccine (KUNrep), Replikun
DMUCP8K CP Replikun Biotech Pty Ltd
DMUCP8K DE Solid tumour/cancer
DM1U0TB ID DM1U0TB
DM1U0TB DN RPR 200765A
DM1U0TB HS Terminated
DM1U0TB SN CHEMBL68211; SCHEMBL5770288; SCHEMBL13819552; SCHEMBL20555598; SCHEMBL18797648
DM1U0TB CP Aventis
DM1U0TB DT Small molecular drug
DM1U0TB PC 9828952
DM1U0TB MW 452.5
DM1U0TB FM C24H25FN4O4
DM1U0TB IC InChI=1S/C24H25FN4O4/c1-24(23(30)29-10-12-31-13-11-29)14-32-22(33-15-24)21-27-19(16-2-4-18(25)5-3-16)20(28-21)17-6-8-26-9-7-17/h2-9,22H,10-15H2,1H3,(H,27,28)
DM1U0TB CS CC1(COC(OC1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)C(=O)N5CCOCC5
DM1U0TB IK YEQUJOKCSZTBFS-UHFFFAOYSA-N
DM1U0TB IU [2-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-morpholin-4-ylmethanone
DM1U0TB DE Rheumatoid arthritis
DM21Y75 ID DM21Y75
DM21Y75 DN RPR-101821
DM21Y75 HS Terminated
DM21Y75 CP Rhone-Poulenc Rorer Inc
DM21Y75 DE Arteriosclerosis
DM9L50N ID DM9L50N
DM9L50N DN RPR-104632
DM9L50N HS Terminated
DM9L50N SN RPR-104632; RPR104632; 154106-92-0; Rpr 104632; Rpr 104,632; AC1L53RY; CHEMBL80741; SCHEMBL9280756; 2H-1,2,4-Benzothiadiazine-1-dioxide-3-carboxylate acid; CTK0H7515; BCP08875; CS-6717; RPR-110750; RPR-110754; HY-101600; 2-[(3-bromophenyl)methyl]-6,8-dichloro-1,1-dioxo-3,4-dihydro-1; 2H-1,2,4-Benzothiadiazine-3-carboxylicacid, 2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-, 1,1-dioxide
DM9L50N DT Small molecular drug
DM9L50N PC 197644
DM9L50N MW 466.1
DM9L50N FM C15H11BrCl2N2O4S
DM9L50N IC InChI=1S/C15H11BrCl2N2O4S/c16-9-3-1-2-8(4-9)7-20-14(15(21)22)19-12-6-10(17)5-11(18)13(12)25(20,23)24/h1-6,14,19H,7H2,(H,21,22)
DM9L50N CS C1=CC(=CC(=C1)Br)CN2C(NC3=C(S2(=O)=O)C(=CC(=C3)Cl)Cl)C(=O)O
DM9L50N IK HNXXFIJGNAGRFN-UHFFFAOYSA-N
DM9L50N IU 2-[(3-bromophenyl)methyl]-6,8-dichloro-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-3-carboxylic acid
DM9L50N CA CAS 154106-92-0
DMJ63GW ID DMJ63GW
DMJ63GW DN RPR-113829
DMJ63GW HS Terminated
DMJ63GW SN RPR-113829; CHEMBL48866; SCHEMBL8750304; BDBM50058204; (S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid
DMJ63GW DT Small molecular drug
DMJ63GW PC 9953221
DMJ63GW MW 407.6
DMJ63GW FM C19H25N3O3S2
DMJ63GW IC InChI=1S/C19H25N3O3S2/c1-27-8-7-17(19(24)25)22-18(23)16-4-2-3-12-9-14(5-6-15(12)16)21-10-13(20)11-26/h2-6,9,13,17,21,26H,7-8,10-11,20H2,1H3,(H,22,23)(H,24,25)/t13-,17+/m1/s1
DMJ63GW CS CSCC[C@@H](C(=O)O)NC(=O)C1=CC=CC2=C1C=CC(=C2)NC[C@H](CS)N
DMJ63GW IK YUXOGMIOPNYIQR-DYVFJYSZSA-N
DMJ63GW IU (2S)-2-[[6-[[(2R)-2-amino-3-sulfanylpropyl]amino]naphthalene-1-carbonyl]amino]-4-methylsulfanylbutanoic acid
DMAIJT6 ID DMAIJT6
DMAIJT6 DN RPR-114334
DMAIJT6 HS Terminated
DMAIJT6 SN RPR-114334; CHEMBL297520; BDBM50058193; (S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid methyl ester
DMAIJT6 DT Small molecular drug
DMAIJT6 PC 10432334
DMAIJT6 MW 421.6
DMAIJT6 FM C20H27N3O3S2
DMAIJT6 IC InChI=1S/C20H27N3O3S2/c1-26-20(25)18(8-9-28-2)23-19(24)17-5-3-4-13-10-15(6-7-16(13)17)22-11-14(21)12-27/h3-7,10,14,18,22,27H,8-9,11-12,21H2,1-2H3,(H,23,24)/t14-,18+/m1/s1
DMAIJT6 CS COC(=O)[C@H](CCSC)NC(=O)C1=CC=CC2=C1C=CC(=C2)NC[C@H](CS)N
DMAIJT6 IK PXCDDWIKPOASGU-KDOFPFPSSA-N
DMAIJT6 IU methyl (2S)-2-[[6-[[(2R)-2-amino-3-sulfanylpropyl]amino]naphthalene-1-carbonyl]amino]-4-methylsulfanylbutanoate
DMKQV9A ID DMKQV9A
DMKQV9A DN RS 86
DMKQV9A HS Terminated
DMKQV9A SN RS-86; UNII-5ASV6M91QU; 5ASV6M91QU; RS 86; 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione hydrobromide; 2,8-Diazaspiro(4,5)decane-1,3-dione, 2-ethyl-8-methyl-, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione hydrobromide(1:1); CHEMBL542883; RS-86 hydrobromide; RS 86, hydrobromide; 2-ethyl-8-methyl-2,8-diazaspiro[4,5]decane-1,3-dione hydrobromide; AC1L3EP8; 7524-74-5; C11H18N2O2.HBr; AC1Q23N4; CTK8D5439; 2-Nitrophenyl -D-galactopyranoside; 2-Nitrophenyl ; A-D-galactopyranoside
DMKQV9A DT Small molecular drug
DMKQV9A PC 87934
DMKQV9A MW 210.27
DMKQV9A FM C11H18N2O2
DMKQV9A IC InChI=1S/C11H18N2O2/c1-3-13-9(14)8-11(10(13)15)4-6-12(2)7-5-11/h3-8H2,1-2H3
DMKQV9A CS CCN1C(=O)CC2(C1=O)CCN(CC2)C
DMKQV9A IK UIHKDOBBVHGTAQ-UHFFFAOYSA-N
DMKQV9A IU 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione
DMKQV9A CA CAS 3576-73-6
DMKQV9A DE Alzheimer disease
DMFJ0KC ID DMFJ0KC
DMFJ0KC DN RS-2135
DMFJ0KC HS Terminated
DMFJ0KC SN (+)-RS-2135; 133775-36-7
DMFJ0KC CP Sankyo Co Ltd
DMFJ0KC DT Small molecular drug
DMFJ0KC PC 159591
DMFJ0KC MW 332.8
DMFJ0KC FM C18H21ClN2O2
DMFJ0KC IC InChI=1S/C18H20N2O2.ClH/c19-12-8-11-17-13(5-2-6-14(17)21)20-15(22)7-9-3-1-4-10(12)16(9)18(11)20;/h2,5-6,9-10,12,16,21H,1,3-4,7-8,19H2;1H/t9-,10+,12-,16+;/m1./s1
DMFJ0KC CS C1C[C@@H]2CC(=O)N3C4=C(C5=C3[C@@H]2[C@@H](C1)[C@@H](C5)N)C(=CC=C4)O.Cl
DMFJ0KC IK MTSROZWZVOQAQW-PECACPRSSA-N
DMFJ0KC IU (10R,11R,15R,19S)-10-amino-6-hydroxy-1-azapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18)-tetraen-17-one;hydrochloride
DMFJ0KC CA CAS 133775-36-7
DMFJ0KC DE Heart arrhythmia
DMT5DH0 ID DMT5DH0
DMT5DH0 DN RS-66252
DMT5DH0 HS Terminated
DMT5DH0 CP Roche Bioscience
DMT5DH0 PC 9803861
DMT5DH0 MW 451.5
DMT5DH0 FM C27H25N5O2
DMT5DH0 IC InChI=1S/C27H25N5O2/c1-2-3-16-32-23-11-7-6-10-22(23)25(27(33)34)24(32)17-18-12-14-19(15-13-18)20-8-4-5-9-21(20)26-28-30-31-29-26/h4-15H,2-3,16-17H2,1H3,(H,33,34)(H,28,29,30,31)
DMT5DH0 CS CCCCN1C2=CC=CC=C2C(=C1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMT5DH0 IK LGRDYINVULLPLL-UHFFFAOYSA-N
DMT5DH0 IU 1-butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]indole-3-carboxylic acid
DMT5DH0 DE Alzheimer disease
DMZHS9U ID DMZHS9U
DMZHS9U DN RS-93522
DMZHS9U HS Terminated
DMZHS9U SN 2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid methyl 2-[4-(2,3-dihydroxypropoxy)phenyl]ethyl diester; 2-[4-(2,3-Dihydroxypropoxy)phenyl]ethyl 2,6-dimethyl-3-(methoxycarbonyl)-4-(3-nitrophenyl)-1,4-dihydropyridine-5-carboxylate
DMZHS9U DT Small molecular drug
DMZHS9U PC 128487
DMZHS9U MW 526.5
DMZHS9U FM C27H30N2O9
DMZHS9U IC InChI=1S/C27H30N2O9/c1-16-23(26(32)36-3)25(19-5-4-6-20(13-19)29(34)35)24(17(2)28-16)27(33)37-12-11-18-7-9-22(10-8-18)38-15-21(31)14-30/h4-10,13,21,25,28,30-31H,11-12,14-15H2,1-3H3
DMZHS9U CS CC1=C(C(C(=C(N1)C)C(=O)OCCC2=CC=C(C=C2)OCC(CO)O)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
DMZHS9U IK QLNAYPDWIWUVHP-UHFFFAOYSA-N
DMZHS9U IU 5-O-[2-[4-(2,3-dihydroxypropoxy)phenyl]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DMZHS9U CA CAS 104060-12-0
DMZHS9U DE Hypertension
DMVW3I9 ID DMVW3I9
DMVW3I9 DN RU 24969
DMVW3I9 HS Terminated
DMVW3I9 SN RU 24969; 66611-26-5; RU-24969; 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole; UNII-2ISE72RACC; 2ISE72RACC; CHEMBL18785; 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole; RU-24,969; KRVMLPUDAOWOGN-UHFFFAOYSA-N; NCGC00024867-01; Tocris-0912; GTPL23; Biomol-NT_000116; AC1Q4F1Q; SCHEMBL2359264; AC1L337E; BPBio1_000177; CHEBI:92005; BDBM81498; CTK1J4546; DTXSID40276045; MolPort-003-983-322; ZINC2568243; PDSP1_001623; PDSP2_001607; PDSP2_001601; PDSP1_001617; AKOS005135871; MCULE-3532976182; CS-3218; CAS_108028; API0006969
DMVW3I9 DT Small molecular drug
DMVW3I9 PC 108029
DMVW3I9 MW 228.29
DMVW3I9 FM C14H16N2O
DMVW3I9 IC InChI=1S/C14H16N2O/c1-17-11-2-3-14-12(8-11)13(9-16-14)10-4-6-15-7-5-10/h2-4,8-9,15-16H,5-7H2,1H3
DMVW3I9 CS COC1=CC2=C(C=C1)NC=C2C3=CCNCC3
DMVW3I9 IK KRVMLPUDAOWOGN-UHFFFAOYSA-N
DMVW3I9 IU 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
DMVW3I9 CA CAS 66611-26-5
DMVW3I9 CB CHEBI:92005
DMSWFMQ ID DMSWFMQ
DMSWFMQ DN RU-33965
DMSWFMQ HS Terminated
DMSWFMQ SN RU-33965; RU 33965; 122321-05-5; AC1L2W1Z; SCHEMBL195494; DTXSID50153570; 6H-Imidazo(1,5-a)(1,4)benzodiazepin-6-one, 3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-
DMSWFMQ CP Aventis Pharma AG
DMSWFMQ DT Small molecular drug
DMSWFMQ PC 129696
DMSWFMQ MW 281.31
DMSWFMQ FM C16H15N3O2
DMSWFMQ IC InChI=1S/C16H15N3O2/c1-18-8-13-14(15(20)10-6-7-10)17-9-19(13)12-5-3-2-4-11(12)16(18)21/h2-5,9-10H,6-8H2,1H3
DMSWFMQ CS CN1CC2=C(N=CN2C3=CC=CC=C3C1=O)C(=O)C4CC4
DMSWFMQ IK KNOYNQIVNYWKJR-UHFFFAOYSA-N
DMSWFMQ IU 3-(cyclopropanecarbonyl)-5-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one
DMSWFMQ CA CAS 122321-05-5
DMSWFMQ DE Alzheimer disease
DM8B1DH ID DM8B1DH
DM8B1DH DN RU-46556
DM8B1DH HS Terminated
DM8B1DH CP Aventis Pharma AG
DM8B1DH DE Endometrial cancer
DMBXDQG ID DMBXDQG
DMBXDQG DN RWJ-22108
DMBXDQG HS Terminated
DMBXDQG SN Rwj-22108; 112769-37-6; 2-(Methyl(phenylmethyl)amino)ethyl 4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methylthiepino(3,2-b)pyridine-3-carboxylate 5,5-dioxide; Thiepino[3,2-b]pyridine-3-carboxylicacid, 4-(2-chloro-6-fluorophenyl)-1,4,6,7,8,9-hexahydro-2-methyl-,2-[methyl(phenylmethyl)amino]ethyl ester, 5,5-dioxide; Rwj 22108; ACMC-20cv3e; AC1L4TSX; AC1Q4O13; CTK4A7965
DMBXDQG CP RW Johnson Pharmaceutical Research Institute
DMBXDQG DT Small molecular drug
DMBXDQG PC 163892
DMBXDQG MW 533.1
DMBXDQG FM C27H30ClFN2O4S
DMBXDQG IC InChI=1S/C27H30ClFN2O4S/c1-18-23(27(32)35-15-14-31(2)17-19-9-4-3-5-10-19)25(24-20(28)11-8-12-21(24)29)26-22(30-18)13-6-7-16-36(26,33)34/h3-5,8-12,25,30H,6-7,13-17H2,1-2H3
DMBXDQG CS CC1=C(C(C2=C(N1)CCCCS2(=O)=O)C3=C(C=CC=C3Cl)F)C(=O)OCCN(C)CC4=CC=CC=C4
DMBXDQG IK AHYGPFWAZFOLSI-UHFFFAOYSA-N
DMBXDQG IU 2-[benzyl(methyl)amino]ethyl 4-(2-chloro-6-fluorophenyl)-2-methyl-5,5-dioxo-1,4,6,7,8,9-hexahydrothiepino[3,2-b]pyridine-3-carboxylate
DMBXDQG CA CAS 112769-37-6
DMBXDQG DE Allergy
DMRQZWN ID DMRQZWN
DMRQZWN DN RWJ-25730
DMRQZWN HS Terminated
DMRQZWN SN RWJ-25730; CHEMBL428175; SCHEMBL9751073; BLFPEKXTSDYQOQ-UHFFFAOYSA-N; BDBM50001869; 1-{5-[4-(2-Isopropoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-piperidin-2-one; 1-[[5-[[4-[2-Isopropyloxyphenyl]-1-piperazinyl]methyl]-1-methyl-1H-pyrrol-2-yl]methyl]piperidin-2-one; 1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]-1 -piperazinyl]methyl]-lH-pyrrol-2-yl]methyl]-2- piperidinone
DMRQZWN DT Small molecular drug
DMRQZWN PC 9910257
DMRQZWN MW 424.6
DMRQZWN FM C25H36N4O2
DMRQZWN IC InChI=1S/C25H36N4O2/c1-20(2)31-24-9-5-4-8-23(24)28-16-14-27(15-17-28)18-21-11-12-22(26(21)3)19-29-13-7-6-10-25(29)30/h4-5,8-9,11-12,20H,6-7,10,13-19H2,1-3H3
DMRQZWN CS CC(C)OC1=CC=CC=C1N2CCN(CC2)CC3=CC=C(N3C)CN4CCCCC4=O
DMRQZWN IK BLFPEKXTSDYQOQ-UHFFFAOYSA-N
DMRQZWN IU 1-[[1-methyl-5-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]pyrrol-2-yl]methyl]piperidin-2-one
DMRQZWN DE Psychotic disorder
DM17WNG ID DM17WNG
DM17WNG DN RWJ-37868
DM17WNG HS Terminated
DM17WNG SN RWJ-37868; CHEMBL43404
DM17WNG CP RW Johnson Pharmaceutical Research Institute
DM17WNG DT Small molecular drug
DM17WNG PC 9799646
DM17WNG MW 372.9
DM17WNG FM C21H25ClN2O2
DM17WNG IC InChI=1S/C21H25ClN2O2/c1-14-19(18(25)13-24-11-5-4-6-12-24)15(2)23(3)20(14)21(26)16-7-9-17(22)10-8-16/h7-10H,4-6,11-13H2,1-3H3
DM17WNG CS CC1=C(N(C(=C1C(=O)CN2CCCCC2)C)C)C(=O)C3=CC=C(C=C3)Cl
DM17WNG IK BCRATZJXVPSAOZ-UHFFFAOYSA-N
DM17WNG IU 1-[5-(4-chlorobenzoyl)-1,2,4-trimethylpyrrol-3-yl]-2-piperidin-1-ylethanone
DM17WNG DE Epilepsy
DMEO7YD ID DMEO7YD
DMEO7YD DN RWJ-46458
DMEO7YD HS Terminated
DMEO7YD SN RWJ-46458; CHEMBL48602; BDBM50049205; L008047; [4-Ethyl-4-methyl-6-oxo-1-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-piperidin-(2E)-ylidene]-acetic acid ethyl ester
DMEO7YD CP RW Johnson Pharmaceutical Research Institute
DMEO7YD DT Small molecular drug
DMEO7YD PC 9912059
DMEO7YD MW 459.5
DMEO7YD FM C26H29N5O3
DMEO7YD IC InChI=1S/C26H29N5O3/c1-4-26(3)15-20(14-24(33)34-5-2)31(23(32)16-26)17-18-10-12-19(13-11-18)21-8-6-7-9-22(21)25-27-29-30-28-25/h6-14H,4-5,15-17H2,1-3H3,(H,27,28,29,30)/b20-14+
DMEO7YD CS CCC1(C/C(=C\\C(=O)OCC)/N(C(=O)C1)CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C
DMEO7YD IK JBEUFWOCGLXNCS-XSFVSMFZSA-N
DMEO7YD IU ethyl (2E)-2-[4-ethyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]piperidin-2-ylidene]acetate
DMEO7YD DE Hypertension
DMUGZMO ID DMUGZMO
DMUGZMO DN RWJ-49815
DMUGZMO HS Terminated
DMUGZMO SN 2-[2-[4-(3,3,3-Triphenylpropoxy)phenyl]ethyl]guanidine; AC1LAN8D; SCHEMBL13339359; AJKCPFPHDCULCG-UHFFFAOYSA-N; 2-(4-(3,3,3-triphenylpropoxy)phenyl)ethylguanidine; 1-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine; 2-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine; RJW-57926
DMUGZMO TC Antifungal Agents
DMUGZMO DT Small molecular drug
DMUGZMO PC 516731
DMUGZMO MW 449.6
DMUGZMO FM C30H31N3O
DMUGZMO IC InChI=1S/C30H31N3O/c31-29(32)33-22-20-24-16-18-28(19-17-24)34-23-21-30(25-10-4-1-5-11-25,26-12-6-2-7-13-26)27-14-8-3-9-15-27/h1-19H,20-23H2,(H4,31,32,33)
DMUGZMO CS C1=CC=C(C=C1)C(CCOC2=CC=C(C=C2)CCN=C(N)N)(C3=CC=CC=C3)C4=CC=CC=C4
DMUGZMO IK AJKCPFPHDCULCG-UHFFFAOYSA-N
DMUGZMO IU 2-[2-[4-(3,3,3-triphenylpropoxy)phenyl]ethyl]guanidine
DMUGZMO DE Obesity; Eating disorder; Fungal infection
DMYXD6A ID DMYXD6A
DMYXD6A DN RWJ-58259
DMYXD6A HS Terminated
DMYXD6A SN RWJ-58259; CHEMBL7642; SCHEMBL14090275; BDBM50098215; LS-30985
DMYXD6A CP RW Johnson Pharmaceutical Research Institute
DMYXD6A DT Small molecular drug
DMYXD6A PC 9832212
DMYXD6A MW 791.7
DMYXD6A FM C40H42Cl2F2N8O3
DMYXD6A IC InChI=1S/C40H42Cl2F2N8O3/c41-30-9-6-10-31(42)29(30)23-52-37-21-27(12-13-28(37)36(50-52)24-51-17-4-5-18-51)47-40(55)49-35(20-26-11-14-32(43)33(44)19-26)39(54)48-34(15-16-45)38(53)46-22-25-7-2-1-3-8-25/h1-3,6-14,19,21,34-35H,4-5,15-18,20,22-24,45H2,(H,46,53)(H,48,54)(H2,47,49,55)/t34-,35-/m0/s1
DMYXD6A CS C1CCN(C1)CC2=NN(C3=C2C=CC(=C3)NC(=O)N[C@@H](CC4=CC(=C(C=C4)F)F)C(=O)N[C@@H](CCN)C(=O)NCC5=CC=CC=C5)CC6=C(C=CC=C6Cl)Cl
DMYXD6A IK KEDDGIDZMJSBEW-PXLJZGITSA-N
DMYXD6A IU (2S)-4-amino-N-benzyl-2-[[(2S)-2-[[1-[(2,6-dichlorophenyl)methyl]-3-(pyrrolidin-1-ylmethyl)indazol-6-yl]carbamoylamino]-3-(3,4-difluorophenyl)propanoyl]amino]butanamide
DMYXD6A DE Artery stenosis
DMUDE1T ID DMUDE1T
DMUDE1T DN RWJ-63556
DMUDE1T HS Terminated
DMUDE1T CP RW Johnson Pharmaceutical Research Institute
DMUDE1T PC 9882374
DMUDE1T MW 287.3
DMUDE1T FM C11H10FNO3S2
DMUDE1T IC InChI=1S/C11H10FNO3S2/c1-18(14,15)13-10-6-7-11(17-10)16-9-4-2-8(12)3-5-9/h2-7,13H,1H3
DMUDE1T CS CS(=O)(=O)NC1=CC=C(S1)OC2=CC=C(C=C2)F
DMUDE1T IK BEIZIEZPGSIQGR-UHFFFAOYSA-N
DMUDE1T IU N-[5-(4-fluorophenoxy)thiophen-2-yl]methanesulfonamide
DMUDE1T DE Arthritis
DMDQGFR ID DMDQGFR
DMDQGFR DN S-1389
DMDQGFR HS Terminated
DMDQGFR SN 711389-S
DMDQGFR CP Shionogi & Co Ltd
DMDQGFR DT Small molecular drug
DMDQGFR PC 146863
DMDQGFR MW 406.7
DMDQGFR FM C17H22Cl3N3O2
DMDQGFR IC InChI=1S/C17H21Cl2N3O2.ClH/c1-11(2)21-8-13(23)9-24-17-15(19)5-4-14(18)16(17)12(3)22-7-6-20-10-22;/h4-7,10-11,13,21,23H,3,8-9H2,1-2H3;1H
DMDQGFR CS CC(C)NCC(COC1=C(C=CC(=C1C(=C)N2C=CN=C2)Cl)Cl)O.Cl
DMDQGFR IK DGLQZJPSOFSWLE-UHFFFAOYSA-N
DMDQGFR IU 1-[3,6-dichloro-2-(1-imidazol-1-ylethenyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
DMDQGFR CA CAS 90742-91-9
DMDQGFR DE Heart arrhythmia
DM759KX ID DM759KX
DM759KX DN S-14080
DM759KX HS Terminated
DM759KX CP Servier
DM759KX PC 9794783
DM759KX MW 241.31
DM759KX FM C14H11NOS
DM759KX IC InChI=1S/C14H11NOS/c16-14(10-4-2-1-3-5-10)11-6-7-12-13(8-11)17-9-15-12/h1-8,15H,9H2
DM759KX CS C1NC2=C(S1)C=C(C=C2)C(=O)C3=CC=CC=C3
DM759KX IK BSJCMEIUFYPGNL-UHFFFAOYSA-N
DM759KX IU 2,3-dihydro-1,3-benzothiazol-6-yl(phenyl)methanone
DM759KX DE Inflammation
DM05IQU ID DM05IQU
DM05IQU DN S-14506
DM05IQU HS Terminated
DM05IQU SN UNII-YVO8LE53MI; S-14506; YVO8LE53MI; 135722-25-7; CHEBI:64101; S14506; 4-fluoro-N-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]benzamide; 4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide; NCGC00025289-01; Tocris-1771; J485.975H; GTPL24; AC1L300Q; SCHEMBL6364443; DTXSID9043986; CHEMBL1590266; CTK8G8605; MolPort-042-665-626; ZINC64725931; N-(2-(4-(7-Methoxy-1-naphthyl)piperazino)ethyl)-4-fluorobenzamide; 4-Fluoro-N-(2-(4-(7-methoxy-1-naphthyl)piperazine-1-yl)ethyl)benzamide; Benzamide, 4-fluoro-N
DM05IQU CP Servier
DM05IQU DT Small molecular drug
DM05IQU PC 131906
DM05IQU MW 407.5
DM05IQU FM C24H26FN3O2
DM05IQU IC InChI=1S/C24H26FN3O2/c1-30-21-10-7-18-3-2-4-23(22(18)17-21)28-15-13-27(14-16-28)12-11-26-24(29)19-5-8-20(25)9-6-19/h2-10,17H,11-16H2,1H3,(H,26,29)
DM05IQU CS COC1=CC2=C(C=CC=C2N3CCN(CC3)CCNC(=O)C4=CC=C(C=C4)F)C=C1
DM05IQU IK IFMQODYDAUKKEN-UHFFFAOYSA-N
DM05IQU IU 4-fluoro-N-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]benzamide
DM05IQU CA CAS 135722-25-7
DM05IQU CB CHEBI:64101
DM05IQU DE Anxiety disorder
DMQ8S4L ID DMQ8S4L
DMQ8S4L DN S-18616
DMQ8S4L HS Terminated
DMQ8S4L CP Servier
DMQ8S4L PC 10468498
DMQ8S4L MW 236.7
DMQ8S4L FM C12H13ClN2O
DMQ8S4L IC InChI=1S/C12H13ClN2O/c13-10-3-1-2-8-4-5-12(6-9(8)10)7-16-11(14)15-12/h1-3H,4-7H2,(H2,14,15)/t12-/m0/s1
DMQ8S4L CS C1C[C@]2(CC3=C1C=CC=C3Cl)COC(=N2)N
DMQ8S4L IK OAXNLMLMEYQSSS-LBPRGKRZSA-N
DMQ8S4L IU (3S)-5-chlorospiro[2,4-dihydro-1H-naphthalene-3,4'-5H-1,3-oxazole]-2'-amine
DMQ8S4L DE Pain
DMQDWMJ ID DMQDWMJ
DMQDWMJ DN S-20928
DMQDWMJ HS Terminated
DMQDWMJ SN 152302-33-5; S-20928; N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide; N-(2-(1-Naphthalenyl)ethyl)cyclobutanecarboxamide; Cyclobutanecarboxamide,N-[2-(1-naphthalenyl)ethyl]-; ACMC-20n6et; AC1L2SR8; S 20928; CHEMBL12296; ZINC5833; GTPL1360; SCHEMBL6254856; CTK4C7390; DTXSID00164994; MolPort-009-303-106; GLXSBZGTGMPDKH-UHFFFAOYSA-N; AKOS030612657; MCULE-2771118083; N-[2-(1-naphthyl)ethyl]cyclobutanecarboxamide; S20928; n-[2-naphth-1-yl-ethyl]-cyclobutyl carboxamide; L000529; N-[2-(naphthalen-1-yl)ethyl]cyclobutanecarboxamide
DMQDWMJ CP Servier
DMQDWMJ DT Small molecular drug
DMQDWMJ PC 127856
DMQDWMJ MW 253.34
DMQDWMJ FM C17H19NO
DMQDWMJ IC InChI=1S/C17H19NO/c19-17(15-8-4-9-15)18-12-11-14-7-3-6-13-5-1-2-10-16(13)14/h1-3,5-7,10,15H,4,8-9,11-12H2,(H,18,19)
DMQDWMJ CS C1CC(C1)C(=O)NCCC2=CC=CC3=CC=CC=C32
DMQDWMJ IK GLXSBZGTGMPDKH-UHFFFAOYSA-N
DMQDWMJ IU N-(2-naphthalen-1-ylethyl)cyclobutanecarboxamide
DMQDWMJ CA CAS 152302-33-5
DMQDWMJ DE Sleep-wake disorder
DMF710M ID DMF710M
DMF710M DN S-33516
DMF710M HS Terminated
DMF710M CP Servier
DMF710M DE Arthritis
DMPQIUH ID DMPQIUH
DMPQIUH DN S-34109
DMPQIUH HS Terminated
DMPQIUH SN S-32730
DMPQIUH CP Kaken Pharmaceutical Co Ltd
DMPQIUH DE Staphylococcus infection
DMEN6YO ID DMEN6YO
DMEN6YO DN Sameridine
DMEN6YO HS Terminated
DMEN6YO SN Sameridine; 143257-97-0; UNII-NQP2Y50Y6B; NQP2Y50Y6B; Sameridine [INN]; sameridine[inn]; AC1Q5ICP; SCHEMBL419071; AC1L24E2; CHEMBL2104504; DTXSID30162367; 4-Piperidinecarboxamide,N-ethyl-1-hexyl-N-methyl-4-phenyl-; ZINC3797855; AKOS015909863; N-Ethyl-1-hexyl-N-methyl-4-phenylisonipecotamide; I14-31849
DMEN6YO CP Astra AB
DMEN6YO DT Small molecular drug
DMEN6YO PC 65996
DMEN6YO MW 330.5
DMEN6YO FM C21H34N2O
DMEN6YO IC InChI=1S/C21H34N2O/c1-4-6-7-11-16-23-17-14-21(15-18-23,20(24)22(3)5-2)19-12-9-8-10-13-19/h8-10,12-13H,4-7,11,14-18H2,1-3H3
DMEN6YO CS CCCCCCN1CCC(CC1)(C2=CC=CC=C2)C(=O)N(C)CC
DMEN6YO IK TYWUGCGYWNSRPS-UHFFFAOYSA-N
DMEN6YO IU N-ethyl-1-hexyl-N-methyl-4-phenylpiperidine-4-carboxamide
DMEN6YO CA CAS 143257-97-0
DMEN6YO DE Pain
DMGUA9Y ID DMGUA9Y
DMGUA9Y DN SAN-61
DMGUA9Y HS Terminated
DMGUA9Y SN SAN-AL-61; Oral beta amyloid inhibitor (Alzheimer's disease), Sanomune
DMGUA9Y CP Sanomune Inc
DMGUA9Y DE Alzheimer disease
DM79E6W ID DM79E6W
DM79E6W DN Saviprazole
DM79E6W HS Terminated
DM79E6W SN Hoe-731
DM79E6W CP Hoechst AG
DM79E6W DT Small molecular drug
DM79E6W PC 65942
DM79E6W MW 461.4
DM79E6W FM C15H10F7N3O2S2
DM79E6W IC InChI=1S/C15H10F7N3O2S2/c16-13(17,14(18,19)15(20,21)22)7-27-9-1-2-23-8(3-9)6-29(26)12-24-10-4-28-5-11(10)25-12/h1-5H,6-7H2,(H,24,25)
DM79E6W CS C1=CN=C(C=C1OCC(C(C(F)(F)F)(F)F)(F)F)CS(=O)C2=NC3=CSC=C3N2
DM79E6W IK ARFGGIRJBPTBPP-UHFFFAOYSA-N
DM79E6W IU 2-[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)pyridin-2-yl]methylsulfinyl]-1H-thieno[3,4-d]imidazole
DM79E6W CA CAS 121617-11-6
DM79E6W DE Peptic ulcer
DMNJ7LY ID DMNJ7LY
DMNJ7LY DN SB 203186
DMNJ7LY HS Terminated
DMNJ7LY SN SB 203186; SB-203186; 2-piperidin-1-ylethyl 1H-indole-3-carboxylate; Tocris-0785; NCGC00015921-01; Lopac-S-0443; Biomol-NT_000150; AC1MN68M; Lopac0_000347; GTPL255; BPBio1_000617; SCHEMBL1041116; CHEMBL1255781; ZINC14457; CHEBI:92477; BDBM85778; YGKPIROTKVQCCU-UHFFFAOYSA-N; CCG-204442; NCGC00024790-03; NCGC00015921-02; NCGC00024790-01; NCGC00024790-02; NCGC00015921-04; NCGC00015921-03; CAS_135938-17-9; (1-piperidinyl)ethyl 1h-indole 3-carboxylate; 2-(1-piperidyl)ethyl 1H-indole-3-carboxylate; 2-(1-Piperidyl)ethyl 1 H-indole-3-carboxy
DMNJ7LY DT Small molecular drug
DMNJ7LY PC 3272300
DMNJ7LY MW 272.34
DMNJ7LY FM C16H20N2O2
DMNJ7LY IC InChI=1S/C16H20N2O2/c19-16(20-11-10-18-8-4-1-5-9-18)14-12-17-15-7-3-2-6-13(14)15/h2-3,6-7,12,17H,1,4-5,8-11H2
DMNJ7LY CS C1CCN(CC1)CCOC(=O)C2=CNC3=CC=CC=C32
DMNJ7LY IK YGKPIROTKVQCCU-UHFFFAOYSA-N
DMNJ7LY IU 2-piperidin-1-ylethyl 1H-indole-3-carboxylate
DMNJ7LY CB CHEBI:92477
DMAET6F ID DMAET6F
DMAET6F DN SB 203580
DMAET6F HS Terminated
DMAET6F SN 152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV
DMAET6F DT Small molecular drug
DMAET6F PC 176155
DMAET6F MW 377.4
DMAET6F FM C21H16FN3OS
DMAET6F IC InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
DMAET6F CS CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
DMAET6F IK CDMGBJANTYXAIV-UHFFFAOYSA-N
DMAET6F IU 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
DMAET6F CA CAS 152121-47-6
DMAET6F CB CHEBI:90705
DMS0QEP ID DMS0QEP
DMS0QEP DN SB 206553
DMS0QEP HS Terminated
DMS0QEP SN SB 206553; 158942-04-2; SB-206553; Tocris-1661; CHEMBL297784; CHEBI:8977; UNII-AL4387525T; AL4387525T; SB-206,553; 1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide; SB-206553 hydrochloride hydrate; SB206553; Lopac-S-180; AC1L1JQU; AC1Q5NRE; Lopac0_001163; GTPL189; SCHEMBL1459242; ZINC5994; DTXSID9043984; CTK8H1211; BDBM50060417; pyrrolo[2,3-f]indole-1(2h)-carboxamide, 3,5-dihydro-5-methyl-n-3-pyridinyl-; AKOS027381420; 5-Methyl-N-(3-pyridinyl)-3,5-dihydropyrrolo[2,3-f]indole-1(2H)-carboxamide; CCG-205237
DMS0QEP DT Small molecular drug
DMS0QEP PC 5163
DMS0QEP MW 292.33
DMS0QEP FM C17H16N4O
DMS0QEP IC InChI=1S/C17H16N4O/c1-20-7-4-12-10-16-13(9-15(12)20)5-8-21(16)17(22)19-14-3-2-6-18-11-14/h2-4,6-7,9-11H,5,8H2,1H3,(H,19,22)
DMS0QEP CS CN1C=CC2=CC3=C(CCN3C(=O)NC4=CN=CC=C4)C=C21
DMS0QEP IK QJQORSLQNXDVGE-UHFFFAOYSA-N
DMS0QEP IU 1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide
DMS0QEP CA CAS 158942-04-2
DMS0QEP CB CHEBI:8977
DMGNZUX ID DMGNZUX
DMGNZUX DN SB-201146
DMGNZUX HS Terminated
DMGNZUX SN CHEMBL112338; SB-201146; AC1O5RO8; SCHEMBL13696780; BDBM50042182; L009515; (E)-3-{6-(3-Amino-benzenesulfinylmethyl)-3-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-yl}-acrylic acid; 3-{6-(3-Amino-benzenesulfinylmethyl)-3-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-yl}-acrylic acid; (E)-3-[6-[(3-aminophenyl)sulfinylmethyl]-3-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]prop-2-enoic acid; (E)-3-[[8-(4-Methoxyphenyl)octyl]oxy]-6-[[(3-aminophenyl)sulfinyl]methyl]pyridine-2-propenoic acid
DMGNZUX DT Small molecular drug
DMGNZUX PC 23675456
DMGNZUX MW 542.6
DMGNZUX FM C30H35LiN2O5S
DMGNZUX IC InChI=1S/C30H36N2O5S.Li/c1-36-26-15-12-23(13-16-26)9-6-4-2-3-5-7-20-37-29-18-14-25(32-28(29)17-19-30(33)34)22-38(35)27-11-8-10-24(31)21-27;/h8,10-19,21H,2-7,9,20,22,31H2,1H3,(H,33,34);/q;+1/p-1/b19-17+;
DMGNZUX CS [Li+].COC1=CC=C(C=C1)CCCCCCCCOC2=C(N=C(C=C2)CS(=O)C3=CC=CC(=C3)N)/C=C/C(=O)[O-]
DMGNZUX IK RVRATNAADXHAQO-ZJSKVYKZSA-M
DMGNZUX IU lithium;(E)-3-[6-[(3-aminophenyl)sulfinylmethyl]-3-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]prop-2-enoate
DMGNZUX CA CAS 141311-11-7
DM5ZPQJ ID DM5ZPQJ
DM5ZPQJ DN SB-206284A
DM5ZPQJ HS Terminated
DM5ZPQJ CP SmithKline Beecham plc
DM5ZPQJ DE Cerebrovascular ischaemia
DMYFE23 ID DMYFE23
DMYFE23 DN SB-206343
DMYFE23 HS Terminated
DMYFE23 SN SB206343; CHEMBL326473; 2-[(1R,3S,4S)-1-BENZYL-4-[N-(BENZYLOXYCARBONYL)-L-VALYL]AMINO-3-PHENYLPENTYL]-4(5)-(2-METHYLPROPIONYL)IMIDAZOLE; RUN; SB-206343; 1hps; SB 206343; AC1L9J53; SCHEMBL13987202; BDBM50037121; N-{(1S,2S,4R)-1-benzyl-2-hydroxy-4-[5-(2-methylpropanoyl)-1H-imidazol-2-yl]-5-phenylpentyl}-N~2~-[(benzyloxy)carbonyl]-L-valinamide; {(S)-1-[(1S,2S,4R)-1-Benzyl-2-hydroxy-4-(5-isobutyryl-1H-imidazol-2-yl)-5-phenyl-pentylcarbamoyl]-2-methyl-propyl}-carbamic acid benzyl ester; benzyl N-[(2S)-1-[[(2S,3S,5R)-3-hydro
DMYFE23 CP SmithKline Beecham plc
DMYFE23 DT Small molecular drug
DMYFE23 PC 446120
DMYFE23 MW 638.8
DMYFE23 FM C38H46N4O5
DMYFE23 IC InChI=1S/C38H46N4O5/c1-25(2)34(42-38(46)47-24-29-18-12-7-13-19-29)37(45)41-31(21-28-16-10-6-11-17-28)33(43)22-30(20-27-14-8-5-9-15-27)36-39-23-32(40-36)35(44)26(3)4/h5-19,23,25-26,30-31,33-34,43H,20-22,24H2,1-4H3,(H,39,40)(H,41,45)(H,42,46)/t30-,31+,33+,34+/m1/s1
DMYFE23 CS CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C[C@@H](CC2=CC=CC=C2)C3=NC=C(N3)C(=O)C(C)C)O)NC(=O)OCC4=CC=CC=C4
DMYFE23 IK RQAVEWKEUKIFLD-LVPKLHHISA-N
DMYFE23 IU benzyl N-[(2S)-1-[[(2S,3S,5R)-3-hydroxy-5-[5-(2-methylpropanoyl)-1H-imidazol-2-yl]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
DMYFE23 DE Human immunodeficiency virus-1 infection
DMJD15H ID DMJD15H
DMJD15H DN SB-208651
DMJD15H HS Terminated
DMJD15H SN SB-208651; CHEMBL85094; BDBM50054827; {8-[(4-Carbamimidoyl-phenyl)-methyl-carbamoyl]-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {8-[(4-Carbamimidoyl-phenyl)-methyl-carbamoyl]-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid(SB-208651)
DMJD15H DT Small molecular drug
DMJD15H PC 9827266
DMJD15H MW 499.6
DMJD15H FM C28H29N5O4
DMJD15H IC InChI=1S/C28H29N5O4/c1-32(22-11-9-19(10-12-22)26(29)30)27(36)20-7-8-21-17-33(14-13-18-5-3-2-4-6-18)28(37)24(16-25(34)35)31-23(21)15-20/h2-12,15,24,31H,13-14,16-17H2,1H3,(H3,29,30)(H,34,35)
DMJD15H CS CN(C1=CC=C(C=C1)C(=N)N)C(=O)C2=CC3=C(CN(C(=O)C(N3)CC(=O)O)CCC4=CC=CC=C4)C=C2
DMJD15H IK WCZAIWWFRSMLCO-UHFFFAOYSA-N
DMJD15H IU 2-[8-[(4-carbamimidoylphenyl)-methylcarbamoyl]-3-oxo-4-(2-phenylethyl)-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid
DMJD15H DE Thrombosis
DMVBNTP ID DMVBNTP
DMVBNTP DN SB-209247
DMVBNTP HS Terminated
DMVBNTP SN Ticolubant; LTB4 antagonist, SB
DMVBNTP CP SmithKline Beecham plc
DMVBNTP DT Small molecular drug
DMVBNTP PC 6441619
DMVBNTP MW 460.4
DMVBNTP FM C23H19Cl2NO3S
DMVBNTP IC InChI=1S/C23H19Cl2NO3S/c24-18-7-4-8-19(25)23(18)30-15-17-9-11-21(20(26-17)10-12-22(27)28)29-14-13-16-5-2-1-3-6-16/h1-12H,13-15H2,(H,27,28)/b12-10+
DMVBNTP CS C1=CC=C(C=C1)CCOC2=C(N=C(C=C2)CSC3=C(C=CC=C3Cl)Cl)/C=C/C(=O)O
DMVBNTP IK ZJLFOOWTDISDIO-ZRDIBKRKSA-N
DMVBNTP IU (E)-3-[6-[(2,6-dichlorophenyl)sulfanylmethyl]-3-(2-phenylethoxy)pyridin-2-yl]prop-2-enoic acid
DMVBNTP CA CAS 154413-61-3
DMVBNTP DE Psoriasis vulgaris
DM58PKG ID DM58PKG
DM58PKG DN SB-213698
DM58PKG HS Terminated
DM58PKG SN TAN-67
DM58PKG PC 9950038
DM58PKG MW 344.4
DM58PKG FM C23H24N2O
DM58PKG IC InChI=1S/C23H24N2O/c1-25-10-9-23(18-6-4-7-20(26)13-18)14-22-17(12-19(23)15-25)11-16-5-2-3-8-21(16)24-22/h2-8,11,13,19,26H,9-10,12,14-15H2,1H3/t19-,23+/m0/s1
DM58PKG CS CN1CC[C@@]2(CC3=NC4=CC=CC=C4C=C3C[C@H]2C1)C5=CC(=CC=C5)O
DM58PKG IK LEPBHAAYNPPRRA-WMZHIEFXSA-N
DM58PKG IU 3-[(4aS,12aR)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a-yl]phenol
DM58PKG CA CAS 148545-09-9
DM58PKG CB CHEBI:124990
DMQW6B0 ID DMQW6B0
DMQW6B0 DN SB-219825
DMQW6B0 HS Terminated
DMQW6B0 CP SmithKline Beecham Corp
DMQW6B0 PC 101105102
DMQW6B0 MW 409.6
DMQW6B0 FM C25H35N3O2
DMQW6B0 IC InChI=1S/C25H35N3O2/c1-5-27-12-11-25(18-9-8-10-20(29)13-18)15-22-21(14-19(25)16-27)17(4)23(26-22)24(30)28(6-2)7-3/h8-10,13,19,26,29H,5-7,11-12,14-16H2,1-4H3/t19-,25-/m1/s1
DMQW6B0 CS CCN1CC[C@@]2(CC3=C(C[C@@H]2C1)C(=C(N3)C(=O)N(CC)CC)C)C4=CC(=CC=C4)O
DMQW6B0 IK LCXJNOQXEGZLDX-KBMIEXCESA-N
DMQW6B0 IU (4aS,8aS)-N,N,6-triethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,7,8,9-hexahydro-1H-pyrrolo[2,3-g]isoquinoline-2-carboxamide
DMQW6B0 DE Pain
DMCZDE9 ID DMCZDE9
DMCZDE9 DN SB-219994
DMCZDE9 HS Terminated
DMCZDE9 SN SB-219993
DMCZDE9 CP SmithKline Beecham plc
DMCZDE9 DT Small molecular drug
DMCZDE9 PC 9845965
DMCZDE9 MW 438.4
DMCZDE9 FM C21H21F3N2O5
DMCZDE9 IC InChI=1S/C21H21F3N2O5/c1-26(20-25-16-4-2-3-5-17(16)31-20)10-11-29-15-8-6-14(7-9-15)12-18(19(27)28)30-13-21(22,23)24/h2-9,18H,10-13H2,1H3,(H,27,28)/t18-/m0/s1
DMCZDE9 CS CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)OCC(F)(F)F)C2=NC3=CC=CC=C3O2
DMCZDE9 IK IRAAJHYKQDFNFO-SFHVURJKSA-N
DMCZDE9 IU (2S)-3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid
DMCZDE9 DE Diabetic complication
DMSBUET ID DMSBUET
DMSBUET DN SB220025
DMSBUET HS Terminated
DMSBUET SN SB220025; 3erk; sb 220025; SB-220025; CHEMBL274064; 165806-53-1; CHEBI:82713; 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine; 4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE; SB4; 5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazole; 4-[5-(4-fluorophenyl)-3-(4-piperidyl)imidazol-4-yl]pyrimidin-2-amine; SB-220025-A; 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-(amino)-4-pyrimidinyl)imidazole
DMSBUET DT Small molecular drug
DMSBUET PC 5164
DMSBUET MW 338.4
DMSBUET FM C18H19FN6
DMSBUET IC InChI=1S/C18H19FN6/c19-13-3-1-12(2-4-13)16-17(15-7-10-22-18(20)24-15)25(11-23-16)14-5-8-21-9-6-14/h1-4,7,10-11,14,21H,5-6,8-9H2,(H2,20,22,24)
DMSBUET CS C1CNCCC1N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F
DMSBUET IK VSPFURGQAYMVAN-UHFFFAOYSA-N
DMSBUET IU 4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]pyrimidin-2-amine
DMSBUET CA CAS 165806-53-1
DMSBUET CB CHEBI:82713
DMSBUET DE Arthritis
DM3JQCF ID DM3JQCF
DM3JQCF DN SB-223245
DM3JQCF HS Terminated
DM3JQCF SN SB-223245; CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid
DM3JQCF DT Small molecular drug
DM3JQCF PC 9823503
DM3JQCF MW 421.4
DM3JQCF FM C22H23N5O4
DM3JQCF IC InChI=1S/C22H23N5O4/c1-26-11-14-9-13(7-8-15(14)23-18(22(26)31)10-20(28)29)21(30)27(2)12-19-24-16-5-3-4-6-17(16)25-19/h3-9,18,23H,10-12H2,1-2H3,(H,24,25)(H,28,29)/t18-/m0/s1
DM3JQCF CS CN1CC2=C(C=CC(=C2)C(=O)N(C)CC3=NC4=CC=CC=C4N3)N[C@H](C1=O)CC(=O)O
DM3JQCF IK PVNQAXDNDZYXIW-SFHVURJKSA-N
DM3JQCF IU 2-[(2S)-7-[1H-benzimidazol-2-ylmethyl(methyl)carbamoyl]-4-methyl-3-oxo-2,5-dihydro-1H-1,4-benzodiazepin-2-yl]acetic acid
DM5JDH1 ID DM5JDH1
DM5JDH1 DN SB-236049
DM5JDH1 HS Terminated
DM5JDH1 SN SB-236080; SB-238569; Tricyclic broad-spectrum metallo-beta-lactamase inhibitors, SmithKline Beecham
DM5JDH1 CP SmithKline Beecham Pharmaceuticals
DM5JDH1 DT Small molecular drug
DM5JDH1 PC 9860695
DM5JDH1 MW 287.22
DM5JDH1 FM C14H9NO6
DM5JDH1 IC InChI=1S/C14H9NO6/c1-5-2-8-6(4-15-5)12(17)10-9(21-8)3-7(16)13(18)11(10)14(19)20/h2-4,16,18H,1H3,(H,19,20)
DM5JDH1 CS CC1=CC2=C(C=N1)C(=O)C3=C(O2)C=C(C(=C3C(=O)O)O)O
DM5JDH1 IK JQSDDXAUCUZICT-UHFFFAOYSA-N
DM5JDH1 IU 7,8-dihydroxy-3-methyl-10-oxochromeno[3,2-c]pyridine-9-carboxylic acid
DM5JDH1 CB CHEBI:68708
DM5JDH1 DE Bacterial infection
DMBCANZ ID DMBCANZ
DMBCANZ DN SB-237376
DMBCANZ HS Terminated
DMBCANZ SN SB-237376; UNII-JED8M29NSU; JED8M29NSU; CHEMBL184461; SB-237376 free base; SCHEMBL6737235; XEAKAKKNLOUHDV-UHFFFAOYSA-N; BDBM50151854; n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide; N-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-propyl}-4-nitro-benzamide; Benzamide, N-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-4-nitro-
DMBCANZ CP SmithKline Beecham plc
DMBCANZ DT Small molecular drug
DMBCANZ PC 9845214
DMBCANZ MW 387.4
DMBCANZ FM C20H25N3O5
DMBCANZ IC InChI=1S/C20H25N3O5/c1-27-18-9-4-15(14-19(18)28-2)10-13-21-11-3-12-22-20(24)16-5-7-17(8-6-16)23(25)26/h4-9,14,21H,3,10-13H2,1-2H3,(H,22,24)
DMBCANZ CS COC1=C(C=C(C=C1)CCNCCCNC(=O)C2=CC=C(C=C2)[N+](=O)[O-])OC
DMBCANZ IK XEAKAKKNLOUHDV-UHFFFAOYSA-N
DMBCANZ IU N-[3-[2-(3,4-dimethoxyphenyl)ethylamino]propyl]-4-nitrobenzamide
DMBCANZ CA CAS 179258-59-4
DMBCANZ DE Arrhythmia
DM8WTGA ID DM8WTGA
DM8WTGA DN SB-269970
DM8WTGA HS Terminated
DM8WTGA SN Pyrrolidine, 1-((3-hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)-, (R)-; 201038-74-6; SB 269970; (R)-3-((2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol; CHEMBL282199; SB269970; 3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol; SB-269,970; NCGC00025229-01; Tocris-1612; [3H]SB269970; AC1O7H0E; Lopac0_001059; SCHEMBL375474; GTPL3247; GTPL3233; CHEBI:92426; BCPP000080; ZINC3982174; BDBM50098551; 2921AH; AKOS024465019; CS-1645; CCG-205136; SB19510
DM8WTGA DT Small molecular drug
DM8WTGA PC 6604889
DM8WTGA MW 352.5
DM8WTGA FM C18H28N2O3S
DM8WTGA IC InChI=1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18/h2,5-6,14-16,21H,3-4,7-13H2,1H3/t16-/m1/s1
DM8WTGA CS CC1CCN(CC1)CC[C@H]2CCCN2S(=O)(=O)C3=CC=CC(=C3)O
DM8WTGA IK HWKROQUZSKPIKQ-MRXNPFEDSA-N
DM8WTGA IU 3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol
DM8WTGA CA CAS 201038-74-6
DM8WTGA CB CHEBI:92426
DM8WTGA DE Sleep-wake disorder
DM3M16Q ID DM3M16Q
DM3M16Q DN SB-277011
DM3M16Q HS Terminated
DM3M16Q SN SB 277011; SB 277011A; SB 277011-A; N-[4-[2-(6-cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide
DM3M16Q CP GlaxoSmithKline
DM3M16Q DT Small molecular drug
DM3M16Q PC 5311096
DM3M16Q MW 438.6
DM3M16Q FM C28H30N4O
DM3M16Q IC InChI=1S/C28H30N4O/c29-18-21-5-8-23-19-32(16-13-22(23)17-21)15-12-20-6-9-24(10-7-20)31-28(33)26-11-14-30-27-4-2-1-3-25(26)27/h1-5,8,11,14,17,20,24H,6-7,9-10,12-13,15-16,19H2,(H,31,33)
DM3M16Q CS C1CC(CCC1CCN2CCC3=C(C2)C=CC(=C3)C#N)NC(=O)C4=CC=NC5=CC=CC=C45
DM3M16Q IK OLWRVVHPJFLNPW-UHFFFAOYSA-N
DM3M16Q IU N-[4-[2-(6-cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide
DM3M16Q CA CAS 215803-78-4
DM3M16Q DE Schizophrenia
DMZLKCF ID DMZLKCF
DMZLKCF DN SB-282241
DMZLKCF HS Terminated
DMZLKCF SN CCR2B antagonists, GlaxoSmithKline; SB-380732; MCP-1 antagonists, GlaxoSmithKline
DMZLKCF CP SmithKline Beecham Pharmaceuticals
DMZLKCF DT Small molecular drug
DMZLKCF PC 10436045
DMZLKCF MW 500.5
DMZLKCF FM C27H31Cl2N3O2
DMZLKCF IC InChI=1S/C27H31Cl2N3O2/c28-24-7-4-19(16-25(24)29)5-9-27(34)30-12-2-1-3-13-32-14-10-20(11-15-32)23-18-31-26-8-6-21(33)17-22(23)26/h4-9,16-18,20,31,33H,1-3,10-15H2,(H,30,34)/b9-5+
DMZLKCF CS C1CN(CCC1C2=CNC3=C2C=C(C=C3)O)CCCCCNC(=O)/C=C/C4=CC(=C(C=C4)Cl)Cl
DMZLKCF IK QBRLVMQBZIFWTB-WEVVVXLNSA-N
DMZLKCF IU (E)-3-(3,4-dichlorophenyl)-N-[5-[4-(5-hydroxy-1H-indol-3-yl)piperidin-1-yl]pentyl]prop-2-enamide
DMZLKCF DE Inflammation
DM9F7R0 ID DM9F7R0
DM9F7R0 DN SBP-002
DM9F7R0 HS Terminated
DM9F7R0 SN Coramsine; Solasonine + solamargine; Solasodine glycosides (cancer, injectable formulation), Solbec; Solasodine glycosides (psoriasis, cream formulation), Solbec; Solasonine + solamargine (cancer), Solbec; Solasonine + solamargine (psoriasis), Solbec; SBP-002 (intravenous, cancer), Solbec; SBP-002 (psoriasis, cream formulation), Solbec
DM9F7R0 CP Curacel International Pty Ltd; Freedom Eye Ltd
DM9F7R0 DE Melanoma
DM1MQ6Z ID DM1MQ6Z
DM1MQ6Z DN SC-102
DM1MQ6Z HS Terminated
DM1MQ6Z SN 4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine; 3hvc; GG5; SCHEMBL1554633; CHEMBL1233024; BDBM19429; BILJSHVAAVZERY-UHFFFAOYSA-N; ZINC16052350; DB07829; 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole; 4-[3-(4-Fluorophenyl)-1H-pyrazole-4-yl]pyridine; 4-(3-(4-fluorophenyl)-1h-pyrazol-4-yl); SC-102; SPC-0038B; SPC-0172; Temoporfin derivatives (cancer); Temoporfin derivatives (cancer), Scotia Holdings; 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
DM1MQ6Z CP Scotia Holdings plc
DM1MQ6Z DT Small molecular drug
DM1MQ6Z PC 12106168
DM1MQ6Z MW 239.25
DM1MQ6Z FM C14H10FN3
DM1MQ6Z IC InChI=1S/C14H10FN3/c15-12-3-1-11(2-4-12)14-13(9-17-18-14)10-5-7-16-8-6-10/h1-9H,(H,17,18)
DM1MQ6Z CS C1=CC(=CC=C1C2=C(C=NN2)C3=CC=NC=C3)F
DM1MQ6Z IK BILJSHVAAVZERY-UHFFFAOYSA-N
DM1MQ6Z IU 4-[5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine
DM1MQ6Z DE Solid tumour/cancer
DMO1URE ID DMO1URE
DMO1URE DN SC-236
DMO1URE HS Terminated
DMO1URE SN SC-791; SC-872; COX-2 inhibitors (anticancer), Pfizer; COX-2 inhibitors (anticancer), Pharmacia
DMO1URE CP GD Searle & Co
DMO1URE DT Small molecular drug
DMO1URE PC 9865808
DMO1URE MW 401.8
DMO1URE FM C16H11ClF3N3O2S
DMO1URE IC InChI=1S/C16H11ClF3N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25)
DMO1URE CS C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)Cl
DMO1URE IK NSQNZEUFHPTJME-UHFFFAOYSA-N
DMO1URE IU 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
DMO1URE CA CAS 170569-86-5
DMO1URE DE Solid tumour/cancer
DM7I6VO ID DM7I6VO
DM7I6VO DN SC-241
DM7I6VO HS Terminated
DM7I6VO CP Bristol-Myers Squibb Pharma Co
DM7I6VO PC 9934089
DM7I6VO MW 463.4
DM7I6VO FM C20H27BrN6O2
DM7I6VO IC InChI=1S/C20H27BrN6O2/c1-13(2)15-6-7-17(16(21)12-15)27-20-18(24-25-27)19(22-14(3)23-20)26(8-10-28-4)9-11-29-5/h6-7,12-13H,8-11H2,1-5H3
DM7I6VO CS CC1=NC2=C(C(=N1)N(CCOC)CCOC)N=NN2C3=C(C=C(C=C3)C(C)C)Br
DM7I6VO IK DMJNPPHUVMMIEQ-UHFFFAOYSA-N
DM7I6VO IU 3-(2-bromo-4-propan-2-ylphenyl)-N,N-bis(2-methoxyethyl)-5-methyltriazolo[4,5-d]pyrimidin-7-amine
DM7I6VO DE Anxiety disorder
DMBPNKT ID DMBPNKT
DMBPNKT DN SC-44463
DMBPNKT HS Terminated
DMBPNKT SN SC-44463; CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth
DMBPNKT DT Small molecular drug
DMBPNKT PC 128564
DMBPNKT MW 379.5
DMBPNKT FM C19H29N3O5
DMBPNKT IC InChI=1S/C19H29N3O5/c1-12(2)9-14(11-17(23)22-26)18(24)21-16(19(25)20-3)10-13-5-7-15(27-4)8-6-13/h5-8,12,14,16,26H,9-11H2,1-4H3,(H,20,25)(H,21,24)(H,22,23)/t14-,16+/m1/s1
DMBPNKT CS CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CC=C(C=C1)OC)C(=O)NC
DMBPNKT IK QYZPDCGWIJYZMN-ZBFHGGJFSA-N
DMBPNKT IU (2R)-N'-hydroxy-N-[(2S)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
DMBPNKT CA CAS 104408-38-0
DMIE039 ID DMIE039
DMIE039 DN SC-47643
DMIE039 HS Terminated
DMIE039 SN CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid
DMIE039 DT Small molecular drug
DMIE039 PC 124392
DMIE039 MW 449.5
DMIE039 FM C22H35N5O5
DMIE039 IC InChI=1S/C22H35N5O5/c1-32-17-10-8-16(9-11-17)12-14-25-21(31)18(15-20(29)30)27-19(28)7-5-3-2-4-6-13-26-22(23)24/h8-11,18H,2-7,12-15H2,1H3,(H,25,31)(H,27,28)(H,29,30)(H4,23,24,26)/t18-/m0/s1
DMIE039 CS COC1=CC=C(C=C1)CCNC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCN=C(N)N
DMIE039 IK LVVRYABDHQGPGK-SFHVURJKSA-N
DMIE039 IU (3S)-3-[8-(diaminomethylideneamino)octanoylamino]-4-[2-(4-methoxyphenyl)ethylamino]-4-oxobutanoic acid
DMIE039 CA CAS 126631-86-5
DMY7KHW ID DMY7KHW
DMY7KHW DN SC-49992
DMY7KHW HS Terminated
DMY7KHW SN (8-Guanidinooctanoyl)-L-aspartyl-L-phenylalanine
DMY7KHW PC 9804438
DMY7KHW MW 463.5
DMY7KHW FM C22H33N5O6
DMY7KHW IC InChI=1S/C22H33N5O6/c23-22(24)25-12-8-3-1-2-7-11-18(28)26-16(14-19(29)30)20(31)27-17(21(32)33)13-15-9-5-4-6-10-15/h4-6,9-10,16-17H,1-3,7-8,11-14H2,(H,26,28)(H,27,31)(H,29,30)(H,32,33)(H4,23,24,25)/t16-,17-/m0/s1
DMY7KHW CS C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCN=C(N)N
DMY7KHW IK PLSJXKVBQIPFJY-IRXDYDNUSA-N
DMY7KHW IU (3S)-4-[[(1S)-1-carboxy-2-phenylethyl]amino]-3-[8-(diaminomethylideneamino)octanoylamino]-4-oxobutanoic acid
DMY7KHW DE Arterial thrombosis
DM8UDSF ID DM8UDSF
DM8UDSF DN SC-50560
DM8UDSF HS Terminated
DM8UDSF SN SC-50560; CHEMBL85595; SCHEMBL8294789; SCHEMBL6444071; BDBM50046078; L006223; 5-[4''-(3,5-Dibutyl-[1,2,4]triazol-1-ylmethyl)-biphenyl-2-yl]-2H-tetrazole
DM8UDSF DT Small molecular drug
DM8UDSF PC 9931685
DM8UDSF MW 415.5
DM8UDSF FM C24H29N7
DM8UDSF IC InChI=1S/C24H29N7/c1-3-5-11-22-25-23(12-6-4-2)31(28-22)17-18-13-15-19(16-14-18)20-9-7-8-10-21(20)24-26-29-30-27-24/h7-10,13-16H,3-6,11-12,17H2,1-2H3,(H,26,27,29,30)
DM8UDSF CS CCCCC1=NN(C(=N1)CCCC)CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4
DM8UDSF IK LRZYXWIVLLNUPK-UHFFFAOYSA-N
DM8UDSF IU 5-[2-[4-[(3,5-dibutyl-1,2,4-triazol-1-yl)methyl]phenyl]phenyl]-2H-tetrazole
DMI0QZ3 ID DMI0QZ3
DMI0QZ3 DN SC-51146
DMI0QZ3 HS Terminated
DMI0QZ3 SN 141059-52-1; CHEMBL328492; 2H-1-Benzopyran-2-propanoicacid,7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy]propoxy]-3,4-dihydro-8-propyl-; ACMC-1C1U2; 7-(3-(2-(Cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid; AC1L52J5; SCHEMBL1890696; CTK4C2448; BDBM50052017; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-p
DMI0QZ3 DT Small molecular drug
DMI0QZ3 PC 196905
DMI0QZ3 MW 539.7
DMI0QZ3 FM C31H41NO7
DMI0QZ3 IC InChI=1S/C31H41NO7/c1-4-6-23-26(14-10-21-9-11-22(39-29(21)23)12-16-28(33)34)37-17-5-18-38-27-15-13-24(31(35)32-2)30(36-3)25(27)19-20-7-8-20/h10,13-15,20,22H,4-9,11-12,16-19H2,1-3H3,(H,32,35)(H,33,34)
DMI0QZ3 CS CCCC1=C(C=CC2=C1OC(CC2)CCC(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CC4CC4
DMI0QZ3 IK YWYUQSGYKDEAMJ-UHFFFAOYSA-N
DMI0QZ3 IU 3-[7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid
DMI0QZ3 CA CAS 141059-52-1
DMB26LO ID DMB26LO
DMB26LO DN SC-51316
DMB26LO HS Terminated
DMB26LO SN SC-51316; SC 51316; 133690-62-7; CHEMBL87778; 2,5-Dibutyl-2,4-dihydro-4-((2-(1H-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-3H-1,2,4-triazol-3-one; ACMC-20mv1m; AC1L2ZJY; SCHEMBL7398914; CTK4B8747; DTXSID30158321; BDBM50044355; 2,5-Dibutyl-2,4-dihydro-4-((2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4'-yl)methyl)-3H-1,2,4-triazol-3-one; L008865; 2,5-Dibutyl-4-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-[1,2,4]triazolidin-3-one; 2,5-dibutyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,2,4-triazol-3-one
DMB26LO CP GD Searle & Co
DMB26LO DT Small molecular drug
DMB26LO PC 131654
DMB26LO MW 431.5
DMB26LO FM C24H29N7O
DMB26LO IC InChI=1S/C24H29N7O/c1-3-5-11-22-27-31(16-6-4-2)24(32)30(22)17-18-12-14-19(15-13-18)20-9-7-8-10-21(20)23-25-28-29-26-23/h7-10,12-15H,3-6,11,16-17H2,1-2H3,(H,25,26,28,29)
DMB26LO CS CCCCC1=NN(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CCCC
DMB26LO IK STODEQQYGGTXOS-UHFFFAOYSA-N
DMB26LO IU 2,5-dibutyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,2,4-triazol-3-one
DMB26LO CA CAS 133690-62-7
DMB26LO DE Hypertension
DMWO107 ID DMWO107
DMWO107 DN SC-51895
DMWO107 HS Terminated
DMWO107 SN SC-51895; CHEMBL9714; SCHEMBL6568041; BDBM50281822; L006787
DMWO107 DT Small molecular drug
DMWO107 PC 9954408
DMWO107 MW 430.5
DMWO107 FM C25H30N6O
DMWO107 IC InChI=1S/C25H30N6O/c1-3-5-9-21-18-30(16-6-4-2)25(32)31(21)17-19-12-14-20(15-13-19)22-10-7-8-11-23(22)24-26-28-29-27-24/h7-8,10-15,18H,3-6,9,16-17H2,1-2H3,(H,26,27,28,29)
DMWO107 CS CCCCC1=CN(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CCCC
DMWO107 IK JYOGXGMOSXSRMV-UHFFFAOYSA-N
DMWO107 IU 1,4-dibutyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-2-one
DMKWJ59 ID DMKWJ59
DMKWJ59 DN SC-52150
DMKWJ59 HS Terminated
DMKWJ59 SN IDDB4363
DMKWJ59 CP GD Searle & Co
DMKWJ59 PC 2734614
DMKWJ59 MW 173.41
DMKWJ59 FM C6H9BClNO2
DMKWJ59 IC InChI=1S/C6H8BNO2.ClH/c8-6-3-1-5(2-4-6)7(9)10;/h1-4,9-10H,8H2;1H
DMKWJ59 CS B(C1=CC=C(C=C1)N)(O)O.Cl
DMKWJ59 IK QBYGJJSFMOVYOA-UHFFFAOYSA-N
DMKWJ59 IU (4-aminophenyl)boronic acid;hydrochloride
DMKWJ59 CA CAS 80460-73-7
DMKWJ59 DE Vomiting
DM2O8SF ID DM2O8SF
DM2O8SF DN SC-53116
DM2O8SF HS Terminated
DM2O8SF SN SC-53116; SC 53116; CHEMBL34291; SC53116; 4-amino-5-chloro-N-[[(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl]-2-methoxybenzamide; 141196-99-8; PDSP2_001604; AC1L30TD; GTPL238; SCHEMBL678624; ZINC3790774; BDBM50005833; SC49518; 4-Amino-5-chloro-N-((hexahydro-1H-pyrrolizin-1-yl)methyl)-2-methoxybenzamide hydrochloride; 4-Amino-5-chloro-N-((hexahydro-1H-pyrrolizin-1-yl)methyl)-2-methoxybenzamide (1S-cis)-; (1S-cis)-4-Amino-5-chloro-N-((hexahydro-1H-pyrrolizin-1-yl)methyl)-2-methoxybenzamide; NCGC00408826-01
DM2O8SF DT Small molecular drug
DM2O8SF PC 132337
DM2O8SF MW 323.82
DM2O8SF FM C16H22ClN3O2
DM2O8SF IC InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-9-10-4-6-20-5-2-3-14(10)20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14-/m0/s1
DM2O8SF CS COC1=CC(=C(C=C1C(=O)NC[C@@H]2CCN3[C@H]2CCC3)Cl)N
DM2O8SF IK GAYSOZKZPOVDSB-HZMBPMFUSA-N
DM2O8SF IU 4-amino-5-chloro-N-[[(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl]-2-methoxybenzamide
DM2O8SF CA CAS 141196-99-8
DM2O8SF DE Gastric motility disorder
DMSKHGQ ID DMSKHGQ
DMSKHGQ DN SC-53228
DMSKHGQ HS Terminated
DMSKHGQ SN SC 53228; CHEMBL419948; 153633-01-3; AC1L4BTY; SCHEMBL1447495; DTXSID40165384; BDBM50037390; 3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid; 3-{(S)-7-[3-(2-Cyclopropylmethyl-3-methoxy-4-methylcarbamoyl-phenoxy)-propoxy]-8-propyl-chroman-2-yl}-propionic acid; 2H-1-Benzopyran-2-propanoic acid, 7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-, (S)-
DMSKHGQ DT Small molecular drug
DMSKHGQ PC 204058
DMSKHGQ MW 539.7
DMSKHGQ FM C31H41NO7
DMSKHGQ IC InChI=1S/C31H41NO7/c1-4-6-23-26(14-10-21-9-11-22(39-29(21)23)12-16-28(33)34)37-17-5-18-38-27-15-13-24(31(35)32-2)30(36-3)25(27)19-20-7-8-20/h10,13-15,20,22H,4-9,11-12,16-19H2,1-3H3,(H,32,35)(H,33,34)/t22-/m0/s1
DMSKHGQ CS CCCC1=C(C=CC2=C1O[C@@H](CC2)CCC(=O)O)OCCCOC3=C(C(=C(C=C3)C(=O)NC)OC)CC4CC4
DMSKHGQ IK YWYUQSGYKDEAMJ-QFIPXVFZSA-N
DMSKHGQ IU 3-[(2S)-7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-(methylcarbamoyl)phenoxy]propoxy]-8-propyl-3,4-dihydro-2H-chromen-2-yl]propanoic acid
DMSKHGQ CA CAS 153633-01-3
DMSKHGQ DE Asthma
DM25MUA ID DM25MUA
DM25MUA DN SC-56525
DM25MUA HS Terminated
DM25MUA CP GD Searle & Co
DM25MUA PC 53416685
DM25MUA MW 356.24
DM25MUA FM C14H14BrNO3S
DM25MUA IC InChI=1S/C14H14BrNO3S/c1-10-6-5-8-12(19-2)14(10)16-20(17,18)13-9-4-3-7-11(13)15/h3-9,16H,1-2H3
DM25MUA CS CC1=C(C(=CC=C1)OC)NS(=O)(=O)C2=CC=CC=C2Br
DM25MUA IK ZENBMAKLSOHDBZ-UHFFFAOYSA-N
DM25MUA IU 2-bromo-N-(2-methoxy-6-methylphenyl)benzenesulfonamide
DM25MUA DE Hypertension
DM874YU ID DM874YU
DM874YU DN SC-58125
DM874YU HS Terminated
DM874YU SN SC-58125; 162054-19-5; SC 58125; C17H12F4N2O2S; 1-((4-Methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole; CHEBI:8983; CHEMBL274990; 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole; 1-[(4-METHYLSULFONYL)PHENYL]-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE; 5-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole; 5-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole; 1H-Pyrazole, 5-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-3-(tr
DM874YU DT Small molecular drug
DM874YU PC 115239
DM874YU MW 384.3
DM874YU FM C17H12F4N2O2S
DM874YU IC InChI=1S/C17H12F4N2O2S/c1-26(24,25)14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3
DM874YU CS CS(=O)(=O)C1=CC=C(C=C1)N2C(=CC(=N2)C(F)(F)F)C3=CC=C(C=C3)F
DM874YU IK JHBIMJKLBUMNAU-UHFFFAOYSA-N
DM874YU IU 5-(4-fluorophenyl)-1-(4-methylsulfonylphenyl)-3-(trifluoromethyl)pyrazole
DM874YU CA CAS 162054-19-5
DM874YU CB CHEBI:8983
DMVGK24 ID DMVGK24
DMVGK24 DN SC-58451
DMVGK24 HS Terminated
DMVGK24 SN SC-58451; SC58451; CHEMBL92154; SCHEMBL215231; ZINC6366; VZCIAZMKVAJRCL-UHFFFAOYSA-N; HY-U00239; BDBM50049041; CS-7410; 168433-84-9; 5-(4-Fluoro-phenyl)-6-(4-methanesulfonyl-phenyl)-spiro[2.4]hept-5-ene
DMVGK24 DT Small molecular drug
DMVGK24 PC 9851770
DMVGK24 MW 342.4
DMVGK24 FM C20H19FO2S
DMVGK24 IC InChI=1S/C20H19FO2S/c1-24(22,23)17-8-4-15(5-9-17)19-13-20(10-11-20)12-18(19)14-2-6-16(21)7-3-14/h2-9H,10-13H2,1H3
DMVGK24 CS CS(=O)(=O)C1=CC=C(C=C1)C2=C(CC3(C2)CC3)C4=CC=C(C=C4)F
DMVGK24 IK VZCIAZMKVAJRCL-UHFFFAOYSA-N
DMVGK24 IU 5-(4-fluorophenyl)-6-(4-methylsulfonylphenyl)spiro[2.4]hept-5-ene
DMW9H4A ID DMW9H4A
DMW9H4A DN SCH 50911
DMW9H4A HS Terminated
DMW9H4A SN SCH 50911; 160415-07-6; UNII-13OB0KEU61; 733717-87-8; 13OB0KEU61; SCH50911; (2S)-(+)-5,5-Dimethyl-2-morpholineacetic acid; SCH-50911; NCGC00024915-02; [(2s)-5,5-Dimethylmorpholin-2-Yl]acetic Acid; DSSTox_RID_81045; DSSTox_CID_25670; DSSTox_GSID_45670; 2-[(2S)-5,5-dimethylmorpholin-2-yl]acetic acid; SCH-50911 free base; CAS-160415-07-6; Spectrum_001764; SCH 50911 free base; AC1NSKM9; Biomol-NT_000243; 2-Morpholineacetic acid, 5,5-dimethyl-, (2S)-; KBioSS_002245; SCHEMBL340881; BPBio1_000749; GTPL1075; ZINC6164; CHEMBL1895916
DMW9H4A DT Small molecular drug
DMW9H4A PC 5311429
DMW9H4A MW 173.21
DMW9H4A FM C8H15NO3
DMW9H4A IC InChI=1S/C8H15NO3/c1-8(2)5-12-6(4-9-8)3-7(10)11/h6,9H,3-5H2,1-2H3,(H,10,11)/t6-/m0/s1
DMW9H4A CS CC1(CO[C@H](CN1)CC(=O)O)C
DMW9H4A IK SEYCKMQSPUVYEF-LURJTMIESA-N
DMW9H4A IU 2-[(2S)-5,5-dimethylmorpholin-2-yl]acetic acid
DMW9H4A CA CAS 733717-87-8
DMW9H4A DE Absence seizure
DM037SB ID DM037SB
DM037SB DN Sch-207758
DM037SB HS Terminated
DM037SB CP Schering-Plough Corp
DM037SB DE Solid tumour/cancer
DMXBJCY ID DMXBJCY
DMXBJCY DN Sch-40120
DMXBJCY HS Terminated
DMXBJCY SN AC1MIW6C; SCHEMBL9535601; 10-(3-Chlorophenyl)-6,8,9,10-tetrahydrobenzo(b)(1,8)-naphthyridine-5(7H)-one; 113077-44-4; 5-(3-chlorophenyl)-7,8,9,10-tetrahydrobenzo[c][1,8]naphthyridin-6-one; Benzo(c)(1,8)naphthyridin-6(5H)-one, 5-(3-chlorophenyl)-7,8,9,10-tetrahydro-
DMXBJCY CP Schering-Plough Corp
DMXBJCY DT Small molecular drug
DMXBJCY PC 184227
DMXBJCY MW 310.8
DMXBJCY FM C18H15ClN2O
DMXBJCY IC InChI=1S/C18H15ClN2O/c19-12-5-3-6-13(11-12)21-16-9-2-1-7-14(16)17(22)15-8-4-10-20-18(15)21/h3-6,8,10-11H,1-2,7,9H2
DMXBJCY CS C1CCC2=C(C1)C(=O)C3=C(N2C4=CC(=CC=C4)Cl)N=CC=C3
DMXBJCY IK SLPWZBSWUHLVRY-UHFFFAOYSA-N
DMXBJCY IU 10-(3-chlorophenyl)-6,7,8,9-tetrahydrobenzo[b][1,8]naphthyridin-5-one
DMXBJCY CA CAS 110545-79-4
DMXBJCY DE Pruritus
DM3G5IB ID DM3G5IB
DM3G5IB DN Sch-40338
DM3G5IB HS Terminated
DM3G5IB SN CHEMBL326821; AIESXMXVDNOKQF-UHFFFAOYSA-N; GTPL1854; SCHEMBL8877591; BDBM50073173; SCH 40338; 1-[4-(8-Chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-piperazin-1-yl]-ethanone; 8-CHLORO-11-(1-ACETYL-4-PIPERAZINYL)-6,11-DIHYDRO-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE
DM3G5IB CP Schering-Plough Corp
DM3G5IB DT Small molecular drug
DM3G5IB PC 9950564
DM3G5IB MW 355.9
DM3G5IB FM C20H22ClN3O
DM3G5IB IC InChI=1S/C20H22ClN3O/c1-14(25)23-9-11-24(12-10-23)20-18-7-6-17(21)13-16(18)5-4-15-3-2-8-22-19(15)20/h2-3,6-8,13,20H,4-5,9-12H2,1H3
DM3G5IB CS CC(=O)N1CCN(CC1)C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl
DM3G5IB IK AIESXMXVDNOKQF-UHFFFAOYSA-N
DM3G5IB IU 1-[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl)piperazin-1-yl]ethanone
DM3G5IB DE Allergy
DMUL4VX ID DMUL4VX
DMUL4VX DN SCH-44342
DMUL4VX HS Terminated
DMUL4VX SN SCH-44342; CHEMBL289404; SCH 44342; sch44342; SCHEMBL2732013; BDBM14454; 1-(4-pyridylacetyl)-4-(8-chloro-5,6-dihydro-11h-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine
DMUL4VX DT Small molecular drug
DMUL4VX PC 9845545
DMUL4VX MW 429.9
DMUL4VX FM C26H24ClN3O
DMUL4VX IC InChI=1S/C26H24ClN3O/c27-22-5-6-23-21(17-22)4-3-20-2-1-11-29-26(20)25(23)19-9-14-30(15-10-19)24(31)16-18-7-12-28-13-8-18/h1-2,5-8,11-13,17H,3-4,9-10,14-16H2
DMUL4VX CS C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)C(=O)CC4=CC=NC=C4)C5=C1C=CC=N5
DMUL4VX IK KIFXOXSGYMUANJ-UHFFFAOYSA-N
DMUL4VX IU 1-[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]-2-pyridin-4-ylethanone
DME9Q3V ID DME9Q3V
DME9Q3V DN Sch-45752
DME9Q3V HS Terminated
DME9Q3V SN Cephalochromin; MLS000876993; CHEMBL463175; NSC627953; NSC201419; 25908-26-3; SMR000440611; cefalochromin; 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one; Sch 45752; AC1Q6DTF; AC1L4N2K; SCHEMBL1111561; MEGxm0_000312; cid_160115; ACon0_000585; ACon1_000126; MolPort-001-739-590; HMS2270H11; BDBM50269745; NSC-201419; NSC-627953; MCULE-6609850631; NCGC00180856-01; SR-01000758207; SR-01000758207-2; CEPHALOCHROMIN
DME9Q3V CP Schering-Plough Corp
DME9Q3V DT Small molecular drug
DME9Q3V PC 160115
DME9Q3V MW 518.5
DME9Q3V FM C28H22O10
DME9Q3V IC InChI=1S/C28H22O10/c1-9-3-13(29)25-19(37-9)5-11-21(15(31)7-17(33)23(11)27(25)35)22-12-6-20-26(14(30)4-10(2)38-20)28(36)24(12)18(34)8-16(22)32/h5-10,31-36H,3-4H2,1-2H3
DME9Q3V CS CC1CC(=O)C2=C(O1)C=C3C(=C2O)C(=CC(=C3C4=C(C=C(C5=C(C6=C(C=C54)OC(CC6=O)C)O)O)O)O)O
DME9Q3V IK JGQBYBXYRUCBQY-UHFFFAOYSA-N
DME9Q3V IU 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one
DME9Q3V CA CAS 25908-26-3
DME9Q3V DE Asthma
DMEWLZ7 ID DMEWLZ7
DMEWLZ7 DN SCH-54470
DMEWLZ7 HS Terminated
DMEWLZ7 SN CHEMBL43370; SCH-54470; BDBM50287430; (S)-2-[(1-{[(R)-1-((S)-6-Amino-2-methanesulfonylamino-hexanoylamino)-2-phenyl-ethyl]-hydroxy-phosphinoylmethyl}-cyclopentanecarbonyl)-amino]-3-(1H-indol-3-yl)-propionic acid
DMEWLZ7 DT Small molecular drug
DMEWLZ7 PC 9810328
DMEWLZ7 MW 703.8
DMEWLZ7 FM C33H46N5O8PS
DMEWLZ7 IC InChI=1S/C33H46N5O8PS/c1-48(45,46)38-27(15-7-10-18-34)30(39)37-29(19-23-11-3-2-4-12-23)47(43,44)22-33(16-8-9-17-33)32(42)36-28(31(40)41)20-24-21-35-26-14-6-5-13-25(24)26/h2-6,11-14,21,27-29,35,38H,7-10,15-20,22,34H2,1H3,(H,36,42)(H,37,39)(H,40,41)(H,43,44)/t27-,28-,29+/m0/s1
DMEWLZ7 CS CS(=O)(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)P(=O)(CC2(CCCC2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)O
DMEWLZ7 IK UBQFBYMIHFXWBF-YTCPBCGMSA-N
DMEWLZ7 IU (2S)-2-[[1-[[[(1R)-1-[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]-2-phenylethyl]-hydroxyphosphoryl]methyl]cyclopentanecarbonyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMGCYPE ID DMGCYPE
DMGCYPE DN Sch-57790
DMGCYPE HS Terminated
DMGCYPE SN SCH-57790; CHEMBL73341; SCH57790; GTPL350; SCHEMBL194921; SCH 57790; BDBM50092317; 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile; L018294
DMGCYPE CP Schering-Plough Corp
DMGCYPE DT Small molecular drug
DMGCYPE PC 9867750
DMGCYPE MW 437.6
DMGCYPE FM C25H31N3O2S
DMGCYPE IC InChI=1S/C25H31N3O2S/c1-30-22-9-13-24(14-10-22)31(29)23-11-7-20(8-12-23)25(19-26)28-17-15-27(16-18-28)21-5-3-2-4-6-21/h7-14,21,25H,2-6,15-18H2,1H3
DMGCYPE CS COC1=CC=C(C=C1)S(=O)C2=CC=C(C=C2)C(C#N)N3CCN(CC3)C4CCCCC4
DMGCYPE IK BFELQLHLUNQIHL-UHFFFAOYSA-N
DMGCYPE IU 2-(4-cyclohexylpiperazin-1-yl)-2-[4-(4-methoxyphenyl)sulfinylphenyl]acetonitrile
DMGCYPE DE Alzheimer disease
DMFZNUA ID DMFZNUA
DMFZNUA DN SCR-44001
DMFZNUA HS Terminated
DMFZNUA SN MTOR pathway inhibitors (cancer); PI3K modulators, BioImage; SCR-0044001; SCR-0334654; SCR-0335319; TOP-216; MTOR pathway inhibitors (cancer), TopoTarget; MTOR pathway inhibitors (cancer), BioImage/TopoTarget
DMFZNUA CP BioImage A/S
DMFZNUA DE Solid tumour/cancer
DMPUVFH ID DMPUVFH
DMPUVFH DN SDZ 216-525
DMPUVFH HS Terminated
DMPUVFH SN Sdz 216-525; Sdz-216-525; 141533-35-9; methyl 4-[4-[4-(1,1,3-trioxo-1,2-benzothiazol-2-yl)butyl]piperazin-1-yl]-1H-indole-2-carboxylate; SDZ216-525; AC1MI2WY; GTPL78; SCHEMBL1041165; BDBM82367; DTXSID10161757; PDSP2_000563; PDSP1_000565; SDZ-216525; SDZ 216,525; Methyl 4-(4-(4-(1,1,3-trioxo-2H-1,2-benzoisothiazol-2-yl)butyl)-1-piperazinyl)-1H-indole-2-carboxylate; CAS_141533-35-9; L006004; 1H-Indole-2-carboxylic acid, 4-(4-(4-(3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl)-1-piperazinyl)-, methyl ester, S,S-dioxide
DMPUVFH DT Small molecular drug
DMPUVFH PC 3037456
DMPUVFH MW 496.6
DMPUVFH FM C25H28N4O5S
DMPUVFH IC InChI=1S/C25H28N4O5S/c1-34-25(31)21-17-19-20(26-21)8-6-9-22(19)28-15-13-27(14-16-28)11-4-5-12-29-24(30)18-7-2-3-10-23(18)35(29,32)33/h2-3,6-10,17,26H,4-5,11-16H2,1H3
DMPUVFH CS COC(=O)C1=CC2=C(N1)C=CC=C2N3CCN(CC3)CCCCN4C(=O)C5=CC=CC=C5S4(=O)=O
DMPUVFH IK LPPRLWFUMJHAKF-UHFFFAOYSA-N
DMPUVFH IU methyl 4-[4-[4-(1,1,3-trioxo-1,2-benzothiazol-2-yl)butyl]piperazin-1-yl]-1H-indole-2-carboxylate
DMPUVFH CA CAS 141533-35-9
DMY1KE8 ID DMY1KE8
DMY1KE8 DN SDZ-224-015
DMY1KE8 HS Terminated
DMY1KE8 SN VE-13045
DMY1KE8 CP Sandoz Research Institute
DMY1KE8 PC 101925102
DMY1KE8 MW 624.5
DMY1KE8 FM C28H31Cl2N3O9
DMY1KE8 IC InChI=1S/C28H31Cl2N3O9/c1-16(2)23(32-28(39)42-14-18-8-5-4-6-9-18)25(37)31-17(3)24(36)33-26(40-13-12-34)21(35)15-41-27(38)22-19(29)10-7-11-20(22)30/h4-12,16-17,23,26H,13-15H2,1-3H3,(H,31,37)(H,32,39)(H,33,36)/t17-,23-,26-/m0/s1
DMY1KE8 CS C[C@@H](C(=O)N[C@H](C(=O)COC(=O)C1=C(C=CC=C1Cl)Cl)OCC=O)NC(=O)[C@H](C(C)C)NC(=O)OCC2=CC=CC=C2
DMY1KE8 IK ABGURXXQCVTOBD-RUJAXMSRSA-N
DMY1KE8 IU [(3S)-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-2-oxo-3-(2-oxoethoxy)propyl] 2,6-dichlorobenzoate
DMY1KE8 DE Rheumatoid arthritis
DMPZLKC ID DMPZLKC
DMPZLKC DN SDZ-249482
DMPZLKC HS Terminated
DMPZLKC SN IDDB15566
DMPZLKC CP Novartis AG
DMPZLKC DE Pain
DMAT657 ID DMAT657
DMAT657 DN SDZ-62-826
DMAT657 HS Terminated
DMAT657 CP Novartis AG
DMAT657 PC 1393
DMAT657 MW 524.7
DMAT657 FM C27H59NO6P+
DMAT657 IC InChI=1S/C27H58NO6P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-23-32-25-27(31-5)26-34-35(29,30)33-24-22-28(2,3)4/h27H,6-26H2,1-5H3/p+1
DMAT657 CS CCCCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCC[N+](C)(C)C)OC
DMAT657 IK MHFRGQHAERHWKZ-UHFFFAOYSA-O
DMAT657 IU 2-[hydroxy-(2-methoxy-3-octadecoxypropoxy)phosphoryl]oxyethyl-trimethylazanium
DMAT657 DE Solid tumour/cancer
DM2CBTU ID DM2CBTU
DM2CBTU DN SDZ-64-412
DM2CBTU HS Terminated
DM2CBTU SN SDZ-64-412; PAF-AN-1; CHEMBL449395; 5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline; SDZ-64412; 115622-31-6; 5-{4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl}-2,3-dihydroimidazo[2,1-a]isoquinoline; AC1L4M0I; SCHEMBL9118339; GTPL1855; CTK6J7710; BDBM50041921; HY-U00040; CS-7323; L024111
DM2CBTU DT Small molecular drug
DM2CBTU PC 159547
DM2CBTU MW 440.5
DM2CBTU FM C28H28N2O3
DM2CBTU IC InChI=1S/C28H28N2O3/c1-31-25-16-20(17-26(32-2)27(25)33-3)9-8-19-10-12-21(13-11-19)24-18-22-6-4-5-7-23(22)28-29-14-15-30(24)28/h4-7,10-13,16-18H,8-9,14-15H2,1-3H3
DM2CBTU CS COC1=CC(=CC(=C1OC)OC)CCC2=CC=C(C=C2)C3=CC4=CC=CC=C4C5=NCCN35
DM2CBTU IK FKRBSORUVOGNEK-UHFFFAOYSA-N
DM2CBTU IU 5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline
DMBY6CQ ID DMBY6CQ
DMBY6CQ DN SDZ-87-469
DMBY6CQ HS Terminated
DMBY6CQ SN SDZ-87-469; AC1OCEZP; CHEMBL328466; SCHEMBL10689408; SDZ-87469
DMBY6CQ CP Novartis AG
DMBY6CQ DT Small molecular drug
DMBY6CQ PC 6918069
DMBY6CQ MW 368.4
DMBY6CQ FM C19H23Cl2NS
DMBY6CQ IC InChI=1S/C19H22ClNS.ClH/c1-19(2,3)11-6-5-7-12-21(4)13-15-9-8-10-16-17(20)14-22-18(15)16;/h5,7-10,14H,12-13H2,1-4H3;1H/b7-5+;
DMBY6CQ CS CC(C)(C)C#C/C=C/CN(C)CC1=C2C(=CC=C1)C(=CS2)Cl.Cl
DMBY6CQ IK INNKFGGCJAUIMK-GZOLSCHFSA-N
DMBY6CQ IU (E)-N-[(3-chloro-1-benzothiophen-7-yl)methyl]-N,6,6-trimethylhept-2-en-4-yn-1-amine;hydrochloride
DMBY6CQ DE Coronary artery disease
DMN5IY7 ID DMN5IY7
DMN5IY7 DN SDZ-ICM-567
DMN5IY7 HS Terminated
DMN5IY7 SN 5-HT3 antagonist, Novartis
DMN5IY7 CP Novartis AG
DMN5IY7 DT Small molecular drug
DMN5IY7 PC 9972931
DMN5IY7 MW 314.4
DMN5IY7 FM C18H22N2O3
DMN5IY7 IC InChI=1S/C18H22N2O3/c1-20-11-6-7-12(20)9-13(8-11)23-18(21)15-10-19-17-14(15)4-3-5-16(17)22-2/h3-5,10-13,19H,6-9H2,1-2H3/t11-,12+,13?
DMN5IY7 CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=C3C=CC=C4OC
DMN5IY7 IK GMKZFWHCKJSRHX-FUNVUKJBSA-N
DMN5IY7 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 7-methoxy-1H-indole-3-carboxylate
DMN5IY7 CA CAS 143207-25-4
DMN5IY7 DE Anxiety disorder
DMSZJUM ID DMSZJUM
DMSZJUM DN SDZ-ISQ-844
DMSZJUM HS Terminated
DMSZJUM SN 143526-87-8; Sdz isq 844; Sdz-isq-844; SDZ ISQ-844; SCHEMBL7298437; AC1L317P; CTK4C3695; 3-Isoquinolinemethanol,1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (3S)-; AKOS030566039; 6,7-Dimethoxy-1-(3,4-dimethoxyphenyl)-3-hydroxymethyl-3,4-dihydroisoquinoline; (S)-1-(3,5-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1-(3,5-dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-, (S)-
DMSZJUM CP Novartis AG
DMSZJUM DT Small molecular drug
DMSZJUM PC 132565
DMSZJUM MW 357.4
DMSZJUM FM C20H23NO5
DMSZJUM IC InChI=1S/C20H23NO5/c1-23-15-6-13(7-16(9-15)24-2)20-17-10-19(26-4)18(25-3)8-12(17)5-14(11-22)21-20/h6-10,14,22H,5,11H2,1-4H3/t14-/m0/s1
DMSZJUM CS COC1=CC(=CC(=C1)C2=N[C@@H](CC3=CC(=C(C=C32)OC)OC)CO)OC
DMSZJUM IK GHBUMWHHZFGRDI-AWEZNQCLSA-N
DMSZJUM IU [(3S)-1-(3,5-dimethoxyphenyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-3-yl]methanol
DMSZJUM CA CAS 143526-87-8
DMSZJUM DE Asthma
DMKCXBJ ID DMKCXBJ
DMKCXBJ DN SDZ-MTH-958
DMKCXBJ HS Terminated
DMKCXBJ SN IDDB8852
DMKCXBJ CP Novartis AG
DMKCXBJ DE Artery stenosis
DM48MCL ID DM48MCL
DM48MCL DN SDZ-PSD-958
DM48MCL HS Terminated
DM48MCL CP Sandoz Pharma Ltd
DM48MCL PC 9906075
DM48MCL MW 342.9
DM48MCL FM C20H23ClN2O
DM48MCL IC InChI=1S/C20H23ClN2O/c1-13-10-15(21)6-7-17(13)23-9-8-22(2)18-11-14-4-3-5-20(24)16(14)12-19(18)23/h3-7,10,18-19,24H,8-9,11-12H2,1-2H3/t18-,19-/m1/s1
DM48MCL CS CC1=C(C=CC(=C1)Cl)N2CCN([C@H]3[C@H]2CC4=C(C3)C=CC=C4O)C
DM48MCL IK VCFAZLUWIBQVRD-RTBURBONSA-N
DM48MCL IU (4aR,10aR)-4-(4-chloro-2-methylphenyl)-1-methyl-2,3,4a,5,10,10a-hexahydrobenzo[g]quinoxalin-6-ol
DM48MCL DE Psychiatric disorder
DMXHW91 ID DMXHW91
DMXHW91 DN SDZ-SER-082
DMXHW91 HS Terminated
DMXHW91 SN SDZ SER-082; Biomol-NT_000136; GTPL195; CHEMBL316069; BPBio1_000024; SCHEMBL13073064; BDBM85099; ZINC16077; SER-082; CAS_141474-54-6; BRD-K31339597-051-01-2
DMXHW91 CP Novartis AG
DMXHW91 DT Small molecular drug
DMXHW91 PC 9859407
DMXHW91 MW 228.33
DMXHW91 FM C15H20N2
DMXHW91 IC InChI=1S/C15H20N2/c1-16-7-5-12-9-17-8-6-11-3-2-4-13(15(11)17)14(12)10-16/h2-4,12,14H,5-10H2,1H3/t12-,14-/m1/s1
DMXHW91 CS CN1CC[C@@H]2CN3CCC4=C3C(=CC=C4)[C@@H]2C1
DMXHW91 IK YASBOGFWAMXINH-TZMCWYRMSA-N
DMXHW91 IU (2R,7S)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene
DMXHW91 CA CAS 141474-54-6
DMXHW91 DE Neurological disorder
DM4ESAP ID DM4ESAP
DM4ESAP DN Selenotifen
DM4ESAP HS Terminated
DM4ESAP SN BN-52256
DM4ESAP CP Ipsen
DM4ESAP DE Asthma
DMXRU72 ID DMXRU72
DMXRU72 DN SEP-227900
DMXRU72 HS Terminated
DMXRU72 CP Sunovion Pharmaceuticals Inc
DMXRU72 DE Cognitive impairment
DMTBWU1 ID DMTBWU1
DMTBWU1 DN Seridopidine
DMTBWU1 HS Terminated
DMTBWU1 SN ACR-343
DMTBWU1 CP A Carlsson Research AB
DMTBWU1 DT Small molecular drug
DMTBWU1 PC 11572784
DMTBWU1 MW 285.38
DMTBWU1 FM C14H20FNO2S
DMTBWU1 IC InChI=1S/C14H20FNO2S/c1-3-16-6-4-11(5-7-16)12-8-13(15)10-14(9-12)19(2,17)18/h8-11H,3-7H2,1-2H3
DMTBWU1 CS CCN1CCC(CC1)C2=CC(=CC(=C2)S(=O)(=O)C)F
DMTBWU1 IK PHRDGRSMZPOCAB-UHFFFAOYSA-N
DMTBWU1 IU 1-ethyl-4-(3-fluoro-5-methylsulfonylphenyl)piperidine
DMTBWU1 CA CAS 883631-51-4
DMTBWU1 DE Neurological disorder
DMT43AI ID DMT43AI
DMT43AI DN SIB-1508Y
DMT43AI HS Terminated
DMT43AI SN CHEMBL111580; 3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine; 179120-51-5; 5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine; 5-Ethynyl Nicotine; 179120-92-4; 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine; AC1L326X; SCHEMBL1155706; BDBM86544; NUPUDYKEEJNZRG-UHFFFAOYSA-N; CHEBI:125396; NSC_6442277; CAS_192231-16-6; 3-ethynyl-5-(1-methylpyrrolidin-2-yl)-pyridine; 3-(1-Methylpyrrolidine-2-yl)-5-ethynylpyridine; A812432
DMT43AI DT Small molecular drug
DMT43AI PC 3036156
DMT43AI MW 186.25
DMT43AI FM C12H14N2
DMT43AI IC InChI=1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1
DMT43AI CS CN1CCC[C@H]1C2=CN=CC(=C2)C#C
DMT43AI IK NUPUDYKEEJNZRG-LBPRGKRZSA-N
DMT43AI IU 3-ethynyl-5-[(2S)-1-methylpyrrolidin-2-yl]pyridine
DMT43AI CA CAS 179120-92-4
DMT43AI DE Parkinson disease
DMO4WB8 ID DMO4WB8
DMO4WB8 DN SIB-1663
DMO4WB8 HS Terminated
DMO4WB8 DT Small molecular drug
DMO4WB8 PC 10198317
DMO4WB8 MW 218.29
DMO4WB8 FM C13H18N2O
DMO4WB8 IC InChI=1S/C13H18N2O/c1-15-6-5-9-3-4-10-7-12(16-2)14-8-11(10)13(9)15/h7-9,13H,3-6H2,1-2H3
DMO4WB8 CS CN1CCC2C1C3=CN=C(C=C3CC2)OC
DMO4WB8 IK MMHQNOZJLLYHKX-UHFFFAOYSA-N
DMO4WB8 IU 7-methoxy-1-methyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-h]isoquinoline
DM6MSKT ID DM6MSKT
DM6MSKT DN SIB-1765F
DM6MSKT HS Terminated
DM6MSKT SN SIB 1765F; Pyridine, 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-, (E)-2-butenedioate (1:1); Pyridine, 3-ethynyl-5-(1-methyl-2-pyrrolidinyl)-, (2E)-2-butenedioate (1:1); C12H14N2.C4H4O4; AC1O5WWQ; SCHEMBL194945; SCHEMBL3099334; SIB 1508Y, fumarate, E-isomer; 179120-52-6; LS-173698
DM6MSKT DT Small molecular drug
DM6MSKT PC 6442277
DM6MSKT MW 302.32
DM6MSKT FM C16H18N2O4
DM6MSKT IC InChI=1S/C12H14N2.C4H4O4/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2;5-3(6)1-2-4(7)8/h1,7-9,12H,4-6H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
DM6MSKT CS CN1CCCC1C2=CN=CC(=C2)C#C.C(=C/C(=O)O)\\C(=O)O
DM6MSKT IK BCPPKHPWLRPWBJ-WLHGVMLRSA-N
DM6MSKT IU (E)-but-2-enedioic acid;3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine
DM6MSKT CA CAS 179120-52-6
DM98K76 ID DM98K76
DM98K76 DN Siguazodan
DM98K76 HS Terminated
DM98K76 SN SKF-94836
DM98K76 CP SmithKline Beecham plc
DM98K76 DT Small molecular drug
DM98K76 PC 72124
DM98K76 MW 284.32
DM98K76 FM C14H16N6O
DM98K76 IC InChI=1S/C14H16N6O/c1-9-7-12(21)19-20-13(9)10-3-5-11(6-4-10)18-14(16-2)17-8-15/h3-6,9H,7H2,1-2H3,(H,19,21)(H2,16,17,18)
DM98K76 CS CC1CC(=O)NN=C1C2=CC=C(C=C2)NC(=NC)NC#N
DM98K76 IK NUHPODZZKHQQET-UHFFFAOYSA-N
DM98K76 IU 1-cyano-2-methyl-3-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]guanidine
DM98K76 CA CAS 115344-47-3
DM98K76 CB CHEBI:91791
DM98K76 DE Allergy
DMBZ7SF ID DMBZ7SF
DMBZ7SF DN SIM-6080
DMBZ7SF HS Terminated
DMBZ7SF SN N1,N2-Dimethyl-N1-[3,3-di(4-fluorophenyl)propyl]-N2-(3,4,5-trimethoxybenzyl)ethylenediamine
DMBZ7SF DT Small molecular drug
DMBZ7SF PC 602534
DMBZ7SF MW 498.6
DMBZ7SF FM C29H36F2N2O3
DMBZ7SF IC InChI=1S/C29H36F2N2O3/c1-32(16-17-33(2)20-21-18-27(34-3)29(36-5)28(19-21)35-4)15-14-26(22-6-10-24(30)11-7-22)23-8-12-25(31)13-9-23/h6-13,18-19,26H,14-17,20H2,1-5H3
DMBZ7SF CS CN(CCC(C1=CC=C(C=C1)F)C2=CC=C(C=C2)F)CCN(C)CC3=CC(=C(C(=C3)OC)OC)OC
DMBZ7SF IK NOMSFNRBXCWAIE-UHFFFAOYSA-N
DMBZ7SF IU N-[3,3-bis(4-fluorophenyl)propyl]-N,N'-dimethyl-N'-[(3,4,5-trimethoxyphenyl)methyl]ethane-1,2-diamine
DMBZ7SF CA CAS 118790-68-4
DMBZ7SF DE Angina pectoris
DM5SBUJ ID DM5SBUJ
DM5SBUJ DN Sipoglitazar
DM5SBUJ HS Terminated
DM5SBUJ SN TAK-654
DM5SBUJ CP Takeda Pharmaceutical Co Ltd
DM5SBUJ PC 9825652
DM5SBUJ MW 463.6
DM5SBUJ FM C25H25N3O4S
DM5SBUJ IC InChI=1S/C25H25N3O4S/c1-2-31-24-20(10-13-23(29)30)15-28(27-24)14-18-8-11-22(12-9-18)32-16-21-17-33-25(26-21)19-6-4-3-5-7-19/h3-9,11-12,15,17H,2,10,13-14,16H2,1H3,(H,29,30)
DM5SBUJ CS CCOC1=NN(C=C1CCC(=O)O)CC2=CC=C(C=C2)OCC3=CSC(=N3)C4=CC=CC=C4
DM5SBUJ IK SRFCAWATPLCLMG-UHFFFAOYSA-N
DM5SBUJ IU 3-[3-ethoxy-1-[[4-[(2-phenyl-1,3-thiazol-4-yl)methoxy]phenyl]methyl]pyrazol-4-yl]propanoic acid
DM5SBUJ CA CAS 342026-92-0
DM5SBUJ DE Diabetic complication
DMB6T7K ID DMB6T7K
DMB6T7K DN Siramesine
DMB6T7K HS Terminated
DMB6T7K SN Siramesine; 147817-50-3; Lu-28-179; UNII-3IX8CWR24V; Lu 28-179; Siramesine(Lu 28-179); 3IX8CWR24V; CHEMBL61479; 1'-(4-(1-(4-fluorophenyl)-1H-indol-3-yl)butyl)-3H-spiro[isobenzofuran-1,4'-piperidine]; Siramesine [INN]; SCHEMBL2090079; QCR-66; C30H31FN2O; EX-A355; DTXSID90163810; XWAONOGAGZNUSF-UHFFFAOYSA-N; ZINC1533883; BCP08745; 4042AH; BDBM50035105; AKOS027251054; CS-1920; API0014138; NCGC00370727-06; HY-14221; 163630-80-6; 1'-(4-(1-(p-Fluorophenyl)indol-3-yl)butyl)spiro(phthalan-1,4'-piperidine)
DMB6T7K DT Small molecular drug
DMB6T7K PC 9829526
DMB6T7K MW 454.6
DMB6T7K FM C30H31FN2O
DMB6T7K IC InChI=1S/C30H31FN2O/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21H,5-7,16-20,22H2
DMB6T7K CS C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F
DMB6T7K IK XWAONOGAGZNUSF-UHFFFAOYSA-N
DMB6T7K IU 1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine]
DMB6T7K CA CAS 147817-50-3
DMG90YW ID DMG90YW
DMG90YW DN Siratiazem
DMG90YW HS Terminated
DMG90YW SN LR-A-113
DMG90YW CP Istituto Lusofarmaco D`Italia SpA
DMG90YW DT Small molecular drug
DMG90YW PC 65989
DMG90YW MW 442.6
DMG90YW FM C24H30N2O4S
DMG90YW IC InChI=1S/C24H30N2O4S/c1-16(2)25(4)14-15-26-20-8-6-7-9-21(20)31-23(22(24(26)28)30-17(3)27)18-10-12-19(29-5)13-11-18/h6-13,16,22-23H,14-15H2,1-5H3/t22-,23+/m1/s1
DMG90YW CS CC(C)N(C)CCN1C2=CC=CC=C2S[C@H]([C@H](C1=O)OC(=O)C)C3=CC=C(C=C3)OC
DMG90YW IK VVZILLNNYUUOIY-PKTZIBPZSA-N
DMG90YW IU [(2S,3S)-2-(4-methoxyphenyl)-5-[2-[methyl(propan-2-yl)amino]ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMG90YW CA CAS 138778-28-6
DMG90YW DE Angina pectoris
DM6X430 ID DM6X430
DM6X430 DN SJA-6017
DM6X430 HS Terminated
DM6X430 SN Calpain Inhibitor VI; SJA-6017; SJA6017; N-(4-Fluorophenylsulfonyl)-L-Valyl-L-Leucinal; CHEMBL288365; SCHEMBL1907361; ZINC1544687; BDBM50114340; J-012283; (S)-2-(4-fluorophenylsulfonamido)-3-methyl-N-((S)-4-methyl-1-oxopentan-2-yl)butanamide; (S)-2-(4-Fluoro-benzenesulfonylamino)-N-((S)-1-formyl-3-methyl-butyl)-3-methyl-butyramide
DM6X430 DT Small molecular drug
DM6X430 PC 9885817
DM6X430 MW 372.5
DM6X430 FM C17H25FN2O4S
DM6X430 IC InChI=1S/C17H25FN2O4S/c1-11(2)9-14(10-21)19-17(22)16(12(3)4)20-25(23,24)15-7-5-13(18)6-8-15/h5-8,10-12,14,16,20H,9H2,1-4H3,(H,19,22)/t14-,16-/m0/s1
DM6X430 CS CC(C)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NS(=O)(=O)C1=CC=C(C=C1)F
DM6X430 IK WSJWUIDLGZAXID-HOCLYGCPSA-N
DM6X430 IU (2S)-2-[(4-fluorophenyl)sulfonylamino]-3-methyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]butanamide
DM6X430 CA CAS 190274-53-4
DMRADBU ID DMRADBU
DMRADBU DN SK&F-104078
DMRADBU HS Terminated
DMRADBU SN SK-104078
DMRADBU DT Small molecular drug
DMRADBU PC 122295
DMRADBU MW 279.8
DMRADBU FM C16H22ClNO
DMRADBU IC InChI=1S/C16H22ClNO/c1-12(2)8-11-19-16-5-4-15(17)13-6-9-18(3)10-7-14(13)16/h4-5,8H,6-7,9-11H2,1-3H3
DMRADBU CS CC(=CCOC1=C2CCN(CCC2=C(C=C1)Cl)C)C
DMRADBU IK MBYSTKNEMJZSIK-UHFFFAOYSA-N
DMRADBU IU 6-chloro-3-methyl-9-(3-methylbut-2-enoxy)-1,2,4,5-tetrahydro-3-benzazepine
DMRADBU CA CAS 110857-22-2
DMRADBU CB CHEBI:125603
DMN91EK ID DMN91EK
DMN91EK DN SK&F-104856
DMN91EK HS Terminated
DMN91EK SN SK-104856
DMN91EK DT Small molecular drug
DMN91EK PC 126225
DMN91EK MW 263.8
DMN91EK FM C14H14ClNS
DMN91EK IC InChI=1S/C14H14ClNS/c1-3-12-10-8-16(2)7-6-9-11(15)4-5-13(17-12)14(9)10/h3-5H,1,6-8H2,2H3
DMN91EK CS CN1CCC2=C(C=CC3=C2C(=C(S3)C=C)C1)Cl
DMN91EK IK WKXSXFYQPCWZOS-UHFFFAOYSA-N
DMN91EK IU 7-chloro-2-ethenyl-11-methyl-3-thia-11-azatricyclo[6.4.1.04,13]trideca-1,4(13),5,7-tetraene
DMN91EK CA CAS 136427-58-2
DMRM7H0 ID DMRM7H0
DMRM7H0 DN SK&F-95601
DMRM7H0 HS Terminated
DMRM7H0 SN 2-[3-Chloro-4-(4-morpholinyl)pyridin-2-ylmethylsulfinyl]-5-methoxybenzimidazole
DMRM7H0 PC 128449
DMRM7H0 MW 406.9
DMRM7H0 FM C18H19ClN4O3S
DMRM7H0 IC InChI=1S/C18H19ClN4O3S/c1-25-12-2-3-13-14(10-12)22-18(21-13)27(24)11-15-17(19)16(4-5-20-15)23-6-8-26-9-7-23/h2-5,10H,6-9,11H2,1H3,(H,21,22)
DMRM7H0 CS COC1=CC2=C(C=C1)N=C(N2)S(=O)CC3=NC=CC(=C3Cl)N4CCOCC4
DMRM7H0 IK OGHHMBMLUJWHGH-UHFFFAOYSA-N
DMRM7H0 IU 4-[3-chloro-2-[(6-methoxy-1H-benzimidazol-2-yl)sulfinylmethyl]pyridin-4-yl]morpholine
DMRM7H0 CA CAS 103949-62-8
DMRM7H0 DE Peptic ulcer
DM6RVXU ID DM6RVXU
DM6RVXU DN SK-951
DM6RVXU HS Terminated
DM6RVXU CP Sanwa Kagaku Kenkyusho Co Ltd
DM6RVXU DT Small molecular drug
DM6RVXU PC 9847989
DM6RVXU MW 480
DM6RVXU FM C23H30ClN3O6
DM6RVXU IC InChI=1S/C19H26ClN3O2.C4H4O4/c1-12-10-13-16(21)15(20)11-14(17(13)25-12)18(24)22-7-6-19-4-2-8-23(19)9-3-5-19;5-3(6)1-2-4(7)8/h11-12H,2-10,21H2,1H3,(H,22,24);1-2H,(H,5,6)(H,7,8)/b;2-1+/t12-;/m0./s1
DM6RVXU CS C[C@H]1CC2=C(O1)C(=CC(=C2N)Cl)C(=O)NCCC34CCCN3CCC4.C(=C/C(=O)O)\\C(=O)O
DM6RVXU IK ILIMVHLSANAUTN-GYDOPSIJSA-N
DM6RVXU IU (2S)-4-amino-5-chloro-N-[2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)ethyl]-2-methyl-2,3-dihydro-1-benzofuran-7-carboxamide;(E)-but-2-enedioic acid
DM6RVXU DE Gastrointestinal disease
DMIMJ8Z ID DMIMJ8Z
DMIMJ8Z DN SKF 38393
DMIMJ8Z HS Terminated
DMIMJ8Z SN SKF-38393; F-38393; 67287-49-4; F 38393; SKF38393; BRN 1543419; CHEMBL286080; 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol; 2,3,4,5-Tetrahydro-1-phenyl-1H-3-benzazepine-7,8-diol; 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; SKF-38,393; SK-38393; C16H17NO2; 5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 1-Phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol
DMIMJ8Z DT Small molecular drug
DMIMJ8Z PC 1242
DMIMJ8Z MW 255.31
DMIMJ8Z FM C16H17NO2
DMIMJ8Z IC InChI=1S/C16H17NO2/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11/h1-5,8-9,14,17-19H,6-7,10H2
DMIMJ8Z CS C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3
DMIMJ8Z IK JUDKOGFHZYMDMF-UHFFFAOYSA-N
DMIMJ8Z IU 5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DMIMJ8Z CA CAS 67287-49-4
DMIMJ8Z CB CHEBI:110200
DMIMJ8Z DE Type-2 diabetes
DM8MWFZ ID DM8MWFZ
DM8MWFZ DN SKF-104351
DM8MWFZ HS Terminated
DM8MWFZ SN 111908-94-2; Skf 104351; F 104351; 5H-Pyrrolo[1,2-a]imidazole,2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; 2-(4-fluorophenyl)-3-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole; F-104351; AC1L3V0R; SCHEMBL7378515; DTXSID90149775; GJFVAEMLAFFGDZ-UHFFFAOYSA-N; ZINC3815711; 5H-Pyrrolo(1,2-a)imidazole, 2-(4-fluorophenyl)-6,7-dihydro-3-(4-pyridinyl)-; KB-292516; 2-p-Fluorophenyl-3-(4-pyridyl)-6,7-dihydro[5H]-pyrrolo[1,2-a]imidazole
DM8MWFZ CP SmithKline Beecham plc
DM8MWFZ DT Small molecular drug
DM8MWFZ PC 122656
DM8MWFZ MW 279.31
DM8MWFZ FM C17H14FN3
DM8MWFZ IC InChI=1S/C17H14FN3/c18-14-5-3-12(4-6-14)16-17(13-7-9-19-10-8-13)21-11-1-2-15(21)20-16/h3-10H,1-2,11H2
DM8MWFZ CS C1CC2=NC(=C(N2C1)C3=CC=NC=C3)C4=CC=C(C=C4)F
DM8MWFZ IK GJFVAEMLAFFGDZ-UHFFFAOYSA-N
DM8MWFZ IU 2-(4-fluorophenyl)-3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
DM8MWFZ CA CAS 111908-94-2
DM8MWFZ DE Rheumatoid arthritis
DM7QPYK ID DM7QPYK
DM7QPYK DN SKF-106760
DM7QPYK HS Terminated
DM7QPYK SN 126053-71-2; F 106760; Skf 106760; F-106760; Ac-Cyclo-S,S-(cys-(N(alpha)-Me)arg-gly-asp-pen)-NH2; AC1Q5IR2; AC1L4UF1; [(4r,7s,13s,16r)-16-(acetylamino)-4-carbamoyl-13-{3-[(diaminomethylidene)amino]propyl}-3,3,14-trimethyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecan-7-yl]acetic acid; CTK4B4925; L-Valinamide,N-acetyl-L-cysteinyl-N2-methyl-L-arginylglycyl-L-a-aspartyl-3-mercapto-, cyclic (1& 5)-disulfide (9CI)
DM7QPYK DT Small molecular drug
DM7QPYK PC 44343680
DM7QPYK MW 605.7
DM7QPYK FM C21H35N9O8S2
DM7QPYK IC InChI=1S/C21H35N9O8S2/c1-10(31)27-13-9-40-39-8-12(17(22)35)29-18(36)11(6-16(33)34)28-15(32)7-26-19(37)14(30(2)20(13)38)4-3-5-25-21(23)24/h11-14H,3-9H2,1-2H3,(H2,22,35)(H,26,37)(H,27,31)(H,28,32)(H,29,36)(H,33,34)(H4,23,24,25)/t11-,12-,13-,14-/m0/s1
DM7QPYK CS CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N(C1=O)C)CCCN=C(N)N)CC(=O)O)C(=O)N
DM7QPYK IK WZFJXIKSGKCGRW-XUXIUFHCSA-N
DM7QPYK IU 2-[(4R,7S,13S,16R)-16-acetamido-4-carbamoyl-13-[3-(diaminomethylideneamino)propyl]-14-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadec-7-yl]acetic acid
DM7QPYK DE Thrombosis
DMM8F0V ID DMM8F0V
DMM8F0V DN SKF-107260
DMM8F0V HS Terminated
DMM8F0V SN F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)
DMM8F0V DT Small molecular drug
DMM8F0V PC 164393
DMM8F0V MW 601.7
DMM8F0V FM C26H31N7O6S2
DMM8F0V IC InChI=1S/C26H31N7O6S2/c1-33-18(9-6-12-29-26(27)28)24(38)30-14-21(34)31-17(13-22(35)36)23(37)32-16-8-3-5-11-20(16)41-40-19-10-4-2-7-15(19)25(33)39/h2-5,7-8,10-11,17-18H,6,9,12-14H2,1H3,(H,30,38)(H,31,34)(H,32,37)(H,35,36)(H4,27,28,29)/t17-,18-/m0/s1
DMM8F0V CS CN1[C@H](C(=O)NCC(=O)N[C@H](C(=O)NC2=CC=CC=C2SSC3=CC=CC=C3C1=O)CC(=O)O)CCCN=C(N)N
DMM8F0V IK YITSCMGHJOGUNC-ROUUACIJSA-N
DMM8F0V IU 2-[(12S,18S)-18-[3-(diaminomethylideneamino)propyl]-19-methyl-11,14,17,20-tetraoxo-2,3-dithia-10,13,16,19-tetrazatricyclo[19.4.0.04,9]pentacosa-1(25),4,6,8,21,23-hexaen-12-yl]acetic acid
DMM8F0V CA CAS 136620-00-3
DM4LGPT ID DM4LGPT
DM4LGPT DN SKF-81297
DM4LGPT HS Terminated
DM4LGPT SN SKF 81297 hydrochloride
DM4LGPT CP SmithKline Beecham Pharmaceuticals
DM4LGPT DT Small molecular drug
DM4LGPT PC 1218
DM4LGPT MW 289.75
DM4LGPT FM C16H16ClNO2
DM4LGPT IC InChI=1S/C16H16ClNO2/c17-15-11-6-7-18-9-13(10-4-2-1-3-5-10)12(11)8-14(19)16(15)20/h1-5,8,13,18-20H,6-7,9H2
DM4LGPT CS C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=CC=C3
DM4LGPT IK GHWJEDJMOVUXEC-UHFFFAOYSA-N
DM4LGPT IU 9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
DM4LGPT CA CAS 71636-61-8
DM4LGPT CB CHEBI:91517
DM4LGPT DE Parkinson disease
DMS2M58 ID DMS2M58
DMS2M58 DN SKF-96231
DMS2M58 HS Terminated
DMS2M58 CP SmithKline Beecham plc
DMS2M58 DT Small molecular drug
DMS2M58 PC 135529458
DMS2M58 MW 270.29
DMS2M58 FM C14H14N4O2
DMS2M58 IC InChI=1S/C14H14N4O2/c1-2-7-20-10-6-4-3-5-9(10)12-17-13-11(14(19)18-12)15-8-16-13/h3-6,8H,2,7H2,1H3,(H2,15,16,17,18,19)
DMS2M58 CS CCCOC1=CC=CC=C1C2=NC3=C(C(=O)N2)NC=N3
DMS2M58 IK PQTJTRTXCNZDFT-UHFFFAOYSA-N
DMS2M58 IU 2-(2-propoxyphenyl)-1,7-dihydropurin-6-one
DMS2M58 CA CAS 119409-07-3
DMS2M58 DE Asthma
DMI79JN ID DMI79JN
DMI79JN DN SKF-96365
DMI79JN HS Terminated
DMI79JN SN SK-96365; 1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazole; 1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole; 1-[beta-[3-(4-Methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole; 1-(2-(3-(4-Methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole; AC1L2XSB; SKF-96365 free base; Imidazole-based ligand, 15; KBioSS_000197; KBioGR_000197; BSPBio_001477; SCHEMBL722014; GTPL2441; CHEMBL258502; KBio3_000394; KBio2_000197; KBio3_000393; KBio2_005333; KBio2_002765; CHEBI:91847; BDBM21164
DMI79JN CP SmithKline Beecham plc
DMI79JN DT Small molecular drug
DMI79JN PC 104955
DMI79JN MW 402.9
DMI79JN FM C22H27ClN2O3
DMI79JN IC InChI=1S/C22H26N2O3.ClH/c1-25-20-9-5-18(6-10-20)4-3-15-27-22(16-24-14-13-23-17-24)19-7-11-21(26-2)12-8-19;/h5-14,17,22H,3-4,15-16H2,1-2H3;1H
DMI79JN CS COC1=CC=C(C=C1)CCCOC(CN2C=CN=C2)C3=CC=C(C=C3)OC.Cl
DMI79JN IK FWLPKVQUECFKSW-UHFFFAOYSA-N
DMI79JN IU 1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]imidazole;hydrochloride
DMI79JN CA CAS 130495-35-1
DMI79JN CB CHEBI:145121
DMI79JN DE Angina pectoris
DMI1WNF ID DMI1WNF
DMI1WNF DN SL-18.1616
DMI1WNF HS Terminated
DMI1WNF CP Sanofi-Synthelabo
DMI1WNF DE Insomnia
DMJ9RLX ID DMJ9RLX
DMJ9RLX DN SL-91.0893
DMJ9RLX HS Terminated
DMJ9RLX CP Synthelabo
DMJ9RLX DE Prostate hyperplasia
DMNTGXQ ID DMNTGXQ
DMNTGXQ DN SL-910102
DMNTGXQ HS Terminated
DMNTGXQ CP Synthelabo
DMNTGXQ DE Hypertension
DMCPDBS ID DMCPDBS
DMCPDBS DN SLV-307
DMCPDBS HS Terminated
DMCPDBS CP Solvay SA
DMCPDBS DE Parkinson disease
DMF0QMD ID DMF0QMD
DMF0QMD DN SM 11044
DMF0QMD HS Terminated
DMF0QMD SN SM 11044; 142784-65-4; SM-11044; DTXSID90162181; AC1L3144; 3-(3,4-Dihydroxyphenyl)-N-(3-(4-fluorophenyl)propyl)serine pyrrolidine amide hydrobromide; Pyrrolidine, 1-(3-(3,4-dihydroxyphenyl)-2-((3-(4-fluorophenyl)propyl)amino)-3-hydroxy-1-oxopropyl)-, monohydrobromide, (R-(R*,S*))-; (2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one hydrobromide
DMF0QMD DT Small molecular drug
DMF0QMD PC 132507
DMF0QMD MW 483.4
DMF0QMD FM C22H28BrFN2O4
DMF0QMD IC InChI=1S/C22H27FN2O4.BrH/c23-17-8-5-15(6-9-17)4-3-11-24-20(22(29)25-12-1-2-13-25)21(28)16-7-10-18(26)19(27)14-16;/h5-10,14,20-21,24,26-28H,1-4,11-13H2;1H/t20-,21+;/m0./s1
DMF0QMD CS C1CCN(C1)C(=O)[C@H]([C@@H](C2=CC(=C(C=C2)O)O)O)NCCCC3=CC=C(C=C3)F.Br
DMF0QMD IK VGHBGPUSJITFJL-JUDYQFGCSA-N
DMF0QMD IU (2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one;hydrobromide
DMF0QMD CA CAS 142784-65-4
DMF0QMD DE Asthma
DMHXJV2 ID DMHXJV2
DMHXJV2 DN SM-16
DMHXJV2 HS Terminated
DMHXJV2 SN TGF-beta receptor inhibitors, Biogen; TGF-beta receptor inhibitors, Biogen Idec
DMHXJV2 CP Biogen Inc
DMHXJV2 DE Fibrosis
DMNX93E ID DMNX93E
DMNX93E DN SM-19712
DMNX93E HS Terminated
DMNX93E SN GTPL5272; sodium 1-[(4-chlorobenzene)sulfonyl]-3-(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)urea
DMNX93E CP Sumitomo Pharmaceuticals Co Ltd
DMNX93E DT Small molecular drug
DMNX93E PC 17757228
DMNX93E MW 437.8
DMNX93E FM C18H13ClN5NaO3S
DMNX93E IC InChI=1S/C18H14ClN5O3S.Na/c1-12-16(11-20)17(24(22-12)14-5-3-2-4-6-14)21-18(25)23-28(26,27)15-9-7-13(19)8-10-15;/h2-10H,1H3,(H2,21,22,23,25);/q;+1/p-1
DMNX93E CS CC1=NN(C(=C1C#N)NC(=O)[N-]S(=O)(=O)C2=CC=C(C=C2)Cl)C3=CC=CC=C3.[Na+]
DMNX93E IK FBSZSOXTWRKLKD-UHFFFAOYSA-M
DMNX93E IU sodium;(4-chlorophenyl)sulfonyl-[(4-cyano-5-methyl-2-phenylpyrazol-3-yl)carbamoyl]azanide
DMNX93E DE Hypertension
DMROJEN ID DMROJEN
DMROJEN DN SNAP-5089
DMROJEN HS Terminated
DMROJEN SN SNAP5089; (-)-SNAP-5089; AC1NSKMU; GTPL498; SCHEMBL5165068; ZINC100002054; 2,6-Dimethyl-4alpha-(4-nitrophenyl)-5-[[3-(4,4-diphenylpiperidino)propyl]carbamoyl]-1,4-dihydro-3-pyridinecarboxylic acid methyl ester; methyl (4R)-5-[3-[4,4-di(phenyl)piperidin-1-yl]propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate; methyl (4R)-5-[3-(4,4-diphenylpiperidin-1-yl)propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DMROJEN DT Small molecular drug
DMROJEN PC 56972175
DMROJEN MW 645.2
DMROJEN FM C36H41ClN4O5
DMROJEN IC InChI=1S/C36H40N4O5.ClH/c1-25-31(33(32(26(2)38-25)35(42)45-3)27-15-17-30(18-16-27)40(43)44)34(41)37-21-10-22-39-23-19-36(20-24-39,28-11-6-4-7-12-28)29-13-8-5-9-14-29;/h4-9,11-18,33,38H,10,19-24H2,1-3H3,(H,37,41);1H
DMROJEN CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)NCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5.Cl
DMROJEN IK MXELDPKESKXREN-UHFFFAOYSA-N
DMROJEN IU methyl 5-[3-(4,4-diphenylpiperidin-1-yl)propylcarbamoyl]-2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-carboxylate;hydrochloride
DMROJEN DE Heart arrhythmia
DMNE4TS ID DMNE4TS
DMNE4TS DN SNAP-6201
DMNE4TS HS Terminated
DMNE4TS SN SNAP-6201; CHEMBL356584; BDBM50082784; L014930; 1-(3-{[5-Carbamoyl-6-(3,4-difluoro-phenyl)-4-ethyl-2-oxo-3,6-dihydro-2H-pyrimidine-1-carbonyl]-amino}-propyl)-4-phenyl-piperidine-4-carboxylic acid methyl ester
DMNE4TS DT Small molecular drug
DMNE4TS PC 10099811
DMNE4TS MW 583.6
DMNE4TS FM C30H35F2N5O5
DMNE4TS IC InChI=1S/C30H35F2N5O5/c1-3-23-24(26(33)38)25(19-10-11-21(31)22(32)18-19)37(29(41)35-23)28(40)34-14-7-15-36-16-12-30(13-17-36,27(39)42-2)20-8-5-4-6-9-20/h4-6,8-11,18,25H,3,7,12-17H2,1-2H3,(H2,33,38)(H,34,40)(H,35,41)
DMNE4TS CS CCC1=C(C(N(C(=O)N1)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C(=O)OC)C4=CC(=C(C=C4)F)F)C(=O)N
DMNE4TS IK YCUQRVLXIFFFNB-UHFFFAOYSA-N
DMNE4TS IU methyl 1-[3-[[5-carbamoyl-4-(3,4-difluorophenyl)-6-ethyl-2-oxo-1,4-dihydropyrimidine-3-carbonyl]amino]propyl]-4-phenylpiperidine-4-carboxylate
DM4CNM9 ID DM4CNM9
DM4CNM9 DN SNF-9007
DM4CNM9 HS Terminated
DM4CNM9 SN Snf-9007; CHEMBL407057; BDBM21146; Asp-Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2; (3S)-3-[(2S)-2-[(2S)-2-{2-[(2R)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-3-(1H-indol-3-yl)-N-methylpropanamido]hexanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid
DM4CNM9 PC 9898185
DM4CNM9 MW 1075.2
DM4CNM9 FM C55H66N10O13
DM4CNM9 IC InChI=1S/C55H66N10O13/c1-3-4-19-45(54(77)64-43(29-48(70)71)53(76)61-40(49(57)72)24-32-13-7-5-8-14-32)65(2)55(78)44(27-35-30-58-39-18-12-11-17-37(35)39)60-46(67)31-59-51(74)41(25-33-15-9-6-10-16-33)63-52(75)42(26-34-20-22-36(66)23-21-34)62-50(73)38(56)28-47(68)69/h5-18,20-23,30,38,40-45,58,66H,3-4,19,24-29,31,56H2,1-2H3,(H2,57,72)(H,59,74)(H,60,67)(H,61,76)(H,62,73)(H,63,75)(H,64,77)(H,68,69)(H,70,71)/t38-,40-,41+,42-,43-,44-,45-/m0/s1
DM4CNM9 CS CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N(C)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)N
DM4CNM9 IK IJHCWGDIGBABKC-GDHOWUIUSA-N
DM4CNM9 IU (3S)-3-amino-4-[[(2S)-1-[[(2R)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]-methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMFI0GW ID DMFI0GW
DMFI0GW DN Sonepiprazole
DMFI0GW HS Terminated
DMFI0GW SN U 101387; U-101387; Isochr-etpip-phso2NH2; 4-(4-(2-(Isochroman-1-yl)ethyl)piperazin-1-yl)benzenesulfonamide; 4-[4-[2-(3,4-dihydro-1H-isochromen-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide; 4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide
DMFI0GW CP Pfizer
DMFI0GW DT Small molecular drug
DMFI0GW PC 133079
DMFI0GW MW 401.5
DMFI0GW FM C21H27N3O3S
DMFI0GW IC InChI=1S/C21H27N3O3S/c22-28(25,26)19-7-5-18(6-8-19)24-14-12-23(13-15-24)11-9-21-20-4-2-1-3-17(20)10-16-27-21/h1-8,21H,9-16H2,(H2,22,25,26)/t21-/m0/s1
DMFI0GW CS C1CO[C@H](C2=CC=CC=C21)CCN3CCN(CC3)C4=CC=C(C=C4)S(=O)(=O)N
DMFI0GW IK WNUQCGWXPNGORO-NRFANRHFSA-N
DMFI0GW IU 4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide
DMFI0GW CA CAS 170858-33-0
DMFI0GW DE Schizophrenia
DM31VE4 ID DM31VE4
DM31VE4 DN Sorbinil
DM31VE4 HS Terminated
DM31VE4 SN SBI; Sorbinilo; Sorbinilum; Sorbinilo [Spanish]; Sorbinilum [Latin]; CP 45634; CP-45634; Sorbinil (USAN/INN); D-6-fluoro-spiro(chroman-4,4'-imidazolidine)-2',5'-dione; (4S)-6-fluoro-2,3-dihydro-2'H,5'H-spiro[chromene-4,4'-imidazolidine]-2',5'-dione; (4S)-6-fluorospiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione
DM31VE4 CP Pfizer
DM31VE4 DT Small molecular drug
DM31VE4 PC 337359
DM31VE4 MW 236.2
DM31VE4 FM C11H9FN2O3
DM31VE4 IC InChI=1S/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)/t11-/m0/s1
DM31VE4 CS C1COC2=C([C@]13C(=O)NC(=O)N3)C=C(C=C2)F
DM31VE4 IK LXANPKRCLVQAOG-NSHDSACASA-N
DM31VE4 IU (4S)-6-fluorospiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione
DM31VE4 CA CAS 68367-52-2
DM31VE4 CB CHEBI:102029
DM31VE4 DE Diabetic cataract
DMTDLHG ID DMTDLHG
DMTDLHG DN SORETOLIDE
DMTDLHG HS Terminated
DMTDLHG SN D-2916; Soretolide; 2,6-Dimethyl-N-(5-methylisozaxol-3-yl)benzamide
DMTDLHG DT Small molecular drug
DMTDLHG PC 198730
DMTDLHG MW 230.26
DMTDLHG FM C13H14N2O2
DMTDLHG IC InChI=1S/C13H14N2O2/c1-8-5-4-6-9(2)12(8)13(16)14-11-7-10(3)17-15-11/h4-7H,1-3H3,(H,14,15,16)
DMTDLHG CS CC1=C(C(=CC=C1)C)C(=O)NC2=NOC(=C2)C
DMTDLHG IK GBTKANSDFYFQBK-UHFFFAOYSA-N
DMTDLHG IU 2,6-dimethyl-N-(5-methyl-1,2-oxazol-3-yl)benzamide
DMTDLHG CA CAS 130403-08-6
DMTDLHG DE Convulsion
DM9HFV7 ID DM9HFV7
DM9HFV7 DN SPD-756
DM9HFV7 HS Terminated
DM9HFV7 SN BCH-13520
DM9HFV7 CP Shire plc
DM9HFV7 DT Small molecular drug
DM9HFV7 PC 485995
DM9HFV7 MW 292.29
DM9HFV7 FM C12H16N6O3
DM9HFV7 IC InChI=1S/C12H16N6O3/c13-12-16-10(15-6-1-2-6)9-11(17-12)18(5-14-9)7-4-20-8(3-19)21-7/h5-8,19H,1-4H2,(H3,13,15,16,17)/t7-,8-/m1/s1
DM9HFV7 CS C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)[C@H]4CO[C@H](O4)CO
DM9HFV7 IK ATSMZGDYBPOXMZ-HTQZYQBOSA-N
DM9HFV7 IU [(2R,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]-1,3-dioxolan-2-yl]methanol
DM9HFV7 CA CAS 280138-71-8
DM9HFV7 DE Human immunodeficiency virus infection
DMD4BFY ID DMD4BFY
DMD4BFY DN Spermine
DMD4BFY HS Terminated
DMD4BFY SN spermine; 71-44-3; neuridine; musculamine; gerontine; Spermin; 4,9-Diaza-1,12-dodecanediamine; Diaminopropyltetramethylenediamine; N,N'-Bis(3-aminopropyl)-1,4-butanediamine; Spermine, puriss; N,N'-Bis(3-aminopropyl)butane-1,4-diamine; 1,4-Butanediamine, N,N'-bis(3-aminopropyl)-; 1,4-Bis(aminopropyl)butanediamine; 4,9-Diazadodecamethylenediamine; 4,9-Diazadodecane-1,12-diamine; N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine); UNII-2FZ7Y3VOQX; 1,4-Bis(aminopropyl) butanediamine; Spermine Derivative; 1,4-Diaminobutane, N,N'-bis
DMD4BFY DT Small molecular drug
DMD4BFY PC 1103
DMD4BFY MW 202.34
DMD4BFY FM C10H26N4
DMD4BFY IC InChI=1S/C10H26N4/c11-5-3-9-13-7-1-2-8-14-10-4-6-12/h13-14H,1-12H2
DMD4BFY CS C(CCNCCCN)CNCCCN
DMD4BFY IK PFNFFQXMRSDOHW-UHFFFAOYSA-N
DMD4BFY IU N,N'-bis(3-aminopropyl)butane-1,4-diamine
DMD4BFY CA CAS 71-44-3
DMD4BFY CB CHEBI:15746
DMTGIUV ID DMTGIUV
DMTGIUV DN SPR-210
DMTGIUV HS Terminated
DMTGIUV SN Spr 210; Spr-210; SCHEMBL1650593; AC1L3164; 2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifuruoro-2-benzothiazolyl)methyl)-; 3,4-Dihydro-3-oxo-4-((4,5,7-trifuruoro-2-benzothiazolyl)methyl)-2H-1,4-benzothiazine-2-acetic acid; 3,4-Dihydro-3-oxo-4-((4,5,7-trifluoro-2-benzothiazolyl)methyl)-2H-1,4-benzothiazine-2-acetic acid; 2-[5-methyl-3-oxo-4-(4,5,7-trifluoro-1,3-benzothiazol-2-yl)-1,4-benzothiazin-2-yl]acetic acid
DMTGIUV DT Small molecular drug
DMTGIUV PC 132542
DMTGIUV MW 424.4
DMTGIUV FM C18H11F3N2O3S2
DMTGIUV IC InChI=1S/C18H11F3N2O3S2/c1-7-3-2-4-10-15(7)23(17(26)11(27-10)6-12(24)25)18-22-14-13(21)8(19)5-9(20)16(14)28-18/h2-5,11H,6H2,1H3,(H,24,25)
DMTGIUV CS CC1=C2C(=CC=C1)SC(C(=O)N2C3=NC4=C(C(=CC(=C4S3)F)F)F)CC(=O)O
DMTGIUV IK ZVSDXQXCVBUOHA-UHFFFAOYSA-N
DMTGIUV IU 2-[5-methyl-3-oxo-4-(4,5,7-trifluoro-1,3-benzothiazol-2-yl)-1,4-benzothiazin-2-yl]acetic acid
DMTGIUV DE Diabetic complication
DM6SW2R ID DM6SW2R
DM6SW2R DN SQ-26332
DM6SW2R HS Terminated
DM6SW2R DT Small molecular drug
DM6SW2R PC 9998020
DM6SW2R MW 350.4
DM6SW2R FM C17H22N2O4S
DM6SW2R IC InChI=1S/C17H22N2O4S/c1-11(16(21)19-9-5-8-13(19)17(22)23)18-15(20)14(24)10-12-6-3-2-4-7-12/h2-4,6-7,11,13-14,24H,5,8-10H2,1H3,(H,18,20)(H,22,23)/t11-,13-,14-/m0/s1
DM6SW2R CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S
DM6SW2R IK YSFYVNRABGRTNY-UBHSHLNASA-N
DM6SW2R IU (2S)-1-[(2S)-2-[[(2S)-3-phenyl-2-sulfanylpropanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DM9DJFS ID DM9DJFS
DM9DJFS DN SQ-28603
DM9DJFS HS Terminated
DM9DJFS SN CHEMBL196902; beta-Alanine, N-(2-(mercaptomethyl)-1-oxo-3-phenylpropyl)-; 100845-83-8; AC1L3X7M; SCHEMBL389731; 3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid; ZCTDTVUDURCGFX-UHFFFAOYSA-N; HY-U00171; BDBM50175499; CS-7234; LS-186925; LS-187575; 3-(2-Benzyl-3-mercapto-propionylamino)-propionic acid; (+/-)-3-[[2-(Mercaptomethyl)-1-oxo-3-phenylpropyl]amino]propanoic acid
DM9DJFS CP Squibb Corp
DM9DJFS DT Small molecular drug
DM9DJFS PC 123742
DM9DJFS MW 267.35
DM9DJFS FM C13H17NO3S
DM9DJFS IC InChI=1S/C13H17NO3S/c15-12(16)6-7-14-13(17)11(9-18)8-10-4-2-1-3-5-10/h1-5,11,18H,6-9H2,(H,14,17)(H,15,16)
DM9DJFS CS C1=CC=C(C=C1)CC(CS)C(=O)NCCC(=O)O
DM9DJFS IK ZCTDTVUDURCGFX-UHFFFAOYSA-N
DM9DJFS IU 3-[(2-benzyl-3-sulfanylpropanoyl)amino]propanoic acid
DM9DJFS CA CAS 100845-83-8
DM9DJFS DE Hypertension
DM083JB ID DM083JB
DM083JB DN SQ-33351
DM083JB HS Terminated
DM083JB CP Squibb Corp
DM083JB DE Hypertension
DMT5LX0 ID DMT5LX0
DMT5LX0 DN SQ-33600
DMT5LX0 HS Terminated
DMT5LX0 SN UNII-3KF8M81W01; 3KF8M81W01; SQ-33600; SQ 33600; SQ 33,600; AC1L2ZMH; SCHEMBL5597751; 133983-25-2; Butanoic acid, 4-(((1-(4-fluorophenyl)-3-(1-methylethyl)-1H-indol-2-yl)ethynyl)hydroxyphosphinyl)-3-hydroxy-, disodium salt, (S)-; disodium (3S)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate
DMT5LX0 CP Bristol-Myers Squibb Co
DMT5LX0 DT Small molecular drug
DMT5LX0 PC 131696
DMT5LX0 MW 487.4
DMT5LX0 FM C23H21FNNa2O5P
DMT5LX0 IC InChI=1S/C23H23FNO5P.2Na/c1-15(2)23-19-5-3-4-6-20(19)25(17-9-7-16(24)8-10-17)21(23)11-12-31(29,30)14-18(26)13-22(27)28;;/h3-10,15,18,26H,13-14H2,1-2H3,(H,27,28)(H,29,30);;/q;2*+1/p-2/t18-;;/m0../s1
DMT5LX0 CS CC(C)C1=C(N(C2=CC=CC=C21)C3=CC=C(C=C3)F)C#CP(=O)(C[C@H](CC(=O)[O-])O)[O-].[Na+].[Na+]
DMT5LX0 IK FXHKSTYWSZZOBF-NTEVMMBTSA-L
DMT5LX0 IU disodium;(3S)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate
DMT5LX0 CA CAS 133983-25-2
DMT5LX0 DE Hyperlipidaemia
DMMRWKP ID DMMRWKP
DMMRWKP DN SQ-33800
DMMRWKP HS Terminated
DMMRWKP CP Bristol-Myers Squibb Co
DMMRWKP DE Hypertension
DMZBQ4I ID DMZBQ4I
DMZBQ4I DN SQ-33961
DMZBQ4I HS Terminated
DMZBQ4I CP Squibb Corp
DMZBQ4I DT Small molecular drug
DMZBQ4I PC 9849156
DMZBQ4I MW 508.6
DMZBQ4I FM C30H40N2O5
DMZBQ4I IC InChI=1S/C30H40N2O5/c33-27(34)16-13-21-11-4-5-12-22(21)18-23-25-14-15-26(37-25)28(23)30-32-24(19-36-30)29(35)31-17-7-6-10-20-8-2-1-3-9-20/h4-5,11-12,19-20,23,25-26,28H,1-3,6-10,13-18H2,(H,31,35)(H,33,34)/t23-,25-,26+,28-/m0/s1
DMZBQ4I CS C1CCC(CC1)CCCCNC(=O)C2=COC(=N2)[C@@H]3[C@H]4CC[C@@H]([C@@H]3CC5=CC=CC=C5CCC(=O)O)O4
DMZBQ4I IK MWTFNTGEEFCRGV-ZEIIVYBKSA-N
DMZBQ4I IU 3-[2-[[(1S,2R,3S,4R)-3-[4-(4-cyclohexylbutylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid
DMZBQ4I DE Thrombosis
DMT7O9V ID DMT7O9V
DMT7O9V DN SQ-34919
DMT7O9V HS Terminated
DMT7O9V SN SQ-34919; CHEMBL286760; SCHEMBL9632769; SCHEMBL9632781; GTPL3101; BDBM50031839; (6,10-Dimethyl-5,9-undecadienylidene)bisphosphonic acid; ((E)-6,10-Dimethyl-1-phosphono-undeca-5,9-dienyl)-phosphonic acid; [(5E)-6,10-dimethyl-1-phosphonoundeca-5,9-dien-1-yl]phosphonic acid
DMT7O9V DT Small molecular drug
DMT7O9V PC 10382597
DMT7O9V MW 340.29
DMT7O9V FM C13H26O6P2
DMT7O9V IC InChI=1S/C13H26O6P2/c1-11(2)7-6-9-12(3)8-4-5-10-13(20(14,15)16)21(17,18)19/h7-8,13H,4-6,9-10H2,1-3H3,(H2,14,15,16)(H2,17,18,19)/b12-8+
DMT7O9V CS CC(=CCC/C(=C/CCCC(P(=O)(O)O)P(=O)(O)O)/C)C
DMT7O9V IK ISMDHWZGHKZNRH-XYOKQWHBSA-N
DMT7O9V IU [(5E)-6,10-dimethyl-1-phosphonoundeca-5,9-dienyl]phosphonic acid
DM4JZPT ID DM4JZPT
DM4JZPT DN Squalestatin 1
DM4JZPT HS Terminated
DM4JZPT SN Zaragozic acid A; squalestatin 1; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo
DM4JZPT CP Glaxo Wellcome plc
DM4JZPT DT Small molecular drug
DM4JZPT PC 6438355
DM4JZPT MW 690.7
DM4JZPT FM C35H46O14
DM4JZPT IC InChI=1S/C35H46O14/c1-7-19(2)17-20(3)13-14-25(37)47-28-27(38)33(48-29(30(39)40)34(45,31(41)42)35(28,49-33)32(43)44)16-15-21(4)26(46-23(6)36)22(5)18-24-11-9-8-10-12-24/h8-14,19-20,22,26-29,38,45H,4,7,15-18H2,1-3,5-6H3,(H,39,40)(H,41,42)(H,43,44)/b14-13+/t19-,20+,22+,26+,27+,28+,29+,33-,34+,35-/m0/s1
DM4JZPT CS CC[C@H](C)C[C@H](C)/C=C/C(=O)O[C@@H]1[C@H]([C@]2(O[C@@H]([C@]([C@@]1(O2)C(=O)O)(C(=O)O)O)C(=O)O)CCC(=C)[C@H]([C@H](C)CC3=CC=CC=C3)OC(=O)C)O
DM4JZPT IK DFKDOZMCHOGOBR-NCSQYGPNSA-N
DM4JZPT IU (1S,3S,4S,5R,6R,7R)-1-[(4S,5R)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-[(E,4S,6S)-4,6-dimethyloct-2-enoyl]oxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DM4JZPT CA CAS 142561-96-4
DM4JZPT CB CHEBI:75170
DM4JZPT DE Arteriosclerosis
DMETDFM ID DMETDFM
DMETDFM DN SR 120819A
DMETDFM HS Terminated
DMETDFM SN SR 120819A; SR120819A; SR-120819A; SR 120107A; AC1NSM40; GTPL1530
DMETDFM DT Small molecular drug
DMETDFM PC 5312150
DMETDFM MW 751
DMETDFM FM C43H54N6O4S
DMETDFM IC InChI=1S/C43H54N6O4S/c1-48(2)30-34-16-14-33(15-17-34)29-45-41(44)36-20-18-32(19-21-36)27-40(43(51)49-24-8-9-25-49)46-42(50)39(26-31-10-4-3-5-11-31)47-54(52,53)38-23-22-35-12-6-7-13-37(35)28-38/h3-7,10-13,18-23,28,33-34,39-40,47H,8-9,14-17,24-27,29-30H2,1-2H3,(H2,44,45)(H,46,50)/t33?,34?,39-,40-/m1/s1
DMETDFM CS CN(C)CC1CCC(CC1)CN=C(C2=CC=C(C=C2)C[C@H](C(=O)N3CCCC3)NC(=O)[C@@H](CC4=CC=CC=C4)NS(=O)(=O)C5=CC6=CC=CC=C6C=C5)N
DMETDFM IK GKKPXBHNFVDHAQ-USNYZCROSA-N
DMETDFM IU (2R)-N-[(2R)-3-[4-[N'-[[4-[(dimethylamino)methyl]cyclohexyl]methyl]carbamimidoyl]phenyl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)-3-phenylpropanamide
DMETDFM DE Eating disorder
DMQG3CK ID DMQG3CK
DMQG3CK DN SR-11237
DMQG3CK HS Terminated
DMQG3CK SN SR 11237; 146670-40-8; SR-11237; SR11237; BMS 649; BMS 188649; CHEMBL112715; 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid; 4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]-benzoic acid; UVI 2108; AC1L2RBO; 4-[2-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-NAPHTHALEN-2-YL)-[1,3]DIOXOLAN-2-YL]-BENZOIC ACID; 4-(2-(5,6,7,8-Tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl)benzoic acid; SCHEMBL2807932; GTPL2809; CTK8F0685; DTXSID10163433
DMQG3CK CP Sanofi
DMQG3CK DT Small molecular drug
DMQG3CK PC 127019
DMQG3CK MW 380.5
DMQG3CK FM C24H28O4
DMQG3CK IC InChI=1S/C24H28O4/c1-22(2)11-12-23(3,4)20-15-18(9-10-19(20)22)24(27-13-14-28-24)17-7-5-16(6-8-17)21(25)26/h5-10,15H,11-14H2,1-4H3,(H,25,26)
DMQG3CK CS CC1(CCC(C2=C1C=CC(=C2)C3(OCCO3)C4=CC=C(C=C4)C(=O)O)(C)C)C
DMQG3CK IK ZZUKALQMHNSWTK-UHFFFAOYSA-N
DMQG3CK IU 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dioxolan-2-yl]benzoic acid
DMQG3CK CA CAS 146670-40-8
DMQG3CK DE Solid tumour/cancer
DMU2ZVY ID DMU2ZVY
DMU2ZVY DN SR12813
DMU2ZVY HS Terminated
DMU2ZVY SN SR 12813; 126411-39-0; SR-12813; SR12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO
DMU2ZVY DT Small molecular drug
DMU2ZVY PC 446313
DMU2ZVY MW 504.5
DMU2ZVY FM C24H42O7P2
DMU2ZVY IC InChI=1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3
DMU2ZVY CS CCOP(=O)(C(=CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OCC)OCC)OCC
DMU2ZVY IK YQLJDECYQDRSBI-UHFFFAOYSA-N
DMU2ZVY IU 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol
DMU2ZVY CA CAS 126411-39-0
DMU2ZVY CB CHEBI:77317
DMU2ZVY DE Arteriosclerosis
DM1GKTS ID DM1GKTS
DM1GKTS DN SR-26831
DM1GKTS HS Terminated
DM1GKTS SN SR 26831; AC1L30OS; ((5-(2-Chlorobenzyl-2-tert-butyloxycarbonyl))-4,5,6,7-tetrahydrothieno(3,2-c)pyridine)-N-oxide; Thieno(3,2-c)pyridinium, 5-((2-chlorophenyl)methyl)-2-(2,2-dimethyl-1-oxopropoxy)-4,5,6,7-tetrahydro-5-hydroxy-; [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate
DM1GKTS CP Sanofi
DM1GKTS DT Small molecular drug
DM1GKTS PC 132270
DM1GKTS MW 380.9
DM1GKTS FM C19H23ClNO3S+
DM1GKTS IC InChI=1S/C19H23ClNO3S/c1-19(2,3)18(22)24-17-10-14-12-21(23,9-8-16(14)25-17)11-13-6-4-5-7-15(13)20/h4-7,10,23H,8-9,11-12H2,1-3H3/q+1
DM1GKTS CS CC(C)(C)C(=O)OC1=CC2=C(S1)CC[N+](C2)(CC3=CC=CC=C3Cl)O
DM1GKTS IK AZEZNHVYMHQRRH-UHFFFAOYSA-N
DM1GKTS IU [5-[(2-chlorophenyl)methyl]-5-hydroxy-6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ium-2-yl] 2,2-dimethylpropanoate
DM1GKTS CA CAS 139995-67-8
DM1GKTS DE Rheumatoid arthritis
DMZ8SXP ID DMZ8SXP
DMZ8SXP DN SR-27950
DMZ8SXP HS Terminated
DMZ8SXP SN SR-27899
DMZ8SXP CP Sanofi
DMZ8SXP DE Eating disorder
DM7ZOLE ID DM7ZOLE
DM7ZOLE DN SR-31742A
DM7ZOLE HS Terminated
DM7ZOLE SN SR 31742A; [(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane hydrochloride; (Z)-1-(3-(3-Chloro-4-cyclohexylphenyl)-2-propenyl)hexahydro-1H-azepine hydrochloride; 3-(Hexahydroazepin-1-yl)-1-(3-chloro-4-cyclohexylphenyl)-1-propene hydrochloride
DM7ZOLE CP Sanofi-Aventis
DM7ZOLE DT Small molecular drug
DM7ZOLE PC 6438730
DM7ZOLE MW 367.4
DM7ZOLE FM C22H32Cl2
DM7ZOLE IC InChI=1S/C22H31Cl.ClH/c23-22-17-19(12-8-11-18-9-4-1-2-5-10-18)15-16-21(22)20-13-6-3-7-14-20;/h8,12,15-18,20H,1-7,9-11,13-14H2;1H/b12-8-;
DM7ZOLE CS C1CCCC(CC1)C/C=C\\C2=CC(=C(C=C2)C3CCCCC3)Cl.Cl
DM7ZOLE IK YAPBCZRQTMBLEF-JCTPKUEWSA-N
DM7ZOLE IU [(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]cycloheptane;hydrochloride
DM7ZOLE CA CAS 139592-99-7
DM7ZOLE DE Schizophrenia
DMS9EJ5 ID DMS9EJ5
DMS9EJ5 DN SR-58878
DMS9EJ5 HS Terminated
DMS9EJ5 CP Sanofi-Synthelabo
DMS9EJ5 PC 68822080
DMS9EJ5 MW 375.8
DMS9EJ5 FM C20H22ClNO4
DMS9EJ5 IC InChI=1S/C20H22ClNO4/c21-16-3-1-2-14(8-16)19(23)11-22-17-6-4-13-5-7-18(10-15(13)9-17)26-12-20(24)25/h1-3,5,7-8,10,17,19,22-23H,4,6,9,11-12H2,(H,24,25)/t17-,19?/m0/s1
DMS9EJ5 CS C1CC2=C(C[C@H]1NCC(C3=CC(=CC=C3)Cl)O)C=C(C=C2)OCC(=O)O
DMS9EJ5 IK PLYWAKPAFSZPAL-KKFHFHRHSA-N
DMS9EJ5 IU 2-[[(7S)-7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetic acid
DMS9EJ5 DE Irritable bowel syndrome
DMQUF9I ID DMQUF9I
DMQUF9I DN SR-58894A
DMQUF9I HS Terminated
DMQUF9I CP Sanofi-Synthelabo
DMQUF9I DE Gastrointestinal disease
DM6ASLF ID DM6ASLF
DM6ASLF DN SR-80027A
DM6ASLF HS Terminated
DM6ASLF SN Org-31550
DM6ASLF CP Sanofi
DM6ASLF DE Thrombosis
DMMPSY2 ID DMMPSY2
DMMPSY2 DN SRI 63-441
DMMPSY2 HS Terminated
DMMPSY2 SN Sri 63-441; 104786-62-1; Sandoz 63-441; Sdz 63-441; AC1L338B; SCHEMBL8702414; DTXSID60146736; 1-(2-(Hydroxy((tetrahydro-5-((octadecylaminocarbonyl)oxy)methyl)furan-2-yl)methoxyphosphinyloxy)ethyl)quinolinium; erythro-Hexitol, 2,5-anhydro-3,4-dideoxy-, octadecylcarbamate 2-quinolinioethyl hydrogen phosphate, hydroxide, inner salt; [(2R,5S)-5-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate; DL-erythro-Hexitol, 2,5-anhydro-3,4-dideoxy-, octadecylcarbamate 2-quinolinioethyl hydrogen p
DMMPSY2 DT Small molecular drug
DMMPSY2 PC 108044
DMMPSY2 MW 662.8
DMMPSY2 FM C36H59N2O7P
DMMPSY2 IC InChI=1S/C36H59N2O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-26-37-36(39)42-30-33-24-25-34(45-33)31-44-46(40,41)43-29-28-38-27-20-22-32-21-17-18-23-35(32)38/h17-18,20-23,27,33-34H,2-16,19,24-26,28-31H2,1H3,(H-,37,39,40,41)/t33-,34+/m0/s1
DMMPSY2 CS CCCCCCCCCCCCCCCCCCNC(=O)OC[C@@H]1CC[C@@H](O1)COP(=O)([O-])OCC[N+]2=CC=CC3=CC=CC=C32
DMMPSY2 IK OLDMQSKCCHULOB-SZAHLOSFSA-N
DMMPSY2 IU [(2R,5S)-5-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl 2-quinolin-1-ium-1-ylethyl phosphate
DMMPSY2 CA CAS 104786-62-1
DMBEUN6 ID DMBEUN6
DMBEUN6 DN SRI-3072
DMBEUN6 HS Terminated
DMBEUN6 SN Mycobacterium tuberculosis FtsZ polymerization inhibitors, Southern Research Institute; SRI-7614; Antimycobacterials (alkoxycarbonylaminopyridines), Southern Research Institute
DMBEUN6 CP Southern Research Institute
DMBEUN6 DT Small molecular drug
DMBEUN6 PC 493469
DMBEUN6 MW 540.7
DMBEUN6 FM C32H40N6O2
DMBEUN6 IC InChI=1S/C32H40N6O2/c1-6-38(7-2)21-22(4)19-23(5)33-26-20-27(35-32(39)40-8-3)34-31-30(26)36-28(24-15-11-9-12-16-24)29(37-31)25-17-13-10-14-18-25/h9-18,20,22-23H,6-8,19,21H2,1-5H3,(H2,33,34,35,37,39)
DMBEUN6 CS CCN(CC)CC(C)CC(C)NC1=CC(=NC2=C1N=C(C(=N2)C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)OCC
DMBEUN6 IK MKJUVACMILVNTO-UHFFFAOYSA-N
DMBEUN6 IU ethyl N-[8-[[5-(diethylamino)-4-methylpentan-2-yl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]carbamate
DMBEUN6 DE Mycobacterium infection
DMFLPU5 ID DMFLPU5
DMFLPU5 DN SRSC-355
DMFLPU5 HS Terminated
DMFLPU5 SN SGX-211; SGX-355; Neuropathic pain therapeutic (systemic depot, CK polymer), Sirus
DMFLPU5 CP Sirus Pharmaceuticals Ltd
DMFLPU5 DE Neuropathic pain
DM8MZWR ID DM8MZWR
DM8MZWR DN SRSS-021
DM8MZWR HS Terminated
DM8MZWR SN Anti-emetic, Sirus
DM8MZWR CP Sirus Pharmaceuticals Ltd
DM8MZWR DE Vomiting
DMUGPDB ID DMUGPDB
DMUGPDB DN SRSS-023
DMUGPDB HS Terminated
DMUGPDB SN Triptan (migraine, sublingual), Sirus; 5HT1 agonist (migraine, sublingual), Sirus
DMUGPDB CP Sirus Pharmaceuticals Ltd
DMUGPDB DE Migraine
DMWL4MI ID DMWL4MI
DMWL4MI DN SSR-69071
DMWL4MI HS Terminated
DMWL4MI SN SSR 69071; 344930-95-6; SSR69071; DSSTox_RID_82301; DSSTox_CID_27368; DSSTox_GSID_47368; MLS006010264; SCHEMBL4295477; CHEMBL1354892; DTXSID1047368; CTK8E8740; CHEBI:93283; MolPort-023-276-460; HMS3269M07; ZINC1490807; Tox21_300247; AKOS024457139; NCGC00254231-01; NCGC00167751-02; NCGC00167751-01; NCGC00167751-03; SMR001822512; RT-015782; LS-191133; FT-0724044; CAS-344930-95-6; J-019626; BRD-K72895815-001-01-4
DMWL4MI CP Sanofi-Synthelabo
DMWL4MI DT Small molecular drug
DMWL4MI PC 9872438
DMWL4MI MW 556.6
DMWL4MI FM C27H32N4O7S
DMWL4MI IC InChI=1S/C27H32N4O7S/c1-18(2)20-14-19(36-3)15-22-25(20)27(33)31(39(22,34)35)17-38-23-16-24(32)30-11-7-8-21(26(30)28-23)37-13-12-29-9-5-4-6-10-29/h7-8,11,14-16,18H,4-6,9-10,12-13,17H2,1-3H3
DMWL4MI CS CC(C)C1=C2C(=CC(=C1)OC)S(=O)(=O)N(C2=O)COC3=CC(=O)N4C=CC=C(C4=N3)OCCN5CCCCC5
DMWL4MI IK DRZXDZYWZSKFDL-UHFFFAOYSA-N
DMWL4MI IU 6-methoxy-1,1-dioxo-2-[[4-oxo-9-(2-piperidin-1-ylethoxy)pyrido[1,2-a]pyrimidin-2-yl]oxymethyl]-4-propan-2-yl-1,2-benzothiazol-3-one
DMWL4MI CA CAS 344930-95-6
DMWL4MI CB CHEBI:93283
DMWL4MI DE Chronic obstructive pulmonary disease
DMOJM08 ID DMOJM08
DMOJM08 DN Steroid hormone conjugates
DMOJM08 HS Terminated
DMOJM08 SN AM-454; Steroid hormone conjugates (diabetes); DHEA-PC, AMUR; DHEA-PC, SuperGen; DHEA-phosphocoline, SuperGen; Steroid hormone conjugates (diabetes), SuperGen
DMOJM08 CP AMUR Pharmaceuticals Inc
DMOJM08 DE Cachexia
DMO9UCK ID DMO9UCK
DMO9UCK DN SU5614
DMO9UCK HS Terminated
DMO9UCK SN SU 5614; SU-5614; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone
DMO9UCK CP Sugen Pharmaceuticals
DMO9UCK DT Small molecular drug
DMO9UCK PC 6536806
DMO9UCK MW 272.73
DMO9UCK FM C15H13ClN2O
DMO9UCK IC InChI=1S/C15H13ClN2O/c1-8-5-9(2)17-14(8)7-12-11-6-10(16)3-4-13(11)18-15(12)19/h3-7,17H,1-2H3,(H,18,19)/b12-7-
DMO9UCK CS CC1=CC(=C(N1)/C=C\\2/C3=C(C=CC(=C3)Cl)NC2=O)C
DMO9UCK IK XLBQNZICMYZIQT-GHXNOFRVSA-N
DMO9UCK IU (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
DMO9UCK CB CHEBI:87159
DMO9UCK DE Airway inflammation
DMWCR1Z ID DMWCR1Z
DMWCR1Z DN SU-740
DMWCR1Z HS Terminated
DMWCR1Z SN SU-840
DMWCR1Z CP Taisho Pharmaceutical Co Ltd
DMWCR1Z PC 6442365
DMWCR1Z MW 422.5
DMWCR1Z FM C26H30O5
DMWCR1Z IC InChI=1S/C26H30O5/c1-18(2)14-15-30-21-11-12-22(24(16-21)31-17-25(28)29)23(27)13-8-19-6-9-20(10-7-19)26(3,4)5/h6-14,16H,15,17H2,1-5H3,(H,28,29)/b13-8+
DMWCR1Z CS CC(=CCOC1=CC(=C(C=C1)C(=O)/C=C/C2=CC=C(C=C2)C(C)(C)C)OCC(=O)O)C
DMWCR1Z IK ANQKJBMYDIXLBL-MDWZMJQESA-N
DMWCR1Z IU 2-[2-[(E)-3-(4-tert-butylphenyl)prop-2-enoyl]-5-(3-methylbut-2-enoxy)phenoxy]acetic acid
DMWCR1Z CA CAS 134336-72-4
DMWCR1Z DE Stomach ulcer
DM4SVIR ID DM4SVIR
DM4SVIR DN Sulotroban
DM4SVIR HS Terminated
DM4SVIR SN BM-13177; SKF-95587
DM4SVIR CP Boehringer Mannheim GmbH
DM4SVIR DT Small molecular drug
DM4SVIR PC 51550
DM4SVIR MW 335.4
DM4SVIR FM C16H17NO5S
DM4SVIR IC InChI=1S/C16H17NO5S/c18-16(19)12-22-14-8-6-13(7-9-14)10-11-17-23(20,21)15-4-2-1-3-5-15/h1-9,17H,10-12H2,(H,18,19)
DM4SVIR CS C1=CC=C(C=C1)S(=O)(=O)NCCC2=CC=C(C=C2)OCC(=O)O
DM4SVIR IK XTNWJMVJVSGKLR-UHFFFAOYSA-N
DM4SVIR IU 2-[4-[2-(benzenesulfonamido)ethyl]phenoxy]acetic acid
DM4SVIR CA CAS 72131-33-0
DM4SVIR DE Asthma
DMC1A42 ID DMC1A42
DMC1A42 DN SUN-11031
DMC1A42 HS Terminated
DMC1A42 SN 6,6,6-trifluoromethionine; AC1L5KZ2; SCHEMBL245985; CTK1D7491; NSC73030; NSC-73030; 2-Amino-4-(trifluoromethylthio)butyric acid; 2-amino-4-(trifluoromethylsulfanyl)butanoic acid
DMC1A42 CP Daiichi Suntory Pharma
DMC1A42 DT Small molecular drug
DMC1A42 PC 251951
DMC1A42 MW 203.19
DMC1A42 FM C5H8F3NO2S
DMC1A42 IC InChI=1S/C5H8F3NO2S/c6-5(7,8)12-2-1-3(9)4(10)11/h3H,1-2,9H2,(H,10,11)
DMC1A42 CS C(CSC(F)(F)F)C(C(=O)O)N
DMC1A42 IK YLJLTSVBCXYTQK-UHFFFAOYSA-N
DMC1A42 IU 2-amino-4-(trifluoromethylsulfanyl)butanoic acid
DMC1A42 DE Anorexia nervosa cachexia
DMAM3OH ID DMAM3OH
DMAM3OH DN SUN-E3001
DMAM3OH HS Terminated
DMAM3OH SN CHS-13340; PTH[1,34], Suntory; RhPTH(1-34); RhPTH[1,34], Daiichi Asubio Pharma; Recombinant human parathyroid hormone[residues 1-34] (osteoporosis), Asubio Pharma; RhPTH[1,34] (osteporosis), Asubio Pharma
DMAM3OH CP Suntory Ltd
DMAM3OH DE Osteoporosis
DMG2SQM ID DMG2SQM
DMG2SQM DN SYN-1134
DMG2SQM HS Terminated
DMG2SQM SN Elastase inhibitors, NAEJA; SYN-1360; SYN-1386; SYN-1389; SYN-1390; SYN-1396
DMG2SQM CP NAEJA Pharmaceuticals Inc
DMG2SQM DE Cystic fibrosis
DMOGQ2L ID DMOGQ2L
DMOGQ2L DN T-686
DMOGQ2L HS Terminated
DMOGQ2L SN PAI-1 inhibitor, Tanabe
DMOGQ2L CP Tanabe Seiyaku Co Ltd
DMOGQ2L DT Small molecular drug
DMOGQ2L PC 6438903
DMOGQ2L MW 365.4
DMOGQ2L FM C21H19NO5
DMOGQ2L IC InChI=1S/C21H19NO5/c1-25-17-11-14(12-18(26-2)19(17)27-3)10-16-15(20(23)22-21(16)24)9-13-7-5-4-6-8-13/h4-12H,1-3H3,(H,22,23,24)/b15-9+,16-10+
DMOGQ2L CS COC1=CC(=CC(=C1OC)OC)/C=C/2\\C(=C/C3=CC=CC=C3)\\C(=O)NC2=O
DMOGQ2L IK YQALUFAJAWGTQV-KAVGSWPWSA-N
DMOGQ2L IU (3E,4E)-3-benzylidene-4-[(3,4,5-trimethoxyphenyl)methylidene]pyrrolidine-2,5-dione
DMOGQ2L CA CAS 152815-51-5
DMOGQ2L DE Arteriosclerosis
DM0TELR ID DM0TELR
DM0TELR DN TAK-779
DM0TELR HS Terminated
DM0TELR SN TAK 779; TAK 799; TAK779; TAK799; E-921; TAK 779 (Chloride); TAK779 & CD4 mAb; E921/TAK-779; TAK-279 & PRO 140; TAK-779 & PA14; TAK-779 (Chloride); TAK 779 (*Chloride*); TAK-779 (*Chloride*); Dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium; Dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium chloride; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium & Monoclonal antibody directed against CD4 receptor; N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium PRO 140 (Anti-CCR5 monoclonal antibody); N,N-Dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium & PRO 140 (Anti-CCR5 monoclonal antibody); N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride; N,N-Dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium; 2H-Pyran-4-aminium, N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetrahydro-, chloride
DM0TELR CP Takeda
DM0TELR DT Small molecular drug
DM0TELR PC 183789
DM0TELR MW 531.1
DM0TELR FM C33H39ClN2O2
DM0TELR IC InChI=1S/C33H38N2O2.ClH/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2,3)32-17-19-37-20-18-32;/h7-16,21-22,32H,4-6,17-20,23H2,1-3H3;1H
DM0TELR CS CC1=CC=C(C=C1)C2=CC3=C(CCCC(=C3)C(=O)NC4=CC=C(C=C4)C[N+](C)(C)C5CCOCC5)C=C2.[Cl-]
DM0TELR IK VDALIBWXVQVFGZ-UHFFFAOYSA-N
DM0TELR IU dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7H-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;chloride
DM0TELR CA CAS 229005-80-5
DM0TELR DE Transplant rejection
DM2OFBT ID DM2OFBT
DM2OFBT DN Talisomycin
DM2OFBT HS Terminated
DM2OFBT SN Talisomycin; Tallysomycin A; Antibiotic BU 2231A; Talisomycin [USAN:INN]; Talisomycinum [INN-Latin]; Talisomycine [INN-French]; Talisomycina [INN-Spanish]; BU 2231A; AC1Q5FXD; AC1L2HKD; N(sup 1)-(4-Amino-5-((3-((4-aminobutyl)amino)propyl)carbamoyl)pentyl)-13-((4-amino-4,6-dideoxy-alpha-L-talopyranosyl)oxy)-19-demethyl-12-hydroxybleomycinamide; Bleomycinamide, N(sup 1)-(4-amino-6-((3-((4-aminobutyl)amino)propyl)amino)-6-oxohexyl)-13-((4-amino-4,6-dideoxy-alpha-L-talopyranosyl)oxy)-19-demethyl-12-hydroxy-
DM2OFBT DT Small molecular drug
DM2OFBT PC 72173
DM2OFBT MW 1731.9
DM2OFBT FM C68H110N22O27S2
DM2OFBT IC InChI=1S/C68H110N22O27S2/c1-25-42(87-57(89-55(25)74)31(16-38(72)95)81-18-30(71)56(75)105)59(107)88-44(52(32-19-78-24-82-32)114-67-54(48(101)45(98)36(20-91)113-67)115-66-50(103)53(116-68(76)110)46(99)37(21-92)112-66)61(109)83-26(2)35(94)17-40(97)86-43(27(3)93)60(108)90-62(117-65-49(102)47(100)41(73)28(4)111-65)51(104)64-85-34(23-119-64)63-84-33(22-118-63)58(106)80-13-7-9-29(70)15-39(96)79-14-8-12-77-11-6-5-10-69/h19,22-24,26-31,35-37,41,43-54,62,65-67,77,81,91-94,98-104H,5-18,20-21,69-71,73H2,1-4H3,(H2,72,95)(H2,75,105)(H2,76,110)(H,78,82)(H,79,96)(H,80,106)(H,83,109)(H,86,97)(H,88,107)(H,90,108)(H2,74,87,89)/t26?,27?,28-,29?,30?,31?,35?,36-,37+,41+,43?,44?,45+,46+,47+,48-,49+,50-,51?,52?,53-,54-,62?,65-,66+,67+/m0/s1
DM2OFBT CS C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)OC(C(C2=NC(=CS2)C3=NC(=CS3)C(=O)NCCCC(CC(=O)NCCCNCCCCN)N)O)NC(=O)C(C(C)O)NC(=O)CC(C(C)NC(=O)C(C(C4=CN=CN4)O[C@@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(=O)N)O)NC(=O)C7=C(C(=NC(=N7)C(CC(=O)N)NCC(C(=O)N)N)N)C)O)O)O)N
DM2OFBT IK VUPBDWQPEOWRQP-SDSCCWNESA-N
DM2OFBT IU [(2R,3S,4S,5R,6R)-2-[(2S,3S,4S,5S,6S)-2-[3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate
DM54V0X ID DM54V0X
DM54V0X DN Tamoxifen methyl iodide
DM54V0X HS Terminated
DM54V0X SN Tamoxifen methiodide; Tamoxifen methyl iodide; CHEMBL1213783; MLS002701640; AC1MHWIV; N-Methyltamoxifen iodide; 107256-99-5; PXJJOGITBQXZEQ-JTHROIFXSA-M; NSC630510; NSC-630510; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N,N-trimethylethanaminium iodide; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium iodide; Ethanaminium, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N,N-trimethyl-, iodide, (Z)-
DM54V0X DT Small molecular drug
DM54V0X PC 3033898
DM54V0X MW 513.5
DM54V0X FM C27H32INO
DM54V0X IC InChI=1S/C27H32NO.HI/c1-5-26(22-12-8-6-9-13-22)27(23-14-10-7-11-15-23)24-16-18-25(19-17-24)29-21-20-28(2,3)4;/h6-19H,5,20-21H2,1-4H3;1H/q+1;/p-1/b27-26-;
DM54V0X CS CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCC[N+](C)(C)C)/C3=CC=CC=C3.[I-]
DM54V0X IK PXJJOGITBQXZEQ-JTHROIFXSA-M
DM54V0X IU 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide
DM54V0X CA CAS 107256-99-5
DMU3BDY ID DMU3BDY
DMU3BDY DN TAN-1496
DMU3BDY HS Terminated
DMU3BDY SN TAN-1496A; TAN-1496B; TAN-1496C; TAN-1496D; TAN-1496E
DMU3BDY CP Takeda Pharmaceutical Co Ltd
DMU3BDY DE Solid tumour/cancer
DM197D0 ID DM197D0
DM197D0 DN TAR-1
DM197D0 HS Terminated
DM197D0 SN P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions
DM197D0 CP Ramot at Tel Aviv University Ltd
DM197D0 DT Antibody
DM197D0 DE Solid tumour/cancer
DMCFGS6 ID DMCFGS6
DMCFGS6 DN TCV-295
DMCFGS6 HS Terminated
DMCFGS6 SN 2-(6-Bromo-7-chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine N-oxide
DMCFGS6 PC 9999062
DMCFGS6 MW 367.62
DMCFGS6 FM C15H12BrClN2O2
DMCFGS6 IC InChI=1S/C15H12BrClN2O2/c1-15(2)18-14(12-5-3-4-6-19(12)20)9-7-10(16)11(17)8-13(9)21-15/h3-8H,1-2H3
DMCFGS6 CS CC1(N=C(C2=CC(=C(C=C2O1)Cl)Br)C3=CC=CC=[N+]3[O-])C
DMCFGS6 IK YUEQBWZPZJXBHY-UHFFFAOYSA-N
DMCFGS6 IU 6-bromo-7-chloro-2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-1,3-benzoxazine
DMCFGS6 DE Hypertension
DMHS5DX ID DMHS5DX
DMHS5DX DN TEI-6522
DMHS5DX HS Terminated
DMHS5DX CP Teijin Ltd
DMHS5DX PC 9953017
DMHS5DX MW 403.6
DMHS5DX FM C24H37NO4
DMHS5DX IC InChI=1S/C24H37NO4/c1-5-6-7-8-9-10-11-12-16-24(2,3)23(27)25-21-20(28-4)14-13-18-19(26)15-17-29-22(18)21/h13-14H,5-12,15-17H2,1-4H3,(H,25,27)
DMHS5DX CS CCCCCCCCCCC(C)(C)C(=O)NC1=C(C=CC2=C1OCCC2=O)OC
DMHS5DX IK DJBINNZKEHJIFK-UHFFFAOYSA-N
DMHS5DX IU N-(7-methoxy-4-oxo-2,3-dihydrochromen-8-yl)-2,2-dimethyldodecanamide
DMHS5DX DE Arteriosclerosis
DMXM3B4 ID DMXM3B4
DMXM3B4 DN TEI-9874
DMXM3B4 HS Terminated
DMXM3B4 CP Teijin Institute for Biomedical Research
DMXM3B4 PC 9935533
DMXM3B4 MW 495.6
DMXM3B4 FM C31H29NO5
DMXM3B4 IC InChI=1S/C31H29NO5/c33-30(32-29-9-5-4-8-28(29)31(34)35)18-21-10-14-25(15-11-21)37-27-17-13-22-19-26(16-12-23(22)20-27)36-24-6-2-1-3-7-24/h4-5,8-17,19-20,24H,1-3,6-7,18H2,(H,32,33)(H,34,35)
DMXM3B4 CS C1CCC(CC1)OC2=CC3=C(C=C2)C=C(C=C3)OC4=CC=C(C=C4)CC(=O)NC5=CC=CC=C5C(=O)O
DMXM3B4 IK XNTHZBOCPVDIQB-UHFFFAOYSA-N
DMXM3B4 IU 2-[[2-[4-(6-cyclohexyloxynaphthalen-2-yl)oxyphenyl]acetyl]amino]benzoic acid
DMXM3B4 DE Allergy
DMQIYZR ID DMQIYZR
DMQIYZR DN TER-16998
DMQIYZR HS Terminated
DMQIYZR SN TER-17411; TER-17529; TLK-16998; TLK-17411; TLK-19780; TLK-19781; Insulin receptor activators (oral, diabetes mellitus); Insulin receptor activators (oral, diabetes mellitus), ReceptorBio; Insulin receptor activators (oral, diabetes), Telik/Sanwa
DMQIYZR CP Telik Inc
DMQIYZR DE Diabetic complication
DM2X5R6 ID DM2X5R6
DM2X5R6 DN TERIKALANT
DM2X5R6 HS Terminated
DM2X5R6 SN Terikalant; Terikalant [INN]; UNII-G8ZMP77RGJ; Terikalantum [INN-Latin]; G8ZMP77RGJ; RP-58866; CHEMBL96153; Terikalant (INN); RP62719; 121277-96-1; C24H31NO3; Terikalantum; (-)-(S)-1-(2-(4-Chromanyl)ethyl)-4-(3,4-dimethoxyphenyl)piperidine; RP-62719; (-)-(s)-1-[2-(4-chromanyl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine; AC1L24AK; SCHEMBL1815992; AC1Q5768; BDBM50131442; RP 62719; 132338-79-5; RP 58866; LS-172487; D09757; (S)-1-(2-(chroman-4-yl)ethyl)-4-(3,4-dimethoxyphenyl)piperidine
DM2X5R6 DT Small molecular drug
DM2X5R6 PC 65941
DM2X5R6 MW 381.5
DM2X5R6 FM C24H31NO3
DM2X5R6 IC InChI=1S/C24H31NO3/c1-26-23-8-7-20(17-24(23)27-2)18-9-13-25(14-10-18)15-11-19-12-16-28-22-6-4-3-5-21(19)22/h3-8,17-19H,9-16H2,1-2H3/t19-/m0/s1
DM2X5R6 CS COC1=C(C=C(C=C1)C2CCN(CC2)CC[C@H]3CCOC4=CC=CC=C34)OC
DM2X5R6 IK UIZPEXQHMIZQPQ-IBGZPJMESA-N
DM2X5R6 IU 1-[2-[(4S)-3,4-dihydro-2H-chromen-4-yl]ethyl]-4-(3,4-dimethoxyphenyl)piperidine
DM2X5R6 CA CAS 121277-96-1
DM2X5R6 DE Cardiac arrhythmias
DMSRDGE ID DMSRDGE
DMSRDGE DN TH-0318
DMSRDGE HS Terminated
DMSRDGE SN ThGLP-1, Theratechnologies; LAP-stabilized GLP-1 analogs (diabetes), Theratechnologies/OctoPlus
DMSRDGE CP Theratechnologies
DMSRDGE DE Diabetic complication
DMG1MPD ID DMG1MPD
DMG1MPD DN TH-9229
DMG1MPD HS Terminated
DMG1MPD SN Protectazem
DMG1MPD CP Theratechnologies Inc
DMG1MPD DE Reperfusion injury
DM8S593 ID DM8S593
DM8S593 DN Thioperamide
DM8S593 HS Terminated
DM8S593 SN Thioperamide; 106243-16-7; Thioperamide maleate; MR 12842; UNII-II4319BWUI; 1-Piperidinecarbothioamide, N-cyclohexyl-4-(1H-imidazol-4-yl)-; II4319BWUI; N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide; CHEMBL260374; N-cyclohexyl-4-(1H-imidazol-5-yl)piperidine-1-carbothioamide; CHEBI:81391; N-Cyclohexyl-4-(1H-imidazol-5-yl)-1-piperidinecarbothioamide; Tocris-0644; Lopac-T-123; Lopac0_001214; SCHEMBL2235762; GTPL1267; AC1MI071; BDBM22914; DTXSID50147555; MolPort-023-275-907; MolPort-015-163-994
DM8S593 DT Small molecular drug
DM8S593 PC 3035905
DM8S593 MW 292.4
DM8S593 FM C15H24N4S
DM8S593 IC InChI=1S/C15H24N4S/c20-15(18-13-4-2-1-3-5-13)19-8-6-12(7-9-19)14-10-16-11-17-14/h10-13H,1-9H2,(H,16,17)(H,18,20)
DM8S593 CS C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
DM8S593 IK QKDDJDBFONZGBW-UHFFFAOYSA-N
DM8S593 IU N-cyclohexyl-4-(1H-imidazol-5-yl)piperidine-1-carbothioamide
DM8S593 CA CAS 106243-16-7
DM8S593 CB CHEBI:81391
DM8S593 DE Cognitive impairment
DM0SCDB ID DM0SCDB
DM0SCDB DN TIAPAFANT
DM0SCDB HS Terminated
DM0SCDB SN PCA-4248; 2,4,6-Trimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-methyl 5-(2-phenylthio)ethyl diester
DM0SCDB DT Small molecular drug
DM0SCDB PC 4698
DM0SCDB MW 361.5
DM0SCDB FM C19H23NO4S
DM0SCDB IC InChI=1S/C19H23NO4S/c1-12-16(18(21)23-4)13(2)20-14(3)17(12)19(22)24-10-11-25-15-8-6-5-7-9-15/h5-9,12,20H,10-11H2,1-4H3
DM0SCDB CS CC1C(=C(NC(=C1C(=O)OCCSC2=CC=CC=C2)C)C)C(=O)OC
DM0SCDB IK DHCNAWNKZMNTIS-UHFFFAOYSA-N
DM0SCDB IU 3-O-methyl 5-O-(2-phenylsulfanylethyl) 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM0SCDB CA CAS 123875-01-4
DM0SCDB CB CHEBI:91615
DM0SCDB DE Sepsis
DMGCI6E ID DMGCI6E
DMGCI6E DN Tipredane
DMGCI6E HS Terminated
DMGCI6E SN Uoderm; Acti-Derm I; SQ-27239
DMGCI6E CP Bristol-Myers Squibb Co
DMGCI6E DT Small molecular drug
DMGCI6E PC 6917939
DMGCI6E MW 410.6
DMGCI6E FM C22H31FO2S2
DMGCI6E IC InChI=1S/C22H31FO2S2/c1-5-27-21(26-4)11-9-16-17-7-6-14-12-15(24)8-10-19(14,2)22(17,23)18(25)13-20(16,21)3/h8,10,12,16-18,25H,5-7,9,11,13H2,1-4H3/t16-,17-,18-,19-,20-,21+,22-/m0/s1
DMGCI6E CS CCS[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)SC
DMGCI6E IK DXEXNWDGDYUITL-FXSSSKFRSA-N
DMGCI6E IU (8S,9R,10S,11S,13S,14S,17R)-17-ethylsulfanyl-9-fluoro-11-hydroxy-10,13-dimethyl-17-methylsulfanyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMGCI6E CA CAS 85197-77-9
DMGCI6E DE Allergy
DM4YQDX ID DM4YQDX
DM4YQDX DN TJN-220
DM4YQDX HS Terminated
DM4YQDX SN O-Ethylfangchinoline; O-ethylfangchinoline, Tsumura; 7-O-ethylfangchinoline, Tsumura
DM4YQDX CP Tsumura & Co
DM4YQDX DT Small molecular drug
DM4YQDX PC 3081672
DM4YQDX MW 636.8
DM4YQDX FM C39H44N2O6
DM4YQDX IC InChI=1S/C39H44N2O6/c1-7-45-38-36(44-6)22-27-15-17-41(3)31-19-25-10-13-32(42-4)34(20-25)46-28-11-8-24(9-12-28)18-30-29-23-35(47-39(38)37(27)31)33(43-5)21-26(29)14-16-40(30)2/h8-13,20-23,30-31H,7,14-19H2,1-6H3/t30-,31-/m0/s1
DM4YQDX CS CCOC1=C(C=C2CCN([C@@H]3C2=C1OC4=C(C=C5CCN([C@H](C5=C4)CC6=CC=C(C=C6)OC7=C(C=CC(=C7)C3)OC)C)OC)C)OC
DM4YQDX IK VNBSKOLSTYLJBG-CONSDPRKSA-N
DM4YQDX IU (1S,14S)-21-ethoxy-9,20,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
DM4YQDX CA CAS 118160-59-1
DM4YQDX DE Hypertension
DMKSPYI ID DMKSPYI
DMKSPYI DN TJN-598
DMKSPYI HS Terminated
DMKSPYI SN Glomerulonephritis therapy, Tsumura
DMKSPYI CP Tsumura & Co
DMKSPYI DE Glomerulonephritis
DMTNB6G ID DMTNB6G
DMTNB6G DN TNFQb therapeutic vaccines
DMTNB6G HS Terminated
DMTNB6G SN TNFQb; CYT-020-TNFQb; TNF-targeted vaccine (inflammation, Immunodrug), Cytos Biotechnology; TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease); TNFQb therapeutic vaccines (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos; Immunodrug vaccines (TNF) (rheumatoid arthritis/psoriasis/Crohn's disease), Cytos
DMTNB6G CP Cytos Biotechnology AG
DMTNB6G DT Vaccine
DMTNB6G DE Crohn disease
DMZKIE0 ID DMZKIE0
DMZKIE0 DN Tolerimab
DMZKIE0 HS Terminated
DMZKIE0 SN Transplant rejection therapy, Innogenetics; MAbs (organ transplant), Innogenetics; Monoclonal antibodies (organ transplant), Innogenetics; ToleriMab (anti-B7.1/B7.2)
DMZKIE0 CP Innogenetics NV
DMZKIE0 DT Antibody
DMZKIE0 DE Transplant rejection
DM385D9 ID DM385D9
DM385D9 DN Tomelukast
DM385D9 HS Terminated
DM385D9 SN LY-171883
DM385D9 CP Eli Lilly & Co
DM385D9 DT Small molecular drug
DM385D9 PC 3969
DM385D9 MW 318.37
DM385D9 FM C16H22N4O3
DM385D9 IC InChI=1S/C16H22N4O3/c1-3-6-13-14(9-8-12(11(2)21)16(13)22)23-10-5-4-7-15-17-19-20-18-15/h8-9,22H,3-7,10H2,1-2H3,(H,17,18,19,20)
DM385D9 CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCC2=NNN=N2
DM385D9 IK MWYHLEQJTQJHSS-UHFFFAOYSA-N
DM385D9 IU 1-[2-hydroxy-3-propyl-4-[4-(2H-tetrazol-5-yl)butoxy]phenyl]ethanone
DM385D9 CA CAS 88107-10-2
DM385D9 CB CHEBI:75310
DM385D9 DE Asthma
DMRBGI6 ID DMRBGI6
DMRBGI6 DN Torbafylline
DMRBGI6 HS Terminated
DMRBGI6 SN Torbaphylline; HWA-448
DMRBGI6 CP Hoechst Marion Roussel Inc
DMRBGI6 DT Small molecular drug
DMRBGI6 PC 65888
DMRBGI6 MW 338.4
DMRBGI6 FM C16H26N4O4
DMRBGI6 IC InChI=1S/C16H26N4O4/c1-5-24-11-19-10-17-13-12(19)14(21)20(15(22)18(13)4)9-7-6-8-16(2,3)23/h10,23H,5-9,11H2,1-4H3
DMRBGI6 CS CCOCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(C)(C)O
DMRBGI6 IK QSXXLDDWVCEBFP-UHFFFAOYSA-N
DMRBGI6 IU 7-(ethoxymethyl)-1-(5-hydroxy-5-methylhexyl)-3-methylpurine-2,6-dione
DMRBGI6 CA CAS 105102-21-4
DMRBGI6 DE Peripheral vascular disease
DM5ZNSQ ID DM5ZNSQ
DM5ZNSQ DN TP-20
DM5ZNSQ HS Terminated
DM5ZNSQ SN SCR1sLex; SLex/sCR1
DM5ZNSQ CP Celldex Therapeutics Inc
DM5ZNSQ DE Cerebrovascular ischaemia
DMQRSMD ID DMQRSMD
DMQRSMD DN Trequinsin
DMQRSMD HS Terminated
DMQRSMD SN trequinsin; Trequinsin [INN]; Trequinsinum [INN-Latin]; Trequinsine [INN-French]; 79855-88-2; UNII-739I2958C1; CHEMBL285913; (2e)-2-(mesitylimino)-9,10-dimethoxy-3-methyl-2,3,6,7-tetrahydro-4h-pyrimido[6,1-a]isoquinolin-4-one; 739I2958C1; Trequinsinum; Trequinsine; C24H27N3O3; 2,3,6,7-Tetrahydro-2-(mesitylimino)-9,10-dimethoxy-3-methyl-4H-pyrimido(6,1-a)isoquinolin-4-one; AC1L1KKE; AC1Q6LSV; Lopac-T-2057; Lopac0_001165; KBioGR_000072; KBioSS_000072; BSPBio_001352; SCHEMBL2777196; SCHEMBL2396911; CHEMBL588593; CHEMBL1411581
DMQRSMD DT Small molecular drug
DMQRSMD PC 5537
DMQRSMD MW 405.5
DMQRSMD FM C24H27N3O3
DMQRSMD IC InChI=1S/C24H27N3O3/c1-14-9-15(2)23(16(3)10-14)25-22-13-19-18-12-21(30-6)20(29-5)11-17(18)7-8-27(19)24(28)26(22)4/h9-13H,7-8H2,1-6H3
DMQRSMD CS CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2C)OC)OC)C
DMQRSMD IK MCMSJVMUSBZUCN-UHFFFAOYSA-N
DMQRSMD IU 9,10-dimethoxy-3-methyl-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one
DMQRSMD CA CAS 79855-88-2
DMQRSMD CB CHEBI:93477
DMUHBSI ID DMUHBSI
DMUHBSI DN Tridegin
DMUHBSI HS Terminated
DMUHBSI CP Biopharm
DMUHBSI DE Thrombosis
DMASENP ID DMASENP
DMASENP DN TULOPAFANT
DMASENP HS Terminated
DMASENP SN RP-59227; Tulopafant; (R)-(+)-3'-Benzoyl-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxanilide; (R)-(+)-N-(3-Benzoylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carboxamide; 59227-RP
DMASENP DT Small molecular drug
DMASENP PC 65927
DMASENP MW 425.5
DMASENP FM C25H19N3O2S
DMASENP IC InChI=1S/C25H19N3O2S/c29-23(17-6-2-1-3-7-17)18-8-4-10-20(14-18)27-24(30)21-11-13-28-22(21)16-31-25(28)19-9-5-12-26-15-19/h1-15,25H,16H2,(H,27,30)
DMASENP CS C1C2=C(C=CN2C(S1)C3=CN=CC=C3)C(=O)NC4=CC=CC(=C4)C(=O)C5=CC=CC=C5
DMASENP IK PQQFNXGONTVQLM-UHFFFAOYSA-N
DMASENP IU N-(3-benzoylphenyl)-3-pyridin-3-yl-1,3-dihydropyrrolo[1,2-c][1,3]thiazole-7-carboxamide
DMASENP DE Cardiac arrhythmias
DMR3S9B ID DMR3S9B
DMR3S9B DN Tyloxapol
DMR3S9B HS Terminated
DMR3S9B SN Alevaire; Enuclene; Macrocyclon; Oxirane; Superinone; Superiuone; Tiloxapol; Tyloxapolum; Tyloxypal; Component of Alevaire; Superiuone [French]; Triton WR 1339; P-Isooctylpolyoxyethylenephenol formaldehyde polymer; Tiloxapol [INN-Spanish]; Triton A-20; Triton WR-1339; Tyloxapolum [INN-Latin]; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Triton W.R.1339; Tyloxapol [USAN:BAN:INN]; Ethylene oxide-formaldehyde-p-octylphenol copolymer; P-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 4-(2,4,4-trimethylpentan-2-yl)phenol
DMR3S9B CP Discovery Laboratories
DMR3S9B DT Small molecular drug
DMR3S9B PC 71388
DMR3S9B MW 280.4
DMR3S9B FM C17H28O3
DMR3S9B IC InChI=1S/C14H22O.C2H4O.CH2O/c1-13(2,3)10-14(4,5)11-6-8-12(15)9-7-11;1-2-3-1;1-2/h6-9,15H,10H2,1-5H3;1-2H2;1H2
DMR3S9B CS CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1
DMR3S9B IK MDYZKJNTKZIUSK-UHFFFAOYSA-N
DMR3S9B IU formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
DMR3S9B CA CAS 25301-02-4
DMR3S9B CB CHEBI:141517
DMR3S9B DE Cystic fibrosis
DM4WUEP ID DM4WUEP
DM4WUEP DN U-54494A
DM4WUEP HS Terminated
DM4WUEP SN C18H24Cl2N2O; U 54494A; U 54494; U-54494; U-54494A; cis-3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzamide; Benzamide, 3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-, trans-; AC1L3TTM; 92953-41-8; AC1Q3O5Y; SCHEMBL11610023; 3,4-dichloro-n-methyl-n-[(1r,2r)-2-(pyrrolidin-1-yl)cyclohexyl]benzamide; LS-178194; A845921; UNII-I3NE36R0XJ component JUBNVWGVNWIXMB-IAGOWNOFSA-N; trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamide
DM4WUEP CP Pharmacia & Upjohn Co
DM4WUEP DT Small molecular drug
DM4WUEP PC 122015
DM4WUEP MW 355.3
DM4WUEP FM C18H24Cl2N2O
DM4WUEP IC InChI=1S/C18H24Cl2N2O/c1-21(18(23)13-8-9-14(19)15(20)12-13)16-6-2-3-7-17(16)22-10-4-5-11-22/h8-9,12,16-17H,2-7,10-11H2,1H3/t16-,17-/m1/s1
DM4WUEP CS CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)C3=CC(=C(C=C3)Cl)Cl
DM4WUEP IK JUBNVWGVNWIXMB-IAGOWNOFSA-N
DM4WUEP IU 3,4-dichloro-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]benzamide
DM4WUEP CA CAS 92953-41-8
DM4WUEP DE Epilepsy
DMRBXEA ID DMRBXEA
DMRBXEA DN U-75875
DMRBXEA HS Terminated
DMRBXEA SN U-75875; U 75875; 112190-24-6; CHEMBL3350189; U75875; Pnu-75875; 1hiv; AC1NUHX2; Noa-his-cha-psi(CH(OH)CH(OH))-val-ile-amp; NOA-HIS-CAV-ILE-APY; SCHEMBL15532017; DTXSID20149940; BDBM50212827; 1-Naphthoxyacetyl-histidyl-5-amino-6-cyclohexyl-3,4-dihydroxy-2-isopropylhexanoyl-isoleucyl-2-aminopyridine; Noa-His-Cha.psi.[CHOHCHOH]Val-Ile-Amp; L-Idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[[(2S)-3-(1H-imidazol-4-yl)-2-[[(1-naphthalenyloxy)acetyl]amino]-1-oxopropyl]amino]-2-(1-methylethyl)-N-[(1S,2S)-2-methyl-1-[[(2-pyridinylmethyl
DMRBXEA CP Pharmacia & Upjohn Co
DMRBXEA DT Small molecular drug
DMRBXEA PC 5479205
DMRBXEA MW 812
DMRBXEA FM C45H61N7O7
DMRBXEA IC InChI=1S/C45H61N7O7/c1-5-29(4)40(45(58)48-25-32-18-11-12-21-47-32)52-44(57)39(28(2)3)42(55)41(54)35(22-30-14-7-6-8-15-30)51-43(56)36(23-33-24-46-27-49-33)50-38(53)26-59-37-20-13-17-31-16-9-10-19-34(31)37/h9-13,16-21,24,27-30,35-36,39-42,54-55H,5-8,14-15,22-23,25-26H2,1-4H3,(H,46,49)(H,48,58)(H,50,53)(H,51,56)(H,52,57)/t29-,35-,36-,39+,40-,41+,42+/m0/s1
DMRBXEA CS CC[C@H](C)[C@@H](C(=O)NCC1=CC=CC=N1)NC(=O)[C@@H]([C@H]([C@@H]([C@H](CC2CCCCC2)NC(=O)[C@H](CC3=CN=CN3)NC(=O)COC4=CC=CC5=CC=CC=C54)O)O)C(C)C
DMRBXEA IK ZTKCGLWIXHAITR-JIFWBGJESA-N
DMRBXEA IU (2R,3R,4R,5S)-6-cyclohexyl-3,4-dihydroxy-5-[[(2S)-3-(1H-imidazol-5-yl)-2-[(2-naphthalen-1-yloxyacetyl)amino]propanoyl]amino]-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]-2-propan-2-ylhexanamide
DMRBXEA CA CAS 112190-24-6
DMRBXEA DE Human immunodeficiency virus infection
DMGUMWP ID DMGUMWP
DMGUMWP DN U-80816
DMGUMWP HS Terminated
DMGUMWP CP Pharmacia & Upjohn Co
DMGUMWP PC 10176765
DMGUMWP MW 216.28
DMGUMWP FM C13H16N2O
DMGUMWP IC InChI=1S/C13H16N2O/c1-12-6-4-10-14(12)8-2-3-9-15-11-5-7-13(15)16/h4,6,10H,5,7-9,11H2,1H3
DMGUMWP CS CC1=CC=CN1CC#CCN2CCCC2=O
DMGUMWP IK RBCXUJODVKKGBN-UHFFFAOYSA-N
DMGUMWP IU 1-[4-(2-methylpyrrol-1-yl)but-2-ynyl]pyrrolidin-2-one
DMGUMWP DE Amnesia
DMTMZJ4 ID DMTMZJ4
DMTMZJ4 DN U-90042
DMTMZJ4 HS Terminated
DMTMZJ4 SN U 90042; 134516-99-7; U90042; Diimidazo[1,5-a:1',2'-c]quinazoline,11-chloro-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-; ACMC-20ejs3; SCHEMBL7326473; CTK4B9224; DTXSID40158771; MolPort-023-276-561; ZINC34033310; AKOS024457266; NCGC00378706-01; B7164; J-006546; 11-Chloro-5-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydrodiimidazo[1,5-a:1',2'-c]quinazoline
DMTMZJ4 CP Pharmacia & Upjohn Co
DMTMZJ4 DT Small molecular drug
DMTMZJ4 PC 9928470
DMTMZJ4 MW 352.8
DMTMZJ4 FM C17H13ClN6O
DMTMZJ4 IC InChI=1S/C17H13ClN6O/c18-10-3-4-12-11(7-10)15-19-5-6-23(15)17-13(20-8-24(12)17)14-21-16(25-22-14)9-1-2-9/h3-4,7-9H,1-2,5-6H2
DMTMZJ4 CS C1CC1C2=NC(=NO2)C3=C4N5CCN=C5C6=C(N4C=N3)C=CC(=C6)Cl
DMTMZJ4 IK CLPSAAPUJUVQPP-UHFFFAOYSA-N
DMTMZJ4 IU 3-(14-chloro-2,4,7,10-tetrazatetracyclo[10.4.0.02,6.07,11]hexadeca-1(12),3,5,10,13,15-hexaen-5-yl)-5-cyclopropyl-1,2,4-oxadiazole
DMTMZJ4 CA CAS 134516-99-7
DMTMZJ4 DE Anxiety disorder
DMTYO3P ID DMTYO3P
DMTYO3P DN U-92032
DMTYO3P HS Terminated
DMTYO3P SN U-92032; U 92032; CHEMBL327057; 142223-92-5; AC1L30XY; SCHEMBL195024; DTXSID70161975; BDBM50091592; u92032; 7-((4-(Bis(4-fluorophenyl)methyl)-1-piperazinyl)methyl)-2-((2-hydroxyethyl)amino)-4-(1-methylethylethyl)-2,4,6-cycloheptatrien-1-one; 7-{4-[Bis-(4-fluoro-phenyl)-methyl]-piperazin-1-ylmethyl}-2-(2-hydroxy-ethylamino)-4-isopropyl-cyclohepta-2,4,6-trienone(U-92032); 2,4,6-Cycloheptatrien-1-one, 7-((4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)methyl)-2-((2-hydroxyethyl)amino)-4-(1-methylethyl)-
DMTYO3P DT Small molecular drug
DMTYO3P PC 132417
DMTYO3P MW 507.6
DMTYO3P FM C30H35F2N3O2
DMTYO3P IC InChI=1S/C30H35F2N3O2/c1-21(2)24-3-4-25(30(37)28(19-24)33-13-18-36)20-34-14-16-35(17-15-34)29(22-5-9-26(31)10-6-22)23-7-11-27(32)12-8-23/h3-12,19,21,29,36H,13-18,20H2,1-2H3,(H,33,37)
DMTYO3P CS CC(C)C1=CC=C(C(=O)C(=C1)NCCO)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DMTYO3P IK UVPCKMJVJLKETQ-UHFFFAOYSA-N
DMTYO3P IU 7-[[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]methyl]-2-(2-hydroxyethylamino)-4-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMTYO3P CA CAS 142223-92-5
DM0Z7PK ID DM0Z7PK
DM0Z7PK DN UC-38
DM0Z7PK HS Terminated
DM0Z7PK SN NSC-629243; NSC-D-629243
DM0Z7PK CP Uniroyal Chemical Co Inc
DM0Z7PK DT Small molecular drug
DM0Z7PK PC 3000477
DM0Z7PK MW 315.8
DM0Z7PK FM C14H18ClNO3S
DM0Z7PK IC InChI=1S/C14H18ClNO3S/c1-8(2)18-13(17)11-7-10(5-6-12(11)15)16-14(20)19-9(3)4/h5-9H,1-4H3,(H,16,20)
DM0Z7PK CS CC(C)OC(=O)C1=C(C=CC(=C1)NC(=S)OC(C)C)Cl
DM0Z7PK IK AXTNFJKQZPETJA-UHFFFAOYSA-N
DM0Z7PK IU propan-2-yl 2-chloro-5-(propan-2-yloxycarbothioylamino)benzoate
DM0Z7PK CA CAS 135812-34-9
DM0Z7PK DE Human immunodeficiency virus infection
DMY9UEZ ID DMY9UEZ
DMY9UEZ DN UC-84
DMY9UEZ HS Terminated
DMY9UEZ SN NSC-615985; NSC-D-615985
DMY9UEZ CP Uniroyal Chemical Co Inc
DMY9UEZ DT Small molecular drug
DMY9UEZ PC 1385
DMY9UEZ MW 355.8
DMY9UEZ FM C16H18ClNO4S
DMY9UEZ IC InChI=1S/C16H18ClNO4S/c1-9(2)22-16(20)12-8-11(4-5-13(12)17)18-15(19)14-10(3)21-6-7-23-14/h4-5,8-9H,6-7H2,1-3H3,(H,18,19)
DMY9UEZ CS CC1=C(SCCO1)C(=O)NC2=CC(=C(C=C2)Cl)C(=O)OC(C)C
DMY9UEZ IK FMQGUMRNTBJHEA-UHFFFAOYSA-N
DMY9UEZ IU propan-2-yl 2-chloro-5-[(6-methyl-2,3-dihydro-1,4-oxathiine-5-carbonyl)amino]benzoate
DMY9UEZ CA CAS 135812-04-3
DMY9UEZ DE Human immunodeficiency virus infection
DMD3CA5 ID DMD3CA5
DMD3CA5 DN UCL-1390
DMD3CA5 HS Terminated
DMD3CA5 SN UCL-1390; CHEMBL113030; AC1O4XEX; 4-[3-(1H-Imidazol-4-yl)propoxy]benzonitrile; SCHEMBL650642; XQNBJFUWFIHAMW-UHFFFAOYSA-N; ZINC1536439; BDBM50053278; 4-[3-(1H-imidazol-5-yl)propoxy]benzonitrile; 4-[3-(1H-Imidazol-4-yl)-propoxy]-benzonitrile; L009128; 4-[3-(1H-Imidazol-4-yl)-propoxy]-benzonitrile (UCL 1390)
DMD3CA5 CP University College London
DMD3CA5 TC Analgesics
DMD3CA5 DT Small molecular drug
DMD3CA5 PC 6421295
DMD3CA5 MW 227.26
DMD3CA5 FM C13H13N3O
DMD3CA5 IC InChI=1S/C13H13N3O/c14-8-11-3-5-13(6-4-11)17-7-1-2-12-9-15-10-16-12/h3-6,9-10H,1-2,7H2,(H,15,16)
DMD3CA5 CS C1=CC(=CC=C1C#N)OCCCC2=CN=CN2
DMD3CA5 IK XQNBJFUWFIHAMW-UHFFFAOYSA-N
DMD3CA5 IU 4-[3-(1H-imidazol-5-yl)propoxy]benzonitrile
DMD3CA5 DE Pain; Epilepsy; Eating disorder
DM9FT5E ID DM9FT5E
DM9FT5E DN UD-CG-212
DM9FT5E HS Terminated
DM9FT5E SN UD-CG-212BS; UD-CG-212Cl
DM9FT5E CP Boehringer Ingelheim Corp
DM9FT5E PC 122345
DM9FT5E MW 320.3
DM9FT5E FM C18H16N4O2
DM9FT5E IC InChI=1S/C18H16N4O2/c1-10-8-16(24)21-22-17(10)12-4-7-14-15(9-12)20-18(19-14)11-2-5-13(23)6-3-11/h2-7,9-10,23H,8H2,1H3,(H,19,20)(H,21,24)
DM9FT5E CS CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)O
DM9FT5E IK QOAXSEARPHDXFC-UHFFFAOYSA-N
DM9FT5E IU 3-[2-(4-hydroxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one
DM9FT5E CA CAS 108381-22-2
DM9FT5E DE Heart failure
DMQFSAB ID DMQFSAB
DMQFSAB DN UK-290795
DMQFSAB HS Terminated
DMQFSAB CP Pfizer Inc
DMQFSAB DE Urinary incontinence
DM23YPS ID DM23YPS
DM23YPS DN UK-51656
DM23YPS HS Terminated
DM23YPS CP Pfizer Ltd
DM23YPS PC 9912345
DM23YPS MW 465.9
DM23YPS FM C22H28ClN3O6
DM23YPS IC InChI=1S/C22H28ClN3O6/c1-4-32-22(29)20-16(12-31-10-9-25-11-17(24)27)26-13(2)18(21(28)30-3)19(20)14-7-5-6-8-15(14)23/h5-8,19,25-26H,4,9-12H2,1-3H3,(H2,24,27)
DM23YPS CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCNCC(=O)N
DM23YPS IK FAKQIHAUXYAVJI-UHFFFAOYSA-N
DM23YPS IU 3-O-ethyl 5-O-methyl 2-[2-[(2-amino-2-oxoethyl)amino]ethoxymethyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
DM23YPS DE Cardiovascular disease
DMKBILF ID DMKBILF
DMKBILF DN UK-78282
DMKBILF HS Terminated
DMKBILF SN UK-78282; CHEMBL9653; AC1LCVJE; UK 78282; UK-78282 monohydrochloride; CHEBI:35042; C13848; 4-(benzhydryloxymethyl)-1-[3-(4-methoxyphenyl)propyl]piperidine; ZINC3798289; DNC004154; BDBM50098785; NCGC00370962-01; AJ-45641; RT-016190; J-006878
DMKBILF DT Small molecular drug
DMKBILF PC 656768
DMKBILF MW 429.6
DMKBILF FM C29H35NO2
DMKBILF IC InChI=1S/C29H35NO2/c1-31-28-16-14-24(15-17-28)9-8-20-30-21-18-25(19-22-30)23-32-29(26-10-4-2-5-11-26)27-12-6-3-7-13-27/h2-7,10-17,25,29H,8-9,18-23H2,1H3
DMKBILF CS COC1=CC=C(C=C1)CCCN2CCC(CC2)COC(C3=CC=CC=C3)C4=CC=CC=C4
DMKBILF IK WRTXEGOLODUQIE-UHFFFAOYSA-N
DMKBILF IU 4-(benzhydryloxymethyl)-1-[3-(4-methoxyphenyl)propyl]piperidine
DMKBILF CB CHEBI:35042
DMKBILF DE Inflammation
DMEIR7F ID DMEIR7F
DMEIR7F DN UP-116-77
DMEIR7F HS Terminated
DMEIR7F SN Mipitroban
DMEIR7F CP Laboratories UPSA
DMEIR7F DT Small molecular drug
DMEIR7F PC 3086644
DMEIR7F MW 392.3
DMEIR7F FM C19H19Cl2N3O2
DMEIR7F IC InChI=1S/C19H19Cl2N3O2/c1-19(2,9-17(25)26)8-16-23-15-7-14(21)10-22-18(15)24(16)11-12-3-5-13(20)6-4-12/h3-7,10H,8-9,11H2,1-2H3,(H,25,26)
DMEIR7F CS CC(C)(CC1=NC2=C(N1CC3=CC=C(C=C3)Cl)N=CC(=C2)Cl)CC(=O)O
DMEIR7F IK NJDYXRUUHUXUDU-UHFFFAOYSA-N
DMEIR7F IU 4-[6-chloro-3-[(4-chlorophenyl)methyl]imidazo[4,5-b]pyridin-2-yl]-3,3-dimethylbutanoic acid
DMEIR7F CA CAS 136122-46-8
DMEIR7F DE Thrombosis
DM37DOC ID DM37DOC
DM37DOC DN UP-275-22
DM37DOC HS Terminated
DM37DOC CP Laboratories UPSA
DM37DOC DE Hypertension
DMV8GUE ID DMV8GUE
DMV8GUE DN UR-12460
DMV8GUE HS Terminated
DMV8GUE CP Grupo Uriach
DMV8GUE PC 9889404
DMV8GUE MW 439.6
DMV8GUE FM C27H29N5O
DMV8GUE IC InChI=1S/C27H29N5O/c1-21-24(13-8-14-29-21)25(19-28)31-15-17-32(18-16-31)26(33)20-30-27(22-9-4-2-5-10-22)23-11-6-3-7-12-23/h2-14,25,27,30H,15-18,20H2,1H3
DMV8GUE CS CC1=C(C=CC=N1)C(C#N)N2CCN(CC2)C(=O)CNC(C3=CC=CC=C3)C4=CC=CC=C4
DMV8GUE IK RJKFZZBPTCGMAY-UHFFFAOYSA-N
DMV8GUE IU 2-[4-[2-(benzhydrylamino)acetyl]piperazin-1-yl]-2-(2-methylpyridin-3-yl)acetonitrile
DMV8GUE DE Thrombosis
DM7F94W ID DM7F94W
DM7F94W DN UR-12670
DM7F94W HS Terminated
DM7F94W SN UR-12670; SCHEMBL8120303
DM7F94W DT Small molecular drug
DM7F94W PC 9867789
DM7F94W MW 438.6
DM7F94W FM C28H30N4O
DM7F94W IC InChI=1S/C28H30N4O/c1-21-30-26-19-29-15-12-27(26)32(21)20-22-13-16-31(17-14-22)28(33)18-25(23-8-4-2-5-9-23)24-10-6-3-7-11-24/h2-12,15,19,22,25H,13-14,16-18,20H2,1H3
DM7F94W CS CC1=NC2=C(N1CC3CCN(CC3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5)C=CN=C2
DM7F94W IK HXCOKIFMWJDWPX-UHFFFAOYSA-N
DM7F94W IU 1-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3,3-diphenylpropan-1-one
DMJC82N ID DMJC82N
DMJC82N DN UR-8225
DMJC82N HS Terminated
DMJC82N SN UR 8225; 149455-36-7; UR-8225; 5,6-Dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-2-naphthalenecarbonitrile; 1,2-Dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile; 2-Naphthalenecarbonitrile, 5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; 2-Naphthalenecarbonitrile,5,6-dihydro-6,6-dimethyl-5-oxo-8-(2-oxo-1(2H)-pyridinyl)-; ACMC-20n5pl; AC1L560X; SCHEMBL6369766; CHEMBL303682; CTK4C6217; DTXSID60164273; LS-94452
DMJC82N CP Grupo Uriach
DMJC82N DT Small molecular drug
DMJC82N PC 198778
DMJC82N MW 290.3
DMJC82N FM C18H14N2O2
DMJC82N IC InChI=1S/C18H14N2O2/c1-18(2)10-15(20-8-4-3-5-16(20)21)14-9-12(11-19)6-7-13(14)17(18)22/h3-10H,1-2H3
DMJC82N CS CC1(C=C(C2=C(C1=O)C=CC(=C2)C#N)N3C=CC=CC3=O)C
DMJC82N IK PJCGOKFHROWGBX-UHFFFAOYSA-N
DMJC82N IU 6,6-dimethyl-5-oxo-8-(2-oxopyridin-1-yl)naphthalene-2-carbonitrile
DMJC82N CA CAS 149455-36-7
DMJC82N DE Asthma
DM6C7WJ ID DM6C7WJ
DM6C7WJ DN UR-8308
DM6C7WJ HS Terminated
DM6C7WJ CP Grupo Uriach
DM6C7WJ DE Asthma
DM4KOTA ID DM4KOTA
DM4KOTA DN UR-8328
DM4KOTA HS Terminated
DM4KOTA CP Grupo Uriach
DM4KOTA DE Asthma
DM73EPK ID DM73EPK
DM73EPK DN Vapaliximab
DM73EPK HS Terminated
DM73EPK SN Huvap; HuvapR; BTT-1002; Chimeric VAP-1 monoclonal antibody (inflammation), BioTie; Chimeric VAP-1 mAb (inflammation), BioTie/Seikagaku
DM73EPK CP BioTie Therapies Corp
DM73EPK DT Antibody
DM73EPK DE Inflammation
DMJLV03 ID DMJLV03
DMJLV03 DN Vapiprost
DMJLV03 HS Terminated
DMJLV03 SN Vapiprost hydrochloride; GR-32191; GR-32191B; SN-309
DMJLV03 CP GlaxoSmithKline KK
DMJLV03 DT Small molecular drug
DMJLV03 PC 6918030
DMJLV03 MW 477.6
DMJLV03 FM C30H39NO4
DMJLV03 IC InChI=1S/C30H39NO4/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34)/b2-1-/t26-,27-,28-,30+/m0/s1
DMJLV03 CS C1CCN(CC1)[C@H]2[C@H](C[C@@H]([C@@H]2CC/C=C\\CCC(=O)O)OCC3=CC=C(C=C3)C4=CC=CC=C4)O
DMJLV03 IK GQGRDYWMOPRROR-XUSMOFMBSA-N
DMJLV03 IU (Z)-7-[(1R,2R,3S,5S)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid
DMJLV03 CA CAS 85505-64-2
DMJLV03 DE Cardiovascular disease
DMHG70W ID DMHG70W
DMHG70W DN VE-16084
DMHG70W HS Terminated
DMHG70W SN ICE inhibitors, Sanofi Winthrop; WIN-67694
DMHG70W CP Sterling Winthrop Products Inc
DMHG70W PC 10009105
DMHG70W MW 624.5
DMHG70W FM C28H31Cl2N3O9
DMHG70W IC InChI=1S/C28H31Cl2N3O9/c1-15(2)24(33-28(40)42-13-17-8-5-4-6-9-17)26(38)31-16(3)25(37)32-20(12-22(35)36)21(34)14-41-27(39)23-18(29)10-7-11-19(23)30/h4-11,15-16,20,24H,12-14H2,1-3H3,(H,31,38)(H,32,37)(H,33,40)(H,35,36)/t16-,20+,24-/m0/s1
DMHG70W CS C[C@@H](C(=O)N[C@H](CC(=O)O)C(=O)COC(=O)C1=C(C=CC=C1Cl)Cl)NC(=O)[C@H](C(C)C)NC(=O)OCC2=CC=CC=C2
DMHG70W IK DFQKZFFVISYVDA-GANZUKCXSA-N
DMHG70W IU (3R)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid
DMHG70W DE Rheumatoid arthritis
DMY0V6J ID DMY0V6J
DMY0V6J DN VG-106
DMY0V6J HS Terminated
DMY0V6J SN Anticancer cytokine, Viragen
DMY0V6J CP Viragen Inc
DMY0V6J DE Solid tumour/cancer
DMLWQOP ID DMLWQOP
DMLWQOP DN VR-147
DMLWQOP HS Terminated
DMLWQOP SN Migraine therapeutic, Vectura; Migraine therapy, Vectura; Triptan (inhaled, migraine), Vectura
DMLWQOP CP Vectura Group plc
DMLWQOP DE Migraine
DM0CWJZ ID DM0CWJZ
DM0CWJZ DN VUF-8929
DM0CWJZ HS Terminated
DM0CWJZ SN 140890-71-7; Vuf 8929; AC1O5RNQ; N-(2-Bis(4-fluorophenyl)methoxy)ethyl-(2-phenyl)ethylamine maleate; Benzeneethanamine, N-(2-(bis(4-fluorophenyl)methoxy)ethyl)-, (2Z)-2-butenedioate (1:1)
DM0CWJZ CP Organon BioSciences
DM0CWJZ DT Small molecular drug
DM0CWJZ PC 6439429
DM0CWJZ MW 483.5
DM0CWJZ FM C27H27F2NO5
DM0CWJZ IC InChI=1S/C23H23F2NO.C4H4O4/c1-2-26(15-14-18-6-4-3-5-7-18)27-17-20-10-13-22(25)16-23(20)19-8-11-21(24)12-9-19;5-3(6)1-2-4(7)8/h3-13,16H,2,14-15,17H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DM0CWJZ CS CCN(CCC1=CC=CC=C1)OCC2=C(C=C(C=C2)F)C3=CC=C(C=C3)F.C(=C\\C(=O)O)\\C(=O)O
DM0CWJZ IK GMPALWBPFJCWPO-BTJKTKAUSA-N
DM0CWJZ IU (Z)-but-2-enedioic acid;N-ethyl-N-[[4-fluoro-2-(4-fluorophenyl)phenyl]methoxy]-2-phenylethanamine
DM0CWJZ CA CAS 140890-71-7
DM0CWJZ DE Heart failure
DMG58FX ID DMG58FX
DMG58FX DN WAY-100635
DMG58FX HS Terminated
DMG58FX SN N-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; 162760-96-5; Way 100635; UNII-71IH826FEG; CHEMBL31354; 71IH826FEG; N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide; WAY100635; Rec 0/0277; [3H]WAY100635; WAY 100,635; WAY-100,635; Lopac-W-108; AC1L1KWK; GTPL80; AC1Q5IB0; SCHEMBL84178; Lopac0_001229; WAY-100635 maleate salt/; GTPL3251; BDBM86708; DTXSID20167467; CHEBI:125619; EX-A1053; ZINC52541473; 2799AH; PDSP2_001699; PDSP1_001716; ABP000343; AKOS027313833; SB19513; NSC_104911; CS-0418; CCG-205303
DMG58FX DT Small molecular drug
DMG58FX PC 5684
DMG58FX MW 422.6
DMG58FX FM C25H34N4O2
DMG58FX IC InChI=1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3
DMG58FX CS COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4
DMG58FX IK SBPRIAGPYFYCRT-UHFFFAOYSA-N
DMG58FX IU N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide
DMG58FX CA CAS 162760-96-5
DMG58FX CB CHEBI:125619
DMG58FX DE Eating disorder
DMMOS8G ID DMMOS8G
DMMOS8G DN WAY-123223
DMMOS8G HS Terminated
DMMOS8G SN Way 123223; Way-123,223; 137941-92-5; AC1L30E8; N-(4-(Phenyloxy-3-(methyl-(2-quinolinylmethyl)amino)propoxy)phenyl)methanesulfonamide
DMMOS8G CP Wyeth-Ayerst Pharmaceuticals Inc
DMMOS8G DT Small molecular drug
DMMOS8G PC 9931676
DMMOS8G MW 415.5
DMMOS8G FM C21H25N3O4S
DMMOS8G IC InChI=1S/C21H25N3O4S/c1-24(13-18-8-7-16-5-3-4-6-21(16)22-18)14-19(25)15-28-20-11-9-17(10-12-20)23-29(2,26)27/h3-12,19,23,25H,13-15H2,1-2H3
DMMOS8G CS CN(CC1=NC2=CC=CC=C2C=C1)CC(COC3=CC=C(C=C3)NS(=O)(=O)C)O
DMMOS8G IK DOUINBOCIFSYBA-UHFFFAOYSA-N
DMMOS8G IU N-[4-[2-hydroxy-3-[methyl(quinolin-2-ylmethyl)amino]propoxy]phenyl]methanesulfonamide
DMMOS8G DE Heart arrhythmia
DMTY7PE ID DMTY7PE
DMTY7PE DN WAY-126227
DMTY7PE HS Terminated
DMTY7PE CP Wyeth-Ayerst Pharmaceuticals Inc
DMTY7PE DE Hypertension
DM2XTB9 ID DM2XTB9
DM2XTB9 DN WAY-132983
DM2XTB9 HS Terminated
DM2XTB9 SN WAY-132983
DM2XTB9 DT Small molecular drug
DM2XTB9 PC 45260374
DM2XTB9 MW 343.9
DM2XTB9 FM C16H26ClN3OS
DM2XTB9 IC InChI=1S/C16H25N3OS.ClH/c1-2-3-4-5-10-21-16-15(17-7-8-18-16)20-14-12-19-9-6-13(14)11-19;/h7-8,13-14H,2-6,9-12H2,1H3;1H/t13?,14-;/m0./s1
DM2XTB9 CS CCCCCCSC1=NC=CN=C1O[C@H]2CN3CCC2C3.Cl
DM2XTB9 IK QAXRREHLPKHWBI-IJDFPQMLSA-N
DM2XTB9 IU (3R)-3-(3-hexylsulfanylpyrazin-2-yl)oxy-1-azabicyclo[2.2.1]heptane;hydrochloride
DMQU8B1 ID DMQU8B1
DMQU8B1 DN WB-4101
DMQU8B1 HS Terminated
DMQU8B1 SN WB-4101; WB4101; WB 4101; (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzodioxan; 613-67-2; CHEMBL25554; CHEBI:64098; N-(2-(2,6-Dimethoxyphenoxy)ethyl)-2,3-dihydro-1,4-benzodioxin-2-methanamine; 1,4-Benzodioxin-2-methanamine, N-(2-(2,6-dimethoxyphenoxy)ethyl)-2,3-dihydro-; N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine; 1,4-benzodioxin-2-methanamine, n-[2-(2,6-dimethoxyphenoxy)ethyl]-2,3-dihydro-; MLS000859914
DMQU8B1 DT Small molecular drug
DMQU8B1 PC 5685
DMQU8B1 MW 345.4
DMQU8B1 FM C19H23NO5
DMQU8B1 IC InChI=1S/C19H23NO5/c1-21-17-8-5-9-18(22-2)19(17)23-11-10-20-12-14-13-24-15-6-3-4-7-16(15)25-14/h3-9,14,20H,10-13H2,1-2H3
DMQU8B1 CS COC1=C(C(=CC=C1)OC)OCCNCC2COC3=CC=CC=C3O2
DMQU8B1 IK GYSZUJHYXCZAKI-UHFFFAOYSA-N
DMQU8B1 IU N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine
DMQU8B1 CA CAS 613-67-2
DMQU8B1 CB CHEBI:64098
DMY9NG1 ID DMY9NG1
DMY9NG1 DN WEB-2347
DMY9NG1 HS Terminated
DMY9NG1 SN Web-2347; Web 2347; AC1MIW90; SCHEMBL8440056; 6-(2-Chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-4H,7H-cyclopenta(4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-8-carboxamide; 4H,7H-Cyclopenta(4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-8-carboxamide, 6-(2-chlorophenyl)-8,9-dihydro-1-methyl-N,N-dipropyl-
DMY9NG1 CP Boehringer Ingelheim Corp
DMY9NG1 DT Small molecular drug
DMY9NG1 PC 3081067
DMY9NG1 MW 482
DMY9NG1 FM C25H28ClN5OS
DMY9NG1 IC InChI=1S/C25H28ClN5OS/c1-4-10-30(11-5-2)24(32)16-12-18-20(13-16)33-25-22(18)23(17-8-6-7-9-19(17)26)27-14-21-29-28-15(3)31(21)25/h6-9,16H,4-5,10-14H2,1-3H3
DMY9NG1 CS CCCN(CCC)C(=O)C1CC2=C(C1)SC3=C2C(=NCC4=NN=C(N43)C)C5=CC=CC=C5Cl
DMY9NG1 IK SCSIRWUYQVAIRL-UHFFFAOYSA-N
DMY9NG1 IU 9-(2-chlorophenyl)-3-methyl-N,N-dipropyl-16-thia-2,4,5,8-tetrazatetracyclo[8.6.0.02,6.011,15]hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxamide
DMY9NG1 CA CAS 114800-19-0
DMY9NG1 DE Allergy
DMBMOI6 ID DMBMOI6
DMBMOI6 DN WF-2421
DMBMOI6 HS Terminated
DMBMOI6 SN FR-900280
DMBMOI6 CP Fujisawa Pharmaceutical Co Ltd
DMBMOI6 DT Small molecular drug
DMBMOI6 PC 195567
DMBMOI6 MW 404.4
DMBMOI6 FM C19H20N2O8
DMBMOI6 IC InChI=1S/C19H20N2O8/c22-8-20-7-16(26)10-1-3-14(24)12(5-10)13-6-11(2-4-15(13)25)18(27)17(19(28)29)21-9-23/h1-6,8-9,16-18,24-27H,7H2,(H,20,22)(H,21,23)(H,28,29)
DMBMOI6 CS C1=CC(=C(C=C1C(CNC=O)O)C2=C(C=CC(=C2)C(C(C(=O)O)NC=O)O)O)O
DMBMOI6 IK WQVWUCSBLUJLNT-UHFFFAOYSA-N
DMBMOI6 IU 2-formamido-3-[3-[5-(2-formamido-1-hydroxyethyl)-2-hydroxyphenyl]-4-hydroxyphenyl]-3-hydroxypropanoic acid
DMBMOI6 CA CAS 128429-19-6
DMBMOI6 DE Diabetic complication
DMACBIW ID DMACBIW
DMACBIW DN WIN-55212-2
DMACBIW HS Terminated
DMACBIW SN Win-55212-2; WIN 55212-2; UNII-5H31GI9502; 131543-22-1; CHEMBL188; WIN55212-2; WIN 55,212-2; CHEBI:73295; 5H31GI9502; (2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate; [(3R)-5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone; (r)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
DMACBIW DT Small molecular drug
DMACBIW PC 5311501
DMACBIW MW 426.5
DMACBIW FM C27H26N2O3
DMACBIW IC InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3/t20-/m1/s1
DMACBIW CS CC1=C(C2=C3N1[C@@H](COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65
DMACBIW IK HQVHOQAKMCMIIM-HXUWFJFHSA-N
DMACBIW IU [(11R)-2-methyl-11-(morpholin-4-ylmethyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-3-yl]-naphthalen-1-ylmethanone
DMACBIW CA CAS 131543-22-1
DMACBIW CB CHEBI:73295
DMRV48P ID DMRV48P
DMRV48P DN WIN-63759
DMRV48P HS Terminated
DMRV48P SN WIN-63759; CHEMBL114992; SCHEMBL7305284; BDBM50036477; 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester(WIN63759); 2,6-Dichloro-3-(2-morpholin-4-yl-ethoxy)-benzoic acid 4-isopropyl-6-methoxy-1,1,3-trioxo-1,3-dihydro-1lambda*6*-benzo[d]isothiazol-2-ylmethyl ester
DMRV48P CP Sterling Winthrop Group Ltd
DMRV48P DT Small molecular drug
DMRV48P PC 9938355
DMRV48P MW 587.5
DMRV48P FM C25H28Cl2N2O8S
DMRV48P IC InChI=1S/C25H28Cl2N2O8S/c1-15(2)17-12-16(34-3)13-20-21(17)24(30)29(38(20,32)33)14-37-25(31)22-18(26)4-5-19(23(22)27)36-11-8-28-6-9-35-10-7-28/h4-5,12-13,15H,6-11,14H2,1-3H3
DMRV48P CS CC(C)C1=C2C(=CC(=C1)OC)S(=O)(=O)N(C2=O)COC(=O)C3=C(C=CC(=C3Cl)OCCN4CCOCC4)Cl
DMRV48P IK AGROLWZEYXFDEB-UHFFFAOYSA-N
DMRV48P IU (6-methoxy-1,1,3-trioxo-4-propan-2-yl-1,2-benzothiazol-2-yl)methyl 2,6-dichloro-3-(2-morpholin-4-ylethoxy)benzoate
DMRV48P DE Emphysema
DM960I8 ID DM960I8
DM960I8 DN WIN-64821
DM960I8 HS Terminated
DM960I8 SN Q-20547A
DM960I8 CP Sterling Winthrop Products Inc
DM960I8 DT Small molecular drug
DM960I8 PC 158365
DM960I8 MW 664.7
DM960I8 FM C40H36N6O4
DM960I8 IC InChI=1S/C40H36N6O4/c47-33-31-21-39(25-15-7-9-17-27(25)43-37(39)45(31)35(49)29(41-33)19-23-11-3-1-4-12-23)40-22-32-34(48)42-30(20-24-13-5-2-6-14-24)36(50)46(32)38(40)44-28-18-10-8-16-26(28)40/h1-18,29-32,37-38,43-44H,19-22H2,(H,41,47)(H,42,48)/t29-,30-,31-,32-,37+,38+,39-,40-/m0/s1
DM960I8 CS C1[C@H]2C(=O)N[C@H](C(=O)N2[C@@H]3[C@]1(C4=CC=CC=C4N3)[C@]56C[C@H]7C(=O)N[C@H](C(=O)N7[C@H]5NC8=CC=CC=C68)CC9=CC=CC=C9)CC1=CC=CC=C1
DM960I8 IK ZEANERNKMXBETI-BJHDJDSNSA-N
DM960I8 IU (1R,4S,7S,9R)-4-benzyl-9-[(1R,4S,7S,9R)-4-benzyl-3,6-dioxo-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-trien-9-yl]-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-triene-3,6-dione
DM960I8 CA CAS 150881-27-9
DM960I8 DE Asthma
DM8EVK5 ID DM8EVK5
DM8EVK5 DN Wortmannin
DM8EVK5 HS Terminated
DM8EVK5 SN wortmannin; 19545-26-7; Wartmannin; KY 12420; Antibiotic SL-2052; SL-2052; UNII-XVA4O219QW; NSC221019; XVA4O219QW; MLS002703028; CHEMBL428496; CHEBI:52289; Wortmannin, 98%; Pi 3-Kinase Inhibitor; NSC 627609; BRN 0067676; (1S,6bR,9aS,11R,11bR)-9a,11b-dimethyl-1-[(methyloxy)methyl]-3,6,9-trioxo-1,6,6b,7,8,9,9a,10,11,11b-decahydro-3H-furo[4,3,2-de]indeno[4,5-h]isochromen-11-yl acetate
DM8EVK5 DT Small molecular drug
DM8EVK5 PC 312145
DM8EVK5 MW 428.4
DM8EVK5 FM C23H24O8
DM8EVK5 IC InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1
DM8EVK5 CS CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C
DM8EVK5 IK QDLHCMPXEPAAMD-QAIWCSMKSA-N
DM8EVK5 IU [(1R,3R,5S,9R,18S)-18-(methoxymethyl)-1,5-dimethyl-6,11,16-trioxo-13,17-dioxapentacyclo[10.6.1.02,10.05,9.015,19]nonadeca-2(10),12(19),14-trien-3-yl] acetate
DM8EVK5 CA CAS 19545-26-7
DM8EVK5 CB CHEBI:52289
DM8EVK5 DE Haematological malignancy
DM89BA1 ID DM89BA1
DM89BA1 DN WS-75624B
DM89BA1 HS Terminated
DM89BA1 CP Fujisawa Pharmaceutical Co Ltd
DM89BA1 DT Small molecular drug
DM89BA1 PC 9951814
DM89BA1 MW 380.5
DM89BA1 FM C18H24N2O5S
DM89BA1 IC InChI=1S/C18H24N2O5S/c1-11(21)7-5-4-6-8-15-19-13(10-26-15)16-17(25-3)14(24-2)9-12(20-16)18(22)23/h9-11,21H,4-8H2,1-3H3,(H,22,23)
DM89BA1 CS CC(CCCCCC1=NC(=CS1)C2=C(C(=CC(=N2)C(=O)O)OC)OC)O
DM89BA1 IK RGHLFUKUTGFTCO-UHFFFAOYSA-N
DM89BA1 IU 6-[2-(6-hydroxyheptyl)-1,3-thiazol-4-yl]-4,5-dimethoxypyridine-2-carboxylic acid
DM89BA1 DE Cardiovascular disease
DMAG86C ID DMAG86C
DMAG86C DN WY-28342
DMAG86C HS Terminated
DMAG86C CP Wyeth-Ayerst International Inc
DMAG86C PC 9882188
DMAG86C MW 281.4
DMAG86C FM C19H23NO
DMAG86C IC InChI=1S/C19H23NO/c1-13-8-10-15(11-9-13)19(21)18-14(2)12-16-6-4-3-5-7-17(16)20-18/h8-12,19,21H,3-7H2,1-2H3
DMAG86C CS CC1=CC=C(C=C1)C(C2=NC3=C(CCCCC3)C=C2C)O
DMAG86C IK KLGYQZZTJRHYIN-UHFFFAOYSA-N
DMAG86C IU (4-methylphenyl)-(3-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)methanol
DMAG86C DE Rheumatoid arthritis
DMGJNQW ID DMGJNQW
DMGJNQW DN WY-48989
DMGJNQW HS Terminated
DMGJNQW SN WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; Wy-48989; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile
DMGJNQW CP Wyeth-Ayerst Pharmaceuticals Inc
DMGJNQW DT Small molecular drug
DMGJNQW PC 132006
DMGJNQW MW 423.9
DMGJNQW FM C25H18ClN5
DMGJNQW IC InChI=1S/C25H18ClN5/c26-18-8-11-21-24(14-18)29-23(12-13-28-19-9-6-17(15-27)7-10-19)22-16-31(30-25(21)22)20-4-2-1-3-5-20/h1-11,14,16,28H,12-13H2
DMGJNQW CS C1=CC=C(C=C1)N2C=C3C(=NC4=C(C3=N2)C=CC(=C4)Cl)CCNC5=CC=C(C=C5)C#N
DMGJNQW IK GYVYUQVVKBZPRY-UHFFFAOYSA-N
DMGJNQW IU 4-[2-(7-chloro-2-phenylpyrazolo[4,3-c]quinolin-4-yl)ethylamino]benzonitrile
DMGJNQW CA CAS 136917-40-3
DMGJNQW DE Rheumatoid arthritis
DM965P4 ID DM965P4
DM965P4 DN XL-541
DM965P4 HS Terminated
DM965P4 SN S1P1R antagonists (oral, cancer), Exelixis
DM965P4 CP Exelixis Inc
DM965P4 DE Solid tumour/cancer
DMFHR2O ID DMFHR2O
DMFHR2O DN XR-1853
DMFHR2O HS Terminated
DMFHR2O SN XR 1853; XR-1853; AC1O5RT5; 3-((4-(2-(Dimethylamino)ethoxy)phenyl)methylene)-6-(phenylmethylene)-2,5-piperazinedione; 158944-02-6
DMFHR2O CP Xenova Ltd
DMFHR2O DT Small molecular drug
DMFHR2O PC 6439506
DMFHR2O MW 377.4
DMFHR2O FM C22H23N3O3
DMFHR2O IC InChI=1S/C22H23N3O3/c1-25(2)12-13-28-18-10-8-17(9-11-18)15-20-22(27)23-19(21(26)24-20)14-16-6-4-3-5-7-16/h3-11,14-15H,12-13H2,1-2H3,(H,23,27)(H,24,26)/b19-14+,20-15-
DMFHR2O CS CN(C)CCOC1=CC=C(C=C1)/C=C\\2/C(=O)N/C(=C/C3=CC=CC=C3)/C(=O)N2
DMFHR2O IK SKAOOZAHHYQXKN-WOBBTWAASA-N
DMFHR2O IU (3E,6Z)-3-benzylidene-6-[[4-[2-(dimethylamino)ethoxy]phenyl]methylidene]piperazine-2,5-dione
DMFHR2O CA CAS 158944-02-6
DMFHR2O DE Thrombosis
DMJLRC7 ID DMJLRC7
DMJLRC7 DN XR-3005
DMJLRC7 HS Terminated
DMJLRC7 CP Xenova Group plc
DMJLRC7 DE Colorectal cancer
DMXI39O ID DMXI39O
DMXI39O DN XR-3054
DMXI39O HS Terminated
DMXI39O CP Xenova Group plc
DMXI39O DE Solid tumour/cancer
DMX0PTO ID DMX0PTO
DMX0PTO DN XR-368
DMX0PTO HS Terminated
DMX0PTO SN Xenovulene; XR-7009
DMX0PTO CP Xenova Ltd
DMX0PTO PC 9863607
DMX0PTO MW 358.5
DMX0PTO FM C22H30O4
DMX0PTO IC InChI=1S/C22H30O4/c1-13-6-7-15-19-16-14(12-25-19)17(23)18(24)20(16)26-22(15,4)10-5-9-21(2,3)11-8-13/h5,8-9,14-16,19,24H,6-7,10-12H2,1-4H3/b9-5+,13-8+/t14-,15-,16-,19-,22+/m0/s1
DMX0PTO CS C/C/1=C\\CC(/C=C/C[C@@]2([C@@H](CC1)[C@H]3[C@@H]4[C@H](CO3)C(=O)C(=C4O2)O)C)(C)C
DMX0PTO IK WDFUVZRTUNQXHC-KVPIFFDFSA-N
DMX0PTO IU (1S,2S,5E,9E,12R,17R,20S)-15-hydroxy-5,8,8,12-tetramethyl-13,19-dioxatetracyclo[12.5.1.02,12.017,20]icosa-5,9,14-trien-16-one
DMX0PTO CB CHEBI:66336
DMX0PTO DE Anxiety disorder
DMEVSZO ID DMEVSZO
DMEVSZO DN XR-5082
DMEVSZO HS Terminated
DMEVSZO SN Plasminogen activator inhibitor inhibitor, Xenova
DMEVSZO CP Xenova Ltd
DMEVSZO DT Small molecular drug
DMEVSZO PC 6439510
DMEVSZO MW 393.5
DMEVSZO FM C22H23N3O2S
DMEVSZO IC InChI=1S/C22H23N3O2S/c1-25(2)12-13-28-18-10-8-17(9-11-18)15-20-22(27)23-19(21(26)24-20)14-16-6-4-3-5-7-16/h3-11,14-15H,12-13H2,1-2H3,(H,23,27)(H,24,26)/b19-14+,20-15-
DMEVSZO CS CN(C)CCSC1=CC=C(C=C1)/C=C\\2/C(=O)N/C(=C/C3=CC=CC=C3)/C(=O)N2
DMEVSZO IK RYRKPESQGOEIQY-WOBBTWAASA-N
DMEVSZO IU (3E,6Z)-3-benzylidene-6-[[4-[2-(dimethylamino)ethylsulfanyl]phenyl]methylidene]piperazine-2,5-dione
DMEVSZO CA CAS 174849-68-4
DMEVSZO DE Thrombosis
DMA13OD ID DMA13OD
DMA13OD DN XR-510
DMA13OD HS Terminated
DMA13OD SN CHEMBL100119; XR-510; SCHEMBL243027; BDBM50032353; N-{3-[5-Ethyl-3-(3-fluoro-2''-isopentyloxycarbonylsulfamoyl-biphenyl-4-ylmethyl)-2-propyl-3H-imidazol-4-yl]-3-oxo-propyl}-N-pyridin-3-yl-butyramide(XR510); isopentyloxy 2-[2-(4-{4-ethyl-5-[3-[3-pyridyl(propyl)carboxamidopropanoyl]-2-propyl-1H-1-imidazolylmethyl}-3-fluorophenyl)phenylsulfonyl]caboxamido
DMA13OD CP Xenova Ltd
DMA13OD DT Small molecular drug
DMA13OD PC 9896750
DMA13OD MW 733.9
DMA13OD FM C39H48FN5O6S
DMA13OD IC InChI=1S/C39H48FN5O6S/c1-6-12-36-42-33(8-3)38(34(46)19-22-44(37(47)13-7-2)30-14-11-21-41-25-30)45(36)26-29-18-17-28(24-32(29)40)31-15-9-10-16-35(31)52(49,50)43-39(48)51-23-20-27(4)5/h9-11,14-18,21,24-25,27H,6-8,12-13,19-20,22-23,26H2,1-5H3,(H,43,48)
DMA13OD CS CCCC1=NC(=C(N1CC2=C(C=C(C=C2)C3=CC=CC=C3S(=O)(=O)NC(=O)OCCC(C)C)F)C(=O)CCN(C4=CN=CC=C4)C(=O)CCC)CC
DMA13OD IK QBFKQSDMKSSMRE-UHFFFAOYSA-N
DMA13OD IU 3-methylbutyl N-[2-[4-[[5-[3-[butanoyl(pyridin-3-yl)amino]propanoyl]-4-ethyl-2-propylimidazol-1-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate
DMA13OD DE Hypertension
DMIK72F ID DMIK72F
DMIK72F DN XR-5118
DMIK72F HS Terminated
DMIK72F SN XR-5118; CHEMBL40180; CHEMBL544314; xr5118; SCHEMBL7359291; BDBM50104518; 3-[1-[5-(2-Dimethylamino-ethylsulfanyl)-thiophen-2-yl]-meth-(Z)-ylidene]-6-[1-phenyl-meth-(Z)-ylidene]-piperazine-2,5-dione
DMIK72F DT Small molecular drug
DMIK72F PC 9932718
DMIK72F MW 399.5
DMIK72F FM C20H21N3O2S2
DMIK72F IC InChI=1S/C20H21N3O2S2/c1-23(2)10-11-26-18-9-8-15(27-18)13-17-20(25)21-16(19(24)22-17)12-14-6-4-3-5-7-14/h3-9,12-13H,10-11H2,1-2H3,(H,21,25)(H,22,24)/b16-12-,17-13-
DMIK72F CS CN(C)CCSC1=CC=C(S1)/C=C\\2/C(=O)N/C(=C\\C3=CC=CC=C3)/C(=O)N2
DMIK72F IK ODQGWMYUSNRXFW-MCOFMCJXSA-N
DMIK72F IU (3Z,6Z)-3-benzylidene-6-[[5-[2-(dimethylamino)ethylsulfanyl]thiophen-2-yl]methylidene]piperazine-2,5-dione
DMIK72F DE Solid tumour/cancer
DM7TQYF ID DM7TQYF
DM7TQYF DN Y-20024
DM7TQYF HS Terminated
DM7TQYF SN N-(1-Butyl-2-pyrrolidinylmethyl)-2-methyl-5-sulfamoyl-2,3-dihydrobenzofuran-7-carboxamide hydrochloride; 5-(Aminosulfonyl)-N-[(1-butyl-2-pyrrolidinyl)methyl]-2-methyl-2,3-dihydro-7-benzofurancarboxamide hydrochloride
DM7TQYF DT Small molecular drug
DM7TQYF PC 130281
DM7TQYF MW 432
DM7TQYF FM C19H30ClN3O4S
DM7TQYF IC InChI=1S/C19H29N3O4S.ClH/c1-3-4-7-22-8-5-6-15(22)12-21-19(23)17-11-16(27(20,24)25)10-14-9-13(2)26-18(14)17;/h10-11,13,15H,3-9,12H2,1-2H3,(H,21,23)(H2,20,24,25);1H
DM7TQYF CS CCCCN1CCCC1CNC(=O)C2=CC(=CC3=C2OC(C3)C)S(=O)(=O)N.Cl
DM7TQYF IK GZXVXVNELOPJSZ-UHFFFAOYSA-N
DM7TQYF IU N-[(1-butylpyrrolidin-2-yl)methyl]-2-methyl-5-sulfamoyl-2,3-dihydro-1-benzofuran-7-carboxamide;hydrochloride
DM7TQYF CA CAS 124842-93-9
DM7TQYF DE Psychotic disorder
DMLAVES ID DMLAVES
DMLAVES DN Y-29794
DMLAVES HS Terminated
DMLAVES SN Y-29794; Y 29794; 129184-48-1; CHEMBL294803; Y29794; AC1L50AM; AC1Q5D6Y; SCHEMBL195545; ZINC3803304; BDBM50038881; 2-(8-Dimethylaminooctylthio)-6-isopropyl-3-pyridyl-2-thienyl ketone citrate; methanone,(2-((8-(dimethylamino)octyl)thio)-6-(1-methylethyl)-3-pyridinyl)-2-thienyl-; KB-81512; BRD-K48449073-034-01-9; [2-[8-(dimethylamino)octylsulfanyl]-6-propan-2-ylpyridin-3-yl]-thiophen-2-ylmethanone; Methanone, (2-((8-(dimethylamino)octyl)thio)-6-(1-methylethyl)-3-pyridinyl)-2-thienyl-
DMLAVES DT Small molecular drug
DMLAVES PC 195609
DMLAVES MW 418.7
DMLAVES FM C23H34N2OS2
DMLAVES IC InChI=1S/C23H34N2OS2/c1-18(2)20-14-13-19(22(26)21-12-11-17-27-21)23(24-20)28-16-10-8-6-5-7-9-15-25(3)4/h11-14,17-18H,5-10,15-16H2,1-4H3
DMLAVES CS CC(C)C1=NC(=C(C=C1)C(=O)C2=CC=CS2)SCCCCCCCCN(C)C
DMLAVES IK HAGHKJDWBDSFKC-UHFFFAOYSA-N
DMLAVES IU [2-[8-(dimethylamino)octylsulfanyl]-6-propan-2-ylpyridin-3-yl]-thiophen-2-ylmethanone
DMLAVES CA CAS 129184-48-1
DMG024B ID DMG024B
DMG024B DN Y-931
DMG024B HS Terminated
DMG024B CP Mitsubishi Pharma
DMG024B DT Small molecular drug
DMG024B PC 9913124
DMG024B MW 366.5
DMG024B FM C20H19FN4S
DMG024B IC InChI=1S/C20H19FN4S/c1-24-8-10-25(11-9-24)19-18-14-4-2-3-5-17(14)26-20(18)23-16-12-13(21)6-7-15(16)22-19/h2-7,12,23H,8-11H2,1H3
DMG024B CS CN1CCN(CC1)C2=NC3=C(C=C(C=C3)F)NC4=C2C5=CC=CC=C5S4
DMG024B IK ILMHNKKMKWQVCE-UHFFFAOYSA-N
DMG024B IU 8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothiolo[2,3-b][1,5]benzodiazepine
DMG024B DE Schizophrenia
DM97ULM ID DM97ULM
DM97ULM DN YM-022
DM97ULM HS Terminated
DM97ULM SN 145084-28-2; YM022; YM-022; YM 022; UNII-772CP7W12N; CHEMBL115121; C32H28N4O3; 772CP7W12N; 1-(2,3-Dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea; (R)-N-[2,3-DIHYDRO-1-[2-(2-METHYLPHENYL)-2-OXOETHYL]-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL]-N'-(3-METHYLPHENYL)-UREA; Urea,N-[(3R)-2,3-dihydro-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)-; Urea, N-(2,3-dihydro-1-(2-(2-methylphenyl)-2-oxoethyl)-2-oxo-5-phenyl-1H-1,4-benzodia
DM97ULM CP Yamanouchi Pharmaceutical Co Ltd
DM97ULM DT Small molecular drug
DM97ULM PC 122130
DM97ULM MW 516.6
DM97ULM FM C32H28N4O3
DM97ULM IC InChI=1S/C32H28N4O3/c1-21-11-10-15-24(19-21)33-32(39)35-30-31(38)36(20-28(37)25-16-7-6-12-22(25)2)27-18-9-8-17-26(27)29(34-30)23-13-4-3-5-14-23/h3-19,30H,20H2,1-2H3,(H2,33,35,39)/t30-/m0/s1
DM97ULM CS CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4)CC(=O)C5=CC=CC=C5C
DM97ULM IK YCXFHPUBGMMWJQ-PMERELPUSA-N
DM97ULM IU 1-(3-methylphenyl)-3-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
DM97ULM CA CAS 145084-28-2
DM97ULM DE Gastrointestinal disease
DMDXLG2 ID DMDXLG2
DMDXLG2 DN YM-099
DMDXLG2 HS Terminated
DMDXLG2 CP Yamanouchi Pharmaceutical Co Ltd
DMDXLG2 DE Hypertension
DMEHAI2 ID DMEHAI2
DMEHAI2 DN YM-26734
DMEHAI2 HS Terminated
DMEHAI2 SN YM 26734; 144337-18-8; CHEMBL444450; 1-Dodecanone,1,1'-[5-[3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-; 1,1'-[5-[3,4-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxy-1,3-phenylene]bis-1-dodecanone; ACMC-20n3vr; CTK4C4039; AOB2291; SYN5086; MolPort-023-276-467; BDBM50274336; AKOS024457146; 4-(3,5-Didodecanoyl-2,4,6-trihydroxyphenyl)-7-hydroxy-2-(4-hydroxyphenyl)chroman; KB-276131; YM-26734, > J-007943; 1-Dodecanone, 1
DMEHAI2 DT Small molecular drug
DMEHAI2 PC 9853400
DMEHAI2 MW 731
DMEHAI2 FM C45H62O8
DMEHAI2 IC InChI=1S/C45H62O8/c1-3-5-7-9-11-13-15-17-19-21-36(48)41-43(50)40(44(51)42(45(41)52)37(49)22-20-18-16-14-12-10-8-6-4-2)35-30-38(31-23-25-32(46)26-24-31)53-39-29-33(47)27-28-34(35)39/h23-29,35,38,46-47,50-52H,3-22,30H2,1-2H3
DMEHAI2 CS CCCCCCCCCCCC(=O)C1=C(C(=C(C(=C1O)C2CC(OC3=C2C=CC(=C3)O)C4=CC=C(C=C4)O)O)C(=O)CCCCCCCCCCC)O
DMEHAI2 IK CEJAYJCUSZHYDS-UHFFFAOYSA-N
DMEHAI2 IU 1-[3-dodecanoyl-2,4,6-trihydroxy-5-[7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]dodecan-1-one
DMEHAI2 CA CAS 144337-18-8
DMEHAI2 DE Rheumatoid arthritis
DMWI094 ID DMWI094
DMWI094 DN YM-43611
DMWI094 HS Terminated
DMWI094 CP Yamanouchi Pharmaceutical Co Ltd
DMWI094 PC 9802631
DMWI094 MW 427.9
DMWI094 FM C23H26ClN3O3
DMWI094 IC InChI=1S/C23H26ClN3O3/c1-30-21-12-20(26-22(28)16-7-8-16)19(24)11-18(21)23(29)25-17-9-10-27(14-17)13-15-5-3-2-4-6-15/h2-6,11-12,16-17H,7-10,13-14H2,1H3,(H,25,29)(H,26,28)/t17-/m0/s1
DMWI094 CS COC1=CC(=C(C=C1C(=O)N[C@H]2CCN(C2)CC3=CC=CC=C3)Cl)NC(=O)C4CC4
DMWI094 IK CPVZPPFHQBIJNB-KRWDZBQOSA-N
DMWI094 IU N-[(3S)-1-benzylpyrrolidin-3-yl]-5-chloro-4-(cyclopropanecarbonylamino)-2-methoxybenzamide
DMWI094 DE Psychotic disorder
DM7VGOC ID DM7VGOC
DM7VGOC DN Ym60828
DM7VGOC HS Terminated
DM7VGOC SN YM-60828; YM 60828; 201933-41-7; CHEMBL20240; 179755-65-8; {[(7-Carbamimidoylnaphthalen-2-Yl)methyl][4-({1-[(1e)-Ethanimidoyl]piperidin-4-Yl}oxy)phenyl]sulfamoyl}acetic Acid; SCHEMBL676753; DTXSID80430967; ZINC3952416; BDBM50084617; ACM179755658; KB-81529; FT-0675886; 2-[[[[7-(Aminoiminomethyl)-2-naphthalenyl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]sulfonyl]acetic Acid Dihydrochloride; [[4-[(1-Acetimidoylpiperidin-4-yl)oxy]phenyl][(7-amidino-2-naphthyl)methyl]sulfamoyl]acetic acid; 0CB
DM7VGOC DT Small molecular drug
DM7VGOC PC 9807238
DM7VGOC MW 537.6
DM7VGOC FM C27H31N5O5S
DM7VGOC IC InChI=1S/C27H31N5O5S/c1-18(28)31-12-10-25(11-13-31)37-24-8-6-23(7-9-24)32(38(35,36)17-26(33)34)16-19-2-3-20-4-5-21(27(29)30)15-22(20)14-19/h2-9,14-15,25,28H,10-13,16-17H2,1H3,(H3,29,30)(H,33,34)
DM7VGOC CS CC(=N)N1CCC(CC1)OC2=CC=C(C=C2)N(CC3=CC4=C(C=C3)C=CC(=C4)C(=N)N)S(=O)(=O)CC(=O)O
DM7VGOC IK NPBKHEMDWREFJJ-UHFFFAOYSA-N
DM7VGOC IU 2-[(7-carbamimidoylnaphthalen-2-yl)methyl-[4-(1-ethanimidoylpiperidin-4-yl)oxyphenyl]sulfamoyl]acetic acid
DM7VGOC CA CAS 179755-65-8
DMK1UJM ID DMK1UJM
DMK1UJM DN YP-004
DMK1UJM HS Terminated
DMK1UJM SN MP-004
DMK1UJM CP Molecular SkinCare Ltd
DMK1UJM DE Solid tumour/cancer
DM2N76V ID DM2N76V
DM2N76V DN YP-008
DM2N76V HS Terminated
DM2N76V SN RPL-228; Cyclopentenone prostaglandin mimetic (PGM) (topical, psoriasis), York Pharma; Natural-defence-prostanoid mimetic (topical, psoriasis), York Pharma
DM2N76V CP Rosanto Pharmaceuticals Ltd
DM2N76V DE Psoriasis vulgaris
DMPXLG2 ID DMPXLG2
DMPXLG2 DN YP-009
DMPXLG2 HS Terminated
DMPXLG2 SN RPL-208; Cyclopentenone prostaglandin mimetic (PGM) (cancer), Rosanto; Cyclopentenone prostaglandin mimetic (PGM) (cancer), York Pharma
DMPXLG2 CP Rosanto Pharmaceuticals Ltd
DMPXLG2 DE Solid tumour/cancer
DMQ6K8J ID DMQ6K8J
DMQ6K8J DN Z-6568
DMQ6K8J HS Terminated
DMQ6K8J CP Zambon Co SpA
DMQ6K8J PC 53408000
DMQ6K8J MW 281.26
DMQ6K8J FM C13H15NO6
DMQ6K8J IC InChI=1S/C13H15NO6/c1-3-19-12(15)8-9-5-6-10(13(16)20-4-2)7-11(9)14(17)18/h5-7H,3-4,8H2,1-2H3
DMQ6K8J CS CCOC(=O)CC1=C(C=C(C=C1)C(=O)OCC)[N+](=O)[O-]
DMQ6K8J IK SKZKACZIGOSXQL-UHFFFAOYSA-N
DMQ6K8J IU ethyl 4-(2-ethoxy-2-oxoethyl)-3-nitrobenzoate
DMQ6K8J CA CAS 891782-57-3
DMQ6K8J DE Hypertension
DMGH3T5 ID DMGH3T5
DMGH3T5 DN Zaprinast
DMGH3T5 HS Terminated
DMGH3T5 DT Small molecular drug
DMGH3T5 PC 135399235
DMGH3T5 MW 271.27
DMGH3T5 FM C13H13N5O2
DMGH3T5 IC InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)
DMGH3T5 CS CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2
DMGH3T5 IK REZGGXNDEMKIQB-UHFFFAOYSA-N
DMGH3T5 IU 5-(2-propoxyphenyl)-2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one
DMGH3T5 CA CAS 37762-06-4
DMGH3T5 CB CHEBI:92215
DMC38FO ID DMC38FO
DMC38FO DN ZARDAVERINE
DMC38FO HS Terminated
DMC38FO SN zardaverine; 101975-10-4; Zardaverina; Zardaverinum; Zardaverine [INN]; Zardaverinum [INN-Latin]; UNII-TQ358GWH6Y; Zardaverina [INN-Spanish]; 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE; C12H10F2N2O3; 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone; TQ358GWH6Y; CHEMBL313842; CHEBI:46548; 6-[4-(difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one; HJMQDJPMQIHLPB-UHFFFAOYSA-N; 6-(4-Difluoromethoxy-3-methoxyphenyl)-3(2H)-pyridazinone; NCGC00016106-04
DMC38FO DT Small molecular drug
DMC38FO PC 5723
DMC38FO MW 268.22
DMC38FO FM C12H10F2N2O3
DMC38FO IC InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)
DMC38FO CS COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F
DMC38FO IK HJMQDJPMQIHLPB-UHFFFAOYSA-N
DMC38FO IU 3-[4-(difluoromethoxy)-3-methoxyphenyl]-1H-pyridazin-6-one
DMC38FO CA CAS 101975-10-4
DMC38FO CB CHEBI:46548
DMC38FO DE Chronic obstructive pulmonary disease
DMNYKOT ID DMNYKOT
DMNYKOT DN Zatebradine
DMNYKOT HS Terminated
DMNYKOT SN UL-FS-49; UL-FS-49CL
DMNYKOT CP Boehringer Ingelheim Corp
DMNYKOT DT Small molecular drug
DMNYKOT PC 65637
DMNYKOT MW 456.6
DMNYKOT FM C26H36N2O5
DMNYKOT IC InChI=1S/C26H36N2O5/c1-27(13-9-19-7-8-22(30-2)23(15-19)31-3)11-6-12-28-14-10-20-16-24(32-4)25(33-5)17-21(20)18-26(28)29/h7-8,15-17H,6,9-14,18H2,1-5H3
DMNYKOT CS CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CCC3=CC(=C(C=C3)OC)OC
DMNYKOT IK KEDQCFRVSHYKLR-UHFFFAOYSA-N
DMNYKOT IU 3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DMNYKOT CA CAS 85175-67-3
DMNYKOT CB CHEBI:93613
DMNYKOT DE Angina pectoris
DM6M9GC ID DM6M9GC
DM6M9GC DN ZD-3638
DM6M9GC HS Terminated
DM6M9GC SN ZD-3638; SCHEMBL1152094; CHEMBL264026
DM6M9GC CP AstraZeneca
DM6M9GC DT Small molecular drug
DM6M9GC PC 9955820
DM6M9GC MW 458.6
DM6M9GC FM C28H30N2O2S
DM6M9GC IC InChI=1S/C28H30N2O2S/c1-2-33(32)26-25(12-7-15-29-26)28(31)13-16-30(17-14-28)19-27-18-22(20-8-3-5-10-23(20)27)21-9-4-6-11-24(21)27/h3-12,15,22,31H,2,13-14,16-19H2,1H3
DM6M9GC CS CCS(=O)C1=C(C=CC=N1)C2(CCN(CC2)CC34CC(C5=CC=CC=C53)C6=CC=CC=C46)O
DM6M9GC IK LVMVFEHQMHETDS-UHFFFAOYSA-N
DM6M9GC IU 4-(2-ethylsulfinylpyridin-3-yl)-1-(1-tetracyclo[6.6.1.02,7.09,14]pentadeca-2,4,6,9,11,13-hexaenylmethyl)piperidin-4-ol
DM6M9GC DE Schizophrenia
DM91IPH ID DM91IPH
DM91IPH DN ZD-3980
DM91IPH HS Terminated
DM91IPH CP AstraZeneca plc
DM91IPH DE Prostate hyperplasia
DMVWRU9 ID DMVWRU9
DMVWRU9 DN ZD-4190
DMVWRU9 HS Terminated
DMVWRU9 SN AC1OCFDK; CHEMBL3544937; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine hydrochloride
DMVWRU9 CP AstraZeneca plc
DMVWRU9 DT Small molecular drug
DMVWRU9 PC 5329032
DMVWRU9 MW 459.3
DMVWRU9 FM C19H16BrFN6O2
DMVWRU9 IC InChI=1S/C19H16BrFN6O2/c1-28-17-9-13-16(10-18(17)29-7-6-27-5-4-24-26-27)22-11-23-19(13)25-15-3-2-12(20)8-14(15)21/h2-5,8-11H,6-7H2,1H3,(H,22,23,25)
DMVWRU9 CS COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C=C(C=C3)Br)F)OCCN4C=CN=N4
DMVWRU9 IK YBTGTVGEKMZEQX-UHFFFAOYSA-N
DMVWRU9 IU N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine
DMVWRU9 DE Solid tumour/cancer
DMU2F6Q ID DMU2F6Q
DMU2F6Q DN ZD-6003
DMU2F6Q HS Terminated
DMU2F6Q CP Zeneca Group plc
DMU2F6Q DE Solid tumour/cancer
DM5KSCI ID DM5KSCI
DM5KSCI DN ZD-7155
DM5KSCI HS Terminated
DM5KSCI SN ZD-7155; CHEMBL159096; 5,7-diethyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-1,6-naphthyridin-2-one; 5,7-Diethyl-1-{[2'-(1h-Tetrazol-5-Yl)biphenyl-4-Yl]methyl}-3,4-Dihydro-1,6-Naphthyridin-2(1h)-One; ZD 7155; Tocris-1211; NCGC00025043-01; AC1NGE69; SCHEMBL7286312; GTPL8324; CHEBI:92194; ZINC3784334; BDBM50049187; L007754; BRD-K11373525-003-01-3; ZD7; 5,7-diethyl-1-[2'-(1h-1,2,3,4-tetrazol-5-yl)-bi-phenyl-4-ylmethyl]-1,2,3,4-tetrahydro-1,6-naphthyridin-2-one
DM5KSCI CP Zeneca Group plc
DM5KSCI DT Small molecular drug
DM5KSCI PC 4673492
DM5KSCI MW 438.5
DM5KSCI FM C26H26N6O
DM5KSCI IC InChI=1S/C26H26N6O/c1-3-19-15-24-22(23(4-2)27-19)13-14-25(33)32(24)16-17-9-11-18(12-10-17)20-7-5-6-8-21(20)26-28-30-31-29-26/h5-12,15H,3-4,13-14,16H2,1-2H3,(H,28,29,30,31)
DM5KSCI CS CCC1=CC2=C(CCC(=O)N2CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=N1)CC
DM5KSCI IK BFVNEYDCFJNLGN-UHFFFAOYSA-N
DM5KSCI IU 5,7-diethyl-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-1,6-naphthyridin-2-one
DM5KSCI CB CHEBI:92194
DM5KSCI DE Hypertension
DMJEZOP ID DMJEZOP
DMJEZOP DN ZD-7717
DMJEZOP HS Terminated
DMJEZOP SN ICI D7717
DMJEZOP CP Zeneca Group plc
DMJEZOP DE Asthma
DMCT1IX ID DMCT1IX
DMCT1IX DN ZD-7944
DMCT1IX HS Terminated
DMCT1IX SN CHEMBL339767; ZD-7944; ZD7944; SCHEMBL7501969; BDBM50409575; (R)-3-((S)-1-(3,4-dichlorophenyl)-3-(4-(2-((S)-methylsulfinyl)phenyl)piperidin-1-yl)propyl)-2-ethylisoindolin-1-one
DMCT1IX CP Zeneca Group plc
DMCT1IX DT Small molecular drug
DMCT1IX PC 44351946
DMCT1IX MW 569.6
DMCT1IX FM C31H34Cl2N2O2S
DMCT1IX IC InChI=1S/C31H34Cl2N2O2S/c1-3-35-30(25-9-4-5-10-26(25)31(35)36)24(22-12-13-27(32)28(33)20-22)16-19-34-17-14-21(15-18-34)23-8-6-7-11-29(23)38(2)37/h4-13,20-21,24,30H,3,14-19H2,1-2H3/t24-,30+,38-/m0/s1
DMCT1IX CS CCN1[C@@H](C2=CC=CC=C2C1=O)[C@@H](CCN3CCC(CC3)C4=CC=CC=C4[S@@](=O)C)C5=CC(=C(C=C5)Cl)Cl
DMCT1IX IK JYCLPXSCZKCIMO-YEFUCVGBSA-N
DMCT1IX IU (3R)-3-[(1S)-1-(3,4-dichlorophenyl)-3-[4-[2-[(S)-methylsulfinyl]phenyl]piperidin-1-yl]propyl]-2-ethyl-3H-isoindol-1-one
DMCT1IX DE Asthma
DMFV47R ID DMFV47R
DMFV47R DN ZD-9720
DMFV47R HS Terminated
DMFV47R SN ZD-7851
DMFV47R CP AstraZeneca plc
DMFV47R DE Arteriosclerosis
DMQUSG9 ID DMQUSG9
DMQUSG9 DN Zenarestat
DMQUSG9 HS Terminated
DMQUSG9 SN 112733-06-9; FR-74366; FK-366; Zenarestat [USAN:INN]; Zenarestatum [INN-Latin]; FR 74366; UNII-180C9PJ8JT; FK 366; [3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-3,4-dihydroquinazolin-1(2h)-yl]acetic acid; CI-1014; CI 1014; CHEMBL10413; 180C9PJ8JT; 2-(7-Chloro-3-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxoquinazolin)-1-acetic acid; Zenarestatum; DSSTox_RID_82249; 3-(4-Bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid; DSSTox_CID_27296; ZES; FR74366; Fk366; Zenarestat (USAN/INN); [3-(4-BROMO-2-FLUORO-BENZYL)-7-CHLORO-2,4-DIOXO-3,4-DIHYDRO-2H-QUINAZOLIN-1-YL]-ACETIC ACID; (3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetic acid; 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid; 3-((4-Bromo-2-fluorophenyl)methyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineaceticacid
DMQUSG9 CP Ono Pharmaceutical; Fujisawa Pharmaceutical
DMQUSG9 DT Small molecular drug
DMQUSG9 PC 5724
DMQUSG9 MW 441.6
DMQUSG9 FM C17H11BrClFN2O4
DMQUSG9 IC InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
DMQUSG9 CS C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
DMQUSG9 IK SXONDGSPUVNZLO-UHFFFAOYSA-N
DMQUSG9 IU 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid
DMQUSG9 CA CAS 112733-06-9
DMQUSG9 DE Diabetic neuropathy
DM81DJV ID DM81DJV
DM81DJV DN Zindoxifene
DM81DJV HS Terminated
DM81DJV SN D-16726
DM81DJV CP Evonik Degussa GmbH
DM81DJV DT Small molecular drug
DM81DJV PC 65645
DM81DJV MW 351.4
DM81DJV FM C21H21NO4
DM81DJV IC InChI=1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3
DM81DJV CS CCN1C2=C(C=C(C=C2)OC(=O)C)C(=C1C3=CC=C(C=C3)OC(=O)C)C
DM81DJV IK KSZGVNZSUJHOJA-UHFFFAOYSA-N
DM81DJV IU [4-(5-acetyloxy-1-ethyl-3-methylindol-2-yl)phenyl] acetate
DM81DJV CA CAS 86111-26-4
DM81DJV CB CHEBI:35052
DM81DJV DE Breast cancer
DMJZH7N ID DMJZH7N
DMJZH7N DN ZK-118182
DMJZH7N HS Terminated
DMJZH7N SN ZK118182; 2-[(Z)-4-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E,3R)-3-hydroxy-3-(2-methylcyclohexyl)prop-1-enyl]cyclopentyl]but-2-enoxy]acetic acid; AC1NSK7N
DMJZH7N CP Bayer Schering Pharma AG
DMJZH7N DT Small molecular drug
DMJZH7N PC 5311208
DMJZH7N MW 400.9
DMJZH7N FM C21H33ClO5
DMJZH7N IC InChI=1S/C21H33ClO5/c1-14-6-2-3-7-15(14)19(23)10-9-17-16(18(22)12-20(17)24)8-4-5-11-27-13-21(25)26/h4-5,9-10,14-20,23-24H,2-3,6-8,11-13H2,1H3,(H,25,26)/b5-4-,10-9+/t14?,15?,16-,17-,18-,19-,20-/m1/s1
DMJZH7N CS CC1CCCCC1[C@@H](/C=C/[C@H]2[C@@H](C[C@H]([C@@H]2C/C=C\\COCC(=O)O)Cl)O)O
DMJZH7N IK JPMWVHYATGJOOX-OSIODEBVSA-N
DMJZH7N IU 2-[(Z)-4-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E,3R)-3-hydroxy-3-(2-methylcyclohexyl)prop-1-enyl]cyclopentyl]but-2-enoxy]acetic acid
DMJZH7N DE Thrombosis
DMKFYDE ID DMKFYDE
DMKFYDE DN ZK-119010
DMKFYDE HS Terminated
DMKFYDE SN ZK-119010; ZK 119010; UNII-80Z22M837F; CHEMBL46903; 80Z22M837F; 127451-69-8; AC1L2YAG; 2-(4-Hydroxyphenyl)-3-methyl-1-(6-(1-pyrrolidinyl)hexyl)indol-5-ol; SCHEMBL9028173; DTXSID50155574; zk119010; BDBM50099586; 1H-Indol-5-ol, 2-(4-hydroxyphenyl)-3-methyl-1-(6-(1-pyrrolidinyl)hexyl)-; LS-191850; 2-(4-hydroxyphenyl)-3-methyl-1-(6-pyrrolidin-1-ylhexyl)indol-5-ol
DMKFYDE DT Small molecular drug
DMKFYDE PC 130936
DMKFYDE MW 392.5
DMKFYDE FM C25H32N2O2
DMKFYDE IC InChI=1S/C25H32N2O2/c1-19-23-18-22(29)12-13-24(23)27(25(19)20-8-10-21(28)11-9-20)17-5-3-2-4-14-26-15-6-7-16-26/h8-13,18,28-29H,2-7,14-17H2,1H3
DMKFYDE CS CC1=C(N(C2=C1C=C(C=C2)O)CCCCCCN3CCCC3)C4=CC=C(C=C4)O
DMKFYDE IK SACIXOLGIWUXTG-UHFFFAOYSA-N
DMKFYDE IU 2-(4-hydroxyphenyl)-3-methyl-1-(6-pyrrolidin-1-ylhexyl)indol-5-ol
DMKFYDE CA CAS 127451-69-8
DMKFYDE DE Carcinoma
DMJYIVA ID DMJYIVA
DMJYIVA DN ZK-91296
DMJYIVA HS Terminated
DMJYIVA SN ZK 91296; 83910-34-3; Ethyl 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-(methoxymethyl)-5-(phenylmethoxy)-, ethyl ester; WFPXOWCKXUEKCA-UHFFFAOYSA-N; AC1Q64YJ; SCHEMBL8845201; AC1L3X51; zk91296; BDBM85040; PDSP2_001753; ethyl 5-(benzyloxy)-4-(methoxymethyl)-9h-; PDSP1_001770; CAS_123700; NSC_123700; LS-187464; LS-186794; 5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic acid-ethyl ester
DMJYIVA CP Bayer Schering Pharma AG
DMJYIVA DT Small molecular drug
DMJYIVA PC 123700
DMJYIVA MW 390.4
DMJYIVA FM C23H22N2O4
DMJYIVA IC InChI=1S/C23H22N2O4/c1-3-28-23(26)22-16(14-27-2)20-18(12-24-22)25-17-10-7-11-19(21(17)20)29-13-15-8-5-4-6-9-15/h4-12,25H,3,13-14H2,1-2H3
DMJYIVA CS CCOC(=O)C1=NC=C2C(=C1COC)C3=C(N2)C=CC=C3OCC4=CC=CC=C4
DMJYIVA IK WFPXOWCKXUEKCA-UHFFFAOYSA-N
DMJYIVA IU ethyl 4-(methoxymethyl)-5-phenylmethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMJYIVA CA CAS 83910-34-3
DMJYIVA DE Alzheimer disease
DMMDQ5T ID DMMDQ5T
DMMDQ5T DN ZK-93426
DMMDQ5T HS Terminated
DMMDQ5T SN ZK-93426; ZK 93426; ZK93426; ZK 93 426; CHEMBL1271047; 89592-45-0; 5-Isopropoxy-4-methyl-beta-carboline-3-carboxylic acid ethyl ester; Ethyl 4-methyl-5-(1-methylethoxy)-9H-pyrido(3,4-b)indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-methyl-5-(1-methylethoxy)-, ethyl ester; AC1L3GQB; SCHEMBL195334; GTPL4347; CHEBI:93201; ZINC5857864; BDBM50329658; NCGC00161396-01; LS-178094; BRD-K68392338-003-01-2; ethyl 5-isopropoxy-4-methyl-9H-pyrido[3,4-b]indole-3-carboxylate; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-
DMMDQ5T CP Bayer Schering Pharma AG
DMMDQ5T DT Small molecular drug
DMMDQ5T PC 115210
DMMDQ5T MW 312.4
DMMDQ5T FM C18H20N2O3
DMMDQ5T IC InChI=1S/C18H20N2O3/c1-5-22-18(21)17-11(4)15-13(9-19-17)20-12-7-6-8-14(16(12)15)23-10(2)3/h6-10,20H,5H2,1-4H3
DMMDQ5T CS CCOC(=O)C1=NC=C2C(=C1C)C3=C(N2)C=CC=C3OC(C)C
DMMDQ5T IK VMDUABMKBUKKPG-UHFFFAOYSA-N
DMMDQ5T IU ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMMDQ5T CA CAS 89592-45-0
DMMDQ5T CB CHEBI:93201
DMMDQ5T DE Alzheimer disease
DM8V0YA ID DM8V0YA
DM8V0YA DN ZM-224832
DM8V0YA HS Terminated
DM8V0YA CP Zeneca Group plc
DM8V0YA DE Hypertension
DM0TBQK ID DM0TBQK
DM0TBQK DN ZM-230487
DM0TBQK HS Terminated
DM0TBQK SN ZM-230487; ZM 230487; 155944-23-3; CHEMBL459236; Ici 230487; ICI-230487; AC1L31ZC; 1-Ethyl-6-((3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxy)methyl)-2-quinolone; SCHEMBL6008852; CTK4C8893; DTXSID70165998; zm230487; ZINC1484223; BDBM50250926; 1-Ethyl-6-((3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy)methyl)-2(1H)-quinolinone; KB-276139; 1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one
DM0TBQK DT Small molecular drug
DM0TBQK PC 132998
DM0TBQK MW 411.5
DM0TBQK FM C24H26FNO4
DM0TBQK IC InChI=1S/C24H26FNO4/c1-3-26-22-6-4-17(12-18(22)5-7-23(26)27)16-30-21-14-19(13-20(25)15-21)24(28-2)8-10-29-11-9-24/h4-7,12-15H,3,8-11,16H2,1-2H3
DM0TBQK CS CCN1C2=C(C=CC1=O)C=C(C=C2)COC3=CC(=CC(=C3)C4(CCOCC4)OC)F
DM0TBQK IK ZROVOGSXAWNIQB-UHFFFAOYSA-N
DM0TBQK IU 1-ethyl-6-[[3-fluoro-5-(4-methoxyoxan-4-yl)phenoxy]methyl]quinolin-2-one
DM0TBQK CA CAS 155944-23-3
DM0TBQK DE Asthma
DMWQ38G ID DMWQ38G
DMWQ38G DN ZM-241385
DMWQ38G HS Terminated
DMWQ38G SN ZM241385; 139180-30-6; ZM 241385; ZM-241385; CHEMBL113142; 4-(2-(7-Amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino)ethyl)phenol; 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 4-(2-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol; 4-{2-[(7-Amino-2-Furan-2-Yl[1,2,4]triazolo[1,5-A][1,3,5]triazin-5-Yl)amino]ethyl}phenol; 4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
DMWQ38G DT Small molecular drug
DMWQ38G PC 176407
DMWQ38G MW 337.34
DMWQ38G FM C16H15N7O2
DMWQ38G IC InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)
DMWQ38G CS C1=COC(=C1)C2=NN3C(=NC(=NC3=N2)NCCC4=CC=C(C=C4)O)N
DMWQ38G IK PWTBZOIUWZOPFT-UHFFFAOYSA-N
DMWQ38G IU 4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
DMWQ38G CA CAS 139180-30-6
DMWQ38G CB CHEBI:92361
DM70HZD ID DM70HZD
DM70HZD DN Zonampanel
DM70HZD HS Terminated
DM70HZD SN Zonampanel; Ym 872; 210245-80-0; YM-872; UNII-9X33544ILS; CHEMBL119625; 9X33544ILS; Zonampanel [USAN:INN]; YM872 anhydrous; Zonampanel anhydrous; YM 872 anhydrous; Zonampanel (INN/USAN); AC1L3WN2; SCHEMBL678832; DTXSID50175232; ZINC1891930; BDBM50133599; AKOS030257633; CS-6830; KB-81523; HY-15072; QC-11463; D09035; 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid; 7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl)acetic acid
DM70HZD DT Small molecular drug
DM70HZD PC 148200
DM70HZD MW 331.24
DM70HZD FM C13H9N5O6
DM70HZD IC InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20)
DM70HZD CS C1=CN(C=N1)C2=C(C=C3C(=C2)N(C(=O)C(=O)N3)CC(=O)O)[N+](=O)[O-]
DM70HZD IK SPXYHZRWPRQLNS-UHFFFAOYSA-N
DM70HZD IU 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid
DM70HZD CA CAS 210245-80-0
DM70TKB ID DM70TKB
DM70TKB DN zoxazolamine
DM70TKB HS Terminated
DM70TKB SN Zoxazolamine; 61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%
DM70TKB DT Small molecular drug
DM70TKB PC 6103
DM70TKB MW 168.58
DM70TKB FM C7H5ClN2O
DM70TKB IC InChI=1S/C7H5ClN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)
DM70TKB CS C1=CC2=C(C=C1Cl)N=C(O2)N
DM70TKB IK YGCODSQDUUUKIV-UHFFFAOYSA-N
DM70TKB IU 5-chloro-1,3-benzoxazol-2-amine
DM70TKB CA CAS 61-80-3
DM70TKB CB CHEBI:35053
DM70TKB DE Multiple myeloma
DM193WR ID DM193WR
DM193WR DN ZT-386
DM193WR HS Terminated
DM193WR CP Taisho Pharmaceutical Co Ltd
DM193WR DE Asthma
DM2TIU3 ID DM2TIU3
DM2TIU3 DN ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine
DM2TIU3 HS Investigative
DM2TIU3 SN CHEMBL498509; ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine; SCHEMBL5808356; BDBM50272715
DM2TIU3 DT Small molecular drug
DM2TIU3 PC 44593693
DM2TIU3 MW 269.34
DM2TIU3 FM C17H19NO2
DM2TIU3 IC InChI=1S/C17H19NO2/c1-12-6-2-4-8-15(12)20-17-13(10-18)11-19-16-9-5-3-7-14(16)17/h2-9,13,17H,10-11,18H2,1H3/t13-,17-/m1/s1
DM2TIU3 CS CC1=CC=CC=C1O[C@@H]2[C@@H](COC3=CC=CC=C23)CN
DM2TIU3 IK RQRGTZIPGLRQOJ-CXAGYDPISA-N
DM2TIU3 IU [(3R,4R)-4-(2-methylphenoxy)-3,4-dihydro-2H-chromen-3-yl]methanamine
DM2TIU3 DE Discovery agent
DMEJRVW ID DMEJRVW
DMEJRVW DN ((E)-3-Amino-propenyl)-methyl-phosphinic acid
DMEJRVW HS Investigative
DMEJRVW SN 3-aminoprop-1-enyl(methyl)phosphinic acid
DMEJRVW DE Discovery agent
DMCW65Q ID DMCW65Q
DMCW65Q DN ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine
DMCW65Q HS Investigative
DMCW65Q SN CHEMBL89459; ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine; BDBM50104655
DMCW65Q DT Small molecular drug
DMCW65Q PC 10012278
DMCW65Q MW 166.26
DMCW65Q FM C10H18N2
DMCW65Q IC InChI=1S/C10H18N2/c1-2-3-6-9-7-4-5-8-10(11)12-9/h2-3,9H,4-8H2,1H3,(H2,11,12)/b3-2+
DMCW65Q CS C/C=C/CC1CCCCC(=N1)N
DMCW65Q IK JYALIDLLQJSBKD-NSCUHMNNSA-N
DMCW65Q IU 2-[(E)-but-2-enyl]-3,4,5,6-tetrahydro-2H-azepin-7-amine
DMCW65Q DE Discovery agent
DM6H0FW ID DM6H0FW
DM6H0FW DN ((Z)-3-Amino-propenyl)-methyl-phosphinic acid
DM6H0FW HS Investigative
DM6H0FW SN CGP-70523; SCHEMBL6679937; PDSP2_001466; PDSP1_001482
DM6H0FW DT Small molecular drug
DM6H0FW PC 91929120
DM6H0FW MW 135.1
DM6H0FW FM C4H10NO2P
DM6H0FW IC InChI=1S/C4H10NO2P/c1-8(6,7)4-2-3-5/h3,5H,2,4H2,1H3,(H,6,7)
DM6H0FW CS CP(=O)(CCC=N)O
DM6H0FW IK CLJLMKDNJNIXPO-UHFFFAOYSA-N
DM6H0FW IU 3-iminopropyl(methyl)phosphinic acid
DM6H0FW DE Discovery agent
DM974LP ID DM974LP
DM974LP DN (-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride
DM974LP HS Investigative
DM974LP SN CHEMBL507970
DM974LP DT Small molecular drug
DM974LP PC 44584678
DM974LP MW 675.2
DM974LP FM C39H47ClN2O6
DM974LP IC InChI=1S/C39H46N2O6.ClH/c1-40-16-14-27-21-35(43-4)37(45-6)23-30(27)32(40)18-25-8-11-29(12-9-25)47-39-20-26(10-13-34(39)42-3)19-33-31-24-38(46-7)36(44-5)22-28(31)15-17-41(33)2;/h8-13,20-24,32-33H,14-19H2,1-7H3;1H/t32-,33+;/m1./s1
DM974LP CS CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@H]5C6=CC(=C(C=C6CCN5C)OC)OC)OC)OC)OC.Cl
DM974LP IK OEBMBMKSAQUFSL-VMXYRSAXSA-N
DM974LP IU (1R)-1-[[4-[5-[[(1S)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline;hydrochloride
DM974LP DE Discovery agent
DMV6EMN ID DMV6EMN
DMV6EMN DN (-)-(R)-efonidipine
DMV6EMN HS Investigative
DMV6EMN SN UNII-BF2E1WS195; BF2E1WS195; ()-2-[benzyl (phenyl) amino] ethyl 1,4-dihydro-2,6- dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethano; Efonidipine, (-)-; (-)-(R)-efonidipine; (R)-(-)-Efonidipine; 128194-13-8; Efonidipine (R)-form [MI]; GTPL2519; ZINC38139973; 3-Pyridinecarboxylic acid, 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, (4R)-
DMV6EMN DT Small molecular drug
DMV6EMN PC 9830707
DMV6EMN MW 631.7
DMV6EMN FM C34H38N3O7P
DMV6EMN IC InChI=1S/C34H38N3O7P/c1-24-30(33(38)42-19-18-36(28-15-9-6-10-16-28)21-26-12-7-5-8-13-26)31(27-14-11-17-29(20-27)37(39)40)32(25(2)35-24)45(41)43-22-34(3,4)23-44-45/h5-17,20,31,35H,18-19,21-23H2,1-4H3/t31-/m1/s1
DMV6EMN CS CC1=C([C@H](C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5
DMV6EMN IK NSVFSAJIGAJDMR-WJOKGBTCSA-N
DMV6EMN IU 2-(N-benzylanilino)ethyl (4R)-5-(5,5-dimethyl-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate
DMV6EMN CA CAS 128194-13-8
DMV6EMN CB CHEBI:146219
DMV6EMN DE Discovery agent
DMEA9KH ID DMEA9KH
DMEA9KH DN (-)-(S)-BayK8644
DMEA9KH HS Investigative
DMEA9KH SN 98625-26-4; (S)-(-)-BAY K 8644; Bay-K-8644 ((S)-(-)-); Bay-K-8644 (S)-(-)-; (S)-(-)-Bay K8644; methyl (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate; S-(-)-1,4-Dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid methyl ester; CHEMBL283013; Tocris-1544; Lopac-B-112; (S)-BayK8644; GTPL4065; AC1O7G05; SCHEMBL2845539; (S)-Bay K8644; CHEBI:93962; (S)-Bay-K-8644; DTXSID50424954; MolPort-003-940-398; CHEBI:131347
DMEA9KH DT Small molecular drug
DMEA9KH PC 6603728
DMEA9KH MW 356.3
DMEA9KH FM C16H15F3N2O4
DMEA9KH IC InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13,20H,1-3H3/t13-/m0/s1
DMEA9KH CS CC1=C([C@@H](C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)OC
DMEA9KH IK ZFLWDHHVRRZMEI-ZDUSSCGKSA-N
DMEA9KH IU methyl (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
DMEA9KH CA CAS 98625-26-4
DMEA9KH CB CHEBI:93962
DMEA9KH DE Discovery agent
DME5TIR ID DME5TIR
DME5TIR DN (-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile
DME5TIR HS Investigative
DME5TIR SN 3-(1-Propyl-3-piperidinyl)benzonitrile; 150336-90-6; 3-(1-propylpiperidin-3-yl)benzonitrile; CHEMBL107492; Benzonitrile,3-(1-propyl-3-piperidinyl)-; DS121 Cpd; 3-(3-Cyanophenyl)-N-n-propylpiperidine; AC1L1JNG; AC1Q4RGX; ACMC-1C3WE; SCHEMBL872942; CTK4C6605; BDBM50041960; 3-(1-Propylpiperidine-3-yl)benzonitrile; 3-(1-Propyl-piperidin-3-yl)-benzonitrile; (+)-3-(1-Propyl-piperidin-3-yl)-benzonitrile; L007862; Benzonitrile, 3-(1-propyl-3-piperidinyl)-, (+-)-
DME5TIR DT Small molecular drug
DME5TIR PC 5119
DME5TIR MW 228.33
DME5TIR FM C15H20N2
DME5TIR IC InChI=1S/C15H20N2/c1-2-8-17-9-4-7-15(12-17)14-6-3-5-13(10-14)11-16/h3,5-6,10,15H,2,4,7-9,12H2,1H3
DME5TIR CS CCCN1CCCC(C1)C2=CC=CC(=C2)C#N
DME5TIR IK GQRIAOUUYRIMLH-UHFFFAOYSA-N
DME5TIR IU 3-(1-propylpiperidin-3-yl)benzonitrile
DME5TIR CA CAS 150336-90-6
DME5TIR DE Discovery agent
DMGC7F5 ID DMGC7F5
DMGC7F5 DN (-)-3,3'-bisdemethylpinoresinol
DMGC7F5 HS Investigative
DMGC7F5 SN CHEMBL227187; BDBM50208822; J3.605.566I
DMGC7F5 DT Small molecular drug
DMGC7F5 PC 24992964
DMGC7F5 MW 330.3
DMGC7F5 FM C18H18O6
DMGC7F5 IC InChI=1S/C18H18O6/c19-13-3-1-9(5-15(13)21)17-11-7-24-18(12(11)8-23-17)10-2-4-14(20)16(22)6-10/h1-6,11-12,17-22H,7-8H2/t11-,12-,17+,18+/m1/s1
DMGC7F5 CS C1[C@@H]2[C@@H](CO[C@H]2C3=CC(=C(C=C3)O)O)[C@@H](O1)C4=CC(=C(C=C4)O)O
DMGC7F5 IK OQSOTSIYXPYTRE-VVDPLQPHSA-N
DMGC7F5 IU 4-[(3R,3aS,6R,6aS)-3-(3,4-dihydroxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]benzene-1,2-diol
DMGC7F5 DE Discovery agent
DMKRTBM ID DMKRTBM
DMKRTBM DN (-)-3-O-acetylspectaline
DMKRTBM HS Investigative
DMKRTBM SN (-)-3-O-Acetylspectaline
DMKRTBM DT Small molecular drug
DMKRTBM PC 10474155
DMKRTBM MW 367.6
DMKRTBM FM C22H41NO3
DMKRTBM IC InChI=1S/C22H41NO3/c1-18(24)14-12-10-8-6-4-5-7-9-11-13-15-21-16-17-22(19(2)23-21)26-20(3)25/h19,21-23H,4-17H2,1-3H3/t19-,21+,22-/m1/s1
DMKRTBM CS C[C@@H]1[C@@H](CC[C@@H](N1)CCCCCCCCCCCCC(=O)C)OC(=O)C
DMKRTBM IK LRKWDKCSHJWJST-BAGYTPMASA-N
DMKRTBM IU [(2R,3R,6S)-2-methyl-6-(13-oxotetradecyl)piperidin-3-yl] acetate
DMKRTBM DE Discovery agent
DM396OK ID DM396OK
DM396OK DN (-)-7-N-methyldibromophakellin
DM396OK HS Investigative
DM396OK SN CHEMBL505073; (-)-7-N-methyldibromophakellin
DM396OK DT Small molecular drug
DM396OK PC 11211821
DM396OK MW 403.07
DM396OK FM C12H13Br2N5O
DM396OK IC InChI=1S/C12H13Br2N5O/c1-17-10-12(16-11(17)15)3-2-4-18(12)9(20)7-5-6(13)8(14)19(7)10/h5,10H,2-4H2,1H3,(H2,15,16)/t10-,12+/m0/s1
DM396OK CS CN1[C@@H]2[C@]3(CCCN3C(=O)C4=CC(=C(N24)Br)Br)N=C1N
DM396OK IK YPAFHZXYEACLQB-CMPLNLGQSA-N
DM396OK IU (1R,5S)-3-amino-7,8-dibromo-4-methyl-2,4,6,12-tetrazatetracyclo[10.3.0.01,5.06,10]pentadeca-2,7,9-trien-11-one
DM396OK DE Discovery agent
DMZOGSK ID DMZOGSK
DMZOGSK DN (-)-CATECHINGALLATE
DMZOGSK HS Investigative
DMZOGSK SN (-)-Catechin gallate; 130405-40-2; (2S,3R)-2-(3,4-Dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; catechin gallate; UNII-0KT1FO6VO6; ent-Catechin 3-O-gallate; 0KT1FO6VO6; CHEMBL129451; CHEBI:76131; (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; (2S,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); (-)-CATECHINGALLATE; Catechin gallate, (-)-; CCRIS 9303; Catechin gallateCG; (-)-Catechin gallate
DMZOGSK DT Small molecular drug
DMZOGSK PC 6419835
DMZOGSK MW 442.4
DMZOGSK FM C22H18O10
DMZOGSK IC InChI=1S/C22H18O10/c23-11-6-14(25)12-8-19(32-22(30)10-4-16(27)20(29)17(28)5-10)21(31-18(12)7-11)9-1-2-13(24)15(26)3-9/h1-7,19,21,23-29H,8H2/t19-,21+/m1/s1
DMZOGSK CS C1[C@H]([C@@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMZOGSK IK LSHVYAFMTMFKBA-CTNGQTDRSA-N
DMZOGSK IU [(2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMZOGSK CA CAS 130405-40-2
DMZOGSK CB CHEBI:76131
DMZOGSK DE Discovery agent
DMJ249P ID DMJ249P
DMJ249P DN (-)-Cercosporamide
DMJ249P HS Investigative
DMJ249P SN Cercosporamide; 131436-22-1; CHEBI:78696; ( )-Cercosporamide; AC1L2Z33; SCHEMBL12658718; CTK8E7014; MolPort-006-822-609; GEWLYFZWVLXQME-MRXNPFEDSA-N; ZINC5114136; ZINC100098020; AKOS024458192; CS-4664; HY-16982; RT-011975; J-006002; (9aS)-8-acetyl-1,3,7-trihydroxy-9a-methyl-9-oxodibenzofuran-4-carboxamide; 4-Dibenzofurancarboxamide, 8-acetyl-9,9a-dihydro-1,3,7-trihydroxy-9a-methyl-9-oxo-, (S)-; (9aS)-8-Acetyl-9,9a-dihydro-1,3,7-trihydroxy-9a-methyl-9-oxo-4-dibenzofurancaboxamide
DMJ249P DT Small molecular drug
DMJ249P PC 131379
DMJ249P MW 331.28
DMJ249P FM C16H13NO7
DMJ249P IC InChI=1S/C16H13NO7/c1-5(18)10-7(20)4-9-16(2,14(10)22)12-8(21)3-6(19)11(15(17)23)13(12)24-9/h3-4,19-21H,1-2H3,(H2,17,23)/t16-/m1/s1
DMJ249P CS CC(=O)C1=C(C=C2[C@@](C1=O)(C3=C(C=C(C(=C3O2)C(=O)N)O)O)C)O
DMJ249P IK GEWLYFZWVLXQME-MRXNPFEDSA-N
DMJ249P IU (9aS)-8-acetyl-1,3,7-trihydroxy-9a-methyl-9-oxodibenzofuran-4-carboxamide
DMJ249P CA CAS 131436-22-1
DMJ249P CB CHEBI:78696
DMJ249P DE Discovery agent
DMPGJE6 ID DMPGJE6
DMPGJE6 DN (-)-clusin
DMPGJE6 HS Investigative
DMPGJE6 SN (-)-clusin; CHEMBL479701; BDBM50259867
DMPGJE6 DT Small molecular drug
DMPGJE6 PC 44575398
DMPGJE6 MW 402.4
DMPGJE6 FM C22H26O7
DMPGJE6 IC InChI=1S/C22H26O7/c1-24-19-9-14(10-20(25-2)21(19)26-3)7-16-15(11-27-22(16)23)6-13-4-5-17-18(8-13)29-12-28-17/h4-5,8-10,15-16,22-23H,6-7,11-12H2,1-3H3/t15-,16+,22?/m0/s1
DMPGJE6 CS COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2O)CC3=CC4=C(C=C3)OCO4
DMPGJE6 IK SOCNBZCAGNYAED-OKFXBHNASA-N
DMPGJE6 IU (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DMPGJE6 DE Discovery agent
DM57LVW ID DM57LVW
DM57LVW DN (-)-cubebin
DM57LVW HS Investigative
DM57LVW SN Cubebin; (-)-Cubebin; 18423-69-3; beta-cubebin; UNII-J237078S8A; (2s,3r,4r)-3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydrofuran-2-ol; EINECS 242-300-6; Tetrahydro-3,4-dipiperonylfuran-2-ol; (8R,8'R,9S)-cubebin; AI3-62265; CHEMBL399831; CHEBI:65684; J237078S8A; 2-Furanol, 3,4-bis(1,3-benzodioxol-5-ylmethyl)tetrahydro-; Cubebine; 9-Hydroxy-3,4:3',4'-bis(methylenedioxy)-9,9'-epoxylignan; 3,4-bis(2H-1,3-benzodioxol-5-ylmethyl)oxolan-2-ol; .beta.-Cubebin; 2-Furanol, tetrahydro-3,4-dipiperonyl-; AC1Q59VI; AC1L3KW2; SCHEMBL4884683
DM57LVW DT Small molecular drug
DM57LVW PC 117443
DM57LVW MW 356.4
DM57LVW FM C20H20O6
DM57LVW IC InChI=1S/C20H20O6/c21-20-15(6-13-2-4-17-19(8-13)26-11-24-17)14(9-22-20)5-12-1-3-16-18(7-12)25-10-23-16/h1-4,7-8,14-15,20-21H,5-6,9-11H2/t14-,15+,20-/m0/s1
DM57LVW CS C1[C@@H]([C@H]([C@H](O1)O)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DM57LVW IK DIYWRNLYKJKHAM-MDOVXXIYSA-N
DM57LVW IU (2S,3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)oxolan-2-ol
DM57LVW CA CAS 18423-69-3
DM57LVW CB CHEBI:65684
DM57LVW DE Discovery agent
DMSTZF9 ID DMSTZF9
DMSTZF9 DN (-)-cubebinin
DMSTZF9 HS Investigative
DMSTZF9 SN (-)-cubebinin; CHEMBL480296; (-)-Cubebinin; BDBM50259873
DMSTZF9 DT Small molecular drug
DMSTZF9 PC 44575401
DMSTZF9 MW 448.5
DMSTZF9 FM C24H32O8
DMSTZF9 IC InChI=1S/C24H32O8/c1-26-18-9-14(10-19(27-2)22(18)30-5)7-16-13-32-24(25)17(16)8-15-11-20(28-3)23(31-6)21(12-15)29-4/h9-12,16-17,24-25H,7-8,13H2,1-6H3/t16-,17+,24?/m0/s1
DMSTZF9 CS COC1=CC(=CC(=C1OC)OC)C[C@H]2COC([C@@H]2CC3=CC(=C(C(=C3)OC)OC)OC)O
DMSTZF9 IK PIYHDSUVUSVLGU-HSQXHLSASA-N
DMSTZF9 IU (3R,4R)-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DMSTZF9 DE Discovery agent
DM8Q6I0 ID DM8Q6I0
DM8Q6I0 DN (-)-cubebininolide
DM8Q6I0 HS Investigative
DM8Q6I0 SN (-)-cubebininolide; CHEMBL479314; Cordigerin; (-)-Cordigerine; (-)-Cubebininolide; VUNCHONBJWJYID-DLBZAZTESA-N; BDBM50259868; (3R,4R)-3,4-bis(3,4,5-Trimethoxybenzyl)dihydrofuran-2(3H)-one; 2(3H)-Furanone, dihydro-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]-, (3R-trans)-; 2(3H)-Furanone, dihydro-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]-, (3R,4R)-
DM8Q6I0 DT Small molecular drug
DM8Q6I0 PC 13916150
DM8Q6I0 MW 446.5
DM8Q6I0 FM C24H30O8
DM8Q6I0 IC InChI=1S/C24H30O8/c1-26-18-9-14(10-19(27-2)22(18)30-5)7-16-13-32-24(25)17(16)8-15-11-20(28-3)23(31-6)21(12-15)29-4/h9-12,16-17H,7-8,13H2,1-6H3/t16-,17+/m0/s1
DM8Q6I0 CS COC1=CC(=CC(=C1OC)OC)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C(=C3)OC)OC)OC
DM8Q6I0 IK VUNCHONBJWJYID-DLBZAZTESA-N
DM8Q6I0 IU (3R,4R)-3,4-bis[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one
DM8Q6I0 CA CAS 93395-16-5
DM8Q6I0 DE Discovery agent
DMC8WS4 ID DMC8WS4
DMC8WS4 DN (-)-cyclorphan
DMC8WS4 HS Investigative
DMC8WS4 SN CHEMBL291468; BDBM50105483; 17-cyclopropylmethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol; 17-cyclopropylmethyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMC8WS4 DT Small molecular drug
DMC8WS4 PC 44299063
DMC8WS4 MW 297.4
DMC8WS4 FM C20H27NO
DMC8WS4 IC InChI=1S/C20H27NO/c22-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-21(19)13-14-4-5-14/h6-7,12,14,17,19,22H,1-5,8-11,13H2/t17?,19-,20-/m1/s1
DMC8WS4 CS C1CC[C@@]23CCN([C@@H](C2C1)CC4=C3C=C(C=C4)O)CC5CC5
DMC8WS4 IK NLBUEDSBXVNAPB-IPNZSQQUSA-N
DMC8WS4 IU (1R,9R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMC8WS4 DE Discovery agent
DM6LGHU ID DM6LGHU
DM6LGHU DN (-)-DEBROMOFLUSTRAMINE B
DM6LGHU HS Investigative
DM6LGHU SN CHEMBL383307; (-)-DEBROMOFLUSTRAMINE B; (-)-DebromoflustramineB; BDBM50241051
DM6LGHU DT Small molecular drug
DM6LGHU PC 10403152
DM6LGHU MW 310.5
DM6LGHU FM C21H30N2
DM6LGHU IC InChI=1S/C21H30N2/c1-16(2)10-12-21-13-15-22(5)20(21)23(14-11-17(3)4)19-9-7-6-8-18(19)21/h6-11,20H,12-15H2,1-5H3/t20-,21+/m1/s1
DM6LGHU CS CC(=CC[C@@]12CCN([C@@H]1N(C3=CC=CC=C23)CC=C(C)C)C)C
DM6LGHU IK NUWYFFDZPIGJJO-RTWAWAEBSA-N
DM6LGHU IU (3aR,8bS)-3-methyl-4,8b-bis(3-methylbut-2-enyl)-2,3a-dihydro-1H-pyrrolo[2,3-b]indole
DM6LGHU DE Discovery agent
DMNYH3X ID DMNYH3X
DMNYH3X DN (-)-dihydroclusin
DMNYH3X HS Investigative
DMNYH3X SN (-)-dihydroclusin; CHEMBL469916; 73149-51-6; (-)-Dihydroclusin; AC1L7BWU; DTXSID10318502; BDBM50259874; NSC332042; NSC-332042
DMNYH3X DT Small molecular drug
DMNYH3X PC 332806
DMNYH3X MW 404.5
DMNYH3X FM C22H28O7
DMNYH3X IC InChI=1S/C22H28O7/c1-25-20-9-15(10-21(26-2)22(20)27-3)7-17(12-24)16(11-23)6-14-4-5-18-19(8-14)29-13-28-18/h4-5,8-10,16-17,23-24H,6-7,11-13H2,1-3H3/t16-,17-/m0/s1
DMNYH3X CS COC1=CC(=CC(=C1OC)OC)C[C@@H](CO)[C@@H](CC2=CC3=C(C=C2)OCO3)CO
DMNYH3X IK FDHFWHRGVDRJIK-IRXDYDNUSA-N
DMNYH3X IU (2R,3R)-2-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]butane-1,4-diol
DMNYH3X CA CAS 73149-51-6
DMNYH3X DE Discovery agent
DMPQBWY ID DMPQBWY
DMPQBWY DN (-)-englerin A
DMPQBWY HS Investigative
DMPQBWY SN Englerin A; (-)-englerin A; CHEBI:72441; (1R,3aR,4S,5R,7R,8S,8aR)-5-(glycoloyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-epoxyazulen-8-yl (2E)-3-phenylacrylate; GTPL8372; SCHEMBL12280306
DMPQBWY DT Small molecular drug
DMPQBWY PC 46242512
DMPQBWY MW 442.5
DMPQBWY FM C26H34O6
DMPQBWY IC InChI=1S/C26H34O6/c1-16(2)26-14-20(30-22(29)15-27)25(4,32-26)19-12-10-17(3)23(19)24(26)31-21(28)13-11-18-8-6-5-7-9-18/h5-9,11,13,16-17,19-20,23-24,27H,10,12,14-15H2,1-4H3/b13-11+/t17-,19-,20-,23-,24+,25+,26-/m1/s1
DMPQBWY CS C[C@@H]1CC[C@@H]2[C@@H]1[C@@H]([C@@]3(C[C@H]([C@]2(O3)C)OC(=O)CO)C(C)C)OC(=O)/C=C/C4=CC=CC=C4
DMPQBWY IK GACOFEKSDCOVMV-RRYXBOBMSA-N
DMPQBWY IU [(1S,2R,5R,6R,7S,8R,10R)-10-(2-hydroxyacetyl)oxy-1,5-dimethyl-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-7-yl] (E)-3-phenylprop-2-enoate
DMPQBWY CB CHEBI:72441
DMPQBWY DE Discovery agent
DMJD34Q ID DMJD34Q
DMJD34Q DN (-)-eseroline
DMJD34Q HS Investigative
DMJD34Q SN Eseroline; (-)-Eseroline; UNII-Q22H41O18D; CHEMBL310934; CHEBI:48845; C13H18N2O; HKGWQUVGHPDEBZ-OLZOCXBDSA-N; Q22H41O18D; (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-ol; 469-22-7; (3as-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol; Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-; (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol; Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS,8aR)-
DMJD34Q DT Small molecular drug
DMJD34Q PC 119198
DMJD34Q MW 218.29
DMJD34Q FM C13H18N2O
DMJD34Q IC InChI=1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3/t12-,13+/m1/s1
DMJD34Q CS C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)O)C)C
DMJD34Q IK HKGWQUVGHPDEBZ-OLZOCXBDSA-N
DMJD34Q IU (3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-ol
DMJD34Q CA CAS 469-22-7
DMJD34Q CB CHEBI:48845
DMJD34Q DE Discovery agent
DMBO9J3 ID DMBO9J3
DMBO9J3 DN (-)-huperzine B
DMBO9J3 HS Investigative
DMBO9J3 SN (-)-Huperzine B; SCHEMBL2759896; BDBM10632
DMBO9J3 DT Small molecular drug
DMBO9J3 PC 23645296
DMBO9J3 MW 256.339
DMBO9J3 FM C16H20N2O
DMBO9J3 IC InChI=1S/C16H20N2O/c1-10-7-11-8-14-13(4-5-15(19)18-14)16(9-10)12(11)3-2-6-17-16/h4-5,7,11-12,17H,2-3,6,8-9H2,1H3,(H,18,19)/t11?,12-,16-/m1/s1
DMBO9J3 CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4
DMBO9J3 IK YYWGABLTRMRUIT-ZLXOECBPSA-N
DMBO9J3 IU (1R,10R)-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMBO9J3 DE Discovery agent
DMJVNQB ID DMJVNQB
DMJVNQB DN (-)-hydroxycitrate
DMJVNQB HS Investigative
DMJVNQB SN Garcinia acid; 3-c-carboxy-2-deoxy-d-erythro-pentaric acid; CHEMBL118715; UNII-8W94T9026R; (1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid; 8W94T9026R; Super CitriMax HCA 600SXS; 4373-35-7; (-)-Hydroxycitrate; 27750-10-3; 7A3; Citric acid, 2-hydroxy-, (-)-; AC1Q5QYE; AC1L4H7S; (2S,3S)-3-Carboxy-2,3-dihydroxy-pentanedioic acid; SCHEMBL6773065; DTXSID20276669; ZINC1656422; BDBM50036210; LMFA01050511; AJ-28889; D-erythro-Pentaric acid,
DMJVNQB DT Small molecular drug
DMJVNQB PC 185620
DMJVNQB MW 208.12
DMJVNQB FM C6H8O8
DMJVNQB IC InChI=1S/C6H8O8/c7-2(8)1-6(14,5(12)13)3(9)4(10)11/h3,9,14H,1H2,(H,7,8)(H,10,11)(H,12,13)/t3-,6+/m1/s1
DMJVNQB CS C(C(=O)O)[C@]([C@@H](C(=O)O)O)(C(=O)O)O
DMJVNQB IK ZMJBYMUCKBYSCP-CVYQJGLWSA-N
DMJVNQB IU (1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid
DMJVNQB CA CAS 27750-10-3
DMJVNQB CB CHEBI:165420
DMJVNQB DE Discovery agent
DMJS6IZ ID DMJS6IZ
DMJS6IZ DN (-)-isoelaeocarpiline
DMJS6IZ HS Investigative
DMJS6IZ SN (-)-isoelaeocarpiline; CHEMBL521711; (-)-Isoelaeocarpiline
DMJS6IZ DT Small molecular drug
DMJS6IZ PC 44583898
DMJS6IZ MW 259.339
DMJS6IZ FM C16H21NO2
DMJS6IZ IC InChI=1S/C16H21NO2/c1-10-4-2-6-12-14(10)16(18)15-11-5-3-8-17(11)9-7-13(15)19-12/h2,6,10-11,13,15H,3-5,7-9H2,1H3/t10-,11-,13+,15-/m0/s1
DMJS6IZ CS C[C@H]1CC=CC2=C1C(=O)[C@H]3[C@@H]4CCCN4CC[C@H]3O2
DMJS6IZ IK RETGXUCYBMOWOH-MEDZGJRSSA-N
DMJS6IZ IU (6aR,11S,12aS,12bS)-11-methyl-1,2,3,5,6,6a,10,11,12a,12b-decahydrochromeno[2,3-g]indolizin-12-one
DMJS6IZ DE Discovery agent
DMOY9J8 ID DMOY9J8
DMOY9J8 DN (-)-norfenfluramine
DMOY9J8 HS Investigative
DMOY9J8 SN l-norfenfluramine; 37577-22-3; (R)-1-(3-TRIFLUOROMETHYLPHENYL)-2-AMINOPROPANE; UNII-ODG984O60W; ODG984O60W; (2R)-1-[3-(trifluoromethyl)phenyl]propan-2-amine; Benzeneethanamine, a-methyl-3-(trifluoromethyl)-, (; (R)-Norfenfluramin; (R)-Norfenfluramine; Norfenfluramine, (R)-; GTPL217; (R)-1-(3-(trifluoromethyl)phenyl)propan-2-amine; SCHEMBL895637; CHEMBL250881; BDBM85598; CTK4H8426; MLBHFBKZUPLWBD-SSDOTTSWSA-N; CHEBI:125653; ZINC2039145; PDSP1_000697; PDSP2_000687; PDSP1_001422; AKOS030231006
DMOY9J8 DT Small molecular drug
DMOY9J8 PC 12895728
DMOY9J8 MW 203.2
DMOY9J8 FM C10H12F3N
DMOY9J8 IC InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3/t7-/m1/s1
DMOY9J8 CS C[C@H](CC1=CC(=CC=C1)C(F)(F)F)N
DMOY9J8 IK MLBHFBKZUPLWBD-SSDOTTSWSA-N
DMOY9J8 IU (2R)-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMOY9J8 CA CAS 37577-22-3
DMOY9J8 CB CHEBI:125653
DMOY9J8 DE Discovery agent
DMVUEW5 ID DMVUEW5
DMVUEW5 DN (-)-Phenethylcymserine
DMVUEW5 HS Investigative
DMVUEW5 SN (-)-Phenethylcymserine; CHEMBL54577; BDBM50077263; (4-Isopropyl-phenyl)-carbamic acid (S)-3a,8-dimethyl-1-phenethyl-1,2,3,3a,8,8a-hexahydro-pyrrolo[2,3-b]indol-5-yl ester
DMVUEW5 DT Small molecular drug
DMVUEW5 PC 11385845
DMVUEW5 MW 469.6
DMVUEW5 FM C30H35N3O2
DMVUEW5 IC InChI=1S/C30H35N3O2/c1-21(2)23-10-12-24(13-11-23)31-29(34)35-25-14-15-27-26(20-25)30(3)17-19-33(28(30)32(27)4)18-16-22-8-6-5-7-9-22/h5-15,20-21,28H,16-19H2,1-4H3,(H,31,34)/t28?,30-/m0/s1
DMVUEW5 CS CC(C)C1=CC=C(C=C1)NC(=O)OC2=CC3=C(C=C2)N(C4[C@]3(CCN4CCC5=CC=CC=C5)C)C
DMVUEW5 IK WKDFOVDLOVYRAJ-TXDWVUBVSA-N
DMVUEW5 IU [(8bS)-4,8b-dimethyl-3-(2-phenylethyl)-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(4-propan-2-ylphenyl)carbamate
DMVUEW5 DE Discovery agent
DM4INSG ID DM4INSG
DM4INSG DN (-)-pinoresinol
DM4INSG HS Investigative
DM4INSG SN Pinoresinol; NSC35444; NSC-35444; bmse010297; AC1Q70QC; (+/-)-PINORESINOL; SCHEMBL122106; AC1L5T18; CHEMBL2252392; CTK2H0032; 4,4'-[(1S,3aR,4S,6aR)-Tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(2-methoxyphenol); HMS3347E17; AKOS025404740; 4,4'-tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diylbis(2-methoxyphenol); phenol, 4,4'-(tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl)bis[2-methoxy-; Phenol,4'-(tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl)bis[2-methoxy-, [1S-(1.alpha.,3a.alpha.,4.alpha.,6a.alpha.)]-
DM4INSG DT Small molecular drug
DM4INSG PC 12309636
DM4INSG MW 358.4
DM4INSG FM C20H22O6
DM4INSG IC InChI=1S/C20H22O6/c1-23-17-7-11(3-5-15(17)21)19-13-9-26-20(14(13)10-25-19)12-4-6-16(22)18(8-12)24-2/h3-8,13-14,19-22H,9-10H2,1-2H3/t13-,14-,19+,20+/m1/s1
DM4INSG CS COC1=C(C=CC(=C1)[C@H]2[C@@H]3CO[C@H]([C@@H]3CO2)C4=CC(=C(C=C4)O)OC)O
DM4INSG IK HGXBRUKMWQGOIE-NSMLZSOPSA-N
DM4INSG IU 4-[(3R,3aS,6R,6aS)-6-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenol
DM4INSG CB CHEBI:67245
DM4INSG DE Discovery agent
DMH6EVM ID DMH6EVM
DMH6EVM DN (-)-Ro 363
DMH6EVM HS Investigative
DMH6EVM SN RO 363
DMH6EVM DT Small molecular drug
DMH6EVM PC 156297
DMH6EVM MW 363.4
DMH6EVM FM C19H25NO6
DMH6EVM IC InChI=1S/C19H25NO6/c1-24-18-6-3-13(9-19(18)25-2)7-8-20-11-14(21)12-26-15-4-5-16(22)17(23)10-15/h3-6,9-10,14,20-23H,7-8,11-12H2,1-2H3
DMH6EVM CS COC1=C(C=C(C=C1)CCNCC(COC2=CC(=C(C=C2)O)O)O)OC
DMH6EVM IK RFNBEBPVKCJZPV-UHFFFAOYSA-N
DMH6EVM IU 4-[3-[2-(3,4-dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]benzene-1,2-diol
DMH6EVM CA CAS 74513-77-2
DMH6EVM DE Discovery agent
DMFE3YK ID DMFE3YK
DMFE3YK DN (-)-SNAP-5399
DMFE3YK HS Investigative
DMFE3YK SN SNAP-5399
DMFE3YK DT Small molecular drug
DMFE3YK PC 44390708
DMFE3YK MW 666.8
DMFE3YK FM C38H46N6O5
DMFE3YK IC InChI=1S/C38H46N6O5/c1-2-31-34(36(40)45)33(27-14-16-30(17-15-27)44(47)48)35(32(42-31)26-49-25-20-39)37(46)41-21-9-22-43-23-18-38(19-24-43,28-10-5-3-6-11-28)29-12-7-4-8-13-29/h3-8,10-17,33,42H,2,9,18-26,39H2,1H3,(H2,40,45)(H,41,46)/t33-/m0/s1
DMFE3YK CS CCC1=C([C@@H](C(=C(N1)COCCN)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=C(C=C5)[N+](=O)[O-])C(=O)N
DMFE3YK IK FLMJQBHJNDEDJH-XIFFEERXSA-N
DMFE3YK IU (4S)-2-(2-aminoethoxymethyl)-3-N-[3-(4,4-diphenylpiperidin-1-yl)propyl]-6-ethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxamide
DMFE3YK DE Discovery agent
DMKWIYP ID DMKWIYP
DMKWIYP DN (-)-thujaplicatintrimethyl ether
DMKWIYP HS Investigative
DMKWIYP SN Thujaplicatin methyl ether; (-)-thujaplicatintrimethyl ether; UNII-2VJD5SJF7V; 2VJD5SJF7V; CHEMBL469917; 6512-67-0; 2(3H)-Furanone, dihydro-3-((4-hydroxy-3,5-dimethoxyphenyl)methyl)-4-((4-hydroxy-3-methoxyphenyl)methyl)-, (3S-trans)-; 3-O-Methylthujaplicatin; AC1Q6MJF; AC1L4V25; CTK2F4686; DTXSID40215434; BDBM50259876; 2(3h)-furanone, dihydro-3-((4-hydroxy-3,5-dimethoxyphenyl)methyl)-4-((4-hydroxy-3-methoxyphenyl)methyl)-,(3s-trans)-
DMKWIYP DT Small molecular drug
DMKWIYP PC 192827
DMKWIYP MW 388.4
DMKWIYP FM C21H24O7
DMKWIYP IC InChI=1S/C21H24O7/c1-25-17-8-12(4-5-16(17)22)6-14-11-28-21(24)15(14)7-13-9-18(26-2)20(23)19(10-13)27-3/h4-5,8-10,14-15,22-23H,6-7,11H2,1-3H3/t14-,15+/m1/s1
DMKWIYP CS COC1=CC(=CC(=C1O)OC)C[C@H]2[C@@H](COC2=O)CC3=CC(=C(C=C3)O)OC
DMKWIYP IK XMLWGUKRPGLJGA-CABCVRRESA-N
DMKWIYP IU (3S,4S)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-4-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
DMKWIYP CA CAS 6512-67-0
DMKWIYP DE Discovery agent
DMAT58Z ID DMAT58Z
DMAT58Z DN (-)-Tolserine
DMAT58Z HS Investigative
DMAT58Z SN CHEMBL300143; Physostigmine Carbamate 17a; SCHEMBL14242946; BDBM10611; (3aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-(2-methylphenyl)carbamate
DMAT58Z DT Small molecular drug
DMAT58Z PC 9906452
DMAT58Z MW 351.4
DMAT58Z FM C21H25N3O2
DMAT58Z IC InChI=1S/C21H25N3O2/c1-14-7-5-6-8-17(14)22-20(25)26-15-9-10-18-16(13-15)21(2)11-12-23(3)19(21)24(18)4/h5-10,13,19H,11-12H2,1-4H3,(H,22,25)/t19?,21-/m0/s1
DMAT58Z CS CC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N(C4[C@]3(CCN4C)C)C
DMAT58Z IK JGAGHIIOCADQOV-QWAKEFERSA-N
DMAT58Z IU [(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(2-methylphenyl)carbamate
DMAT58Z DE Discovery agent
DMITWZ7 ID DMITWZ7
DMITWZ7 DN (-)-trans-H2-PAT
DMITWZ7 HS Investigative
DMITWZ7 SN H2-Pat
DMITWZ7 DT Small molecular drug
DMITWZ7 PC 10015055
DMITWZ7 MW 251.4
DMITWZ7 FM C18H21N
DMITWZ7 IC InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18-/m0/s1
DMITWZ7 CS CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMITWZ7 IK DXJUCAUQIHNOAF-WMZOPIPTSA-N
DMITWZ7 IU (2R,4S)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMITWZ7 CA CAS 152786-06-6
DMITWZ7 DE Discovery agent
DMRGVNJ ID DMRGVNJ
DMRGVNJ DN (-)-uniflorine A
DMRGVNJ HS Investigative
DMRGVNJ SN (-)-uniflorine A; CHEMBL1076191; Uniflorine A
DMRGVNJ DT Small molecular drug
DMRGVNJ PC 9794258
DMRGVNJ MW 205.21
DMRGVNJ FM C8H15NO5
DMRGVNJ IC InChI=1S/C8H15NO5/c10-3-1-9-2-4(11)7(13)8(14)5(9)6(3)12/h3-8,10-14H,1-2H2/t3-,4+,5-,6-,7-,8-/m1/s1
DMRGVNJ CS C1[C@H]([C@H]([C@H]2N1C[C@@H]([C@H]([C@@H]2O)O)O)O)O
DMRGVNJ IK KSWHMQGAWBUNLD-XAZAIFFQSA-N
DMRGVNJ IU (1S,2R,6S,7R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,6,7,8-pentol
DMRGVNJ DE Discovery agent
DMDHGIR ID DMDHGIR
DMDHGIR DN (-)-yatein
DMDHGIR HS Investigative
DMDHGIR SN Yatein; (-)-yatein; Dihydroanhydropodorhizol; 40456-50-6; (-)-deoxypodorhizone; Deoxypodorhizone; AC1L9DHE; CHEBI:4553; CHEMBL471067; C22H24O7; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one; (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]tetrahydrofuran-2-one; 2(3H)-Furanone, 4-(1,3-benzodioxol-5-ylmethyl)dihydro-3-[(3,4,5-trimethoxyphenyl)methyl]-, (3R,4R)-; Deoxypodorhizon; SCHEMBL1037807; DTXSID50193471; MolPort-035-706-087; GMLDZDDTZKXJLU-JKSUJKDBSA-N
DMDHGIR DT Small molecular drug
DMDHGIR PC 442835
DMDHGIR MW 400.4
DMDHGIR FM C22H24O7
DMDHGIR IC InChI=1S/C22H24O7/c1-24-19-9-14(10-20(25-2)21(19)26-3)7-16-15(11-27-22(16)23)6-13-4-5-17-18(8-13)29-12-28-17/h4-5,8-10,15-16H,6-7,11-12H2,1-3H3/t15-,16+/m0/s1
DMDHGIR CS COC1=CC(=CC(=C1OC)OC)C[C@@H]2[C@H](COC2=O)CC3=CC4=C(C=C3)OCO4
DMDHGIR IK GMLDZDDTZKXJLU-JKSUJKDBSA-N
DMDHGIR IU (3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one
DMDHGIR CA CAS 40456-50-6
DMDHGIR CB CHEBI:4553
DMDHGIR DE Discovery agent
DMF62GN ID DMF62GN
DMF62GN DN (+)-(1R,1'S)-berbamunine hydrochloride
DMF62GN HS Investigative
DMF62GN SN CHEMBL503882; (+)-(1R,1'S)-Berbamunine HCl
DMF62GN DT Small molecular drug
DMF62GN PC 44584679
DMF62GN MW 633.2
DMF62GN FM C36H41ClN2O6
DMF62GN IC InChI=1S/C36H40N2O6.ClH/c1-37-13-11-24-18-34(42-3)32(40)20-27(24)29(37)15-22-5-8-26(9-6-22)44-36-17-23(7-10-31(36)39)16-30-28-21-33(41)35(43-4)19-25(28)12-14-38(30)2;/h5-10,17-21,29-30,39-41H,11-16H2,1-4H3;1H/t29-,30+;/m0./s1
DMF62GN CS CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)O)O)OC.Cl
DMF62GN IK JOARPLDATXXJHM-XCCPJCIBSA-N
DMF62GN IU (1S)-1-[[4-[2-hydroxy-5-[[(1R)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]phenoxy]phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol;hydrochloride
DMF62GN DE Discovery agent
DM521S4 ID DM521S4
DM521S4 DN (+)-(1R,1'S)-thaligrisine hydrochloride
DM521S4 HS Investigative
DM521S4 SN CHEMBL451734; (+)-(1R,1'S)-Thaligrisine HCl
DM521S4 DT Small molecular drug
DM521S4 PC 44584680
DM521S4 MW 647.2
DM521S4 FM C37H43ClN2O6
DM521S4 IC InChI=1S/C37H42N2O6.ClH/c1-38-14-12-25-19-35(43-4)32(40)21-28(25)30(38)16-23-6-9-27(10-7-23)45-37-18-24(8-11-34(37)42-3)17-31-29-22-33(41)36(44-5)20-26(29)13-15-39(31)2;/h6-11,18-22,30-31,40-41H,12-17H2,1-5H3;1H/t30-,31+;/m0./s1
DM521S4 CS CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)O)OC)O)OC.Cl
DM521S4 IK NSNGMSCZFBHCEX-LBYXUWKHSA-N
DM521S4 IU (1S)-1-[[4-[5-[[(1R)-7-hydroxy-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol;hydrochloride
DM521S4 DE Discovery agent
DMLDQWT ID DMLDQWT
DMLDQWT DN (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol
DMLDQWT HS Investigative
DMLDQWT SN CHEMBL456949; (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol
DMLDQWT DT Small molecular drug
DMLDQWT PC 44584373
DMLDQWT MW 328.4
DMLDQWT FM C21H28O3
DMLDQWT IC InChI=1S/C21H28O3/c1-20(2)8-5-9-21(3)14-10-13-11-18(23-4)15(22)12-17(13)24-16(14)6-7-19(20)21/h10-12,16,19,22H,5-9H2,1-4H3/t16-,19-,21+/m0/s1
DMLDQWT CS C[C@]12CCCC([C@@H]1CC[C@H]3C2=CC4=CC(=C(C=C4O3)O)OC)(C)C
DMLDQWT IK VKVKDSPLZVAEMG-NBHGPNQESA-N
DMLDQWT IU (4aS,6aS,12bS)-10-methoxy-4,4,12b-trimethyl-2,3,4a,5,6,6a-hexahydro-1H-benzo[a]xanthen-9-ol
DMLDQWT DE Discovery agent
DMU7BJA ID DMU7BJA
DMU7BJA DN (+)-(5S,8S,10S)-20-methoxypuupehenol
DMU7BJA HS Investigative
DMU7BJA SN CHEMBL459185; (+)-(5S,8S,10S)-20-methoxypuupehenol; BDBM50242017; (+)-(5S,8S,9R,10S)-15,20-Dimethoxypuupehenol
DMU7BJA DT Small molecular drug
DMU7BJA PC 11740143
DMU7BJA MW 374.5
DMU7BJA FM C23H34O4
DMU7BJA IC InChI=1S/C23H34O4/c1-21(2)9-7-10-22(3)18(21)8-11-23(4)20(22)19(26-6)14-12-17(25-5)15(24)13-16(14)27-23/h12-13,18-20,24H,7-11H2,1-6H3/t18-,19+,20+,22-,23-/m0/s1
DMU7BJA CS C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2[C@@H](C4=CC(=C(C=C4O3)O)OC)OC)C)(C)C
DMU7BJA IK JAGJWSBNJZPDNL-FCSJJDFTSA-N
DMU7BJA IU (4aS,6aS,12S,12aS,12bS)-10,12-dimethoxy-4,4,6a,12b-tetramethyl-1,2,3,4a,5,6,12,12a-octahydrobenzo[a]xanthen-9-ol
DMU7BJA DE Discovery agent
DMD4YPO ID DMD4YPO
DMD4YPO DN (+)-(5S,8S,9R,10S)-20-methoxypuupehenone
DMD4YPO HS Investigative
DMD4YPO SN (+)-(5S,8S,9R,10S)-20-Methoxypuupehenone; CHEMBL463805; Methoxypuupehenone; AC1LCV1Q; BDBM50242010; (4aS,6aS,12aR,12bS)-10-methoxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one; 9H-benzo[a]xanthen-9-one, 1,2,3,4,4a,5,6,6a,12a,12b-decahydro-10-methoxy-4,4,6a,12b-tetramethyl-, (4aS,6aS,12aR,12bS)-; InChI=1/C22H30O3/c1-20(2)8-6-9-21(3)18(20)7-10-22(4)19(21)12-14-11-17(24-5)15(23)13-16(14)25-22/h11-13,18-19H,6-10H2,1-5H3/t18-,19+,21-,22-/m0/s
DMD4YPO DT Small molecular drug
DMD4YPO PC 637821
DMD4YPO MW 342.5
DMD4YPO FM C22H30O3
DMD4YPO IC InChI=1S/C22H30O3/c1-20(2)8-6-9-21(3)18(20)7-10-22(4)19(21)12-14-11-17(24-5)15(23)13-16(14)25-22/h11-13,18-19H,6-10H2,1-5H3/t18-,19+,21-,22-/m0/s1
DMD4YPO CS C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2C=C4C=C(C(=O)C=C4O3)OC)C)(C)C
DMD4YPO IK ZBJMJNFORKVCHU-MXNKGDRCSA-N
DMD4YPO IU (4aS,6aS,12aR,12bS)-10-methoxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one
DMD4YPO DE Discovery agent
DMNUWVB ID DMNUWVB
DMNUWVB DN (+)-3,3'-bisdemethyltanegool
DMNUWVB HS Investigative
DMNUWVB SN CHEMBL436990; (+)-3,3'-bisdemethyltanegool; (+)-3,3''-bisdemethyltanegool
DMNUWVB DT Small molecular drug
DMNUWVB PC 44423052
DMNUWVB MW 348.3
DMNUWVB FM C18H20O7
DMNUWVB IC InChI=1S/C18H20O7/c19-7-11-12(17(24)9-1-3-13(20)15(22)5-9)8-25-18(11)10-2-4-14(21)16(23)6-10/h1-6,11-12,17-24H,7-8H2/t11-,12+,17-,18-/m1/s1
DMNUWVB CS C1[C@@H]([C@H]([C@H](O1)C2=CC(=C(C=C2)O)O)CO)[C@@H](C3=CC(=C(C=C3)O)O)O
DMNUWVB IK XRDXBFUYROIFCX-FVEFGIFQSA-N
DMNUWVB IU 4-[(2S,3S,4R)-4-[(S)-(3,4-dihydroxyphenyl)-hydroxymethyl]-3-(hydroxymethyl)oxolan-2-yl]benzene-1,2-diol
DMNUWVB DE Discovery agent
DM2CHX8 ID DM2CHX8
DM2CHX8 DN (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
DM2CHX8 HS Investigative
DM2CHX8 SN CHEMBL375493; GTPL1589; SCHEMBL3111157; BDBM50208137; (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid; 5-(5-bromothiophen-3-yl)-5-methyl-4-oxofuran-2-carboxylic acid; 5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydrofuran-2-carboxylic acid; (+)-5-(5-bromo-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid; 5-(5-bromo-thiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid
DM2CHX8 DT Small molecular drug
DM2CHX8 PC 11483496
DM2CHX8 MW 303.13
DM2CHX8 FM C10H7BrO4S
DM2CHX8 IC InChI=1S/C10H7BrO4S/c1-10(5-2-8(11)16-4-5)7(12)3-6(15-10)9(13)14/h2-4H,1H3,(H,13,14)
DM2CHX8 CS CC1(C(=O)C=C(O1)C(=O)O)C2=CSC(=C2)Br
DM2CHX8 IK WJDLYZAOTHNUJX-UHFFFAOYSA-N
DM2CHX8 IU 5-(5-bromothiophen-3-yl)-5-methyl-4-oxofuran-2-carboxylic acid
DM2CHX8 DE Discovery agent
DMF8C50 ID DMF8C50
DMF8C50 DN (+)-5-deoxyadeenophorine
DMF8C50 HS Investigative
DMF8C50 SN (+)-5-deoxyadeenophorine; CHEMBL380089; 262615-98-5; 5-Deoxyadenophorine; SCHEMBL17249944; CTK0I6251; DTXSID00441676; BDBM50185228; AKOS030538296; 3,4-Piperidinediol, 6-ethyl-2-(hydroxymethyl)-, (2R,3S,4S,6R)-
DMF8C50 DT Small molecular drug
DMF8C50 PC 10559165
DMF8C50 MW 175.23
DMF8C50 FM C8H17NO3
DMF8C50 IC InChI=1S/C8H17NO3/c1-2-5-3-7(11)8(12)6(4-10)9-5/h5-12H,2-4H2,1H3/t5-,6-,7+,8+/m1/s1
DMF8C50 CS CC[C@@H]1C[C@@H]([C@H]([C@H](N1)CO)O)O
DMF8C50 IK QWEWPBRDYZVGBR-NGJRWZKOSA-N
DMF8C50 IU (2R,3S,4S,6R)-6-ethyl-2-(hydroxymethyl)piperidine-3,4-diol
DMF8C50 CA CAS 262615-98-5
DMF8C50 DE Discovery agent
DMXWCVY ID DMXWCVY
DMXWCVY DN (+)-ADTN
DMXWCVY HS Investigative
DMXWCVY SN (+)-ADTN (aminotetralin-6,7-diol)
DMXWCVY DT Small molecular drug
DMXWCVY PC 3153
DMXWCVY MW 179.22
DMXWCVY FM C10H13NO2
DMXWCVY IC InChI=1S/C10H13NO2/c11-8-2-1-6-4-9(12)10(13)5-7(6)3-8/h4-5,8,12-13H,1-3,11H2
DMXWCVY CS C1CC2=CC(=C(C=C2CC1N)O)O
DMXWCVY IK ASXGAOFCKGHGMF-UHFFFAOYSA-N
DMXWCVY IU 6-amino-5,6,7,8-tetrahydronaphthalene-2,3-diol
DMXWCVY CA CAS 53463-78-8
DMXWCVY DE Discovery agent
DMEDMC0 ID DMEDMC0
DMEDMC0 DN (+)-AJ76
DMEDMC0 HS Investigative
DMEDMC0 SN AJ 76; AJ-76; 5-methoxy-1-methyl-2-(n-propylamino)tetralin; 85379-09-5; CHEMBL27441; (+)-AJ 76; CHEBI:64117; (1S,2R)-5-methoxy-1-methyl-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine; cis-(+)-5-methoxy-1-methyl-2-(propylamino)tetralin; (1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin; 2-Naphthalenamine, 1,2,3,4-tetrahydro-5-methoxy-1-methyl-N-propyl-, (1S-cis)-; Tocris-0678; (+)-AJ76; AC1L3UEJ; a j76; Biomol-NT_000004; GTPL970; SCHEMBL276252; AJ76; BPBio1_001129; DTXSID1043889; BDBM81797; ZINC3995669; PDSP2_000777; BDBM50041959
DMEDMC0 DT Small molecular drug
DMEDMC0 PC 122334
DMEDMC0 MW 233.35
DMEDMC0 FM C15H23NO
DMEDMC0 IC InChI=1S/C15H23NO/c1-4-10-16-14-9-8-13-12(11(14)2)6-5-7-15(13)17-3/h5-7,11,14,16H,4,8-10H2,1-3H3/t11-,14+/m0/s1
DMEDMC0 CS CCCN[C@@H]1CCC2=C([C@@H]1C)C=CC=C2OC
DMEDMC0 IK YGHLYBIUVOLKCV-SMDDNHRTSA-N
DMEDMC0 IU (1S,2R)-5-methoxy-1-methyl-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMEDMC0 CA CAS 85379-09-5
DMEDMC0 CB CHEBI:64117
DMEDMC0 DE Discovery agent
DMX6UYN ID DMX6UYN
DMX6UYN DN (+)-BUTACLAMOL
DMX6UYN HS Investigative
DMX6UYN SN d-Butaclamol; (+)-Butaclamol; BUTACLAMOL; CHEMBL8514; 56245-67-1; 1H-Benzo(6,7)cyclohepta(1,2,3-de)pyrido(2,1-a)isoquinolin-3-ol, 2,3,4,4a,8,9,13b,14-octahydro-3-(1,1-dimethylethyl)-, (3S-(3-alpha,4a-alpha,13b-beta))-; (+/-)-Butaclamol hydrochloride; BUTACLAMOL,d-; AC1L1XRQ; BUTACLAMOL,(+); GTPL62; BUTACLAMOL, (-); Biomol-NT_000018; Lopac0_000475; Lopac0_000187; SCHEMBL122821; BPBio1_001177; ZZJYIKPMDIWRSN-HWBMXIPRSA-N; CHEBI:109533; HMS2089C08; ZINC2008410; PDSP2_000547; PDSP2_001512; BDBM50008735; CCG-204282; NCGC00162085-04
DMX6UYN DT Small molecular drug
DMX6UYN PC 37459
DMX6UYN MW 361.5
DMX6UYN FM C25H31NO
DMX6UYN IC InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m0/s1
DMX6UYN CS CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O
DMX6UYN IK ZZJYIKPMDIWRSN-HWBMXIPRSA-N
DMX6UYN IU (1S,6S,8S)-6-tert-butyl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol
DMX6UYN CA CAS 56245-67-1
DMX6UYN CB CHEBI:109533
DMX6UYN DE Discovery agent
DMDFR59 ID DMDFR59
DMDFR59 DN (+)-cis-H2-PAT
DMDFR59 HS Investigative
DMDFR59 SN N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine; GTPL1208; BDBM86031; ZINC5965220
DMDFR59 DT Small molecular drug
DMDFR59 PC 15657195
DMDFR59 MW 251.4
DMDFR59 FM C18H21N
DMDFR59 IC InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18+/m0/s1
DMDFR59 CS CN(C)[C@@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMDFR59 IK DXJUCAUQIHNOAF-FUHWJXTLSA-N
DMDFR59 IU (2R,4R)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMDFR59 DE Discovery agent
DMKWEAJ ID DMKWEAJ
DMKWEAJ DN (+)-HA966
DMKWEAJ HS Investigative
DMKWEAJ SN (R)-(+)-HA-966
DMKWEAJ DT Small molecular drug
DMKWEAJ PC 6603720
DMKWEAJ MW 116.12
DMKWEAJ FM C4H8N2O2
DMKWEAJ IC InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2/t3-/m1/s1
DMKWEAJ CS C1CN(C(=O)[C@@H]1N)O
DMKWEAJ IK HCKUBNLZMKAEIN-GSVOUGTGSA-N
DMKWEAJ IU (3R)-3-amino-1-hydroxypyrrolidin-2-one
DMKWEAJ CA CAS 123931-04-4
DMKWEAJ DE Discovery agent
DMG5QJB ID DMG5QJB
DMG5QJB DN (+)-MCPG
DMG5QJB HS Investigative
DMG5QJB SN (S)-Mcpg; (S)-MCPG; (+)-alpha-Methyl-4-carboxyphenylglycine; (S)-(ALPHA)-METHYL-4-CARBOXYPHENYLGLYCINE; 4-[(1S)-1-amino-1-carboxyethyl]benzoic acid; 4-(1-AMINO-1-CARBOXY-ETHYL)-BENZOIC ACID; UNII-61F6J48NHR; alpha-Mcpg; 61F6J48NHR; CHEMBL257626; CHEBI:43876; alpha-Methyl-cpgly; (S)-a-methyl-4-carboxyphenylglycine; (S)- -Methyl-4-carboxyphenylglycine; (S)-4-(1-amino-1-carboxyethyl)benzoic acid; (S)-(+)-alpha-methyl-4-carboxyphenylglycine; MCG; (S)-(+)-alpha-amino-4-carboxy-2-methylbenzeneacetic; alpha-Mcpg; alpha-methyl-4-carboxyphenylglycine; alpha-methyl-cpgly; 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid
DMG5QJB DT Small molecular drug
DMG5QJB PC 446355
DMG5QJB MW 209.2
DMG5QJB FM C10H11NO4
DMG5QJB IC InChI=1S/C10H11NO4/c1-10(11,9(14)15)7-4-2-6(3-5-7)8(12)13/h2-5H,11H2,1H3,(H,12,13)(H,14,15)/t10-/m0/s1
DMG5QJB CS C[C@](C1=CC=C(C=C1)C(=O)O)(C(=O)O)N
DMG5QJB IK DNCAZYRLRMTVSF-JTQLQIEISA-N
DMG5QJB IU 4-[(1S)-1-amino-1-carboxyethyl]benzoic acid
DMG5QJB CA CAS 150145-89-4
DMG5QJB CB CHEBI:43876
DMG5QJB DE Discovery agent
DM7FZHI ID DM7FZHI
DM7FZHI DN (+)-Myristinin A
DM7FZHI HS Investigative
DM7FZHI SN (+)-Myristinin A; Myristinin A; CHEMBL465365; 1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]dodecan-1-one; 1-(2,4,6-TRIHYDROXY-3-((2S,4R)-7-HYDROXY-2-(4-HYDROXYPHENYL)-3,4-DIHYDRO-2H-CHROMEN-4-YL)PHENYL)DODECAN-1-ONE; AC1LAXHL; SCHEMBL3486855; LMPK12020229; BDBM50250426; 1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-yl]phenyl]dodecan-1-one; 1-Dodecanone, 1-[3-[(2S,4R)-3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydr
DM7FZHI DT Small molecular drug
DM7FZHI PC 497359
DM7FZHI MW 548.7
DM7FZHI FM C33H40O7
DM7FZHI IC InChI=1S/C33H40O7/c1-2-3-4-5-6-7-8-9-10-11-26(36)32-28(38)20-27(37)31(33(32)39)25-19-29(21-12-14-22(34)15-13-21)40-30-18-23(35)16-17-24(25)30/h12-18,20,25,29,34-35,37-39H,2-11,19H2,1H3/t25-,29+/m1/s1
DM7FZHI CS CCCCCCCCCCCC(=O)C1=C(C=C(C(=C1O)[C@@H]2C[C@H](OC3=C2C=CC(=C3)O)C4=CC=C(C=C4)O)O)O
DM7FZHI IK JGXZVDAPLSTBGZ-IRPSRAIASA-N
DM7FZHI IU 1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]dodecan-1-one
DM7FZHI DE Discovery agent
DMEK07T ID DMEK07T
DMEK07T DN (+)-Myristinin D
DMEK07T HS Investigative
DMEK07T SN (+)-Myristinin D; CHEMBL448072; Myristinis D; Myristinin D; AC1LAXHR; BDBM50250427; 9-phenyl-1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-yl]phenyl]nonan-1-one; 9-phenyl-1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]nonan-1-one; 1-Nonanone, 1-[3-[(2S,4R)-3,4-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-2H-1-benzopyran-4-yl]-2,4,6-trihydroxyphenyl]-9-phenyl-
DMEK07T DT Small molecular drug
DMEK07T PC 497362
DMEK07T MW 582.7
DMEK07T FM C36H38O7
DMEK07T IC InChI=1S/C36H38O7/c37-25-16-14-24(15-17-25)32-21-28(27-19-18-26(38)20-33(27)43-32)34-30(40)22-31(41)35(36(34)42)29(39)13-9-4-2-1-3-6-10-23-11-7-5-8-12-23/h5,7-8,11-12,14-20,22,28,32,37-38,40-42H,1-4,6,9-10,13,21H2/t28-,32+/m1/s1
DMEK07T CS C1[C@H](C2=C(C=C(C=C2)O)O[C@@H]1C3=CC=C(C=C3)O)C4=C(C(=C(C=C4O)O)C(=O)CCCCCCCCC5=CC=CC=C5)O
DMEK07T IK NWJOIWGNEIDTTG-NSJVFKKDSA-N
DMEK07T IU 9-phenyl-1-[2,4,6-trihydroxy-3-[(2S,4R)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]phenyl]nonan-1-one
DMEK07T DE Discovery agent
DMOZJA5 ID DMOZJA5
DMOZJA5 DN (+)-norfenfluramine
DMOZJA5 HS Investigative
DMOZJA5 SN (S)-norfenfluramine
DMOZJA5 DT Small molecular drug
DMOZJA5 PC 9815618
DMOZJA5 MW 203.2
DMOZJA5 FM C10H12F3N
DMOZJA5 IC InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3/t7-/m0/s1
DMOZJA5 CS C[C@@H](CC1=CC(=CC=C1)C(F)(F)F)N
DMOZJA5 IK MLBHFBKZUPLWBD-ZETCQYMHSA-N
DMOZJA5 IU (2S)-1-[3-(trifluoromethyl)phenyl]propan-2-amine
DMOZJA5 CA CAS 19036-73-8
DMOZJA5 CB CHEBI:125533
DMOZJA5 DE Discovery agent
DMX7ECD ID DMX7ECD
DMX7ECD DN (+)-S-14297
DMX7ECD HS Investigative
DMX7ECD SN (+)S14297
DMX7ECD DT Small molecular drug
DMX7ECD PC 115007
DMX7ECD MW 273.4
DMX7ECD FM C18H27NO
DMX7ECD IC InChI=1S/C18H27NO/c1-3-8-19(9-4-2)17-6-5-14-11-15-7-10-20-18(15)13-16(14)12-17/h11,13,17H,3-10,12H2,1-2H3
DMX7ECD CS CCCN(CCC)C1CCC2=CC3=C(C=C2C1)OCC3
DMX7ECD IK IJICKINLCUKIHY-UHFFFAOYSA-N
DMX7ECD IU N,N-dipropyl-2,3,5,6,7,8-hexahydrobenzo[f][1]benzofuran-7-amine
DMX7ECD CA CAS 121454-18-0
DMX7ECD DE Discovery agent
DM1QPA4 ID DM1QPA4
DM1QPA4 DN (+)-SK&F10047
DM1QPA4 HS Investigative
DM1QPA4 SN (+)-SKF 10.047
DM1QPA4 DT Small molecular drug
DM1QPA4 PC 3036222
DM1QPA4 MW 257.37
DM1QPA4 FM C17H23NO
DM1QPA4 IC InChI=1S/C17H23NO/c1-4-8-18-9-7-17(3)12(2)16(18)10-13-5-6-14(19)11-15(13)17/h4-6,11-12,16,19H,1,7-10H2,2-3H3/t12-,16+,17+/m1/s1
DM1QPA4 CS C[C@@H]1[C@@H]2CC3=C([C@]1(CCN2CC=C)C)C=C(C=C3)O
DM1QPA4 IK LGQCVMYAEFTEFN-DQYPLSBCSA-N
DM1QPA4 IU (1S,9S,13S)-1,13-dimethyl-10-prop-2-enyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM1QPA4 CA CAS 58640-82-7
DM1QPA4 DE Discovery agent
DMAN63P ID DMAN63P
DMAN63P DN (+)-trans-H2-PAT
DMAN63P HS Investigative
DMAN63P SN (2S,4R)-N,N-Dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine; trans-PAT; (2S,4R)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine; (plusmn)-trans-H2-PAT; SCHEMBL3755418; CHEMBL127307; GTPL1209; GTPL1207; BDBM86032; ZINC5965166; PDSP2_000942; PDSP1_000957
DMAN63P DT Small molecular drug
DMAN63P PC 10106214
DMAN63P MW 251.4
DMAN63P FM C18H21N
DMAN63P IC InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18-/m1/s1
DMAN63P CS CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMAN63P IK DXJUCAUQIHNOAF-SJLPKXTDSA-N
DMAN63P IU (2S,4R)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMAN63P DE Discovery agent
DMDXKQ6 ID DMDXKQ6
DMDXKQ6 DN (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one
DMDXKQ6 HS Investigative
DMDXKQ6 SN CHEMBL598394; BDBM50307363
DMDXKQ6 DT Small molecular drug
DMDXKQ6 PC 46233265
DMDXKQ6 MW 299.4
DMDXKQ6 FM C17H17NO2S
DMDXKQ6 IC InChI=1S/C17H17NO2S/c19-17-12-21-16(10-18-17)14-6-8-15(9-7-14)20-11-13-4-2-1-3-5-13/h1-9,16H,10-12H2,(H,18,19)
DMDXKQ6 CS C1C(SCC(=O)N1)C2=CC=C(C=C2)OCC3=CC=CC=C3
DMDXKQ6 IK WREDZZPMENXHRK-UHFFFAOYSA-N
DMDXKQ6 IU 6-(4-phenylmethoxyphenyl)thiomorpholin-3-one
DMDXKQ6 DE Discovery agent
DMCB74T ID DMCB74T
DMCB74T DN (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine
DMCB74T HS Investigative
DMCB74T SN CHEMBL597373; BDBM50307362
DMCB74T DT Small molecular drug
DMCB74T PC 46233269
DMCB74T MW 285.4
DMCB74T FM C17H19NOS
DMCB74T IC InChI=1S/C17H19NOS/c1-2-4-14(5-3-1)13-19-16-8-6-15(7-9-16)17-12-18-10-11-20-17/h1-9,17-18H,10-13H2
DMCB74T CS C1CSC(CN1)C2=CC=C(C=C2)OCC3=CC=CC=C3
DMCB74T IK JTMKALFHDSWYGH-UHFFFAOYSA-N
DMCB74T IU 2-(4-phenylmethoxyphenyl)thiomorpholine
DMCB74T DE Discovery agent
DM1WCJV ID DM1WCJV
DM1WCJV DN (+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one
DM1WCJV HS Investigative
DM1WCJV SN CHEMBL598393; BDBM50307364
DM1WCJV DT Small molecular drug
DM1WCJV PC 46233264
DM1WCJV MW 265.37
DM1WCJV FM C14H19NO2S
DM1WCJV IC InChI=1S/C14H19NO2S/c1-2-3-8-17-12-6-4-11(5-7-12)13-9-15-14(16)10-18-13/h4-7,13H,2-3,8-10H2,1H3,(H,15,16)
DM1WCJV CS CCCCOC1=CC=C(C=C1)C2CNC(=O)CS2
DM1WCJV IK ATDGSQDDAVNPIE-UHFFFAOYSA-N
DM1WCJV IU 6-(4-butoxyphenyl)thiomorpholin-3-one
DM1WCJV DE Discovery agent
DMG3MF2 ID DMG3MF2
DMG3MF2 DN (+/-)-2-(4'-Butoxyphenyl)thiomorpholine
DMG3MF2 HS Investigative
DMG3MF2 SN CHEMBL597372; BDBM50307367
DMG3MF2 DT Small molecular drug
DMG3MF2 PC 46233268
DMG3MF2 MW 251.39
DMG3MF2 FM C14H21NOS
DMG3MF2 IC InChI=1S/C14H21NOS/c1-2-3-9-16-13-6-4-12(5-7-13)14-11-15-8-10-17-14/h4-7,14-15H,2-3,8-11H2,1H3
DMG3MF2 CS CCCCOC1=CC=C(C=C1)C2CNCCS2
DMG3MF2 IK SHHIIRIFRIVAFS-UHFFFAOYSA-N
DMG3MF2 IU 2-(4-butoxyphenyl)thiomorpholine
DMG3MF2 DE Discovery agent
DM1YBJ2 ID DM1YBJ2
DM1YBJ2 DN (+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one
DM1YBJ2 HS Investigative
DM1YBJ2 SN CHEMBL597769; 2-(4'-ethoxyphenyl)thiomorpholin-5-one; BDBM50307371; 1218947-79-5
DM1YBJ2 DT Small molecular drug
DM1YBJ2 PC 46233198
DM1YBJ2 MW 237.32
DM1YBJ2 FM C12H15NO2S
DM1YBJ2 IC InChI=1S/C12H15NO2S/c1-2-15-10-5-3-9(4-6-10)11-7-13-12(14)8-16-11/h3-6,11H,2,7-8H2,1H3,(H,13,14)
DM1YBJ2 CS CCOC1=CC=C(C=C1)C2CNC(=O)CS2
DM1YBJ2 IK CBRYZPDPVZGCMA-UHFFFAOYSA-N
DM1YBJ2 IU 6-(4-ethoxyphenyl)thiomorpholin-3-one
DM1YBJ2 DE Discovery agent
DMKPX7W ID DMKPX7W
DMKPX7W DN (+/-)-2-(4'-Ethoxyphenyl)thiomorpholine
DMKPX7W HS Investigative
DMKPX7W SN CHEMBL597371; 2-(4'-ethoxyphenyl)thiomorpholine; BDBM50307370; AKOS022307820; 1218947-83-1
DMKPX7W DT Small molecular drug
DMKPX7W PC 46233266
DMKPX7W MW 223.34
DMKPX7W FM C12H17NOS
DMKPX7W IC InChI=1S/C12H17NOS/c1-2-14-11-5-3-10(4-6-11)12-9-13-7-8-15-12/h3-6,12-13H,2,7-9H2,1H3
DMKPX7W CS CCOC1=CC=C(C=C1)C2CNCCS2
DMKPX7W IK GGYNYZIHJHLRIZ-UHFFFAOYSA-N
DMKPX7W IU 2-(4-ethoxyphenyl)thiomorpholine
DMKPX7W DE Discovery agent
DMGY5WB ID DMGY5WB
DMGY5WB DN (+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMGY5WB HS Investigative
DMGY5WB SN CHEMBL598746
DMGY5WB DT Small molecular drug
DMGY5WB PC 15731432
DMGY5WB MW 272.27
DMGY5WB FM C16H13FO3
DMGY5WB IC InChI=1S/C16H13FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15H,9H2,1H3
DMGY5WB CS COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)F
DMGY5WB IK LIINIWOYEGBFDA-UHFFFAOYSA-N
DMGY5WB IU 2-(4-fluorophenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMGY5WB DE Discovery agent
DMHL7BC ID DMHL7BC
DMHL7BC DN (+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one
DMHL7BC HS Investigative
DMHL7BC SN CHEMBL600596; (+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one
DMHL7BC DT Small molecular drug
DMHL7BC PC 46231665
DMHL7BC MW 256.269
DMHL7BC FM C16H13FO2
DMHL7BC IC InChI=1S/C16H13FO2/c1-10-2-7-13-14(18)9-15(19-16(13)8-10)11-3-5-12(17)6-4-11/h2-8,15H,9H2,1H3
DMHL7BC CS CC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)F
DMHL7BC IK ZWJDAELXCJQOJQ-UHFFFAOYSA-N
DMHL7BC IU 2-(4-fluorophenyl)-7-methyl-2,3-dihydrochromen-4-one
DMHL7BC DE Discovery agent
DMXK4HR ID DMXK4HR
DMXK4HR DN (+/-)-2-(4-fluorophenyl)chroman-4-one
DMXK4HR HS Investigative
DMXK4HR SN 4'-(Fluoro)flavanone; CHEMBL60720; 1840-02-4; 4h-1-benzopyran-4-one,2-(4-fluorophenyl)-2,3-dihydro-; 4'-Fluoroflavanone; (+/-)-2-(4-fluorophenyl)chroman-4-one; SCHEMBL2474548; CTK0E2543; DTXSID90452670; RFDPVHCUOLBALB-UHFFFAOYSA-N; BDBM50310197; AKOS030552931; KB-290728; 4H-1-Benzopyran-4-one, 2-(4-fluorophenyl)-2,3-dihydro-
DMXK4HR DT Small molecular drug
DMXK4HR PC 11032058
DMXK4HR MW 242.24
DMXK4HR FM C15H11FO2
DMXK4HR IC InChI=1S/C15H11FO2/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-8,15H,9H2
DMXK4HR CS C1C(OC2=CC=CC=C2C1=O)C3=CC=C(C=C3)F
DMXK4HR IK RFDPVHCUOLBALB-UHFFFAOYSA-N
DMXK4HR IU 2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DMXK4HR CA CAS 1840-02-4
DMXK4HR DE Discovery agent
DMTUFOE ID DMTUFOE
DMTUFOE DN (+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one
DMTUFOE HS Investigative
DMTUFOE SN CHEMBL598913; 7-Methyl-4'-methoxyflavanone; (+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one
DMTUFOE DT Small molecular drug
DMTUFOE PC 15462540
DMTUFOE MW 268.31
DMTUFOE FM C17H16O3
DMTUFOE IC InChI=1S/C17H16O3/c1-11-3-8-14-15(18)10-16(20-17(14)9-11)12-4-6-13(19-2)7-5-12/h3-9,16H,10H2,1-2H3
DMTUFOE CS CC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)OC
DMTUFOE IK OVTRXNFXZXVKKU-UHFFFAOYSA-N
DMTUFOE IU 2-(4-methoxyphenyl)-7-methyl-2,3-dihydrochromen-4-one
DMTUFOE DE Discovery agent
DM7BY4T ID DM7BY4T
DM7BY4T DN (+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one
DM7BY4T HS Investigative
DM7BY4T SN CHEMBL597768; 2-(4'-methoxyphenyl)thiomorpholin-5-one; BDBM50307373; 42109-48-8
DM7BY4T DT Small molecular drug
DM7BY4T PC 46233197
DM7BY4T MW 223.29
DM7BY4T FM C11H13NO2S
DM7BY4T IC InChI=1S/C11H13NO2S/c1-14-9-4-2-8(3-5-9)10-6-12-11(13)7-15-10/h2-5,10H,6-7H2,1H3,(H,12,13)
DM7BY4T CS COC1=CC=C(C=C1)C2CNC(=O)CS2
DM7BY4T IK KTKPTOSTWLGTNI-UHFFFAOYSA-N
DM7BY4T IU 6-(4-methoxyphenyl)thiomorpholin-3-one
DM7BY4T DE Discovery agent
DMKFSQ8 ID DMKFSQ8
DMKFSQ8 DN (+/-)-2-(4'-Methoxyphenyl)thiomorpholine
DMKFSQ8 HS Investigative
DMKFSQ8 SN 2-(4-methoxyphenyl)thiomorpholine; CHEMBL598395; AC1Q4AWZ; 2-(4-Methoxyphenyl) Thiomorpholine Hydrochloride; SCHEMBL1636984; AC1NM467; YAPWTYUHWOWUHY-UHFFFAOYSA-N; 2-(4-methoxyphenyl)-thiomorpholine; 2-(4'-methoxyphenyl)thiomorpholine; BDBM50307365; AKOS022304555; MCULE-4309621221; 1001940-39-1
DMKFSQ8 DT Small molecular drug
DMKFSQ8 PC 4996817
DMKFSQ8 MW 209.31
DMKFSQ8 FM C11H15NOS
DMKFSQ8 IC InChI=1S/C11H15NOS/c1-13-10-4-2-9(3-5-10)11-8-12-6-7-14-11/h2-5,11-12H,6-8H2,1H3
DMKFSQ8 CS COC1=CC=C(C=C1)C2CNCCS2
DMKFSQ8 IK YAPWTYUHWOWUHY-UHFFFAOYSA-N
DMKFSQ8 IU 2-(4-methoxyphenyl)thiomorpholine
DMKFSQ8 CA CAS 1001940-39-1
DMKFSQ8 DE Discovery agent
DMY1W20 ID DMY1W20
DMY1W20 DN (+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one
DMY1W20 HS Investigative
DMY1W20 SN CHEMBL596955; BDBM50307368
DMY1W20 DT Small molecular drug
DMY1W20 PC 46233199
DMY1W20 MW 251.35
DMY1W20 FM C13H17NO2S
DMY1W20 IC InChI=1S/C13H17NO2S/c1-2-7-16-11-5-3-10(4-6-11)12-8-14-13(15)9-17-12/h3-6,12H,2,7-9H2,1H3,(H,14,15)
DMY1W20 CS CCCOC1=CC=C(C=C1)C2CNC(=O)CS2
DMY1W20 IK WOEGUBDEEHNIKD-UHFFFAOYSA-N
DMY1W20 IU 6-(4-propoxyphenyl)thiomorpholin-3-one
DMY1W20 DE Discovery agent
DMUPYN1 ID DMUPYN1
DMUPYN1 DN (+/-)-2-(4'-Propoxyphenyl)thiomorpholine
DMUPYN1 HS Investigative
DMUPYN1 SN CHEMBL608141; BDBM50307366; AKOS022549334
DMUPYN1 DT Small molecular drug
DMUPYN1 PC 46233267
DMUPYN1 MW 237.36
DMUPYN1 FM C13H19NOS
DMUPYN1 IC InChI=1S/C13H19NOS/c1-2-8-15-12-5-3-11(4-6-12)13-10-14-7-9-16-13/h3-6,13-14H,2,7-10H2,1H3
DMUPYN1 CS CCCOC1=CC=C(C=C1)C2CNCCS2
DMUPYN1 IK MHUSNQPPWZGBBB-UHFFFAOYSA-N
DMUPYN1 IU 2-(4-propoxyphenyl)thiomorpholine
DMUPYN1 DE Discovery agent
DMX768L ID DMX768L
DMX768L DN (+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid
DMX768L HS Investigative
DMX768L SN 2-Aminotetralin-2-carboxylic acid; 74444-77-2; D,L-2-Aminotetralin-2-carboxylic acid; 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid; 6331-63-1; CHEMBL8708; 2-amino-3,4-dihydro-1H-naphthalene-2-carboxylic acid; 2-Amino-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid; 2-AMINO-1,2,3,4-TETRAHYDRO-2-NAPHTHALENECARBOXYLIC ACID; 2-Naphthalenecarboxylic acid, 2-amino-1,2,3,4-tetrahydro-; ACMC-20apiw; ACMC-20apfh; CB 1647; AC1L5ULH; SCHEMBL268919; (+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid; NIOSH/QL2303010
DMX768L DT Small molecular drug
DMX768L PC 235533
DMX768L MW 191.23
DMX768L FM C11H13NO2
DMX768L IC InChI=1S/C11H13NO2/c12-11(10(13)14)6-5-8-3-1-2-4-9(8)7-11/h1-4H,5-7,12H2,(H,13,14)
DMX768L CS C1CC(CC2=CC=CC=C21)(C(=O)O)N
DMX768L IK CDULPPOISZOUTK-UHFFFAOYSA-N
DMX768L IU 2-amino-3,4-dihydro-1H-naphthalene-2-carboxylic acid
DMX768L CA CAS 74444-77-2
DMX768L DE Discovery agent
DML5URN ID DML5URN
DML5URN DN (+/-)-2-Aminoindane-2-carboxylic acid
DML5URN HS Investigative
DML5URN SN 27473-62-7; 2-Amino-2-indancarboxylic acid; 2-amino-2,3-dihydro-1H-indene-2-carboxylic acid; 2-Aminoindane-2-carboxylic acid; 2-AMINOINDAN-2-CARBOXYLIC ACID; 2-Aminoindan-2-carboxylicacid; 2-Amino-indan-2-carboxylic acid; 2-amino-1,3-dihydroindene-2-carboxylic acid; CHEMBL1082953; 2-azanyl-1,3-dihydroindene-2-carboxylic acid; 1H-Indene-2-carboxylicacid, 2-amino-2,3-dihydro-; 2-amino-2-indancarboxylicacid; NSC70943; (+/-)-2-Aminoindane-2-carboxylic acid; AC1L5IQE; AC1Q50FV; AC1Q5UK7; SCHEMBL122942; 1H-Indene-2-carboxylic acid
DML5URN DT Small molecular drug
DML5URN PC 250936
DML5URN MW 177.2
DML5URN FM C10H11NO2
DML5URN IC InChI=1S/C10H11NO2/c11-10(9(12)13)5-7-3-1-2-4-8(7)6-10/h1-4H,5-6,11H2,(H,12,13)
DML5URN CS C1C2=CC=CC=C2CC1(C(=O)O)N
DML5URN IK UHQFXIWMAQOCAN-UHFFFAOYSA-N
DML5URN IU 2-amino-1,3-dihydroindene-2-carboxylic acid
DML5URN CA CAS 27473-62-7
DML5URN DE Discovery agent
DMJ6MPO ID DMJ6MPO
DMJ6MPO DN (+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole
DMJ6MPO HS Investigative
DMJ6MPO SN Efetozole; CHEMBL1269155; Efetozole [INN]; 2-methyl-1-(1-phenylethyl)-1H-imidazole; AC1L4LLD; (+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole; SCHEMBL2109012; MolPort-020-890-666; CGP-22364A; BDBM50330055; 2-methyl-1-(1-phenylethyl)imidazole; AKOS013440375; 90408-21-2; (+-)-2-Methyl-1-(alpha-methylbenzyl)imidazole; (- )-2-Methyl-1-(alpha-methylbenzyl)imidazole.
DMJ6MPO DT Small molecular drug
DMJ6MPO PC 208911
DMJ6MPO MW 186.25
DMJ6MPO FM C12H14N2
DMJ6MPO IC InChI=1S/C12H14N2/c1-10(12-6-4-3-5-7-12)14-9-8-13-11(14)2/h3-10H,1-2H3
DMJ6MPO CS CC1=NC=CN1C(C)C2=CC=CC=C2
DMJ6MPO IK CILDGVODBJAMGO-UHFFFAOYSA-N
DMJ6MPO IU 2-methyl-1-(1-phenylethyl)imidazole
DMJ6MPO CA CAS 99500-54-6
DMJ6MPO DE Discovery agent
DMSHDNO ID DMSHDNO
DMSHDNO DN (+/-)-2-Phenylthiomorpholin-5-one
DMSHDNO HS Investigative
DMSHDNO SN 2-phenylthiomorpholin-5-one; CHEMBL592160; 42109-49-9; (+/-)-2-Phenylthiomorpholin-5-one; 6-phenylthiomorpholin-3-one; SCHEMBL10833495; MolPort-039-240-430; BDBM50307372; AKOS027196661
DMSHDNO DT Small molecular drug
DMSHDNO PC 20242416
DMSHDNO MW 193.27
DMSHDNO FM C10H11NOS
DMSHDNO IC InChI=1S/C10H11NOS/c12-10-7-13-9(6-11-10)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,11,12)
DMSHDNO CS C1C(SCC(=O)N1)C2=CC=CC=C2
DMSHDNO IK RTCSYBNOEYGSSX-UHFFFAOYSA-N
DMSHDNO IU 6-phenylthiomorpholin-3-one
DMSHDNO DE Discovery agent
DMNR3YL ID DMNR3YL
DMNR3YL DN (+/-)-2-Phenylthiomorpholine
DMNR3YL HS Investigative
DMNR3YL SN 2-phenylthiomorpholine; 77082-31-6; 2-PHENYL-THIOMORPHOLINE; CHEMBL608438; Thiomorpholine,2-phenyl-; (+/-)-2-Phenylthiomorpholine; AC1NMBWZ; AC1Q1ICC; Thiomorpholine, 2-phenyl-; SCHEMBL1636929; CTK5E3816; DTXSID20407436; MolPort-001-791-006; SRYHBJDVLOEJNP-UHFFFAOYSA-N; 2-Phenyl-thiomorpholine, AldrichCPR; BDBM50307369; AKOS006230101; MCULE-8074427790; QC-5067; NE56940; KB-69531; EN300-80273
DMNR3YL DT Small molecular drug
DMNR3YL PC 5004199
DMNR3YL MW 179.28
DMNR3YL FM C10H13NS
DMNR3YL IC InChI=1S/C10H13NS/c1-2-4-9(5-3-1)10-8-11-6-7-12-10/h1-5,10-11H,6-8H2
DMNR3YL CS C1CSC(CN1)C2=CC=CC=C2
DMNR3YL IK SRYHBJDVLOEJNP-UHFFFAOYSA-N
DMNR3YL IU 2-phenylthiomorpholine
DMNR3YL CA CAS 77082-31-6
DMNR3YL DE Discovery agent
DMYJGZ4 ID DMYJGZ4
DMYJGZ4 DN (+/-)-2-p-tolylchroman-4-one
DMYJGZ4 HS Investigative
DMYJGZ4 SN 4'-methylflavanone; CHEMBL596690; (+/-)-2-p-tolylchroman-4-one; AC1MCXMJ; Oprea1_810740; Oprea1_128105; SCHEMBL1890733; MolPort-003-699-848; HITISLKGAFZTFZ-UHFFFAOYSA-N; 2-(4-methylphenyl)chroman-4-one; BDBM50310196; AKOS003614932
DMYJGZ4 DT Small molecular drug
DMYJGZ4 PC 2802466
DMYJGZ4 MW 238.28
DMYJGZ4 FM C16H14O2
DMYJGZ4 IC InChI=1S/C16H14O2/c1-11-6-8-12(9-7-11)16-10-14(17)13-4-2-3-5-15(13)18-16/h2-9,16H,10H2,1H3
DMYJGZ4 CS CC1=CC=C(C=C1)C2CC(=O)C3=CC=CC=C3O2
DMYJGZ4 IK HITISLKGAFZTFZ-UHFFFAOYSA-N
DMYJGZ4 IU 2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMYJGZ4 DE Discovery agent
DML68KX ID DML68KX
DML68KX DN (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine
DML68KX HS Investigative
DML68KX SN CHEMBL451460; (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine; SCHEMBL2227832; BDBM50278523
DML68KX DT Small molecular drug
DML68KX PC 44592197
DML68KX MW 227.3
DML68KX FM C15H17NO
DML68KX IC InChI=1S/C15H17NO/c1-2-4-14-9-15(6-5-13(14)3-1)17-11-12-7-8-16-10-12/h1-6,9,12,16H,7-8,10-11H2
DML68KX CS C1CNCC1COC2=CC3=CC=CC=C3C=C2
DML68KX IK FXQBHPKGRGPIKE-UHFFFAOYSA-N
DML68KX IU 3-(naphthalen-2-yloxymethyl)pyrrolidine
DML68KX CA CAS 946682-24-2
DML68KX DE Discovery agent
DM9AJSU ID DM9AJSU
DM9AJSU DN (+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one
DM9AJSU HS Investigative
DM9AJSU SN CHEMBL454297; (+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one
DM9AJSU DT Small molecular drug
DM9AJSU PC 44560666
DM9AJSU MW 207.27
DM9AJSU FM C12H17NO2
DM9AJSU IC InChI=1S/C12H17NO2/c1-3-5-7-10-9-13(12(10)15)11(14)8-6-4-2/h3-4,10H,1-2,5-9H2
DM9AJSU CS C=CCCC1CN(C1=O)C(=O)CCC=C
DM9AJSU IK GINOGVHXZZDXCD-UHFFFAOYSA-N
DM9AJSU IU 3-but-3-enyl-1-pent-4-enoylazetidin-2-one
DM9AJSU DE Discovery agent
DMWIABE ID DMWIABE
DMWIABE DN (+/-)-3-(pent-4-enyl)azetidin-2-one
DMWIABE HS Investigative
DMWIABE SN CHEMBL505129
DMWIABE DT Small molecular drug
DMWIABE PC 44560663
DMWIABE MW 139.19
DMWIABE FM C8H13NO
DMWIABE IC InChI=1S/C8H13NO/c1-2-3-4-5-7-6-9-8(7)10/h2,7H,1,3-6H2,(H,9,10)
DMWIABE CS C=CCCCC1CNC1=O
DMWIABE IK ABPZGIHKPZCCMN-UHFFFAOYSA-N
DMWIABE IU 3-pent-4-enylazetidin-2-one
DMWIABE DE Discovery agent
DMS5AWP ID DMS5AWP
DMS5AWP DN (+/-)-3-allyl-1-pent-4-enoylazetidin-2-one
DMS5AWP HS Investigative
DMS5AWP SN CHEMBL487448; (+/-)-3-allyl-1-pent-4-enoylazetidin-2-one; 1-(4'-pentenoyl)-3-(2'-propenyl)-2-azetidinone; BDBM50243198
DMS5AWP DT Small molecular drug
DMS5AWP PC 44560665
DMS5AWP MW 193.24
DMS5AWP FM C11H15NO2
DMS5AWP IC InChI=1S/C11H15NO2/c1-3-5-7-10(13)12-8-9(6-4-2)11(12)14/h3-4,9H,1-2,5-8H2
DMS5AWP CS C=CCCC(=O)N1CC(C1=O)CC=C
DMS5AWP IK QVTWEMBUZOBMIJ-UHFFFAOYSA-N
DMS5AWP IU 1-pent-4-enoyl-3-prop-2-enylazetidin-2-one
DMS5AWP DE Discovery agent
DMK42RU ID DMK42RU
DMK42RU DN (+/-)-3-allylazetidin-2-one
DMK42RU HS Investigative
DMK42RU SN 3-(2'-propenyl)-2-azetidinone; 1058693-04-1; allyl-beta-lactam; CHEMBL447982
DMK42RU DT Small molecular drug
DMK42RU PC 20449950
DMK42RU MW 111.14
DMK42RU FM C6H9NO
DMK42RU IC InChI=1S/C6H9NO/c1-2-3-5-4-7-6(5)8/h2,5H,1,3-4H2,(H,7,8)
DMK42RU CS C=CCC1CNC1=O
DMK42RU IK XWLCLNCCEDQVSS-UHFFFAOYSA-N
DMK42RU IU 3-prop-2-enylazetidin-2-one
DMK42RU DE Discovery agent
DMSN7GJ ID DMSN7GJ
DMSN7GJ DN (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ HS Investigative
DMSN7GJ SN CHEMBL572982; (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid
DMSN7GJ DT Small molecular drug
DMSN7GJ PC 11391583
DMSN7GJ MW 270.32
DMSN7GJ FM C17H18O3
DMSN7GJ IC InChI=1S/C17H18O3/c18-16(12-17(19)20)11-8-13-6-9-15(10-7-13)14-4-2-1-3-5-14/h1-7,9-10,16,18H,8,11-12H2,(H,19,20)
DMSN7GJ CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(CC(=O)O)O
DMSN7GJ IK ILGSIIFHQGOKKV-UHFFFAOYSA-N
DMSN7GJ IU 3-hydroxy-5-(4-phenylphenyl)pentanoic acid
DMSN7GJ DE Discovery agent
DMSNWA6 ID DMSNWA6
DMSNWA6 DN (+/-)-5-amino-2-(mercaptomethyl)pentanoic acid
DMSNWA6 HS Investigative
DMSNWA6 SN CHEMBL237008; (+/-)-5-amino-2-(mercaptomethyl)pentanoic acid; SCHEMBL11507369; IKYCTNVIQZAWIB-UHFFFAOYSA-N; BDBM50226603; 5-Amino-2-mercaptomethylpentanoic acid
DMSNWA6 DT Small molecular drug
DMSNWA6 PC 20384315
DMSNWA6 MW 163.24
DMSNWA6 FM C6H13NO2S
DMSNWA6 IC InChI=1S/C6H13NO2S/c7-3-1-2-5(4-10)6(8)9/h5,10H,1-4,7H2,(H,8,9)
DMSNWA6 CS C(CC(CS)C(=O)O)CN
DMSNWA6 IK IKYCTNVIQZAWIB-UHFFFAOYSA-N
DMSNWA6 IU 5-amino-2-(sulfanylmethyl)pentanoic acid
DMSNWA6 DE Discovery agent
DMQP5U9 ID DMQP5U9
DMQP5U9 DN (+/-)-5'-deoxy-4'-fluoro-5'-methylthio-DADMe-ImmH
DMQP5U9 HS Investigative
DMQP5U9 DT Small molecular drug
DMQP5U9 PC 44563309
DMQP5U9 DE Discovery agent
DM23W58 ID DM23W58
DM23W58 DN (+/-)-6-(2-chlorophenyl)cyclohex-3-enamine
DM23W58 HS Investigative
DM23W58 SN cyclohexene analog 6; SCHEMBL3750136; CHEMBL216578; BDBM12649
DM23W58 DT Small molecular drug
DM23W58 PC 16049437
DM23W58 MW 207.7
DM23W58 FM C12H14ClN
DM23W58 IC InChI=1S/C12H14ClN/c13-11-7-3-1-5-9(11)10-6-2-4-8-12(10)14/h1-5,7,10,12H,6,8,14H2/t10-,12+/m1/s1
DM23W58 CS C1C=CC[C@@H]([C@H]1C2=CC=CC=C2Cl)N
DM23W58 IK UAUINBMLUPAKPF-PWSUYJOCSA-N
DM23W58 IU (1S,6R)-6-(2-chlorophenyl)cyclohex-3-en-1-amine
DM23W58 DE Discovery agent
DMKWBY8 ID DMKWBY8
DMKWBY8 DN (+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMKWBY8 HS Investigative
DMKWBY8 SN CHEMBL600390
DMKWBY8 DT Small molecular drug
DMKWBY8 PC 46231663
DMKWBY8 MW 260.23
DMKWBY8 FM C15H10F2O2
DMKWBY8 IC InChI=1S/C15H10F2O2/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14H,8H2
DMKWBY8 CS C1C(OC2=C(C1=O)C=CC(=C2)F)C3=CC=C(C=C3)F
DMKWBY8 IK YKJLGNVYFBPKJK-UHFFFAOYSA-N
DMKWBY8 IU 7-fluoro-2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DMKWBY8 DE Discovery agent
DMYHV9P ID DMYHV9P
DMYHV9P DN (+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one
DMYHV9P HS Investigative
DMYHV9P SN CHEMBL598720; 844-66-6; 4h-1-benzopyran-4-one,7-fluoro-2,3-dihydro-2-(4-methoxyphenyl)-; 4H-1-Benzopyran-4-one, 7-fluoro-2,3-dihydro-2-(4-methoxyphenyl)-; AC1NRRFL; (+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one; CTK3D0370; DTXSID70414918; BDBM50310194; AKOS030553462; KB-306159; 7-fluoro-2-(4-methoxyphenyl)chroman-4-one
DMYHV9P DT Small molecular drug
DMYHV9P PC 5271543
DMYHV9P MW 272.27
DMYHV9P FM C16H13FO3
DMYHV9P IC InChI=1S/C16H13FO3/c1-19-12-5-2-10(3-6-12)15-9-14(18)13-7-4-11(17)8-16(13)20-15/h2-8,15H,9H2,1H3
DMYHV9P CS COC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)F
DMYHV9P IK MQUZZZVJAVDIPR-UHFFFAOYSA-N
DMYHV9P IU 7-fluoro-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMYHV9P CA CAS 844-66-6
DMYHV9P DE Discovery agent
DMJEBXA ID DMJEBXA
DMJEBXA DN (+/-)-7-fluoro-2-phenylchroman-4-one
DMJEBXA HS Investigative
DMJEBXA SN 7-Fluoroflavanone; 4H-1-Benzopyran-4-one, 7-fluoro-2,3-dihydro-2-phenyl-; 98769-92-7; 7-fluoro-flavanone; AC1NRPFB; ACMC-20m2iw; CHEMBL596693; SCHEMBL10360962; CTK3G7728; DTXSID20414862; SZNYRENOXQIQMR-UHFFFAOYSA-N; 7-fluoro-2-phenyl-chroman-4-one; AKOS030553463
DMJEBXA DT Small molecular drug
DMJEBXA PC 5270543
DMJEBXA MW 242.24
DMJEBXA FM C15H11FO2
DMJEBXA IC InChI=1S/C15H11FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14H,9H2
DMJEBXA CS C1C(OC2=C(C1=O)C=CC(=C2)F)C3=CC=CC=C3
DMJEBXA IK SZNYRENOXQIQMR-UHFFFAOYSA-N
DMJEBXA IU 7-fluoro-2-phenyl-2,3-dihydrochromen-4-one
DMJEBXA CA CAS 98769-92-7
DMJEBXA DE Discovery agent
DM4H1JO ID DM4H1JO
DM4H1JO DN (+/-)-7-fluoro-2-p-tolylchroman-4-one
DM4H1JO HS Investigative
DM4H1JO SN CHEMBL600391
DM4H1JO DT Small molecular drug
DM4H1JO PC 46231664
DM4H1JO MW 256.269
DM4H1JO FM C16H13FO2
DM4H1JO IC InChI=1S/C16H13FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-8,15H,9H2,1H3
DM4H1JO CS CC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)F
DM4H1JO IK QNQXLNDULBVXEX-UHFFFAOYSA-N
DM4H1JO IU 7-fluoro-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DM4H1JO DE Discovery agent
DMYJGDK ID DMYJGDK
DMYJGDK DN (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one
DMYJGDK HS Investigative
DMYJGDK SN 7-methoxy-2-(4-methoxyphenyl)chroman-4-one
DMYJGDK PC 5271544
DMYJGDK MW 284.31
DMYJGDK FM C17H16O4
DMYJGDK IC InChI=1S/C17H16O4/c1-19-12-5-3-11(4-6-12)16-10-15(18)14-8-7-13(20-2)9-17(14)21-16/h3-9,16H,10H2,1-2H3
DMYJGDK CS COC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)OC
DMYJGDK IK YAEYGSBLDUIDTP-UHFFFAOYSA-N
DMYJGDK IU 7-methoxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMYJGDK CA CAS 25826-69-1
DMYJGDK CB CHEBI:91819
DMYJGDK DE Discovery agent
DMC0OKA ID DMC0OKA
DMC0OKA DN (+/-)-7-methoxy-2-phenylchroman-4-one
DMC0OKA HS Investigative
DMC0OKA SN 7-methoxy-2-phenylchroman-4-one
DMC0OKA PC 2825024
DMC0OKA MW 254.28
DMC0OKA FM C16H14O3
DMC0OKA IC InChI=1S/C16H14O3/c1-18-12-7-8-13-14(17)10-15(19-16(13)9-12)11-5-3-2-4-6-11/h2-9,15H,10H2,1H3
DMC0OKA CS COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=CC=C3
DMC0OKA IK VYESEQLQFXUROZ-UHFFFAOYSA-N
DMC0OKA IU 7-methoxy-2-phenyl-2,3-dihydrochromen-4-one
DMC0OKA DE Discovery agent
DMJMTVQ ID DMJMTVQ
DMJMTVQ DN (+/-)-7-methoxy-2-p-tolylchroman-4-one
DMJMTVQ HS Investigative
DMJMTVQ SN CHEMBL602141; (+/-)-7-methoxy-2-p-tolylchroman-4-one; SCHEMBL13394439
DMJMTVQ DT Small molecular drug
DMJMTVQ PC 15098246
DMJMTVQ MW 268.31
DMJMTVQ FM C17H16O3
DMJMTVQ IC InChI=1S/C17H16O3/c1-11-3-5-12(6-4-11)16-10-15(18)14-8-7-13(19-2)9-17(14)20-16/h3-9,16H,10H2,1-2H3
DMJMTVQ CS CC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)OC
DMJMTVQ IK JVZDRFASOQJJTF-UHFFFAOYSA-N
DMJMTVQ IU 7-methoxy-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMJMTVQ DE Discovery agent
DMI3URD ID DMI3URD
DMI3URD DN (+/-)-7-methyl-2-phenylchroman-4-one
DMI3URD HS Investigative
DMI3URD SN 64919-60-4; 7-Methylflavanone; SCHEMBL1895393; CHEMBL600392; CTK1I3915; DTXSID70502203; AKOS030552841; 7-Methyl-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-methyl-2-phenyl-
DMI3URD DT Small molecular drug
DMI3URD PC 12549536
DMI3URD MW 238.28
DMI3URD FM C16H14O2
DMI3URD IC InChI=1S/C16H14O2/c1-11-7-8-13-14(17)10-15(18-16(13)9-11)12-5-3-2-4-6-12/h2-9,15H,10H2,1H3
DMI3URD CS CC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=CC=C3
DMI3URD IK FNOKOVWLKVWYRY-UHFFFAOYSA-N
DMI3URD IU 7-methyl-2-phenyl-2,3-dihydrochromen-4-one
DMI3URD CA CAS 64919-60-4
DMI3URD DE Discovery agent
DMBN3WE ID DMBN3WE
DMBN3WE DN (+/-)-7-methyl-2-p-tolylchroman-4-one
DMBN3WE HS Investigative
DMBN3WE SN CHEMBL600597
DMBN3WE DT Small molecular drug
DMBN3WE PC 46231666
DMBN3WE MW 252.31
DMBN3WE FM C17H16O2
DMBN3WE IC InChI=1S/C17H16O2/c1-11-3-6-13(7-4-11)16-10-15(18)14-8-5-12(2)9-17(14)19-16/h3-9,16H,10H2,1-2H3
DMBN3WE CS CC1=CC=C(C=C1)C2CC(=O)C3=C(O2)C=C(C=C3)C
DMBN3WE IK MIEPNGHJBCGJAW-UHFFFAOYSA-N
DMBN3WE IU 7-methyl-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMBN3WE DE Discovery agent
DMY3J0B ID DMY3J0B
DMY3J0B DN (+/-)-cis-2-CAMP
DMY3J0B HS Investigative
DMY3J0B SN 215597-45-8; 2-(Aminomethyl)cyclopropanecarboxylic acid; 2-(aminomethyl)cyclopropane-1-carboxylic acid; Cyclopropanecarboxylicacid, 2-(aminomethyl)-; (plusmn)-cis-2-CAMP; AC1N3MNT; SCHEMBL3943045; GTPL4067; CHEMBL284310; CTK1A0098; BDBM50087269; AKOS006277884; KB-163238; (cis)-2-Aminomethyl-cyclopropanecarboxylic acid; A29700; (trans)-2-Aminomethyl-cyclopropanecarboxylic acid; (+)-2-(aminomethyl)-cyclopropane-1-carboxylic acid
DMY3J0B DT Small molecular drug
DMY3J0B PC 4067175
DMY3J0B MW 115.13
DMY3J0B FM C5H9NO2
DMY3J0B IC InChI=1S/C5H9NO2/c6-2-3-1-4(3)5(7)8/h3-4H,1-2,6H2,(H,7,8)
DMY3J0B CS C1C(C1C(=O)O)CN
DMY3J0B IK QUFMERRXRMSAPZ-UHFFFAOYSA-N
DMY3J0B IU 2-(aminomethyl)cyclopropane-1-carboxylic acid
DMY3J0B DE Discovery agent
DMAHO9M ID DMAHO9M
DMAHO9M DN (+/-)-cis-H2-PAT
DMAHO9M HS Investigative
DMAHO9M SN (plusmn)-cis-H2-PAT; GTPL1206; CHEMBL340199; SCHEMBL12998410; BDBM86030; ZINC5965164; N,N-Dimethyl-4beta-phenyltetralin-2beta-amine
DMAHO9M DT Small molecular drug
DMAHO9M PC 10037815
DMAHO9M MW 251.4
DMAHO9M FM C18H21N
DMAHO9M IC InChI=1S/C18H21N/c1-19(2)16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,12-13H2,1-2H3/t16-,18+/m1/s1
DMAHO9M CS CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
DMAHO9M IK DXJUCAUQIHNOAF-AEFFLSMTSA-N
DMAHO9M IU (2S,4S)-N,N-dimethyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine
DMAHO9M DE Discovery agent
DMBSH5L ID DMBSH5L
DMBSH5L DN (+/-)-Daedalin A
DMBSH5L HS Investigative
DMBSH5L SN CHEMBL590726
DMBSH5L DT Small molecular drug
DMBSH5L PC 46230831
DMBSH5L MW 192.21
DMBSH5L FM C11H12O3
DMBSH5L IC InChI=1S/C11H12O3/c1-11(13-2)6-5-8-7-9(12)3-4-10(8)14-11/h3-7,12H,1-2H3
DMBSH5L CS CC1(C=CC2=C(O1)C=CC(=C2)O)OC
DMBSH5L IK DLZKKUHAZDHCSL-UHFFFAOYSA-N
DMBSH5L IU 2-methoxy-2-methylchromen-6-ol
DMBSH5L DE Discovery agent
DM0L3GE ID DM0L3GE
DM0L3GE DN (+/-)-nantenine
DM0L3GE HS Investigative
DM0L3GE PC 181743
DM0L3GE MW 339.4
DM0L3GE FM C20H21NO4
DM0L3GE IC InChI=1S/C20H21NO4/c1-21-5-4-11-7-17(22-2)20(23-3)19-13-9-16-15(24-10-25-16)8-12(13)6-14(21)18(11)19/h7-9,14H,4-6,10H2,1-3H3
DM0L3GE CS CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC
DM0L3GE IK WSVWKHTVFGTTKJ-UHFFFAOYSA-N
DM0L3GE IU 18,19-dimethoxy-13-methyl-5,7-dioxa-13-azapentacyclo[10.7.1.02,10.04,8.016,20]icosa-1(20),2,4(8),9,16,18-hexaene
DM0L3GE CA CAS 42971-15-3
DM0L3GE DE Discovery agent
DM8023E ID DM8023E
DM8023E DN (+/-)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate
DM8023E HS Investigative
DM8023E SN CHEMBL230968; 213738-77-3; SCHEMBL4979121; BDBM50220357; UCM710, > oxiran-2-ylmethyl (9z)-hexadec-9-enoate
DM8023E DT Small molecular drug
DM8023E PC 23624909
DM8023E MW 310.5
DM8023E FM C19H34O3
DM8023E IC InChI=1S/C19H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(20)22-17-18-16-21-18/h7-8,18H,2-6,9-17H2,1H3/b8-7-
DM8023E CS CCCCCC/C=C\\CCCCCCCC(=O)OCC1CO1
DM8023E IK FWEHVPCBXKCYHE-FPLPWBNLSA-N
DM8023E IU oxiran-2-ylmethyl (Z)-hexadec-9-enoate
DM8023E DE Discovery agent
DMI5R3E ID DMI5R3E
DMI5R3E DN (+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate
DMI5R3E HS Investigative
DMI5R3E SN Glycidyl oleate; Glycidol oleate; Oleic acid glycidyl ester; 2,3-Epoxypropyl oleate; Glycidyl octadecenoate; 5431-33-4; 2,3-Epoxy-1-propanol oleate; NSC 13542; 2,3-Epoxypropyl ester of oleic acid; Oxiranylmethyl ester of 9-octadecenoic acid; Oleic acid, 2,3-epoxypropyl ester; EINECS 226-588-0; Glycidylester kyseliny olejove [Czech]; AI3-03518; CHEMBL230967; CHEBI:82469; VWYIWOYBERNXLX-KTKRTIGZSA-N; 9-OCTADECENOIC ACID (Z)-, OXIRANYLMETHYL ESTER; Oxiranyl methyl ester 9-octadecenoic acid; 9-Octadecenoic acid (9Z)-, oxiranylmet
DMI5R3E DT Small molecular drug
DMI5R3E PC 5354568
DMI5R3E MW 338.5
DMI5R3E FM C21H38O3
DMI5R3E IC InChI=1S/C21H38O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(22)24-19-20-18-23-20/h9-10,20H,2-8,11-19H2,1H3/b10-9-
DMI5R3E CS CCCCCCCC/C=C\\CCCCCCCC(=O)OCC1CO1
DMI5R3E IK VWYIWOYBERNXLX-KTKRTIGZSA-N
DMI5R3E IU oxiran-2-ylmethyl (Z)-octadec-9-enoate
DMI5R3E CA CAS 5431-33-4
DMI5R3E CB CHEBI:82469
DMI5R3E DE Discovery agent
DMFSZ8H ID DMFSZ8H
DMFSZ8H DN (+/-)-threo-3',4'-Dichloromethylphenidate amide
DMFSZ8H HS Investigative
DMFSZ8H SN CHEMBL1253379; BDBM50327177; (+/-)-threo-3'',4''-Dichloromethylphenidate amide
DMFSZ8H DT Small molecular drug
DMFSZ8H PC 52941144
DMFSZ8H MW 287.18
DMFSZ8H FM C13H16Cl2N2O
DMFSZ8H IC InChI=1S/C13H16Cl2N2O/c14-9-5-4-8(7-10(9)15)12(13(16)18)11-3-1-2-6-17-11/h4-5,7,11-12,17H,1-3,6H2,(H2,16,18)/t11-,12-/m1/s1
DMFSZ8H CS C1CCN[C@H](C1)[C@@H](C2=CC(=C(C=C2)Cl)Cl)C(=O)N
DMFSZ8H IK OUZYXOJONCTZTI-VXGBXAGGSA-N
DMFSZ8H IU (2R)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetamide
DMFSZ8H DE Discovery agent
DM5MLZ0 ID DM5MLZ0
DM5MLZ0 DN (+/-)-threo-3',4'-Dichlororitalinol methyl ether
DM5MLZ0 HS Investigative
DM5MLZ0 SN CHEMBL1253378; BDBM50327167; (+/-)-threo-3'',4''-Dichlororitalinol methyl ether
DM5MLZ0 DT Small molecular drug
DM5MLZ0 PC 52942344
DM5MLZ0 MW 288.2
DM5MLZ0 FM C14H19Cl2NO
DM5MLZ0 IC InChI=1S/C14H19Cl2NO/c1-18-9-11(14-4-2-3-7-17-14)10-5-6-12(15)13(16)8-10/h5-6,8,11,14,17H,2-4,7,9H2,1H3/t11-,14-/m1/s1
DM5MLZ0 CS COC[C@@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)Cl)Cl
DM5MLZ0 IK JJZIIHYRMWUFJU-BXUZGUMPSA-N
DM5MLZ0 IU (2R)-2-[(1R)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine
DM5MLZ0 DE Discovery agent
DM4UQBI ID DM4UQBI
DM4UQBI DN (+/-)-threo-3',5'-Dichloromethylphenidate
DM4UQBI HS Investigative
DM4UQBI SN CHEMBL1253691; BDBM50327135
DM4UQBI DT Small molecular drug
DM4UQBI PC 52942419
DM4UQBI MW 302.2
DM4UQBI FM C14H17Cl2NO2
DM4UQBI IC InChI=1S/C14H17Cl2NO2/c1-19-14(18)13(12-4-2-3-5-17-12)9-6-10(15)8-11(16)7-9/h6-8,12-13,17H,2-5H2,1H3/t12-,13-/m1/s1
DM4UQBI CS COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC(=CC(=C2)Cl)Cl
DM4UQBI IK DRFWSKBVUOJFQQ-CHWSQXEVSA-N
DM4UQBI IU methyl (2R)-2-(3,5-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetate
DM4UQBI DE Discovery agent
DMUWKNX ID DMUWKNX
DMUWKNX DN (+/-)-threo-3',5'-Dimethylmethylphenidate
DMUWKNX HS Investigative
DMUWKNX SN CHEMBL1253692; BDBM50327134
DMUWKNX DT Small molecular drug
DMUWKNX PC 52946039
DMUWKNX MW 261.36
DMUWKNX FM C16H23NO2
DMUWKNX IC InChI=1S/C16H23NO2/c1-11-8-12(2)10-13(9-11)15(16(18)19-3)14-6-4-5-7-17-14/h8-10,14-15,17H,4-7H2,1-3H3/t14-,15-/m1/s1
DMUWKNX CS CC1=CC(=CC(=C1)[C@H]([C@H]2CCCCN2)C(=O)OC)C
DMUWKNX IK OQNVWHLLYQJVEV-HUUCEWRRSA-N
DMUWKNX IU methyl (2R)-2-(3,5-dimethylphenyl)-2-[(2R)-piperidin-2-yl]acetate
DMUWKNX DE Discovery agent
DM3O4FI ID DM3O4FI
DM3O4FI DN (+/-)-threo-3-Fluororitalinol
DM3O4FI HS Investigative
DM3O4FI SN CHEMBL1253340; (+/-)-threo-3-Fluororitalinol
DM3O4FI DT Small molecular drug
DM3O4FI PC 52947218
DM3O4FI MW 223.29
DM3O4FI FM C13H18FNO
DM3O4FI IC InChI=1S/C13H18FNO/c14-11-5-3-4-10(8-11)12(9-16)13-6-1-2-7-15-13/h3-5,8,12-13,15-16H,1-2,6-7,9H2/t12-,13-/m1/s1
DM3O4FI CS C1CCN[C@H](C1)[C@H](CO)C2=CC(=CC=C2)F
DM3O4FI IK AXNMDZNGNYLXHQ-CHWSQXEVSA-N
DM3O4FI IU (2R)-2-(3-fluorophenyl)-2-[(2R)-piperidin-2-yl]ethanol
DM3O4FI DE Discovery agent
DMU5T28 ID DMU5T28
DMU5T28 DN (+/-)-threo-4'-Ethylmethylphenidate
DMU5T28 HS Investigative
DMU5T28 SN CHEMBL1253519; BDBM50327106
DMU5T28 DT Small molecular drug
DMU5T28 PC 52947243
DMU5T28 MW 261.36
DMU5T28 FM C16H23NO2
DMU5T28 IC InChI=1S/C16H23NO2/c1-3-12-7-9-13(10-8-12)15(16(18)19-2)14-6-4-5-11-17-14/h7-10,14-15,17H,3-6,11H2,1-2H3/t14-,15-/m1/s1
DMU5T28 CS CCC1=CC=C(C=C1)[C@H]([C@H]2CCCCN2)C(=O)OC
DMU5T28 IK WNIYTNIFAQJHLP-HUUCEWRRSA-N
DMU5T28 IU methyl (2R)-2-(4-ethylphenyl)-2-[(2R)-piperidin-2-yl]acetate
DMU5T28 DE Discovery agent
DM9TSW0 ID DM9TSW0
DM9TSW0 DN (+/-)-threo-Benzylphenidate
DM9TSW0 HS Investigative
DM9TSW0 SN CHEMBL1254759; (+/-)-threo-Benzylphenidate
DM9TSW0 DT Small molecular drug
DM9TSW0 PC 52948225
DM9TSW0 MW 309.4
DM9TSW0 FM C20H23NO2
DM9TSW0 IC InChI=1S/C20H23NO2/c22-20(23-15-16-9-3-1-4-10-16)19(17-11-5-2-6-12-17)18-13-7-8-14-21-18/h1-6,9-12,18-19,21H,7-8,13-15H2/t18-,19-/m1/s1
DM9TSW0 CS C1CCN[C@H](C1)[C@@H](C2=CC=CC=C2)C(=O)OCC3=CC=CC=C3
DM9TSW0 IK MNFUKEWWCUWTRK-RTBURBONSA-N
DM9TSW0 IU benzyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
DM9TSW0 DE Discovery agent
DMRZOVP ID DMRZOVP
DMRZOVP DN (+/-)-threo-Methylphenidate amide
DMRZOVP HS Investigative
DMRZOVP SN UNII-HS1P4T2LCV; HS1P4T2LCV; CHEMBL1253490; 160707-37-9; 50288-62-5; SCHEMBL14453323; ZINC5934431; BDBM50327105; D-threo-; A-Phenyl-2-piperidineacetamide; AJ-55250; AR,2R)-; FT-0673813; FT-0673810; (D,L)-threo-; (alphaR,2R)-alpha-Phenyl-2-piperidineacetamide; AR,2R)-rel-; (D,L)-threo-alpha-Phenyl-2-piperidineacetamide; alpha-Phenyl-2-piperidineacetamide, threo-(+)-
DMRZOVP DT Small molecular drug
DMRZOVP PC 11085277
DMRZOVP MW 218.29
DMRZOVP FM C13H18N2O
DMRZOVP IC InChI=1S/C13H18N2O/c14-13(16)12(10-6-2-1-3-7-10)11-8-4-5-9-15-11/h1-3,6-7,11-12,15H,4-5,8-9H2,(H2,14,16)/t11-,12-/m1/s1
DMRZOVP CS C1CCN[C@H](C1)[C@@H](C2=CC=CC=C2)C(=O)N
DMRZOVP IK LJLMNWPXAYKPGV-VXGBXAGGSA-N
DMRZOVP IU (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetamide
DMRZOVP CA CAS 160707-37-9
DMRZOVP DE Discovery agent
DM80JOH ID DM80JOH
DM80JOH DN (+/-)-threo-N-(2-Chlorobenzyl)methylphenidate
DM80JOH HS Investigative
DM80JOH SN CHEMBL1253919; (+/-)-threo-N-(2-Chlorobenzyl)methylphenidate
DM80JOH DT Small molecular drug
DM80JOH PC 52945289
DM80JOH MW 357.9
DM80JOH FM C21H24ClNO2
DM80JOH IC InChI=1S/C21H24ClNO2/c1-25-21(24)20(16-9-3-2-4-10-16)19-13-7-8-14-23(19)15-17-11-5-6-12-18(17)22/h2-6,9-12,19-20H,7-8,13-15H2,1H3/t19-,20-/m1/s1
DM80JOH CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2Cl)C3=CC=CC=C3
DM80JOH IK AQQXLSKTANRVGK-WOJBJXKFSA-N
DM80JOH IU methyl (2R)-2-[(2R)-1-[(2-chlorophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DM80JOH DE Discovery agent
DM6CWBO ID DM6CWBO
DM6CWBO DN (+/-)-threo-N-(2-Methylfuran)methylphenidate
DM6CWBO HS Investigative
DM6CWBO SN CHEMBL1254929; (+/-)-threo-N-(2-Methylfuran)methylphenidate; BDBM50327129; (alphaR)-alpha-[(2R)-1-(2-Furanylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DM6CWBO DT Small molecular drug
DM6CWBO PC 52947085
DM6CWBO MW 313.4
DM6CWBO FM C19H23NO3
DM6CWBO IC InChI=1S/C19H23NO3/c1-22-19(21)18(15-8-3-2-4-9-15)17-11-5-6-12-20(17)14-16-10-7-13-23-16/h2-4,7-10,13,17-18H,5-6,11-12,14H2,1H3/t17-,18-/m1/s1
DM6CWBO CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CO2)C3=CC=CC=C3
DM6CWBO IK PKLJJOYWJBBUAO-QZTJIDSGSA-N
DM6CWBO IU methyl (2R)-2-[(2R)-1-(furan-2-ylmethyl)piperidin-2-yl]-2-phenylacetate
DM6CWBO DE Discovery agent
DMN6ZX9 ID DMN6ZX9
DMN6ZX9 DN (+/-)-threo-N-(2-Methylpyridine)methylphenidate
DMN6ZX9 HS Investigative
DMN6ZX9 SN CHEMBL1255015; (+/-)-threo-N-(2-Methylpyridine)methylphenidate; BDBM50327126; (alphaR)-alpha-[(2R)-1-(2-Pyridinylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMN6ZX9 DT Small molecular drug
DMN6ZX9 PC 52943483
DMN6ZX9 MW 324.4
DMN6ZX9 FM C20H24N2O2
DMN6ZX9 IC InChI=1S/C20H24N2O2/c1-24-20(23)19(16-9-3-2-4-10-16)18-12-6-8-14-22(18)15-17-11-5-7-13-21-17/h2-5,7,9-11,13,18-19H,6,8,12,14-15H2,1H3/t18-,19-/m1/s1
DMN6ZX9 CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=N2)C3=CC=CC=C3
DMN6ZX9 IK AZQUBJDTVAIXBC-RTBURBONSA-N
DMN6ZX9 IU methyl (2R)-2-phenyl-2-[(2R)-1-(pyridin-2-ylmethyl)piperidin-2-yl]acetate
DMN6ZX9 DE Discovery agent
DMWUGSV ID DMWUGSV
DMWUGSV DN (+/-)-threo-N-(2-Methylthiopene)methylphenidate
DMWUGSV HS Investigative
DMWUGSV SN CHEMBL1254843; (+/-)-threo-N-(2-Methylthiopene)methylphenidate; BDBM50327131; (alphaR)-alpha-[(2R)-1-(2-Thienylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMWUGSV DT Small molecular drug
DMWUGSV PC 52945836
DMWUGSV MW 329.5
DMWUGSV FM C19H23NO2S
DMWUGSV IC InChI=1S/C19H23NO2S/c1-22-19(21)18(15-8-3-2-4-9-15)17-11-5-6-12-20(17)14-16-10-7-13-23-16/h2-4,7-10,13,17-18H,5-6,11-12,14H2,1H3/t17-,18-/m1/s1
DMWUGSV CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CS2)C3=CC=CC=C3
DMWUGSV IK XGTZBGNNSZZVLK-QZTJIDSGSA-N
DMWUGSV IU methyl (2R)-2-phenyl-2-[(2R)-1-(thiophen-2-ylmethyl)piperidin-2-yl]acetate
DMWUGSV DE Discovery agent
DM2WRED ID DM2WRED
DM2WRED DN (+/-)-threo-N-(2-Phenylethyl)methylphenidate
DM2WRED HS Investigative
DM2WRED SN CHEMBL1254101; (+/-)-threo-N-(2-Phenylethyl)methylphenidate; BDBM50327116; (alphaR,2R)-alpha-Phenyl-1-phenethylpiperidine-2beta-acetic acid methyl ester
DM2WRED DT Small molecular drug
DM2WRED PC 52943716
DM2WRED MW 337.5
DM2WRED FM C22H27NO2
DM2WRED IC InChI=1S/C22H27NO2/c1-25-22(24)21(19-12-6-3-7-13-19)20-14-8-9-16-23(20)17-15-18-10-4-2-5-11-18/h2-7,10-13,20-21H,8-9,14-17H2,1H3/t20-,21-/m1/s1
DM2WRED CS COC(=O)[C@@H]([C@H]1CCCCN1CCC2=CC=CC=C2)C3=CC=CC=C3
DM2WRED IK XALKSMFHDRJAKZ-NHCUHLMSSA-N
DM2WRED IU methyl (2R)-2-phenyl-2-[(2R)-1-(2-phenylethyl)piperidin-2-yl]acetate
DM2WRED DE Discovery agent
DM9Y3MT ID DM9Y3MT
DM9Y3MT DN (+/-)-threo-N-(2-Phenylethyl)ritalinol
DM9Y3MT HS Investigative
DM9Y3MT SN CHEMBL1254280; (+/-)-threo-N-(2-Phenylethyl)ritalinol; BDBM50327113; (betaR)-beta-[(2R)-1-Phenethylpiperidine-2beta-yl]phenethyl alcohol
DM9Y3MT DT Small molecular drug
DM9Y3MT PC 52944989
DM9Y3MT MW 309.4
DM9Y3MT FM C21H27NO
DM9Y3MT IC InChI=1S/C21H27NO/c23-17-20(19-11-5-2-6-12-19)21-13-7-8-15-22(21)16-14-18-9-3-1-4-10-18/h1-6,9-12,20-21,23H,7-8,13-17H2/t20-,21-/m1/s1
DM9Y3MT CS C1CCN([C@H](C1)[C@H](CO)C2=CC=CC=C2)CCC3=CC=CC=C3
DM9Y3MT IK BWPOQJVXDJYEQS-NHCUHLMSSA-N
DM9Y3MT IU (2R)-2-phenyl-2-[(2R)-1-(2-phenylethyl)piperidin-2-yl]ethanol
DM9Y3MT DE Discovery agent
DMU08WO ID DMU08WO
DMU08WO DN (+/-)-threo-N-(3-Chlorobenzyl)methylphenidate
DMU08WO HS Investigative
DMU08WO SN CHEMBL1254195; (+/-)-threo-N-(3-Chlorobenzyl)methylphenidate
DMU08WO DT Small molecular drug
DMU08WO PC 52943751
DMU08WO MW 357.9
DMU08WO FM C21H24ClNO2
DMU08WO IC InChI=1S/C21H24ClNO2/c1-25-21(24)20(17-9-3-2-4-10-17)19-12-5-6-13-23(19)15-16-8-7-11-18(22)14-16/h2-4,7-11,14,19-20H,5-6,12-13,15H2,1H3/t19-,20-/m1/s1
DMU08WO CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC(=CC=C2)Cl)C3=CC=CC=C3
DMU08WO IK MOEMZDNFRMSDIA-WOJBJXKFSA-N
DMU08WO IU methyl (2R)-2-[(2R)-1-[(3-chlorophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DMU08WO DE Discovery agent
DMHPE4L ID DMHPE4L
DMHPE4L DN (+/-)-threo-N-(3-Methylfuran)methylphenidate
DMHPE4L HS Investigative
DMHPE4L SN CHEMBL1254842; (+/-)-threo-N-(3-Methylfuran)methylphenidate; BDBM50327132; (alphaR)-alpha-[(2R)-1-(3-Furanylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMHPE4L DT Small molecular drug
DMHPE4L PC 52942853
DMHPE4L MW 313.4
DMHPE4L FM C19H23NO3
DMHPE4L IC InChI=1S/C19H23NO3/c1-22-19(21)18(16-7-3-2-4-8-16)17-9-5-6-11-20(17)13-15-10-12-23-14-15/h2-4,7-8,10,12,14,17-18H,5-6,9,11,13H2,1H3/t17-,18-/m1/s1
DMHPE4L CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=COC=C2)C3=CC=CC=C3
DMHPE4L IK GUHBNEJVQSVUMF-QZTJIDSGSA-N
DMHPE4L IU methyl (2R)-2-[(2R)-1-(furan-3-ylmethyl)piperidin-2-yl]-2-phenylacetate
DMHPE4L DE Discovery agent
DMDMTZK ID DMDMTZK
DMDMTZK DN (+/-)-threo-N-(3-Methylpyridine)methylphenidate
DMDMTZK HS Investigative
DMDMTZK SN CHEMBL1255014; (+/-)-threo-N-(3-Methylpyridine)methylphenidate; BDBM50327127; (alphaR)-alpha-[(2R)-1-(3-Pyridinylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMDMTZK DT Small molecular drug
DMDMTZK PC 52943482
DMDMTZK MW 324.4
DMDMTZK FM C20H24N2O2
DMDMTZK IC InChI=1S/C20H24N2O2/c1-24-20(23)19(17-9-3-2-4-10-17)18-11-5-6-13-22(18)15-16-8-7-12-21-14-16/h2-4,7-10,12,14,18-19H,5-6,11,13,15H2,1H3/t18-,19-/m1/s1
DMDMTZK CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CN=CC=C2)C3=CC=CC=C3
DMDMTZK IK NCMGDVQEMNIZAB-RTBURBONSA-N
DMDMTZK IU methyl (2R)-2-phenyl-2-[(2R)-1-(pyridin-3-ylmethyl)piperidin-2-yl]acetate
DMDMTZK DE Discovery agent
DMIJ7PC ID DMIJ7PC
DMIJ7PC DN (+/-)-threo-N-(3-Methylthiopene)methylphenidate
DMIJ7PC HS Investigative
DMIJ7PC SN CHEMBL1254928; (+/-)-threo-N-(3-Methylthiopene)methylphenidate; BDBM50327130; (alphaR)-alpha-[(2R)-1-(3-Thienylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMIJ7PC DT Small molecular drug
DMIJ7PC PC 52947084
DMIJ7PC MW 329.5
DMIJ7PC FM C19H23NO2S
DMIJ7PC IC InChI=1S/C19H23NO2S/c1-22-19(21)18(16-7-3-2-4-8-16)17-9-5-6-11-20(17)13-15-10-12-23-14-15/h2-4,7-8,10,12,14,17-18H,5-6,9,11,13H2,1H3/t17-,18-/m1/s1
DMIJ7PC CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CSC=C2)C3=CC=CC=C3
DMIJ7PC IK LNROKOGUORZBBV-QZTJIDSGSA-N
DMIJ7PC IU methyl (2R)-2-phenyl-2-[(2R)-1-(thiophen-3-ylmethyl)piperidin-2-yl]acetate
DMIJ7PC DE Discovery agent
DMD926H ID DMD926H
DMD926H DN (+/-)-threo-N-(3-Phenylpropyl)methylphenidate
DMD926H HS Investigative
DMD926H SN CHEMBL1254196; (+/-)-threo-N-(3-Phenylpropyl)methylphenidate
DMD926H DT Small molecular drug
DMD926H PC 52948633
DMD926H MW 351.5
DMD926H FM C23H29NO2
DMD926H IC InChI=1S/C23H29NO2/c1-26-23(25)22(20-14-6-3-7-15-20)21-16-8-9-17-24(21)18-10-13-19-11-4-2-5-12-19/h2-7,11-12,14-15,21-22H,8-10,13,16-18H2,1H3/t21-,22-/m1/s1
DMD926H CS COC(=O)[C@@H]([C@H]1CCCCN1CCCC2=CC=CC=C2)C3=CC=CC=C3
DMD926H IK ALPWYQATULXWEM-FGZHOGPDSA-N
DMD926H IU methyl (2R)-2-phenyl-2-[(2R)-1-(3-phenylpropyl)piperidin-2-yl]acetate
DMD926H DE Discovery agent
DMVP183 ID DMVP183
DMVP183 DN (+/-)-threo-N-(3-Phenylpropyl)ritalinol
DMVP183 HS Investigative
DMVP183 SN CHEMBL1254359; (+/-)-threo-N-(3-Phenylpropyl)ritalinol
DMVP183 DT Small molecular drug
DMVP183 PC 52945256
DMVP183 MW 323.5
DMVP183 FM C22H29NO
DMVP183 IC InChI=1S/C22H29NO/c24-18-21(20-13-5-2-6-14-20)22-15-7-8-16-23(22)17-9-12-19-10-3-1-4-11-19/h1-6,10-11,13-14,21-22,24H,7-9,12,15-18H2/t21-,22-/m1/s1
DMVP183 CS C1CCN([C@H](C1)[C@H](CO)C2=CC=CC=C2)CCCC3=CC=CC=C3
DMVP183 IK QQICWLNJJOCDRX-FGZHOGPDSA-N
DMVP183 IU (2R)-2-phenyl-2-[(2R)-1-(3-phenylpropyl)piperidin-2-yl]ethanol
DMVP183 DE Discovery agent
DM3HWQY ID DM3HWQY
DM3HWQY DN (+/-)-threo-N-(4-Chlorobenzyl)methylphenidate
DM3HWQY HS Investigative
DM3HWQY SN CHEMBL1253840; (+/-)-threo-N-(4-Chlorobenzyl)methylphenidate
DM3HWQY DT Small molecular drug
DM3HWQY PC 52949753
DM3HWQY MW 357.9
DM3HWQY FM C21H24ClNO2
DM3HWQY IC InChI=1S/C21H24ClNO2/c1-25-21(24)20(17-7-3-2-4-8-17)19-9-5-6-14-23(19)15-16-10-12-18(22)13-11-16/h2-4,7-8,10-13,19-20H,5-6,9,14-15H2,1H3/t19-,20-/m1/s1
DM3HWQY CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)Cl)C3=CC=CC=C3
DM3HWQY IK SUYRDAUAEDYGHW-WOJBJXKFSA-N
DM3HWQY IU methyl (2R)-2-[(2R)-1-[(4-chlorophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DM3HWQY DE Discovery agent
DMHIKD2 ID DMHIKD2
DMHIKD2 DN (+/-)-threo-N-(4-Methoxybenzyl)methylphenidate
DMHIKD2 HS Investigative
DMHIKD2 SN CHEMBL1255100; (+/-)-threo-N-(4-Methoxybenzyl)methylphenidate
DMHIKD2 DT Small molecular drug
DMHIKD2 PC 52942312
DMHIKD2 MW 353.5
DMHIKD2 FM C22H27NO3
DMHIKD2 IC InChI=1S/C22H27NO3/c1-25-19-13-11-17(12-14-19)16-23-15-7-6-10-20(23)21(22(24)26-2)18-8-4-3-5-9-18/h3-5,8-9,11-14,20-21H,6-7,10,15-16H2,1-2H3/t20-,21-/m1/s1
DMHIKD2 CS COC1=CC=C(C=C1)CN2CCCC[C@@H]2[C@@H](C3=CC=CC=C3)C(=O)OC
DMHIKD2 IK PMKFGPNZRGUOSJ-NHCUHLMSSA-N
DMHIKD2 IU methyl (2R)-2-[(2R)-1-[(4-methoxyphenyl)methyl]piperidin-2-yl]-2-phenylacetate
DMHIKD2 DE Discovery agent
DM9QIAL ID DM9QIAL
DM9QIAL DN (+/-)-threo-N-(4-Methylpyridine)methylphenidate
DM9QIAL HS Investigative
DM9QIAL SN CHEMBL1254930; (+/-)-threo-N-(4-Methylpyridine)methylphenidate; BDBM50327128; (alphaR)-alpha-[(2R)-1-(4-Pyridinylmethyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DM9QIAL DT Small molecular drug
DM9QIAL PC 52950138
DM9QIAL MW 324.4
DM9QIAL FM C20H24N2O2
DM9QIAL IC InChI=1S/C20H24N2O2/c1-24-20(23)19(17-7-3-2-4-8-17)18-9-5-6-14-22(18)15-16-10-12-21-13-11-16/h2-4,7-8,10-13,18-19H,5-6,9,14-15H2,1H3/t18-,19-/m1/s1
DM9QIAL CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=NC=C2)C3=CC=CC=C3
DM9QIAL IK RLLOCIZJNXWKIC-RTBURBONSA-N
DM9QIAL IU methyl (2R)-2-phenyl-2-[(2R)-1-(pyridin-4-ylmethyl)piperidin-2-yl]acetate
DM9QIAL DE Discovery agent
DMB3JY8 ID DMB3JY8
DMB3JY8 DN (+/-)-threo-N-(4-Nitrobenzyl)methylphenidate
DMB3JY8 HS Investigative
DMB3JY8 SN CHEMBL1253839; (+/-)-threo-N-(4-Nitrobenzyl)methylphenidate
DMB3JY8 DT Small molecular drug
DMB3JY8 PC 52943636
DMB3JY8 MW 368.4
DMB3JY8 FM C21H24N2O4
DMB3JY8 IC InChI=1S/C21H24N2O4/c1-27-21(24)20(17-7-3-2-4-8-17)19-9-5-6-14-22(19)15-16-10-12-18(13-11-16)23(25)26/h2-4,7-8,10-13,19-20H,5-6,9,14-15H2,1H3/t19-,20-/m1/s1
DMB3JY8 CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=C(C=C2)[N+](=O)[O-])C3=CC=CC=C3
DMB3JY8 IK WXZFAWFIMBPTEP-WOJBJXKFSA-N
DMB3JY8 IU methyl (2R)-2-[(2R)-1-[(4-nitrophenyl)methyl]piperidin-2-yl]-2-phenylacetate
DMB3JY8 DE Discovery agent
DMK6IJW ID DMK6IJW
DMK6IJW DN (+/-)-threo-N-(4-Phenylbutyl)methylphenidate
DMK6IJW HS Investigative
DMK6IJW SN CHEMBL1254100; (+/-)-threo-N-(4-Phenylbutyl)methylphenidate; BDBM50327117; (alphaR)-alpha-[(2R)-1-(4-Phenylbutyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMK6IJW DT Small molecular drug
DMK6IJW PC 52946144
DMK6IJW MW 365.5
DMK6IJW FM C24H31NO2
DMK6IJW IC InChI=1S/C24H31NO2/c1-27-24(26)23(21-15-6-3-7-16-21)22-17-9-11-19-25(22)18-10-8-14-20-12-4-2-5-13-20/h2-7,12-13,15-16,22-23H,8-11,14,17-19H2,1H3/t22-,23-/m1/s1
DMK6IJW CS COC(=O)[C@@H]([C@H]1CCCCN1CCCCC2=CC=CC=C2)C3=CC=CC=C3
DMK6IJW IK TYKSHJPRQWJNHO-DHIUTWEWSA-N
DMK6IJW IU methyl (2R)-2-phenyl-2-[(2R)-1-(4-phenylbutyl)piperidin-2-yl]acetate
DMK6IJW DE Discovery agent
DMG3FA1 ID DMG3FA1
DMG3FA1 DN (+/-)-threo-N-(4-Phenylbutyl)ritalinol
DMG3FA1 HS Investigative
DMG3FA1 SN CHEMBL1254281; (+/-)-threo-N-(4-Phenylbutyl)ritalinol
DMG3FA1 DT Small molecular drug
DMG3FA1 PC 52941366
DMG3FA1 MW 337.5
DMG3FA1 FM C23H31NO
DMG3FA1 IC InChI=1S/C23H31NO/c25-19-22(21-14-5-2-6-15-21)23-16-8-10-18-24(23)17-9-7-13-20-11-3-1-4-12-20/h1-6,11-12,14-15,22-23,25H,7-10,13,16-19H2/t22-,23-/m1/s1
DMG3FA1 CS C1CCN([C@H](C1)[C@H](CO)C2=CC=CC=C2)CCCCC3=CC=CC=C3
DMG3FA1 IK MGISPZACVQKKJZ-DHIUTWEWSA-N
DMG3FA1 IU (2R)-2-phenyl-2-[(2R)-1-(4-phenylbutyl)piperidin-2-yl]ethanol
DMG3FA1 DE Discovery agent
DMHNQO9 ID DMHNQO9
DMHNQO9 DN (+/-)-threo-N-(5-Phenylpentyl)methylphenidate
DMHNQO9 HS Investigative
DMHNQO9 SN CHEMBL1254009; (+/-)-threo-N-(5-Phenylpentyl)methylphenidate; BDBM50327118; (alphaR)-alpha-[(2R)-1-(5-Phenylpentyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMHNQO9 DT Small molecular drug
DMHNQO9 PC 52943691
DMHNQO9 MW 379.5
DMHNQO9 FM C25H33NO2
DMHNQO9 IC InChI=1S/C25H33NO2/c1-28-25(27)24(22-16-8-3-9-17-22)23-18-10-12-20-26(23)19-11-4-7-15-21-13-5-2-6-14-21/h2-3,5-6,8-9,13-14,16-17,23-24H,4,7,10-12,15,18-20H2,1H3/t23-,24-/m1/s1
DMHNQO9 CS COC(=O)[C@@H]([C@H]1CCCCN1CCCCCC2=CC=CC=C2)C3=CC=CC=C3
DMHNQO9 IK CYCPZJLWKPRDTM-DNQXCXABSA-N
DMHNQO9 IU methyl (2R)-2-phenyl-2-[(2R)-1-(5-phenylpentyl)piperidin-2-yl]acetate
DMHNQO9 DE Discovery agent
DMG1K5H ID DMG1K5H
DMG1K5H DN (+/-)-threo-N-(6-Phenylhexyl)methylphenidate
DMG1K5H HS Investigative
DMG1K5H SN CHEMBL1254008; (+/-)-threo-N-(6-Phenylhexyl)methylphenidate; BDBM50327119; (alphaR)-alpha-[(2R)-1-(6-Phenylhexyl)-2beta-piperidinyl]benzeneacetic acid methyl ester
DMG1K5H DT Small molecular drug
DMG1K5H PC 52945263
DMG1K5H MW 393.6
DMG1K5H FM C26H35NO2
DMG1K5H IC InChI=1S/C26H35NO2/c1-29-26(28)25(23-17-9-5-10-18-23)24-19-11-13-21-27(24)20-12-3-2-6-14-22-15-7-4-8-16-22/h4-5,7-10,15-18,24-25H,2-3,6,11-14,19-21H2,1H3/t24-,25-/m1/s1
DMG1K5H CS COC(=O)[C@@H]([C@H]1CCCCN1CCCCCCC2=CC=CC=C2)C3=CC=CC=C3
DMG1K5H IK JMGUVGDMBREFCW-JWQCQUIFSA-N
DMG1K5H IU methyl (2R)-2-phenyl-2-[(2R)-1-(6-phenylhexyl)piperidin-2-yl]acetate
DMG1K5H DE Discovery agent
DMYNO71 ID DMYNO71
DMYNO71 DN (+/-)-threo-N-Allylmethylphenidate
DMYNO71 HS Investigative
DMYNO71 SN CHEMBL1253918; (+/-)-threo-N-Allylmethylphenidate
DMYNO71 DT Small molecular drug
DMYNO71 PC 52947332
DMYNO71 MW 273.37
DMYNO71 FM C17H23NO2
DMYNO71 IC InChI=1S/C17H23NO2/c1-3-12-18-13-8-7-11-15(18)16(17(19)20-2)14-9-5-4-6-10-14/h3-6,9-10,15-16H,1,7-8,11-13H2,2H3/t15-,16-/m1/s1
DMYNO71 CS COC(=O)[C@@H]([C@H]1CCCCN1CC=C)C2=CC=CC=C2
DMYNO71 IK WMEIWLRYZFKRDU-HZPDHXFCSA-N
DMYNO71 IU methyl (2R)-2-phenyl-2-[(2R)-1-prop-2-enylpiperidin-2-yl]acetate
DMYNO71 DE Discovery agent
DMOJXCK ID DMOJXCK
DMOJXCK DN (+/-)-threo-N-Benzyl-3',4'-dichlororitalinol
DMOJXCK HS Investigative
DMOJXCK SN CHEMBL1254675; BDBM50327175
DMOJXCK DT Small molecular drug
DMOJXCK PC 52945159
DMOJXCK MW 364.3
DMOJXCK FM C20H23Cl2NO
DMOJXCK IC InChI=1S/C20H23Cl2NO/c21-18-10-9-16(12-19(18)22)17(14-24)20-8-4-5-11-23(20)13-15-6-2-1-3-7-15/h1-3,6-7,9-10,12,17,20,24H,4-5,8,11,13-14H2/t17-,20-/m1/s1
DMOJXCK CS C1CCN([C@H](C1)[C@H](CO)C2=CC(=C(C=C2)Cl)Cl)CC3=CC=CC=C3
DMOJXCK IK NRJOAYKSGZHTCR-YLJYHZDGSA-N
DMOJXCK IU (2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-(3,4-dichlorophenyl)ethanol
DMOJXCK DE Discovery agent
DM15LE0 ID DM15LE0
DM15LE0 DN (+/-)-threo-N-Benzyl-3'-chloromethylphenidate
DM15LE0 HS Investigative
DM15LE0 SN CHEMBL1254517; BDBM50327168
DM15LE0 DT Small molecular drug
DM15LE0 PC 52945094
DM15LE0 MW 357.9
DM15LE0 FM C21H24ClNO2
DM15LE0 IC InChI=1S/C21H24ClNO2/c1-25-21(24)20(17-10-7-11-18(22)14-17)19-12-5-6-13-23(19)15-16-8-3-2-4-9-16/h2-4,7-11,14,19-20H,5-6,12-13,15H2,1H3/t19-,20-/m1/s1
DM15LE0 CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2)C3=CC(=CC=C3)Cl
DM15LE0 IK QUIVXFJDADACBW-WOJBJXKFSA-N
DM15LE0 IU methyl (2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-(3-chlorophenyl)acetate
DM15LE0 DE Discovery agent
DMUACDH ID DMUACDH
DMUACDH DN (+/-)-threo-N-Benzylmethylphenidate amide
DMUACDH HS Investigative
DMUACDH SN CHEMBL1254596; (+/-)-threo-N-Benzylmethylphenidate amide
DMUACDH DT Small molecular drug
DMUACDH PC 52946374
DMUACDH MW 308.4
DMUACDH FM C20H24N2O
DMUACDH IC InChI=1S/C20H24N2O/c21-20(23)19(17-11-5-2-6-12-17)18-13-7-8-14-22(18)15-16-9-3-1-4-10-16/h1-6,9-12,18-19H,7-8,13-15H2,(H2,21,23)/t18-,19-/m1/s1
DMUACDH CS C1CCN([C@H](C1)[C@@H](C2=CC=CC=C2)C(=O)N)CC3=CC=CC=C3
DMUACDH IK UMTRWYIEQNNYPX-RTBURBONSA-N
DMUACDH IU (2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-phenylacetamide
DMUACDH DE Discovery agent
DM6D18M ID DM6D18M
DM6D18M DN (+/-)-threo-N-Methyl-30-methylmethylphenidate
DM6D18M HS Investigative
DM6D18M SN CHEMBL19686; BDBM50291690; (R)-((R)-1-Methyl-piperidin-2-yl)-m-tolyl-acetic acid methyl ester
DM6D18M DT Small molecular drug
DM6D18M PC 44273085
DM6D18M MW 261.36
DM6D18M FM C16H23NO2
DM6D18M IC InChI=1S/C16H23NO2/c1-12-7-6-8-13(11-12)15(16(18)19-3)14-9-4-5-10-17(14)2/h6-8,11,14-15H,4-5,9-10H2,1-3H3/t14-,15-/m1/s1
DM6D18M CS CC1=CC(=CC=C1)[C@H]([C@H]2CCCCN2C)C(=O)OC
DM6D18M IK NEQATLAJGKQCLO-HUUCEWRRSA-N
DM6D18M IU methyl (2R)-2-(3-methylphenyl)-2-[(2R)-1-methylpiperidin-2-yl]acetate
DM6D18M DE Discovery agent
DMYE0MZ ID DMYE0MZ
DMYE0MZ DN (+/-)-threo-N-Propargylmethylphenidate
DMYE0MZ HS Investigative
DMYE0MZ SN CHEMBL1254282; (+/-)-threo-N-Propargylmethylphenidate
DMYE0MZ DT Small molecular drug
DMYE0MZ PC 52948667
DMYE0MZ MW 271.35
DMYE0MZ FM C17H21NO2
DMYE0MZ IC InChI=1S/C17H21NO2/c1-3-12-18-13-8-7-11-15(18)16(17(19)20-2)14-9-5-4-6-10-14/h1,4-6,9-10,15-16H,7-8,11-13H2,2H3/t15-,16-/m1/s1
DMYE0MZ CS COC(=O)[C@@H]([C@H]1CCCCN1CC#C)C2=CC=CC=C2
DMYE0MZ IK JZWSHRDYZHBSBM-HZPDHXFCSA-N
DMYE0MZ IU methyl (2R)-2-phenyl-2-[(2R)-1-prop-2-ynylpiperidin-2-yl]acetate
DMYE0MZ DE Discovery agent
DMM2QOX ID DMM2QOX
DMM2QOX DN (+/-)-TRANS-U-50488 METHANESULFONATE
DMM2QOX HS Investigative
DMM2QOX SN NCG-C00093883-01
DMM2QOX DT Small molecular drug
DMM2QOX PC 9912313
DMM2QOX MW 465.4
DMM2QOX FM C20H30Cl2N2O4S
DMM2QOX IC InChI=1S/C19H26Cl2N2O.CH4O3S/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23;1-5(2,3)4/h8-9,12,17-18H,2-7,10-11,13H2,1H3;1H3,(H,2,3,4)/t17-,18-;/m0./s1
DMM2QOX CS CN([C@H]1CCCC[C@@H]1N2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.CS(=O)(=O)O
DMM2QOX IK OJPHNZCUXUUVKU-APTPAJQOSA-N
DMM2QOX IU 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S,2S)-2-pyrrolidin-1-ylcyclohexyl]acetamide;methanesulfonic acid
DMM2QOX DE Discovery agent
DMDK59X ID DMDK59X
DMDK59X DN (1,1-Difluoro-pentadecyl)-phosphonic acid
DMDK59X HS Investigative
DMDK59X SN CHEMBL188859; (1,1-Difluoro-pentadecyl)-phosphonic acid; SCHEMBL193245; YGXPAGSHLFJKFV-UHFFFAOYSA-N; BDBM50170861; ZINC36178965; (1,1-Difluoro-pentadecyl)Phosphonic Acid; (1,1-Difluoro-pentadecyl) Phosphonic Acid
DMDK59X DT Small molecular drug
DMDK59X PC 11393306
DMDK59X MW 328.37
DMDK59X FM C15H31F2O3P
DMDK59X IC InChI=1S/C15H31F2O3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(16,17)21(18,19)20/h2-14H2,1H3,(H2,18,19,20)
DMDK59X CS CCCCCCCCCCCCCCC(F)(F)P(=O)(O)O
DMDK59X IK YGXPAGSHLFJKFV-UHFFFAOYSA-N
DMDK59X IU 1,1-difluoropentadecylphosphonic acid
DMDK59X DE Discovery agent
DMF6WHC ID DMF6WHC
DMF6WHC DN (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol
DMF6WHC HS Investigative
DMF6WHC SN 63006-93-9; (1,2,3,4-Tetrahydroisoquinolin-3-yl)methanol; 1,2,3,4-Tetrahydroisoquinoline-3-methanol; (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol; 1,2,3,4-tetrahydroisoquinolin-3-ylmethanol; (S)-(-)-1,2,3,4-Tetrahydro-3-isoquinolinemethanol; 62928-94-3; CHEMBL60068; 1,2,3,4-tetrahydro-3-isoquinolinemethanol; 3-Isoquinolinemethanol, 1,2,3,4-tetrahydro-; 3-Hydroxymethyl-1,2,3,4-tetrahydroisoquinoline; F2147-1627; PubChem5794; AC1MWNWL; (S)-1,2,3,4-Tetrahydroisoquinolylmethan-3-ol; ACMC-209err; ChemDiv2_003241
DMF6WHC DT Small molecular drug
DMF6WHC PC 3752277
DMF6WHC MW 163.22
DMF6WHC FM C10H13NO
DMF6WHC IC InChI=1S/C10H13NO/c12-7-10-5-8-3-1-2-4-9(8)6-11-10/h1-4,10-12H,5-7H2
DMF6WHC CS C1C(NCC2=CC=CC=C21)CO
DMF6WHC IK ZSKDXMLMMQFHGW-UHFFFAOYSA-N
DMF6WHC IU 1,2,3,4-tetrahydroisoquinolin-3-ylmethanol
DMF6WHC DE Discovery agent
DM2J9RI ID DM2J9RI
DM2J9RI DN (10H-phenothiazin-10-yl)(m-tolyl)methanone
DM2J9RI HS Investigative
DM2J9RI SN CHEMBL239401; AC1MRTR9; (10H-phenothiazin-10-yl)(m-tolyl)methanone; Oprea1_358386; BDBM50219209; AKOS005197735; AKOS002684869
DM2J9RI DT Small molecular drug
DM2J9RI PC 3473842
DM2J9RI MW 317.4
DM2J9RI FM C20H15NOS
DM2J9RI IC InChI=1S/C20H15NOS/c1-14-7-6-8-15(13-14)20(22)21-16-9-2-4-11-18(16)23-19-12-5-3-10-17(19)21/h2-13H,1H3
DM2J9RI CS CC1=CC(=CC=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM2J9RI IK JSMJNESPMFVMAA-UHFFFAOYSA-N
DM2J9RI IU (3-methylphenyl)-phenothiazin-10-ylmethanone
DM2J9RI DE Discovery agent
DM8BKTV ID DM8BKTV
DM8BKTV DN (10H-phenothiazin-10-yl)(o-tolyl)methanone
DM8BKTV HS Investigative
DM8BKTV SN CHEMBL397099; AC1MRTR1; (10H-phenothiazin-10-yl)(o-tolyl)methanone; Oprea1_791821; BDBM50219215
DM8BKTV DT Small molecular drug
DM8BKTV PC 3473839
DM8BKTV MW 317.4
DM8BKTV FM C20H15NOS
DM8BKTV IC InChI=1S/C20H15NOS/c1-14-8-2-3-9-15(14)20(22)21-16-10-4-6-12-18(16)23-19-13-7-5-11-17(19)21/h2-13H,1H3
DM8BKTV CS CC1=CC=CC=C1C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM8BKTV IK PYIIIOAOKBCILO-UHFFFAOYSA-N
DM8BKTV IU (2-methylphenyl)-phenothiazin-10-ylmethanone
DM8BKTV DE Discovery agent
DMT3GAD ID DMT3GAD
DMT3GAD DN (10H-phenothiazin-10-yl)(phenyl)methanone
DMT3GAD HS Investigative
DMT3GAD SN 10h-phenothiazin-10-yl(phenyl)methanone; CHEMBL239400; phenothiazin-10-yl(phenyl)methanone; 10-BENZOYL-10H-PHENOTHIAZINE; 38076-73-2; NSC95774; 10-benzoylphenothiazine; (10H-phenothiazin-10-yl)(phenyl)methanone; AC1Q5K0F; Oprea1_507390; Oprea1_637573; SCHEMBL343497; AC1L678I; CTK4H9286; phenyl phenothiazin-10-yl ketone; DTXSID00294306; MolPort-000-182-685; ZINC402121; NSC-95774; BDBM50219217; STL371969; AKOS000279791; MCULE-2324671928
DMT3GAD DT Small molecular drug
DMT3GAD PC 262319
DMT3GAD MW 303.4
DMT3GAD FM C19H13NOS
DMT3GAD IC InChI=1S/C19H13NOS/c21-19(14-8-2-1-3-9-14)20-15-10-4-6-12-17(15)22-18-13-7-5-11-16(18)20/h1-13H
DMT3GAD CS C1=CC=C(C=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMT3GAD IK RVBAUHGQSLEOSR-UHFFFAOYSA-N
DMT3GAD IU phenothiazin-10-yl(phenyl)methanone
DMT3GAD CA CAS 38076-73-2
DMT3GAD DE Discovery agent
DMRQ0ZF ID DMRQ0ZF
DMRQ0ZF DN (10H-phenothiazin-10-yl)(p-tolyl)methanone
DMRQ0ZF HS Investigative
DMRQ0ZF SN CHEMBL397100; AC1MRSS1; (10H-phenothiazin-10-yl)(p-tolyl)methanone; Oprea1_194230; MLS002608923; cid_3473393; CHEBI:93656; BDBM50219212; SMR001537727; (4-methylphenyl)-phenothiazin-10-ylmethanone
DMRQ0ZF DT Small molecular drug
DMRQ0ZF PC 3473393
DMRQ0ZF MW 317.4
DMRQ0ZF FM C20H15NOS
DMRQ0ZF IC InChI=1S/C20H15NOS/c1-14-10-12-15(13-11-14)20(22)21-16-6-2-4-8-18(16)23-19-9-5-3-7-17(19)21/h2-13H,1H3
DMRQ0ZF CS CC1=CC=C(C=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMRQ0ZF IK BXCIQPXSBSOIQX-UHFFFAOYSA-N
DMRQ0ZF IU (4-methylphenyl)-phenothiazin-10-ylmethanone
DMRQ0ZF CB CHEBI:93656
DMRQ0ZF DE Discovery agent
DMVTLF9 ID DMVTLF9
DMVTLF9 DN (10r)-10-Formyl-5,8,10-Trideazafolic Acid
DMVTLF9 HS Investigative
DMVTLF9 SN (10R)-10-FORMYL-5,8,10-TRIDEAZAFOLIC ACID; NHR; 2-{4-[2-(2-AMINO-4-HYDROXY-QUINAZOLIN-6-YL)-1-CARBOXY-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; 1c3e; AC1L9GSR; DB04264; 8937-EP2308866A1; 8937-EP2308846A2; 8937-EP2305697A2; 8937-EP2298780A1; 8937-EP2277872A1; 8937-EP2316829A1; 8937-EP2308872A1; 8937-EP2308845A2; 8937-EP2305698A2; 8937-EP2305695A2; 8937-EP2301932A1; 8937-EP2287167A1; 8937-EP2283898A1; 8937-EP2281563A1; 8937-EP2316459A1; 8937-EP2308844A2; 8937-EP2277869A1; 8937-EP2270018A1; 8937-EP2308812A2; 8937-EP2305696A2
DMVTLF9 DT Small molecular drug
DMVTLF9 PC 135460968
DMVTLF9 MW 482.4
DMVTLF9 FM C23H22N4O8
DMVTLF9 IC InChI=1S/C23H22N4O8/c24-23-26-16-6-1-11(10-15(16)20(31)27-23)9-14(21(32)33)12-2-4-13(5-3-12)19(30)25-17(22(34)35)7-8-18(28)29/h1-6,10,14,17H,7-9H2,(H,25,30)(H,28,29)(H,32,33)(H,34,35)(H3,24,26,27,31)/t14-,17+/m1/s1
DMVTLF9 CS C1=CC(=CC=C1[C@@H](CC2=CC3=C(C=C2)N=C(NC3=O)N)C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMVTLF9 IK DAOQLLQRJAXMGY-PBHICJAKSA-N
DMVTLF9 IU (2S)-2-[[4-[(1R)-2-(2-amino-4-oxo-3H-quinazolin-6-yl)-1-carboxyethyl]benzoyl]amino]pentanedioic acid
DMVTLF9 DE Discovery agent
DMTPQ84 ID DMTPQ84
DMTPQ84 DN (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE
DMTPQ84 HS Investigative
DMTPQ84 SN Corticosterone; CORTICOSTERONE; 50-22-6; 17-Deoxycortisol; Reichstein's substance H; Kendall's compound B; Corticosteron; 11beta,21-Dihydroxyprogesterone; Compound B; Reichstein's B; 11-Hydroxycorticoaldosterone; (11beta)-11,21-Dihydroxypregn-4-ene-3,20-dione; 11beta,21-Dihydroxy-4-pregnene-3,20-dione; 4-Pregnene-11beta,21-diol-3,20-dione; 11,21-Dihydroxyprogesterone; 11Beta,21-dihydroxypregn-4-ene-3,20-dione; 11,12-Dihydroxyprogesterone; UNII-W980KJ009P; CCRIS 6753; 11-beta,21-Dihydroxypregn-3,20-dione; CHEBI:16827; NSC9705; corticosterone
DMTPQ84 DT Small molecular drug
DMTPQ84 PC 5753
DMTPQ84 MW 346.5
DMTPQ84 FM C21H30O4
DMTPQ84 IC InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1
DMTPQ84 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@H]4C(=O)CO)C)O
DMTPQ84 IK OMFXVFTZEKFJBZ-HJTSIMOOSA-N
DMTPQ84 IU (8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMTPQ84 CA CAS 50-22-6
DMTPQ84 CB CHEBI:16827
DMTPQ84 DE Discovery agent
DMZ5YMH ID DMZ5YMH
DMZ5YMH DN (11E)-OCTADEC-11-ENOIC ACID
DMZ5YMH HS Investigative
DMZ5YMH SN cis-vaccenic acid; (Z)-octadec-11-enoic acid; cis-11-Octadecenoic acid; 506-17-2; 11Z-Octadecenoic acid; (11E)-octadec-11-enoic acid; Asclepic acid; (Z)-11-Octadecenoic acid; 11-Octadecenoic acid, (Z)-; UNII-400K7322UW; CHEBI:50464; 400K7322UW; cis-octadec-11-enoic acid; VCA; trans-11-Octadecensaeure; 11-cis-Octadecenoic acid; C18:1n-7; cis-11-Vaccenic acid; AC1NR0QT; 11(Z)-Octadecenoic acid; cis-D11-Octadecenoic acid; SCHEMBL97463; (11Z)octadec-11-enoic acid; (11Z)-octadec-11-enoic acid; CHEMBL1236642; UWHZIFQPPBDJPM-FPLPWBNLSA-N
DMZ5YMH DT Small molecular drug
DMZ5YMH PC 5282761
DMZ5YMH MW 282.5
DMZ5YMH FM C18H34O2
DMZ5YMH IC InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h7-8H,2-6,9-17H2,1H3,(H,19,20)/b8-7-
DMZ5YMH CS CCCCCC/C=C\\CCCCCCCCCC(=O)O
DMZ5YMH IK UWHZIFQPPBDJPM-FPLPWBNLSA-N
DMZ5YMH IU (Z)-octadec-11-enoic acid
DMZ5YMH CA CAS 506-17-2
DMZ5YMH CB CHEBI:50464
DMZ5YMH DE Discovery agent
DMSUPVE ID DMSUPVE
DMSUPVE DN (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid
DMSUPVE HS Investigative
DMSUPVE SN CHEMBL33378; ZINC29221898
DMSUPVE DT Small molecular drug
DMSUPVE PC 13640140
DMSUPVE MW 256.25
DMSUPVE FM C15H12O4
DMSUPVE IC InChI=1S/C15H12O4/c16-15(17)8-10-5-6-12-11(7-10)9-18-13-3-1-2-4-14(13)19-12/h1-7H,8-9H2,(H,16,17)
DMSUPVE CS C1C2=C(C=CC(=C2)CC(=O)O)OC3=CC=CC=C3O1
DMSUPVE IK UCLQILVHNXYKJH-UHFFFAOYSA-N
DMSUPVE IU 2-(6H-benzo[b][1,4]benzodioxepin-8-yl)acetic acid
DMSUPVE DE Discovery agent
DM5ZTXL ID DM5ZTXL
DM5ZTXL DN (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid
DM5ZTXL HS Investigative
DM5ZTXL SN CHEMBL32961; ZINC29223888
DM5ZTXL DT Small molecular drug
DM5ZTXL PC 13640143
DM5ZTXL MW 256.25
DM5ZTXL FM C15H12O4
DM5ZTXL IC InChI=1S/C15H12O4/c16-15(17)8-10-5-6-13-14(7-10)19-12-4-2-1-3-11(12)9-18-13/h1-7H,8-9H2,(H,16,17)
DM5ZTXL CS C1C2=CC=CC=C2OC3=C(O1)C=CC(=C3)CC(=O)O
DM5ZTXL IK MREFHNNUMIAIHP-UHFFFAOYSA-N
DM5ZTXL IU 2-(6H-benzo[b][1,4]benzodioxepin-2-yl)acetic acid
DM5ZTXL DE Discovery agent
DMBY623 ID DMBY623
DMBY623 DN (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid
DMBY623 HS Investigative
DMBY623 SN CHEMBL33814; ZINC29223313
DMBY623 DT Small molecular drug
DMBY623 PC 13640144
DMBY623 MW 256.25
DMBY623 FM C15H12O4
DMBY623 IC InChI=1S/C15H12O4/c16-15(17)8-10-5-6-13-14(7-10)18-9-11-3-1-2-4-12(11)19-13/h1-7H,8-9H2,(H,16,17)
DMBY623 CS C1C2=CC=CC=C2OC3=C(O1)C=C(C=C3)CC(=O)O
DMBY623 IK QTBPZEAQRRAFFF-UHFFFAOYSA-N
DMBY623 IU 2-(6H-benzo[b][1,4]benzodioxepin-3-yl)acetic acid
DMBY623 DE Discovery agent
DMJNLQ5 ID DMJNLQ5
DMJNLQ5 DN (12E,20Z,18S)-8-hydroxyvariabilin
DMJNLQ5 HS Investigative
DMJNLQ5 SN (12E,20Z,18S)-8-hydroxyvariabilin; GTPL4072
DMJNLQ5 DT Small molecular drug
DMJNLQ5 PC 54726845
DMJNLQ5 MW 416.5
DMJNLQ5 FM C25H36O5
DMJNLQ5 IC InChI=1S/C25H36O5/c1-18(8-5-9-19(2)16-22-23(26)20(3)24(27)30-22)10-6-13-25(4,28)14-7-11-21-12-15-29-17-21/h10,12,15-17,19,26,28H,5-9,11,13-14H2,1-4H3/b18-10+,22-16-/t19-,25?/m0/s1
DMJNLQ5 CS CC1=C(/C(=C/[C@@H](C)CCC/C(=C/CCC(C)(CCCC2=COC=C2)O)/C)/OC1=O)O
DMJNLQ5 IK QFBUNOKEKXMSCV-UYYPKTQPSA-N
DMJNLQ5 IU (5Z)-5-[(E,2S)-13-(furan-3-yl)-10-hydroxy-2,6,10-trimethyltridec-6-enylidene]-4-hydroxy-3-methylfuran-2-one
DMJNLQ5 DE Discovery agent
DMXD8H1 ID DMXD8H1
DMXD8H1 DN (1-Amino-2-phenyl-ethyl)-phosphinic acid
DMXD8H1 HS Investigative
DMXD8H1 SN CHEMBL37846; 80744-66-7; (1-AMINO-2-PHENYLETHYL)PHOSPHINIC ACID; Phosphinic acid, (1-amino-2-phenylethyl)-; AC1O49RT; MLS004256549; SCHEMBL3862224; CTK5E8078; DTXSID90422994; APQRSTHZZSRXIS-UHFFFAOYSA-N; AKOS006273173; SMR003081569; (1-amino-2-phenylethyl)-hydroxy-oxophosphanium; Phosphinic acid,(1-amino-2-phenylethyl)- (9CI)
DMXD8H1 DT Small molecular drug
DMXD8H1 PC 54297424
DMXD8H1 MW 183.14
DMXD8H1 FM C8H10NO2P
DMXD8H1 IC InChI=1S/C8H10NO2P/c9-8(12(10)11)6-7-4-2-1-3-5-7/h1-5,9-11H,6H2
DMXD8H1 CS C1=CC=C(C=C1)CC(=N)P(O)O
DMXD8H1 IK SBTPFRFIHZOOQM-UHFFFAOYSA-N
DMXD8H1 IU (2-phenylethanimidoyl)phosphonous acid
DMXD8H1 DE Discovery agent
DMNUO79 ID DMNUO79
DMNUO79 DN (1-Amino-3-methyl-butyl)-phosphinic acid
DMNUO79 HS Investigative
DMNUO79 SN AC1O4HVH; Phosphinic acid, P-(1-amino-3-methylbutyl)-; SCHEMBL5037193; 80744-65-6
DMNUO79 DT Small molecular drug
DMNUO79 PC 54361028
DMNUO79 MW 149.13
DMNUO79 FM C5H12NO2P
DMNUO79 IC InChI=1S/C5H12NO2P/c1-4(2)3-5(6)9(7)8/h4,6-8H,3H2,1-2H3
DMNUO79 CS CC(C)CC(=N)P(O)O
DMNUO79 IK UMMREILHNONHFP-UHFFFAOYSA-N
DMNUO79 IU 3-methylbutanimidoylphosphonous acid
DMNUO79 DE Discovery agent
DMJL8QZ ID DMJL8QZ
DMJL8QZ DN (1-Amino-3-methylsulfanyl-propyl)-phosphinic acid
DMJL8QZ HS Investigative
DMJL8QZ SN METHIONINE PHOSPHINATE; (1-AMINO-3-METHYLSULFANYL-PROPYL)-PHOSPHINIC ACID; MPJ; AC1O4QJ4; SCHEMBL4316253; ZINC29326788; DB04015; [(1R)-1-amino-3-methylsulfanylpropyl]-hydroxy-oxophosphanium; (R)-[(1R)-1-amino-3-(methylsulfanyl)propyl]phosphinic acid
DMJL8QZ DT Small molecular drug
DMJL8QZ PC 6398483
DMJL8QZ MW 168.18
DMJL8QZ FM C4H11NO2PS+
DMJL8QZ IC InChI=1S/C4H10NO2PS/c1-9-3-2-4(5)8(6)7/h4H,2-3,5H2,1H3/p+1/t4-/m1/s1
DMJL8QZ CS CSCC[C@H](N)[P+](=O)O
DMJL8QZ IK BSTOZABDPPHMGK-SCSAIBSYSA-O
DMJL8QZ IU [(1R)-1-amino-3-methylsulfanylpropyl]-hydroxy-oxophosphanium
DMJL8QZ DE Discovery agent
DMXD697 ID DMXD697
DMXD697 DN (1-Amino-3-phenyl-propyl)-phosphinic acid
DMXD697 HS Investigative
DMXD697 SN SCHEMBL11199485
DMXD697 DT Small molecular drug
DMXD697 PC 91931115
DMXD697 MW 197.17
DMXD697 FM C9H12NO2P
DMXD697 IC InChI=1S/C9H12NO2P/c10-9(13(11)12)7-6-8-4-2-1-3-5-8/h1-5,10-12H,6-7H2
DMXD697 CS C1=CC=C(C=C1)CCC(=N)P(O)O
DMXD697 IK YDYGVRIQAWAHCJ-UHFFFAOYSA-N
DMXD697 IU 3-phenylpropanimidoylphosphonous acid
DMXD697 DE Discovery agent
DMUACZF ID DMUACZF
DMUACZF DN (1-Amino-ethyl)-phosphinic acid
DMUACZF HS Investigative
DMUACZF SN 1-Aminoethylphosphinic acid; AMINOETHYLPHOSPHINIC ACID; 74333-44-1; 71937-28-5; 1-Aminoethylphosphinate; (1-Aminoethyl)phosphonous acid; Aminoethylphosphinic acid [INCI]; Phosphinic acid, (1-aminoethyl)-; Phosphinic acid, P-(1-aminoethyl)-; AC1O4DZP; Phosphinic acid, (1-aminoethyl)-, (+/-)-; 1-aminoethyl phosphinic acid; SCHEMBL579981; (1-aminoethyl)phosphinic acid; (1-Aminoethyl)-phosphinic acid; CTK5D5277; TVKUNRSARHGLNB-UHFFFAOYSA-N; 1-aminoethyl-hydroxy-oxophosphanium; AKOS006273172; Phosphinic acid, (1-aminoethyl)-, (-)-
DMUACZF DT Small molecular drug
DMUACZF PC 53957231
DMUACZF MW 107.05
DMUACZF FM C2H6NO2P
DMUACZF IC InChI=1S/C2H6NO2P/c1-2(3)6(4)5/h3-5H,1H3
DMUACZF CS CC(=N)P(O)O
DMUACZF IK JIMKERQURQBVPW-UHFFFAOYSA-N
DMUACZF IU ethanimidoylphosphonous acid
DMUACZF DE Discovery agent
DMNIP7J ID DMNIP7J
DMNIP7J DN (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine
DMNIP7J HS Investigative
DMNIP7J SN CHEMBL284485; (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8561085; BDBM50099965
DMNIP7J DT Small molecular drug
DMNIP7J PC 44279444
DMNIP7J MW 351.4
DMNIP7J FM C22H17N5
DMNIP7J IC InChI=1S/C22H17N5/c1-2-6-16(7-3-1)14-27-21-11-10-18(12-17(21)13-25-27)26-22-19-8-4-5-9-20(19)23-15-24-22/h1-13,15H,14H2,(H,23,24,26)
DMNIP7J CS C1=CC=C(C=C1)CN2C3=C(C=C(C=C3)NC4=NC=NC5=CC=CC=C54)C=N2
DMNIP7J IK FIBNGENIDQNCFP-UHFFFAOYSA-N
DMNIP7J IU N-(1-benzylindazol-5-yl)quinazolin-4-amine
DMNIP7J DE Discovery agent
DM0SCW9 ID DM0SCW9
DM0SCW9 DN (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine
DM0SCW9 HS Investigative
DM0SCW9 SN CHEMBL287591; (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine; SCHEMBL8554934; BDBM50099967
DM0SCW9 DT Small molecular drug
DM0SCW9 PC 44279279
DM0SCW9 MW 350.4
DM0SCW9 FM C23H18N4
DM0SCW9 IC InChI=1S/C23H18N4/c1-2-6-17(7-3-1)15-27-13-12-18-14-19(10-11-22(18)27)26-23-20-8-4-5-9-21(20)24-16-25-23/h1-14,16H,15H2,(H,24,25,26)
DM0SCW9 CS C1=CC=C(C=C1)CN2C=CC3=C2C=CC(=C3)NC4=NC=NC5=CC=CC=C54
DM0SCW9 IK HSEFNFDMTWKPLM-UHFFFAOYSA-N
DM0SCW9 IU N-(1-benzylindol-5-yl)quinazolin-4-amine
DM0SCW9 CA CAS 187667-74-9
DM0SCW9 DE Discovery agent
DMWK3RO ID DMWK3RO
DMWK3RO DN (1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester
DMWK3RO HS Investigative
DMWK3RO SN Cbz-L-Phenylalaninal; 59830-60-3; (S)-Benzyl (1-oxo-3-phenylpropan-2-yl)carbamate; CHEMBL412423; AK-43912; N-Cbz-phenylalaninal; PubChem16008; N-Cbz-L-Phenylalaninal; AC1ODUQ7; (1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester; SCHEMBL630290; KS-00000FVM; DTXSID40427338; ZX-AFC000446; MolPort-009-682-951; HZDPJHOWPIVWMR-INIZCTEOSA-N; n-benzyloxycarbonyl-l-phenylalaninal; ZINC2569810; BDBM50014568; 8910AB; ANW-72305; AKOS005146049; CC-1855; KB-75975; N-((Benzyloxy)carbonyl)-L-phenylalaninal; AC-23793; DS-14328; AJ-41774; AX8120205
DMWK3RO DT Small molecular drug
DMWK3RO PC 7021150
DMWK3RO MW 283.32
DMWK3RO FM C17H17NO3
DMWK3RO IC InChI=1S/C17H17NO3/c19-12-16(11-14-7-3-1-4-8-14)18-17(20)21-13-15-9-5-2-6-10-15/h1-10,12,16H,11,13H2,(H,18,20)/t16-/m0/s1
DMWK3RO CS C1=CC=C(C=C1)C[C@@H](C=O)NC(=O)OCC2=CC=CC=C2
DMWK3RO IK HZDPJHOWPIVWMR-INIZCTEOSA-N
DMWK3RO IU benzyl N-[(2S)-1-oxo-3-phenylpropan-2-yl]carbamate
DMWK3RO CA CAS 59830-60-3
DMWK3RO DE Discovery agent
DMPKM9B ID DMPKM9B
DMPKM9B DN (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine
DMPKM9B HS Investigative
DMPKM9B SN CHEMBL74544; 1H-Benzimidazol-6-amine, N-1H-imidazol-2-yl-; 185312-13-4; (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine; BDBM50055831; AKOS027401219
DMPKM9B DT Small molecular drug
DMPKM9B PC 10655607
DMPKM9B MW 199.21
DMPKM9B FM C10H9N5
DMPKM9B IC InChI=1S/C10H9N5/c1-2-8-9(14-6-13-8)5-7(1)15-10-11-3-4-12-10/h1-6H,(H,13,14)(H2,11,12,15)
DMPKM9B CS C1=CC2=C(C=C1NC3=NC=CN3)NC=N2
DMPKM9B IK NFSIDEIKDWWMOX-UHFFFAOYSA-N
DMPKM9B IU N-(1H-imidazol-2-yl)-3H-benzimidazol-5-amine
DMPKM9B DE Discovery agent
DM4FSTL ID DM4FSTL
DM4FSTL DN (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl
DM4FSTL HS Investigative
DM4FSTL SN CHEMBL19533; BDBM50011598; ZINC13821052; 4-Phenylamino-1H-imidazo[4,5-c]quinoline
DM4FSTL DT Small molecular drug
DM4FSTL PC 14896611
DM4FSTL MW 260.29
DM4FSTL FM C16H12N4
DM4FSTL IC InChI=1S/C16H12N4/c1-2-6-11(7-3-1)19-16-15-14(17-10-18-15)12-8-4-5-9-13(12)20-16/h1-10H,(H,17,18)(H,19,20)
DM4FSTL CS C1=CC=C(C=C1)NC2=NC3=CC=CC=C3C4=C2NC=N4
DM4FSTL IK BWQWMNKFCIJEBY-UHFFFAOYSA-N
DM4FSTL IU N-phenyl-3H-imidazo[4,5-c]quinolin-4-amine
DM4FSTL DE Discovery agent
DMRDHL2 ID DMRDHL2
DMRDHL2 DN (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine
DMRDHL2 HS Investigative
DMRDHL2 SN CHEMBL74449; 6-Quinoxalinamine, N-1H-imidazol-2-yl-; (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine; BDBM50055838
DMRDHL2 DT Small molecular drug
DMRDHL2 PC 10632290
DMRDHL2 MW 211.22
DMRDHL2 FM C11H9N5
DMRDHL2 IC InChI=1S/C11H9N5/c1-2-9-10(13-4-3-12-9)7-8(1)16-11-14-5-6-15-11/h1-7H,(H2,14,15,16)
DMRDHL2 CS C1=CC2=NC=CN=C2C=C1NC3=NC=CN3
DMRDHL2 IK CDFWKVORAWOKDO-UHFFFAOYSA-N
DMRDHL2 IU N-(1H-imidazol-2-yl)quinoxalin-6-amine
DMRDHL2 DE Discovery agent
DM21CXZ ID DM21CXZ
DM21CXZ DN (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ HS Investigative
DM21CXZ SN CHEMBL7296; Bis(1H-2-indolyl)methanone 11; AC1NS9BZ; BDBM6573; ZINC8571; SCHEMBL6865103; 5-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-5-methoxy-1H-indole; 1H-indol-2-yl-(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ DT Small molecular drug
DM21CXZ PC 5330527
DM21CXZ MW 290.3
DM21CXZ FM C18H14N2O2
DM21CXZ IC InChI=1S/C18H14N2O2/c1-22-13-6-7-15-12(8-13)10-17(20-15)18(21)16-9-11-4-2-3-5-14(11)19-16/h2-10,19-20H,1H3
DM21CXZ CS COC1=CC2=C(C=C1)NC(=C2)C(=O)C3=CC4=CC=CC=C4N3
DM21CXZ IK QTIQVLAVCXXZPS-UHFFFAOYSA-N
DM21CXZ IU 1H-indol-2-yl-(5-methoxy-1H-indol-2-yl)methanone
DM21CXZ DE Discovery agent
DM94XJ2 ID DM94XJ2
DM94XJ2 DN (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2 HS Investigative
DM94XJ2 SN CHEMBL210425; (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2 DT Small molecular drug
DM94XJ2 PC 44411967
DM94XJ2 MW 352.4
DM94XJ2 FM C23H16N2O2
DM94XJ2 IC InChI=1S/C23H16N2O2/c26-23(21-13-15-6-4-5-9-19(15)24-21)22-14-16-12-18(10-11-20(16)25-22)27-17-7-2-1-3-8-17/h1-14,24-25H
DM94XJ2 CS C1=CC=C(C=C1)OC2=CC3=C(C=C2)NC(=C3)C(=O)C4=CC5=CC=CC=C5N4
DM94XJ2 IK XSKBJPGCRXDUEV-UHFFFAOYSA-N
DM94XJ2 IU 1H-indol-2-yl-(5-phenoxy-1H-indol-2-yl)methanone
DM94XJ2 DE Discovery agent
DM7KDNM ID DM7KDNM
DM7KDNM DN (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM HS Investigative
DM7KDNM SN CHEMBL7602; Bis(1H-2-indolyl)methanone 12; AC1NS9C2; SCHEMBL6864570; BDBM6574; ZINC13472534; 6-Methoxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-6-methoxy-1H-indole; 1H-indol-2-yl-(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM DT Small molecular drug
DM7KDNM PC 5330528
DM7KDNM MW 290.3
DM7KDNM FM C18H14N2O2
DM7KDNM IC InChI=1S/C18H14N2O2/c1-22-13-7-6-12-9-17(20-15(12)10-13)18(21)16-8-11-4-2-3-5-14(11)19-16/h2-10,19-20H,1H3
DM7KDNM CS COC1=CC2=C(C=C1)C=C(N2)C(=O)C3=CC4=CC=CC=C4N3
DM7KDNM IK RSMLCEQJLGXMPQ-UHFFFAOYSA-N
DM7KDNM IU 1H-indol-2-yl-(6-methoxy-1H-indol-2-yl)methanone
DM7KDNM DE Discovery agent
DMW15DS ID DMW15DS
DMW15DS DN (1H-indol-2-yl)(piperazin-1-yl)methanone
DMW15DS HS Investigative
DMW15DS SN 2-(piperazin-1-ylcarbonyl)-1H-indole; 136818-95-6; CHEMBL129660; 1H-indol-2-yl-1-piperazinyl-Methanone; 1H-indol-2-yl(piperazin-1-yl)methanone; 2-(piperazine-1-carbonyl)-1H-indole; (1H-Indol-2-yl)-piperazin-1-yl-methanone; piperazoylindole; AC1LJDZ7; (1H-indol-2-yl)(piperazin-1-yl)methanone; Oprea1_711133; SCHEMBL2679610; DTXSID30358889; MolPort-002-566-226; FIVCRRVYLAXYFC-UHFFFAOYSA-N; ZINC509902; ALBB-016237; STL484224; BDBM50133002; 4012AD; AKOS000210389; MCULE-2536499366; NS-02944; Piperazine, 1-(1H-indol-2-ylcarbonyl)-
DMW15DS DT Small molecular drug
DMW15DS PC 921599
DMW15DS MW 229.28
DMW15DS FM C13H15N3O
DMW15DS IC InChI=1S/C13H15N3O/c17-13(16-7-5-14-6-8-16)12-9-10-3-1-2-4-11(10)15-12/h1-4,9,14-15H,5-8H2
DMW15DS CS C1CN(CCN1)C(=O)C2=CC3=CC=CC=C3N2
DMW15DS IK FIVCRRVYLAXYFC-UHFFFAOYSA-N
DMW15DS IU 1H-indol-2-yl(piperazin-1-yl)methanone
DMW15DS CA CAS 136818-95-6
DMW15DS DE Discovery agent
DMHEYOK ID DMHEYOK
DMHEYOK DN (1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone
DMHEYOK HS Investigative
DMHEYOK SN CHEMBL589252; Phenothiazin-10-yl-piperidin-1-yl-methanone; AC1LE3IL; ChemDiv3_004237; Oprea1_668518; ZINC91249; MolPort-001-995-166; HMS1485A13; STK004206; BDBM50308415; AKOS000643159; CCG-113845; MCULE-9139922844; IDI1_022147; BAS 04087808; phenothiazin-10-yl(piperidin-1-yl)methanone; SR-01000506180; 10H-phenothiazin-10-yl(piperidin-1-yl)methanone; SR-01000506180-1
DMHEYOK DT Small molecular drug
DMHEYOK PC 705775
DMHEYOK MW 310.4
DMHEYOK FM C18H18N2OS
DMHEYOK IC InChI=1S/C18H18N2OS/c21-18(19-12-6-1-7-13-19)20-14-8-2-4-10-16(14)22-17-11-5-3-9-15(17)20/h2-5,8-11H,1,6-7,12-13H2
DMHEYOK CS C1CCN(CC1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMHEYOK IK ZYAXTAFPNAMCKA-UHFFFAOYSA-N
DMHEYOK IU phenothiazin-10-yl(piperidin-1-yl)methanone
DMHEYOK DE Discovery agent
DMACN68 ID DMACN68
DMACN68 DN (1H-pyrazol-1-yl)(o-tolyl)methanone
DMACN68 HS Investigative
DMACN68 SN AC1LEF7F; Methanone, (2-methylphenyl)-1H-pyrazol-1-yl-; N-Benzoylpyrazole deriv., 26; SCHEMBL5091107; CHEMBL243419; 2-methylphenyl pyrazolyl ketone; ZINC52093; BDBM23718; MolPort-001-495-866; STK458861; AKOS003267448; MCULE-5548346973; (2-methylphenyl)-pyrazol-1-ylmethanone; ST073761; 312317-26-3; 1-[(2-methylphenyl)carbonyl]-1H-pyrazole; (2-methylphenyl)(1H-pyrazol-1-yl)methanone; SR-01000520970; SR-01000520970-1
DMACN68 DT Small molecular drug
DMACN68 PC 685230
DMACN68 MW 186.21
DMACN68 FM C11H10N2O
DMACN68 IC InChI=1S/C11H10N2O/c1-9-5-2-3-6-10(9)11(14)13-8-4-7-12-13/h2-8H,1H3
DMACN68 CS CC1=CC=CC=C1C(=O)N2C=CC=N2
DMACN68 IK RYSRFZOAAPABLM-UHFFFAOYSA-N
DMACN68 IU (2-methylphenyl)-pyrazol-1-ylmethanone
DMACN68 DE Discovery agent
DM5L8WX ID DM5L8WX
DM5L8WX DN (1-hydroxy-1-phosphono-heptyl)-phosphonic acid
DM5L8WX HS Investigative
DM5L8WX SN (1-Hydroxyheptane-1,1-Diyl)bis(Phosphonic Acid); CHEMBL55264; Phosphonic acid, (1-hydroxyheptylidene)bis-; (1-hydroxy-1-phosphonoheptyl)phosphonic acid; bisphosphonate, 10; AC1NQOTY; SCHEMBL10686529; BDBM25298; 1-Hydroxyheptylidenebisphosphonic acid; AKOS028110532; DB06830; 56375-74-7; 1-hydroxy-1-phosphonoheptylphosphonic acid; (1-hydroxy-1-phosphono-heptyl)phosphonic acid
DM5L8WX DT Small molecular drug
DM5L8WX PC 5276520
DM5L8WX MW 276.16
DM5L8WX FM C7H18O7P2
DM5L8WX IC InChI=1S/C7H18O7P2/c1-2-3-4-5-6-7(8,15(9,10)11)16(12,13)14/h8H,2-6H2,1H3,(H2,9,10,11)(H2,12,13,14)
DM5L8WX CS CCCCCCC(O)(P(=O)(O)O)P(=O)(O)O
DM5L8WX IK IJEGNOYPWRBKAE-UHFFFAOYSA-N
DM5L8WX IU (1-hydroxy-1-phosphonoheptyl)phosphonic acid
DM5L8WX DE Discovery agent
DMXY9R5 ID DMXY9R5
DMXY9R5 DN (1-Phenethyl-piperidin-4-yl)-phenyl-methanone
DMXY9R5 HS Investigative
DMXY9R5 SN CHEMBL19589; (1-Phenethyl-piperidin-4-yl)-phenyl-methanone; SCHEMBL7839803; GEFOLRNTTIQKBZ-UHFFFAOYSA-N; ZINC13740924; BDBM50034203; Phenyl(1-phenethyl-4-piperidinyl) ketone; phenyl-[1-(2-phenylethyl)-4-piperidyl]-ketone
DMXY9R5 DT Small molecular drug
DMXY9R5 PC 10379653
DMXY9R5 MW 293.4
DMXY9R5 FM C20H23NO
DMXY9R5 IC InChI=1S/C20H23NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19H,11-16H2
DMXY9R5 CS C1CN(CCC1C(=O)C2=CC=CC=C2)CCC3=CC=CC=C3
DMXY9R5 IK GEFOLRNTTIQKBZ-UHFFFAOYSA-N
DMXY9R5 IU phenyl-[1-(2-phenylethyl)piperidin-4-yl]methanone
DMXY9R5 DE Discovery agent
DM0TUKZ ID DM0TUKZ
DM0TUKZ DN (1-phenylcyclopentyl)methanamine
DM0TUKZ HS Investigative
DM0TUKZ SN (1-Phenylcyclopentyl)methanamine; 17511-89-6; 1-Phenylcyclopentanemethylamine; 1-(1-PHENYLCYCLOPENTYL)METHANAMINE; (1-phenylcyclopentyl)methylamine; 1-(1-phenylcyclopentyl)methylamine; 1-METHYLAMINE-1-BENZYL-CYCLOPENTANE; 1-Phenylcyclopentanemethanamine; C-(1-Phenyl-cyclopentyl)-methylamine; Cyclopentanemethylamine, 1-phenyl-; BRN 2936636; Cyclopentanemethanamine,1-phenyl-; CHEMBL382127; CHEBI:39505; Cyclopentanemethanamine, 1-phenyl-; (phenylcyclopentyl)methylamine; (1-Phenylcyclopentyl)methylamine hydrochloride; 2bua
DM0TUKZ DT Small molecular drug
DM0TUKZ PC 205131
DM0TUKZ MW 175.27
DM0TUKZ FM C12H17N
DM0TUKZ IC InChI=1S/C12H17N/c13-10-12(8-4-5-9-12)11-6-2-1-3-7-11/h1-3,6-7H,4-5,8-10,13H2
DM0TUKZ CS C1CCC(C1)(CN)C2=CC=CC=C2
DM0TUKZ IK SJWOFBVBNFLWLP-UHFFFAOYSA-N
DM0TUKZ IU (1-phenylcyclopentyl)methanamine
DM0TUKZ CA CAS 17511-89-6
DM0TUKZ CB CHEBI:39505
DM0TUKZ DE Discovery agent
DMECH9W ID DMECH9W
DMECH9W DN (1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine
DMECH9W HS Investigative
DMECH9W SN CHEMBL72703; AC1LTN5B; (1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine; cid_5051334; ZINC1773076; BDBM50116318; 2-phenyl-N-[(1S)-1-phenylethyl]quinazolin-4-amine
DMECH9W DT Small molecular drug
DMECH9W PC 1564646
DMECH9W MW 325.4
DMECH9W FM C22H19N3
DMECH9W IC InChI=1S/C22H19N3/c1-16(17-10-4-2-5-11-17)23-22-19-14-8-9-15-20(19)24-21(25-22)18-12-6-3-7-13-18/h2-16H,1H3,(H,23,24,25)/t16-/m1/s1
DMECH9W CS C[C@H](C1=CC=CC=C1)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4
DMECH9W IK AEXWSMVZORVWML-MRXNPFEDSA-N
DMECH9W IU 2-phenyl-N-[(1R)-1-phenylethyl]quinazolin-4-amine
DMECH9W DE Discovery agent
DMZU2VG ID DMZU2VG
DMZU2VG DN (1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine
DMZU2VG HS Investigative
DMZU2VG SN CHEMBL96014; (1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine
DMZU2VG DT Small molecular drug
DMZU2VG PC 44329715
DMZU2VG MW 329.4
DMZU2VG FM C20H19N5
DMZU2VG IC InChI=1S/C20H19N5/c1-2-17(15-9-5-3-6-10-15)24-19-18-20(22-13-21-19)25(14-23-18)16-11-7-4-8-12-16/h3-14,17H,2H2,1H3,(H,21,22,24)/t17-/m1/s1
DMZU2VG CS CC[C@H](C1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)C4=CC=CC=C4
DMZU2VG IK KOEVJHYBDHDPOK-QGZVFWFLSA-N
DMZU2VG IU 9-phenyl-N-[(1R)-1-phenylpropyl]purin-6-amine
DMZU2VG DE Discovery agent
DMVE34H ID DMVE34H
DMVE34H DN (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate
DMVE34H HS Investigative
DMVE34H SN GD7
DMVE34H DT Small molecular drug
DMVE34H PC 52947808
DMVE34H MW 163.17
DMVE34H FM C7H16O2P+
DMVE34H IC InChI=1S/C7H16O2P/c1-6(7(2,3)4)9-10(5)8/h6H,1-5H3/q+1/t6-/m1/s1
DMVE34H CS C[C@H](C(C)(C)C)O[P+](=O)C
DMVE34H IK AYQIEWWYFGQKPK-ZCFIWIBFSA-N
DMVE34H IU [(2R)-3,3-dimethylbutan-2-yl]oxy-methyl-oxophosphanium
DMVE34H DE Discovery agent
DMCVKTB ID DMCVKTB
DMCVKTB DN (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE
DMCVKTB HS Investigative
DMCVKTB SN GD8
DMCVKTB DT Small molecular drug
DMCVKTB PC 16058619
DMCVKTB MW 180.18
DMCVKTB FM C7H17O3P
DMCVKTB IC InChI=1S/C7H17O3P/c1-6(7(2,3)4)10-11(5,8)9/h6H,1-5H3,(H,8,9)/t6-/m1/s1
DMCVKTB CS C[C@H](C(C)(C)C)OP(=O)(C)O
DMCVKTB IK BLALDUPQYCGKAG-ZCFIWIBFSA-N
DMCVKTB IU [(2R)-3,3-dimethylbutan-2-yl]oxy-methylphosphinic acid
DMCVKTB DE Discovery agent
DMGAJYW ID DMGAJYW
DMGAJYW DN (1R)-MENTHYL HEXYL PHOSPHONATE GROUP
DMGAJYW HS Investigative
DMGAJYW SN (1R)-MENTHYL HEXYL PHOSPHONATE GROUP; AC1L9KBM; DB08200; hexyl[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]oxyphosphinic acid; hexyl-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid; (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl hydrogen (S)-hexylphosphonate
DMGAJYW DT Small molecular drug
DMGAJYW PC 446980
DMGAJYW MW 304.4
DMGAJYW FM C16H33O3P
DMGAJYW IC InChI=1S/C16H33O3P/c1-5-6-7-8-11-20(17,18)19-16-12-14(4)9-10-15(16)13(2)3/h13-16H,5-12H2,1-4H3,(H,17,18)/t14-,15+,16-/m1/s1
DMGAJYW CS CCCCCCP(=O)(O)O[C@@H]1C[C@@H](CC[C@H]1C(C)C)C
DMGAJYW IK WAVIZOVSJOXCKT-OWCLPIDISA-N
DMGAJYW IU hexyl-[(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid
DMGAJYW DE Discovery agent
DM18E9D ID DM18E9D
DM18E9D DN (1R,2R)-1,2-diphenylethane-1,2-diamine
DM18E9D HS Investigative
DM18E9D SN 35132-20-8; (1R,2R)-(+)-1,2-Diphenylethylenediamine; (1R,2R)-rel-1,2-Diphenylethane-1,2-diamine; (1R,2R)-1,2-Diphenylethylenediamine; 16635-95-3; (+)-1,2-diphenylethylenediamine; MFCD00082769; (+)-STILBENEDIAMINE; (R,R)-DPEN; (r,r)-(+)-1,2-diphenylethylenediamine; CHEMBL381340; (1r,2r)-1,2-diphenyl-ethane-1,2-diamine; 1,2-Ethanediamine, 1,2-diphenyl-, (1R,2R)-; (1R,2R)-(+)-1,2-Diphenyl-1,2-ethane diam
DM18E9D DT Small molecular drug
DM18E9D PC 2724998
DM18E9D MW 212.29
DM18E9D FM C14H16N2
DM18E9D IC InChI=1S/C14H16N2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13-14H,15-16H2/t13-,14-/m1/s1
DM18E9D CS C1=CC=C(C=C1)[C@H]([C@@H](C2=CC=CC=C2)N)N
DM18E9D IK PONXTPCRRASWKW-ZIAGYGMSSA-N
DM18E9D IU (1R,2R)-1,2-diphenylethane-1,2-diamine
DM18E9D CA CAS 35132-20-8
DM18E9D DE Discovery agent
DM5ROS1 ID DM5ROS1
DM5ROS1 DN (1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine
DM5ROS1 HS Investigative
DM5ROS1 SN CHEMBL40378; (1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine; BDBM50034706; AKOS006360607
DM5ROS1 DT Small molecular drug
DM5ROS1 PC 10374533
DM5ROS1 MW 139.2
DM5ROS1 FM C7H13N3
DM5ROS1 IC InChI=1S/C7H13N3/c1-5(6(2)8)7-3-9-4-10-7/h3-6H,8H2,1-2H3,(H,9,10)/t5-,6-/m1/s1
DM5ROS1 CS C[C@@H](C1=CN=CN1)[C@@H](C)N
DM5ROS1 IK QQTWSOMOTYJIQP-PHDIDXHHSA-N
DM5ROS1 IU (2R,3R)-3-(1H-imidazol-5-yl)butan-2-amine
DM5ROS1 DE Discovery agent
DMYLPV1 ID DMYLPV1
DMYLPV1 DN (1R,2R)-N-Arachidonoylcyclopropanolamide
DMYLPV1 HS Investigative
DMYLPV1 SN Rac-trans N-arachidonoylcyclopropanolamide
DMYLPV1 DT Small molecular drug
DMYLPV1 PC 42617984
DMYLPV1 MW 359.5
DMYLPV1 FM C23H37NO2
DMYLPV1 IC InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22-/m1/s1
DMYLPV1 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@@H]1C[C@H]1O
DMYLPV1 IK LZHCSJBKBARIFQ-OXAAUTCPSA-N
DMYLPV1 IU (5Z,8Z,11Z,14Z)-N-[(1R,2R)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DMYLPV1 DE Discovery agent
DM28D9E ID DM28D9E
DM28D9E DN (1R,2S)-1,2-diphenylethane-1,2-diamine
DM28D9E HS Investigative
DM28D9E SN meso-1,2-Diphenylethylenediamine; 951-87-1; CHEMBL206743; (1S,2R)-1,2-diphenylethane-1,2-diamine; Racemic stilbenediamine; AC1OC2I9; SCHEMBL2067094; MolPort-002-746-466; ZINC6581845; STK689613; BDBM50178427; BBL104274; AKOS005602166; MCULE-2915779897; meso-1,2-Diphenylethylenediamine, 98%; SC-21360; ST084935; AJ-94609; AS-11936; AB1010174; Z3396
DM28D9E DT Small molecular drug
DM28D9E PC 6931234
DM28D9E MW 212.29
DM28D9E FM C14H16N2
DM28D9E IC InChI=1S/C14H16N2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13-14H,15-16H2/t13-,14+
DM28D9E CS C1=CC=C(C=C1)[C@H]([C@H](C2=CC=CC=C2)N)N
DM28D9E IK PONXTPCRRASWKW-OKILXGFUSA-N
DM28D9E IU (1R,2S)-1,2-diphenylethane-1,2-diamine
DM28D9E DE Discovery agent
DMZ3DMX ID DMZ3DMX
DMZ3DMX DN (1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine
DMZ3DMX HS Investigative
DMZ3DMX SN CHEMBL277341; (1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine; BDBM50034711
DMZ3DMX DT Small molecular drug
DMZ3DMX PC 9972056
DMZ3DMX MW 139.2
DMZ3DMX FM C7H13N3
DMZ3DMX IC InChI=1S/C7H13N3/c1-5(6(2)8)7-3-9-4-10-7/h3-6H,8H2,1-2H3,(H,9,10)/t5-,6+/m0/s1
DMZ3DMX CS C[C@H](C1=CN=CN1)[C@@H](C)N
DMZ3DMX IK QQTWSOMOTYJIQP-NTSWFWBYSA-N
DMZ3DMX IU (2R,3S)-3-(1H-imidazol-5-yl)butan-2-amine
DMZ3DMX DE Discovery agent
DM39AFU ID DM39AFU
DM39AFU DN (1R,2S)-N-Arachidonoylcyclopropanolamide
DM39AFU HS Investigative
DM39AFU SN (1R,2S)-N-Arachidonoylcyclopropanolamide; cyclopropanolamide, 14a; CHEMBL485368
DM39AFU DT Small molecular drug
DM39AFU PC 42617989
DM39AFU MW 359.5
DM39AFU FM C23H37NO2
DM39AFU IC InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22+/m0/s1
DM39AFU CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@H]1C[C@H]1O
DM39AFU IK LZHCSJBKBARIFQ-MTVZMXCXSA-N
DM39AFU IU (5Z,8Z,11Z,14Z)-N-[(1S,2R)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DM39AFU DE Discovery agent
DMITW5P ID DMITW5P
DMITW5P DN (1R,2S)-N-Oleoylcyclopropanolamide
DMITW5P HS Investigative
DMITW5P SN (1R,2S)-N-Oleoylcyclopropanolamide
DMITW5P DT Small molecular drug
DMITW5P PC 44591632
DMITW5P MW 311.5
DMITW5P FM C19H37NO2
DMITW5P IC InChI=1S/C19H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)20-17-16-18(17)21/h17-18,21H,2-16H2,1H3,(H,20,22)/t17-,18+/m0/s1
DMITW5P CS CCCCCCCCCCCCCCCC(=O)N[C@H]1C[C@H]1O
DMITW5P IK LIBNBUULGCFJNR-ZWKOTPCHSA-N
DMITW5P IU N-[(1S,2R)-2-hydroxycyclopropyl]hexadecanamide
DMITW5P DE Discovery agent
DMUJ7ZE ID DMUJ7ZE
DMUJ7ZE DN (1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX)
DMUJ7ZE HS Investigative
DMUJ7ZE SN CHEMBL525369; BDBM14023; (1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX); Macrocyclic 3-Aminopyrrolidinone analog 83
DMUJ7ZE DT Small molecular drug
DMUJ7ZE PC 11761968
DMUJ7ZE MW 439.5
DMUJ7ZE FM C26H25N5O2
DMUJ7ZE IC InChI=1S/C26H25N5O2/c27-12-19-5-4-17-10-25(19)33-21-7-6-18-2-1-3-24(22(18)11-21)31-9-8-23(26(31)32)29-14-20-13-28-16-30(20)15-17/h4-7,10-11,13,16,23-24,29H,1-3,8-9,14-15H2/t23-,24-/m1/s1
DMUJ7ZE CS C1C[C@@H]2C3=C(C1)C=CC(=C3)OC4=C(C=CC(=C4)CN5C=NC=C5CN[C@@H]6CCN2C6=O)C#N
DMUJ7ZE IK VWNBOOIWICWEPL-DNQXCXABSA-N
DMUJ7ZE IU (1R,5R)-30-oxo-19-oxa-2,6,10,12-tetrazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-8,10,14(29),15,17,20(28),21,23(27)-octaene-17-carbonitrile
DMUJ7ZE DE Discovery agent
DMJ2WD5 ID DMJ2WD5
DMJ2WD5 DN (1S)-MENTHYL HEXYL PHOSPHONATE GROUP
DMJ2WD5 HS Investigative
DMJ2WD5 SN (1S)-MENTHYL HEXYL PHOSPHONATE GROUP; AC1L9KBO; DB08201; hexyl[(1S,2R,5S)-2-isopropyl-5-methylcyclohexyl]oxyphosphinic acid; hexyl-[(1S,2R,5S)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid; (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl hydrogen (S)-hexylphosphonate
DMJ2WD5 DT Small molecular drug
DMJ2WD5 PC 446981
DMJ2WD5 MW 304.4
DMJ2WD5 FM C16H33O3P
DMJ2WD5 IC InChI=1S/C16H33O3P/c1-5-6-7-8-11-20(17,18)19-16-12-14(4)9-10-15(16)13(2)3/h13-16H,5-12H2,1-4H3,(H,17,18)/t14-,15+,16-/m0/s1
DMJ2WD5 CS CCCCCCP(=O)(O)O[C@H]1C[C@H](CC[C@@H]1C(C)C)C
DMJ2WD5 IK WAVIZOVSJOXCKT-XHSDSOJGSA-N
DMJ2WD5 IU hexyl-[(1S,2R,5S)-5-methyl-2-propan-2-ylcyclohexyl]oxyphosphinic acid
DMJ2WD5 DE Discovery agent
DMZCS2K ID DMZCS2K
DMZCS2K DN (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine
DMZCS2K HS Investigative
DMZCS2K SN CHEMBL289383; (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine
DMZCS2K DT Small molecular drug
DMZCS2K PC 10240978
DMZCS2K MW 151.21
DMZCS2K FM C8H13N3
DMZCS2K IC InChI=1S/C8H13N3/c9-7-3-1-2-6(7)8-4-10-5-11-8/h4-7H,1-3,9H2,(H,10,11)/t6-,7-/m0/s1
DMZCS2K CS C1C[C@@H]([C@H](C1)N)C2=CN=CN2
DMZCS2K IK MUHUWRJWVGDFJX-BQBZGAKWSA-N
DMZCS2K IU (1S,2S)-2-(1H-imidazol-5-yl)cyclopentan-1-amine
DMZCS2K DE Discovery agent
DMKA0ON ID DMKA0ON
DMKA0ON DN (1S,2S)-N-Arachidonoylcyclopropanolamide
DMKA0ON HS Investigative
DMKA0ON SN (1S,2S)-N-Arachidonoylcyclopropanolamide; cyclopropanolamide, 11a; CHEMBL485369
DMKA0ON DT Small molecular drug
DMKA0ON PC 42617990
DMKA0ON MW 359.5
DMKA0ON FM C23H37NO2
DMKA0ON IC InChI=1S/C23H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)24-21-20-22(21)25/h6-7,9-10,12-13,15-16,21-22,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)/b7-6-,10-9-,13-12-,16-15-/t21-,22-/m0/s1
DMKA0ON CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@H]1C[C@@H]1O
DMKA0ON IK LZHCSJBKBARIFQ-NILUWUTCSA-N
DMKA0ON IU (5Z,8Z,11Z,14Z)-N-[(1S,2S)-2-hydroxycyclopropyl]icosa-5,8,11,14-tetraenamide
DMKA0ON DE Discovery agent
DMIV2OY ID DMIV2OY
DMIV2OY DN (1S,2S)-N-Oleoylcyclopropanolamide
DMIV2OY HS Investigative
DMIV2OY SN (1S,2S)-N-Oleoylcyclopropanolamide
DMIV2OY DT Small molecular drug
DMIV2OY PC 44591633
DMIV2OY MW 311.5
DMIV2OY FM C19H37NO2
DMIV2OY IC InChI=1S/C19H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)20-17-16-18(17)21/h17-18,21H,2-16H2,1H3,(H,20,22)/t17-,18-/m0/s1
DMIV2OY CS CCCCCCCCCCCCCCCC(=O)N[C@H]1C[C@@H]1O
DMIV2OY IK LIBNBUULGCFJNR-ROUUACIJSA-N
DMIV2OY IU N-[(1S,2S)-2-hydroxycyclopropyl]hexadecanamide
DMIV2OY DE Discovery agent
DM5DOAF ID DM5DOAF
DM5DOAF DN (1S,3R)-ACPD
DM5DOAF HS Investigative
DM5DOAF SN (1S,3R)-1-ACPD; trans-ACPD; (1S,3S)-ACPD; 1S,3R-ACPD
DM5DOAF DT Small molecular drug
DM5DOAF PC 104766
DM5DOAF MW 173.17
DM5DOAF FM C7H11NO4
DM5DOAF IC InChI=1S/C7H11NO4/c8-7(6(11)12)2-1-4(3-7)5(9)10/h4H,1-3,8H2,(H,9,10)(H,11,12)/t4-,7+/m1/s1
DM5DOAF CS C1C[C@](C[C@@H]1C(=O)O)(C(=O)O)N
DM5DOAF IK YFYNOWXBIBKGHB-FBCQKBJTSA-N
DM5DOAF IU (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid
DM5DOAF CA CAS 111900-32-4
DM5DOAF DE Discovery agent
DMYOTMP ID DMYOTMP
DMYOTMP DN (2-(2-chlorophenyl)pyridin-3-yl)methanamine
DMYOTMP HS Investigative
DMYOTMP SN CHEMBL378152; (2-(2-chlorophenyl)pyridin-3-yl)methanamine
DMYOTMP DT Small molecular drug
DMYOTMP PC 44408767
DMYOTMP MW 218.68
DMYOTMP FM C12H11ClN2
DMYOTMP IC InChI=1S/C12H11ClN2/c13-11-6-2-1-5-10(11)12-9(8-14)4-3-7-15-12/h1-7H,8,14H2
DMYOTMP CS C1=CC=C(C(=C1)C2=C(C=CC=N2)CN)Cl
DMYOTMP IK FTTHUIFIPJIQEI-UHFFFAOYSA-N
DMYOTMP IU [2-(2-chlorophenyl)pyridin-3-yl]methanamine
DMYOTMP CA CAS 876170-47-7
DMYOTMP DE Discovery agent
DMA15WU ID DMA15WU
DMA15WU DN (2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine
DMA15WU HS Investigative
DMA15WU SN CHEMBL233845; (2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine; SCHEMBL5699914; [5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methanamine; BDBM50205765; AKOS010099713; Benzenemethanamine, 5-bromo-2-[(4-chlorophenyl)methoxy]-
DMA15WU DT Small molecular drug
DMA15WU PC 11267381
DMA15WU MW 326.61
DMA15WU FM C14H13BrClNO
DMA15WU IC InChI=1S/C14H13BrClNO/c15-12-3-6-14(11(7-12)8-17)18-9-10-1-4-13(16)5-2-10/h1-7H,8-9,17H2
DMA15WU CS C1=CC(=CC=C1COC2=C(C=C(C=C2)Br)CN)Cl
DMA15WU IK YKPADUDRSOXMQB-UHFFFAOYSA-N
DMA15WU IU [5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methanamine
DMA15WU DE Discovery agent
DM2ATRC ID DM2ATRC
DM2ATRC DN (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate
DM2ATRC HS Investigative
DM2ATRC SN CHEMBL172215; (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate; 103596-21-0; Sulfamic acid, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester; ACMC-20m6fs; SCHEMBL18063439; CTK0G6911; DTXSID50545931; BDBM50188393; Sulfamic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester
DM2ATRC DT Small molecular drug
DM2ATRC PC 13654029
DM2ATRC MW 211.24
DM2ATRC FM C6H13NO5S
DM2ATRC IC InChI=1S/C6H13NO5S/c1-6(2)10-3-5(12-6)4-11-13(7,8)9/h5H,3-4H2,1-2H3,(H2,7,8,9)
DM2ATRC CS CC1(OCC(O1)COS(=O)(=O)N)C
DM2ATRC IK QFFBTRPNKKXQCZ-UHFFFAOYSA-N
DM2ATRC IU (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate
DM2ATRC CA CAS 103596-21-0
DM2ATRC DE Discovery agent
DMNGEFS ID DMNGEFS
DMNGEFS DN (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine
DMNGEFS HS Investigative
DMNGEFS SN CHEMBL175596; 872872-12-3; (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; SCHEMBL4045943; CTK3C4931; DTXSID20468426; BDBM50179205; AKOS030605024; Indeno[1,2-c]pyrazol-3-amine, 1,4-dihydro-N-phenyl-
DMNGEFS DT Small molecular drug
DMNGEFS PC 11550535
DMNGEFS MW 247.29
DMNGEFS FM C16H13N3
DMNGEFS IC InChI=1S/C16H13N3/c1-2-7-12(8-3-1)17-16-14-10-11-6-4-5-9-13(11)15(14)18-19-16/h1-9H,10H2,(H2,17,18,19)
DMNGEFS CS C1C2=CC=CC=C2C3=C1C(=NN3)NC4=CC=CC=C4
DMNGEFS IK HXUODZKNCJWKGP-UHFFFAOYSA-N
DMNGEFS IU N-phenyl-1,4-dihydroindeno[1,2-c]pyrazol-3-amine
DMNGEFS CA CAS 872872-12-3
DMNGEFS DE Discovery agent
DM97GFB ID DM97GFB
DM97GFB DN (2,5-Diphenyl-furan-3-yl)-phenyl-methanone
DM97GFB HS Investigative
DM97GFB SN 2,5-Diphenyl-3-benzoylfuran; CHEMBL109280; (2,5-Diphenyl-furan-3-yl)-phenyl-methanone
DM97GFB DT Small molecular drug
DM97GFB PC 44339577
DM97GFB MW 324.4
DM97GFB FM C23H16O2
DM97GFB IC InChI=1S/C23H16O2/c24-22(18-12-6-2-7-13-18)20-16-21(17-10-4-1-5-11-17)25-23(20)19-14-8-3-9-15-19/h1-16H
DM97GFB CS C1=CC=C(C=C1)C2=CC(=C(O2)C3=CC=CC=C3)C(=O)C4=CC=CC=C4
DM97GFB IK QGPDONYUANCEMJ-UHFFFAOYSA-N
DM97GFB IU (2,5-diphenylfuran-3-yl)-phenylmethanone
DM97GFB DE Discovery agent
DMWRCM1 ID DMWRCM1
DMWRCM1 DN (2,6-Diamino-pyridin-3-yl)-phenyl-methanone
DMWRCM1 HS Investigative
DMWRCM1 SN (2,6-Diaminopyridin-3-yl)(phenyl)methanone; 157924-28-2; 3-Acyl-2,6-diaminopyridine deriv. 3c; (2,6-diamino-3-pyridinyl)phenylmethanone; AC1NS9QT; SCHEMBL4419093; BDBM6908; CHEMBL193590; 3-benzoylpyridine-2,6-diamine; 852997-66-1
DMWRCM1 DT Small molecular drug
DMWRCM1 PC 5330842
DMWRCM1 MW 213.23
DMWRCM1 FM C12H11N3O
DMWRCM1 IC InChI=1S/C12H11N3O/c13-10-7-6-9(12(14)15-10)11(16)8-4-2-1-3-5-8/h1-7H,(H4,13,14,15)
DMWRCM1 CS C1=CC=C(C=C1)C(=O)C2=C(N=C(C=C2)N)N
DMWRCM1 IK CUQWNLDNYKQYLY-UHFFFAOYSA-N
DMWRCM1 IU (2,6-diaminopyridin-3-yl)-phenylmethanone
DMWRCM1 DE Discovery agent
DM27TH9 ID DM27TH9
DM27TH9 DN (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine
DM27TH9 HS Investigative
DM27TH9 SN CHEMBL1022; (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine; SCHEMBL13767327
DM27TH9 DT Small molecular drug
DM27TH9 PC 10489502
DM27TH9 MW 228.07
DM27TH9 FM C9H7Cl2N3
DM27TH9 IC InChI=1S/C9H7Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-5H,(H2,12,13,14)
DM27TH9 CS C1=CC(=C(C(=C1)Cl)NC2=NC=CN2)Cl
DM27TH9 IK JMIQFISPBOHMQG-UHFFFAOYSA-N
DM27TH9 IU N-(2,6-dichlorophenyl)-1H-imidazol-2-amine
DM27TH9 DE Discovery agent
DM1RYH9 ID DM1RYH9
DM1RYH9 DN (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid
DM1RYH9 HS Investigative
DM1RYH9 SN CHEMBL519411; (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid
DM1RYH9 DT Small molecular drug
DM1RYH9 PC 44558952
DM1RYH9 MW 470.7
DM1RYH9 FM C31H50O3
DM1RYH9 IC InChI=1S/C31H50O3/c1-20(26(33)34)10-9-11-21(2)29(6)18-19-30(7)23-12-13-24-27(3,4)25(32)15-16-28(24,5)22(23)14-17-31(29,30)8/h10,12,21-22,24-25,32H,9,11,13-19H2,1-8H3,(H,33,34)/b20-10+/t21-,22-,24-,25-,28+,29-,30+,31-/m0/s1
DM1RYH9 CS C[C@@H](CC/C=C(\\C)/C(=O)O)[C@@]1(CC[C@]2([C@]1(CC[C@H]3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)C
DM1RYH9 IK PSSOTMPEBLYOAS-MGULVPRESA-N
DM1RYH9 IU (E,6S)-6-[(3S,5R,9R,10R,13S,14R,17S)-3-hydroxy-4,4,10,13,14,17-hexamethyl-1,2,3,5,6,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid
DM1RYH9 DE Discovery agent
DMPL80G ID DMPL80G
DMPL80G DN (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol
DMPL80G HS Investigative
DMPL80G SN CHEMBL202119; (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol
DMPL80G DT Small molecular drug
DMPL80G PC 44407193
DMPL80G MW 410.7
DMPL80G FM C29H46O
DMPL80G IC InChI=1S/C29H46O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-11,15,19-26,30H,7,12-14,16-18H2,1-6H3/b9-8+/t20-,21-,22?,23+,24+,25-,26+,28+,29-/m1/s1
DMPL80G CS CC[C@H](/C=C/[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC=C3[C@H]2C=CC4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C
DMPL80G IK ZFRLPKWDPDXIMP-BLDYNFBXSA-N
DMPL80G IU (3S,8S,10S,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,5,8,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMPL80G DE Discovery agent
DMLEZKJ ID DMLEZKJ
DMLEZKJ DN (2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid
DMLEZKJ HS Investigative
DMLEZKJ SN CHEMBL79325; 2-(2-Amino-2-thiazolin-4-yl)acetic acid; AC1NQ6SQ; SCHEMBL2711624; 2-(2-amino-4,5-dihydro-1,3-thiazol-4-yl)acetic Acid; ANCWBXJZUCHVHL-UHFFFAOYSA-N
DMLEZKJ DT Small molecular drug
DMLEZKJ PC 5216267
DMLEZKJ MW 160.2
DMLEZKJ FM C5H8N2O2S
DMLEZKJ IC InChI=1S/C5H8N2O2S/c6-5-7-3(2-10-5)1-4(8)9/h3H,1-2H2,(H2,6,7)(H,8,9)
DMLEZKJ CS C1C(N=C(S1)N)CC(=O)O
DMLEZKJ IK ANCWBXJZUCHVHL-UHFFFAOYSA-N
DMLEZKJ IU 2-(2-amino-4,5-dihydro-1,3-thiazol-4-yl)acetic acid
DMLEZKJ DE Discovery agent
DMFRPGX ID DMFRPGX
DMFRPGX DN (2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine
DMFRPGX HS Investigative
DMFRPGX SN CHEMBL187420; (2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine; BDBM50151051
DMFRPGX DT Small molecular drug
DMFRPGX PC 11437461
DMFRPGX MW 280.4
DMFRPGX FM C19H24N2
DMFRPGX IC InChI=1S/C19H24N2/c1-2-8-17(9-3-1)16-18-10-4-5-11-19(18)20-12-15-21-13-6-7-14-21/h1-5,8-11,20H,6-7,12-16H2
DMFRPGX CS C1CCN(C1)CCNC2=CC=CC=C2CC3=CC=CC=C3
DMFRPGX IK KMSBBZPJDRRRGH-UHFFFAOYSA-N
DMFRPGX IU 2-benzyl-N-(2-pyrrolidin-1-ylethyl)aniline
DMFRPGX DE Discovery agent
DMTW0GD ID DMTW0GD
DMTW0GD DN (2-biphenyl-3-yl-ethyl)-dimethyl-amine
DMTW0GD HS Investigative
DMTW0GD SN CHEMBL234882
DMTW0GD DT Small molecular drug
DMTW0GD PC 44431718
DMTW0GD MW 225.33
DMTW0GD FM C16H19N
DMTW0GD IC InChI=1S/C16H19N/c1-17(2)12-11-14-7-6-10-16(13-14)15-8-4-3-5-9-15/h3-10,13H,11-12H2,1-2H3
DMTW0GD CS CN(C)CCC1=CC(=CC=C1)C2=CC=CC=C2
DMTW0GD IK ZMTHYJFLTGNPHJ-UHFFFAOYSA-N
DMTW0GD IU N,N-dimethyl-2-(3-phenylphenyl)ethanamine
DMTW0GD DE Discovery agent
DMZSP7F ID DMZSP7F
DMZSP7F DN (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE
DMZSP7F HS Investigative
DMZSP7F SN (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE; 2-bromoethyl 2-(4-amino-2-formylphenyl)acetate; AC1NE0SL; DB07955; 2-bromoethyl (4-amino-2-formylphenyl)acetate
DMZSP7F DT Small molecular drug
DMZSP7F PC 4634717
DMZSP7F MW 286.12
DMZSP7F FM C11H12BrNO3
DMZSP7F IC InChI=1S/C11H12BrNO3/c12-3-4-16-11(15)6-8-1-2-10(13)5-9(8)7-14/h1-2,5,7H,3-4,6,13H2
DMZSP7F CS C1=CC(=C(C=C1N)C=O)CC(=O)OCCBr
DMZSP7F IK SMKXVWWBCFWRMP-UHFFFAOYSA-N
DMZSP7F IU 2-bromoethyl 2-(4-amino-2-formylphenyl)acetate
DMZSP7F DE Discovery agent
DM8N79M ID DM8N79M
DM8N79M DN (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine
DM8N79M HS Investigative
DM8N79M SN CHEMBL76457; (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine; 2-(2-Bromoanilino)-1H-imidazole; BDBM50055833
DM8N79M DT Small molecular drug
DM8N79M PC 10490084
DM8N79M MW 238.08
DM8N79M FM C9H8BrN3
DM8N79M IC InChI=1S/C9H8BrN3/c10-7-3-1-2-4-8(7)13-9-11-5-6-12-9/h1-6H,(H2,11,12,13)
DM8N79M CS C1=CC=C(C(=C1)NC2=NC=CN2)Br
DM8N79M IK KHNAVCNEASQADL-UHFFFAOYSA-N
DM8N79M IU N-(2-bromophenyl)-1H-imidazol-2-amine
DM8N79M DE Discovery agent
DMFX9H8 ID DMFX9H8
DMFX9H8 DN (2-bromophenyl)difluoromethanesulfonamide
DMFX9H8 HS Investigative
DMFX9H8 SN CHEMBL199493; (2-bromophenyl)difluoromethanesulfonamide
DMFX9H8 DT Small molecular drug
DMFX9H8 PC 44405179
DMFX9H8 MW 286.1
DMFX9H8 FM C7H6BrF2NO2S
DMFX9H8 IC InChI=1S/C7H6BrF2NO2S/c8-6-4-2-1-3-5(6)7(9,10)14(11,12)13/h1-4H,(H2,11,12,13)
DMFX9H8 CS C1=CC=C(C(=C1)C(F)(F)S(=O)(=O)N)Br
DMFX9H8 IK QUUHLCHEVDHKEL-UHFFFAOYSA-N
DMFX9H8 IU (2-bromophenyl)-difluoromethanesulfonamide
DMFX9H8 DE Discovery agent
DMLTMPC ID DMLTMPC
DMLTMPC DN (2-Butyryloxy-ethyl)-trimethyl-ammonium iodide
DMLTMPC HS Investigative
DMLTMPC DE Discovery agent
DMOS864 ID DMOS864
DMOS864 DN (2-chloro-6-phenoxyphenyl)methanamine
DMOS864 HS Investigative
DMOS864 SN 2-Chloro-6-phenoxybenzylamine; 175136-89-7; (2-chloro-6-phenoxyphenyl)methanamine; CHEMBL203105; AC1MCRJE; rarechem al bw 1398; SCHEMBL112755; AC1Q53T0; 2-chloro-6-phenoxy-benzylamine; CTK4D5311; DTXSID20380412; SNTOZVXKDWQFEW-UHFFFAOYSA-N; MolPort-000-144-285; ZINC159665; ZX-AT024720; 2-aminomethyl-3-chlorodiphenylether; SBB098143; BDBM50178429; (6-chloro-2-phenoxyphenyl)methylamine; 2-chloro-6-phenoxybenzylamine, 95+%; AKOS009159323; Benzenemethanamine,2-chloro-6-phenoxy-; KB-68526; SC-40136; AJ-15516; ACM175136897; DB-030613
DMOS864 DT Small molecular drug
DMOS864 PC 2777206
DMOS864 MW 233.69
DMOS864 FM C13H12ClNO
DMOS864 IC InChI=1S/C13H12ClNO/c14-12-7-4-8-13(11(12)9-15)16-10-5-2-1-3-6-10/h1-8H,9,15H2
DMOS864 CS C1=CC=C(C=C1)OC2=C(C(=CC=C2)Cl)CN
DMOS864 IK SNTOZVXKDWQFEW-UHFFFAOYSA-N
DMOS864 IU (2-chloro-6-phenoxyphenyl)methanamine
DMOS864 CA CAS 175136-89-7
DMOS864 DE Discovery agent
DMCE1SU ID DMCE1SU
DMCE1SU DN (2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine
DMCE1SU HS Investigative
DMCE1SU SN CHEMBL98779; (2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine; 2-chloro-9-methyl-N6-phenyladenine; 135394-17-1; SCHEMBL183230; DBTWDYPKBBODMU-UHFFFAOYSA-N; BDBM50009679; 2-Chloro-9-methyl-N-phenyl-9H-purin-6-amine
DMCE1SU DT Small molecular drug
DMCE1SU PC 15693956
DMCE1SU MW 259.69
DMCE1SU FM C12H10ClN5
DMCE1SU IC InChI=1S/C12H10ClN5/c1-18-7-14-9-10(16-12(13)17-11(9)18)15-8-5-3-2-4-6-8/h2-7H,1H3,(H,15,16,17)
DMCE1SU CS CN1C=NC2=C(N=C(N=C21)Cl)NC3=CC=CC=C3
DMCE1SU IK DBTWDYPKBBODMU-UHFFFAOYSA-N
DMCE1SU IU 2-chloro-9-methyl-N-phenylpurin-6-amine
DMCE1SU CA CAS 135394-17-1
DMCE1SU DE Discovery agent
DM6DH15 ID DM6DH15
DM6DH15 DN (2-Chloro-ethyl)-trimethyl-ammonium chloride
DM6DH15 HS Investigative
DM6DH15 DE Discovery agent
DMKWRFA ID DMKWRFA
DMKWRFA DN (2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID
DMKWRFA HS Investigative
DMKWRFA SN (2e)-3-(2-Oct-1-Yn-1-Ylphenyl)acrylic Acid; 1lox; SCHEMBL4947304; SCHEMBL4947296; DB08492; (2E)-3-(2-oct-1-yn-1-ylphenyl)prop-2-enoic acid; (2E)-3-[2-(oct-1-yn-1-yl)phenyl]prop-2-enoic acid
DMKWRFA DT Small molecular drug
DMKWRFA PC 10308106
DMKWRFA MW 256.339
DMKWRFA FM C17H20O2
DMKWRFA IC InChI=1S/C17H20O2/c1-2-3-4-5-6-7-10-15-11-8-9-12-16(15)13-14-17(18)19/h8-9,11-14H,2-6H2,1H3,(H,18,19)/b14-13+
DMKWRFA CS CCCCCCC#CC1=CC=CC=C1/C=C/C(=O)O
DMKWRFA IK KRDSGPLHVQJFLM-BUHFOSPRSA-N
DMKWRFA IU (E)-3-(2-oct-1-ynylphenyl)prop-2-enoic acid
DMKWRFA DE Discovery agent
DM3ST2Y ID DM3ST2Y
DM3ST2Y DN (2E, 6E)-farnesylbisphosphonate
DM3ST2Y HS Investigative
DM3ST2Y SN (2E, 6E)-farnesylbisphosphonate; GTPL3200; SCHEMBL8916061; SCHEMBL2875241; (e,e)-(4,8,12-trimethyl-3,7,11-tridecatrienylidene)bisphosphonic acid; [(3E,7E)-4,8,12-trimethyl-1-phosphonotrideca-3,7,11-trien-1-yl]phosphonic acid
DM3ST2Y DT Small molecular drug
DM3ST2Y PC 9871730
DM3ST2Y MW 380.35
DM3ST2Y FM C16H30O6P2
DM3ST2Y IC InChI=1S/C16H30O6P2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16(23(17,18)19)24(20,21)22/h7,9,11,16H,5-6,8,10,12H2,1-4H3,(H2,17,18,19)(H2,20,21,22)/b14-9+,15-11+
DM3ST2Y CS CC(=CCC/C(=C/CC/C(=C/CC(P(=O)(O)O)P(=O)(O)O)/C)/C)C
DM3ST2Y IK QBAOBDKNTDWTHR-YFVJMOTDSA-N
DM3ST2Y IU [(3E,7E)-4,8,12-trimethyl-1-phosphonotrideca-3,7,11-trienyl]phosphonic acid
DM3ST2Y DE Discovery agent
DMA9RIS ID DMA9RIS
DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate
DMA9RIS HS Investigative
DMA9RIS SN CHEMBL31541; SCHEMBL3063088; (4S)-4-Amino-2-pentenoic acid; [S,E,( )]-4-Amino-2-pentenoic acid
DMA9RIS DT Small molecular drug
DMA9RIS PC 14074394
DMA9RIS MW 115.13
DMA9RIS FM C5H9NO2
DMA9RIS IC InChI=1S/C5H9NO2/c1-4(6)2-3-5(7)8/h2-4H,6H2,1H3,(H,7,8)/b3-2+/t4-/m0/s1
DMA9RIS CS C[C@@H](/C=C/C(=O)O)N
DMA9RIS IK SCUXCFWYAJSHJI-ZPYNKGFJSA-N
DMA9RIS IU (E,4S)-4-aminopent-2-enoic acid
DMA9RIS DE Discovery agent
DMN7XT9 ID DMN7XT9
DMN7XT9 DN (2-Ethoxy-ethyl)-trimethyl-ammonium iodide
DMN7XT9 HS Investigative
DMN7XT9 DE Discovery agent
DMFV76H ID DMFV76H
DMFV76H DN (2-fluorophenyl)-(4-fluorophenyl)phenylacetamide
DMFV76H HS Investigative
DMFV76H SN CHEMBL42205; (2-fluorophenyl)-(4-fluorophenyl)phenylacetamide; SCHEMBL1443821; UFALWTGZIJAUPP-UHFFFAOYSA-N; BDBM50099566; ICA-15451; (2-fluorophenyl)-(4 fluorophenyl)phenylacetamide
DMFV76H DT Small molecular drug
DMFV76H PC 9966986
DMFV76H MW 323.3
DMFV76H FM C20H15F2NO
DMFV76H IC InChI=1S/C20H15F2NO/c21-16-12-10-15(11-13-16)20(19(23)24,14-6-2-1-3-7-14)17-8-4-5-9-18(17)22/h1-13H,(H2,23,24)
DMFV76H CS C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=CC=C3F)C(=O)N
DMFV76H IK UFALWTGZIJAUPP-UHFFFAOYSA-N
DMFV76H IU 2-(2-fluorophenyl)-2-(4-fluorophenyl)-2-phenylacetamide
DMFV76H DE Discovery agent
DMCHJL1 ID DMCHJL1
DMCHJL1 DN (2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine
DMCHJL1 HS Investigative
DMCHJL1 SN 1-(Isopropylamino)-3-phenoxypropan-2-ol; 7695-63-8; 1-phenoxy-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-phenoxy-propan-2-ol; 1-(isopropylamino)-3-phenoxy-2-propanol; Metoprolol IMpurity 06; CHEMBL7154; H-9/64; 2-PROPANOL, 1-[(1-METHYLETHYL)AMINO]-3-PHENOXY-; 1-[(1-methylethyl)amino]-3-phenoxy-2-Propanol; 2-Propanol, 1-((1-methylethyl)amino)-3-phenoxy-; (2RS)-1-((1-Methylethyl)amino)-3-phenoxypropan-2-ol; Desmethoxyethyl metoprolol; NIP
DMCHJL1 DT Small molecular drug
DMCHJL1 PC 3123920
DMCHJL1 MW 209.28
DMCHJL1 FM C12H19NO2
DMCHJL1 IC InChI=1S/C12H19NO2/c1-10(2)13-8-11(14)9-15-12-6-4-3-5-7-12/h3-7,10-11,13-14H,8-9H2,1-2H3
DMCHJL1 CS CC(C)NCC(COC1=CC=CC=C1)O
DMCHJL1 IK ONXLHKFGTDDVLQ-UHFFFAOYSA-N
DMCHJL1 IU 1-phenoxy-3-(propan-2-ylamino)propan-2-ol
DMCHJL1 CA CAS 7695-63-8
DMCHJL1 DE Discovery agent
DMEZNXS ID DMEZNXS
DMEZNXS DN (2-hydroxyphenyl)(4-hydroxyphenyl)methanone
DMEZNXS HS Investigative
DMEZNXS SN 2,4'-Dihydroxybenzophenone; 606-12-2; (2-Hydroxyphenyl)(4-hydroxyphenyl)methanone; Benzophenone, 2,4'-dihydroxy-; Methanone, (2-hydroxyphenyl)(4-hydroxyphenyl)-; CHEMBL510074; HUYKZYIAFUBPAQ-UHFFFAOYSA-N; (2-hydroxyphenyl)-(4-hydroxyphenyl)methanone; Methanone,(2-hydroxyphenyl)(4-hydroxyphenyl)-; NSC2832; ACMC-209mky; AC1Q5FLY; AC1L58KX; Benzophenone,4'-dihydroxy-; Oprea1_236403; 4,2'-dihydroxy-benzophenone; SCHEMBL1568564; CTK5B1906; DTXSID80277556; MolPort-003-809-367; ZINC340411; KS-000014KT; NSC-2832; BDBM50262042; ANW-33536
DMEZNXS DT Small molecular drug
DMEZNXS PC 220295
DMEZNXS MW 214.22
DMEZNXS FM C13H10O3
DMEZNXS IC InChI=1S/C13H10O3/c14-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)15/h1-8,14-15H
DMEZNXS CS C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)O)O
DMEZNXS IK HUYKZYIAFUBPAQ-UHFFFAOYSA-N
DMEZNXS IU (2-hydroxyphenyl)-(4-hydroxyphenyl)methanone
DMEZNXS CA CAS 606-12-2
DMEZNXS DE Discovery agent
DM24E08 ID DM24E08
DM24E08 DN (2-Indol-1-yl-ethyl)-dimethyl-amine
DM24E08 HS Investigative
DM24E08 SN 1H-Indole-1-ethanamine, N,N-dimethyl-; CHEMBL38633; 87482-09-5; (2-Indol-1-yl-ethyl)-dimethyl-amine; SCHEMBL4060777; CTK3C3615; DTXSID80579188; PSHKCPACSIZILK-UHFFFAOYSA-N; (2-Indol-1-ylethyl)dimethylamine; BDBM50108308; N,N-Dimethyl-1H-indole-1-ethanamine; AKOS013123773; [2-(1H-indol-1-yl)ethyl]dimethylamine; 2-(1H-Indol-1-yl)-N,N-dimethylethan-1-amine
DM24E08 DT Small molecular drug
DM24E08 PC 15893127
DM24E08 MW 188.27
DM24E08 FM C12H16N2
DM24E08 IC InChI=1S/C12H16N2/c1-13(2)9-10-14-8-7-11-5-3-4-6-12(11)14/h3-8H,9-10H2,1-2H3
DM24E08 CS CN(C)CCN1C=CC2=CC=CC=C21
DM24E08 IK PSHKCPACSIZILK-UHFFFAOYSA-N
DM24E08 IU 2-indol-1-yl-N,N-dimethylethanamine
DM24E08 CA CAS 87482-09-5
DM24E08 DE Discovery agent
DMCJKOQ ID DMCJKOQ
DMCJKOQ DN (2-Mercapto-ethyl)-trimethyl-ammonium iodide
DMCJKOQ HS Investigative
DMCJKOQ DE Discovery agent
DMQWD75 ID DMQWD75
DMQWD75 DN (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMQWD75 HS Investigative
DMQWD75 SN N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine; GW577921A; 2-Anilino-5-aryloxazole 9; AC1NS7R2; SCHEMBL5232183; CHEMBL194027; BDBM5848; NCGC00242189-01; AB01092075-01; N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMQWD75 DT Small molecular drug
DMQWD75 PC 5329844
DMQWD75 MW 266.29
DMQWD75 FM C16H14N2O2
DMQWD75 IC InChI=1S/C16H14N2O2/c1-19-14-10-6-5-9-13(14)18-16-17-11-15(20-16)12-7-3-2-4-8-12/h2-11H,1H3,(H,17,18)
DMQWD75 CS COC1=CC=CC=C1NC2=NC=C(O2)C3=CC=CC=C3
DMQWD75 IK DLHCYJIQXKETIN-UHFFFAOYSA-N
DMQWD75 IU N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine
DMQWD75 DE Discovery agent
DME6MYZ ID DME6MYZ
DME6MYZ DN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DME6MYZ HS Investigative
DME6MYZ SN CHEMBL154945; (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7608050; BDBM50048573
DME6MYZ DT Small molecular drug
DME6MYZ PC 10515839
DME6MYZ MW 265.35
DME6MYZ FM C17H19N3
DME6MYZ IC InChI=1S/C17H19N3/c1-3-12-19(16-8-10-18-11-9-16)20-14(2)13-15-6-4-5-7-17(15)20/h4-11,13H,3,12H2,1-2H3
DME6MYZ CS CCCN(C1=CC=NC=C1)N2C(=CC3=CC=CC=C32)C
DME6MYZ IK JCEBKNUYKMFQGZ-UHFFFAOYSA-N
DME6MYZ IU 2-methyl-N-propyl-N-pyridin-4-ylindol-1-amine
DME6MYZ DE Discovery agent
DMQ2XUE ID DMQ2XUE
DMQ2XUE DN (2R)-1-(2,6-dimethylphenoxy)propan-2-amine
DMQ2XUE HS Investigative
DMQ2XUE SN 94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; (2R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N
DMQ2XUE DT Small molecular drug
DMQ2XUE PC 180621
DMQ2XUE MW 179.26
DMQ2XUE FM C11H17NO
DMQ2XUE IC InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1
DMQ2XUE CS CC1=C(C(=CC=C1)C)OC[C@@H](C)N
DMQ2XUE IK VLPIATFUUWWMKC-SNVBAGLBSA-N
DMQ2XUE IU (2R)-1-(2,6-dimethylphenoxy)propan-2-amine
DMQ2XUE CA CAS 94991-73-8
DMQ2XUE DE Discovery agent
DM3K2TI ID DM3K2TI
DM3K2TI DN (2R)-2-Methyl-4,5-dideoxy
DM3K2TI HS Investigative
DM3K2TI DT Small molecular drug
DM3K2TI PC 11064567
DM3K2TI MW 242.16
DM3K2TI FM C7H15O7P
DM3K2TI IC InChI=1S/C7H15O7P/c1-5(7(9)10)6(8)3-2-4-14-15(11,12)13/h5-6,8H,2-4H2,1H3,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1
DM3K2TI CS C[C@H]([C@H](CCCOP(=O)(O)O)O)C(=O)O
DM3K2TI IK MQRCYOMQUQMVCH-RITPCOANSA-N
DM3K2TI IU (2R,3S)-3-hydroxy-2-methyl-6-phosphonooxyhexanoic acid
DM3K2TI DE Discovery agent
DMXPQU6 ID DMXPQU6
DMXPQU6 DN (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMXPQU6 HS Investigative
DMXPQU6 SN CHEMBL1083646; (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); SCHEMBL1404538; BDBM50320177
DMXPQU6 DT Small molecular drug
DMXPQU6 PC 25059294
DMXPQU6 MW 505.8
DMXPQU6 FM C25H23Cl3N2O3
DMXPQU6 IC InChI=1S/C25H23Cl3N2O3/c1-13(31)23(32)29-21-12-25(2,3)33-24-19(21)11-18(14-4-6-15(26)7-5-14)22(30-24)17-9-8-16(27)10-20(17)28/h4-11,13,21,31H,12H2,1-3H3,(H,29,32)/t13-,21?/m1/s1
DMXPQU6 CS C[C@H](C(=O)NC1CC(OC2=C1C=C(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)(C)C)O
DMXPQU6 IK XCFWDLWOCXSJOK-ILRUXTBWSA-N
DMXPQU6 IU (2R)-N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxypropanamide
DMXPQU6 DE Discovery agent
DMX0YIV ID DMX0YIV
DMX0YIV DN (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMX0YIV HS Investigative
DMX0YIV SN CHEMBL1083619; SCHEMBL1404711; BDBM50320187; (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); (2R)-N-(7''-(2-CHLOROPHENYL)-6''-(4-CHLOROPHENYL)-3'',4''-DIHYDROSPIRO[CYCLOHEXANE-1,2''-PYRANO[2,3-B]PYRIDINE]-4''-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMX0YIV DT Small molecular drug
DMX0YIV PC 24995603
DMX0YIV MW 511.4
DMX0YIV FM C28H28Cl2N2O3
DMX0YIV IC InChI=1S/C28H28Cl2N2O3/c1-17(33)26(34)31-24-16-28(13-5-2-6-14-28)35-27-22(24)15-21(18-9-11-19(29)12-10-18)25(32-27)20-7-3-4-8-23(20)30/h3-4,7-12,15,17,24,33H,2,5-6,13-14,16H2,1H3,(H,31,34)/t17-,24?/m1/s1
DMX0YIV CS C[C@H](C(=O)NC1CC2(CCCCC2)OC3=C1C=C(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)O
DMX0YIV IK CBNQOXMUNJAOJO-BPNWFJGMSA-N
DMX0YIV IU (2R)-N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclohexane]-4-yl]-2-hydroxypropanamide
DMX0YIV DE Discovery agent
DMYRHFI ID DMYRHFI
DMYRHFI DN (2R,3R)-iodoreboxetine
DMYRHFI HS Investigative
DMYRHFI SN (2R,3R)-iodoreboxetine; CHEMBL477406
DMYRHFI DT Small molecular drug
DMYRHFI PC 44578857
DMYRHFI MW 439.3
DMYRHFI FM C19H22INO3
DMYRHFI IC InChI=1S/C19H22INO3/c1-2-22-16-5-3-4-6-17(16)24-19(18-13-21-11-12-23-18)14-7-9-15(20)10-8-14/h3-10,18-19,21H,2,11-13H2,1H3/t18-,19-/m1/s1
DMYRHFI CS CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=C(C=C3)I
DMYRHFI IK RVASAZVCHKJYMY-RTBURBONSA-N
DMYRHFI IU (2R)-2-[(R)-(2-ethoxyphenoxy)-(4-iodophenyl)methyl]morpholine
DMYRHFI DE Discovery agent
DMY2FX8 ID DMY2FX8
DMY2FX8 DN (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine
DMY2FX8 HS Investigative
DMY2FX8 SN CHEMBL568336; (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine
DMY2FX8 DT Small molecular drug
DMY2FX8 PC 45487451
DMY2FX8 MW 395.23
DMY2FX8 FM C17H18INO2
DMY2FX8 IC InChI=1S/C17H18INO2/c18-14-8-4-5-9-15(14)21-17(13-6-2-1-3-7-13)16-12-19-10-11-20-16/h1-9,16-17,19H,10-12H2/t16-,17+/m1/s1
DMY2FX8 CS C1CO[C@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC=CC=C3I
DMY2FX8 IK BHMLFPOTZYRDKA-SJORKVTESA-N
DMY2FX8 IU (2R)-2-[(S)-(2-iodophenoxy)-phenylmethyl]morpholine
DMY2FX8 DE Discovery agent
DM260TI ID DM260TI
DM260TI DN (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine
DM260TI HS Investigative
DM260TI SN CHEMBL569927; (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine
DM260TI DT Small molecular drug
DM260TI PC 45487450
DM260TI MW 395.23
DM260TI FM C17H18INO2
DM260TI IC InChI=1S/C17H18INO2/c18-14-7-4-8-15(11-14)21-17(13-5-2-1-3-6-13)16-12-19-9-10-20-16/h1-8,11,16-17,19H,9-10,12H2/t16-,17+/m1/s1
DM260TI CS C1CO[C@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC(=CC=C3)I
DM260TI IK DUYCYXZOEGDUNB-SJORKVTESA-N
DM260TI IU (2R)-2-[(S)-(3-iodophenoxy)-phenylmethyl]morpholine
DM260TI DE Discovery agent
DMKM8E2 ID DMKM8E2
DMKM8E2 DN (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine
DMKM8E2 HS Investigative
DMKM8E2 SN CHEMBL579221; (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine
DMKM8E2 DT Small molecular drug
DMKM8E2 PC 45487461
DMKM8E2 MW 395.23
DMKM8E2 FM C17H18INO2
DMKM8E2 IC InChI=1S/C17H18INO2/c18-14-6-8-15(9-7-14)21-17(13-4-2-1-3-5-13)16-12-19-10-11-20-16/h1-9,16-17,19H,10-12H2/t16-,17+/m1/s1
DMKM8E2 CS C1CO[C@H](CN1)[C@H](C2=CC=CC=C2)OC3=CC=C(C=C3)I
DMKM8E2 IK SFIZDMBLVRMOCD-SJORKVTESA-N
DMKM8E2 IU (2R)-2-[(S)-(4-iodophenoxy)-phenylmethyl]morpholine
DMKM8E2 DE Discovery agent
DM852Z6 ID DM852Z6
DM852Z6 DN (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6 HS Investigative
DM852Z6 SN 3-(6-Amino-purin-9-yl)-nonan-2-ol
DM852Z6 PC 149784
DM852Z6 MW 277.37
DM852Z6 FM C14H23N5O
DM852Z6 IC InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)/t10-,11+/m1/s1
DM852Z6 CS CCCCCC[C@@H]([C@@H](C)O)N1C=NC2=C(N=CN=C21)N
DM852Z6 IK IOSAAWHGJUZBOG-MNOVXSKESA-N
DM852Z6 IU (2R,3S)-3-(6-aminopurin-9-yl)nonan-2-ol
DM852Z6 CA CAS 79813-68-6
DM852Z6 CB CHEBI:63058
DM852Z6 DE Discovery agent
DMDS8AN ID DMDS8AN
DMDS8AN DN (2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol
DMDS8AN HS Investigative
DMDS8AN SN CHEMBL1090540; (2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol; SCHEMBL19829307; BDBM50315255
DMDS8AN DT Small molecular drug
DMDS8AN PC 46866608
DMDS8AN MW 217.31
DMDS8AN FM C11H23NO3
DMDS8AN IC InChI=1S/C11H23NO3/c1-2-3-4-5-6-8-10(14)11(15)9(13)7-12-8/h8-15H,2-7H2,1H3/t8-,9-,10+,11+/m1/s1
DMDS8AN CS CCCCCC[C@@H]1[C@@H]([C@H]([C@@H](CN1)O)O)O
DMDS8AN IK JVCIUBNETYXXOR-ZNSHCXBVSA-N
DMDS8AN IU (2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol
DMDS8AN DE Discovery agent
DMIQNX9 ID DMIQNX9
DMIQNX9 DN (2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol
DMIQNX9 HS Investigative
DMIQNX9 SN CHEMBL1091214; (2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol; SCHEMBL19831655; BDBM50315250
DMIQNX9 DT Small molecular drug
DMIQNX9 PC 11988371
DMIQNX9 MW 259.38
DMIQNX9 FM C14H29NO3
DMIQNX9 IC InChI=1S/C14H29NO3/c1-2-3-4-5-6-7-8-9-11-13(17)14(18)12(16)10-15-11/h11-18H,2-10H2,1H3/t11-,12-,13+,14+/m1/s1
DMIQNX9 CS CCCCCCCCC[C@@H]1[C@@H]([C@H]([C@@H](CN1)O)O)O
DMIQNX9 IK WVYPOMDXOXCTJU-MQYQWHSLSA-N
DMIQNX9 IU (2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol
DMIQNX9 DE Discovery agent
DM7GI94 ID DM7GI94
DM7GI94 DN (2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94 HS Investigative
DM7GI94 SN CHEMBL1089185; (2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94 DT Small molecular drug
DM7GI94 PC 46884602
DM7GI94 MW 175.23
DM7GI94 FM C8H17NO3
DM7GI94 IC InChI=1S/C8H17NO3/c1-2-3-5-7(11)8(12)6(10)4-9-5/h5-12H,2-4H2,1H3/t5-,6-,7+,8+/m1/s1
DM7GI94 CS CCC[C@@H]1[C@@H]([C@H]([C@@H](CN1)O)O)O
DM7GI94 IK JFOGNLDWQBZRQJ-NGJRWZKOSA-N
DM7GI94 IU (2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol
DM7GI94 DE Discovery agent
DMYW40T ID DMYW40T
DMYW40T DN (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate
DMYW40T HS Investigative
DMYW40T SN (2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid; (2R,4R)-APDC; (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid; 169209-63-6; 2R,4R-APDC; CHEMBL40086; CHEBI:40139; EN300-88063; 2R, 4R-APDC monohydrate; 52A; 4-amino-2,4-pyrrolidinedicarboxylic acid; AC1NSJRT; AC1Q4UAD; SCHEMBL158843; 2R, 4R-APDC; (2R,3R)-APDC; GTPL1392; CTK0E5090; DTXSID10415500; MolPort-003-982-102; BDBM50052398; ZINC32628523; SBB067830; MFCD16875409; AKOS015916056; AKOS015854214; RTC-065564; FCH3884669; NCGC00025040-02; LY314593; AJ-85443; SC-48823; TC-065564; B6634
DMYW40T DT Small molecular drug
DMYW40T PC 5310984
DMYW40T MW 174.15
DMYW40T FM C6H10N2O4
DMYW40T IC InChI=1S/C6H10N2O4/c7-6(5(11)12)1-3(4(9)10)8-2-6/h3,8H,1-2,7H2,(H,9,10)(H,11,12)/t3-,6-/m1/s1
DMYW40T CS C1[C@@H](NC[C@]1(C(=O)O)N)C(=O)O
DMYW40T IK XZFMJVJDSYRWDQ-AWFVSMACSA-N
DMYW40T IU (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid
DMYW40T CA CAS 169209-63-6
DMYW40T CB CHEBI:40139
DMYW40T DE Discovery agent
DMSFXEO ID DMSFXEO
DMSFXEO DN (2R,5R)-delta-methyl-alpha-acetylenic putrescine
DMSFXEO HS Investigative
DMSFXEO SN 6-Heptyne-2,5-diamine; Methylacetylenic putrescine; Methyl-acetylenicputrescine; Mdl 72175; 8-Methyl-8-acetylenic putrescine; delta-Methyl-alpha acetylene putrescine; Hept-6-yne-2,5-diamine; MDL-72175; AC1L3U4J; 81645-70-7; SCHEMBL4808395; CTK5F9486; AC1Q2832; AKOS006338563; 1-Ethynyl-4-methyl-1,4-butanediamine
DMSFXEO DT Small molecular drug
DMSFXEO PC 122175
DMSFXEO MW 126.2
DMSFXEO FM C7H14N2
DMSFXEO IC InChI=1S/C7H14N2/c1-3-7(9)5-4-6(2)8/h1,6-7H,4-5,8-9H2,2H3
DMSFXEO CS CC(CCC(C#C)N)N
DMSFXEO IK QIADQCOYEFCREQ-UHFFFAOYSA-N
DMSFXEO IU hept-6-yne-2,5-diamine
DMSFXEO CA CAS 81645-70-7
DMSFXEO DE Discovery agent
DMIS39C ID DMIS39C
DMIS39C DN (2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine
DMIS39C HS Investigative
DMIS39C SN CHEMBL261476; SCHEMBL905958
DMIS39C DT Small molecular drug
DMIS39C PC 44452811
DMIS39C MW 215.25
DMIS39C FM C12H13N3O
DMIS39C IC InChI=1S/C12H13N3O/c1-8(13)7-15-12-9(6-14-15)2-3-11-10(12)4-5-16-11/h2-6,8H,7,13H2,1H3/t8-/m0/s1
DMIS39C CS C[C@@H](CN1C2=C(C=CC3=C2C=CO3)C=N1)N
DMIS39C IK XAEAYQWCVVRSFL-QMMMGPOBSA-N
DMIS39C IU (2S)-1-furo[2,3-g]indazol-1-ylpropan-2-amine
DMIS39C DE Discovery agent
DMW4ARM ID DMW4ARM
DMW4ARM DN (2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine
DMW4ARM HS Investigative
DMW4ARM SN CHEMBL257503; (S)-1-(5-Fluoro-1H-indazol-1-yl)propan-2-amine; 210580-57-7; BDBM50375463; AKOS024258782
DMW4ARM DT Small molecular drug
DMW4ARM PC 44452853
DMW4ARM MW 193.22
DMW4ARM FM C10H12FN3
DMW4ARM IC InChI=1S/C10H12FN3/c1-7(12)6-14-10-3-2-9(11)4-8(10)5-13-14/h2-5,7H,6,12H2,1H3/t7-/m0/s1
DMW4ARM CS C[C@@H](CN1C2=C(C=C(C=C2)F)C=N1)N
DMW4ARM IK ILPBKZWYZJHZAZ-ZETCQYMHSA-N
DMW4ARM IU (2S)-1-(5-fluoroindazol-1-yl)propan-2-amine
DMW4ARM DE Discovery agent
DM31SNW ID DM31SNW
DM31SNW DN (2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine
DM31SNW HS Investigative
DM31SNW SN CHEMBL256623
DM31SNW DT Small molecular drug
DM31SNW PC 9859429
DM31SNW MW 193.22
DM31SNW FM C10H12FN3
DM31SNW IC InChI=1S/C10H12FN3/c1-7(12)6-14-10-4-9(11)3-2-8(10)5-13-14/h2-5,7H,6,12H2,1H3/t7-/m0/s1
DM31SNW CS C[C@@H](CN1C2=C(C=CC(=C2)F)C=N1)N
DM31SNW IK OARAVURQNSHWSP-ZETCQYMHSA-N
DM31SNW IU (2S)-1-(6-fluoroindazol-1-yl)propan-2-amine
DM31SNW DE Discovery agent
DMYALON ID DMYALON
DMYALON DN (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine
DMYALON HS Investigative
DMYALON SN (S)-2-(6-methoxyindazol-1-yl)-1-methylethylamine
DMYALON PC 11708275
DMYALON MW 205.26
DMYALON FM C11H15N3O
DMYALON IC InChI=1S/C11H15N3O/c1-8(12)7-14-11-5-10(15-2)4-3-9(11)6-13-14/h3-6,8H,7,12H2,1-2H3/t8-/m0/s1
DMYALON CS C[C@@H](CN1C2=C(C=CC(=C2)OC)C=N1)N
DMYALON IK WSEWULCWBQDNEH-QMMMGPOBSA-N
DMYALON IU (2S)-1-(6-methoxyindazol-1-yl)propan-2-amine
DMYALON DE Discovery agent
DMNKEUG ID DMNKEUG
DMNKEUG DN (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMNKEUG HS Investigative
DMNKEUG SN (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid
DMNKEUG DT Small molecular drug
DMNKEUG PC 11460087
DMNKEUG MW 276.71
DMNKEUG FM C15H13ClO3
DMNKEUG IC InChI=1S/C15H13ClO3/c16-12-6-8-13(9-7-12)19-14(15(17)18)10-11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)/t14-/m0/s1
DMNKEUG CS C1=CC=C(C=C1)C[C@@H](C(=O)O)OC2=CC=C(C=C2)Cl
DMNKEUG IK CPBLTMSKPQDJPW-AWEZNQCLSA-N
DMNKEUG IU (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMNKEUG DE Discovery agent
DMYBXHF ID DMYBXHF
DMYBXHF DN (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
DMYBXHF HS Investigative
DMYBXHF SN (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid; CHEMBL191060; ZINC13671697; BDBM50171895; DB07842; (S)-2-(4-Ethyl-phenoxy)-3-phenyl-propionic acid
DMYBXHF DT Small molecular drug
DMYBXHF PC 11149906
DMYBXHF MW 270.32
DMYBXHF FM C17H18O3
DMYBXHF IC InChI=1S/C17H18O3/c1-2-13-8-10-15(11-9-13)20-16(17(18)19)12-14-6-4-3-5-7-14/h3-11,16H,2,12H2,1H3,(H,18,19)/t16-/m0/s1
DMYBXHF CS CCC1=CC=C(C=C1)O[C@@H](CC2=CC=CC=C2)C(=O)O
DMYBXHF IK CJMVTSLLWMPEKQ-INIZCTEOSA-N
DMYBXHF IU (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
DMYBXHF DE Discovery agent
DM73TPQ ID DM73TPQ
DM73TPQ DN (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
DM73TPQ HS Investigative
DM73TPQ SN LT175; (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid; 862901-87-9; CHEMBL191275; LRG; (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic Acid; SCHEMBL20553479; BDBM28759; SYN5198; AOB2972; MolPort-039-138-772; ZINC13671695; LT 175; DB08121; LT175 (S-1); NCGC00402292-03
DM73TPQ DT Small molecular drug
DM73TPQ PC 11483970
DM73TPQ MW 318.4
DM73TPQ FM C21H18O3
DM73TPQ IC InChI=1S/C21H18O3/c22-21(23)20(15-16-7-3-1-4-8-16)24-19-13-11-18(12-14-19)17-9-5-2-6-10-17/h1-14,20H,15H2,(H,22,23)/t20-/m0/s1
DM73TPQ CS C1=CC=C(C=C1)C[C@@H](C(=O)O)OC2=CC=C(C=C2)C3=CC=CC=C3
DM73TPQ IK TZTPJJNNACUQQR-FQEVSTJZSA-N
DM73TPQ IU (2S)-3-phenyl-2-(4-phenylphenoxy)propanoic acid
DM73TPQ DE Discovery agent
DMMP8TR ID DMMP8TR
DMMP8TR DN (2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE
DMMP8TR HS Investigative
DMMP8TR SN (2s)-2-(Butyryloxy)-3-Hydroxypropyl Nonanoate; (2S)-2-(butanoyloxy)-3-hydroxypropyl nonanoate; B3H; AC1L9LSC; DB07416; [(2S)-2-butanoyloxy-3-hydroxypropyl] nonanoate
DMMP8TR DT Small molecular drug
DMMP8TR PC 448271
DMMP8TR MW 302.41
DMMP8TR FM C16H30O5
DMMP8TR IC InChI=1S/C16H30O5/c1-3-5-6-7-8-9-11-15(18)20-13-14(12-17)21-16(19)10-4-2/h14,17H,3-13H2,1-2H3/t14-/m0/s1
DMMP8TR CS CCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC
DMMP8TR IK JCEXPOMAGTUEEX-AWEZNQCLSA-N
DMMP8TR IU [(2S)-2-butanoyloxy-3-hydroxypropyl] nonanoate
DMMP8TR DE Discovery agent
DMZOX43 ID DMZOX43
DMZOX43 DN (2S)-2'-methoxy kurarinone
DMZOX43 HS Investigative
DMZOX43 SN 2'-Methoxykurarinone; (2S)-2'-methoxykurarinone; 270249-38-2; CHEMBL496451; CHEBI:66151; (2S)-2'-methoxy kurarinone; (2S)-7,4'-Dihydroxy-8-lavandulyl-5,2'-dimethoxyflavanone; MolPort-039-337-150; ZINC14711635; LMPK12140500; BDBM50377944; AKOS032962578; 7,4'-dihydroxy-5,2'-dimethoxy-8-lavandulylflavanone; 4H-1-Benzopyran-4-one,2,3-dihydro-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2R)-5-methyl-2-(1-methylethenyl)-4-hexenyl]-, (2S)-
DMZOX43 DT Small molecular drug
DMZOX43 PC 11982641
DMZOX43 MW 452.5
DMZOX43 FM C27H32O6
DMZOX43 IC InChI=1S/C27H32O6/c1-15(2)7-8-17(16(3)4)11-20-21(29)13-25(32-6)26-22(30)14-24(33-27(20)26)19-10-9-18(28)12-23(19)31-5/h7,9-10,12-13,17,24,28-29H,3,8,11,14H2,1-2,4-6H3/t17-,24+/m1/s1
DMZOX43 CS CC(=CC[C@H](CC1=C2C(=C(C=C1O)OC)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C
DMZOX43 IK KTAQQSUPNZAWEY-OSPHWJPCSA-N
DMZOX43 IU (2S)-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMZOX43 CB CHEBI:66151
DMZOX43 DE Discovery agent
DMYVBHT ID DMYVBHT
DMYVBHT DN (2S)-5,7,2',4'-tetrahydroxyflavanone
DMYVBHT HS Investigative
DMYVBHT SN steppogenin; 56486-94-3; (2S)-5,7,2',4'-tetrahydroxyflavanone; CHEMBL458395; (+)-Norartocarpanone; SCHEMBL6822729; QBLQLKNOKUHRCH-ZDUSSCGKSA-N; MolPort-035-705-966; ZINC14728050; BDBM50251005; AKOS032962442; (2S)-5,7,2'',4''-tetrahydroxyflavanone; W1600; (S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; (2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4h-chromen -4-one
DMYVBHT DT Small molecular drug
DMYVBHT PC 10356745
DMYVBHT MW 288.25
DMYVBHT FM C15H12O6
DMYVBHT IC InChI=1S/C15H12O6/c16-7-1-2-9(10(18)3-7)13-6-12(20)15-11(19)4-8(17)5-14(15)21-13/h1-5,13,16-19H,6H2/t13-/m0/s1
DMYVBHT CS C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=C(C=C(C=C3)O)O
DMYVBHT IK QBLQLKNOKUHRCH-ZDUSSCGKSA-N
DMYVBHT IU (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMYVBHT CA CAS 56486-94-3
DMYVBHT DE Discovery agent
DM5V3M1 ID DM5V3M1
DM5V3M1 DN (2S)-abyssinone II
DM5V3M1 HS Investigative
DM5V3M1 SN Licoflavanone; (2S)-abyssinone II; CHEMBL457680; SCHEMBL3364539; MolPort-006-668-332; BDBM50251004; LMPK12140288; AKOS027393733; MCULE-9485581712; 4',5,7-trihydroxy-3'-prenylflavanone; (S)-4',5,7-Trihydroxy-3'-prenylflavanone
DM5V3M1 DT Small molecular drug
DM5V3M1 PC 14218027
DM5V3M1 MW 340.4
DM5V3M1 FM C20H20O5
DM5V3M1 IC InChI=1S/C20H20O5/c1-11(2)3-4-12-7-13(5-6-15(12)22)18-10-17(24)20-16(23)8-14(21)9-19(20)25-18/h3,5-9,18,21-23H,4,10H2,1-2H3
DM5V3M1 CS CC(=CCC1=C(C=CC(=C1)C2CC(=O)C3=C(C=C(C=C3O2)O)O)O)C
DM5V3M1 IK CGKWSLSAYABZTL-UHFFFAOYSA-N
DM5V3M1 IU 5,7-dihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DM5V3M1 CA CAS 119240-82-3
DM5V3M1 DE Discovery agent
DMWQK86 ID DMWQK86
DMWQK86 DN (2S)-aminobutyryl-(R)-pipecolinic acid amide
DMWQK86 HS Investigative
DMWQK86 SN CHEMBL225617; (2S)-aminobutyryl-(R)-pipecolinic acid amide
DMWQK86 DT Small molecular drug
DMWQK86 PC 11672950
DMWQK86 MW 213.28
DMWQK86 FM C10H19N3O2
DMWQK86 IC InChI=1S/C10H19N3O2/c1-2-7(11)10(15)13-6-4-3-5-8(13)9(12)14/h7-8H,2-6,11H2,1H3,(H2,12,14)/t7-,8+/m0/s1
DMWQK86 CS CC[C@@H](C(=O)N1CCCC[C@@H]1C(=O)N)N
DMWQK86 IK CRFULCBPWYMTAL-JGVFFNPUSA-N
DMWQK86 IU (2R)-1-[(2S)-2-aminobutanoyl]piperidine-2-carboxamide
DMWQK86 DE Discovery agent
DMG0QKL ID DMG0QKL
DMG0QKL DN (2S)-aminobutyryl-L-prolinamide
DMG0QKL HS Investigative
DMG0QKL SN CHEMBL224063; (2S)-aminobutyryl-L-prolinamide
DMG0QKL DT Small molecular drug
DMG0QKL PC 11579307
DMG0QKL MW 199.25
DMG0QKL FM C9H17N3O2
DMG0QKL IC InChI=1S/C9H17N3O2/c1-2-6(10)9(14)12-5-3-4-7(12)8(11)13/h6-7H,2-5,10H2,1H3,(H2,11,13)/t6-,7-/m0/s1
DMG0QKL CS CC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMG0QKL IK JNTYXKIFNYMZLM-BQBZGAKWSA-N
DMG0QKL IU (2S)-1-[(2S)-2-aminobutanoyl]pyrrolidine-2-carboxamide
DMG0QKL DE Discovery agent
DMTFP0Z ID DMTFP0Z
DMTFP0Z DN (2S)-aminobutyryl-L-proline (R)-sec-butylamide
DMTFP0Z HS Investigative
DMTFP0Z SN CHEMBL376183; (2S)-aminobutyryl-L-proline (R)-sec-butylamide
DMTFP0Z DT Small molecular drug
DMTFP0Z PC 11579736
DMTFP0Z MW 255.36
DMTFP0Z FM C13H25N3O2
DMTFP0Z IC InChI=1S/C13H25N3O2/c1-4-9(3)15-12(17)11-7-6-8-16(11)13(18)10(14)5-2/h9-11H,4-8,14H2,1-3H3,(H,15,17)/t9-,10+,11+/m1/s1
DMTFP0Z CS CC[C@@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DMTFP0Z IK VEBCSYAWQCGSMV-VWYCJHECSA-N
DMTFP0Z IU (2S)-1-[(2S)-2-aminobutanoyl]-N-[(2R)-butan-2-yl]pyrrolidine-2-carboxamide
DMTFP0Z CA CAS 885007-99-8
DMTFP0Z DE Discovery agent
DMO5ZEK ID DMO5ZEK
DMO5ZEK DN (2S)-aminobutyryl-L-proline isobutylamide
DMO5ZEK HS Investigative
DMO5ZEK SN CHEMBL223556; (2S)-aminobutyryl-L-proline isobutylamide; SCHEMBL6241779
DMO5ZEK DT Small molecular drug
DMO5ZEK PC 11499834
DMO5ZEK MW 255.36
DMO5ZEK FM C13H25N3O2
DMO5ZEK IC InChI=1S/C13H25N3O2/c1-4-10(14)13(18)16-7-5-6-11(16)12(17)15-8-9(2)3/h9-11H,4-8,14H2,1-3H3,(H,15,17)/t10-,11-/m0/s1
DMO5ZEK CS CC[C@@H](C(=O)N1CCC[C@H]1C(=O)NCC(C)C)N
DMO5ZEK IK IJQXRRHHARNIBV-QWRGUYRKSA-N
DMO5ZEK IU (2S)-1-[(2S)-2-aminobutanoyl]-N-(2-methylpropyl)pyrrolidine-2-carboxamide
DMO5ZEK DE Discovery agent
DM12Q9O ID DM12Q9O
DM12Q9O DN (2S)-aminobutyryl-L-proline n-butylamide
DM12Q9O HS Investigative
DM12Q9O SN CHEMBL225540; (2S)-aminobutyryl-L-proline n-butylamide; SCHEMBL6242775
DM12Q9O DT Small molecular drug
DM12Q9O PC 11514390
DM12Q9O MW 255.36
DM12Q9O FM C13H25N3O2
DM12Q9O IC InChI=1S/C13H25N3O2/c1-3-5-8-15-12(17)11-7-6-9-16(11)13(18)10(14)4-2/h10-11H,3-9,14H2,1-2H3,(H,15,17)/t10-,11-/m0/s1
DM12Q9O CS CCCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DM12Q9O IK ZUFOHXXZTMOECH-QWRGUYRKSA-N
DM12Q9O IU (2S)-1-[(2S)-2-aminobutanoyl]-N-butylpyrrolidine-2-carboxamide
DM12Q9O DE Discovery agent
DM1DJX2 ID DM1DJX2
DM1DJX2 DN (2S)-aminobutyryl-L-proline n-pentylamide
DM1DJX2 HS Investigative
DM1DJX2 SN CHEMBL376374; (2S)-aminobutyryl-L-proline n-pentylamide; SCHEMBL6242559
DM1DJX2 DT Small molecular drug
DM1DJX2 PC 11615987
DM1DJX2 MW 269.38
DM1DJX2 FM C14H27N3O2
DM1DJX2 IC InChI=1S/C14H27N3O2/c1-3-5-6-9-16-13(18)12-8-7-10-17(12)14(19)11(15)4-2/h11-12H,3-10,15H2,1-2H3,(H,16,18)/t11-,12-/m0/s1
DM1DJX2 CS CCCCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DM1DJX2 IK DFWCJPNYAWVSTR-RYUDHWBXSA-N
DM1DJX2 IU (2S)-1-[(2S)-2-aminobutanoyl]-N-pentylpyrrolidine-2-carboxamide
DM1DJX2 DE Discovery agent
DM6WXJO ID DM6WXJO
DM6WXJO DN (2S)-aminobutyryl-L-proline n-propylamide
DM6WXJO HS Investigative
DM6WXJO SN CHEMBL225539; (2S)-aminobutyryl-L-proline n-propylamide; SCHEMBL6243789
DM6WXJO DT Small molecular drug
DM6WXJO PC 11637307
DM6WXJO MW 241.33
DM6WXJO FM C12H23N3O2
DM6WXJO IC InChI=1S/C12H23N3O2/c1-3-7-14-11(16)10-6-5-8-15(10)12(17)9(13)4-2/h9-10H,3-8,13H2,1-2H3,(H,14,16)/t9-,10-/m0/s1
DM6WXJO CS CCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DM6WXJO IK PGTCIDPUBJUXTD-UWVGGRQHSA-N
DM6WXJO IU (2S)-1-[(2S)-2-aminobutanoyl]-N-propylpyrrolidine-2-carboxamide
DM6WXJO DE Discovery agent
DMEWU6Z ID DMEWU6Z
DMEWU6Z DN (2S)-aminobutyryl-L-proline-(2S)-methylbutylamide
DMEWU6Z HS Investigative
DMEWU6Z SN CHEMBL223719; (2S)-aminobutyryl-L-proline-(2S)-methylbutylamide
DMEWU6Z DT Small molecular drug
DMEWU6Z PC 11623159
DMEWU6Z MW 269.38
DMEWU6Z FM C14H27N3O2
DMEWU6Z IC InChI=1S/C14H27N3O2/c1-4-10(3)9-16-13(18)12-7-6-8-17(12)14(19)11(15)5-2/h10-12H,4-9,15H2,1-3H3,(H,16,18)/t10-,11-,12-/m0/s1
DMEWU6Z CS CC[C@H](C)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC)N
DMEWU6Z IK KKFKEHDSJNUMHG-SRVKXCTJSA-N
DMEWU6Z IU (2S)-1-[(2S)-2-aminobutanoyl]-N-[(2S)-2-methylbutyl]pyrrolidine-2-carboxamide
DMEWU6Z DE Discovery agent
DM6L0KZ ID DM6L0KZ
DM6L0KZ DN (2S)-euchrenone a7
DM6L0KZ HS Investigative
DM6L0KZ SN (2S)-euchrenone a7; CHEMBL457686; JJOUBYOHNYJCOU-IBGZPJMESA-N
DM6L0KZ DT Small molecular drug
DM6L0KZ PC 44593508
DM6L0KZ MW 340.4
DM6L0KZ FM C20H20O5
DM6L0KZ IC InChI=1S/C20H20O5/c1-11(2)3-5-14-16(22)8-7-15-18(24)10-19(25-20(14)15)13-6-4-12(21)9-17(13)23/h3-4,6-9,19,21-23H,5,10H2,1-2H3/t19-/m0/s1
DM6L0KZ CS CC(=CCC1=C(C=CC2=C1O[C@@H](CC2=O)C3=C(C=C(C=C3)O)O)O)C
DM6L0KZ IK JJOUBYOHNYJCOU-IBGZPJMESA-N
DM6L0KZ IU (2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
DM6L0KZ DE Discovery agent
DMRCMIT ID DMRCMIT
DMRCMIT DN (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMRCMIT HS Investigative
DMRCMIT SN CHEMBL1084820; SCHEMBL1404587; BDBM50320186; (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); (2S)-N-(7''-(2-CHLOROPHENYL)-6''-(4-CHLOROPHENYL)-3'',4''-DIHYDROSPIRO[CYCLOHEXANE-1,2''-PYRANO[2,3-B]PYRIDINE]-4''-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMRCMIT DT Small molecular drug
DMRCMIT PC 24995604
DMRCMIT MW 511.4
DMRCMIT FM C28H28Cl2N2O3
DMRCMIT IC InChI=1S/C28H28Cl2N2O3/c1-17(33)26(34)31-24-16-28(13-5-2-6-14-28)35-27-22(24)15-21(18-9-11-19(29)12-10-18)25(32-27)20-7-3-4-8-23(20)30/h3-4,7-12,15,17,24,33H,2,5-6,13-14,16H2,1H3,(H,31,34)/t17-,24?/m0/s1
DMRCMIT CS C[C@@H](C(=O)NC1CC2(CCCCC2)OC3=C1C=C(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)O
DMRCMIT IK CBNQOXMUNJAOJO-KEJDIYNNSA-N
DMRCMIT IU (2S)-N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclohexane]-4-yl]-2-hydroxypropanamide
DMRCMIT DE Discovery agent
DMZON3T ID DMZON3T
DMZON3T DN (2s)-Pyrrolidin-2-Ylmethylamine
DMZON3T HS Investigative
DMZON3T SN (S)-pyrrolidin-2-ylmethanamine; 69500-64-7; (S)-(+)-2-(Aminomethyl)pyrrolidine; (2S)-PYRROLIDIN-2-YLMETHYLAMINE; (S)-2-(Aminomethyl)pyrrolidine; (S)-2-aminomethylpyrrolidine; (S)-pyrrolidin-2-ylmethylamine; [(2S)-pyrrolidin-2-yl]methanamine; 1-[(2S)-pyrrolidin-2-yl]methanamine; 2-Pyrrolidinemethanamine, (2S)-; (S)-(+)-2-(Aminomethyl)pyrrolidine, 98%; AC1MC09B; SCHEMBL83314; CHEBI:44632; CTK5D0186; (2S)-pyrrolidin-2-ylmethanamine; MolPort-003-932-494; AUKXFNABVHIUAC-YFKPBYRVSA-N; (2S)-Pyrrolidin-2-yl-methylamine; ZINC39357503
DMZON3T DT Small molecular drug
DMZON3T PC 2734054
DMZON3T MW 100.16
DMZON3T FM C5H12N2
DMZON3T IC InChI=1S/C5H12N2/c6-4-5-2-1-3-7-5/h5,7H,1-4,6H2/t5-/m0/s1
DMZON3T CS C1C[C@H](NC1)CN
DMZON3T IK AUKXFNABVHIUAC-YFKPBYRVSA-N
DMZON3T IU [(2S)-pyrrolidin-2-yl]methanamine
DMZON3T CB CHEBI:44632
DMZON3T DE Discovery agent
DMLS29E ID DMLS29E
DMLS29E DN (2S,1'R,2'S)-2-(2'-phosphonocyclopropyl)glycine
DMLS29E HS Investigative
DMLS29E SN CHEMBL442076; BDBM50207814
DMLS29E DT Small molecular drug
DMLS29E PC 11708219
DMLS29E MW 195.11
DMLS29E FM C5H10NO5P
DMLS29E IC InChI=1S/C5H10NO5P/c6-4(5(7)8)2-1-3(2)12(9,10)11/h2-4H,1,6H2,(H,7,8)(H2,9,10,11)/t2-,3-,4?/m0/s1
DMLS29E CS C1[C@@H]([C@H]1P(=O)(O)O)C(C(=O)O)N
DMLS29E IK KZOMBNQLBSHMFV-LPGMDIISSA-N
DMLS29E IU 2-amino-2-[(1R,2S)-2-phosphonocyclopropyl]acetic acid
DMLS29E DE Discovery agent
DMJE83O ID DMJE83O
DMJE83O DN (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone
DMJE83O HS Investigative
DMJE83O SN CHEMBL212678; (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone; BDBM50186510
DMJE83O DT Small molecular drug
DMJE83O PC 44413811
DMJE83O MW 234.29
DMJE83O FM C14H18O3
DMJE83O IC InChI=1S/C14H18O3/c1-16-13-9-5-8-12(15)14(13)17-10-11-6-3-2-4-7-11/h2-4,6-7,13-14H,5,8-10H2,1H3/t13-,14-/m1/s1
DMJE83O CS CO[C@@H]1CCCC(=O)[C@H]1OCC2=CC=CC=C2
DMJE83O IK KUAHCCGAHBFAKU-ZIAGYGMSSA-N
DMJE83O IU (2S,3R)-3-methoxy-2-phenylmethoxycyclohexan-1-one
DMJE83O DE Discovery agent
DM4JQCR ID DM4JQCR
DM4JQCR DN (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol
DM4JQCR HS Investigative
DM4JQCR SN CHEMBL296435; (2S,3R)-EHNA; CHEBI:63059; (2S,3R)-3-(6-aminopurin-9-yl)nonan-2-ol; 79813-69-7; (S,R)-6-amino-beta-hexyl-alpha-methyl-9H-purine-9-ethanol; HWC 46; 2z7g; AC1L3ZQL; (+)-erythro-9-(2-Hydroxy-3-nonyl)adenine; SCHEMBL1742728; CTK2H9986; BDBM28393; IOSAAWHGJUZBOG-WDEREUQCSA-N; ZINC1558334; EH9; (S-(R*,S*))-6-Amino-beta-hexyl-alpha-methyl-9H-purine-9-ethanol; AKOS030531307; 9H-Purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, (S-(R*,S*))-; DB07711
DM4JQCR DT Small molecular drug
DM4JQCR PC 149790
DM4JQCR MW 277.37
DM4JQCR FM C14H23N5O
DM4JQCR IC InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)/t10-,11+/m0/s1
DM4JQCR CS CCCCCC[C@H]([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DM4JQCR IK IOSAAWHGJUZBOG-WDEREUQCSA-N
DM4JQCR IU (2S,3R)-3-(6-aminopurin-9-yl)nonan-2-ol
DM4JQCR CA CAS 79813-69-7
DM4JQCR CB CHEBI:63059
DM4JQCR DE Discovery agent
DMDUI8R ID DMDUI8R
DMDUI8R DN (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol
DMDUI8R HS Investigative
DMDUI8R SN CHEMBL1173277; (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol; SCHEMBL15007654; RLZACOPBIXSOEX-SMDDNHRTSA-N
DMDUI8R DT Small molecular drug
DMDUI8R PC 46837650
DMDUI8R MW 235.32
DMDUI8R FM C14H21NO2
DMDUI8R IC InChI=1S/C14H21NO2/c1-10-6-5-7-12(8-10)14(16)11(2)15-13(3,4)9-17-14/h5-8,11,15-16H,9H2,1-4H3/t11-,14+/m0/s1
DMDUI8R CS C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC(=C2)C)O
DMDUI8R IK RLZACOPBIXSOEX-SMDDNHRTSA-N
DMDUI8R IU (2S,3S)-3,5,5-trimethyl-2-(3-methylphenyl)morpholin-2-ol
DMDUI8R DE Discovery agent
DMDUGZS ID DMDUGZS
DMDUGZS DN (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol
DMDUGZS HS Investigative
DMDUGZS SN CHEMBL1173274; (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol; SCHEMBL15007461; NGHJSSNVKXEBAB-GXFFZTMASA-N
DMDUGZS DT Small molecular drug
DMDUGZS PC 46837647
DMDUGZS MW 221.29
DMDUGZS FM C13H19NO2
DMDUGZS IC InChI=1S/C13H19NO2/c1-10-13(15,11-7-5-4-6-8-11)16-9-12(2,3)14-10/h4-8,10,14-15H,9H2,1-3H3/t10-,13+/m0/s1
DMDUGZS CS C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC=CC=C2)O
DMDUGZS IK NGHJSSNVKXEBAB-GXFFZTMASA-N
DMDUGZS IU (2S,3S)-3,5,5-trimethyl-2-phenylmorpholin-2-ol
DMDUGZS DE Discovery agent
DMBEOIQ ID DMBEOIQ
DMBEOIQ DN (2S,3S)-iodoreboxetine
DMBEOIQ HS Investigative
DMBEOIQ SN (2S,3S)-iodoreboxetine; CHEMBL490996; BDBM50264064
DMBEOIQ DT Small molecular drug
DMBEOIQ PC 44579601
DMBEOIQ MW 439.3
DMBEOIQ FM C19H22INO3
DMBEOIQ IC InChI=1S/C19H22INO3/c1-2-22-16-5-3-4-6-17(16)24-19(18-13-21-11-12-23-18)14-7-9-15(20)10-8-14/h3-10,18-19,21H,2,11-13H2,1H3/t18-,19-/m0/s1
DMBEOIQ CS CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=C(C=C3)I
DMBEOIQ IK RVASAZVCHKJYMY-OALUTQOASA-N
DMBEOIQ IU (2S)-2-[(S)-(2-ethoxyphenoxy)-(4-iodophenyl)methyl]morpholine
DMBEOIQ DE Discovery agent
DMTQF2G ID DMTQF2G
DMTQF2G DN (2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid
DMTQF2G HS Investigative
DMTQF2G SN CHEMBL482080; (2s,4r)-4-(3-Methoxy-3-Oxopropyl) Glutamic Acid; (2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid; ZINC40934342; BDBM50252048; (4R)-4-(3-methoxy-3-oxopropyl)-L-glutamic acid; (2S,4R)-2-amino-4-(3-methoxy-3-oxopropyl)pentanedioic acid
DMTQF2G DT Small molecular drug
DMTQF2G PC 24905704
DMTQF2G MW 233.22
DMTQF2G FM C9H15NO6
DMTQF2G IC InChI=1S/C9H15NO6/c1-16-7(11)3-2-5(8(12)13)4-6(10)9(14)15/h5-6H,2-4,10H2,1H3,(H,12,13)(H,14,15)/t5-,6+/m1/s1
DMTQF2G CS COC(=O)CC[C@H](C[C@@H](C(=O)O)N)C(=O)O
DMTQF2G IK IPTIKQIFOOZKAT-RITPCOANSA-N
DMTQF2G IU (2S,4R)-2-amino-4-(3-methoxy-3-oxopropyl)pentanedioic acid
DMTQF2G DE Discovery agent
DMGXRSZ ID DMGXRSZ
DMGXRSZ DN (2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime
DMGXRSZ HS Investigative
DMGXRSZ DT Small molecular drug
DMGXRSZ PC 46222473
DMGXRSZ DE Discovery agent
DM6AUHR ID DM6AUHR
DM6AUHR DN (2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime
DM6AUHR HS Investigative
DM6AUHR DT Small molecular drug
DM6AUHR PC 46222693
DM6AUHR DE Discovery agent
DMD7WGM ID DMD7WGM
DMD7WGM DN (2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime
DMD7WGM HS Investigative
DMD7WGM DT Small molecular drug
DMD7WGM PC 46222245
DMD7WGM DE Discovery agent
DMZ0V6G ID DMZ0V6G
DMZ0V6G DN (2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime
DMZ0V6G HS Investigative
DMZ0V6G DT Small molecular drug
DMZ0V6G PC 46222697
DMZ0V6G DE Discovery agent
DMO7RFL ID DMO7RFL
DMO7RFL DN (2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime
DMO7RFL HS Investigative
DMO7RFL DT Small molecular drug
DMO7RFL PC 46222474
DMO7RFL DE Discovery agent
DMJ4ABD ID DMJ4ABD
DMJ4ABD DN (2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime
DMJ4ABD HS Investigative
DMJ4ABD DT Small molecular drug
DMJ4ABD PC 46222694
DMJ4ABD DE Discovery agent
DM9LQH1 ID DM9LQH1
DM9LQH1 DN (2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime
DM9LQH1 HS Investigative
DM9LQH1 DT Small molecular drug
DM9LQH1 PC 46222470
DM9LQH1 DE Discovery agent
DMQDH3N ID DMQDH3N
DMQDH3N DN (2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime
DMQDH3N HS Investigative
DMQDH3N DT Small molecular drug
DMQDH3N PC 46223585
DMQDH3N DE Discovery agent
DMAS3JC ID DMAS3JC
DMAS3JC DN (2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime
DMAS3JC HS Investigative
DMAS3JC DT Small molecular drug
DMAS3JC PC 46222698
DMAS3JC DE Discovery agent
DMYLX0U ID DMYLX0U
DMYLX0U DN (2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime
DMYLX0U HS Investigative
DMYLX0U DT Small molecular drug
DMYLX0U PC 46222472
DMYLX0U DE Discovery agent
DMXZ2UC ID DMXZ2UC
DMXZ2UC DN (2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime
DMXZ2UC HS Investigative
DMXZ2UC DT Small molecular drug
DMXZ2UC PC 46222476
DMXZ2UC DE Discovery agent
DM0S82C ID DM0S82C
DM0S82C DN (2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime
DM0S82C HS Investigative
DM0S82C DT Small molecular drug
DM0S82C PC 46222244
DM0S82C DE Discovery agent
DMLOIUK ID DMLOIUK
DMLOIUK DN (2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime
DMLOIUK HS Investigative
DMLOIUK DT Small molecular drug
DMLOIUK PC 46223584
DMLOIUK DE Discovery agent
DM6BA5L ID DM6BA5L
DM6BA5L DN (2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime
DM6BA5L HS Investigative
DM6BA5L DT Small molecular drug
DM6BA5L PC 46222696
DM6BA5L DE Discovery agent
DMUIOAP ID DMUIOAP
DMUIOAP DN (2'Z,3'E)-7-Azaindirubin-3'-oxime
DMUIOAP HS Investigative
DMUIOAP DT Small molecular drug
DMUIOAP PC 44614397
DMUIOAP DE Discovery agent
DMBZJT5 ID DMBZJT5
DMBZJT5 DN (3-((1H-imidazol-1-yl)methyl)phenyl)methanol
DMBZJT5 HS Investigative
DMBZJT5 SN [3-(1H-Imidazol-1-ylmethyl)phenyl]methanol; 151055-79-7; CHEMBL597368; W-205714; [3-(imidazol-1-ylmethyl)phenyl]methanol; Benzenemethanol, 3-(1H-imidazol-1-ylmethyl)-; (3-((1H-imidazol-1-yl)methyl)phenyl)methanol; SCHEMBL3092795; DTXSID60439216; MolPort-000-143-255; ZX-AT016572; BDBM50307217; ZINC12370274; SBB090815; FCH921386; AKOS006343964; RP03595; [3-(imidazolylmethyl)phenyl]methan-1-ol; DB-063877; FT-0703495; Y7599; Benzenemethanol,3-(1H-imidazol-1-ylmethyl)-
DMBZJT5 DT Small molecular drug
DMBZJT5 PC 10397593
DMBZJT5 MW 188.23
DMBZJT5 FM C11H12N2O
DMBZJT5 IC InChI=1S/C11H12N2O/c14-8-11-3-1-2-10(6-11)7-13-5-4-12-9-13/h1-6,9,14H,7-8H2
DMBZJT5 CS C1=CC(=CC(=C1)CO)CN2C=CN=C2
DMBZJT5 IK TXQZIKDWFOLTSC-UHFFFAOYSA-N
DMBZJT5 IU [3-(imidazol-1-ylmethyl)phenyl]methanol
DMBZJT5 CA CAS 151055-79-7
DMBZJT5 DE Discovery agent
DMR6JTQ ID DMR6JTQ
DMR6JTQ DN (3-(2-methylquinolin-7-yl)phenyl)methanol
DMR6JTQ HS Investigative
DMR6JTQ SN CHEMBL231986; (3-(2-methylquinolin-7-yl)phenyl)methanol
DMR6JTQ DT Small molecular drug
DMR6JTQ PC 44432665
DMR6JTQ MW 249.31
DMR6JTQ FM C17H15NO
DMR6JTQ IC InChI=1S/C17H15NO/c1-12-5-6-14-7-8-16(10-17(14)18-12)15-4-2-3-13(9-15)11-19/h2-10,19H,11H2,1H3
DMR6JTQ CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)CO
DMR6JTQ IK IPRCARTWCVTTOP-UHFFFAOYSA-N
DMR6JTQ IU [3-(2-methylquinolin-7-yl)phenyl]methanol
DMR6JTQ DE Discovery agent
DMNVDLI ID DMNVDLI
DMNVDLI DN (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone
DMNVDLI HS Investigative
DMNVDLI SN AC1LDSBN; BAS 02052919; (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone; N-Benzoylpyrazole deriv., 8; CHEMBL244917; ZINC37156; BDBM23706; MolPort-001-906-669; 3,4-dichlorophenyl pyrazolyl ketone; STK044137; AKOS000577014; MCULE-6190861509; ST033189; (3,4-dichlorophenyl)-pyrazol-1-ylmethanone; (3,4-Dichloro-phenyl)-pyrazol-1-yl-methanone; 1-[(3,4-dichlorophenyl)carbonyl]-1H-pyrazole; SR-01000521426; SR-01000521426-1
DMNVDLI DT Small molecular drug
DMNVDLI PC 674628
DMNVDLI MW 241.07
DMNVDLI FM C10H6Cl2N2O
DMNVDLI IC InChI=1S/C10H6Cl2N2O/c11-8-3-2-7(6-9(8)12)10(15)14-5-1-4-13-14/h1-6H
DMNVDLI CS C1=CN(N=C1)C(=O)C2=CC(=C(C=C2)Cl)Cl
DMNVDLI IK PPOZMMBGUFTQOQ-UHFFFAOYSA-N
DMNVDLI IU (3,4-dichlorophenyl)-pyrazol-1-ylmethanone
DMNVDLI DE Discovery agent
DMTB41W ID DMTB41W
DMTB41W DN (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
DMTB41W HS Investigative
DMTB41W SN (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE; BIE; AC1OCAA0; SCHEMBL5898857; ICLKAUQIPVFHOI-UHFFFAOYSA-N; 3,4-dihydroxy-2-nitrobenzophenone; 4-benzoyl-3-nitrobenzene-1,2-diol; BIA-8-176; ZINC13677656; DB07462; (3,4-dihydroxy-2-nitrophenyl)phenylmethanone
DMTB41W DT Small molecular drug
DMTB41W PC 6914595
DMTB41W MW 259.209
DMTB41W FM C13H9NO5
DMTB41W IC InChI=1S/C13H9NO5/c15-10-7-6-9(11(13(10)17)14(18)19)12(16)8-4-2-1-3-5-8/h1-7,15,17H
DMTB41W CS C1=CC=C(C=C1)C(=O)C2=C(C(=C(C=C2)O)O)[N+](=O)[O-]
DMTB41W IK ICLKAUQIPVFHOI-UHFFFAOYSA-N
DMTB41W IU (3,4-dihydroxy-2-nitrophenyl)-phenylmethanone
DMTB41W DE Discovery agent
DMAF43E ID DMAF43E
DMAF43E DN (3,4-dimethylphenyl)(4-phenoxyphenyl)methanone
DMAF43E HS Investigative
DMAF43E SN (3,4-dimethylphenyl)(4-phenoxyphenyl)methanone; CHEMBL557722; CBDivE_001397; AC1MOFBF; AC1Q2DSA; Oprea1_371703; Oprea1_274103; MolPort-001-813-132; (3,4-DIMETHYL-PHENYL)-(4-PHENOXY-PHENYL)-METHANONE; ZINC2496519; STK333119; BDBM50296685; AKOS024330770; MCULE-5159255282
DMAF43E DT Small molecular drug
DMAF43E PC 3342765
DMAF43E MW 302.4
DMAF43E FM C21H18O2
DMAF43E IC InChI=1S/C21H18O2/c1-15-8-9-18(14-16(15)2)21(22)17-10-12-20(13-11-17)23-19-6-4-3-5-7-19/h3-14H,1-2H3
DMAF43E CS CC1=C(C=C(C=C1)C(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)C
DMAF43E IK WAJARHMGAQFYHB-UHFFFAOYSA-N
DMAF43E IU (3,4-dimethylphenyl)-(4-phenoxyphenyl)methanone
DMAF43E DE Discovery agent
DM9PDCA ID DM9PDCA
DM9PDCA DN (3,5-Dibromo-4-butoxy-phenyl)-acetic acid
DM9PDCA HS Investigative
DM9PDCA SN Benzeneacetic acid, 3,5-dibromo-4-butoxy-; SCHEMBL4890007; CHEMBL192490; BDBM18899; 340697-16-7; 2-(3,5-dibromo-4-butoxyphenyl)acetic acid; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9b
DM9PDCA DT Small molecular drug
DM9PDCA PC 9925361
DM9PDCA MW 366.05
DM9PDCA FM C12H14Br2O3
DM9PDCA IC InChI=1S/C12H14Br2O3/c1-2-3-4-17-12-9(13)5-8(6-10(12)14)7-11(15)16/h5-6H,2-4,7H2,1H3,(H,15,16)
DM9PDCA CS CCCCOC1=C(C=C(C=C1Br)CC(=O)O)Br
DM9PDCA IK PDWWLSBHJFKDFA-UHFFFAOYSA-N
DM9PDCA IU 2-(3,5-dibromo-4-butoxyphenyl)acetic acid
DM9PDCA DE Discovery agent
DM5GN46 ID DM5GN46
DM5GN46 DN (3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid
DM5GN46 HS Investigative
DM5GN46 SN CHEMBL192639; SCHEMBL4900725; BDBM18902; ZINC13643202; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9e; 2-[3,5-dibromo-4-(hexyloxy)phenyl]acetic acid
DM5GN46 DT Small molecular drug
DM5GN46 PC 11153607
DM5GN46 MW 394.1
DM5GN46 FM C14H18Br2O3
DM5GN46 IC InChI=1S/C14H18Br2O3/c1-2-3-4-5-6-19-14-11(15)7-10(8-12(14)16)9-13(17)18/h7-8H,2-6,9H2,1H3,(H,17,18)
DM5GN46 CS CCCCCCOC1=C(C=C(C=C1Br)CC(=O)O)Br
DM5GN46 IK VJKVJESSSPWLJY-UHFFFAOYSA-N
DM5GN46 IU 2-(3,5-dibromo-4-hexoxyphenyl)acetic acid
DM5GN46 DE Discovery agent
DMB5KVZ ID DMB5KVZ
DMB5KVZ DN (3,5-Dibromo-4-pentyloxy-phenyl)-acetic acid
DMB5KVZ HS Investigative
DMB5KVZ SN SCHEMBL4899221; CHEMBL193152; BDBM18900; ZINC13643198; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9c; 2-[3,5-dibromo-4-(pentyloxy)phenyl]acetic acid
DMB5KVZ DT Small molecular drug
DMB5KVZ PC 11291923
DMB5KVZ MW 380.07
DMB5KVZ FM C13H16Br2O3
DMB5KVZ IC InChI=1S/C13H16Br2O3/c1-2-3-4-5-18-13-10(14)6-9(7-11(13)15)8-12(16)17/h6-7H,2-5,8H2,1H3,(H,16,17)
DMB5KVZ CS CCCCCOC1=C(C=C(C=C1Br)CC(=O)O)Br
DMB5KVZ IK DMILDBSUKKQQDG-UHFFFAOYSA-N
DMB5KVZ IU 2-(3,5-dibromo-4-pentoxyphenyl)acetic acid
DMB5KVZ DE Discovery agent
DM3OPNE ID DM3OPNE
DM3OPNE DN (35)S-labeled oligonucleotide
DM3OPNE HS Investigative
DM3OPNE TC Antisense
DM3OPNE DT Antisense drug
DM3OPNE DE Discovery agent
DMPHCX7 ID DMPHCX7
DMPHCX7 DN (3-Amino-1-ethyl-propyl)-methyl-phosphinic acid
DMPHCX7 HS Investigative
DMPHCX7 SN CHEMBL113092; 133345-70-7; Phosphinic acid, (3-amino-1-ethylpropyl)methyl-; ACMC-20muwd; (3-Amino-1-ethyl-propyl)-methyl-phosphinic acid; SCHEMBL341182; CTK0C0402; DTXSID30435583; CCGFQGUALPHBIC-UHFFFAOYSA-N; BDBM50032974; P-(5-aminopent-3-yl)-P-methylphosphinic acid; P-(5-aminopent-3-yl)-P-methyl-phosphinic acid; Phosphinic acid, P-(3-amino-1-ethylpropyl)-P-methyl-
DMPHCX7 DT Small molecular drug
DMPHCX7 PC 10103488
DMPHCX7 MW 165.17
DMPHCX7 FM C6H16NO2P
DMPHCX7 IC InChI=1S/C6H16NO2P/c1-3-6(4-5-7)10(2,8)9/h6H,3-5,7H2,1-2H3,(H,8,9)
DMPHCX7 CS CCC(CCN)P(=O)(C)O
DMPHCX7 IK CCGFQGUALPHBIC-UHFFFAOYSA-N
DMPHCX7 IU 1-aminopentan-3-yl(methyl)phosphinic acid
DMPHCX7 CA CAS 133345-70-7
DMPHCX7 DE Discovery agent
DM7HF4I ID DM7HF4I
DM7HF4I DN (3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid
DM7HF4I HS Investigative
DM7HF4I SN SCHEMBL341289
DM7HF4I DT Small molecular drug
DM7HF4I PC 53719915
DM7HF4I MW 152.11
DM7HF4I FM C4H11NO3P+
DM7HF4I IC InChI=1S/C4H11NO3P/c1-9(7,8)4(6)2-3-5/h7-8H,2-3,5H2,1H3/q+1
DM7HF4I CS C[P+](C(=O)CCN)(O)O
DM7HF4I IK XRHWOLGPXAOKPF-UHFFFAOYSA-N
DM7HF4I IU 3-aminopropanoyl-dihydroxy-methylphosphanium
DM7HF4I DE Discovery agent
DMP2G5W ID DMP2G5W
DMP2G5W DN (3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone
DMP2G5W HS Investigative
DMP2G5W SN CHEMBL591458; (3-Amino-5-bromo-benzofuran-2-yl)-phenyl-methanone; (3-amino-5-bromo-1-benzofuran-2-yl)(phenyl)methanone; SMR000010549; MLS000031617; AC1LCKCT; regid849115; Oprea1_732422; Oprea1_454471; MLS002534670; (3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone; SCHEMBL13102601; ZINC97827; CTK5I8073; MolPort-000-164-762; HMS2395L21; STK078344; BDBM50306745; AKOS000510990; MCULE-9438936220; ST037109; BAS 01507283; EU-0018517; 3-amino-5-bromobenzo[d]furan-2-yl phenyl ketone; SR-01000523207; SR-01000523207-1
DMP2G5W DT Small molecular drug
DMP2G5W PC 651586
DMP2G5W MW 316.15
DMP2G5W FM C15H10BrNO2
DMP2G5W IC InChI=1S/C15H10BrNO2/c16-10-6-7-12-11(8-10)13(17)15(19-12)14(18)9-4-2-1-3-5-9/h1-8H,17H2
DMP2G5W CS C1=CC=C(C=C1)C(=O)C2=C(C3=C(O2)C=CC(=C3)Br)N
DMP2G5W IK SBFAYONAJFSEPC-UHFFFAOYSA-N
DMP2G5W IU (3-amino-5-bromo-1-benzofuran-2-yl)-phenylmethanone
DMP2G5W DE Discovery agent
DMDGFS0 ID DMDGFS0
DMDGFS0 DN (3-Amino-phenyl)-phosphonic acid diphenyl ester
DMDGFS0 HS Investigative
DMDGFS0 SN CHEMBL158955
DMDGFS0 DT Small molecular drug
DMDGFS0 PC 44373237
DMDGFS0 MW 325.3
DMDGFS0 FM C18H16NO3P
DMDGFS0 IC InChI=1S/C18H16NO3P/c19-15-8-7-13-18(14-15)23(20,21-16-9-3-1-4-10-16)22-17-11-5-2-6-12-17/h1-14H,19H2
DMDGFS0 CS C1=CC=C(C=C1)OP(=O)(C2=CC=CC(=C2)N)OC3=CC=CC=C3
DMDGFS0 IK CJCPJYQCUVSSBA-UHFFFAOYSA-N
DMDGFS0 IU 3-diphenoxyphosphorylaniline
DMDGFS0 DE Discovery agent
DMBJYTD ID DMBJYTD
DMBJYTD DN (3-Amino-propyl)-hexyl-phosphinic acid
DMBJYTD HS Investigative
DMBJYTD SN 3-Aminopropyl(hexyl)phosphinic acid; 3-Aphpa; 123691-31-6; 3-Aminopropyl(n-hexyl)phosphinic acid; CHEMBL113571; Phosphinic acid,(3-aminopropyl)hexyl- (9CI); ACMC-20mqpl; (3-Amino-propyl)-hexyl-phosphinic acid; AC1L2WN2; SCHEMBL6354602; CTK4B3595; DTXSID90154066
DMBJYTD DT Small molecular drug
DMBJYTD PC 130023
DMBJYTD MW 207.25
DMBJYTD FM C9H22NO2P
DMBJYTD IC InChI=1S/C9H22NO2P/c1-2-3-4-5-8-13(11,12)9-6-7-10/h2-10H2,1H3,(H,11,12)
DMBJYTD CS CCCCCCP(=O)(CCCN)O
DMBJYTD IK QVUUPQCCYOPHFY-UHFFFAOYSA-N
DMBJYTD IU 3-aminopropyl(hexyl)phosphinic acid
DMBJYTD CA CAS 123691-31-6
DMBJYTD DE Discovery agent
DMGFIJV ID DMGFIJV
DMGFIJV DN (3-Amino-propyl)-hydroxymethyl-phosphinic acid
DMGFIJV HS Investigative
DMGFIJV SN AC1MTETN; SCHEMBL341290; MolPort-002-514-611; STL513587; ZINC20112625; AKOS030493595; MCULE-2944312169; 3-aminopropyl(hydroxymethyl)phosphinic acid; (Hydroxymethyl)(3-aminopropyl)phosphinic acid; (3-aminopropyl)(hydroxymethyl)phosphinic acid
DMGFIJV DT Small molecular drug
DMGFIJV PC 91929121
DMGFIJV MW 152.11
DMGFIJV FM C4H11NO3P+
DMGFIJV IC InChI=1S/C4H11NO3P/c5-2-1-3-9(7,8)4-6/h4,7-8H,1-3,5H2/q+1
DMGFIJV CS C(CN)C[P+](C=O)(O)O
DMGFIJV IK WKJVZSFFUHQPOM-UHFFFAOYSA-N
DMGFIJV IU 3-aminopropyl-formyl-dihydroxyphosphanium
DMGFIJV DE Discovery agent
DMK3JZS ID DMK3JZS
DMK3JZS DN (3-Amino-propyl)-phosphonic acid
DMK3JZS HS Investigative
DMK3JZS SN 3-Aminopropylphosphonic acid; 13138-33-5; (3-aminopropyl)phosphonic acid; Aminopropylphosphonate; 3-Aminopropylphosphonicacid; UNII-VM92T06VPB; (3-Amino-propyl)-phosphonic acid; Phosphonic acid, (3-aminopropyl)-; VM92T06VPB; CHEMBL286077; GSZQTIFGANBTNF-UHFFFAOYSA-N; GEO-00218; NSC-133832; 3-phosphonopropylamine; AK-33107; 3-Appn; (3-Aminopropyl)phosphonic acid, 97%; NSC 133832; Phosphate analogue, 8; PubChem10325; ACMC-1BXXY; AC1L3YTO; 3-aminopropyl-phosphonate; timtec-bb sbb004184; Lopac-A-7162; AC1Q6RQ7; SCHEMBL35883
DMK3JZS DT Small molecular drug
DMK3JZS PC 97587
DMK3JZS MW 139.09
DMK3JZS FM C3H10NO3P
DMK3JZS IC InChI=1S/C3H10NO3P/c4-2-1-3-8(5,6)7/h1-4H2,(H2,5,6,7)
DMK3JZS CS C(CN)CP(=O)(O)O
DMK3JZS IK GSZQTIFGANBTNF-UHFFFAOYSA-N
DMK3JZS IU 3-aminopropylphosphonic acid
DMK3JZS CA CAS 13138-33-5
DMK3JZS CB CHEBI:142993
DMK3JZS DE Discovery agent
DMHF01G ID DMHF01G
DMHF01G DN (3-Bromobenzoylpyridine)thiosemicarbazone
DMHF01G HS Investigative
DMHF01G SN (3-Bromobenzoylpyridine)thiosemicarbazone; CHEMBL1269715
DMHF01G DT Small molecular drug
DMHF01G PC 52940642
DMHF01G MW 335.22
DMHF01G FM C13H11BrN4S
DMHF01G IC InChI=1S/C13H11BrN4S/c14-11-5-1-3-9(7-11)12(17-18-13(15)19)10-4-2-6-16-8-10/h1-8H,(H3,15,18,19)/b17-12-
DMHF01G CS C1=CC(=CC(=C1)Br)/C(=N/NC(=S)N)/C2=CN=CC=C2
DMHF01G IK DPTPEKAUCAAQNG-ATVHPVEESA-N
DMHF01G IU [(Z)-[(3-bromophenyl)-pyridin-3-ylmethylidene]amino]thiourea
DMHF01G DE Discovery agent
DMIJH7W ID DMIJH7W
DMIJH7W DN (3-bromophenyl)(10H-phenothiazin-10-yl)methanone
DMIJH7W HS Investigative
DMIJH7W SN CHEMBL239616; (3-bromophenyl)(10H-phenothiazin-10-yl)methanone; (3-Bromo-phenyl)-phenothiazin-10-yl-methanone; AC1LCW7V; ChemDiv1_023786; C19H12BrNOS; HMS654J04; XWGLMCFWNRNHDU-UHFFFAOYSA-N; MolPort-002-545-921; 10-(3-Bromobenzoyl)phenothiazine; ZINC4785817; STL361327; BDBM50219221; AKOS001639315; MCULE-3829813488; BAS 00721881; 10-(3-Bromobenzoyl)-10H-phenothiazine #; (3-bromophenyl)-phenothiazin-10-ylmethanone; EU-0008504; SR-01000465493; SR-01000465493-1
DMIJH7W DT Small molecular drug
DMIJH7W PC 607810
DMIJH7W MW 382.3
DMIJH7W FM C19H12BrNOS
DMIJH7W IC InChI=1S/C19H12BrNOS/c20-14-7-5-6-13(12-14)19(22)21-15-8-1-3-10-17(15)23-18-11-4-2-9-16(18)21/h1-12H
DMIJH7W CS C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC(=CC=C4)Br
DMIJH7W IK XWGLMCFWNRNHDU-UHFFFAOYSA-N
DMIJH7W IU (3-bromophenyl)-phenothiazin-10-ylmethanone
DMIJH7W DE Discovery agent
DMHLF2S ID DMHLF2S
DMHLF2S DN (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine
DMHLF2S HS Investigative
DMHLF2S SN N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41
DMHLF2S DT Small molecular drug
DMHLF2S PC 5328038
DMHLF2S MW 345.15
DMHLF2S FM C14H9BrN4O2
DMHLF2S IC InChI=1S/C14H9BrN4O2/c15-9-3-1-4-10(7-9)18-14-13-11(16-8-17-14)5-2-6-12(13)19(20)21/h1-8H,(H,16,17,18)
DMHLF2S CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C(=CC=C3)[N+](=O)[O-]
DMHLF2S IK CFLDNHCFXUEPKN-UHFFFAOYSA-N
DMHLF2S IU N-(3-bromophenyl)-5-nitroquinazolin-4-amine
DMHLF2S DE Discovery agent
DMMIPZ8 ID DMMIPZ8
DMMIPZ8 DN (3-Bromo-phenyl)-quinazolin-4-yl-amine
DMMIPZ8 HS Investigative
DMMIPZ8 SN N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)-
DMMIPZ8 DT Small molecular drug
DMMIPZ8 PC 735125
DMMIPZ8 MW 300.15
DMMIPZ8 FM C14H10BrN3
DMMIPZ8 IC InChI=1S/C14H10BrN3/c15-10-4-3-5-11(8-10)18-14-12-6-1-2-7-13(12)16-9-17-14/h1-9H,(H,16,17,18)
DMMIPZ8 CS C1=CC=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br
DMMIPZ8 IK SUTRLYZWRGPLSJ-UHFFFAOYSA-N
DMMIPZ8 IU N-(3-bromophenyl)quinazolin-4-amine
DMMIPZ8 DE Discovery agent
DMUJ18K ID DMUJ18K
DMUJ18K DN (3-Bromo-propyl)-trimethyl-ammonium
DMUJ18K HS Investigative
DMUJ18K DT Small molecular drug
DMUJ18K PC 151145
DMUJ18K MW 261
DMUJ18K FM C6H15Br2N
DMUJ18K IC InChI=1S/C6H15BrN.BrH/c1-8(2,3)6-4-5-7;/h4-6H2,1-3H3;1H/q+1;/p-1
DMUJ18K CS C[N+](C)(C)CCCBr.[Br-]
DMUJ18K IK NNZGNZHUGJAKKT-UHFFFAOYSA-M
DMUJ18K IU 3-bromopropyl(trimethyl)azanium;bromide
DMUJ18K CA CAS 3779-42-8
DMUJ18K DE Discovery agent
DMHODXG ID DMHODXG
DMHODXG DN (3-Chloro-4-Propoxy-Phenyl)-Acetic Acid
DMHODXG HS Investigative
DMHODXG SN (3-chloro-4-propoxyphenyl)acetic acid; (3-CHLORO-4-PROPOXY-PHENYL)-ACETIC ACID; 2-(3-chloro-4-propoxyphenyl)acetic acid; AC1L1CVR; SCHEMBL4321455; CTK6E6068; MolPort-005-983-242; HMS3604N10; ZINC3871464; STL386671; AKOS000296250; MCULE-5882985924
DMHODXG DT Small molecular drug
DMHODXG PC 2084
DMHODXG MW 228.67
DMHODXG FM C11H13ClO3
DMHODXG IC InChI=1S/C11H13ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h3-4,6H,2,5,7H2,1H3,(H,13,14)
DMHODXG CS CCCOC1=C(C=C(C=C1)CC(=O)O)Cl
DMHODXG IK QEJHPAGTOOIBFT-UHFFFAOYSA-N
DMHODXG IU 2-(3-chloro-4-propoxyphenyl)acetic acid
DMHODXG CA CAS 23914-91-2
DMHODXG DE Discovery agent
DM7U02R ID DM7U02R
DM7U02R DN (3-Chloro-phenyl)-piperazin-1-yl-methanone
DM7U02R HS Investigative
DM7U02R SN 100939-90-0; 1-(3-chlorobenzoyl)piperazine; (3-chlorophenyl)(piperazin-1-yl)methanone; (3-Chloro-phenyl)-piperazin-1-yl-methanone; BAS 04443403; (3-Chlorophenyl)(1-piperazinyl)methanone; CHEMBL160911; Methanone, (3-chlorophenyl)-1-piperazinyl-; 1-[(3-chlorophenyl)carbonyl]piperazine; 3-chlorophenyl piperazinyl ketone; AC1LLWSU; AC1Q3I0G; TimTec1_008470; 4-(3-chlorobenzoyl)piperazine; SCHEMBL2733887; 1-(3-Chlorobenzoyl)-piperazine; CTK6H2326; DTXSID70360082; MolPort-000-163-293; FBTDRVSCKFZIQH-UHFFFAOYSA-N; ZINC782987
DM7U02R DT Small molecular drug
DM7U02R PC 1074765
DM7U02R MW 224.68
DM7U02R FM C11H13ClN2O
DM7U02R IC InChI=1S/C11H13ClN2O/c12-10-3-1-2-9(8-10)11(15)14-6-4-13-5-7-14/h1-3,8,13H,4-7H2
DM7U02R CS C1CN(CCN1)C(=O)C2=CC(=CC=C2)Cl
DM7U02R IK FBTDRVSCKFZIQH-UHFFFAOYSA-N
DM7U02R IU (3-chlorophenyl)-piperazin-1-ylmethanone
DM7U02R CA CAS 100939-90-0
DM7U02R DE Discovery agent
DMG1KIJ ID DMG1KIJ
DMG1KIJ DN (3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine
DMG1KIJ HS Investigative
DMG1KIJ SN CHEMBL194743; (3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine; SCHEMBL5582608
DMG1KIJ DT Small molecular drug
DMG1KIJ PC 11321863
DMG1KIJ MW 215.25
DMG1KIJ FM C12H13N3O
DMG1KIJ IC InChI=1S/C12H13N3O/c1-2-16-10-6-5-9-14-12(10)15-11-7-3-4-8-13-11/h3-9H,2H2,1H3,(H,13,14,15)
DMG1KIJ CS CCOC1=C(N=CC=C1)NC2=CC=CC=N2
DMG1KIJ IK QXDACVHUAQTTKS-UHFFFAOYSA-N
DMG1KIJ IU 3-ethoxy-N-pyridin-2-ylpyridin-2-amine
DMG1KIJ DE Discovery agent
DM5WJBH ID DM5WJBH
DM5WJBH DN (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DM5WJBH HS Investigative
DM5WJBH SN CHEMBL154228; (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7616000; BDBM50048611
DM5WJBH DT Small molecular drug
DM5WJBH PC 10850308
DM5WJBH MW 279.4
DM5WJBH FM C18H21N3
DM5WJBH IC InChI=1S/C18H21N3/c1-3-13-20(16-9-11-19-12-10-16)21-14-15(4-2)17-7-5-6-8-18(17)21/h5-12,14H,3-4,13H2,1-2H3
DM5WJBH CS CCCN(C1=CC=NC=C1)N2C=C(C3=CC=CC=C32)CC
DM5WJBH IK KHGNFQVPPCBUSI-UHFFFAOYSA-N
DM5WJBH IU 3-ethyl-N-propyl-N-pyridin-4-ylindol-1-amine
DM5WJBH DE Discovery agent
DMPHM23 ID DMPHM23
DMPHM23 DN (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMPHM23 HS Investigative
DMPHM23 SN CHEMBL382214; (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMPHM23 DT Small molecular drug
DMPHM23 PC 11530398
DMPHM23 MW 350.3
DMPHM23 FM C21H15FO4
DMPHM23 IC InChI=1S/C21H15FO4/c22-19-12-14(13-20(23)24)6-11-18(19)21(25)15-7-9-17(10-8-15)26-16-4-2-1-3-5-16/h1-12H,13H2,(H,23,24)
DMPHM23 CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=C(C=C(C=C3)CC(=O)O)F
DMPHM23 IK DXGWDHUXZJQMIN-UHFFFAOYSA-N
DMPHM23 IU 2-[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
DMPHM23 DE Discovery agent
DM08UQF ID DM08UQF
DM08UQF DN (3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium
DM08UQF HS Investigative
DM08UQF DT Small molecular drug
DM08UQF PC 46905907
DM08UQF MW 313.05
DM08UQF FM C9H17Br2N2+
DM08UQF IC InChI=1S/C9H15N2.2BrH/c1-11(2,3)9-6-4-5-8(10)7-9;;/h4-7H,10H2,1-3H3;2*1H/q+1;;
DM08UQF CS C[N+](C)(C)C1=CC=CC(=C1)N.Br.Br
DM08UQF IK XSYKHNGMJVWEPB-UHFFFAOYSA-N
DM08UQF IU (3-aminophenyl)-trimethylazanium;dihydrobromide
DM08UQF DE Discovery agent
DMX5CY3 ID DMX5CY3
DMX5CY3 DN (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMX5CY3 HS Investigative
DMX5CY3 SN CHEMBL201762; (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid
DMX5CY3 DT Small molecular drug
DMX5CY3 PC 11717189
DMX5CY3 MW 346.4
DMX5CY3 FM C22H18O4
DMX5CY3 IC InChI=1S/C22H18O4/c1-15-13-16(14-21(23)24)7-12-20(15)22(25)17-8-10-19(11-9-17)26-18-5-3-2-4-6-18/h2-13H,14H2,1H3,(H,23,24)
DMX5CY3 CS CC1=C(C=CC(=C1)CC(=O)O)C(=O)C2=CC=C(C=C2)OC3=CC=CC=C3
DMX5CY3 IK XPAYPQXQKZWIEL-UHFFFAOYSA-N
DMX5CY3 IU 2-[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
DMX5CY3 DE Discovery agent
DMHED9G ID DMHED9G
DMHED9G DN (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
DMHED9G HS Investigative
DMHED9G SN CHEMBL350692; (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine; SCHEMBL7612026; BDBM50048587
DMHED9G DT Small molecular drug
DMHED9G PC 10635415
DMHED9G MW 265.35
DMHED9G FM C17H19N3
DMHED9G IC InChI=1S/C17H19N3/c1-3-12-19(15-8-10-18-11-9-15)20-13-14(2)16-6-4-5-7-17(16)20/h4-11,13H,3,12H2,1-2H3
DMHED9G CS CCCN(C1=CC=NC=C1)N2C=C(C3=CC=CC=C32)C
DMHED9G IK JFXXREWKFGYUCE-UHFFFAOYSA-N
DMHED9G IU 3-methyl-N-propyl-N-pyridin-4-ylindol-1-amine
DMHED9G DE Discovery agent
DMD4Z6H ID DMD4Z6H
DMD4Z6H DN (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMD4Z6H HS Investigative
DMD4Z6H SN (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone; AC1LDSPA; 3-nitropyrazolyl phenyl ketone; N-Benzoylpyrazole deriv., 19; CHEMBL244940; 1-benzoyl-3-nitro-1H-pyrazole; BDBM23711; ZINC79624; MolPort-002-705-611; STK760577; AKOS001756309; (3-nitropyrazol-1-yl)-phenylmethanone; MCULE-2233615430; ST073764; SR-01000524822; SR-01000524822-1
DMD4Z6H DT Small molecular drug
DMD4Z6H PC 700133
DMD4Z6H MW 217.18
DMD4Z6H FM C10H7N3O3
DMD4Z6H IC InChI=1S/C10H7N3O3/c14-10(8-4-2-1-3-5-8)12-7-6-9(11-12)13(15)16/h1-7H
DMD4Z6H CS C1=CC=C(C=C1)C(=O)N2C=CC(=N2)[N+](=O)[O-]
DMD4Z6H IK MIWUBRDWBKJULS-UHFFFAOYSA-N
DMD4Z6H IU (3-nitropyrazol-1-yl)-phenylmethanone
DMD4Z6H DE Discovery agent
DMT9FZD ID DMT9FZD
DMT9FZD DN (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone
DMT9FZD HS Investigative
DMT9FZD SN (4-methylphenyl)(3-nitro-1H-pyrazol-1-yl)methanone; AC1LF99H; N-Benzoylpyrazole deriv., 18; CHEMBL244939; ZINC78678; BDBM23710; A2012/0084499; MolPort-002-705-255; STK760276; AKOS001746005; 4-methylphenyl 3-nitropyrazolyl ketone; MCULE-9242110239; ST073763; (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone; SR-01000524341; 1-[(4-methylphenyl)carbonyl]-3-nitro-1H-pyrazole
DMT9FZD DT Small molecular drug
DMT9FZD PC 699665
DMT9FZD MW 231.21
DMT9FZD FM C11H9N3O3
DMT9FZD IC InChI=1S/C11H9N3O3/c1-8-2-4-9(5-3-8)11(15)13-7-6-10(12-13)14(16)17/h2-7H,1H3
DMT9FZD CS CC1=CC=C(C=C1)C(=O)N2C=CC(=N2)[N+](=O)[O-]
DMT9FZD IK PQRIEIACDJITID-UHFFFAOYSA-N
DMT9FZD IU (4-methylphenyl)-(3-nitropyrazol-1-yl)methanone
DMT9FZD DE Discovery agent
DMGYAP7 ID DMGYAP7
DMGYAP7 DN (3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine
DMGYAP7 HS Investigative
DMGYAP7 SN N-(3-phenoxyphenyl)-5-phenyl-1,3-oxazol-2-amine; 2-Anilino-5-aryloxazole 11; AC1NS7R8; CHEMBL191626
DMGYAP7 DT Small molecular drug
DMGYAP7 PC 5329846
DMGYAP7 MW 328.4
DMGYAP7 FM C21H16N2O2
DMGYAP7 IC InChI=1S/C21H16N2O2/c1-3-8-16(9-4-1)20-15-22-21(25-20)23-17-10-7-13-19(14-17)24-18-11-5-2-6-12-18/h1-15H,(H,22,23)
DMGYAP7 CS C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC(=CC=C3)OC4=CC=CC=C4
DMGYAP7 IK JTIZQZSOCSALNJ-UHFFFAOYSA-N
DMGYAP7 IU N-(3-phenoxyphenyl)-5-phenyl-1,3-oxazol-2-amine
DMGYAP7 DE Discovery agent
DM1C90Y ID DM1C90Y
DM1C90Y DN (3-Phenyl-propyl)-quinazolin-4-yl-amine
DM1C90Y HS Investigative
DM1C90Y SN CHEMBL42565; N-(3-phenylpropyl)quinazolin-4-amine; (3-Phenyl-propyl)-quinazolin-4-yl-amine; MolPort-011-928-362; BDBM50282106; ZINC13476428; AKOS009045718; MCULE-1024483265; Z127145812
DM1C90Y DT Small molecular drug
DM1C90Y PC 44288306
DM1C90Y MW 263.34
DM1C90Y FM C17H17N3
DM1C90Y IC InChI=1S/C17H17N3/c1-2-7-14(8-3-1)9-6-12-18-17-15-10-4-5-11-16(15)19-13-20-17/h1-5,7-8,10-11,13H,6,9,12H2,(H,18,19,20)
DM1C90Y CS C1=CC=C(C=C1)CCCNC2=NC=NC3=CC=CC=C32
DM1C90Y IK OAPMCZLOWYUSSD-UHFFFAOYSA-N
DM1C90Y IU N-(3-phenylpropyl)quinazolin-4-amine
DM1C90Y DE Discovery agent
DM49YTN ID DM49YTN
DM49YTN DN (3r)-1-Acetyl-3-Methylpiperidine
DM49YTN HS Investigative
DM49YTN SN (3R)-1-ACETYL-3-METHYLPIPERIDINE; 1-[(3R)-3-methylpiperidin-1-yl]ethanone; 1P3; 1w8l; AC1L9MR1; SCHEMBL4309663; ZINC389643; DB01742
DM49YTN DT Small molecular drug
DM49YTN PC 449120
DM49YTN MW 141.21
DM49YTN FM C8H15NO
DM49YTN IC InChI=1S/C8H15NO/c1-7-4-3-5-9(6-7)8(2)10/h7H,3-6H2,1-2H3/t7-/m1/s1
DM49YTN CS C[C@@H]1CCCN(C1)C(=O)C
DM49YTN IK XKFPNHDGLSYZRC-SSDOTTSWSA-N
DM49YTN IU 1-[(3R)-3-methylpiperidin-1-yl]ethanone
DM49YTN DE Discovery agent
DMEUBGY ID DMEUBGY
DMEUBGY DN (3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine
DMEUBGY HS Investigative
DMEUBGY SN CHEMBL566788; (3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine
DMEUBGY DT Small molecular drug
DMEUBGY PC 11275885
DMEUBGY MW 212.29
DMEUBGY FM C14H16N2
DMEUBGY IC InChI=1S/C14H16N2/c1-9-6-7-11-13(8-9)16-12-5-3-2-4-10(12)14(11)15/h2-5,9H,6-8H2,1H3,(H2,15,16)/t9-/m1/s1
DMEUBGY CS C[C@@H]1CCC2=C(C3=CC=CC=C3N=C2C1)N
DMEUBGY IK WVQOYPIATZDPLZ-SECBINFHSA-N
DMEUBGY IU (3R)-3-methyl-1,2,3,4-tetrahydroacridin-9-amine
DMEUBGY DE Discovery agent
DM47BEG ID DM47BEG
DM47BEG DN (3R,4S)-293B
DM47BEG HS Investigative
DM47BEG SN LS-185874
DM47BEG DT Small molecular drug
DM47BEG PC 121846
DM47BEG MW 324.4
DM47BEG FM C15H20N2O4S
DM47BEG IC InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3/t13-,14+/m0/s1
DM47BEG CS CCS(=O)(=O)N(C)[C@@H]1[C@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O
DM47BEG IK HVSJHHXUORMCGK-UONOGXRCSA-N
DM47BEG IU N-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
DM47BEG CA CAS 163163-23-3
DM47BEG CB CHEBI:34637
DM47BEG DE Discovery agent
DMET6IS ID DMET6IS
DMET6IS DN (3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol
DMET6IS HS Investigative
DMET6IS SN CHEMBL311850
DMET6IS DT Small molecular drug
DMET6IS PC 44314178
DMET6IS MW 282.4
DMET6IS FM C19H22O2
DMET6IS IC InChI=1S/C19H22O2/c1-13(2)15-8-9-17-18(11-15)21-12-16(19(17)20)10-14-6-4-3-5-7-14/h3-9,11,13,16,19-20H,10,12H2,1-2H3/t16-,19+/m0/s1
DMET6IS CS CC(C)C1=CC2=C(C=C1)[C@@H]([C@H](CO2)CC3=CC=CC=C3)O
DMET6IS IK OJNGOFXPXHHONH-QFBILLFUSA-N
DMET6IS IU (3S,4R)-3-benzyl-7-propan-2-yl-3,4-dihydro-2H-chromen-4-ol
DMET6IS DE Discovery agent
DMAEXO3 ID DMAEXO3
DMAEXO3 DN (3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3 HS Investigative
DMAEXO3 SN CHEMBL394662; (3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3 DT Small molecular drug
DMAEXO3 PC 44431745
DMAEXO3 MW 232.36
DMAEXO3 FM C15H24N2
DMAEXO3 IC InChI=1S/C15H24N2/c1-2-3-7-13-12-17(11-10-15(13)16)14-8-5-4-6-9-14/h4-6,8-9,13,15H,2-3,7,10-12,16H2,1H3/t13-,15+/m0/s1
DMAEXO3 CS CCCC[C@H]1CN(CC[C@H]1N)C2=CC=CC=C2
DMAEXO3 IK YRWPYATYRUCVQO-DZGCQCFKSA-N
DMAEXO3 IU (3S,4R)-3-butyl-1-phenylpiperidin-4-amine
DMAEXO3 DE Discovery agent
DM6P35D ID DM6P35D
DM6P35D DN (3-Tetradecylamino-cyclohexyl)-phosphonic acid
DM6P35D HS Investigative
DM6P35D SN CHEMBL186921; (3-Tetradecylamino-cyclohexyl)-phosphonic acid
DM6P35D DT Small molecular drug
DM6P35D PC 44394220
DM6P35D MW 375.5
DM6P35D FM C20H42NO3P
DM6P35D IC InChI=1S/C20H42NO3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-21-19-15-14-16-20(18-19)25(22,23)24/h19-21H,2-18H2,1H3,(H2,22,23,24)
DM6P35D CS CCCCCCCCCCCCCCNC1CCCC(C1)P(=O)(O)O
DM6P35D IK GFAWKWDBAGVYFO-UHFFFAOYSA-N
DM6P35D IU [3-(tetradecylamino)cyclohexyl]phosphonic acid
DM6P35D DE Discovery agent
DMFMBPT ID DMFMBPT
DMFMBPT DN (3-Tetradecylamino-cyclopentyl)-phosphonic acid
DMFMBPT HS Investigative
DMFMBPT SN CHEMBL184591; (3-Tetradecylamino-cyclopentyl)-phosphonic acid
DMFMBPT DT Small molecular drug
DMFMBPT PC 44394248
DMFMBPT MW 361.5
DMFMBPT FM C19H40NO3P
DMFMBPT IC InChI=1S/C19H40NO3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-20-18-14-15-19(17-18)24(21,22)23/h18-20H,2-17H2,1H3,(H2,21,22,23)
DMFMBPT CS CCCCCCCCCCCCCCNC1CCC(C1)P(=O)(O)O
DMFMBPT IK MVIUMKOQNNKAJB-UHFFFAOYSA-N
DMFMBPT IU [3-(tetradecylamino)cyclopentyl]phosphonic acid
DMFMBPT DE Discovery agent
DMI9N8G ID DMI9N8G
DMI9N8G DN (3Z)-1H-indole-2,3-dione 3-thiosemicarbazone
DMI9N8G HS Investigative
DMI9N8G DT Small molecular drug
DMI9N8G PC 690109
DMI9N8G MW 220.25
DMI9N8G FM C9H8N4OS
DMI9N8G IC InChI=1S/C9H8N4OS/c10-9(15)13-12-7-5-3-1-2-4-6(5)11-8(7)14/h1-4,11,14H,(H2,10,15)
DMI9N8G CS C1=CC=C2C(=C1)C(=C(N2)O)N=NC(=S)N
DMI9N8G IK PEYNLAQGUNUQLY-UHFFFAOYSA-N
DMI9N8G IU (2-hydroxy-1H-indol-3-yl)iminothiourea
DMI9N8G CA CAS 487-16-1
DMI9N8G DE Discovery agent
DMWS35F ID DMWS35F
DMWS35F DN (4-((1H-imidazol-1-yl)methyl)phenyl)methanol
DMWS35F HS Investigative
DMWS35F SN [4-(1H-Imidazol-1-ylmethyl)phenyl]methanol; 103573-92-8; CHEMBL590987; (4-((1H-imidazol-1-yl)methyl)phenyl)methanol; {4-[(1H-Imidazol-1-yl)methyl]phenyl}methanol; [4-(imidazol-1-ylmethyl)phenyl]methanol; SCHEMBL10661787; CTK8G4735; DTXSID80575387; FSLVBXCLXDGFRE-UHFFFAOYSA-N; MolPort-000-143-260; SBB090788; ZINC12370277; BDBM50307211; AKOS006344218; RP03593; [4-(imidazolylmethyl)phenyl]methan-1-ol; KB-63739; DB-059022; 4-(1H-Imidazole-1-ylmethyl)benzenemethanol; Y6875; FT-0708208; 4-((1H-imidazol-1-yl)methyl)phenylmethanol
DMWS35F DT Small molecular drug
DMWS35F PC 15594569
DMWS35F MW 188.23
DMWS35F FM C11H12N2O
DMWS35F IC InChI=1S/C11H12N2O/c14-8-11-3-1-10(2-4-11)7-13-6-5-12-9-13/h1-6,9,14H,7-8H2
DMWS35F CS C1=CC(=CC=C1CN2C=CN=C2)CO
DMWS35F IK FSLVBXCLXDGFRE-UHFFFAOYSA-N
DMWS35F IU [4-(imidazol-1-ylmethyl)phenyl]methanol
DMWS35F CA CAS 103573-92-8
DMWS35F DE Discovery agent
DMUOFW8 ID DMUOFW8
DMUOFW8 DN (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol
DMUOFW8 HS Investigative
DMUOFW8 SN CHEMBL594669; (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol; SCHEMBL4442909
DMUOFW8 DT Small molecular drug
DMUOFW8 PC 25069592
DMUOFW8 MW 311.34
DMUOFW8 FM C16H17N5O2
DMUOFW8 IC InChI=1S/C16H17N5O2/c22-9-11-1-3-12(4-2-11)14-19-15-13(17-10-18-15)16(20-14)21-5-7-23-8-6-21/h1-4,10,22H,5-9H2,(H,17,18,19,20)
DMUOFW8 CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=C(C=C4)CO
DMUOFW8 IK GSYUMLARWMDMOF-UHFFFAOYSA-N
DMUOFW8 IU [4-(6-morpholin-4-yl-7H-purin-2-yl)phenyl]methanol
DMUOFW8 DE Discovery agent
DMV2CKN ID DMV2CKN
DMV2CKN DN (4-(thiophen-2-yl)phenyl)methanamine
DMV2CKN HS Investigative
DMV2CKN SN 4-(2-Thienyl)benzylamine; 4-(2-THIENYL)BENZYLAMINE; 203436-48-0; 1-(4-thiophen-2-ylphenyl)methanamine; [4-(Thiophen-2-Yl)Phenyl]Methanamine; CHEMBL539640; Benzenemethanamine,4-(2-thienyl)-; Benzenemethanamine, 4-(2-thienyl)-; SDCCGMLS-0065961P001; AC1MCQW2; AC1Q53XJ; 4-(2-thienyl) benzylamine; 4-(Thien-2-yl)benzylamine; SCHEMBL112455; CTK4E3973; DTXSID90379994; YKNLMMDEWQZCLJ-UHFFFAOYSA-N; MolPort-000-142-431; HMS3604G04; ZINC158702; (4-(2-thienyl)phenyl)methylamine; (4-thiophen-2-ylphenyl)methanamine; SBB091000
DMV2CKN DT Small molecular drug
DMV2CKN PC 2776332
DMV2CKN MW 189.28
DMV2CKN FM C11H11NS
DMV2CKN IC InChI=1S/C11H11NS/c12-8-9-3-5-10(6-4-9)11-2-1-7-13-11/h1-7H,8,12H2
DMV2CKN CS C1=CSC(=C1)C2=CC=C(C=C2)CN
DMV2CKN IK YKNLMMDEWQZCLJ-UHFFFAOYSA-N
DMV2CKN IU (4-thiophen-2-ylphenyl)methanamine
DMV2CKN CA CAS 203436-48-0
DMV2CKN DE Discovery agent
DM1XY7C ID DM1XY7C
DM1XY7C DN (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone
DM1XY7C HS Investigative
DM1XY7C SN CHEMBL1088730; AC1LKN75; (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone; Oprea1_813517; Oprea1_627428; AC1Q5F91; MolPort-001-543-551; STK413456; BDBM50312578; ZINC19834645; AKOS003287837; MCULE-5141193554; ST50927985; 4-(diphenylmethyl)piperazinyl cyclohexyl ketone; (4-benzhydrylpiperazin-1-yl)-cyclohexylmethanone; 1-cyclohexanecarbonyl-4-(diphenylmethyl)piperazine
DM1XY7C DT Small molecular drug
DM1XY7C PC 994313
DM1XY7C MW 362.5
DM1XY7C FM C24H30N2O
DM1XY7C IC InChI=1S/C24H30N2O/c27-24(22-14-8-3-9-15-22)26-18-16-25(17-19-26)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23H,3,8-9,14-19H2
DM1XY7C CS C1CCC(CC1)C(=O)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4
DM1XY7C IK OZIJATBNGVKZLU-UHFFFAOYSA-N
DM1XY7C IU (4-benzhydrylpiperazin-1-yl)-cyclohexylmethanone
DM1XY7C DE Discovery agent
DMGVDEL ID DMGVDEL
DMGVDEL DN (4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone
DMGVDEL HS Investigative
DMGVDEL SN piperidine, b2; AC1LDIRK; BAS 00406731; TimTec1_006842; Oprea1_680829; Oprea1_417039; (4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone; CHEMBL437002; BDBM25791; ZINC27165; MolPort-001-494-392; HMS1553G22; STK183068; AKOS000612363; MCULE-2005927034; 2-fluorophenyl 4-benzylpiperidyl ketone; ST50002204; (4-benzylpiperidino)(2-fluorophenyl)methanone; 4-benzyl-1-[(2-fluorophenyl)carbonyl]piperidine; (4-benzylpiperidin-1-yl)-(2-fluorophenyl)methanone
DMGVDEL DT Small molecular drug
DMGVDEL PC 667749
DMGVDEL MW 297.4
DMGVDEL FM C19H20FNO
DMGVDEL IC InChI=1S/C19H20FNO/c20-18-9-5-4-8-17(18)19(22)21-12-10-16(11-13-21)14-15-6-2-1-3-7-15/h1-9,16H,10-14H2
DMGVDEL CS C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F
DMGVDEL IK LEVTWCPGXIVKEH-UHFFFAOYSA-N
DMGVDEL IU (4-benzylpiperidin-1-yl)-(2-fluorophenyl)methanone
DMGVDEL DE Discovery agent
DMEQZ5M ID DMEQZ5M
DMEQZ5M DN (4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone
DMEQZ5M HS Investigative
DMEQZ5M SN (4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone; (4-Benzyl-piperidin-1-yl)-(3-chloro-phenyl)-methanone; piperidine, b1; Oprea1_631709; Oprea1_092044; AC1LG526; CHEMBL240318; SCHEMBL17730065; BDBM25790; MolPort-001-632-510; GHPWLZRRFXHNMA-UHFFFAOYSA-N; ZINC327248; STK093701; AKOS000612405; MCULE-5547370853; 3-chlorophenyl 4-benzylpiperidyl ketone; BAS 00406738; ST50299727; 4-benzyl-1-[(3-chlorophenyl)carbonyl]piperidine; AB00087773-01; SR-01000478204; SR-01000478204-1
DMEQZ5M DT Small molecular drug
DMEQZ5M PC 814705
DMEQZ5M MW 313.8
DMEQZ5M FM C19H20ClNO
DMEQZ5M IC InChI=1S/C19H20ClNO/c20-18-8-4-7-17(14-18)19(22)21-11-9-16(10-12-21)13-15-5-2-1-3-6-15/h1-8,14,16H,9-13H2
DMEQZ5M CS C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC(=CC=C3)Cl
DMEQZ5M IK GHPWLZRRFXHNMA-UHFFFAOYSA-N
DMEQZ5M IU (4-benzylpiperidin-1-yl)-(3-chlorophenyl)methanone
DMEQZ5M DE Discovery agent
DMS16CO ID DMS16CO
DMS16CO DN (4-benzylpiperidin-1-yl)(m-tolyl)methanone
DMS16CO HS Investigative
DMS16CO SN piperidine, b4; BAS 00542495; AC1LQMX7; Cambridge id 5343426; Oprea1_494969; Oprea1_767846; SCHEMBL8299183; CHEMBL240531; BDBM25793; MolPort-000-214-462; ZINC1230195; STK396149; AKOS002707217; MCULE-3325448237; 3-methylphenyl 4-benzylpiperidyl ketone; ST50683773; (4-Benzyl-piperidin-1-yl)-m-tolyl-methanone; AB00081546-01; 4-benzyl-1-[(3-methylphenyl)carbonyl]piperidine; (4-benzylpiperidin-1-yl)(3-methylphenyl)methanone
DMS16CO DT Small molecular drug
DMS16CO PC 1378917
DMS16CO MW 293.4
DMS16CO FM C20H23NO
DMS16CO IC InChI=1S/C20H23NO/c1-16-6-5-9-19(14-16)20(22)21-12-10-18(11-13-21)15-17-7-3-2-4-8-17/h2-9,14,18H,10-13,15H2,1H3
DMS16CO CS CC1=CC(=CC=C1)C(=O)N2CCC(CC2)CC3=CC=CC=C3
DMS16CO IK POFAJEKTXKRKHK-UHFFFAOYSA-N
DMS16CO IU (4-benzylpiperidin-1-yl)-(3-methylphenyl)methanone
DMS16CO DE Discovery agent
DMJ81M3 ID DMJ81M3
DMJ81M3 DN (4-benzylpiperidin-1-yl)(p-tolyl)methanone
DMJ81M3 HS Investigative
DMJ81M3 SN N-(4-Methylbenzoyl)-4-Benzylpiperidine; 4-benzyl-1-[(4-methylphenyl)carbonyl]piperidine; piperidine, b3; BAS 00804661; AC1LR0DT; Oprea1_533510; Oprea1_593272; CHEMBL240530; BDBM25792; MolPort-000-214-461; HMS3604C03; ZINC1295794; STK003473; AKOS000595364; MCULE-3623165331; DB07123; 4-methylphenyl 4-benzylpiperidyl ketone; 4-benzyl-1-(4-methylbenzoyl)piperidine; ST50324491; (4-benzylpiperidino)(4-methylphenyl)methanone; (4-Benzyl-piperidin-1-yl)-p-tolyl-methanone; AB00081647-01; N-(4-METHYLBENZOYL)-4-BENZYLPIPERIDINE
DMJ81M3 DT Small molecular drug
DMJ81M3 PC 1415427
DMJ81M3 MW 293.4
DMJ81M3 FM C20H23NO
DMJ81M3 IC InChI=1S/C20H23NO/c1-16-7-9-19(10-8-16)20(22)21-13-11-18(12-14-21)15-17-5-3-2-4-6-17/h2-10,18H,11-15H2,1H3
DMJ81M3 CS CC1=CC=C(C=C1)C(=O)N2CCC(CC2)CC3=CC=CC=C3
DMJ81M3 IK DVOLWKZEIDCCES-UHFFFAOYSA-N
DMJ81M3 IU (4-benzylpiperidin-1-yl)-(4-methylphenyl)methanone
DMJ81M3 DE Discovery agent
DMS9125 ID DMS9125
DMS9125 DN (4-bromo-1H-pyrazol-1-yl)(m-tolyl)methanone
DMS9125 HS Investigative
DMS9125 SN (4-bromo-1H-pyrazol-1-yl)(3-methylphenyl)methanone; AC1LDSCC; N-Benzoylpyrazole deriv., 22; CHEMBL397270; BDBM23714; ZINC37185; MolPort-002-705-233; STK662514; 4-bromopyrazolyl 3-methylphenyl ketone; AKOS005526022; MCULE-2046425213; ST033221; (4-bromopyrazol-1-yl)-(3-methylphenyl)methanone; SR-01000524314; 4-bromo-1-[(3-methylphenyl)carbonyl]-1H-pyrazole; SR-01000524314-1
DMS9125 DT Small molecular drug
DMS9125 PC 674653
DMS9125 MW 265.11
DMS9125 FM C11H9BrN2O
DMS9125 IC InChI=1S/C11H9BrN2O/c1-8-3-2-4-9(5-8)11(15)14-7-10(12)6-13-14/h2-7H,1H3
DMS9125 CS CC1=CC(=CC=C1)C(=O)N2C=C(C=N2)Br
DMS9125 IK WACJMZOPBBWBAJ-UHFFFAOYSA-N
DMS9125 IU (4-bromopyrazol-1-yl)-(3-methylphenyl)methanone
DMS9125 DE Discovery agent
DM5QDK9 ID DM5QDK9
DM5QDK9 DN (4-bromo-1H-pyrazol-1-yl)(o-tolyl)methanone
DM5QDK9 HS Investigative
DM5QDK9 SN (4-bromo-1H-pyrazol-1-yl)(2-methylphenyl)methanone; AC1LDSC9; N-Benzoylpyrazole deriv., 23; CHEMBL245163; ZINC37182; BDBM23715; MolPort-002-118-506; STK059624; AKOS001747311; 4-bromopyrazolyl 2-methylphenyl ketone; MCULE-5811997287; ST033218; (4-bromopyrazol-1-yl)-(2-methylphenyl)methanone; SR-01000524307; SR-01000524307-1; 4-bromo-1-[(2-methylphenyl)carbonyl]-1H-pyrazole
DM5QDK9 DT Small molecular drug
DM5QDK9 PC 674650
DM5QDK9 MW 265.11
DM5QDK9 FM C11H9BrN2O
DM5QDK9 IC InChI=1S/C11H9BrN2O/c1-8-4-2-3-5-10(8)11(15)14-7-9(12)6-13-14/h2-7H,1H3
DM5QDK9 CS CC1=CC=CC=C1C(=O)N2C=C(C=N2)Br
DM5QDK9 IK PNYXHXJNRYYIKD-UHFFFAOYSA-N
DM5QDK9 IU (4-bromopyrazol-1-yl)-(2-methylphenyl)methanone
DM5QDK9 DE Discovery agent
DM31OSD ID DM31OSD
DM31OSD DN (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone
DM31OSD HS Investigative
DM31OSD SN AC1LDSCF; N-Benzoylpyrazole deriv., 7; CHEMBL244909; ZINC37188; BDBM23705; MolPort-002-174-815; AKOS000576906; 4-bromopyrazolyl 4-methylphenyl ketone; MCULE-8194486011; ST033225; AB00100488-01; (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone; SR-01000521427; SR-01000521427-1
DM31OSD DT Small molecular drug
DM31OSD PC 674656
DM31OSD MW 265.11
DM31OSD FM C11H9BrN2O
DM31OSD IC InChI=1S/C11H9BrN2O/c1-8-2-4-9(5-3-8)11(15)14-7-10(12)6-13-14/h2-7H,1H3
DM31OSD CS CC1=CC=C(C=C1)C(=O)N2C=C(C=N2)Br
DM31OSD IK ZIILQHVFVJLRAB-UHFFFAOYSA-N
DM31OSD IU (4-bromopyrazol-1-yl)-(4-methylphenyl)methanone
DM31OSD DE Discovery agent
DMU1HFM ID DMU1HFM
DMU1HFM DN (4-Bromo-butyl)-trimethyl-ammonium
DMU1HFM HS Investigative
DMU1HFM DT Small molecular drug
DMU1HFM PC 15209645
DMU1HFM MW 275.02
DMU1HFM FM C7H17Br2N
DMU1HFM IC InChI=1S/C7H17BrN.BrH/c1-9(2,3)7-5-4-6-8;/h4-7H2,1-3H3;1H/q+1;/p-1
DMU1HFM CS C[N+](C)(C)CCCCBr.[Br-]
DMU1HFM IK ZQKJDSWJSPZYNR-UHFFFAOYSA-M
DMU1HFM IU 4-bromobutyl(trimethyl)azanium;bromide
DMU1HFM CA CAS 6875-49-6
DMU1HFM DE Discovery agent
DMLAEPF ID DMLAEPF
DMLAEPF DN (4-bromophenyl)(10H-phenothiazin-10-yl)methanone
DMLAEPF HS Investigative
DMLAEPF SN CHEMBL239617; AC1MRSRY; Oprea1_099691; (4-bromophenyl)(10H-phenothiazin-10-yl)methanone; BDBM50219219; AKOS002684887
DMLAEPF DT Small molecular drug
DMLAEPF PC 3473392
DMLAEPF MW 382.3
DMLAEPF FM C19H12BrNOS
DMLAEPF IC InChI=1S/C19H12BrNOS/c20-14-11-9-13(10-12-14)19(22)21-15-5-1-3-7-17(15)23-18-8-4-2-6-16(18)21/h1-12H
DMLAEPF CS C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC=C(C=C4)Br
DMLAEPF IK HIHPKBOMPNDAIA-UHFFFAOYSA-N
DMLAEPF IU (4-bromophenyl)-phenothiazin-10-ylmethanone
DMLAEPF DE Discovery agent
DMOCYZJ ID DMOCYZJ
DMOCYZJ DN (4-bromophenyl)difluoromethanesulfonamide
DMOCYZJ HS Investigative
DMOCYZJ SN CHEMBL370854; (4-bromophenyl)difluoromethanesulfonamide; BDBM50175009
DMOCYZJ DT Small molecular drug
DMOCYZJ PC 44405186
DMOCYZJ MW 286.1
DMOCYZJ FM C7H6BrF2NO2S
DMOCYZJ IC InChI=1S/C7H6BrF2NO2S/c8-6-3-1-5(2-4-6)7(9,10)14(11,12)13/h1-4H,(H2,11,12,13)
DMOCYZJ CS C1=CC(=CC=C1C(F)(F)S(=O)(=O)N)Br
DMOCYZJ IK LKSACQKQUJUBBP-UHFFFAOYSA-N
DMOCYZJ IU (4-bromophenyl)-difluoromethanesulfonamide
DMOCYZJ DE Discovery agent
DM4MAZ1 ID DM4MAZ1
DM4MAZ1 DN (4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone
DM4MAZ1 HS Investigative
DM4MAZ1 SN Pyrazole, 4-chloro-1-(2-methylbenzoyl)-; Cambridge id 5909430; TimTec1_002284; N-Benzoylpyrazole deriv., 21; AC1LB684; CHEMBL396796; ZINC37175; BDBM23713; CTK6H3704; LBFRMVGIANQWAQ-UHFFFAOYSA-N; MolPort-002-174-898; HMS1540H18; STK023958; AKOS000576907; MCULE-4587218544; 4-chloropyrazolyl 2-methylphenyl ketone; ST033210; 4-Chloro-1-(2-methylbenzoyl)-1H-pyrazole; 4-Chloro-1-(2-methylbenzoyl)-1H-pyrazole #; SR-01000524613; (4-chloropyrazol-1-yl)-(2-methylphenyl)methanone; SR-01000524613-1
DM4MAZ1 DT Small molecular drug
DM4MAZ1 PC 577102
DM4MAZ1 MW 220.65
DM4MAZ1 FM C11H9ClN2O
DM4MAZ1 IC InChI=1S/C11H9ClN2O/c1-8-4-2-3-5-10(8)11(15)14-7-9(12)6-13-14/h2-7H,1H3
DM4MAZ1 CS CC1=CC=CC=C1C(=O)N2C=C(C=N2)Cl
DM4MAZ1 IK LBFRMVGIANQWAQ-UHFFFAOYSA-N
DM4MAZ1 IU (4-chloropyrazol-1-yl)-(2-methylphenyl)methanone
DM4MAZ1 DE Discovery agent
DMRIWH2 ID DMRIWH2
DMRIWH2 DN (4-Dipropylamino-cyclohexylidene)-acetonitrile
DMRIWH2 HS Investigative
DMRIWH2 SN CHEMBL350161
DMRIWH2 DT Small molecular drug
DMRIWH2 PC 10775317
DMRIWH2 MW 220.35
DMRIWH2 FM C14H24N2
DMRIWH2 IC InChI=1S/C14H24N2/c1-3-11-16(12-4-2)14-7-5-13(6-8-14)9-10-15/h9,14H,3-8,11-12H2,1-2H3
DMRIWH2 CS CCCN(CCC)C1CCC(=CC#N)CC1
DMRIWH2 IK FMKZTRTUGPXJFV-UHFFFAOYSA-N
DMRIWH2 IU 2-[4-(dipropylamino)cyclohexylidene]acetonitrile
DMRIWH2 DE Discovery agent
DMG27K1 ID DMG27K1
DMG27K1 DN (4e)-4-Aminohex-4-Enoic Acid
DMG27K1 HS Investigative
DMG27K1 SN (4E)-4-AMINOHEX-4-ENOIC ACID; AC1NRBEN; SCHEMBL4320657; (E)-4-aminohex-4-enoic acid
DMG27K1 DT Small molecular drug
DMG27K1 PC 5288385
DMG27K1 MW 129.16
DMG27K1 FM C6H11NO2
DMG27K1 IC InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2H,3-4,7H2,1H3,(H,8,9)/b5-2+
DMG27K1 CS C/C=C(\\CCC(=O)O)/N
DMG27K1 IK KQFBUAIXCIGKAP-GORDUTHDSA-N
DMG27K1 IU (E)-4-aminohex-4-enoic acid
DMG27K1 DE Discovery agent
DMHQCRU ID DMHQCRU
DMHQCRU DN (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine
DMHQCRU HS Investigative
DMHQCRU SN 4-ethynyl-N,N-dipropylcyclohex-3-enamine
DMHQCRU PC 4420454
DMHQCRU MW 205.34
DMHQCRU FM C14H23N
DMHQCRU IC InChI=1S/C14H23N/c1-4-11-15(12-5-2)14-9-7-13(6-3)8-10-14/h3,7,14H,4-5,8-12H2,1-2H3
DMHQCRU CS CCCN(CCC)C1CCC(=CC1)C#C
DMHQCRU IK IOUKEEFTYOZOKJ-UHFFFAOYSA-N
DMHQCRU IU 4-ethynyl-N,N-dipropylcyclohex-3-en-1-amine
DMHQCRU DE Discovery agent
DM75EAT ID DM75EAT
DM75EAT DN (4-Fluoro-phenyl)-(9H-purin-6-yl)-amine
DM75EAT HS Investigative
DM75EAT SN 73663-95-3; N-(p-Fluorophenyl)adenine; (4-Fluorophenyl)(9H-purin-6-yl)amine; NSC 21554; N-(4-fluorophenyl)-9H-purin-6-amine; 7H-ADENINE, N-(p-FLUOROPHENYL)-; N-(4-fluorophenyl)-7H-purin-6-amine; 1H-Purin-6-amine, N-(4-fluorophenyl)-; CHEMBL361227; N-(4-Fluorophenyl)-1H-purin-6-amine; W-203680; (4-Fluoro-phenyl)-(9H-purin-6-yl)-amine; AC1L1C3G; 6-(4-Fluoroanilino)purine; Oprea1_396984; SCHEMBL4922514; N-(p-Fluorophenyl)-1H-adenine; CTK5D8432; (4-fluorophenyl)purin-6-ylamine; DTXSID30223881; MolPort-000-384-310; NSC21554
DM75EAT DT Small molecular drug
DM75EAT PC 51998
DM75EAT MW 229.21
DM75EAT FM C11H8FN5
DM75EAT IC InChI=1S/C11H8FN5/c12-7-1-3-8(4-2-7)17-11-9-10(14-5-13-9)15-6-16-11/h1-6H,(H2,13,14,15,16,17)
DM75EAT CS C1=CC(=CC=C1NC2=NC=NC3=C2NC=N3)F
DM75EAT IK SCRHVVOELSYCSO-UHFFFAOYSA-N
DM75EAT IU N-(4-fluorophenyl)-7H-purin-6-amine
DM75EAT CA CAS 73663-95-3
DM75EAT DE Discovery agent
DMYAJQU ID DMYAJQU
DMYAJQU DN (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine
DMYAJQU HS Investigative
DMYAJQU SN SCHEMBL6659391
DMYAJQU DT Small molecular drug
DMYAJQU PC 11195892
DMYAJQU MW 243.24
DMYAJQU FM C12H10FN5
DMYAJQU IC InChI=1S/C12H10FN5/c1-18-7-16-10-11(14-6-15-12(10)18)17-9-4-2-8(13)3-5-9/h2-7H,1H3,(H,14,15,17)
DMYAJQU CS CN1C=NC2=C(N=CN=C21)NC3=CC=C(C=C3)F
DMYAJQU IK JDDWQQHPEXJAKO-UHFFFAOYSA-N
DMYAJQU IU N-(4-fluorophenyl)-9-methylpurin-6-amine
DMYAJQU DE Discovery agent
DMOS68D ID DMOS68D
DMOS68D DN (4-fluorophenyl)(pyridin-4-yl)methanone
DMOS68D HS Investigative
DMOS68D SN 4-(4-Fluorobenzoyl)pyridine; 41538-36-7; (4-fluorophenyl)(pyridin-4-yl)methanone; Methanone, (4-fluorophenyl)-4-pyridinyl-; CHEMBL563196; 4-fluorophenyl 4-pyridyl ketone; (4-fluorophenyl)-pyridin-4-ylmethanone; AC1ODYVS; 3fu0; ACMC-20amw5; AC1Q4LVT; SCHEMBL4618020; CTK1D3778; DTXSID60427471; MolPort-001-628-204; WTRWBYGUMQEFFI-UHFFFAOYSA-N; ZINC2583439; (4-Pyridyl)(p-fluorophenyl) ketone; BDBM50294173; MFCD02683088; SBB092751; 4-[(4-fluorophenyl)carbonyl]pyridine; AKOS003603273; MCULE-1391167832; DB06917; NE40002
DMOS68D DT Small molecular drug
DMOS68D PC 7023019
DMOS68D MW 201.2
DMOS68D FM C12H8FNO
DMOS68D IC InChI=1S/C12H8FNO/c13-11-3-1-9(2-4-11)12(15)10-5-7-14-8-6-10/h1-8H
DMOS68D CS C1=CC(=CC=C1C(=O)C2=CC=NC=C2)F
DMOS68D IK WTRWBYGUMQEFFI-UHFFFAOYSA-N
DMOS68D IU (4-fluorophenyl)-pyridin-4-ylmethanone
DMOS68D CA CAS 41538-36-7
DMOS68D DE Discovery agent
DM0KXP1 ID DM0KXP1
DM0KXP1 DN (4-guanidino-benzyl)-carbamic acid benzyl ester
DM0KXP1 HS Investigative
DM0KXP1 SN CHEMBL391969; (4-guanidino-benzyl)-carbamic acid benzyl ester
DM0KXP1 DT Small molecular drug
DM0KXP1 PC 44436702
DM0KXP1 MW 298.34
DM0KXP1 FM C16H18N4O2
DM0KXP1 IC InChI=1S/C16H18N4O2/c17-15(18)20-14-8-6-12(7-9-14)10-19-16(21)22-11-13-4-2-1-3-5-13/h1-9H,10-11H2,(H,19,21)(H4,17,18,20)
DM0KXP1 CS C1=CC=C(C=C1)COC(=O)NCC2=CC=C(C=C2)N=C(N)N
DM0KXP1 IK NXBMHZOVQPKBKA-UHFFFAOYSA-N
DM0KXP1 IU benzyl N-[[4-(diaminomethylideneamino)phenyl]methyl]carbamate
DM0KXP1 DE Discovery agent
DM1WZXL ID DM1WZXL
DM1WZXL DN (4-hexylphenyl)(oxiran-2-yl)methanone
DM1WZXL HS Investigative
DM1WZXL SN epoxy-ketone, 8g; CHEMBL236543; BDBM18859
DM1WZXL DT Small molecular drug
DM1WZXL PC 23635860
DM1WZXL MW 232.32
DM1WZXL FM C15H20O2
DM1WZXL IC InChI=1S/C15H20O2/c1-2-3-4-5-6-12-7-9-13(10-8-12)15(16)14-11-17-14/h7-10,14H,2-6,11H2,1H3
DM1WZXL CS CCCCCCC1=CC=C(C=C1)C(=O)C2CO2
DM1WZXL IK MHFYINHLDHITER-UHFFFAOYSA-N
DM1WZXL IU (4-hexylphenyl)-(oxiran-2-yl)methanone
DM1WZXL DE Discovery agent
DMRCM5O ID DMRCM5O
DMRCM5O DN (4-Hydroxy-phenoxy)-acetic acid
DMRCM5O HS Investigative
DMRCM5O SN 1878-84-8; 4-Hydroxyphenoxyacetic acid; (4-Hydroxyphenoxy)acetic acid; 2-(4-Hydroxyphenoxy)acetic acid; 4-Hydroxypheoxyacetate; Acetic acid, (4-hydroxyphenoxy)-; (4-Hydroxy-phenoxy)-acetic acid; Acetic acid, 2-(4-hydroxyphenoxy)-; CHEBI:1881; CHEMBL297343; P-HYDROXYPHENOXYACETIC ACID; PKGWLCZTTHWKIZ-UHFFFAOYSA-N; MFCD00014362; (4-Hydroxyphenoxy)acetic acid, 98%; Acetic acid, (p-hydroxyphenoxy)-; EINECS 217-525-8; 4-(Carboxymethoxy)phenol; AC1L26TI; ACMC-1CC13; (4-Hydroxyphenoxy)aceticAcid; SCHEMBL274850; AC1Q766A
DMRCM5O DT Small molecular drug
DMRCM5O PC 15881
DMRCM5O MW 168.15
DMRCM5O FM C8H8O4
DMRCM5O IC InChI=1S/C8H8O4/c9-6-1-3-7(4-2-6)12-5-8(10)11/h1-4,9H,5H2,(H,10,11)
DMRCM5O CS C1=CC(=CC=C1O)OCC(=O)O
DMRCM5O IK PKGWLCZTTHWKIZ-UHFFFAOYSA-N
DMRCM5O IU 2-(4-hydroxyphenoxy)acetic acid
DMRCM5O CA CAS 1878-84-8
DMRCM5O CB CHEBI:1881
DMRCM5O DE Discovery agent
DMOWFE5 ID DMOWFE5
DMOWFE5 DN (4-Iodo-butyl)-trimethyl-ammonium iodide
DMOWFE5 HS Investigative
DMOWFE5 DE Discovery agent
DMZD0KG ID DMZD0KG
DMZD0KG DN (4-methoxyphenyl)(4-phenylazepan-1-yl)methanone
DMZD0KG HS Investigative
DMZD0KG SN CHEMBL562195; (4-methoxyphenyl)(4-phenylazepan-1-yl)methanone; SCHEMBL19248204
DMZD0KG DT Small molecular drug
DMZD0KG PC 45269321
DMZD0KG MW 309.4
DMZD0KG FM C20H23NO2
DMZD0KG IC InChI=1S/C20H23NO2/c1-23-19-11-9-18(10-12-19)20(22)21-14-5-8-17(13-15-21)16-6-3-2-4-7-16/h2-4,6-7,9-12,17H,5,8,13-15H2,1H3
DMZD0KG CS COC1=CC=C(C=C1)C(=O)N2CCCC(CC2)C3=CC=CC=C3
DMZD0KG IK SLZXHOMMTNEABC-UHFFFAOYSA-N
DMZD0KG IU (4-methoxyphenyl)-(4-phenylazepan-1-yl)methanone
DMZD0KG DE Discovery agent
DMPU7KE ID DMPU7KE
DMPU7KE DN (4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid
DMPU7KE HS Investigative
DMPU7KE SN 103368-21-4; (4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid; 1(2h)-quinolineacetic acid, 4-methyl-2-oxo-; NSC108456; (4-methyl-2-oxoquinolin-1(2H)-yl)acetic acid; CHEMBL64455; 2-(4-methyl-2-oxoquinolin-1(2H)-yl)acetic acid; BAS 02839786; (4-Methyl-2-oxo-1(2H)-quinolinyl)acetic acid; 2-(4-methyl-2-oxohydroquinolyl)acetic acid; AC1L6JZ1; AC1Q6I1O; MLS000714792; SCHEMBL15709048; CTK4A2028; DTXSID20296246; MolPort-001-984-878; ZINC380285; HMS2670L06; HMS1681E20; HMS3482A22; ZX-AN005388; ALBB-005471; BB_SC-06267; ZX-CM004260; BBL010328
DMPU7KE DT Small molecular drug
DMPU7KE PC 268297
DMPU7KE MW 217.22
DMPU7KE FM C12H11NO3
DMPU7KE IC InChI=1S/C12H11NO3/c1-8-6-11(14)13(7-12(15)16)10-5-3-2-4-9(8)10/h2-6H,7H2,1H3,(H,15,16)
DMPU7KE CS CC1=CC(=O)N(C2=CC=CC=C12)CC(=O)O
DMPU7KE IK VKKWCKNFSMMXJZ-UHFFFAOYSA-N
DMPU7KE IU 2-(4-methyl-2-oxoquinolin-1-yl)acetic acid
DMPU7KE CA CAS 103368-21-4
DMPU7KE DE Discovery agent
DMBPL3J ID DMBPL3J
DMBPL3J DN (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone
DMBPL3J HS Investigative
DMBPL3J SN BAS 02052986; AC1LDSC0; N-Benzoylpyrazole deriv., 20; CHEMBL244072; ZINC37170; BDBM23712; MolPort-001-971-782; AKOS000577347; 2-methylphenyl 4-nitropyrazolyl ketone; MCULE-4726161589; ST033205; (4-Nitro-pyrazol-1-yl)-o-tolyl-methanone; (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone
DMBPL3J DT Small molecular drug
DMBPL3J PC 674641
DMBPL3J MW 231.21
DMBPL3J FM C11H9N3O3
DMBPL3J IC InChI=1S/C11H9N3O3/c1-8-4-2-3-5-10(8)11(15)13-7-9(6-12-13)14(16)17/h2-7H,1H3
DMBPL3J CS CC1=CC=CC=C1C(=O)N2C=C(C=N2)[N+](=O)[O-]
DMBPL3J IK ORXYMBYYSLQOLK-UHFFFAOYSA-N
DMBPL3J IU (2-methylphenyl)-(4-nitropyrazol-1-yl)methanone
DMBPL3J DE Discovery agent
DMIDUO9 ID DMIDUO9
DMIDUO9 DN (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone
DMIDUO9 HS Investigative
DMIDUO9 SN BAS 02052938; AC1LDSCA; N-Benzoylpyrazole deriv., 5; 4-nitropyrazolyl phenyl ketone; CHEMBL244908; 1-benzoyl-4-nitro-1H-pyrazole; ZINC37183; BDBM23703; AKOS000577075; (4-nitropyrazol-1-yl)-phenylmethanone; MCULE-3158742884; ST033219; (4-Nitro-pyrazol-1-yl)-phenyl-methanone; SR-01000312627
DMIDUO9 DT Small molecular drug
DMIDUO9 PC 674651
DMIDUO9 MW 217.18
DMIDUO9 FM C10H7N3O3
DMIDUO9 IC InChI=1S/C10H7N3O3/c14-10(8-4-2-1-3-5-8)12-7-9(6-11-12)13(15)16/h1-7H
DMIDUO9 CS C1=CC=C(C=C1)C(=O)N2C=C(C=N2)[N+](=O)[O-]
DMIDUO9 IK DLDKTRBBAKTGJH-UHFFFAOYSA-N
DMIDUO9 IU (4-nitropyrazol-1-yl)-phenylmethanone
DMIDUO9 DE Discovery agent
DM1YC0B ID DM1YC0B
DM1YC0B DN (4-nitrophenyl)(10H-phenothiazin-10-yl)methanone
DM1YC0B HS Investigative
DM1YC0B SN CHEMBL239834; AC1MJHMR; Oprea1_338082; Oprea1_035764; (4-nitrophenyl)(10H-phenothiazin-10-yl)methanone; SCHEMBL10490281; ZINC4725769; BDBM50219213; AKOS000731103; BAS 00604089; (4-nitrophenyl)-phenothiazin-10-ylmethanone
DM1YC0B DT Small molecular drug
DM1YC0B PC 3112604
DM1YC0B MW 348.4
DM1YC0B FM C19H12N2O3S
DM1YC0B IC InChI=1S/C19H12N2O3S/c22-19(13-9-11-14(12-10-13)21(23)24)20-15-5-1-3-7-17(15)25-18-8-4-2-6-16(18)20/h1-12H
DM1YC0B CS C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C4=CC=C(C=C4)[N+](=O)[O-]
DM1YC0B IK TUBVLHCMQWIBNP-UHFFFAOYSA-N
DM1YC0B IU (4-nitrophenyl)-phenothiazin-10-ylmethanone
DM1YC0B DE Discovery agent
DMFO8DR ID DMFO8DR
DMFO8DR DN (4-Phenoxy-phenyl)-quinazolin-4-yl-amine
DMFO8DR HS Investigative
DMFO8DR SN CHEMBL304760; N-(4-phenoxyphenyl)quinazolin-4-amine; (4-Phenoxy-phenyl)-quinazolin-4-yl-amine; AC1LEH7Z; Neuro1_000298; Oprea1_168469; SCHEMBL5568872; MolPort-000-668-533; ZINC104659; BDBM50092231; STK918072; (4-phenoxyphenyl)quinazolin-4-ylamine; AKOS002241807; N-(4-Phenoxyphenyl)-4-quinazolinamine; MCULE-2087445269; ST50197248; EU-0074581; SR-01000459365
DMFO8DR DT Small molecular drug
DMFO8DR PC 712152
DMFO8DR MW 313.4
DMFO8DR FM C20H15N3O
DMFO8DR IC InChI=1S/C20H15N3O/c1-2-6-16(7-3-1)24-17-12-10-15(11-13-17)23-20-18-8-4-5-9-19(18)21-14-22-20/h1-14H,(H,21,22,23)
DMFO8DR CS C1=CC=C(C=C1)OC2=CC=C(C=C2)NC3=NC=NC4=CC=CC=C43
DMFO8DR IK RJOICMFRJBMONF-UHFFFAOYSA-N
DMFO8DR IU N-(4-phenoxyphenyl)quinazolin-4-amine
DMFO8DR DE Discovery agent
DMQM8O5 ID DMQM8O5
DMQM8O5 DN (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine
DMQM8O5 HS Investigative
DMQM8O5 SN CHEMBL166325; (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine
DMQM8O5 DT Small molecular drug
DMQM8O5 PC 10564794
DMQM8O5 MW 281.4
DMQM8O5 FM C20H27N
DMQM8O5 IC InChI=1S/C20H27N/c1-3-16-21(17-4-2)20-14-12-19(13-15-20)11-10-18-8-6-5-7-9-18/h5-9,12,20H,3-4,13-17H2,1-2H3
DMQM8O5 CS CCCN(CCC)C1CCC(=CC1)C#CC2=CC=CC=C2
DMQM8O5 IK QQFDMLZEFWKHHH-UHFFFAOYSA-N
DMQM8O5 IU 4-(2-phenylethynyl)-N,N-dipropylcyclohex-3-en-1-amine
DMQM8O5 DE Discovery agent
DM0NTA3 ID DM0NTA3
DM0NTA3 DN (4-phenylpiperazin-1-yl)(p-tolyl)methanone
DM0NTA3 HS Investigative
DM0NTA3 SN (4-Phenyl-piperazin-1-yl)-p-tolyl-methanone; piperazine, a2; Cambridge id 5345452; AC1LF9G0; Oprea1_767331; Oprea1_285639; CHEMBL239457; SCHEMBL10721885; BDBM25773; MolPort-001-016-695; ZINC196133; HMS1676A12; STK020131; AKOS000671240; MCULE-2746904510; BAS 00500757; 4-methylphenyl 4-phenylpiperazinyl ketone; ST50682677; AB00081719-01; 1-[(4-methylphenyl)carbonyl]-4-phenylpiperazine; SR-01000406866; (4-methylphenyl)(4-phenylpiperazin-1-yl)methanone; (4-methylphenyl)-(4-phenylpiperazin-1-yl)methanone
DM0NTA3 DT Small molecular drug
DM0NTA3 PC 749125
DM0NTA3 MW 280.4
DM0NTA3 FM C18H20N2O
DM0NTA3 IC InChI=1S/C18H20N2O/c1-15-7-9-16(10-8-15)18(21)20-13-11-19(12-14-20)17-5-3-2-4-6-17/h2-10H,11-14H2,1H3
DM0NTA3 CS CC1=CC=C(C=C1)C(=O)N2CCN(CC2)C3=CC=CC=C3
DM0NTA3 IK MPTWQLUMMRYFPO-UHFFFAOYSA-N
DM0NTA3 IU (4-methylphenyl)-(4-phenylpiperazin-1-yl)methanone
DM0NTA3 CA CAS 219989-26-1
DM0NTA3 DE Discovery agent
DMKF3U6 ID DMKF3U6
DMKF3U6 DN (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid
DMKF3U6 HS Investigative
DMKF3U6 SN CHEMBL468498; AC1LEONH; (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid
DMKF3U6 DT Small molecular drug
DMKF3U6 PC 715494
DMKF3U6 MW 271.31
DMKF3U6 FM C15H17N3O2
DMKF3U6 IC InChI=1S/C15H17N3O2/c19-15(20)11-17-7-9-18(10-8-17)14-6-5-12-3-1-2-4-13(12)16-14/h1-6H,7-11H2,(H,19,20)
DMKF3U6 CS C1CN(CCN1CC(=O)O)C2=NC3=CC=CC=C3C=C2
DMKF3U6 IK HCRXUFYSLPXCDW-UHFFFAOYSA-N
DMKF3U6 IU 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid
DMKF3U6 DE Discovery agent
DMZFTI4 ID DMZFTI4
DMZFTI4 DN (4R)-4-ammoniopentanoate
DMZFTI4 HS Investigative
DMZFTI4 SN (R)-4-Aminopentanoic acid; 4R-aminopentanoic acid; 5937-83-7; UNII-UPX83HFN1B; UPX83HFN1B; (4R)-4-aminopentanoic acid; (R)-(+)-4-Aminovaleric acid; (4R)-4-ammoniopentanoate; AC1L9GD1; 4-Aminovaleric acid, (R)-; CHEMBL281098; SCHEMBL15177649; Pentanoic acid, 4-amino-, (R)-; ZINC1706201; Pentanoic acid, 4-amino-, (4R)-; LMFA01100021; AKOS006337463; Valeric acid, 4-amino-, (R)-(+)-; UNII-CDM626IVRT component ABSTXSZPGHDTAF-SCSAIBSYSA-N
DMZFTI4 DT Small molecular drug
DMZFTI4 PC 444458
DMZFTI4 MW 117.15
DMZFTI4 FM C5H11NO2
DMZFTI4 IC InChI=1S/C5H11NO2/c1-4(6)2-3-5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DMZFTI4 CS C[C@H](CCC(=O)O)N
DMZFTI4 IK ABSTXSZPGHDTAF-SCSAIBSYSA-N
DMZFTI4 IU (4R)-4-aminopentanoic acid
DMZFTI4 CA CAS 5937-83-7
DMZFTI4 DE Discovery agent
DMBLAY1 ID DMBLAY1
DMBLAY1 DN (4S)-4-ammoniopentanoate
DMBLAY1 HS Investigative
DMBLAY1 SN (S)-4-Aminovaleric acid; (S)-4-Aminopentanoic acid; (4S)-4-aminopentanoic acid; 4S-aminopentanoic acid; UNII-G98ZJ0KD1D; G98ZJ0KD1D; 1558-59-4; Pentanoic acid, 4-amino-, (S)-; (4S)-4-ammoniopentanoate; 4-Aminovaleric acid, (S)-; AC1NSNZ5; SCHEMBL288484; CHEMBL284327; ZINC3581353; LMFA01100022; Pentanoic acid, 4-amino-, (4S)-; (2E,4S)-4-aminopent-2-enoic acid; AKOS027321168; UNII-CDM626IVRT component ABSTXSZPGHDTAF-BYPYZUCNSA-N
DMBLAY1 DT Small molecular drug
DMBLAY1 PC 5312968
DMBLAY1 MW 117.15
DMBLAY1 FM C5H11NO2
DMBLAY1 IC InChI=1S/C5H11NO2/c1-4(6)2-3-5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
DMBLAY1 CS C[C@@H](CCC(=O)O)N
DMBLAY1 IK ABSTXSZPGHDTAF-BYPYZUCNSA-N
DMBLAY1 IU (4S)-4-aminopentanoic acid
DMBLAY1 CA CAS 1558-59-4
DMBLAY1 DE Discovery agent
DMM6QV5 ID DMM6QV5
DMM6QV5 DN (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DMM6QV5 HS Investigative
DMM6QV5 SN CHEMBL108319; (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine; BDBM50138198
DMM6QV5 DT Small molecular drug
DMM6QV5 PC 44337349
DMM6QV5 MW 142.2
DMM6QV5 FM C7H14N2O
DMM6QV5 IC InChI=1S/C7H14N2O/c1-3-5-6(4-2)10-7(8)9-5/h5-6H,3-4H2,1-2H3,(H2,8,9)/t5-,6+/m0/s1
DMM6QV5 CS CC[C@H]1[C@H](OC(=N1)N)CC
DMM6QV5 IK KYKDCIRQVPPSOP-NTSWFWBYSA-N
DMM6QV5 IU (4S,5R)-4,5-diethyl-4,5-dihydro-1,3-oxazol-2-amine
DMM6QV5 DE Discovery agent
DM0V9HB ID DM0V9HB
DM0V9HB DN (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine
DM0V9HB HS Investigative
DM0V9HB SN CHEMBL110789; (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine; BDBM50138184
DM0V9HB DT Small molecular drug
DM0V9HB PC 44337382
DM0V9HB MW 114.15
DM0V9HB FM C5H10N2O
DM0V9HB IC InChI=1S/C5H10N2O/c1-3-4(2)8-5(6)7-3/h3-4H,1-2H3,(H2,6,7)/t3-,4+/m0/s1
DM0V9HB CS C[C@H]1[C@H](OC(=N1)N)C
DM0V9HB IK CBBZZWUQMBKNEY-IUYQGCFVSA-N
DM0V9HB IU (4S,5R)-4,5-dimethyl-4,5-dihydro-1,3-oxazol-2-amine
DM0V9HB DE Discovery agent
DMDC84U ID DMDC84U
DMDC84U DN (4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
DMDC84U HS Investigative
DMDC84U SN CHEMBL322085; (4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine; BDBM50138197
DMDC84U DT Small molecular drug
DMDC84U PC 44337347
DMDC84U MW 170.25
DMDC84U FM C9H18N2O
DMDC84U IC InChI=1S/C9H18N2O/c1-3-5-7-8(6-4-2)12-9(10)11-7/h7-8H,3-6H2,1-2H3,(H2,10,11)/t7-,8+/m0/s1
DMDC84U CS CCC[C@H]1[C@H](OC(=N1)N)CCC
DMDC84U IK LRHNWJTUXJXJRP-JGVFFNPUSA-N
DMDC84U IU (4S,5R)-4,5-dipropyl-4,5-dihydro-1,3-oxazol-2-amine
DMDC84U DE Discovery agent
DM1VJUZ ID DM1VJUZ
DM1VJUZ DN (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine
DM1VJUZ HS Investigative
DM1VJUZ SN CHEMBL105820; (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine; BDBM50138195; AKOS006377258
DM1VJUZ DT Small molecular drug
DM1VJUZ PC 44337366
DM1VJUZ MW 142.2
DM1VJUZ FM C7H14N2O
DM1VJUZ IC InChI=1S/C7H14N2O/c1-3-5-6(4-2)10-7(8)9-5/h5-6H,3-4H2,1-2H3,(H2,8,9)/t5-,6-/m0/s1
DM1VJUZ CS CC[C@H]1[C@@H](OC(=N1)N)CC
DM1VJUZ IK KYKDCIRQVPPSOP-WDSKDSINSA-N
DM1VJUZ IU (4S,5S)-4,5-diethyl-4,5-dihydro-1,3-oxazol-2-amine
DM1VJUZ DE Discovery agent
DM5EKF4 ID DM5EKF4
DM5EKF4 DN (4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
DM5EKF4 HS Investigative
DM5EKF4 SN CHEMBL110498; (4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine; BDBM50138199
DM5EKF4 DT Small molecular drug
DM5EKF4 PC 10678756
DM5EKF4 MW 170.25
DM5EKF4 FM C9H18N2O
DM5EKF4 IC InChI=1S/C9H18N2O/c1-3-5-7-8(6-4-2)12-9(10)11-7/h7-8H,3-6H2,1-2H3,(H2,10,11)/t7-,8-/m0/s1
DM5EKF4 CS CCC[C@H]1[C@@H](OC(=N1)N)CCC
DM5EKF4 IK LRHNWJTUXJXJRP-YUMQZZPRSA-N
DM5EKF4 IU (4S,5S)-4,5-dipropyl-4,5-dihydro-1,3-oxazol-2-amine
DM5EKF4 DE Discovery agent
DMGCZOI ID DMGCZOI
DMGCZOI DN (4-sulfamoylphenylethylthioureido)fluorescein
DMGCZOI HS Investigative
DMGCZOI SN CHEMBL501130; SCHEMBL13263774
DMGCZOI DT Small molecular drug
DMGCZOI PC 44577440
DMGCZOI MW 573.6
DMGCZOI FM C29H23N3O8S
DMGCZOI IC InChI=1S/C29H23N3O8S/c30-41(38,39)20-6-1-16(2-7-20)11-12-31-29(37)32-17-3-8-21(24(13-17)28(35)36)27-22-9-4-18(33)14-25(22)40-26-15-19(34)5-10-23(26)27/h1-10,13-15,33H,11-12H2,(H,35,36)(H2,30,38,39)(H2,31,32,37)
DMGCZOI CS C1=CC(=CC=C1CCNC(=O)NC2=CC(=C(C=C2)C3=C4C=CC(=O)C=C4OC5=C3C=CC(=C5)O)C(=O)O)S(=O)(=O)N
DMGCZOI IK IYBVEUKFGRJHGL-UHFFFAOYSA-N
DMGCZOI IU 2-(3-hydroxy-6-oxoxanthen-9-yl)-5-[2-(4-sulfamoylphenyl)ethylcarbamoylamino]benzoic acid
DMGCZOI DE Discovery agent
DM15P2G ID DM15P2G
DM15P2G DN (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol
DM15P2G HS Investigative
DM15P2G SN Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1
DM15P2G DT Small molecular drug
DM15P2G PC 5712
DM15P2G MW 304.3
DM15P2G FM C19H16N2O2
DM15P2G IC InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
DM15P2G CS C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO
DM15P2G IK OQQVFCKUDYMWGV-UHFFFAOYSA-N
DM15P2G IU [5-(1-benzylindazol-3-yl)furan-2-yl]methanol
DM15P2G CA CAS 170632-47-0
DM15P2G CB CHEBI:93060
DM15P2G DE Discovery agent
DMTC5VF ID DMTC5VF
DMTC5VF DN (5-(pyridin-3-yl)furan-2-yl)methanamine
DMTC5VF HS Investigative
DMTC5VF SN (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE; [5-(pyridin-3-yl)furan-2-yl]methanamine; (5-pyridin-3-ylfuran-2-yl)methanamine; 1-(5-pyridin-3-ylfuran-2-yl)methanamine; CHEMBL178090; CHEBI:41804; (5-Pyridin-3-yl-2-furyl)methylamine; 837376-48-4; 2-Furanmethanamine, 5-(3-pyridinyl)-; SCHEMBL1791769; GTPL8754; BDBM12345; MolPort-022-593-431; ZINC13607134; nicotine 3-heteroaromatic analogue 2a; AKOS022808436; DB07621; compound 39a [PMID: 15634016]; D3G; US8609708, 2; US8609708, 47; F2167-0893
DMTC5VF DT Small molecular drug
DMTC5VF PC 11332763
DMTC5VF MW 174.2
DMTC5VF FM C10H10N2O
DMTC5VF IC InChI=1S/C10H10N2O/c11-6-9-3-4-10(13-9)8-2-1-5-12-7-8/h1-5,7H,6,11H2
DMTC5VF CS C1=CC(=CN=C1)C2=CC=C(O2)CN
DMTC5VF IK LENAVORGWBTPJR-UHFFFAOYSA-N
DMTC5VF IU (5-pyridin-3-ylfuran-2-yl)methanamine
DMTC5VF CA CAS 837376-48-4
DMTC5VF CB CHEBI:41804
DMTC5VF DE Discovery agent
DMF0YJ3 ID DMF0YJ3
DMF0YJ3 DN (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone
DMF0YJ3 HS Investigative
DMF0YJ3 SN 54606-37-0; (5-Amino-1-phenyl-1H-pyrazol-4-yl)phenyl methanone; (5-AMINO-1-PHENYL-1H-PYRAZOL-4-YL)(PHENYL)METHANONE; 4-benzoyl-5-aminopyrazole 1; CHEMBL203333; (5-amino-1-phenyl-1H-pyrazol-4-yl)-phenyl-methanone; SCHEMBL13662120; BDBM15714; 5-amino-4-benzoyl-1-phenylpyrazole; ZINC12365464; 1-Phenyl-4-benzoyl-1H-pyrazol-5-amine; 4-benzoyl-1-phenyl-1H-pyrazol-5-amine; KB-208557; FT-0728731; (5-Amino-1-phenyl-1H-pyrazol-4-yl)(phenyl)methanone, AldrichCPR
DMF0YJ3 DT Small molecular drug
DMF0YJ3 PC 15311937
DMF0YJ3 MW 263.29
DMF0YJ3 FM C16H13N3O
DMF0YJ3 IC InChI=1S/C16H13N3O/c17-16-14(15(20)12-7-3-1-4-8-12)11-18-19(16)13-9-5-2-6-10-13/h1-11H,17H2
DMF0YJ3 CS C1=CC=C(C=C1)C(=O)C2=C(N(N=C2)C3=CC=CC=C3)N
DMF0YJ3 IK YMGWYPXWGVJIAJ-UHFFFAOYSA-N
DMF0YJ3 IU (5-amino-1-phenylpyrazol-4-yl)-phenylmethanone
DMF0YJ3 DE Discovery agent
DMVQ6RN ID DMVQ6RN
DMVQ6RN DN (5BETA)-PREGNANE-3,20-DIONE
DMVQ6RN HS Investigative
DMVQ6RN SN 5beta-Pregnane-3,20-dione; 3,20-Pregnanedione; 5beta-Pregnan-3,20-dione; 128-23-4; 5beta-Dihydroprogesterone; (5BETA)-PREGNANE-3,20-DIONE; NSC 82868; UNII-105J2Q45A0; 5beta-Dihydro Progesterone; 5.beta.-Dihydroprogesterone; 5.beta.-Pregnan-3,20-dione; CHEBI:30154; Pregnane-3,20-dione, (5b)-; XMRPGKVKISIQBV-XWOJZHJZSA-N; 105J2Q45A0; 5b-pregnane-3,20-dione; CI2; (5R,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one; 5.beta.-Pregnane-3,20-dione
DMVQ6RN DT Small molecular drug
DMVQ6RN PC 92745
DMVQ6RN MW 316.5
DMVQ6RN FM C21H32O2
DMVQ6RN IC InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14,16-19H,4-12H2,1-3H3/t14-,16+,17-,18+,19+,20+,21-/m1/s1
DMVQ6RN CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CCC(=O)C4)C)C
DMVQ6RN IK XMRPGKVKISIQBV-XWOJZHJZSA-N
DMVQ6RN IU (5R,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
DMVQ6RN CA CAS 128-23-4
DMVQ6RN CB CHEBI:30154
DMVQ6RN DE Discovery agent
DM4EH2J ID DM4EH2J
DM4EH2J DN (5-Bromo-pentyl)-trimethyl-ammonium
DM4EH2J HS Investigative
DM4EH2J DT Small molecular drug
DM4EH2J PC 11098210
DM4EH2J MW 289.05
DM4EH2J FM C8H19Br2N
DM4EH2J IC InChI=1S/C8H19BrN.BrH/c1-10(2,3)8-6-4-5-7-9;/h4-8H2,1-3H3;1H/q+1;/p-1
DM4EH2J CS C[N+](C)(C)CCCCCBr.[Br-]
DM4EH2J IK GEIHNRASRNQTDE-UHFFFAOYSA-M
DM4EH2J IU 5-bromopentyl(trimethyl)azanium;bromide
DM4EH2J CA CAS 15008-33-0
DM4EH2J DE Discovery agent
DM8JHWS ID DM8JHWS
DM8JHWS DN (5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal
DM8JHWS HS Investigative
DM8JHWS SN CHEMBL373333; (5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal; SCHEMBL1800772
DM8JHWS DT Small molecular drug
DM8JHWS PC 22020504
DM8JHWS MW 288.5
DM8JHWS FM C20H32O
DM8JHWS IC InChI=1S/C20H32O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21/h6-7,9-10,12-13,15-16,20H,2-5,8,11,14,17-19H2,1H3/b7-6+,10-9+,13-12+,16-15+
DM8JHWS CS CCCCC/C=C/C/C=C/C/C=C/C/C=C/CCCC=O
DM8JHWS IK XTZSIVLWZNRBAB-CGRWFSSPSA-N
DM8JHWS IU (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenal
DM8JHWS DE Discovery agent
DMIV4BU ID DMIV4BU
DMIV4BU DN (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU HS Investigative
DMIV4BU SN CHEMBL209042; (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU DT Small molecular drug
DMIV4BU PC 11500099
DMIV4BU MW 278.28
DMIV4BU FM C17H11FN2O
DMIV4BU IC InChI=1S/C17H11FN2O/c18-12-5-6-14-11(7-12)9-16(20-14)17(21)15-8-10-3-1-2-4-13(10)19-15/h1-9,19-20H
DMIV4BU CS C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)F
DMIV4BU IK HXWDONFZGUZRTN-UHFFFAOYSA-N
DMIV4BU IU (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMIV4BU DE Discovery agent
DMPBNYM ID DMPBNYM
DMPBNYM DN (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone
DMPBNYM HS Investigative
DMPBNYM SN CHEMBL7735; PDGF Receptor Tyrosine Kinase Inhibitor I; D-64406; (5-Hydroxy-1H-2-indolyl)(1H-2-indolyl)-methanone; 249762-62-7; AC1NS9CN; BDBM6581; SCHEMBL4456469; CHEBI:92486; ZINC24261; CTK0J4476; DTXSID20416205; Bis(1H-2-indolyl)methanone 39; IN1158; HSCI1_000198; NCGC00185731-01; 5-Hydroxy-[2,2'-carbonylbis(1H-indole)]; 2-(1H-indol-2-ylcarbonyl)-1H-indol-5-ol; BRD-K27665173-001-01-3; (5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone; Methanone, (5-hydroxy-1H-indol-2-yl)-1H-indol-2-yl-
DMPBNYM DT Small molecular drug
DMPBNYM PC 5330535
DMPBNYM MW 276.29
DMPBNYM FM C17H12N2O2
DMPBNYM IC InChI=1S/C17H12N2O2/c20-12-5-6-14-11(7-12)9-16(19-14)17(21)15-8-10-3-1-2-4-13(10)18-15/h1-9,18-20H
DMPBNYM CS C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)O
DMPBNYM IK AALNCHNFTKRFEL-UHFFFAOYSA-N
DMPBNYM IU (5-hydroxy-1H-indol-2-yl)-(1H-indol-2-yl)methanone
DMPBNYM CA CAS 249762-62-7
DMPBNYM CB CHEBI:92486
DMPBNYM DE Discovery agent
DMBKZDJ ID DMBKZDJ
DMBKZDJ DN (5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ HS Investigative
DMBKZDJ SN CHEMBL361722; (5-Imino-[1,4]thiazepan-3-yl)-methanol
DMBKZDJ DT Small molecular drug
DMBKZDJ PC 44396191
DMBKZDJ MW 160.24
DMBKZDJ FM C6H12N2OS
DMBKZDJ IC InChI=1S/C6H12N2OS/c7-6-1-2-10-4-5(3-9)8-6/h5,9H,1-4H2,(H2,7,8)
DMBKZDJ CS C1CSCC(N=C1N)CO
DMBKZDJ IK LARUWSZSMYBJIP-UHFFFAOYSA-N
DMBKZDJ IU (5-amino-2,3,6,7-tetrahydro-1,4-thiazepin-3-yl)methanol
DMBKZDJ DE Discovery agent
DMOPMNC ID DMOPMNC
DMOPMNC DN (5-methoxy-1H-indol-3-yl)methanamine
DMOPMNC HS Investigative
DMOPMNC SN (5-methoxy-1H-indol-3-yl)methanamine; 60523-82-2; 5-Methoxy-1h-indol-3-methylamine; 3-(AMINOMETHYL)-5-METHOXYINDOLE; CHEMBL1276050; 5-METHOXYINDOLE-3-METHYLAMINE; SCHEMBL3976318; CTK5B1636; DTXSID20563182; MolPort-006-831-850; ZX-AN081076; ALBB-030269; FCH853008; BDBM50330861; 9026AB; ZINC20269183; AKOS005214650; MB03907; CM-1862; SC-45599; KB-43524; AJ-76727; AK112525; ST2402466; DB-012273; AX8104451; FT-0691098; 4CH-017193; 1-(5-METHOXY-1H-INDOL-3-YL)METHANAMINE
DMOPMNC DT Small molecular drug
DMOPMNC PC 14702424
DMOPMNC MW 176.21
DMOPMNC FM C10H12N2O
DMOPMNC IC InChI=1S/C10H12N2O/c1-13-8-2-3-10-9(4-8)7(5-11)6-12-10/h2-4,6,12H,5,11H2,1H3
DMOPMNC CS COC1=CC2=C(C=C1)NC=C2CN
DMOPMNC IK CAHOMULUOHSWPI-UHFFFAOYSA-N
DMOPMNC IU (5-methoxy-1H-indol-3-yl)methanamine
DMOPMNC CA CAS 60523-82-2
DMOPMNC DE Discovery agent
DM4FJHO ID DM4FJHO
DM4FJHO DN (5-Methoxy-chroman-3-yl)-dipropyl-amine
DM4FJHO HS Investigative
DM4FJHO SN 5-Meo-dpac; 5-Methoxy-3-(di-n-propylamino)chroman; CHEMBL283606; 3-Dipropylamino-5-methyloxychroman; 5-Methoxy-3-(dipropylamino)chroman; (5-Methoxy-chroman-3-yl)-dipropyl-amine; AC1MIZ4R; 110927-00-9; SCHEMBL2217080; CTK8G5655; GOWYIQOIWRLZLO-UHFFFAOYSA-N; BDBM50036862; 3-(Di-n-propylamino)-5-methoxychroman; L023817; 5-methoxy-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine; 5-methoxy-3,4-dihydro-N,N-dipropyl-2H-[1]-benzopyran-3-amine; 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-methoxy-N,N-dipropyl-
DM4FJHO DT Small molecular drug
DM4FJHO PC 3082597
DM4FJHO MW 263.37
DM4FJHO FM C16H25NO2
DM4FJHO IC InChI=1S/C16H25NO2/c1-4-9-17(10-5-2)13-11-14-15(18-3)7-6-8-16(14)19-12-13/h6-8,13H,4-5,9-12H2,1-3H3
DM4FJHO CS CCCN(CCC)C1CC2=C(C=CC=C2OC)OC1
DM4FJHO IK GOWYIQOIWRLZLO-UHFFFAOYSA-N
DM4FJHO IU 5-methoxy-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine
DM4FJHO CA CAS 110927-00-9
DM4FJHO DE Discovery agent
DM2HCUK ID DM2HCUK
DM2HCUK DN (5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine
DM2HCUK HS Investigative
DM2HCUK SN CHEMBL255554; SCHEMBL3149686; ZINC11687646
DM2HCUK DT Small molecular drug
DM2HCUK PC 11615508
DM2HCUK MW 223.27
DM2HCUK FM C14H13N3
DM2HCUK IC InChI=1S/C14H13N3/c15-8-12-11(10-4-2-1-3-5-10)6-7-13-14(12)17-9-16-13/h1-7,9H,8,15H2,(H,16,17)
DM2HCUK CS C1=CC=C(C=C1)C2=C(C3=C(C=C2)NC=N3)CN
DM2HCUK IK IYXQHXUCPDCZDQ-UHFFFAOYSA-N
DM2HCUK IU (5-phenyl-1H-benzimidazol-4-yl)methanamine
DM2HCUK DE Discovery agent
DMORD8S ID DMORD8S
DMORD8S DN (5-phenylfuran-2-yl)methanamine
DMORD8S HS Investigative
DMORD8S SN (5-phenylfuran-2-yl)methanamine; 39170-18-8; 2-Furanmethanamine, 5-phenyl-; 5-phenylfurfurylamine; AC1Q53ZI; SCHEMBL720013; (5-phenyl-2-furyl)methylamine; CHEMBL214859; CTK7E5186; BDBM12363; MolPort-004-306-048; 1-(5-phenyl-2-furyl)methanamine; ZINC14949858; nicotine 3-heteroaromatic analogue 22; AKOS000143046; MCULE-3484411839; AJ-65506; EN300-49879
DMORD8S DT Small molecular drug
DMORD8S PC 11993871
DMORD8S MW 173.21
DMORD8S FM C11H11NO
DMORD8S IC InChI=1S/C11H11NO/c12-8-10-6-7-11(13-10)9-4-2-1-3-5-9/h1-7H,8,12H2
DMORD8S CS C1=CC=C(C=C1)C2=CC=C(O2)CN
DMORD8S IK HQHHWOJYOUTZHZ-UHFFFAOYSA-N
DMORD8S IU (5-phenylfuran-2-yl)methanamine
DMORD8S CA CAS 39170-18-8
DMORD8S DE Discovery agent
DM1R5SF ID DM1R5SF
DM1R5SF DN (5-Phenyl-oxazol-2-yl)-m-tolyl-amine
DM1R5SF HS Investigative
DM1R5SF SN GW632046X; N-(3-methylphenyl)-5-phenyl-1,3-oxazol-2-amine; 2-Anilino-5-aryloxazole 14; AC1NS7RH; SCHEMBL5475472; CHEMBL192417; BDBM5853; HMS3305J21; HMS3303N24; NCGC00242232-01
DM1R5SF DT Small molecular drug
DM1R5SF PC 5329849
DM1R5SF MW 250.29
DM1R5SF FM C16H14N2O
DM1R5SF IC InChI=1S/C16H14N2O/c1-12-6-5-9-14(10-12)18-16-17-11-15(19-16)13-7-3-2-4-8-13/h2-11H,1H3,(H,17,18)
DM1R5SF CS CC1=CC(=CC=C1)NC2=NC=C(O2)C3=CC=CC=C3
DM1R5SF IK XLGKHWGSIZWZNN-UHFFFAOYSA-N
DM1R5SF IU N-(3-methylphenyl)-5-phenyl-1,3-oxazol-2-amine
DM1R5SF DE Discovery agent
DMKC2BE ID DMKC2BE
DMKC2BE DN (5-pyridin-3-yl-furan-2-yl)methanethiol
DMKC2BE HS Investigative
DMKC2BE SN 2-Furanmethanethiol, 5-(3-pyridinyl)-; 859239-19-3; (5-pyridin-3-yl-furan-2-yl)methanethiol; CHEMBL214784; SCHEMBL3611340; CTK2I3858; BDBM12360; DTXSID30475409; GLMNDKCXHHOKIQ-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 14; [5-(pyridin-3-yl)furan-2-yl]methanethiol
DMKC2BE DT Small molecular drug
DMKC2BE PC 11993866
DMKC2BE MW 191.25
DMKC2BE FM C10H9NOS
DMKC2BE IC InChI=1S/C10H9NOS/c13-7-9-3-4-10(12-9)8-2-1-5-11-6-8/h1-6,13H,7H2
DMKC2BE CS C1=CC(=CN=C1)C2=CC=C(O2)CS
DMKC2BE IK GLMNDKCXHHOKIQ-UHFFFAOYSA-N
DMKC2BE IU (5-pyridin-3-ylfuran-2-yl)methanethiol
DMKC2BE CA CAS 859239-19-3
DMKC2BE DE Discovery agent
DMREVX9 ID DMREVX9
DMREVX9 DN (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone
DMREVX9 HS Investigative
DMREVX9 SN CHEMBL378672; (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone; GS416
DMREVX9 DT Small molecular drug
DMREVX9 PC 11809004
DMREVX9 MW 308.4
DMREVX9 FM C20H20O3
DMREVX9 IC InChI=1S/C20H20O3/c21-18-12-7-13-19(22-14-16-8-3-1-4-9-16)20(18)23-15-17-10-5-2-6-11-17/h1-12,19-20H,13-15H2/t19-,20-/m1/s1
DMREVX9 CS C1C=CC(=O)[C@H]([C@@H]1OCC2=CC=CC=C2)OCC3=CC=CC=C3
DMREVX9 IK PHZAKVRYDXRMRQ-WOJBJXKFSA-N
DMREVX9 IU (5R,6S)-5,6-bis(phenylmethoxy)cyclohex-2-en-1-one
DMREVX9 DE Discovery agent
DMHG7MU ID DMHG7MU
DMHG7MU DN (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone
DMHG7MU HS Investigative
DMHG7MU SN CHEMBL212055; (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone; BDBM50186506
DMHG7MU DT Small molecular drug
DMHG7MU PC 15071517
DMHG7MU MW 232.27
DMHG7MU FM C14H16O3
DMHG7MU IC InChI=1S/C14H16O3/c1-16-13-9-5-8-12(15)14(13)17-10-11-6-3-2-4-7-11/h2-8,13-14H,9-10H2,1H3/t13-,14-/m1/s1
DMHG7MU CS CO[C@@H]1CC=CC(=O)[C@H]1OCC2=CC=CC=C2
DMHG7MU IK KGCDPLUOCMBBAM-ZIAGYGMSSA-N
DMHG7MU IU (5R,6S)-5-methoxy-6-phenylmethoxycyclohex-2-en-1-one
DMHG7MU DE Discovery agent
DMA5DO2 ID DMA5DO2
DMA5DO2 DN (5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione
DMA5DO2 HS Investigative
DMA5DO2 SN (5s)-5-iododihydro-2,4(1h,3h)-pyrimidinedione; IDH; AC1NRBRW; SCHEMBL4316335; DB02303; (5S)-5-iodo-1,3-diazinane-2,4-dione
DMA5DO2 DT Small molecular drug
DMA5DO2 PC 5288605
DMA5DO2 MW 240
DMA5DO2 FM C4H5IN2O2
DMA5DO2 IC InChI=1S/C4H5IN2O2/c5-2-1-6-4(9)7-3(2)8/h2H,1H2,(H2,6,7,8,9)/t2-/m0/s1
DMA5DO2 CS C1[C@@H](C(=O)NC(=O)N1)I
DMA5DO2 IK YGKCTZPSAOUUMT-REOHCLBHSA-N
DMA5DO2 IU (5S)-5-iodo-1,3-diazinane-2,4-dione
DMA5DO2 DE Discovery agent
DMT9CXD ID DMT9CXD
DMT9CXD DN (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD HS Investigative
DMT9CXD SN CHEMBL193007; (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine
DMT9CXD DT Small molecular drug
DMT9CXD PC 44399940
DMT9CXD MW 152.24
DMT9CXD FM C9H16N2
DMT9CXD IC InChI=1S/C9H16N2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h7-8H,1-6H2,(H2,10,11)/t7-,8+/m1/s1
DMT9CXD CS C1CC[C@H]2[C@H](C1)CCC(=N2)N
DMT9CXD IK AEIXJVBMYJIICX-SFYZADRCSA-N
DMT9CXD IU (4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydroquinolin-2-amine
DMT9CXD DE Discovery agent
DMP4UC1 ID DMP4UC1
DMP4UC1 DN (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1 HS Investigative
DMP4UC1 SN CHEMBL364230; (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine
DMP4UC1 DT Small molecular drug
DMP4UC1 PC 44399941
DMP4UC1 MW 152.24
DMP4UC1 FM C9H16N2
DMP4UC1 IC InChI=1S/C9H16N2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h7-8H,1-6H2,(H2,10,11)/t7-,8-/m0/s1
DMP4UC1 CS C1CC[C@H]2[C@@H](C1)CCC(=N2)N
DMP4UC1 IK AEIXJVBMYJIICX-YUMQZZPRSA-N
DMP4UC1 IU (4aS,8aS)-3,4,4a,5,6,7,8,8a-octahydroquinolin-2-amine
DMP4UC1 DE Discovery agent
DMA97CS ID DMA97CS
DMA97CS DN (5Z,9Z)-5,9-heptacosadienoic acid
DMA97CS HS Investigative
DMA97CS SN (5Z,9Z)-5,9-heptacosadienoic acid; 5Z,9Z-heptacosadienoic acid; CHEMBL463437; 27:2(5Z,9Z); LMFA01020363
DMA97CS DT Small molecular drug
DMA97CS PC 44567153
DMA97CS MW 406.7
DMA97CS FM C27H50O2
DMA97CS IC InChI=1S/C27H50O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27(28)29/h18-19,22-23H,2-17,20-21,24-26H2,1H3,(H,28,29)/b19-18-,23-22-
DMA97CS CS CCCCCCCCCCCCCCCCC/C=C\\CC/C=C\\CCCC(=O)O
DMA97CS IK QHCUSXRHMXVISV-ZCIBKELESA-N
DMA97CS IU (5Z,9Z)-heptacosa-5,9-dienoic acid
DMA97CS DE Discovery agent
DMAXS9H ID DMAXS9H
DMAXS9H DN (6-Benzylamino-9H-beta-carbolin-3-yl)-methanol
DMAXS9H HS Investigative
DMAXS9H SN [6-(benzylamino)-9H-pyrido[3,4-b]indol-3-yl]methanol; NSC629814; AC1NTT2B; CHEMBL166270; CHEMBL2008860; NCI60_009695; (6-(Benzylamino)-9H-beta-carbolin-3-yl)methanol hydrochloride
DMAXS9H DT Small molecular drug
DMAXS9H PC 5387929
DMAXS9H MW 303.4
DMAXS9H FM C19H17N3O
DMAXS9H IC InChI=1S/C19H17N3O/c23-12-15-9-17-16-8-14(20-10-13-4-2-1-3-5-13)6-7-18(16)22-19(17)11-21-15/h1-9,11,20,22-23H,10,12H2
DMAXS9H CS C1=CC=C(C=C1)CNC2=CC3=C(C=C2)NC4=C3C=C(N=C4)CO
DMAXS9H IK PCESGKMKSBKSOT-UHFFFAOYSA-N
DMAXS9H IU [6-(benzylamino)-9H-pyrido[3,4-b]indol-3-yl]methanol
DMAXS9H DE Discovery agent
DMF7LST ID DMF7LST
DMF7LST DN (6-Benzyloxy-2-naphthyl)-2-aminopropane
DMF7LST HS Investigative
DMF7LST SN CHEMBL456006; (6-Benzyloxy-2-naphthyl)-2-aminopropane
DMF7LST DT Small molecular drug
DMF7LST PC 44590780
DMF7LST MW 291.4
DMF7LST FM C20H21NO
DMF7LST IC InChI=1S/C20H21NO/c1-15(21)11-17-7-8-19-13-20(10-9-18(19)12-17)22-14-16-5-3-2-4-6-16/h2-10,12-13,15H,11,14,21H2,1H3
DMF7LST CS CC(CC1=CC2=C(C=C1)C=C(C=C2)OCC3=CC=CC=C3)N
DMF7LST IK KDDLNYYBHKHYRE-UHFFFAOYSA-N
DMF7LST IU 1-(6-phenylmethoxynaphthalen-2-yl)propan-2-amine
DMF7LST DE Discovery agent
DM7BK9A ID DM7BK9A
DM7BK9A DN (6-Butoxy-2-naphthyl)-2-aminopropane
DM7BK9A HS Investigative
DM7BK9A SN CHEMBL447882; (6-Butoxy-2-naphthyl)-2-aminopropane
DM7BK9A DT Small molecular drug
DM7BK9A PC 44590779
DM7BK9A MW 257.37
DM7BK9A FM C17H23NO
DM7BK9A IC InChI=1S/C17H23NO/c1-3-4-9-19-17-8-7-15-11-14(10-13(2)18)5-6-16(15)12-17/h5-8,11-13H,3-4,9-10,18H2,1-2H3
DM7BK9A CS CCCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
DM7BK9A IK HQJXBGMWVQCDJS-UHFFFAOYSA-N
DM7BK9A IU 1-(6-butoxynaphthalen-2-yl)propan-2-amine
DM7BK9A DE Discovery agent
DMM2EX6 ID DMM2EX6
DMM2EX6 DN (6-Ethoxy-2-naphthyl)-2-aminopropane
DMM2EX6 HS Investigative
DMM2EX6 SN CHEMBL450964; (6-Ethoxy-2-naphthyl)-2-aminopropane
DMM2EX6 DT Small molecular drug
DMM2EX6 PC 44590294
DMM2EX6 MW 229.32
DMM2EX6 FM C15H19NO
DMM2EX6 IC InChI=1S/C15H19NO/c1-3-17-15-7-6-13-9-12(8-11(2)16)4-5-14(13)10-15/h4-7,9-11H,3,8,16H2,1-2H3
DMM2EX6 CS CCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
DMM2EX6 IK RIBPBDJODPIITD-UHFFFAOYSA-N
DMM2EX6 IU 1-(6-ethoxynaphthalen-2-yl)propan-2-amine
DMM2EX6 DE Discovery agent
DMQJ5RU ID DMQJ5RU
DMQJ5RU DN (6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMQJ5RU HS Investigative
DMQJ5RU SN CHEMBL291659; (6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid; BDBM50022252
DMQJ5RU DT Small molecular drug
DMQJ5RU PC 13683080
DMQJ5RU MW 219.19
DMQJ5RU FM C11H9NO4
DMQJ5RU IC InChI=1S/C11H9NO4/c13-8-2-3-9-7(5-8)1-4-10(14)12(9)6-11(15)16/h1-5,13H,6H2,(H,15,16)
DMQJ5RU CS C1=CC2=C(C=CC(=O)N2CC(=O)O)C=C1O
DMQJ5RU IK VDYFIKQEBBKQES-UHFFFAOYSA-N
DMQJ5RU IU 2-(6-hydroxy-2-oxoquinolin-1-yl)acetic acid
DMQJ5RU DE Discovery agent
DM6YGQ3 ID DM6YGQ3
DM6YGQ3 DN (6-Methoxy-2-naphthyl)-2-aminopropane
DM6YGQ3 HS Investigative
DM6YGQ3 SN CHEMBL443427; (6-Methoxy-2-naphthyl)-2-aminopropane; SCHEMBL13484409; CTK7A8193; BDBM50276190; AKOS000161922; AKOS022489543
DM6YGQ3 DT Small molecular drug
DM6YGQ3 PC 18070083
DM6YGQ3 MW 215.29
DM6YGQ3 FM C14H17NO
DM6YGQ3 IC InChI=1S/C14H17NO/c1-10(15)7-11-3-4-13-9-14(16-2)6-5-12(13)8-11/h3-6,8-10H,7,15H2,1-2H3
DM6YGQ3 CS CC(CC1=CC2=C(C=C1)C=C(C=C2)OC)N
DM6YGQ3 IK YYZOZFYDYBTLPQ-UHFFFAOYSA-N
DM6YGQ3 IU 1-(6-methoxynaphthalen-2-yl)propan-2-amine
DM6YGQ3 DE Discovery agent
DMTYXFU ID DMTYXFU
DMTYXFU DN (6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMTYXFU HS Investigative
DMTYXFU SN CHEMBL305164; 6-methoxy-2-oxo-1,2-dihydro-1-quinolineacetic acid; 103368-22-5; (6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid; SCHEMBL8368861; BDBM50022249
DMTYXFU DT Small molecular drug
DMTYXFU PC 13683078
DMTYXFU MW 233.22
DMTYXFU FM C12H11NO4
DMTYXFU IC InChI=1S/C12H11NO4/c1-17-9-3-4-10-8(6-9)2-5-11(14)13(10)7-12(15)16/h2-6H,7H2,1H3,(H,15,16)
DMTYXFU CS COC1=CC2=C(C=C1)N(C(=O)C=C2)CC(=O)O
DMTYXFU IK CHNXZDVEGNIZLG-UHFFFAOYSA-N
DMTYXFU IU 2-(6-methoxy-2-oxoquinolin-1-yl)acetic acid
DMTYXFU CA CAS 103368-22-5
DMTYXFU DE Discovery agent
DM39W5K ID DM39W5K
DM39W5K DN (6-methylthio-2-naphthyl)isopropylamine
DM39W5K HS Investigative
DM39W5K SN CHEMBL455558; (6-methylthio-2-naphthyl)isopropylamine
DM39W5K DT Small molecular drug
DM39W5K PC 44590781
DM39W5K MW 231.36
DM39W5K FM C14H17NS
DM39W5K IC InChI=1S/C14H17NS/c1-10(15)7-11-3-4-13-9-14(16-2)6-5-12(13)8-11/h3-6,8-10H,7,15H2,1-2H3
DM39W5K CS CC(CC1=CC2=C(C=C1)C=C(C=C2)SC)N
DM39W5K IK YTLQCSVRMANEOQ-UHFFFAOYSA-N
DM39W5K IU 1-(6-methylsulfanylnaphthalen-2-yl)propan-2-amine
DM39W5K DE Discovery agent
DMIFL3V ID DMIFL3V
DMIFL3V DN (6-Propoxy-2-naphthyl)-2-aminopropane
DMIFL3V HS Investigative
DMIFL3V SN CHEMBL471840; (6-Propoxy-2-naphthyl)-2-aminopropane
DMIFL3V DT Small molecular drug
DMIFL3V PC 44590295
DMIFL3V MW 243.34
DMIFL3V FM C16H21NO
DMIFL3V IC InChI=1S/C16H21NO/c1-3-8-18-16-7-6-14-10-13(9-12(2)17)4-5-15(14)11-16/h4-7,10-12H,3,8-9,17H2,1-2H3
DMIFL3V CS CCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)N
DMIFL3V IK CRXAYNAYXGFRGO-UHFFFAOYSA-N
DMIFL3V IU 1-(6-propoxynaphthalen-2-yl)propan-2-amine
DMIFL3V DE Discovery agent
DMOD9R7 ID DMOD9R7
DMOD9R7 DN (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin
DMOD9R7 HS Investigative
DMOD9R7 DT Small molecular drug
DMOD9R7 PC 135905887
DMOD9R7 MW 241.25
DMOD9R7 FM C9H15N5O3
DMOD9R7 IC InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4-,6+/m1/s1
DMOD9R7 CS C[C@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMOD9R7 IK FNKQXYHWGSIFBK-KODRXGBYSA-N
DMOD9R7 IU (6R)-2-amino-6-[(1R,2R)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMOD9R7 DE Discovery agent
DMRAC6T ID DMRAC6T
DMRAC6T DN (6s)-5,6,7,8-Tetrahydrofolate
DMRAC6T HS Investigative
DMRAC6T DT Small molecular drug
DMRAC6T PC 135398650
DMRAC6T MW 445.4
DMRAC6T FM C19H23N7O6
DMRAC6T IC InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11-,12-/m0/s1
DMRAC6T CS C1[C@@H](NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMRAC6T IK MSTNYGQPCMXVAQ-RYUDHWBXSA-N
DMRAC6T IU (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DMRAC6T CA CAS 135-16-0
DMRAC6T CB CHEBI:15635
DMRAC6T DE Discovery agent
DMB9YAO ID DMB9YAO
DMB9YAO DN (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
DMB9YAO HS Investigative
DMB9YAO SN CHEMBL572768; (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
DMB9YAO DT Small molecular drug
DMB9YAO PC 44541754
DMB9YAO MW 291.3
DMB9YAO FM C18H13NO3
DMB9YAO IC InChI=1S/C18H13NO3/c19-9-8-14-10-18(20)22-17-11-15(6-7-16(14)17)21-12-13-4-2-1-3-5-13/h1-7,10-11H,8,12H2
DMB9YAO CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)C(=CC(=O)O3)CC#N
DMB9YAO IK QXYWJHCXXQZBTQ-UHFFFAOYSA-N
DMB9YAO IU 2-(2-oxo-7-phenylmethoxychromen-4-yl)acetonitrile
DMB9YAO DE Discovery agent
DMRU0IB ID DMRU0IB
DMRU0IB DN (8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid
DMRU0IB HS Investigative
DMRU0IB SN CHEMBL64312; (8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid; BDBM50022245
DMRU0IB DT Small molecular drug
DMRU0IB PC 13683079
DMRU0IB MW 219.19
DMRU0IB FM C11H9NO4
DMRU0IB IC InChI=1S/C11H9NO4/c13-8-3-1-2-7-4-5-9(14)12(11(7)8)6-10(15)16/h1-5,13H,6H2,(H,15,16)
DMRU0IB CS C1=CC2=C(C(=C1)O)N(C(=O)C=C2)CC(=O)O
DMRU0IB IK YRQSYBRKGTYSAL-UHFFFAOYSA-N
DMRU0IB IU 2-(8-hydroxy-2-oxoquinolin-1-yl)acetic acid
DMRU0IB DE Discovery agent
DM1UGQN ID DM1UGQN
DM1UGQN DN (8R,8'R)-4-hydroxycubebinone
DM1UGQN HS Investigative
DM1UGQN SN (8R,8'R)-4-hydroxycubebinone; CHEMBL482034; AC1MHYPL; (8R,8''R)-4-hydroxycubebinone; BDBM50259848; 2(3H)-furanone, dihydro-4-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-3-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-, (3R,4R)-
DM1UGQN DT Small molecular drug
DM1UGQN PC 3013841
DM1UGQN MW 416.4
DM1UGQN FM C22H24O8
DM1UGQN IC InChI=1S/C22H24O8/c1-25-16-6-12(7-17(26-2)20(16)23)4-14-10-28-22(24)15(14)5-13-8-18(27-3)21-19(9-13)29-11-30-21/h6-9,14-15,23H,4-5,10-11H2,1-3H3/t14-,15+/m0/s1
DM1UGQN CS COC1=CC(=CC(=C1O)OC)C[C@H]2COC(=O)[C@@H]2CC3=CC4=C(C(=C3)OC)OCO4
DM1UGQN IK LSSNBHGWOAHIQS-LSDHHAIUSA-N
DM1UGQN IU (3R,4R)-4-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-3-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]oxolan-2-one
DM1UGQN DE Discovery agent
DMVIHTF ID DMVIHTF
DMVIHTF DN (8R,8'R,9'S)-5-methoxyclusin
DMVIHTF HS Investigative
DMVIHTF SN (8R,8'R,9'S)-5-methoxyclusin; CHEMBL482233; BDBM50259849
DMVIHTF DT Small molecular drug
DMVIHTF PC 11259008
DMVIHTF MW 432.5
DMVIHTF FM C23H28O8
DMVIHTF IC InChI=1S/C23H28O8/c1-25-17-8-14(9-18(26-2)21(17)28-4)6-16-15(11-29-23(16)24)5-13-7-19(27-3)22-20(10-13)30-12-31-22/h7-10,15-16,23-24H,5-6,11-12H2,1-4H3/t15-,16+,23-/m0/s1
DMVIHTF CS COC1=CC(=CC2=C1OCO2)C[C@H]3CO[C@@H]([C@@H]3CC4=CC(=C(C(=C4)OC)OC)OC)O
DMVIHTF IK ADGULOHTKSMBCP-PXAQALGRSA-N
DMVIHTF IU (2S,3R,4R)-4-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DMVIHTF DE Discovery agent
DMHJG5N ID DMHJG5N
DMHJG5N DN (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine
DMHJG5N HS Investigative
DMHJG5N SN CHEMBL7583
DMHJG5N DT Small molecular drug
DMHJG5N PC 14022446
DMHJG5N MW 265.31
DMHJG5N FM C15H15N5
DMHJG5N IC InChI=1S/C15H15N5/c1-2-4-11(5-3-1)8-20-10-18-13-14(19-12-6-7-12)16-9-17-15(13)20/h1-5,9-10,12H,6-8H2,(H,16,17,19)
DMHJG5N CS C1CC1NC2=C3C(=NC=N2)N(C=N3)CC4=CC=CC=C4
DMHJG5N IK AVSPKBDDPGPKRA-UHFFFAOYSA-N
DMHJG5N IU 9-benzyl-N-cyclopropylpurin-6-amine
DMHJG5N DE Discovery agent
DMKI2Y9 ID DMKI2Y9
DMKI2Y9 DN (9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester
DMKI2Y9 HS Investigative
DMKI2Y9 SN NSC608075; AC1Q65MC; AC1L75O0; SCHEMBL2215023; CHEMBL353674; ZINC1610755; ethyl 9H-; A-carbolin-3-ylcarbamate; NSC-608075; ethyl N-(9H-pyrido[3,4-b]indol-3-yl)carbamate
DMKI2Y9 DT Small molecular drug
DMKI2Y9 PC 355090
DMKI2Y9 MW 255.27
DMKI2Y9 FM C14H13N3O2
DMKI2Y9 IC InChI=1S/C14H13N3O2/c1-2-19-14(18)17-13-7-10-9-5-3-4-6-11(9)16-12(10)8-15-13/h3-8,16H,2H2,1H3,(H,15,17,18)
DMKI2Y9 CS CCOC(=O)NC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMKI2Y9 IK ABHBEIYQTPYXQQ-UHFFFAOYSA-N
DMKI2Y9 IU ethyl N-(9H-pyrido[3,4-b]indol-3-yl)carbamate
DMKI2Y9 DE Discovery agent
DMVHMPC ID DMVHMPC
DMVHMPC DN (9H-beta-Carbolin-3-yl)-ethyl-amine
DMVHMPC HS Investigative
DMVHMPC SN 9H-Pyrido[3,4-b]indol-3-amine, N-ethyl-; 95935-52-7; ACMC-20m0fc; CHEMBL353967; N-Ethyl-beta-carboline-3-amine; CTK3F3147; DTXSID30541219; N-Ethyl-9H-beta-carbolin-3-amine
DMVHMPC DT Small molecular drug
DMVHMPC PC 13450926
DMVHMPC MW 211.26
DMVHMPC FM C13H13N3
DMVHMPC IC InChI=1S/C13H13N3/c1-2-14-13-7-10-9-5-3-4-6-11(9)16-12(10)8-15-13/h3-8,16H,2H2,1H3,(H,14,15)
DMVHMPC CS CCNC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMVHMPC IK AANHPEPPBKKLLX-UHFFFAOYSA-N
DMVHMPC IU N-ethyl-9H-pyrido[3,4-b]indol-3-amine
DMVHMPC CA CAS 95935-52-7
DMVHMPC DE Discovery agent
DMUF16A ID DMUF16A
DMUF16A DN (9H-beta-Carbolin-3-yl)-methanol
DMUF16A HS Investigative
DMUF16A SN 3-hydroxymethyl-beta-carboline; 65474-79-5; UNII-00QJ5EQT3E; 9H-pyrido[3,4-b]indol-3-ylmethanol; 00QJ5EQT3E; 3-HMC; 3-(hydroxymethyl)-beta-carboline; 3-HYDROXYMETHYL-b-CARBOLINE; 9H-Pyrido[3,4-b]indole-3-methanol; 9H-pyrido(3,4-b)indole-3-methanol; Prestwick_970; Biomol-NT_000286; AC1NS42Q; DivK1c_000628; 9H-beta-carboline-3-methanol; CHEMBL417982; SCHEMBL2216848; BPBio1_001234; KBio1_000628; CTK2F5969; HMS501P10; DTXSID20215795; MolPort-005-942-230; CPBYHTDUBNSBQM-UHFFFAOYSA-N; CHEBI:114188; NINDS_000628; ZINC11535632
DMUF16A DT Small molecular drug
DMUF16A PC 5353338
DMUF16A MW 198.22
DMUF16A FM C12H10N2O
DMUF16A IC InChI=1S/C12H10N2O/c15-7-8-5-10-9-3-1-2-4-11(9)14-12(10)6-13-8/h1-6,14-15H,7H2
DMUF16A CS C1=CC=C2C(=C1)C3=C(N2)C=NC(=C3)CO
DMUF16A IK CPBYHTDUBNSBQM-UHFFFAOYSA-N
DMUF16A IU 9H-pyrido[3,4-b]indol-3-ylmethanol
DMUF16A CA CAS 65474-79-5
DMUF16A CB CHEBI:114188
DMUF16A DE Discovery agent
DMWJNFC ID DMWJNFC
DMWJNFC DN (9-Methyl-9H-purin-6-yl)-phenyl-amine
DMWJNFC HS Investigative
DMWJNFC SN CHEMBL321749; 9H-Purin-6-amine, 9-methyl-N-phenyl-; (9-Methyl-9H-purin-6-yl)-phenyl-amine; SCHEMBL6660171; ZINC4055; 6-Phenylamino-9-methyl-9H-purine; BDBM50009703; 84602-82-4
DMWJNFC DT Small molecular drug
DMWJNFC PC 13439250
DMWJNFC MW 225.25
DMWJNFC FM C12H11N5
DMWJNFC IC InChI=1S/C12H11N5/c1-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-2-4-6-9/h2-8H,1H3,(H,13,14,16)
DMWJNFC CS CN1C=NC2=C(N=CN=C21)NC3=CC=CC=C3
DMWJNFC IK STTSYIXNIOADQX-UHFFFAOYSA-N
DMWJNFC IU 9-methyl-N-phenylpurin-6-amine
DMWJNFC DE Discovery agent
DM12GHQ ID DM12GHQ
DM12GHQ DN (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
DM12GHQ HS Investigative
DM12GHQ SN 13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid; 29623-28-7; 13(S)-HODE; (13S)-Hydroxyoctadecadienoic acid; 13S-HODE; 13-Hydroxyoctadecadienoic acid; CHEMBL451721; CHEBI:34154; 13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)-Hydroxy-9(Z),11(E)-octadecadienoic acid; (9Z, 11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; (9Z,11E)-(13S)-13-Hydroxyoctadeca-9,11-dienoic acid; 9,11-Octadecadienoic acid, 13-hydroxy-, (R-(E,Z))-; 5204-88-6; 10219-69-9; (S)-Coriolic acid; AC1O5YAH
DM12GHQ DT Small molecular drug
DM12GHQ PC 6443013
DM12GHQ MW 296.4
DM12GHQ FM C18H32O3
DM12GHQ IC InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1
DM12GHQ CS CCCCC[C@@H](/C=C/C=C\\CCCCCCCC(=O)O)O
DM12GHQ IK HNICUWMFWZBIFP-IRQZEAMPSA-N
DM12GHQ IU (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
DM12GHQ CA CAS 29623-28-7
DM12GHQ CB CHEBI:34154
DM12GHQ DE Discovery agent
DM2REIN ID DM2REIN
DM2REIN DN (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid
DM2REIN HS Investigative
DM2REIN SN (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid; 12-Nitrolinoleic acid; 12-Nitro-9Z,12Z-octadecadienoic acid; CHEMBL554608; CHEBI:34150; AC1NQZV1; C13958; SCHEMBL2371323; BDBM50295045; LMFA01120002; 12-Nitro-9-cis,12-cis-octadecadienoic acid; (9Z,12Z)-12-Nitrooctadeca-9,12-dienoic acid
DM2REIN DT Small molecular drug
DM2REIN PC 5282316
DM2REIN MW 325.4
DM2REIN FM C18H31NO4
DM2REIN IC InChI=1S/C18H31NO4/c1-2-3-4-11-14-17(19(22)23)15-12-9-7-5-6-8-10-13-16-18(20)21/h9,12,14H,2-8,10-11,13,15-16H2,1H3,(H,20,21)/b12-9-,17-14+
DM2REIN CS CCCCC/C=C(\\C/C=C\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DM2REIN IK ZYFTUIURWQWFKQ-QIAGQCQHSA-N
DM2REIN IU (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid
DM2REIN CB CHEBI:34150
DM2REIN DE Discovery agent
DMS4ZVK ID DMS4ZVK
DMS4ZVK DN (Amino-phenyl-methyl)-phosphinic acid
DMS4ZVK HS Investigative
DMS4ZVK SN Phosphinic acid, (aminophenylmethyl)-; 126529-62-2; 1-amino-1-phenylmethylphosphinic acid; ACMC-20ms0y; AC1O46MZ; SCHEMBL1764684; CTK0F6605; (aminophenylmethyl)phosphinic acid; DTXSID00422960; JLTNHFQJNQZJTC-UHFFFAOYSA-N
DMS4ZVK DT Small molecular drug
DMS4ZVK PC 57013015
DMS4ZVK MW 169.12
DMS4ZVK FM C7H8NO2P
DMS4ZVK IC InChI=1S/C7H8NO2P/c8-7(11(9)10)6-4-2-1-3-5-6/h1-5,8-10H
DMS4ZVK CS C1=CC=C(C=C1)C(=N)P(O)O
DMS4ZVK IK HYRMSZQUBBPTOQ-UHFFFAOYSA-N
DMS4ZVK IU benzenecarboximidoylphosphonous acid
DMS4ZVK DE Discovery agent
DME80RK ID DME80RK
DME80RK DN (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone
DME80RK HS Investigative
DME80RK SN CHEMBL226183; (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone; BDBM50202215; (Benzofuran-2-yl)(1H-indole-2-yl) ketone
DME80RK DT Small molecular drug
DME80RK PC 44423635
DME80RK MW 261.269
DME80RK FM C17H11NO2
DME80RK IC InChI=1S/C17H11NO2/c19-17(14-9-11-5-1-3-7-13(11)18-14)16-10-12-6-2-4-8-15(12)20-16/h1-10,18H
DME80RK CS C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=CC=CC=C4O3
DME80RK IK NWBGABGOSKEFQJ-UHFFFAOYSA-N
DME80RK IU 1-benzofuran-2-yl(1H-indol-2-yl)methanone
DME80RK DE Discovery agent
DMVWQ26 ID DMVWQ26
DMVWQ26 DN (beta-CCE)9H-beta-Carboline-3-carboxylic acid
DMVWQ26 HS Investigative
DMVWQ26 SN Carboline-3-carboxylic acid; 9H-pyrido[3,4-b]indole-3-carboxylic acid; 74214-63-4; 9H-beta-carboline-3-carboxylic acid; beta-carboline-3-carboxylic acid; NSC623957; 9H-Pyrido(3,4-b)indole-3-carboxylic acid; beta-Carboline carboxylic acid; 3-carboxy-beta-carboline; AC1L59WQ; MLS001198085; CHEMBL11908; b-carboline-3-carboxylic acid; SCHEMBL1180278; beta-carbolin-3-carboxylic acid; DTXSID30225209; MolPort-000-872-217; ARLVFKCLBYUINL-UHFFFAOYSA-N; HMS3433I21; HMS1620B11; ZINC20104435; AKOS021730281; CCG-125106; NSC-623957
DMVWQ26 DT Small molecular drug
DMVWQ26 PC 173262
DMVWQ26 MW 212.2
DMVWQ26 FM C12H8N2O2
DMVWQ26 IC InChI=1S/C12H8N2O2/c15-12(16)10-5-8-7-3-1-2-4-9(7)14-11(8)6-13-10/h1-6,14H,(H,15,16)
DMVWQ26 CS C1=CC=C2C(=C1)C3=CC(=NC=C3N2)C(=O)O
DMVWQ26 IK ARLVFKCLBYUINL-UHFFFAOYSA-N
DMVWQ26 IU 9H-pyrido[3,4-b]indole-3-carboxylic acid
DMVWQ26 CA CAS 74214-63-4
DMVWQ26 DE Discovery agent
DMGB97I ID DMGB97I
DMGB97I DN (biphenyl-3-ylamino)methylenediphosphonic acid
DMGB97I HS Investigative
DMGB97I SN CHEMBL55371; AC1NQQUY; (biphenyl-3-ylamino)methylenediphosphonic acid; BPH-218; NSC725581; BDBM50138040; ZINC13532369; NSC-725581; [(3-phenylanilino)-phosphonomethyl]phosphonic acid; [(3-phenylanilino)-phosphono-methyl]phosphonic acid; [(Biphenyl-3-ylamino)-phosphono-methyl]-phosphonic acid; (Biphenyl-3-yl)- aminomethylene-1,1-bisphosphonate (dihydrate); Phosphonic acid, [([1,1'-biphenyl]-3-ylamino)methylene]bis-
DMGB97I DT Small molecular drug
DMGB97I PC 5277466
DMGB97I MW 343.21
DMGB97I FM C13H15NO6P2
DMGB97I IC InChI=1S/C13H15NO6P2/c15-21(16,17)13(22(18,19)20)14-12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,13-14H,(H2,15,16,17)(H2,18,19,20)
DMGB97I CS C1=CC=C(C=C1)C2=CC(=CC=C2)NC(P(=O)(O)O)P(=O)(O)O
DMGB97I IK IXFMBXNLOHKCPT-UHFFFAOYSA-N
DMGB97I IU [(3-phenylanilino)-phosphonomethyl]phosphonic acid
DMGB97I DE Discovery agent
DM5WH6R ID DM5WH6R
DM5WH6R DN (C8-R)-Hydantocidin 5'-Phosphate
DM5WH6R HS Investigative
DM5WH6R SN (C8-R)-HYDANTOCIDIN 5'-PHOSPHATE; 1qf4; AC1L9LL4; DB02666; 5-{(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-[(phosphonooxy)methyl]-6-oxa-1,3-diazaspiro[4.4]non-3-yl}-N-hydroxy-N-(hydroxymethyl)-D-norvaline; (2R)-5-[(1R,2S,3R,5S)-1,2-dihydroxy-6,8-dioxo-3-(phosphonooxymethyl)-4-oxa-7,9-diazaspiro[4.4]nonan-7-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DM5WH6R DT Small molecular drug
DM5WH6R PC 448088
DM5WH6R MW 459.3
DM5WH6R FM C13H22N3O13P
DM5WH6R IC InChI=1S/C13H22N3O13P/c17-5-16(24)6(10(20)21)2-1-3-15-11(22)13(14-12(15)23)9(19)8(18)7(29-13)4-28-30(25,26)27/h6-9,17-19,24H,1-5H2,(H,14,23)(H,20,21)(H2,25,26,27)/t6-,7-,8-,9-,13+/m1/s1
DM5WH6R CS C(C[C@H](C(=O)O)N(CO)O)CN1C(=O)[C@@]2([C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC1=O
DM5WH6R IK MAXSFYCTFIBEAR-OJMIUMIFSA-N
DM5WH6R IU (2R)-5-[(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-(phosphonooxymethyl)-6-oxa-1,3-diazaspiro[4.4]nonan-3-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DM5WH6R DE Discovery agent
DMMH179 ID DMMH179
DMMH179 DN (C8-S)-Hydantocidin 5'-Phosphate
DMMH179 HS Investigative
DMMH179 SN (C8-S)-HYDANTOCIDIN 5'-PHOSPHATE; 1qf5; AC1NRD1T; DB04460; 5-{(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-[(phosphonooxy)methyl]-6-oxa-1,3-diazaspiro[4.4]non-3-yl}-N-hydroxy-N-(hydroxymethyl)-L-norvaline; (2S)-5-[(1R,2S,3R,5S)-1,2-dihydroxy-6,8-dioxo-3-(phosphonooxymethyl)-4-oxa-7,9-diazaspiro[4.4]nonan-7-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DMMH179 DT Small molecular drug
DMMH179 PC 5289306
DMMH179 MW 459.3
DMMH179 FM C13H22N3O13P
DMMH179 IC InChI=1S/C13H22N3O13P/c17-5-16(24)6(10(20)21)2-1-3-15-11(22)13(14-12(15)23)9(19)8(18)7(29-13)4-28-30(25,26)27/h6-9,17-19,24H,1-5H2,(H,14,23)(H,20,21)(H2,25,26,27)/t6-,7+,8+,9+,13-/m0/s1
DMMH179 CS C(C[C@@H](C(=O)O)N(CO)O)CN1C(=O)[C@@]2([C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC1=O
DMMH179 IK MAXSFYCTFIBEAR-FUIMDIGMSA-N
DMMH179 IU (2S)-5-[(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-7-(phosphonooxymethyl)-6-oxa-1,3-diazaspiro[4.4]nonan-3-yl]-2-[hydroxy(hydroxymethyl)amino]pentanoic acid
DMMH179 DE Discovery agent
DMZB0C3 ID DMZB0C3
DMZB0C3 DN (Carboxyhydroxyamino)Ethanoic Acid
DMZB0C3 HS Investigative
DMZB0C3 SN AC1NRBMN; N-(carboxymethyl)-N-hydroxycarbamate
DMZB0C3 DT Small molecular drug
DMZB0C3 PC 4633094
DMZB0C3 MW 135.08
DMZB0C3 FM C3H5NO5
DMZB0C3 IC InChI=1S/C3H5NO5/c5-2(6)1-4(9)3(7)8/h9H,1H2,(H,5,6)(H,7,8)
DMZB0C3 CS C(C(=O)O)N(C(=O)O)O
DMZB0C3 IK LJSQPIOQKDFEKE-UHFFFAOYSA-N
DMZB0C3 IU 2-[carboxy(hydroxy)amino]acetic acid
DMZB0C3 DE Discovery agent
DMD0P4G ID DMD0P4G
DMD0P4G DN (CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMD0P4G HS Investigative
DMD0P4G SN CHEMBL440986; (CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMD0P4G PC 44306414
DMD0P4G MW 1033.3
DMD0P4G FM C49H72N14O9S
DMD0P4G IC InChI=1S/C49H72N14O9S/c1-26(2)16-35(44(68)59-34(41(50)65)14-15-73-9)60-45(69)37(18-30-21-51-24-55-30)58-39(64)23-54-47(71)40(27(3)4)63-42(66)28(5)57-43(67)36(17-29-20-53-33-13-11-10-12-32(29)33)61-46(70)38(19-31-22-52-25-56-31)62-48(72)49(6,7)8/h10-13,20-22,24-28,34-38,40,53H,14-19,23H2,1-9H3,(H2,50,65)(H,51,55)(H,52,56)(H,54,71)(H,57,67)(H,58,64)(H,59,68)(H,60,69)(H,61,70)(H,62,72)(H,63,66)/t28-,34-,35-,36-,37-,38-,40-/m0/s1
DMD0P4G CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C(C)(C)C
DMD0P4G IK PKBMJVZFJGPSPI-MEIFHOCSSA-N
DMD0P4G IU (2S)-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(2,2-dimethylpropanoylamino)-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanamide
DMD0P4G DE Discovery agent
DMMC139 ID DMMC139
DMMC139 DN (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane
DMMC139 HS Investigative
DMMC139 SN CHEMBL488473; (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane
DMMC139 DT Small molecular drug
DMMC139 PC 44561135
DMMC139 MW 235.32
DMMC139 FM C17H17N
DMMC139 IC InChI=1S/C17H17N/c1-3-7-13(8-4-1)16-15-11-18-12-17(15,16)14-9-5-2-6-10-14/h1-10,15-16,18H,11-12H2/t15-,16-,17+/m1/s1
DMMC139 CS C1[C@@H]2[C@H]([C@@]2(CN1)C3=CC=CC=C3)C4=CC=CC=C4
DMMC139 IK MVCAANSQOXMPQN-ZACQAIPSSA-N
DMMC139 IU (1S,5R,6S)-1,6-diphenyl-3-azabicyclo[3.1.0]hexane
DMMC139 DE Discovery agent
DMGXTSB ID DMGXTSB
DMGXTSB DN (D)-Ala-Pro-Glu
DMGXTSB HS Investigative
DMGXTSB SN CHEMBL205662
DMGXTSB DT Small molecular drug
DMGXTSB PC 11370470
DMGXTSB MW 315.32
DMGXTSB FM C13H21N3O6
DMGXTSB IC InChI=1S/C13H21N3O6/c1-7(14)12(20)16-6-2-3-9(16)11(19)15-8(13(21)22)4-5-10(17)18/h7-9H,2-6,14H2,1H3,(H,15,19)(H,17,18)(H,21,22)/t7-,8+,9+/m1/s1
DMGXTSB CS C[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DMGXTSB IK IORKCNUBHNIMKY-VGMNWLOBSA-N
DMGXTSB IU (2S)-2-[[(2S)-1-[(2R)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMGXTSB DE Discovery agent
DMWE42T ID DMWE42T
DMWE42T DN (D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(d)Phe-Phe-Arg
DMWE42T HS Investigative
DMWE42T PC 44273865
DMWE42T MW 1282.5
DMWE42T FM C60H87N19O13
DMWE42T IC InChI=1S/C60H87N19O13/c61-39(20-10-24-68-58(62)63)49(83)73-40(21-11-25-69-59(64)65)55(89)78-27-13-23-46(78)56(90)79-33-38(81)31-47(79)54(88)71-32-48(82)72-42(28-35-14-4-1-5-15-35)50(84)77-45(34-80)53(87)76-44(30-37-18-8-3-9-19-37)52(86)75-43(29-36-16-6-2-7-17-36)51(85)74-41(57(91)92)22-12-26-70-60(66)67/h1-9,14-19,38-47,80-81H,10-13,20-34,61H2,(H,71,88)(H,72,82)(H,73,83)(H,74,85)(H,75,86)(H,76,87)(H,77,84)(H,91,92)(H4,62,63,68)(H4,64,65,69)(H4,66,67,70)/t38?,39-,40-,41?,42+,43?,44?,45?,46-,47-/m0/s1
DMWE42T CS C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)N[C@H](CC3=CC=CC=C3)C(=O)NC(CO)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMWE42T IK RBIXVHPHNGXTCI-QWTWDILDSA-N
DMWE42T IU 2-[[2-[[2-[[2-[[(2R)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMWE42T DE Discovery agent
DMYSE3O ID DMYSE3O
DMYSE3O DN (D)Arg-Arg-Pro-Hyp-Gly-Thi-Cys-(D)Phe-Phe-Cys-Arg
DMYSE3O HS Investigative
DMYSE3O PC 44274056
DMYSE3O MW 1405.7
DMYSE3O FM C61H88N20O13S3
DMYSE3O IC InChI=1S/C61H88N20O13S3/c62-38(17-7-21-69-59(63)64)49(84)74-39(18-8-22-70-60(65)66)56(91)80-24-10-20-46(80)57(92)81-31-36(82)28-47(81)55(90)72-30-48(83)73-43(29-37-16-11-25-95-37)52(87)79-45-33-97-96-32-44(53(88)75-40(58(93)94)19-9-23-71-61(67)68)78-51(86)42(27-35-14-5-2-6-15-35)76-50(85)41(77-54(45)89)26-34-12-3-1-4-13-34/h1-6,11-16,25,36,38-47,82H,7-10,17-24,26-33,62H2,(H,72,90)(H,73,83)(H,74,84)(H,75,88)(H,76,85)(H,77,89)(H,78,86)(H,79,87)(H,93,94)(H4,63,64,69)(H4,65,66,70)(H4,67,68,71)/t36?,38-,39-,40?,41-,42?,43?,44?,45-,46-,47-/m1/s1
DMYSE3O CS C1C[C@@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@@H]4CSSCC(NC(=O)C(NC(=O)[C@H](NC4=O)CC5=CC=CC=C5)CC6=CC=CC=C6)C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMYSE3O IK QRPRDXXCSGEGJN-AAAINLOGSA-N
DMYSE3O IU 2-[[(10R,13S)-13-[[2-[[2-[[(2R)-1-[(2R)-1-[(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-7,10-dibenzyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMYSE3O DE Discovery agent
DMLSJKM ID DMLSJKM
DMLSJKM DN (D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Aoc-Arg
DMLSJKM HS Investigative
DMLSJKM PC 44273898
DMLSJKM MW 1290.5
DMLSJKM FM C58H87N19O13S
DMLSJKM IC InChI=1S/C58H87N19O13S/c59-36(13-4-18-66-56(60)61)47(81)71-37(14-5-19-67-57(62)63)51(85)74-21-7-17-42(74)53(87)76-29-34(79)25-43(76)49(83)69-27-46(80)70-39(26-35-12-8-22-91-35)48(82)73-40(30-78)52(86)75-28-33-10-2-1-9-31(33)23-45(75)54(88)77-41-16-3-11-32(41)24-44(77)50(84)72-38(55(89)90)15-6-20-68-58(64)65/h1-2,8-10,12,22,32,34,36-45,78-79H,3-7,11,13-21,23-30,59H2,(H,69,83)(H,70,80)(H,71,81)(H,72,84)(H,73,82)(H,89,90)(H4,60,61,66)(H4,62,63,67)(H4,64,65,68)/t32?,34?,36-,37-,38?,39?,40-,41?,42-,43-,44?,45?/m1/s1
DMLSJKM CS C1C[C@@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@H](CO)C(=O)N4CC5=CC=CC=C5CC4C(=O)N6C7CCCC7CC6C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMLSJKM IK TZXGWOFUQYJXKR-OSXXQWSASA-N
DMLSJKM IU 2-[[1-[2-[(2R)-2-[[2-[[2-[[(2R)-1-[(2R)-1-[(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMLSJKM DE Discovery agent
DMP0627 ID DMP0627
DMP0627 DN (D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Tic-Arg
DMP0627 HS Investigative
DMP0627 PC 44274015
DMP0627 MW 1312.5
DMP0627 FM C60H85N19O13S
DMP0627 IC InChI=1S/C60H85N19O13S/c61-39(15-5-19-68-58(62)63)49(83)73-40(16-6-20-69-59(64)65)53(87)76-22-8-18-44(76)55(89)79-31-37(81)26-46(79)51(85)71-28-48(82)72-42(27-38-14-9-23-93-38)50(84)75-43(32-80)54(88)78-30-36-13-4-2-11-34(36)25-47(78)56(90)77-29-35-12-3-1-10-33(35)24-45(77)52(86)74-41(57(91)92)17-7-21-70-60(66)67/h1-4,9-14,23,37,39-47,80-81H,5-8,15-22,24-32,61H2,(H,71,85)(H,72,82)(H,73,83)(H,74,86)(H,75,84)(H,91,92)(H4,62,63,68)(H4,64,65,69)(H4,66,67,70)/t37?,39-,40-,41?,42?,43-,44-,45?,46-,47?/m1/s1
DMP0627 CS C1C[C@@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)C(=O)N2CC(C[C@@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@H](CO)C(=O)N4CC5=CC=CC=C5CC4C(=O)N6CC7=CC=CC=C7CC6C(=O)NC(CCCN=C(N)N)C(=O)O)O
DMP0627 IK GFWURPIOGZMEAS-RFHUBXOQSA-N
DMP0627 IU 2-[[2-[2-[(2R)-2-[[2-[[2-[[(2R)-1-[(2R)-1-[(2R)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMP0627 DE Discovery agent
DM5ZIUW ID DM5ZIUW
DM5ZIUW DN (D)-Phe-(D)-Phe-NH2
DM5ZIUW HS Investigative
DM5ZIUW SN CHEMBL590276; (D)-Phe-(D)-Phe-NH2; AC1OEQ8I; BDBM50308389
DM5ZIUW DT Small molecular drug
DM5ZIUW PC 7037588
DM5ZIUW MW 311.4
DM5ZIUW FM C18H21N3O2
DM5ZIUW IC InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16-/m1/s1
DM5ZIUW CS C1=CC=C(C=C1)C[C@H](C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N)N
DM5ZIUW IK XXPXQEQOAZMUDD-HZPDHXFCSA-N
DM5ZIUW IU (2R)-2-amino-N-[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DM5ZIUW DE Discovery agent
DMS32YA ID DMS32YA
DMS32YA DN (D)-Phe-(L)-Phe-NH2
DMS32YA HS Investigative
DMS32YA SN CHEMBL592133; (D)-Phe-(L)-Phe-NH2; AC1OEWDU; BDBM50308390
DMS32YA DT Small molecular drug
DMS32YA PC 7088456
DMS32YA MW 311.4
DMS32YA FM C18H21N3O2
DMS32YA IC InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16+/m1/s1
DMS32YA CS C1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)N
DMS32YA IK XXPXQEQOAZMUDD-CVEARBPZSA-N
DMS32YA IU (2R)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DMS32YA DE Discovery agent
DMQN14X ID DMQN14X
DMQN14X DN (D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2
DMQN14X HS Investigative
DMQN14X SN CHEMBL269024; (D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2
DMQN14X PC 44315629
DMQN14X MW 1069.3
DMQN14X FM C53H76N14O10
DMQN14X IC InChI=1S/C53H76N14O10/c1-28(2)19-39(46(56)70)64-51(75)40(20-29(3)4)65-52(76)42(23-34-25-57-27-60-34)62-44(69)26-59-53(77)45(30(5)6)67-47(71)31(7)61-50(74)41(22-33-24-58-37-16-12-11-15-35(33)37)66-49(73)38(17-18-43(55)68)63-48(72)36(54)21-32-13-9-8-10-14-32/h8-16,24-25,27-31,36,38-42,45,58H,17-23,26,54H2,1-7H3,(H2,55,68)(H2,56,70)(H,57,60)(H,59,77)(H,61,74)(H,62,69)(H,63,72)(H,64,75)(H,65,76)(H,66,73)(H,67,71)/t31-,36-,38-,39-,40-,41-,42-,45-/m0/s1
DMQN14X CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)N
DMQN14X IK HLAREJIMNCKKSS-CENAJWRVSA-N
DMQN14X IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]pentanediamide
DMQN14X DE Discovery agent
DMI39LV ID DMI39LV
DMI39LV DN (D-Arg)(9)-p19(ARF) 26-44 peptide
DMI39LV HS Investigative
DMI39LV DE Discovery agent
DMHSJAT ID DMHSJAT
DMHSJAT DN (E)-(thiophen-2-ylmethylidene)amino benzoate
DMHSJAT HS Investigative
DMHSJAT SN CHEMBL362066; (E)-(thiophen-2-ylmethylidene)amino benzoate; SCHEMBL13431312
DMHSJAT DT Small molecular drug
DMHSJAT PC 11701397
DMHSJAT MW 231.27
DMHSJAT FM C12H9NO2S
DMHSJAT IC InChI=1S/C12H9NO2S/c14-12(10-5-2-1-3-6-10)15-13-9-11-7-4-8-16-11/h1-9H/b13-9+
DMHSJAT CS C1=CC=C(C=C1)C(=O)O/N=C/C2=CC=CS2
DMHSJAT IK VRGHYBJYCUKCSY-UKTHLTGXSA-N
DMHSJAT IU [(E)-thiophen-2-ylmethylideneamino] benzoate
DMHSJAT DE Discovery agent
DMBXK5L ID DMBXK5L
DMBXK5L DN (E)-1-(4-heptylphenyl)but-2-en-1-one
DMBXK5L HS Investigative
DMBXK5L SN Enone, 4b; CHEMBL396089; BDBM18827; ZINC14968962
DMBXK5L DT Small molecular drug
DMBXK5L PC 23635476
DMBXK5L MW 244.37
DMBXK5L FM C17H24O
DMBXK5L IC InChI=1S/C17H24O/c1-3-5-6-7-8-10-15-11-13-16(14-12-15)17(18)9-4-2/h4,9,11-14H,3,5-8,10H2,1-2H3/b9-4+
DMBXK5L CS CCCCCCCC1=CC=C(C=C1)C(=O)/C=C/C
DMBXK5L IK LCSOCUYXJADQCV-RUDMXATFSA-N
DMBXK5L IU (E)-1-(4-heptylphenyl)but-2-en-1-one
DMBXK5L DE Discovery agent
DMEP903 ID DMEP903
DMEP903 DN (E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone
DMEP903 HS Investigative
DMEP903 SN CHEMBL187434; (E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone; SCHEMBL4298443; ZINC13584328
DMEP903 DT Small molecular drug
DMEP903 PC 44396914
DMEP903 MW 254.24
DMEP903 FM C14H10N2O3
DMEP903 IC InChI=1S/C14H10N2O3/c17-14(9-6-12-3-1-2-10-15-12)11-4-7-13(8-5-11)16(18)19/h1-10H/b9-6+
DMEP903 CS C1=CC=NC(=C1)/C=C/C(=O)C2=CC=C(C=C2)[N+](=O)[O-]
DMEP903 IK DYGZKSFWHRDUCX-RMKNXTFCSA-N
DMEP903 IU (E)-1-(4-nitrophenyl)-3-pyridin-2-ylprop-2-en-1-one
DMEP903 DE Discovery agent
DMO38CP ID DMO38CP
DMO38CP DN (E)-10-Nitrohexadec-9-enoic Acid
DMO38CP HS Investigative
DMO38CP SN CHEMBL564368; (E)-10-Nitrohexadec-9-enoic Acid; 10-nitropalmitoleic acid; E-10-nitropalmitoleic acid; SCHEMBL15633718; WZWPBDQYCAJWSX-FYWRMAATSA-N
DMO38CP DT Small molecular drug
DMO38CP PC 44220887
DMO38CP MW 299.41
DMO38CP FM C16H29NO4
DMO38CP IC InChI=1S/C16H29NO4/c1-2-3-4-9-12-15(17(20)21)13-10-7-5-6-8-11-14-16(18)19/h13H,2-12,14H2,1H3,(H,18,19)/b15-13+
DMO38CP CS CCCCCC/C(=C\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMO38CP IK WZWPBDQYCAJWSX-FYWRMAATSA-N
DMO38CP IU (E)-10-nitrohexadec-9-enoic acid
DMO38CP DE Discovery agent
DMTF7JA ID DMTF7JA
DMTF7JA DN (E)-10-nitrooctadec-9-enoic acid
DMTF7JA HS Investigative
DMTF7JA SN 10-nitrooleic acid; 10-nitro-9E-octadecenoic acid; 10-Nitro Oleic Acid; (E)-10-nitrooctadec-9-enoic acid; 10-nitroelaidic acid; 875685-46-4; UNII-1N19AGY57Y; CHEMBL561371; 1N19AGY57Y; CHEBI:86285; (9E)-10-nitrooctadecenoic acid; 10-Nitrooleate; 10-nitro-oleic acid; 10-Nitroelaidate; 88127-53-1; 9-Octadecenoic acid, 10-nitro-, (9E)-; E-10-nitrooleic acid; Oa-NO2; 10-nitro-9E-Octadecenoate; (9E)-10-Nitrooctadecenoate; 10-Nitro-9-octadecenoic acid; SCHEMBL1018141; CXA-10; (e)-10-Nitrooctadec-9-enoate; WRADPCFZZWXOTI-BMRADRMJSA-N
DMTF7JA DT Small molecular drug
DMTF7JA PC 24836820
DMTF7JA MW 327.5
DMTF7JA FM C18H33NO4
DMTF7JA IC InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
DMTF7JA CS CCCCCCCC/C(=C\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMTF7JA IK WRADPCFZZWXOTI-BMRADRMJSA-N
DMTF7JA IU (E)-10-nitrooctadec-9-enoic acid
DMTF7JA CB CHEBI:86285
DMTF7JA DE Discovery agent
DMBQTZL ID DMBQTZL
DMBQTZL DN (E)-12-Nitrooctadec-12-enoic Acid
DMBQTZL HS Investigative
DMBQTZL SN CHEMBL549351; (E)-12-Nitrooctadec-12-enoic Acid; BDBM50295043; (E)-12-Nitro-12-octadecenoic acid
DMBQTZL DT Small molecular drug
DMBQTZL PC 44221100
DMBQTZL MW 327.5
DMBQTZL FM C18H33NO4
DMBQTZL IC InChI=1S/C18H33NO4/c1-2-3-4-11-14-17(19(22)23)15-12-9-7-5-6-8-10-13-16-18(20)21/h14H,2-13,15-16H2,1H3,(H,20,21)/b17-14+
DMBQTZL CS CCCCC/C=C(\\CCCCCCCCCCC(=O)O)/[N+](=O)[O-]
DMBQTZL IK LCOAELZDXRYQHF-SAPNQHFASA-N
DMBQTZL IU (E)-12-nitrooctadec-12-enoic acid
DMBQTZL DE Discovery agent
DMF74GJ ID DMF74GJ
DMF74GJ DN (E)-13-Nitrooctadec-12-enoic Acid
DMF74GJ HS Investigative
DMF74GJ SN CHEMBL540732; (E)-13-Nitrooctadec-12-enoic Acid
DMF74GJ DT Small molecular drug
DMF74GJ PC 44221101
DMF74GJ MW 327.5
DMF74GJ FM C18H33NO4
DMF74GJ IC InChI=1S/C18H33NO4/c1-2-3-11-14-17(19(22)23)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
DMF74GJ CS CCCCC/C(=C\\CCCCCCCCCCC(=O)O)/[N+](=O)[O-]
DMF74GJ IK PQAOIUQONUIELV-BMRADRMJSA-N
DMF74GJ IU (E)-13-nitrooctadec-12-enoic acid
DMF74GJ DE Discovery agent
DMQ9TWD ID DMQ9TWD
DMQ9TWD DN (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone
DMQ9TWD HS Investigative
DMQ9TWD SN CHEMBL554700; (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone; SCHEMBL5511163
DMQ9TWD DT Small molecular drug
DMQ9TWD PC 44517772
DMQ9TWD MW 317.4
DMQ9TWD FM C22H23NO
DMQ9TWD IC InChI=1S/C22H23NO/c24-21(22-11-16-7-17(12-22)9-18(8-16)13-22)6-5-15-10-19-3-1-2-4-20(19)23-14-15/h1-6,10,14,16-18H,7-9,11-13H2/b6-5+
DMQ9TWD CS C1C2CC3CC1CC(C2)(C3)C(=O)/C=C/C4=CC5=CC=CC=C5N=C4
DMQ9TWD IK IHMKNCCPYWKVEH-AATRIKPKSA-N
DMQ9TWD IU (E)-1-(1-adamantyl)-3-quinolin-3-ylprop-2-en-1-one
DMQ9TWD DE Discovery agent
DMI146O ID DMI146O
DMI146O DN (E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMI146O HS Investigative
DMI146O SN CHEMBL496308; (E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMI146O DT Small molecular drug
DMI146O PC 44576946
DMI146O MW 329.4
DMI146O FM C20H27NO3
DMI146O IC InChI=1S/C20H27NO3/c1-2-3-4-5-6-7-8-11-14-21-18-13-10-9-12-16(18)17(20(21)24)15-19(22)23/h9-10,12-13,15H,2-8,11,14H2,1H3,(H,22,23)/b17-15+
DMI146O CS CCCCCCCCCCN1C2=CC=CC=C2/C(=C\\C(=O)O)/C1=O
DMI146O IK LIUQXAWYSKFADK-BMRADRMJSA-N
DMI146O IU (2E)-2-(1-decyl-2-oxoindol-3-ylidene)acetic acid
DMI146O DE Discovery agent
DMH2U4Z ID DMH2U4Z
DMH2U4Z DN (E)-2-(4-(methylsulfonyl)styryl)furan
DMH2U4Z HS Investigative
DMH2U4Z SN CHEMBL1288742; (E)-2-(4-(methylsulfonyl)styryl)furan
DMH2U4Z DT Small molecular drug
DMH2U4Z PC 52946891
DMH2U4Z MW 248.3
DMH2U4Z FM C13H12O3S
DMH2U4Z IC InChI=1S/C13H12O3S/c1-17(14,15)13-8-5-11(6-9-13)4-7-12-3-2-10-16-12/h2-10H,1H3/b7-4+
DMH2U4Z CS CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=CC=CO2
DMH2U4Z IK WFCBWFJZEUDGIS-QPJJXVBHSA-N
DMH2U4Z IU 2-[(E)-2-(4-methylsulfonylphenyl)ethenyl]furan
DMH2U4Z DE Discovery agent
DMDFE1R ID DMDFE1R
DMDFE1R DN (E)-2-(4-(methylsulfonyl)styryl)thiophene
DMDFE1R HS Investigative
DMDFE1R SN CHEMBL1288781; (E)-2-(4-(methylsulfonyl)styryl)thiophene
DMDFE1R DT Small molecular drug
DMDFE1R PC 50908698
DMDFE1R MW 264.4
DMDFE1R FM C13H12O2S2
DMDFE1R IC InChI=1S/C13H12O2S2/c1-17(14,15)13-8-5-11(6-9-13)4-7-12-3-2-10-16-12/h2-10H,1H3/b7-4+
DMDFE1R CS CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=CC=CS2
DMDFE1R IK JTGRXCMSCWBAQN-QPJJXVBHSA-N
DMDFE1R IU 2-[(E)-2-(4-methylsulfonylphenyl)ethenyl]thiophene
DMDFE1R DE Discovery agent
DMTJI4F ID DMTJI4F
DMTJI4F DN (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F HS Investigative
DMTJI4F SN CHEMBL240886; (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine
DMTJI4F DT Small molecular drug
DMTJI4F PC 44439386
DMTJI4F MW 323.4
DMTJI4F FM C19H14FNOS
DMTJI4F IC InChI=1S/C19H14FNOS/c20-16-9-6-15(7-10-16)8-11-17-12-13-19(14-21-17)23(22)18-4-2-1-3-5-18/h1-14H/b11-8+
DMTJI4F CS C1=CC=C(C=C1)S(=O)C2=CN=C(C=C2)/C=C/C3=CC=C(C=C3)F
DMTJI4F IK YFWOOEBYKGJCJO-DHZHZOJOSA-N
DMTJI4F IU 5-(benzenesulfinyl)-2-[(E)-2-(4-fluorophenyl)ethenyl]pyridine
DMTJI4F DE Discovery agent
DM7P5VM ID DM7P5VM
DM7P5VM DN (E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine
DM7P5VM HS Investigative
DM7P5VM SN CHEMBL394729; (E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine
DM7P5VM DT Small molecular drug
DM7P5VM PC 44439376
DM7P5VM MW 339.4
DM7P5VM FM C19H14FNO2S
DM7P5VM IC InChI=1S/C19H14FNO2S/c20-16-9-6-15(7-10-16)8-11-17-12-13-19(14-21-17)24(22,23)18-4-2-1-3-5-18/h1-14H/b11-8+
DM7P5VM CS C1=CC=C(C=C1)S(=O)(=O)C2=CN=C(C=C2)/C=C/C3=CC=C(C=C3)F
DM7P5VM IK ANNXZFGXMGNRDN-DHZHZOJOSA-N
DM7P5VM IU 5-(benzenesulfonyl)-2-[(E)-2-(4-fluorophenyl)ethenyl]pyridine
DM7P5VM DE Discovery agent
DM1LG27 ID DM1LG27
DM1LG27 DN (E)-3-(2,3-dichlorophenylimino)indolin-2-one
DM1LG27 HS Investigative
DM1LG27 DT Small molecular drug
DM1LG27 PC 135559217
DM1LG27 MW 291.1
DM1LG27 FM C14H8Cl2N2O
DM1LG27 IC InChI=1S/C14H8Cl2N2O/c15-9-5-3-7-11(12(9)16)17-13-8-4-1-2-6-10(8)18-14(13)19/h1-7H,(H,17,18,19)
DM1LG27 CS C1=CC=C2C(=C1)C(=NC3=C(C(=CC=C3)Cl)Cl)C(=O)N2
DM1LG27 IK AUBZCTXOLGPERG-UHFFFAOYSA-N
DM1LG27 IU 3-(2,3-dichlorophenyl)imino-1H-indol-2-one
DM1LG27 DE Discovery agent
DMOWGT3 ID DMOWGT3
DMOWGT3 DN (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid
DMOWGT3 HS Investigative
DMOWGT3 SN CHEMBL201736; (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid
DMOWGT3 DT Small molecular drug
DMOWGT3 PC 11501077
DMOWGT3 MW 344.4
DMOWGT3 FM C22H16O4
DMOWGT3 IC InChI=1S/C22H16O4/c23-21(24)15-8-16-6-9-17(10-7-16)22(25)18-11-13-20(14-12-18)26-19-4-2-1-3-5-19/h1-15H,(H,23,24)/b15-8+
DMOWGT3 CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)/C=C/C(=O)O
DMOWGT3 IK UXUCKEBTHPCTFJ-OVCLIPMQSA-N
DMOWGT3 IU (E)-3-[4-(4-phenoxybenzoyl)phenyl]prop-2-enoic acid
DMOWGT3 DE Discovery agent
DMUS0D8 ID DMUS0D8
DMUS0D8 DN (E)-3-(4-(methylsulfonyl)styryl)thiophene
DMUS0D8 HS Investigative
DMUS0D8 SN CHEMBL1288782; (E)-3-(4-(methylsulfonyl)styryl)thiophene
DMUS0D8 DT Small molecular drug
DMUS0D8 PC 52949357
DMUS0D8 MW 264.4
DMUS0D8 FM C13H12O2S2
DMUS0D8 IC InChI=1S/C13H12O2S2/c1-17(14,15)13-6-4-11(5-7-13)2-3-12-8-9-16-10-12/h2-10H,1H3/b3-2+
DMUS0D8 CS CS(=O)(=O)C1=CC=C(C=C1)/C=C/C2=CSC=C2
DMUS0D8 IK HPDGNEAMPZEKTB-NSCUHMNNSA-N
DMUS0D8 IU 3-[(E)-2-(4-methylsulfonylphenyl)ethenyl]thiophene
DMUS0D8 DE Discovery agent
DMPOYK2 ID DMPOYK2
DMPOYK2 DN (E)-3-(4-chlorophenylimino)indolin-2-one
DMPOYK2 HS Investigative
DMPOYK2 DT Small molecular drug
DMPOYK2 PC 135411931
DMPOYK2 MW 256.68
DMPOYK2 FM C14H9ClN2O
DMPOYK2 IC InChI=1S/C14H9ClN2O/c15-9-5-7-10(8-6-9)16-13-11-3-1-2-4-12(11)17-14(13)18/h1-8H,(H,16,17,18)
DMPOYK2 CS C1=CC=C2C(=C1)C(=NC3=CC=C(C=C3)Cl)C(=O)N2
DMPOYK2 IK CPOOLXVTWFEFNO-UHFFFAOYSA-N
DMPOYK2 IU 3-(4-chlorophenyl)imino-1H-indol-2-one
DMPOYK2 CA CAS 57644-24-3
DMPOYK2 DE Discovery agent
DMX4U9L ID DMX4U9L
DMX4U9L DN (E)-3-(4-hydroxybenzylidene)indolin-2-one
DMX4U9L HS Investigative
DMX4U9L SN CHEMBL103307; (E)-3-(4-hydroxybenzylidene)indolin-2-one; 3-(4-Hydroxybenzylidenyl)indolin-2-one; SCHEMBL16442341; BDBM50131995; ZINC12568108; AKOS001309473; 3-(4-hydroxybenzylidene)indolin-2-one; NCGC00343741-01; ACM293302144; AB00756566-01
DMX4U9L DT Small molecular drug
DMX4U9L PC 10561847
DMX4U9L MW 237.25
DMX4U9L FM C15H11NO2
DMX4U9L IC InChI=1S/C15H11NO2/c17-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)16-15(13)18/h1-9,17H,(H,16,18)/b13-9+
DMX4U9L CS C1=CC=C2C(=C1)/C(=C\\C3=CC=C(C=C3)O)/C(=O)N2
DMX4U9L IK PLAOAGFXNCEZMZ-UKTHLTGXSA-N
DMX4U9L IU (3E)-3-[(4-hydroxyphenyl)methylidene]-1H-indol-2-one
DMX4U9L DE Discovery agent
DMTKCAL ID DMTKCAL
DMTKCAL DN (E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide
DMTKCAL HS Investigative
DMTKCAL SN CHEMBL426634; (2E)-3-[4-(tert-butyl)phenyl]-N-phenylprop-2-enamide; AC1NYN2M; (E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide; SCHEMBL4006434; SCHEMBL4006429; MolPort-006-388-008; AVMIAJAOFXDOSN-SDNWHVSQSA-N; ZINC5903656; STK411584; BDBM50158648; AKOS003298323; 3-(4-tert-butylphenyl)-N-phenylacrylamide; ST50943451; (E)-3-(4-tert-butylphenyl)-N-phenylprop-2-enamide
DMTKCAL DT Small molecular drug
DMTKCAL PC 5885566
DMTKCAL MW 279.4
DMTKCAL FM C19H21NO
DMTKCAL IC InChI=1S/C19H21NO/c1-19(2,3)16-12-9-15(10-13-16)11-14-18(21)20-17-7-5-4-6-8-17/h4-14H,1-3H3,(H,20,21)/b14-11+
DMTKCAL CS CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2
DMTKCAL IK AVMIAJAOFXDOSN-SDNWHVSQSA-N
DMTKCAL IU (E)-3-(4-tert-butylphenyl)-N-phenylprop-2-enamide
DMTKCAL DE Discovery agent
DMITXKJ ID DMITXKJ
DMITXKJ DN (E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine
DMITXKJ HS Investigative
DMITXKJ SN CHEMBL382527; (E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine; SCHEMBL4148449; SCHEMBL4148438
DMITXKJ DT Small molecular drug
DMITXKJ PC 11715388
DMITXKJ MW 202.28
DMITXKJ FM C11H10N2S
DMITXKJ IC InChI=1S/C11H10N2S/c1-9-13-11(8-14-9)5-4-10-3-2-6-12-7-10/h2-8H,1H3/b5-4+
DMITXKJ CS CC1=NC(=CS1)/C=C/C2=CN=CC=C2
DMITXKJ IK HHLKCNHXNVMBFW-SNAWJCMRSA-N
DMITXKJ IU 2-methyl-4-[(E)-2-pyridin-3-ylethenyl]-1,3-thiazole
DMITXKJ DE Discovery agent
DMDF7M4 ID DMDF7M4
DMDF7M4 DN (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide
DMDF7M4 HS Investigative
DMDF7M4 SN CHEMBL1288783; (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide
DMDF7M4 DT Small molecular drug
DMDF7M4 PC 52946892
DMDF7M4 MW 249.29
DMDF7M4 FM C12H11NO3S
DMDF7M4 IC InChI=1S/C12H11NO3S/c13-17(14,15)12-7-4-10(5-8-12)3-6-11-2-1-9-16-11/h1-9H,(H2,13,14,15)/b6-3+
DMDF7M4 CS C1=COC(=C1)/C=C/C2=CC=C(C=C2)S(=O)(=O)N
DMDF7M4 IK LUXIPMZZPXZHSJ-ZZXKWVIFSA-N
DMDF7M4 IU 4-[(E)-2-(furan-2-yl)ethenyl]benzenesulfonamide
DMDF7M4 DE Discovery agent
DM7204O ID DM7204O
DM7204O DN (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide
DM7204O HS Investigative
DM7204O SN CHEMBL1288801; (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide
DM7204O DT Small molecular drug
DM7204O PC 50908697
DM7204O MW 265.4
DM7204O FM C12H11NO2S2
DM7204O IC InChI=1S/C12H11NO2S2/c13-17(14,15)12-7-4-10(5-8-12)3-6-11-2-1-9-16-11/h1-9H,(H2,13,14,15)/b6-3+
DM7204O CS C1=CSC(=C1)/C=C/C2=CC=C(C=C2)S(=O)(=O)N
DM7204O IK OZEBJQJPQRQDDH-ZZXKWVIFSA-N
DM7204O IU 4-[(E)-2-thiophen-2-ylethenyl]benzenesulfonamide
DM7204O DE Discovery agent
DMTAB8W ID DMTAB8W
DMTAB8W DN (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide
DMTAB8W HS Investigative
DMTAB8W SN CHEMBL1288802; (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide
DMTAB8W DT Small molecular drug
DMTAB8W PC 50908699
DMTAB8W MW 265.4
DMTAB8W FM C12H11NO2S2
DMTAB8W IC InChI=1S/C12H11NO2S2/c13-17(14,15)12-5-3-10(4-6-12)1-2-11-7-8-16-9-11/h1-9H,(H2,13,14,15)/b2-1+
DMTAB8W CS C1=CC(=CC=C1/C=C/C2=CSC=C2)S(=O)(=O)N
DMTAB8W IK JQHQATMSMAURMY-OWOJBTEDSA-N
DMTAB8W IU 4-[(E)-2-thiophen-3-ylethenyl]benzenesulfonamide
DMTAB8W DE Discovery agent
DMYXI2V ID DMYXI2V
DMYXI2V DN (E)-4-(3,5-dimethoxystyryl)phenol
DMYXI2V HS Investigative
DMYXI2V SN Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene
DMYXI2V DT Small molecular drug
DMYXI2V PC 5281727
DMYXI2V MW 256.3
DMYXI2V FM C16H16O3
DMYXI2V IC InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+
DMYXI2V CS COC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)O)OC
DMYXI2V IK VLEUZFDZJKSGMX-ONEGZZNKSA-N
DMYXI2V IU 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol
DMYXI2V CA CAS 537-42-8
DMYXI2V CB CHEBI:8630
DMYXI2V DE Discovery agent
DMJGAFV ID DMJGAFV
DMJGAFV DN (E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one
DMJGAFV HS Investigative
DMJGAFV SN CHEMBL572128; (E)-4,4-dimethyl-1-quinolin-3-yl-pent-1-en-3-one; SCHEMBL5503755
DMJGAFV DT Small molecular drug
DMJGAFV PC 11644388
DMJGAFV MW 239.31
DMJGAFV FM C16H17NO
DMJGAFV IC InChI=1S/C16H17NO/c1-16(2,3)15(18)9-8-12-10-13-6-4-5-7-14(13)17-11-12/h4-11H,1-3H3/b9-8+
DMJGAFV CS CC(C)(C)C(=O)/C=C/C1=CC2=CC=CC=C2N=C1
DMJGAFV IK XROFVTPRFZVYMN-CMDGGOBGSA-N
DMJGAFV IU (E)-4,4-dimethyl-1-quinolin-3-ylpent-1-en-3-one
DMJGAFV DE Discovery agent
DM75OHG ID DM75OHG
DM75OHG DN (E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine
DM75OHG HS Investigative
DM75OHG SN CHEMBL501620; (E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine; SCHEMBL15091007; SCHEMBL15091006; QHUQCHMVBGZYHI-ONEGZZNKSA-N; ZINC40424901; BDBM50267274
DM75OHG DT Small molecular drug
DM75OHG PC 42625452
DM75OHG MW 148.2
DM75OHG FM C9H12N2
DM75OHG IC InChI=1S/C9H12N2/c1-3-4-8-5-7(2)6-9(10)11-8/h3-6H,1-2H3,(H2,10,11)/b4-3+
DM75OHG CS C/C=C/C1=NC(=CC(=C1)C)N
DM75OHG IK QHUQCHMVBGZYHI-ONEGZZNKSA-N
DM75OHG IU 4-methyl-6-[(E)-prop-1-enyl]pyridin-2-amine
DM75OHG DE Discovery agent
DMLIQUA ID DMLIQUA
DMLIQUA DN (E)-5-(3-Chlorostyryl)isatin
DMLIQUA HS Investigative
DMLIQUA SN CHEMBL447307; (E)-5-(3-Chlorostyryl)isatin
DMLIQUA DT Small molecular drug
DMLIQUA PC 44575103
DMLIQUA MW 283.71
DMLIQUA FM C16H10ClNO2
DMLIQUA IC InChI=1S/C16H10ClNO2/c17-12-3-1-2-10(8-12)4-5-11-6-7-14-13(9-11)15(19)16(20)18-14/h1-9H,(H,18,19,20)/b5-4+
DMLIQUA CS C1=CC(=CC(=C1)Cl)/C=C/C2=CC3=C(C=C2)NC(=O)C3=O
DMLIQUA IK ZKYUNESJTCRBIF-SNAWJCMRSA-N
DMLIQUA IU 5-[(E)-2-(3-chlorophenyl)ethenyl]-1H-indole-2,3-dione
DMLIQUA DE Discovery agent
DMP4T9Z ID DMP4T9Z
DMP4T9Z DN (E)-5-(3-Fluorostyryl)isatin
DMP4T9Z HS Investigative
DMP4T9Z SN CHEMBL506301; (E)-5-(3-Fluorostyryl)isatin
DMP4T9Z DT Small molecular drug
DMP4T9Z PC 44575104
DMP4T9Z MW 267.25
DMP4T9Z FM C16H10FNO2
DMP4T9Z IC InChI=1S/C16H10FNO2/c17-12-3-1-2-10(8-12)4-5-11-6-7-14-13(9-11)15(19)16(20)18-14/h1-9H,(H,18,19,20)/b5-4+
DMP4T9Z CS C1=CC(=CC(=C1)F)/C=C/C2=CC3=C(C=C2)NC(=O)C3=O
DMP4T9Z IK UQOGXLMBLXKBJJ-SNAWJCMRSA-N
DMP4T9Z IU 5-[(E)-2-(3-fluorophenyl)ethenyl]-1H-indole-2,3-dione
DMP4T9Z DE Discovery agent
DM81JRF ID DM81JRF
DM81JRF DN (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin
DM81JRF HS Investigative
DM81JRF SN CHEMBL213560; (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin; SCHEMBL16693054; BDBM50187134
DM81JRF DT Small molecular drug
DM81JRF PC 15984068
DM81JRF MW 308.3
DM81JRF FM C18H16N2O3
DM81JRF IC InChI=1S/C18H16N2O3/c21-15-8-6-14(7-9-15)12-16-17(22)19-18(23)20(16)11-10-13-4-2-1-3-5-13/h1-9,12,21H,10-11H2,(H,19,22,23)/b16-12+
DM81JRF CS C1=CC=C(C=C1)CCN2/C(=C/C3=CC=C(C=C3)O)/C(=O)NC2=O
DM81JRF IK SXBULDIKCMKRBS-FOWTUZBSSA-N
DM81JRF IU (5E)-5-[(4-hydroxyphenyl)methylidene]-1-(2-phenylethyl)imidazolidine-2,4-dione
DM81JRF DE Discovery agent
DMJKOFW ID DMJKOFW
DMJKOFW DN (E)-5-Nitrooctadec-5-enoic Acid
DMJKOFW HS Investigative
DMJKOFW SN CHEMBL561776; (E)-5-Nitrooctadec-5-enoic Acid; (E)-5-Nitro-5-octadecenoic acid; BDBM50295050
DMJKOFW DT Small molecular drug
DMJKOFW PC 44220888
DMJKOFW MW 327.5
DMJKOFW FM C18H33NO4
DMJKOFW IC InChI=1S/C18H33NO4/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19(22)23)15-13-16-18(20)21/h14H,2-13,15-16H2,1H3,(H,20,21)/b17-14+
DMJKOFW CS CCCCCCCCCCCC/C=C(\\CCCC(=O)O)/[N+](=O)[O-]
DMJKOFW IK UWYMGOJUTJPTOD-SAPNQHFASA-N
DMJKOFW IU (E)-5-nitrooctadec-5-enoic acid
DMJKOFW DE Discovery agent
DMIPY3W ID DMIPY3W
DMIPY3W DN (E)-5-octadecen-7,9-diynoic acid
DMIPY3W HS Investigative
DMIPY3W SN 5E-Octadecene-7,9-diynoic acid; CHEMBL489540; LMFA01030737; GTPL2963; ACon1_001719; BDBM50292398; compound 6a [Patil et al, 1989]; (5E)-octadec-5-en-7,9-diynoic acid; NCGC00180210-01; compound 6a (Patil et al., 1989)
DMIPY3W DT Small molecular drug
DMIPY3W PC 9543636
DMIPY3W MW 274.4
DMIPY3W FM C18H26O2
DMIPY3W IC InChI=1S/C18H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h13-14H,2-8,15-17H2,1H3,(H,19,20)/b14-13+
DMIPY3W CS CCCCCCCCC#CC#C/C=C/CCCC(=O)O
DMIPY3W IK IGVKWAAPMVVTFX-BUHFOSPRSA-N
DMIPY3W IU (E)-octadec-5-en-7,9-diynoic acid
DMIPY3W DE Discovery agent
DM1PCIX ID DM1PCIX
DM1PCIX DN (E)-5-Styrylisatin
DM1PCIX HS Investigative
DM1PCIX SN (E)-5-Styrylisatin; CHEMBL466872
DM1PCIX DT Small molecular drug
DM1PCIX PC 42628986
DM1PCIX MW 249.26
DM1PCIX FM C16H11NO2
DM1PCIX IC InChI=1S/C16H11NO2/c18-15-13-10-12(8-9-14(13)17-16(15)19)7-6-11-4-2-1-3-5-11/h1-10H,(H,17,18,19)/b7-6+
DM1PCIX CS C1=CC=C(C=C1)/C=C/C2=CC3=C(C=C2)NC(=O)C3=O
DM1PCIX IK KJZBRZRRHIURGP-VOTSOKGWSA-N
DM1PCIX IU 5-[(E)-2-phenylethenyl]-1H-indole-2,3-dione
DM1PCIX DE Discovery agent
DMACVNM ID DMACVNM
DMACVNM DN (E)-6-Nitrooctadec-5-enoic Acid
DMACVNM HS Investigative
DMACVNM SN CHEMBL569372; (E)-6-Nitrooctadec-5-enoic Acid
DMACVNM DT Small molecular drug
DMACVNM PC 44220889
DMACVNM MW 327.5
DMACVNM FM C18H33NO4
DMACVNM IC InChI=1S/C18H33NO4/c1-2-3-4-5-6-7-8-9-10-11-14-17(19(22)23)15-12-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+
DMACVNM CS CCCCCCCCCCCC/C(=C\\CCCC(=O)O)/[N+](=O)[O-]
DMACVNM IK ZNCCLONFJQTFGL-BMRADRMJSA-N
DMACVNM IU (E)-6-nitrooctadec-5-enoic acid
DMACVNM DE Discovery agent
DMG47QU ID DMG47QU
DMG47QU DN (E)-6-Styrylisatin
DMG47QU HS Investigative
DMG47QU SN (E)-6-Styrylisatin; CHEMBL450239
DMG47QU DT Small molecular drug
DMG47QU PC 42629116
DMG47QU MW 249.26
DMG47QU FM C16H11NO2
DMG47QU IC InChI=1S/C16H11NO2/c18-15-13-9-8-12(10-14(13)17-16(15)19)7-6-11-4-2-1-3-5-11/h1-10H,(H,17,18,19)/b7-6+
DMG47QU CS C1=CC=C(C=C1)/C=C/C2=CC3=C(C=C2)C(=O)C(=O)N3
DMG47QU IK ZQOJVXBKHOCLGH-VOTSOKGWSA-N
DMG47QU IU 6-[(E)-2-phenylethenyl]-1H-indole-2,3-dione
DMG47QU DE Discovery agent
DMQT15Z ID DMQT15Z
DMQT15Z DN (E)-8-(3-chlorostyryl)-caffeine
DMQT15Z HS Investigative
DMQT15Z SN 8-[(E)-2-(3-Chlorophenyl)ethenyl]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-(3-Chlorostyryl)caffeine; Csc cpd; 8-CSC; CSC; 148589-13-3; CHEMBL26138; CHEBI:53115; 8-(2-(3-Chlorophenyl)methyl)-3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 8-(2-(3-chlorophenyl)methyl)-3,7-dihydro-1,3,7-trimethyl-; Lopac0_000393; 8-(3-chlorostyryl) caffine; MLS000860039; SCHEMBL537055; 8-[2-(3-chlorophenyl)ethenyl]-1,3,7-trimethylpurine-2,6-dione; AC1NS448; GTPL5609; cid_5353365; AOB5970; DTXSID60872447
DMQT15Z DT Small molecular drug
DMQT15Z PC 5353365
DMQT15Z MW 330.77
DMQT15Z FM C16H15ClN4O2
DMQT15Z IC InChI=1S/C16H15ClN4O2/c1-19-12(8-7-10-5-4-6-11(17)9-10)18-14-13(19)15(22)21(3)16(23)20(14)2/h4-9H,1-3H3/b8-7+
DMQT15Z CS CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C3=CC(=CC=C3)Cl
DMQT15Z IK WBWFIUAVMCNYPG-BQYQJAHWSA-N
DMQT15Z IU 8-[(E)-2-(3-chlorophenyl)ethenyl]-1,3,7-trimethylpurine-2,6-dione
DMQT15Z CA CAS 147700-11-6
DMQT15Z CB CHEBI:53115
DMQT15Z DE Discovery agent
DM5LSY9 ID DM5LSY9
DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one
DM5LSY9 HS Investigative
DM5LSY9 SN CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201
DM5LSY9 DT Small molecular drug
DM5LSY9 PC 44350655
DM5LSY9 MW 345.4
DM5LSY9 FM C23H23NO2
DM5LSY9 IC InChI=1S/C23H23NO2/c25-22(23-24-17-18-26-23)12-8-3-1-2-5-9-19-13-15-21(16-14-19)20-10-6-4-7-11-20/h4-7,9-11,13-18H,1-3,8,12H2/b9-5+
DM5LSY9 CS C1=CC=C(C=C1)C2=CC=C(C=C2)/C=C/CCCCCC(=O)C3=NC=CO3
DM5LSY9 IK AHIZRRNUFLYTPT-WEVVVXLNSA-N
DM5LSY9 IU (E)-1-(1,3-oxazol-2-yl)-8-(4-phenylphenyl)oct-7-en-1-one
DM5LSY9 DE Discovery agent
DMULW35 ID DMULW35
DMULW35 DN (E)-9-Nitrohexadec-9-enoicAcid
DMULW35 HS Investigative
DMULW35 SN CHEMBL560513; (E)-9-Nitrohexadec-9-enoicAcid; 9-nitropalmitoleic acid; E-9-nitropalmitoleic acid; SCHEMBL15633556; YZNSJIAWRWPQGX-NTCAYCPXSA-N; (E)-9-Nitro-9-hexadecenoic acid; BDBM50295047
DMULW35 DT Small molecular drug
DMULW35 PC 44220886
DMULW35 MW 299.41
DMULW35 FM C16H29NO4
DMULW35 IC InChI=1S/C16H29NO4/c1-2-3-4-6-9-12-15(17(20)21)13-10-7-5-8-11-14-16(18)19/h12H,2-11,13-14H2,1H3,(H,18,19)/b15-12+
DMULW35 CS CCCCCC/C=C(\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMULW35 IK YZNSJIAWRWPQGX-NTCAYCPXSA-N
DMULW35 IU (E)-9-nitrohexadec-9-enoic acid
DMULW35 DE Discovery agent
DMWC2F9 ID DMWC2F9
DMWC2F9 DN (E)-9-nitrooctadec-9-enoic acid
DMWC2F9 HS Investigative
DMWC2F9 SN (E)-9-Nitrooctadec-9-enoic Acid; 9-nitro-9E-octadecenoic acid; 9-Nitro Oleic Acid; (E)-9-nitrooctadec-9-enoic Acid; 9-Nitrooleic acid; Nitroleic Acid; 875685-44-2; 9-Nitrooleate; CHEMBL550762; (9E)-9-nitrooctadecenoic acid; CHEBI:86329; 9-nitro-9E-Octadecenoate; (9E)-9-Nitrooctadecenoate; 9-Nitro-9-octadecenoic acid; (e)-9-Nitrooctadec-9-enoate; GTPL6296; SCHEMBL1015108; MolPort-027-641-228; CQOAKBVRRVHWKV-SAPNQHFASA-N; (e)-9-nitro-octadec-9-enoic acid; (9E)-9-nitrooctadec-9-enoic acid; (9E)-9-Nitro-9-octadecenoic Acid; BDBM50295048; 1573AH; LMFA01120004; nitrooleic acid
DMWC2F9 DT Small molecular drug
DMWC2F9 PC 11645581
DMWC2F9 MW 327.5
DMWC2F9 FM C18H33NO4
DMWC2F9 IC InChI=1S/C18H33NO4/c1-2-3-4-5-6-8-11-14-17(19(22)23)15-12-9-7-10-13-16-18(20)21/h14H,2-13,15-16H2,1H3,(H,20,21)/b17-14+
DMWC2F9 CS CCCCCCCC/C=C(\\CCCCCCCC(=O)O)/[N+](=O)[O-]
DMWC2F9 IK CQOAKBVRRVHWKV-SAPNQHFASA-N
DMWC2F9 IU (E)-9-nitrooctadec-9-enoic acid
DMWC2F9 CA CAS 875685-44-2
DMWC2F9 CB CHEBI:86329
DMWC2F9 DE Discovery agent
DM9WHD2 ID DM9WHD2
DM9WHD2 DN (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide
DM9WHD2 HS Investigative
DM9WHD2 SN CHEMBL373056; (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide
DM9WHD2 DT Small molecular drug
DM9WHD2 PC 44406064
DM9WHD2 MW 347.5
DM9WHD2 FM C21H33NO3
DM9WHD2 IC InChI=1S/C21H33NO3/c1-4-5-6-7-8-9-10-11-12-21(23)22-14-13-18-15-19(24-2)17-20(16-18)25-3/h11-12,15-17H,4-10,13-14H2,1-3H3,(H,22,23)/b12-11+
DM9WHD2 CS CCCCCCCC/C=C/C(=O)NCCC1=CC(=CC(=C1)OC)OC
DM9WHD2 IK RWXZZBVYJHEKRB-VAWYXSNFSA-N
DM9WHD2 IU (E)-N-[2-(3,5-dimethoxyphenyl)ethyl]undec-2-enamide
DM9WHD2 DE Discovery agent
DMW3RJL ID DMW3RJL
DMW3RJL DN (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n
DMW3RJL HS Investigative
DMW3RJL DE Discovery agent
DML6PJD ID DML6PJD
DML6PJD DN (E)-N-(4-methoxyphenethyl)undec-2-enamide
DML6PJD HS Investigative
DML6PJD SN CHEMBL198182; (E)-N-(4-methoxyphenethyl)undec-2-enamide
DML6PJD DT Small molecular drug
DML6PJD PC 44406097
DML6PJD MW 317.5
DML6PJD FM C20H31NO2
DML6PJD IC InChI=1S/C20H31NO2/c1-3-4-5-6-7-8-9-10-11-20(22)21-17-16-18-12-14-19(23-2)15-13-18/h10-15H,3-9,16-17H2,1-2H3,(H,21,22)/b11-10+
DML6PJD CS CCCCCCCC/C=C/C(=O)NCCC1=CC=C(C=C1)OC
DML6PJD IK WHWQEVQBWRYYLL-ZHACJKMWSA-N
DML6PJD IU (E)-N-[2-(4-methoxyphenyl)ethyl]undec-2-enamide
DML6PJD DE Discovery agent
DM1PCEM ID DM1PCEM
DM1PCEM DN (E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM HS Investigative
DM1PCEM SN CHEMBL198132; (E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM DT Small molecular drug
DM1PCEM PC 44406107
DM1PCEM MW 289.4
DM1PCEM FM C18H27NO2
DM1PCEM IC InChI=1S/C18H27NO2/c1-3-4-5-6-7-8-9-10-11-18(20)19-16-12-14-17(21-2)15-13-16/h10-15H,3-9H2,1-2H3,(H,19,20)/b11-10+
DM1PCEM CS CCCCCCCC/C=C/C(=O)NC1=CC=C(C=C1)OC
DM1PCEM IK ZYKABORTQCIYBC-ZHACJKMWSA-N
DM1PCEM IU (E)-N-(4-methoxyphenyl)undec-2-enamide
DM1PCEM DE Discovery agent
DM7XIH3 ID DM7XIH3
DM7XIH3 DN (E)-N-(4-Phenylthiazol-2-yl) cinnamamide
DM7XIH3 HS Investigative
DM7XIH3 SN CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; (E)-N-(4-Phenylthiazol-2-yl) cinnamamide; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152
DM7XIH3 DT Small molecular drug
DM7XIH3 PC 690181
DM7XIH3 MW 306.4
DM7XIH3 FM C18H14N2OS
DM7XIH3 IC InChI=1S/C18H14N2OS/c21-17(12-11-14-7-3-1-4-8-14)20-18-19-16(13-22-18)15-9-5-2-6-10-15/h1-13H,(H,19,20,21)/b12-11+
DM7XIH3 CS C1=CC=C(C=C1)/C=C/C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DM7XIH3 IK WOJRHCOBUKJCAJ-VAWYXSNFSA-N
DM7XIH3 IU (E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide
DM7XIH3 DE Discovery agent
DMHKXPM ID DMHKXPM
DMHKXPM DN (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide
DMHKXPM HS Investigative
DMHKXPM SN CHEMBL1086176; (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide
DMHKXPM DT Small molecular drug
DMHKXPM PC 22319483
DMHKXPM MW 243.3
DMHKXPM FM C14H17N3O
DMHKXPM IC InChI=1S/C14H17N3O/c1-3-5-10-7-8-11-12(9-10)16-17-14(11)15-13(18)6-4-2/h3,5,7-9H,4,6H2,1-2H3,(H2,15,16,17,18)/b5-3+
DMHKXPM CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)/C=C/C
DMHKXPM IK KPYYGELCJSEEPK-HWKANZROSA-N
DMHKXPM IU N-[6-[(E)-prop-1-enyl]-1H-indazol-3-yl]butanamide
DMHKXPM DE Discovery agent
DMXYAIQ ID DMXYAIQ
DMXYAIQ DN (E)-Octadec-9-enal
DMXYAIQ HS Investigative
DMXYAIQ SN 9-OCTADECENAL; Octadecenyl aldehyde; (E)-Octadec-9-enal; UNII-979G27P46D; CHEMBL190707; 979G27P46D; 9-Octadecenal, (9E)-; 5090-41-5; E-9-Octadecenal; 9-Octadecenal, (E)-; FEMA No. 4059, E-; 10009-79-7; (9E)-9-Octadecenal; (9E)-9-Octadecenal #; AC1NR25P; SCHEMBL260834; DTXSID9074305; ZENZJGDPWWLORF-MDZDMXLPSA-N; MolPort-044-723-520; LMFA06000099; BDBM50170061; UNII-971UC454BB component ZENZJGDPWWLORF-MDZDMXLPSA-N
DMXYAIQ DT Small molecular drug
DMXYAIQ PC 5283381
DMXYAIQ MW 266.5
DMXYAIQ FM C18H34O
DMXYAIQ IC InChI=1S/C18H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h9-10,18H,2-8,11-17H2,1H3/b10-9+
DMXYAIQ CS CCCCCCCC/C=C/CCCCCCCC=O
DMXYAIQ IK ZENZJGDPWWLORF-MDZDMXLPSA-N
DMXYAIQ IU (E)-octadec-9-enal
DMXYAIQ CA CAS 5090-41-5
DMXYAIQ DE Discovery agent
DMP7TK0 ID DMP7TK0
DMP7TK0 DN (E)-Octadec-9-enoic acid phenylamide
DMP7TK0 HS Investigative
DMP7TK0 SN n-phenyloctadec-9-enamide; AC1O0YDP; AC1Q5NBV; SCHEMBL4143904; (E)-N-phenyloctadec-9-enamide; (9E)-N-phenyl-9-octadecenamide
DMP7TK0 DT Small molecular drug
DMP7TK0 PC 6105762
DMP7TK0 MW 357.6
DMP7TK0 FM C24H39NO
DMP7TK0 IC InChI=1S/C24H39NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-24(26)25-23-20-17-16-18-21-23/h9-10,16-18,20-21H,2-8,11-15,19,22H2,1H3,(H,25,26)/b10-9+
DMP7TK0 CS CCCCCCCC/C=C/CCCCCCCC(=O)NC1=CC=CC=C1
DMP7TK0 IK YPUOCYKJOLQYQS-MDZDMXLPSA-N
DMP7TK0 IU (E)-N-phenyloctadec-9-enamide
DMP7TK0 DE Discovery agent
DMBLGF6 ID DMBLGF6
DMBLGF6 DN (E)-octadecan-9-ynoic acid
DMBLGF6 HS Investigative
DMBLGF6 SN CHEMBL482803; (E)-octadecan-9-ynoic acid; 7E-Octadecen-9-ynoic acid; LMFA01031047
DMBLGF6 DT Small molecular drug
DMBLGF6 PC 14309404
DMBLGF6 MW 278.4
DMBLGF6 FM C18H30O2
DMBLGF6 IC InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h11-12H,2-8,13-17H2,1H3,(H,19,20)/b12-11+
DMBLGF6 CS CCCCCCCCC#C/C=C/CCCCCC(=O)O
DMBLGF6 IK BWSIKEZDJMZITO-VAWYXSNFSA-N
DMBLGF6 IU (E)-octadec-7-en-9-ynoic acid
DMBLGF6 DE Discovery agent
DMWU17O ID DMWU17O
DMWU17O DN (E,E)-1,7-Diphenyl-4,6-heptadien-3-one
DMWU17O HS Investigative
DMWU17O SN Alnustone; 33457-62-4; Alnusone; CHEMBL461082; 1,7-diphenylhepta-4,6-dien-3-one; 1,7-Diphenyl-4,6-heptadien-3-one; HEP-DIENE-ONE DER FR ALPINA KATSUMANDAI; AC1NSVUW; 4,6-Heptadien-3-one, 1,7-diphenyl-; (E,E)-1,7-Diphenyl-4,6-heptadien-3-one; DAH-3-keto-4,6-dien; (4E,6E)-1,7-diphenylhepta-4,6-dien-3-one; DTXSID30415724; OWMJDOUOHDOUFG-FNCQTZNRSA-N; MolPort-028-600-133; ZINC1538308; NSC378841; BDBM50300191; AKOS030524791; NSC-378841; AK544086; Y0026; trans,trans-1,7-diphenyl-1,3-heptadien-5-one
DMWU17O DT Small molecular drug
DMWU17O PC 5317598
DMWU17O MW 262.3
DMWU17O FM C19H18O
DMWU17O IC InChI=1S/C19H18O/c20-19(16-15-18-11-5-2-6-12-18)14-8-7-13-17-9-3-1-4-10-17/h1-14H,15-16H2/b13-7+,14-8+
DMWU17O CS C1=CC=C(C=C1)CCC(=O)/C=C/C=C/C2=CC=CC=C2
DMWU17O IK OWMJDOUOHDOUFG-FNCQTZNRSA-N
DMWU17O IU (4E,6E)-1,7-diphenylhepta-4,6-dien-3-one
DMWU17O CA CAS 33457-62-4
DMWU17O DE Discovery agent
DMBIV6M ID DMBIV6M
DMBIV6M DN (E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one
DMBIV6M HS Investigative
DMBIV6M DT Small molecular drug
DMBIV6M PC 13347323
DMBIV6M MW 278.3
DMBIV6M FM C19H18O2
DMBIV6M IC InChI=1S/C19H18O2/c20-18(13-11-16-7-3-1-4-8-16)15-19(21)14-12-17-9-5-2-6-10-17/h1-11,13H,12,14-15H2/b13-11+
DMBIV6M CS C1=CC=C(C=C1)CCC(=O)CC(=O)/C=C/C2=CC=CC=C2
DMBIV6M IK WKUKRFYTEUQNEF-ACCUITESSA-N
DMBIV6M IU (E)-1,7-diphenylhept-1-ene-3,5-dione
DMBIV6M DE Discovery agent
DMPIUKZ ID DMPIUKZ
DMPIUKZ DN (E,E)-8-(4-Phenylbutadien-1-yl)caffeine
DMPIUKZ HS Investigative
DMPIUKZ SN CHEMBL483663; (E,E)-8-(4-Phenylbutadien-1-yl)caffeine; SCHEMBL15647106; BDBM50264585; (e,e)-8-(4-phenylbutadien-1-yl) caffeine
DMPIUKZ DT Small molecular drug
DMPIUKZ PC 44579939
DMPIUKZ MW 322.4
DMPIUKZ FM C18H18N4O2
DMPIUKZ IC InChI=1S/C18H18N4O2/c1-20-14(12-8-7-11-13-9-5-4-6-10-13)19-16-15(20)17(23)22(3)18(24)21(16)2/h4-12H,1-3H3/b11-7+,12-8+
DMPIUKZ CS CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC=CC=C3
DMPIUKZ IK NDTZOLIJIQKCRC-MKICQXMISA-N
DMPIUKZ IU 1,3,7-trimethyl-8-[(1E,3E)-4-phenylbuta-1,3-dienyl]purine-2,6-dione
DMPIUKZ DE Discovery agent
DMPEV7S ID DMPEV7S
DMPEV7S DN (E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine
DMPEV7S HS Investigative
DMPEV7S SN CHEMBL522256; (E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine
DMPEV7S DT Small molecular drug
DMPEV7S PC 44579962
DMPEV7S MW 401.3
DMPEV7S FM C18H17BrN4O2
DMPEV7S IC InChI=1S/C18H17BrN4O2/c1-21-14(10-5-4-7-12-8-6-9-13(19)11-12)20-16-15(21)17(24)23(3)18(25)22(16)2/h4-11H,1-3H3/b7-4+,10-5+
DMPEV7S CS CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC(=CC=C3)Br
DMPEV7S IK YJBUYKLAHVOOFW-HOZCHFDZSA-N
DMPEV7S IU 8-[(1E,3E)-4-(3-bromophenyl)buta-1,3-dienyl]-1,3,7-trimethylpurine-2,6-dione
DMPEV7S DE Discovery agent
DMY4W25 ID DMY4W25
DMY4W25 DN (E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine
DMY4W25 HS Investigative
DMY4W25 SN CHEMBL489390; (E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine
DMY4W25 DT Small molecular drug
DMY4W25 PC 44579960
DMY4W25 MW 356.8
DMY4W25 FM C18H17ClN4O2
DMY4W25 IC InChI=1S/C18H17ClN4O2/c1-21-14(10-5-4-7-12-8-6-9-13(19)11-12)20-16-15(21)17(24)23(3)18(25)22(16)2/h4-11H,1-3H3/b7-4+,10-5+
DMY4W25 CS CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC(=CC=C3)Cl
DMY4W25 IK MINUIDFUFCXYDK-HOZCHFDZSA-N
DMY4W25 IU 8-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dienyl]-1,3,7-trimethylpurine-2,6-dione
DMY4W25 DE Discovery agent
DMPHJO2 ID DMPHJO2
DMPHJO2 DN (E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine
DMPHJO2 HS Investigative
DMPHJO2 SN CHEMBL489391; (E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine
DMPHJO2 DT Small molecular drug
DMPHJO2 PC 44579961
DMPHJO2 MW 340.4
DMPHJO2 FM C18H17FN4O2
DMPHJO2 IC InChI=1S/C18H17FN4O2/c1-21-14(10-5-4-7-12-8-6-9-13(19)11-12)20-16-15(21)17(24)23(3)18(25)22(16)2/h4-11H,1-3H3/b7-4+,10-5+
DMPHJO2 CS CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)/C=C/C=C/C3=CC(=CC=C3)F
DMPHJO2 IK PAJAMQUTBUEFEH-HOZCHFDZSA-N
DMPHJO2 IU 8-[(1E,3E)-4-(3-fluorophenyl)buta-1,3-dienyl]-1,3,7-trimethylpurine-2,6-dione
DMPHJO2 DE Discovery agent
DMVKJ0H ID DMVKJ0H
DMVKJ0H DN (H-261)Boc-His-Pro-Phe-His-Leu(OH)-Val-Ile-His-OH
DMVKJ0H HS Investigative
DMVKJ0H PC 44293339
DMVKJ0H MW 1101.3
DMVKJ0H FM C54H80N14O11
DMVKJ0H IC InChI=1S/C54H80N14O11/c1-10-32(6)44(50(74)64-41(52(76)77)23-36-26-57-29-60-36)67-49(73)43(31(4)5)66-47(71)37(19-30(2)3)61-46(70)39(21-34-24-55-27-58-34)62-45(69)38(20-33-15-12-11-13-16-33)63-48(72)42-17-14-18-68(42)51(75)40(22-35-25-56-28-59-35)65-53(78)79-54(7,8)9/h11-13,15-16,24-32,37-44,47,66,71H,10,14,17-23H2,1-9H3,(H,55,58)(H,56,59)(H,57,60)(H,61,70)(H,62,69)(H,63,72)(H,64,74)(H,65,78)(H,67,73)(H,76,77)
DMVKJ0H CS CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)O)NC(=O)C(C(C)C)NC(C(CC(C)C)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC3=CC=CC=C3)NC(=O)C4CCCN4C(=O)C(CC5=CN=CN5)NC(=O)OC(C)(C)C)O
DMVKJ0H IK UIOXZRLXAROYRL-UHFFFAOYSA-N
DMVKJ0H IU 2-[[2-[[2-[[1-hydroxy-2-[[3-(1H-imidazol-5-yl)-2-[[2-[[1-[3-(1H-imidazol-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylpentyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid
DMVKJ0H DE Discovery agent
DMSCQ64 ID DMSCQ64
DMSCQ64 DN (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)
DMSCQ64 HS Investigative
DMSCQ64 SN CHEMBL426320; (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2)
DMSCQ64 DT Small molecular drug
DMSCQ64 PC 44412158
DMSCQ64 MW 919
DMSCQ64 FM C49H58N8O10
DMSCQ64 IC InChI=1S/C49H58N8O10/c1-27-18-34(58)19-28(2)35(27)24-38(50)49(67)56-25-31-11-8-7-10-29(31)23-41(56)46(64)54-39(15-16-43(60)61)45(63)52-17-9-5-6-12-42(59)53-40(44(51)62)26-57-47(65)36-21-30-13-14-33(55(3)4)20-32(30)22-37(36)48(57)66/h7-8,10-11,13-14,18-22,38-41,58H,5-6,9,12,15-17,23-26,50H2,1-4H3,(H2,51,62)(H,52,63)(H,53,59)(H,54,64)(H,60,61)/t38-,39-,40?,41?/m0/s1
DMSCQ64 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H](CCC(=O)O)C(=O)NCCCCCC(=O)NC(CN4C(=O)C5=C(C4=O)C=C6C=C(C=CC6=C5)N(C)C)C(=O)N)N)C)O
DMSCQ64 IK DURKEIXAKJIEGD-JHIBKCPMSA-N
DMSCQ64 IU (4S)-5-[[6-[[1-amino-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-oxopentanoic acid
DMSCQ64 DE Discovery agent
DMY6FUD ID DMY6FUD
DMY6FUD DN (Hydroxyethyloxy)Tri(Ethyloxy)Octane
DMY6FUD HS Investigative
DMY6FUD SN 19327-39-0; 3,6,9,12-tetraoxaicosan-1-ol; 3,6,9,12-Tetraoxaeicosan-1-ol; TETRAETHYLENE GLYCOL MONOOCTYL ETHER; (Hydroxyethyloxy)tri(Ethyloxy)octane; Tetraethylene glycol monoctyl ether; C8E4; FEOZZFHAVXYAMB-UHFFFAOYSA-N; C8E; Octyltetraglycol; Octyltetraethyleneoxide; AC1L1KAZ; AC1Q58VY; SCHEMBL185557; Octyl tetraethylene glycol ether; DTXSID3066479; CHEBI:41323; CTK0H5811; Tetraethylene glycol, octyl ether; tetraethyleneglycol monooctyl ether; MolPort-003-939-472; MFCD00043033; ZINC14881140; AKOS027320403; DB04233; KS-00000Y06
DMY6FUD DT Small molecular drug
DMY6FUD PC 5414
DMY6FUD MW 306.44
DMY6FUD FM C16H34O5
DMY6FUD IC InChI=1S/C16H34O5/c1-2-3-4-5-6-7-9-18-11-13-20-15-16-21-14-12-19-10-8-17/h17H,2-16H2,1H3
DMY6FUD CS CCCCCCCCOCCOCCOCCOCCO
DMY6FUD IK FEOZZFHAVXYAMB-UHFFFAOYSA-N
DMY6FUD IU 2-[2-[2-(2-octoxyethoxy)ethoxy]ethoxy]ethanol
DMY6FUD CA CAS 19327-39-0
DMY6FUD CB CHEBI:41323
DMY6FUD DE Discovery agent
DMOJUEC ID DMOJUEC
DMOJUEC DN (hydroxymethylphenyl)agomelatine
DMOJUEC HS Investigative
DMOJUEC SN compound 21 [PMID: 18778943]
DMOJUEC DT Small molecular drug
DMOJUEC PC 9798456
DMOJUEC MW 349.4
DMOJUEC FM C22H23NO3
DMOJUEC IC InChI=1S/C22H23NO3/c1-15(25)23-9-8-19-12-20(17-5-3-4-16(10-17)14-24)11-18-6-7-21(26-2)13-22(18)19/h3-7,10-13,24H,8-9,14H2,1-2H3,(H,23,25)
DMOJUEC CS CC(=O)NCCC1=C2C=C(C=CC2=CC(=C1)C3=CC=CC(=C3)CO)OC
DMOJUEC IK BHDVJMSEODZSTD-UHFFFAOYSA-N
DMOJUEC IU N-[2-[3-[3-(hydroxymethyl)phenyl]-7-methoxynaphthalen-1-yl]ethyl]acetamide
DMOJUEC DE Discovery agent
DMP9ZVQ ID DMP9ZVQ
DMP9ZVQ DN (L)-Phe-(D)-Phe-NH2
DMP9ZVQ HS Investigative
DMP9ZVQ SN CHEMBL590275; (L)-Phe-(D)-Phe-NH2; AC1OEWE6; BDBM50308388
DMP9ZVQ DT Small molecular drug
DMP9ZVQ PC 7088460
DMP9ZVQ MW 311.4
DMP9ZVQ FM C18H21N3O2
DMP9ZVQ IC InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16+/m0/s1
DMP9ZVQ CS C1=CC=C(C=C1)C[C@@H](C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N)N
DMP9ZVQ IK XXPXQEQOAZMUDD-JKSUJKDBSA-N
DMP9ZVQ IU (2S)-2-amino-N-[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DMP9ZVQ DE Discovery agent
DMDUN83 ID DMDUN83
DMDUN83 DN (L-)-S-adenosyl-L-homocysteine
DMDUN83 HS Investigative
DMDUN83 SN S-Adenosyl-L-homocysteine; S-adenosylhomocysteine; S-adenosyl-L-homocysteine; 979-92-0; AdoHcy; S-(5'-adenosyl)-L-homocysteine; adenosylhomocysteine; Formycinylhomocysteine; Adenosyl-L-homocysteine; S-(5'-deoxyadenosin-5'-yl)-L-homocysteine; 2-S-adenosyl-L-homocysteine; 5'-Deoxy-S-adenosyl-L-homocysteine; S-adenosyl-homocysteine; S-Adenosyl Homocysteine; L-S-Adenosylhomocysteine; L-Homocysteine, S-(5'-deoxyadenosin-5'-yl)-; adenosylhomo-cys; adenosyl-homo-cys; UNII-8K31Q2S66S; (S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine; BRN 5166233; SAH; S-Adenosylhomocysteine; S-Adenosyl-L-Homocysteine
DMDUN83 DT Small molecular drug
DMDUN83 PC 439155
DMDUN83 MW 384.41
DMDUN83 FM C14H20N6O5S
DMDUN83 IC InChI=1S/C14H20N6O5S/c15-6(14(23)24)1-2-26-3-7-9(21)10(22)13(25-7)20-5-19-8-11(16)17-4-18-12(8)20/h4-7,9-10,13,21-22H,1-3,15H2,(H,23,24)(H2,16,17,18)/t6-,7+,9+,10+,13+/m0/s1
DMDUN83 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O)N
DMDUN83 IK ZJUKTBDSGOFHSH-WFMPWKQPSA-N
DMDUN83 IU (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DMDUN83 CA CAS 979-92-0
DMDUN83 CB CHEBI:16680
DMDUN83 DE Discovery agent
DMRGIF3 ID DMRGIF3
DMRGIF3 DN (LTB4-(Csa)4)2-Glu-H Conjugate
DMRGIF3 HS Investigative
DMRGIF3 SN CHEMBL412510; (LTB4-(Csa)4)2-Glu-H Conjugate; SCHEMBL5052860
DMRGIF3 PC 44403368
DMRGIF3 MW 2752.1
DMRGIF3 FM C109H159N23O44S8
DMRGIF3 IC InChI=1S/C109H159N23O44S8/c1-108(2,41-19-23-53-175-95-65-79(75-29-9-5-10-30-75)63-82(116-95)77-33-13-7-14-34-77)106-125-127-129-131(106)47-21-17-37-92(133)111-43-25-49-169-55-59-173-61-57-171-51-27-45-113-98(137)84(67-177(145,146)147)119-102(141)88(71-181(157,158)159)123-104(143)90(73-183(163,164)165)121-100(139)86(69-179(151,152)153)115-94(135)40-39-81(110)97(136)118-87(70-180(154,155)156)101(140)122-91(74-184(166,167)168)105(144)124-89(72-182(160,161)162)103(142)120-85(68-178(148,149)150)99(138)114-46-28-52-172-58-62-174-60-56-170-50-26-44-112-93(134)38-18-22-48-132-107(126-128-130-132)109(3,4)42-20-24-54-176-96-66-80(76-31-11-6-12-32-76)64-83(117-96)78-35-15-8-16-36-78/h5-16,29-36,63-66,81,84-91H,17-28,37-62,67-74,110H2,1-4H3,(H,111,133)(H,112,134)(H,113,137)(H,114,138)(H,115,135)(H,118,136)(H,119,141)(H,120,142)(H,121,139)(H,122,140)(H,123,143)(H,124,144)(H,145,146,147)(H,148,149,150)(H,151,152,153)(H,154,155,156)(H,157,158,159)(H,160,161,162)(H,163,164,165)(H,166,167,168)/t81-,84-,85-,86-,87-,88-,89-,90-,91-/m0/s1
DMRGIF3 CS CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CC[C@@H](C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN5C(=NN=N5)C(C)(C)CCCCOC6=CC(=CC(=N6)C7=CC=CC=C7)C8=CC=CC=C8)N
DMRGIF3 IK LBTVXEXIIAMTIW-WSJKXOGOSA-N
DMRGIF3 IU (2R)-2-[[(4S)-4-amino-5-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-5-oxopentanoyl]amino]-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-3-oxopropane-1-sulfonic acid
DMRGIF3 DE Discovery agent
DM9ATZ8 ID DM9ATZ8
DM9ATZ8 DN (N-(3-phenoxycinnamyl)-acetohydroxamic acid
DM9ATZ8 HS Investigative
DM9ATZ8 SN CHEMBL529218
DM9ATZ8 DT Small molecular drug
DM9ATZ8 PC 44583183
DM9ATZ8 MW 297.3
DM9ATZ8 FM C17H15NO4
DM9ATZ8 IC InChI=1S/C17H15NO4/c1-13(19)18(21)17(20)11-10-14-6-5-9-16(12-14)22-15-7-3-2-4-8-15/h2-12,21H,1H3/b11-10+
DM9ATZ8 CS CC(=O)N(C(=O)/C=C/C1=CC(=CC=C1)OC2=CC=CC=C2)O
DM9ATZ8 IK REDOCAPSVCSQLX-ZHACJKMWSA-N
DM9ATZ8 IU (E)-N-acetyl-N-hydroxy-3-(3-phenoxyphenyl)prop-2-enamide
DM9ATZ8 DE Discovery agent
DM6SV7I ID DM6SV7I
DM6SV7I DN (N)methanocarba-UTP
DM6SV7I HS Investigative
DM6SV7I SN (N)methanocarba-UTP; GTPL1740; ({[({[4-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2,3-dihydroxybicyclo[3.1.0]hexan-1-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid
DM6SV7I DT Small molecular drug
DM6SV7I PC 44309485
DM6SV7I MW 494.18
DM6SV7I FM C11H17N2O14P3
DM6SV7I IC InChI=1S/C11H17N2O14P3/c14-6-1-2-13(10(17)12-6)7-5-3-11(5,9(16)8(7)15)4-25-29(21,22)27-30(23,24)26-28(18,19)20/h1-2,5,7-9,15-16H,3-4H2,(H,21,22)(H,23,24)(H,12,14,17)(H2,18,19,20)
DM6SV7I CS C1C2C1(C(C(C2N3C=CC(=O)NC3=O)O)O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM6SV7I IK XWFVJTIKQWQNID-UHFFFAOYSA-N
DM6SV7I IU [[4-(2,4-dioxopyrimidin-1-yl)-2,3-dihydroxy-1-bicyclo[3.1.0]hexanyl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM6SV7I DE Discovery agent
DMPYK1T ID DMPYK1T
DMPYK1T DN (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine
DMPYK1T HS Investigative
DMPYK1T SN CHEMBL435162; (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine
DMPYK1T DT Small molecular drug
DMPYK1T PC 44275861
DMPYK1T MW 698.8
DMPYK1T FM C36H46N2O12
DMPYK1T IC InChI=1S/C36H46N2O12/c1-20(2)33(44)27(49-26(40)23-12-9-16-37-23)34(45)29(4)19-32(43)30(33,5)36(34,46)35(50-32)25(21(3)13-15-31(29,35)42)48-24(39)14-17-38-28(41)47-18-22-10-7-6-8-11-22/h6-12,16,20-21,25,27,37,42-46H,13-15,17-19H2,1-5H3,(H,38,41)/t21?,25-,27-,29+,30?,31?,32?,33?,34?,35?,36?/m1/s1
DMPYK1T CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCNC(=O)OCC6=CC=CC=C6)O4)O)O)OC(=O)C7=CC=CN7)(C(C)C)O)C)O)C)O
DMPYK1T IK YNAMTGCWRIKJBG-IQCGZQJLSA-N
DMPYK1T IU [(2R,7S,12R)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-2-[3-(phenylmethoxycarbonylamino)propanoyloxy]-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMPYK1T DE Discovery agent
DMRSZGB ID DMRSZGB
DMRSZGB DN (O10eq)-beta-alanyl-anhydro-ryanodine
DMRSZGB HS Investigative
DMRSZGB SN CHEMBL28261; (O10eq)-beta-alanyl-anhydro-ryanodine
DMRSZGB DT Small molecular drug
DMRSZGB PC 44275928
DMRSZGB MW 546.6
DMRSZGB FM C28H38N2O9
DMRSZGB IC InChI=1S/C28H38N2O9/c1-14(2)20-16(4)26(35)27(36,22(20)38-23(33)17-7-6-12-30-17)24(5)13-19(32)39-28(26)21(37-18(31)9-11-29)15(3)8-10-25(24,28)34/h6-7,12,14-15,21-22,30,34-36H,8-11,13,29H2,1-5H3/t15?,21-,22-,24+,25?,26?,27?,28?/m1/s1
DMRSZGB CS CC1CCC2([C@@]3(CC(=O)OC2([C@@H]1OC(=O)CCN)C4(C3([C@@H](C(=C4C)C(C)C)OC(=O)C5=CC=CN5)O)O)C)O
DMRSZGB IK NJCSEUYLWFFKSS-FCKNYIKNSA-N
DMRSZGB IU [(5R,7S,12R)-12-(3-aminopropanoyloxy)-2,6,8-trihydroxy-3,7,11-trimethyl-14-oxo-4-propan-2-yl-13-oxatetracyclo[5.5.3.01,8.02,6]pentadec-3-en-5-yl] 1H-pyrrole-2-carboxylate
DMRSZGB DE Discovery agent
DMVGARN ID DMVGARN
DMVGARN DN (O10eq)-beta-alanylryanodine
DMVGARN HS Investigative
DMVGARN SN CHEMBL282089; (O10eq)-beta-alanylryanodine
DMVGARN DT Small molecular drug
DMVGARN PC 44275867
DMVGARN MW 564.6
DMVGARN FM C28H40N2O10
DMVGARN IC InChI=1S/C28H40N2O10/c1-14(2)25(35)20(39-19(32)16-7-6-12-30-16)26(36)21(4)13-24(34)22(25,5)28(26,37)27(40-24)18(38-17(31)9-11-29)15(3)8-10-23(21,27)33/h6-7,12,14-15,18,20,30,33-37H,8-11,13,29H2,1-5H3/t15?,18-,20-,21+,22?,23?,24?,25?,26?,27?,28?/m1/s1
DMVGARN CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCN)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMVGARN IK RNYNXNCQNFQWFI-UHHIQCFMSA-N
DMVGARN IU [(2R,7S,12R)-2-(3-aminopropanoyloxy)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMVGARN DE Discovery agent
DMSV8XM ID DMSV8XM
DMSV8XM DN (O10eq)-beta-guanidinopropionylryanodine
DMSV8XM HS Investigative
DMSV8XM SN CHEMBL27669; (O10eq)-beta-guanidinopropionylryanodine
DMSV8XM DT Small molecular drug
DMSV8XM PC 44275926
DMSV8XM MW 606.7
DMSV8XM FM C29H42N4O10
DMSV8XM IC InChI=1S/C29H42N4O10/c1-14(2)26(38)20(42-19(35)16-7-6-11-32-16)27(39)22(4)13-25(37)23(26,5)29(27,40)28(43-25)18(15(3)8-10-24(22,28)36)41-17(34)9-12-33-21(30)31/h6-7,11,14-15,18,20,32,36-40H,8-10,12-13H2,1-5H3,(H4,30,31,33)/t15?,18-,20-,22+,23?,24?,25?,26?,27?,28?,29?/m1/s1
DMSV8XM CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CCN=C(N)N)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMSV8XM IK ZCZPMYVYWWNDNA-IYRTUPHRSA-N
DMSV8XM IU [(2R,7S,12R)-2-[3-(diaminomethylideneamino)propanoyloxy]-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMSV8XM DE Discovery agent
DM97W5T ID DM97W5T
DM97W5T DN (O10eq)-guanidino acetylryanodine
DM97W5T HS Investigative
DM97W5T SN CHEMBL435362; (O10eq)-guanidino acetylryanodine
DM97W5T DT Small molecular drug
DM97W5T PC 44275894
DM97W5T MW 592.6
DM97W5T FM C28H40N4O10
DM97W5T IC InChI=1S/C28H40N4O10/c1-13(2)25(37)19(41-18(34)15-7-6-10-31-15)26(38)21(4)12-24(36)22(25,5)28(26,39)27(42-24)17(14(3)8-9-23(21,27)35)40-16(33)11-32-20(29)30/h6-7,10,13-14,17,19,31,35-39H,8-9,11-12H2,1-5H3,(H4,29,30,32)/t14?,17-,19-,21+,22?,23?,24?,25?,26?,27?,28?/m1/s1
DM97W5T CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CN=C(N)N)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DM97W5T IK JJIABRHLFSNGBC-BTZWEUFCSA-N
DM97W5T IU [(2R,7S,12R)-2-[2-(diaminomethylideneamino)acetyl]oxy-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DM97W5T DE Discovery agent
DMB8NWI ID DMB8NWI
DMB8NWI DN (P-Iodophenylacetylamino)Methylphosphinic Acid
DMB8NWI HS Investigative
DMB8NWI SN (p-iodophenylacetylamino)methylphosphinic acid; AC1O3GBT; AC1L1B5E; C9H11INO3P; SCHEMBL4311614; [[2-(4-iodophenyl)acetyl]amino]methylphosphinic acid; (R)-({[(4-iodophenyl)acetyl]amino}methyl)phosphinic acid
DMB8NWI DT Small molecular drug
DMB8NWI PC 6327749
DMB8NWI MW 338.06
DMB8NWI FM C9H10INO3P+
DMB8NWI IC InChI=1S/C9H9INO3P/c10-8-3-1-7(2-4-8)5-9(12)11-6-15(13)14/h1-4H,5-6H2,(H-,11,12,13,14)/p+1
DMB8NWI CS C1=CC(=CC=C1CC(=O)NC[P+](=O)O)I
DMB8NWI IK HVYODBROOQYJGM-UHFFFAOYSA-O
DMB8NWI IU hydroxy-[[[2-(4-iodophenyl)acetyl]amino]methyl]-oxophosphanium
DMB8NWI DE Discovery agent
DMYJAM5 ID DMYJAM5
DMYJAM5 DN (R)-(-)-10-methyl-11-hydroxyaporphine
DMYJAM5 HS Investigative
DMYJAM5 SN PM 1000; PM-1000; CHEMBL53510; (R)-(-)-10-methyl-11-hydroxyaporphine; 111635-19-9; 10-Methyl-11-hydroxyaporphine; 11-Hmapp; 11-Hydroxy-10-methylaporphine; AC1MIZ6C; ZINC6368; SCHEMBL1349467; DTXSID90149699; BDBM50036286; (R)-6,10-Dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol; 4H-Dibenzo(de,g)quinolin-11-ol, 5,6,6a,7-tetrahydro-6,10-dimethyl-, (R)-
DMYJAM5 DT Small molecular drug
DMYJAM5 PC 3082625
DMYJAM5 MW 265.3
DMYJAM5 FM C18H19NO
DMYJAM5 IC InChI=1S/C18H19NO/c1-11-6-7-13-10-15-16-12(8-9-19(15)2)4-3-5-14(16)17(13)18(11)20/h3-7,15,20H,8-10H2,1-2H3/t15-/m1/s1
DMYJAM5 CS CC1=C(C2=C(C[C@@H]3C4=C(CCN3C)C=CC=C42)C=C1)O
DMYJAM5 IK YGOZTDLAUVOPMF-OAHLLOKOSA-N
DMYJAM5 IU (6aR)-6,10-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DMYJAM5 CA CAS 111635-19-9
DMYJAM5 DE Discovery agent
DMKB621 ID DMKB621
DMKB621 DN (R)-(-)-11-hydroxy-N-n-propylnoraporphine
DMKB621 HS Investigative
DMKB621 SN 11-Hydroxy-N-propylnoraporphine
DMKB621 DE Discovery agent
DMQ2INJ ID DMQ2INJ
DMQ2INJ DN (R)-(-)-2-methoxy-11-hydroxyaporphine
DMQ2INJ HS Investigative
DMQ2INJ SN CHEMBL270426; 2-Methoxy-11-hydroxyaporphine; (R)-(-)-2-methoxy-11-hydroxyaporphine; SCHEMBL1204517; BDBM50234265
DMQ2INJ DT Small molecular drug
DMQ2INJ PC 24766199
DMQ2INJ MW 281.3
DMQ2INJ FM C18H19NO2
DMQ2INJ IC InChI=1S/C18H19NO2/c1-19-7-6-12-8-13(21-2)10-14-17(12)15(19)9-11-4-3-5-16(20)18(11)14/h3-5,8,10,15,20H,6-7,9H2,1-2H3/t15-/m1/s1
DMQ2INJ CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)O
DMQ2INJ IK UGNGRDRWDHJJJI-OAHLLOKOSA-N
DMQ2INJ IU (6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DMQ2INJ DE Discovery agent
DMLXB62 ID DMLXB62
DMLXB62 DN (R)-(-)-2-methoxy-N-npropylnorapomorphine
DMLXB62 HS Investigative
DMLXB62 SN 2-Methoxy-N-n-propylnorapomorphine; CHEMBL53294; 126874-82-6; 2-Mnpna; (R)-(-)-2-methoxy-N-npropylnorapomorphine; AC1L2Y8J; SCHEMBL12284193; DTXSID70155319; 2-Methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; BDBM50010692; (R)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; 4H-dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-2-methoxy-6-propyl-, (R)-
DMLXB62 DT Small molecular drug
DMLXB62 PC 130907
DMLXB62 MW 325.4
DMLXB62 FM C20H23NO3
DMLXB62 IC InChI=1S/C20H23NO3/c1-3-7-21-8-6-13-9-14(24-2)11-15-18(13)16(21)10-12-4-5-17(22)20(23)19(12)15/h4-5,9,11,16,22-23H,3,6-8,10H2,1-2H3/t16-/m1/s1
DMLXB62 CS CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=C(C=C4)O)O
DMLXB62 IK WNNMRMNAGNMVEW-MRXNPFEDSA-N
DMLXB62 IU (6aR)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMLXB62 CA CAS 126874-82-6
DMLXB62 DE Discovery agent
DMAYEJL ID DMAYEJL
DMAYEJL DN (R)-(-)-2-Methyl-apomorphine hydrochloride
DMAYEJL HS Investigative
DMAYEJL SN CHEMBL507567
DMAYEJL DT Small molecular drug
DMAYEJL PC 44567292
DMAYEJL MW 281.3
DMAYEJL FM C18H19NO2
DMAYEJL IC InChI=1S/C18H19NO2/c1-10-7-12-5-6-19(2)14-9-11-3-4-15(20)18(21)17(11)13(8-10)16(12)14/h3-4,7-8,14,20-21H,5-6,9H2,1-2H3/t14-/m1/s1
DMAYEJL CS CC1=CC2=C3[C@@H](CC4=C(C3=C1)C(=C(C=C4)O)O)N(CC2)C
DMAYEJL IK QRJZCXSRTBCYIW-CQSZACIVSA-N
DMAYEJL IU (6aR)-2,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMAYEJL DE Discovery agent
DME62U0 ID DME62U0
DME62U0 DN (R)-(-)-2-Phenyl-apomorphine hydrochloride
DME62U0 HS Investigative
DME62U0 SN CHEMBL458397
DME62U0 DT Small molecular drug
DME62U0 PC 11515697
DME62U0 MW 343.4
DME62U0 FM C23H21NO2
DME62U0 IC InChI=1S/C23H21NO2/c1-24-10-9-16-11-17(14-5-3-2-4-6-14)12-18-21(16)19(24)13-15-7-8-20(25)23(26)22(15)18/h2-8,11-12,19,25-26H,9-10,13H2,1H3/t19-/m1/s1
DME62U0 CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C5=CC=CC=C5)C(=C(C=C4)O)O
DME62U0 IK NJWHLJABYCIZPL-LJQANCHMSA-N
DME62U0 IU (6aR)-6-methyl-2-phenyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DME62U0 DE Discovery agent
DMPSEZV ID DMPSEZV
DMPSEZV DN (R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine
DMPSEZV HS Investigative
DMPSEZV SN SCHEMBL1204538
DMPSEZV DT Small molecular drug
DMPSEZV PC 57340748
DMPSEZV MW 295.4
DMPSEZV FM C19H21NO2
DMPSEZV IC InChI=1S/C19H21NO2/c1-3-20-8-7-13-9-14(22-2)11-15-18(13)16(20)10-12-5-4-6-17(21)19(12)15/h4-6,9,11,16,21H,3,7-8,10H2,1-2H3
DMPSEZV CS CCN1CCC2=C3C1CC4=C(C3=CC(=C2)OC)C(=CC=C4)O
DMPSEZV IK OQCBYARNXRSEMX-UHFFFAOYSA-N
DMPSEZV IU 6-ethyl-2-methoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DMPSEZV DE Discovery agent
DM48SML ID DM48SML
DM48SML DN (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine
DM48SML HS Investigative
DM48SML SN CHEMBL405345; 2-methoxy-11-hydroxy-N-propylnoraporphine; (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine; SCHEMBL1204062; BDBM50336856
DM48SML DT Small molecular drug
DM48SML PC 24800688
DM48SML MW 309.4
DM48SML FM C20H23NO2
DM48SML IC InChI=1S/C20H23NO2/c1-3-8-21-9-7-14-10-15(23-2)12-16-19(14)17(21)11-13-5-4-6-18(22)20(13)16/h4-6,10,12,17,22H,3,7-9,11H2,1-2H3/t17-/m1/s1
DM48SML CS CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)O
DM48SML IK PGKMOUOGPCFQTK-QGZVFWFLSA-N
DM48SML IU (6aR)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol
DM48SML DE Discovery agent
DM9DBHU ID DM9DBHU
DM9DBHU DN (R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine
DM9DBHU HS Investigative
DM9DBHU SN CHEMBL379780; 890309-57-6; Jimscaline; (R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine; CTK2I1398; DTXSID30470414; ZINC35569551; BDBM50190615; 1H-Indene-1-methanamine, 2,3-dihydro-4,5,6-trimethoxy-, (1R)-
DM9DBHU DT Small molecular drug
DM9DBHU PC 11673493
DM9DBHU MW 237.29
DM9DBHU FM C13H19NO3
DM9DBHU IC InChI=1S/C13H19NO3/c1-15-11-6-10-8(7-14)4-5-9(10)12(16-2)13(11)17-3/h6,8H,4-5,7,14H2,1-3H3/t8-/m0/s1
DM9DBHU CS COC1=C(C(=C2CC[C@H](C2=C1)CN)OC)OC
DM9DBHU IK AFTIZGHFDCOQFS-QMMMGPOBSA-N
DM9DBHU IU [(1R)-4,5,6-trimethoxy-2,3-dihydro-1H-inden-1-yl]methanamine
DM9DBHU CA CAS 890309-57-6
DM9DBHU DE Discovery agent
DM5UOFY ID DM5UOFY
DM5UOFY DN (R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DM5UOFY HS Investigative
DM5UOFY SN CHEMBL600385; (R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DM5UOFY DT Small molecular drug
DM5UOFY PC 46232144
DM5UOFY MW 272.27
DM5UOFY FM C16H13FO3
DM5UOFY IC InChI=1S/C16H13FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15H,9H2,1H3/t15-/m1/s1
DM5UOFY CS COC1=CC2=C(C=C1)C(=O)C[C@@H](O2)C3=CC=C(C=C3)F
DM5UOFY IK LIINIWOYEGBFDA-OAHLLOKOSA-N
DM5UOFY IU (2R)-2-(4-fluorophenyl)-7-methoxy-2,3-dihydrochromen-4-one
DM5UOFY DE Discovery agent
DM6WTLZ ID DM6WTLZ
DM6WTLZ DN (R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DM6WTLZ HS Investigative
DM6WTLZ SN CHEMBL599762; (R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DM6WTLZ DT Small molecular drug
DM6WTLZ PC 46232077
DM6WTLZ MW 260.23
DM6WTLZ FM C15H10F2O2
DM6WTLZ IC InChI=1S/C15H10F2O2/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14H,8H2/t14-/m1/s1
DM6WTLZ CS C1[C@@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=C(C=C3)F
DM6WTLZ IK YKJLGNVYFBPKJK-CQSZACIVSA-N
DM6WTLZ IU (2R)-7-fluoro-2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DM6WTLZ DE Discovery agent
DMJCN0Y ID DMJCN0Y
DMJCN0Y DN (R)(+)-7-fluoro-2-phenylchroman-4-one
DMJCN0Y HS Investigative
DMJCN0Y SN CHEMBL599761; (R)(+)-7-fluoro-2-phenylchroman-4-one; SCHEMBL10360819
DMJCN0Y DT Small molecular drug
DMJCN0Y PC 46232075
DMJCN0Y MW 242.24
DMJCN0Y FM C15H11FO2
DMJCN0Y IC InChI=1S/C15H11FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14H,9H2/t14-/m1/s1
DMJCN0Y CS C1[C@@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=CC=C3
DMJCN0Y IK SZNYRENOXQIQMR-CQSZACIVSA-N
DMJCN0Y IU (2R)-7-fluoro-2-phenyl-2,3-dihydrochromen-4-one
DMJCN0Y DE Discovery agent
DMHNKWR ID DMHNKWR
DMHNKWR DN (R)(+)-7-fluoro-2-p-tolylchroman-4-one
DMHNKWR HS Investigative
DMHNKWR SN CHEMBL598151; (R)(+)-7-fluoro-2-p-tolylchroman-4-one
DMHNKWR DT Small molecular drug
DMHNKWR PC 46232079
DMHNKWR MW 256.269
DMHNKWR FM C16H13FO2
DMHNKWR IC InChI=1S/C16H13FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-8,15H,9H2,1H3/t15-/m1/s1
DMHNKWR CS CC1=CC=C(C=C1)[C@H]2CC(=O)C3=C(O2)C=C(C=C3)F
DMHNKWR IK QNQXLNDULBVXEX-OAHLLOKOSA-N
DMHNKWR IU (2R)-7-fluoro-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMHNKWR DE Discovery agent
DM8ZHYR ID DM8ZHYR
DM8ZHYR DN (R)(+)-7-methyl-2-phenylchroman-4-one
DM8ZHYR HS Investigative
DM8ZHYR SN CHEMBL601844; (R)(+)-7-methyl-2-phenylchroman-4-one; SCHEMBL1895390; FNOKOVWLKVWYRY-OAHLLOKOSA-N; BDBM50310170; (R)-7-methyl-2-phenylchroman-4-one
DM8ZHYR DT Small molecular drug
DM8ZHYR PC 46232081
DM8ZHYR MW 238.28
DM8ZHYR FM C16H14O2
DM8ZHYR IC InChI=1S/C16H14O2/c1-11-7-8-13-14(17)10-15(18-16(13)9-11)12-5-3-2-4-6-12/h2-9,15H,10H2,1H3/t15-/m1/s1
DM8ZHYR CS CC1=CC2=C(C=C1)C(=O)C[C@@H](O2)C3=CC=CC=C3
DM8ZHYR IK FNOKOVWLKVWYRY-OAHLLOKOSA-N
DM8ZHYR IU (2R)-7-methyl-2-phenyl-2,3-dihydrochromen-4-one
DM8ZHYR DE Discovery agent
DMVN50D ID DMVN50D
DMVN50D DN (R)(+)-7-methyl-2-p-tolylchroman-4-one
DMVN50D HS Investigative
DMVN50D SN CHEMBL598321; (R)(+)-7-methyl-2-p-tolylchroman-4-one
DMVN50D DT Small molecular drug
DMVN50D PC 46232142
DMVN50D MW 252.31
DMVN50D FM C17H16O2
DMVN50D IC InChI=1S/C17H16O2/c1-11-3-6-13(7-4-11)16-10-15(18)14-8-5-12(2)9-17(14)19-16/h3-9,16H,10H2,1-2H3/t16-/m1/s1
DMVN50D CS CC1=CC=C(C=C1)[C@H]2CC(=O)C3=C(O2)C=C(C=C3)C
DMVN50D IK MIEPNGHJBCGJAW-MRXNPFEDSA-N
DMVN50D IU (2R)-7-methyl-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMVN50D DE Discovery agent
DM7C148 ID DM7C148
DM7C148 DN (R)-(+)-coclaurine
DM7C148 HS Investigative
DM7C148 SN (R)-Coclaurine; d-Coclaurine; 2196-60-3; Sanjoinine K; CHEMBL256448; CHEBI:27482; (1R)-1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol; 6-Methoxy-7-hydroxy-(1R)-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline; (1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-Isoquinolinol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-6-methoxy-, (R)-; (R)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-7-isoquinolinol; (R)-d-Coclaurine
DM7C148 DT Small molecular drug
DM7C148 PC 440989
DM7C148 MW 285.34
DM7C148 FM C17H19NO3
DM7C148 IC InChI=1S/C17H19NO3/c1-21-17-9-12-6-7-18-15(14(12)10-16(17)20)8-11-2-4-13(19)5-3-11/h2-5,9-10,15,18-20H,6-8H2,1H3/t15-/m1/s1
DM7C148 CS COC1=C(C=C2[C@H](NCCC2=C1)CC3=CC=C(C=C3)O)O
DM7C148 IK LVVKXRQZSRUVPY-OAHLLOKOSA-N
DM7C148 IU (1R)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
DM7C148 CA CAS 2196-60-3
DM7C148 CB CHEBI:27482
DM7C148 DE Discovery agent
DMBXRKS ID DMBXRKS
DMBXRKS DN (R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol
DMBXRKS HS Investigative
DMBXRKS SN CHEMBL207712; (R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol; SCHEMBL14202964
DMBXRKS DT Small molecular drug
DMBXRKS PC 44410091
DMBXRKS MW 283.4
DMBXRKS FM C18H21NO2
DMBXRKS IC InChI=1S/C18H21NO2/c20-18(16-9-5-2-6-10-16,17-14-19-11-12-21-17)13-15-7-3-1-4-8-15/h1-10,17,19-20H,11-14H2/t17-,18+/m0/s1
DMBXRKS CS C1CO[C@@H](CN1)[C@@](CC2=CC=CC=C2)(C3=CC=CC=C3)O
DMBXRKS IK VGJFVJKZCAUGKE-ZWKOTPCHSA-N
DMBXRKS IU (1R)-1-[(2S)-morpholin-2-yl]-1,2-diphenylethanol
DMBXRKS DE Discovery agent
DMYBC24 ID DMYBC24
DMYBC24 DN (R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea
DMYBC24 HS Investigative
DMYBC24 SN CHEMBL397459; indazole antagonist, (R)-16b; BDBM20407
DMYBC24 DT Small molecular drug
DMYBC24 PC 24768211
DMYBC24 MW 294.35
DMYBC24 FM C17H18N4O
DMYBC24 IC InChI=1S/C17H18N4O/c1-11-6-8-13(9-7-11)12(2)19-17(22)20-15-4-3-5-16-14(15)10-18-21-16/h3-10,12H,1-2H3,(H,18,21)(H2,19,20,22)/t12-/m1/s1
DMYBC24 CS CC1=CC=C(C=C1)[C@@H](C)NC(=O)NC2=CC=CC3=C2C=NN3
DMYBC24 IK SHOUDGQMQHLAFL-GFCCVEGCSA-N
DMYBC24 IU 1-(1H-indazol-4-yl)-3-[(1R)-1-(4-methylphenyl)ethyl]urea
DMYBC24 DE Discovery agent
DMGD026 ID DMGD026
DMGD026 DN (R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid
DMGD026 HS Investigative
DMGD026 SN Gly-boroPro; CHEMBL67089; Glycinyl-(R)-Boroproline; (R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid; SCHEMBL10022738
DMGD026 DT Small molecular drug
DMGD026 PC 10607286
DMGD026 MW 171.99
DMGD026 FM C6H13BN2O3
DMGD026 IC InChI=1S/C6H13BN2O3/c8-4-6(10)9-3-1-2-5(9)7(11)12/h5,11-12H,1-4,8H2/t5-/m0/s1
DMGD026 CS B([C@@H]1CCCN1C(=O)CN)(O)O
DMGD026 IK BZTBBVKEKPNNBE-YFKPBYRVSA-N
DMGD026 IU [(2R)-1-(2-aminoacetyl)pyrrolidin-2-yl]boronic acid
DMGD026 DE Discovery agent
DMMY0NF ID DMMY0NF
DMMY0NF DN (R)-1-(2-methoxyphenethyl)-2-methylpyrrolidine
DMMY0NF HS Investigative
DMMY0NF SN CHEMBL404375
DMMY0NF DT Small molecular drug
DMMY0NF PC 44456095
DMMY0NF MW 219.32
DMMY0NF FM C14H21NO
DMMY0NF IC InChI=1S/C14H21NO/c1-12-6-5-10-15(12)11-9-13-7-3-4-8-14(13)16-2/h3-4,7-8,12H,5-6,9-11H2,1-2H3/t12-/m1/s1
DMMY0NF CS C[C@@H]1CCCN1CCC2=CC=CC=C2OC
DMMY0NF IK KDVUGYDZNTZESD-GFCCVEGCSA-N
DMMY0NF IU (2R)-1-[2-(2-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMMY0NF DE Discovery agent
DM76SZK ID DM76SZK
DM76SZK DN (R)-1-(3-methoxyphenethyl)-2-methylpyrrolidine
DM76SZK HS Investigative
DM76SZK SN CHEMBL439429
DM76SZK DT Small molecular drug
DM76SZK PC 44456091
DM76SZK MW 219.32
DM76SZK FM C14H21NO
DM76SZK IC InChI=1S/C14H21NO/c1-12-5-4-9-15(12)10-8-13-6-3-7-14(11-13)16-2/h3,6-7,11-12H,4-5,8-10H2,1-2H3/t12-/m1/s1
DM76SZK CS C[C@@H]1CCCN1CCC2=CC(=CC=C2)OC
DM76SZK IK INKHQVYBVMGBHD-GFCCVEGCSA-N
DM76SZK IU (2R)-1-[2-(3-methoxyphenyl)ethyl]-2-methylpyrrolidine
DM76SZK DE Discovery agent
DMDC297 ID DMDC297
DMDC297 DN (R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
DMDC297 HS Investigative
DMDC297 SN (R)-1-(4-Iodo-2,5-dimethoxyphenyl)propan-2-amine; CHEMBL134519; R-DOI; Lopac0_000478; GTPL157; (R)-DOI; SCHEMBL713061; ZINC2516053; PDSP2_001372; Benzeneethanamine, 4-iodo-2,5-dimethoxy-alpha-methyl-, (alphaR)-; BDBM50133231; PDSP1_001388; CCG-204569; NCGC00162167-01; AJ-36945; 82864-06-0; (2R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine; (r)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane; (R)-2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine; (R)-2-(4-Iodo-2,5-dimethoxy-phenyl)-1-methyl-ethylamine; UNII-OOM10GW9UE
DMDC297 DT Small molecular drug
DMDC297 PC 9840090
DMDC297 MW 321.15
DMDC297 FM C11H16INO2
DMDC297 IC InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3/t7-/m1/s1
DMDC297 CS C[C@H](CC1=CC(=C(C=C1OC)I)OC)N
DMDC297 IK BGMZUEKZENQUJY-SSDOTTSWSA-N
DMDC297 IU (2R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine
DMDC297 DE Discovery agent
DMR3DSG ID DMR3DSG
DMR3DSG DN (R)-1-(4-methoxyphenethyl)-2-methylpyrrolidine
DMR3DSG HS Investigative
DMR3DSG SN CHEMBL271898
DMR3DSG DT Small molecular drug
DMR3DSG PC 44456056
DMR3DSG MW 219.32
DMR3DSG FM C14H21NO
DMR3DSG IC InChI=1S/C14H21NO/c1-12-4-3-10-15(12)11-9-13-5-7-14(16-2)8-6-13/h5-8,12H,3-4,9-11H2,1-2H3/t12-/m1/s1
DMR3DSG CS C[C@@H]1CCCN1CCC2=CC=C(C=C2)OC
DMR3DSG IK NPUSLESRSBDEHN-GFCCVEGCSA-N
DMR3DSG IU (2R)-1-[2-(4-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMR3DSG DE Discovery agent
DMNROUV ID DMNROUV
DMNROUV DN (R)-1-(4-nitrophenethyl)-2-methylpyrrolidine
DMNROUV HS Investigative
DMNROUV SN CHEMBL440996; SCHEMBL1574678; PFZYNGPCNCRLFU-LLVKDONJSA-N; BDBM50372333; ZINC29131354
DMNROUV DT Small molecular drug
DMNROUV PC 23635021
DMNROUV MW 234.29
DMNROUV FM C13H18N2O2
DMNROUV IC InChI=1S/C13H18N2O2/c1-11-3-2-9-14(11)10-8-12-4-6-13(7-5-12)15(16)17/h4-7,11H,2-3,8-10H2,1H3/t11-/m1/s1
DMNROUV CS C[C@@H]1CCCN1CCC2=CC=C(C=C2)[N+](=O)[O-]
DMNROUV IK PFZYNGPCNCRLFU-LLVKDONJSA-N
DMNROUV IU (2R)-2-methyl-1-[2-(4-nitrophenyl)ethyl]pyrrolidine
DMNROUV DE Discovery agent
DMKJWMC ID DMKJWMC
DMKJWMC DN (R)-11-Amino-2-methoxyaporphine
DMKJWMC HS Investigative
DMKJWMC SN CHEMBL506721; (R)-11-Amino-2-methoxyaporphine
DMKJWMC DT Small molecular drug
DMKJWMC PC 44568533
DMKJWMC MW 280.4
DMKJWMC FM C18H20N2O
DMKJWMC IC InChI=1S/C18H20N2O/c1-20-7-6-12-8-13(21-2)10-14-17-11(4-3-5-15(17)19)9-16(20)18(12)14/h3-5,8,10,16H,6-7,9,19H2,1-2H3/t16-/m1/s1
DMKJWMC CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)N
DMKJWMC IK RHZAGARGKYFZJB-MRXNPFEDSA-N
DMKJWMC IU (6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-amine
DMKJWMC DE Discovery agent
DMXUHV3 ID DMXUHV3
DMXUHV3 DN (R)-2-((4-benzylphenoxy)methyl)piperidine
DMXUHV3 HS Investigative
DMXUHV3 SN CHEMBL1099180; (R)-2-((4-benzylphenoxy)methyl)piperidine; SCHEMBL13809077
DMXUHV3 DT Small molecular drug
DMXUHV3 PC 46888101
DMXUHV3 MW 281.4
DMXUHV3 FM C19H23NO
DMXUHV3 IC InChI=1S/C19H23NO/c1-2-6-16(7-3-1)14-17-9-11-19(12-10-17)21-15-18-8-4-5-13-20-18/h1-3,6-7,9-12,18,20H,4-5,8,13-15H2/t18-/m1/s1
DMXUHV3 CS C1CCN[C@H](C1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DMXUHV3 IK YZRAMLLKPOGYCE-GOSISDBHSA-N
DMXUHV3 IU (2R)-2-[(4-benzylphenoxy)methyl]piperidine
DMXUHV3 DE Discovery agent
DM6KJ3D ID DM6KJ3D
DM6KJ3D DN (R)-2-((4-phenoxyphenoxy)methyl)piperidine
DM6KJ3D HS Investigative
DM6KJ3D SN CHEMBL1099181; (R)-2-((4-phenoxyphenoxy)methyl)piperidine; SCHEMBL13809073
DM6KJ3D DT Small molecular drug
DM6KJ3D PC 29293603
DM6KJ3D MW 283.4
DM6KJ3D FM C18H21NO2
DM6KJ3D IC InChI=1S/C18H21NO2/c1-2-7-17(8-3-1)21-18-11-9-16(10-12-18)20-14-15-6-4-5-13-19-15/h1-3,7-12,15,19H,4-6,13-14H2/t15-/m1/s1
DM6KJ3D CS C1CCN[C@H](C1)COC2=CC=C(C=C2)OC3=CC=CC=C3
DM6KJ3D IK CSJNBXMUZIPBKQ-OAHLLOKOSA-N
DM6KJ3D IU (2R)-2-[(4-phenoxyphenoxy)methyl]piperidine
DM6KJ3D DE Discovery agent
DMFDW4C ID DMFDW4C
DMFDW4C DN (R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol
DMFDW4C HS Investigative
DMFDW4C SN CHEMBL404834
DMFDW4C DT Small molecular drug
DMFDW4C PC 44456330
DMFDW4C MW 205.3
DMFDW4C FM C13H19NO
DMFDW4C IC InChI=1S/C13H19NO/c1-11-5-4-9-14(11)10-8-12-6-2-3-7-13(12)15/h2-3,6-7,11,15H,4-5,8-10H2,1H3/t11-/m1/s1
DMFDW4C CS C[C@@H]1CCCN1CCC2=CC=CC=C2O
DMFDW4C IK XLLMSPMZEFQVLD-LLVKDONJSA-N
DMFDW4C IU 2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]phenol
DMFDW4C DE Discovery agent
DM0L6ES ID DM0L6ES
DM0L6ES DN (R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DM0L6ES HS Investigative
DM0L6ES SN CHEMBL270807
DM0L6ES DT Small molecular drug
DM0L6ES PC 44455953
DM0L6ES MW 190.28
DM0L6ES FM C12H18N2
DM0L6ES IC InChI=1S/C12H18N2/c1-11-5-4-9-14(11)10-7-12-6-2-3-8-13-12/h2-3,6,8,11H,4-5,7,9-10H2,1H3/t11-/m1/s1
DM0L6ES CS C[C@@H]1CCCN1CCC2=CC=CC=N2
DM0L6ES IK ICWSPDRNRGQWAB-LLVKDONJSA-N
DM0L6ES IU 2-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DM0L6ES DE Discovery agent
DMVEMNA ID DMVEMNA
DMVEMNA DN (R)-2-(2-naphthamido)-3-m-tolylpropanoic acid
DMVEMNA HS Investigative
DMVEMNA SN CHEMBL1091064; (R)-2-(2-naphthamido)-3-m-tolylpropanoic acid
DMVEMNA DT Small molecular drug
DMVEMNA PC 46884012
DMVEMNA MW 333.4
DMVEMNA FM C21H19NO3
DMVEMNA IC InChI=1S/C21H19NO3/c1-14-5-4-6-15(11-14)12-19(21(24)25)22-20(23)18-10-9-16-7-2-3-8-17(16)13-18/h2-11,13,19H,12H2,1H3,(H,22,23)(H,24,25)/t19-/m1/s1
DMVEMNA CS CC1=CC(=CC=C1)C[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DMVEMNA IK ZDRUGIXKFVQOIJ-LJQANCHMSA-N
DMVEMNA IU (2R)-3-(3-methylphenyl)-2-(naphthalene-2-carbonylamino)propanoic acid
DMVEMNA DE Discovery agent
DMXGCYZ ID DMXGCYZ
DMXGCYZ DN (R)-2-(2-naphthamido)-3-p-tolylpropanoic acid
DMXGCYZ HS Investigative
DMXGCYZ SN CHEMBL1093715; (R)-2-(2-naphthamido)-3-p-tolylpropanoic acid
DMXGCYZ DT Small molecular drug
DMXGCYZ PC 46884149
DMXGCYZ MW 333.4
DMXGCYZ FM C21H19NO3
DMXGCYZ IC InChI=1S/C21H19NO3/c1-14-6-8-15(9-7-14)12-19(21(24)25)22-20(23)18-11-10-16-4-2-3-5-17(16)13-18/h2-11,13,19H,12H2,1H3,(H,22,23)(H,24,25)/t19-/m1/s1
DMXGCYZ CS CC1=CC=C(C=C1)C[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DMXGCYZ IK AYMZFPGSRYDLJL-LJQANCHMSA-N
DMXGCYZ IU (2R)-3-(4-methylphenyl)-2-(naphthalene-2-carbonylamino)propanoic acid
DMXGCYZ DE Discovery agent
DM9WL6O ID DM9WL6O
DM9WL6O DN (R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid
DM9WL6O HS Investigative
DM9WL6O SN CHEMBL1090378; (R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid; SCHEMBL16550496
DM9WL6O DT Small molecular drug
DM9WL6O PC 46884229
DM9WL6O MW 343.4
DM9WL6O FM C22H17NO3
DM9WL6O IC InChI=1S/C22H17NO3/c24-21(19-14-13-17-10-4-5-11-18(17)15-19)23-20(22(25)26)12-6-9-16-7-2-1-3-8-16/h1-5,7-8,10-11,13-15,20H,12H2,(H,23,24)(H,25,26)/t20-/m1/s1
DM9WL6O CS C1=CC=C(C=C1)C#CC[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DM9WL6O IK IIZVJSCXCNYCFJ-HXUWFJFHSA-N
DM9WL6O IU (2R)-2-(naphthalene-2-carbonylamino)-5-phenylpent-4-ynoic acid
DM9WL6O DE Discovery agent
DM74IWX ID DM74IWX
DM74IWX DN (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX HS Investigative
DM74IWX SN CHEMBL1084971; (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM74IWX DT Small molecular drug
DM74IWX PC 46890321
DM74IWX MW 282.4
DM74IWX FM C18H22N2O
DM74IWX IC InChI=1S/C18H22N2O/c21-18-9-5-4-8-16(18)14-17(15-6-2-1-3-7-15)20-12-10-19-11-13-20/h1-9,17,19,21H,10-14H2/t17-/m1/s1
DM74IWX CS C1CN(CCN1)[C@H](CC2=CC=CC=C2O)C3=CC=CC=C3
DM74IWX IK SBKGLFTUHHUCII-QGZVFWFLSA-N
DM74IWX IU 2-[(2R)-2-phenyl-2-piperazin-1-ylethyl]phenol
DM74IWX CA CAS 1238669-95-8
DM74IWX DE Discovery agent
DM1GCV3 ID DM1GCV3
DM1GCV3 DN (R)-2-(4-Benzylphenoxymethyl)pyrrolidine
DM1GCV3 HS Investigative
DM1GCV3 SN (R)-2-(4-Benzylphenoxymethyl)pyrrolidine; CHEMBL571091; (2r)-2-[(4-Benzylphenoxy)methyl]pyrrolidine; SCHEMBL4319733; NXNMORHGFGYRDN-QGZVFWFLSA-N; BDBM50303648
DM1GCV3 DT Small molecular drug
DM1GCV3 PC 16222640
DM1GCV3 MW 267.4
DM1GCV3 FM C18H21NO
DM1GCV3 IC InChI=1S/C18H21NO/c1-2-5-15(6-3-1)13-16-8-10-18(11-9-16)20-14-17-7-4-12-19-17/h1-3,5-6,8-11,17,19H,4,7,12-14H2/t17-/m1/s1
DM1GCV3 CS C1C[C@@H](NC1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DM1GCV3 IK NXNMORHGFGYRDN-QGZVFWFLSA-N
DM1GCV3 IU (2R)-2-[(4-benzylphenoxy)methyl]pyrrolidine
DM1GCV3 DE Discovery agent
DMR8E0G ID DMR8E0G
DMR8E0G DN (R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide
DMR8E0G HS Investigative
DMR8E0G SN CHEMBL190899; SCHEMBL13952025; Benzeneacetamide,N-methoxy-alpha-methyl-4-(2-methylpropyl)-,(alphaR)-
DMR8E0G DT Small molecular drug
DMR8E0G PC 11322291
DMR8E0G MW 235.32
DMR8E0G FM C14H21NO2
DMR8E0G IC InChI=1S/C14H21NO2/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-17-4/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
DMR8E0G CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NOC
DMR8E0G IK UOURTTOYLTUYKY-LLVKDONJSA-N
DMR8E0G IU (2R)-N-methoxy-2-[4-(2-methylpropyl)phenyl]propanamide
DMR8E0G DE Discovery agent
DMAD4JY ID DMAD4JY
DMAD4JY DN (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide
DMAD4JY HS Investigative
DMAD4JY SN AC1LGDRI; SCHEMBL4372856; CHEMBL190952; ZINC250026; (2R)-2-(4-Isobutylphenyl)-N-phenylpropionamide
DMAD4JY DT Small molecular drug
DMAD4JY PC 769367
DMAD4JY MW 281.4
DMAD4JY FM C19H23NO
DMAD4JY IC InChI=1S/C19H23NO/c1-14(2)13-16-9-11-17(12-10-16)15(3)19(21)20-18-7-5-4-6-8-18/h4-12,14-15H,13H2,1-3H3,(H,20,21)/t15-/m1/s1
DMAD4JY CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NC2=CC=CC=C2
DMAD4JY IK UHKIXOMKDZNTLI-OAHLLOKOSA-N
DMAD4JY IU (2R)-2-[4-(2-methylpropyl)phenyl]-N-phenylpropanamide
DMAD4JY DE Discovery agent
DMBQ0PR ID DMBQ0PR
DMBQ0PR DN (R)-2-(4-Isobutyl-phenyl)-propionamide
DMBQ0PR HS Investigative
DMBQ0PR SN UNII-LMA883899Q; LMA883899Q; 121839-78-9; (R)-Ibuprofenamide; (-)-Ibuprofenamide; Ibuprofenamide, (R)-; (R)-2-(4-(Isobutylphenyl)propanamide; AC1LEPBR; SCHEMBL1883571; CHEMBL190950; Benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-, (R)-; Benzeneacetamide,alpha-methyl-4-(2-methylpropyl)-,(alphaR)-; ZINC112491; Benzeneacetamide, alpha-methyl-4-(2-methylpropyl)-, (alphaR)-; ZB003774; (R)-alpha-Methyl-4-isobutylbenzeneacetamide; (2R)-2-[4-(2-methylpropyl)phenyl]propanamide; UNII-74M0104F2J component REUQKCDCQVNKLW-SNVBAGLBSA-
DMBQ0PR DT Small molecular drug
DMBQ0PR PC 715794
DMBQ0PR MW 205.3
DMBQ0PR FM C13H19NO
DMBQ0PR IC InChI=1S/C13H19NO/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H2,14,15)/t10-/m1/s1
DMBQ0PR CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)N
DMBQ0PR IK REUQKCDCQVNKLW-SNVBAGLBSA-N
DMBQ0PR IU (2R)-2-[4-(2-methylpropyl)phenyl]propanamide
DMBQ0PR CA CAS 121839-78-9
DMBQ0PR DE Discovery agent
DMJVQN8 ID DMJVQN8
DMJVQN8 DN (R)-2-(Benzylamino-methyl)-chroman-7-ol
DMJVQN8 HS Investigative
DMJVQN8 SN CHEMBL64553; CHEMBL134807; BDBM50061669; ZINC13527706; (2R)-2-(Benzylaminomethyl)chroman-7-ol; (r)-2-[(benzylamino)methyl]chroman-7-ol
DMJVQN8 DT Small molecular drug
DMJVQN8 PC 10378389
DMJVQN8 MW 269.34
DMJVQN8 FM C17H19NO2
DMJVQN8 IC InChI=1S/C17H19NO2/c19-15-8-6-14-7-9-16(20-17(14)10-15)12-18-11-13-4-2-1-3-5-13/h1-6,8,10,16,18-19H,7,9,11-12H2/t16-/m1/s1
DMJVQN8 CS C1CC2=C(C=C(C=C2)O)O[C@H]1CNCC3=CC=CC=C3
DMJVQN8 IK DWUAAOIZQFTYQP-MRXNPFEDSA-N
DMJVQN8 IU (2R)-2-[(benzylamino)methyl]-3,4-dihydro-2H-chromen-7-ol
DMJVQN8 DE Discovery agent
DM16JFS ID DM16JFS
DM16JFS DN (R)-2-(biphenyl-4-sulfonylamino)-propionic acid
DM16JFS HS Investigative
DM16JFS SN SCHEMBL4651862; CHEMBL198184; BDBM24034; biphenylsulfonamide carboxylate, 11; (2R)-2-[(4-phenylbenzene)sulfonamido]propanoic acid
DM16JFS DT Small molecular drug
DM16JFS PC 24901481
DM16JFS MW 305.4
DM16JFS FM C15H15NO4S
DM16JFS IC InChI=1S/C15H15NO4S/c1-11(15(17)18)16-21(19,20)14-9-7-13(8-10-14)12-5-3-2-4-6-12/h2-11,16H,1H3,(H,17,18)/t11-/m1/s1
DM16JFS CS C[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DM16JFS IK KXVXZFCETOKHTC-LLVKDONJSA-N
DM16JFS IU (2R)-2-[(4-phenylphenyl)sulfonylamino]propanoic acid
DM16JFS DE Discovery agent
DM70ZIF ID DM70ZIF
DM70ZIF DN (R)-2,11-Diaminoaporphine
DM70ZIF HS Investigative
DM70ZIF SN (R)-2,11-Diaminoaporphine; CHEMBL455051
DM70ZIF DT Small molecular drug
DM70ZIF PC 44568534
DM70ZIF MW 265.35
DM70ZIF FM C17H19N3
DM70ZIF IC InChI=1S/C17H19N3/c1-20-6-5-11-7-12(18)9-13-16-10(3-2-4-14(16)19)8-15(20)17(11)13/h2-4,7,9,15H,5-6,8,18-19H2,1H3/t15-/m1/s1
DM70ZIF CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)N)C(=CC=C4)N
DM70ZIF IK SBZULQRCMCHLCL-OAHLLOKOSA-N
DM70ZIF IU (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,11-diamine
DM70ZIF DE Discovery agent
DMRO9C7 ID DMRO9C7
DMRO9C7 DN (R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol
DMRO9C7 HS Investigative
DMRO9C7 SN CHEMBL87169; (R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol
DMRO9C7 DT Small molecular drug
DMRO9C7 PC 44320078
DMRO9C7 MW 193.2
DMRO9C7 FM C7H15NO5
DMRO9C7 IC InChI=1S/C7H15NO5/c9-1-3-5(11)7(13)6(12)4(2-10)8-3/h3-13H,1-2H2/t3?,4?,5-,6?,7?/m1/s1
DMRO9C7 CS C(C1[C@H](C(C(C(N1)CO)O)O)O)O
DMRO9C7 IK CLVUFWXGNIFGNC-BQHSNLCNSA-N
DMRO9C7 IU (3R)-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol
DMRO9C7 DE Discovery agent
DMZXT34 ID DMZXT34
DMZXT34 DN (R)-2-amino-3-(4-octylphenylamino)propan-1-ol
DMZXT34 HS Investigative
DMZXT34 SN CHEMBL572686; (R)-2-amino-3-(4-octylphenylamino)propan-1-ol; SCHEMBL1312243
DMZXT34 DT Small molecular drug
DMZXT34 PC 45255203
DMZXT34 MW 278.4
DMZXT34 FM C17H30N2O
DMZXT34 IC InChI=1S/C17H30N2O/c1-2-3-4-5-6-7-8-15-9-11-17(12-10-15)19-13-16(18)14-20/h9-12,16,19-20H,2-8,13-14,18H2,1H3/t16-/m1/s1
DMZXT34 CS CCCCCCCCC1=CC=C(C=C1)NC[C@H](CO)N
DMZXT34 IK RCARSJSFSXRXLF-MRXNPFEDSA-N
DMZXT34 IU (2R)-2-amino-3-(4-octylanilino)propan-1-ol
DMZXT34 DE Discovery agent
DMA1EFL ID DMA1EFL
DMA1EFL DN (R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DMA1EFL HS Investigative
DMA1EFL SN CHEMBL572687; (R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide; SCHEMBL1312879; QJTVTVAQRCRXSM-QGZVFWFLSA-N
DMA1EFL DT Small molecular drug
DMA1EFL PC 45254608
DMA1EFL MW 306.4
DMA1EFL FM C18H30N2O2
DMA1EFL IC InChI=1S/C18H30N2O2/c1-2-3-4-5-6-7-8-15-9-11-16(12-10-15)20-18(22)17(19)13-14-21/h9-12,17,21H,2-8,13-14,19H2,1H3,(H,20,22)/t17-/m1/s1
DMA1EFL CS CCCCCCCCC1=CC=C(C=C1)NC(=O)[C@@H](CCO)N
DMA1EFL IK QJTVTVAQRCRXSM-QGZVFWFLSA-N
DMA1EFL IU (2R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DMA1EFL DE Discovery agent
DMSY4CK ID DMSY4CK
DMSY4CK DN (R)-2-Amino-5-phosphono-pentanoic acid
DMSY4CK HS Investigative
DMSY4CK SN 76326-31-3; 5-Phosphononorvaline; DL-AP5; 2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphovaleric acid; DL-2-Amino-5-phosphonopentanoic acid; 2-Amino-5-phosphopentanoic acid; 2-Amino-5-phosphonovaleric Acid; 2-AMINO-5-PHOSPHONOVALERATE; DL-2-Amino-5-phosphonovaleric acid; dl-APV; 2-Amino-5-phosphonopentanoate; AP-5; Norvaline, 5-phosphono-; 76726-92-6; CHEMBL28862; CHEBI:138644; 2-Amino-5-phosphono-pentanoic acid; (+/-)-Amino-5-phosphono-pentanoic acid; (+/-)-2-Amino-5-phosphonopentanoic acid; App acid; C5H12NO5P; Apv acid
DMSY4CK DT Small molecular drug
DMSY4CK PC 1216
DMSY4CK MW 197.13
DMSY4CK FM C5H12NO5P
DMSY4CK IC InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)
DMSY4CK CS C(CC(C(=O)O)N)CP(=O)(O)O
DMSY4CK IK VOROEQBFPPIACJ-UHFFFAOYSA-N
DMSY4CK IU 2-amino-5-phosphonopentanoic acid
DMSY4CK CA CAS 76326-31-3
DMSY4CK CB CHEBI:138644
DMSY4CK DE Discovery agent
DM4XEHR ID DM4XEHR
DM4XEHR DN (R)-2-Amino-7-phosphono-heptanoic acid
DM4XEHR HS Investigative
DM4XEHR SN 81338-23-0; UNII-89FET0690I; (2R)-2-amino-7-phosphonoheptanoic acid; D(-)-2-Amino-7-phosphonoheptanoic acid; Heptanoic acid, 2-amino-7-phosphono-, (2R)-; CHEMBL302783; 89FET0690I; D-(-)-2-Amino-7-phosphonoheptanoic acid; (R)-AP7; D-(-)-2-Amino-7-phosphonoheptanoate; AC1LUTYN; Tocris-0164; Tocris-0104; Lopac-A-167; Lopac-A-5157; Lopac0_000157; SCHEMBL9848541; ZINC1856281; BDBM50017226; STL526509; BN0090; AKOS024456719; CCG-204252
DM4XEHR DT Small molecular drug
DM4XEHR PC 1617430
DM4XEHR MW 225.18
DM4XEHR FM C7H16NO5P
DM4XEHR IC InChI=1S/C7H16NO5P/c8-6(7(9)10)4-2-1-3-5-14(11,12)13/h6H,1-5,8H2,(H,9,10)(H2,11,12,13)/t6-/m1/s1
DM4XEHR CS C(CC[C@H](C(=O)O)N)CCP(=O)(O)O
DM4XEHR IK MYDMWESTDPJANS-ZCFIWIBFSA-N
DM4XEHR IU (2R)-2-amino-7-phosphonoheptanoic acid
DM4XEHR CA CAS 81338-23-0
DM4XEHR DE Discovery agent
DMT8HP1 ID DMT8HP1
DMT8HP1 DN (R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
DMT8HP1 HS Investigative
DMT8HP1 SN CHEMBL257915
DMT8HP1 DT Small molecular drug
DMT8HP1 PC 44456132
DMT8HP1 MW 203.32
DMT8HP1 FM C14H21N
DMT8HP1 IC InChI=1S/C14H21N/c1-12-5-3-7-14(11-12)8-10-15-9-4-6-13(15)2/h3,5,7,11,13H,4,6,8-10H2,1-2H3/t13-/m1/s1
DMT8HP1 CS C[C@@H]1CCCN1CCC2=CC=CC(=C2)C
DMT8HP1 IK PXZKWHANTMQGIH-CYBMUJFWSA-N
DMT8HP1 IU (2R)-2-methyl-1-[2-(3-methylphenyl)ethyl]pyrrolidine
DMT8HP1 DE Discovery agent
DMA1FUH ID DMA1FUH
DMA1FUH DN (R)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine
DMA1FUH HS Investigative
DMA1FUH SN CHEMBL403052
DMA1FUH DT Small molecular drug
DMA1FUH PC 44456127
DMA1FUH MW 203.32
DMA1FUH FM C14H21N
DMA1FUH IC InChI=1S/C14H21N/c1-12-5-7-14(8-6-12)9-11-15-10-3-4-13(15)2/h5-8,13H,3-4,9-11H2,1-2H3/t13-/m1/s1
DMA1FUH CS C[C@@H]1CCCN1CCC2=CC=C(C=C2)C
DMA1FUH IK BFMXEUSPYLVDSY-CYBMUJFWSA-N
DMA1FUH IU (2R)-2-methyl-1-[2-(4-methylphenyl)ethyl]pyrrolidine
DMA1FUH DE Discovery agent
DMRZDM0 ID DMRZDM0
DMRZDM0 DN (R)-3-(1'-Adamantanecarbonyl)amino-caprolactam
DMRZDM0 HS Investigative
DMRZDM0 SN CHEMBL512094
DMRZDM0 DT Small molecular drug
DMRZDM0 PC 44157844
DMRZDM0 MW 290.4
DMRZDM0 FM C17H26N2O2
DMRZDM0 IC InChI=1S/C17H26N2O2/c20-15-14(3-1-2-4-18-15)19-16(21)17-8-11-5-12(9-17)7-13(6-11)10-17/h11-14H,1-10H2,(H,18,20)(H,19,21)/t11?,12?,13?,14-,17?/m1/s1
DMRZDM0 CS C1CCNC(=O)[C@@H](C1)NC(=O)C23CC4CC(C2)CC(C4)C3
DMRZDM0 IK FRJOFURBYVCNEN-DLUQRMLASA-N
DMRZDM0 IU N-[(3R)-2-oxoazepan-3-yl]adamantane-1-carboxamide
DMRZDM0 DE Discovery agent
DMCSHI3 ID DMCSHI3
DMCSHI3 DN (R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DMCSHI3 HS Investigative
DMCSHI3 SN CHEMBL1080089; BDBM50311765; BDBM50074071; [(1R)-1-Methylpropyl]carbamic acid 3-(1H-imidazole-4-yl)propyl ester; ((R)-sec-Butyl)-carbamic acid 3-(1H-imidazol-4-yl)-propyl ester
DMCSHI3 DT Small molecular drug
DMCSHI3 PC 10680721
DMCSHI3 MW 225.29
DMCSHI3 FM C11H19N3O2
DMCSHI3 IC InChI=1S/C11H19N3O2/c1-3-9(2)14-11(15)16-6-4-5-10-7-12-8-13-10/h7-9H,3-6H2,1-2H3,(H,12,13)(H,14,15)/t9-/m1/s1
DMCSHI3 CS CC[C@@H](C)NC(=O)OCCCC1=CN=CN1
DMCSHI3 IK RSHJCGZZSGNBHO-SECBINFHSA-N
DMCSHI3 IU 3-(1H-imidazol-5-yl)propyl N-[(2R)-butan-2-yl]carbamate
DMCSHI3 DE Discovery agent
DMUFP7W ID DMUFP7W
DMUFP7W DN (R)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMUFP7W HS Investigative
DMUFP7W SN CHEMBL271226
DMUFP7W DT Small molecular drug
DMUFP7W PC 44455920
DMUFP7W MW 190.28
DMUFP7W FM C12H18N2
DMUFP7W IC InChI=1S/C12H18N2/c1-11-4-3-8-14(11)9-6-12-5-2-7-13-10-12/h2,5,7,10-11H,3-4,6,8-9H2,1H3/t11-/m1/s1
DMUFP7W CS C[C@@H]1CCCN1CCC2=CN=CC=C2
DMUFP7W IK WJLLZUXQRCOTAJ-LLVKDONJSA-N
DMUFP7W IU 3-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DMUFP7W DE Discovery agent
DM5TH2W ID DM5TH2W
DM5TH2W DN (R)-3-(2-naphthamido)-4-m-tolylbutanoic acid
DM5TH2W HS Investigative
DM5TH2W SN CHEMBL1091065; (R)-3-(2-naphthamido)-4-m-tolylbutanoic acid
DM5TH2W DT Small molecular drug
DM5TH2W PC 46884013
DM5TH2W MW 347.4
DM5TH2W FM C22H21NO3
DM5TH2W IC InChI=1S/C22H21NO3/c1-15-5-4-6-16(11-15)12-20(14-21(24)25)23-22(26)19-10-9-17-7-2-3-8-18(17)13-19/h2-11,13,20H,12,14H2,1H3,(H,23,26)(H,24,25)/t20-/m1/s1
DM5TH2W CS CC1=CC(=CC=C1)C[C@H](CC(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DM5TH2W IK LDUFWTJAUGDLSR-HXUWFJFHSA-N
DM5TH2W IU (3R)-4-(3-methylphenyl)-3-(naphthalene-2-carbonylamino)butanoic acid
DM5TH2W DE Discovery agent
DMQ2KF8 ID DMQ2KF8
DMQ2KF8 DN (R)-3-(4-Isobutyl-phenyl)-butan-2-one
DMQ2KF8 HS Investigative
DMQ2KF8 SN 2-Butanone,3-[4-(2-methylpropyl)phenyl]-,(3R)-; SCHEMBL4471196; CHEMBL371421; ZINC13646153
DMQ2KF8 DT Small molecular drug
DMQ2KF8 PC 9794254
DMQ2KF8 MW 204.31
DMQ2KF8 FM C14H20O
DMQ2KF8 IC InChI=1S/C14H20O/c1-10(2)9-13-5-7-14(8-6-13)11(3)12(4)15/h5-8,10-11H,9H2,1-4H3/t11-/m0/s1
DMQ2KF8 CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)C
DMQ2KF8 IK VOYZJYGIHFRNAG-NSHDSACASA-N
DMQ2KF8 IU (3R)-3-[4-(2-methylpropyl)phenyl]butan-2-one
DMQ2KF8 DE Discovery agent
DMC73DY ID DMC73DY
DMC73DY DN (R)-3-(4-propylmorpholin-2-yl)phenol
DMC73DY HS Investigative
DMC73DY SN CHEMBL250403; 710654-74-3; pf-219061; (R)-3-(4-propylmorpholin-2-yl)phenol; SCHEMBL2078437; DTXSID90430791; ZINC26822913; BDBM50226008; KB-274981
DMC73DY DT Small molecular drug
DMC73DY PC 9794475
DMC73DY MW 221.29
DMC73DY FM C13H19NO2
DMC73DY IC InChI=1S/C13H19NO2/c1-2-6-14-7-8-16-13(10-14)11-4-3-5-12(15)9-11/h3-5,9,13,15H,2,6-8,10H2,1H3/t13-/m0/s1
DMC73DY CS CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
DMC73DY IK WYEGTIGJSHGEID-ZDUSSCGKSA-N
DMC73DY IU 3-[(2R)-4-propylmorpholin-2-yl]phenol
DMC73DY CA CAS 710654-74-3
DMC73DY DE Discovery agent
DM2DVNT ID DM2DVNT
DM2DVNT DN (R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM2DVNT HS Investigative
DM2DVNT SN CHEMBL377707; (R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid; SCHEMBL6382413
DM2DVNT DT Small molecular drug
DM2DVNT PC 12985750
DM2DVNT MW 183.2
DM2DVNT FM C9H13NO3
DM2DVNT IC InChI=1S/C9H13NO3/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)/t7-/m1/s1
DM2DVNT CS C1=COC(=C1)C[C@H](CC(=O)O)CN
DM2DVNT IK JASKMEUWYOXVFB-SSDOTTSWSA-N
DM2DVNT IU (3R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM2DVNT DE Discovery agent
DM94B12 ID DM94B12
DM94B12 DN (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12 HS Investigative
DM94B12 SN CHEMBL469809; (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12 DT Small molecular drug
DM94B12 PC 44592119
DM94B12 MW 227.3
DM94B12 FM C15H17NO
DM94B12 IC InChI=1S/C15H17NO/c1-2-4-14-9-12(5-6-13(14)3-1)11-17-15-7-8-16-10-15/h1-6,9,15-16H,7-8,10-11H2/t15-/m1/s1
DM94B12 CS C1CNC[C@@H]1OCC2=CC3=CC=CC=C3C=C2
DM94B12 IK IQZVBBALTJFFCB-OAHLLOKOSA-N
DM94B12 IU (3R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM94B12 DE Discovery agent
DM98L2X ID DM98L2X
DM98L2X DN (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DM98L2X HS Investigative
DM98L2X SN (R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline; 179893-97-1; CHEMBL293023; (3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline; AC1OM1IT; (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL1690519; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-, (3R)-; UEKQPSAKUNXFHL-MRVPVSSYSA-N; ZINC19928405; FCH952510; BDBM50052885; AKOS024259472; AJ-75700
DM98L2X DT Small molecular drug
DM98L2X PC 7462300
DM98L2X MW 147.22
DM98L2X FM C10H13N
DM98L2X IC InChI=1S/C10H13N/c1-8-6-9-4-2-3-5-10(9)7-11-8/h2-5,8,11H,6-7H2,1H3/t8-/m1/s1
DM98L2X CS C[C@@H]1CC2=CC=CC=C2CN1
DM98L2X IK UEKQPSAKUNXFHL-MRVPVSSYSA-N
DM98L2X IU (3R)-3-methyl-1,2,3,4-tetrahydroisoquinoline
DM98L2X DE Discovery agent
DMPEV2W ID DMPEV2W
DMPEV2W DN (R)-3-Prop-2-ynylamino-indan-5-ol
DMPEV2W HS Investigative
DMPEV2W SN 5-Hydroxy-N-propargyl-1(R)-aminoindan; 5-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN; CHEMBL371428; 6-hydroxy-n-propargyl-1(r)-aminoindan; (3R)-3-(PROP-2-YNYLAMINO)INDAN-5-OL; (3R)-3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-ol; R-HPAI; AC1NRD0T; Aminoindan deriv (R)39u; SCHEMBL4188273; BDBM10799; 1H-Inden-5-ol, 2,3-dihydro-3-(2-propyn-1-ylamino)-, (3R)-; DB04307; 479206-03-6; 5-Hydroxy-N-Propargyl-1(R)-Aminoindan
DMPEV2W DT Small molecular drug
DMPEV2W PC 5289289
DMPEV2W MW 187.24
DMPEV2W FM C12H13NO
DMPEV2W IC InChI=1S/C12H13NO/c1-2-7-13-12-6-4-9-3-5-10(14)8-11(9)12/h1,3,5,8,12-14H,4,6-7H2/t12-/m1/s1
DMPEV2W CS C#CCN[C@@H]1CCC2=C1C=C(C=C2)O
DMPEV2W IK NRSDGDXUWMMUEV-GFCCVEGCSA-N
DMPEV2W IU (3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-ol
DMPEV2W DE Discovery agent
DM1Y9MZ ID DM1Y9MZ
DM1Y9MZ DN (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DM1Y9MZ HS Investigative
DM1Y9MZ SN CHEMBL186985; (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DM1Y9MZ DT Small molecular drug
DM1Y9MZ PC 15463450
DM1Y9MZ MW 172.29
DM1Y9MZ FM C8H16N2S
DM1Y9MZ IC InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)/t7-/m1/s1
DM1Y9MZ CS CCC[C@@H]1CSCCC(=N1)N
DM1Y9MZ IK SWOQAUBWIBZBLQ-SSDOTTSWSA-N
DM1Y9MZ IU (3R)-3-propyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DM1Y9MZ DE Discovery agent
DM5CL8B ID DM5CL8B
DM5CL8B DN (R)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DM5CL8B HS Investigative
DM5CL8B SN CHEMBL271722
DM5CL8B DT Small molecular drug
DM5CL8B PC 44456501
DM5CL8B MW 190.28
DM5CL8B FM C12H18N2
DM5CL8B IC InChI=1S/C12H18N2/c1-11-3-2-9-14(11)10-6-12-4-7-13-8-5-12/h4-5,7-8,11H,2-3,6,9-10H2,1H3/t11-/m1/s1
DM5CL8B CS C[C@@H]1CCCN1CCC2=CC=NC=C2
DM5CL8B IK HTPLEJUDOQHUSX-LLVKDONJSA-N
DM5CL8B IU 4-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DM5CL8B DE Discovery agent
DMRVOLN ID DMRVOLN
DMRVOLN DN (R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206)
DMRVOLN HS Investigative
DMRVOLN DE Discovery agent
DM3F56O ID DM3F56O
DM3F56O DN (R)-4-amino-2-methylbutanoic acid
DM3F56O HS Investigative
DM3F56O SN CHEMBL257443; 96192-37-9; (2R)-4-amino-2-methylbutanoic acid; Butanoic acid, 4-amino-2-methyl-, (2R)-; AC1LIBFM; SCHEMBL14518787; CTK3G8616; ZINC518267; (R)-2-Methyl-4-aminobutyric acid; BDBM50374650; AKOS006341386
DM3F56O DT Small molecular drug
DM3F56O PC 928194
DM3F56O MW 117.15
DM3F56O FM C5H11NO2
DM3F56O IC InChI=1S/C5H11NO2/c1-4(2-3-6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m1/s1
DM3F56O CS C[C@H](CCN)C(=O)O
DM3F56O IK AEBRINKRALSWNY-SCSAIBSYSA-N
DM3F56O IU (2R)-4-amino-2-methylbutanoic acid
DM3F56O DE Discovery agent
DMW87OE ID DMW87OE
DMW87OE DN (R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid
DMW87OE HS Investigative
DMW87OE SN CHEMBL62361; (R)-Homobaclofen; (R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid
DMW87OE DT Small molecular drug
DMW87OE PC 10491829
DMW87OE MW 227.69
DMW87OE FM C11H14ClNO2
DMW87OE IC InChI=1S/C11H14ClNO2/c12-10-3-1-8(2-4-10)9(5-6-13)7-11(14)15/h1-4,9H,5-7,13H2,(H,14,15)/t9-/m1/s1
DMW87OE CS C1=CC(=CC=C1[C@H](CCN)CC(=O)O)Cl
DMW87OE IK QXAGSDSDBMVSQR-SECBINFHSA-N
DMW87OE IU (3R)-5-amino-3-(4-chlorophenyl)pentanoic acid
DMW87OE DE Discovery agent
DMOESL1 ID DMOESL1
DMOESL1 DN (R)-5-diphosphomevalonate
DMOESL1 HS Investigative
DMOESL1 SN mevalonate 5-diphosphate
DMOESL1 DT Small molecular drug
DMOESL1 PC 439418
DMOESL1 MW 308.12
DMOESL1 FM C6H14O10P2
DMOESL1 IC InChI=1S/C6H14O10P2/c1-6(9,4-5(7)8)2-3-15-18(13,14)16-17(10,11)12/h9H,2-4H2,1H3,(H,7,8)(H,13,14)(H2,10,11,12)/t6-/m1/s1
DMOESL1 CS C[C@@](CCOP(=O)(O)OP(=O)(O)O)(CC(=O)O)O
DMOESL1 IK SIGQQUBJQXSAMW-ZCFIWIBFSA-N
DMOESL1 IU (3R)-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMOESL1 CA CAS 4872-34-8
DMOESL1 CB CHEBI:15899
DMOESL1 DE Discovery agent
DM3LQFK ID DM3LQFK
DM3LQFK DN (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
DM3LQFK HS Investigative
DM3LQFK SN CHEMBL1086032; (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline
DM3LQFK DT Small molecular drug
DM3LQFK PC 46890563
DM3LQFK MW 240.34
DM3LQFK FM C16H20N2
DM3LQFK IC InChI=1S/C16H20N2/c1-13-4-3-10-18(13)11-8-14-6-7-16-15(12-14)5-2-9-17-16/h2,5-7,9,12-13H,3-4,8,10-11H2,1H3/t13-/m1/s1
DM3LQFK CS C[C@@H]1CCCN1CCC2=CC3=C(C=C2)N=CC=C3
DM3LQFK IK HUQYUKHHFHNJRR-CYBMUJFWSA-N
DM3LQFK IU 6-[2-[(2R)-2-methylpyrrolidin-1-yl]ethyl]quinoline
DM3LQFK DE Discovery agent
DM134UV ID DM134UV
DM134UV DN (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM134UV HS Investigative
DM134UV SN CHEMBL506397; (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM134UV DT Small molecular drug
DM134UV PC 44592199
DM134UV MW 252.31
DM134UV FM C16H16N2O
DM134UV IC InChI=1S/C16H16N2O/c17-9-12-1-2-15-8-16(4-3-14(15)7-12)19-11-13-5-6-18-10-13/h1-4,7-8,13,18H,5-6,10-11H2/t13-/m1/s1
DM134UV CS C1CNC[C@@H]1COC2=CC3=C(C=C2)C=C(C=C3)C#N
DM134UV IK PYEILVKGQDUINV-CYBMUJFWSA-N
DM134UV IU 6-[[(3R)-pyrrolidin-3-yl]methoxy]naphthalene-2-carbonitrile
DM134UV DE Discovery agent
DMCY76E ID DMCY76E
DMCY76E DN (R)-8-phenyl-N,N-dipropylchroman-3-amine
DMCY76E HS Investigative
DMCY76E SN CHEMBL186112; (R)-8-phenyl-N,N-dipropylchroman-3-amine; BDBM50150676
DMCY76E DT Small molecular drug
DMCY76E PC 11267988
DMCY76E MW 309.4
DMCY76E FM C21H27NO
DMCY76E IC InChI=1S/C21H27NO/c1-3-13-22(14-4-2)19-15-18-11-8-12-20(21(18)23-16-19)17-9-6-5-7-10-17/h5-12,19H,3-4,13-16H2,1-2H3/t19-/m1/s1
DMCY76E CS CCCN(CCC)[C@@H]1CC2=C(C(=CC=C2)C3=CC=CC=C3)OC1
DMCY76E IK OYEKUFKQGCYWCG-LJQANCHMSA-N
DMCY76E IU (3R)-8-phenyl-N,N-dipropyl-3,4-dihydro-2H-chromen-3-amine
DMCY76E DE Discovery agent
DMKAW4P ID DMKAW4P
DMKAW4P DN (R)-alpha-methylhistamine
DMKAW4P HS Investigative
DMKAW4P SN (R)-alpha-Methylhistamine; CHEBI:73337; r-alpha-methylhistamine; (R)alpha-Me-histamine; CHEMBL268229; (R)-(-)-alpha-methylhistamine; (2R)-1-(1H-imidazol-4-yl)propan-2-amine; 75614-87-8; 1H-Imidazole-4-ethanamine, alpha-methyl-, (alphaR)-; (R)-(-)-4-(2-aminopropyl)imidazole; (2R)-1-(3H-imidazol-4-yl)propan-2-amine; (2R)-1-(1H-imidazol-5-yl)propan-2-amine; Alpha-Methylhistamine-R; C6H11N3; [3H]-R-alpha-Methylhistamine; (R)-[3H]alpha-methylhistamine; [3H](R)-alpha-methylhistamine
DMKAW4P DT Small molecular drug
DMKAW4P PC 156615
DMKAW4P MW 125.17
DMKAW4P FM C6H11N3
DMKAW4P IC InChI=1S/C6H11N3/c1-5(7)2-6-3-8-4-9-6/h3-5H,2,7H2,1H3,(H,8,9)/t5-/m1/s1
DMKAW4P CS C[C@H](CC1=CN=CN1)N
DMKAW4P IK XNQIOISZPFVUFG-RXMQYKEDSA-N
DMKAW4P IU (2R)-1-(1H-imidazol-5-yl)propan-2-amine
DMKAW4P CA CAS 75614-87-8
DMKAW4P CB CHEBI:73337
DMKAW4P DE Discovery agent
DMECK7H ID DMECK7H
DMECK7H DN (R)-DULOXETINE
DMECK7H HS Investigative
DMECK7H SN (R)-duloxetine; Duloxetine, (R)-; 116539-60-7; UNII-TK9VOT90JQ; R-Duloxetine HCl; TK9VOT90JQ; CHEMBL336920; CHEBI:36797; (3R)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3R)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; Duloxetine impurity A; Ariclaim; Duloxetine hydrochloride impurity A [EP]; Duloxetine hydrochloride specified impurity A [EP]; SCHEMBL1200511; (r)-n-methyl-3-(1-naphthoxy)-3-(2-thienyl)propylamine; DTXSID40151424; ZINC1536780; PDSP1_000970
DMECK7H DT Small molecular drug
DMECK7H PC 10334821
DMECK7H MW 297.4
DMECK7H FM C18H19NOS
DMECK7H IC InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m1/s1
DMECK7H CS CNCC[C@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
DMECK7H IK ZEUITGRIYCTCEM-QGZVFWFLSA-N
DMECK7H IU (3R)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DMECK7H CA CAS 116539-60-7
DMECK7H CB CHEBI:36797
DMECK7H DE Discovery agent
DM297MU ID DM297MU
DM297MU DN (R)-EF-1520
DM297MU HS Investigative
DM297MU SN (R)-EF-1520; GTPL6512
DM297MU DT Small molecular drug
DM297MU PC 53321930
DM297MU MW 414.6
DM297MU FM C22H26N2O2S2
DM297MU IC InChI=1S/C22H26N2O2S2/c1-14-9-12-27-20(14)16(21-15(2)10-13-28-21)6-5-11-24(3)17-7-4-8-18-19(17)22(25)23-26-18/h6,9-10,12-13,17H,4-5,7-8,11H2,1-3H3,(H,23,25)/t17-/m1/s1
DM297MU CS CC1=C(SC=C1)C(=CCCN(C)[C@@H]2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
DM297MU IK CUESOMOCKVRNIW-QGZVFWFLSA-N
DM297MU IU (4R)-4-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl-methylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DM297MU DE Discovery agent
DM2KBOU ID DM2KBOU
DM2KBOU DN (R)-flurocarazolol
DM2KBOU HS Investigative
DM2KBOU SN (R)-flurocarazolol; GTPL65; CHEMBL418834; PDSP2_000795; PDSP1_000808
DM2KBOU DT Small molecular drug
DM2KBOU PC 9995893
DM2KBOU MW 316.4
DM2KBOU FM C18H21FN2O2
DM2KBOU IC InChI=1S/C18H21FN2O2/c1-12(9-19)20-10-13(22)11-23-17-8-4-7-16-18(17)14-5-2-3-6-15(14)21-16/h2-8,12-13,20-22H,9-11H2,1H3/t12?,13-/m1/s1
DM2KBOU CS CC(CF)NC[C@H](COC1=CC=CC2=C1C3=CC=CC=C3N2)O
DM2KBOU IK QHLGXPUIUKSADT-ZGTCLIOFSA-N
DM2KBOU IU (2R)-1-(9H-carbazol-4-yloxy)-3-(1-fluoropropan-2-ylamino)propan-2-ol
DM2KBOU DE Discovery agent
DMKFPMC ID DMKFPMC
DMKFPMC DN (R)-Indan-1-yl-methyl-prop-2-ynyl-amine
DMKFPMC HS Investigative
DMKFPMC SN Indan-1-yl-methyl-prop-2-ynyl-amine
DMKFPMC DE Discovery agent
DMEXLUR ID DMEXLUR
DMEXLUR DN (R)-Mevalonate
DMEXLUR HS Investigative
DMEXLUR SN (R)-mevalonate; mevalonate; mevalonic acid; (3R)-3,5-dihydroxy-3-methylpentanoate; AC1NRC4P; GTPL3042; CHEBI:36464; CTK4B1152; DTXSID50415347
DMEXLUR DT Small molecular drug
DMEXLUR PC 5288798
DMEXLUR MW 147.15
DMEXLUR FM C6H11O4-
DMEXLUR IC InChI=1S/C6H12O4/c1-6(10,2-3-7)4-5(8)9/h7,10H,2-4H2,1H3,(H,8,9)/p-1/t6-/m1/s1
DMEXLUR CS C[C@@](CCO)(CC(=O)[O-])O
DMEXLUR IK KJTLQQUUPVSXIM-ZCFIWIBFSA-M
DMEXLUR IU (3R)-3,5-dihydroxy-3-methylpentanoate
DMEXLUR CB CHEBI:36464
DMEXLUR DE Discovery agent
DMPKWIN ID DMPKWIN
DMPKWIN DN (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide
DMPKWIN HS Investigative
DMPKWIN SN CHEMBL242835; (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide; SCHEMBL2185997
DMPKWIN DT Small molecular drug
DMPKWIN PC 23625205
DMPKWIN MW 318.8
DMPKWIN FM C17H19ClN2O2
DMPKWIN IC InChI=1S/C17H19ClN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m1/s1
DMPKWIN CS C[C@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)Cl
DMPKWIN IK JFADNUHMEURSIM-GFCCVEGCSA-N
DMPKWIN IU (2R)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide
DMPKWIN DE Discovery agent
DMEVM6G ID DMEVM6G
DMEVM6G DN (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide
DMEVM6G HS Investigative
DMEVM6G SN CHEMBL244771; (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide; SCHEMBL2017087
DMEVM6G DT Small molecular drug
DMEVM6G PC 11382066
DMEVM6G MW 334.8
DMEVM6G FM C17H19ClN2O3
DMEVM6G IC InChI=1S/C17H19ClN2O3/c18-14-3-1-2-13(8-14)11-23-15-6-4-12(5-7-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m1/s1
DMEVM6G CS C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CN[C@H](CO)C(=O)N
DMEVM6G IK WYDCYPPIJUASJE-MRXNPFEDSA-N
DMEVM6G IU (2R)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMEVM6G DE Discovery agent
DMU49JN ID DMU49JN
DMU49JN DN (R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide
DMU49JN HS Investigative
DMU49JN SN CHEMBL82327; 174756-44-6; (R)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamide; AC1NUPG0; SCHEMBL194169; CHEBI:94774; BDBM50080950; ZINC26506755; AKOS030631890; AN-31998; BRD-K84639753-066-01-9; (R)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide
DMU49JN DT Small molecular drug
DMU49JN PC 5487407
DMU49JN MW 302.34
DMU49JN FM C17H19FN2O2
DMU49JN IC InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m1/s1
DMU49JN CS C[C@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
DMU49JN IK NEMGRZFTLSKBAP-GFCCVEGCSA-N
DMU49JN IU (2R)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
DMU49JN CB CHEBI:94774
DMU49JN DE Discovery agent
DMM8TE0 ID DMM8TE0
DMM8TE0 DN (R)-N-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline
DMM8TE0 HS Investigative
DMM8TE0 SN N-Benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline; N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline; CHEMBL570775; SCHEMBL4314176; HITMFLNAOQIZSN-QGZVFWFLSA-N; BDBM50294163; DB07260
DMM8TE0 DT Small molecular drug
DMM8TE0 PC 44129620
DMM8TE0 MW 282.4
DMM8TE0 FM C18H22N2O
DMM8TE0 IC InChI=1S/C18H22N2O/c1-2-5-15(6-3-1)13-20-16-8-10-18(11-9-16)21-14-17-7-4-12-19-17/h1-3,5-6,8-11,17,19-20H,4,7,12-14H2/t17-/m1/s1
DMM8TE0 CS C1C[C@@H](NC1)COC2=CC=C(C=C2)NCC3=CC=CC=C3
DMM8TE0 IK HITMFLNAOQIZSN-QGZVFWFLSA-N
DMM8TE0 IU N-benzyl-4-[[(2R)-pyrrolidin-2-yl]methoxy]aniline
DMM8TE0 DE Discovery agent
DMWRIQG ID DMWRIQG
DMWRIQG DN (R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide
DMWRIQG HS Investigative
DMWRIQG SN CHEMBL190266; ZINC5284667; UNII-O3LD16O96Z component BYPIURIATSUHDW-SNVBAGLBSA-N
DMWRIQG DT Small molecular drug
DMWRIQG PC 11458696
DMWRIQG MW 221.29
DMWRIQG FM C13H19NO2
DMWRIQG IC InChI=1S/C13H19NO2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(15)14-16/h4-7,9-10,16H,8H2,1-3H3,(H,14,15)/t10-/m1/s1
DMWRIQG CS C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NO
DMWRIQG IK BYPIURIATSUHDW-SNVBAGLBSA-N
DMWRIQG IU (2R)-N-hydroxy-2-[4-(2-methylpropyl)phenyl]propanamide
DMWRIQG DE Discovery agent
DMWGB40 ID DMWGB40
DMWGB40 DN (R)-nipecotic acid
DMWGB40 HS Investigative
DMWGB40 SN (R)-piperidine-3-carboxylic acid; 25137-00-2; (R)-(-)-Nipecotic acid; (3R)-piperidine-3-carboxylic acid; (R)-(-)-3-Piperidinecarboxylic acid; (-)-nipecotic acid; (3R)-nipecotic acid; (3R)-(-)-piperidine-3-carboxylic acid; D(-)-Nipecotic acid; r-(-)-3-piperidinecarboxylic acid; 3-Piperidinecarboxylic acid, (R)-; (R)-hexahydronicotinic acid; (R)-(-)-piperidine-3-carboxylic acid; (-)-hexahydronicotinic acid; (3R)-hexahydronicotinic acid; CHEMBL77575; (r)-3-piperidinecarboxylic acid
DMWGB40 DT Small molecular drug
DMWGB40 PC 1796510
DMWGB40 MW 129.16
DMWGB40 FM C6H11NO2
DMWGB40 IC InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)/t5-/m1/s1
DMWGB40 CS C1C[C@H](CNC1)C(=O)O
DMWGB40 IK XJLSEXAGTJCILF-RXMQYKEDSA-N
DMWGB40 IU (3R)-piperidine-3-carboxylic acid
DMWGB40 CA CAS 25137-00-2
DMWGB40 CB CHEBI:60120
DMWGB40 DE Discovery agent
DMJFH97 ID DMJFH97
DMJFH97 DN (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMJFH97 HS Investigative
DMJFH97 SN CHEMBL577283; (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide; SCHEMBL6416013
DMJFH97 DT Small molecular drug
DMJFH97 PC 11323940
DMJFH97 MW 296.4
DMJFH97 FM C19H24N2O
DMJFH97 IC InChI=1S/C19H24N2O/c1-14(2)13-21(18-9-10-20-12-18)19(22)17-8-7-15-5-3-4-6-16(15)11-17/h3-8,11,14,18,20H,9-10,12-13H2,1-2H3/t18-/m1/s1
DMJFH97 CS CC(C)CN([C@@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
DMJFH97 IK CEUJKSVEPJAVKD-GOSISDBHSA-N
DMJFH97 IU N-(2-methylpropyl)-N-[(3R)-pyrrolidin-3-yl]naphthalene-2-carboxamide
DMJFH97 DE Discovery agent
DMQIUOB ID DMQIUOB
DMQIUOB DN (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMQIUOB HS Investigative
DMQIUOB SN CHEMBL565639; (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMQIUOB DT Small molecular drug
DMQIUOB PC 45487774
DMQIUOB MW 282.4
DMQIUOB FM C18H22N2O
DMQIUOB IC InChI=1S/C18H22N2O/c1-13(2)20(17-9-10-19-12-17)18(21)16-8-7-14-5-3-4-6-15(14)11-16/h3-8,11,13,17,19H,9-10,12H2,1-2H3/t17-/m1/s1
DMQIUOB CS CC(C)N([C@@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
DMQIUOB IK ZQHFQDYTXXQENI-QGZVFWFLSA-N
DMQIUOB IU N-propan-2-yl-N-[(3R)-pyrrolidin-3-yl]naphthalene-2-carboxamide
DMQIUOB DE Discovery agent
DMIHR14 ID DMIHR14
DMIHR14 DN (R)-N-oleoyltyrosinol
DMIHR14 HS Investigative
DMIHR14 SN (R)-N-oleoyltyrosinol; GTPL5720; 616884-63-0; ZINC95862771
DMIHR14 DT Small molecular drug
DMIHR14 PC 73755147
DMIHR14 MW 431.7
DMIHR14 FM C27H45NO3
DMIHR14 IC InChI=1S/C27H45NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(31)28-25(23-29)22-24-18-20-26(30)21-19-24/h9-10,18-21,25,29-30H,2-8,11-17,22-23H2,1H3,(H,28,31)/b10-9+/t25-/m1/s1
DMIHR14 CS CCCCCCCC/C=C/CCCCCCCC(=O)N[C@H](CC1=CC=C(C=C1)O)CO
DMIHR14 IK ICDMLAQPOAVWNH-YHZGQTRVSA-N
DMIHR14 IU (E)-N-[(2R)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide
DMIHR14 DE Discovery agent
DMS30KU ID DMS30KU
DMS30KU DN (R)-Norfluoxetine
DMS30KU HS Investigative
DMS30KU SN 130194-43-3; UNII-05UQ1299DN; (R)-3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine; CHEMBL446084; 05UQ1299DN; (R)-3-(4-Trifluoromethylphenoxy)-3-phenylpropylamine; Norfluoxetine, (R)-; (3r)-3-Phenyl-3-[4-(Trifluoromethyl)phenoxy]propan-1-Amine; R-Norfluoxetine; SCHEMBL3750512; CTK8E9557; MolPort-028-616-048; ZINC1645453; Benzenepropanamine, gamma-(4-(trifluoromethyl)phenoxy)-, (gammaR)-; BDBM50254791; 9049AH; AKOS027384575; NE64378; AJ-28674; RT-014016; FT-0673087; J-005760
DMS30KU DT Small molecular drug
DMS30KU PC 9797657
DMS30KU MW 295.3
DMS30KU FM C16H16F3NO
DMS30KU IC InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m1/s1
DMS30KU CS C1=CC=C(C=C1)[C@@H](CCN)OC2=CC=C(C=C2)C(F)(F)F
DMS30KU IK WIQRCHMSJFFONW-OAHLLOKOSA-N
DMS30KU IU (3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DMS30KU CA CAS 130194-43-3
DMS30KU DE Discovery agent
DMCYD8Q ID DMCYD8Q
DMCYD8Q DN (R)-ONDANSETRON
DMCYD8Q HS Investigative
DMCYD8Q SN Ondansetron, (3R)-; UNII-8KTH918W9P; CHEMBL428411; 8KTH918W9P; 99614-60-5; 3R-Ondansetron [MI]; Ondansetron (base and/or unspecified salts); AC1LDIAR; SCHEMBL848379; ZINC4448; DTXSID20244166; BDBM50241365; PDSP1_000036; PDSP2_000036; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, (R)-; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, (3R)-; UNII-4AF302ESOS component FELGMEQIXOGIFQ-CYBMUJFWSA-N
DMCYD8Q DT Small molecular drug
DMCYD8Q PC 667538
DMCYD8Q MW 293.4
DMCYD8Q FM C18H19N3O
DMCYD8Q IC InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3/t13-/m1/s1
DMCYD8Q CS CC1=NC=CN1C[C@H]2CCC3=C(C2=O)C4=CC=CC=C4N3C
DMCYD8Q IK FELGMEQIXOGIFQ-CYBMUJFWSA-N
DMCYD8Q IU (3R)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
DMCYD8Q CA CAS 99614-60-5
DMCYD8Q DE Discovery agent
DM03N5V ID DM03N5V
DM03N5V DN (R)PK-11195
DM03N5V HS Investigative
DM03N5V SN N-[(2r)-Butan-2-Yl]-1-(2-Chlorophenyl)-N-Methylisoquinoline-3-Carboxamide; CHEMBL416715; SCHEMBL3126094; ZINC3870481; BDBM50054139; (R)-PK11195; LS-85395; B6401; UNII-YNF83VN1RL component RAVIZVQZGXBOQO-CQSZACIVSA-N; (R)1-(2-Chloro-phenyl)-isoquinoline-3-carboxylic acid sec-butyl-methyl-amide
DM03N5V DT Small molecular drug
DM03N5V PC 24839733
DM03N5V MW 352.9
DM03N5V FM C21H21ClN2O
DM03N5V IC InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3/t14-/m1/s1
DM03N5V CS CC[C@@H](C)N(C)C(=O)C1=CC2=CC=CC=C2C(=N1)C3=CC=CC=C3Cl
DM03N5V IK RAVIZVQZGXBOQO-CQSZACIVSA-N
DM03N5V IU N-[(2R)-butan-2-yl]-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide
DM03N5V DE Discovery agent
DM95Z4Q ID DM95Z4Q
DM95Z4Q DN (R)-Rolipram
DM95Z4Q HS Investigative
DM95Z4Q SN (R)-(-)-Rolipram; 85416-75-7; (R)-ROLIPRAM; (4R)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE; R-Rolipram; UNII-DPX51KUP08; DPX51KUP08; CHEMBL430893; CHEBI:40133; 1xmy; NCGC00016899-01; CAS-61413-54-5; Tocris-1349; Tocris-0905; Tocris-1350; PubChem18284; 1ro6; 3g4k; 1q9m; AC1L9LJS; Lopac-R-6520; SCHEMBL576805; ZINC4982; KS-00000QDB; MolPort-003-983-801; HMS3267P19; BCP14111
DM95Z4Q DT Small molecular drug
DM95Z4Q PC 448055
DM95Z4Q MW 275.34
DM95Z4Q FM C16H21NO3
DM95Z4Q IC InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m0/s1
DM95Z4Q CS COC1=C(C=C(C=C1)[C@H]2CC(=O)NC2)OC3CCCC3
DM95Z4Q IK HJORMJIFDVBMOB-LBPRGKRZSA-N
DM95Z4Q IU (4R)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
DM95Z4Q CA CAS 85416-75-7
DM95Z4Q CB CHEBI:40133
DM95Z4Q DE Discovery agent
DMV1IS8 ID DMV1IS8
DMV1IS8 DN (R)-sirtinol
DMV1IS8 HS Investigative
DMV1IS8 DT Small molecular drug
DMV1IS8 PC 1376646
DMV1IS8 MW 394.5
DMV1IS8 FM C26H22N2O2
DMV1IS8 IC InChI=1S/C26H22N2O2/c1-18(19-9-3-2-4-10-19)28-26(30)22-13-7-8-14-24(22)27-17-23-21-12-6-5-11-20(21)15-16-25(23)29/h2-18,29H,1H3,(H,28,30)/t18-/m1/s1
DMV1IS8 CS C[C@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2N=CC3=C(C=CC4=CC=CC=C43)O
DMV1IS8 IK UXJFDYIHRJGPFS-GOSISDBHSA-N
DMV1IS8 IU 2-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-[(1R)-1-phenylethyl]benzamide
DMV1IS8 DE Discovery agent
DMSFA2D ID DMSFA2D
DMSFA2D DN (R)-tacrine(10)-hupyridone
DMSFA2D HS Investigative
DMSFA2D SN (R)-TACRINE(10)-HUPYRIDONE; (5R)-5-{[10-(1,2,3,4-TETRAHYDROACRIDIN-9-YLAMINO)DECYL]AMINO}-5,6,7,8-TETRAHYDROQUINOLIN-2(1H)-ONE; A1E; 1zgb; AC1NS1ED; DB04614; (R)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE; (5R)-5-[10-(1,2,3,4-Tetrahydroacridine-9-ylamino)decylamino]-1,2,5,6,7,8-hexahydroquinoline-2-one; (R)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE; (R)-TACRINE(10)-HUPYRIDONE
DMSFA2D DT Small molecular drug
DMSFA2D PC 5326966
DMSFA2D MW 500.7
DMSFA2D FM C32H44N4O
DMSFA2D IC InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)/t27-/m1/s1
DMSFA2D CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCCCN[C@@H]4CCCC5=C4C=CC(=O)N5
DMSFA2D IK ROTFGKJJMRTWBD-HHHXNRCGSA-N
DMSFA2D IU (5R)-5-[10-(1,2,3,4-tetrahydroacridin-9-ylamino)decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMSFA2D DE Discovery agent
DMT6J51 ID DMT6J51
DMT6J51 DN (R)-zacopride
DMT6J51 HS Investigative
DMT6J51 SN CHEMBL27846; UNII-38126EQF7A; 38126EQF7A; ZACOPRIDE,S; r-zacopride; (R)ZACOPRIDE; (R)-(+)-Zacopride; ZINC848; GTPL2288; SCHEMBL5387843; BDBM50031475; PDSP2_001683; PDSP1_001700; UNII-9GN3OT4156 component FEROPKNOYKURCJ-ZDUSSCGKSA-N; 4-Amino-N-(R)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(8R)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide
DMT6J51 DT Small molecular drug
DMT6J51 PC 9819593
DMT6J51 MW 309.79
DMT6J51 FM C15H20ClN3O2
DMT6J51 IC InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20)/t13-/m0/s1
DMT6J51 CS COC1=CC(=C(C=C1C(=O)N[C@H]2CN3CCC2CC3)Cl)N
DMT6J51 IK FEROPKNOYKURCJ-ZDUSSCGKSA-N
DMT6J51 IU 4-amino-N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide
DMT6J51 CA CAS 123441-85-0
DMT6J51 DE Discovery agent
DMCW5A9 ID DMCW5A9
DMCW5A9 DN (R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid
DMCW5A9 HS Investigative
DMCW5A9 SN CHEMBL1090714; (2R,4E)-2-[(naphthalen-2-ylcarbonyl)amino]-5-phenylpent-4-enoic acid; (R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid; SCHEMBL16550527; SCHEMBL16550525; BDBM50314705
DMCW5A9 DT Small molecular drug
DMCW5A9 PC 45100499
DMCW5A9 MW 345.4
DMCW5A9 FM C22H19NO3
DMCW5A9 IC InChI=1S/C22H19NO3/c24-21(19-14-13-17-10-4-5-11-18(17)15-19)23-20(22(25)26)12-6-9-16-7-2-1-3-8-16/h1-11,13-15,20H,12H2,(H,23,24)(H,25,26)/b9-6+/t20-/m1/s1
DMCW5A9 CS C1=CC=C(C=C1)/C=C/C[C@H](C(=O)O)NC(=O)C2=CC3=CC=CC=C3C=C2
DMCW5A9 IK OOTIJYFZZMIZHN-AQDCRGGLSA-N
DMCW5A9 IU (E,2R)-2-(naphthalene-2-carbonylamino)-5-phenylpent-4-enoic acid
DMCW5A9 DE Discovery agent
DM3FQYS ID DM3FQYS
DM3FQYS DN (R,R)-(-)-fenoterol
DM3FQYS HS Investigative
DM3FQYS SN UNII-5Z64M7W0JM; CHEMBL388570; 5Z64M7W0JM; R,R-Fenoterol; Fenoterol, R,R'-; Men 1191; Fenoterol [MI]; Fenoterol [INN]; (R,R)-Fenoterol; Fenoterol [USAN]; Fenoterol [VANDF]; Fenoterol [MART.]; (R,R')-Fenoterol; Fenoterol [WHO-DD]; AC1LEM52; 69421-37-0; SCHEMBL249376; ZINC57320; BDBM50213098; 130156-24-0; UNII-22M9P70OQ9 component LSLYOANBFKQKPT-DIFFPNOSSA-N; 5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DM3FQYS DT Small molecular drug
DM3FQYS PC 688468
DM3FQYS MW 303.35
DM3FQYS FM C17H21NO4
DM3FQYS IC InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3/t11-,17+/m1/s1
DM3FQYS CS C[C@H](CC1=CC=C(C=C1)O)NC[C@@H](C2=CC(=CC(=C2)O)O)O
DM3FQYS IK LSLYOANBFKQKPT-DIFFPNOSSA-N
DM3FQYS IU 5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DM3FQYS CA CAS 69421-37-0
DM3FQYS DE Discovery agent
DMETQBI ID DMETQBI
DMETQBI DN (R,S)-(-)-fenoterol
DMETQBI HS Investigative
DMETQBI SN CHEMBL229476; (R,S)-(-)-fenoterol; (R,S)-Fenoterol; AC1LEM4Z; SCHEMBL9971022; ZINC57319; BDBM50213106; 5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMETQBI DT Small molecular drug
DMETQBI PC 688467
DMETQBI MW 303.35
DMETQBI FM C17H21NO4
DMETQBI IC InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3/t11-,17-/m0/s1
DMETQBI CS C[C@@H](CC1=CC=C(C=C1)O)NC[C@@H](C2=CC(=CC(=C2)O)O)O
DMETQBI IK LSLYOANBFKQKPT-GTNSWQLSSA-N
DMETQBI IU 5-[(1R)-1-hydroxy-2-[[(2S)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMETQBI DE Discovery agent
DMKZ4C6 ID DMKZ4C6
DMKZ4C6 DN (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine
DMKZ4C6 HS Investigative
DMKZ4C6 SN CHEMBL276673; 1H-Indole-1-ethanamine, 5-bromo-alpha-methyl-; (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine; SCHEMBL8959875; BDBM50321879; 169675-12-1
DMKZ4C6 DT Small molecular drug
DMKZ4C6 PC 10753358
DMKZ4C6 MW 253.14
DMKZ4C6 FM C11H13BrN2
DMKZ4C6 IC InChI=1S/C11H13BrN2/c1-8(13)7-14-5-4-9-6-10(12)2-3-11(9)14/h2-6,8H,7,13H2,1H3
DMKZ4C6 CS CC(CN1C=CC2=C1C=CC(=C2)Br)N
DMKZ4C6 IK UOWVUNAMIYCETC-UHFFFAOYSA-N
DMKZ4C6 IU 1-(5-bromoindol-1-yl)propan-2-amine
DMKZ4C6 DE Discovery agent
DMTZDAJ ID DMTZDAJ
DMTZDAJ DN (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine
DMTZDAJ HS Investigative
DMTZDAJ SN CHEMBL328844; 1H-Indole-1-ethanamine, 5-chloro-alpha-methyl-; (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine; SCHEMBL7092716; BDBM50321880; 169674-96-8
DMTZDAJ DT Small molecular drug
DMTZDAJ PC 9855823
DMTZDAJ MW 208.69
DMTZDAJ FM C11H13ClN2
DMTZDAJ IC InChI=1S/C11H13ClN2/c1-8(13)7-14-5-4-9-6-10(12)2-3-11(9)14/h2-6,8H,7,13H2,1H3
DMTZDAJ CS CC(CN1C=CC2=C1C=CC(=C2)Cl)N
DMTZDAJ IK XXCLNSYNUQMDML-UHFFFAOYSA-N
DMTZDAJ IU 1-(5-chloroindol-1-yl)propan-2-amine
DMTZDAJ DE Discovery agent
DMAU1M5 ID DMAU1M5
DMAU1M5 DN (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine
DMAU1M5 HS Investigative
DMAU1M5 SN CHEMBL96883; 1H-Indole-1-ethanamine, 5-fluoro-alpha-methyl-; (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine; SCHEMBL7994160; BDBM50321881; 169674-98-0
DMAU1M5 DT Small molecular drug
DMAU1M5 PC 9964324
DMAU1M5 MW 192.23
DMAU1M5 FM C11H13FN2
DMAU1M5 IC InChI=1S/C11H13FN2/c1-8(13)7-14-5-4-9-6-10(12)2-3-11(9)14/h2-6,8H,7,13H2,1H3
DMAU1M5 CS CC(CN1C=CC2=C1C=CC(=C2)F)N
DMAU1M5 IK DUUXOYARAAZWLV-UHFFFAOYSA-N
DMAU1M5 IU 1-(5-fluoroindol-1-yl)propan-2-amine
DMAU1M5 DE Discovery agent
DMS2DI9 ID DMS2DI9
DMS2DI9 DN (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine
DMS2DI9 HS Investigative
DMS2DI9 SN CHEMBL93850; (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine; SCHEMBL9233990; BDBM50321882
DMS2DI9 DT Small molecular drug
DMS2DI9 PC 10845306
DMS2DI9 MW 188.27
DMS2DI9 FM C12H16N2
DMS2DI9 IC InChI=1S/C12H16N2/c1-9-3-4-12-11(7-9)5-6-14(12)8-10(2)13/h3-7,10H,8,13H2,1-2H3
DMS2DI9 CS CC1=CC2=C(C=C1)N(C=C2)CC(C)N
DMS2DI9 IK WETMFNBRIOBNTK-UHFFFAOYSA-N
DMS2DI9 IU 1-(5-methylindol-1-yl)propan-2-amine
DMS2DI9 DE Discovery agent
DM0YELX ID DM0YELX
DM0YELX DN (R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine
DM0YELX HS Investigative
DM0YELX SN 1H-Indole-1-ethanamine, 6-fluoro-alpha-methyl-; CHEMBL92656; SCHEMBL8959596
DM0YELX DT Small molecular drug
DM0YELX PC 10679289
DM0YELX MW 192.23
DM0YELX FM C11H13FN2
DM0YELX IC InChI=1S/C11H13FN2/c1-8(13)7-14-5-4-9-2-3-10(12)6-11(9)14/h2-6,8H,7,13H2,1H3
DM0YELX CS CC(CN1C=CC2=C1C=C(C=C2)F)N
DM0YELX IK WZMZEXSQEAPONX-UHFFFAOYSA-N
DM0YELX IU 1-(6-fluoroindol-1-yl)propan-2-amine
DM0YELX DE Discovery agent
DM7COSH ID DM7COSH
DM7COSH DN (R,S)-4-phosphonophenylglycine
DM7COSH HS Investigative
DM7COSH SN (RS)-PPG; 120667-15-4; 2-amino-2-(4-phosphonophenyl)acetic acid; CHEMBL277475; AC1ND7MS; (RS)PPG; (RS) PPG; C8H10NO5P; (RS)-4-Phosphonophenylglycine; GTPL1406; SCHEMBL9150881; CTK8F0597; (R,S)-4-PPG; MolPort-003-983-668; BN0429; BDBM50004881; AKOS015911887; Amino-(4-phosphono-phenyl)-acetic acid; NCGC00025051-02; RT-015313; V2034; Amino-(4-phosphono-phenyl)-acetic acid(RS-PPG); SR-01000597406; 667P154; L000025; SR-01000597406-1; J-004376
DM7COSH DT Small molecular drug
DM7COSH PC 4545574
DM7COSH MW 231.14
DM7COSH FM C8H10NO5P
DM7COSH IC InChI=1S/C8H10NO5P/c9-7(8(10)11)5-1-3-6(4-2-5)15(12,13)14/h1-4,7H,9H2,(H,10,11)(H2,12,13,14)
DM7COSH CS C1=CC(=CC=C1C(C(=O)O)N)P(=O)(O)O
DM7COSH IK JRQRKFDFHAPMGQ-UHFFFAOYSA-N
DM7COSH IU 2-amino-2-(4-phosphonophenyl)acetic acid
DM7COSH DE Discovery agent
DMUG451 ID DMUG451
DMUG451 DN (R,S)-homoaromaline hydrochloride
DMUG451 HS Investigative
DMUG451 SN CHEMBL443953; (R,S)-Homoaromaline HCl
DMUG451 DT Small molecular drug
DMUG451 PC 9851833
DMUG451 MW 608.7
DMUG451 FM C37H40N2O6
DMUG451 IC InChI=1S/C37H40N2O6/c1-38-14-12-24-19-31(42-4)33-21-27(24)28(38)17-23-8-11-30(41-3)32(18-23)44-26-9-6-22(7-10-26)16-29-35-25(13-15-39(29)2)20-34(43-5)36(40)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m0/s1
DMUG451 CS CN1CCC2=CC(=C(C3=C2[C@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=CC(=C(C=C7CCN6C)OC)O3)OC)O)OC
DMUG451 IK YJRWQNIRFXVBRB-URLMMPGGSA-N
DMUG451 IU (1S,14R)-6,20,25-trimethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.29,12.13,7.114,18.027,31.022,33]hexatriaconta-3(36),4,6,9(35),10,12(34),18,20,22(33),24,26,31-dodecaen-21-ol
DMUG451 DE Discovery agent
DMPDO43 ID DMPDO43
DMPDO43 DN (R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide
DMPDO43 HS Investigative
DMPDO43 SN N-(1-phenylethyl)-1H-pyrrole-2-carboxamide; pyrrole inhibitor 24; AC1MOG77; (R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide; CHEMBL373648; SCHEMBL15771458; BDBM15599
DMPDO43 DT Small molecular drug
DMPDO43 PC 3343155
DMPDO43 MW 214.26
DMPDO43 FM C13H14N2O
DMPDO43 IC InChI=1S/C13H14N2O/c1-10(11-6-3-2-4-7-11)15-13(16)12-8-5-9-14-12/h2-10,14H,1H3,(H,15,16)
DMPDO43 CS CC(C1=CC=CC=C1)NC(=O)C2=CC=CN2
DMPDO43 IK ZCDCLWRYDWKALM-UHFFFAOYSA-N
DMPDO43 IU N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
DMPDO43 DE Discovery agent
DMQO71C ID DMQO71C
DMQO71C DN (R,S)-PHPNECA
DMQO71C HS Investigative
DMQO71C SN (R,S)-2-phenylhydroxypropynyl-NECA; 2-(3-hydroxy-3-phenyl)propyn-1-yladenosine-5'-N-ethyluronamide
DMQO71C DT Small molecular drug
DMQO71C PC 91827339
DMQO71C MW 438.4
DMQO71C FM C21H22N6O5
DMQO71C IC InChI=1S/C21H22N6O5/c1-2-23-20(31)17-15(29)16(30)21(32-17)27-10-24-14-18(22)25-13(26-19(14)27)9-8-12(28)11-6-4-3-5-7-11/h3-7,10,12,15-17,21,28-30H,2H2,1H3,(H,23,31)(H2,22,25,26)/t12?,15-,16+,17+,21-/m1/s1
DMQO71C CS CCNC(=O)[C@@H]1[C@@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)C#CC(C4=CC=CC=C4)O)N)O)O
DMQO71C IK WOAZCBPWCCREDO-CERUIEQFSA-N
DMQO71C IU (2S,3R,4S,5R)-5-[6-amino-2-(3-hydroxy-3-phenylprop-1-ynyl)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMQO71C DE Discovery agent
DM8I6MG ID DM8I6MG
DM8I6MG DN (R/R)BEFLOXATONE
DM8I6MG HS Investigative
DM8I6MG SN CHEMBL18101; (R/R)BEFLOXATONE; SCHEMBL9463614; BDBM50110715
DM8I6MG DT Small molecular drug
DM8I6MG PC 18646248
DM8I6MG MW 349.3
DM8I6MG FM C15H18F3NO5
DM8I6MG IC InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m0/s1
DM8I6MG CS COC[C@@H]1CN(C(=O)O1)C2=CC=C(C=C2)OCC[C@@H](C(F)(F)F)O
DM8I6MG IK IALVDLPLCLFBCF-STQMWFEESA-N
DM8I6MG IU (5S)-5-(methoxymethyl)-3-[4-[(3S)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-1,3-oxazolidin-2-one
DM8I6MG DE Discovery agent
DMYDG27 ID DMYDG27
DMYDG27 DN (R/S) EF-1500
DMYDG27 HS Investigative
DMYDG27 SN (R/S) EF-1500; GTPL4583
DMYDG27 DT Small molecular drug
DMYDG27 PC 53319290
DMYDG27 MW 400.6
DMYDG27 FM C21H24N2O2S2
DMYDG27 IC InChI=1S/C21H24N2O2S2/c1-13-8-11-26-19(13)15(20-14(2)9-12-27-20)5-4-10-22-16-6-3-7-17-18(16)21(24)23-25-17/h5,8-9,11-12,16,22H,3-4,6-7,10H2,1-2H3,(H,23,24)
DMYDG27 CS CC1=C(SC=C1)C(=CCCNC2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
DMYDG27 IK TYXWOLAOXRISSO-UHFFFAOYSA-N
DMYDG27 IU 4-[4,4-bis(3-methylthiophen-2-yl)but-3-enylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DMYDG27 DE Discovery agent
DM3MEQB ID DM3MEQB
DM3MEQB DN (R/S)-2-((4-benzylphenoxy)methyl)piperazine
DM3MEQB HS Investigative
DM3MEQB SN CHEMBL1098820; (R/S)-2-((4-benzylphenoxy)methyl)piperazine
DM3MEQB DT Small molecular drug
DM3MEQB PC 46888243
DM3MEQB MW 282.4
DM3MEQB FM C18H22N2O
DM3MEQB IC InChI=1S/C18H22N2O/c1-2-4-15(5-3-1)12-16-6-8-18(9-7-16)21-14-17-13-19-10-11-20-17/h1-9,17,19-20H,10-14H2
DM3MEQB CS C1CNC(CN1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DM3MEQB IK NQEDMJQVVYPBBZ-UHFFFAOYSA-N
DM3MEQB IU 2-[(4-benzylphenoxy)methyl]piperazine
DM3MEQB DE Discovery agent
DMRXD82 ID DMRXD82
DMRXD82 DN (R/S)-2-((4-benzylphenoxy)methyl)piperidine
DMRXD82 HS Investigative
DMRXD82 SN CHEMBL1098351; (R/S)-2-((4-benzylphenoxy)methyl)piperidine; SCHEMBL7332735; BDBM50317491
DMRXD82 DT Small molecular drug
DMRXD82 PC 46888070
DMRXD82 MW 281.4
DMRXD82 FM C19H23NO
DMRXD82 IC InChI=1S/C19H23NO/c1-2-6-16(7-3-1)14-17-9-11-19(12-10-17)21-15-18-8-4-5-13-20-18/h1-3,6-7,9-12,18,20H,4-5,8,13-15H2
DMRXD82 CS C1CCNC(C1)COC2=CC=C(C=C2)CC3=CC=CC=C3
DMRXD82 IK YZRAMLLKPOGYCE-UHFFFAOYSA-N
DMRXD82 IU 2-[(4-benzylphenoxy)methyl]piperidine
DMRXD82 DE Discovery agent
DMDA285 ID DMDA285
DMDA285 DN (R/S)-2-((4-phenoxyphenoxy)methyl)piperidine
DMDA285 HS Investigative
DMDA285 SN CHEMBL1097151; (R/S)-2-((4-phenoxyphenoxy)methyl)piperidine; SCHEMBL13809108; BDBM50317492
DMDA285 DT Small molecular drug
DMDA285 PC 45253769
DMDA285 MW 283.4
DMDA285 FM C18H21NO2
DMDA285 IC InChI=1S/C18H21NO2/c1-2-7-17(8-3-1)21-18-11-9-16(10-12-18)20-14-15-6-4-5-13-19-15/h1-3,7-12,15,19H,4-6,13-14H2
DMDA285 CS C1CCNC(C1)COC2=CC=C(C=C2)OC3=CC=CC=C3
DMDA285 IK CSJNBXMUZIPBKQ-UHFFFAOYSA-N
DMDA285 IU 2-[(4-phenoxyphenoxy)methyl]piperidine
DMDA285 DE Discovery agent
DMYZCRF ID DMYZCRF
DMYZCRF DN (RS)-(tetrazol-5-yl)glycine
DMYZCRF HS Investigative
DMYZCRF SN (RS)-(tetrazol-5-yl)glycine; 138199-51-6; Tet-glycine; Tetrazol-5-yl-gly; 5-Tetrazolyl-glycine; (Tetrazol-5-yl)glycine; Tetrazolylglycine; 2-amino-2-(1H-1,2,3,4-tetrazol-5-yl)acetic acid; 2-amino-2-(2H-tetrazol-5-yl)acetic acid; CHEBI:35003; alpha-tetrazolylglycine; LY 285 265; Biomol-NT_000191; C13738; AC1L2Q8Q; GTPL4068; BPBio1_001214; CHEMBL140784; SCHEMBL10231795; MolPort-023-275-877; HMS3266G07; AKOS006272482; AKOS024048687; NCGC00024531-02; RT-015857; 2-amino-2-(1H-tetrazol-5-yl)acetic acid; T-205
DMYZCRF DT Small molecular drug
DMYZCRF PC 126383
DMYZCRF MW 143.1
DMYZCRF FM C3H5N5O2
DMYZCRF IC InChI=1S/C3H5N5O2/c4-1(3(9)10)2-5-7-8-6-2/h1H,4H2,(H,9,10)(H,5,6,7,8)
DMYZCRF CS C1(=NNN=N1)C(C(=O)O)N
DMYZCRF IK UKBRUIZWQZHXFL-UHFFFAOYSA-N
DMYZCRF IU 2-amino-2-(2H-tetrazol-5-yl)acetic acid
DMYZCRF CA CAS 138199-51-6
DMYZCRF CB CHEBI:35003
DMYZCRF DE Discovery agent
DMCPEBF ID DMCPEBF
DMCPEBF DN (RS)-5-diphosphomevalonate
DMCPEBF HS Investigative
DMCPEBF SN 5-Diphosphomevalonic acid; (RS)-5-diphosphomevalonate; AC1L19ES; AC1Q6T4D; SCHEMBL183248; GTPL3055; CTK0I1968; 3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylpentans; 1492-08-6; 4872-34-8; 5-(Phosphonooxyphosphonyloxy)-3-hydroxy-3-methylpentanoic acid; 3-hydroxy-5-(hydroxy-phosphonooxyphosphoryl)oxy-3-methylpentanoic acid; 3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid; 6,8-Dioxa-7,9-diphosphanonanoicacid, 3,7,9,9-tetrahydroxy-3-methyl-, 7,9-dioxide
DMCPEBF DT Small molecular drug
DMCPEBF PC 516
DMCPEBF MW 308.12
DMCPEBF FM C6H14O10P2
DMCPEBF IC InChI=1S/C6H14O10P2/c1-6(9,4-5(7)8)2-3-15-18(13,14)16-17(10,11)12/h9H,2-4H2,1H3,(H,7,8)(H,13,14)(H2,10,11,12)
DMCPEBF CS CC(CCOP(=O)(O)OP(=O)(O)O)(CC(=O)O)O
DMCPEBF IK SIGQQUBJQXSAMW-UHFFFAOYSA-N
DMCPEBF IU 3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMCPEBF CA CAS 1492-08-6
DMCPEBF DE Discovery agent
DMA8DEG ID DMA8DEG
DMA8DEG DN (RS)-PPCC
DMA8DEG HS Investigative
DMA8DEG SN CHEMBL222301; (RS)-PPCC; GTPL6676; SCHEMBL18261107; BDBM50206578; methyl 2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropane-1-carboxylate; methyl (1R,2S/1S,2R)-2-[(4-hydroxy-4-phenylpiperidin-1-yl)-methyl]-1-(4-methylphenyl)cyclopropanecarboxylate
DMA8DEG DT Small molecular drug
DMA8DEG PC 16726095
DMA8DEG MW 379.5
DMA8DEG FM C24H29NO3
DMA8DEG IC InChI=1S/C24H29NO3/c1-18-8-10-20(11-9-18)24(22(26)28-2)16-21(24)17-25-14-12-23(27,13-15-25)19-6-4-3-5-7-19/h3-11,21,27H,12-17H2,1-2H3
DMA8DEG CS CC1=CC=C(C=C1)C2(CC2CN3CCC(CC3)(C4=CC=CC=C4)O)C(=O)OC
DMA8DEG IK BDSYECBSUUOPCT-UHFFFAOYSA-N
DMA8DEG IU methyl 2-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-(4-methylphenyl)cyclopropane-1-carboxylate
DMA8DEG DE Discovery agent
DMCN6WR ID DMCN6WR
DMCN6WR DN (RS)-tacrine(10)-hupyridone
DMCN6WR HS Investigative
DMCN6WR SN (RS)-tacrine(10)-hupyridone; CHEMBL76658; BDBM50080157
DMCN6WR DT Small molecular drug
DMCN6WR PC 10028957
DMCN6WR MW 500.7
DMCN6WR FM C32H44N4O
DMCN6WR IC InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)
DMCN6WR CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCCCNC4CCCC5=C4C=CC(=O)N5
DMCN6WR IK ROTFGKJJMRTWBD-UHFFFAOYSA-N
DMCN6WR IU 5-[10-(1,2,3,4-tetrahydroacridin-9-ylamino)decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMCN6WR DE Discovery agent
DM6EYQ2 ID DM6EYQ2
DM6EYQ2 DN (RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine
DM6EYQ2 HS Investigative
DM6EYQ2 SN CHEMBL219649; (RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine; BDBM50202396
DM6EYQ2 DT Small molecular drug
DM6EYQ2 PC 16102764
DM6EYQ2 MW 286.2
DM6EYQ2 FM C15H21Cl2N
DM6EYQ2 IC InChI=1S/C15H21Cl2N/c1-2-5-12(15-6-3-4-9-18-15)11-7-8-13(16)14(17)10-11/h7-8,10,12,15,18H,2-6,9H2,1H3
DM6EYQ2 CS CCCC(C1CCCCN1)C2=CC(=C(C=C2)Cl)Cl
DM6EYQ2 IK USGRALLMTYXJMV-UHFFFAOYSA-N
DM6EYQ2 IU 2-[1-(3,4-dichlorophenyl)butyl]piperidine
DM6EYQ2 DE Discovery agent
DMGHWJ5 ID DMGHWJ5
DMGHWJ5 DN (RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5 HS Investigative
DMGHWJ5 SN CHEMBL218847; (RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5 DT Small molecular drug
DMGHWJ5 PC 16102751
DMGHWJ5 MW 251.79
DMGHWJ5 FM C15H22ClN
DMGHWJ5 IC InChI=1S/C15H22ClN/c1-2-5-14(15-6-3-4-11-17-15)12-7-9-13(16)10-8-12/h7-10,14-15,17H,2-6,11H2,1H3
DMGHWJ5 CS CCCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMGHWJ5 IK OICPVJMMZDEJMO-UHFFFAOYSA-N
DMGHWJ5 IU 2-[1-(4-chlorophenyl)butyl]piperidine
DMGHWJ5 DE Discovery agent
DMAIGM2 ID DMAIGM2
DMAIGM2 DN (RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine
DMAIGM2 HS Investigative
DMAIGM2 SN CHEMBL219224; (RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine; BDBM50202385
DMAIGM2 DT Small molecular drug
DMAIGM2 PC 16102749
DMAIGM2 MW 223.74
DMAIGM2 FM C13H18ClN
DMAIGM2 IC InChI=1S/C13H18ClN/c1-10(13-4-2-3-9-15-13)11-5-7-12(14)8-6-11/h5-8,10,13,15H,2-4,9H2,1H3
DMAIGM2 CS CC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMAIGM2 IK BMRJUXFHOOHDBF-UHFFFAOYSA-N
DMAIGM2 IU 2-[1-(4-chlorophenyl)ethyl]piperidine
DMAIGM2 DE Discovery agent
DMDVMSP ID DMDVMSP
DMDVMSP DN (RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine
DMDVMSP HS Investigative
DMDVMSP SN CHEMBL219703; (RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine; BDBM50202394
DMDVMSP DT Small molecular drug
DMDVMSP PC 16102754
DMDVMSP MW 279.8
DMDVMSP FM C17H26ClN
DMDVMSP IC InChI=1S/C17H26ClN/c1-2-3-4-7-16(17-8-5-6-13-19-17)14-9-11-15(18)12-10-14/h9-12,16-17,19H,2-8,13H2,1H3
DMDVMSP CS CCCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMDVMSP IK PAZWPXLTYQROKI-UHFFFAOYSA-N
DMDVMSP IU 2-[1-(4-chlorophenyl)hexyl]piperidine
DMDVMSP DE Discovery agent
DMMUV7R ID DMMUV7R
DMMUV7R DN (RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine
DMMUV7R HS Investigative
DMMUV7R SN CHEMBL218849; (RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine; BDBM50202388
DMMUV7R DT Small molecular drug
DMMUV7R PC 16102753
DMMUV7R MW 265.82
DMMUV7R FM C16H24ClN
DMMUV7R IC InChI=1S/C16H24ClN/c1-2-3-6-15(16-7-4-5-12-18-16)13-8-10-14(17)11-9-13/h8-11,15-16,18H,2-7,12H2,1H3
DMMUV7R CS CCCCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMMUV7R IK ZYPXTTXHMBCKFT-UHFFFAOYSA-N
DMMUV7R IU 2-[1-(4-chlorophenyl)pentyl]piperidine
DMMUV7R DE Discovery agent
DMPQAGL ID DMPQAGL
DMPQAGL DN (RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine
DMPQAGL HS Investigative
DMPQAGL SN CHEMBL376852; (RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine; BDBM50202382
DMPQAGL DT Small molecular drug
DMPQAGL PC 16102750
DMPQAGL MW 237.77
DMPQAGL FM C14H20ClN
DMPQAGL IC InChI=1S/C14H20ClN/c1-2-13(14-5-3-4-10-16-14)11-6-8-12(15)9-7-11/h6-9,13-14,16H,2-5,10H2,1H3
DMPQAGL CS CCC(C1CCCCN1)C2=CC=C(C=C2)Cl
DMPQAGL IK CJUVIUZOUUBMJB-UHFFFAOYSA-N
DMPQAGL IU 2-[1-(4-chlorophenyl)propyl]piperidine
DMPQAGL DE Discovery agent
DML1GP5 ID DML1GP5
DML1GP5 DN (S-(2-oxo)pentadecyl-CoA)
DML1GP5 HS Investigative
DML1GP5 SN CHEMBL448516; Coenzyme A, S-(2-oxopentadecyl)-; (S-(2-oxo)pentadecyl-CoA); 121124-66-1; NSC618486; AC1L9QGK; S-(2-Oxopentadecyl) CoA; S-2-Ketopentadecyl Coenzyme A, Sodium Salt; BDBM50270015; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-[2-(2-oxopentadecylsulfanyl)ethylamino]propyl]amino]butyl] hydrogen phosphate
DML1GP5 DT Small molecular drug
DML1GP5 PC 452663
DML1GP5 MW 991.9
DML1GP5 FM C36H64N7O17P3S
DML1GP5 IC InChI=1S/C36H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-25(44)21-64-19-18-38-27(45)16-17-39-34(48)31(47)36(2,3)22-57-63(54,55)60-62(52,53)56-20-26-30(59-61(49,50)51)29(46)35(58-26)43-24-42-28-32(37)40-23-41-33(28)43/h23-24,26,29-31,35,46-47H,4-22H2,1-3H3,(H,38,45)(H,39,48)(H,52,53)(H,54,55)(H2,37,40,41)(H2,49,50,51)/t26-,29-,30-,31?,35-/m1/s1
DML1GP5 CS CCCCCCCCCCCCCC(=O)CSCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DML1GP5 IK JKWHUJMJVNMKEF-DJEJIMQCSA-N
DML1GP5 IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-[2-(2-oxopentadecylsulfanyl)ethylamino]propyl]amino]butyl] hydrogen phosphate
DML1GP5 DE Discovery agent
DMUNQY7 ID DMUNQY7
DMUNQY7 DN (S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine
DMUNQY7 HS Investigative
DMUNQY7 SN CHEMBL211301; 890309-58-7; (S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine; CTK2I1397; DTXSID10467882; ZINC35569548; BDBM50190614; 1H-Indene-1-methanamine, 2,3-dihydro-4,5,6-trimethoxy-, (1S)-
DMUNQY7 DT Small molecular drug
DMUNQY7 PC 11514605
DMUNQY7 MW 237.29
DMUNQY7 FM C13H19NO3
DMUNQY7 IC InChI=1S/C13H19NO3/c1-15-11-6-10-8(7-14)4-5-9(10)12(16-2)13(11)17-3/h6,8H,4-5,7,14H2,1-3H3/t8-/m1/s1
DMUNQY7 CS COC1=C(C(=C2CC[C@@H](C2=C1)CN)OC)OC
DMUNQY7 IK AFTIZGHFDCOQFS-MRVPVSSYSA-N
DMUNQY7 IU [(1S)-4,5,6-trimethoxy-2,3-dihydro-1H-inden-1-yl]methanamine
DMUNQY7 CA CAS 890309-58-7
DMUNQY7 DE Discovery agent
DMC5Z2I ID DMC5Z2I
DMC5Z2I DN (S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMC5Z2I HS Investigative
DMC5Z2I SN CHEMBL598096; (S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one
DMC5Z2I DT Small molecular drug
DMC5Z2I PC 46232145
DMC5Z2I MW 272.27
DMC5Z2I FM C16H13FO3
DMC5Z2I IC InChI=1S/C16H13FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15H,9H2,1H3/t15-/m0/s1
DMC5Z2I CS COC1=CC2=C(C=C1)C(=O)C[C@H](O2)C3=CC=C(C=C3)F
DMC5Z2I IK LIINIWOYEGBFDA-HNNXBMFYSA-N
DMC5Z2I IU (2S)-2-(4-fluorophenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMC5Z2I DE Discovery agent
DMILWE7 ID DMILWE7
DMILWE7 DN (S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMILWE7 HS Investigative
DMILWE7 SN CHEMBL601843; (S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one
DMILWE7 DT Small molecular drug
DMILWE7 PC 46232078
DMILWE7 MW 260.23
DMILWE7 FM C15H10F2O2
DMILWE7 IC InChI=1S/C15H10F2O2/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14H,8H2/t14-/m0/s1
DMILWE7 CS C1[C@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=C(C=C3)F
DMILWE7 IK YKJLGNVYFBPKJK-AWEZNQCLSA-N
DMILWE7 IU (2S)-7-fluoro-2-(4-fluorophenyl)-2,3-dihydrochromen-4-one
DMILWE7 DE Discovery agent
DMHR1IB ID DMHR1IB
DMHR1IB DN (S)(+)-7-fluoro-2-phenylchroman-4-one
DMHR1IB HS Investigative
DMHR1IB SN CHEMBL592764; (S)(+)-7-fluoro-2-phenylchroman-4-one
DMHR1IB DT Small molecular drug
DMHR1IB PC 46232076
DMHR1IB MW 242.24
DMHR1IB FM C15H11FO2
DMHR1IB IC InChI=1S/C15H11FO2/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14H,9H2/t14-/m0/s1
DMHR1IB CS C1[C@H](OC2=C(C1=O)C=CC(=C2)F)C3=CC=CC=C3
DMHR1IB IK SZNYRENOXQIQMR-AWEZNQCLSA-N
DMHR1IB IU (2S)-7-fluoro-2-phenyl-2,3-dihydrochromen-4-one
DMHR1IB DE Discovery agent
DMTFZBQ ID DMTFZBQ
DMTFZBQ DN (S)(+)-7-fluoro-2-p-tolylchroman-4-one
DMTFZBQ HS Investigative
DMTFZBQ SN CHEMBL597472; (S)(+)-7-fluoro-2-p-tolylchroman-4-one
DMTFZBQ DT Small molecular drug
DMTFZBQ PC 46232080
DMTFZBQ MW 256.269
DMTFZBQ FM C16H13FO2
DMTFZBQ IC InChI=1S/C16H13FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-8,15H,9H2,1H3/t15-/m0/s1
DMTFZBQ CS CC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)F
DMTFZBQ IK QNQXLNDULBVXEX-HNNXBMFYSA-N
DMTFZBQ IU (2S)-7-fluoro-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMTFZBQ DE Discovery agent
DMBG4KN ID DMBG4KN
DMBG4KN DN (S)(+)-7-methyl-2-phenylchroman-4-one
DMBG4KN HS Investigative
DMBG4KN SN CHEMBL601205; (S)(+)-7-methyl-2-phenylchroman-4-one
DMBG4KN DT Small molecular drug
DMBG4KN PC 46232141
DMBG4KN MW 238.28
DMBG4KN FM C16H14O2
DMBG4KN IC InChI=1S/C16H14O2/c1-11-7-8-13-14(17)10-15(18-16(13)9-11)12-5-3-2-4-6-12/h2-9,15H,10H2,1H3/t15-/m0/s1
DMBG4KN CS CC1=CC2=C(C=C1)C(=O)C[C@H](O2)C3=CC=CC=C3
DMBG4KN IK FNOKOVWLKVWYRY-HNNXBMFYSA-N
DMBG4KN IU (2S)-7-methyl-2-phenyl-2,3-dihydrochromen-4-one
DMBG4KN DE Discovery agent
DMVBD6H ID DMVBD6H
DMVBD6H DN (S)(+)-7-methyl-2-p-tolylchroman-4-one
DMVBD6H HS Investigative
DMVBD6H SN CHEMBL600384; (S)(+)-7-methyl-2-p-tolylchroman-4-one
DMVBD6H DT Small molecular drug
DMVBD6H PC 46232143
DMVBD6H MW 252.31
DMVBD6H FM C17H16O2
DMVBD6H IC InChI=1S/C17H16O2/c1-11-3-6-13(7-4-11)16-10-15(18)14-8-5-12(2)9-17(14)19-16/h3-9,16H,10H2,1-2H3/t16-/m0/s1
DMVBD6H CS CC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)C
DMVBD6H IK MIEPNGHJBCGJAW-INIZCTEOSA-N
DMVBD6H IU (2S)-7-methyl-2-(4-methylphenyl)-2,3-dihydrochromen-4-one
DMVBD6H DE Discovery agent
DMPDOY8 ID DMPDOY8
DMPDOY8 DN (S)-(+)-CBPG
DMPDOY8 HS Investigative
DMPDOY8 SN CBPG; 3-[(S)-amino(carboxy)methyl]bicyclo[1.1.1]pentane-1-carboxylic acid; 180465-02-5; (S)-3-(amino(carboxy)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; CHEMBL43412; S-(+)-CBPG; EN300-88066; (S)-(+)-CBPG; AC1NSJVN; AC1Q4UAL; SCHEMBL1308145; GTPL3421; (R)-3-(amino(carboxy)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid; CTK7I3432; MolPort-044-812-180; MolPort-005-313-665; ZINC1485767; BDBM50052256; AKOS026740795; FCH4013584; AS-44366; OR312475; CS-0078773; KS-00000111; (s)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine
DMPDOY8 DT Small molecular drug
DMPDOY8 PC 5311040
DMPDOY8 MW 185.18
DMPDOY8 FM C8H11NO4
DMPDOY8 IC InChI=1S/C8H11NO4/c9-4(5(10)11)7-1-8(2-7,3-7)6(12)13/h4H,1-3,9H2,(H,10,11)(H,12,13)/t4-,7?,8?/m1/s1
DMPDOY8 CS C1C2(CC1(C2)C(=O)O)[C@@H](C(=O)O)N
DMPDOY8 IK KNSHLWJBSDBBRH-XOJFDHPMSA-N
DMPDOY8 IU 3-[(S)-amino(carboxy)methyl]bicyclo[1.1.1]pentane-1-carboxylic acid
DMPDOY8 DE Discovery agent
DMF2IY8 ID DMF2IY8
DMF2IY8 DN (S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea
DMF2IY8 HS Investigative
DMF2IY8 SN indazole antagonist, (S)-16b; CHEMBL231392; BDBM20406
DMF2IY8 DT Small molecular drug
DMF2IY8 PC 24768210
DMF2IY8 MW 294.35
DMF2IY8 FM C17H18N4O
DMF2IY8 IC InChI=1S/C17H18N4O/c1-11-6-8-13(9-7-11)12(2)19-17(22)20-15-4-3-5-16-14(15)10-18-21-16/h3-10,12H,1-2H3,(H,18,21)(H2,19,20,22)/t12-/m0/s1
DMF2IY8 CS CC1=CC=C(C=C1)[C@H](C)NC(=O)NC2=CC=CC3=C2C=NN3
DMF2IY8 IK SHOUDGQMQHLAFL-LBPRGKRZSA-N
DMF2IY8 IU 1-(1H-indazol-4-yl)-3-[(1S)-1-(4-methylphenyl)ethyl]urea
DMF2IY8 DE Discovery agent
DMF9YLR ID DMF9YLR
DMF9YLR DN (S)-1-(2-methoxyphenethyl)-2-methylpyrrolidine
DMF9YLR HS Investigative
DMF9YLR SN CHEMBL404912
DMF9YLR DT Small molecular drug
DMF9YLR PC 44456094
DMF9YLR MW 219.32
DMF9YLR FM C14H21NO
DMF9YLR IC InChI=1S/C14H21NO/c1-12-6-5-10-15(12)11-9-13-7-3-4-8-14(13)16-2/h3-4,7-8,12H,5-6,9-11H2,1-2H3/t12-/m0/s1
DMF9YLR CS C[C@H]1CCCN1CCC2=CC=CC=C2OC
DMF9YLR IK KDVUGYDZNTZESD-LBPRGKRZSA-N
DMF9YLR IU (2S)-1-[2-(2-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMF9YLR DE Discovery agent
DM8UWT9 ID DM8UWT9
DM8UWT9 DN (S)-1-(3-methoxyphenethyl)-2-methylpyrrolidine
DM8UWT9 HS Investigative
DM8UWT9 SN CHEMBL272306
DM8UWT9 DT Small molecular drug
DM8UWT9 PC 44456090
DM8UWT9 MW 219.32
DM8UWT9 FM C14H21NO
DM8UWT9 IC InChI=1S/C14H21NO/c1-12-5-4-9-15(12)10-8-13-6-3-7-14(11-13)16-2/h3,6-7,11-12H,4-5,8-10H2,1-2H3/t12-/m0/s1
DM8UWT9 CS C[C@H]1CCCN1CCC2=CC(=CC=C2)OC
DM8UWT9 IK INKHQVYBVMGBHD-LBPRGKRZSA-N
DM8UWT9 IU (2S)-1-[2-(3-methoxyphenyl)ethyl]-2-methylpyrrolidine
DM8UWT9 DE Discovery agent
DMDBHY1 ID DMDBHY1
DMDBHY1 DN (S)-1-(4-methoxyphenethyl)-2-methylpyrrolidine
DMDBHY1 HS Investigative
DMDBHY1 SN CHEMBL404532
DMDBHY1 DT Small molecular drug
DMDBHY1 PC 44456055
DMDBHY1 MW 219.32
DMDBHY1 FM C14H21NO
DMDBHY1 IC InChI=1S/C14H21NO/c1-12-4-3-10-15(12)11-9-13-5-7-14(16-2)8-6-13/h5-8,12H,3-4,9-11H2,1-2H3/t12-/m0/s1
DMDBHY1 CS C[C@H]1CCCN1CCC2=CC=C(C=C2)OC
DMDBHY1 IK NPUSLESRSBDEHN-LBPRGKRZSA-N
DMDBHY1 IU (2S)-1-[2-(4-methoxyphenyl)ethyl]-2-methylpyrrolidine
DMDBHY1 DE Discovery agent
DMG7XL5 ID DMG7XL5
DMG7XL5 DN (S)-1-(4-nitrophenethyl)-2-methylpyrrolidine
DMG7XL5 HS Investigative
DMG7XL5 SN CHEMBL257235
DMG7XL5 DT Small molecular drug
DMG7XL5 PC 44456366
DMG7XL5 MW 234.29
DMG7XL5 FM C13H18N2O2
DMG7XL5 IC InChI=1S/C13H18N2O2/c1-11-3-2-9-14(11)10-8-12-4-6-13(7-5-12)15(16)17/h4-7,11H,2-3,8-10H2,1H3/t11-/m0/s1
DMG7XL5 CS C[C@H]1CCCN1CCC2=CC=C(C=C2)[N+](=O)[O-]
DMG7XL5 IK PFZYNGPCNCRLFU-NSHDSACASA-N
DMG7XL5 IU (2S)-2-methyl-1-[2-(4-nitrophenyl)ethyl]pyrrolidine
DMG7XL5 DE Discovery agent
DMEIB8F ID DMEIB8F
DMEIB8F DN (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine
DMEIB8F HS Investigative
DMEIB8F SN CHEMBL40726; SCHEMBL8959516; (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine; BDBM50108306; (S)-1-(5,6-Difluoro-1H-indol-1-yl)-2-propanamine
DMEIB8F DT Small molecular drug
DMEIB8F PC 10330734
DMEIB8F MW 210.22
DMEIB8F FM C11H12F2N2
DMEIB8F IC InChI=1S/C11H12F2N2/c1-7(14)6-15-3-2-8-4-9(12)10(13)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1
DMEIB8F CS C[C@@H](CN1C=CC2=CC(=C(C=C21)F)F)N
DMEIB8F IK MYZDBEVPJGKIQS-ZETCQYMHSA-N
DMEIB8F IU (2S)-1-(5,6-difluoroindol-1-yl)propan-2-amine
DMEIB8F DE Discovery agent
DM1U7MC ID DM1U7MC
DM1U7MC DN (S)-1,7-Diphenyl-6(E)-hepten-3-ol
DM1U7MC HS Investigative
DM1U7MC SN CHEMBL461017; (S)-1,7-Diphenyl-6(E)-hepten-3-ol; (S)-1,7-diphenylhept-6-en-3-ol; BDBM50300189; (3S,6E)-1,7-Diphenyl-6-heptene-3-ol
DM1U7MC DT Small molecular drug
DM1U7MC PC 44560846
DM1U7MC MW 266.4
DM1U7MC FM C19H22O
DM1U7MC IC InChI=1S/C19H22O/c20-19(16-15-18-11-5-2-6-12-18)14-8-7-13-17-9-3-1-4-10-17/h1-7,9-13,19-20H,8,14-16H2/b13-7+/t19-/m0/s1
DM1U7MC CS C1=CC=C(C=C1)CC[C@H](CC/C=C/C2=CC=CC=C2)O
DM1U7MC IK DPRCKWANIKZGTF-KRSRXSRCSA-N
DM1U7MC IU (E,3S)-1,7-diphenylhept-6-en-3-ol
DM1U7MC DE Discovery agent
DMICUQK ID DMICUQK
DMICUQK DN (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate
DMICUQK HS Investigative
DMICUQK SN CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester
DMICUQK DT Small molecular drug
DMICUQK PC 10062714
DMICUQK MW 317.4
DMICUQK FM C19H27NO3
DMICUQK IC InChI=1S/C19H27NO3/c1-2-3-11-17(15-21)20-18(22)23-19(12-7-8-13-19)14-16-9-5-4-6-10-16/h4-6,9-10,15,17H,2-3,7-8,11-14H2,1H3,(H,20,22)/t17-/m0/s1
DMICUQK CS CCCC[C@@H](C=O)NC(=O)OC1(CCCC1)CC2=CC=CC=C2
DMICUQK IK ONABDOMWRCXLPX-KRWDZBQOSA-N
DMICUQK IU (1-benzylcyclopentyl) N-[(2S)-1-oxohexan-2-yl]carbamate
DMICUQK DE Discovery agent
DM2VOAS ID DM2VOAS
DM2VOAS DN (S)-2-((4-phenoxyphenoxy)methyl)piperidine
DM2VOAS HS Investigative
DM2VOAS SN CHEMBL1099182; (S)-2-((4-phenoxyphenoxy)methyl)piperidine; SCHEMBL13809079
DM2VOAS DT Small molecular drug
DM2VOAS PC 29293599
DM2VOAS MW 283.4
DM2VOAS FM C18H21NO2
DM2VOAS IC InChI=1S/C18H21NO2/c1-2-7-17(8-3-1)21-18-11-9-16(10-12-18)20-14-15-6-4-5-13-19-15/h1-3,7-12,15,19H,4-6,13-14H2/t15-/m0/s1
DM2VOAS CS C1CCN[C@@H](C1)COC2=CC=C(C=C2)OC3=CC=CC=C3
DM2VOAS IK CSJNBXMUZIPBKQ-HNNXBMFYSA-N
DM2VOAS IU (2S)-2-[(4-phenoxyphenoxy)methyl]piperidine
DM2VOAS DE Discovery agent
DMQGCKX ID DMQGCKX
DMQGCKX DN (S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol
DMQGCKX HS Investigative
DMQGCKX SN CHEMBL408617
DMQGCKX DT Small molecular drug
DMQGCKX PC 44456332
DMQGCKX MW 205.3
DMQGCKX FM C13H19NO
DMQGCKX IC InChI=1S/C13H19NO/c1-11-5-4-9-14(11)10-8-12-6-2-3-7-13(12)15/h2-3,6-7,11,15H,4-5,8-10H2,1H3/t11-/m0/s1
DMQGCKX CS C[C@H]1CCCN1CCC2=CC=CC=C2O
DMQGCKX IK XLLMSPMZEFQVLD-NSHDSACASA-N
DMQGCKX IU 2-[2-[(2S)-2-methylpyrrolidin-1-yl]ethyl]phenol
DMQGCKX DE Discovery agent
DMVKL84 ID DMVKL84
DMVKL84 DN (S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMVKL84 HS Investigative
DMVKL84 SN CHEMBL429740
DMVKL84 DT Small molecular drug
DMVKL84 PC 44455952
DMVKL84 MW 190.28
DMVKL84 FM C12H18N2
DMVKL84 IC InChI=1S/C12H18N2/c1-11-5-4-9-14(11)10-7-12-6-2-3-8-13-12/h2-3,6,8,11H,4-5,7,9-10H2,1H3/t11-/m0/s1
DMVKL84 CS C[C@H]1CCCN1CCC2=CC=CC=N2
DMVKL84 IK ICWSPDRNRGQWAB-NSHDSACASA-N
DMVKL84 IU 2-[2-[(2S)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DMVKL84 DE Discovery agent
DMPQ53V ID DMPQ53V
DMPQ53V DN (S)-2-amino-1-(4-butylthiophenyl)-propane
DMPQ53V HS Investigative
DMPQ53V SN CHEMBL387778; (S)-2-amino-1-(4-butylthiophenyl)-propane
DMPQ53V DT Small molecular drug
DMPQ53V PC 23661626
DMPQ53V MW 223.38
DMPQ53V FM C13H21NS
DMPQ53V IC InChI=1S/C13H21NS/c1-3-4-9-15-13-7-5-12(6-8-13)10-11(2)14/h5-8,11H,3-4,9-10,14H2,1-2H3/t11-/m0/s1
DMPQ53V CS CCCCSC1=CC=C(C=C1)C[C@H](C)N
DMPQ53V IK RRHFSAVFMIWFCE-NSHDSACASA-N
DMPQ53V IU (2S)-1-(4-butylsulfanylphenyl)propan-2-amine
DMPQ53V DE Discovery agent
DMFK7O1 ID DMFK7O1
DMFK7O1 DN (S)-2-amino-1-(4-ethylthiophenyl)-propane
DMFK7O1 HS Investigative
DMFK7O1 SN CHEMBL387777; (S)-2-amino-1-(4-ethylthiophenyl)-propane; BDBM50213676
DMFK7O1 DT Small molecular drug
DMFK7O1 PC 44424447
DMFK7O1 MW 195.33
DMFK7O1 FM C11H17NS
DMFK7O1 IC InChI=1S/C11H17NS/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3/t9-/m0/s1
DMFK7O1 CS CCSC1=CC=C(C=C1)C[C@H](C)N
DMFK7O1 IK WOBAXWXQKSIHCH-VIFPVBQESA-N
DMFK7O1 IU (2S)-1-(4-ethylsulfanylphenyl)propan-2-amine
DMFK7O1 DE Discovery agent
DM06NUM ID DM06NUM
DM06NUM DN (S)-2-amino-1-(4-methylthiophenyl)-propane
DM06NUM HS Investigative
DM06NUM SN CHEMBL439193; (S)-2-amino-1-(4-methylthiophenyl)-propane; ZINC6021007; BDBM50213675; (S)-alpha-Methyl-4-methylthiobenzeneethanamine; UNII-6JP2T8KXTR component OLEWMKVPSUCNLG-QMMMGPOBSA-N
DM06NUM DT Small molecular drug
DM06NUM PC 44424446
DM06NUM MW 181.3
DM06NUM FM C10H15NS
DM06NUM IC InChI=1S/C10H15NS/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3/t8-/m0/s1
DM06NUM CS C[C@@H](CC1=CC=C(C=C1)SC)N
DM06NUM IK OLEWMKVPSUCNLG-QMMMGPOBSA-N
DM06NUM IU (2S)-1-(4-methylsulfanylphenyl)propan-2-amine
DM06NUM DE Discovery agent
DMAN7YJ ID DMAN7YJ
DMAN7YJ DN (S)-2-amino-1-(4-propylthiophenyl)-propane
DMAN7YJ HS Investigative
DMAN7YJ SN CHEMBL229472; (S)-2-amino-1-(4-propylthiophenyl)-propane
DMAN7YJ DT Small molecular drug
DMAN7YJ PC 44424448
DMAN7YJ MW 209.35
DMAN7YJ FM C12H19NS
DMAN7YJ IC InChI=1S/C12H19NS/c1-3-8-14-12-6-4-11(5-7-12)9-10(2)13/h4-7,10H,3,8-9,13H2,1-2H3/t10-/m0/s1
DMAN7YJ CS CCCSC1=CC=C(C=C1)C[C@H](C)N
DMAN7YJ IK HIOIYGZUYPHUTC-JTQLQIEISA-N
DMAN7YJ IU (2S)-1-(4-propylsulfanylphenyl)propan-2-amine
DMAN7YJ DE Discovery agent
DMWBH9N ID DMWBH9N
DMWBH9N DN (S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone
DMWBH9N HS Investigative
DMWBH9N SN CHEMBL194258; (S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone
DMWBH9N DT Small molecular drug
DMWBH9N PC 44403067
DMWBH9N MW 196.29
DMWBH9N FM C11H20N2O
DMWBH9N IC InChI=1S/C11H20N2O/c12-10(9-5-2-1-3-6-9)11(14)13-7-4-8-13/h9-10H,1-8,12H2/t10-/m0/s1
DMWBH9N CS C1CCC(CC1)[C@@H](C(=O)N2CCC2)N
DMWBH9N IK ZFOKLNMBWVCMDT-JTQLQIEISA-N
DMWBH9N IU (2S)-2-amino-1-(azetidin-1-yl)-2-cyclohexylethanone
DMWBH9N DE Discovery agent
DMORFZE ID DMORFZE
DMORFZE DN (S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione
DMORFZE HS Investigative
DMORFZE SN CHEMBL318401; (S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione; BDBM50118934
DMORFZE DT Small molecular drug
DMORFZE PC 44328273
DMORFZE MW 176.3
DMORFZE FM C6H12N2S2
DMORFZE IC InChI=1S/C6H12N2S2/c1-5(7)6(9)8-2-3-10-4-8/h5H,2-4,7H2,1H3/t5-/m0/s1
DMORFZE CS C[C@@H](C(=S)N1CCSC1)N
DMORFZE IK NRUOPZCNSMPDPG-YFKPBYRVSA-N
DMORFZE IU (2S)-2-amino-1-(1,3-thiazolidin-3-yl)propane-1-thione
DMORFZE DE Discovery agent
DMVD05E ID DMVD05E
DMVD05E DN (S)-2-amino-2-cyclohexylacetic acid
DMVD05E HS Investigative
DMVD05E SN 14328-51-9; h-chg-oh; l-alpha-cyclohexylglycine; L-Cyclohexylglycine; (S)-2-amino-2-cyclohexylacetic acid; h-cyclohexyl-gly-oh; L-(+)-2-Cyclohexylglycine; (2s)-amino(cyclohexyl)acetic acid; CYCLOHEXYLGLYCYL; 2-Cyclohexyl-L-glycine; (2S)-2-amino-2-cyclohexylacetic acid; CYCLOHEXYL-GLYCINE; l-cyclohexyl glycine; (s)-cyclohexylglycine; L-2-Cyclohexylglycine; h-cyclohexyl-d-gly-oh; CHEMBL382372; UNII-59Q5O5615E; (S)-Amino-cyclohexyl-acetic acid; (2S)-amino(cyclohexyl)ethanoic acid; MFCD01311679; 59Q5O5615E; l-(-)-cyclohexylglycine
DMVD05E DT Small molecular drug
DMVD05E PC 736848
DMVD05E MW 157.21
DMVD05E FM C8H15NO2
DMVD05E IC InChI=1S/C8H15NO2/c9-7(8(10)11)6-4-2-1-3-5-6/h6-7H,1-5,9H2,(H,10,11)/t7-/m0/s1
DMVD05E CS C1CCC(CC1)[C@@H](C(=O)O)N
DMVD05E IK WAMWSIDTKSNDCU-ZETCQYMHSA-N
DMVD05E IU (2S)-2-amino-2-cyclohexylacetic acid
DMVD05E CA CAS 14328-51-9
DMVD05E DE Discovery agent
DMG9KMN ID DMG9KMN
DMG9KMN DN (S)-2-amino-2-o-tolylacetic acid
DMG9KMN HS Investigative
DMG9KMN SN (S)-Amino-o-tolyl-acetic acid; 339274-33-8; CHEMBL204179; (S)-2-AMINO-2-(O-TOLYL)ACETIC ACID; (2S)-2-amino-2-(2-methylphenyl)acetic acid; (S)-2-amino-2-o-tolylacetic acid; 2-Methyl-L-phenylglycine; AC1LT3T3; SCHEMBL3611200; FLYIRERUSAMCDQ-QMMMGPOBSA-N; ZINC4202377; BDBM50179691; AKOS006284304; AB30505; SC-21704; AJ-48395; AB1006782
DMG9KMN DT Small molecular drug
DMG9KMN PC 1501939
DMG9KMN MW 165.19
DMG9KMN FM C9H11NO2
DMG9KMN IC InChI=1S/C9H11NO2/c1-6-4-2-3-5-7(6)8(10)9(11)12/h2-5,8H,10H2,1H3,(H,11,12)/t8-/m0/s1
DMG9KMN CS CC1=CC=CC=C1[C@@H](C(=O)O)N
DMG9KMN IK FLYIRERUSAMCDQ-QMMMGPOBSA-N
DMG9KMN IU (2S)-2-amino-2-(2-methylphenyl)acetic acid
DMG9KMN DE Discovery agent
DMFEGPX ID DMFEGPX
DMFEGPX DN (S)-2-Amino-2-phenyl-ethanethiol
DMFEGPX HS Investigative
DMFEGPX SN CHEMBL286865; (S)-2-Amino-2-phenyl-ethanethiol; BDBM50078138
DMFEGPX DT Small molecular drug
DMFEGPX PC 44284631
DMFEGPX MW 153.25
DMFEGPX FM C8H11NS
DMFEGPX IC InChI=1S/C8H11NS/c9-8(6-10)7-4-2-1-3-5-7/h1-5,8,10H,6,9H2/t8-/m1/s1
DMFEGPX CS C1=CC=C(C=C1)[C@@H](CS)N
DMFEGPX IK BYWNHDXZFZXBLV-MRVPVSSYSA-N
DMFEGPX IU (2S)-2-amino-2-phenylethanethiol
DMFEGPX DE Discovery agent
DM2104G ID DM2104G
DM2104G DN (S)-2-amino-2-phenylpropanoic acid
DM2104G HS Investigative
DM2104G SN 13398-26-0; (S)-2-amino-2-phenylpropanoic acid; (2S)-2-amino-2-phenylpropanoic acid; (S)-2-AMINO-2-PHENYL-PROPIONIC ACID; Benzeneacetic acid, a-amino-a-methyl-, (aS)-; (S)-ALPHA-METHYL-PHENYLGLYCINE; 2-phenyl-d-alanine; 2-(s)-phenylalanine; AC1LGXHO; (+)-2-Phenyl-D-alanine; SCHEMBL222049; CHEMBL3085306; CTK4B8907; (S)-2-Methyl-2-phenyl glycine; HTCSFFGLRQDZDE-VIFPVBQESA-N; MolPort-021-795-057; ZINC8461952; KS-00001G1D; AKOS006287023; AB33354; SC-84682; AJ-57568; KB-04049; (+)-(2S)-2-amino-2-phenylpropionic acid; FT-0695117
DM2104G DT Small molecular drug
DM2104G PC 853461
DM2104G MW 165.19
DM2104G FM C9H11NO2
DM2104G IC InChI=1S/C9H11NO2/c1-9(10,8(11)12)7-5-3-2-4-6-7/h2-6H,10H2,1H3,(H,11,12)/t9-/m0/s1
DM2104G CS C[C@](C1=CC=CC=C1)(C(=O)O)N
DM2104G IK HTCSFFGLRQDZDE-VIFPVBQESA-N
DM2104G IU (2S)-2-amino-2-phenylpropanoic acid
DM2104G DE Discovery agent
DMCDZ8A ID DMCDZ8A
DMCDZ8A DN (S)-2-amino-2-p-tolylacetic acid
DMCDZ8A HS Investigative
DMCDZ8A SN 119615-71-3; CHEMBL378582; (S)-2-Amino-2-(p-tolyl)acetic acid; (2S)-2-amino-2-(4-methylphenyl)acetic acid; (S)-2-amino-2-p-tolylacetic acid; AC1ODTRS; 4-Methyl-L-phenylglycine; (S)-Amino-p-tolyl-acetic acid; SCHEMBL11728987; DTXSID20427275; ZINC2567159; BENZENEACETIC ACID, ALPHA-AMINO-4-METHYL-, (ALPHAS)- (9CI); BDBM50179719; AKOS006275863; (2S)-Amino(4-methylphenyl)acetic acid; AJ-41354; KB-276738; AB1006787; Benzeneacetic acid, a-amino-4-methyl-, (aS)-
DMCDZ8A DT Small molecular drug
DMCDZ8A PC 7020729
DMCDZ8A MW 165.19
DMCDZ8A FM C9H11NO2
DMCDZ8A IC InChI=1S/C9H11NO2/c1-6-2-4-7(5-3-6)8(10)9(11)12/h2-5,8H,10H2,1H3,(H,11,12)/t8-/m0/s1
DMCDZ8A CS CC1=CC=C(C=C1)[C@@H](C(=O)O)N
DMCDZ8A IK RZRRCPHBUKHOEY-QMMMGPOBSA-N
DMCDZ8A IU (2S)-2-amino-2-(4-methylphenyl)acetic acid
DMCDZ8A CA CAS 119615-71-3
DMCDZ8A DE Discovery agent
DM6OUW0 ID DM6OUW0
DM6OUW0 DN (S)-2-amino-3-(benzylthio)propanoic acid
DM6OUW0 HS Investigative
DM6OUW0 SN H-D-Cys(Bzl)-OH; 23032-53-3; S-benzyl-D-cysteine; (S)-Benzyl-D-Cys; CHEMBL204162; CCRIS 1971; Alanine, 3-(benzylthio)-, L-; EINECS 221-273-4; (S)-2-AMINO-3-(S-BENZYLTHIO)PROPANOIC ACID; AC1Q5R1B; AC1L2QY5; SCHEMBL1927561; D-Cysteine, S-(phenylmethyl)-; CTK7D0951; MolPort-005-937-279; GHBAYRBVXCRIHT-SECBINFHSA-N; ZINC404299; BDBM50179697; AS-49045; AJ-22311; AX8012175; LS-188299
DM6OUW0 DT Small molecular drug
DM6OUW0 PC 76454
DM6OUW0 MW 211.28
DM6OUW0 FM C10H13NO2S
DM6OUW0 IC InChI=1S/C10H13NO2S/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m1/s1
DM6OUW0 CS C1=CC=C(C=C1)CSC[C@H](C(=O)O)N
DM6OUW0 IK GHBAYRBVXCRIHT-SECBINFHSA-N
DM6OUW0 IU (2S)-2-amino-3-benzylsulfanylpropanoic acid
DM6OUW0 DE Discovery agent
DM1GBX8 ID DM1GBX8
DM1GBX8 DN (S)-2-amino-3-cyclohexylpropanoic acid
DM1GBX8 HS Investigative
DM1GBX8 SN 27527-05-5; (S)-2-amino-3-cyclohexylpropanoic acid; L-Cyclohexylalanine; H-Cha-OH; (2S)-2-amino-3-cyclohexylpropanoic acid; 3-Cyclohexyl-L-alanine; L-3-Cyclohexylalanine; (S)-2-Amino-3-cyclohexylpropionic acid; BETA-CYCLOHEXYL-ALANINE; L-beta-Cyclohexylalanine; UNII-GYR4SF0FVQ; GYR4SF0FVQ; CHEMBL383208; Cyclohexanepropanoic acid, alpha-amino-, (alphaS)-; 2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID; 3-cyclohexylalanine; b-cyclohexyl alanine; beta-cyclohexylalanine; PubChem5760; beta-cyclohexyl alanine; AC1LEHTM; AC1Q5QKA
DM1GBX8 DT Small molecular drug
DM1GBX8 PC 712421
DM1GBX8 MW 171.24
DM1GBX8 FM C9H17NO2
DM1GBX8 IC InChI=1S/C9H17NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h7-8H,1-6,10H2,(H,11,12)/t8-/m0/s1
DM1GBX8 CS C1CCC(CC1)C[C@@H](C(=O)O)N
DM1GBX8 IK ORQXBVXKBGUSBA-QMMMGPOBSA-N
DM1GBX8 IU (2S)-2-amino-3-cyclohexylpropanoic acid
DM1GBX8 CA CAS 27527-05-5
DM1GBX8 DE Discovery agent
DMMAUKO ID DMMAUKO
DMMAUKO DN (S)-2-Amino-3-phenyl-propane-1-thiol
DMMAUKO HS Investigative
DMMAUKO SN CHEMBL34907; 2-Amino-3-phenyl-propane-1-thiol; (S)-2-Amino-3-phenyl-propane-1-thiol; SCHEMBL6805553; BDBM50078129
DMMAUKO DT Small molecular drug
DMMAUKO PC 44284634
DMMAUKO MW 167.27
DMMAUKO FM C9H13NS
DMMAUKO IC InChI=1S/C9H13NS/c10-9(7-11)6-8-4-2-1-3-5-8/h1-5,9,11H,6-7,10H2/t9-/m0/s1
DMMAUKO CS C1=CC=C(C=C1)C[C@@H](CS)N
DMMAUKO IK BUAPSNKVPWEGPA-VIFPVBQESA-N
DMMAUKO IU (2S)-2-amino-3-phenylpropane-1-thiol
DMMAUKO DE Discovery agent
DMF8I2W ID DMF8I2W
DMF8I2W DN (S)-2-amino-4-(benzylthio)butanoic acid
DMF8I2W HS Investigative
DMF8I2W SN S-Benzyl-L-homocysteine; S-benzylhomocysteine; CHEMBL380911; 7689-60-3; (S)-2-amino-4-(benzylthio)butanoic acid; SCHEMBL2829688; S-(Phenylmethyl)-L-homocysteine; 2-Amino-4-benzylthiobutyric Acid; KIPDMPPOTUGMPW-JTQLQIEISA-N; ZINC2035154; BDBM50179713; NSC 206263; NSC 164657; L-2-Amino-4-(benzylthio)butyric Acid
DMF8I2W DT Small molecular drug
DMF8I2W PC 11736265
DMF8I2W MW 225.31
DMF8I2W FM C11H15NO2S
DMF8I2W IC InChI=1S/C11H15NO2S/c12-10(11(13)14)6-7-15-8-9-4-2-1-3-5-9/h1-5,10H,6-8,12H2,(H,13,14)/t10-/m0/s1
DMF8I2W CS C1=CC=C(C=C1)CSCC[C@@H](C(=O)O)N
DMF8I2W IK KIPDMPPOTUGMPW-JTQLQIEISA-N
DMF8I2W IU (2S)-2-amino-4-benzylsulfanylbutanoic acid
DMF8I2W DE Discovery agent
DM8A1HG ID DM8A1HG
DM8A1HG DN (S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DM8A1HG HS Investigative
DM8A1HG SN CHEMBL583979; (S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide; SCHEMBL1311702; QJTVTVAQRCRXSM-KRWDZBQOSA-N
DM8A1HG DT Small molecular drug
DM8A1HG PC 45483175
DM8A1HG MW 306.4
DM8A1HG FM C18H30N2O2
DM8A1HG IC InChI=1S/C18H30N2O2/c1-2-3-4-5-6-7-8-15-9-11-16(12-10-15)20-18(22)17(19)13-14-21/h9-12,17,21H,2-8,13-14,19H2,1H3,(H,20,22)/t17-/m0/s1
DM8A1HG CS CCCCCCCCC1=CC=C(C=C1)NC(=O)[C@H](CCO)N
DM8A1HG IK QJTVTVAQRCRXSM-KRWDZBQOSA-N
DM8A1HG IU (2S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide
DM8A1HG DE Discovery agent
DM96XYI ID DM96XYI
DM96XYI DN (S)-2-Amino-4-methyl-pentane-1-thiol
DM96XYI HS Investigative
DM96XYI SN CHEMBL448735; 88264-65-7; Leucinthiol; 2-Amino-4-methyl-pentane-1-thiol; L-LEUCINETHIOL; (S)-2-Amino-4-methyl-pentane-1-thiol; AC1L3ELJ; 1-Pentanethiol, 2-amino-4-methyl-, (2S)-; SCHEMBL2002339; GXEDNWSUKCJLLB-LURJTMIESA-N; ZINC403014; BDBM50078133; AKOS006342069; (S)-2-Amino-4-methyl-1-pentanethiol; (S)-2-Amino-4-methylpentane-1-thiol; (2S)-2-amino-4-methylpentane-1-thiol; 1-Pentanethiol, 2-amino-4-methyl-, (S)-; L-Leucinethiol, oxidized dihydrochloride, leucine aminopeptidase inhibitor
DM96XYI DT Small molecular drug
DM96XYI PC 139311
DM96XYI MW 133.26
DM96XYI FM C6H15NS
DM96XYI IC InChI=1S/C6H15NS/c1-5(2)3-6(7)4-8/h5-6,8H,3-4,7H2,1-2H3/t6-/m0/s1
DM96XYI CS CC(C)C[C@@H](CS)N
DM96XYI IK GXEDNWSUKCJLLB-LURJTMIESA-N
DM96XYI IU (2S)-2-amino-4-methylpentane-1-thiol
DM96XYI CA CAS 88264-65-7
DM96XYI DE Discovery agent
DMOVQ1T ID DMOVQ1T
DMOVQ1T DN (S)-2-Amino-4-methylsulfanyl-butane-1-thiol
DMOVQ1T HS Investigative
DMOVQ1T SN CHEMBL36661; (S)-2-Amino-4-methylsulfanyl-butane-1-thiol; 1-Butanethiol, 2-amino-4-(methylthio)-, (2S)-; SCHEMBL7164846; PC-18; BDBM50078128; 139428-86-7
DMOVQ1T DT Small molecular drug
DMOVQ1T PC 22885599
DMOVQ1T MW 151.3
DMOVQ1T FM C5H13NS2
DMOVQ1T IC InChI=1S/C5H13NS2/c1-8-3-2-5(6)4-7/h5,7H,2-4,6H2,1H3/t5-/m0/s1
DMOVQ1T CS CSCC[C@@H](CS)N
DMOVQ1T IK NSPBTQHSHXESOT-YFKPBYRVSA-N
DMOVQ1T IU (2S)-2-amino-4-methylsulfanylbutane-1-thiol
DMOVQ1T DE Discovery agent
DMJEGMI ID DMJEGMI
DMJEGMI DN (S)-2-Amino-4-phenyl-butane-1-thiol
DMJEGMI HS Investigative
DMJEGMI SN CHEMBL34963; (S)-2-Amino-4-phenyl-butane-1-thiol; BDBM50078121
DMJEGMI DT Small molecular drug
DMJEGMI PC 44284635
DMJEGMI MW 181.3
DMJEGMI FM C10H15NS
DMJEGMI IC InChI=1S/C10H15NS/c11-10(8-12)7-6-9-4-2-1-3-5-9/h1-5,10,12H,6-8,11H2/t10-/m0/s1
DMJEGMI CS C1=CC=C(C=C1)CC[C@@H](CS)N
DMJEGMI IK OMEJZTIVCZZOPI-JTQLQIEISA-N
DMJEGMI IU (2S)-2-amino-4-phenylbutane-1-thiol
DMJEGMI DE Discovery agent
DMZSWDM ID DMZSWDM
DMZSWDM DN (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid
DMZSWDM HS Investigative
DMZSWDM SN delta-N-Methylarginine; N(5)-methyl-L-arginine; CHEMBL99636; N(5)-carbamimidoyl-N(5)-methyl-L-ornithine; CHEBI:21848; 77044-73-6; L-NMA; 6-monomethyl-l-arginine; AC1Q3XG3; AC1L5A8F; SCHEMBL2307076; DTXSID70227848; BDBM50049254; L-Ornithine, N(5)-(aminoiminomethyl)-N(5)-methyl-; (2S)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid; (2S)-2-amino-5-(carbamimidoyl-methylamino)pentanoic acid
DMZSWDM DT Small molecular drug
DMZSWDM PC 173566
DMZSWDM MW 188.23
DMZSWDM FM C7H16N4O2
DMZSWDM IC InChI=1S/C7H16N4O2/c1-11(7(9)10)4-2-3-5(8)6(12)13/h5H,2-4,8H2,1H3,(H3,9,10)(H,12,13)/t5-/m0/s1
DMZSWDM CS CN(CCC[C@@H](C(=O)O)N)C(=N)N
DMZSWDM IK XKCWNEVAXQCMGP-YFKPBYRVSA-N
DMZSWDM IU (2S)-2-amino-5-[carbamimidoyl(methyl)amino]pentanoic acid
DMZSWDM CA CAS 77044-73-6
DMZSWDM CB CHEBI:21848
DMZSWDM DE Discovery agent
DMRG80O ID DMRG80O
DMRG80O DN (S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid
DMRG80O HS Investigative
DMRG80O DT Small molecular drug
DMRG80O PC 44374166
DMRG80O MW 172.22
DMRG80O FM C8H16N2O2
DMRG80O IC InChI=1S/C8H16N2O2/c1-2-10-6-4-3-5-7(9)8(11)12/h6-7H,2-5,9H2,1H3,(H,11,12)/t7-/m0/s1
DMRG80O CS CCN=CCCC[C@@H](C(=O)O)N
DMRG80O IK SWSFWCQRQUCVNB-ZETCQYMHSA-N
DMRG80O IU (2S)-2-amino-6-ethyliminohexanoic acid
DMRG80O DE Discovery agent
DMG0CSZ ID DMG0CSZ
DMG0CSZ DN (S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide
DMG0CSZ HS Investigative
DMG0CSZ SN CHEMBL568698; (S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide; SCHEMBL1311633; UKLIXHBQCDTKPU-IBGZPJMESA-N
DMG0CSZ DT Small molecular drug
DMG0CSZ PC 45256207
DMG0CSZ MW 334.5
DMG0CSZ FM C20H34N2O2
DMG0CSZ IC InChI=1S/C20H34N2O2/c1-2-3-4-5-6-7-10-17-12-14-18(15-13-17)22-20(24)19(21)11-8-9-16-23/h12-15,19,23H,2-11,16,21H2,1H3,(H,22,24)/t19-/m0/s1
DMG0CSZ CS CCCCCCCCC1=CC=C(C=C1)NC(=O)[C@H](CCCCO)N
DMG0CSZ IK UKLIXHBQCDTKPU-IBGZPJMESA-N
DMG0CSZ IU (2S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide
DMG0CSZ DE Discovery agent
DMN1G8L ID DMN1G8L
DMN1G8L DN (S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide
DMN1G8L HS Investigative
DMN1G8L SN CHEMBL379542; (S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide; Acetamide, 2-amino-N-[(1S)-1-cyano-2-phenylethyl]-; BDBM50186094
DMN1G8L DT Small molecular drug
DMN1G8L PC 44413276
DMN1G8L MW 203.24
DMN1G8L FM C11H13N3O
DMN1G8L IC InChI=1S/C11H13N3O/c12-7-10(14-11(15)8-13)6-9-4-2-1-3-5-9/h1-5,10H,6,8,13H2,(H,14,15)/t10-/m0/s1
DMN1G8L CS C1=CC=C(C=C1)C[C@@H](C#N)NC(=O)CN
DMN1G8L IK QLVGHFBUSGYCCG-JTQLQIEISA-N
DMN1G8L IU 2-amino-N-[(1S)-1-cyano-2-phenylethyl]acetamide
DMN1G8L DE Discovery agent
DMDWFHV ID DMDWFHV
DMDWFHV DN (S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide
DMDWFHV HS Investigative
DMDWFHV SN thiolate analogue, 26a; CHEMBL235911; SCHEMBL16338810; BDBM19139
DMDWFHV DT Small molecular drug
DMDWFHV PC 23634888
DMDWFHV MW 244.4
DMDWFHV FM C12H24N2OS
DMDWFHV IC InChI=1S/C12H24N2OS/c13-11(8-2-1-5-9-16)12(15)14-10-6-3-4-7-10/h10-11,16H,1-9,13H2,(H,14,15)/t11-/m0/s1
DMDWFHV CS C1CCC(C1)NC(=O)[C@H](CCCCCS)N
DMDWFHV IK BNEXTTBMNDFSSZ-NSHDSACASA-N
DMDWFHV IU (2S)-2-amino-N-cyclopentyl-7-sulfanylheptanamide
DMDWFHV DE Discovery agent
DMYG8EV ID DMYG8EV
DMYG8EV DN (S)-2-Amino-propane-1-thiol
DMYG8EV HS Investigative
DMYG8EV SN CHEMBL37279; 2(R,S)-aminopropanethiol; (S)-2-Amino-propane-1-thiol; (S)-2-Aminopropane-1-thiol; ZINC5138737; BDBM50078126
DMYG8EV DT Small molecular drug
DMYG8EV PC 18609630
DMYG8EV MW 91.18
DMYG8EV FM C3H9NS
DMYG8EV IC InChI=1S/C3H9NS/c1-3(4)2-5/h3,5H,2,4H2,1H3/t3-/m0/s1
DMYG8EV CS C[C@@H](CS)N
DMYG8EV IK DJJIBYYAHJOUMY-VKHMYHEASA-N
DMYG8EV IU (2S)-2-aminopropane-1-thiol
DMYG8EV DE Discovery agent
DMQGCM3 ID DMQGCM3
DMQGCM3 DN (S)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine
DMQGCM3 HS Investigative
DMQGCM3 SN CHEMBL257914
DMQGCM3 DT Small molecular drug
DMQGCM3 PC 44456131
DMQGCM3 MW 203.32
DMQGCM3 FM C14H21N
DMQGCM3 IC InChI=1S/C14H21N/c1-12-5-3-7-14(11-12)8-10-15-9-4-6-13(15)2/h3,5,7,11,13H,4,6,8-10H2,1-2H3/t13-/m0/s1
DMQGCM3 CS C[C@H]1CCCN1CCC2=CC=CC(=C2)C
DMQGCM3 IK PXZKWHANTMQGIH-ZDUSSCGKSA-N
DMQGCM3 IU (2S)-2-methyl-1-[2-(3-methylphenyl)ethyl]pyrrolidine
DMQGCM3 DE Discovery agent
DMJFI75 ID DMJFI75
DMJFI75 DN (S)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine
DMJFI75 HS Investigative
DMJFI75 SN CHEMBL257911
DMJFI75 DT Small molecular drug
DMJFI75 PC 44456126
DMJFI75 MW 203.32
DMJFI75 FM C14H21N
DMJFI75 IC InChI=1S/C14H21N/c1-12-5-7-14(8-6-12)9-11-15-10-3-4-13(15)2/h5-8,13H,3-4,9-11H2,1-2H3/t13-/m0/s1
DMJFI75 CS C[C@H]1CCCN1CCC2=CC=C(C=C2)C
DMJFI75 IK BFMXEUSPYLVDSY-ZDUSSCGKSA-N
DMJFI75 IU (2S)-2-methyl-1-[2-(4-methylphenyl)ethyl]pyrrolidine
DMJFI75 DE Discovery agent
DMS5IHX ID DMS5IHX
DMS5IHX DN (S)-3-(1'-Adamantanecarbonyl)amino-caprolactam
DMS5IHX HS Investigative
DMS5IHX SN SCHEMBL195373
DMS5IHX DT Small molecular drug
DMS5IHX PC 11659300
DMS5IHX MW 290.4
DMS5IHX FM C17H26N2O2
DMS5IHX IC InChI=1S/C17H26N2O2/c20-15-14(3-1-2-4-18-15)19-16(21)17-8-11-5-12(9-17)7-13(6-11)10-17/h11-14H,1-10H2,(H,18,20)(H,19,21)/t11?,12?,13?,14-,17?/m0/s1
DMS5IHX CS C1CCNC(=O)[C@H](C1)NC(=O)C23CC4CC(C2)CC(C4)C3
DMS5IHX IK FRJOFURBYVCNEN-ZZTKBFGJSA-N
DMS5IHX IU N-[(3S)-2-oxoazepan-3-yl]adamantane-1-carboxamide
DMS5IHX DE Discovery agent
DM435QN ID DM435QN
DM435QN DN (S)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate
DM435QN HS Investigative
DM435QN SN CHEMBL1080090; BDBM50311766; BDBM50074077; [(1S)-1-Methylpropyl]carbamic acid 3-(1H-imidazole-4-yl)propyl ester; ((S)-sec-Butyl)-carbamic acid 3-(1H-imidazol-4-yl)-propyl ester
DM435QN DT Small molecular drug
DM435QN PC 10489384
DM435QN MW 225.29
DM435QN FM C11H19N3O2
DM435QN IC InChI=1S/C11H19N3O2/c1-3-9(2)14-11(15)16-6-4-5-10-7-12-8-13-10/h7-9H,3-6H2,1-2H3,(H,12,13)(H,14,15)/t9-/m0/s1
DM435QN CS CC[C@H](C)NC(=O)OCCCC1=CN=CN1
DM435QN IK RSHJCGZZSGNBHO-VIFPVBQESA-N
DM435QN IU 3-(1H-imidazol-5-yl)propyl N-[(2S)-butan-2-yl]carbamate
DM435QN DE Discovery agent
DMANICH ID DMANICH
DMANICH DN (S)-3-(2',2'-Dimethyl-propionyl)amino-caprolactam
DMANICH HS Investigative
DMANICH SN CHEMBL512607
DMANICH DT Small molecular drug
DMANICH PC 11735999
DMANICH MW 212.29
DMANICH FM C11H20N2O2
DMANICH IC InChI=1S/C11H20N2O2/c1-11(2,3)10(15)13-8-6-4-5-7-12-9(8)14/h8H,4-7H2,1-3H3,(H,12,14)(H,13,15)/t8-/m0/s1
DMANICH CS CC(C)(C)C(=O)N[C@H]1CCCCNC1=O
DMANICH IK FAFRIRJGUOTURZ-QMMMGPOBSA-N
DMANICH IU 2,2-dimethyl-N-[(3S)-2-oxoazepan-3-yl]propanamide
DMANICH DE Discovery agent
DMTBG57 ID DMTBG57
DMTBG57 DN (S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DMTBG57 HS Investigative
DMTBG57 SN CHEMBL208216; (S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid; SCHEMBL6375241
DMTBG57 DT Small molecular drug
DMTBG57 PC 12985748
DMTBG57 MW 183.2
DMTBG57 FM C9H13NO3
DMTBG57 IC InChI=1S/C9H13NO3/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)/t7-/m0/s1
DMTBG57 CS C1=COC(=C1)C[C@@H](CC(=O)O)CN
DMTBG57 IK JASKMEUWYOXVFB-ZETCQYMHSA-N
DMTBG57 IU (3S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DMTBG57 DE Discovery agent
DMB9CQL ID DMB9CQL
DMB9CQL DN (S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine
DMB9CQL HS Investigative
DMB9CQL SN UNII-XY1C8J4WGF; XY1C8J4WGF; CHEMBL308538; 186588-98-7; F-A-85380; CHEMBL449437; F-A 85380 Tartrate; (S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine; 2-Fluoro-A 85380; 2-Fluoro-A-85380; A-85380, 2-fluoro; 2-Fluoro-3-(((2S)-2-azetidinyl)methoxy)pyridine; Pyridine, 3-[(2S)-2-azetidinylmethoxy]-2-fluoro-; SCHEMBL1220341; ZINC6525315; FCH858175; BDBM50066788; BDBM50263094; AKOS006285963; ACM209530938; J1.007.103H; 2-fluoro-3-(2(s)-azetidinylmethoxy)pyridine; 3-((S)-1-Azetidin-2-ylmethoxy)-2-fluoro-pyridine; Pyridine, 3-((2S)-2-azetidin
DMB9CQL DT Small molecular drug
DMB9CQL PC 10241442
DMB9CQL MW 182.19
DMB9CQL FM C9H11FN2O
DMB9CQL IC InChI=1S/C9H11FN2O/c10-9-8(2-1-4-12-9)13-6-7-3-5-11-7/h1-2,4,7,11H,3,5-6H2/t7-/m0/s1
DMB9CQL CS C1CN[C@@H]1COC2=C(N=CC=C2)F
DMB9CQL IK GVOOYVOZPRROMP-ZETCQYMHSA-N
DMB9CQL IU 3-[[(2S)-azetidin-2-yl]methoxy]-2-fluoropyridine
DMB9CQL CA CAS 186588-98-7
DMB9CQL DE Discovery agent
DM5ILK1 ID DM5ILK1
DM5ILK1 DN (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1 HS Investigative
DM5ILK1 SN CHEMBL445794; (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1 DT Small molecular drug
DM5ILK1 PC 44592118
DM5ILK1 MW 227.3
DM5ILK1 FM C15H17NO
DM5ILK1 IC InChI=1S/C15H17NO/c1-2-4-14-9-12(5-6-13(14)3-1)11-17-15-7-8-16-10-15/h1-6,9,15-16H,7-8,10-11H2/t15-/m0/s1
DM5ILK1 CS C1CNC[C@H]1OCC2=CC3=CC=CC=C3C=C2
DM5ILK1 IK IQZVBBALTJFFCB-HNNXBMFYSA-N
DM5ILK1 IU (3S)-3-(naphthalen-2-ylmethoxy)pyrrolidine
DM5ILK1 CA CAS 1159509-09-7
DM5ILK1 DE Discovery agent
DMG5BUA ID DMG5BUA
DMG5BUA DN (S)-3,4-DCPG
DMG5BUA HS Investigative
DMG5BUA SN (S)-3,4-dicarboxylphenylglycine
DMG5BUA DT Small molecular drug
DMG5BUA PC 16062593
DMG5BUA MW 239.18
DMG5BUA FM C10H9NO6
DMG5BUA IC InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m0/s1
DMG5BUA CS C1=CC(=C(C=C1[C@@H](C(=O)O)N)C(=O)O)C(=O)O
DMG5BUA IK IJVMOGKBEVRBPP-ZETCQYMHSA-N
DMG5BUA IU 4-[(S)-amino(carboxy)methyl]phthalic acid
DMG5BUA CA CAS 201730-11-2
DMG5BUA DE Discovery agent
DMQ0FVJ ID DMQ0FVJ
DMQ0FVJ DN (S)-3HPG
DMQ0FVJ HS Investigative
DMQ0FVJ SN 3-hydroxyphenylglycine
DMQ0FVJ DT Small molecular drug
DMQ0FVJ PC 6604712
DMQ0FVJ MW 167.16
DMQ0FVJ FM C8H9NO3
DMQ0FVJ IC InChI=1S/C8H9NO3/c9-7(8(11)12)5-2-1-3-6(10)4-5/h1-4,7,10H,9H2,(H,11,12)/t7-/m0/s1
DMQ0FVJ CS C1=CC(=CC(=C1)O)[C@@H](C(=O)O)N
DMQ0FVJ IK DQLYTFPAEVJTFM-ZETCQYMHSA-N
DMQ0FVJ IU (2S)-2-amino-2-(3-hydroxyphenyl)acetic acid
DMQ0FVJ DE Discovery agent
DM3TW9V ID DM3TW9V
DM3TW9V DN (S)-3-hydroxy-3-methylglutaryl-CoA
DM3TW9V HS Investigative
DM3TW9V SN hydroxymethylglutaryl-CoA; 3-Hydroxy-3-methylglutaryl-CoA ; 3-hydroxy-3-methylglutaryl-coenzyme A; HMG-CoA
DM3TW9V DT Small molecular drug
DM3TW9V PC 445127
DM3TW9V MW 911.7
DM3TW9V FM C27H44N7O20P3S
DM3TW9V IC InChI=1S/C27H44N7O20P3S/c1-26(2,21(40)24(41)30-5-4-15(35)29-6-7-58-17(38)9-27(3,42)8-16(36)37)11-51-57(48,49)54-56(46,47)50-10-14-20(53-55(43,44)45)19(39)25(52-14)34-13-33-18-22(28)31-12-32-23(18)34/h12-14,19-21,25,39-40,42H,4-11H2,1-3H3,(H,29,35)(H,30,41)(H,36,37)(H,46,47)(H,48,49)(H2,28,31,32)(H2,43,44,45)/t14-,19-,20-,21+,25-,27+/m1/s1
DM3TW9V CS C[C@](CC(=O)O)(CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O
DM3TW9V IK CABVTRNMFUVUDM-VRHQGPGLSA-N
DM3TW9V IU (3S)-5-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-3-hydroxy-3-methyl-5-oxopentanoic acid
DM3TW9V CA CAS 1553-55-5
DM3TW9V CB CHEBI:15467
DM3TW9V DE Discovery agent
DMS4JAG ID DMS4JAG
DMS4JAG DN (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMS4JAG HS Investigative
DMS4JAG SN (3S)-3-methyl-1,2,3,4-tetrahydroisoquinoline; CHEMBL294079; (s)-3-methyl-1,2,3,4-tetrahydroisoquinoline; 15547-43-0; J-501273; AC1OM1IZ; (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL1690518; ZINC19928408; FCH855835; BDBM50052884; AKOS006286080; AB39365; AJ-75701; KB-31985; (3S)-1,2,3,4-tetrahydro-3-methyl-isoquinoline; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-, (3S)-
DMS4JAG DT Small molecular drug
DMS4JAG PC 7462302
DMS4JAG MW 147.22
DMS4JAG FM C10H13N
DMS4JAG IC InChI=1S/C10H13N/c1-8-6-9-4-2-3-5-10(9)7-11-8/h2-5,8,11H,6-7H2,1H3/t8-/m0/s1
DMS4JAG CS C[C@H]1CC2=CC=CC=C2CN1
DMS4JAG IK UEKQPSAKUNXFHL-QMMMGPOBSA-N
DMS4JAG IU (3S)-3-methyl-1,2,3,4-tetrahydroisoquinoline
DMS4JAG DE Discovery agent
DMIG9H3 ID DMIG9H3
DMIG9H3 DN (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMIG9H3 HS Investigative
DMIG9H3 SN CHEMBL186431; (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7678842
DMIG9H3 DT Small molecular drug
DMIG9H3 PC 10198539
DMIG9H3 MW 172.29
DMIG9H3 FM C8H16N2S
DMIG9H3 IC InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)/t7-/m0/s1
DMIG9H3 CS CCC[C@H]1CSCCC(=N1)N
DMIG9H3 IK SWOQAUBWIBZBLQ-ZETCQYMHSA-N
DMIG9H3 IU (3S)-3-propyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMIG9H3 DE Discovery agent
DMLZBJT ID DMLZBJT
DMLZBJT DN (S)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine
DMLZBJT HS Investigative
DMLZBJT SN CHEMBL405069
DMLZBJT DT Small molecular drug
DMLZBJT PC 44456500
DMLZBJT MW 190.28
DMLZBJT FM C12H18N2
DMLZBJT IC InChI=1S/C12H18N2/c1-11-3-2-9-14(11)10-6-12-4-7-13-8-5-12/h4-5,7-8,11H,2-3,6,9-10H2,1H3/t11-/m0/s1
DMLZBJT CS C[C@H]1CCCN1CCC2=CC=NC=C2
DMLZBJT IK HTPLEJUDOQHUSX-NSHDSACASA-N
DMLZBJT IU 4-[2-[(2S)-2-methylpyrrolidin-1-yl]ethyl]pyridine
DMLZBJT DE Discovery agent
DMN9YXL ID DMN9YXL
DMN9YXL DN (S)-4-AHCP
DMN9YXL HS Investigative
DMN9YXL SN CHEMBL28472; 3-(3-HYDROXY-7,8-DIHYDRO-6H-CYCLOHEPTA[D]ISOXAZOL-4-YL)-L-ALANINE; 2-AMINO-3-(3-HYDROXY-7,8-DIHYDRO-6H-CYCLOHEPTA[D]-4-ISOXAZOLYL)PROPIONIC ACID; (2S)-2-amino-3-(3-oxo-7,8-dihydro-6H-cyclohepta[d][1,2]oxazol-4-yl)propanoic acid; (S)-4-AHCP; 1wvj; AC1NRBRE; GTPL4069; BDBM50126764; DB04152; (S)-2-Amino-3-[(3-hydroxy-7,8-dihydro-6H-cyclohept[d]isoxazol)-4-yl]propionic acid; (2S)-2-amino-3-{3-oxo-2H,6H,7H,8H-cyclohepta[d][1,2]oxazol-4-yl}propanoic acid
DMN9YXL DT Small molecular drug
DMN9YXL PC 5288598
DMN9YXL MW 238.24
DMN9YXL FM C11H14N2O4
DMN9YXL IC InChI=1S/C11H14N2O4/c12-7(11(15)16)5-6-3-1-2-4-8-9(6)10(14)13-17-8/h3,7H,1-2,4-5,12H2,(H,13,14)(H,15,16)/t7-/m0/s1
DMN9YXL CS C1CC=C(C2=C(C1)ONC2=O)C[C@@H](C(=O)O)N
DMN9YXL IK HJEPOXZLPHUVFE-ZETCQYMHSA-N
DMN9YXL IU (2S)-2-amino-3-(3-oxo-7,8-dihydro-6H-cyclohepta[d][1,2]oxazol-4-yl)propanoic acid
DMN9YXL DE Discovery agent
DMQK4I2 ID DMQK4I2
DMQK4I2 DN (S)-4C3HPG
DMQK4I2 HS Investigative
DMQK4I2 SN (S)-4-CARBOXY-3-HYDROXYPHENYLGLYCINE; 85148-82-9; (s)-4C3HPG; DFS3SIU1ME; UNII-DFS3SIU1ME; (S)-4-(amino(carboxy)methyl)-2-hydroxybenzoic acid; CHEMBL39372; (S)-4C3H-PG; Benzeneacetic acid, alpha-amino-4-carboxy-3-hydroxy-, (alphaS)-; 4-[(1S)-1-amino-2-hydroxy-2-oxoethyl]-2-hydroxybenzoic acid; 4C3HPG; Tocris-0320; 4-Carboxy-3-hydroxyphenylglycine, (S)-; AC1NSKO9; GTPL1374; SCHEMBL12648356; CTK8F2145; MolPort-003-983-491; ZINC2559031; PDSP1_001316; PDSP2_001300; BDBM50053585; 4-Carboxy-3-hydroxy-L-phenylglycine; BN0022
DMQK4I2 DT Small molecular drug
DMQK4I2 PC 5311455
DMQK4I2 MW 211.17
DMQK4I2 FM C9H9NO5
DMQK4I2 IC InChI=1S/C9H9NO5/c10-7(9(14)15)4-1-2-5(8(12)13)6(11)3-4/h1-3,7,11H,10H2,(H,12,13)(H,14,15)/t7-/m0/s1
DMQK4I2 CS C1=CC(=C(C=C1[C@@H](C(=O)O)N)O)C(=O)O
DMQK4I2 IK GXZSAQLJWLCLOX-ZETCQYMHSA-N
DMQK4I2 IU 4-[(S)-amino(carboxy)methyl]-2-hydroxybenzoic acid
DMQK4I2 CA CAS 85148-82-9
DMQK4I2 DE Discovery agent
DMI12X9 ID DMI12X9
DMI12X9 DN (S)-4-CMTB
DMI12X9 HS Investigative
DMI12X9 SN CHEMBL594525; (S)-4-CMTB; GTPL3420; SCHEMBL16369612; BDBM50305980; (S)-2-(4-chlorophenyl)-N-(5-fluorothiazol-2-yl)-3-methylbutanamide
DMI12X9 DT Small molecular drug
DMI12X9 PC 46226252
DMI12X9 MW 312.8
DMI12X9 FM C14H14ClFN2OS
DMI12X9 IC InChI=1S/C14H14ClFN2OS/c1-8(2)12(9-3-5-10(15)6-4-9)13(19)18-14-17-7-11(16)20-14/h3-8,12H,1-2H3,(H,17,18,19)/t12-/m0/s1
DMI12X9 CS CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=NC=C(S2)F
DMI12X9 IK VMELOMANPNYLFR-LBPRGKRZSA-N
DMI12X9 IU (2S)-2-(4-chlorophenyl)-N-(5-fluoro-1,3-thiazol-2-yl)-3-methylbutanamide
DMI12X9 DE Discovery agent
DMZ9UIL ID DMZ9UIL
DMZ9UIL DN (S)-4CPG
DMZ9UIL HS Investigative
DMZ9UIL SN (S)-4-carboxyphenylglycine
DMZ9UIL DT Small molecular drug
DMZ9UIL PC 5311459
DMZ9UIL MW 195.17
DMZ9UIL FM C9H9NO4
DMZ9UIL IC InChI=1S/C9H9NO4/c10-7(9(13)14)5-1-3-6(4-2-5)8(11)12/h1-4,7H,10H2,(H,11,12)(H,13,14)/t7-/m0/s1
DMZ9UIL CS C1=CC(=CC=C1[C@@H](C(=O)O)N)C(=O)O
DMZ9UIL IK VTMJKPGFERYGJF-ZETCQYMHSA-N
DMZ9UIL IU 4-[(S)-amino(carboxy)methyl]benzoic acid
DMZ9UIL DE Discovery agent
DMCIZ7P ID DMCIZ7P
DMCIZ7P DN (S)-5-fluorowillardiine
DMCIZ7P HS Investigative
DMCIZ7P SN 5-Fluorowillardiine; (S)-(-)-5-fluorowillardiine; 140187-23-1; FLUORO-WILLARDIINE; (S)-F-Willardiine; (S)-5-FLUOROWILLARDIINE; 2-AMINO-3-(5-FLUORO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; CHEMBL123132; CHEBI:42549; 3-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; (S)-alpha-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimmidinepropanoic acid; 3-(5-fluorouracil-1-yl)-L-alanine; (2S)-2-amino-3-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propanoic acid; (S)-(-)-5-fluorowillardine
DMCIZ7P DT Small molecular drug
DMCIZ7P PC 126569
DMCIZ7P MW 217.15
DMCIZ7P FM C7H8FN3O4
DMCIZ7P IC InChI=1S/C7H8FN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15)/t4-/m0/s1
DMCIZ7P CS C1=C(C(=O)NC(=O)N1C[C@@H](C(=O)O)N)F
DMCIZ7P IK DBWPFHJYSTVBCZ-BYPYZUCNSA-N
DMCIZ7P IU (2S)-2-amino-3-(5-fluoro-2,4-dioxopyrimidin-1-yl)propanoic acid
DMCIZ7P CA CAS 140187-23-1
DMCIZ7P CB CHEBI:42549
DMCIZ7P DE Discovery agent
DM1DNRP ID DM1DNRP
DM1DNRP DN (S)-5-iodowillardiine
DM1DNRP HS Investigative
DM1DNRP SN IODO-WILLARDIINE; S-5-Iodowillardiine; (S)-(-)-5-IODOWILLARDIINE; (s)-5-iodowillardiine; 140187-25-3; CHEMBL121915; 2-AMINO-3-(5-IODO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; IWD; 5 Iodowillardine; 5-iodowillardiine; 1mqg; Tocris-0307; AC1L9KKQ; Lopac0_001239; SCHEMBL401659; GTPL4071; SCHEMBL13319969; DTXSID90332246; MolPort-006-069-040; ZINC2047688; BDBM50060627; AKOS024457411; DB02818; CCG-205313; NCGC00024529-01; NCGC00024529-02; EU-0101239; B6252; W-110; SR-01000597629; SR-01000075424; SR-01000075424-1; J-007367
DM1DNRP DT Small molecular drug
DM1DNRP PC 447196
DM1DNRP MW 325.06
DM1DNRP FM C7H8IN3O4
DM1DNRP IC InChI=1S/C7H8IN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15)/t4-/m0/s1
DM1DNRP CS C1=C(C(=O)NC(=O)N1C[C@@H](C(=O)O)N)I
DM1DNRP IK AXXYLTBQIQBTES-BYPYZUCNSA-N
DM1DNRP IU (2S)-2-amino-3-(5-iodo-2,4-dioxopyrimidin-1-yl)propanoic acid
DM1DNRP CA CAS 140187-25-3
DM1DNRP DE Discovery agent
DM32PJ5 ID DM32PJ5
DM32PJ5 DN (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM32PJ5 HS Investigative
DM32PJ5 SN CHEMBL469551; (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile
DM32PJ5 DT Small molecular drug
DM32PJ5 PC 44592198
DM32PJ5 MW 252.31
DM32PJ5 FM C16H16N2O
DM32PJ5 IC InChI=1S/C16H16N2O/c17-9-12-1-2-15-8-16(4-3-14(15)7-12)19-11-13-5-6-18-10-13/h1-4,7-8,13,18H,5-6,10-11H2/t13-/m0/s1
DM32PJ5 CS C1CNC[C@H]1COC2=CC3=C(C=C2)C=C(C=C3)C#N
DM32PJ5 IK PYEILVKGQDUINV-ZDUSSCGKSA-N
DM32PJ5 IU 6-[[(3S)-pyrrolidin-3-yl]methoxy]naphthalene-2-carbonitrile
DM32PJ5 DE Discovery agent
DMG58HM ID DMG58HM
DMG58HM DN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid
DMG58HM HS Investigative
DMG58HM SN iminoethyl-lysin
DMG58HM DT Small molecular drug
DMG58HM PC 11446787
DMG58HM MW 187.24
DMG58HM FM C8H17N3O2
DMG58HM IC InChI=1S/C8H17N3O2/c9-4-2-1-3-7(8(12)13)11-6-5-10/h5,7,10-11H,1-4,6,9H2,(H,12,13)/t7-/m0/s1
DMG58HM CS C(CCN)C[C@@H](C(=O)O)NCC=N
DMG58HM IK NNRMAICNBIUGOW-ZETCQYMHSA-N
DMG58HM IU (2S)-6-amino-2-(2-iminoethylamino)hexanoic acid
DMG58HM DE Discovery agent
DMTUZIN ID DMTUZIN
DMTUZIN DN (S)-alpha-methylhistamine
DMTUZIN HS Investigative
DMTUZIN SN (S)-alpha-MeHA
DMTUZIN DT Small molecular drug
DMTUZIN PC 6603865
DMTUZIN MW 125.17
DMTUZIN FM C6H11N3
DMTUZIN IC InChI=1S/C6H11N3/c1-5(7)2-6-3-8-4-9-6/h3-5H,2,7H2,1H3,(H,8,9)/t5-/m0/s1
DMTUZIN CS C[C@@H](CC1=CN=CN1)N
DMTUZIN IK XNQIOISZPFVUFG-YFKPBYRVSA-N
DMTUZIN IU (2S)-1-(1H-imidazol-5-yl)propan-2-amine
DMTUZIN CA CAS 75614-93-6
DMTUZIN CB CHEBI:125525
DMTUZIN DE Discovery agent
DMNJSTM ID DMNJSTM
DMNJSTM DN (S)-AMPA
DMNJSTM HS Investigative
DMNJSTM SN (S)-AMPA; 83643-88-3; (S)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; UNII-9280SC28GD; CHEMBL276815; 9280SC28GD; (S)-2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)-propionic acid; AMPA, L-; AMQ; glutamate-AMPA; 1ftm; Tocris-0254; Tocris-0169; Tocris-1074; S-AMPA; 1p1q; L-AMPA; Lopac-G-017; AC1L4JUQ; Biomol-NT_000216; (S)-a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; SCHEMBL667915; BPBio1_001304; CTK7I3476; BDBM17662; BDBM85214; UUDAMDVQRQNNHZ-YFKPBYRVSA-N; MolPort-003-940-001; MolPort-003-983-512; HMS3266E09
DMNJSTM DT Small molecular drug
DMNJSTM PC 158397
DMNJSTM MW 186.17
DMNJSTM FM C7H10N2O4
DMNJSTM IC InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)/t5-/m0/s1
DMNJSTM CS CC1=C(C(=O)NO1)C[C@@H](C(=O)O)N
DMNJSTM IK UUDAMDVQRQNNHZ-YFKPBYRVSA-N
DMNJSTM IU (2S)-2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
DMNJSTM CA CAS 83643-88-3
DMNJSTM DE Discovery agent
DMEKGIX ID DMEKGIX
DMEKGIX DN (S)APOMORPHINE
DMEKGIX HS Investigative
DMEKGIX SN S-(+)-apomorphine; S-apomorphine; UNII-LH812IV7LI; LH812IV7LI; CHEMBL416288; 39478-62-1; (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (S)-; S(+)-APOMORPHINE; (+)-10,11-Dihydroxyaporphine; Apomorphine, S-; AC1LEHBI; Lopac-A-4393; Oprea1_044402; SCHEMBL6922802; GTPL8285; CTK1C3986; cid_6852389; BDBM29643; DTXSID40192615; MolPort-002-507-063; (6as)-10,11-dihydroxyaporphine; ZINC155525; PDSP1_001504
DMEKGIX DT Small molecular drug
DMEKGIX PC 736083
DMEKGIX MW 267.32
DMEKGIX FM C17H17NO2
DMEKGIX IC InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m0/s1
DMEKGIX CS CN1CCC2=C3[C@@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O
DMEKGIX IK VMWNQDUVQKEIOC-ZDUSSCGKSA-N
DMEKGIX IU (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMEKGIX CA CAS 39478-62-1
DMEKGIX DE Discovery agent
DMA43NY ID DMA43NY
DMA43NY DN (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate
DMA43NY HS Investigative
DMA43NY SN Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)-
DMA43NY DT Small molecular drug
DMA43NY PC 5491980
DMA43NY MW 255.7
DMA43NY FM C12H14ClNO3
DMA43NY IC InChI=1S/C12H14ClNO3/c1-9(11(15)7-13)14-12(16)17-8-10-5-3-2-4-6-10/h2-6,9H,7-8H2,1H3,(H,14,16)/t9-/m0/s1
DMA43NY CS C[C@@H](C(=O)CCl)NC(=O)OCC1=CC=CC=C1
DMA43NY IK ASDQMJAOUJQRCM-VIFPVBQESA-N
DMA43NY IU benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate
DMA43NY CA CAS 41036-43-5
DMA43NY DE Discovery agent
DMPI0AX ID DMPI0AX
DMPI0AX DN (S)-BULBOCAPNINE
DMPI0AX HS Investigative
DMPI0AX SN Bulbocapnine; 298-45-3; UNII-O0TGI865QO; Bulbokaprin; O0TGI865QO; CHEMBL157912; CHEBI:3211; (S)-BULBOCAPNINE; EINECS 206-061-1; Bulbocapnin; Buibocapnine hydrochloride; AC1L1ZLR; 632-47-3; ZINC103; SCHEMBL678694; 6a-alpha-APORPHIN-11-OL, 10-METHOXY-1,2-(METHYLENEDIOXY)-; AC1Q703Q; DTXSID20183940; BDBM50016018; 9126AF; PDSP2_000621; ACM298453; AKOS000276822; C09367; 11-Methoxy-7-methyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinolin-12-ol (Bulbocapnine)
DMPI0AX DT Small molecular drug
DMPI0AX PC 12441
DMPI0AX MW 325.4
DMPI0AX FM C19H19NO4
DMPI0AX IC InChI=1S/C19H19NO4/c1-20-6-5-11-8-14-19(24-9-23-14)17-15(11)12(20)7-10-3-4-13(22-2)18(21)16(10)17/h3-4,8,12,21H,5-7,9H2,1-2H3/t12-/m0/s1
DMPI0AX CS CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=C4C(=C(C=C5)OC)O)OCO3
DMPI0AX IK LODGIKWNLDQZBM-LBPRGKRZSA-N
DMPI0AX IU (12S)-17-methoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaen-18-ol
DMPI0AX CA CAS 298-45-3
DMPI0AX CB CHEBI:3211
DMPI0AX DE Discovery agent
DMJN659 ID DMJN659
DMJN659 DN (S)-cetirizine
DMJN659 HS Investigative
DMJN659 SN UNII-V57G6B5I8Z; V57G6B5I8Z; 130018-76-7; (2-{4-[(S)-(4-Chlorophenyl)(Phenyl)methyl]piperazin-1-Yl}ethoxy)acetic Acid; Dextrocetirizine Dihydrochloride; 2-[2-[4-[(S)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid; Dextrocetirizine; (s)cetirizine; Cetirizine, (S)-; (S)-dextrocetirizine; Cetirizine (+) isomer; NCGC00016949-01; CAS-83881-52-1; GTPL1215; SCHEMBL5526985; AC1L44V3; (+)-Cetirizine Dihydrochloride; CHEMBL1334217; BDBM85029; (S)-(+)-DEXTROCETIRIZINE; ZINC19364229
DMJN659 DT Small molecular drug
DMJN659 PC 150716
DMJN659 MW 388.9
DMJN659 FM C21H25ClN2O3
DMJN659 IC InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m0/s1
DMJN659 CS C1CN(CCN1CCOCC(=O)O)[C@@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl
DMJN659 IK ZKLPARSLTMPFCP-NRFANRHFSA-N
DMJN659 IU 2-[2-[4-[(S)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
DMJN659 CA CAS 130018-76-7
DMJN659 DE Discovery agent
DMQSC21 ID DMQSC21
DMQSC21 DN (S)-DHPA
DMQSC21 HS Investigative
DMQSC21 SN S-Dihydroxypropyladenine; (S)-9-(2,3-Dihydroxypropyl)adenine; (S)-DHPA; 9-D-(2,3-Dihydroxypropyl)adenine; 54262-83-8; BRN 0990757; (2s)-3-(6-amino-9h-purin-9-yl)propane-1,2-diol; (2S)-3-(6-aminopurin-9-yl)propane-1,2-diol; (S)-3-(6-Amino-9H-purin-9-yl)-1,2-propanediol; 1,2-Propanediol, 3-(6-amino-9H-purin-9-yl)-, (S)-; 9-(S)-(2,3-Dihydroxypropyl)adenine; AC1Q4VGK; DHPA, (S)-DHPA; AC1L2JB5; 5-26-16-00201 (Beilstein Handbook Reference); SCHEMBL936286; CHEMBL494759; CTK5A0230; 9-(1,2-dihydroxypropyl)adenine; ZINC370772
DMQSC21 DT Small molecular drug
DMQSC21 PC 73124
DMQSC21 MW 209.21
DMQSC21 FM C8H11N5O2
DMQSC21 IC InChI=1S/C8H11N5O2/c9-7-6-8(11-3-10-7)13(4-12-6)1-5(15)2-14/h3-5,14-15H,1-2H2,(H2,9,10,11)/t5-/m0/s1
DMQSC21 CS C1=NC(=C2C(=N1)N(C=N2)C[C@@H](CO)O)N
DMQSC21 IK GSLQFBVNOFBPRJ-YFKPBYRVSA-N
DMQSC21 IU (2S)-3-(6-aminopurin-9-yl)propane-1,2-diol
DMQSC21 CA CAS 54262-83-8
DMQSC21 DE Discovery agent
DM0SEYN ID DM0SEYN
DM0SEYN DN (S)-dimethylenastron
DM0SEYN HS Investigative
DM0SEYN SN ZINC22309237
DM0SEYN DT Small molecular drug
DM0SEYN PC 49863704
DM0SEYN MW 302.4
DM0SEYN FM C16H18N2O2S
DM0SEYN IC InChI=1S/C16H18N2O2S/c1-16(2)7-11-13(12(20)8-16)14(18-15(21)17-11)9-4-3-5-10(19)6-9/h3-6,14,19H,7-8H2,1-2H3,(H2,17,18,21)/t14-/m0/s1
DM0SEYN CS CC1(CC2=C([C@@H](NC(=S)N2)C3=CC(=CC=C3)O)C(=O)C1)C
DM0SEYN IK RUOOPLOUUAYNPY-AWEZNQCLSA-N
DM0SEYN IU (4S)-4-(3-hydroxyphenyl)-7,7-dimethyl-2-sulfanylidene-3,4,6,8-tetrahydro-1H-quinazolin-5-one
DM0SEYN DE Discovery agent
DM0EQTM ID DM0EQTM
DM0EQTM DN (S)-EF-1520
DM0EQTM HS Investigative
DM0EQTM SN (S)-EF-1520; GTPL6513
DM0EQTM DT Small molecular drug
DM0EQTM PC 53324619
DM0EQTM MW 414.6
DM0EQTM FM C22H26N2O2S2
DM0EQTM IC InChI=1S/C22H26N2O2S2/c1-14-9-12-27-20(14)16(21-15(2)10-13-28-21)6-5-11-24(3)17-7-4-8-18-19(17)22(25)23-26-18/h6,9-10,12-13,17H,4-5,7-8,11H2,1-3H3,(H,23,25)/t17-/m0/s1
DM0EQTM CS CC1=C(SC=C1)C(=CCCN(C)[C@H]2CCCC3=C2C(=O)NO3)C4=C(C=CS4)C
DM0EQTM IK CUESOMOCKVRNIW-KRWDZBQOSA-N
DM0EQTM IU (4S)-4-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl-methylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DM0EQTM DE Discovery agent
DMWNEA1 ID DMWNEA1
DMWNEA1 DN (S)-enastron
DMWNEA1 HS Investigative
DMWNEA1 SN AC1LFOER; 2x7c; ZINC2601603; (4S)-4-(3-hydroxyphenyl)-2-sulfanylidene-1,3,4,6,7,8-hexahydroquinazolin-5-one
DMWNEA1 DT Small molecular drug
DMWNEA1 PC 757000
DMWNEA1 MW 274.34
DMWNEA1 FM C14H14N2O2S
DMWNEA1 IC InChI=1S/C14H14N2O2S/c17-9-4-1-3-8(7-9)13-12-10(15-14(19)16-13)5-2-6-11(12)18/h1,3-4,7,13,17H,2,5-6H2,(H2,15,16,19)/t13-/m0/s1
DMWNEA1 CS C1CC2=C([C@@H](NC(=S)N2)C3=CC(=CC=C3)O)C(=O)C1
DMWNEA1 IK BJTGVSGWTIUCSM-ZDUSSCGKSA-N
DMWNEA1 IU (4S)-4-(3-hydroxyphenyl)-2-sulfanylidene-1,3,4,6,7,8-hexahydroquinazolin-5-one
DMWNEA1 DE Discovery agent
DMFSXTJ ID DMFSXTJ
DMFSXTJ DN (S)-Ethyl 6-(2-oxohexadecanamido)decanoate
DMFSXTJ HS Investigative
DMFSXTJ SN CHEMBL462543
DMFSXTJ DT Small molecular drug
DMFSXTJ PC 44562726
DMFSXTJ MW 467.7
DMFSXTJ FM C28H53NO4
DMFSXTJ IC InChI=1S/C28H53NO4/c1-4-7-9-10-11-12-13-14-15-16-17-18-23-26(30)28(32)29-25(21-8-5-2)22-19-20-24-27(31)33-6-3/h25H,4-24H2,1-3H3,(H,29,32)/t25-/m0/s1
DMFSXTJ CS CCCCCCCCCCCCCCC(=O)C(=O)N[C@@H](CCCC)CCCCC(=O)OCC
DMFSXTJ IK HEZLMGZNPUCJHH-VWLOTQADSA-N
DMFSXTJ IU ethyl (6S)-6-(2-oxohexadecanoylamino)decanoate
DMFSXTJ DE Discovery agent
DM715AS ID DM715AS
DM715AS DN (S)-flurocarazolol
DM715AS HS Investigative
DM715AS SN (S)-flurocarazolol; GTPL66; CHEMBL326418; SCHEMBL14155316; PDSP2_000794; PDSP1_000807
DM715AS DT Small molecular drug
DM715AS PC 10358392
DM715AS MW 316.4
DM715AS FM C18H21FN2O2
DM715AS IC InChI=1S/C18H21FN2O2/c1-12(9-19)20-10-13(22)11-23-17-8-4-7-16-18(17)14-5-2-3-6-15(14)21-16/h2-8,12-13,20-22H,9-11H2,1H3/t12?,13-/m0/s1
DM715AS CS CC(CF)NC[C@@H](COC1=CC=CC2=C1C3=CC=CC=C3N2)O
DM715AS IK QHLGXPUIUKSADT-ABLWVSNPSA-N
DM715AS IU (2S)-1-(9H-carbazol-4-yloxy)-3-(1-fluoropropan-2-ylamino)propan-2-ol
DM715AS DE Discovery agent
DM5WETL ID DM5WETL
DM5WETL DN (S)-FTY720P
DM5WETL HS Investigative
DM5WETL SN CHEMBL1213480
DM5WETL DT Small molecular drug
DM5WETL PC 11452022
DM5WETL MW 387.5
DM5WETL FM C19H34NO5P
DM5WETL IC InChI=1S/C19H34NO5P/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-25-26(22,23)24/h9-12,21H,2-8,13-16,20H2,1H3,(H2,22,23,24)/t19-/m0/s1
DM5WETL CS CCCCCCCCC1=CC=C(C=C1)CC[C@](CO)(COP(=O)(O)O)N
DM5WETL IK LRFKWQGGENFBFO-IBGZPJMESA-N
DM5WETL IU [(2S)-2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate
DM5WETL CA CAS 402616-26-6
DM8H0ND ID DM8H0ND
DM8H0ND DN (S)-Methyl 4-(2-oxohexadecanamido)octanoate
DM8H0ND HS Investigative
DM8H0ND SN CHEMBL462361
DM8H0ND DT Small molecular drug
DM8H0ND PC 44562672
DM8H0ND MW 425.6
DM8H0ND FM C25H47NO4
DM8H0ND IC InChI=1S/C25H47NO4/c1-4-6-8-9-10-11-12-13-14-15-16-17-19-23(27)25(29)26-22(18-7-5-2)20-21-24(28)30-3/h22H,4-21H2,1-3H3,(H,26,29)/t22-/m0/s1
DM8H0ND CS CCCCCCCCCCCCCCC(=O)C(=O)N[C@@H](CCCC)CCC(=O)OC
DM8H0ND IK RFWRXBDBLIGDAF-QFIPXVFZSA-N
DM8H0ND IU methyl (4S)-4-(2-oxohexadecanoylamino)octanoate
DM8H0ND DE Discovery agent
DMLR0N3 ID DMLR0N3
DMLR0N3 DN (S)-N-(1-phenylethyl)acetimidamide hydrobromide
DMLR0N3 HS Investigative
DMLR0N3 SN CHEMBL448703; 1-[(1-Phenylethyl)amino]ethaniminium bromide
DMLR0N3 DT Small molecular drug
DMLR0N3 PC 25231669
DMLR0N3 MW 243.14
DMLR0N3 FM C10H15BrN2
DMLR0N3 IC InChI=1S/C10H14N2.BrH/c1-8(12-9(2)11)10-6-4-3-5-7-10;/h3-8H,1-2H3,(H2,11,12);1H/t8-;/m0./s1
DMLR0N3 CS C[C@@H](C1=CC=CC=C1)N=C(C)N.Br
DMLR0N3 IK SXSWEEJYFGUAON-QRPNPIFTSA-N
DMLR0N3 IU N'-[(1S)-1-phenylethyl]ethanimidamide;hydrobromide
DMLR0N3 DE Discovery agent
DMGFOQJ ID DMGFOQJ
DMGFOQJ DN (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide
DMGFOQJ HS Investigative
DMGFOQJ SN (S)-1 [PMID: 16904708]; compound 2 [PMID: 12852750]
DMGFOQJ DT Small molecular drug
DMGFOQJ PC 9949648
DMGFOQJ MW 336.4
DMGFOQJ FM C21H24N2O2
DMGFOQJ IC InChI=1S/C21H24N2O2/c1-17(22-21(24)11-10-18-6-3-2-4-7-18)19-8-5-9-20(16-19)23-12-14-25-15-13-23/h2-11,16-17H,12-15H2,1H3,(H,22,24)/b11-10+/t17-/m0/s1
DMGFOQJ CS C[C@@H](C1=CC(=CC=C1)N2CCOCC2)NC(=O)/C=C/C3=CC=CC=C3
DMGFOQJ IK QMIMHUDEVKGOTQ-DVQDXYAYSA-N
DMGFOQJ IU (E)-N-[(1S)-1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylprop-2-enamide
DMGFOQJ DE Discovery agent
DMGMAPB ID DMGMAPB
DMGMAPB DN (S)-N2-[4-(benzyloxy)benzyl]alaninamide
DMGMAPB HS Investigative
DMGMAPB SN CHEMBL352004; (S)-N2-[4-(benzyloxy)benzyl]alaninamide; SCHEMBL4456855; BDBM50221295; (S)-2-(4-Benzyloxy-benzylamino)-propionamide
DMGMAPB DT Small molecular drug
DMGMAPB PC 10517190
DMGMAPB MW 284.35
DMGMAPB FM C17H20N2O2
DMGMAPB IC InChI=1S/C17H20N2O2/c1-13(17(18)20)19-11-14-7-9-16(10-8-14)21-12-15-5-3-2-4-6-15/h2-10,13,19H,11-12H2,1H3,(H2,18,20)/t13-/m0/s1
DMGMAPB CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2
DMGMAPB IK IEHDKRBHKAGVKZ-ZDUSSCGKSA-N
DMGMAPB IU (2S)-2-[(4-phenylmethoxyphenyl)methylamino]propanamide
DMGMAPB DE Discovery agent
DMW5ZK7 ID DMW5ZK7
DMW5ZK7 DN (S)-N2-[4-(benzyloxy)benzyl]serinamide
DMW5ZK7 HS Investigative
DMW5ZK7 SN CHEMBL243058; (S)-N2-[4-(benzyloxy)benzyl]serinamide; SCHEMBL7394895; ZINC28711471
DMW5ZK7 DT Small molecular drug
DMW5ZK7 PC 10756633
DMW5ZK7 MW 300.35
DMW5ZK7 FM C17H20N2O3
DMW5ZK7 IC InChI=1S/C17H20N2O3/c18-17(21)16(11-20)19-10-13-6-8-15(9-7-13)22-12-14-4-2-1-3-5-14/h1-9,16,19-20H,10-12H2,(H2,18,21)/t16-/m0/s1
DMW5ZK7 CS C1=CC=C(C=C1)COC2=CC=C(C=C2)CN[C@@H](CO)C(=O)N
DMW5ZK7 IK JMIJOQDPXHRPOI-INIZCTEOSA-N
DMW5ZK7 IU (2S)-3-hydroxy-2-[(4-phenylmethoxyphenyl)methylamino]propanamide
DMW5ZK7 DE Discovery agent
DMKMJBL ID DMKMJBL
DMKMJBL DN (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide
DMKMJBL HS Investigative
DMKMJBL SN CHEMBL242618; (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide; SCHEMBL2018555
DMKMJBL DT Small molecular drug
DMKMJBL PC 10087289
DMKMJBL MW 318.8
DMKMJBL FM C17H19ClN2O2
DMKMJBL IC InChI=1S/C17H19ClN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMKMJBL CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)Cl
DMKMJBL IK JFADNUHMEURSIM-LBPRGKRZSA-N
DMKMJBL IU (2S)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide
DMKMJBL DE Discovery agent
DMINLCJ ID DMINLCJ
DMINLCJ DN (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide
DMINLCJ HS Investigative
DMINLCJ SN CHEMBL394347; (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide; SCHEMBL2017824
DMINLCJ DT Small molecular drug
DMINLCJ PC 23625507
DMINLCJ MW 334.8
DMINLCJ FM C17H19ClN2O3
DMINLCJ IC InChI=1S/C17H19ClN2O3/c18-14-3-1-2-13(8-14)11-23-15-6-4-12(5-7-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m0/s1
DMINLCJ CS C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CN[C@@H](CO)C(=O)N
DMINLCJ IK WYDCYPPIJUASJE-INIZCTEOSA-N
DMINLCJ IU (2S)-2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMINLCJ DE Discovery agent
DMSC8ZW ID DMSC8ZW
DMSC8ZW DN (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide
DMSC8ZW HS Investigative
DMSC8ZW SN CHEMBL243059; (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide; SCHEMBL2014885
DMSC8ZW DT Small molecular drug
DMSC8ZW PC 23625355
DMSC8ZW MW 318.34
DMSC8ZW FM C17H19FN2O3
DMSC8ZW IC InChI=1S/C17H19FN2O3/c18-14-3-1-2-13(8-14)11-23-15-6-4-12(5-7-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m0/s1
DMSC8ZW CS C1=CC(=CC(=C1)F)COC2=CC=C(C=C2)CN[C@@H](CO)C(=O)N
DMSC8ZW IK UTIKAYGNKRMHTP-INIZCTEOSA-N
DMSC8ZW IU (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMSC8ZW DE Discovery agent
DMU3F7H ID DMU3F7H
DMU3F7H DN (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide
DMU3F7H HS Investigative
DMU3F7H SN CHEMBL397987; (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide
DMU3F7H DT Small molecular drug
DMU3F7H PC 23625354
DMU3F7H MW 318.8
DMU3F7H FM C17H19ClN2O2
DMU3F7H IC InChI=1S/C17H19ClN2O2/c1-12(17(19)21)20-10-13-4-8-16(9-5-13)22-11-14-2-6-15(18)7-3-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
DMU3F7H CS C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=C(C=C2)Cl
DMU3F7H IK JAJNPDROJVQSPW-LBPRGKRZSA-N
DMU3F7H IU (2S)-2-[[4-[(4-chlorophenyl)methoxy]phenyl]methylamino]propanamide
DMU3F7H DE Discovery agent
DMLFOPV ID DMLFOPV
DMLFOPV DN (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide
DMLFOPV HS Investigative
DMLFOPV SN CHEMBL243077; (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide
DMLFOPV DT Small molecular drug
DMLFOPV PC 23625208
DMLFOPV MW 334.8
DMLFOPV FM C17H19ClN2O3
DMLFOPV IC InChI=1S/C17H19ClN2O3/c18-14-5-1-13(2-6-14)11-23-15-7-3-12(4-8-15)9-20-16(10-21)17(19)22/h1-8,16,20-21H,9-11H2,(H2,19,22)/t16-/m0/s1
DMLFOPV CS C1=CC(=CC=C1CN[C@@H](CO)C(=O)N)OCC2=CC=C(C=C2)Cl
DMLFOPV IK NKJUZCSUSIWWQG-INIZCTEOSA-N
DMLFOPV IU (2S)-2-[[4-[(4-chlorophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanamide
DMLFOPV DE Discovery agent
DMLP63J ID DMLP63J
DMLP63J DN (S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide
DMLP63J HS Investigative
DMLP63J SN CHEMBL243079; (S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide
DMLP63J DT Small molecular drug
DMLP63J PC 23625356
DMLP63J MW 345.3
DMLP63J FM C17H19N3O5
DMLP63J IC InChI=1S/C17H19N3O5/c18-17(22)16(10-21)19-9-12-3-7-15(8-4-12)25-11-13-1-5-14(6-2-13)20(23)24/h1-8,16,19,21H,9-11H2,(H2,18,22)/t16-/m0/s1
DMLP63J CS C1=CC(=CC=C1CN[C@@H](CO)C(=O)N)OCC2=CC=C(C=C2)[N+](=O)[O-]
DMLP63J IK XVFXQICJBNSYEW-INIZCTEOSA-N
DMLP63J IU (2S)-3-hydroxy-2-[[4-[(4-nitrophenyl)methoxy]phenyl]methylamino]propanamide
DMLP63J DE Discovery agent
DMUAYZJ ID DMUAYZJ
DMUAYZJ DN (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide
DMUAYZJ HS Investigative
DMUAYZJ SN CHEMBL567932; (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide; SCHEMBL4634335
DMUAYZJ DT Small molecular drug
DMUAYZJ PC 11220185
DMUAYZJ MW 296.4
DMUAYZJ FM C19H24N2O
DMUAYZJ IC InChI=1S/C19H24N2O/c1-14(2)13-21(18-9-10-20-12-18)19(22)17-8-7-15-5-3-4-6-16(15)11-17/h3-8,11,14,18,20H,9-10,12-13H2,1-2H3/t18-/m0/s1
DMUAYZJ CS CC(C)CN([C@H]1CCNC1)C(=O)C2=CC3=CC=CC=C3C=C2
DMUAYZJ IK CEUJKSVEPJAVKD-SFHVURJKSA-N
DMUAYZJ IU N-(2-methylpropyl)-N-[(3S)-pyrrolidin-3-yl]naphthalene-2-carboxamide
DMUAYZJ DE Discovery agent
DMNOWZ2 ID DMNOWZ2
DMNOWZ2 DN (S)-N-oleoyltyrosinol
DMNOWZ2 HS Investigative
DMNOWZ2 SN OMDM-1
DMNOWZ2 DT Small molecular drug
DMNOWZ2 PC 10410511
DMNOWZ2 MW 431.7
DMNOWZ2 FM C27H45NO3
DMNOWZ2 IC InChI=1S/C27H45NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(31)28-25(23-29)22-24-18-20-26(30)21-19-24/h9-10,18-21,25,29-30H,2-8,11-17,22-23H2,1H3,(H,28,31)/b10-9-/t25-/m0/s1
DMNOWZ2 CS CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)CO
DMNOWZ2 IK ICDMLAQPOAVWNH-JRUKXMRZSA-N
DMNOWZ2 IU (Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide
DMNOWZ2 DE Discovery agent
DMULFYA ID DMULFYA
DMULFYA DN (S)-NORDULOXETINE
DMULFYA HS Investigative
DMULFYA SN CHEMBL595063; (S)-NORDULOXETINE; SCHEMBL4573573; ZINC34220632; BDBM50304388; (S)-gamma-(1-Naphthyloxy)-2-thiophenepropan-1-amine
DMULFYA DT Small molecular drug
DMULFYA PC 10107888
DMULFYA MW 283.4
DMULFYA FM C17H17NOS
DMULFYA IC InChI=1S/C17H17NOS/c18-11-10-16(17-9-4-12-20-17)19-15-8-3-6-13-5-1-2-7-14(13)15/h1-9,12,16H,10-11,18H2/t16-/m0/s1
DMULFYA CS C1=CC=C2C(=C1)C=CC=C2O[C@@H](CCN)C3=CC=CS3
DMULFYA IK ZMXLKLOJDLMZFC-INIZCTEOSA-N
DMULFYA IU (3S)-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
DMULFYA CA CAS 178273-35-3
DMULFYA DE Discovery agent
DM8ZTPF ID DM8ZTPF
DM8ZTPF DN (S)-Norfluoxetine
DM8ZTPF HS Investigative
DM8ZTPF SN 126924-38-7; SEPROXETINE; UNII-25CO3X0R31; (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE; CHEMBL465123; (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; 25CO3X0R31; (S)-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine; Seproxetine [INN]; S-Norfluoxetine; AC1MHW5Z; SCHEMBL272873; ZINC4531; CTK8E9555; MolPort-005-941-621; 9173AH; BDBM50254790; AKOS027384574; DB06731; AJ-08214; RT-014029; FT-0673089; NFL_296.1257_14.5; J-005451
DM8ZTPF DT Small molecular drug
DM8ZTPF PC 3058751
DM8ZTPF MW 295.3
DM8ZTPF FM C16H16F3NO
DM8ZTPF IC InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m0/s1
DM8ZTPF CS C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F
DM8ZTPF IK WIQRCHMSJFFONW-HNNXBMFYSA-N
DM8ZTPF IU (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
DM8ZTPF CA CAS 126924-38-7
DM8ZTPF DE Discovery agent
DMAI1HU ID DMAI1HU
DMAI1HU DN (S)-phenylglycine
DMAI1HU HS Investigative
DMAI1HU SN 2935-35-5; H-Phg-Oh; L-Phenylglycine; (S)-2-Amino-2-phenylacetic acid; L-(+)-alpha-Phenylglycine; L-2-Phenylglycine; (2S)-amino(phenyl)acetic acid; L-(+)-2-Phenylglycine; Phenylglycine; (2S)-2-amino-2-phenylacetic acid; L-(+)-alpha-Aminophenylacetic acid; UNII-3I753R0XI6; L-alpha-Phenylglycine; L(+)-alpha-Phenylglycine; (S)-(+)-2-Phenylglycine; CHEMBL378605; (2S)-amino(phenyl)ethanoic acid; CHEBI:439819; 3I753R0XI6; MFCD00064403; (alphaS)-alpha-aminobenzeneacetic acid
DMAI1HU DT Small molecular drug
DMAI1HU PC 99291
DMAI1HU MW 151.16
DMAI1HU FM C8H9NO2
DMAI1HU IC InChI=1S/C8H9NO2/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7H,9H2,(H,10,11)/t7-/m0/s1
DMAI1HU CS C1=CC=C(C=C1)[C@@H](C(=O)O)N
DMAI1HU IK ZGUNAGUHMKGQNY-ZETCQYMHSA-N
DMAI1HU IU (2S)-2-amino-2-phenylacetic acid
DMAI1HU CA CAS 2935-35-5
DMAI1HU CB CHEBI:439819
DMAI1HU DE Discovery agent
DM04BHI ID DM04BHI
DM04BHI DN (S)-PIA
DM04BHI HS Investigative
DM04BHI SN CHEMBL420705; 38594-97-7; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(2S)-1-phenylpropan-2-yl]amino]purin-9-yl]oxolane-3,4-diol; S-PIA; N6-((S)-1-Methyl-2-phenylethyl)adenosine; AC1NSM10; GTPL415; SCHEMBL6762494; CTK1C3340; 2-Hydroxymethyl-5-[6-(1-methyl-2-phenyl-ethylamino)-purin-9-yl]-tetrahydro-furan-3,4-diol; S(+)-N6-(2-PHENYLISOPROPYL)ADENOSINE (S( +)-PIA); N6-(D-2-Phenylisopropyl)adenosine; ZINC1320081; PDSP2_001015; PDSP1_000298; PDSP2_000296; PDSP1_001031; BDBM50080398
DM04BHI DT Small molecular drug
DM04BHI PC 5312112
DM04BHI MW 385.4
DM04BHI FM C19H23N5O4
DM04BHI IC InChI=1S/C19H23N5O4/c1-11(7-12-5-3-2-4-6-12)23-17-14-18(21-9-20-17)24(10-22-14)19-16(27)15(26)13(8-25)28-19/h2-6,9-11,13,15-16,19,25-27H,7-8H2,1H3,(H,20,21,23)/t11-,13+,15+,16+,19+/m0/s1
DM04BHI CS C[C@@H](CC1=CC=CC=C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM04BHI IK RIRGCFBBHQEQQH-KFAHYOAQSA-N
DM04BHI IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(2S)-1-phenylpropan-2-yl]amino]purin-9-yl]oxolane-3,4-diol
DM04BHI DE Discovery agent
DMST89H ID DMST89H
DMST89H DN (S)-Piperidine-3-carboxylic acid
DMST89H HS Investigative
DMST89H SN 59045-82-8; (S)-(+)-Nipecotic acid; (3S)-piperidine-3-carboxylic acid; (S)-nipecotic acid; (3S)-nipecotic acid; (S)-(+)-3-Piperidinecarboxylic acid; (S)-hexahydronicotinic acid; L(+)-NIPECOTIC ACID; (3S)-hexahydronicotinic acid; CHEBI:222169; (3S)-3-piperidinecarboxylic acid; 3-Piperidinecarboxylic acid, (3S)-; (S)-(+)-PIPERIDINE-3-CARBOXYLIC ACID; UNII-2635N2PS4Q; (3S)-(+)-piperidine-3-carboxylic acid; L-PIPERIDINE-3-CARBOXYLIC ACID
DMST89H DT Small molecular drug
DMST89H PC 6575389
DMST89H MW 129.16
DMST89H FM C6H11NO2
DMST89H IC InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)/t5-/m0/s1
DMST89H CS C1C[C@@H](CNC1)C(=O)O
DMST89H IK XJLSEXAGTJCILF-YFKPBYRVSA-N
DMST89H IU (3S)-piperidine-3-carboxylic acid
DMST89H CA CAS 59045-82-8
DMST89H CB CHEBI:222169
DMST89H DE Discovery agent
DMXVQJI ID DMXVQJI
DMXVQJI DN (S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone
DMXVQJI HS Investigative
DMXVQJI SN CHEMBL403882; L-Prolin-pyrrolidid; (S)-1-prolylpyrrolidine; 1-(L-Prolyl)pyrrolidine; (S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone; 41721-00-0; SCHEMBL1383434; HDLWINONZUFKQV-QMMMGPOBSA-N; ZINC11754367; BDBM50228295; AKOS022180332; AJ-60015; Pyrrolidine, 1-[(2S)-2-pyrrolidinylcarbonyl
DMXVQJI DT Small molecular drug
DMXVQJI PC 13578534
DMXVQJI MW 168.24
DMXVQJI FM C9H16N2O
DMXVQJI IC InChI=1S/C9H16N2O/c12-9(8-4-3-5-10-8)11-6-1-2-7-11/h8,10H,1-7H2/t8-/m0/s1
DMXVQJI CS C1CCN(C1)C(=O)[C@@H]2CCCN2
DMXVQJI IK HDLWINONZUFKQV-QMMMGPOBSA-N
DMXVQJI IU pyrrolidin-1-yl-[(2S)-pyrrolidin-2-yl]methanone
DMXVQJI DE Discovery agent
DM16N7Z ID DM16N7Z
DM16N7Z DN (S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone
DM16N7Z HS Investigative
DM16N7Z SN CHEMBL224435; (S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone; SCHEMBL2711156
DM16N7Z DT Small molecular drug
DM16N7Z PC 44422449
DM16N7Z MW 186.28
DM16N7Z FM C8H14N2OS
DM16N7Z IC InChI=1S/C8H14N2OS/c11-8(7-2-1-3-9-7)10-4-5-12-6-10/h7,9H,1-6H2/t7-/m0/s1
DM16N7Z CS C1C[C@H](NC1)C(=O)N2CCSC2
DM16N7Z IK GTTPYCGIEGLJPF-ZETCQYMHSA-N
DM16N7Z IU [(2S)-pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
DM16N7Z DE Discovery agent
DM1SJZ3 ID DM1SJZ3
DM1SJZ3 DN (S)-Rolipram
DM1SJZ3 HS Investigative
DM1SJZ3 SN (S)-(+)-rolipram; 85416-73-5; S-(+)-Rolipram; (S)-ROLIPRAM; S- (+)-Rolipram; UNII-H6G4VMQ24K; H6G4VMQ24K; CHEMBL325795; CHEBI:59540; (4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE; (S)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one; (4S)-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-pyrrolidin-2-one; S-rolipram; 1oyn; 1xn0; AC1L4KJV; MLS006011228; SCHEMBL5321568; CTK8G3018; DTXSID30234634; HJORMJIFDVBMOB-GFCCVEGCSA-N
DM1SJZ3 DT Small molecular drug
DM1SJZ3 PC 158758
DM1SJZ3 MW 275.34
DM1SJZ3 FM C16H21NO3
DM1SJZ3 IC InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m1/s1
DM1SJZ3 CS COC1=C(C=C(C=C1)[C@@H]2CC(=O)NC2)OC3CCCC3
DM1SJZ3 IK HJORMJIFDVBMOB-GFCCVEGCSA-N
DM1SJZ3 IU (4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
DM1SJZ3 CA CAS 85416-73-5
DM1SJZ3 CB CHEBI:59540
DM1SJZ3 DE Discovery agent
DMG4KIU ID DMG4KIU
DMG4KIU DN (S)-secoantioquine hydrochloride
DMG4KIU HS Investigative
DMG4KIU SN CHEMBL506299; (S)-Secoantioquine HCl
DMG4KIU DT Small molecular drug
DMG4KIU PC 44584689
DMG4KIU MW 675.2
DMG4KIU FM C37H39ClN2O8
DMG4KIU IC InChI=1S/C37H38N2O8.ClH/c1-38-12-11-24-18-33(46-5)35(42)36(47-32-19-25-23(17-31(32)45-4)10-13-39(2)37(25)43)34(24)28(38)16-21-7-9-30(44-3)27(14-21)26-15-22(20-40)6-8-29(26)41;/h6-9,14-15,17-20,28,41-42H,10-13,16H2,1-5H3;1H/t28-;/m0./s1
DMG4KIU CS CN1CCC2=CC(=C(C(=C2[C@@H]1CC3=CC(=C(C=C3)OC)C4=C(C=CC(=C4)C=O)O)OC5=C(C=C6CCN(C(=O)C6=C5)C)OC)O)OC.Cl
DMG4KIU IK UOCXQPQQPWZQIB-JCOPYZAKSA-N
DMG4KIU IU 4-hydroxy-3-[5-[[(1S)-7-hydroxy-6-methoxy-8-[(6-methoxy-2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)oxy]-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenyl]benzaldehyde;hydrochloride
DMG4KIU DE Discovery agent
DMS8WG3 ID DMS8WG3
DMS8WG3 DN (S)-sirtinol
DMS8WG3 HS Investigative
DMS8WG3 DT Small molecular drug
DMS8WG3 PC 1376645
DMS8WG3 MW 394.5
DMS8WG3 FM C26H22N2O2
DMS8WG3 IC InChI=1S/C26H22N2O2/c1-18(19-9-3-2-4-10-19)28-26(30)22-13-7-8-14-24(22)27-17-23-21-12-6-5-11-20(21)15-16-25(23)29/h2-18,29H,1H3,(H,28,30)/t18-/m0/s1
DMS8WG3 CS C[C@@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2N=CC3=C(C=CC4=CC=CC=C43)O
DMS8WG3 IK UXJFDYIHRJGPFS-SFHVURJKSA-N
DMS8WG3 IU 2-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-[(1S)-1-phenylethyl]benzamide
DMS8WG3 DE Discovery agent
DMH7QZ2 ID DMH7QZ2
DMH7QZ2 DN (S)-tacrine(10)-hupyridone
DMH7QZ2 HS Investigative
DMH7QZ2 SN (S)-TACRINE(10)-HUPYRIDONE; (5S)-5-{[10-(1,2,3,4-TETRAHYDROACRIDIN-9-YLAMINO)DECYL]AMINO}-5,6,7,8-TETRAHYDROQUINOLIN-2(1H)-ONE; AC1NS1EG; DB04615; (5S)-5-[10-(1,2,3,4-Tetrahydroacridine-9-ylamino)decylamino]-1,2,5,6,7,8-hexahydroquinoline-2-one; (S)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE; (S)-TACRINE(10)-HUPYRIDONE; (S)-N-9 -(1 ,2 ,3 ,4 -TETRAHYDROACRIDINYL)-N'-5 -[5 ,6 ,7 ,8 -TETRAHYDRO-2'(1'H)-QUINOLINONYL]-1,10-DIAMINODECANE
DMH7QZ2 DT Small molecular drug
DMH7QZ2 PC 5326967
DMH7QZ2 MW 500.7
DMH7QZ2 FM C32H44N4O
DMH7QZ2 IC InChI=1S/C32H44N4O/c37-31-21-20-24-27(18-13-19-28(24)36-31)33-22-11-5-3-1-2-4-6-12-23-34-32-25-14-7-9-16-29(25)35-30-17-10-8-15-26(30)32/h7,9,14,16,20-21,27,33H,1-6,8,10-13,15,17-19,22-23H2,(H,34,35)(H,36,37)/t27-/m0/s1
DMH7QZ2 CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCCCCN[C@H]4CCCC5=C4C=CC(=O)N5
DMH7QZ2 IK ROTFGKJJMRTWBD-MHZLTWQESA-N
DMH7QZ2 IU (5S)-5-[10-(1,2,3,4-tetrahydroacridin-9-ylamino)decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMH7QZ2 DE Discovery agent
DM68XFZ ID DM68XFZ
DM68XFZ DN (S)-TBPG
DM68XFZ HS Investigative
DM68XFZ SN S-TBPG
DM68XFZ DT Small molecular drug
DM68XFZ PC 10058919
DM68XFZ MW 209.21
DM68XFZ FM C8H11N5O2
DM68XFZ IC InChI=1S/C8H11N5O2/c9-4(5(14)15)7-1-8(2-7,3-7)6-10-12-13-11-6/h4H,1-3,9H2,(H,14,15)(H,10,11,12,13)/t4-,7?,8?/m1/s1
DM68XFZ CS C1C2(CC1(C2)[C@@H](C(=O)O)N)C3=NNN=N3
DM68XFZ IK XYCORZCGVTXZFU-XOJFDHPMSA-N
DM68XFZ IU (2S)-2-amino-2-[3-(2H-tetrazol-5-yl)-1-bicyclo[1.1.1]pentanyl]acetic acid
DM68XFZ DE Discovery agent
DMAQX4K ID DMAQX4K
DMAQX4K DN (S)-tert-butyl 1-oxohexan-2-ylcarbamate
DMAQX4K HS Investigative
DMAQX4K SN CHEMBL96875; ((S)-1-Formyl-pentyl)-carbamic acid tert-butyl ester; BML-244; (S)-tert-butyl 1-oxohexan-2-ylcarbamate; Carbamic acid, [(1S)-1-formylpentyl]-, 1,1-dimethylethyl ester; SCHEMBL3285479; CTK0G6629; OBMGXPJNZKYOQY-VIFPVBQESA-N; ZINC13588585; BDBM50137790; AKOS030572335; tert-butyl(1S)-1-formylpentylcarbamate; CCG-207873; 2(S)-(tert-Butoxycarbonylamino)hexanal; tert-butyl (1S)-1-formylpentylcarbamate; (2S)-2-(tert-Butoxycarbonylamino)hexanal; (S)-2-(tert-butoxycarbonylamino)-5-methylpentanal
DMAQX4K DT Small molecular drug
DMAQX4K PC 10420833
DMAQX4K MW 215.29
DMAQX4K FM C11H21NO3
DMAQX4K IC InChI=1S/C11H21NO3/c1-5-6-7-9(8-13)12-10(14)15-11(2,3)4/h8-9H,5-7H2,1-4H3,(H,12,14)/t9-/m0/s1
DMAQX4K CS CCCC[C@@H](C=O)NC(=O)OC(C)(C)C
DMAQX4K IK OBMGXPJNZKYOQY-VIFPVBQESA-N
DMAQX4K IU tert-butyl N-[(2S)-1-oxohexan-2-yl]carbamate
DMAQX4K DE Discovery agent
DMLG8Q2 ID DMLG8Q2
DMLG8Q2 DN (S)-tert-Butyl 4-(2-oxohexadecanamido)pentanoate
DMLG8Q2 HS Investigative
DMLG8Q2 SN CHEMBL462362
DMLG8Q2 DT Small molecular drug
DMLG8Q2 PC 44562673
DMLG8Q2 MW 425.6
DMLG8Q2 FM C25H47NO4
DMLG8Q2 IC InChI=1S/C25H47NO4/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-22(27)24(29)26-21(2)19-20-23(28)30-25(3,4)5/h21H,6-20H2,1-5H3,(H,26,29)/t21-/m0/s1
DMLG8Q2 CS CCCCCCCCCCCCCCC(=O)C(=O)N[C@@H](C)CCC(=O)OC(C)(C)C
DMLG8Q2 IK MWODQGJPDWEORS-NRFANRHFSA-N
DMLG8Q2 IU tert-butyl (4S)-4-(2-oxohexadecanoylamino)pentanoate
DMLG8Q2 DE Discovery agent
DMR1HQ3 ID DMR1HQ3
DMR1HQ3 DN (S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate
DMR1HQ3 HS Investigative
DMR1HQ3 SN 58521-45-2; TERT-BUTYL (S)1-FORMYL-3-METHYLBUTYLCARBAMATE; Boc-Leucinal; N-t-butoxycarbonyl-L-leucinal; CHEMBL96823; N-Boc-2(S)-2-amino-4-methyl-pentanal; tert-butyl N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate; Boc-Leu-H; Boc--L--Leucinal; (S)-Boc-Leucinal; t-Boc-Leu-H; BOC-L-LEUCINAL; BOC-LEU-CHO; AC1L2WGL; N--BOC--L--leucinal; t-butoxycarbonyl-L-leucinal; tert-butyl (1S)-1-formyl-3-methylbutylcarbamate; tert-butyloxycarbonyl-leucinal; SCHEMBL739719; N-tert-butoxycarbonyl-L-leucinal; (t-Butyloxycarbonyl)-L-Leucinal
DMR1HQ3 DT Small molecular drug
DMR1HQ3 PC 104275
DMR1HQ3 MW 215.29
DMR1HQ3 FM C11H21NO3
DMR1HQ3 IC InChI=1S/C11H21NO3/c1-8(2)6-9(7-13)12-10(14)15-11(3,4)5/h7-9H,6H2,1-5H3,(H,12,14)/t9-/m0/s1
DMR1HQ3 CS CC(C)C[C@@H](C=O)NC(=O)OC(C)(C)C
DMR1HQ3 IK RQSBRFZHUKLKNO-VIFPVBQESA-N
DMR1HQ3 IU tert-butyl N-[(2S)-4-methyl-1-oxopentan-2-yl]carbamate
DMR1HQ3 DE Discovery agent
DMXQ47M ID DMXQ47M
DMXQ47M DN (S)-WILLARDIINE
DMXQ47M HS Investigative
DMXQ47M SN (S)-WILLARDIINE; Willardiine; S(-)-Willardiine; 21416-43-3; 3-(Uracil-1-yl)-L-alanine; (-)-Willardiine; CHEMBL122005; CHEBI:15851; 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; HWD; 2-AMINO-3-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; 1mqj; 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)alanine; AC1L98KY; Lopac0_001219; SCHEMBL401191; SCHEMBL13319907; BDBM17661; CTK5H8581; MolPort-003-959-938; ZINC901774; 96108-98-4; 2990AH; AKOS006281897; DB04129; CCG-205293; CS-3618; NCGC00094464-03; HY-12499; EU-0101219; C03584
DMXQ47M DT Small molecular drug
DMXQ47M PC 440053
DMXQ47M MW 199.16
DMXQ47M FM C7H9N3O4
DMXQ47M IC InChI=1S/C7H9N3O4/c8-4(6(12)13)3-10-2-1-5(11)9-7(10)14/h1-2,4H,3,8H2,(H,12,13)(H,9,11,14)/t4-/m0/s1
DMXQ47M CS C1=CN(C(=O)NC1=O)C[C@@H](C(=O)O)N
DMXQ47M IK FACUYWPMDKTVFU-BYPYZUCNSA-N
DMXQ47M IU (2S)-2-amino-3-(2,4-dioxopyrimidin-1-yl)propanoic acid
DMXQ47M CA CAS 21416-43-3
DMXQ47M CB CHEBI:15851
DMXQ47M DE Discovery agent
DM6BON2 ID DM6BON2
DM6BON2 DN (S)-zacopride
DM6BON2 HS Investigative
DM6BON2 SN CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide
DM6BON2 DT Small molecular drug
DM6BON2 PC 6604914
DM6BON2 MW 309.79
DM6BON2 FM C15H20ClN3O2
DM6BON2 IC InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20)/t13-/m1/s1
DM6BON2 CS COC1=CC(=C(C=C1C(=O)N[C@@H]2CN3CCC2CC3)Cl)N
DM6BON2 IK FEROPKNOYKURCJ-CYBMUJFWSA-N
DM6BON2 IU 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide
DM6BON2 DE Discovery agent
DMA30RW ID DMA30RW
DMA30RW DN (S,R)-(+)-fenoterol
DMA30RW HS Investigative
DMA30RW SN (S,R)-(+)-fenoterol; CHEMBL229477; (S,R)-Fenoterol; AC1LDIMM; SCHEMBL9971023; ZINC20252; BDBM50213103; 5-[(1S)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMA30RW DT Small molecular drug
DMA30RW PC 667688
DMA30RW MW 303.35
DMA30RW FM C17H21NO4
DMA30RW IC InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3/t11-,17-/m1/s1
DMA30RW CS C[C@H](CC1=CC=C(C=C1)O)NC[C@H](C2=CC(=CC(=C2)O)O)O
DMA30RW IK LSLYOANBFKQKPT-PIGZYNQJSA-N
DMA30RW IU 5-[(1S)-1-hydroxy-2-[[(2R)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol
DMA30RW DE Discovery agent
DMIV0MT ID DMIV0MT
DMIV0MT DN (S,R)-antioquine hydrochloride
DMIV0MT HS Investigative
DMIV0MT SN CHEMBL446564; (S,R)-Antioquine HCl
DMIV0MT DT Small molecular drug
DMIV0MT PC 44584687
DMIV0MT MW 645.2
DMIV0MT FM C37H41ClN2O6
DMIV0MT IC InChI=1S/C37H40N2O6.ClH/c1-38-12-10-23-18-32(43-4)33-20-25(23)28(38)16-21-6-8-30(40)26(14-21)27-15-22(7-9-31(27)42-3)17-29-35-24(11-13-39(29)2)19-34(44-5)36(41)37(35)45-33;/h6-9,14-15,18-20,28-29,40-41H,10-13,16-17H2,1-5H3;1H/t28-,29+;/m1./s1
DMIV0MT CS CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)O)C5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC.Cl
DMIV0MT IK XMYUKGNJCHUIHP-XZVFQGBBSA-N
DMIV0MT IU (1R,14S)-9,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaene-6,21-diol;hydrochloride
DMIV0MT DE Discovery agent
DMZV52W ID DMZV52W
DMZV52W DN (S,R)-isotetrandrine hydrochloride
DMZV52W HS Investigative
DMZV52W SN CHEMBL506025; (S,R)-Isotetrandrine HCl
DMZV52W DT Small molecular drug
DMZV52W PC 44584681
DMZV52W MW 659.2
DMZV52W FM C38H43ClN2O6
DMZV52W IC InChI=1S/C38H42N2O6.ClH/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34;/h7-12,19-22,29-30H,13-18H2,1-6H3;1H/t29-,30+;/m0./s1
DMZV52W CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC.Cl
DMZV52W IK RJAXUPVPTQWJKH-XCCPJCIBSA-N
DMZV52W IU (1S,14R)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene;hydrochloride
DMZV52W DE Discovery agent
DMMRUVF ID DMMRUVF
DMMRUVF DN (S,R)-pseudoxandrine hydrochloride
DMMRUVF HS Investigative
DMMRUVF SN CHEMBL504303; (S,R)-Pseudoxandrine HCl
DMMRUVF DT Small molecular drug
DMMRUVF PC 44584686
DMMRUVF MW 622.7
DMMRUVF FM C37H38N2O7
DMMRUVF IC InChI=1S/C37H38N2O7/c1-38-12-10-21-17-30(44-4)31-19-24(21)27(38)15-20-6-9-29(43-3)26(14-20)25-16-23(7-8-28(25)40)35(41)34-33-22(11-13-39(34)2)18-32(45-5)36(42)37(33)46-31/h6-9,14,16-19,27,34,40,42H,10-13,15H2,1-5H3/t27-,34+/m1/s1
DMMRUVF CS CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)OC)C5=C(C=CC(=C5)C(=O)[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)O)OC
DMMRUVF IK RUAKOEPLVVXTGN-YJNPBZNESA-N
DMMRUVF IU (1R,14S)-9,21-dihydroxy-6,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaen-13-one
DMMRUVF DE Discovery agent
DMBR1JS ID DMBR1JS
DMBR1JS DN (S,S)-(-)-bis(10)-hupyridone
DMBR1JS HS Investigative
DMBR1JS SN E10; (s,s)-(-)-n,n'-di-5'-[5',6',7',8'-tetrahydro- 2'(1'h)-quinolynyl]-1,10-diaminodecane dihydrochloride; (S,S)-(-)-bis(10)-hupyridone; AC1L9IVU; CHEMBL483090; BDBM10439; 1h22; 5,5'-(1,10-Decanediylbisimino)bis[(5S)-5,6,7,8-tetrahydro-2(1H)-quinolinone]; (5S,5'S)-5,5'-(decane-1,10-diyldiimino)di(5,6,7,8-tetrahydroquinolin-2(1H)-one); (5S)-5-[10-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMBR1JS DT Small molecular drug
DMBR1JS PC 445974
DMBR1JS MW 466.7
DMBR1JS FM C28H42N4O2
DMBR1JS IC InChI=1S/C28H42N4O2/c33-27-17-15-21-23(11-9-13-25(21)31-27)29-19-7-5-3-1-2-4-6-8-20-30-24-12-10-14-26-22(24)16-18-28(34)32-26/h15-18,23-24,29-30H,1-14,19-20H2,(H,31,33)(H,32,34)/t23-,24-/m0/s1
DMBR1JS CS C1C[C@@H](C2=C(C1)NC(=O)C=C2)NCCCCCCCCCCN[C@H]3CCCC4=C3C=CC(=O)N4
DMBR1JS IK CKFAWHBPSZAYLS-ZEQRLZLVSA-N
DMBR1JS IU (5S)-5-[10-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]decylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DMBR1JS CA CAS 286381-86-0
DMBR1JS DE Discovery agent
DM6PQ8D ID DM6PQ8D
DM6PQ8D DN (S,S)-(-)-bis(12)-hupyridone
DM6PQ8D HS Investigative
DM6PQ8D SN E12; (s,s)-(-)-n,n'-di-5'-[5',6',7',8'-tetrahydro- 2'(1'h)-quinolynyl]-1,12-diaminododecane dihydrochloride; (S,S)-(-)-bis(12)-hupyridone; AC1L9IVX; CHEMBL519154; BDBM10440; 1h23; 5,5'-(1,12-Dodecanediylbisimino)bis[(5S)-5,6,7,8-tetrahydro-2(1H)-quinolinone]; (5S,5'S)-5,5'-(dodecane-1,12-diyldiimino)di(5,6,7,8-tetrahydroquinolin-2(1H)-one); (5S)-5-[12-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]dodecylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DM6PQ8D DT Small molecular drug
DM6PQ8D PC 445975
DM6PQ8D MW 494.7
DM6PQ8D FM C30H46N4O2
DM6PQ8D IC InChI=1S/C30H46N4O2/c35-29-19-17-23-25(13-11-15-27(23)33-29)31-21-9-7-5-3-1-2-4-6-8-10-22-32-26-14-12-16-28-24(26)18-20-30(36)34-28/h17-20,25-26,31-32H,1-16,21-22H2,(H,33,35)(H,34,36)/t25-,26-/m0/s1
DM6PQ8D CS C1C[C@@H](C2=C(C1)NC(=O)C=C2)NCCCCCCCCCCCCN[C@H]3CCCC4=C3C=CC(=O)N4
DM6PQ8D IK VFFGYPZORQBRNM-UIOOFZCWSA-N
DM6PQ8D IU (5S)-5-[12-[[(5S)-2-oxo-5,6,7,8-tetrahydro-1H-quinolin-5-yl]amino]dodecylamino]-5,6,7,8-tetrahydro-1H-quinolin-2-one
DM6PQ8D DE Discovery agent
DMYDS6F ID DMYDS6F
DMYDS6F DN (S,S)-oxandrine hydrochloride
DMYDS6F HS Investigative
DMYDS6F SN CHEMBL445011; (S,S)-Oxandrine HCl
DMYDS6F DT Small molecular drug
DMYDS6F PC 44584684
DMYDS6F MW 622.7
DMYDS6F FM C37H38N2O7
DMYDS6F IC InChI=1S/C37H38N2O7/c1-38-12-11-22-18-32(45-5)36(42)37-33(22)27(38)15-20-6-9-29(43-3)26(14-20)25-16-23(7-8-28(25)40)35(41)34-24-19-31(46-37)30(44-4)17-21(24)10-13-39(34)2/h6-9,14,16-19,27,34,40,42H,10-13,15H2,1-5H3/t27-,34-/m0/s1
DMYDS6F CS CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C4)OC)C5=C(C=CC(=C5)C(=O)[C@@H]6C7=CC(=C(C=C7CCN6C)OC)O3)O)O)OC
DMYDS6F IK XCZPVAXCZZECDL-FOPBOCKXSA-N
DMYDS6F IU (1S,14S)-6,21-dihydroxy-9,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaen-2-one
DMYDS6F DE Discovery agent
DMJL8SE ID DMJL8SE
DMJL8SE DN (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K
DMJL8SE HS Investigative
DMJL8SE SN CHEMBL460706; (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K
DMJL8SE PC 44563953
DMJL8SE MW 2029.5
DMJL8SE FM C98H161N23O23
DMJL8SE IC InChI=1S/C98H161N23O23/c1-11-12-13-14-15-16-17-36-80(126)105-44-27-23-34-69(88(133)111-67(85(103)130)31-20-24-41-99)113-89(134)68(32-21-25-42-100)112-90(135)70(33-22-26-43-101)114-96(141)77-35-28-45-121(77)82(128)54-108-87(132)71(46-57(2)3)115-91(136)72(47-58(4)5)116-93(138)74(49-62-37-39-64(124)40-38-62)110-81(127)53-107-86(131)60(8)109-95(140)76(56-122)119-94(139)75(51-79(102)125)117-92(137)73(48-59(6)7)118-98(143)84(61(9)123)120-97(142)78(144-83(129)55-104-10)50-63-52-106-66-30-19-18-29-65(63)66/h18-19,29-30,37-40,52,57-61,67-78,84,104,106,122-124H,11-17,20-28,31-36,41-51,53-56,99-101H2,1-10H3,(H2,102,125)(H2,103,130)(H,105,126)(H,107,131)(H,108,132)(H,109,140)(H,110,127)(H,111,133)(H,112,135)(H,113,134)(H,114,141)(H,115,136)(H,116,138)(H,117,137)(H,118,143)(H,119,139)(H,120,142)/t60-,61+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,84-/m0/s1
DMJL8SE CS CCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMJL8SE IK PSJWDZZPEFDHOW-QSNPNBGOSA-N
DMJL8SE IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-(decanoylamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMJL8SE DE Discovery agent
DMPZHIE ID DMPZHIE
DMPZHIE DN (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K
DMPZHIE HS Investigative
DMPZHIE SN CHEMBL507733; (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K
DMPZHIE PC 44563954
DMPZHIE MW 2057.5
DMPZHIE FM C100H165N23O23
DMPZHIE IC InChI=1S/C100H165N23O23/c1-11-12-13-14-15-16-17-18-19-38-82(128)107-46-29-25-36-71(90(135)113-69(87(105)132)33-22-26-43-101)115-91(136)70(34-23-27-44-102)114-92(137)72(35-24-28-45-103)116-98(143)79-37-30-47-123(79)84(130)56-110-89(134)73(48-59(2)3)117-93(138)74(49-60(4)5)118-95(140)76(51-64-39-41-66(126)42-40-64)112-83(129)55-109-88(133)62(8)111-97(142)78(58-124)121-96(141)77(53-81(104)127)119-94(139)75(50-61(6)7)120-100(145)86(63(9)125)122-99(144)80(146-85(131)57-106-10)52-65-54-108-68-32-21-20-31-67(65)68/h20-21,31-32,39-42,54,59-63,69-80,86,106,108,124-126H,11-19,22-30,33-38,43-53,55-58,101-103H2,1-10H3,(H2,104,127)(H2,105,132)(H,107,128)(H,109,133)(H,110,134)(H,111,142)(H,112,129)(H,113,135)(H,114,137)(H,115,136)(H,116,143)(H,117,138)(H,118,140)(H,119,139)(H,120,145)(H,121,141)(H,122,144)/t62-,63+,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,86-/m0/s1
DMPZHIE CS CCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMPZHIE IK MNPLGRICQVXCSX-IUVNOECISA-N
DMPZHIE IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(dodecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMPZHIE DE Discovery agent
DMQIHZU ID DMQIHZU
DMQIHZU DN (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
DMQIHZU HS Investigative
DMQIHZU SN CHEMBL505299; (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K
DMQIHZU PC 44563958
DMQIHZU MW 2123.5
DMQIHZU FM C99H163N23O28
DMQIHZU IC InChI=1S/C99H163N23O28/c1-58(2)46-72(88(133)109-54-83(129)122-37-21-28-78(122)97(142)115-71(26-15-19-35-102)91(136)113-69(25-14-18-34-101)90(135)114-70(89(134)112-68(86(104)131)24-13-17-33-100)27-16-20-36-106-82(128)57-149-45-44-148-43-42-147-41-40-146-39-38-145-10)116-92(137)73(47-59(3)4)117-94(139)75(49-63-29-31-65(125)32-30-63)111-81(127)53-108-87(132)61(7)110-96(141)77(56-123)120-95(140)76(51-80(103)126)118-93(138)74(48-60(5)6)119-99(144)85(62(8)124)121-98(143)79(150-84(130)55-105-9)50-64-52-107-67-23-12-11-22-66(64)67/h11-12,22-23,29-32,52,58-62,68-79,85,105,107,123-125H,13-21,24-28,33-51,53-57,100-102H2,1-10H3,(H2,103,126)(H2,104,131)(H,106,128)(H,108,132)(H,109,133)(H,110,141)(H,111,127)(H,112,134)(H,113,136)(H,114,135)(H,115,142)(H,116,137)(H,117,139)(H,118,138)(H,119,144)(H,120,140)(H,121,143)/t61-,62+,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,85-/m0/s1
DMQIHZU CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCNC(=O)COCCOCCOCCOCCOC)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC)O
DMQIHZU IK MJZZQPFMLULOPB-UJNSRDRFSA-N
DMQIHZU IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-[[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]acetyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMQIHZU DE Discovery agent
DMVHDF4 ID DMVHDF4
DMVHDF4 DN (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K
DMVHDF4 HS Investigative
DMVHDF4 SN CHEMBL524678; (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K
DMVHDF4 PC 44563955
DMVHDF4 MW 2085.6
DMVHDF4 FM C102H169N23O23
DMVHDF4 IC InChI=1S/C102H169N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-40-84(130)109-48-31-27-38-73(92(137)115-71(89(107)134)35-24-28-45-103)117-93(138)72(36-25-29-46-104)116-94(139)74(37-26-30-47-105)118-100(145)81-39-32-49-125(81)86(132)58-112-91(136)75(50-61(2)3)119-95(140)76(51-62(4)5)120-97(142)78(53-66-41-43-68(128)44-42-66)114-85(131)57-111-90(135)64(8)113-99(144)80(60-126)123-98(143)79(55-83(106)129)121-96(141)77(52-63(6)7)122-102(147)88(65(9)127)124-101(146)82(148-87(133)59-108-10)54-67-56-110-70-34-23-22-33-69(67)70/h22-23,33-34,41-44,56,61-65,71-82,88,108,110,126-128H,11-21,24-32,35-40,45-55,57-60,103-105H2,1-10H3,(H2,106,129)(H2,107,134)(H,109,130)(H,111,135)(H,112,136)(H,113,144)(H,114,131)(H,115,137)(H,116,139)(H,117,138)(H,118,145)(H,119,140)(H,120,142)(H,121,141)(H,122,147)(H,123,143)(H,124,146)/t64-,65+,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,88-/m0/s1
DMVHDF4 CS CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMVHDF4 IK KPRCBTZIVGRZHY-OPDXRYIWSA-N
DMVHDF4 IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxo-6-(tetradecanoylamino)hexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMVHDF4 DE Discovery agent
DMX3K4E ID DMX3K4E
DMX3K4E DN (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K
DMX3K4E HS Investigative
DMX3K4E SN CHEMBL503900; (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K
DMX3K4E PC 44563952
DMX3K4E MW 2001.4
DMX3K4E FM C96H157N23O23
DMX3K4E IC InChI=1S/C96H157N23O23/c1-11-12-13-14-15-34-78(124)103-42-25-21-32-67(86(131)109-65(83(101)128)29-18-22-39-97)111-87(132)66(30-19-23-40-98)110-88(133)68(31-20-24-41-99)112-94(139)75-33-26-43-119(75)80(126)52-106-85(130)69(44-55(2)3)113-89(134)70(45-56(4)5)114-91(136)72(47-60-35-37-62(122)38-36-60)108-79(125)51-105-84(129)58(8)107-93(138)74(54-120)117-92(137)73(49-77(100)123)115-90(135)71(46-57(6)7)116-96(141)82(59(9)121)118-95(140)76(142-81(127)53-102-10)48-61-50-104-64-28-17-16-27-63(61)64/h16-17,27-28,35-38,50,55-59,65-76,82,102,104,120-122H,11-15,18-26,29-34,39-49,51-54,97-99H2,1-10H3,(H2,100,123)(H2,101,128)(H,103,124)(H,105,129)(H,106,130)(H,107,138)(H,108,125)(H,109,131)(H,110,133)(H,111,132)(H,112,139)(H,113,134)(H,114,136)(H,115,135)(H,116,141)(H,117,137)(H,118,140)/t58-,59+,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,82-/m0/s1
DMX3K4E CS CCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMX3K4E IK XODIEYZRWNAUJL-MBNUXEJASA-N
DMX3K4E IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(octanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMX3K4E DE Discovery agent
DMSVMI8 ID DMSVMI8
DMSVMI8 DN (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K
DMSVMI8 HS Investigative
DMSVMI8 SN CHEMBL507353; (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K
DMSVMI8 PC 44563956
DMSVMI8 MW 2113.6
DMSVMI8 FM C104H173N23O23
DMSVMI8 IC InChI=1S/C104H173N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(132)111-50-33-29-40-75(94(139)117-73(91(109)136)37-26-30-47-105)119-95(140)74(38-27-31-48-106)118-96(141)76(39-28-32-49-107)120-102(147)83-41-34-51-127(83)88(134)60-114-93(138)77(52-63(2)3)121-97(142)78(53-64(4)5)122-99(144)80(55-68-43-45-70(130)46-44-68)116-87(133)59-113-92(137)66(8)115-101(146)82(62-128)125-100(145)81(57-85(108)131)123-98(143)79(54-65(6)7)124-104(149)90(67(9)129)126-103(148)84(150-89(135)61-110-10)56-69-58-112-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,63-67,73-84,90,110,112,128-130H,11-23,26-34,37-42,47-57,59-62,105-107H2,1-10H3,(H2,108,131)(H2,109,136)(H,111,132)(H,113,137)(H,114,138)(H,115,146)(H,116,133)(H,117,139)(H,118,141)(H,119,140)(H,120,147)(H,121,142)(H,122,144)(H,123,143)(H,124,149)(H,125,145)(H,126,148)/t66-,67+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,90-/m0/s1
DMSVMI8 CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMSVMI8 IK JPTGYQMVTVXYRV-CMDPNKGGSA-N
DMSVMI8 IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMSVMI8 DE Discovery agent
DMO6N7C ID DMO6N7C
DMO6N7C DN (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K
DMO6N7C HS Investigative
DMO6N7C SN CHEMBL450827; (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K
DMO6N7C PC 44563957
DMO6N7C MW 2141.7
DMO6N7C FM C106H177N23O23
DMO6N7C IC InChI=1S/C106H177N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-44-88(134)113-52-35-31-42-77(96(141)119-75(93(111)138)39-28-32-49-107)121-97(142)76(40-29-33-50-108)120-98(143)78(41-30-34-51-109)122-104(149)85-43-36-53-129(85)90(136)62-116-95(140)79(54-65(2)3)123-99(144)80(55-66(4)5)124-101(146)82(57-70-45-47-72(132)48-46-70)118-89(135)61-115-94(139)68(8)117-103(148)84(64-130)127-102(147)83(59-87(110)133)125-100(145)81(56-67(6)7)126-106(151)92(69(9)131)128-105(150)86(152-91(137)63-112-10)58-71-60-114-74-38-27-26-37-73(71)74/h26-27,37-38,45-48,60,65-69,75-86,92,112,114,130-132H,11-25,28-36,39-44,49-59,61-64,107-109H2,1-10H3,(H2,110,133)(H2,111,138)(H,113,134)(H,115,139)(H,116,140)(H,117,148)(H,118,135)(H,119,141)(H,120,143)(H,121,142)(H,122,149)(H,123,144)(H,124,146)(H,125,145)(H,126,151)(H,127,147)(H,128,150)/t68-,69+,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,92-/m0/s1
DMO6N7C CS CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC
DMO6N7C IK IJKWJUNWQVNEKE-QPWLOKLFSA-N
DMO6N7C IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(octadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMO6N7C DE Discovery agent
DMT2NVG ID DMT2NVG
DMT2NVG DN (Sar)WTLNSAGYLLGPKKKK
DMT2NVG HS Investigative
DMT2NVG SN CHEMBL508036; (Sar)WTLNSAGYLLGPKKKK
DMT2NVG PC 44563951
DMT2NVG MW 1875.2
DMT2NVG FM C88H143N23O22
DMT2NVG IC InChI=1S/C88H143N23O22/c1-48(2)37-62(77(121)98-45-72(117)111-36-20-27-68(111)86(130)104-61(26-15-19-35-92)80(124)103-60(25-14-18-34-91)79(123)102-59(24-13-17-33-90)78(122)101-58(75(94)119)23-12-16-32-89)105-81(125)63(38-49(3)4)106-83(127)65(40-53-28-30-55(114)31-29-53)100-71(116)44-97-76(120)51(7)99-85(129)67(47-112)109-84(128)66(42-70(93)115)107-82(126)64(39-50(5)6)108-88(132)74(52(8)113)110-87(131)69(133-73(118)46-95-9)41-54-43-96-57-22-11-10-21-56(54)57/h10-11,21-22,28-31,43,48-52,58-69,74,95-96,112-114H,12-20,23-27,32-42,44-47,89-92H2,1-9H3,(H2,93,115)(H2,94,119)(H,97,120)(H,98,121)(H,99,129)(H,100,116)(H,101,122)(H,102,123)(H,103,124)(H,104,130)(H,105,125)(H,106,127)(H,107,126)(H,108,132)(H,109,128)(H,110,131)/t51-,52+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,74-/m0/s1
DMT2NVG CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)OC(=O)CNC)O
DMT2NVG IK JTWAWYOTWKLDAO-GFUYWXIVSA-N
DMT2NVG IU [(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl] 2-(methylamino)acetate
DMT2NVG DE Discovery agent
DMT3S72 ID DMT3S72
DMT3S72 DN (South)-Methanocarba-Thymidine
DMT3S72 HS Investigative
DMT3S72 SN (SOUTH)-METHANOCARBA-THYMIDINE; south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921
DMT3S72 DT Small molecular drug
DMT3S72 PC 447628
DMT3S72 MW 252.27
DMT3S72 FM C12H16N2O4
DMT3S72 IC InChI=1S/C12H16N2O4/c1-6-4-14(11(18)13-10(6)17)12-2-8(12)7(5-15)9(16)3-12/h4,7-9,15-16H,2-3,5H2,1H3,(H,13,17,18)/t7-,8-,9-,12-/m0/s1
DMT3S72 CS CC1=CN(C(=O)NC1=O)[C@]23C[C@H]2[C@@H]([C@H](C3)O)CO
DMT3S72 IK XRMLXZVSFIBRRJ-PEFMBERDSA-N
DMT3S72 IU 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)-1-bicyclo[3.1.0]hexanyl]-5-methylpyrimidine-2,4-dione
DMT3S72 CB CHEBI:45586
DMT3S72 DE Discovery agent
DMLW7TV ID DMLW7TV
DMLW7TV DN (Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine
DMLW7TV HS Investigative
DMLW7TV SN (TERT-BUTYLOXYCARBONYL)-ALANYL-ALANYL-AMINE; Boc-Ala-Ala-NH2; AC1NUZE3; SCHEMBL4327766; CTK5J1322; DB03757; 41036-24-2; N-(tert-butoxycarbonyl)-L-alanyl-L-alaninamide; tert-butyl N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamate
DMLW7TV DT Small molecular drug
DMLW7TV PC 5497045
DMLW7TV MW 259.3
DMLW7TV FM C11H21N3O4
DMLW7TV IC InChI=1S/C11H21N3O4/c1-6(8(12)15)13-9(16)7(2)14-10(17)18-11(3,4)5/h6-7H,1-5H3,(H2,12,15)(H,13,16)(H,14,17)/t6-,7-/m0/s1
DMLW7TV CS C[C@@H](C(=O)N)NC(=O)[C@H](C)NC(=O)OC(C)(C)C
DMLW7TV IK OAXZAMSRJZWMEV-BQBZGAKWSA-N
DMLW7TV IU tert-butyl N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamate
DMLW7TV CA CAS 41036-24-2
DMLW7TV DE Discovery agent
DMVZYNH ID DMVZYNH
DMVZYNH DN (Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one
DMVZYNH HS Investigative
DMVZYNH SN CHEMBL177471; (Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one; SCHEMBL3185614; BDBM50163160
DMVZYNH DT Small molecular drug
DMVZYNH PC 10070106
DMVZYNH MW 409.6
DMVZYNH FM C27H39NO2
DMVZYNH IC InChI=1S/C27H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-26(29)27-28-25(23-30-27)24-20-17-16-18-21-24/h9-10,16-18,20-21,23H,2-8,11-15,19,22H2,1H3/b10-9-
DMVZYNH CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC(=CO1)C2=CC=CC=C2
DMVZYNH IK KOOKQMBHKMEODJ-KTKRTIGZSA-N
DMVZYNH IU (Z)-1-(4-phenyl-1,3-oxazol-2-yl)octadec-9-en-1-one
DMVZYNH DE Discovery agent
DMNBDGH ID DMNBDGH
DMNBDGH DN (Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one
DMNBDGH HS Investigative
DMNBDGH SN CHEMBL285678; (Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one; SCHEMBL3964233; BDBM50100871; LS-97768; 1-Benzooxazol-2-yl-nonadec-10-en-2-one; (Z)-1-Benzooxazol-2-yl-octadec-9-en-1-one; (9Z)-1-(Benzoxazole-2-yl)-9-octadecene-1-one
DMNBDGH DT Small molecular drug
DMNBDGH PC 10293363
DMNBDGH MW 383.6
DMNBDGH FM C25H37NO2
DMNBDGH IC InChI=1S/C25H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-23(27)25-26-22-19-17-18-21-24(22)28-25/h9-10,17-19,21H,2-8,11-16,20H2,1H3/b10-9-
DMNBDGH CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC2=CC=CC=C2O1
DMNBDGH IK APIPEDDJLOMNRC-KTKRTIGZSA-N
DMNBDGH IU (Z)-1-(1,3-benzoxazol-2-yl)octadec-9-en-1-one
DMNBDGH DE Discovery agent
DMMTXKO ID DMMTXKO
DMMTXKO DN (Z)-1-(pyridazin-3-yl)octadec-9-en-1-one
DMMTXKO HS Investigative
DMMTXKO SN CHEMBL405089; SCHEMBL3967504; BDBM50374371; (9z)-1-pyridazin-3-yloctadec-9-en-1-one
DMMTXKO DT Small molecular drug
DMMTXKO PC 12071714
DMMTXKO MW 344.5
DMMTXKO FM C22H36N2O
DMMTXKO IC InChI=1S/C22H36N2O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-22(25)21-18-17-20-23-24-21/h9-10,17-18,20H,2-8,11-16,19H2,1H3/b10-9-
DMMTXKO CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NN=CC=C1
DMMTXKO IK REQRZXMTFPJHJQ-KTKRTIGZSA-N
DMMTXKO IU (Z)-1-pyridazin-3-yloctadec-9-en-1-one
DMMTXKO DE Discovery agent
DMSVBZO ID DMSVBZO
DMSVBZO DN (Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one
DMSVBZO HS Investigative
DMSVBZO SN CHEMBL1098397
DMSVBZO DT Small molecular drug
DMSVBZO PC 25137229
DMSVBZO MW 434.5
DMSVBZO FM C21H33F7O
DMSVBZO IC InChI=1S/C21H33F7O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(29)19(22,23)20(24,25)21(26,27)28/h9-10H,2-8,11-17H2,1H3/b10-9-
DMSVBZO CS CCCCCCCC/C=C\\CCCCCCCC(=O)C(C(C(F)(F)F)(F)F)(F)F
DMSVBZO IK CAINANTZOVVNLF-KTKRTIGZSA-N
DMSVBZO IU (Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one
DMSVBZO DE Discovery agent
DMBTMDG ID DMBTMDG
DMBTMDG DN (Z)-1,1,1-Trifluoro-nonadec-10-en-2-one
DMBTMDG HS Investigative
DMBTMDG SN CHEMBL422064; (Z)-1,1,1-Trifluoro-nonadec-10-en-2-one; SCHEMBL8059738; C19H33F3O; MolPort-009-018-697; HMS3649G07; BDBM50069273; 1964AH; ZINC34803437; LS-96805; (Z)-1,1,1-Trifluoro-10-nonadecen-2-one; (10z)-1,1,1-trifluorononadec-10-en-2-one; SR-01000946571; SR-01000946571-1
DMBTMDG DT Small molecular drug
DMBTMDG PC 9840659
DMBTMDG MW 334.5
DMBTMDG FM C19H33F3O
DMBTMDG IC InChI=1S/C19H33F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(23)19(20,21)22/h9-10H,2-8,11-17H2,1H3/b10-9-
DMBTMDG CS CCCCCCCC/C=C\\CCCCCCCC(=O)C(F)(F)F
DMBTMDG IK SOJGXPSMVNTNQL-KTKRTIGZSA-N
DMBTMDG IU (Z)-1,1,1-trifluorononadec-10-en-2-one
DMBTMDG CA CAS 177987-23-4
DMBTMDG DE Discovery agent
DMKQ679 ID DMKQ679
DMKQ679 DN (Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMKQ679 HS Investigative
DMKQ679 SN CHEMBL493798; (Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid
DMKQ679 DT Small molecular drug
DMKQ679 PC 44576974
DMKQ679 MW 329.4
DMKQ679 FM C20H27NO3
DMKQ679 IC InChI=1S/C20H27NO3/c1-2-3-4-5-6-7-8-11-14-21-18-13-10-9-12-16(18)17(20(21)24)15-19(22)23/h9-10,12-13,15H,2-8,11,14H2,1H3,(H,22,23)/b17-15-
DMKQ679 CS CCCCCCCCCCN1C2=CC=CC=C2/C(=C/C(=O)O)/C1=O
DMKQ679 IK LIUQXAWYSKFADK-ICFOKQHNSA-N
DMKQ679 IU (2Z)-2-(1-decyl-2-oxoindol-3-ylidene)acetic acid
DMKQ679 DE Discovery agent
DM2HZX8 ID DM2HZX8
DM2HZX8 DN (Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one
DM2HZX8 HS Investigative
DM2HZX8 SN CHEMBL36655; (Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one; BDBM50100875
DM2HZX8 DT Small molecular drug
DM2HZX8 PC 11371880
DM2HZX8 MW 361.6
DM2HZX8 FM C23H39NO2
DM2HZX8 IC InChI=1S/C23H39NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(2,3)21(25)22-24-19-20-26-22/h11-12,19-20H,4-10,13-18H2,1-3H3/b12-11-
DM2HZX8 CS CCCCCCCC/C=C\\CCCCCCC(C)(C)C(=O)C1=NC=CO1
DM2HZX8 IK UIQYHSVDCXHKSQ-QXMHVHEDSA-N
DM2HZX8 IU (Z)-2,2-dimethyl-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
DM2HZX8 DE Discovery agent
DMFLDPU ID DMFLDPU
DMFLDPU DN (Z)-2,6-diisopropyl-N-phenyloctadec-9-enamide
DMFLDPU HS Investigative
DMFLDPU SN CHEMBL272675
DMFLDPU DT Small molecular drug
DMFLDPU PC 44457420
DMFLDPU MW 441.7
DMFLDPU FM C30H51NO
DMFLDPU IC InChI=1S/C30H51NO/c1-6-7-8-9-10-11-12-13-14-16-20-27(25(2)3)21-19-24-29(26(4)5)30(32)31-28-22-17-15-18-23-28/h13-15,17-18,22-23,25-27,29H,6-12,16,19-21,24H2,1-5H3,(H,31,32)/b14-13-
DMFLDPU CS CCCCCCCC/C=C\\CCC(CCCC(C(C)C)C(=O)NC1=CC=CC=C1)C(C)C
DMFLDPU IK HUQXXTSZFWLRDE-YPKPFQOOSA-N
DMFLDPU IU (Z)-N-phenyl-2,6-di(propan-2-yl)octadec-9-enamide
DMFLDPU DE Discovery agent
DM0OEQJ ID DM0OEQJ
DM0OEQJ DN (Z)-2'-des-methyl sulindac sulfide
DM0OEQJ HS Investigative
DM0OEQJ SN CHEMBL561959; SCHEMBL2697270; BDBM50293599; ZINC43075511; (Z)-2''-des-methyl sulindac sulfide
DM0OEQJ DT Small molecular drug
DM0OEQJ PC 44224199
DM0OEQJ MW 326.4
DM0OEQJ FM C19H15FO2S
DM0OEQJ IC InChI=1S/C19H15FO2S/c1-23-16-5-2-12(3-6-16)8-13-9-14(10-19(21)22)18-11-15(20)4-7-17(13)18/h2-9,11H,10H2,1H3,(H,21,22)/b13-8-
DM0OEQJ CS CSC1=CC=C(C=C1)/C=C\\2/C=C(C3=C2C=CC(=C3)F)CC(=O)O
DM0OEQJ IK NEQPIGQSLNSVDO-JYRVWZFOSA-N
DM0OEQJ IU 2-[(3Z)-6-fluoro-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid
DM0OEQJ DE Discovery agent
DMYH9BC ID DMYH9BC
DMYH9BC DN (Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one
DMYH9BC HS Investigative
DMYH9BC SN CHEMBL37044; (Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one; BDBM50100866
DMYH9BC DT Small molecular drug
DMYH9BC PC 11221755
DMYH9BC MW 347.5
DMYH9BC FM C22H37NO2
DMYH9BC IC InChI=1S/C22H37NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(2)21(24)22-23-18-19-25-22/h10-11,18-20H,3-9,12-17H2,1-2H3/b11-10-
DMYH9BC CS CCCCCCCC/C=C\\CCCCCCC(C)C(=O)C1=NC=CO1
DMYH9BC IK VNDQKKVLWCFNIJ-KHPPLWFESA-N
DMYH9BC IU (Z)-2-methyl-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
DMYH9BC DE Discovery agent
DM18R6J ID DM18R6J
DM18R6J DN (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid
DM18R6J HS Investigative
DM18R6J SN Chaetomellic acid A; CHEMBL103955; 148796-51-4; AC1MI36H; (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid; ZINC14276303; BDBM50059863; (Z)-2-methyl-3-tetradecylbut-2-enedioic acid; 2-Butenedioic acid, 2-methyl-3-tetradecyl-, (Z)-
DM18R6J DT Small molecular drug
DM18R6J PC 3037595
DM18R6J MW 326.5
DM18R6J FM C19H34O4
DM18R6J IC InChI=1S/C19H34O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-17(19(22)23)16(2)18(20)21/h3-15H2,1-2H3,(H,20,21)(H,22,23)/b17-16-
DM18R6J CS CCCCCCCCCCCCCC/C(=C(\\C)/C(=O)O)/C(=O)O
DM18R6J IK ULSDRNDLXFVDED-MSUUIHNZSA-N
DM18R6J IU (Z)-2-methyl-3-tetradecylbut-2-enedioic acid
DM18R6J CA CAS 148796-51-4
DM18R6J DE Discovery agent
DM27WDP ID DM27WDP
DM27WDP DN (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one
DM27WDP HS Investigative
DM27WDP SN oxindole i; CHEMBL86755; 3-(1H-Pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; oxindole 1; AC1NZGXV; K00027; (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one; Indolinone based inhibitor, 1; SCHEMBL1162655; SCHEMBL13819612; BDBM17015; MolPort-023-197-743; SEZFNTZQMWJIAI-FLIBITNWSA-N; ZINC3874586; HSCI1_000049; NCGC00343760-01; BRD-K51816706-001-01-7; (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; 3-[(1H-Pyrrole-2-yl)methylene]-1H-indole-2(3H)-one; Z-(1H-Pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one; Oxindole I
DM27WDP DT Small molecular drug
DM27WDP PC 5908088
DM27WDP MW 210.23
DM27WDP FM C13H10N2O
DM27WDP IC InChI=1S/C13H10N2O/c16-13-11(8-9-4-3-7-14-9)10-5-1-2-6-12(10)15-13/h1-8,14H,(H,15,16)/b11-8-
DM27WDP CS C1=CC=C2C(=C1)/C(=C/C3=CC=CN3)/C(=O)N2
DM27WDP IK SEZFNTZQMWJIAI-FLIBITNWSA-N
DM27WDP IU (3Z)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DM27WDP DE Discovery agent
DMIQ14F ID DMIQ14F
DMIQ14F DN (Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31
DMIQ14F HS Investigative
DMIQ14F DT Small molecular drug
DMIQ14F PC 10313754
DMIQ14F MW 317.4
DMIQ14F FM C22H23NO
DMIQ14F IC InChI=1S/C22H23NO/c1-2-4-21-17(3-1)13-19-14-20(5-6-22(19)21)24-12-9-18-15-23-10-7-16(18)8-11-23/h1-6,9,14,16H,7-8,10-13,15H2/b18-9+
DMIQ14F CS C1CN2CCC1/C(=C/COC3=CC4=C(C=C3)C5=CC=CC=C5C4)/C2
DMIQ14F IK VVZXRJARBWKUDG-GIJQJNRQSA-N
DMIQ14F IU (3Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-1-azabicyclo[2.2.2]octane
DMIQ14F DE Discovery agent
DM30YQF ID DM30YQF
DM30YQF DN (Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid
DM30YQF HS Investigative
DM30YQF SN Substituted Acrylamide, 7b; CHEMBL235904; BDBM18847; (2Z)-3-[(4-hexylphenyl)carbamoyl]prop-2-enoic acid; (2z)-4-[(4-hexylphenyl)amino]-4-oxobut-2-enoic acid
DM30YQF DT Small molecular drug
DM30YQF PC 23635730
DM30YQF MW 275.34
DM30YQF FM C16H21NO3
DM30YQF IC InChI=1S/C16H21NO3/c1-2-3-4-5-6-13-7-9-14(10-8-13)17-15(18)11-12-16(19)20/h7-12H,2-6H2,1H3,(H,17,18)(H,19,20)/b12-11-
DM30YQF CS CCCCCCC1=CC=C(C=C1)NC(=O)/C=C\\C(=O)O
DM30YQF IK OOWYMHDWBQTCOX-QXMHVHEDSA-N
DM30YQF IU (Z)-4-(4-hexylanilino)-4-oxobut-2-enoic acid
DM30YQF DE Discovery agent
DMPJAKL ID DMPJAKL
DMPJAKL DN (Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one
DMPJAKL HS Investigative
DMPJAKL SN CHEMBL591696; (3Z)-5-AMINO-3-[(4-METHOXYPHENYL)METHYLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE; 2x2l; (Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one
DMPJAKL DT Small molecular drug
DMPJAKL PC 46233144
DMPJAKL MW 266.29
DMPJAKL FM C16H14N2O2
DMPJAKL IC InChI=1S/C16H14N2O2/c1-20-12-5-2-10(3-6-12)8-14-13-9-11(17)4-7-15(13)18-16(14)19/h2-9H,17H2,1H3,(H,18,19)/b14-8-
DMPJAKL CS COC1=CC=C(C=C1)/C=C\\2/C3=C(C=CC(=C3)N)NC2=O
DMPJAKL IK DYCBCUFDDRQCID-ZSOIEALJSA-N
DMPJAKL IU (3Z)-5-amino-3-[(4-methoxyphenyl)methylidene]-1H-indol-2-one
DMPJAKL DE Discovery agent
DM3ALJD ID DM3ALJD
DM3ALJD DN (Z)-5-Benzylidene-2-thioxothiazolidin-4-one
DM3ALJD HS Investigative
DM3ALJD SN 5-Benzylidenrodanin; 5-Benzylidenerhodanine; Rhodanine, 5-benzylidene-; NSC 43398; 5-Benzylidene-2-thioxo-4-thiazolidinone; CHEMBL305763; 5-(Phenylmethylene)-2-thioxo-4-thiazolidinone; (5Z)-5-benzylidene-2-sulfanyl-1,3-thiazol-4(5H)-one; 4-Thiazolidinone, 5-(phenylmethylene)-2-thioxo-; 3806-42-6; MLS002608541; 5-Benzyliden-rhodanin; AC1LOXMG; Rhodanine, 5-benzylidene; (Z)-5-Benzylidene-2-thioxothiazolidin-4-one; SCHEMBL3491175; MolPort-001-579-311; MolPort-000-420-057; HMS3087E14; HMS1786A04; ZINC1088586; 174813-23-1; STK441367
DM3ALJD DT Small molecular drug
DM3ALJD PC 1273210
DM3ALJD MW 221.3
DM3ALJD FM C10H7NOS2
DM3ALJD IC InChI=1S/C10H7NOS2/c12-9-8(14-10(13)11-9)6-7-4-2-1-3-5-7/h1-6H,(H,11,12,13)/b8-6-
DM3ALJD CS C1=CC=C(C=C1)/C=C\\2/C(=O)NC(=S)S2
DM3ALJD IK OONWCXLYKDWKOU-VURMDHGXSA-N
DM3ALJD IU (5Z)-5-benzylidene-2-sulfanylidene-1,3-thiazolidin-4-one
DM3ALJD CA CAS 3806-42-6
DM3ALJD DE Discovery agent
DMLRWAF ID DMLRWAF
DMLRWAF DN (Z)-5-Butylidene-2-thioxothiazolidin-4-one
DMLRWAF HS Investigative
DMLRWAF DT Small molecular drug
DMLRWAF PC 91934927
DMLRWAF MW 187.3
DMLRWAF FM C7H9NOS2
DMLRWAF IC InChI=1S/C7H9NOS2/c1-2-3-4-5-6(9)8-7(10)11-5/h3-4,9H,2H2,1H3,(H,8,10)/b4-3+
DMLRWAF CS CC/C=C/C1=C(NC(=S)S1)O
DMLRWAF IK KKMMHMVDVICNOR-ONEGZZNKSA-N
DMLRWAF IU 5-[(E)-but-1-enyl]-4-hydroxy-3H-1,3-thiazole-2-thione
DMLRWAF DE Discovery agent
DM5U1M8 ID DM5U1M8
DM5U1M8 DN (Z)-5-Decylidene-2-thioxothiazolidin-4-one
DM5U1M8 HS Investigative
DM5U1M8 DT Small molecular drug
DM5U1M8 PC 91934932
DM5U1M8 MW 271.4
DM5U1M8 FM C13H21NOS2
DM5U1M8 IC InChI=1S/C13H21NOS2/c1-2-3-4-5-6-7-8-9-10-11-12(15)14-13(16)17-11/h9-10,15H,2-8H2,1H3,(H,14,16)/b10-9-
DM5U1M8 CS CCCCCCCC/C=C\\C1=C(NC(=S)S1)O
DM5U1M8 IK PVHZHDOPGHHBGQ-KTKRTIGZSA-N
DM5U1M8 IU 5-[(Z)-dec-1-enyl]-4-hydroxy-3H-1,3-thiazole-2-thione
DM5U1M8 DE Discovery agent
DMV70YA ID DMV70YA
DMV70YA DN (Z)-5-Hexylidene-2-thioxothiazolidin-4-one
DMV70YA HS Investigative
DMV70YA DT Small molecular drug
DMV70YA PC 91934930
DMV70YA MW 215.3
DMV70YA FM C9H13NOS2
DMV70YA IC InChI=1S/C9H13NOS2/c1-2-3-4-5-6-7-8(11)10-9(12)13-7/h5-6,11H,2-4H2,1H3,(H,10,12)/b6-5-
DMV70YA CS CCCC/C=C\\C1=C(NC(=S)S1)O
DMV70YA IK NRLPFFHZVUFORL-WAYWQWQTSA-N
DMV70YA IU 5-[(Z)-hex-1-enyl]-4-hydroxy-3H-1,3-thiazole-2-thione
DMV70YA DE Discovery agent
DM4X9GW ID DM4X9GW
DM4X9GW DN (Z)-5-octadecen-7,9-diynoic acid
DM4X9GW HS Investigative
DM4X9GW SN CHEMBL504781; 5Z-Octadecene-7,9-diynoic acid; (Z)-5-octadecen-7,9-diynoic acid; BDBM50292397
DM4X9GW DT Small molecular drug
DM4X9GW PC 9543637
DM4X9GW MW 274.4
DM4X9GW FM C18H26O2
DM4X9GW IC InChI=1S/C18H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h13-14H,2-8,15-17H2,1H3,(H,19,20)/b14-13-
DM4X9GW CS CCCCCCCCC#CC#C/C=C\\CCCC(=O)O
DM4X9GW IK IGVKWAAPMVVTFX-YPKPFQOOSA-N
DM4X9GW IU (Z)-octadec-5-en-7,9-diynoic acid
DM4X9GW DE Discovery agent
DMEJNFS ID DMEJNFS
DMEJNFS DN (Z)-5-Octylidene-2-thioxothiazolidin-4-one
DMEJNFS HS Investigative
DMEJNFS DT Small molecular drug
DMEJNFS PC 91934931
DMEJNFS MW 243.4
DMEJNFS FM C11H17NOS2
DMEJNFS IC InChI=1S/C11H17NOS2/c1-2-3-4-5-6-7-8-9-10(13)12-11(14)15-9/h7-8,13H,2-6H2,1H3,(H,12,14)/b8-7-
DMEJNFS CS CCCCCC/C=C\\C1=C(NC(=S)S1)O
DMEJNFS IK FMOVNYUOJKHVOR-FPLPWBNLSA-N
DMEJNFS IU 4-hydroxy-5-[(Z)-oct-1-enyl]-3H-1,3-thiazole-2-thione
DMEJNFS DE Discovery agent
DMKWLSB ID DMKWLSB
DMKWLSB DN (Z)-7-octedecan-9-ynoic acid
DMKWLSB HS Investigative
DMKWLSB SN CHEMBL482601; (Z)-7-octedecan-9-ynoic acid; (Z)-7-Octadecene-9-ynoic acid
DMKWLSB DT Small molecular drug
DMKWLSB PC 14309405
DMKWLSB MW 278.4
DMKWLSB FM C18H30O2
DMKWLSB IC InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h11-12H,2-8,13-17H2,1H3,(H,19,20)/b12-11-
DMKWLSB CS CCCCCCCCC#C/C=C\\CCCCCC(=O)O
DMKWLSB IK BWSIKEZDJMZITO-QXMHVHEDSA-N
DMKWLSB IU (Z)-octadec-7-en-9-ynoic acid
DMKWLSB DE Discovery agent
DMOB9E4 ID DMOB9E4
DMOB9E4 DN (Z)-8-(3-chlorostyryl)caffeine
DMOB9E4 HS Investigative
DMOB9E4 SN CHEMBL483243; (Z)-8-(3-chlorostyryl)caffeine
DMOB9E4 DT Small molecular drug
DMOB9E4 PC 44579921
DMOB9E4 MW 332.78
DMOB9E4 FM C16H17ClN4O2
DMOB9E4 IC InChI=1S/C16H17ClN4O2/c1-19-12(8-7-10-5-4-6-11(17)9-10)18-14-13(19)15(22)21(3)16(23)20(14)2/h4-9,13-14H,1-3H3/b8-7+
DMOB9E4 CS CN1C2C(N=C1/C=C/C3=CC(=CC=C3)Cl)N(C(=O)N(C2=O)C)C
DMOB9E4 IK SIKKJYKLUJCDNQ-BQYQJAHWSA-N
DMOB9E4 IU 8-[(E)-2-(3-chlorophenyl)ethenyl]-1,3,7-trimethyl-4,5-dihydropurine-2,6-dione
DMOB9E4 DE Discovery agent
DMX0G7E ID DMX0G7E
DMX0G7E DN [(125)I] RB129
DMX0G7E HS Investigative
DMX0G7E SN GLYCYRRHETINIC ACID; Uralenic acid; 18-beta-Glycyrrhetinic acid; Arthrodont; Glycyrrhetin; Jintan; Rhetinic Acid; 18beta-Glycyrrhetinic acid; Biosone; alpha-Glycyrrhetinic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolonum [INN-Latin]; Enoxolona [INN-Spanish]; UNII-P540XA09DR; Enoxolone [INN:BAN:DCF]; CCRIS 3962; EINECS 207-444-6; NSC 35347; 3-Glycyrrhetinic acid; BRN 2229654; Glycyrrhetinate; MLS000028748; CHEMBL230006; P540XA09DR; Glycyrrhetinic acid
DMX0G7E DT Small molecular drug
DMX0G7E DE Discovery agent
DMG1ATX ID DMG1ATX
DMG1ATX DN [(1e)-4-Phenylbut-1-Enyl]Benzene
DMG1ATX HS Investigative
DMG1ATX SN [(1E)-4-PHENYLBUT-1-ENYL]BENZENE; 1,4-DIPHENYL-1-BUTENE; 14213-84-4; AC1NR9PT; (E)-1,4-Diphenyl-1-butene; [(E)-4-phenylbut-1-enyl]benzene; ZINC14880527; [(1E)-4-phenyl-1-butenyl]benzene; [(E)-4-phenyl-but-1-enyl]-benzene; 1,1'-(1E)-but-1-ene-1,4-diyldibenzene
DMG1ATX DT Small molecular drug
DMG1ATX PC 5287453
DMG1ATX MW 208.3
DMG1ATX FM C16H16
DMG1ATX IC InChI=1S/C16H16/c1-3-9-15(10-4-1)13-7-8-14-16-11-5-2-6-12-16/h1-7,9-13H,8,14H2/b13-7+
DMG1ATX CS C1=CC=C(C=C1)CC/C=C/C2=CC=CC=C2
DMG1ATX IK NJJOGKAVAWZLAU-NTUHNPAUSA-N
DMG1ATX IU [(E)-4-phenylbut-1-enyl]benzene
DMG1ATX DE Discovery agent
DM3WDOY ID DM3WDOY
DM3WDOY DN [(2-aminooxyethyl)methylamino]-5'-deoxyadenosine
DM3WDOY HS Investigative
DM3WDOY SN MAO; 5'-DEOXY-5'-[N-METHYL-N-(2-AMINOOXYETHYL) AMINO]ADENOSINE; 112621-39-3; AC1L9JAL; MAOEA, 5; SCHEMBL956861; Adenosine,5'-[[2-(aminooxy)ethyl]methylamino]-5'-deoxy- (9CI); CHEMBL461780; CTK4A7898; BDBM28431; AKOS030589585; 5'-[(2-Aminooxyethyl)methylamino]-5'-deoxyadenosine; 5'-{[2-(aminooxy)ethyl](methyl)amino}-5'-deoxyadenosine; (2R,3S,4R,5R)-2-[[2-aminooxyethyl(methyl)amino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DM3WDOY DT Small molecular drug
DM3WDOY PC 446204
DM3WDOY MW 339.35
DM3WDOY FM C13H21N7O4
DM3WDOY IC InChI=1S/C13H21N7O4/c1-19(2-3-23-15)4-7-9(21)10(22)13(24-7)20-6-18-8-11(14)16-5-17-12(8)20/h5-7,9-10,13,21-22H,2-4,15H2,1H3,(H2,14,16,17)/t7-,9-,10-,13-/m1/s1
DM3WDOY CS CN(CCON)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM3WDOY IK PPIPUCUVJJZYEK-QYVSTXNMSA-N
DM3WDOY IU (2R,3S,4R,5R)-2-[[2-aminooxyethyl(methyl)amino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DM3WDOY DE Discovery agent
DMTK9V7 ID DMTK9V7
DMTK9V7 DN [(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone
DMTK9V7 HS Investigative
DMTK9V7 SN CHEMBL602092; [(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone
DMTK9V7 DT Small molecular drug
DMTK9V7 PC 46232847
DMTK9V7 MW 348.3
DMTK9V7 FM C15H14BrN3S
DMTK9V7 IC InChI=1S/C15H14BrN3S/c1-10-4-2-5-11(8-10)14(18-19-15(17)20)12-6-3-7-13(16)9-12/h2-9H,1H3,(H3,17,19,20)/b18-14+
DMTK9V7 CS CC1=CC(=CC=C1)/C(=N\\NC(=S)N)/C2=CC(=CC=C2)Br
DMTK9V7 IK UUHYYCURIRMTND-NBVRZTHBSA-N
DMTK9V7 IU [(E)-[(3-bromophenyl)-(3-methylphenyl)methylidene]amino]thiourea
DMTK9V7 DE Discovery agent
DMZG7TH ID DMZG7TH
DMZG7TH DN [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone
DMZG7TH HS Investigative
DMZG7TH SN CHEMBL590497; [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone
DMZG7TH DT Small molecular drug
DMZG7TH PC 46232967
DMZG7TH MW 348.3
DMZG7TH FM C15H14BrN3S
DMZG7TH IC InChI=1S/C15H14BrN3S/c1-10-5-7-11(8-6-10)14(18-19-15(17)20)12-3-2-4-13(16)9-12/h2-9H,1H3,(H3,17,19,20)/b18-14+
DMZG7TH CS CC1=CC=C(C=C1)/C(=N\\NC(=S)N)/C2=CC(=CC=C2)Br
DMZG7TH IK IOXFIFMULNCUSH-NBVRZTHBSA-N
DMZG7TH IU [(E)-[(3-bromophenyl)-(4-methylphenyl)methylidene]amino]thiourea
DMZG7TH DE Discovery agent
DM9YHA7 ID DM9YHA7
DM9YHA7 DN [(40-OH) MeLeu]4-CsA derivatives
DM9YHA7 HS Investigative
DM9YHA7 DE Discovery agent
DM1ZM5R ID DM1ZM5R
DM1ZM5R DN [(40-OH)MeLeu]4-Cyclosporin A
DM1ZM5R HS Investigative
DM1ZM5R SN [(40-OH)MeLeu]4-Cyclosporin A; CHEMBL442519; AC1O51FB; [(4'-OH)MeLeu]4-CsA; SCHEMBL18736971; [.gamma.-Hydroxy-MeLeu]4-CsA; DFZMWWCBMPCKFD-DTLHCQOUSA-N; [gamma-hydroxy-MeLeu]4 -Ciclosporin; BDBM50136487; [.gamma.-Hydroxy-MeLeu]4-Ciclosporin; [.gamma.-Hydroxy-MeLeu]4-Cyclosporin
DM1ZM5R PC 6475368
DM1ZM5R MW 1218.6
DM1ZM5R FM C62H111N11O13
DM1ZM5R IC InChI=1S/C62H111N11O13/c1-25-27-28-39(13)51(75)50-55(79)65-42(26-2)57(81)67(18)33-47(74)68(19)46(32-62(16,17)86)54(78)66-48(37(9)10)60(84)69(20)43(29-34(3)4)53(77)63-40(14)52(76)64-41(15)56(80)70(21)44(30-35(5)6)58(82)71(22)45(31-36(7)8)59(83)72(23)49(38(11)12)61(85)73(50)24/h25,27,34-46,48-51,75,86H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t39-,40+,41-,42+,43+,44+,45+,46+,48+,49+,50?,51-/m1/s1
DM1ZM5R CS CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)C
DM1ZM5R IK DFZMWWCBMPCKFD-DTLHCQOUSA-N
DM1ZM5R IU (3S,6S,9S,12R,15S,18S,21S,24S,30S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DM1ZM5R DE Discovery agent
DMV30N2 ID DMV30N2
DMV30N2 DN [(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A
DMV30N2 HS Investigative
DMV30N2 SN CHEMBL405301; [(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A
DMV30N2 PC 44358392
DMV30N2 MW 1248.6
DMV30N2 FM C63H113N11O14
DMV30N2 IC InChI=1S/C63H113N11O14/c1-25-27-28-39(13)51(76)50-55(80)66-42(26-2)57(82)72(22)47(33-75)60(85)71(21)46(32-63(16,17)88)54(79)67-48(37(9)10)61(86)68(18)43(29-34(3)4)53(78)64-40(14)52(77)65-41(15)56(81)69(19)44(30-35(5)6)58(83)70(20)45(31-36(7)8)59(84)73(23)49(38(11)12)62(87)74(50)24/h25,27,34-51,75-76,88H,26,28-33H2,1-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b27-25+/t39-,40+,41-,42+,43+,44+,45+,46+,47-,48+,49+,50?,51-/m1/s1
DMV30N2 CS CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)(C)O)C)CO)C
DMV30N2 IK XCXAXJCKONNWJE-HXEFTPTGSA-N
DMV30N2 IU (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S)-30-ethyl-27-(hydroxymethyl)-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMV30N2 DE Discovery agent
DMVWCTL ID DMVWCTL
DMVWCTL DN [(N4-Bzdig)0,Nle14]BB(7-14)
DMVWCTL HS Investigative
DMVWCTL SN CHEMBL266079; [(N4-Bzdig)0,Nle14]BB(7-14)
DMVWCTL PC 11434815
DMVWCTL MW 1285.5
DMVWCTL FM C62H96N18O12
DMVWCTL IC InChI=1S/C62H96N18O12/c1-7-8-12-46(56(66)85)77-60(89)48(24-36(2)3)78-61(90)50(27-43-31-69-35-72-43)76-52(82)32-71-62(91)55(37(4)5)80-57(86)38(6)73-59(88)49(26-41-30-70-45-13-10-9-11-44(41)45)79-58(87)47(18-19-51(65)81)75-54(84)34-92-33-53(83)74-42-16-14-39(15-17-42)25-40(28-67-22-20-63)29-68-23-21-64/h9-11,13-17,30-31,35-38,40,46-50,55,67-68,70H,7-8,12,18-29,32-34,63-64H2,1-6H3,(H2,65,81)(H2,66,85)(H,69,72)(H,71,91)(H,73,88)(H,74,83)(H,75,84)(H,76,82)(H,77,89)(H,78,90)(H,79,87)(H,80,86)/t38-,46-,47-,48-,49-,50-,55-/m0/s1
DMVWCTL CS CCCC[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)COCC(=O)NC4=CC=C(C=C4)CC(CNCCN)CNCCN
DMVWCTL IK XDFRCEDKCPCBTG-KGOWMPLXSA-N
DMVWCTL IU (2S)-2-[[2-[2-[4-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propyl]anilino]-2-oxoethoxy]acetyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMVWCTL DE Discovery agent
DMD4BSJ ID DMD4BSJ
DMD4BSJ DN [(N4-Bzdig)0]BB(7-14)
DMD4BSJ HS Investigative
DMD4BSJ SN CHEMBL414307; [(N4-Bzdig)0]BB(7-14)
DMD4BSJ PC 11389266
DMD4BSJ MW 1303.6
DMD4BSJ FM C61H94N18O12S
DMD4BSJ IC InChI=1S/C61H94N18O12S/c1-35(2)23-47(59(88)76-45(55(65)84)17-22-92-6)77-60(89)49(26-42-30-68-34-71-42)75-51(81)31-70-61(90)54(36(3)4)79-56(85)37(5)72-58(87)48(25-40-29-69-44-10-8-7-9-43(40)44)78-57(86)46(15-16-50(64)80)74-53(83)33-91-32-52(82)73-41-13-11-38(12-14-41)24-39(27-66-20-18-62)28-67-21-19-63/h7-14,29-30,34-37,39,45-49,54,66-67,69H,15-28,31-33,62-63H2,1-6H3,(H2,64,80)(H2,65,84)(H,68,71)(H,70,90)(H,72,87)(H,73,82)(H,74,83)(H,75,81)(H,76,88)(H,77,89)(H,78,86)(H,79,85)/t37-,45-,46-,47-,48-,49-,54-/m0/s1
DMD4BSJ CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)COCC(=O)NC4=CC=C(C=C4)CC(CNCCN)CNCCN
DMD4BSJ IK IKKYIPCELZIPRY-RNXDXMLZSA-N
DMD4BSJ IU (2S)-2-[[2-[2-[4-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propyl]anilino]-2-oxoethoxy]acetyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMD4BSJ DE Discovery agent
DMPFUBE ID DMPFUBE
DMPFUBE DN [(R)-(+)-deoxytylophorinidine
DMPFUBE HS Investigative
DMPFUBE SN CHEMBL250474; [(R)-(+)-deoxytylophorinidine; BDBM50213932
DMPFUBE DT Small molecular drug
DMPFUBE PC 44443385
DMPFUBE MW 349.4
DMPFUBE FM C22H23NO3
DMPFUBE IC InChI=1S/C22H23NO3/c1-25-14-5-6-15-16-8-13-4-3-7-23(13)12-20(16)19-11-22(26-2)21(24)10-18(19)17(15)9-14/h5-6,9-11,13,24H,3-4,7-8,12H2,1-2H3/t13-/m1/s1
DMPFUBE CS COC1=CC2=C(C=C1)C3=C(CN4CCC[C@@H]4C3)C5=CC(=C(C=C52)O)OC
DMPFUBE IK DACRWRGHESRUQW-CYBMUJFWSA-N
DMPFUBE IU (13aR)-3,7-dimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[10,9-f]indolizin-6-ol
DMPFUBE DE Discovery agent
DMU9F2P ID DMU9F2P
DMU9F2P DN [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
DMU9F2P HS Investigative
DMU9F2P SN [[4-(AMINOMETHYL)PHENYL]AMINO]OXO-ACETIC ACID,; 840454-25-3; LO1; Acetic acid, 2-[[4-(aminomethyl)phenyl]amino]-2-oxo-; 1wax; 2-[4-(aminomethyl)anilino]-2-oxoacetic acid; AC1L9MR9; SCHEMBL4317924; CHEMBL426815; CTK3D0907; DTXSID60332298; DB02420; {[4-(aminomethyl)phenyl]carbamoyl}formic acid; {[4-(aminomethyl)phenyl]amino}(oxo)acetic acid; Acetic acid, [[4-(aminomethyl)phenyl]amino]oxo-
DMU9F2P DT Small molecular drug
DMU9F2P PC 449125
DMU9F2P MW 194.19
DMU9F2P FM C9H10N2O3
DMU9F2P IC InChI=1S/C9H10N2O3/c10-5-6-1-3-7(4-2-6)11-8(12)9(13)14/h1-4H,5,10H2,(H,11,12)(H,13,14)
DMU9F2P CS C1=CC(=CC=C1CN)NC(=O)C(=O)O
DMU9F2P IK RKILOCCSAVHHJT-UHFFFAOYSA-N
DMU9F2P IU 2-[4-(aminomethyl)anilino]-2-oxoacetic acid
DMU9F2P CA CAS 840454-25-3
DMU9F2P DE Discovery agent
DM86305 ID DM86305
DM86305 DN [[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate
DM86305 HS Investigative
DM86305 SN [[n-(benzyloxycarbonyl)amino]methyl]phosphate; (BENZYLOXYCARBONYLAMINO)METHYLPHOSPHONIC ACID; ({[(benzyloxy)carbonyl]amino}methyl)phosphonic acid; AC1L1CL8; SCHEMBL5586441; CHEMBL1232804; CTK7G8496; WUNKRZNFNIYEPN-UHFFFAOYSA-N; DB02642; (N-carbobenzoxy-amino)methylphosphonic acid; phenylmethoxycarbonylaminomethylphosphonic acid
DM86305 DT Small molecular drug
DM86305 PC 1950
DM86305 MW 245.17
DM86305 FM C9H12NO5P
DM86305 IC InChI=1S/C9H12NO5P/c11-9(10-7-16(12,13)14)15-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H,10,11)(H2,12,13,14)
DM86305 CS C1=CC=C(C=C1)COC(=O)NCP(=O)(O)O
DM86305 IK WUNKRZNFNIYEPN-UHFFFAOYSA-N
DM86305 IU phenylmethoxycarbonylaminomethylphosphonic acid
DM86305 DE Discovery agent
DMAGW3R ID DMAGW3R
DMAGW3R DN [1-(4-p-Tolyl-butyl)-piperidin-4-yl]-methanol
DMAGW3R HS Investigative
DMAGW3R SN CHEMBL570915
DMAGW3R DT Small molecular drug
DMAGW3R PC 45485499
DMAGW3R MW 261.399
DMAGW3R FM C17H27NO
DMAGW3R IC InChI=1S/C17H27NO/c1-15-5-7-16(8-6-15)4-2-3-11-18-12-9-17(14-19)10-13-18/h5-8,17,19H,2-4,9-14H2,1H3
DMAGW3R CS CC1=CC=C(C=C1)CCCCN2CCC(CC2)CO
DMAGW3R IK VTDHRHRPPVJGSU-UHFFFAOYSA-N
DMAGW3R IU [1-[4-(4-methylphenyl)butyl]piperidin-4-yl]methanol
DMAGW3R DE Discovery agent
DMVOY4D ID DMVOY4D
DMVOY4D DN [1,1':2',1'']-terphenyl-4,3'',5''-triol
DMVOY4D HS Investigative
DMVOY4D SN CHEMBL208098; BDBM50186757; ZINC35856323
DMVOY4D DT Small molecular drug
DMVOY4D PC 11579996
DMVOY4D MW 278.3
DMVOY4D FM C18H14O3
DMVOY4D IC InChI=1S/C18H14O3/c19-14-7-5-12(6-8-14)17-3-1-2-4-18(17)13-9-15(20)11-16(21)10-13/h1-11,19-21H
DMVOY4D CS C1=CC=C(C(=C1)C2=CC=C(C=C2)O)C3=CC(=CC(=C3)O)O
DMVOY4D IK UGGGRFWZAHTXBI-UHFFFAOYSA-N
DMVOY4D IU 5-[2-(4-hydroxyphenyl)phenyl]benzene-1,3-diol
DMVOY4D DE Discovery agent
DMFXA8P ID DMFXA8P
DMFXA8P DN [1,1':2',1'']Terphenyl-4'-carbaldehyde oxime
DMFXA8P HS Investigative
DMFXA8P DT Small molecular drug
DMFXA8P PC 11780703
DMFXA8P MW 273.3
DMFXA8P FM C19H15NO
DMFXA8P IC InChI=1S/C19H15NO/c21-20-14-15-11-12-18(16-7-3-1-4-8-16)19(13-15)17-9-5-2-6-10-17/h1-14,21H/b20-14+
DMFXA8P CS C1=CC=C(C=C1)C2=C(C=C(C=C2)/C=N/O)C3=CC=CC=C3
DMFXA8P IK XSIHFOOFJWBVHK-XSFVSMFZSA-N
DMFXA8P IU (NE)-N-[(3,4-diphenylphenyl)methylidene]hydroxylamine
DMFXA8P DE Discovery agent
DMPV0QN ID DMPV0QN
DMPV0QN DN [1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one
DMPV0QN HS Investigative
DMPV0QN SN [1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one; 150454-83-4; ACMC-1C8D4; CHEMBL365930; CTK0G9579; DTXSID10435607; AKOS027398551
DMPV0QN DT Small molecular drug
DMPV0QN PC 10103893
DMPV0QN MW 186.17
DMPV0QN FM C9H6N4O
DMPV0QN IC InChI=1S/C9H6N4O/c14-9-8-10-5-11-13(8)7-4-2-1-3-6(7)12-9/h1-5H,(H,12,14)
DMPV0QN CS C1=CC=C2C(=C1)NC(=O)C3=NC=NN23
DMPV0QN IK OEIMIUHARCZWJY-UHFFFAOYSA-N
DMPV0QN IU 5H-[1,2,4]triazolo[1,5-a]quinoxalin-4-one
DMPV0QN CA CAS 150454-83-4
DMPV0QN DE Discovery agent
DMDX6W4 ID DMDX6W4
DMDX6W4 DN [1,3]Oxazinan-(2E)-ylideneamine
DMDX6W4 HS Investigative
DMDX6W4 SN 5,6-dihydro-4h-1,3-oxazin-2-amine; CHEMBL161118; 1848-68-6; [1,3]Oxazinan-(2E)-ylideneamine; SCHEMBL31223; 2-iminotetrahydro-1,3-oxazine; MolPort-044-586-586; BDBM50049258; ZINC13746441; AKOS025312622; AKOS006338233; 2-amino-5,6-dihydro-4h-1,3-oxazine
DMDX6W4 DT Small molecular drug
DMDX6W4 PC 23042899
DMDX6W4 MW 100.12
DMDX6W4 FM C4H8N2O
DMDX6W4 IC InChI=1S/C4H8N2O/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)
DMDX6W4 CS C1CN=C(OC1)N
DMDX6W4 IK VPVZSRIIAONGMU-UHFFFAOYSA-N
DMDX6W4 IU 5,6-dihydro-4H-1,3-oxazin-2-amine
DMDX6W4 DE Discovery agent
DMOEIHC ID DMOEIHC
DMOEIHC DN [1,3]Thiazinan-(2E)-ylideneamine
DMOEIHC HS Investigative
DMOEIHC SN 2-Amino-5,6-dihydro-4H-1,3-thiazine; 5,6-Dihydro-4H-1,3-thiazin-2-amine; 30480-64-9; CHEMBL306541; 2-Iminotetrahydro-1,3-thiazine; [1,3]Thiazinan-(2E)-ylideneamine; AC1Q4UKS; AC1L4O0Q; SCHEMBL30950; 2799-75-9 (hydrobromide); CTK4G5273; DTXSID60184552; [1,3]Thiazinan-(2Z)-ylideneamine; BDBM50049250; ZINC17744492; FCH991782; AKOS006347653; AKOS003362396; 4H-1,3-Thiazin-2-amine,5,6-dihydro-; EN300-203949; 3,4,5,6-Tetrahydro-2H-1,3-thiazin-2-imine
DMOEIHC DT Small molecular drug
DMOEIHC PC 189081
DMOEIHC MW 116.19
DMOEIHC FM C4H8N2S
DMOEIHC IC InChI=1S/C4H8N2S/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)
DMOEIHC CS C1CN=C(SC1)N
DMOEIHC IK PQXQEOIFIUJLIE-UHFFFAOYSA-N
DMOEIHC IU 5,6-dihydro-4H-1,3-thiazin-2-amine
DMOEIHC CA CAS 30480-64-9
DMOEIHC DE Discovery agent
DMX58NK ID DMX58NK
DMX58NK DN [1,4]Oxazepan-(3E)-ylideneamine
DMX58NK HS Investigative
DMX58NK SN CHEMBL362772; [1,4]Oxazepan-(3E)-ylideneamine; SCHEMBL2593607; BDBM50155790
DMX58NK DT Small molecular drug
DMX58NK PC 44396203
DMX58NK MW 114.15
DMX58NK FM C5H10N2O
DMX58NK IC InChI=1S/C5H10N2O/c6-5-4-8-3-1-2-7-5/h1-4H2,(H2,6,7)
DMX58NK CS C1CN=C(COC1)N
DMX58NK IK WKPUJGILMQAMEH-UHFFFAOYSA-N
DMX58NK IU 2,5,6,7-tetrahydro-1,4-oxazepin-3-amine
DMX58NK DE Discovery agent
DMMUZVS ID DMMUZVS
DMMUZVS DN [1,4]Oxazepan-(5E)-ylideneamine
DMMUZVS HS Investigative
DMMUZVS SN CHEMBL330548; [1,4]Oxazepan-(5E)-ylideneamine; SCHEMBL2590253; 5-Iminohexahydro-1,4-oxazepine; [1,4]Oxazepan-(5Z)-ylideneamine; BDBM50104659
DMMUZVS DT Small molecular drug
DMMUZVS PC 15463448
DMMUZVS MW 114.15
DMMUZVS FM C5H10N2O
DMMUZVS IC InChI=1S/C5H10N2O/c6-5-1-3-8-4-2-7-5/h1-4H2,(H2,6,7)
DMMUZVS CS C1COCCN=C1N
DMMUZVS IK IJBIVIJNRYYPRZ-UHFFFAOYSA-N
DMMUZVS IU 2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DMMUZVS DE Discovery agent
DMCBFJQ ID DMCBFJQ
DMCBFJQ DN [1,4]Thiazepan-(3E)-ylideneamine
DMCBFJQ HS Investigative
DMCBFJQ SN CHEMBL186856; [1,4]Thiazepan-(3E)-ylideneamine; BDBM50155780
DMCBFJQ DT Small molecular drug
DMCBFJQ PC 44396204
DMCBFJQ MW 130.21
DMCBFJQ FM C5H10N2S
DMCBFJQ IC InChI=1S/C5H10N2S/c6-5-4-8-3-1-2-7-5/h1-4H2,(H2,6,7)
DMCBFJQ CS C1CN=C(CSC1)N
DMCBFJQ IK GMUCRJMNMMHHFX-UHFFFAOYSA-N
DMCBFJQ IU 2,5,6,7-tetrahydro-1,4-thiazepin-3-amine
DMCBFJQ DE Discovery agent
DMFQ0Z4 ID DMFQ0Z4
DMFQ0Z4 DN [1,4]Thiazepan-(5E)-ylideneamine
DMFQ0Z4 HS Investigative
DMFQ0Z4 SN CHEMBL88308; [1,4]Thiazepan-(5E)-ylideneamine; SCHEMBL10239183; 5-Iminohexahydro-1,4-thiazepine; [1,4]Thiazepan-(5Z)-ylideneamine; BDBM50104653
DMFQ0Z4 DT Small molecular drug
DMFQ0Z4 PC 15463447
DMFQ0Z4 MW 130.21
DMFQ0Z4 FM C5H10N2S
DMFQ0Z4 IC InChI=1S/C5H10N2S/c6-5-1-3-8-4-2-7-5/h1-4H2,(H2,6,7)
DMFQ0Z4 CS C1CSCCN=C1N
DMFQ0Z4 IK VXILVSMPTBRDEC-UHFFFAOYSA-N
DMFQ0Z4 IU 2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMFQ0Z4 CA CAS 73028-68-9
DMFQ0Z4 DE Discovery agent
DMF62JR ID DMF62JR
DMF62JR DN [1,5]Thiazocan-(4E)-ylideneamine
DMF62JR HS Investigative
DMF62JR SN CHEMBL92422; [1,5]Thiazocan-(4E)-ylideneamine; 4-Iminohexahydro-2H-1,5-thiazocine; BDBM50104658
DMF62JR DT Small molecular drug
DMF62JR PC 44322961
DMF62JR MW 144.24
DMF62JR FM C6H12N2S
DMF62JR IC InChI=1S/C6H12N2S/c7-6-2-5-9-4-1-3-8-6/h1-5H2,(H2,7,8)
DMF62JR CS C1CN=C(CCSC1)N
DMF62JR IK CMKCQRINBMEZKA-UHFFFAOYSA-N
DMF62JR IU 3,4,7,8-tetrahydro-2H-1,5-thiazocin-6-amine
DMF62JR DE Discovery agent
DMMZUPX ID DMMZUPX
DMMZUPX DN [11C]AZ10419369
DMMZUPX HS Investigative
DMMZUPX SN [11C]AZ10419369 (PET ligand)
DMMZUPX DT Small molecular drug
DMMZUPX PC 42608431
DMMZUPX MW 461.5
DMMZUPX FM C26H30N4O4
DMMZUPX IC InChI=1S/C26H30N4O4/c1-18-3-8-21(30-11-9-28(2)10-12-30)25-24(18)22(31)17-23(34-25)26(32)27-19-4-6-20(7-5-19)29-13-15-33-16-14-29/h3-8,17H,9-16H2,1-2H3,(H,27,32)/i2-1
DMMZUPX CS CC1=C2C(=O)C=C(OC2=C(C=C1)N3CCN(CC3)[11CH3])C(=O)NC4=CC=C(C=C4)N5CCOCC5
DMMZUPX IK JKPWOPNZKYPRPZ-JVVVGQRLSA-N
DMMZUPX IU 5-methyl-8-(4-(111C)methylpiperazin-1-yl)-N-(4-morpholin-4-ylphenyl)-4-oxochromene-2-carboxamide
DMMZUPX DE Discovery agent
DMQP03A ID DMQP03A
DMQP03A DN [11C]butylthio-TZTP
DMQP03A HS Investigative
DMQP03A SN [11C]butylthio-TZTP (PET ligand)
DMQP03A DT Small molecular drug
DMQP03A PC 73755038
DMQP03A MW 268.4
DMQP03A FM C12H19N3S2
DMQP03A IC InChI=1S/C12H19N3S2/c1-3-4-8-16-12-11(13-17-14-12)10-6-5-7-15(2)9-10/h6H,3-5,7-9H2,1-2H3/i1-1
DMQP03A CS CN1CCC=C(C1)C2=NSN=C2SCCC[11CH3]
DMQP03A IK SFXHHGRYNXLPKT-BJUDXGSMSA-N
DMQP03A IU 3-(411C)butylsulfanyl-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMQP03A DE Discovery agent
DM4ZANH ID DM4ZANH
DM4ZANH DN [11C]DTBZ
DM4ZANH HS Investigative
DM4ZANH SN [11C]-DTBZ ; [11C]-DTBZ (PET ligand); dihydrotetrabenazine
DM4ZANH DT Small molecular drug
DM4ZANH PC 73755103
DM4ZANH MW 332.5
DM4ZANH FM C20H31NO3
DM4ZANH IC InChI=1S/C20H31NO3/c1-13(2)8-15-12-21-7-6-14-9-18(23-4)19(24-5)10-16(14)20(21,3)11-17(15)22/h9-10,13,15,17,22H,6-8,11-12H2,1-5H3/t15-,17-,20-/m0/s1/i4-1
DM4ZANH CS CC(C)C[C@H]1CN2CCC3=CC(=C(C=C3[C@@]2(C[C@@H]1O)C)OC)O[11CH3]
DM4ZANH IK QJPLBORGTBURBF-VEFADGFBSA-N
DM4ZANH IU (2S,3S,11bS)-10-methoxy-9-(111C)methoxy-11b-methyl-3-(2-methylpropyl)-1,2,3,4,6,7-hexahydrobenzo[a]quinolizin-2-ol
DM4ZANH DE Discovery agent
DM5Q08F ID DM5Q08F
DM5Q08F DN [11C]GlySar
DM5Q08F HS Investigative
DM5Q08F SN [11C]-GlySar; [11C]glycylsarcosine
DM5Q08F DT Small molecular drug
DM5Q08F PC 24971238
DM5Q08F MW 145.15
DM5Q08F FM C5H10N2O3
DM5Q08F IC InChI=1S/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)/i1-1
DM5Q08F CS [11CH3]N(CC(=O)O)C(=O)CN
DM5Q08F IK VYAMLSCELQQRAE-BJUDXGSMSA-N
DM5Q08F IU 2-[(2-aminoacetyl)-(111C)methylamino]acetic acid
DM5Q08F DE Discovery agent
DMQRSP7 ID DMQRSP7
DMQRSP7 DN [11C]MMTP
DMQRSP7 HS Investigative
DMQRSP7 SN [11C]MMTP; GTPL6212; CHEMBL1082810; Dimethylamino-3(4-[11C]methoxyphenyl)-3H-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one
DMQRSP7 DT Small molecular drug
DMQRSP7 PC 46891047
DMQRSP7 MW 351.4
DMQRSP7 FM C18H16N4O2S
DMQRSP7 IC InChI=1S/C18H16N4O2S/c1-21(2)13-8-9-19-17-14(13)15-16(25-17)18(23)22(10-20-15)11-4-6-12(24-3)7-5-11/h4-10H,1-3H3/i3-1
DMQRSP7 CS CN(C)C1=C2C3=C(C(=O)N(C=N3)C4=CC=C(C=C4)O[11CH3])SC2=NC=C1
DMQRSP7 IK COQPVKMATNFNLG-KTXUZGJCSA-N
DMQRSP7 IU 13-(dimethylamino)-5-(4-(111C)methoxyphenyl)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMQRSP7 DE Discovery agent
DMOZ8E3 ID DMOZ8E3
DMOZ8E3 DN [11C]SB207145
DMOZ8E3 HS Investigative
DMOZ8E3 SN [11C] SB207145 (PET ligand)
DMOZ8E3 DT Small molecular drug
DMOZ8E3 PC 73755034
DMOZ8E3 MW 339.8
DMOZ8E3 FM C16H21ClN2O4
DMOZ8E3 IC InChI=1S/C16H21ClN2O4/c1-19-4-2-10(3-5-19)9-23-16(20)11-8-12(17)13(18)15-14(11)21-6-7-22-15/h8,10H,2-7,9,18H2,1H3/i1-1
DMOZ8E3 CS [11CH3]N1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)Cl
DMOZ8E3 IK FWDOTRBSNDBFMN-BJUDXGSMSA-N
DMOZ8E3 IU (1-(111C)methylpiperidin-4-yl)methyl 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylate
DMOZ8E3 DE Discovery agent
DMCQTYW ID DMCQTYW
DMCQTYW DN [11C]volinanserin
DMCQTYW HS Investigative
DMCQTYW SN [11C]M100907 (PET ligand); [11C]MDL100907
DMCQTYW DT Small molecular drug
DMCQTYW PC 449851
DMCQTYW MW 372.5
DMCQTYW FM C22H28FNO3
DMCQTYW IC InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1/i1-1
DMCQTYW CS COC1=C(C=CC=C1O[11CH3])[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DMCQTYW IK HXTGXYRHXAGCFP-AVUPQLEMSA-N
DMCQTYW IU (R)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]-(2-methoxy-3-(111C)methoxyphenyl)methanol
DMCQTYW CA CAS 174792-03-1
DMCQTYW DE Discovery agent
DMXIEA1 ID DMXIEA1
DMXIEA1 DN [11C]WAY100635
DMXIEA1 HS Investigative
DMXIEA1 SN [11C]WAY100635 (PET ligand); [11C]WAY-100635
DMXIEA1 DT Small molecular drug
DMXIEA1 PC 449645
DMXIEA1 MW 421.6
DMXIEA1 FM C25H34N4O2
DMXIEA1 IC InChI=1S/C25H34N4O2/c1-31-23-12-6-5-11-22(23)28-18-15-27(16-19-28)17-20-29(24-13-7-8-14-26-24)25(30)21-9-3-2-4-10-21/h5-8,11-14,21H,2-4,9-10,15-20H2,1H3/i25-1
DMXIEA1 CS COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)[11C](=O)C4CCCCC4
DMXIEA1 IK SBPRIAGPYFYCRT-FNNGWQQSSA-N
DMXIEA1 IU N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide
DMXIEA1 CA CAS 162760-97-6
DMXIEA1 DE Discovery agent
DM742L9 ID DM742L9
DM742L9 DN [11C]xanomeline
DM742L9 HS Investigative
DM742L9 SN [11C]xanomeline (PET ligand)
DM742L9 DT Small molecular drug
DM742L9 PC 73755040
DM742L9 MW 280.42
DM742L9 FM C14H23N3OS
DM742L9 IC InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3/i2-1
DM742L9 CS CCCCCCOC1=NSN=C1C2=CCCN(C2)[11CH3]
DM742L9 IK JOLJIIDDOBNFHW-JVVVGQRLSA-N
DM742L9 IU 3-hexoxy-4-(1-(111C)methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DM742L9 DE Discovery agent
DMHWNOS ID DMHWNOS
DMHWNOS DN [123I] iodobenzoyl 12-Ex4
DMHWNOS HS Investigative
DMHWNOS CP Kyoto University
DMHWNOS DE Diabetic complication
DMCJQ0P ID DMCJQ0P
DMCJQ0P DN [123I]AM251
DMCJQ0P HS Investigative
DMCJQ0P SN [123I]AM251
DMCJQ0P DT Small molecular drug
DMCJQ0P PC 10506880
DMCJQ0P MW 551.2
DMCJQ0P FM C22H21Cl2IN4O
DMCJQ0P IC InChI=1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)/i25-4
DMCJQ0P CS CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)[123I]
DMCJQ0P IK BUZAJRPLUGXRAB-VEFBWTBNSA-N
DMCJQ0P IU 1-(2,4-dichlorophenyl)-5-(4-(123I)iodanylphenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMCJQ0P DE Discovery agent
DMOZGLM ID DMOZGLM
DMOZGLM DN [123I]iodobenzovesamicol
DMOZGLM HS Investigative
DMOZGLM SN [123I]-iodobenzovesamicol ; [123I]-IBVM
DMOZGLM DT Small molecular drug
DMOZGLM PC 450460
DMOZGLM MW 429.3
DMOZGLM FM C21H24INO
DMOZGLM IC InChI=1S/C21H24INO/c22-19-8-4-7-17-13-21(24)20(14-18(17)19)23-11-9-16(10-12-23)15-5-2-1-3-6-15/h1-8,16,20-21,24H,9-14H2/t20-,21-/m1/s1/i22-4
DMOZGLM CS C1CN(CCC1C2=CC=CC=C2)[C@@H]3CC4=C(C[C@H]3O)C=CC=C4[123I]
DMOZGLM IK FHYAUNJNVMGZQN-YKBXEZAISA-N
DMOZGLM IU (2R,3R)-5-(123I)iodanyl-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol
DMOZGLM DE Discovery agent
DM5SRT1 ID DM5SRT1
DM5SRT1 DN [123I]iodoproxyfan
DM5SRT1 HS Investigative
DM5SRT1 DT Small molecular drug
DM5SRT1 PC 449663
DM5SRT1 MW 338.18
DM5SRT1 FM C13H15IN2O
DM5SRT1 IC InChI=1S/C13H15IN2O/c14-12-5-3-11(4-6-12)9-17-7-1-2-13-8-15-10-16-13/h3-6,8,10H,1-2,7,9H2,(H,15,16)/i14-4
DM5SRT1 CS C1=CC(=CC=C1COCCCC2=CN=CN2)[123I]
DM5SRT1 IK DCQNAFOCXVCDLB-CKVWVWRJSA-N
DM5SRT1 IU 5-[3-[(4-(123I)iodanylphenyl)methoxy]propyl]-1H-imidazole
DM5SRT1 DE Discovery agent
DMMG1TA ID DMMG1TA
DMMG1TA DN [123I]SB 207710
DMMG1TA HS Investigative
DMMG1TA SN [123I]SB 207710; GTPL3243; [123I]SB207710; (1-Butyl-4-piperidinylmethyl)-8-amino-7-[123I]iodo-1,4-benzodioxan-5-carboxylate; (1-butylpiperidin-4-yl)methyl 8-amino-7-(123I)iodo-2,3-dihydro-1,4-benzodioxine-5-carboxylate
DMMG1TA DT Small molecular drug
DMMG1TA PC 32057519
DMMG1TA MW 470.3
DMMG1TA FM C19H27IN2O4
DMMG1TA IC InChI=1S/C19H27IN2O4/c1-2-3-6-22-7-4-13(5-8-22)12-26-19(23)14-11-15(20)16(21)18-17(14)24-9-10-25-18/h11,13H,2-10,12,21H2,1H3/i20-4
DMMG1TA CS CCCCN1CCC(CC1)COC(=O)C2=CC(=C(C3=C2OCCO3)N)[123I]
DMMG1TA IK FCKKCDRMGKXQDK-BMILMZPDSA-N
DMMG1TA IU (1-butylpiperidin-4-yl)methyl 5-amino-6-(123I)iodanyl-2,3-dihydro-1,4-benzodioxine-8-carboxylate
DMMG1TA DE Discovery agent
DMFT5N9 ID DMFT5N9
DMFT5N9 DN [125I]7-azido-8-iodoketanserine
DMFT5N9 HS Investigative
DMFT5N9 SN [125I]-7-azido-8-iodoketanserine (photoaffinity ligand); [125I]azidoiodoketanserin; [125I]AZIK
DMFT5N9 DT Small molecular drug
DMFT5N9 PC 3037022
DMFT5N9 MW 560.3
DMFT5N9 FM C22H20FIN6O3
DMFT5N9 IC InChI=1S/C22H20FIN6O3/c23-15-3-1-13(2-4-15)20(31)14-7-9-29(10-8-14)11-12-30-21(32)16-5-6-17(27-28-25)18(24)19(16)26-22(30)33/h1-6,14H,7-12H2,(H,26,33)/i24-2
DMFT5N9 CS C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=C(C(=C(C=C4)N=[N+]=[N-])[125I])NC3=O
DMFT5N9 IK OALSEJAYBSRMHM-XXFZXMJFSA-N
DMFT5N9 IU 7-azido-3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-8-(125I)iodanyl-1H-quinazoline-2,4-dione
DMFT5N9 CA CAS 136769-36-3
DMFT5N9 DE Discovery agent
DM8EQFL ID DM8EQFL
DM8EQFL DN [125I]AB-MECA
DM8EQFL HS Investigative
DM8EQFL SN [125I]5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyl-oxolane-2-carboxamide; [125I]N(6)-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide; [125I]-AB-MECA
DM8EQFL DT Small molecular drug
DM8EQFL PC 73754993
DM8EQFL MW 523.299
DM8EQFL FM C18H20IN7O4
DM8EQFL IC InChI=1S/C18H20IN7O4/c1-21-17(29)14-12(27)13(28)18(30-14)26-7-25-11-15(23-6-24-16(11)26)22-5-8-2-3-10(20)9(19)4-8/h2-4,6-7,12-14,18,27-28H,5,20H2,1H3,(H,21,29)(H,22,23,24)/t12-,13+,14-,18+/m0/s1/i19-2
DM8EQFL CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=C(C=C4)N)[125I])O)O
DM8EQFL IK LOGOEBMHHXYBID-WBKNRDRNSA-N
DM8EQFL IU (2S,3S,4R,5R)-5-[6-[(4-amino-3-(125I)iodanylphenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DM8EQFL DE Discovery agent
DMZBNK9 ID DMZBNK9
DMZBNK9 DN [125I]ABOPX
DMZBNK9 HS Investigative
DMZBNK9 SN [125I]3-(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine
DMZBNK9 DT Small molecular drug
DMZBNK9 PC 14016348
DMZBNK9 MW 573.4
DMZBNK9 FM C23H22IN5O5
DMZBNK9 IC InChI=1S/C23H22IN5O5/c1-2-9-28-22(32)19-21(29(23(28)33)11-13-3-8-17(25)16(24)10-13)27-20(26-19)14-4-6-15(7-5-14)34-12-18(30)31/h3-8,10H,2,9,11-12,25H2,1H3,(H,26,27)(H,30,31)/i24-2
DMZBNK9 CS CCCN1C(=O)C2=C(N=C(N2)C3=CC=C(C=C3)OCC(=O)O)N(C1=O)CC4=CC(=C(C=C4)N)[125I]
DMZBNK9 IK DKJMGIXWGPEEFF-XXFZXMJFSA-N
DMZBNK9 IU 2-[4-[3-[(4-amino-3-(125I)iodanylphenyl)methyl]-2,6-dioxo-1-propyl-7H-purin-8-yl]phenoxy]acetic acid
DMZBNK9 DE Discovery agent
DM95A4Z ID DM95A4Z
DM95A4Z DN [125I]APNEA
DM95A4Z HS Investigative
DM95A4Z SN CHEMBL326958; 2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; [3H]N6-2-(4-Aminophenyl)ethyladenosine; AC1L1I2P; AC1Q4Y3F; Lopac0_000118; GTPL417; GTPL462; ChEMBL_198532; SCHEMBL16585344; HMS3260G18; n-[2-(4-aminophenyl)ethyl]-9-pentofuranosyl-9h-purin-6-amine; Tox21_500118; BDBM50037785; LP00118; CCG-204213; NCGC00260803-01; NCGC00093612-03; NCGC00015017-04; NCGC00093612-02; NCGC00093612-01; NCGC00015017-05; NCGC00015017-03; NCGC00015017-02; [3H]N6-2-(4-aminophenyl)ethyladenosine
DM95A4Z DT Small molecular drug
DM95A4Z PC 4397
DM95A4Z MW 386.4
DM95A4Z FM C18H22N6O4
DM95A4Z IC InChI=1S/C18H22N6O4/c19-11-3-1-10(2-4-11)5-6-20-16-13-17(22-8-21-16)24(9-23-13)18-15(27)14(26)12(7-25)28-18/h1-4,8-9,12,14-15,18,25-27H,5-7,19H2,(H,20,21,22)
DM95A4Z CS C1=CC(=CC=C1CCNC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
DM95A4Z IK XTPOZVLRZZIEBW-UHFFFAOYSA-N
DM95A4Z IU 2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM95A4Z DE Discovery agent
DMYBQOG ID DMYBQOG
DMYBQOG DN [125I]-BDZ2
DMYBQOG HS Investigative
DMYBQOG SN CHEMBL515288; [125I]-BDZ2; GTPL6667
DMYBQOG DT Small molecular drug
DMYBQOG PC 44572147
DMYBQOG MW 508.3
DMYBQOG FM C23H19IN4O2
DMYBQOG IC InChI=1S/C23H19IN4O2/c1-28-19-13-6-5-12-18(19)20(15-8-3-2-4-9-15)26-21(22(28)29)27-23(30)25-17-11-7-10-16(24)14-17/h2-14,21H,1H3,(H2,25,27,30)/t21-/m0/s1/i24-2
DMYBQOG CS CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC(=CC=C3)[125I])C4=CC=CC=C4
DMYBQOG IK VLKJKVMACAESPP-MRDSYVANSA-N
DMYBQOG IU 1-(3-(125I)iodanylphenyl)-3-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea
DMYBQOG DE Discovery agent
DM7GVYF ID DM7GVYF
DM7GVYF DN [125I]BE-2254
DM7GVYF HS Investigative
DM7GVYF SN HEAT; 2-{p-(4-hydroxy-3-[125I]iodophenyl)ethylaminomethyl}-tetralone; 2-[[2-(4-hydroxy-3-iodanylphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
DM7GVYF DT Small molecular drug
DM7GVYF PC 449744
DM7GVYF MW 419.3
DM7GVYF FM C19H20INO2
DM7GVYF IC InChI=1S/C19H20INO2/c20-17-11-13(5-8-18(17)22)9-10-21-12-15-7-6-14-3-1-2-4-16(14)19(15)23/h1-5,8,11,15,21-22H,6-7,9-10,12H2/i20-2
DM7GVYF CS C1CC2=CC=CC=C2C(=O)C1CNCCC3=CC(=C(C=C3)O)[125I]
DM7GVYF IK DUOOAUBZMQZYLO-STTHPYEQSA-N
DM7GVYF IU 2-[[2-(4-hydroxy-3-(125I)iodanylphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
DM7GVYF DE Discovery agent
DMV6I7H ID DMV6I7H
DMV6I7H DN [125I]BOP
DMV6I7H HS Investigative
DMV6I7H SN [125I]-I-BOP
DMV6I7H DT Small molecular drug
DMV6I7H PC 23986047
DMV6I7H MW 510.4
DMV6I7H FM C23H29IO5
DMV6I7H IC InChI=1S/C23H29IO5/c24-16-7-10-18(11-8-16)28-15-17(25)9-12-20-19(21-13-14-22(20)29-21)5-3-1-2-4-6-23(26)27/h1,3,7-12,17,19-22,25H,2,4-6,13-15H2,(H,26,27)/b3-1+,12-9+/t17-,19-,20-,21+,22-/m1/s1/i24-2
DMV6I7H CS C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)C/C=C/CCCC(=O)O)/C=C/[C@H](COC3=CC=C(C=C3)[125I])O
DMV6I7H IK UYFMSCHBODMWON-ZKBYQGIHSA-N
DMV6I7H IU (E)-7-[(1S,2R,3R,4R)-3-[(E,3R)-3-hydroxy-4-(4-(125I)iodanylphenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMV6I7H DE Discovery agent
DM0X824 ID DM0X824
DM0X824 DN [125I]cetrorelix
DM0X824 HS Investigative
DM0X824 SN [125I]cetrorelix
DM0X824 DT Small molecular drug
DM0X824 PC 73754999
DM0X824 MW 1520.5
DM0X824 FM C70H92IN17O14
DM0X824 IC InChI=1S/C70H92IN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1/i71-2
DM0X824 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)[125I])NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM0X824 IK MVDPNTCYCFVFOX-SZENRQNHSA-N
DM0X824 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-(125I)iodanylphenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM0X824 DE Discovery agent
DMIAO4V ID DMIAO4V
DMIAO4V DN [125I]CGP 64213
DMIAO4V HS Investigative
DMIAO4V SN [125I]CGP64213
DMIAO4V DT Small molecular drug
DMIAO4V PC 53323294
DMIAO4V MW 644.5
DMIAO4V FM C26H36IN2O7P
DMIAO4V IC InChI=1S/C26H36IN2O7P/c1-18(20-6-5-7-21(15-20)26(33)34)29-16-22(30)17-37(35,36)13-4-2-3-12-28-25(32)11-9-19-8-10-24(31)23(27)14-19/h5-8,10,14-15,18,22,29-31H,2-4,9,11-13,16-17H2,1H3,(H,28,32)(H,33,34)(H,35,36)/t18-,22+/m1/s1/i27-2
DMIAO4V CS C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)CCC2=CC(=C(C=C2)O)[125I])O)O
DMIAO4V IK RLYLJDJFHZHCTR-ZNAYHWKRSA-N
DMIAO4V IU 3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[5-[3-(4-hydroxy-3-(125I)iodanylphenyl)propanoylamino]pentyl]phosphoryl]propyl]amino]ethyl]benzoic acid
DMIAO4V DE Discovery agent
DMQVW4E ID DMQVW4E
DMQVW4E DN [125I]CGP 71872
DMQVW4E HS Investigative
DMQVW4E SN [125I]CGP71872
DMQVW4E DT Small molecular drug
DMQVW4E PC 53323295
DMQVW4E MW 657.4
DMQVW4E FM C24H31IN5O7P
DMQVW4E IC InChI=1S/C24H31IN5O7P/c1-15(16-6-5-7-17(10-16)24(34)35)28-13-18(31)14-38(36,37)9-4-2-3-8-27-23(33)19-11-20(25)21(29-30-26)12-22(19)32/h5-7,10-12,15,18,28,31-32H,2-4,8-9,13-14H2,1H3,(H,27,33)(H,34,35)(H,36,37)/t15-,18+/m1/s1/i25-2
DMQVW4E CS C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)C2=CC(=C(C=C2O)N=[N+]=[N-])[125I])O)O
DMQVW4E IK IHFUJPDKHJTHGQ-DQPKGEOYSA-N
DMQVW4E IU 3-[(1R)-1-[[(2S)-3-[5-[(4-azido-2-hydroxy-5-(125I)iodanylbenzoyl)amino]pentyl-hydroxyphosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid
DMQVW4E DE Discovery agent
DM1NXDA ID DM1NXDA
DM1NXDA DN [125I]CGP42112
DM1NXDA HS Investigative
DM1NXDA SN UXGNARZDONUMMK-LRMQDCNJSA-N; Cgp-42112A; Cgp 42112; 127060-75-7; CGP 42112A; CGP-42112; Cgp 42112B; CGP42112A; Nicotinic acid-tyr-(N(sigma)-benzyloxycarbonyl-arg)lys-his-pro-ile-OH; Nicotinic acid-tyrosyl-(N(sigma)-benzyloxycarbonyl-arginyl)lysyl-histidyl-prolyl-isoleucine-OH; L-Isoleucine, N-(1-(N-(N6-(N2-((phenylmethoxy)carbonyl)-L-arginyl)-N2-(N-(3-pyridinylcarbonyl)-L-tyrosyl)-L-lysyl)-L-histidyl)-L-prolyl)-; CGP42112; Cgp 42112B; [125I]-CGP42112
DM1NXDA DT Small molecular drug
DM1NXDA PC 123794
DM1NXDA MW 1052.2
DM1NXDA FM C52H69N13O11
DM1NXDA IC InChI=1S/C52H69N13O11/c1-3-32(2)43(50(73)74)64-48(71)42-17-11-25-65(42)49(72)41(27-36-29-56-31-59-36)62-46(69)39(60-47(70)40(26-33-18-20-37(66)21-19-33)61-44(67)35-14-9-22-55-28-35)15-7-8-23-57-45(68)38(16-10-24-58-51(53)54)63-52(75)76-30-34-12-5-4-6-13-34/h4-6,9,12-14,18-22,28-29,31-32,38-43,66H,3,7-8,10-11,15-17,23-27,30H2,1-2H3,(H,56,59)(H,57,68)(H,60,70)(H,61,67)(H,62,69)(H,63,75)(H,64,71)(H,73,74)(H4,53,54,58)/t32-,38-,39-,40-,41-,42-,43-/m0/s1
DM1NXDA CS CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCCNC(=O)[C@H](CCCN=C(N)N)NC(=O)OCC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)C5=CN=CC=C5
DM1NXDA IK UXGNARZDONUMMK-LRMQDCNJSA-N
DM1NXDA IU (2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-[[(2S)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-2-[[(2S)-3-(4-hydroxyphenyl)-2-(pyridine-3-carbonylamino)propanoyl]amino]hexanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid
DM1NXDA CA CAS 127060-75-7
DM1NXDA CB CHEBI:147302
DM1NXDA DE Discovery agent
DMEPT8H ID DMEPT8H
DMEPT8H DN [125I]DIV880
DMEPT8H HS Investigative
DMEPT8H SN [125I]DIV880
DMEPT8H DT Small molecular drug
DMEPT8H PC 86277837
DMEPT8H MW 526.4
DMEPT8H FM C23H29IO6
DMEPT8H IC InChI=1S/C23H29IO6/c1-23(2,3)30-22(25)12-15-10-19(27-5)18(26-4)9-14(15)8-16-11-20(28-6)21(29-7)13-17(16)24/h9-11,13H,8,12H2,1-7H3/i24-2
DMEPT8H CS CC(C)(C)OC(=O)CC1=CC(=C(C=C1CC2=CC(=C(C=C2[125I])OC)OC)OC)OC
DMEPT8H IK UIYQREMVBQNPNM-XXFZXMJFSA-N
DMEPT8H IU tert-butyl 2-[2-[(2-(125I)iodanyl-4,5-dimethoxyphenyl)methyl]-4,5-dimethoxyphenyl]acetate
DMEPT8H DE Discovery agent
DMQUY08 ID DMQUY08
DMQUY08 DN [125I]DOI
DMQUY08 HS Investigative
DMQUY08 SN [125I]DOI
DMQUY08 DT Small molecular drug
DMQUY08 PC 13547416
DMQUY08 MW 319.15
DMQUY08 FM C11H16INO2
DMQUY08 IC InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3/i12-2
DMQUY08 CS CC(CC1=CC(=C(C=C1OC)[125I])OC)N
DMQUY08 IK BGMZUEKZENQUJY-DACUFJSSSA-N
DMQUY08 IU 1-(4-(125I)iodanyl-2,5-dimethoxyphenyl)propan-2-amine
DMQUY08 DE Discovery agent
DMZWQH3 ID DMZWQH3
DMZWQH3 DN [125I]epibatidine
DMZWQH3 HS Investigative
DMZWQH3 SN CHEMBL6623; NLPRAJRHRHZCQQ-UHFFFAOYSA-N; 140111-52-0; [3H]EPIBATIDINE; SR-01000597620; [125I]EPIBATIDINE; AC1Q3PYA; AC1L1AYB; 208/210 Epibatidine; KBioSS_000603; KBioGR_000603; BSPBio_001263; (R)-2-(6-Chloro-pyridin-3-yl)-7-aza-bicyclo[221]heptane; [3H]epibatidine
DMZWQH3 DT Small molecular drug
DMZWQH3 PC 1204
DMZWQH3 MW 208.69
DMZWQH3 FM C11H13ClN2
DMZWQH3 IC InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2
DMZWQH3 CS C1CC2C(CC1N2)C3=CN=C(C=C3)Cl
DMZWQH3 IK NLPRAJRHRHZCQQ-UHFFFAOYSA-N
DMZWQH3 IU 2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane
DMZWQH3 CB CHEBI:91678
DMZWQH3 DE Discovery agent
DMEKGZS ID DMEKGZS
DMEKGZS DN [125I]EXP985
DMEKGZS HS Investigative
DMEKGZS SN [125I]-EXP985
DMEKGZS DT Small molecular drug
DMEKGZS PC 73755063
DMEKGZS MW 665.9
DMEKGZS FM C29H27ClIN7O2
DMEKGZS IC InChI=1S/C29H27ClIN7O2/c1-2-5-25-33-27(30)26(29(40)32-15-14-18-10-13-24(39)23(31)16-18)38(25)17-19-8-11-20(12-9-19)21-6-3-4-7-22(21)28-34-36-37-35-28/h3-4,6-13,16,39H,2,5,14-15,17H2,1H3,(H,32,40)(H,34,35,36,37)/i31-2
DMEKGZS CS CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)NCCC5=CC(=C(C=C5)O)[125I])Cl
DMEKGZS IK WMCDNTWPKXBICS-DYSJZCPFSA-N
DMEKGZS IU 5-chloro-N-[2-(4-hydroxy-3-(125I)iodanylphenyl)ethyl]-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxamide
DMEKGZS DE Discovery agent
DMFWE4H ID DMFWE4H
DMFWE4H DN [125I]GR231118
DMFWE4H HS Investigative
DMFWE4H SN [125I]1229U91; [125I]GW1229
DMFWE4H DT Small molecular drug
DMFWE4H PC 56947140
DMFWE4H MW 2352.7
DMFWE4H FM C110H170N34O24
DMFWE4H IC InChI=1S/C110H170N34O24/c1-9-59(7)87(111)103(165)133-73-39-41-85(149)127-55-81(99(161)139-79(53-63-27-35-67(147)36-28-63)97(159)131-71(19-13-45-125-109(119)120)93(155)137-77(49-57(3)4)95(157)129-69(17-11-43-123-107(115)116)91(153)135-75(89(113)151)51-61-23-31-65(145)32-24-61)142-102(164)84-22-16-48-144(84)106(168)74(134-104(166)88(112)60(8)10-2)40-42-86(150)128-56-82(141-101(163)83-21-15-47-143(83)105(73)167)100(162)140-80(54-64-29-37-68(148)38-30-64)98(160)132-72(20-14-46-126-110(121)122)94(156)138-78(50-58(5)6)96(158)130-70(18-12-44-124-108(117)118)92(154)136-76(90(114)152)52-62-25-33-66(146)34-26-62/h23-38,57-60,69-84,87-88,145-148H,9-22,39-56,111-112H2,1-8H3,(H2,113,151)(H2,114,152)(H,127,149)(H,128,150)(H,129,157)(H,130,158)(H,131,159)(H,132,160)(H,133,165)(H,134,166)(H,135,153)(H,136,154)(H,137,155)(H,138,156)(H,139,161)(H,140,162)(H,141,163)(H,142,164)(H4,115,116,123)(H4,117,118,124)(H4,119,120,125)(H4,121,122,126)/t59-,60-,69-,70-,71-,72-,73-,74+,75-,76-,77-,78-,79-,80-,81-,82+,83-,84-,87-,88-/m0/s1
DMFWE4H CS CC[C@H](C)[C@@H](C(=N[C@@H]1CCC(=NC[C@@H](N=C([C@@H]2CCCN2C(=O)[C@H](CCC(=NC[C@H](N=C([C@@H]3CCCN3C1=O)O)C(=N[C@@H](CC4=CC=C(C=C4)O)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC5=CC=C(C=C5)O)C(=N)O)O)O)O)O)O)O)N=C([C@H]([C@@H](C)CC)N)O)O)C(=N[C@@H](CC6=CC=C(C=C6)O)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CC7=CC=C(C=C7)O)C(=N)O)O)O)O)O)O)O)O)N
DMFWE4H IK RJRBRCCJETZJLT-VHUVHYDGSA-N
DMFWE4H IU (3R,9R,12S,18S,24S,27S)-3,18-bis[[(2S,3S)-2-amino-1-hydroxy-3-methylpentylidene]amino]-9-N,24-N-bis[(2S)-1-[(2S)-5-carbamimidamido-1-[(2S)-1-[(2S)-5-carbamimidamido-1-hydroxy-1-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-iminopropan-2-yl]iminopentan-2-yl]imino-1-hydroxy-4-methylpentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]-6,11,21,26-tetrahydroxy-2,17-dioxo-1,7,10,16,22,25-hexazatricyclo[25.3.0.012,16]triaconta-6,10,21,25-tetraene-9,24-dicarboximidic acid
DMFWE4H DE Discovery agent
DMSYT5P ID DMSYT5P
DMSYT5P DN [125I]GTI
DMSYT5P HS Investigative
DMSYT5P SN serotonin-5-O-carboxymethyl-glycyl-(125I)tyrosinamide
DMSYT5P DT Small molecular drug
DMSYT5P PC 73755035
DMSYT5P MW 577.4
DMSYT5P FM C23H26IN5O5
DMSYT5P IC InChI=1S/C23H26IN5O5/c24-17-7-13(1-4-20(17)30)8-19(23(26)33)29-21(31)11-28-22(32)12-34-15-2-3-18-16(9-15)14(5-6-25)10-27-18/h1-4,7,9-10,19,27,30H,5-6,8,11-12,25H2,(H2,26,33)(H,28,32)(H,29,31)/t19-/m0/s1/i24-2
DMSYT5P CS C1=CC(=C(C=C1C[C@@H](C(=O)N)NC(=O)CNC(=O)COC2=CC3=C(C=C2)NC=C3CCN)[125I])O
DMSYT5P IK JVQSCVCNDUJMMW-BYWNROPASA-N
DMSYT5P IU (2S)-2-[[2-[[2-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]amino]acetyl]amino]-3-(4-hydroxy-3-(125I)iodanylphenyl)propanamide
DMSYT5P DE Discovery agent
DMTFP5Q ID DMTFP5Q
DMTFP5Q DN [125I]HEAT
DMTFP5Q HS Investigative
DMTFP5Q SN [125I]-HEAT
DMTFP5Q DT Small molecular drug
DMTFP5Q PC 73754995
DMTFP5Q MW 419.3
DMTFP5Q FM C19H20INO2
DMTFP5Q IC InChI=1S/C19H20INO2/c20-18-11-16(22)8-7-14(18)9-10-21-12-15-6-5-13-3-1-2-4-17(13)19(15)23/h1-4,7-8,11,15,21-22H,5-6,9-10,12H2/i20-2
DMTFP5Q CS C1CC2=CC=CC=C2C(=O)C1CNCCC3=C(C=C(C=C3)O)[125I]
DMTFP5Q IK MIQRUWUVLIWVAW-STTHPYEQSA-N
DMTFP5Q IU 2-[[2-(4-hydroxy-2-(125I)iodanylphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one
DMTFP5Q DE Discovery agent
DM3BQHO ID DM3BQHO
DM3BQHO DN [125I]ICYP
DM3BQHO HS Investigative
DM3BQHO SN [125I]iodocyanopindolol
DM3BQHO DT Small molecular drug
DM3BQHO PC 73754996
DM3BQHO MW 397.23
DM3BQHO FM C15H18IN3O2
DM3BQHO IC InChI=1S/C15H18IN3O2/c1-9(2)18-7-10(20)8-21-13-5-3-4-11-14(13)15(16)12(6-17)19-11/h3-5,9-10,18-20H,7-8H2,1-2H3/i16-2
DM3BQHO CS CC(C)NCC(COC1=CC=CC2=C1C(=C(N2)C#N)[125I])O
DM3BQHO IK WGSPBWSPJOBKNT-RFLHHMENSA-N
DM3BQHO IU 4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3-(125I)iodanyl-1H-indole-2-carbonitrile
DM3BQHO DE Discovery agent
DMHJL58 ID DMHJL58
DMHJL58 DN [125I]iodoaminopotentidine
DMHJL58 HS Investigative
DMHJL58 SN [125I]APT; [125I]-iodoaminopotentidine
DMHJL58 DT Small molecular drug
DMHJL58 PC 73755000
DMHJL58 MW 601.5
DMHJL58 FM C26H34IN7O2
DMHJL58 IC InChI=1S/C26H34IN7O2/c27-23-17-21(8-9-24(23)29)25(35)30-11-12-32-26(33-19-28)31-10-5-15-36-22-7-4-6-20(16-22)18-34-13-2-1-3-14-34/h4,6-9,16-17H,1-3,5,10-15,18,29H2,(H,30,35)(H2,31,32,33)/i27-2
DMHJL58 CS C1CCN(CC1)CC2=CC(=CC=C2)OCCCN=C(NCCNC(=O)C3=CC(=C(C=C3)N)[125I])NC#N
DMHJL58 IK VJTYCMQYDRXNNY-ALRLDUCRSA-N
DMHJL58 IU 4-amino-N-[2-[[N-cyano-N'-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]carbamimidoyl]amino]ethyl]-3-(125I)iodanylbenzamide
DMHJL58 DE Discovery agent
DMN4ABU ID DMN4ABU
DMN4ABU DN [125I]iodophenpropit
DMN4ABU HS Investigative
DMN4ABU SN (1S)-1-[3-(3H-Imidazol-4-yl)propylsulfanyl]-N-[2-(4-iodophenyl)ethyl]methanediamine; (1S)-1-[3-(3H-imidazol-4-yl)propylsulfanyl]-N-[2-(4-iodophenyl)ethyl]methanediamine; [125I]IODOPHENPROPIT; AC1NSK68; GTPL3960; GTPL1266; IODOPHENPROPIT
DMN4ABU DT Small molecular drug
DMN4ABU PC 5311186
DMN4ABU MW 416.3
DMN4ABU FM C15H21IN4S
DMN4ABU IC InChI=1S/C15H21IN4S/c16-13-5-3-12(4-6-13)7-8-19-15(17)21-9-1-2-14-10-18-11-20-14/h3-6,10-11,15,19H,1-2,7-9,17H2,(H,18,20)/t15-/m0/s1
DMN4ABU CS C1=CC(=CC=C1CCN[C@H](N)SCCCC2=CN=CN2)I
DMN4ABU IK UWFACTDPNOOPFV-HNNXBMFYSA-N
DMN4ABU IU (1S)-1-[3-(1H-imidazol-5-yl)propylsulfanyl]-N'-[2-(4-iodophenyl)ethyl]methanediamine
DMN4ABU DE Discovery agent
DMVEHI7 ID DMVEHI7
DMVEHI7 DN [125I]IRL1620
DMVEHI7 HS Investigative
DMVEHI7 SN [125I]IRL 1620; [125I]-IRL1620
DMVEHI7 DT Small molecular drug
DMVEHI7 PC 16130933
DMVEHI7 MW 1820.9
DMVEHI7 FM C86H117N17O27
DMVEHI7 IC InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
DMVEHI7 CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
DMVEHI7 IK DXPHNGAMYPPTBJ-TZMIJSMNSA-N
DMVEHI7 IU (4S)-4-[[(2S)-4-carboxy-2-[[(2S)-3-carboxy-2-(3-carboxypropanoylamino)propanoyl]amino]butanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMVEHI7 CA CAS 142569-99-1
DMVEHI7 DE Discovery agent
DMKSI80 ID DMKSI80
DMKSI80 DN [125I]L703,606
DMKSI80 HS Investigative
DMKSI80 SN [125I]L703606; [125I]-L703,606
DMKSI80 DT Small molecular drug
DMKSI80 PC 53326807
DMKSI80 MW 506.4
DMKSI80 FM C27H29IN2
DMKSI80 IC InChI=1S/C27H29IN2/c28-24-14-8-7-13-23(24)19-29-26-22-15-17-30(18-16-22)27(26)25(20-9-3-1-4-10-20)21-11-5-2-6-12-21/h1-14,22,25-27,29H,15-19H2/t26-,27-/m1/s1/i28-2
DMKSI80 CS C1CN2CCC1[C@H]([C@H]2C(C3=CC=CC=C3)C4=CC=CC=C4)NCC5=CC=CC=C5[125I]
DMKSI80 IK WSLTYZVXORBNLB-BRXFWFLGSA-N
DMKSI80 IU (2R,3R)-2-benzhydryl-N-[(2-(125I)iodanylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DMKSI80 DE Discovery agent
DMO7VRJ ID DMO7VRJ
DMO7VRJ DN [125I]L750667
DMO7VRJ HS Investigative
DMO7VRJ SN [125I]-L750667
DMO7VRJ DT Small molecular drug
DMO7VRJ PC 5311214
DMO7VRJ MW 416.3
DMO7VRJ FM C18H19IN4
DMO7VRJ IC InChI=1S/C18H19IN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)/i19-2
DMO7VRJ CS C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)[125I]
DMO7VRJ IK OOEUHRGMLFVKQO-GBVACIEGSA-N
DMO7VRJ IU 3-[[4-(4-(125I)iodanylphenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DMO7VRJ DE Discovery agent
DMP69QG ID DMP69QG
DMP69QG DN [125I]LSD
DMP69QG HS Investigative
DMP69QG SN [125I]N,N-diethyllysergamide; [125I]lysergamid; [125I]lysergic acid diethylamide; [125I]lysergide
DMP69QG DT Small molecular drug
DMP69QG PC 73754990
DMP69QG MW 447.3
DMP69QG FM C20H24IN3O
DMP69QG IC InChI=1S/C20H24IN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1/i21-2
DMP69QG CS CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)[125I])C
DMP69QG IK OBCUQRYIGTWROI-YUPRZBKSSA-N
DMP69QG IU (6aR,9R)-N,N-diethyl-5-(125I)iodanyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMP69QG DE Discovery agent
DMEHK9M ID DMEHK9M
DMEHK9M DN [125I]PD142308
DMEHK9M HS Investigative
DMEHK9M SN (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-amino-3-iodophenyl)butanoic acid; [125I]PD142308
DMEHK9M DT Small molecular drug
DMEHK9M PC 73755055
DMEHK9M MW 696.6
DMEHK9M FM C33H39IN4O5
DMEHK9M IC InChI=1S/C33H39IN4O5/c1-33(16-23-17-36-28-5-3-2-4-25(23)28,38-32(42)43-30-21-9-19-8-20(11-21)12-22(30)10-19)31(41)37-24(15-29(39)40)13-18-6-7-27(35)26(34)14-18/h2-7,14,17,19-22,24,30,36H,8-13,15-16,35H2,1H3,(H,37,41)(H,38,42)(H,39,40)/t19?,20?,21?,22?,24-,30?,33+/m0/s1/i34-2
DMEHK9M CS C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@@H](CC3=CC(=C(C=C3)N)[125I])CC(=O)O)NC(=O)OC4C5CC6CC(C5)CC4C6
DMEHK9M IK YMNQSYWYYQDKJU-PDZULBFKSA-N
DMEHK9M IU (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-amino-3-(125I)iodanylphenyl)butanoic acid
DMEHK9M DE Discovery agent
DM4HLO5 ID DM4HLO5
DM4HLO5 DN [125I]PD151242
DM4HLO5 HS Investigative
DM4HLO5 SN [125I](N-[{hexahydro-1-azepinyl}carbonyl])Leu(1-Me)-DTrp-DTyr; [125I]-PD151242
DM4HLO5 DT Small molecular drug
DM4HLO5 PC 132991
DM4HLO5 MW 619.7
DM4HLO5 FM C34H45N5O6
DM4HLO5 IC InChI=1S/C34H45N5O6/c1-22(2)18-27(37-34(45)39-16-8-4-5-9-17-39)31(41)35-28(20-24-21-38(3)30-11-7-6-10-26(24)30)32(42)36-29(33(43)44)19-23-12-14-25(40)15-13-23/h6-7,10-15,21-22,27-29,40H,4-5,8-9,16-20H2,1-3H3,(H,35,41)(H,36,42)(H,37,45)(H,43,44)/t27-,28+,29+/m0/s1
DM4HLO5 CS CC(C)C[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)N4CCCCCC4
DM4HLO5 IK JVILFANCFWZBFU-ZGIBFIJWSA-N
DM4HLO5 IU (2R)-2-[[(2R)-2-[[(2S)-2-(azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM4HLO5 CA CAS 155561-67-4
DM4HLO5 DE Discovery agent
DMROKJP ID DMROKJP
DMROKJP DN [125I]PTA-OH
DMROKJP HS Investigative
DMROKJP SN I-PTA-OH
DMROKJP DT Small molecular drug
DMROKJP PC 73755023
DMROKJP MW 539.5
DMROKJP FM C25H36INO4
DMROKJP IC InChI=1S/C25H36INO4/c1-25(2)17-13-20(25)19(7-5-3-4-6-8-24(30)31)22(14-17)27-15-18(28)11-16-9-10-23(29)21(26)12-16/h3,5,9-10,12,17-20,22,27-29H,4,6-8,11,13-15H2,1-2H3,(H,30,31)/b5-3+/i26-2
DMROKJP CS CC1(C2CC1C(C(C2)NCC(CC3=CC(=C(C=C3)O)[125I])O)C/C=C/CCCC(=O)O)C
DMROKJP IK RCPAWLXQBMAVGJ-WEGMHNBISA-N
DMROKJP IU (E)-7-[3-[[2-hydroxy-3-(4-hydroxy-3-(125I)iodanylphenyl)propyl]amino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMROKJP DE Discovery agent
DMUD3A8 ID DMUD3A8
DMUD3A8 DN [125I]resiniferatoxin
DMUD3A8 HS Investigative
DMUD3A8 SN [125I]resiniferatoxin
DMUD3A8 DT Small molecular drug
DMUD3A8 PC 73755027
DMUD3A8 MW 752.6
DMUD3A8 FM C37H39IO9
DMUD3A8 IC InChI=1S/C37H39IO9/c1-20(2)35-16-22(4)37-26(33(35)45-36(46-35,47-37)18-23-9-7-6-8-10-23)12-25(17-34(42)29(37)11-21(3)32(34)41)19-44-30(39)15-24-13-27(38)31(40)28(14-24)43-5/h6-14,22,26,29,33,40,42H,1,15-19H2,2-5H3/t22-,26+,29-,33-,34-,35-,36-,37-/m1/s1/i38-2
DMUD3A8 CS C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C(=C6)[125I])O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C
DMUD3A8 IK TZUJORCXGLGWDV-FOFZJNPASA-N
DMUD3A8 IU [(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-(125I)iodanyl-5-methoxyphenyl)acetate
DMUD3A8 DE Discovery agent
DMHC6KX ID DMHC6KX
DMHC6KX DN [125I]S70254
DMHC6KX HS Investigative
DMHC6KX SN [125I]S70254
DMHC6KX DT Small molecular drug
DMHC6KX PC 86277839
DMHC6KX MW 483.3
DMHC6KX FM C22H20IN3O2
DMHC6KX IC InChI=1S/C22H20IN3O2/c1-28-20-10-9-18-22(26-20)17(11-12-24-19(27)13-23)21(25-18)16-8-4-6-14-5-2-3-7-15(14)16/h2-10,25H,11-13H2,1H3,(H,24,27)/i23-2
DMHC6KX CS COC1=NC2=C(C=C1)NC(=C2CCNC(=O)C[125I])C3=CC=CC4=CC=CC=C43
DMHC6KX IK ZYVDSJZCXRMXGR-FOKFMTIASA-N
DMHC6KX IU 2-(125I)iodanyl-N-[2-(5-methoxy-2-naphthalen-1-yl-1H-pyrrolo[3,2-b]pyridin-3-yl)ethyl]acetamide
DMHC6KX DE Discovery agent
DM1DXHG ID DM1DXHG
DM1DXHG DN [125I]SAP
DM1DXHG HS Investigative
DM1DXHG SN Isap acid; [125I]-SAP
DM1DXHG DT Small molecular drug
DM1DXHG PC 73755024
DM1DXHG MW 529.4
DM1DXHG FM C22H30INO4S
DM1DXHG IC InChI=1S/C22H30INO4S/c1-22(2)15-13-19(22)18(7-5-3-4-6-8-21(25)26)20(14-15)24-29(27,28)17-11-9-16(23)10-12-17/h3,5,9-12,15,18-20,24H,4,6-8,13-14H2,1-2H3,(H,25,26)/b5-3-/t15-,18-,19+,20-/m0/s1/i23-2
DM1DXHG CS CC1([C@H]2C[C@@H]1[C@@H]([C@H](C2)NS(=O)(=O)C3=CC=C(C=C3)[125I])C/C=C\\CCCC(=O)O)C
DM1DXHG IK SZNMERGTFJHNSM-NTVCQXSRSA-N
DM1DXHG IU (Z)-7-[(1R,2S,3S,5S)-3-[(4-(125I)iodanylphenyl)sulfonylamino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DM1DXHG DE Discovery agent
DM0XUPK ID DM0XUPK
DM0XUPK DN [125I]SB-236636
DM0XUPK HS Investigative
DM0XUPK SN [125I]SB-236636; GTPL2710; (2S)-3-(4-{2-[(1,3-benzoxazol-2-yl)(methyl)amino]ethoxy}-3-(125I)iodophenyl)-2-ethoxypropanoic acid
DM0XUPK DT Small molecular drug
DM0XUPK PC 73755028
DM0XUPK MW 508.3
DM0XUPK FM C21H23IN2O5
DM0XUPK IC InChI=1S/C21H23IN2O5/c1-3-27-19(20(25)26)13-14-8-9-17(15(22)12-14)28-11-10-24(2)21-23-16-6-4-5-7-18(16)29-21/h4-9,12,19H,3,10-11,13H2,1-2H3,(H,25,26)/t19-/m0/s1/i22-2
DM0XUPK CS CCO[C@@H](CC1=CC(=C(C=C1)OCCN(C)C2=NC3=CC=CC=C3O2)[125I])C(=O)O
DM0XUPK IK VMBRNDMISRCGGM-DYZOOXQFSA-N
DM0XUPK IU (2S)-3-[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]-3-(125I)iodanylphenyl]-2-ethoxypropanoic acid
DM0XUPK DE Discovery agent
DMXWZCB ID DMXWZCB
DMXWZCB DN [125I]SB-258585
DMXWZCB HS Investigative
DMXWZCB SN GTPL3245; SCHEMBL14113984
DMXWZCB DT Small molecular drug
DMXWZCB PC 10743500
DMXWZCB MW 485.4
DMXWZCB FM C18H22IN3O3S
DMXWZCB IC InChI=1S/C18H22IN3O3S/c1-21-9-11-22(12-10-21)17-13-15(5-8-18(17)25-2)20-26(23,24)16-6-3-14(19)4-7-16/h3-8,13,20H,9-12H2,1-2H3/i19-2
DMXWZCB CS CN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)[125I])OC
DMXWZCB IK BDHMSYNBSBZCAF-GBVACIEGSA-N
DMXWZCB IU 4-(125I)iodanyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide
DMXWZCB DE Discovery agent
DM06S9X ID DM06S9X
DM06S9X DN [125I]SCH23982
DM06S9X HS Investigative
DM06S9X SN [125I]-SCH23982
DM06S9X DT Small molecular drug
DM06S9X PC 119353
DM06S9X MW 377.23
DM06S9X FM C17H18INO
DM06S9X IC InChI=1S/C17H18INO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3/t15-/m1/s1/i18-2
DM06S9X CS CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC=C3)O)[125I]
DM06S9X IK JGBTWNOVLISURM-QFLNOARHSA-N
DM06S9X IU (5R)-8-(125I)iodanyl-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
DM06S9X CA CAS 116780-39-3
DM06S9X DE Discovery agent
DM285MQ ID DM285MQ
DM285MQ DN [125I]SD6
DM285MQ HS Investigative
DM285MQ SN [125I]SD6
DM285MQ DT Small molecular drug
DM285MQ PC 86277836
DM285MQ MW 356.17
DM285MQ FM C13H15IN2O2
DM285MQ IC InChI=1S/C13H15IN2O2/c1-18-10-2-3-12-11(6-10)9(8-16-12)4-5-15-13(17)7-14/h2-3,6,8,16H,4-5,7H2,1H3,(H,15,17)/i14-2
DM285MQ CS COC1=CC2=C(C=C1)NC=C2CCNC(=O)C[125I]
DM285MQ IK BCFPPJOYYKSYLA-XSBOKVBDSA-N
DM285MQ IU 2-(125I)iodanyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
DM285MQ DE Discovery agent
DM0GKMA ID DM0GKMA
DM0GKMA DN [125I]SQ-29548
DM0GKMA HS Investigative
DM0GKMA SN [125I]SQ-29548; GTPL1983; (5Z)-7-[(1S,2R,3R,4R)-3-{[({[4-(125I)iodophenyl]carbamoyl}amino)amino]methyl}-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM0GKMA DT Small molecular drug
DM0GKMA PC 73755025
DM0GKMA MW 511.4
DM0GKMA FM C21H28IN3O4
DM0GKMA IC InChI=1S/C21H28IN3O4/c22-14-7-9-15(10-8-14)24-21(28)25-23-13-17-16(18-11-12-19(17)29-18)5-3-1-2-4-6-20(26)27/h1,3,7-10,16-19,23H,2,4-6,11-13H2,(H,26,27)(H2,24,25,28)/b3-1-/t16-,17+,18+,19-/m1/s1/i22-2
DM0GKMA CS C1C[C@@H]2[C@H]([C@H]([C@H]1O2)C/C=C\\CCCC(=O)O)CNNC(=O)NC3=CC=C(C=C3)[125I]
DM0GKMA IK AMZRVJWBVXWSAC-BYMOSMHDSA-N
DM0GKMA IU (Z)-7-[(1S,2R,3R,4R)-3-[[2-[(4-(125I)iodanylphenyl)carbamoyl]hydrazinyl]methyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM0GKMA DE Discovery agent
DME53D6 ID DME53D6
DME53D6 DN [125I]ZM-241385
DME53D6 HS Investigative
DME53D6 SN [125I]ZM-241385; GTPL430
DME53D6 DT Small molecular drug
DME53D6 PC 73754992
DME53D6 MW 461.23
DME53D6 FM C16H14IN7O2
DME53D6 IC InChI=1S/C16H14IN7O2/c17-10-8-9(3-4-11(10)25)5-6-19-15-21-14(18)24-16(22-15)20-13(23-24)12-2-1-7-26-12/h1-4,7-8,25H,5-6H2,(H3,18,19,20,21,22,23)/i17-2
DME53D6 CS C1=COC(=C1)C2=NN3C(=NC(=NC3=N2)NCCC4=CC(=C(C=C4)O)[125I])N
DME53D6 IK RVECQPQWOUQTSZ-QZIRHQCUSA-N
DME53D6 IU 4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-(125I)iodanylphenol
DME53D6 DE Discovery agent
DM42B5D ID DM42B5D
DM42B5D DN [14C]acetylCoA
DM42B5D HS Investigative
DM42B5D SN [14C]-acetylCoA
DM42B5D DT Small molecular drug
DM42B5D PC 73755097
DM42B5D MW 811.6
DM42B5D FM C23H38N7O17P3S
DM42B5D IC InChI=1S/C23H38N7O17P3S/c1-12(31)51-7-6-25-14(32)4-5-26-21(35)18(34)23(2,3)9-44-50(41,42)47-49(39,40)43-8-13-17(46-48(36,37)38)16(33)22(45-13)30-11-29-15-19(24)27-10-28-20(15)30/h10-11,13,16-18,22,33-34H,4-9H2,1-3H3,(H,25,32)(H,26,35)(H,39,40)(H,41,42)(H2,24,27,28)(H2,36,37,38)/t13-,16-,17-,18+,22-/m1/s1/i12+2
DM42B5D CS C[14C](=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DM42B5D IK ZSLZBFCDCINBPY-YHBLMJDYSA-N
DM42B5D IU S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (114C)ethanethioate
DM42B5D DE Discovery agent
DMGLQ72 ID DMGLQ72
DMGLQ72 DN [14C]GlySar
DMGLQ72 HS Investigative
DMGLQ72 SN [14C]-GlySar; glycylsarcosine
DMGLQ72 DT Small molecular drug
DMGLQ72 PC 73755101
DMGLQ72 MW 148.14
DMGLQ72 FM C5H10N2O3
DMGLQ72 IC InChI=1S/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)/i4+2
DMGLQ72 CS CN(CC(=O)O)[14C](=O)CN
DMGLQ72 IK VYAMLSCELQQRAE-DOMIDYPGSA-N
DMGLQ72 IU 2-[(2-aminoacetyl)-methylamino]acetic acid
DMGLQ72 DE Discovery agent
DMVUF71 ID DMVUF71
DMVUF71 DN [14C]histidine
DMVUF71 HS Investigative
DMVUF71 SN [14C]-histidine
DMVUF71 DT Small molecular drug
DMVUF71 PC 73755104
DMVUF71 MW 157.15
DMVUF71 FM C6H9N3O2
DMVUF71 IC InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/i5+2
DMVUF71 CS C1=C(NC=N1)C[14C@@H](C(=O)O)N
DMVUF71 IK HNDVDQJCIGZPNO-YDUYVQCESA-N
DMVUF71 IU (2S)-2-amino-3-(1H-imidazol-5-yl)(214C)propanoic acid
DMVUF71 DE Discovery agent
DMRBZ3X ID DMRBZ3X
DMRBZ3X DN [14C]methylamine
DMRBZ3X HS Investigative
DMRBZ3X SN [14C]-methylamine
DMRBZ3X DT Small molecular drug
DMRBZ3X PC 190331
DMRBZ3X MW 33.05
DMRBZ3X FM CH5N
DMRBZ3X IC InChI=1S/CH5N/c1-2/h2H2,1H3/i1+2
DMRBZ3X CS [14CH3]N
DMRBZ3X IK BAVYZALUXZFZLV-NJFSPNSNSA-N
DMRBZ3X IU (114C)methanamine
DMRBZ3X DE Discovery agent
DMG17IU ID DMG17IU
DMG17IU DN [14C]MTEP
DMG17IU HS Investigative
DMG17IU DT Small molecular drug
DMG17IU PC 9990429
DMG17IU MW 202.25
DMG17IU FM C11H8N2S
DMG17IU IC InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)5-4-10-3-2-6-12-7-10/h2-3,6-8H,1H3/i11+2
DMG17IU CS CC1=N[14C](=CS1)C#CC2=CN=CC=C2
DMG17IU IK NRBNGHCYDWUVLC-OZUIXNLOSA-N
DMG17IU IU 2-methyl-4-(2-pyridin-3-ylethynyl)-(414C)1,3-thiazole
DMG17IU DE Discovery agent
DM6SFYH ID DM6SFYH
DM6SFYH DN [14C]TEA
DM6SFYH HS Investigative
DM6SFYH SN Tetraethylammonium; Tetrylammonium; TETRAETHYLAMMONIUM ION; Tetramon; tetraethylazanium; N,N,N-Triethylethanaminium; tetraethylamine; UNII-5AV7G7EIEE; Tetraetilammonio [Italian]; 66-40-0; 5AV7G7EIEE; BRN 1738225; CHEMBL9324; AMMONIUM, TETRAETHYL-; CHEBI:44296; C8H20N; Tetraetilammonio; [14C]-TEA; tetraethyl ammonium; AC1L1KAW; Lopac-T-2265; 77-98-5 (hydroxide); 71-91-0 (bromide); 56-34-8 (chloride); 68-05-3 (iodide); SCHEMBL16267; 4-04-00-00331 (Beilstein Handbook Reference); NEt4(+); GTPL4575; GTPL2343; Ethanaminium,; [14C]-TEA ; tetraethylammonium
DM6SFYH DT Small molecular drug
DM6SFYH PC 5413
DM6SFYH MW 130.25
DM6SFYH FM C8H20N+
DM6SFYH IC InChI=1S/C8H20N/c1-5-9(6-2,7-3)8-4/h5-8H2,1-4H3/q+1
DM6SFYH CS CC[N+](CC)(CC)CC
DM6SFYH IK CBXCPBUEXACCNR-UHFFFAOYSA-N
DM6SFYH IU tetraethylazanium
DM6SFYH CA CAS 66-40-0
DM6SFYH CB CHEBI:44296
DM6SFYH DE Discovery agent
DMZJQC0 ID DMZJQC0
DMZJQC0 DN [18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate
DMZJQC0 HS Investigative
DMZJQC0 SN (R,R)-quinuclidinyl-4-[18F]-fluoromethyl-benzilate; (R,R)-quinuclidinyl-4-[18F]-fluoromethylbenzilate(PET ligand); [18F]-FMeQNB; (R,R)-[18F]-FMeQNB
DMZJQC0 DT Small molecular drug
DMZJQC0 PC 73755039
DMZJQC0 MW 368.4
DMZJQC0 FM C22H24FNO3
DMZJQC0 IC InChI=1S/C22H24FNO3/c23-14-16-6-8-19(9-7-16)22(26,18-4-2-1-3-5-18)21(25)27-20-15-24-12-10-17(20)11-13-24/h1-9,17,20,26H,10-15H2/t20-,22+/m0/s1/i23-1
DMZJQC0 CS C1CN2CCC1[C@H](C2)OC(=O)[C@@](C3=CC=CC=C3)(C4=CC=C(C=C4)C[18F])O
DMZJQC0 IK WYNSCFORRAXQPA-IFWCHYDGSA-N
DMZJQC0 IU [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2R)-2-[4-((18F)fluoranylmethyl)phenyl]-2-hydroxy-2-phenylacetate
DMZJQC0 DE Discovery agent
DM65BDN ID DM65BDN
DM65BDN DN [18F]altanserin
DM65BDN HS Investigative
DM65BDN SN [18F]altanserin (PET ligand)
DM65BDN DT Small molecular drug
DM65BDN PC 5312287
DM65BDN MW 410.5
DM65BDN FM C22H22FN3O2S
DM65BDN IC InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)/i23-1
DM65BDN CS C1CN(CCC1C(=O)C2=CC=C(C=C2)[18F])CCN3C(=O)C4=CC=CC=C4NC3=S
DM65BDN IK SMYALUSCZJXWHG-VNRZBHCFSA-N
DM65BDN IU 3-[2-[4-(4-(18F)fluoranylbenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
DM65BDN CA CAS 139418-52-3
DM65BDN DE Discovery agent
DM4VQNE ID DM4VQNE
DM4VQNE DN [18F]FITM
DM4VQNE HS Investigative
DM4VQNE SN [18F]FITM; GTPL6213; CHEMBL1771389; 4-(18F)fluoro-N-methyl-N-(4-{6-[(propan-2-yl)amino]pyrimidin-4-yl}-1,3-thiazol-2-yl)benzamide
DM4VQNE DT Small molecular drug
DM4VQNE PC 53233900
DM4VQNE MW 370.4
DM4VQNE FM C18H18FN5OS
DM4VQNE IC InChI=1S/C18H18FN5OS/c1-11(2)22-16-8-14(20-10-21-16)15-9-26-18(23-15)24(3)17(25)12-4-6-13(19)7-5-12/h4-11H,1-3H3,(H,20,21,22)/i19-1
DM4VQNE CS CC(C)NC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)[18F]
DM4VQNE IK WIVGIKIKQHUFOD-AWDFDDCISA-N
DM4VQNE IU 4-(18F)fluoranyl-N-methyl-N-[4-[6-(propan-2-ylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]benzamide
DM4VQNE DE Discovery agent
DMPWART ID DMPWART
DMPWART DN [18F]fluoroethylflumazenil
DMPWART HS Investigative
DMPWART SN [18F]fluoroethylflumazenil (PET ligand)
DMPWART DT Small molecular drug
DMPWART PC 126761
DMPWART MW 334.31
DMPWART FM C16H15F2N3O3
DMPWART IC InChI=1S/C16H15F2N3O3/c1-2-24-16(23)14-13-8-20(6-5-17)15(22)11-7-10(18)3-4-12(11)21(13)9-19-14/h3-4,7,9H,2,5-6,8H2,1H3/i17-1
DMPWART CS CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)CC[18F]
DMPWART IK NRBIGDVWCXXFLI-SJPDSGJFSA-N
DMPWART IU ethyl 5-(2-(18F)fluoranylethyl)-8-fluoro-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMPWART CA CAS 143693-57-6
DMPWART DE Discovery agent
DMRQ6XD ID DMRQ6XD
DMRQ6XD DN [18F]FPIT
DMRQ6XD HS Investigative
DMRQ6XD SN [18F]FPIT; GTPL6392; 5-{1-[2-(18F)fluoropyridin-3-yl]-5-methyl-1H-1,2,3-triazol-4-yl}-2-(propan-2-yl)-2,3-dihydro-1H-isoindol-1-one
DMRQ6XD DT Small molecular drug
DMRQ6XD PC 70702462
DMRQ6XD MW 350.4
DMRQ6XD FM C19H18FN5O
DMRQ6XD IC InChI=1S/C19H18FN5O/c1-11(2)24-10-14-9-13(6-7-15(14)19(24)26)17-12(3)25(23-22-17)16-5-4-8-21-18(16)20/h4-9,11H,10H2,1-3H3/i20-1
DMRQ6XD CS CC1=C(N=NN1C2=C(N=CC=C2)[18F])C3=CC4=C(C=C3)C(=O)N(C4)C(C)C
DMRQ6XD IK ZUWMBBZBDLJVHD-LRFGSCOBSA-N
DMRQ6XD IU 5-[1-(2-(18F)fluoranylpyridin-3-yl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one
DMRQ6XD DE Discovery agent
DMM2YU9 ID DMM2YU9
DMM2YU9 DN [18F]FP-TZTP
DMM2YU9 HS Investigative
DMM2YU9 SN [18F]FP-TZTP (PET ligand)
DMM2YU9 DT Small molecular drug
DMM2YU9 PC 449812
DMM2YU9 MW 272.4
DMM2YU9 FM C11H16FN3S2
DMM2YU9 IC InChI=1S/C11H16FN3S2/c1-15-6-2-4-9(8-15)10-11(14-17-13-10)16-7-3-5-12/h4H,2-3,5-8H2,1H3/i12-1
DMM2YU9 CS CN1CCC=C(C1)C2=NSN=C2SCCC[18F]
DMM2YU9 IK NQKPPQNBFQLLIZ-DWSYCVKZSA-N
DMM2YU9 IU 3-(3-(18F)fluoranylpropylsulfanyl)-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
DMM2YU9 CA CAS 161395-77-3
DMM2YU9 DE Discovery agent
DMQ6AR5 ID DMQ6AR5
DMQ6AR5 DN [18F]MK-1312
DMQ6AR5 HS Investigative
DMQ6AR5 SN CHEMBL1645349; GTPL6334; MK-1312
DMQ6AR5 DT Small molecular drug
DMQ6AR5 PC 53316847
DMQ6AR5 MW 350.4
DMQ6AR5 FM C19H18FN5O
DMQ6AR5 IC InChI=1S/C19H18FN5O/c1-3-9-24-11-14-10-13(6-7-15(14)19(24)26)17-12(2)25(23-22-17)16-5-4-8-21-18(16)20/h4-8,10H,3,9,11H2,1-2H3/i20-1
DMQ6AR5 CS CCCN1CC2=C(C1=O)C=CC(=C2)C3=C(N(N=N3)C4=C(N=CC=C4)[18F])C
DMQ6AR5 IK NYDVTBHNZHBCKX-LRFGSCOBSA-N
DMQ6AR5 IU 5-[1-(2-(18F)fluoranylpyridin-3-yl)-5-methyltriazol-4-yl]-2-propyl-3H-isoindol-1-one
DMQ6AR5 DE Discovery agent
DMXIO84 ID DMXIO84
DMXIO84 DN [18F]SPA-RQ
DMXIO84 HS Investigative
DMXIO84 SN [18F]-SPA-RQ
DMXIO84 DT Small molecular drug
DMXIO84 PC 6914513
DMXIO84 MW 449.4
DMXIO84 FM C21H22F4N6O
DMXIO84 IC InChI=1S/C21H22F4N6O/c22-13-32-18-9-8-16(31-20(21(23,24)25)28-29-30-31)11-15(18)12-27-17-7-4-10-26-19(17)14-5-2-1-3-6-14/h1-3,5-6,8-9,11,17,19,26-27H,4,7,10,12-13H2/t17-,19-/m0/s1/i22-1
DMXIO84 CS C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)NCC3=C(C=CC(=C3)N4C(=NN=N4)C(F)(F)F)OC[18F]
DMXIO84 IK KSKJMSAKVZSMMV-LBXDGNDASA-N
DMXIO84 IU (2S,3S)-N-[[2-((18F)fluoranylmethoxy)-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine
DMXIO84 CA CAS 262598-99-2
DMXIO84 DE Discovery agent
DMH3BG5 ID DMH3BG5
DMH3BG5 DN [1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine
DMH3BG5 HS Investigative
DMH3BG5 SN CHEMBL56173; [1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine; BDBM50030521; 1-Benzyl N-hexylquinolin-4(1H)-imine
DMH3BG5 DT Small molecular drug
DMH3BG5 PC 44298928
DMH3BG5 MW 318.5
DMH3BG5 FM C22H26N2
DMH3BG5 IC InChI=1S/C22H26N2/c1-2-3-4-10-16-23-21-15-17-24(18-19-11-6-5-7-12-19)22-14-9-8-13-20(21)22/h5-9,11-15,17H,2-4,10,16,18H2,1H3
DMH3BG5 CS CCCCCCN=C1C=CN(C2=CC=CC=C12)CC3=CC=CC=C3
DMH3BG5 IK GRLRXFAGAKMYSQ-UHFFFAOYSA-N
DMH3BG5 IU 1-benzyl-N-hexylquinolin-4-imine
DMH3BG5 DE Discovery agent
DMS1YN3 ID DMS1YN3
DMS1YN3 DN [1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate
DMS1YN3 HS Investigative
DMS1YN3 SN [1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate; GTPL6991; CHEMBL3621354
DMS1YN3 DT Small molecular drug
DMS1YN3 PC 23682233
DMS1YN3 MW 509.4
DMS1YN3 FM C20H39BrNaO6P
DMS1YN3 IC InChI=1S/C20H40BrO6P.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26;/h18-19,22H,2-17H2,1H3,(H2,24,25,26);/q;+1/p-1/t18-,19?;/m0./s1
DMS1YN3 CS CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)[O-])Br)O.[Na+]
DMS1YN3 IK XCUPLWPVEJCIBO-HMEPSURWSA-M
DMS1YN3 IU sodium;[(3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]-hydroxyphosphinate
DMS1YN3 DE Discovery agent
DMSPMHE ID DMSPMHE
DMSPMHE DN [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine
DMSPMHE HS Investigative
DMSPMHE SN CHEMBL89420; [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine; SCHEMBL8120489; BDBM50081111
DMSPMHE DT Small molecular drug
DMSPMHE PC 9881815
DMSPMHE MW 267.33
DMSPMHE FM C16H17N3O
DMSPMHE IC InChI=1S/C16H17N3O/c1-2-5-13(6-3-1)11-17-9-10-20-15-8-4-7-14-16(15)19-12-18-14/h1-8,12,17H,9-11H2,(H,18,19)
DMSPMHE CS C1=CC=C(C=C1)CNCCOC2=CC=CC3=C2N=CN3
DMSPMHE IK XQWCSGWUJUEAQM-UHFFFAOYSA-N
DMSPMHE IU 2-(1H-benzimidazol-4-yloxy)-N-benzylethanamine
DMSPMHE DE Discovery agent
DMAJCVL ID DMAJCVL
DMAJCVL DN [2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine
DMAJCVL HS Investigative
DMAJCVL SN CHEMBL194174; [2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine
DMAJCVL DT Small molecular drug
DMAJCVL PC 44401277
DMAJCVL MW 263.4
DMAJCVL FM C19H21N
DMAJCVL IC InChI=1S/C19H21N/c1-20-12-11-16-14-17(13-15-7-3-2-4-8-15)19-10-6-5-9-18(16)19/h2-10,14,17,20H,11-13H2,1H3
DMAJCVL CS CNCCC1=CC(C2=CC=CC=C21)CC3=CC=CC=C3
DMAJCVL IK UHYPQIJLHJTNMK-UHFFFAOYSA-N
DMAJCVL IU 2-(3-benzyl-3H-inden-1-yl)-N-methylethanamine
DMAJCVL DE Discovery agent
DMU5P8O ID DMU5P8O
DMU5P8O DN [2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine
DMU5P8O HS Investigative
DMU5P8O DT Small molecular drug
DMU5P8O PC 44393544
DMU5P8O MW 279.4
DMU5P8O FM C19H23N2+
DMU5P8O IC InChI=1S/C19H23N2/c1-20(2)12-13-21-15-17(14-16-8-4-3-5-9-16)18-10-6-7-11-19(18)21/h3-11,15,17H,12-14H2,1-2H3/q+1
DMU5P8O CS CN(C)CC[N+]1=CC(C2=CC=CC=C21)CC3=CC=CC=C3
DMU5P8O IK CEOWUNUFGJBATQ-UHFFFAOYSA-N
DMU5P8O IU 2-(3-benzyl-3H-indol-1-ium-1-yl)-N,N-dimethylethanamine
DMU5P8O DE Discovery agent
DMBTRN6 ID DMBTRN6
DMBTRN6 DN [2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine
DMBTRN6 HS Investigative
DMBTRN6 SN CHEMBL186621; [2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine; SCHEMBL3328890
DMBTRN6 DT Small molecular drug
DMBTRN6 PC 20722800
DMBTRN6 MW 278.4
DMBTRN6 FM C19H22N2
DMBTRN6 IC InChI=1S/C19H22N2/c1-20(2)12-13-21-15-17(14-16-8-4-3-5-9-16)18-10-6-7-11-19(18)21/h3-11,15H,12-14H2,1-2H3
DMBTRN6 CS CN(C)CCN1C=C(C2=CC=CC=C21)CC3=CC=CC=C3
DMBTRN6 IK OYHBRXFQPGMFDE-UHFFFAOYSA-N
DMBTRN6 IU 2-(3-benzylindol-1-yl)-N,N-dimethylethanamine
DMBTRN6 DE Discovery agent
DM1RW4U ID DM1RW4U
DM1RW4U DN [2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine
DM1RW4U HS Investigative
DM1RW4U SN CHEMBL363035; [2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine
DM1RW4U DT Small molecular drug
DM1RW4U PC 44393574
DM1RW4U MW 189.28
DM1RW4U FM C12H17N2+
DM1RW4U IC InChI=1S/C12H17N2/c1-13(2)9-10-14-8-7-11-5-3-4-6-12(11)14/h3-6,8H,7,9-10H2,1-2H3/q+1
DM1RW4U CS CN(C)CC[N+]1=CCC2=CC=CC=C21
DM1RW4U IK YJCMFAZIOVDTLE-UHFFFAOYSA-N
DM1RW4U IU 2-(3H-indol-1-ium-1-yl)-N,N-dimethylethanamine
DM1RW4U DE Discovery agent
DMDIH96 ID DMDIH96
DMDIH96 DN [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMDIH96 HS Investigative
DMDIH96 SN CHEMBL197646; SCHEMBL6108769; [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine; ISJZKVWGUWBUFG-UHFFFAOYSA-N; BDBM50171264; 1644-64-0; 4-fluoro-3-(dimethylaminoethyl)-1H-indole
DMDIH96 DT Small molecular drug
DMDIH96 PC 11492162
DMDIH96 MW 206.26
DMDIH96 FM C12H15FN2
DMDIH96 IC InChI=1S/C12H15FN2/c1-15(2)7-6-9-8-14-11-5-3-4-10(13)12(9)11/h3-5,8,14H,6-7H2,1-2H3
DMDIH96 CS CN(C)CCC1=CNC2=C1C(=CC=C2)F
DMDIH96 IK ISJZKVWGUWBUFG-UHFFFAOYSA-N
DMDIH96 IU 2-(4-fluoro-1H-indol-3-yl)-N,N-dimethylethanamine
DMDIH96 DE Discovery agent
DMOZ73L ID DMOZ73L
DMOZ73L DN [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine
DMOZ73L HS Investigative
DMOZ73L SN CHEMBL50492; 171783-25-8; 5-Ethyl-DMT; [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine; DTXSID30444736; BDBM50049099
DMOZ73L DT Small molecular drug
DMOZ73L PC 10775128
DMOZ73L MW 216.32
DMOZ73L FM C14H20N2
DMOZ73L IC InChI=1S/C14H20N2/c1-4-11-5-6-14-13(9-11)12(10-15-14)7-8-16(2)3/h5-6,9-10,15H,4,7-8H2,1-3H3
DMOZ73L CS CCC1=CC2=C(C=C1)NC=C2CCN(C)C
DMOZ73L IK ZEHXYLDGQMEYAX-UHFFFAOYSA-N
DMOZ73L IU 2-(5-ethyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMOZ73L CA CAS 171783-25-8
DMOZ73L DE Discovery agent
DM5LVIR ID DM5LVIR
DM5LVIR DN [2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid
DM5LVIR HS Investigative
DM5LVIR SN CHEMBL452354; [2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid; SCHEMBL3983260
DM5LVIR DT Small molecular drug
DM5LVIR PC 25140321
DM5LVIR MW 342.57
DM5LVIR FM C7H9ClN4O6P2
DM5LVIR IC InChI=1S/C7H9ClN4O6P2/c8-6-5-7(10-2-9-6)12(3-11-5)1-4(19(13,14)15)20(16,17)18/h2-4H,1H2,(H2,13,14,15)(H2,16,17,18)
DM5LVIR CS C1=NC2=C(C(=N1)Cl)N=CN2CC(P(=O)(O)O)P(=O)(O)O
DM5LVIR IK SCQIYVIHMOWGRK-UHFFFAOYSA-N
DM5LVIR IU [2-(6-chloropurin-9-yl)-1-phosphonoethyl]phosphonic acid
DM5LVIR DE Discovery agent
DMHPBQC ID DMHPBQC
DMHPBQC DN [2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine
DMHPBQC HS Investigative
DMHPBQC SN CHEMBL38742; [2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine; BDBM50108320; ZINC13586848
DMHPBQC DT Small molecular drug
DMHPBQC PC 44287445
DMHPBQC MW 218.29
DMHPBQC FM C13H18N2O
DMHPBQC IC InChI=1S/C13H18N2O/c1-14(2)8-9-15-7-6-11-4-5-12(16-3)10-13(11)15/h4-7,10H,8-9H2,1-3H3
DMHPBQC CS CN(C)CCN1C=CC2=C1C=C(C=C2)OC
DMHPBQC IK VIEWFQAHIRFETA-UHFFFAOYSA-N
DMHPBQC IU 2-(6-methoxyindol-1-yl)-N,N-dimethylethanamine
DMHPBQC DE Discovery agent
DM98MXT ID DM98MXT
DM98MXT DN [2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid
DM98MXT HS Investigative
DM98MXT SN CHEMBL457423; AC1NQQY7; [2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid; [2-(benzoimidazol-1-yl)ethylidene]bisphosphonic acid; SCHEMBL20385726; BDBM50273716; 847738-31-2; [2-(benzimidazol-1-yl)-1-phosphonoethyl]phosphonic acid; Phosphonic acid, [2-(1H-benzimidazol-1-yl)ethylidene]bis-; [2-(benzimidazol-1-yl)-1-phosphono-ethyl]phosphonic acid
DM98MXT DT Small molecular drug
DM98MXT PC 5277505
DM98MXT MW 306.15
DM98MXT FM C9H12N2O6P2
DM98MXT IC InChI=1S/C9H12N2O6P2/c12-18(13,14)9(19(15,16)17)5-11-6-10-7-3-1-2-4-8(7)11/h1-4,6,9H,5H2,(H2,12,13,14)(H2,15,16,17)
DM98MXT CS C1=CC=C2C(=C1)N=CN2CC(P(=O)(O)O)P(=O)(O)O
DM98MXT IK ISSICOMKRRPVPD-UHFFFAOYSA-N
DM98MXT IU [2-(benzimidazol-1-yl)-1-phosphonoethyl]phosphonic acid
DM98MXT DE Discovery agent
DM37C25 ID DM37C25
DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25 HS Investigative
DM37C25 SN CHEMBL573935; [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid
DM37C25 DT Small molecular drug
DM37C25 PC 44479701
DM37C25 MW 352.4
DM37C25 FM C20H16O4S
DM37C25 IC InChI=1S/C20H16O4S/c21-20(22)14-17-8-4-5-9-19(17)25(23,24)18-12-10-16(11-13-18)15-6-2-1-3-7-15/h1-13H,14H2,(H,21,22)
DM37C25 CS C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3CC(=O)O
DM37C25 IK HGICQEUHJFERNR-UHFFFAOYSA-N
DM37C25 IU 2-[2-(4-phenylphenyl)sulfonylphenyl]acetic acid
DM37C25 DE Discovery agent
DMQZUD9 ID DMQZUD9
DMQZUD9 DN [2-(Imidazol-1-yl)ethyl]-bisphosphonic acid
DMQZUD9 HS Investigative
DMQZUD9 SN CHEMBL446734; 1-deshydroxyzoledronate; [2-(Imidazol-1-yl)ethyl]-bisphosphonic acid; SCHEMBL515542; FBSQLNMIJFINOJ-UHFFFAOYSA-N; BDBM50273714; 2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 2-(1H-Imidazole-1-yl)ethylidenebisphosphonic acid
DMQZUD9 DT Small molecular drug
DMQZUD9 PC 23043560
DMQZUD9 MW 256.089
DMQZUD9 FM C5H10N2O6P2
DMQZUD9 IC InChI=1S/C5H10N2O6P2/c8-14(9,10)5(15(11,12)13)3-7-2-1-6-4-7/h1-2,4-5H,3H2,(H2,8,9,10)(H2,11,12,13)
DMQZUD9 CS C1=CN(C=N1)CC(P(=O)(O)O)P(=O)(O)O
DMQZUD9 IK FBSQLNMIJFINOJ-UHFFFAOYSA-N
DMQZUD9 IU (2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
DMQZUD9 DE Discovery agent
DMBVDY5 ID DMBVDY5
DMBVDY5 DN [2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid
DMBVDY5 HS Investigative
DMBVDY5 SN CHEMBL504429; [2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid
DMBVDY5 DT Small molecular drug
DMBVDY5 PC 25140170
DMBVDY5 MW 288.16
DMBVDY5 FM C5H10N2O6P2S
DMBVDY5 IC InChI=1S/C5H10N2O6P2S/c8-14(9,10)4(15(11,12)13)3-16-5-6-1-2-7-5/h1-2,4H,3H2,(H,6,7)(H2,8,9,10)(H2,11,12,13)
DMBVDY5 CS C1=CN=C(N1)SCC(P(=O)(O)O)P(=O)(O)O
DMBVDY5 IK KVMQBCIVXMEYRO-UHFFFAOYSA-N
DMBVDY5 IU [2-(1H-imidazol-2-ylsulfanyl)-1-phosphonoethyl]phosphonic acid
DMBVDY5 DE Discovery agent
DM3VT8M ID DM3VT8M
DM3VT8M DN [2-(Purin-9-yl)ethyl]-bisphosphonic acid
DM3VT8M HS Investigative
DM3VT8M SN CHEMBL457424; [2-(Purin-9-yl)ethyl]-bisphosphonic acid; SCHEMBL3976006
DM3VT8M DT Small molecular drug
DM3VT8M PC 25140171
DM3VT8M MW 308.13
DM3VT8M FM C7H10N4O6P2
DM3VT8M IC InChI=1S/C7H10N4O6P2/c12-18(13,14)6(19(15,16)17)2-11-4-10-5-1-8-3-9-7(5)11/h1,3-4,6H,2H2,(H2,12,13,14)(H2,15,16,17)
DM3VT8M CS C1=C2C(=NC=N1)N(C=N2)CC(P(=O)(O)O)P(=O)(O)O
DM3VT8M IK JGHPTTVGCUEGGI-UHFFFAOYSA-N
DM3VT8M IU (1-phosphono-2-purin-9-ylethyl)phosphonic acid
DM3VT8M DE Discovery agent
DMJN8XK ID DMJN8XK
DMJN8XK DN [2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid
DMJN8XK HS Investigative
DMJN8XK SN CHEMBL457069; 2-(pyrazol-1-yl)ethane-1,1-diphosphonic acid; [2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid; SCHEMBL10410288; UUGUSMHQBIUYKQ-UHFFFAOYSA-N; BDBM50273715
DMJN8XK DT Small molecular drug
DMJN8XK PC 23043575
DMJN8XK MW 256.089
DMJN8XK FM C5H10N2O6P2
DMJN8XK IC InChI=1S/C5H10N2O6P2/c8-14(9,10)5(15(11,12)13)4-7-3-1-2-6-7/h1-3,5H,4H2,(H2,8,9,10)(H2,11,12,13)
DMJN8XK CS C1=CN(N=C1)CC(P(=O)(O)O)P(=O)(O)O
DMJN8XK IK UUGUSMHQBIUYKQ-UHFFFAOYSA-N
DMJN8XK IU (1-phosphono-2-pyrazol-1-ylethyl)phosphonic acid
DMJN8XK DE Discovery agent
DMI9RLZ ID DMI9RLZ
DMI9RLZ DN [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
DMI9RLZ HS Investigative
DMI9RLZ SN [2(R,S)-2-Sulfanylheptanoyl]-phe-ala; [2(R,S)-2-SULFANYLHEPTANOYL]-PHE-ALA; TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic
DMI9RLZ DT Small molecular drug
DMI9RLZ PC 5289469
DMI9RLZ MW 380.5
DMI9RLZ FM C19H28N2O4S
DMI9RLZ IC InChI=1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1
DMI9RLZ CS CCCCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)S
DMI9RLZ IK GOIYKVXXGCPHQU-BPUTZDHNSA-N
DMI9RLZ IU (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid
DMI9RLZ DE Discovery agent
DMRQC1F ID DMRQC1F
DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol
DMRQC1F HS Investigative
DMRQC1F SN CHEMBL76100; BDBM50217032
DMRQC1F DT Small molecular drug
DMRQC1F PC 44313272
DMRQC1F MW 278.4
DMRQC1F FM C13H10OS3
DMRQC1F IC InChI=1S/C13H10OS3/c14-7-9-6-13(16-8-9)12-4-3-11(17-12)10-2-1-5-15-10/h1-6,8,14H,7H2
DMRQC1F CS C1=CSC(=C1)C2=CC=C(S2)C3=CC(=CS3)CO
DMRQC1F IK CTGDOERMEKYCRZ-UHFFFAOYSA-N
DMRQC1F IU [5-(5-thiophen-2-ylthiophen-2-yl)thiophen-3-yl]methanol
DMRQC1F DE Discovery agent
DMWDNLI ID DMWDNLI
DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde
DMWDNLI HS Investigative
DMWDNLI SN CHEMBL74983; BDBM50217036
DMWDNLI DT Small molecular drug
DMWDNLI PC 9972316
DMWDNLI MW 304.4
DMWDNLI FM C14H8O2S3
DMWDNLI IC InChI=1S/C14H8O2S3/c15-6-9-5-14(17-8-9)13-4-3-12(19-13)11-2-1-10(7-16)18-11/h1-8H
DMWDNLI CS C1=C(SC(=C1)C2=CC=C(S2)C3=CC(=CS3)C=O)C=O
DMWDNLI IK PYABIFKTOKMEQD-UHFFFAOYSA-N
DMWDNLI IU 5-[5-(4-formylthiophen-2-yl)thiophen-2-yl]thiophene-2-carbaldehyde
DMWDNLI DE Discovery agent
DM2S5EJ ID DM2S5EJ
DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde
DM2S5EJ HS Investigative
DM2S5EJ SN CHEMBL73495; BDBM50217040
DM2S5EJ DT Small molecular drug
DM2S5EJ PC 44313051
DM2S5EJ MW 276.4
DM2S5EJ FM C13H8OS3
DM2S5EJ IC InChI=1S/C13H8OS3/c14-7-9-6-13(16-8-9)12-4-3-11(17-12)10-2-1-5-15-10/h1-8H
DM2S5EJ CS C1=CSC(=C1)C2=CC=C(S2)C3=CC(=CS3)C=O
DM2S5EJ IK IAQDUXQCKAZHSN-UHFFFAOYSA-N
DM2S5EJ IU 5-(5-thiophen-2-ylthiophen-2-yl)thiophene-3-carbaldehyde
DM2S5EJ DE Discovery agent
DM4WXD2 ID DM4WXD2
DM4WXD2 DN [2-Phenylacetophenone]thiosemicarbazone
DM4WXD2 HS Investigative
DM4WXD2 SN CHEMBL1269810; [2-Phenylacetophenone]thiosemicarbazone
DM4WXD2 DT Small molecular drug
DM4WXD2 PC 52945875
DM4WXD2 MW 269.4
DM4WXD2 FM C15H15N3S
DM4WXD2 IC InChI=1S/C15H15N3S/c16-15(19)18-17-14(13-9-5-2-6-10-13)11-12-7-3-1-4-8-12/h1-10H,11H2,(H3,16,18,19)/b17-14+
DM4WXD2 CS C1=CC=C(C=C1)C/C(=N\\NC(=S)N)/C2=CC=CC=C2
DM4WXD2 IK WHRFFXUXTGIZOH-SAPNQHFASA-N
DM4WXD2 IU [(E)-1,2-diphenylethylideneamino]thiourea
DM4WXD2 DE Discovery agent
DM4BYEQ ID DM4BYEQ
DM4BYEQ DN [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine
DM4BYEQ HS Investigative
DM4BYEQ SN CHEMBL296602; AC1L1GIZ; SCHEMBL11128740; BDBM50021226; 3-(3,4-Dichlorophenyl)-2,3-dihydro-N-methyl-1H-inden-1-amine
DM4BYEQ DT Small molecular drug
DM4BYEQ PC 3703
DM4BYEQ MW 292.2
DM4BYEQ FM C16H15Cl2N
DM4BYEQ IC InChI=1S/C16H15Cl2N/c1-19-16-9-13(11-4-2-3-5-12(11)16)10-6-7-14(17)15(18)8-10/h2-8,13,16,19H,9H2,1H3
DM4BYEQ CS CNC1CC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DM4BYEQ IK SVFXPTLYMIXFRX-UHFFFAOYSA-N
DM4BYEQ IU 3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
DM4BYEQ CA CAS 86939-10-8
DM4BYEQ DE Discovery agent
DMGD487 ID DMGD487
DMGD487 DN [3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid
DMGD487 HS Investigative
DMGD487 SN CHEMBL118860; 569684-50-0; [3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid; SCHEMBL3846202; CTK1E1410; DTXSID10471181; IYOGKTIRIRHPOH-UHFFFAOYSA-N; BDBM50148394; N-(4-Nonylbenzyl)-3-aminopropylphosphonic acid; Phosphonic acid, [3-[[(4-nonylphenyl)methyl]amino]propyl]-
DMGD487 DT Small molecular drug
DMGD487 PC 11725751
DMGD487 MW 355.5
DMGD487 FM C19H34NO3P
DMGD487 IC InChI=1S/C19H34NO3P/c1-2-3-4-5-6-7-8-10-18-11-13-19(14-12-18)17-20-15-9-16-24(21,22)23/h11-14,20H,2-10,15-17H2,1H3,(H2,21,22,23)
DMGD487 CS CCCCCCCCCC1=CC=C(C=C1)CNCCCP(=O)(O)O
DMGD487 IK IYOGKTIRIRHPOH-UHFFFAOYSA-N
DMGD487 IU 3-[(4-nonylphenyl)methylamino]propylphosphonic acid
DMGD487 CA CAS 569684-50-0
DMGD487 DE Discovery agent
DMD0LCU ID DMD0LCU
DMD0LCU DN [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol
DMD0LCU HS Investigative
DMD0LCU SN 3-(5-phenyl-oxazol-2-ylamino)phenylmethanol; 681002-56-2; [3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]methanol; {3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}methanol; 2-Anilino-5-aryloxazole 12; AC1NS7RB; CHEMBL194113; BDBM5851; SCHEMBL5185668; ZINC13611262; KB-305372; N-(3-Hydroxymethylphenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMD0LCU DT Small molecular drug
DMD0LCU PC 5329847
DMD0LCU MW 266.29
DMD0LCU FM C16H14N2O2
DMD0LCU IC InChI=1S/C16H14N2O2/c19-11-12-5-4-8-14(9-12)18-16-17-10-15(20-16)13-6-2-1-3-7-13/h1-10,19H,11H2,(H,17,18)
DMD0LCU CS C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC(=C3)CO
DMD0LCU IK WTSNQZLKTLSHSD-UHFFFAOYSA-N
DMD0LCU IU [3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl]methanol
DMD0LCU DE Discovery agent
DMRBJ4V ID DMRBJ4V
DMRBJ4V DN [3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine
DMRBJ4V HS Investigative
DMRBJ4V SN CHEMBL132091; [3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine; N,N-dimethyl-3-(4-phenylphenoxy)propan-1-amine; AC1L9UWB; SCHEMBL10679594; ZINC4842179; BDBM50133286
DMRBJ4V DT Small molecular drug
DMRBJ4V PC 501375
DMRBJ4V MW 255.35
DMRBJ4V FM C17H21NO
DMRBJ4V IC InChI=1S/C17H21NO/c1-18(2)13-6-14-19-17-11-9-16(10-12-17)15-7-4-3-5-8-15/h3-5,7-12H,6,13-14H2,1-2H3
DMRBJ4V CS CN(C)CCCOC1=CC=C(C=C1)C2=CC=CC=C2
DMRBJ4V IK ITTYRYJIHNHJBL-UHFFFAOYSA-N
DMRBJ4V IU N,N-dimethyl-3-(4-phenylphenoxy)propan-1-amine
DMRBJ4V DE Discovery agent
DMHU4NS ID DMHU4NS
DMHU4NS DN [3,4''']biflavone
DMHU4NS HS Investigative
DMHU4NS SN CHEMBL204948; [3,4'''''']biflavone; BDBM50183244
DMHU4NS DT Small molecular drug
DMHU4NS PC 44410505
DMHU4NS MW 442.5
DMHU4NS FM C30H18O4
DMHU4NS IC InChI=1S/C30H18O4/c31-24-18-27(33-25-12-6-4-10-22(24)25)19-14-16-20(17-15-19)28-29(32)23-11-5-7-13-26(23)34-30(28)21-8-2-1-3-9-21/h1-18H
DMHU4NS CS C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)C4=CC=C(C=C4)C5=CC(=O)C6=CC=CC=C6O5
DMHU4NS IK DKAAIRCEBVCHAT-UHFFFAOYSA-N
DMHU4NS IU 3-[4-(4-oxochromen-2-yl)phenyl]-2-phenylchromen-4-one
DMHU4NS DE Discovery agent
DMEMVY5 ID DMEMVY5
DMEMVY5 DN [32P]MRS2500
DMEMVY5 HS Investigative
DMEMVY5 SN [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate
DMEMVY5 DT Small molecular drug
DMEMVY5 PC 91827341
DMEMVY5 MW 562.16
DMEMVY5 FM C13H18IN5O8P2
DMEMVY5 IC InChI=1S/C13H18IN5O8P2/c1-15-10-9-11(18-12(14)17-10)19(5-16-9)7-2-8(27-29(23,24)25)13(3-6(7)13)4-26-28(20,21)22/h5-8H,2-4H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t6-,7+,8+,13+/m1/s1/i28+1
DMEMVY5 CS CNC1=C2C(=NC(=N1)I)N(C=N2)[C@H]3C[C@@H]([C@]4([C@@H]3C4)CO[32P](=O)(O)O)OP(=O)(O)O
DMEMVY5 IK NMVWLEUONAKGCD-PNGSNQAVSA-N
DMEMVY5 IU [(1R,2S,4S,5S)-1-((32P)dihydroxy(32P)phosphoryloxymethyl)-4-[2-iodo-6-(methylamino)purin-9-yl]-2-bicyclo[3.1.0]hexanyl] dihydrogen phosphate
DMEMVY5 DE Discovery agent
DM218VZ ID DM218VZ
DM218VZ DN [33P]2MeSADP
DM218VZ HS Investigative
DM218VZ SN [33P]2-methylthio-ADP
DM218VZ DT Small molecular drug
DM218VZ PC 73755009
DM218VZ MW 477.29
DM218VZ FM C11H17N5O10P2S
DM218VZ IC InChI=1S/C11H17N5O10P2S/c1-29-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(25-10)2-24-28(22,23)26-27(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1/i27+2,28+2
DM218VZ CS CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO[33P](=O)(O)O[33P](=O)(O)O)O)O)N
DM218VZ IK WLMZTKAZJUWXCB-JLOOSCHCSA-N
DM218VZ IU [(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxy(33P)phosphoryl hydrogen phosphate
DM218VZ DE Discovery agent
DMVUEYM ID DMVUEYM
DMVUEYM DN [35S]ACPPB
DMVUEYM HS Investigative
DMVUEYM SN [35S]-ACPPB
DMVUEYM DT Small molecular drug
DMVUEYM PC 53321933
DMVUEYM MW 466.9
DMVUEYM FM C23H30ClN3O3S
DMVUEYM IC InChI=1S/C23H30ClN3O3S/c1-3-16-31(29,30)27-14-12-23(13-15-27,18-8-5-4-6-9-18)17(2)26-22(28)21-19(24)10-7-11-20(21)25/h4-11,17H,3,12-16,25H2,1-2H3,(H,26,28)/t17-/m0/s1/i31+3
DMVUEYM CS CCC[35S](=O)(=O)N1CCC(CC1)(C2=CC=CC=C2)[C@H](C)NC(=O)C3=C(C=CC=C3Cl)N
DMVUEYM IK CPNFHRRINJHHNO-BMHXGNRYSA-N
DMVUEYM IU 2-amino-6-chloro-N-[(1S)-1-(4-phenyl-1-propyl(35S)sulfonylpiperidin-4-yl)ethyl]benzamide
DMVUEYM DE Discovery agent
DMAYPTO ID DMAYPTO
DMAYPTO DN [35S]ADPbetaS
DMAYPTO HS Investigative
DMAYPTO SN [35S]ADPbetaS; GTPL3408; [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](sulfanylidene)phosphonous acid
DMAYPTO DT Small molecular drug
DMAYPTO PC 73755052
DMAYPTO MW 446.17
DMAYPTO FM C10H15N5O9P2S
DMAYPTO IC InChI=1S/C10H15N5O9P2S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(23-10)1-22-25(18,19)24-26(20,21)27/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H2,20,21,27)/t4-,6-,7-,10-/m1/s1/i27+3
DMAYPTO CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=[35S])(O)O)O)O)N
DMAYPTO IK HCIKUKNAJRJFOW-JWNXZZODSA-N
DMAYPTO IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxy(35S)phosphinothioyl hydrogen phosphate
DMAYPTO DE Discovery agent
DMQ0NK8 ID DMQ0NK8
DMQ0NK8 DN [35S]ibutamoren
DMQ0NK8 HS Investigative
DMQ0NK8 SN [35S]MK-0677
DMQ0NK8 DT Small molecular drug
DMQ0NK8 PC 10578170
DMQ0NK8 MW 531.6
DMQ0NK8 FM C27H36N4O5S
DMQ0NK8 IC InChI=1S/C27H36N4O5S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27/h4-12,22H,13-19,28H2,1-3H3,(H,29,33)/t22-/m1/s1/i37+3
DMQ0NK8 CS CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)[35S](=O)(=O)C)N
DMQ0NK8 IK UMUPQWIGCOZEOY-KRTHATKOSA-N
DMQ0NK8 IU 2-amino-2-methyl-N-[(2R)-1-(1-methyl(35S)sulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
DMQ0NK8 DE Discovery agent
DMSHOQ8 ID DMSHOQ8
DMSHOQ8 DN [35S]-non-peptide OT antagonist
DMSHOQ8 HS Investigative
DMSHOQ8 SN [35S]-non-peptide OT antagonist; GTPL3484; [35S]non-peptide OT antagonist
DMSHOQ8 DT Small molecular drug
DMSHOQ8 PC 73755057
DMSHOQ8 MW 626.6
DMSHOQ8 FM C30H36F3N3O6S
DMSHOQ8 IC InChI=1S/C30H36F3N3O6S/c1-43(39,40)35-16-12-24(13-17-35)42-25-8-6-22(27(19-25)41-20-30(31,32)33)18-29(38)34-14-10-23(11-15-34)36-26-5-3-2-4-21(26)7-9-28(36)37/h2-6,8,19,23-24H,7,9-18,20H2,1H3/i43+3
DMSHOQ8 CS C[35S](=O)(=O)N1CCC(CC1)OC2=CC(=C(C=C2)CC(=O)N3CCC(CC3)N4C(=O)CCC5=CC=CC=C54)OCC(F)(F)F
DMSHOQ8 IK WGABGZOBUZZBRA-FFSUGBGASA-N
DMSHOQ8 IU 1-[1-[2-[4-(1-methyl(35S)sulfonylpiperidin-4-yl)oxy-2-(2,2,2-trifluoroethoxy)phenyl]acetyl]piperidin-4-yl]-3,4-dihydroquinolin-2-one
DMSHOQ8 DE Discovery agent
DMSD51L ID DMSD51L
DMSD51L DN [35S]TBPS
DMSD51L HS Investigative
DMSD51L SN [35S]TBPS; 35S-TBPS; GTPL4369
DMSD51L DT Small molecular drug
DMSD51L PC 59896759
DMSD51L MW 225.15
DMSD51L FM C8H15O3PS
DMSD51L IC InChI=1S/C8H15O3PS/c1-7(2,3)8-4-9-12(13,10-5-8)11-6-8/h4-6H2,1-3H3/i13+3
DMSD51L CS CC(C)(C)C12COP(=[35S])(OC1)OC2
DMSD51L IK VTBHBNXGFPTBJL-DLSVHHIMSA-N
DMSD51L IU 4-tert-butyl-1-(35S)sulfanylidene-2,6,7-trioxa-1lambda5-phosphabicyclo[2.2.2]octane
DMSD51L DE Discovery agent
DMN35BY ID DMN35BY
DMN35BY DN [3H](-)CGP 12177
DMN35BY HS Investigative
DMN35BY SN UNII-Z7YP8B158Q; CHEMBL36060; Z7YP8B158Q; 4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one; Tocris-1134; Lopac-C-125; AC1O7G0V; GTPL531; SCHEMBL12329633; ZINC3979132; BDBM50098668; NCGC00025024-01; NCGC00015184-01; NCGC00015184-02; CGP-12177, (S)-; (S)-(-)-CGP-12177; UNII-R89UMZ82MJ component UMQUQWCJKFOUGV-VIFPVBQESA-N; 4-(3-tert-Butylamino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one; 95840-76-9; 2H-Benzimidazol-2-one, 4-((2S)-3-((1,1-d
DMN35BY DT Small molecular drug
DMN35BY PC 6603756
DMN35BY MW 279.33
DMN35BY FM C14H21N3O3
DMN35BY IC InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)/t9-/m0/s1
DMN35BY CS CC(C)(C)NC[C@@H](COC1=CC=CC2=C1NC(=O)N2)O
DMN35BY IK UMQUQWCJKFOUGV-VIFPVBQESA-N
DMN35BY IU 4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one
DMN35BY CA CAS 95840-76-9
DMN35BY DE Discovery agent
DM0KGHP ID DM0KGHP
DM0KGHP DN [3H](-)devapamil
DM0KGHP HS Investigative
DM0KGHP SN (-)-Desmethoxyverapamil; (-)-Devapamil; 4-Desmethoxyverapamil; UNII-99EAI85506; 99EAI85506; 93468-87-2; (2S)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; AC1L32ZZ; AC1Q4Q2Z; 4-DMV; (-)-H3-Desmethoxyverapamil; GTPL2515; GTPL2517; SCHEMBL10453636; 4-desmethoxyverapamil (4-DMV); ZINC2016058; PDSP2_001070; PDSP1_001086; benzeneacetonitrile, 3,4-dimethoxy-; A-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-; A-(1-methylethyl)-,(s)-; D888; D 888; D-888; (-)-D888; Desmethoxyverapamil
DM0KGHP DT Small molecular drug
DM0KGHP PC 107928
DM0KGHP MW 424.6
DM0KGHP FM C26H36N2O3
DM0KGHP IC InChI=1S/C26H36N2O3/c1-20(2)26(19-27,22-11-12-24(30-5)25(18-22)31-6)14-8-15-28(3)16-13-21-9-7-10-23(17-21)29-4/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t26-/m0/s1
DM0KGHP CS CC(C)[C@](CCCN(C)CCC1=CC(=CC=C1)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM0KGHP IK VMVKIDPOEOLUFS-SANMLTNESA-N
DM0KGHP IU (2S)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM0KGHP CA CAS 93468-87-2
DM0KGHP DE Discovery agent
DMP6XL9 ID DMP6XL9
DMP6XL9 DN [3H](+)-cis-diltiazem
DMP6XL9 HS Investigative
DMP6XL9 SN [3H]-(+)-cis-diltiazem
DMP6XL9 DT Small molecular drug
DMP6XL9 PC 3076
DMP6XL9 MW 414.5
DMP6XL9 FM C22H26N2O4S
DMP6XL9 IC InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3
DMP6XL9 CS CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMP6XL9 IK HSUGRBWQSSZJOP-UHFFFAOYSA-N
DMP6XL9 IU [5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMP6XL9 CA CAS 34933-06-7
DMP6XL9 CB CHEBI:82814
DMP6XL9 DE Discovery agent
DM7QE1J ID DM7QE1J
DM7QE1J DN [3H](+)-isradipine
DM7QE1J HS Investigative
DM7QE1J SN (+)-[3H]isradipine; (+)-[3H]O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 3H-(+)-PN 200-110
DM7QE1J DT Small molecular drug
DM7QE1J PC 158617
DM7QE1J MW 371.4
DM7QE1J FM C19H21N3O5
DM7QE1J IC InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3/t16-/m0/s1
DM7QE1J CS CC1=C([C@@H](C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
DM7QE1J IK HMJIYCCIJYRONP-INIZCTEOSA-N
DM7QE1J IU 3-O-methyl 5-O-propan-2-yl (4S)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM7QE1J CA CAS 84260-64-0
DM7QE1J DE Discovery agent
DMRPS2X ID DMRPS2X
DMRPS2X DN [3H](R)-NPTS
DMRPS2X HS Investigative
DMRPS2X SN [3H]-(R)-NPTS
DMRPS2X DT Small molecular drug
DMRPS2X PC 45270374
DMRPS2X MW 417.5
DMRPS2X FM C26H27NO4
DMRPS2X IC InChI=1S/C26H27NO4/c1-19-8-10-21(11-9-19)26(30)22-12-14-23(15-13-22)31-24(20-6-4-3-5-7-20)16-17-27(2)18-25(28)29/h3-15,24H,16-18H2,1-2H3,(H,28,29)/t24-/m1/s1
DMRPS2X CS CC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)O[C@H](CCN(C)CC(=O)O)C3=CC=CC=C3
DMRPS2X IK HNBKNDFZJLEZLZ-XMMPIXPASA-N
DMRPS2X IU 2-[methyl-[(3R)-3-[4-(4-methylbenzoyl)phenoxy]-3-phenylpropyl]amino]acetic acid
DMRPS2X DE Discovery agent
DM0B54M ID DM0B54M
DM0B54M DN [3H](S)-zacopride
DM0B54M HS Investigative
DM0B54M SN [3H](S)-zacopride; GTPL4074
DM0B54M DT Small molecular drug
DM0B54M PC 53321935
DM0B54M MW 315.81
DM0B54M FM C15H20ClN3O2
DM0B54M IC InChI=1S/C15H20ClN3O2/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20)/t13-/m1/s1/i1T3
DM0B54M CS [3H]C([3H])([3H])OC1=CC(=C(C=C1C(=O)N[C@@H]2CN3CCC2CC3)Cl)N
DM0B54M IK FEROPKNOYKURCJ-RYASAWMLSA-N
DM0B54M IU 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-(tritritiomethoxy)benzamide
DM0B54M DE Discovery agent
DMQO8AF ID DMQO8AF
DMQO8AF DN [3H]2,2,2-TEMPS
DMQO8AF HS Investigative
DMQO8AF SN 2,2,2-Trifluoro-N-(3-pentan-2-yloxyphenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide; CHEMBL105296; 2,2,2-trifluoro-N-(3-pentan-2-yloxyphenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide; [3H]-PAM; 2,2,2-TEMPS; SCHEMBL6735527; GTPL6329; GTPL6328; BDBM50147143; 2,2,2-Trifluoro-ethanesulfonic acid [3-(1-methyl-butoxy)-phenyl]-pyridin-3-ylmethyl-amide; [3H]-PAM
DMQO8AF DT Small molecular drug
DMQO8AF PC 11362035
DMQO8AF MW 416.5
DMQO8AF FM C19H23F3N2O3S
DMQO8AF IC InChI=1S/C19H23F3N2O3S/c1-3-6-15(2)27-18-9-4-8-17(11-18)24(13-16-7-5-10-23-12-16)28(25,26)14-19(20,21)22/h4-5,7-12,15H,3,6,13-14H2,1-2H3
DMQO8AF CS CCCC(C)OC1=CC=CC(=C1)N(CC2=CN=CC=C2)S(=O)(=O)CC(F)(F)F
DMQO8AF IK ICFXZBZASBXILF-UHFFFAOYSA-N
DMQO8AF IU 2,2,2-trifluoro-N-(3-pentan-2-yloxyphenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMQO8AF DE Discovery agent
DM5SWI1 ID DM5SWI1
DM5SWI1 DN [3H]4NMPB
DM5SWI1 HS Investigative
DM5SWI1 SN [3H](1-methyl-4-piperidyl) 2-hydroxy-2,2-diphenyl-acetate; [3H]1-Methyl-4-piperidyl diphenylglycolate; [3H]enpiperate
DM5SWI1 DT Small molecular drug
DM5SWI1 PC 77157
DM5SWI1 MW 325.4
DM5SWI1 FM C20H23NO3
DM5SWI1 IC InChI=1S/C20H23NO3/c1-21-14-12-18(13-15-21)24-19(22)20(23,16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18,23H,12-15H2,1H3
DM5SWI1 CS CN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O
DM5SWI1 IK UGYPGJCVNPPUPE-UHFFFAOYSA-N
DM5SWI1 IU (1-methylpiperidin-4-yl) 2-hydroxy-2,2-diphenylacetate
DM5SWI1 CA CAS 3608-67-1
DM5SWI1 DE Discovery agent
DMEAHFZ ID DMEAHFZ
DMEAHFZ DN [3H]5-CT
DMEAHFZ HS Investigative
DMEAHFZ SN tritiated 5-carbamidotryptamine; [3H]5-carboxamidotryptamine
DMEAHFZ DT Small molecular drug
DMEAHFZ PC 53324620
DMEAHFZ MW 211.27
DMEAHFZ FM C11H13N3O
DMEAHFZ IC InChI=1S/C11H13N3O/c12-4-3-8-6-14-10-2-1-7(11(13)15)5-9(8)10/h1-2,5-6,14H,3-4,12H2,(H2,13,15)/i3T2,4T2
DMEAHFZ CS [3H]C([3H])(C1=CNC2=C1C=C(C=C2)C(=O)N)C([3H])([3H])N
DMEAHFZ IK WKZLNEWVIAGNAW-DOMYTETQSA-N
DMEAHFZ IU 3-(2-amino-1,1,2,2-tetratritioethyl)-1H-indole-5-carboxamide
DMEAHFZ DE Discovery agent
DMYJXV7 ID DMYJXV7
DMYJXV7 DN [3H]5-HT
DMYJXV7 HS Investigative
DMYJXV7 SN [3H]-5-HT
DMYJXV7 DT Small molecular drug
DMYJXV7 PC 53317992
DMYJXV7 MW 180.23
DMYJXV7 FM C10H12N2O
DMYJXV7 IC InChI=1S/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2/i3T,4T
DMYJXV7 CS [3H]C(C1=CNC2=C1C=C(C=C2)O)C([3H])N
DMYJXV7 IK QZAYGJVTTNCVMB-PZFLKRBQSA-N
DMYJXV7 IU 3-(2-amino-1,2-ditritioethyl)-1H-indol-5-ol
DMYJXV7 DE Discovery agent
DM50WFM ID DM50WFM
DM50WFM DN [3H]5-oxo-ETE
DM50WFM HS Investigative
DM50WFM SN 5-Oxo-ETE; 5-Oxoete; 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; 5-Kete; 5-Oxoeicosatetraenoic acid; 5-ketoeicosatetraenoic acid; CHEMBL18028; CHEBI:52449; (6E,8Z,11Z,14Z)-5-Oxoicosa-6,8,11,14-tetraenoic acid; 106154-18-1; 5-Oxo-eicosatetraenoate; 5-Oxoicosatetraenoic acid; [3H]-5-oxo-ETE; 5-Keto-6,8,11,14-eicosatetraenoic acid; 5-keto-ETE; ETE-5-Oxo; AC1NR1NN; BSPBio_001453; SCHEMBL139762; BML1-D12; GTPL3391; GTPL3416; MEASLHGILYBXFO-XTDASVJISA-N; HMS3402I15; HMS1791I15; HMS1989I15; HMS1361I15; ZINC4655377; LMFA03060011; [3H]-5-oxo-ETE; 5-oxo-ETE
DM50WFM DT Small molecular drug
DM50WFM PC 5283159
DM50WFM MW 318.4
DM50WFM FM C20H30O3
DM50WFM IC InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+
DM50WFM CS CCCCC/C=C\\C/C=C\\C/C=C\\C=C\\C(=O)CCCC(=O)O
DM50WFM IK MEASLHGILYBXFO-XTDASVJISA-N
DM50WFM IU (6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoic acid
DM50WFM CA CAS 106154-18-1
DM50WFM CB CHEBI:52449
DM50WFM DE Discovery agent
DM2PW8T ID DM2PW8T
DM2PW8T DN [3H]7-OH-DPAT
DM2PW8T HS Investigative
DM2PW8T SN 7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol; 7-OH-DPAT; 7-Ohdpat; DP-7-AT; 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol; 7-Hydroxy-N,N-di-n-propyl-2-aminotetralin; 7-Hydroxy-2-N,N-dipropylaminotetralin; N,N-Di-n-propyl-7-hydroxy-2-aminotetralin; CHEMBL285755; 7-(Dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol; 2-Naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-; 7-Hydroxy-DPAT hydrobromide; (+)-7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide; [3H]-7-OH-DPAT; (+)7-OH-DPAT; AC1Q7AGR; AC1L1AZK; [3H]-7-OH-DPAT; (+/-)-7-hydroxy-2-(N,N-di-n-propylamino)tetralin
DM2PW8T DT Small molecular drug
DM2PW8T PC 1219
DM2PW8T MW 247.38
DM2PW8T FM C16H25NO
DM2PW8T IC InChI=1S/C16H25NO/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3
DM2PW8T CS CCCN(CCC)C1CCC2=C(C1)C=C(C=C2)O
DM2PW8T IK BLYMJBIZMIGWFK-UHFFFAOYSA-N
DM2PW8T IU 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol
DM2PW8T CA CAS 74938-11-7
DM2PW8T CB CHEBI:111176
DM2PW8T DE Discovery agent
DM4KCYU ID DM4KCYU
DM4KCYU DN [3H]8-OH-DPAT
DM4KCYU HS Investigative
DM4KCYU SN 8-OH-Dpat; 78950-78-4; 8-HYDROXY-2-(DI-n-PROPYLAMINO)TETRALIN; 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; 8-Hydroxy-DPAT; CHEMBL56; Ro-31-8220 in solution; CHEBI:73364; 1-Naphthalenol, 7-(dipropylamino)-5,6,7,8-tetrahydro-; S(-)-8-HYDROXY-DPAT HYDROBROMIDE PARTIAL 5-HT1A SECROT; (+/-)-8-HYDROXY-2-DIPROPYL-AMINOTETRALIN; [3H]-8-OH-DPAT; (+/-)-8-Hydroxy-DPAT hydrobromide; [3H]8-OH-DPAT; (+-)-8-OH-DPAT; S(-)-8-OH-DPAT HBr; S(-)-8-Hydroxy-DPAT hydrobromide; dl-8-Hydroxy-2-(dipropylamino)tetralin; GTPL7; 8OH-DPAT
DM4KCYU DT Small molecular drug
DM4KCYU PC 1220
DM4KCYU MW 247.38
DM4KCYU FM C16H25NO
DM4KCYU IC InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-9-8-13-6-5-7-16(18)15(13)12-14/h5-7,14,18H,3-4,8-12H2,1-2H3
DM4KCYU CS CCCN(CCC)C1CCC2=C(C1)C(=CC=C2)O
DM4KCYU IK ASXGJMSKWNBENU-UHFFFAOYSA-N
DM4KCYU IU 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
DM4KCYU CA CAS 78950-78-4
DM4KCYU CB CHEBI:73364
DM4KCYU DE Discovery agent
DMTBAXD ID DMTBAXD
DMTBAXD DN [3H]A317491
DMTBAXD HS Investigative
DMTBAXD SN A-317491; 475205-49-3; UNII-H327N08IPV; H327N08IPV; A 317491; 5-{[(3-phenoxyphenyl)methyl][(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}benzene-1,2,4-tricarboxylic acid; A317491; VQGBOYBIENNKMI-LJAQVGFWSA-N; antagonist A-317491; [3H]A-317491; [3H]A 317491; SCHEMBL1160095; GTPL5407; GTPL4115; CHEMBL596234; CTK4J0070; BDBM86478; DTXSID40197185; MolPort-028-749-920; ZINC3990058; s8519; 475205-49-3 (free acid); AKOS030526820; CS-1250; NCGC00165956-01; 1,2,4-Benzenetricarboxylic acid,; [3H]A-317491
DMTBAXD DT Small molecular drug
DMTBAXD PC 9829395
DMTBAXD MW 565.6
DMTBAXD FM C33H27NO8
DMTBAXD IC InChI=1S/C33H27NO8/c35-30(25-17-27(32(38)39)28(33(40)41)18-26(25)31(36)37)34(29-15-7-10-21-9-4-5-14-24(21)29)19-20-8-6-13-23(16-20)42-22-11-2-1-3-12-22/h1-6,8-9,11-14,16-18,29H,7,10,15,19H2,(H,36,37)(H,38,39)(H,40,41)/t29-/m0/s1
DMTBAXD CS C1C[C@@H](C2=CC=CC=C2C1)N(CC3=CC(=CC=C3)OC4=CC=CC=C4)C(=O)C5=CC(=C(C=C5C(=O)O)C(=O)O)C(=O)O
DMTBAXD IK VQGBOYBIENNKMI-LJAQVGFWSA-N
DMTBAXD IU 5-[(3-phenoxyphenyl)methyl-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl]benzene-1,2,4-tricarboxylic acid
DMTBAXD CA CAS 475205-49-3
DMTBAXD DE Discovery agent
DMSDY2Z ID DMSDY2Z
DMSDY2Z DN [3H]A-585539
DMSDY2Z HS Investigative
DMSDY2Z SN [3H]A-585539; GTPL3974; SCHEMBL18833113
DMSDY2Z DT Small molecular drug
DMSDY2Z PC 23643135
DMSDY2Z MW 281.38
DMSDY2Z FM C17H21N4+
DMSDY2Z IC InChI=1S/C17H21N4/c1-21(2)12-14-10-15(21)11-20(14)17-9-8-16(18-19-17)13-6-4-3-5-7-13/h3-9,14-15H,10-12H2,1-2H3/q+1
DMSDY2Z CS C[N+]1(CC2CC1CN2C3=NN=C(C=C3)C4=CC=CC=C4)C
DMSDY2Z IK AKMKIDQMKPFYDJ-UHFFFAOYSA-N
DMSDY2Z IU 2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane
DMSDY2Z DE Discovery agent
DMVJKCH ID DMVJKCH
DMVJKCH DN [3H]A778317
DMVJKCH HS Investigative
DMVJKCH SN [3H]A778317; GTPL4076
DMVJKCH DT Small molecular drug
DMVJKCH PC 53321936
DMVJKCH MW 363.5
DMVJKCH FM C23H25N3O
DMVJKCH IC InChI=1S/C23H25N3O/c1-23(2,3)17-8-9-18-15(13-17)7-10-21(18)26-22(27)25-20-6-4-5-16-14-24-12-11-19(16)20/h4-6,8-9,11-14,21H,7,10H2,1-3H3,(H2,25,26,27)/t21-/m1/s1/i5T,6T
DMVJKCH CS [3H]C1=CC(=C(C2=C1C=NC=C2)NC(=O)N[C@@H]3CCC4=C3C=CC(=C4)C(C)(C)C)[3H]
DMVJKCH IK VPSCJCQPUGKRNC-ZVVBTKFUSA-N
DMVJKCH IU 1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-(6,8-ditritioisoquinolin-5-yl)urea
DMVJKCH DE Discovery agent
DMWV5C3 ID DMWV5C3
DMWV5C3 DN [3H]alphabeta-meATP
DMWV5C3 HS Investigative
DMWV5C3 SN Diphosphomethylphosphonic acid adenosyl ester; alpha,beta-Methylene ATP; alpha,beta-meATP; 7292-42-4; UNII-NYX13NT29D; diphosphomethylphosphonic acid adenosyl ester; alpha,beta-Methyleneadenosine 5'-triphosphate; EINECS 230-723-9; NYX13NT29D; ALPHA,BETA-METHYLENEADENOSINE-5'-TRIPHOSPHATE; CHEMBL132722; CHEBI:35056; 5'-O-(hydroxy{[hydroxy(phosphonooxy)phosphoryl]methyl}phosphoryl)adenosine; 5'-(Hydrogen((hydroxy(phosphonooxy)phosphinyl)methyl)phosphonate)adenosine; adenosine 5'-[alpha,beta-methylene]triphosphate; AMP-CPP; Adenosine 5'-(hydrogen; Alpha,Beta-Methyleneadenosine-5'-Triphosphate
DMWV5C3 DT Small molecular drug
DMWV5C3 PC 91557
DMWV5C3 MW 505.21
DMWV5C3 FM C11H18N5O12P3
DMWV5C3 IC InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-29(19,20)4-30(21,22)28-31(23,24)25/h2-3,5,7-8,11,17-18H,1,4H2,(H,19,20)(H,21,22)(H2,12,13,14)(H2,23,24,25)/t5-,7-,8-,11-/m1/s1
DMWV5C3 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O)O)N
DMWV5C3 IK CAWZRIXWFRFUQB-IOSLPCCCSA-N
DMWV5C3 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMWV5C3 CA CAS 7292-42-4
DMWV5C3 CB CHEBI:35056
DMWV5C3 DE Discovery agent
DMLF7SG ID DMLF7SG
DMLF7SG DN [3H]AMPA
DMLF7SG HS Investigative
DMLF7SG SN alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ampa; 74341-63-2; 77521-29-0; (RS)-AMPA; AMPA (pharmaceutical); CHEMBL13378; CHEBI:34018; 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo-; gamma-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; dl-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; (+-)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D,L-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; AMPA
DMLF7SG DT Small molecular drug
DMLF7SG PC 1221
DMLF7SG MW 186.17
DMLF7SG FM C7H10N2O4
DMLF7SG IC InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)
DMLF7SG CS CC1=C(C(=O)NO1)CC(C(=O)O)N
DMLF7SG IK UUDAMDVQRQNNHZ-UHFFFAOYSA-N
DMLF7SG IU 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
DMLF7SG CA CAS 77521-29-0
DMLF7SG CB CHEBI:34018
DMPVG5Y ID DMPVG5Y
DMPVG5Y DN [3H]AZ11637326
DMPVG5Y HS Investigative
DMPVG5Y SN [3H]AZ11637326; GTPL3971
DMPVG5Y DT Small molecular drug
DMPVG5Y PC 73755064
DMPVG5Y MW 310.4
DMPVG5Y FM C19H19FN2O
DMPVG5Y IC InChI=1S/C19H19FN2O/c20-17-3-1-2-13(9-17)15-8-14-10-19(23-18(14)21-11-15)12-22-6-4-16(19)5-7-22/h1-3,8-9,11,16H,4-7,10,12H2/t19-/m0/s1
DMPVG5Y CS C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC(=C4)C5=CC(=CC=C5)F
DMPVG5Y IK MRVNNESNVNUKCV-IBGZPJMESA-N
DMPVG5Y IU (3R)-5'-(3-fluorophenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
DMPVG5Y DE Discovery agent
DMKL9X7 ID DMKL9X7
DMKL9X7 DN [3H]bag-2
DMKL9X7 HS Investigative
DMKL9X7 SN 2-[4-[2-[5-(Cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid; Bag-2; CHEMBL1084942; 2-[4-[2-[5-(cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid; GTPL6189; SCHEMBL6982673; GTPL8506; BDBM50313741; 4''-(2-(5-(cyclopentylmethyl)-1H-imidazol-2-yl)ethyl)biphenyl-2-carboxylic acid; bag-2
DMKL9X7 DT Small molecular drug
DMKL9X7 PC 25025654
DMKL9X7 MW 374.5
DMKL9X7 FM C24H26N2O2
DMKL9X7 IC InChI=1S/C24H26N2O2/c27-24(28)22-8-4-3-7-21(22)19-12-9-17(10-13-19)11-14-23-25-16-20(26-23)15-18-5-1-2-6-18/h3-4,7-10,12-13,16,18H,1-2,5-6,11,14-15H2,(H,25,26)(H,27,28)
DMKL9X7 CS C1CCC(C1)CC2=CN=C(N2)CCC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O
DMKL9X7 IK OENIXTHWZWFYIV-UHFFFAOYSA-N
DMKL9X7 IU 2-[4-[2-[5-(cyclopentylmethyl)-1H-imidazol-2-yl]ethyl]phenyl]benzoic acid
DMKL9X7 DE Discovery agent
DMG8T3W ID DMG8T3W
DMG8T3W DN [3H]BQ123
DMG8T3W HS Investigative
DMG8T3W SN [3H]cyc(DTrp-DAsp-Pro-DVal-Leu; [3H]-BQ123
DMG8T3W DT Small molecular drug
DMG8T3W PC 70686617
DMG8T3W MW 612.7
DMG8T3W FM C31H42N6O7
DMG8T3W IC InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23-,24-,26+/m0/s1/i14T/t14?,21-,22+,23-,24-,26+
DMG8T3W CS [3H]C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC3=CNC4=CC=CC=C43)CC(C)C)C(C)C)C(=O)O
DMG8T3W IK VYCMAAOURFJIHD-HCGDBENESA-N
DMG8T3W IU 2-[(3S,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]-2-tritioacetic acid
DMG8T3W DE Discovery agent
DMZRQU7 ID DMZRQU7
DMZRQU7 DN [3H]cAMP
DMZRQU7 HS Investigative
DMZRQU7 SN Cyclic AMP; cAMP; 60-92-4; Adenosine 3',5'-cyclic monophosphate; 3',5'-cyclic AMP; Adenosine 3',5'-phosphate; Adenosine 3',5'-cyclophosphate; cyclic 3',5'-AMP; Adenosine cyclic monophosphate; cyclic 3',5'-Adenylic acid; Adenosine 3',5'-monophosphate; Adenosine-3',5'-cyclophosphate; Adenosine cyclophosphate; Cyclic Adenosine Monophosphate; cyclic Adenosine 3',5'-phosphate; Cyclic adenylic acid; Adenosine cyclic 3',5'-monophosphate; 3',5'-AMP; cyclic Adenosine 3',5'-monophosphate; Adenosine cyclic 3',5'-phosphate; [3H]-cAMP
DMZRQU7 DT Small molecular drug
DMZRQU7 PC 6076
DMZRQU7 MW 329.21
DMZRQU7 FM C10H12N5O6P
DMZRQU7 IC InChI=1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7-4(20-10)1-19-22(17,18)21-7/h2-4,6-7,10,16H,1H2,(H,17,18)(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
DMZRQU7 CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)O)OP(=O)(O1)O
DMZRQU7 IK IVOMOUWHDPKRLL-KQYNXXCUSA-N
DMZRQU7 IU (4aR,6R,7R,7aS)-6-(6-aminopurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
DMZRQU7 CA CAS 60-92-4
DMZRQU7 CB CHEBI:17489
DMZRQU7 DE Discovery agent
DMHDGB3 ID DMHDGB3
DMHDGB3 DN [3H]CCPA
DMHDGB3 HS Investigative
DMHDGB3 SN 2-Chloro-N6-cyclopentyladenosine; CCPA; 37739-05-2; 2-CHLORO-N-CYCLOPENTYLADENOSINE; 2-chloro-N(6)cyclopentyladenosine; Adenosine, 2-chloro-N-cyclopentyl-; BRN 4888162; CHEMBL284969; (2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 2-Chloro-N6-cyclopentyladenosine hemihydrate; C15H20ClN5O4; [3H]-CCPA; ccpa (biochemistry); AC1L3XBY; 2-Cl-CPA; [3H]-CCPA; 2-chloro-N6-cyclopentyladenosine
DMHDGB3 DT Small molecular drug
DMHDGB3 PC 123807
DMHDGB3 MW 369.8
DMHDGB3 FM C15H20ClN5O4
DMHDGB3 IC InChI=1S/C15H20ClN5O4/c16-15-19-12(18-7-3-1-2-4-7)9-13(20-15)21(6-17-9)14-11(24)10(23)8(5-22)25-14/h6-8,10-11,14,22-24H,1-5H2,(H,18,19,20)/t8-,10-,11-,14-/m1/s1
DMHDGB3 CS C1CCC(C1)NC2=C3C(=NC(=N2)Cl)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMHDGB3 IK XSMYYYQVWPZWIZ-IDTAVKCVSA-N
DMHDGB3 IU (2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMHDGB3 CA CAS 37739-05-2
DMHDGB3 DE Discovery agent
DMZN1A3 ID DMZN1A3
DMZN1A3 DN [3H]CGP12177
DMZN1A3 HS Investigative
DMZN1A3 SN 4-(3-Tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one; Tbhpbo; 81047-99-6; 4-(3-tert-Butylamino-2-hydroxypropoxy)benzimidazol-2-one; CHEBI:73288; C14H19N3O3; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one; 2H-Benzimidazol-2-one, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,3-dihydro-; (+/-)-CGP-12177A hydrochloride; Spectrum_001907; SpecPlus_000776; Spectrum4_000777; AC1Q6M3F
DMZN1A3 DT Small molecular drug
DMZN1A3 PC 2687
DMZN1A3 MW 279.33
DMZN1A3 FM C14H21N3O3
DMZN1A3 IC InChI=1S/C14H21N3O3/c1-14(2,3)15-7-9(18)8-20-11-6-4-5-10-12(11)17-13(19)16-10/h4-6,9,15,18H,7-8H2,1-3H3,(H2,16,17,19)
DMZN1A3 CS CC(C)(C)NCC(COC1=CC=CC2=C1NC(=O)N2)O
DMZN1A3 IK UMQUQWCJKFOUGV-UHFFFAOYSA-N
DMZN1A3 IU 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one
DMZN1A3 CA CAS 81047-99-6
DMZN1A3 CB CHEBI:73288
DMZN1A3 DE Discovery agent
DMQTBRM ID DMQTBRM
DMQTBRM DN [3H]CGP27492
DMQTBRM HS Investigative
DMQTBRM SN 3-Aminopropylphosphinic acid; 3-aminopropylphosphinic acid; 3-Aminopropanephosphinic acid; CGP-27492; Cgp 27492; 3-Aminopropylphosphonous acid; Phosphinic acid, (3-aminopropyl); 3-aminopropyl-hydroxy-oxophosphanium; CHEMBL112203; [3H]3-APPA; [3H]-3-APPA; Cgp 27 492; [3H]-CGP27492; AC1O3S7O; SCHEMBL341549; GTPL5381; GTPL1081; BDBM24184; CTK8G4752; (3-Amino-propyl)-phosphinic acid; ZTHNRNOOZGJLRR-UHFFFAOYSA-N; MolPort-019-939-257; CGP27492; 3-aminopropyl-hydroxy-oxo-phosphonium; BN0804; PDSP2_001468; PDSP1_001484; FCH933647; 3-aminopropylphosphinic; [3H]-CGP27492
DMQTBRM DT Small molecular drug
DMQTBRM PC 6335948
DMQTBRM MW 122.08
DMQTBRM FM C3H9NO2P+
DMQTBRM IC InChI=1S/C3H8NO2P/c4-2-1-3-7(5)6/h1-4H2/p+1
DMQTBRM CS C(CN)C[P+](=O)O
DMQTBRM IK MQIWYGZSHIXQIU-UHFFFAOYSA-O
DMQTBRM IU 3-aminopropyl-hydroxy-oxophosphanium
DMQTBRM CA CAS 103680-47-3
DMQTBRM DE Discovery agent
DMITR7A ID DMITR7A
DMITR7A DN [3H]CGP39653
DMITR7A HS Investigative
DMITR7A SN (E)-2-amino-4-(phosphonomethyl)hept-3-enoic acid; 132472-31-2; [3H]CGP39653; ACMC-20muiw; GTPL4078; CTK0H6852; 2-amino-4-(phosphonomethyl)hept-3-enoic acid
DMITR7A DT Small molecular drug
DMITR7A PC 114756
DMITR7A MW 237.19
DMITR7A FM C8H16NO5P
DMITR7A IC InChI=1S/C8H16NO5P/c1-2-3-6(5-15(12,13)14)4-7(9)8(10)11/h4,7H,2-3,5,9H2,1H3,(H,10,11)(H2,12,13,14)
DMITR7A CS CCCC(=CC(C(=O)O)N)CP(=O)(O)O
DMITR7A IK ZEFQYTSQDVUMEU-UHFFFAOYSA-N
DMITR7A IU 2-amino-4-(phosphonomethyl)hept-3-enoic acid
DMITR7A DE Discovery agent
DM7H3JN ID DM7H3JN
DM7H3JN DN [3H]CGS19755
DM7H3JN HS Investigative
DM7H3JN SN ACMC-20mhnp; ACMC-20bxqj; 4-(phosphonomethyl)-2-piperidinecarboxylic acid; AC1N8SPX; SCHEMBL120235; 2-Piperidinecarboxylicacid, 4-(phosphonomethyl)-, (2R,4S)-rel-; GTPL4080; 113229-89-3; AKOS005066562; 4-phosphonomethyl-2-piperidinecarboxylic acid; A802182
DM7H3JN DT Small molecular drug
DM7H3JN PC 4324257
DM7H3JN MW 223.16
DM7H3JN FM C7H14NO5P
DM7H3JN IC InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)
DM7H3JN CS C1CNC(CC1CP(=O)(O)O)C(=O)O
DM7H3JN IK LPMRCCNDNGONCD-UHFFFAOYSA-N
DM7H3JN IU 4-(phosphonomethyl)piperidine-2-carboxylic acid
DM7H3JN CA CAS 110347-85-8
DM7H3JN DE Discovery agent
DMLP68J ID DMLP68J
DMLP68J DN [3H]CGS8216
DMLP68J HS Investigative
DMLP68J SN 2-Phenylpyrazolo(4,3-c)quinolin-3(5H)-one; Cgs 8216; CGS-8216; 77779-60-3; 2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one; BRN 4257286; 2-phenyl-1,2-dihydro-3h-pyrazolo[4,3-c]quinolin-3-one; 2,5-Dihydro-2-phenyl-3H-pyrazolo(4,3-c)quinolin-3-one; 3H-Pyrazolo(4,3-c)quinolin-3-one, 2,5-dihydro-2-phenyl-; 2-phenyl-1H-pyrazolo[4,5-c]quinolin-3-one; 2,5-DIHYDRO-2-PHENYL-3H-PYRAZOLO[4,3-C]QUINOLIN-3-ONE; AC1Q6FQG; AC1Q6NJI; AC1L2XPQ; 2-phenyl-1H-pyrazolo[4,3-c]quinolin-3-one; 2-phenyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one; GTPL4366; GTPL4156; SCHEMBL1466280
DMLP68J DT Small molecular drug
DMLP68J PC 104916
DMLP68J MW 261.279
DMLP68J FM C16H11N3O
DMLP68J IC InChI=1S/C16H11N3O/c20-16-13-10-17-14-9-5-4-8-12(14)15(13)18-19(16)11-6-2-1-3-7-11/h1-10,18H
DMLP68J CS C1=CC=C(C=C1)N2C(=O)C3=C(N2)C4=CC=CC=C4N=C3
DMLP68J IK XTYGFVVANLMBHE-UHFFFAOYSA-N
DMLP68J IU 2-phenyl-1H-pyrazolo[4,3-c]quinolin-3-one
DMLP68J CA CAS 77779-60-3
DMLP68J DE Inflammation
DMIFKUX ID DMIFKUX
DMIFKUX DN [3H]CNQX
DMIFKUX HS Investigative
DMIFKUX SN 6-Cyano-7-nitroquinoxaline-2,3-dione; CNQX; 115066-14-3; 6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; 7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile; UNII-6OTE87SCCW; FG 9065; 6OTE87SCCW; FG-9065; 6-Cyano-2,3-dihydroxy-7-nitroquinoxaline; CHEBI:34468; 1,4-dihydro-2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile; 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-; ST50405216; 2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; FG9065; AC1MWAKF; Tocris-0190; Biomol-NT_000200; 6-cyano-7-nitroquinoxaline-2,3-dione
DMIFKUX DT Small molecular drug
DMIFKUX PC 3721046
DMIFKUX MW 232.15
DMIFKUX FM C9H4N4O4
DMIFKUX IC InChI=1S/C9H4N4O4/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5/h1-2H,(H,11,14)(H,12,15)
DMIFKUX CS C1=C(C(=CC2=C1NC(=O)C(=O)N2)[N+](=O)[O-])C#N
DMIFKUX IK RPXVIAFEQBNEAX-UHFFFAOYSA-N
DMIFKUX IU 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile
DMIFKUX CA CAS 115066-14-3
DMIFKUX CB CHEBI:34468
DMIFKUX DE Discovery agent
DMU7FC5 ID DMU7FC5
DMU7FC5 DN [3H]CP55940
DMU7FC5 HS Investigative
DMU7FC5 SN 5-(1,1-Dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol; CP55940; CP-55940; UNII-KFY70972J5; CP55,940; CP 55940; CP 55,940; KFY70972J5; 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol; 83002-04-4; CP-55,940; 83003-12-7; C24H40O3; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; Phenol, 5-(1,1-dimethylheptyl)-2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, rel-
DMU7FC5 DT Small molecular drug
DMU7FC5 PC 104895
DMU7FC5 MW 376.6
DMU7FC5 FM C24H40O3
DMU7FC5 IC InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1
DMU7FC5 CS CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O)O
DMU7FC5 IK YNZFFALZMRAPHQ-SYYKKAFVSA-N
DMU7FC5 IU 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
DMU7FC5 CA CAS 83002-04-4
DMU7FC5 DE Discovery agent
DMR5UBF ID DMR5UBF
DMR5UBF DN [3H]CPP
DMR5UBF HS Investigative
DMR5UBF SN 100828-16-8; 4-(3-phosphonopropyl)piperazine-2-carboxylic acid; (RS)-CPP; 3-2-Cpp; CARBOXYPEPTIDASE P; 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid; (+/-)-CPP; 4-(3-Phosphonopropyl)-2-piperazinecarboxylic acid; CHEMBL22304; DL-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid; 4-(3-Phosphono-propyl)-piperazine-2-carboxylic acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-; (+)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphoric Acid; 2-Piperazinecarboxylic acid, 4-(3-phosphonopropyl)-, (+-)-; 108549-42-4
DMR5UBF DT Small molecular drug
DMR5UBF PC 1228
DMR5UBF MW 252.2
DMR5UBF FM C8H17N2O5P
DMR5UBF IC InChI=1S/C8H17N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h7,9H,1-6H2,(H,11,12)(H2,13,14,15)
DMR5UBF CS C1CN(CC(N1)C(=O)O)CCCP(=O)(O)O
DMR5UBF IK CUVGUPIVTLGRGI-UHFFFAOYSA-N
DMR5UBF IU 4-(3-phosphonopropyl)piperazine-2-carboxylic acid
DMR5UBF CA CAS 100828-16-8
DMR5UBF DE Discovery agent
DMVLRHW ID DMVLRHW
DMVLRHW DN [3H]cytisine
DMVLRHW HS Investigative
DMVLRHW SN [3H]CYTISINE
DMVLRHW DT Small molecular drug
DMVLRHW PC 53321937
DMVLRHW MW 194.26
DMVLRHW FM C11H14N2O
DMVLRHW IC InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1/i2T,3T
DMVLRHW CS [3H]C1=CC(=C2[C@@H]3C[C@@H](CNC3)CN2C1=O)[3H]
DMVLRHW IK ANJTVLIZGCUXLD-ZIAKYUPESA-N
DMVLRHW IU (1R,9S)-3,5-ditritio-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
DMVLRHW DE Discovery agent
DM4NXRO ID DM4NXRO
DM4NXRO DN [3H]devazepide
DM4NXRO HS Investigative
DM4NXRO SN N-(1-Methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide; Rac-Devazepide; CHEMBL39263; BRN 5156082; C25H20N4O2; N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide; [3H]-devazepide; [3H]DEVAZEPIDE; AC1L1RVE; AC1Q5GGS; ACMC-20m69q; GTPL878; SCHEMBL4884074; GTPL3476; CTK8G4712; 1H-Indole-2-carboxamide,N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-; 103420-82-2; 1H-Indole-2-carboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, (S)-
DM4NXRO DT Small molecular drug
DM4NXRO PC 59751
DM4NXRO MW 408.5
DM4NXRO FM C25H20N4O2
DM4NXRO IC InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)
DM4NXRO CS CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5
DM4NXRO IK NFHRQQKPEBFUJK-UHFFFAOYSA-N
DM4NXRO IU N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide
DM4NXRO DE Discovery agent
DMBWAIE ID DMBWAIE
DMBWAIE DN [3H]dimethyl-W84
DMBWAIE HS Investigative
DMBWAIE SN Dimethyl-W84; dimethyl-W84; 6-[dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azaniumyl]hexyl-dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azanium; Dimethyl-W-84; GTPL364
DMBWAIE DT Small molecular drug
DMBWAIE PC 10350027
DMBWAIE MW 576.8
DMBWAIE FM C34H48N4O4+2
DMBWAIE IC InChI=1S/C34H48N4O4/c1-25-15-11-17-27-29(25)33(41)35(31(27)39)19-13-23-37(3,4)21-9-7-8-10-22-38(5,6)24-14-20-36-32(40)28-18-12-16-26(2)30(28)34(36)42/h11-12,15-18H,7-10,13-14,19-24H2,1-6H3/q+2
DMBWAIE CS CC1=C2C(=CC=C1)C(=O)N(C2=O)CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCN3C(=O)C4=CC=CC(=C4C3=O)C
DMBWAIE IK HMXRJKOINNJHNS-UHFFFAOYSA-N
DMBWAIE IU 6-[dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azaniumyl]hexyl-dimethyl-[3-(4-methyl-1,3-dioxoisoindol-2-yl)propyl]azanium
DMBWAIE DE Discovery agent
DMBMS1U ID DMBMS1U
DMBMS1U DN [3H]diprenorphine
DMBMS1U HS Investigative
DMBMS1U SN [15,16-3H]diprenorphine
DMBMS1U DT Small molecular drug
DMBMS1U PC 6858272
DMBMS1U MW 429.6
DMBMS1U FM C26H35NO4
DMBMS1U IC InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1/i10T,11T/t10?,11?,18-,19-,22-,24-,25+,26-
DMBMS1U CS [3H]C1C(N([C@@H]2CC3=C4[C@@]15[C@@]26CC[C@]([C@@H]5OC4=C(C=C3)O)([C@H](C6)C(C)(C)O)OC)CC7CC7)[3H]
DMBMS1U IK OIJXLIIMXHRJJH-ZXJLXYCOSA-N
DMBMS1U IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-3,4-ditritio-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMBMS1U DE Discovery agent
DMEC2PF ID DMEC2PF
DMEC2PF DN [3H]dizocilpine
DMEC2PF HS Investigative
DMEC2PF SN [3H]MK-801
DMEC2PF DT Small molecular drug
DMEC2PF PC 1207
DMEC2PF MW 221.3
DMEC2PF FM C16H15N
DMEC2PF IC InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3
DMEC2PF CS CC12C3=CC=CC=C3CC(N1)C4=CC=CC=C24
DMEC2PF IK LBOJYSIDWZQNJS-UHFFFAOYSA-N
DMEC2PF IU 1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene
DMEC2PF CA CAS 70449-94-4
DMEC2PF DE Discovery agent
DM9GY7O ID DM9GY7O
DM9GY7O DN [3H]DPCPX
DM9GY7O HS Investigative
DM9GY7O SN [3H]-DPCPX
DM9GY7O DT Small molecular drug
DM9GY7O PC 53319341
DM9GY7O MW 312.42
DM9GY7O FM C16H24N4O2
DM9GY7O IC InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)/i1T,2T,9T,10T
DM9GY7O CS [3H]CCC([3H])N1C2=C(C(=O)N(C1=O)C([3H])CC[3H])NC(=N2)C3CCCC3
DM9GY7O IK FFBDFADSZUINTG-LEZITTIZSA-N
DM9GY7O IU 8-cyclopentyl-1,3-bis(1,3-ditritiopropyl)-7H-purine-2,6-dione
DM9GY7O DE Discovery agent
DMDTYRV ID DMDTYRV
DMDTYRV DN [3H]eletriptan
DMDTYRV HS Investigative
DMDTYRV SN [3H]eletriptan; GTPL118
DMDTYRV DT Small molecular drug
DMDTYRV PC 53318014
DMDTYRV MW 388.5
DMDTYRV FM C22H26N2O2S
DMDTYRV IC InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1/i1T3
DMDTYRV CS [3H]C([3H])([3H])N1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
DMDTYRV IK PWVXXGRKLHYWKM-YWMWWHSFSA-N
DMDTYRV IU 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-(tritritiomethyl)pyrrolidin-2-yl]methyl]-1H-indole
DMDTYRV DE Discovery agent
DMM1KBW ID DMM1KBW
DMM1KBW DN [3H]EM-TBPC
DMM1KBW HS Investigative
DMM1KBW SN 1-Ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidine-5-carbonitrile; EM-TBPC; GTPL3363; GTPL1390; SCHEMBL6952709; E-165; 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidine-5-carbonitrile; 1-Ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile; 1-ethyl-2-methyl-6-oxo-4-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)-1,6-dihydropyrimidine-5-carbonitrile
DMM1KBW DT Small molecular drug
DMM1KBW PC 9904703
DMM1KBW MW 308.4
DMM1KBW FM C18H20N4O
DMM1KBW IC InChI=1S/C18H20N4O/c1-3-22-13(2)20-17(16(12-19)18(22)23)21-10-8-14-6-4-5-7-15(14)9-11-21/h4-7H,3,8-11H2,1-2H3
DMM1KBW CS CCN1C(=NC(=C(C1=O)C#N)N2CCC3=CC=CC=C3CC2)C
DMM1KBW IK QNUVWRAGDSGAKX-UHFFFAOYSA-N
DMM1KBW IU 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidine-5-carbonitrile
DMM1KBW DE Discovery agent
DM3KJ45 ID DM3KJ45
DM3KJ45 DN [3H]estradiol-17beta-glucuronide
DM3KJ45 HS Investigative
DM3KJ45 SN [3H]-estradiol-17beta-glucuronide
DM3KJ45 DT Small molecular drug
DM3KJ45 PC 5281887
DM3KJ45 MW 448.5
DM3KJ45 FM C24H32O8
DM3KJ45 IC InChI=1S/C24H32O8/c1-24-9-8-14-13-5-3-12(25)10-11(13)2-4-15(14)16(24)6-7-17(24)31-23-20(28)18(26)19(27)21(32-23)22(29)30/h3,5,10,14-21,23,25-28H,2,4,6-9H2,1H3,(H,29,30)/t14-,15-,16+,17+,18+,19+,20-,21+,23-,24+/m1/s1
DM3KJ45 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CCC5=C3C=CC(=C5)O
DM3KJ45 IK MTKNDAQYHASLID-QXYWQCSFSA-N
DM3KJ45 IU (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]oxane-2-carboxylic acid
DM3KJ45 CA CAS 1806-98-0
DM3KJ45 CB CHEBI:791
DM3KJ45 DE Discovery agent
DMGPF0N ID DMGPF0N
DMGPF0N DN [3H]estrone-3-sulphate
DMGPF0N HS Investigative
DMGPF0N SN [3H]-estrone hydrogen sulfate; [3H]-estrone-3-sulphate; [3H]estrone-3-sulfate
DMGPF0N DT Small molecular drug
DMGPF0N PC 3001028
DMGPF0N MW 350.4
DMGPF0N FM C18H22O5S
DMGPF0N IC InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1
DMGPF0N CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
DMGPF0N IK JKKFKPJIXZFSSB-CBZIJGRNSA-N
DMGPF0N IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMGPF0N CA CAS 481-97-0
DMGPF0N CB CHEBI:17474
DMGPF0N DE Discovery agent
DMWGY61 ID DMWGY61
DMWGY61 DN [3H]ETB-TBOA
DMWGY61 HS Investigative
DMWGY61 SN [3H]-ETB-TBOA
DMWGY61 DT Small molecular drug
DMWGY61 PC 73755093
DMWGY61 MW 390.4
DMWGY61 FM C20H22N2O6
DMWGY61 IC InChI=1S/C20H22N2O6/c1-2-12-6-8-14(9-7-12)18(23)22-15-5-3-4-13(10-15)11-28-17(20(26)27)16(21)19(24)25/h3-10,16-17H,2,11,21H2,1H3,(H,22,23)(H,24,25)(H,26,27)/t16-,17-/m0/s1/i1T,2T/t2?,16-,17-
DMWGY61 CS [3H]CC([3H])C1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O
DMWGY61 IK GFSLJGCKUUCABJ-YQFXYRMXSA-N
DMWGY61 IU (2S,3S)-2-amino-3-[[3-[[4-(1,2-ditritioethyl)benzoyl]amino]phenyl]methoxy]butanedioic acid
DMWGY61 DE Discovery agent
DME0XHN ID DME0XHN
DME0XHN DN [3H]folinic acid
DME0XHN HS Investigative
DME0XHN DT Small molecular drug
DME0XHN PC 135403648
DME0XHN MW 473.4
DME0XHN FM C20H23N7O7
DME0XHN IC InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
DME0XHN CS C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DME0XHN IK VVIAGPKUTFNRDU-ABLWVSNPSA-N
DME0XHN IU (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DME0XHN CA CAS 58-05-9
DME0XHN CB CHEBI:15640
DME0XHN DE Discovery agent
DMGQDLU ID DMGQDLU
DMGQDLU DN [3H]GBR12935
DMGQDLU HS Investigative
DMGQDLU SN 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine; Gbr 12935; 76778-22-8; GBR-12935; GBR12935; 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine; UNII-9J9974WIBA; CHEMBL26320; 9J9974WIBA; CHEBI:64093; 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine; 1-(2-(benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine; Piperazine, 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)-; Piperazine, 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-; 1-(2-(diphenylmethoxy)ethyl)-4-(3-phenylpropyl)piperazine; 1-(2-(Benzhydryloxy)ethyl)-4-(3-phenylpropyl)piperazine; [3H]-GBR12935
DMGQDLU DT Small molecular drug
DMGQDLU PC 3456
DMGQDLU MW 414.6
DMGQDLU FM C28H34N2O
DMGQDLU IC InChI=1S/C28H34N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-9,11-12,14-17,28H,10,13,18-24H2
DMGQDLU CS C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4
DMGQDLU IK RAQPOZGWANIDQT-UHFFFAOYSA-N
DMGQDLU IU 1-(2-benzhydryloxyethyl)-4-(3-phenylpropyl)piperazine
DMGQDLU CA CAS 76778-22-8
DMGQDLU CB CHEBI:64093
DMGQDLU DE Discovery agent
DMFEYLS ID DMFEYLS
DMFEYLS DN [3H]GlySar
DMFEYLS HS Investigative
DMFEYLS SN [3H]-GlySar; tritiated glycylsarcosine
DMFEYLS DT Small molecular drug
DMFEYLS PC 93131
DMFEYLS MW 146.14
DMFEYLS FM C5H10N2O3
DMFEYLS IC InChI=1S/C5H10N2O3/c1-7(3-5(9)10)4(8)2-6/h2-3,6H2,1H3,(H,9,10)
DMFEYLS CS CN(CC(=O)O)C(=O)CN
DMFEYLS IK VYAMLSCELQQRAE-UHFFFAOYSA-N
DMFEYLS IU 2-[(2-aminoacetyl)-methylamino]acetic acid
DMFEYLS CA CAS 29816-01-1
DMFEYLS CB CHEBI:155876
DMFEYLS DE Discovery agent
DM4URBO ID DM4URBO
DM4URBO DN [3H]GR 125,743
DM4URBO HS Investigative
DM4URBO SN [3H]GR125743
DM4URBO DT Small molecular drug
DM4URBO PC 53321959
DM4URBO MW 422.5
DM4URBO FM C25H28N4O2
DM4URBO IC InChI=1S/C25H28N4O2/c1-18-16-20(4-6-22(18)19-8-10-26-11-9-19)25(30)27-21-5-7-24(31-3)23(17-21)29-14-12-28(2)13-15-29/h4-11,16-17H,12-15H2,1-3H3,(H,27,30)/i2T3
DM4URBO CS [3H]C([3H])([3H])N1CCN(CC1)C2=C(C=CC(=C2)NC(=O)C3=CC(=C(C=C3)C4=CC=NC=C4)C)OC
DM4URBO IK GNOXPYACARZYMW-BHTRQJOGSA-N
DM4URBO IU N-[4-methoxy-3-[4-(tritritiomethyl)piperazin-1-yl]phenyl]-3-methyl-4-pyridin-4-ylbenzamide
DM4URBO DE Discovery agent
DMMHSYA ID DMMHSYA
DMMHSYA DN [3H]GR65630
DMMHSYA HS Investigative
DMMHSYA SN [3H]-GR65630
DMMHSYA DT Small molecular drug
DMMHSYA PC 5311136
DMMHSYA MW 267.33
DMMHSYA FM C16H17N3O
DMMHSYA IC InChI=1S/C16H17N3O/c1-11-14(18-10-17-11)7-8-16(20)13-9-19(2)15-6-4-3-5-12(13)15/h3-6,9-10H,7-8H2,1-2H3,(H,17,18)
DMMHSYA CS CC1=C(N=CN1)CCC(=O)C2=CN(C3=CC=CC=C32)C
DMMHSYA IK QZNZJWLUNDXZQA-UHFFFAOYSA-N
DMMHSYA IU 3-(5-methyl-1H-imidazol-4-yl)-1-(1-methylindol-3-yl)propan-1-one
DMMHSYA CB CHEBI:87784
DMMHSYA DE Discovery agent
DMB9VGW ID DMB9VGW
DMB9VGW DN [3H]granisetron
DMB9VGW HS Investigative
DMB9VGW SN [3H]-granisetron; [3H]-BRL-43694
DMB9VGW DT Small molecular drug
DMB9VGW PC 3510
DMB9VGW MW 312.4
DMB9VGW FM C18H24N4O
DMB9VGW IC InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)
DMB9VGW CS CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
DMB9VGW IK MFWNKCLOYSRHCJ-UHFFFAOYSA-N
DMB9VGW IU 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide
DMB9VGW CA CAS 109889-09-0
DMB9VGW DE Discovery agent
DMU6A3W ID DMU6A3W
DMU6A3W DN [3H]GSK931145
DMU6A3W HS Investigative
DMU6A3W SN [3H]-GSK931145
DMU6A3W DT Small molecular drug
DMU6A3W PC 73755091
DMU6A3W MW 356.5
DMU6A3W FM C23H30N2O
DMU6A3W IC InChI=1S/C23H30N2O/c1-17-11-10-12-18(2)20(17)22(26)24-21(19-13-6-5-7-14-19)23(25(3)4)15-8-9-16-23/h5-7,10-14,21H,8-9,15-16H2,1-4H3,(H,24,26)/t21-/m0/s1/i3T3
DMU6A3W CS [3H]C([3H])([3H])N(C)C1(CCCC1)[C@H](C2=CC=CC=C2)NC(=O)C3=C(C=CC=C3C)C
DMU6A3W IK BMXRRRIDMAIEKX-IUNCQSRSSA-N
DMU6A3W IU 2,6-dimethyl-N-[(S)-[1-[methyl(tritritiomethyl)amino]cyclopentyl]-phenylmethyl]benzamide
DMU6A3W DE Discovery agent
DMJT6D3 ID DMJT6D3
DMJT6D3 DN [3H]GW2331
DMJT6D3 HS Investigative
DMJT6D3 SN [3H]GW2331; GTPL2706; 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
DMJT6D3 DT Small molecular drug
DMJT6D3 PC 10624977
DMJT6D3 MW 492.6
DMJT6D3 FM C27H36F2N2O4
DMJT6D3 IC InChI=1S/C27H36F2N2O4/c1-4-6-7-8-9-17-31(26(34)30-24-15-12-21(28)19-23(24)29)18-16-20-10-13-22(14-11-20)35-27(3,5-2)25(32)33/h10-15,19H,4-9,16-18H2,1-3H3,(H,30,34)(H,32,33)/i15T
DMJT6D3 CS [3H]C1=CC(=CC(=C1NC(=O)N(CCCCCCC)CCC2=CC=C(C=C2)OC(C)(CC)C(=O)O)F)F
DMJT6D3 IK VGSJXSLGVQINOL-BBSCNJGJSA-N
DMJT6D3 IU 2-[4-[2-[(2,4-difluoro-6-tritiophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
DMJT6D3 DE Discovery agent
DMEO6AH ID DMEO6AH
DMEO6AH DN [3H]HEMADO
DMEO6AH HS Investigative
DMEO6AH SN Hemado; HEMADO; CHEMBL260563; 403842-38-6; (2R,3R,4S,5R)-2-(2-hex-1-ynyl-6-methylaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; SCHEMBL935096; GTPL5736; GTPL5599; MolPort-006-822-566; 2-(1-Hexynyl)-N-methyladenosine; 2-(1-Hexynyl)-N6-methyladenosine; ZINC3995955; BDBM50003273; AKOS024456680; HEMADO, >=99% (HPLC), solid
DMEO6AH DT Small molecular drug
DMEO6AH PC 10981286
DMEO6AH MW 361.4
DMEO6AH FM C17H23N5O4
DMEO6AH IC InChI=1S/C17H23N5O4/c1-3-4-5-6-7-11-20-15(18-2)12-16(21-11)22(9-19-12)17-14(25)13(24)10(8-23)26-17/h9-10,13-14,17,23-25H,3-5,8H2,1-2H3,(H,18,20,21)/t10-,13-,14-,17-/m1/s1
DMEO6AH CS CCCCC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NC
DMEO6AH IK KOCIMZNSNPOGOP-IWCJZZDYSA-N
DMEO6AH IU (2R,3R,4S,5R)-2-[2-hex-1-ynyl-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMEO6AH DE Discovery agent
DM190QW ID DM190QW
DM190QW DN [3H]hemicholinium-3
DM190QW HS Investigative
DM190QW SN [3H]-HC-3 ; [3H]-hemicholinium-3; [3H]HC-3
DM190QW DT Small molecular drug
DM190QW PC 9399
DM190QW MW 574.3
DM190QW FM C24H34Br2N2O4
DM190QW IC InChI=1S/C24H34N2O4.2BrH/c1-25(2)13-15-29-23(27,17-25)21-9-5-19(6-10-21)20-7-11-22(12-8-20)24(28)18-26(3,4)14-16-30-24;;/h5-12,27-28H,13-18H2,1-4H3;2*1H/q+2;;/p-2
DM190QW CS C[N+]1(CCOC(C1)(C2=CC=C(C=C2)C3=CC=C(C=C3)C4(C[N+](CCO4)(C)C)O)O)C.[Br-].[Br-]
DM190QW IK OPYKHUMNFAMIBL-UHFFFAOYSA-L
DM190QW IU 2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol;dibromide
DM190QW CA CAS 312-45-8
DMJ5BDQ ID DMJ5BDQ
DMJ5BDQ DN [3H]histidine
DMJ5BDQ HS Investigative
DMJ5BDQ SN [3H]-histidine
DMJ5BDQ DT Small molecular drug
DMJ5BDQ PC 6274
DMJ5BDQ MW 155.15
DMJ5BDQ FM C6H9N3O2
DMJ5BDQ IC InChI=1S/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1
DMJ5BDQ CS C1=C(NC=N1)C[C@@H](C(=O)O)N
DMJ5BDQ IK HNDVDQJCIGZPNO-YFKPBYRVSA-N
DMJ5BDQ IU (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid
DMJ5BDQ CA CAS 71-00-1
DMJ5BDQ CB CHEBI:15971
DM8YUW6 ID DM8YUW6
DM8YUW6 DN [3H]HU-243
DM8YUW6 HS Investigative
DM8YUW6 SN 140835-18-3; (3H)HU 243; (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; AC1MIXOL; 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol; BCP9000763; 6H-Dibenzo(b,d)pyran-8-t-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,8,9,10,10a-hexahydro-9-t-1-hydroxy-6,6-diemthyl-, (6aR-(6aalpha,8beta,9alpha,10abeta))-
DM8YUW6 DT Small molecular drug
DM8YUW6 PC 73754997
DM8YUW6 MW 392.6
DM8YUW6 FM C25H40O3
DM8YUW6 IC InChI=1S/C25H40O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h14-15,17,19-20,26-27H,6-13,16H2,1-5H3/t17-,19-,20-/m1/s1/i10T,17T/t10?,17-,19-,20-
DM8YUW6 CS [3H]C1C[C@@H]2[C@@H](C[C@]1([3H])CO)C3=C(C=C(C=C3OC2(C)C)C(C)(C)CCCCCC)O
DM8YUW6 IK MVEVPDCVOXJVBD-AENGYHINSA-N
DM8YUW6 IU (6aR,9R,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol
DM8YUW6 DE Discovery agent
DMJCI2A ID DMJCI2A
DMJCI2A DN [3H]JB-93182
DMJCI2A HS Investigative
DMJCI2A SN CHEMBL14557; [3H]JB-93182; GTPL908; SCHEMBL7096084; BDBM50213845; JB-93182; 5-[[(2S)-2-[[6-(1-adamantylmethylcarbamoyl)1H-indole-5-carbonyl]amino]-3-phenylpropanoyl]amino]benzene-1,3-dicarboxylic acid
DMJCI2A DT Small molecular drug
DMJCI2A PC 9939572
DMJCI2A MW 662.7
DMJCI2A FM C38H38N4O7
DMJCI2A IC InChI=1S/C38H38N4O7/c43-33(40-20-38-17-22-8-23(18-38)10-24(9-22)19-38)30-16-31-25(6-7-39-31)15-29(30)34(44)42-32(11-21-4-2-1-3-5-21)35(45)41-28-13-26(36(46)47)12-27(14-28)37(48)49/h1-7,12-16,22-24,32,39H,8-11,17-20H2,(H,40,43)(H,41,45)(H,42,44)(H,46,47)(H,48,49)/t22?,23?,24?,32-,38?/m0/s1
DMJCI2A CS C1C2CC3CC1CC(C2)(C3)CNC(=O)C4=C(C=C5C=CNC5=C4)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)NC7=CC(=CC(=C7)C(=O)O)C(=O)O
DMJCI2A IK DKYQJTXTKSMTHK-FGLZHOHTSA-N
DMJCI2A IU 5-[[(2S)-2-[[6-(1-adamantylmethylcarbamoyl)-1H-indole-5-carbonyl]amino]-3-phenylpropanoyl]amino]benzene-1,3-dicarboxylic acid
DMJCI2A DE Discovery agent
DMZT8UD ID DMZT8UD
DMZT8UD DN [3H]JNJ 7777120
DMZT8UD HS Investigative
DMZT8UD SN 1-[(5-Chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine; JNJ-7777120; 459168-41-3; JNJ7777120; JNJ 7777120; UNII-4H1AU2V37X; HUQJRYMLJBBEDO-UHFFFAOYSA-N; 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine; 4H1AU2V37X; CHEMBL129198; 1-[(5-CHLORO-1H-INDOL-2-YL)CARBONYL]-4-METHYL-PIPERAZINE; 1-((5-chloro-1H-indol-2-yl)carbonyl)-4-methylpiperazine; (5-chloro-1H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone; (5-chloro-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone; METHANONE, (5-CHLORO-1H-INDOL-2-YL)(4-METHYL-1-PIPERAZINYL)-; STK175446; [3H]-JNJ7777120; [3H]-JNJ7777120
DMZT8UD DT Small molecular drug
DMZT8UD PC 4908365
DMZT8UD MW 277.75
DMZT8UD FM C14H16ClN3O
DMZT8UD IC InChI=1S/C14H16ClN3O/c1-17-4-6-18(7-5-17)14(19)13-9-10-8-11(15)2-3-12(10)16-13/h2-3,8-9,16H,4-7H2,1H3
DMZT8UD CS CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl
DMZT8UD IK HUQJRYMLJBBEDO-UHFFFAOYSA-N
DMZT8UD IU (5-chloro-1H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone
DMZT8UD CA CAS 459168-41-3
DMZT8UD DE Inflammation
DMSE56B ID DMSE56B
DMSE56B DN [3H]JNJ-40068782
DMSE56B HS Investigative
DMSE56B SN RVRHQHDKALSKLY-UHFFFAOYSA-N; CHEMBL3337510; JNJ-40068782; SCHEMBL101802; GTPL6330; GTPL6331; RVRHQHDKALSKLY-UHFFFAOYSA-N; BDBM50051571; 1-(cyclopropylmethyl)-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridine-3-carbonitrile
DMSE56B DT Small molecular drug
DMSE56B PC 59234231
DMSE56B MW 333.4
DMSE56B FM C21H23N3O
DMSE56B IC InChI=1S/C21H23N3O/c22-14-19-20(10-13-24(21(19)25)15-16-6-7-16)23-11-8-18(9-12-23)17-4-2-1-3-5-17/h1-5,10,13,16,18H,6-9,11-12,15H2
DMSE56B CS C1CC1CN2C=CC(=C(C2=O)C#N)N3CCC(CC3)C4=CC=CC=C4
DMSE56B IK RVRHQHDKALSKLY-UHFFFAOYSA-N
DMSE56B IU 1-(cyclopropylmethyl)-2-oxo-4-(4-phenylpiperidin-1-yl)pyridine-3-carbonitrile
DMSE56B DE Discovery agent
DMMK7XU ID DMMK7XU
DMMK7XU DN [3H]kainate
DMMK7XU HS Investigative
DMMK7XU SN (2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4231; (2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4085; KAINATE
DMMK7XU DT Small molecular drug
DMMK7XU PC 73755076
DMMK7XU MW 211.21
DMMK7XU FM C10H13NO4-2
DMMK7XU IC InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/p-2/t6-,7+,9-/m0/s1
DMMK7XU CS CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)[O-])C(=O)[O-]
DMMK7XU IK VLSMHEGGTFMBBZ-OOZYFLPDSA-L
DMMK7XU IU (2S,3S,4S)-3-(carboxylatomethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylate
DMMK7XU CB CHEBI:156548
DMMK7XU DE Discovery agent
DMUZ9LX ID DMUZ9LX
DMUZ9LX DN [3H]L655708
DMUZ9LX HS Investigative
DMUZ9LX SN YKYOQIXTECBVBB-UHFFFAOYSA-N; ethyl 15-methoxy-12-oxo-2,4,11-triazatetracyclo[11400^{2,6}0^{7,11}]heptadeca-1(13),3,5,14,16-pentaene-5-carboxylate; AC1N5TG4; GTPL4363; GTPL4238; CHEBI:91920; HMS3267P07
DMUZ9LX DT Small molecular drug
DMUZ9LX PC 4203080
DMUZ9LX MW 341.4
DMUZ9LX FM C18H19N3O4
DMUZ9LX IC InChI=1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3
DMUZ9LX CS CCOC(=O)C1=C2C3CCCN3C(=O)C4=C(N2C=N1)C=CC(=C4)OC
DMUZ9LX IK YKYOQIXTECBVBB-UHFFFAOYSA-N
DMUZ9LX IU ethyl 15-methoxy-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DMUZ9LX CB CHEBI:91920
DMUZ9LX DE Discovery agent
DM0YJHS ID DM0YJHS
DM0YJHS DN [3H]LSD
DM0YJHS HS Investigative
DM0YJHS SN [3H]N,N-diethyllysergamide; [3H]lysergic acid diethylamide; [3H]lysergide
DM0YJHS DT Small molecular drug
DM0YJHS PC 44559100
DM0YJHS MW 329.5
DM0YJHS FM C20H25N3O
DM0YJHS IC InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1/i3T3
DM0YJHS CS [3H]C([3H])([3H])N1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N(CC)CC
DM0YJHS IK VAYOSLLFUXYJDT-QZGBZKRISA-N
DM0YJHS IU (6aR,9R)-N,N-diethyl-7-(tritritiomethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DM0YJHS DE Discovery agent
DMDOJVX ID DMDOJVX
DMDOJVX DN [3H]LTB4
DMDOJVX HS Investigative
DMDOJVX SN Delta(6)-trans,Delta(8)-cis-leukotriene B4; (6E,8Z)-LTB4; (5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; Delta(6)-trans,Delta(8)-cis-LTB4; 5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-icosatetraenoic acid; (5S,12R,6E,8Z,10E,14Z)-5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid; 5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-eicosatetraenoic acid; (5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyeicosa-6,8,10,14-tetraenoic acid; [3H]LTB4; SCHEMBL247274; GTPL3413; CHEBI:53027; ZINC27642911
DMDOJVX DT Small molecular drug
DMDOJVX PC 9949656
DMDOJVX MW 336.5
DMDOJVX FM C20H32O4
DMDOJVX IC InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7-,9-6-,14-10+,15-11+/t18-,19-/m1/s1
DMDOJVX CS CCCCC/C=C\\C[C@H](/C=C/C=C\\C=C\\[C@H](CCCC(=O)O)O)O
DMDOJVX IK VNYSSYRCGWBHLG-GEWAPNICSA-N
DMDOJVX IU (5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DMDOJVX CB CHEBI:53027
DMDOJVX DE Discovery agent
DMD09BO ID DMD09BO
DMD09BO DN [3H]LTC4
DMD09BO HS Investigative
DMD09BO SN [3H]LTC4
DMD09BO DT Small molecular drug
DMD09BO PC 73755045
DMD09BO MW 481.6
DMD09BO FM C25H39NO6S
DMD09BO IC InChI=1S/C25H39NO6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(27)15-14-17-24(29)30)33-19-18-23(28)26-20-25(31)32/h6-7,9-13,16,21-22,27H,2-5,8,14-15,17-20H2,1H3,(H,26,28)(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t21-,22+/m0/s1
DMD09BO CS CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SCCC(=O)NCC(=O)O
DMD09BO IK SEOZZZSLGDJWJL-FSKXFZJASA-N
DMD09BO IU (5S,6R,7E,9E,11Z,14Z)-6-[3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DMD09BO DE Discovery agent
DMGX0Y8 ID DMGX0Y8
DMGX0Y8 DN [3H]LY341495
DMGX0Y8 HS Investigative
DMGX0Y8 SN GTVQXKHWYDSDNM-JRHNIRLTSA-N; AC1O44IH; CTK8F0257; AN-16504; (1S,2S)-2-[(2S)-2-amino-3-(2,6-dioxo-3H-purin-9-yl)-1-hydroxy-1-oxopropan-2-yl]cyclopropane-1-carboxylic acid; (1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(2,6-dioxo-3H-purin-9-yl)ethyl]cyclopropanecarboxylic; [3H]alpha-9'-xantheylmethyl-2-(carboxycyclopropyl)glycine; LY341495
DMGX0Y8 DT Small molecular drug
DMGX0Y8 PC 9819927
DMGX0Y8 MW 353.4
DMGX0Y8 FM C20H19NO5
DMGX0Y8 IC InChI=1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20-/m0/s1
DMGX0Y8 CS C1[C@@H]([C@H]1[C@@](CC2C3=CC=CC=C3OC4=CC=CC=C24)(C(=O)O)N)C(=O)O
DMGX0Y8 IK VLZBRVJVCCNPRJ-KPHUOKFYSA-N
DMGX0Y8 IU (1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(9H-xanthen-9-yl)ethyl]cyclopropane-1-carboxylic acid
DMGX0Y8 CA CAS 201943-63-7
DMGX0Y8 CB CHEBI:93224
DMGX0Y8 DE Discovery agent
DMPKGHB ID DMPKGHB
DMPKGHB DN [3H]MDL105519
DMPKGHB HS Investigative
DMPKGHB SN AC1L1H8N; GTPL4088; CTK6G6780; CTK0I1827; HMS3370K17; (E)-3-(2-Carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid; (Z)-3-(2-carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid; 1H-Indole-2-carboxylicacid, 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-
DMPKGHB DT Small molecular drug
DMPKGHB PC 4023
DMPKGHB MW 376.2
DMPKGHB FM C18H11Cl2NO4
DMPKGHB IC InChI=1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)
DMPKGHB CS C1=CC=C(C=C1)C(=CC2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O)C(=O)O
DMPKGHB IK LPWVUDLZUVBQGP-UHFFFAOYSA-N
DMPKGHB IU 3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid
DMPKGHB DE Discovery agent
DMEX6GT ID DMEX6GT
DMEX6GT DN [3H]meclinertant
DMEX6GT HS Investigative
DMEX6GT SN [3H]-SR48692; [3H]reminertant; [3H]SR-48692
DMEX6GT DT Small molecular drug
DMEX6GT PC 53323315
DMEX6GT MW 599.1
DMEX6GT FM C32H31ClN4O5
DMEX6GT IC InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)/i1T3,2T3
DMEX6GT CS [3H]C([3H])([3H])OC1=C(C(=CC=C1)OC([3H])([3H])[3H])C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O
DMEX6GT IK DYLJVOXRWLXDIG-VQBNBCTGSA-N
DMEX6GT IU 2-[[5-[2,6-bis(tritritiomethoxy)phenyl]-1-(7-chloroquinolin-4-yl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
DMEX6GT DE Discovery agent
DM8K6VF ID DM8K6VF
DM8K6VF DN [3H]mesulergine
DM8K6VF HS Investigative
DM8K6VF SN [3H]mesulergine; AC1L1HDA; GTPL232; SCHEMBL11890532
DM8K6VF DT Small molecular drug
DM8K6VF PC 4081
DM8K6VF MW 361.5
DM8K6VF FM C19H27N3O2S
DM8K6VF IC InChI=1S/C19H27N3O2S/c1-20(2)25(23,24)12-13-8-16-15-6-5-7-17-19(15)14(11-22(17)4)9-18(16)21(3)10-13/h5-7,11,13,16,18H,8-10,12H2,1-4H3
DM8K6VF CS CN1CC(CC2C1CC3=CN(C4=CC=CC2=C34)C)CS(=O)(=O)N(C)C
DM8K6VF IK WYCMFCPHWDZHMR-UHFFFAOYSA-N
DM8K6VF IU 1-(4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl)-N,N-dimethylmethanesulfonamide
DM8K6VF DE Discovery agent
DMONI13 ID DMONI13
DMONI13 DN [3H]methoxymethyl-MTEP
DMONI13 HS Investigative
DMONI13 SN 3-(Methoxymethyl)-5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; Pyridine, 3-(methoxymethyl)-5-[(2-methyl-4-thiazolyl)ethynyl]-; CHEMBL1169453; 3-(methoxymethyl)-5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; methoxymethyl-MTEP; 524924-75-2; [3H]-methoxymethyl-MTEP; CHEMBL420533; GTPL5394; GTPL3345; SCHEMBL5652003; CTK1E4453; DTXSID90438611; AWDRAHDWMICWJM-UHFFFAOYSA-N; BDBM50366853; 3-Methoxymethyl-5-(2-methyl-thiazol-4-ylethynyl)-pyridine; 3-(2-Methyl-4-thiazolylethynyl)-5-(methoxymethyl)pyridine; [3H]-methoxymethyl-MTEP
DMONI13 DT Small molecular drug
DMONI13 PC 10354477
DMONI13 MW 244.31
DMONI13 FM C13H12N2OS
DMONI13 IC InChI=1S/C13H12N2OS/c1-10-15-13(9-17-10)4-3-11-5-12(8-16-2)7-14-6-11/h5-7,9H,8H2,1-2H3
DMONI13 CS CC1=NC(=CS1)C#CC2=CN=CC(=C2)COC
DMONI13 IK AWDRAHDWMICWJM-UHFFFAOYSA-N
DMONI13 IU 4-[2-[5-(methoxymethyl)pyridin-3-yl]ethynyl]-2-methyl-1,3-thiazole
DMONI13 CA CAS 524924-75-2
DMONI13 DE Discovery agent
DMZ2R1O ID DMZ2R1O
DMZ2R1O DN [3H]methoxy-PEPy
DMZ2R1O HS Investigative
DMZ2R1O SN CHEMBL1169452; [3H]methoxy-PEPy; GTPL6425; SCHEMBL14573621
DMZ2R1O DT Small molecular drug
DMZ2R1O PC 10910934
DMZ2R1O MW 216.25
DMZ2R1O FM C13H10N2O
DMZ2R1O IC InChI=1S/C13H10N2O/c1-16-13-8-11(9-14-10-13)5-6-12-4-2-3-7-15-12/h2-4,7-10H,1H3/i1T3
DMZ2R1O CS [3H]C([3H])([3H])OC1=CN=CC(=C1)C#CC2=CC=CC=N2
DMZ2R1O IK VRTFKUFTEWQHDD-RLXJOQACSA-N
DMZ2R1O IU 3-(2-pyridin-2-ylethynyl)-5-(tritritiomethoxy)pyridine
DMZ2R1O CA CAS 524924-80-9
DMZ2R1O DE Discovery agent
DMYWGCS ID DMYWGCS
DMYWGCS DN [3H]methyllycaconitine
DMYWGCS HS Investigative
DMYWGCS SN 21019-30-7; MLK; 2byr; [(1S,2R,3R,4S,5R,6S,8R,9S,10S,13S,16S,17R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7721^{2,5}0^{1,10}0^{3,8}0^{13,17}]nonadecan-13-yl]methyl 2-[(3S)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate; GTPL3980; GTPL4005; ZINC24707797; BRD-K43192255-048-03-6; [(1beta,5alpha,6alpha,8alpha,9alpha,13alpha,14beta,16alpha)-20-ethyl-7,8-dihydroxy-1,6,14,16-tetramethoxyaconitan-4-yl]methyl
DMYWGCS DT Small molecular drug
DMYWGCS PC 5288811
DMYWGCS MW 682.8
DMYWGCS FM C37H50N2O10
DMYWGCS IC InChI=1S/C37H50N2O10/c1-7-38-17-34(18-49-32(42)20-10-8-9-11-23(20)39-26(40)14-19(2)31(39)41)13-12-25(46-4)36-22-15-21-24(45-3)16-35(43,27(22)28(21)47-5)37(44,33(36)38)30(48-6)29(34)36/h8-11,19,21-22,24-25,27-30,33,43-44H,7,12-18H2,1-6H3/t19-,21+,22+,24-,25-,27+,28-,29+,30-,33-,34-,35+,36-,37+/m0/s1
DMYWGCS CS CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@]([C@H]31)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)C[C@@H](C8=O)C
DMYWGCS IK XLTANAWLDBYGFU-VTLKBQQISA-N
DMYWGCS IU [(1S,2R,3R,4S,5R,6S,8R,9S,10S,13S,16S,17R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]methyl 2-[(3S)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate
DMYWGCS CA CAS 1356-60-1
DMYWGCS DE Discovery agent
DMTSGOW ID DMTSGOW
DMTSGOW DN [3H]methyltrienolone
DMTSGOW HS Investigative
DMTSGOW SN Methyltrienolone; METRIBOLONE; 965-93-5; R1881; Metribolona; 17alpha-Methyltrienolone; Metribolonum; RU 1881; Ru-1881; R 1881; UNII-2C323EGI97; 17beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R-1881; R1881 (synthetic androgen); CHEBI:379896; 2C323EGI97; (17BETA)-17-HYDROXY-17-METHYLESTRA-4,9,11-TRIEN-3-ONE; 17-methyloestra-4,9,11-trien-3-one,17beta-ol; 17-beta-hydroxy-17-methylestra-4,9,11-trien-3-one (9CI); Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17b)-; [3H]-R1881; [3H]R1881
DMTSGOW DT Small molecular drug
DMTSGOW PC 261000
DMTSGOW MW 284.4
DMTSGOW FM C19H24O2
DMTSGOW IC InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1
DMTSGOW CS C[C@@]1(CC[C@@H]2[C@@]1(C=CC3=C4CCC(=O)C=C4CC[C@@H]23)C)O
DMTSGOW IK CCCIJQPRIXGQOE-XWSJACJDSA-N
DMTSGOW IU (8S,13S,14S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
DMTSGOW CA CAS 965-93-5
DMTSGOW CB CHEBI:379896
DMTSGOW DE Discovery agent
DM6HDKQ ID DM6HDKQ
DM6HDKQ DN [3H]mibolerone
DM6HDKQ HS Investigative
DM6HDKQ SN Mibolerone; MIBOLERONE; 3704/9/4; Miboleronum; Mibolerona; Cheque; U-10,997; UNII-9OGY4BOR8D; NSC 72260; 9OGY4BOR8D; U 10997; Matenon; Miboleron; 17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one; CHEBI:34849; U-10997; 17beta-Hydroxy-7alpha,17-dimethylestr-4-en-3-one; (7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one; 7alpha-17alpha-dimethyl-19-nortestosterone; CDB 904; Cheque (Veterinary)
DM6HDKQ DT Small molecular drug
DM6HDKQ PC 251636
DM6HDKQ MW 302.5
DM6HDKQ FM C20H30O2
DM6HDKQ IC InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1
DM6HDKQ CS C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C)O
DM6HDKQ IK PTQMMNYJKCSPET-OMHQDGTGSA-N
DM6HDKQ IU (7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
DM6HDKQ CA CAS 3704-09-4
DM6HDKQ CB CHEBI:34849
DM6HDKQ DE Discovery agent
DMO89N0 ID DMO89N0
DMO89N0 DN [3H]MK-912
DMO89N0 HS Investigative
DMO89N0 SN [3H]L-657,743
DMO89N0 DT Small molecular drug
DMO89N0 PC 91827340
DMO89N0 MW 345.5
DMO89N0 FM C20H25N3O2
DMO89N0 IC InChI=1S/C20H25N3O2/c1-21-11-8-20(22(2)19(21)24)9-12-23-10-7-15-14-5-3-4-6-17(14)25-18(15)16(23)13-20/h3-6,16H,7-13H2,1-2H3/t16-,20+/m1/s1/i1T3
DMO89N0 CS [3H]C([3H])([3H])N1CC[C@@]2(CCN3CCC4=C([C@H]3C2)OC5=CC=CC=C45)N(C1=O)C
DMO89N0 IK JRDUBBHIPPPSLP-NFEZXYISSA-N
DMO89N0 IU (2R,12bR)-3'-methyl-1'-(tritritiomethyl)spiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one
DMO89N0 DE Discovery agent
DM0THB9 ID DM0THB9
DM0THB9 DN [3H]N5-methylfolate
DM0THB9 HS Investigative
DM0THB9 DT Small molecular drug
DM0THB9 PC 135402010
DM0THB9 MW 459.5
DM0THB9 FM C20H25N7O6
DM0THB9 IC InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)
DM0THB9 CS CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DM0THB9 IK ZNOVTXRBGFNYRX-UHFFFAOYSA-N
DM0THB9 IU 2-[[4-[(2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DM0THB9 CA CAS 134-35-0
DM0THB9 DE Discovery agent
DMQW3A9 ID DMQW3A9
DMQW3A9 DN [3H]naltrindole
DMQW3A9 HS Investigative
DMQW3A9 SN Naltrindole; UNII-G167Z38QA4; 111555-53-4; CHEBI:81528; G167Z38QA4; [3H]-naltrindole; 17-Cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2',3'-indolomorphinan; CHEMBL1237164; (4bs,8r,8as,14br)-7-(Cyclopropylmethyl)-5,6,7,8,14,14b-Hexahydro-4,8-Methano[1]benzofuro[2,3-A]pyrido[4,3-B]carbazole-1,8a(9h)-Diol; 4,8-Methanobenzofuro(2,3-a)pyrido(4,3-b)carbazole-1,8a(9H)-diol, 7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-, (8R-(4bS*,8alpha,8abeta,14bbeta))-; NTI; EJ4; [3H]-naltrindole
DMQW3A9 DT Small molecular drug
DMQW3A9 PC 5497186
DMQW3A9 MW 414.5
DMQW3A9 FM C26H26N2O3
DMQW3A9 IC InChI=1S/C26H26N2O3/c29-19-8-7-15-11-20-26(30)12-17-16-3-1-2-4-18(16)27-22(17)24-25(26,21(15)23(19)31-24)9-10-28(20)13-14-5-6-14/h1-4,7-8,14,20,24,27,29-30H,5-6,9-13H2/t20-,24+,25+,26-/m1/s1
DMQW3A9 CS C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8N6
DMQW3A9 IK WIYUZYBFCWCCQJ-IFKAHUTRSA-N
DMQW3A9 IU (1S,2S,13R,21R)-22-(cyclopropylmethyl)-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
DMQW3A9 CA CAS 111555-53-4
DMQW3A9 CB CHEBI:81528
DMQW3A9 DE Discovery agent
DMAO9SH ID DMAO9SH
DMAO9SH DN [3H]NECA
DMAO9SH HS Investigative
DMAO9SH SN 5'-N-Ethylcarboxamidoadenosine; NECA; 35920-39-9; Adenosine-5'-(N-ethylcarboxamide); N-ethyl-5'-carboxamidoadenosine; 1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide; N-ETHYL-5'-CARBOXAMIDO ADENOSINE; MLS000069759; CHEMBL464859; CHEBI:73284; 5'-N-ETHYLCARBOXAMIDO-ADENOSINE; SMR000058759; N-Ethylcarboxamidoadenosine; 5'-N(Sup 6)-Ethylcarboxamidoadenosine; (2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide; [3H]adenosine-5'-(N-ethylcarboxamide)
DMAO9SH DT Small molecular drug
DMAO9SH PC 448222
DMAO9SH MW 308.29
DMAO9SH FM C12H16N6O4
DMAO9SH IC InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1
DMAO9SH CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMAO9SH IK JADDQZYHOWSFJD-FLNNQWSLSA-N
DMAO9SH IU (2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
DMAO9SH CA CAS 35920-39-9
DMAO9SH CB CHEBI:73284
DMAO9SH DE Discovery agent
DM0163O ID DM0163O
DM0163O DN [3H]nelivaptan
DM0163O HS Investigative
DM0163O SN [3H]-SSR149415; [3H]SSR149415
DM0163O DT Small molecular drug
DM0163O PC 70692936
DM0163O MW 642.2
DM0163O FM C30H32ClN3O8S
DM0163O IC InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1/i3T3,5T3
DM0163O CS [3H]C([3H])([3H])OC1=CC(=C(C=C1)S(=O)(=O)N2C3=C(C=C(C=C3)Cl)[C@](C2=O)(C4=CC=CC=C4OC)N5C[C@@H](C[C@H]5C(=O)N(C)C)O)OC([3H])([3H])[3H]
DM0163O IK NJXZWIIMWNEOGJ-KGKCFUOPSA-N
DM0163O IU (2S,4R)-1-[(3R)-1-[2,4-bis(tritritiomethoxy)phenyl]sulfonyl-5-chloro-3-(2-methoxyphenyl)-2-oxoindol-3-yl]-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide
DM0163O DE Discovery agent
DM6PO49 ID DM6PO49
DM6PO49 DN [3H]NFPS
DM6PO49 HS Investigative
DM6PO49 SN 405225-21-0; CHEMBL26512; A1-01880; N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine; n-[3-([1,1-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-n-methylglycine; 2-((3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl)(methyl)amino)acetic acid; [3H]-NFPS; AC1NSKCW; SCHEMBL427134; GTPL4620; GTPL4619; CTK8E8383; DTXSID30415522; MolPort-023-276-580; KS-000000NE; BCP21210; BCP17140; ( inverted exclamation
DM6PO49 DT Small molecular drug
DM6PO49 PC 5311283
DM6PO49 MW 393.4
DM6PO49 FM C24H24FNO3
DM6PO49 IC InChI=1S/C24H24FNO3/c1-26(17-24(27)28)16-15-23(20-7-11-21(25)12-8-20)29-22-13-9-19(10-14-22)18-5-3-2-4-6-18/h2-14,23H,15-17H2,1H3,(H,27,28)
DM6PO49 CS CN(CCC(C1=CC=C(C=C1)F)OC2=CC=C(C=C2)C3=CC=CC=C3)CC(=O)O
DM6PO49 IK FDORQEIHOKEJNX-UHFFFAOYSA-N
DM6PO49 IU 2-[[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid
DM6PO49 CA CAS 405225-21-0
DM6PO49 DE Discovery agent
DM9E2YI ID DM9E2YI
DM9E2YI DN [3H]nicotine
DM9E2YI HS Investigative
DM9E2YI SN 3-(1-methylpyrrolidin-2-yl)pyridine; 22083-74-5; Nikotin; (R,S)-Nicotine; Black Leaf 40; Pyridine, 3-(1-methyl-2-pyrrolidinyl)-; Black leaf; Nicotine alkaloid; Nicotin; Nicocide; Tendust; (RS)-Nicotine; Nico-dust; Emo-nik; Nico-Fume; Mach-Nic; Nic-Sal; Nicotina; Nikotyna; CHEMBL440464; (+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine; NSC5065; SNICXCGAKADSCV-UHFFFAOYSA-N; BRN 0082111; 3-(1-Methyl-2-pyrrolidinyl)pyridine
DM9E2YI DT Small molecular drug
DM9E2YI PC 942
DM9E2YI MW 162.23
DM9E2YI FM C10H14N2
DM9E2YI IC InChI=1S/C10H14N2/c1-12-7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3
DM9E2YI CS CN1CCCC1C2=CN=CC=C2
DM9E2YI IK SNICXCGAKADSCV-UHFFFAOYSA-N
DM9E2YI IU 3-(1-methylpyrrolidin-2-yl)pyridine
DM9E2YI CA CAS 22083-74-5
DM9E2YI CB CHEBI:18723
DM9E2YI DE Discovery agent
DMS3WNG ID DMS3WNG
DMS3WNG DN [3H]nisoxetine
DMS3WNG HS Investigative
DMS3WNG SN [3H]-nisoxetine
DMS3WNG DT Small molecular drug
DMS3WNG PC 53323310
DMS3WNG MW 277.38
DMS3WNG FM C17H21NO2
DMS3WNG IC InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3/i1T3
DMS3WNG CS [3H]C([3H])([3H])NCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC
DMS3WNG IK ITJNARMNRKSWTA-RLXJOQACSA-N
DMS3WNG IU 3-(2-methoxyphenoxy)-3-phenyl-N-(tritritiomethyl)propan-1-amine
DMS3WNG DE Discovery agent
DM5TDFQ ID DM5TDFQ
DM5TDFQ DN [3H]nitrobenzylmercaptopurine ribonucleoside
DM5TDFQ HS Investigative
DM5TDFQ SN [3H]NBTI; [3H]-NBTI; (2S,3R,4S,5R)-2-(6-hydroxy-9H-purin-9-yl)-5-(hydroxymethyl)-2-{[(2-nitrophenyl)methyl]sulfanyl}oxolane-3,4-diol; [3H]NBMPR; SCHEMBL290700; GTPL4511
DM5TDFQ DT Small molecular drug
DM5TDFQ PC 135796589
DM5TDFQ MW 435.4
DM5TDFQ FM C17H17N5O7S
DM5TDFQ IC InChI=1S/C17H17N5O7S/c23-5-11-13(24)14(25)17(29-11,21-8-20-12-15(21)18-7-19-16(12)26)30-6-9-3-1-2-4-10(9)22(27)28/h1-4,7-8,11,13-14,23-25H,5-6H2,(H,18,19,26)/t11-,13-,14-,17+/m1/s1
DM5TDFQ CS C1=CC=C(C(=C1)CS[C@@]2([C@@H]([C@@H]([C@H](O2)CO)O)O)N3C=NC4=C3N=CNC4=O)[N+](=O)[O-]
DM5TDFQ IK NVQXRTPYOZKYMZ-GDLHICMESA-N
DM5TDFQ IU 9-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2-nitrophenyl)methylsulfanyl]oxolan-2-yl]-1H-purin-6-one
DM5TDFQ DE Discovery agent
DMG1TIV ID DMG1TIV
DMG1TIV DN [3H]NLX-112
DMG1TIV HS Investigative
DMG1TIV SN [3H]F13640
DMG1TIV DT Small molecular drug
DMG1TIV PC 9865384
DMG1TIV MW 393.9
DMG1TIV FM C20H22ClF2N3O
DMG1TIV IC InChI=1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3
DMG1TIV CS CC1=CN=C(C=C1)CNCC2(CCN(CC2)C(=O)C3=CC(=C(C=C3)F)Cl)F
DMG1TIV IK PKZXLMVXBZICTF-UHFFFAOYSA-N
DMG1TIV IU (3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone
DMG1TIV CA CAS 208110-64-9
DMG1TIV DE Discovery agent
DM5176Y ID DM5176Y
DM5176Y DN [3H]N-methylspiperone
DM5176Y HS Investigative
DM5176Y SN 3-N-Methylspiperone; N-Methylspiperone; N-Methylspiroperidol; 87539-19-3; UNII-5U54JM2T8G; 5U54JM2T8G; CHEMBL267932; 8-[4-(4-fluorophenyl)-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(4-(4-Fluorophenyl)-4-oxobutyl)-3-methyl-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 1,3,8-Triazaspiro(45)decan-4-one, 8-(4-(4-fluorophenyl)-4-oxobutyl)-3-methyl-1-phenyl-; C24H28FN3O2; [3H]methylspiperone; Mespiperone; [3H]methylspiperone; N-METHYLSPIPERONE
DM5176Y DT Small molecular drug
DM5176Y PC 119146
DM5176Y MW 409.5
DM5176Y FM C24H28FN3O2
DM5176Y IC InChI=1S/C24H28FN3O2/c1-26-18-28(21-6-3-2-4-7-21)24(23(26)30)13-16-27(17-14-24)15-5-8-22(29)19-9-11-20(25)12-10-19/h2-4,6-7,9-12H,5,8,13-18H2,1H3
DM5176Y CS CN1CN(C2(C1=O)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4
DM5176Y IK QHJLPOSPWKZACG-UHFFFAOYSA-N
DM5176Y IU 8-[4-(4-fluorophenyl)-4-oxobutyl]-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DM5176Y CA CAS 87539-19-3
DM5176Y DE Discovery agent
DMX4RJ8 ID DMX4RJ8
DMX4RJ8 DN [3H]N-methyl-SSR504734
DMX4RJ8 HS Investigative
DMX4RJ8 SN 2-Chloro-N-[(S)-[(2S)-1-methylpiperidin-2-yl](phenyl)methyl]-3-(trifluoromethyl)benzamide; CHEMBL1939495; N-methyl-SSR504734; 2-chloro-N-[(S)-[(2S)-1-methylpiperidin-2-yl](phenyl)methyl]-3-(trifluoromethyl)benzamide; [3H]-N-methyl-SSR504734; SCHEMBL4245201; GTPL4603; GTPL4604; [3H]-N-methyl-SSR504734
DMX4RJ8 DT Small molecular drug
DMX4RJ8 PC 11704260
DMX4RJ8 MW 410.9
DMX4RJ8 FM C21H22ClF3N2O
DMX4RJ8 IC InChI=1S/C21H22ClF3N2O/c1-27-13-6-5-12-17(27)19(14-8-3-2-4-9-14)26-20(28)15-10-7-11-16(18(15)22)21(23,24)25/h2-4,7-11,17,19H,5-6,12-13H2,1H3,(H,26,28)/t17-,19-/m0/s1
DMX4RJ8 CS CN1CCCC[C@H]1[C@H](C2=CC=CC=C2)NC(=O)C3=C(C(=CC=C3)C(F)(F)F)Cl
DMX4RJ8 IK XPXKFXNVIAOBEI-HKUYNNGSSA-N
DMX4RJ8 IU 2-chloro-N-[(S)-[(2S)-1-methylpiperidin-2-yl]-phenylmethyl]-3-(trifluoromethyl)benzamide
DMX4RJ8 DE Discovery agent
DM4BY5J ID DM4BY5J
DM4BY5J DN [3H]OSIP339391
DM4BY5J HS Investigative
DM4BY5J SN MIUCZFWBCFZKEU-UHFFFAOYSA-N; OSIP-339391; UCS15A; CHEMBL485862; N-[2-[[2-phenyl-6-[4-(3-phenylpropyl)piperazine-1-carbonyl]-7H-pyrrolo[3,2-e]pyrimidin-4-yl]amino]ethyl]acetamide; AC1NSJVQ; GTPL454; GTPL450; SCHEMBL2550652; OSIP339391; BDBM50268107; L000728; N-[2-[[2-phenyl-6-[4-(3-phenylpropyl)piperazine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]ethyl]acetamide; N-(2-{2-phenyl-6-[4-(3-phenylpropyl)-piperazine-1-carbonyl]-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino}ethyl)acetamide
DM4BY5J DT Small molecular drug
DM4BY5J PC 5311041
DM4BY5J MW 525.6
DM4BY5J FM C30H35N7O2
DM4BY5J IC InChI=1S/C30H35N7O2/c1-22(38)31-14-15-32-28-25-21-26(33-29(25)35-27(34-28)24-12-6-3-7-13-24)30(39)37-19-17-36(18-20-37)16-8-11-23-9-4-2-5-10-23/h2-7,9-10,12-13,21H,8,11,14-20H2,1H3,(H,31,38)(H2,32,33,34,35)
DM4BY5J CS CC(=O)NCCNC1=NC(=NC2=C1C=C(N2)C(=O)N3CCN(CC3)CCCC4=CC=CC=C4)C5=CC=CC=C5
DM4BY5J IK MIUCZFWBCFZKEU-UHFFFAOYSA-N
DM4BY5J IU N-[2-[[2-phenyl-6-[4-(3-phenylpropyl)piperazine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]ethyl]acetamide
DM4BY5J DE Discovery agent
DM5L7D3 ID DM5L7D3
DM5L7D3 DN [3H]oxotremorine-M
DM5L7D3 HS Investigative
DM5L7D3 SN Oxotremorine M; oxotremorine-M; CHEBI:38322; N,N,N-trimethyl-4-(2-oxopyrrolidin-1-yl)but-2-yn-1-aminium; 63939-65-1; trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium; N,N,N-Trimethyl-4-(2-oxo-1-pyrrolidinyl)-2-butyn-1-aminium; 2-Butyn-1-aminium, N,N,N-trimethyl-4-(2-oxo-1-pyrrolidinyl)-; CHEMBL23957; Tocris-1067; Spectrum_001982; OXO-M; Lopac-O-100; AC1L1ILG; AC1Q6FK0; Lopac0_000954; GTPL303; KBioSS_002548; CHEMBL44674; DivK1c_000379; SCHEMBL4542695; GTPL8595; KBio2_005107; KBio2_002539; KBio1_000379
DM5L7D3 DT Small molecular drug
DM5L7D3 PC 4629
DM5L7D3 MW 195.28
DM5L7D3 FM C11H19N2O+
DM5L7D3 IC InChI=1S/C11H19N2O/c1-13(2,3)10-5-4-8-12-9-6-7-11(12)14/h6-10H2,1-3H3/q+1
DM5L7D3 CS C[N+](C)(C)CC#CCN1CCCC1=O
DM5L7D3 IK CANZROMYQDHYHR-UHFFFAOYSA-N
DM5L7D3 IU trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium
DM5L7D3 CA CAS 63939-65-1
DM5L7D3 CB CHEBI:38322
DM5L7D3 DE Discovery agent
DMK46C7 ID DMK46C7
DMK46C7 DN [3H]PBC-264
DMK46C7 HS Investigative
DMK46C7 SN [3H]propionyl-BC-264; [3H]-Propionyl-BC264; [3H]-Propionyl-BC-264
DMK46C7 DT Small molecular drug
DMK46C7 PC 5748434
DMK46C7 MW 1072.2
DMK46C7 FM C51H67N9O14S
DMK46C7 IC InChI=1S/C51H67N9O14S/c1-5-8-18-37(52-4)46(65)57-41(28-45(63)64)47(66)56-39(25-31-15-11-10-12-16-31)49(68)60-50(69)40(27-33-29-53-36-19-14-13-17-35(33)36)58-51(70)42(61)30-54-43(20-9-6-2)59-48(67)38(55-44(62)7-3)26-32-21-23-34(24-22-32)74-75(71,72)73/h10-17,19,21-24,29,37-41,43,52-54H,5-9,18,20,25-28,30H2,1-4H3,(H,55,62)(H,56,66)(H,57,65)(H,58,70)(H,59,67)(H,63,64)(H,60,68,69)(H,71,72,73)/t37-,38-,39-,40-,41-,43-/m0/s1/i3T3,7T2
DMK46C7 CS [3H]C([3H])([3H])C([3H])([3H])C(=O)N[C@@H](CC1=CC=C(C=C1)OS(=O)(=O)O)C(=O)N[C@@H](CCCC)NCC(=O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCC)NC
DMK46C7 IK VNNMDTHCFFZSSJ-LWSGDBLMSA-N
DMK46C7 IU (3S)-4-[[(2S)-1-[[(2S)-3-(1H-indol-3-yl)-2-[[2-oxo-3-[[(1S)-1-[[(2S)-2-(2,2,3,3,3-pentatritiopropanoylamino)-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]propanoyl]amino]propanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-(methylamino)hexanoyl]amino]-4-oxobutanoic acid
DMK46C7 CA CAS 125236-85-3
DMK46C7 DE Discovery agent
DMWAT5S ID DMWAT5S
DMWAT5S DN [3H]PD140376
DMWAT5S HS Investigative
DMWAT5S SN [3H]PD 140376; [3H]-PD140,376
DMWAT5S DT Small molecular drug
DMWAT5S PC 91827344
DMWAT5S MW 576.7
DMWAT5S FM C33H40N4O5
DMWAT5S IC InChI=1S/C33H40N4O5/c1-33(17-24-18-35-28-5-3-2-4-27(24)28,31(40)36-26(16-29(38)39)15-19-6-8-25(34)9-7-19)37-32(41)42-30-22-11-20-10-21(13-22)14-23(30)12-20/h2-9,18,20-23,26,30,35H,10-17,34H2,1H3,(H,36,40)(H,37,41)(H,38,39)/t20?,21?,22?,23?,26-,30?,33+/m0/s1/i8T,9T
DMWAT5S CS [3H]C1=CC(=CC(=C1N)[3H])C[C@@H](CC(=O)O)NC(=O)[C@@](C)(CC2=CNC3=CC=CC=C32)NC(=O)OC4C5CC6CC(C5)CC4C6
DMWAT5S IK ADYHBZJCWPIGJS-CXVPADNPSA-N
DMWAT5S IU (3S)-3-[[(2R)-2-(2-adamantyloxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-amino-3,5-ditritiophenyl)butanoic acid
DMWAT5S DE Discovery agent
DMF4TWE ID DMF4TWE
DMF4TWE DN [3H]pentazocine
DMF4TWE HS Investigative
DMF4TWE SN (+)-[3H]-Pentazocine; [3H]-(+)-Pentazocine; CHEMBL2311194; [3H]pentazocine
DMF4TWE DT Small molecular drug
DMF4TWE PC 71717297
DMF4TWE MW 289.4
DMF4TWE FM C19H27NO
DMF4TWE IC InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m1/s1/i6T,12T
DMF4TWE CS [3H]C1=CC2=C(C(=C1O)[3H])[C@]3(CCN([C@@H](C2)[C@H]3C)CC=C(C)C)C
DMF4TWE IK VOKSWYLNZZRQPF-BXKNQVALSA-N
DMF4TWE IU (1S,9S,13S)-1,13-dimethyl-10-(3-methylbut-2-enyl)-3,5-ditritio-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMF4TWE DE Discovery agent
DMPE1B2 ID DMPE1B2
DMPE1B2 DN [3H]PGF2alpha
DMPE1B2 HS Investigative
DMPE1B2 SN [3H]dinoprost; [3H]prostaglandin F2alpha
DMPE1B2 DT Small molecular drug
DMPE1B2 PC 10832988
DMPE1B2 MW 370.5
DMPE1B2 FM C20H34O5
DMPE1B2 IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1/i4T,7T,12T,15T,16T,17T,18T,19T
DMPE1B2 CS [3H]/C(=C(\\[3H])/C[C@]1([C@@](C[C@@]([C@]1([3H])/C=C(\\[3H])/[C@]([3H])(CCCCC)O)([3H])O)([3H])O)[3H])/CCCC(=O)O
DMPE1B2 IK PXGPLTODNUVGFL-WEMOGKSOSA-N
DMPE1B2 IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-2,3-ditritiooct-1-enyl]-1,2,3,5-tetratritiocyclopentyl]-5,6-ditritiohept-5-enoic acid
DMPE1B2 DE Discovery agent
DMAMD5H ID DMAMD5H
DMAMD5H DN [3H]pirenzepine
DMAMD5H HS Investigative
DMAMD5H SN [3H]PZ
DMAMD5H DT Small molecular drug
DMAMD5H PC 53325462
DMAMD5H MW 357.4
DMAMD5H FM C19H21N5O2
DMAMD5H IC InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)/i1T3
DMAMD5H CS [3H]C([3H])([3H])N1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMAMD5H IK RMHMFHUVIITRHF-RLXJOQACSA-N
DMAMD5H IU 11-[2-[4-(tritritiomethyl)piperazin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMAMD5H DE Discovery agent
DM2LA9X ID DM2LA9X
DM2LA9X DN [3H]p-MPPF
DM2LA9X HS Investigative
DM2LA9X SN 155204-26-5; p-MPPF; MPPF; CHEMBL286607; UNII-81KHI46E5L; 81KHI46E5L; 4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide; 4-Fluoro-N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl)benzamide; 4-Fluoro-N-{2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethyl}-N-pyridin-2-yl-benzamide; [3H]p-MPPF; MPPF authentic; Lopac-M-226; GTPL81; AC1O7G4Q; Lopac0_000825; SCHEMBL4014204; CTK4C8576; DTXSID20424966; ZINC52542163; BDBM50035513; AKOS022184256; CCG-204909; FC-1062; NCGC00162265-01; NCGC00015641-03
DM2LA9X DT Small molecular drug
DM2LA9X PC 6603915
DM2LA9X MW 434.5
DM2LA9X FM C25H27FN4O2
DM2LA9X IC InChI=1S/C25H27FN4O2/c1-32-23-7-3-2-6-22(23)29-17-14-28(15-18-29)16-19-30(24-8-4-5-13-27-24)25(31)20-9-11-21(26)12-10-20/h2-13H,14-19H2,1H3
DM2LA9X CS COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4=CC=C(C=C4)F
DM2LA9X IK YJZYDPRMWYWYCG-UHFFFAOYSA-N
DM2LA9X IU 4-fluoro-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylbenzamide
DM2LA9X CA CAS 155204-26-5
DM2LA9X DE Discovery agent
DMP98AQ ID DMP98AQ
DMP98AQ DN [3H]PSB-0413
DMP98AQ HS Investigative
DMP98AQ SN [3H]AR-C67085; [3H]AR-C67085MX
DMP98AQ DT Small molecular drug
DMP98AQ PC 44405630
DMP98AQ MW 658.3
DMP98AQ FM C14H22Cl2N5O12P3S
DMP98AQ IC InChI=1S/C14H22Cl2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1/i1T3,2T2
DMP98AQ CS [3H]C([3H])([3H])C([3H])([3H])CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)N
DMP98AQ IK ZLIAJZQKKBOFJR-WNJXVAICSA-N
DMP98AQ IU [[[[(2R,3S,4R,5R)-5-[6-amino-2-(2,2,3,3,3-pentatritiopropylsulfanyl)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid
DMP98AQ DE Discovery agent
DMFDCJK ID DMFDCJK
DMFDCJK DN [3H]PSB-11
DMFDCJK HS Investigative
DMFDCJK DT Small molecular drug
DMFDCJK PC 135921139
DMFDCJK MW 295.34
DMFDCJK FM C16H17N5O
DMFDCJK IC InChI=1S/C16H17N5O/c1-3-11-9-21-15(17-11)12-14(20(2)16(21)22)19-13(18-12)10-7-5-4-6-8-10/h4-8,11,17H,3,9H2,1-2H3
DMFDCJK CS CCC1CN2C(=C3C(=NC(=N3)C4=CC=CC=C4)N(C2=O)C)N1
DMFDCJK IK XNWDEMWJNJVCBD-UHFFFAOYSA-N
DMFDCJK IU 8-ethyl-4-methyl-2-phenyl-8,9-dihydro-7H-imidazo[2,1-f]purin-5-one
DMFDCJK DE Discovery agent
DMC1WHR ID DMC1WHR
DMC1WHR DN [3H]QNB
DMC1WHR HS Investigative
DMC1WHR SN 3-Quinuclidinyl benzilate; 6581/6/2; 3-Chinuclidylbenzilate; 3-Quinuclidyl benzilate; 3-quinuclidinylbenzilate; 3-Quinuclidinol benzilate; Ro 2-3308; CHEMBL12980; Benzilic acid, 3-quinuclidinyl ester; (+/-)-QNB; NSC 173698; QNB; EA 2277; CS 4030; BZ; 1-Azabicyclo(222)octan-3-ol, benzilate; Buzz; Agent BZ; 1-azabicyclo[222]octan-3-yl 2-hydroxy-2,2-diphenylacetate; BZ [anticholinergic]; 4478-53-9; NSC170423; Benzilic acid, 3-quinuclidinyl ester, (+-)-; 3-quinuclidinyl-benzilate; [3H]quinuclidinylbenzilate; Benzeneacetic; [3H]quinuclidinylbenzilate
DMC1WHR DT Small molecular drug
DMC1WHR PC 23056
DMC1WHR MW 337.4
DMC1WHR FM C21H23NO3
DMC1WHR IC InChI=1S/C21H23NO3/c23-20(25-19-15-22-13-11-16(19)12-14-22)21(24,17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-10,16,19,24H,11-15H2
DMC1WHR CS C1CN2CCC1C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMC1WHR IK HGMITUYOCPPQLE-UHFFFAOYSA-N
DMC1WHR IU 1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2,2-diphenylacetate
DMC1WHR CA CAS 6581-06-2
DMC1WHR DE Discovery agent
DMDQBTX ID DMDQBTX
DMDQBTX DN [3H]quisqualate
DMDQBTX HS Investigative
DMDQBTX SN Quisqualic acid; QUISQUALIC ACID; Quisqualate; L-Quisqualic acid; 52809-07-1; (+)-Quisqualic acid; UNII-8OC22C1B99; C5H7N3O5; CHEBI:8734; CHEMBL279956; 8OC22C1B99; (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid; 3-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine; 2jbk; 1,2,4-Oxadiazolidine-2-propanoic acid, alpha-amino-3,5-dioxo-, (S)-; (S)-2-AMINO-3-(3,5-DIOXO-[1,2,4]OXADIAZOLIDIN-2-YL)-PROPIONIC ACID; 2or4; AC1ODZB5; (S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid; QUS; SR-01000075471; QUISQUALATE
DMDQBTX DT Small molecular drug
DMDQBTX PC 40539
DMDQBTX MW 189.13
DMDQBTX FM C5H7N3O5
DMDQBTX IC InChI=1S/C5H7N3O5/c6-2(3(9)10)1-8-4(11)7-5(12)13-8/h2H,1,6H2,(H,9,10)(H,7,11,12)/t2-/m0/s1
DMDQBTX CS C([C@@H](C(=O)O)N)N1C(=O)NC(=O)O1
DMDQBTX IK ASNFTDCKZKHJSW-REOHCLBHSA-N
DMDQBTX IU (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
DMDQBTX CA CAS 52809-07-1
DMDQBTX CB CHEBI:8734
DMDQBTX DE Discovery agent
DM21B46 ID DM21B46
DM21B46 DN [3H]ramosetron
DM21B46 HS Investigative
DM21B46 SN [3H]ramosetron
DM21B46 DT Small molecular drug
DM21B46 PC 91827343
DM21B46 MW 285.36
DM21B46 FM C17H17N3O
DM21B46 IC InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1/i1T3
DM21B46 CS [3H]C([3H])([3H])N1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
DM21B46 IK NTHPAPBPFQJABD-WENCKANPSA-N
DM21B46 IU [(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]-[1-(tritritiomethyl)indol-3-yl]methanone
DM21B46 DE Discovery agent
DMBQZ2H ID DMBQZ2H
DMBQZ2H DN [3H]rauwolscine
DMBQZ2H HS Investigative
DMBQZ2H SN Rauwolscine; alpha-Yohimbine; Mesoyohimbine; Isoyohimbine; Corynanthidine; 131-03-3; UNII-T4LJ7LU45W; Methyl (16beta,17alpha,20alpha)-17-hydroxyyohimban-16-carboxylate; T4LJ7LU45W; CHEMBL10347; CHEBI:48562; 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylic acid methyl ester; NCGC00017260-05; methyl 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylate; 17-alpha-Hydroxy-20-alpha-yohimban-16-beta-carboxylic acid methyl ester; EINECS 205-006-9; 20-alpha-Yohimban-16-beta-carboxylic acid, 17-alpha-hydroxy-, methyl ester
DMBQZ2H DT Small molecular drug
DMBQZ2H PC 643606
DMBQZ2H MW 354.4
DMBQZ2H FM C21H26N2O3
DMBQZ2H IC InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15+,17+,18+,19+/m1/s1
DMBQZ2H CS COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
DMBQZ2H IK BLGXFZZNTVWLAY-DIRVCLHFSA-N
DMBQZ2H IU methyl (1S,15S,18S,19S,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
DMBQZ2H CA CAS 131-03-3
DMBQZ2H CB CHEBI:48562
DMBQZ2H DE Discovery agent
DMFT0HU ID DMFT0HU
DMFT0HU DN [3H]resolvin D1
DMFT0HU HS Investigative
DMFT0HU SN OIWTWACQMDFHJG-LDOXQWQISA-N; RvD1; [3H]-RvD1; GTPL4356; GTPL3934; SCHEMBL13150511; (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic; OIWTWACQMDFHJG-LDOXQWQISA-N; (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid; resolvin D1
DMFT0HU DT Small molecular drug
DMFT0HU PC 73755062
DMFT0HU MW 376.5
DMFT0HU FM C22H32O5
DMFT0HU IC InChI=1S/C22H32O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-12,15-16,19-21,23-25H,2,13-14,17-18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,12-8-,15-10+,16-11+/t19-,20-,21-/m0/s1
DMFT0HU CS CC/C=C\\C[C@@H](/C=C/C=C\\C=C\\C=C\\[C@@H]([C@H](C/C=C\\CCC(=O)O)O)O)O
DMFT0HU IK OIWTWACQMDFHJG-LDOXQWQISA-N
DMFT0HU IU (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
DMFT0HU DE Discovery agent
DMAMK3P ID DMAMK3P
DMAMK3P DN [3H]resolvin E1
DMAMK3P HS Investigative
DMAMK3P SN Resolvin E1; RvE1; 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; UNII-GND3JH08JA; GND3JH08JA; 552830-51-0; resolvinE1; (5S,6Z,8E,10E,12R,14Z,16E,18R)-5,12,18-trihydroxyicosa-6,8,10,14,16-pentaenoic acid; 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-EPA; FA(20:5(OH3)); GTPL3333; SCHEMBL3321593; CHEBI:81559; ZINC56875015; LMFA03140003; DB13105; J2218407E; C18171; (5S,12R,18R)-trihydroxy-(6Z,8E,10E,14Z,16E)-eicosapentaenoic acid; (5S,12R,18R)-trihydroxy-(6Z,8E,10E,14Z,16E)-icosapentaenoic acid; [3H]RvE1; [(3)H]-labeled RvE1; resolvin E1
DMAMK3P DT Small molecular drug
DMAMK3P PC 52921890
DMAMK3P MW 350.4
DMAMK3P FM C20H30O5
DMAMK3P IC InChI=1S/C20H30O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,11-8+,12-6+,13-7-/t17-,18-,19+/m0/s1
DMAMK3P CS CC[C@@H](/C=C/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O)O
DMAMK3P IK AOPOCGPBAIARAV-JJVMZPRHSA-N
DMAMK3P IU (5S,6Z,8E,10E,12R,14Z,16E,18S)-5,12,18-trihydroxyicosa-6,8,10,14,16-pentaenoic acid
DMAMK3P CB CHEBI:137038
DM5XSMN ID DM5XSMN
DM5XSMN DN [3H]Ro 63-0563
DM5XSMN HS Investigative
DM5XSMN SN 4-Amino-N-[2,6-bis(methylamino)pyridin-4-yl]benzenesulfonamide; Ro-63-0563; Ro 63-0563; CHEMBL46071; 4-amino-N-[2,6-bis(methylamino)pyridin-4-yl]benzenesulfonamide; AC1NSM3I; GTPL275; SCHEMBL679027; GTPL3246; Ro630563; BDBM50090524; Ro-630563; L000518; 4-Amino-N-(2,6-diamino-pyridin-4-yl)-benzenesulfonamide; N-(2,6-bis(methylamino)pyridin-4-yl)-4-aminobenzenesulfonamide; 4-amino-N-(2,6 bis-methylamino-pyridin-4-yl)-benzene sulfonamide
DM5XSMN DT Small molecular drug
DM5XSMN PC 5312144
DM5XSMN MW 307.37
DM5XSMN FM C13H17N5O2S
DM5XSMN IC InChI=1S/C13H17N5O2S/c1-15-12-7-10(8-13(16-2)17-12)18-21(19,20)11-5-3-9(14)4-6-11/h3-8H,14H2,1-2H3,(H3,15,16,17,18)
DM5XSMN CS CNC1=CC(=CC(=N1)NC)NS(=O)(=O)C2=CC=C(C=C2)N
DM5XSMN IK PTFNKZLSFWJYFJ-UHFFFAOYSA-N
DM5XSMN IU 4-amino-N-[2,6-bis(methylamino)pyridin-4-yl]benzenesulfonamide
DM5XSMN DE Discovery agent
DMMBWKL ID DMMBWKL
DMMBWKL DN [3H]Ro154513
DMMBWKL HS Investigative
DMMBWKL SN Ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ro 15-4513; RO-154513; Ro15-4513; 91917-65-6; UNII-S5XGL82O5Y; S5XGL82O5Y; Ethyl-8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-1,4-benzodiazepine-3-carboxylate; ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ethyl 8-azido-6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; Ethyl 8-azido-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate; Ro-154513
DMMBWKL DT Small molecular drug
DMMBWKL PC 5081
DMMBWKL MW 326.31
DMMBWKL FM C15H14N6O3
DMMBWKL IC InChI=1S/C15H14N6O3/c1-3-24-15(23)13-12-7-20(2)14(22)10-6-9(18-19-16)4-5-11(10)21(12)8-17-13/h4-6,8H,3,7H2,1-2H3
DMMBWKL CS CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)N=[N+]=[N-])C
DMMBWKL IK CFSOJZTUTOQNIA-UHFFFAOYSA-N
DMMBWKL IU ethyl 8-azido-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMMBWKL CA CAS 91917-65-6
DMMBWKL CB CHEBI:93452
DMMBWKL DE Discovery agent
DMK1TRG ID DMK1TRG
DMK1TRG DN [3H]robalzotan
DMK1TRG HS Investigative
DMK1TRG SN [3H]NAD-299; [3H]NAD 299
DMK1TRG DT Small molecular drug
DMK1TRG PC 10591800
DMK1TRG MW 320.4
DMK1TRG FM C18H23FN2O2
DMK1TRG IC InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1/i7T
DMK1TRG CS [3H]C1=CC(=C2C(=C1C(=O)N)C[C@H](CO2)N(C3CCC3)C4CCC4)F
DMK1TRG IK MQTUXRKNJYPMCG-FZQCOGARSA-N
DMK1TRG IU (3R)-3-[di(cyclobutyl)amino]-8-fluoro-6-tritio-3,4-dihydro-2H-chromene-5-carboxamide
DMK1TRG DE Discovery agent
DM6IRN4 ID DM6IRN4
DM6IRN4 DN [3H]RX821002
DM6IRN4 HS Investigative
DM6IRN4 SN 2-Methoxyidazoxan; RX-821002; RX 821002; 102575-24-6; RX821002; alpha-methoxyidazoxan; RX 821001; CHEMBL10332; CHEBI:73287; 2-(2,3-Dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-; 2-[2-(2-methoxy-1,4-benzodioxanyl)]imidazoline; 2-(2-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; [3H]2-methoxyidazoxan; 2-(2-methoxy-3H-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; 2-ethoxy-idazoxan; PubChem2676; Spectrum_001808; [3H]2-methoxyidazoxan
DM6IRN4 DT Small molecular drug
DM6IRN4 PC 108094
DM6IRN4 MW 234.25
DM6IRN4 FM C12H14N2O3
DM6IRN4 IC InChI=1S/C12H14N2O3/c1-15-12(11-13-6-7-14-11)8-16-9-4-2-3-5-10(9)17-12/h2-5H,6-8H2,1H3,(H,13,14)
DM6IRN4 CS COC1(COC2=CC=CC=C2O1)C3=NCCN3
DM6IRN4 IK HQGWKNGAKBPTBX-UHFFFAOYSA-N
DM6IRN4 IU 2-(3-methoxy-2H-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole
DM6IRN4 CA CAS 102575-24-6
DM6IRN4 CB CHEBI:73287
DM6IRN4 DE Discovery agent
DMJKWNY ID DMJKWNY
DMJKWNY DN [3H]RY80
DMJKWNY HS Investigative
DMJKWNY SN CHEMBL286594; ethyl 8-ethynyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; RY80; [3H]RY80; AC1NSKLC; SCHEMBL7454519; GTPL4364; BDBM25877; RY-80; PDSP2_001730; PDSP1_001747; RY-80, 1; LS-193636; ethyl 8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate; ethyl 12-ethynyl-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,10,12-pentaene-5-carboxylate
DMJKWNY DT Small molecular drug
DMJKWNY PC 5311418
DMJKWNY MW 309.32
DMJKWNY FM C17H15N3O3
DMJKWNY IC InChI=1S/C17H15N3O3/c1-4-11-6-7-13-12(8-11)16(21)19(3)9-14-15(17(22)23-5-2)18-10-20(13)14/h1,6-8,10H,5,9H2,2-3H3
DMJKWNY CS CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)C#C)C
DMJKWNY IK WDTNKNNGHGOKBH-UHFFFAOYSA-N
DMJKWNY IU ethyl 8-ethynyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMJKWNY DE Discovery agent
DM32IAB ID DM32IAB
DM32IAB DN [3H]S0139
DM32IAB HS Investigative
DM32IAB SN [3H]-S0139; [3H]S-0139
DM32IAB DT Small molecular drug
DM32IAB PC 73755056
DM32IAB MW 727.9
DM32IAB FM C43H53NO9-2
DM32IAB IC InChI=1S/C43H55NO9/c1-38(2)19-20-42(37(51)52)21-22-43(25-53-36(50)14-7-26-23-27(45)8-10-30(26)44-34(47)12-13-35(48)49)28(29(42)24-38)9-11-32-40(5)17-16-33(46)39(3,4)31(40)15-18-41(32,43)6/h7-10,12-14,23,29,31-32,45H,11,15-22,24-25H2,1-6H3,(H,44,47)(H,48,49)(H,51,52)/p-2/b13-12+,14-7+/t29-,31?,32?,40-,41+,42-,43-/m0/s1
DM32IAB CS C[C@]12CCC(=O)C(C1CC[C@@]3(C2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)[O-])COC(=O)/C=C/C6=C(C=CC(=C6)[O-])NC(=O)/C=C/C(=O)O)C)(C)C
DM32IAB IK NZCHLXQRTYIWRL-VDJOMVRUSA-L
DM32IAB IU (4aS,6aR,6bR,12aR,14bS)-6a-[[(E)-3-[2-[[(E)-3-carboxyprop-2-enoyl]amino]-5-oxidophenyl]prop-2-enoyl]oxymethyl]-2,2,6b,9,9,12a-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylate
DM32IAB DE Discovery agent
DMO9L38 ID DMO9L38
DMO9L38 DN [3H]SB-674042
DMO9L38 HS Investigative
DMO9L38 SN CHEMBL2413521; [3H]SB-674042; GTPL1706
DMO9L38 DT Small molecular drug
DMO9L38 PC 73349109
DMO9L38 MW 452.5
DMO9L38 FM C24H21FN4O2S
DMO9L38 IC InChI=1S/C24H21FN4O2S/c1-15-26-21(22(32-15)18-11-5-6-12-19(18)25)24(30)29-13-7-10-17(29)14-20-27-28-23(31-20)16-8-3-2-4-9-16/h2-6,8-9,11-12,17H,7,10,13-14H2,1H3/t17-/m0/s1/i8T,9T
DMO9L38 CS [3H]C1=C(C(=CC=C1)[3H])C2=NN=C(O2)C[C@@H]3CCCN3C(=O)C4=C(SC(=N4)C)C5=CC=CC=C5F
DMO9L38 IK HYBZWVLPALMACV-JQGZANCBSA-N
DMO9L38 IU [(2S)-2-[[5-(2,6-ditritiophenyl)-1,3,4-oxadiazol-2-yl]methyl]pyrrolidin-1-yl]-[5-(2-fluorophenyl)-2-methyl-1,3-thiazol-4-yl]methanone
DMO9L38 DE Discovery agent
DMUS7EH ID DMUS7EH
DMUS7EH DN [3H]SB-733993
DMUS7EH HS Investigative
DMUS7EH SN [3H]-(2R)-3-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-2-hydroxy-S-(naphthalen-1-yl)propane-1-sulfonamido ; [3H]-SB-733993
DMUS7EH DT Small molecular drug
DMUS7EH PC 73755092
DMUS7EH MW 378.5
DMUS7EH FM C20H28N2O3S
DMUS7EH IC InChI=1S/C20H28N2O3S/c1-15-7-5-8-16(2)22(15)14-18(23)13-21-26(24,25)20-12-6-10-17-9-3-4-11-19(17)20/h3-4,6,9-12,15-16,18,21,23H,5,7-8,13-14H2,1-2H3/t15-,16+,18-/m1/s1/i10T
DMUS7EH CS [3H]C1=CC=C(C2=CC=CC=C12)S(=O)(=O)NC[C@H](CN3[C@@H](CCC[C@@H]3C)C)O
DMUS7EH IK GJXFPIGLCXZHTN-LDHSEPLKSA-N
DMUS7EH IU N-[(2S)-3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]-2-hydroxypropyl]-4-tritionaphthalene-1-sulfonamide
DMUS7EH DE Discovery agent
DM0MLU9 ID DM0MLU9
DM0MLU9 DN [3H]SNAP-7941
DM0MLU9 HS Investigative
DM0MLU9 SN 387825-78-7; [3H]SNAP-7941; GTPL1318; ZINC65731246; KB-80596; methyl (6S)-6-(3,4-difluorophenyl)-4-(methoxymethyl)-2-oxo-1-[3-[4-[3-(propanoylamino)phenyl]piperidin-1-yl]propylcarbamoyl]-3,6-dihydropyrimidine-5-carboxylate
DM0MLU9 DT Small molecular drug
DM0MLU9 PC 10121975
DM0MLU9 MW 627.7
DM0MLU9 FM C32H39F2N5O6
DM0MLU9 IC InChI=1S/C32H39F2N5O6/c1-4-27(40)36-23-8-5-7-21(17-23)20-11-15-38(16-12-20)14-6-13-35-31(42)39-29(22-9-10-24(33)25(34)18-22)28(30(41)45-3)26(19-44-2)37-32(39)43/h5,7-10,17-18,20,29H,4,6,11-16,19H2,1-3H3,(H,35,42)(H,36,40)(H,37,43)/t29-/m0/s1
DM0MLU9 CS CCC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCNC(=O)N3[C@H](C(=C(NC3=O)COC)C(=O)OC)C4=CC(=C(C=C4)F)F
DM0MLU9 IK PTSDBXLVMLZQHY-LJAQVGFWSA-N
DM0MLU9 IU methyl (4S)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-3-[3-[4-[3-(propanoylamino)phenyl]piperidin-1-yl]propylcarbamoyl]-1,4-dihydropyrimidine-5-carboxylate
DM0MLU9 DE Discovery agent
DMWHEV8 ID DMWHEV8
DMWHEV8 DN [3H]spiperone
DMWHEV8 HS Investigative
DMWHEV8 SN Spiperone; spiperone; Spiroperidol; Spiropitan; 749-02-0; Espiperona; Spiperonum; [3H]-spiperone; R 5147; Spiperonum [INN-Latin]; Espiperona [INN-Spanish]; E 525; UNII-4X6E73CJ0Q; NSC 170983; MLS000028615; Spiperone [USAN:INN:BAN:JAN]; 8-(3-(p-Fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(45)decan-4-one; 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[45]decan-4-one; 8-(3-p-Fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane; EINECS 212-024-0; BRN 0632204; SMR000058674; [3H]-spiperone; SPIPERONE
DMWHEV8 DT Small molecular drug
DMWHEV8 PC 5265
DMWHEV8 MW 395.5
DMWHEV8 FM C23H26FN3O2
DMWHEV8 IC InChI=1S/C23H26FN3O2/c24-19-10-8-18(9-11-19)21(28)7-4-14-26-15-12-23(13-16-26)22(29)25-17-27(23)20-5-2-1-3-6-20/h1-3,5-6,8-11H,4,7,12-17H2,(H,25,29)
DMWHEV8 CS C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F
DMWHEV8 IK DKGZKTPJOSAWFA-UHFFFAOYSA-N
DMWHEV8 IU 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
DMWHEV8 CA CAS 749-02-0
DMWHEV8 CB CHEBI:9233
DMWHEV8 DE Discovery agent
DM0Y2SC ID DM0Y2SC
DM0Y2SC DN [3H]strychnine
DM0Y2SC HS Investigative
DM0Y2SC SN Strychnine; strychnine; 57-24-9; (-)-Strychnine; Strychnidin-10-one; Strychnin; UNII-H9Y79VD43J; Sanaseed; CHEBI:28973; Estricnina; Strychinos; Strychnos; Gopher-gitter; Gopher bait; Mouse-nots; Mole death; Boomer-rid; Mouse-rid; H9Y79VD43J; Mouse-tox; Kwik-kil; Hare-Rid; Dolco mouse cereal; Strychnin [German]; Stricnina [Italian]; Pied piper mouse seed; Caswell No 805; Strychnine [BSI:ISO]; RCRA waste number P108; (-)-Strychnine, 98%; HSDB 2001; NSC 5365; EINECS 200-319-7; UN1692; EPA Pesticide Chemical Code 076901; STRYCHNINE
DM0Y2SC DT Small molecular drug
DM0Y2SC PC 441071
DM0Y2SC MW 334.4
DM0Y2SC FM C21H22N2O2
DM0Y2SC IC InChI=1S/C21H22N2O2/c24-18-10-16-19-13-9-17-21(6-7-22(17)11-12(13)5-8-25-16)14-3-1-2-4-15(14)23(18)20(19)21/h1-5,13,16-17,19-20H,6-11H2/t13-,16-,17-,19-,20-,21+/m0/s1
DM0Y2SC CS C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75
DM0Y2SC IK QMGVPVSNSZLJIA-FVWCLLPLSA-N
DM0Y2SC IU (4aR,5aS,8aR,13aS,15aS,15bR)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one
DM0Y2SC CA CAS 57-24-9
DM0Y2SC CB CHEBI:28973
DM0Y2SC DE Discovery agent
DM3MBGV ID DM3MBGV
DM3MBGV DN [3H]sumatriptan
DM3MBGV HS Investigative
DM3MBGV SN [3H]sumatriptan; GTPL119
DM3MBGV DT Small molecular drug
DM3MBGV PC 53325948
DM3MBGV MW 307.45
DM3MBGV FM C14H21N3O2S
DM3MBGV IC InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3/i2T3,3T3
DM3MBGV CS [3H]C([3H])([3H])N(CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)NC)C([3H])([3H])[3H]
DM3MBGV IK KQKPFRSPSRPDEB-KERYDJPLSA-N
DM3MBGV IU 1-[3-[2-[bis(tritritiomethyl)amino]ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
DM3MBGV DE Discovery agent
DMSHW2E ID DMSHW2E
DMSHW2E DN [3H]thiamine
DMSHW2E HS Investigative
DMSHW2E SN thiamin; Aneurin; Antiberiberi factor; Thiadoxine; Betaxin; thiaminium; Vitaneuron; Biamine; Bequin; Bewon; Thiamine ion; thiamine(1+) ion; thiamine(1+); Clotiamina; Bethiazine; Vinothiam; Tiaminal; Thiaminal; Metabolin; Eskaphen; Bithiamin; Tiamidon; Thiavit; Benerva; Begiolan; Thiamol; Bivatin; Bevitine; Beatine; Slowten; Eskapen; Bevitex; Biuno; Berin; Bivita; Beuion; Bedome; Hybee; Apate drops; Lixa-beta; Vetalin S; Thiamin dichloride; [3H]-thiamine; [3H]vitamin B1
DMSHW2E DT Small molecular drug
DMSHW2E PC 1130
DMSHW2E MW 265.36
DMSHW2E FM C12H17N4OS+
DMSHW2E IC InChI=1S/C12H17N4OS/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15)/q+1
DMSHW2E CS CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO
DMSHW2E IK JZRWCGZRTZMZEH-UHFFFAOYSA-N
DMSHW2E IU 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
DMSHW2E CA CAS 70-16-6
DMSHW2E CB CHEBI:18385
DMSHW2E DE Discovery agent
DM6RSZ9 ID DM6RSZ9
DM6RSZ9 DN [3H]U69593
DM6RSZ9 HS Investigative
DM6RSZ9 SN U-69593; U69593; 96744-75-1; U 69593; UNII-J5S4K6TKTG; U 69,593; J5S4K6TKTG; N-Methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)benzeneacetamide; CHEBI:73357; n-methyl-2-phenyl-n-[(5r,7s,8s)-7-(pyrrolidin-1-yl)-1-oxaspiro[45]dec-8-yl]acetamide; Benzeneacetamide, N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(45)dec-8-yl)-, (5alpha,7alpha,8beta)-(-)-; NCGC00163179-01; DSSTox_CID_26326; DSSTox_RID_81542; U69,593; DSSTox_GSID_46326; [3H]-U69593
DM6RSZ9 DT Small molecular drug
DM6RSZ9 PC 105104
DM6RSZ9 MW 356.5
DM6RSZ9 FM C22H32N2O2
DM6RSZ9 IC InChI=1S/C22H32N2O2/c1-23(21(25)16-18-8-3-2-4-9-18)19-10-12-22(11-7-15-26-22)17-20(19)24-13-5-6-14-24/h2-4,8-9,19-20H,5-7,10-17H2,1H3/t19-,20-,22-/m0/s1
DM6RSZ9 CS CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC=CC=C4
DM6RSZ9 IK PGZRDDYTKFZSFR-ONTIZHBOSA-N
DM6RSZ9 IU N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
DM6RSZ9 CA CAS 96744-75-1
DM6RSZ9 CB CHEBI:73357
DM6RSZ9 DE Discovery agent
DM3MK8S ID DM3MK8S
DM3MK8S DN [3H]vesamicol
DM3MK8S HS Investigative
DM3MK8S SN [3H]-vesamicol
DM3MK8S DT Small molecular drug
DM3MK8S PC 54580503
DM3MK8S MW 261.39
DM3MK8S FM C17H25NO
DM3MK8S IC InChI=1S/C17H25NO/c19-17-9-5-4-8-16(17)18-12-10-15(11-13-18)14-6-2-1-3-7-14/h1-3,6-7,15-17,19H,4-5,8-13H2/i19T
DM3MK8S CS [3H]OC1CCCCC1N2CCC(CC2)C3=CC=CC=C3
DM3MK8S IK YSSBJODGIYRAMI-SETVJMCQSA-N
DM3MK8S IU 4-phenyl-1-(2-tritiooxycyclohexyl)piperidine
DM3MK8S DE Discovery agent
DMI8RU0 ID DMI8RU0
DMI8RU0 DN [3H]WIN35428
DMI8RU0 HS Investigative
DMI8RU0 SN beta-Cft; Win 35428; 2-Cmft; 50370-56-4; 2-CFT; WIN 35,428; 2-Carbomethoxy-3-(4-fluorophenyl)tropane; (3H)2-Carbomethoxy-3-(4-fluorophenyl)tropane; (1R,2S,3S,5S)-Methyl 3-(4-fluorophenyl)-8-methyl-8-azabicyclo[321]octane-2-carboxylate; 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane; WIN35428; methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[321]octane-2-carboxylate; [3H]WIN 35,428; (1R-(exo,exo))-3-(4-Fluorophenyl)-8-methyl-8-azabicyclo(321)octane-2-carboxylic acid, methyl ester; [3H]-2beta-carboxymethy-3beta-(4-fluorophenyl)tropane ; [3H]-WIN35428 ; [3H]-beta-CFT; WIN_35428
DMI8RU0 DT Small molecular drug
DMI8RU0 PC 105056
DMI8RU0 MW 277.33
DMI8RU0 FM C16H20FNO2
DMI8RU0 IC InChI=1S/C16H20FNO2/c1-18-12-7-8-14(18)15(16(19)20-2)13(9-12)10-3-5-11(17)6-4-10/h3-6,12-15H,7-9H2,1-2H3/t12-,13+,14+,15-/m0/s1
DMI8RU0 CS CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(C=C3)F)C(=O)OC
DMI8RU0 IK QUSLQENMLDRCTO-YJNKXOJESA-N
DMI8RU0 IU methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
DMI8RU0 CA CAS 50370-56-4
DMI8RU0 DE Discovery agent
DM0TRAZ ID DM0TRAZ
DM0TRAZ DN [3H]WIN55212-2
DM0TRAZ HS Investigative
DM0TRAZ SN 131513-18-3; (5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; (5-Methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino-[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone; [5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone; 134959-51-6; AC1Q5GBM; AC1L1KWZ; GTPL736; SCHEMBL3680086; CHEMBL283206; CTK4B9570; HQVHOQAKMCMIIM-UHFFFAOYSA-N
DM0TRAZ DT Small molecular drug
DM0TRAZ PC 5689
DM0TRAZ MW 426.5
DM0TRAZ FM C27H26N2O3
DM0TRAZ IC InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3
DM0TRAZ CS CC1=C(C2=C3N1C(COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65
DM0TRAZ IK HQVHOQAKMCMIIM-UHFFFAOYSA-N
DM0TRAZ IU [2-methyl-11-(morpholin-4-ylmethyl)-9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraen-3-yl]-naphthalen-1-ylmethanone
DM0TRAZ DE Discovery agent
DMKU4YQ ID DMKU4YQ
DMKU4YQ DN [3H]ZM 241385
DMKU4YQ HS Investigative
DMKU4YQ SN [3H]-ZM241385
DMKU4YQ DT Small molecular drug
DMKU4YQ PC 53316647
DMKU4YQ MW 339.34
DMKU4YQ FM C16H15N7O2
DMKU4YQ IC InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22)/i5T
DMKU4YQ CS [3H]C1=CC(=CC=C1O)CCNC2=NC3=NC(=NN3C(=N2)N)C4=CC=CO4
DMKU4YQ IK PWTBZOIUWZOPFT-XHHURNKPSA-N
DMKU4YQ IU 4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-tritiophenol
DMKU4YQ DE Discovery agent
DMNCAE9 ID DMNCAE9
DMNCAE9 DN [4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid
DMNCAE9 HS Investigative
DMNCAE9 SN CHEMBL478147; [4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid; SCHEMBL12932182; BDBM50267207
DMNCAE9 DT Small molecular drug
DMNCAE9 PC 44582486
DMNCAE9 MW 328.4
DMNCAE9 FM C19H24N2O3
DMNCAE9 IC InChI=1S/C19H24N2O3/c22-17(23)8-12-1-3-16(4-2-12)20-18(24)21-19-9-13-5-14(10-19)7-15(6-13)11-19/h1-4,13-15H,5-11H2,(H,22,23)(H2,20,21,24)
DMNCAE9 CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=C(C=C4)CC(=O)O
DMNCAE9 IK QDEKKGRIPYLLDK-UHFFFAOYSA-N
DMNCAE9 IU 2-[4-(1-adamantylcarbamoylamino)phenyl]acetic acid
DMNCAE9 DE Discovery agent
DM7JSQL ID DM7JSQL
DM7JSQL DN [4',4''']-biflavone
DM7JSQL HS Investigative
DM7JSQL SN CHEMBL205219; [4'',4'''''']-biflavone; BDBM50183248
DM7JSQL DT Small molecular drug
DM7JSQL PC 11962186
DM7JSQL MW 442.5
DM7JSQL FM C30H18O4
DM7JSQL IC InChI=1S/C30H18O4/c31-25-17-29(33-27-7-3-1-5-23(25)27)21-13-9-19(10-14-21)20-11-15-22(16-12-20)30-18-26(32)24-6-2-4-8-28(24)34-30/h1-18H
DM7JSQL CS C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CC(=O)C6=CC=CC=C6O5
DM7JSQL IK HTPYEYLGDZAIRX-UHFFFAOYSA-N
DM7JSQL IU 2-[4-[4-(4-oxochromen-2-yl)phenyl]phenyl]chromen-4-one
DM7JSQL CA CAS 1109-30-4
DM7JSQL DE Discovery agent
DM86Z4H ID DM86Z4H
DM86Z4H DN [4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix
DM86Z4H HS Investigative
DM86Z4H SN CHEMBL409044; [4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix
DM86Z4H PC 16155593
DM86Z4H MW 1768.4
DM86Z4H FM C88H119ClN18O19
DM86Z4H IC InChI=1S/C88H119ClN18O19/c1-53(2)44-68(78(112)99-67(17-10-11-35-93-54(3)4)86(120)107-37-13-18-75(107)85(119)95-55(5)77(90)111)100-80(114)71(47-59-24-31-66(32-25-59)98-87(91)121)102-82(116)72(48-58-22-29-65(30-23-58)97-76(110)33-38-124-40-42-126-43-41-125-39-36-94-88(122)106-123-7)104-84(118)74(52-108)105-83(117)73(50-61-14-12-34-92-51-61)103-81(115)70(46-57-20-27-64(89)28-21-57)101-79(113)69(96-56(6)109)49-60-19-26-62-15-8-9-16-63(62)45-60/h8-9,12,14-16,19-32,34,45,51,53-55,67-75,93,108H,10-11,13,17-18,33,35-44,46-50,52H2,1-7H3,(H2,90,111)(H,95,119)(H,96,109)(H,97,110)(H,99,112)(H,100,114)(H,101,113)(H,102,116)(H,103,115)(H,104,118)(H,105,117)(H3,91,98,121)(H2,94,106,122)/t55-,67+,68+,69-,70-,71-,72+,73-,74+,75+/m1/s1
DM86Z4H CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)CCOCCOCCOCCNC(=O)NOC)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM86Z4H IK UZNPTQUBATXHSV-POQOSWQFSA-N
DM86Z4H IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[3-[2-[2-[2-(methoxycarbamoylamino)ethoxy]ethoxy]ethoxy]propanoylamino]phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM86Z4H DE Discovery agent
DM4IXJA ID DM4IXJA
DM4IXJA DN [4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix
DM4IXJA HS Investigative
DM4IXJA SN CHEMBL219532; [4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix
DM4IXJA PC 16202050
DM4IXJA MW 1651.3
DM4IXJA FM C84H112ClN17O16
DM4IXJA IC InChI=1S/C84H112ClN17O16/c1-8-117-39-40-118-38-36-90-84(116)94-63-32-25-56(26-33-63)45-69(78(110)98-68(44-55-23-30-62(31-24-55)93-83(87)115)76(108)96-65(41-50(2)3)74(106)95-64(18-11-12-35-89-51(4)5)82(114)102-37-14-19-72(102)81(113)91-52(6)73(86)105)100-80(112)71(49-103)101-79(111)70(47-58-15-13-34-88-48-58)99-77(109)67(43-54-21-28-61(85)29-22-54)97-75(107)66(92-53(7)104)46-57-20-27-59-16-9-10-17-60(59)42-57/h9-10,13,15-17,20-34,42,48,50-52,64-72,89,103H,8,11-12,14,18-19,35-41,43-47,49H2,1-7H3,(H2,86,105)(H,91,113)(H,92,104)(H,95,106)(H,96,108)(H,97,107)(H,98,110)(H,99,109)(H,100,112)(H,101,111)(H3,87,93,115)(H2,90,94,116)/t52-,64+,65+,66-,67-,68-,69+,70-,71+,72+/m1/s1
DM4IXJA CS CCOCCOCCNC(=O)NC1=CC=C(C=C1)C[C@@H](C(=O)N[C@H](CC2=CC=C(C=C2)NC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM4IXJA IK RTPDWFYCUSPDLA-CEUPRWEVSA-N
DM4IXJA IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[2-(2-ethoxyethoxy)ethylcarbamoylamino]phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM4IXJA DE Discovery agent
DM57TIU ID DM57TIU
DM57TIU DN [4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix
DM57TIU HS Investigative
DM57TIU SN CHEMBL219061; [4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix
DM57TIU PC 16156445
DM57TIU MW 1595.2
DM57TIU FM C80H104ClN17O16
DM57TIU IC InChI=1S/C80H104ClN17O16/c1-46(2)37-61(70(102)89-60(18-11-12-35-84-47(3)4)78(110)98-36-14-19-68(98)77(109)85-48(5)69(82)101)90-72(104)64(40-51-23-30-58(31-24-51)87-79(111)96-113-7)92-74(106)65(41-52-25-32-59(33-26-52)88-80(112)97-114-8)94-76(108)67(45-99)95-75(107)66(43-54-15-13-34-83-44-54)93-73(105)63(39-50-21-28-57(81)29-22-50)91-71(103)62(86-49(6)100)42-53-20-27-55-16-9-10-17-56(55)38-53/h9-10,13,15-17,20-34,38,44,46-48,60-68,84,99H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)(H2,87,96,111)(H2,88,97,112)/t48-,60+,61+,62-,63-,64-,65+,66-,67+,68+/m1/s1
DM57TIU CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)NOC)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)NOC)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM57TIU IK MBXSPUXZEDANHS-KHEFCMSFSA-N
DM57TIU IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-(methoxycarbamoylamino)phenyl]propanoyl]amino]-3-[4-(methoxycarbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM57TIU DE Discovery agent
DM6C8K1 ID DM6C8K1
DM6C8K1 DN [4Aph(CO-NH-OCH3)5]degarelix
DM6C8K1 HS Investigative
DM6C8K1 SN CHEMBL407661; [4Aph(CO-NH-OCH3)5]degarelix
DM6C8K1 PC 16155587
DM6C8K1 MW 1565.2
DM6C8K1 FM C79H102ClN17O15
DM6C8K1 IC InChI=1S/C79H102ClN17O15/c1-45(2)36-60(69(101)89-59(17-10-11-34-84-46(3)4)77(109)97-35-13-18-67(97)76(108)85-47(5)68(81)100)90-71(103)63(39-50-22-29-57(30-23-50)87-78(82)110)92-73(105)64(40-51-24-31-58(32-25-51)88-79(111)96-112-7)94-75(107)66(44-98)95-74(106)65(42-53-14-12-33-83-43-53)93-72(104)62(38-49-20-27-56(80)28-21-49)91-70(102)61(86-48(6)99)41-52-19-26-54-15-8-9-16-55(54)37-52/h8-9,12,14-16,19-33,37,43,45-47,59-67,84,98H,10-11,13,17-18,34-36,38-42,44H2,1-7H3,(H2,81,100)(H,85,108)(H,86,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,107)(H,95,106)(H3,82,87,110)(H2,88,96,111)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+/m1/s1
DM6C8K1 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)NOC)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM6C8K1 IK UXIBYNMMLXYZBN-PQAUVRRKSA-N
DM6C8K1 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-(methoxycarbamoylamino)phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM6C8K1 DE Discovery agent
DMFMB31 ID DMFMB31
DMFMB31 DN [4Aph(CO-NH-OH)5]degarelix
DMFMB31 HS Investigative
DMFMB31 SN CHEMBL429527; [4Aph(CO-NH-OH)5]degarelix
DMFMB31 PC 16156634
DMFMB31 MW 1551.2
DMFMB31 FM C78H100ClN17O15
DMFMB31 IC InChI=1S/C78H100ClN17O15/c1-44(2)35-59(68(100)88-58(16-9-10-33-83-45(3)4)76(108)96-34-12-17-66(96)75(107)84-46(5)67(80)99)89-70(102)62(38-49-21-28-56(29-22-49)86-77(81)109)91-72(104)63(39-50-23-30-57(31-24-50)87-78(110)95-111)93-74(106)65(43-97)94-73(105)64(41-52-13-11-32-82-42-52)92-71(103)61(37-48-19-26-55(79)27-20-48)90-69(101)60(85-47(6)98)40-51-18-25-53-14-7-8-15-54(53)36-51/h7-8,11,13-15,18-32,36,42,44-46,58-66,83,97,111H,9-10,12,16-17,33-35,37-41,43H2,1-6H3,(H2,80,99)(H,84,107)(H,85,98)(H,88,100)(H,89,102)(H,90,101)(H,91,104)(H,92,103)(H,93,106)(H,94,105)(H3,81,86,109)(H2,87,95,110)/t46-,58+,59+,60-,61-,62-,63+,64-,65+,66+/m1/s1
DMFMB31 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)NO)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMFMB31 IK WHBXYDIDMRDUDF-ZVSGBDDQSA-N
DMFMB31 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-(hydroxycarbamoylamino)phenyl]propanoyl]amino]-3-[4-(carbamoylamino)phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFMB31 DE Discovery agent
DMA9PW7 ID DMA9PW7
DMA9PW7 DN [6,3''']biflavone
DMA9PW7 HS Investigative
DMA9PW7 SN CHEMBL383336; [6,3'''''']biflavone; BDBM50183246
DMA9PW7 DT Small molecular drug
DMA9PW7 PC 23661736
DMA9PW7 MW 442.5
DMA9PW7 FM C30H18O4
DMA9PW7 IC InChI=1S/C30H18O4/c31-25-17-30(33-27-12-5-4-11-23(25)27)22-10-6-9-20(15-22)21-13-14-28-24(16-21)26(32)18-29(34-28)19-7-2-1-3-8-19/h1-18H
DMA9PW7 CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC(=CC=C4)C5=CC(=O)C6=CC=CC=C6O5
DMA9PW7 IK ATBFVHXRFRVXOQ-UHFFFAOYSA-N
DMA9PW7 IU 6-[3-(4-oxochromen-2-yl)phenyl]-2-phenylchromen-4-one
DMA9PW7 DE Discovery agent
DMVOX4L ID DMVOX4L
DMVOX4L DN [6,4''']biflavone
DMVOX4L HS Investigative
DMVOX4L SN CHEMBL205326; [6,4'''''']biflavone; BDBM50183245
DMVOX4L DT Small molecular drug
DMVOX4L PC 44410408
DMVOX4L MW 442.5
DMVOX4L FM C30H18O4
DMVOX4L IC InChI=1S/C30H18O4/c31-25-17-30(33-27-9-5-4-8-23(25)27)21-12-10-19(11-13-21)22-14-15-28-24(16-22)26(32)18-29(34-28)20-6-2-1-3-7-20/h1-18H
DMVOX4L CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=C(C=C4)C5=CC(=O)C6=CC=CC=C6O5
DMVOX4L IK YQQFWTHRAHFRMC-UHFFFAOYSA-N
DMVOX4L IU 6-[4-(4-oxochromen-2-yl)phenyl]-2-phenylchromen-4-one
DMVOX4L DE Discovery agent
DMUCAXT ID DMUCAXT
DMUCAXT DN [Aib7]OT
DMUCAXT HS Investigative
DMUCAXT SN CHEMBL395430; [Aib7]OT
DMUCAXT DT Small molecular drug
DMUCAXT PC 16737793
DMUCAXT MW 995.2
DMUCAXT FM C42H66N12O12S2
DMUCAXT IC InChI=1S/C42H66N12O12S2/c1-7-21(4)33-40(65)48-25(12-13-30(44)56)36(61)50-28(16-31(45)57)37(62)51-29(39(64)54-42(5,6)41(66)52-26(14-20(2)3)35(60)47-17-32(46)58)19-68-67-18-24(43)34(59)49-27(38(63)53-33)15-22-8-10-23(55)11-9-22/h8-11,20-21,24-29,33,55H,7,12-19,43H2,1-6H3,(H2,44,56)(H2,45,57)(H2,46,58)(H,47,60)(H,48,65)(H,49,59)(H,50,61)(H,51,62)(H,52,66)(H,53,63)(H,54,64)/t21-,24-,25-,26-,27-,28-,29-,33-/m0/s1
DMUCAXT CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMUCAXT IK VQOHKFLFXMHMBH-LQGOSMBMSA-N
DMUCAXT IU (4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-N-[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMUCAXT DE Discovery agent
DMHJEQL ID DMHJEQL
DMHJEQL DN [Asp6,Lys10]N/OFQ(1-13)NH2
DMHJEQL HS Investigative
DMHJEQL SN CHEMBL507269; [Asp6,Lys10]N/OFQ(1-13)NH2
DMHJEQL PC 25084509
DMHJEQL MW 1480.7
DMHJEQL FM C66H109N23O16
DMHJEQL IC InChI=1S/C66H109N23O16/c1-37(55(96)84-46(25-16-30-76-65(72)73)59(100)83-43(54(71)95)22-10-13-27-67)80-58(99)44(23-11-14-28-68)86-60(101)45(24-12-15-29-69)87-61(102)47(26-17-31-77-66(74)75)85-56(97)38(2)81-62(103)49(34-52(93)94)88-64(105)53(39(3)90)89-63(104)48(33-41-20-8-5-9-21-41)82-51(92)36-78-50(91)35-79-57(98)42(70)32-40-18-6-4-7-19-40/h4-9,18-21,37-39,42-49,53,90H,10-17,22-36,67-70H2,1-3H3,(H2,71,95)(H,78,91)(H,79,98)(H,80,99)(H,81,103)(H,82,92)(H,83,100)(H,84,96)(H,85,97)(H,86,101)(H,87,102)(H,88,105)(H,89,104)(H,93,94)(H4,72,73,76)(H4,74,75,77)/t37-,38-,39+,42-,43-,44-,45-,46-,47-,48-,49-,53-/m0/s1
DMHJEQL CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMHJEQL IK WSFUYLTYXFNGET-WYNMOEERSA-N
DMHJEQL IU (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoic acid
DMHJEQL DE Discovery agent
DMN70VT ID DMN70VT
DMN70VT DN [Au(CN)2]-
DMN70VT HS Investigative
DMN70VT PC 446142
DMN70VT MW 249
DMN70VT FM C2AuN2-
DMN70VT IC InChI=1S/2CN.Au/c2*1-2;/q2*-1;+1
DMN70VT CS [C-]#N.[C-]#N.[Au+]
DMN70VT IK QGIPNVHDSSGMAA-UHFFFAOYSA-N
DMN70VT IU gold(1+);dicyanide
DMN70VT CA CAS 14950-87-9
DMN70VT CB CHEBI:49491
DMN70VT DE Discovery agent
DMB78GP ID DMB78GP
DMB78GP DN [Bpa1]AngII
DMB78GP HS Investigative
DMB78GP SN CHEMBL1076612; [Bpa1]AngII
DMB78GP PC 46880540
DMB78GP MW 1182.4
DMB78GP FM C62H79N13O11
DMB78GP IC InChI=1S/C62H79N13O11/c1-5-37(4)52(59(83)71-48(33-43-34-66-35-68-43)60(84)75-29-13-19-50(75)57(81)72-49(61(85)86)32-38-14-8-6-9-15-38)74-56(80)47(31-40-22-26-44(76)27-23-40)70-58(82)51(36(2)3)73-55(79)46(18-12-28-67-62(64)65)69-54(78)45(63)30-39-20-24-42(25-21-39)53(77)41-16-10-7-11-17-41/h6-11,14-17,20-27,34-37,45-52,76H,5,12-13,18-19,28-33,63H2,1-4H3,(H,66,68)(H,69,78)(H,70,82)(H,71,83)(H,72,81)(H,73,79)(H,74,80)(H,85,86)(H4,64,65,67)/t37-,45-,46-,47-,48-,49-,50-,51-,52-/m0/s1
DMB78GP CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)N
DMB78GP IK SSPYRQDCPZQEBX-LWJOARRHSA-N
DMB78GP IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-benzoylphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMB78GP DE Discovery agent
DMV6NP1 ID DMV6NP1
DMV6NP1 DN [Cu(CN)2]-
DMV6NP1 HS Investigative
DMV6NP1 PC 60167587
DMV6NP1 MW 115.58
DMV6NP1 FM C2CuN2-
DMV6NP1 IC InChI=1S/2CN.Cu/c2*1-2;/q2*-1;+1
DMV6NP1 CS [C-]#N.[C-]#N.[Cu+]
DMV6NP1 IK FKUKJMKUXQUDHB-UHFFFAOYSA-N
DMV6NP1 IU copper(1+);dicyanide
DMV6NP1 CA CAS 18973-62-1
DMV6NP1 DE Discovery agent
DMQ8CD3 ID DMQ8CD3
DMQ8CD3 DN [Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid
DMQ8CD3 HS Investigative
DMQ8CD3 SN CHEMBL324703; [Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid; BDBM50020839
DMQ8CD3 DT Small molecular drug
DMQ8CD3 PC 44340887
DMQ8CD3 MW 292.29
DMQ8CD3 FM C14H16N2O5
DMQ8CD3 IC InChI=1S/C14H16N2O5/c17-13(18)9-15(10-5-1-2-6-10)14(19)11-7-3-4-8-12(11)16(20)21/h3-4,7-8,10H,1-2,5-6,9H2,(H,17,18)
DMQ8CD3 CS C1CCC(C1)N(CC(=O)O)C(=O)C2=CC=CC=C2[N+](=O)[O-]
DMQ8CD3 IK QLSOVPLMYSMOSO-UHFFFAOYSA-N
DMQ8CD3 IU 2-[cyclopentyl-(2-nitrobenzoyl)amino]acetic acid
DMQ8CD3 DE Discovery agent
DMWFGBC ID DMWFGBC
DMWFGBC DN [Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMWFGBC HS Investigative
DMWFGBC PC 16201387
DMWFGBC MW 1760.1
DMWFGBC FM C80H118N28O14S2
DMWFGBC IC InChI=1S/C80H118N28O14S2/c1-3-13-55(69(115)101-59(21-11-33-95-79(89)90)73(119)105-61(65(83)111)35-43-23-27-47(109)28-24-43)99-71(117)57(19-9-31-93-77(85)86)103-75(121)63(37-45-39-97-53-17-7-5-15-49(45)53)107-67(113)51(81)41-123-124-42-52(82)68(114)108-64(38-46-40-98-54-18-8-6-16-50(46)54)76(122)104-58(20-10-32-94-78(87)88)72(118)100-56(14-4-2)70(116)102-60(22-12-34-96-80(91)92)74(120)106-62(66(84)112)36-44-25-29-48(110)30-26-44/h5-8,15-18,23-30,39-40,51-52,55-64,97-98,109-110H,3-4,9-14,19-22,31-38,41-42,81-82H2,1-2H3,(H2,83,111)(H2,84,112)(H,99,117)(H,100,118)(H,101,115)(H,102,116)(H,103,121)(H,104,122)(H,105,119)(H,106,120)(H,107,113)(H,108,114)(H4,85,86,93)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t51-,52-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1
DMWFGBC CS CCC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N)N)N
DMWFGBC IK QUIHYEFPGVPGCQ-HCHGDIHTSA-N
DMWFGBC IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]pentanoyl]amino]-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-5-carbamimidamidopentanamide
DMWFGBC DE Discovery agent
DMFKTJ8 ID DMFKTJ8
DMFKTJ8 DN [D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix
DMFKTJ8 HS Investigative
DMFKTJ8 SN CHEMBL438239; [D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix
DMFKTJ8 PC 16156573
DMFKTJ8 MW 1748.4
DMFKTJ8 FM C88H115ClN18O18
DMFKTJ8 IC InChI=1S/C88H115ClN18O18/c1-8-124-39-40-125-38-36-93-87(122)97-64-32-25-57(26-33-64)44-69(80(115)99-66(41-51(2)3)78(113)98-65(18-11-12-35-92-52(4)5)86(121)107-37-14-19-74(107)85(120)94-53(6)76(90)111)101-82(117)70(45-56-23-30-63(31-24-56)96-77(112)72-48-75(110)106-88(123)105-72)103-84(119)73(50-108)104-83(118)71(47-59-15-13-34-91-49-59)102-81(116)68(43-55-21-28-62(89)29-22-55)100-79(114)67(95-54(7)109)46-58-20-27-60-16-9-10-17-61(60)42-58/h9-10,13,15-17,20-34,42,49,51-53,65-74,92,108H,8,11-12,14,18-19,35-41,43-48,50H2,1-7H3,(H2,90,111)(H,94,120)(H,95,109)(H,96,112)(H,98,113)(H,99,115)(H,100,114)(H,101,117)(H,102,116)(H,103,119)(H,104,118)(H2,93,97,122)(H2,105,106,110,123)/t53-,65+,66+,67-,68-,69-,70+,71-,72+,73+,74+/m1/s1
DMFKTJ8 CS CCOCCOCCNC(=O)NC1=CC=C(C=C1)C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DMFKTJ8 IK LXDBVFUKTKJYLL-UODKESISSA-N
DMFKTJ8 IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-[2-(2-ethoxyethoxy)ethylcarbamoylamino]phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMFKTJ8 DE Discovery agent
DMR7TEQ ID DMR7TEQ
DMR7TEQ DN [D-4Aph(CO-NH-OCH3)6]degarelix
DMR7TEQ HS Investigative
DMR7TEQ SN CHEMBL435141; [D-4Aph(CO-NH-OCH3)6]degarelix
DMR7TEQ PC 16155709
DMR7TEQ MW 1662.3
DMR7TEQ FM C83H105ClN18O17
DMR7TEQ IC InChI=1S/C83H105ClN18O17/c1-46(2)36-61(73(108)92-60(17-10-11-34-87-47(3)4)81(116)102-35-13-18-69(102)80(115)88-48(5)71(85)106)93-75(110)64(39-52-24-31-59(32-25-52)91-83(118)101-119-7)95-77(112)65(40-51-22-29-58(30-23-51)90-72(107)67-43-70(105)100-82(117)99-67)97-79(114)68(45-103)98-78(113)66(42-54-14-12-33-86-44-54)96-76(111)63(38-50-20-27-57(84)28-21-50)94-74(109)62(89-49(6)104)41-53-19-26-55-15-8-9-16-56(55)37-53/h8-9,12,14-16,19-33,37,44,46-48,60-69,87,103H,10-11,13,17-18,34-36,38-43,45H2,1-7H3,(H2,85,106)(H,88,115)(H,89,104)(H,90,107)(H,92,108)(H,93,110)(H,94,109)(H,95,112)(H,96,111)(H,97,114)(H,98,113)(H2,91,101,118)(H2,99,100,105,117)/t48-,60+,61+,62-,63-,64-,65+,66-,67+,68+,69+/m1/s1
DMR7TEQ CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)NOC)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DMR7TEQ IK GSLYUOBUEBSTPA-BWBLBVTNSA-N
DMR7TEQ IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(methoxycarbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMR7TEQ DE Discovery agent
DMMVIX7 ID DMMVIX7
DMMVIX7 DN [D-4Aph(CO-NH-OH)6]degarelix
DMMVIX7 HS Investigative
DMMVIX7 SN CHEMBL427976; [D-4Aph(CO-NH-OH)6]degarelix
DMMVIX7 PC 16156699
DMMVIX7 MW 1648.3
DMMVIX7 FM C82H103ClN18O17
DMMVIX7 IC InChI=1S/C82H103ClN18O17/c1-45(2)35-60(72(107)91-59(16-9-10-33-86-46(3)4)80(115)101-34-12-17-68(101)79(114)87-47(5)70(84)105)92-74(109)63(38-51-23-30-58(31-24-51)90-82(117)100-118)94-76(111)64(39-50-21-28-57(29-22-50)89-71(106)66-42-69(104)99-81(116)98-66)96-78(113)67(44-102)97-77(112)65(41-53-13-11-32-85-43-53)95-75(110)62(37-49-19-26-56(83)27-20-49)93-73(108)61(88-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,86,102,118H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,87,114)(H,88,103)(H,89,106)(H,91,107)(H,92,109)(H,93,108)(H,94,111)(H,95,110)(H,96,113)(H,97,112)(H2,90,100,117)(H2,98,99,104,116)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
DMMVIX7 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)NO)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
DMMVIX7 IK ZYLCANLEJMKHHC-XYAYPHGZSA-N
DMMVIX7 IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(hydroxycarbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMMVIX7 DE Discovery agent
DM18ZNJ ID DM18ZNJ
DM18ZNJ DN [D-Ala2]Met-enkephalinamide
DM18ZNJ HS Investigative
DM18ZNJ SN CHEMBL287480
DM18ZNJ DT Small molecular drug
DM18ZNJ PC 44280469
DM18ZNJ MW 586.7
DM18ZNJ FM C28H38N6O6S
DM18ZNJ IC InChI=1S/C28H38N6O6S/c1-17(32-27(39)21(29)14-19-8-10-20(35)11-9-19)26(38)31-16-24(36)33-23(15-18-6-4-3-5-7-18)28(40)34-22(25(30)37)12-13-41-2/h3-11,17,21-23,35H,12-16,29H2,1-2H3,(H2,30,37)(H,31,38)(H,32,39)(H,33,36)(H,34,40)/t17-,21-,22-,23-/m0/s1
DM18ZNJ CS C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM18ZNJ IK ANZXICRKKYOVMY-ZMVGRULKSA-N
DM18ZNJ IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide
DM18ZNJ DE Discovery agent
DMSGW51 ID DMSGW51
DMSGW51 DN [D-Asp7,Lys10]N/OFQ(1-13)NH2
DMSGW51 HS Investigative
DMSGW51 SN CHEMBL507653; [D-Asp7,Lys10]N/OFQ(1-13)NH2
DMSGW51 PC 25084510
DMSGW51 MW 1466.7
DMSGW51 FM C65H107N23O16
DMSGW51 IC InChI=1S/C65H107N23O16/c1-37(55(96)84-45(24-15-29-75-64(71)72)58(99)83-42(54(70)95)21-9-12-26-66)80-57(98)43(22-10-13-27-67)85-59(100)44(23-11-14-28-68)86-60(101)46(25-16-30-76-65(73)74)87-61(102)48(33-52(93)94)82-51(92)36-79-63(104)53(38(2)89)88-62(103)47(32-40-19-7-4-8-20-40)81-50(91)35-77-49(90)34-78-56(97)41(69)31-39-17-5-3-6-18-39/h3-8,17-20,37-38,41-48,53,89H,9-16,21-36,66-69H2,1-2H3,(H2,70,95)(H,77,90)(H,78,97)(H,79,104)(H,80,98)(H,81,91)(H,82,92)(H,83,99)(H,84,96)(H,85,100)(H,86,101)(H,87,102)(H,88,103)(H,93,94)(H4,71,72,75)(H4,73,74,76)/t37-,38+,41-,42-,43-,44-,45-,46-,47-,48+,53-/m0/s1
DMSGW51 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMSGW51 IK RZSPAJQVMVZCJC-YRLNDPIWSA-N
DMSGW51 IU (3R)-4-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMSGW51 DE Discovery agent
DM23GCK ID DM23GCK
DM23GCK DN [Dcp1]Dyn A(1-11)-NH2
DM23GCK HS Investigative
DM23GCK SN CHEMBL412997; [Dcp1]Dyn A(1-11)-NH2
DM23GCK PC 44415282
DM23GCK MW 1564.9
DM23GCK FM C75H117N23O14
DM23GCK IC InChI=1S/C75H117N23O14/c1-7-43(4)62(71(111)95-54(22-15-33-87-75(83)84)72(112)98-34-16-23-58(98)70(110)92-51(64(78)104)19-11-12-30-76)97-67(107)53(21-14-32-86-74(81)82)93-66(106)52(20-13-31-85-73(79)80)94-68(108)55(35-42(2)3)96-69(109)57(38-46-17-9-8-10-18-46)91-61(102)41-88-60(101)40-89-65(105)56(39-47-24-26-49(99)27-25-47)90-59(100)29-28-50-44(5)36-48(63(77)103)37-45(50)6/h8-10,17-18,24-27,36-37,42-43,51-58,62,99H,7,11-16,19-23,28-35,38-41,76H2,1-6H3,(H2,77,103)(H2,78,104)(H,88,101)(H,89,105)(H,90,100)(H,91,102)(H,92,110)(H,93,106)(H,94,108)(H,95,111)(H,96,109)(H,97,107)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t43-,51-,52-,53-,54-,55-,56-,57-,58-,62-/m0/s1
DM23GCK CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)CCC4=C(C=C(C=C4C)C(=O)N)C
DM23GCK IK YPSMIMXFFGKHRC-DJQAJQEISA-N
DM23GCK IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[3-(4-carbamoyl-2,6-dimethylphenyl)propanoylamino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2S)-1,6-diamino-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DM23GCK DE Discovery agent
DMEZKX0 ID DMEZKX0
DMEZKX0 DN [D-Dab(CO-NH-OCH3)3]degarelix
DMEZKX0 HS Investigative
DMEZKX0 SN CHEMBL411337; [D-Dab(CO-NH-OCH3)3]degarelix
DMEZKX0 PC 16155098
DMEZKX0 MW 1657.3
DMEZKX0 FM C80H106ClN19O18
DMEZKX0 IC InChI=1S/C80H106ClN19O18/c1-43(2)35-58(70(107)91-57(15-10-11-32-84-44(3)4)77(114)100-34-12-16-65(100)76(113)86-45(5)67(82)104)92-73(110)61(38-49-22-29-55(30-23-49)89-78(83)115)94-74(111)62(39-48-20-27-54(28-21-48)88-69(106)63-41-66(103)98-80(117)97-63)95-75(112)64(42-101)96-68(105)56(31-33-85-79(116)99-118-7)90-72(109)60(37-47-18-25-53(81)26-19-47)93-71(108)59(87-46(6)102)40-50-17-24-51-13-8-9-14-52(51)36-50/h8-9,13-14,17-30,36,43-45,56-65,84,101H,10-12,15-16,31-35,37-42H2,1-7H3,(H2,82,104)(H,86,113)(H,87,102)(H,88,106)(H,90,109)(H,91,107)(H,92,110)(H,93,108)(H,94,111)(H,95,112)(H,96,105)(H3,83,89,115)(H2,85,99,116)(H2,97,98,103,117)/t45-,56-,57+,58+,59-,60-,61-,62+,63+,64+,65+/m1/s1
DMEZKX0 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CCNC(=O)NOC)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMEZKX0 IK DBLYRXMPBSXJDM-GOZSSGHVSA-N
DMEZKX0 IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-4-(methoxycarbamoylamino)butanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMEZKX0 DE Discovery agent
DMRVPN1 ID DMRVPN1
DMRVPN1 DN [D-Dab(CO-NH-OH)3]degarelix
DMRVPN1 HS Investigative
DMRVPN1 SN CHEMBL425813; [D-Dab(CO-NH-OH)3]degarelix
DMRVPN1 PC 16155654
DMRVPN1 MW 1643.2
DMRVPN1 FM C79H104ClN19O18
DMRVPN1 IC InChI=1S/C79H104ClN19O18/c1-42(2)34-57(69(106)90-56(14-9-10-31-83-43(3)4)76(113)99-33-11-15-64(99)75(112)85-44(5)66(81)103)91-72(109)60(37-48-21-28-54(29-22-48)88-77(82)114)93-73(110)61(38-47-19-26-53(27-20-47)87-68(105)62-40-65(102)97-79(116)96-62)94-74(111)63(41-100)95-67(104)55(30-32-84-78(115)98-117)89-71(108)59(36-46-17-24-52(80)25-18-46)92-70(107)58(86-45(6)101)39-49-16-23-50-12-7-8-13-51(50)35-49/h7-8,12-13,16-29,35,42-44,55-64,83,100,117H,9-11,14-15,30-34,36-41H2,1-6H3,(H2,81,103)(H,85,112)(H,86,101)(H,87,105)(H,89,108)(H,90,106)(H,91,109)(H,92,107)(H,93,110)(H,94,111)(H,95,104)(H3,82,88,114)(H2,84,98,115)(H2,96,97,102,116)/t44-,55-,56+,57+,58-,59-,60-,61+,62+,63+,64+/m1/s1
DMRVPN1 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CCNC(=O)NO)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMRVPN1 IK GJGANCMMPWJOQC-UFLOVSMNSA-N
DMRVPN1 IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-4-(hydroxycarbamoylamino)butanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMRVPN1 DE Discovery agent
DM5ZR4S ID DM5ZR4S
DM5ZR4S DN [D-Dap(CO-NH-OCH3)3]degarelix
DM5ZR4S HS Investigative
DM5ZR4S SN CHEMBL411381; [D-Dap(CO-NH-OCH3)3]degarelix
DM5ZR4S PC 16156517
DM5ZR4S MW 1643.2
DM5ZR4S FM C79H104ClN19O18
DM5ZR4S IC InChI=1S/C79H104ClN19O18/c1-42(2)33-56(68(105)89-55(15-10-11-31-83-43(3)4)76(113)99-32-12-16-64(99)75(112)85-44(5)66(81)103)90-70(107)58(36-48-22-29-54(30-23-48)88-77(82)114)92-71(108)59(37-47-20-27-53(28-21-47)87-67(104)61-39-65(102)97-79(116)96-61)93-74(111)63(41-100)95-73(110)62(40-84-78(115)98-117-7)94-72(109)60(35-46-18-25-52(80)26-19-46)91-69(106)57(86-45(6)101)38-49-17-24-50-13-8-9-14-51(50)34-49/h8-9,13-14,17-30,34,42-44,55-64,83,100H,10-12,15-16,31-33,35-41H2,1-7H3,(H2,81,103)(H,85,112)(H,86,101)(H,87,104)(H,89,105)(H,90,107)(H,91,106)(H,92,108)(H,93,111)(H,94,109)(H,95,110)(H3,82,88,114)(H2,84,98,115)(H2,96,97,102,116)/t44-,55+,56+,57-,58-,59+,60-,61+,62-,63+,64+/m1/s1
DM5ZR4S CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CNC(=O)NOC)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM5ZR4S IK AJPARKCOZVUOMV-NOXGGNAKSA-N
DM5ZR4S IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(methoxycarbamoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DM5ZR4S DE Discovery agent
DMS0LFT ID DMS0LFT
DMS0LFT DN [D-Dap(CO-NH-OH)3]degarelix
DMS0LFT HS Investigative
DMS0LFT SN CHEMBL428484; [D-Dap(CO-NH-OH)3]degarelix
DMS0LFT PC 16155218
DMS0LFT MW 1629.2
DMS0LFT FM C78H102ClN19O18
DMS0LFT IC InChI=1S/C78H102ClN19O18/c1-41(2)32-55(67(104)88-54(14-9-10-30-82-42(3)4)75(112)98-31-11-15-63(98)74(111)84-43(5)65(80)102)89-69(106)57(35-47-21-28-53(29-22-47)87-76(81)113)91-70(107)58(36-46-19-26-52(27-20-46)86-66(103)60-38-64(101)96-78(115)95-60)92-73(110)62(40-99)94-72(109)61(39-83-77(114)97-116)93-71(108)59(34-45-17-24-51(79)25-18-45)90-68(105)56(85-44(6)100)37-48-16-23-49-12-7-8-13-50(49)33-48/h7-8,12-13,16-29,33,41-43,54-63,82,99,116H,9-11,14-15,30-32,34-40H2,1-6H3,(H2,80,102)(H,84,111)(H,85,100)(H,86,103)(H,88,104)(H,89,106)(H,90,105)(H,91,107)(H,92,110)(H,93,108)(H,94,109)(H3,81,87,113)(H2,83,97,114)(H2,95,96,101,115)/t43-,54+,55+,56-,57-,58+,59-,60+,61-,62+,63+/m1/s1
DMS0LFT CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CNC(=O)NO)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMS0LFT IK QJTXGVWJYSNZTE-PTPJWVMESA-N
DMS0LFT IU (4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(hydroxycarbamoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMS0LFT DE Discovery agent
DMEL0SZ ID DMEL0SZ
DMEL0SZ DN [des-Arg9]bradykinin
DMEL0SZ HS Investigative
DMEL0SZ SN [des-Arg9]BK
DMEL0SZ DT Small molecular drug
DMEL0SZ PC 5128451
DMEL0SZ MW 904
DMEL0SZ FM C44H61N11O10
DMEL0SZ IC InChI=1S/C44H61N11O10/c45-29(15-7-19-48-44(46)47)40(61)55-22-10-18-35(55)42(63)54-21-8-16-33(54)38(59)49-25-36(57)50-30(23-27-11-3-1-4-12-27)37(58)52-32(26-56)41(62)53-20-9-17-34(53)39(60)51-31(43(64)65)24-28-13-5-2-6-14-28/h1-6,11-14,29-35,56H,7-10,15-26,45H2,(H,49,59)(H,50,57)(H,51,60)(H,52,58)(H,64,65)(H4,46,47,48)
DMEL0SZ CS C1CC(N(C1)C(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)O
DMEL0SZ IK VCEHWDBVPZFHAG-UHFFFAOYSA-N
DMEL0SZ IU 2-[[1-[2-[[2-[[2-[[1-[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMEL0SZ DE Discovery agent
DM1EPZB ID DM1EPZB
DM1EPZB DN [des-His1,Tyr5,Glu9,D-Ala10]glucagon-NH2
DM1EPZB HS Investigative
DM1EPZB PC 44460671
DM1EPZB MW 3328.6
DM1EPZB FM C147H219N41O46S
DM1EPZB IC InChI=1S/C147H219N41O46S/c1-70(2)54-95(131(220)172-94(49-53-235-11)130(219)180-102(61-111(153)200)140(229)187-117(75(9)193)119(154)208)175-135(224)101(60-81-64-161-86-29-19-18-28-84(81)86)179-129(218)92(43-47-110(152)199)173-144(233)116(72(5)6)186-138(227)99(56-77-24-14-12-15-25-77)178-136(225)103(62-114(204)205)181-128(217)91(42-46-109(151)198)166-120(209)73(7)163-124(213)88(31-22-51-159-146(155)156)168-126(215)89(32-23-52-160-147(157)158)170-142(231)106(68-191)184-137(226)104(63-115(206)207)182-132(221)96(55-71(3)4)174-134(223)98(59-80-35-39-83(196)40-36-80)176-127(216)87(30-20-21-50-148)169-141(230)105(67-190)183-121(210)74(8)164-125(214)93(44-48-113(202)203)171-143(232)107(69-192)185-145(234)118(76(10)194)188-139(228)100(57-78-26-16-13-17-27-78)177-133(222)97(58-79-33-37-82(195)38-34-79)165-112(201)65-162-123(212)90(41-45-108(150)197)167-122(211)85(149)66-189/h12-19,24-29,33-40,64,70-76,85,87-107,116-118,161,189-196H,20-23,30-32,41-63,65-69,148-149H2,1-11H3,(H2,150,197)(H2,151,198)(H2,152,199)(H2,153,200)(H2,154,208)(H,162,212)(H,163,213)(H,164,214)(H,165,201)(H,166,209)(H,167,211)(H,168,215)(H,169,230)(H,170,231)(H,171,232)(H,172,220)(H,173,233)(H,174,223)(H,175,224)(H,176,216)(H,177,222)(H,178,225)(H,179,218)(H,180,219)(H,181,217)(H,182,221)(H,183,210)(H,184,226)(H,185,234)(H,186,227)(H,187,229)(H,188,228)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,159)(H4,157,158,160)/t73-,74-,75+,76+,85-,87-,88-,89-,90-,91-,92-,93+,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,116-,117-,118-/m0/s1
DM1EPZB CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DM1EPZB IK PSHWUKAXGHEOPB-XGBCNKCESA-N
DM1EPZB IU (4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DM1EPZB DE Discovery agent
DM06Q2V ID DM06Q2V
DM06Q2V DN [des-His1,Tyr5,Glu9,D-Phe10]glucagon-NH2
DM06Q2V HS Investigative
DM06Q2V PC 44460638
DM06Q2V MW 3404.7
DM06Q2V FM C153H223N41O46S
DM06Q2V IC InChI=1S/C153H223N41O46S/c1-75(2)58-100(136(225)177-99(53-57-241-10)135(224)186-108(66-117(159)206)146(235)193-123(79(8)199)125(160)214)180-141(230)107(65-86-69-167-91-33-21-20-32-89(86)91)185-133(222)97(47-51-116(158)205)178-150(239)122(77(5)6)192-144(233)105(61-82-28-16-12-17-29-82)184-142(231)109(67-120(210)211)187-132(221)96(46-50-115(157)204)171-126(215)78(7)169-129(218)93(35-24-55-165-152(161)162)173-130(219)94(36-25-56-166-153(163)164)175-148(237)112(73-197)190-143(232)110(68-121(212)213)188-137(226)101(59-76(3)4)179-139(228)104(64-85-39-43-88(202)44-40-85)181-131(220)92(34-22-23-54-154)174-147(236)111(72-196)189-140(229)103(60-81-26-14-11-15-27-81)182-134(223)98(48-52-119(208)209)176-149(238)113(74-198)191-151(240)124(80(9)200)194-145(234)106(62-83-30-18-13-19-31-83)183-138(227)102(63-84-37-41-87(201)42-38-84)170-118(207)70-168-128(217)95(45-49-114(156)203)172-127(216)90(155)71-195/h11-21,26-33,37-44,69,75-80,90,92-113,122-124,167,195-202H,22-25,34-36,45-68,70-74,154-155H2,1-10H3,(H2,156,203)(H2,157,204)(H2,158,205)(H2,159,206)(H2,160,214)(H,168,217)(H,169,218)(H,170,207)(H,171,215)(H,172,216)(H,173,219)(H,174,236)(H,175,237)(H,176,238)(H,177,225)(H,178,239)(H,179,228)(H,180,230)(H,181,220)(H,182,223)(H,183,227)(H,184,231)(H,185,222)(H,186,224)(H,187,221)(H,188,226)(H,189,229)(H,190,232)(H,191,240)(H,192,233)(H,193,235)(H,194,234)(H,208,209)(H,210,211)(H,212,213)(H4,161,162,165)(H4,163,164,166)/t78-,79+,80+,90-,92-,93-,94-,95-,96-,97-,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
DM06Q2V CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DM06Q2V IK MBFPGOMXVAUTEP-VXJQVJGISA-N
DM06Q2V IU (4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DM06Q2V DE Discovery agent
DMFLVED ID DMFLVED
DMFLVED DN [des-His1,Tyr5,Glu9,D-Tyr10]glucagon-NH2
DMFLVED HS Investigative
DMFLVED SN CHEMBL413666
DMFLVED PC 44461181
DMFLVED MW 3420.7
DMFLVED FM C153H223N41O47S
DMFLVED IC InChI=1S/C153H223N41O47S/c1-74(2)57-100(136(226)177-99(52-56-242-10)135(225)186-108(65-117(159)207)146(236)193-123(78(8)199)125(160)215)180-141(231)107(64-85-68-167-91-28-18-17-27-89(85)91)185-133(223)97(46-50-116(158)206)178-150(240)122(76(5)6)192-144(234)105(59-80-23-13-11-14-24-80)184-142(232)109(66-120(211)212)187-132(222)96(45-49-115(157)205)171-126(216)77(7)169-129(219)93(30-21-54-165-152(161)162)173-130(220)94(31-22-55-166-153(163)164)175-148(238)112(72-197)190-143(233)110(67-121(213)214)188-137(227)101(58-75(3)4)179-139(229)103(62-83-34-40-87(202)41-35-83)181-131(221)92(29-19-20-53-154)174-147(237)111(71-196)189-140(230)104(63-84-36-42-88(203)43-37-84)182-134(224)98(47-51-119(209)210)176-149(239)113(73-198)191-151(241)124(79(9)200)194-145(235)106(60-81-25-15-12-16-26-81)183-138(228)102(61-82-32-38-86(201)39-33-82)170-118(208)69-168-128(218)95(44-48-114(156)204)172-127(217)90(155)70-195/h11-18,23-28,32-43,68,74-79,90,92-113,122-124,167,195-203H,19-22,29-31,44-67,69-73,154-155H2,1-10H3,(H2,156,204)(H2,157,205)(H2,158,206)(H2,159,207)(H2,160,215)(H,168,218)(H,169,219)(H,170,208)(H,171,216)(H,172,217)(H,173,220)(H,174,237)(H,175,238)(H,176,239)(H,177,226)(H,178,240)(H,179,229)(H,180,231)(H,181,221)(H,182,224)(H,183,228)(H,184,232)(H,185,223)(H,186,225)(H,187,222)(H,188,227)(H,189,230)(H,190,233)(H,191,241)(H,192,234)(H,193,236)(H,194,235)(H,209,210)(H,211,212)(H,213,214)(H4,161,162,165)(H4,163,164,166)/t77-,78+,79+,90-,92-,93-,94-,95-,96-,97-,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
DMFLVED CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DMFLVED IK SNCODYSDFYHLPQ-HYDYTQAJSA-N
DMFLVED IU (4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMFLVED DE Discovery agent
DM93I0B ID DM93I0B
DM93I0B DN [des-His1,Tyr5,Glu9]glucagon-NH2
DM93I0B HS Investigative
DM93I0B PC 44460796
DM93I0B MW 3420.7
DM93I0B FM C153H223N41O47S
DM93I0B IC InChI=1S/C153H223N41O47S/c1-74(2)57-100(136(226)177-99(52-56-242-10)135(225)186-108(65-117(159)207)146(236)193-123(78(8)199)125(160)215)180-141(231)107(64-85-68-167-91-28-18-17-27-89(85)91)185-133(223)97(46-50-116(158)206)178-150(240)122(76(5)6)192-144(234)105(59-80-23-13-11-14-24-80)184-142(232)109(66-120(211)212)187-132(222)96(45-49-115(157)205)171-126(216)77(7)169-129(219)93(30-21-54-165-152(161)162)173-130(220)94(31-22-55-166-153(163)164)175-148(238)112(72-197)190-143(233)110(67-121(213)214)188-137(227)101(58-75(3)4)179-139(229)103(62-83-34-40-87(202)41-35-83)181-131(221)92(29-19-20-53-154)174-147(237)111(71-196)189-140(230)104(63-84-36-42-88(203)43-37-84)182-134(224)98(47-51-119(209)210)176-149(239)113(73-198)191-151(241)124(79(9)200)194-145(235)106(60-81-25-15-12-16-26-81)183-138(228)102(61-82-32-38-86(201)39-33-82)170-118(208)69-168-128(218)95(44-48-114(156)204)172-127(217)90(155)70-195/h11-18,23-28,32-43,68,74-79,90,92-113,122-124,167,195-203H,19-22,29-31,44-67,69-73,154-155H2,1-10H3,(H2,156,204)(H2,157,205)(H2,158,206)(H2,159,207)(H2,160,215)(H,168,218)(H,169,219)(H,170,208)(H,171,216)(H,172,217)(H,173,220)(H,174,237)(H,175,238)(H,176,239)(H,177,226)(H,178,240)(H,179,229)(H,180,231)(H,181,221)(H,182,224)(H,183,228)(H,184,232)(H,185,223)(H,186,225)(H,187,222)(H,188,227)(H,189,230)(H,190,233)(H,191,241)(H,192,234)(H,193,236)(H,194,235)(H,209,210)(H,211,212)(H,213,214)(H4,161,162,165)(H4,163,164,166)/t77-,78?,79+,90-,92-,93-,94-,95-,96-,97-,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-/m0/s1
DM93I0B CS C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)O)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)O
DM93I0B IK SNCODYSDFYHLPQ-MBYQMCMRSA-N
DM93I0B IU (4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DM93I0B DE Discovery agent
DMP1D7Q ID DMP1D7Q
DMP1D7Q DN [D-Gln3,D-Ncy(isopropyl)7]acyline
DMP1D7Q HS Investigative
DMP1D7Q SN CHEMBL428795; [D-Gln3,D-Ncy(isopropyl)7]acyline
DMP1D7Q PC 16221613
DMP1D7Q MW 1531.2
DMP1D7Q FM C76H100ClN15O15S
DMP1D7Q IC InChI=1S/C76H100ClN15O15S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(108-43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75-/m1/s1
DMP1D7Q CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)SC(C)C
DMP1D7Q IK JPMOBCPTBLZEAW-YSZAJMORSA-N
DMP1D7Q IU (2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1R)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfanylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMP1D7Q DE Discovery agent
DMFAX1Q ID DMFAX1Q
DMFAX1Q DN [D-Gln3,D-Ncy(SO,isopropyl)7]acyline
DMFAX1Q HS Investigative
DMFAX1Q SN CHEMBL415380; [D-Gln3,D-Ncy(SO,isopropyl)7]acyline
DMFAX1Q PC 16221379
DMFAX1Q MW 1547.2
DMFAX1Q FM C76H100ClN15O16S
DMFAX1Q IC InChI=1S/C76H100ClN15O16S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(109(108)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75-,109?/m1/s1
DMFAX1Q CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)C(C)C
DMFAX1Q IK KYASUQFVWOOHIK-JKWOHFGQSA-N
DMFAX1Q IU (2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1R)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfinylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMFAX1Q DE Discovery agent
DM3H0CX ID DM3H0CX
DM3H0CX DN [D-Gln3,D-Ncy(SO2,isopropyl)7]acyline
DM3H0CX HS Investigative
DM3H0CX SN CHEMBL373725; [D-Gln3,D-Ncy(SO2,isopropyl)7]acyline
DM3H0CX PC 16221614
DM3H0CX MW 1563.2
DM3H0CX FM C76H100ClN15O17S
DM3H0CX IC InChI=1S/C76H100ClN15O17S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(110(108,109)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75-/m1/s1
DM3H0CX CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)(=O)C(C)C
DM3H0CX IK FVPKWKBSMZRQEW-YSZAJMORSA-N
DM3H0CX IU (2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1R)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfonylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DM3H0CX DE Discovery agent
DMMEQ3R ID DMMEQ3R
DMMEQ3R DN [D-Gln3,Ncy(isopropyl)7]acyline
DMMEQ3R HS Investigative
DMMEQ3R SN CHEMBL228197; [D-Gln3,Ncy(isopropyl)7]acyline
DMMEQ3R PC 16221328
DMMEQ3R MW 1531.2
DMMEQ3R FM C76H100ClN15O15S
DMMEQ3R IC InChI=1S/C76H100ClN15O15S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(108-43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75+/m1/s1
DMMEQ3R CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)SC(C)C
DMMEQ3R IK JPMOBCPTBLZEAW-RKSVTEAUSA-N
DMMEQ3R IU (2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1S)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfanylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMMEQ3R DE Discovery agent
DM2QDXW ID DM2QDXW
DM2QDXW DN [D-Gln3,Ncy(SO,isopropyl)7]acyline
DM2QDXW HS Investigative
DM2QDXW SN CHEMBL425486; [D-Gln3,Ncy(SO,isopropyl)7]acyline
DM2QDXW PC 16221557
DM2QDXW MW 1547.2
DM2QDXW FM C76H100ClN15O16S
DM2QDXW IC InChI=1S/C76H100ClN15O16S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(109(108)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75+,109?/m1/s1
DM2QDXW CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)C(C)C
DM2QDXW IK KYASUQFVWOOHIK-WEDCXYFKSA-N
DM2QDXW IU (2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1S)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfinylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DM2QDXW DE Discovery agent
DMJSCO7 ID DMJSCO7
DMJSCO7 DN [D-Gln3,Ncy(SO2,isopropyl)7]acyline
DMJSCO7 HS Investigative
DMJSCO7 SN CHEMBL373724; [D-Gln3,Ncy(SO2,isopropyl)7]acyline
DMJSCO7 PC 16221329
DMJSCO7 MW 1563.2
DMJSCO7 FM C76H100ClN15O17S
DMJSCO7 IC InChI=1S/C76H100ClN15O17S/c1-42(2)80-34-12-11-16-58(76(107)92-35-13-17-64(92)73(105)81-44(5)66(79)98)86-74(106)75(110(108,109)43(3)4)91-71(103)62(39-50-23-30-56(31-24-50)83-46(7)95)88-70(102)61(38-49-21-28-55(29-22-49)82-45(6)94)89-72(104)63(41-93)90-67(99)57(32-33-65(78)97)85-69(101)60(37-48-19-26-54(77)27-20-48)87-68(100)59(84-47(8)96)40-51-18-25-52-14-9-10-15-53(52)36-51/h9-10,14-15,18-31,36,42-44,57-64,75,80,93H,11-13,16-17,32-35,37-41H2,1-8H3,(H2,78,97)(H2,79,98)(H,81,105)(H,82,94)(H,83,95)(H,84,96)(H,85,101)(H,86,106)(H,87,100)(H,88,102)(H,89,104)(H,90,99)(H,91,103)/t44-,57-,58+,59-,60-,61+,62-,63+,64+,75+/m1/s1
DMJSCO7 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)S(=O)(=O)C(C)C
DMJSCO7 IK FVPKWKBSMZRQEW-RKSVTEAUSA-N
DMJSCO7 IU (2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-N-[(2S)-1-[[(2S)-3-(4-acetamidophenyl)-1-[[(2R)-3-(4-acetamidophenyl)-1-[[(1S)-2-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-2-oxo-1-propan-2-ylsulfonylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMJSCO7 DE Discovery agent
DMAFNTL ID DMAFNTL
DMAFNTL DN [D-Ncy(2-naphthyl)1]acyline
DMAFNTL HS Investigative
DMAFNTL SN CHEMBL227861; [D-Ncy(2-naphthyl)1]acyline
DMAFNTL PC 16221104
DMAFNTL MW 1551.2
DMAFNTL FM C79H100ClN15O14S
DMAFNTL IC InChI=1S/C79H100ClN15O14S/c1-45(2)37-62(70(101)88-61(18-11-12-35-83-46(3)4)79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)89-71(102)63(39-52-22-29-58(30-23-52)85-48(6)97)90-72(103)64(40-53-24-31-59(32-25-53)86-49(7)98)92-75(106)67(44-96)94-74(105)66(41-54-15-13-34-82-43-54)91-73(104)65(38-51-20-27-57(80)28-21-51)93-77(108)78(87-50(8)99)110-60-33-26-55-16-9-10-17-56(55)42-60/h9-10,13,15-17,20-34,42-43,45-47,61-68,78,83,96H,11-12,14,18-19,35-41,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,101)(H,89,102)(H,90,103)(H,91,104)(H,92,106)(H,93,108)(H,94,105)/t47-,61+,62+,63-,64+,65-,66-,67+,68+,78-/m1/s1
DMAFNTL CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](NC(=O)C)SC6=CC7=CC=CC=C7C=C6
DMAFNTL IK JRWSZLDRIJBUBZ-GJCYDJOFSA-N
DMAFNTL IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-2-naphthalen-2-ylsulfanylacetyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMAFNTL DE Discovery agent
DMVBTAM ID DMVBTAM
DMVBTAM DN [D-Ncy(isopropyl)7]acyline
DMVBTAM HS Investigative
DMVBTAM SN CHEMBL227451; [D-Ncy(isopropyl)7]acyline
DMVBTAM PC 16221495
DMVBTAM MW 1551.2
DMVBTAM FM C79H100ClN15O14S
DMVBTAM IC InChI=1S/C79H100ClN15O14S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(110-46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78-/m1/s1
DMVBTAM CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC(C)C
DMVBTAM IK GFSHJVRBLLVKAZ-UQWNDQPVSA-N
DMVBTAM IU (2S)-1-[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfanylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMVBTAM DE Discovery agent
DM9TORW ID DM9TORW
DM9TORW DN [D-Ncy(methyl)10] acyline
DM9TORW HS Investigative
DM9TORW SN CHEMBL387499; [D-Ncy(methyl)10] acyline
DM9TORW PC 16221267
DM9TORW MW 1565.3
DM9TORW FM C80H102ClN15O14S
DM9TORW IC InChI=1S/C80H102ClN15O14S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(111-8)70(82)101)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79+/m0/s1
DM9TORW CS CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)SC)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9TORW IK MNOHGPTZCIGJAF-NNRJBHNWSA-N
DM9TORW IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1R)-2-amino-1-methylsulfanyl-2-oxoethyl]pyrrolidine-2-carboxamide
DM9TORW DE Discovery agent
DM63FN5 ID DM63FN5
DM63FN5 DN [D-Ncy(methyl)4]acyline
DM63FN5 HS Investigative
DM63FN5 SN CHEMBL268297; [D-Ncy(methyl)4]acyline
DM63FN5 PC 16221434
DM63FN5 MW 1549.3
DM63FN5 FM C80H102ClN15O13S
DM63FN5 IC InChI=1S/C80H102ClN15O13S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(110-9)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79-/m1/s1
DM63FN5 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC
DM63FN5 IK HPTFWQIEIVLQOX-GHGJXBRZSA-N
DM63FN5 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfanylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM63FN5 DE Discovery agent
DME9AN4 ID DME9AN4
DME9AN4 DN [D-Ncy(SO,isopropyl)7]acyline
DME9AN4 HS Investigative
DME9AN4 SN CHEMBL427269; [D-Ncy(SO,isopropyl)7]acyline
DME9AN4 PC 16221212
DME9AN4 MW 1567.2
DME9AN4 FM C79H100ClN15O15S
DME9AN4 IC InChI=1S/C79H100ClN15O15S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(111(110)46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78-,111?/m1/s1
DME9AN4 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C(C)C
DME9AN4 IK KEFJIAHSOLWSII-JBSZQXIRSA-N
DME9AN4 IU (2S)-1-[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfinylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DME9AN4 DE Discovery agent
DMT2X98 ID DMT2X98
DMT2X98 DN [D-Ncy(SO,methyl)10]acyline
DMT2X98 HS Investigative
DMT2X98 SN CHEMBL434371; [D-Ncy(SO,methyl)10]acyline
DMT2X98 PC 16221556
DMT2X98 MW 1581.3
DMT2X98 FM C80H102ClN15O15S
DMT2X98 IC InChI=1S/C80H102ClN15O15S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(70(82)101)112(8)111)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79+,112?/m0/s1
DMT2X98 CS CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)S(=O)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMT2X98 IK SELUBVJEWYERMJ-PGGNZVFSSA-N
DMT2X98 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1R)-2-amino-1-methylsulfinyl-2-oxoethyl]pyrrolidine-2-carboxamide
DMT2X98 DE Discovery agent
DM6HEXG ID DM6HEXG
DM6HEXG DN [D-Ncy(SO,methyl)4]acyline
DM6HEXG HS Investigative
DM6HEXG SN CHEMBL389945; [D-Ncy(SO,methyl)4]acyline
DM6HEXG PC 16221151
DM6HEXG MW 1565.3
DM6HEXG FM C80H102ClN15O14S
DM6HEXG IC InChI=1S/C80H102ClN15O14S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(111(9)110)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79-,111?/m1/s1
DM6HEXG CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C
DM6HEXG IK VCYXYVFYPVPVGF-QUDAQTMVSA-N
DM6HEXG IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfinylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM6HEXG DE Discovery agent
DME8W3R ID DME8W3R
DME8W3R DN [D-Tic7]OT
DME8W3R HS Investigative
DME8W3R SN CHEMBL435159; [D-Tic7]OT
DME8W3R PC 16738356
DME8W3R MW 1069.3
DME8W3R FM C48H68N12O12S2
DME8W3R IC InChI=1S/C48H68N12O12S2/c1-5-25(4)40-47(71)54-31(14-15-37(50)62)43(67)56-34(19-38(51)63)44(68)58-35(23-74-73-22-30(49)41(65)55-33(45(69)59-40)17-26-10-12-29(61)13-11-26)48(72)60-21-28-9-7-6-8-27(28)18-36(60)46(70)57-32(16-24(2)3)42(66)53-20-39(52)64/h6-13,24-25,30-36,40,61H,5,14-23,49H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,66)(H,54,71)(H,55,65)(H,56,67)(H,57,70)(H,58,68)(H,59,69)/t25-,30-,31-,32-,33-,34-,35-,36+,40-/m0/s1
DME8W3R CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DME8W3R IK GJHLANNXTOQRKG-VLMAQVDPSA-N
DME8W3R IU (3R)-2-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DME8W3R DE Discovery agent
DMWGADP ID DMWGADP
DMWGADP DN [Fe(CN)6]4-
DMWGADP HS Investigative
DMWGADP SN FERROCYANIDE; Hexacyanoferrate(II); Hexacyanoferrate II; Hexazyanoferrat(II); hexacyanoferrate(4-); hexacyanidoferrate(II); hexacyanidoferrate(4-); [Fe(CN)6](4-); Iron-hexacyanide; Ferrocyanide salts; hexacyanoferrate(4)-; CHEBI:5032; ORXDSIPBTFAEKJ-UHFFFAOYSA-N; Hexakis(cyano-C)-(OC-6-11)-Ferrate(3-); C01913
DMWGADP DT Small molecular drug
DMWGADP PC 9552077
DMWGADP MW 211.95
DMWGADP FM C6FeN6-4
DMWGADP IC InChI=1S/6CN.Fe/c6*1-2;/q6*-1;+2
DMWGADP CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2]
DMWGADP IK UETZVSHORCDDTH-UHFFFAOYSA-N
DMWGADP IU iron(2+);hexacyanide
DMWGADP CA CAS 13408-63-4
DMWGADP CB CHEBI:5032
DMWGADP DE Discovery agent
DMZM3GB ID DMZM3GB
DMZM3GB DN [Gly(But)7]OT
DMZM3GB HS Investigative
DMZM3GB SN CHEMBL234363; [Gly(But)7]OT
DMZM3GB PC 44429264
DMZM3GB MW 1023.2
DMZM3GB FM C44H70N12O12S2
DMZM3GB IC InChI=1S/C44H70N12O12S2/c1-8-22(4)34-42(67)50-26(13-14-31(46)58)38(63)52-29(17-32(47)59)39(64)54-30(20-70-69-19-25(45)36(61)51-28(40(65)55-34)16-23-9-11-24(57)12-10-23)41(66)56-35(44(5,6)7)43(68)53-27(15-21(2)3)37(62)49-18-33(48)60/h9-12,21-22,25-30,34-35,57H,8,13-20,45H2,1-7H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,61)(H,52,63)(H,53,68)(H,54,64)(H,55,65)(H,56,66)/t22-,25-,26-,27-,28-,29-,30-,34-,35-/m0/s1
DMZM3GB CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)C(C)(C)C)CC(=O)N)CCC(=O)N
DMZM3GB IK ZQBKWQKQBINQEI-PJCZHVSHSA-N
DMZM3GB IU (4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-N-[(2R)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMZM3GB DE Discovery agent
DM9SP2U ID DM9SP2U
DM9SP2U DN [Gly8, aib22]GLP-1(7-37)-NH2
DM9SP2U HS Investigative
DM9SP2U PC 91935382
DM9SP2U MW 3368.7
DM9SP2U FM C152H231N41O46
DM9SP2U IC InChI=1S/C152H231N41O46/c1-18-78(10)121(147(236)170-81(13)126(215)177-105(61-87-64-162-92-37-26-25-36-90(87)92)136(225)179-101(57-75(4)5)137(226)189-119(76(6)7)145(234)176-94(38-27-29-53-153)129(218)165-68-113(203)171-93(40-31-55-161-151(158)159)128(217)163-66-111(157)201)191-138(227)103(58-84-32-21-19-22-33-84)180-133(222)97(47-51-116(207)208)174-132(221)95(39-28-30-54-154)173-125(214)80(12)168-124(213)79(11)169-131(220)98(45-49-110(156)200)187-150(239)152(16,17)193-144(233)99(48-52-117(209)210)175-134(223)100(56-74(2)3)178-135(224)102(60-86-41-43-89(199)44-42-86)181-141(230)107(70-194)184-143(232)109(72-196)185-146(235)120(77(8)9)190-140(229)106(63-118(211)212)182-142(231)108(71-195)186-149(238)123(83(15)198)192-139(228)104(59-85-34-23-20-24-35-85)183-148(237)122(82(14)197)188-114(204)69-166-130(219)96(46-50-115(205)206)172-112(202)67-164-127(216)91(155)62-88-65-160-73-167-88/h19-26,32-37,41-44,64-65,73-83,91,93-109,119-123,162,194-199H,18,27-31,38-40,45-63,66-72,153-155H2,1-17H3,(H2,156,200)(H2,157,201)(H,160,167)(H,163,217)(H,164,216)(H,165,218)(H,166,219)(H,168,213)(H,169,220)(H,170,236)(H,171,203)(H,172,202)(H,173,214)(H,174,221)(H,175,223)(H,176,234)(H,177,215)(H,178,224)(H,179,225)(H,180,222)(H,181,230)(H,182,231)(H,183,237)(H,184,232)(H,185,235)(H,186,238)(H,187,239)(H,188,204)(H,189,226)(H,190,229)(H,191,227)(H,192,228)(H,193,233)(H,205,206)(H,207,208)(H,209,210)(H,211,212)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,119-,120-,121-,122-,123-/m0/s1
DM9SP2U CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DM9SP2U IK SNUALFGPRGVVPK-CCGBATFTSA-N
DM9SP2U IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM9SP2U DE Discovery agent
DMO8U3S ID DMO8U3S
DMO8U3S DN [Gly8,Glu22]GLP-1(7,37)-NH2
DMO8U3S HS Investigative
DMO8U3S PC 77281783
DMO8U3S MW 3413.7
DMO8U3S FM C153H230N40O49
DMO8U3S IC InChI=1S/C153H230N40O49/c1-16-78(10)123(150(240)170-81(13)128(218)179-106(61-87-64-162-92-35-24-23-34-90(87)92)140(230)181-102(57-75(4)5)141(231)190-121(76(6)7)148(238)178-94(36-25-27-53-154)131(221)164-67-113(202)171-93(38-29-55-161-153(158)159)130(220)166-69-120(214)215)192-142(232)104(58-84-30-19-17-20-31-84)182-137(227)100(47-52-118(210)211)175-134(224)95(37-26-28-54-155)173-127(217)80(12)168-126(216)79(11)169-133(223)97(43-48-111(157)200)174-135(225)98(45-50-116(206)207)176-136(226)99(46-51-117(208)209)177-138(228)101(56-74(2)3)180-139(229)103(60-86-39-41-89(199)42-40-86)183-145(235)108(70-194)186-147(237)110(72-196)187-149(239)122(77(8)9)191-144(234)107(63-119(212)213)184-146(236)109(71-195)188-152(242)125(83(15)198)193-143(233)105(59-85-32-21-18-22-33-85)185-151(241)124(82(14)197)189-114(203)68-165-132(222)96(44-49-115(204)205)172-112(201)66-163-129(219)91(156)62-88-65-160-73-167-88/h17-24,30-35,39-42,64-65,73-83,91,93-110,121-125,162,194-199H,16,25-29,36-38,43-63,66-72,154-156H2,1-15H3,(H2,157,200)(H,160,167)(H,163,219)(H,164,221)(H,165,222)(H,166,220)(H,168,216)(H,169,223)(H,170,240)(H,171,202)(H,172,201)(H,173,217)(H,174,225)(H,175,224)(H,176,226)(H,177,228)(H,178,238)(H,179,218)(H,180,229)(H,181,230)(H,182,227)(H,183,235)(H,184,236)(H,185,241)(H,186,237)(H,187,239)(H,188,242)(H,189,203)(H,190,231)(H,191,234)(H,192,232)(H,193,233)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,121-,122-,123-,124-,125-/m0/s1
DMO8U3S CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DMO8U3S IK PDPPZBIGLPYQFY-KYYFCHEUSA-N
DMO8U3S IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMO8U3S DE Discovery agent
DM1SOT4 ID DM1SOT4
DM1SOT4 DN [Gly8]GLP-1(7-37)-NH2
DM1SOT4 HS Investigative
DM1SOT4 PC 91935381
DM1SOT4 MW 3341.6
DM1SOT4 FM C150H226N40O47
DM1SOT4 IC InChI=1S/C150H226N40O47/c1-16-77(10)121(147(235)168-80(13)126(214)176-104(59-86-62-159-91-35-24-23-34-89(86)91)137(225)178-100(55-74(4)5)138(226)187-119(75(6)7)145(233)175-93(36-25-27-51-151)129(217)161-65-111(199)169-92(38-29-53-158-150(155)156)128(216)164-68-118(210)211)189-139(227)102(56-83-30-19-17-20-31-83)179-134(222)98(46-50-116(206)207)174-133(221)94(37-26-28-52-152)172-125(213)79(12)166-124(212)78(11)167-132(220)97(43-47-109(154)197)171-112(200)66-162-131(219)96(45-49-115(204)205)173-135(223)99(54-73(2)3)177-136(224)101(58-85-39-41-88(196)42-40-85)180-142(230)106(69-191)183-144(232)108(71-193)184-146(234)120(76(8)9)188-141(229)105(61-117(208)209)181-143(231)107(70-192)185-149(237)123(82(15)195)190-140(228)103(57-84-32-21-18-22-33-84)182-148(236)122(81(14)194)186-113(201)67-163-130(218)95(44-48-114(202)203)170-110(198)64-160-127(215)90(153)60-87-63-157-72-165-87/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,159,191-196H,16,25-29,36-38,43-61,64-71,151-153H2,1-15H3,(H2,154,197)(H,157,165)(H,160,215)(H,161,217)(H,162,219)(H,163,218)(H,164,216)(H,166,212)(H,167,220)(H,168,235)(H,169,199)(H,170,198)(H,171,200)(H,172,213)(H,173,223)(H,174,221)(H,175,233)(H,176,214)(H,177,224)(H,178,225)(H,179,222)(H,180,230)(H,181,231)(H,182,236)(H,183,232)(H,184,234)(H,185,237)(H,186,201)(H,187,226)(H,188,229)(H,189,227)(H,190,228)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,155,156,158)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
DM1SOT4 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DM1SOT4 IK XXYMTCGQDUSUOO-RHBBJNDVSA-N
DM1SOT4 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM1SOT4 DE Discovery agent
DMLZNK6 ID DMLZNK6
DMLZNK6 DN [HO1][Lys8(5/6C-Flu)]VT
DMLZNK6 HS Investigative
DMLZNK6 PC 44320996
DMLZNK6 MW 1339.5
DMLZNK6 FM C62H74N12O18S2
DMLZNK6 IC InChI=1S/C62H74N12O18S2/c1-3-30(2)50-58(87)69-41(19-20-48(64)79)54(83)70-42(26-49(65)80)55(84)71-43(27-93-94-28-45(78)57(86)73-51(59(88)72-50)31-9-12-33(75)13-10-31)60(89)74-22-6-8-44(74)56(85)68-40(53(82)67-29-63)7-4-5-21-66-52(81)32-11-16-36-39(23-32)62(92-61(36)90)37-17-14-34(76)24-46(37)91-47-25-35(77)15-18-38(47)62/h9-18,23-25,30,40-45,50-51,75-78H,3-8,19-22,26-29,63H2,1-2H3,(H2,64,79)(H2,65,80)(H,66,81)(H,67,82)(H,68,85)(H,69,87)(H,70,83)(H,71,84)(H,72,88)(H,73,86)/t30?,40-,41+,42+,43+,44+,45?,50+,51-/m0/s1
DMLZNK6 CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DMLZNK6 IK UHOYWVNHWOKOQC-USAPJFQBSA-N
DMLZNK6 IU (2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-19-hydroxy-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMLZNK6 DE Discovery agent
DMFK9V5 ID DMFK9V5
DMFK9V5 DN [HO1][Orn8(5/6C-Flu)]VT
DMFK9V5 HS Investigative
DMFK9V5 PC 44321041
DMFK9V5 MW 1325.4
DMFK9V5 FM C61H72N12O18S2
DMFK9V5 IC InChI=1S/C61H72N12O18S2/c1-3-29(2)49-57(86)68-40(18-19-47(63)78)53(82)69-41(25-48(64)79)54(83)70-42(26-92-93-27-44(77)56(85)72-50(58(87)71-49)30-8-11-32(74)12-9-30)59(88)73-21-5-7-43(73)55(84)67-39(52(81)66-28-62)6-4-20-65-51(80)31-10-15-35-38(22-31)61(91-60(35)89)36-16-13-33(75)23-45(36)90-46-24-34(76)14-17-37(46)61/h8-17,22-24,29,39-44,49-50,74-77H,3-7,18-21,25-28,62H2,1-2H3,(H2,63,78)(H2,64,79)(H,65,80)(H,66,81)(H,67,84)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,72,85)/t29?,39-,40+,41+,42+,43+,44?,49+,50-/m0/s1
DMFK9V5 CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DMFK9V5 IK AKOGSKPWCBYRCU-IRJYFLAISA-N
DMFK9V5 IU (2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-19-hydroxy-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMFK9V5 DE Discovery agent
DM7COAM ID DM7COAM
DM7COAM DN [HO1][Orn8(5/6C-Rhm)]VT
DM7COAM HS Investigative
DM7COAM PC 44321159
DM7COAM MW 1382.6
DM7COAM FM C65H85N14O16S2+
DM7COAM IC InChI=1S/C65H84N14O16S2/c1-7-33(2)54-62(90)72-44(22-23-51(67)82)58(86)73-45(29-52(68)83)59(87)74-46(30-96-97-31-48(81)61(89)76-55(63(91)75-54)34-12-17-38(80)18-13-34)64(92)79-25-9-11-47(79)60(88)71-43(57(85)70-32-66)10-8-24-69-56(84)35-14-19-39(42(26-35)65(93)94)53-40-20-15-36(77(3)4)27-49(40)95-50-28-37(78(5)6)16-21-41(50)53/h12-21,26-28,33,40,43-48,50,54-55,81H,7-11,22-25,29-32,66H2,1-6H3,(H13-,67,68,69,70,71,72,73,74,75,76,80,82,83,84,85,86,87,88,89,90,91,93,94)/p+1/t33?,40?,43-,44+,45+,46+,47+,48?,50?,54+,55-/m0/s1
DM7COAM CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC(=C(C=C4)C5=C6C=CC(=CC6OC7=CC(=[N+](C)C)C=CC75)N(C)C)C(=O)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DM7COAM IK XSTBAVMTSHGRBE-CEBVGXOVSA-O
DM7COAM IU [9-[4-[[(4S)-5-(aminomethylamino)-4-[[(2R)-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-19-hydroxy-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentyl]carbamoyl]-2-carboxyphenyl]-6-(dimethylamino)-9a,10a-dihydroxanthen-3-ylidene]-dimethylazanium
DM7COAM DE Discovery agent
DMT2UYR ID DMT2UYR
DMT2UYR DN [HO1][Thr4,Lys8(5/6C-Flu)]VT
DMT2UYR HS Investigative
DMT2UYR PC 44321257
DMT2UYR MW 1312.4
DMT2UYR FM C61H73N11O18S2
DMT2UYR IC InChI=1S/C61H73N11O18S2/c1-4-29(2)48-56(84)70-49(30(3)73)57(85)67-41(25-47(63)78)53(81)68-42(26-91-92-27-44(77)55(83)71-50(58(86)69-48)31-10-13-33(74)14-11-31)59(87)72-21-7-9-43(72)54(82)66-40(52(80)65-28-62)8-5-6-20-64-51(79)32-12-17-36-39(22-32)61(90-60(36)88)37-18-15-34(75)23-45(37)89-46-24-35(76)16-19-38(46)61/h10-19,22-24,29-30,40-44,48-50,73-77H,4-9,20-21,25-28,62H2,1-3H3,(H2,63,78)(H,64,79)(H,65,80)(H,66,82)(H,67,85)(H,68,81)(H,69,86)(H,70,84)(H,71,83)/t29?,30?,40-,41+,42+,43+,44?,48+,49+,50-/m0/s1
DMT2UYR CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DMT2UYR IK FKCHDAOTEPJVRR-FBPATOIMSA-N
DMT2UYR IU (2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-19-hydroxy-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMT2UYR DE Discovery agent
DM81B4W ID DM81B4W
DM81B4W DN [HO1][Thr4,Orn8(5/6C-Flu)]VT
DM81B4W HS Investigative
DM81B4W PC 44321040
DM81B4W MW 1298.4
DM81B4W FM C60H71N11O18S2
DM81B4W IC InChI=1S/C60H71N11O18S2/c1-4-28(2)47-55(83)69-48(29(3)72)56(84)66-40(24-46(62)77)52(80)67-41(25-90-91-26-43(76)54(82)70-49(57(85)68-47)30-9-12-32(73)13-10-30)58(86)71-20-6-8-42(71)53(81)65-39(51(79)64-27-61)7-5-19-63-50(78)31-11-16-35-38(21-31)60(89-59(35)87)36-17-14-33(74)22-44(36)88-45-23-34(75)15-18-37(45)60/h9-18,21-23,28-29,39-43,47-49,72-76H,4-8,19-20,24-27,61H2,1-3H3,(H2,62,77)(H,63,78)(H,64,79)(H,65,81)(H,66,84)(H,67,80)(H,68,85)(H,69,83)(H,70,82)/t28?,29?,39-,40+,41+,42+,43?,47+,48+,49-/m0/s1
DM81B4W CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCC(C(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DM81B4W IK QZZVYFFNKFRZQH-NYIBOZPTSA-N
DM81B4W IU (2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-19-hydroxy-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM81B4W DE Discovery agent
DM7NXMB ID DM7NXMB
DM7NXMB DN [HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL
DM7NXMB HS Investigative
DM7NXMB SN [HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL; SB-485345; 2ai7; 2ai8; AC1NRD35; DB08523
DM7NXMB DT Small molecular drug
DM7NXMB PC 5289329
DM7NXMB MW 181.23
DM7NXMB FM C10H15NO2
DM7NXMB IC InChI=1S/C10H15NO2/c12-9-11(13)8-4-7-10-5-2-1-3-6-10/h1-3,5-6,12-13H,4,7-9H2
DM7NXMB CS C1=CC=C(C=C1)CCCN(CO)O
DM7NXMB IK GELOPWXSYZDPJT-UHFFFAOYSA-N
DM7NXMB IU [hydroxy(3-phenylpropyl)amino]methanol
DM7NXMB DE Discovery agent
DMXTY6L ID DMXTY6L
DMXTY6L DN [Leu13]motilin (human)
DMXTY6L HS Investigative
DMXTY6L SN [Leu13]-Motilin porcine; GTPL1453; 116283-54-6; [Leu13]-Motilin porcine, >
DMXTY6L DT Small molecular drug
DMXTY6L PC 16198245
DMXTY6L MW 2681
DMXTY6L FM C121H190N34O35
DMXTY6L IC InChI=1S/C121H190N34O35/c1-10-65(8)98(153-115(185)87-32-23-53-155(87)118(188)97(64(6)7)152-100(170)71(124)56-67-24-13-11-14-25-67)116(186)151-85(57-68-26-15-12-16-27-68)114(184)154-99(66(9)156)117(187)150-84(58-69-33-35-70(157)36-34-69)102(172)136-60-92(162)137-76(40-46-94(164)165)106(176)148-83(55-63(4)5)112(182)145-77(37-43-88(125)158)107(177)141-74(30-21-51-133-120(129)130)104(174)147-82(54-62(2)3)111(181)146-78(38-44-89(126)159)108(178)144-80(42-48-96(168)169)109(179)140-73(29-18-20-50-123)103(173)143-79(41-47-95(166)167)110(180)142-75(31-22-52-134-121(131)132)105(175)149-86(59-91(128)161)113(183)139-72(28-17-19-49-122)101(171)135-61-93(163)138-81(119(189)190)39-45-90(127)160/h11-16,24-27,33-36,62-66,71-87,97-99,156-157H,10,17-23,28-32,37-61,122-124H2,1-9H3,(H2,125,158)(H2,126,159)(H2,127,160)(H2,128,161)(H,135,171)(H,136,172)(H,137,162)(H,138,163)(H,139,183)(H,140,179)(H,141,177)(H,142,180)(H,143,173)(H,144,178)(H,145,182)(H,146,181)(H,147,174)(H,148,176)(H,149,175)(H,150,187)(H,151,186)(H,152,170)(H,153,185)(H,154,184)(H,164,165)(H,166,167)(H,168,169)(H,189,190)(H4,129,130,133)(H4,131,132,134)/t65-,66+,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,97-,98-,99-/m0/s1
DMXTY6L CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N
DMXTY6L IK GFOZQXMKARUPQI-HYOAWBISSA-N
DMXTY6L IU (2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMXTY6L CA CAS 116283-54-6
DMXTY6L DE Discovery agent
DMA0N32 ID DMA0N32
DMA0N32 DN [Leu5]enkephalin
DMA0N32 HS Investigative
DMA0N32 SN [Leu5]-Enkephalin; 58822-25-6; Enkephalin; Enkephalin L; [Leu 5]enkephalin; UNII-RI01R707R6; [5-Leucine]Enkephalin; Tyr-Gly-Gly-Phe-Leu-OH; CHEMBL8234; H-Tyr-Gly-Gly-Phe-Leu-OH; CHEBI:89656; RI01R707R6; Enkephalins; L-Leucine, N-(N-(N-(N-L-tyrosylglycyl)glycyl)-L-phenylalanyl)-; Leucyl-enkephalin
DMA0N32 DT Small molecular drug
DMA0N32 PC 9985128
DMA0N32 MW 554.6
DMA0N32 FM C28H38N6O6
DMA0N32 IC InChI=1S/C28H38N6O6/c1-17(2)12-22(26(30)38)34-28(40)23(14-18-6-4-3-5-7-18)33-25(37)16-31-24(36)15-32-27(39)21(29)13-19-8-10-20(35)11-9-19/h3-11,17,21-23,35H,12-16,29H2,1-2H3,(H2,30,38)(H,31,36)(H,32,39)(H,33,37)(H,34,40)/t21-,22-,23-/m0/s1
DMA0N32 CS CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMA0N32 IK YZXGODHVAJPXSG-VABKMULXSA-N
DMA0N32 IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide
DMA0N32 DE Discovery agent
DM3JHRC ID DM3JHRC
DM3JHRC DN [Leu8,des-Arg9]bradykinin
DM3JHRC HS Investigative
DM3JHRC SN 8-Leu-9-des-arg-BK; 8-Leu-9-de-arg-bradykinin; Bradykinin, leu(8) (1-8); bradykinin, Leu(8)-des-Arg(9)-; Bradykinin, leucyl(8)-des-arginine(9)-; CHEMBL80472; 64695-06-3; Bradykinin, 8-L-leucine-9-de-L-arginine-; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu; (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
DM3JHRC DT Small molecular drug
DM3JHRC PC 123884
DM3JHRC MW 870
DM3JHRC FM C41H63N11O10
DM3JHRC IC InChI=1S/C41H63N11O10/c1-24(2)20-28(40(61)62)48-36(57)31-14-8-17-50(31)38(59)29(23-53)49-34(55)27(21-25-10-4-3-5-11-25)47-33(54)22-46-35(56)30-13-7-18-51(30)39(60)32-15-9-19-52(32)37(58)26(42)12-6-16-45-41(43)44/h3-5,10-11,24,26-32,53H,6-9,12-23,42H2,1-2H3,(H,46,56)(H,47,54)(H,48,57)(H,49,55)(H,61,62)(H4,43,44,45)/t26-,27-,28-,29-,30-,31-,32-/m0/s1
DM3JHRC CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DM3JHRC IK BGAPYBBQGHUQNM-YYGRSCHNSA-N
DM3JHRC IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
DM3JHRC CA CAS 64695-06-3
DM3JHRC DE Discovery agent
DMHUMDR ID DMHUMDR
DMHUMDR DN [L-Tic7]OT
DMHUMDR HS Investigative
DMHUMDR SN CHEMBL397407; [L-Tic7]OT
DMHUMDR PC 16738355
DMHUMDR MW 1069.3
DMHUMDR FM C48H68N12O12S2
DMHUMDR IC InChI=1S/C48H68N12O12S2/c1-5-25(4)40-47(71)54-31(14-15-37(50)62)43(67)56-34(19-38(51)63)44(68)58-35(23-74-73-22-30(49)41(65)55-33(45(69)59-40)17-26-10-12-29(61)13-11-26)48(72)60-21-28-9-7-6-8-27(28)18-36(60)46(70)57-32(16-24(2)3)42(66)53-20-39(52)64/h6-13,24-25,30-36,40,61H,5,14-23,49H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,66)(H,54,71)(H,55,65)(H,56,67)(H,57,70)(H,58,68)(H,59,69)/t25-,30-,31-,32-,33-,34-,35-,36-,40-/m0/s1
DMHUMDR CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CC4=CC=CC=C4C[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMHUMDR IK GJHLANNXTOQRKG-FGTHJCBLSA-N
DMHUMDR IU (3S)-2-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMHUMDR DE Discovery agent
DM7STF6 ID DM7STF6
DM7STF6 DN [Lys8(Alexa 488) ]PVA
DM7STF6 HS Investigative
DM7STF6 SN CHEMBL1161978
DM7STF6 PC 44428107
DM7STF6 MW 2060.6
DM7STF6 FM C94H122Cl3N17O23S3
DM7STF6 IC InChI=1S/C94H122Cl3N17O23S3/c1-48-44-93(3,4)110-77-56(48)41-58-71(59-42-57-49(2)45-94(5,6)111-78(57)83(140(134,135)136)80(59)137-79(58)82(77)139(131,132)133)72-73(91(129)130)74(95)76(97)81(75(72)96)138-47-68(119)104-36-15-9-12-21-70(121)114(64(84(101)122)20-13-14-35-98)89(127)53-34-38-113(46-53)90(128)61(19-16-37-105-92(102)103)107-87(125)63(43-67(100)118)108-85(123)60(31-32-66(99)117)106-86(124)62(39-51-17-10-8-11-18-51)109-88(126)65(40-52-24-29-55(116)30-25-52)112(7)69(120)33-26-50-22-27-54(115)28-23-50/h8,10-11,17-18,22-25,27-30,41,48-49,53,57,60-65,80,83,110,115-116H,9,12-16,19-21,26,31-40,42-47,98H2,1-7H3,(H2,99,117)(H2,100,118)(H2,101,122)(H,104,119)(H,106,124)(H,107,125)(H,108,123)(H,109,126)(H,129,130)(H4,102,103,105)(H,131,132,133)(H,134,135,136)/t48?,49?,53-,57?,60-,61-,62-,63-,64-,65+,80?,83?/m0/s1
DM7STF6 CS CC1CC(N=C2C1CC3=C(C4=C(C(=C5C(=C4)C(CC(N5)(C)C)C)S(=O)(=O)O)OC3C2S(=O)(=O)O)C6=C(C(=C(C(=C6Cl)SCC(=O)NCCCCCC(=O)N([C@@H](CCCCN)C(=O)N)C(=O)[C@H]7CCN(C7)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@@H](CC9=CC=C(C=C9)O)N(C)C(=O)CCC1=CC=C(C=C1)O)Cl)Cl)C(=O)O)(C)C
DM7STF6 IK SVLGRIWNJNOFJU-CRAMPYNJSA-N
DM7STF6 IU 4-[2-[[6-[[(3S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2R)-3-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)propanoyl-methylamino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-3-carbonyl]-[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethyl]sulfanyl-2,3,5-trichloro-6-(7,7,9,17,19,19-hexamethyl-4,22-disulfo-2-oxa-6,20-diazapentacyclo[12.8.0.03,12.05,10.016,21]docosa-1(14),5,12,15,21-pentaen-13-yl)benzoic acid
DM7STF6 DE Discovery agent
DM38L6U ID DM38L6U
DM38L6U DN [Lys8(Alexa 546) ]PVA
DM38L6U HS Investigative
DM38L6U SN CHEMBL1161979
DM38L6U PC 44428109
DM38L6U MW 1629.7
DM38L6U FM C75H88N16O22S2
DM38L6U IC InChI=1S/C75H88N16O22S2/c1-89(60(96)29-16-39-12-18-44(92)19-13-39)57(35-41-14-20-45(93)21-15-41)70(101)88-54(34-40-8-3-2-4-9-40)68(99)85-52(27-28-58(79)94)67(98)87-55(37-59(80)95)69(100)86-53(10-7-32-84-75(82)83)73(104)90-33-30-43(38-90)72(103)91(56(66(81)97)11-5-6-31-76)71(102)42-17-22-46(49(36-42)74(105)106)61-47-23-25-50(77)64(114(107,108)109)62(47)113-63-48(61)24-26-51(78)65(63)115(110,111)112/h2-4,8-9,12-15,17-26,36,43,52-57,77,92-93H,5-7,10-11,16,27-35,37-38,76,78H2,1H3,(H2,79,94)(H2,80,95)(H2,81,97)(H,85,99)(H,86,100)(H,87,98)(H,88,101)(H,105,106)(H4,82,83,84)(H,107,108,109)(H,110,111,112)/t43-,52-,53-,54-,55-,56-,57+/m0/s1
DM38L6U CS CN([C@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CC[C@@H](C3)C(=O)N([C@@H](CCCCN)C(=O)N)C(=O)C4=CC(=C(C=C4)C5=C6C=CC(=N)C(=C6OC7=C5C=CC(=C7S(=O)(=O)O)N)S(=O)(=O)O)C(=O)O)C(=O)CCC8=CC=C(C=C8)O
DM38L6U IK JTPJNKPWLHDAAT-RHFIIQKYSA-N
DM38L6U IU 5-[[(3S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2R)-3-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)propanoyl-methylamino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-3-carbonyl]-[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamoyl]-2-(3-amino-6-imino-4,5-disulfoxanthen-9-yl)benzoic acid
DM38L6U DE Discovery agent
DM27LNU ID DM27LNU
DM27LNU DN [Mpa1, D-Tic2, Aib7]OT
DM27LNU HS Investigative
DM27LNU SN CHEMBL394268; [Mpa1, D-Tic2, Aib7]OT
DM27LNU DT Small molecular drug
DM27LNU PC 16736614
DM27LNU MW 976.2
DM27LNU FM C43H65N11O11S2
DM27LNU IC InChI=1S/C43H65N11O11S2/c1-7-23(4)35-41(64)48-26(12-13-31(44)55)37(60)49-28(18-32(45)56)38(61)50-29(39(62)53-43(5,6)42(65)51-27(16-22(2)3)36(59)47-19-33(46)57)21-67-66-15-14-34(58)54-20-25-11-9-8-10-24(25)17-30(54)40(63)52-35/h8-11,22-23,26-30,35H,7,12-21H2,1-6H3,(H2,44,55)(H2,45,56)(H2,46,57)(H,47,59)(H,48,64)(H,49,60)(H,50,61)(H,51,65)(H,52,63)(H,53,62)/t23-,26-,27-,28-,29-,30+,35-/m0/s1
DM27LNU CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N2CC3=CC=CC=C3C[C@@H]2C(=O)N1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM27LNU IK JBEGYQDVCITYKL-JEDRZNSQSA-N
DM27LNU IU (8R,11S,14S,17S,20R)-11-(2-amino-2-oxoethyl)-N-[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-14-(3-amino-3-oxopropyl)-17-[(2S)-butan-2-yl]-2,10,13,16,19-pentaoxo-5,6-dithia-1,9,12,15,18-pentazatricyclo[18.8.0.022,27]octacosa-22,24,26-triene-8-carboxamide
DM27LNU DE Discovery agent
DMPT1ME ID DMPT1ME
DMPT1ME DN [Mpa1, D-Tic7]OT
DMPT1ME HS Investigative
DMPT1ME SN CHEMBL265630; [Mpa1, D-Tic7]OT
DMPT1ME PC 16737618
DMPT1ME MW 1054.2
DMPT1ME FM C48H67N11O12S2
DMPT1ME IC InChI=1S/C48H67N11O12S2/c1-5-26(4)41-47(70)54-31(14-15-37(49)61)43(66)55-34(21-38(50)62)44(67)57-35(24-73-72-17-16-40(64)53-33(45(68)58-41)19-27-10-12-30(60)13-11-27)48(71)59-23-29-9-7-6-8-28(29)20-36(59)46(69)56-32(18-25(2)3)42(65)52-22-39(51)63/h6-13,25-26,31-36,41,60H,5,14-24H2,1-4H3,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,64)(H,54,70)(H,55,66)(H,56,69)(H,57,67)(H,58,68)/t26-,31-,32-,33-,34-,35-,36+,41-/m0/s1
DMPT1ME CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMPT1ME IK BEKGLOSGJVQNHG-CKIXOVHCSA-N
DMPT1ME IU (3R)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMPT1ME DE Discovery agent
DMBPVSD ID DMBPVSD
DMBPVSD DN [Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT
DMBPVSD HS Investigative
DMBPVSD SN CHEMBL233080; [Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT
DMBPVSD PC 44429304
DMBPVSD MW 1062.3
DMBPVSD FM C48H75N11O12S2
DMBPVSD IC InChI=1S/C48H75N11O12S2/c1-8-27(5)39-45(68)53-30(17-18-36(49)60)41(64)54-32(24-37(50)61)42(65)55-34(25-73-72-21-19-38(62)52-31(43(66)57-39)23-28-13-15-29(16-14-28)71-9-2)44(67)58-48(6,7)47(70)56-33(22-26(3)4)46(69)59-20-11-10-12-35(59)40(51)63/h13-16,26-27,30-35,39H,8-12,17-25H2,1-7H3,(H2,49,60)(H2,50,61)(H2,51,63)(H,52,62)(H,53,68)(H,54,64)(H,55,65)(H,56,70)(H,57,66)(H,58,67)/t27-,30-,31-,32-,33-,34-,35+,39-/m0/s1
DMBPVSD CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)N3CCCC[C@@H]3C(=O)N)CC(=O)N)CCC(=O)N
DMBPVSD IK UMBCXADJMGHVRX-AYLPWDSMSA-N
DMBPVSD IU (4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-N-[1-[[(2S)-1-[(2R)-2-carbamoylpiperidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMBPVSD DE Discovery agent
DMQSG6Y ID DMQSG6Y
DMQSG6Y DN [Mpa1, D-Tyr(Et)2, Aib7]OT
DMQSG6Y HS Investigative
DMQSG6Y SN CHEMBL393021; [Mpa1, D-Tyr(Et)2, Aib7]OT
DMQSG6Y PC 44429303
DMQSG6Y MW 1008.2
DMQSG6Y FM C44H69N11O12S2
DMQSG6Y IC InChI=1S/C44H69N11O12S2/c1-8-24(5)36-42(65)50-27(14-15-32(45)56)38(61)51-30(20-33(46)57)39(62)52-31(41(64)55-44(6,7)43(66)53-28(18-23(3)4)37(60)48-21-34(47)58)22-69-68-17-16-35(59)49-29(40(63)54-36)19-25-10-12-26(13-11-25)67-9-2/h10-13,23-24,27-31,36H,8-9,14-22H2,1-7H3,(H2,45,56)(H2,46,57)(H2,47,58)(H,48,60)(H,49,59)(H,50,65)(H,51,61)(H,52,62)(H,53,66)(H,54,63)(H,55,64)/t24-,27-,28-,29-,30-,31-,36-/m0/s1
DMQSG6Y CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMQSG6Y IK OGLIRWYQKYWIBI-YGTZAJLESA-N
DMQSG6Y IU (4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-N-[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMQSG6Y DE Discovery agent
DM5GSXC ID DM5GSXC
DM5GSXC DN [Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT
DM5GSXC HS Investigative
DM5GSXC SN CHEMBL438849; [Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT
DM5GSXC PC 44429295
DM5GSXC MW 1110.4
DM5GSXC FM C52H75N11O12S2
DM5GSXC IC InChI=1S/C52H75N11O12S2/c1-8-29(5)43-49(72)57-34(18-19-40(53)64)44(67)58-37(25-41(54)65)45(68)60-38(27-77-76-21-20-42(66)56-36(46(69)61-43)23-30-14-16-33(17-15-30)75-9-2)50(73)63-26-32-13-11-10-12-31(32)24-39(63)48(71)59-35(22-28(3)4)47(70)62-52(6,7)51(55)74/h10-17,28-29,34-39,43H,8-9,18-27H2,1-7H3,(H2,53,64)(H2,54,65)(H2,55,74)(H,56,66)(H,57,72)(H,58,67)(H,59,71)(H,60,68)(H,61,69)(H,62,70)/t29-,34-,35-,36-,37-,38-,39+,43-/m0/s1
DM5GSXC CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N)CC(=O)N)CCC(=O)N
DM5GSXC IK OKJBACYELSLYOC-QNDTVFEZSA-N
DM5GSXC IU (3R)-N-[(2S)-1-[(1-amino-2-methyl-1-oxopropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM5GSXC DE Discovery agent
DMI9MBO ID DMI9MBO
DMI9MBO DN [Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT
DMI9MBO HS Investigative
DMI9MBO SN CHEMBL434193; [Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT
DMI9MBO PC 44429294
DMI9MBO MW 1184.4
DMI9MBO FM C58H77N11O12S2
DMI9MBO IC InChI=1S/C58H77N11O12S2/c1-6-33(5)50-56(78)63-40(20-21-47(59)70)52(74)64-42(28-48(60)71)53(75)66-44(31-83-82-23-22-49(72)62-41(54(76)67-50)25-34-16-18-39(19-17-34)81-7-2)58(80)69-30-38-15-11-9-13-36(38)27-46(69)55(77)65-43(24-32(3)4)57(79)68-29-37-14-10-8-12-35(37)26-45(68)51(61)73/h8-19,32-33,40-46,50H,6-7,20-31H2,1-5H3,(H2,59,70)(H2,60,71)(H2,61,73)(H,62,72)(H,63,78)(H,64,74)(H,65,77)(H,66,75)(H,67,76)/t33-,40-,41-,42-,43-,44-,45+,46+,50-/m0/s1
DMI9MBO CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)N5CC6=CC=CC=C6C[C@@H]5C(=O)N)CC(=O)N)CCC(=O)N
DMI9MBO IK WNQPWZVGNWMXJD-YJDWKIOXSA-N
DMI9MBO IU (3R)-2-[(2S)-2-[[(3R)-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-methylpentanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMI9MBO DE Discovery agent
DM3T4JF ID DM3T4JF
DM3T4JF DN [Mpa1, D-Tyr(Et)2, D-Tic7]OT
DM3T4JF HS Investigative
DM3T4JF SN CHEMBL233328; [Mpa1, D-Tyr(Et)2, D-Tic7]OT
DM3T4JF PC 44429290
DM3T4JF MW 1082.3
DM3T4JF FM C50H71N11O12S2
DM3T4JF IC InChI=1S/C50H71N11O12S2/c1-6-28(5)43-49(71)56-33(16-17-39(51)62)45(67)57-36(23-40(52)63)46(68)59-37(26-75-74-19-18-42(65)55-35(47(69)60-43)21-29-12-14-32(15-13-29)73-7-2)50(72)61-25-31-11-9-8-10-30(31)22-38(61)48(70)58-34(20-27(3)4)44(66)54-24-41(53)64/h8-15,27-28,33-38,43H,6-7,16-26H2,1-5H3,(H2,51,62)(H2,52,63)(H2,53,64)(H,54,66)(H,55,65)(H,56,71)(H,57,67)(H,58,70)(H,59,68)(H,60,69)/t28-,33-,34-,35-,36-,37-,38+,43-/m0/s1
DM3T4JF CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM3T4JF IK XCBFBYRYXJOIRC-ABNDKVESSA-N
DM3T4JF IU (3R)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM3T4JF DE Discovery agent
DML8V4F ID DML8V4F
DML8V4F DN [Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT
DML8V4F HS Investigative
DML8V4F SN CHEMBL232501; [Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT
DML8V4F PC 44429300
DML8V4F MW 1036.3
DML8V4F FM C46H73N11O12S2
DML8V4F IC InChI=1S/C46H73N11O12S2/c1-10-69-26-13-11-25(12-14-26)20-29-41(65)56-36(45(4,5)6)43(67)52-27(15-16-32(47)58)39(63)53-30(21-33(48)59)40(64)55-31(23-71-70-18-17-35(61)51-29)42(66)57-37(46(7,8)9)44(68)54-28(19-24(2)3)38(62)50-22-34(49)60/h11-14,24,27-31,36-37H,10,15-23H2,1-9H3,(H2,47,58)(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,63)(H,54,68)(H,55,64)(H,56,65)(H,57,66)/t27-,28-,29-,30-,31-,36+,37+/m0/s1
DML8V4F CS CCOC1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)C(C)(C)C)CC(=O)N)CCC(=O)N)C(C)(C)C
DML8V4F IK DUQYFIXOZDQOES-CQRJDLEJSA-N
DML8V4F IU (4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-N-[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-10-(3-amino-3-oxopropyl)-13-tert-butyl-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DML8V4F DE Discovery agent
DMX2SU9 ID DMX2SU9
DMX2SU9 DN [Mpa1, D-Tyr(Et)2, Gly(But)7]OT
DMX2SU9 HS Investigative
DMX2SU9 SN CHEMBL441128; [Mpa1, D-Tyr(Et)2, Gly(But)7]OT
DMX2SU9 PC 44429299
DMX2SU9 MW 1036.3
DMX2SU9 FM C46H73N11O12S2
DMX2SU9 IC InChI=1S/C46H73N11O12S2/c1-9-25(5)37-44(67)52-28(15-16-33(47)58)40(63)53-31(21-34(48)59)41(64)55-32(43(66)57-38(46(6,7)8)45(68)54-29(19-24(3)4)39(62)50-22-35(49)60)23-71-70-18-17-36(61)51-30(42(65)56-37)20-26-11-13-27(14-12-26)69-10-2/h11-14,24-25,28-32,37-38H,9-10,15-23H2,1-8H3,(H2,47,58)(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,63)(H,54,68)(H,55,64)(H,56,65)(H,57,66)/t25-,28-,29-,30-,31-,32-,37-,38+/m0/s1
DMX2SU9 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)C(C)(C)C)CC(=O)N)CCC(=O)N
DMX2SU9 IK BTBKJAGQCVEVDA-GDQBDYHJSA-N
DMX2SU9 IU (4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-N-[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMX2SU9 DE Discovery agent
DM0H3NV ID DM0H3NV
DM0H3NV DN [Mpa1, D-Tyr(Et)2, L-Tic7]OT
DM0H3NV HS Investigative
DM0H3NV SN CHEMBL234377; [Mpa1, D-Tyr(Et)2, L-Tic7]OT
DM0H3NV PC 44429288
DM0H3NV MW 1082.3
DM0H3NV FM C50H71N11O12S2
DM0H3NV IC InChI=1S/C50H71N11O12S2/c1-6-28(5)43-49(71)56-33(16-17-39(51)62)45(67)57-36(23-40(52)63)46(68)59-37(26-75-74-19-18-42(65)55-35(47(69)60-43)21-29-12-14-32(15-13-29)73-7-2)50(72)61-25-31-11-9-8-10-30(31)22-38(61)48(70)58-34(20-27(3)4)44(66)54-24-41(53)64/h8-15,27-28,33-38,43H,6-7,16-26H2,1-5H3,(H2,51,62)(H2,52,63)(H2,53,64)(H,54,66)(H,55,65)(H,56,71)(H,57,67)(H,58,70)(H,59,68)(H,60,69)/t28-,33-,34-,35-,36-,37-,38-,43-/m0/s1
DM0H3NV CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC4=CC=CC=C4C[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM0H3NV IK XCBFBYRYXJOIRC-SXXMFYQFSA-N
DM0H3NV IU (3S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM0H3NV DE Discovery agent
DM6W4LR ID DM6W4LR
DM6W4LR DN [Mpa1, D-Tyr(Et)2, Pip7]OT
DM6W4LR HS Investigative
DM6W4LR SN CHEMBL393020; [Mpa1, D-Tyr(Et)2, Pip7]OT
DM6W4LR PC 44429298
DM6W4LR MW 1034.3
DM6W4LR FM C46H71N11O12S2
DM6W4LR IC InChI=1S/C46H71N11O12S2/c1-6-26(5)39-45(67)52-29(15-16-35(47)58)41(63)53-32(22-36(48)59)42(64)55-33(24-71-70-19-17-38(61)51-31(43(65)56-39)21-27-11-13-28(14-12-27)69-7-2)46(68)57-18-9-8-10-34(57)44(66)54-30(20-25(3)4)40(62)50-23-37(49)60/h11-14,25-26,29-34,39H,6-10,15-24H2,1-5H3,(H2,47,58)(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,63)(H,54,66)(H,55,64)(H,56,65)/t26-,29-,30-,31-,32-,33-,34-,39-/m0/s1
DM6W4LR CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DM6W4LR IK NMLWRIDSUBGNGP-IHJZLXGESA-N
DM6W4LR IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]piperidine-2-carboxamide
DM6W4LR DE Discovery agent
DMB4J3N ID DMB4J3N
DMB4J3N DN [Mpa1, L-Tic7]OT
DMB4J3N HS Investigative
DMB4J3N SN CHEMBL415418; [Mpa1, L-Tic7]OT
DMB4J3N PC 16737617
DMB4J3N MW 1054.2
DMB4J3N FM C48H67N11O12S2
DMB4J3N IC InChI=1S/C48H67N11O12S2/c1-5-26(4)41-47(70)54-31(14-15-37(49)61)43(66)55-34(21-38(50)62)44(67)57-35(24-73-72-17-16-40(64)53-33(45(68)58-41)19-27-10-12-30(60)13-11-27)48(71)59-23-29-9-7-6-8-28(29)20-36(59)46(69)56-32(18-25(2)3)42(65)52-22-39(51)63/h6-13,25-26,31-36,41,60H,5,14-24H2,1-4H3,(H2,49,61)(H2,50,62)(H2,51,63)(H,52,65)(H,53,64)(H,54,70)(H,55,66)(H,56,69)(H,57,67)(H,58,68)/t26-,31-,32-,33-,34-,35-,36-,41-/m0/s1
DMB4J3N CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)N3CC4=CC=CC=C4C[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMB4J3N IK BEKGLOSGJVQNHG-JSRVRBLWSA-N
DMB4J3N IU (3S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-2-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMB4J3N DE Discovery agent
DMW9AST ID DMW9AST
DMW9AST DN [N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX)
DMW9AST HS Investigative
DMW9AST DE Discovery agent
DM6EAHF ID DM6EAHF
DM6EAHF DN [N40,Pro1,Tyr4,Nle 14]BB
DM6EAHF HS Investigative
DM6EAHF PC 91933168
DM6EAHF MW 1838.1
DM6EAHF FM C84H132N28O19
DM6EAHF IC InChI=1S/C84H132N28O19/c1-7-8-9-16-55(71(90)119)104-78(126)59(33-45(2)3)108-79(127)62(36-51-41-95-44-100-51)102-69(118)43-99-82(130)70(46(4)5)111-72(120)47(6)101-77(125)61(35-49-40-97-54-15-11-10-14-53(49)54)110-76(124)57(23-25-65(87)114)106-80(128)63(37-67(89)116)103-68(117)42-98-73(121)60(34-48-19-21-52(113)22-20-48)109-74(122)56(17-12-29-96-84(91)92)105-75(123)58(24-26-66(88)115)107-81(129)64-18-13-32-112(64)83(131)50(38-93-30-27-85)39-94-31-28-86/h10-11,14-15,19-22,40-41,44-47,50,55-64,70,93-94,97,113H,7-9,12-13,16-18,23-39,42-43,85-86H2,1-6H3,(H2,87,114)(H2,88,115)(H2,89,116)(H2,90,119)(H,95,100)(H,98,121)(H,99,130)(H,101,125)(H,102,118)(H,103,117)(H,104,126)(H,105,123)(H,106,128)(H,107,129)(H,108,127)(H,109,122)(H,110,124)(H,111,120)(H4,91,92,96)/t47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64?,70-/m0/s1
DM6EAHF CS CCCCC[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C5CCCN5C(=O)C(CNCCN)CNCCN
DM6EAHF IK KQHZZRQJOXXKSD-LJBQZBCTSA-N
DM6EAHF IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxoheptan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[1-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]pyrrolidine-2-carbonyl]amino]pentanediamide
DM6EAHF DE Discovery agent
DMVFHNM ID DMVFHNM
DMVFHNM DN [N40,Pro1,Tyr4]BB
DMVFHNM HS Investigative
DMVFHNM PC 91933169
DMVFHNM MW 1856.2
DMVFHNM FM C83H130N28O19S
DMVFHNM IC InChI=1S/C83H130N28O19S/c1-44(2)32-58(77(125)103-54(70(89)118)15-11-31-131-6)107-78(126)61(35-50-40-94-43-99-50)101-68(117)42-98-81(129)69(45(3)4)110-71(119)46(5)100-76(124)60(34-48-39-96-53-13-8-7-12-52(48)53)109-75(123)56(21-23-64(86)113)105-79(127)62(36-66(88)115)102-67(116)41-97-72(120)59(33-47-17-19-51(112)20-18-47)108-73(121)55(14-9-27-95-83(90)91)104-74(122)57(22-24-65(87)114)106-80(128)63-16-10-30-111(63)82(130)49(37-92-28-25-84)38-93-29-26-85/h7-8,12-13,17-20,39-40,43-46,49,54-63,69,92-93,96,112H,9-11,14-16,21-38,41-42,84-85H2,1-6H3,(H2,86,113)(H2,87,114)(H2,88,115)(H2,89,118)(H,94,99)(H,97,120)(H,98,129)(H,100,124)(H,101,117)(H,102,116)(H,103,125)(H,104,122)(H,105,127)(H,106,128)(H,107,126)(H,108,121)(H,109,123)(H,110,119)(H4,90,91,95)/t46-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63?,69-/m0/s1
DMVFHNM CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C5CCCN5C(=O)C(CNCCN)CNCCN
DMVFHNM IK WPAOEAXJLCSDBY-UKYQNQGLSA-N
DMVFHNM IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-methylsulfanyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[1-[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]pyrrolidine-2-carbonyl]amino]pentanediamide
DMVFHNM DE Discovery agent
DMW6LIJ ID DMW6LIJ
DMW6LIJ DN [N-Ac,des-Sar]Gal-B2
DMW6LIJ HS Investigative
DMW6LIJ SN CHEMBL578317; [N-Ac,des-Sar]Gal-B2
DMW6LIJ PC 45104656
DMW6LIJ MW 2083.6
DMW6LIJ FM C103H171N23O22
DMW6LIJ IC InChI=1S/C103H171N23O22/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(132)109-50-33-29-40-75(93(138)116-73(90(108)135)37-26-30-47-104)118-94(139)74(38-27-31-48-105)117-95(140)76(39-28-32-49-106)119-102(147)84-41-34-51-126(84)88(134)60-112-92(137)77(52-62(2)3)120-96(141)78(53-63(4)5)121-98(143)80(55-68-43-45-70(130)46-44-68)115-87(133)59-111-91(136)65(8)113-101(146)83(61-127)124-99(144)82(57-85(107)131)122-97(142)79(54-64(6)7)123-103(148)89(66(9)128)125-100(145)81(114-67(10)129)56-69-58-110-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,62-66,73-84,89,110,127-128,130H,11-23,26-34,37-42,47-57,59-61,104-106H2,1-10H3,(H2,107,131)(H2,108,135)(H,109,132)(H,111,136)(H,112,137)(H,113,146)(H,114,129)(H,115,133)(H,116,138)(H,117,140)(H,118,139)(H,119,147)(H,120,141)(H,121,143)(H,122,142)(H,123,148)(H,124,144)(H,125,145)/t65-,66+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,89-/m0/s1
DMW6LIJ CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)C
DMW6LIJ IK ODFVMHJVAFRRKO-QWBMYOKVSA-N
DMW6LIJ IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMW6LIJ DE Discovery agent
DME6LKY ID DME6LKY
DME6LKY DN [Ncy(2-naphthyl)1]acyline
DME6LKY HS Investigative
DME6LKY SN CHEMBL414344; [Ncy(2-naphthyl)1]acyline
DME6LKY PC 16138575
DME6LKY MW 1533.2
DME6LKY FM C80H102ClN15O14
DME6LKY IC InChI=1S/C80H102ClN15O14/c1-46(2)37-63(72(102)89-62(18-11-12-35-84-47(3)4)80(110)96-36-14-19-70(96)79(109)85-48(5)71(82)101)90-74(104)66(40-53-23-30-60(31-24-53)86-49(6)98)92-76(106)67(41-54-25-32-61(33-26-54)87-50(7)99)94-78(108)69(45-97)95-77(107)68(43-56-15-13-34-83-44-56)93-75(105)65(39-52-21-28-59(81)29-22-52)91-73(103)64(88-51(8)100)42-55-20-27-57-16-9-10-17-58(57)38-55/h9-10,13,15-17,20-34,38,44,46-48,62-70,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,109)(H,86,98)(H,87,99)(H,88,100)(H,89,102)(H,90,104)(H,91,103)(H,92,106)(H,93,105)(H,94,108)(H,95,107)/t48-,62+,63+,64+,65-,66-,67+,68-,69+,70+/m1/s1
DME6LKY CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DME6LKY IK ZWNUQDJANZGVFO-ITULWGTLSA-N
DME6LKY IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DME6LKY DE Discovery agent
DM5CS8U ID DM5CS8U
DM5CS8U DN [Ncy(isopropyl)7]acyline
DM5CS8U HS Investigative
DM5CS8U SN CHEMBL415659; [Ncy(isopropyl)7]acyline
DM5CS8U PC 16221494
DM5CS8U MW 1551.2
DM5CS8U FM C79H100ClN15O14S
DM5CS8U IC InChI=1S/C79H100ClN15O14S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(110-46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78+/m1/s1
DM5CS8U CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC(C)C
DM5CS8U IK GFSHJVRBLLVKAZ-FYZIRFIYSA-N
DM5CS8U IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfanylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM5CS8U DE Discovery agent
DM9RC3O ID DM9RC3O
DM9RC3O DN [Ncy(methyl)10]acyline
DM9RC3O HS Investigative
DM9RC3O SN CHEMBL427438; [Ncy(methyl)10]acyline
DM9RC3O PC 16221266
DM9RC3O MW 1565.3
DM9RC3O FM C80H102ClN15O14S
DM9RC3O IC InChI=1S/C80H102ClN15O14S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(111-8)70(82)101)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79-/m0/s1
DM9RC3O CS CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)SC)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DM9RC3O IK MNOHGPTZCIGJAF-SLOMUXTRSA-N
DM9RC3O IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1S)-2-amino-1-methylsulfanyl-2-oxoethyl]pyrrolidine-2-carboxamide
DM9RC3O DE Discovery agent
DMLK8YQ ID DMLK8YQ
DMLK8YQ DN [Ncy(methyl)4]acyline
DMLK8YQ HS Investigative
DMLK8YQ SN CHEMBL388369; [Ncy(methyl)4]acyline
DMLK8YQ PC 16221433
DMLK8YQ MW 1549.3
DMLK8YQ FM C80H102ClN15O13S
DMLK8YQ IC InChI=1S/C80H102ClN15O13S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(110-9)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79+/m1/s1
DMLK8YQ CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)SC
DMLK8YQ IK HPTFWQIEIVLQOX-CYCWPGSHSA-N
DMLK8YQ IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfanylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMLK8YQ DE Discovery agent
DMEFIQ9 ID DMEFIQ9
DMEFIQ9 DN [Ncy(SO,isopropyl)7]acyline
DMEFIQ9 HS Investigative
DMEFIQ9 SN CHEMBL441211; [Ncy(SO,isopropyl)7]acyline
DMEFIQ9 PC 16221211
DMEFIQ9 MW 1567.2
DMEFIQ9 FM C79H100ClN15O15S
DMEFIQ9 IC InChI=1S/C79H100ClN15O15S/c1-45(2)83-35-12-11-18-61(79(109)95-36-14-19-68(95)76(107)84-47(5)69(81)100)88-77(108)78(111(110)46(3)4)94-74(105)65(40-53-25-32-60(33-26-53)86-49(7)98)90-72(103)64(39-52-23-30-59(31-24-52)85-48(6)97)92-75(106)67(44-96)93-73(104)66(42-55-15-13-34-82-43-55)91-71(102)63(38-51-21-28-58(80)29-22-51)89-70(101)62(87-50(8)99)41-54-20-27-56-16-9-10-17-57(56)37-54/h9-10,13,15-17,20-34,37,43,45-47,61-68,78,83,96H,11-12,14,18-19,35-36,38-42,44H2,1-8H3,(H2,81,100)(H,84,107)(H,85,97)(H,86,98)(H,87,99)(H,88,108)(H,89,101)(H,90,103)(H,91,102)(H,92,106)(H,93,104)(H,94,105)/t47-,61+,62-,63-,64+,65-,66-,67+,68+,78+,111?/m1/s1
DMEFIQ9 CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C(C)C
DMEFIQ9 IK KEFJIAHSOLWSII-RUFKGVBESA-N
DMEFIQ9 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-2-propan-2-ylsulfinylacetyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMEFIQ9 DE Discovery agent
DMT8X45 ID DMT8X45
DMT8X45 DN [Ncy(SO,methyl)10]acyline
DMT8X45 HS Investigative
DMT8X45 SN CHEMBL389248; [Ncy(SO,methyl)10]acyline
DMT8X45 PC 16221496
DMT8X45 MW 1581.3
DMT8X45 FM C80H102ClN15O15S
DMT8X45 IC InChI=1S/C80H102ClN15O15S/c1-46(2)37-62(71(102)88-61(18-11-12-35-84-47(3)4)80(110)96-36-14-19-69(96)78(109)95-79(70(82)101)112(8)111)89-73(104)65(40-52-23-30-59(31-24-52)85-48(5)98)91-75(106)66(41-53-25-32-60(33-26-53)86-49(6)99)93-77(108)68(45-97)94-76(107)67(43-55-15-13-34-83-44-55)92-74(105)64(39-51-21-28-58(81)29-22-51)90-72(103)63(87-50(7)100)42-54-20-27-56-16-9-10-17-57(56)38-54/h9-10,13,15-17,20-34,38,44,46-47,61-69,79,84,97H,11-12,14,18-19,35-37,39-43,45H2,1-8H3,(H2,82,101)(H,85,98)(H,86,99)(H,87,100)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,105)(H,93,108)(H,94,107)(H,95,109)/t61-,62-,63+,64+,65+,66-,67+,68-,69-,79-,112?/m0/s1
DMT8X45 CS CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)S(=O)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
DMT8X45 IK SELUBVJEWYERMJ-DDPYUAONSA-N
DMT8X45 IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(1S)-2-amino-1-methylsulfinyl-2-oxoethyl]pyrrolidine-2-carboxamide
DMT8X45 DE Discovery agent
DM057MP ID DM057MP
DM057MP DN [Ncy(SO,methyl)4]acyline
DM057MP HS Investigative
DM057MP SN CHEMBL415432; [Ncy(SO,methyl)4]acyline
DM057MP PC 16221150
DM057MP MW 1565.3
DM057MP FM C80H102ClN15O14S
DM057MP IC InChI=1S/C80H102ClN15O14S/c1-46(2)38-63(71(101)89-62(19-12-13-36-84-47(3)4)80(109)96-37-15-20-69(96)77(107)85-48(5)70(82)100)90-73(103)66(41-53-24-31-60(32-25-53)86-49(6)97)92-75(105)67(42-54-26-33-61(34-27-54)87-50(7)98)94-78(108)79(111(9)110)95-76(106)68(44-56-16-14-35-83-45-56)93-74(104)65(40-52-22-29-59(81)30-23-52)91-72(102)64(88-51(8)99)43-55-21-28-57-17-10-11-18-58(57)39-55/h10-11,14,16-18,21-35,39,45-48,62-69,79,84H,12-13,15,19-20,36-38,40-44H2,1-9H3,(H2,82,100)(H,85,107)(H,86,97)(H,87,98)(H,88,99)(H,89,101)(H,90,103)(H,91,102)(H,92,105)(H,93,104)(H,94,108)(H,95,106)/t48-,62+,63+,64-,65-,66-,67+,68-,69+,79+,111?/m1/s1
DM057MP CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)C)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)C)NC(=O)[C@@H](NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)S(=O)C
DM057MP IK VCYXYVFYPVPVGF-SBGSYDNWSA-N
DM057MP IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-2-methylsulfinylacetyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-3-(4-acetamidophenyl)propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM057MP DE Discovery agent
DM4XFOH ID DM4XFOH
DM4XFOH DN [N-Me,des-Sar]Gal-B2
DM4XFOH HS Investigative
DM4XFOH SN CHEMBL604991; [N-Me,des-Sar]Gal-B2
DM4XFOH PC 45104657
DM4XFOH MW 2055.6
DM4XFOH FM C102H171N23O21
DM4XFOH IC InChI=1S/C102H171N23O21/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-85(130)109-50-33-29-40-74(92(136)115-72(89(107)133)37-26-30-47-103)117-93(137)73(38-27-31-48-104)116-94(138)75(39-28-32-49-105)118-101(145)83-41-34-51-125(83)87(132)60-112-91(135)77(52-62(2)3)119-96(140)78(53-63(4)5)120-98(142)80(55-67-43-45-69(128)46-44-67)114-86(131)59-111-90(134)65(8)113-100(144)82(61-126)123-99(143)81(57-84(106)129)121-97(141)79(54-64(6)7)122-102(146)88(66(9)127)124-95(139)76(108-10)56-68-58-110-71-36-25-24-35-70(68)71/h24-25,35-36,43-46,58,62-66,72-83,88,108,110,126-128H,11-23,26-34,37-42,47-57,59-61,103-105H2,1-10H3,(H2,106,129)(H2,107,133)(H,109,130)(H,111,134)(H,112,135)(H,113,144)(H,114,131)(H,115,136)(H,116,138)(H,117,137)(H,118,145)(H,119,140)(H,120,142)(H,121,141)(H,122,146)(H,123,143)(H,124,139)/t65-,66+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,88-/m0/s1
DM4XFOH CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC
DM4XFOH IK WZUYPFZMVKTBDB-CWYLLMHLSA-N
DM4XFOH IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-3-(1H-indol-3-yl)-2-(methylamino)propanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]butanediamide
DM4XFOH DE Discovery agent
DMTG17Q ID DMTG17Q
DMTG17Q DN [Nphe(1)]-nociceptin (1-13)-NH(2)
DMTG17Q HS Investigative
DMTG17Q DT Small molecular drug
DMTG17Q PC 24776433
DMTG17Q MW 500.4
DMTG17Q FM C21H27F2N4O6P
DMTG17Q IC InChI=1S/C18H19F2N3O.C3H8NO5P/c1-23-9-14(16(22-23)17(19)20)18(24)21-15-5-3-2-4-11(15)13-8-12(13)10-6-7-10;5-3(6)1-4-2-10(7,8)9/h2-5,9-10,12-13,17H,6-8H2,1H3,(H,21,24);4H,1-2H2,(H,5,6)(H2,7,8,9)
DMTG17Q CS CN1C=C(C(=N1)C(F)F)C(=O)NC2=CC=CC=C2C3CC3C4CC4.C(C(=O)O)NCP(=O)(O)O
DMTG17Q IK ZLEQCJLOZSQAHT-UHFFFAOYSA-N
DMTG17Q IU N-[2-(2-cyclopropylcyclopropyl)phenyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide;2-(phosphonomethylamino)acetic acid
DMTG17Q DE Discovery agent
DMK18CS ID DMK18CS
DMK18CS DN [Phe3]OT
DMK18CS HS Investigative
DMK18CS SN [Phe3]oxytocin; oxypressin
DMK18CS DT Small molecular drug
DMK18CS PC 164712
DMK18CS MW 1041.2
DMK18CS FM C46H64N12O12S2
DMK18CS IC InChI=1S/C46H64N12O12S2/c1-24(2)17-30(40(64)51-21-38(50)62)56-45(69)35-9-6-16-58(35)46(70)34-23-72-71-22-28(47)39(63)53-31(19-26-10-12-27(59)13-11-26)43(67)54-32(18-25-7-4-3-5-8-25)42(66)52-29(14-15-36(48)60)41(65)55-33(20-37(49)61)44(68)57-34/h3-5,7-8,10-13,24,28-35,59H,6,9,14-23,47H2,1-2H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,51,64)(H,52,66)(H,53,63)(H,54,67)(H,55,65)(H,56,69)(H,57,68)/t28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
DMK18CS CS CC(C)C[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N
DMK18CS IK WTHKESHUHBGMGM-DZCXQCEKSA-N
DMK18CS IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMK18CS CA CAS 642-35-3
DMK18CS DE Discovery agent
DMXJDEA ID DMXJDEA
DMXJDEA DN [Pip7]OT
DMXJDEA HS Investigative
DMXJDEA SN CHEMBL395290; [Pip7]OT
DMXJDEA PC 44429250
DMXJDEA MW 1021.2
DMXJDEA FM C44H68N12O12S2
DMXJDEA IC InChI=1S/C44H68N12O12S2/c1-5-23(4)36-43(67)50-27(13-14-33(46)58)39(63)52-30(18-34(47)59)40(64)54-31(21-70-69-20-26(45)37(61)51-29(41(65)55-36)17-24-9-11-25(57)12-10-24)44(68)56-15-7-6-8-32(56)42(66)53-28(16-22(2)3)38(62)49-19-35(48)60/h9-12,22-23,26-32,36,57H,5-8,13-21,45H2,1-4H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,61)(H,52,63)(H,53,66)(H,54,64)(H,55,65)/t23-,26-,27-,28-,29-,30-,31-,32-,36-/m0/s1
DMXJDEA CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
DMXJDEA IK AEGMQTAGVURKHK-CKNUHMDMSA-N
DMXJDEA IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]piperidine-2-carboxamide
DMXJDEA DE Discovery agent
DM4ZY79 ID DM4ZY79
DM4ZY79 DN [Pterin-6-Yl Methanyl]-Phosphonophosphate
DM4ZY79 HS Investigative
DM4ZY79 DT Small molecular drug
DM4ZY79 PC 135440058
DM4ZY79 MW 353.12
DM4ZY79 FM C7H9N5O8P2
DM4ZY79 IC InChI=1S/C7H9N5O8P2/c8-7-11-5-4(6(13)12-7)10-3(1-9-5)2-19-22(17,18)20-21(14,15)16/h1H,2H2,(H,17,18)(H2,14,15,16)(H3,8,9,11,12,13)
DM4ZY79 CS C1=C(N=C2C(=O)NC(=NC2=N1)N)COP(=O)(O)OP(=O)(O)O
DM4ZY79 IK AMDUVUKDRBIVAH-UHFFFAOYSA-N
DM4ZY79 IU (2-amino-4-oxo-3H-pteridin-6-yl)methyl phosphono hydrogen phosphate
DM4ZY79 CA CAS 6863-06-5
DM4ZY79 DE Discovery agent
DM8YF3V ID DM8YF3V
DM8YF3V DN [R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether
DM8YF3V HS Investigative
DM8YF3V SN CHEMBL457275; BDBM50251328
DM8YF3V DT Small molecular drug
DM8YF3V PC 44567595
DM8YF3V MW 327.4
DM8YF3V FM C19H21NO4
DM8YF3V IC InChI=1S/C19H21NO4/c1-20-5-4-12-8-13(24-7-6-21)10-14-17(12)15(20)9-11-2-3-16(22)19(23)18(11)14/h2-3,8,10,15,21-23H,4-7,9H2,1H3/t15-/m1/s1
DM8YF3V CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCO)C(=C(C=C4)O)O
DM8YF3V IK MLSWBRKIYGJEGT-OAHLLOKOSA-N
DM8YF3V IU (6aR)-2-(2-hydroxyethoxy)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM8YF3V DE Discovery agent
DMUF7DP ID DMUF7DP
DMUF7DP DN [Sar,D-Phe8,des-Arg9]bradykinin
DMUF7DP HS Investigative
DMUF7DP SN [N-methylglycine,D-Phe8,des-Arg9]bradykinin; [sarcosine,D-Phe8,des-Arg9]bradykinin; Sar[DPhe8][des-Arg9]BK
DMUF7DP DT Small molecular drug
DMUF7DP PC 164234
DMUF7DP MW 975.1
DMUF7DP FM C47H66N12O11
DMUF7DP IC InChI=1S/C47H66N12O11/c1-50-26-38(61)53-31(16-8-20-51-47(48)49)43(66)59-23-11-19-37(59)45(68)58-22-9-17-35(58)41(64)52-27-39(62)54-32(24-29-12-4-2-5-13-29)40(63)56-34(28-60)44(67)57-21-10-18-36(57)42(65)55-33(46(69)70)25-30-14-6-3-7-15-30/h2-7,12-15,31-37,50,60H,8-11,16-28H2,1H3,(H,52,64)(H,53,61)(H,54,62)(H,55,65)(H,56,63)(H,69,70)(H4,48,49,51)/t31-,32-,33+,34-,35-,36-,37-/m0/s1
DMUF7DP CS CNCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@H](CC5=CC=CC=C5)C(=O)O
DMUF7DP IK YIUBSFCQATYQJB-VCMDLEIESA-N
DMUF7DP IU (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMUF7DP CA CAS 126959-88-4
DMUF7DP DE Discovery agent
DM1HQ3D ID DM1HQ3D
DM1HQ3D DN [Sar1,Bpa2]AngII
DM1HQ3D HS Investigative
DM1HQ3D SN CHEMBL1076601; [Sar1,Bpa2]AngII
DM1HQ3D PC 45140373
DM1HQ3D MW 1097.3
DM1HQ3D FM C59H72N10O11
DM1HQ3D IC InChI=1S/C59H72N10O11/c1-6-36(4)51(57(77)65-46(31-42-32-61-34-62-42)58(78)69-27-13-18-48(69)55(75)66-47(59(79)80)30-37-14-9-7-10-15-37)68-54(74)45(29-39-21-25-43(70)26-22-39)64-56(76)50(35(2)3)67-53(73)44(63-49(71)33-60-5)28-38-19-23-41(24-20-38)52(72)40-16-11-8-12-17-40/h7-12,14-17,19-26,32,34-36,44-48,50-51,60,70H,6,13,18,27-31,33H2,1-5H3,(H,61,62)(H,63,71)(H,64,76)(H,65,77)(H,66,75)(H,67,73)(H,68,74)(H,79,80)/t36-,44-,45-,46-,47-,48-,50-,51-/m0/s1
DM1HQ3D CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)NC(=O)CNC
DM1HQ3D IK BXRVAHMUUBZAPK-RUFDXANVSA-N
DM1HQ3D IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-benzoylphenyl)-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DM1HQ3D DE Discovery agent
DMP64XH ID DMP64XH
DMP64XH DN [Sar1,Bpa3]AngII
DMP64XH HS Investigative
DMP64XH SN CHEMBL1076603; [Sar1,Bpa3]AngII
DMP64XH PC 46880541
DMP64XH MW 1154.3
DMP64XH FM C60H75N13O11
DMP64XH IC InChI=1S/C60H75N13O11/c1-4-36(2)51(57(81)70-47(32-42-33-64-35-66-42)58(82)73-28-12-18-49(73)56(80)71-48(59(83)84)31-37-13-7-5-8-14-37)72-55(79)46(30-39-21-25-43(74)26-22-39)69-54(78)45(29-38-19-23-41(24-20-38)52(76)40-15-9-6-10-16-40)68-53(77)44(67-50(75)34-63-3)17-11-27-65-60(61)62/h5-10,13-16,19-26,33,35-36,44-49,51,63,74H,4,11-12,17-18,27-32,34H2,1-3H3,(H,64,66)(H,67,75)(H,68,77)(H,69,78)(H,70,81)(H,71,80)(H,72,79)(H,83,84)(H4,61,62,65)/t36-,44-,45-,46-,47-,48-,49-,51-/m0/s1
DMP64XH CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMP64XH IK PXNIGPMZOUUXMA-FSKISDTGSA-N
DMP64XH IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-(4-benzoylphenyl)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMP64XH DE Discovery agent
DMWC10R ID DMWC10R
DMWC10R DN [Sar1,Bpa8]AngII
DMWC10R HS Investigative
DMWC10R SN CHEMBL1076632; [Sar1,Bpa8]AngII
DMWC10R PC 46880544
DMWC10R MW 1106.3
DMWC10R FM C56H75N13O11
DMWC10R IC InChI=1S/C56H75N13O11/c1-6-33(4)47(68-50(74)41(26-35-18-22-39(70)23-19-35)64-52(76)46(32(2)3)67-49(73)40(63-45(71)30-59-5)14-10-24-61-56(57)58)53(77)65-42(28-38-29-60-31-62-38)54(78)69-25-11-15-44(69)51(75)66-43(55(79)80)27-34-16-20-37(21-17-34)48(72)36-12-8-7-9-13-36/h7-9,12-13,16-23,29,31-33,40-44,46-47,59,70H,6,10-11,14-15,24-28,30H2,1-5H3,(H,60,62)(H,63,71)(H,64,76)(H,65,77)(H,66,75)(H,67,73)(H,68,74)(H,79,80)(H4,57,58,61)/t33-,40-,41-,42-,43-,44-,46-,47-/m0/s1
DMWC10R CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=C(C=C3)C(=O)C4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMWC10R IK CLBUUAFJDOTEBS-AAVPAQJNSA-N
DMWC10R IU (2S)-3-(4-benzoylphenyl)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid
DMWC10R DE Discovery agent
DM4AUFR ID DM4AUFR
DM4AUFR DN [Sar1,Tdf2]AngII
DM4AUFR HS Investigative
DM4AUFR SN CHEMBL1076602; [Sar1,Tdf2]AngII
DM4AUFR PC 45140942
DM4AUFR MW 1101.2
DM4AUFR FM C54H67F3N12O10
DM4AUFR IC InChI=1S/C54H67F3N12O10/c1-6-31(4)45(50(76)63-40(26-36-27-59-29-60-36)51(77)69-22-10-13-42(69)48(74)64-41(52(78)79)25-32-11-8-7-9-12-32)66-47(73)39(24-34-16-20-37(70)21-17-34)62-49(75)44(30(2)3)65-46(72)38(61-43(71)28-58-5)23-33-14-18-35(19-15-33)53(67-68-53)54(55,56)57/h7-9,11-12,14-21,27,29-31,38-42,44-45,58,70H,6,10,13,22-26,28H2,1-5H3,(H,59,60)(H,61,71)(H,62,75)(H,63,76)(H,64,74)(H,65,72)(H,66,73)(H,78,79)/t31-,38-,39-,40-,41-,42-,44-,45-/m0/s1
DM4AUFR CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)C6(N=N6)C(F)(F)F)NC(=O)CNC
DM4AUFR IK IANMQZMQGQLRSI-LTTXXCTBSA-N
DM4AUFR IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-3-methyl-2-[[(2S)-2-[[2-(methylamino)acetyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]butanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DM4AUFR DE Discovery agent
DMWCS4Y ID DMWCS4Y
DMWCS4Y DN [Sar1,Tdf3]AngII
DMWCS4Y HS Investigative
DMWCS4Y SN CHEMBL1076604; [Sar1,Tdf3]AngII
DMWCS4Y PC 45141142
DMWCS4Y MW 1158.2
DMWCS4Y FM C55H70F3N15O10
DMWCS4Y IC InChI=1S/C55H70F3N15O10/c1-4-31(2)45(50(80)68-41(27-36-28-62-30-64-36)51(81)73-23-9-13-43(73)49(79)69-42(52(82)83)26-32-10-6-5-7-11-32)70-48(78)40(25-34-16-20-37(74)21-17-34)67-47(77)39(24-33-14-18-35(19-15-33)54(71-72-54)55(56,57)58)66-46(76)38(65-44(75)29-61-3)12-8-22-63-53(59)60/h5-7,10-11,14-21,28,30-31,38-43,45,61,74H,4,8-9,12-13,22-27,29H2,1-3H3,(H,62,64)(H,65,75)(H,66,76)(H,67,77)(H,68,80)(H,69,79)(H,70,78)(H,82,83)(H4,59,60,63)/t31-,38-,39-,40-,41-,42-,43-,45-/m0/s1
DMWCS4Y CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=C(C=C5)C6(N=N6)C(F)(F)F)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMWCS4Y IK SMLIEFKCEBMVHX-YUDJOFGFSA-N
DMWCS4Y IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMWCS4Y DE Discovery agent
DMTNGCW ID DMTNGCW
DMTNGCW DN [Sar1,Tdf8]AngII
DMTNGCW HS Investigative
DMTNGCW SN CHEMBL1076633; [Sar1,Tdf8]AngII
DMTNGCW PC 46880545
DMTNGCW MW 1110.2
DMTNGCW FM C51H70F3N15O10
DMTNGCW IC InChI=1S/C51H70F3N15O10/c1-6-28(4)41(66-43(73)35(21-30-13-17-33(70)18-14-30)62-45(75)40(27(2)3)65-42(72)34(61-39(71)25-57-5)9-7-19-59-49(55)56)46(76)63-36(23-32-24-58-26-60-32)47(77)69-20-8-10-38(69)44(74)64-37(48(78)79)22-29-11-15-31(16-12-29)50(67-68-50)51(52,53)54/h11-18,24,26-28,34-38,40-41,57,70H,6-10,19-23,25H2,1-5H3,(H,58,60)(H,61,71)(H,62,75)(H,63,76)(H,64,74)(H,65,72)(H,66,73)(H,78,79)(H4,55,56,59)/t28-,34-,35-,36-,37-,38-,40-,41-/m0/s1
DMTNGCW CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=C(C=C3)C4(N=N4)C(F)(F)F)C(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC
DMTNGCW IK KSJIPXWEUUGTIY-LNEAKYCGSA-N
DMTNGCW IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoic acid
DMTNGCW DE Discovery agent
DMUD0LA ID DMUD0LA
DMUD0LA DN [Sar1Ala]GAL-B2
DMUD0LA HS Investigative
DMUD0LA SN CHEMBL578910; [Sar1Ala]GAL-B2
DMUD0LA PC 45104655
DMUD0LA MW 2112.6
DMUD0LA FM C104H174N24O22
DMUD0LA IC InChI=1S/C104H174N24O22/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(133)111-50-33-29-40-75(94(140)117-73(90(110)136)37-26-30-47-105)119-95(141)74(38-27-31-48-106)118-96(142)76(39-28-32-49-107)120-103(149)84-41-34-51-128(84)88(135)60-114-93(139)77(52-62(2)3)122-97(143)78(53-63(4)5)123-99(145)80(55-68-43-45-70(131)46-44-68)116-87(134)59-113-92(138)66(9)115-102(148)83(61-129)126-100(146)82(57-85(109)132)124-98(144)79(54-64(6)7)125-104(150)89(67(10)130)127-101(147)81(121-91(137)65(8)108)56-69-58-112-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,62-67,73-84,89,112,129-131H,11-23,26-34,37-42,47-57,59-61,105-108H2,1-10H3,(H2,109,132)(H2,110,136)(H,111,133)(H,113,138)(H,114,139)(H,115,148)(H,116,134)(H,117,140)(H,118,142)(H,119,141)(H,120,149)(H,121,137)(H,122,143)(H,123,145)(H,124,144)(H,125,150)(H,126,146)(H,127,147)/t65-,66-,67+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,89-/m0/s1
DMUD0LA CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](C)N
DMUD0LA IK SYZGVJVRSWLTDO-ZYVMWFDRSA-N
DMUD0LA IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]butanediamide
DMUD0LA DE Discovery agent
DMUI0XV ID DMUI0XV
DMUI0XV DN [Sar1Gly]GAL-B2
DMUI0XV HS Investigative
DMUI0XV SN CHEMBL499807; [Sar1Gly]GAL-B2
DMUI0XV PC 25180489
DMUI0XV MW 2098.6
DMUI0XV FM C103H172N24O22
DMUI0XV IC InChI=1S/C103H172N24O22/c1-10-11-12-13-14-15-16-17-18-19-20-21-22-41-85(132)110-49-32-28-39-74(93(139)117-72(90(109)136)36-25-29-46-104)119-94(140)73(37-26-30-47-105)118-95(141)75(38-27-31-48-106)120-102(148)83-40-33-50-127(83)88(135)60-113-92(138)76(51-62(2)3)121-96(142)77(52-63(4)5)122-98(144)79(54-67-42-44-69(130)45-43-67)116-87(134)59-112-91(137)65(8)114-101(147)82(61-128)125-99(145)81(56-84(108)131)123-97(143)78(53-64(6)7)124-103(149)89(66(9)129)126-100(146)80(115-86(133)57-107)55-68-58-111-71-35-24-23-34-70(68)71/h23-24,34-35,42-45,58,62-66,72-83,89,111,128-130H,10-22,25-33,36-41,46-57,59-61,104-107H2,1-9H3,(H2,108,131)(H2,109,136)(H,110,132)(H,112,137)(H,113,138)(H,114,147)(H,115,133)(H,116,134)(H,117,139)(H,118,141)(H,119,140)(H,120,148)(H,121,142)(H,122,144)(H,123,143)(H,124,149)(H,125,145)(H,126,146)/t65-,66+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DMUI0XV CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CN
DMUI0XV IK FUVBWPLFMCRKPJ-RUUCUJBTSA-N
DMUI0XV IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMUI0XV DE Discovery agent
DMYF85Q ID DMYF85Q
DMYF85Q DN [Sar9,Met(O2)11]-SP
DMYF85Q HS Investigative
DMYF85Q PC 44338651
DMYF85Q MW 1393.7
DMYF85Q FM C64H100N18O15S
DMYF85Q IC InChI=1S/C64H100N18O15S/c1-37(2)34-46(58(90)74-42(53(69)85)28-33-98(4,96)97)78-54(86)38(3)73-57(89)47(35-39-16-7-5-8-17-39)80-59(91)48(36-40-18-9-6-10-19-40)79-56(88)43(24-26-51(67)83)75-55(87)44(25-27-52(68)84)76-60(92)50-23-15-32-82(50)63(95)45(21-11-12-29-65)77-61(93)49-22-14-31-81(49)62(94)41(66)20-13-30-72-64(70)71/h5-10,16-19,37-38,41-50H,11-15,20-36,65-66H2,1-4H3,(H2,67,83)(H2,68,84)(H2,69,85)(H,73,89)(H,74,90)(H,75,87)(H,76,92)(H,77,93)(H,78,86)(H,79,88)(H,80,91)(H4,70,71,72)/t38?,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMYF85Q CS CC(C)C[C@@H](C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)N)NC(=O)C(C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMYF85Q IK VRAGPHDTXRPMRS-RGKHVPTMSA-N
DMYF85Q IU (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfonyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMYF85Q DE Discovery agent
DMN0BT3 ID DMN0BT3
DMN0BT3 DN [Tdf1]AngII
DMN0BT3 HS Investigative
DMN0BT3 SN CHEMBL1076613; [Tdf1]AngII
DMN0BT3 PC 45140941
DMN0BT3 MW 1186.3
DMN0BT3 FM C57H74F3N15O10
DMN0BT3 IC InChI=1S/C57H74F3N15O10/c1-5-32(4)46(52(82)69-42(28-37-29-64-30-66-37)53(83)75-24-10-14-44(75)50(80)70-43(54(84)85)27-33-11-7-6-8-12-33)72-49(79)41(26-35-17-21-38(76)22-18-35)68-51(81)45(31(2)3)71-48(78)40(13-9-23-65-55(62)63)67-47(77)39(61)25-34-15-19-36(20-16-34)56(73-74-56)57(58,59)60/h6-8,11-12,15-22,29-32,39-46,76H,5,9-10,13-14,23-28,61H2,1-4H3,(H,64,66)(H,67,77)(H,68,81)(H,69,82)(H,70,80)(H,71,78)(H,72,79)(H,84,85)(H4,62,63,65)/t32-,39-,40-,41-,42-,43-,44-,45-,46-/m0/s1
DMN0BT3 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)C6(N=N6)C(F)(F)F)N
DMN0BT3 IK OGNWPDVTXMDCHR-PYRLQILWSA-N
DMN0BT3 IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMN0BT3 DE Discovery agent
DM7QAKB ID DM7QAKB
DM7QAKB DN [Thr4,Gly7]OT
DM7QAKB HS Investigative
DM7QAKB SN [Thr4,Gly7]oxytocin
DM7QAKB DT Small molecular drug
DM7QAKB PC 3080871
DM7QAKB MW 940.1
DM7QAKB FM C39H61N11O12S2
DM7QAKB IC InChI=1S/C39H61N11O12S2/c1-6-19(4)31(49-37(60)25(46-33(56)23(40)16-63)12-21-7-9-22(52)10-8-21)38(61)50-32(20(5)51)39(62)47-26(13-28(41)53)36(59)48-27(17-64)35(58)44-15-30(55)45-24(11-18(2)3)34(57)43-14-29(42)54/h7-10,16,18-20,23-27,31-32,51-52,64H,6,11-15,17,40H2,1-5H3,(H2,41,53)(H2,42,54)(H,43,57)(H,44,58)(H,45,55)(H,46,56)(H,47,62)(H,48,59)(H,49,60)(H,50,61)/t19-,20+,23-,24-,25-,26-,27-,31-,32-/m0/s1
DM7QAKB CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C=S)N
DM7QAKB IK SJRRTEZQOSELMP-IKNHWLCZSA-N
DM7QAKB IU (2S)-N-[(2R)-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylidenepropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]butanediamide
DM7QAKB CA CAS 60786-59-6
DM7QAKB DE Discovery agent
DMA6VNI ID DMA6VNI
DMA6VNI DN [Tyr4]Bombesin
DMA6VNI HS Investigative
DMA6VNI PC 44388197
DMA6VNI MW 1669.9
DMA6VNI FM C74H108N24O19S
DMA6VNI IC InChI=1S/C74H108N24O19S/c1-36(2)26-50(70(114)91-45(62(78)106)23-25-118-6)95-71(115)53(29-41-32-81-35-86-41)89-60(105)34-85-73(117)61(37(3)4)98-63(107)38(5)87-69(113)52(28-40-31-83-44-11-8-7-10-43(40)44)97-68(112)49(18-21-56(76)101)94-72(116)54(30-57(77)102)90-59(104)33-84-64(108)51(27-39-13-15-42(99)16-14-39)96-65(109)46(12-9-24-82-74(79)80)92-67(111)48(17-20-55(75)100)93-66(110)47-19-22-58(103)88-47/h7-8,10-11,13-16,31-32,35-38,45-54,61,83,99H,9,12,17-30,33-34H2,1-6H3,(H2,75,100)(H2,76,101)(H2,77,102)(H2,78,106)(H,81,86)(H,84,108)(H,85,117)(H,87,113)(H,88,103)(H,89,105)(H,90,104)(H,91,114)(H,92,111)(H,93,110)(H,94,116)(H,95,115)(H,96,109)(H,97,112)(H,98,107)(H4,79,80,82)/t38-,45-,46-,47?,48-,49-,50-,51-,52-,53-,54-,61-/m0/s1
DMA6VNI CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C5CCC(=O)N5
DMA6VNI IK QORXQELQSJVKIL-MOPZKQSYSA-N
DMA6VNI IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-2-[(5-oxopyrrolidine-2-carbonyl)amino]pentanediamide
DMA6VNI DE Discovery agent
DM61RG2 ID DM61RG2
DM61RG2 DN [Tyr-Pro-Phe-NH-]2
DM61RG2 HS Investigative
DM61RG2 SN CHEMBL179946; [Tyr-Pro-Phe-NH-]2
DM61RG2 DT Small molecular drug
DM61RG2 PC 44390663
DM61RG2 MW 832
DM61RG2 FM C46H53N7O8
DM61RG2 IC InChI=1S/C46H53N7O8/c47-35(25-31-15-19-33(54)20-16-31)45(60)52-23-7-13-39(52)44(59)50-37(27-30-11-5-2-6-12-30)42(57)51-38(28-32-17-21-34(55)22-18-32)46(61)53-24-8-14-40(53)43(58)49-36(41(48)56)26-29-9-3-1-4-10-29/h1-6,9-12,15-22,35-40,54-55H,7-8,13-14,23-28,47H2,(H2,48,56)(H,49,58)(H,50,59)(H,51,57)/t35-,36-,37-,38-,39-,40-/m0/s1
DM61RG2 CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N
DM61RG2 IK PMYWZDRRZPJWHV-UNHORJANSA-N
DM61RG2 IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM61RG2 DE Discovery agent
DMZTRQ0 ID DMZTRQ0
DMZTRQ0 DN [Tyr-Pro-Phe-NH-CH2-]2
DMZTRQ0 HS Investigative
DMZTRQ0 SN CHEMBL180286; [Tyr-Pro-Phe-NH-CH2-]2
DMZTRQ0 DT Small molecular drug
DMZTRQ0 PC 44390664
DMZTRQ0 MW 860
DMZTRQ0 FM C48H57N7O8
DMZTRQ0 IC InChI=1S/C48H57N7O8/c49-37(27-33-15-19-35(56)20-16-33)47(62)54-25-7-13-41(54)45(60)52-38(28-31-9-3-1-4-10-31)43(58)23-24-51-40(30-34-17-21-36(57)22-18-34)48(63)55-26-8-14-42(55)46(61)53-39(44(50)59)29-32-11-5-2-6-12-32/h1-6,9-12,15-22,37-42,51,56-57H,7-8,13-14,23-30,49H2,(H2,50,59)(H,52,60)(H,53,61)/t37-,38-,39-,40-,41-,42-/m0/s1
DMZTRQ0 CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)CCN[C@@H](CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N
DMZTRQ0 IK SDEZJRFUZMVTCN-UJKKYYSESA-N
DMZTRQ0 IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-5-[[(2S)-1-[(2S)-2-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxo-1-phenylpentan-2-yl]pyrrolidine-2-carboxamide
DMZTRQ0 DE Discovery agent
DME6TNL ID DME6TNL
DME6TNL DN [Tyr-Pro-Phe-Phe-NH-]2
DME6TNL HS Investigative
DME6TNL SN CHEMBL386887
DME6TNL PC 44390628
DME6TNL MW 1126.3
DME6TNL FM C64H71N9O10
DME6TNL IC InChI=1S/C64H71N9O10/c65-49(35-45-25-29-47(74)30-26-45)63(82)72-33-13-23-55(72)61(80)70-53(39-44-21-11-4-12-22-44)59(78)68-51(37-42-17-7-2-8-18-42)60(79)71-54(40-46-27-31-48(75)32-28-46)64(83)73-34-14-24-56(73)62(81)69-52(38-43-19-9-3-10-20-43)58(77)67-50(57(66)76)36-41-15-5-1-6-16-41/h1-12,15-22,25-32,49-56,74-75H,13-14,23-24,33-40,65H2,(H2,66,76)(H,67,77)(H,68,78)(H,69,81)(H,70,80)(H,71,79)/t49-,50-,51-,52-,53-,54-,55-,56-/m0/s1
DME6TNL CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N
DME6TNL IK DEEQOLBYTQLJHH-MENCHSDRSA-N
DME6TNL IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DME6TNL DE Discovery agent
DMFGO4W ID DMFGO4W
DMFGO4W DN [Tyr-Pro-Phe-Phe-NH-CH2-]2
DMFGO4W HS Investigative
DMFGO4W SN CHEMBL409336; [Tyr-Pro-Phe-Phe-NH-CH2-]2
DMFGO4W PC 44390629
DMFGO4W MW 1154.4
DMFGO4W FM C66H75N9O10
DMFGO4W IC InChI=1S/C66H75N9O10/c67-51(37-47-25-29-49(76)30-26-47)65(84)74-35-13-23-57(74)63(82)72-54(40-45-19-9-3-10-20-45)61(80)70-52(38-43-15-5-1-6-16-43)59(78)33-34-69-56(42-48-27-31-50(77)32-28-48)66(85)75-36-14-24-58(75)64(83)73-55(41-46-21-11-4-12-22-46)62(81)71-53(60(68)79)39-44-17-7-2-8-18-44/h1-12,15-22,25-32,51-58,69,76-77H,13-14,23-24,33-42,67H2,(H2,68,79)(H,70,80)(H,71,81)(H,72,82)(H,73,83)/t51-,52-,53-,54-,55-,56-,57-,58-/m0/s1
DMFGO4W CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)CCN[C@@H](CC5=CC=C(C=C5)O)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC8=CC=CC=C8)C(=O)N
DMFGO4W IK YHWMMBKGEDGQFW-LEPIMFGVSA-N
DMFGO4W IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-5-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxo-1-phenylpentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMFGO4W DE Discovery agent
DMP3I6E ID DMP3I6E
DMP3I6E DN [U-13C]ascomycin
DMP3I6E HS Investigative
DMP3I6E DE Discovery agent
DMW82ZT ID DMW82ZT
DMW82ZT DN [Val4]AVP
DMW82ZT HS Investigative
DMW82ZT SN 4-Val-argipressin
DMW82ZT DT Small molecular drug
DMW82ZT PC 171113
DMW82ZT MW 1055.2
DMW82ZT FM C46H66N14O11S2
DMW82ZT IC InChI=1S/C46H66N14O11S2/c1-24(2)37-44(70)57-32(20-35(48)62)41(67)58-33(45(71)60-17-7-11-34(60)43(69)54-29(10-6-16-52-46(50)51)39(65)53-21-36(49)63)23-73-72-22-28(47)38(64)55-30(19-26-12-14-27(61)15-13-26)40(66)56-31(42(68)59-37)18-25-8-4-3-5-9-25/h3-5,8-9,12-15,24,28-34,37,61H,6-7,10-11,16-23,47H2,1-2H3,(H2,48,62)(H2,49,63)(H,53,65)(H,54,69)(H,55,64)(H,56,66)(H,57,70)(H,58,67)(H,59,68)(H4,50,51,52)/t28-,29+,30-,31-,32-,33-,34-,37-/m0/s1
DMW82ZT CS CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)N)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DMW82ZT IK JITASQOSGITBPR-FMCGBTBPSA-N
DMW82ZT IU (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMW82ZT CA CAS 52049-52-2
DMW82ZT DE Discovery agent
DMMB4US ID DMMB4US
DMMB4US DN {[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine
DMMB4US HS Investigative
DMMB4US SN CHEMBL570566; {[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine; SCHEMBL3117233
DMMB4US DT Small molecular drug
DMMB4US PC 16103195
DMMB4US MW 346.6
DMMB4US FM C18H38N2O2S
DMMB4US IC InChI=1S/C18H38N2O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-23(19,21)22/h9-10,20H,2-8,11-18H2,1H3,(H2,19,21,22)/b10-9-
DMMB4US CS CCCCCCCC/C=C\\CCCCCCCCNS(=O)(=O)N
DMMB4US IK VIGWMDIVSRLQST-KTKRTIGZSA-N
DMMB4US IU (Z)-1-(sulfamoylamino)octadec-9-ene
DMMB4US DE Discovery agent
DM3FBAZ ID DM3FBAZ
DM3FBAZ DN {2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine
DM3FBAZ HS Investigative
DM3FBAZ SN SCHEMBL3565077; CHEMBL608380; BDBM35240; 3-(phenylsulfonyl)-1H-indole, 18m
DM3FBAZ DT Small molecular drug
DM3FBAZ PC 24861406
DM3FBAZ MW 300.4
DM3FBAZ FM C16H16N2O2S
DM3FBAZ IC InChI=1S/C16H16N2O2S/c17-10-9-12-5-4-8-14-16(12)15(11-18-14)21(19,20)13-6-2-1-3-7-13/h1-8,11,18H,9-10,17H2
DM3FBAZ CS C1=CC=C(C=C1)S(=O)(=O)C2=CNC3=CC=CC(=C32)CCN
DM3FBAZ IK RSVUNKKDIROCQS-UHFFFAOYSA-N
DM3FBAZ IU 2-[3-(benzenesulfonyl)-1H-indol-4-yl]ethanamine
DM3FBAZ DE Discovery agent
DMX53OY ID DMX53OY
DMX53OY DN {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid
DMX53OY HS Investigative
DMX53OY SN CHEMBL201138; {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid
DMX53OY DT Small molecular drug
DMX53OY PC 11495248
DMX53OY MW 411.2
DMX53OY FM C21H15BrO4
DMX53OY IC InChI=1S/C21H15BrO4/c22-17-7-11-19(12-8-17)26-18-9-5-16(6-10-18)21(25)15-3-1-14(2-4-15)13-20(23)24/h1-12H,13H2,(H,23,24)
DMX53OY CS C1=CC(=CC=C1CC(=O)O)C(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)Br
DMX53OY IK XVHMPUZJYISELN-UHFFFAOYSA-N
DMX53OY IU 2-[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
DMX53OY DE Discovery agent
DMQEJVU ID DMQEJVU
DMQEJVU DN 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
DMQEJVU HS Investigative
DMQEJVU SN 1-((2-Chlorophenyl)diphenylmethyl)-1H-pyrazole; TRAM-34; 289905-88-0; Tram 34; 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole; AC1LCVHZ; CHEMBL498270; CHEBI:34990; 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole; 1-(2-Chlorophenyl)diphenyl)methyl]-1H-pyrazole; SureCN41130; TRAM34; SCHEMBL41130; GTPL2336; KS-00000OJW; CTK0J1643; DTXSID70349650; MolPort-003-850-592; EX-A2316; BCP01324; ZINC3975392; BDBM50279107; ANW-72309; s1160; MFCD09842562; AKOS005146304; CS-1921; ACN-048484; MP-2041; API0000868; DS-2617; NCGC00165909-03; NCGC00165909-02
DMQEJVU DT Small molecular drug
DMQEJVU PC 656734
DMQEJVU MW 344.8
DMQEJVU FM C22H17ClN2
DMQEJVU IC InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H
DMQEJVU CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4
DMQEJVU IK KBFUQFVFYYBHBT-UHFFFAOYSA-N
DMQEJVU IU 1-[(2-chlorophenyl)-diphenylmethyl]pyrazole
DMQEJVU CA CAS 289905-88-0
DMQEJVU CB CHEBI:34990
DMQEJVU DE Conjunctival fibrosis
DMGRV8U ID DMGRV8U
DMGRV8U DN 1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole
DMGRV8U HS Investigative
DMGRV8U SN CHEMBL501198; 1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole; SCHEMBL8609682; QOKBMECMKDLYIV-UHFFFAOYSA-N; BDBM50272209; 1-[1-(9H-Fluoren-2-yl)ethyl]-1H-imidazole; 1-[1-(9H-fluoren-2-yl) ethyl]-1H-imidazole
DMGRV8U DT Small molecular drug
DMGRV8U PC 9861000
DMGRV8U MW 260.3
DMGRV8U FM C18H16N2
DMGRV8U IC InChI=1S/C18H16N2/c1-13(20-9-8-19-12-20)14-6-7-18-16(10-14)11-15-4-2-3-5-17(15)18/h2-10,12-13H,11H2,1H3
DMGRV8U CS CC(C1=CC2=C(C=C1)C3=CC=CC=C3C2)N4C=CN=C4
DMGRV8U IK QOKBMECMKDLYIV-UHFFFAOYSA-N
DMGRV8U IU 1-[1-(9H-fluoren-2-yl)ethyl]imidazole
DMGRV8U DE Discovery agent
DMPBJ9L ID DMPBJ9L
DMPBJ9L DN 1-((9H-Fluoren-2-yl)methyl)-1H-imidazole
DMPBJ9L HS Investigative
DMPBJ9L SN CHEMBL502542; 1-((9H-Fluoren-2-yl)methyl)-1H-imidazole; SCHEMBL8607720
DMPBJ9L DT Small molecular drug
DMPBJ9L PC 18976090
DMPBJ9L MW 246.31
DMPBJ9L FM C17H14N2
DMPBJ9L IC InChI=1S/C17H14N2/c1-2-4-16-14(3-1)10-15-9-13(5-6-17(15)16)11-19-8-7-18-12-19/h1-9,12H,10-11H2
DMPBJ9L CS C1C2=CC=CC=C2C3=C1C=C(C=C3)CN4C=CN=C4
DMPBJ9L IK OLHTVPMFDRPUTG-UHFFFAOYSA-N
DMPBJ9L IU 1-(9H-fluoren-2-ylmethyl)imidazole
DMPBJ9L DE Discovery agent
DM74R0E ID DM74R0E
DM74R0E DN 1-((R)-2-aminopropyl)-1H-indazol-6-ol
DM74R0E HS Investigative
DM74R0E DT Small molecular drug
DM74R0E PC 135399666
DM74R0E MW 191.23
DM74R0E FM C10H13N3O
DM74R0E IC InChI=1S/C10H13N3O/c1-7(11)6-13-10-4-9(14)3-2-8(10)5-12-13/h2-5,7,14H,6,11H2,1H3/t7-/m1/s1
DM74R0E CS C[C@H](CN1C2=C(C=CC(=C2)O)C=N1)N
DM74R0E IK WBYHTZYHAFNBKW-SSDOTTSWSA-N
DM74R0E IU 1-[(2R)-2-aminopropyl]indazol-6-ol
DM74R0E DE Discovery agent
DMU83KP ID DMU83KP
DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol
DMU83KP HS Investigative
DMU83KP DT Small molecular drug
DMU83KP PC 135453290
DMU83KP MW 191.23
DMU83KP FM C10H13N3O
DMU83KP IC InChI=1S/C10H13N3O/c1-7(11)6-13-10-4-9(14)3-2-8(10)5-12-13/h2-5,7,14H,6,11H2,1H3/t7-/m0/s1
DMU83KP CS C[C@@H](CN1C2=C(C=CC(=C2)O)C=N1)N
DMU83KP IK WBYHTZYHAFNBKW-ZETCQYMHSA-N
DMU83KP IU 1-[(2S)-2-aminopropyl]indazol-6-ol
DMU83KP CA CAS 210580-75-9
DMU83KP DE Discovery agent
DMRFJNC ID DMRFJNC
DMRFJNC DN 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol
DMRFJNC HS Investigative
DMRFJNC DT Small molecular drug
DMRFJNC PC 135509961
DMRFJNC MW 225.67
DMRFJNC FM C10H12ClN3O
DMRFJNC IC InChI=1S/C10H12ClN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
DMRFJNC CS C[C@@H](CN1C2=C(C=CC(=C2Cl)O)C=N1)N
DMRFJNC IK VCXUEWRCJZWCJB-LURJTMIESA-N
DMRFJNC IU 1-[(2S)-2-aminopropyl]-7-chloroindazol-6-ol
DMRFJNC DE Discovery agent
DM76JVB ID DM76JVB
DM76JVB DN 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol
DM76JVB HS Investigative
DM76JVB DT Small molecular drug
DM76JVB PC 135399866
DM76JVB MW 209.22
DM76JVB FM C10H12FN3O
DM76JVB IC InChI=1S/C10H12FN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
DM76JVB CS C[C@@H](CN1C2=C(C=CC(=C2F)O)C=N1)N
DM76JVB IK TZBBLWXEAUOTGZ-LURJTMIESA-N
DM76JVB IU 1-[(2S)-2-aminopropyl]-7-fluoroindazol-6-ol
DM76JVB DE Discovery agent
DMR2SXL ID DMR2SXL
DMR2SXL DN 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol
DMR2SXL HS Investigative
DMR2SXL DT Small molecular drug
DMR2SXL PC 135427931
DMR2SXL MW 317.13
DMR2SXL FM C10H12IN3O
DMR2SXL IC InChI=1S/C10H12IN3O/c1-6(12)5-14-10-7(4-13-14)2-3-8(15)9(10)11/h2-4,6,15H,5,12H2,1H3/t6-/m0/s1
DMR2SXL CS C[C@@H](CN1C2=C(C=CC(=C2I)O)C=N1)N
DMR2SXL IK NTWCUBZMEYKYQE-LURJTMIESA-N
DMR2SXL IU 1-[(2S)-2-aminopropyl]-7-iodoindazol-6-ol
DMR2SXL DE Discovery agent
DM8MNZG ID DM8MNZG
DM8MNZG DN 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol
DM8MNZG HS Investigative
DM8MNZG DT Small molecular drug
DM8MNZG PC 135414348
DM8MNZG MW 205.26
DM8MNZG FM C11H15N3O
DM8MNZG IC InChI=1S/C11H15N3O/c1-7(12)6-14-11-8(2)10(15)4-3-9(11)5-13-14/h3-5,7,15H,6,12H2,1-2H3/t7-/m0/s1
DM8MNZG CS CC1=C(C=CC2=C1N(N=C2)C[C@H](C)N)O
DM8MNZG IK UFWMKRXWOOOKPI-ZETCQYMHSA-N
DM8MNZG IU 1-[(2S)-2-aminopropyl]-7-methylindazol-6-ol
DM8MNZG DE Discovery agent
DMCSOAV ID DMCSOAV
DMCSOAV DN 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMCSOAV HS Investigative
DMCSOAV SN CHEMBL1083426; 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX); SCHEMBL5443198; BDBM50319828; 1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine; (-)-1-(1-(2-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine
DMCSOAV DT Small molecular drug
DMCSOAV PC 46890492
DMCSOAV MW 368.4
DMCSOAV FM C19H20F4N2O
DMCSOAV IC InChI=1S/C19H20F4N2O/c20-16-7-3-2-6-15(16)17(25-11-9-24-10-12-25)13-14-5-1-4-8-18(14)26-19(21,22)23/h1-8,17,24H,9-13H2
DMCSOAV CS C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=CC=C3F
DMCSOAV IK WARUECLCXNMKJR-UHFFFAOYSA-N
DMCSOAV IU 1-[1-(2-fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl]piperazine
DMCSOAV DE Discovery agent
DM0XNMP ID DM0XNMP
DM0XNMP DN 1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide
DM0XNMP HS Investigative
DM0XNMP SN CHEMBL373586; 1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide; SCHEMBL6337198
DM0XNMP DT Small molecular drug
DM0XNMP PC 25234549
DM0XNMP MW 252.3
DM0XNMP FM C10H12N4O2S
DM0XNMP IC InChI=1S/C10H12N4O2S/c1-2-9(12-13-10(11)17)7-4-3-5-8(6-7)14(15)16/h3-6H,2H2,1H3,(H3,11,13,17)/b12-9+
DM0XNMP CS CC/C(=N\\NC(=S)N)/C1=CC(=CC=C1)[N+](=O)[O-]
DM0XNMP IK BTQZWQBDFKXQEG-FMIVXFBMSA-N
DM0XNMP IU [(E)-1-(3-nitrophenyl)propylideneamino]thiourea
DM0XNMP DE Discovery agent
DMXJ58Z ID DMXJ58Z
DMXJ58Z DN 1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide
DMXJ58Z HS Investigative
DMXJ58Z SN CHEMBL258261; NSC521067; AC1NSLKG; 16546-06-8; ZINC4709233; 4'-Bromoacetophenonethiosemicarbazone; BDBM50376212; AKOS002388584; AKOS008939483; NSC-521067
DMXJ58Z DT Small molecular drug
DMXJ58Z PC 5365424
DMXJ58Z MW 272.17
DMXJ58Z FM C9H10BrN3S
DMXJ58Z IC InChI=1S/C9H10BrN3S/c1-6(12-13-9(11)14)7-2-4-8(10)5-3-7/h2-5H,1H3,(H3,11,13,14)/b12-6-
DMXJ58Z CS C/C(=N/NC(=S)N)/C1=CC=C(C=C1)Br
DMXJ58Z IK OKNJXRBJRXAECS-SDQBBNPISA-N
DMXJ58Z IU [(Z)-1-(4-bromophenyl)ethylideneamino]thiourea
DMXJ58Z CA CAS 16546-06-8
DMXJ58Z DE Discovery agent
DMOQPKT ID DMOQPKT
DMOQPKT DN 1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole
DMOQPKT HS Investigative
DMOQPKT SN CHEMBL496257; BDBM50272583
DMOQPKT DT Small molecular drug
DMOQPKT PC 44587321
DMOQPKT MW 290.4
DMOQPKT FM C20H22N2
DMOQPKT IC InChI=1S/C20H22N2/c1-3-16-5-7-17(8-6-16)18-9-11-19(12-10-18)20(4-2)22-14-13-21-15-22/h5-15,20H,3-4H2,1-2H3
DMOQPKT CS CCC1=CC=C(C=C1)C2=CC=C(C=C2)C(CC)N3C=CN=C3
DMOQPKT IK QQMBOZZNCNQCSN-UHFFFAOYSA-N
DMOQPKT IU 1-[1-[4-(4-ethylphenyl)phenyl]propyl]imidazole
DMOQPKT DE Discovery agent
DMS9PZ7 ID DMS9PZ7
DMS9PZ7 DN 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMS9PZ7 HS Investigative
DMS9PZ7 SN CHEMBL1084033; 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX); SCHEMBL5447674; BDBM50319830; 1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine; (-)-1-(1-(4-fluorophenyl)-2-(2-(trifluoromethoxy)phenyl)ethyl)piperazine
DMS9PZ7 DT Small molecular drug
DMS9PZ7 PC 46890532
DMS9PZ7 MW 368.4
DMS9PZ7 FM C19H20F4N2O
DMS9PZ7 IC InChI=1S/C19H20F4N2O/c20-16-7-5-14(6-8-16)17(25-11-9-24-10-12-25)13-15-3-1-2-4-18(15)26-19(21,22)23/h1-8,17,24H,9-13H2
DMS9PZ7 CS C1CN(CCN1)C(CC2=CC=CC=C2OC(F)(F)F)C3=CC=C(C=C3)F
DMS9PZ7 IK SQSFWPVYWBTHEX-UHFFFAOYSA-N
DMS9PZ7 IU 1-[1-(4-fluorophenyl)-2-[2-(trifluoromethoxy)phenyl]ethyl]piperazine
DMS9PZ7 DE Discovery agent
DMQBHGK ID DMQBHGK
DMQBHGK DN 1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide
DMQBHGK HS Investigative
DMQBHGK SN CHEMBL429500; NSC118183; AC1NUA7B; BDBM50376208; ZINC12350299; AKOS008939384; NSC-118183; [(Z)-1-(4-fluorophenyl)ethylideneamino]thiourea; 1-[1-(4-Fluorophenyl)ethylidene]thiosemicarbazide
DMQBHGK DT Small molecular drug
DMQBHGK PC 5397679
DMQBHGK MW 211.26
DMQBHGK FM C9H10FN3S
DMQBHGK IC InChI=1S/C9H10FN3S/c1-6(12-13-9(11)14)7-2-4-8(10)5-3-7/h2-5H,1H3,(H3,11,13,14)/b12-6-
DMQBHGK CS C/C(=N/NC(=S)N)/C1=CC=C(C=C1)F
DMQBHGK IK JBOMIBNEKCISGH-SDQBBNPISA-N
DMQBHGK IU [(Z)-1-(4-fluorophenyl)ethylideneamino]thiourea
DMQBHGK CA CAS 777-16-2
DMQBHGK DE Discovery agent
DMEIH5N ID DMEIH5N
DMEIH5N DN 1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole
DMEIH5N HS Investigative
DMEIH5N SN CHEMBL273191; SCHEMBL18770412
DMEIH5N DT Small molecular drug
DMEIH5N PC 25099145
DMEIH5N MW 254.4
DMEIH5N FM C15H14N2S
DMEIH5N IC InChI=1S/C15H14N2S/c1-12(17-8-7-16-11-17)13-2-4-14(5-3-13)15-6-9-18-10-15/h2-12H,1H3
DMEIH5N CS CC(C1=CC=C(C=C1)C2=CSC=C2)N3C=CN=C3
DMEIH5N IK CPEUHVZSVWFLMC-UHFFFAOYSA-N
DMEIH5N IU 1-[1-(4-thiophen-3-ylphenyl)ethyl]imidazole
DMEIH5N DE Discovery agent
DMQF2N5 ID DMQF2N5
DMQF2N5 DN 1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole
DMQF2N5 HS Investigative
DMQF2N5 SN CHEMBL403475; SCHEMBL18770345
DMQF2N5 DT Small molecular drug
DMQF2N5 PC 25099144
DMQF2N5 MW 268.4
DMQF2N5 FM C16H16N2S
DMQF2N5 IC InChI=1S/C16H16N2S/c1-2-16(18-9-8-17-12-18)14-5-3-13(4-6-14)15-7-10-19-11-15/h3-12,16H,2H2,1H3
DMQF2N5 CS CCC(C1=CC=C(C=C1)C2=CSC=C2)N3C=CN=C3
DMQF2N5 IK JCRCIQARESXRFA-UHFFFAOYSA-N
DMQF2N5 IU 1-[1-(4-thiophen-3-ylphenyl)propyl]imidazole
DMQF2N5 DE Discovery agent
DMPGM0V ID DMPGM0V
DMPGM0V DN 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine
DMPGM0V HS Investigative
DMPGM0V SN BTCP; 112726-66-6; 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine; 1-Btcp; GK 13; 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine; 1-(1-Benzo(b)thien-2-ylcyclohexyl)piperidine; N-(1-(2-Benzo(b)thiophenyl)cyclohexyl)piperidine; GK-13; UNII-Q1WR6UP7MW; Q1WR6UP7MW; CHEMBL279556; CHEBI:64145; 1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine; Piperidine, 1-(1-benzo(b)thien-2-ylcyclohexyl)-; 1-(1-benzo[b]thien-2-ylcyclohexyl)Piperidine; Benocyclidine; C19H25NS; Tocris-0702; Lopac-B-138; Biomol-NT_000007; AC1L3X4G; Lopac0_000226
DMPGM0V DT Small molecular drug
DMPGM0V PC 123692
DMPGM0V MW 299.5
DMPGM0V FM C19H25NS
DMPGM0V IC InChI=1S/C19H25NS/c1-5-11-19(12-6-1,20-13-7-2-8-14-20)18-15-16-9-3-4-10-17(16)21-18/h3-4,9-10,15H,1-2,5-8,11-14H2
DMPGM0V CS C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCC4
DMPGM0V IK RGSVXQJPSWZXOP-UHFFFAOYSA-N
DMPGM0V IU 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine
DMPGM0V CA CAS 112726-66-6
DMPGM0V CB CHEBI:64145
DMPGM0V DE Discovery agent
DMLJ7WA ID DMLJ7WA
DMLJ7WA DN 1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole
DMLJ7WA HS Investigative
DMLJ7WA SN CHEMBL443865; 1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole
DMLJ7WA DT Small molecular drug
DMLJ7WA PC 44586827
DMLJ7WA MW 260.3
DMLJ7WA FM C18H16N2
DMLJ7WA IC InChI=1S/C18H16N2/c1-2-18(20-13-12-19-14-20)17-10-8-16(9-11-17)15-6-4-3-5-7-15/h2-14,18H,1H2
DMLJ7WA CS C=CC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMLJ7WA IK VEPBIHWDSCDYJS-UHFFFAOYSA-N
DMLJ7WA IU 1-[1-(4-phenylphenyl)prop-2-enyl]imidazole
DMLJ7WA DE Discovery agent
DM7WJOY ID DM7WJOY
DM7WJOY DN 1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide
DM7WJOY HS Investigative
DM7WJOY SN CHEMBL401556; AC1NT9J5; 142564-78-1; BDBM50376205; ZINC26974934; AKOS014545779; 1-(2-Pyrazinyl)ethanone thiosemicarbazone
DM7WJOY DT Small molecular drug
DM7WJOY PC 5375406
DM7WJOY MW 195.25
DM7WJOY FM C7H9N5S
DM7WJOY IC InChI=1S/C7H9N5S/c1-5(11-12-7(8)13)6-4-9-2-3-10-6/h2-4H,1H3,(H3,8,12,13)/b11-5-
DM7WJOY CS C/C(=N/NC(=S)N)/C1=NC=CN=C1
DM7WJOY IK LNRWBLGPWCJQEM-WZUFQYTHSA-N
DM7WJOY IU [(Z)-1-pyrazin-2-ylethylideneamino]thiourea
DM7WJOY DE Discovery agent
DMJ21XT ID DMJ21XT
DMJ21XT DN 1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide
DMJ21XT HS Investigative
DMJ21XT SN CHEMBL272957; 3-Acetylpyridine thiosemicarbazone; AC1NT9I3; ZINC4535030; 13370-86-0; BDBM50376203; AKOS008939674
DMJ21XT DT Small molecular drug
DMJ21XT PC 5375357
DMJ21XT MW 194.26
DMJ21XT FM C8H10N4S
DMJ21XT IC InChI=1S/C8H10N4S/c1-6(11-12-8(9)13)7-3-2-4-10-5-7/h2-5H,1H3,(H3,9,12,13)/b11-6-
DMJ21XT CS C/C(=N/NC(=S)N)/C1=CN=CC=C1
DMJ21XT IK PFDWFNDHRREIDD-WDZFZDKYSA-N
DMJ21XT IU [(Z)-1-pyridin-3-ylethylideneamino]thiourea
DMJ21XT DE Discovery agent
DMQSEF6 ID DMQSEF6
DMQSEF6 DN 1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide
DMQSEF6 HS Investigative
DMQSEF6 SN CHEMBL401925; 1-(2-thienyl)ethanone thiosemicarbazone; AC1NT9MW; ZINC4603414; BDBM50376204; AKOS006242416; AKOS002388583; 1-(2-Thienyl)ethanonethiosemicarbazone; [(Z)-1-thiophen-2-ylethylideneamino]thiourea
DMQSEF6 DT Small molecular drug
DMQSEF6 PC 5375570
DMQSEF6 MW 199.3
DMQSEF6 FM C7H9N3S2
DMQSEF6 IC InChI=1S/C7H9N3S2/c1-5(9-10-7(8)11)6-3-2-4-12-6/h2-4H,1H3,(H3,8,10,11)/b9-5-
DMQSEF6 CS C/C(=N/NC(=S)N)/C1=CC=CS1
DMQSEF6 IK PJVHAJJEMJNPHN-UITAMQMPSA-N
DMQSEF6 IU [(Z)-1-thiophen-2-ylethylideneamino]thiourea
DMQSEF6 DE Discovery agent
DMPMLZF ID DMPMLZF
DMPMLZF DN 1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one
DMPMLZF HS Investigative
DMPMLZF SN CHEMBL469050; 1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one; SCHEMBL2162025
DMPMLZF DT Small molecular drug
DMPMLZF PC 24951006
DMPMLZF MW 258.32
DMPMLZF FM C15H18N2O2
DMPMLZF IC InChI=1S/C15H18N2O2/c18-14(15-16-12-19-17-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMPMLZF CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NOC=N2
DMPMLZF IK YLPRJWHRSWGCQQ-UHFFFAOYSA-N
DMPMLZF IU 1-(1,2,4-oxadiazol-3-yl)-7-phenylheptan-1-one
DMPMLZF DE Discovery agent
DMBS90M ID DMBS90M
DMBS90M DN 1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one
DMBS90M HS Investigative
DMBS90M SN CHEMBL448922; 1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one; SCHEMBL2161958
DMBS90M DT Small molecular drug
DMBS90M PC 24951000
DMBS90M MW 258.32
DMBS90M FM C15H18N2O2
DMBS90M IC InChI=1S/C15H18N2O2/c18-14(15-16-12-17-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMBS90M CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=NO2
DMBS90M IK ZZEHRRGWKDFITC-UHFFFAOYSA-N
DMBS90M IU 1-(1,2,4-oxadiazol-5-yl)-7-phenylheptan-1-one
DMBS90M DE Discovery agent
DMOR9EK ID DMOR9EK
DMOR9EK DN 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK HS Investigative
DMOR9EK SN CHEMBL397945; 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK DT Small molecular drug
DMOR9EK PC 44426814
DMOR9EK MW 357.5
DMOR9EK FM C25H27NO
DMOR9EK IC InChI=1S/C25H27NO/c27-25(23-14-8-3-9-15-23)16-18-26(19-17-25)24(22-12-6-2-7-13-22)20-21-10-4-1-5-11-21/h1-15,24,27H,16-20H2
DMOR9EK CS C1CN(CCC1(C2=CC=CC=C2)O)C(CC3=CC=CC=C3)C4=CC=CC=C4
DMOR9EK IK FEOIETAFCTYQIE-UHFFFAOYSA-N
DMOR9EK IU 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol
DMOR9EK DE Discovery agent
DM0ARKB ID DM0ARKB
DM0ARKB DN 1-(1,2-diphenylethyl)piperazine
DM0ARKB HS Investigative
DM0ARKB SN CHEMBL214237; 88144-93-8; 1-(1,2-diphenylethyl)piperazine; SCHEMBL6171525; CTK3B7060; N-(1,2-diphenylethyl)piperazine; DTXSID00483036; BDBM50188059; AKOS010287239; Piperazine, 1-(1,2-diphenylethyl)-
DM0ARKB DT Small molecular drug
DM0ARKB PC 12263801
DM0ARKB MW 266.4
DM0ARKB FM C18H22N2
DM0ARKB IC InChI=1S/C18H22N2/c1-3-7-16(8-4-1)15-18(17-9-5-2-6-10-17)20-13-11-19-12-14-20/h1-10,18-19H,11-15H2
DM0ARKB CS C1CN(CCN1)C(CC2=CC=CC=C2)C3=CC=CC=C3
DM0ARKB IK NIBIYLDNVMUKNB-UHFFFAOYSA-N
DM0ARKB IU 1-(1,2-diphenylethyl)piperazine
DM0ARKB CA CAS 88144-93-8
DM0ARKB DE Discovery agent
DMHIYB3 ID DMHIYB3
DMHIYB3 DN 1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one
DMHIYB3 HS Investigative
DMHIYB3 SN CHEMBL467796; 1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2161990
DMHIYB3 DT Small molecular drug
DMHIYB3 PC 24950841
DMHIYB3 MW 258.32
DMHIYB3 FM C15H18N2O2
DMHIYB3 IC InChI=1S/C15H18N2O2/c18-14(15-17-16-12-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMHIYB3 CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CO2
DMHIYB3 IK SRGOKBDAYNCSOV-UHFFFAOYSA-N
DMHIYB3 IU 1-(1,3,4-oxadiazol-2-yl)-7-phenylheptan-1-one
DMHIYB3 DE Discovery agent
DMZ1GH0 ID DMZ1GH0
DMZ1GH0 DN 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one
DMZ1GH0 HS Investigative
DMZ1GH0 SN CHEMBL178791; 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one; BDBM50161529; 1-[1,3,4]Oxadiazol-2-yl-octadec-9-en-1-one
DMZ1GH0 DT Small molecular drug
DMZ1GH0 PC 44389962
DMZ1GH0 MW 334.5
DMZ1GH0 FM C20H34N2O2
DMZ1GH0 IC InChI=1S/C20H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(23)20-22-21-18-24-20/h9-10,18H,2-8,11-17H2,1H3/b10-9-
DMZ1GH0 CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NN=CO1
DMZ1GH0 IK JPZIIIRVMJASPM-KTKRTIGZSA-N
DMZ1GH0 IU (Z)-1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one
DMZ1GH0 DE Discovery agent
DM6B14Q ID DM6B14Q
DM6B14Q DN 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one
DM6B14Q HS Investigative
DM6B14Q SN CHEMBL467354; 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one; SCHEMBL2162931; OGPJTMSGDUTXCW-KTKRTIGZSA-N; BDBM50262029
DM6B14Q DT Small molecular drug
DM6B14Q PC 24950688
DM6B14Q MW 350.6
DM6B14Q FM C20H34N2OS
DM6B14Q IC InChI=1S/C20H34N2OS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(23)20-22-21-18-24-20/h9-10,18H,2-8,11-17H2,1H3/b10-9-
DM6B14Q CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NN=CS1
DM6B14Q IK OGPJTMSGDUTXCW-KTKRTIGZSA-N
DM6B14Q IU (Z)-1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one
DM6B14Q DE Discovery agent
DMTC98X ID DMTC98X
DMTC98X DN 1-(1,3-diphenylpropyl)piperazine
DMTC98X HS Investigative
DMTC98X SN CHEMBL209707; 1-(1,3-diphenylpropyl)piperazine; SCHEMBL5444533
DMTC98X DT Small molecular drug
DMTC98X PC 44414840
DMTC98X MW 280.4
DMTC98X FM C19H24N2
DMTC98X IC InChI=1S/C19H24N2/c1-3-7-17(8-4-1)11-12-19(18-9-5-2-6-10-18)21-15-13-20-14-16-21/h1-10,19-20H,11-16H2
DMTC98X CS C1CN(CCN1)C(CCC2=CC=CC=C2)C3=CC=CC=C3
DMTC98X IK QKYQOSPSZVKFEL-UHFFFAOYSA-N
DMTC98X IU 1-(1,3-diphenylpropyl)piperazine
DMTC98X DE Discovery agent
DMYI3F5 ID DMYI3F5
DMYI3F5 DN 1-(1,3-diphenylpropylidene)thiosemicarbazide
DMYI3F5 HS Investigative
DMYI3F5 SN CHEMBL429858; BDBM50377591
DMYI3F5 DT Small molecular drug
DMYI3F5 PC 44449925
DMYI3F5 MW 283.4
DMYI3F5 FM C16H17N3S
DMYI3F5 IC InChI=1S/C16H17N3S/c17-16(20)19-18-15(14-9-5-2-6-10-14)12-11-13-7-3-1-4-8-13/h1-10H,11-12H2,(H3,17,19,20)/b18-15-
DMYI3F5 CS C1=CC=C(C=C1)CC/C(=N/NC(=S)N)/C2=CC=CC=C2
DMYI3F5 IK AEHHXKHHRMBYLD-SDXDJHTJSA-N
DMYI3F5 IU [(Z)-1,3-diphenylpropylideneamino]thiourea
DMYI3F5 DE Discovery agent
DMHNOLA ID DMHNOLA
DMHNOLA DN 1-(1,4-diacetylphenyl)dithiosemicarbazide
DMHNOLA HS Investigative
DMHNOLA SN CHEMBL256865; NSC627218; AC1NTSUI; ZINC5883102; BDBM50376201; [(Z)-1-[4-[(Z)-N-(carbamothioylamino)-C-methylcarbonimidoyl]phenyl]ethylideneamino]thiourea; Hydrazinecarbothioamide, 2,2'-[1,4-phenylenedi(1Z)ethylidyne]bis-, (2Z,2'Z)-
DMHNOLA DT Small molecular drug
DMHNOLA PC 5387783
DMHNOLA MW 308.4
DMHNOLA FM C12H16N6S2
DMHNOLA IC InChI=1S/C12H16N6S2/c1-7(15-17-11(13)19)9-3-5-10(6-4-9)8(2)16-18-12(14)20/h3-6H,1-2H3,(H3,13,17,19)(H3,14,18,20)/b15-7-,16-8-
DMHNOLA CS C/C(=N/NC(=S)N)/C1=CC=C(C=C1)/C(=N\\NC(=S)N)/C
DMHNOLA IK IFFLYNGBOLZAGJ-DUGOVBPYSA-N
DMHNOLA IU [(Z)-1-[4-[(Z)-N-(carbamothioylamino)-C-methylcarbonimidoyl]phenyl]ethylideneamino]thiourea
DMHNOLA DE Discovery agent
DM8Z1QU ID DM8Z1QU
DM8Z1QU DN 1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU HS Investigative
DM8Z1QU SN CHEMBL384687; 1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU DT Small molecular drug
DM8Z1QU PC 44414856
DM8Z1QU MW 294.4
DM8Z1QU FM C20H26N2
DM8Z1QU IC InChI=1S/C20H26N2/c1-3-7-18(8-4-1)11-12-20(22-15-13-21-14-16-22)17-19-9-5-2-6-10-19/h1-10,20-21H,11-17H2
DM8Z1QU CS C1CN(CCN1)C(CCC2=CC=CC=C2)CC3=CC=CC=C3
DM8Z1QU IK OGFNNMZMCOBWPR-UHFFFAOYSA-N
DM8Z1QU IU 1-(1,4-diphenylbutan-2-yl)piperazine
DM8Z1QU DE Discovery agent
DM2AEO0 ID DM2AEO0
DM2AEO0 DN 1-(10-Bromoanthracen-9-yl)-2-aminopropane
DM2AEO0 HS Investigative
DM2AEO0 SN CHEMBL465525; 1-(10-Bromoanthracen-9-yl)-2-aminopropane
DM2AEO0 DT Small molecular drug
DM2AEO0 PC 24939279
DM2AEO0 MW 314.2
DM2AEO0 FM C17H16BrN
DM2AEO0 IC InChI=1S/C17H16BrN/c1-11(19)10-16-12-6-2-4-8-14(12)17(18)15-9-5-3-7-13(15)16/h2-9,11H,10,19H2,1H3
DM2AEO0 CS CC(CC1=C2C=CC=CC2=C(C3=CC=CC=C31)Br)N
DM2AEO0 IK TUYLBDQSCRSJBH-UHFFFAOYSA-N
DM2AEO0 IU 1-(10-bromoanthracen-9-yl)propan-2-amine
DM2AEO0 DE Discovery agent
DMKIWBT ID DMKIWBT
DMKIWBT DN 1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one
DMKIWBT HS Investigative
DMKIWBT SN CHEMBL240261; 1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one
DMKIWBT DT Small molecular drug
DMKIWBT PC 44435196
DMKIWBT MW 345.5
DMKIWBT FM C22H19NOS
DMKIWBT IC InChI=1S/C22H19NOS/c1-2-17(16-10-4-3-5-11-16)22(24)23-18-12-6-8-14-20(18)25-21-15-9-7-13-19(21)23/h3-15,17H,2H2,1H3
DMKIWBT CS CCC(C1=CC=CC=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMKIWBT IK LASZSIUHSRRUPB-UHFFFAOYSA-N
DMKIWBT IU 1-phenothiazin-10-yl-2-phenylbutan-1-one
DMKIWBT DE Discovery agent
DM5WBMY ID DM5WBMY
DM5WBMY DN 1-(10H-phenothiazin-10-yl)-2-phenylethanone
DM5WBMY HS Investigative
DM5WBMY SN CHEMBL394753; AC1LODHB; 1-(10H-phenothiazin-10-yl)-2-phenylethanone; Oprea1_136899; SCHEMBL7966578; MolPort-019-780-057; ZINC1022328; BDBM50219227; 1-phenothiazin-10-yl-2-phenylethanone; 1-(10H-Phenothiazine-10-yl)-2-phenylethanone; 1-(10H-Phenothiazin-10-yl)-2-phenylethan-1-one
DM5WBMY DT Small molecular drug
DM5WBMY PC 1238015
DM5WBMY MW 317.4
DM5WBMY FM C20H15NOS
DM5WBMY IC InChI=1S/C20H15NOS/c22-20(14-15-8-2-1-3-9-15)21-16-10-4-6-12-18(16)23-19-13-7-5-11-17(19)21/h1-13H,14H2
DM5WBMY CS C1=CC=C(C=C1)CC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM5WBMY IK ODRJXAKDUXFICI-UHFFFAOYSA-N
DM5WBMY IU 1-phenothiazin-10-yl-2-phenylethanone
DM5WBMY DE Discovery agent
DMYWG7D ID DMYWG7D
DMYWG7D DN 1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one
DMYWG7D HS Investigative
DMYWG7D SN CHEMBL240045; 1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one
DMYWG7D DT Small molecular drug
DMYWG7D PC 44435193
DMYWG7D MW 331.4
DMYWG7D FM C21H17NOS
DMYWG7D IC InChI=1S/C21H17NOS/c1-15(16-9-3-2-4-10-16)21(23)22-17-11-5-7-13-19(17)24-20-14-8-6-12-18(20)22/h2-15H,1H3
DMYWG7D CS CC(C1=CC=CC=C1)C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMYWG7D IK JSTQBEJYZPIVJU-UHFFFAOYSA-N
DMYWG7D IU 1-phenothiazin-10-yl-2-phenylpropan-1-one
DMYWG7D DE Discovery agent
DMZCPAQ ID DMZCPAQ
DMZCPAQ DN 1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one
DMZCPAQ HS Investigative
DMZCPAQ SN CHEMBL240262; 1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one
DMZCPAQ DT Small molecular drug
DMZCPAQ PC 44435197
DMZCPAQ MW 345.5
DMZCPAQ FM C22H19NOS
DMZCPAQ IC InChI=1S/C22H19NOS/c1-16(17-9-3-2-4-10-17)15-22(24)23-18-11-5-7-13-20(18)25-21-14-8-6-12-19(21)23/h2-14,16H,15H2,1H3
DMZCPAQ CS CC(CC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31)C4=CC=CC=C4
DMZCPAQ IK WFXGFQNNLYOETN-UHFFFAOYSA-N
DMZCPAQ IU 1-phenothiazin-10-yl-3-phenylbutan-1-one
DMZCPAQ DE Discovery agent
DMJQNLR ID DMJQNLR
DMJQNLR DN 1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one
DMJQNLR HS Investigative
DMJQNLR SN 1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one; CHEMBL240047; AC1LHUPA; 1-phenothiazin-10-yl-3-phenylpropan-1-one; MolPort-027-839-061; MolPort-002-255-240; ZINC469770; STL138828; BDBM50219214; AKOS005715472; MCULE-9350992214; 10-(3-phenylpropanoyl)-10H-phenothiazine; AO-365/41906550
DMJQNLR DT Small molecular drug
DMJQNLR PC 893336
DMJQNLR MW 331.4
DMJQNLR FM C21H17NOS
DMJQNLR IC InChI=1S/C21H17NOS/c23-21(15-14-16-8-2-1-3-9-16)22-17-10-4-6-12-19(17)24-20-13-7-5-11-18(20)22/h1-13H,14-15H2
DMJQNLR CS C1=CC=C(C=C1)CCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMJQNLR IK UFAZLVHMPFPAHH-UHFFFAOYSA-N
DMJQNLR IU 1-phenothiazin-10-yl-3-phenylpropan-1-one
DMJQNLR DE Discovery agent
DMGY32O ID DMGY32O
DMGY32O DN 1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one
DMGY32O HS Investigative
DMGY32O SN CHEMBL394755; 1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one
DMGY32O DT Small molecular drug
DMGY32O PC 44435200
DMGY32O MW 345.5
DMGY32O FM C22H19NOS
DMGY32O IC InChI=1S/C22H19NOS/c24-22(16-8-11-17-9-2-1-3-10-17)23-18-12-4-6-14-20(18)25-21-15-7-5-13-19(21)23/h1-7,9-10,12-15H,8,11,16H2
DMGY32O CS C1=CC=C(C=C1)CCCC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMGY32O IK IDGMQHJPMVCZGQ-UHFFFAOYSA-N
DMGY32O IU 1-phenothiazin-10-yl-4-phenylbutan-1-one
DMGY32O DE Discovery agent
DM7G2AB ID DM7G2AB
DM7G2AB DN 1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea
DM7G2AB HS Investigative
DM7G2AB SN CHEMBL214943; US8501783, 1163; SCHEMBL2731282; BDBM100426; BDBM100363; BDBM50191887
DM7G2AB DT Small molecular drug
DM7G2AB PC 24849910
DM7G2AB MW 333.5
DM7G2AB FM C19H31N3O2
DM7G2AB IC InChI=1S/C19H31N3O2/c1-2-17(23)22-5-3-16(4-6-22)20-18(24)21-19-10-13-7-14(11-19)9-15(8-13)12-19/h13-16H,2-12H2,1H3,(H2,20,21,24)
DM7G2AB CS CCC(=O)N1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DM7G2AB IK LFQPHKTUDTUJEA-UHFFFAOYSA-N
DM7G2AB IU 1-(1-adamantyl)-3-(1-propanoylpiperidin-4-yl)urea
DM7G2AB DE Discovery agent
DM2T1CD ID DM2T1CD
DM2T1CD DN 1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane
DM2T1CD HS Investigative
DM2T1CD SN CHEMBL18190; 1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane; BDBM50040196
DM2T1CD DT Small molecular drug
DM2T1CD PC 14952700
DM2T1CD MW 327.5
DM2T1CD FM C21H29NS
DM2T1CD IC InChI=1S/C21H29NS/c1-2-8-14-21(13-7-1,22-15-9-3-4-10-16-22)20-17-18-11-5-6-12-19(18)23-20/h5-6,11-12,17H,1-4,7-10,13-16H2
DM2T1CD CS C1CCCC(CC1)(C2=CC3=CC=CC=C3S2)N4CCCCCC4
DM2T1CD IK SHYAOKYYAHMSCY-UHFFFAOYSA-N
DM2T1CD IU 1-[1-(1-benzothiophen-2-yl)cycloheptyl]azepane
DM2T1CD DE Discovery agent
DMEFP15 ID DMEFP15
DMEFP15 DN 1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane
DMEFP15 HS Investigative
DMEFP15 SN CHEMBL17945; 1-[1-(1-benzothiophen-2-yl)cyclohexyl]azepane; NCI60_038332; AC1L9GGF; 1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane; CTK5J7197; QDGRJLAJZNWVGV-UHFFFAOYSA-N; BDBM50040192; 1-[1-(1-Benzothien-2-yl)cyclohexyl]azepane #; Thionaphthene, 2-[1-(1-azacycloheptyl)cyclohexyl]-
DMEFP15 DT Small molecular drug
DMEFP15 PC 398369
DMEFP15 MW 313.5
DMEFP15 FM C20H27NS
DMEFP15 IC InChI=1S/C20H27NS/c1-2-9-15-21(14-8-1)20(12-6-3-7-13-20)19-16-17-10-4-5-11-18(17)22-19/h4-5,10-11,16H,1-3,6-9,12-15H2
DMEFP15 CS C1CCCN(CC1)C2(CCCCC2)C3=CC4=CC=CC=C4S3
DMEFP15 IK QDGRJLAJZNWVGV-UHFFFAOYSA-N
DMEFP15 IU 1-[1-(1-benzothiophen-2-yl)cyclohexyl]azepane
DMEFP15 DE Discovery agent
DM1Q36W ID DM1Q36W
DM1Q36W DN 1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane
DM1Q36W HS Investigative
DM1Q36W SN CHEMBL18025; AC1LCXWM; 1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane; XZXHOFZYYWGLCJ-UHFFFAOYSA-N; BDBM50040198; 1-[1-(1-Benzothien-2-yl)cyclopentyl]azepane #; 1-[1-(1-benzothiophen-2-yl)cyclopentyl]azepane; Thionaphthene, 2-[1-(1-azacycloheptyl)cyclopentyl]-
DM1Q36W DT Small molecular drug
DM1Q36W PC 608630
DM1Q36W MW 299.5
DM1Q36W FM C19H25NS
DM1Q36W IC InChI=1S/C19H25NS/c1-2-8-14-20(13-7-1)19(11-5-6-12-19)18-15-16-9-3-4-10-17(16)21-18/h3-4,9-10,15H,1-2,5-8,11-14H2
DM1Q36W CS C1CCCN(CC1)C2(CCCC2)C3=CC4=CC=CC=C4S3
DM1Q36W IK XZXHOFZYYWGLCJ-UHFFFAOYSA-N
DM1Q36W IU 1-[1-(1-benzothiophen-2-yl)cyclopentyl]azepane
DM1Q36W DE Discovery agent
DMLBCE5 ID DMLBCE5
DMLBCE5 DN 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole
DMLBCE5 HS Investigative
DMLBCE5 SN CHEMBL491222; AC1LAA5O; 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole; BDBM50263812; 1-[1-benzyl-2-(4-phenylphenyl)ethyl]imidazole; 1-[1-phenyl-3-(4-phenylphenyl)propan-2-yl]imidazole; 1H-Imidazole, 1-[2-[1,1'-biphenyl]-4-yl-1-(phenylmethyl)ethyl]-
DMLBCE5 DT Small molecular drug
DMLBCE5 PC 510040
DMLBCE5 MW 338.4
DMLBCE5 FM C24H22N2
DMLBCE5 IC InChI=1S/C24H22N2/c1-3-7-20(8-4-1)17-24(26-16-15-25-19-26)18-21-11-13-23(14-12-21)22-9-5-2-6-10-22/h1-16,19,24H,17-18H2
DMLBCE5 CS C1=CC=C(C=C1)CC(CC2=CC=C(C=C2)C3=CC=CC=C3)N4C=CN=C4
DMLBCE5 IK BHZGAVDQPKAVLD-UHFFFAOYSA-N
DMLBCE5 IU 1-[1-phenyl-3-(4-phenylphenyl)propan-2-yl]imidazole
DMLBCE5 DE Discovery agent
DMPEIQT ID DMPEIQT
DMPEIQT DN 1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole
DMPEIQT HS Investigative
DMPEIQT SN CHEMBL496468; 1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole
DMPEIQT DT Small molecular drug
DMPEIQT PC 44587266
DMPEIQT MW 276.4
DMPEIQT FM C19H20N2
DMPEIQT IC InChI=1S/C19H20N2/c1-15(2)19(21-13-12-20-14-21)18-10-8-17(9-11-18)16-6-4-3-5-7-16/h3-15,19H,1-2H3
DMPEIQT CS CC(C)C(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMPEIQT IK IYAQGZVBLONFOB-UHFFFAOYSA-N
DMPEIQT IU 1-[2-methyl-1-(4-phenylphenyl)propyl]imidazole
DMPEIQT DE Discovery agent
DMCTF8X ID DMCTF8X
DMCTF8X DN 1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole
DMCTF8X HS Investigative
DMCTF8X SN CHEMBL526293; 1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole
DMCTF8X DT Small molecular drug
DMCTF8X PC 13416469
DMCTF8X MW 324.4
DMCTF8X FM C23H20N2
DMCTF8X IC InChI=1S/C23H20N2/c1-3-7-19(8-4-1)17-23(25-16-15-24-18-25)22-13-11-21(12-14-22)20-9-5-2-6-10-20/h1-16,18,23H,17H2
DMCTF8X CS C1=CC=C(C=C1)CC(C2=CC=C(C=C2)C3=CC=CC=C3)N4C=CN=C4
DMCTF8X IK TVOGKVRUROHUOE-UHFFFAOYSA-N
DMCTF8X IU 1-[2-phenyl-1-(4-phenylphenyl)ethyl]imidazole
DMCTF8X DE Discovery agent
DMWME7I ID DMWME7I
DMWME7I DN 1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole
DMWME7I HS Investigative
DMWME7I SN CHEMBL497851; 1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole
DMWME7I DT Small molecular drug
DMWME7I PC 44587268
DMWME7I MW 290.4
DMWME7I FM C20H22N2
DMWME7I IC InChI=1S/C20H22N2/c1-16(2)14-20(22-13-12-21-15-22)19-10-8-18(9-11-19)17-6-4-3-5-7-17/h3-13,15-16,20H,14H2,1-2H3
DMWME7I CS CC(C)CC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMWME7I IK WLSWBXVWEUOVLV-UHFFFAOYSA-N
DMWME7I IU 1-[3-methyl-1-(4-phenylphenyl)butyl]imidazole
DMWME7I DE Discovery agent
DM4XILF ID DM4XILF
DM4XILF DN 1-(1-Biphenyl-4-yl-butyl)-1H-imidazole
DM4XILF HS Investigative
DM4XILF SN CHEMBL449343; 1-(1-Biphenyl-4-yl-butyl)-1H-imidazole
DM4XILF DT Small molecular drug
DM4XILF PC 44587265
DM4XILF MW 276.4
DM4XILF FM C19H20N2
DM4XILF IC InChI=1S/C19H20N2/c1-2-6-19(21-14-13-20-15-21)18-11-9-17(10-12-18)16-7-4-3-5-8-16/h3-5,7-15,19H,2,6H2,1H3
DM4XILF CS CCCC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DM4XILF IK SLKWPFBZPUBKHY-UHFFFAOYSA-N
DM4XILF IU 1-[1-(4-phenylphenyl)butyl]imidazole
DM4XILF DE Discovery agent
DMW85CH ID DMW85CH
DMW85CH DN 1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole
DMW85CH HS Investigative
DMW85CH SN CHEMBL497499; 1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole; SCHEMBL10649315; BDBM50272506
DMW85CH DT Small molecular drug
DMW85CH PC 10354661
DMW85CH MW 248.32
DMW85CH FM C17H16N2
DMW85CH IC InChI=1S/C17H16N2/c1-14(19-12-11-18-13-19)15-7-9-17(10-8-15)16-5-3-2-4-6-16/h2-14H,1H3
DMW85CH CS CC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMW85CH IK XGUZZPBTOANTPR-UHFFFAOYSA-N
DMW85CH IU 1-[1-(4-phenylphenyl)ethyl]imidazole
DMW85CH DE Discovery agent
DM3AD7E ID DM3AD7E
DM3AD7E DN 1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole
DM3AD7E HS Investigative
DM3AD7E SN CHEMBL498523; 1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole
DM3AD7E DT Small molecular drug
DM3AD7E PC 44587267
DM3AD7E MW 290.4
DM3AD7E FM C20H22N2
DM3AD7E IC InChI=1S/C20H22N2/c1-2-3-9-20(22-15-14-21-16-22)19-12-10-18(11-13-19)17-7-5-4-6-8-17/h4-8,10-16,20H,2-3,9H2,1H3
DM3AD7E CS CCCCC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DM3AD7E IK LJLOALSYDDARJF-UHFFFAOYSA-N
DM3AD7E IU 1-[1-(4-phenylphenyl)pentyl]imidazole
DM3AD7E DE Discovery agent
DMGVE3F ID DMGVE3F
DMGVE3F DN 1-(1-Biphenyl-4-yl-propyl)-1H-imidazole
DMGVE3F HS Investigative
DMGVE3F SN CHEMBL497500; 1-(1-Biphenyl-4-yl-propyl)-1H-imidazole
DMGVE3F DT Small molecular drug
DMGVE3F PC 44587233
DMGVE3F MW 262.3
DMGVE3F FM C18H18N2
DMGVE3F IC InChI=1S/C18H18N2/c1-2-18(20-13-12-19-14-20)17-10-8-16(9-11-17)15-6-4-3-5-7-15/h3-14,18H,2H2,1H3
DMGVE3F CS CCC(C1=CC=C(C=C1)C2=CC=CC=C2)N3C=CN=C3
DMGVE3F IK IGUCGOUQZFQHGU-UHFFFAOYSA-N
DMGVE3F IU 1-[1-(4-phenylphenyl)propyl]imidazole
DMGVE3F DE Discovery agent
DM9MCAU ID DM9MCAU
DM9MCAU DN 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea
DM9MCAU HS Investigative
DM9MCAU SN Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea
DM9MCAU DT Small molecular drug
DM9MCAU PC 5330597
DM9MCAU MW 253.26
DM9MCAU FM C13H11N5O
DM9MCAU IC InChI=1S/C13H11N5O/c19-13(17-12-3-1-2-6-14-12)16-10-5-4-9-8-15-18-11(9)7-10/h1-8H,(H,15,18)(H2,14,16,17,19)
DM9MCAU CS C1=CC=NC(=C1)NC(=O)NC2=CC3=C(C=C2)C=NN3
DM9MCAU IK YGKMQQVUBKWTIJ-UHFFFAOYSA-N
DM9MCAU IU 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea
DM9MCAU DE Discovery agent
DMSUPCD ID DMSUPCD
DMSUPCD DN 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol
DMSUPCD HS Investigative
DMSUPCD SN CHEMBL37989
DMSUPCD DT Small molecular drug
DMSUPCD PC 13626879
DMSUPCD MW 310.4
DMSUPCD FM C19H22N2O2
DMSUPCD IC InChI=1S/C19H22N2O2/c22-16(13-20-11-9-15-5-2-1-3-6-15)14-23-19-8-4-7-18-17(19)10-12-21-18/h1-8,10,12,16,20-22H,9,11,13-14H2
DMSUPCD CS C1=CC=C(C=C1)CCNCC(COC2=CC=CC3=C2C=CN3)O
DMSUPCD IK MDPRLCKPDFRPJV-UHFFFAOYSA-N
DMSUPCD IU 1-(1H-indol-4-yloxy)-3-(2-phenylethylamino)propan-2-ol
DMSUPCD DE Discovery agent
DM6X9J3 ID DM6X9J3
DM6X9J3 DN 1-(1-Naphthyl)-2-aminopropane
DM6X9J3 HS Investigative
DM6X9J3 SN CHEMBL471838; 1-(1-Naphthyl)-2-aminopropane; 1-napthyl-2-aminopropane; SCHEMBL266931; AC1L96M0; 1-(1-Naphthyl)propane-2-amine; CTK6A7125; 1-naphthalen-1-ylpropan-2-amine; BDBM50276188; AKOS022488614; AKOS000151865; 12687-37-5; 1-(NAPHTHALEN-1-YL)PROPAN-2-AMINE
DM6X9J3 DT Small molecular drug
DM6X9J3 PC 413939
DM6X9J3 MW 185.26
DM6X9J3 FM C13H15N
DM6X9J3 IC InChI=1S/C13H15N/c1-10(14)9-12-7-4-6-11-5-2-3-8-13(11)12/h2-8,10H,9,14H2,1H3
DM6X9J3 CS CC(CC1=CC=CC2=CC=CC=C21)N
DM6X9J3 IK ODTJDLMNBKMVGR-UHFFFAOYSA-N
DM6X9J3 IU 1-naphthalen-1-ylpropan-2-amine
DM6X9J3 CA CAS 12687-37-5
DM6X9J3 DE Discovery agent
DMSUC85 ID DMSUC85
DMSUC85 DN 1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one
DMSUC85 HS Investigative
DMSUC85 SN CHEMBL1082938; 1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one
DMSUC85 DT Small molecular drug
DMSUC85 PC 46890076
DMSUC85 MW 233.29
DMSUC85 FM C11H11N3OS
DMSUC85 IC InChI=1S/C11H11N3OS/c1-9(15)8-16-11-7-12-13-14(11)10-5-3-2-4-6-10/h2-7H,8H2,1H3
DMSUC85 CS CC(=O)CSC1=CN=NN1C2=CC=CC=C2
DMSUC85 IK ZEWXXPJFFAXSFB-UHFFFAOYSA-N
DMSUC85 IU 1-(3-phenyltriazol-4-yl)sulfanylpropan-2-one
DMSUC85 DE Discovery agent
DM54ZKU ID DM54ZKU
DM54ZKU DN 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine
DM54ZKU HS Investigative
DM54ZKU SN CHEMBL213754; 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine; SCHEMBL5447617
DM54ZKU DT Small molecular drug
DM54ZKU PC 44414723
DM54ZKU MW 324.5
DM54ZKU FM C21H28N2O
DM54ZKU IC InChI=1S/C21H28N2O/c1-2-16-24-21-11-7-6-10-19(21)17-20(18-8-4-3-5-9-18)23-14-12-22-13-15-23/h3-11,20,22H,2,12-17H2,1H3
DM54ZKU CS CCCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DM54ZKU IK PSIGDYKJTYBHDY-UHFFFAOYSA-N
DM54ZKU IU 1-[1-phenyl-2-(2-propoxyphenyl)ethyl]piperazine
DM54ZKU DE Discovery agent
DMIZBP6 ID DMIZBP6
DMIZBP6 DN 1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine
DMIZBP6 HS Investigative
DMIZBP6 SN CHEMBL376952; 1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine
DMIZBP6 DT Small molecular drug
DMIZBP6 PC 44414862
DMIZBP6 MW 267.37
DMIZBP6 FM C17H21N3
DMIZBP6 IC InChI=1S/C17H21N3/c1-2-6-15(7-3-1)17(20-12-10-18-11-13-20)14-16-8-4-5-9-19-16/h1-9,17-18H,10-14H2
DMIZBP6 CS C1CN(CCN1)C(CC2=CC=CC=N2)C3=CC=CC=C3
DMIZBP6 IK BAYDYCDSOWCJTI-UHFFFAOYSA-N
DMIZBP6 IU 1-(1-phenyl-2-pyridin-2-ylethyl)piperazine
DMIZBP6 DE Discovery agent
DMTVPZC ID DMTVPZC
DMTVPZC DN 1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine
DMTVPZC HS Investigative
DMTVPZC SN CHEMBL214004; 1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine; SCHEMBL7967173
DMTVPZC DT Small molecular drug
DMTVPZC PC 44414874
DMTVPZC MW 267.37
DMTVPZC FM C17H21N3
DMTVPZC IC InChI=1S/C17H21N3/c1-2-4-16(5-3-1)17(20-12-10-19-11-13-20)14-15-6-8-18-9-7-15/h1-9,17,19H,10-14H2
DMTVPZC CS C1CN(CCN1)C(CC2=CC=NC=C2)C3=CC=CC=C3
DMTVPZC IK QVONDVLKKQSPCH-UHFFFAOYSA-N
DMTVPZC IU 1-(1-phenyl-2-pyridin-4-ylethyl)piperazine
DMTVPZC DE Discovery agent
DMZ6QX0 ID DMZ6QX0
DMZ6QX0 DN 1-(1-phenyl-2-o-tolylethyl)piperazine
DMZ6QX0 HS Investigative
DMZ6QX0 SN CHEMBL210028; 1-(1-phenyl-2-o-tolylethyl)piperazine; SCHEMBL5453605
DMZ6QX0 DT Small molecular drug
DMZ6QX0 PC 44414708
DMZ6QX0 MW 280.4
DMZ6QX0 FM C19H24N2
DMZ6QX0 IC InChI=1S/C19H24N2/c1-16-7-5-6-10-18(16)15-19(17-8-3-2-4-9-17)21-13-11-20-12-14-21/h2-10,19-20H,11-15H2,1H3
DMZ6QX0 CS CC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DMZ6QX0 IK XPYLNZBNFQMTKZ-UHFFFAOYSA-N
DMZ6QX0 IU 1-[2-(2-methylphenyl)-1-phenylethyl]piperazine
DMZ6QX0 DE Discovery agent
DMN5SL6 ID DMN5SL6
DMN5SL6 DN 1-(1-phenylethylidene)thiosemicarbazide
DMN5SL6 HS Investigative
DMN5SL6 SN CHEMBL256868; Acetophenone thiosemicarbazone; AC1NSE5V; SCHEMBL17666972; MolPort-000-248-706; ACETOPHENONE-THIOSEMICARBAZONE; BDBM50376200; ZINC13655939; AKOS002388568; AKOS002238721; [(Z)-1-phenylethylideneamino]thiourea; [(Z)-(1-phenylethylidene)amino]thiourea; KB-106912; ST50101590; (z)-2-(1-phenylethylidene)hydrazinecarbothioamide
DMN5SL6 DT Small molecular drug
DMN5SL6 PC 5359703
DMN5SL6 MW 193.27
DMN5SL6 FM C9H11N3S
DMN5SL6 IC InChI=1S/C9H11N3S/c1-7(11-12-9(10)13)8-5-3-2-4-6-8/h2-6H,1H3,(H3,10,12,13)/b11-7-
DMN5SL6 CS C/C(=N/NC(=S)N)/C1=CC=CC=C1
DMN5SL6 IK JMULZUQMMLAALR-XFFZJAGNSA-N
DMN5SL6 IU [(Z)-1-phenylethylideneamino]thiourea
DMN5SL6 DE Discovery agent
DMER0IY ID DMER0IY
DMER0IY DN 1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DMER0IY HS Investigative
DMER0IY SN CHEMBL151773; AC1MHEIH; 1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea; SCHEMBL6284442; BDBM50097039; 1-(1-phenylpropyl)-3-thiazol-2-yl-thiourea; N-(alpha-Ethylbenzyl]-N'-[2-(thiazolyl)]thiourea
DMER0IY DT Small molecular drug
DMER0IY PC 3003038
DMER0IY MW 277.4
DMER0IY FM C13H15N3S2
DMER0IY IC InChI=1S/C13H15N3S2/c1-2-11(10-6-4-3-5-7-10)15-12(17)16-13-14-8-9-18-13/h3-9,11H,2H2,1H3,(H2,14,15,16,17)
DMER0IY CS CCC(C1=CC=CC=C1)NC(=S)NC2=NC=CS2
DMER0IY IK PBDIRHCFDNJKQO-UHFFFAOYSA-N
DMER0IY IU 1-(1-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
DMER0IY DE Discovery agent
DMAZR9C ID DMAZR9C
DMAZR9C DN 1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea
DMAZR9C HS Investigative
DMAZR9C SN CHEMBL1257755; 1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea; SCHEMBL2719775; BDBM50327819
DMAZR9C DT Small molecular drug
DMAZR9C PC 49782798
DMAZR9C MW 289.37
DMAZR9C FM C16H23N3O2
DMAZR9C IC InChI=1S/C16H23N3O2/c1-3-15(20)19-9-7-13(8-10-19)17-16(21)18-14-6-4-5-12(2)11-14/h4-6,11,13H,3,7-10H2,1-2H3,(H2,17,18,21)
DMAZR9C CS CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=CC(=C2)C
DMAZR9C IK CWZWLJHZFNKFSC-UHFFFAOYSA-N
DMAZR9C IU 1-(3-methylphenyl)-3-(1-propanoylpiperidin-4-yl)urea
DMAZR9C DE Discovery agent
DMUH59X ID DMUH59X
DMUH59X DN 1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea
DMUH59X HS Investigative
DMUH59X SN CHEMBL1257633; 1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea; SCHEMBL2720137; BDBM50327838
DMUH59X DT Small molecular drug
DMUH59X PC 49782797
DMUH59X MW 289.37
DMUH59X FM C16H23N3O2
DMUH59X IC InChI=1S/C16H23N3O2/c1-3-15(20)19-10-8-13(9-11-19)17-16(21)18-14-7-5-4-6-12(14)2/h4-7,13H,3,8-11H2,1-2H3,(H2,17,18,21)
DMUH59X CS CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=CC=C2C
DMUH59X IK CBKNSQNPJUKLHL-UHFFFAOYSA-N
DMUH59X IU 1-(2-methylphenyl)-3-(1-propanoylpiperidin-4-yl)urea
DMUH59X DE Discovery agent
DMWUBI4 ID DMWUBI4
DMWUBI4 DN 1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea
DMWUBI4 HS Investigative
DMWUBI4 SN CHEMBL1257756; 1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea; SCHEMBL2719286; BDBM50327828
DMWUBI4 DT Small molecular drug
DMWUBI4 PC 49782799
DMWUBI4 MW 289.37
DMWUBI4 FM C16H23N3O2
DMWUBI4 IC InChI=1S/C16H23N3O2/c1-3-15(20)19-10-8-14(9-11-19)18-16(21)17-13-6-4-12(2)5-7-13/h4-7,14H,3,8-11H2,1-2H3,(H2,17,18,21)
DMWUBI4 CS CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=C(C=C2)C
DMWUBI4 IK JYILGCQJFUIUHF-UHFFFAOYSA-N
DMWUBI4 IU 1-(4-methylphenyl)-3-(1-propanoylpiperidin-4-yl)urea
DMWUBI4 DE Discovery agent
DM2PQFE ID DM2PQFE
DM2PQFE DN 1-(1-p-tolylethylidene)thiosemicarbazide
DM2PQFE HS Investigative
DM2PQFE SN CHEMBL256866; 7410-54-0; NSC8380; AC1NS5IF; DTXSID70417787; MolPort-020-322-439; ZINC502706; 1-p-Tolylethanone thiosemicarbazone; NSC-8380; BDBM50376198; AKOS002388601; AKOS008939485
DM2PQFE DT Small molecular drug
DM2PQFE PC 5354385
DM2PQFE MW 207.3
DM2PQFE FM C10H13N3S
DM2PQFE IC InChI=1S/C10H13N3S/c1-7-3-5-9(6-4-7)8(2)12-13-10(11)14/h3-6H,1-2H3,(H3,11,13,14)/b12-8-
DM2PQFE CS CC1=CC=C(C=C1)/C(=N\\NC(=S)N)/C
DM2PQFE IK CLXMWTWYQLEKAI-WQLSENKSSA-N
DM2PQFE IU [(Z)-1-(4-methylphenyl)ethylideneamino]thiourea
DM2PQFE CA CAS 7410-54-0
DM2PQFE DE Discovery agent
DMJXKOF ID DMJXKOF
DMJXKOF DN 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine
DMJXKOF HS Investigative
DMJXKOF SN CHEMBL575700; 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine; SCHEMBL2191560
DMJXKOF DT Small molecular drug
DMJXKOF PC 45483467
DMJXKOF MW 286.34
DMJXKOF FM C17H19FN2O
DMJXKOF IC InChI=1S/C17H19FN2O/c18-15-5-3-6-16(12-15)21-13-14-4-1-2-7-17(14)20-10-8-19-9-11-20/h1-7,12,19H,8-11,13H2
DMJXKOF CS C1CN(CCN1)C2=CC=CC=C2COC3=CC(=CC=C3)F
DMJXKOF IK IGKKFJKUWPDJDR-UHFFFAOYSA-N
DMJXKOF IU 1-[2-[(3-fluorophenoxy)methyl]phenyl]piperazine
DMJXKOF DE Discovery agent
DMUJ2WB ID DMUJ2WB
DMUJ2WB DN 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)
DMUJ2WB HS Investigative
DMUJ2WB SN CHEMBL1083708; 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX); SCHEMBL5447686; BDBM50319818; 1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine; (-)-1-(2-(2-(difluoromethoxy)phenyl)-1-phenylethyl)piperazine
DMUJ2WB DT Small molecular drug
DMUJ2WB PC 46890395
DMUJ2WB MW 332.4
DMUJ2WB FM C19H22F2N2O
DMUJ2WB IC InChI=1S/C19H22F2N2O/c20-19(21)24-18-9-5-4-8-16(18)14-17(15-6-2-1-3-7-15)23-12-10-22-11-13-23/h1-9,17,19,22H,10-14H2
DMUJ2WB CS C1CN(CCN1)C(CC2=CC=CC=C2OC(F)F)C3=CC=CC=C3
DMUJ2WB IK VCVDPONUNCPTCQ-UHFFFAOYSA-N
DMUJ2WB IU 1-[2-[2-(difluoromethoxy)phenyl]-1-phenylethyl]piperazine
DMUJ2WB DE Discovery agent
DMPRALC ID DMPRALC
DMPRALC DN 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine
DMPRALC HS Investigative
DMPRALC SN CHEMBL378418; 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine; SCHEMBL5442011
DMPRALC DT Small molecular drug
DMPRALC PC 44414750
DMPRALC MW 345.3
DMPRALC FM C18H21BrN2
DMPRALC IC InChI=1S/C18H21BrN2/c19-17-9-5-4-8-16(17)14-18(15-6-2-1-3-7-15)21-12-10-20-11-13-21/h1-9,18,20H,10-14H2
DMPRALC CS C1CN(CCN1)C(CC2=CC=CC=C2Br)C3=CC=CC=C3
DMPRALC IK KVNXQYJMNFSXRE-UHFFFAOYSA-N
DMPRALC IU 1-[2-(2-bromophenyl)-1-phenylethyl]piperazine
DMPRALC DE Discovery agent
DM9CVX5 ID DM9CVX5
DM9CVX5 DN 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine
DM9CVX5 HS Investigative
DM9CVX5 SN CHEMBL599593; 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine
DM9CVX5 DT Small molecular drug
DM9CVX5 PC 46230818
DM9CVX5 MW 289.76
DM9CVX5 FM C15H16ClN3O
DM9CVX5 IC InChI=1S/C15H16ClN3O/c16-12-4-1-2-6-14(12)20-15-13(5-3-7-18-15)19-10-8-17-9-11-19/h1-7,17H,8-11H2
DM9CVX5 CS C1CN(CCN1)C2=C(N=CC=C2)OC3=CC=CC=C3Cl
DM9CVX5 IK LVSZWRFDLAUNPF-UHFFFAOYSA-N
DM9CVX5 IU 1-[2-(2-chlorophenoxy)pyridin-3-yl]piperazine
DM9CVX5 DE Discovery agent
DMUM4YQ ID DMUM4YQ
DMUM4YQ DN 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine
DMUM4YQ HS Investigative
DMUM4YQ SN CHEMBL213287; 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine; SCHEMBL5444180
DMUM4YQ DT Small molecular drug
DMUM4YQ PC 44414719
DMUM4YQ MW 300.8
DMUM4YQ FM C18H21ClN2
DMUM4YQ IC InChI=1S/C18H21ClN2/c19-17-9-5-4-8-16(17)14-18(15-6-2-1-3-7-15)21-12-10-20-11-13-21/h1-9,18,20H,10-14H2
DMUM4YQ CS C1CN(CCN1)C(CC2=CC=CC=C2Cl)C3=CC=CC=C3
DMUM4YQ IK SDLVJPBOBLQFEW-UHFFFAOYSA-N
DMUM4YQ IU 1-[2-(2-chlorophenyl)-1-phenylethyl]piperazine
DMUM4YQ DE Discovery agent
DMBRS3D ID DMBRS3D
DMBRS3D DN 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine
DMBRS3D HS Investigative
DMBRS3D SN CHEMBL386224; 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine; SCHEMBL5450115
DMBRS3D DT Small molecular drug
DMBRS3D PC 11289879
DMBRS3D MW 310.4
DMBRS3D FM C20H26N2O
DMBRS3D IC InChI=1S/C20H26N2O/c1-2-23-20-11-7-6-10-18(20)16-19(17-8-4-3-5-9-17)22-14-12-21-13-15-22/h3-11,19,21H,2,12-16H2,1H3
DMBRS3D CS CCOC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DMBRS3D IK CVFBVSUFNWOPLD-UHFFFAOYSA-N
DMBRS3D IU 1-[2-(2-ethoxyphenyl)-1-phenylethyl]piperazine
DMBRS3D DE Discovery agent
DMKWRCD ID DMKWRCD
DMKWRCD DN 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine
DMKWRCD HS Investigative
DMKWRCD SN CHEMBL210126; 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine; SCHEMBL5458859
DMKWRCD DT Small molecular drug
DMKWRCD PC 44414709
DMKWRCD MW 294.4
DMKWRCD FM C20H26N2
DMKWRCD IC InChI=1S/C20H26N2/c1-2-17-8-6-7-11-19(17)16-20(18-9-4-3-5-10-18)22-14-12-21-13-15-22/h3-11,20-21H,2,12-16H2,1H3
DMKWRCD CS CCC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DMKWRCD IK USQDYFAONFKQLW-UHFFFAOYSA-N
DMKWRCD IU 1-[2-(2-ethylphenyl)-1-phenylethyl]piperazine
DMKWRCD DE Discovery agent
DM6XCPV ID DM6XCPV
DM6XCPV DN 1-(2-(2-fluorobenzyloxy)phenyl)piperazine
DM6XCPV HS Investigative
DM6XCPV SN CHEMBL575899; 1-(2-(2-fluorobenzyloxy)phenyl)piperazine; BDBM50299784
DM6XCPV DT Small molecular drug
DM6XCPV PC 45483446
DM6XCPV MW 286.34
DM6XCPV FM C17H19FN2O
DM6XCPV IC InChI=1S/C17H19FN2O/c18-15-6-2-1-5-14(15)13-21-17-8-4-3-7-16(17)20-11-9-19-10-12-20/h1-8,19H,9-13H2
DM6XCPV CS C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3F
DM6XCPV IK XMQIWPUGABPALG-UHFFFAOYSA-N
DM6XCPV IU 1-[2-[(2-fluorophenyl)methoxy]phenyl]piperazine
DM6XCPV DE Discovery agent
DM2H38V ID DM2H38V
DM2H38V DN 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V HS Investigative
DM2H38V SN CHEMBL214335; 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine; SCHEMBL5440547; BDBM50188048; (-)-1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine
DM2H38V DT Small molecular drug
DM2H38V PC 44414722
DM2H38V MW 296.4
DM2H38V FM C19H24N2O
DM2H38V IC InChI=1S/C19H24N2O/c1-22-19-10-6-5-9-17(19)15-18(16-7-3-2-4-8-16)21-13-11-20-12-14-21/h2-10,18,20H,11-15H2,1H3
DM2H38V CS COC1=CC=CC=C1CC(C2=CC=CC=C2)N3CCNCC3
DM2H38V IK PFTJCYRHNKTTTO-UHFFFAOYSA-N
DM2H38V IU 1-[2-(2-methoxyphenyl)-1-phenylethyl]piperazine
DM2H38V DE Discovery agent
DM4WEGM ID DM4WEGM
DM4WEGM DN 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine
DM4WEGM HS Investigative
DM4WEGM SN CHEMBL214240; 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine; SCHEMBL5448643
DM4WEGM DT Small molecular drug
DM4WEGM PC 44414720
DM4WEGM MW 300.8
DM4WEGM FM C18H21ClN2
DM4WEGM IC InChI=1S/C18H21ClN2/c19-17-8-4-5-15(13-17)14-18(16-6-2-1-3-7-16)21-11-9-20-10-12-21/h1-8,13,18,20H,9-12,14H2
DM4WEGM CS C1CN(CCN1)C(CC2=CC(=CC=C2)Cl)C3=CC=CC=C3
DM4WEGM IK LTKQGPSHVUGDKE-UHFFFAOYSA-N
DM4WEGM IU 1-[2-(3-chlorophenyl)-1-phenylethyl]piperazine
DM4WEGM DE Discovery agent
DMXV2KQ ID DMXV2KQ
DMXV2KQ DN 1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ HS Investigative
DMXV2KQ SN CHEMBL573973; 1-(2-(3-fluorophenoxy)phenyl)piperazine
DMXV2KQ DT Small molecular drug
DMXV2KQ PC 45483432
DMXV2KQ MW 272.32
DMXV2KQ FM C16H17FN2O
DMXV2KQ IC InChI=1S/C16H17FN2O/c17-13-4-3-5-14(12-13)20-16-7-2-1-6-15(16)19-10-8-18-9-11-19/h1-7,12,18H,8-11H2
DMXV2KQ CS C1CN(CCN1)C2=CC=CC=C2OC3=CC(=CC=C3)F
DMXV2KQ IK ZTEDPRVVBLHAKJ-UHFFFAOYSA-N
DMXV2KQ IU 1-[2-(3-fluorophenoxy)phenyl]piperazine
DMXV2KQ DE Discovery agent
DM8V5IH ID DM8V5IH
DM8V5IH DN 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine
DM8V5IH HS Investigative
DM8V5IH SN CHEMBL212763; 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine; 61311-72-6; 1-[2-(3-Methoxyphenyl)-1-phenylethyl]piperazine; SCHEMBL11504855; CTK2E2732; DTXSID40552210; BDBM50188044; Piperazine, 1-[2-(3-methoxyphenyl)-1-phenylethyl]-
DM8V5IH DT Small molecular drug
DM8V5IH PC 13904719
DM8V5IH MW 296.4
DM8V5IH FM C19H24N2O
DM8V5IH IC InChI=1S/C19H24N2O/c1-22-18-9-5-6-16(14-18)15-19(17-7-3-2-4-8-17)21-12-10-20-11-13-21/h2-9,14,19-20H,10-13,15H2,1H3
DM8V5IH CS COC1=CC=CC(=C1)CC(C2=CC=CC=C2)N3CCNCC3
DM8V5IH IK CTAHXNUPBZTDFO-UHFFFAOYSA-N
DM8V5IH IU 1-[2-(3-methoxyphenyl)-1-phenylethyl]piperazine
DM8V5IH CA CAS 61311-72-6
DM8V5IH DE Discovery agent
DMU082P ID DMU082P
DMU082P DN 1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P HS Investigative
DMU082P SN CHEMBL573972; 1-(2-(4-fluorophenoxy)phenyl)piperazine
DMU082P DT Small molecular drug
DMU082P PC 45483431
DMU082P MW 272.32
DMU082P FM C16H17FN2O
DMU082P IC InChI=1S/C16H17FN2O/c17-13-5-7-14(8-6-13)20-16-4-2-1-3-15(16)19-11-9-18-10-12-19/h1-8,18H,9-12H2
DMU082P CS C1CN(CCN1)C2=CC=CC=C2OC3=CC=C(C=C3)F
DMU082P IK VWVYZCFGGWGOMP-UHFFFAOYSA-N
DMU082P IU 1-[2-(4-fluorophenoxy)phenyl]piperazine
DMU082P DE Discovery agent
DMR4DJ1 ID DMR4DJ1
DMR4DJ1 DN 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1 HS Investigative
DMR4DJ1 SN CHEMBL465515; 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine
DMR4DJ1 DT Small molecular drug
DMR4DJ1 PC 44592244
DMR4DJ1 MW 258.329
DMR4DJ1 FM C16H19FN2
DMR4DJ1 IC InChI=1S/C16H19FN2/c17-16-4-3-14-11-13(1-2-15(14)12-16)5-8-19-9-6-18-7-10-19/h1-4,11-12,18H,5-10H2
DMR4DJ1 CS C1CN(CCN1)CCC2=CC3=C(C=C2)C=C(C=C3)F
DMR4DJ1 IK AVSJNVNTDDYDEP-UHFFFAOYSA-N
DMR4DJ1 IU 1-[2-(6-fluoronaphthalen-2-yl)ethyl]piperazine
DMR4DJ1 DE Discovery agent
DMB3HI4 ID DMB3HI4
DMB3HI4 DN 1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole
DMB3HI4 HS Investigative
DMB3HI4 SN CHEMBL460382; Benzo[b]thiophene 32; BDBM10038; ZINC13808220; 1-[2-(1-benzothiophen-4-yl)ethyl]-1H-imidazole; 4-[2-(1H-Imidazole-1-yl)ethyl]benzo[b]thiophene
DMB3HI4 DT Small molecular drug
DMB3HI4 PC 10537337
DMB3HI4 MW 228.31
DMB3HI4 FM C13H12N2S
DMB3HI4 IC InChI=1S/C13H12N2S/c1-2-11(4-7-15-8-6-14-10-15)12-5-9-16-13(12)3-1/h1-3,5-6,8-10H,4,7H2
DMB3HI4 CS C1=CC(=C2C=CSC2=C1)CCN3C=CN=C3
DMB3HI4 IK ZEWHOUCPWZPPGK-UHFFFAOYSA-N
DMB3HI4 IU 1-[2-(1-benzothiophen-4-yl)ethyl]imidazole
DMB3HI4 DE Discovery agent
DM0UZHL ID DM0UZHL
DM0UZHL DN 1-(2-(benzyloxy)phenyl)piperazine
DM0UZHL HS Investigative
DM0UZHL SN 1-(2-(benzyloxy)phenyl)piperazine; 96221-84-0; 1-(2-Benzyloxy-phenyl)-piperazine; CHEMBL582928; 1-[2-(benzyloxy)phenyl]piperazine; SCHEMBL4673484; 1-(2-benzyloxyphenyl)piperazine; CTK7D1689; ZINC2527252; BDBM50299797; 9395AH; AKOS010941582; AB19552; AJ-37911; DA-00144; BBV-33344054; KB-212806; AX8291986; FT-0752442; Z-7800
DM0UZHL DT Small molecular drug
DM0UZHL PC 22615724
DM0UZHL MW 268.35
DM0UZHL FM C17H20N2O
DM0UZHL IC InChI=1S/C17H20N2O/c1-2-6-15(7-3-1)14-20-17-9-5-4-8-16(17)19-12-10-18-11-13-19/h1-9,18H,10-14H2
DM0UZHL CS C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3
DM0UZHL IK PPQUPQGZDGZYJI-UHFFFAOYSA-N
DM0UZHL IU 1-(2-phenylmethoxyphenyl)piperazine
DM0UZHL DE Discovery agent
DMU5BOW ID DMU5BOW
DMU5BOW DN 1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea
DMU5BOW HS Investigative
DMU5BOW SN CHEMBL305516; 1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea; BDBM50088469; 1-[2-(Diethylamino)-4-quinazolinyl]-3-phenylurea
DMU5BOW DT Small molecular drug
DMU5BOW PC 10640536
DMU5BOW MW 335.4
DMU5BOW FM C19H21N5O
DMU5BOW IC InChI=1S/C19H21N5O/c1-3-24(4-2)18-21-16-13-9-8-12-15(16)17(22-18)23-19(25)20-14-10-6-5-7-11-14/h5-13H,3-4H2,1-2H3,(H2,20,21,22,23,25)
DMU5BOW CS CCN(CC)C1=NC2=CC=CC=C2C(=N1)NC(=O)NC3=CC=CC=C3
DMU5BOW IK OACDZTWEJRHLMO-UHFFFAOYSA-N
DMU5BOW IU 1-[2-(diethylamino)quinazolin-4-yl]-3-phenylurea
DMU5BOW DE Discovery agent
DMXL7Z5 ID DMXL7Z5
DMXL7Z5 DN 1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine
DMXL7Z5 HS Investigative
DMXL7Z5 SN CHEMBL212878; 1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine
DMXL7Z5 DT Small molecular drug
DMXL7Z5 PC 44414861
DMXL7Z5 MW 316.4
DMXL7Z5 FM C22H24N2
DMXL7Z5 IC InChI=1S/C22H24N2/c1-2-8-19(9-3-1)22(24-15-13-23-14-16-24)17-20-11-6-10-18-7-4-5-12-21(18)20/h1-12,22-23H,13-17H2
DMXL7Z5 CS C1CN(CCN1)C(CC2=CC=CC3=CC=CC=C32)C4=CC=CC=C4
DMXL7Z5 IK VWOWSEBOGHLBFX-UHFFFAOYSA-N
DMXL7Z5 IU 1-(2-naphthalen-1-yl-1-phenylethyl)piperazine
DMXL7Z5 DE Discovery agent
DMTEBP0 ID DMTEBP0
DMTEBP0 DN 1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine
DMTEBP0 HS Investigative
DMTEBP0 SN CHEMBL425961; 1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine
DMTEBP0 DT Small molecular drug
DMTEBP0 PC 44414860
DMTEBP0 MW 316.4
DMTEBP0 FM C22H24N2
DMTEBP0 IC InChI=1S/C22H24N2/c1-2-7-20(8-3-1)22(24-14-12-23-13-15-24)17-18-10-11-19-6-4-5-9-21(19)16-18/h1-11,16,22-23H,12-15,17H2
DMTEBP0 CS C1CN(CCN1)C(CC2=CC3=CC=CC=C3C=C2)C4=CC=CC=C4
DMTEBP0 IK HSPJWADLPHSZQN-UHFFFAOYSA-N
DMTEBP0 IU 1-(2-naphthalen-2-yl-1-phenylethyl)piperazine
DMTEBP0 DE Discovery agent
DMS7YF6 ID DMS7YF6
DMS7YF6 DN 1-(2-(naphthalen-2-yl)ethyl)piperazine
DMS7YF6 HS Investigative
DMS7YF6 SN 1-(2-(naphthalen-2-yl)ethyl)piperazine; CHEMBL503234; 194943-70-9; SCHEMBL8671948; BDBM50278561; ZINC40379086; AKOS011777831; DA-08636
DMS7YF6 DT Small molecular drug
DMS7YF6 PC 44592243
DMS7YF6 MW 240.34
DMS7YF6 FM C16H20N2
DMS7YF6 IC InChI=1S/C16H20N2/c1-2-4-16-13-14(5-6-15(16)3-1)7-10-18-11-8-17-9-12-18/h1-6,13,17H,7-12H2
DMS7YF6 CS C1CN(CCN1)CCC2=CC3=CC=CC=C3C=C2
DMS7YF6 IK MXNHEKIHSVXJPG-UHFFFAOYSA-N
DMS7YF6 IU 1-(2-naphthalen-2-ylethyl)piperazine
DMS7YF6 DE Discovery agent
DMYFKID ID DMYFKID
DMYFKID DN 1-(2-(naphthalen-2-yl)ethyl)pyrrolidine
DMYFKID HS Investigative
DMYFKID SN CHEMBL270410
DMYFKID DT Small molecular drug
DMYFKID PC 44455950
DMYFKID MW 225.33
DMYFKID FM C16H19N
DMYFKID IC InChI=1S/C16H19N/c1-2-6-16-13-14(7-8-15(16)5-1)9-12-17-10-3-4-11-17/h1-2,5-8,13H,3-4,9-12H2
DMYFKID CS C1CCN(C1)CCC2=CC3=CC=CC=C3C=C2
DMYFKID IK BUFGWZZSSJWXIJ-UHFFFAOYSA-N
DMYFKID IU 1-(2-naphthalen-2-ylethyl)pyrrolidine
DMYFKID DE Discovery agent
DM7Z19T ID DM7Z19T
DM7Z19T DN 1-(2-(phenoxymethyl)phenyl)piperazine
DM7Z19T HS Investigative
DM7Z19T SN CHEMBL574127; 1-(2-(phenoxymethyl)phenyl)piperazine; SCHEMBL2189855
DM7Z19T DT Small molecular drug
DM7Z19T PC 45483466
DM7Z19T MW 268.35
DM7Z19T FM C17H20N2O
DM7Z19T IC InChI=1S/C17H20N2O/c1-2-7-16(8-3-1)20-14-15-6-4-5-9-17(15)19-12-10-18-11-13-19/h1-9,18H,10-14H2
DM7Z19T CS C1CN(CCN1)C2=CC=CC=C2COC3=CC=CC=C3
DM7Z19T IK WLIGTTARDYGFBV-UHFFFAOYSA-N
DM7Z19T IU 1-[2-(phenoxymethyl)phenyl]piperazine
DM7Z19T DE Discovery agent
DMNX6CE ID DMNX6CE
DMNX6CE DN 1-(2,2'-bithiophen-5-yl)methanamine
DMNX6CE HS Investigative
DMNX6CE SN 4380-96-5; [2,2'-Bithiophen]-5-ylmethanamine; 2,2'-bithiophene-5-methylamine; 2,2'-bithiophen-5-ylmethanamine; [2,2'-Bithiophene]-5-methanamine; 1-(2,2'-bithiophen-5-yl)methanamine; 2,2-Bithiophene-5-methylamine; CHEMBL538940; (5-(2-thienyl)-2-thienyl)methylamine; [5-(Thiophen-2-Yl)Thiophen-2-Yl]Methanamine; SDCCGMLS-0065983.P001; AC1MCQYM; SCHEMBL2690127; CTK1D7717; DTXSID50380066; MolPort-000-142-515; FHYTVXBZSXZMGD-UHFFFAOYSA-N; ZINC158800; 2,2''-bithiophen-5-ylmethanamine; AC1Q5409; QC-966; SBB091920; BDBM50294164
DMNX6CE DT Small molecular drug
DMNX6CE PC 2776424
DMNX6CE MW 195.3
DMNX6CE FM C9H9NS2
DMNX6CE IC InChI=1S/C9H9NS2/c10-6-7-3-4-9(12-7)8-2-1-5-11-8/h1-5H,6,10H2
DMNX6CE CS C1=CSC(=C1)C2=CC=C(S2)CN
DMNX6CE IK FHYTVXBZSXZMGD-UHFFFAOYSA-N
DMNX6CE IU (5-thiophen-2-ylthiophen-2-yl)methanamine
DMNX6CE CA CAS 4380-96-5
DMNX6CE DE Discovery agent
DM1Q0TM ID DM1Q0TM
DM1Q0TM DN 1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)
DM1Q0TM HS Investigative
DM1Q0TM SN CHEMBL1094208; 1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX); BDBM50316566; 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol
DM1Q0TM DT Small molecular drug
DM1Q0TM PC 46888467
DM1Q0TM MW 455.2
DM1Q0TM FM C21H12Cl2F4N2O
DM1Q0TM IC InChI=1S/C21H12Cl2F4N2O/c22-17-3-1-2-16(19(17)23)20(30,21(25,26)27)13-4-9-18-12(10-13)11-28-29(18)15-7-5-14(24)6-8-15/h1-11,30H
DM1Q0TM CS C1=CC(=C(C(=C1)Cl)Cl)C(C2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)(C(F)(F)F)O
DM1Q0TM IK SGKVPHOMCZNDPT-UHFFFAOYSA-N
DM1Q0TM IU 1-(2,3-dichlorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)indazol-5-yl]ethanol
DM1Q0TM DE Discovery agent
DM0URSE ID DM0URSE
DM0URSE DN 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine
DM0URSE HS Investigative
DM0URSE SN CHEMBL31171; 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine; 1H-Indole-5-ethanamine, alpha-ethyl-2,3-dihydro-; BDBM50025077
DM0URSE DT Small molecular drug
DM0URSE PC 13660291
DM0URSE MW 190.28
DM0URSE FM C12H18N2
DM0URSE IC InChI=1S/C12H18N2/c1-2-11(13)8-9-3-4-12-10(7-9)5-6-14-12/h3-4,7,11,14H,2,5-6,8,13H2,1H3
DM0URSE CS CCC(CC1=CC2=C(C=C1)NCC2)N
DM0URSE IK WHXRWSJORCUAFO-UHFFFAOYSA-N
DM0URSE IU 1-(2,3-dihydro-1H-indol-5-yl)butan-2-amine
DM0URSE DE Discovery agent
DM31CVR ID DM31CVR
DM31CVR DN 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine
DM31CVR HS Investigative
DM31CVR SN CHEMBL160344; ZINC27714862; BDBM50226210
DM31CVR DT Small molecular drug
DM31CVR PC 13599004
DM31CVR MW 236.31
DM31CVR FM C13H20N2O2
DM31CVR IC InChI=1S/C13H20N2O2/c1-10-8-13(17-3)11(9-12(10)16-2)15-6-4-14-5-7-15/h8-9,14H,4-7H2,1-3H3
DM31CVR CS CC1=CC(=C(C=C1OC)N2CCNCC2)OC
DM31CVR IK XJDJQRVAYJTBHO-UHFFFAOYSA-N
DM31CVR IU 1-(2,5-dimethoxy-4-methylphenyl)piperazine
DM31CVR DE Discovery agent
DMNETHQ ID DMNETHQ
DMNETHQ DN 1-(2,5-Dimethoxy-phenyl)-piperazine
DMNETHQ HS Investigative
DMNETHQ SN 1-(2,5-dimethoxyphenyl)piperazine; 1-(2,5-Dimethoxy-phenyl)-piperazine; CHEMBL156216; 1019-06-3; Piperazine, 1-(2,5-dimethoxyphenyl)-; AC1MBY8N; Oprea1_560724; SCHEMBL2349863; CTK0G7924; DTXSID10374340; IZFHRJZAZNTUOI-UHFFFAOYSA-N; 4-[2,5-Dimethoxyphenyl]piperazine; ZINC11632569; BDBM50226212; MFCD03444397; AKOS003591177; DB-017049
DMNETHQ DT Small molecular drug
DMNETHQ PC 2758473
DMNETHQ MW 222.28
DMNETHQ FM C12H18N2O2
DMNETHQ IC InChI=1S/C12H18N2O2/c1-15-10-3-4-12(16-2)11(9-10)14-7-5-13-6-8-14/h3-4,9,13H,5-8H2,1-2H3
DMNETHQ CS COC1=CC(=C(C=C1)OC)N2CCNCC2
DMNETHQ IK IZFHRJZAZNTUOI-UHFFFAOYSA-N
DMNETHQ IU 1-(2,5-dimethoxyphenyl)piperazine
DMNETHQ CA CAS 1019-06-3
DMNETHQ DE Discovery agent
DM043N8 ID DM043N8
DM043N8 DN 1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8 HS Investigative
DM043N8 SN 2-(2,5-Dimethoxy-phenyl)-1-methyl-ethylamine
DM043N8 DT Small molecular drug
DM043N8 PC 62787
DM043N8 MW 195.26
DM043N8 FM C11H17NO2
DM043N8 IC InChI=1S/C11H17NO2/c1-8(12)6-9-7-10(13-2)4-5-11(9)14-3/h4-5,7-8H,6,12H2,1-3H3
DM043N8 CS CC(CC1=C(C=CC(=C1)OC)OC)N
DM043N8 IK LATVFYDIBMDBSY-UHFFFAOYSA-N
DM043N8 IU 1-(2,5-dimethoxyphenyl)propan-2-amine
DM043N8 CA CAS 2801-68-5
DM043N8 DE Discovery agent
DM3FHJK ID DM3FHJK
DM3FHJK DN 1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea
DM3FHJK HS Investigative
DM3FHJK SN 1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea; CHEMBL466982; 70436-68-9; BDBM50268203; ZINC40413177
DM3FHJK DT Small molecular drug
DM3FHJK PC 42605400
DM3FHJK MW 169.25
DM3FHJK FM C7H11N3S
DM3FHJK IC InChI=1S/C7H11N3S/c1-5-3-4-6(2)10(5)9-7(8)11/h3-4H,1-2H3,(H3,8,9,11)
DM3FHJK CS CC1=CC=C(N1NC(=S)N)C
DM3FHJK IK XNQJQAUTZJGWDW-UHFFFAOYSA-N
DM3FHJK IU (2,5-dimethylpyrrol-1-yl)thiourea
DM3FHJK DE Discovery agent
DMV0C6F ID DMV0C6F
DMV0C6F DN 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine
DMV0C6F HS Investigative
DMV0C6F SN 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine; CHEMBL293399; 80888-36-4; Psi-DOM; SCHEMBL2562975; DTXSID20548454; 2,6-dimethoxy-4-methylamphetamine; BDBM50115832; 2,6-Dimethoxy-alpha,4-dimethylbenzeneethanamine; Benzeneethanamine, 2,6-dimethoxy-alpha,4-dimethyl-
DMV0C6F DT Small molecular drug
DMV0C6F PC 13753734
DMV0C6F MW 209.28
DMV0C6F FM C12H19NO2
DMV0C6F IC InChI=1S/C12H19NO2/c1-8-5-11(14-3)10(7-9(2)13)12(6-8)15-4/h5-6,9H,7,13H2,1-4H3
DMV0C6F CS CC1=CC(=C(C(=C1)OC)CC(C)N)OC
DMV0C6F IK CFFJUEYUTHKVMQ-UHFFFAOYSA-N
DMV0C6F IU 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine
DMV0C6F CA CAS 80888-36-4
DMV0C6F DE Discovery agent
DMRHY2M ID DMRHY2M
DMRHY2M DN 1-(2-adamantyl)-3-benzylpyrrolidin-2-one
DMRHY2M HS Investigative
DMRHY2M SN 1-(2-adamantyl)-3-benzylpyrrolidin-2-one; CHEMBL218286; CHEMBL3085039; SCHEMBL13435191
DMRHY2M DT Small molecular drug
DMRHY2M PC 44419251
DMRHY2M MW 309.4
DMRHY2M FM C21H27NO
DMRHY2M IC InChI=1S/C21H27NO/c23-21-17(9-14-4-2-1-3-5-14)6-7-22(21)20-18-10-15-8-16(12-18)13-19(20)11-15/h1-5,15-20H,6-13H2
DMRHY2M CS C1CN(C(=O)C1CC2=CC=CC=C2)C3C4CC5CC(C4)CC3C5
DMRHY2M IK HAAVSDQVLBVURQ-UHFFFAOYSA-N
DMRHY2M IU 1-(2-adamantyl)-3-benzylpyrrolidin-2-one
DMRHY2M DE Discovery agent
DMLV0PQ ID DMLV0PQ
DMLV0PQ DN 1-(2-allylphenoxy)-3-morpholinopropan-2-ol
DMLV0PQ HS Investigative
DMLV0PQ SN CHEMBL1083667; 1-morpholin-4-yl-3-(2-prop-2-enylphenoxy)propan-2-ol; BAS 00134198; AC1MCHI5; 1-(2-allylphenoxy)-3-morpholinopropan-2-ol; Oprea1_670642; Oprea1_634560; MLS001143833; MolPort-001-916-053; HMS2803P24; STK843731; BDBM50318978; AKOS016050431; AKOS000525780; MCULE-7265762065; SMR000473272; ST50000343; EN300-241692; 1-(2-allylphenoxy)-3-morpholin-4-ylpropan-2-ol; 1-(2-Allyl-phenoxy)-3-morpholin-4-yl-propan-2-ol
DMLV0PQ DT Small molecular drug
DMLV0PQ PC 2769774
DMLV0PQ MW 277.36
DMLV0PQ FM C16H23NO3
DMLV0PQ IC InChI=1S/C16H23NO3/c1-2-5-14-6-3-4-7-16(14)20-13-15(18)12-17-8-10-19-11-9-17/h2-4,6-7,15,18H,1,5,8-13H2
DMLV0PQ CS C=CCC1=CC=CC=C1OCC(CN2CCOCC2)O
DMLV0PQ IK BKDPODVOOWQEGE-UHFFFAOYSA-N
DMLV0PQ IU 1-morpholin-4-yl-3-(2-prop-2-enylphenoxy)propan-2-ol
DMLV0PQ DE Discovery agent
DMAE8BF ID DMAE8BF
DMAE8BF DN 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea
DMAE8BF HS Investigative
DMAE8BF SN CHEMBL397745; 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea
DMAE8BF DT Small molecular drug
DMAE8BF PC 44430622
DMAE8BF MW 252.4
DMAE8BF FM C10H12N4S2
DMAE8BF IC InChI=1S/C10H12N4S2/c1-2-15-9(11)13-6-3-4-8-7(5-6)14-10(12)16-8/h3-5H,2H2,1H3,(H2,11,13)(H2,12,14)
DMAE8BF CS CCSC(=NC1=CC2=C(C=C1)SC(=N2)N)N
DMAE8BF IK NXVMLACGHCLFBM-UHFFFAOYSA-N
DMAE8BF IU ethyl N'-(2-amino-1,3-benzothiazol-5-yl)carbamimidothioate
DMAE8BF DE Discovery agent
DMCSHRL ID DMCSHRL
DMCSHRL DN 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea
DMCSHRL HS Investigative
DMCSHRL SN CHEMBL233022; 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea; SCHEMBL6067873
DMCSHRL DT Small molecular drug
DMCSHRL PC 10467406
DMCSHRL MW 252.4
DMCSHRL FM C10H12N4S2
DMCSHRL IC InChI=1S/C10H12N4S2/c1-2-15-9(11)13-6-3-4-7-8(5-6)16-10(12)14-7/h3-5H,2H2,1H3,(H2,11,13)(H2,12,14)
DMCSHRL CS CCSC(=NC1=CC2=C(C=C1)N=C(S2)N)N
DMCSHRL IK ROUITZBECQQTSH-UHFFFAOYSA-N
DMCSHRL IU ethyl N'-(2-amino-1,3-benzothiazol-6-yl)carbamimidothioate
DMCSHRL DE Discovery agent
DMKWO6A ID DMKWO6A
DMKWO6A DN 1-(2-aminoethyl)-1H-indazol-6-ol
DMKWO6A HS Investigative
DMKWO6A DT Small molecular drug
DMKWO6A PC 135520431
DMKWO6A MW 177.2
DMKWO6A FM C9H11N3O
DMKWO6A IC InChI=1S/C9H11N3O/c10-3-4-12-9-5-8(13)2-1-7(9)6-11-12/h1-2,5-6,13H,3-4,10H2
DMKWO6A CS C1=CC2=C(C=C1O)N(N=C2)CCN
DMKWO6A IK RVQKKYXTHSVLLB-UHFFFAOYSA-N
DMKWO6A IU 1-(2-aminoethyl)indazol-6-ol
DMKWO6A DE Discovery agent
DMYF8ES ID DMYF8ES
DMYF8ES DN 1-(2-bromoethyl)-1H-indole-2,3-dione
DMYF8ES HS Investigative
DMYF8ES SN 1-(2-bromoethyl)-1H-indole-2,3-dione; 4290-78-2; 1-(2-Bromoethyl)indoline-2,3-dione; 1-(2-bromoethyl)-2,3-dihydro-1H-indole-2,3-dione; AC1MSZWL; 1-(2-bromoethyl)isatin; Isatin-based compound, 5; 1H-Indole-2,3-dione, 1-(2-bromoethyl)-; CHEMBL223000; SCHEMBL10685462; TOS-BB-0914; BDBM22785; CTK4I6774; DTXSID90393478; MolPort-000-453-141; SJALPCXFOSGNST-UHFFFAOYSA-N; ZINC2668691; 1-(2-bromoethyl)indole-2,3-dione; STK866424; BBL023389; 1-(2-bromoethyl)-indole-2,3-dione; AKOS000245669; MCULE-3160954506; KB-85508; AJ-44119
DMYF8ES DT Small molecular drug
DMYF8ES PC 3542734
DMYF8ES MW 254.08
DMYF8ES FM C10H8BrNO2
DMYF8ES IC InChI=1S/C10H8BrNO2/c11-5-6-12-8-4-2-1-3-7(8)9(13)10(12)14/h1-4H,5-6H2
DMYF8ES CS C1=CC=C2C(=C1)C(=O)C(=O)N2CCBr
DMYF8ES IK SJALPCXFOSGNST-UHFFFAOYSA-N
DMYF8ES IU 1-(2-bromoethyl)indole-2,3-dione
DMYF8ES CA CAS 4290-78-2
DMYF8ES DE Discovery agent
DMUSEOW ID DMUSEOW
DMUSEOW DN 1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea
DMUSEOW HS Investigative
DMUSEOW SN CHEMBL184637; 1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea
DMUSEOW DT Small molecular drug
DMUSEOW PC 44393620
DMUSEOW MW 323.14
DMUSEOW FM C13H11BrN2O3
DMUSEOW IC InChI=1S/C13H11BrN2O3/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17)7-12(11)18/h1-7,17-18H,(H2,15,16,19)
DMUSEOW CS C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)O)O)Br
DMUSEOW IK UUVQJGFAYHMNII-UHFFFAOYSA-N
DMUSEOW IU 1-(2-bromophenyl)-3-(2,4-dihydroxyphenyl)urea
DMUSEOW DE Discovery agent
DMU9T3A ID DMU9T3A
DMU9T3A DN 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea
DMU9T3A HS Investigative
DMU9T3A SN CHEMBL27863; 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea; SCHEMBL3705632; ZINC13559608; BDBM50140796
DMU9T3A DT Small molecular drug
DMU9T3A PC 9949456
DMU9T3A MW 332.15
DMU9T3A FM C14H10BrN3O2
DMU9T3A IC InChI=1S/C14H10BrN3O2/c15-10-3-1-2-4-11(10)17-14(20)18-12-6-5-9(8-16)7-13(12)19/h1-7,19H,(H2,17,18,20)
DMU9T3A CS C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)C#N)O)Br
DMU9T3A IK VIKJECVSALYBJB-UHFFFAOYSA-N
DMU9T3A IU 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea
DMU9T3A DE Discovery agent
DMT5S2O ID DMT5S2O
DMT5S2O DN 1-(2-Butoxy-phenyl)-piperazine
DMT5S2O HS Investigative
DMT5S2O SN CHEMBL9452; Piperazine, 1-(2-butoxyphenyl)-; 106476-37-3; 1-(2-Butoxy-phenyl)-piperazine; ACMC-20ma64; 1-(2-Butoxyphenyl)piperazine; SCHEMBL9319475; CTK0G3319; DTXSID60560817; ZINC25997855; BDBM50017460
DMT5S2O DT Small molecular drug
DMT5S2O PC 14479837
DMT5S2O MW 234.34
DMT5S2O FM C14H22N2O
DMT5S2O IC InChI=1S/C14H22N2O/c1-2-3-12-17-14-7-5-4-6-13(14)16-10-8-15-9-11-16/h4-7,15H,2-3,8-12H2,1H3
DMT5S2O CS CCCCOC1=CC=CC=C1N2CCNCC2
DMT5S2O IK YNPHKRWUIFAKLL-UHFFFAOYSA-N
DMT5S2O IU 1-(2-butoxyphenyl)piperazine
DMT5S2O CA CAS 106476-37-3
DMT5S2O DE Discovery agent
DMGSKAO ID DMGSKAO
DMGSKAO DN 1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea
DMGSKAO HS Investigative
DMGSKAO SN NSC695051; MLS000665964; 1-(2-chlorophenyl)-3-pyridin-2-ylthiourea; CHEMBL1253185; SMR000294655; 1-(2-chlorophenyl)-3-(2-pyridyl)thiourea; N-(2-chlorophenyl)-N'-2-pyridinylthiourea; 61966-21-0; 1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea; AC1LJD94; cid_972361; CTK2C9582; BDBM47541; DTXSID20359567; MolPort-001-585-178; HMS2680I19; ZINC5933945; STK164730; AKOS002331850; NSC-695051; MCULE-5727736228; NCI60_034026; Thiourea, N-(chlorophenyl)-N'-2-pyridinyl-; ST50765308; 1-(2-chlorophenyl)-3-(2-pyridinyl)thiourea
DMGSKAO DT Small molecular drug
DMGSKAO PC 972361
DMGSKAO MW 263.75
DMGSKAO FM C12H10ClN3S
DMGSKAO IC InChI=1S/C12H10ClN3S/c13-9-5-1-2-6-10(9)15-12(17)16-11-7-3-4-8-14-11/h1-8H,(H2,14,15,16,17)
DMGSKAO CS C1=CC=C(C(=C1)NC(=S)NC2=CC=CC=N2)Cl
DMGSKAO IK ZRDDWFAJQXEXAI-UHFFFAOYSA-N
DMGSKAO IU 1-(2-chlorophenyl)-3-pyridin-2-ylthiourea
DMGSKAO CA CAS 61966-21-0
DMGSKAO DE Discovery agent
DMKTZSY ID DMKTZSY
DMKTZSY DN 1-(2'-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY HS Investigative
DMKTZSY SN CHEMBL224976; BDBM50177103; 1,4-Pentadien-3-one, 1-(2-chlorophenyl)-; 1-(2''-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY DT Small molecular drug
DMKTZSY PC 11665560
DMKTZSY MW 192.64
DMKTZSY FM C11H9ClO
DMKTZSY IC InChI=1S/C11H9ClO/c1-2-10(13)8-7-9-5-3-4-6-11(9)12/h2-8H,1H2/b8-7+
DMKTZSY CS C=CC(=O)/C=C/C1=CC=CC=C1Cl
DMKTZSY IK DIYSCNLXRVKMMK-BQYQJAHWSA-N
DMKTZSY IU (1E)-1-(2-chlorophenyl)penta-1,4-dien-3-one
DMKTZSY DE Discovery agent
DM5RE71 ID DM5RE71
DM5RE71 DN 1-(2-Chloro-phenyl)-piperazine
DM5RE71 HS Investigative
DM5RE71 SN 1-(2-Chlorophenyl)piperazine; 39512-50-0; 1-(2-Chloro-phenyl)-piperazine; Piperazine, 1-(2-chlorophenyl)-; CHEMBL9841; 1-(2-chlorophenyl) piperazine; PWZDJIUQHUGFRJ-UHFFFAOYSA-N; 1-(o-CHLOROPHENYL)PIPERAZINE; (2-chlorophenyl)piperazine; Chlorphenylpiperazin; EINECS 254-480-3; PubChem14571; AC1Q3KEP; ACMC-1AIF1; ortho-chlorophenylpiperazine; AC1L9A0W; DSSTox_RID_97408; DSSTox_CID_31523; N-(o-Chlorophenyl)piperazine; DSSTox_GSID_57734; N-(2-Chlorophenyl)piperazine; KSC224M6P; SCHEMBL230424; N-(o-chlorophenyl)-piperazine
DM5RE71 DT Small molecular drug
DM5RE71 PC 415628
DM5RE71 MW 196.67
DM5RE71 FM C10H13ClN2
DM5RE71 IC InChI=1S/C10H13ClN2/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13/h1-4,12H,5-8H2
DM5RE71 CS C1CN(CCN1)C2=CC=CC=C2Cl
DM5RE71 IK PWZDJIUQHUGFRJ-UHFFFAOYSA-N
DM5RE71 IU 1-(2-chlorophenyl)piperazine
DM5RE71 CA CAS 39512-50-0
DM5RE71 DE Discovery agent
DMM3LET ID DMM3LET
DMM3LET DN 1-(2-Dimethylamino-ethyl)-1H-indol-4-ol
DMM3LET HS Investigative
DMM3LET SN CHEMBL194203; 1-(2-dimethylamino-ethyl)-indol-4-ol; 1-(2-Dimethylamino-ethyl)-1H-indol-4-ol; BDBM50171268
DMM3LET DT Small molecular drug
DMM3LET PC 44404907
DMM3LET MW 204.27
DMM3LET FM C12H16N2O
DMM3LET IC InChI=1S/C12H16N2O/c1-13(2)8-9-14-7-6-10-11(14)4-3-5-12(10)15/h3-7,15H,8-9H2,1-2H3
DMM3LET CS CN(C)CCN1C=CC2=C1C=CC=C2O
DMM3LET IK PKWAUGJGYFZHOE-UHFFFAOYSA-N
DMM3LET IU 1-[2-(dimethylamino)ethyl]indol-4-ol
DMM3LET DE Discovery agent
DMV3FSH ID DMV3FSH
DMV3FSH DN 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH HS Investigative
DMV3FSH SN CHEMBL228687; 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH DT Small molecular drug
DMV3FSH PC 44426817
DMV3FSH MW 325.4
DMV3FSH FM C21H27NO2
DMV3FSH IC InChI=1S/C21H27NO2/c1-2-24-17-20(18-9-5-3-6-10-18)22-15-13-21(23,14-16-22)19-11-7-4-8-12-19/h3-12,20,23H,2,13-17H2,1H3
DMV3FSH CS CCOCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMV3FSH IK ZZEVNYNMIVJANK-UHFFFAOYSA-N
DMV3FSH IU 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol
DMV3FSH DE Discovery agent
DM2P7YX ID DM2P7YX
DM2P7YX DN 1-(2-Ethoxy-phenyl)-piperazine
DM2P7YX HS Investigative
DM2P7YX SN 1-(2-Ethoxyphenyl)piperazine; 13339-01-0; 1-(2-Ethoxy-phenyl)-piperazine; CHEMBL273923; Piperazine,1-(2-ethoxyphenyl)-; FBQIUSDQWOLCNY-UHFFFAOYSA-N; 1-(2-Ethoxyphenyl)piperazinium chloride; ehoxyphenylpiperazine; EINECS 236-389-0; AC1Q57PR; AC1Q37ZC; Oprea1_356570; labotest-bb lt00233165; 4(2-eth-oxyphenyl)piperazine; SCHEMBL255189; 2-ethoxy-1-piperazinylbenzene; 1-(2-ehoxyphenyl)-piperazine; N-(2-ethoxyphenyl)-piperazine; AC1L359U; 1-(2-ethoxyphenyl)-piperazine; N-(2-ethyoxyphenyl)-piperazine; CTK4B8518
DM2P7YX DT Small molecular drug
DM2P7YX PC 83357
DM2P7YX MW 206.28
DM2P7YX FM C12H18N2O
DM2P7YX IC InChI=1S/C12H18N2O/c1-2-15-12-6-4-3-5-11(12)14-9-7-13-8-10-14/h3-6,13H,2,7-10H2,1H3
DM2P7YX CS CCOC1=CC=CC=C1N2CCNCC2
DM2P7YX IK FBQIUSDQWOLCNY-UHFFFAOYSA-N
DM2P7YX IU 1-(2-ethoxyphenyl)piperazine
DM2P7YX CA CAS 13339-01-0
DM2P7YX DE Discovery agent
DM94LID ID DM94LID
DM94LID DN 1-(2-Fluoro-phenyl)-piperazine
DM94LID HS Investigative
DM94LID SN 1-(2-Fluorophenyl)piperazine; 1011-15-0; Piperazine, 1-(2-fluorophenyl)-; 1-(2-Fluorophenyl)-piperazine; 1-(2-Fluoro-phenyl)-piperazine; CHEMBL9429; IVTZRJKKXSKXKO-UHFFFAOYSA-N; 1-(2-Fluorophenyl)piperazine, 97%; MFCD00040726; (2-fluorophenyl)piperazine; EINECS 213-780-4; oFPP; PubChem8573; 1-(2-fluorophenyl)piperazinehydrochloride; 2-fluorophenylpiperazine; 2-Fluorophenyl piperazine; ACMC-1BX8H; ortho-fluorophenylpiperazine; 4-(fluorophenyl)piperazine; AC1Q4O5O; AC1Q4L3C; AC1L2EA5; 1-(2-flurophenyl)piperazine
DM94LID DT Small molecular drug
DM94LID PC 70529
DM94LID MW 180.22
DM94LID FM C10H13FN2
DM94LID IC InChI=1S/C10H13FN2/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13/h1-4,12H,5-8H2
DM94LID CS C1CN(CCN1)C2=CC=CC=C2F
DM94LID IK IVTZRJKKXSKXKO-UHFFFAOYSA-N
DM94LID IU 1-(2-fluorophenyl)piperazine
DM94LID CA CAS 1011-15-0
DM94LID DE Discovery agent
DM0K2T1 ID DM0K2T1
DM0K2T1 DN 1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea
DM0K2T1 HS Investigative
DM0K2T1 SN 172505-85-0; Thiourea, N-(2-(2-furanyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-furanyl)ethyl]-N'-2-thiazolyl-; PETT Analog 29; PETT Furyl deriv.; AC1MHDKI; CHEMBL359410; BDBM1922; 1-[2-(furan-2-yl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; DTXSID70169335; N-(2-(2-furyl)ethyl)-N-(2-thiazolyl)thiou; 1-[2-(2-furyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-(furan-2-yl)ethyl]thiourea
DM0K2T1 DT Small molecular drug
DM0K2T1 PC 3001099
DM0K2T1 MW 253.3
DM0K2T1 FM C10H11N3OS2
DM0K2T1 IC InChI=1S/C10H11N3OS2/c15-9(13-10-12-5-7-16-10)11-4-3-8-2-1-6-14-8/h1-2,5-7H,3-4H2,(H2,11,12,13,15)
DM0K2T1 CS C1=COC(=C1)CCNC(=S)NC2=NC=CS2
DM0K2T1 IK HSLMRTQANDUJDA-UHFFFAOYSA-N
DM0K2T1 IU 1-[2-(furan-2-yl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DM0K2T1 CA CAS 172505-85-0
DM0K2T1 DE Discovery agent
DM3WXET ID DM3WXET
DM3WXET DN 1-(2-Hydroxy-3-nitro-phenyl)-3-phenyl-urea
DM3WXET HS Investigative
DM3WXET SN CHEMBL283736; 1-(2-hydroxy-3-nitro-phenyl)-3-phenyl-urea; SCHEMBL7491596; BDBM50140793
DM3WXET DT Small molecular drug
DM3WXET PC 11414633
DM3WXET MW 273.24
DM3WXET FM C13H11N3O4
DM3WXET IC InChI=1S/C13H11N3O4/c17-12-10(7-4-8-11(12)16(19)20)15-13(18)14-9-5-2-1-3-6-9/h1-8,17H,(H2,14,15,18)
DM3WXET CS C1=CC=C(C=C1)NC(=O)NC2=C(C(=CC=C2)[N+](=O)[O-])O
DM3WXET IK DZLCFOMBBDNYIQ-UHFFFAOYSA-N
DM3WXET IU 1-(2-hydroxy-3-nitrophenyl)-3-phenylurea
DM3WXET DE Discovery agent
DMN4G7U ID DMN4G7U
DMN4G7U DN 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea
DMN4G7U HS Investigative
DMN4G7U SN 1-(2-Hydroxy-4-nitrophenyl)-3-phenylurea; 80883-76-7; CHEMBL280711; NSC157449; AC1MUHEY; 1-(2-Hydroxy-4-nitro-phenyl)-3-phenyl-urea; SKampF 83589; GTPL834; SCHEMBL5595180; CTK9A5291; DTXSID00394355; ZINC3936851; BDBM50140794; AKOS024384917; NSC-157449; MCULE-1458670709; NSC 157449; N-(2-hydroxy-4-nitrophenyl)-N'-phenylurea; ST51035446; [(2-hydroxy-4-nitrophenyl)amino]-N-benzamide; N-(2-hydroxy-4-nitrophenyl)-N'-(phenyl); 1-(2-Hydroxy-4-nitro-phenyl)-3-phenyl-urea; SK&F 83589
DMN4G7U DT Small molecular drug
DMN4G7U PC 3618472
DMN4G7U MW 273.24
DMN4G7U FM C13H11N3O4
DMN4G7U IC InChI=1S/C13H11N3O4/c17-12-8-10(16(19)20)6-7-11(12)15-13(18)14-9-4-2-1-3-5-9/h1-8,17H,(H2,14,15,18)
DMN4G7U CS C1=CC=C(C=C1)NC(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])O
DMN4G7U IK SAUHQYBXEGARCC-UHFFFAOYSA-N
DMN4G7U IU 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea
DMN4G7U CA CAS 80883-76-7
DMN4G7U DE Discovery agent
DMPLHEY ID DMPLHEY
DMPLHEY DN 1-(2-Hydroxy-5-nitro-phenyl)-3-phenyl-urea
DMPLHEY HS Investigative
DMPLHEY SN CHEMBL24912; 1-(2-hydroxy-5-nitro-phenyl)-3-phenyl-urea; SCHEMBL5595042; MHNNUSRLYWTBJF-UHFFFAOYSA-N; ZINC13559606; BDBM50140790; AKOS016618380; N-[5-nitro-2-hydroxyphenyl]-N'-phenylurea; N-[5-nitro-2-hydroxyphenyl]-N'-phenyl urea
DMPLHEY DT Small molecular drug
DMPLHEY PC 11818139
DMPLHEY MW 273.24
DMPLHEY FM C13H11N3O4
DMPLHEY IC InChI=1S/C13H11N3O4/c17-12-7-6-10(16(19)20)8-11(12)15-13(18)14-9-4-2-1-3-5-9/h1-8,17H,(H2,14,15,18)
DMPLHEY CS C1=CC=C(C=C1)NC(=O)NC2=C(C=CC(=C2)[N+](=O)[O-])O
DMPLHEY IK MHNNUSRLYWTBJF-UHFFFAOYSA-N
DMPLHEY IU 1-(2-hydroxy-5-nitrophenyl)-3-phenylurea
DMPLHEY DE Discovery agent
DMAFS7J ID DMAFS7J
DMAFS7J DN 1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one
DMAFS7J HS Investigative
DMAFS7J SN 2'-Hydroxy-4-methylchalcone; 1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one; AC1NTAGW; 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-(4-methylphenyl)-; 4-Methyl-2'-hydroxychalcone; MLS000777737; CHEMBL476598; SCHEMBL2807968; MolPort-000-648-204; OOEWKJHFFYCQBM-ZHACJKMWSA-N; Chalcone, 2'-hydroxy-4-methyl-; HMS2760H03; ZX-AT026696; ZINC4252606; 2'-Hydroxy-4-methyl-trans-chalcone; STK530118; AKOS005463239; SMR000414122; ST098968; 2'-Hydroxy-4-methylchalcone, AldrichCPR
DMAFS7J DT Small molecular drug
DMAFS7J PC 5376916
DMAFS7J MW 238.28
DMAFS7J FM C16H14O2
DMAFS7J IC InChI=1S/C16H14O2/c1-12-6-8-13(9-7-12)10-11-16(18)14-4-2-3-5-15(14)17/h2-11,17H,1H3/b11-10+
DMAFS7J CS CC1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O
DMAFS7J IK OOEWKJHFFYCQBM-ZHACJKMWSA-N
DMAFS7J IU (E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one
DMAFS7J CA CAS 16635-14-6
DMAFS7J DE Discovery agent
DM1MSAC ID DM1MSAC
DM1MSAC DN 1-(2-iodoethyl)-1H-indole-2,3-dione
DM1MSAC HS Investigative
DM1MSAC SN 1-(2-iodoethyl)indole-2,3-dione; AC1N4VNK; Isatin-based compound, 6; CHEMBL376518; BDBM22786; ZINC5738958; AKOS024343322; MCULE-9804545910; 1-(2-IODO-ETHYL)-1H-INDOLE-2,3-DIONE
DM1MSAC DT Small molecular drug
DM1MSAC PC 4135273
DM1MSAC MW 301.08
DM1MSAC FM C10H8INO2
DM1MSAC IC InChI=1S/C10H8INO2/c11-5-6-12-8-4-2-1-3-7(8)9(13)10(12)14/h1-4H,5-6H2
DM1MSAC CS C1=CC=C2C(=C1)C(=O)C(=O)N2CCI
DM1MSAC IK OBYVXAUONRVYHA-UHFFFAOYSA-N
DM1MSAC IU 1-(2-iodoethyl)indole-2,3-dione
DM1MSAC DE Discovery agent
DM5KAH6 ID DM5KAH6
DM5KAH6 DN 1-(2-Isopropoxy-phenyl)-piperazine
DM5KAH6 HS Investigative
DM5KAH6 SN 1-(2-isopropoxyphenyl)piperazine; 1-(2-Isopropoxy-phenyl)-piperazine; CHEMBL9669; 54013-91-1; 2-isopropoxyphenyl piperazine; SCHEMBL3867980; CTK1F9762; DTXSID40449277; QJULELIONYLITF-UHFFFAOYSA-N; ZINC26001539; BDBM50017448; 1-[2-(methylethoxy)phenyl]piperazine; AKOS010941535; N-[2-(1-methylethoxy)phenyl]piperazine; 1-[2-(1-methylethoxy)phenyl]piperazine; DA-05081; BC4321135; Piperazine, 1-[2-(1-methylethoxy)phenyl]-; FT-0741526
DM5KAH6 DT Small molecular drug
DM5KAH6 PC 10944016
DM5KAH6 MW 220.31
DM5KAH6 FM C13H20N2O
DM5KAH6 IC InChI=1S/C13H20N2O/c1-11(2)16-13-6-4-3-5-12(13)15-9-7-14-8-10-15/h3-6,11,14H,7-10H2,1-2H3
DM5KAH6 CS CC(C)OC1=CC=CC=C1N2CCNCC2
DM5KAH6 IK QJULELIONYLITF-UHFFFAOYSA-N
DM5KAH6 IU 1-(2-propan-2-yloxyphenyl)piperazine
DM5KAH6 CA CAS 54013-91-1
DM5KAH6 DE Discovery agent
DMK209P ID DMK209P
DMK209P DN 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol
DMK209P HS Investigative
DMK209P SN CHEMBL1083668; 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol; Oprea1_740178; AC1N31P0; 1-morpholin-4-yl-3-(2-propan-2-ylphenoxy)propan-2-ol; BDBM50318979
DMK209P DT Small molecular drug
DMK209P PC 4080436
DMK209P MW 279.37
DMK209P FM C16H25NO3
DMK209P IC InChI=1S/C16H25NO3/c1-13(2)15-5-3-4-6-16(15)20-12-14(18)11-17-7-9-19-10-8-17/h3-6,13-14,18H,7-12H2,1-2H3
DMK209P CS CC(C)C1=CC=CC=C1OCC(CN2CCOCC2)O
DMK209P IK OFEYQVJHAZFCJS-UHFFFAOYSA-N
DMK209P IU 1-morpholin-4-yl-3-(2-propan-2-ylphenoxy)propan-2-ol
DMK209P DE Discovery agent
DMIPAMW ID DMIPAMW
DMIPAMW DN 1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea
DMIPAMW HS Investigative
DMIPAMW SN CHEMBL459135; 1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea
DMIPAMW DT Small molecular drug
DMIPAMW PC 44587908
DMIPAMW MW 274.4
DMIPAMW FM C10H14N2O3S2
DMIPAMW IC InChI=1S/C10H14N2O3S2/c1-8-3-2-4-9(7-8)17(14,15)12-10(13)11-5-6-16/h2-4,7,16H,5-6H2,1H3,(H2,11,12,13)
DMIPAMW CS CC1=CC(=CC=C1)S(=O)(=O)NC(=O)NCCS
DMIPAMW IK CALOUQXNCIXXTN-UHFFFAOYSA-N
DMIPAMW IU 1-(3-methylphenyl)sulfonyl-3-(2-sulfanylethyl)urea
DMIPAMW DE Discovery agent
DMDQVSU ID DMDQVSU
DMDQVSU DN 1-(2-methoxyphenethyl)pyrrolidine
DMDQVSU HS Investigative
DMDQVSU SN CHEMBL257913; 2-(2-methoxyphenyl)-1-(pyrrolidin-1-yl)ethane; 123902-10-3; 1-(2-methoxyphenethyl)pyrrolidine; ZINC29130875; BDBM50372328
DMDQVSU DT Small molecular drug
DMDQVSU PC 23061353
DMDQVSU MW 205.3
DMDQVSU FM C13H19NO
DMDQVSU IC InChI=1S/C13H19NO/c1-15-13-7-3-2-6-12(13)8-11-14-9-4-5-10-14/h2-3,6-7H,4-5,8-11H2,1H3
DMDQVSU CS COC1=CC=CC=C1CCN2CCCC2
DMDQVSU IK YLUDJHIUYWQPKA-UHFFFAOYSA-N
DMDQVSU IU 1-[2-(2-methoxyphenyl)ethyl]pyrrolidine
DMDQVSU DE Discovery agent
DM0EZSR ID DM0EZSR
DM0EZSR DN 1-(2-methoxyphenyl)-4-pentylpiperazine
DM0EZSR HS Investigative
DM0EZSR SN CHEMBL1269289; 1-(2-methoxyphenyl)-4-pentylpiperazine; SCHEMBL13875119; BDBM50329677
DM0EZSR DT Small molecular drug
DM0EZSR PC 10422832
DM0EZSR MW 262.39
DM0EZSR FM C16H26N2O
DM0EZSR IC InChI=1S/C16H26N2O/c1-3-4-7-10-17-11-13-18(14-12-17)15-8-5-6-9-16(15)19-2/h5-6,8-9H,3-4,7,10-14H2,1-2H3
DM0EZSR CS CCCCCN1CCN(CC1)C2=CC=CC=C2OC
DM0EZSR IK KOQVTIBXMDYTOB-UHFFFAOYSA-N
DM0EZSR IU 1-(2-methoxyphenyl)-4-pentylpiperazine
DM0EZSR DE Discovery agent
DMCADRI ID DMCADRI
DMCADRI DN 1-(2-Methoxy-phenyl)-4-propyl-piperazine
DMCADRI HS Investigative
DMCADRI SN 1-(2-methoxyphenyl)-4-propylpiperazine; CHEMBL92887; 1-(2-Methoxy-phenyl)-4-propyl-piperazine; AC1L8ZT0; Oprea1_562540; SCHEMBL3261221; MolPort-009-059-633; ZINC1663859; BDBM50039783; AKOS034319760; MCULE-3739556252; Z432755564
DMCADRI DT Small molecular drug
DMCADRI PC 410747
DMCADRI MW 234.34
DMCADRI FM C14H22N2O
DMCADRI IC InChI=1S/C14H22N2O/c1-3-8-15-9-11-16(12-10-15)13-6-4-5-7-14(13)17-2/h4-7H,3,8-12H2,1-2H3
DMCADRI CS CCCN1CCN(CC1)C2=CC=CC=C2OC
DMCADRI IK CXGGCNYHKKNQGW-UHFFFAOYSA-N
DMCADRI IU 1-(2-methoxyphenyl)-4-propylpiperazine
DMCADRI DE Discovery agent
DM3M4RA ID DM3M4RA
DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine
DM3M4RA HS Investigative
DM3M4RA SN 1-(2-Methoxyphenyl)piperazine; 35386-24-4; 1-(o-Methoxyphenyl)piperazine; 1-(2-Methoxyphenyl)-piperazine; 2-MPP; UNII-81NJO1330A; N-(2-methoxyphenyl)piperazine; 1-(2-methoxy phenyl) piperazine; Piperazine, 1-(2-methoxyphenyl)-; 2-methoxyphenylpiperazine; 1-(2-METHOXYPHENYL) PIPERAZINE; CHEMBL9666; VNZLQLYBRIOLFZ-UHFFFAOYSA-N; 81NJO1330A; MFCD00005958; 1-(2-methoxyphenyl)piperazinehydrochloride; 2-methoxy-1-piperazinylbenzene; 1-(2-Methoxyphenyl)piperazine, 98+%; 1-(2-methoxyphenyl)piperazin
DM3M4RA DT Small molecular drug
DM3M4RA PC 1346
DM3M4RA MW 192.26
DM3M4RA FM C11H16N2O
DM3M4RA IC InChI=1S/C11H16N2O/c1-14-11-5-3-2-4-10(11)13-8-6-12-7-9-13/h2-5,12H,6-9H2,1H3
DM3M4RA CS COC1=CC=CC=C1N2CCNCC2
DM3M4RA IK VNZLQLYBRIOLFZ-UHFFFAOYSA-N
DM3M4RA IU 1-(2-methoxyphenyl)piperazine
DM3M4RA CA CAS 35386-24-4
DM3M4RA CB CHEBI:104020
DM3M4RA DE Discovery agent
DMBWCOZ ID DMBWCOZ
DMBWCOZ DN 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBWCOZ HS Investigative
DMBWCOZ SN CHEMBL203403; 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4935428
DMBWCOZ DT Small molecular drug
DMBWCOZ PC 11311147
DMBWCOZ MW 245.36
DMBWCOZ FM C16H23NO
DMBWCOZ IC InChI=1S/C16H23NO/c1-3-8-15(17-11-6-7-12-17)16(18)14-10-5-4-9-13(14)2/h4-5,9-10,15H,3,6-8,11-12H2,1-2H3
DMBWCOZ CS CCCC(C(=O)C1=CC=CC=C1C)N2CCCC2
DMBWCOZ IK VVIVTDYOMWHKAE-UHFFFAOYSA-N
DMBWCOZ IU 1-(2-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one
DMBWCOZ DE Discovery agent
DMZF0D3 ID DMZF0D3
DMZF0D3 DN 1-(2-morpholinoethyl)-1H-indol-3-yl acetate
DMZF0D3 HS Investigative
DMZF0D3 SN CHEMBL495249
DMZF0D3 DT Small molecular drug
DMZF0D3 PC 24851127
DMZF0D3 MW 288.34
DMZF0D3 FM C16H20N2O3
DMZF0D3 IC InChI=1S/C16H20N2O3/c1-13(19)21-16-12-18(15-5-3-2-4-14(15)16)7-6-17-8-10-20-11-9-17/h2-5,12H,6-11H2,1H3
DMZF0D3 CS CC(=O)OC1=CN(C2=CC=CC=C21)CCN3CCOCC3
DMZF0D3 IK WNJZFVIJUKGTLU-UHFFFAOYSA-N
DMZF0D3 IU [1-(2-morpholin-4-ylethyl)indol-3-yl] acetate
DMZF0D3 DE Discovery agent
DMKITY6 ID DMKITY6
DMKITY6 DN 1-(2-m-tolyl-ethyl)-pyrrolidine
DMKITY6 HS Investigative
DMKITY6 SN CHEMBL257919; SCHEMBL14426311
DMKITY6 DT Small molecular drug
DMKITY6 PC 44456174
DMKITY6 MW 189.3
DMKITY6 FM C13H19N
DMKITY6 IC InChI=1S/C13H19N/c1-12-5-4-6-13(11-12)7-10-14-8-2-3-9-14/h4-6,11H,2-3,7-10H2,1H3
DMKITY6 CS CC1=CC(=CC=C1)CCN2CCCC2
DMKITY6 IK AXQOVIUHTPHFNE-UHFFFAOYSA-N
DMKITY6 IU 1-[2-(3-methylphenyl)ethyl]pyrrolidine
DMKITY6 DE Discovery agent
DMBNZKH ID DMBNZKH
DMBNZKH DN 1-(2-Naphthyl)-2-aminopropane
DMBNZKH HS Investigative
DMBNZKH SN 1-(naphthalen-2-yl)propan-2-amine; CHEMBL471839; 1-(2-Naphthyl)-2-aminopropane; AC1Q2BAX; SCHEMBL268036; 1-(2-naphthyl)propan-2-amine; 1-(2-Naphthyl)-2-propanamine; CTK6A7105; MolPort-004-323-272; BDBM50276189; AKOS022488613; AKOS000160972; MCULE-4757807613; NE51647; EN300-62738
DMBNZKH DT Small molecular drug
DMBNZKH PC 10219723
DMBNZKH MW 185.26
DMBNZKH FM C13H15N
DMBNZKH IC InChI=1S/C13H15N/c1-10(14)8-11-6-7-12-4-2-3-5-13(12)9-11/h2-7,9-10H,8,14H2,1H3
DMBNZKH CS CC(CC1=CC2=CC=CC=C2C=C1)N
DMBNZKH IK UPQSZFKXKRKCGZ-UHFFFAOYSA-N
DMBNZKH IU 1-naphthalen-2-ylpropan-2-amine
DMBNZKH CA CAS 18085-03-5
DMBNZKH DE Discovery agent
DMR12KP ID DMR12KP
DMR12KP DN 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine
DMR12KP HS Investigative
DMR12KP SN CHEMBL540744; 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine
DMR12KP DT Small molecular drug
DMR12KP PC 45272467
DMR12KP MW 267.28
DMR12KP FM C15H13N3O2
DMR12KP IC InChI=1S/C15H13N3O2/c19-18(20)14-5-2-1-4-12(14)7-10-17-11-8-13-15(17)6-3-9-16-13/h1-6,8-9,11H,7,10H2
DMR12KP CS C1=CC=C(C(=C1)CCN2C=CC3=C2C=CC=N3)[N+](=O)[O-]
DMR12KP IK CEHGVNIFTRLUOI-UHFFFAOYSA-N
DMR12KP IU 1-[2-(2-nitrophenyl)ethyl]pyrrolo[3,2-b]pyridine
DMR12KP DE Discovery agent
DM69T3A ID DM69T3A
DM69T3A DN 1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione
DM69T3A HS Investigative
DM69T3A SN CHEMBL84747; AKOS009237487
DM69T3A DT Small molecular drug
DM69T3A PC 28476323
DM69T3A MW 279.29
DM69T3A FM C17H13NO3
DM69T3A IC InChI=1S/C17H13NO3/c1-11-6-8-12(9-7-11)15(19)10-18-14-5-3-2-4-13(14)16(20)17(18)21/h2-9H,10H2,1H3
DM69T3A CS CC1=CC=C(C=C1)C(=O)CN2C3=CC=CC=C3C(=O)C2=O
DM69T3A IK PJQULSIUMHBSSF-UHFFFAOYSA-N
DM69T3A IU 1-[2-(4-methylphenyl)-2-oxoethyl]indole-2,3-dione
DM69T3A DE Discovery agent
DMLY4ER ID DMLY4ER
DMLY4ER DN 1-(2-phenoxybenzyl)-1H-imidazole
DMLY4ER HS Investigative
DMLY4ER SN CHEMBL1082760; 1-(2-phenoxybenzyl)-1H-imidazole; SCHEMBL11704850
DMLY4ER DT Small molecular drug
DMLY4ER PC 46889432
DMLY4ER MW 250.29
DMLY4ER FM C16H14N2O
DMLY4ER IC InChI=1S/C16H14N2O/c1-2-7-15(8-3-1)19-16-9-5-4-6-14(16)12-18-11-10-17-13-18/h1-11,13H,12H2
DMLY4ER CS C1=CC=C(C=C1)OC2=CC=CC=C2CN3C=CN=C3
DMLY4ER IK DFVDKHRBBOONAK-UHFFFAOYSA-N
DMLY4ER IU 1-[(2-phenoxyphenyl)methyl]imidazole
DMLY4ER DE Discovery agent
DMOMAXJ ID DMOMAXJ
DMOMAXJ DN 1-(2-Phenoxy-ethyl)-1H-imidazole
DMOMAXJ HS Investigative
DMOMAXJ SN CHEMBL284827; 1-(2-Phenoxy-ethyl)-1H-imidazole; 1H-Imidazole, 1-(2-phenoxyethyl)-; 1-(2-Phenoxyethyl)imidazole; SCHEMBL10370478; INUSBZKZIYQSRM-UHFFFAOYSA-N; ZINC26473891; BDBM50025988; AKOS002677376
DMOMAXJ DT Small molecular drug
DMOMAXJ PC 13569172
DMOMAXJ MW 188.23
DMOMAXJ FM C11H12N2O
DMOMAXJ IC InChI=1S/C11H12N2O/c1-2-4-11(5-3-1)14-9-8-13-7-6-12-10-13/h1-7,10H,8-9H2
DMOMAXJ CS C1=CC=C(C=C1)OCCN2C=CN=C2
DMOMAXJ IK INUSBZKZIYQSRM-UHFFFAOYSA-N
DMOMAXJ IU 1-(2-phenoxyethyl)imidazole
DMOMAXJ DE Discovery agent
DMC1IKP ID DMC1IKP
DMC1IKP DN 1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea
DMC1IKP HS Investigative
DMC1IKP SN CHEMBL345996; AC1MHEHQ; 1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea; BDBM50097040; 1-(2-phenoxyethyl)-3-thiazol-2-yl-thiourea; 1-(2-Phenoxyethyl)-3-(2-thiazolyl)thiourea; 1-(2-phenoxyethyl)-3-(1,3-thiazol-2-yl)thiourea
DMC1IKP DT Small molecular drug
DMC1IKP PC 3003029
DMC1IKP MW 279.4
DMC1IKP FM C12H13N3OS2
DMC1IKP IC InChI=1S/C12H13N3OS2/c17-11(15-12-14-7-9-18-12)13-6-8-16-10-4-2-1-3-5-10/h1-5,7,9H,6,8H2,(H2,13,14,15,17)
DMC1IKP CS C1=CC=C(C=C1)OCCNC(=S)NC2=NC=CS2
DMC1IKP IK MJPUUVIJLSCJEY-UHFFFAOYSA-N
DMC1IKP IU 1-(2-phenoxyethyl)-3-(1,3-thiazol-2-yl)thiourea
DMC1IKP DE Discovery agent
DMWFCYN ID DMWFCYN
DMWFCYN DN 1-(2-phenoxyphenyl)piperazine
DMWFCYN HS Investigative
DMWFCYN SN 1-(2-phenoxyphenyl)piperazine; CHEMBL573532; SCHEMBL546735; VAXHGPCUAFNAQS-UHFFFAOYSA-N; 1-(2-Phenoxy-phenyl)-piperazine; ZINC37635596; BDBM50299785
DMWFCYN DT Small molecular drug
DMWFCYN PC 12996705
DMWFCYN MW 254.33
DMWFCYN FM C16H18N2O
DMWFCYN IC InChI=1S/C16H18N2O/c1-2-6-14(7-3-1)19-16-9-5-4-8-15(16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DMWFCYN CS C1CN(CCN1)C2=CC=CC=C2OC3=CC=CC=C3
DMWFCYN IK VAXHGPCUAFNAQS-UHFFFAOYSA-N
DMWFCYN IU 1-(2-phenoxyphenyl)piperazine
DMWFCYN DE Discovery agent
DMXG10E ID DMXG10E
DMXG10E DN 1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DMXG10E HS Investigative
DMXG10E SN Thiourea, N-(2-phenylpropyl)-N'-2-thiazolyl-; 149486-09-9; PETT Analog 33; AC1MHDKK; BDBM1867; CHEMBL144136; 1-(2-phenylpropyl)-3-thiazol-2-yl-thiourea; 1-(beta-Methylphenethyl)-3-(2-thiazolyl)thiourea; 1-(2-phenylpropyl)-3-1,3-thiazol-2-ylthiourea; 1-(2-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea; N-(1-(2-Phenylpropyl))-N -(2-thiazolyl)thiourea
DMXG10E DT Small molecular drug
DMXG10E PC 3001101
DMXG10E MW 277.4
DMXG10E FM C13H15N3S2
DMXG10E IC InChI=1S/C13H15N3S2/c1-10(11-5-3-2-4-6-11)9-15-12(17)16-13-14-7-8-18-13/h2-8,10H,9H2,1H3,(H2,14,15,16,17)
DMXG10E CS CC(CNC(=S)NC1=NC=CS1)C2=CC=CC=C2
DMXG10E IK NQIQJPRBRMXGMW-UHFFFAOYSA-N
DMXG10E IU 1-(2-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
DMXG10E CA CAS 149486-09-9
DMXG10E DE Discovery agent
DMDLKPI ID DMDLKPI
DMDLKPI DN 1-(2-p-tolyl-ethyl)-pyrrolidine
DMDLKPI HS Investigative
DMDLKPI SN CHEMBL257912; SCHEMBL13164030
DMDLKPI DT Small molecular drug
DMDLKPI PC 44456128
DMDLKPI MW 189.3
DMDLKPI FM C13H19N
DMDLKPI IC InChI=1S/C13H19N/c1-12-4-6-13(7-5-12)8-11-14-9-2-3-10-14/h4-7H,2-3,8-11H2,1H3
DMDLKPI CS CC1=CC=C(C=C1)CCN2CCCC2
DMDLKPI IK RLADTPQRCGVXDS-UHFFFAOYSA-N
DMDLKPI IU 1-[2-(4-methylphenyl)ethyl]pyrrolidine
DMDLKPI DE Discovery agent
DM4B2EN ID DM4B2EN
DM4B2EN DN 1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea
DM4B2EN HS Investigative
DM4B2EN SN 149486-07-7; Thiourea, N-(2-(2-pyridinyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-pyridinyl)ethyl]-N'-2-thiazolyl-; PETT Analog 25; AC1MHDKE; CHEMBL145709; SCHEMBL6956252; BDBM1918; DTXSID70164300; 1-(2-pyridin-2-ylethyl)-3-(1,3-thiazol-2-yl)thiourea; 1-[2-(2-pyridyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-(2-pyridyl)ethyl]thiourea; N-(2-(2-Pyridylethyl))-N -(2-thiazolyl)thiourea
DM4B2EN DT Small molecular drug
DM4B2EN PC 3001095
DM4B2EN MW 264.4
DM4B2EN FM C11H12N4S2
DM4B2EN IC InChI=1S/C11H12N4S2/c16-10(15-11-14-7-8-17-11)13-6-4-9-3-1-2-5-12-9/h1-3,5,7-8H,4,6H2,(H2,13,14,15,16)
DM4B2EN CS C1=CC=NC(=C1)CCNC(=S)NC2=NC=CS2
DM4B2EN IK XNZLMIJCCHZKKA-UHFFFAOYSA-N
DM4B2EN IU 1-(2-pyridin-2-ylethyl)-3-(1,3-thiazol-2-yl)thiourea
DM4B2EN CA CAS 149486-07-7
DM4B2EN DE Discovery agent
DMEDSLZ ID DMEDSLZ
DMEDSLZ DN 1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane
DMEDSLZ HS Investigative
DMEDSLZ SN CHEMBL476465; 1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane
DMEDSLZ DT Small molecular drug
DMEDSLZ PC 44582620
DMEDSLZ MW 307.4
DMEDSLZ FM C18H29NO3
DMEDSLZ IC InChI=1S/C18H29NO3/c1-20-17-8-6-9-18(16-17)22-15-14-21-13-7-12-19-10-4-2-3-5-11-19/h6,8-9,16H,2-5,7,10-15H2,1H3
DMEDSLZ CS COC1=CC(=CC=C1)OCCOCCCN2CCCCCC2
DMEDSLZ IK CRNTZNDTRWBBPM-UHFFFAOYSA-N
DMEDSLZ IU 1-[3-[2-(3-methoxyphenoxy)ethoxy]propyl]azepane
DMEDSLZ DE Discovery agent
DMD25N9 ID DMD25N9
DMD25N9 DN 1-(3-(2-methylquinolin-7-yl)phenyl)ethanone
DMD25N9 HS Investigative
DMD25N9 SN CHEMBL233370; 1-(3-(2-methylquinolin-7-yl)phenyl)ethanone
DMD25N9 DT Small molecular drug
DMD25N9 PC 44432663
DMD25N9 MW 261.3
DMD25N9 FM C18H15NO
DMD25N9 IC InChI=1S/C18H15NO/c1-12-6-7-14-8-9-17(11-18(14)19-12)16-5-3-4-15(10-16)13(2)20/h3-11H,1-2H3
DMD25N9 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)C(=O)C
DMD25N9 IK RDDPBRGDKLSJLB-UHFFFAOYSA-N
DMD25N9 IU 1-[3-(2-methylquinolin-7-yl)phenyl]ethanone
DMD25N9 DE Discovery agent
DM3EBFS ID DM3EBFS
DM3EBFS DN 1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea
DM3EBFS HS Investigative
DM3EBFS SN CHEMBL540430; 1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea; SCHEMBL4263031; ANYYSWDTIHWUQV-UHFFFAOYSA-N
DM3EBFS DT Small molecular drug
DM3EBFS PC 25015710
DM3EBFS MW 355.4
DM3EBFS FM C20H25N3O3
DM3EBFS IC InChI=1S/C20H25N3O3/c24-20(21-17-6-2-1-3-7-17)22-18-8-4-9-19(16-18)26-13-5-10-23-11-14-25-15-12-23/h1-4,6-9,16H,5,10-15H2,(H2,21,22,24)
DM3EBFS CS C1COCCN1CCCOC2=CC=CC(=C2)NC(=O)NC3=CC=CC=C3
DM3EBFS IK ANYYSWDTIHWUQV-UHFFFAOYSA-N
DM3EBFS IU 1-[3-(3-morpholin-4-ylpropoxy)phenyl]-3-phenylurea
DM3EBFS DE Discovery agent
DM3EYOL ID DM3EYOL
DM3EYOL DN 1-(3-(3-phenylpropoxy)propyl)piperidine
DM3EYOL HS Investigative
DM3EYOL SN CHEMBL462606; 1-(3-(3-phenylpropoxy)propyl)piperidine; 1-[3-(3-phenylpropoxy)propyl]piperidine; SCHEMBL491655; UYLNHGRGPLPMFD-UHFFFAOYSA-N; BDBM50247055; 3-Phenylpropyl 3-piperidinopropyl ether
DM3EYOL DT Small molecular drug
DM3EYOL PC 9903343
DM3EYOL MW 261.399
DM3EYOL FM C17H27NO
DM3EYOL IC InChI=1S/C17H27NO/c1-3-9-17(10-4-1)11-7-15-19-16-8-14-18-12-5-2-6-13-18/h1,3-4,9-10H,2,5-8,11-16H2
DM3EYOL CS C1CCN(CC1)CCCOCCCC2=CC=CC=C2
DM3EYOL IK UYLNHGRGPLPMFD-UHFFFAOYSA-N
DM3EYOL IU 1-[3-(3-phenylpropoxy)propyl]piperidine
DM3EYOL DE Discovery agent
DMHEIKQ ID DMHEIKQ
DMHEIKQ DN 1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine
DMHEIKQ HS Investigative
DMHEIKQ SN CHEMBL449484; 1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine
DMHEIKQ DT Small molecular drug
DMHEIKQ PC 44592097
DMHEIKQ MW 265.37
DMHEIKQ FM C16H24FNO
DMHEIKQ IC InChI=1S/C16H24FNO/c17-10-9-15-5-7-16(8-6-15)19-14-4-13-18-11-2-1-3-12-18/h5-8H,1-4,9-14H2
DMHEIKQ CS C1CCN(CC1)CCCOC2=CC=C(C=C2)CCF
DMHEIKQ IK CKQQSVANJMAKBB-UHFFFAOYSA-N
DMHEIKQ IU 1-[3-[4-(2-fluoroethyl)phenoxy]propyl]piperidine
DMHEIKQ DE Discovery agent
DMVXCPE ID DMVXCPE
DMVXCPE DN 1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine
DMVXCPE HS Investigative
DMVXCPE SN CHEMBL469388; 1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine
DMVXCPE DT Small molecular drug
DMVXCPE PC 44592096
DMVXCPE MW 251.34
DMVXCPE FM C15H22FNO
DMVXCPE IC InChI=1S/C15H22FNO/c16-13-14-5-7-15(8-6-14)18-12-4-11-17-9-2-1-3-10-17/h5-8H,1-4,9-13H2
DMVXCPE CS C1CCN(CC1)CCCOC2=CC=C(C=C2)CF
DMVXCPE IK JRFMDYWVKRGBGL-UHFFFAOYSA-N
DMVXCPE IU 1-[3-[4-(fluoromethyl)phenoxy]propyl]piperidine
DMVXCPE DE Discovery agent
DMM36DE ID DMM36DE
DMM36DE DN 1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine
DMM36DE HS Investigative
DMM36DE SN CHEMBL381487; 1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine
DMM36DE DT Small molecular drug
DMM36DE PC 44409445
DMM36DE MW 284.74
DMM36DE FM C15H13ClN4
DMM36DE IC InChI=1S/C15H13ClN4/c16-11-7-5-10(6-8-11)9-14-15(20-17)19-13-4-2-1-3-12(13)18-14/h1-8H,9,17H2,(H,19,20)
DMM36DE CS C1=CC=C2C(=C1)N=C(C(=N2)NN)CC3=CC=C(C=C3)Cl
DMM36DE IK SMGDWLQUFKXCFA-UHFFFAOYSA-N
DMM36DE IU [3-[(4-chlorophenyl)methyl]quinoxalin-2-yl]hydrazine
DMM36DE DE Discovery agent
DMIFARP ID DMIFARP
DMIFARP DN 1-(3-(4-chlorophenyl)propyl)-1H-imidazole
DMIFARP HS Investigative
DMIFARP SN CHEMBL213493; 1-(3-(4-chlorophenyl)propyl)-1H-imidazole; 1-[3-(4-Chlorophenyl)propyl]-1H-imidazole; 1H-Imidazole,1-[3-(4-chlorophenyl)propyl]-; SCHEMBL20570009; BDBM50191792
DMIFARP DT Small molecular drug
DMIFARP PC 9991046
DMIFARP MW 220.7
DMIFARP FM C12H13ClN2
DMIFARP IC InChI=1S/C12H13ClN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
DMIFARP CS C1=CC(=CC=C1CCCN2C=CN=C2)Cl
DMIFARP IK CLJJKXWBLJQDDT-UHFFFAOYSA-N
DMIFARP IU 1-[3-(4-chlorophenyl)propyl]imidazole
DMIFARP DE Discovery agent
DMWKXZ2 ID DMWKXZ2
DMWKXZ2 DN 1-(3-(4-fluorophenyl)propyl)-1H-imidazole
DMWKXZ2 HS Investigative
DMWKXZ2 SN CHEMBL214932; 1-(3-(4-fluorophenyl)propyl)-1H-imidazole; 1-[3-(4-Fluorophenyl)propyl]-1H-imidazole
DMWKXZ2 DT Small molecular drug
DMWKXZ2 PC 10081625
DMWKXZ2 MW 204.24
DMWKXZ2 FM C12H13FN2
DMWKXZ2 IC InChI=1S/C12H13FN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
DMWKXZ2 CS C1=CC(=CC=C1CCCN2C=CN=C2)F
DMWKXZ2 IK BEKCOALNZLRGJA-UHFFFAOYSA-N
DMWKXZ2 IU 1-[3-(4-fluorophenyl)propyl]imidazole
DMWKXZ2 DE Discovery agent
DMQ4MUF ID DMQ4MUF
DMQ4MUF DN 1-(3-(benzyloxy)-2-methylphenyl)piperazine
DMQ4MUF HS Investigative
DMQ4MUF SN tolylpiperazine, 1; SCHEMBL4931607; CHEMBL483148; BDBM28584
DMQ4MUF DT Small molecular drug
DMQ4MUF PC 25263303
DMQ4MUF MW 282.4
DMQ4MUF FM C18H22N2O
DMQ4MUF IC InChI=1S/C18H22N2O/c1-15-17(20-12-10-19-11-13-20)8-5-9-18(15)21-14-16-6-3-2-4-7-16/h2-9,19H,10-14H2,1H3
DMQ4MUF CS CC1=C(C=CC=C1OCC2=CC=CC=C2)N3CCNCC3
DMQ4MUF IK LLKMJMQVKKJDAT-UHFFFAOYSA-N
DMQ4MUF IU 1-(2-methyl-3-phenylmethoxyphenyl)piperazine
DMQ4MUF DE Discovery agent
DMX5N3V ID DMX5N3V
DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine
DMX5N3V HS Investigative
DMX5N3V SN CHEMBL239434
DMX5N3V DT Small molecular drug
DMX5N3V PC 23643874
DMX5N3V MW 261.26
DMX5N3V FM C9H12F5NS
DMX5N3V IC InChI=1S/C9H12F5NS/c1-7(15)5-8-3-2-4-9(6-8)16(10,11,12,13)14/h2-4,6-7H,5,15H2,1H3
DMX5N3V CS CC(CC1=CC(=CC=C1)S(F)(F)(F)(F)F)N
DMX5N3V IK YGBSUVPUXAMOTQ-UHFFFAOYSA-N
DMX5N3V IU 1-[3-(pentafluoro-lambda6-sulfanyl)phenyl]propan-2-amine
DMX5N3V DE Discovery agent
DMXUNMW ID DMXUNMW
DMXUNMW DN 1-(3-(phenylthio)propyl)-4-m-tolylpiperazine
DMXUNMW HS Investigative
DMXUNMW SN CHEMBL239159; 1-(3-(phenylthio)propyl)-4-m-tolylpiperazine
DMXUNMW DT Small molecular drug
DMXUNMW PC 10245844
DMXUNMW MW 326.5
DMXUNMW FM C20H26N2S
DMXUNMW IC InChI=1S/C20H26N2S/c1-18-7-5-8-19(17-18)22-14-12-21(13-15-22)11-6-16-23-20-9-3-2-4-10-20/h2-5,7-10,17H,6,11-16H2,1H3
DMXUNMW CS CC1=CC(=CC=C1)N2CCN(CC2)CCCSC3=CC=CC=C3
DMXUNMW IK ZHUHEUSMACZXIP-UHFFFAOYSA-N
DMXUNMW IU 1-(3-methylphenyl)-4-(3-phenylsulfanylpropyl)piperazine
DMXUNMW DE Discovery agent
DMNZYWR ID DMNZYWR
DMNZYWR DN 1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione
DMNZYWR HS Investigative
DMNZYWR SN 1-(3,3-dimethyl-2-oxobutyl)-1H-indole-2,3-dione; 1-(3,3-dimethyl-2-oxobutyl)indole-2,3-dione; 214417-82-0; CHEMBL82686; AC1MU297; CTK7F3764; MolPort-003-013-041; ZINC3037941; ALBB-006420; STK506481; AKOS001570268; MCULE-7778783398; CCG-198354; TR-059060; SR-01000550574; 1-(2-Oxo-3,3-dimethylbutyl)-2,3-indolinedione
DMNZYWR DT Small molecular drug
DMNZYWR PC 3659236
DMNZYWR MW 245.27
DMNZYWR FM C14H15NO3
DMNZYWR IC InChI=1S/C14H15NO3/c1-14(2,3)11(16)8-15-10-7-5-4-6-9(10)12(17)13(15)18/h4-7H,8H2,1-3H3
DMNZYWR CS CC(C)(C)C(=O)CN1C2=CC=CC=C2C(=O)C1=O
DMNZYWR IK GGQBSDZGSYIVQW-UHFFFAOYSA-N
DMNZYWR IU 1-(3,3-dimethyl-2-oxobutyl)indole-2,3-dione
DMNZYWR DE Discovery agent
DM6RO2L ID DM6RO2L
DM6RO2L DN 1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea
DM6RO2L HS Investigative
DM6RO2L SN CHEMBL9312; 1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea
DM6RO2L DT Small molecular drug
DM6RO2L PC 44265928
DM6RO2L MW 342.4
DM6RO2L FM C23H22N2O
DM6RO2L IC InChI=1S/C23H22N2O/c1-18-9-8-14-21(17-18)25-23(26)24-16-15-22(19-10-4-2-5-11-19)20-12-6-3-7-13-20/h2-15,17H,16H2,1H3,(H2,24,25,26)
DM6RO2L CS CC1=CC(=CC=C1)NC(=O)NCC=C(C2=CC=CC=C2)C3=CC=CC=C3
DM6RO2L IK AQCRRYHNTDGOLK-UHFFFAOYSA-N
DM6RO2L IU 1-(3,3-diphenylprop-2-enyl)-3-(3-methylphenyl)urea
DM6RO2L DE Discovery agent
DMJDK7Z ID DMJDK7Z
DMJDK7Z DN 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z HS Investigative
DMJDK7Z SN CHEMBL230033; 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z DT Small molecular drug
DMJDK7Z PC 44426803
DMJDK7Z MW 371.5
DMJDK7Z FM C26H29NO
DMJDK7Z IC InChI=1S/C26H29NO/c28-26(24-14-8-3-9-15-24)17-20-27(21-18-26)19-16-25(22-10-4-1-5-11-22)23-12-6-2-7-13-23/h1-15,25,28H,16-21H2
DMJDK7Z CS C1CN(CCC1(C2=CC=CC=C2)O)CCC(C3=CC=CC=C3)C4=CC=CC=C4
DMJDK7Z IK VJCUYHKRHUNZBN-UHFFFAOYSA-N
DMJDK7Z IU 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol
DMJDK7Z DE Discovery agent
DMX6PKO ID DMX6PKO
DMX6PKO DN 1-(3,4-dichlorobenzyl)-1H-imidazole
DMX6PKO HS Investigative
DMX6PKO SN 1-(3,4-dichlorobenzyl)-1H-imidazole; CHEMBL379436; 56643-72-2; 1-(3,4-Dichloro-benzyl)-1H-imidazole; 1-(3,4-Dichlorobenzyl)imidazole; BAS 11721008; AC1MGEX9; CTK1F4149; DTXSID40388096; MolPort-000-511-619; ZINC4385934; BDBM50188095; STK951804; AKOS000586982; [(3,4-dichlorophenyl)methyl]imidazole; MCULE-5938366655; 1-[(3,4-dichlorophenyl)methyl]imidazole; ST50162194; 1H-Imidazole, 1-[(3,4-dichlorophenyl)methyl]-; SR-01000301759
DMX6PKO DT Small molecular drug
DMX6PKO PC 2985081
DMX6PKO MW 227.09
DMX6PKO FM C10H8Cl2N2
DMX6PKO IC InChI=1S/C10H8Cl2N2/c11-9-2-1-8(5-10(9)12)6-14-4-3-13-7-14/h1-5,7H,6H2
DMX6PKO CS C1=CC(=C(C=C1CN2C=CN=C2)Cl)Cl
DMX6PKO IK AYZFQKPOALRPNQ-UHFFFAOYSA-N
DMX6PKO IU 1-[(3,4-dichlorophenyl)methyl]imidazole
DMX6PKO CA CAS 56643-72-2
DMX6PKO DE Discovery agent
DMX71K9 ID DMX71K9
DMX71K9 DN 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione
DMX71K9 HS Investigative
DMX71K9 SN Apoptosis Activator 2; 79183-19-0; 1-(3,4-Dichlorobenzyl)-1H-indole-2,3-dione; Apoptosis Activator II; 1-(3,4-dichlorobenzyl)indoline-2,3-dione; MDK83190; 1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione; J-503075; 1H-Indole-2,3-dione,1-[(3,4-dichlorophenyl)methyl]-; SR-01000411093; ApoptosisActivator2; AC1LYJSJ; Tocris-2098; AC1Q3JHQ; CBMicro_042945; Isatin-based compound, 16; CHEMBL375126; SCHEMBL5426477; BDBM22796; CHEBI:92273; KS-00001DBG; CTK5E6556; cid_1901244; DTXSID30365533; EX-A147; AOB2639; MolPort-002-181-853; HMS3651L12
DMX71K9 DT Small molecular drug
DMX71K9 PC 1901244
DMX71K9 MW 306.1
DMX71K9 FM C15H9Cl2NO2
DMX71K9 IC InChI=1S/C15H9Cl2NO2/c16-11-6-5-9(7-12(11)17)8-18-13-4-2-1-3-10(13)14(19)15(18)20/h1-7H,8H2
DMX71K9 CS C1=CC=C2C(=C1)C(=O)C(=O)N2CC3=CC(=C(C=C3)Cl)Cl
DMX71K9 IK KGRJPLRFGLMQMV-UHFFFAOYSA-N
DMX71K9 IU 1-[(3,4-dichlorophenyl)methyl]indole-2,3-dione
DMX71K9 CA CAS 79183-19-0
DMX71K9 CB CHEBI:92273
DMX71K9 DE Discovery agent
DM4YWEL ID DM4YWEL
DM4YWEL DN 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone
DM4YWEL HS Investigative
DM4YWEL SN CHEMBL238835; 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)-1-ethanone; 344266-52-0; AC1LS77V; 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone; MolPort-002-876-897; ZINC1396961; BDBM50212532; AKOS005097772; MCULE-8898035078; 7H-370S; KS-00001Z97; 2-(benzenesulfonyl)-1-(3,4-dichlorophenyl)ethanone
DM4YWEL DT Small molecular drug
DM4YWEL PC 1483443
DM4YWEL MW 329.2
DM4YWEL FM C14H10Cl2O3S
DM4YWEL IC InChI=1S/C14H10Cl2O3S/c15-12-7-6-10(8-13(12)16)14(17)9-20(18,19)11-4-2-1-3-5-11/h1-8H,9H2
DM4YWEL CS C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC(=C(C=C2)Cl)Cl
DM4YWEL IK LZBIUNZNOUZDPA-UHFFFAOYSA-N
DM4YWEL IU 2-(benzenesulfonyl)-1-(3,4-dichlorophenyl)ethanone
DM4YWEL DE Discovery agent
DMNOQ49 ID DMNOQ49
DMNOQ49 DN 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea
DMNOQ49 HS Investigative
DMNOQ49 SN CHEMBL255505; 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea; AC1LKCSZ; CBMicro_019879; AC1Q3IF4; MolPort-000-644-777; ZINC639843; CCG-8060; 1-(3,4-DICHLORO-PHENYL)-3-(3,5-DICHLORO-PHENYL)-UREA; BDBM50373332; AKOS002934710; MCULE-5556566180; BIM-0020045.P001; ST50982277; SJ000146676
DMNOQ49 DT Small molecular drug
DMNOQ49 PC 989142
DMNOQ49 MW 350
DMNOQ49 FM C13H8Cl4N2O
DMNOQ49 IC InChI=1S/C13H8Cl4N2O/c14-7-3-8(15)5-10(4-7)19-13(20)18-9-1-2-11(16)12(17)6-9/h1-6H,(H2,18,19,20)
DMNOQ49 CS C1=CC(=C(C=C1NC(=O)NC2=CC(=CC(=C2)Cl)Cl)Cl)Cl
DMNOQ49 IK IMDDDJBDFZQNJH-UHFFFAOYSA-N
DMNOQ49 IU 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea
DMNOQ49 DE Discovery agent
DMN4JU0 ID DMN4JU0
DMN4JU0 DN 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0 HS Investigative
DMN4JU0 SN CHEMBL315697; 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol
DMN4JU0 DT Small molecular drug
DMN4JU0 PC 44322661
DMN4JU0 MW 350.3
DMN4JU0 FM C19H21Cl2NO
DMN4JU0 IC InChI=1S/C19H21Cl2NO/c1-3-22(4-2)19-11-15(12-5-8-17(20)18(21)9-12)14-7-6-13(23)10-16(14)19/h5-10,15,19,23H,3-4,11H2,1-2H3
DMN4JU0 CS CCN(CC)C1CC(C2=C1C=C(C=C2)O)C3=CC(=C(C=C3)Cl)Cl
DMN4JU0 IK NIIGXDSCJHJWSY-UHFFFAOYSA-N
DMN4JU0 IU 1-(3,4-dichlorophenyl)-3-(diethylamino)-2,3-dihydro-1H-inden-5-ol
DMN4JU0 DE Discovery agent
DMVOJ7K ID DMVOJ7K
DMVOJ7K DN 1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K HS Investigative
DMVOJ7K SN 1-(3,4-Dichlorophenyl)-3-hydroxyurea; N-(3,4-Dichlorophenyl)-N'-hydroxyurea; 31225-17-9; Dichlorphenyloxyurea; Urea, N-(3,4-dichlorophenyl)-N'-hydroxy-; Urea, 1-(3,4-dichlorophenyl)-3-hydroxy-; EINECS 250-519-3; NSC125191; NSC 125191; BRN 2806578; AI3-63029; CHEMBL213348; AC1L3YKI; AC1Q3OJ7; SCHEMBL6791055; DTXSID8067602; CTK4G6577; Urea,4-dichlorophenyl)-3-hydroxy-; ZINC4809416; Urea,4-dichlorophenyl)-N'-hydroxy-; BDBM50188774; AKOS024368418; NSC-125191; MCULE-3584918333; 1-(3,4-dichlorophenyl)-3-hydroxy-urea; LS-159754
DMVOJ7K DT Small molecular drug
DMVOJ7K PC 97463
DMVOJ7K MW 221.04
DMVOJ7K FM C7H6Cl2N2O2
DMVOJ7K IC InChI=1S/C7H6Cl2N2O2/c8-5-2-1-4(3-6(5)9)10-7(12)11-13/h1-3,13H,(H2,10,11,12)
DMVOJ7K CS C1=CC(=C(C=C1NC(=O)NO)Cl)Cl
DMVOJ7K IK VKYZMAVGJARVPE-UHFFFAOYSA-N
DMVOJ7K IU 1-(3,4-dichlorophenyl)-3-hydroxyurea
DMVOJ7K CA CAS 31225-17-9
DMVOJ7K DE Discovery agent
DMWIEDN ID DMWIEDN
DMWIEDN DN 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN HS Investigative
DMWIEDN SN CHEMBL301514; 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol
DMWIEDN DT Small molecular drug
DMWIEDN PC 13543873
DMWIEDN MW 308.2
DMWIEDN FM C16H15Cl2NO
DMWIEDN IC InChI=1S/C16H15Cl2NO/c1-19-16-8-12(9-2-5-14(17)15(18)6-9)11-4-3-10(20)7-13(11)16/h2-7,12,16,19-20H,8H2,1H3
DMWIEDN CS CNC1CC(C2=C1C=C(C=C2)O)C3=CC(=C(C=C3)Cl)Cl
DMWIEDN IK QAOIAICAGBDCEV-UHFFFAOYSA-N
DMWIEDN IU 1-(3,4-dichlorophenyl)-3-(methylamino)-2,3-dihydro-1H-inden-5-ol
DMWIEDN DE Discovery agent
DMYZ548 ID DMYZ548
DMYZ548 DN 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMYZ548 HS Investigative
DMYZ548 SN SCHEMBL3194096; CHEMBL1173532; BDBM50322698; 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX); rel-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane
DMYZ548 DT Small molecular drug
DMYZ548 PC 24802842
DMYZ548 MW 286.2
DMYZ548 FM C14H17Cl2NO
DMYZ548 IC InChI=1S/C14H17Cl2NO/c1-18-9-13-7-14(13,4-5-17-8-13)10-2-3-11(15)12(16)6-10/h2-3,6,17H,4-5,7-9H2,1H3/t13-,14-/m1/s1
DMYZ548 CS COC[C@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl
DMYZ548 IK ICXJGCSEMJXNQF-ZIAGYGMSSA-N
DMYZ548 IU (1R,6S)-6-(3,4-dichlorophenyl)-1-(methoxymethyl)-3-azabicyclo[4.1.0]heptane
DMYZ548 DE Discovery agent
DMRXD2P ID DMRXD2P
DMRXD2P DN 1-(3,4-difluorobenzyl)-1H-imidazole
DMRXD2P HS Investigative
DMRXD2P SN 1-(3,4-difluorobenzyl)-1H-imidazole; 1-(3,4-Difluorobenzyl)imidazole; CHEMBL373588; 906478-71-5; ZINC36322898; BDBM50188090
DMRXD2P DT Small molecular drug
DMRXD2P PC 44414157
DMRXD2P MW 194.18
DMRXD2P FM C10H8F2N2
DMRXD2P IC InChI=1S/C10H8F2N2/c11-9-2-1-8(5-10(9)12)6-14-4-3-13-7-14/h1-5,7H,6H2
DMRXD2P CS C1=CC(=C(C=C1CN2C=CN=C2)F)F
DMRXD2P IK YOWSCWVTVGDNPQ-UHFFFAOYSA-N
DMRXD2P IU 1-[(3,4-difluorophenyl)methyl]imidazole
DMRXD2P DE Discovery agent
DM5C7I8 ID DM5C7I8
DM5C7I8 DN 1-(3,4-dihydronaphthalen-1-yl)ethanone
DM5C7I8 HS Investigative
DM5C7I8 SN CHEMBL378621; 1-(3,4-dihydro-naphthalen-1-yl)-ethanone; 67106-36-9; 1-(3,4-dihydronaphthalen-1-yl)ethanone; SCHEMBL6337844; 1-acetyl-3,4-dihydronaphthalene; CTK1J3902; DTXSID40447596; BDBM50189272; AKOS030597011; 1-(3,4-dihydro-1-naphthalenyl)ethanone; Ethanone, 1-(3,4-dihydro-1-naphthalenyl)-
DM5C7I8 DT Small molecular drug
DM5C7I8 PC 10899142
DM5C7I8 MW 172.22
DM5C7I8 FM C12H12O
DM5C7I8 IC InChI=1S/C12H12O/c1-9(13)11-8-4-6-10-5-2-3-7-12(10)11/h2-3,5,7-8H,4,6H2,1H3
DM5C7I8 CS CC(=O)C1=CCCC2=CC=CC=C21
DM5C7I8 IK OUZPHFHCYBXKAY-UHFFFAOYSA-N
DM5C7I8 IU 1-(3,4-dihydronaphthalen-1-yl)ethanone
DM5C7I8 DE Discovery agent
DMP93HZ ID DMP93HZ
DMP93HZ DN 1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole
DMP93HZ HS Investigative
DMP93HZ SN BRN 4745179; 89781-63-5; 1H-Imidazole, 1-(3,4-dihydro-2-naphthalenyl)-; 1-(3,4-Dihydro-2-naphthalenyl)-1H-imidazole; 1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole; 1H-Imidazole,1-(3,4-dihydro-2-naphthalenyl)-; ACMC-20lqcl; Dihydronaphthalene 13; AC1MIBH1; SCHEMBL4513496; CHEMBL208471; BDBM8898; 1-(3,4-DIHYDRO-NAPHTHALEN-2-YL)-1H-IMIDAZOLE; CTK5G3471; DTXSID50237889; ZINC13684552; AKOS006279027; 1-(3,4-dihydronaphthalen-2-yl)imidazole; LS-78473
DMP93HZ DT Small molecular drug
DMP93HZ PC 3021558
DMP93HZ MW 196.25
DMP93HZ FM C13H12N2
DMP93HZ IC InChI=1S/C13H12N2/c1-2-4-12-9-13(6-5-11(12)3-1)15-8-7-14-10-15/h1-4,7-10H,5-6H2
DMP93HZ CS C1CC(=CC2=CC=CC=C21)N3C=CN=C3
DMP93HZ IK DHUCLDOIXQGVDQ-UHFFFAOYSA-N
DMP93HZ IU 1-(3,4-dihydronaphthalen-2-yl)imidazole
DMP93HZ CA CAS 89781-63-5
DMP93HZ DE Discovery agent
DM9M5D1 ID DM9M5D1
DM9M5D1 DN 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone
DM9M5D1 HS Investigative
DM9M5D1 SN CHEMBL197115; 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone; SCHEMBL7431618
DM9M5D1 DT Small molecular drug
DM9M5D1 PC 9900163
DM9M5D1 MW 273.24
DM9M5D1 FM C14H11NO5
DM9M5D1 IC InChI=1S/C14H11NO5/c16-11-7-6-10(13(14(11)18)15(19)20)12(17)8-9-4-2-1-3-5-9/h1-7,16,18H,8H2
DM9M5D1 CS C1=CC=C(C=C1)CC(=O)C2=C(C(=C(C=C2)O)O)[N+](=O)[O-]
DM9M5D1 IK WQKGHRQZAOQUHW-UHFFFAOYSA-N
DM9M5D1 IU 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone
DM9M5D1 DE Discovery agent
DMKI719 ID DMKI719
DMKI719 DN 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone
DMKI719 HS Investigative
DMKI719 SN CHEMBL374904; SCHEMBL7251537
DMKI719 DT Small molecular drug
DMKI719 PC 9900598
DMKI719 MW 289.24
DMKI719 FM C14H11NO6
DMKI719 IC InChI=1S/C14H11NO6/c16-12-7-9(6-11(14(12)18)15(19)20)13(17)8-21-10-4-2-1-3-5-10/h1-7,16,18H,8H2
DMKI719 CS C1=CC=C(C=C1)OCC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
DMKI719 IK JFIYNCBDNTXFDN-UHFFFAOYSA-N
DMKI719 IU 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone
DMKI719 DE Discovery agent
DMCHILK ID DMCHILK
DMCHILK DN 1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione
DMCHILK HS Investigative
DMCHILK SN 1-(3,4-dimethylphenyl)-2-phenylethane-1,2-dione; 59411-15-3; PubChem22503; AC1M6ONN; Benzil-based compound, 19; AC1Q2DS8; SCHEMBL2156354; CHEMBL193140; 1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione; CTK5A9919; BDBM22741; DTXSID20368619; MolPort-000-513-246; ZINC3311689; AKOS000118620; MCULE-1712710570; NE45262; AJ-44881; ST010102; KB-213539; J3.541.808C; EN300-11497
DMCHILK DT Small molecular drug
DMCHILK PC 2427416
DMCHILK MW 238.28
DMCHILK FM C16H14O2
DMCHILK IC InChI=1S/C16H14O2/c1-11-8-9-14(10-12(11)2)16(18)15(17)13-6-4-3-5-7-13/h3-10H,1-2H3
DMCHILK CS CC1=C(C=C(C=C1)C(=O)C(=O)C2=CC=CC=C2)C
DMCHILK IK UJARQLWFLLIFBN-UHFFFAOYSA-N
DMCHILK IU 1-(3,4-dimethylphenyl)-2-phenylethane-1,2-dione
DMCHILK CA CAS 59411-15-3
DMCHILK DE Discovery agent
DM5WOK8 ID DM5WOK8
DM5WOK8 DN 1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole
DM5WOK8 HS Investigative
DM5WOK8 SN CHEMBL213596; 1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole
DM5WOK8 DT Small molecular drug
DM5WOK8 PC 44414156
DM5WOK8 MW 294.2
DM5WOK8 FM C12H8F6N2
DM5WOK8 IC InChI=1S/C12H8F6N2/c13-11(14,15)9-3-8(6-20-2-1-19-7-20)4-10(5-9)12(16,17)18/h1-5,7H,6H2
DM5WOK8 CS C1=CN(C=N1)CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F
DM5WOK8 IK XITLEILYHLIBPC-UHFFFAOYSA-N
DM5WOK8 IU 1-[[3,5-bis(trifluoromethyl)phenyl]methyl]imidazole
DM5WOK8 CA CAS 906478-70-4
DM5WOK8 DE Discovery agent
DMNRCM0 ID DMNRCM0
DMNRCM0 DN 1-(3,5-dibromobenzyl)-1H-imidazole
DMNRCM0 HS Investigative
DMNRCM0 SN CHEMBL211276; 528543-94-4; 1-(3,5-dibromobenzyl)-1H-imidazole; CTK1G1925; DTXSID30658795; BDBM50188091; 1-[(3,5-Dibromophenyl)methyl]-1H-imidazole; 1H-Imidazole, 1-[(3,5-dibromophenyl)methyl]-
DMNRCM0 DT Small molecular drug
DMNRCM0 PC 44414099
DMNRCM0 MW 315.99
DMNRCM0 FM C10H8Br2N2
DMNRCM0 IC InChI=1S/C10H8Br2N2/c11-9-3-8(4-10(12)5-9)6-14-2-1-13-7-14/h1-5,7H,6H2
DMNRCM0 CS C1=CN(C=N1)CC2=CC(=CC(=C2)Br)Br
DMNRCM0 IK QXITVPZFTOHIGY-UHFFFAOYSA-N
DMNRCM0 IU 1-[(3,5-dibromophenyl)methyl]imidazole
DMNRCM0 CA CAS 528543-94-4
DMNRCM0 DE Discovery agent
DMLSWHP ID DMLSWHP
DMLSWHP DN 1-(3,5-dichlorobenzyl)-1H-imidazole
DMLSWHP HS Investigative
DMLSWHP SN CHEMBL210125; 1-(3,5-dichlorobenzyl)-1H-imidazole; SCHEMBL3980802
DMLSWHP DT Small molecular drug
DMLSWHP PC 44414074
DMLSWHP MW 227.09
DMLSWHP FM C10H8Cl2N2
DMLSWHP IC InChI=1S/C10H8Cl2N2/c11-9-3-8(4-10(12)5-9)6-14-2-1-13-7-14/h1-5,7H,6H2
DMLSWHP CS C1=CN(C=N1)CC2=CC(=CC(=C2)Cl)Cl
DMLSWHP IK RNVCIUBPHQDEID-UHFFFAOYSA-N
DMLSWHP IU 1-[(3,5-dichlorophenyl)methyl]imidazole
DMLSWHP DE Discovery agent
DMEAI6V ID DMEAI6V
DMEAI6V DN 1-(3,5-difluorobenzyl)-1H-imidazole
DMEAI6V HS Investigative
DMEAI6V SN 1-(3,5-difluorobenzyl)-1H-imidazole; CHEMBL446946; 170166-01-5; SCHEMBL10518956; CTK0E4909; DTXSID20474067; 1-(3,5-Difluorobenzyl)imidazole; ZINC36466875; BDBM50188089; AKOS027391623; 1-[(3,5-difluorophenyl)methyl]-1H-imidazole; 1H-Imidazole, 1-[(3,5-difluorophenyl)methyl]-
DMEAI6V DT Small molecular drug
DMEAI6V PC 11830301
DMEAI6V MW 194.18
DMEAI6V FM C10H8F2N2
DMEAI6V IC InChI=1S/C10H8F2N2/c11-9-3-8(4-10(12)5-9)6-14-2-1-13-7-14/h1-5,7H,6H2
DMEAI6V CS C1=CN(C=N1)CC2=CC(=CC(=C2)F)F
DMEAI6V IK HGEAQRQBZSYPGD-UHFFFAOYSA-N
DMEAI6V IU 1-[(3,5-difluorophenyl)methyl]imidazole
DMEAI6V CA CAS 170166-01-5
DMEAI6V DE Discovery agent
DMYJ4EG ID DMYJ4EG
DMYJ4EG DN 1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone
DMYJ4EG HS Investigative
DMYJ4EG SN CHEMBL239261; 1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone; BDBM50212547
DMYJ4EG DT Small molecular drug
DMYJ4EG PC 44437607
DMYJ4EG MW 288.4
DMYJ4EG FM C16H16O3S
DMYJ4EG IC InChI=1S/C16H16O3S/c1-12-8-9-15(13(2)10-12)16(17)11-20(18,19)14-6-4-3-5-7-14/h3-10H,11H2,1-2H3
DMYJ4EG CS CC1=CC(=C(C=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2)C
DMYJ4EG IK MYSKHEDYGIVTKV-UHFFFAOYSA-N
DMYJ4EG IU 2-(benzenesulfonyl)-1-(2,4-dimethylphenyl)ethanone
DMYJ4EG DE Discovery agent
DMEJZAC ID DMEJZAC
DMEJZAC DN 1-(3-Amino-benzyl)-1H-indole-5-carboxamidine
DMEJZAC HS Investigative
DMEJZAC SN CHEMBL319122; 1-(3-Amino-benzyl)-1H-indole-5-carboxamidine; ZINC26750418
DMEJZAC DT Small molecular drug
DMEJZAC PC 44332077
DMEJZAC MW 264.32
DMEJZAC FM C16H16N4
DMEJZAC IC InChI=1S/C16H16N4/c17-14-3-1-2-11(8-14)10-20-7-6-12-9-13(16(18)19)4-5-15(12)20/h1-9H,10,17H2,(H3,18,19)
DMEJZAC CS C1=CC(=CC(=C1)N)CN2C=CC3=C2C=CC(=C3)C(=N)N
DMEJZAC IK PHWLXNIGOXPBJT-UHFFFAOYSA-N
DMEJZAC IU 1-[(3-aminophenyl)methyl]indole-5-carboximidamide
DMEJZAC DE Discovery agent
DMTY41F ID DMTY41F
DMTY41F DN 1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F HS Investigative
DMTY41F SN CHEMBL382886; 1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F DT Small molecular drug
DMTY41F PC 44409446
DMTY41F MW 319.2
DMTY41F FM C15H12Cl2N4
DMTY41F IC InChI=1S/C15H12Cl2N4/c16-10-7-12-13(8-11(10)17)20-15(21-18)14(19-12)6-9-4-2-1-3-5-9/h1-5,7-8H,6,18H2,(H,20,21)
DMTY41F CS C1=CC=C(C=C1)CC2=NC3=CC(=C(C=C3N=C2NN)Cl)Cl
DMTY41F IK UMCSOEDKYUEPEK-UHFFFAOYSA-N
DMTY41F IU (3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine
DMTY41F DE Discovery agent
DMDZAVU ID DMDZAVU
DMDZAVU DN 1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea
DMDZAVU HS Investigative
DMDZAVU SN CHEMBL202880; 877458-90-7; 1-PHENYL-3-(3-(PHENYLMETHOXY)(2-PYRIDYL))UREA; 1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea; AC1MUB56; MolPort-006-755-114; KS-000029KK; ZINC13680188; BDBM50181486; AKOS016664347; MS-8514; 1-(3-benzyloxy-2-pyridyl)-3-phenyl-urea; 3-[3-(benzyloxy)pyridin-2-yl]-1-phenylurea; 1-phenyl-3-(3-phenylmethoxypyridin-2-yl)urea; Urea, N-(3-phenyl)-N'-[3-(phenylmethoxy)-2-pyridinyl]-
DMDZAVU DT Small molecular drug
DMDZAVU PC 3663276
DMDZAVU MW 319.4
DMDZAVU FM C19H17N3O2
DMDZAVU IC InChI=1S/C19H17N3O2/c23-19(21-16-10-5-2-6-11-16)22-18-17(12-7-13-20-18)24-14-15-8-3-1-4-9-15/h1-13H,14H2,(H2,20,21,22,23)
DMDZAVU CS C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=CC=C3
DMDZAVU IK PFMMAQSZJDBKOE-UHFFFAOYSA-N
DMDZAVU IU 1-phenyl-3-(3-phenylmethoxypyridin-2-yl)urea
DMDZAVU DE Discovery agent
DMJCVQN ID DMJCVQN
DMJCVQN DN 1-(3-benzylquinoxalin-2-yl)hydrazine
DMJCVQN HS Investigative
DMJCVQN SN 2-benzyl-3-hydrazinoquinoxaline; 223929-23-5; 2-benzyl-3-hydrazinylquinoxaline; CHEMBL379678; 1-(3-benzylquinoxalin-2-yl)hydrazine; AC1LAIMJ; benzylhydrazinoquinoxaline; SCHEMBL7628856; 3-benzyl-2-hydrazinoquinoxaline; KS-00001USU; CTK7F1811; 3-benzylquinoxaline-2-ylhydrazine; DTXSID80333186; MolPort-009-195-340; (3-benzylquinoxalin-2-yl)hydrazine; ZINC6580943; SBB100772; BDBM50179015; 7662AD; AKOS005070001; RTR-063098; RP14269; AJ-56391; TR-063098; 2R-0102
DMJCVQN DT Small molecular drug
DMJCVQN PC 488815
DMJCVQN MW 250.3
DMJCVQN FM C15H14N4
DMJCVQN IC InChI=1S/C15H14N4/c16-19-15-14(10-11-6-2-1-3-7-11)17-12-8-4-5-9-13(12)18-15/h1-9H,10,16H2,(H,18,19)
DMJCVQN CS C1=CC=C(C=C1)CC2=NC3=CC=CC=C3N=C2NN
DMJCVQN IK VVXTVQMXZGMAAH-UHFFFAOYSA-N
DMJCVQN IU (3-benzylquinoxalin-2-yl)hydrazine
DMJCVQN CA CAS 223929-23-5
DMJCVQN DE Discovery agent
DMA59TP ID DMA59TP
DMA59TP DN 1-(3-Bromobenzyl)-1H-imidazole
DMA59TP HS Investigative
DMA59TP SN 1-(3-Bromobenzyl)-1H-imidazole; 72459-47-3; 1-(3-bromobenzyl)imidazole; CHEMBL598391; 1H-Imidazole,1-[(3-bromophenyl)methyl]-; 1-[(3-bromophenyl)methyl]imidazole; SCHEMBL1848631; CTK5D6138; [(3-bromophenyl)methyl]imidazole; DTXSID00436926; BGYZLOIBJCHCTI-UHFFFAOYSA-N; MolPort-000-143-256; SBB098740; ZINC12370275; BDBM50307216; AKOS013124377; RP05747; KB-63888; 1-[(3-bromophenyl)methyl]-1H-imidazole; AJ-61784; DB-074567; ST24037191; Y9919; FT-0708606; 1-(3-bromobenzyl)-1H-imidazole, AldrichCPR; J-503102; Z1532751877
DMA59TP DT Small molecular drug
DMA59TP PC 10220337
DMA59TP MW 237.1
DMA59TP FM C10H9BrN2
DMA59TP IC InChI=1S/C10H9BrN2/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7H2
DMA59TP CS C1=CC(=CC(=C1)Br)CN2C=CN=C2
DMA59TP IK BGYZLOIBJCHCTI-UHFFFAOYSA-N
DMA59TP IU 1-[(3-bromophenyl)methyl]imidazole
DMA59TP CA CAS 72459-47-3
DMA59TP DE Discovery agent
DM58S47 ID DM58S47
DM58S47 DN 1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone
DM58S47 HS Investigative
DM58S47 SN 3-Trifluoroacetylbenzyl bromide; 370104-05-5; 1-[3-(bromomethyl)phenyl]-2,2,2-trifluoroethan-1-one; CHEMBL322727; SCHEMBL19745468; BDBM10502; MolPort-039-241-133; ZINC13864123; 1-[3-(bromomethyl)phenyl]-2,2,2-trifluoroethanone; 1-[3-(bromomethyl)-phenyl]-2,2,2-trifluoro-ethanone
DM58S47 DT Small molecular drug
DM58S47 PC 10858440
DM58S47 MW 267.04
DM58S47 FM C9H6BrF3O
DM58S47 IC InChI=1S/C9H6BrF3O/c10-5-6-2-1-3-7(4-6)8(14)9(11,12)13/h1-4H,5H2
DM58S47 CS C1=CC(=CC(=C1)C(=O)C(F)(F)F)CBr
DM58S47 IK PJBFZGACRBKRKV-UHFFFAOYSA-N
DM58S47 IU 1-[3-(bromomethyl)phenyl]-2,2,2-trifluoroethanone
DM58S47 CA CAS 370104-05-5
DM58S47 DE Discovery agent
DM2SEXH ID DM2SEXH
DM2SEXH DN 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one
DM2SEXH HS Investigative
DM2SEXH SN 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one; CHEMBL565396; AC1MHR9I; SCHEMBL769683; BDBM50302930
DM2SEXH DT Small molecular drug
DM2SEXH PC 3031062
DM2SEXH MW 284.19
DM2SEXH FM C13H18BrNO
DM2SEXH IC InChI=1S/C13H18BrNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM2SEXH CS CC(C(=O)C1=CC(=CC=C1)Br)NC(C)(C)C
DM2SEXH IK GIDJZDYNVHMFAH-UHFFFAOYSA-N
DM2SEXH IU 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one
DM2SEXH DE Discovery agent
DMJXOUK ID DMJXOUK
DMJXOUK DN 1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX)
DMJXOUK HS Investigative
DMJXOUK SN CHEMBL1094231; 1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX); SCHEMBL4285350; BDBM50316561; 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-(4-fluorophenyl)-1H-indazol-5-yl)ethanol
DMJXOUK DT Small molecular drug
DMJXOUK PC 46888441
DMJXOUK MW 438.8
DMJXOUK FM C21H12ClF5N2O
DMJXOUK IC InChI=1S/C21H12ClF5N2O/c22-17-10-14(1-7-18(17)24)20(30,21(25,26)27)13-2-8-19-12(9-13)11-28-29(19)16-5-3-15(23)4-6-16/h1-11,30H
DMJXOUK CS C1=CC(=CC=C1N2C3=C(C=C(C=C3)C(C4=CC(=C(C=C4)F)Cl)(C(F)(F)F)O)C=N2)F
DMJXOUK IK DAXGWLCLIPNRDH-UHFFFAOYSA-N
DMJXOUK IU 1-(3-chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)indazol-5-yl]ethanol
DMJXOUK DE Discovery agent
DM3SQBH ID DM3SQBH
DM3SQBH DN 1-(3-Chlorobenzyl)-1H-imidazole
DM3SQBH HS Investigative
DM3SQBH SN 1-(3-Chlorobenzyl)-1H-imidazole; CHEMBL608437; 56643-68-6; 1-(3-Chlorobenzyl)imidazole; N-(3-chlorobenzyl)-imidazole; 1-(3-chlorobenzyl)-imidazole; SCHEMBL9661609; DARGVYVMURXBSO-UHFFFAOYSA-N; MolPort-008-647-602; BDBM50307215; ZINC35143438; AKOS003644458; MCULE-2532110476; 1-[(3-chlorophenyl)methyl]-1H-imidazole
DM3SQBH DT Small molecular drug
DM3SQBH PC 12229386
DM3SQBH MW 192.64
DM3SQBH FM C10H9ClN2
DM3SQBH IC InChI=1S/C10H9ClN2/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7H2
DM3SQBH CS C1=CC(=CC(=C1)Cl)CN2C=CN=C2
DM3SQBH IK DARGVYVMURXBSO-UHFFFAOYSA-N
DM3SQBH IU 1-[(3-chlorophenyl)methyl]imidazole
DM3SQBH DE Discovery agent
DMFYJ5V ID DMFYJ5V
DMFYJ5V DN 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one
DMFYJ5V HS Investigative
DMFYJ5V SN CHEMBL566830; 2-(N,N-Dimethylamino)-3'-chloropropiophenone; 740079-95-2; 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one; SCHEMBL769582; BDBM50302908; AKOS009983839; 2-(N,N-Dimethylamino)-3''-chloropropiophenone
DMFYJ5V DT Small molecular drug
DMFYJ5V PC 43794735
DMFYJ5V MW 211.69
DMFYJ5V FM C11H14ClNO
DMFYJ5V IC InChI=1S/C11H14ClNO/c1-8(13(2)3)11(14)9-5-4-6-10(12)7-9/h4-8H,1-3H3
DMFYJ5V CS CC(C(=O)C1=CC(=CC=C1)Cl)N(C)C
DMFYJ5V IK UYZAXUWVJGHEFL-UHFFFAOYSA-N
DMFYJ5V IU 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one
DMFYJ5V DE Discovery agent
DMPOVUY ID DMPOVUY
DMPOVUY DN 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one
DMPOVUY HS Investigative
DMPOVUY SN 2-Piperidino-3'-chloropropiophenone
DMPOVUY PC 43227131
DMPOVUY MW 251.75
DMPOVUY FM C14H18ClNO
DMPOVUY IC InChI=1S/C14H18ClNO/c1-11(16-8-3-2-4-9-16)14(17)12-6-5-7-13(15)10-12/h5-7,10-11H,2-4,8-9H2,1H3
DMPOVUY CS CC(C(=O)C1=CC(=CC=C1)Cl)N2CCCCC2
DMPOVUY IK LOWDJVQAZMFOLZ-UHFFFAOYSA-N
DMPOVUY IU 1-(3-chlorophenyl)-2-piperidin-1-ylpropan-1-one
DMPOVUY DE Discovery agent
DMC5PI4 ID DMC5PI4
DMC5PI4 DN 1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea
DMC5PI4 HS Investigative
DMC5PI4 SN CHEMBL66498; 1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea
DMC5PI4 DT Small molecular drug
DMC5PI4 PC 11255879
DMC5PI4 MW 326.9
DMC5PI4 FM C17H27ClN2O2
DMC5PI4 IC InChI=1S/C17H27ClN2O2/c1-2-3-4-5-10-16(21)11-7-12-19-17(22)20-15-9-6-8-14(18)13-15/h6,8-9,13,16,21H,2-5,7,10-12H2,1H3,(H2,19,20,22)
DMC5PI4 CS CCCCCCC(CCCNC(=O)NC1=CC(=CC=C1)Cl)O
DMC5PI4 IK ZDFKGBJPFGFBQJ-UHFFFAOYSA-N
DMC5PI4 IU 1-(3-chlorophenyl)-3-(4-hydroxydecyl)urea
DMC5PI4 DE Discovery agent
DM1VLMC ID DM1VLMC
DM1VLMC DN 1-(3-Chloro-phenyl)-3-cyclohexyl-urea
DM1VLMC HS Investigative
DM1VLMC SN 1-(3-chlorophenyl)-3-cyclohexylurea; CHEMBL192293; N-(3-chlorophenyl)-N'-cyclohexylurea; 72802-45-0; 1-(3-Chloro-phenyl)-3-cyclohexyl-urea; SMR000102236; AC1Q3IFF; AC1LFC0I; CBDivE_015961; MLS000105355; ARONIS24036; SCHEMBL12196175; REGID_for_CID_751320; DTXSID50353755; MolPort-001-819-362; ZINC201053; HMS2404F16; KS-000046HM; BDBM50167035; STK903181; 3-(3-chlorophenyl)-1-cyclohexylurea; AKOS002956586; MCULE-2109883694; 1-(3-chlorophenyl)-3-cyclohexyl-urea; KB-101580; ST45053223; N-(3-chlorophenyl)(cyclohexylamino)carboxamide
DM1VLMC DT Small molecular drug
DM1VLMC PC 751320
DM1VLMC MW 252.74
DM1VLMC FM C13H17ClN2O
DM1VLMC IC InChI=1S/C13H17ClN2O/c14-10-5-4-8-12(9-10)16-13(17)15-11-6-2-1-3-7-11/h4-5,8-9,11H,1-3,6-7H2,(H2,15,16,17)
DM1VLMC CS C1CCC(CC1)NC(=O)NC2=CC(=CC=C2)Cl
DM1VLMC IK WUPWWTKSYQSCFQ-UHFFFAOYSA-N
DM1VLMC IU 1-(3-chlorophenyl)-3-cyclohexylurea
DM1VLMC CA CAS 72802-45-0
DM1VLMC DE Discovery agent
DM6LWR2 ID DM6LWR2
DM6LWR2 DN 1-(3-chloropyridin-2-yl)-4-tosylpiperazine
DM6LWR2 HS Investigative
DM6LWR2 SN arylsulfonylpiperazine, 25; CHEMBL403685; SCHEMBL3217790; BDBM32553
DM6LWR2 DT Small molecular drug
DM6LWR2 PC 44237028
DM6LWR2 MW 351.9
DM6LWR2 FM C16H18ClN3O2S
DM6LWR2 IC InChI=1S/C16H18ClN3O2S/c1-13-4-6-14(7-5-13)23(21,22)20-11-9-19(10-12-20)16-15(17)3-2-8-18-16/h2-8H,9-12H2,1H3
DM6LWR2 CS CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl
DM6LWR2 IK DAJKQJMXMSAPCV-UHFFFAOYSA-N
DM6LWR2 IU 1-(3-chloropyridin-2-yl)-4-(4-methylphenyl)sulfonylpiperazine
DM6LWR2 DE Discovery agent
DM8DR1B ID DM8DR1B
DM8DR1B DN 1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea
DM8DR1B HS Investigative
DM8DR1B SN CHEMBL333482; AC1LABSI; 1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea; BDBM50133727; 1-(3-cyano-1-methylindol-6-yl)-3-phenylurea; 1-(3-Cyano-1-methyl-1H-indol-6-yl)-3-phenyl-urea
DM8DR1B DT Small molecular drug
DM8DR1B PC 510913
DM8DR1B MW 290.32
DM8DR1B FM C17H14N4O
DM8DR1B IC InChI=1S/C17H14N4O/c1-21-11-12(10-18)15-8-7-14(9-16(15)21)20-17(22)19-13-5-3-2-4-6-13/h2-9,11H,1H3,(H2,19,20,22)
DM8DR1B CS CN1C=C(C2=C1C=C(C=C2)NC(=O)NC3=CC=CC=C3)C#N
DM8DR1B IK DKHWZIZMXRFFLI-UHFFFAOYSA-N
DM8DR1B IU 1-(3-cyano-1-methylindol-6-yl)-3-phenylurea
DM8DR1B DE Discovery agent
DM9KTH6 ID DM9KTH6
DM9KTH6 DN 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea
DM9KTH6 HS Investigative
DM9KTH6 SN CHEMBL239558; 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea; SCHEMBL7488503
DM9KTH6 DT Small molecular drug
DM9KTH6 PC 44439692
DM9KTH6 MW 253.26
DM9KTH6 FM C14H11N3O2
DM9KTH6 IC InChI=1S/C14H11N3O2/c15-9-10-5-4-8-12(13(10)18)17-14(19)16-11-6-2-1-3-7-11/h1-8,18H,(H2,16,17,19)
DM9KTH6 CS C1=CC=C(C=C1)NC(=O)NC2=CC=CC(=C2O)C#N
DM9KTH6 IK JFGPRCHQZYGZRH-UHFFFAOYSA-N
DM9KTH6 IU 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea
DM9KTH6 DE Discovery agent
DMVTCGP ID DMVTCGP
DMVTCGP DN 1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid
DMVTCGP HS Investigative
DMVTCGP SN CHEMBL169728; 1-(3-CYANOPHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID; 1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid; SCHEMBL15579010; BDBM50098064; AKOS009563536
DMVTCGP DT Small molecular drug
DMVTCGP PC 43542927
DMVTCGP MW 213.19
DMVTCGP FM C11H7N3O2
DMVTCGP IC InChI=1S/C11H7N3O2/c12-5-8-2-1-3-10(4-8)14-7-9(6-13-14)11(15)16/h1-4,6-7H,(H,15,16)
DMVTCGP CS C1=CC(=CC(=C1)N2C=C(C=N2)C(=O)O)C#N
DMVTCGP IK FFNALGQEMPFZAF-UHFFFAOYSA-N
DMVTCGP IU 1-(3-cyanophenyl)pyrazole-4-carboxylic acid
DMVTCGP DE Discovery agent
DM18DB3 ID DM18DB3
DM18DB3 DN 1-(3-Fluorobenzyl)-1H-imidazole
DM18DB3 HS Investigative
DM18DB3 SN 1-(3-Fluorobenzyl)-1H-imidazole; 109485-43-0; 1H-Imidazole, 1-[(3-fluorophenyl)methyl]-; CHEMBL598390; ACMC-20mcbr; 1-(3-Fluorobenzyl)imidazole; N-(3-fluorobenzyl)-imidazole; SCHEMBL9747422; CTK0D5768; DTXSID10601148; CJNXVRZKOSWWND-UHFFFAOYSA-N; BDBM50307214; ZINC41391477; AKOS009098433
DM18DB3 DT Small molecular drug
DM18DB3 PC 19902087
DM18DB3 MW 176.19
DM18DB3 FM C10H9FN2
DM18DB3 IC InChI=1S/C10H9FN2/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7H2
DM18DB3 CS C1=CC(=CC(=C1)F)CN2C=CN=C2
DM18DB3 IK CJNXVRZKOSWWND-UHFFFAOYSA-N
DM18DB3 IU 1-[(3-fluorophenyl)methyl]imidazole
DM18DB3 CA CAS 109485-43-0
DM18DB3 DE Discovery agent
DM2SNR0 ID DM2SNR0
DM2SNR0 DN 1-(3-Fluoro-phenyl)-piperazine
DM2SNR0 HS Investigative
DM2SNR0 SN 1-(3-Fluorophenyl)piperazine; 3801-89-6; 1-(3-Fluoro-phenyl)-piperazine; Piperazine, 1-(3-fluorophenyl)-; 1-(3-fluorophenyl)-piperazine; CHEMBL269784; Piperazine,1-(3-fluorophenyl)-; EINECS 223-271-9; AC1Q4NBT; 3-fluorophenyl piperazine; (3-fluorophenyl)piperazine; AC1L2T0A; 4-(3-fluorophenyl)piperazine; N-(3-Fluorophenyl)piperazine; SCHEMBL315894; CTK4H9144; DTXSID40191426; MolPort-000-155-895; KIFCSMQTGWVMOD-UHFFFAOYSA-N; ZINC2529848; SBB089693; ANW-61692; 4877AB; BDBM50017455; AKOS000101159; FS-1513; KB-85106; AS-10296
DM2SNR0 DT Small molecular drug
DM2SNR0 PC 77418
DM2SNR0 MW 180.22
DM2SNR0 FM C10H13FN2
DM2SNR0 IC InChI=1S/C10H13FN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
DM2SNR0 CS C1CN(CCN1)C2=CC(=CC=C2)F
DM2SNR0 IK KIFCSMQTGWVMOD-UHFFFAOYSA-N
DM2SNR0 IU 1-(3-fluorophenyl)piperazine
DM2SNR0 CA CAS 3801-89-6
DM2SNR0 DE Discovery agent
DMWFU3T ID DMWFU3T
DMWFU3T DN 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine
DMWFU3T HS Investigative
DMWFU3T SN 85386-90-9; 1-(3-fluoropyridin-2-yl)-4-methylpiperazine; CHEMBL280514; 1-Methyl-4-(3-fluoro-2-pyridinyl)piperazine; 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine; Piperazine, 1-(3-Fluoro-2-pyridinyl)-4-methyl- (9ci); SCHEMBL10964078; KZNJAAWCEFRAPW-UHFFFAOYSA-N; ZINC36237989; BDBM50026633; AKOS025286419; AM87258
DMWFU3T DT Small molecular drug
DMWFU3T PC 13298530
DMWFU3T MW 195.24
DMWFU3T FM C10H14FN3
DMWFU3T IC InChI=1S/C10H14FN3/c1-13-5-7-14(8-6-13)10-9(11)3-2-4-12-10/h2-4H,5-8H2,1H3
DMWFU3T CS CN1CCN(CC1)C2=C(C=CC=N2)F
DMWFU3T IK KZNJAAWCEFRAPW-UHFFFAOYSA-N
DMWFU3T IU 1-(3-fluoropyridin-2-yl)-4-methylpiperazine
DMWFU3T DE Discovery agent
DMQHFOX ID DMQHFOX
DMQHFOX DN 1-(3-Hydroxyphenyl)-4-propylpiperazine
DMQHFOX HS Investigative
DMQHFOX SN CHEMBL447809; 1-(3-Hydroxyphenyl)-4-propylpiperazine; SCHEMBL3453730; AWROKCIGUWAVRF-UHFFFAOYSA-N; 3-(4-Propyl-1-piperazinyl)phenol; BDBM50308023
DMQHFOX DT Small molecular drug
DMQHFOX PC 22397846
DMQHFOX MW 220.31
DMQHFOX FM C13H20N2O
DMQHFOX IC InChI=1S/C13H20N2O/c1-2-6-14-7-9-15(10-8-14)12-4-3-5-13(16)11-12/h3-5,11,16H,2,6-10H2,1H3
DMQHFOX CS CCCN1CCN(CC1)C2=CC(=CC=C2)O
DMQHFOX IK AWROKCIGUWAVRF-UHFFFAOYSA-N
DMQHFOX IU 3-(4-propylpiperazin-1-yl)phenol
DMQHFOX DE Discovery agent
DMPEZ1V ID DMPEZ1V
DMPEZ1V DN 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPEZ1V HS Investigative
DMPEZ1V SN CHEMBL426304; 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4938442
DMPEZ1V DT Small molecular drug
DMPEZ1V PC 11210506
DMPEZ1V MW 357.23
DMPEZ1V FM C15H20INO
DMPEZ1V IC InChI=1S/C15H20INO/c1-2-6-14(17-9-3-4-10-17)15(18)12-7-5-8-13(16)11-12/h5,7-8,11,14H,2-4,6,9-10H2,1H3
DMPEZ1V CS CCCC(C(=O)C1=CC(=CC=C1)I)N2CCCC2
DMPEZ1V IK NYDUTEZMPZHSRY-UHFFFAOYSA-N
DMPEZ1V IU 1-(3-iodophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMPEZ1V DE Discovery agent
DM30M9H ID DM30M9H
DM30M9H DN 1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione
DM30M9H HS Investigative
DM30M9H SN CHEMBL324722; 1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione; BDBM50133632; AKOS000245789; VU0238422-1; 1-(3-methoxybenzyl)-5-methylindoline-2,3-dione; 1-(3-methoxybenzyl)-5-methyl-1h-indole-2,3-dione
DM30M9H DT Small molecular drug
DM30M9H PC 25798544
DM30M9H MW 281.3
DM30M9H FM C17H15NO3
DM30M9H IC InChI=1S/C17H15NO3/c1-11-6-7-15-14(8-11)16(19)17(20)18(15)10-12-4-3-5-13(9-12)21-2/h3-9H,10H2,1-2H3
DM30M9H CS CC1=CC2=C(C=C1)N(C(=O)C2=O)CC3=CC(=CC=C3)OC
DM30M9H IK ZSPZSZMUOMBLFZ-UHFFFAOYSA-N
DM30M9H IU 1-[(3-methoxyphenyl)methyl]-5-methylindole-2,3-dione
DM30M9H DE Discovery agent
DM16U5F ID DM16U5F
DM16U5F DN 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole
DM16U5F HS Investigative
DM16U5F SN 1H-Imidazole, 1-(3-methoxy-2-naphthalenyl)-; 674309-81-0; CHEMBL194472; SCHEMBL4508354; BDBM8917; CTK1H7855; DTXSID70465102; Imidazole-substituted naphthalene 24; ZINC13674482; AKOS030619217; 1-(3-methoxy-2-naphthyl)-1h-imidazole
DM16U5F DT Small molecular drug
DM16U5F PC 11413434
DM16U5F MW 224.26
DM16U5F FM C14H12N2O
DM16U5F IC InChI=1S/C14H12N2O/c1-17-14-9-12-5-3-2-4-11(12)8-13(14)16-7-6-15-10-16/h2-10H,1H3
DM16U5F CS COC1=CC2=CC=CC=C2C=C1N3C=CN=C3
DM16U5F IK HDJQGQGNKJFUSV-UHFFFAOYSA-N
DM16U5F IU 1-(3-methoxynaphthalen-2-yl)imidazole
DM16U5F CA CAS 674309-81-0
DM16U5F DE Discovery agent
DMGU7MO ID DMGU7MO
DMGU7MO DN 1-(3-methoxyphenethyl)pyrrolidine
DMGU7MO HS Investigative
DMGU7MO SN CHEMBL404911; 1-(3-methoxyphenethyl)pyrrolidine; SCHEMBL10669091; JLMYWUJQHKXCOU-UHFFFAOYSA-N; 3-(2-pyrrolidin-1-ylethyl)anisole
DMGU7MO DT Small molecular drug
DMGU7MO PC 18365007
DMGU7MO MW 205.3
DMGU7MO FM C13H19NO
DMGU7MO IC InChI=1S/C13H19NO/c1-15-13-6-4-5-12(11-13)7-10-14-8-2-3-9-14/h4-6,11H,2-3,7-10H2,1H3
DMGU7MO CS COC1=CC=CC(=C1)CCN2CCCC2
DMGU7MO IK JLMYWUJQHKXCOU-UHFFFAOYSA-N
DMGU7MO IU 1-[2-(3-methoxyphenyl)ethyl]pyrrolidine
DMGU7MO DE Discovery agent
DMR0ICB ID DMR0ICB
DMR0ICB DN 1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone
DMR0ICB HS Investigative
DMR0ICB SN CHEMBL393079; 1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone; BDBM50212534
DMR0ICB DT Small molecular drug
DMR0ICB PC 16750524
DMR0ICB MW 290.3
DMR0ICB FM C15H14O4S
DMR0ICB IC InChI=1S/C15H14O4S/c1-19-13-7-5-6-12(10-13)15(16)11-20(17,18)14-8-3-2-4-9-14/h2-10H,11H2,1H3
DMR0ICB CS COC1=CC=CC(=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2
DMR0ICB IK HHEJEAZSXBXRPO-UHFFFAOYSA-N
DMR0ICB IU 2-(benzenesulfonyl)-1-(3-methoxyphenyl)ethanone
DMR0ICB DE Discovery agent
DMI15LJ ID DMI15LJ
DMI15LJ DN 1-(3-Methylbutylidene)thiosemicarbazide
DMI15LJ HS Investigative
DMI15LJ SN CHEMBL467890; isobutyraldehyde-thiosemicarbazone; 1-(3-Methylbutylidene)thiosemicarbazide; AC1NYENJ; ZINC5452593; BDBM50268195; AKOS032954865
DMI15LJ DT Small molecular drug
DMI15LJ PC 5828118
DMI15LJ MW 145.23
DMI15LJ FM C5H11N3S
DMI15LJ IC InChI=1S/C5H11N3S/c1-4(2)3-7-8-5(6)9/h3-4H,1-2H3,(H3,6,8,9)/b7-3-
DMI15LJ CS CC(C)/C=N\\NC(=S)N
DMI15LJ IK ISGCVMPYARLSFM-CLTKARDFSA-N
DMI15LJ IU [(Z)-2-methylpropylideneamino]thiourea
DMI15LJ DE Discovery agent
DMB9T6F ID DMB9T6F
DMB9T6F DN 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMB9T6F HS Investigative
DMB9T6F SN CHEMBL204254; 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4939486
DMB9T6F DT Small molecular drug
DMB9T6F PC 11470616
DMB9T6F MW 245.36
DMB9T6F FM C16H23NO
DMB9T6F IC InChI=1S/C16H23NO/c1-3-7-15(17-10-4-5-11-17)16(18)14-9-6-8-13(2)12-14/h6,8-9,12,15H,3-5,7,10-11H2,1-2H3
DMB9T6F CS CCCC(C(=O)C1=CC=CC(=C1)C)N2CCCC2
DMB9T6F IK HHSYAWUBPBEDMP-UHFFFAOYSA-N
DMB9T6F IU 1-(3-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one
DMB9T6F DE Discovery agent
DMYH9M0 ID DMYH9M0
DMYH9M0 DN 1-(3-methylpyridin-2-yl)-4-tosylpiperazine
DMYH9M0 HS Investigative
DMYH9M0 SN arylsulfonylpiperazine, 24; CHEMBL257782
DMYH9M0 DT Small molecular drug
DMYH9M0 PC 44237027
DMYH9M0 MW 331.4
DMYH9M0 FM C17H21N3O2S
DMYH9M0 IC InChI=1S/C17H21N3O2S/c1-14-5-7-16(8-6-14)23(21,22)20-12-10-19(11-13-20)17-15(2)4-3-9-18-17/h3-9H,10-13H2,1-2H3
DMYH9M0 CS CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)C
DMYH9M0 IK VJVLLYXNCKJIIY-UHFFFAOYSA-N
DMYH9M0 IU 1-(4-methylphenyl)sulfonyl-4-(3-methylpyridin-2-yl)piperazine
DMYH9M0 DE Discovery agent
DM3RGLE ID DM3RGLE
DM3RGLE DN 1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine
DM3RGLE HS Investigative
DM3RGLE SN CHEMBL329730; 1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine; BDBM50027293
DM3RGLE DT Small molecular drug
DM3RGLE PC 44332057
DM3RGLE MW 294.31
DM3RGLE FM C16H14N4O2
DM3RGLE IC InChI=1S/C16H14N4O2/c17-16(18)13-4-5-15-12(9-13)6-7-19(15)10-11-2-1-3-14(8-11)20(21)22/h1-9H,10H2,(H3,17,18)
DM3RGLE CS C1=CC(=CC(=C1)[N+](=O)[O-])CN2C=CC3=C2C=CC(=C3)C(=N)N
DM3RGLE IK SHTQZODGNRZEIP-UHFFFAOYSA-N
DM3RGLE IU 1-[(3-nitrophenyl)methyl]indole-5-carboximidamide
DM3RGLE DE Discovery agent
DMMJC5E ID DMMJC5E
DMMJC5E DN 1-(3-Nitro-phenyl)-piperazine
DMMJC5E HS Investigative
DMMJC5E SN 1-(3-nitrophenyl)piperazine; 54054-85-2; 1-(3-Nitro-phenyl)-piperazine; 1-(3-nitrophenyl)-piperazine; CHEMBL267153; Piperazine, 1-(3-nitrophenyl)-; (3-nitrophenyl)piperazine; 3-nitrophenylpiperazine; AC1Q1X8X; AC1MC26R; SCHEMBL519878; Piperazine,1-(3-nitrophenyl)-; CTK4J9414; DTXSID20375060; MolPort-000-005-114; LHHZRIYUOZPKSG-UHFFFAOYSA-N; ZINC4244898; SBB055462; CN-052; BDBM50017449; ANW-49084; AKOS003587736; CS-W019388; MCULE-2930089958; BR-49879; AN-40610; KB-63925; AJ-49640; RT-006025; DB-024583; AB0025386; W6842; FT-0660276
DMMJC5E DT Small molecular drug
DMMJC5E PC 2760216
DMMJC5E MW 207.23
DMMJC5E FM C10H13N3O2
DMMJC5E IC InChI=1S/C10H13N3O2/c14-13(15)10-3-1-2-9(8-10)12-6-4-11-5-7-12/h1-3,8,11H,4-7H2
DMMJC5E CS C1CN(CCN1)C2=CC(=CC=C2)[N+](=O)[O-]
DMMJC5E IK LHHZRIYUOZPKSG-UHFFFAOYSA-N
DMMJC5E IU 1-(3-nitrophenyl)piperazine
DMMJC5E CA CAS 54054-85-2
DMMJC5E DE Discovery agent
DM3FP6J ID DM3FP6J
DM3FP6J DN 1-(3-nitropyridin-2-yl)-4-tosylpiperazine
DM3FP6J HS Investigative
DM3FP6J SN AC1PKJ5N; arylsulfonylpiperazine, 26; CHEMBL257825; BDBM32554; MolPort-005-603-659; 1-(4-methylphenyl)sulfonyl-4-(3-nitropyridin-2-yl)piperazine; ZINC24082236; AKOS034151568; MCULE-2914079043; AB00774122-01; Z31097365; 1-(4-methylbenzenesulfonyl)-4-(3-nitropyridin-2-yl)piperazine
DM3FP6J DT Small molecular drug
DM3FP6J PC 9111347
DM3FP6J MW 362.4
DM3FP6J FM C16H18N4O4S
DM3FP6J IC InChI=1S/C16H18N4O4S/c1-13-4-6-14(7-5-13)25(23,24)19-11-9-18(10-12-19)16-15(20(21)22)3-2-8-17-16/h2-8H,9-12H2,1H3
DM3FP6J CS CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)[N+](=O)[O-]
DM3FP6J IK JYSIWWVOXFISJK-UHFFFAOYSA-N
DM3FP6J IU 1-(4-methylphenyl)sulfonyl-4-(3-nitropyridin-2-yl)piperazine
DM3FP6J DE Discovery agent
DMEMHIF ID DMEMHIF
DMEMHIF DN 1-(3-Oxocyclohexylidene)thiosemicarbazide
DMEMHIF HS Investigative
DMEMHIF DT Small molecular drug
DMEMHIF PC 91935109
DMEMHIF MW 185.25
DMEMHIF FM C7H11N3OS
DMEMHIF IC InChI=1S/C7H11N3OS/c8-7(12)10-9-5-2-1-3-6(11)4-5/h4,9H,1-3H2,(H3,8,10,12)
DMEMHIF CS C1CC(=CC(=O)C1)NNC(=S)N
DMEMHIF IK DGPXORDYODTKDF-UHFFFAOYSA-N
DMEMHIF IU [(3-oxocyclohexen-1-yl)amino]thiourea
DMEMHIF DE Discovery agent
DMG8DLM ID DMG8DLM
DMG8DLM DN 1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine
DMG8DLM HS Investigative
DMG8DLM SN CHEMBL428756; 1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine
DMG8DLM DT Small molecular drug
DMG8DLM PC 24744901
DMG8DLM MW 302.5
DMG8DLM FM C19H30N2O
DMG8DLM IC InChI=1S/C19H30N2O/c1-3-8-19(9-4-1)22-17-7-12-20-15-10-18(11-16-20)21-13-5-2-6-14-21/h1,3-4,8-9,18H,2,5-7,10-17H2
DMG8DLM CS C1CCN(CC1)C2CCN(CC2)CCCOC3=CC=CC=C3
DMG8DLM IK GCJKCPQHXFIKIF-UHFFFAOYSA-N
DMG8DLM IU 1-(3-phenoxypropyl)-4-piperidin-1-ylpiperidine
DMG8DLM DE Discovery agent
DMFPUGV ID DMFPUGV
DMFPUGV DN 1-(3-Phenylallylidene)thiosemicarbazide
DMFPUGV HS Investigative
DMFPUGV SN Cinnamaldehyde thiosemicarbazone; CHEMBL388025; 5351-70-2; 1-(3-Phenylallylidene)thiosemicarbazide; AC1NVG31; Cinnamaldehydethiosemicarbazone; 3-Phenylpropenalthiosemicarbazone; BDBM50241213; ZINC11536050; 3-phenylacrylaldehyde thiosemicarbazone; AKOS023092594; (Z)-1-((E)-3-phenylallylidene)thiosemicarbazide; AF-960/00472016; [(Z)-[(E)-3-phenylprop-2-enylidene]amino]thiourea; F3111-2831; N'-[(3-phenylprop-2-en-1-ylidene)amino]carbamimidothioic acid; (1Z,N'Z)-N'-((E)-3-phenylallylidene)carbamohydrazonothioic acid
DMFPUGV DT Small molecular drug
DMFPUGV PC 5559203
DMFPUGV MW 205.28
DMFPUGV FM C10H11N3S
DMFPUGV IC InChI=1S/C10H11N3S/c11-10(14)13-12-8-4-7-9-5-2-1-3-6-9/h1-8H,(H3,11,13,14)/b7-4+,12-8-
DMFPUGV CS C1=CC=C(C=C1)/C=C/C=N\\NC(=S)N
DMFPUGV IK SHUQFXIRXYXNOZ-JHLWKMQHSA-N
DMFPUGV IU [(Z)-[(E)-3-phenylprop-2-enylidene]amino]thiourea
DMFPUGV DE Discovery agent
DMPAWFJ ID DMPAWFJ
DMPAWFJ DN 1-(3-phenylpropyl)-1H-imidazole
DMPAWFJ HS Investigative
DMPAWFJ SN 1-(3-phenylpropyl)-1H-imidazole; CHEMBL380271; 1-(3-phenylpropyl)imidazole; 1H-Imidazole, 1-(3-phenylpropyl)-; SCHEMBL3160306; DDGQVFKVBFAACE-UHFFFAOYSA-N; BDBM50191796; AKOS009137296
DMPAWFJ DT Small molecular drug
DMPAWFJ PC 9989980
DMPAWFJ MW 186.25
DMPAWFJ FM C12H14N2
DMPAWFJ IC InChI=1S/C12H14N2/c1-2-5-12(6-3-1)7-4-9-14-10-8-13-11-14/h1-3,5-6,8,10-11H,4,7,9H2
DMPAWFJ CS C1=CC=C(C=C1)CCCN2C=CN=C2
DMPAWFJ IK DDGQVFKVBFAACE-UHFFFAOYSA-N
DMPAWFJ IU 1-(3-phenylpropyl)imidazole
DMPAWFJ CA CAS 56643-92-6
DMPAWFJ DE Discovery agent
DM37RI9 ID DM37RI9
DM37RI9 DN 1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea
DM37RI9 HS Investigative
DM37RI9 SN Thiourea, N-(3-phenylpropyl)-N'-2-thiazolyl-; 149485-04-1; AC1MHDKJ; SCHEMBL6959149; CHEMBL145260; DTXSID10164283; AYXFDRTXLUHLOL-UHFFFAOYSA-N; ZINC12354016; AKOS030030954; N-(3-Phenylpropyl)-N'-(2-thiazolyl)thiourea; 1-(3-phenylpropyl)-3-thiazol-2-yl-thiourea; N-(3-Phenylpropyl)-N'-(2-thiazolyl) thiourea
DM37RI9 DT Small molecular drug
DM37RI9 PC 3001100
DM37RI9 MW 277.4
DM37RI9 FM C13H15N3S2
DM37RI9 IC InChI=1S/C13H15N3S2/c17-12(16-13-15-9-10-18-13)14-8-4-7-11-5-2-1-3-6-11/h1-3,5-6,9-10H,4,7-8H2,(H2,14,15,16,17)
DM37RI9 CS C1=CC=C(C=C1)CCCNC(=S)NC2=NC=CS2
DM37RI9 IK AYXFDRTXLUHLOL-UHFFFAOYSA-N
DM37RI9 IU 1-(3-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
DM37RI9 CA CAS 149485-04-1
DM37RI9 DE Discovery agent
DMZPJM4 ID DMZPJM4
DMZPJM4 DN 1-(3-tritylaminopropyl)uracil
DMZPJM4 HS Investigative
DMZPJM4 SN CHEMBL211905; 1-(3-tritylaminopropyl)uracil; 1-[3-(tritylamino)propyl]pyrimidine-2,4-dione; SCHEMBL913253
DMZPJM4 DT Small molecular drug
DMZPJM4 PC 11589642
DMZPJM4 MW 411.5
DMZPJM4 FM C26H25N3O2
DMZPJM4 IC InChI=1S/C26H25N3O2/c30-24-17-20-29(25(31)28-24)19-10-18-27-26(21-11-4-1-5-12-21,22-13-6-2-7-14-22)23-15-8-3-9-16-23/h1-9,11-17,20,27H,10,18-19H2,(H,28,30,31)
DMZPJM4 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)NCCCN4C=CC(=O)NC4=O
DMZPJM4 IK FFJOPHQHIVRWNN-UHFFFAOYSA-N
DMZPJM4 IU 1-[3-(tritylamino)propyl]pyrimidine-2,4-dione
DMZPJM4 DE Discovery agent
DMUDVRM ID DMUDVRM
DMUDVRM DN 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine
DMUDVRM HS Investigative
DMUDVRM SN CHEMBL210318; 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine; MolPort-009-381-113; ZINC12523427; BDBM50184798; AKOS033005282; MCULE-2217757517; Z104379906; 1-phenyl-4-{[4-(1H-pyrazol-1-yl)phenyl]methyl}piperazine
DMUDVRM DT Small molecular drug
DMUDVRM PC 25333445
DMUDVRM MW 318.4
DMUDVRM FM C20H22N4
DMUDVRM IC InChI=1S/C20H22N4/c1-2-5-19(6-3-1)23-15-13-22(14-16-23)17-18-7-9-20(10-8-18)24-12-4-11-21-24/h1-12H,13-17H2
DMUDVRM CS C1CN(CCN1CC2=CC=C(C=C2)N3C=CC=N3)C4=CC=CC=C4
DMUDVRM IK PKQSDHHTBMYENT-UHFFFAOYSA-N
DMUDVRM IU 1-phenyl-4-[(4-pyrazol-1-ylphenyl)methyl]piperazine
DMUDVRM DE Discovery agent
DMYIK9W ID DMYIK9W
DMYIK9W DN 1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea
DMYIK9W HS Investigative
DMYIK9W SN CHEMBL561382; 1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea; SCHEMBL4256144; HTAZKQMMJVVVSK-UHFFFAOYSA-N; BDBM50296222
DMYIK9W DT Small molecular drug
DMYIK9W PC 25014697
DMYIK9W MW 355.4
DMYIK9W FM C20H25N3O3
DMYIK9W IC InChI=1S/C20H25N3O3/c24-20(21-17-5-2-1-3-6-17)22-18-7-9-19(10-8-18)26-14-4-11-23-12-15-25-16-13-23/h1-3,5-10H,4,11-16H2,(H2,21,22,24)
DMYIK9W CS C1COCCN1CCCOC2=CC=C(C=C2)NC(=O)NC3=CC=CC=C3
DMYIK9W IK HTAZKQMMJVVVSK-UHFFFAOYSA-N
DMYIK9W IU 1-[4-(3-morpholin-4-ylpropoxy)phenyl]-3-phenylurea
DMYIK9W DE Discovery agent
DMM18AQ ID DMM18AQ
DMM18AQ DN 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one
DMM18AQ HS Investigative
DMM18AQ SN CHEMBL394080; 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one; BDBM50216042; 1,3-Dihydro-1-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2H-indole-2-one
DMM18AQ DT Small molecular drug
DMM18AQ PC 10667433
DMM18AQ MW 379.5
DMM18AQ FM C23H29N3O2
DMM18AQ IC InChI=1S/C23H29N3O2/c1-28-22-11-5-4-10-21(22)25-16-14-24(15-17-25)12-6-7-13-26-20-9-3-2-8-19(20)18-23(26)27/h2-5,8-11H,6-7,12-18H2,1H3
DMM18AQ CS COC1=CC=CC=C1N2CCN(CC2)CCCCN3C(=O)CC4=CC=CC=C43
DMM18AQ IK VJMHUOSOEAGNQW-UHFFFAOYSA-N
DMM18AQ IU 1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-3H-indol-2-one
DMM18AQ DE Discovery agent
DMT3H0K ID DMT3H0K
DMT3H0K DN 1-(4-(benzyloxy)phenethyl)pyrrolidine
DMT3H0K HS Investigative
DMT3H0K SN CHEMBL271661
DMT3H0K DT Small molecular drug
DMT3H0K PC 44455916
DMT3H0K MW 281.4
DMT3H0K FM C19H23NO
DMT3H0K IC InChI=1S/C19H23NO/c1-2-6-18(7-3-1)16-21-19-10-8-17(9-11-19)12-15-20-13-4-5-14-20/h1-3,6-11H,4-5,12-16H2
DMT3H0K CS C1CCN(C1)CCC2=CC=C(C=C2)OCC3=CC=CC=C3
DMT3H0K IK VREWPTOWOFJSKF-UHFFFAOYSA-N
DMT3H0K IU 1-[2-(4-phenylmethoxyphenyl)ethyl]pyrrolidine
DMT3H0K DE Discovery agent
DM7FWK8 ID DM7FWK8
DM7FWK8 DN 1-(4-(benzyloxy)phenyl)-3-hydroxyurea
DM7FWK8 HS Investigative
DM7FWK8 SN CHEMBL259768
DM7FWK8 DT Small molecular drug
DM7FWK8 PC 11637459
DM7FWK8 MW 258.269
DM7FWK8 FM C14H14N2O3
DM7FWK8 IC InChI=1S/C14H14N2O3/c17-14(16-18)15-12-6-8-13(9-7-12)19-10-11-4-2-1-3-5-11/h1-9,18H,10H2,(H2,15,16,17)
DM7FWK8 CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)NO
DM7FWK8 IK PQXBDBGXKAZUEX-UHFFFAOYSA-N
DM7FWK8 IU 1-hydroxy-3-(4-phenylmethoxyphenyl)urea
DM7FWK8 DE Discovery agent
DMT81N3 ID DMT81N3
DMT81N3 DN 1-(4-(benzyloxy)phenyl)propan-2-amine
DMT81N3 HS Investigative
DMT81N3 SN 4-Benzyloxyamphetamine; 1-(4-phenylmethoxyphenyl)propan-2-amine; CHEMBL456013; 7176-39-8; ZDZASCUBDMUTSR-UHFFFAOYSA-N; p-benzyloxyamphetamine; 1-(4-(benzyloxy)phenyl)propan-2-amine; Phenethylamine, p-(benzyloxy)-alpha-methyl-; alpha-Methyl-4-(phenylmethoxy)benzeneethanamine; AC1L34WV; Benzeneethanamine, alpha-methyl-4-(phenylmethoxy)-; SCHEMBL2750286; AC1Q56Y9; CTK2H7369; BDBM50276775; AKOS022489255; AKOS000152896; 1-(4-phenylmethoxyphenyl)-2-propanamine; 1-Methyl-2-(4-benzyloxyphenyl)ethanamine
DMT81N3 DT Small molecular drug
DMT81N3 PC 134616
DMT81N3 MW 241.33
DMT81N3 FM C16H19NO
DMT81N3 IC InChI=1S/C16H19NO/c1-13(17)11-14-7-9-16(10-8-14)18-12-15-5-3-2-4-6-15/h2-10,13H,11-12,17H2,1H3
DMT81N3 CS CC(CC1=CC=C(C=C1)OCC2=CC=CC=C2)N
DMT81N3 IK ZDZASCUBDMUTSR-UHFFFAOYSA-N
DMT81N3 IU 1-(4-phenylmethoxyphenyl)propan-2-amine
DMT81N3 CA CAS 7176-39-8
DMT81N3 DE Discovery agent
DMLODAM ID DMLODAM
DMLODAM DN 1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one
DMLODAM HS Investigative
DMLODAM SN CHEMBL561245; 1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one
DMLODAM DT Small molecular drug
DMLODAM PC 24843916
DMLODAM MW 319.4
DMLODAM FM C19H29NO3
DMLODAM IC InChI=1S/C19H29NO3/c1-2-3-4-5-14-23-18-8-6-17(7-9-18)19(21)10-11-20-12-15-22-16-13-20/h6-9H,2-5,10-16H2,1H3
DMLODAM CS CCCCCCOC1=CC=C(C=C1)C(=O)CCN2CCOCC2
DMLODAM IK VJZCZCUEZMGVCL-UHFFFAOYSA-N
DMLODAM IU 1-(4-hexoxyphenyl)-3-morpholin-4-ylpropan-1-one
DMLODAM DE Discovery agent
DMCE7G0 ID DMCE7G0
DMCE7G0 DN 1-(4-(methylsulfonyl)phenyl)-1H-indole
DMCE7G0 HS Investigative
DMCE7G0 SN CHEMBL1240964; 1-(4-(methylsulfonyl)phenyl)-1H-indole; 1-[4-(Methylsulfonyl)phenyl]-1H-indole; ZINC64475267
DMCE7G0 DT Small molecular drug
DMCE7G0 PC 11958319
DMCE7G0 MW 271.3
DMCE7G0 FM C15H13NO2S
DMCE7G0 IC InChI=1S/C15H13NO2S/c1-19(17,18)14-8-6-13(7-9-14)16-11-10-12-4-2-3-5-15(12)16/h2-11H,1H3
DMCE7G0 CS CS(=O)(=O)C1=CC=C(C=C1)N2C=CC3=CC=CC=C32
DMCE7G0 IK XRGCFRFZQVGLLT-UHFFFAOYSA-N
DMCE7G0 IU 1-(4-methylsulfonylphenyl)indole
DMCE7G0 DE Discovery agent
DMYFBRQ ID DMYFBRQ
DMYFBRQ DN 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole
DMYFBRQ HS Investigative
DMYFBRQ SN CHEMBL1240963; 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole; 1-[4-(Methylsulfonyl)phenyl]-1H-pyrrole; ZINC35120168; BDBM50326521; AKOS008961779; 1-(4-methanesulfonylphenyl)-1H-pyrrole
DMYFBRQ DT Small molecular drug
DMYFBRQ PC 22316981
DMYFBRQ MW 221.28
DMYFBRQ FM C11H11NO2S
DMYFBRQ IC InChI=1S/C11H11NO2S/c1-15(13,14)11-6-4-10(5-7-11)12-8-2-3-9-12/h2-9H,1H3
DMYFBRQ CS CS(=O)(=O)C1=CC=C(C=C1)N2C=CC=C2
DMYFBRQ IK NIVLUABJSRHBFE-UHFFFAOYSA-N
DMYFBRQ IU 1-(4-methylsulfonylphenyl)pyrrole
DMYFBRQ DE Discovery agent
DMH7RY0 ID DMH7RY0
DMH7RY0 DN 1-(4-(methylsulfonyl)phenyl)-3-phenylurea
DMH7RY0 HS Investigative
DMH7RY0 SN CHEMBL252433; 1-(4-(methylsulfonyl)phenyl)-3-phenylurea; 1-[4-(methylsulfonyl)phenyl]-3-phenylurea; SCHEMBL9913187; MolPort-019-692-584; STL012316; ZINC29038894; BDBM50233182; AKOS005673001
DMH7RY0 DT Small molecular drug
DMH7RY0 PC 44447099
DMH7RY0 MW 290.34
DMH7RY0 FM C14H14N2O3S
DMH7RY0 IC InChI=1S/C14H14N2O3S/c1-20(18,19)13-9-7-12(8-10-13)16-14(17)15-11-5-3-2-4-6-11/h2-10H,1H3,(H2,15,16,17)
DMH7RY0 CS CS(=O)(=O)C1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2
DMH7RY0 IK BNCVKEKVEUVIPN-UHFFFAOYSA-N
DMH7RY0 IU 1-(4-methylsulfonylphenyl)-3-phenylurea
DMH7RY0 DE Discovery agent
DMMSQLC ID DMMSQLC
DMMSQLC DN 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea
DMMSQLC HS Investigative
DMMSQLC SN CHEMBL253402; 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea; SCHEMBL12793734
DMMSQLC DT Small molecular drug
DMMSQLC PC 44447102
DMMSQLC MW 304.4
DMMSQLC FM C15H16N2O3S
DMMSQLC IC InChI=1S/C15H16N2O3S/c1-11-3-5-12(6-4-11)16-15(18)17-13-7-9-14(10-8-13)21(2,19)20/h3-10H,1-2H3,(H2,16,17,18)
DMMSQLC CS CC1=CC=C(C=C1)NC(=O)NC2=CC=C(C=C2)S(=O)(=O)C
DMMSQLC IK ZWDYDUJTBVZZLR-UHFFFAOYSA-N
DMMSQLC IU 1-(4-methylphenyl)-3-(4-methylsulfonylphenyl)urea
DMMSQLC DE Discovery agent
DM170BV ID DM170BV
DM170BV DN 1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one
DM170BV HS Investigative
DM170BV SN CHEMBL461543; 1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162586
DM170BV DT Small molecular drug
DM170BV PC 44554446
DM170BV MW 299.4
DM170BV FM C18H21NO3
DM170BV IC InChI=1S/C18H21NO3/c1-14(20)16-13-22-18(19-16)17(21)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DM170BV CS CC(=O)C1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DM170BV IK YLVGVXYZOJMUNJ-UHFFFAOYSA-N
DM170BV IU 1-(4-acetyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DM170BV DE Discovery agent
DMOZAM6 ID DMOZAM6
DMOZAM6 DN 1-(4-Aminobenzyl)-1H-imidazole
DMOZAM6 HS Investigative
DMOZAM6 SN 56643-85-7; 4-Imidazol-1-ylmethylphenylamine; 4-(1H-imidazol-1-ylmethyl)aniline; 4-((1H-imidazol-1-yl)methyl)aniline; 4-(imidazol-1-ylmethyl)aniline; 4-[(1-Imidazolyl)methyl]aniline; 4-Imidazol-1-ylmethyl-phenylamine; 4-[(1H-Imidazol-1-yl)methyl]aniline; 1-(4-Aminobenzyl)imidazole; CHEMBL598389; 4-(imidazolylmethyl)phenylamine; Benzenamine, 4-(1H-imidazol-1-ylmethyl)-; 1-(4-Aminobenzyl)-1H-imidazole; BAS 06504682; AC1LOLP2; SCHEMBL77025; AC1Q520P; CTK5A5496; DTXSID40361425; 4-(imidazol-1-yl)methyl-aniline
DMOZAM6 DT Small molecular drug
DMOZAM6 PC 1265319
DMOZAM6 MW 173.21
DMOZAM6 FM C10H11N3
DMOZAM6 IC InChI=1S/C10H11N3/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7,11H2
DMOZAM6 CS C1=CC(=CC=C1CN2C=CN=C2)N
DMOZAM6 IK DGHAOTHIDTUSJY-UHFFFAOYSA-N
DMOZAM6 IU 4-(imidazol-1-ylmethyl)aniline
DMOZAM6 CA CAS 56643-85-7
DMOZAM6 DE Discovery agent
DMMYT4W ID DMMYT4W
DMMYT4W DN 1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone
DMMYT4W HS Investigative
DMMYT4W SN 1-(4-aminophenyl)-2-(1h-imidazol-1-yl)ethanone; CHEMBL162431; AC1Q5E94; AC1L1F89; SCHEMBL9663730; BDBM50322067; AKOS022646799; 73932-42-0; 1-(4-aminophenyl)-2-imidazol-1-ylethanone; 1-(4-Amino-phenyl)-2-imidazol-1-yl-ethanone; alpha-(1H-Imidazole-1-yl)-4'-aminoacetophenone; Ethanone, 1-(4-aminophenyl)-2-(1H-imidazol-1-yl)-
DMMYT4W DT Small molecular drug
DMMYT4W PC 53602
DMMYT4W MW 201.22
DMMYT4W FM C11H11N3O
DMMYT4W IC InChI=1S/C11H11N3O/c12-10-3-1-9(2-4-10)11(15)7-14-6-5-13-8-14/h1-6,8H,7,12H2
DMMYT4W CS C1=CC(=CC=C1C(=O)CN2C=CN=C2)N
DMMYT4W IK QRMNVYHFJCGDDI-UHFFFAOYSA-N
DMMYT4W IU 1-(4-aminophenyl)-2-imidazol-1-ylethanone
DMMYT4W DE Discovery agent
DMY7TDZ ID DMY7TDZ
DMY7TDZ DN 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMY7TDZ HS Investigative
DMY7TDZ SN CHEMBL555491; 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMY7TDZ DT Small molecular drug
DMY7TDZ PC 45268750
DMY7TDZ MW 246.35
DMY7TDZ FM C15H22N2O
DMY7TDZ IC InChI=1S/C15H22N2O/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11,16H2,1H3
DMY7TDZ CS CCCC(C(=O)C1=CC=C(C=C1)N)N2CCCC2
DMY7TDZ IK DUNXFOYJTLLKNQ-UHFFFAOYSA-N
DMY7TDZ IU 1-(4-aminophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMY7TDZ DE Discovery agent
DM4G0NH ID DM4G0NH
DM4G0NH DN 1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea
DM4G0NH HS Investigative
DM4G0NH SN CHEMBL497689; 4-Amino-N-[(2-Sulfanylethyl)carbamoyl]benzenesulfonamide; 1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea; BDBM50272611; DB08484; 1-(4-aminobenzenesulfonyl)-3-(2-sulfanylethyl)urea
DM4G0NH DT Small molecular drug
DM4G0NH PC 24856357
DM4G0NH MW 275.4
DM4G0NH FM C9H13N3O3S2
DM4G0NH IC InChI=1S/C9H13N3O3S2/c10-7-1-3-8(4-2-7)17(14,15)12-9(13)11-5-6-16/h1-4,16H,5-6,10H2,(H2,11,12,13)
DM4G0NH CS C1=CC(=CC=C1N)S(=O)(=O)NC(=O)NCCS
DM4G0NH IK LHVDNDIAMJOEKH-UHFFFAOYSA-N
DM4G0NH IU 1-(4-aminophenyl)sulfonyl-3-(2-sulfanylethyl)urea
DM4G0NH DE Discovery agent
DMWA6G1 ID DMWA6G1
DMWA6G1 DN 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene
DMWA6G1 HS Investigative
DMWA6G1 SN CHEMBL265444
DMWA6G1 DT Small molecular drug
DMWA6G1 PC 44452471
DMWA6G1 MW 258.3
DMWA6G1 FM C13H10N2O2S
DMWA6G1 IC InChI=1S/C13H10N2O2S/c14-18(16,17)13-8-5-11(6-9-13)4-7-12-3-1-2-10-15-12/h1-3,5-6,8-10H,(H2,14,16,17)
DMWA6G1 CS C1=CC=NC(=C1)C#CC2=CC=C(C=C2)S(=O)(=O)N
DMWA6G1 IK GZRBQSAJFPOMOT-UHFFFAOYSA-N
DMWA6G1 IU 4-(2-pyridin-2-ylethynyl)benzenesulfonamide
DMWA6G1 DE Discovery agent
DMP93E2 ID DMP93E2
DMP93E2 DN 1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene
DMP93E2 HS Investigative
DMP93E2 SN CHEMBL406989
DMP93E2 DT Small molecular drug
DMP93E2 PC 44452472
DMP93E2 MW 258.3
DMP93E2 FM C13H10N2O2S
DMP93E2 IC InChI=1S/C13H10N2O2S/c14-18(16,17)13-5-3-11(4-6-13)1-2-12-7-9-15-10-8-12/h3-10H,(H2,14,16,17)
DMP93E2 CS C1=CC(=CC=C1C#CC2=CC=NC=C2)S(=O)(=O)N
DMP93E2 IK WAURLAKEIUZSMJ-UHFFFAOYSA-N
DMP93E2 IU 4-(2-pyridin-4-ylethynyl)benzenesulfonamide
DMP93E2 DE Discovery agent
DMXV9S7 ID DMXV9S7
DMXV9S7 DN 1-(4-Benzylsulfanyl-phenyl)-propylamine
DMXV9S7 HS Investigative
DMXV9S7 SN CHEMBL1079057; 1-(4-Benzylsulfanyl-phenyl)-propylamine; BDBM50310833
DMXV9S7 DT Small molecular drug
DMXV9S7 PC 46882993
DMXV9S7 MW 257.399
DMXV9S7 FM C16H19NS
DMXV9S7 IC InChI=1S/C16H19NS/c1-13(17)11-14-7-9-16(10-8-14)18-12-15-5-3-2-4-6-15/h2-10,13H,11-12,17H2,1H3
DMXV9S7 CS CC(CC1=CC=C(C=C1)SCC2=CC=CC=C2)N
DMXV9S7 IK TXLRFCSLKMDOTM-UHFFFAOYSA-N
DMXV9S7 IU 1-(4-benzylsulfanylphenyl)propan-2-amine
DMXV9S7 DE Discovery agent
DMMLCSG ID DMMLCSG
DMMLCSG DN 1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane
DMMLCSG HS Investigative
DMMLCSG SN CHEMBL509461; 1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane
DMMLCSG DT Small molecular drug
DMMLCSG PC 44567544
DMMLCSG MW 250.08
DMMLCSG FM C9H10BrF2N
DMMLCSG IC InChI=1S/C9H10BrF2N/c1-5(13)2-6-3-9(12)7(10)4-8(6)11/h3-5H,2,13H2,1H3
DMMLCSG CS CC(CC1=CC(=C(C=C1F)Br)F)N
DMMLCSG IK TWIJKLXSGANTJL-UHFFFAOYSA-N
DMMLCSG IU 1-(4-bromo-2,5-difluorophenyl)propan-2-amine
DMMLCSG DE Discovery agent
DMCH6R1 ID DMCH6R1
DMCH6R1 DN 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine
DMCH6R1 HS Investigative
DMCH6R1 SN CHEMBL348140; AC1NHEA9; 1-(2,5-dimethoxy-4-bromophenyl)piperazine; Oprea1_700068; BDBM50226218; AKOS003587698; 100939-87-5
DMCH6R1 DT Small molecular drug
DMCH6R1 PC 4738744
DMCH6R1 MW 301.18
DMCH6R1 FM C12H17BrN2O2
DMCH6R1 IC InChI=1S/C12H17BrN2O2/c1-16-11-8-10(12(17-2)7-9(11)13)15-5-3-14-4-6-15/h7-8,14H,3-6H2,1-2H3
DMCH6R1 CS COC1=CC(=C(C=C1N2CCNCC2)OC)Br
DMCH6R1 IK JLAQUWGWRNMYGA-UHFFFAOYSA-N
DMCH6R1 IU 1-(4-bromo-2,5-dimethoxyphenyl)piperazine
DMCH6R1 DE Discovery agent
DM2C7U0 ID DM2C7U0
DM2C7U0 DN 1-(4-Bromobenzyl)-1H-imidazole
DM2C7U0 HS Investigative
DM2C7U0 SN 1-(4-bromobenzyl)-1H-imidazole; 72459-46-2; 1-(4-bromobenzyl)imidazole; 1H-Imidazole, 1-[(4-bromophenyl)methyl]-; CHEMBL211207; 1-[(4-bromophenyl)methyl]imidazole; 1H-Imidazole,1-[(4-bromophenyl)methyl]-; [(4-bromophenyl)methyl]imidazole; AC1MGP7Q; SCHEMBL707075; 1-(4Bromobenzyl)-1H-imidazole; KS-00000LSK; CTK5D6137; DTXSID20388130; MZJSYLIOMLCYIS-UHFFFAOYSA-N; MolPort-000-143-261; 1-(4bromo-benzyl)-1H-imidazole; HMS1603K13; CS-D0078; ZINC4810192; STK951803; ANW-63041; CB-660; SBB098736; BDBM50188088; AKOS002272497; RP05746
DM2C7U0 DT Small molecular drug
DM2C7U0 PC 2989557
DM2C7U0 MW 237.1
DM2C7U0 FM C10H9BrN2
DM2C7U0 IC InChI=1S/C10H9BrN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DM2C7U0 CS C1=CC(=CC=C1CN2C=CN=C2)Br
DM2C7U0 IK MZJSYLIOMLCYIS-UHFFFAOYSA-N
DM2C7U0 IU 1-[(4-bromophenyl)methyl]imidazole
DM2C7U0 CA CAS 72459-46-2
DM2C7U0 DE Discovery agent
DMTPD4R ID DMTPD4R
DMTPD4R DN 1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea
DMTPD4R HS Investigative
DMTPD4R SN quinazoline deriv., 20b; CHEMBL175831; BDBM20420
DMTPD4R DT Small molecular drug
DMTPD4R PC 11302766
DMTPD4R MW 357.2
DMTPD4R FM C16H13BrN4O
DMTPD4R IC InChI=1S/C16H13BrN4O/c17-13-6-4-11(5-7-13)8-19-16(22)21-14-3-1-2-12-9-18-10-20-15(12)14/h1-7,9-10H,8H2,(H2,19,21,22)
DMTPD4R CS C1=CC2=CN=CN=C2C(=C1)NC(=O)NCC3=CC=C(C=C3)Br
DMTPD4R IK HUPXBWYDCNIXNH-UHFFFAOYSA-N
DMTPD4R IU 1-[(4-bromophenyl)methyl]-3-quinazolin-8-ylurea
DMTPD4R DE Discovery agent
DMCW8RT ID DMCW8RT
DMCW8RT DN 1-(4-Bromobenzyl)-5-phenyl-1H-imidazole
DMCW8RT HS Investigative
DMCW8RT SN CHEMBL597173; 1-(4-Bromobenzyl)-5-phenyl-1H-imidazole; SCHEMBL3822956
DMCW8RT DT Small molecular drug
DMCW8RT PC 45103810
DMCW8RT MW 313.19
DMCW8RT FM C16H13BrN2
DMCW8RT IC InChI=1S/C16H13BrN2/c17-15-8-6-13(7-9-15)11-19-12-18-10-16(19)14-4-2-1-3-5-14/h1-10,12H,11H2
DMCW8RT CS C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)Br
DMCW8RT IK LHMVBZUXJAMAAP-UHFFFAOYSA-N
DMCW8RT IU 1-[(4-bromophenyl)methyl]-5-phenylimidazole
DMCW8RT DE Discovery agent
DMUMNYZ ID DMUMNYZ
DMUMNYZ DN 1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one
DMUMNYZ HS Investigative
DMUMNYZ SN CHEMBL448688; 1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162450
DMUMNYZ DT Small molecular drug
DMUMNYZ PC 44554272
DMUMNYZ MW 336.22
DMUMNYZ FM C16H18BrNO2
DMUMNYZ IC InChI=1S/C16H18BrNO2/c17-15-12-20-16(18-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMUMNYZ CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)Br
DMUMNYZ IK PCSNCSLGTDBRDM-UHFFFAOYSA-N
DMUMNYZ IU 1-(4-bromo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMUMNYZ DE Discovery agent
DME8B15 ID DME8B15
DME8B15 DN 1-(4-bromophenethyl)-1H-imidazole
DME8B15 HS Investigative
DME8B15 SN CHEMBL215320; 1-(4-bromophenethyl)-1H-imidazole; SCHEMBL6986190
DME8B15 DT Small molecular drug
DME8B15 PC 19371551
DME8B15 MW 251.12
DME8B15 FM C11H11BrN2
DME8B15 IC InChI=1S/C11H11BrN2/c12-11-3-1-10(2-4-11)5-7-14-8-6-13-9-14/h1-4,6,8-9H,5,7H2
DME8B15 CS C1=CC(=CC=C1CCN2C=CN=C2)Br
DME8B15 IK PAYXPBIBNFYADE-UHFFFAOYSA-N
DME8B15 IU 1-[2-(4-bromophenyl)ethyl]imidazole
DME8B15 DE Discovery agent
DMW6YDK ID DMW6YDK
DMW6YDK DN 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK HS Investigative
DMW6YDK SN CHEMBL566001; SCHEMBL770168; 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one; BDBM50302910; AKOS022330096
DMW6YDK DT Small molecular drug
DMW6YDK PC 44542509
DMW6YDK MW 284.19
DMW6YDK FM C13H18BrNO
DMW6YDK IC InChI=1S/C13H18BrNO/c1-9(15-13(2,3)4)12(16)10-5-7-11(14)8-6-10/h5-9,15H,1-4H3
DMW6YDK CS CC(C(=O)C1=CC=C(C=C1)Br)NC(C)(C)C
DMW6YDK IK QYLKSFXBRALDIS-UHFFFAOYSA-N
DMW6YDK IU 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
DMW6YDK DE Discovery agent
DMPLEC0 ID DMPLEC0
DMPLEC0 DN 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMPLEC0 HS Investigative
DMPLEC0 SN CHEMBL202420; 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one; 4-Bromo-alpha-pvp; SCHEMBL4937387; BDBM50182578; 4'-Bromo-alpha-pyrrolidinopentiophenone; 2-(Pyrrolidin-1-yl)-1-(4-bromophenyl)pentan-1-one; 1-Pentanone, 1-(4-bromophenyl)-2-(1-pyrrolidinyl)-; 1-(4-bromophenyl)-2-(pyrrolidin-1-yl)pentan-1-one
DMPLEC0 DT Small molecular drug
DMPLEC0 PC 11220599
DMPLEC0 MW 310.23
DMPLEC0 FM C15H20BrNO
DMPLEC0 IC InChI=1S/C15H20BrNO/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11H2,1H3
DMPLEC0 CS CCCC(C(=O)C1=CC=C(C=C1)Br)N2CCCC2
DMPLEC0 IK RAHKQMUBMIJUFG-UHFFFAOYSA-N
DMPLEC0 IU 1-(4-bromophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMPLEC0 CA CAS 850352-59-9
DMPLEC0 DE Discovery agent
DMEUHDL ID DMEUHDL
DMEUHDL DN 1-(4-bromophenyl)-3-hydroxyurea
DMEUHDL HS Investigative
DMEUHDL SN 1-(4-bromophenyl)-3-hydroxyurea; CHEMBL259767; 89677-50-9; AC1N5XPQ; AC1Q7DJ1; SCHEMBL5443582; QFELVVGTIKGYJL-UHFFFAOYSA-N; ZINC396739; N-(4-bromophenyl)-N'-hydroxyurea; BDBM50377111; AKOS024335516
DMEUHDL DT Small molecular drug
DMEUHDL PC 4251126
DMEUHDL MW 231.05
DMEUHDL FM C7H7BrN2O2
DMEUHDL IC InChI=1S/C7H7BrN2O2/c8-5-1-3-6(4-2-5)9-7(11)10-12/h1-4,12H,(H2,9,10,11)
DMEUHDL CS C1=CC(=CC=C1NC(=O)NO)Br
DMEUHDL IK QFELVVGTIKGYJL-UHFFFAOYSA-N
DMEUHDL IU 1-(4-bromophenyl)-3-hydroxyurea
DMEUHDL DE Discovery agent
DMOEGZV ID DMOEGZV
DMOEGZV DN 1-(4-Butoxy-phenyl)-1H-imidazole
DMOEGZV HS Investigative
DMOEGZV SN CHEMBL112532; 1-(4-Butoxy-phenyl)-1H-imidazole; SCHEMBL14129854; 1-(4-Butoxyphenyl)-1H-imidazole; ZINC13530153
DMOEGZV DT Small molecular drug
DMOEGZV PC 11321889
DMOEGZV MW 216.28
DMOEGZV FM C13H16N2O
DMOEGZV IC InChI=1S/C13H16N2O/c1-2-3-10-16-13-6-4-12(5-7-13)15-9-8-14-11-15/h4-9,11H,2-3,10H2,1H3
DMOEGZV CS CCCCOC1=CC=C(C=C1)N2C=CN=C2
DMOEGZV IK QJWFZZZHWWOBNM-UHFFFAOYSA-N
DMOEGZV IU 1-(4-butoxyphenyl)imidazole
DMOEGZV DE Discovery agent
DM7GIZL ID DM7GIZL
DM7GIZL DN 1-(4-butoxyphenyl)propan-2-amine
DM7GIZL HS Investigative
DM7GIZL SN CHEMBL456012; 1-(4-butoxyphenyl)propan-2-amine; BDBM50276774
DM7GIZL DT Small molecular drug
DM7GIZL PC 21341306
DM7GIZL MW 207.31
DM7GIZL FM C13H21NO
DM7GIZL IC InChI=1S/C13H21NO/c1-3-4-9-15-13-7-5-12(6-8-13)10-11(2)14/h5-8,11H,3-4,9-10,14H2,1-2H3
DM7GIZL CS CCCCOC1=CC=C(C=C1)CC(C)N
DM7GIZL IK XYGSKZYABPNAKO-UHFFFAOYSA-N
DM7GIZL IU 1-(4-butoxyphenyl)propan-2-amine
DM7GIZL DE Discovery agent
DMIGDCK ID DMIGDCK
DMIGDCK DN 1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea
DMIGDCK HS Investigative
DMIGDCK SN PETT Analog 41; AC1MHDKS; BDBM1874; CHEMBL254840; ZINC13744899; 1-(4-butylthiazol-2-yl)-3-phenethyl-thiourea; 1-(4-butyl-1,3-thiazol-2-yl)-3-phenethylthiourea; N-(2-Phenethyl)-N -(2-(4-butylthiazolyl))thiourea
DMIGDCK DT Small molecular drug
DMIGDCK PC 3001109
DMIGDCK MW 319.5
DMIGDCK FM C16H21N3S2
DMIGDCK IC InChI=1S/C16H21N3S2/c1-2-3-9-14-12-21-16(18-14)19-15(20)17-11-10-13-7-5-4-6-8-13/h4-8,12H,2-3,9-11H2,1H3,(H2,17,18,19,20)
DMIGDCK CS CCCCC1=CSC(=N1)NC(=S)NCCC2=CC=CC=C2
DMIGDCK IK SXKJLZJKVYKNHV-UHFFFAOYSA-N
DMIGDCK IU 1-(4-butyl-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DMIGDCK DE Discovery agent
DMBR9TQ ID DMBR9TQ
DMBR9TQ DN 1-(4-chlorobenzyl)-1H-imidazole
DMBR9TQ HS Investigative
DMBR9TQ SN 1-(4-chlorobenzyl)-1H-imidazole; 42032-27-9; CHEMBL441367; 1-[(4-chlorophenyl)methyl]imidazole; chlorbenzyl imidazole; AC1MCUZ8; 1H-Imidazole, 1-[(4-chlorophenyl)methyl]-; 1-(p-chlorobenzyl)imidazole; 1-(4-Chlorobenzyl)imidazole; SCHEMBL570342; CTK6H0128; MolPort-001-764-407; RPLWYOLCHGTNSX-UHFFFAOYSA-N; ZINC161401; BDBM50188097; AKOS002677375; MCULE-5157261929
DMBR9TQ DT Small molecular drug
DMBR9TQ PC 2779191
DMBR9TQ MW 192.64
DMBR9TQ FM C10H9ClN2
DMBR9TQ IC InChI=1S/C10H9ClN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DMBR9TQ CS C1=CC(=CC=C1CN2C=CN=C2)Cl
DMBR9TQ IK RPLWYOLCHGTNSX-UHFFFAOYSA-N
DMBR9TQ IU 1-[(4-chlorophenyl)methyl]imidazole
DMBR9TQ DE Discovery agent
DMOUPNT ID DMOUPNT
DMOUPNT DN 1-(4-chlorobenzyl)-1H-indole-2,3-dione
DMOUPNT HS Investigative
DMOUPNT SN 1-(4-Chlorobenzyl)-1H-indole-2,3-dione; 26960-66-7; 1-(4-chloro-benzyl)-1h-indole-2,3-dione; 1-(4-Chlorobenzyl)indoline-2,3-dione; NSC127077; 1-[(4-chlorophenyl)methyl]-2,3-dihydro-1H-indole-2,3-dione; 1-[(4-chlorophenyl)methyl]indole-2,3-dione; 1-[(4-chlorophenyl)methyl]benzo[d]azolidine-2,3-dione; 4-chlorobenzylisatin; NSC 127077; AC1Q3JHP; AC1Q3NUX; AC1Q3JHO; CBMicro_042181; AC1L5N5R; Isatin-based compound, 15; Cambridge id 6046772; 1-(4-chlorobenzyl)-isatin; CHEMBL376291; SCHEMBL3027106; BDBM22795; CTK4F8812; KS-00001RNX
DMOUPNT DT Small molecular drug
DMOUPNT PC 277990
DMOUPNT MW 271.7
DMOUPNT FM C15H10ClNO2
DMOUPNT IC InChI=1S/C15H10ClNO2/c16-11-7-5-10(6-8-11)9-17-13-4-2-1-3-12(13)14(18)15(17)19/h1-8H,9H2
DMOUPNT CS C1=CC=C2C(=C1)C(=O)C(=O)N2CC3=CC=C(C=C3)Cl
DMOUPNT IK VEBLIIOSJXGVAW-UHFFFAOYSA-N
DMOUPNT IU 1-[(4-chlorophenyl)methyl]indole-2,3-dione
DMOUPNT CA CAS 26960-66-7
DMOUPNT DE Discovery agent
DMASLUF ID DMASLUF
DMASLUF DN 1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole
DMASLUF HS Investigative
DMASLUF SN CHEMBL597101; 1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole; SCHEMBL1949527
DMASLUF DT Small molecular drug
DMASLUF PC 45103809
DMASLUF MW 268.74
DMASLUF FM C16H13ClN2
DMASLUF IC InChI=1S/C16H13ClN2/c17-15-8-6-13(7-9-15)11-19-12-18-10-16(19)14-4-2-1-3-5-14/h1-10,12H,11H2
DMASLUF CS C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)Cl
DMASLUF IK ILEPDNSLDAJTII-UHFFFAOYSA-N
DMASLUF IU 1-[(4-chlorophenyl)methyl]-5-phenylimidazole
DMASLUF DE Discovery agent
DMXGB38 ID DMXGB38
DMXGB38 DN 1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one
DMXGB38 HS Investigative
DMXGB38 SN CHEMBL462432; 1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162562
DMXGB38 DT Small molecular drug
DMXGB38 PC 44554440
DMXGB38 MW 291.77
DMXGB38 FM C16H18ClNO2
DMXGB38 IC InChI=1S/C16H18ClNO2/c17-15-12-20-16(18-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMXGB38 CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)Cl
DMXGB38 IK HEJGWGQTJYVGGY-UHFFFAOYSA-N
DMXGB38 IU 1-(4-chloro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMXGB38 DE Discovery agent
DM9MDZG ID DM9MDZG
DM9MDZG DN 1-(4-chlorophenethyl)-1H-imidazole
DM9MDZG HS Investigative
DM9MDZG SN CHEMBL379290; 1-(4-chlorophenethyl)-1H-imidazole; 1H-Imidazole, 1-[2-(4-chlorophenyl)ethyl]-; BDBM50191793; 56643-90-4
DM9MDZG DT Small molecular drug
DM9MDZG PC 10330640
DM9MDZG MW 206.67
DM9MDZG FM C11H11ClN2
DM9MDZG IC InChI=1S/C11H11ClN2/c12-11-3-1-10(2-4-11)5-7-14-8-6-13-9-14/h1-4,6,8-9H,5,7H2
DM9MDZG CS C1=CC(=CC=C1CCN2C=CN=C2)Cl
DM9MDZG IK MOYFWXULYXUBOS-UHFFFAOYSA-N
DM9MDZG IU 1-[2-(4-chlorophenyl)ethyl]imidazole
DM9MDZG DE Discovery agent
DMV8C7I ID DMV8C7I
DMV8C7I DN 1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMV8C7I HS Investigative
DMV8C7I SN 1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX); SCHEMBL675964; CHEMBL1088223; BDBM50378776
DMV8C7I DT Small molecular drug
DMV8C7I PC 23654364
DMV8C7I MW 511.8
DMV8C7I FM C22H21Cl3N4O2S
DMV8C7I IC InChI=1S/C22H21Cl3N4O2S/c1-32(31)22-19(21(30)27-28-11-3-2-4-12-28)26-20(17-10-7-15(24)13-18(17)25)29(22)16-8-5-14(23)6-9-16/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMV8C7I CS CS(=O)C1=C(N=C(N1C2=CC=C(C=C2)Cl)C3=C(C=C(C=C3)Cl)Cl)C(=O)NN4CCCCC4
DMV8C7I IK XQPOHFLWEFPJAR-UHFFFAOYSA-N
DMV8C7I IU 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylsulfinyl-N-piperidin-1-ylimidazole-4-carboxamide
DMV8C7I DE Discovery agent
DMQHTR4 ID DMQHTR4
DMQHTR4 DN 1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone
DMQHTR4 HS Investigative
DMQHTR4 SN 1-(4-Chlorophenyl)-2-(phenylsulfonyl)ethanone; 38488-19-6; CHEMBL238834; 1-(4-chlorophenyl)-2-(phenylsulfonyl)-1-ethanone; 4-Chlorophenacylphenyl sulfone; AC1LBPW5; SCHEMBL10931021; ZINC58239; CTK6G9147; MolPort-002-876-864; KZACHGLUJYSTGQ-UHFFFAOYSA-N; BDBM50212531; CCG-43075; AKOS003310153; MCULE-9299558448; 7H-330S; KS-00001Z91; ST50308734; Ethanone, 1-(4-chlorophenyl)-2-phenylsulfonyl-; 4'-CHLORO-2(PHENYL SULFONYL)ACETOPHENONE; 2-(benzenesulfonyl)-1-(4-chlorophenyl)ethanone; AF-731/00081054
DMQHTR4 DT Small molecular drug
DMQHTR4 PC 586971
DMQHTR4 MW 294.8
DMQHTR4 FM C14H11ClO3S
DMQHTR4 IC InChI=1S/C14H11ClO3S/c15-12-8-6-11(7-9-12)14(16)10-19(17,18)13-4-2-1-3-5-13/h1-9H,10H2
DMQHTR4 CS C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC=C(C=C2)Cl
DMQHTR4 IK KZACHGLUJYSTGQ-UHFFFAOYSA-N
DMQHTR4 IU 2-(benzenesulfonyl)-1-(4-chlorophenyl)ethanone
DMQHTR4 DE Discovery agent
DMCDV1O ID DMCDV1O
DMCDV1O DN 1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione
DMCDV1O HS Investigative
DMCDV1O SN 4-Chlorobenzil; 22711-23-5; 1-(4-chlorophenyl)-2-phenylethane-1,2-dione; 4-Chlorodibenzoyl; (p-Chlorophenyl)phenylethanedione; QDCKVAZDINMMHO-UHFFFAOYSA-N; 1-(4-Chlorophenyl)-2-phenylethan-1,2-dione; 1-(4-Chlorophenyl)-2-phenyl-1,2-ethanedione; 1,2-Ethanedione,1-(4-chlorophenyl)-2-phenyl-; p-Chlorbenzil; EINECS 245-169-3; ACMC-20amkt; 1-(4-Chloro-phenyl)-2-phenyl-ethane; AC1L3IMU; Benzil-based compound, 15; SCHEMBL912515; CHEMBL192180; CTK4F0011; BDBM22737; DTXSID00177246; 4-Chlorobibenzyl-alpha,beta-dione; MolPort-001-763-274
DMCDV1O DT Small molecular drug
DMCDV1O PC 89801
DMCDV1O MW 244.67
DMCDV1O FM C14H9ClO2
DMCDV1O IC InChI=1S/C14H9ClO2/c15-12-8-6-11(7-9-12)14(17)13(16)10-4-2-1-3-5-10/h1-9H
DMCDV1O CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)Cl
DMCDV1O IK QDCKVAZDINMMHO-UHFFFAOYSA-N
DMCDV1O IU 1-(4-chlorophenyl)-2-phenylethane-1,2-dione
DMCDV1O CA CAS 22711-23-5
DMCDV1O DE Discovery agent
DMOGVZ2 ID DMOGVZ2
DMOGVZ2 DN 1-(4-Chloro-phenyl)-2-p-tolyl-ethane-1,2-dione
DMOGVZ2 HS Investigative
DMOGVZ2 SN 86508-29-4; 1-(4-chlorophenyl)-2-(4-methylphenyl)ethane-1,2-dione; 1-(4-Chlorophenyl)-2-(p-tolyl)ethane-1,2-dione; 1-(4-Chlorophenyl)-2-(4-methylphenyl)-ethane-1,2-dione; 1,2-Ethanedione,1-(4-chlorophenyl)-2-(4-methylphenyl)-; AC1MCRLY; Benzil-based compound, 16; SCHEMBL2156105; CHEMBL192252; BDBM22738; CTK5F6872; DTXSID10380461; ZINC2510245; ZX-AT024772; SBB102088; 1010AF; AKOS025117220; KB-147233; FT-0605685; I14-93818; 1-(4-Chlorophenyl)-2-(4-methylphenyl)ethan-1,2-dione
DMOGVZ2 DT Small molecular drug
DMOGVZ2 PC 2777298
DMOGVZ2 MW 258.7
DMOGVZ2 FM C15H11ClO2
DMOGVZ2 IC InChI=1S/C15H11ClO2/c1-10-2-4-11(5-3-10)14(17)15(18)12-6-8-13(16)9-7-12/h2-9H,1H3
DMOGVZ2 CS CC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)Cl
DMOGVZ2 IK FKOYORNUXJRIQT-UHFFFAOYSA-N
DMOGVZ2 IU 1-(4-chlorophenyl)-2-(4-methylphenyl)ethane-1,2-dione
DMOGVZ2 CA CAS 86508-29-4
DMOGVZ2 DE Discovery agent
DM3YI5G ID DM3YI5G
DM3YI5G DN 1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea
DM3YI5G HS Investigative
DM3YI5G SN CHEMBL9308; 1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea; BDBM50005456
DM3YI5G DT Small molecular drug
DM3YI5G PC 44265973
DM3YI5G MW 362.8
DM3YI5G FM C22H19ClN2O
DM3YI5G IC InChI=1S/C22H19ClN2O/c23-19-11-13-20(14-12-19)25-22(26)24-16-15-21(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-15H,16H2,(H2,24,25,26)
DM3YI5G CS C1=CC=C(C=C1)C(=CCNC(=O)NC2=CC=C(C=C2)Cl)C3=CC=CC=C3
DM3YI5G IK BVFBYUIDPPDGCS-UHFFFAOYSA-N
DM3YI5G IU 1-(4-chlorophenyl)-3-(3,3-diphenylprop-2-enyl)urea
DM3YI5G DE Discovery agent
DMUW1GI ID DMUW1GI
DMUW1GI DN 1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea
DMUW1GI HS Investigative
DMUW1GI SN CHEMBL422036; 1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea; BDBM50005450
DMUW1GI DT Small molecular drug
DMUW1GI PC 44265967
DMUW1GI MW 350.9
DMUW1GI FM C20H31ClN2O
DMUW1GI IC InChI=1S/C20H31ClN2O/c1-3-5-7-9-17(10-8-6-4-2)15-16-22-20(24)23-19-13-11-18(21)12-14-19/h11-15H,3-10,16H2,1-2H3,(H2,22,23,24)
DMUW1GI CS CCCCCC(=CCNC(=O)NC1=CC=C(C=C1)Cl)CCCCC
DMUW1GI IK CIWRUSYLNXXOOQ-UHFFFAOYSA-N
DMUW1GI IU 1-(4-chlorophenyl)-3-(3-pentyloct-2-enyl)urea
DMUW1GI DE Discovery agent
DMVCHSI ID DMVCHSI
DMVCHSI DN 1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI HS Investigative
DMVCHSI SN 1-(4-chlorophenyl)-4-phenyl-1H-imidazole
DMVCHSI DT Small molecular drug
DMVCHSI PC 12718449
DMVCHSI MW 254.71
DMVCHSI FM C15H11ClN2
DMVCHSI IC InChI=1S/C15H11ClN2/c16-13-6-8-14(9-7-13)18-10-15(17-11-18)12-4-2-1-3-5-12/h1-11H
DMVCHSI CS C1=CC=C(C=C1)C2=CN(C=N2)C3=CC=C(C=C3)Cl
DMVCHSI IK CPDGQKJPYYDYQG-UHFFFAOYSA-N
DMVCHSI IU 1-(4-chlorophenyl)-4-phenylimidazole
DMVCHSI DE Discovery agent
DMEJXWG ID DMEJXWG
DMEJXWG DN 1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol
DMEJXWG HS Investigative
DMEJXWG SN CHEMBL562534; 1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol; SCHEMBL12550078
DMEJXWG DT Small molecular drug
DMEJXWG PC 25192460
DMEJXWG MW 365.9
DMEJXWG FM C18H20ClNO3S
DMEJXWG IC InChI=1S/C18H20ClNO3S/c19-16-7-9-17(10-8-16)24(22,23)20-13-4-11-18(21,12-14-20)15-5-2-1-3-6-15/h1-3,5-10,21H,4,11-14H2
DMEJXWG CS C1CC(CCN(C1)S(=O)(=O)C2=CC=C(C=C2)Cl)(C3=CC=CC=C3)O
DMEJXWG IK RVUCFBVJACHZFJ-UHFFFAOYSA-N
DMEJXWG IU 1-(4-chlorophenyl)sulfonyl-4-phenylazepan-4-ol
DMEJXWG DE Discovery agent
DMIU3C8 ID DMIU3C8
DMIU3C8 DN 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea
DMIU3C8 HS Investigative
DMIU3C8 SN CHEMBL25573; 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea; 1-(4-cyano-2-hydroxy-phenyl)-3-phenyl-urea; SCHEMBL7489930; ZINC13559607
DMIU3C8 DT Small molecular drug
DMIU3C8 PC 11184341
DMIU3C8 MW 253.26
DMIU3C8 FM C14H11N3O2
DMIU3C8 IC InChI=1S/C14H11N3O2/c15-9-10-6-7-12(13(18)8-10)17-14(19)16-11-4-2-1-3-5-11/h1-8,18H,(H2,16,17,19)
DMIU3C8 CS C1=CC=C(C=C1)NC(=O)NC2=C(C=C(C=C2)C#N)O
DMIU3C8 IK XRZHCICQICNYCB-UHFFFAOYSA-N
DMIU3C8 IU 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea
DMIU3C8 DE Discovery agent
DMKDAJ2 ID DMKDAJ2
DMKDAJ2 DN 1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole
DMKDAJ2 HS Investigative
DMKDAJ2 SN CHEMBL599603; 1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole; SCHEMBL3826070
DMKDAJ2 DT Small molecular drug
DMKDAJ2 PC 45103912
DMKDAJ2 MW 277.29
DMKDAJ2 FM C17H12FN3
DMKDAJ2 IC InChI=1S/C17H12FN3/c18-16-4-2-1-3-15(16)17-10-20-12-21(17)11-14-7-5-13(9-19)6-8-14/h1-8,10,12H,11H2
DMKDAJ2 CS C1=CC=C(C(=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N)F
DMKDAJ2 IK HPGUXAXJZVHMRJ-UHFFFAOYSA-N
DMKDAJ2 IU 4-[[5-(2-fluorophenyl)imidazol-1-yl]methyl]benzonitrile
DMKDAJ2 DE Discovery agent
DMAJXYO ID DMAJXYO
DMAJXYO DN 1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole
DMAJXYO HS Investigative
DMAJXYO SN CHEMBL610513; 1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole; SCHEMBL3822526
DMAJXYO DT Small molecular drug
DMAJXYO PC 44187006
DMAJXYO MW 273.3
DMAJXYO FM C18H15N3
DMAJXYO IC InChI=1S/C18H15N3/c1-14-4-2-3-5-17(14)18-11-20-13-21(18)12-16-8-6-15(10-19)7-9-16/h2-9,11,13H,12H2,1H3
DMAJXYO CS CC1=CC=CC=C1C2=CN=CN2CC3=CC=C(C=C3)C#N
DMAJXYO IK PMVNVHAWQMXUIC-UHFFFAOYSA-N
DMAJXYO IU 4-[[5-(2-methylphenyl)imidazol-1-yl]methyl]benzonitrile
DMAJXYO DE Discovery agent
DMVS4D5 ID DMVS4D5
DMVS4D5 DN 1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole
DMVS4D5 HS Investigative
DMVS4D5 SN CHEMBL598789; 1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole; SCHEMBL3828287
DMVS4D5 DT Small molecular drug
DMVS4D5 PC 44206698
DMVS4D5 MW 277.29
DMVS4D5 FM C17H12FN3
DMVS4D5 IC InChI=1S/C17H12FN3/c18-16-3-1-2-15(8-16)17-10-20-12-21(17)11-14-6-4-13(9-19)5-7-14/h1-8,10,12H,11H2
DMVS4D5 CS C1=CC(=CC(=C1)F)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMVS4D5 IK XBUPVQPMTRYFDV-UHFFFAOYSA-N
DMVS4D5 IU 4-[[5-(3-fluorophenyl)imidazol-1-yl]methyl]benzonitrile
DMVS4D5 DE Discovery agent
DMI8UC7 ID DMI8UC7
DMI8UC7 DN 1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
DMI8UC7 HS Investigative
DMI8UC7 SN CHEMBL607862; 1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole
DMI8UC7 DT Small molecular drug
DMI8UC7 PC 45103913
DMI8UC7 MW 273.3
DMI8UC7 FM C18H15N3
DMI8UC7 IC InChI=1S/C18H15N3/c1-14-3-2-4-17(9-14)18-11-20-13-21(18)12-16-7-5-15(10-19)6-8-16/h2-9,11,13H,12H2,1H3
DMI8UC7 CS CC1=CC(=CC=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMI8UC7 IK PLRIEAPRLTXNAI-UHFFFAOYSA-N
DMI8UC7 IU 4-[[5-(3-methylphenyl)imidazol-1-yl]methyl]benzonitrile
DMI8UC7 DE Discovery agent
DM7C3VD ID DM7C3VD
DM7C3VD DN 1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
DM7C3VD HS Investigative
DM7C3VD SN CHEMBL598790; 1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole
DM7C3VD DT Small molecular drug
DM7C3VD PC 45103914
DM7C3VD MW 277.29
DM7C3VD FM C17H12FN3
DM7C3VD IC InChI=1S/C17H12FN3/c18-16-7-5-15(6-8-16)17-10-20-12-21(17)11-14-3-1-13(9-19)2-4-14/h1-8,10,12H,11H2
DM7C3VD CS C1=CC(=CC=C1CN2C=NC=C2C3=CC=C(C=C3)F)C#N
DM7C3VD IK KZBKCANQPHILBI-UHFFFAOYSA-N
DM7C3VD IU 4-[[5-(4-fluorophenyl)imidazol-1-yl]methyl]benzonitrile
DM7C3VD DE Discovery agent
DMQX37R ID DMQX37R
DMQX37R DN 1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
DMQX37R HS Investigative
DMQX37R SN CHEMBL607567; 1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole
DMQX37R DT Small molecular drug
DMQX37R PC 45103915
DMQX37R MW 273.3
DMQX37R FM C18H15N3
DMQX37R IC InChI=1S/C18H15N3/c1-14-2-8-17(9-3-14)18-11-20-13-21(18)12-16-6-4-15(10-19)5-7-16/h2-9,11,13H,12H2,1H3
DMQX37R CS CC1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMQX37R IK DWILASUQXSLXIX-UHFFFAOYSA-N
DMQX37R IU 4-[[5-(4-methylphenyl)imidazol-1-yl]methyl]benzonitrile
DMQX37R DE Discovery agent
DM372EG ID DM372EG
DM372EG DN 1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
DM372EG HS Investigative
DM372EG SN CHEMBL599602; 1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole
DM372EG DT Small molecular drug
DM372EG PC 45103911
DM372EG MW 260.29
DM372EG FM C16H12N4
DM372EG IC InChI=1S/C16H12N4/c17-9-13-1-3-14(4-2-13)11-20-12-19-10-16(20)15-5-7-18-8-6-15/h1-8,10,12H,11H2
DM372EG CS C1=CC(=CC=C1CN2C=NC=C2C3=CC=NC=C3)C#N
DM372EG IK JQIVWNYGSDPIRG-UHFFFAOYSA-N
DM372EG IU 4-[(5-pyridin-4-ylimidazol-1-yl)methyl]benzonitrile
DM372EG DE Discovery agent
DMBUMDG ID DMBUMDG
DMBUMDG DN 1-(4-Cyanobenzyl)-5-bromo-1H-imidazole
DMBUMDG HS Investigative
DMBUMDG SN 1-(4-Cyanobenzyl)-5-bromo-1H-imidazole; CHEMBL599223; SCHEMBL3829392; BDBM50307238
DMBUMDG DT Small molecular drug
DMBUMDG PC 45103910
DMBUMDG MW 262.1
DMBUMDG FM C11H8BrN3
DMBUMDG IC InChI=1S/C11H8BrN3/c12-11-6-14-8-15(11)7-10-3-1-9(5-13)2-4-10/h1-4,6,8H,7H2
DMBUMDG CS C1=CC(=CC=C1CN2C=NC=C2Br)C#N
DMBUMDG IK MHDGKGCOBILXLM-UHFFFAOYSA-N
DMBUMDG IU 4-[(5-bromoimidazol-1-yl)methyl]benzonitrile
DMBUMDG DE Discovery agent
DM2THVK ID DM2THVK
DM2THVK DN 1-(4-Cyanobenzyl)-5-formyl-1H-imidazole
DM2THVK HS Investigative
DM2THVK SN 183500-37-0; CHEMBL611680; 4-(5-formylimidazol-1-ylmethyl)benzonitrile; 4-[(5-formyl-1H-imidazol-1-yl)methyl]benzonitrile; 4-(5-FORMYL-IMIDAZOL-1-YLMETHYL)-BENZONITRILE; 4-((5-formyl-1h-imidazol-1-yl)methyl)benzonitrile; 1-(4-Cyanobenzyl)-5-formyl-1H-imidazole; SCHEMBL1064258; CTK4D8501; DTXSID30442752; AMUOEEKBBOOOCV-UHFFFAOYSA-N; ZINC39118604; BDBM50307239; 1-(4-cyanobenzyl)-5-formylimidazole; AKOS015911901; ACM183500370; SC-55448; KB-238611; FT-0714561; 1-(4-cyanobenzyl)-5-imidazolecarboxaldehyde
DM2THVK DT Small molecular drug
DM2THVK PC 10632289
DM2THVK MW 211.22
DM2THVK FM C12H9N3O
DM2THVK IC InChI=1S/C12H9N3O/c13-5-10-1-3-11(4-2-10)7-15-9-14-6-12(15)8-16/h1-4,6,8-9H,7H2
DM2THVK CS C1=CC(=CC=C1CN2C=NC=C2C=O)C#N
DM2THVK IK AMUOEEKBBOOOCV-UHFFFAOYSA-N
DM2THVK IU 4-[(5-formylimidazol-1-yl)methyl]benzonitrile
DM2THVK CA CAS 183500-37-0
DM2THVK DE Discovery agent
DMCUE25 ID DMCUE25
DMCUE25 DN 1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole
DMCUE25 HS Investigative
DMCUE25 SN 183500-36-9; CHEMBL599601; 4-(5-HYDROXYMETHYLIMIDAZOL-1-YLMETHYL)BENZONITRILE; 1-(4-cyanobenzyl)-5-hydroxymethylimidazole; 1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole; SCHEMBL3630524; CTK4D8500; DTXSID40436662; ACFSBQWDVYWNRT-UHFFFAOYSA-N; ZINC45368822; BDBM50307240; ACM183500369; KB-238618; 1-(4-Cyanobenzyl)-5-Hydroxymethyl-imidazole; 1-(4-Cyanobenzyl)-5-(hydroxymethyl)imidazole; 1-(4-cyanobenzyl)-5-(hydroxymethyl) imidazole; 1-(4-cyanobenzyl)-5-(hydroxymethyl)-imidazole; 3-(4-cyanobenzyl)-3H-imidazol-4-ylmethyl alcohol
DMCUE25 DT Small molecular drug
DMCUE25 PC 10198247
DMCUE25 MW 213.23
DMCUE25 FM C12H11N3O
DMCUE25 IC InChI=1S/C12H11N3O/c13-5-10-1-3-11(4-2-10)7-15-9-14-6-12(15)8-16/h1-4,6,9,16H,7-8H2
DMCUE25 CS C1=CC(=CC=C1CN2C=NC=C2CO)C#N
DMCUE25 IK ACFSBQWDVYWNRT-UHFFFAOYSA-N
DMCUE25 IU 4-[[5-(hydroxymethyl)imidazol-1-yl]methyl]benzonitrile
DMCUE25 CA CAS 183500-36-9
DMCUE25 DE Discovery agent
DMKC52N ID DMKC52N
DMKC52N DN 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole
DMKC52N HS Investigative
DMKC52N SN 4-(5-Methyl-imidazol-1-ylmethyl)-benzonitrile
DMKC52N PC 14231155
DMKC52N MW 197.24
DMKC52N FM C12H11N3
DMKC52N IC InChI=1S/C12H11N3/c1-10-7-14-9-15(10)8-12-4-2-11(6-13)3-5-12/h2-5,7,9H,8H2,1H3
DMKC52N CS CC1=CN=CN1CC2=CC=C(C=C2)C#N
DMKC52N IK JYTDMONWVZXEMX-UHFFFAOYSA-N
DMKC52N IU 4-[(5-methylimidazol-1-yl)methyl]benzonitrile
DMKC52N DE Discovery agent
DMQF8DY ID DMQF8DY
DMQF8DY DN 1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole
DMQF8DY HS Investigative
DMQF8DY SN CHEMBL597578; 1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole; SCHEMBL1949482
DMQF8DY DT Small molecular drug
DMQF8DY PC 44206482
DMQF8DY MW 259.3
DMQF8DY FM C17H13N3
DMQF8DY IC InChI=1S/C17H13N3/c18-10-14-6-8-15(9-7-14)12-20-13-19-11-17(20)16-4-2-1-3-5-16/h1-9,11,13H,12H2
DMQF8DY CS C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)C#N
DMQF8DY IK HPKNNFRLCPHIRD-UHFFFAOYSA-N
DMQF8DY IU 4-[(5-phenylimidazol-1-yl)methyl]benzonitrile
DMQF8DY DE Discovery agent
DM9EK3T ID DM9EK3T
DM9EK3T DN 1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea
DM9EK3T HS Investigative
DM9EK3T SN PETT CN deriv.; PETT Analog 42; AC1MHDKT; CHEMBL148106; BDBM1875; ZINC13744901; 1-(4-cyanothiazol-2-yl)-3-phenethyl-thiourea; 1-(4-cyano-1,3-thiazol-2-yl)-3-phenethylthiourea; N-(2-Phenethyl)-N -(2-(4-cyanothiazolyl))thiourea; N-(2-Phenylethyl)-N'-[2-(4-cyanothiazolyl)]thiourea
DM9EK3T DT Small molecular drug
DM9EK3T PC 3001110
DM9EK3T MW 288.4
DM9EK3T FM C13H12N4S2
DM9EK3T IC InChI=1S/C13H12N4S2/c14-8-11-9-19-13(16-11)17-12(18)15-7-6-10-4-2-1-3-5-10/h1-5,9H,6-7H2,(H2,15,16,17,18)
DM9EK3T CS C1=CC=C(C=C1)CCNC(=S)NC2=NC(=CS2)C#N
DM9EK3T IK BZAWZCHHJAFXDY-UHFFFAOYSA-N
DM9EK3T IU 1-(4-cyano-1,3-thiazol-2-yl)-3-(2-phenylethyl)thiourea
DM9EK3T DE Discovery agent
DMZR94D ID DMZR94D
DMZR94D DN 1-(4-ethoxyphenyl)propan-2-amine
DMZR94D HS Investigative
DMZR94D SN 4-Ethoxyamphetamine; dl-p-Ethoxyamphetamine; 129476-58-0; 1-(4-ethoxyphenyl)propan-2-amine; CHEMBL161985; 135014-85-6; 1-(4-ethoxyphenyl)prop-2-ylamine; Para-Ethoxyamphetamine; Benzeneethanamine, 4-ethoxy-alpha-methyl-; AC1L2OHT; ACMC-1BZ3A; Benzeneethanamine, 4-ethoxy-alpha-methyl-, (+-)-; SCHEMBL2553013; CTK0H5621; CCAMEVFYMFXHEN-UHFFFAOYSA-N; BDBM50005270; AKOS016298265; AKOS017269155; AKOS000155579; 1-(4-Ethoxyphenyl)-2-propanamine #; 2-(4-Ethoxy-phenyl)-1-methyl-ethylamine
DMZR94D DT Small molecular drug
DMZR94D PC 125379
DMZR94D MW 179.26
DMZR94D FM C11H17NO
DMZR94D IC InChI=1S/C11H17NO/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3
DMZR94D CS CCOC1=CC=C(C=C1)CC(C)N
DMZR94D IK CCAMEVFYMFXHEN-UHFFFAOYSA-N
DMZR94D IU 1-(4-ethoxyphenyl)propan-2-amine
DMZR94D CA CAS 129476-58-0
DMZR94D DE Discovery agent
DMIYLXU ID DMIYLXU
DMIYLXU DN 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
DMIYLXU HS Investigative
DMIYLXU SN 2,5-Dimethoxy-4-ethylamphetamine; 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine; 22004-32-6; DOET; CHEMBL8224; NCGC00247691-01; SCHEMBL1740704; DOET,(-); AC1L1D54; CTK4E8216; BDBM81965; HXJKWPGVENNMCC-UHFFFAOYSA-N; 4-Ethyl-2,5-dimethoxyamphetamine; PDSP2_000785; CAS_62066; PDSP1_001371; PDSP2_001355; PDSP1_000797; NSC_62066; DB01467; ACM22004326; 2,5-dimethoxy-4-ethylamphetamine (''DOEt''); L001150; Benzeneethanamine,4-ethyl-2,5-dimethoxy-a-methyl-; 1-(4-Ethyl-2,5-dimethoxyphenyl)-2-propanamine #; Phenethylamine, 4-ethyl-2,5-dimeth
DMIYLXU DT Small molecular drug
DMIYLXU PC 27402
DMIYLXU MW 223.31
DMIYLXU FM C13H21NO2
DMIYLXU IC InChI=1S/C13H21NO2/c1-5-10-7-13(16-4)11(6-9(2)14)8-12(10)15-3/h7-9H,5-6,14H2,1-4H3
DMIYLXU CS CCC1=CC(=C(C=C1OC)CC(C)N)OC
DMIYLXU IK HXJKWPGVENNMCC-UHFFFAOYSA-N
DMIYLXU IU 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine
DMIYLXU CA CAS 22004-32-6
DMIYLXU DE Discovery agent
DMXUIS2 ID DMXUIS2
DMXUIS2 DN 1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol
DMXUIS2 HS Investigative
DMXUIS2 SN CHEMBL562684; 1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol; SCHEMBL12549978
DMXUIS2 DT Small molecular drug
DMXUIS2 PC 25192457
DMXUIS2 MW 359.5
DMXUIS2 FM C20H25NO3S
DMXUIS2 IC InChI=1S/C20H25NO3S/c1-2-17-9-11-19(12-10-17)25(23,24)21-15-6-13-20(22,14-16-21)18-7-4-3-5-8-18/h3-5,7-12,22H,2,6,13-16H2,1H3
DMXUIS2 CS CCC1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)(C3=CC=CC=C3)O
DMXUIS2 IK BUVJJRPTSWXSAA-UHFFFAOYSA-N
DMXUIS2 IU 1-(4-ethylphenyl)sulfonyl-4-phenylazepan-4-ol
DMXUIS2 DE Discovery agent
DMRK0Z1 ID DMRK0Z1
DMRK0Z1 DN 1-(4-ethylpiperazin-1-yl)-2-phenylethanone
DMRK0Z1 HS Investigative
DMRK0Z1 SN 1-(4-ethylpiperazin-1-yl)-2-phenylethanone; CHEMBL439203; 1-ethyl-4-(phenylacetyl)piperazine; AC1MNIR9; SCHEMBL20353684; MolPort-019-032-483; ZINC23379273; BDBM50207797; AKOS003796844; MCULE-6061952446
DMRK0Z1 DT Small molecular drug
DMRK0Z1 PC 3328378
DMRK0Z1 MW 232.32
DMRK0Z1 FM C14H20N2O
DMRK0Z1 IC InChI=1S/C14H20N2O/c1-2-15-8-10-16(11-9-15)14(17)12-13-6-4-3-5-7-13/h3-7H,2,8-12H2,1H3
DMRK0Z1 CS CCN1CCN(CC1)C(=O)CC2=CC=CC=C2
DMRK0Z1 IK ZKLSFAKJJJDQSA-UHFFFAOYSA-N
DMRK0Z1 IU 1-(4-ethylpiperazin-1-yl)-2-phenylethanone
DMRK0Z1 DE Discovery agent
DMBJCGA ID DMBJCGA
DMBJCGA DN 1-(4-fluorobenzyl)-1H-imidazole
DMBJCGA HS Investigative
DMBJCGA SN 1-(4-fluorobenzyl)-1H-imidazole; CHEMBL377770; 56643-73-3; 1-(4-Fluorobenzyl)imidazole; SCHEMBL11082155; CTK1F4148; DTXSID90481445; ZINC5588657; BDBM50188085; AKOS003644474; 1H-Imidazole, 1-[(4-fluorophenyl)methyl]-
DMBJCGA DT Small molecular drug
DMBJCGA PC 12229388
DMBJCGA MW 176.19
DMBJCGA FM C10H9FN2
DMBJCGA IC InChI=1S/C10H9FN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DMBJCGA CS C1=CC(=CC=C1CN2C=CN=C2)F
DMBJCGA IK LOHJXVMUYVDWOW-UHFFFAOYSA-N
DMBJCGA IU 1-[(4-fluorophenyl)methyl]imidazole
DMBJCGA CA CAS 56643-73-3
DMBJCGA DE Discovery agent
DMT2ZSV ID DMT2ZSV
DMT2ZSV DN 1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole
DMT2ZSV HS Investigative
DMT2ZSV SN CHEMBL610501; 1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole; SCHEMBL3823466
DMT2ZSV DT Small molecular drug
DMT2ZSV PC 45103808
DMT2ZSV MW 252.29
DMT2ZSV FM C16H13FN2
DMT2ZSV IC InChI=1S/C16H13FN2/c17-15-8-6-13(7-9-15)11-19-12-18-10-16(19)14-4-2-1-3-5-14/h1-10,12H,11H2
DMT2ZSV CS C1=CC=C(C=C1)C2=CN=CN2CC3=CC=C(C=C3)F
DMT2ZSV IK OLGSJJAJXFNAKF-UHFFFAOYSA-N
DMT2ZSV IU 1-[(4-fluorophenyl)methyl]-5-phenylimidazole
DMT2ZSV DE Discovery agent
DMZLNAP ID DMZLNAP
DMZLNAP DN 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone
DMZLNAP HS Investigative
DMZLNAP SN CHEMBL238832; 41024-58-2; Ethanone, 1-(4-fluorophenyl)-2-(phenylsulfonyl)-; 1-(4-fluorophenyl)-2-(phenylsulfonyl)-1-ethanone; 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone; AC1LS74Y; CTK1D4107; DTXSID90363277; MolPort-002-876-867; ZINC1396918; BDBM50212525; AKOS005098035; MCULE-9386710722; 7H-334S; KS-00001Z92; 4'-Fluoro-alpha-(phenylsulfonyl)acetophenone; 2-(benzenesulfonyl)-1-(4-fluorophenyl)ethanone
DMZLNAP DT Small molecular drug
DMZLNAP PC 1483401
DMZLNAP MW 278.3
DMZLNAP FM C14H11FO3S
DMZLNAP IC InChI=1S/C14H11FO3S/c15-12-8-6-11(7-9-12)14(16)10-19(17,18)13-4-2-1-3-5-13/h1-9H,10H2
DMZLNAP CS C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC=C(C=C2)F
DMZLNAP IK FCXNRTNBPQUTBL-UHFFFAOYSA-N
DMZLNAP IU 2-(benzenesulfonyl)-1-(4-fluorophenyl)ethanone
DMZLNAP CA CAS 41024-58-2
DMZLNAP DE Discovery agent
DM6ARQF ID DM6ARQF
DM6ARQF DN 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DM6ARQF HS Investigative
DM6ARQF SN CHEMBL203640; 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one; 4-Fluoro-alpha-pvp; FPVP; SCHEMBL4938098; BDBM50182583; 4'-Fluoro-alpha-pyrrolidinopentiophenone; 1-(4-Fluorophenyl)-2-pyrrolizinopentane-1-one; 4-Fluoro-alpha-2-(1-pyrrolidinyl)-valerophenone; 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)-1-pentanone; 2-(Pyrrolidin-1-yl)-1-(4-fluorophenyl)pentan-1-one; 1-Pentanone, 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)-
DM6ARQF DT Small molecular drug
DM6ARQF PC 11322641
DM6ARQF MW 249.32
DM6ARQF FM C15H20FNO
DM6ARQF IC InChI=1S/C15H20FNO/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11H2,1H3
DM6ARQF CS CCCC(C(=O)C1=CC=C(C=C1)F)N2CCCC2
DM6ARQF IK BQLSUBYYRRZHRK-UHFFFAOYSA-N
DM6ARQF IU 1-(4-fluorophenyl)-2-pyrrolidin-1-ylpentan-1-one
DM6ARQF CA CAS 850352-62-4
DM6ARQF DE Discovery agent
DMKATOJ ID DMKATOJ
DMKATOJ DN 1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one
DMKATOJ HS Investigative
DMKATOJ SN CHEMBL397827; 1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one; ZINC28874847; BDBM50212549
DMKATOJ DT Small molecular drug
DMKATOJ PC 44437632
DMKATOJ MW 292.3
DMKATOJ FM C15H13FO3S
DMKATOJ IC InChI=1S/C15H13FO3S/c16-13-8-6-12(7-9-13)15(17)10-11-20(18,19)14-4-2-1-3-5-14/h1-9H,10-11H2
DMKATOJ CS C1=CC=C(C=C1)S(=O)(=O)CCC(=O)C2=CC=C(C=C2)F
DMKATOJ IK DMAMKPWVVZCTDR-UHFFFAOYSA-N
DMKATOJ IU 3-(benzenesulfonyl)-1-(4-fluorophenyl)propan-1-one
DMKATOJ DE Discovery agent
DMIQ0VA ID DMIQ0VA
DMIQ0VA DN 1-(4-heptylphenyl)prop-2-en-1-one
DMIQ0VA HS Investigative
DMIQ0VA SN CHEMBL237035
DMIQ0VA DT Small molecular drug
DMIQ0VA PC 44435784
DMIQ0VA MW 230.34
DMIQ0VA FM C16H22O
DMIQ0VA IC InChI=1S/C16H22O/c1-3-5-6-7-8-9-14-10-12-15(13-11-14)16(17)4-2/h4,10-13H,2-3,5-9H2,1H3
DMIQ0VA CS CCCCCCCC1=CC=C(C=C1)C(=O)C=C
DMIQ0VA IK WZQJNZZJSOSTIH-UHFFFAOYSA-N
DMIQ0VA IU 1-(4-heptylphenyl)prop-2-en-1-one
DMIQ0VA DE Discovery agent
DM5QLGH ID DM5QLGH
DM5QLGH DN 1-(4-hexylphenyl)-3-(propylamino)propan-1-one
DM5QLGH HS Investigative
DM5QLGH SN beta-Aminophenylketone, 3k; 1-(4-hexylphenyl)-3-(propylamino)propan-1-one; CHEMBL396873; BDBM18824
DM5QLGH DT Small molecular drug
DM5QLGH PC 23635367
DM5QLGH MW 275.4
DM5QLGH FM C18H29NO
DM5QLGH IC InChI=1S/C18H29NO/c1-3-5-6-7-8-16-9-11-17(12-10-16)18(20)13-15-19-14-4-2/h9-12,19H,3-8,13-15H2,1-2H3
DM5QLGH CS CCCCCCC1=CC=C(C=C1)C(=O)CCNCCC
DM5QLGH IK IHAKHGFZWJHPER-UHFFFAOYSA-N
DM5QLGH IU 1-(4-hexylphenyl)-3-(propylamino)propan-1-one
DM5QLGH DE Discovery agent
DMFN8T6 ID DMFN8T6
DMFN8T6 DN 1-(4-hexylphenyl)-3-morpholinopropan-1-one
DMFN8T6 HS Investigative
DMFN8T6 SN beta-Aminophenylketone, 3e; CHEMBL236132; BDBM18818; AKOS022274318
DMFN8T6 DT Small molecular drug
DMFN8T6 PC 23635362
DMFN8T6 MW 303.4
DMFN8T6 FM C19H29NO2
DMFN8T6 IC InChI=1S/C19H29NO2/c1-2-3-4-5-6-17-7-9-18(10-8-17)19(21)11-12-20-13-15-22-16-14-20/h7-10H,2-6,11-16H2,1H3
DMFN8T6 CS CCCCCCC1=CC=C(C=C1)C(=O)CCN2CCOCC2
DMFN8T6 IK DRNLQHKMQJOYPM-UHFFFAOYSA-N
DMFN8T6 IU 1-(4-hexylphenyl)-3-morpholin-4-ylpropan-1-one
DMFN8T6 DE Discovery agent
DMX7PJH ID DMX7PJH
DMX7PJH DN 1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE
DMX7PJH HS Investigative
DMX7PJH SN 1-(4-hexylphenyl)prop-2-en-1-one; 1-(4-Hexyphenyl)-2-propane-1-one; 131906-57-5; 1-(4-HEXYLPHENYL)-2-PROPEN-1-ONE; cpd L3; Enone, 1; L3 Antagonist TR-SIR-2; SCHEMBL2583757; CHEMBL237600; BDBM18825; DTXSID40565143; MFCD08702653; ZINC13829389; DB08085; NCGC00165805-01; NCGC00165805-02; KB-214837; J-006082; 1-(4-Hexyphenyl)-2-propane-1-one, >=98% (HPLC), oil
DMX7PJH DT Small molecular drug
DMX7PJH PC 14899645
DMX7PJH MW 216.32
DMX7PJH FM C15H20O
DMX7PJH IC InChI=1S/C15H20O/c1-3-5-6-7-8-13-9-11-14(12-10-13)15(16)4-2/h4,9-12H,2-3,5-8H2,1H3
DMX7PJH CS CCCCCCC1=CC=C(C=C1)C(=O)C=C
DMX7PJH IK IINHTEWASPUCMH-UHFFFAOYSA-N
DMX7PJH IU 1-(4-hexylphenyl)prop-2-en-1-one
DMX7PJH CA CAS 131906-57-5
DMX7PJH DE Discovery agent
DM145QS ID DM145QS
DM145QS DN 1-(4-hydroxyphenyl)prop-2-en-1-one
DM145QS HS Investigative
DM145QS SN 1-(4-hydroxyphenyl)prop-2-en-1-one; 4-acryloylphenol; CHEMBL378577; 95605-38-2; 4-hydroxyphenyl Vinyl Ketone; SCHEMBL2394894; GTPL8841; MolPort-007-991-476; NKPPNPJUBLEKAD-UHFFFAOYSA-N; ZINC28567957; BDBM50177407; AKOS005200150; FCH1599833; 1-(4-Hydroxyphenyl)-2-propene-1-one; EN300-246996
DM145QS DT Small molecular drug
DM145QS PC 16036927
DM145QS MW 148.16
DM145QS FM C9H8O2
DM145QS IC InChI=1S/C9H8O2/c1-2-9(11)7-3-5-8(10)6-4-7/h2-6,10H,1H2
DM145QS CS C=CC(=O)C1=CC=C(C=C1)O
DM145QS IK NKPPNPJUBLEKAD-UHFFFAOYSA-N
DM145QS IU 1-(4-hydroxyphenyl)prop-2-en-1-one
DM145QS DE Discovery agent
DMM17I0 ID DMM17I0
DMM17I0 DN 1-(4-iodobenzyl)-1H-imidazole
DMM17I0 HS Investigative
DMM17I0 SN 4-Iodobenzyl Imidazole; CHEMBL427399; 1-(4-iodobenzyl)-1H-imidazole; SCHEMBL2393534; MolPort-023-162-403; WZKZRSOWLZKJCL-UHFFFAOYSA-N; 1-(4-Iodo-benzyl)-1H-imidazole; ZINC34849755; BDBM50188092; AKOS014827972; MCULE-7536799973; 1-[(4-iodophenyl)methyl]-1H-imidazole; 906478-69-1
DMM17I0 DT Small molecular drug
DMM17I0 PC 15984072
DMM17I0 MW 284.1
DMM17I0 FM C10H9IN2
DMM17I0 IC InChI=1S/C10H9IN2/c11-10-3-1-9(2-4-10)7-13-6-5-12-8-13/h1-6,8H,7H2
DMM17I0 CS C1=CC(=CC=C1CN2C=CN=C2)I
DMM17I0 IK WZKZRSOWLZKJCL-UHFFFAOYSA-N
DMM17I0 IU 1-[(4-iodophenyl)methyl]imidazole
DMM17I0 DE Discovery agent
DMDY93H ID DMDY93H
DMDY93H DN 1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one
DMDY93H HS Investigative
DMDY93H SN CHEMBL462302; 1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162540
DMDY93H DT Small molecular drug
DMDY93H PC 44554441
DMDY93H MW 383.22
DMDY93H FM C16H18INO2
DMDY93H IC InChI=1S/C16H18INO2/c17-15-12-20-16(18-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMDY93H CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)I
DMDY93H IK JCDUQBRWCLLJHF-UHFFFAOYSA-N
DMDY93H IU 1-(4-iodo-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMDY93H DE Discovery agent
DMBV8PT ID DMBV8PT
DMBV8PT DN 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DMBV8PT HS Investigative
DMBV8PT SN CHEMBL202479; 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4933112
DMBV8PT DT Small molecular drug
DMBV8PT PC 11152502
DMBV8PT MW 357.23
DMBV8PT FM C15H20INO
DMBV8PT IC InChI=1S/C15H20INO/c1-2-5-14(17-10-3-4-11-17)15(18)12-6-8-13(16)9-7-12/h6-9,14H,2-5,10-11H2,1H3
DMBV8PT CS CCCC(C(=O)C1=CC=C(C=C1)I)N2CCCC2
DMBV8PT IK QXBWECFEEZMKTN-UHFFFAOYSA-N
DMBV8PT IU 1-(4-iodophenyl)-2-pyrrolidin-1-ylpentan-1-one
DMBV8PT DE Discovery agent
DMZWRU7 ID DMZWRU7
DMZWRU7 DN 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol
DMZWRU7 HS Investigative
DMZWRU7 SN CHEMBL176319; 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol; SCHEMBL7212147
DMZWRU7 DT Small molecular drug
DMZWRU7 PC 15516781
DMZWRU7 MW 302.5
DMZWRU7 FM C14H22O3S2
DMZWRU7 IC InChI=1S/C14H22O3S2/c1-3-4-5-13(18)10-11-19(15,16)14-8-6-12(17-2)7-9-14/h6-9,13,18H,3-5,10-11H2,1-2H3
DMZWRU7 CS CCCCC(CCS(=O)(=O)C1=CC=C(C=C1)OC)S
DMZWRU7 IK XJUQEFFNMKAWSV-UHFFFAOYSA-N
DMZWRU7 IU 1-(4-methoxyphenyl)sulfonylheptane-3-thiol
DMZWRU7 DE Discovery agent
DMSWJKZ ID DMSWJKZ
DMSWJKZ DN 1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole
DMSWJKZ HS Investigative
DMSWJKZ SN 1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole; 1192811-38-3; CHEMBL591697; SCHEMBL1950743; DTXSID90668214; ZINC45338026; BDBM50307235; AKOS016012754; KB-214961; AJ-110482; AX8249207
DMSWJKZ DT Small molecular drug
DMSWJKZ PC 45103811
DMSWJKZ MW 264.32
DMSWJKZ FM C17H16N2O
DMSWJKZ IC InChI=1S/C17H16N2O/c1-20-16-9-7-14(8-10-16)12-19-13-18-11-17(19)15-5-3-2-4-6-15/h2-11,13H,12H2,1H3
DMSWJKZ CS COC1=CC=C(C=C1)CN2C=NC=C2C3=CC=CC=C3
DMSWJKZ IK AZQFSYIIRUWICT-UHFFFAOYSA-N
DMSWJKZ IU 1-[(4-methoxyphenyl)methyl]-5-phenylimidazole
DMSWJKZ CA CAS 1192811-38-3
DMSWJKZ DE Discovery agent
DMEPJRD ID DMEPJRD
DMEPJRD DN 1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one
DMEPJRD HS Investigative
DMEPJRD SN CHEMBL526161; 1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2163269
DMEPJRD DT Small molecular drug
DMEPJRD PC 44554788
DMEPJRD MW 287.35
DMEPJRD FM C17H21NO3
DMEPJRD IC InChI=1S/C17H21NO3/c1-20-16-13-21-17(18-16)15(19)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMEPJRD CS COC1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DMEPJRD IK PLTPISAOEFIJFK-UHFFFAOYSA-N
DMEPJRD IU 1-(4-methoxy-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMEPJRD DE Discovery agent
DMAW78K ID DMAW78K
DMAW78K DN 1-(4-methoxyphenethyl)pyrrolidine
DMAW78K HS Investigative
DMAW78K SN CHEMBL272307; 1-(4-methoxyphenethyl)pyrrolidine
DMAW78K DT Small molecular drug
DMAW78K PC 17805318
DMAW78K MW 205.3
DMAW78K FM C13H19NO
DMAW78K IC InChI=1S/C13H19NO/c1-15-13-6-4-12(5-7-13)8-11-14-9-2-3-10-14/h4-7H,2-3,8-11H2,1H3
DMAW78K CS COC1=CC=C(C=C1)CCN2CCCC2
DMAW78K IK JMIPWGFKCQDIBK-UHFFFAOYSA-N
DMAW78K IU 1-[2-(4-methoxyphenyl)ethyl]pyrrolidine
DMAW78K DE Discovery agent
DMRC7V8 ID DMRC7V8
DMRC7V8 DN 1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone
DMRC7V8 HS Investigative
DMRC7V8 SN CHEMBL238620; 27918-37-2; 1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone; 1-(4-methoxyphenyl)-2-(phenylsulfonyl)-1-ethanone; AC1N74YZ; Oprea1_356612; 2-(benzenesulfonyl)-1-(4-methoxyphenyl)ethanone; SCHEMBL6203408; CTK0J2325; DTXSID00401432; MolPort-002-876-892; ZINC399878; KS-00003CN3; BDBM50212535; AKOS005097711; 7H-365S; MCULE-5138703884; 4'-Methoxy-alpha-(phenylsulfonyl)acetophenone; 4'-METHOXY-2-(PHENYLSULFONYL)ACETOPHENONE; Ethanone, 1-(4-methoxyphenyl)-2-(phenylsulfonyl)-
DMRC7V8 DT Small molecular drug
DMRC7V8 PC 4271571
DMRC7V8 MW 290.3
DMRC7V8 FM C15H14O4S
DMRC7V8 IC InChI=1S/C15H14O4S/c1-19-13-9-7-12(8-10-13)15(16)11-20(17,18)14-5-3-2-4-6-14/h2-10H,11H2,1H3
DMRC7V8 CS COC1=CC=C(C=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2
DMRC7V8 IK ZVVAUSXHYOKZSR-UHFFFAOYSA-N
DMRC7V8 IU 2-(benzenesulfonyl)-1-(4-methoxyphenyl)ethanone
DMRC7V8 CA CAS 27918-37-2
DMRC7V8 DE Discovery agent
DM5R8KU ID DM5R8KU
DM5R8KU DN 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione
DM5R8KU HS Investigative
DM5R8KU SN 4-Methoxybenzil; p-Methoxybenzil; BENZIL, 4-METHOXY-; 22711-21-3; Ethanedione, (4-methoxyphenyl)phenyl-; NSC 39465; 1-(4-methoxyphenyl)-2-phenylethane-1,2-dione; BRN 2052507; NTINAJCDYRYMML-UHFFFAOYSA-N; NSC39465; Dibenzoyl, 4-methoxy; AC1L1LPW; Benzil-based compound, 20; 4-08-00-02532 (Beilstein Handbook Reference); SCHEMBL2156563; CHEMBL192474; BDBM22742; DTXSID40177245; MolPort-001-788-309; 4-Methoxybibenzyl-alpha,beta-dione; ZINC1671392; STK863335; NSC-39465; BBL023172; NSC602911; AKOS000298817; NSC-602911; MCULE-6173981634
DM5R8KU DT Small molecular drug
DM5R8KU PC 31494
DM5R8KU MW 240.25
DM5R8KU FM C15H12O3
DM5R8KU IC InChI=1S/C15H12O3/c1-18-13-9-7-12(8-10-13)15(17)14(16)11-5-3-2-4-6-11/h2-10H,1H3
DM5R8KU CS COC1=CC=C(C=C1)C(=O)C(=O)C2=CC=CC=C2
DM5R8KU IK NTINAJCDYRYMML-UHFFFAOYSA-N
DM5R8KU IU 1-(4-methoxyphenyl)-2-phenylethane-1,2-dione
DM5R8KU CA CAS 22711-21-3
DM5R8KU DE Discovery agent
DMNJ2CS ID DMNJ2CS
DMNJ2CS DN 1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea
DMNJ2CS HS Investigative
DMNJ2CS SN CHEMBL389884; ZINC28225822
DMNJ2CS DT Small molecular drug
DMNJ2CS PC 35523889
DMNJ2CS MW 250.28
DMNJ2CS FM C10H10N4O2S
DMNJ2CS IC InChI=1S/C10H10N4O2S/c1-16-8-4-2-7(3-5-8)12-9(15)13-10-14-11-6-17-10/h2-6H,1H3,(H2,12,13,14,15)
DMNJ2CS CS COC1=CC=C(C=C1)NC(=O)NC2=NN=CS2
DMNJ2CS IK WRRMEHJVEKNTQJ-UHFFFAOYSA-N
DMNJ2CS IU 1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea
DMNJ2CS DE Discovery agent
DMYPC0W ID DMYPC0W
DMYPC0W DN 1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea
DMYPC0W HS Investigative
DMYPC0W SN CHEMBL375257
DMYPC0W DT Small molecular drug
DMYPC0W PC 44423266
DMYPC0W MW 263.32
DMYPC0W FM C12H13N3O2S
DMYPC0W IC InChI=1S/C12H13N3O2S/c1-8-7-18-12(13-8)15-11(16)14-9-3-5-10(17-2)6-4-9/h3-7H,1-2H3,(H2,13,14,15,16)
DMYPC0W CS CC1=CSC(=N1)NC(=O)NC2=CC=C(C=C2)OC
DMYPC0W IK DEHFWCRYQNJICK-UHFFFAOYSA-N
DMYPC0W IU 1-(4-methoxyphenyl)-3-(4-methyl-1,3-thiazol-2-yl)urea
DMYPC0W DE Discovery agent
DMVWIE5 ID DMVWIE5
DMVWIE5 DN 1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea
DMVWIE5 HS Investigative
DMVWIE5 SN AC1LGH35; CHEMBL226324
DMVWIE5 DT Small molecular drug
DMVWIE5 PC 771042
DMVWIE5 MW 263.32
DMVWIE5 FM C12H13N3O2S
DMVWIE5 IC InChI=1S/C12H13N3O2S/c1-8-7-13-12(18-8)15-11(16)14-9-3-5-10(17-2)6-4-9/h3-7H,1-2H3,(H2,13,14,15,16)
DMVWIE5 CS CC1=CN=C(S1)NC(=O)NC2=CC=C(C=C2)OC
DMVWIE5 IK OHPUNXDCCJNSEH-UHFFFAOYSA-N
DMVWIE5 IU 1-(4-methoxyphenyl)-3-(5-methyl-1,3-thiazol-2-yl)urea
DMVWIE5 DE Discovery agent
DMG7PKA ID DMG7PKA
DMG7PKA DN 1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol
DMG7PKA HS Investigative
DMG7PKA SN CHEMBL561076; 1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol; SCHEMBL12549973
DMG7PKA DT Small molecular drug
DMG7PKA PC 25192455
DMG7PKA MW 361.5
DMG7PKA FM C19H23NO4S
DMG7PKA IC InChI=1S/C19H23NO4S/c1-24-17-8-10-18(11-9-17)25(22,23)20-14-5-12-19(21,13-15-20)16-6-3-2-4-7-16/h2-4,6-11,21H,5,12-15H2,1H3
DMG7PKA CS COC1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)(C3=CC=CC=C3)O
DMG7PKA IK CTMRNVLOBOSBEA-UHFFFAOYSA-N
DMG7PKA IU 1-(4-methoxyphenyl)sulfonyl-4-phenylazepan-4-ol
DMG7PKA DE Discovery agent
DMNDJTL ID DMNDJTL
DMNDJTL DN 1'-(4-Methyl-benzyl)-[1,4']bipiperidinyl
DMNDJTL HS Investigative
DMNDJTL SN CHEMBL399558; Tyrosinase Inhibitor, 4; BDBM50218211
DMNDJTL DT Small molecular drug
DMNDJTL PC 23727896
DMNDJTL MW 272.4
DMNDJTL FM C18H28N2
DMNDJTL IC InChI=1S/C18H28N2/c1-16-5-7-17(8-6-16)15-19-13-9-18(10-14-19)20-11-3-2-4-12-20/h5-8,18H,2-4,9-15H2,1H3
DMNDJTL CS CC1=CC=C(C=C1)CN2CCC(CC2)N3CCCCC3
DMNDJTL IK XJYLZLHTPACMIL-UHFFFAOYSA-N
DMNDJTL IU 1-[(4-methylphenyl)methyl]-4-piperidin-1-ylpiperidine
DMNDJTL DE Discovery agent
DM48ISZ ID DM48ISZ
DM48ISZ DN 1-(4-methyl-benzyl)-1H-imidazole
DM48ISZ HS Investigative
DM48ISZ SN 1-(4-methylbenzyl)-1H-imidazole; CHEMBL212741; 18994-86-0; 1-(4-methyl-benzyl)-1H-imidazole; 1H-Imidazole, 1-[(4-methylphenyl)methyl]-; 1-(4-Methylbenzyl)imidazole; SCHEMBL171734; BDBM50188087; ZINC35143440
DM48ISZ DT Small molecular drug
DM48ISZ PC 12229395
DM48ISZ MW 172.23
DM48ISZ FM C11H12N2
DM48ISZ IC InChI=1S/C11H12N2/c1-10-2-4-11(5-3-10)8-13-7-6-12-9-13/h2-7,9H,8H2,1H3
DM48ISZ CS CC1=CC=C(C=C1)CN2C=CN=C2
DM48ISZ IK DQXGQHAFADWCKG-UHFFFAOYSA-N
DM48ISZ IU 1-[(4-methylphenyl)methyl]imidazole
DM48ISZ DE Discovery agent
DMVI2PM ID DMVI2PM
DMVI2PM DN 1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one
DMVI2PM HS Investigative
DMVI2PM SN CHEMBL462405; 1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL2162404
DMVI2PM DT Small molecular drug
DMVI2PM PC 44554442
DMVI2PM MW 271.35
DMVI2PM FM C17H21NO2
DMVI2PM IC InChI=1S/C17H21NO2/c1-14-13-20-17(18-14)16(19)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMVI2PM CS CC1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DMVI2PM IK UCOJBUIULZAIKB-UHFFFAOYSA-N
DMVI2PM IU 1-(4-methyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMVI2PM DE Discovery agent
DM3NVLB ID DM3NVLB
DM3NVLB DN 1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide
DM3NVLB HS Investigative
DM3NVLB SN CHEMBL444251; 1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide
DM3NVLB DT Small molecular drug
DM3NVLB PC 44583134
DM3NVLB MW 171.27
DM3NVLB FM C7H13N3S
DM3NVLB IC InChI=1S/C7H13N3S/c1-5(2)4-6(3)9-10-7(8)11/h4H,1-3H3,(H3,8,10,11)/b9-6-
DM3NVLB CS CC(=C/C(=N\\NC(=S)N)/C)C
DM3NVLB IK KSBSSDJKRMIXES-TWGQIWQCSA-N
DM3NVLB IU [(Z)-4-methylpent-3-en-2-ylideneamino]thiourea
DM3NVLB DE Discovery agent
DMSRBUE ID DMSRBUE
DMSRBUE DN 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole
DMSRBUE HS Investigative
DMSRBUE SN CHEMBL1083653; 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole
DMSRBUE DT Small molecular drug
DMSRBUE PC 46867546
DMSRBUE MW 295.29
DMSRBUE FM C16H13N3O3
DMSRBUE IC InChI=1S/C16H13N3O3/c20-19(21)14-7-6-13(11-18-9-8-17-12-18)16(10-14)22-15-4-2-1-3-5-15/h1-10,12H,11H2
DMSRBUE CS C1=CC=C(C=C1)OC2=C(C=CC(=C2)[N+](=O)[O-])CN3C=CN=C3
DMSRBUE IK JIPGEBKJKOMJSL-UHFFFAOYSA-N
DMSRBUE IU 1-[(4-nitro-2-phenoxyphenyl)methyl]imidazole
DMSRBUE DE Discovery agent
DMCP089 ID DMCP089
DMCP089 DN 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole
DMCP089 HS Investigative
DMCP089 SN CHEMBL1085936; 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole
DMCP089 DT Small molecular drug
DMCP089 PC 46867547
DMCP089 MW 311.4
DMCP089 FM C16H13N3O2S
DMCP089 IC InChI=1S/C16H13N3O2S/c20-19(21)14-7-6-13(11-18-9-8-17-12-18)16(10-14)22-15-4-2-1-3-5-15/h1-10,12H,11H2
DMCP089 CS C1=CC=C(C=C1)SC2=C(C=CC(=C2)[N+](=O)[O-])CN3C=CN=C3
DMCP089 IK FOCINXPGESCYHX-UHFFFAOYSA-N
DMCP089 IU 1-[(4-nitro-2-phenylsulfanylphenyl)methyl]imidazole
DMCP089 DE Discovery agent
DMKT2MB ID DMKT2MB
DMKT2MB DN 1-(4-nitrobenzyl)-1H-imidazole
DMKT2MB HS Investigative
DMKT2MB SN 1-(4-Nitrobenzyl)-1H-imidazole; 18994-90-6; 1-(4-Nitrobenzyl)imidazole; 1-[(4-nitrophenyl)methyl]imidazole; Imidazole, 1-(4-nitrobenzyl)-; CHEMBL13784; 1H-Imidazole, 1-[(4-nitrophenyl)methyl]-; FLYGQJXMRPZYHQ-UHFFFAOYSA-N; 1-(4-Nitro-benzyl)-1H-imidazole; [(4-nitrophenyl)methyl]imidazole; AC1LBNLW; AC1Q1ZC3; ACMC-1C81T; SCHEMBL78081; CTK4E0266; DTXSID10342908; MolPort-001-494-965; KS-000024IG; ZINC1027711; ALBB-024046; CN-460; ANW-23472; STK149522; SBB093104; BDBM50188093; 1-(4-Nitrobenzyl)-1H-imidazole #; AKOS003266265; VI10027
DMKT2MB DT Small molecular drug
DMKT2MB PC 585819
DMKT2MB MW 203.2
DMKT2MB FM C10H9N3O2
DMKT2MB IC InChI=1S/C10H9N3O2/c14-13(15)10-3-1-9(2-4-10)7-12-6-5-11-8-12/h1-6,8H,7H2
DMKT2MB CS C1=CC(=CC=C1CN2C=CN=C2)[N+](=O)[O-]
DMKT2MB IK FLYGQJXMRPZYHQ-UHFFFAOYSA-N
DMKT2MB IU 1-[(4-nitrophenyl)methyl]imidazole
DMKT2MB CA CAS 18994-90-6
DMKT2MB DE Discovery agent
DMKR8BI ID DMKR8BI
DMKR8BI DN 1-(4-nitrophenethyl)pyrrolidine
DMKR8BI HS Investigative
DMKR8BI SN 1-(4-nitrophenethyl)pyrrolidine; CHEMBL273004; 168897-19-6; Pyrrolidine, 1-[2-(4-nitrophenyl)ethyl]-; SCHEMBL3156895; CTK0E5156; DTXSID90441428; YFOCDNYNVHXLJE-UHFFFAOYSA-N; BDBM50372307; ZINC29131362; 1-[2-(4-nitrophenyl)-ethyl]-pyrrolidine
DMKR8BI DT Small molecular drug
DMKR8BI PC 10536901
DMKR8BI MW 220.27
DMKR8BI FM C12H16N2O2
DMKR8BI IC InChI=1S/C12H16N2O2/c15-14(16)12-5-3-11(4-6-12)7-10-13-8-1-2-9-13/h3-6H,1-2,7-10H2
DMKR8BI CS C1CCN(C1)CCC2=CC=C(C=C2)[N+](=O)[O-]
DMKR8BI IK YFOCDNYNVHXLJE-UHFFFAOYSA-N
DMKR8BI IU 1-[2-(4-nitrophenyl)ethyl]pyrrolidine
DMKR8BI CA CAS 168897-19-6
DMKR8BI DE Discovery agent
DM1M67Q ID DM1M67Q
DM1M67Q DN 1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone
DM1M67Q HS Investigative
DM1M67Q SN CHEMBL393284; 38488-17-4; 1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone; 4-Nitrophenacylphenyl sulfone; SCHEMBL6908652; CTK1B4829; DTXSID80456743; BDBM50212551; AKOS003309631; Ethanone, 1-(4-nitrophenyl)-2-(phenylsulfonyl)-
DM1M67Q DT Small molecular drug
DM1M67Q PC 11141268
DM1M67Q MW 305.31
DM1M67Q FM C14H11NO5S
DM1M67Q IC InChI=1S/C14H11NO5S/c16-14(11-6-8-12(9-7-11)15(17)18)10-21(19,20)13-4-2-1-3-5-13/h1-9H,10H2
DM1M67Q CS C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CC=C(C=C2)[N+](=O)[O-]
DM1M67Q IK GBLYERGOMLTORH-UHFFFAOYSA-N
DM1M67Q IU 2-(benzenesulfonyl)-1-(4-nitrophenyl)ethanone
DM1M67Q CA CAS 38488-17-4
DM1M67Q DE Discovery agent
DMOC67J ID DMOC67J
DMOC67J DN 1-(4-Nitro-phenyl)-2-phenyl-ethane-1,2-dione
DMOC67J HS Investigative
DMOC67J SN 4-Nitrobenzil; 1-(4-nitrophenyl)-2-phenylethane-1,2-dione; 22711-24-6; Benzil, 4-nitro-; p-Nitrobenzil; Ethanedione, (4-nitrophenyl)phenyl-; NSC139153; Benzil-based compound, 27; AC1Q5B1C; AC1L5ZN0; SCHEMBL1370034; CHEMBL192589; BDBM22749; CTK4F0012; 4-Nitrobibenzyl-alpha,beta-dione; DTXSID10300826; GPDKREBNFFEDHW-UHFFFAOYSA-N; MolPort-000-146-024; ZX-AT021384; ZINC2555760; STK325617; SBB101571; AKOS004902243; OR28786; NSC-139153; MCULE-2855880102; ACM22711246; KB-147450; DB-045974; FT-0605764; ST51043016
DMOC67J DT Small molecular drug
DMOC67J PC 283893
DMOC67J MW 255.22
DMOC67J FM C14H9NO4
DMOC67J IC InChI=1S/C14H9NO4/c16-13(10-4-2-1-3-5-10)14(17)11-6-8-12(9-7-11)15(18)19/h1-9H
DMOC67J CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)[N+](=O)[O-]
DMOC67J IK GPDKREBNFFEDHW-UHFFFAOYSA-N
DMOC67J IU 1-(4-nitrophenyl)-2-phenylethane-1,2-dione
DMOC67J CA CAS 22711-24-6
DMOC67J DE Discovery agent
DME435S ID DME435S
DME435S DN 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one
DME435S HS Investigative
DME435S SN CHEMBL379446; 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4938101
DME435S DT Small molecular drug
DME435S PC 11357862
DME435S MW 276.33
DME435S FM C15H20N2O3
DME435S IC InChI=1S/C15H20N2O3/c1-2-5-14(16-10-3-4-11-16)15(18)12-6-8-13(9-7-12)17(19)20/h6-9,14H,2-5,10-11H2,1H3
DME435S CS CCCC(C(=O)C1=CC=C(C=C1)[N+](=O)[O-])N2CCCC2
DME435S IK NAHZCGQMXZCULW-UHFFFAOYSA-N
DME435S IU 1-(4-nitrophenyl)-2-pyrrolidin-1-ylpentan-1-one
DME435S DE Discovery agent
DMQKMCG ID DMQKMCG
DMQKMCG DN 1-(4-nonylbenzyl)azetidine-3-carboxylic acid
DMQKMCG HS Investigative
DMQKMCG SN CHEMBL224623; 570423-68-6; 1-(4-nonylbenzyl)azetidine-3-carboxylic acid; SCHEMBL13271128; CTK1F3133; DTXSID30436176; BDBM50158342; AKOS030540874; 3-Azetidinecarboxylic acid, 1-[(4-nonylphenyl)methyl]-
DMQKMCG DT Small molecular drug
DMQKMCG PC 10149721
DMQKMCG MW 317.5
DMQKMCG FM C20H31NO2
DMQKMCG IC InChI=1S/C20H31NO2/c1-2-3-4-5-6-7-8-9-17-10-12-18(13-11-17)14-21-15-19(16-21)20(22)23/h10-13,19H,2-9,14-16H2,1H3,(H,22,23)
DMQKMCG CS CCCCCCCCCC1=CC=C(C=C1)CN2CC(C2)C(=O)O
DMQKMCG IK OVHZTRSKNATTNM-UHFFFAOYSA-N
DMQKMCG IU 1-[(4-nonylphenyl)methyl]azetidine-3-carboxylic acid
DMQKMCG CA CAS 570423-68-6
DMQKMCG DE Discovery agent
DM8U2HP ID DM8U2HP
DM8U2HP DN 1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid
DM8U2HP HS Investigative
DM8U2HP SN CHEMBL184349; 570423-38-0; 1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid; SCHEMBL13937997; CTK1F3135; DTXSID10437782; PRUUCTGBHIGGOH-UHFFFAOYSA-N; BDBM50152329; [1-(4-Nonyl-benzyl)-pyrrolidin-3-yl]-phosphonic acid; (r/s)-1-(4-nonylbenzyl)-pyrrolidin-3-ylphosphonic acid; Phosphonic acid, [1-[(4-nonylphenyl)methyl]-3-pyrrolidinyl]-
DM8U2HP DT Small molecular drug
DM8U2HP PC 10287034
DM8U2HP MW 367.5
DM8U2HP FM C20H34NO3P
DM8U2HP IC InChI=1S/C20H34NO3P/c1-2-3-4-5-6-7-8-9-18-10-12-19(13-11-18)16-21-15-14-20(17-21)25(22,23)24/h10-13,20H,2-9,14-17H2,1H3,(H2,22,23,24)
DM8U2HP CS CCCCCCCCCC1=CC=C(C=C1)CN2CCC(C2)P(=O)(O)O
DM8U2HP IK PRUUCTGBHIGGOH-UHFFFAOYSA-N
DM8U2HP IU [1-[(4-nonylphenyl)methyl]pyrrolidin-3-yl]phosphonic acid
DM8U2HP CA CAS 570423-38-0
DM8U2HP DE Discovery agent
DMAR39L ID DMAR39L
DMAR39L DN 1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid
DMAR39L HS Investigative
DMAR39L SN CHEMBL224703; 570423-46-0; 1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid; SCHEMBL6179612; CTK1F3134; DTXSID10436795; BDBM50158343; AKOS030543683; 3-Pyrrolidinecarboxylic acid, 1-[(4-nonylphenyl)methyl]-
DMAR39L DT Small molecular drug
DMAR39L PC 10215259
DMAR39L MW 331.5
DMAR39L FM C21H33NO2
DMAR39L IC InChI=1S/C21H33NO2/c1-2-3-4-5-6-7-8-9-18-10-12-19(13-11-18)16-22-15-14-20(17-22)21(23)24/h10-13,20H,2-9,14-17H2,1H3,(H,23,24)
DMAR39L CS CCCCCCCCCC1=CC=C(C=C1)CN2CCC(C2)C(=O)O
DMAR39L IK JXGNTXCFTVWCAS-UHFFFAOYSA-N
DMAR39L IU 1-[(4-nonylphenyl)methyl]pyrrolidine-3-carboxylic acid
DMAR39L CA CAS 570423-46-0
DMAR39L DE Discovery agent
DM9KVBJ ID DM9KVBJ
DM9KVBJ DN 1-(4-octylphenyl)prop-2-en-1-one
DM9KVBJ HS Investigative
DM9KVBJ SN CHEMBL237241
DM9KVBJ DT Small molecular drug
DM9KVBJ PC 44435785
DM9KVBJ MW 244.37
DM9KVBJ FM C17H24O
DM9KVBJ IC InChI=1S/C17H24O/c1-3-5-6-7-8-9-10-15-11-13-16(14-12-15)17(18)4-2/h4,11-14H,2-3,5-10H2,1H3
DM9KVBJ CS CCCCCCCCC1=CC=C(C=C1)C(=O)C=C
DM9KVBJ IK GXBVBDUWTMDYAH-UHFFFAOYSA-N
DM9KVBJ IU 1-(4-octylphenyl)prop-2-en-1-one
DM9KVBJ DE Discovery agent
DMVCM0I ID DMVCM0I
DMVCM0I DN 1-(4-Phenoxyphenyl)piperazine
DMVCM0I HS Investigative
DMVCM0I SN 1-(4-Phenoxyphenyl)piperazine; CHEMBL576512; 62755-61-7; EINECS 263-715-9; AC1MI4LW; Oprea1_372692; SCHEMBL2156502; 1-(4-phenoxylphenyl)piperazine; 1-(4-phenoxyphenyl)-piperazine; CEDIEUVYUSGIDQ-UHFFFAOYSA-N; Piperazine, 1-(4-phenoxyphenyl)-; BDBM50303652; ZINC11632570; AKOS000365585
DMVCM0I DT Small molecular drug
DMVCM0I PC 3017356
DMVCM0I MW 254.33
DMVCM0I FM C16H18N2O
DMVCM0I IC InChI=1S/C16H18N2O/c1-2-4-15(5-3-1)19-16-8-6-14(7-9-16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DMVCM0I CS C1CN(CCN1)C2=CC=C(C=C2)OC3=CC=CC=C3
DMVCM0I IK CEDIEUVYUSGIDQ-UHFFFAOYSA-N
DMVCM0I IU 1-(4-phenoxyphenyl)piperazine
DMVCM0I CA CAS 62755-61-7
DMVCM0I DE Discovery agent
DMKNA5U ID DMKNA5U
DMKNA5U DN 1-(4-propoxyphenyl)propan-2-amine
DMKNA5U HS Investigative
DMKNA5U SN 1-(4-propoxyphenyl)propan-2-amine; CHEMBL455991; AC1MHJ8Q; BDBM50276773
DMKNA5U DT Small molecular drug
DMKNA5U PC 3027265
DMKNA5U MW 193.28
DMKNA5U FM C12H19NO
DMKNA5U IC InChI=1S/C12H19NO/c1-3-8-14-12-6-4-11(5-7-12)9-10(2)13/h4-7,10H,3,8-9,13H2,1-2H3
DMKNA5U CS CCCOC1=CC=C(C=C1)CC(C)N
DMKNA5U IK NVNUOGJMXPVHLF-UHFFFAOYSA-N
DMKNA5U IU 1-(4-propoxyphenyl)propan-2-amine
DMKNA5U DE Discovery agent
DMFYK6T ID DMFYK6T
DMFYK6T DN 1-(4-p-Tolyl-butyl)-piperidine
DMFYK6T HS Investigative
DMFYK6T SN CHEMBL571073; 1-(4-p-Tolyl-butyl)-piperidine
DMFYK6T DT Small molecular drug
DMFYK6T PC 45485498
DMFYK6T MW 231.38
DMFYK6T FM C16H25N
DMFYK6T IC InChI=1S/C16H25N/c1-15-8-10-16(11-9-15)7-3-6-14-17-12-4-2-5-13-17/h8-11H,2-7,12-14H2,1H3
DMFYK6T CS CC1=CC=C(C=C1)CCCCN2CCCCC2
DMFYK6T IK ZJZNOPQUDXUEDU-UHFFFAOYSA-N
DMFYK6T IU 1-[4-(4-methylphenyl)butyl]piperidine
DMFYK6T DE Discovery agent
DMM7IJZ ID DMM7IJZ
DMM7IJZ DN 1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane
DMM7IJZ HS Investigative
DMM7IJZ SN CHEMBL560396; 1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane; SCHEMBL12549992
DMM7IJZ DT Small molecular drug
DMM7IJZ PC 25192606
DMM7IJZ MW 325.5
DMM7IJZ FM C17H27NO3S
DMM7IJZ IC InChI=1S/C17H27NO3S/c1-17(2,3)14-7-9-16(10-8-14)22(19,20)18-12-5-6-15(21-4)11-13-18/h7-10,15H,5-6,11-13H2,1-4H3
DMM7IJZ CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)OC
DMM7IJZ IK XPMSNNNCHQEDRB-UHFFFAOYSA-N
DMM7IJZ IU 1-(4-tert-butylphenyl)sulfonyl-4-methoxyazepane
DMM7IJZ DE Discovery agent
DMQECWT ID DMQECWT
DMQECWT DN 1-(4-tert-butylphenylsulfonyl)azepan-4-ol
DMQECWT HS Investigative
DMQECWT SN CHEMBL539200; 1-(4-tert-butylphenylsulfonyl)azepan-4-ol; SCHEMBL12550392
DMQECWT DT Small molecular drug
DMQECWT PC 25192605
DMQECWT MW 311.4
DMQECWT FM C16H25NO3S
DMQECWT IC InChI=1S/C16H25NO3S/c1-16(2,3)13-6-8-15(9-7-13)21(19,20)17-11-4-5-14(18)10-12-17/h6-9,14,18H,4-5,10-12H2,1-3H3
DMQECWT CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N2CCCC(CC2)O
DMQECWT IK GHPTYGKGUJYMFW-UHFFFAOYSA-N
DMQECWT IU 1-(4-tert-butylphenyl)sulfonylazepan-4-ol
DMQECWT DE Discovery agent
DMPL3UZ ID DMPL3UZ
DMPL3UZ DN 1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one
DMPL3UZ HS Investigative
DMPL3UZ SN CHEMBL174048; 1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one; SCHEMBL3196395; BDBM50157127; (Z)-1-(5-Furan-2-yl-oxazol-2-yl)-octadec-9-en-1-one
DMPL3UZ DT Small molecular drug
DMPL3UZ PC 11361560
DMPL3UZ MW 399.6
DMPL3UZ FM C25H37NO3
DMPL3UZ IC InChI=1S/C25H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-22(27)25-26-21-24(29-25)23-19-17-20-28-23/h9-10,17,19-21H,2-8,11-16,18H2,1H3/b10-9-
DMPL3UZ CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CO2
DMPL3UZ IK RZGSPAWMLKONHZ-KTKRTIGZSA-N
DMPL3UZ IU (Z)-1-[5-(furan-2-yl)-1,3-oxazol-2-yl]octadec-9-en-1-one
DMPL3UZ DE Discovery agent
DM4V9IB ID DM4V9IB
DM4V9IB DN 1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one
DM4V9IB HS Investigative
DM4V9IB SN CHEMBL177757; 1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one; SCHEMBL3184225; VESZWTBYTDWAEO-UHFFFAOYSA-N; BDBM50163165
DM4V9IB DT Small molecular drug
DM4V9IB PC 11450288
DM4V9IB MW 328.4
DM4V9IB FM C20H28N2O2
DM4V9IB IC InChI=1S/C20H28N2O2/c1-2-3-4-5-6-7-8-9-10-14-18(23)20-22-16-19(24-20)17-13-11-12-15-21-17/h11-13,15-16H,2-10,14H2,1H3
DM4V9IB CS CCCCCCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DM4V9IB IK VESZWTBYTDWAEO-UHFFFAOYSA-N
DM4V9IB IU 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)dodecan-1-one
DM4V9IB DE Discovery agent
DMICZK0 ID DMICZK0
DMICZK0 DN 1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one
DMICZK0 HS Investigative
DMICZK0 SN CHEMBL426230; SCHEMBL3193600; 1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one; 2-Oleoyl-5-(2-pyridyl)oxazole; BDBM50157122; AKOS030561894; 1-(5-Pyridin-2-yl-oxazol-2-yl)-nonadec-10-en-2-one; (Z)-1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-en-1-one
DMICZK0 DT Small molecular drug
DMICZK0 PC 11327355
DMICZK0 MW 410.6
DMICZK0 FM C26H38N2O2
DMICZK0 IC InChI=1S/C26H38N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-24(29)26-28-22-25(30-26)23-19-17-18-21-27-23/h9-10,17-19,21-22H,2-8,11-16,20H2,1H3/b10-9-
DMICZK0 CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DMICZK0 IK MTEOAQVTLKPFRA-KTKRTIGZSA-N
DMICZK0 IU (Z)-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octadec-9-en-1-one
DMICZK0 CA CAS 639819-38-8
DMICZK0 DE Discovery agent
DMZNEIB ID DMZNEIB
DMZNEIB DN 1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one
DMZNEIB HS Investigative
DMZNEIB SN CHEMBL175021; 1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one; SCHEMBL3197441; VLJKBQYNIDBQEJ-UHFFFAOYSA-N; BDBM50163176
DMZNEIB DT Small molecular drug
DMZNEIB PC 11173328
DMZNEIB MW 272.34
DMZNEIB FM C16H20N2O2
DMZNEIB IC InChI=1S/C16H20N2O2/c1-2-3-4-5-6-10-14(19)16-18-12-15(20-16)13-9-7-8-11-17-13/h7-9,11-12H,2-6,10H2,1H3
DMZNEIB CS CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DMZNEIB IK VLJKBQYNIDBQEJ-UHFFFAOYSA-N
DMZNEIB IU 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octan-1-one
DMZNEIB DE Discovery agent
DM6FDAY ID DM6FDAY
DM6FDAY DN 1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one
DM6FDAY HS Investigative
DM6FDAY SN CHEMBL174951; 1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one; SCHEMBL3194478; BDBM50163189
DM6FDAY DT Small molecular drug
DM6FDAY PC 11401957
DM6FDAY MW 230.26
DM6FDAY FM C13H14N2O2
DM6FDAY IC InChI=1S/C13H14N2O2/c1-2-3-7-11(16)13-15-9-12(17-13)10-6-4-5-8-14-10/h4-6,8-9H,2-3,7H2,1H3
DM6FDAY CS CCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DM6FDAY IK ZGJFSRIJAXSNIH-UHFFFAOYSA-N
DM6FDAY IU 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)pentan-1-one
DM6FDAY DE Discovery agent
DMDTYAF ID DMDTYAF
DMDTYAF DN 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea
DMDTYAF HS Investigative
DMDTYAF SN CHEMBL430376; 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea; 117745-34-3; Urea, N-(5-chloro-2-hydroxy-4-nitrophenyl)-N'-phenyl-; ACMC-20mnej; AC1MXJKZ; SCHEMBL4241814; CTK0G0114; DTXSID10396461; MolPort-001-764-839; ZX-AT026392; ZINC3917497; BDBM50203018; AKOS024384929; MCULE-2402836101; ST51035461; 3-(5-chloro-2-hydroxy-4-nitrophenyl)-1-phenylurea
DMDTYAF DT Small molecular drug
DMDTYAF PC 3791448
DMDTYAF MW 307.69
DMDTYAF FM C13H10ClN3O4
DMDTYAF IC InChI=1S/C13H10ClN3O4/c14-9-6-10(12(18)7-11(9)17(20)21)16-13(19)15-8-4-2-1-3-5-8/h1-7,18H,(H2,15,16,19)
DMDTYAF CS C1=CC=C(C=C1)NC(=O)NC2=CC(=C(C=C2O)[N+](=O)[O-])Cl
DMDTYAF IK ASMCVDDUQQZBFK-UHFFFAOYSA-N
DMDTYAF IU 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea
DMDTYAF CA CAS 117745-34-3
DMDTYAF DE Discovery agent
DMD8IYZ ID DMD8IYZ
DMD8IYZ DN 1-(5-fluorooxazol-2-yl)-7-phenylheptan-1-one
DMD8IYZ HS Investigative
DMD8IYZ SN CHEMBL373906; SCHEMBL3145274; BDBM50374375
DMD8IYZ DT Small molecular drug
DMD8IYZ PC 11991891
DMD8IYZ MW 275.32
DMD8IYZ FM C16H18FNO2
DMD8IYZ IC InChI=1S/C16H18FNO2/c17-15-12-18-16(20-15)14(19)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMD8IYZ CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)F
DMD8IYZ IK KUKHXFUDITXZRG-UHFFFAOYSA-N
DMD8IYZ IU 1-(5-fluoro-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMD8IYZ DE Discovery agent
DMWQ9ZP ID DMWQ9ZP
DMWQ9ZP DN 1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one
DMWQ9ZP HS Investigative
DMWQ9ZP SN CHEMBL220938; SCHEMBL3144951; BDBM50374374; 1-(5-Methyl-2-oxazolyl)-7-phenyl-1-heptanone
DMWQ9ZP DT Small molecular drug
DMWQ9ZP PC 11991888
DMWQ9ZP MW 271.35
DMWQ9ZP FM C17H21NO2
DMWQ9ZP IC InChI=1S/C17H21NO2/c1-14-13-18-17(20-14)16(19)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMWQ9ZP CS CC1=CN=C(O1)C(=O)CCCCCCC2=CC=CC=C2
DMWQ9ZP IK PBGYMEUYJWSKDY-UHFFFAOYSA-N
DMWQ9ZP IU 1-(5-methyl-1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMWQ9ZP DE Discovery agent
DMRITHA ID DMRITHA
DMRITHA DN 1-(5-phenyloxazol-2-yl)octadec-9-en-1-one
DMRITHA HS Investigative
DMRITHA SN CHEMBL426410; 2-Oleoyl-5-phenyloxazole; 1-(5-phenyloxazol-2-yl)octadec-9-en-1-one; SCHEMBL3205790; BDBM50161521; AKOS030561892; 1-(5-Phenyl-oxazol-2-yl)-nonadec-10-en-2-one; (Z)-1-(5-phenyloxazol-2-yl)octadec-9-en-1-one
DMRITHA DT Small molecular drug
DMRITHA PC 11154099
DMRITHA MW 409.6
DMRITHA FM C27H39NO2
DMRITHA IC InChI=1S/C27H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-25(29)27-28-23-26(30-27)24-20-17-16-18-21-24/h9-10,16-18,20-21,23H,2-8,11-15,19,22H2,1H3/b10-9-
DMRITHA CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=C2
DMRITHA IK JBJNKCWDUQMEEA-KTKRTIGZSA-N
DMRITHA IU (Z)-1-(5-phenyl-1,3-oxazol-2-yl)octadec-9-en-1-one
DMRITHA CA CAS 681135-40-0
DMRITHA DE Discovery agent
DM4IMON ID DM4IMON
DM4IMON DN 1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one
DM4IMON HS Investigative
DM4IMON SN CHEMBL174397; SCHEMBL3202757; 1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one
DM4IMON DT Small molecular drug
DM4IMON PC 11441196
DM4IMON MW 408.6
DM4IMON FM C26H36N2O2
DM4IMON IC InChI=1S/C26H36N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-24(29)26-28-22-25(30-26)23-19-17-18-21-27-23/h17-19,21-22H,2-8,11-16,20H2,1H3
DM4IMON CS CCCCCCCCC#CCCCCCCCC(=O)C1=NC=C(O1)C2=CC=CC=N2
DM4IMON IK PFSWYEYBMPLGTD-UHFFFAOYSA-N
DM4IMON IU 1-(5-pyridin-2-yl-1,3-oxazol-2-yl)octadec-9-yn-1-one
DM4IMON DE Discovery agent
DMUS9Z3 ID DMUS9Z3
DMUS9Z3 DN 1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3 HS Investigative
DMUS9Z3 SN CHEMBL500364; 1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3 DT Small molecular drug
DMUS9Z3 PC 42625616
DMUS9Z3 MW 166.22
DMUS9Z3 FM C9H14N2O
DMUS9Z3 IC InChI=1S/C9H14N2O/c1-6-3-8(5-7(2)12)11-9(10)4-6/h3-4,7,12H,5H2,1-2H3,(H2,10,11)
DMUS9Z3 CS CC1=CC(=NC(=C1)N)CC(C)O
DMUS9Z3 IK KSEWELLLEMDLDQ-UHFFFAOYSA-N
DMUS9Z3 IU 1-(6-amino-4-methylpyridin-2-yl)propan-2-ol
DMUS9Z3 DE Discovery agent
DMEHK4F ID DMEHK4F
DMEHK4F DN 1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole
DMEHK4F HS Investigative
DMEHK4F SN BDBM8918; CHEMBL195629; SCHEMBL4499181; Imidazole-substituted naphthalene 25; ZINC13674484; 1-(6-methoxy-2-naphthyl)-1h-imidazole
DMEHK4F DT Small molecular drug
DMEHK4F PC 11514098
DMEHK4F MW 224.26
DMEHK4F FM C14H12N2O
DMEHK4F IC InChI=1S/C14H12N2O/c1-17-14-5-3-11-8-13(4-2-12(11)9-14)16-7-6-15-10-16/h2-10H,1H3
DMEHK4F CS COC1=CC2=C(C=C1)C=C(C=C2)N3C=CN=C3
DMEHK4F IK IARFMQDFBJWHDO-UHFFFAOYSA-N
DMEHK4F IU 1-(6-methoxynaphthalen-2-yl)imidazole
DMEHK4F DE Discovery agent
DM7OGLI ID DM7OGLI
DM7OGLI DN 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea
DM7OGLI HS Investigative
DM7OGLI SN Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea
DM7OGLI DT Small molecular drug
DM7OGLI PC 5330595
DM7OGLI MW 279.29
DM7OGLI FM C16H13N3O2
DM7OGLI IC InChI=1S/C16H13N3O2/c20-12-8-7-11-4-3-5-14(13(11)10-12)18-16(21)19-15-6-1-2-9-17-15/h1-10,20H,(H2,17,18,19,21)
DM7OGLI CS C1=CC=NC(=C1)NC(=O)NC2=CC=CC3=C2C=C(C=C3)O
DM7OGLI IK PLKPAJOIRNQZMG-UHFFFAOYSA-N
DM7OGLI IU 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea
DM7OGLI DE Discovery agent
DMLHDE3 ID DMLHDE3
DMLHDE3 DN 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole
DMLHDE3 HS Investigative
DMLHDE3 SN CHEMBL95109; 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole
DMLHDE3 DT Small molecular drug
DMLHDE3 PC 10267149
DMLHDE3 MW 306.4
DMLHDE3 FM C19H18N2O2
DMLHDE3 IC InChI=1S/C19H18N2O2/c1-22-15-7-8-16-17(21-10-9-20-13-21)12-18(23-19(16)11-15)14-5-3-2-4-6-14/h2-11,13,17-18H,12H2,1H3
DMLHDE3 CS COC1=CC2=C(C=C1)C(CC(O2)C3=CC=CC=C3)N4C=CN=C4
DMLHDE3 IK JEQHTTKNYWNYDK-UHFFFAOYSA-N
DMLHDE3 IU 1-(7-methoxy-2-phenyl-3,4-dihydro-2H-chromen-4-yl)imidazole
DMLHDE3 DE Discovery agent
DM1MJCE ID DM1MJCE
DM1MJCE DN 1-(7-Methoxy-naphthalen-2-yl)-piperazine
DM1MJCE HS Investigative
DM1MJCE SN 1-(7-methoxynaphthalen-2-yl)piperazine; CHEMBL129661; 1174207-86-3; 1-(7-Methoxy-naphthalen-2-yl)-piperazine; ZINC27313663; BDBM50061300; DA-15050
DM1MJCE DT Small molecular drug
DM1MJCE PC 44351692
DM1MJCE MW 242.32
DM1MJCE FM C15H18N2O
DM1MJCE IC InChI=1S/C15H18N2O/c1-18-15-5-3-12-2-4-14(10-13(12)11-15)17-8-6-16-7-9-17/h2-5,10-11,16H,6-9H2,1H3
DM1MJCE CS COC1=CC2=C(C=CC(=C2)N3CCNCC3)C=C1
DM1MJCE IK FRTFBUOBLXTGSL-UHFFFAOYSA-N
DM1MJCE IU 1-(7-methoxynaphthalen-2-yl)piperazine
DM1MJCE DE Discovery agent
DMKHJBI ID DMKHJBI
DMKHJBI DN 1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI HS Investigative
DMKHJBI SN CHEMBL1173069; 1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI DT Small molecular drug
DMKHJBI PC 44191653
DMKHJBI MW 223.27
DMKHJBI FM C15H13NO
DMKHJBI IC InChI=1S/C15H13NO/c1-9-3-5-12-13-8-11(10(2)17)4-6-14(13)16-15(12)7-9/h3-8,16H,1-2H3
DMKHJBI CS CC1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(=O)C
DMKHJBI IK YNKFXJJSPLSRRJ-UHFFFAOYSA-N
DMKHJBI IU 1-(7-methyl-9H-carbazol-3-yl)ethanone
DMKHJBI DE Discovery agent
DMC3PYM ID DMC3PYM
DMC3PYM DN 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
DMC3PYM HS Investigative
DMC3PYM SN PhiKan 083; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
DMC3PYM DT Small molecular drug
DMC3PYM PC 4722579
DMC3PYM MW 238.33
DMC3PYM FM C16H18N2
DMC3PYM IC InChI=1S/C16H18N2/c1-3-18-15-7-5-4-6-13(15)14-10-12(11-17-2)8-9-16(14)18/h4-10,17H,3,11H2,1-2H3
DMC3PYM CS CCN1C2=C(C=C(C=C2)CNC)C3=CC=CC=C31
DMC3PYM IK LBPNOEAFWYTTEB-UHFFFAOYSA-N
DMC3PYM IU 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
DMC3PYM DE Discovery agent
DMA96U5 ID DMA96U5
DMA96U5 DN 1-(9H-beta-Carbolin-3-yl)-butan-1-one
DMA96U5 HS Investigative
DMA96U5 SN CHEMBL69719; AC1NFSYI; 1-(9H-beta-Carbolin-3-yl)-butan-1-one; 3-Butyryl-beta-carboline; CHEMBL510764; ZINC7260873; BDBM50001474
DMA96U5 DT Small molecular drug
DMA96U5 PC 4713438
DMA96U5 MW 238.28
DMA96U5 FM C15H14N2O
DMA96U5 IC InChI=1S/C15H14N2O/c1-2-5-15(18)13-8-11-10-6-3-4-7-12(10)17-14(11)9-16-13/h3-4,6-9,17H,2,5H2,1H3
DMA96U5 CS CCCC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMA96U5 IK QIZPCEVRKTWHIE-UHFFFAOYSA-N
DMA96U5 IU 1-(9H-pyrido[3,4-b]indol-3-yl)butan-1-one
DMA96U5 DE Discovery agent
DMFOD2L ID DMFOD2L
DMFOD2L DN 1-(9H-beta-Carbolin-3-yl)-ethanone
DMFOD2L HS Investigative
DMFOD2L SN 82596-93-8; 3-acetyl-beta-carboline; 1-(9H-pyrido[3,4-b]indol-3-yl)-ethanone; CHEMBL11863; SCHEMBL10857122; CTK3D8180; DTXSID90509895; MPLXFBXMWYMAFN-UHFFFAOYSA-N; ZINC26025316; AKOS030597437; 1-(9H-beta-Carbolin-3-yl)ethan-1-one; Ethanone, 1-(9H-pyrido[3,4-b]indol-3-yl)-
DMFOD2L DT Small molecular drug
DMFOD2L PC 12789146
DMFOD2L MW 210.23
DMFOD2L FM C13H10N2O
DMFOD2L IC InChI=1S/C13H10N2O/c1-8(16)12-6-10-9-4-2-3-5-11(9)15-13(10)7-14-12/h2-7,15H,1H3
DMFOD2L CS CC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMFOD2L IK MPLXFBXMWYMAFN-UHFFFAOYSA-N
DMFOD2L IU 1-(9H-pyrido[3,4-b]indol-3-yl)ethanone
DMFOD2L CA CAS 82596-93-8
DMFOD2L DE Discovery agent
DMH49OD ID DMH49OD
DMH49OD DN 1-(9H-fluoren-9-yl)-1H-imidazole
DMH49OD HS Investigative
DMH49OD SN 1-(9H-fluoren-9-yl)-1H-imidazole; CHEMBL225447; 35214-35-8; Fluorenyl deriv. 13; AC1MY9SZ; SCHEMBL9633309; BDBM9464; 1-(9H-fluoren-9-yl)imidazole; MolPort-002-538-233; ZINC4645069; STL321422; AKOS022141595; MCULE-5499035128; DA-06525
DMH49OD DT Small molecular drug
DMH49OD PC 3828439
DMH49OD MW 232.28
DMH49OD FM C16H12N2
DMH49OD IC InChI=1S/C16H12N2/c1-3-7-14-12(5-1)13-6-2-4-8-15(13)16(14)18-10-9-17-11-18/h1-11,16H
DMH49OD CS C1=CC=C2C(=C1)C(C3=CC=CC=C32)N4C=CN=C4
DMH49OD IK TULIZIRHYBBLAI-UHFFFAOYSA-N
DMH49OD IU 1-(9H-fluoren-9-yl)imidazole
DMH49OD DE Discovery agent
DM30FNL ID DM30FNL
DM30FNL DN 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea
DM30FNL HS Investigative
DM30FNL SN Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea
DM30FNL DT Small molecular drug
DM30FNL PC 5330596
DM30FNL MW 315.3
DM30FNL FM C19H13N3O2
DM30FNL IC InChI=1S/C19H13N3O2/c23-18-13-7-2-1-6-12(13)17-14(18)8-5-9-15(17)21-19(24)22-16-10-3-4-11-20-16/h1-11H,(H2,20,21,22,24)
DM30FNL CS C1=CC=C2C(=C1)C3=C(C2=O)C=CC=C3NC(=O)NC4=CC=CC=N4
DM30FNL IK XVVDNGPUSVDRAJ-UHFFFAOYSA-N
DM30FNL IU 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea
DM30FNL DE Discovery agent
DMVJZ0C ID DMVJZ0C
DMVJZ0C DN 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole
DMVJZ0C HS Investigative
DMVJZ0C SN CHEMBL376371; 1H-1,2,4-Triazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 828265-51-6; Fluorenyl deriv. 17; BDBM9468; 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole; CTK3D6011
DMVJZ0C DT Small molecular drug
DMVJZ0C PC 11232117
DMVJZ0C MW 309.4
DMVJZ0C FM C21H15N3
DMVJZ0C IC InChI=1S/C21H15N3/c1-2-8-16(9-3-1)21(24-15-22-14-23-24)19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h1-15H
DMVJZ0C CS C1=CC=C(C=C1)C2(C3=CC=CC=C3C4=CC=CC=C42)N5C=NC=N5
DMVJZ0C IK KVOFEYRUEAXEJQ-UHFFFAOYSA-N
DMVJZ0C IU 1-(9-phenylfluoren-9-yl)-1,2,4-triazole
DMVJZ0C CA CAS 828265-51-6
DMVJZ0C DE Discovery agent
DMLIJYS ID DMLIJYS
DMLIJYS DN 1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole
DMLIJYS HS Investigative
DMLIJYS SN CHEMBL223874; 1H-Imidazole, 1-(9-phenyl-9H-fluoren-9-yl)-; 27608-12-4; Fluorenyl deriv. 14; BDBM9465; CTK0J2505; DTXSID90432952
DMLIJYS DT Small molecular drug
DMLIJYS PC 9926623
DMLIJYS MW 308.4
DMLIJYS FM C22H16N2
DMLIJYS IC InChI=1S/C22H16N2/c1-2-8-17(9-3-1)22(24-15-14-23-16-24)20-12-6-4-10-18(20)19-11-5-7-13-21(19)22/h1-16H
DMLIJYS CS C1=CC=C(C=C1)C2(C3=CC=CC=C3C4=CC=CC=C42)N5C=CN=C5
DMLIJYS IK DNCKVRPGVMTVNH-UHFFFAOYSA-N
DMLIJYS IU 1-(9-phenylfluoren-9-yl)imidazole
DMLIJYS CA CAS 27608-12-4
DMLIJYS DE Discovery agent
DMOTJWZ ID DMOTJWZ
DMOTJWZ DN 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone
DMOTJWZ HS Investigative
DMOTJWZ SN 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone; CHEMBL493448; SCHEMBL10247513; CHEMBL1187207; BDBM50252801; DB07342; 1(adamantan1yl) 2(1himidazol1yl) ethanone; 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone; 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone hydrochloride
DMOTJWZ DT Small molecular drug
DMOTJWZ PC 20541332
DMOTJWZ MW 244.33
DMOTJWZ FM C15H20N2O
DMOTJWZ IC InChI=1S/C15H20N2O/c18-14(9-17-2-1-16-10-17)15-6-11-3-12(7-15)5-13(4-11)8-15/h1-2,10-13H,3-9H2
DMOTJWZ CS C1C2CC3CC1CC(C2)(C3)C(=O)CN4C=CN=C4
DMOTJWZ IK BBCQJSMDKDHVKG-UHFFFAOYSA-N
DMOTJWZ IU 1-(1-adamantyl)-2-imidazol-1-ylethanone
DMOTJWZ DE Discovery agent
DMOJC9Z ID DMOJC9Z
DMOJC9Z DN 1-(Benzhydrylamino)ethaniminium bromide
DMOJC9Z HS Investigative
DMOJC9Z SN 1-(Benzhydrylamino)ethaniminium bromide
DMOJC9Z DT Small molecular drug
DMOJC9Z PC 50899558
DMOJC9Z MW 305.21
DMOJC9Z FM C15H17BrN2
DMOJC9Z IC InChI=1S/C15H16N2.BrH/c1-12(16)17-15(13-8-4-2-5-9-13)14-10-6-3-7-11-14;/h2-11,15H,1H3,(H2,16,17);1H
DMOJC9Z CS CC(=NC(C1=CC=CC=C1)C2=CC=CC=C2)N.Br
DMOJC9Z IK SCBRUNBFSUXITM-UHFFFAOYSA-N
DMOJC9Z IU N'-benzhydrylethanimidamide;hydrobromide
DMOJC9Z DE Discovery agent
DMGNL2A ID DMGNL2A
DMGNL2A DN 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMGNL2A HS Investigative
DMGNL2A SN CHEMBL509158; 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMGNL2A DT Small molecular drug
DMGNL2A PC 44561205
DMGNL2A MW 199.25
DMGNL2A FM C13H13NO
DMGNL2A IC InChI=1S/C13H13NO/c1-2-4-11-9(3-1)5-12(15-11)13-6-10(13)7-14-8-13/h1-5,10,14H,6-8H2
DMGNL2A CS C1C2C1(CNC2)C3=CC4=CC=CC=C4O3
DMGNL2A IK FRXUZFQLSGFGPV-UHFFFAOYSA-N
DMGNL2A IU 1-(1-benzofuran-2-yl)-3-azabicyclo[3.1.0]hexane
DMGNL2A DE Discovery agent
DMVSC3O ID DMVSC3O
DMVSC3O DN 1-(benzyloxy)-2-(2-phenylethyl)benzene
DMVSC3O HS Investigative
DMVSC3O SN CHEMBL215010; 1-(benzyloxy)-2-(2-phenylethyl)benzene; SCHEMBL4183309; 1-(benzyloxy)-2-phenethylbenzene
DMVSC3O DT Small molecular drug
DMVSC3O PC 11973811
DMVSC3O MW 288.4
DMVSC3O FM C21H20O
DMVSC3O IC InChI=1S/C21H20O/c1-3-9-18(10-4-1)15-16-20-13-7-8-14-21(20)22-17-19-11-5-2-6-12-19/h1-14H,15-17H2
DMVSC3O CS C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CC=CC=C3
DMVSC3O IK BMTUNIXXDMVUOW-UHFFFAOYSA-N
DMVSC3O IU 1-(2-phenylethyl)-2-phenylmethoxybenzene
DMVSC3O DE Discovery agent
DMVB7P3 ID DMVB7P3
DMVB7P3 DN 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene
DMVB7P3 HS Investigative
DMVB7P3 SN CHEMBL214739; 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene; BDBM50197201
DMVB7P3 DT Small molecular drug
DMVB7P3 PC 11973927
DMVB7P3 MW 318.4
DMVB7P3 FM C22H22O2
DMVB7P3 IC InChI=1S/C22H22O2/c1-23-21-12-7-10-18(16-21)14-15-20-11-5-6-13-22(20)24-17-19-8-3-2-4-9-19/h2-13,16H,14-15,17H2,1H3
DMVB7P3 CS COC1=CC=CC(=C1)CCC2=CC=CC=C2OCC3=CC=CC=C3
DMVB7P3 IK SDDBNQDQBZPCGB-UHFFFAOYSA-N
DMVB7P3 IU 1-methoxy-3-[2-(2-phenylmethoxyphenyl)ethyl]benzene
DMVB7P3 DE Discovery agent
DMA15X9 ID DMA15X9
DMA15X9 DN 1(beta)-O-galloylpedunculagin
DMA15X9 HS Investigative
DMA15X9 SN Casuarictin; 1(beta)-O-Galloylpedunculagin; CHEMBL446979; CHEBI:3461; 79786-00-8; Sanguiin H 11; cuspinin; 1(.beta.)-O-Galloylpedunculagin; (10ar,11s,12ar,25ar,25bs)-2,3,4,5,6,7,17,18,19,20,21,22-dodecahydroxy-9,15,24,27-tetraoxo-9,10a,11,12a,13,15,24,25a,25b,27-decahydrodibenzo[g,i]dibenzo[6',7':8',9'][1,4]dioxecino[2',3':4,5]pyrano[3,2-b][1,5]dioxacycloundecin-11-yl 3,4,5-trihydroxybenzoate; AC1Q6P15; AC1L2K81; BDBM50250990; C10212; .beta.-D-Glucopyranose, cyclic 2,3:4,6-bis[(1S)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphen
DMA15X9 DT Small molecular drug
DMA15X9 PC 73644
DMA15X9 MW 936.6
DMA15X9 FM C41H28O26
DMA15X9 IC InChI=1S/C41H28O26/c42-13-1-8(2-14(43)24(13)48)36(57)67-41-35-34(65-39(60)11-5-17(46)27(51)31(55)22(11)23-12(40(61)66-35)6-18(47)28(52)32(23)56)33-19(63-41)7-62-37(58)9-3-15(44)25(49)29(53)20(9)21-10(38(59)64-33)4-16(45)26(50)30(21)54/h1-6,19,33-35,41-56H,7H2/t19-,33-,34+,35-,41+/m1/s1
DMA15X9 CS C1[C@@H]2[C@H]([C@H]3[C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O3)O)O)O)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O
DMA15X9 IK SWRFKGRMQVLMKA-JIZJWZDPSA-N
DMA15X9 IU [(1R,2S,19R,20S,22R)-7,8,9,12,13,14,28,29,30,33,34,35-dodecahydroxy-4,17,25,38-tetraoxo-3,18,21,24,39-pentaoxaheptacyclo[20.17.0.02,19.05,10.011,16.026,31.032,37]nonatriaconta-5,7,9,11,13,15,26,28,30,32,34,36-dodecaen-20-yl] 3,4,5-trihydroxybenzoate
DMA15X9 CA CAS 79786-00-8
DMA15X9 CB CHEBI:3461
DMA15X9 DE Discovery agent
DMGVPMT ID DMGVPMT
DMGVPMT DN 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole
DMGVPMT HS Investigative
DMGVPMT SN CHEMBL598847; 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole; SCHEMBL10172554
DMGVPMT DT Small molecular drug
DMGVPMT PC 23585406
DMGVPMT MW 235.28
DMGVPMT FM C15H13N3
DMGVPMT IC InChI=1S/C15H13N3/c1-2-6-14(7-3-1)15-8-4-5-13(9-15)10-18-12-16-11-17-18/h1-9,11-12H,10H2
DMGVPMT CS C1=CC=C(C=C1)C2=CC=CC(=C2)CN3C=NC=N3
DMGVPMT IK OZOOKYPKFWRQMO-UHFFFAOYSA-N
DMGVPMT IU 1-[(3-phenylphenyl)methyl]-1,2,4-triazole
DMGVPMT CA CAS 942154-20-3
DMGVPMT DE Discovery agent
DM5KZ74 ID DM5KZ74
DM5KZ74 DN 1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea
DM5KZ74 HS Investigative
DM5KZ74 SN CHEMBL1086332; 1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea; SCHEMBL13527422
DM5KZ74 DT Small molecular drug
DM5KZ74 PC 46831055
DM5KZ74 MW 351.5
DM5KZ74 FM C22H29N3O
DM5KZ74 IC InChI=1S/C22H29N3O/c26-22(23-15-5-8-18-25-16-6-2-7-17-25)24-21-13-11-20(12-14-21)19-9-3-1-4-10-19/h1,3-4,9-14H,2,5-8,15-18H2,(H2,23,24,26)
DM5KZ74 CS C1CCN(CC1)CCCCNC(=O)NC2=CC=C(C=C2)C3=CC=CC=C3
DM5KZ74 IK MUIUUGJVKFYPIF-UHFFFAOYSA-N
DM5KZ74 IU 1-(4-phenylphenyl)-3-(4-piperidin-1-ylbutyl)urea
DM5KZ74 DE Discovery agent
DMTZ71K ID DMTZ71K
DMTZ71K DN 1-(bis(3-bromophenyl)methylene)thiosemicarbazide
DMTZ71K HS Investigative
DMTZ71K SN CHEMBL384296; 1-(bis(3-bromophenyl)methylene)thiosemicarbazide; SCHEMBL2675409; DLNPHAFNMNLYRY-UHFFFAOYSA-N; BDBM50189279; Bis(3-bromophenyl) ketone thiosemicarbazone
DMTZ71K DT Small molecular drug
DMTZ71K PC 16061497
DMTZ71K MW 413.1
DMTZ71K FM C14H11Br2N3S
DMTZ71K IC InChI=1S/C14H11Br2N3S/c15-11-5-1-3-9(7-11)13(18-19-14(17)20)10-4-2-6-12(16)8-10/h1-8H,(H3,17,19,20)
DMTZ71K CS C1=CC(=CC(=C1)Br)C(=NNC(=S)N)C2=CC(=CC=C2)Br
DMTZ71K IK DLNPHAFNMNLYRY-UHFFFAOYSA-N
DMTZ71K IU [bis(3-bromophenyl)methylideneamino]thiourea
DMTZ71K DE Discovery agent
DMYO8D3 ID DMYO8D3
DMYO8D3 DN 1-(bis(4-bromophenyl)methyl)-3-phenylurea
DMYO8D3 HS Investigative
DMYO8D3 SN CHEMBL224748; 1-(bis(4-bromophenyl)methyl)-3-phenylurea
DMYO8D3 DT Small molecular drug
DMYO8D3 PC 44421550
DMYO8D3 MW 460.2
DMYO8D3 FM C20H16Br2N2O
DMYO8D3 IC InChI=1S/C20H16Br2N2O/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DMYO8D3 CS C1=CC=C(C=C1)NC(=O)NC(C2=CC=C(C=C2)Br)C3=CC=C(C=C3)Br
DMYO8D3 IK MNUYZVNTMQHNEW-UHFFFAOYSA-N
DMYO8D3 IU 1-[bis(4-bromophenyl)methyl]-3-phenylurea
DMYO8D3 DE Discovery agent
DMTVNO3 ID DMTVNO3
DMTVNO3 DN 1-(bis(4-chlorophenyl)methyl)-3-phenylurea
DMTVNO3 HS Investigative
DMTVNO3 SN CHEMBL375286; 1-(bis(4-chlorophenyl)methyl)-3-phenylurea; ZINC13676236
DMTVNO3 DT Small molecular drug
DMTVNO3 PC 44421549
DMTVNO3 MW 371.3
DMTVNO3 FM C20H16Cl2N2O
DMTVNO3 IC InChI=1S/C20H16Cl2N2O/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DMTVNO3 CS C1=CC=C(C=C1)NC(=O)NC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMTVNO3 IK VLXCCHGDBPKKAK-UHFFFAOYSA-N
DMTVNO3 IU 1-[bis(4-chlorophenyl)methyl]-3-phenylurea
DMTVNO3 DE Discovery agent
DMF3D5R ID DMF3D5R
DMF3D5R DN 1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole
DMF3D5R HS Investigative
DMF3D5R SN CHEMBL498534; 1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole; SCHEMBL11349905
DMF3D5R DT Small molecular drug
DMF3D5R PC 20298212
DMF3D5R MW 386.5
DMF3D5R FM C28H22N2
DMF3D5R IC InChI=1S/C28H22N2/c1-3-7-22(8-4-1)24-11-15-26(16-12-24)28(30-20-19-29-21-30)27-17-13-25(14-18-27)23-9-5-2-6-10-23/h1-21,28H
DMF3D5R CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=C(C=C3)C4=CC=CC=C4)N5C=CN=C5
DMF3D5R IK CKRNCVRILASGRW-UHFFFAOYSA-N
DMF3D5R IU 1-[bis(4-phenylphenyl)methyl]imidazole
DMF3D5R DE Discovery agent
DMEULBF ID DMEULBF
DMEULBF DN 1-(But-2-enylidene)thiosemicarbazide
DMEULBF HS Investigative
DMEULBF SN CHEMBL505588; 1-(But-2-enylidene)thiosemicarbazide; Crotonaldehyde thiosemicarbazone; 2-Butenal thiosemicarbazone; AC1O21BI; ZINC5179201; 22113-96-8; BDBM50268196
DMEULBF DT Small molecular drug
DMEULBF PC 6188165
DMEULBF MW 143.21
DMEULBF FM C5H9N3S
DMEULBF IC InChI=1S/C5H9N3S/c1-2-3-4-7-8-5(6)9/h2-4H,1H3,(H3,6,8,9)/b3-2+,7-4-
DMEULBF CS C/C=C/C=N\\NC(=S)N
DMEULBF IK OWTTWSQTSRNFHY-SWBALALESA-N
DMEULBF IU [(Z)-[(E)-but-2-enylidene]amino]thiourea
DMEULBF DE Discovery agent
DMTMZAJ ID DMTMZAJ
DMTMZAJ DN 1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid
DMTMZAJ HS Investigative
DMTMZAJ SN CHEMBL262598; BDBM50374761; [1-phosphono-2-(sec-butylamino)ethyl]phosphonic acid
DMTMZAJ DT Small molecular drug
DMTMZAJ PC 44451344
DMTMZAJ MW 261.149
DMTMZAJ FM C6H17NO6P2
DMTMZAJ IC InChI=1S/C6H17NO6P2/c1-3-5(2)7-4-6(14(8,9)10)15(11,12)13/h5-7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13)
DMTMZAJ CS CCC(C)NCC(P(=O)(O)O)P(=O)(O)O
DMTMZAJ IK BDBDLQIJTHDVGZ-UHFFFAOYSA-N
DMTMZAJ IU [2-(butan-2-ylamino)-1-phosphonoethyl]phosphonic acid
DMTMZAJ DE Discovery agent
DMXU1EF ID DMXU1EF
DMXU1EF DN 1-(Butan-2-ylidene)thiosemicarbazide
DMXU1EF HS Investigative
DMXU1EF SN CHEMBL458405; 1752-40-5; AC1NSGXA; WLN: SUYZMNUY2& 2-butanone thiosemicarbazone; NSC709; NSC-709; [(Z)-butan-2-ylideneamino]thiourea; ZINC13115335; BDBM50268198
DMXU1EF DT Small molecular drug
DMXU1EF PC 5363036
DMXU1EF MW 145.23
DMXU1EF FM C5H11N3S
DMXU1EF IC InChI=1S/C5H11N3S/c1-3-4(2)7-8-5(6)9/h3H2,1-2H3,(H3,6,8,9)/b7-4-
DMXU1EF CS CC/C(=N\\NC(=S)N)/C
DMXU1EF IK NCQXVINEPVAIDB-DAXSKMNVSA-N
DMXU1EF IU [(Z)-butan-2-ylideneamino]thiourea
DMXU1EF CA CAS 1752-40-5
DMXU1EF DE Discovery agent
DMS3XUC ID DMS3XUC
DMS3XUC DN 1-(cyclohexyl)methyl-5'-O-tritylinosine
DMS3XUC HS Investigative
DMS3XUC SN CHEMBL211259; BDBM50194181
DMS3XUC DT Small molecular drug
DMS3XUC PC 16082760
DMS3XUC MW 606.7
DMS3XUC FM C36H38N4O5
DMS3XUC IC InChI=1S/C36H38N4O5/c41-31-29(22-44-36(26-15-7-2-8-16-26,27-17-9-3-10-18-27)28-19-11-4-12-20-28)45-35(32(31)42)40-24-37-30-33(40)38-23-39(34(30)43)21-25-13-5-1-6-14-25/h2-4,7-12,15-20,23-25,29,31-32,35,41-42H,1,5-6,13-14,21-22H2/t29-,31-,32-,35-/m1/s1
DMS3XUC CS C1CCC(CC1)CN2C=NC3=C(C2=O)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COC(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DMS3XUC IK CFSSQQKSMHGUJB-QSYCCZFCSA-N
DMS3XUC IU 1-(cyclohexylmethyl)-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-one
DMS3XUC DE Discovery agent
DMDU3X7 ID DMDU3X7
DMDU3X7 DN 1-(cyclopropyl)methyl-5'-O-tritylinosine
DMDU3X7 HS Investigative
DMDU3X7 SN CHEMBL379981; BDBM50194179
DMDU3X7 DT Small molecular drug
DMDU3X7 PC 16082776
DMDU3X7 MW 564.6
DMDU3X7 FM C33H32N4O5
DMDU3X7 IC InChI=1S/C33H32N4O5/c38-28-26(42-32(29(28)39)37-21-34-27-30(37)35-20-36(31(27)40)18-22-16-17-22)19-41-33(23-10-4-1-5-11-23,24-12-6-2-7-13-24)25-14-8-3-9-15-25/h1-15,20-22,26,28-29,32,38-39H,16-19H2/t26-,28-,29-,32-/m1/s1
DMDU3X7 CS C1CC1CN2C=NC3=C(C2=O)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COC(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DMDU3X7 IK UTXUWUTZGDAURC-DWCTZGTLSA-N
DMDU3X7 IU 1-(cyclopropylmethyl)-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-one
DMDU3X7 DE Discovery agent
DMLYO8P ID DMLYO8P
DMLYO8P DN 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P HS Investigative
DMLYO8P SN CHEMBL389665; 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol
DMLYO8P DT Small molecular drug
DMLYO8P PC 9820782
DMLYO8P MW 371.5
DMLYO8P FM C26H29NO
DMLYO8P IC InChI=1S/C26H29NO/c1-20-10-6-8-14-23(20)25(24-15-9-7-11-21(24)2)27-18-16-26(28,17-19-27)22-12-4-3-5-13-22/h3-15,25,28H,16-19H2,1-2H3
DMLYO8P CS CC1=CC=CC=C1C(C2=CC=CC=C2C)N3CCC(CC3)(C4=CC=CC=C4)O
DMLYO8P IK MHYKPRJMOSXVFG-UHFFFAOYSA-N
DMLYO8P IU 1-[bis(2-methylphenyl)methyl]-4-phenylpiperidin-4-ol
DMLYO8P DE Discovery agent
DMBTLIJ ID DMBTLIJ
DMBTLIJ DN 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE
DMBTLIJ HS Investigative
DMBTLIJ SN 8-(hydroxymethylamino)octan-1-ol; AC1NDZBQ; 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE; 8-[(hydroxymethyl)amino]octan-1-ol
DMBTLIJ DT Small molecular drug
DMBTLIJ PC 4634038
DMBTLIJ MW 175.27
DMBTLIJ FM C9H21NO2
DMBTLIJ IC InChI=1S/C9H21NO2/c11-8-6-4-2-1-3-5-7-10-9-12/h10-12H,1-9H2
DMBTLIJ CS C(CCCCO)CCCNCO
DMBTLIJ IK SJEVZMRZAJQYFZ-UHFFFAOYSA-N
DMBTLIJ IU 8-(hydroxymethylamino)octan-1-ol
DMBTLIJ DE Discovery agent
DMOTICP ID DMOTICP
DMOTICP DN 1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea
DMOTICP HS Investigative
DMOTICP SN isoquinoline antagonist, 5m; CHEMBL230772; BDBM20395
DMOTICP DT Small molecular drug
DMOTICP PC 24768203
DMOTICP MW 305.4
DMOTICP FM C19H19N3O
DMOTICP IC InChI=1S/C19H19N3O/c1-2-17(14-7-4-3-5-8-14)21-19(23)22-18-10-6-9-15-13-20-12-11-16(15)18/h3-13,17H,2H2,1H3,(H2,21,22,23)
DMOTICP CS CCC(C1=CC=CC=C1)NC(=O)NC2=CC=CC3=C2C=CN=C3
DMOTICP IK MDUZRJXYUICAEF-UHFFFAOYSA-N
DMOTICP IU 1-isoquinolin-5-yl-3-(1-phenylpropyl)urea
DMOTICP DE Discovery agent
DMHWITR ID DMHWITR
DMHWITR DN 1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea
DMHWITR HS Investigative
DMHWITR SN Isoquinoline Analogue, 35; CHEMBL231105; SCHEMBL4023640; BDBM20341; LAJBRLBYOVKUOY-UHFFFAOYSA-N; N-5-isoquinolinyl-N'-[4-(4-morpholinyl)benzyl]urea; N-isoquinolin-5-yl-N'-[(4-morpholin-4-ylphenyl)methyl]urea
DMHWITR DT Small molecular drug
DMHWITR PC 10248092
DMHWITR MW 362.4
DMHWITR FM C21H22N4O2
DMHWITR IC InChI=1S/C21H22N4O2/c26-21(24-20-3-1-2-17-15-22-9-8-19(17)20)23-14-16-4-6-18(7-5-16)25-10-12-27-13-11-25/h1-9,15H,10-14H2,(H2,23,24,26)
DMHWITR CS C1COCCN1C2=CC=C(C=C2)CNC(=O)NC3=CC=CC4=C3C=CN=C4
DMHWITR IK LAJBRLBYOVKUOY-UHFFFAOYSA-N
DMHWITR IU 1-isoquinolin-5-yl-3-[(4-morpholin-4-ylphenyl)methyl]urea
DMHWITR DE Discovery agent
DMI479T ID DMI479T
DMI479T DN 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMI479T HS Investigative
DMI479T SN SCHEMBL3260073; CHEMBL1172744; BDBM50322697; 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX)
DMI479T DT Small molecular drug
DMI479T PC 24803184
DMI479T MW 267.4
DMI479T FM C18H21NO
DMI479T IC InChI=1S/C18H21NO/c1-20-13-17-11-18(17,8-9-19-12-17)16-7-6-14-4-2-3-5-15(14)10-16/h2-7,10,19H,8-9,11-13H2,1H3/t17-,18-/m1/s1
DMI479T CS COC[C@]12C[C@]1(CCNC2)C3=CC4=CC=CC=C4C=C3
DMI479T IK KTJHVHZJTXJNIH-QZTJIDSGSA-N
DMI479T IU (1R,6S)-1-(methoxymethyl)-6-naphthalen-2-yl-3-azabicyclo[4.1.0]heptane
DMI479T DE Discovery agent
DMUEQC8 ID DMUEQC8
DMUEQC8 DN 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DMUEQC8 HS Investigative
DMUEQC8 SN CHEMBL452045; 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane; SCHEMBL4177088; BDBM50243942; SY247368; MFCD28902249 (97%)
DMUEQC8 DT Small molecular drug
DMUEQC8 PC 16068204
DMUEQC8 MW 209.29
DMUEQC8 FM C15H15N
DMUEQC8 IC InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2
DMUEQC8 CS C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3
DMUEQC8 IK HKHCSWPSUSWGLI-UHFFFAOYSA-N
DMUEQC8 IU 1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane
DMUEQC8 DE Discovery agent
DMXT2ZL ID DMXT2ZL
DMXT2ZL DN 1-(oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one
DMXT2ZL HS Investigative
DMXT2ZL SN CHEMBL441735
DMXT2ZL DT Small molecular drug
DMXT2ZL PC 24799659
DMXT2ZL MW 293.3
DMXT2ZL FM C18H15NO3
DMXT2ZL IC InChI=1S/C18H15NO3/c20-17(18-19-12-13-21-18)11-8-14-6-9-16(10-7-14)22-15-4-2-1-3-5-15/h1-7,9-10,12-13H,8,11H2
DMXT2ZL CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CCC(=O)C3=NC=CO3
DMXT2ZL IK LLQSCQSWBWHWLL-UHFFFAOYSA-N
DMXT2ZL IU 1-(1,3-oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one
DMXT2ZL DE Discovery agent
DMEOS8P ID DMEOS8P
DMEOS8P DN 1-(oxazol-2-yl)-4-(piperidin-4-yl)butan-1-one
DMEOS8P HS Investigative
DMEOS8P SN CHEMBL270404
DMEOS8P DT Small molecular drug
DMEOS8P PC 44453945
DMEOS8P MW 222.28
DMEOS8P FM C12H18N2O2
DMEOS8P IC InChI=1S/C12H18N2O2/c15-11(12-14-8-9-16-12)3-1-2-10-4-6-13-7-5-10/h8-10,13H,1-7H2
DMEOS8P CS C1CNCCC1CCCC(=O)C2=NC=CO2
DMEOS8P IK PKVYQZQOXHRPTR-UHFFFAOYSA-N
DMEOS8P IU 1-(1,3-oxazol-2-yl)-4-piperidin-4-ylbutan-1-one
DMEOS8P CA CAS 938222-90-3
DMEOS8P DE Discovery agent
DMLKA5O ID DMLKA5O
DMLKA5O DN 1-(oxazol-2-yl)-7-phenylheptan-1-one
DMLKA5O HS Investigative
DMLKA5O SN CHEMBL220125; 1-(oxazol-2-yl)-7-phenylheptan-1-one; SCHEMBL12403823; BDBM50204493; ZINC34803651
DMLKA5O DT Small molecular drug
DMLKA5O PC 11991808
DMLKA5O MW 257.329
DMLKA5O FM C16H19NO2
DMLKA5O IC InChI=1S/C16H19NO2/c18-15(16-17-12-13-19-16)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,12-13H,1-2,4,7-8,11H2
DMLKA5O CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=CO2
DMLKA5O IK GWMQJJIAUUBGNE-UHFFFAOYSA-N
DMLKA5O IU 1-(1,3-oxazol-2-yl)-7-phenylheptan-1-one
DMLKA5O DE Discovery agent
DM1ATS3 ID DM1ATS3
DM1ATS3 DN 1-(oxazol-2-yl)octadec-9-en-1-one
DM1ATS3 HS Investigative
DM1ATS3 SN CHEMBL39412; 1-(oxazol-2-yl)octadec-9-en-1-one; SCHEMBL13764125; BDBM50100864; AKOS030561890; 1-Oxazol-2-yl-nonadec-10-en-2-one; (Z)-1-Oxazol-2-yl-octadec-9-en-1-one; (Z)-1-(oxazol-2-yl)octadec-9-en-1-one; (9Z)-1-(2-Oxazolyl)-9-octadecene-1-one
DM1ATS3 DT Small molecular drug
DM1ATS3 PC 44285344
DM1ATS3 MW 333.5
DM1ATS3 FM C21H35NO2
DM1ATS3 IC InChI=1S/C21H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-22-18-19-24-21/h9-10,18-19H,2-8,11-17H2,1H3/b10-9-
DM1ATS3 CS CCCCCCCC/C=C\\CCCCCCCC(=O)C1=NC=CO1
DM1ATS3 IK WWYUNXGFLPTVRR-KTKRTIGZSA-N
DM1ATS3 IU (Z)-1-(1,3-oxazol-2-yl)octadec-9-en-1-one
DM1ATS3 CA CAS 288862-40-8
DM1ATS3 DE Discovery agent
DMT7P2Z ID DMT7P2Z
DMT7P2Z DN 1-(oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one
DMT7P2Z HS Investigative
DMT7P2Z SN 1-OXAZOLO[4,5-B]PYRIDIN-2-YL-1-DODECANONE; 288862-73-7; CHEMBL257307; SCHEMBL3964457; MolPort-009-018-944; HMS3649B18; BDBM50350547; 1312AH; ZINC34803705; AKOS027301548; ACM288862737; SR-01000946699; 1-[1,3]oxazolo[4,5-b]pyridin-2-yldodecan-1-one
DMT7P2Z DT Small molecular drug
DMT7P2Z PC 9972176
DMT7P2Z MW 302.4
DMT7P2Z FM C18H26N2O2
DMT7P2Z IC InChI=1S/C18H26N2O2/c1-2-3-4-5-6-7-8-9-10-12-15(21)18-20-17-16(22-18)13-11-14-19-17/h11,13-14H,2-10,12H2,1H3
DMT7P2Z CS CCCCCCCCCCCC(=O)C1=NC2=C(O1)C=CC=N2
DMT7P2Z IK XUWBDQAPIZBSRY-UHFFFAOYSA-N
DMT7P2Z IU 1-([1,3]oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one
DMT7P2Z DE Discovery agent
DMFGUXZ ID DMFGUXZ
DMFGUXZ DN 1-(oxazolo[4,5-b]pyridin-2-yl)octan-1-one
DMFGUXZ HS Investigative
DMFGUXZ SN CHEMBL257305; SCHEMBL3966136; BDBM50350545
DMFGUXZ DT Small molecular drug
DMFGUXZ PC 22486174
DMFGUXZ MW 246.3
DMFGUXZ FM C14H18N2O2
DMFGUXZ IC InChI=1S/C14H18N2O2/c1-2-3-4-5-6-8-11(17)14-16-13-12(18-14)9-7-10-15-13/h7,9-10H,2-6,8H2,1H3
DMFGUXZ CS CCCCCCCC(=O)C1=NC2=C(O1)C=CC=N2
DMFGUXZ IK HTWHWGPGIJSJQP-UHFFFAOYSA-N
DMFGUXZ IU 1-([1,3]oxazolo[4,5-b]pyridin-2-yl)octan-1-one
DMFGUXZ DE Discovery agent
DMH2G13 ID DMH2G13
DMH2G13 DN 1-(oxazolo[4,5-b]pyridin-2-yl)pentan-1-one
DMH2G13 HS Investigative
DMH2G13 SN CHEMBL402740; SCHEMBL3961770; BDBM50350542; 288862-78-2; 1-(oxazolo[4,5-b]pyridin-2-yl)-1-oxo-pentane
DMH2G13 DT Small molecular drug
DMH2G13 PC 22486203
DMH2G13 MW 204.22
DMH2G13 FM C11H12N2O2
DMH2G13 IC InChI=1S/C11H12N2O2/c1-2-3-5-8(14)11-13-10-9(15-11)6-4-7-12-10/h4,6-7H,2-3,5H2,1H3
DMH2G13 CS CCCCC(=O)C1=NC2=C(O1)C=CC=N2
DMH2G13 IK FBFLUTUPSIYUIG-UHFFFAOYSA-N
DMH2G13 IU 1-([1,3]oxazolo[4,5-b]pyridin-2-yl)pentan-1-one
DMH2G13 DE Discovery agent
DMJQ7T0 ID DMJQ7T0
DMJQ7T0 DN 1-(pentyloxy)-4-phenoxybenzene
DMJQ7T0 HS Investigative
DMJQ7T0 SN CHEMBL472892; 1-(pentyloxy)-4-phenoxybenzene; SCHEMBL1335892
DMJQ7T0 DT Small molecular drug
DMJQ7T0 PC 21883856
DMJQ7T0 MW 256.339
DMJQ7T0 FM C17H20O2
DMJQ7T0 IC InChI=1S/C17H20O2/c1-2-3-7-14-18-15-10-12-17(13-11-15)19-16-8-5-4-6-9-16/h4-6,8-13H,2-3,7,14H2,1H3
DMJQ7T0 CS CCCCCOC1=CC=C(C=C1)OC2=CC=CC=C2
DMJQ7T0 IK LFCVQUJWFGBKJK-UHFFFAOYSA-N
DMJQ7T0 IU 1-pentoxy-4-phenoxybenzene
DMJQ7T0 DE Discovery agent
DMU10CY ID DMU10CY
DMU10CY DN 1-(phenyl(p-tolyl)methylene)thiosemicarbazide
DMU10CY HS Investigative
DMU10CY SN CHEMBL402465; 1-(phenyl(p-tolyl)methylene)thiosemicarbazide
DMU10CY DT Small molecular drug
DMU10CY PC 15722900
DMU10CY MW 269.4
DMU10CY FM C15H15N3S
DMU10CY IC InChI=1S/C15H15N3S/c1-11-7-9-13(10-8-11)14(17-18-15(16)19)12-5-3-2-4-6-12/h2-10H,1H3,(H3,16,18,19)/b17-14+
DMU10CY CS CC1=CC=C(C=C1)/C(=N/NC(=S)N)/C2=CC=CC=C2
DMU10CY IK DZOZYORQEZEOCT-SAPNQHFASA-N
DMU10CY IU [(E)-[(4-methylphenyl)-phenylmethylidene]amino]thiourea
DMU10CY DE Discovery agent
DM8APLN ID DM8APLN
DM8APLN DN 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine
DM8APLN HS Investigative
DM8APLN SN 1-(Phenylsulfonyl)-4-azaindole; 677302-44-2; CHEMBL556118; 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine; SCHEMBL3705420; HGOGRVVSSAWHTO-UHFFFAOYSA-N; BDBM50295729; ZINC42923799; AKOS032961360; KB-3354225
DM8APLN DT Small molecular drug
DM8APLN PC 45270766
DM8APLN MW 258.3
DM8APLN FM C13H10N2O2S
DM8APLN IC InChI=1S/C13H10N2O2S/c16-18(17,11-5-2-1-3-6-11)15-10-8-12-13(15)7-4-9-14-12/h1-10H
DM8APLN CS C1=CC=C(C=C1)S(=O)(=O)N2C=CC3=C2C=CC=N3
DM8APLN IK HGOGRVVSSAWHTO-UHFFFAOYSA-N
DM8APLN IU 1-(benzenesulfonyl)pyrrolo[3,2-b]pyridine
DM8APLN DE Discovery agent
DM7W25U ID DM7W25U
DM7W25U DN 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole
DM7W25U HS Investigative
DM7W25U SN CHEMBL370779; 1-(phenylsulfonyl)-4-(1-piperazinyl)-1h-indole; 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole; 412049-71-9; 1-Benzenesulfonyl-4-piperazin-1-yl-1H-indole; SCHEMBL1136504; ZINC3210; DTXSID90436238; OPAMDWUUNKYGOR-UHFFFAOYSA-N; BDBM50174269; 1-(phenylsulfonyl)-4-piperazin-1-yl-indole; FT-0724295; 1-(benzenesulfonyl)-4-(1-piperazinyl)indole; 1-(phenylsulfonyl)-4-piperzin-1-yl-1H-indole; 1-(phenylsulfonyl)-4-piperazin-1-yl-1H-indole; 1-(phenylsulfonyl)-4-piperazin-1-y1-1H-indole
DM7W25U DT Small molecular drug
DM7W25U PC 10154392
DM7W25U MW 341.4
DM7W25U FM C18H19N3O2S
DM7W25U IC InChI=1S/C18H19N3O2S/c22-24(23,15-5-2-1-3-6-15)21-12-9-16-17(7-4-8-18(16)21)20-13-10-19-11-14-20/h1-9,12,19H,10-11,13-14H2
DM7W25U CS C1CN(CCN1)C2=CC=CC3=C2C=CN3S(=O)(=O)C4=CC=CC=C4
DM7W25U IK OPAMDWUUNKYGOR-UHFFFAOYSA-N
DM7W25U IU 1-(benzenesulfonyl)-4-piperazin-1-ylindole
DM7W25U CA CAS 412049-71-9
DM7W25U DE Discovery agent
DMRGD8W ID DMRGD8W
DMRGD8W DN 1-(phenylsulfonyl)butan-2-one
DMRGD8W HS Investigative
DMRGD8W SN CHEMBL240761; 1-(phenylsulfonyl)-2-butanone; 33597-94-3; 1-(phenylsulfonyl)butan-2-one; SCHEMBL12925480; CTK1B8309; DTXSID40452605; 2-Butanone, 1-(phenylsulfonyl)-; BDBM50212545
DMRGD8W DT Small molecular drug
DMRGD8W PC 11031155
DMRGD8W MW 212.27
DMRGD8W FM C10H12O3S
DMRGD8W IC InChI=1S/C10H12O3S/c1-2-9(11)8-14(12,13)10-6-4-3-5-7-10/h3-7H,2,8H2,1H3
DMRGD8W CS CCC(=O)CS(=O)(=O)C1=CC=CC=C1
DMRGD8W IK SMYSSDAIMUTBFY-UHFFFAOYSA-N
DMRGD8W IU 1-(benzenesulfonyl)butan-2-one
DMRGD8W CA CAS 33597-94-3
DMRGD8W DE Discovery agent
DMEP80C ID DMEP80C
DMEP80C DN 1-(piperazin-1-yl)isoquinoline
DMEP80C HS Investigative
DMEP80C SN 1-(piperazin-1-yl)isoquinoline; 126653-00-7; 1-Piperazine-1-yl-isoquinoline; 1-Piperazin-1-yl-isoquinoline; 1-(1-isoquinolinyl)piperazine; 1-(1-piperazinyl)isoquinoline; CHEMBL595552; Isoquinoline,1-(1-piperazinyl)-; Isoquinoline, 1-(1-piperazinyl)-; W-205253; 1-[1-Piperazinyl]isoquinoline; PubChem8306; ACMC-209ymu; piperazinohydroisoquinoline; 1-piperazin-1-ylisoquinoline; 1-Pyperazin-1-yl-isoquinoline; SCHEMBL2076366; TPC-A003; 1-(Isoquinolin-1-yl)piperazine; CTK4B5291; KS-00000JYY; IDFYLSABDUMICK-UHFFFAOYSA-N
DMEP80C DT Small molecular drug
DMEP80C PC 15887436
DMEP80C MW 213.28
DMEP80C FM C13H15N3
DMEP80C IC InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-15-13(12)16-9-7-14-8-10-16/h1-6,14H,7-10H2
DMEP80C CS C1CN(CCN1)C2=NC=CC3=CC=CC=C32
DMEP80C IK IDFYLSABDUMICK-UHFFFAOYSA-N
DMEP80C IU 1-piperazin-1-ylisoquinoline
DMEP80C DE Discovery agent
DMVRN0I ID DMVRN0I
DMVRN0I DN 1-(piperidin-3-ylmethyl)pyridin-2(1H)-one
DMVRN0I HS Investigative
DMVRN0I SN 1-(piperidin-3-ylmethyl)pyridin-2(1H)-one; 820231-74-1; 2(1H)-Pyridinone, 1-(3-piperidinylmethyl)-; CHEMBL205267; SCHEMBL2503319; CTK3E3069; DTXSID80658785; CRXGPVZZFUWGAF-UHFFFAOYSA-N; AKOS010944098; 1-Piperidin-3-ylmethyl-1H-pyridin-2-one; 1-[(Piperidin-3-yl)methyl]pyridin-2(1H)-one
DMVRN0I DT Small molecular drug
DMVRN0I PC 44410533
DMVRN0I MW 192.26
DMVRN0I FM C11H16N2O
DMVRN0I IC InChI=1S/C11H16N2O/c14-11-5-1-2-7-13(11)9-10-4-3-6-12-8-10/h1-2,5,7,10,12H,3-4,6,8-9H2
DMVRN0I CS C1CC(CNC1)CN2C=CC=CC2=O
DMVRN0I IK CRXGPVZZFUWGAF-UHFFFAOYSA-N
DMVRN0I IU 1-(piperidin-3-ylmethyl)pyridin-2-one
DMVRN0I CA CAS 820231-74-1
DMVRN0I DE Discovery agent
DMKQZB7 ID DMKQZB7
DMKQZB7 DN 1-(piperidin-4-ylmethyl)pyridin-2(1H)-one
DMKQZB7 HS Investigative
DMKQZB7 SN 1-(piperidin-4-ylmethyl)pyridin-2(1H)-one; 2(1H)-Pyridinone, 1-(4-piperidinylmethyl)-; CHEMBL206887; SCHEMBL3217361; MolPort-008-735-437; ZINC13686304; AKOS010953288; 888729-52-0; 1-(piperidin-4-ylmethyl)-1,2-dihydropyridin-2-one
DMKQZB7 DT Small molecular drug
DMKQZB7 PC 44410571
DMKQZB7 MW 192.26
DMKQZB7 FM C11H16N2O
DMKQZB7 IC InChI=1S/C11H16N2O/c14-11-3-1-2-8-13(11)9-10-4-6-12-7-5-10/h1-3,8,10,12H,4-7,9H2
DMKQZB7 CS C1CNCCC1CN2C=CC=CC2=O
DMKQZB7 IK WLPUWPRHPIZJQK-UHFFFAOYSA-N
DMKQZB7 IU 1-(piperidin-4-ylmethyl)pyridin-2-one
DMKQZB7 DE Discovery agent
DMO10FD ID DMO10FD
DMO10FD DN 1-(Propan-2-ylidene)thiosemicarbazide
DMO10FD HS Investigative
DMO10FD SN Acetone thiosemicarbazone; 1752-30-3; Thiosemicarbazone acetone; ACETONE THIOSEMICARBAZIDE; Acetone, thiosemicarbazone; Hydrazinecarbothioamide, 2-(1-methylethylidene)-; Acetonthiosemikarbazon; Acetonethiosemicarbazone; 2-(1-Methylethylidene)hydrazinecarbothioamide; NSC 711; Acetonthiosemikarbazon [Czech]; UNII-C3U604L47F; HSDB 6422; EINECS 217-137-9; (isopropylideneamino)thiourea; AI3-22961; CHEMBL500557; (propan-2-ylideneamino)thiourea; C3U604L47F; 2-(propan-2-ylidene)hydrazinecarbothioamide; WLN: SUYZMNUY1& AC1MCI32
DMO10FD DT Small molecular drug
DMO10FD PC 2770166
DMO10FD MW 131.2
DMO10FD FM C4H9N3S
DMO10FD IC InChI=1S/C4H9N3S/c1-3(2)6-7-4(5)8/h1-2H3,(H3,5,7,8)
DMO10FD CS CC(=NNC(=S)N)C
DMO10FD IK FQUDPIIGGVBZEQ-UHFFFAOYSA-N
DMO10FD IU (propan-2-ylideneamino)thiourea
DMO10FD CA CAS 1752-30-3
DMO10FD DE Discovery agent
DMKE7FG ID DMKE7FG
DMKE7FG DN 1-(pyridin-2-yl)piperazine
DMKE7FG HS Investigative
DMKE7FG SN 1-Pyridin-2-yl-piperazine
DMKE7FG DT Small molecular drug
DMKE7FG PC 94459
DMKE7FG MW 163.22
DMKE7FG FM C9H13N3
DMKE7FG IC InChI=1S/C9H13N3/c1-2-4-11-9(3-1)12-7-5-10-6-8-12/h1-4,10H,5-8H2
DMKE7FG CS C1CN(CCN1)C2=CC=CC=N2
DMKE7FG IK GZRKXKUVVPSREJ-UHFFFAOYSA-N
DMKE7FG IU 1-pyridin-2-ylpiperazine
DMKE7FG CA CAS 34803-66-2
DMKE7FG DE Discovery agent
DM78AJ1 ID DM78AJ1
DM78AJ1 DN 1-(pyridin-4-yl)piperazine
DM78AJ1 HS Investigative
DM78AJ1 SN 1-(4-Pyridyl)piperazine; 1008-91-9; 1-(pyridin-4-yl)piperazine; 1-Pyridin-4-yl-piperazine; 4-Piperazinopyridine; 1-(4-pyridyl)-piperazine; 4-pyridylpiperazine; 1-pyridin-4-ylpiperazine; 1-(4-pyridyl) piperazine; PIPERAZINE, 1-(4-PYRIDINYL)-; MFCD00040745; 4-(1-piperazino)pyridine; 1-(4-pyridinyl)piperazine; CHEMBL339069; 4-(1-PIPERAZINYL)PYRIDINE; 1-[4-pyridyl]piperazine; EINECS 213-764-7; 4-pyridyl piperazine; (4-pyridyl)piperazine; PubChem22899; l-(4-pyridyl)piperazine; AC1Q4WUQ; N-(4-Pyridyl)piperazine
DM78AJ1 DT Small molecular drug
DM78AJ1 PC 70517
DM78AJ1 MW 163.22
DM78AJ1 FM C9H13N3
DM78AJ1 IC InChI=1S/C9H13N3/c1-3-10-4-2-9(1)12-7-5-11-6-8-12/h1-4,11H,5-8H2
DM78AJ1 CS C1CN(CCN1)C2=CC=NC=C2
DM78AJ1 IK OQZBAQXTXNIPRA-UHFFFAOYSA-N
DM78AJ1 IU 1-pyridin-4-ylpiperazine
DM78AJ1 CA CAS 1008-91-9
DM78AJ1 DE Discovery agent
DM6J1AK ID DM6J1AK
DM6J1AK DN 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DM6J1AK HS Investigative
DM6J1AK SN CHEMBL500739; 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane
DM6J1AK DT Small molecular drug
DM6J1AK PC 44561207
DM6J1AK MW 165.26
DM6J1AK FM C9H11NS
DM6J1AK IC InChI=1S/C9H11NS/c1-2-8(11-3-1)9-4-7(9)5-10-6-9/h1-3,7,10H,4-6H2
DM6J1AK CS C1C2C1(CNC2)C3=CC=CS3
DM6J1AK IK DMILNTFRFSJCOO-UHFFFAOYSA-N
DM6J1AK IU 1-thiophen-2-yl-3-azabicyclo[3.1.0]hexane
DM6J1AK DE Discovery agent
DMD6CHB ID DMD6CHB
DMD6CHB DN 1-(trifluoromethyl)-9H-carbazole
DMD6CHB HS Investigative
DMD6CHB SN CHEMBL1169609; 1-(trifluoromethyl)-9H-carbazole; SCHEMBL6961593
DMD6CHB DT Small molecular drug
DMD6CHB PC 42611736
DMD6CHB MW 235.2
DMD6CHB FM C13H8F3N
DMD6CHB IC InChI=1S/C13H8F3N/c14-13(15,16)10-6-3-5-9-8-4-1-2-7-11(8)17-12(9)10/h1-7,17H
DMD6CHB CS C1=CC=C2C(=C1)C3=C(N2)C(=CC=C3)C(F)(F)F
DMD6CHB IK RDMKBOMNZUKIDD-UHFFFAOYSA-N
DMD6CHB IU 1-(trifluoromethyl)-9H-carbazole
DMD6CHB DE Discovery agent
DMWHN2J ID DMWHN2J
DMWHN2J DN 1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one
DMWHN2J HS Investigative
DMWHN2J SN SCHEMBL3487311
DMWHN2J DT Small molecular drug
DMWHN2J PC 25060073
DMWHN2J MW 348.23
DMWHN2J FM C14H12F8O
DMWHN2J IC InChI=1S/C14H12F8O/c15-10(8-4-7-9-5-2-1-3-6-9)11(23)12(16,17)13(18,19)14(20,21)22/h1-3,5-6,10H,4,7-8H2
DMWHN2J CS C1=CC=C(C=C1)CCCC(C(=O)C(C(C(F)(F)F)(F)F)(F)F)F
DMWHN2J IK MSCLPOMDBKAOHB-UHFFFAOYSA-N
DMWHN2J IU 1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one
DMWHN2J DE Discovery agent
DM45NF1 ID DM45NF1
DM45NF1 DN 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol
DM45NF1 HS Investigative
DM45NF1 SN SCHEMBL13498528
DM45NF1 DT Small molecular drug
DM45NF1 PC 25137230
DM45NF1 MW 332.26
DM45NF1 FM C14H15F7O
DM45NF1 IC InChI=1S/C14H15F7O/c15-12(16,13(17,18)14(19,20)21)11(22)9-5-4-8-10-6-2-1-3-7-10/h1-3,6-7,11,22H,4-5,8-9H2
DM45NF1 CS C1=CC=C(C=C1)CCCCC(C(C(C(F)(F)F)(F)F)(F)F)O
DM45NF1 IK JTXDZUWPNVVKQF-UHFFFAOYSA-N
DM45NF1 IU 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol
DM45NF1 DE Discovery agent
DMN68K4 ID DMN68K4
DMN68K4 DN 1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one
DMN68K4 HS Investigative
DMN68K4 SN CHEMBL1096057
DMN68K4 DT Small molecular drug
DMN68K4 PC 25060074
DMN68K4 MW 298.22
DMN68K4 FM C13H12F6O
DMN68K4 IC InChI=1S/C13H12F6O/c14-10(11(20)12(15,16)13(17,18)19)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8H2
DMN68K4 CS C1=CC=C(C=C1)CCCC(C(=O)C(C(F)(F)F)(F)F)F
DMN68K4 IK NOYVSSPMDRUWCC-UHFFFAOYSA-N
DMN68K4 IU 1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one
DMN68K4 DE Discovery agent
DM7U8LD ID DM7U8LD
DM7U8LD DN 1,1,1,2,2-Pentafluoro-8-phenyl-octan-3-one
DM7U8LD HS Investigative
DM7U8LD SN SCHEMBL3487432; CHEMBL462548
DM7U8LD DT Small molecular drug
DM7U8LD PC 25059299
DM7U8LD MW 294.26
DM7U8LD FM C14H15F5O
DM7U8LD IC InChI=1S/C14H15F5O/c15-13(16,14(17,18)19)12(20)10-6-2-5-9-11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10H2
DM7U8LD CS C1=CC=C(C=C1)CCCCCC(=O)C(C(F)(F)F)(F)F
DM7U8LD IK SZHLULFEEMJIQU-UHFFFAOYSA-N
DM7U8LD IU 1,1,1,2,2-pentafluoro-8-phenyloctan-3-one
DM7U8LD DE Discovery agent
DMSEHNV ID DMSEHNV
DMSEHNV DN 1,1,1,2,2-Pentafluoro-9-phenyl-nonan-3-one
DMSEHNV HS Investigative
DMSEHNV SN SCHEMBL3489036; CHEMBL500496
DMSEHNV DT Small molecular drug
DMSEHNV PC 25059300
DMSEHNV MW 308.29
DMSEHNV FM C15H17F5O
DMSEHNV IC InChI=1S/C15H17F5O/c16-14(17,15(18,19)20)13(21)11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2
DMSEHNV CS C1=CC=C(C=C1)CCCCCCC(=O)C(C(F)(F)F)(F)F
DMSEHNV IK DTHPBVZMSGVQFQ-UHFFFAOYSA-N
DMSEHNV IU 1,1,1,2,2-pentafluoro-9-phenylnonan-3-one
DMSEHNV DE Discovery agent
DMLDH4Z ID DMLDH4Z
DMLDH4Z DN 1,1,1,3-Tetrafluoro-6-phenylhexan-2-one
DMLDH4Z HS Investigative
DMLDH4Z SN 1,1,1,3-Tetrafluoro-6-phenylhexan-2-one; 1071001-32-5; SCHEMBL3487610; CHEMBL1095335; ZJWMBXPFXFSELY-UHFFFAOYSA-N
DMLDH4Z DT Small molecular drug
DMLDH4Z PC 25059820
DMLDH4Z MW 248.22
DMLDH4Z FM C12H12F4O
DMLDH4Z IC InChI=1S/C12H12F4O/c13-10(11(17)12(14,15)16)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8H2
DMLDH4Z CS C1=CC=C(C=C1)CCCC(C(=O)C(F)(F)F)F
DMLDH4Z IK ZJWMBXPFXFSELY-UHFFFAOYSA-N
DMLDH4Z IU 1,1,1,3-tetrafluoro-6-phenylhexan-2-one
DMLDH4Z DE Discovery agent
DMV0CXN ID DMV0CXN
DMV0CXN DN 1,1,1,3-Tetrafluoro-7-phenylheptan-2-one
DMV0CXN HS Investigative
DMV0CXN SN SCHEMBL3489536; CHEMBL1096056; NWIVHHJMCFVMET-UHFFFAOYSA-N; 1,1,1,3-Tetrafluoro-7-phenyl-2-heptanone
DMV0CXN DT Small molecular drug
DMV0CXN PC 25059821
DMV0CXN MW 262.24
DMV0CXN FM C13H14F4O
DMV0CXN IC InChI=1S/C13H14F4O/c14-11(12(18)13(15,16)17)9-5-4-8-10-6-2-1-3-7-10/h1-3,6-7,11H,4-5,8-9H2
DMV0CXN CS C1=CC=C(C=C1)CCCCC(C(=O)C(F)(F)F)F
DMV0CXN IK NWIVHHJMCFVMET-UHFFFAOYSA-N
DMV0CXN IU 1,1,1,3-tetrafluoro-7-phenylheptan-2-one
DMV0CXN DE Discovery agent
DMD36WS ID DMD36WS
DMD36WS DN 1,1,1,3-Tetrafluoro-heptadecan-2-one
DMD36WS HS Investigative
DMD36WS SN CHEMBL462389
DMD36WS DT Small molecular drug
DMD36WS PC 25059819
DMD36WS MW 326.4
DMD36WS FM C17H30F4O
DMD36WS IC InChI=1S/C17H30F4O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(18)16(22)17(19,20)21/h15H,2-14H2,1H3
DMD36WS CS CCCCCCCCCCCCCCC(C(=O)C(F)(F)F)F
DMD36WS IK HCIDRHZIAMIVIL-UHFFFAOYSA-N
DMD36WS IU 1,1,1,3-tetrafluoroheptadecan-2-one
DMD36WS DE Discovery agent
DMJ0ZMT ID DMJ0ZMT
DMJ0ZMT DN 1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one
DMJ0ZMT HS Investigative
DMJ0ZMT SN CHEMBL155396; 1,1,1-trifluoro-3-(hexane-1-sulfinyl)propane-2-one; 479669-33-5
DMJ0ZMT DT Small molecular drug
DMJ0ZMT PC 11010182
DMJ0ZMT MW 244.28
DMJ0ZMT FM C9H15F3O2S
DMJ0ZMT IC InChI=1S/C9H15F3O2S/c1-2-3-4-5-6-15(14)7-8(13)9(10,11)12/h2-7H2,1H3
DMJ0ZMT CS CCCCCCS(=O)CC(=O)C(F)(F)F
DMJ0ZMT IK LSJUTEXGKKBNFU-UHFFFAOYSA-N
DMJ0ZMT IU 1,1,1-trifluoro-3-hexylsulfinylpropan-2-one
DMJ0ZMT DE Discovery agent
DMWDUCH ID DMWDUCH
DMWDUCH DN 1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one
DMWDUCH HS Investigative
DMWDUCH SN CHEMBL155621
DMWDUCH DT Small molecular drug
DMWDUCH PC 11821337
DMWDUCH MW 260.279
DMWDUCH FM C9H15F3O3S
DMWDUCH IC InChI=1S/C9H15F3O3S/c1-2-3-4-5-6-16(14,15)7-8(13)9(10,11)12/h2-7H2,1H3
DMWDUCH CS CCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMWDUCH IK MAGOHNFKWBKUKQ-UHFFFAOYSA-N
DMWDUCH IU 1,1,1-trifluoro-3-hexylsulfonylpropan-2-one
DMWDUCH DE Discovery agent
DMWGSP6 ID DMWGSP6
DMWGSP6 DN 1,1,1-trifluoro-3-(hexylthio)propan-2-one
DMWGSP6 HS Investigative
DMWGSP6 SN CHEMBL440542; 133311-65-6; 1,1,1-trifluoro-3-hexylsulfanylpropan-2-one; 2-Propanone, 1,1,1-trifluoro-3-(hexylthio)-; ACMC-20muvv; CTK0C0416; DTXSID00434189
DMWGSP6 DT Small molecular drug
DMWGSP6 PC 10013998
DMWGSP6 MW 228.28
DMWGSP6 FM C9H15F3OS
DMWGSP6 IC InChI=1S/C9H15F3OS/c1-2-3-4-5-6-14-7-8(13)9(10,11)12/h2-7H2,1H3
DMWGSP6 CS CCCCCCSCC(=O)C(F)(F)F
DMWGSP6 IK JKYLDTTWQQEIHX-UHFFFAOYSA-N
DMWGSP6 IU 1,1,1-trifluoro-3-hexylsulfanylpropan-2-one
DMWGSP6 CA CAS 133311-65-6
DMWGSP6 DE Discovery agent
DMLBT0E ID DMLBT0E
DMLBT0E DN 1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one
DMLBT0E HS Investigative
DMLBT0E SN CHEMBL270373
DMLBT0E DT Small molecular drug
DMLBT0E PC 44455866
DMLBT0E MW 272.33
DMLBT0E FM C11H19F3O2S
DMLBT0E IC InChI=1S/C11H19F3O2S/c1-2-3-4-5-6-7-8-17(16)9-10(15)11(12,13)14/h2-9H2,1H3
DMLBT0E CS CCCCCCCCS(=O)CC(=O)C(F)(F)F
DMLBT0E IK WVDSELHSQAACKS-UHFFFAOYSA-N
DMLBT0E IU 1,1,1-trifluoro-3-octylsulfinylpropan-2-one
DMLBT0E DE Discovery agent
DMT29SN ID DMT29SN
DMT29SN DN 1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one
DMT29SN HS Investigative
DMT29SN SN CHEMBL273139
DMT29SN DT Small molecular drug
DMT29SN PC 44455840
DMT29SN MW 288.33
DMT29SN FM C11H19F3O3S
DMT29SN IC InChI=1S/C11H19F3O3S/c1-2-3-4-5-6-7-8-18(16,17)9-10(15)11(12,13)14/h2-9H2,1H3
DMT29SN CS CCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMT29SN IK LGBYSBJDEXOENJ-UHFFFAOYSA-N
DMT29SN IU 1,1,1-trifluoro-3-octylsulfonylpropan-2-one
DMT29SN DE Discovery agent
DMU4EJW ID DMU4EJW
DMU4EJW DN 1,1,1-trifluoro-3-(octylthio)propan-2-one
DMU4EJW HS Investigative
DMU4EJW SN 89820-00-8; 3-Octylthio-1,1,1-trifluoro-2-propanone; CHEMBL89506; 2-Propanone,1,1,1-trifluoro-3-(octylthio)-; 1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE; 3-Octylthio-1,1,1-trifluoropropan-2-one; 2-Propanone, 1,1,1-trifluoro-3-(octylthio)-; 1,1,1-trifluoro-3-(octylsulfanyl)propan-2-one; 3-Otfp; 1,1,1-Trifluoro-3-octylsulfanyl-propan-2-one; OTFP; ACMC-20lqwm; AC1L3SIW; SCHEMBL4224604; CTK5G3533; DTXSID40237914; WMQHRXUKAYSPPK-UHFFFAOYSA-N; ZINC34803731; BDBM50371970; AKOS028111069; DB08612; 1,1,1-Trifluoro-3-(octylsulfanyl)acetone
DMU4EJW DT Small molecular drug
DMU4EJW PC 146089
DMU4EJW MW 256.329
DMU4EJW FM C11H19F3OS
DMU4EJW IC InChI=1S/C11H19F3OS/c1-2-3-4-5-6-7-8-16-9-10(15)11(12,13)14/h2-9H2,1H3
DMU4EJW CS CCCCCCCCSCC(=O)C(F)(F)F
DMU4EJW IK WMQHRXUKAYSPPK-UHFFFAOYSA-N
DMU4EJW IU 1,1,1-trifluoro-3-octylsulfanylpropan-2-one
DMU4EJW CA CAS 89820-00-8
DMU4EJW DE Discovery agent
DMODCAM ID DMODCAM
DMODCAM DN 1,1,1-Trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one
DMODCAM HS Investigative
DMODCAM SN CHEMBL462596
DMODCAM DT Small molecular drug
DMODCAM PC 25059817
DMODCAM MW 302.33
DMODCAM FM C16H21F3O2
DMODCAM IC InChI=1S/C16H21F3O2/c1-2-3-4-5-12-21-14-9-6-13(7-10-14)8-11-15(20)16(17,18)19/h6-7,9-10H,2-5,8,11-12H2,1H3
DMODCAM CS CCCCCCOC1=CC=C(C=C1)CCC(=O)C(F)(F)F
DMODCAM IK UOOMUFUVLSIOFF-UHFFFAOYSA-N
DMODCAM IU 1,1,1-trifluoro-4-(4-hexoxyphenyl)butan-2-one
DMODCAM DE Discovery agent
DMI2XWY ID DMI2XWY
DMI2XWY DN 1,1,1-Trifluoro-5-(4-octylphenoxy)pentan-2-one
DMI2XWY HS Investigative
DMI2XWY SN SCHEMBL3490532
DMI2XWY DT Small molecular drug
DMI2XWY PC 25059559
DMI2XWY MW 344.4
DMI2XWY FM C19H27F3O2
DMI2XWY IC InChI=1S/C19H27F3O2/c1-2-3-4-5-6-7-9-16-11-13-17(14-12-16)24-15-8-10-18(23)19(20,21)22/h11-14H,2-10,15H2,1H3
DMI2XWY CS CCCCCCCCC1=CC=C(C=C1)OCCCC(=O)C(F)(F)F
DMI2XWY IK UMRJNULJIAZHAL-UHFFFAOYSA-N
DMI2XWY IU 1,1,1-trifluoro-5-(4-octylphenoxy)pentan-2-one
DMI2XWY DE Discovery agent
DMCAQ5T ID DMCAQ5T
DMCAQ5T DN 1,1,1-Trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one
DMCAQ5T HS Investigative
DMCAQ5T SN SCHEMBL3488416
DMCAQ5T DT Small molecular drug
DMCAQ5T PC 25059556
DMCAQ5T MW 330.4
DMCAQ5T FM C18H25F3O2
DMCAQ5T IC InChI=1S/C18H25F3O2/c1-2-3-4-7-14-23-16-12-10-15(11-13-16)8-5-6-9-17(22)18(19,20)21/h10-13H,2-9,14H2,1H3
DMCAQ5T CS CCCCCCOC1=CC=C(C=C1)CCCCC(=O)C(F)(F)F
DMCAQ5T IK AKKQOQJOIIZUSW-UHFFFAOYSA-N
DMCAQ5T IU 1,1,1-trifluoro-6-(4-hexoxyphenyl)hexan-2-one
DMCAQ5T DE Discovery agent
DMZ2VE3 ID DMZ2VE3
DMZ2VE3 DN 1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one
DMZ2VE3 HS Investigative
DMZ2VE3 SN FKGK18; 1071001-09-6; FKGK-18; SCHEMBL3489194; CHEMBL1095003; AOB4846; ZINC49114263; NCGC00402329-01
DMZ2VE3 DT Small molecular drug
DMZ2VE3 PC 25060069
DMZ2VE3 MW 280.28
DMZ2VE3 FM C16H15F3O
DMZ2VE3 IC InChI=1S/C16H15F3O/c17-16(18,19)15(20)8-4-1-5-12-9-10-13-6-2-3-7-14(13)11-12/h2-3,6-7,9-11H,1,4-5,8H2
DMZ2VE3 CS C1=CC=C2C=C(C=CC2=C1)CCCCC(=O)C(F)(F)F
DMZ2VE3 IK VCWWTQMRNJSJGC-UHFFFAOYSA-N
DMZ2VE3 IU 1,1,1-trifluoro-6-naphthalen-2-ylhexan-2-one
DMZ2VE3 DE Discovery agent
DMLHVWP ID DMLHVWP
DMLHVWP DN 1,1,1-Trifluoro-7-phenylheptan-2-one
DMLHVWP HS Investigative
DMLHVWP SN 1,1,1-Trifluoro-7-phenyl-heptan-2-one
DMLHVWP DT Small molecular drug
DMLHVWP PC 9878121
DMLHVWP MW 244.25
DMLHVWP FM C13H15F3O
DMLHVWP IC InChI=1S/C13H15F3O/c14-13(15,16)12(17)10-6-2-5-9-11-7-3-1-4-8-11/h1,3-4,7-8H,2,5-6,9-10H2
DMLHVWP CS C1=CC=C(C=C1)CCCCCC(=O)C(F)(F)F
DMLHVWP IK OYIOJJUJKLHWGM-UHFFFAOYSA-N
DMLHVWP IU 1,1,1-trifluoro-7-phenylheptan-2-one
DMLHVWP DE Discovery agent
DM6GI4Z ID DM6GI4Z
DM6GI4Z DN 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one
DM6GI4Z HS Investigative
DM6GI4Z SN CHEMBL117916; SCHEMBL7366611; BDBM50217945
DM6GI4Z DT Small molecular drug
DM6GI4Z PC 44342905
DM6GI4Z MW 366.4
DM6GI4Z FM C20H21F3O3
DM6GI4Z IC InChI=1S/C20H21F3O3/c21-20(22,23)19(24)10-6-1-2-7-15-25-16-11-13-18(14-12-16)26-17-8-4-3-5-9-17/h3-5,8-9,11-14H,1-2,6-7,10,15H2
DM6GI4Z CS C1=CC=C(C=C1)OC2=CC=C(C=C2)OCCCCCCC(=O)C(F)(F)F
DM6GI4Z IK ZZPVOJAAHDFZNF-UHFFFAOYSA-N
DM6GI4Z IU 1,1,1-trifluoro-8-(4-phenoxyphenoxy)octan-2-one
DM6GI4Z DE Discovery agent
DM41R2O ID DM41R2O
DM41R2O DN 1,1,1-Trifluoro-8-phenoxy-octan-2-one
DM41R2O HS Investigative
DM41R2O SN CHEMBL114796; BDBM50217940
DM41R2O DT Small molecular drug
DM41R2O PC 44342886
DM41R2O MW 274.28
DM41R2O FM C14H17F3O2
DM41R2O IC InChI=1S/C14H17F3O2/c15-14(16,17)13(18)10-6-1-2-7-11-19-12-8-4-3-5-9-12/h3-5,8-9H,1-2,6-7,10-11H2
DM41R2O CS C1=CC=C(C=C1)OCCCCCCC(=O)C(F)(F)F
DM41R2O IK MSSNESMCPBOBIG-UHFFFAOYSA-N
DM41R2O IU 1,1,1-trifluoro-8-phenoxyoctan-2-one
DM41R2O DE Discovery agent
DMYENI7 ID DMYENI7
DMYENI7 DN 1,1,1-Trifluoro-8-phenyl-octan-2-one
DMYENI7 HS Investigative
DMYENI7 SN 1,1,1-Trifluoro-8-phenyloctan-2-one
DMYENI7 PC 9813810
DMYENI7 MW 258.279
DMYENI7 FM C14H17F3O
DMYENI7 IC InChI=1S/C14H17F3O/c15-14(16,17)13(18)11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2
DMYENI7 CS C1=CC=C(C=C1)CCCCCCC(=O)C(F)(F)F
DMYENI7 IK LKXJGCHERZYPOU-UHFFFAOYSA-N
DMYENI7 IU 1,1,1-trifluoro-8-phenyloctan-2-one
DMYENI7 DE Discovery agent
DM7DWVL ID DM7DWVL
DM7DWVL DN 1,1,1-Trifluoro-9-phenyl-nonan-2-one
DM7DWVL HS Investigative
DM7DWVL SN CHEMBL91417; 1,1,1-trifluoro-9-phenyl-nonan-2-one; SCHEMBL5267943; BDBM50073987
DM7DWVL DT Small molecular drug
DM7DWVL PC 9795477
DM7DWVL MW 272.31
DM7DWVL FM C15H19F3O
DM7DWVL IC InChI=1S/C15H19F3O/c16-15(17,18)14(19)12-8-3-1-2-5-9-13-10-6-4-7-11-13/h4,6-7,10-11H,1-3,5,8-9,12H2
DM7DWVL CS C1=CC=C(C=C1)CCCCCCCC(=O)C(F)(F)F
DM7DWVL IK BAGRIDDIIFOCBK-UHFFFAOYSA-N
DM7DWVL IU 1,1,1-trifluoro-9-phenylnonan-2-one
DM7DWVL DE Discovery agent
DMW6CQV ID DMW6CQV
DMW6CQV DN 1,1,1-trifluorododecan-2-one
DMW6CQV HS Investigative
DMW6CQV SN 1,1,1-trifluorododecan-2-one; CHEMBL86668; 26902-72-7; 2-Dodecanone, 1,1,1-trifluoro-; AC1L424F; 1,1,1-Trifluoro-2-dodecanone; BDBM50371959
DMW6CQV DT Small molecular drug
DMW6CQV PC 176445
DMW6CQV MW 238.29
DMW6CQV FM C12H21F3O
DMW6CQV IC InChI=1S/C12H21F3O/c1-2-3-4-5-6-7-8-9-10-11(16)12(13,14)15/h2-10H2,1H3
DMW6CQV CS CCCCCCCCCCC(=O)C(F)(F)F
DMW6CQV IK YXTBWTOMSMZIMA-UHFFFAOYSA-N
DMW6CQV IU 1,1,1-trifluorododecan-2-one
DMW6CQV CA CAS 26902-72-7
DMW6CQV DE Discovery agent
DMB5U3P ID DMB5U3P
DMB5U3P DN 1,1,1-trifluoroheptadecan-2-one
DMB5U3P HS Investigative
DMB5U3P SN PACOCF3; 1,1,1-trifluoroheptadecan-2-one; 141022-99-3; palmityl trifluoromethyl ketone; Palmitoyl Trifluoromethyl Ketone; CHEMBL99344; 1,1,1-Trifluoro-2-heptadecanone; SR-01000597566; Tocris-1460; AC1L1IOS; AC1Q4I4P; SCHEMBL4653611; Pentadecyl trifluoromethyl ketone; CTK4C2431; C17H31F3O; DTXSID00274441; MAHYXYTYTLCTQD-UHFFFAOYSA-N; MolPort-003-983-793; HMS3649G09; 1,1,1-Trifluoroheptadecen-2-one; HMS3267L18; ZINC8036041; IN1174; BS0141; HSCI1_000022; BDBM50085494; 1974AH; 1,1,1-Trifluoro-2-heptadecanone #; AKOS017343267
DMB5U3P DT Small molecular drug
DMB5U3P PC 4670
DMB5U3P MW 308.4
DMB5U3P FM C17H31F3O
DMB5U3P IC InChI=1S/C17H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(21)17(18,19)20/h2-15H2,1H3
DMB5U3P CS CCCCCCCCCCCCCCCC(=O)C(F)(F)F
DMB5U3P IK MAHYXYTYTLCTQD-UHFFFAOYSA-N
DMB5U3P IU 1,1,1-trifluoroheptadecan-2-one
DMB5U3P CA CAS 141022-99-3
DMB5U3P DE Discovery agent
DM8TWY7 ID DM8TWY7
DM8TWY7 DN 1,1,1-Trifluoro-nonadecan-2-one
DM8TWY7 HS Investigative
DM8TWY7 SN 2-Nonadecanone, 1,1,1-trifluoro-; CHEMBL89946; 1,1,1-trifluorononadecan-2-one; 81124-01-8; 1,1,1-Trifluoro-nonadecan-2-one; AC1L4IKT; CTK5E8478; DTXSID90230910; 1,1,1-Trifluoro-2-nonadecanone; 2-Nonadecanone,1,1,1-trifluoro-
DM8TWY7 DT Small molecular drug
DM8TWY7 PC 157730
DM8TWY7 MW 336.5
DM8TWY7 FM C19H35F3O
DM8TWY7 IC InChI=1S/C19H35F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(23)19(20,21)22/h2-17H2,1H3
DM8TWY7 CS CCCCCCCCCCCCCCCCCC(=O)C(F)(F)F
DM8TWY7 IK SYQIFPOSGNRRCM-UHFFFAOYSA-N
DM8TWY7 IU 1,1,1-trifluorononadecan-2-one
DM8TWY7 CA CAS 81124-01-8
DM8TWY7 DE Discovery agent
DM4CEQP ID DM4CEQP
DM4CEQP DN 1,1,1-Trifluoro-tridecan-2-one
DM4CEQP HS Investigative
DM4CEQP SN 1,1,1-trifluorotridecan-2-one; CHEMBL90308; 86571-23-5; 1,1,1-Trifluoro-tridecan-2-one; CTK2I3319; DTXSID20571888; 2-Tridecanone, 1,1,1-trifluoro-
DM4CEQP DT Small molecular drug
DM4CEQP PC 15353606
DM4CEQP MW 252.32
DM4CEQP FM C13H23F3O
DM4CEQP IC InChI=1S/C13H23F3O/c1-2-3-4-5-6-7-8-9-10-11-12(17)13(14,15)16/h2-11H2,1H3
DM4CEQP CS CCCCCCCCCCCC(=O)C(F)(F)F
DM4CEQP IK ZSPZNVMNSATHGF-UHFFFAOYSA-N
DM4CEQP IU 1,1,1-trifluorotridecan-2-one
DM4CEQP CA CAS 86571-23-5
DM4CEQP DE Discovery agent
DMX2SFW ID DMX2SFW
DMX2SFW DN 1,1,1-Trifluoro-undecan-2-one
DMX2SFW HS Investigative
DMX2SFW SN CHEMBL90258; 1,1,1-trifluoroundecan-2-one; 1,1,1-trifluoro-2-undecanone; 1,1,1-Trifluoro-undecan-2-one; BDBM50073985; AKOS012260318; 3-octyl-1,1,1-trifluoro-2-propanone; 3-Octyl-1,1,1-trifluoropropan-2-one
DMX2SFW DT Small molecular drug
DMX2SFW PC 10609180
DMX2SFW MW 224.26
DMX2SFW FM C11H19F3O
DMX2SFW IC InChI=1S/C11H19F3O/c1-2-3-4-5-6-7-8-9-10(15)11(12,13)14/h2-9H2,1H3
DMX2SFW CS CCCCCCCCCC(=O)C(F)(F)F
DMX2SFW IK ZKJPGCCWKBTIBE-UHFFFAOYSA-N
DMX2SFW IU 1,1,1-trifluoroundecan-2-one
DMX2SFW DE Discovery agent
DMGHAC7 ID DMGHAC7
DMGHAC7 DN 1,1':4',1''-terphenyl-3,3''-diol
DMGHAC7 HS Investigative
DMGHAC7 SN [1,1':4',1'']Terphenyl-3,3''-diol
DMGHAC7 DT Small molecular drug
DMGHAC7 PC 44542195
DMGHAC7 MW 280.3
DMGHAC7 FM C18H13FO2
DMGHAC7 IC InChI=1S/C18H13FO2/c19-17-11-15(8-9-18(17)21)13-6-4-12(5-7-13)14-2-1-3-16(20)10-14/h1-11,20-21H
DMGHAC7 CS C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC(=C(C=C3)O)F
DMGHAC7 IK JNOWDEFWQPRYLB-UHFFFAOYSA-N
DMGHAC7 IU 2-fluoro-4-[4-(3-hydroxyphenyl)phenyl]phenol
DMGHAC7 DE Discovery agent
DMA3LZ9 ID DMA3LZ9
DMA3LZ9 DN 1,1':4',1''-terphenyl-3,4''-diol
DMA3LZ9 HS Investigative
DMA3LZ9 SN CHEMBL459976; SCHEMBL1180998; BDBM25864; RPJZTMNVHGSNCA-UHFFFAOYSA-N; ZINC40394061; hydroxyphenyl substituted benzene, 36; 3-[4-(4-hydroxyphenyl)phenyl]phenol
DMA3LZ9 DT Small molecular drug
DMA3LZ9 PC 25093397
DMA3LZ9 MW 262.3
DMA3LZ9 FM C18H14O2
DMA3LZ9 IC InChI=1S/C18H14O2/c19-17-10-8-14(9-11-17)13-4-6-15(7-5-13)16-2-1-3-18(20)12-16/h1-12,19-20H
DMA3LZ9 CS C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC=C(C=C3)O
DMA3LZ9 IK RPJZTMNVHGSNCA-UHFFFAOYSA-N
DMA3LZ9 IU 3-[4-(4-hydroxyphenyl)phenyl]phenol
DMA3LZ9 DE Discovery agent
DMYVBD2 ID DMYVBD2
DMYVBD2 DN 1,10-(methylenedi-4,1-phenylene)bismaleimide
DMYVBD2 HS Investigative
DMYVBD2 SN Bismaleimide; 13676-54-5; Bismaleimide S; Bis(4-maleimidophenyl)methane; p,p'-Dimaleimidodiphenylmethane; Diphenylmethanebismaleimide; 4,4'-Methylenebis(N-phenylmaleimide); Bis(p-maleimidophenyl)methane; 4,4'-Diphenylmethanedimaleimide; 4,4'-Dimaleimidodiphenylmethane; 4,4'-Diphenylmethanebismaleimide; 4,4'-Biphenylmethanebismaleimide; 4,4'-Bismaleimidodiphenylmethane; 1H-Pyrrole-2,5-dione, 1,1'-(methylenedi-4,1-phenylene)bis-; 4,4'-Methylenebis(phenylmaleimide); p,p'-Methylenebis(N-phenylmaleimide)
DMYVBD2 DT Small molecular drug
DMYVBD2 PC 83648
DMYVBD2 MW 358.3
DMYVBD2 FM C21H14N2O4
DMYVBD2 IC InChI=1S/C21H14N2O4/c24-18-9-10-19(25)22(18)16-5-1-14(2-6-16)13-15-3-7-17(8-4-15)23-20(26)11-12-21(23)27/h1-12H,13H2
DMYVBD2 CS C1=CC(=CC=C1CC2=CC=C(C=C2)N3C(=O)C=CC3=O)N4C(=O)C=CC4=O
DMYVBD2 IK XQUPVDVFXZDTLT-UHFFFAOYSA-N
DMYVBD2 IU 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione
DMYVBD2 CA CAS 13676-54-5
DMYVBD2 DE Discovery agent
DM9UGFQ ID DM9UGFQ
DM9UGFQ DN 1,10-bis-(Dmt-Tic-amino)decane
DM9UGFQ HS Investigative
DM9UGFQ SN CHEMBL373192; 1,10-bis-(Dmt-Tic-amino)decane
DM9UGFQ DT Small molecular drug
DM9UGFQ PC 44405160
DM9UGFQ MW 873.1
DM9UGFQ FM C52H68N6O6
DM9UGFQ IC InChI=1S/C52H68N6O6/c1-33-23-41(59)24-34(2)43(33)29-45(53)51(63)57-31-39-19-13-11-17-37(39)27-47(57)49(61)55-21-15-9-7-5-6-8-10-16-22-56-50(62)48-28-38-18-12-14-20-40(38)32-58(48)52(64)46(54)30-44-35(3)25-42(60)26-36(44)4/h11-14,17-20,23-26,45-48,59-60H,5-10,15-16,21-22,27-32,53-54H2,1-4H3,(H,55,61)(H,56,62)/t45-,46-,47?,48?/m0/s1
DM9UGFQ CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N)N)C)O
DM9UGFQ IK WGSCXEFFOVZNEM-QCSGVJIWSA-N
DM9UGFQ IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[10-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]decyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM9UGFQ DE Discovery agent
DM6VCI3 ID DM6VCI3
DM6VCI3 DN 1,10-bis(pyridinium)-decane dibromide
DM6VCI3 HS Investigative
DM6VCI3 SN P.M. 458; 1,1'-Decamethylenebis(pyridinium bromide); NSC 36864; 6266-40-6; G.L. 110; CHEMBL225689; 1-[10-(pyridin-1-ium-1-yl)decyl]pyridin-1-ium dibromide; Pyridinium, 1,1'-decamethylenebis-, dibromide; 1,10-bis(pyridinium)-decane dibromide; AC1L46P1; MolPort-023-233-174; 1,10-bis(pyridinium)decane dibromide; AKOS033332200; MCULE-1765937122; NE55775; LS-132391; 1,1'-decane-1,10-diyldipyridinium dibromide; Z1424831827; 1-(10-pyridin-1-ium-1-yldecyl)pyridin-1-ium dibromide
DM6VCI3 DT Small molecular drug
DM6VCI3 PC 201563
DM6VCI3 MW 458.3
DM6VCI3 FM C20H30Br2N2
DM6VCI3 IC InChI=1S/C20H30N2.2BrH/c1(3-5-9-15-21-17-11-7-12-18-21)2-4-6-10-16-22-19-13-8-14-20-22;;/h7-8,11-14,17-20H,1-6,9-10,15-16H2;2*1H/q+2;;/p-2
DM6VCI3 CS C1=CC=[N+](C=C1)CCCCCCCCCC[N+]2=CC=CC=C2.[Br-].[Br-]
DM6VCI3 IK XZZPVHYTBRRMNM-UHFFFAOYSA-L
DM6VCI3 IU 1-(10-pyridin-1-ium-1-yldecyl)pyridin-1-ium;dibromide
DM6VCI3 CA CAS 6266-40-6
DM6VCI3 DE Discovery agent
DM5LVD2 ID DM5LVD2
DM5LVD2 DN 1,10-phenanthroline-5,6-dione
DM5LVD2 HS Investigative
DM5LVD2 SN 1,10-Phenanthroline-5,6-dione; 27318-90-7; [1,10]Phenanthroline-5,6-dione; UNII-8JD7KXA2W0; 8JD7KXA2W0; MLS003171048; KCALAFIVPCAXJI-UHFFFAOYSA-N; 1 10-Phenanthroline-5 6-Dione 97; AK-27690; J-400086; pyridino[3,2-h]quinoline-5,6-dione; 1,10-Phenanthroline-5,6-dione, 98%; Phen-5,6-dione; 1,10-Pad; NSC346882; NSC 346882; PubChem16755; ACMC-209gwd; AC1L2IPW; PHOX31; KSC204S8L; cid_72810; SCHEMBL460433; CHEMBL235504; AC1Q6N66; KS-00000LQX; CTK1A4985; BDBM22860; DTXSID60181763; MolPort-002-720-727; 1,2-Dione-Based Compound, 17; ZX-AT019110
DM5LVD2 DT Small molecular drug
DM5LVD2 PC 72810
DM5LVD2 MW 210.19
DM5LVD2 FM C12H6N2O2
DM5LVD2 IC InChI=1S/C12H6N2O2/c15-11-7-3-1-5-13-9(7)10-8(12(11)16)4-2-6-14-10/h1-6H
DM5LVD2 CS C1=CC2=C(C3=C(C=CC=N3)C(=O)C2=O)N=C1
DM5LVD2 IK KCALAFIVPCAXJI-UHFFFAOYSA-N
DM5LVD2 IU 1,10-phenanthroline-5,6-dione
DM5LVD2 CA CAS 27318-90-7
DM5LVD2 DE Discovery agent
DMVXYZL ID DMVXYZL
DMVXYZL DN 1,11-bis(pyridinium)-undecane dibromide
DMVXYZL HS Investigative
DMVXYZL SN 1,11-bis(pyridinium)-undecane dibromide; CHEMBL430886; SCHEMBL6354341; RCBQYFFDMCXGIU-UHFFFAOYSA-L; N,N'-Undecane-1,11-diyl-bis-pyridinium Dibromide; 1,11-Di(1-Pyridiniumyl)Undecane With Dibromide Ions
DMVXYZL DT Small molecular drug
DMVXYZL PC 11351920
DMVXYZL MW 472.3
DMVXYZL FM C21H32Br2N2
DMVXYZL IC InChI=1S/C21H32N2.2BrH/c1(2-4-6-10-16-22-18-12-8-13-19-22)3-5-7-11-17-23-20-14-9-15-21-23;;/h8-9,12-15,18-21H,1-7,10-11,16-17H2;2*1H/q+2;;/p-2
DMVXYZL CS C1=CC=[N+](C=C1)CCCCCCCCCCC[N+]2=CC=CC=C2.[Br-].[Br-]
DMVXYZL IK RCBQYFFDMCXGIU-UHFFFAOYSA-L
DMVXYZL IU 1-(11-pyridin-1-ium-1-ylundecyl)pyridin-1-ium;dibromide
DMVXYZL DE Discovery agent
DMG362U ID DMG362U
DMG362U DN 1,1-bisphosphonate esters
DMG362U HS Investigative
DMG362U DE Discovery agent
DM9XTY7 ID DM9XTY7
DM9XTY7 DN 1,1-Dimethyl-4-phenyl-piperazin-1-ium iodide
DM9XTY7 HS Investigative
DM9XTY7 DE Discovery agent
DMOGHRS ID DMOGHRS
DMOGHRS DN 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one
DMOGHRS HS Investigative
DMOGHRS SN 5-Oxaspiro[2.4]heptan-4-one, 1,1-dimethyl-; 65652-09-7; CHEMBL97270
DMOGHRS DT Small molecular drug
DMOGHRS PC 10464406
DMOGHRS MW 140.18
DMOGHRS FM C8H12O2
DMOGHRS IC InChI=1S/C8H12O2/c1-7(2)5-8(7)3-4-10-6(8)9/h3-5H2,1-2H3
DMOGHRS CS CC1(CC12CCOC2=O)C
DMOGHRS IK KTGHZHGRFYRANW-UHFFFAOYSA-N
DMOGHRS IU 2,2-dimethyl-5-oxaspiro[2.4]heptan-4-one
DMOGHRS DE Discovery agent
DMZDUSA ID DMZDUSA
DMZDUSA DN 1,1-diphenyl-2-(3-tropanyl)ethanol
DMZDUSA HS Investigative
DMZDUSA SN 1,1-diphenyl-2-(3-tropanyl)ethanol; CHEMBL558034; BDBM50345674; 2-(exo-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1,1-diphenylethanol
DMZDUSA DT Small molecular drug
DMZDUSA PC 45271007
DMZDUSA MW 321.5
DMZDUSA FM C22H27NO
DMZDUSA IC InChI=1S/C22H27NO/c1-23-20-12-13-21(23)15-17(14-20)16-22(24,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20-21,24H,12-16H2,1H3/t20-,21-/m1/s1
DMZDUSA CS CN1[C@@H]2CC[C@@H]1CC(C2)CC(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMZDUSA IK LAOBIJDCKIAALB-NHCUHLMSSA-N
DMZDUSA IU 2-[(1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-1,1-diphenylethanol
DMZDUSA DE Discovery agent
DM7SQ4H ID DM7SQ4H
DM7SQ4H DN 1,1-diphenyl-3-(phenylsulfonyl)propan-2-one
DM7SQ4H HS Investigative
DM7SQ4H SN CHEMBL239469; 1,1-diphenyl-3-(phenylsulfonyl)propan-2-one
DM7SQ4H DT Small molecular drug
DM7SQ4H PC 44437611
DM7SQ4H MW 350.4
DM7SQ4H FM C21H18O3S
DM7SQ4H IC InChI=1S/C21H18O3S/c22-20(16-25(23,24)19-14-8-3-9-15-19)21(17-10-4-1-5-11-17)18-12-6-2-7-13-18/h1-15,21H,16H2
DM7SQ4H CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)CS(=O)(=O)C3=CC=CC=C3
DM7SQ4H IK SKWQLTIDKRSBES-UHFFFAOYSA-N
DM7SQ4H IU 3-(benzenesulfonyl)-1,1-diphenylpropan-2-one
DM7SQ4H DE Discovery agent
DMDYX7P ID DMDYX7P
DMDYX7P DN 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline
DMDYX7P HS Investigative
DMDYX7P SN CHEMBL133947; 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline; 67728-01-2; SCHEMBL4107088; CTK1J3020; DTXSID80603290; BDBM50219331; AKOS023412127; 1,2,3,4,4a,5,10,10a-Octahydrobenzo[g]quinoline; Benzo[g]quinoline, 1,2,3,4,4a,5,10,10a-octahydro-
DMDYX7P DT Small molecular drug
DMDYX7P PC 20186598
DMDYX7P MW 187.28
DMDYX7P FM C13H17N
DMDYX7P IC InChI=1S/C13H17N/c1-2-5-11-9-13-12(6-3-7-14-13)8-10(11)4-1/h1-2,4-5,12-14H,3,6-9H2
DMDYX7P CS C1CC2CC3=CC=CC=C3CC2NC1
DMDYX7P IK PXDWMPVOPNRION-UHFFFAOYSA-N
DMDYX7P IU 1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline
DMDYX7P CA CAS 67728-01-2
DMDYX7P DE Discovery agent
DM7JMCI ID DM7JMCI
DM7JMCI DN 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one
DM7JMCI HS Investigative
DM7JMCI SN CHEMBL84044; 7403-93-2; NSC403412; AC1L83AN; 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one; SCHEMBL6645911; DTXSID70323238; BDBM50131013; NSC-403412; 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one; 1,3,4,4a,5,10b-Hexahydro-2H-phenanthridin-6-one
DM7JMCI DT Small molecular drug
DM7JMCI PC 345678
DM7JMCI MW 201.26
DM7JMCI FM C13H15NO
DM7JMCI IC InChI=1S/C13H15NO/c15-13-11-7-2-1-5-9(11)10-6-3-4-8-12(10)14-13/h1-2,5,7,10,12H,3-4,6,8H2,(H,14,15)
DM7JMCI CS C1CCC2C(C1)C3=CC=CC=C3C(=O)N2
DM7JMCI IK CQQBPJQEIHYWQX-UHFFFAOYSA-N
DM7JMCI IU 2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-one
DM7JMCI CA CAS 7403-93-2
DM7JMCI DE Discovery agent
DMVD702 ID DMVD702
DMVD702 DN 1,2,3,4,5,6-hexabromocyclohexane
DMVD702 HS Investigative
DMVD702 SN 1,2,3,4,5,6-Hexabromocyclohexane; 1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694
DMVD702 DT Small molecular drug
DMVD702 PC 74603
DMVD702 MW 557.5
DMVD702 FM C6H6Br6
DMVD702 IC InChI=1S/C6H6Br6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-6H
DMVD702 CS C1(C(C(C(C(C1Br)Br)Br)Br)Br)Br
DMVD702 IK QFQZKISCBJKVHI-UHFFFAOYSA-N
DMVD702 IU 1,2,3,4,5,6-hexabromocyclohexane
DMVD702 CA CAS 1837-91-8
DMVD702 CB CHEBI:93940
DMVD702 DE Liver cancer
DMTKYFE ID DMTKYFE
DMTKYFE DN 1,2,3,4,5,6-Hexahydro-benzo[c]azocine
DMTKYFE HS Investigative
DMTKYFE SN 1,2,3,4,5,6-Hexahydro-benzo[c]azocine; CHEMBL116945; SCHEMBL4503618; BDBM50052889; 7124-94-9; 1,2,3,4,5,6-hexahydro-2-benzazocine; 2-Benzazocine, 1,2,3,4,5,6-hexahydro-
DMTKYFE DT Small molecular drug
DMTKYFE PC 13698159
DMTKYFE MW 161.24
DMTKYFE FM C11H15N
DMTKYFE IC InChI=1S/C11H15N/c1-2-7-11-9-12-8-4-3-6-10(11)5-1/h1-2,5,7,12H,3-4,6,8-9H2
DMTKYFE CS C1CCNCC2=CC=CC=C2C1
DMTKYFE IK QLEFVMRRZCGFFA-UHFFFAOYSA-N
DMTKYFE IU 1,2,3,4,5,6-hexahydro-2-benzazocine
DMTKYFE DE Discovery agent
DMTK650 ID DMTK650
DMTK650 DN 1,2,3,4,6-penta-O-galloyl-beta-D-glucose
DMTK650 HS Investigative
DMTK650 SN Pentagalloyl glucose; Penta-O-galloyl-beta-glucoside
DMTK650 DT Small molecular drug
DMTK650 PC 65238
DMTK650 MW 940.7
DMTK650 FM C41H32O26
DMTK650 IC InChI=1S/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33-,34+,35-,41+/m1/s1
DMTK650 CS C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O
DMTK650 IK QJYNZEYHSMRWBK-NIKIMHBISA-N
DMTK650 IU [(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate
DMTK650 CA CAS 14937-32-7
DMTK650 CB CHEBI:18082
DMTK650 DE Discovery agent
DM9ICSA ID DM9ICSA
DM9ICSA DN 1,2,3,4,6-penta-O-galloyl-D-glucopyranose
DM9ICSA HS Investigative
DM9ICSA SN D-Glucopyranose, pentakis(3,4,5-trihydroxybenzoate); 40410-94-4; 1,2,3,4,6-pentakis-o-(3,4,5-trihydroxybenzoyl)-d-glucopyranose; AC1L4RL6; SCHEMBL675693; AC1Q62I0; DTXSID00193426; 2,3,4,5,6-Pentagalloylglucose; BDBM175525; 3-O-Digalloyl-1,2,6-trigalloylglucose; 1,2,3,4,6-penta-O-galloyl--d-glucopyranose; US9120744, CDE-001 (or 073); 1-O,2-O,3-O,4-O,6-O-Pentagalloyl-D-glucopyranose; D-Glucose, 2,3,4,5,6-pentakis(3,4,5-trihydroxybenzoate); [(2R,3R,4S,5R)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 3,4,5-
DM9ICSA DT Small molecular drug
DM9ICSA PC 129651024
DM9ICSA MW 945.7
DM9ICSA FM C41H32O26
DM9ICSA IC InChI=1S/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33-,34+,35-,41?/m1/s1/i1D,3D,5D,7D,9D
DM9ICSA CS [2H]C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H](C(O2)OC(=O)C3=C(C(=C(C(=C3)O)O)O)[2H])OC(=O)C4=C(C(=C(C(=C4)O)O)O)[2H])OC(=O)C5=C(C(=C(C(=C5)O)O)O)[2H])OC(=O)C6=C(C(=C(C(=C6)O)O)O)[2H]
DM9ICSA IK QJYNZEYHSMRWBK-GYNONJAESA-N
DM9ICSA IU [(2R,3R,4S,5R)-3,4,5,6-tetrakis[(2-deuterio-3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl]methyl 2-deuterio-3,4,5-trihydroxybenzoate
DM9ICSA DE Discovery agent
DMHKANE ID DMHKANE
DMHKANE DN 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol
DMHKANE HS Investigative
DMHKANE SN CHEMBL130744; 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol; BDBM50061318; 1,2,3,4-Tetrahydrobenz[h]isoquinolin-8-ol
DMHKANE DT Small molecular drug
DMHKANE PC 9990355
DMHKANE MW 199.25
DMHKANE FM C13H13NO
DMHKANE IC InChI=1S/C13H13NO/c15-11-3-4-12-10(7-11)2-1-9-5-6-14-8-13(9)12/h1-4,7,14-15H,5-6,8H2
DMHKANE CS C1CNCC2=C1C=CC3=C2C=CC(=C3)O
DMHKANE IK MWWTWCVGHVVXBZ-UHFFFAOYSA-N
DMHKANE IU 1,2,3,4-tetrahydrobenzo[h]isoquinolin-8-ol
DMHKANE DE Discovery agent
DM5VLIE ID DM5VLIE
DM5VLIE DN 1,2,3,4-Tetrahydro-isoquinolin-7-ol
DM5VLIE HS Investigative
DM5VLIE SN 1,2,3,4-tetrahydroisoquinolin-7-ol; 30798-64-2; 1,2,3,4-Tetrahydro-isoquinolin-7-ol; 1,2,3,4-Tetrahydro-7-isoquinolinol; 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline; CHEMBL27730; RADQTHXRZJGDQI-UHFFFAOYSA-N; 7-Isoquinolinol, 1,2,3,4-tetrahydro-; 1,2,3,4-Tetrahydro-iosquinoline-7-ol; AC1L9HE2; 7-Hydroxytetrahydroisochinolin; SCHEMBL470826; AC1Q798F; DTXSID40329303; MolPort-005-312-666; ZINC3847389; BDBM50024826; ANW-75301; AKOS006222928; MB05747; RP21285; AC-9597; MCULE-2692939705; KB-74165; KB-64192; BS-13490; AJ-45863; TC-062003
DM5VLIE DT Small molecular drug
DM5VLIE PC 419268
DM5VLIE MW 149.19
DM5VLIE FM C9H11NO
DM5VLIE IC InChI=1S/C9H11NO/c11-9-2-1-7-3-4-10-6-8(7)5-9/h1-2,5,10-11H,3-4,6H2
DM5VLIE CS C1CNCC2=C1C=CC(=C2)O
DM5VLIE IK RADQTHXRZJGDQI-UHFFFAOYSA-N
DM5VLIE IU 1,2,3,4-tetrahydroisoquinolin-7-ol
DM5VLIE CA CAS 30798-64-2
DM5VLIE DE Discovery agent
DMZGCEQ ID DMZGCEQ
DMZGCEQ DN 1,2,3,4-tetrahydroisoquinoline
DMZGCEQ HS Investigative
DMZGCEQ SN 1,2,3,4-Tetrahydroisoquinoline; 91-21-4; Tetrahydroisoquinoline; 1,2,3,4-Tetrahydro-isoquinoline; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-; 1,2,3,4-Tetrahydro isoquinoline; EINECS 202-050-0; NSC 15312; 1,2,3,4-Tetrahydro-2-isoquinoline; 1,2,3,4-Tetrahydro-2-azanaphthalene; BRN 0116156; UNII-56W89FBX3E; CHEMBL14346; AI3-15931; 56W89FBX3E; UWYZHKAOTLEWKK-UHFFFAOYSA-N; MFCD00006896; 1,2,3,4-Tetrahydroisoquinoline, 95%; 3,4-dihydro-1H-isoquinoline; tetrahydroisoquinolin; tetrahyroisoquinoline; tetrahydro-isoquinoline; PubChem7253; AC1L1NVS
DMZGCEQ DT Small molecular drug
DMZGCEQ PC 7046
DMZGCEQ MW 133.19
DMZGCEQ FM C9H11N
DMZGCEQ IC InChI=1S/C9H11N/c1-2-4-9-7-10-6-5-8(9)3-1/h1-4,10H,5-7H2
DMZGCEQ CS C1CNCC2=CC=CC=C21
DMZGCEQ IK UWYZHKAOTLEWKK-UHFFFAOYSA-N
DMZGCEQ IU 1,2,3,4-tetrahydroisoquinoline
DMZGCEQ CA CAS 91-21-4
DMZGCEQ CB CHEBI:125498
DMZGCEQ DE Discovery agent
DMNXQ7Z ID DMNXQ7Z
DMNXQ7Z DN 1,2,3,4-Tetrahydro-naphthalen-1-ylamine
DMNXQ7Z HS Investigative
DMNXQ7Z SN 1,2,3,4-Tetrahydro-1-naphthylamine; 2217-40-5; 1,2,3,4-tetrahydronaphthalen-1-amine; 1-Aminotetralin; Aminotetralin; 1-Amino-1,2,3,4-tetrahydro-naphthalene; Aminotetralin [Czech]; 1,2,3,4-tetrahydronaphthylamine; JRZGPXSSNPTNMA-UHFFFAOYSA-N; EINECS 220-973-7; beta-1,2,3,4-Tetrahydronaphthylamine; Naphthalenamine, 1,2,3,4-tetrahydro-; BRN 1102357; 1-Amino-1,2,3,4-tetrahydronaphthalene; 1,2,3,4-tetrahydronaphthalen-1-ylamine; 1-Naphthalenamine, 1,2,3,4-tetrahydro-
DMNXQ7Z DT Small molecular drug
DMNXQ7Z PC 18066
DMNXQ7Z MW 147.22
DMNXQ7Z FM C10H13N
DMNXQ7Z IC InChI=1S/C10H13N/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-2,4,6,10H,3,5,7,11H2
DMNXQ7Z CS C1CC(C2=CC=CC=C2C1)N
DMNXQ7Z IK JRZGPXSSNPTNMA-UHFFFAOYSA-N
DMNXQ7Z IU 1,2,3,4-tetrahydronaphthalen-1-amine
DMNXQ7Z CA CAS 2217-40-5
DMNXQ7Z DE Discovery agent
DMP4DLV ID DMP4DLV
DMP4DLV DN 1,2,3,4-Tetrahydro-naphthalen-2-ylamine
DMP4DLV HS Investigative
DMP4DLV SN 1,2,3,4-tetrahydronaphthalen-2-amine; 2954-50-9; 1,2,3,4-Tetrahydro-2-naphthylamine; 2-Aminotetralin; 2-Naphthalenamine, 1,2,3,4-tetrahydro-; 1,2,3,4-Tetrahydro-2-naphthalenamine; CHEMBL30294; LCGFVWKNXLRFIF-UHFFFAOYSA-N; 617700-25-1; 2-1,2,3,4-tetrahydronaphthylamine; 2-amino-tetralin; tetralin-2-amine; ACMC-20ac6z; AC1Q53DS; AC1L1S2C; SCHEMBL42952; .beta.-tetrahydronaphthylamine; BDBM23981; Tetrahydronaphthalen-2-amine, 3a; MolPort-001-779-767
DMP4DLV DT Small molecular drug
DMP4DLV PC 34677
DMP4DLV MW 147.22
DMP4DLV FM C10H13N
DMP4DLV IC InChI=1S/C10H13N/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-4,10H,5-7,11H2
DMP4DLV CS C1CC2=CC=CC=C2CC1N
DMP4DLV IK LCGFVWKNXLRFIF-UHFFFAOYSA-N
DMP4DLV IU 1,2,3,4-tetrahydronaphthalen-2-amine
DMP4DLV CA CAS 2954-50-9
DMP4DLV CB CHEBI:125359
DMP4DLV DE Discovery agent
DM3JGVF ID DM3JGVF
DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole
DM3JGVF HS Investigative
DM3JGVF SN 1,2,3,4-tetrahydropyrazino[1,2-a]indole; 41838-39-5; 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole; CHEMBL6393; A1-02013; Pyrazino[1,2-a]indole, 1,2,3,4-tetrahydro-; SCHEMBL2356686; AEIDURNZWCNQIM-UHFFFAOYSA-N; MolPort-022-905-760; 2,3-dihydropyrazino[1,2-a]indole; ZINC13586839; STL290420; BDBM50108307; AKOS015996057; FCH1167619; OR70091; AJ-64212; AX8245433; KB-216229; FT-0682685; BB 0256492
DM3JGVF DT Small molecular drug
DM3JGVF PC 14595509
DM3JGVF MW 172.23
DM3JGVF FM C11H12N2
DM3JGVF IC InChI=1S/C11H12N2/c1-2-4-11-9(3-1)7-10-8-12-5-6-13(10)11/h1-4,7,12H,5-6,8H2
DM3JGVF CS C1CN2C(=CC3=CC=CC=C32)CN1
DM3JGVF IK AEIDURNZWCNQIM-UHFFFAOYSA-N
DM3JGVF IU 1,2,3,4-tetrahydropyrazino[1,2-a]indole
DM3JGVF CA CAS 41838-39-5
DM3JGVF DE Discovery agent
DMFDK4N ID DMFDK4N
DMFDK4N DN 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl
DMFDK4N HS Investigative
DMFDK4N SN 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl; 50461-51-3; CHEMBL278934; 1',2',3',6'-tetrahydro-2,4'-bipyridine; 2-(1,2,3,6-tetrahydropyridin-4-yl)pyridine; 2,4'-Bipyridine, 1',2',3',6'-tetrahydro-; SCHEMBL169400; CTK4J2646; DTXSID50569450; IVRPDZRVHKIBBG-UHFFFAOYSA-N; ZINC19811349; BDBM50026630; AKOS000205268
DMFDK4N DT Small molecular drug
DMFDK4N PC 15166842
DMFDK4N MW 160.22
DMFDK4N FM C10H12N2
DMFDK4N IC InChI=1S/C10H12N2/c1-2-6-12-10(3-1)9-4-7-11-8-5-9/h1-4,6,11H,5,7-8H2
DMFDK4N CS C1CNCC=C1C2=CC=CC=N2
DMFDK4N IK IVRPDZRVHKIBBG-UHFFFAOYSA-N
DMFDK4N IU 2-(1,2,3,6-tetrahydropyridin-4-yl)pyridine
DMFDK4N CA CAS 50461-51-3
DMFDK4N DE Discovery agent
DMYDGAZ ID DMYDGAZ
DMYDGAZ DN 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol
DMYDGAZ HS Investigative
DMYDGAZ SN CHEMBL253530; 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol
DMYDGAZ DT Small molecular drug
DMYDGAZ PC 44448059
DMYDGAZ MW 251.32
DMYDGAZ FM C17H17NO
DMYDGAZ IC InChI=1S/C17H17NO/c19-15-8-13-5-6-18-16-10-12-4-2-1-3-11(12)7-14(9-15)17(13)16/h1-4,8-9,16,18-19H,5-7,10H2
DMYDGAZ CS C1CNC2CC3=CC=CC=C3CC4=CC(=CC1=C24)O
DMYDGAZ IK ZCATUTKNMGBMKU-UHFFFAOYSA-N
DMYDGAZ IU 11-azatetracyclo[8.7.1.03,8.014,18]octadeca-1(17),3,5,7,14(18),15-hexaen-16-ol
DMYDGAZ DE Discovery agent
DMAJ0B4 ID DMAJ0B4
DMAJ0B4 DN 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
DMAJ0B4 HS Investigative
DMAJ0B4 SN CHEMBL253948; 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol
DMAJ0B4 DT Small molecular drug
DMAJ0B4 PC 44448066
DMAJ0B4 MW 267.32
DMAJ0B4 FM C17H17NO2
DMAJ0B4 IC InChI=1S/C17H17NO2/c19-15-9-12-5-6-18-14-8-11-4-2-1-3-10(11)7-13(16(12)14)17(15)20/h1-4,9,14,18-20H,5-8H2
DMAJ0B4 CS C1CNC2CC3=CC=CC=C3CC4=C2C1=CC(=C4O)O
DMAJ0B4 IK SVRDMCXMTWERHI-UHFFFAOYSA-N
DMAJ0B4 IU 11-azatetracyclo[8.7.1.03,8.014,18]octadeca-1(18),3,5,7,14,16-hexaene-16,17-diol
DMAJ0B4 DE Discovery agent
DMXL5R7 ID DMXL5R7
DMXL5R7 DN 1,2,3-benzenetricarboxylic acid
DMXL5R7 HS Investigative
DMXL5R7 SN 1,2,3-benzenetricarboxylate
DMXL5R7 DT Small molecular drug
DMXL5R7 PC 11288
DMXL5R7 MW 210.14
DMXL5R7 FM C9H6O6
DMXL5R7 IC InChI=1S/C9H6O6/c10-7(11)4-2-1-3-5(8(12)13)6(4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15)
DMXL5R7 CS C1=CC(=C(C(=C1)C(=O)O)C(=O)O)C(=O)O
DMXL5R7 IK UJMDYLWCYJJYMO-UHFFFAOYSA-N
DMXL5R7 IU benzene-1,2,3-tricarboxylic acid
DMXL5R7 CA CAS 569-51-7
DMXL5R7 DE Discovery agent
DM73F5A ID DM73F5A
DM73F5A DN 1,2,4-Triazole
DM73F5A HS Investigative
DM73F5A SN 1H-1,2,4-Triazole; 1,2,4-TRIAZOLE; 288-88-0; 4H-1,2,4-triazole; Pyrrodiazole; s-Triazole; 1,2,4-1H-Triazole; 1H-1,2,4-triazol; UNII-10MS0Y1RDI; NSC 83128; 1,2,4 triazole; 1,2,4-triazol; 4H-1,2,4-Triazole (VAN); EINECS 206-022-9; 63598-71-0; 1H-[1,2,4]triazole; 10MS0Y1RDI; AI3-51031; CHEBI:46077; NSPMIYGKQJPBQR-UHFFFAOYSA-N; MFCD00005228; [1,2,4]-triazole; (1,2,4)-triazole; 1,2,4-1H-Triazole, 99.5%; InChI=1/C2H3N3/c1-3-2-5-4-1/h1-2H,(H,3,4,5; HSDB 7860; 1,4-Triazole; 1,2,4triazole; 1,3,4-triazole; 4H-1,4-Triazole; 1H-1,4-Triazole; 1,2, 4-
DM73F5A DT Small molecular drug
DM73F5A PC 9257
DM73F5A MW 69.07
DM73F5A FM C2H3N3
DM73F5A IC InChI=1S/C2H3N3/c1-3-2-5-4-1/h1-2H,(H,3,4,5)
DM73F5A CS C1=NC=NN1
DM73F5A IK NSPMIYGKQJPBQR-UHFFFAOYSA-N
DM73F5A IU 1H-1,2,4-triazole
DM73F5A CA CAS 288-88-0
DM73F5A CB CHEBI:46077
DM73F5A DE Discovery agent
DMOXLHT ID DMOXLHT
DMOXLHT DN 1,2,4-Triazole-Carboxamidine
DMOXLHT HS Investigative
DMOXLHT SN 1,2,4-TRIAZOLE-CARBOXAMIDINE; AC1MPLO2; TZC; ZINC162503468; DB02048; CJ-13028; amino(1H-1,2,4-triazol-1-yl)methaniminium
DMOXLHT DT Small molecular drug
DMOXLHT PC 3387240
DMOXLHT MW 112.11
DMOXLHT FM C3H6N5+
DMOXLHT IC InChI=1S/C3H5N5/c4-3(5)8-2-6-1-7-8/h1-2H,(H3,4,5)/p+1
DMOXLHT CS C1=NN(C=N1)C(=[NH2+])N
DMOXLHT IK CDIOIIJXUJXYPB-UHFFFAOYSA-O
DMOXLHT IU [amino(1,2,4-triazol-1-yl)methylidene]azanium
DMOXLHT DE Discovery agent
DM7BAU2 ID DM7BAU2
DM7BAU2 DN 1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one
DM7BAU2 HS Investigative
DM7BAU2 SN CHEMBL96006; 1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one; SCHEMBL6820047; ZINC22616; BDBM50072191; AKOS023799425; 1,2,5,6-Tetrahydro-3H-benzo[c]quinolizine-3-one
DM7BAU2 DT Small molecular drug
DM7BAU2 PC 10081476
DM7BAU2 MW 199.25
DM7BAU2 FM C13H13NO
DM7BAU2 IC InChI=1S/C13H13NO/c15-12-7-8-14-11(9-12)6-5-10-3-1-2-4-13(10)14/h1-4,9H,5-8H2
DM7BAU2 CS C1CC2=CC(=O)CCN2C3=CC=CC=C31
DM7BAU2 IK OPJKPSOLCGGXEW-UHFFFAOYSA-N
DM7BAU2 IU 1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one
DM7BAU2 DE Discovery agent
DM9VYOI ID DM9VYOI
DM9VYOI DN 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
DM9VYOI HS Investigative
DM9VYOI SN NSC648146; 1,2,5-Thiadiazolidin-3-one 1,1-dioxide; 1,1-dioxo-1,2,5-thiadiazolidin-3-one; AC1Q6H1D; SCHEMBL630051; CHEMBL1996483; CTK7H4434; AC1L8566; NSC-648146; NCI60_016689; 1,5-Thiadiazolidin-3-one, 1,1-dioxide; 1,2,5-thiadiazolidine-3-one-1,1-dioxide; 1,2,5-Thiadiazolidine-3-one 1,1-dioxide; 1,2,5-Thiadiazolidin-3-one, 1,1-dioxide
DM9VYOI DT Small molecular drug
DM9VYOI PC 4369452
DM9VYOI MW 212.23
DM9VYOI FM C8H8N2O3S
DM9VYOI IC InChI=1S/C8H8N2O3S/c11-8-6-10(14(12,13)9-8)7-4-2-1-3-5-7/h1-5H,6H2,(H,9,11)
DM9VYOI CS C1C(=O)NS(=O)(=O)N1C2=CC=CC=C2
DM9VYOI IK LDCZCUKQWRZSDT-UHFFFAOYSA-N
DM9VYOI IU 1,1-dioxo-5-phenyl-1,2,5-thiadiazolidin-3-one
DM9VYOI DE Discovery agent
DMWGN3F ID DMWGN3F
DMWGN3F DN 1,2,6-tri-O-galloyl-beta-D-glucose
DMWGN3F HS Investigative
DMWGN3F SN AC1L3XRG; 1,2,6-Tri-O-galloyl-.beta.-D-glucose; 1,2,6-Tri-O-galloyl-.beta.-D-glucopyranose; .beta.-D-Glucopyranose, 1,2,6-tris(3,4,5-trihydroxybenzoate); [(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]tetrahydrofuran-2-yl]methyl 3,4,5-trihydroxybenzoate; [(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate
DMWGN3F DT Small molecular drug
DMWGN3F PC 124024
DMWGN3F MW 636.5
DMWGN3F FM C27H24O18
DMWGN3F IC InChI=1S/C27H24O18/c28-12-1-9(2-13(29)19(12)34)23(37)42-7-18-22(45-25(39)11-5-16(32)21(36)17(33)6-11)27(41,26(40)44-18)8-43-24(38)10-3-14(30)20(35)15(31)4-10/h1-6,18,22,26,28-36,40-41H,7-8H2/t18?,22?,26-,27?/m1/s1
DMWGN3F CS C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C(C([C@@H](O2)O)(COC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMWGN3F IK KCQFLGUEZXYOER-IPKUFKRGSA-N
DMWGN3F IU [(5R)-4,5-dihydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-4-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate
DMWGN3F CA CAS 79886-49-0
DMWGN3F DE Discovery agent
DMZSL7H ID DMZSL7H
DMZSL7H DN 1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone
DMZSL7H HS Investigative
DMZSL7H SN CHEMBL244631; 1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone
DMZSL7H DT Small molecular drug
DMZSL7H PC 16745302
DMZSL7H MW 320.19
DMZSL7H FM C14H6F6O2
DMZSL7H IC InChI=1S/C14H6F6O2/c15-7-3-1-5(9(17)11(7)19)13(21)14(22)6-2-4-8(16)12(20)10(6)18/h1-4,13,21H
DMZSL7H CS C1=CC(=C(C(=C1C(C(=O)C2=C(C(=C(C=C2)F)F)F)O)F)F)F
DMZSL7H IK ICSVRGYUGLAIDB-UHFFFAOYSA-N
DMZSL7H IU 2-hydroxy-1,2-bis(2,3,4-trifluorophenyl)ethanone
DMZSL7H DE Discovery agent
DML5ECR ID DML5ECR
DML5ECR DN 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR HS Investigative
DML5ECR SN CHEMBL242931; 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR DT Small molecular drug
DML5ECR PC 44428841
DML5ECR MW 318.17
DML5ECR FM C14H4F6O2
DML5ECR IC InChI=1S/C14H4F6O2/c15-7-3-1-5(9(17)11(7)19)13(21)14(22)6-2-4-8(16)12(20)10(6)18/h1-4H
DML5ECR CS C1=CC(=C(C(=C1C(=O)C(=O)C2=C(C(=C(C=C2)F)F)F)F)F)F
DML5ECR IK PWUSEBWVFQBDEQ-UHFFFAOYSA-N
DML5ECR IU 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione
DML5ECR DE Discovery agent
DMD9HP8 ID DMD9HP8
DMD9HP8 DN 1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone
DMD9HP8 HS Investigative
DMD9HP8 SN CHEMBL244630; 1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone
DMD9HP8 DT Small molecular drug
DMD9HP8 PC 44428834
DMD9HP8 MW 320.19
DMD9HP8 FM C14H6F6O2
DMD9HP8 IC InChI=1S/C14H6F6O2/c15-5-1-7(11(19)9(17)3-5)13(21)14(22)8-2-6(16)4-10(18)12(8)20/h1-4,13,21H
DMD9HP8 CS C1=C(C=C(C(=C1C(C(=O)C2=C(C(=CC(=C2)F)F)F)O)F)F)F
DMD9HP8 IK FWTYPBLNNIDCIZ-UHFFFAOYSA-N
DMD9HP8 IU 2-hydroxy-1,2-bis(2,3,5-trifluorophenyl)ethanone
DMD9HP8 DE Discovery agent
DMZHWAV ID DMZHWAV
DMZHWAV DN 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV HS Investigative
DMZHWAV SN CHEMBL242930; 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV DT Small molecular drug
DMZHWAV PC 44428840
DMZHWAV MW 318.17
DMZHWAV FM C14H4F6O2
DMZHWAV IC InChI=1S/C14H4F6O2/c15-5-1-7(11(19)9(17)3-5)13(21)14(22)8-2-6(16)4-10(18)12(8)20/h1-4H
DMZHWAV CS C1=C(C=C(C(=C1C(=O)C(=O)C2=C(C(=CC(=C2)F)F)F)F)F)F
DMZHWAV IK KLUCLGJNULKHIS-UHFFFAOYSA-N
DMZHWAV IU 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione
DMZHWAV DE Discovery agent
DMWS2HL ID DMWS2HL
DMWS2HL DN 1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL HS Investigative
DMWS2HL SN CHEMBL242722; 1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL DT Small molecular drug
DMWS2HL PC 44428839
DMWS2HL MW 318.17
DMWS2HL FM C14H4F6O2
DMWS2HL IC InChI=1S/C14H4F6O2/c15-5-3-6(11(19)9(18)4-5)13(21)14(22)10-7(16)1-2-8(17)12(10)20/h1-4H
DMWS2HL CS C1=CC(=C(C(=C1F)C(=O)C(=O)C2=C(C(=CC(=C2)F)F)F)F)F
DMWS2HL IK NHBDBTHCQQXYBY-UHFFFAOYSA-N
DMWS2HL IU 1-(2,3,5-trifluorophenyl)-2-(2,3,6-trifluorophenyl)ethane-1,2-dione
DMWS2HL DE Discovery agent
DMZ0D5W ID DMZ0D5W
DMZ0D5W DN 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W HS Investigative
DMZ0D5W SN CHEMBL244427; 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W DT Small molecular drug
DMZ0D5W PC 44428831
DMZ0D5W MW 284.2
DMZ0D5W FM C14H8F4O2
DMZ0D5W IC InChI=1S/C14H8F4O2/c15-9-5-1-3-7(11(9)17)13(19)14(20)8-4-2-6-10(16)12(8)18/h1-6,13,19H
DMZ0D5W CS C1=CC(=C(C(=C1)F)F)C(C(=O)C2=C(C(=CC=C2)F)F)O
DMZ0D5W IK PYTAIIXDDDIUHU-UHFFFAOYSA-N
DMZ0D5W IU 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone
DMZ0D5W DE Discovery agent
DM9Z1NY ID DM9Z1NY
DM9Z1NY DN 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione
DM9Z1NY HS Investigative
DM9Z1NY SN CHEMBL395018; 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione; SCHEMBL3184940
DM9Z1NY DT Small molecular drug
DM9Z1NY PC 22574224
DM9Z1NY MW 282.19
DM9Z1NY FM C14H6F4O2
DM9Z1NY IC InChI=1S/C14H6F4O2/c15-9-5-1-3-7(11(9)17)13(19)14(20)8-4-2-6-10(16)12(8)18/h1-6H
DM9Z1NY CS C1=CC(=C(C(=C1)F)F)C(=O)C(=O)C2=C(C(=CC=C2)F)F
DM9Z1NY IK LJRGNWLITYAYFC-UHFFFAOYSA-N
DM9Z1NY IU 1,2-bis(2,3-difluorophenyl)ethane-1,2-dione
DM9Z1NY DE Discovery agent
DMLMCBW ID DMLMCBW
DMLMCBW DN 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW HS Investigative
DMLMCBW SN CHEMBL244425; 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW DT Small molecular drug
DMLMCBW PC 44428828
DMLMCBW MW 284.2
DMLMCBW FM C14H8F4O2
DMLMCBW IC InChI=1S/C14H8F4O2/c15-7-1-3-9(11(17)5-7)13(19)14(20)10-4-2-8(16)6-12(10)18/h1-6,13,19H
DMLMCBW CS C1=CC(=C(C=C1F)F)C(C(=O)C2=C(C=C(C=C2)F)F)O
DMLMCBW IK MOZRQJUPHVESBZ-UHFFFAOYSA-N
DMLMCBW IU 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone
DMLMCBW DE Discovery agent
DMUZHPS ID DMUZHPS
DMUZHPS DN 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione
DMUZHPS HS Investigative
DMUZHPS SN CHEMBL242287; 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione; SCHEMBL8070666
DMUZHPS DT Small molecular drug
DMUZHPS PC 19377173
DMUZHPS MW 282.19
DMUZHPS FM C14H6F4O2
DMUZHPS IC InChI=1S/C14H6F4O2/c15-7-1-3-9(11(17)5-7)13(19)14(20)10-4-2-8(16)6-12(10)18/h1-6H
DMUZHPS CS C1=CC(=C(C=C1F)F)C(=O)C(=O)C2=C(C=C(C=C2)F)F
DMUZHPS IK GMRRDQVLRFWXPQ-UHFFFAOYSA-N
DMUZHPS IU 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione
DMUZHPS DE Discovery agent
DM9EW2F ID DM9EW2F
DM9EW2F DN 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F HS Investigative
DM9EW2F SN CHEMBL244428; 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F DT Small molecular drug
DM9EW2F PC 44428832
DM9EW2F MW 284.2
DM9EW2F FM C14H8F4O2
DM9EW2F IC InChI=1S/C14H8F4O2/c15-7-1-3-11(17)9(5-7)13(19)14(20)10-6-8(16)2-4-12(10)18/h1-6,13,19H
DM9EW2F CS C1=CC(=C(C=C1F)C(C(=O)C2=C(C=CC(=C2)F)F)O)F
DM9EW2F IK DMPZBXMNYCXAQZ-UHFFFAOYSA-N
DM9EW2F IU 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone
DM9EW2F DE Discovery agent
DMVLMBQ ID DMVLMBQ
DMVLMBQ DN 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione
DMVLMBQ HS Investigative
DMVLMBQ SN CHEMBL242721; 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione; SCHEMBL3180092
DMVLMBQ DT Small molecular drug
DMVLMBQ PC 22574258
DMVLMBQ MW 282.19
DMVLMBQ FM C14H6F4O2
DMVLMBQ IC InChI=1S/C14H6F4O2/c15-7-1-3-11(17)9(5-7)13(19)14(20)10-6-8(16)2-4-12(10)18/h1-6H
DMVLMBQ CS C1=CC(=C(C=C1F)C(=O)C(=O)C2=C(C=CC(=C2)F)F)F
DMVLMBQ IK IWSRHXHMXUIXCZ-UHFFFAOYSA-N
DMVLMBQ IU 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione
DMVLMBQ DE Discovery agent
DMSMVCH ID DMSMVCH
DMSMVCH DN 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH HS Investigative
DMSMVCH SN CHEMBL244426; 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH DT Small molecular drug
DMSMVCH PC 44428829
DMSMVCH MW 284.2
DMSMVCH FM C14H8F4O2
DMSMVCH IC InChI=1S/C14H8F4O2/c15-7-3-1-4-8(16)11(7)13(19)14(20)12-9(17)5-2-6-10(12)18/h1-6,13,19H
DMSMVCH CS C1=CC(=C(C(=C1)F)C(C(=O)C2=C(C=CC=C2F)F)O)F
DMSMVCH IK JVCMBBUYARXRIK-UHFFFAOYSA-N
DMSMVCH IU 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone
DMSMVCH DE Discovery agent
DM351EA ID DM351EA
DM351EA DN 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA HS Investigative
DM351EA SN CHEMBL242288; 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA DT Small molecular drug
DM351EA PC 44428837
DM351EA MW 282.19
DM351EA FM C14H6F4O2
DM351EA IC InChI=1S/C14H6F4O2/c15-7-3-1-4-8(16)11(7)13(19)14(20)12-9(17)5-2-6-10(12)18/h1-6H
DM351EA CS C1=CC(=C(C(=C1)F)C(=O)C(=O)C2=C(C=CC=C2F)F)F
DM351EA IK ZQTHCEAXUHQYSG-UHFFFAOYSA-N
DM351EA IU 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione
DM351EA DE Discovery agent
DMZF4IC ID DMZF4IC
DMZF4IC DN 1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione
DMZF4IC HS Investigative
DMZF4IC SN 2,2'-Dichlorobenzil; 21854-95-5; 1,2-bis(2-chlorophenyl)ethane-1,2-dione; 2,2'-Dichlorodibenzoyl; Ethanedione, bis(2-chlorophenyl)-; Benzil, 2,2'-dichloro-; MFCD00018263; 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-; AE-562/43458948; NSC114829; Benzil,2'-dichloro-; ACMC-20aok0; AC1Q5FHJ; Benzil-based compound, 10; Bis(2-chlorophenyl) diketone; 2,2'-Dichlorobenzil, 97%; SCHEMBL2156567; CHEMBL365392; AC1L3H37; DTXSID1066736; CTK4E7789; BDBM22732; VOSNNSVWVJFJCR-UHFFFAOYSA-N; MolPort-003-915-120; ZINC1704748; Benzil, 2,2'-dichloro- (8CI)
DMZF4IC DT Small molecular drug
DMZF4IC PC 89076
DMZF4IC MW 279.1
DMZF4IC FM C14H8Cl2O2
DMZF4IC IC InChI=1S/C14H8Cl2O2/c15-11-7-3-1-5-9(11)13(17)14(18)10-6-2-4-8-12(10)16/h1-8H
DMZF4IC CS C1=CC=C(C(=C1)C(=O)C(=O)C2=CC=CC=C2Cl)Cl
DMZF4IC IK VOSNNSVWVJFJCR-UHFFFAOYSA-N
DMZF4IC IU 1,2-bis(2-chlorophenyl)ethane-1,2-dione
DMZF4IC CA CAS 21854-95-5
DMZF4IC DE Discovery agent
DMNWM5S ID DMNWM5S
DMNWM5S DN 1,2-bis(2-fluorophenyl)-2-hydroxyethanone
DMNWM5S HS Investigative
DMNWM5S SN CHEMBL242768; 1,2-bis(2-fluorophenyl)-2-hydroxyethanone; SCHEMBL7414865; XQFHNDNXOUWJPU-UHFFFAOYSA-N; BDBM50209403
DMNWM5S DT Small molecular drug
DMNWM5S PC 19971657
DMNWM5S MW 248.22
DMNWM5S FM C14H10F2O2
DMNWM5S IC InChI=1S/C14H10F2O2/c15-11-7-3-1-5-9(11)13(17)14(18)10-6-2-4-8-12(10)16/h1-8,13,17H
DMNWM5S CS C1=CC=C(C(=C1)C(C(=O)C2=CC=CC=C2F)O)F
DMNWM5S IK XQFHNDNXOUWJPU-UHFFFAOYSA-N
DMNWM5S IU 1,2-bis(2-fluorophenyl)-2-hydroxyethanone
DMNWM5S DE Discovery agent
DM9FMUE ID DM9FMUE
DM9FMUE DN 1,2-bis(2-fluorophenyl)ethane-1,2-dione
DM9FMUE HS Investigative
DM9FMUE SN 1,2-bis(2-fluorophenyl)ethane-1,2-dione; CHEMBL244633; 573-43-3; Bis(2-fluorophenyl) diketone; SCHEMBL2156696; CTK1F2289; DTXSID60453098; Ethanedione, bis(2-fluorophenyl)-; ZINC28713881; BDBM50209423; AKOS030595584; 1,2-bis(2-fluorophenyl)-1,2-ethanedione
DM9FMUE DT Small molecular drug
DM9FMUE PC 11043027
DM9FMUE MW 246.21
DM9FMUE FM C14H8F2O2
DM9FMUE IC InChI=1S/C14H8F2O2/c15-11-7-3-1-5-9(11)13(17)14(18)10-6-2-4-8-12(10)16/h1-8H
DM9FMUE CS C1=CC=C(C(=C1)C(=O)C(=O)C2=CC=CC=C2F)F
DM9FMUE IK UWQCHLREAXYCBW-UHFFFAOYSA-N
DM9FMUE IU 1,2-bis(2-fluorophenyl)ethane-1,2-dione
DM9FMUE CA CAS 573-43-3
DM9FMUE DE Discovery agent
DM0LWAV ID DM0LWAV
DM0LWAV DN 1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone
DM0LWAV HS Investigative
DM0LWAV SN CHEMBL394806; 1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone
DM0LWAV DT Small molecular drug
DM0LWAV PC 44428835
DM0LWAV MW 320.19
DM0LWAV FM C14H6F6O2
DM0LWAV IC InChI=1S/C14H6F6O2/c15-7-1-5(2-8(16)11(7)19)13(21)14(22)6-3-9(17)12(20)10(18)4-6/h1-4,13,21H
DM0LWAV CS C1=C(C=C(C(=C1F)F)F)C(C(=O)C2=CC(=C(C(=C2)F)F)F)O
DM0LWAV IK BBOPAMQNZSQMGE-UHFFFAOYSA-N
DM0LWAV IU 2-hydroxy-1,2-bis(3,4,5-trifluorophenyl)ethanone
DM0LWAV DE Discovery agent
DMPJT3V ID DMPJT3V
DMPJT3V DN 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
DMPJT3V HS Investigative
DMPJT3V SN CHEMBL193180; 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione; Benzil-based compound, 13; SCHEMBL2156255
DMPJT3V DT Small molecular drug
DMPJT3V PC 11392969
DMPJT3V MW 318.17
DMPJT3V FM C14H4F6O2
DMPJT3V IC InChI=1S/C14H4F6O2/c15-7-1-5(2-8(16)11(7)19)13(21)14(22)6-3-9(17)12(20)10(18)4-6/h1-4H
DMPJT3V CS C1=C(C=C(C(=C1F)F)F)C(=O)C(=O)C2=CC(=C(C(=C2)F)F)F
DMPJT3V IK FMFHXBPXDZLEKC-UHFFFAOYSA-N
DMPJT3V IU 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
DMPJT3V DE Discovery agent
DMRCUKJ ID DMRCUKJ
DMRCUKJ DN 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ HS Investigative
DMRCUKJ SN CHEMBL394557; 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ DT Small molecular drug
DMRCUKJ PC 44428830
DMRCUKJ MW 284.2
DMRCUKJ FM C14H8F4O2
DMRCUKJ IC InChI=1S/C14H8F4O2/c15-9-3-1-7(5-11(9)17)13(19)14(20)8-2-4-10(16)12(18)6-8/h1-6,13,19H
DMRCUKJ CS C1=CC(=C(C=C1C(C(=O)C2=CC(=C(C=C2)F)F)O)F)F
DMRCUKJ IK VPCIITRKAXBIRA-UHFFFAOYSA-N
DMRCUKJ IU 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone
DMRCUKJ DE Discovery agent
DMBZ5RN ID DMBZ5RN
DMBZ5RN DN 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione
DMBZ5RN HS Investigative
DMBZ5RN SN CHEMBL397739; 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione; BDBM50209399
DMBZ5RN DT Small molecular drug
DMBZ5RN PC 44428838
DMBZ5RN MW 282.19
DMBZ5RN FM C14H6F4O2
DMBZ5RN IC InChI=1S/C14H6F4O2/c15-9-3-1-7(5-11(9)17)13(19)14(20)8-2-4-10(16)12(18)6-8/h1-6H
DMBZ5RN CS C1=CC(=C(C=C1C(=O)C(=O)C2=CC(=C(C=C2)F)F)F)F
DMBZ5RN IK IBDJXLAQEHPROM-UHFFFAOYSA-N
DMBZ5RN IU 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione
DMBZ5RN DE Discovery agent
DMQTPX2 ID DMQTPX2
DMQTPX2 DN 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2 HS Investigative
DMQTPX2 SN CHEMBL437373; 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2 DT Small molecular drug
DMQTPX2 PC 44428833
DMQTPX2 MW 284.2
DMQTPX2 FM C14H8F4O2
DMQTPX2 IC InChI=1S/C14H8F4O2/c15-9-1-7(2-10(16)5-9)13(19)14(20)8-3-11(17)6-12(18)4-8/h1-6,13,19H
DMQTPX2 CS C1=C(C=C(C=C1F)F)C(C(=O)C2=CC(=CC(=C2)F)F)O
DMQTPX2 IK RDAYGBPKZORYGI-UHFFFAOYSA-N
DMQTPX2 IU 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone
DMQTPX2 DE Discovery agent
DM3K5RI ID DM3K5RI
DM3K5RI DN 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione
DM3K5RI HS Investigative
DM3K5RI SN 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione; CHEMBL193229; 223707-22-0; Benzil-based compound, 12; SCHEMBL2156965; BDBM22734
DM3K5RI DT Small molecular drug
DM3K5RI PC 11437501
DM3K5RI MW 282.19
DM3K5RI FM C14H6F4O2
DM3K5RI IC InChI=1S/C14H6F4O2/c15-9-1-7(2-10(16)5-9)13(19)14(20)8-3-11(17)6-12(18)4-8/h1-6H
DM3K5RI CS C1=C(C=C(C=C1F)F)C(=O)C(=O)C2=CC(=CC(=C2)F)F
DM3K5RI IK ZDXXQKFXZDPNLI-UHFFFAOYSA-N
DM3K5RI IU 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione
DM3K5RI DE Discovery agent
DM8XGD0 ID DM8XGD0
DM8XGD0 DN 1,2-bis(3-fluorophenyl)-2-hydroxyethanon
DM8XGD0 HS Investigative
DM8XGD0 SN CHEMBL396977; 1,2-bis(3-fluorophenyl)-2-hydroxyethanon; 1,2-bis(3-fluorophenyl)-2-hydroxy-ethanone; SCHEMBL11382156; BDBM50209422
DM8XGD0 DT Small molecular drug
DM8XGD0 PC 10868634
DM8XGD0 MW 248.22
DM8XGD0 FM C14H10F2O2
DM8XGD0 IC InChI=1S/C14H10F2O2/c15-11-5-1-3-9(7-11)13(17)14(18)10-4-2-6-12(16)8-10/h1-8,13,17H
DM8XGD0 CS C1=CC(=CC(=C1)F)C(C(=O)C2=CC(=CC=C2)F)O
DM8XGD0 IK AELVPDSJUJGTJH-UHFFFAOYSA-N
DM8XGD0 IU 1,2-bis(3-fluorophenyl)-2-hydroxyethanone
DM8XGD0 DE Discovery agent
DMM3I1P ID DMM3I1P
DMM3I1P DN 1,2-bis(3-fluorophenyl)ethane-1,2-dione
DMM3I1P HS Investigative
DMM3I1P SN 1,2-bis(3-fluorophenyl)ethane-1,2-dione; CHEMBL242067; 3,3'-Difluorobenzil; SCHEMBL3169331; NIOZEPOIIGVTTO-UHFFFAOYSA-N; BDBM50209414
DMM3I1P DT Small molecular drug
DMM3I1P PC 22574214
DMM3I1P MW 246.21
DMM3I1P FM C14H8F2O2
DMM3I1P IC InChI=1S/C14H8F2O2/c15-11-5-1-3-9(7-11)13(17)14(18)10-4-2-6-12(16)8-10/h1-8H
DMM3I1P CS C1=CC(=CC(=C1)F)C(=O)C(=O)C2=CC(=CC=C2)F
DMM3I1P IK NIOZEPOIIGVTTO-UHFFFAOYSA-N
DMM3I1P IU 1,2-bis(3-fluorophenyl)ethane-1,2-dione
DMM3I1P CA CAS 70028-89-6
DMM3I1P DE Discovery agent
DMWY1QN ID DMWY1QN
DMWY1QN DN 1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione
DMWY1QN HS Investigative
DMWY1QN SN 40101-17-5; 3,3'-Dimethoxybenzil; 1,2-bis(3-methoxyphenyl)ethane-1,2-dione; Ethanedione, bis(3-methoxyphenyl)-; 1,2-Ethanedione, 1,2-bis(3-methoxyphenyl)-; PJGXOGKIVAJFTE-UHFFFAOYSA-N; MFCD00038221; Bis(3-methoxyphenyl)ethanedione; EINECS 254-793-5; ACMC-20a2cz; 3,3'-dimethoxy benzil; AC1Q5BUM; AC1L3WPM; 3,3'-Dimethoxydibenzoyl; Bis(3-methoxyphenyl)glyoxal; Benzil-based compound, 22; CHEMBL435109; SCHEMBL2156482; 3,3'-Dimethoxybenzil, 99%; DTXSID7068213; BDBM22744; CTK4I2455; 3,3''-Dimethoxybenzil, 99+%; ZINC2168289; 5327AB
DMWY1QN DT Small molecular drug
DMWY1QN PC 123493
DMWY1QN MW 270.28
DMWY1QN FM C16H14O4
DMWY1QN IC InChI=1S/C16H14O4/c1-19-13-7-3-5-11(9-13)15(17)16(18)12-6-4-8-14(10-12)20-2/h3-10H,1-2H3
DMWY1QN CS COC1=CC=CC(=C1)C(=O)C(=O)C2=CC(=CC=C2)OC
DMWY1QN IK PJGXOGKIVAJFTE-UHFFFAOYSA-N
DMWY1QN IU 1,2-bis(3-methoxyphenyl)ethane-1,2-dione
DMWY1QN CA CAS 40101-17-5
DMWY1QN DE Discovery agent
DMGSTKZ ID DMGSTKZ
DMGSTKZ DN 1,2-Bis-(3-nitro-phenyl)-ethane-1,2-dione
DMGSTKZ HS Investigative
DMGSTKZ SN 3,3'-Dinitrobenzil; 3,5'-Dinitrobenzil; Benzil, 3,5'-dinitro-; Bis(m-nitrophenyl)ethanedione; 1,2-bis(3-nitrophenyl)ethane-1,2-dione; 5913-06-4; Ethanedione, bis(3-nitrophenyl)-; NSC 408976; BRN 2003620; 1,2-bis{3-nitrophenyl}-1,2-ethanedione; AI3-61771; NSC408976; Benzil,5'-dinitro-; AC1L2QPJ; Bis-(m,m'-nitrobenzil); Benzil-based compound, 29; AC1Q5B0Z; SCHEMBL2156825; CHEMBL191796; BDBM22751; CTK7F3460; DTXSID90207869; MolPort-003-803-953; ZINC1601014; NSC-408976; 1,2-Bis(m-nitrophenyl)ethane-1,2-dione; LS-32448; Ethanedione, bis(3
DMGSTKZ DT Small molecular drug
DMGSTKZ PC 101375
DMGSTKZ MW 300.22
DMGSTKZ FM C14H8N2O6
DMGSTKZ IC InChI=1S/C14H8N2O6/c17-13(9-3-1-5-11(7-9)15(19)20)14(18)10-4-2-6-12(8-10)16(21)22/h1-8H
DMGSTKZ CS C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)C(=O)C2=CC(=CC=C2)[N+](=O)[O-]
DMGSTKZ IK SGKVXDKTNJHBCA-UHFFFAOYSA-N
DMGSTKZ IU 1,2-bis(3-nitrophenyl)ethane-1,2-dione
DMGSTKZ CA CAS 5913-06-4
DMGSTKZ DE Discovery agent
DMUW2EJ ID DMUW2EJ
DMUW2EJ DN 1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione
DMUW2EJ HS Investigative
DMUW2EJ SN 4,4'-Dibromobenzil; 35578-47-3; Ethanedione, bis(4-bromophenyl)-; p,p'-Dibromobenzil; 1,2-bis(4-bromophenyl)ethane-1,2-dione; Benzyl, 4,4'-dibromo-; UNII-O4TXV8A656; Bis(4-bromophenyl)ethanedione; 4,4'-Dibromodibenzoyl; O4TXV8A656; 1,2-Ethanedione, 1,2-bis(4-bromophenyl)-; NYCBYBDDECLFPE-UHFFFAOYSA-N; MFCD00000104; W-110862; NSC74075; EINECS 252-628-1; NSC 74075; Benzyl,4'-dibromo-; 4,4'-dibromo-benzil; ACMC-209ihu; AI3-25040; AC1L3WFW; 1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione; Benzil-based compound, 11; NCIOpen2_008898
DMUW2EJ DT Small molecular drug
DMUW2EJ PC 96430
DMUW2EJ MW 368.02
DMUW2EJ FM C14H8Br2O2
DMUW2EJ IC InChI=1S/C14H8Br2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H
DMUW2EJ CS C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)Br)Br
DMUW2EJ IK NYCBYBDDECLFPE-UHFFFAOYSA-N
DMUW2EJ IU 1,2-bis(4-bromophenyl)ethane-1,2-dione
DMUW2EJ CA CAS 35578-47-3
DMUW2EJ DE Discovery agent
DM0E5FH ID DM0E5FH
DM0E5FH DN 1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione
DM0E5FH HS Investigative
DM0E5FH SN 4,4'-Dichlorobenzil; 3457-46-3; 1,2-bis(4-chlorophenyl)ethane-1,2-dione; 4,4'-Dichlorodibenzoyl; BIS(4-CHLOROPHENYL)ETHANEDIONE; 1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione; Ethanedione, bis(4-chlorophenyl)-; Bis(p-chlorophenyl)ethanedione; 1,2-bis(4-chlorophenyl)-1,2-ethanedione; bis(4-chlorophenyl)ethane-1,2-dione; 88372-92-3; 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-; Benzil, 4,4'-dichloro-; dichlorbenzil; C14H8Cl2O2; NSC274; NSC 274; EINECS 222-387-7; PubChem3923; p-p'-Dichloro-benzil; Benzil,4'-dichloro-; 4,4'-Dichloro benz
DM0E5FH DT Small molecular drug
DM0E5FH PC 18946
DM0E5FH MW 279.1
DM0E5FH FM C14H8Cl2O2
DM0E5FH IC InChI=1S/C14H8Cl2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H
DM0E5FH CS C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)Cl)Cl
DM0E5FH IK XMAWUPHYEABFDR-UHFFFAOYSA-N
DM0E5FH IU 1,2-bis(4-chlorophenyl)ethane-1,2-dione
DM0E5FH CA CAS 3457-46-3
DM0E5FH DE Discovery agent
DM38Q7W ID DM38Q7W
DM38Q7W DN 1,2-bis(4-fluorophenyl)ethane-1,2-dione
DM38Q7W HS Investigative
DM38Q7W SN 4,4'-Difluorobenzil; 579-39-5; 1,2-bis(4-fluorophenyl)ethane-1,2-dione; Ethanedione, bis(4-fluorophenyl)-; 4,4'-Difluorodibenzoyl; CHEMBL192410; 1,2-Ethanedione, 1,2-bis(4-fluorophenyl)-; BRKULQOUSCHDGS-UHFFFAOYSA-N; MFCD00134541; 1,2-Bis(4-fluorophenyl)-1,2-ethanedione; difluorobenzil; C14H8F2O2; 4,4'difluorobenzil; PubChem7683; ACMC-1AYLX; 4,4'-Difluorobibenzoyl; AC1L3VST; Benzil-based compound, 8; AC1Q5E6G; SCHEMBL716295; 4,4'-Difluorobenzil, 98%; DTXSID3060374; BDBM22730; MolPort-000-154-273; ZX-AP007762; ZINC2504724
DM38Q7W DT Small molecular drug
DM38Q7W PC 123072
DM38Q7W MW 246.21
DM38Q7W FM C14H8F2O2
DM38Q7W IC InChI=1S/C14H8F2O2/c15-11-5-1-9(2-6-11)13(17)14(18)10-3-7-12(16)8-4-10/h1-8H
DM38Q7W CS C1=CC(=CC=C1C(=O)C(=O)C2=CC=C(C=C2)F)F
DM38Q7W IK BRKULQOUSCHDGS-UHFFFAOYSA-N
DM38Q7W IU 1,2-bis(4-fluorophenyl)ethane-1,2-dione
DM38Q7W CA CAS 579-39-5
DM38Q7W DE Discovery agent
DM9RF1T ID DM9RF1T
DM9RF1T DN 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol
DM9RF1T HS Investigative
DM9RF1T SN CHEMBL26865; 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol
DM9RF1T DT Small molecular drug
DM9RF1T PC 11638264
DM9RF1T MW 316.3
DM9RF1T FM C21H16O3
DM9RF1T IC InChI=1S/C21H16O3/c22-16-5-1-13(2-6-16)20-12-15-11-18(24)9-10-19(15)21(20)14-3-7-17(23)8-4-14/h1-11,22-24H,12H2
DM9RF1T CS C1C2=C(C=CC(=C2)O)C(=C1C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DM9RF1T IK PTZCIKOPLAEWTE-UHFFFAOYSA-N
DM9RF1T IU 1,2-bis(4-hydroxyphenyl)-3H-inden-5-ol
DM9RF1T DE Discovery agent
DMCGRV7 ID DMCGRV7
DMCGRV7 DN 1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione
DMCGRV7 HS Investigative
DMCGRV7 SN 4,4'-Dimethoxybenzil; 1226-42-2; p-Anisil; Anisil; 1,2-bis(4-methoxyphenyl)ethane-1,2-dione; Bis(4-methoxyphenyl)ethanedione; Ethanedione, bis(4-methoxyphenyl)-; Di-p-anisoyl; p,p'-Dimethoxybenzil; 1,2-ethanedione, 1,2-bis(4-methoxyphenyl)-; YNANGXWUZWWFKX-UHFFFAOYSA-N; MFCD00008405; 1,2-Bis(4-methoxyphenyl)-1,2-ethanedione; 1,2-bis(4-methoxyphenyl)-ethane-1,2-dione; AE-641/01115007; W-108428; 4,4'-Dimethoxybenzil, 99+%; EINECS 214-960-5; NSC 19218; ACMC-1BZIL; p-Anisil; Di-p-anisoyl; 4,4\'-Dimethoxybenzil
DMCGRV7 DT Small molecular drug
DMCGRV7 PC 71043
DMCGRV7 MW 270.28
DMCGRV7 FM C16H14O4
DMCGRV7 IC InChI=1S/C16H14O4/c1-19-13-7-3-11(4-8-13)15(17)16(18)12-5-9-14(20-2)10-6-12/h3-10H,1-2H3
DMCGRV7 CS COC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)OC
DMCGRV7 IK YNANGXWUZWWFKX-UHFFFAOYSA-N
DMCGRV7 IU 1,2-bis(4-methoxyphenyl)ethane-1,2-dione
DMCGRV7 CA CAS 1226-42-2
DMCGRV7 DE Discovery agent
DM9ENXO ID DM9ENXO
DM9ENXO DN 1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane
DM9ENXO HS Investigative
DM9ENXO SN CHEMBL442926; BDBM50251330
DM9ENXO DT Small molecular drug
DM9ENXO PC 44567597
DM9ENXO MW 592.7
DM9ENXO FM C36H36N2O6
DM9ENXO IC InChI=1S/C36H36N2O6/c1-37-9-7-21-13-23(17-25-31(21)27(37)15-19-3-5-29(39)35(41)33(19)25)43-11-12-44-24-14-22-8-10-38(2)28-16-20-4-6-30(40)36(42)34(20)26(18-24)32(22)28/h3-6,13-14,17-18,27-28,39-42H,7-12,15-16H2,1-2H3/t27-,28-/m1/s1
DM9ENXO CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCOC5=CC6=C7[C@@H](CC8=C(C7=C5)C(=C(C=C8)O)O)N(CC6)C)C(=C(C=C4)O)O
DM9ENXO IK KWKONXOZQQYOJW-VSGBNLITSA-N
DM9ENXO IU (6aR)-2-[2-[[(6aR)-10,11-dihydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-2-yl]oxy]ethoxy]-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM9ENXO DE Discovery agent
DMJAK0E ID DMJAK0E
DMJAK0E DN 1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione
DMJAK0E HS Investigative
DMJAK0E SN 1,2-ethanedione, 1,2-di-10h-phenothiazin-10-yl-; CHEMBL391727; 6283-46-1; NSC7508; AC1L5BDH; 1,2-di(phenothiazin-10-yl)ethane-1,2-dione; AC1Q5KI6; 1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione; CTK5B6284; DTXSID40278468; NSC-7508
DMJAK0E DT Small molecular drug
DMJAK0E PC 222149
DMJAK0E MW 452.6
DMJAK0E FM C26H16N2O2S2
DMJAK0E IC InChI=1S/C26H16N2O2S2/c29-25(27-17-9-1-5-13-21(17)31-22-14-6-2-10-18(22)27)26(30)28-19-11-3-7-15-23(19)32-24-16-8-4-12-20(24)28/h1-16H
DMJAK0E CS C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)C(=O)N4C5=CC=CC=C5SC6=CC=CC=C64
DMJAK0E IK LWNPJAXCRSELQF-UHFFFAOYSA-N
DMJAK0E IU 1,2-di(phenothiazin-10-yl)ethane-1,2-dione
DMJAK0E CA CAS 6283-46-1
DMJAK0E DE Discovery agent
DM7S1D5 ID DM7S1D5
DM7S1D5 DN 1,2-Di(berberine-9-O-yl)ethane dibromide
DM7S1D5 HS Investigative
DM7S1D5 SN CHEMBL1163560
DM7S1D5 DT Small molecular drug
DM7S1D5 PC 46906937
DM7S1D5 MW 670.7
DM7S1D5 FM C40H34N2O8+2
DM7S1D5 IC InChI=1S/C40H34N2O8/c1-43-33-5-3-23-13-31-27-17-37-35(47-21-49-37)15-25(27)7-9-41(31)19-29(23)39(33)45-11-12-46-40-30-20-42-10-8-26-16-36-38(50-22-48-36)18-28(26)32(42)14-24(30)4-6-34(40)44-2/h3-6,13-20H,7-12,21-22H2,1-2H3/q+2
DM7S1D5 CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCOC6=C(C=CC7=CC8=[N+](CCC9=CC1=C(C=C98)OCO1)C=C76)OC
DM7S1D5 IK KHTZNQPZFCEMGU-UHFFFAOYSA-N
DM7S1D5 IU 17-methoxy-16-[2-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]ethoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM7S1D5 DE Discovery agent
DMBAX2L ID DMBAX2L
DMBAX2L DN 1,2-Diacetoxylycorine
DMBAX2L HS Investigative
DMBAX2L SN 1,2-Diacetoxylycorine; 1,2-Diacetyllycorine; CHEMBL465295; Lycorin diacetate; LYCORINE DIACETATE; 1,2-Di-O-acetyllycorine; SCHEMBL12319317; BDBM50293602; (1S,17S,18S,19S)-17-(acetyloxy)-5,7-dioxa-12-azapentacyclo[10.6.1.0^{2,10}.0^{4,8}.0^{15,19}]nonadeca-2,4(8),9,15-tetraen-18-yl acetate
DMBAX2L DT Small molecular drug
DMBAX2L PC 10429288
DMBAX2L MW 371.4
DMBAX2L FM C20H21NO6
DMBAX2L IC InChI=1S/C20H21NO6/c1-10(22)26-17-5-12-3-4-21-8-13-6-15-16(25-9-24-15)7-14(13)18(19(12)21)20(17)27-11(2)23/h5-7,17-20H,3-4,8-9H2,1-2H3/t17-,18-,19+,20+/m0/s1
DMBAX2L CS CC(=O)O[C@H]1C=C2CCN3[C@H]2[C@@H]([C@@H]1OC(=O)C)C4=CC5=C(C=C4C3)OCO5
DMBAX2L IK LMZHAKUXAHOCST-VNTMZGSJSA-N
DMBAX2L IU [(1S,17S,18S,19S)-18-acetyloxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-17-yl] acetate
DMBAX2L DE Discovery agent
DMDJYHK ID DMDJYHK
DMDJYHK DN 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane
DMDJYHK HS Investigative
DMDJYHK SN 1,2-DIBROMO-4-(1,2-DIBROMOETHYL)CYCLOHEXANE; 3322-93-8; Citex BCL 462; Saytex BCL 462; Cyclohexane, 1,2-dibromo-4-(1,2-dibromoethyl)-; 1-(1,2-Dibromoethyl)-3,4-dibromocyclohexane; Vinylcyclohexene tetrabromide; 1,2-DIBROMO-4-(1,2-DIBROMOETHYL)-CYCLOHEXANE; 4-(1,2-Dibromoethyl)-1,2-dibromocyclohexane; CCRIS 3743; HSDB 6146; EINECS 222-036-8; BRN 1927455; CHEMBL375107; AK-78933; C8H12Br4; TBECH; AC1L2COC; DSSTox_CID_4947; DSSTox_RID_77594; DSSTox_GSID_24947; MLS002454355; 3-05-00-00093 (Beilstein Handbook Reference); SCHEMBL332771
DMDJYHK DT Small molecular drug
DMDJYHK PC 18728
DMDJYHK MW 427.8
DMDJYHK FM C8H12Br4
DMDJYHK IC InChI=1S/C8H12Br4/c9-4-8(12)5-1-2-6(10)7(11)3-5/h5-8H,1-4H2
DMDJYHK CS C1CC(C(CC1C(CBr)Br)Br)Br
DMDJYHK IK PQRRSJBLKOPVJV-UHFFFAOYSA-N
DMDJYHK IU 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane
DMDJYHK CA CAS 3322-93-8
DMDJYHK DE Discovery agent
DM75OR8 ID DM75OR8
DM75OR8 DN 1,2-dicyclohexylethane-1,2-dione
DM75OR8 HS Investigative
DM75OR8 SN Ethanedione, dicyclohexyl-; 951-88-2; 1,2-dicyclohexylethane-1,2-dione; 1,2-Dicyclohexylethanedione; SCHEMBL3071715; CHEMBL235287; 1,2-Dione-Based Compound, 7; BDBM22850; CTK3G8986; DTXSID40473153; 1,2-dicyclohexyl-1,2-ethanedione; 1,2-dicyclohexyl-ethane-1,2-dione
DM75OR8 DT Small molecular drug
DM75OR8 PC 11806279
DM75OR8 MW 222.32
DM75OR8 FM C14H22O2
DM75OR8 IC InChI=1S/C14H22O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h11-12H,1-10H2
DM75OR8 CS C1CCC(CC1)C(=O)C(=O)C2CCCCC2
DM75OR8 IK ZWDFMOMBVDVEHE-UHFFFAOYSA-N
DM75OR8 IU 1,2-dicyclohexylethane-1,2-dione
DM75OR8 CA CAS 951-88-2
DM75OR8 DE Discovery agent
DM542I9 ID DM542I9
DM542I9 DN 1,2-dihydro-2-oxoquinazoline-4-carboxyanilide
DM542I9 HS Investigative
DM542I9 SN CHEMBL279403; 1,2-dihydro-2-oxoquinazoline-4-carboxyanilide; BDBM50228374; AKOS027611184
DM542I9 DT Small molecular drug
DM542I9 PC 24749598
DM542I9 MW 265.27
DM542I9 FM C15H11N3O2
DM542I9 IC InChI=1S/C15H11N3O2/c19-14(16-10-6-2-1-3-7-10)13-11-8-4-5-9-12(11)17-15(20)18-13/h1-9H,(H,16,19)(H,17,18,20)
DM542I9 CS C1=CC=C(C=C1)NC(=O)C2=NC(=O)NC3=CC=CC=C32
DM542I9 IK IBKXBRUBWALIOJ-UHFFFAOYSA-N
DM542I9 IU 2-oxo-N-phenyl-1H-quinazoline-4-carboxamide
DM542I9 DE Discovery agent
DMST60D ID DMST60D
DMST60D DN 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene
DMST60D HS Investigative
DMST60D SN CHEMBL229245; 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene
DMST60D DT Small molecular drug
DMST60D PC 44424402
DMST60D MW 296.4
DMST60D FM C19H20O3
DMST60D IC InChI=1S/C19H20O3/c1-20-17-11-10-16(18(21-2)19(17)22-3)15-9-8-13-6-4-5-7-14(13)12-15/h4-7,10-12H,8-9H2,1-3H3
DMST60D CS COC1=C(C(=C(C=C1)C2=CC3=CC=CC=C3CC2)OC)OC
DMST60D IK WOSGVZBVAWUJJN-UHFFFAOYSA-N
DMST60D IU 3-(2,3,4-trimethoxyphenyl)-1,2-dihydronaphthalene
DMST60D DE Discovery agent
DM9G7DT ID DM9G7DT
DM9G7DT DN 1,2-Dihydro-indazol-3-one
DM9G7DT HS Investigative
DM9G7DT SN 1H-Indazol-3-ol; 3-Indazolinone; 7364-25-2; 1H-indazol-3(2H)-one; 100922-96-1; Indazolinone; 3-Hydroxy-1H-indazole; 3-Hydroxyindazole; 1,2-dihydroindazol-3-one; 1,2-Dihydro-3H-indazol-3-one; 3-Oxo-1,2-indazole; 3H-Indazol-3-one, 1,2-dihydro-; 3-Indazolone; 2H-Indazol-3-ol; hydroxyindazole; 2,3-Dihydro-1H-indazol-3-one; NSC 9352; UNII-8E254S9S1R; CCRIS 6800; EINECS 230-904-2; CHEMBL276725; SWEICGMKXPNXNU-UHFFFAOYSA-N; 8E254S9S1R; MFCD00005685; 1H-2-hydroindazol-3-one; benzopyrazolone; 1,2-Dihydro-indazol-3-one; 3-Oxoindazoline
DM9G7DT DT Small molecular drug
DM9G7DT PC 81829
DM9G7DT MW 134.14
DM9G7DT FM C7H6N2O
DM9G7DT IC InChI=1S/C7H6N2O/c10-7-5-3-1-2-4-6(5)8-9-7/h1-4H,(H2,8,9,10)
DM9G7DT CS C1=CC=C2C(=C1)C(=O)NN2
DM9G7DT IK SWEICGMKXPNXNU-UHFFFAOYSA-N
DM9G7DT IU 1,2-dihydroindazol-3-one
DM9G7DT CA CAS 7364-25-2
DM9G7DT DE Discovery agent
DMASC8K ID DMASC8K
DMASC8K DN 1,2-Dihydroxy-10H-anthracen-9-one
DMASC8K HS Investigative
DMASC8K SN CHEMBL123692; 1,2-Dihydroxy-10H-anthracen-9-one; 1,2-Dihydroxy-9-anthron; SCHEMBL6418805; ZINC13606491; BDBM50060891
DMASC8K DT Small molecular drug
DMASC8K PC 15259267
DMASC8K MW 226.23
DMASC8K FM C14H10O3
DMASC8K IC InChI=1S/C14H10O3/c15-11-6-5-9-7-8-3-1-2-4-10(8)13(16)12(9)14(11)17/h1-6,15,17H,7H2
DMASC8K CS C1C2=C(C(=C(C=C2)O)O)C(=O)C3=CC=CC=C31
DMASC8K IK VQTRJTVHFJIZMI-UHFFFAOYSA-N
DMASC8K IU 1,2-dihydroxy-10H-anthracen-9-one
DMASC8K DE Discovery agent
DMGXMF0 ID DMGXMF0
DMGXMF0 DN 1,2-Di-naphthalen-2-yl-ethane-1,2-dione
DMGXMF0 HS Investigative
DMGXMF0 SN CHEMBL189162; 1,2-dinaphthalen-2-ylethane-1,2-dione; Bis(2-naphthyl)glyoxal; AC1MN9RI; 1,2-Di-naphthalen-2-yl-ethane-1,2-dione; SCHEMBL7220072; MolPort-003-808-637; ZINC5705162; BDBM50171924
DMGXMF0 DT Small molecular drug
DMGXMF0 PC 3274712
DMGXMF0 MW 310.3
DMGXMF0 FM C22H14O2
DMGXMF0 IC InChI=1S/C22H14O2/c23-21(19-11-9-15-5-1-3-7-17(15)13-19)22(24)20-12-10-16-6-2-4-8-18(16)14-20/h1-14H
DMGXMF0 CS C1=CC=C2C=C(C=CC2=C1)C(=O)C(=O)C3=CC4=CC=CC=C4C=C3
DMGXMF0 IK CUUMQBIJNWGQLU-UHFFFAOYSA-N
DMGXMF0 IU 1,2-dinaphthalen-2-ylethane-1,2-dione
DMGXMF0 DE Discovery agent
DMEAB03 ID DMEAB03
DMEAB03 DN 1,2-dioctanoyl-sn-glycerol
DMEAB03 HS Investigative
DMEAB03 SN 60514-48-9; Dicaprylglyceride; sn-1,2-Dioctanoylglycerol; (S)-3-Hydroxypropane-1,2-diyl dioctanoate; 1,2-Dicapryloyl-sn-glycerol; D-alpha,beta-Dicaprylin; BRN 1714754; CHEMBL55267; CHEBI:76979; Octanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester, (S)-; DG(8:0/8:0/0:0); sn-1,2-dicaprilin; A-Dicaprylin; AC1L3XZK; 1,2-octanoyl-sn-diglyceride; CBiol_001868; KBioGR_000011; BSPBio_001291; KBioSS_000011; 4-02-00-00990 (Beilstein Handbook Reference); SCHEMBL466152
DMEAB03 DT Small molecular drug
DMEAB03 PC 148879
DMEAB03 MW 344.5
DMEAB03 FM C19H36O5
DMEAB03 IC InChI=1S/C19H36O5/c1-3-5-7-9-11-13-18(21)23-16-17(15-20)24-19(22)14-12-10-8-6-4-2/h17,20H,3-16H2,1-2H3/t17-/m0/s1
DMEAB03 CS CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC
DMEAB03 IK ZQBULZYTDGUSSK-KRWDZBQOSA-N
DMEAB03 IU [(2S)-3-hydroxy-2-octanoyloxypropyl] octanoate
DMEAB03 CA CAS 60514-48-9
DMEAB03 CB CHEBI:76979
DMEAB03 DE Discovery agent
DMFXB21 ID DMFXB21
DMFXB21 DN 1,2-Di-p-tolyl-ethane-1,2-dione
DMFXB21 HS Investigative
DMFXB21 SN 4,4'-Dimethylbenzil; 3457-48-5; 1,2-Di-p-tolylethane-1,2-dione; p-Tolil; 1,2-bis(4-methylphenyl)ethane-1,2-dione; Ethanedione, bis(4-methylphenyl)-; 4,4'-Dimethyldibenzoyl; Ethandione, bis(p-tolyl)-; 1,2-dip-tolylethane-1,2-dione; BCWCEHMHCDCJAD-UHFFFAOYSA-N; MFCD00008554; AK105959; 1,2-Bis(4-methylphenyl)-1,2-ethanedione; AE-562/06268025; Di-p-tolylethanedione; EINECS 222-388-2; AC1Q5DTX; ACMC-209i8d; AC1L2S4L; Benzil-based compound, 18; SCHEMBL167254; 4,4'-Dimethylbenzil, 97%; CHEMBL192625; BDBM22740; DTXSID60188116
DMFXB21 DT Small molecular drug
DMFXB21 PC 76996
DMFXB21 MW 238.28
DMFXB21 FM C16H14O2
DMFXB21 IC InChI=1S/C16H14O2/c1-11-3-7-13(8-4-11)15(17)16(18)14-9-5-12(2)6-10-14/h3-10H,1-2H3
DMFXB21 CS CC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C
DMFXB21 IK BCWCEHMHCDCJAD-UHFFFAOYSA-N
DMFXB21 IU 1,2-bis(4-methylphenyl)ethane-1,2-dione
DMFXB21 CA CAS 3457-48-5
DMFXB21 DE Discovery agent
DMV275G ID DMV275G
DMV275G DN 1,2-indanedione
DMV275G HS Investigative
DMV275G SN 16214-27-0; 1H-Indene-1,2(3H)-dione; 1,2-Indanedione; Indan-1,2-dione; 1,2-Indandione; Indandione; 3H-indene-1,2-dione; 2,3-dihydro-1H-indene-1,2-dione; indane dione; NSC62555; indane-1,2-dione; ACMC-20a7vb; AI3-25041; AC1L3WEO; AC1Q6K5I; 1,2-Indanedione, 95%; Indan-1,2-dione, 97%; 1H-Indene-1,2(3H)dione; SCHEMBL669542; CHEMBL235288; 1,2-Dione-Based Compound, 9; CTK0I2756; BDBM22852; DTXSID50167314; 1,2-IND; MolPort-000-004-392; WFFZGYRTVIPBFN-UHFFFAOYSA-N; ZINC1691218; KS-00000C3N; NSC-62555; BBL103322; 8216AA; STL557132; ANW-61125
DMV275G DT Small molecular drug
DMV275G PC 123358
DMV275G MW 146.14
DMV275G FM C9H6O2
DMV275G IC InChI=1S/C9H6O2/c10-8-5-6-3-1-2-4-7(6)9(8)11/h1-4H,5H2
DMV275G CS C1C2=CC=CC=C2C(=O)C1=O
DMV275G IK WFFZGYRTVIPBFN-UHFFFAOYSA-N
DMV275G IU 3H-indene-1,2-dione
DMV275G CA CAS 16214-27-0
DMV275G DE Discovery agent
DMYXELH ID DMYXELH
DMYXELH DN 1,2-NAPHTHOQUINONE
DMYXELH HS Investigative
DMYXELH SN 1,2-NAPHTHOQUINONE; 524-42-5; 1,2-Naphthalenedione; naphthalene-1,2-dione; o-Naphthoquinone; beta-Naphthoquinone; 1,2-Naphthaquinone; 1,2-Naftochinon; .beta.-Naphthoquinone; 1,2-Naftochinon [Czech]; CCRIS 1558; UNII-804K62F61Q; HSDB 2036; 1,2-dihydronaphthalene-1,2-dione; NSC 9831; EINECS 208-360-2; 1,2-Dihydro-1,2-diketo-naphthalene; BRN 0606546; CHEMBL52347; MLS000069467; AI3-14930; CHEBI:34055; C10H6O2; KETQAJRQOHHATG-UHFFFAOYSA-N; 804K62F61Q; SMR000059112; 1,2-Naphthoquinone, 95%, tech.; NAPHTHALENEDIONE; b-naphthoquinone
DMYXELH DT Small molecular drug
DMYXELH PC 10667
DMYXELH MW 158.15
DMYXELH FM C10H6O2
DMYXELH IC InChI=1S/C10H6O2/c11-9-6-5-7-3-1-2-4-8(7)10(9)12/h1-6H
DMYXELH CS C1=CC=C2C(=C1)C=CC(=O)C2=O
DMYXELH IK KETQAJRQOHHATG-UHFFFAOYSA-N
DMYXELH IU naphthalene-1,2-dione
DMYXELH CA CAS 524-42-5
DMYXELH CB CHEBI:34055
DMYXELH DE Discovery agent
DMNCWXZ ID DMNCWXZ
DMNCWXZ DN 1,3,5-BENZENETRICARBOXYLIC ACID
DMNCWXZ HS Investigative
DMNCWXZ SN Trimesic acid; 554-95-0; 1,3,5-BENZENETRICARBOXYLIC ACID; benzene-1,3,5-tricarboxylic acid; Trimesinic acid; Trimesitinic acid; 5-Carboxyisophthalic acid; 1,3,5-Benzene tricarboxylic acid; 1,3,5-Tricarboxybenzene; UNII-OU36OO5MTN; NSC 3998; EINECS 209-077-7; OU36OO5MTN; CHEMBL77562; AI3-06468; CHEBI:46032; QMKYBPDZANOJGF-UHFFFAOYSA-N; MFCD00002517; Trimesicacid; 1,3,5-Benzenetricarboxylic acid, 98%; 1.3.5-Benzenetricarboxylic Acid; H3BTCt; Trimesic acid, 95%; 1,5-Tricarboxybenzene; PubChem18615; H3TMA; AC1Q1GOL; DSSTox_CID_1488
DMNCWXZ DT Small molecular drug
DMNCWXZ PC 11138
DMNCWXZ MW 210.14
DMNCWXZ FM C9H6O6
DMNCWXZ IC InChI=1S/C9H6O6/c10-7(11)4-1-5(8(12)13)3-6(2-4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15)
DMNCWXZ CS C1=C(C=C(C=C1C(=O)O)C(=O)O)C(=O)O
DMNCWXZ IK QMKYBPDZANOJGF-UHFFFAOYSA-N
DMNCWXZ IU benzene-1,3,5-tricarboxylic acid
DMNCWXZ CA CAS 554-95-0
DMNCWXZ CB CHEBI:46032
DMNCWXZ DE Discovery agent
DM7U6S0 ID DM7U6S0
DM7U6S0 DN 1,3,5-triphenylimidazolidine-2,4-dione
DM7U6S0 HS Investigative
DM7U6S0 SN CHEMBL381136; 61505-60-0; SCHEMBL2791034; CTK2D8602; DTXSID10469422; 1,3,5-triphenylimidazoline-2,4-dione; 2,4-Imidazolidinedione, 1,3,5-triphenyl-
DM7U6S0 DT Small molecular drug
DM7U6S0 PC 11609579
DM7U6S0 MW 328.4
DM7U6S0 FM C21H16N2O2
DM7U6S0 IC InChI=1S/C21H16N2O2/c24-20-19(16-10-4-1-5-11-16)22(17-12-6-2-7-13-17)21(25)23(20)18-14-8-3-9-15-18/h1-15,19H
DM7U6S0 CS C1=CC=C(C=C1)C2C(=O)N(C(=O)N2C3=CC=CC=C3)C4=CC=CC=C4
DM7U6S0 IK YEGAYNNVHYHYEO-UHFFFAOYSA-N
DM7U6S0 IU 1,3,5-triphenylimidazolidine-2,4-dione
DM7U6S0 CA CAS 61505-60-0
DM7U6S0 DE Discovery agent
DMDNM05 ID DMDNM05
DMDNM05 DN 1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione
DMDNM05 HS Investigative
DMDNM05 DT Small molecular drug
DMDNM05 PC 91936518
DMDNM05 MW 431.7
DMDNM05 FM C21H13Cl3N2O2
DMDNM05 IC InChI=1S/C21H13Cl3N2O2/c22-14-3-1-13(2-4-14)19-20(27)26(18-11-7-16(24)8-12-18)21(28)25(19)17-9-5-15(23)6-10-17/h1-12,27H
DMDNM05 CS C1=CC(=CC=C1C2=C(N(C(=O)N2C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)O)Cl
DMDNM05 IK FXRARDZLGGDTOS-UHFFFAOYSA-N
DMDNM05 IU 1,3,4-tris(4-chlorophenyl)-5-hydroxyimidazol-2-one
DMDNM05 DE Discovery agent
DMFA8CW ID DMFA8CW
DMFA8CW DN 1,3,7-trihydroxyacridone
DMFA8CW HS Investigative
DMFA8CW DE Discovery agent
DMNCJ5R ID DMNCJ5R
DMNCJ5R DN 1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione
DMNCJ5R HS Investigative
DMNCJ5R SN 1,3,7-Tripropylxanthine; CHEMBL417834; 1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione; SCHEMBL316171
DMNCJ5R DT Small molecular drug
DMNCJ5R PC 11492842
DMNCJ5R MW 278.35
DMNCJ5R FM C14H22N4O2
DMNCJ5R IC InChI=1S/C14H22N4O2/c1-4-7-16-10-15-12-11(16)13(19)18(9-6-3)14(20)17(12)8-5-2/h10H,4-9H2,1-3H3
DMNCJ5R CS CCCN1C=NC2=C1C(=O)N(C(=O)N2CCC)CCC
DMNCJ5R IK PMJKNRZFAZJNRA-UHFFFAOYSA-N
DMNCJ5R IU 1,3,7-tripropylpurine-2,6-dione
DMNCJ5R DE Discovery agent
DMRP03X ID DMRP03X
DMRP03X DN 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one
DMRP03X HS Investigative
DMRP03X SN Emodin anthrone; Emodinanthrone; 491-60-1; 1,3,8-Trihydroxy-6-methylanthrone; 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one; UNII-77C500W1A2; 2,4,5-trihydroxy-7-methylanthracen-10(9H)-one; CHEMBL122192; 77C500W1A2; 1,6,8-trihydroxy-3-methyl-10-hydroanthracen-9-one; 9(10H)-Anthracenone, 1,3,8-trihydroxy-6-methyl-; Emodinanthranol; Emodinol; Protophyscihydrone; Frangulaemodinanthrone; Frangulaemodinanthranol; Frangula emodin anthrone; AC1L3UZ6; SCHEMBL6046328; DTXSID80197684; LAJSXCAVRQXZIO-UHFFFAOYSA-N; ZINC6070245; BCP29231
DMRP03X DT Small molecular drug
DMRP03X PC 122635
DMRP03X MW 256.25
DMRP03X FM C15H12O4
DMRP03X IC InChI=1S/C15H12O4/c1-7-2-8-4-9-5-10(16)6-12(18)14(9)15(19)13(8)11(17)3-7/h2-3,5-6,16-18H,4H2,1H3
DMRP03X CS CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2)C=C(C=C3O)O
DMRP03X IK LAJSXCAVRQXZIO-UHFFFAOYSA-N
DMRP03X IU 1,3,8-trihydroxy-6-methyl-10H-anthracen-9-one
DMRP03X CA CAS 491-60-1
DMRP03X CB CHEBI:150013
DMRP03X DE Discovery agent
DMOZEKU ID DMOZEKU
DMOZEKU DN 1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione
DMOZEKU HS Investigative
DMOZEKU SN 830-65-9; 8-Methyltheophylline; 1,3,8-Trimethyl-1H-purine-2,6(3H,7H)-dione; Theophylline, 8-methyl-; Xanthine, 1,3,8-trimethyl-; 1,3,8-Trimethyl-2,6-dioxopurine; 1,3,8-trimethylxanthine; NSC 14289; 1,3,8-trimethyl-3,9-dihydro-1h-purine-2,6-dione; CHEMBL89062; 3,7-Dihydro-1,3,8-trimethyl-1H-purine-2,6-dione; 1,3,8-trimethyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione; 8-methyltheophyllin; NSC14289; 8-Methyltheophyline; AC1Q6LAN; AC1L3TFC; Xanthine,3,8-trimethyl-; 1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione; SCHEMBL461786
DMOZEKU DT Small molecular drug
DMOZEKU PC 95030
DMOZEKU MW 194.19
DMOZEKU FM C8H10N4O2
DMOZEKU IC InChI=1S/C8H10N4O2/c1-4-9-5-6(10-4)11(2)8(14)12(3)7(5)13/h1-3H3,(H,9,10)
DMOZEKU CS CC1=NC2=C(N1)C(=O)N(C(=O)N2C)C
DMOZEKU IK WZBKGWBHAPBSBF-UHFFFAOYSA-N
DMOZEKU IU 1,3,8-trimethyl-7H-purine-2,6-dione
DMOZEKU CA CAS 830-65-9
DMOZEKU DE Discovery agent
DM7U31Q ID DM7U31Q
DM7U31Q DN 1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one
DM7U31Q HS Investigative
DM7U31Q DT Small molecular drug
DM7U31Q PC 20200511
DM7U31Q DE Discovery agent
DMP86R3 ID DMP86R3
DMP86R3 DN 1,3-bis(1,3-benzothiazol-2-ylthio)acetone
DMP86R3 HS Investigative
DMP86R3 SN 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; 1,3-bis(1,3-benzothiazol-2-ylthio)acetone; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409
DMP86R3 DT Small molecular drug
DMP86R3 PC 1240423
DMP86R3 MW 388.6
DMP86R3 FM C17H12N2OS4
DMP86R3 IC InChI=1S/C17H12N2OS4/c20-11(9-21-16-18-12-5-1-3-7-14(12)23-16)10-22-17-19-13-6-2-4-8-15(13)24-17/h1-8H,9-10H2
DMP86R3 CS C1=CC=C2C(=C1)N=C(S2)SCC(=O)CSC3=NC4=CC=CC=C4S3
DMP86R3 IK BWTBZOLHOSVREZ-UHFFFAOYSA-N
DMP86R3 IU 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one
DMP86R3 DE Glioma; Melanoma
DMELSV1 ID DMELSV1
DMELSV1 DN 1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one
DMELSV1 HS Investigative
DMELSV1 SN CHEMBL225618; 3,3',4,4'-tetrahydroxychalcone; 1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one; SCHEMBL109015; BDBM50157562; 3,3'',4,4''-tetrahydroxychalcone; ZINC13541162
DMELSV1 DT Small molecular drug
DMELSV1 PC 10038861
DMELSV1 MW 272.25
DMELSV1 FM C15H12O5
DMELSV1 IC InChI=1S/C15H12O5/c16-11(10-3-6-13(18)15(20)8-10)4-1-9-2-5-12(17)14(19)7-9/h1-8,17-20H/b4-1+
DMELSV1 CS C1=CC(=C(C=C1/C=C/C(=O)C2=CC(=C(C=C2)O)O)O)O
DMELSV1 IK DOWSJIIZLUFMFM-DAFODLJHSA-N
DMELSV1 IU (E)-1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one
DMELSV1 DE Discovery agent
DM78UPQ ID DM78UPQ
DM78UPQ DN 1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea
DM78UPQ HS Investigative
DM78UPQ SN Imidocarb; 27885-92-3; Imidocarbum; Imidocarbe; Imidocarbo; 1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea; Imidocarb [INN:BAN]; UNII-8USS3K0VDH; Imidocarbum [INN-Latin]; Imidocarbe [INN-French]; Imidocarbo [INN-Spanish]; 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)urea; 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)harnstoff; C19H20N6O; TCMDC-124304; N,N'-Bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)urea; EINECS 248-711-7; 8USS3K0VDH; CARBANILIDE, 3,3'-DI-2-IMIDAZOLIN-2-YL-; BRN 0964732; CHEMBL427342; NSC 51189; Urea, N,N'-bis[3-(4,5-dihydro-
DM78UPQ DT Small molecular drug
DM78UPQ PC 21389
DM78UPQ MW 348.4
DM78UPQ FM C19H20N6O
DM78UPQ IC InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)
DM78UPQ CS C1CN=C(N1)C2=CC(=CC=C2)NC(=O)NC3=CC=CC(=C3)C4=NCCN4
DM78UPQ IK SCEVFJUWLLRELN-UHFFFAOYSA-N
DM78UPQ IU 1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea
DM78UPQ CA CAS 27885-92-3
DM78UPQ CB CHEBI:51804
DM78UPQ DE Discovery agent
DMIK7XV ID DMIK7XV
DMIK7XV DN 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate
DMIK7XV HS Investigative
DMIK7XV SN CHEMBL467905; 1,3-dinitrooxy-2-propyl 2-acetoxybenzoate; 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate; SCHEMBL8318285; BDBM50258493
DMIK7XV DT Small molecular drug
DMIK7XV PC 44219619
DMIK7XV MW 344.23
DMIK7XV FM C12H12N2O10
DMIK7XV IC InChI=1S/C12H12N2O10/c1-8(15)23-11-5-3-2-4-10(11)12(16)24-9(6-21-13(17)18)7-22-14(19)20/h2-5,9H,6-7H2,1H3
DMIK7XV CS CC(=O)OC1=CC=CC=C1C(=O)OC(CO[N+](=O)[O-])CO[N+](=O)[O-]
DMIK7XV IK KDHWEMULLOVCEH-UHFFFAOYSA-N
DMIK7XV IU 1,3-dinitrooxypropan-2-yl 2-acetyloxybenzoate
DMIK7XV DE Discovery agent
DMZKUOX ID DMZKUOX
DMZKUOX DN 1,3-Di(berberine-9-O-yl)ethane dibromide
DMZKUOX HS Investigative
DMZKUOX SN CHEMBL1163253
DMZKUOX DT Small molecular drug
DMZKUOX PC 11643451
DMZKUOX MW 684.7
DMZKUOX FM C41H36N2O8+2
DMZKUOX IC InChI=1S/C41H36N2O8/c1-44-34-6-4-24-14-32-28-18-38-36(48-22-50-38)16-26(28)8-10-42(32)20-30(24)40(34)46-12-3-13-47-41-31-21-43-11-9-27-17-37-39(51-23-49-37)19-29(27)33(43)15-25(31)5-7-35(41)45-2/h4-7,14-21H,3,8-13,22-23H2,1-2H3/q+2
DMZKUOX CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCOC6=C(C=CC7=CC8=[N+](CCC9=CC1=C(C=C98)OCO1)C=C76)OC
DMZKUOX IK AOMDJTYUICYNJP-UHFFFAOYSA-N
DMZKUOX IU 17-methoxy-16-[3-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]propoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMZKUOX DE Discovery agent
DMEV8G2 ID DMEV8G2
DMEV8G2 DN 1,3-Diallyl-3,7-dihydro-purine-2,6-dione
DMEV8G2 HS Investigative
DMEV8G2 SN CHEMBL286785; 1.3-Diallylxanthin; 1,3-Diallyl-3,7-dihydro-purine-2,6-dione; SCHEMBL516503; 1H-Purine-2,6-dione, 3,9-dihydro-1,3-di-2-propen-1-yl-; BDBM50022725; 31542-64-0
DMEV8G2 DT Small molecular drug
DMEV8G2 PC 22995178
DMEV8G2 MW 232.24
DMEV8G2 FM C11H12N4O2
DMEV8G2 IC InChI=1S/C11H12N4O2/c1-3-5-14-9-8(12-7-13-9)10(16)15(6-4-2)11(14)17/h3-4,7H,1-2,5-6H2,(H,12,13)
DMEV8G2 CS C=CCN1C2=C(C(=O)N(C1=O)CC=C)NC=N2
DMEV8G2 IK NUZFZZOVBJUJQN-UHFFFAOYSA-N
DMEV8G2 IU 1,3-bis(prop-2-enyl)-7H-purine-2,6-dione
DMEV8G2 DE Discovery agent
DM4G2IE ID DM4G2IE
DM4G2IE DN 1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione
DM4G2IE HS Investigative
DM4G2IE SN CHEMBL26406; 1,3-diallyl-7-methylxanthine; 1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione; BDBM50025574; 1,3-Di(2-propenyl)-7-methylxanthine
DM4G2IE DT Small molecular drug
DM4G2IE PC 44459941
DM4G2IE MW 246.27
DM4G2IE FM C12H14N4O2
DM4G2IE IC InChI=1S/C12H14N4O2/c1-4-6-15-10-9(14(3)8-13-10)11(17)16(7-5-2)12(15)18/h4-5,8H,1-2,6-7H2,3H3
DM4G2IE CS CN1C=NC2=C1C(=O)N(C(=O)N2CC=C)CC=C
DM4G2IE IK YAUBCZNTZIWFJS-UHFFFAOYSA-N
DM4G2IE IU 7-methyl-1,3-bis(prop-2-enyl)purine-2,6-dione
DM4G2IE CA CAS 102284-65-1
DM4G2IE DE Discovery agent
DMMOBPN ID DMMOBPN
DMMOBPN DN 1,3-dibenzyl urea
DMMOBPN HS Investigative
DMMOBPN SN 1,3-Dibenzylurea; N,N'-Dibenzylurea; 1466-67-7; sym-Dibenzylurea; Urea, N,N'-bis(phenylmethyl)-; 1,3-dibenzyl urea; 1,3-Dibenzyl-urea; CHEMBL504463; KATOLVAXCGIBLO-UHFFFAOYSA-N; N-benzyl[benzylamino]carboxamide; dibenzylurea; EINECS 215-984-9; NSC408007; NSC 408007; N,N'-Dibenzylharnstoff; AI3-19855; AC1Q5OY5; AC1L2IW5; Oprea1_448978; Urea,N'-bis(phenylmethyl)-; SCHEMBL714625; Urea,N,N'-bis(phenylmethyl)-; DTXSID3061710; ZINC84096; KS-00001BSB; CTK4C5047; MolPort-000-421-383; HMS1697A06; STK008269; BDBM50248768; SBB023417; CCG-48904
DMMOBPN DT Small molecular drug
DMMOBPN PC 72889
DMMOBPN MW 240.3
DMMOBPN FM C15H16N2O
DMMOBPN IC InChI=1S/C15H16N2O/c18-15(16-11-13-7-3-1-4-8-13)17-12-14-9-5-2-6-10-14/h1-10H,11-12H2,(H2,16,17,18)
DMMOBPN CS C1=CC=C(C=C1)CNC(=O)NCC2=CC=CC=C2
DMMOBPN IK KATOLVAXCGIBLO-UHFFFAOYSA-N
DMMOBPN IU 1,3-dibenzylurea
DMMOBPN CA CAS 1466-67-7
DMMOBPN DE Discovery agent
DM8NARQ ID DM8NARQ
DM8NARQ DN 1,3-Dibenzyl-[1,3]diazetidine-2,4-dione
DM8NARQ HS Investigative
DM8NARQ SN CHEMBL47394; 1,3-dibenzyl-1,3-diazetidine-2,4-dione; GTPL6542; BDBM50101132; compound 1 [PMID: 11425539]
DM8NARQ DT Small molecular drug
DM8NARQ PC 10038543
DM8NARQ MW 266.29
DM8NARQ FM C16H14N2O2
DM8NARQ IC InChI=1S/C16H14N2O2/c19-15-17(11-13-7-3-1-4-8-13)16(20)18(15)12-14-9-5-2-6-10-14/h1-10H,11-12H2
DM8NARQ CS C1=CC=C(C=C1)CN2C(=O)N(C2=O)CC3=CC=CC=C3
DM8NARQ IK PGIXYPNBNAOYHW-UHFFFAOYSA-N
DM8NARQ IU 1,3-dibenzyl-1,3-diazetidine-2,4-dione
DM8NARQ DE Discovery agent
DM2WSG5 ID DM2WSG5
DM2WSG5 DN 1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione
DM2WSG5 HS Investigative
DM2WSG5 SN 1,3-dibenzyl-3,7-dihydro-1h-purine-2,6-dione; CHEMBL24774; 31542-68-4; NSC70563; AC1Q6LGR; 1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione; 1,3-Dibenzyl-1H-purine-2,6(3H,7H)-dione; AC1L5IF2; SCHEMBL3107001; CTK4G7326; NSC-70563; BDBM50025573; 1,3-dibenzyl-7H-purine-2,6-dione
DM2WSG5 DT Small molecular drug
DM2WSG5 PC 250782
DM2WSG5 MW 332.4
DM2WSG5 FM C19H16N4O2
DM2WSG5 IC InChI=1S/C19H16N4O2/c24-18-16-17(21-13-20-16)22(11-14-7-3-1-4-8-14)19(25)23(18)12-15-9-5-2-6-10-15/h1-10,13H,11-12H2,(H,20,21)
DM2WSG5 CS C1=CC=C(C=C1)CN2C3=C(C(=O)N(C2=O)CC4=CC=CC=C4)NC=N3
DM2WSG5 IK NHCLZKKZQJJXER-UHFFFAOYSA-N
DM2WSG5 IU 1,3-dibenzyl-7H-purine-2,6-dione
DM2WSG5 CA CAS 31542-68-4
DM2WSG5 DE Discovery agent
DMKYE16 ID DMKYE16
DMKYE16 DN 1,3-Diethyl-3,7-dihydro-purine-2,6-dione
DMKYE16 HS Investigative
DMKYE16 SN 1,3-Diethylxanthine; SC 2079; 5169-95-9; 1,3-diethyl-3,9-dihydro-1h-purine-2,6-dione; CHEMBL416013; UNII-4550Q64O79; 4550Q64O79; 1,3-Diethylxantine; Xanthine,3-diethyl-; NSC 515479; 1,3-diethyl-xanthine; AC1L2QSV; AC1Q6LGQ; 1,3-diethyl-1H-purine-2,6(3H,7H)-dione; SCHEMBL515564; BDBM82021; CTK8I9744; CTK8D7769; DTXSID40199644; 1H-Purine-2,6-dione, 1,3-diethyl-3,7-dihydro- (9CI); GIMNFISWKTZFKJ-UHFFFAOYSA-N; Xanthine, 1,3-diethyl- (8CI); NSC515479; 1,3-diethyl-7H-purine-2,6-dione; AKOS030616954; NSC_101420; NSC-515479; CAS_101420
DMKYE16 DT Small molecular drug
DMKYE16 PC 101420
DMKYE16 MW 208.22
DMKYE16 FM C9H12N4O2
DMKYE16 IC InChI=1S/C9H12N4O2/c1-3-12-7-6(10-5-11-7)8(14)13(4-2)9(12)15/h5H,3-4H2,1-2H3,(H,10,11)
DMKYE16 CS CCN1C2=C(C(=O)N(C1=O)CC)NC=N2
DMKYE16 IK GIMNFISWKTZFKJ-UHFFFAOYSA-N
DMKYE16 IU 1,3-diethyl-7H-purine-2,6-dione
DMKYE16 CA CAS 5169-95-9
DMKYE16 DE Discovery agent
DMB9XR5 ID DMB9XR5
DMB9XR5 DN 1,3-Dihydro-imidazo[4,5-b]quinolin-2-one
DMB9XR5 HS Investigative
DMB9XR5 SN CHEMBL98604; 1,3-Dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL2014813; BDBM50007220; 1H-Imidazo[4,5-b]quinolin-2(3H)-one
DMB9XR5 DT Small molecular drug
DMB9XR5 PC 10867033
DMB9XR5 MW 185.18
DMB9XR5 FM C10H7N3O
DMB9XR5 IC InChI=1S/C10H7N3O/c14-10-12-8-5-6-3-1-2-4-7(6)11-9(8)13-10/h1-5H,(H2,11,12,13,14)
DMB9XR5 CS C1=CC=C2C(=C1)C=C3C(=N2)NC(=O)N3
DMB9XR5 IK BINWKEIURMBREF-UHFFFAOYSA-N
DMB9XR5 IU 1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMB9XR5 DE Discovery agent
DM8CYOP ID DM8CYOP
DM8CYOP DN 1,3-Dihydro-naphtho[2,3-d]imidazol-2-one
DM8CYOP HS Investigative
DM8CYOP SN 1H-Naphtho[2,3-d]imidazol-2(3H)-one; 5649-76-3; CHEMBL316599; 1,3-Dihydro-naphtho[2,3-d]imidazol-2-one; SCHEMBL17206226; SCHEMBL11357960; ZINC13824637; BDBM50007236; FCH995480; AKOS024262366; 1H-Naphth[2,3-d]imidazol-2(3H)-one; AJ-64431; AX8292028; 1,3-Dihydro-2H-naphth[2,3-d]imidazol-2-one
DM8CYOP DT Small molecular drug
DM8CYOP PC 13724742
DM8CYOP MW 184.19
DM8CYOP FM C11H8N2O
DM8CYOP IC InChI=1S/C11H8N2O/c14-11-12-9-5-7-3-1-2-4-8(7)6-10(9)13-11/h1-6H,(H2,12,13,14)
DM8CYOP CS C1=CC=C2C=C3C(=CC2=C1)NC(=O)N3
DM8CYOP IK HUOPXZLFTBYAML-UHFFFAOYSA-N
DM8CYOP IU 1,3-dihydrobenzo[f]benzimidazol-2-one
DM8CYOP DE Discovery agent
DMZ80CT ID DMZ80CT
DMZ80CT DN 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione
DMZ80CT HS Investigative
DMZ80CT SN 1,3-Diisobutylxanthine; Xanthine, 1,3-diisobutyl-; BRN 1143460; CHEMBL26350; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-bis(2-methylpropyl)-; 3,7-Dihydro-1,3-bis(2-methylpropyl)-1H-purine-2,6-dione; 63908-24-7; AC1MIMT3; 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione; DTXSID70213605; BDBM50022731; LS-126573
DMZ80CT DT Small molecular drug
DMZ80CT PC 3048504
DMZ80CT MW 264.32
DMZ80CT FM C13H20N4O2
DMZ80CT IC InChI=1S/C13H20N4O2/c1-8(2)5-16-11-10(14-7-15-11)12(18)17(13(16)19)6-9(3)4/h7-9H,5-6H2,1-4H3,(H,14,15)
DMZ80CT CS CC(C)CN1C2=C(C(=O)N(C1=O)CC(C)C)NC=N2
DMZ80CT IK IPUAJXHKDUKOCH-UHFFFAOYSA-N
DMZ80CT IU 1,3-bis(2-methylpropyl)-7H-purine-2,6-dione
DMZ80CT CA CAS 63908-24-7
DMZ80CT DE Discovery agent
DM1KND6 ID DM1KND6
DM1KND6 DN 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one
DM1KND6 HS Investigative
DM1KND6 SN 100008-84-2; [1]Benzopyrano[4,3-c]pyrazol-4(1H)-one, 1,3-diphenyl-; ACMC-20m32m; CHEMBL99633; CTK0G9179; DTXSID70541117; AKOS030534409; J3.620.041C; 1,3-Diphenyl[1]benzopyrano[4,3-c]pyrazole-4(1H)-one
DM1KND6 DT Small molecular drug
DM1KND6 PC 13448492
DM1KND6 MW 338.4
DM1KND6 FM C22H14N2O2
DM1KND6 IC InChI=1S/C22H14N2O2/c25-22-19-20(15-9-3-1-4-10-15)23-24(16-11-5-2-6-12-16)21(19)17-13-7-8-14-18(17)26-22/h1-14H
DM1KND6 CS C1=CC=C(C=C1)C2=NN(C3=C2C(=O)OC4=CC=CC=C43)C5=CC=CC=C5
DM1KND6 IK ZPXTZMAWXDLUOO-UHFFFAOYSA-N
DM1KND6 IU 1,3-diphenylchromeno[4,3-c]pyrazol-4-one
DM1KND6 CA CAS 100008-84-2
DM1KND6 DE Discovery agent
DMI4H05 ID DMI4H05
DMI4H05 DN 1,3-DIPHENYLUREA
DMI4H05 HS Investigative
DMI4H05 SN 1,3-Diphenylurea; 102-07-8; N,N'-Diphenylurea; CARBANILIDE; Diphenylurea; Diphenylcarbamide; Urea, N,N'-diphenyl-; s-Diphenylurea; sym-Diphenylurea; Acardite I; Acardite; N-Phenyl-N'-phenylurea; 1,3-Diphenylcarbamide; Karbanilid; N,N'-Difenylmocovina; USAF EK-534; Urea, 1,3-diphenyl-; Karbanilid [Czech]; 1,3-diphenyl-urea; AD 30; UNII-94YD8RMX5B; NSC 227401; N,N'-Difenylmocovina [Czech]; CCRIS 4634; HSDB 2757; Urea-based compound, 7; EINECS 203-003-7; BRN 0782650; 94YD8RMX5B; AI3-52320; CHEBI:41320; GWEHVDNNLFDJLR-UHFFFAOYSA-N
DMI4H05 DT Small molecular drug
DMI4H05 PC 7595
DMI4H05 MW 212.25
DMI4H05 FM C13H12N2O
DMI4H05 IC InChI=1S/C13H12N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1-10H,(H2,14,15,16)
DMI4H05 CS C1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2
DMI4H05 IK GWEHVDNNLFDJLR-UHFFFAOYSA-N
DMI4H05 IU 1,3-diphenylurea
DMI4H05 CA CAS 102-07-8
DMI4H05 CB CHEBI:41320
DMI4H05 DE Discovery agent
DMUL2B3 ID DMUL2B3
DMUL2B3 DN 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione
DMUL2B3 HS Investigative
DMUL2B3 SN 1,3-Dipropylxanthine; 31542-62-8; 1,3-Dipropyl-1H-purine-2,6(3H,7H)-dione; UNII-Z02T66W92D; CHEMBL157655; Z02T66W92D; 1,3-dipropyl-7H-purine-2,6-dione; 1,3-dipropyl-3,7-dihydro-1h-purine-2,6-dione; 1,3-dipropyl-xanthine; AC1Q6LGS; 1,3-di-n-propylxanthine; AC1L53IX; GTPL427; SCHEMBL515771; 1H-Purine-2,6-dione, 3,9-dihydro-1,3-dipropyl-; BDBM82032; CTK4G7324; DTXSID00185447; MJVIGUCNSRXAFO-UHFFFAOYSA-N; ZINC4654890; PDSP2_000967; PDSP1_000983; PDSP1_000328; PDSP2_001217; BDBM50227331
DMUL2B3 DT Small molecular drug
DMUL2B3 PC 169317
DMUL2B3 MW 236.27
DMUL2B3 FM C11H16N4O2
DMUL2B3 IC InChI=1S/C11H16N4O2/c1-3-5-14-9-8(12-7-13-9)10(16)15(6-4-2)11(14)17/h7H,3-6H2,1-2H3,(H,12,13)
DMUL2B3 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC=N2
DMUL2B3 IK MJVIGUCNSRXAFO-UHFFFAOYSA-N
DMUL2B3 IU 1,3-dipropyl-7H-purine-2,6-dione
DMUL2B3 CA CAS 31542-62-8
DMUL2B3 DE Discovery agent
DMHNUWG ID DMHNUWG
DMHNUWG DN 1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione
DMHNUWG HS Investigative
DMHNUWG SN CHEMBL296771; 1,3-bis(4-methylphenyl)-1,3-diazetidine-2,4-dione; 1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione; AC1MRG54; SCHEMBL19214040
DMHNUWG DT Small molecular drug
DMHNUWG PC 3492365
DMHNUWG MW 266.29
DMHNUWG FM C16H14N2O2
DMHNUWG IC InChI=1S/C16H14N2O2/c1-11-3-7-13(8-4-11)17-15(19)18(16(17)20)14-9-5-12(2)6-10-14/h3-10H,1-2H3
DMHNUWG CS CC1=CC=C(C=C1)N2C(=O)N(C2=O)C3=CC=C(C=C3)C
DMHNUWG IK AZZFGWWOGRBVOV-UHFFFAOYSA-N
DMHNUWG IU 1,3-bis(4-methylphenyl)-1,3-diazetidine-2,4-dione
DMHNUWG DE Discovery agent
DM04KS1 ID DM04KS1
DM04KS1 DN 1,3-ditolylguanidine
DM04KS1 HS Investigative
DM04KS1 SN 1,3-Di-o-tolylguanidine; 97-39-2; Di-o-tolylguanidine; DOTG; Vulkacite DOTG; 1,3-Ditolylguanidine; Vulkacit DOTG; Eveite DOTG; ditolylguanidine; Vulkacit dotg/C; Nocceler DT; Sanceler DT; DOTG accelerator; Soxinol DT; Akrochem DOTG; Vulcafor DOTG; 1,3-Bis(o-tolyl)guanidine; Guanidine, N,N'-bis(2-methylphenyl)-; Diorthotolylguanidine; 1,3-Di-o-tolyguanidine; N,N'-Di-o-tolylguanidine; Guanidine, 1,3-di-o-tolyl-; USAF A-6598; NSC 473; CNS 1001; N,N'-Di-o-tolueylguanidine; UNII-LL2P01I17O; 1,3-di-(2-tolyl)guanidine; NSC 132023; [3H]-di-o-tolylguanidine; DITOLYLGUANIDINE
DM04KS1 DT Small molecular drug
DM04KS1 PC 7333
DM04KS1 MW 239.32
DM04KS1 FM C15H17N3
DM04KS1 IC InChI=1S/C15H17N3/c1-11-7-3-5-9-13(11)17-15(16)18-14-10-6-4-8-12(14)2/h3-10H,1-2H3,(H3,16,17,18)
DM04KS1 CS CC1=CC=CC=C1NC(=NC2=CC=CC=C2C)N
DM04KS1 IK OPNUROKCUBTKLF-UHFFFAOYSA-N
DM04KS1 IU 1,2-bis(2-methylphenyl)guanidine
DM04KS1 CA CAS 97-39-2
DM04KS1 CB CHEBI:92585
DM04KS1 DE Discovery agent
DMVBI2C ID DMVBI2C
DMVBI2C DN 1,3-propanediphosphonic acid
DMVBI2C HS Investigative
DMVBI2C SN 1,3-Propylenediphosphonic Acid; 1,3-propanediphosphonic acid; Propane-1,3-Diylbis(Phosphonic Acid); 3-phosphonopropylphosphonic acid; CHEMBL1230579; 7702-51-4; AC1L92ZA; SCHEMBL182326; propane-1,3-diphosphonic acid; CTK2H9782; 1,3-Propanediylbisphosphonic acid; ZINC31962397; BDBM50326711; AKOS025402728; P2304; I04-10331
DMVBI2C DT Small molecular drug
DMVBI2C PC 437081
DMVBI2C MW 204.06
DMVBI2C FM C3H10O6P2
DMVBI2C IC InChI=1S/C3H10O6P2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H2,4,5,6)(H2,7,8,9)
DMVBI2C CS C(CP(=O)(O)O)CP(=O)(O)O
DMVBI2C IK PUVMVPFLXCHEOY-UHFFFAOYSA-N
DMVBI2C IU 3-phosphonopropylphosphonic acid
DMVBI2C DE Discovery agent
DMLBHXN ID DMLBHXN
DMLBHXN DN 1,4-bis-(Dmt-Tic-amino)butane
DMLBHXN HS Investigative
DMLBHXN SN CHEMBL370197; 1,4-bis-(Dmt-Tic-amino)butane
DMLBHXN DT Small molecular drug
DMLBHXN PC 44405158
DMLBHXN MW 789
DMLBHXN FM C46H56N6O6
DMLBHXN IC InChI=1S/C46H56N6O6/c1-27-17-35(53)18-28(2)37(27)23-39(47)45(57)51-25-33-13-7-5-11-31(33)21-41(51)43(55)49-15-9-10-16-50-44(56)42-22-32-12-6-8-14-34(32)26-52(42)46(58)40(48)24-38-29(3)19-36(54)20-30(38)4/h5-8,11-14,17-20,39-42,53-54H,9-10,15-16,21-26,47-48H2,1-4H3,(H,49,55)(H,50,56)/t39-,40-,41?,42?/m0/s1
DMLBHXN CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N)N)C)O
DMLBHXN IK JSRJJBASKHLXAZ-YZNAZWRISA-N
DMLBHXN IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]butyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMLBHXN DE Discovery agent
DMC4LMT ID DMC4LMT
DMC4LMT DN 1,4-bis(malimido)xylene
DMC4LMT HS Investigative
DMC4LMT SN 1,4-bis(malimido)xylene; CHEMBL565711; SCHEMBL146412; BDBM50300349
DMC4LMT DT Small molecular drug
DMC4LMT PC 22022556
DMC4LMT MW 296.28
DMC4LMT FM C16H12N2O4
DMC4LMT IC InChI=1S/C16H12N2O4/c19-13-5-6-14(20)17(13)9-11-1-2-12(4-3-11)10-18-15(21)7-8-16(18)22/h1-8H,9-10H2
DMC4LMT CS C1=CC(=CC=C1CN2C(=O)C=CC2=O)CN3C(=O)C=CC3=O
DMC4LMT IK XFRPTDABLAIJMY-UHFFFAOYSA-N
DMC4LMT IU 1-[[4-[(2,5-dioxopyrrol-1-yl)methyl]phenyl]methyl]pyrrole-2,5-dione
DMC4LMT DE Discovery agent
DMVHKZT ID DMVHKZT
DMVHKZT DN 1,4-Butanediol
DMVHKZT HS Investigative
DMVHKZT SN 1,4-BUTANEDIOL; Butane-1,4-diol; 110-63-4; 1,4-Butylene glycol; Tetramethylene glycol; 1,4-Dihydroxybutane; 1,4-Tetramethylene glycol; Tetramethylene 1,4-diol; Sucol B; 1,4-BD; DIOL 14B; Agrisynth B1D; UNII-7XOO2LE6G3; HO(CH2)4OH; NSC 406696; CCRIS 5984; 1,4-Dihdyroxybutane; HSDB 1112; EINECS 203-786-5; HOCH2CH2CH2CH2OH; BRN 1633445; 7XOO2LE6G3; AI3-07553; CHEBI:41189; WERYXYBDKMZEQL-UHFFFAOYSA-N; MFCD00002968; DSSTox_CID_4666; DSSTox_RID_77492; DSSTox_GSID_24666; BDO; CAS-110-63-4; BU1; 1,4-Butanediol, homopolymer; 4-hydroxybutanol
DMVHKZT DT Small molecular drug
DMVHKZT PC 8064
DMVHKZT MW 90.12
DMVHKZT FM C4H10O2
DMVHKZT IC InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2
DMVHKZT CS C(CCO)CO
DMVHKZT IK WERYXYBDKMZEQL-UHFFFAOYSA-N
DMVHKZT IU butane-1,4-diol
DMVHKZT CA CAS 110-63-4
DMVHKZT CB CHEBI:41189
DMVHKZT DE Discovery agent
DM87MWN ID DM87MWN
DM87MWN DN 1,4-Di(berberine-9-O-yl)ethane dibromide
DM87MWN HS Investigative
DM87MWN SN CHEMBL1165194
DM87MWN DT Small molecular drug
DM87MWN PC 44400818
DM87MWN MW 698.8
DM87MWN FM C42H38N2O8+2
DM87MWN IC InChI=1S/C42H38N2O8/c1-45-35-7-5-25-15-33-29-19-39-37(49-23-51-39)17-27(29)9-11-43(33)21-31(25)41(35)47-13-3-4-14-48-42-32-22-44-12-10-28-18-38-40(52-24-50-38)20-30(28)34(44)16-26(32)6-8-36(42)46-2/h5-8,15-22H,3-4,9-14,23-24H2,1-2H3/q+2
DM87MWN CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=C(C=CC7=CC8=[N+](CCC9=CC1=C(C=C98)OCO1)C=C76)OC
DM87MWN IK SJALLAIALHPUMH-UHFFFAOYSA-N
DM87MWN IU 17-methoxy-16-[4-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]butoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM87MWN DE Discovery agent
DMIHYKG ID DMIHYKG
DMIHYKG DN 1,4-diaminoanthracene-9,10-dione
DMIHYKG HS Investigative
DMIHYKG SN 1,4-Diaminoanthraquinone; 128-95-0; 1,4-diaminoanthracene-9,10-dione; Disperse violet 1; Krisolamine; 1,4-Diamino anthraquinone; Grasol Violet R; Seacyl Violet R; Acetate Red Violet R; 9,10-Anthracenedione, 1,4-diamino-; Setacyl Violet R; Oil Violet R; Disperse Violet K; Resiren Violet TR; Oracet Violet 2R; Gracet Violet 2R; Setile Violet 3R; Duranol Violet 2R; Nacelan Violet 4R; Cibacet Violet 2R; Amacel heliotrope R; Dispersive Violet K; Solvent Violet 11; Cibacete Violet 2R; Perliton Violet 3R; Nyloquinone Violet R; Artisil Viole
DMIHYKG DT Small molecular drug
DMIHYKG PC 31420
DMIHYKG MW 238.24
DMIHYKG FM C14H10N2O2
DMIHYKG IC InChI=1S/C14H10N2O2/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6H,15-16H2
DMIHYKG CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)N)N
DMIHYKG IK FBMQNRKSAWNXBT-UHFFFAOYSA-N
DMIHYKG IU 1,4-diaminoanthracene-9,10-dione
DMIHYKG CA CAS 128-95-0
DMIHYKG DE Discovery agent
DMB5VQK ID DMB5VQK
DMB5VQK DN 1,4-dideoxy-1,4-imino-D-arabinito
DMB5VQK HS Investigative
DMB5VQK SN 1,4-dideoxy-1,4-imino-d-arabinitol; imino-D-arabinitol; CHEMBL80254; 3,4-Pyrrolidinediol, 2-(hydroxymethyl-14C)-, (2R,3R,4R)-; (2R,3R,4R)-2-(hydroxymethyl)pyrrolidine-3,4-diol; 259140-24-4; (2R,3R,4R)-2-Hydroxymethyl-pyrrolidine-3,4-diol; BDBM50031485; AC1L9PZY; 100937-52-8; DAB-1; Lopac0_000366; MLS002153179; SCHEMBL143519; CHEMBL305131; DTXSID10180589; OQEBIHBLFRADNM-UOWFLXDJSA-N; HMS2233K17; ZINC1492250; 1,4-Dideoxy-1,4-imino-arabinitol; BDBM50016703
DMB5VQK DT Small molecular drug
DMB5VQK PC 451991
DMB5VQK MW 133.15
DMB5VQK FM C5H11NO3
DMB5VQK IC InChI=1S/C5H11NO3/c7-2-3-5(9)4(8)1-6-3/h3-9H,1-2H2/t3-,4-,5-/m1/s1
DMB5VQK CS C1[C@H]([C@@H]([C@H](N1)CO)O)O
DMB5VQK IK OQEBIHBLFRADNM-UOWFLXDJSA-N
DMB5VQK IU (2R,3R,4R)-2-(hydroxymethyl)pyrrolidine-3,4-diol
DMB5VQK CA CAS 259140-24-4
DMB5VQK DE Discovery agent
DM4RD2S ID DM4RD2S
DM4RD2S DN 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
DM4RD2S HS Investigative
DM4RD2S SN AC1NRDG1; (3S,4S)-4-hydroxy-3-sulfooxy-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4RD2S DT Small molecular drug
DM4RD2S PC 46936854
DM4RD2S MW 240.19
DM4RD2S FM C6H8O8S
DM4RD2S IC InChI=1S/C6H8O8S/c7-3-1-4(6(8)9)13-2-5(3)14-15(10,11)12/h1,3,5,7H,2H2,(H,8,9)(H,10,11,12)/t3-,5-/m1/s1
DM4RD2S CS C1[C@H]([C@@H](C=C(O1)C(=O)O)O)OS(=O)(=O)O
DM4RD2S IK SLBOXLMLDIGNGG-NQXXGFSBSA-N
DM4RD2S IU (3R,4R)-4-hydroxy-3-sulfooxy-3,4-dihydro-2H-pyran-6-carboxylic acid
DM4RD2S DE Discovery agent
DM9KUQZ ID DM9KUQZ
DM9KUQZ DN 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
DM9KUQZ HS Investigative
DM9KUQZ SN AC1NRBS8; (2R,4S,5S)-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KUQZ DT Small molecular drug
DM9KUQZ PC 46936835
DM9KUQZ MW 242.21
DM9KUQZ FM C6H10O8S
DM9KUQZ IC InChI=1S/C6H10O8S/c7-3-1-4(6(8)9)13-2-5(3)14-15(10,11)12/h3-5,7H,1-2H2,(H,8,9)(H,10,11,12)/t3-,4-,5-/m1/s1
DM9KUQZ CS C1[C@H]([C@@H](CO[C@H]1C(=O)O)OS(=O)(=O)O)O
DM9KUQZ IK IRTONBQROPNEJZ-UOWFLXDJSA-N
DM9KUQZ IU (2R,4R,5R)-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid
DM9KUQZ DE Discovery agent
DMI36WC ID DMI36WC
DMI36WC DN 1,4-Diethylene Dioxide
DMI36WC HS Investigative
DMI36WC SN 1,4-DIOXANE; Dioxane; 123-91-1; p-Dioxane; 1,4-Diethylene dioxide; Diethylene ether; Dioxan; 1,4-Dioxacyclohexane; Dioxanne; Tetrahydro-p-dioxin; Di(ethylene oxide); Tetrahydro-1,4-dioxin; Dioxane-1,4; Diethylene dioxide; Glycol ethylene ether; 1,4-Dioxan; p-Dioxan; Dioxan-1,4; Dioxyethylene ether; Dioksan; Diokan; para-Dioxane; Tetrahydro-para-dioxin; Diossano-1,4; Dioxaan-1,4; p-Dioxin, tetrahydro-; Glycolethylenether; Dioksan [Polish]; Dioxanne [French]; RCRA waste number U108; p-Dioxan [Czech]; 1,4-Dioxanne; NCI-C03689
DMI36WC DT Small molecular drug
DMI36WC PC 31275
DMI36WC MW 88.11
DMI36WC FM C4H8O2
DMI36WC IC InChI=1S/C4H8O2/c1-2-6-4-3-5-1/h1-4H2
DMI36WC CS C1COCCO1
DMI36WC IK RYHBNJHYFVUHQT-UHFFFAOYSA-N
DMI36WC IU 1,4-dioxane
DMI36WC CA CAS 123-91-1
DMI36WC CB CHEBI:47032
DMI36WC DE Discovery agent
DMNHGVD ID DMNHGVD
DMNHGVD DN 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide
DMNHGVD HS Investigative
DMNHGVD SN CHEMBL1240572; 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide; 182556-18-9; SCHEMBL8320257; BDBM50326118; ZINC39054006; NSC744701; AKOS027401058; NSC-744701; KB-184852; 1,4-Dihydro-1-methyl-4-oxopyridine-3-sulfonamide
DMNHGVD DT Small molecular drug
DMNHGVD PC 45028895
DMNHGVD MW 188.21
DMNHGVD FM C6H8N2O3S
DMNHGVD IC InChI=1S/C6H8N2O3S/c1-8-3-2-5(9)6(4-8)12(7,10)11/h2-4H,1H3,(H2,7,10,11)
DMNHGVD CS CN1C=CC(=O)C(=C1)S(=O)(=O)N
DMNHGVD IK HTPSIFNKXNIAJZ-UHFFFAOYSA-N
DMNHGVD IU 1-methyl-4-oxopyridine-3-sulfonamide
DMNHGVD CA CAS 182556-18-9
DMNHGVD DE Discovery agent
DMMGP9X ID DMMGP9X
DMMGP9X DN 1,4-dihydroindeno[1,2-c]-pyrazole
DMMGP9X HS Investigative
DMMGP9X SN CHEMBL218957; SCHEMBL14746942; BDBM50176977
DMMGP9X DT Small molecular drug
DMMGP9X PC 44418727
DMMGP9X MW 461.8
DMMGP9X FM C22H19Cl3N4O
DMMGP9X IC InChI=1S/C22H19Cl3N4O/c23-14-4-6-16-13(10-14)11-17-20(22(30)27-28-8-2-1-3-9-28)26-29(21(16)17)19-7-5-15(24)12-18(19)25/h4-7,10,12H,1-3,8-9,11H2,(H,27,30)
DMMGP9X CS C1CCN(CC1)NC(=O)C2=NN(C3=C2CC4=C3C=CC(=C4)Cl)C5=C(C=C(C=C5)Cl)Cl
DMMGP9X IK AOONPZHOPMGIMM-UHFFFAOYSA-N
DMMGP9X IU 6-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4H-indeno[1,2-c]pyrazole-3-carboxamide
DMMGP9X DE Discovery agent
DMRT13B ID DMRT13B
DMRT13B DN 1,4-Dimethylquinolin-2(1H)-one
DMRT13B HS Investigative
DMRT13B SN 1,4-dimethylquinolin-2(1h)-one; 2584-47-6; 2(1H)-Quinolinone, 1,4-dimethyl-; 1,4-Dimethyl-2(1H)-quinolinone; 1,4-dimethyl-1,2-dihydroquinolin-2-one; UNII-6WT6AG3ZQJ; 6WT6AG3ZQJ; 1,4-dimethyl-2-quinolone; 1,4-dimethylquinolin-2-one; ST019653; Q-101237; 2(1H)-quinolinone,1,4-dimethyl-; NSC108420; NSC 108420; 1,4-DIMETHYL-2(1H)-QUINOLONE; casimiroin analogue, 1d; 1,4-dimethylcarbostyril; 4-methyl-n-methylquinolone; AC1Q6I1L; AC1L3Y4F; KSC497K0B; MLS000764269; CHEMBL60376; SCHEMBL436564; ZINC32147; CTK3J7500; BDBM29215
DMRT13B DT Small molecular drug
DMRT13B PC 97252
DMRT13B MW 173.21
DMRT13B FM C11H11NO
DMRT13B IC InChI=1S/C11H11NO/c1-8-7-11(13)12(2)10-6-4-3-5-9(8)10/h3-7H,1-2H3
DMRT13B CS CC1=CC(=O)N(C2=CC=CC=C12)C
DMRT13B IK CEONKCOBRZOYJS-UHFFFAOYSA-N
DMRT13B IU 1,4-dimethylquinolin-2-one
DMRT13B CA CAS 2584-47-6
DMRT13B DE Discovery agent
DMFY3VS ID DMFY3VS
DMFY3VS DN 1,4-diphenyl-(1E,3E)-1,3-butadiene
DMFY3VS HS Investigative
DMFY3VS SN Bistyryl; 1,4-Diphenyl-1,3-butadiene; 1,4-Diphenylbutadiene; trans,trans-1,4-Diphenyl-1,3-butadiene; 538-81-8; 1,4-Diphenylerythrene; Distyryl; trans,trans-1,4-Diphenylbuta-1,3-diene; (1E,3E)-1,4-Diphenylbuta-1,3-diene; 886-65-7; NSC 122702; 1,4-Diphenylbuta-1,3-diene; UNII-R7P15V6543; 1,1'-(1E,3E)-buta-1,3-diene-1,4-diyldibenzene; 1,3-Butadiene, 1,4-diphenyl-; EINECS 212-952-6; CHEMBL198810; CHEBI:35100; JFLKFZNIIQFQBS-FNCQTZNRSA-N; (4-phenyl-1,3-butadienyl)benzene; R7P15V6543; 1,1'-buta-1,3-diene-1,4-diyldibenzene
DMFY3VS DT Small molecular drug
DMFY3VS PC 641683
DMFY3VS MW 206.28
DMFY3VS FM C16H14
DMFY3VS IC InChI=1S/C16H14/c1-3-9-15(10-4-1)13-7-8-14-16-11-5-2-6-12-16/h1-14H/b13-7+,14-8+
DMFY3VS CS C1=CC=C(C=C1)/C=C/C=C/C2=CC=CC=C2
DMFY3VS IK JFLKFZNIIQFQBS-FNCQTZNRSA-N
DMFY3VS IU [(1E,3E)-4-phenylbuta-1,3-dienyl]benzene
DMFY3VS CA CAS 538-81-8
DMFY3VS CB CHEBI:35100
DMFY3VS DE Discovery agent
DMIFOXE ID DMIFOXE
DMIFOXE DN 1,4-Dithiothreitol
DMIFOXE HS Investigative
DMIFOXE SN Cleland's reagent; Dithiothreitol; 1,4-Dithiothreitol; Dithiotreitol; 1,4-Dimercaptobutane-2,3-diol; dl-Dithiothreitol; rac-Dithiothreitol; Cleland reagent; 7634-42-6; 1,4-disulfanylbutane-2,3-diol; Clelands reagent; Sputolysin; DL-threo-1,4-Dimercapto-2,3-butanediol; 1,4-dimercapto-2,3-butanediol; 3483-12-3; 2,3-Butanediol, 1,4-dimercapto-; Threitol, 1,4-dithio-; 1,4-bis(sulfanyl)butane-2,3-diol; trans-1,4-Dimercaptobutane-2,3-diol; L-1,4-Dithiothreitol; L-Dithiothreitol; CHEBI:18320; 1,4-Bissulfanylbutane-2,3-diol
DMIFOXE DT Small molecular drug
DMIFOXE PC 19001
DMIFOXE MW 154.3
DMIFOXE FM C4H10O2S2
DMIFOXE IC InChI=1S/C4H10O2S2/c5-3(1-7)4(6)2-8/h3-8H,1-2H2
DMIFOXE CS C(C(C(CS)O)O)S
DMIFOXE IK VHJLVAABSRFDPM-UHFFFAOYSA-N
DMIFOXE IU 1,4-bis(sulfanyl)butane-2,3-diol
DMIFOXE CA CAS 7634-42-6
DMIFOXE CB CHEBI:18320
DMIFOXE DE Discovery agent
DMTCMH7 ID DMTCMH7
DMTCMH7 DN 1,4-Naphthoquinone
DMTCMH7 HS Investigative
DMTCMH7 SN 1,4-NAPHTHOQUINONE; 130-15-4; naphthalene-1,4-dione; p-Naphthoquinone; NAPHTHOQUINONE; alpha-Naphthoquinone; 1,4-Naphthylquinone; USAF CY-10; 1,4-dihydronaphthalene-1,4-dione; 1,4-Dihydro-1,4-diketonaphthalene; 1,4-Naftochinon; RCRA waste number U166; UNII-RBF5ZU7R7K; NSC 9583; 1,4-Naftochinon [Czech]; 1,4-Naphthaquinone; CCRIS 5424; HSDB 2037; EINECS 204-977-6; RBF5ZU7R7K; RCRA waste no U166; CHEMBL55934; AI3-24292; NQ-1; CHEBI:27418; NSC9583; FRASJONUBLZVQX-UHFFFAOYSA-N; MFCD00001676; 1,4-naphtho-quinone
DMTCMH7 DT Small molecular drug
DMTCMH7 PC 8530
DMTCMH7 MW 158.15
DMTCMH7 FM C10H6O2
DMTCMH7 IC InChI=1S/C10H6O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6H
DMTCMH7 CS C1=CC=C2C(=O)C=CC(=O)C2=C1
DMTCMH7 IK FRASJONUBLZVQX-UHFFFAOYSA-N
DMTCMH7 IU naphthalene-1,4-dione
DMTCMH7 CA CAS 130-15-4
DMTCMH7 CB CHEBI:27418
DMTCMH7 DE Discovery agent
DMEDBO2 ID DMEDBO2
DMEDBO2 DN 1,4-phenylene disulfamate
DMEDBO2 HS Investigative
DMEDBO2 SN 1,4-phenylene disulfamate; CHEMBL461964
DMEDBO2 DT Small molecular drug
DMEDBO2 PC 44564283
DMEDBO2 MW 268.3
DMEDBO2 FM C6H8N2O6S2
DMEDBO2 IC InChI=1S/C6H8N2O6S2/c7-15(9,10)13-5-1-2-6(4-3-5)14-16(8,11)12/h1-4H,(H2,7,9,10)(H2,8,11,12)
DMEDBO2 CS C1=CC(=CC=C1OS(=O)(=O)N)OS(=O)(=O)N
DMEDBO2 IK BPEJBYDTMVTZIA-UHFFFAOYSA-N
DMEDBO2 IU (4-sulfamoyloxyphenyl) sulfamate
DMEDBO2 DE Discovery agent
DMF0RXK ID DMF0RXK
DMF0RXK DN 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole
DMF0RXK HS Investigative
DMF0RXK SN CHEMBL503677; 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole
DMF0RXK DT Small molecular drug
DMF0RXK PC 44572111
DMF0RXK MW 290.1
DMF0RXK FM C14H9Cl2N3
DMF0RXK IC InChI=1S/C14H9Cl2N3/c15-11-3-1-10(2-4-11)14-9-17-18-19(14)13-7-5-12(16)6-8-13/h1-9H
DMF0RXK CS C1=CC(=CC=C1C2=CN=NN2C3=CC=C(C=C3)Cl)Cl
DMF0RXK IK RXDUBIUDBWNEMF-UHFFFAOYSA-N
DMF0RXK IU 1,5-bis(4-chlorophenyl)triazole
DMF0RXK DE Discovery agent
DMPOAB7 ID DMPOAB7
DMPOAB7 DN 1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one
DMPOAB7 HS Investigative
DMPOAB7 SN 3654-49-7; (1E,4E)-1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one; 1,5-Bis(4-hydroxyphenyl)penta-1,4-dien-3-one; Bis-1,5-(4-Hydroxyphenyl)-1,4-Pentadien-3-one; 1,5-Bis-(4-hydroxyphenyl)-1,4-pentadien-3-one; CHEMBL129134; EINECS 222-896-4; AC1O5NFJ; 1,5-Di(p-hydroxyphenyl)-1,4-pentadien-3-one; 1,5-BIS(4-HYDROXYPHENYL)-1,4-PENTADIEN-3-ONE; 4,4'-Dihydroxydistyrylketon; ZINC6092599; BDBM50067044; AKOS015962226; CD-1056; M064; CC-03405; AC-16155; A823289; C-35230; 654B497; 1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one; W-106603
DMPOAB7 DT Small molecular drug
DMPOAB7 PC 6437306
DMPOAB7 MW 266.29
DMPOAB7 FM C17H14O3
DMPOAB7 IC InChI=1S/C17H14O3/c18-15-7-1-13(2-8-15)5-11-17(20)12-6-14-3-9-16(19)10-4-14/h1-12,18-19H/b11-5+,12-6+
DMPOAB7 CS C1=CC(=CC=C1/C=C/C(=O)/C=C/C2=CC=C(C=C2)O)O
DMPOAB7 IK FTEGUKWEUQPKIS-YDWXAUTNSA-N
DMPOAB7 IU (1E,4E)-1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one
DMPOAB7 CA CAS 3654-49-7
DMPOAB7 DE Discovery agent
DMZU1GD ID DMZU1GD
DMZU1GD DN 1,5-Dideoxy-1,5-imino-D-xylitol
DMZU1GD HS Investigative
DMZU1GD SN PIPERIDINE-3,4,5-TRIOL; (3R,4r,5S)-piperidine-3,4,5-triol; CHEMBL110830; 13042-55-2; 1,5-dideoxy-1,5-imino-xylitol; XYLOSE-DERIVED 1-DEOXY-NOJIRIMYCIN; XDN; dideoxyiminoxylitol; 1,5-Dideoxy-1,5-imino-D-xylitol; AC1L9IA9; SCHEMBL955713; SCHEMBL2435095; SCHEMBL2435099; 1,5-dideoxy-1,5-iminoxylitol; MolPort-042-605-431; 172588-13-5; 3alpha,4beta,5alpha-Piperidinetriol; FCH951710; 3alpha,4alpha,5alpha-Piperidinetriol; BDBM50182798; (3S,5R)-piperidine-3,4,5-triol; AKOS006351347; ZINC104595290; ZINC100872034; AKOS006294154
DMZU1GD DT Small molecular drug
DMZU1GD PC 445612
DMZU1GD MW 133.15
DMZU1GD FM C5H11NO3
DMZU1GD IC InChI=1S/C5H11NO3/c7-3-1-6-2-4(8)5(3)9/h3-9H,1-2H2/t3-,4+,5?
DMZU1GD CS C1[C@H](C([C@H](CN1)O)O)O
DMZU1GD IK RMCNETIHECSPMZ-NGQZWQHPSA-N
DMZU1GD IU (3S,5R)-piperidine-3,4,5-triol
DMZU1GD DE Discovery agent
DMYA25G ID DMYA25G
DMYA25G DN 1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one
DMYA25G HS Investigative
DMYA25G DT Small molecular drug
DMYA25G PC 10130278
DMYA25G DE Discovery agent
DMC7FLT ID DMC7FLT
DMC7FLT DN 1,5-Dihydroxy-10H-anthracen-9-one
DMC7FLT HS Investigative
DMC7FLT SN 1,5-dihydroxyanthrone; CHEMBL333452; 1,5-Dihydroxy-10H-anthracen-9-one; SCHEMBL8756171; MYYRAEQRSBLQQO-UHFFFAOYSA-N; ZINC13606493; BDBM50060873
DMC7FLT DT Small molecular drug
DMC7FLT PC 13486778
DMC7FLT MW 226.23
DMC7FLT FM C14H10O3
DMC7FLT IC InChI=1S/C14H10O3/c15-11-5-2-4-9-10(11)7-8-3-1-6-12(16)13(8)14(9)17/h1-6,15-16H,7H2
DMC7FLT CS C1C2=C(C(=CC=C2)O)C(=O)C3=C1C(=CC=C3)O
DMC7FLT IK MYYRAEQRSBLQQO-UHFFFAOYSA-N
DMC7FLT IU 1,5-dihydroxy-10H-anthracen-9-one
DMC7FLT DE Discovery agent
DMDFU6S ID DMDFU6S
DMDFU6S DN 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane
DMDFU6S HS Investigative
DMDFU6S SN CHEMBL1171823; 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane; SCHEMBL4525555
DMDFU6S DT Small molecular drug
DMDFU6S PC 11641429
DMDFU6S MW 475.5
DMDFU6S FM C26H36Cl2N4
DMDFU6S IC InChI=1S/C26H36Cl2N4/c27-23-7-5-9-25(21-23)31-17-13-29(14-18-31)11-3-1-2-4-12-30-15-19-32(20-16-30)26-10-6-8-24(28)22-26/h5-10,21-22H,1-4,11-20H2
DMDFU6S CS C1CN(CCN1CCCCCCN2CCN(CC2)C3=CC(=CC=C3)Cl)C4=CC(=CC=C4)Cl
DMDFU6S IK YWGRWBCJUGEEBA-UHFFFAOYSA-N
DMDFU6S IU 1-(3-chlorophenyl)-4-[6-[4-(3-chlorophenyl)piperazin-1-yl]hexyl]piperazine
DMDFU6S DE Discovery agent
DMNLUKS ID DMNLUKS
DMNLUKS DN 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane
DMNLUKS HS Investigative
DMNLUKS SN CHEMBL1172206; 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane; SCHEMBL4525293
DMNLUKS DT Small molecular drug
DMNLUKS PC 11568942
DMNLUKS MW 466.7
DMNLUKS FM C28H42N4O2
DMNLUKS IC InChI=1S/C28H42N4O2/c1-33-27-11-7-9-25(23-27)31-19-15-29(16-20-31)13-5-3-4-6-14-30-17-21-32(22-18-30)26-10-8-12-28(24-26)34-2/h7-12,23-24H,3-6,13-22H2,1-2H3
DMNLUKS CS COC1=CC=CC(=C1)N2CCN(CC2)CCCCCCN3CCN(CC3)C4=CC(=CC=C4)OC
DMNLUKS IK IMWNCWRNMUKPGO-UHFFFAOYSA-N
DMNLUKS IU 1-(3-methoxyphenyl)-4-[6-[4-(3-methoxyphenyl)piperazin-1-yl]hexyl]piperazine
DMNLUKS DE Discovery agent
DM0GRMD ID DM0GRMD
DM0GRMD DN 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane
DM0GRMD HS Investigative
DM0GRMD SN CHEMBL1171644; 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane; SCHEMBL4519313
DM0GRMD DT Small molecular drug
DM0GRMD PC 11524350
DM0GRMD MW 408.6
DM0GRMD FM C24H36N6
DM0GRMD IC InChI=1S/C24H36N6/c1(7-13-27-15-19-29(20-16-27)23-9-3-5-11-25-23)2-8-14-28-17-21-30(22-18-28)24-10-4-6-12-26-24/h3-6,9-12H,1-2,7-8,13-22H2
DM0GRMD CS C1CN(CCN1CCCCCCN2CCN(CC2)C3=CC=CC=N3)C4=CC=CC=N4
DM0GRMD IK OSEVIYJKDQCRJK-UHFFFAOYSA-N
DM0GRMD IU 1-pyridin-2-yl-4-[6-(4-pyridin-2-ylpiperazin-1-yl)hexyl]piperazine
DM0GRMD DE Discovery agent
DM70ODN ID DM70ODN
DM70ODN DN 1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene
DM70ODN HS Investigative
DM70ODN SN CHEMBL208456; SCHEMBL9750157; ZINC13686481; BDBM50185992
DM70ODN DT Small molecular drug
DM70ODN PC 11507217
DM70ODN MW 262.3
DM70ODN FM C18H18N2
DM70ODN IC InChI=1S/C18H18N2/c19-17-11-7-15(8-12-17)5-3-1-2-4-6-16-9-13-18(20)14-10-16/h1-14H,19-20H2/b2-1+,5-3+,6-4+
DM70ODN CS C1=CC(=CC=C1/C=C/C=C/C=C/C2=CC=C(C=C2)N)N
DM70ODN IK IZOOKGZEMKOBQA-CRQXNEITSA-N
DM70ODN IU 4-[(1E,3E,5E)-6-(4-aminophenyl)hexa-1,3,5-trienyl]aniline
DM70ODN DE Discovery agent
DMBCU6W ID DMBCU6W
DMBCU6W DN 1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene
DMBCU6W HS Investigative
DMBCU6W SN CHEMBL377929; BDBM50185990; 1,6-Bis[4-(dimethylamino)phenyl]-1,3,5-hexatriene; 1,6-bis(4''-dimethylaminophenyl)-hexa-1,3,5-triene
DMBCU6W DT Small molecular drug
DMBCU6W PC 11537013
DMBCU6W MW 318.5
DMBCU6W FM C22H26N2
DMBCU6W IC InChI=1S/C22H26N2/c1-23(2)21-15-11-19(12-16-21)9-7-5-6-8-10-20-13-17-22(18-14-20)24(3)4/h5-18H,1-4H3/b6-5+,9-7+,10-8+
DMBCU6W CS CN(C1=CC=C(C=C1)/C=C/C=C/C=C/C2=CC=C(C=C2)N(C)C)C
DMBCU6W IK JGQHLETVKDCCET-NRIIQWGUSA-N
DMBCU6W IU 4-[(1E,3E,5E)-6-[4-(dimethylamino)phenyl]hexa-1,3,5-trienyl]-N,N-dimethylaniline
DMBCU6W DE Discovery agent
DMEU3MN ID DMEU3MN
DMEU3MN DN 1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene
DMEU3MN HS Investigative
DMEU3MN SN CHEMBL381731; ZINC13686478; BDBM50185986; 4,4'-(1,3,5-Hexatriene-1,6-diyl)bisphenol
DMEU3MN DT Small molecular drug
DMEU3MN PC 11587026
DMEU3MN MW 264.3
DMEU3MN FM C18H16O2
DMEU3MN IC InChI=1S/C18H16O2/c19-17-11-7-15(8-12-17)5-3-1-2-4-6-16-9-13-18(20)14-10-16/h1-14,19-20H/b2-1+,5-3+,6-4+
DMEU3MN CS C1=CC(=CC=C1/C=C/C=C/C=C/C2=CC=C(C=C2)O)O
DMEU3MN IK FXGYAFMJWIVHGO-CRQXNEITSA-N
DMEU3MN IU 4-[(1E,3E,5E)-6-(4-hydroxyphenyl)hexa-1,3,5-trienyl]phenol
DMEU3MN DE Discovery agent
DM0D6JN ID DM0D6JN
DM0D6JN DN 1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene
DM0D6JN HS Investigative
DM0D6JN SN CHEMBL208457; ZINC13686485; BDBM50185991
DM0D6JN DT Small molecular drug
DM0D6JN PC 11608986
DM0D6JN MW 290.4
DM0D6JN FM C20H22N2
DM0D6JN IC InChI=1S/C20H22N2/c1-21-19-13-9-17(10-14-19)7-5-3-4-6-8-18-11-15-20(22-2)16-12-18/h3-16,21-22H,1-2H3/b4-3+,7-5+,8-6+
DM0D6JN CS CNC1=CC=C(C=C1)/C=C/C=C/C=C/C2=CC=C(C=C2)NC
DM0D6JN IK SWZSFUMMCHKHMM-OKWWDJPNSA-N
DM0D6JN IU N-methyl-4-[(1E,3E,5E)-6-[4-(methylamino)phenyl]hexa-1,3,5-trienyl]aniline
DM0D6JN DE Discovery agent
DM5Z6XG ID DM5Z6XG
DM5Z6XG DN 1,6-bis(4-m-tolylpiperazin-1-yl)hexane
DM5Z6XG HS Investigative
DM5Z6XG SN CHEMBL1172204; 1,6-bis(4-m-tolylpiperazin-1-yl)hexane; SCHEMBL4519876
DM5Z6XG DT Small molecular drug
DM5Z6XG PC 11669239
DM5Z6XG MW 434.7
DM5Z6XG FM C28H42N4
DM5Z6XG IC InChI=1S/C28H42N4/c1-25-9-7-11-27(23-25)31-19-15-29(16-20-31)13-5-3-4-6-14-30-17-21-32(22-18-30)28-12-8-10-26(2)24-28/h7-12,23-24H,3-6,13-22H2,1-2H3
DM5Z6XG CS CC1=CC(=CC=C1)N2CCN(CC2)CCCCCCN3CCN(CC3)C4=CC=CC(=C4)C
DM5Z6XG IK CQEUVRXXXLSTIL-UHFFFAOYSA-N
DM5Z6XG IU 1-(3-methylphenyl)-4-[6-[4-(3-methylphenyl)piperazin-1-yl]hexyl]piperazine
DM5Z6XG DE Discovery agent
DMQY75B ID DMQY75B
DMQY75B DN 1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene
DMQY75B HS Investigative
DMQY75B SN CHEMBL205899; 1,6-Bis(4-nitrophenyl)-1,3,5-hexatriene; AC1O1Q5Y; SCHEMBL9750443; ZINC3080662; BDBM50185989; AKOS024339803; 1,6-bis(4''-nitrophenyl)-hexa-1,3,5-triene; (1E,3E,5E)-1,6-Bis(4-nitrophenyl)-1,3,5-hexatriene
DMQY75B DT Small molecular drug
DMQY75B PC 6177872
DMQY75B MW 322.3
DMQY75B FM C18H14N2O4
DMQY75B IC InChI=1S/C18H14N2O4/c21-19(22)17-11-7-15(8-12-17)5-3-1-2-4-6-16-9-13-18(14-10-16)20(23)24/h1-14H/b2-1+,5-3+,6-4+
DMQY75B CS C1=CC(=CC=C1/C=C/C=C/C=C/C2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]
DMQY75B IK OYPMHQIMQGZDHK-CRQXNEITSA-N
DMQY75B IU 1-nitro-4-[(1E,3E,5E)-6-(4-nitrophenyl)hexa-1,3,5-trienyl]benzene
DMQY75B DE Discovery agent
DMD3EUI ID DMD3EUI
DMD3EUI DN 1,6-bis(4-phenylpiperazin-1-yl)hexane
DMD3EUI HS Investigative
DMD3EUI SN CHEMBL1172205; 1,6-bis(4-phenylpiperazin-1-yl)hexane; SCHEMBL4528457
DMD3EUI DT Small molecular drug
DMD3EUI PC 11567667
DMD3EUI MW 406.6
DMD3EUI FM C26H38N4
DMD3EUI IC InChI=1S/C26H38N4/c1(9-15-27-17-21-29(22-18-27)25-11-5-3-6-12-25)2-10-16-28-19-23-30(24-20-28)26-13-7-4-8-14-26/h3-8,11-14H,1-2,9-10,15-24H2
DMD3EUI CS C1CN(CCN1CCCCCCN2CCN(CC2)C3=CC=CC=C3)C4=CC=CC=C4
DMD3EUI IK ORESESSHUCUUFK-UHFFFAOYSA-N
DMD3EUI IU 1-phenyl-4-[6-(4-phenylpiperazin-1-yl)hexyl]piperazine
DMD3EUI DE Discovery agent
DMRG2CU ID DMRG2CU
DMRG2CU DN 1,6-bis-(Dmt-Tic-amino)hexane
DMRG2CU HS Investigative
DMRG2CU SN CHEMBL197185; 1,6-bis-(Dmt-Tic-amino)hexane
DMRG2CU DT Small molecular drug
DMRG2CU PC 44405159
DMRG2CU MW 817
DMRG2CU FM C48H60N6O6
DMRG2CU IC InChI=1S/C48H60N6O6/c1-29-19-37(55)20-30(2)39(29)25-41(49)47(59)53-27-35-15-9-7-13-33(35)23-43(53)45(57)51-17-11-5-6-12-18-52-46(58)44-24-34-14-8-10-16-36(34)28-54(44)48(60)42(50)26-40-31(3)21-38(56)22-32(40)4/h7-10,13-16,19-22,41-44,55-56H,5-6,11-12,17-18,23-28,49-50H2,1-4H3,(H,51,57)(H,52,58)/t41-,42-,43?,44?/m0/s1
DMRG2CU CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N)N)C)O
DMRG2CU IK VJIXEMXKNBJTQB-GCGBLBKRSA-N
DMRG2CU IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMRG2CU DE Discovery agent
DMMUZK9 ID DMMUZK9
DMMUZK9 DN 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane
DMMUZK9 HS Investigative
DMMUZK9 SN CHEMBL370399; 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane
DMMUZK9 DT Small molecular drug
DMMUZK9 PC 44405153
DMMUZK9 MW 873.1
DMMUZK9 FM C52H68N6O6
DMMUZK9 IC InChI=1S/C52H68N6O6/c1-33-23-41(59)24-34(2)43(33)29-47(55(5)6)51(63)57-31-39-19-13-11-17-37(39)27-45(57)49(61)53-21-15-9-10-16-22-54-50(62)46-28-38-18-12-14-20-40(38)32-58(46)52(64)48(56(7)8)30-44-35(3)25-42(60)26-36(44)4/h11-14,17-20,23-26,45-48,59-60H,9-10,15-16,21-22,27-32H2,1-8H3,(H,53,61)(H,54,62)/t45?,46?,47-,48-/m0/s1
DMMUZK9 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)C4CC5=CC=CC=C5CN4C(=O)[C@H](CC6=C(C=C(C=C6C)O)C)N(C)C)N(C)C)C)O
DMMUZK9 IK WQLMNYRHCQXDKA-QYXCYUBVSA-N
DMMUZK9 IU 2-[(2S)-2-(dimethylamino)-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[2-[(2S)-2-(dimethylamino)-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMMUZK9 DE Discovery agent
DMLB3RT ID DMLB3RT
DMLB3RT DN 1,6-hexamethylene diisocyanate
DMLB3RT HS Investigative
DMLB3RT SN HMDI; HDI
DMLB3RT DT Small molecular drug
DMLB3RT PC 13192
DMLB3RT MW 168.19
DMLB3RT FM C8H12N2O2
DMLB3RT IC InChI=1S/C8H12N2O2/c11-7-9-5-3-1-2-4-6-10-8-12/h1-6H2
DMLB3RT CS C(CCCN=C=O)CCN=C=O
DMLB3RT IK RRAMGCGOFNQTLD-UHFFFAOYSA-N
DMLB3RT IU 1,6-diisocyanatohexane
DMLB3RT CA CAS 822-06-0
DMLB3RT CB CHEBI:53578
DMLB3RT DE Discovery agent
DMBU796 ID DMBU796
DMBU796 DN 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione
DMBU796 HS Investigative
DMBU796 SN CHEMBL201907; 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione; SCHEMBL2086780; ZINC28569089
DMBU796 DT Small molecular drug
DMBU796 PC 11506860
DMBU796 MW 226.23
DMBU796 FM C13H10N2O2
DMBU796 IC InChI=1S/C13H10N2O2/c16-12-9-6-2-1-3-7(6)11-8(4-5-14-11)10(9)13(17)15-12/h4-5,14H,1-3H2,(H,15,16,17)
DMBU796 CS C1CC2=C3C(=C4C=CNC4=C2C1)C(=O)NC3=O
DMBU796 IK NMFHMHLMLQVGMW-UHFFFAOYSA-N
DMBU796 IU 3,9-diazatetracyclo[10.3.0.02,6.07,11]pentadeca-1,4,6,11-tetraene-8,10-dione
DMBU796 DE Discovery agent
DMVHE1P ID DMVHE1P
DMVHE1P DN 1,8,9-Trimethoxy-9,10-dihydro-anthracene
DMVHE1P HS Investigative
DMVHE1P SN CHEMBL125328; 1,8,9-Trimethoxy-9,10-dihydro-anthracene
DMVHE1P DT Small molecular drug
DMVHE1P PC 44348682
DMVHE1P MW 270.32
DMVHE1P FM C17H18O3
DMVHE1P IC InChI=1S/C17H18O3/c1-18-13-8-4-6-11-10-12-7-5-9-14(19-2)16(12)17(20-3)15(11)13/h4-9,17H,10H2,1-3H3
DMVHE1P CS COC1C2=C(CC3=C1C(=CC=C3)OC)C=CC=C2OC
DMVHE1P IK SEFFBCQMWOLCMQ-UHFFFAOYSA-N
DMVHE1P IU 1,8,9-trimethoxy-9,10-dihydroanthracene
DMVHE1P DE Discovery agent
DMKJGTH ID DMKJGTH
DMKJGTH DN 1,8-bis-maleimidodiethyleneglycol
DMKJGTH HS Investigative
DMKJGTH SN 115597-84-7; UNII-R20U86RE9F; 1,8-bis-maleimidodiethyleneglycol; 1,8-Bis(maleimido)-3,6-dioxaoctane; CHEMBL575383; R20U86RE9F; 2,2'-(Ethylenedioxy)bis(ethylmaleimide); Liqwd; 1H-Pyrrole-2,5-dione, 1,1'-(1,2-ethanediylbis(oxy-2,1-ethanediyl))bis-; Bis-(maleimidoethoxy) ethane; BM(peg)2; 1,1'-[ethane-1,2-Diylbis(Oxyethane-2,1-Diyl)]bis(1h-Pyrrole-2,5-Dione); 1H-Pyrrole-2,5-dione, 1,1'-[1,2-ethanediylbis(oxy-2,1-ethanediyl)]bis-; 1,2-bis(2-maleimidoethoxy)ethane; Bis-(maleimidoethoxy) ethane [INCI]; AC1MVX1G; SCHEMBL349749
DMKJGTH DT Small molecular drug
DMKJGTH PC 3690297
DMKJGTH MW 308.29
DMKJGTH FM C14H16N2O6
DMKJGTH IC InChI=1S/C14H16N2O6/c17-11-1-2-12(18)15(11)5-7-21-9-10-22-8-6-16-13(19)3-4-14(16)20/h1-4H,5-10H2
DMKJGTH CS C1=CC(=O)N(C1=O)CCOCCOCCN2C(=O)C=CC2=O
DMKJGTH IK FERLGYOHRKHQJP-UHFFFAOYSA-N
DMKJGTH IU 1-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethyl]pyrrole-2,5-dione
DMKJGTH CA CAS 115597-84-7
DMKJGTH DE Discovery agent
DMZK4DL ID DMZK4DL
DMZK4DL DN 1,8-Dichloro-10H-anthracen-9-one
DMZK4DL HS Investigative
DMZK4DL SN 1,8-Dichloro-10H-anthracen-9-one; CHEMBL122022; 50259-93-3; NSC162539; 1,8-Dichloroanthrone; AC1Q3KGA; AC1L9O6M; SCHEMBL7103871; CTK1H2907; DTXSID70329816; ZINC393214; BDBM50060867; AKOS024331862; NSC-162539; MCULE-9362278595
DMZK4DL DT Small molecular drug
DMZK4DL PC 424114
DMZK4DL MW 263.1
DMZK4DL FM C14H8Cl2O
DMZK4DL IC InChI=1S/C14H8Cl2O/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6H,7H2
DMZK4DL CS C1C2=C(C(=CC=C2)Cl)C(=O)C3=C1C=CC=C3Cl
DMZK4DL IK AYDNUUZHQKPRKA-UHFFFAOYSA-N
DMZK4DL IU 1,8-dichloro-10H-anthracen-9-one
DMZK4DL CA CAS 50259-93-3
DMZK4DL DE Discovery agent
DMKJBRZ ID DMKJBRZ
DMKJBRZ DN 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMKJBRZ HS Investigative
DMKJBRZ SN CHEMBL192876; 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL4456831; YTFVBUBYMJJWQZ-UHFFFAOYSA-N; ZINC13645103; BDBM50168322
DMKJBRZ DT Small molecular drug
DMKJBRZ PC 10149584
DMKJBRZ MW 305.2
DMKJBRZ FM C16H10Cl2O2
DMKJBRZ IC InChI=1S/C16H10Cl2O2/c17-13-8-11(9-1-4-12(19)5-2-9)7-10-3-6-14(20)16(18)15(10)13/h1-8,19-20H
DMKJBRZ CS C1=CC(=CC=C1C2=CC(=C3C(=C2)C=CC(=C3Cl)O)Cl)O
DMKJBRZ IK YTFVBUBYMJJWQZ-UHFFFAOYSA-N
DMKJBRZ IU 1,8-dichloro-6-(4-hydroxyphenyl)naphthalen-2-ol
DMKJBRZ DE Discovery agent
DMDFBSX ID DMDFBSX
DMDFBSX DN 1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one
DMDFBSX HS Investigative
DMDFBSX SN CHEMBL126057; 1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one; BDBM50060901
DMDFBSX DT Small molecular drug
DMDFBSX PC 10779243
DMDFBSX MW 282.29
DMDFBSX FM C17H14O4
DMDFBSX IC InChI=1S/C17H14O4/c1-2-12(18)11-7-6-10-8-9-4-3-5-13(19)14(9)17(21)15(10)16(11)20/h3-7,19-20H,2,8H2,1H3
DMDFBSX CS CCC(=O)C1=C(C2=C(CC3=C(C2=O)C(=CC=C3)O)C=C1)O
DMDFBSX IK KGAHUIIBPUKUER-UHFFFAOYSA-N
DMDFBSX IU 1,8-dihydroxy-2-propanoyl-10H-anthracen-9-one
DMDFBSX DE Discovery agent
DMWC7QE ID DMWC7QE
DMWC7QE DN 1,9-bis(pyridinium)-nonane dibromide
DMWC7QE HS Investigative
DMWC7QE SN 1,9-bis(pyridinium)-nonane dibromide; CHEMBL105742; SCHEMBL3591238; UOOOOWOODBZUKX-UHFFFAOYSA-L; N,N'-Nonane-1,9-diyl-bis-pyridinium Dibromide; 1,9-Di(1-Pyridiniumyl)Nonane With Dibromide Ions
DMWC7QE DT Small molecular drug
DMWC7QE PC 11408144
DMWC7QE MW 444.2
DMWC7QE FM C19H28Br2N2
DMWC7QE IC InChI=1S/C19H28N2.2BrH/c1(2-4-8-14-20-16-10-6-11-17-20)3-5-9-15-21-18-12-7-13-19-21;;/h6-7,10-13,16-19H,1-5,8-9,14-15H2;2*1H/q+2;;/p-2
DMWC7QE CS C1=CC=[N+](C=C1)CCCCCCCCC[N+]2=CC=CC=C2.[Br-].[Br-]
DMWC7QE IK UOOOOWOODBZUKX-UHFFFAOYSA-L
DMWC7QE IU 1-(9-pyridin-1-ium-1-ylnonyl)pyridin-1-ium;dibromide
DMWC7QE DE Discovery agent
DMW613U ID DMW613U
DMW613U DN 1,9-dideoxyforskolin
DMW613U HS Investigative
DMW613U SN 1,9-DIDEOXYFORSKOLIN; UNII-OAW710HWIX; 64657-18-7; OAW710HWIX; CHEBI:50295; (3R,4aS,5S,6S,6aS,10aS,10bR)-3-ethenyl-6-hydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate; 7beta-acetoxy-8,13-epoxy-6beta-hydroxylabd-14-en-11-one; (3R,4aS,5S,6S,6aS,10aS,10bR)-5-(acetyloxy)-3-ethenyldodecahydro-6-hydroxy-3,4a,7,7,10a-pentamethyl-1H-naphtho(2,1-b)pyran-1-one
DMW613U DT Small molecular drug
DMW613U PC 107948
DMW613U MW 378.5
DMW613U FM C22H34O5
DMW613U IC InChI=1S/C22H34O5/c1-8-20(5)12-14(24)16-21(6)11-9-10-19(3,4)17(21)15(25)18(26-13(2)23)22(16,7)27-20/h8,15-18,25H,1,9-12H2,2-7H3/t15-,16+,17-,18-,20-,21+,22-/m0/s1
DMW613U CS CC(=O)O[C@H]1[C@H]([C@@H]2[C@](CCCC2(C)C)([C@@H]3[C@@]1(O[C@@](CC3=O)(C)C=C)C)C)O
DMW613U IK ZKZMDXUDDJYAIB-SUCLLAFCSA-N
DMW613U IU [(3R,4aS,5S,6S,6aS,10aS,10bR)-3-ethenyl-6-hydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-2,5,6,6a,8,9,10,10b-octahydrobenzo[f]chromen-5-yl] acetate
DMW613U CA CAS 64657-18-7
DMW613U CB CHEBI:50295
DMW613U DE Discovery agent
DM7U0XW ID DM7U0XW
DM7U0XW DN 1-[(3-Methoxybenzyl)amino]ethaniminium chloride
DM7U0XW HS Investigative
DM7U0XW SN 1-[(3-Methoxybenzyl)amino]ethaniminium chloride
DM7U0XW DT Small molecular drug
DM7U0XW PC 52940828
DM7U0XW MW 214.69
DM7U0XW FM C10H15ClN2O
DM7U0XW IC InChI=1S/C10H14N2O.ClH/c1-8(11)12-7-9-4-3-5-10(6-9)13-2;/h3-6H,7H2,1-2H3,(H2,11,12);1H
DM7U0XW CS CC(=NCC1=CC(=CC=C1)OC)N.Cl
DM7U0XW IK KAHXLIVOQBJXSB-UHFFFAOYSA-N
DM7U0XW IU N'-[(3-methoxyphenyl)methyl]ethanimidamide;hydrochloride
DM7U0XW DE Discovery agent
DM3UHDW ID DM3UHDW
DM3UHDW DN 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene
DM3UHDW HS Investigative
DM3UHDW DT Small molecular drug
DM3UHDW PC 11973921
DM3UHDW MW 318.4
DM3UHDW FM C22H22O2
DM3UHDW IC InChI=1S/C22H22O2/c1-23-21-12-7-10-19(16-21)17-24-22-13-6-5-11-20(22)15-14-18-8-3-2-4-9-18/h2-13,16H,14-15,17H2,1H3
DM3UHDW CS COC1=CC=CC(=C1)COC2=CC=CC=C2CCC3=CC=CC=C3
DM3UHDW IK GYSNUAVEYIUVBT-UHFFFAOYSA-N
DM3UHDW IU 1-methoxy-3-[[2-(2-phenylethyl)phenoxy]methyl]benzene
DM3UHDW DE Discovery agent
DMNJMGK ID DMNJMGK
DMNJMGK DN 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole
DMNJMGK HS Investigative
DMNJMGK SN CHEMBL1098424; 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole
DMNJMGK DT Small molecular drug
DMNJMGK PC 46887506
DMNJMGK MW 226.25
DMNJMGK FM C14H11FN2
DMNJMGK IC InChI=1S/C14H11FN2/c15-14-4-3-12-2-1-11(7-13(12)8-14)9-17-6-5-16-10-17/h1-8,10H,9H2
DMNJMGK CS C1=CC(=CC2=C1C=CC(=C2)F)CN3C=CN=C3
DMNJMGK IK SFBANCVOUQRQEX-UHFFFAOYSA-N
DMNJMGK IU 1-[(7-fluoronaphthalen-2-yl)methyl]imidazole
DMNJMGK DE Discovery agent
DM1JQPW ID DM1JQPW
DM1JQPW DN 1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid
DM1JQPW HS Investigative
DM1JQPW SN CHEMBL261432; [2-(Cyclohexylamino)ethane-1,1-Diyl]bisphosphonic Acid; 2-(cyclohexylamino)ethylidene-1,1-bisphosphonic acid; SCHEMBL9564518; BDBM50374762; 146829-50-7; [2-(cyclohexylamino)-1-phosphono-ethyl]phosphonic acid
DM1JQPW DT Small molecular drug
DM1JQPW PC 21803454
DM1JQPW MW 287.19
DM1JQPW FM C8H19NO6P2
DM1JQPW IC InChI=1S/C8H19NO6P2/c10-16(11,12)8(17(13,14)15)6-9-7-4-2-1-3-5-7/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15)
DM1JQPW CS C1CCC(CC1)NCC(P(=O)(O)O)P(=O)(O)O
DM1JQPW IK OAHUDYBQKIUBMC-UHFFFAOYSA-N
DM1JQPW IU [2-(cyclohexylamino)-1-phosphonoethyl]phosphonic acid
DM1JQPW DE Discovery agent
DMQPFT3 ID DMQPFT3
DMQPFT3 DN 1-[(Furan-2(5H)-one)-4-methyl]-desloratadine
DMQPFT3 HS Investigative
DMQPFT3 SN CHEMBL597381
DMQPFT3 DT Small molecular drug
DMQPFT3 PC 46233181
DMQPFT3 MW 406.9
DMQPFT3 FM C24H23ClN2O2
DMQPFT3 IC InChI=1S/C24H23ClN2O2/c25-20-5-6-21-19(13-20)4-3-18-2-1-9-26-24(18)23(21)17-7-10-27(11-8-17)14-16-12-22(28)29-15-16/h1-2,5-6,9,12-13H,3-4,7-8,10-11,14-15H2
DMQPFT3 CS C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CC4=CC(=O)OC4)C5=C1C=CC=N5
DMQPFT3 IK CHEQBNZJRBHHQT-UHFFFAOYSA-N
DMQPFT3 IU 3-[[4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidin-1-yl]methyl]-2H-furan-5-one
DMQPFT3 DE Discovery agent
DM8VNYA ID DM8VNYA
DM8VNYA DN 1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM8VNYA HS Investigative
DM8VNYA SN CHEMBL406087; SCHEMBL7538729; BDBM50374767; [2-(Butylamino)ethylidene]bisphosphonic acid; [2-(butylamino)-1-phosphono-ethyl]phosphonic acid
DM8VNYA DT Small molecular drug
DM8VNYA PC 15390275
DM8VNYA MW 261.149
DM8VNYA FM C6H17NO6P2
DM8VNYA IC InChI=1S/C6H17NO6P2/c1-2-3-4-7-5-6(14(8,9)10)15(11,12)13/h6-7H,2-5H2,1H3,(H2,8,9,10)(H2,11,12,13)
DM8VNYA CS CCCCNCC(P(=O)(O)O)P(=O)(O)O
DM8VNYA IK HFKAJGBERMPCOS-UHFFFAOYSA-N
DM8VNYA IU [2-(butylamino)-1-phosphonoethyl]phosphonic acid
DM8VNYA DE Discovery agent
DM4ABTN ID DM4ABTN
DM4ABTN DN 1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM4ABTN HS Investigative
DM4ABTN SN CHEMBL259192; [2-(Hexylamino)ethane-1,1-Diyl]bis(Phosphonic Acid); 1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid; SCHEMBL8674064; BDBM50341917; 2-(hexylamino)ethane-1,1-diyldiphosphonic acid; [2-(hexylamino)-1-phosphono-ethyl]phosphonic acid
DM4ABTN DT Small molecular drug
DM4ABTN PC 19689034
DM4ABTN MW 289.2
DM4ABTN FM C8H21NO6P2
DM4ABTN IC InChI=1S/C8H21NO6P2/c1-2-3-4-5-6-9-7-8(16(10,11)12)17(13,14)15/h8-9H,2-7H2,1H3,(H2,10,11,12)(H2,13,14,15)
DM4ABTN CS CCCCCCNCC(P(=O)(O)O)P(=O)(O)O
DM4ABTN IK QDLXIUDMSHZYCG-UHFFFAOYSA-N
DM4ABTN IU [2-(hexylamino)-1-phosphonoethyl]phosphonic acid
DM4ABTN DE Discovery agent
DM9ZK0D ID DM9ZK0D
DM9ZK0D DN 1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid
DM9ZK0D HS Investigative
DM9ZK0D SN CHEMBL260601; 1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid; SCHEMBL11418940; BDBM50341916; 2-(octylamino)ethane-1,1-diyldiphosphonic acid; [2-(octylamino)-1-phosphono-ethyl]phosphonic acid
DM9ZK0D DT Small molecular drug
DM9ZK0D PC 44451417
DM9ZK0D MW 317.26
DM9ZK0D FM C10H25NO6P2
DM9ZK0D IC InChI=1S/C10H25NO6P2/c1-2-3-4-5-6-7-8-11-9-10(18(12,13)14)19(15,16)17/h10-11H,2-9H2,1H3,(H2,12,13,14)(H2,15,16,17)
DM9ZK0D CS CCCCCCCCNCC(P(=O)(O)O)P(=O)(O)O
DM9ZK0D IK NTUHKTMOLKDMDP-UHFFFAOYSA-N
DM9ZK0D IU [2-(octylamino)-1-phosphonoethyl]phosphonic acid
DM9ZK0D DE Discovery agent
DMCRHVI ID DMCRHVI
DMCRHVI DN 1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid
DMCRHVI HS Investigative
DMCRHVI SN CHEMBL408745; [2-(Propylamino)ethane-1,1-Diyl]bis(Phosphonic Acid); SCHEMBL7074253; BDBM50374757; [2-(Propylamino)ethylidene]bisphosphonic acid; [1-phosphono-2-(propylamino)ethyl]phosphonic acid
DMCRHVI DT Small molecular drug
DMCRHVI PC 15390273
DMCRHVI MW 247.12
DMCRHVI FM C5H15NO6P2
DMCRHVI IC InChI=1S/C5H15NO6P2/c1-2-3-6-4-5(13(7,8)9)14(10,11)12/h5-6H,2-4H2,1H3,(H2,7,8,9)(H2,10,11,12)
DMCRHVI CS CCCNCC(P(=O)(O)O)P(=O)(O)O
DMCRHVI IK YFFJUBPLIKXHAO-UHFFFAOYSA-N
DMCRHVI IU [1-phosphono-2-(propylamino)ethyl]phosphonic acid
DMCRHVI DE Discovery agent
DMSCN8J ID DMSCN8J
DMSCN8J DN 1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid
DMSCN8J HS Investigative
DMSCN8J SN CHEMBL407221; SCHEMBL8675602; BDBM50374764; [2-(isopropylamino)-1-phosphono-ethyl]phosphonic acid
DMSCN8J DT Small molecular drug
DMSCN8J PC 19689020
DMSCN8J MW 247.12
DMSCN8J FM C5H15NO6P2
DMSCN8J IC InChI=1S/C5H15NO6P2/c1-4(2)6-3-5(13(7,8)9)14(10,11)12/h4-6H,3H2,1-2H3,(H2,7,8,9)(H2,10,11,12)
DMSCN8J CS CC(C)NCC(P(=O)(O)O)P(=O)(O)O
DMSCN8J IK XUKNZUJYUAFJQJ-UHFFFAOYSA-N
DMSCN8J IU [1-phosphono-2-(propan-2-ylamino)ethyl]phosphonic acid
DMSCN8J DE Discovery agent
DMLDY3H ID DMLDY3H
DMLDY3H DN 1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid
DMLDY3H HS Investigative
DMLDY3H SN CHEMBL405827; SCHEMBL8677583; BDBM50374763; [2-(tert-butylamino)-1-phosphono-ethyl]phosphonic acid
DMLDY3H DT Small molecular drug
DMLDY3H PC 19689018
DMLDY3H MW 261.149
DMLDY3H FM C6H17NO6P2
DMLDY3H IC InChI=1S/C6H17NO6P2/c1-6(2,3)7-4-5(14(8,9)10)15(11,12)13/h5,7H,4H2,1-3H3,(H2,8,9,10)(H2,11,12,13)
DMLDY3H CS CC(C)(C)NCC(P(=O)(O)O)P(=O)(O)O
DMLDY3H IK XGRIOZQTBVXIFW-UHFFFAOYSA-N
DMLDY3H IU [2-(tert-butylamino)-1-phosphonoethyl]phosphonic acid
DMLDY3H DE Discovery agent
DMU3VWA ID DMU3VWA
DMU3VWA DN 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine
DMU3VWA HS Investigative
DMU3VWA SN CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione
DMU3VWA DT Small molecular drug
DMU3VWA PC 6477686
DMU3VWA MW 438.5
DMU3VWA FM C28H26N2O3
DMU3VWA IC InChI=1S/C28H26N2O3/c1-22-21-30(27(32)29-26(22)31)19-11-12-20-33-28(23-13-5-2-6-14-23,24-15-7-3-8-16-24)25-17-9-4-10-18-25/h2-18,21H,19-20H2,1H3,(H,29,31,32)/b12-11-
DMU3VWA CS CC1=CN(C(=O)NC1=O)C/C=C\\COC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMU3VWA IK BHMZJUVAVWRNLN-QXMHVHEDSA-N
DMU3VWA IU 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione
DMU3VWA DE Discovery agent
DMIHBFO ID DMIHBFO
DMIHBFO DN 1-[(Z)-4-trityloxy-2-butenyl]uracil
DMIHBFO HS Investigative
DMIHBFO SN CHEMBL377199; 1-[(Z)-4-trityloxy-2-butenyl]uracil; SCHEMBL12268304
DMIHBFO DT Small molecular drug
DMIHBFO PC 11704530
DMIHBFO MW 424.5
DMIHBFO FM C27H24N2O3
DMIHBFO IC InChI=1S/C27H24N2O3/c30-25-18-20-29(26(31)28-25)19-10-11-21-32-27(22-12-4-1-5-13-22,23-14-6-2-7-15-23)24-16-8-3-9-17-24/h1-18,20H,19,21H2,(H,28,30,31)/b11-10-
DMIHBFO CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC/C=C\\CN4C=CC(=O)NC4=O
DMIHBFO IK ISRBLVQOVMVNRK-KHPPLWFESA-N
DMIHBFO IU 1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione
DMIHBFO DE Discovery agent
DMEHP8M ID DMEHP8M
DMEHP8M DN 1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine
DMEHP8M HS Investigative
DMEHP8M SN CHEMBL272140
DMEHP8M DT Small molecular drug
DMEHP8M PC 44456331
DMEHP8M MW 217.35
DMEHP8M FM C15H23N
DMEHP8M IC InChI=1S/C15H23N/c1-12-10-13(2)15(14(3)11-12)6-9-16-7-4-5-8-16/h10-11H,4-9H2,1-3H3
DMEHP8M CS CC1=CC(=C(C(=C1)C)CCN2CCCC2)C
DMEHP8M IK IYOUBSBBWJSRIG-UHFFFAOYSA-N
DMEHP8M IU 1-[2-(2,4,6-trimethylphenyl)ethyl]pyrrolidine
DMEHP8M DE Discovery agent
DMTNRG7 ID DMTNRG7
DMTNRG7 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine
DMTNRG7 HS Investigative
DMTNRG7 SN CHEMBL364565; 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine; SCHEMBL8773745; BDBM50151048
DMTNRG7 DT Small molecular drug
DMTNRG7 PC 44396220
DMTNRG7 MW 295.4
DMTNRG7 FM C20H25NO
DMTNRG7 IC InChI=1S/C20H25NO/c1-3-9-18(10-4-1)17-19-11-5-6-12-20(19)22-16-15-21-13-7-2-8-14-21/h1,3-6,9-12H,2,7-8,13-17H2
DMTNRG7 CS C1CCN(CC1)CCOC2=CC=CC=C2CC3=CC=CC=C3
DMTNRG7 IK QKRCVHKKBOUVNT-UHFFFAOYSA-N
DMTNRG7 IU 1-[2-(2-benzylphenoxy)ethyl]piperidine
DMTNRG7 DE Discovery agent
DMLSU30 ID DMLSU30
DMLSU30 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine
DMLSU30 HS Investigative
DMLSU30 SN CHEMBL435505; 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine; BDBM50151045
DMLSU30 DT Small molecular drug
DMLSU30 PC 44396235
DMLSU30 MW 281.4
DMLSU30 FM C19H23NO
DMLSU30 IC InChI=1S/C19H23NO/c1-2-8-17(9-3-1)16-18-10-4-5-11-19(18)21-15-14-20-12-6-7-13-20/h1-5,8-11H,6-7,12-16H2
DMLSU30 CS C1CCN(C1)CCOC2=CC=CC=C2CC3=CC=CC=C3
DMLSU30 IK MNZXCYDDVWTITD-UHFFFAOYSA-N
DMLSU30 IU 1-[2-(2-benzylphenoxy)ethyl]pyrrolidine
DMLSU30 DE Discovery agent
DMDZA83 ID DMDZA83
DMDZA83 DN 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine
DMDZA83 HS Investigative
DMDZA83 SN CHEMBL219905; 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine
DMDZA83 DT Small molecular drug
DMDZA83 PC 16098875
DMDZA83 MW 456.5
DMDZA83 FM C28H28N2O4
DMDZA83 IC InChI=1S/C28H28N2O4/c1-22-21-30(27(32)29-26(22)31)17-18-33-19-20-34-28(23-11-5-2-6-12-23,24-13-7-3-8-14-24)25-15-9-4-10-16-25/h2-16,21H,17-20H2,1H3,(H,29,31,32)
DMDZA83 CS CC1=CN(C(=O)NC1=O)CCOCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMDZA83 IK XTVPTIAFWYQSSW-UHFFFAOYSA-N
DMDZA83 IU 5-methyl-1-[2-(2-trityloxyethoxy)ethyl]pyrimidine-2,4-dione
DMDZA83 DE Discovery agent
DM98F0U ID DM98F0U
DM98F0U DN 1-[2-(trityloxy)ethoxymethyl]uracil
DM98F0U HS Investigative
DM98F0U SN 1-[2-(trityloxy)ethoxymethyl]uracil; CHEMBL424704; SCHEMBL912787; US8530490, Comparative 1; QEKAGWDUKXATPZ-UHFFFAOYSA-N; BDBM50190553
DM98F0U DT Small molecular drug
DM98F0U PC 11750725
DM98F0U MW 428.5
DM98F0U FM C26H24N2O4
DM98F0U IC InChI=1S/C26H24N2O4/c29-24-16-17-28(25(30)27-24)20-31-18-19-32-26(21-10-4-1-5-11-21,22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-17H,18-20H2,(H,27,29,30)
DM98F0U CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCOCN4C=CC(=O)NC4=O
DM98F0U IK QEKAGWDUKXATPZ-UHFFFAOYSA-N
DM98F0U IU 1-(2-trityloxyethoxymethyl)pyrimidine-2,4-dione
DM98F0U DE Discovery agent
DMD2NXL ID DMD2NXL
DMD2NXL DN 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine
DMD2NXL HS Investigative
DMD2NXL SN CHEMBL187367; 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine; ZINC13581632
DMD2NXL DT Small molecular drug
DMD2NXL PC 11335419
DMD2NXL MW 295.4
DMD2NXL FM C20H25NO
DMD2NXL IC InChI=1S/C20H25NO/c1-2-9-18(10-3-1)17-19-11-4-5-12-20(19)22-16-8-15-21-13-6-7-14-21/h1-5,9-12H,6-8,13-17H2
DMD2NXL CS C1CCN(C1)CCCOC2=CC=CC=C2CC3=CC=CC=C3
DMD2NXL IK SECXHJRGBAZUCO-UHFFFAOYSA-N
DMD2NXL IU 1-[3-(2-benzylphenoxy)propyl]pyrrolidine
DMD2NXL DE Discovery agent
DMLRS8I ID DMLRS8I
DMLRS8I DN 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMLRS8I HS Investigative
DMLRS8I SN CHEMBL212743; SCHEMBL14506371; 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMLRS8I DT Small molecular drug
DMLRS8I PC 11580459
DMLRS8I MW 313.4
DMLRS8I FM C20H15N3O
DMLRS8I IC InChI=1S/C20H15N3O/c24-19-11-5-10-18(13-19)23-14-21-22-20(23)17-9-4-8-16(12-17)15-6-2-1-3-7-15/h1-14,24H
DMLRS8I CS C1=CC=C(C=C1)C2=CC(=CC=C2)C3=NN=CN3C4=CC(=CC=C4)O
DMLRS8I IK XGXZTGGFJHBJDN-UHFFFAOYSA-N
DMLRS8I IU 3-[3-(3-phenylphenyl)-1,2,4-triazol-4-yl]phenol
DMLRS8I DE Discovery agent
DMB1NF0 ID DMB1NF0
DMB1NF0 DN 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMB1NF0 HS Investigative
DMB1NF0 SN CHEMBL208801; 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol
DMB1NF0 DT Small molecular drug
DMB1NF0 PC 11645313
DMB1NF0 MW 313.4
DMB1NF0 FM C20H15N3O
DMB1NF0 IC InChI=1S/C20H15N3O/c24-19-8-4-7-18(13-19)23-14-21-22-20(23)17-11-9-16(10-12-17)15-5-2-1-3-6-15/h1-14,24H
DMB1NF0 CS C1=CC=C(C=C1)C2=CC=C(C=C2)C3=NN=CN3C4=CC(=CC=C4)O
DMB1NF0 IK MENDTFDIUWAVMQ-UHFFFAOYSA-N
DMB1NF0 IU 3-[3-(4-phenylphenyl)-1,2,4-triazol-4-yl]phenol
DMB1NF0 DE Discovery agent
DMS192I ID DMS192I
DMS192I DN 1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine
DMS192I HS Investigative
DMS192I SN CHEMBL596801; 1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine; SCHEMBL3453749; IIFAQXPNYXJBMU-UHFFFAOYSA-N; BDBM50308027
DMS192I DT Small molecular drug
DMS192I PC 11529282
DMS192I MW 282.4
DMS192I FM C14H22N2O2S
DMS192I IC InChI=1S/C14H22N2O2S/c1-3-7-15-8-10-16(11-9-15)13-5-4-6-14(12-13)19(2,17)18/h4-6,12H,3,7-11H2,1-2H3
DMS192I CS CCCN1CCN(CC1)C2=CC(=CC=C2)S(=O)(=O)C
DMS192I IK IIFAQXPNYXJBMU-UHFFFAOYSA-N
DMS192I IU 1-(3-methylsulfonylphenyl)-4-propylpiperazine
DMS192I DE Discovery agent
DME1R96 ID DME1R96
DME1R96 DN 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine
DME1R96 HS Investigative
DME1R96 SN 1-[4-(2-Oxo-2-Phenylethyl)phenyl]guanidine; SCHEMBL20553177; DB07122
DME1R96 DT Small molecular drug
DME1R96 PC 16758228
DME1R96 MW 253.3
DME1R96 FM C15H15N3O
DME1R96 IC InChI=1S/C15H15N3O/c16-15(17)18-13-8-6-11(7-9-13)10-14(19)12-4-2-1-3-5-12/h1-9H,10H2,(H4,16,17,18)
DME1R96 CS C1=CC=C(C=C1)C(=O)CC2=CC=C(C=C2)N=C(N)N
DME1R96 IK MERNPSIIBFTCAI-UHFFFAOYSA-N
DME1R96 IU 2-(4-phenacylphenyl)guanidine
DME1R96 DE Discovery agent
DM0I2RH ID DM0I2RH
DM0I2RH DN 1-[4-(4-Iodophenoxy)phenyl]piperazine
DM0I2RH HS Investigative
DM0I2RH SN CHEMBL567267; 1-[4-(4-Iodophenoxy)phenyl]piperazine; SCHEMBL13234979
DM0I2RH DT Small molecular drug
DM0I2RH PC 16039611
DM0I2RH MW 380.22
DM0I2RH FM C16H17IN2O
DM0I2RH IC InChI=1S/C16H17IN2O/c17-13-1-5-15(6-2-13)20-16-7-3-14(4-8-16)19-11-9-18-10-12-19/h1-8,18H,9-12H2
DM0I2RH CS C1CN(CCN1)C2=CC=C(C=C2)OC3=CC=C(C=C3)I
DM0I2RH IK AFIBQMXKOKSOEJ-UHFFFAOYSA-N
DM0I2RH IU 1-[4-(4-iodophenoxy)phenyl]piperazine
DM0I2RH DE Discovery agent
DM4F1GJ ID DM4F1GJ
DM4F1GJ DN 1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ol
DM4F1GJ HS Investigative
DM4F1GJ SN Benzthiazole compound, 33e; CHEMBL479752; SCHEMBL4692452; BDBM24232
DM4F1GJ DT Small molecular drug
DM4F1GJ PC 11473281
DM4F1GJ MW 340.4
DM4F1GJ FM C19H20N2O2S
DM4F1GJ IC InChI=1S/C19H20N2O2S/c22-15-9-11-21(12-10-15)13-14-5-7-16(8-6-14)23-19-20-17-3-1-2-4-18(17)24-19/h1-8,15,22H,9-13H2
DM4F1GJ CS C1CN(CCC1O)CC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DM4F1GJ IK CFTXJKKITUELKJ-UHFFFAOYSA-N
DM4F1GJ IU 1-[[4-(1,3-benzothiazol-2-yloxy)phenyl]methyl]piperidin-4-ol
DM4F1GJ DE Discovery agent
DMHXAMR ID DMHXAMR
DMHXAMR DN 1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil
DMHXAMR HS Investigative
DMHXAMR SN CHEMBL378101; 1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil; SCHEMBL913211
DMHXAMR DT Small molecular drug
DMHXAMR PC 11683928
DMHXAMR MW 455.5
DMHXAMR FM C28H29N3O3
DMHXAMR IC InChI=1S/C28H29N3O3/c32-21-22(16-18-31-19-17-26(33)30-27(31)34)20-29-28(23-10-4-1-5-11-23,24-12-6-2-7-13-24)25-14-8-3-9-15-25/h1-15,17,19,22,29,32H,16,18,20-21H2,(H,30,33,34)
DMHXAMR CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)NCC(CCN4C=CC(=O)NC4=O)CO
DMHXAMR IK AROLDFLIRWDCKX-UHFFFAOYSA-N
DMHXAMR IU 1-[3-(hydroxymethyl)-4-(tritylamino)butyl]pyrimidine-2,4-dione
DMHXAMR DE Discovery agent
DM8NMAV ID DM8NMAV
DM8NMAV DN 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine
DM8NMAV HS Investigative
DM8NMAV SN CHEMBL521211; 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine; BDBM50270649
DM8NMAV DT Small molecular drug
DM8NMAV PC 24857857
DM8NMAV MW 290.74
DM8NMAV FM C15H15ClN2O2
DM8NMAV IC InChI=1S/C15H15ClN2O2/c16-12-3-1-11(2-4-12)13-5-6-14(20-13)15(19)18-9-7-17-8-10-18/h1-6,17H,7-10H2
DM8NMAV CS C1CN(CCN1)C(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl
DM8NMAV IK FSVUGYFGMKVKHY-UHFFFAOYSA-N
DM8NMAV IU [5-(4-chlorophenyl)furan-2-yl]-piperazin-1-ylmethanone
DM8NMAV DE Discovery agent
DMFHBJM ID DMFHBJM
DMFHBJM DN 1-[5-(triphenylmethoxy)pentyl]thymine
DMFHBJM HS Investigative
DMFHBJM SN 1-[5-(triphenylmethoxy)pentyl]thymine; CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-
DMFHBJM DT Small molecular drug
DMFHBJM PC 16098859
DMFHBJM MW 454.6
DMFHBJM FM C29H30N2O3
DMFHBJM IC InChI=1S/C29H30N2O3/c1-23-22-31(28(33)30-27(23)32)20-12-5-13-21-34-29(24-14-6-2-7-15-24,25-16-8-3-9-17-25)26-18-10-4-11-19-26/h2-4,6-11,14-19,22H,5,12-13,20-21H2,1H3,(H,30,32,33)
DMFHBJM CS CC1=CN(C(=O)NC1=O)CCCCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMFHBJM IK SLJLMYFAIDHROH-UHFFFAOYSA-N
DMFHBJM IU 5-methyl-1-(5-trityloxypentyl)pyrimidine-2,4-dione
DMFHBJM CA CAS 921587-92-0
DMFHBJM DE Discovery agent
DM5NVHO ID DM5NVHO
DM5NVHO DN 1-[6-(triphenylmethoxy)hexyl]thymine
DM5NVHO HS Investigative
DM5NVHO SN 1-[6-(triphenylmethoxy)hexyl]thymine; CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-
DM5NVHO DT Small molecular drug
DM5NVHO PC 44418795
DM5NVHO MW 468.6
DM5NVHO FM C30H32N2O3
DM5NVHO IC InChI=1S/C30H32N2O3/c1-24-23-32(29(34)31-28(24)33)21-13-2-3-14-22-35-30(25-15-7-4-8-16-25,26-17-9-5-10-18-26)27-19-11-6-12-20-27/h4-12,15-20,23H,2-3,13-14,21-22H2,1H3,(H,31,33,34)
DM5NVHO CS CC1=CN(C(=O)NC1=O)CCCCCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DM5NVHO IK POQKPOUSJVGFHD-UHFFFAOYSA-N
DM5NVHO IU 5-methyl-1-(6-trityloxyhexyl)pyrimidine-2,4-dione
DM5NVHO CA CAS 921587-93-1
DM5NVHO DE Discovery agent
DMQ05F2 ID DMQ05F2
DMQ05F2 DN 1-[7-(triphenylmethoxy)heptyl]thymine
DMQ05F2 HS Investigative
DMQ05F2 SN 1-[7-(triphenylmethoxy)heptyl]thymine; CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-
DMQ05F2 DT Small molecular drug
DMQ05F2 PC 16098874
DMQ05F2 MW 482.6
DMQ05F2 FM C31H34N2O3
DMQ05F2 IC InChI=1S/C31H34N2O3/c1-25-24-33(30(35)32-29(25)34)22-14-3-2-4-15-23-36-31(26-16-8-5-9-17-26,27-18-10-6-11-19-27)28-20-12-7-13-21-28/h5-13,16-21,24H,2-4,14-15,22-23H2,1H3,(H,32,34,35)
DMQ05F2 CS CC1=CN(C(=O)NC1=O)CCCCCCCOC(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMQ05F2 IK MYFJLJCVSVNEDV-UHFFFAOYSA-N
DMQ05F2 IU 5-methyl-1-(7-trityloxyheptyl)pyrimidine-2,4-dione
DMQ05F2 CA CAS 921587-94-2
DMQ05F2 DE Discovery agent
DM13D4E ID DM13D4E
DM13D4E DN 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E HS Investigative
DM13D4E SN CHEMBL224904; 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E DT Small molecular drug
DM13D4E PC 11576518
DM13D4E MW 476.2
DM13D4E FM C20H16Br2N2S
DM13D4E IC InChI=1S/C20H16Br2N2S/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DM13D4E CS C1=CC=C(C=C1)NC(=S)NC(C2=CC=C(C=C2)Br)C3=CC=C(C=C3)Br
DM13D4E IK JQWBRSQRBYVWFQ-UHFFFAOYSA-N
DM13D4E IU 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea
DM13D4E DE Discovery agent
DMN2LHM ID DMN2LHM
DMN2LHM DN 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-
DMN2LHM HS Investigative
DMN2LHM SN CHEMBL224113; 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-; ZINC13676240
DMN2LHM DT Small molecular drug
DMN2LHM PC 11524275
DMN2LHM MW 405.7
DMN2LHM FM C20H15Cl3N2O
DMN2LHM IC InChI=1S/C20H15Cl3N2O/c21-15-5-1-13(2-6-15)19(14-3-7-16(22)8-4-14)25-20(26)24-18-11-9-17(23)10-12-18/h1-12,19H,(H2,24,25,26)
DMN2LHM CS C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)NC(=O)NC3=CC=C(C=C3)Cl)Cl
DMN2LHM IK IQLQNNIZPSPERD-UHFFFAOYSA-N
DMN2LHM IU 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)urea
DMN2LHM DE Discovery agent
DMFMR2N ID DMFMR2N
DMFMR2N DN 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea
DMFMR2N HS Investigative
DMFMR2N SN CHEMBL391003; 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea; ZINC13676247
DMFMR2N DT Small molecular drug
DMFMR2N PC 11552795
DMFMR2N MW 387.3
DMFMR2N FM C20H16Cl2N2S
DMFMR2N IC InChI=1S/C20H16Cl2N2S/c21-16-10-6-14(7-11-16)19(15-8-12-17(22)13-9-15)24-20(25)23-18-4-2-1-3-5-18/h1-13,19H,(H2,23,24,25)
DMFMR2N CS C1=CC=C(C=C1)NC(=S)NC(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl
DMFMR2N IK SYUQZYSPZLUEIG-UHFFFAOYSA-N
DMFMR2N IU 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea
DMFMR2N DE Discovery agent
DMJT7VI ID DMJT7VI
DMJT7VI DN 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI HS Investigative
DMJT7VI SN CHEMBL388398; 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI DT Small molecular drug
DMJT7VI PC 11498260
DMJT7VI MW 633.1
DMJT7VI FM C20H15BrI2N2O
DMJT7VI IC InChI=1S/C20H15BrI2N2O/c21-15-5-11-18(12-6-15)24-20(26)25-19(13-1-7-16(22)8-2-13)14-3-9-17(23)10-4-14/h1-12,19H,(H2,24,25,26)
DMJT7VI CS C1=CC(=CC=C1C(C2=CC=C(C=C2)I)NC(=O)NC3=CC=C(C=C3)Br)I
DMJT7VI IK ALTGZVPJBKOZHG-UHFFFAOYSA-N
DMJT7VI IU 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea
DMJT7VI DE Discovery agent
DML745Y ID DML745Y
DML745Y DN 10,10-difluoro TXA2
DML745Y HS Investigative
DML745Y SN 10,10-difluoro TXA2; GTPL6069; (Z)-7-[(1S,3R,4R,5R)-7,7-difluoro-3-[(E,3S)-3-hydroxyoct-1-enyl]-6-oxabicyclo[3.1.1]heptan-4-yl]hept-5-enoic acid
DML745Y DT Small molecular drug
DML745Y PC 73755171
DML745Y MW 386.5
DML745Y FM C21H32F2O4
DML745Y IC InChI=1S/C21H32F2O4/c1-2-3-6-9-16(24)13-12-15-14-18-21(22,23)20(27-18)17(15)10-7-4-5-8-11-19(25)26/h4,7,12-13,15-18,20,24H,2-3,5-6,8-11,14H2,1H3,(H,25,26)/b7-4-,13-12+/t15-,16-,17+,18-,20+/m0/s1
DML745Y CS CCCCC[C@@H](/C=C/[C@H]1C[C@H]2C([C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O2)(F)F)O
DML745Y IK CIYZUODQUHAGKZ-SCVXEUJASA-N
DML745Y IU (Z)-7-[(1R,2R,3R,5S)-7,7-difluoro-3-[(E,3S)-3-hydroxyoct-1-enyl]-6-oxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid
DML745Y DE Discovery agent
DMS5ICY ID DMS5ICY
DMS5ICY DN 10,11-dihydro-5H-dibenzo[b,f]azepine
DMS5ICY HS Investigative
DMS5ICY SN Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenzo[b,f]azepine; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N
DMS5ICY DT Small molecular drug
DMS5ICY PC 10308
DMS5ICY MW 195.26
DMS5ICY FM C14H13N
DMS5ICY IC InChI=1S/C14H13N/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)15-13/h1-8,15H,9-10H2
DMS5ICY CS C1CC2=CC=CC=C2NC3=CC=CC=C31
DMS5ICY IK ZSMRRZONCYIFNB-UHFFFAOYSA-N
DMS5ICY IU 6,11-dihydro-5H-benzo[b][1]benzazepine
DMS5ICY CA CAS 494-19-9
DMS5ICY DE Discovery agent
DM5BUXZ ID DM5BUXZ
DM5BUXZ DN 10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one
DM5BUXZ HS Investigative
DM5BUXZ SN 10-Acetyl dithranol; CCRIS 2039; CHEMBL339332; 3022-61-5; 10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one; 9(10H)-Anthracenone, 10-acetyl-1,8-dihydroxy-; 10-Acetylanthraline; AC1MIVB6; SCHEMBL10630399; DTXSID30184322; 1,8-Dihydroxy-10-acetylanthrone; JLVFGQSHNYEUIN-UHFFFAOYSA-N; 1,8-dihydroxy-10-acetyl anthrone; ZINC13606543; BDBM50060870
DM5BUXZ DT Small molecular drug
DM5BUXZ PC 3080591
DM5BUXZ MW 268.26
DM5BUXZ FM C16H12O4
DM5BUXZ IC InChI=1S/C16H12O4/c1-8(17)13-9-4-2-6-11(18)14(9)16(20)15-10(13)5-3-7-12(15)19/h2-7,13,18-19H,1H3
DM5BUXZ CS CC(=O)C1C2=C(C(=CC=C2)O)C(=O)C3=C1C=CC=C3O
DM5BUXZ IK JLVFGQSHNYEUIN-UHFFFAOYSA-N
DM5BUXZ IU 10-acetyl-1,8-dihydroxy-10H-anthracen-9-one
DM5BUXZ CA CAS 3022-61-5
DM5BUXZ DE Discovery agent
DM1JLUV ID DM1JLUV
DM1JLUV DN 10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DM1JLUV HS Investigative
DM1JLUV SN 10Allyl-DBOA-11one; 10-Ally-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-46-7; 10-Ally-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 11; AC1L9R9L; CHEMBL301443; BDBM1972; DTXSID50159537; 5-allylbenzo[b][1,4]benzoxazepin-6-one; 5-prop-2-enylbenzo[b][1,4]benzoxazepin-6-one; 10-(2-Propenyl)dibenz[b,f][1,4]oxazepin-11(10H)-one
DM1JLUV DT Small molecular drug
DM1JLUV PC 453916
DM1JLUV MW 251.28
DM1JLUV FM C16H13NO2
DM1JLUV IC InChI=1S/C16H13NO2/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h2-10H,1,11H2
DM1JLUV CS C=CCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DM1JLUV IK QANXXCPLBYYJSG-UHFFFAOYSA-N
DM1JLUV IU 5-prop-2-enylbenzo[b][1,4]benzoxazepin-6-one
DM1JLUV CA CAS 135810-46-7
DM1JLUV DE Discovery agent
DM4M2VU ID DM4M2VU
DM4M2VU DN 10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one
DM4M2VU HS Investigative
DM4M2VU SN CHEMBL123724; 10-benzoyl-1,8-dihydroxy-10H-anthracen-9-one; BDBM50060881
DM4M2VU DT Small molecular drug
DM4M2VU PC 10592514
DM4M2VU MW 330.3
DM4M2VU FM C21H14O4
DM4M2VU IC InChI=1S/C21H14O4/c22-15-10-4-8-13-17(20(24)12-6-2-1-3-7-12)14-9-5-11-16(23)19(14)21(25)18(13)15/h1-11,17,22-23H
DM4M2VU CS C1=CC=C(C=C1)C(=O)C2C3=C(C(=CC=C3)O)C(=O)C4=C2C=CC=C4O
DM4M2VU IK ZIWVGWPZACHOMW-UHFFFAOYSA-N
DM4M2VU IU 10-benzoyl-1,8-dihydroxy-10H-anthracen-9-one
DM4M2VU DE Discovery agent
DMQOUJ7 ID DMQOUJ7
DMQOUJ7 DN 10-CF3C(OH)2-DDACTHF
DMQOUJ7 HS Investigative
DMQOUJ7 SN Hydrolyzed Form of 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid
DMQOUJ7 DT Small molecular drug
DMQOUJ7 PC 46936711
DMQOUJ7 MW 549.5
DMQOUJ7 FM C22H30F3N5O8
DMQOUJ7 IC InChI=1S/C22H30F3N5O8/c23-22(24,25)21(37,38)13(3-1-2-12-16(26)29-20(27)30-18(12)34)10-4-6-11(7-5-10)17(33)28-14(19(35)36)8-9-15(31)32/h4-7,12-14,16,20,29,37-38H,1-3,8-9,26-27H2,(H,28,33)(H,30,34)(H,31,32)(H,35,36)/t12-,13+,14-,16+,20-/m1/s1
DMQOUJ7 CS C1=CC(=CC=C1[C@H](CCC[C@@H]2[C@H](N[C@H](NC2=O)N)N)C(C(F)(F)F)(O)O)C(=O)N[C@H](CCC(=O)O)C(=O)O
DMQOUJ7 IK KOLDLUFBEMUZIM-WUAYEBGVSA-N
DMQOUJ7 IU (2R)-2-[[4-[(3S)-6-[(2R,4S,5R)-2,4-diamino-6-oxo-1,3-diazinan-5-yl]-1,1,1-trifluoro-2,2-dihydroxyhexan-3-yl]benzoyl]amino]pentanedioic acid
DMQOUJ7 DE Discovery agent
DMDQ7Z9 ID DMDQ7Z9
DMDQ7Z9 DN 10-EPI-8-DEOXY-CUMAMBRIN B
DMDQ7Z9 HS Investigative
DMDQ7Z9 SN 10-Epi-8-deoxy-cumambrin B; CHEMBL1099308
DMDQ7Z9 DT Small molecular drug
DMDQ7Z9 PC 46887018
DMDQ7Z9 MW 218.29
DMDQ7Z9 FM C14H18O2
DMDQ7Z9 IC InChI=1S/C14H18O2/c1-8-6-7-10-4-3-5-11-9(2)14(15)16-13(11)12(8)10/h6,10-13H,2-5,7H2,1H3/t10-,11+,12+,13+/m1/s1
DMDQ7Z9 CS CC1=CC[C@@H]2[C@H]1[C@@H]3[C@@H](CCC2)C(=C)C(=O)O3
DMDQ7Z9 IK PFGQZVWFUUWHOT-VOAKCMCISA-N
DMDQ7Z9 IU (3aS,6aR,9aR,9bS)-9-methyl-3-methylidene-3a,4,5,6,6a,7,9a,9b-octahydroazuleno[4,5-b]furan-2-one
DMDQ7Z9 DE Discovery agent
DMGT82V ID DMGT82V
DMGT82V DN 10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMGT82V HS Investigative
DMGT82V SN 10Et-DBOA-11one; 10-Ethyl-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 17296-50-3; 5-ethylbenzo[b][1,4]benzoxazepin-6-one; 10-Ethyl-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 10; AC1L9R9K; CHEMBL299710; BDBM1971; SCHEMBL8401275; DTXSID20169441; ZINC6385234; 10-Ethyldibenz[b,f][1,4]oxazepin-11(10H)-one
DMGT82V DT Small molecular drug
DMGT82V PC 453915
DMGT82V MW 239.27
DMGT82V FM C15H13NO2
DMGT82V IC InChI=1S/C15H13NO2/c1-2-16-12-8-4-6-10-14(12)18-13-9-5-3-7-11(13)15(16)17/h3-10H,2H2,1H3
DMGT82V CS CCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DMGT82V IK MRBRHCRUXKHKKI-UHFFFAOYSA-N
DMGT82V IU 5-ethylbenzo[b][1,4]benzoxazepin-6-one
DMGT82V CA CAS 17296-50-3
DMGT82V DE Discovery agent
DMEBHML ID DMEBHML
DMEBHML DN 10-Formyl-5,8,10-Trideazafolic Acid
DMEBHML HS Investigative
DMEBHML SN 10-formyl-5,8,10-trideazafolic
DMEBHML DT Small molecular drug
DMEBHML PC 135460967
DMEBHML MW 482.4
DMEBHML FM C23H22N4O8
DMEBHML IC InChI=1S/C23H22N4O8/c24-23-26-16-6-1-11(10-15(16)20(31)27-23)9-14(21(32)33)12-2-4-13(5-3-12)19(30)25-17(22(34)35)7-8-18(28)29/h1-6,10,14,17H,7-9H2,(H,25,30)(H,28,29)(H,32,33)(H,34,35)(H3,24,26,27,31)/t14-,17-/m0/s1
DMEBHML CS C1=CC(=CC=C1[C@H](CC2=CC3=C(C=C2)N=C(NC3=O)N)C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMEBHML IK DAOQLLQRJAXMGY-YOEHRIQHSA-N
DMEBHML IU (2S)-2-[[4-[(1S)-2-(2-amino-4-oxo-3H-quinazolin-6-yl)-1-carboxyethyl]benzoyl]amino]pentanedioic acid
DMEBHML DE Discovery agent
DM4R7X8 ID DM4R7X8
DM4R7X8 DN 10-hydroxy-18-methoxybetaenone
DM4R7X8 HS Investigative
DM4R7X8 SN CHEMBL498247; 10-hydroxy-18-methoxybetaenone; BDBM50269144
DM4R7X8 DT Small molecular drug
DM4R7X8 PC 10644450
DM4R7X8 MW 396.5
DM4R7X8 FM C22H36O6
DM4R7X8 IC InChI=1S/C22H36O6/c1-8-13(2)16-20(5,15(23)9-10-28-7)17-14(3)11-19(4,25)12-22(17,27)18(24)21(16,6)26/h9-10,13-14,16-17,25-27H,8,11-12H2,1-7H3/b10-9+/t13?,14-,16-,17-,19-,20-,21+,22-/m1/s1
DM4R7X8 CS CCC(C)[C@@H]1[C@@]([C@H]2[C@@H](C[C@@](C[C@@]2(C(=O)[C@@]1(C)O)O)(C)O)C)(C)C(=O)/C=C/OC
DM4R7X8 IK ONZDNBGTAVEQQN-FJXLOMMUSA-N
DM4R7X8 IU (2S,3R,4R,4aR,5R,7R,8aR)-3-butan-2-yl-2,7,8a-trihydroxy-4-[(E)-3-methoxyprop-2-enoyl]-2,4,5,7-tetramethyl-4a,5,6,8-tetrahydro-3H-naphthalen-1-one
DM4R7X8 DE Discovery agent
DM9WLN4 ID DM9WLN4
DM9WLN4 DN 10-hydroxycamptothecin
DM9WLN4 HS Investigative
DM9WLN4 SN 10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-Hydroxy camptothecin; Hydroxycamptothecine; Camptothecin, hydroxy-; 10-Hydroxy-Camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Camptothecin, 10-hydroxy-; Camptothecine, 10-hydroxy-; UNII-9Z01632KRV; NSC 107124; HCPT; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-Hydroxycamptothecin hydrate; NSC107124
DM9WLN4 DT Small molecular drug
DM9WLN4 PC 97226
DM9WLN4 MW 364.4
DM9WLN4 FM C20H16N2O5
DM9WLN4 IC InChI=1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1
DM9WLN4 CS CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O
DM9WLN4 IK HAWSQZCWOQZXHI-FQEVSTJZSA-N
DM9WLN4 IU (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
DM9WLN4 CA CAS 19685-09-7
DM9WLN4 CB CHEBI:81395
DM9WLN4 DE Discovery agent
DM5H73W ID DM5H73W
DM5H73W DN 10-Hydroxy-infractopicrin
DM5H73W HS Investigative
DM5H73W SN 10-Hydroxy-infractopicrin
DM5H73W DT Small molecular drug
DM5H73W PC 46228997
DM5H73W MW 312.7
DM5H73W FM C17H13ClN2O2
DM5H73W IC InChI=1S/C17H12N2O2.ClH/c20-11-3-4-14-13(9-11)12-5-7-18-6-1-2-10-8-15(21)19(14)17(12)16(10)18;/h3-5,7-9H,1-2,6H2;1H
DM5H73W CS C1CC2=CC(=O)N3C4=C(C=C(C=C4)O)C5=C3C2=[N+](C1)C=C5.[Cl-]
DM5H73W IK NTHWONPMICHNIA-UHFFFAOYSA-N
DM5H73W IU 5-hydroxy-1-aza-11-azoniapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2(7),3,5,8(18),9,11(19),15-heptaen-17-one;chloride
DM5H73W DE Discovery agent
DMCXA1Y ID DMCXA1Y
DMCXA1Y DN 10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMCXA1Y HS Investigative
DMCXA1Y SN 10iPr-DBOA-11one; 10-Isopropyl-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-42-3; 10-Isopropyl-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 12; AC1L9R9N; CHEMBL56567; SCHEMBL7955434; BDBM1974; DTXSID10159533; ACJZSMFIMMQNTP-UHFFFAOYSA-N; 5-isopropylbenzo[b][1,4]benzoxazepin-6-one; 5-propan-2-ylbenzo[b][1,4]benzoxazepin-6-one; 10-Isopropyldibenz[b,f][1,4]oxazepin-11(10H)-one; 10-isopropyl-10H-dibenz[b,f][1,4]oxazepin-11-one
DMCXA1Y DT Small molecular drug
DMCXA1Y PC 453918
DMCXA1Y MW 253.29
DMCXA1Y FM C16H15NO2
DMCXA1Y IC InChI=1S/C16H15NO2/c1-11(2)17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h3-11H,1-2H3
DMCXA1Y CS CC(C)N1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DMCXA1Y IK ACJZSMFIMMQNTP-UHFFFAOYSA-N
DMCXA1Y IU 5-propan-2-ylbenzo[b][1,4]benzoxazepin-6-one
DMCXA1Y CA CAS 135810-42-3
DMCXA1Y DE Discovery agent
DM2H6KD ID DM2H6KD
DM2H6KD DN 10-methoxy-ginkgolide C
DM2H6KD HS Investigative
DM2H6KD SN 10-methoxy-ginkgolide C; CHEMBL221823
DM2H6KD DT Small molecular drug
DM2H6KD PC 44420890
DM2H6KD MW 454.4
DM2H6KD FM C21H26O11
DM2H6KD IC InChI=1S/C21H26O11/c1-6-13(24)29-11-10(23)19-7-8(22)9(17(2,3)4)18(19)12(28-5)15(26)30-16(18)32-21(19,20(6,11)27)31-14(7)25/h6-12,16,22-23,27H,1-5H3/t6-,7+,8+,9+,10+,11+,12+,16+,18+,19+,20-,21+/m1/s1
DM2H6KD CS C[C@@H]1C(=O)O[C@@H]2[C@]1([C@]34[C@]5([C@H]2O)[C@@H]([C@@H]([C@H]([C@@]56[C@H](C(=O)O[C@H]6O3)OC)C(C)(C)C)O)C(=O)O4)O
DM2H6KD IK RYOIKJMKJWXJLR-XWGAEZTCSA-N
DM2H6KD IU (1R,3R,6R,7S,8S,9R,10S,11R,12R,13S,16S,17R)-8-tert-butyl-9,12,17-trihydroxy-6-methoxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,19-trione
DM2H6KD DE Discovery agent
DMJW25X ID DMJW25X
DMJW25X DN 10-methoxy-N(1)-methylburnamine-17-O-veratrate
DMJW25X HS Investigative
DMJW25X SN CHEMBL592603; 10-methoxy-N(1)-methylburnamine-17-O-veratrate
DMJW25X DT Small molecular drug
DMJW25X PC 46229075
DMJW25X MW 576.6
DMJW25X FM C32H36N2O8
DMJW25X IC InChI=1S/C32H36N2O8/c1-7-18-16-34-26-14-21(18)30(29(36)40-6,17-41-28(35)19-8-11-24(38-4)25(12-19)39-5)31-15-27(34)42-32(26,31)33(2)23-10-9-20(37-3)13-22(23)31/h7-13,21,26-27H,14-17H2,1-6H3/b18-7-/t21-,26-,27-,30-,31-,32-/m0/s1
DMJW25X CS C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(N(C6=C4C=C(C=C6)OC)C)O[C@H]2C5)(COC(=O)C7=CC(=C(C=C7)OC)OC)C(=O)OC
DMJW25X IK DTINADCHYFZWSG-BUVDGYSPSA-N
DMJW25X IU methyl (1R,9S,11S,14E,15S,17S,19R)-19-[(3,4-dimethoxybenzoyl)oxymethyl]-14-ethylidene-6-methoxy-2-methyl-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3(8),4,6-triene-19-carboxylate
DMJW25X DE Discovery agent
DMM9GEA ID DMM9GEA
DMM9GEA DN 10-OBn-7alpha-F-gingkolide B
DMM9GEA HS Investigative
DMM9GEA SN compound 17 [PMID: 12570381]
DMM9GEA DT Small molecular drug
DMM9GEA PC 73755010
DMM9GEA MW 532.5
DMM9GEA FM C27H29FO10
DMM9GEA IC InChI=1S/C27H29FO10/c1-11-19(30)35-17-15(29)25-16-13(28)14(23(2,3)4)24(25)18(34-10-12-8-6-5-7-9-12)20(31)37-22(24)38-27(25,21(32)36-16)26(11,17)33/h5-9,11,13-18,22,29,33H,10H2,1-4H3/t11?,13-,14?,15?,16?,17-,18-,22?,24?,25?,26+,27-/m0/s1
DMM9GEA CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C([C@@H]5F)C(C)(C)C)O
DMM9GEA IK LFVHCLPCEWRXME-CLNXZACASA-N
DMM9GEA IU (1S,6R,9S,13S,17R)-8-tert-butyl-9-fluoro-12,17-dihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMM9GEA DE Discovery agent
DMAM5WJ ID DMAM5WJ
DMAM5WJ DN 10-OBn-epi-ginkgolide C
DMAM5WJ HS Investigative
DMAM5WJ SN 10-OBn-epi-ginkgolide C; 10-OBn-epi-GC
DMAM5WJ DT Small molecular drug
DMAM5WJ PC 73755013
DMAM5WJ MW 530.5
DMAM5WJ FM C27H30O11
DMAM5WJ IC InChI=1S/C27H30O11/c1-11-19(30)35-17-15(29)25-16-13(28)14(23(2,3)4)24(25)18(34-10-12-8-6-5-7-9-12)20(31)37-22(24)38-27(25,21(32)36-16)26(11,17)33/h5-9,11,13-18,22,28-29,33H,10H2,1-4H3/t11?,13-,14?,15?,16?,17-,18-,22?,24?,25?,26+,27-/m0/s1
DMAM5WJ CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C([C@@H]5O)C(C)(C)C)O
DMAM5WJ IK YPOMAFCMSAKBRX-CLNXZACASA-N
DMAM5WJ IU (1S,6R,9S,13S,17R)-8-tert-butyl-9,12,17-trihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMAM5WJ DE Discovery agent
DMS0I5V ID DMS0I5V
DMS0I5V DN 10-OBn-ginkgolide B
DMS0I5V HS Investigative
DMS0I5V SN 10-OBn-ginkgolide B; 10-OBn-GB
DMS0I5V DT Small molecular drug
DMS0I5V PC 73755011
DMS0I5V MW 514.5
DMS0I5V FM C27H30O10
DMS0I5V IC InChI=1S/C27H30O10/c1-12-19(29)35-17-16(28)25-15-10-14(23(2,3)4)24(25)18(33-11-13-8-6-5-7-9-13)20(30)36-22(24)37-27(25,21(31)34-15)26(12,17)32/h5-9,12,14-18,22,28,32H,10-11H2,1-4H3/t12?,14?,15?,16?,17-,18-,22?,24?,25?,26+,27-/m0/s1
DMS0I5V CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C(C5)C(C)(C)C)O
DMS0I5V IK PHJOWQWLQBFEEM-ZTPSGWAGSA-N
DMS0I5V IU (1S,6R,13S,17R)-8-tert-butyl-12,17-dihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMS0I5V DE Discovery agent
DMOXKLH ID DMOXKLH
DMOXKLH DN 10-OBn-ginkgolide C
DMOXKLH HS Investigative
DMOXKLH SN 10-OBn-ginkgolide C; 10-OBn-GC
DMOXKLH DT Small molecular drug
DMOXKLH PC 73755012
DMOXKLH MW 530.5
DMOXKLH FM C27H30O11
DMOXKLH IC InChI=1S/C27H30O11/c1-11-19(30)35-17-15(29)25-16-13(28)14(23(2,3)4)24(25)18(34-10-12-8-6-5-7-9-12)20(31)37-22(24)38-27(25,21(32)36-16)26(11,17)33/h5-9,11,13-18,22,28-29,33H,10H2,1-4H3/t11?,13-,14?,15?,16?,17+,18+,22?,24?,25?,26-,27+/m1/s1
DMOXKLH CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)OCC7=CC=CC=C7)C([C@H]5O)C(C)(C)C)O
DMOXKLH IK YPOMAFCMSAKBRX-WULOTIIESA-N
DMOXKLH IU (1S,6R,9R,13S,17R)-8-tert-butyl-9,12,17-trihydroxy-16-methyl-6-phenylmethoxy-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMOXKLH DE Discovery agent
DMR3A5N ID DMR3A5N
DMR3A5N DN 10-Propargyl-5,8-Dideazafolic Acid
DMR3A5N HS Investigative
DMR3A5N DT Small molecular drug
DMR3A5N PC 135438608
DMR3A5N MW 477.5
DMR3A5N FM C24H23N5O6
DMR3A5N IC InChI=1S/C24H23N5O6/c1-2-11-29(13-14-3-8-18-17(12-14)22(33)28-24(25)27-18)16-6-4-15(5-7-16)21(32)26-19(23(34)35)9-10-20(30)31/h1,3-8,12,19H,9-11,13H2,(H,26,32)(H,30,31)(H,34,35)(H3,25,27,28,33)/t19-/m0/s1
DMR3A5N CS C#CCN(CC1=CC2=C(C=C1)N=C(NC2=O)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMR3A5N IK LTKHPMDRMUCUEB-IBGZPJMESA-N
DMR3A5N IU (2S)-2-[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]benzoyl]amino]pentanedioic acid
DMR3A5N CA CAS 76849-19-9
DMR3A5N CB CHEBI:3258
DMD1258 ID DMD1258
DMD1258 DN 10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
DMD1258 HS Investigative
DMD1258 SN 10Pr-DBOA-11one; 10-Propyl-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-41-2; 5-propylbenzo[b][1,4]benzoxazepin-6-one; 10-Propyl-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 1; AC1L9R9M; CHEMBL56451; SCHEMBL9004262; BDBM1973; DTXSID50159532; OGPOBJPKGVLINB-UHFFFAOYSA-N; 10-propyl-10H-dibenz[b,f][1.4]oxazepin-11-one; 10-Propyldibenz[b,f][1,4]oxazepin-11(10H)-one
DMD1258 DT Small molecular drug
DMD1258 PC 453917
DMD1258 MW 253.29
DMD1258 FM C16H15NO2
DMD1258 IC InChI=1S/C16H15NO2/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h3-10H,2,11H2,1H3
DMD1258 CS CCCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
DMD1258 IK OGPOBJPKGVLINB-UHFFFAOYSA-N
DMD1258 IU 5-propylbenzo[b][1,4]benzoxazepin-6-one
DMD1258 CA CAS 135810-41-2
DMD1258 DE Discovery agent
DMZ3N8A ID DMZ3N8A
DMZ3N8A DN 10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one
DMZ3N8A HS Investigative
DMZ3N8A SN 10Pr-DBTA-11one; 10-Propyl-dibenz(b,f)(1,4)thiazepin-11-(10H)-one; 135810-44-5; 5-propylbenzo[b][1,4]benzothiazepin-6-one; 10-Propyl-dibenz[b,f][1,4]thiazepin-11-(10H)-one; Dibenzoxazepinone 5; AC1L9R9G; CHEMBL55258; BDBM1994; SCHEMBL9004259; DTXSID30159535; ARJSKRFEYLKXQL-UHFFFAOYSA-N; 10-Propyldibenzo[b,f][1,4]thiazepin-11(10H)-one; 10-n-propyl-dibenz[b,f][1,4]thiazepin-11(10H)-one
DMZ3N8A DT Small molecular drug
DMZ3N8A PC 453911
DMZ3N8A MW 269.4
DMZ3N8A FM C16H15NOS
DMZ3N8A IC InChI=1S/C16H15NOS/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h3-10H,2,11H2,1H3
DMZ3N8A CS CCCN1C2=CC=CC=C2SC3=CC=CC=C3C1=O
DMZ3N8A IK ARJSKRFEYLKXQL-UHFFFAOYSA-N
DMZ3N8A IU 5-propylbenzo[b][1,4]benzothiazepin-6-one
DMZ3N8A CA CAS 135810-44-5
DMZ3N8A DE Discovery agent
DM8XRCT ID DM8XRCT
DM8XRCT DN 10R-hydroxylobel-7-ene
DM8XRCT HS Investigative
DM8XRCT SN CHEMBL217815; 10R-hydroxylobel-7-ene
DM8XRCT DT Small molecular drug
DM8XRCT PC 44416422
DM8XRCT MW 321.5
DM8XRCT FM C22H27NO
DM8XRCT IC InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22-/m1/s1
DM8XRCT CS CN1[C@@H](CCC[C@@H]1/C=C/C2=CC=CC=C2)C[C@H](C3=CC=CC=C3)O
DM8XRCT IK IKYXUFYHDWVXST-LRGONLHBSA-N
DM8XRCT IU (1R)-2-[(2S,6R)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DM8XRCT DE Discovery agent
DMN93QT ID DMN93QT
DMN93QT DN 10R-hydroxylobelane
DMN93QT HS Investigative
DMN93QT SN 10R-hydroxylobelane; CHEMBL213148
DMN93QT DT Small molecular drug
DMN93QT PC 44416453
DMN93QT MW 323.5
DMN93QT FM C22H29NO
DMN93QT IC InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22-/m1/s1
DMN93QT CS CN1[C@H](CCC[C@H]1C[C@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMN93QT IK MUSFCRGEWKAWEE-BHIFYINESA-N
DMN93QT IU (1R)-2-[(2S,6R)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DMN93QT DE Discovery agent
DMN1YQ6 ID DMN1YQ6
DMN1YQ6 DN 10S-hydroxylobel-7-ene
DMN1YQ6 HS Investigative
DMN1YQ6 SN CHEMBL124219; 10S-hydroxylobel-7-ene; SCHEMBL14178950; BDBM50080826; (S)-1-Phenyl-2-(1-methyl-6alpha-trans-styryl-2alpha-piperidinyl)ethanol
DMN1YQ6 DT Small molecular drug
DMN1YQ6 PC 10687251
DMN1YQ6 MW 321.5
DMN1YQ6 FM C22H27NO
DMN1YQ6 IC InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22+/m1/s1
DMN1YQ6 CS CN1[C@@H](CCC[C@@H]1/C=C/C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMN1YQ6 IK IKYXUFYHDWVXST-XIGZGLEXSA-N
DMN1YQ6 IU (1S)-2-[(2S,6R)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DMN1YQ6 DE Discovery agent
DM54AKV ID DM54AKV
DM54AKV DN 10S-hydroxylobelane
DM54AKV HS Investigative
DM54AKV SN 10S-hydroxylobelane; CHEMBL122317; SCHEMBL14178961; BDBM50080814; (S)-2-((2S,6R)-1-Methyl-6-phenethyl-piperidin-2-yl)-1-phenyl-ethanol
DM54AKV DT Small molecular drug
DM54AKV PC 10782199
DM54AKV MW 323.5
DM54AKV FM C22H29NO
DM54AKV IC InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22+/m1/s1
DM54AKV CS CN1[C@H](CCC[C@H]1C[C@@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DM54AKV IK MUSFCRGEWKAWEE-FSSWDIPSSA-N
DM54AKV IU (1S)-2-[(2S,6R)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DM54AKV DE Discovery agent
DMEAGI6 ID DMEAGI6
DMEAGI6 DN 10-trifluoroacetyl-DDACTHF
DMEAGI6 HS Investigative
DMEAGI6 DT Small molecular drug
DMEAGI6 PC 135929093
DMEAGI6 MW 527.4
DMEAGI6 FM C22H24F3N5O7
DMEAGI6 IC InChI=1S/C22H24F3N5O7/c23-22(24,25)16(33)12(2-1-3-13-17(26)29-21(27)30-19(13)35)10-4-6-11(7-5-10)18(34)28-14(20(36)37)8-9-15(31)32/h4-7,12,14H,1-3,8-9H2,(H,28,34)(H,31,32)(H,36,37)(H5,26,27,29,30,35)
DMEAGI6 CS C1=CC(=CC=C1C(CCCC2=C(N=C(NC2=O)N)N)C(=O)C(F)(F)F)C(=O)NC(CCC(=O)O)C(=O)O
DMEAGI6 IK GMLVQBYTPQKEQF-UHFFFAOYSA-N
DMEAGI6 IU 2-[[4-[6-(2,4-diamino-6-oxo-1H-pyrimidin-5-yl)-1,1,1-trifluoro-2-oxohexan-3-yl]benzoyl]amino]pentanedioic acid
DMEAGI6 DE Discovery agent
DMIRSA5 ID DMIRSA5
DMIRSA5 DN 10Z-Hymenialdisine
DMIRSA5 HS Investigative
DMIRSA5 SN Hymenialdisine; (Z)-Hymenialdisine; CHEMBL361708; 95569-43-0; 82005-12-7; (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; Hymenialdisine, 1; 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one; AC1MHZEP; SCHEMBL155899; STO156; BDBM7491; SCHEMBL15426167; MolPort-006-394-608; 4-(2-Amino-5-oxo-3,5-dihydro-imidazol-4-ylidene)-2-bromo-4,5,6,7-tetrahydro-1H-pyrrolo[2,3-c]azepin-8-one; NSC607173
DMIRSA5 DT Small molecular drug
DMIRSA5 PC 135413546
DMIRSA5 MW 324.13
DMIRSA5 FM C11H10BrN5O2
DMIRSA5 IC InChI=1S/C11H10BrN5O2/c12-6-3-5-4(7-10(19)17-11(13)16-7)1-2-14-9(18)8(5)15-6/h3,15H,1-2H2,(H,14,18)(H3,13,16,17,19)/b7-4-
DMIRSA5 CS C\\1CNC(=O)C2=C(/C1=C\\3/C(=O)NC(=N3)N)C=C(N2)Br
DMIRSA5 IK ATBAETXFFCOZOY-DAXSKMNVSA-N
DMIRSA5 IU (4Z)-4-(2-amino-5-oxo-1H-imidazol-4-ylidene)-2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one
DMIRSA5 CA CAS 82005-12-7
DMIRSA5 DE Discovery agent
DME0OGM ID DME0OGM
DME0OGM DN 11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione
DME0OGM HS Investigative
DME0OGM SN AC1MBM6T; CHEMBL235931; SCHEMBL13712393; ZINC3848035; AKOS004901956
DME0OGM DT Small molecular drug
DME0OGM PC 2752926
DME0OGM MW 236.26
DME0OGM FM C16H12O2
DME0OGM IC InChI=1S/C16H12O2/c17-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)16(15)18/h1-8H,9-10H2
DME0OGM CS C1CC2=CC=CC=C2C(=O)C(=O)C3=CC=CC=C31
DME0OGM IK FBFVXHNJGVOZPS-UHFFFAOYSA-N
DME0OGM IU tricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaene-2,3-dione
DME0OGM DE Discovery agent
DMFVP6K ID DMFVP6K
DMFVP6K DN 11A1
DMFVP6K HS Investigative
DMFVP6K CP Tokyo Metropolitan Institute of Gerontology
DMFVP6K DT Antibody
DMFVP6K DE Alzheimer disease
DM0EPJT ID DM0EPJT
DM0EPJT DN 11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B
DM0EPJT HS Investigative
DM0EPJT SN CHEMBL1097371; 11beta,13-Dihydro-10-epi-8-deoxycumam-brin B; BDBM50318411; LS-23585; 11betaH,13-Dihydro-10-epi-8-deoxycumambrin B
DM0EPJT DT Small molecular drug
DM0EPJT PC 10354739
DM0EPJT MW 250.33
DM0EPJT FM C15H22O3
DM0EPJT IC InChI=1S/C15H22O3/c1-8-4-5-11-12(8)13-10(6-7-15(11,3)17)9(2)14(16)18-13/h4,9-13,17H,5-7H2,1-3H3/t9-,10-,11+,12-,13-,15-/m0/s1
DM0EPJT CS C[C@H]1[C@@H]2CC[C@]([C@@H]3CC=C([C@@H]3[C@H]2OC1=O)C)(C)O
DM0EPJT IK CWACFPQPFUIHTR-WBSYEDSCSA-N
DM0EPJT IU (3S,3aS,6S,6aR,9aR,9bS)-6-hydroxy-3,6,9-trimethyl-3,3a,4,5,6a,7,9a,9b-octahydroazuleno[4,5-b]furan-2-one
DM0EPJT DE Discovery agent
DMH5QEA ID DMH5QEA
DMH5QEA DN 11-Butyryloxy-N-n-propylnoraporphine
DMH5QEA HS Investigative
DMH5QEA SN CHEMBL478671; 11-Butyryloxy-N-n-propylnoraporphine
DMH5QEA DT Small molecular drug
DMH5QEA PC 25141414
DMH5QEA MW 349.5
DMH5QEA FM C23H27NO2
DMH5QEA IC InChI=1S/C23H27NO2/c1-3-7-21(25)26-20-11-6-9-17-15-19-22-16(12-14-24(19)13-4-2)8-5-10-18(22)23(17)20/h5-6,8-11,19H,3-4,7,12-15H2,1-2H3/t19-/m1/s1
DMH5QEA CS CCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMH5QEA IK PSFOXKHONDMYHK-LJQANCHMSA-N
DMH5QEA IU [(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] butanoate
DMH5QEA DE Discovery agent
DMYGE3K ID DMYGE3K
DMYGE3K DN 11C-PBR-170
DMYGE3K HS Investigative
DMYGE3K SN Radiolabeled peripheral benzodiazepine receptor ligand, Royal Prince Alfred Hospital; PRB-170-[11C]; Carbon-11-PBR-170
DMYGE3K CP Royal Prince Alfred Hospital
DMYGE3K DE Discovery agent
DM1ERJC ID DM1ERJC
DM1ERJC DN 11-deoxy-PGE1
DM1ERJC HS Investigative
DM1ERJC SN 11-deoxyprostaglandin E1; doproston
DM1ERJC DT Small molecular drug
DM1ERJC PC 5283055
DM1ERJC MW 338.5
DM1ERJC FM C20H34O4
DM1ERJC IC InChI=1S/C20H34O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h12,14,16-18,21H,2-11,13,15H2,1H3,(H,23,24)/b14-12+/t16-,17-,18+/m0/s1
DM1ERJC CS CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1CCCCCCC(=O)O)O
DM1ERJC IK DPNOTBLPQOITGU-LDDQNKHRSA-N
DM1ERJC IU 7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
DM1ERJC CA CAS 37786-00-8
DM1ERJC DE Discovery agent
DMXLWOK ID DMXLWOK
DMXLWOK DN 11-deoxy-PGE2
DMXLWOK HS Investigative
DMXLWOK SN 11-deoxy-PGE2; 11-deoxy Prostaglandin E2; 9-oxo-15S-hydroxy-5Z,13E-prostadienoic acid; (Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 11-Deoxyprostaglandin E2; 35536-53-9; LMFA03010061; AC1NR1FV; 11-deoxy-Prostaglandin E2; SCHEMBL9247000; GTPL1945; MolPort-039-138-850; HMS3648H09; ZINC27640133; 1151AH; SR-01000946427
DMXLWOK DT Small molecular drug
DMXLWOK PC 5283062
DMXLWOK MW 336.5
DMXLWOK FM C20H32O4
DMXLWOK IC InChI=1S/C20H32O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h4,7,12,14,16-18,21H,2-3,5-6,8-11,13,15H2,1H3,(H,23,24)/b7-4-,14-12+/t16-,17-,18+/m0/s1
DMXLWOK CS CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O
DMXLWOK IK CTHZICXYLKQMKI-FOSBLDSVSA-N
DMXLWOK IU (Z)-7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DMXLWOK CA CAS 35536-53-9
DMXLWOK CB CHEBI:165301
DMXLWOK DE Discovery agent
DMK41DJ ID DMK41DJ
DMK41DJ DN 11H-benzo[a]carbazole
DMK41DJ HS Investigative
DMK41DJ SN 11H-Benzo[a]carbazole; Benzocarbazole; 239-01-0; 1,2-Benzocarbazole; 1,2-Benzcarbazole; 11-Azachrysofluorene; Benzo[a]carbazole; 11H-Benzo(a)carbazole; BENZO(A)CARBAZOLE; UNII-3Y3SPE26QX; EINECS 205-945-4; NSC 403640; BRN 0155940; 3Y3SPE26QX; CHEMBL1173622; MYKQKWIPLZEVOW-UHFFFAOYSA-N; 67526-84-5; WLN: T D6 B566 CMJ; benzo[3,4]carbazole; benzo[1,2]carbazole; 1,2-Benzo-carbazole; AC1L1SJA; AC1Q4W1R; AC1Q1IZ3; SCHEMBL70791; 5-20-08-00456 (Beilstein Handbook Reference); CTK1A2947; MolPort-001-815-051; ZINC1690207; NSC60421; NSC403640
DMK41DJ DT Small molecular drug
DMK41DJ PC 9196
DMK41DJ MW 217.26
DMK41DJ FM C16H11N
DMK41DJ IC InChI=1S/C16H11N/c1-2-6-12-11(5-1)9-10-14-13-7-3-4-8-15(13)17-16(12)14/h1-10,17H
DMK41DJ CS C1=CC=C2C(=C1)C=CC3=C2NC4=CC=CC=C34
DMK41DJ IK MYKQKWIPLZEVOW-UHFFFAOYSA-N
DMK41DJ IU 11H-benzo[a]carbazole
DMK41DJ CA CAS 239-01-0
DMK41DJ DE Discovery agent
DMX4I9D ID DMX4I9D
DMX4I9D DN 11-Heptanoyloxy-N-n-propylnoraporphine
DMX4I9D HS Investigative
DMX4I9D SN CHEMBL516580; 11-Heptanoyloxy-N-n-propylnoraporphine
DMX4I9D DT Small molecular drug
DMX4I9D PC 44579031
DMX4I9D MW 391.5
DMX4I9D FM C26H33NO2
DMX4I9D IC InChI=1S/C26H33NO2/c1-3-5-6-7-14-24(28)29-23-13-9-11-20-18-22-25-19(15-17-27(22)16-4-2)10-8-12-21(25)26(20)23/h8-13,22H,3-7,14-18H2,1-2H3/t22-/m1/s1
DMX4I9D CS CCCCCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMX4I9D IK KWMUKPVHQQVHLC-JOCHJYFZSA-N
DMX4I9D IU [(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] heptanoate
DMX4I9D DE Discovery agent
DMRYV9E ID DMRYV9E
DMRYV9E DN 11-Hexanoyloxy-N-n-propylnoraporphine
DMRYV9E HS Investigative
DMRYV9E SN CHEMBL515342; 11-Hexanoyloxy-N-n-propylnoraporphine
DMRYV9E DT Small molecular drug
DMRYV9E PC 44579030
DMRYV9E MW 377.5
DMRYV9E FM C25H31NO2
DMRYV9E IC InChI=1S/C25H31NO2/c1-3-5-6-13-23(27)28-22-12-8-10-19-17-21-24-18(14-16-26(21)15-4-2)9-7-11-20(24)25(19)22/h7-12,21H,3-6,13-17H2,1-2H3/t21-/m1/s1
DMRYV9E CS CCCCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMRYV9E IK IHDFATFMTYOPPY-OAQYLSRUSA-N
DMRYV9E IU [(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] hexanoate
DMRYV9E DE Discovery agent
DMM6CJI ID DMM6CJI
DMM6CJI DN 11-keto-beta-boswellicacid
DMM6CJI HS Investigative
DMM6CJI SN 11-Keto-beta-boswellic acid; UNII-0S3BIF6H0Q; 11-Keto Boswellic Acid; 0S3BIF6H0Q; 17019-92-0; CHEMBL437964; 11-Oxo-beta-boswellic acid; (4R)-3alpha-hydroxy-11-oxo-urs-12-en-23-oic acid; Keto-b-boswellic acid; 3alpha-Hydroxy-11-oxours-12-en-24-oic acid; 11-Oxo-; 11-Keto-; BETA-BOSWELLIC ACID,11-KETO; A-Hydroxy-11-oxours-12-en-24-oic acid; 11-Oxo-b-boswellic acid; 11-Keto-b-boswellic acid; SCHEMBL4388405; (3alpha,4beta)-3-Hydroxy-11-oxours-12-en-23-oic acid
DMM6CJI DT Small molecular drug
DMM6CJI PC 9847548
DMM6CJI MW 470.7
DMM6CJI FM C30H46O4
DMM6CJI IC InChI=1S/C30H46O4/c1-17-8-11-26(3)14-15-28(5)19(23(26)18(17)2)16-20(31)24-27(4)12-10-22(32)30(7,25(33)34)21(27)9-13-29(24,28)6/h16-18,21-24,32H,8-15H2,1-7H3,(H,33,34)/t17-,18+,21-,22-,23+,24-,26-,27+,28-,29-,30-/m1/s1
DMM6CJI CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)O)C)C)[C@@H]2[C@H]1C)C)C
DMM6CJI IK YIMHGPSYDOGBPI-YZCVQEKWSA-N
DMM6CJI IU (3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bS)-3-hydroxy-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4a,5,6,7,8,9,10,11,12,12a,14a-tetradecahydropicene-4-carboxylic acid
DMM6CJI CA CAS 17019-92-0
DMM6CJI DE Discovery agent
DM1WPE3 ID DM1WPE3
DM1WPE3 DN 11-keto-ursolic acid
DM1WPE3 HS Investigative
DM1WPE3 SN 11-keto-ursolic acid; Obtusilin; CHEMBL603710; 105870-59-5; MolPort-039-339-172; ZINC45385190; BDBM50307108; AKOS016036263; 3beta-Hydroxy-11-oxours-12-en-28-oic acid
DM1WPE3 DT Small molecular drug
DM1WPE3 PC 21671982
DM1WPE3 MW 470.7
DM1WPE3 FM C30H46O4
DM1WPE3 IC InChI=1S/C30H46O4/c1-17-8-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)16-20(31)24-27(5)11-10-22(32)26(3,4)21(27)9-12-29(24,28)7/h16-18,21-24,32H,8-15H2,1-7H3,(H,33,34)/t17-,18+,21+,22+,23+,24-,27+,28-,29-,30+/m1/s1
DM1WPE3 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM1WPE3 IK MDQJVSLVPQYJLP-HUWCOUCRSA-N
DM1WPE3 IU (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
DM1WPE3 DE Discovery agent
DM9IHFY ID DM9IHFY
DM9IHFY DN 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol
DM9IHFY HS Investigative
DM9IHFY SN CHEMBL207706; 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol
DM9IHFY DT Small molecular drug
DM9IHFY PC 44411876
DM9IHFY MW 249.31
DM9IHFY FM C17H15NO
DM9IHFY IC InChI=1S/C17H15NO/c1-18-16-10-12(19)7-9-14(16)15-8-6-11-4-2-3-5-13(11)17(15)18/h2-5,7,9-10,19H,6,8H2,1H3
DM9IHFY CS CN1C2=C(C=CC(=C2)O)C3=C1C4=CC=CC=C4CC3
DM9IHFY IK MZXLONQJNNQZJT-UHFFFAOYSA-N
DM9IHFY IU 11-methyl-5,6-dihydrobenzo[a]carbazol-9-ol
DM9IHFY DE Discovery agent
DM62FEH ID DM62FEH
DM62FEH DN 11-Propionyloxy-N-n-propylnoraporphine
DM62FEH HS Investigative
DM62FEH SN CHEMBL515187; 11-Propionyloxy-N-n-propylnoraporphine
DM62FEH DT Small molecular drug
DM62FEH PC 44578927
DM62FEH MW 335.4
DM62FEH FM C22H25NO2
DM62FEH IC InChI=1S/C22H25NO2/c1-3-12-23-13-11-15-7-5-9-17-21(15)18(23)14-16-8-6-10-19(22(16)17)25-20(24)4-2/h5-10,18H,3-4,11-14H2,1-2H3/t18-/m1/s1
DM62FEH CS CCCN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=CC=C4)OC(=O)CC
DM62FEH IK FKAOLIWLWAYCIA-GOSISDBHSA-N
DM62FEH IU [(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] propanoate
DM62FEH DE Discovery agent
DMM91WE ID DMM91WE
DMM91WE DN 11-valeryloxynoraporphine
DMM91WE HS Investigative
DMM91WE SN 11-valeryloxynoraporphine; CHEMBL403550; BDBM50202292; pentanoic acid (R)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl ester
DMM91WE DT Small molecular drug
DMM91WE PC 44447998
DMM91WE MW 363.5
DMM91WE FM C24H29NO2
DMM91WE IC InChI=1S/C24H29NO2/c1-3-5-12-22(26)27-21-11-7-9-18-16-20-23-17(13-15-25(20)14-4-2)8-6-10-19(23)24(18)21/h6-11,20H,3-5,12-16H2,1-2H3/t20-/m1/s1
DMM91WE CS CCCCC(=O)OC1=CC=CC2=C1C3=CC=CC4=C3[C@@H](C2)N(CC4)CCC
DMM91WE IK JGCVBGVDWQJTDF-HXUWFJFHSA-N
DMM91WE IU [(6aR)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] pentanoate
DMM91WE DE Discovery agent
DM84YCI ID DM84YCI
DM84YCI DN 12-(3-Adamantan-1-yl-ureido)-dodeca noic acid
DM84YCI HS Investigative
DM84YCI SN AUDA; 479413-70-2; CHEMBL215387; Urea-based compound, 18; 12-[(adamantan-1-ylcarbamoyl)amino]dodecanoic acid; MLS002415562; SCHEMBL120588; CTK8F0781; BDBM25737; DTXSID20435153; HMS3650M09; HMS2204E15; HMS3332K06; AUDA, > ZINC27645646; MFCD12912267; 1631AH; SMR001339077; ACM479413702; RT-011342; 12-(3-adamantan-1-yl-ureido)-dodecanoic acid; SR-01000860315; SR-01000860315-2; 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid
DM84YCI DT Small molecular drug
DM84YCI PC 10069117
DM84YCI MW 392.6
DM84YCI FM C23H40N2O3
DM84YCI IC InChI=1S/C23H40N2O3/c26-21(27)10-8-6-4-2-1-3-5-7-9-11-24-22(28)25-23-15-18-12-19(16-23)14-20(13-18)17-23/h18-20H,1-17H2,(H,26,27)(H2,24,25,28)
DM84YCI CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCCCCCCCC(=O)O
DM84YCI IK XLGSEOAVLVTJDH-UHFFFAOYSA-N
DM84YCI IU 12-(1-adamantylcarbamoylamino)dodecanoic acid
DM84YCI CA CAS 479413-70-2
DM84YCI DE Discovery agent
DM0F3SR ID DM0F3SR
DM0F3SR DN 12-(3-n-Hexylureido)dodec-8(Z)-enoic acid
DM0F3SR HS Investigative
DM0F3SR SN CHEMBL560029; 12-(3-n-Hexylureido)dodec-8(Z)-enoic acid
DM0F3SR DT Small molecular drug
DM0F3SR PC 44234914
DM0F3SR MW 340.5
DM0F3SR FM C19H36N2O3
DM0F3SR IC InChI=1S/C19H36N2O3/c1-2-3-4-13-16-20-19(24)21-17-14-11-9-7-5-6-8-10-12-15-18(22)23/h7,9H,2-6,8,10-17H2,1H3,(H,22,23)(H2,20,21,24)/b9-7-
DM0F3SR CS CCCCCCNC(=O)NCCC/C=C\\CCCCCCC(=O)O
DM0F3SR IK CQPDPYBIHJYCBO-CLFYSBASSA-N
DM0F3SR IU (Z)-12-(hexylcarbamoylamino)dodec-8-enoic acid
DM0F3SR DE Discovery agent
DMAFNXZ ID DMAFNXZ
DMAFNXZ DN 12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid
DMAFNXZ HS Investigative
DMAFNXZ SN CHEMBL560419; 12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid
DMAFNXZ DT Small molecular drug
DMAFNXZ PC 44234917
DMAFNXZ MW 342.5
DMAFNXZ FM C18H34N2O4
DMAFNXZ IC InChI=1S/C18H34N2O4/c1-2-3-12-15-19-18(23)20-24-16-13-10-8-6-4-5-7-9-11-14-17(21)22/h6,8H,2-5,7,9-16H2,1H3,(H,21,22)(H2,19,20,23)/b8-6-
DMAFNXZ CS CCCCCNC(=O)NOCCC/C=C\\CCCCCCC(=O)O
DMAFNXZ IK QHNVLXQJNGLGOO-VURMDHGXSA-N
DMAFNXZ IU (Z)-12-(pentylcarbamoylamino)oxydodec-8-enoic acid
DMAFNXZ DE Discovery agent
DMVP39I ID DMVP39I
DMVP39I DN 12,13-DEHYDRO-8-O-ACETYLMANZAMINE A
DMVP39I HS Investigative
DMVP39I SN 12,13-dehydro-8-O-acetylmanzamine A; CHEMBL252520
DMVP39I DT Small molecular drug
DMVP39I PC 23643836
DMVP39I MW 588.8
DMVP39I FM C38H44N4O2
DMVP39I IC InChI=1S/C38H44N4O2/c1-26(43)44-33-16-12-15-29-30-17-19-39-35(36(30)40-34(29)33)31-23-27-13-8-4-2-3-6-10-20-41-22-18-32(31)38(25-41)24-28-14-9-5-7-11-21-42(28)37(27)38/h2,4,9,12-17,19,23,28,32,37,40H,3,5-8,10-11,18,20-22,24-25H2,1H3/b4-2-,14-9-,27-13-/t28-,32?,37-,38-/m0/s1
DMVP39I CS CC(=O)OC1=CC=CC2=C1NC3=C2C=CN=C3C4=C/C/5=C/C/C=C\\CCCCN6CCC4[C@]7(C6)[C@H]5N8CCCC/C=C\\[C@H]8C7
DMVP39I IK XANHIHHFYZZCBY-CVNPAURDSA-N
DMVP39I IU [1-[(2R,4R,5Z,12S,13Z,16Z)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,13,16,25-tetraen-25-yl]-9H-pyrido[3,4-b]indol-8-yl] acetate
DMVP39I DE Discovery agent
DM8XAWU ID DM8XAWU
DM8XAWU DN 12,13-DEHYDROMANZAMINE A
DM8XAWU HS Investigative
DM8XAWU SN 12,13-dehydromanzamine A; CHEMBL268202
DM8XAWU DT Small molecular drug
DM8XAWU PC 23643835
DM8XAWU MW 530.7
DM8XAWU FM C36H42N4
DM8XAWU IC InChI=1S/C36H42N4/c1-2-5-11-20-39-22-18-31-30(33-34-29(17-19-37-33)28-15-9-10-16-32(28)38-34)23-26(13-7-3-1)35-36(31,25-39)24-27-14-8-4-6-12-21-40(27)35/h1,3,8-10,13-17,19,23,27,31,35,38H,2,4-7,11-12,18,20-22,24-25H2/b3-1-,14-8-,26-13-/t27-,31?,35-,36-/m0/s1
DM8XAWU CS C1CCN2CCC3C(=C/C(=C/C/C=C\\C1)/[C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)C6=NC=CC7=C6NC8=CC=CC=C78
DM8XAWU IK XJPQQKQCGFEXKO-SGYLFFKUSA-N
DM8XAWU IU (2R,4R,5Z,12S,13Z,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,13,16,25-tetraene
DM8XAWU DE Discovery agent
DMAUPQR ID DMAUPQR
DMAUPQR DN 12,17-dehydroxyriccardin C
DMAUPQR HS Investigative
DMAUPQR SN 12,17-dehydroxyriccardin C; Riccardin C derivative, 20e; CHEMBL429324; BDBM23852
DMAUPQR DT Small molecular drug
DMAUPQR PC 24860514
DMAUPQR MW 392.5
DMAUPQR FM C28H24O2
DMAUPQR IC InChI=1S/C28H24O2/c29-27-18-12-22-6-5-20-8-14-24(15-9-20)26-4-2-1-3-23(26)13-7-21-10-16-25(17-11-21)30-28(27)19-22/h1-4,8-12,14-19,29H,5-7,13H2
DMAUPQR CS C1CC2=CC(=C(C=C2)O)OC3=CC=C(CCC4=CC=CC=C4C5=CC=C1C=C5)C=C3
DMAUPQR IK CTGIBRGBEVEPID-UHFFFAOYSA-N
DMAUPQR IU 14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaen-16-ol
DMAUPQR DE Discovery agent
DMW172Q ID DMW172Q
DMW172Q DN 123I-DRM-106
DMW172Q HS Investigative
DMW172Q SN DRM-106-[123I]; Iodine-123-DRM-106; SPECT diagnostic (Alzheimer's disease), Fujifilm RI Pharma Co Ltd
DMW172Q CP FUJIFILM Corp
DMW172Q DT Small molecular drug
DMW172Q PC 49801966
DMW172Q MW 382.19
DMW172Q FM C16H11IN4
DMW172Q IC InChI=1S/C16H11IN4/c17-13-5-6-16-19-15(10-21(16)9-13)12-3-1-11(2-4-12)14-7-8-18-20-14/h1-10H,(H,18,20)/i17-4
DMW172Q CS C1=CC(=CC=C1C2=CC=NN2)C3=CN4C=C(C=CC4=N3)[123I]
DMW172Q IK OLFQWTDIJLVADS-HHRLKWFBSA-N
DMW172Q IU 6-(123I)iodanyl-2-[4-(1H-pyrazol-5-yl)phenyl]imidazo[1,2-a]pyridine
DMW172Q DE Alzheimer disease
DMTOSXF ID DMTOSXF
DMTOSXF DN 12-dehydroxyriccardin C
DMTOSXF HS Investigative
DMTOSXF SN 12-dehydroxyriccardin C; Riccardin C derivative, 20c; CHEMBL260632; BDBM23850; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-4'-ol
DMTOSXF DT Small molecular drug
DMTOSXF PC 24860512
DMTOSXF MW 408.5
DMTOSXF FM C28H24O3
DMTOSXF IC InChI=1S/C28H24O3/c29-24-12-15-26-22-9-3-19(4-10-22)1-2-21-8-16-27(30)28(17-21)31-25-13-6-20(7-14-25)5-11-23(26)18-24/h3-4,6-10,12-18,29-30H,1-2,5,11H2
DMTOSXF CS C1CC2=CC(=C(C=C2)O)OC3=CC=C(CCC4=C(C=CC(=C4)O)C5=CC=C1C=C5)C=C3
DMTOSXF IK VSXIMYQGZUVRSK-UHFFFAOYSA-N
DMTOSXF IU 14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-5,16-diol
DMTOSXF DE Discovery agent
DM9JI8C ID DM9JI8C
DM9JI8C DN 12-epi LTB4
DM9JI8C HS Investigative
DM9JI8C SN 12(S)-Leukotriene B4
DM9JI8C DT Small molecular drug
DM9JI8C PC 5283130
DM9JI8C MW 336.5
DM9JI8C FM C20H32O4
DM9JI8C IC InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11-/t18-,19+/m0/s1
DM9JI8C CS CCCCC/C=C\\C[C@@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O
DM9JI8C IK VNYSSYRCGWBHLG-CBBLYLIKSA-N
DM9JI8C IU (5S,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid
DM9JI8C CA CAS 83709-73-3
DM9JI8C CB CHEBI:72795
DM9JI8C DE Discovery agent
DMZ9PW3 ID DMZ9PW3
DMZ9PW3 DN 12-EPI-SALVINORIN A
DMZ9PW3 HS Investigative
DMZ9PW3 SN 12-epi-Salvinorin A; CHEMBL458235; SCHEMBL10071862; OBSYBRPAKCASQB-KWMFLVSKSA-N
DMZ9PW3 DT Small molecular drug
DMZ9PW3 PC 25242485
DMZ9PW3 MW 432.5
DMZ9PW3 FM C23H28O8
DMZ9PW3 IC InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17+,19-,22-,23-/m0/s1
DMZ9PW3 CS CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DMZ9PW3 IK OBSYBRPAKCASQB-KWMFLVSKSA-N
DMZ9PW3 IU methyl (2R,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMZ9PW3 DE Discovery agent
DMA2EIK ID DMA2EIK
DMA2EIK DN 12-hydroxyheptadecatrienoic acid
DMA2EIK HS Investigative
DMA2EIK SN 12S-HHTrE
DMA2EIK DT Small molecular drug
DMA2EIK PC 5283141
DMA2EIK MW 280.4
DMA2EIK FM C17H28O3
DMA2EIK IC InChI=1S/C17H28O3/c1-2-3-10-13-16(18)14-11-8-6-4-5-7-9-12-15-17(19)20/h5-8,11,14,16,18H,2-4,9-10,12-13,15H2,1H3,(H,19,20)/b7-5-,8-6+,14-11+/t16-/m0/s1
DMA2EIK CS CCCCC[C@@H](/C=C/C=C/C/C=C\\CCCC(=O)O)O
DMA2EIK IK KUKJHGXXZWHSBG-WBGSEQOASA-N
DMA2EIK IU (5Z,8E,10E,12S)-12-hydroxyheptadeca-5,8,10-trienoic acid
DMA2EIK CA CAS 54397-84-1
DMA2EIK CB CHEBI:63977
DMA2EIK DE Discovery agent
DMKH0OC ID DMKH0OC
DMKH0OC DN 12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin
DMKH0OC HS Investigative
DMKH0OC SN CHEMBL251695; CHEBI:68038; 12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin; BDBM50226460
DMKH0OC DT Small molecular drug
DMKH0OC PC 24178658
DMKH0OC MW 402.6
DMKH0OC FM C25H38O4
DMKH0OC IC InChI=1S/C25H38O4/c1-22(14-26)9-5-10-23(2)17(22)8-11-24(3)18-7-6-15-16(13-29-21(15)28)25(18,4)20(27)12-19(23)24/h6,16-20,26-27H,5,7-14H2,1-4H3/t16-,17-,18-,19+,20+,22-,23-,24-,25+/m0/s1
DMKH0OC CS C[C@]1(CCC[C@]2([C@H]1CC[C@@]3([C@@H]2C[C@H]([C@]4([C@H]3CC=C5[C@@H]4COC5=O)C)O)C)C)CO
DMKH0OC IK LXWMXTKOJPFGPW-NFXGRNOLSA-N
DMKH0OC IU (5aS,5bR,7aR,8R,11aR,11bR,13R,13aS,13bR)-13-hydroxy-8-(hydroxymethyl)-5b,8,11a,13a-tetramethyl-5,5a,6,7,7a,9,10,11,11b,12,13,13b-dodecahydro-1H-phenanthro[2,1-e][2]benzofuran-3-one
DMKH0OC CA CAS 957131-96-3
DMKH0OC CB CHEBI:68038
DMKH0OC DE Discovery agent
DMLR2FB ID DMLR2FB
DMLR2FB DN 12-Phenylheme
DMLR2FB HS Investigative
DMLR2FB DT Small molecular drug
DMLR2FB PC 5287448
DMLR2FB MW 694.6
DMLR2FB FM C40H38FeN4O4
DMLR2FB IC InChI=1S/C40H40N4O4.Fe/c1-7-26-24(6)39-38(25-12-10-9-11-13-25)40-27(8-2)21(3)32(43-40)18-30-22(4)28(14-16-36(45)46)34(41-30)20-35-29(15-17-37(47)48)23(5)31(42-35)19-33(26)44-39;/h7-13,18-20,24,26H,1-2,14-17H2,3-6H3,(H4,41,42,43,44,45,46,47,48);/q;+2/p-2
DMLR2FB CS CC1C(C2=NC1=C(C3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=C2)[N-]5)C)CCC(=O)O)CCC(=O)O)C)C)C=C)C6=CC=CC=C6)C=C.[Fe+2]
DMLR2FB IK ODMHOWCUYFSODS-UHFFFAOYSA-L
DMLR2FB IU 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethyl-10-phenyl-7,8-dihydroporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)
DMLR2FB DE Discovery agent
DMK0GJ3 ID DMK0GJ3
DMK0GJ3 DN 12R-HETE
DMK0GJ3 HS Investigative
DMK0GJ3 SN 12r-HETE
DMK0GJ3 DT Small molecular drug
DMK0GJ3 PC 5283156
DMK0GJ3 MW 320.5
DMK0GJ3 FM C20H32O3
DMK0GJ3 IC InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+/t19-/m1/s1
DMK0GJ3 CS CCCCC/C=C\\C[C@H](/C=C/C=C\\C/C=C\\CCCC(=O)O)O
DMK0GJ3 IK ZNHVWPKMFKADKW-ZYBDYUKJSA-N
DMK0GJ3 IU (5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
DMK0GJ3 CA CAS 82337-46-0
DMK0GJ3 CB CHEBI:34144
DMK0GJ3 DE Discovery agent
DMBEZ09 ID DMBEZ09
DMBEZ09 DN 12S-HETE
DMBEZ09 HS Investigative
DMBEZ09 SN 12S-Hete; 12(S)-HETE; 54397-83-0; 12(S)-Hydroxyeicosatetraenoic acid; CHEBI:34146; 12-Hete; (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid; 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid; 12-Hydroxyeicosatetraenoic acid; 12(S)-Hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoic acid; (5Z,8Z,10E,14Z)-(12S)-12-Hydroxyicosa-5,8,10,14-tetraenoic acid; (5Z,8Z,10E,14Z)-(12S)-12-Hydroxyeicosa-5,8,10,14-tetraenoic acid; (S)-12-HETE; 12S-[3H]HETE; 12 hete; 12-L-Hydroxy-5,8,10,14-eicosatetraenoic acid; AC1NR1NB; 12(S)-hydroxyeicosatetraenoic acid
DMBEZ09 DT Small molecular drug
DMBEZ09 PC 5283155
DMBEZ09 MW 320.5
DMBEZ09 FM C20H32O3
DMBEZ09 IC InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+/t19-/m0/s1
DMBEZ09 CS CCCCC/C=C\\C[C@@H](/C=C/C=C\\C/C=C\\CCCC(=O)O)O
DMBEZ09 IK ZNHVWPKMFKADKW-LQWMCKPYSA-N
DMBEZ09 IU (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
DMBEZ09 CA CAS 54397-83-0
DMBEZ09 CB CHEBI:34146
DMBEZ09 DE Discovery agent
DM6ZX1O ID DM6ZX1O
DM6ZX1O DN 12S-HPETE
DM6ZX1O HS Investigative
DM6ZX1O SN 12-(S)-hydroperoxyeicosatetraenoic acid; 12-(S)-HPETE
DM6ZX1O DT Small molecular drug
DM6ZX1O PC 5280892
DM6ZX1O MW 336.5
DM6ZX1O FM C20H32O4
DM6ZX1O IC InChI=1S/C20H32O4/c1-2-3-4-5-10-13-16-19(24-23)17-14-11-8-6-7-9-12-15-18-20(21)22/h7-11,13-14,17,19,23H,2-6,12,15-16,18H2,1H3,(H,21,22)/b9-7-,11-8-,13-10-,17-14+/t19-/m0/s1
DM6ZX1O CS CCCCC/C=C\\C[C@@H](/C=C/C=C\\C/C=C\\CCCC(=O)O)OO
DM6ZX1O IK ZIOZYRSDNLNNNJ-LQWMCKPYSA-N
DM6ZX1O IU (5Z,8Z,10E,12S,14Z)-12-hydroperoxyicosa-5,8,10,14-tetraenoic acid
DM6ZX1O CA CAS 71774-10-2
DM6ZX1O CB CHEBI:15626
DM6ZX1O DE Discovery agent
DMRO1IU ID DMRO1IU
DMRO1IU DN 1-3 Sugar Ring of Pentamannosyl 6-Phosphate
DMRO1IU HS Investigative
DMRO1IU SN 1-3 SUGAR RING OF PENTAMANNOSYL 6-PHOSPHATE; P3M; AC1L9GSL; DB02755; WURCS=2.0/2,3,2/[a1122h-1a_1-5][a1122h-1a_1-5_6*OPO/3O/3=O]/1-1-2/a3-b1_b3-c1; 6-O-phosphono-alpha-D-mannopyranosyl-(1->3)-alpha-D-mannopyranosyl-(1->3)-alpha-D-mannopyranose; [(2R,3S,4S,5S,6R)-6-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2S,3S,4S,5R,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMRO1IU DT Small molecular drug
DMRO1IU PC 444727
DMRO1IU MW 584.4
DMRO1IU FM C18H33O19P
DMRO1IU IC InChI=1S/C18H33O19P/c19-1-4-8(22)14(12(26)16(28)33-4)36-18-13(27)15(9(23)5(2-20)34-18)37-17-11(25)10(24)7(21)6(35-17)3-32-38(29,30)31/h4-28H,1-3H2,(H2,29,30,31)/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17-,18-/m1/s1
DMRO1IU CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O[C@@H]2[C@H]([C@H]([C@@H]([C@H](O2)CO)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)O)O)O)O
DMRO1IU IK HDQMHAJOIVYOIP-NAVBLJQLSA-N
DMRO1IU IU [(2R,3S,4S,5S,6R)-6-[(2R,3R,4S,5S,6R)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2S,3S,4S,5R,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyoxan-4-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMRO1IU DE Discovery agent
DMIY9DB ID DMIY9DB
DMIY9DB DN 13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid
DMIY9DB HS Investigative
DMIY9DB SN CHEMBL551158; 13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid
DMIY9DB DT Small molecular drug
DMIY9DB PC 44234660
DMIY9DB MW 356.6
DMIY9DB FM C19H36N2O2S
DMIY9DB IC InChI=1S/C19H36N2O2S/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h5,7H,2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)/b7-5-
DMIY9DB CS CCCCCNC(=S)NCCCC/C=C\\CCCCCCC(=O)O
DMIY9DB IK XZCDMUCBAMBZQK-ALCCZGGFSA-N
DMIY9DB IU (Z)-13-(pentylcarbamothioylamino)tridec-8-enoic acid
DMIY9DB DE Discovery agent
DM0NRJG ID DM0NRJG
DM0NRJG DN 13-(3-n-Pentylureido)tridec-5(Z)-enoic acid
DM0NRJG HS Investigative
DM0NRJG SN CHEMBL551162; 13-(3-n-Pentylureido)tridec-5(Z)-enoic acid
DM0NRJG DT Small molecular drug
DM0NRJG PC 44234912
DM0NRJG MW 340.5
DM0NRJG FM C19H36N2O3
DM0NRJG IC InChI=1S/C19H36N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h6,8H,2-5,7,9-17H2,1H3,(H,22,23)(H2,20,21,24)/b8-6-
DM0NRJG CS CCCCCNC(=O)NCCCCCCC/C=C\\CCCC(=O)O
DM0NRJG IK YUYHEPLRNYDYLU-VURMDHGXSA-N
DM0NRJG IU (Z)-13-(pentylcarbamoylamino)tridec-5-enoic acid
DM0NRJG DE Discovery agent
DM17DY6 ID DM17DY6
DM17DY6 DN 13-(3-n-Pentylureido)tridec-8(E)-enoic acid
DM17DY6 HS Investigative
DM17DY6 SN CHEMBL559573; 13-(3-n-Pentylureido)tridec-8(E)-enoic acid
DM17DY6 DT Small molecular drug
DM17DY6 PC 44234663
DM17DY6 MW 340.5
DM17DY6 FM C19H36N2O3
DM17DY6 IC InChI=1S/C19H36N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h5,7H,2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)/b7-5+
DM17DY6 CS CCCCCNC(=O)NCCCC/C=C/CCCCCCC(=O)O
DM17DY6 IK CVIWLKCFJOISPD-FNORWQNLSA-N
DM17DY6 IU (E)-13-(pentylcarbamoylamino)tridec-8-enoic acid
DM17DY6 DE Discovery agent
DM9VDOG ID DM9VDOG
DM9VDOG DN 13-(3-n-Pentylureido)tridec-8-ynoic acid
DM9VDOG HS Investigative
DM9VDOG SN CHEMBL551161; 13-(3-n-Pentylureido)tridec-8-ynoic acid
DM9VDOG DT Small molecular drug
DM9VDOG PC 44234911
DM9VDOG MW 338.5
DM9VDOG FM C19H34N2O3
DM9VDOG IC InChI=1S/C19H34N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)
DM9VDOG CS CCCCCNC(=O)NCCCCC#CCCCCCCC(=O)O
DM9VDOG IK CFQZBGUYWSZYQK-UHFFFAOYSA-N
DM9VDOG IU 13-(pentylcarbamoylamino)tridec-8-ynoic acid
DM9VDOG DE Discovery agent
DM3I6PS ID DM3I6PS
DM3I6PS DN 13-(3-Pentyluredo)tridec-8(Z)-enoic acid
DM3I6PS HS Investigative
DM3I6PS SN CHEMBL558097; 13-(3-Pentyluredo)tridec-8(Z)-enoic acid; SCHEMBL13193158
DM3I6PS DT Small molecular drug
DM3I6PS PC 44234656
DM3I6PS MW 340.5
DM3I6PS FM C19H36N2O3
DM3I6PS IC InChI=1S/C19H36N2O3/c1-2-3-13-16-20-19(24)21-17-14-11-9-7-5-4-6-8-10-12-15-18(22)23/h5,7H,2-4,6,8-17H2,1H3,(H,22,23)(H2,20,21,24)/b7-5-
DM3I6PS CS CCCCCNC(=O)NCCCC/C=C\\CCCCCCC(=O)O
DM3I6PS IK CVIWLKCFJOISPD-ALCCZGGFSA-N
DM3I6PS IU (Z)-13-(pentylcarbamoylamino)tridec-8-enoic acid
DM3I6PS DE Discovery agent
DM8HRTC ID DM8HRTC
DM8HRTC DN 13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid
DM8HRTC HS Investigative
DM8HRTC SN CHEMBL559279; 13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid
DM8HRTC DT Small molecular drug
DM8HRTC PC 44235412
DM8HRTC MW 348.5
DM8HRTC FM C22H36O3
DM8HRTC IC InChI=1S/C22H36O3/c1-2-3-12-15-20-18-19-21(25-20)16-13-10-8-6-4-5-7-9-11-14-17-22(23)24/h4,6,18-19H,2-3,5,7-17H2,1H3,(H,23,24)/b6-4-
DM8HRTC CS CCCCCC1=CC=C(O1)CCCC/C=C\\CCCCCCC(=O)O
DM8HRTC IK SJFMNLQBZCGDPV-XQRVVYSFSA-N
DM8HRTC IU (Z)-13-(5-pentylfuran-2-yl)tridec-8-enoic acid
DM8HRTC DE Discovery agent
DMXK6D2 ID DMXK6D2
DMXK6D2 DN 13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid
DMXK6D2 HS Investigative
DMXK6D2 SN CHEMBL560026; 13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid; SCHEMBL15645552
DMXK6D2 DT Small molecular drug
DMXK6D2 PC 44235173
DMXK6D2 MW 381.6
DMXK6D2 FM C23H43NO3
DMXK6D2 IC InChI=1S/C23H43NO3/c1-4-5-6-15-18-22(25)24(21(2)3)20-17-14-12-10-8-7-9-11-13-16-19-23(26)27/h8,10,21H,4-7,9,11-20H2,1-3H3,(H,26,27)/b10-8-
DMXK6D2 CS CCCCCCC(=O)N(CCCC/C=C\\CCCCCCC(=O)O)C(C)C
DMXK6D2 IK SWWIYFCSVNBILX-NTMALXAHSA-N
DMXK6D2 IU (Z)-13-[heptanoyl(propan-2-yl)amino]tridec-8-enoic acid
DMXK6D2 DE Discovery agent
DM689TH ID DM689TH
DM689TH DN 13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid
DM689TH HS Investigative
DM689TH SN CHEMBL559454; 13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid
DM689TH DT Small molecular drug
DM689TH PC 44235172
DM689TH MW 353.5
DM689TH FM C21H39NO3
DM689TH IC InChI=1S/C21H39NO3/c1-3-4-5-14-17-20(23)22(2)19-16-13-11-9-7-6-8-10-12-15-18-21(24)25/h7,9H,3-6,8,10-19H2,1-2H3,(H,24,25)/b9-7-
DM689TH CS CCCCCCC(=O)N(C)CCCC/C=C\\CCCCCCC(=O)O
DM689TH IK CJHOGNAQWWHHBN-CLFYSBASSA-N
DM689TH IU (Z)-13-[heptanoyl(methyl)amino]tridec-8-enoic acid
DM689TH DE Discovery agent
DMSF3C8 ID DMSF3C8
DMSF3C8 DN 13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid
DMSF3C8 HS Investigative
DMSF3C8 SN CHEMBL558485; 13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid
DMSF3C8 DT Small molecular drug
DMSF3C8 PC 44234662
DMSF3C8 MW 341.5
DMSF3C8 FM C19H35NO4
DMSF3C8 IC InChI=1S/C19H35NO4/c1-2-3-13-16-20-19(23)24-17-14-11-9-7-5-4-6-8-10-12-15-18(21)22/h5,7H,2-4,6,8-17H2,1H3,(H,20,23)(H,21,22)/b7-5-
DMSF3C8 CS CCCCCNC(=O)OCCCC/C=C\\CCCCCCC(=O)O
DMSF3C8 IK MSASWGXYEFVTGT-ALCCZGGFSA-N
DMSF3C8 IU (Z)-13-(pentylcarbamoyloxy)tridec-8-enoic acid
DMSF3C8 DE Discovery agent
DMZVWCG ID DMZVWCG
DMZVWCG DN 13,14-dihydro-15-keto-PGD2
DMZVWCG HS Investigative
DMZVWCG SN 13,14-dihydro-15-keto-prostaglandin D2; 13,14-dihydro-15-ketoprostaglandin D2; DK-PGD2; 13,14-dihydro-15-oxo PGD2
DMZVWCG DT Small molecular drug
DMZVWCG PC 5283036
DMZVWCG MW 352.5
DMZVWCG FM C20H32O5
DMZVWCG IC InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-18,22H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,18+/m1/s1
DMZVWCG CS CCCCCC(=O)CC[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O
DMZVWCG IK VSRXYLYXIXYEST-KZTWKYQFSA-N
DMZVWCG IU (Z)-7-[(1R,2R,5S)-5-hydroxy-3-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
DMZVWCG CA CAS 59894-07-4
DMZVWCG CB CHEBI:72603
DMZVWCG DE Discovery agent
DMNT1XI ID DMNT1XI
DMNT1XI DN 13,14-dihydro-15-keto-PGF2alpha
DMNT1XI HS Investigative
DMNT1XI SN Dhk-pgf2alpha
DMNT1XI DT Small molecular drug
DMNT1XI PC 5283039
DMNT1XI MW 354.5
DMNT1XI FM C20H34O5
DMNT1XI IC InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-19,22-23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,18+,19-/m1/s1
DMNT1XI CS CCCCCC(=O)CC[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)O)O
DMNT1XI IK VKTIONYPMSCHQI-XAGFEHLVSA-N
DMNT1XI IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid
DMNT1XI CA CAS 27376-76-7
DMNT1XI CB CHEBI:63976
DMNT1XI DE Discovery agent
DMNRMTX ID DMNRMTX
DMNRMTX DN 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha
DMNRMTX HS Investigative
DMNRMTX SN CHEMBL36041; 7-[(1R,2R,3R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-3,5-dihydroxycyclopentyl]heptanoic acid; AC1NSKAB; GTPL1955; 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha; 13,14-Dihydro-16-m-Chlorophenoxy-Omega-Tetranor PGF-1alpha; BDBM50085911; 7-{2-[4-(3-Chloro-phenoxy)-3-hydroxy-butyl]-3,5-dihydroxy-cyclopentyl}-heptanoic acid; 7-[(1R)-2beta-[(3R)-3-Hydroxy-4-(3-chlorophenoxy)butyl]-3alpha,5alpha-dihydroxycyclopentane-1alpha-yl]heptanoic acid
DMNRMTX DT Small molecular drug
DMNRMTX PC 5311240
DMNRMTX MW 428.9
DMNRMTX FM C22H33ClO6
DMNRMTX IC InChI=1S/C22H33ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h5-7,12,16,18-21,24-26H,1-4,8-11,13-14H2,(H,27,28)/t16-,18-,19-,20+,21-/m1/s1
DMNRMTX CS C1[C@@H]([C@@H]([C@H]([C@@H]1O)CC[C@H](COC2=CC(=CC=C2)Cl)O)CCCCCCC(=O)O)O
DMNRMTX IK XECZBZWECQIBDA-LELZANKISA-N
DMNRMTX IU 7-[(1R,2R,3R,5S)-2-[(3R)-4-(3-chlorophenoxy)-3-hydroxybutyl]-3,5-dihydroxycyclopentyl]heptanoic acid
DMNRMTX DE Discovery agent
DMTEACQ ID DMTEACQ
DMTEACQ DN 13,14-dihydro-PGE1
DMTEACQ HS Investigative
DMTEACQ SN 13,14-dihydro-prostaglandin E1
DMTEACQ DT Small molecular drug
DMTEACQ PC 161273
DMTEACQ MW 356.5
DMTEACQ FM C20H36O5
DMTEACQ IC InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h15-17,19,21,23H,2-14H2,1H3,(H,24,25)/t15-,16+,17+,19+/m0/s1
DMTEACQ CS CCCCC[C@@H](CC[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
DMTEACQ IK DPOINJQWXDTOSF-DODZYUBVSA-N
DMTEACQ IU 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid
DMTEACQ CA CAS 19313-28-1
DMTEACQ CB CHEBI:89310
DMTEACQ DE Discovery agent
DMMTPK3 ID DMMTPK3
DMMTPK3 DN 135PAM1
DMMTPK3 HS Investigative
DMMTPK3 SN 135PAM1; GTPL8343; 3-[3,5-bis(trifluoromethyl)phenyl]-1-[(3,4-dichlorophenyl)methyl]-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea
DMMTPK3 DT Small molecular drug
DMMTPK3 PC 56953333
DMMTPK3 MW 604.4
DMMTPK3 FM C27H21Cl2F6N3O2
DMMTPK3 IC InChI=1S/C27H21Cl2F6N3O2/c1-40-20-3-5-24-21(12-20)16(13-36-24)6-7-38(14-15-2-4-22(28)23(29)8-15)25(39)37-19-10-17(26(30,31)32)9-18(11-19)27(33,34)35/h2-5,8-13,36H,6-7,14H2,1H3,(H,37,39)
DMMTPK3 CS COC1=CC2=C(C=C1)NC=C2CCN(CC3=CC(=C(C=C3)Cl)Cl)C(=O)NC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMMTPK3 IK FAXDMTURZKFXIY-UHFFFAOYSA-N
DMMTPK3 IU 3-[3,5-bis(trifluoromethyl)phenyl]-1-[(3,4-dichlorophenyl)methyl]-1-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea
DMMTPK3 DE Discovery agent
DMJ2T7P ID DMJ2T7P
DMJ2T7P DN 13-Acetylphorbol
DMJ2T7P HS Investigative
DMJ2T7P SN Phorbol 13-acetate; 13-Acetylphorbol; Phorbol-13-acetate; Phorbol 13-monoacetate; 32752-29-7; CHEBI:45127; Phorbol13-acetate; (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulen-9a-yl acetate; PRB; 5H-Cyclopropa(3,4)benz(1,2-e)azulen-5-one, 1,1a-alpha,1b-beta,4,4a,7a-alpha,7b,8,9,9a-decahydro-4a-alpha,7b-alpha,9-beta,9a-alpha-tetrahydroxy-3-hydroxymethyl-1,1,6,8-alpha-tetramethyl-, 9a-acetate
DMJ2T7P DT Small molecular drug
DMJ2T7P PC 499953
DMJ2T7P MW 406.5
DMJ2T7P FM C22H30O7
DMJ2T7P IC InChI=1S/C22H30O7/c1-10-6-15-20(27,17(10)25)8-13(9-23)7-14-16-19(4,5)22(16,29-12(3)24)18(26)11(2)21(14,15)28/h6-7,11,14-16,18,23,26-28H,8-9H2,1-5H3/t11-,14+,15-,16-,18-,20-,21-,22-/m1/s1
DMJ2T7P CS C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C)O
DMJ2T7P IK SDSVJYOOAPRSDA-RPCQODIISA-N
DMJ2T7P IU [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] acetate
DMJ2T7P CA CAS 32752-29-7
DMJ2T7P CB CHEBI:45127
DMJ2T7P DE Discovery agent
DMRVQCB ID DMRVQCB
DMRVQCB DN 13-n-Heptanamidotridec-5-ynoic acid
DMRVQCB HS Investigative
DMRVQCB SN CHEMBL550898; 13-n-Heptanamidotridec-5-ynoic acid
DMRVQCB DT Small molecular drug
DMRVQCB PC 44235174
DMRVQCB MW 337.5
DMRVQCB FM C20H35NO3
DMRVQCB IC InChI=1S/C20H35NO3/c1-2-3-4-13-16-19(22)21-18-15-12-10-8-6-5-7-9-11-14-17-20(23)24/h2-6,8,10-18H2,1H3,(H,21,22)(H,23,24)
DMRVQCB CS CCCCCCC(=O)NCCCCCCCC#CCCCC(=O)O
DMRVQCB IK UGVCHIUURWYSNO-UHFFFAOYSA-N
DMRVQCB IU 13-(heptanoylamino)tridec-5-ynoic acid
DMRVQCB DE Discovery agent
DM0LGWJ ID DM0LGWJ
DM0LGWJ DN 13-n-Heptanamidotridec-8(Z)-enoic acid
DM0LGWJ HS Investigative
DM0LGWJ SN CHEMBL560420; 13-n-Heptanamidotridec-8(Z)-enoic acid
DM0LGWJ DT Small molecular drug
DM0LGWJ PC 44235171
DM0LGWJ MW 339.5
DM0LGWJ FM C20H37NO3
DM0LGWJ IC InChI=1S/C20H37NO3/c1-2-3-4-13-16-19(22)21-18-15-12-10-8-6-5-7-9-11-14-17-20(23)24/h6,8H,2-5,7,9-18H2,1H3,(H,21,22)(H,23,24)/b8-6-
DM0LGWJ CS CCCCCCC(=O)NCCCC/C=C\\CCCCCCC(=O)O
DM0LGWJ IK QCBRCTHDMJHJJU-VURMDHGXSA-N
DM0LGWJ IU (Z)-13-(heptanoylamino)tridec-8-enoic acid
DM0LGWJ DE Discovery agent
DM5NFB6 ID DM5NFB6
DM5NFB6 DN 14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid
DM5NFB6 HS Investigative
DM5NFB6 SN CHEMBL561706; 14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid
DM5NFB6 DT Small molecular drug
DM5NFB6 PC 44235175
DM5NFB6 MW 339.5
DM5NFB6 FM C20H37NO3
DM5NFB6 IC InChI=1S/C20H37NO3/c1-2-3-4-15-18-21-19(22)16-13-11-9-7-5-6-8-10-12-14-17-20(23)24/h5,7H,2-4,6,8-18H2,1H3,(H,21,22)(H,23,24)/b7-5-
DM5NFB6 CS CCCCCCNC(=O)CCCC/C=C\\CCCCCCC(=O)O
DM5NFB6 IK RDDSCWVCGRBWBZ-ALCCZGGFSA-N
DM5NFB6 IU (Z)-14-(hexylamino)-14-oxotetradec-8-enoic acid
DM5NFB6 DE Discovery agent
DMLZT64 ID DMLZT64
DMLZT64 DN 1400W
DMLZT64 HS Investigative
DMLZT64 SN N-(3-(Aminomethyl)benzyl)acetamidine; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; 180001-34-7; N-(3-(aminomethyl)benzyl)-acetamidine; n-[3-(aminomethyl)benzyl]ethanimidamide; CHEMBL107251; CHEBI:90721; N-{[3-(aminomethyl)phenyl]methyl}ethanimidamide; RODUKNYOEVZQPR-UHFFFAOYSA-N; n-[3-(aminomethyl)benzyl]acetamidine; N-(3-(aminomethyl)benzyl)acetimidamide; N-(3-Aminomethyl-benzyl)-acetamidine; CHEMBL544788; 14W; N-[[3-(Aminomethyl)phenyl]methyl]ethanimidamide; Bio1_001405; Tocris-1415; AC1Q4SXP; AC1L1BGT; Lopac-W-4262; W 1400; SCHEMBL4467; Lopac0_001258; W 1400; N-(3-(Aminomethyl)Benzyl)Acetamidine; N-(3-(aminomethyl)-benzyl)acetamidine
DMLZT64 DT Small molecular drug
DMLZT64 PC 1433
DMLZT64 MW 177.25
DMLZT64 FM C10H15N3
DMLZT64 IC InChI=1S/C10H15N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5H,6-7,11H2,1H3,(H2,12,13)
DMLZT64 CS CC(=NCC1=CC=CC(=C1)CN)N
DMLZT64 IK RODUKNYOEVZQPR-UHFFFAOYSA-N
DMLZT64 IU N'-[[3-(aminomethyl)phenyl]methyl]ethanimidamide
DMLZT64 CA CAS 180001-34-7
DMLZT64 CB CHEBI:90721
DMLZT64 DE Discovery agent
DMI7LXH ID DMI7LXH
DMI7LXH DN 14-O-phenylpropylnaltrexone
DMI7LXH HS Investigative
DMI7LXH SN 14-O-phenylpropylnaltrexone; CHEMBL514774; SCHEMBL3167650; BDBM50249017
DMI7LXH DT Small molecular drug
DMI7LXH PC 44565511
DMI7LXH MW 459.6
DMI7LXH FM C29H33NO4
DMI7LXH IC InChI=1S/C29H33NO4/c31-22-11-10-21-17-24-29(33-16-4-7-19-5-2-1-3-6-19)13-12-23(32)27-28(29,25(21)26(22)34-27)14-15-30(24)18-20-8-9-20/h1-3,5-6,10-11,20,24,27,31H,4,7-9,12-18H2/t24-,27+,28+,29-/m1/s1
DMI7LXH CS C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)OCCCC7=CC=CC=C7
DMI7LXH IK KOXWKZKLXNZQAO-ZLPBPMGLSA-N
DMI7LXH IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-9-hydroxy-4a-(3-phenylpropoxy)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMI7LXH DE Discovery agent
DMY9ZT8 ID DMY9ZT8
DMY9ZT8 DN 15(R)-15-methyl-PGD2
DMY9ZT8 HS Investigative
DMY9ZT8 SN 15R-15-methyl PGD2
DMY9ZT8 DT Small molecular drug
DMY9ZT8 PC 5283097
DMY9ZT8 MW 366.5
DMY9ZT8 FM C21H34O5
DMY9ZT8 IC InChI=1S/C21H34O5/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25/h5,7,12,14,16-18,22,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25)/b7-5-,14-12+/t16-,17-,18+,21-/m1/s1
DMY9ZT8 CS CCCCC[C@](C)(/C=C/[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O)O
DMY9ZT8 IK CTXLUMAOXBULOZ-BKVRKCTKSA-N
DMY9ZT8 IU (Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3R)-3-hydroxy-3-methyloct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
DMY9ZT8 CA CAS 210978-26-0
DMY9ZT8 DE Discovery agent
DMG273T ID DMG273T
DMG273T DN 15(S)-15-methyl-PGD2
DMG273T HS Investigative
DMG273T SN BRN 5989341
DMG273T DT Small molecular drug
DMG273T PC 5283051
DMG273T MW 366.5
DMG273T FM C21H34O5
DMG273T IC InChI=1S/C21H34O5/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25/h5,7,12,14,16-18,22,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25)/b7-5-,14-12+/t16-,17-,18+,21+/m1/s1
DMG273T CS CCCCC[C@@](C)(/C=C/[C@@H]1[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O)O
DMG273T IK CTXLUMAOXBULOZ-QEQARHSSSA-N
DMG273T IU (Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxy-3-methyloct-1-enyl]-3-oxocyclopentyl]hept-5-enoic acid
DMG273T CA CAS 85280-90-6
DMG273T DE Discovery agent
DMLSZW2 ID DMLSZW2
DMLSZW2 DN 15-ACETOXY-EREMANTHOLIDE B
DMLSZW2 HS Investigative
DMLSZW2 SN 15-acetoxy-eremantholide B
DMLSZW2 DT Small molecular drug
DMLSZW2 PC 44398297
DMLSZW2 MW 420.5
DMLSZW2 FM C22H28O8
DMLSZW2 IC InChI=1S/C22H28O8/c1-6-11(2)22(26)21(5)18-15(28-19(21)25)7-13(10-27-12(3)23)14-8-17(24)20(4,29-14)9-16(18)30-22/h7-8,11,15-16,18,26H,6,9-10H2,1-5H3/b13-7-/t11-,15-,16+,18?,20-,21-,22-/m1/s1
DMLSZW2 CS CC[C@@H](C)[C@@]1([C@@]2(C3[C@@H](O1)C[C@@]4(C(=O)C=C(O4)/C(=C\\[C@H]3OC2=O)/COC(=O)C)C)C)O
DMLSZW2 IK UNFGCPCUYMXWDG-MRPVOENGSA-N
DMLSZW2 IU [(1S,3R,7Z,9R,12S,13R)-13-[(2R)-butan-2-yl]-13-hydroxy-3,12-dimethyl-4,11-dioxo-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-dien-7-yl]methyl acetate
DMLSZW2 DE Discovery agent
DMJC0NQ ID DMJC0NQ
DMJC0NQ DN 15-DEOXYBUDLEIN A
DMJC0NQ HS Investigative
DMJC0NQ SN 15-deoxybudlein A; Atripliciolide angelate
DMJC0NQ DT Small molecular drug
DMJC0NQ PC 14314511
DMJC0NQ MW 358.4
DMJC0NQ FM C20H22O6
DMJC0NQ IC InChI=1S/C20H22O6/c1-6-10(2)18(22)25-15-9-20(5)16(21)8-13(26-20)11(3)7-14-17(15)12(4)19(23)24-14/h6-8,14-15,17H,4,9H2,1-3,5H3/b10-6-,11-7-/t14-,15-,17+,20-/m1/s1
DMJC0NQ CS C/C=C(/C)\\C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/C)C
DMJC0NQ IK QATUWZPYBIHFFR-JWHLFBEVSA-N
DMJC0NQ IU [(2Z,4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (Z)-2-methylbut-2-enoate
DMJC0NQ DE Discovery agent
DM8VUX3 ID DM8VUX3
DM8VUX3 DN 15-deoxy-Delta(12, 14)-prostaglandin J(2)
DM8VUX3 HS Investigative
DM8VUX3 SN 15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2
DM8VUX3 DT Small molecular drug
DM8VUX3 PC 5311211
DM8VUX3 MW 316.4
DM8VUX3 FM C20H28O3
DM8VUX3 IC InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6+,18-13+/t17-/m0/s1
DM8VUX3 CS CCCCC/C=C/C=C/1\\[C@H](C=CC1=O)C/C=C\\CCCC(=O)O
DM8VUX3 IK VHRUMKCAEVRUBK-GODQJPCRSA-N
DM8VUX3 IU (Z)-7-[(1S,5E)-5-[(E)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DM8VUX3 CA CAS 87893-55-8
DM8VUX3 CB CHEBI:34159
DM8VUX3 DE Discovery agent
DMJ27QT ID DMJ27QT
DMJ27QT DN 15-deoxy-Delta12,14-PGD2
DMJ27QT HS Investigative
DMJ27QT SN 15-deoxy-Delta12,14-prostaglandin D2; 15d-Delta12,14-PGD2
DMJ27QT DT Small molecular drug
DMJ27QT PC 5283052
DMJ27QT MW 334.4
DMJ27QT FM C20H30O4
DMJ27QT IC InChI=1S/C20H30O4/c1-2-3-4-5-6-9-12-16-17(19(22)15-18(16)21)13-10-7-8-11-14-20(23)24/h6-7,9-10,12,17,19,22H,2-5,8,11,13-15H2,1H3,(H,23,24)/b9-6+,10-7-,16-12+/t17-,19+/m1/s1
DMJ27QT CS CCCCC/C=C/C=C/1\\[C@H]([C@H](CC1=O)O)C/C=C\\CCCC(=O)O
DMJ27QT IK QUGBPWLPAUHDTI-PLGLXCLHSA-N
DMJ27QT IU (Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(E)-oct-2-enylidene]-3-oxocyclopentyl]hept-5-enoic acid
DMJ27QT CA CAS 85235-11-6
DMJ27QT DE Discovery agent
DMNDECA ID DMNDECA
DMNDECA DN 15-deoxy-Delta12,14-PGJ2
DMNDECA HS Investigative
DMNDECA SN 15d-Delta12,14-PGJ2; LS-125843
DMNDECA DT Small molecular drug
DMNDECA PC 5283035
DMNDECA MW 316.4
DMNDECA FM C20H28O3
DMNDECA IC InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6-,18-13+/t17-/m0/s1
DMNDECA CS CCCCC/C=C\\C=C\\1/[C@H](C=CC1=O)C/C=C\\CCCC(=O)O
DMNDECA IK VHRUMKCAEVRUBK-WKELIDJCSA-N
DMNDECA IU (Z)-7-[(1S,5E)-5-[(Z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DMNDECA CA CAS 87893-55-8
DMNDECA DE Discovery agent
DMR9SFM ID DMR9SFM
DMR9SFM DN 15-deoxygoiazensolide
DMR9SFM HS Investigative
DMR9SFM SN Calaxin; CHEBI:3302; 15-deoxygoiazensolide; 30412-86-3; C09353; CHEMBL189790; 2-Propenoic acid, 2-methyl-, 2,3,3a,4,5,6,7,11a-octahydro-6,10-dimethyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca(b)furan-4-yl ester, (3aR-(3aR*,4R*,6R*,10Z,11aR*))-
DMR9SFM DT Small molecular drug
DMR9SFM PC 5281431
DMR9SFM MW 344.4
DMR9SFM FM C19H20O6
DMR9SFM IC InChI=1S/C19H20O6/c1-9(2)17(21)24-14-8-19(5)15(20)7-12(25-19)10(3)6-13-16(14)11(4)18(22)23-13/h6-7,13-14,16H,1,4,8H2,2-3,5H3/b10-6-/t13-,14-,16+,19-/m1/s1
DMR9SFM CS C/C/1=C/[C@@H]2[C@@H]([C@@H](C[C@@]3(C(=O)C=C1O3)C)OC(=O)C(=C)C)C(=C)C(=O)O2
DMR9SFM IK RYBHZNMPMHOBAR-IRNKKCRZSA-N
DMR9SFM IU [(2Z,4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] 2-methylprop-2-enoate
DMR9SFM CA CAS 30412-86-3
DMR9SFM CB CHEBI:3302
DMR9SFM DE Discovery agent
DMEML8B ID DMEML8B
DMEML8B DN 15-hydroxyeicosatetraenoic acid
DMEML8B HS Investigative
DMEML8B SN 15-Hydroxyeicosatetraenoic acid; Eicosatetraenoic acid, 15-hydroxy-; AC1O5OKC; SCHEMBL462602; LS-63796; (2E,4E,6E,8E)-15-hydroxyicosa-2,4,6,8-tetraenoic acid
DMEML8B DT Small molecular drug
DMEML8B PC 6437873
DMEML8B MW 320.5
DMEML8B FM C20H32O3
DMEML8B IC InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-6,8,10,12,15,18-19,21H,2-3,7,9,11,13-14,16-17H2,1H3,(H,22,23)/b5-4+,8-6+,12-10+,18-15+
DMEML8B CS CCCCCC(CCCCC/C=C/C=C/C=C/C=C/C(=O)O)O
DMEML8B IK GQHZVWMHPQXBIA-QYANQBPOSA-N
DMEML8B IU (2E,4E,6E,8E)-15-hydroxyicosa-2,4,6,8-tetraenoic acid
DMEML8B CA CAS 73180-00-4
DMEML8B DE Discovery agent
DMQCRUG ID DMQCRUG
DMQCRUG DN 15-isobutyrylmiguanin
DMQCRUG HS Investigative
DMQCRUG SN 15-isobutyrylmiguanin
DMQCRUG DT Small molecular drug
DMQCRUG PC 12039267
DMQCRUG MW 348.4
DMQCRUG FM C19H24O6
DMQCRUG IC InChI=1S/C19H24O6/c1-11(2)18(22)24-10-13-5-4-6-14(9-20)16(21)8-15-12(3)19(23)25-17(15)7-13/h6-7,11,15,17,20H,3-5,8-10H2,1-2H3/b13-7-,14-6+/t15-,17+/m0/s1
DMQCRUG CS CC(C)C(=O)OC/C/1=C\\[C@@H]2[C@@H](CC(=O)/C(=C/CC1)/CO)C(=C)C(=O)O2
DMQCRUG IK TXZUNEFLWSLHBF-UZBZFLIQSA-N
DMQCRUG IU [(3aS,6E,10Z,11aR)-6-(hydroxymethyl)-3-methylidene-2,5-dioxo-4,8,9,11a-tetrahydro-3aH-cyclodeca[b]furan-10-yl]methyl 2-methylpropanoate
DMQCRUG DE Discovery agent
DMDKFGX ID DMDKFGX
DMDKFGX DN 15-nor-18-Methoxycornaridine
DMDKFGX HS Investigative
DMDKFGX SN CHEMBL607096
DMDKFGX DT Small molecular drug
DMDKFGX PC 46877891
DMDKFGX MW 354.4
DMDKFGX FM C21H26N2O3
DMDKFGX IC InChI=1S/C21H26N2O3/c1-25-10-8-14-13-11-21(20(24)26-2)18-16(7-9-23(12-13)19(14)21)15-5-3-4-6-17(15)22-18/h3-6,13-14,19,22H,7-12H2,1-2H3/t13?,14?,19-,21+/m0/s1
DMDKFGX CS COCCC1[C@H]2[C@]3(CC1CN2CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMDKFGX IK VNPGFSWKZRZJCI-XZKBRSTLSA-N
DMDKFGX IU methyl (1S,17S)-16-(2-methoxyethyl)-3,13-diazapentacyclo[13.2.1.02,10.04,9.013,17]octadeca-2(10),4,6,8-tetraene-1-carboxylate
DMDKFGX DE Discovery agent
DM41LV6 ID DM41LV6
DM41LV6 DN 15S-HPETE
DM41LV6 HS Investigative
DM41LV6 SN 15(S)-HPETE; 15-(S)-hydroperoxyeicosatetraenoic acid
DM41LV6 DT Small molecular drug
DM41LV6 PC 5280893
DM41LV6 MW 336.5
DM41LV6 FM C20H32O4
DM41LV6 IC InChI=1S/C20H32O4/c1-2-3-13-16-19(24-23)17-14-11-9-7-5-4-6-8-10-12-15-18-20(21)22/h4-5,8-11,14,17,19,23H,2-3,6-7,12-13,15-16,18H2,1H3,(H,21,22)/b5-4-,10-8-,11-9-,17-14+/t19-/m0/s1
DM41LV6 CS CCCCC[C@@H](/C=C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O)OO
DM41LV6 IK BFWYTORDSFIVKP-VAEKSGALSA-N
DM41LV6 IU (5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
DM41LV6 CA CAS 70981-96-3
DM41LV6 CB CHEBI:15628
DM41LV6 DE Discovery agent
DMK4N2F ID DMK4N2F
DMK4N2F DN 16-(2',2'-Dimethyl)-propylidene-estradiol
DMK4N2F HS Investigative
DMK4N2F SN SCHEMBL12379675
DMK4N2F DT Small molecular drug
DMK4N2F PC 44407372
DMK4N2F MW 340.5
DMK4N2F FM C23H32O2
DMK4N2F IC InChI=1S/C23H32O2/c1-22(2,3)13-15-12-20-19-7-5-14-11-16(24)6-8-17(14)18(19)9-10-23(20,4)21(15)25/h6,8,11,13,18-21,24-25H,5,7,9-10,12H2,1-4H3/b15-13+/t18?,19?,20?,21-,23-/m0/s1
DMK4N2F CS C[C@]12CCC3C(C1C/C(=C\\C(C)(C)C)/[C@@H]2O)CCC4=C3C=CC(=C4)O
DMK4N2F IK GJYCOULXILNZBK-LBIHAFKNSA-N
DMK4N2F IU (13S,16E,17S)-16-(2,2-dimethylpropylidene)-13-methyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMK4N2F DE Discovery agent
DMQYJB1 ID DMQYJB1
DMQYJB1 DN 16-(2',2'-Dimethyl)-propylidene-estrone
DMQYJB1 HS Investigative
DMQYJB1 SN SCHEMBL12379631
DMQYJB1 DT Small molecular drug
DMQYJB1 PC 44407482
DMQYJB1 MW 338.5
DMQYJB1 FM C23H30O2
DMQYJB1 IC InChI=1S/C23H30O2/c1-22(2,3)13-15-12-20-19-7-5-14-11-16(24)6-8-17(14)18(19)9-10-23(20,4)21(15)25/h6,8,11,13,18-20,24H,5,7,9-10,12H2,1-4H3/b15-13+/t18?,19?,20?,23-/m0/s1
DMQYJB1 CS C[C@]12CCC3C(C1C/C(=C\\C(C)(C)C)/C2=O)CCC4=C3C=CC(=C4)O
DMQYJB1 IK FSXMOAXUKSPGCO-MIWZRYNRSA-N
DMQYJB1 IU (13S,16E)-16-(2,2-dimethylpropylidene)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DMQYJB1 DE Discovery agent
DMCHMNF ID DMCHMNF
DMCHMNF DN 16-(3-Ethylureido)hexadec-11(Z)-enoic acid
DMCHMNF HS Investigative
DMCHMNF SN CHEMBL560030; 16-(3-Ethylureido)hexadec-11(Z)-enoic acid; SCHEMBL3702468; BDBM50295084
DMCHMNF DT Small molecular drug
DMCHMNF PC 44234916
DMCHMNF MW 340.5
DMCHMNF FM C19H36N2O3
DMCHMNF IC InChI=1S/C19H36N2O3/c1-2-20-19(24)21-17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18(22)23/h7,9H,2-6,8,10-17H2,1H3,(H,22,23)(H2,20,21,24)/b9-7-
DMCHMNF CS CCNC(=O)NCCCC/C=C\\CCCCCCCCCC(=O)O
DMCHMNF IK OUFBVXMGWWCVFO-CLFYSBASSA-N
DMCHMNF IU (Z)-16-(ethylcarbamoylamino)hexadec-11-enoic acid
DMCHMNF DE Discovery agent
DMTAXZI ID DMTAXZI
DMTAXZI DN 16-(4-cyano-benzylidene)-estradiol
DMTAXZI HS Investigative
DMTAXZI SN SCHEMBL12379740
DMTAXZI DT Small molecular drug
DMTAXZI PC 44407411
DMTAXZI MW 385.5
DMTAXZI FM C26H27NO2
DMTAXZI IC InChI=1S/C26H27NO2/c1-26-11-10-22-21-9-7-20(28)13-18(21)6-8-23(22)24(26)14-19(25(26)29)12-16-2-4-17(15-27)5-3-16/h2-5,7,9,12-13,22-25,28-29H,6,8,10-11,14H2,1H3/b19-12+/t22?,23?,24?,25-,26-/m0/s1
DMTAXZI CS C[C@]12CCC3C(C1C/C(=C\\C4=CC=C(C=C4)C#N)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMTAXZI IK RMEMBAHSFFEOKG-HNTYVEMZSA-N
DMTAXZI IU 4-[(E)-[(13S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthren-16-ylidene]methyl]benzonitrile
DMTAXZI DE Discovery agent
DMEH8I0 ID DMEH8I0
DMEH8I0 DN 16-(4-dimethylamino-benzylidene)-estradiol
DMEH8I0 HS Investigative
DMEH8I0 SN SCHEMBL12379373
DMEH8I0 DT Small molecular drug
DMEH8I0 PC 44407495
DMEH8I0 MW 403.6
DMEH8I0 FM C27H33NO2
DMEH8I0 IC InChI=1S/C27H33NO2/c1-27-13-12-23-22-11-9-21(29)15-18(22)6-10-24(23)25(27)16-19(26(27)30)14-17-4-7-20(8-5-17)28(2)3/h4-5,7-9,11,14-15,23-26,29-30H,6,10,12-13,16H2,1-3H3/b19-14+/t23?,24?,25?,26-,27-/m0/s1
DMEH8I0 CS C[C@]12CCC3C(C1C/C(=C\\C4=CC=C(C=C4)N(C)C)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMEH8I0 IK HUZDSTZYTXBRMO-BACVCVEMSA-N
DMEH8I0 IU (13S,16E,17S)-16-[[4-(dimethylamino)phenyl]methylidene]-13-methyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMEH8I0 DE Discovery agent
DMX8YCK ID DMX8YCK
DMX8YCK DN 16-(4-dimethylamino-benzylidene)-estrone
DMX8YCK HS Investigative
DMX8YCK SN SCHEMBL12379372
DMX8YCK DT Small molecular drug
DMX8YCK PC 44407477
DMX8YCK MW 401.5
DMX8YCK FM C27H31NO2
DMX8YCK IC InChI=1S/C27H31NO2/c1-27-13-12-23-22-11-9-21(29)15-18(22)6-10-24(23)25(27)16-19(26(27)30)14-17-4-7-20(8-5-17)28(2)3/h4-5,7-9,11,14-15,23-25,29H,6,10,12-13,16H2,1-3H3/b19-14+/t23?,24?,25?,27-/m0/s1
DMX8YCK CS C[C@]12CCC3C(C1C/C(=C\\C4=CC=C(C=C4)N(C)C)/C2=O)CCC5=C3C=CC(=C5)O
DMX8YCK IK ZDWWQQXXGWLFMH-IMNIJDOTSA-N
DMX8YCK IU (13S,16E)-16-[[4-(dimethylamino)phenyl]methylidene]-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DMX8YCK DE Discovery agent
DMIC0OU ID DMIC0OU
DMIC0OU DN 16-(pyridin-2-yl)methylene-estradiol
DMIC0OU HS Investigative
DMIC0OU SN SCHEMBL12379723
DMIC0OU DT Small molecular drug
DMIC0OU PC 44407498
DMIC0OU MW 361.5
DMIC0OU FM C24H27NO2
DMIC0OU IC InChI=1S/C24H27NO2/c1-24-10-9-20-19-8-6-18(26)13-15(19)5-7-21(20)22(24)14-16(23(24)27)12-17-4-2-3-11-25-17/h2-4,6,8,11-13,20-23,26-27H,5,7,9-10,14H2,1H3/b16-12+/t20?,21?,22?,23-,24-/m0/s1
DMIC0OU CS C[C@]12CCC3C(C1C/C(=C\\C4=CC=CC=N4)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMIC0OU IK NEJZGGCMSBCPLE-NSLXHHGFSA-N
DMIC0OU IU (13S,16E,17S)-13-methyl-16-(pyridin-2-ylmethylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMIC0OU DE Discovery agent
DMSXFG0 ID DMSXFG0
DMSXFG0 DN 16-(pyridin-2-yl)methyl-estradiol
DMSXFG0 HS Investigative
DMSXFG0 DT Small molecular drug
DMSXFG0 PC 44407461
DMSXFG0 MW 363.5
DMSXFG0 FM C24H29NO2
DMSXFG0 IC InChI=1S/C24H29NO2/c1-24-10-9-20-19-8-6-18(26)13-15(19)5-7-21(20)22(24)14-16(23(24)27)12-17-4-2-3-11-25-17/h2-4,6,8,11,13,16,20-23,26-27H,5,7,9-10,12,14H2,1H3/t16-,20?,21?,22?,23-,24-/m0/s1
DMSXFG0 CS C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CC4=CC=CC=N4)CCC5=C3C=CC(=C5)O
DMSXFG0 IK SJHBYTOZADGQDY-CCXBEIMISA-N
DMSXFG0 IU (13S,16R,17S)-13-methyl-16-(pyridin-2-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMSXFG0 DE Discovery agent
DMIMZ21 ID DMIMZ21
DMIMZ21 DN 16-(pyridin-3-yl)methylene-estradiol
DMIMZ21 HS Investigative
DMIMZ21 SN SCHEMBL12379725
DMIMZ21 DT Small molecular drug
DMIMZ21 PC 44407494
DMIMZ21 MW 361.5
DMIMZ21 FM C24H27NO2
DMIMZ21 IC InChI=1S/C24H27NO2/c1-24-9-8-20-19-7-5-18(26)12-16(19)4-6-21(20)22(24)13-17(23(24)27)11-15-3-2-10-25-14-15/h2-3,5,7,10-12,14,20-23,26-27H,4,6,8-9,13H2,1H3/b17-11+/t20?,21?,22?,23-,24-/m0/s1
DMIMZ21 CS C[C@]12CCC3C(C1C/C(=C\\C4=CN=CC=C4)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMIMZ21 IK FCVLVYMOBDNAMK-PLNMCULSSA-N
DMIMZ21 IU (13S,16E,17S)-13-methyl-16-(pyridin-3-ylmethylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMIMZ21 DE Discovery agent
DMTD5AO ID DMTD5AO
DMTD5AO DN 16-(pyridin-3-yl)methyl-estradiol
DMTD5AO HS Investigative
DMTD5AO DT Small molecular drug
DMTD5AO PC 44407419
DMTD5AO MW 363.5
DMTD5AO FM C24H29NO2
DMTD5AO IC InChI=1S/C24H29NO2/c1-24-9-8-20-19-7-5-18(26)12-16(19)4-6-21(20)22(24)13-17(23(24)27)11-15-3-2-10-25-14-15/h2-3,5,7,10,12,14,17,20-23,26-27H,4,6,8-9,11,13H2,1H3/t17-,20?,21?,22?,23-,24-/m0/s1
DMTD5AO CS C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CC4=CN=CC=C4)CCC5=C3C=CC(=C5)O
DMTD5AO IK QLYAKILKANOLBC-ZCTINNFXSA-N
DMTD5AO IU (13S,16R,17S)-13-methyl-16-(pyridin-3-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMTD5AO DE Discovery agent
DMOTNPC ID DMOTNPC
DMOTNPC DN 16-(pyridin-4-yl)methylene-estradiol
DMOTNPC HS Investigative
DMOTNPC SN SCHEMBL12379722
DMOTNPC DT Small molecular drug
DMOTNPC PC 44407490
DMOTNPC MW 361.5
DMOTNPC FM C24H27NO2
DMOTNPC IC InChI=1S/C24H27NO2/c1-24-9-6-20-19-5-3-18(26)13-16(19)2-4-21(20)22(24)14-17(23(24)27)12-15-7-10-25-11-8-15/h3,5,7-8,10-13,20-23,26-27H,2,4,6,9,14H2,1H3/b17-12+/t20?,21?,22?,23-,24-/m0/s1
DMOTNPC CS C[C@]12CCC3C(C1C/C(=C\\C4=CC=NC=C4)/[C@@H]2O)CCC5=C3C=CC(=C5)O
DMOTNPC IK SOWVSBMETYFGLF-PHKWELIGSA-N
DMOTNPC IU (13S,16E,17S)-13-methyl-16-(pyridin-4-ylmethylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMOTNPC DE Discovery agent
DM7NSRI ID DM7NSRI
DM7NSRI DN 16-(pyridin-4-yl)methyl-estradiol
DM7NSRI HS Investigative
DM7NSRI DT Small molecular drug
DM7NSRI PC 44407464
DM7NSRI MW 363.5
DM7NSRI FM C24H29NO2
DM7NSRI IC InChI=1S/C24H29NO2/c1-24-9-6-20-19-5-3-18(26)13-16(19)2-4-21(20)22(24)14-17(23(24)27)12-15-7-10-25-11-8-15/h3,5,7-8,10-11,13,17,20-23,26-27H,2,4,6,9,12,14H2,1H3/t17-,20?,21?,22?,23-,24-/m0/s1
DM7NSRI CS C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CC4=CC=NC=C4)CCC5=C3C=CC(=C5)O
DM7NSRI IK HTDAGQQNWZEQOG-ZCTINNFXSA-N
DM7NSRI IU (13S,16R,17S)-13-methyl-16-(pyridin-4-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DM7NSRI DE Discovery agent
DME3XS4 ID DME3XS4
DME3XS4 DN 16-(thiophen-2-yl)methylene-estrone
DME3XS4 HS Investigative
DME3XS4 SN SCHEMBL12379730
DME3XS4 DT Small molecular drug
DME3XS4 PC 44407400
DME3XS4 MW 364.5
DME3XS4 FM C23H24O2S
DME3XS4 IC InChI=1S/C23H24O2S/c1-23-9-8-19-18-7-5-16(24)11-14(18)4-6-20(19)21(23)13-15(22(23)25)12-17-3-2-10-26-17/h2-3,5,7,10-12,19-21,24H,4,6,8-9,13H2,1H3/b15-12+/t19?,20?,21?,23-/m0/s1
DME3XS4 CS C[C@]12CCC3C(C1C/C(=C\\C4=CC=CS4)/C2=O)CCC5=C3C=CC(=C5)O
DME3XS4 IK NTDFYDJSLAOTRY-LUYQZUMISA-N
DME3XS4 IU (13S,16E)-3-hydroxy-13-methyl-16-(thiophen-2-ylmethylidene)-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DME3XS4 DE Discovery agent
DMI49D0 ID DMI49D0
DMI49D0 DN 16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid
DMI49D0 HS Investigative
DMI49D0 SN 16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid; CHEMBL379581; CHEMBL2373418
DMI49D0 DT Small molecular drug
DMI49D0 PC 44411588
DMI49D0 MW 404.6
DMI49D0 FM C25H40O4
DMI49D0 IC InChI=1S/C25H40O4/c1-16(2)12-21(26)29-15-18-14-25-11-8-19-23(3,20(25)7-6-17(18)13-25)9-5-10-24(19,4)22(27)28/h16-20H,5-15H2,1-4H3,(H,27,28)/t17-,18-,19?,20?,23-,24-,25+/m1/s1
DMI49D0 CS CC(C)CC(=O)OC[C@H]1C[C@@]23CCC4[C@](C2CC[C@@H]1C3)(CCC[C@@]4(C)C(=O)O)C
DMI49D0 IK ZOILZTWSQHWPGH-SLLFEXPVSA-N
DMI49D0 IU (1S,5R,9S,13R,14S)-5,9-dimethyl-14-(3-methylbutanoyloxymethyl)tetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
DMI49D0 DE Discovery agent
DMCMP9B ID DMCMP9B
DMCMP9B DN 16beta-cyano-estradiol
DMCMP9B HS Investigative
DMCMP9B DT Small molecular drug
DMCMP9B PC 53322423
DMCMP9B MW 297.4
DMCMP9B FM C19H23NO2
DMCMP9B IC InChI=1S/C19H23NO2/c1-19-7-6-15-14-5-3-13(21)8-11(14)2-4-16(15)17(19)9-12(10-20)18(19)22/h3,5,8,12,15-18,21-22H,2,4,6-7,9H2,1H3/t12-,15-,16-,17+,18+,19+/m1/s1
DMCMP9B CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2O)C#N)CCC4=C3C=CC(=C4)O
DMCMP9B IK IWVYOPUBSXDPSW-IEQBIMPXSA-N
DMCMP9B IU (8R,9S,13S,14S,16R,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carbonitrile
DMCMP9B DE Discovery agent
DMWJNV5 ID DMWJNV5
DMWJNV5 DN 16-beta-ethoxymethyl-estrone
DMWJNV5 HS Investigative
DMWJNV5 DT Small molecular drug
DMWJNV5 PC 44407402
DMWJNV5 MW 328.4
DMWJNV5 FM C21H28O3
DMWJNV5 IC InChI=1S/C21H28O3/c1-3-24-12-14-11-19-18-6-4-13-10-15(22)5-7-16(13)17(18)8-9-21(19,2)20(14)23/h5,7,10,14,17-19,22H,3-4,6,8-9,11-12H2,1-2H3/t14-,17?,18?,19?,21+/m1/s1
DMWJNV5 CS CCOC[C@H]1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMWJNV5 IK UOFWRCJSMZKWLE-NCHCSYJDSA-N
DMWJNV5 IU (13S,16R)-16-(ethoxymethyl)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DMWJNV5 DE Discovery agent
DMUW07J ID DMUW07J
DMUW07J DN 16-beta-hydroxymethyl-estradiol
DMUW07J HS Investigative
DMUW07J DT Small molecular drug
DMUW07J PC 44407401
DMUW07J MW 302.4
DMUW07J FM C19H26O3
DMUW07J IC InChI=1S/C19H26O3/c1-19-7-6-15-14-5-3-13(21)8-11(14)2-4-16(15)17(19)9-12(10-20)18(19)22/h3,5,8,12,15-18,20-22H,2,4,6-7,9-10H2,1H3/t12-,15?,16?,17?,18+,19+/m1/s1
DMUW07J CS C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)CO)CCC4=C3C=CC(=C4)O
DMUW07J IK MWYASXMURYJSCR-CMYKETFCSA-N
DMUW07J IU (13S,16R,17S)-16-(hydroxymethyl)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
DMUW07J DE Discovery agent
DMTZG68 ID DMTZG68
DMTZG68 DN 16-isobutylidene-estradiol
DMTZG68 HS Investigative
DMTZG68 SN SCHEMBL12379628
DMTZG68 DT Small molecular drug
DMTZG68 PC 53322980
DMTZG68 MW 326.5
DMTZG68 FM C22H30O2
DMTZG68 IC InChI=1S/C22H30O2/c1-13(2)10-15-12-20-19-6-4-14-11-16(23)5-7-17(14)18(19)8-9-22(20,3)21(15)24/h5,7,10-11,13,18-21,23-24H,4,6,8-9,12H2,1-3H3/b15-10+/t18-,19-,20+,21+,22+/m1/s1
DMTZG68 CS CC(C)/C=C/1\\C[C@H]2[C@@H]3CCC4=C([C@H]3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMTZG68 IK NOFDRMUQQIVAPE-PIEVVZFUSA-N
DMTZG68 IU (8R,9S,13S,14S,16E,17S)-13-methyl-16-(2-methylpropylidene)-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
DMTZG68 DE Discovery agent
DMS7PL3 ID DMS7PL3
DMS7PL3 DN 16-isobutylidene-estrone
DMS7PL3 HS Investigative
DMS7PL3 SN 16-isobutylidene-estrone
DMS7PL3 DT Small molecular drug
DMS7PL3 PC 11493555
DMS7PL3 MW 324.5
DMS7PL3 FM C22H28O2
DMS7PL3 IC InChI=1S/C22H28O2/c1-13(2)10-15-12-20-19-6-4-14-11-16(23)5-7-17(14)18(19)8-9-22(20,3)21(15)24/h5,7,10-11,13,18-20,23H,4,6,8-9,12H2,1-3H3/b15-10+/t18-,19-,20+,22+/m1/s1
DMS7PL3 CS CC(C)/C=C/1\\C[C@H]2[C@@H]3CCC4=C([C@H]3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMS7PL3 IK PTANBYHUNIXKEU-HDLVZFDGSA-N
DMS7PL3 IU (8R,9S,13S,14S,16E)-3-hydroxy-13-methyl-16-(2-methylpropylidene)-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-one
DMS7PL3 DE Discovery agent
DMDR1M6 ID DMDR1M6
DMDR1M6 DN 17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA)
DMDR1M6 HS Investigative
DMDR1M6 DE Discovery agent
DMUQWPZ ID DMUQWPZ
DMUQWPZ DN 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ HS Investigative
DMUQWPZ SN CHEMBL570225; 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine
DMUQWPZ DT Small molecular drug
DMUQWPZ PC 44627903
DMUQWPZ MW 386.6
DMUQWPZ FM C27H34N2
DMUQWPZ IC InChI=1S/C27H34N2/c1-2-9-22(10-3-1)28-23-13-12-21-17-26-24-11-4-5-14-27(24,25(21)18-23)15-16-29(26)19-20-7-6-8-20/h1-3,9-10,12-13,18,20,24,26,28H,4-8,11,14-17,19H2/t24-,26+,27+/m0/s1
DMUQWPZ CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC5=CC=CC=C5)CC6CCC6
DMUQWPZ IK JXXVPNRGUCGAEU-WYMJOSIYSA-N
DMUQWPZ IU (1R,9R,10R)-17-(cyclobutylmethyl)-N-phenyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DMUQWPZ DE Discovery agent
DM174HN ID DM174HN
DM174HN DN 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN HS Investigative
DM174HN SN CHEMBL568757; 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine
DM174HN DT Small molecular drug
DM174HN PC 44627900
DM174HN MW 372.5
DM174HN FM C26H32N2
DM174HN IC InChI=1S/C26H32N2/c1-2-6-21(7-3-1)27-22-12-11-20-16-25-23-8-4-5-13-26(23,24(20)17-22)14-15-28(25)18-19-9-10-19/h1-3,6-7,11-12,17,19,23,25,27H,4-5,8-10,13-16,18H2/t23-,25+,26+/m0/s1
DM174HN CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC5=CC=CC=C5)CC6CC6
DM174HN IK UVUFQEMGPJPSIS-SKBVVQJISA-N
DM174HN IU (1R,9R,10R)-17-(cyclopropylmethyl)-N-phenyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DM174HN DE Discovery agent
DMLC2VE ID DMLC2VE
DMLC2VE DN 177Lu-labelled RM2
DMLC2VE HS Investigative
DMLC2VE CP ABX GmbH
DMLC2VE DT Radiopharmaceutical therapy agent
DMLC2VE DE Solid tumour/cancer
DMT2EPG ID DMT2EPG
DMT2EPG DN 17alpha-hydroxypregnenolone
DMT2EPG HS Investigative
DMT2EPG SN 17alpha hydroxypregnenolone; 17-OH-pregnenolone; 17-hydroxypregnenolone
DMT2EPG DT Small molecular drug
DMT2EPG PC 91451
DMT2EPG MW 332.5
DMT2EPG FM C21H32O3
DMT2EPG IC InChI=1S/C21H32O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,15-18,23-24H,5-12H2,1-3H3/t15-,16+,17-,18-,19-,20-,21-/m0/s1
DMT2EPG CS CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)O
DMT2EPG IK JERGUCIJOXJXHF-TVWVXWENSA-N
DMT2EPG IU 1-[(3S,8R,9S,10R,13S,14S,17R)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
DMT2EPG CA CAS 387-79-1
DMT2EPG CB CHEBI:28750
DMT2EPG DE Discovery agent
DM7UHJS ID DM7UHJS
DM7UHJS DN 17-dehydroxyriccardin C
DM7UHJS HS Investigative
DM7UHJS SN 17-dehydroxyriccardin C; Riccardin C derivative, 20b; CHEMBL409652; BDBM23849; 2',4-[Ethylene-1,4-phenylene-oxy-(6-hydroxy-1,3-phenylene)-ethylene]-1,1'-biphenyl-2-ol
DM7UHJS DT Small molecular drug
DM7UHJS PC 24860511
DM7UHJS MW 408.5
DM7UHJS FM C28H24O3
DM7UHJS IC InChI=1S/C28H24O3/c29-26-16-11-21-6-5-20-10-15-25(27(30)17-20)24-4-2-1-3-22(24)12-7-19-8-13-23(14-9-19)31-28(26)18-21/h1-4,8-11,13-18,29-30H,5-7,12H2
DM7UHJS CS C1CC2=CC=CC=C2C3=C(C=C(CCC4=CC(=C(C=C4)O)OC5=CC=C1C=C5)C=C3)O
DM7UHJS IK OAEVJFPPXJHCKV-UHFFFAOYSA-N
DM7UHJS IU 14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaene-16,24-diol
DM7UHJS DE Discovery agent
DMCALYO ID DMCALYO
DMCALYO DN 17-desmethoxy-17-aminogeldanamycin
DMCALYO HS Investigative
DMCALYO SN UNII-SLQ1AJG3VB; SLQ1AJG3VB; 17-Aminogeldanamycin; 17-Amino-17-demethoxygeldanamycin; Geldanamycin, 17-amino-17-demethoxy-; 17-Amino Geldanamycin; SCHEMBL8250568; SCHEMBL16226317; XYFFWTYOFPSZRM-TWNAANEASA-N; DB13023; 1174669-94-3
DMCALYO DT Small molecular drug
DMCALYO PC 91929099
DMCALYO MW 545.6
DMCALYO FM C28H39N3O8
DMCALYO IC InChI=1S/C28H39N3O8/c1-14-10-18-23(29)20(32)13-19(25(18)34)31-27(35)15(2)8-7-9-21(37-5)26(39-28(30)36)17(4)12-16(3)24(33)22(11-14)38-6/h7-10,12-13,16,21-22,24,26,32-34H,11,29H2,1-6H3,(H2,30,36)(H,31,35)/b9-7-,14-10-,15-8+,17-12+/t16-,21-,22-,24+,26-/m0/s1
DMCALYO CS C[C@H]1/C=C(/[C@@H]([C@H](/C=C\\C=C(\\C(=O)NC2=CC(=C(C(=C2O)/C=C(\\C[C@@H]([C@@H]1O)OC)/C)N)O)/C)OC)OC(=O)N)\\C
DMCALYO IK VWTYNHIROMEOBP-PQMSMOMXSA-N
DMCALYO IU [(4E,6Z,8S,9S,10E,12S,13R,14S,16Z)-19-amino-13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,16,18(22),19-heptaen-9-yl] carbamate
DMCALYO DE Discovery agent
DMKUGH1 ID DMKUGH1
DMKUGH1 DN 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
DMKUGH1 HS Investigative
DMKUGH1 SN 17-Methyl-17-Alpha-Dihydroequilenin; 2b1z; ZINC5048688; DB06871; 17beta-Methyl-17alpha-dihydroequilenin; 17M; (13alpha,17beta)-17-methylestra-1(10),2,4,6,8-pentaene-3,17-diol
DMKUGH1 DT Small molecular drug
DMKUGH1 PC 9549180
DMKUGH1 MW 282.4
DMKUGH1 FM C19H22O2
DMKUGH1 IC InChI=1S/C19H22O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h3-6,11,17,20-21H,7-10H2,1-2H3/t17-,18-,19+/m0/s1
DMKUGH1 CS C[C@]12CCC3=C([C@@H]1CC[C@@]2(C)O)C=CC4=C3C=CC(=C4)O
DMKUGH1 IK FQMQOMRDADWGJJ-GBESFXJTSA-N
DMKUGH1 IU (13S,14S,17R)-13,17-dimethyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthrene-3,17-diol
DMKUGH1 CA CAS 1011733-40-6
DMKUGH1 DE Discovery agent
DMMEB64 ID DMMEB64
DMMEB64 DN 17-methyl-4'-methyldihydromorphinone
DMMEB64 HS Investigative
DMMEB64 SN CHEMBL607018
DMMEB64 DT Small molecular drug
DMMEB64 PC 44415081
DMMEB64 MW 444.5
DMMEB64 FM C27H28N2O4
DMMEB64 IC InChI=1S/C27H28N2O4/c1-16-3-5-17(6-4-16)7-10-22(32)28-27-12-11-20(31)25-26(27)13-14-29(2)21(27)15-18-8-9-19(30)24(33-25)23(18)26/h3-10,21,25,30H,11-15H2,1-2H3,(H,28,32)/b10-7+/t21?,25-,26-,27+/m0/s1
DMMEB64 CS CC1=CC=C(C=C1)/C=C/C(=O)N[C@@]23CCC(=O)[C@H]4[C@@]25CCN(C3CC6=C5C(=C(C=C6)O)O4)C
DMMEB64 IK JRFZMFGBYRTYRZ-KPAXYDNFSA-N
DMMEB64 IU (E)-N-[(4aS,7aR,12bR)-9-hydroxy-3-methyl-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-methylphenyl)prop-2-enamide
DMMEB64 DE Discovery agent
DMI4WCQ ID DMI4WCQ
DMI4WCQ DN 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ HS Investigative
DMI4WCQ SN CHEMBL568989; 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate
DMI4WCQ DT Small molecular drug
DMI4WCQ PC 44627904
DMI4WCQ MW 502.4
DMI4WCQ FM C24H27IN2O2
DMI4WCQ IC InChI=1S/C24H27IN2O2/c1-27-13-12-24-11-3-2-4-20(24)22(27)14-16-5-10-19(15-21(16)24)29-23(28)26-18-8-6-17(25)7-9-18/h5-10,15,20,22H,2-4,11-14H2,1H3,(H,26,28)/t20-,22+,24+/m0/s1
DMI4WCQ CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)OC(=O)NC5=CC=C(C=C5)I
DMI4WCQ IK YGDGBZQTGCWFHN-BGWNEDDSSA-N
DMI4WCQ IU [(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-(4-iodophenyl)carbamate
DMI4WCQ DE Discovery agent
DM9OMI3 ID DM9OMI3
DM9OMI3 DN 17-phenyl-omega-trinor-PGE2
DM9OMI3 HS Investigative
DM9OMI3 SN 17-phenyl-omega-trinor-prostaglandin E2; 17-phenyl-trinor-PGE2; 17-Ph-omega-trinor-PGE2; 17-phenyl-PGE2
DM9OMI3 DT Small molecular drug
DM9OMI3 PC 5283068
DM9OMI3 MW 386.5
DM9OMI3 FM C23H30O5
DM9OMI3 IC InChI=1S/C23H30O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-20,22,24,26H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,22+/m0/s1
DM9OMI3 CS C1[C@H]([C@@H]([C@H](C1=O)C/C=C\\CCCC(=O)O)/C=C/[C@H](CCC2=CC=CC=C2)O)O
DM9OMI3 IK FOBVMYJQWZOGGJ-XYRJXBATSA-N
DM9OMI3 IU (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
DM9OMI3 CA CAS 38315-43-4
DM9OMI3 CB CHEBI:87820
DM9OMI3 DE Discovery agent
DMYS6DB ID DMYS6DB
DMYS6DB DN 18alpha-Glycyrrhetic acid
DMYS6DB HS Investigative
DMYS6DB SN 18a-Glycyrrhetic acid; 18a-glycyrrhetinic acid; 1449-05-4; CHEMBL378653; 18ss -Glycyrrhetinic acid; SCHEMBL18539; MolPort-027-835-537; BDBM50185128; AKOS016009638; DS-5150; 3A-Hydroxy-11-oxo-18ss20ss -olean-12-en-29-oic acid
DMYS6DB DT Small molecular drug
DMYS6DB PC 12193680
DMYS6DB MW 470.7
DMYS6DB FM C30H46O4
DMYS6DB IC InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21?,22+,23-,26-,27+,28+,29-,30-/m1/s1
DMYS6DB CS C[C@]12CC[C@](C[C@@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C(C5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O
DMYS6DB IK MPDGHEJMBKOTSU-NFYGSHHYSA-N
DMYS6DB IU (2S,4aS,6aR,6aS,6bR,10S,12aS,14bS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
DMYS6DB CA CAS 471-53-4
DMYS6DB DE Discovery agent
DMFMRN8 ID DMFMRN8
DMFMRN8 DN 18beta-Glycyrrhetic acid
DMFMRN8 HS Investigative
DMFMRN8 SN 18b-Glycyrrhetic acid; CHEMBL208873; 18b-Glycyrrhetinic acid; Glycyrrhetinic Acid, 8; 18; A-Glycyrrhetintic Acid; SCHEMBL231125; BDBM23195; pentacyclic triterpene compound 8; MolPort-023-220-126; AKOS016009607; cent-GLYCYRRHETINTIC ACID; AS-11631; SC-17800; (2S,4aS,6aS,6bR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
DMFMRN8 DT Small molecular drug
DMFMRN8 PC 10114
DMFMRN8 MW 470.7
DMFMRN8 FM C30H46O4
DMFMRN8 IC InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1
DMFMRN8 CS C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O
DMFMRN8 IK MPDGHEJMBKOTSU-YKLVYJNSSA-N
DMFMRN8 IU (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
DMFMRN8 CA CAS 471-53-4
DMFMRN8 CB CHEBI:30853
DMFMRN8 DE Discovery agent
DM0JEQ6 ID DM0JEQ6
DM0JEQ6 DN 18-Dimethylaminocoronaridine
DM0JEQ6 HS Investigative
DM0JEQ6 SN 18-Dimethylaminocoronaridine
DM0JEQ6 DT Small molecular drug
DM0JEQ6 PC 46877893
DM0JEQ6 MW 381.5
DM0JEQ6 FM C23H31N3O2
DM0JEQ6 IC InChI=1S/C23H31N3O2/c1-25(2)10-8-16-12-15-13-23(22(27)28-3)20-18(9-11-26(14-15)21(16)23)17-6-4-5-7-19(17)24-20/h4-7,15-16,21,24H,8-14H2,1-3H3/t15?,16-,21-,23+/m0/s1
DM0JEQ6 CS CN(C)CC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DM0JEQ6 IK WUYGHHRQOSQDIC-NVVKDKPXSA-N
DM0JEQ6 IU methyl (1S,17R,18S)-17-[2-(dimethylamino)ethyl]-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DM0JEQ6 DE Discovery agent
DMAPI2G ID DMAPI2G
DMAPI2G DN 18F-AV-45 dimer
DMAPI2G HS Investigative
DMAPI2G SN AV-45 dimer
DMAPI2G CP Avid Radiopharmaceuticals Inc
DMAPI2G DE Cerebral amyloid angiopathy
DM2VZMC ID DM2VZMC
DM2VZMC DN 18F-SMIBR-K5
DM2VZMC HS Investigative
DM2VZMC SN SMIBR-K5; RGD-K5-[18F]; Fluorine-18-SMIBR-K5; Cyclic triazole bearing RGD peptide integrin alpha-v beta-3 imaging agent (cancer), Siemens; 18F-RGD-K5
DM2VZMC CP Siemens Medical Solutions Molecular Imaging
DM2VZMC DE Solid tumour/cancer
DMBG9Z3 ID DMBG9Z3
DMBG9Z3 DN 18-methoxycoronaridinate 2-Hydroxyethylamide
DMBG9Z3 HS Investigative
DMBG9Z3 SN 18-methoxycoronaridinate 2-Hydroxyethylamide
DMBG9Z3 DT Small molecular drug
DMBG9Z3 PC 46877897
DMBG9Z3 MW 397.5
DMBG9Z3 FM C23H31N3O3
DMBG9Z3 IC InChI=1S/C23H31N3O3/c1-29-11-7-16-12-15-13-23(22(28)24-8-10-27)20-18(6-9-26(14-15)21(16)23)17-4-2-3-5-19(17)25-20/h2-5,15-16,21,25,27H,6-14H2,1H3,(H,24,28)/t15?,16-,21-,23+/m0/s1
DMBG9Z3 CS COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)NCCO
DMBG9Z3 IK RPYHLEHPZWHJIE-NVVKDKPXSA-N
DMBG9Z3 IU (1S,17R,18S)-N-(2-hydroxyethyl)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxamide
DMBG9Z3 DE Discovery agent
DMSBAC0 ID DMSBAC0
DMSBAC0 DN 18-methoxycoronaridinate 2-methoxyethylamide
DMSBAC0 HS Investigative
DMSBAC0 SN 18-methoxycoronaridinate 2-methoxyethylamide
DMSBAC0 DT Small molecular drug
DMSBAC0 PC 46877896
DMSBAC0 MW 411.5
DMSBAC0 FM C24H33N3O3
DMSBAC0 IC InChI=1S/C24H33N3O3/c1-29-11-8-17-13-16-14-24(23(28)25-9-12-30-2)21-19(7-10-27(15-16)22(17)24)18-5-3-4-6-20(18)26-21/h3-6,16-17,22,26H,7-15H2,1-2H3,(H,25,28)/t16?,17-,22-,24+/m0/s1
DMSBAC0 CS COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)NCCOC
DMSBAC0 IK OLGJSZRDLAADNK-SAJNPJMVSA-N
DMSBAC0 IU (1S,17R,18S)-N,17-bis(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxamide
DMSBAC0 DE Discovery agent
DMTJ384 ID DMTJ384
DMTJ384 DN 18-Methoxycoronaridine
DMTJ384 HS Investigative
DMTJ384 SN 18-methoxycoronaridine; 308123-60-6; DTXSID40437331
DMTJ384 DT Small molecular drug
DMTJ384 PC 15479177
DMTJ384 MW 368.5
DMTJ384 FM C22H28N2O3
DMTJ384 IC InChI=1S/C22H28N2O3/c1-26-10-8-15-11-14-12-22(21(25)27-2)19-17(7-9-24(13-14)20(15)22)16-5-3-4-6-18(16)23-19/h3-6,14-15,20,23H,7-13H2,1-2H3/t14-,15+,20+,22-/m1/s1
DMTJ384 CS COCC[C@H]1C[C@@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMTJ384 IK DTJQBBHYRQYDEG-SVBQBFEESA-N
DMTJ384 IU methyl (1S,15R,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMTJ384 CA CAS 308123-60-6
DMTJ384 DE Drug abuse
DMOYC0U ID DMOYC0U
DMOYC0U DN 18-Methylaminocoronaridine
DMOYC0U HS Investigative
DMOYC0U SN 18-Methylaminocoronaridine
DMOYC0U DT Small molecular drug
DMOYC0U PC 46877894
DMOYC0U MW 367.5
DMOYC0U FM C22H29N3O2
DMOYC0U IC InChI=1S/C22H29N3O2/c1-23-9-7-15-11-14-12-22(21(26)27-2)19-17(8-10-25(13-14)20(15)22)16-5-3-4-6-18(16)24-19/h3-6,14-15,20,23-24H,7-13H2,1-2H3/t14?,15-,20-,22+/m0/s1
DMOYC0U CS CNCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMOYC0U IK YKMOJVPLIUXEIP-JNBMDGLNSA-N
DMOYC0U IU methyl (1S,17R,18S)-17-[2-(methylamino)ethyl]-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMOYC0U DE Discovery agent
DMGUKCF ID DMGUKCF
DMGUKCF DN 19(R)-OH-PGE2
DMGUKCF HS Investigative
DMGUKCF SN 19(R)-hydroxy-PGE2; 19R-(OH)-PGE2
DMGUKCF DT Small molecular drug
DMGUKCF PC 5283038
DMGUKCF MW 368.5
DMGUKCF FM C20H32O6
DMGUKCF IC InChI=1S/C20H32O6/c1-14(21)7-6-8-15(22)11-12-17-16(18(23)13-19(17)24)9-4-2-3-5-10-20(25)26/h2,4,11-12,14-17,19,21-22,24H,3,5-10,13H2,1H3,(H,25,26)/b4-2-,12-11+/t14-,15+,16-,17-,19-/m1/s1
DMGUKCF CS C[C@H](CCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\\CCCC(=O)O)O)O)O
DMGUKCF IK WTJYDBMHYPQFNJ-ZUVVJKHESA-N
DMGUKCF IU (Z)-7-[(1R,2R,3R)-2-[(E,3S,7R)-3,7-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid
DMGUKCF CA CAS 64625-54-3
DMGUKCF CB CHEBI:165313
DMGUKCF DE Discovery agent
DMP168O ID DMP168O
DMP168O DN 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid
DMP168O HS Investigative
DMP168O SN CHEMBL494111; 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid; BDBM50253117; 3-Oxo-19,24-dihydroxyurs-12-ene-28-oic acid
DMP168O DT Small molecular drug
DMP168O PC 10600994
DMP168O MW 486.7
DMP168O FM C30H46O5
DMP168O IC InChI=1S/C30H46O5/c1-18-9-14-30(24(33)34)16-15-27(4)19(23(30)29(18,6)35)7-8-21-25(2)12-11-22(32)26(3,17-31)20(25)10-13-28(21,27)5/h7,18,20-21,23,31,35H,8-17H2,1-6H3,(H,33,34)/t18-,20-,21-,23-,25+,26-,27-,28-,29-,30+/m1/s1
DMP168O CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CCC(=O)[C@]5(C)CO)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O
DMP168O IK DICFMPCEXYENLE-OGHVSZAPSA-N
DMP168O IU (1R,2R,4aS,6aR,6aS,6bR,8aR,9S,12aR,14bS)-1-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-2H-picene-4a-carboxylic acid
DMP168O DE Discovery agent
DM92ZCU ID DM92ZCU
DM92ZCU DN 1-acetamido-5-sulfonamidoindane
DM92ZCU HS Investigative
DM92ZCU SN N-(5-Sulfamoyl-indan-1-yl)-acetamide
DM92ZCU PC 11680415
DM92ZCU MW 254.31
DM92ZCU FM C11H14N2O3S
DM92ZCU IC InChI=1S/C11H14N2O3S/c1-7(14)13-11-5-2-8-6-9(17(12,15)16)3-4-10(8)11/h3-4,6,11H,2,5H2,1H3,(H,13,14)(H2,12,15,16)
DM92ZCU CS CC(=O)NC1CCC2=C1C=CC(=C2)S(=O)(=O)N
DM92ZCU IK RUUYVLNZHGCPRP-UHFFFAOYSA-N
DM92ZCU IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)acetamide
DM92ZCU DE Discovery agent
DM7DL03 ID DM7DL03
DM7DL03 DN 1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine
DM7DL03 HS Investigative
DM7DL03 SN CHEMBL564408; 1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine; 1-Acetoxy-2-TBS-lycorine; BDBM50293601; (1S,2S,3a1S,12bS)-2-(tert-butyldimethylsilyloxy)-2,3a1,4,5,7,12b-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-1-yl acetate
DM7DL03 DT Small molecular drug
DM7DL03 PC 44191463
DM7DL03 MW 443.6
DM7DL03 FM C24H33NO5Si
DM7DL03 IC InChI=1S/C24H33NO5Si/c1-14(26)29-23-20(30-31(5,6)24(2,3)4)9-15-7-8-25-12-16-10-18-19(28-13-27-18)11-17(16)21(23)22(15)25/h9-11,20-23H,7-8,12-13H2,1-6H3/t20-,21-,22+,23+/m0/s1
DM7DL03 CS CC(=O)O[C@@H]1[C@H](C=C2CCN3[C@H]2[C@@H]1C4=CC5=C(C=C4C3)OCO5)O[Si](C)(C)C(C)(C)C
DM7DL03 IK IQOBLYMQXROOIM-MYDTUXCISA-N
DM7DL03 IU [(1S,17S,18S,19S)-17-[tert-butyl(dimethyl)silyl]oxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-18-yl] acetate
DM7DL03 DE Discovery agent
DMMP7HU ID DMMP7HU
DMMP7HU DN 1'-acetoxychavicol acetate
DMMP7HU HS Investigative
DMMP7HU SN 1'-Acetoxychavicol acetate; 52946-22-2; 1'-Acetoxychavicol; UNII-SQV3080A20; CHEBI:469; 1'S-1'-Acetoxychavicol acetate; SQV3080A20; (alphaS)-4-(Acetyloxy)-alpha-ethenylbenzenemethanol; [4-[(1S)-1-acetyloxyprop-2-enyl]phenyl] acetate; Galangal acetate; (1S)-1-[4-(acetyloxy)phenyl]prop-2-en-1-yl acetate; Benzenemethanol, 4-(acetyloxy)-.alpha.-ethenyl-, acetate, (.alpha.S)-; CCRIS 7708; 1'-Acethoxychavicol; AC1Q60ZN; AC1L3O7Q; GTPL6298; CHEMBL323727; SCHEMBL17454871; (S)-1'-Acetoxychavicol Acetate; benzenemethanol, 4-(acetyloxy)-
DMMP7HU DT Small molecular drug
DMMP7HU PC 119104
DMMP7HU MW 234.25
DMMP7HU FM C13H14O4
DMMP7HU IC InChI=1S/C13H14O4/c1-4-13(17-10(3)15)11-5-7-12(8-6-11)16-9(2)14/h4-8,13H,1H2,2-3H3/t13-/m0/s1
DMMP7HU CS CC(=O)OC1=CC=C(C=C1)[C@H](C=C)OC(=O)C
DMMP7HU IK JAMQIUWGGBSIKZ-ZDUSSCGKSA-N
DMMP7HU IU [4-[(1S)-1-acetyloxyprop-2-enyl]phenyl] acetate
DMMP7HU CA CAS 52946-22-2
DMMP7HU CB CHEBI:469
DMMP7HU DE Discovery agent
DMQH1MS ID DMQH1MS
DMQH1MS DN 1-Acetoxylycorine
DMQH1MS HS Investigative
DMQH1MS SN 1-O-Acetyllycorine; 1-Acetoxylycorine; 1-Acetyllycorine; CHEMBL251077; CHEBI:31045; C12166; AC1L9EZ8; SCHEMBL12319390; BDBM50221063; acetic acid (1S,2S,12bS,12cS)-2-hydroxy-1,2,4,5,12b,12c-hexahydro-7H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-1-yl ester; (1S,2S,12bS,12cS)-1,2-Diol-2,4,5,7, 12b,12c-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1-acetate
DMQH1MS DT Small molecular drug
DMQH1MS PC 443672
DMQH1MS MW 329.3
DMQH1MS FM C18H19NO5
DMQH1MS IC InChI=1S/C18H19NO5/c1-9(20)24-18-13(21)4-10-2-3-19-7-11-5-14-15(23-8-22-14)6-12(11)16(18)17(10)19/h4-6,13,16-18,21H,2-3,7-8H2,1H3/t13-,16-,17+,18+/m0/s1
DMQH1MS CS CC(=O)O[C@@H]1[C@H](C=C2CCN3[C@H]2[C@@H]1C4=CC5=C(C=C4C3)OCO5)O
DMQH1MS IK BIGUPJIJZYZJMV-VIBAHUMZSA-N
DMQH1MS IU [(1S,17S,18S,19S)-17-hydroxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-18-yl] acetate
DMQH1MS CB CHEBI:31045
DMQH1MS DE Discovery agent
DMRJSG7 ID DMRJSG7
DMRJSG7 DN 1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea
DMRJSG7 HS Investigative
DMRJSG7 SN CHEMBL222080; 1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea
DMRJSG7 DT Small molecular drug
DMRJSG7 PC 44419692
DMRJSG7 MW 298.4
DMRJSG7 FM C19H26N2O
DMRJSG7 IC InChI=1S/C19H26N2O/c1-13(17-5-3-2-4-6-17)20-18(22)21-19-10-14-7-15(11-19)9-16(8-14)12-19/h2-6,13-16H,7-12H2,1H3,(H2,20,21,22)/t13-,14?,15?,16?,19?/m1/s1
DMRJSG7 CS C[C@H](C1=CC=CC=C1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMRJSG7 IK ODVZFEPLOWORBJ-PGBRGIIUSA-N
DMRJSG7 IU 1-(1-adamantyl)-3-[(1R)-1-phenylethyl]urea
DMRJSG7 DE Discovery agent
DMNXU1O ID DMNXU1O
DMNXU1O DN 1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea
DMNXU1O HS Investigative
DMNXU1O SN CHEMBL387034; AC1MG4WB; 1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea; SCHEMBL4349264; MolPort-001-589-466; BDBM100357; ZINC5041294; STK455719; BDBM50191877; AKOS003332205; MCULE-1433138775; ST50939640; SR-01000276706; 1-(1-adamantyl)-3-(1-benzylpiperidin-4-yl)urea; US8501783, 1158; SR-01000276706-1; N-adamantanyl{[1-benzyl(4-piperidyl)]amino}carboxamide
DMNXU1O DT Small molecular drug
DMNXU1O PC 2955557
DMNXU1O MW 367.5
DMNXU1O FM C23H33N3O
DMNXU1O IC InChI=1S/C23H33N3O/c27-22(25-23-13-18-10-19(14-23)12-20(11-18)15-23)24-21-6-8-26(9-7-21)16-17-4-2-1-3-5-17/h1-5,18-21H,6-16H2,(H2,24,25,27)
DMNXU1O CS C1CN(CCC1NC(=O)NC23CC4CC(C2)CC(C4)C3)CC5=CC=CC=C5
DMNXU1O IK SZCGIFNKYJVHTL-UHFFFAOYSA-N
DMNXU1O IU 1-(1-adamantyl)-3-(1-benzylpiperidin-4-yl)urea
DMNXU1O DE Discovery agent
DMAJC42 ID DMAJC42
DMAJC42 DN 1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea
DMAJC42 HS Investigative
DMAJC42 SN CHEMBL386820; 1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea; SCHEMBL5144023; BDBM100356; BDBM50191894; US8501783, 1160
DMAJC42 DT Small molecular drug
DMAJC42 PC 24849868
DMAJC42 MW 333.5
DMAJC42 FM C20H35N3O
DMAJC42 IC InChI=1S/C20H35N3O/c1-2-3-6-23-7-4-18(5-8-23)21-19(24)22-20-12-15-9-16(13-20)11-17(10-15)14-20/h15-18H,2-14H2,1H3,(H2,21,22,24)
DMAJC42 CS CCCCN1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMAJC42 IK FTNAVCVMGWLLJE-UHFFFAOYSA-N
DMAJC42 IU 1-(1-adamantyl)-3-(1-butylpiperidin-4-yl)urea
DMAJC42 DE Discovery agent
DMY1Z2X ID DMY1Z2X
DMY1Z2X DN 1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea
DMY1Z2X HS Investigative
DMY1Z2X SN CHEMBL214534; 1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea; SCHEMBL5146577
DMY1Z2X DT Small molecular drug
DMY1Z2X PC 44416958
DMY1Z2X MW 305.5
DMY1Z2X FM C18H31N3O
DMY1Z2X IC InChI=1S/C18H31N3O/c1-2-21-5-3-16(4-6-21)19-17(22)20-18-10-13-7-14(11-18)9-15(8-13)12-18/h13-16H,2-12H2,1H3,(H2,19,20,22)
DMY1Z2X CS CCN1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMY1Z2X IK SMBXAXBAAIGIAK-UHFFFAOYSA-N
DMY1Z2X IU 1-(1-adamantyl)-3-(1-ethylpiperidin-4-yl)urea
DMY1Z2X DE Discovery agent
DM2K7TX ID DM2K7TX
DM2K7TX DN 1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea
DM2K7TX HS Investigative
DM2K7TX SN CHEMBL215168; 1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea; SCHEMBL5144236; MolPort-028-759-082; BDBM100355; BDBM50191872; ZINC36330629; AKOS034496458; MCULE-1016100156; US8501783, 1155; 1-(adamantan-1-yl)-3-(1-propylpiperidin-4-yl)urea; Z642063290
DM2K7TX DT Small molecular drug
DM2K7TX PC 24849867
DM2K7TX MW 319.5
DM2K7TX FM C19H33N3O
DM2K7TX IC InChI=1S/C19H33N3O/c1-2-5-22-6-3-17(4-7-22)20-18(23)21-19-11-14-8-15(12-19)10-16(9-14)13-19/h14-17H,2-13H2,1H3,(H2,20,21,23)
DM2K7TX CS CCCN1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DM2K7TX IK OYDLKUZQSIKGSE-UHFFFAOYSA-N
DM2K7TX IU 1-(1-adamantyl)-3-(1-propylpiperidin-4-yl)urea
DM2K7TX DE Discovery agent
DMRIYX9 ID DMRIYX9
DMRIYX9 DN 1-adamantan-1-yl-3-(2-heptyloxyethyl)urea
DMRIYX9 HS Investigative
DMRIYX9 SN CHEMBL388004; 1-adamantan-1-yl-3-(2-heptyloxyethyl)urea; SCHEMBL12931851
DMRIYX9 DT Small molecular drug
DMRIYX9 PC 23631474
DMRIYX9 MW 336.5
DMRIYX9 FM C20H36N2O2
DMRIYX9 IC InChI=1S/C20H36N2O2/c1-2-3-4-5-6-8-24-9-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMRIYX9 CS CCCCCCCOCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMRIYX9 IK ADHBJDWCKMOLCA-UHFFFAOYSA-N
DMRIYX9 IU 1-(1-adamantyl)-3-(2-heptoxyethyl)urea
DMRIYX9 DE Discovery agent
DMDO9YM ID DMDO9YM
DMDO9YM DN 1-adamantan-1-yl-3-(2-hydroxyethyl)urea
DMDO9YM HS Investigative
DMDO9YM SN 1-adamantan-1-yl-3-(2-hydroxyethyl)urea; CHEMBL398166; 120615-92-1; NSC98656; 1-(1-adamantyl)-3-(2-hydroxyethyl)urea; AC1L6ASW; Oprea1_805585; CTK8A5210; MolPort-000-709-916; HMS1608K05; ZINC1643992; STK862338; BDBM50223393; IMED57309943; NSC-98656; AKOS023552817; AKOS001482962; MCULE-6824900815; N-1-adamantyl-N'-(2-hydroxyethyl)urea; EN300-234857; SR-01000396891; SR-01000396891-1; F0266-0451
DMDO9YM DT Small molecular drug
DMDO9YM PC 263942
DMDO9YM MW 238.33
DMDO9YM FM C13H22N2O2
DMDO9YM IC InChI=1S/C13H22N2O2/c16-2-1-14-12(17)15-13-6-9-3-10(7-13)5-11(4-9)8-13/h9-11,16H,1-8H2,(H2,14,15,17)
DMDO9YM CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCO
DMDO9YM IK BBHYFNMMUBVBEX-UHFFFAOYSA-N
DMDO9YM IU 1-(1-adamantyl)-3-(2-hydroxyethyl)urea
DMDO9YM DE Discovery agent
DMJ8ZS6 ID DMJ8ZS6
DMJ8ZS6 DN 1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea
DMJ8ZS6 HS Investigative
DMJ8ZS6 SN CHEMBL477670; 1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea; SCHEMBL6565549; BDBM50267092
DMJ8ZS6 DT Small molecular drug
DMJ8ZS6 PC 22932333
DMJ8ZS6 MW 286.37
DMJ8ZS6 FM C17H22N2O2
DMJ8ZS6 IC InChI=1S/C17H22N2O2/c20-15-4-2-1-3-14(15)18-16(21)19-17-8-11-5-12(9-17)7-13(6-11)10-17/h1-4,11-13,20H,5-10H2,(H2,18,19,21)
DMJ8ZS6 CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=CC=C4O
DMJ8ZS6 IK LYHYUDXVHBEHPM-UHFFFAOYSA-N
DMJ8ZS6 IU 1-(1-adamantyl)-3-(2-hydroxyphenyl)urea
DMJ8ZS6 DE Discovery agent
DMRBVFO ID DMRBVFO
DMRBVFO DN 1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea
DMRBVFO HS Investigative
DMRBVFO SN CHEMBL445531; 1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea; Oprea1_425301; Oprea1_433459; MolPort-001-590-368; ZINC5676460; STL504055; BDBM50267095; AKOS003326568; MCULE-4523135214; 1-(1-adamantyl)-3-(2-methoxyphenyl)urea; ST50933621; N-adamantanyl[(2-methoxyphenyl)amino]carboxamide
DMRBVFO DT Small molecular drug
DMRBVFO PC 17375075
DMRBVFO MW 300.4
DMRBVFO FM C18H24N2O2
DMRBVFO IC InChI=1S/C18H24N2O2/c1-22-16-5-3-2-4-15(16)19-17(21)20-18-9-12-6-13(10-18)8-14(7-12)11-18/h2-5,12-14H,6-11H2,1H3,(H2,19,20,21)
DMRBVFO CS COC1=CC=CC=C1NC(=O)NC23CC4CC(C2)CC(C4)C3
DMRBVFO IK KVPRHLDYUVRHBP-UHFFFAOYSA-N
DMRBVFO IU 1-(1-adamantyl)-3-(2-methoxyphenyl)urea
DMRBVFO DE Discovery agent
DMGEXOZ ID DMGEXOZ
DMGEXOZ DN 1-adamantan-1-yl-3-(3-hexyloxypropyl)urea
DMGEXOZ HS Investigative
DMGEXOZ SN CHEMBL245127; 1-adamantan-1-yl-3-(3-hexyloxypropyl)urea; SCHEMBL12931853
DMGEXOZ DT Small molecular drug
DMGEXOZ PC 23631475
DMGEXOZ MW 336.5
DMGEXOZ FM C20H36N2O2
DMGEXOZ IC InChI=1S/C20H36N2O2/c1-2-3-4-5-8-24-9-6-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMGEXOZ CS CCCCCCOCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMGEXOZ IK XMBHPHYTFZFYFH-UHFFFAOYSA-N
DMGEXOZ IU 1-(1-adamantyl)-3-(3-hexoxypropyl)urea
DMGEXOZ DE Discovery agent
DM8SEJP ID DM8SEJP
DM8SEJP DN 1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea
DM8SEJP HS Investigative
DM8SEJP SN CHEMBL477671; 1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea; SCHEMBL6568488; BDBM50267093
DM8SEJP DT Small molecular drug
DM8SEJP PC 22932424
DM8SEJP MW 286.37
DM8SEJP FM C17H22N2O2
DM8SEJP IC InChI=1S/C17H22N2O2/c20-15-3-1-2-14(7-15)18-16(21)19-17-8-11-4-12(9-17)6-13(5-11)10-17/h1-3,7,11-13,20H,4-6,8-10H2,(H2,18,19,21)
DM8SEJP CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC(=CC=C4)O
DM8SEJP IK FBTNUWJYRWKVCD-UHFFFAOYSA-N
DM8SEJP IU 1-(1-adamantyl)-3-(3-hydroxyphenyl)urea
DM8SEJP DE Discovery agent
DMZX72E ID DMZX72E
DMZX72E DN 1-adamantan-1-yl-3-(3-hydroxypropyl)urea
DMZX72E HS Investigative
DMZX72E SN CHEMBL242592; SMR000144635; 1-adamantan-1-yl-3-(3-hydroxypropyl)urea; AC1M3CD5; MLS000538598; MolPort-001-628-514; HMS2462I06; ZINC2882943; 1-(3-hydroxypropyl)-3-tricyclo[3.3.1.1~3,7~]dec-1-ylurea; STK207014; BDBM50223385; AKOS016321670; AKOS003366277; AKOS002318484; MCULE-4878985284; N-1-adamantyl-N'-(3-hydroxypropyl)urea; 1-(1-adamantyl)-3-(3-hydroxypropyl)urea; ST50766260
DMZX72E DT Small molecular drug
DMZX72E PC 2235217
DMZX72E MW 252.35
DMZX72E FM C14H24N2O2
DMZX72E IC InChI=1S/C14H24N2O2/c17-3-1-2-15-13(18)16-14-7-10-4-11(8-14)6-12(5-10)9-14/h10-12,17H,1-9H2,(H2,15,16,18)
DMZX72E CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCO
DMZX72E IK QADGUCFKHPQVSD-UHFFFAOYSA-N
DMZX72E IU 1-(1-adamantyl)-3-(3-hydroxypropyl)urea
DMZX72E DE Discovery agent
DMHAS3G ID DMHAS3G
DMHAS3G DN 1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea
DMHAS3G HS Investigative
DMHAS3G SN CHEMBL516890; 1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea; ZINC8167942; BDBM50267096
DMHAS3G DT Small molecular drug
DMHAS3G PC 44582391
DMHAS3G MW 300.4
DMHAS3G FM C18H24N2O2
DMHAS3G IC InChI=1S/C18H24N2O2/c1-22-16-4-2-3-15(8-16)19-17(21)20-18-9-12-5-13(10-18)7-14(6-12)11-18/h2-4,8,12-14H,5-7,9-11H2,1H3,(H2,19,20,21)
DMHAS3G CS COC1=CC=CC(=C1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMHAS3G IK QPAGLMBLMPXYKJ-UHFFFAOYSA-N
DMHAS3G IU 1-(1-adamantyl)-3-(3-methoxyphenyl)urea
DMHAS3G DE Discovery agent
DM53G1V ID DM53G1V
DM53G1V DN 1-adamantan-1-yl-3-(4-hydroxybutyl)urea
DM53G1V HS Investigative
DM53G1V SN CHEMBL397197; 1-adamantan-1-yl-3-(4-hydroxybutyl)urea
DM53G1V DT Small molecular drug
DM53G1V PC 16756510
DM53G1V MW 266.38
DM53G1V FM C15H26N2O2
DM53G1V IC InChI=1S/C15H26N2O2/c18-4-2-1-3-16-14(19)17-15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13,18H,1-10H2,(H2,16,17,19)
DM53G1V CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCO
DM53G1V IK GVVAZSZYNJNYGI-UHFFFAOYSA-N
DM53G1V IU 1-(1-adamantyl)-3-(4-hydroxybutyl)urea
DM53G1V DE Discovery agent
DMHKG89 ID DMHKG89
DMHKG89 DN 1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea
DMHKG89 HS Investigative
DMHKG89 SN CHEMBL195796; 1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea
DMHKG89 DT Small molecular drug
DMHKG89 PC 11772500
DMHKG89 MW 350.5
DMHKG89 FM C21H38N2O2
DMHKG89 IC InChI=1S/C21H38N2O2/c1-2-3-4-5-7-19(24)8-6-9-22-20(25)23-21-13-16-10-17(14-21)12-18(11-16)15-21/h16-19,24H,2-15H2,1H3,(H2,22,23,25)
DMHKG89 CS CCCCCCC(CCCNC(=O)NC12CC3CC(C1)CC(C3)C2)O
DMHKG89 IK BQABXUIGNYSGOR-UHFFFAOYSA-N
DMHKG89 IU 1-(1-adamantyl)-3-(4-hydroxydecyl)urea
DMHKG89 DE Discovery agent
DMUPAR1 ID DMUPAR1
DMUPAR1 DN 1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea
DMUPAR1 HS Investigative
DMUPAR1 SN CHEMBL477872; 1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea; SCHEMBL12932185; BDBM50267094; AKOS009210324
DMUPAR1 DT Small molecular drug
DMUPAR1 PC 28787671
DMUPAR1 MW 286.37
DMUPAR1 FM C17H22N2O2
DMUPAR1 IC InChI=1S/C17H22N2O2/c20-15-3-1-14(2-4-15)18-16(21)19-17-8-11-5-12(9-17)7-13(6-11)10-17/h1-4,11-13,20H,5-10H2,(H2,18,19,21)
DMUPAR1 CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=C(C=C4)O
DMUPAR1 IK NGFXIFJXNYMTPD-UHFFFAOYSA-N
DMUPAR1 IU 1-(1-adamantyl)-3-(4-hydroxyphenyl)urea
DMUPAR1 DE Discovery agent
DMMBYOD ID DMMBYOD
DMMBYOD DN 1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea
DMMBYOD HS Investigative
DMMBYOD SN 1-(1-adamantyl)-3-(4-methoxyphenyl)urea; CHEMBL477067; AC1MT5QX; 1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea; Oprea1_591947; BDBM50267097
DMMBYOD DT Small molecular drug
DMMBYOD PC 3545369
DMMBYOD MW 300.4
DMMBYOD FM C18H24N2O2
DMMBYOD IC InChI=1S/C18H24N2O2/c1-22-16-4-2-15(3-5-16)19-17(21)20-18-9-12-6-13(10-18)8-14(7-12)11-18/h2-5,12-14H,6-11H2,1H3,(H2,19,20,21)
DMMBYOD CS COC1=CC=C(C=C1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMMBYOD IK SITQZMUGNIFVIS-UHFFFAOYSA-N
DMMBYOD IU 1-(1-adamantyl)-3-(4-methoxyphenyl)urea
DMMBYOD DE Discovery agent
DM3RE2D ID DM3RE2D
DM3RE2D DN 1-adamantan-1-yl-3-(4-pentyloxybutyl)urea
DM3RE2D HS Investigative
DM3RE2D SN CHEMBL191767; 1-adamantan-1-yl-3-(4-pentyloxybutyl)urea; SCHEMBL12931855; BDBM50167050
DM3RE2D DT Small molecular drug
DM3RE2D PC 11186744
DM3RE2D MW 336.5
DM3RE2D FM C20H36N2O2
DM3RE2D IC InChI=1S/C20H36N2O2/c1-2-3-5-8-24-9-6-4-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DM3RE2D CS CCCCCOCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DM3RE2D IK UCGGVDAPMCFWNI-UHFFFAOYSA-N
DM3RE2D IU 1-(1-adamantyl)-3-(4-pentoxybutyl)urea
DM3RE2D DE Discovery agent
DMUZ3OS ID DMUZ3OS
DMUZ3OS DN 1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea
DMUZ3OS HS Investigative
DMUZ3OS SN CHEMBL439577; CHEMBL2031926; 1-(1-adamantyl)-3-(4-pentoxycyclohexyl)urea; 1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea; SCHEMBL3178050; BDBM50383478
DMUZ3OS DT Small molecular drug
DMUZ3OS PC 11417158
DMUZ3OS MW 362.5
DMUZ3OS FM C22H38N2O2
DMUZ3OS IC InChI=1S/C22H38N2O2/c1-2-3-4-9-26-20-7-5-19(6-8-20)23-21(25)24-22-13-16-10-17(14-22)12-18(11-16)15-22/h16-20H,2-15H2,1H3,(H2,23,24,25)
DMUZ3OS CS CCCCCOC1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMUZ3OS IK VIWCJPKZDQYQRJ-UHFFFAOYSA-N
DMUZ3OS IU 1-(1-adamantyl)-3-(4-pentoxycyclohexyl)urea
DMUZ3OS DE Discovery agent
DMEDQVX ID DMEDQVX
DMEDQVX DN 1-adamantan-1-yl-3-(5-butoxypentyl)urea
DMEDQVX HS Investigative
DMEDQVX SN CHEMBL245142; 1-adamantan-1-yl-3-(5-butoxypentyl)urea; SCHEMBL2050549
DMEDQVX DT Small molecular drug
DMEDQVX PC 23631476
DMEDQVX MW 336.5
DMEDQVX FM C20H36N2O2
DMEDQVX IC InChI=1S/C20H36N2O2/c1-2-3-8-24-9-6-4-5-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMEDQVX CS CCCCOCCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMEDQVX IK KBTVUXWBRNQXPI-UHFFFAOYSA-N
DMEDQVX IU 1-(1-adamantyl)-3-(5-butoxypentyl)urea
DMEDQVX DE Discovery agent
DMV6824 ID DMV6824
DMV6824 DN 1-adamantan-1-yl-3-(5-hydroxypentyl)urea
DMV6824 HS Investigative
DMV6824 SN CHEMBL245141; 1-adamantan-1-yl-3-(5-hydroxypentyl)urea; BDBM50223381
DMV6824 DT Small molecular drug
DMV6824 PC 23631733
DMV6824 MW 280.41
DMV6824 FM C16H28N2O2
DMV6824 IC InChI=1S/C16H28N2O2/c19-5-3-1-2-4-17-15(20)18-16-9-12-6-13(10-16)8-14(7-12)11-16/h12-14,19H,1-11H2,(H2,17,18,20)
DMV6824 CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCO
DMV6824 IK MMIRJMPACJKTFC-UHFFFAOYSA-N
DMV6824 IU 1-(1-adamantyl)-3-(5-hydroxypentyl)urea
DMV6824 DE Discovery agent
DMOX5MC ID DMOX5MC
DMOX5MC DN 1-adamantan-1-yl-3-(6-hydroxyhexyl)urea
DMOX5MC HS Investigative
DMOX5MC SN CHEMBL245143; 1-adamantan-1-yl-3-(6-hydroxyhexyl)urea
DMOX5MC DT Small molecular drug
DMOX5MC PC 23631734
DMOX5MC MW 294.4
DMOX5MC FM C17H30N2O2
DMOX5MC IC InChI=1S/C17H30N2O2/c20-6-4-2-1-3-5-18-16(21)19-17-10-13-7-14(11-17)9-15(8-13)12-17/h13-15,20H,1-12H2,(H2,18,19,21)
DMOX5MC CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCCCO
DMOX5MC IK FUMIBHNYGFMWPI-UHFFFAOYSA-N
DMOX5MC IU 1-(1-adamantyl)-3-(6-hydroxyhexyl)urea
DMOX5MC DE Discovery agent
DMO1L3I ID DMO1L3I
DMO1L3I DN 1-adamantan-1-yl-3-(6-propyloxyhexyl)urea
DMO1L3I HS Investigative
DMO1L3I SN CHEMBL245144; 1-adamantan-1-yl-3-(6-propyloxyhexyl)urea; SCHEMBL12931856
DMO1L3I DT Small molecular drug
DMO1L3I PC 9927748
DMO1L3I MW 336.5
DMO1L3I FM C20H36N2O2
DMO1L3I IC InChI=1S/C20H36N2O2/c1-2-8-24-9-6-4-3-5-7-21-19(23)22-20-13-16-10-17(14-20)12-18(11-16)15-20/h16-18H,2-15H2,1H3,(H2,21,22,23)
DMO1L3I CS CCCOCCCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMO1L3I IK GXOBIXGHFWBEMM-UHFFFAOYSA-N
DMO1L3I IU 1-(1-adamantyl)-3-(6-propoxyhexyl)urea
DMO1L3I DE Discovery agent
DMXRHKQ ID DMXRHKQ
DMXRHKQ DN 1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea
DMXRHKQ HS Investigative
DMXRHKQ SN CHEMBL387810; 1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea; BDBM50217475
DMXRHKQ DT Small molecular drug
DMXRHKQ PC 16756389
DMXRHKQ MW 360.5
DMXRHKQ FM C21H29FN2O2
DMXRHKQ IC InChI=1S/C21H29FN2O2/c22-18-3-5-19(6-4-18)26-8-2-1-7-23-20(25)24-21-12-15-9-16(13-21)11-17(10-15)14-21/h3-6,15-17H,1-2,7-14H2,(H2,23,24,25)
DMXRHKQ CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCCCCOC4=CC=C(C=C4)F
DMXRHKQ IK PVCKSZSZTVYJKW-UHFFFAOYSA-N
DMXRHKQ IU 1-(1-adamantyl)-3-[4-(4-fluorophenoxy)butyl]urea
DMXRHKQ DE Discovery agent
DMLD2G3 ID DMLD2G3
DMLD2G3 DN 1-Adamantan-1-yl-3-decyl-urea
DMLD2G3 HS Investigative
DMLD2G3 SN CHEMBL69663; 1-Adamantan-1-yl-3-decyl-urea; SCHEMBL4445372
DMLD2G3 DT Small molecular drug
DMLD2G3 PC 11151795
DMLD2G3 MW 334.5
DMLD2G3 FM C21H38N2O
DMLD2G3 IC InChI=1S/C21H38N2O/c1-2-3-4-5-6-7-8-9-10-22-20(24)23-21-14-17-11-18(15-21)13-19(12-17)16-21/h17-19H,2-16H2,1H3,(H2,22,23,24)
DMLD2G3 CS CCCCCCCCCCNC(=O)NC12CC3CC(C1)CC(C3)C2
DMLD2G3 IK KDYRDODPBAFNHJ-UHFFFAOYSA-N
DMLD2G3 IU 1-(1-adamantyl)-3-decylurea
DMLD2G3 DE Discovery agent
DMCFKX0 ID DMCFKX0
DMCFKX0 DN 1-Adamantan-1-yl-3-phenyl-urea
DMCFKX0 HS Investigative
DMCFKX0 SN 1-Adamantan-1-yl-3-phenyl-urea; CHEMBL516415; AC1MJEST; BAS 00102691; AC1Q5LN2; Oprea1_605405; Oprea1_553434; SCHEMBL1420838; IFLab1_001789; 1-(1-adamantyl)-3-phenylurea; 1-adamantan-1-yl-3-phenylurea; N-(1-adamantyl)-N'-phenylurea; 1-(1-adamantyl)-3-phenyl-urea; BOKJLWGPHOTBQZ-UHFFFAOYSA-N; MolPort-000-434-175; HMS1417B07; 3-(adamantan-1-yl)-1-phenylurea; ZINC6645734; N-adamantanyl(phenylamino)carboxamide; STL263876; BDBM50267067; AKOS003625202; AKOS001215839; MCULE-9094796377; UPCMLD0ENAT5533559:001; ST50049182; SR-01000363562
DMCFKX0 DT Small molecular drug
DMCFKX0 PC 3090774
DMCFKX0 MW 270.37
DMCFKX0 FM C17H22N2O
DMCFKX0 IC InChI=1S/C17H22N2O/c20-16(18-15-4-2-1-3-5-15)19-17-9-12-6-13(10-17)8-14(7-12)11-17/h1-5,12-14H,6-11H2,(H2,18,19,20)
DMCFKX0 CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=CC=C4
DMCFKX0 IK BOKJLWGPHOTBQZ-UHFFFAOYSA-N
DMCFKX0 IU 1-(1-adamantyl)-3-phenylurea
DMCFKX0 DE Discovery agent
DMGPIL0 ID DMGPIL0
DMGPIL0 DN 1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea
DMGPIL0 HS Investigative
DMGPIL0 SN CHEMBL216287; 1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea; SCHEMBL8925408; BDBM50191866
DMGPIL0 DT Small molecular drug
DMGPIL0 PC 14322900
DMGPIL0 MW 291.4
DMGPIL0 FM C17H29N3O
DMGPIL0 IC InChI=1S/C17H29N3O/c21-16(19-11-12-1-3-18-4-2-12)20-17-8-13-5-14(9-17)7-15(6-13)10-17/h12-15,18H,1-11H2,(H2,19,20,21)
DMGPIL0 CS C1CNCCC1CNC(=O)NC23CC4CC(C2)CC(C4)C3
DMGPIL0 IK ZQMNKAGVCNSSIW-UHFFFAOYSA-N
DMGPIL0 IU 1-(1-adamantyl)-3-(piperidin-4-ylmethyl)urea
DMGPIL0 DE Discovery agent
DMTNPBH ID DMTNPBH
DMTNPBH DN 1-adamantan-1-yl-3-piperidin-4-yl-urea
DMTNPBH HS Investigative
DMTNPBH SN ASN 06482309; 1-Adamantan-1-yl-3-piperidin-4-yl-urea; CHEMBL215356; AC1MLKMS; SCHEMBL8234307; BDBM50191891; AKOS000794965
DMTNPBH DT Small molecular drug
DMTNPBH PC 3221297
DMTNPBH MW 277.4
DMTNPBH FM C16H27N3O
DMTNPBH IC InChI=1S/C16H27N3O/c20-15(18-14-1-3-17-4-2-14)19-16-8-11-5-12(9-16)7-13(6-11)10-16/h11-14,17H,1-10H2,(H2,18,19,20)
DMTNPBH CS C1CNCCC1NC(=O)NC23CC4CC(C2)CC(C4)C3
DMTNPBH IK NWWZZPCDHOXVSZ-UHFFFAOYSA-N
DMTNPBH IU 1-(1-adamantyl)-3-piperidin-4-ylurea
DMTNPBH DE Discovery agent
DM60Y8M ID DM60Y8M
DM60Y8M DN 1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea
DM60Y8M HS Investigative
DM60Y8M SN CHEMBL149161; AC1MHEHW; 1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea; SCHEMBL6281905; PHI-535; BDBM50097038; 1-(1-adamantylmethyl)-3-thiazol-2-yl-thiourea; 1-(1-Adamantylmethyl)-3-(2-thiazolyl)thiourea; 1-(1-adamantylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DM60Y8M DT Small molecular drug
DM60Y8M PC 3003031
DM60Y8M MW 307.5
DM60Y8M FM C15H21N3S2
DM60Y8M IC InChI=1S/C15H21N3S2/c19-13(18-14-16-1-2-20-14)17-9-15-6-10-3-11(7-15)5-12(4-10)8-15/h1-2,10-12H,3-9H2,(H2,16,17,18,19)
DM60Y8M CS C1C2CC3CC1CC(C2)(C3)CNC(=S)NC4=NC=CS4
DM60Y8M IK YVDWMGNODCFVJL-UHFFFAOYSA-N
DM60Y8M IU 1-(1-adamantylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DM60Y8M DE Discovery agent
DMQJ9RZ ID DMQJ9RZ
DMQJ9RZ DN 1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole
DMQJ9RZ HS Investigative
DMQJ9RZ SN 1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole; GTPL3136; SCHEMBL8249304
DMQJ9RZ DT Small molecular drug
DMQJ9RZ PC 9949081
DMQJ9RZ MW 322.4
DMQJ9RZ FM C21H26N2O
DMQJ9RZ IC InChI=1S/C21H26N2O/c1-4-8-18-20(24-14-7-13-22-15(2)3)12-11-17-16-9-5-6-10-19(16)23-21(17)18/h4-6,9-12,15,22-23H,1,7-8,13-14H2,2-3H3
DMQJ9RZ CS CC(C)NCCCOC1=C(C2=C(C=C1)C3=CC=CC=C3N2)CC=C
DMQJ9RZ IK UQDMMPHZGIOABI-UHFFFAOYSA-N
DMQJ9RZ IU N-propan-2-yl-3-[(1-prop-2-enyl-9H-carbazol-2-yl)oxy]propan-1-amine
DMQJ9RZ DE Discovery agent
DMNDW4J ID DMNDW4J
DMNDW4J DN 1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one
DMNDW4J HS Investigative
DMNDW4J SN GTPL3135; SCHEMBL16792026; 1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one
DMNDW4J DT Small molecular drug
DMNDW4J PC 56947004
DMNDW4J MW 351.4
DMNDW4J FM C22H25NO3
DMNDW4J IC InChI=1S/C22H25NO3/c1-4-8-16-18(25-14-7-13-23-15(2)3)11-12-20-21(16)22(24)17-9-5-6-10-19(17)26-20/h4-6,9-12,15,23H,1,7-8,13-14H2,2-3H3
DMNDW4J CS CC(C)NCCCOC1=C(C2=C(C=C1)OC3=CC=CC=C3C2=O)CC=C
DMNDW4J IK NZEPLPVSYIYMMM-UHFFFAOYSA-N
DMNDW4J IU 2-[3-(propan-2-ylamino)propoxy]-1-prop-2-enylxanthen-9-one
DMNDW4J DE Discovery agent
DML54H2 ID DML54H2
DML54H2 DN 1-Allyl-3,7-dihydro-purine-2,6-dione
DML54H2 HS Investigative
DML54H2 SN CHEMBL66899; 1H-Purine-2,6-dione, 3,9-dihydro-1-(2-propen-1-yl)-; 146830-80-0; 1-allylxanthine; 1-Allyl-3,7-dihydro-purine-2,6-dione; SCHEMBL6464355; BDBM50042206
DML54H2 DT Small molecular drug
DML54H2 PC 14969716
DML54H2 MW 192.17
DML54H2 FM C8H8N4O2
DML54H2 IC InChI=1S/C8H8N4O2/c1-2-3-12-7(13)5-6(10-4-9-5)11-8(12)14/h2,4H,1,3H2,(H,9,10)(H,11,14)
DML54H2 CS C=CCN1C(=O)C2=C(NC1=O)N=CN2
DML54H2 IK IPKIKTHDWDXHPU-UHFFFAOYSA-N
DML54H2 IU 1-prop-2-enyl-3,7-dihydropurine-2,6-dione
DML54H2 DE Discovery agent
DMZE5GX ID DMZE5GX
DMZE5GX DN 1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione
DMZE5GX HS Investigative
DMZE5GX SN Allyltheobromine; 1-Allyltheobromine; Theobromine, 1-allyl-; UNII-4JG7O04XYX; 2530-99-6; 4JG7O04XYX; CHEMBL25427; 1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione; Allyltheobromin; NSC40882; AC1L5YRZ; 3,7-dimethyl-1-prop-2-enylpurine-2,6-dione; AC1Q6LF9; SCHEMBL8435386; CTK4F5434; MolPort-001-981-271; HMS1586E14; ZINC349954; NSC-40882; BDBM50025568; STL378446; AKOS002340304; MCULE-9142254572; BAS 02549760; WLN: T56 BN DN FNVNVJ B1 F1 H1U2; 1H-Purine-2, 3,7-dihydro-3,7-dimethyl-1-(2-propenyl)-
DMZE5GX DT Small molecular drug
DMZE5GX PC 237430
DMZE5GX MW 220.23
DMZE5GX FM C10H12N4O2
DMZE5GX IC InChI=1S/C10H12N4O2/c1-4-5-14-9(15)7-8(11-6-12(7)2)13(3)10(14)16/h4,6H,1,5H2,2-3H3
DMZE5GX CS CN1C=NC2=C1C(=O)N(C(=O)N2C)CC=C
DMZE5GX IK BTFHIKZOEZREBX-UHFFFAOYSA-N
DMZE5GX IU 3,7-dimethyl-1-prop-2-enylpurine-2,6-dione
DMZE5GX CA CAS 2530-99-6
DMZE5GX DE Discovery agent
DM2J5WH ID DM2J5WH
DM2J5WH DN 1-allyl-5'-O-tritylinosine
DM2J5WH HS Investigative
DM2J5WH SN CHEMBL213891; 1-allyl-5''-O-tritylinosine
DM2J5WH DT Small molecular drug
DM2J5WH PC 16082759
DM2J5WH MW 550.6
DM2J5WH FM C32H30N4O5
DM2J5WH IC InChI=1S/C32H30N4O5/c1-2-18-35-20-34-29-26(30(35)39)33-21-36(29)31-28(38)27(37)25(41-31)19-40-32(22-12-6-3-7-13-22,23-14-8-4-9-15-23)24-16-10-5-11-17-24/h2-17,20-21,25,27-28,31,37-38H,1,18-19H2/t25-,27-,28-,31-/m1/s1
DM2J5WH CS C=CCN1C=NC2=C(C1=O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)O)O
DM2J5WH IK WUKAFOPIIOGNJA-QWOIFIOOSA-N
DM2J5WH IU 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]-1-prop-2-enylpurin-6-one
DM2J5WH DE Discovery agent
DMRAN9T ID DMRAN9T
DMRAN9T DN 1-amino-2,4-bis(phenylthio)anthracene-9,10-dione
DMRAN9T HS Investigative
DMRAN9T SN CHEMBL600009; ChemDiv1_000050; AC1MZ0W8; 1-amino-2,4-bis(phenylthio)anthracene-9,10-dione; SCHEMBL13944330; HMS587C06; MolPort-003-717-430; ZINC4421222; BDBM50306772; AKOS001588262; MCULE-8570323585; 1-amino-2,4-bis(phenylthio)anthra-9,10-quinone
DMRAN9T DT Small molecular drug
DMRAN9T PC 3890693
DMRAN9T MW 439.6
DMRAN9T FM C26H17NO2S2
DMRAN9T IC InChI=1S/C26H17NO2S2/c27-24-21(31-17-11-5-2-6-12-17)15-20(30-16-9-3-1-4-10-16)22-23(24)26(29)19-14-8-7-13-18(19)25(22)28/h1-15H,27H2
DMRAN9T CS C1=CC=C(C=C1)SC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)SC5=CC=CC=C5
DMRAN9T IK XAJKSCYRAOFPAT-UHFFFAOYSA-N
DMRAN9T IU 1-amino-2,4-bis(phenylsulfanyl)anthracene-9,10-dione
DMRAN9T DE Discovery agent
DMWCXM4 ID DMWCXM4
DMWCXM4 DN 1-amino-2-phenoxyanthracene-9,10-dione
DMWCXM4 HS Investigative
DMWCXM4 SN 1-amino-2-phenoxyanthracene-9,10-dione; CHEMBL601856; AC1MDASQ; 1-Amino-2-phenoxy-anthraquinone; MolPort-001-914-416; ZINC3878658; BDBM50306773; AKOS000668569; MCULE-3398092458; BAS 00096273
DMWCXM4 DT Small molecular drug
DMWCXM4 PC 2833773
DMWCXM4 MW 315.3
DMWCXM4 FM C20H13NO3
DMWCXM4 IC InChI=1S/C20H13NO3/c21-18-16(24-12-6-2-1-3-7-12)11-10-15-17(18)20(23)14-9-5-4-8-13(14)19(15)22/h1-11H,21H2
DMWCXM4 CS C1=CC=C(C=C1)OC2=C(C3=C(C=C2)C(=O)C4=CC=CC=C4C3=O)N
DMWCXM4 IK LTBODPBDLZJCLH-UHFFFAOYSA-N
DMWCXM4 IU 1-amino-2-phenoxyanthracene-9,10-dione
DMWCXM4 DE Discovery agent
DMOAQC4 ID DMOAQC4
DMOAQC4 DN 1-Amino-3-(aminoxy)-2-propanol Dihydrochloride
DMOAQC4 HS Investigative
DMOAQC4 SN CHEMBL1209777
DMOAQC4 DT Small molecular drug
DMOAQC4 PC 49862726
DMOAQC4 MW 142.58
DMOAQC4 FM C3H11ClN2O2
DMOAQC4 IC InChI=1S/C3H10N2O2.ClH/c4-1-3(6)2-7-5;/h3,6H,1-2,4-5H2;1H
DMOAQC4 CS C(C(CON)O)N.Cl
DMOAQC4 IK CDNYZQKHCXXBPH-UHFFFAOYSA-N
DMOAQC4 IU 1-amino-3-aminooxypropan-2-ol;hydrochloride
DMOAQC4 DE Discovery agent
DMJMDNX ID DMJMDNX
DMJMDNX DN 1-amino-4-chloroanthracene-9,10-dione
DMJMDNX HS Investigative
DMJMDNX SN 1-Amino-4-chloroanthraquinone; 1-amino-4-chloroanthracene-9,10-dione; 2872-47-1; 4-Chloro-1-aminoanthraquinone; 4-Amino-4-chloroanthraquinone; ANTHRAQUINONE, 1-AMINO-4-CHLORO-; C.I. 62805; NSC 39927; BRN 0916373; 1-Amino-4-chloro-9,10-anthracenedione; 9,10-Anthracenedione, 1-amino-4-chloro-; CHEMBL603094; NSC39927; AC1L2AVQ; 9, 1-amino-4-chloro-; 4-14-00-00440 (Beilstein Handbook Reference); SCHEMBL5109323; CTK4G1984; DTXSID50182880; MolPort-000-643-769; AWACQBFBMROGQC-UHFFFAOYSA-N; ZINC4792024; NSC-39927; BDBM50306769; STK238272
DMJMDNX DT Small molecular drug
DMJMDNX PC 17884
DMJMDNX MW 257.67
DMJMDNX FM C14H8ClNO2
DMJMDNX IC InChI=1S/C14H8ClNO2/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6H,16H2
DMJMDNX CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)Cl)N
DMJMDNX IK AWACQBFBMROGQC-UHFFFAOYSA-N
DMJMDNX IU 1-amino-4-chloroanthracene-9,10-dione
DMJMDNX CA CAS 2872-47-1
DMJMDNX DE Discovery agent
DM7X5BP ID DM7X5BP
DM7X5BP DN 1-amino-4-methoxyanthracene-9,10-dione
DM7X5BP HS Investigative
DM7X5BP SN 1-Amino-4-methoxyanthraquinone; 1-amino-4-methoxyanthracene-9,10-dione; 116-83-6; 4-Methoxy-1-anthraquinonylamine; 1-Amino-4-methoxy-9,10-anthraquinone; UNII-BCH9T82ZKZ; NSC 84162; BCH9T82ZKZ; BRN 2218945; ANTHRAQUINONE, 1-AMINO-4-METHOXY-; CHEMBL600008; 9,10-Anthracenedione, 1-amino-4-methoxy- (9CI); NSC84162; AC1L1QQQ; cid_8321; 9, 1-amino-4-methoxy-; MLS000585344; 1-Methoxy-4-aminoanthraquinone; SCHEMBL2303569; CTK4A9995; DTXSID40151262; KXOGXZAXERYOTC-UHFFFAOYSA-N; HMS2536C23; ZINC3874026; NSC-84162; BDBM50306771; AKOS001666411
DM7X5BP DT Small molecular drug
DM7X5BP PC 8321
DM7X5BP MW 253.25
DM7X5BP FM C15H11NO3
DM7X5BP IC InChI=1S/C15H11NO3/c1-19-11-7-6-10(16)12-13(11)15(18)9-5-3-2-4-8(9)14(12)17/h2-7H,16H2,1H3
DM7X5BP CS COC1=C2C(=C(C=C1)N)C(=O)C3=CC=CC=C3C2=O
DM7X5BP IK KXOGXZAXERYOTC-UHFFFAOYSA-N
DM7X5BP IU 1-amino-4-methoxyanthracene-9,10-dione
DM7X5BP CA CAS 116-83-6
DM7X5BP DE Discovery agent
DM6AV2S ID DM6AV2S
DM6AV2S DN 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
DM6AV2S HS Investigative
DM6AV2S SN 1-AMINO-6-CYCLOHEX-3-ENYLMETHYLOXYPURINE; 872556-74-6; 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine; AC1L9IVC; CTK2I2667; DTXSID90332206; 3h-imidazo[4,5-c]pyridin-6-amine,4-(cyclohexylmethoxy)-; ZINC20149007; AKOS030619175; DB02603; KB-268453; 1H-Imidazo[4,5-c]pyridin-6-amine, 4-(cyclohexylmethoxy)-
DM6AV2S DT Small molecular drug
DM6AV2S PC 445967
DM6AV2S MW 246.31
DM6AV2S FM C13H18N4O
DM6AV2S IC InChI=1S/C13H18N4O/c14-11-6-10-12(16-8-15-10)13(17-11)18-7-9-4-2-1-3-5-9/h6,8-9H,1-5,7H2,(H2,14,17)(H,15,16)
DM6AV2S CS C1CCC(CC1)COC2=C3C(=CC(=N2)N)NC=N3
DM6AV2S IK VPUIDVRYMVIXGO-UHFFFAOYSA-N
DM6AV2S IU 4-(cyclohexylmethoxy)-1H-imidazo[4,5-c]pyridin-6-amine
DM6AV2S CA CAS 872556-74-6
DM6AV2S DE Discovery agent
DMGU76I ID DMGU76I
DMGU76I DN 1-aminoanthracene-9,10-dione
DMGU76I HS Investigative
DMGU76I SN 1-AMINOANTHRAQUINONE; 82-45-1; 1-aminoanthracene-9,10-dione; Diazo Fast Red AL; 1-Amino anthraquinone; Anthraquinone, 1-amino-; 1-Aminoanthrachinon; 1-Amino-anthraquinone; 9,10-Anthracenedione, 1-amino-; alpha-Aminoanthraquinone; 1-Amino-9,10-anthraquinone; C.I. 37275; 1-Amino-9,10-anthracenedione; alpha-Anthraquinonylamine; UNII-N5YYY1NEUI; NSC 458; 1-Aminoquinone; .alpha.-Aminoanthraquinone; NSC 30415; 1-Aminoanthrachinon [Czech]; 9,10-Anthracenedione, amino-; N5YYY1NEUI; EINECS 201-423-5; .alpha.-Anthraquinonylamine; BRN 039636
DMGU76I DT Small molecular drug
DMGU76I PC 6710
DMGU76I MW 223.23
DMGU76I FM C14H9NO2
DMGU76I IC InChI=1S/C14H9NO2/c15-11-7-3-6-10-12(11)14(17)9-5-2-1-4-8(9)13(10)16/h1-7H,15H2
DMGU76I CS C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)N
DMGU76I IK KHUFHLFHOQVFGB-UHFFFAOYSA-N
DMGU76I IU 1-aminoanthracene-9,10-dione
DMGU76I CA CAS 82-45-1
DMGU76I DE Discovery agent
DM4TFN6 ID DM4TFN6
DM4TFN6 DN 1-aminobutylphosphonic acid
DM4TFN6 HS Investigative
DM4TFN6 SN (1-aminobutyl)phosphonic acid; 1-aminobutylphosphonic acid; 13138-36-8; Phosphonic acid, (1-aminobutyl)-; NSC-117799; CHEMBL1089898; Phosphonic acid,P-(1-aminobutyl)-; alpha-Aminobutanephosphonic acid; DL-(1-Aminobutyl)phosphonic acid; Phosphonic acid, P-(1-aminobutyl)-; NSC117799; (+/-)-(1-Aminobutyl)phosphonic acid; J441.089K; AC1Q6RLK; AC1L6SK2; SCHEMBL745916; alpha-aminobutylphosphonic acid; CTK4B7247; BDBM50316029; AKOS015854597; FCH1112358; TRA0100955; KB-00224; TR-032039; DB-042023; FT-0636808; C-51169
DM4TFN6 DT Small molecular drug
DM4TFN6 PC 272986
DM4TFN6 MW 153.12
DM4TFN6 FM C4H12NO3P
DM4TFN6 IC InChI=1S/C4H12NO3P/c1-2-3-4(5)9(6,7)8/h4H,2-3,5H2,1H3,(H2,6,7,8)
DM4TFN6 CS CCCC(N)P(=O)(O)O
DM4TFN6 IK UAEPDDGDPAPPHZ-UHFFFAOYSA-N
DM4TFN6 IU 1-aminobutylphosphonic acid
DM4TFN6 CA CAS 13138-36-8
DM4TFN6 DE Discovery agent
DMFUABI ID DMFUABI
DMFUABI DN 1-aminohexylphosphonic acid
DMFUABI HS Investigative
DMFUABI SN (1-Aminohexyl)phosphonic acid; 1-aminohexylphosphonic Acid; 63207-60-3; CHEMBL40508; 109638-78-0; ACMC-20mcgx; AC1MC01Z; SCHEMBL625939; CTK6D6935; DTXSID70370060; 1-AMINOHEXYL PHOSPHONIC ACID; Phosphonic acid, P-(1-aminohexyl)-; AKOS015892987; DB-054431; FT-0640877
DMFUABI DT Small molecular drug
DMFUABI PC 2733961
DMFUABI MW 181.17
DMFUABI FM C6H16NO3P
DMFUABI IC InChI=1S/C6H16NO3P/c1-2-3-4-5-6(7)11(8,9)10/h6H,2-5,7H2,1H3,(H2,8,9,10)
DMFUABI CS CCCCCC(N)P(=O)(O)O
DMFUABI IK ODMTWOKJHVPSLP-UHFFFAOYSA-N
DMFUABI IU 1-aminohexylphosphonic acid
DMFUABI CA CAS 109638-78-0
DMFUABI DE Discovery agent
DML6UJM ID DML6UJM
DML6UJM DN 1-aminohexylphosphonic acid monophenyl ester
DML6UJM HS Investigative
DML6UJM SN 1-aminohexylphosphonic acid monophenyl ester; CHEMBL1093531
DML6UJM DT Small molecular drug
DML6UJM PC 46886335
DML6UJM MW 257.269
DML6UJM FM C12H20NO3P
DML6UJM IC InChI=1S/C12H20NO3P/c1-2-3-5-10-12(13)17(14,15)16-11-8-6-4-7-9-11/h4,6-9,12H,2-3,5,10,13H2,1H3,(H,14,15)
DML6UJM CS CCCCCC(N)P(=O)(O)OC1=CC=CC=C1
DML6UJM IK DHJINNDLWRRCRC-UHFFFAOYSA-N
DML6UJM IU 1-aminohexyl(phenoxy)phosphinic acid
DML6UJM DE Discovery agent
DMBWNL6 ID DMBWNL6
DMBWNL6 DN 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol
DMBWNL6 HS Investigative
DMBWNL6 SN CHEMBL100572; 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol; SCHEMBL10380336; BDBM50008832
DMBWNL6 DT Small molecular drug
DMBWNL6 PC 15696466
DMBWNL6 MW 277.36
DMBWNL6 FM C16H23NO3
DMBWNL6 IC InChI=1S/C16H23NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h6-7,10,14-15,18-19H,1-5,8-9,17H2/t14-,15-/m0/s1
DMBWNL6 CS C1CCC(CC1)[C@@H]2CC3=C(C=CC(=C3O)O)[C@@H](O2)CN
DMBWNL6 IK BOKASTZDGGZFET-GJZGRUSLSA-N
DMBWNL6 IU (1R,3S)-1-(aminomethyl)-3-cyclohexyl-3,4-dihydro-1H-isochromene-5,6-diol
DMBWNL6 DE Discovery agent
DMJNG8A ID DMJNG8A
DMJNG8A DN 1-Aminomethyl-3-phenyl-isochroman-5,6-diol
DMJNG8A HS Investigative
DMJNG8A SN CHEMBL83080; SCHEMBL7447363; SUHGRZPINGKYNV-HUUCEWRRSA-N; ZINC4637270; BDBM50007136; AJ-51787; [1S,3R]1-aminomethyl-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran
DMJNG8A DT Small molecular drug
DMJNG8A PC 14809026
DMJNG8A MW 271.31
DMJNG8A FM C16H17NO3
DMJNG8A IC InChI=1S/C16H17NO3/c17-9-15-11-6-7-13(18)16(19)12(11)8-14(20-15)10-4-2-1-3-5-10/h1-7,14-15,18-19H,8-9,17H2/t14-,15-/m1/s1
DMJNG8A CS C1[C@@H](O[C@@H](C2=C1C(=C(C=C2)O)O)CN)C3=CC=CC=C3
DMJNG8A IK SUHGRZPINGKYNV-HUUCEWRRSA-N
DMJNG8A IU (1S,3R)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-isochromene-5,6-diol
DMJNG8A DE Discovery agent
DM50GS7 ID DM50GS7
DM50GS7 DN 1-Aminomethyl-isochroman-5,6-diol
DM50GS7 HS Investigative
DM50GS7 SN CHEMBL99361; SCHEMBL8726506; 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-; BDBM50010891; 83694-56-8; 1-Aminomethyl-3,4-dihydro-1H-2-benzopyran-5,6-diol
DM50GS7 DT Small molecular drug
DM50GS7 PC 13864381
DM50GS7 MW 195.21
DM50GS7 FM C10H13NO3
DM50GS7 IC InChI=1S/C10H13NO3/c11-5-9-6-1-2-8(12)10(13)7(6)3-4-14-9/h1-2,9,12-13H,3-5,11H2
DM50GS7 CS C1COC(C2=C1C(=C(C=C2)O)O)CN
DM50GS7 IK JBSRTZUQAXYSQB-UHFFFAOYSA-N
DM50GS7 IU 1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol
DM50GS7 DE Discovery agent
DMMV30B ID DMMV30B
DMMV30B DN 1-aminopentylphosphonic acid monophenyl ester
DMMV30B HS Investigative
DMMV30B SN CHEMBL1090367; 1-aminopentylphosphonic acid monophenyl ester
DMMV30B DT Small molecular drug
DMMV30B PC 46886334
DMMV30B MW 243.24
DMMV30B FM C11H18NO3P
DMMV30B IC InChI=1S/C11H18NO3P/c1-2-3-9-11(12)16(13,14)15-10-7-5-4-6-8-10/h4-8,11H,2-3,9,12H2,1H3,(H,13,14)
DMMV30B CS CCCCC(N)P(=O)(O)OC1=CC=CC=C1
DMMV30B IK WRTBDONQGQRUNP-UHFFFAOYSA-N
DMMV30B IU 1-aminopentyl(phenoxy)phosphinic acid
DMMV30B DE Discovery agent
DMPYCK5 ID DMPYCK5
DMPYCK5 DN 1-Aminopropane-1,2,3-tricarboxylic acid
DMPYCK5 HS Investigative
DMPYCK5 SN 1-Aminopropane-1,2,3-tricarboxylic acid; 2393-15-9; NSC206248; AC1L7BSJ; SCHEMBL2774681; CHEMBL1190722
DMPYCK5 DT Small molecular drug
DMPYCK5 PC 307919
DMPYCK5 MW 191.14
DMPYCK5 FM C6H9NO6
DMPYCK5 IC InChI=1S/C6H9NO6/c7-4(6(12)13)2(5(10)11)1-3(8)9/h2,4H,1,7H2,(H,8,9)(H,10,11)(H,12,13)
DMPYCK5 CS C(C(C(C(=O)O)N)C(=O)O)C(=O)O
DMPYCK5 IK BZJZJZZWFXEMRG-UHFFFAOYSA-N
DMPYCK5 IU 1-aminopropane-1,2,3-tricarboxylic acid
DMPYCK5 DE Discovery agent
DMNGY0E ID DMNGY0E
DMNGY0E DN 1-anilinonaphthalene-8-sulfonic acid
DMNGY0E HS Investigative
DMNGY0E SN CHEMBL471741; SCHEMBL3327539; BDBM50243721; 8-(Phenylamino)naphthalene-1-ol sulfate
DMNGY0E DT Small molecular drug
DMNGY0E PC 1369
DMNGY0E MW 299.3
DMNGY0E FM C16H13NO3S
DMNGY0E IC InChI=1S/C16H13NO3S/c18-21(19,20)15-11-5-7-12-6-4-10-14(16(12)15)17-13-8-2-1-3-9-13/h1-11,17H,(H,18,19,20)
DMNGY0E CS C1=CC=C(C=C1)NC2=CC=CC3=C2C(=CC=C3)S(=O)(=O)O
DMNGY0E IK FWEOQOXTVHGIFQ-UHFFFAOYSA-N
DMNGY0E IU 8-anilinonaphthalene-1-sulfonic acid
DMNGY0E CA CAS 82-76-8
DMNGY0E CB CHEBI:39708
DMJD1QF ID DMJD1QF
DMJD1QF DN 1-arylmethylpyrrolidin-2-yl ethanol amine
DMJD1QF HS Investigative
DMJD1QF SN compound 26a [PMID: 16216508]
DMJD1QF DT Small molecular drug
DMJD1QF PC 44405854
DMJD1QF MW 433.6
DMJD1QF FM C26H31N3OS
DMJD1QF IC InChI=1S/C26H31N3OS/c1-26(2,15-22-14-21-9-3-4-11-25(21)31-22)28-17-24(30)23-10-6-12-29(23)18-20-8-5-7-19(13-20)16-27/h3-5,7-9,11,13-14,23-24,28,30H,6,10,12,15,17-18H2,1-2H3/t23-,24-/m1/s1
DMJD1QF CS CC(C)(CC1=CC2=CC=CC=C2S1)NC[C@H]([C@H]3CCCN3CC4=CC(=CC=C4)C#N)O
DMJD1QF IK HCLQARMRCPEALF-DNQXCXABSA-N
DMJD1QF IU 3-[[(2R)-2-[(1R)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile
DMJD1QF DE Discovery agent
DMQ1EVT ID DMQ1EVT
DMQ1EVT DN 1-benzene sulfonyl-cis-2,6-dimethyl piperidine
DMQ1EVT HS Investigative
DMQ1EVT SN CHEMBL575619; AC1LDWTF; 1-benzene sulfonyl-cis-2,6-dimethyl piperidine; BDBM50298422; ZINC12417747
DMQ1EVT DT Small molecular drug
DMQ1EVT PC 726586
DMQ1EVT MW 253.36
DMQ1EVT FM C13H19NO2S
DMQ1EVT IC InChI=1S/C13H19NO2S/c1-11-7-6-8-12(2)14(11)17(15,16)13-9-4-3-5-10-13/h3-5,9-12H,6-8H2,1-2H3/t11-,12+
DMQ1EVT CS C[C@@H]1CCC[C@@H](N1S(=O)(=O)C2=CC=CC=C2)C
DMQ1EVT IK JINDARNDFYFWDT-TXEJJXNPSA-N
DMQ1EVT IU (2S,6R)-1-(benzenesulfonyl)-2,6-dimethylpiperidine
DMQ1EVT DE Discovery agent
DM781L6 ID DM781L6
DM781L6 DN 1-Benzenesulfonyl-2-nitro-benzene
DM781L6 HS Investigative
DM781L6 SN 31515-43-2; 2-Nitrophenyl phenyl sulfone; 1-Nitro-2-(phenylsulfonyl)benzene; 2-Nitrodiphenyl Sulfone; 2-Nitro diphenyl sulfone; Benzene, 1-nitro-2-(phenylsulfonyl)-; 2'-Nitrophenylphenylsulfone; 1-(benzenesulfonyl)-2-nitrobenzene; 1-Nitro-2-(phenylsulphonyl)benzene; 2NO2Ph-SO2-Ph; NSC-624231; NSC624231; NSC 624231; 144113-81-5; W-106894; SMR000554655; o-Nitrophenyl phenyl sulfone; Sulfone, o-nitrophenyl phenyl; EINECS 250-672-6; 2-Nitrodiphenylsulfone; PubChem10856; 2-nitrophenylphenylsulfone; ACMC-209hn5; AC1L22CT; MLS001074875
DM781L6 DT Small molecular drug
DM781L6 PC 64984
DM781L6 MW 263.27
DM781L6 FM C12H9NO4S
DM781L6 IC InChI=1S/C12H9NO4S/c14-13(15)11-8-4-5-9-12(11)18(16,17)10-6-2-1-3-7-10/h1-9H
DM781L6 CS C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC=C2[N+](=O)[O-]
DM781L6 IK GKNMUCPEXSCGKC-UHFFFAOYSA-N
DM781L6 IU 1-(benzenesulfonyl)-2-nitrobenzene
DM781L6 CA CAS 31515-43-2
DM781L6 DE Discovery agent
DM1N4LK ID DM1N4LK
DM1N4LK DN 1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole
DM1N4LK HS Investigative
DM1N4LK SN CHEMBL371292; piperidinylindole, 7; 1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole; SCHEMBL5251020; BDBM34148
DM1N4LK DT Small molecular drug
DM1N4LK PC 9902533
DM1N4LK MW 340.4
DM1N4LK FM C19H20N2O2S
DM1N4LK IC InChI=1S/C19H20N2O2S/c22-24(23,16-8-2-1-3-9-16)21-14-18(15-7-6-12-20-13-15)17-10-4-5-11-19(17)21/h1-5,8-11,14-15,20H,6-7,12-13H2
DM1N4LK CS C1CC(CNC1)C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DM1N4LK IK QUUSSZWUXRDTJG-UHFFFAOYSA-N
DM1N4LK IU 1-(benzenesulfonyl)-3-piperidin-3-ylindole
DM1N4LK DE Discovery agent
DMRA9VG ID DMRA9VG
DMRA9VG DN 1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole
DMRA9VG HS Investigative
DMRA9VG SN CHEMBL180826; 1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole
DMRA9VG DT Small molecular drug
DMRA9VG PC 44388931
DMRA9VG MW 340.4
DMRA9VG FM C19H20N2O2S
DMRA9VG IC InChI=1S/C19H20N2O2S/c22-24(23,16-6-2-1-3-7-16)21-14-18(15-10-12-20-13-11-15)17-8-4-5-9-19(17)21/h1-9,14-15,20H,10-13H2
DMRA9VG CS C1CNCCC1C2=CN(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DMRA9VG IK CACLUIQWYMWMBO-UHFFFAOYSA-N
DMRA9VG IU 1-(benzenesulfonyl)-3-piperidin-4-ylindole
DMRA9VG DE Discovery agent
DMQSK3H ID DMQSK3H
DMQSK3H DN 1-benzhydryl-3-(isoquinolin-5-yl)urea
DMQSK3H HS Investigative
DMQSK3H SN isoquinoline antagonist, 5h; SCHEMBL4026073; CHEMBL397897; BDBM20390
DMQSK3H DT Small molecular drug
DMQSK3H PC 10473280
DMQSK3H MW 353.4
DMQSK3H FM C23H19N3O
DMQSK3H IC InChI=1S/C23H19N3O/c27-23(25-21-13-7-12-19-16-24-15-14-20(19)21)26-22(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-16,22H,(H2,25,26,27)
DMQSK3H CS C1=CC=C(C=C1)C(C2=CC=CC=C2)NC(=O)NC3=CC=CC4=C3C=CN=C4
DMQSK3H IK ZBZSZXCYOYRLKL-UHFFFAOYSA-N
DMQSK3H IU 1-benzhydryl-3-isoquinolin-5-ylurea
DMQSK3H DE Discovery agent
DMBAZG3 ID DMBAZG3
DMBAZG3 DN 1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3 HS Investigative
DMBAZG3 SN CHEMBL234414; 1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3 DT Small molecular drug
DMBAZG3 PC 11674875
DMBAZG3 MW 322.5
DMBAZG3 FM C22H30N2
DMBAZG3 IC InChI=1S/C22H30N2/c1-2-3-10-20-17-24(16-15-21(20)23)22(18-11-6-4-7-12-18)19-13-8-5-9-14-19/h4-9,11-14,20-22H,2-3,10,15-17,23H2,1H3
DMBAZG3 CS CCCCC1CN(CCC1N)C(C2=CC=CC=C2)C3=CC=CC=C3
DMBAZG3 IK OJLIZWWFCLNTKT-UHFFFAOYSA-N
DMBAZG3 IU 1-benzhydryl-3-butylpiperidin-4-amine
DMBAZG3 DE Discovery agent
DMTANPG ID DMTANPG
DMTANPG DN 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG HS Investigative
DMTANPG SN CHEMBL232476; 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG DT Small molecular drug
DMTANPG PC 44430007
DMTANPG MW 361.5
DMTANPG FM C24H24FNO
DMTANPG IC InChI=1S/C24H24FNO/c25-22-14-8-7-13-21(22)24(27)15-17-26(18-16-24)23(19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-14,23,27H,15-18H2
DMTANPG CS C1CN(CCC1(C2=CC=CC=C2F)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMTANPG IK RGFPDLNQIQLMPK-UHFFFAOYSA-N
DMTANPG IU 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol
DMTANPG DE Discovery agent
DMWHMNY ID DMWHMNY
DMWHMNY DN 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY HS Investigative
DMWHMNY SN CHEMBL233493; 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY DT Small molecular drug
DMWHMNY PC 44430016
DMWHMNY MW 373.5
DMWHMNY FM C25H27NO2
DMWHMNY IC InChI=1S/C25H27NO2/c1-28-23-15-9-8-14-22(23)25(27)16-18-26(19-17-25)24(20-10-4-2-5-11-20)21-12-6-3-7-13-21/h2-15,24,27H,16-19H2,1H3
DMWHMNY CS COC1=CC=CC=C1C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMWHMNY IK MMHFMRZIXGSYBY-UHFFFAOYSA-N
DMWHMNY IU 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol
DMWHMNY DE Discovery agent
DMTYKMR ID DMTYKMR
DMTYKMR DN 1-benzhydryl-4-(3,3-diphenylpropyl)piperazine
DMTYKMR HS Investigative
DMTYKMR SN CHEMBL1081018
DMTYKMR DT Small molecular drug
DMTYKMR PC 44756847
DMTYKMR MW 446.6
DMTYKMR FM C32H34N2
DMTYKMR IC InChI=1S/C32H34N2/c1-5-13-27(14-6-1)31(28-15-7-2-8-16-28)21-22-33-23-25-34(26-24-33)32(29-17-9-3-10-18-29)30-19-11-4-12-20-30/h1-20,31-32H,21-26H2
DMTYKMR CS C1CN(CCN1CCC(C2=CC=CC=C2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DMTYKMR IK CLZJJBZJUIWHJT-UHFFFAOYSA-N
DMTYKMR IU 1-benzhydryl-4-(3,3-diphenylpropyl)piperazine
DMTYKMR DE Discovery agent
DMXZFPB ID DMXZFPB
DMXZFPB DN 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB HS Investigative
DMXZFPB SN CHEMBL395838; 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB DT Small molecular drug
DMXZFPB PC 44430008
DMXZFPB MW 361.5
DMXZFPB FM C24H24FNO
DMXZFPB IC InChI=1S/C24H24FNO/c25-22-13-7-12-21(18-22)24(27)14-16-26(17-15-24)23(19-8-3-1-4-9-19)20-10-5-2-6-11-20/h1-13,18,23,27H,14-17H2
DMXZFPB CS C1CN(CCC1(C2=CC(=CC=C2)F)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMXZFPB IK AXBTYZPRVDTMRF-UHFFFAOYSA-N
DMXZFPB IU 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol
DMXZFPB DE Discovery agent
DM1QYS8 ID DM1QYS8
DM1QYS8 DN 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8 HS Investigative
DM1QYS8 SN CHEMBL233494; 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8 DT Small molecular drug
DM1QYS8 PC 44430018
DM1QYS8 MW 373.5
DM1QYS8 FM C25H27NO2
DM1QYS8 IC InChI=1S/C25H27NO2/c1-28-23-14-8-13-22(19-23)25(27)15-17-26(18-16-25)24(20-9-4-2-5-10-20)21-11-6-3-7-12-21/h2-14,19,24,27H,15-18H2,1H3
DM1QYS8 CS COC1=CC=CC(=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DM1QYS8 IK KFPUCANOYSPKNM-UHFFFAOYSA-N
DM1QYS8 IU 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol
DM1QYS8 DE Discovery agent
DMIT7SH ID DMIT7SH
DMIT7SH DN 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH HS Investigative
DMIT7SH SN CHEMBL231664; 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH DT Small molecular drug
DMIT7SH PC 44430029
DMIT7SH MW 385.5
DMIT7SH FM C27H31NO
DMIT7SH IC InChI=1S/C27H31NO/c29-27(18-10-13-23-11-4-1-5-12-23)19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-9,11-12,14-17,26,29H,10,13,18-22H2
DMIT7SH CS C1CN(CCC1(CCCC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMIT7SH IK LBCGIDHKEKGBGS-UHFFFAOYSA-N
DMIT7SH IU 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol
DMIT7SH DE Discovery agent
DM5SWL7 ID DM5SWL7
DM5SWL7 DN 1-benzhydryl-4-(4,4-diphenylbutyl)piperazine
DM5SWL7 HS Investigative
DM5SWL7 SN CHEMBL1081016
DM5SWL7 DT Small molecular drug
DM5SWL7 PC 46879832
DM5SWL7 MW 460.7
DM5SWL7 FM C33H36N2
DM5SWL7 IC InChI=1S/C33H36N2/c1-5-14-28(15-6-1)32(29-16-7-2-8-17-29)22-13-23-34-24-26-35(27-25-34)33(30-18-9-3-10-19-30)31-20-11-4-12-21-31/h1-12,14-21,32-33H,13,22-27H2
DM5SWL7 CS C1CN(CCN1CCCC(C2=CC=CC=C2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DM5SWL7 IK MICPQZJRSOUTGV-UHFFFAOYSA-N
DM5SWL7 IU 1-benzhydryl-4-(4,4-diphenylbutyl)piperazine
DM5SWL7 DE Discovery agent
DM0BQYX ID DM0BQYX
DM0BQYX DN 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX HS Investigative
DM0BQYX SN 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol; CHEMBL232067; BDBM50210228
DM0BQYX DT Small molecular drug
DM0BQYX PC 10093682
DM0BQYX MW 422.4
DM0BQYX FM C24H24BrNO
DM0BQYX IC InChI=1S/C24H24BrNO/c25-22-13-11-21(12-14-22)24(27)15-17-26(18-16-24)23(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2
DM0BQYX CS C1CN(CCC1(C2=CC=C(C=C2)Br)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DM0BQYX IK FIHWNAAGEWTLGW-UHFFFAOYSA-N
DM0BQYX IU 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol
DM0BQYX DE Discovery agent
DMMAJW9 ID DMMAJW9
DMMAJW9 DN 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9 HS Investigative
DMMAJW9 SN CHEMBL233287; 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9 DT Small molecular drug
DMMAJW9 PC 44430014
DMMAJW9 MW 399.6
DMMAJW9 FM C28H33NO
DMMAJW9 IC InChI=1S/C28H33NO/c1-2-3-10-23-15-17-26(18-16-23)28(30)19-21-29(22-20-28)27(24-11-6-4-7-12-24)25-13-8-5-9-14-25/h4-9,11-18,27,30H,2-3,10,19-22H2,1H3
DMMAJW9 CS CCCCC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMMAJW9 IK RVNGGHXLYIZGKP-UHFFFAOYSA-N
DMMAJW9 IU 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol
DMMAJW9 DE Discovery agent
DMWYG8K ID DMWYG8K
DMWYG8K DN 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K HS Investigative
DMWYG8K SN CHEMBL392753; 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K DT Small molecular drug
DMWYG8K PC 10091033
DMWYG8K MW 377.9
DMWYG8K FM C24H24ClNO
DMWYG8K IC InChI=1S/C24H24ClNO/c25-22-13-11-21(12-14-22)24(27)15-17-26(18-16-24)23(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2
DMWYG8K CS C1CN(CCC1(C2=CC=C(C=C2)Cl)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMWYG8K IK LTTPWCPNNZPPLF-UHFFFAOYSA-N
DMWYG8K IU 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol
DMWYG8K DE Discovery agent
DME0BJD ID DME0BJD
DME0BJD DN 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD HS Investigative
DME0BJD SN CHEMBL234543; 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD DT Small molecular drug
DME0BJD PC 44430012
DME0BJD MW 371.5
DME0BJD FM C26H29NO
DME0BJD IC InChI=1S/C26H29NO/c1-2-21-13-15-24(16-14-21)26(28)17-19-27(20-18-26)25(22-9-5-3-6-10-22)23-11-7-4-8-12-23/h3-16,25,28H,2,17-20H2,1H3
DME0BJD CS CCC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DME0BJD IK JHTQREMVHFRWEJ-UHFFFAOYSA-N
DME0BJD IU 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol
DME0BJD DE Discovery agent
DMRNZD6 ID DMRNZD6
DMRNZD6 DN 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6 HS Investigative
DMRNZD6 SN CHEMBL232066; 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6 DT Small molecular drug
DMRNZD6 PC 10089987
DMRNZD6 MW 361.5
DMRNZD6 FM C24H24FNO
DMRNZD6 IC InChI=1S/C24H24FNO/c25-22-13-11-21(12-14-22)24(27)15-17-26(18-16-24)23(19-7-3-1-4-8-19)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2
DMRNZD6 CS C1CN(CCC1(C2=CC=C(C=C2)F)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMRNZD6 IK WBNMPDBWSUFASE-UHFFFAOYSA-N
DMRNZD6 IU 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol
DMRNZD6 DE Discovery agent
DMXT894 ID DMXT894
DMXT894 DN 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894 HS Investigative
DMXT894 SN CHEMBL401234; 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894 DT Small molecular drug
DMXT894 PC 10384734
DMXT894 MW 373.5
DMXT894 FM C25H27NO2
DMXT894 IC InChI=1S/C25H27NO2/c1-28-23-14-12-22(13-15-23)25(27)16-18-26(19-17-25)24(20-8-4-2-5-9-20)21-10-6-3-7-11-21/h2-15,24,27H,16-19H2,1H3
DMXT894 CS COC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMXT894 IK UWUHHENFQBTZCW-UHFFFAOYSA-N
DMXT894 IU 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol
DMXT894 DE Discovery agent
DMJDUM5 ID DMJDUM5
DMJDUM5 DN 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5 HS Investigative
DMJDUM5 SN CHEMBL393675; 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5 DT Small molecular drug
DMJDUM5 PC 44430013
DMJDUM5 MW 385.5
DMJDUM5 FM C27H31NO
DMJDUM5 IC InChI=1S/C27H31NO/c1-2-9-22-14-16-25(17-15-22)27(29)18-20-28(21-19-27)26(23-10-5-3-6-11-23)24-12-7-4-8-13-24/h3-8,10-17,26,29H,2,9,18-21H2,1H3
DMJDUM5 CS CCCC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMJDUM5 IK BVRSNRCGJVPHBA-UHFFFAOYSA-N
DMJDUM5 IU 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol
DMJDUM5 DE Discovery agent
DMDRUBL ID DMDRUBL
DMDRUBL DN 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL HS Investigative
DMDRUBL SN CHEMBL229018; 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine
DMDRUBL DT Small molecular drug
DMDRUBL PC 10388166
DMDRUBL MW 433.6
DMDRUBL FM C31H31NO
DMDRUBL IC InChI=1S/C31H31NO/c1-5-13-26(14-6-1)25-33-31(29-19-11-4-12-20-29)21-23-32(24-22-31)30(27-15-7-2-8-16-27)28-17-9-3-10-18-28/h1-20,30H,21-25H2
DMDRUBL CS C1CN(CCC1(C2=CC=CC=C2)OCC3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5
DMDRUBL IK KSNUQMXXRSKFOM-UHFFFAOYSA-N
DMDRUBL IU 1-benzhydryl-4-phenyl-4-phenylmethoxypiperidine
DMDRUBL DE Discovery agent
DMMB2GV ID DMMB2GV
DMMB2GV DN 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV HS Investigative
DMMB2GV SN CHEMBL231874; 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV DT Small molecular drug
DMMB2GV PC 10336926
DMMB2GV MW 333.4
DMMB2GV FM C22H23NO2
DMMB2GV IC InChI=1S/C22H23NO2/c24-22(20-12-7-17-25-20)13-15-23(16-14-22)21(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-12,17,21,24H,13-16H2
DMMB2GV CS C1CN(CCC1(C2=CC=CO2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMMB2GV IK RANYWKODIKNHDB-UHFFFAOYSA-N
DMMB2GV IU 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol
DMMB2GV DE Discovery agent
DMJ8F60 ID DMJ8F60
DMJ8F60 DN 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60 HS Investigative
DMJ8F60 SN CHEMBL393971; 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol
DMJ8F60 DT Small molecular drug
DMJ8F60 PC 10427620
DMJ8F60 MW 344.4
DMJ8F60 FM C23H24N2O
DMJ8F60 IC InChI=1S/C23H24N2O/c26-23(21-13-7-8-16-24-21)14-17-25(18-15-23)22(19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-13,16,22,26H,14-15,17-18H2
DMJ8F60 CS C1CN(CCC1(C2=CC=CC=N2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMJ8F60 IK RQPLUPANAPAMMF-UHFFFAOYSA-N
DMJ8F60 IU 1-benzhydryl-4-pyridin-2-ylpiperidin-4-ol
DMJ8F60 DE Discovery agent
DMNOZR2 ID DMNOZR2
DMNOZR2 DN 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2 HS Investigative
DMNOZR2 SN CHEMBL233323; 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol
DMNOZR2 DT Small molecular drug
DMNOZR2 PC 10315818
DMNOZR2 MW 349.5
DMNOZR2 FM C22H23NOS
DMNOZR2 IC InChI=1S/C22H23NOS/c24-22(20-12-7-17-25-20)13-15-23(16-14-22)21(18-8-3-1-4-9-18)19-10-5-2-6-11-19/h1-12,17,21,24H,13-16H2
DMNOZR2 CS C1CN(CCC1(C2=CC=CS2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMNOZR2 IK LBJDYBPTWNSHBS-UHFFFAOYSA-N
DMNOZR2 IU 1-benzhydryl-4-thiophen-2-ylpiperidin-4-ol
DMNOZR2 DE Discovery agent
DMVBR36 ID DMVBR36
DMVBR36 DN 1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36 HS Investigative
DMVBR36 SN CHEMBL231661; 1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36 DT Small molecular drug
DMVBR36 PC 44430028
DMVBR36 MW 357.5
DMVBR36 FM C25H27NO
DMVBR36 IC InChI=1S/C25H27NO/c27-25(20-21-10-4-1-5-11-21)16-18-26(19-17-25)24(22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-15,24,27H,16-20H2
DMVBR36 CS C1CN(CCC1(CC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DMVBR36 IK DJXDWBRLMRAPJG-UHFFFAOYSA-N
DMVBR36 IU 1-benzhydryl-4-benzylpiperidin-4-ol
DMVBR36 DE Discovery agent
DMRN7SC ID DMRN7SC
DMRN7SC DN 1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC HS Investigative
DMRN7SC SN CHEMBL397761; 1-benzhydryl-4-butylpiperidin-4-ol; SCHEMBL13597038
DMRN7SC DT Small molecular drug
DMRN7SC PC 22970051
DMRN7SC MW 323.5
DMRN7SC FM C22H29NO
DMRN7SC IC InChI=1S/C22H29NO/c1-2-3-14-22(24)15-17-23(18-16-22)21(19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,21,24H,2-3,14-18H2,1H3
DMRN7SC CS CCCCC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMRN7SC IK REUKRNAMFNVGPA-UHFFFAOYSA-N
DMRN7SC IU 1-benzhydryl-4-butylpiperidin-4-ol
DMRN7SC DE Discovery agent
DMZVSYD ID DMZVSYD
DMZVSYD DN 1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD HS Investigative
DMZVSYD SN CHEMBL394695; 1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD DT Small molecular drug
DMZVSYD PC 10043439
DMZVSYD MW 349.5
DMZVSYD FM C24H31NO
DMZVSYD IC InChI=1S/C24H31NO/c26-24(22-14-8-3-9-15-22)16-18-25(19-17-24)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23,26H,3,8-9,14-19H2
DMZVSYD CS C1CCC(CC1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMZVSYD IK RJWCOGYISGJIPN-UHFFFAOYSA-N
DMZVSYD IU 1-benzhydryl-4-cyclohexylpiperidin-4-ol
DMZVSYD DE Discovery agent
DMM94Y2 ID DMM94Y2
DMM94Y2 DN 1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2 HS Investigative
DMM94Y2 SN CHEMBL398039; 1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2 DT Small molecular drug
DMM94Y2 PC 44430024
DMM94Y2 MW 307.4
DMM94Y2 FM C21H25NO
DMM94Y2 IC InChI=1S/C21H25NO/c23-21(19-11-12-19)13-15-22(16-14-21)20(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-10,19-20,23H,11-16H2
DMM94Y2 CS C1CC1C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMM94Y2 IK DWUKNKDABPWVAE-UHFFFAOYSA-N
DMM94Y2 IU 1-benzhydryl-4-cyclopropylpiperidin-4-ol
DMM94Y2 DE Discovery agent
DM6PIL2 ID DM6PIL2
DM6PIL2 DN 1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2 HS Investigative
DM6PIL2 SN CHEMBL229016; 1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2 DT Small molecular drug
DM6PIL2 PC 10022129
DM6PIL2 MW 371.5
DM6PIL2 FM C26H29NO
DM6PIL2 IC InChI=1S/C26H29NO/c1-2-28-26(24-16-10-5-11-17-24)18-20-27(21-19-26)25(22-12-6-3-7-13-22)23-14-8-4-9-15-23/h3-17,25H,2,18-21H2,1H3
DM6PIL2 CS CCOC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DM6PIL2 IK HFALMYBPBZADRA-UHFFFAOYSA-N
DM6PIL2 IU 1-benzhydryl-4-ethoxy-4-phenylpiperidine
DM6PIL2 DE Discovery agent
DMUK95S ID DMUK95S
DMUK95S DN 1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S HS Investigative
DMUK95S SN CHEMBL234773; 1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S DT Small molecular drug
DMUK95S PC 44430026
DMUK95S MW 351.5
DMUK95S FM C24H33NO
DMUK95S IC InChI=1S/C24H33NO/c1-2-3-4-11-16-24(26)17-19-25(20-18-24)23(21-12-7-5-8-13-21)22-14-9-6-10-15-22/h5-10,12-15,23,26H,2-4,11,16-20H2,1H3
DMUK95S CS CCCCCCC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMUK95S IK MJJFIAIFQWXWHK-UHFFFAOYSA-N
DMUK95S IU 1-benzhydryl-4-hexylpiperidin-4-ol
DMUK95S DE Discovery agent
DMGYCQ3 ID DMGYCQ3
DMGYCQ3 DN 1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3 HS Investigative
DMGYCQ3 SN CHEMBL233721; 1-benzhydryl-4-isopropylpiperidin-4-ol
DMGYCQ3 DT Small molecular drug
DMGYCQ3 PC 44430025
DMGYCQ3 MW 309.4
DMGYCQ3 FM C21H27NO
DMGYCQ3 IC InChI=1S/C21H27NO/c1-17(2)21(23)13-15-22(16-14-21)20(18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17,20,23H,13-16H2,1-2H3
DMGYCQ3 CS CC(C)C1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMGYCQ3 IK BOIJUJOJZXIYHU-UHFFFAOYSA-N
DMGYCQ3 IU 1-benzhydryl-4-propan-2-ylpiperidin-4-ol
DMGYCQ3 DE Discovery agent
DMBG0N8 ID DMBG0N8
DMBG0N8 DN 1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8 HS Investigative
DMBG0N8 SN CHEMBL228965; 1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8 DT Small molecular drug
DMBG0N8 PC 10043898
DMBG0N8 MW 357.5
DMBG0N8 FM C25H27NO
DMBG0N8 IC InChI=1S/C25H27NO/c1-27-25(23-15-9-4-10-16-23)17-19-26(20-18-25)24(21-11-5-2-6-12-21)22-13-7-3-8-14-22/h2-16,24H,17-20H2,1H3
DMBG0N8 CS COC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMBG0N8 IK ULOWZIQCEGBTDH-UHFFFAOYSA-N
DMBG0N8 IU 1-benzhydryl-4-methoxy-4-phenylpiperidine
DMBG0N8 DE Discovery agent
DMVJH1S ID DMVJH1S
DMVJH1S DN 1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S HS Investigative
DMVJH1S SN CHEMBL437380; 1-benzhydryl-4-m-tolylpiperidin-4-ol
DMVJH1S DT Small molecular drug
DMVJH1S PC 44430009
DMVJH1S MW 357.5
DMVJH1S FM C25H27NO
DMVJH1S IC InChI=1S/C25H27NO/c1-20-9-8-14-23(19-20)25(27)15-17-26(18-16-25)24(21-10-4-2-5-11-21)22-12-6-3-7-13-22/h2-14,19,24,27H,15-18H2,1H3
DMVJH1S CS CC1=CC(=CC=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMVJH1S IK IFEJQGWUIGIJPD-UHFFFAOYSA-N
DMVJH1S IU 1-benzhydryl-4-(3-methylphenyl)piperidin-4-ol
DMVJH1S DE Discovery agent
DMVUMSF ID DMVUMSF
DMVUMSF DN 1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF HS Investigative
DMVUMSF SN CHEMBL232273; 1-benzhydryl-4-o-tolylpiperidin-4-ol
DMVUMSF DT Small molecular drug
DMVUMSF PC 20481138
DMVUMSF MW 357.5
DMVUMSF FM C25H27NO
DMVUMSF IC InChI=1S/C25H27NO/c1-20-10-8-9-15-23(20)25(27)16-18-26(19-17-25)24(21-11-4-2-5-12-21)22-13-6-3-7-14-22/h2-15,24,27H,16-19H2,1H3
DMVUMSF CS CC1=CC=CC=C1C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DMVUMSF IK WOOXDHAITFKPDQ-UHFFFAOYSA-N
DMVUMSF IU 1-benzhydryl-4-(2-methylphenyl)piperidin-4-ol
DMVUMSF DE Discovery agent
DMEB968 ID DMEB968
DMEB968 DN 1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968 HS Investigative
DMEB968 SN CHEMBL229017; 1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968 DT Small molecular drug
DMEB968 PC 10317947
DMEB968 MW 385.5
DMEB968 FM C27H31NO
DMEB968 IC InChI=1S/C27H31NO/c1-2-22-29-27(25-16-10-5-11-17-25)18-20-28(21-19-27)26(23-12-6-3-7-13-23)24-14-8-4-9-15-24/h3-17,26H,2,18-22H2,1H3
DMEB968 CS CCCOC1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMEB968 IK RCNHZINTASPDKK-UHFFFAOYSA-N
DMEB968 IU 1-benzhydryl-4-phenyl-4-propoxypiperidine
DMEB968 DE Discovery agent
DM7KU1X ID DM7KU1X
DM7KU1X DN 1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X HS Investigative
DM7KU1X SN CHEMBL228690; 1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X DT Small molecular drug
DM7KU1X PC 10269001
DM7KU1X MW 343.5
DM7KU1X FM C24H25NO
DM7KU1X IC InChI=1S/C24H25NO/c26-24(22-14-8-3-9-15-22)16-18-25(19-17-24)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-15,23,26H,16-19H2
DM7KU1X CS C1CN(CCC1(C2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DM7KU1X IK PMLFKOKTRMHUPA-UHFFFAOYSA-N
DM7KU1X IU 1-benzhydryl-4-phenylpiperidin-4-ol
DM7KU1X DE Discovery agent
DM679RC ID DM679RC
DM679RC DN 1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC HS Investigative
DM679RC SN CHEMBL393985; 1-benzhydryl-4-p-tolylpiperidin-4-ol
DM679RC DT Small molecular drug
DM679RC PC 9924923
DM679RC MW 357.5
DM679RC FM C25H27NO
DM679RC IC InChI=1S/C25H27NO/c1-20-12-14-23(15-13-20)25(27)16-18-26(19-17-25)24(21-8-4-2-5-9-21)22-10-6-3-7-11-22/h2-15,24,27H,16-19H2,1H3
DM679RC CS CC1=CC=C(C=C1)C2(CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)O
DM679RC IK ZDADQNJEUZQHKH-UHFFFAOYSA-N
DM679RC IU 1-benzhydryl-4-(4-methylphenyl)piperidin-4-ol
DM679RC DE Discovery agent
DMM5DTF ID DMM5DTF
DMM5DTF DN 1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF HS Investigative
DMM5DTF SN CHEMBL234771; 1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF DT Small molecular drug
DMM5DTF PC 10314141
DMM5DTF MW 323.5
DMM5DTF FM C22H29NO
DMM5DTF IC InChI=1S/C22H29NO/c1-21(2,3)22(24)14-16-23(17-15-22)20(18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13,20,24H,14-17H2,1-3H3
DMM5DTF CS CC(C)(C)C1(CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)O
DMM5DTF IK CSHMHUZYEYOBPL-UHFFFAOYSA-N
DMM5DTF IU 1-benzhydryl-4-tert-butylpiperidin-4-ol
DMM5DTF DE Discovery agent
DMMN5TA ID DMMN5TA
DMMN5TA DN 1-Benzo[b]thiophen-2-yl-cycloheptylamine
DMMN5TA HS Investigative
DMMN5TA SN CHEMBL18811; NCI60_038329; 1-Benzo[b]thiophen-2-yl-cycloheptylamine; AC1L9GG6; CTK7D5124; ZINC1657601; BDBM50040194; 1-(benzothiophen-2-yl)cycloheptan-1-amine; 1-(1-benzothiophen-2-yl)cycloheptan-1-amine
DMMN5TA DT Small molecular drug
DMMN5TA PC 398365
DMMN5TA MW 245.4
DMMN5TA FM C15H19NS
DMMN5TA IC InChI=1S/C15H19NS/c16-15(9-5-1-2-6-10-15)14-11-12-7-3-4-8-13(12)17-14/h3-4,7-8,11H,1-2,5-6,9-10,16H2
DMMN5TA CS C1CCCC(CC1)(C2=CC3=CC=CC=C3S2)N
DMMN5TA IK BCBMINBNEZGMJJ-UHFFFAOYSA-N
DMMN5TA IU 1-(1-benzothiophen-2-yl)cycloheptan-1-amine
DMMN5TA DE Discovery agent
DMR97FU ID DMR97FU
DMR97FU DN 1-Benzo[b]thiophen-2-yl-cyclohexylamine
DMR97FU HS Investigative
DMR97FU SN Cyclohexanamine, 1-benzo[b]thien-2-yl-; CHEMBL18556; 143603-26-3; NSC708121; ACMC-20bbzv; 1-Benzo[b]thiophen-2-yl-cyclohexylamine; AC1L9GJR; SCHEMBL7095248; CTK0B4318; DTXSID80327969; HYVMNAZTYJDWIZ-UHFFFAOYSA-N; ZINC1657638; BDBM50040190; AKOS030613260; NSC-708121; 1-(1-Benzothien-2-yl)cyclohexanamine #; Thionaphthene, 2-[1-aminocyclohex-1-yl]-; 1-(1-benzothiophen-2-yl)cyclohexan-1-amine
DMR97FU DT Small molecular drug
DMR97FU PC 398415
DMR97FU MW 231.36
DMR97FU FM C14H17NS
DMR97FU IC InChI=1S/C14H17NS/c15-14(8-4-1-5-9-14)13-10-11-6-2-3-7-12(11)16-13/h2-3,6-7,10H,1,4-5,8-9,15H2
DMR97FU CS C1CCC(CC1)(C2=CC3=CC=CC=C3S2)N
DMR97FU IK HYVMNAZTYJDWIZ-UHFFFAOYSA-N
DMR97FU IU 1-(1-benzothiophen-2-yl)cyclohexan-1-amine
DMR97FU CA CAS 143603-26-3
DMR97FU DE Discovery agent
DM6EF1L ID DM6EF1L
DM6EF1L DN 1-Benzo[b]thiophen-2-yl-cyclopentylamine
DM6EF1L HS Investigative
DM6EF1L SN CHEMBL18502; NCI60_038335; 1-Benzo[b]thiophen-2-yl-cyclopentylamine; AC1L9GGU; CTK7D5118; ZINC1657608; BDBM50040195; 1-(benzothiophen-2-yl)cyclopentan-1-amine; 1-(1-benzothiophen-2-yl)cyclopentan-1-amine
DM6EF1L DT Small molecular drug
DM6EF1L PC 398376
DM6EF1L MW 217.33
DM6EF1L FM C13H15NS
DM6EF1L IC InChI=1S/C13H15NS/c14-13(7-3-4-8-13)12-9-10-5-1-2-6-11(10)15-12/h1-2,5-6,9H,3-4,7-8,14H2
DM6EF1L CS C1CCC(C1)(C2=CC3=CC=CC=C3S2)N
DM6EF1L IK CHUXWBUYFQVPQD-UHFFFAOYSA-N
DM6EF1L IU 1-(1-benzothiophen-2-yl)cyclopentan-1-amine
DM6EF1L DE Discovery agent
DM153Y8 ID DM153Y8
DM153Y8 DN 1-Benzooxazol-2-yl-6-phenyl-hexan-1-one
DM153Y8 HS Investigative
DM153Y8 SN CHEMBL366907; 1-Benzooxazol-2-yl-6-phenyl-hexan-1-one
DM153Y8 DT Small molecular drug
DM153Y8 PC 44387731
DM153Y8 MW 293.4
DM153Y8 FM C19H19NO2
DM153Y8 IC InChI=1S/C19H19NO2/c21-17(19-20-16-12-7-8-14-18(16)22-19)13-6-2-5-11-15-9-3-1-4-10-15/h1,3-4,7-10,12,14H,2,5-6,11,13H2
DM153Y8 CS C1=CC=C(C=C1)CCCCCC(=O)C2=NC3=CC=CC=C3O2
DM153Y8 IK PCLBCMUYLOBYMW-UHFFFAOYSA-N
DM153Y8 IU 1-(1,3-benzoxazol-2-yl)-6-phenylhexan-1-one
DM153Y8 DE Discovery agent
DMEZPC8 ID DMEZPC8
DMEZPC8 DN 1-Benzothiazol-2-yl-3-phenethyl-thiourea
DMEZPC8 HS Investigative
DMEZPC8 SN Thiourea, N-2-benzothiazolyl-N'-(2-phenylethyl)-; 149485-21-2; PETT Analog 54; PETT Bzthiazol deriv.; AC1MHDL2; SCHEMBL6951823; CHEMBL147099; BDBM1887; DTXSID30164285; ZINC13744911; 1-Phenethyl-3-(benzothiazol-2-yl)thiourea; N-(2-Phenethyl)-N -(2-benzothiazolyl)thiourea; 1-(1,3-benzothiazol-2-yl)-3-phenethylthiourea; 1-(1,3-benzothiazol-2-yl)-3-phenethyl-thiourea
DMEZPC8 DT Small molecular drug
DMEZPC8 PC 3001119
DMEZPC8 MW 313.4
DMEZPC8 FM C16H15N3S2
DMEZPC8 IC InChI=1S/C16H15N3S2/c20-15(17-11-10-12-6-2-1-3-7-12)19-16-18-13-8-4-5-9-14(13)21-16/h1-9H,10-11H2,(H2,17,18,19,20)
DMEZPC8 CS C1=CC=C(C=C1)CCNC(=S)NC2=NC3=CC=CC=C3S2
DMEZPC8 IK PKNPAMNXDLTPNX-UHFFFAOYSA-N
DMEZPC8 IU 1-(1,3-benzothiazol-2-yl)-3-(2-phenylethyl)thiourea
DMEZPC8 CA CAS 149485-21-2
DMEZPC8 DE Discovery agent
DMF9X2T ID DMF9X2T
DMF9X2T DN 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T HS Investigative
DMF9X2T SN CHEMBL379434; 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one
DMF9X2T DT Small molecular drug
DMF9X2T PC 16037828
DMF9X2T MW 291.3
DMF9X2T FM C19H17NO2
DMF9X2T IC InChI=1S/C19H17NO2/c21-18-12-7-13-20(19(22)16-10-5-2-6-11-16)17(18)14-15-8-3-1-4-9-15/h1-12,17H,13-14H2
DMF9X2T CS C1C=CC(=O)C(N1C(=O)C2=CC=CC=C2)CC3=CC=CC=C3
DMF9X2T IK CKNOOIXBZFVOCF-UHFFFAOYSA-N
DMF9X2T IU 1-benzoyl-2-benzyl-2,6-dihydropyridin-3-one
DMF9X2T DE Discovery agent
DMG5MNZ ID DMG5MNZ
DMG5MNZ DN 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide
DMG5MNZ HS Investigative
DMG5MNZ SN AC1LERN1; 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide; TimTec1_001906; Oprea1_174326; N-Benzoylpyrazole deriv., 6; CHEMBL388239; BDBM23704; MolPort-001-664-680; ZINC115253; HMS1539G14; STK398485; AKOS003748858; MCULE-1390939767; 1-benzoyl-N-phenylpyrazole-3-carboxamide; ST025783; N-phenyl[1-(phenylcarbonyl)pyrazol-3-yl]carboxamide
DMG5MNZ DT Small molecular drug
DMG5MNZ PC 716930
DMG5MNZ MW 291.3
DMG5MNZ FM C17H13N3O2
DMG5MNZ IC InChI=1S/C17H13N3O2/c21-16(18-14-9-5-2-6-10-14)15-11-12-20(19-15)17(22)13-7-3-1-4-8-13/h1-12H,(H,18,21)
DMG5MNZ CS C1=CC=C(C=C1)C(=O)N2C=CC(=N2)C(=O)NC3=CC=CC=C3
DMG5MNZ IK ZYYMCOZRPAHLRN-UHFFFAOYSA-N
DMG5MNZ IU 1-benzoyl-N-phenylpyrazole-3-carboxamide
DMG5MNZ DE Discovery agent
DM17TIX ID DM17TIX
DM17TIX DN 1-Benzyl-1,2-dihydro-indazol-3-one
DM17TIX HS Investigative
DM17TIX SN 1-Benzyl-3-hydroxy-1H-indazole; 2215-63-6; 1-Benzyl-1H-indazol-3-ol; 1-Benzyl-1,2-dihydro-3H-indazol-3-one; 1-benzyl-2H-indazol-3-one; 1-Benzyl-1,2-dihydro-indazol-3-one; 1-benzylindazol-3-ol; CHEMBL8612; SXPJFDSMKWLOAB-UHFFFAOYSA-N; 3H-Indazol-3-one, 1,2-dihydro-1-(phenylmethyl)-; 1-Benzyl-2,3-dihydroindazol-3-one; CBMicro_007258; EINECS 218-680-4; 5-Hydroxybenzydamine; AC1Q6GZH; ACMC-1CR7T; ChemDiv2_000492; 1-Benzyl-3-hydroxyindazole; AC1Q6K7E; AC1L2O7R; Oprea1_591436; Oprea1_122894; MLS001211149; SCHEMBL376005
DM17TIX DT Small molecular drug
DM17TIX PC 75181
DM17TIX MW 224.26
DM17TIX FM C14H12N2O
DM17TIX IC InChI=1S/C14H12N2O/c17-14-12-8-4-5-9-13(12)16(15-14)10-11-6-2-1-3-7-11/h1-9H,10H2,(H,15,17)
DM17TIX CS C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)N2
DM17TIX IK SXPJFDSMKWLOAB-UHFFFAOYSA-N
DM17TIX IU 1-benzyl-2H-indazol-3-one
DM17TIX CA CAS 2215-63-6
DM17TIX DE Discovery agent
DMUXSH5 ID DMUXSH5
DMUXSH5 DN 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide
DMUXSH5 HS Investigative
DMUXSH5 SN 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide; CHEMBL1240573; 182556-28-1
DMUXSH5 DT Small molecular drug
DMUXSH5 PC 46933593
DMUXSH5 MW 264.3
DMUXSH5 FM C12H12N2O3S
DMUXSH5 IC InChI=1S/C12H12N2O3S/c13-18(16,17)12-9-14(7-6-11(12)15)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H2,13,16,17)
DMUXSH5 CS C1=CC=C(C=C1)CN2C=CC(=O)C(=C2)S(=O)(=O)N
DMUXSH5 IK WIIFYOJVUKTZDG-UHFFFAOYSA-N
DMUXSH5 IU 1-benzyl-4-oxopyridine-3-sulfonamide
DMUXSH5 DE Discovery agent
DMYGZ8V ID DMYGZ8V
DMYGZ8V DN 1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione
DMYGZ8V HS Investigative
DMYGZ8V SN CHEMBL112256; 1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione
DMYGZ8V DT Small molecular drug
DMYGZ8V PC 21604934
DMYGZ8V MW 292.29
DMYGZ8V FM C16H12N4O2
DMYGZ8V IC InChI=1S/C16H12N4O2/c21-15-13-14(17-12-8-4-5-9-19(12)13)20(16(22)18-15)10-11-6-2-1-3-7-11/h1-9H,10H2,(H,18,21,22)
DMYGZ8V CS C1=CC=C(C=C1)CN2C3=C(C(=O)NC2=O)N4C=CC=CC4=N3
DMYGZ8V IK JHTRSVKUCQEETB-UHFFFAOYSA-N
DMYGZ8V IU 1-benzylpurino[7,8-a]pyridine-2,4-dione
DMYGZ8V DE Discovery agent
DM2UFXE ID DM2UFXE
DM2UFXE DN 1-benzyl-1H-indole-2,3-dione
DM2UFXE HS Investigative
DM2UFXE SN 1-Benzyl-1H-indole-2,3-dione; 1217-89-6; 1-benzylisatin; 1-benzylindole-2,3-dione; 1-benzyl-2,3-dihydro-1H-indole-2,3-dione; 1-benzylindoline-2,3-dione; 1-Benzyl-2,3-indolinedione; 1H-indole-2,3-dione, 1-(phenylmethyl)-; 1H-Indole-2,3-dione,1-(phenylmethyl)-; benzylisatin; N-benzylisatin; N-benzyl isatin; 4kwf; NSC100000; AC1Q6FLI; AC1Q6FLG; AC1L6CGC; Isatin-based compound, 14; AC1Q6K6Z; N1-benzyl-indole-2,3-dione; CHEMBL115581; SCHEMBL2087729; BDBM22794; CTK4B2748; DTXSID30295164; SIISFRLGYDVIRG-UHFFFAOYSA-N; MolPort-000-322-417
DM2UFXE DT Small molecular drug
DM2UFXE PC 264734
DM2UFXE MW 237.25
DM2UFXE FM C15H11NO2
DM2UFXE IC InChI=1S/C15H11NO2/c17-14-12-8-4-5-9-13(12)16(15(14)18)10-11-6-2-1-3-7-11/h1-9H,10H2
DM2UFXE CS C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)C2=O
DM2UFXE IK SIISFRLGYDVIRG-UHFFFAOYSA-N
DM2UFXE IU 1-benzylindole-2,3-dione
DM2UFXE CA CAS 1217-89-6
DM2UFXE DE Discovery agent
DMW0Y92 ID DMW0Y92
DMW0Y92 DN 1-Benzyl-1H-indole-5-carboxamidine
DMW0Y92 HS Investigative
DMW0Y92 SN CHEMBL101343; 1-Benzyl-1H-indole-5-carboxamidine; BDBM50027286
DMW0Y92 DT Small molecular drug
DMW0Y92 PC 29012033
DMW0Y92 MW 249.31
DMW0Y92 FM C16H15N3
DMW0Y92 IC InChI=1S/C16H15N3/c17-16(18)14-6-7-15-13(10-14)8-9-19(15)11-12-4-2-1-3-5-12/h1-10H,11H2,(H3,17,18)
DMW0Y92 CS C1=CC=C(C=C1)CN2C=CC3=C2C=CC(=C3)C(=N)N
DMW0Y92 IK LHXHNJWJHADGSJ-UHFFFAOYSA-N
DMW0Y92 IU 1-benzylindole-5-carboximidamide
DMW0Y92 DE Discovery agent
DMEVSFY ID DMEVSFY
DMEVSFY DN 1-benzyl-1H-pyrrolo[3,2-b]pyridine
DMEVSFY HS Investigative
DMEVSFY SN 1-benzyl-1H-pyrrolo[3,2-b]pyridine; CHEMBL561256; 1-benzyl-4-azaindole; 1h-pyrrolo[3,2-b]pyridine,1-(phenylmethyl)-; SCHEMBL4716978; LOGFFHFLSCMKJF-UHFFFAOYSA-N; BDBM50295764; ZINC43079815; 50426-35-2
DMEVSFY DT Small molecular drug
DMEVSFY PC 45267314
DMEVSFY MW 208.26
DMEVSFY FM C14H12N2
DMEVSFY IC InChI=1S/C14H12N2/c1-2-5-12(6-3-1)11-16-10-8-13-14(16)7-4-9-15-13/h1-10H,11H2
DMEVSFY CS C1=CC=C(C=C1)CN2C=CC3=C2C=CC=N3
DMEVSFY IK LOGFFHFLSCMKJF-UHFFFAOYSA-N
DMEVSFY IU 1-benzylpyrrolo[3,2-b]pyridine
DMEVSFY DE Discovery agent
DMQFS2D ID DMQFS2D
DMQFS2D DN 1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid
DMQFS2D HS Investigative
DMQFS2D SN CHEMBL515599; 1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid; SCHEMBL6686678
DMQFS2D DT Small molecular drug
DMQFS2D PC 44564825
DMQFS2D MW 279.3
DMQFS2D FM C18H17NO2
DMQFS2D IC InChI=1S/C18H17NO2/c1-12-13(2)19(11-14-7-4-3-5-8-14)17-15(12)9-6-10-16(17)18(20)21/h3-10H,11H2,1-2H3,(H,20,21)
DMQFS2D CS CC1=C(N(C2=C1C=CC=C2C(=O)O)CC3=CC=CC=C3)C
DMQFS2D IK NSKDMNCONIAVGH-UHFFFAOYSA-N
DMQFS2D IU 1-benzyl-2,3-dimethylindole-7-carboxylic acid
DMQFS2D DE Discovery agent
DMEVO6M ID DMEVO6M
DMEVO6M DN 1-Benzyl-2-methyl-1H-imidazole
DMEVO6M HS Investigative
DMEVO6M SN 1-Benzyl-2-methyl-1H-imidazole; 1-Benzyl-2-methylimidazole; 13750-62-4; N-Benzyl-2-methylimidazole; Imidazole, 1-benzyl-2-methyl-; 1H-Imidazole, 2-methyl-1-(phenylmethyl)-; EINECS 237-333-8; 1H-Imidazole, methyl(phenylmethyl)-; 2-methyl-1-benzylimidazole; PubChem9442; ACMC-209ccp; SCHEMBL81625; 1-benzyl-2-methyl imidazole; labotest-bb lt00455538; KSC427M1B; MLS001074953; BDBM7885; AC1Q4X69; AC1L35Z6; CHEMBL1269154; DTXSID4065604; FBHPRUXJQNWTEW-UHFFFAOYSA-N; MolPort-003-931-164; HMS3372N18; ZINC156633; HMS2231D21; SBB058028
DMEVO6M DT Small molecular drug
DMEVO6M PC 83699
DMEVO6M MW 172.23
DMEVO6M FM C11H12N2
DMEVO6M IC InChI=1S/C11H12N2/c1-10-12-7-8-13(10)9-11-5-3-2-4-6-11/h2-8H,9H2,1H3
DMEVO6M CS CC1=NC=CN1CC2=CC=CC=C2
DMEVO6M IK FBHPRUXJQNWTEW-UHFFFAOYSA-N
DMEVO6M IU 1-benzyl-2-methylimidazole
DMEVO6M CA CAS 13750-62-4
DMEVO6M DE Discovery agent
DMPTMKU ID DMPTMKU
DMPTMKU DN 1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU HS Investigative
DMPTMKU SN CHEMBL271819; 1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU DT Small molecular drug
DMPTMKU PC 24823606
DMPTMKU MW 231.29
DMPTMKU FM C14H17NO2
DMPTMKU IC InChI=1S/C14H17NO2/c1-3-14(4-2)12(16)15(13(14)17)10-11-8-6-5-7-9-11/h5-9H,3-4,10H2,1-2H3
DMPTMKU CS CCC1(C(=O)N(C1=O)CC2=CC=CC=C2)CC
DMPTMKU IK FWKVKYCYDHDEBH-UHFFFAOYSA-N
DMPTMKU IU 1-benzyl-3,3-diethylazetidine-2,4-dione
DMPTMKU DE Discovery agent
DMW59XA ID DMW59XA
DMW59XA DN 1-benzyl-3,3-dimethylazetidine-2,4-dione
DMW59XA HS Investigative
DMW59XA SN 1-benzyl-3,3-dimethylazetidine-2,4-dione; CHEMBL556728
DMW59XA DT Small molecular drug
DMW59XA PC 24823444
DMW59XA MW 203.24
DMW59XA FM C12H13NO2
DMW59XA IC InChI=1S/C12H13NO2/c1-12(2)10(14)13(11(12)15)8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3
DMW59XA CS CC1(C(=O)N(C1=O)CC2=CC=CC=C2)C
DMW59XA IK LGZSEGMYAOALQU-UHFFFAOYSA-N
DMW59XA IU 1-benzyl-3,3-dimethylazetidine-2,4-dione
DMW59XA DE Discovery agent
DMMRV21 ID DMMRV21
DMMRV21 DN 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMMRV21 HS Investigative
DMMRV21 SN CHEMBL63944; 120642-81-1; 1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(phenylmethyl)-; phenyltheophylline; ACMC-20mp1i; 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione; SCHEMBL7453870; CTK0C3768; DTXSID50473801
DMMRV21 DT Small molecular drug
DMMRV21 PC 11821203
DMMRV21 MW 256.26
DMMRV21 FM C13H12N4O2
DMMRV21 IC InChI=1S/C13H12N4O2/c1-16-11-10(14-8-15-11)12(18)17(13(16)19)7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,14,15)
DMMRV21 CS CN1C2=C(C(=O)N(C1=O)CC3=CC=CC=C3)NC=N2
DMMRV21 IK YAYRUHPCXIPTID-UHFFFAOYSA-N
DMMRV21 IU 1-benzyl-3-methyl-7H-purine-2,6-dione
DMMRV21 CA CAS 120642-81-1
DMMRV21 DE Discovery agent
DMMNH4K ID DMMNH4K
DMMNH4K DN 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione
DMMNH4K HS Investigative
DMMNH4K SN Benzetimidum; 14051-33-3; Benzetimide [INN]; 5633-14-7; CHEMBL10272; Benzetimide (INN); NCGC00160474-01; 2-(1-Benzyl-4-piperidyl)-2-phenylglutarimide; Dexbenzetimide; 119391-55-8; Dextrobenzetimide; Benzezimida; Benzetimidum [INN-Latin]; 2-[1-BENZYL-4-PIPERIDYL]-2-PHENYLGLUTARIMIDE; Benzezimida [INN-Spanish]; [3,4'-Bipiperidine]-2,6-dione, 3-phenyl-1'-(phenylmethyl)-, (S)-; Benzetimide(hydrochloride); 1''-Benzyl-3-phenyl-[3,4'']bipiperidinyl-2,6-dione; AC1L2J7P; DSSTox_RID_81404; DSSTox_CID_26173
DMMNH4K DT Small molecular drug
DMMNH4K PC 21847
DMMNH4K MW 362.5
DMMNH4K FM C23H26N2O2
DMMNH4K IC InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)
DMMNH4K CS C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4
DMMNH4K IK LQQIVYSCPWCSSD-UHFFFAOYSA-N
DMMNH4K IU 3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione
DMMNH4K CA CAS 14051-33-3
DMMNH4K DE Discovery agent
DMV7UC0 ID DMV7UC0
DMV7UC0 DN 1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione
DMV7UC0 HS Investigative
DMV7UC0 SN CHEMBL520083; 1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione; ZINC9926727; BDBM50251699
DMV7UC0 DT Small molecular drug
DMV7UC0 PC 17132382
DMV7UC0 MW 328.4
DMV7UC0 FM C21H16N2O2
DMV7UC0 IC InChI=1S/C21H16N2O2/c24-20-18-13-7-8-14-19(18)22(15-16-9-3-1-4-10-16)21(25)23(20)17-11-5-2-6-12-17/h1-14H,15H2
DMV7UC0 CS C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=O)N(C2=O)C4=CC=CC=C4
DMV7UC0 IK CUMHESHKEAHQDE-UHFFFAOYSA-N
DMV7UC0 IU 1-benzyl-3-phenylquinazoline-2,4-dione
DMV7UC0 DE Discovery agent
DMNWGOE ID DMNWGOE
DMNWGOE DN 1-Benzyl-3-thiazol-2-yl-thiourea
DMNWGOE HS Investigative
DMNWGOE SN 1-Benzyl-3-thiazol-2-yl-thiourea; Thiourea, N-(phenylmethyl)-N'-2-thiazolyl-; 51623-90-6; BAS 00581141; 1-benzyl-3-(1,3-thiazol-2-yl)thiourea; PETT Bz deriv.; PETT Analog 30; AC1LDT48; MLS001208035; BDBM1923; SCHEMBL5455503; CHEMBL145897; REGID_for_CID_700723; CTK1G4420; ZINC80959; DTXSID90351457; PDHMEDMWKUZUAB-UHFFFAOYSA-N; MolPort-000-656-277; N-(benzyl)-N'-[2-thiazolyl]thiourea; AKOS000533873; 1-benzyl-3-1,3-thiazol-2-ylthiourea; MCULE-4774117095; N-(benzyl)-N'-[2-thiazolyl] thiourea; SMR000514687
DMNWGOE DT Small molecular drug
DMNWGOE PC 700723
DMNWGOE MW 249.4
DMNWGOE FM C11H11N3S2
DMNWGOE IC InChI=1S/C11H11N3S2/c15-10(14-11-12-6-7-16-11)13-8-9-4-2-1-3-5-9/h1-7H,8H2,(H2,12,13,14,15)
DMNWGOE CS C1=CC=C(C=C1)CNC(=S)NC2=NC=CS2
DMNWGOE IK PDHMEDMWKUZUAB-UHFFFAOYSA-N
DMNWGOE IU 1-benzyl-3-(1,3-thiazol-2-yl)thiourea
DMNWGOE CA CAS 51623-90-6
DMNWGOE DE Discovery agent
DMGDY4X ID DMGDY4X
DMGDY4X DN 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
DMGDY4X HS Investigative
DMGDY4X SN 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine; CHEMBL395208
DMGDY4X DT Small molecular drug
DMGDY4X PC 44440618
DMGDY4X MW 321.2
DMGDY4X FM C17H18Cl2N2
DMGDY4X IC InChI=1S/C17H18Cl2N2/c18-13-6-7-14(16(19)8-13)15-10-21(11-17(15)20)9-12-4-2-1-3-5-12/h1-8,15,17H,9-11,20H2
DMGDY4X CS C1C(C(CN1CC2=CC=CC=C2)N)C3=C(C=C(C=C3)Cl)Cl
DMGDY4X IK OHYGBKLWBNYXTE-UHFFFAOYSA-N
DMGDY4X IU 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine
DMGDY4X DE Discovery agent
DMF0GXD ID DMF0GXD
DMF0GXD DN 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine
DMF0GXD HS Investigative
DMF0GXD SN CHEMBL325104; 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine; BDBM50082164
DMF0GXD DT Small molecular drug
DMF0GXD PC 15508240
DMF0GXD MW 264.4
DMF0GXD FM C18H20N2
DMF0GXD IC InChI=1S/C18H20N2/c1-2-17-9-6-12-20(17)18-10-13-19(14-11-18)15-16-7-4-3-5-8-16/h1,3-9,12,18H,10-11,13-15H2
DMF0GXD CS C#CC1=CC=CN1C2CCN(CC2)CC3=CC=CC=C3
DMF0GXD IK CNGQSMFIQRDDKI-UHFFFAOYSA-N
DMF0GXD IU 1-benzyl-4-(2-ethynylpyrrol-1-yl)piperidine
DMF0GXD DE Discovery agent
DMBRJ5S ID DMBRJ5S
DMBRJ5S DN 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine
DMBRJ5S HS Investigative
DMBRJ5S SN 1-Benzyl-4-(2-iodo-1H-pyrrol-1-yl)piperidine; CHEMBL106635; 254115-95-2; 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine; CTK7C3535; BDBM50082171; ZINC20358060; SBB054419; AKOS027449108; 4-(2-iodopyrrolyl)-1-benzylpiperidine
DMBRJ5S DT Small molecular drug
DMBRJ5S PC 15508243
DMBRJ5S MW 366.24
DMBRJ5S FM C16H19IN2
DMBRJ5S IC InChI=1S/C16H19IN2/c17-16-7-4-10-19(16)15-8-11-18(12-9-15)13-14-5-2-1-3-6-14/h1-7,10,15H,8-9,11-13H2
DMBRJ5S CS C1CN(CCC1N2C=CC=C2I)CC3=CC=CC=C3
DMBRJ5S IK LZMIVAWAFVXKJL-UHFFFAOYSA-N
DMBRJ5S IU 1-benzyl-4-(2-iodopyrrol-1-yl)piperidine
DMBRJ5S DE Discovery agent
DMSBNY8 ID DMSBNY8
DMSBNY8 DN 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMSBNY8 HS Investigative
DMSBNY8 SN CHEMBL104453; 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine; BDBM50082166
DMSBNY8 DT Small molecular drug
DMSBNY8 PC 10357869
DMSBNY8 MW 307.4
DMSBNY8 FM C19H21N3O
DMSBNY8 IC InChI=1S/C19H21N3O/c1-2-5-16(6-3-1)14-21-11-8-17(9-12-21)22-10-4-7-18(22)19-13-20-15-23-19/h1-7,10,13,15,17H,8-9,11-12,14H2
DMSBNY8 CS C1CN(CCC1N2C=CC=C2C3=CN=CO3)CC4=CC=CC=C4
DMSBNY8 IK JTHXHSNJAJMWTQ-UHFFFAOYSA-N
DMSBNY8 IU 5-[1-(1-benzylpiperidin-4-yl)pyrrol-2-yl]-1,3-oxazole
DMSBNY8 DE Discovery agent
DMCO0JU ID DMCO0JU
DMCO0JU DN 1-Benzyl-4-(3-hydroxyphenyl)piperidine
DMCO0JU HS Investigative
DMCO0JU SN CHEMBL592377; 1-Benzyl-4-(3-hydroxyphenyl)piperidine; SCHEMBL4826023
DMCO0JU DT Small molecular drug
DMCO0JU PC 22397839
DMCO0JU MW 267.4
DMCO0JU FM C18H21NO
DMCO0JU IC InChI=1S/C18H21NO/c20-18-8-4-7-17(13-18)16-9-11-19(12-10-16)14-15-5-2-1-3-6-15/h1-8,13,16,20H,9-12,14H2
DMCO0JU CS C1CN(CCC1C2=CC(=CC=C2)O)CC3=CC=CC=C3
DMCO0JU IK BPNZNQGAIFMNES-UHFFFAOYSA-N
DMCO0JU IU 3-(1-benzylpiperidin-4-yl)phenol
DMCO0JU DE Discovery agent
DMCJZVA ID DMCJZVA
DMCJZVA DN 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine
DMCJZVA HS Investigative
DMCJZVA SN CHEMBL107529; 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine; BDBM50082170
DMCJZVA DT Small molecular drug
DMCJZVA PC 9995378
DMCJZVA MW 307.4
DMCJZVA FM C19H21N3O
DMCJZVA IC InChI=1S/C19H21N3O/c1-2-4-16(5-3-1)13-21-9-7-18(8-10-21)22-11-6-17(14-22)19-12-20-15-23-19/h1-6,11-12,14-15,18H,7-10,13H2
DMCJZVA CS C1CN(CCC1N2C=CC(=C2)C3=CN=CO3)CC4=CC=CC=C4
DMCJZVA IK ASGPPKHUWWRTLM-UHFFFAOYSA-N
DMCJZVA IU 5-[1-(1-benzylpiperidin-4-yl)pyrrol-3-yl]-1,3-oxazole
DMCJZVA DE Discovery agent
DM4NGUL ID DM4NGUL
DM4NGUL DN 1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine
DM4NGUL HS Investigative
DM4NGUL SN 1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine; CHEMBL496013; 1-benzyl-4-(4-phenylpiperazino)phthalazine; 320418-04-0; AC1O4EAW; Oprea1_653246; SCHEMBL13444952; KS-000031YH; ZINC1393434; BDBM50269040; AKOS005082019
DM4NGUL DT Small molecular drug
DM4NGUL PC 6404568
DM4NGUL MW 380.5
DM4NGUL FM C25H24N4
DM4NGUL IC InChI=1S/C25H24N4/c1-3-9-20(10-4-1)19-24-22-13-7-8-14-23(22)25(27-26-24)29-17-15-28(16-18-29)21-11-5-2-6-12-21/h1-14H,15-19H2
DM4NGUL CS C1CN(CCN1C2=CC=CC=C2)C3=NN=C(C4=CC=CC=C43)CC5=CC=CC=C5
DM4NGUL IK PMNLMFUHSIYHHB-UHFFFAOYSA-N
DM4NGUL IU 1-benzyl-4-(4-phenylpiperazin-1-yl)phthalazine
DM4NGUL CA CAS 320418-04-0
DM4NGUL DE Discovery agent
DMOF07G ID DMOF07G
DMOF07G DN 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine
DMOF07G HS Investigative
DMOF07G SN CHEMBL597413; 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine
DMOF07G DT Small molecular drug
DMOF07G PC 45380179
DMOF07G MW 330.4
DMOF07G FM C18H22N2O2S
DMOF07G IC InChI=1S/C18H22N2O2S/c1-23(21,22)18-9-5-8-17(14-18)20-12-10-19(11-13-20)15-16-6-3-2-4-7-16/h2-9,14H,10-13,15H2,1H3
DMOF07G CS CS(=O)(=O)C1=CC=CC(=C1)N2CCN(CC2)CC3=CC=CC=C3
DMOF07G IK DABGEKAEKHHGFN-UHFFFAOYSA-N
DMOF07G IU 1-benzyl-4-(3-methylsulfonylphenyl)piperazine
DMOF07G DE Discovery agent
DME0MDL ID DME0MDL
DME0MDL DN 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine
DME0MDL HS Investigative
DME0MDL SN CHEMBL596800; 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine; SCHEMBL4825273
DME0MDL DT Small molecular drug
DME0MDL PC 22397829
DME0MDL MW 329.5
DME0MDL FM C19H23NO2S
DME0MDL IC InChI=1S/C19H23NO2S/c1-23(21,22)19-9-5-8-18(14-19)17-10-12-20(13-11-17)15-16-6-3-2-4-7-16/h2-9,14,17H,10-13,15H2,1H3
DME0MDL CS CS(=O)(=O)C1=CC=CC(=C1)C2CCN(CC2)CC3=CC=CC=C3
DME0MDL IK KOPPWFMKOOMORI-UHFFFAOYSA-N
DME0MDL IU 1-benzyl-4-(3-methylsulfonylphenyl)piperidine
DME0MDL DE Discovery agent
DMAQSBV ID DMAQSBV
DMAQSBV DN 1-Benzyl-4-chroman-2-ylmethyl-piperazine
DMAQSBV HS Investigative
DMAQSBV SN CHEMBL179648; 1-Benzyl-4-chroman-2-ylmethyl-piperazine; SCHEMBL8031431; AJZBPCAHQHCXMX-UHFFFAOYSA-N; BDBM50159018; 1-[(chroman-2-yl)methyl]-4-benzylpiperazine
DMAQSBV DT Small molecular drug
DMAQSBV PC 10758200
DMAQSBV MW 322.4
DMAQSBV FM C21H26N2O
DMAQSBV IC InChI=1S/C21H26N2O/c1-2-6-18(7-3-1)16-22-12-14-23(15-13-22)17-20-11-10-19-8-4-5-9-21(19)24-20/h1-9,20H,10-17H2
DMAQSBV CS C1CC2=CC=CC=C2OC1CN3CCN(CC3)CC4=CC=CC=C4
DMAQSBV IK AJZBPCAHQHCXMX-UHFFFAOYSA-N
DMAQSBV IU 1-benzyl-4-(3,4-dihydro-2H-chromen-2-ylmethyl)piperazine
DMAQSBV DE Discovery agent
DMETDQC ID DMETDQC
DMETDQC DN 1-Benzyl-4-methyl-piperazine
DMETDQC HS Investigative
DMETDQC SN 1-benzyl-4-methylpiperazine; 62226-74-8; 1-benzyl-4-methyl-piperazine; CHEMBL363603; Piperazine, 1-methyl-4-(phenylmethyl)-; 4-Benzyl-1-methylpiperazine; 1-Benzyl-4-methylpiperazinehydrochloride; PubChem10987; AC1LG1B6; Cambridge id 5263722; N-benzyl-N'-methylpiperazine; SCHEMBL221139; Methyl piperazine, polymer-bound; CTK2C4522; DTXSID90354100; Methyl piperazinomethyl polystyrene; MolPort-000-882-836; MLJOKPBESJWYGL-UHFFFAOYSA-N; HMS1579O15; BCP22253; MFCD00976530; ZINC19536830; STK115879; BDBM50174044
DMETDQC DT Small molecular drug
DMETDQC PC 763557
DMETDQC MW 190.28
DMETDQC FM C12H18N2
DMETDQC IC InChI=1S/C12H18N2/c1-13-7-9-14(10-8-13)11-12-5-3-2-4-6-12/h2-6H,7-11H2,1H3
DMETDQC CS CN1CCN(CC1)CC2=CC=CC=C2
DMETDQC IK MLJOKPBESJWYGL-UHFFFAOYSA-N
DMETDQC IU 1-benzyl-4-methylpiperazine
DMETDQC CA CAS 62226-74-8
DMETDQC DE Discovery agent
DMNTELW ID DMNTELW
DMNTELW DN 1-benzyl-4-phenylpiperidin-4-ol
DMNTELW HS Investigative
DMNTELW SN 1-Benzyl-4-phenylpiperidin-4-ol; 63843-83-4; 1-Benzyl-4-phenyl-4-piperidinol; 4-Piperidinol, 1-benzyl-4-phenyl-; 1-Benzyl-4-phenyl-piperidin-4-ol; EINECS 264-512-8; 1-benzyl-4-hydroxy-4-phenylpiperidine; 1-benzyl-4-hydroxy-4-phenyl piperidine; BRN 0235839; CHEMBL230141; F1446-0078; NSC116051; AC1L3YAO; Oprea1_213406; Oprea1_173104; SCHEMBL1411499; AC1Q7B56; CTK5B9985; DTXSID60213290; MolPort-001-954-320; FCLMXEAPEVBCKQ-UHFFFAOYSA-N; ZINC320034; HMS1672E06; BCP13431; ANW-45516; BDBM50210409; STK081775; AKOS000541462
DMNTELW DT Small molecular drug
DMNTELW PC 97333
DMNTELW MW 267.4
DMNTELW FM C18H21NO
DMNTELW IC InChI=1S/C18H21NO/c20-18(17-9-5-2-6-10-17)11-13-19(14-12-18)15-16-7-3-1-4-8-16/h1-10,20H,11-15H2
DMNTELW CS C1CN(CCC1(C2=CC=CC=C2)O)CC3=CC=CC=C3
DMNTELW IK FCLMXEAPEVBCKQ-UHFFFAOYSA-N
DMNTELW IU 1-benzyl-4-phenylpiperidin-4-ol
DMNTELW CA CAS 63843-83-4
DMNTELW DE Discovery agent
DMNWEC9 ID DMNWEC9
DMNWEC9 DN 1-Benzyl-4-pyrrol-1-yl-piperidine
DMNWEC9 HS Investigative
DMNWEC9 SN 1-benzyl-4-(1H-pyrrol-1-yl)piperidine; 254115-91-8; CHEMBL326877; 1-(phenylmethyl)-4-pyrrol-1-yl-piperidine; 1-benzyl-4-pyrrolylpiperidine; 1-benzyl-4-pyrrol-1-yl-piperidine; AC1MCV5B; AC1Q28X7; CTK5J6306; KS-00003TOT; MolPort-001-764-445; ZINC161500; 1-benzyl-4-pyrrol-1-ylpiperidine; BDBM50082169; SBB056067; 1-benzyl-4-(pyrrol-1-yl)piperidine; AKOS008965823; NE54439; MCULE-3402690429; TS-03355; 1-Benzyl-4-(1H-pyrrole-1-yl)piperidine; KB-152224; ST50950067; EN300-52430; Z56618096
DMNWEC9 DT Small molecular drug
DMNWEC9 PC 2779264
DMNWEC9 MW 240.34
DMNWEC9 FM C16H20N2
DMNWEC9 IC InChI=1S/C16H20N2/c1-2-6-15(7-3-1)14-17-12-8-16(9-13-17)18-10-4-5-11-18/h1-7,10-11,16H,8-9,12-14H2
DMNWEC9 CS C1CN(CCC1N2C=CC=C2)CC3=CC=CC=C3
DMNWEC9 IK UPRFZLANTXURKF-UHFFFAOYSA-N
DMNWEC9 IU 1-benzyl-4-pyrrol-1-ylpiperidine
DMNWEC9 DE Discovery agent
DMH0ZVR ID DMH0ZVR
DMH0ZVR DN 1-benzyl-5'-O-tritylinosine
DMH0ZVR HS Investigative
DMH0ZVR SN CHEMBL441540; 5'-O-trityl-1-benzylinosine; 1-benzyl-5''-O-tritylinosine; AUYLAWYEMLZGBM-QSYCCZFCSA-N
DMH0ZVR DT Small molecular drug
DMH0ZVR PC 16082777
DMH0ZVR MW 600.7
DMH0ZVR FM C36H32N4O5
DMH0ZVR IC InChI=1S/C36H32N4O5/c41-31-29(22-44-36(26-15-7-2-8-16-26,27-17-9-3-10-18-27)28-19-11-4-12-20-28)45-35(32(31)42)40-24-37-30-33(40)38-23-39(34(30)43)21-25-13-5-1-6-14-25/h1-20,23-24,29,31-32,35,41-42H,21-22H2/t29-,31-,32-,35-/m1/s1
DMH0ZVR CS C1=CC=C(C=C1)CN2C=NC3=C(C2=O)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)COC(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)O)O
DMH0ZVR IK AUYLAWYEMLZGBM-QSYCCZFCSA-N
DMH0ZVR IU 1-benzyl-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]purin-6-one
DMH0ZVR DE Discovery agent
DM8GUN9 ID DM8GUN9
DM8GUN9 DN 1-Benzyl-5-phenyl-1H-imidazole
DM8GUN9 HS Investigative
DM8GUN9 SN 1-benzyl-5-phenyl-1H-imidazole; 53704-79-3; 1-benzyl-5-phenylimidazole; SCHEMBL1501929; CHEMBL463582; CTK1G0360; BDBM24655; DTXSID30440036; AWZYHJQWJWUOHS-UHFFFAOYSA-N; AKOS015905520; 4-phenylimidazole (4-PI) derivative, 27; 1H-Imidazole, 5-phenyl-1-(phenylmethyl)-
DM8GUN9 DT Small molecular drug
DM8GUN9 PC 10444038
DM8GUN9 MW 234.29
DM8GUN9 FM C16H14N2
DM8GUN9 IC InChI=1S/C16H14N2/c1-3-7-14(8-4-1)12-18-13-17-11-16(18)15-9-5-2-6-10-15/h1-11,13H,12H2
DM8GUN9 CS C1=CC=C(C=C1)CN2C=NC=C2C3=CC=CC=C3
DM8GUN9 IK AWZYHJQWJWUOHS-UHFFFAOYSA-N
DM8GUN9 IU 1-benzyl-5-phenylimidazole
DM8GUN9 CA CAS 53704-79-3
DM8GUN9 DE Discovery agent
DMCX3N1 ID DMCX3N1
DMCX3N1 DN 1-Benzyl-7-chloro-4-hexyloxy-quinolinium
DMCX3N1 HS Investigative
DMCX3N1 DT Small molecular drug
DMCX3N1 PC 10433084
DMCX3N1 MW 434.8
DMCX3N1 FM C22H25BrClNO
DMCX3N1 IC InChI=1S/C22H25ClNO.BrH/c1-2-3-4-8-15-25-22-13-14-24(17-18-9-6-5-7-10-18)21-16-19(23)11-12-20(21)22;/h5-7,9-14,16H,2-4,8,15,17H2,1H3;1H/q+1;/p-1
DMCX3N1 CS CCCCCCOC1=C2C=CC(=CC2=[N+](C=C1)CC3=CC=CC=C3)Cl.[Br-]
DMCX3N1 IK RZJKFYPDZZJFFA-UHFFFAOYSA-M
DMCX3N1 IU 1-benzyl-7-chloro-4-hexoxyquinolin-1-ium;bromide
DMCX3N1 DE Discovery agent
DMJHXMY ID DMJHXMY
DMJHXMY DN 1-benzyl-APDC
DMJHXMY HS Investigative
DMJHXMY SN CHEMBL60238; 171336-76-8; (2R,4R)-1-BENZYL-4-AMINO-PYRROLIDINE-2,4-DIcarboxylic acid; GTPL1436; SCHEMBL8061968; CTK0A8043; DTXSID60573467; ZINC39952128; BDBM50071161; DB-064818; AJ-101168; FT-0772028; 4-amino-1-(phenylmethyl)pyrrolidine-2,4-dicarboxylic acid; (2R,4R)-4-amino-1-benzylpyrrolidine-2,4-dicarboxylic acid; (2R,4R)-4-Amino-1-benzyl-pyrrolidine-2,4-dicarboxylic acid; (2R)-1-Benzyl-4-aminopyrrolidine-2beta,4alpha-dicarboxylic acid; 4-Amino-1-benzyl-pyrrolidine-2,4-dicarboxylic acid(1-benzyl-APDC)
DMJHXMY DT Small molecular drug
DMJHXMY PC 15508178
DMJHXMY MW 264.28
DMJHXMY FM C13H16N2O4
DMJHXMY IC InChI=1S/C13H16N2O4/c14-13(12(18)19)6-10(11(16)17)15(8-13)7-9-4-2-1-3-5-9/h1-5,10H,6-8,14H2,(H,16,17)(H,18,19)/t10-,13-/m1/s1
DMJHXMY CS C1[C@@H](N(C[C@]1(C(=O)O)N)CC2=CC=CC=C2)C(=O)O
DMJHXMY IK LYCSUAGKQMUTBR-ZWNOBZJWSA-N
DMJHXMY IU (2R,4R)-4-amino-1-benzylpyrrolidine-2,4-dicarboxylic acid
DMJHXMY CA CAS 171336-76-8
DMJHXMY DE Discovery agent
DM7GDEK ID DM7GDEK
DM7GDEK DN 1-benzylpiperidine hydrochloride
DM7GDEK HS Investigative
DM7GDEK SN 1-Benzylpiperidine hydrochloride; 6295-81-4; Piperidine, 1-benzyl-, hydrochloride; 1-Benzyl-Piperidine HCl; Piperidine, 1-(phenylmethyl)-, hydrochloride; AC1L46RA; benzylpiperidine hydrochloride; CHEMBL555311; SCHEMBL7409551; 2905-56-8 (Parent); DTXSID70212153; NSC49527; NSC-49527; LS-114289; KB-218184
DM7GDEK DT Small molecular drug
DM7GDEK PC 201590
DM7GDEK MW 211.73
DM7GDEK FM C12H18ClN
DM7GDEK IC InChI=1S/C12H17N.ClH/c1-3-7-12(8-4-1)11-13-9-5-2-6-10-13;/h1,3-4,7-8H,2,5-6,9-11H2;1H
DM7GDEK CS C1CCN(CC1)CC2=CC=CC=C2.Cl
DM7GDEK IK MPPIBJJDFLONMO-UHFFFAOYSA-N
DM7GDEK IU 1-benzylpiperidine;hydrochloride
DM7GDEK CA CAS 6295-81-4
DM7GDEK DE Discovery agent
DMHR90S ID DMHR90S
DMHR90S DN 1beta-methoxy-miller-9Z-enolide
DMHR90S HS Investigative
DMHR90S SN CHEMBL425948
DMHR90S DT Small molecular drug
DMHR90S PC 44409505
DMHR90S MW 376.4
DMHR90S FM C20H24O7
DMHR90S IC InChI=1S/C20H24O7/c1-10(2)19(23)26-15-8-13(9-21)14(25-5)7-6-11(3)17(22)18-16(15)12(4)20(24)27-18/h8-9,14-18,22H,1,3-4,6-7H2,2,5H3/b13-8+/t14-,15-,16-,17+,18+/m1/s1
DMHR90S CS CC(=C)C(=O)O[C@@H]1/C=C(/[C@@H](CCC(=C)[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)OC)\\C=O
DMHR90S IK JYJDQGQWAQKPAO-FLTPFCGOSA-N
DMHR90S IU [(3aR,4R,5Z,7R,11S,11aS)-6-formyl-11-hydroxy-7-methoxy-3,10-dimethylidene-2-oxo-4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DMHR90S DE Discovery agent
DMKJYCU ID DMKJYCU
DMKJYCU DN 1-biphenyl-2-ylmethanamine
DMKJYCU HS Investigative
DMKJYCU SN 2-Phenylbenzylamine; 1924-77-2; [1,1'-biphenyl]-2-ylmethanamine; 1-Biphenyl-2-Ylmethanamine; [1,1'-Biphenyl]-2-methanamine; (2-phenylphenyl)methanamine; biphenyl-2-methanamine; CHEMBL257036; (2-phenylphenyl)methylamine; 1-(biphenyl-2-yl)methanamine; biphenyl-2-ylmethanamine hydrochloride; NSC97774; 2-phenylbenzyl amine; 2-aminomethylbiphenyl; biphenyl-2-ylmethylamine; biphenyl-2-ylmethanamine; AC1Q1IHD; (2-biphenylylmethyl)amine; 2-phenylbenzylamine ,98%; 2-phenyl-phenylmethyl amine; c-biphenyl-2-yl-methylamine; SCHEMBL469051
DMKJYCU DT Small molecular drug
DMKJYCU PC 263366
DMKJYCU MW 183.25
DMKJYCU FM C13H13N
DMKJYCU IC InChI=1S/C13H13N/c14-10-12-8-4-5-9-13(12)11-6-2-1-3-7-11/h1-9H,10,14H2
DMKJYCU CS C1=CC=C(C=C1)C2=CC=CC=C2CN
DMKJYCU IK YHXKXVFQHWJYOD-UHFFFAOYSA-N
DMKJYCU IU (2-phenylphenyl)methanamine
DMKJYCU CA CAS 1924-77-2
DMKJYCU DE Discovery agent
DM6E7TA ID DM6E7TA
DM6E7TA DN 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane
DM6E7TA HS Investigative
DM6E7TA SN CHEMBL505313; 86225-52-7; 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane; SCHEMBL4713453; CTK2I3607; DTXSID40534177; BDBM50243943; 1-([1,1'-Biphenyl]-4-yl)-3-azabicyclo[3.1.0]hexane; 3-Azabicyclo[3.1.0]hexane, 1-[1,1'-biphenyl]-4-yl-
DM6E7TA DT Small molecular drug
DM6E7TA PC 13279027
DM6E7TA MW 235.32
DM6E7TA FM C17H17N
DM6E7TA IC InChI=1S/C17H17N/c1-2-4-13(5-3-1)14-6-8-15(9-7-14)17-10-16(17)11-18-12-17/h1-9,16,18H,10-12H2
DM6E7TA CS C1C2C1(CNC2)C3=CC=C(C=C3)C4=CC=CC=C4
DM6E7TA IK FKKPHPHBDNQCCQ-UHFFFAOYSA-N
DM6E7TA IU 1-(4-phenylphenyl)-3-azabicyclo[3.1.0]hexane
DM6E7TA CA CAS 86225-52-7
DM6E7TA DE Discovery agent
DM9QTWB ID DM9QTWB
DM9QTWB DN 1-Biphenyl-4-ylmaleimide
DM9QTWB HS Investigative
DM9QTWB SN N-(4-Biphenylyl)maleimide; MALEIMIDE, N-4-BIPHENYLYL-; BRN 0183921; 58609-75-9; AI3-02979; CHEMBL567545; 1-(4-phenylphenyl)pyrrole-2,5-dione; 1H-Pyrrole-2,5-dione, 1-(1,1'-biphenyl)-4-yl-; 1-Biphenyl-4-ylmaleimide; Cyto6B10; Maybridge3_004857; AC1L28LA; CBDivE_004932; 4-21-00-04634 (Beilstein Handbook Reference); SCHEMBL9719419; DTXSID30207328; MolPort-000-929-072; HMS1444M17; ZINC186459; STK003872; BDBM50300341; AKOS000296044; MCULE-5728148499; IDI1_016244; LS-88673
DM9QTWB DT Small molecular drug
DM9QTWB PC 42797
DM9QTWB MW 249.26
DM9QTWB FM C16H11NO2
DM9QTWB IC InChI=1S/C16H11NO2/c18-15-10-11-16(19)17(15)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-11H
DM9QTWB CS C1=CC=C(C=C1)C2=CC=C(C=C2)N3C(=O)C=CC3=O
DM9QTWB IK RXWKCYQPTDVVSI-UHFFFAOYSA-N
DM9QTWB IU 1-(4-phenylphenyl)pyrrole-2,5-dione
DM9QTWB CA CAS 58609-75-9
DM9QTWB DE Discovery agent
DMKL201 ID DMKL201
DMKL201 DN 1-Biphenyl-4-ylmethylmaleimide
DMKL201 HS Investigative
DMKL201 SN CHEMBL576859; 1-Biphenyl-4-ylmethylmaleimide
DMKL201 DT Small molecular drug
DMKL201 PC 45483984
DMKL201 MW 263.29
DMKL201 FM C17H13NO2
DMKL201 IC InChI=1S/C17H13NO2/c19-16-10-11-17(20)18(16)12-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-11H,12H2
DMKL201 CS C1=CC=C(C=C1)C2=CC=C(C=C2)CN3C(=O)C=CC3=O
DMKL201 IK LMMOMHSYMJTOJF-UHFFFAOYSA-N
DMKL201 IU 1-[(4-phenylphenyl)methyl]pyrrole-2,5-dione
DMKL201 CA CAS 913733-40-1
DMKL201 DE Discovery agent
DMGL4MJ ID DMGL4MJ
DMGL4MJ DN 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one
DMGL4MJ HS Investigative
DMGL4MJ SN CHEMBL421829; 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one; BDBM50097367; 4-((1H-imidazol-1-yl)methyl)-1-bromo-9H-xanthen-9-one
DMGL4MJ DT Small molecular drug
DMGL4MJ PC 10546089
DMGL4MJ MW 355.2
DMGL4MJ FM C17H11BrN2O2
DMGL4MJ IC InChI=1S/C17H11BrN2O2/c18-13-6-5-11(9-20-8-7-19-10-20)17-15(13)16(21)12-3-1-2-4-14(12)22-17/h1-8,10H,9H2
DMGL4MJ CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)CN4C=CN=C4)Br
DMGL4MJ IK DPCAMTPMSZHJLT-UHFFFAOYSA-N
DMGL4MJ IU 1-bromo-4-(imidazol-1-ylmethyl)xanthen-9-one
DMGL4MJ DE Discovery agent
DMU2PSQ ID DMU2PSQ
DMU2PSQ DN 1-Bromo-6-(3-hydroxyphenyl)-2-naphthol
DMU2PSQ HS Investigative
DMU2PSQ SN CHEMBL467151; 1-Bromo-6-(3-hydroxyphenyl)-2-naphthol; SCHEMBL3009237; WIVQIQQCUPQEGH-UHFFFAOYSA-N; ZINC40876206; BDBM50261887; 1-bromo-6-(3-hydroxyphenyl)naphthalene-2-ol
DMU2PSQ DT Small molecular drug
DMU2PSQ PC 24950391
DMU2PSQ MW 315.16
DMU2PSQ FM C16H11BrO2
DMU2PSQ IC InChI=1S/C16H11BrO2/c17-16-14-6-4-11(8-12(14)5-7-15(16)19)10-2-1-3-13(18)9-10/h1-9,18-19H
DMU2PSQ CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)Br
DMU2PSQ IK WIVQIQQCUPQEGH-UHFFFAOYSA-N
DMU2PSQ IU 1-bromo-6-(3-hydroxyphenyl)naphthalen-2-ol
DMU2PSQ DE Discovery agent
DM2T4NL ID DM2T4NL
DM2T4NL DN 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM2T4NL HS Investigative
DM2T4NL SN CHEMBL194936; 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3936480; IPBYYNRPJBGKET-UHFFFAOYSA-N; ZINC13645011; BDBM50168334
DM2T4NL DT Small molecular drug
DM2T4NL PC 10149684
DM2T4NL MW 315.16
DM2T4NL FM C16H11BrO2
DM2T4NL IC InChI=1S/C16H11BrO2/c17-16-14-7-3-11(9-12(14)4-8-15(16)19)10-1-5-13(18)6-2-10/h1-9,18-19H
DM2T4NL CS C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)Br)O
DM2T4NL IK IPBYYNRPJBGKET-UHFFFAOYSA-N
DM2T4NL IU 1-bromo-6-(4-hydroxyphenyl)naphthalen-2-ol
DM2T4NL DE Discovery agent
DMXMATS ID DMXMATS
DMXMATS DN 1-butoxy-4-phenoxybenzene
DMXMATS HS Investigative
DMXMATS SN CHEMBL475731; 1-butoxy-4-phenoxybenzene; 4-Butoxydiphenyl ether; SCHEMBL13545912; BDBM50246008
DMXMATS DT Small molecular drug
DMXMATS PC 44562812
DMXMATS MW 242.31
DMXMATS FM C16H18O2
DMXMATS IC InChI=1S/C16H18O2/c1-2-3-13-17-14-9-11-16(12-10-14)18-15-7-5-4-6-8-15/h4-12H,2-3,13H2,1H3
DMXMATS CS CCCCOC1=CC=C(C=C1)OC2=CC=CC=C2
DMXMATS IK NSCFOXCKETUFMF-UHFFFAOYSA-N
DMXMATS IU 1-butoxy-4-phenoxybenzene
DMXMATS DE Discovery agent
DMO7NXE ID DMO7NXE
DMO7NXE DN 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE HS Investigative
DMO7NXE SN CHEMBL198124; 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol
DMO7NXE DT Small molecular drug
DMO7NXE PC 44404886
DMO7NXE MW 260.37
DMO7NXE FM C16H24N2O
DMO7NXE IC InChI=1S/C16H24N2O/c1-4-5-10-18-12-13(9-11-17(2)3)16-14(18)7-6-8-15(16)19/h6-8,12,19H,4-5,9-11H2,1-3H3
DMO7NXE CS CCCCN1C=C(C2=C1C=CC=C2O)CCN(C)C
DMO7NXE IK HVOYRIYIBILDHN-UHFFFAOYSA-N
DMO7NXE IU 1-butyl-3-[2-(dimethylamino)ethyl]indol-4-ol
DMO7NXE DE Discovery agent
DMOE2ZV ID DMOE2ZV
DMOE2ZV DN 1-Butyl-3,7-dihydro-purine-2,6-dione
DMOE2ZV HS Investigative
DMOE2ZV SN 1-Butylxanthine; CHEMBL68278; 1-Butyl-3,7-dihydro-purine-2,6-dione; SCHEMBL6233166
DMOE2ZV DT Small molecular drug
DMOE2ZV PC 14969715
DMOE2ZV MW 208.22
DMOE2ZV FM C9H12N4O2
DMOE2ZV IC InChI=1S/C9H12N4O2/c1-2-3-4-13-8(14)6-7(11-5-10-6)12-9(13)15/h5H,2-4H2,1H3,(H,10,11)(H,12,15)
DMOE2ZV CS CCCCN1C(=O)C2=C(NC1=O)N=CN2
DMOE2ZV IK HZPVRRDNEDXPAJ-UHFFFAOYSA-N
DMOE2ZV IU 1-butyl-3,7-dihydropurine-2,6-dione
DMOE2ZV CA CAS 60942-22-5
DMOE2ZV DE Discovery agent
DM9GRN8 ID DM9GRN8
DM9GRN8 DN 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione
DM9GRN8 HS Investigative
DM9GRN8 SN CHEMBL130503; 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione; SCHEMBL7109948; 1H-Purine-2,6-dione, 1-butyl-3,9-dihydro-3-methyl-; XT-56; BDBM50001494
DM9GRN8 DT Small molecular drug
DM9GRN8 PC 12905389
DM9GRN8 MW 222.24
DM9GRN8 FM C10H14N4O2
DM9GRN8 IC InChI=1S/C10H14N4O2/c1-3-4-5-14-9(15)7-8(12-6-11-7)13(2)10(14)16/h6H,3-5H2,1-2H3,(H,11,12)
DM9GRN8 CS CCCCN1C(=O)C2=C(N=CN2)N(C1=O)C
DM9GRN8 IK GDRIWEXJHHARCU-UHFFFAOYSA-N
DM9GRN8 IU 1-butyl-3-methyl-7H-purine-2,6-dione
DM9GRN8 DE Discovery agent
DM6QULO ID DM6QULO
DM6QULO DN 1-Butyl-4-(2-methoxy-phenyl)-piperazine
DM6QULO HS Investigative
DM6QULO SN CHEMBL26789; 1-Butyl-4-(2-methoxy-phenyl)-piperazine; Oprea1_525926; SCHEMBL10414460; ZINC13738286; BDBM50039791; AKOS008298691
DM6QULO DT Small molecular drug
DM6QULO PC 10354670
DM6QULO MW 248.36
DM6QULO FM C15H24N2O
DM6QULO IC InChI=1S/C15H24N2O/c1-3-4-9-16-10-12-17(13-11-16)14-7-5-6-8-15(14)18-2/h5-8H,3-4,9-13H2,1-2H3
DM6QULO CS CCCCN1CCN(CC1)C2=CC=CC=C2OC
DM6QULO IK DCFYVNHQUVKFKK-UHFFFAOYSA-N
DM6QULO IU 1-butyl-4-(2-methoxyphenyl)piperazine
DM6QULO DE Discovery agent
DMSNK98 ID DMSNK98
DMSNK98 DN 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98 HS Investigative
DMSNK98 SN CHEMBL8789; 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSNK98 DT Small molecular drug
DMSNK98 PC 11781054
DMSNK98 MW 284.31
DMSNK98 FM C15H16N4O2
DMSNK98 IC InChI=1S/C15H16N4O2/c1-2-3-9-19-14(20)11-13(18-15(19)21)17-12(16-11)10-7-5-4-6-8-10/h4-8H,2-3,9H2,1H3,(H,16,17)(H,18,21)
DMSNK98 CS CCCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=CC=C3
DMSNK98 IK UGAWDWCYTZJBPQ-UHFFFAOYSA-N
DMSNK98 IU 1-butyl-8-phenyl-3,7-dihydropurine-2,6-dione
DMSNK98 DE Discovery agent
DMVFCLO ID DMVFCLO
DMVFCLO DN 1-butyryl-1H-indole-2,3-dione
DMVFCLO HS Investigative
DMVFCLO SN 1-butyryl-1H-indole-2,3-dione; 92675-59-7; Butyrylisatin; AC1MXQ1S; Isatin-based compound, 10; 1-butanoylindole-2,3-dione; CHEMBL374970; BDBM22790; MolPort-002-322-431; 1-butanoyl-1H-indole-2,3-dione; ZINC3160706; STK370040; AKOS001849110; MCULE-5909492944; CCG-139393; 1-butanoylbenzo[d]azolidine-2,3-dione; ST50561436
DMVFCLO DT Small molecular drug
DMVFCLO PC 3794313
DMVFCLO MW 217.22
DMVFCLO FM C12H11NO3
DMVFCLO IC InChI=1S/C12H11NO3/c1-2-5-10(14)13-9-7-4-3-6-8(9)11(15)12(13)16/h3-4,6-7H,2,5H2,1H3
DMVFCLO CS CCCC(=O)N1C2=CC=CC=C2C(=O)C1=O
DMVFCLO IK LYWOFWNKZLWLPZ-UHFFFAOYSA-N
DMVFCLO IU 1-butanoylindole-2,3-dione
DMVFCLO DE Discovery agent
DM13HGN ID DM13HGN
DM13HGN DN 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene
DM13HGN HS Investigative
DM13HGN SN CHEMBL191195; 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene
DM13HGN DT Small molecular drug
DM13HGN PC 44400752
DM13HGN MW 334.9
DM13HGN FM C18H19ClO2S
DM13HGN IC InChI=1S/C18H19ClO2S/c19-16-9-11-17(12-10-16)22(20,21)18(13-5-2-6-14-18)15-7-3-1-4-8-15/h1,3-4,7-12H,2,5-6,13-14H2
DM13HGN CS C1CCC(CC1)(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)Cl
DM13HGN IK XMYNJSLMUBGZIQ-UHFFFAOYSA-N
DM13HGN IU 1-chloro-4-(1-phenylcyclohexyl)sulfonylbenzene
DM13HGN DE Discovery agent
DM0MGFQ ID DM0MGFQ
DM0MGFQ DN 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
DM0MGFQ HS Investigative
DM0MGFQ SN 1-Chloro-6-(4-hydroxyphenyl)-2-naphthol; CHEMBL364092; 1-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol; 4NA; 1yy4; AC1O0UUG; 1-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3933824; YHEHVRSGKUYDON-UHFFFAOYSA-N; ZINC13645009; BDBM50168323
DM0MGFQ DT Small molecular drug
DM0MGFQ PC 6102690
DM0MGFQ MW 270.71
DM0MGFQ FM C16H11ClO2
DM0MGFQ IC InChI=1S/C16H11ClO2/c17-16-14-7-3-11(9-12(14)4-8-15(16)19)10-1-5-13(18)6-2-10/h1-9,18-19H
DM0MGFQ CS C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)Cl)O
DM0MGFQ IK YHEHVRSGKUYDON-UHFFFAOYSA-N
DM0MGFQ IU 1-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol
DM0MGFQ DE Discovery agent
DMA2607 ID DMA2607
DMA2607 DN 1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea
DMA2607 HS Investigative
DMA2607 SN CHEMBL1257632; 1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2719520
DMA2607 DT Small molecular drug
DMA2607 PC 49782569
DMA2607 MW 295.42
DMA2607 FM C16H29N3O2
DMA2607 IC InChI=1S/C16H29N3O2/c1-2-15(20)19-11-9-14(10-12-19)18-16(21)17-13-7-5-3-4-6-8-13/h13-14H,2-12H2,1H3,(H2,17,18,21)
DMA2607 CS CCC(=O)N1CCC(CC1)NC(=O)NC2CCCCCC2
DMA2607 IK VEXSVFHEOLIFHA-UHFFFAOYSA-N
DMA2607 IU 1-cycloheptyl-3-(1-propanoylpiperidin-4-yl)urea
DMA2607 DE Discovery agent
DMS10LE ID DMS10LE
DMS10LE DN 1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea
DMS10LE HS Investigative
DMS10LE SN CHEMBL399930; 1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea
DMS10LE DT Small molecular drug
DMS10LE PC 24776961
DMS10LE MW 275.3
DMS10LE FM C12H24N2Se
DMS10LE IC InChI=1S/C12H24N2Se/c1-10(2)14(12(15)13(3)4)11-8-6-5-7-9-11/h10-11H,5-9H2,1-4H3
DMS10LE CS CC(C)N(C1CCCCC1)C(=[Se])N(C)C
DMS10LE IK WEFWDSQOLMAXHJ-UHFFFAOYSA-N
DMS10LE IU 1-cyclohexyl-3,3-dimethyl-1-propan-2-ylselenourea
DMS10LE DE Discovery agent
DMAZYCD ID DMAZYCD
DMAZYCD DN 1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea
DMAZYCD HS Investigative
DMAZYCD SN CHEMBL1256164; 1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2730613; BDBM50327823
DMAZYCD DT Small molecular drug
DMAZYCD PC 47379736
DMAZYCD MW 281.39
DMAZYCD FM C15H27N3O2
DMAZYCD IC InChI=1S/C15H27N3O2/c1-2-14(19)18-10-8-13(9-11-18)17-15(20)16-12-6-4-3-5-7-12/h12-13H,2-11H2,1H3,(H2,16,17,20)
DMAZYCD CS CCC(=O)N1CCC(CC1)NC(=O)NC2CCCCC2
DMAZYCD IK VZLSZVQSSZTJPS-UHFFFAOYSA-N
DMAZYCD IU 1-cyclohexyl-3-(1-propanoylpiperidin-4-yl)urea
DMAZYCD DE Discovery agent
DMESUD7 ID DMESUD7
DMESUD7 DN 1-Cyclohexyl-3-(4-methoxy-phenyl)-urea
DMESUD7 HS Investigative
DMESUD7 SN 1-cyclohexyl-3-(4-methoxyphenyl)urea; CHEMBL191968; N-cyclohexyl-N'-(4-methoxyphenyl)urea; 148806-87-5; Urea, N-cyclohexyl-N'-(4-methoxyphenyl)-; 1-Cyclohexyl-3-(4-methoxy-phenyl)-urea; AC1MQ7FX; ACMC-20n5j8; AC1Q4DC4; SCHEMBL12196154; CTK0E8825; DTXSID20392116; ZINC395455; STL268801; BDBM50167053; AKOS003408864; N-(4-Methoxyphenyl)-N'-cyclohexylurea; MCULE-4247297698; KB-104482; US8815951, 67
DMESUD7 DT Small molecular drug
DMESUD7 PC 3397178
DMESUD7 MW 248.32
DMESUD7 FM C14H20N2O2
DMESUD7 IC InChI=1S/C14H20N2O2/c1-18-13-9-7-12(8-10-13)16-14(17)15-11-5-3-2-4-6-11/h7-11H,2-6H2,1H3,(H2,15,16,17)
DMESUD7 CS COC1=CC=C(C=C1)NC(=O)NC2CCCCC2
DMESUD7 IK KZOFCHITIRGEGY-UHFFFAOYSA-N
DMESUD7 IU 1-cyclohexyl-3-(4-methoxyphenyl)urea
DMESUD7 CA CAS 148806-87-5
DMESUD7 DE Discovery agent
DMH9O6V ID DMH9O6V
DMH9O6V DN 1-Cyclohexyl-3-phenethyl-urea
DMH9O6V HS Investigative
DMH9O6V SN N-cyclohexyl-N'-(2-phenylethyl)urea; 1-cyclohexyl-3-phenethylurea; CHEMBL193888; MLS000061067; 1-Cyclohexyl-3-phenethyl-urea; AC1LEVP0; AC1Q5P4E; Cambridge id 5402894; Oprea1_499442; SCHEMBL12196137; CHEBI:108334; MolPort-001-839-964; ZINC182146; HMS2444C08; HMS1582O21; 1-cyclohexyl-3-(2-phenylethyl)urea; 3-cyclohexyl-1-(2-phenylethyl)urea; BDBM50167058; AKOS001026537; MCULE-2992993146; SMR000069580; US8815951, 36; AB00084095-01; Z44585920
DMH9O6V DT Small molecular drug
DMH9O6V PC 742677
DMH9O6V MW 246.35
DMH9O6V FM C15H22N2O
DMH9O6V IC InChI=1S/C15H22N2O/c18-15(17-14-9-5-2-6-10-14)16-12-11-13-7-3-1-4-8-13/h1,3-4,7-8,14H,2,5-6,9-12H2,(H2,16,17,18)
DMH9O6V CS C1CCC(CC1)NC(=O)NCCC2=CC=CC=C2
DMH9O6V IK YJAMPQZPTKVFIU-UHFFFAOYSA-N
DMH9O6V IU 1-cyclohexyl-3-(2-phenylethyl)urea
DMH9O6V CB CHEBI:108334
DMH9O6V DE Discovery agent
DM9K8HA ID DM9K8HA
DM9K8HA DN 1-Cyclohexyl-3-phenyl-urea
DM9K8HA HS Investigative
DM9K8HA SN 1-cyclohexyl-3-phenylurea; N-CYCLOHEXYL-N'-PHENYLUREA; CHEMBL365939; Urea, N-cyclohexyl-N'-phenyl-; 886-59-9; WPLYTRWMCWBZEN-UHFFFAOYSA-N; (cyclohexylamino)-N-benzamide; 1-Cyclohexyl-3-phenyl-urea; NSC80588; CBMicro_019203; 3-cyclohexyl-1-phenylurea; 1-phenyl-3-cyclohexylurea; Cambridge id 5353538; AC1Q5NF9; 1-cyclohexyl 3-phenyl urea; MLS000532450; SCHEMBL812273; N-Cyclohexyl-N'-phenylurea #; AC1L21R9; ZINC65313; MolPort-001-837-644; HMS3323I20; HMS2169M05; HMS1775L19; CCG-7124; NSC-80588; SBB056567; BDBM50167056; AKOS001021945
DM9K8HA DT Small molecular drug
DM9K8HA PC 13451
DM9K8HA MW 218.29
DM9K8HA FM C13H18N2O
DM9K8HA IC InChI=1S/C13H18N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1,3-4,7-8,12H,2,5-6,9-10H2,(H2,14,15,16)
DM9K8HA CS C1CCC(CC1)NC(=O)NC2=CC=CC=C2
DM9K8HA IK WPLYTRWMCWBZEN-UHFFFAOYSA-N
DM9K8HA IU 1-cyclohexyl-3-phenylurea
DM9K8HA CA CAS 886-59-9
DM9K8HA DE Discovery agent
DMFPQME ID DMFPQME
DMFPQME DN 1-cyclohexylamido-5-sulfonamidoindane
DMFPQME HS Investigative
DMFPQME SN CHEMBL206830; 1-cyclohexylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 11b; BDBM11032
DMFPQME DT Small molecular drug
DMFPQME PC 11659798
DMFPQME MW 322.4
DMFPQME FM C16H22N2O3S
DMFPQME IC InChI=1S/C16H22N2O3S/c17-22(20,21)13-7-8-14-12(10-13)6-9-15(14)18-16(19)11-4-2-1-3-5-11/h7-8,10-11,15H,1-6,9H2,(H,18,19)(H2,17,20,21)
DMFPQME CS C1CCC(CC1)C(=O)NC2CCC3=C2C=CC(=C3)S(=O)(=O)N
DMFPQME IK XUDBTOFDMYBQSW-UHFFFAOYSA-N
DMFPQME IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)cyclohexanecarboxamide
DMFPQME DE Discovery agent
DM7A50Z ID DM7A50Z
DM7A50Z DN 1-Cyclohexylidenethiosemicarbazide
DM7A50Z HS Investigative
DM7A50Z SN (cyclohexylideneamino)thiourea; Cyclohexanone thiosemicarbazone; 5351-77-9; Cyclohexanone, thiosemicarbazone; 1-Cyclohexylidenethiosemicarbazide; 2-cyclohexylidenehydrazinecarbothioamide; Hydrazinecarbothioamide, 2-cyclohexylidene-; CHEMBL510328; amino[(cyclohexylideneazamethyl)amino]methane-1-thione; AC1MD1GF; Thiosemicarbazonecyclohexanone; SCHEMBL941085; Thiosemicarbazone, cyclohexanone; NSC717; CTK1H1977; DTXSID20385240; NSC-717; MolPort-000-248-718; GYRDZVHNPFBIST-UHFFFAOYSA-N; HMS1577F04; ZINC5413245; SBB041170
DM7A50Z DT Small molecular drug
DM7A50Z PC 2829394
DM7A50Z MW 171.27
DM7A50Z FM C7H13N3S
DM7A50Z IC InChI=1S/C7H13N3S/c8-7(11)10-9-6-4-2-1-3-5-6/h1-5H2,(H3,8,10,11)
DM7A50Z CS C1CCC(=NNC(=S)N)CC1
DM7A50Z IK GYRDZVHNPFBIST-UHFFFAOYSA-N
DM7A50Z IU (cyclohexylideneamino)thiourea
DM7A50Z CA CAS 5351-77-9
DM7A50Z DE Discovery agent
DMEMQFH ID DMEMQFH
DMEMQFH DN 1-Cyclopentyl-3,7-dihydro-purine-2,6-dione
DMEMQFH HS Investigative
DMEMQFH SN CHEMBL302344; cyclopentylxanthine; 1-Cyclopentyl-3,7-dihydro-purine-2,6-dione; SCHEMBL2520260; BDBM50042198
DMEMQFH DT Small molecular drug
DMEMQFH PC 10998551
DMEMQFH MW 220.23
DMEMQFH FM C10H12N4O2
DMEMQFH IC InChI=1S/C10H12N4O2/c15-9-7-8(12-5-11-7)13-10(16)14(9)6-3-1-2-4-6/h5-6H,1-4H2,(H,11,12)(H,13,16)
DMEMQFH CS C1CCC(C1)N2C(=O)C3=C(NC2=O)N=CN3
DMEMQFH IK IBCDFVYWAHQNAA-UHFFFAOYSA-N
DMEMQFH IU 1-cyclopentyl-3,7-dihydropurine-2,6-dione
DMEMQFH DE Discovery agent
DMDGWAY ID DMDGWAY
DMDGWAY DN 1-Cyclopentylidenethiosemicarbazide
DMDGWAY HS Investigative
DMDGWAY SN cyclopentanone thiosemicarbazone; 7283-39-8; Hydrazinecarbothioamide, 2-cyclopentylidene-; (cyclopentylideneamino)thiourea; Cyclopentanone, thiosemicarbazone; 1-Cyclopentylidenethiosemicarbazide; 2-cyclopentylidenehydrazinecarbothioamide; CHEMBL483262; PKHFATUAFMXAKP-UHFFFAOYSA-N; amino[(cyclopentylideneazamethyl)amino]methane-1-thione; NSC8269; AC1Q7EGW; AC1LEPE5; SCHEMBL4100479; MolPort-000-248-728; KS-000027YL; NSC-8269; STK391362; BDBM50268200; SBB041172; ZINC17730060; AKOS000269515; MCULE-1053883982
DMDGWAY DT Small molecular drug
DMDGWAY PC 690102
DMDGWAY MW 157.24
DMDGWAY FM C6H11N3S
DMDGWAY IC InChI=1S/C6H11N3S/c7-6(10)9-8-5-3-1-2-4-5/h1-4H2,(H3,7,9,10)
DMDGWAY CS C1CCC(=NNC(=S)N)C1
DMDGWAY IK PKHFATUAFMXAKP-UHFFFAOYSA-N
DMDGWAY IU (cyclopentylideneamino)thiourea
DMDGWAY CA CAS 7283-39-8
DMDGWAY DE Discovery agent
DMGSQTK ID DMGSQTK
DMGSQTK DN 1D05
DMGSQTK HS Investigative
DMGSQTK SN Humanized monoclonal antibody (coronary heart disease), Merck
DMGSQTK CP Merck & Co Inc
DMGSQTK DT Antibody
DMGSQTK DE Coronary artery disease
DMG0VN6 ID DMG0VN6
DMG0VN6 DN 1-Deaza-Adenosine
DMG0VN6 HS Investigative
DMG0VN6 SN 1-Deazaadenosine; 1-deaza-adenosine; 14432-09-8; CHEMBL115824; 1DA; 1add; 1-Deaza-A; AC1L4ME8; AC1Q4XY1; adenosine-N,1,3-15N3; SCHEMBL18490353; A-d-ribofuranosyl)-3h-imidazo[4,5-b]pyridin-7-amine; MolPort-023-278-902; 3H-Imidazo(4,5-b)pyridin-7-amine, 3-beta-D-ribofuranosyl-; ZINC3814313; PDSP1_001078; BDBM50060165; PDSP2_001062; AKOS024458188; DB04218; NCGC00163308-01; 3- -D-Ribofuranosyl-3H-imidazo[4,5-b]pyridin-7-amine; 3-beta-D-ribofuranosyl-3H-imidazo[4,5-b]pyridin-7-amine; 3H-Imidazo[4,5-B]Pyridine, 7-Amino-3-ss-D-Ribof
DMG0VN6 DT Small molecular drug
DMG0VN6 PC 159738
DMG0VN6 MW 266.25
DMG0VN6 FM C11H14N4O4
DMG0VN6 IC InChI=1S/C11H14N4O4/c12-5-1-2-13-10-7(5)14-4-15(10)11-9(18)8(17)6(3-16)19-11/h1-2,4,6,8-9,11,16-18H,3H2,(H2,12,13)/t6-,8-,9-,11-/m1/s1
DMG0VN6 CS C1=CN=C2C(=C1N)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMG0VN6 IK NVUDDRWKCUAERS-PNHWDRBUSA-N
DMG0VN6 IU (2R,3R,4S,5R)-2-(7-aminoimidazo[4,5-b]pyridin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMG0VN6 CA CAS 14432-09-8
DMG0VN6 DE Discovery agent
DMOEQDP ID DMOEQDP
DMOEQDP DN 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose
DMOEQDP HS Investigative
DMOEQDP SN 1-DEOXY-1-METHOXYCARBAMIDO-BETA-D-GLUCOPYRANOSE; CHEMBL134529; CR1; AC1L9IGO; Carbamic acid, N-beta-D-glucopyranosyl-, methyl ester; BDBM50363873; DB03657; 188679-87-0; N-(methoxycarbonyl)-beta-D-glucopyranosylamine; methyl N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamate
DMOEQDP DT Small molecular drug
DMOEQDP PC 445722
DMOEQDP MW 237.21
DMOEQDP FM C8H15NO7
DMOEQDP IC InChI=1S/C8H15NO7/c1-15-8(14)9-7-6(13)5(12)4(11)3(2-10)16-7/h3-7,10-13H,2H2,1H3,(H,9,14)/t3-,4-,5+,6-,7-/m1/s1
DMOEQDP CS COC(=O)N[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMOEQDP IK IZZJOGWXTFEDLL-XUUWZHRGSA-N
DMOEQDP IU methyl N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamate
DMOEQDP CA CAS 188679-87-0
DMOEQDP DE Discovery agent
DMAEWHB ID DMAEWHB
DMAEWHB DN 1-Deoxy-1-Thio-Heptaethylene Glycol
DMAEWHB HS Investigative
DMAEWHB SN 1-DEOXY-1-THIO-HEPTAETHYLENE GLYCOL; PE7; 20-sulfanyl-3,6,9,12,15,18-hexaoxaicosan-1-ol; AC1L9JR2; MolPort-006-168-364; ZINC5828797; DB02404; 3,6,9,12,15,18-Hexaoxa-20-mercaptoicosane-1-ol
DMAEWHB DT Small molecular drug
DMAEWHB PC 446506
DMAEWHB MW 342.45
DMAEWHB FM C14H30O7S
DMAEWHB IC InChI=1S/C14H30O7S/c15-1-2-16-3-4-17-5-6-18-7-8-19-9-10-20-11-12-21-13-14-22/h15,22H,1-14H2
DMAEWHB CS C(COCCOCCOCCOCCOCCOCCS)O
DMAEWHB IK ACMBXVJDKVNCGH-UHFFFAOYSA-N
DMAEWHB IU 2-[2-[2-[2-[2-[2-(2-sulfanylethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
DMAEWHB DE Discovery agent
DMCSPU4 ID DMCSPU4
DMCSPU4 DN 1-Deoxy-D-Xylulose-5-Phosphate
DMCSPU4 HS Investigative
DMCSPU4 SN 1-Deoxy-xylulose 5-phosphate; deoxyxylulose-5-phosphate; D-1-deoxyxylulose-5-P; 1-deoxy-D-threo-pentulose 5-phosphate; DXP; CHEBI:57792; 1-deoxy-5-O-phosphonato-D-xylulose; 1-deoxy-D-xylulose 5-phosphate(2-); 1-deoxy-D-xylulose 5-phosphate dianion
DMCSPU4 DT Small molecular drug
DMCSPU4 PC 443201
DMCSPU4 MW 214.11
DMCSPU4 FM C5H11O7P
DMCSPU4 IC InChI=1S/C5H11O7P/c1-3(6)5(8)4(7)2-12-13(9,10)11/h4-5,7-8H,2H2,1H3,(H2,9,10,11)/t4-,5-/m1/s1
DMCSPU4 CS CC(=O)[C@H]([C@@H](COP(=O)(O)O)O)O
DMCSPU4 IK AJPADPZSRRUGHI-RFZPGFLSSA-N
DMCSPU4 IU [(2R,3S)-2,3-dihydroxy-4-oxopentyl] dihydrogen phosphate
DMCSPU4 CA CAS 190079-18-6
DMCSPU4 CB CHEBI:16493
DMCSPU4 DE Discovery agent
DMH9WFD ID DMH9WFD
DMH9WFD DN 1-Deoxy-Ribofuranose-5'-Phosphate
DMH9WFD HS Investigative
DMH9WFD SN 1-DEOXY-RIBOFURANOSE-5'-PHOSPHATE; AC1NRD1H; DB03936; [(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMH9WFD DT Small molecular drug
DMH9WFD PC 5289299
DMH9WFD MW 214.11
DMH9WFD FM C5H11O7P
DMH9WFD IC InChI=1S/C5H11O7P/c6-3-1-11-4(5(3)7)2-12-13(8,9)10/h3-7H,1-2H2,(H2,8,9,10)/t3-,4+,5+/m0/s1
DMH9WFD CS C1[C@@H]([C@H]([C@H](O1)COP(=O)(O)O)O)O
DMH9WFD IK CYZZKTRFOOKUMT-VPENINKCSA-N
DMH9WFD IU [(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMH9WFD DE Discovery agent
DM4NBUH ID DM4NBUH
DM4NBUH DN 1-D-glucopyranosyl cytosine
DM4NBUH HS Investigative
DM4NBUH SN 1-D-glucopyranosyl cytosine; CHEMBL1096136; 4-Amino-1-Beta-D-Glucopyranosylpyrimidin-2(1h)-One; 1-D-glucopyranosyl-cytosine; SCHEMBL7520145; 1-beta-D-Glucopyranosylcytosine; BDBM50316588
DM4NBUH DT Small molecular drug
DM4NBUH PC 21678292
DM4NBUH MW 273.24
DM4NBUH FM C10H15N3O6
DM4NBUH IC InChI=1S/C10H15N3O6/c11-5-1-2-13(10(18)12-5)9-8(17)7(16)6(15)4(3-14)19-9/h1-2,4,6-9,14-17H,3H2,(H2,11,12,18)/t4-,6-,7+,8-,9-/m1/s1
DM4NBUH CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM4NBUH IK YYUQXKHCNLFJNF-DDIGBBAMSA-N
DM4NBUH IU 4-amino-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]pyrimidin-2-one
DM4NBUH DE Discovery agent
DM90ULM ID DM90ULM
DM90ULM DN 1-D-glucopyranosyl uracil
DM90ULM HS Investigative
DM90ULM SN 1-D-glucopyranosyl uracil; CHEMBL1096135; 1-Beta-D-Glucopyranosylpyrimidine-2,4(1h,3h)-Dione; 3bcs; CJB; 3t3d; 1-D-glucopyranosyl-uracil; SCHEMBL8712423; BDBM50316587
DM90ULM DT Small molecular drug
DM90ULM PC 15042826
DM90ULM MW 274.23
DM90ULM FM C10H14N2O7
DM90ULM IC InChI=1S/C10H14N2O7/c13-3-4-6(15)7(16)8(17)9(19-4)12-2-1-5(14)11-10(12)18/h1-2,4,6-9,13,15-17H,3H2,(H,11,14,18)/t4-,6-,7+,8-,9-/m1/s1
DM90ULM CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM90ULM IK PBGBADORVLQASN-DDIGBBAMSA-N
DM90ULM IU 1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]pyrimidine-2,4-dione
DM90ULM DE Discovery agent
DMOL2Y0 ID DMOL2Y0
DMOL2Y0 DN 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine
DMOL2Y0 HS Investigative
DMOL2Y0 SN RMI 60947; CHEMBL89970; piperazine, 1-dibenz[b,f]oxepin-10-yl-4-methyl-; Piperazine, 1-dibenz(b,f)oxepin-10-yl-4-methyl-; BRN 0624016; 1-Dibenz(b,f)oxepin-10-yl-4-methylpiperazine; 22012-06-2; AC1L4PU3; 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine; AC1Q70N4; CTK8D8624; DTXSID60176452; ZINC26648468; BDBM50028598; AKOS005065368; 11-(4-Methylpiperazino)dibenz[b,f]oxepin; LS-111456; 1-benzo[b][1]benzoxepin-5-yl-4-methylpiperazine; 5-23-02-00446 (Beilstein Handbook Reference)
DMOL2Y0 DT Small molecular drug
DMOL2Y0 PC 210956
DMOL2Y0 MW 292.4
DMOL2Y0 FM C19H20N2O
DMOL2Y0 IC InChI=1S/C19H20N2O/c1-20-10-12-21(13-11-20)17-14-15-6-2-4-8-18(15)22-19-9-5-3-7-16(17)19/h2-9,14H,10-13H2,1H3
DMOL2Y0 CS CN1CCN(CC1)C2=CC3=CC=CC=C3OC4=CC=CC=C42
DMOL2Y0 IK ZCCUIFWJESTQQQ-UHFFFAOYSA-N
DMOL2Y0 IU 1-benzo[b][1]benzoxepin-5-yl-4-methylpiperazine
DMOL2Y0 CA CAS 22012-06-2
DMOL2Y0 DE Discovery agent
DMOSRET ID DMOSRET
DMOSRET DN 1DMe
DMOSRET HS Investigative
DMOSRET SN [D.Tyr1,(N.Me)Phe3]NPFF; [D-Tyr1,(NMe)Phe3]neuropeptide FF
DMOSRET DT Small molecular drug
DMOSRET PC 132709
DMOSRET MW 1111.3
DMOSRET FM C55H78N14O11
DMOSRET IC InChI=1S/C55H78N14O11/c1-32(2)28-44(68(3)53(79)37(56)29-35-18-20-36(70)21-19-35)52(78)67-42(31-34-14-8-5-9-15-34)50(76)65-40(23-25-46(58)72)54(80)69-27-11-17-43(69)51(77)64-39(22-24-45(57)71)49(75)63-38(16-10-26-62-55(60)61)48(74)66-41(47(59)73)30-33-12-6-4-7-13-33/h4-9,12-15,18-21,32,37-44,70H,10-11,16-17,22-31,56H2,1-3H3,(H2,57,71)(H2,58,72)(H2,59,73)(H,63,75)(H,64,77)(H,65,76)(H,66,74)(H,67,78)(H4,60,61,62)/t37-,38-,39-,40-,41-,42-,43-,44-/m0/s1
DMOSRET CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)N(C)C(=O)[C@H](CC4=CC=C(C=C4)O)N
DMOSRET IK UQGBICZACVFETI-YTAGXALCSA-N
DMOSRET IU (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-methylamino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMOSRET CA CAS 145274-94-8
DMOSRET DE Discovery agent
DM7P3N5 ID DM7P3N5
DM7P3N5 DN 1-DODECANOL
DM7P3N5 HS Investigative
DM7P3N5 SN 1-DODECANOL; Dodecyl alcohol; Dodecan-1-ol; Lauryl alcohol; Dodecanol; 112-53-8; n-Dodecyl alcohol; Lauric alcohol; Laurinic alcohol; Undecyl carbinol; Dodecylalcohol; Pisol; 1-Dodecyl alcohol; n-Dodecan-1-ol; Duodecyl alcohol; 1-Hydroxydodecane; Siponol L5; Karukoru 20; Siponol 25; Lorol 7; Lorol 5; n-Dodecanol; Lauryl 24; Alcohol C-12; Sipol L12; Lorol 11; Alfol 12; Siponol L2; Dytol J-68; Cachalot L-50; Cachalot L-90; Lauroyl alcohol; n-Lauryl alcohol; C12 alcohol; Hainol 12SS; Hydroxydodecane; Conol 20P; Lorol; Conol 20PP; Dodecyl alcoho
DM7P3N5 DT Small molecular drug
DM7P3N5 PC 8193
DM7P3N5 MW 186.33
DM7P3N5 FM C12H26O
DM7P3N5 IC InChI=1S/C12H26O/c1-2-3-4-5-6-7-8-9-10-11-12-13/h13H,2-12H2,1H3
DM7P3N5 CS CCCCCCCCCCCCO
DM7P3N5 IK LQZZUXJYWNFBMV-UHFFFAOYSA-N
DM7P3N5 IU dodecan-1-ol
DM7P3N5 CA CAS 112-53-8
DM7P3N5 CB CHEBI:28878
DM7P3N5 DE Discovery agent
DMK6BWV ID DMK6BWV
DMK6BWV DN 1-dodecyl-1H-indole-2,3-dione
DMK6BWV HS Investigative
DMK6BWV SN 1-dodecylindoline-2,3-dione
DMK6BWV DT Small molecular drug
DMK6BWV PC 1897797
DMK6BWV MW 315.4
DMK6BWV FM C20H29NO2
DMK6BWV IC InChI=1S/C20H29NO2/c1-2-3-4-5-6-7-8-9-10-13-16-21-18-15-12-11-14-17(18)19(22)20(21)23/h11-12,14-15H,2-10,13,16H2,1H3
DMK6BWV CS CCCCCCCCCCCCN1C2=CC=CC=C2C(=O)C1=O
DMK6BWV IK GQEQKTGRIPEAKW-UHFFFAOYSA-N
DMK6BWV IU 1-dodecylindole-2,3-dione
DMK6BWV DE Discovery agent
DMJBFN0 ID DMJBFN0
DMJBFN0 DN 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE
DMJBFN0 HS Investigative
DMJBFN0 SN 2-Ethoxyethyl ether; DIETHYLENE GLYCOL DIETHYL ETHER; 112-36-7; Diethyl carbitol; 1-Ethoxy-2-(2-ethoxyethoxy)ethane; Ethyl diglyme; Bis(2-ethoxyethyl) ether; Diethyldiethylene glycol; 3,6,9-Trioxaundecane; DEGDEE; Ether, bis(2-ethoxyethyl); Ethane, 1,1'-oxybis[2-ethoxy-; 2-(2-Ethoxyethoxy)-1-ethoxyethane; Diethylether diethylenglykolu; HSDB 68; UNII-ZH086O935Z; Ethanol, 2,2'-oxybis-, diethyl ether; Ethane, 1,1'-oxybis(2-ethoxy-; Glycol, diethylene-, diethyl ether; EINECS 203-963-7; Diethylether diethylenglykolu [Czech]
DMJBFN0 DT Small molecular drug
DMJBFN0 PC 8179
DMJBFN0 MW 162.23
DMJBFN0 FM C8H18O3
DMJBFN0 IC InChI=1S/C8H18O3/c1-3-9-5-7-11-8-6-10-4-2/h3-8H2,1-2H3
DMJBFN0 CS CCOCCOCCOCC
DMJBFN0 IK RRQYJINTUHWNHW-UHFFFAOYSA-N
DMJBFN0 IU 1-ethoxy-2-(2-ethoxyethoxy)ethane
DMJBFN0 CA CAS 112-36-7
DMJBFN0 CB CHEBI:44664
DMJBFN0 DE Discovery agent
DM5UWH9 ID DM5UWH9
DM5UWH9 DN 1-Ethyl-3-imidazol-1-ylmethyl-1H-indole
DM5UWH9 HS Investigative
DM5UWH9 SN CHEMBL115899; 72818-64-5; 1-Ethyl-3-imidazol-1-ylmethyl-1H-indole; SCHEMBL11496228; CTK2G2099; DTXSID10438234; BDBM50022117; ZINC27096766; 1-Ethyl-3-[(1H-imidazol-1-yl)methyl]-1H-indole; 1H-Indole, 1-ethyl-3-(1H-imidazol-1-ylmethyl)-
DM5UWH9 DT Small molecular drug
DM5UWH9 PC 10331244
DM5UWH9 MW 225.29
DM5UWH9 FM C14H15N3
DM5UWH9 IC InChI=1S/C14H15N3/c1-2-17-10-12(9-16-8-7-15-11-16)13-5-3-4-6-14(13)17/h3-8,10-11H,2,9H2,1H3
DM5UWH9 CS CCN1C=C(C2=CC=CC=C21)CN3C=CN=C3
DM5UWH9 IK KIIFZBAPVHIJQJ-UHFFFAOYSA-N
DM5UWH9 IU 1-ethyl-3-(imidazol-1-ylmethyl)indole
DM5UWH9 CA CAS 72818-64-5
DM5UWH9 DE Discovery agent
DMSFINY ID DMSFINY
DMSFINY DN 1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione
DMSFINY HS Investigative
DMSFINY SN 1-Ethyl-3-methylxanthine; CHEMBL24107; 1-ethyl-3,7-dihydro-3-methyl-1H-purine-2,6-dione; 37102-58-2; 1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione; SCHEMBL7016029; KVSRUALMCYFLEP-UHFFFAOYSA-N
DMSFINY DT Small molecular drug
DMSFINY PC 12905388
DMSFINY MW 194.19
DMSFINY FM C8H10N4O2
DMSFINY IC InChI=1S/C8H10N4O2/c1-3-12-7(13)5-6(10-4-9-5)11(2)8(12)14/h4H,3H2,1-2H3,(H,9,10)
DMSFINY CS CCN1C(=O)C2=C(N=CN2)N(C1=O)C
DMSFINY IK KVSRUALMCYFLEP-UHFFFAOYSA-N
DMSFINY IU 1-ethyl-3-methyl-7H-purine-2,6-dione
DMSFINY DE Discovery agent
DMGKP9Y ID DMGKP9Y
DMGKP9Y DN 1-Ethyl-4-(2-methoxy-phenyl)-piperazine
DMGKP9Y HS Investigative
DMGKP9Y SN CHEMBL91689; 1-ethyl-4-(2-methoxyphenyl)piperazine; 1-Ethyl-4-(2-methoxy-phenyl)-piperazine; SCHEMBL4617829; ZINC13738285; BDBM50039788
DMGKP9Y DT Small molecular drug
DMGKP9Y PC 10376185
DMGKP9Y MW 220.31
DMGKP9Y FM C13H20N2O
DMGKP9Y IC InChI=1S/C13H20N2O/c1-3-14-8-10-15(11-9-14)12-6-4-5-7-13(12)16-2/h4-7H,3,8-11H2,1-2H3
DMGKP9Y CS CCN1CCN(CC1)C2=CC=CC=C2OC
DMGKP9Y IK VLKJSRWSKNCNBI-UHFFFAOYSA-N
DMGKP9Y IU 1-ethyl-4-(2-methoxyphenyl)piperazine
DMGKP9Y DE Discovery agent
DMUOSJG ID DMUOSJG
DMUOSJG DN 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole
DMUOSJG HS Investigative
DMUOSJG SN CHEMBL112074; 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole
DMUOSJG DT Small molecular drug
DMUOSJG PC 44341253
DMUOSJG MW 301.4
DMUOSJG FM C20H19N3
DMUOSJG IC InChI=1S/C20H19N3/c1-2-22-12-10-17-14-18(8-9-19(17)22)20(23-13-11-21-15-23)16-6-4-3-5-7-16/h3-15,20H,2H2,1H3
DMUOSJG CS CCN1C=CC2=C1C=CC(=C2)C(C3=CC=CC=C3)N4C=CN=C4
DMUOSJG IK WUILDCCEKAPXPV-UHFFFAOYSA-N
DMUOSJG IU 1-ethyl-5-[imidazol-1-yl(phenyl)methyl]indole
DMUOSJG DE Discovery agent
DMQRKZO ID DMQRKZO
DMQRKZO DN 1-Ethylidenethiosemicarbazide
DMQRKZO HS Investigative
DMQRKZO SN 1-Ethylidenethiosemicarbazide; CHEMBL449882; Ethanone thiosemicarbazone; AC1NUX6Z; [(Z)-ethylideneamino]thiourea; SCHEMBL3066172; ZINC38825875
DMQRKZO DT Small molecular drug
DMQRKZO PC 5463036
DMQRKZO MW 117.18
DMQRKZO FM C3H7N3S
DMQRKZO IC InChI=1S/C3H7N3S/c1-2-5-6-3(4)7/h2H,1H3,(H3,4,6,7)/b5-2-
DMQRKZO CS C/C=N\\NC(=S)N
DMQRKZO IK OOPAKHKIEGNKDU-DJWKRKHSSA-N
DMQRKZO IU [(Z)-ethylideneamino]thiourea
DMQRKZO DE Discovery agent
DM0Q46C ID DM0Q46C
DM0Q46C DN 1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane
DM0Q46C HS Investigative
DM0Q46C SN CHEMBL519717; 1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane
DM0Q46C DT Small molecular drug
DM0Q46C PC 44561133
DM0Q46C MW 177.22
DM0Q46C FM C11H12FN
DM0Q46C IC InChI=1S/C11H12FN/c12-11-6-10(11,7-13-8-11)9-4-2-1-3-5-9/h1-5,13H,6-8H2
DM0Q46C CS C1C2(C1(CNC2)F)C3=CC=CC=C3
DM0Q46C IK OSYUYUPNSGSVAL-UHFFFAOYSA-N
DM0Q46C IU 1-fluoro-5-phenyl-3-azabicyclo[3.1.0]hexane
DM0Q46C DE Discovery agent
DM8BC1M ID DM8BC1M
DM8BC1M DN 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DM8BC1M HS Investigative
DM8BC1M SN CHEMBL192782; 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3925203; VQATUPWMFYRKSD-UHFFFAOYSA-N; BDBM50168380; ZINC13645014
DM8BC1M DT Small molecular drug
DM8BC1M PC 10214633
DM8BC1M MW 254.25
DM8BC1M FM C16H11FO2
DM8BC1M IC InChI=1S/C16H11FO2/c17-16-14-7-3-11(9-12(14)4-8-15(16)19)10-1-5-13(18)6-2-10/h1-9,18-19H
DM8BC1M CS C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)F)O
DM8BC1M IK VQATUPWMFYRKSD-UHFFFAOYSA-N
DM8BC1M IU 1-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol
DM8BC1M DE Discovery agent
DM7UK56 ID DM7UK56
DM7UK56 DN 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3)
DM7UK56 HS Investigative
DM7UK56 SN FPP 028; 86969-15-5; BRN 5552278; 4-Ethyl-4,7-dihydro-2-phenylpyrazolo(1,5-a)pyrimidin-7-one; FPP-028; 4-Ethyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7(4H)-one; 4,7-Dihydro-4-ethyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-one; Pyrazolo(1,5-a)pyrimidin-7(4H)-one, 4-ethyl-2-phenyl-; AC1Q6I4H; CHEMBL45806; AC1L375B; 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7(4h)-one; CTK5F7460; DTXSID70236016; ZINC5957034; LS-129307; 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-one
DM7UK56 DT Small molecular drug
DM7UK56 PC 135819
DM7UK56 MW 239.27
DM7UK56 FM C14H13N3O
DM7UK56 IC InChI=1S/C14H13N3O/c1-2-16-9-8-14(18)17-13(16)10-12(15-17)11-6-4-3-5-7-11/h3-10H,2H2,1H3
DM7UK56 CS CCN1C=CC(=O)N2C1=CC(=N2)C3=CC=CC=C3
DM7UK56 IK JEWOUZIOCRUZPT-UHFFFAOYSA-N
DM7UK56 IU 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-one
DM7UK56 CA CAS 86969-15-5
DM7UK56 DE Discovery agent
DMF4BCP ID DMF4BCP
DMF4BCP DN 1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea
DMF4BCP HS Investigative
DMF4BCP SN CHEMBL148698; AC1MHEHZ; 1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea; PHI-536; BDBM50097046; AKOS030027701; 1-(2-furylmethyl)-3-thiazol-2-yl-thiourea; 1-(2-Furanylmethyl)-3-(2-thiazolyl)thiourea; 1-(furan-2-ylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DMF4BCP DT Small molecular drug
DMF4BCP PC 3003032
DMF4BCP MW 239.3
DMF4BCP FM C9H9N3OS2
DMF4BCP IC InChI=1S/C9H9N3OS2/c14-8(12-9-10-3-5-15-9)11-6-7-2-1-4-13-7/h1-5H,6H2,(H2,10,11,12,14)
DMF4BCP CS C1=COC(=C1)CNC(=S)NC2=NC=CS2
DMF4BCP IK OLLCKULTVXOISU-UHFFFAOYSA-N
DMF4BCP IU 1-(furan-2-ylmethyl)-3-(1,3-thiazol-2-yl)thiourea
DMF4BCP DE Discovery agent
DMEB8CG ID DMEB8CG
DMEB8CG DN 1G244
DMEB8CG HS Investigative
DMEB8CG SN 1G244; CHEMBL1814633; (2~{S})-2-azanyl-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-(1,3-dihydroisoindol-2-yl)butane-1,4-dione; GTPL8551; SCHEMBL19350285; C29H30N4O2F2; ZINC14949370; BDBM50350169; AKOS030528223; 847928-32-9; (S)-2-amino-4-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1-(isoindolin-2-yl)butane-1,4-dione; Y0432
DMEB8CG DT Small molecular drug
DMEB8CG PC 56658139
DMEB8CG MW 504.6
DMEB8CG FM C29H30F2N4O2
DMEB8CG IC InChI=1S/C29H30F2N4O2/c30-24-9-5-20(6-10-24)28(21-7-11-25(31)12-8-21)34-15-13-33(14-16-34)27(36)17-26(32)29(37)35-18-22-3-1-2-4-23(22)19-35/h1-12,26,28H,13-19,32H2/t26-/m0/s1
DMEB8CG CS C1CN(CCN1C(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)C[C@@H](C(=O)N4CC5=CC=CC=C5C4)N
DMEB8CG IK ZKIQFLSGMMYCGS-SANMLTNESA-N
DMEB8CG IU (2S)-2-amino-4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-1-(1,3-dihydroisoindol-2-yl)butane-1,4-dione
DMEB8CG DE Discovery agent
DM42IY7 ID DM42IY7
DM42IY7 DN 1-Guanidinium-7-Aminoheptane
DM42IY7 HS Investigative
DM42IY7 SN 1-Guanidinium-7-aminoheptane; 1-GUANIDINIUM-7-AMINOHEPTANE; AC1NRBDQ; N-(7-aminoheptyl)methanetriamine; N"-(7-aminoheptyl)methanetriamine; GC7
DM42IY7 DT Small molecular drug
DM42IY7 PC 5288371
DM42IY7 MW 174.29
DM42IY7 FM C8H22N4
DM42IY7 IC InChI=1S/C8H22N4/c9-6-4-2-1-3-5-7-12-8(10)11/h8,12H,1-7,9-11H2
DM42IY7 CS C(CCCN)CCCNC(N)N
DM42IY7 IK SKGAVCHIFDRDTK-UHFFFAOYSA-N
DM42IY7 IU N'-(7-aminoheptyl)methanetriamine
DM42IY7 DE Discovery agent
DM48TIN ID DM48TIN
DM48TIN DN 1-guanidino-7-isoquinolinesulphonamide
DM48TIN HS Investigative
DM48TIN SN SCHEMBL6436143; CHEMBL227583; 7-Isoquinolinesulfonamide, 1-[(aminoiminomethyl)amino]-; BDBM16130; NRVVFOKWKSWIIV-UHFFFAOYSA-N; 1-Guanidino-7-sulphamoylisoquinoline; 1-guanidino-7-sulfonamidoisoquinoline 4; 2-(7-sulfamoylisoquinolin-1-yl)guanidine
DM48TIN DT Small molecular drug
DM48TIN PC 16658352
DM48TIN MW 265.29
DM48TIN FM C10H11N5O2S
DM48TIN IC InChI=1S/C10H11N5O2S/c11-10(12)15-9-8-5-7(18(13,16)17)2-1-6(8)3-4-14-9/h1-5H,(H2,13,16,17)(H4,11,12,14,15)
DM48TIN CS C1=CC(=CC2=C1C=CN=C2N=C(N)N)S(=O)(=O)N
DM48TIN IK NRVVFOKWKSWIIV-UHFFFAOYSA-N
DM48TIN IU 2-(7-sulfamoylisoquinolin-1-yl)guanidine
DM48TIN DE Discovery agent
DMTF1HL ID DMTF1HL
DMTF1HL DN 1-guanidino-N-phenyl-7-isoquinolinesulphonamide
DMTF1HL HS Investigative
DMTF1HL SN SCHEMBL6435184; CHEMBL227781; BDBM16131; NNEJXIJKGKRBBF-UHFFFAOYSA-N; 1-guanidino-7-sulfonamidoisoquinoline 5; 1-guanidino-7-phenylsulphamoylisoquinoline
DMTF1HL DT Small molecular drug
DMTF1HL PC 16658631
DMTF1HL MW 341.4
DMTF1HL FM C16H15N5O2S
DMTF1HL IC InChI=1S/C16H15N5O2S/c17-16(18)20-15-14-10-13(7-6-11(14)8-9-19-15)24(22,23)21-12-4-2-1-3-5-12/h1-10,21H,(H4,17,18,19,20)
DMTF1HL CS C1=CC=C(C=C1)NS(=O)(=O)C2=CC3=C(C=C2)C=CN=C3N=C(N)N
DMTF1HL IK NNEJXIJKGKRBBF-UHFFFAOYSA-N
DMTF1HL IU 2-[7-(phenylsulfamoyl)isoquinolin-1-yl]guanidine
DMTF1HL DE Discovery agent
DM9KAI5 ID DM9KAI5
DM9KAI5 DN 1H-1,2,3-benzotriazol-1-amine
DM9KAI5 HS Investigative
DM9KAI5 SN 1-aminobenzotriazole; 1614-12-6; 1H-Benzotriazol-1-amine; 1H-benzo[d][1,2,3]triazol-1-amine; 1-Benzotriazolamine; benzotriazol-1-amine; 1H-1,2,3-Benzotriazol-1-amine; 1-Abtz; 1H-1,2,3-Benzotriazol-1-ylamine; UNII-9EFF75BJ1O; NSC 114498; 9EFF75BJ1O; CHEMBL101168; benzotriazolylamine; MFCD00132902; NSC656987; 1-Aminobenzotriazole, 98%; AK-830/25033013; Q-102063; 1-benzotriazolylamine; benzotriazol-1-ylamine; PubChem19954; rarechem aq nn 0550; ACMC-1BVFA; AC1L1BBK; timtec-bb sbb004208; Lopac-A-3940; ABT; 1-Benzotriazolamine
DM9KAI5 DT Small molecular drug
DM9KAI5 PC 1367
DM9KAI5 MW 134.14
DM9KAI5 FM C6H6N4
DM9KAI5 IC InChI=1S/C6H6N4/c7-10-6-4-2-1-3-5(6)8-9-10/h1-4H,7H2
DM9KAI5 CS C1=CC=C2C(=C1)N=NN2N
DM9KAI5 IK JCXKHYLLVKZPKE-UHFFFAOYSA-N
DM9KAI5 IU benzotriazol-1-amine
DM9KAI5 CA CAS 1614-12-6
DM9KAI5 DE Discovery agent
DMNZAVE ID DMNZAVE
DMNZAVE DN 1h-Benoximidazole-2-Carboxylic Acid
DMNZAVE HS Investigative
DMNZAVE SN 1H-Benzimidazole-2-carboxylic acid; 2849-93-6; 2-Benzimidazolecarboxylic acid; 1H-benzo[d]imidazole-2-carboxylic acid; Benzimidazole-2-carboxylic acid; 1H-Benzoimidazole-2-carboxylic acid; 1H-1,3-benzodiazole-2-carboxylic acid; Benzoimidazole-2-carboxylic acid; benzimidazole-2-yl-carboxylic acid; 1H-BENOXIMIDAZOLE-2-CARBOXYLIC ACID; 1h-1,3-benzimidazole-2-carboxylic acid; RHXSYTACTOMVLJ-UHFFFAOYSA-N; PubChem8062; AC1L5PLZ; benzimidazolecarboxylic acid; AC1Q1HJ4; benzimidazole carboxylic acid; 2-Carboxy-1H-benzimidazole
DMNZAVE DT Small molecular drug
DMNZAVE PC 233240
DMNZAVE MW 162.15
DMNZAVE FM C8H6N2O2
DMNZAVE IC InChI=1S/C8H6N2O2/c11-8(12)7-9-5-3-1-2-4-6(5)10-7/h1-4H,(H,9,10)(H,11,12)
DMNZAVE CS C1=CC=C2C(=C1)NC(=N2)C(=O)O
DMNZAVE IK RHXSYTACTOMVLJ-UHFFFAOYSA-N
DMNZAVE IU 1H-benzimidazole-2-carboxylic acid
DMNZAVE CA CAS 2849-93-6
DMNZAVE CB CHEBI:46117
DMNZAVE DE Discovery agent
DM4OWM6 ID DM4OWM6
DM4OWM6 DN 1-hexadecyl-1H-indole-2,3-dione
DM4OWM6 HS Investigative
DM4OWM6 SN 1-hexadecyl-1H-indole-2,3-dione; C24H37NO2; 1-hexadecylindole-2,3-dione; AC1MXWVN; Isatin-based compound, 63; CHEMBL221512; BDBM22843; MolPort-000-704-286; STK527744; ZINC14979621; AKOS005460820; MCULE-4252873887; 28035-35-0
DM4OWM6 DT Small molecular drug
DM4OWM6 PC 3772674
DM4OWM6 MW 371.6
DM4OWM6 FM C24H37NO2
DM4OWM6 IC InChI=1S/C24H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-20-25-22-19-16-15-18-21(22)23(26)24(25)27/h15-16,18-19H,2-14,17,20H2,1H3
DM4OWM6 CS CCCCCCCCCCCCCCCCN1C2=CC=CC=C2C(=O)C1=O
DM4OWM6 IK JLUGWHXZCKLPBY-UHFFFAOYSA-N
DM4OWM6 IU 1-hexadecylindole-2,3-dione
DM4OWM6 DE Discovery agent
DMME09C ID DMME09C
DMME09C DN 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl
DMME09C HS Investigative
DMME09C SN 3H-imidazo[4,5-c]quinolin-4-amine; 1H-Imidazo[4,5-c]quinolin-4-amine; CHEMBL19191; 4-amino-1h-imidazo[4,5-c]quinoline; 132207-04-6; SCHEMBL482926; SCHEMBL212131; imidazo[4,5-c]quinolin-4-amine; imidazo(4,5-c)quinolin 4-amine; WUUCVVFSWNXYRD-UHFFFAOYSA-N; HQBUPOAKJGJGCD-UHFFFAOYSA-N; CS-B1117; BDBM50011593; ZINC28222586; AKOS027322300; 1h-imidazo-[4,5-c]quinolin-4-amine; SB22857; 1H-Imidazo[4,5-c]quinolin-4-ylamine
DMME09C DT Small molecular drug
DMME09C PC 14896613
DMME09C MW 184.2
DMME09C FM C10H8N4
DMME09C IC InChI=1S/C10H8N4/c11-10-9-8(12-5-13-9)6-3-1-2-4-7(6)14-10/h1-5H,(H2,11,14)(H,12,13)
DMME09C CS C1=CC=C2C(=C1)C3=C(C(=N2)N)NC=N3
DMME09C IK HQBUPOAKJGJGCD-UHFFFAOYSA-N
DMME09C IU 3H-imidazo[4,5-c]quinolin-4-amine
DMME09C DE Discovery agent
DMOZ91H ID DMOZ91H
DMOZ91H DN 1H-Indole-2,3-dione
DMOZ91H HS Investigative
DMOZ91H SN Isatin; 91-56-5; Indoline-2,3-dione; 2,3-Indolinedione; INDOLE-2,3-DIONE; 2,3-Dioxoindoline; Isatine; Pseudoisatin; Isatic acid lactam; Tribulin; Isotin; 2,3-Diketoindoline; Isatinic acid anhydride; 2,3-Ketoindoline; o-Aminobenzoylformic anhydride; 2,3-Dioxo-2,3-dihydroindole; 2,3-dihydro-1H-indole-2,3-dione; NSC 9262; UNII-82X95S7M06; EINECS 202-077-8; BRN 0383659; AI3-03111; CHEMBL326294; 2,3-dihydroindole-2,3-dione; CHEBI:27539; JXDYKVIHCLTXOP-UHFFFAOYSA-N; MFCD00005718; 82X95S7M06; 84788-92-1; Isatin, 98%
DMOZ91H DT Small molecular drug
DMOZ91H PC 7054
DMOZ91H MW 147.13
DMOZ91H FM C8H5NO2
DMOZ91H IC InChI=1S/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11)
DMOZ91H CS C1=CC=C2C(=C1)C(=O)C(=O)N2
DMOZ91H IK JXDYKVIHCLTXOP-UHFFFAOYSA-N
DMOZ91H IU 1H-indole-2,3-dione
DMOZ91H CA CAS 91-56-5
DMOZ91H CB CHEBI:27539
DMOZ91H DE Discovery agent
DMNDVMH ID DMNDVMH
DMNDVMH DN 1H-indole-4,7-dione
DMNDVMH HS Investigative
DMNDVMH SN Indole-4,7-dione; 1H-Indole-4,7-dione; 20342-64-7; indole-4,7-quinone; CHEBI:51637; Indolequinone, 19; AC1L483C; CHEMBL500863; SCHEMBL1650480; CTK1A3633; BDBM21979; DTXSID20174252; ZINC6091591; 4,7-dihydro-1H-indole-4,7-dione; AKOS006347266
DMNDVMH DT Small molecular drug
DMNDVMH PC 152300
DMNDVMH MW 147.13
DMNDVMH FM C8H5NO2
DMNDVMH IC InChI=1S/C8H5NO2/c10-6-1-2-7(11)8-5(6)3-4-9-8/h1-4,9H
DMNDVMH CS C1=CC(=O)C2=C(C1=O)C=CN2
DMNDVMH IK QMRIWYCCTCNABA-UHFFFAOYSA-N
DMNDVMH IU 1H-indole-4,7-dione
DMNDVMH CA CAS 20342-64-7
DMNDVMH CB CHEBI:51637
DMNDVMH DE Discovery agent
DM4V6JE ID DM4V6JE
DM4V6JE DN 1H-Pyrazole-3-carboxylic acid
DM4V6JE HS Investigative
DM4V6JE SN 1H-Pyrazole-3-carboxylic acid; 1621-91-6; Pyrazole-3-carboxylic acid; 1H-Pyrazole-5-carboxylic acid; 2H-PYRAZOLE-3-CARBOXYLIC ACID; 5-Pyrazolecarboxylic acid; 3-Pyrazolecarboxylic acid; 797027-83-9; 3-carboxy-1h-pyrazole; Pyrazolic acid; CHEMBL128679; KOPFEFZSAMLEHK-UHFFFAOYSA-N; pyrazolecarboxylic; 3-Carboxypyrazole; 2H-PYRAZOLE-3-CARBOXYLICACID; zlchem 656; pyrazolecarboxylic acid; pyrazole-5-carboxylic; PubChem12935; AC1Q5UBI; AC1LCCJ7; 3-pyrazole carboxylic acid; pyrazole 3-carboxylic acid; ACMC-209z0p; Pyrazole-5-carboxylic a
DM4V6JE DT Small molecular drug
DM4V6JE PC 574310
DM4V6JE MW 112.09
DM4V6JE FM C4H4N2O2
DM4V6JE IC InChI=1S/C4H4N2O2/c7-4(8)3-1-2-5-6-3/h1-2H,(H,5,6)(H,7,8)
DM4V6JE CS C1=C(NN=C1)C(=O)O
DM4V6JE IK KOPFEFZSAMLEHK-UHFFFAOYSA-N
DM4V6JE IU 1H-pyrazole-5-carboxylic acid
DM4V6JE CA CAS 1621-91-6
DM4V6JE DE Discovery agent
DM235CQ ID DM235CQ
DM235CQ DN 1-Hydroxy-10H-anthracen-9-one
DM235CQ HS Investigative
DM235CQ SN 1-Hydroxyanthrone; 1-Hydroxy-9-anthrone; 1715-81-7; 1-Hydroxy-10H-anthracen-9-one; 9-Anthrone, 1-hydroxy-; 9-Anthronol; BRN 3530761; CHEMBL123161; 1-HYDROXY-9,10-DIHYDROANTHRACEN-9-ONE; hydroxyanthrone; AC1L45BO; SCHEMBL1204733; CTK4D3980; DTXSID10169112; 1-Hydroxyanthracen-9(10H)-one; MolPort-022-384-226; 9(10H)-Anthracenone,1-hydroxy-; ZINC6117388; BDBM50060879; AKOS022650101; LS-20754
DM235CQ DT Small molecular drug
DM235CQ PC 150937
DM235CQ MW 210.23
DM235CQ FM C14H10O2
DM235CQ IC InChI=1S/C14H10O2/c15-12-7-3-5-10-8-9-4-1-2-6-11(9)14(16)13(10)12/h1-7,15H,8H2
DM235CQ CS C1C2=C(C(=CC=C2)O)C(=O)C3=CC=CC=C31
DM235CQ IK AXHRXVXCOMMNLG-UHFFFAOYSA-N
DM235CQ IU 1-hydroxy-10H-anthracen-9-one
DM235CQ CA CAS 1715-81-7
DM235CQ DE Discovery agent
DMIOTQ8 ID DMIOTQ8
DMIOTQ8 DN 1-Hydroxy-1-Thio-Glycerol
DMIOTQ8 HS Investigative
DMIOTQ8 SN 1-HYDROXY-1-THIO-GLYCEROL; SGL; AC1NRD54; SCHEMBL5003699; DB01684; (2R)-3-hydroxysulfanylpropane-1,2-diol; (2R)-2,3-dihydroxypropane-1-sulfenic acid
DMIOTQ8 DT Small molecular drug
DMIOTQ8 PC 5289354
DMIOTQ8 MW 124.16
DMIOTQ8 FM C3H8O3S
DMIOTQ8 IC InChI=1S/C3H8O3S/c4-1-3(5)2-7-6/h3-6H,1-2H2/t3-/m1/s1
DMIOTQ8 CS C([C@H](CSO)O)O
DMIOTQ8 IK DLQCXFUWHQZWJQ-GSVOUGTGSA-N
DMIOTQ8 IU (2R)-3-hydroxysulfanylpropane-1,2-diol
DMIOTQ8 DE Discovery agent
DM9EWN8 ID DM9EWN8
DM9EWN8 DN 1-Hydroxy-2-Amino-3-Cyclohexylpropane
DM9EWN8 HS Investigative
DM9EWN8 SN (S)-2-Amino-3-cyclohexylpropan-1-ol; 131288-67-0; (S)-2-Amino-3-cyclohexyl-propan-1-ol; 1-Hydroxy-2-Amino-3-Cyclohexylpropane; CHEMBL1231778; (S)-2-AMINO-3-CYCLOHEXYL-1-PROPANOL; (2S)-2-Amino-3-Cyclohexylpropan-1-Ol Hydrochloride; 205445-49-4; (2S)-2-amino-3-cyclohexylpropan-1-ol; AC1L9GJG; AC1Q4UB7; SCHEMBL82667; S-2-Amino-3-cyclohexylpropanol; KS-00000LNV; QWDRYURVUDZKSG-VIFPVBQESA-N; MolPort-000-000-987; ZINC154757; ZX-CM013052; (S)-cyclohexylalaninol, AldrichCPR; BDBM50367060; FCH835925; AKOS022180681; MB00862; DB04387
DM9EWN8 DT Small molecular drug
DM9EWN8 PC 444569
DM9EWN8 MW 157.25
DM9EWN8 FM C9H19NO
DM9EWN8 IC InChI=1S/C9H19NO/c10-9(7-11)6-8-4-2-1-3-5-8/h8-9,11H,1-7,10H2/t9-/m0/s1
DM9EWN8 CS C1CCC(CC1)C[C@@H](CO)N
DM9EWN8 IK QWDRYURVUDZKSG-VIFPVBQESA-N
DM9EWN8 IU (2S)-2-amino-3-cyclohexylpropan-1-ol
DM9EWN8 CA CAS 205445-49-4
DM9EWN8 DE Discovery agent
DMGBSWP ID DMGBSWP
DMGBSWP DN 1-hydroxy-2-dodecyl-4(1H)quinolone
DMGBSWP HS Investigative
DMGBSWP SN 1-hydroxy-2-dodecyl-4(1H)quinolone; CHEMBL224182; AC1LCHH0; SCHEMBL8535434; 2-dodecyl-1-hydroxyquinolin-4-one; 2-dodecyl-1-hydroxy-quinolin-4-one; BDBM50203194; 1-Hydroxy-2-dodecyl-4(1H)quinoline; 1-hydroxy-2-dodecyl-4-(1H)quinoline; (1-Hydroxy-2-dodecyl-4(1H)quinolone); 1-Hydroxy-2-dodecylquinoline-4(1H)-one; 2-dodecyl-1-oxidanidyl-quinolin-1-ium-4-ol; 2-dodecyl -4-HYDROXY QUINOLINE N-OXIDE
DMGBSWP DT Small molecular drug
DMGBSWP PC 600305
DMGBSWP MW 329.5
DMGBSWP FM C21H31NO2
DMGBSWP IC InChI=1S/C21H31NO2/c1-2-3-4-5-6-7-8-9-10-11-14-18-17-21(23)19-15-12-13-16-20(19)22(18)24/h12-13,15-17,24H,2-11,14H2,1H3
DMGBSWP CS CCCCCCCCCCCCC1=CC(=O)C2=CC=CC=C2N1O
DMGBSWP IK SBALADRDZPFHLM-UHFFFAOYSA-N
DMGBSWP IU 2-dodecyl-1-hydroxyquinolin-4-one
DMGBSWP DE Discovery agent
DMGNVEF ID DMGNVEF
DMGNVEF DN 1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea
DMGNVEF HS Investigative
DMGNVEF SN CHEMBL260172; SCHEMBL12491371
DMGNVEF DT Small molecular drug
DMGNVEF PC 11651456
DMGNVEF MW 220.15
DMGNVEF FM C8H7F3N2O2
DMGNVEF IC InChI=1S/C8H7F3N2O2/c9-8(10,11)5-1-3-6(4-2-5)12-7(14)13-15/h1-4,15H,(H2,12,13,14)
DMGNVEF CS C1=CC(=CC=C1C(F)(F)F)NC(=O)NO
DMGNVEF IK DRFSQRMYIQLAMQ-UHFFFAOYSA-N
DMGNVEF IU 1-hydroxy-3-[4-(trifluoromethyl)phenyl]urea
DMGNVEF DE Discovery agent
DMZ7GUP ID DMZ7GUP
DMZ7GUP DN 1-hydroxy-3-(4-nitrophenyl)urea
DMZ7GUP HS Investigative
DMZ7GUP SN 1-hydroxy-3-(4-nitrophenyl)urea; CHEMBL259979; 53731-88-7; NSC163567; AC1NQIZ7; SCHEMBL16005844; CTK1H3407; DTXSID10411168; BDBM50377113
DMZ7GUP DT Small molecular drug
DMZ7GUP PC 5222748
DMZ7GUP MW 197.15
DMZ7GUP FM C7H7N3O4
DMZ7GUP IC InChI=1S/C7H7N3O4/c11-7(9-12)8-5-1-3-6(4-2-5)10(13)14/h1-4,12H,(H2,8,9,11)
DMZ7GUP CS C1=CC(=CC=C1NC(=O)NO)[N+](=O)[O-]
DMZ7GUP IK DXBVARSUKIUCDK-UHFFFAOYSA-N
DMZ7GUP IU 1-hydroxy-3-(4-nitrophenyl)urea
DMZ7GUP CA CAS 53731-88-7
DMZ7GUP DE Discovery agent
DMZ8IL9 ID DMZ8IL9
DMZ8IL9 DN 1-Hydroxy-3-Methylbutane
DMZ8IL9 HS Investigative
DMZ8IL9 SN 3-Methyl-1-butanol; Isoamyl alcohol; Isopentyl alcohol; 3-Methylbutan-1-ol; Isopentanol; 123-51-3; 3-Methylbutanol; 1-Butanol, 3-methyl-; Isoamylol; Isobutylcarbinol; Fusel Oil; Iso-amylalkohol; Isobutyl carbinol; Iso-amyl alcohol; 2-Methyl-4-butanol; ISOAMYLALCOHOL; Alcool isoamylique; Fermentation amyl alcohol; Isoamyl alkohol; Amylowy alkohol; Alcool amilico; i-Amyl Alcohol; Primary isoamyl alcohol; 3-Metil-butanolo; isopentan-1-ol; Isoamyl alcohol (natural); 1-Hydroxy-3-Methylbutane; Isoamyl alcohol, primary; FEMA Number 2057
DMZ8IL9 DT Small molecular drug
DMZ8IL9 PC 31260
DMZ8IL9 MW 88.15
DMZ8IL9 FM C5H12O
DMZ8IL9 IC InChI=1S/C5H12O/c1-5(2)3-4-6/h5-6H,3-4H2,1-2H3
DMZ8IL9 CS CC(C)CCO
DMZ8IL9 IK PHTQWCKDNZKARW-UHFFFAOYSA-N
DMZ8IL9 IU 3-methylbutan-1-ol
DMZ8IL9 CA CAS 123-51-3
DMZ8IL9 CB CHEBI:15837
DMZ8IL9 DE Discovery agent
DM4TSVC ID DM4TSVC
DM4TSVC DN 1-hydroxy-3-phenylurea
DM4TSVC HS Investigative
DM4TSVC SN 1-hydroxy-3-phenylurea; Urea, N-hydroxy-N'-phenyl-; Urea, 1-hydroxy-3-phenyl-; 7335-35-5; CHEMBL125955; NSC52953; NSC 52953; WLN: QMVMR; AI3-63229; AC1Q5NHR; SCHEMBL676383; AC1L322W; DTXSID20223597; MolPort-003-699-942; ZINC161805; BDBM50377106; NSC-52953; AKOS024336836
DM4TSVC DT Small molecular drug
DM4TSVC PC 81786
DM4TSVC MW 152.15
DM4TSVC FM C7H8N2O2
DM4TSVC IC InChI=1S/C7H8N2O2/c10-7(9-11)8-6-4-2-1-3-5-6/h1-5,11H,(H2,8,9,10)
DM4TSVC CS C1=CC=C(C=C1)NC(=O)NO
DM4TSVC IK AAVSQBMWOCNSDL-UHFFFAOYSA-N
DM4TSVC IU 1-hydroxy-3-phenylurea
DM4TSVC CA CAS 7335-35-5
DM4TSVC DE Discovery agent
DMRNO5U ID DMRNO5U
DMRNO5U DN 1-Hydroxy-8-methoxy-10H-anthracen-9-one
DMRNO5U HS Investigative
DMRNO5U SN CHEMBL125592; 9(10H)-Anthracenone, 1-hydroxy-8-methoxy-; 138591-01-2; ACMC-20mxto; 1-Hydroxy-8-methoxy-10H-anthracen-9-one; 1-Hydroxy-8-methoxyanthrone; SCHEMBL12775753; CTK0B8005; DTXSID10568303; ZINC13366515; BDBM50060886; AKOS030561671
DMRNO5U DT Small molecular drug
DMRNO5U PC 15107209
DMRNO5U MW 240.25
DMRNO5U FM C15H12O3
DMRNO5U IC InChI=1S/C15H12O3/c1-18-12-7-3-5-10-8-9-4-2-6-11(16)13(9)15(17)14(10)12/h2-7,16H,8H2,1H3
DMRNO5U CS COC1=CC=CC2=C1C(=O)C3=C(C2)C=CC=C3O
DMRNO5U IK KXNCIFRRMSGNPW-UHFFFAOYSA-N
DMRNO5U IU 1-hydroxy-8-methoxy-10H-anthracen-9-one
DMRNO5U CA CAS 138591-01-2
DMRNO5U DE Discovery agent
DM6FLXW ID DM6FLXW
DM6FLXW DN 1-Hydroxyamine-2-Isobutylmalonic Acid
DM6FLXW HS Investigative
DM6FLXW SN 1-HYDROXYAMINE-2-ISOBUTYLMALONIC ACID; (2R)-2-(hydroxycarbamoyl)-4-methylpentanoic acid; AC1O43QE; DB02326
DM6FLXW DT Small molecular drug
DM6FLXW PC 6323374
DM6FLXW MW 175.18
DM6FLXW FM C7H13NO4
DM6FLXW IC InChI=1S/C7H13NO4/c1-4(2)3-5(7(10)11)6(9)8-12/h4-5,12H,3H2,1-2H3,(H,8,9)(H,10,11)/t5-/m1/s1
DM6FLXW CS CC(C)C[C@H](C(=O)NO)C(=O)O
DM6FLXW IK CINIOMOBGSHXRK-RXMQYKEDSA-N
DM6FLXW IU (2R)-2-(hydroxycarbamoyl)-4-methylpentanoic acid
DM6FLXW DE Discovery agent
DM3JHVL ID DM3JHVL
DM3JHVL DN 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL HS Investigative
DM3JHVL SN CHEMBL598974; 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL DT Small molecular drug
DM3JHVL PC 46230393
DM3JHVL MW 328.4
DM3JHVL FM C20H28N2O2
DM3JHVL IC InChI=1S/C20H28N2O2/c1-2-3-4-5-6-7-8-18-9-11-20(12-10-18)24-16-19(23)15-22-14-13-21-17-22/h9-14,17H,2-8,15-16H2,1H3
DM3JHVL CS CCCCCCCCC1=CC=C(C=C1)OCC(=O)CN2C=CN=C2
DM3JHVL IK CGVPWFIJGMBNPP-UHFFFAOYSA-N
DM3JHVL IU 1-imidazol-1-yl-3-(4-octylphenoxy)propan-2-one
DM3JHVL DE Discovery agent
DMN7KHS ID DMN7KHS
DMN7KHS DN 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one
DMN7KHS HS Investigative
DMN7KHS SN CHEMBL307160; 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one; BDBM50097363; 1-(imidazol-1-ylmethyl)-4-nitro-9h-9-xanthenone; 4-Nitro-1-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one
DMN7KHS DT Small molecular drug
DMN7KHS PC 10853186
DMN7KHS MW 321.29
DMN7KHS FM C17H11N3O4
DMN7KHS IC InChI=1S/C17H11N3O4/c21-16-12-3-1-2-4-14(12)24-17-13(20(22)23)6-5-11(15(16)17)9-19-8-7-18-10-19/h1-8,10H,9H2
DMN7KHS CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)[N+](=O)[O-])CN4C=CN=C4
DMN7KHS IK VKGUMSNSPMTJMS-UHFFFAOYSA-N
DMN7KHS IU 1-(imidazol-1-ylmethyl)-4-nitroxanthen-9-one
DMN7KHS DE Discovery agent
DMIDX7P ID DMIDX7P
DMIDX7P DN 1-Imidazol-1-ylmethylxanthen-9-one
DMIDX7P HS Investigative
DMIDX7P SN CHEMBL1083652; 1-Imidazol-1-ylmethylxanthen-9-one
DMIDX7P DT Small molecular drug
DMIDX7P PC 46867545
DMIDX7P MW 276.29
DMIDX7P FM C17H12N2O2
DMIDX7P IC InChI=1S/C17H12N2O2/c20-17-13-5-1-2-6-14(13)21-15-7-3-4-12(16(15)17)10-19-9-8-18-11-19/h1-9,11H,10H2
DMIDX7P CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC=C3O2)CN4C=CN=C4
DMIDX7P IK FJYGKMHQKKRCON-UHFFFAOYSA-N
DMIDX7P IU 1-(imidazol-1-ylmethyl)xanthen-9-one
DMIDX7P DE Discovery agent
DMYIQDE ID DMYIQDE
DMYIQDE DN 1-Iodyl-3-nitro-benzene
DMYIQDE HS Investigative
DMYIQDE SN Benzene, 1-iodyl-3-nitro-; CHEMBL118998; 16825-78-8; 1-iodyl-3-nitro-benzene; 1-iodoxy-3-nitrobenzene; SCHEMBL2217800; CTK0E5266; DTXSID30438317
DMYIQDE DT Small molecular drug
DMYIQDE PC 10333896
DMYIQDE MW 281
DMYIQDE FM C6H4INO4
DMYIQDE IC InChI=1S/C6H4INO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4H
DMYIQDE CS C1=CC(=CC(=C1)I(=O)=O)[N+](=O)[O-]
DMYIQDE IK PSLSYWRHLJIBMS-UHFFFAOYSA-N
DMYIQDE IU 1-iodyl-3-nitrobenzene
DMYIQDE CA CAS 16825-78-8
DMYIQDE DE Discovery agent
DMF1WA6 ID DMF1WA6
DMF1WA6 DN 1-Iodyl-4-nitro-benzene
DMF1WA6 HS Investigative
DMF1WA6 SN CHEMBL118424; 1-iodyl-4-nitro-benzene; p-Iodoxynitrobenzene; 1-Iodoxy-4-nitrobenzene; SCHEMBL1572451; BDBM50075023
DMF1WA6 DT Small molecular drug
DMF1WA6 PC 10107739
DMF1WA6 MW 281
DMF1WA6 FM C6H4INO4
DMF1WA6 IC InChI=1S/C6H4INO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4H
DMF1WA6 CS C1=CC(=CC=C1[N+](=O)[O-])I(=O)=O
DMF1WA6 IK BMXXYWBYOJKMLW-UHFFFAOYSA-N
DMF1WA6 IU 1-iodyl-4-nitrobenzene
DMF1WA6 DE Discovery agent
DMD7WNV ID DMD7WNV
DMD7WNV DN 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
DMD7WNV HS Investigative
DMD7WNV SN Triglyme; 2,5,8,11-TETRAOXADODECANE; 112-49-2; Triethylene glycol dimethyl ether; 1,2-Bis(2-methoxyethoxy)ethane; Glyme 4; Ansul ether 161; Glyme-3; TEGDME; TEGDIME; 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE; UNII-32YXG88KK0; Ethane, 1,2-bis(2-methoxyethoxy)-; NSC 66400; 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane; Dimethyl ether of triethylene glycol; EINECS 203-977-3; Glycol, triethylene-, dimethyl ether; BRN 1700630; AI3-28582; triethyleneglycol dimethyl ether; 32YXG88KK0; CHEBI:44842; YFNKIDBQEZZDLK-UHFFFAOYSA-N; Triethylene
DMD7WNV DT Small molecular drug
DMD7WNV PC 8189
DMD7WNV MW 178.23
DMD7WNV FM C8H18O4
DMD7WNV IC InChI=1S/C8H18O4/c1-9-3-5-11-7-8-12-6-4-10-2/h3-8H2,1-2H3
DMD7WNV CS COCCOCCOCCOC
DMD7WNV IK YFNKIDBQEZZDLK-UHFFFAOYSA-N
DMD7WNV IU 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane
DMD7WNV CA CAS 112-49-2
DMD7WNV CB CHEBI:44842
DMD7WNV DE Discovery agent
DM7DTRM ID DM7DTRM
DM7DTRM DN 1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea
DM7DTRM HS Investigative
DM7DTRM SN CHEMBL205218; 1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea
DM7DTRM DT Small molecular drug
DM7DTRM PC 44410473
DM7DTRM MW 282.3
DM7DTRM FM C15H14N4O2
DM7DTRM IC InChI=1S/C15H14N4O2/c1-21-19-15(20)18-11-2-3-12-13(9-17-14(12)8-11)10-4-6-16-7-5-10/h2-9,17H,1H3,(H2,18,19,20)
DM7DTRM CS CONC(=O)NC1=CC2=C(C=C1)C(=CN2)C3=CC=NC=C3
DM7DTRM IK XYNMCCVGHHUPIU-UHFFFAOYSA-N
DM7DTRM IU 1-methoxy-3-(3-pyridin-4-yl-1H-indol-6-yl)urea
DM7DTRM DE Discovery agent
DMFVSBK ID DMFVSBK
DMFVSBK DN 1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one
DMFVSBK HS Investigative
DMFVSBK SN 1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one; CHEMBL1242450; SCHEMBL11029477
DMFVSBK DT Small molecular drug
DMFVSBK PC 46932895
DMFVSBK MW 298.29
DMFVSBK FM C17H14O5
DMFVSBK IC InChI=1S/C17H14O5/c1-19-14-6-10(20-8-11-9-21-11)7-15-16(14)17(18)12-4-2-3-5-13(12)22-15/h2-7,11H,8-9H2,1H3
DMFVSBK CS COC1=CC(=CC2=C1C(=O)C3=CC=CC=C3O2)OCC4CO4
DMFVSBK IK DTYOZZZAYPACPN-UHFFFAOYSA-N
DMFVSBK IU 1-methoxy-3-(oxiran-2-ylmethoxy)xanthen-9-one
DMFVSBK DE Discovery agent
DM8YQ2O ID DM8YQ2O
DM8YQ2O DN 1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine
DM8YQ2O HS Investigative
DM8YQ2O SN CHEMBL292721; 1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine; SCHEMBL7234473; MVULNNIYAGEMCC-UHFFFAOYSA-N; BDBM50144165
DM8YQ2O DT Small molecular drug
DM8YQ2O PC 18189209
DM8YQ2O MW 303.4
DM8YQ2O FM C20H17NO2
DM8YQ2O IC InChI=1S/C20H17NO2/c1-22-17-8-5-9-18-19(17)15-11-10-14(21)12-16(15)20(23-18)13-6-3-2-4-7-13/h2-12,20H,21H2,1H3
DM8YQ2O CS COC1=CC=CC2=C1C3=C(C=C(C=C3)N)C(O2)C4=CC=CC=C4
DM8YQ2O IK MVULNNIYAGEMCC-UHFFFAOYSA-N
DM8YQ2O IU 1-methoxy-6-phenyl-6H-benzo[c]chromen-8-amine
DM8YQ2O DE Discovery agent
DM2D5HB ID DM2D5HB
DM2D5HB DN 1-Methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB HS Investigative
DM2D5HB SN CHEMBL63422; 1-Methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB DT Small molecular drug
DM2D5HB PC 44305900
DM2D5HB MW 288.3
DM2D5HB FM C20H16O2
DM2D5HB IC InChI=1S/C20H16O2/c1-21-17-12-7-13-18-19(17)15-10-5-6-11-16(15)20(22-18)14-8-3-2-4-9-14/h2-13,20H,1H3
DM2D5HB CS COC1=CC=CC2=C1C3=CC=CC=C3C(O2)C4=CC=CC=C4
DM2D5HB IK SZYXTCHBPGBQPM-UHFFFAOYSA-N
DM2D5HB IU 1-methoxy-6-phenyl-6H-benzo[c]chromene
DM2D5HB DE Discovery agent
DMAUZHJ ID DMAUZHJ
DMAUZHJ DN 1-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMAUZHJ HS Investigative
DMAUZHJ SN CHEMBL497156; 1-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264948
DMAUZHJ DT Small molecular drug
DMAUZHJ PC 44580316
DMAUZHJ MW 239.31
DMAUZHJ FM C16H17NO
DMAUZHJ IC InChI=1S/C16H17NO/c1-18-15-8-4-6-12-9-11-5-2-3-7-13(11)14(10-17)16(12)15/h2-8,14H,9-10,17H2,1H3
DMAUZHJ CS COC1=CC=CC2=C1C(C3=CC=CC=C3C2)CN
DMAUZHJ IK MVQHAVPXHRGPMI-UHFFFAOYSA-N
DMAUZHJ IU (1-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMAUZHJ DE Discovery agent
DM9KCXI ID DM9KCXI
DM9KCXI DN 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea
DM9KCXI HS Investigative
DM9KCXI SN CHEMBL110018; 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea; BDBM50004732
DM9KCXI DT Small molecular drug
DM9KCXI PC 15669672
DM9KCXI MW 195.26
DM9KCXI FM C10H17N3O
DM9KCXI IC InChI=1S/C10H17N3O/c1-12(10(11)14)6-2-3-7-13-8-4-5-9-13/h4-9H2,1H3,(H2,11,14)
DM9KCXI CS CN(CC#CCN1CCCC1)C(=O)N
DM9KCXI IK NSYYEAWIQXWYBA-UHFFFAOYSA-N
DM9KCXI IU 1-methyl-1-(4-pyrrolidin-1-ylbut-2-ynyl)urea
DM9KCXI DE Discovery agent
DMI6P91 ID DMI6P91
DMI6P91 DN 1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol
DMI6P91 HS Investigative
DMI6P91 SN 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol; 525-72-4; (+/-) Salsolinol; CHEMBL416732; 1-Methyl-6,7-dihydroxytetrahydroisoquinoline; CHEBI:88801; (R)-Salsolinol; IBRKLUSXDYATLG-UHFFFAOYSA-N; 1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol; 6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-methyl-; 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; Sasolinol; (+)-Salsolinol; (R)-(+)-Salsolinol; (+)-(R)-Salsolinol; AC1L1H1L; Oprea1_470083; SCHEMBL1627427; CTK4J6115; 1,2,3,4-TETRAHYDRO-1-METHYL-6,7-ISOQUINOLINEDIOL
DMI6P91 DT Small molecular drug
DMI6P91 PC 54456
DMI6P91 MW 179.22
DMI6P91 FM C10H13NO2
DMI6P91 IC InChI=1S/C10H13NO2/c1-6-8-5-10(13)9(12)4-7(8)2-3-11-6/h4-6,11-13H,2-3H2,1H3
DMI6P91 CS CC1C2=CC(=C(C=C2CCN1)O)O
DMI6P91 IK IBRKLUSXDYATLG-UHFFFAOYSA-N
DMI6P91 IU 1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
DMI6P91 CA CAS 525-72-4
DMI6P91 CB CHEBI:88801
DMI6P91 DE Discovery agent
DM1BGQN ID DM1BGQN
DM1BGQN DN 1-Methyl-1,2-dihydro-indazol-3-one
DM1BGQN HS Investigative
DM1BGQN SN 1006-19-5; 1-METHYL-1H-INDAZOL-3(2H)-ONE; 1H-Indazol-3-ol, 1-methyl-; 1,2-dihydro-1-methyl-3H-indazol-3-one; CHEMBL412905; 3H-Indazol-3-one, 1,2-dihydro-1-methyl-; 100922-97-2; 1-methyl-2,3-dihydro-1H-indazol-3-one; N-methylindazolone; 1,2-dihydro-1-methylindazol-3-one; NSC512755; 1-Methyl-1,2-dihydro-indazol-3-one; ACMC-1BUMW; AC1L6WKF; 1-methyl-3-hydroxyindazole; 1-methyl-2H-indazol-3-one; 1-Methyl-1H-indazole-3-ol; SCHEMBL2270654; SCHEMBL12998307; CTK0D9874; KS-00000SDI; ONNIFDMRZCMQQM-UHFFFAOYSA-N; MolPort-035-688-834
DM1BGQN DT Small molecular drug
DM1BGQN PC 350589
DM1BGQN MW 148.16
DM1BGQN FM C8H8N2O
DM1BGQN IC InChI=1S/C8H8N2O/c1-10-7-5-3-2-4-6(7)8(11)9-10/h2-5H,1H3,(H,9,11)
DM1BGQN CS CN1C2=CC=CC=C2C(=O)N1
DM1BGQN IK ONNIFDMRZCMQQM-UHFFFAOYSA-N
DM1BGQN IU 1-methyl-2H-indazol-3-one
DM1BGQN CA CAS 100922-97-2
DM1BGQN DE Discovery agent
DMMX7V8 ID DMMX7V8
DMMX7V8 DN 1-Methyl-1,3-dihydro-indol-2-one
DMMX7V8 HS Investigative
DMMX7V8 PC 6096
DMMX7V8 MW 147.17
DMMX7V8 FM C9H9NO
DMMX7V8 IC InChI=1S/C9H9NO/c1-10-8-5-3-2-4-7(8)6-9(10)11/h2-5H,6H2,1H3
DMMX7V8 CS CN1C(=O)CC2=CC=CC=C21
DMMX7V8 IK RSQUAQMIGSMNNE-UHFFFAOYSA-N
DMMX7V8 IU 1-methyl-3H-indol-2-one
DMMX7V8 CA CAS 61-70-1
DMMX7V8 DE Discovery agent
DMPW75L ID DMPW75L
DMPW75L DN 1-methyl-1H-indole-2,3-dione
DMPW75L HS Investigative
DMPW75L SN N-Methylisatin; 2058-74-4; 1-Methylisatin; 1-methylindoline-2,3-dione; 1-Methyl-1H-indole-2,3-dione; 1-methylindole-2,3-dione; 1H-Indole-2,3-dione, 1-methyl-; 1-Methyl-indole-2,3-dione; NSC 42449; 1 methylisatine; OL-57; 1-methyl-2,3-dihydro-1H-indole-2,3-dione; 1-Methyl-2,3-indolinedione; INDOLE-2,3-DIONE, 1-METHYL-; EINECS 218-164-9; N-methylindol-2,3-dione; BRN 0128280; N-Methylindoline-2,3-dione; 1-Methyl-2,3-dihydroindole-2,3-dione; CHEMBL60569; VCYBVWFTGAZHGH-UHFFFAOYSA-N; MFCD00005812; 1-Methylisatin, 98%
DMPW75L DT Small molecular drug
DMPW75L PC 16358
DMPW75L MW 161.16
DMPW75L FM C9H7NO2
DMPW75L IC InChI=1S/C9H7NO2/c1-10-7-5-3-2-4-6(7)8(11)9(10)12/h2-5H,1H3
DMPW75L CS CN1C2=CC=CC=C2C(=O)C1=O
DMPW75L IK VCYBVWFTGAZHGH-UHFFFAOYSA-N
DMPW75L IU 1-methylindole-2,3-dione
DMPW75L CA CAS 2058-74-4
DMPW75L DE Discovery agent
DMDZ1FR ID DMDZ1FR
DMDZ1FR DN 1-methyl-1H-indole-3-carbaldehyde
DMDZ1FR HS Investigative
DMDZ1FR SN 1-Methyl-1H-indole-3-carbaldehyde; 19012-03-4; 1-Methylindole-3-carboxaldehyde; 1-methylindole-3-carbaldehyde; 3-Formyl-1-methylindole; 1-Methyl-indole-3-carbaldehyde; 1H-Indole-3-carboxaldehyde, 1-methyl-; 1-Methyl-3-formylindole; N-Methyl-3-formylindole; Indole-3-carboxaldehyde, 1-methyl-; 3-Formyl-1-methyl-1H-indole; CHEMBL210779; N-Methyl-3-indolecarboxaldehyde; KXYBYRKRRGSZCX-UHFFFAOYSA-N; MFCD00014570; 1-Methylindole-3-carboxaldehyde, 97%; NSC83042; EINECS 242-750-3; PubChem7503; AI3-51477; AC1L3EMK; AC1Q6QCU; AC1Q3YTB
DMDZ1FR DT Small molecular drug
DMDZ1FR PC 87894
DMDZ1FR MW 159.18
DMDZ1FR FM C10H9NO
DMDZ1FR IC InChI=1S/C10H9NO/c1-11-6-8(7-12)9-4-2-3-5-10(9)11/h2-7H,1H3
DMDZ1FR CS CN1C=C(C2=CC=CC=C21)C=O
DMDZ1FR IK KXYBYRKRRGSZCX-UHFFFAOYSA-N
DMDZ1FR IU 1-methylindole-3-carbaldehyde
DMDZ1FR CA CAS 19012-03-4
DMDZ1FR DE Discovery agent
DML5FQT ID DML5FQT
DML5FQT DN 1-methyl-1H-indole-3-carbonitrile
DML5FQT HS Investigative
DML5FQT SN 1-Methyl-1H-indole-3-carbonitrile; 24662-37-1; 1-methylindole-3-carbonitrile; 3-Cyano-1-methylindole; 1H-Indole-3-carbonitrile, 1-methyl-; 1H-Indole-3-carbonitrile,1-methyl-; CHEMBL205035; F9995-1129; AC1M4H5X; SCHEMBL1778037; 3-Cyano(1-methyl-1H-indole); CTK4F4137; FBAXZPMXGBNBPE-UHFFFAOYSA-; DTXSID30367996; MolPort-000-002-609; FBAXZPMXGBNBPE-UHFFFAOYSA-N; HMS1753J21; ZINC3165608; BDBM50182877; STK386450; MFCD00466602; AKOS001015339; MCULE-7170650231; AS-9400; AJ-44684; KB-12784; DA-07730; ST50875554; AM20040004; FT-0719960
DML5FQT DT Small molecular drug
DML5FQT PC 2307681
DML5FQT MW 156.18
DML5FQT FM C10H8N2
DML5FQT IC InChI=1S/C10H8N2/c1-12-7-8(6-11)9-4-2-3-5-10(9)12/h2-5,7H,1H3
DML5FQT CS CN1C=C(C2=CC=CC=C21)C#N
DML5FQT IK FBAXZPMXGBNBPE-UHFFFAOYSA-N
DML5FQT IU 1-methylindole-3-carbonitrile
DML5FQT CA CAS 24662-37-1
DML5FQT DE Discovery agent
DMUKAH6 ID DMUKAH6
DMUKAH6 DN 1-methyl-1H-indole-3-carboxamide
DMUKAH6 HS Investigative
DMUKAH6 SN 1-methyl-1H-indole-3-carboxamide; 118959-44-7; 1H-Indole-3-carboxamide, 1-methyl-; 1-methylindole-3-carboxamide; CHEMBL382602; AC1LGL0W; ACMC-20mo37; MLS001049055; SCHEMBL2174829; CTK0F9691; DTXSID00356397; MolPort-002-560-820; UHQHFXKJFJHBAE-UHFFFAOYSA-N; HMS2271M13; ZINC341025; BDBM50427552; STK721948; AKOS009024585; MCULE-8790085472; AS-9399; SMR000386893; AJ-19941; KB-219182; FT-0721669
DMUKAH6 DT Small molecular drug
DMUKAH6 PC 823187
DMUKAH6 MW 174.2
DMUKAH6 FM C10H10N2O
DMUKAH6 IC InChI=1S/C10H10N2O/c1-12-6-8(10(11)13)7-4-2-3-5-9(7)12/h2-6H,1H3,(H2,11,13)
DMUKAH6 CS CN1C=C(C2=CC=CC=C21)C(=O)N
DMUKAH6 IK UHQHFXKJFJHBAE-UHFFFAOYSA-N
DMUKAH6 IU 1-methylindole-3-carboxamide
DMUKAH6 CA CAS 118959-44-7
DMUKAH6 DE Discovery agent
DMYU348 ID DMYU348
DMYU348 DN 1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine
DMYU348 HS Investigative
DMYU348 SN CHEMBL1078716; 1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine; BDBM50310835
DMYU348 DT Small molecular drug
DMYU348 PC 44613329
DMYU348 MW 243.4
DMYU348 FM C15H17NS
DMYU348 IC InChI=1S/C15H17NS/c1-12(16)11-13-7-9-15(10-8-13)17-14-5-3-2-4-6-14/h2-10,12H,11,16H2,1H3
DMYU348 CS CC(CC1=CC=C(C=C1)SC2=CC=CC=C2)N
DMYU348 IK FPOOXERVBCKPAG-UHFFFAOYSA-N
DMYU348 IU 1-(4-phenylsulfanylphenyl)propan-2-amine
DMYU348 DE Discovery agent
DM5GELS ID DM5GELS
DM5GELS DN 1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine
DM5GELS HS Investigative
DM5GELS SN 1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine; 1,5,5-trimethylpyrrolidin-2-one; 119715-71-8; AC1L9GJJ; SCHEMBL4329315; 1,5,5-trimethylpyrrolid-2one; CHEBI:43533; 1,5,5-Trimethyl-2-pyrrolidone; 1,5,5-trimethylpyrrolid-2-one; YARDEGUIPATLSG-UHFFFAOYSA-N; 1,5,5-trimethyl-pyrrolidin-2-one; 2-Pyrrolidinone, 1,5,5-trimethyl-; DB03968
DM5GELS DT Small molecular drug
DM5GELS PC 444570
DM5GELS MW 127.18
DM5GELS FM C7H13NO
DM5GELS IC InChI=1S/C7H13NO/c1-7(2)5-4-6(9)8(7)3/h4-5H2,1-3H3
DM5GELS CS CC1(CCC(=O)N1C)C
DM5GELS IK YARDEGUIPATLSG-UHFFFAOYSA-N
DM5GELS IU 1,5,5-trimethylpyrrolidin-2-one
DM5GELS CA CAS 119715-71-8
DM5GELS CB CHEBI:43533
DM5GELS DE Discovery agent
DMC3IGK ID DMC3IGK
DMC3IGK DN 1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide
DMC3IGK HS Investigative
DMC3IGK SN CHEMBL1173603
DMC3IGK DT Small molecular drug
DMC3IGK PC 49799304
DMC3IGK MW 229.25
DMC3IGK FM C13H13N2O2+
DMC3IGK IC InChI=1S/C13H12N2O2/c1-15-9-5-8-12(10-15)17-13(16)14-11-6-3-2-4-7-11/h2-10H,1H3/p+1
DMC3IGK CS C[N+]1=CC=CC(=C1)OC(=O)NC2=CC=CC=C2
DMC3IGK IK HFCGFRPAGMNQAZ-UHFFFAOYSA-O
DMC3IGK IU (1-methylpyridin-1-ium-3-yl) N-phenylcarbamate
DMC3IGK DE Discovery agent
DMICQWN ID DMICQWN
DMICQWN DN 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
DMICQWN HS Investigative
DMICQWN SN 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID; (2-METHYL-5-PHENYL-2H-PYRAZOL-3-YL)-SULFAMIC ACID; UN3; AC1NS1QY; SULFAMIC ACID Analog 13; BDBM13529; DB04800; (2-methyl-5-phenylpyrazol-3-yl)sulfamic acid; N-(2-methyl-5-phenylpyrazol-3-yl)sulfamic acid; (1-methyl-3-phenyl-1H-pyrazol-5-yl)sulfamic acid; N-(1-methyl-3-phenyl-1H-pyrazol-5-yl)sulfamic acid
DMICQWN DT Small molecular drug
DMICQWN PC 5327154
DMICQWN MW 253.28
DMICQWN FM C10H11N3O3S
DMICQWN IC InChI=1S/C10H11N3O3S/c1-13-10(12-17(14,15)16)7-9(11-13)8-5-3-2-4-6-8/h2-7,12H,1H3,(H,14,15,16)
DMICQWN CS CN1C(=CC(=N1)C2=CC=CC=C2)NS(=O)(=O)O
DMICQWN IK OTZLVSGSRPNRFT-UHFFFAOYSA-N
DMICQWN IU (2-methyl-5-phenylpyrazol-3-yl)sulfamic acid
DMICQWN DE Discovery agent
DM90LWT ID DM90LWT
DM90LWT DN 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione
DM90LWT HS Investigative
DM90LWT SN Xanthine, 1-methyl-3-propyl-; 1-methyl-3-propyl-7H-purine-2,6-dione; CHEMBL286976; 118024-67-2; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-propyl-; 1H-Purine-2,6-dione,3,9-dihydro-3-methyl-1-propyl-; AC1L3BCB; 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione; SCHEMBL9765669; CTK5D5561; ZINC4770328; BDBM50001509; AKOS030229248
DM90LWT DT Small molecular drug
DM90LWT PC 86344
DM90LWT MW 208.22
DM90LWT FM C9H12N4O2
DM90LWT IC InChI=1S/C9H12N4O2/c1-3-4-13-7-6(10-5-11-7)8(14)12(2)9(13)15/h5H,3-4H2,1-2H3,(H,10,11)
DM90LWT CS CCCN1C2=C(C(=O)N(C1=O)C)NC=N2
DM90LWT IK MCPROACZLSAAPY-UHFFFAOYSA-N
DM90LWT IU 1-methyl-3-propyl-7H-purine-2,6-dione
DM90LWT CA CAS 118024-67-2
DM90LWT CB CHEBI:145517
DM90LWT DE Discovery agent
DMBWSCR ID DMBWSCR
DMBWSCR DN 1-Methyl-4-(1-phenyl-ethyl)-piperazine
DMBWSCR HS Investigative
DMBWSCR SN CHEMBL195009; 1-Methyl-4-(1-phenyl-ethyl)-piperazine; SCHEMBL2625061; BDBM50174064
DMBWSCR DT Small molecular drug
DMBWSCR PC 14364677
DMBWSCR MW 204.31
DMBWSCR FM C13H20N2
DMBWSCR IC InChI=1S/C13H20N2/c1-12(13-6-4-3-5-7-13)15-10-8-14(2)9-11-15/h3-7,12H,8-11H2,1-2H3
DMBWSCR CS CC(C1=CC=CC=C1)N2CCN(CC2)C
DMBWSCR IK CQTKDGNXBCFBTR-UHFFFAOYSA-N
DMBWSCR IU 1-methyl-4-(1-phenylethyl)piperazine
DMBWSCR DE Discovery agent
DMPWB8G ID DMPWB8G
DMPWB8G DN 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
DMPWB8G HS Investigative
DMPWB8G SN 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPTP; 28289-54-5; CCRIS 2186; 1,2,3,6-Tetrahydro-1-methyl-4-phenylpyridine; HSDB 6942; PYRIDINE, 1,2,3,6-TETRAHYDRO-1-METHYL-4-PHENYL-; 1-METHYL-4-PHENYL-PIPERIDINE-3-EN; UNII-9P21XSP91P; N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NSC 139654; EINECS 248-939-7; 1-Methyl-4-phenyl-1,2,3,6-tetrahydroxpyridine; BRN 0133712; CHEMBL24172; 9P21XSP91P; 1-methyl-4-phenyl-3,6-dihydro-2H-pyridine; CHEBI:17963; 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine; PLRACCBDVIHHLZ-UHFFFAOYSA-N
DMPWB8G DT Small molecular drug
DMPWB8G PC 1388
DMPWB8G MW 173.25
DMPWB8G FM C12H15N
DMPWB8G IC InChI=1S/C12H15N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-7H,8-10H2,1H3
DMPWB8G CS CN1CCC(=CC1)C2=CC=CC=C2
DMPWB8G IK PLRACCBDVIHHLZ-UHFFFAOYSA-N
DMPWB8G IU 1-methyl-4-phenyl-3,6-dihydro-2H-pyridine
DMPWB8G CA CAS 28289-54-5
DMPWB8G CB CHEBI:17963
DMPWB8G DE Discovery agent
DM6XFMT ID DM6XFMT
DM6XFMT DN 1-Methyl-4-p-tolyl-piperidine-4-carbonitrile
DM6XFMT HS Investigative
DM6XFMT SN CHEMBL111498; 1-Methyl-4-p-tolyl-piperidine-4-carbonitrile; 1-methyl-4-(4-methylphenyl)piperidine-4-carbonitrile; ZINC13610036; BDBM50083527
DM6XFMT DT Small molecular drug
DM6XFMT PC 11184286
DM6XFMT MW 214.31
DM6XFMT FM C14H18N2
DM6XFMT IC InChI=1S/C14H18N2/c1-12-3-5-13(6-4-12)14(11-15)7-9-16(2)10-8-14/h3-6H,7-10H2,1-2H3
DM6XFMT CS CC1=CC=C(C=C1)C2(CCN(CC2)C)C#N
DM6XFMT IK UWFQWENRHDTJQQ-UHFFFAOYSA-N
DM6XFMT IU 1-methyl-4-(4-methylphenyl)piperidine-4-carbonitrile
DM6XFMT DE Discovery agent
DM4HS92 ID DM4HS92
DM4HS92 DN 1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one
DM4HS92 HS Investigative
DM4HS92 SN CHEMBL56908; 1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one; BDBM50091710; 1-Methyl-5-[(E)-azobenzene-4-yl]piperidine-2-one
DM4HS92 DT Small molecular drug
DM4HS92 PC 10017278
DM4HS92 MW 293.4
DM4HS92 FM C18H19N3O
DM4HS92 IC InChI=1S/C18H19N3O/c1-21-13-15(9-12-18(21)22)14-7-10-17(11-8-14)20-19-16-5-3-2-4-6-16/h2-8,10-11,15H,9,12-13H2,1H3
DM4HS92 CS CN1CC(CCC1=O)C2=CC=C(C=C2)N=NC3=CC=CC=C3
DM4HS92 IK GUDNFCRTZUCEOP-UHFFFAOYSA-N
DM4HS92 IU 1-methyl-5-(4-phenyldiazenylphenyl)piperidin-2-one
DM4HS92 DE Discovery agent
DMX2FWN ID DMX2FWN
DMX2FWN DN 1-Methyl-5-oxa-spiro[2.4]heptan-4-one
DMX2FWN HS Investigative
DMX2FWN SN SCHEMBL19526372
DMX2FWN DT Small molecular drug
DMX2FWN PC 12421856
DMX2FWN MW 126.15
DMX2FWN FM C7H10O2
DMX2FWN IC InChI=1S/C7H10O2/c1-5-4-7(5)2-3-9-6(7)8/h5H,2-4H2,1H3
DMX2FWN CS CC1CC12CCOC2=O
DMX2FWN IK FQIBVSQKGHYUKI-UHFFFAOYSA-N
DMX2FWN IU 2-methyl-5-oxaspiro[2.4]heptan-4-one
DMX2FWN DE Discovery agent
DMB3JO2 ID DMB3JO2
DMB3JO2 DN 1-Methyl-5-phenyl-piperidin-2-one
DMB3JO2 HS Investigative
DMB3JO2 SN 1-Methyl-5-phenyl-piperidin-2-one; CHEMBL55261; SCHEMBL16591470; 1-Methyl-5-phenylpiperidine-2-one; BDBM50091702
DMB3JO2 DT Small molecular drug
DMB3JO2 PC 12012176
DMB3JO2 MW 189.25
DMB3JO2 FM C12H15NO
DMB3JO2 IC InChI=1S/C12H15NO/c1-13-9-11(7-8-12(13)14)10-5-3-2-4-6-10/h2-6,11H,7-9H2,1H3
DMB3JO2 CS CN1CC(CCC1=O)C2=CC=CC=C2
DMB3JO2 IK ASTTXNJRFSDNDJ-UHFFFAOYSA-N
DMB3JO2 IU 1-methyl-5-phenylpiperidin-2-one
DMB3JO2 DE Discovery agent
DMSTH24 ID DMSTH24
DMSTH24 DN 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione
DMSTH24 HS Investigative
DMSTH24 SN 2850-37-5; CHEMBL9069; 1-methyl-8-phenylxanthine; NSC282736; CBMicro_029762; Cambridge id 5733876; AC1L88FA; Oprea1_619029; Oprea1_215826; 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione; SCHEMBL515920; 1-methyl-8-phenyl-3,9-dihydro-1H-purine-2,6-dione; SCHEMBL13977442; CTK8I0059; DTXSID40314411; MolPort-002-516-863; MolPort-000-816-326; STK169388; ZINC18270697; BDBM50018157; AKOS005409446; NSC-282736; MCULE-2769568078; BIM-0029837.P001; 1-methyl-8-phenyl-3,7-dihydropurine-2,6-dione; 1-methyl-8-phenyl-1H-purine-2,6(3H,9H)-dione
DMSTH24 DT Small molecular drug
DMSTH24 PC 323342
DMSTH24 MW 242.23
DMSTH24 FM C12H10N4O2
DMSTH24 IC InChI=1S/C12H10N4O2/c1-16-11(17)8-10(15-12(16)18)14-9(13-8)7-5-3-2-4-6-7/h2-6H,1H3,(H,13,14)(H,15,18)
DMSTH24 CS CN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=CC=C3
DMSTH24 IK UOOOWRVLSKCKGJ-UHFFFAOYSA-N
DMSTH24 IU 1-methyl-8-phenyl-3,7-dihydropurine-2,6-dione
DMSTH24 CA CAS 2850-37-5
DMSTH24 DE Discovery agent
DMDIH07 ID DMDIH07
DMDIH07 DN 1-methylcyclopropanecarboxylic acid
DMDIH07 HS Investigative
DMDIH07 SN 1-Methylcyclopropane-1-carboxylic acid; 6914-76-7; 1-Methylcyclopropanecarboxylic acid; 1-Methyl-cyclopropanecarboxylic acid; Cyclopropanecarboxylic acid, 1-methyl-; DIZKLZKLNKQFGB-UHFFFAOYSA-N; Cyclopropanecarboxylicacid, 1-methyl-; 1-Methylcyclopropanecarboxylic acid, 98%; EINECS 230-020-7; PubChem16037; AC1Q5TAN; AC1Q2CXA; 1-methylcyclopropanoic acid; ACMC-209o6g; SCHEMBL113962; 1-Carboxy-1-methylcyclopropane; GTPL6500; DIZKLZKLNKQFGB-UHFFFAOYSA-; CTK2F4732; Methyl-cyclopropanecarboxylic acid; DTXSID50219201
DMDIH07 DT Small molecular drug
DMDIH07 PC 81326
DMDIH07 MW 100.12
DMDIH07 FM C5H8O2
DMDIH07 IC InChI=1S/C5H8O2/c1-5(2-3-5)4(6)7/h2-3H2,1H3,(H,6,7)
DMDIH07 CS CC1(CC1)C(=O)O
DMDIH07 IK DIZKLZKLNKQFGB-UHFFFAOYSA-N
DMDIH07 IU 1-methylcyclopropane-1-carboxylic acid
DMDIH07 CA CAS 6914-76-7
DMDIH07 DE Discovery agent
DMFR7JW ID DMFR7JW
DMFR7JW DN 1-Methyloxy-4-Sulfone-Benzene
DMFR7JW HS Investigative
DMFR7JW SN 1-METHYLOXY-4-SULFONE-BENZENE; 4-methoxybenzenesulfinate; AC1MZTZ7; SCHEMBL13838953; YVZWQPOTHRMEQW-UHFFFAOYSA-M; SBB082464; 1-(dioxidosulfanyl)-4-methoxybenzene; ZINC150339282; AKOS004898433; DB03033
DMFR7JW DT Small molecular drug
DMFR7JW PC 3952261
DMFR7JW MW 171.2
DMFR7JW FM C7H7O3S-
DMFR7JW IC InChI=1S/C7H8O3S/c1-10-6-2-4-7(5-3-6)11(8)9/h2-5H,1H3,(H,8,9)/p-1
DMFR7JW CS COC1=CC=C(C=C1)S(=O)[O-]
DMFR7JW IK YVZWQPOTHRMEQW-UHFFFAOYSA-M
DMFR7JW IU 4-methoxybenzenesulfinate
DMFR7JW DE Discovery agent
DM2WQ1E ID DM2WQ1E
DM2WQ1E DN 1-METHYLXANTHINE
DM2WQ1E HS Investigative
DM2WQ1E SN 1-Methylxanthine; 6136-37-4; 1-Methyl-3,7-dihydro-purine-2,6-dione; 1-Methyl-1H-purine-2,6(3H,7H)-dione; Methylxanthine; Xanthine, 1-methyl-; UNII-7EE8WCA32U; 2,6-Dihydroxy-1-methylpurine; CCRIS 5816; 1-methyl-7H-xanthine; EINECS 228-108-5; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-; 7EE8WCA32U; CHEMBL1250; 2,6 Dihydroxy-1-methylpurine; CHEBI:68444; 3,7-Dihydro-1-methyl-1H-purine-2,6-dione; MVOYJPOZRLFTCP-UHFFFAOYSA-N; 1-methyl-3,7-dihydropurine-2,6-dione; 1-methyl-3,9-dihydropurine-2,6-dione
DM2WQ1E DT Small molecular drug
DM2WQ1E PC 80220
DM2WQ1E MW 166.14
DM2WQ1E FM C6H6N4O2
DM2WQ1E IC InChI=1S/C6H6N4O2/c1-10-5(11)3-4(8-2-7-3)9-6(10)12/h2H,1H3,(H,7,8)(H,9,12)
DM2WQ1E CS CN1C(=O)C2=C(NC1=O)N=CN2
DM2WQ1E IK MVOYJPOZRLFTCP-UHFFFAOYSA-N
DM2WQ1E IU 1-methyl-3,7-dihydropurine-2,6-dione
DM2WQ1E CA CAS 6136-37-4
DM2WQ1E CB CHEBI:68444
DM2WQ1E DE Discovery agent
DMYOJ01 ID DMYOJ01
DMYOJ01 DN 1-Morpholin-4-yl-benzo[f]chromen-3-one
DMYOJ01 HS Investigative
DMYOJ01 SN CHEMBL178969; 1-Morpholin-4-yl-benzo[f]chromen-3-one
DMYOJ01 DT Small molecular drug
DMYOJ01 PC 11277489
DMYOJ01 MW 281.3
DMYOJ01 FM C17H15NO3
DMYOJ01 IC InChI=1S/C17H15NO3/c19-16-11-14(18-7-9-20-10-8-18)17-13-4-2-1-3-12(13)5-6-15(17)21-16/h1-6,11H,7-10H2
DMYOJ01 CS C1COCCN1C2=CC(=O)OC3=C2C4=CC=CC=C4C=C3
DMYOJ01 IK BYCFTTKUJHROAO-UHFFFAOYSA-N
DMYOJ01 IU 1-morpholin-4-ylbenzo[f]chromen-3-one
DMYOJ01 DE Discovery agent
DM0A1YI ID DM0A1YI
DM0A1YI DN 1na
DM0A1YI HS Investigative
DM0A1YI SN 3946-01-8; Methyl 2-acetamido-2-deoxy-beta-D-glucopyranoside; N-((2R,3R,4R,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3-yl)acetamide; Alpha-Methyl-N-Acetyl-D-Glucosamine; Beta-Methyl-N-Acetyl-D-Glucosamine; Methyl 2-acetamido-2-deoxy-b-D-glucopyranoside; AC1L9IIR; SCHEMBL1673962; ZEVOCXOZYFLVKN-JGKVKWKGSA-N; MolPort-000-189-911; ZINC5234411; methyl n-acetyl-beta-d-glucosaminide; AKOS002687842; N-ACETYL-O-METHYL-D-GLUCOSAMINE; DB04426; N-acetyl-1-O-methyl-beta-d-glucosamine
DM0A1YI DT Small molecular drug
DM0A1YI PC 445750
DM0A1YI MW 235.23
DM0A1YI FM C9H17NO6
DM0A1YI IC InChI=1S/C9H17NO6/c1-4(12)10-6-8(14)7(13)5(3-11)16-9(6)15-2/h5-9,11,13-14H,3H2,1-2H3,(H,10,12)/t5-,6-,7-,8-,9-/m1/s1
DM0A1YI CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC)CO)O)O
DM0A1YI IK ZEVOCXOZYFLVKN-JGKVKWKGSA-N
DM0A1YI IU N-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-methoxyoxan-3-yl]acetamide
DM0A1YI DE Discovery agent
DMF87Z5 ID DMF87Z5
DMF87Z5 DN 1-N-Acetyl-Beta-D-Glucosamine
DMF87Z5 HS Investigative
DMF87Z5 SN 1-N-ACETYL-BETA-D-GLUCOSAMINE; N-Acetyl-beta-D-glucopyranosylamine; CHEMBL335315; N-beta-D-Glucopyranosylacetamide; NBG; 6983-36-4; Acetamide, N-beta-D-glucopyranosyl-; 2prj; AC1L9HVU; SCHEMBL4388634; n-acetyl-b-d-glucopyranosylamine; BDBM50240802; DB02320; N-(3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-acetamide; N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide
DMF87Z5 DT Small molecular drug
DMF87Z5 PC 445382
DMF87Z5 MW 221.21
DMF87Z5 FM C8H15NO6
DMF87Z5 IC InChI=1S/C8H15NO6/c1-3(11)9-8-7(14)6(13)5(12)4(2-10)15-8/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8-/m1/s1
DMF87Z5 CS CC(=O)N[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMF87Z5 IK IBONACLSSOLHFU-JAJWTYFOSA-N
DMF87Z5 IU N-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide
DMF87Z5 CA CAS 6983-36-4
DMF87Z5 DE Discovery agent
DMTBZJL ID DMTBZJL
DMTBZJL DN 1-Naphthalen-2-yl-1H-imidazole
DMTBZJL HS Investigative
DMTBZJL SN 1-(naphthalen-2-yl)-1H-imidazole; 1-(2-naphthyl)-1h-imidazole; 25372-01-4; 1H-Imidazole, 1-(2-naphthalenyl)-; SCHEMBL2071832; CHEMBL195996; BDBM8916; MolPort-009-323-053; Imidazole-substituted naphthalene 23; ZINC13674480; AKOS034336039; MCULE-9753314459
DMTBZJL DT Small molecular drug
DMTBZJL PC 23644748
DMTBZJL MW 194.23
DMTBZJL FM C13H10N2
DMTBZJL IC InChI=1S/C13H10N2/c1-2-4-12-9-13(6-5-11(12)3-1)15-8-7-14-10-15/h1-10H
DMTBZJL CS C1=CC=C2C=C(C=CC2=C1)N3C=CN=C3
DMTBZJL IK LHAAPZJTEBPKBJ-UHFFFAOYSA-N
DMTBZJL IU 1-naphthalen-2-ylimidazole
DMTBZJL DE Discovery agent
DMU04ZQ ID DMU04ZQ
DMU04ZQ DN 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one
DMU04ZQ HS Investigative
DMU04ZQ SN naphyrone; 1-(Naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one; 850352-11-3; 850352-53-3; Naphyrone (O-2482); CHEMBL204759; naphthylpyrovalerone; beta-Naphyrone; O-2482; 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one; SCHEMBL4939526; DEA No. 1258; CTK8C0838; ACT06821; BDBM50182546; ANW-65341; AKOS015898953; KB-215797; AX8234386; AB1004335; TC-154086; I14-12001; 1-Pentanone, 1-(2-naphthalenyl)-2-(1-pyrrolidinyl)-; 850352-53-3,850352-11-3(HCl); 1-(1-(naphthalen-2-yl)-1-oxopentan-2-yl)pyrrolidinium chloride
DMU04ZQ DT Small molecular drug
DMU04ZQ PC 11243002
DMU04ZQ MW 281.4
DMU04ZQ FM C19H23NO
DMU04ZQ IC InChI=1S/C19H23NO/c1-2-7-18(20-12-5-6-13-20)19(21)17-11-10-15-8-3-4-9-16(15)14-17/h3-4,8-11,14,18H,2,5-7,12-13H2,1H3
DMU04ZQ CS CCCC(C(=O)C1=CC2=CC=CC=C2C=C1)N3CCCC3
DMU04ZQ IK DTNUPBSOODGRKW-UHFFFAOYSA-N
DMU04ZQ IU 1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one
DMU04ZQ CA CAS 850352-53-3
DMU04ZQ DE Discovery agent
DMJK0MF ID DMJK0MF
DMJK0MF DN 1-Naphthalen-2-yl-piperazine
DMJK0MF HS Investigative
DMJK0MF SN 1-(naphthalen-2-yl)piperazine; 57536-91-1; 1-Naphthalen-2-yl-piperazine; 1-(2-NAPHTHYL)PIPERAZINE; CHEMBL278509; 1-naphthalen-2-ylpiperazine; Oprea1_405543; AC1MC234; SCHEMBL3138664; LWLBVIFUVSUSAY-UHFFFAOYSA-N; ZINC3716177; SBB076290; BDBM50007411; AKOS003591179; MCULE-5668438904
DMJK0MF DT Small molecular drug
DMJK0MF PC 2760172
DMJK0MF MW 212.29
DMJK0MF FM C14H16N2
DMJK0MF IC InChI=1S/C14H16N2/c1-2-4-13-11-14(6-5-12(13)3-1)16-9-7-15-8-10-16/h1-6,11,15H,7-10H2
DMJK0MF CS C1CN(CCN1)C2=CC3=CC=CC=C3C=C2
DMJK0MF IK LWLBVIFUVSUSAY-UHFFFAOYSA-N
DMJK0MF IU 1-naphthalen-2-ylpiperazine
DMJK0MF DE Discovery agent
DM6BIWK ID DM6BIWK
DM6BIWK DN 1-naphthylpiperazine
DM6BIWK HS Investigative
DM6BIWK SN 1-(1-Naphthyl)piperazine; 1-Naphthylpiperazine; 57536-86-4; 1-(naphthalen-1-yl)piperazine; 1-naphthalen-1-ylpiperazine; 1-Naphthalen-1-yl-piperazine; CHEMBL277120; Piperazine, 1-(1-naphthalenyl)-; Piperazine,1-(1-naphthalenyl)-; 4-(naphth-1-yl)piperazine; Naphthylpiperazine; GTPL3; Lopac-S-003; AC1Q1INU; N-(1-naphthyl)piperazine; 4-(1-naphthyl)piperazine; Biomol-NT_000100; N-(1- naphthyl)piperazine; N-(1-naphthyl)-piperazine; N-(1-naphthyl) piperazine; AC1L1B9K; 4-(1-naphthyl) piperazine; 1-(naphth-1-yl)piperazine; Oprea1_621306; 1-NP
DM6BIWK DT Small molecular drug
DM6BIWK PC 1342
DM6BIWK MW 212.29
DM6BIWK FM C14H16N2
DM6BIWK IC InChI=1S/C14H16N2/c1-2-6-13-12(4-1)5-3-7-14(13)16-10-8-15-9-11-16/h1-7,15H,8-11H2
DM6BIWK CS C1CN(CCN1)C2=CC=CC3=CC=CC=C32
DM6BIWK IK VNICFCQJUVFULD-UHFFFAOYSA-N
DM6BIWK IU 1-naphthalen-1-ylpiperazine
DM6BIWK CA CAS 57536-86-4
DM6BIWK CB CHEBI:108599
DM6BIWK DE Discovery agent
DMP6VOK ID DMP6VOK
DMP6VOK DN 1-nitro-2-(2-nitrophenylsulfonyl)benzene
DMP6VOK HS Investigative
DMP6VOK SN Bis(2-nitrophenyl)sulfone; NSC633001; 14665-52-2; Benzene, 1,1'-sulfonylbis[2-nitro-; NSC-633001; 1-nitro-2-[(2-nitrophenyl)sulfonyl]benzene; Bis(2NO2Ph)SO2; AC1Q6URW; AC1L7QPG; NCIMech_000590; MLS001196654; SCHEMBL2039879; BDBM1780; CHEMBL415959; CTK0E9275; DTXSID40327122; MolPort-006-834-474; Benzene,1'-sulfonylbis(2-nitro-; HMS2872L23; ZINC1622822; CCG-35737; AKOS001662347; MCULE-4947941526; 1-nitro-2-(2-nitrophenyl)sulfonylbenzene; 2-Amino-6-arylthiobenzonitrile deriv. 4b; SMR000556031; NCI60_010909
DMP6VOK DT Small molecular drug
DMP6VOK PC 365388
DMP6VOK MW 308.27
DMP6VOK FM C12H8N2O6S
DMP6VOK IC InChI=1S/C12H8N2O6S/c15-13(16)9-5-1-3-7-11(9)21(19,20)12-8-4-2-6-10(12)14(17)18/h1-8H
DMP6VOK CS C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)C2=CC=CC=C2[N+](=O)[O-]
DMP6VOK IK IHZVFZOUXUNSPQ-UHFFFAOYSA-N
DMP6VOK IU 1-nitro-2-(2-nitrophenyl)sulfonylbenzene
DMP6VOK CA CAS 14665-52-2
DMP6VOK DE Discovery agent
DM9OJ7T ID DM9OJ7T
DM9OJ7T DN 1-Octyl-3-(1-propionylpiperidin-4-yl)urea
DM9OJ7T HS Investigative
DM9OJ7T SN CHEMBL1257514; 1-Octyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2721029
DM9OJ7T DT Small molecular drug
DM9OJ7T PC 49782570
DM9OJ7T MW 311.5
DM9OJ7T FM C17H33N3O2
DM9OJ7T IC InChI=1S/C17H33N3O2/c1-3-5-6-7-8-9-12-18-17(22)19-15-10-13-20(14-11-15)16(21)4-2/h15H,3-14H2,1-2H3,(H2,18,19,22)
DM9OJ7T CS CCCCCCCCNC(=O)NC1CCN(CC1)C(=O)CC
DM9OJ7T IK QCBCCMKAGKJZIU-UHFFFAOYSA-N
DM9OJ7T IU 1-octyl-3-(1-propanoylpiperidin-4-yl)urea
DM9OJ7T DE Discovery agent
DMYHMEK ID DMYHMEK
DMYHMEK DN 1-OH-PGE1
DMYHMEK HS Investigative
DMYHMEK SN 19-hydroxy-PGE1; 19-hydroxyprostaglandin E1; 19-OH PGE1
DMYHMEK DT Small molecular drug
DMYHMEK PC 6438402
DMYHMEK MW 370.5
DMYHMEK FM C20H34O6
DMYHMEK IC InChI=1S/C20H34O6/c1-14(21)7-6-8-15(22)11-12-17-16(18(23)13-19(17)24)9-4-2-3-5-10-20(25)26/h11-12,14-17,19,21-22,24H,2-10,13H2,1H3,(H,25,26)/b12-11+/t14?,15-,16+,17+,19+/m0/s1
DMYHMEK CS CC(CCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O)O
DMYHMEK IK QVVXWHIDRKRPMO-LXCOYWBSSA-N
DMYHMEK IU 7-[(1R,2R,3R)-2-[(E,3S)-3,7-dihydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]heptanoic acid
DMYHMEK CA CAS 55123-67-6
DMYHMEK DE Discovery agent
DM5KU8S ID DM5KU8S
DM5KU8S DN 1-oleoyl glycerol
DM5KU8S HS Investigative
DM5KU8S SN 2,3-Dihydroxypropyl oleate; Monoolein; Glyceryl monooleate; 1-Monoolein; 111-03-5; 1-Oleoylglycerol; Glyceryl oleate; 1-Oleoyl-rac-glycerol; 1-Glyceryl oleate; 1-Monooleoylglycerol; Glycerol 1-monooleate; rac-1-Monoolein; Aldo MO; Aldo HMO; Danisco MO 90; 1-Monooleoyl-rac-glycerol; Glycerin 1-monooleate; Monooleoylglycerol; Oleic monoglyceride; rac-1-Monooleoylglycerol; Olein, 1-mono-; Oleoylglycerol; Olicine; Peceol; Supeol; alpha-Monoolein; Sinnoester ogc; Oleylmonoglyceride; Emalsy MO; Emalsy OL; Dimodan LSQK; Glycerol alpha-monooleat
DM5KU8S DT Small molecular drug
DM5KU8S PC 5283468
DM5KU8S MW 356.5
DM5KU8S FM C21H40O4
DM5KU8S IC InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h9-10,20,22-23H,2-8,11-19H2,1H3/b10-9-
DM5KU8S CS CCCCCCCC/C=C\\CCCCCCCC(=O)OCC(CO)O
DM5KU8S IK RZRNAYUHWVFMIP-KTKRTIGZSA-N
DM5KU8S IU 2,3-dihydroxypropyl (Z)-octadec-9-enoate
DM5KU8S CA CAS 111-03-5
DM5KU8S CB CHEBI:75342
DM5KU8S DE Discovery agent
DMPMGLO ID DMPMGLO
DMPMGLO DN 1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one
DMPMGLO HS Investigative
DMPMGLO SN PHOP; 288862-83-9; CHEMBL175854; 1-(oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one; 1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one; SCHEMBL3964367; CTK8E9849; LEI-104; DTXSID10435440; MolPort-009-018-760; HMS3649E22; ZINC13611906; BDBM50161518; ACM288862839; RT-015038; SR-01000946606; J-017316; SR-01000946606-1
DMPMGLO DT Small molecular drug
DMPMGLO PC 10085812
DMPMGLO MW 294.3
DMPMGLO FM C18H18N2O2
DMPMGLO IC InChI=1S/C18H18N2O2/c21-15(18-20-17-16(22-18)12-7-13-19-17)11-6-2-5-10-14-8-3-1-4-9-14/h1,3-4,7-9,12-13H,2,5-6,10-11H2
DMPMGLO CS C1=CC=C(C=C1)CCCCCC(=O)C2=NC3=C(O2)C=CC=N3
DMPMGLO IK VPZHQLPAKFVGKX-UHFFFAOYSA-N
DMPMGLO IU 1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-6-phenylhexan-1-one
DMPMGLO CA CAS 288862-83-9
DMPMGLO DE Discovery agent
DM9BY8D ID DM9BY8D
DM9BY8D DN 1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one
DM9BY8D HS Investigative
DM9BY8D SN 1-oxazolo[4,5-b]pyridin-2-yl-9-octadecyn-1-one; 288862-89-5; CHEMBL175580; 1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one; SCHEMBL1811297; CTK8E3290; DTXSID50433602; HMS3649E20; BDBM50163152; ZINC34803574; ACM288862895; RT-006406; SR-01000946605; SR-01000946605-1; J-017317
DM9BY8D DT Small molecular drug
DM9BY8D PC 9977214
DM9BY8D MW 382.5
DM9BY8D FM C24H34N2O2
DM9BY8D IC InChI=1S/C24H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-21(27)24-26-23-22(28-24)19-17-20-25-23/h17,19-20H,2-8,11-16,18H2,1H3
DM9BY8D CS CCCCCCCCC#CCCCCCCCC(=O)C1=NC2=C(O1)C=CC=N2
DM9BY8D IK DBMKKVSGBYKSFI-UHFFFAOYSA-N
DM9BY8D IU 1-([1,3]oxazolo[4,5-b]pyridin-2-yl)octadec-9-yn-1-one
DM9BY8D CA CAS 288862-89-5
DM9BY8D DE Discovery agent
DM9ZK0M ID DM9ZK0M
DM9ZK0M DN 1-palmitoyl-lysophosphatidylcholine
DM9ZK0M HS Investigative
DM9ZK0M SN lysophosphatidylcholine(16:0); LPC 16:0
DM9ZK0M DT Small molecular drug
DM9ZK0M PC 10097314
DM9ZK0M MW 495.6
DM9ZK0M FM C24H50NO7P
DM9ZK0M IC InChI=1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m0/s1
DM9ZK0M CS CCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DM9ZK0M IK ASWBNKHCZGQVJV-QHCPKHFHSA-N
DM9ZK0M IU [(2S)-3-hexadecanoyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DM9ZK0M DE Discovery agent
DM9PNTQ ID DM9PNTQ
DM9PNTQ DN 1-pentafluorophenylamido-5-sulfonamidoindane
DM9PNTQ HS Investigative
DM9PNTQ SN CHEMBL205867; 1-pentafluorophenylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 11c; BDBM11034
DM9PNTQ DT Small molecular drug
DM9PNTQ PC 11640067
DM9PNTQ MW 406.3
DM9PNTQ FM C16H11F5N2O3S
DM9PNTQ IC InChI=1S/C16H11F5N2O3S/c17-11-10(12(18)14(20)15(21)13(11)19)16(24)23-9-4-1-6-5-7(27(22,25)26)2-3-8(6)9/h2-3,5,9H,1,4H2,(H,23,24)(H2,22,25,26)
DM9PNTQ CS C1CC2=C(C1NC(=O)C3=C(C(=C(C(=C3F)F)F)F)F)C=CC(=C2)S(=O)(=O)N
DM9PNTQ IK GSDOCCQCQXIOCL-UHFFFAOYSA-N
DM9PNTQ IU 2,3,4,5,6-pentafluoro-N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)benzamide
DM9PNTQ DE Discovery agent
DMNUAB9 ID DMNUAB9
DMNUAB9 DN 1-pentenyl-4-(aminosulfonyl)benzoate
DMNUAB9 HS Investigative
DMNUAB9 SN CHEMBL200074; 1-pentenyl-4-(aminosulfonyl)benzoate
DMNUAB9 DT Small molecular drug
DMNUAB9 PC 11630396
DMNUAB9 MW 269.32
DMNUAB9 FM C12H15NO4S
DMNUAB9 IC InChI=1S/C12H15NO4S/c1-2-3-4-9-17-12(14)10-5-7-11(8-6-10)18(13,15)16/h2,5-8H,1,3-4,9H2,(H2,13,15,16)
DMNUAB9 CS C=CCCCOC(=O)C1=CC=C(C=C1)S(=O)(=O)N
DMNUAB9 IK IEMQKTRDDVFPKZ-UHFFFAOYSA-N
DMNUAB9 IU pent-4-enyl 4-sulfamoylbenzoate
DMNUAB9 DE Discovery agent
DMA29SX ID DMA29SX
DMA29SX DN 1-Phenethyl-3,7-dihydro-purine-2,6-dione
DMA29SX HS Investigative
DMA29SX SN CHEMBL67949; 1-Phenethyl-3,7-dihydro-purine-2,6-dione; BDBM50042215
DMA29SX DT Small molecular drug
DMA29SX PC 14969717
DMA29SX MW 256.26
DMA29SX FM C13H12N4O2
DMA29SX IC InChI=1S/C13H12N4O2/c18-12-10-11(15-8-14-10)16-13(19)17(12)7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H,14,15)(H,16,19)
DMA29SX CS C1=CC=C(C=C1)CCN2C(=O)C3=C(NC2=O)N=CN3
DMA29SX IK WZIAGOQSFXTMAJ-UHFFFAOYSA-N
DMA29SX IU 1-(2-phenylethyl)-3,7-dihydropurine-2,6-dione
DMA29SX DE Discovery agent
DM32WSM ID DM32WSM
DM32WSM DN 1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea
DM32WSM HS Investigative
DM32WSM SN Thiourea, N-(2-phenylethyl)-N'-1,3,4-thiadiazol-2-yl-; 149484-90-2; 1-phenethyl-3-(1,3,4-thiadiazol-2-yl)thiourea; PETT Analog 48; AC1MHDKZ; PETT Thiadiazol deriv.; SCHEMBL8886004; BDBM1881; CHEMBL144420; DTXSID90164281; 1-(2-phenylethyl)-3-1,3,4-thiadiazol-2-ylthiourea; N-(2-Phenethyl)-N -(2-(1,3,4-thiadiazolyl))thiourea
DM32WSM DT Small molecular drug
DM32WSM PC 3001116
DM32WSM MW 264.4
DM32WSM FM C11H12N4S2
DM32WSM IC InChI=1S/C11H12N4S2/c16-10(14-11-15-13-8-17-11)12-7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,12,14,15,16)
DM32WSM CS C1=CC=C(C=C1)CCNC(=S)NC2=NN=CS2
DM32WSM IK CKSSUWZTRWMHOY-UHFFFAOYSA-N
DM32WSM IU 1-(2-phenylethyl)-3-(1,3,4-thiadiazol-2-yl)thiourea
DM32WSM CA CAS 149484-90-2
DM32WSM DE Discovery agent
DM0DH98 ID DM0DH98
DM0DH98 DN 1-phenyl-1-(piperidin-2-yl)propan-2-one
DM0DH98 HS Investigative
DM0DH98 SN CHEMBL219540; 1-phenyl-1-(piperidin-2-yl)propan-2-one
DM0DH98 DT Small molecular drug
DM0DH98 PC 16102777
DM0DH98 MW 217.31
DM0DH98 FM C14H19NO
DM0DH98 IC InChI=1S/C14H19NO/c1-11(16)14(12-7-3-2-4-8-12)13-9-5-6-10-15-13/h2-4,7-8,13-15H,5-6,9-10H2,1H3
DM0DH98 CS CC(=O)C(C1CCCCN1)C2=CC=CC=C2
DM0DH98 IK IYNBYQDXVFMDGE-UHFFFAOYSA-N
DM0DH98 IU 1-phenyl-1-piperidin-2-ylpropan-2-one
DM0DH98 DE Discovery agent
DMGV6BI ID DMGV6BI
DMGV6BI DN 1-Phenyl-1H-benzoimidazol-5-ol
DMGV6BI HS Investigative
DMGV6BI SN 1-Phenyl-5-hydroxybenzimidazole; 1-phenyl-1H-Benzimidazol-5-ol; 69445-45-0; 1-Phenylbenzimidazole deriv. 65; AC1LDIKP; 1-phenylbenzimidazol-5-ol; CHEMBL80873; SCHEMBL4280861; BDBM3848; 5-hydroxy-1-phenylbenzimidazole; CTK5C9901; ZINC17525; DTXSID70349872; 1-Phenyl-1H-benzimidazole-5-ol; 1H-Benzimidazol-5-ol,1-phenyl-; OQAPWZCMAFFBBL-UHFFFAOYSA-N; 1-phenyl-1H-1,3-benzodiazol-5-ol; AKOS022650144; 5-Substituted 1-Phenylbenzimidazole 5; DA-04176; KB-219704; FT-0734974
DMGV6BI DT Small molecular drug
DMGV6BI PC 667662
DMGV6BI MW 210.23
DMGV6BI FM C13H10N2O
DMGV6BI IC InChI=1S/C13H10N2O/c16-11-6-7-13-12(8-11)14-9-15(13)10-4-2-1-3-5-10/h1-9,16H
DMGV6BI CS C1=CC=C(C=C1)N2C=NC3=C2C=CC(=C3)O
DMGV6BI IK OQAPWZCMAFFBBL-UHFFFAOYSA-N
DMGV6BI IU 1-phenylbenzimidazol-5-ol
DMGV6BI CA CAS 69445-45-0
DMGV6BI DE Discovery agent
DM8YPH0 ID DM8YPH0
DM8YPH0 DN 1-Phenyl-1H-benzoimidazole
DM8YPH0 HS Investigative
DM8YPH0 SN 1-Phenyl-1H-benzoimidazole; 2622-60-8; 1-phenyl-1H-benzo[d]imidazole; 1-phenylbenzimidazole; 1-Phenyl-1H-benzimidazole; 97542-80-8; 1H-Benzimidazole,1-phenyl-; BAS 00350928; 1H-Benzimidazole, 1-phenyl-; XNCMQRWVMWLODV-UHFFFAOYSA-N; 1-PHENYL-1H-1,3-BENZODIAZOLE; AK123264; AC1LCTXI; PubChem19972; 1-Phenyl benzoimidazole; 1-Phenylbenzimidazole 3; phenyl-1H- Benzimidazole; 1-phenyl-1,3-benzodiazole; MLS000765952; SCHEMBL157265; 1-Phenyl-1H-benzimidazole #; CHEMBL310080; BDBM3794; CTK4F7433; DTXSID10345732; 1-Phenylbenzimidazole deriv.
DM8YPH0 DT Small molecular drug
DM8YPH0 PC 606669
DM8YPH0 MW 194.23
DM8YPH0 FM C13H10N2
DM8YPH0 IC InChI=1S/C13H10N2/c1-2-6-11(7-3-1)15-10-14-12-8-4-5-9-13(12)15/h1-10H
DM8YPH0 CS C1=CC=C(C=C1)N2C=NC3=CC=CC=C32
DM8YPH0 IK XNCMQRWVMWLODV-UHFFFAOYSA-N
DM8YPH0 IU 1-phenylbenzimidazole
DM8YPH0 CA CAS 2622-60-8
DM8YPH0 DE Discovery agent
DM74RMP ID DM74RMP
DM74RMP DN 1-phenyl-1H-indole-2,3-dione
DM74RMP HS Investigative
DM74RMP SN 1-Phenylisatin; 723-89-7; 1-Phenylindoline-2,3-dione; 1-Phenyl-1H-indole-2,3-dione; 1-phenylindole-2,3-dione; 1H-Indole-2,3-dione, 1-phenyl-; 1-Phenyl-indole-2,3-dione; INDOLE-2,3-DIONE, 1-PHENYL-; NSC 100013; BRN 0164531; 1H-Indole-2,3-dione, 1-phenyl- (9CI); 1-phenyl-2,3-dihydro-1H-indole-2,3-dione; UWCPWBIMRYXUOU-UHFFFAOYSA-N; AE-641/30401023; N-Phenylisatin; SMR000131753; phenylisatin; phenylindoledione; Phenyl Isatin; N-phenyl isatin; 1-phenyl isatin; NSC100013; 1-Phenylisatin,98%; 1-Phenylisatin, 97%; Isatin-based compound,
DM74RMP DT Small molecular drug
DM74RMP PC 12884
DM74RMP MW 223.23
DM74RMP FM C14H9NO2
DM74RMP IC InChI=1S/C14H9NO2/c16-13-11-8-4-5-9-12(11)15(14(13)17)10-6-2-1-3-7-10/h1-9H
DM74RMP CS C1=CC=C(C=C1)N2C3=CC=CC=C3C(=O)C2=O
DM74RMP IK UWCPWBIMRYXUOU-UHFFFAOYSA-N
DM74RMP IU 1-phenylindole-2,3-dione
DM74RMP CA CAS 723-89-7
DM74RMP DE Discovery agent
DMZM9AI ID DMZM9AI
DMZM9AI DN 1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone
DMZM9AI HS Investigative
DMZM9AI SN CHEMBL1082497; 1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone
DMZM9AI DT Small molecular drug
DMZM9AI PC 46890243
DMZM9AI MW 279.29
DMZM9AI FM C16H13N3O2
DMZM9AI IC InChI=1S/C16H13N3O2/c20-15(13-7-3-1-4-8-13)12-21-16-11-17-18-19(16)14-9-5-2-6-10-14/h1-11H,12H2
DMZM9AI CS C1=CC=C(C=C1)C(=O)COC2=CN=NN2C3=CC=CC=C3
DMZM9AI IK NFBZAZXCZDAVSL-UHFFFAOYSA-N
DMZM9AI IU 1-phenyl-2-(3-phenyltriazol-4-yl)oxyethanone
DMZM9AI DE Discovery agent
DMW9CRT ID DMW9CRT
DMW9CRT DN 1-Phenyl-2-p-tolyl-ethane-1,2-dione
DMW9CRT HS Investigative
DMW9CRT SN p-Methylbenzil; 4-Methylbenzil; 2431-00-7; Ethanedione, (4-methylphenyl)phenyl-; 1-(4-methylphenyl)-2-phenylethane-1,2-dione; 1-(4-methylphenyl)-2-phenyl-ethane-1,2-dione; ethanedione,(4-methylphenyl)phenyl-; EINECS 219-396-3; 1-Phenyl-2-(p-tolyl)ethane-1,2-dione; AC1Q5DTY; AC1L2OX0; Benzil-based compound, 17; SCHEMBL2157002; CHEMBL371858; CTK1A7291; BDBM22739; (4-Methylphenyl)phenylethanedione; DTXSID80179046; QKFICTUTRIMBEX-UHFFFAOYSA-N; ZINC1841234; 1-Phenyl-2-p-tolylethane-1,2-dione; AKOS023905136
DMW9CRT DT Small molecular drug
DMW9CRT PC 75511
DMW9CRT MW 224.25
DMW9CRT FM C15H12O2
DMW9CRT IC InChI=1S/C15H12O2/c1-11-7-9-13(10-8-11)15(17)14(16)12-5-3-2-4-6-12/h2-10H,1H3
DMW9CRT CS CC1=CC=C(C=C1)C(=O)C(=O)C2=CC=CC=C2
DMW9CRT IK QKFICTUTRIMBEX-UHFFFAOYSA-N
DMW9CRT IU 1-(4-methylphenyl)-2-phenylethane-1,2-dione
DMW9CRT CA CAS 2431-00-7
DMW9CRT DE Discovery agent
DM8EDI7 ID DM8EDI7
DM8EDI7 DN 1-Phenyl-2-pyridin-3-yl-propan-1-one
DM8EDI7 HS Investigative
DM8EDI7 SN CHEMBL53248; 62144-16-5; 1-phenyl-2-pyridin-3-yl-propan-1-one; alpha-(3-Pyridyl)propiophenone; SCHEMBL4810062; CTK2C6291; DTXSID40463372; BDBM50028159; 1-phenyl-2-(3-pyridinyl)-1-propanone; 1-Propanone, 1-phenyl-2-(3-pyridinyl)-
DM8EDI7 DT Small molecular drug
DM8EDI7 PC 11356288
DM8EDI7 MW 211.26
DM8EDI7 FM C14H13NO
DM8EDI7 IC InChI=1S/C14H13NO/c1-11(13-8-5-9-15-10-13)14(16)12-6-3-2-4-7-12/h2-11H,1H3
DM8EDI7 CS CC(C1=CN=CC=C1)C(=O)C2=CC=CC=C2
DM8EDI7 IK NFHIPZYAYZPXJE-UHFFFAOYSA-N
DM8EDI7 IU 1-phenyl-2-pyridin-3-ylpropan-1-one
DM8EDI7 CA CAS 62144-16-5
DM8EDI7 DE Discovery agent
DM6QU5B ID DM6QU5B
DM6QU5B DN 1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea
DM6QU5B HS Investigative
DM6QU5B SN 1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea; CHEMBL1253381; AC1LHWR1; SCHEMBL13779380; MolPort-002-153-004; ZINC436272; BDBM50326573; AKOS000986880; MCULE-5997854144; SDCCGMLS-0064737.P001; ST50980881; AB00086777-01; SR-01000210707; SR-01000210707-1; Z56753795; (phenylamino)(1,3,4-thiadiazol-2-ylamino)methane-1-thione
DM6QU5B DT Small molecular drug
DM6QU5B PC 870537
DM6QU5B MW 236.3
DM6QU5B FM C9H8N4S2
DM6QU5B IC InChI=1S/C9H8N4S2/c14-8(12-9-13-10-6-15-9)11-7-4-2-1-3-5-7/h1-6H,(H2,11,12,13,14)
DM6QU5B CS C1=CC=C(C=C1)NC(=S)NC2=NN=CS2
DM6QU5B IK CSUHGRXUQXQHRB-UHFFFAOYSA-N
DM6QU5B IU 1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea
DM6QU5B DE Discovery agent
DMCHOFK ID DMCHOFK
DMCHOFK DN 1-Phenyl-3-(1-propionylpiperidin-4-yl)urea
DMCHOFK HS Investigative
DMCHOFK SN CHEMBL1256163; 1-Phenyl-3-(1-propionylpiperidin-4-yl)urea; SCHEMBL2729525; BDBM50327829
DMCHOFK DT Small molecular drug
DMCHOFK PC 47379737
DMCHOFK MW 275.35
DMCHOFK FM C15H21N3O2
DMCHOFK IC InChI=1S/C15H21N3O2/c1-2-14(19)18-10-8-13(9-11-18)17-15(20)16-12-6-4-3-5-7-12/h3-7,13H,2,8-11H2,1H3,(H2,16,17,20)
DMCHOFK CS CCC(=O)N1CCC(CC1)NC(=O)NC2=CC=CC=C2
DMCHOFK IK XOEKGIBLQVJFBB-UHFFFAOYSA-N
DMCHOFK IU 1-phenyl-3-(1-propanoylpiperidin-4-yl)urea
DMCHOFK DE Discovery agent
DM9SKYC ID DM9SKYC
DM9SKYC DN 1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea
DM9SKYC HS Investigative
DM9SKYC SN CHEMBL423311; 1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea; BDBM50088476; 1-[2-(2-Pyridyl)-4-quinazolinyl]-3-phenylurea
DM9SKYC DT Small molecular drug
DM9SKYC PC 10712256
DM9SKYC MW 341.4
DM9SKYC FM C20H15N5O
DM9SKYC IC InChI=1S/C20H15N5O/c26-20(22-14-8-2-1-3-9-14)25-18-15-10-4-5-11-16(15)23-19(24-18)17-12-6-7-13-21-17/h1-13H,(H2,22,23,24,25,26)
DM9SKYC CS C1=CC=C(C=C1)NC(=O)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=N4
DM9SKYC IK XZUXPDFYRHJJLN-UHFFFAOYSA-N
DM9SKYC IU 1-phenyl-3-(2-pyridin-2-ylquinazolin-4-yl)urea
DM9SKYC DE Discovery agent
DMQKB6W ID DMQKB6W
DMQKB6W DN 1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea
DMQKB6W HS Investigative
DMQKB6W SN CHEMBL305512; 1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea; BDBM50088462; 1-[2-(3-Pyridyl)-4-quinazolinyl]-3-phenylurea
DMQKB6W DT Small molecular drug
DMQKB6W PC 10688595
DMQKB6W MW 341.4
DMQKB6W FM C20H15N5O
DMQKB6W IC InChI=1S/C20H15N5O/c26-20(22-15-8-2-1-3-9-15)25-19-16-10-4-5-11-17(16)23-18(24-19)14-7-6-12-21-13-14/h1-13H,(H2,22,23,24,25,26)
DMQKB6W CS C1=CC=C(C=C1)NC(=O)NC2=NC(=NC3=CC=CC=C32)C4=CN=CC=C4
DMQKB6W IK GDOLLVJHBJTNPM-UHFFFAOYSA-N
DMQKB6W IU 1-phenyl-3-(2-pyridin-3-ylquinazolin-4-yl)urea
DMQKB6W DE Discovery agent
DMJVITG ID DMJVITG
DMJVITG DN 1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea
DMJVITG HS Investigative
DMJVITG SN acyclic urea, 1; CHEMBL392228; BDBM20816
DMJVITG DT Small molecular drug
DMJVITG PC 24768279
DMJVITG MW 296.3
DMJVITG FM C15H12N4OS
DMJVITG IC InChI=1S/C15H12N4OS/c20-15(17-12-4-2-1-3-5-12)19-13-10-21-14(18-13)11-6-8-16-9-7-11/h1-10H,(H2,17,19,20)
DMJVITG CS C1=CC=C(C=C1)NC(=O)NC2=CSC(=N2)C3=CC=NC=C3
DMJVITG IK AXDWPTZOIRLDDO-UHFFFAOYSA-N
DMJVITG IU 1-phenyl-3-(2-pyridin-4-yl-1,3-thiazol-4-yl)urea
DMJVITG DE Discovery agent
DMJNAX5 ID DMJNAX5
DMJNAX5 DN 1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea
DMJNAX5 HS Investigative
DMJNAX5 SN CHEMBL70553; 1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea; BDBM50088465; 1-Phenyl-3-[3-(2-pyridyl)-1-isoquinolyl]urea
DMJNAX5 DT Small molecular drug
DMJNAX5 PC 10640891
DMJNAX5 MW 340.4
DMJNAX5 FM C21H16N4O
DMJNAX5 IC InChI=1S/C21H16N4O/c26-21(23-16-9-2-1-3-10-16)25-20-17-11-5-4-8-15(17)14-19(24-20)18-12-6-7-13-22-18/h1-14H,(H2,23,24,25,26)
DMJNAX5 CS C1=CC=C(C=C1)NC(=O)NC2=NC(=CC3=CC=CC=C32)C4=CC=CC=N4
DMJNAX5 IK IJXVHHOSRPNGFG-UHFFFAOYSA-N
DMJNAX5 IU 1-phenyl-3-(3-pyridin-2-ylisoquinolin-1-yl)urea
DMJNAX5 DE Discovery agent
DMJ723D ID DMJ723D
DMJ723D DN 1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea
DMJ723D HS Investigative
DMJ723D SN CHEMBL164422; 1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea; TCMDC-143133; BDBM50097425; AKOS028168115; 1-Phenyl-3-[4-(2-pyridyl)-2-thiazolyl]urea
DMJ723D DT Small molecular drug
DMJ723D PC 10590030
DMJ723D MW 296.3
DMJ723D FM C15H12N4OS
DMJ723D IC InChI=1S/C15H12N4OS/c20-14(17-11-6-2-1-3-7-11)19-15-18-13(10-21-15)12-8-4-5-9-16-12/h1-10H,(H2,17,18,19,20)
DMJ723D CS C1=CC=C(C=C1)NC(=O)NC2=NC(=CS2)C3=CC=CC=N3
DMJ723D IK SDGJJDKFCDDMKK-UHFFFAOYSA-N
DMJ723D IU 1-phenyl-3-(4-pyridin-2-yl-1,3-thiazol-2-yl)urea
DMJ723D DE Discovery agent
DM8ZBHF ID DM8ZBHF
DM8ZBHF DN 1-phenyl-3-(phenylsulfonyl)propan-1-one
DM8ZBHF HS Investigative
DM8ZBHF SN 1-phenyl-3-(phenylsulfonyl)propan-1-one; CHEMBL240292; ZINC28874843
DM8ZBHF DT Small molecular drug
DM8ZBHF PC 44437631
DM8ZBHF MW 274.3
DM8ZBHF FM C15H14O3S
DM8ZBHF IC InChI=1S/C15H14O3S/c16-15(13-7-3-1-4-8-13)11-12-19(17,18)14-9-5-2-6-10-14/h1-10H,11-12H2
DM8ZBHF CS C1=CC=C(C=C1)C(=O)CCS(=O)(=O)C2=CC=CC=C2
DM8ZBHF IK IOTOILGYCOMTGK-UHFFFAOYSA-N
DM8ZBHF IU 3-(benzenesulfonyl)-1-phenylpropan-1-one
DM8ZBHF CA CAS 65885-28-1
DM8ZBHF DE Discovery agent
DMZOEQY ID DMZOEQY
DMZOEQY DN 1-phenyl-3-(quinazolin-4-yl)urea
DMZOEQY HS Investigative
DMZOEQY SN CHEMBL309974; 1-phenyl-3-(quinazolin-4-yl)urea; SCHEMBL4689838; 1-Phenyl-3-quinazolin-4-yl-urea; 1-(4-Quinazolinyl)-3-phenylurea; BDBM50088472
DMZOEQY DT Small molecular drug
DMZOEQY PC 10563562
DMZOEQY MW 264.28
DMZOEQY FM C15H12N4O
DMZOEQY IC InChI=1S/C15H12N4O/c20-15(18-11-6-2-1-3-7-11)19-14-12-8-4-5-9-13(12)16-10-17-14/h1-10H,(H2,16,17,18,19,20)
DMZOEQY CS C1=CC=C(C=C1)NC(=O)NC2=NC=NC3=CC=CC=C32
DMZOEQY IK IYKBZJSFOBYNTL-UHFFFAOYSA-N
DMZOEQY IU 1-phenyl-3-quinazolin-4-ylurea
DMZOEQY DE Discovery agent
DMUA72F ID DMUA72F
DMUA72F DN 1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMUA72F HS Investigative
DMUA72F SN 1-phenyl-3-azabicyclo[3.1.0]hexane; 67644-21-7; 1-phenyl-3-aza-bicyclo[3.1.0]hexane; CHEMBL503383; 1-PHENYL-3-AZABICYCLO(3.1.0)HEXANE; 66505-14-4; SCHEMBL4557697; CTK5C4827; HYXPTPHIWQWOQF-UHFFFAOYSA-N; BDBM50243891; AKOS006370964; 1-phenyl-3-azabicyclo-[3.1.0]hexane; 1-phenyl-3-azabicyclo[3.1.0]-hexane
DMUA72F DT Small molecular drug
DMUA72F PC 10130094
DMUA72F MW 159.23
DMUA72F FM C11H13N
DMUA72F IC InChI=1S/C11H13N/c1-2-4-9(5-3-1)11-6-10(11)7-12-8-11/h1-5,10,12H,6-8H2
DMUA72F CS C1C2C1(CNC2)C3=CC=CC=C3
DMUA72F IK HYXPTPHIWQWOQF-UHFFFAOYSA-N
DMUA72F IU 1-phenyl-3-azabicyclo[3.1.0]hexane
DMUA72F DE Discovery agent
DMKV17L ID DMKV17L
DMKV17L DN 1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one
DMKV17L HS Investigative
DMKV17L SN CHEMBL1083423; 1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one
DMKV17L DT Small molecular drug
DMKV17L PC 46890339
DMKV17L MW 292.33
DMKV17L FM C17H16N4O
DMKV17L IC InChI=1S/C17H16N4O/c22-16(13-14-7-3-1-4-8-14)11-12-17-18-19-20-21(17)15-9-5-2-6-10-15/h1-10H,11-13H2
DMKV17L CS C1=CC=C(C=C1)CC(=O)CCC2=NN=NN2C3=CC=CC=C3
DMKV17L IK FPYZSRILLJGVMX-UHFFFAOYSA-N
DMKV17L IU 1-phenyl-4-(1-phenyltetrazol-5-yl)butan-2-one
DMKV17L DE Discovery agent
DMA4XGL ID DMA4XGL
DMA4XGL DN 1-phenylbiguanide
DMA4XGL HS Investigative
DMA4XGL SN phenylbiguanide; 1-Phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide
DMA4XGL DT Small molecular drug
DMA4XGL PC 4780
DMA4XGL MW 177.21
DMA4XGL FM C8H11N5
DMA4XGL IC InChI=1S/C8H11N5/c9-7(10)13-8(11)12-6-4-2-1-3-5-6/h1-5H,(H6,9,10,11,12,13)
DMA4XGL CS C1=CC=C(C=C1)N=C(N)N=C(N)N
DMA4XGL IK CUQCMXFWIMOWRP-UHFFFAOYSA-N
DMA4XGL IU 1-(diaminomethylidene)-2-phenylguanidine
DMA4XGL CA CAS 102-02-3
DMA4XGL CB CHEBI:75377
DMA4XGL DE Discovery agent
DM04SWY ID DM04SWY
DM04SWY DN 1-Phenyl-propane-1,2-dione
DM04SWY HS Investigative
DM04SWY SN 1-PHENYL-1,2-PROPANEDIONE; 1-Phenylpropane-1,2-dione; 579-07-7; Acetylbenzoyl; Acetyl benzoyl; Benzoylacetyl; 1,2-Propanedione, 1-phenyl-; Methylphenylglyoxal; Pyruvophenone; Phenylmethyldiketone; Benzoyl methyl ketone; Methyl phenyl diketone; 3-Phenyl-2,3-propanedione; Methyl phenyl glyoxal; Phenyl methyl diketone; UNII-ZB5XA3GD0I; 1-phenyl-1,2-propandione; 1-Phenyl-propane-1,2-dione; FEMA No. 3226; CCRIS 6297; NSC 7643; EINECS 209-435-2; ZB5XA3GD0I; AI3-23868; CHEBI:63552; BVQVLAIMHVDZEL-UHFFFAOYSA-N; 1-Phenyl-1,2-propanedione, 98
DM04SWY DT Small molecular drug
DM04SWY PC 11363
DM04SWY MW 148.16
DM04SWY FM C9H8O2
DM04SWY IC InChI=1S/C9H8O2/c1-7(10)9(11)8-5-3-2-4-6-8/h2-6H,1H3
DM04SWY CS CC(=O)C(=O)C1=CC=CC=C1
DM04SWY IK BVQVLAIMHVDZEL-UHFFFAOYSA-N
DM04SWY IU 1-phenylpropane-1,2-dione
DM04SWY CA CAS 579-07-7
DM04SWY CB CHEBI:63552
DM04SWY DE Discovery agent
DM5REQ9 ID DM5REQ9
DM5REQ9 DN 1-phenylthio-N,N-dimethyltryptamine
DM5REQ9 HS Investigative
DM5REQ9 SN CHEMBL253397; 1-phenylthio-N,N-dimethyltryptamine
DM5REQ9 DT Small molecular drug
DM5REQ9 PC 24776941
DM5REQ9 MW 296.4
DM5REQ9 FM C18H20N2S
DM5REQ9 IC InChI=1S/C18H20N2S/c1-19(2)13-12-15-14-20(18-11-7-6-10-17(15)18)21-16-8-4-3-5-9-16/h3-11,14H,12-13H2,1-2H3
DM5REQ9 CS CN(C)CCC1=CN(C2=CC=CC=C21)SC3=CC=CC=C3
DM5REQ9 IK APYJLIWKKMRCGM-UHFFFAOYSA-N
DM5REQ9 IU N,N-dimethyl-2-(1-phenylsulfanylindol-3-yl)ethanamine
DM5REQ9 DE Discovery agent
DMCBX7R ID DMCBX7R
DMCBX7R DN 1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione
DMCBX7R HS Investigative
DMCBX7R SN CHEMBL67415; 1H-Purine-2,6-dione, 3,9-dihydro-1-(2-propyn-1-yl)-; 146830-81-1; 1-propargylxanthine; 1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione; SCHEMBL3423318; BDBM50042217
DMCBX7R DT Small molecular drug
DMCBX7R PC 10219753
DMCBX7R MW 190.16
DMCBX7R FM C8H6N4O2
DMCBX7R IC InChI=1S/C8H6N4O2/c1-2-3-12-7(13)5-6(10-4-9-5)11-8(12)14/h1,4H,3H2,(H,9,10)(H,11,14)
DMCBX7R CS C#CCN1C(=O)C2=C(NC1=O)N=CN2
DMCBX7R IK HJYAFKKSAAYVHQ-UHFFFAOYSA-N
DMCBX7R IU 1-prop-2-ynyl-3,7-dihydropurine-2,6-dione
DMCBX7R DE Discovery agent
DM1TNWG ID DM1TNWG
DM1TNWG DN 1-propionyl-1H-indole-2,3-dione
DM1TNWG HS Investigative
DM1TNWG SN 1-Propionyl-1H-indole-2,3-dione; 17529-69-0; 1-propanoyl-2,3-dihydro-1H-indole-2,3-dione; Propionylisatin; Isatin-based compound, 9; AC1LBV75; 1-propanoylindole-2,3-dione; CHEMBL386000; BDBM22789; MolPort-002-488-122; IHNYAHBLLCMRCD-UHFFFAOYSA-N; ZINC3086180; ZX-AN080727; ALBB-029917; AKOS001849000; 1-Propionyl-1H-indole-2,3-dione #; MCULE-1099895518; CCG-139392; 1H-Indole-2,3-dione, 1-(1-oxopropyl)-; EU-0084456; 1H-Isoindole-2,3(2H)-dione, 1-propionyl-; SR-01000512691
DM1TNWG DT Small molecular drug
DM1TNWG PC 589576
DM1TNWG MW 203.19
DM1TNWG FM C11H9NO3
DM1TNWG IC InChI=1S/C11H9NO3/c1-2-9(13)12-8-6-4-3-5-7(8)10(14)11(12)15/h3-6H,2H2,1H3
DM1TNWG CS CCC(=O)N1C2=CC=CC=C2C(=O)C1=O
DM1TNWG IK IHNYAHBLLCMRCD-UHFFFAOYSA-N
DM1TNWG IU 1-propanoylindole-2,3-dione
DM1TNWG DE Discovery agent
DMOCAUL ID DMOCAUL
DMOCAUL DN 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL HS Investigative
DMOCAUL SN CHEMBL310607; 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
DMOCAUL DT Small molecular drug
DMOCAUL PC 44460502
DMOCAUL MW 257.29
DMOCAUL FM C14H18F3N
DMOCAUL IC InChI=1S/C14H18F3N/c1-2-7-18-8-6-12(10-18)11-4-3-5-13(9-11)14(15,16)17/h3-5,9,12H,2,6-8,10H2,1H3
DMOCAUL CS CCCN1CCC(C1)C2=CC(=CC=C2)C(F)(F)F
DMOCAUL IK YATKXAPVZGTXAR-UHFFFAOYSA-N
DMOCAUL IU 1-propyl-3-[3-(trifluoromethyl)phenyl]pyrrolidine
DMOCAUL DE Discovery agent
DML5J94 ID DML5J94
DML5J94 DN 1-Propyl-3,7-dihydro-purine-2,6-dione
DML5J94 HS Investigative
DML5J94 SN 1-Propylxanthine; 104285-82-7; CHEMBL39986; 1H-Purine-2,6-dione,3,9-dihydro-1-propyl-; 1-Propyl-3,7-dihydro-purine-2,6-dione; ACMC-1BNN6; AC1L2TY0; SCHEMBL4423680; SCHEMBL8930198; CTK4A2909; DTXSID10146367; IWBONKMODGBEOX-UHFFFAOYSA-N; BDBM50001490; 1-propyl-3,7-dihydropurine-2,6-dione; 1H-Purine-2,6-dione, 3,7-dihydro-1-propyl-
DML5J94 DT Small molecular drug
DML5J94 PC 128525
DML5J94 MW 194.19
DML5J94 FM C8H10N4O2
DML5J94 IC InChI=1S/C8H10N4O2/c1-2-3-12-7(13)5-6(10-4-9-5)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,14)
DML5J94 CS CCCN1C(=O)C2=C(NC1=O)N=CN2
DML5J94 IK IWBONKMODGBEOX-UHFFFAOYSA-N
DML5J94 IU 1-propyl-3,7-dihydropurine-2,6-dione
DML5J94 CA CAS 104285-82-7
DML5J94 DE Discovery agent
DM1387P ID DM1387P
DM1387P DN 1-Propyl-3-m-tolyl-piperidine hydrochloride
DM1387P HS Investigative
DM1387P DE Discovery agent
DM1O6KQ ID DM1O6KQ
DM1O6KQ DN 1-Propyl-3-o-tolyl-piperidine hydrochloride
DM1O6KQ HS Investigative
DM1O6KQ DE Discovery agent
DMPMIN9 ID DMPMIN9
DMPMIN9 DN 1-Propyl-3-p-tolyl-piperidine hydrochloride
DMPMIN9 HS Investigative
DMPMIN9 DE Discovery agent
DM5P01L ID DM5P01L
DM5P01L DN 1-propyl-5'-O-tritylinosine
DM5P01L HS Investigative
DM5P01L SN CHEMBL213890; 1-propyl-5''-O-tritylinosine
DM5P01L DT Small molecular drug
DM5P01L PC 16082758
DM5P01L MW 552.6
DM5P01L FM C32H32N4O5
DM5P01L IC InChI=1S/C32H32N4O5/c1-2-18-35-20-34-29-26(30(35)39)33-21-36(29)31-28(38)27(37)25(41-31)19-40-32(22-12-6-3-7-13-22,23-14-8-4-9-15-23)24-16-10-5-11-17-24/h3-17,20-21,25,27-28,31,37-38H,2,18-19H2,1H3/t25-,27-,28-,31-/m1/s1
DM5P01L CS CCCN1C=NC2=C(C1=O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)O)O
DM5P01L IK GTLQVJJXEZWWMS-QWOIFIOOSA-N
DM5P01L IU 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(trityloxymethyl)oxolan-2-yl]-1-propylpurin-6-one
DM5P01L DE Discovery agent
DMXOUFI ID DMXOUFI
DMXOUFI DN 1-Propylidenethiosemicarbazide
DMXOUFI HS Investigative
DMXOUFI SN 1-Propylidenethiosemicarbazide; CHEMBL452107; [(Z)-propylideneamino]thiourea; propionaldehyde thiosemicarbazone; AC1O0DHJ; 22042-87-1; ZINC5447671; BDBM50268175
DMXOUFI DT Small molecular drug
DMXOUFI PC 6036901
DMXOUFI MW 131.2
DMXOUFI FM C4H9N3S
DMXOUFI IC InChI=1S/C4H9N3S/c1-2-3-6-7-4(5)8/h3H,2H2,1H3,(H3,5,7,8)/b6-3-
DMXOUFI CS CC/C=N\\NC(=S)N
DMXOUFI IK SREKQYKLPZJBJG-UTCJRWHESA-N
DMXOUFI IU [(Z)-propylideneamino]thiourea
DMXOUFI DE Discovery agent
DMTMXN4 ID DMTMXN4
DMTMXN4 DN 1-Pyridin-2-yl-3-quinolin-5-yl-urea
DMTMXN4 HS Investigative
DMTMXN4 SN Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea
DMTMXN4 DT Small molecular drug
DMTMXN4 PC 5330598
DMTMXN4 MW 264.28
DMTMXN4 FM C15H12N4O
DMTMXN4 IC InChI=1S/C15H12N4O/c20-15(19-14-8-1-2-9-17-14)18-13-7-3-6-12-11(13)5-4-10-16-12/h1-10H,(H2,17,18,19,20)
DMTMXN4 CS C1=CC=NC(=C1)NC(=O)NC2=CC=CC3=C2C=CC=N3
DMTMXN4 IK XJYQTPJBOGSWBE-UHFFFAOYSA-N
DMTMXN4 IU 1-pyridin-2-yl-3-quinolin-5-ylurea
DMTMXN4 DE Discovery agent
DM7Y5AN ID DM7Y5AN
DM7Y5AN DN 1S,2R-milnacipran
DM7Y5AN HS Investigative
DM7Y5AN SN CHEMBL471001; AC1MHWCG; SCHEMBL1707471; ZINC5649654; BDBM50275771; NCGC00165825-02; AJ-54473; FT-0696627; cyclopropanecarboxamide,2-(aminomethyl)-n,n-diethyl-1-phenyl-, (1r,2s)-; N,N-Diethyl-1-phenyl-2alpha-(aminomethyl)cyclopropane-1beta-carboxamide
DM7Y5AN DT Small molecular drug
DM7Y5AN PC 3033806
DM7Y5AN MW 246.35
DM7Y5AN FM C15H22N2O
DM7Y5AN IC InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15-/m0/s1
DM7Y5AN CS CCN(CC)C(=O)[C@@]1(C[C@H]1CN)C2=CC=CC=C2
DM7Y5AN IK GJJFMKBJSRMPLA-ZFWWWQNUSA-N
DM7Y5AN IU (1R,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DM7Y5AN DE Discovery agent
DM7K0B3 ID DM7K0B3
DM7K0B3 DN 1-stearoyl-lysophosphatidylcholine
DM7K0B3 HS Investigative
DM7K0B3 SN LPC 18:0; lysophosphatidylcholine (18:0); stearoyl alpha-lysolecithin
DM7K0B3 DT Small molecular drug
DM7K0B3 PC 497299
DM7K0B3 MW 523.7
DM7K0B3 FM C26H54NO7P
DM7K0B3 IC InChI=1S/C26H54NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26(29)32-23-25(28)24-34-35(30,31)33-22-21-27(2,3)4/h25,28H,5-24H2,1-4H3/t25-/m1/s1
DM7K0B3 CS CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DM7K0B3 IK IHNKQIMGVNPMTC-RUZDIDTESA-N
DM7K0B3 IU [(2R)-2-hydroxy-3-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DM7K0B3 CA CAS 19420-57-6
DM7K0B3 CB CHEBI:73858
DM7K0B3 DE Discovery agent
DMPSM4O ID DMPSM4O
DMPSM4O DN 1-tert-butyl-9H-carbazole
DMPSM4O HS Investigative
DMPSM4O SN 1-tert-butyl-9H-carbazole; CHEMBL1172393; t-butyl carbazole; SCHEMBL3866477
DMPSM4O DT Small molecular drug
DMPSM4O PC 18504802
DMPSM4O MW 223.31
DMPSM4O FM C16H17N
DMPSM4O IC InChI=1S/C16H17N/c1-16(2,3)13-9-6-8-12-11-7-4-5-10-14(11)17-15(12)13/h4-10,17H,1-3H3
DMPSM4O CS CC(C)(C)C1=CC=CC2=C1NC3=CC=CC=C23
DMPSM4O IK BKPDQETYXNGMRE-UHFFFAOYSA-N
DMPSM4O IU 1-tert-butyl-9H-carbazole
DMPSM4O DE Discovery agent
DMAQKO1 ID DMAQKO1
DMAQKO1 DN 1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea
DMAQKO1 HS Investigative
DMAQKO1 SN Thiourea, N-(2-(2-methylphenyl)ethyl)-N'-2-thiazolyl-; 149486-23-7; PETT Analog 8; Thiourea, N-[2-(2-methylphenyl)ethyl]-N'-2-thiazolyl-; AC1MHDME; BDBM1901; CHEMBL254207; SCHEMBL6955476; DTXSID90164302; ZINC13744851; AKOS030030934; 1-[2-(o-tolyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-methylphenethyl]thiourea; N-(2-(2-Methylphenethyl))-N -(2-thiazolyl)thiourea; 1-[2-(2-methylphenyl)ethyl]-3-1,3-thiazol-2-ylthiourea
DMAQKO1 DT Small molecular drug
DMAQKO1 PC 3001167
DMAQKO1 MW 277.4
DMAQKO1 FM C13H15N3S2
DMAQKO1 IC InChI=1S/C13H15N3S2/c1-10-4-2-3-5-11(10)6-7-14-12(17)16-13-15-8-9-18-13/h2-5,8-9H,6-7H2,1H3,(H2,14,15,16,17)
DMAQKO1 CS CC1=CC=CC=C1CCNC(=S)NC2=NC=CS2
DMAQKO1 IK VTSYVNSWDAGAAS-UHFFFAOYSA-N
DMAQKO1 IU 1-[2-(2-methylphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMAQKO1 CA CAS 149486-23-7
DMAQKO1 DE Discovery agent
DMCIA40 ID DMCIA40
DMCIA40 DN 1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea
DMCIA40 HS Investigative
DMCIA40 SN CHEMBL149100; 149484-92-4; Thiourea, N-[2-(4-methylphenyl)ethyl]-N'-2-thiazolyl-; AC1MHEHT; ACMC-20n5ps; 1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea; SCHEMBL6284717; CTK0B1828; DTXSID70388246; BDBM50097037; AKOS030030944; 1-[2-(p-tolyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(4-Methylphenethyl)-3-(2-thiazolyl)thiourea; [2-(4-Methylphenyl)ethyl]-N''-[2-(thiazolyl)]thiourea
DMCIA40 DT Small molecular drug
DMCIA40 PC 3003030
DMCIA40 MW 277.4
DMCIA40 FM C13H15N3S2
DMCIA40 IC InChI=1S/C13H15N3S2/c1-10-2-4-11(5-3-10)6-7-14-12(17)16-13-15-8-9-18-13/h2-5,8-9H,6-7H2,1H3,(H2,14,15,16,17)
DMCIA40 CS CC1=CC=C(C=C1)CCNC(=S)NC2=NC=CS2
DMCIA40 IK SIJMMWOYIWBAFY-UHFFFAOYSA-N
DMCIA40 IU 1-[2-(4-methylphenyl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
DMCIA40 CA CAS 149484-92-4
DMCIA40 DE Discovery agent
DM9SYEP ID DM9SYEP
DM9SYEP DN 1'-tosylspiro[indene-1,4'-piperidine]
DM9SYEP HS Investigative
DM9SYEP SN CHEMBL341490; SCHEMBL7381332; VRVIZJNFYYAUKC-UHFFFAOYSA-N; ZINC13728182; BDBM50001405; L-342643; 1'-((4-Methylphenyl)sulfonyl)spiro(1H-indene-1,4'-piperidine)
DM9SYEP DT Small molecular drug
DM9SYEP PC 9797987
DM9SYEP MW 339.5
DM9SYEP FM C20H21NO2S
DM9SYEP IC InChI=1S/C20H21NO2S/c1-16-6-8-18(9-7-16)24(22,23)21-14-12-20(13-15-21)11-10-17-4-2-3-5-19(17)20/h2-11H,12-15H2,1H3
DM9SYEP CS CC1=CC=C(C=C1)S(=O)(=O)N2CCC3(CC2)C=CC4=CC=CC=C34
DM9SYEP IK VRVIZJNFYYAUKC-UHFFFAOYSA-N
DM9SYEP IU 1'-(4-methylphenyl)sulfonylspiro[indene-1,4'-piperidine]
DM9SYEP DE Discovery agent
DM9ZRU2 ID DM9ZRU2
DM9ZRU2 DN 1-valproylamido-5-sulfonamidoindane
DM9ZRU2 HS Investigative
DM9ZRU2 SN CHEMBL204941; 1-valproylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 11a; BDBM11030
DM9ZRU2 DT Small molecular drug
DM9ZRU2 PC 11638641
DM9ZRU2 MW 338.5
DM9ZRU2 FM C17H26N2O3S
DM9ZRU2 IC InChI=1S/C17H26N2O3S/c1-3-5-12(6-4-2)17(20)19-16-10-7-13-11-14(23(18,21)22)8-9-15(13)16/h8-9,11-12,16H,3-7,10H2,1-2H3,(H,19,20)(H2,18,21,22)
DM9ZRU2 CS CCCC(CCC)C(=O)NC1CCC2=C1C=CC(=C2)S(=O)(=O)N
DM9ZRU2 IK FCGKZIRRZCVIGR-UHFFFAOYSA-N
DM9ZRU2 IU 2-propyl-N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)pentanamide
DM9ZRU2 DE Discovery agent
DM1TK45 ID DM1TK45
DM1TK45 DN 2-((1H-imidazol-4-yl)methyl)pyridine
DM1TK45 HS Investigative
DM1TK45 SN CHEMBL81644; 2-((1H-imidazol-4-yl)methyl)pyridine; BDBM50326296
DM1TK45 DT Small molecular drug
DM1TK45 PC 9877454
DM1TK45 MW 159.19
DM1TK45 FM C9H9N3
DM1TK45 IC InChI=1S/C9H9N3/c1-2-4-11-8(3-1)5-9-6-10-7-12-9/h1-4,6-7H,5H2,(H,10,12)
DM1TK45 CS C1=CC=NC(=C1)CC2=CN=CN2
DM1TK45 IK YSOIYRCVNZBHGT-UHFFFAOYSA-N
DM1TK45 IU 2-(1H-imidazol-5-ylmethyl)pyridine
DM1TK45 CA CAS 87976-01-0
DM1TK45 DE Discovery agent
DM91PA5 ID DM91PA5
DM91PA5 DN 2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine
DM91PA5 HS Investigative
DM91PA5 SN CHEMBL495543; 2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine
DM91PA5 DT Small molecular drug
DM91PA5 PC 12226576
DM91PA5 MW 279.37
DM91PA5 FM C16H25NO3
DM91PA5 IC InChI=1S/C16H25NO3/c1-4-18-15-7-5-6-8-16(15)20-12-14-11-17(13(2)3)9-10-19-14/h5-8,13-14H,4,9-12H2,1-3H3
DM91PA5 CS CCOC1=CC=CC=C1OCC2CN(CCO2)C(C)C
DM91PA5 IK YIUUQQVMBNHWQV-UHFFFAOYSA-N
DM91PA5 IU 2-[(2-ethoxyphenoxy)methyl]-4-propan-2-ylmorpholine
DM91PA5 DE Discovery agent
DMS1AOK ID DMS1AOK
DMS1AOK DN 2-((2-iodophenoxy)(phenyl)methyl)morpholine
DMS1AOK HS Investigative
DMS1AOK SN CHEMBL396328; 2-((2-iodophenoxy)(phenyl)methyl)morpholine
DMS1AOK DT Small molecular drug
DMS1AOK PC 44438550
DMS1AOK MW 395.23
DMS1AOK FM C17H18INO2
DMS1AOK IC InChI=1S/C17H18INO2/c18-14-8-4-5-9-15(14)21-17(13-6-2-1-3-7-13)16-12-19-10-11-20-16/h1-9,16-17,19H,10-12H2
DMS1AOK CS C1COC(CN1)C(C2=CC=CC=C2)OC3=CC=CC=C3I
DMS1AOK IK BHMLFPOTZYRDKA-UHFFFAOYSA-N
DMS1AOK IU 2-[(2-iodophenoxy)-phenylmethyl]morpholine
DMS1AOK DE Discovery agent
DM1BI65 ID DM1BI65
DM1BI65 DN 2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DM1BI65 HS Investigative
DM1BI65 DT Small molecular drug
DM1BI65 PC 44417638
DM1BI65 DE Discovery agent
DMS21CR ID DMS21CR
DMS21CR DN 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
DMS21CR HS Investigative
DMS21CR SN CHEMBL439030; 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
DMS21CR DT Small molecular drug
DMS21CR PC 44438489
DMS21CR MW 409.3
DMS21CR FM C18H20INO2
DMS21CR IC InChI=1S/C18H20INO2/c1-13-5-2-3-8-16(13)22-18(17-12-20-9-10-21-17)14-6-4-7-15(19)11-14/h2-8,11,17-18,20H,9-10,12H2,1H3
DMS21CR CS CC1=CC=CC=C1OC(C2CNCCO2)C3=CC(=CC=C3)I
DMS21CR IK GUJGIDDFMFZKIV-UHFFFAOYSA-N
DMS21CR IU 2-[(3-iodophenyl)-(2-methylphenoxy)methyl]morpholine
DMS21CR DE Discovery agent
DMFXDY3 ID DMFXDY3
DMFXDY3 DN 2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid
DMFXDY3 HS Investigative
DMFXDY3 SN CHEMBL602385; 2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid
DMFXDY3 DT Small molecular drug
DMFXDY3 PC 46227565
DMFXDY3 MW 213.32
DMFXDY3 FM C12H23NO2
DMFXDY3 IC InChI=1S/C12H23NO2/c1-2-3-4-10-5-6-12(7-10,9-13)8-11(14)15/h10H,2-9,13H2,1H3,(H,14,15)
DMFXDY3 CS CCCCC1CCC(C1)(CC(=O)O)CN
DMFXDY3 IK USZXKKPNEFLRDV-UHFFFAOYSA-N
DMFXDY3 IU 2-[1-(aminomethyl)-3-butylcyclopentyl]acetic acid
DMFXDY3 DE Discovery agent
DM1ASK6 ID DM1ASK6
DM1ASK6 DN 2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid
DM1ASK6 HS Investigative
DM1ASK6 SN CHEMBL594478; 2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid; SCHEMBL5433016; BDBM50304693
DM1ASK6 DT Small molecular drug
DM1ASK6 PC 21879702
DM1ASK6 MW 185.26
DM1ASK6 FM C10H19NO2
DM1ASK6 IC InChI=1S/C10H19NO2/c1-2-8-3-4-10(5-8,7-11)6-9(12)13/h8H,2-7,11H2,1H3,(H,12,13)
DM1ASK6 CS CCC1CCC(C1)(CC(=O)O)CN
DM1ASK6 IK JUNVYYPZXPVIAH-UHFFFAOYSA-N
DM1ASK6 IU 2-[1-(aminomethyl)-3-ethylcyclopentyl]acetic acid
DM1ASK6 DE Discovery agent
DM3D8WI ID DM3D8WI
DM3D8WI DN 2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine
DM3D8WI HS Investigative
DM3D8WI SN CHEMBL363275; SCHEMBL1357126; BDBM21341; N1-Phenylsulfonyltryptamine, 11a
DM3D8WI DT Small molecular drug
DM3D8WI PC 21071574
DM3D8WI MW 300.4
DM3D8WI FM C16H16N2O2S
DM3D8WI IC InChI=1S/C16H16N2O2S/c17-11-10-13-12-18(16-9-5-4-8-15(13)16)21(19,20)14-6-2-1-3-7-14/h1-9,12H,10-11,17H2
DM3D8WI CS C1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)CCN
DM3D8WI IK GSOZASAZEKGFMK-UHFFFAOYSA-N
DM3D8WI IU 2-[1-(benzenesulfonyl)indol-3-yl]ethanamine
DM3D8WI DE Discovery agent
DMUE0D6 ID DMUE0D6
DMUE0D6 DN 2-(1,1'-Biphenyl-4-Yl)Propanoic Acid
DMUE0D6 HS Investigative
DMUE0D6 SN alpha-Methyl-4-biphenylacetic acid; 6341-72-6; BPPA; NSC 16300; Ly 71130; 2-(p-Biphenyl)propionic acid; 2-(4-phenylphenyl)propanoic acid; 4-BIPHENYLACETIC ACID, alpha-METHYL-; CHEMBL317434; 2-Biphenyl-4-yl-propionic acid; Biprofen; 2-(4-Biphenylyl)propionic Acid; (1,1'-Biphenyl)-4-acetic acid, alpha-methyl-; 2-[1,1'-biphenyl]-4-ylpropanoic acid; [1,1'-Biphenyl]-4-aceticacid, a-methyl-; [1,1'-Biphenyl]-4-acetic acid, alpha-methyl-; alpha-Methyl-4-biphenyl-acetic acid; p-Phenylhydratropic Acid; 2-(4-Biphenyl)propionic acid,; Alpha-Methyl-4-biphenyl-acetic acid
DMUE0D6 DT Small molecular drug
DMUE0D6 PC 448006
DMUE0D6 MW 226.27
DMUE0D6 FM C15H14O2
DMUE0D6 IC InChI=1S/C15H14O2/c1-11(15(16)17)12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-11H,1H3,(H,16,17)/t11-/m0/s1
DMUE0D6 CS C[C@@H](C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O
DMUE0D6 IK JALUUBQFLPUJMY-NSHDSACASA-N
DMUE0D6 IU (2S)-2-(4-phenylphenyl)propanoic acid
DMUE0D6 CA CAS 10532-14-6
DMUE0D6 DE Discovery agent
DMZ83G9 ID DMZ83G9
DMZ83G9 DN 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine
DMZ83G9 HS Investigative
DMZ83G9 SN CHEMBL583693; SCHEMBL12041243; BDBM50299006
DMZ83G9 DT Small molecular drug
DMZ83G9 PC 45482707
DMZ83G9 MW 302.4
DMZ83G9 FM C16H22N4S
DMZ83G9 IC InChI=1S/C16H22N4S/c1-2-9-19(10-3-1)13-6-11-20(12-7-13)16-18-15-14(21-16)5-4-8-17-15/h4-5,8,13H,1-3,6-7,9-12H2
DMZ83G9 CS C1CCN(CC1)C2CCN(CC2)C3=NC4=C(S3)C=CC=N4
DMZ83G9 IK LHPSMXXBNXLHOD-UHFFFAOYSA-N
DMZ83G9 IU 2-(4-piperidin-1-ylpiperidin-1-yl)-[1,3]thiazolo[4,5-b]pyridine
DMZ83G9 DE Discovery agent
DMEKSAZ ID DMEKSAZ
DMEKSAZ DN 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine
DMEKSAZ HS Investigative
DMEKSAZ SN CHEMBL574615; SCHEMBL12041449; BDBM50299011
DMEKSAZ DT Small molecular drug
DMEKSAZ PC 45482781
DMEKSAZ MW 302.4
DMEKSAZ FM C16H22N4S
DMEKSAZ IC InChI=1S/C16H22N4S/c1-2-8-19(9-3-1)13-5-10-20(11-6-13)16-18-14-12-17-7-4-15(14)21-16/h4,7,12-13H,1-3,5-6,8-11H2
DMEKSAZ CS C1CCN(CC1)C2CCN(CC2)C3=NC4=C(S3)C=CN=C4
DMEKSAZ IK CYASDRJNADLAFT-UHFFFAOYSA-N
DMEKSAZ IU 2-(4-piperidin-1-ylpiperidin-1-yl)-[1,3]thiazolo[4,5-c]pyridine
DMEKSAZ DE Discovery agent
DMVXN01 ID DMVXN01
DMVXN01 DN 2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione
DMVXN01 HS Investigative
DMVXN01 SN CHEMBL166731; 2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione; SCHEMBL10655149; DOVKNTJKHQSOTE-UHFFFAOYSA-N; BDBM50024103; 2[10-(1H-imidazol-1-yl)decyl]-1H-isoindole-1,3(2H)dione
DMVXN01 DT Small molecular drug
DMVXN01 PC 13588977
DMVXN01 MW 353.5
DMVXN01 FM C21H27N3O2
DMVXN01 IC InChI=1S/C21H27N3O2/c25-20-18-11-7-8-12-19(18)21(26)24(20)15-10-6-4-2-1-3-5-9-14-23-16-13-22-17-23/h7-8,11-13,16-17H,1-6,9-10,14-15H2
DMVXN01 CS C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCCCCCCN3C=CN=C3
DMVXN01 IK DOVKNTJKHQSOTE-UHFFFAOYSA-N
DMVXN01 IU 2-(10-imidazol-1-yldecyl)isoindole-1,3-dione
DMVXN01 DE Discovery agent
DM05OJD ID DM05OJD
DM05OJD DN 2-(1-adamantyl) piperidine
DM05OJD HS Investigative
DM05OJD SN 2-(1-adamantyl)piperidine; 2-adamantanylpiperidine; 2-Adamantan-1-yl-piperidine; AC1LAFGW; Oprea1_303203; MLS000121957; SCHEMBL587889; 2-(adamantan-1-yl)piperidine; CHEMBL294443; CTK5J6774; MolPort-002-006-546; HMS2382E07; STL326117; AKOS016346316; AKOS000201213; MCULE-8550112936; BAS 06744019; SMR000119379; ST50340078; J3.628.419F
DM05OJD DT Small molecular drug
DM05OJD PC 467461
DM05OJD MW 219.37
DM05OJD FM C15H25N
DM05OJD IC InChI=1S/C15H25N/c1-2-4-16-14(3-1)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-14,16H,1-10H2
DM05OJD CS C1CCNC(C1)C23CC4CC(C2)CC(C4)C3
DM05OJD IK CGRWFWOAXCFBRF-UHFFFAOYSA-N
DM05OJD IU 2-(1-adamantyl)piperidine
DM05OJD DE Discovery agent
DMMSFEU ID DMMSFEU
DMMSFEU DN 2-(1-adamantyl) pyrrolidine
DMMSFEU HS Investigative
DMMSFEU SN 2-(1-adamantyl)pyrrolidine; 2-(adamantan-1-yl)pyrrolidine; 180258-96-2; 2-Adamantan-1-yl-pyrrolidine; 2-(tricyclo[3.3.1.1~3,7~]dec-1-yl)pyrrolidine; AC1LADDP; SCHEMBL587943; CHEMBL323901; CTK5J7450; YVRRAISBZUMEJB-UHFFFAOYSA-N; MolPort-004-320-513; ALBB-007403; ZX-AN006941; BBL022461; STK504519; AKOS016345558; AKOS000157977; RTR-059731; MCULE-4533332464; ACM180258962; TR-059731; W-9623; Pyrrolidine, 2-tricyclo[3.3.1.1~3,7~]dec-1-yl-, (2S)-
DMMSFEU DT Small molecular drug
DMMSFEU PC 511811
DMMSFEU MW 205.34
DMMSFEU FM C14H23N
DMMSFEU IC InChI=1S/C14H23N/c1-2-13(15-3-1)14-7-10-4-11(8-14)6-12(5-10)9-14/h10-13,15H,1-9H2
DMMSFEU CS C1CC(NC1)C23CC4CC(C2)CC(C4)C3
DMMSFEU IK YVRRAISBZUMEJB-UHFFFAOYSA-N
DMMSFEU IU 2-(1-adamantyl)pyrrolidine
DMMSFEU DE Discovery agent
DMIGRMV ID DMIGRMV
DMIGRMV DN 2-(1-adamantyl)-2-methyl-pyrrolidine
DMIGRMV HS Investigative
DMIGRMV SN SCHEMBL588363
DMIGRMV DT Small molecular drug
DMIGRMV PC 11964505
DMIGRMV MW 219.37
DMIGRMV FM C15H25N
DMIGRMV IC InChI=1S/C15H25N/c1-14(3-2-4-16-14)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13,16H,2-10H2,1H3
DMIGRMV CS CC1(CCCN1)C23CC4CC(C2)CC(C4)C3
DMIGRMV IK JQQSEBALQVRCLA-UHFFFAOYSA-N
DMIGRMV IU 2-(1-adamantyl)-2-methylpyrrolidine
DMIGRMV DE Discovery agent
DMB5LHA ID DMB5LHA
DMB5LHA DN 2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine
DMB5LHA HS Investigative
DMB5LHA SN CHEMBL457351; 2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine; SCHEMBL3320417
DMB5LHA DT Small molecular drug
DMB5LHA PC 11818252
DMB5LHA MW 277.4
DMB5LHA FM C20H23N
DMB5LHA IC InChI=1S/C20H23N/c1-21(2)13-12-17-15-18(14-16-8-4-3-5-9-16)20-11-7-6-10-19(17)20/h3-11,15,18H,12-14H2,1-2H3
DMB5LHA CS CN(C)CCC1=CC(C2=CC=CC=C21)CC3=CC=CC=C3
DMB5LHA IK CKYIFJXFLBXUQQ-UHFFFAOYSA-N
DMB5LHA IU 2-(3-benzyl-3H-inden-1-yl)-N,N-dimethylethanamine
DMB5LHA DE Discovery agent
DMML3XI ID DMML3XI
DMML3XI DN 2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMML3XI HS Investigative
DMML3XI SN CHEMBL188144; 2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine; BDBM50164758
DMML3XI DT Small molecular drug
DMML3XI PC 44397102
DMML3XI MW 278.4
DMML3XI FM C19H22N2
DMML3XI IC InChI=1S/C19H22N2/c1-20(2)13-12-17-15-21(14-16-8-4-3-5-9-16)19-11-7-6-10-18(17)19/h3-11,15H,12-14H2,1-2H3
DMML3XI CS CN(C)CCC1=CN(C2=CC=CC=C21)CC3=CC=CC=C3
DMML3XI IK QBWKAYAFIXQNCU-UHFFFAOYSA-N
DMML3XI IU 2-(1-benzylindol-3-yl)-N,N-dimethylethanamine
DMML3XI DE Discovery agent
DMF2XHZ ID DMF2XHZ
DMF2XHZ DN 2-(1-dodecyl-1H-indol-3-yl)acetic acid
DMF2XHZ HS Investigative
DMF2XHZ SN CHEMBL521836; 2-(1-dodecyl-1H-indol-3-yl)acetic acid
DMF2XHZ DT Small molecular drug
DMF2XHZ PC 44577010
DMF2XHZ MW 343.5
DMF2XHZ FM C22H33NO2
DMF2XHZ IC InChI=1S/C22H33NO2/c1-2-3-4-5-6-7-8-9-10-13-16-23-18-19(17-22(24)25)20-14-11-12-15-21(20)23/h11-12,14-15,18H,2-10,13,16-17H2,1H3,(H,24,25)
DMF2XHZ CS CCCCCCCCCCCCN1C=C(C2=CC=CC=C21)CC(=O)O
DMF2XHZ IK BFCFBVXYQIIZAF-UHFFFAOYSA-N
DMF2XHZ IU 2-(1-dodecylindol-3-yl)acetic acid
DMF2XHZ DE Discovery agent
DM0Y2P1 ID DM0Y2P1
DM0Y2P1 DN 2-(1H-benzo[d]imidazol-2-yl)quinoxaline
DM0Y2P1 HS Investigative
DM0Y2P1 SN CHEMBL200636; benzimidazolylquinoxaline; benzimidazole-quinoxaline, C1; BDBM21215; 2-(1H-benzimidazol-2-yl)quinoxaline; 2-(1H-Benzoimidazole-2-yl)quinoxaline
DM0Y2P1 DT Small molecular drug
DM0Y2P1 PC 11658819
DM0Y2P1 MW 246.27
DM0Y2P1 FM C15H10N4
DM0Y2P1 IC InChI=1S/C15H10N4/c1-2-6-11-10(5-1)16-9-14(17-11)15-18-12-7-3-4-8-13(12)19-15/h1-9H,(H,18,19)
DM0Y2P1 CS C1=CC=C2C(=C1)NC(=N2)C3=NC4=CC=CC=C4N=C3
DM0Y2P1 IK AYFBMQMYJRNGIM-UHFFFAOYSA-N
DM0Y2P1 IU 2-(1H-benzimidazol-2-yl)quinoxaline
DM0Y2P1 DE Discovery agent
DMXA20E ID DMXA20E
DMXA20E DN 2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline
DMXA20E HS Investigative
DMXA20E SN CHEMBL380770; 2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline; ZINC13678127
DMXA20E DT Small molecular drug
DMXA20E PC 11536096
DMXA20E MW 247.25
DMXA20E FM C14H9N5
DMXA20E IC InChI=1S/C14H9N5/c1-2-4-10-9(3-1)16-8-13(17-10)14-18-11-5-6-15-7-12(11)19-14/h1-8H,(H,18,19)
DMXA20E CS C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=NC=C4
DMXA20E IK UYUCQGUDIHPICB-UHFFFAOYSA-N
DMXA20E IU 2-(3H-imidazo[4,5-c]pyridin-2-yl)quinoxaline
DMXA20E DE Discovery agent
DMFK9GA ID DMFK9GA
DMFK9GA DN 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone
DMFK9GA HS Investigative
DMFK9GA SN 37910-79-5; n-(4-nitrophenacyl)imidazole; CHEMBL162549; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone; Ethanone, 2-(1H-imidazol-1-yl)-1-(4-nitrophenyl)-; AC1Q5DPC; 2-imidazol-1-yl-1-(4-nitrophenyl)ethanone; AC1Q1XG1; SCHEMBL5730977; AC1L1F83; CTK1A9243; DTXSID00275594; BDBM50240895; ZINC19595447; AKOS009984680; 2-Imidazol-1-yl-1-(4-nitro-phenyl)-ethanone; I90114; alpha-(1H-Imidazole-1-yl)-4'-nitroacetophenone; 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)-ethanone
DMFK9GA DT Small molecular drug
DMFK9GA PC 53600
DMFK9GA MW 231.21
DMFK9GA FM C11H9N3O3
DMFK9GA IC InChI=1S/C11H9N3O3/c15-11(7-13-6-5-12-8-13)9-1-3-10(4-2-9)14(16)17/h1-6,8H,7H2
DMFK9GA CS C1=CC(=CC=C1C(=O)CN2C=CN=C2)[N+](=O)[O-]
DMFK9GA IK SBPGWXSTCFNGPY-UHFFFAOYSA-N
DMFK9GA IU 2-imidazol-1-yl-1-(4-nitrophenyl)ethanone
DMFK9GA CA CAS 37910-79-5
DMFK9GA DE Discovery agent
DM2PZ1B ID DM2PZ1B
DM2PZ1B DN 2-(1H-Imidazol-4-yl)benzene-1,3-diol
DM2PZ1B HS Investigative
DM2PZ1B SN 2-(1H-Imidazol-4-yl)benzene-1,3-diol; 1048983-14-7; CHEMBL509549; SCHEMBL1502239; BDBM24664; 2-(1H-imidazol-4-yl)benzene-1,3-diol, 11
DM2PZ1B DT Small molecular drug
DM2PZ1B PC 24971326
DM2PZ1B MW 176.17
DM2PZ1B FM C9H8N2O2
DM2PZ1B IC InChI=1S/C9H8N2O2/c12-7-2-1-3-8(13)9(7)6-4-10-5-11-6/h1-5,12-13H,(H,10,11)
DM2PZ1B CS C1=CC(=C(C(=C1)O)C2=CN=CN2)O
DM2PZ1B IK VMNQZTQDHXFNPD-UHFFFAOYSA-N
DM2PZ1B IU 2-(1H-imidazol-5-yl)benzene-1,3-diol
DM2PZ1B DE Discovery agent
DM6MR82 ID DM6MR82
DM6MR82 DN 2-(1H-Imidazol-4-yl)phenol
DM6MR82 HS Investigative
DM6MR82 SN 2-(1H-Imidazol-4-yl)phenol; 19170-74-2; 2-(1H-Imidazol-5-yl)-phenol; 2-(1H-Imidazol-5-yl)phenol; CHEMBL457063; SCHEMBL1502109; BDBM24663; 2-(1H-imidazol-4-yl)phenol, 1
DM6MR82 DT Small molecular drug
DM6MR82 PC 10307884
DM6MR82 MW 160.17
DM6MR82 FM C9H8N2O
DM6MR82 IC InChI=1S/C9H8N2O/c12-9-4-2-1-3-7(9)8-5-10-6-11-8/h1-6,12H,(H,10,11)
DM6MR82 CS C1=CC=C(C(=C1)C2=CN=CN2)O
DM6MR82 IK BYAAMOMNSVKNMA-UHFFFAOYSA-N
DM6MR82 IU 2-(1H-imidazol-5-yl)phenol
DM6MR82 DE Discovery agent
DMCG1HE ID DMCG1HE
DMCG1HE DN 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole
DMCG1HE HS Investigative
DMCG1HE SN CHEMBL289060; 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole; BDBM50014174
DMCG1HE DT Small molecular drug
DMCG1HE PC 14742545
DMCG1HE MW 241.31
DMCG1HE FM C13H11N3S
DMCG1HE IC InChI=1S/C13H11N3S/c1-2-4-10(5-3-1)12-8-17-13(16-12)6-11-7-14-9-15-11/h1-5,7-9H,6H2,(H,14,15)
DMCG1HE CS C1=CC=C(C=C1)C2=CSC(=N2)CC3=CN=CN3
DMCG1HE IK TVRYIDIUBFYXFE-UHFFFAOYSA-N
DMCG1HE IU 2-(1H-imidazol-5-ylmethyl)-4-phenyl-1,3-thiazole
DMCG1HE DE Discovery agent
DM0CSH8 ID DM0CSH8
DM0CSH8 DN 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole
DM0CSH8 HS Investigative
DM0CSH8 SN 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE; CHEMBL383990; 3-(1H-1,3-benzodiazol-2-yl)-2H-indazole; 2-(2H-indazol-3-yl)-1H-1,3-benzodiazole; IDZ; 1097816-83-5; Indazole Compound 2; 2c3l; AC1Q4XAS; AC1NS1P1; SCHEMBL311148; BDBM16590; 3-benzimidazol-2-yl-1h-indazole; JTKFRFMSUBOCIQ-UHFFFAOYSA-N; MolPort-016-542-829; ZINC14961821; AKOS009356321; NE25942; MCULE-6782886882; DB07959; 2-(1H-indazol-3-yl)-1H-benzimidazole; 3-(1H-benzoimidazol-2-yl)-1H-indazole; 2-(1H-Indazole-3-yl)-1H-benzoimidazole; EN300-70692
DM0CSH8 DT Small molecular drug
DM0CSH8 PC 135464491
DM0CSH8 MW 234.26
DM0CSH8 FM C14H10N4
DM0CSH8 IC InChI=1S/C14H10N4/c1-2-6-10-9(5-1)13(18-17-10)14-15-11-7-3-4-8-12(11)16-14/h1-8H,(H,15,16)(H,17,18)
DM0CSH8 CS C1=CC=C2C(=C1)C(=NN2)C3=NC4=CC=CC=C4N3
DM0CSH8 IK JTKFRFMSUBOCIQ-UHFFFAOYSA-N
DM0CSH8 IU 2-(1H-indazol-3-yl)-1H-benzimidazole
DM0CSH8 DE Discovery agent
DMFAME4 ID DMFAME4
DMFAME4 DN 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide
DMFAME4 HS Investigative
DMFAME4 SN 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide; USGVPHMVQJFJJD-UHFFFAOYSA-N; 2-(1H-indol-3-yl)-2-oxo-N-(2-phenylethyl)acetamide; 2-(1H-Indol-3-yl)-2-oxo-N-[2-phenylethyl]acetamide; AC1M2UTB; MLS001212145; CHEMBL68442; SCHEMBL4760802; MolPort-000-249-097; HMS3430C11; ZINC2815535; STK710826; AKOS000530675; MCULE-7691246998; 94209-12-8; BAS 04280191; SMR000518992; ST4091858; MLS-0351990.0002; 2-(1H-indol-3-yl)-2-oxo-N-phenethylacetamide; 2-indol-3-yl-2-oxo-N-(2-phenylethyl)acetamide; Acetamide, 2-(1H-indol-3-yl)-2-oxo-N-phenethyl-
DMFAME4 DT Small molecular drug
DMFAME4 PC 2176767
DMFAME4 MW 292.3
DMFAME4 FM C18H16N2O2
DMFAME4 IC InChI=1S/C18H16N2O2/c21-17(15-12-20-16-9-5-4-8-14(15)16)18(22)19-11-10-13-6-2-1-3-7-13/h1-9,12,20H,10-11H2,(H,19,22)
DMFAME4 CS C1=CC=C(C=C1)CCNC(=O)C(=O)C2=CNC3=CC=CC=C32
DMFAME4 IK USGVPHMVQJFJJD-UHFFFAOYSA-N
DMFAME4 IU 2-(1H-indol-3-yl)-2-oxo-N-(2-phenylethyl)acetamide
DMFAME4 DE Discovery agent
DMR9Q4Y ID DMR9Q4Y
DMR9Q4Y DN 2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y HS Investigative
DMR9Q4Y SN N,N-Dimethyltryptamine; N,N-DIMETHYLTRYPTAMINE; DIMETHYLTRYPTAMINE; 61-50-7; 3-(2-Dimethylaminoethyl)indole; 2-(3-Indolyl)ethyldimethylamine; N,N-Dimethyl-1H-indole-3-ethylamine; 2-(1H-Indol-3-yl)-N,N-dimethylethanamine; 1H-Indole-3-ethanamine, N,N-dimethyl-; DMT (psychogenic); (psychogenic); UNII-WUB601BHAA; 3-[2-(dimethylamino)ethyl]indole; EINECS 200-508-4; NSC 63795; WUB601BHAA; N,N-dimethyl-1H-Indole-3-ethanamine; BRN 0138259; CHEMBL12420; DEA No 7435; CHEBI:28969; DMULVCHRPCFFGV-UHFFFAOYSA-N; (2-Indol-3-ylethyl)dimethylamine; Indole,; Dimethyltryptamine
DMR9Q4Y DT Small molecular drug
DMR9Q4Y PC 6089
DMR9Q4Y MW 188.27
DMR9Q4Y FM C12H16N2
DMR9Q4Y IC InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3
DMR9Q4Y CS CN(C)CCC1=CNC2=CC=CC=C21
DMR9Q4Y IK DMULVCHRPCFFGV-UHFFFAOYSA-N
DMR9Q4Y IU 2-(1H-indol-3-yl)-N,N-dimethylethanamine
DMR9Q4Y CA CAS 61-50-7
DMR9Q4Y CB CHEBI:28969
DMR9Q4Y DE Discovery agent
DMB7AU5 ID DMB7AU5
DMB7AU5 DN 2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one
DMB7AU5 HS Investigative
DMB7AU5 SN CHEMBL3144574; CHEMBL8374; 2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one; BDBM50009014
DMB7AU5 DT Small molecular drug
DMB7AU5 PC 44265197
DMB7AU5 MW 263.29
DMB7AU5 FM C16H13N3O
DMB7AU5 IC InChI=1S/C16H13N3O/c20-16-13-6-2-4-8-15(13)18-19(16)10-11-9-17-14-7-3-1-5-12(11)14/h1-9,17-18H,10H2
DMB7AU5 CS C1=CC=C2C(=C1)C(=CN2)CN3C(=O)C4=CC=CC=C4N3
DMB7AU5 IK IAJFPXRONWWXNK-UHFFFAOYSA-N
DMB7AU5 IU 2-(1H-indol-3-ylmethyl)-1H-indazol-3-one
DMB7AU5 DE Discovery agent
DMZNML4 ID DMZNML4
DMZNML4 DN 2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one
DMZNML4 HS Investigative
DMZNML4 SN CHEMBL222745; 2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one
DMZNML4 DT Small molecular drug
DMZNML4 PC 16203946
DMZNML4 MW 296.32
DMZNML4 FM C17H16N2O3
DMZNML4 IC InChI=1S/C17H16N2O3/c20-14-10-16(13-1-2-15-12(9-13)3-4-18-15)22-17(11-14)19-5-7-21-8-6-19/h1-4,9-11,18H,5-8H2
DMZNML4 CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC4=C(C=C3)NC=C4
DMZNML4 IK AWODDYAKSFDGCI-UHFFFAOYSA-N
DMZNML4 IU 2-(1H-indol-5-yl)-6-morpholin-4-ylpyran-4-one
DMZNML4 DE Discovery agent
DMHSORL ID DMHSORL
DMHSORL DN 2-(1H-pyrazol-3-yl)-1H-benzimidazole
DMHSORL HS Investigative
DMHSORL DT Small molecular drug
DMHSORL PC 763936
DMHSORL MW 184.2
DMHSORL FM C10H8N4
DMHSORL IC InChI=1S/C10H8N4/c1-2-4-8-7(3-1)12-10(13-8)9-5-6-11-14-9/h1-6H,(H,11,14)(H,12,13)
DMHSORL CS C1=CC=C2C(=C1)NC(=N2)C3=CC=NN3
DMHSORL IK IYTGPPNUOLLGBE-UHFFFAOYSA-N
DMHSORL IU 2-(1H-pyrazol-5-yl)-1H-benzimidazole
DMHSORL DE Discovery agent
DMUY75A ID DMUY75A
DMUY75A DN 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
DMUY75A HS Investigative
DMUY75A SN 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol; 1-(2,4,6-trihydroxybenzoyl)pyrrole; 288839-58-7; 3eko; CHEMBL513225; DB08443; 2-(1-Pyrrolylcarbonyl)benzene-1,3,5-triol; 2-(pyrrole-1-carbonyl)benzene-1,3,5-triol
DMUY75A DT Small molecular drug
DMUY75A PC 11160307
DMUY75A MW 219.19
DMUY75A FM C11H9NO4
DMUY75A IC InChI=1S/C11H9NO4/c13-7-5-8(14)10(9(15)6-7)11(16)12-3-1-2-4-12/h1-6,13-15H
DMUY75A CS C1=CN(C=C1)C(=O)C2=C(C=C(C=C2O)O)O
DMUY75A IK RYGSNHBTZDYVSS-UHFFFAOYSA-N
DMUY75A IU pyrrol-1-yl-(2,4,6-trihydroxyphenyl)methanone
DMUY75A DE Discovery agent
DM4MIXK ID DM4MIXK
DM4MIXK DN 2-(1-Imidazol-1-yl-ethyl)-9H-carbazole
DM4MIXK HS Investigative
DM4MIXK SN CHEMBL499882; 2-(1-Imidazol-1-yl-ethyl)-9H-carbazole; SCHEMBL9020993; VCFYTQOGKYSBGI-UHFFFAOYSA-N; BDBM50272211; YM 55208; 2-[1-(1H-imidazol-1-yl) ethyl]carbazole
DM4MIXK DT Small molecular drug
DM4MIXK PC 18976091
DM4MIXK MW 261.32
DM4MIXK FM C17H15N3
DM4MIXK IC InChI=1S/C17H15N3/c1-12(20-9-8-18-11-20)13-6-7-15-14-4-2-3-5-16(14)19-17(15)10-13/h2-12,19H,1H3
DM4MIXK CS CC(C1=CC2=C(C=C1)C3=CC=CC=C3N2)N4C=CN=C4
DM4MIXK IK VCFYTQOGKYSBGI-UHFFFAOYSA-N
DM4MIXK IU 2-(1-imidazol-1-ylethyl)-9H-carbazole
DM4MIXK DE Discovery agent
DMY35HG ID DMY35HG
DMY35HG DN 2-(1-o-tolyl-1H-pyrrol-3-yl)ethanamine
DMY35HG HS Investigative
DMY35HG SN CHEMBL232994
DMY35HG DT Small molecular drug
DMY35HG PC 44431707
DMY35HG MW 200.28
DMY35HG FM C13H16N2
DMY35HG IC InChI=1S/C13H16N2/c1-11-4-2-3-5-13(11)15-9-7-12(10-15)6-8-14/h2-5,7,9-10H,6,8,14H2,1H3
DMY35HG CS CC1=CC=CC=C1N2C=CC(=C2)CCN
DMY35HG IK MQJFADBSJHNKPK-UHFFFAOYSA-N
DMY35HG IU 2-[1-(2-methylphenyl)pyrrol-3-yl]ethanamine
DMY35HG DE Discovery agent
DMR0HDF ID DMR0HDF
DMR0HDF DN 2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole
DMR0HDF HS Investigative
DMR0HDF SN CHEMBL119494; SCHEMBL4814520
DMR0HDF DT Small molecular drug
DMR0HDF PC 9944114
DMR0HDF MW 298.5
DMR0HDF FM C20H30N2
DMR0HDF IC InChI=1S/C20H30N2/c1-3-5-8-14-18(15-9-6-4-2)20-21-16-19(22-20)17-12-10-7-11-13-17/h7,10-13,16,18H,3-6,8-9,14-15H2,1-2H3,(H,21,22)
DMR0HDF CS CCCCCC(CCCCC)C1=NC=C(N1)C2=CC=CC=C2
DMR0HDF IK XYWGMJFQZHLYDO-UHFFFAOYSA-N
DMR0HDF IU 5-phenyl-2-undecan-6-yl-1H-imidazole
DMR0HDF DE Discovery agent
DMXCID6 ID DMXCID6
DMXCID6 DN 2-(1-tosyl-1H-indol-3-yl)ethanamine
DMXCID6 HS Investigative
DMXCID6 SN CHEMBL394303; SCHEMBL15250049; BDBM21349; 1-Tosyl-1H-indole-3-ethaneamine; Substituted phenylsulfonyltryptamine, 11h
DMXCID6 DT Small molecular drug
DMXCID6 PC 14571158
DMXCID6 MW 314.4
DMXCID6 FM C17H18N2O2S
DMXCID6 IC InChI=1S/C17H18N2O2S/c1-13-6-8-15(9-7-13)22(20,21)19-12-14(10-11-18)16-4-2-3-5-17(16)19/h2-9,12H,10-11,18H2,1H3
DMXCID6 CS CC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)CCN
DMXCID6 IK XKKWGBDMWUAPLE-UHFFFAOYSA-N
DMXCID6 IU 2-[1-(4-methylphenyl)sulfonylindol-3-yl]ethanamine
DMXCID6 DE Discovery agent
DMGZKCT ID DMGZKCT
DMGZKCT DN 2-(2-((benzylamino)methyl)phenoxy)-5-chlorophenol
DMGZKCT HS Investigative
DMGZKCT DE Discovery agent
DM54M6C ID DM54M6C
DM54M6C DN 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid
DM54M6C HS Investigative
DM54M6C SN CHEMBL77981; 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid; SCHEMBL7166052; JSJQNYIFLKCXRE-UHFFFAOYSA-N; ZINC13809288; BDBM50090679; 2-(2,5-Dichloroanilino)benzeneacetic acid; 2-[(2,5-dichlorophenyl)amino]phenylacetic acid; [2-(2,5-Dichloro-phenylamino)-phenyl]-acetic acid
DM54M6C DT Small molecular drug
DM54M6C PC 14076674
DM54M6C MW 296.1
DM54M6C FM C14H11Cl2NO2
DM54M6C IC InChI=1S/C14H11Cl2NO2/c15-10-5-6-11(16)13(8-10)17-12-4-2-1-3-9(12)7-14(18)19/h1-6,8,17H,7H2,(H,18,19)
DM54M6C CS C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC(=C2)Cl)Cl
DM54M6C IK JSJQNYIFLKCXRE-UHFFFAOYSA-N
DM54M6C IU 2-[2-(2,5-dichloroanilino)phenyl]acetic acid
DM54M6C DE Discovery agent
DMJ2DE4 ID DMJ2DE4
DMJ2DE4 DN 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid
DMJ2DE4 HS Investigative
DMJ2DE4 SN CHEMBL76154; SCHEMBL6239733; CTK8H7205; ICJTVRXTYOYEOT-UHFFFAOYSA-N; BDBM50375601; ZINC26399260; 2-(2,6-Dimethylanilino)benzeneacetic acid; 2-[(2,6-dimethylphenyl]amino]phenylacetic acid; 2-[(2,6-dimethylphenyl] amino] phenylacetic acid
DMJ2DE4 DT Small molecular drug
DMJ2DE4 PC 14762941
DMJ2DE4 MW 255.31
DMJ2DE4 FM C16H17NO2
DMJ2DE4 IC InChI=1S/C16H17NO2/c1-11-6-5-7-12(2)16(11)17-14-9-4-3-8-13(14)10-15(18)19/h3-9,17H,10H2,1-2H3,(H,18,19)
DMJ2DE4 CS CC1=C(C(=CC=C1)C)NC2=CC=CC=C2CC(=O)O
DMJ2DE4 IK ICJTVRXTYOYEOT-UHFFFAOYSA-N
DMJ2DE4 IU 2-[2-(2,6-dimethylanilino)phenyl]acetic acid
DMJ2DE4 DE Discovery agent
DMBP1TQ ID DMBP1TQ
DMBP1TQ DN 2-(2-(2-chlorophenoxy)phenyl)acetic acid
DMBP1TQ HS Investigative
DMBP1TQ SN CHEMBL30038; 2-(2-(2-chlorophenoxy)phenyl)acetic acid; BDBM50295282; ZINC28766380; [2-(2-Chloro-phenoxy)-phenyl]-acetic acid
DMBP1TQ DT Small molecular drug
DMBP1TQ PC 15581854
DMBP1TQ MW 262.69
DMBP1TQ FM C14H11ClO3
DMBP1TQ IC InChI=1S/C14H11ClO3/c15-11-6-2-4-8-13(11)18-12-7-3-1-5-10(12)9-14(16)17/h1-8H,9H2,(H,16,17)
DMBP1TQ CS C1=CC=C(C(=C1)CC(=O)O)OC2=CC=CC=C2Cl
DMBP1TQ IK SYANOAWCBFRXNL-UHFFFAOYSA-N
DMBP1TQ IU 2-[2-(2-chlorophenoxy)phenyl]acetic acid
DMBP1TQ CA CAS 81682-40-8
DMBP1TQ DE Discovery agent
DMPLV3A ID DMPLV3A
DMPLV3A DN 2-(2-(2-chlorophenylamino)phenyl)acetic acid
DMPLV3A HS Investigative
DMPLV3A SN CHEMBL77823; 488862-17-5; 2-(2-(2-chlorophenylamino)phenyl)acetic acid; SCHEMBL6243911; CTK1D1110; DTXSID00548437; RXRLPBIKRNGLJD-UHFFFAOYSA-N; ZINC26400000; BDBM50295275; AKOS030583290; [2-(2-Chloroanilino)phenyl]acetic acid; 2-(2-Chlorophenylamino)benzeneacetic acid; 2-[(2-chlorophenyl)amino]phenylacetic acid; Benzeneacetic acid, 2-[(chlorophenyl)amino]-; [2-(2-Chloro-phenylamino)-phenyl]-acetic acid
DMPLV3A DT Small molecular drug
DMPLV3A PC 13752584
DMPLV3A MW 261.7
DMPLV3A FM C14H12ClNO2
DMPLV3A IC InChI=1S/C14H12ClNO2/c15-11-6-2-4-8-13(11)16-12-7-3-1-5-10(12)9-14(17)18/h1-8,16H,9H2,(H,17,18)
DMPLV3A CS C1=CC=C(C(=C1)CC(=O)O)NC2=CC=CC=C2Cl
DMPLV3A IK RXRLPBIKRNGLJD-UHFFFAOYSA-N
DMPLV3A IU 2-[2-(2-chloroanilino)phenyl]acetic acid
DMPLV3A CA CAS 488862-17-5
DMPLV3A DE Discovery agent
DMDSUR2 ID DMDSUR2
DMDSUR2 DN 2-(2-(2-fluorophenoxy)phenyl)acetic acid
DMDSUR2 HS Investigative
DMDSUR2 SN CHEMBL29804; 2-(2-(2-fluorophenoxy)phenyl)acetic acid; BDBM50295281; ZINC28767088; AKOS022663030; [2-(2-Fluoro-phenoxy)-phenyl]-acetic acid
DMDSUR2 DT Small molecular drug
DMDSUR2 PC 13409348
DMDSUR2 MW 246.23
DMDSUR2 FM C14H11FO3
DMDSUR2 IC InChI=1S/C14H11FO3/c15-11-6-2-4-8-13(11)18-12-7-3-1-5-10(12)9-14(16)17/h1-8H,9H2,(H,16,17)
DMDSUR2 CS C1=CC=C(C(=C1)CC(=O)O)OC2=CC=CC=C2F
DMDSUR2 IK LAVKHAMQQVBXLL-UHFFFAOYSA-N
DMDSUR2 IU 2-[2-(2-fluorophenoxy)phenyl]acetic acid
DMDSUR2 DE Discovery agent
DMVQ68F ID DMVQ68F
DMVQ68F DN 2-(2-(2-fluorophenylamino)phenyl)acetic acid
DMVQ68F HS Investigative
DMVQ68F SN CHEMBL427739; 2-(2-(2-fluorophenylamino)phenyl)acetic acid; SCHEMBL7165042; DWKOQWOOVUATNI-UHFFFAOYSA-N; BDBM50295276; 2-[(2-fluorophenyl)amino]phenylacetic acid
DMVQ68F DT Small molecular drug
DMVQ68F PC 18546352
DMVQ68F MW 245.25
DMVQ68F FM C14H12FNO2
DMVQ68F IC InChI=1S/C14H12FNO2/c15-11-6-2-4-8-13(11)16-12-7-3-1-5-10(12)9-14(17)18/h1-8,16H,9H2,(H,17,18)
DMVQ68F CS C1=CC=C(C(=C1)CC(=O)O)NC2=CC=CC=C2F
DMVQ68F IK DWKOQWOOVUATNI-UHFFFAOYSA-N
DMVQ68F IU 2-[2-(2-fluoroanilino)phenyl]acetic acid
DMVQ68F DE Discovery agent
DMKT51Z ID DMKT51Z
DMKT51Z DN 2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid
DMKT51Z HS Investigative
DMKT51Z SN CHEMBL443733; Oprea1_160526; 2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid; SCHEMBL3987191; 2-[[2-(4-tert-butylphenoxy)acetyl]amino]benzoic Acid; MolPort-001-494-161; ZINC4546761; AC1N7082; STK000456; BDBM50264188; AKOS002944005; MCULE-2716737007; 2-{[(4-tert-butylphenoxy)acetyl]amino}benzoic acid
DMKT51Z DT Small molecular drug
DMKT51Z PC 4268702
DMKT51Z MW 327.4
DMKT51Z FM C19H21NO4
DMKT51Z IC InChI=1S/C19H21NO4/c1-19(2,3)13-8-10-14(11-9-13)24-12-17(21)20-16-7-5-4-6-15(16)18(22)23/h4-11H,12H2,1-3H3,(H,20,21)(H,22,23)
DMKT51Z CS CC(C)(C)C1=CC=C(C=C1)OCC(=O)NC2=CC=CC=C2C(=O)O
DMKT51Z IK RZQIBGXCHZEONC-UHFFFAOYSA-N
DMKT51Z IU 2-[[2-(4-tert-butylphenoxy)acetyl]amino]benzoic acid
DMKT51Z DE Discovery agent
DMZVBPG ID DMZVBPG
DMZVBPG DN 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
DMZVBPG HS Investigative
DMZVBPG SN 4-(2-(4-tert-butylphenylthio)ethyl)-1H-imidazole; 4-(2-(40-tert-butylphenylthio)ethyl)-1H-imidazole
DMZVBPG PC 46222048
DMZVBPG MW 260.399
DMZVBPG FM C15H20N2S
DMZVBPG IC InChI=1S/C15H20N2S/c1-15(2,3)12-4-6-14(7-5-12)18-9-8-13-10-16-11-17-13/h4-7,10-11H,8-9H2,1-3H3,(H,16,17)
DMZVBPG CS CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2
DMZVBPG IK PQPVHIHIJVIEQG-UHFFFAOYSA-N
DMZVBPG IU 5-[2-(4-tert-butylphenyl)sulfanylethyl]-1H-imidazole
DMZVBPG DE Discovery agent
DMDR50V ID DMDR50V
DMDR50V DN 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid
DMDR50V HS Investigative
DMDR50V SN CHEMBL572947; 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid
DMDR50V DT Small molecular drug
DMDR50V PC 21496278
DMDR50V MW 288.4
DMDR50V FM C16H16O3S
DMDR50V IC InChI=1S/C16H16O3S/c17-16(18)12-20(19)11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
DMDR50V CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCS(=O)CC(=O)O
DMDR50V IK JPUWBNMOSGBVRW-UHFFFAOYSA-N
DMDR50V IU 2-[2-(4-phenylphenyl)ethylsulfinyl]acetic acid
DMDR50V DE Discovery agent
DM95B4J ID DM95B4J
DM95B4J DN 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
DM95B4J HS Investigative
DM95B4J SN CHEMBL566511; 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
DM95B4J DT Small molecular drug
DM95B4J PC 45483015
DM95B4J MW 304.4
DM95B4J FM C16H16O4S
DM95B4J IC InChI=1S/C16H16O4S/c17-16(18)12-21(19,20)11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
DM95B4J CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCS(=O)(=O)CC(=O)O
DM95B4J IK PPYPHJNYICUMPA-UHFFFAOYSA-N
DM95B4J IU 2-[2-(4-phenylphenyl)ethylsulfonyl]acetic acid
DM95B4J DE Discovery agent
DMBZIUC ID DMBZIUC
DMBZIUC DN 2-(2-(biphenyl-4-yl)ethylthio)acetic acid
DMBZIUC HS Investigative
DMBZIUC SN CHEMBL572980; 2-(2-(biphenyl-4-yl)ethylthio)acetic acid
DMBZIUC DT Small molecular drug
DMBZIUC PC 20348772
DMBZIUC MW 272.4
DMBZIUC FM C16H16O2S
DMBZIUC IC InChI=1S/C16H16O2S/c17-16(18)12-19-11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
DMBZIUC CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCSCC(=O)O
DMBZIUC IK VNCUHIXOCDBZGU-UHFFFAOYSA-N
DMBZIUC IU 2-[2-(4-phenylphenyl)ethylsulfanyl]acetic acid
DMBZIUC DE Discovery agent
DMZA8M7 ID DMZA8M7
DMZA8M7 DN 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid
DMZA8M7 HS Investigative
DMZA8M7 SN 4-anilinopyrimidine 7a; CHEMBL394869; BDBM15986; AKOS029246132; 2-{[2-(butylamino)pyrimidin-4-yl]amino}benzoic acid
DMZA8M7 DT Small molecular drug
DMZA8M7 PC 23647246
DMZA8M7 MW 286.33
DMZA8M7 FM C15H18N4O2
DMZA8M7 IC InChI=1S/C15H18N4O2/c1-2-3-9-16-15-17-10-8-13(19-15)18-12-7-5-4-6-11(12)14(20)21/h4-8,10H,2-3,9H2,1H3,(H,20,21)(H2,16,17,18,19)
DMZA8M7 CS CCCCNC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMZA8M7 IK FSZJHCURVIQYSG-UHFFFAOYSA-N
DMZA8M7 IU 2-[[2-(butylamino)pyrimidin-4-yl]amino]benzoic acid
DMZA8M7 DE Discovery agent
DM4KS27 ID DM4KS27
DM4KS27 DN 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid
DM4KS27 HS Investigative
DM4KS27 SN 4-anilinopyrimidine 6c; CHEMBL242701; BDBM15981; 2-{[2-(pentyloxy)pyrimidin-4-yl]amino}benzoic acid
DM4KS27 DT Small molecular drug
DM4KS27 PC 23647241
DM4KS27 MW 301.34
DM4KS27 FM C16H19N3O3
DM4KS27 IC InChI=1S/C16H19N3O3/c1-2-3-6-11-22-16-17-10-9-14(19-16)18-13-8-5-4-7-12(13)15(20)21/h4-5,7-10H,2-3,6,11H2,1H3,(H,20,21)(H,17,18,19)
DM4KS27 CS CCCCCOC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DM4KS27 IK QOFCYNIGWDGPEN-UHFFFAOYSA-N
DM4KS27 IU 2-[(2-pentoxypyrimidin-4-yl)amino]benzoic acid
DM4KS27 DE Discovery agent
DM5GAOZ ID DM5GAOZ
DM5GAOZ DN 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide
DM5GAOZ HS Investigative
DM5GAOZ SN 4-anilinopyrimidine 2a; CHEMBL428213; BDBM15995
DM5GAOZ DT Small molecular drug
DM5GAOZ PC 23647253
DM5GAOZ MW 305.33
DM5GAOZ FM C17H15N5O
DM5GAOZ IC InChI=1S/C17H15N5O/c18-16(23)13-8-4-5-9-14(13)21-15-10-11-19-17(22-15)20-12-6-2-1-3-7-12/h1-11H,(H2,18,23)(H2,19,20,21,22)
DM5GAOZ CS C1=CC=C(C=C1)NC2=NC=CC(=N2)NC3=CC=CC=C3C(=O)N
DM5GAOZ IK TVKTVNQGZQPCAT-UHFFFAOYSA-N
DM5GAOZ IU 2-[(2-anilinopyrimidin-4-yl)amino]benzamide
DM5GAOZ DE Discovery agent
DMCHZ8J ID DMCHZ8J
DMCHZ8J DN 2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole
DMCHZ8J HS Investigative
DMCHZ8J SN CHEMBL271899
DMCHZ8J DT Small molecular drug
DMCHZ8J PC 44456057
DMCHZ8J MW 214.31
DMCHZ8J FM C14H18N2
DMCHZ8J IC InChI=1S/C14H18N2/c1-2-6-14-12(5-1)11-13(15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2
DMCHZ8J CS C1CCN(C1)CCC2=CC3=CC=CC=C3N2
DMCHZ8J IK IVJNJVNKYYOCPC-UHFFFAOYSA-N
DMCHZ8J IU 2-(2-pyrrolidin-1-ylethyl)-1H-indole
DMCHZ8J DE Discovery agent
DMQ0WKA ID DMQ0WKA
DMQ0WKA DN 2-(2-(pyrrolidin-1-yl)ethyl)phenol
DMQ0WKA HS Investigative
DMQ0WKA SN CHEMBL273002
DMQ0WKA DT Small molecular drug
DMQ0WKA PC 44456361
DMQ0WKA MW 191.27
DMQ0WKA FM C12H17NO
DMQ0WKA IC InChI=1S/C12H17NO/c14-12-6-2-1-5-11(12)7-10-13-8-3-4-9-13/h1-2,5-6,14H,3-4,7-10H2
DMQ0WKA CS C1CCN(C1)CCC2=CC=CC=C2O
DMQ0WKA IK MCYUAYDQGCYEGH-UHFFFAOYSA-N
DMQ0WKA IU 2-(2-pyrrolidin-1-ylethyl)phenol
DMQ0WKA DE Discovery agent
DMGQC2F ID DMGQC2F
DMGQC2F DN 2-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMGQC2F HS Investigative
DMGQC2F SN 2-(2-Pyrrolidinoethyl)Pyridine; 6311-90-6; CHEMBL270595; 2-[2-(Pyrrolidin-1-yl)ethyl]pyridine; N-(2-(2-pyridyl)ethyl)pyrrolidine; NSC42644; 2-[2-(1-Pyrrolidinyl)ethyl]pyridine; AC1Q4VNT; AC1L60PK; AC1Q28PR; SCHEMBL868571; 2-(2-Pyrrolizinoethyl)pyridine; CTK5B7636; DTXSID60285694; OXEFHEYEQUISKC-UHFFFAOYSA-N; ZINC393798; NSC-42644; 2-(2-pyrrolidin-1-ylethyl)pyridine; BDBM50372289; AKOS006243249; MCULE-8128571557; 2-(2-Pyrrolidin-1-yl-ethyl)-pyridine; Pyridine,2-[2-(1-pyrrolidinyl)ethyl]-; 2-[2-(1-Pyrrolidinyl)ethyl]pyridine #
DMGQC2F DT Small molecular drug
DMGQC2F PC 238317
DMGQC2F MW 176.26
DMGQC2F FM C11H16N2
DMGQC2F IC InChI=1S/C11H16N2/c1-2-7-12-11(5-1)6-10-13-8-3-4-9-13/h1-2,5,7H,3-4,6,8-10H2
DMGQC2F CS C1CCN(C1)CCC2=CC=CC=N2
DMGQC2F IK OXEFHEYEQUISKC-UHFFFAOYSA-N
DMGQC2F IU 2-(2-pyrrolidin-1-ylethyl)pyridine
DMGQC2F CA CAS 6311-90-6
DMGQC2F DE Discovery agent
DMFU1PK ID DMFU1PK
DMFU1PK DN 2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK HS Investigative
DMFU1PK SN CHEMBL228561; 2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK DT Small molecular drug
DMFU1PK PC 23627032
DMFU1PK MW 282.3
DMFU1PK FM C18H18O3
DMFU1PK IC InChI=1S/C18H18O3/c1-19-16-9-8-15(17(20-2)18(16)21-3)14-10-12-6-4-5-7-13(12)11-14/h4-10H,11H2,1-3H3
DMFU1PK CS COC1=C(C(=C(C=C1)C2=CC3=CC=CC=C3C2)OC)OC
DMFU1PK IK ULQHBVJHLIJHLL-UHFFFAOYSA-N
DMFU1PK IU 2-(2,3,4-trimethoxyphenyl)-1H-indene
DMFU1PK DE Discovery agent
DM1T8IP ID DM1T8IP
DM1T8IP DN 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid
DM1T8IP HS Investigative
DM1T8IP SN CHEMBL212860; 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid; SCHEMBL5664165; JDODANGOYUAOQT-UHFFFAOYSA-N; BDBM50192463; 2,3-bis[(2-chlorophenyl)methoxy]benzeneacetic acid
DM1T8IP DT Small molecular drug
DM1T8IP PC 10126984
DM1T8IP MW 417.3
DM1T8IP FM C22H18Cl2O4
DM1T8IP IC InChI=1S/C22H18Cl2O4/c23-18-9-3-1-6-16(18)13-27-20-11-5-8-15(12-21(25)26)22(20)28-14-17-7-2-4-10-19(17)24/h1-11H,12-14H2,(H,25,26)
DM1T8IP CS C1=CC=C(C(=C1)COC2=CC=CC(=C2OCC3=CC=CC=C3Cl)CC(=O)O)Cl
DM1T8IP IK JDODANGOYUAOQT-UHFFFAOYSA-N
DM1T8IP IU 2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]acetic acid
DM1T8IP DE Discovery agent
DM56NK4 ID DM56NK4
DM56NK4 DN 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine
DM56NK4 HS Investigative
DM56NK4 SN CHEMBL32958; 1H-Indole-5-ethanamine, 2,3-dihydro-alpha-methyl-; 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine; BDBM50025081
DM56NK4 DT Small molecular drug
DM56NK4 PC 13660281
DM56NK4 MW 176.26
DM56NK4 FM C11H16N2
DM56NK4 IC InChI=1S/C11H16N2/c1-8(12)6-9-2-3-11-10(7-9)4-5-13-11/h2-3,7-8,13H,4-6,12H2,1H3
DM56NK4 CS CC(CC1=CC2=C(C=C1)NCC2)N
DM56NK4 IK YAVKNEHUAXPRSK-UHFFFAOYSA-N
DM56NK4 IU 1-(2,3-dihydro-1H-indol-5-yl)propan-2-amine
DM56NK4 DE Discovery agent
DM4XL8Z ID DM4XL8Z
DM4XL8Z DN 2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol
DM4XL8Z HS Investigative
DM4XL8Z SN CHEMBL259403; 2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol; Triclosan derivative, 12; BDBM25411
DM4XL8Z DT Small molecular drug
DM4XL8Z PC 25023962
DM4XL8Z MW 325.2
DM4XL8Z FM C17H18Cl2O2
DM4XL8Z IC InChI=1S/C17H18Cl2O2/c1-3-11(2)8-12-4-6-17(15(20)9-12)21-16-7-5-13(18)10-14(16)19/h4-7,9-11,20H,3,8H2,1-2H3
DM4XL8Z CS CCC(C)CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DM4XL8Z IK LHFFQFRAOUEGEB-UHFFFAOYSA-N
DM4XL8Z IU 2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol
DM4XL8Z DE Discovery agent
DME3FUD ID DME3FUD
DME3FUD DN 2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol
DME3FUD HS Investigative
DME3FUD SN 2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol; JPN; Triclosan derivative, 22; CHEMBL259880; BDBM25421; 6760-EP2316452A1; 6760-EP2311801A1; 6760-EP2311797A1; 6760-EP2311455A1; 6760-EP2301536A1; 6760-EP2298767A1; 6760-EP2281818A1; 6760-EP2311798A1; 6760-EP2308509A1; 6760-EP2305250A1; 6760-EP2301627A1; 6760-EP2301538A1; 6760-EP2298734A2; 6760-EP2295053A1; 6760-EP2292614A1; 6760-EP2287155A1; 6760-EP2277876A1; 6760-EP1441224A2; 6760-EP2314587A1; 6760-EP2311831A1; 6760-EP2311799A1; 6760-EP2308874A1; 6760-EP2308873A1; 6760-EP2305653A1
DME3FUD DT Small molecular drug
DME3FUD PC 16220126
DME3FUD MW 373.3
DME3FUD FM C21H18Cl2O2
DME3FUD IC InChI=1S/C21H18Cl2O2/c22-17-10-12-20(18(23)14-17)25-21-11-9-16(13-19(21)24)8-4-7-15-5-2-1-3-6-15/h1-3,5-6,9-14,24H,4,7-8H2
DME3FUD CS C1=CC=C(C=C1)CCCC2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DME3FUD IK MJRPBNSOVIMDHN-UHFFFAOYSA-N
DME3FUD IU 2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol
DME3FUD DE Discovery agent
DMPSR1O ID DMPSR1O
DMPSR1O DN 2-(2,4-dichlorophenoxy)-5-ethylphenol
DMPSR1O HS Investigative
DMPSR1O SN Triclosan derivative, 8; CHEMBL260753; BDBM25407; 2-(2,4-dichlorophenoxy)-5-ethyl-phenol; ethylphenol (11)
DMPSR1O DT Small molecular drug
DMPSR1O PC 25023958
DMPSR1O MW 283.1
DMPSR1O FM C14H12Cl2O2
DMPSR1O IC InChI=1S/C14H12Cl2O2/c1-2-9-3-5-14(12(17)7-9)18-13-6-4-10(15)8-11(13)16/h3-8,17H,2H2,1H3
DMPSR1O CS CCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMPSR1O IK UUSUFMSMUYHSBH-UHFFFAOYSA-N
DMPSR1O IU 2-(2,4-dichlorophenoxy)-5-ethylphenol
DMPSR1O DE Discovery agent
DMKOFRE ID DMKOFRE
DMKOFRE DN 2-(2,4-dichlorophenoxy)-5-isobutylphenol
DMKOFRE HS Investigative
DMKOFRE SN Triclosan derivative, 11; CHEMBL261521; BDBM25410
DMKOFRE DT Small molecular drug
DMKOFRE PC 25023961
DMKOFRE MW 311.2
DMKOFRE FM C16H16Cl2O2
DMKOFRE IC InChI=1S/C16H16Cl2O2/c1-10(2)7-11-3-5-16(14(19)8-11)20-15-6-4-12(17)9-13(15)18/h3-6,8-10,19H,7H2,1-2H3
DMKOFRE CS CC(C)CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMKOFRE IK ZPZSZEVICIKUBD-UHFFFAOYSA-N
DMKOFRE IU 2-(2,4-dichlorophenoxy)-5-(2-methylpropyl)phenol
DMKOFRE DE Discovery agent
DME0LZ2 ID DME0LZ2
DME0LZ2 DN 2-(2,4-dichlorophenoxy)-5-isopentylphenol
DME0LZ2 HS Investigative
DME0LZ2 SN Triclosan derivative, 13; CHEMBL261144; BDBM25412; 2-(2,4-dichlorophenoxy)-5-isopentyl-phenol
DME0LZ2 DT Small molecular drug
DME0LZ2 PC 25023963
DME0LZ2 MW 325.2
DME0LZ2 FM C17H18Cl2O2
DME0LZ2 IC InChI=1S/C17H18Cl2O2/c1-11(2)3-4-12-5-7-17(15(20)9-12)21-16-8-6-13(18)10-14(16)19/h5-11,20H,3-4H2,1-2H3
DME0LZ2 CS CC(C)CCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DME0LZ2 IK CODNLKSZUDXSLW-UHFFFAOYSA-N
DME0LZ2 IU 2-(2,4-dichlorophenoxy)-5-(3-methylbutyl)phenol
DME0LZ2 DE Discovery agent
DM1L3US ID DM1L3US
DM1L3US DN 2-(2,4-dichlorophenoxy)-5-methylphenol
DM1L3US HS Investigative
DM1L3US SN 2-(2,4-dichlorophenoxy)-5-methylphenol; Triclosan derivative, 2; CHEMBL258569; SCHEMBL12286177; BDBM25401
DM1L3US DT Small molecular drug
DM1L3US PC 22947105
DM1L3US MW 269.12
DM1L3US FM C13H10Cl2O2
DM1L3US IC InChI=1S/C13H10Cl2O2/c1-8-2-4-13(11(16)6-8)17-12-5-3-9(14)7-10(12)15/h2-7,16H,1H3
DM1L3US CS CC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DM1L3US IK FHTKTADYDYDEMS-UHFFFAOYSA-N
DM1L3US IU 2-(2,4-dichlorophenoxy)-5-methylphenol
DM1L3US DE Discovery agent
DM6ZNR3 ID DM6ZNR3
DM6ZNR3 DN 2-(2,4-dichlorophenoxy)-5-phenethylphenol
DM6ZNR3 HS Investigative
DM6ZNR3 SN 2-(2,4-Dichlorophenoxy)-5-(2-Phenylethyl)phenol; JPJ; Triclosan derivative, 21; CHEMBL260061; BDBM25420
DM6ZNR3 DT Small molecular drug
DM6ZNR3 PC 16220128
DM6ZNR3 MW 359.2
DM6ZNR3 FM C20H16Cl2O2
DM6ZNR3 IC InChI=1S/C20H16Cl2O2/c21-16-9-11-19(17(22)13-16)24-20-10-8-15(12-18(20)23)7-6-14-4-2-1-3-5-14/h1-5,8-13,23H,6-7H2
DM6ZNR3 CS C1=CC=C(C=C1)CCC2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DM6ZNR3 IK SOSAEWQXZFTNAQ-UHFFFAOYSA-N
DM6ZNR3 IU 2-(2,4-dichlorophenoxy)-5-(2-phenylethyl)phenol
DM6ZNR3 DE Discovery agent
DMKP974 ID DMKP974
DMKP974 DN 2-(2,4-dichlorophenoxy)-5-propylphenol
DMKP974 HS Investigative
DMKP974 SN 2-(2,4-dichlorophenoxy)-5-propylphenol; Triclosan derivative, 9; CHEMBL263896; BDBM25408
DMKP974 DT Small molecular drug
DMKP974 PC 25023959
DMKP974 MW 297.2
DMKP974 FM C15H14Cl2O2
DMKP974 IC InChI=1S/C15H14Cl2O2/c1-2-3-10-4-6-15(13(18)8-10)19-14-7-5-11(16)9-12(14)17/h4-9,18H,2-3H2,1H3
DMKP974 CS CCCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMKP974 IK ILBQDZVPNAVUMD-UHFFFAOYSA-N
DMKP974 IU 2-(2,4-dichlorophenoxy)-5-propylphenol
DMKP974 DE Discovery agent
DMDUF21 ID DMDUF21
DMDUF21 DN 2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole
DMDUF21 HS Investigative
DMDUF21 SN 2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole; CHEMBL489080; 61033-72-5; 2-(2,4-dichlorophenyl)-2-imidazoline; CTK2E8089; DTXSID20492004; BDBM50266030; ZINC40976675; AKOS027869670; DB-072897; FT-0720309; 1H-Imidazole, 2-(2,4-dichlorophenyl)-4,5-dihydro-
DMDUF21 DT Small molecular drug
DMDUF21 PC 12341497
DMDUF21 MW 215.08
DMDUF21 FM C9H8Cl2N2
DMDUF21 IC InChI=1S/C9H8Cl2N2/c10-6-1-2-7(8(11)5-6)9-12-3-4-13-9/h1-2,5H,3-4H2,(H,12,13)
DMDUF21 CS C1CN=C(N1)C2=C(C=C(C=C2)Cl)Cl
DMDUF21 IK DSQMJENLNWSEMO-UHFFFAOYSA-N
DMDUF21 IU 2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole
DMDUF21 CA CAS 61033-72-5
DMDUF21 DE Discovery agent
DMSND8U ID DMSND8U
DMSND8U DN 2-(2,4-difluorophenyl)-2,2-diphenylacetamide
DMSND8U HS Investigative
DMSND8U SN CHEMBL270913; SCHEMBL14437488
DMSND8U DT Small molecular drug
DMSND8U PC 20684853
DMSND8U MW 323.3
DMSND8U FM C20H15F2NO
DMSND8U IC InChI=1S/C20H15F2NO/c21-16-11-12-17(18(22)13-16)20(19(23)24,14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13H,(H2,23,24)
DMSND8U CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=C(C=C(C=C3)F)F)C(=O)N
DMSND8U IK GASORINMDZETOC-UHFFFAOYSA-N
DMSND8U IU 2-(2,4-difluorophenyl)-2,2-diphenylacetamide
DMSND8U DE Discovery agent
DMG49N2 ID DMG49N2
DMG49N2 DN 2-(2,4-diphenylthiazol-5-yl)acetic acid
DMG49N2 HS Investigative
DMG49N2 SN 2-(2,4-diphenyl-1,3-thiazol-5-yl)acetic acid; 21256-15-5; 2-(2,4-diphenylthiazol-5-yl)acetic acid; CHEMBL592001; SMR000168586; diphenylthiazolylaceticacid; Bionet2_000936; AC1MC90U; Oprea1_148343; MLS000327963; SCHEMBL4497493; CTK4E6215; DTXSID40377203; MolPort-002-345-061; ZINC169124; HMS2377A22; HMS1366K12; KS-00001A6R; 7213AD; SBB077302; BDBM50309445; AKOS005070458; RP15938; MCULE-6578968783; 4K-539S; (diphenyl-1,3-thiazol-5-yl)acetic acid; AM803507; AJ-17064; KB-220568; TR-009976; CS-0039039; FT-0680367; I04-4316; J-505484
DMG49N2 DT Small molecular drug
DMG49N2 PC 2763923
DMG49N2 MW 295.4
DMG49N2 FM C17H13NO2S
DMG49N2 IC InChI=1S/C17H13NO2S/c19-15(20)11-14-16(12-7-3-1-4-8-12)18-17(21-14)13-9-5-2-6-10-13/h1-10H,11H2,(H,19,20)
DMG49N2 CS C1=CC=C(C=C1)C2=C(SC(=N2)C3=CC=CC=C3)CC(=O)O
DMG49N2 IK WNGOHXAHAKLKAR-UHFFFAOYSA-N
DMG49N2 IU 2-(2,4-diphenyl-1,3-thiazol-5-yl)acetic acid
DMG49N2 CA CAS 21256-15-5
DMG49N2 DE Discovery agent
DM7JUK0 ID DM7JUK0
DM7JUK0 DN 2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole
DM7JUK0 HS Investigative
DM7JUK0 SN CHEMBL71033; SCHEMBL953521; 2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-[(2,6-dimethylphenyl)methyl]-4,5-dihydro-; BDBM50064817; 2-(2,6-Dimethylbenzyl)-2-imidazoline
DM7JUK0 DT Small molecular drug
DM7JUK0 PC 24782016
DM7JUK0 MW 188.27
DM7JUK0 FM C12H16N2
DM7JUK0 IC InChI=1S/C12H16N2/c1-9-4-3-5-10(2)11(9)8-12-13-6-7-14-12/h3-5H,6-8H2,1-2H3,(H,13,14)
DM7JUK0 CS CC1=C(C(=CC=C1)C)CC2=NCCN2
DM7JUK0 IK GPUVYOKQAJEFBO-UHFFFAOYSA-N
DM7JUK0 IU 2-[(2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
DM7JUK0 DE Discovery agent
DMITKZY ID DMITKZY
DMITKZY DN 2-(2-acetyl-4-bromophenoxy)acetic acid
DMITKZY HS Investigative
DMITKZY SN 2-(2-acetyl-4-bromophenoxy)acetic acid; 34849-51-9; CHEMBL384130; SCHEMBL789387; ZPKLKLLENLTZEX-UHFFFAOYSA-N; MolPort-035-831-033; 2-Acetyl-4-bromophenoxyacetic acid; BDBM50200252; ZINC36127031; AKOS005215962; (2-Acetyl-4-bromophenoxy)acetic acid; AS-30410; SY028375; [(2-acetyl-4-bromophenyl)oxy]acetic Acid; Aceticacid,2-(2-acetyl-4-bromophenoxy)-; Acetic acid, (2-acetyl-4-bromophenoxy)-; MFCD27949767 (95%)
DMITKZY DT Small molecular drug
DMITKZY PC 19261363
DMITKZY MW 273.08
DMITKZY FM C10H9BrO4
DMITKZY IC InChI=1S/C10H9BrO4/c1-6(12)8-4-7(11)2-3-9(8)15-5-10(13)14/h2-4H,5H2,1H3,(H,13,14)
DMITKZY CS CC(=O)C1=C(C=CC(=C1)Br)OCC(=O)O
DMITKZY IK ZPKLKLLENLTZEX-UHFFFAOYSA-N
DMITKZY IU 2-(2-acetyl-4-bromophenoxy)acetic acid
DMITKZY DE Discovery agent
DMP1KZW ID DMP1KZW
DMP1KZW DN 2-(2-adamantyl) piperidine
DMP1KZW HS Investigative
DMP1KZW SN 2-(2-Adamantyl)piperidine; AC1LADJJ; SCHEMBL587506; 2-(adamantan-2-yl)piperidine; CHEMBL117334
DMP1KZW DT Small molecular drug
DMP1KZW PC 511919
DMP1KZW MW 219.37
DMP1KZW FM C15H25N
DMP1KZW IC InChI=1S/C15H25N/c1-2-4-16-14(3-1)15-12-6-10-5-11(8-12)9-13(15)7-10/h10-16H,1-9H2
DMP1KZW CS C1CCNC(C1)C2C3CC4CC(C3)CC2C4
DMP1KZW IK XNMHSNFFGAZILT-UHFFFAOYSA-N
DMP1KZW IU 2-(2-adamantyl)piperidine
DMP1KZW DE Discovery agent
DMXDGEF ID DMXDGEF
DMXDGEF DN 2-(2-allyl-4-chlorophenoxy)acetic acid
DMXDGEF HS Investigative
DMXDGEF SN CHEMBL245707; 6964-26-7; (2-allyl-4-chloro-phenoxy)-acetic acid; NSC66309; [4-chloro-2-(prop-2-en-1-yl)phenoxy]acetic acid; 2-(2-allyl-4-chlorophenoxy)acetic acid; AC1Q3LUZ; 2-(4-chloro-2-prop-2-enylphenoxy)acetic acid; AC1L6N6K; SCHEMBL4879038; CTK5D0709; DTXSID60290061; NSC-66309; BDBM50213925; AKOS005352797; Acetic acid,2-[4-chloro-2-(2-propen-1-yl)phenoxy]-
DMXDGEF DT Small molecular drug
DMXDGEF PC 248828
DMXDGEF MW 226.65
DMXDGEF FM C11H11ClO3
DMXDGEF IC InChI=1S/C11H11ClO3/c1-2-3-8-6-9(12)4-5-10(8)15-7-11(13)14/h2,4-6H,1,3,7H2,(H,13,14)
DMXDGEF CS C=CCC1=C(C=CC(=C1)Cl)OCC(=O)O
DMXDGEF IK SUGLMNNOLUZPQE-UHFFFAOYSA-N
DMXDGEF IU 2-(4-chloro-2-prop-2-enylphenoxy)acetic acid
DMXDGEF CA CAS 6964-26-7
DMXDGEF DE Discovery agent
DMVTD1F ID DMVTD1F
DMVTD1F DN 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran
DMVTD1F HS Investigative
DMVTD1F SN CHEMBL448912; SCHEMBL2691374; BDBM50276507
DMVTD1F DT Small molecular drug
DMVTD1F PC 11672904
DMVTD1F MW 205.3
DMVTD1F FM C13H19NO
DMVTD1F IC InChI=1S/C13H19NO/c14-9-8-12-6-7-13(15-12)10-11-4-2-1-3-5-11/h1-5,12-13H,6-10,14H2
DMVTD1F CS C1CC(OC1CCN)CC2=CC=CC=C2
DMVTD1F IK FZRYLYZNENTFJM-UHFFFAOYSA-N
DMVTD1F IU 2-(5-benzyloxolan-2-yl)ethanamine
DMVTD1F DE Discovery agent
DM3JM7V ID DM3JM7V
DM3JM7V DN 2-(2-Amino-ethyl)-7-imino-azepane
DM3JM7V HS Investigative
DM3JM7V SN CHEMBL92475; 2-(2-Amino-ethyl)-7-imino-azepane; SCHEMBL6976741; BDBM50104654
DM3JM7V DT Small molecular drug
DM3JM7V PC 9995251
DM3JM7V MW 155.24
DM3JM7V FM C8H17N3
DM3JM7V IC InChI=1S/C8H17N3/c9-6-5-7-3-1-2-4-8(10)11-7/h7H,1-6,9H2,(H2,10,11)
DM3JM7V CS C1CCC(=NC(C1)CCN)N
DM3JM7V IK KENFUNZIVHXJNM-UHFFFAOYSA-N
DM3JM7V IU 2-(2-aminoethyl)-3,4,5,6-tetrahydro-2H-azepin-7-amine
DM3JM7V DE Discovery agent
DMDFYJR ID DMDFYJR
DMDFYJR DN 2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one
DMDFYJR HS Investigative
DMDFYJR SN CHEMBL1163331
DMDFYJR DT Small molecular drug
DMDFYJR PC 46907250
DMDFYJR MW 263.29
DMDFYJR FM C16H13N3O
DMDFYJR IC InChI=1S/C16H13N3O/c17-8-9-19-13-7-3-6-12-14(13)15(18-19)10-4-1-2-5-11(10)16(12)20/h1-7H,8-9,17H2
DMDFYJR CS C1=CC=C2C(=C1)C3=NN(C4=CC=CC(=C43)C2=O)CCN
DMDFYJR IK BELLEOUYTCSNAZ-UHFFFAOYSA-N
DMDFYJR IU 14-(2-aminoethyl)-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
DMDFYJR DE Discovery agent
DMM9A8G ID DMM9A8G
DMM9A8G DN 2-(2-aminophenoxy)-5-hexylphenol
DMM9A8G HS Investigative
DMM9A8G SN CHEMBL264434; 2-(2-Azanylphenoxy)-5-Hexyl-Phenol; 2-(2-aminophenoxy)-5-hexylphenol; PT13; BDBM50373348
DMM9A8G DT Small molecular drug
DMM9A8G PC 44450094
DMM9A8G MW 285.4
DMM9A8G FM C18H23NO2
DMM9A8G IC InChI=1S/C18H23NO2/c1-2-3-4-5-8-14-11-12-18(16(20)13-14)21-17-10-7-6-9-15(17)19/h6-7,9-13,20H,2-5,8,19H2,1H3
DMM9A8G CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2N)O
DMM9A8G IK UGZFBZMADDXZRA-UHFFFAOYSA-N
DMM9A8G IU 2-(2-aminophenoxy)-5-hexylphenol
DMM9A8G DE Discovery agent
DM0CWHT ID DM0CWHT
DM0CWHT DN 2-(2-Amino-phenyl)-6-methyl-chromen-4-one
DM0CWHT HS Investigative
DM0CWHT SN CHEMBL132035
DM0CWHT DT Small molecular drug
DM0CWHT PC 11107795
DM0CWHT MW 251.28
DM0CWHT FM C16H13NO2
DM0CWHT IC InChI=1S/C16H13NO2/c1-10-6-7-15-12(8-10)14(18)9-16(19-15)11-4-2-3-5-13(11)17/h2-9H,17H2,1H3
DM0CWHT CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3N
DM0CWHT IK FGXFHSSFMRVHFP-UHFFFAOYSA-N
DM0CWHT IU 2-(2-aminophenyl)-6-methylchromen-4-one
DM0CWHT DE Discovery agent
DMCLSJZ ID DMCLSJZ
DMCLSJZ DN 2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one
DMCLSJZ HS Investigative
DMCLSJZ SN CHEMBL375346; 2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one
DMCLSJZ DT Small molecular drug
DMCLSJZ PC 16203354
DMCLSJZ MW 272.3
DMCLSJZ FM C15H16N2O3
DMCLSJZ IC InChI=1S/C15H16N2O3/c16-13-4-2-1-3-12(13)14-9-11(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8,16H2
DMCLSJZ CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC=C3N
DMCLSJZ IK SGCZGVONFZVNLU-UHFFFAOYSA-N
DMCLSJZ IU 2-(2-aminophenyl)-6-morpholin-4-ylpyran-4-one
DMCLSJZ DE Discovery agent
DMZNRFG ID DMZNRFG
DMZNRFG DN 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol
DMZNRFG HS Investigative
DMZNRFG SN CHEMBL61002; Phenol, 2-(2-aminopropyl)-5-bromo-4-methoxy-; BDBM50226139
DMZNRFG DT Small molecular drug
DMZNRFG PC 13547424
DMZNRFG MW 260.13
DMZNRFG FM C10H14BrNO2
DMZNRFG IC InChI=1S/C10H14BrNO2/c1-6(12)3-7-4-10(14-2)8(11)5-9(7)13/h4-6,13H,3,12H2,1-2H3
DMZNRFG CS CC(CC1=CC(=C(C=C1O)Br)OC)N
DMZNRFG IK YMEPEWSDHUFKSX-UHFFFAOYSA-N
DMZNRFG IU 2-(2-aminopropyl)-5-bromo-4-methoxyphenol
DMZNRFG DE Discovery agent
DMN6IV2 ID DMN6IV2
DMN6IV2 DN 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid
DMN6IV2 HS Investigative
DMN6IV2 SN CHEMBL603459; 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid; SCHEMBL5056681; BDBM50309282
DMN6IV2 DT Small molecular drug
DMN6IV2 PC 46230226
DMN6IV2 MW 385.5
DMN6IV2 FM C24H19NO2S
DMN6IV2 IC InChI=1S/C24H19NO2S/c26-21(27)16-20-23(19-14-8-3-9-15-19)25-24(28-20)22(17-10-4-1-5-11-17)18-12-6-2-7-13-18/h1-15,22H,16H2,(H,26,27)
DMN6IV2 CS C1=CC=C(C=C1)C2=C(SC(=N2)C(C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)O
DMN6IV2 IK GSFLUFCQJVKCFD-UHFFFAOYSA-N
DMN6IV2 IU 2-(2-benzhydryl-4-phenyl-1,3-thiazol-5-yl)acetic acid
DMN6IV2 DE Discovery agent
DMLOD2Y ID DMLOD2Y
DMLOD2Y DN 2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y HS Investigative
DMLOD2Y SN CHEMBL217591; 2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y DT Small molecular drug
DMLOD2Y PC 44417452
DMLOD2Y MW 335.15
DMLOD2Y FM C15H11BrO4
DMLOD2Y IC InChI=1S/C15H11BrO4/c16-11-6-7-13(20-9-14(17)18)12(8-11)15(19)10-4-2-1-3-5-10/h1-8H,9H2,(H,17,18)
DMLOD2Y CS C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)Br)OCC(=O)O
DMLOD2Y IK QCXHRPLPQPZWKP-UHFFFAOYSA-N
DMLOD2Y IU 2-(2-benzoyl-4-bromophenoxy)acetic acid
DMLOD2Y DE Discovery agent
DMFK0GM ID DMFK0GM
DMFK0GM DN 2-(2-bromo-2-naphthamido)benzoic acid
DMFK0GM HS Investigative
DMFK0GM SN CHEMBL199574; SCHEMBL18120563; BDBM16096; 2-[(6-bromonaphthalene-2-)amido]benzoic acid; 2-{[(6-bromonaphthalen-2-yl)carbonyl]amino}benzoic acid
DMFK0GM DT Small molecular drug
DMFK0GM PC 23647297
DMFK0GM MW 370.2
DMFK0GM FM C18H12BrNO3
DMFK0GM IC InChI=1S/C18H12BrNO3/c19-14-8-7-11-9-13(6-5-12(11)10-14)17(21)20-16-4-2-1-3-15(16)18(22)23/h1-10H,(H,20,21)(H,22,23)
DMFK0GM CS C1=CC=C(C(=C1)C(=O)O)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)Br
DMFK0GM IK KNVPXLPBRSRJCV-UHFFFAOYSA-N
DMFK0GM IU 2-[(6-bromonaphthalene-2-carbonyl)amino]benzoic acid
DMFK0GM DE Discovery agent
DM3VH7F ID DM3VH7F
DM3VH7F DN 2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione
DM3VH7F HS Investigative
DM3VH7F SN 2-(2-Bromobenzoyl)cyclohexane-1,3-dione; CHEMBL168906; 88562-08-7; 1,3-Cyclohexanedione, 2-(2-bromobenzoyl)-; ACMC-20lbdp; 2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione; CTK3A9588; DTXSID70558700
DM3VH7F DT Small molecular drug
DM3VH7F PC 14301627
DM3VH7F MW 295.13
DM3VH7F FM C13H11BrO3
DM3VH7F IC InChI=1S/C13H11BrO3/c14-9-5-2-1-4-8(9)13(17)12-10(15)6-3-7-11(12)16/h1-2,4-5,12H,3,6-7H2
DM3VH7F CS C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2Br
DM3VH7F IK XECQPEVQAQFNOX-UHFFFAOYSA-N
DM3VH7F IU 2-(2-bromobenzoyl)cyclohexane-1,3-dione
DM3VH7F CA CAS 88562-08-7
DM3VH7F DE Discovery agent
DMHBE0X ID DMHBE0X
DMHBE0X DN 2-(2-Bromophenoxy)-N,N-dimethylethanamine
DMHBE0X HS Investigative
DMHBE0X SN 886851-37-2; 2-(2-Dimethylaminoethoxy)-bromobenzene; 2-(2-Bromophenoxy)-N,N-dimethylethanamine; CHEMBL599818; [2-(2-bromophenoxy)ethyl]dimethylamine; AC1LHJHJ; SCHEMBL1857526; DTXSID50358341; MolPort-004-331-572; ZINC4914895; KS-000000PE; BDBM50307492; 2-(2-dimethylaminoethoxy)bromobenzene; AKOS000170274; MCULE-8721188188; AM87375; AS-44355; AJ-52607; KB-323008; Y-0778
DMHBE0X DT Small molecular drug
DMHBE0X PC 888311
DMHBE0X MW 244.13
DMHBE0X FM C10H14BrNO
DMHBE0X IC InChI=1S/C10H14BrNO/c1-12(2)7-8-13-10-6-4-3-5-9(10)11/h3-6H,7-8H2,1-2H3
DMHBE0X CS CN(C)CCOC1=CC=CC=C1Br
DMHBE0X IK OUWAXRLVNYTZJK-UHFFFAOYSA-N
DMHBE0X IU 2-(2-bromophenoxy)-N,N-dimethylethanamine
DMHBE0X CA CAS 886851-37-2
DMHBE0X DE Discovery agent
DMHJMUX ID DMHJMUX
DMHJMUX DN 2-(2-Bromophenylthio)-N,N-dimethylethanamine
DMHJMUX HS Investigative
DMHJMUX SN 2-(2-Bromophenylthio)-N,N-dimethylethanamine; CHEMBL610515; 1222866-87-6; BDBM50307491
DMHJMUX DT Small molecular drug
DMHJMUX PC 46233353
DMHJMUX MW 260.2
DMHJMUX FM C10H14BrNS
DMHJMUX IC InChI=1S/C10H14BrNS/c1-12(2)7-8-13-10-6-4-3-5-9(10)11/h3-6H,7-8H2,1-2H3
DMHJMUX CS CN(C)CCSC1=CC=CC=C1Br
DMHJMUX IK WXAWOWHEHSIUMN-UHFFFAOYSA-N
DMHJMUX IU 2-(2-bromophenyl)sulfanyl-N,N-dimethylethanamine
DMHJMUX DE Discovery agent
DMLTU3J ID DMLTU3J
DMLTU3J DN 2-(2-butoxypyrimidin-4-ylamino)benzoic acid
DMLTU3J HS Investigative
DMLTU3J SN 2-[(2-butoxypyrimidin-4-yl)amino]benzoic Acid; 4-anilinopyrimidine 1; AC1LZD2G; CHEMBL242488; BDBM15977; MolPort-002-549-430; ZINC2272106; STL297947; AKOS003630983; MCULE-6330252818
DMLTU3J DT Small molecular drug
DMLTU3J PC 1897784
DMLTU3J MW 287.31
DMLTU3J FM C15H17N3O3
DMLTU3J IC InChI=1S/C15H17N3O3/c1-2-3-10-21-15-16-9-8-13(18-15)17-12-7-5-4-6-11(12)14(19)20/h4-9H,2-3,10H2,1H3,(H,19,20)(H,16,17,18)
DMLTU3J CS CCCCOC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMLTU3J IK YTFVMUTWNFDKIY-UHFFFAOYSA-N
DMLTU3J IU 2-[(2-butoxypyrimidin-4-yl)amino]benzoic acid
DMLTU3J DE Discovery agent
DMEGY0T ID DMEGY0T
DMEGY0T DN 2-(2-carboxy-5-mercaptopentyl)benzoic acid
DMEGY0T HS Investigative
DMEGY0T SN Thiol-Based Inhibitor, 6b; SCHEMBL5053172; CHEMBL207314; CTK8A8856; BDBM17761; AKOS015966159; 2-(2-CARBOXY-5-MERCAPTO-PENTYL)-BENZOIC ACID; 2-[2-carboxy-2-(3-sulfanylpropyl)ethyl]benzoic acid
DMEGY0T DT Small molecular drug
DMEGY0T PC 9921539
DMEGY0T MW 268.33
DMEGY0T FM C13H16O4S
DMEGY0T IC InChI=1S/C13H16O4S/c14-12(15)10(5-3-7-18)8-9-4-1-2-6-11(9)13(16)17/h1-2,4,6,10,18H,3,5,7-8H2,(H,14,15)(H,16,17)
DMEGY0T CS C1=CC=C(C(=C1)CC(CCCS)C(=O)O)C(=O)O
DMEGY0T IK AJRYUIBEXXWDCQ-UHFFFAOYSA-N
DMEGY0T IU 2-(2-carboxy-5-sulfanylpentyl)benzoic acid
DMEGY0T DE Discovery agent
DMR98ML ID DMR98ML
DMR98ML DN 2-(2-carboxy-7-mercaptoheptyl)benzoic acid
DMR98ML HS Investigative
DMR98ML SN CHEMBL206804
DMR98ML DT Small molecular drug
DMR98ML PC 44410794
DMR98ML MW 296.4
DMR98ML FM C15H20O4S
DMR98ML IC InChI=1S/C15H20O4S/c16-14(17)12(7-2-1-5-9-20)10-11-6-3-4-8-13(11)15(18)19/h3-4,6,8,12,20H,1-2,5,7,9-10H2,(H,16,17)(H,18,19)
DMR98ML CS C1=CC=C(C(=C1)CC(CCCCCS)C(=O)O)C(=O)O
DMR98ML IK MLFBNUWBZSWDEZ-UHFFFAOYSA-N
DMR98ML IU 2-(2-carboxy-7-sulfanylheptyl)benzoic acid
DMR98ML DE Discovery agent
DMWDV71 ID DMWDV71
DMWDV71 DN 2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMWDV71 HS Investigative
DMWDV71 DT Small molecular drug
DMWDV71 PC 135528624
DMWDV71 MW 261.66
DMWDV71 FM C13H8ClNO3
DMWDV71 IC InChI=1S/C13H8ClNO3/c14-10-5-7(16)1-3-9(10)13-15-11-6-8(17)2-4-12(11)18-13/h1-6,16-17H
DMWDV71 CS C1=CC(=C(C=C1O)Cl)C2=NC3=C(O2)C=CC(=C3)O
DMWDV71 IK RDNJWPGDJWLTPJ-UHFFFAOYSA-N
DMWDV71 IU 2-(2-chloro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMWDV71 DE Discovery agent
DMG6ABE ID DMG6ABE
DMG6ABE DN 2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione
DMG6ABE HS Investigative
DMG6ABE SN 2-(2-Chlorobenzoyl)cyclohexane-1,3-dione; CHEMBL166951; 88562-09-8; 1,3-Cyclohexanedione, 2-(2-chlorobenzoyl)-; ACMC-20lbdq; 2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione; SCHEMBL10192439; CTK3A9587; DTXSID30558701
DMG6ABE DT Small molecular drug
DMG6ABE PC 14301628
DMG6ABE MW 250.68
DMG6ABE FM C13H11ClO3
DMG6ABE IC InChI=1S/C13H11ClO3/c14-9-5-2-1-4-8(9)13(17)12-10(15)6-3-7-11(12)16/h1-2,4-5,12H,3,6-7H2
DMG6ABE CS C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2Cl
DMG6ABE IK TYJXBELAFWQDPT-UHFFFAOYSA-N
DMG6ABE IU 2-(2-chlorobenzoyl)cyclohexane-1,3-dione
DMG6ABE CA CAS 88562-09-8
DMG6ABE DE Discovery agent
DM1ULEX ID DM1ULEX
DM1ULEX DN 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine
DM1ULEX HS Investigative
DM1ULEX SN CHEMBL609904; 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine; SCHEMBL13769617
DM1ULEX DT Small molecular drug
DM1ULEX PC 44133853
DM1ULEX MW 288.77
DM1ULEX FM C16H17ClN2O
DM1ULEX IC InChI=1S/C16H17ClN2O/c17-14-5-1-2-6-15(14)20-16-13(4-3-9-19-16)12-7-10-18-11-8-12/h1-6,9,12,18H,7-8,10-11H2
DM1ULEX CS C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3Cl
DM1ULEX IK OLCRHPXGKWMFIP-UHFFFAOYSA-N
DM1ULEX IU 2-(2-chlorophenoxy)-3-piperidin-4-ylpyridine
DM1ULEX DE Discovery agent
DM60RWZ ID DM60RWZ
DM60RWZ DN 2-(2-chlorophenyl)-2,2-diphenylethanamide
DM60RWZ HS Investigative
DM60RWZ SN CHEMBL406683; AC1NNFGO; Amino-2-chlorotrityl resin; SCHEMBL1001586; 2-Chlorotriphenylmethyl amine resin; (2-chlorophenyl)-diphenylmethanamine; 2-Chlorotrityl amine, polymer-bound; BDBM50371377; 2-Chlorotrityl amine, polymer-bound, 100-200 mesh, extent of labeling: 1.3-1.8 mmol/g loading, 1 % cross-linked
DM60RWZ DT Small molecular drug
DM60RWZ PC 5068018
DM60RWZ MW 293.8
DM60RWZ FM C19H16ClN
DM60RWZ IC InChI=1S/C19H16ClN/c20-18-14-8-7-13-17(18)19(21,15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14H,21H2
DM60RWZ CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N
DM60RWZ IK AXCRTHNDHLRNOA-UHFFFAOYSA-N
DM60RWZ IU (2-chlorophenyl)-diphenylmethanamine
DM60RWZ CA CAS 42074-69-1
DM60RWZ DE Discovery agent
DMTYDX2 ID DMTYDX2
DMTYDX2 DN 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide
DMTYDX2 HS Investigative
DMTYDX2 SN CHEMBL1094952; 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265265
DMTYDX2 DT Small molecular drug
DMTYDX2 PC 44549373
DMTYDX2 MW 271.7
DMTYDX2 FM C14H10ClN3O
DMTYDX2 IC InChI=1S/C14H10ClN3O/c15-11-6-1-2-7-12(11)18-8-9-4-3-5-10(14(16)19)13(9)17-18/h1-8H,(H2,16,19)
DMTYDX2 CS C1=CC=C(C(=C1)N2C=C3C=CC=C(C3=N2)C(=O)N)Cl
DMTYDX2 IK CYJGVBUKZAGGCY-UHFFFAOYSA-N
DMTYDX2 IU 2-(2-chlorophenyl)indazole-7-carboxamide
DMTYDX2 DE Discovery agent
DMFG2S5 ID DMFG2S5
DMFG2S5 DN 2-(2-chlorophenyl)-2-morpholinoethanamine
DMFG2S5 HS Investigative
DMFG2S5 SN 866782-01-6; 2-(2-Chlorophenyl)-2-morpholin-4-ylethylamine; 2-(2-chlorophenyl)-2-(morpholin-4-yl)ethan-1-amine; 2-(2-chlorophenyl)-2-morpholinoethanamine; CHEMBL382382; 4-Morpholineethanamine,b-(2-chlorophenyl)-; 2-(2-chlorophenyl)-2-morpholin-4-ylethanamine; 2-(2-Chlorophenyl)-2-morpholinoethylamine; 2-(2-Chlorophenyl)-2-(morpholin-4-yl)ethylamine; beta-phenethylamine 6; AC1MZFUY; AC1Q53NI; SCHEMBL8276869; CTK5F7083; BDBM11556; DCA-S02-0; DTXSID90397254; MolPort-001-760-150; KS-000029ZH; 4759AH; SBB073200; AR3509
DMFG2S5 DT Small molecular drug
DMFG2S5 PC 3847395
DMFG2S5 MW 240.73
DMFG2S5 FM C12H17ClN2O
DMFG2S5 IC InChI=1S/C12H17ClN2O/c13-11-4-2-1-3-10(11)12(9-14)15-5-7-16-8-6-15/h1-4,12H,5-9,14H2
DMFG2S5 CS C1COCCN1C(CN)C2=CC=CC=C2Cl
DMFG2S5 IK OJHPTRVTZGOWAO-UHFFFAOYSA-N
DMFG2S5 IU 2-(2-chlorophenyl)-2-morpholin-4-ylethanamine
DMFG2S5 CA CAS 866782-01-6
DMFG2S5 DE Discovery agent
DMJ38LE ID DMJ38LE
DMJ38LE DN 2-(2-chlorophenylamino)-5-methylthiazol-4(5H)-one
DMJ38LE HS Investigative
DMJ38LE DT Small molecular drug
DMJ38LE PC 91181036
DMJ38LE MW 240.71
DMJ38LE FM C10H9ClN2OS
DMJ38LE IC InChI=1S/C10H9ClN2OS/c1-6-9(14)13-10(15-6)12-8-5-3-2-4-7(8)11/h2-5,14H,1H3,(H,12,13)
DMJ38LE CS CC1=C(N=C(S1)NC2=CC=CC=C2Cl)O
DMJ38LE IK JVRHHSAVCUJPIO-UHFFFAOYSA-N
DMJ38LE IU 2-(2-chloroanilino)-5-methyl-1,3-thiazol-4-ol
DMJ38LE DE Discovery agent
DM187UQ ID DM187UQ
DM187UQ DN 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole
DM187UQ HS Investigative
DM187UQ SN CHEMBL248050; 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole; AC1NRV52; BDBM50326635; Cycloheptanone, (4-phenyl-2-thiazolyl)hydrazone; N-(cycloheptylideneamino)-4-phenyl-thiazol-2-amine; 1-cycloheptylidene-2-(4-phenylthiazol-2-yl)hydrazine
DM187UQ DT Small molecular drug
DM187UQ PC 5273551
DM187UQ MW 285.4
DM187UQ FM C16H19N3S
DM187UQ IC InChI=1S/C16H19N3S/c1-2-7-11-14(10-6-1)18-19-16-17-15(12-20-16)13-8-4-3-5-9-13/h3-5,8-9,12H,1-2,6-7,10-11H2,(H,17,19)
DM187UQ CS C1CCCC(=NNC2=NC(=CS2)C3=CC=CC=C3)CC1
DM187UQ IK HFWROKPXAPGNOY-UHFFFAOYSA-N
DM187UQ IU N-(cycloheptylideneamino)-4-phenyl-1,3-thiazol-2-amine
DM187UQ DE Discovery agent
DMUN2CS ID DMUN2CS
DMUN2CS DN 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid
DMUN2CS HS Investigative
DMUN2CS SN CHEMBL246312; 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid; SCHEMBL4886140
DMUN2CS DT Small molecular drug
DMUN2CS PC 44441190
DMUN2CS MW 252.28
DMUN2CS FM C14H17FO3
DMUN2CS IC InChI=1S/C14H17FO3/c15-11-6-7-13(18-9-14(16)17)12(8-11)10-4-2-1-3-5-10/h6-8,10H,1-5,9H2,(H,16,17)
DMUN2CS CS C1CCC(CC1)C2=C(C=CC(=C2)F)OCC(=O)O
DMUN2CS IK QBBFFBYIFRGECW-UHFFFAOYSA-N
DMUN2CS IU 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid
DMUN2CS DE Discovery agent
DMSI07M ID DMSI07M
DMSI07M DN 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid
DMSI07M HS Investigative
DMSI07M SN CHEMBL245701; (2-Cyclohexyl-4-methoxyphenoxy)acetic acid; 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid; SCHEMBL4885675; BDBM50213921
DMSI07M DT Small molecular drug
DMSI07M PC 11587023
DMSI07M MW 264.32
DMSI07M FM C15H20O4
DMSI07M IC InChI=1S/C15H20O4/c1-18-12-7-8-14(19-10-15(16)17)13(9-12)11-5-3-2-4-6-11/h7-9,11H,2-6,10H2,1H3,(H,16,17)
DMSI07M CS COC1=CC(=C(C=C1)OCC(=O)O)C2CCCCC2
DMSI07M IK PJEFVLZYUWCSGF-UHFFFAOYSA-N
DMSI07M IU 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid
DMSI07M DE Discovery agent
DMVCY42 ID DMVCY42
DMVCY42 DN 2-(2-cyclohexyl-4-methylphenoxy)acetic acid
DMVCY42 HS Investigative
DMVCY42 SN CHEMBL397651; 2-(2-cyclohexyl-4-methylphenoxy)acetic acid; SCHEMBL4883828
DMVCY42 DT Small molecular drug
DMVCY42 PC 44441192
DMVCY42 MW 248.32
DMVCY42 FM C15H20O3
DMVCY42 IC InChI=1S/C15H20O3/c1-11-7-8-14(18-10-15(16)17)13(9-11)12-5-3-2-4-6-12/h7-9,12H,2-6,10H2,1H3,(H,16,17)
DMVCY42 CS CC1=CC(=C(C=C1)OCC(=O)O)C2CCCCC2
DMVCY42 IK QMGSFVNEZAIRGD-UHFFFAOYSA-N
DMVCY42 IU 2-(2-cyclohexyl-4-methylphenoxy)acetic acid
DMVCY42 DE Discovery agent
DMPNGXE ID DMPNGXE
DMPNGXE DN 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole
DMPNGXE HS Investigative
DMPNGXE SN CHEMBL220495; 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole; AC1P6Q43; SCHEMBL19017688; ZINC7350105; BDBM50326652; AKOS005139675; ST51067929; N-(cyclohexylideneamino)-4-phenyl-thiazol-2-amine; 1-cyclohexylidene-2-(4-phenylthiazol-2-yl)hydrazine; N-(cyclohexylideneamino)-4-phenyl-1,3-thiazol-2-amine
DMPNGXE DT Small molecular drug
DMPNGXE PC 8443728
DMPNGXE MW 271.4
DMPNGXE FM C15H17N3S
DMPNGXE IC InChI=1S/C15H17N3S/c1-3-7-12(8-4-1)14-11-19-15(16-14)18-17-13-9-5-2-6-10-13/h1,3-4,7-8,11H,2,5-6,9-10H2,(H,16,18)
DMPNGXE CS C1CCC(=NNC2=NC(=CS2)C3=CC=CC=C3)CC1
DMPNGXE IK RQMWJSWLKXHIEZ-UHFFFAOYSA-N
DMPNGXE IU N-(cyclohexylideneamino)-4-phenyl-1,3-thiazol-2-amine
DMPNGXE DE Discovery agent
DMTFWAQ ID DMTFWAQ
DMTFWAQ DN 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole
DMTFWAQ HS Investigative
DMTFWAQ SN CHEMBL1253700; 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole; BDBM50326648; ZINC54362881; AKOS005139686; ST51067932
DMTFWAQ DT Small molecular drug
DMTFWAQ PC 50876172
DMTFWAQ MW 285.4
DMTFWAQ FM C16H19N3S
DMTFWAQ IC InChI=1S/C16H19N3S/c1-12-7-9-13(10-8-12)15-11-20-16(17-15)19-18-14-5-3-2-4-6-14/h7-11H,2-6H2,1H3,(H,17,19)
DMTFWAQ CS CC1=CC=C(C=C1)C2=CSC(=N2)NN=C3CCCCC3
DMTFWAQ IK KHLVZVWWHKJADP-UHFFFAOYSA-N
DMTFWAQ IU N-(cyclohexylideneamino)-4-(4-methylphenyl)-1,3-thiazol-2-amine
DMTFWAQ DE Discovery agent
DM81WJK ID DM81WJK
DM81WJK DN 2-(2-cyclohexylphenoxy)acetic acid
DM81WJK HS Investigative
DM81WJK SN 2-(2-cyclohexylphenoxy)acetic acid; CHEMBL247739; 82506-00-1; NSC405039; SCHEMBL4883839; AC1L85O4; DTXSID50323877; ZINC1597753; BDBM50213918
DM81WJK DT Small molecular drug
DM81WJK PC 346737
DM81WJK MW 234.29
DM81WJK FM C14H18O3
DM81WJK IC InChI=1S/C14H18O3/c15-14(16)10-17-13-9-5-4-8-12(13)11-6-2-1-3-7-11/h4-5,8-9,11H,1-3,6-7,10H2,(H,15,16)
DM81WJK CS C1CCC(CC1)C2=CC=CC=C2OCC(=O)O
DM81WJK IK SIYNBMWECIIUOX-UHFFFAOYSA-N
DM81WJK IU 2-(2-cyclohexylphenoxy)acetic acid
DM81WJK CA CAS 82506-00-1
DM81WJK DE Discovery agent
DMH1VCE ID DMH1VCE
DMH1VCE DN 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole
DMH1VCE HS Investigative
DMH1VCE SN CHEMBL386941; AC1LBKTO; 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole; SCHEMBL18998987; WUSIIHCESPBBHG-UHFFFAOYSA-N; MolPort-002-698-743; ZINC7350034; BDBM50326626; STK673148; AKOS005593088; MCULE-7323011972; Cyclopentanone, (4-phenyl-2-thiazolyl)hydrazone; N-(cyclopentylideneamino)-4-phenyl-thiazol-2-amine; 1-cyclopentylidene-2-(4-phenylthiazol-2-yl)hydrazine; N-(cyclopentylideneamino)-4-phenyl-1,3-thiazol-2-amine; A1355/0061138; Cyclopentanone ((2Z)-4-phenyl-1,3-thiazol-2(3H)-ylidene)hydrazone #
DMH1VCE DT Small molecular drug
DMH1VCE PC 584447
DMH1VCE MW 257.36
DMH1VCE FM C14H15N3S
DMH1VCE IC InChI=1S/C14H15N3S/c1-2-6-11(7-3-1)13-10-18-14(15-13)17-16-12-8-4-5-9-12/h1-3,6-7,10H,4-5,8-9H2,(H,15,17)
DMH1VCE CS C1CCC(=NNC2=NC(=CS2)C3=CC=CC=C3)C1
DMH1VCE IK WUSIIHCESPBBHG-UHFFFAOYSA-N
DMH1VCE IU N-(cyclopentylideneamino)-4-phenyl-1,3-thiazol-2-amine
DMH1VCE DE Discovery agent
DM1SN37 ID DM1SN37
DM1SN37 DN 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine
DM1SN37 HS Investigative
DM1SN37 SN CHEMBL597530; 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine; SCHEMBL13769759
DM1SN37 DT Small molecular drug
DM1SN37 PC 44133851
DM1SN37 MW 272.32
DM1SN37 FM C16H17FN2O
DM1SN37 IC InChI=1S/C16H17FN2O/c17-14-5-1-2-6-15(14)20-16-13(4-3-9-19-16)12-7-10-18-11-8-12/h1-6,9,12,18H,7-8,10-11H2
DM1SN37 CS C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3F
DM1SN37 IK OTTUCFBNHXCUBH-UHFFFAOYSA-N
DM1SN37 IU 2-(2-fluorophenoxy)-3-piperidin-4-ylpyridine
DM1SN37 DE Discovery agent
DMDUG9M ID DMDUG9M
DMDUG9M DN 2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one
DMDUG9M HS Investigative
DMDUG9M SN CHEMBL361608; 2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one
DMDUG9M DT Small molecular drug
DMDUG9M PC 11415057
DMDUG9M MW 290.3
DMDUG9M FM C19H11FO2
DMDUG9M IC InChI=1S/C19H11FO2/c20-16-8-4-3-7-14(16)18-11-17(21)15-10-9-12-5-1-2-6-13(12)19(15)22-18/h1-11H
DMDUG9M CS C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC=CC=C4F
DMDUG9M IK PBCBXDLSTLVGDE-UHFFFAOYSA-N
DMDUG9M IU 2-(2-fluorophenyl)benzo[h]chromen-4-one
DMDUG9M DE Discovery agent
DMMEBH3 ID DMMEBH3
DMMEBH3 DN 2-(2-formylphenoxy)acetic acid
DMMEBH3 HS Investigative
DMMEBH3 SN 2-Formylphenoxyacetic acid; 2-(2-Formylphenoxy)acetic acid; 6280-80-4; (2-Formylphenoxy)acetic acid; o-Formylphenoxyacetic acid; Acetic acid, (2-formylphenoxy)-; 2-Carboxymethoxybenzaldehyde; ortho-Formylphenoxyacetic acid; Acetic acid, (o-formylphenoxy)-; 2-Formylphenoxyaceticacid; Acetic acid, 2-(2-formylphenoxy)-; CHEMBL384289; ANWMNLAAFDCKMT-UHFFFAOYSA-N; NSC 6140; EINECS 228-480-9; NSC 133590; o-Formyphenoxyacetic acid; o-formyl phenoxyacetic acid; AC1L2G6R; 2-formyl phenoxyacetic acid; 2-monoformylphenoxyacetic acid
DMMEBH3 DT Small molecular drug
DMMEBH3 PC 46533
DMMEBH3 MW 180.16
DMMEBH3 FM C9H8O4
DMMEBH3 IC InChI=1S/C9H8O4/c10-5-7-3-1-2-4-8(7)13-6-9(11)12/h1-5H,6H2,(H,11,12)
DMMEBH3 CS C1=CC=C(C(=C1)C=O)OCC(=O)O
DMMEBH3 IK ANWMNLAAFDCKMT-UHFFFAOYSA-N
DMMEBH3 IU 2-(2-formylphenoxy)acetic acid
DMMEBH3 CA CAS 6280-80-4
DMMEBH3 DE Discovery agent
DMXGWOT ID DMXGWOT
DMXGWOT DN 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine
DMXGWOT HS Investigative
DMXGWOT SN CHEMBL399529; 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine; 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-ylamine; 856171-18-1; SCHEMBL1489577; SSPIGFDAVQVRCH-UHFFFAOYSA-N; BDBM50232155
DMXGWOT DT Small molecular drug
DMXGWOT PC 11424684
DMXGWOT MW 227.22
DMXGWOT FM C11H9N5O
DMXGWOT IC InChI=1S/C11H9N5O/c12-9-7-10(16-5-2-4-13-16)15-11(14-9)8-3-1-6-17-8/h1-7H,(H2,12,14,15)
DMXGWOT CS C1=CN(N=C1)C2=NC(=NC(=C2)N)C3=CC=CO3
DMXGWOT IK SSPIGFDAVQVRCH-UHFFFAOYSA-N
DMXGWOT IU 2-(furan-2-yl)-6-pyrazol-1-ylpyrimidin-4-amine
DMXGWOT DE Discovery agent
DMSI41E ID DMSI41E
DMSI41E DN 2-(2-hexylphenyl)isoindoline-1,3-dione
DMSI41E HS Investigative
DMSI41E SN CHEMBL245943; PP60; BDBM23841
DMSI41E DT Small molecular drug
DMSI41E PC 10638446
DMSI41E MW 307.4
DMSI41E FM C20H21NO2
DMSI41E IC InChI=1S/C20H21NO2/c1-2-3-4-5-10-15-11-6-9-14-18(15)21-19(22)16-12-7-8-13-17(16)20(21)23/h6-9,11-14H,2-5,10H2,1H3
DMSI41E CS CCCCCCC1=CC=CC=C1N2C(=O)C3=CC=CC=C3C2=O
DMSI41E IK USXHUJLIZBGCGH-UHFFFAOYSA-N
DMSI41E IU 2-(2-hexylphenyl)isoindole-1,3-dione
DMSI41E DE Discovery agent
DMMEL39 ID DMMEL39
DMMEL39 DN 2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid
DMMEL39 HS Investigative
DMMEL39 SN CHEMBL63454; 475653-52-2; 2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid; SCHEMBL13996820; CTK1C7211; DTXSID40609753; BDBM50129195; 2-[3-Oxo-3-(hydroxyamino)propyl]pentanedioic acid; 2-[3-(Hydroxyamino)-3-oxopropyl]pentanedioic acid; Pentanedioic acid, 2-[3-(hydroxyamino)-3-oxopropyl]-
DMMEL39 DT Small molecular drug
DMMEL39 PC 20778197
DMMEL39 MW 219.19
DMMEL39 FM C8H13NO6
DMMEL39 IC InChI=1S/C8H13NO6/c10-6(9-15)3-1-5(8(13)14)2-4-7(11)12/h5,15H,1-4H2,(H,9,10)(H,11,12)(H,13,14)
DMMEL39 CS C(CC(=O)NO)C(CCC(=O)O)C(=O)O
DMMEL39 IK HTZIUDNKEYUDDE-UHFFFAOYSA-N
DMMEL39 IU 2-[3-(hydroxyamino)-3-oxopropyl]pentanedioic acid
DMMEL39 CA CAS 475653-52-2
DMMEL39 DE Discovery agent
DMRPCL7 ID DMRPCL7
DMRPCL7 DN 2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one
DMRPCL7 HS Investigative
DMRPCL7 SN SCHEMBL11120339
DMRPCL7 DT Small molecular drug
DMRPCL7 PC 46907248
DMRPCL7 MW 264.28
DMRPCL7 FM C16H12N2O2
DMRPCL7 IC InChI=1S/C16H12N2O2/c19-9-8-18-13-7-3-6-12-14(13)15(17-18)10-4-1-2-5-11(10)16(12)20/h1-7,19H,8-9H2
DMRPCL7 CS C1=CC=C2C(=C1)C3=NN(C4=CC=CC(=C43)C2=O)CCO
DMRPCL7 IK IWTWHJYONHLOQB-UHFFFAOYSA-N
DMRPCL7 IU 14-(2-hydroxyethyl)-14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
DMRPCL7 DE Discovery agent
DM3UMYD ID DM3UMYD
DM3UMYD DN 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine
DM3UMYD HS Investigative
DM3UMYD SN 2-(2-hydroxy-phenyl)-1h-indole-5-carboxamidine; amino[2-(2-hydroxyphenyl)-1H-indol-5-yl]methaniminium; AC1L1BMI; BDBM13942; CTK8A0256; APC-8328; DB02463; [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium
DM3UMYD DT Small molecular drug
DM3UMYD PC 1507
DM3UMYD MW 252.29
DM3UMYD FM C15H14N3O+
DM3UMYD IC InChI=1S/C15H13N3O/c16-15(17)9-5-6-12-10(7-9)8-13(18-12)11-3-1-2-4-14(11)19/h1-8,18-19H,(H3,16,17)/p+1
DM3UMYD CS C1=CC=C(C(=C1)C2=CC3=C(N2)C=CC(=C3)C(=[NH2+])N)O
DM3UMYD IK JPGNPKIYCTXJPG-UHFFFAOYSA-O
DM3UMYD IU [amino-[2-(2-hydroxyphenyl)-1H-indol-5-yl]methylidene]azanium
DM3UMYD DE Discovery agent
DMOANXP ID DMOANXP
DMOANXP DN 2-(2-Hydroxy-phenyl)-6-methyl-chromen-4-one
DMOANXP HS Investigative
DMOANXP SN CHEMBL134408
DMOANXP DT Small molecular drug
DMOANXP PC 11032345
DMOANXP MW 252.26
DMOANXP FM C16H12O3
DMOANXP IC InChI=1S/C16H12O3/c1-10-6-7-15-12(8-10)14(18)9-16(19-15)11-4-2-3-5-13(11)17/h2-9,17H,1H3
DMOANXP CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3O
DMOANXP IK JWTNDTDENSEMQI-UHFFFAOYSA-N
DMOANXP IU 2-(2-hydroxyphenyl)-6-methylchromen-4-one
DMOANXP DE Discovery agent
DMCLIN8 ID DMCLIN8
DMCLIN8 DN 2-(2''-indolylethyloxy)adenosine
DMCLIN8 HS Investigative
DMCLIN8 SN CHEMBL374461; SCHEMBL4234414; 2-(2'-Indolylethyloxy)Adenosine; BDBM50208812
DMCLIN8 DT Small molecular drug
DMCLIN8 PC 16203431
DMCLIN8 MW 426.4
DMCLIN8 FM C20H22N6O5
DMCLIN8 IC InChI=1S/C20H22N6O5/c21-17-14-18(26(9-22-14)19-16(29)15(28)13(8-27)31-19)25-20(24-17)30-6-5-11-7-10-3-1-2-4-12(10)23-11/h1-4,7,9,13,15-16,19,23,27-29H,5-6,8H2,(H2,21,24,25)/t13-,15-,16-,19-/m1/s1
DMCLIN8 CS C1=CC=C2C(=C1)C=C(N2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMCLIN8 IK VWETWISDPZSJHC-NVQRDWNXSA-N
DMCLIN8 IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-indol-2-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMCLIN8 DE Discovery agent
DMSVHU9 ID DMSVHU9
DMSVHU9 DN 2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione
DMSVHU9 HS Investigative
DMSVHU9 SN 2-(2-Iodobenzoyl)cyclohexane-1,3-dione; CHEMBL165937; 88562-10-1; 1,3-Cyclohexanedione, 2-(2-iodobenzoyl)-; ACMC-20lbdr; 2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione; CTK3A9586; DTXSID90558702
DMSVHU9 DT Small molecular drug
DMSVHU9 PC 14301629
DMSVHU9 MW 342.13
DMSVHU9 FM C13H11IO3
DMSVHU9 IC InChI=1S/C13H11IO3/c14-9-5-2-1-4-8(9)13(17)12-10(15)6-3-7-11(12)16/h1-2,4-5,12H,3,6-7H2
DMSVHU9 CS C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2I
DMSVHU9 IK OGHGLYVCKWVCJJ-UHFFFAOYSA-N
DMSVHU9 IU 2-(2-iodobenzoyl)cyclohexane-1,3-dione
DMSVHU9 CA CAS 88562-10-1
DMSVHU9 DE Discovery agent
DMPA4S0 ID DMPA4S0
DMPA4S0 DN 2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one
DMPA4S0 HS Investigative
DMPA4S0 SN CHEMBL10378; NSC165772; AC1L6PF7; 2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one; SCHEMBL913450; BDBM50063703; NSC-165772; 2-(2-iodophenyl)-3,1-benzoxazin-4-one
DMPA4S0 DT Small molecular drug
DMPA4S0 PC 296008
DMPA4S0 MW 349.12
DMPA4S0 FM C14H8INO2
DMPA4S0 IC InChI=1S/C14H8INO2/c15-11-7-3-1-5-9(11)13-16-12-8-4-2-6-10(12)14(17)18-13/h1-8H
DMPA4S0 CS C1=CC=C2C(=C1)C(=O)OC(=N2)C3=CC=CC=C3I
DMPA4S0 IK VEBIXPCJYGGBAF-UHFFFAOYSA-N
DMPA4S0 IU 2-(2-iodophenyl)-3,1-benzoxazin-4-one
DMPA4S0 DE Discovery agent
DMGELY0 ID DMGELY0
DMGELY0 DN 2-(2-Mercapto-ethyl)-pentanedioic acid
DMGELY0 HS Investigative
DMGELY0 SN 2-(2-sulfanylethyl)pentanedioic Acid; CHEMBL292562; 254737-18-3; Pentanedioic acid, 2-(2-mercaptoethyl)-; 2-(2-Mercapto-ethyl)-pentanedioic acid; SCHEMBL2058227; CTK0J4031; DTXSID80430765; SMGZBRVSYVJHCB-UHFFFAOYSA-N
DMGELY0 DT Small molecular drug
DMGELY0 PC 9794137
DMGELY0 MW 192.24
DMGELY0 FM C7H12O4S
DMGELY0 IC InChI=1S/C7H12O4S/c8-6(9)2-1-5(3-4-12)7(10)11/h5,12H,1-4H2,(H,8,9)(H,10,11)
DMGELY0 CS C(CC(=O)O)C(CCS)C(=O)O
DMGELY0 IK SMGZBRVSYVJHCB-UHFFFAOYSA-N
DMGELY0 IU 2-(2-sulfanylethyl)pentanedioic acid
DMGELY0 CA CAS 254737-18-3
DMGELY0 DE Discovery agent
DMESMBO ID DMESMBO
DMESMBO DN 2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione
DMESMBO HS Investigative
DMESMBO SN CHEMBL167062; 2-(2-Methoxybenzoyl)cyclohexane-1,3-dione; 2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione; SCHEMBL10192397
DMESMBO DT Small molecular drug
DMESMBO PC 12723197
DMESMBO MW 246.26
DMESMBO FM C14H14O4
DMESMBO IC InChI=1S/C14H14O4/c1-18-12-8-3-2-5-9(12)14(17)13-10(15)6-4-7-11(13)16/h2-3,5,8,13H,4,6-7H2,1H3
DMESMBO CS COC1=CC=CC=C1C(=O)C2C(=O)CCCC2=O
DMESMBO IK ADJLOHOSFKJYEC-UHFFFAOYSA-N
DMESMBO IU 2-(2-methoxybenzoyl)cyclohexane-1,3-dione
DMESMBO DE Discovery agent
DM9Z8V5 ID DM9Z8V5
DM9Z8V5 DN 2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one
DM9Z8V5 HS Investigative
DM9Z8V5 SN CHEMBL469340; 2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one
DM9Z8V5 DT Small molecular drug
DM9Z8V5 PC 44592011
DM9Z8V5 MW 316.3
DM9Z8V5 FM C21H16O3
DM9Z8V5 IC InChI=1S/C21H16O3/c1-23-19-9-5-3-7-15(19)12-16-13-18-17-8-4-2-6-14(17)10-11-20(18)24-21(16)22/h2-11,13H,12H2,1H3
DM9Z8V5 CS COC1=CC=CC=C1CC2=CC3=C(C=CC4=CC=CC=C43)OC2=O
DM9Z8V5 IK VCXYTPBLXWPGOC-UHFFFAOYSA-N
DM9Z8V5 IU 2-[(2-methoxyphenyl)methyl]benzo[f]chromen-3-one
DM9Z8V5 DE Discovery agent
DMYVDJQ ID DMYVDJQ
DMYVDJQ DN 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ HS Investigative
DMYVDJQ SN CHEMBL597531; 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine
DMYVDJQ DT Small molecular drug
DMYVDJQ PC 44133674
DMYVDJQ MW 284.35
DMYVDJQ FM C17H20N2O2
DMYVDJQ IC InChI=1S/C17H20N2O2/c1-20-15-6-2-3-7-16(15)21-17-14(5-4-10-19-17)13-8-11-18-12-9-13/h2-7,10,13,18H,8-9,11-12H2,1H3
DMYVDJQ CS COC1=CC=CC=C1OC2=C(C=CC=N2)C3CCNCC3
DMYVDJQ IK GZJLFOYGSNAXDK-UHFFFAOYSA-N
DMYVDJQ IU 2-(2-methoxyphenoxy)-3-piperidin-4-ylpyridine
DMYVDJQ DE Discovery agent
DMXFYN8 ID DMXFYN8
DMXFYN8 DN 2-(2-methoxyphenyl)-1H-indene
DMXFYN8 HS Investigative
DMXFYN8 SN CHEMBL376583; 2-(2-methoxyphenyl)-1H-indene; 2-(o-Methoxyphenyl)-1H-indene; SCHEMBL16621596
DMXFYN8 DT Small molecular drug
DMXFYN8 PC 44424412
DMXFYN8 MW 222.28
DMXFYN8 FM C16H14O
DMXFYN8 IC InChI=1S/C16H14O/c1-17-16-9-5-4-8-15(16)14-10-12-6-2-3-7-13(12)11-14/h2-10H,11H2,1H3
DMXFYN8 CS COC1=CC=CC=C1C2=CC3=CC=CC=C3C2
DMXFYN8 IK APOFCYAJMPJCJI-UHFFFAOYSA-N
DMXFYN8 IU 2-(2-methoxyphenyl)-1H-indene
DMXFYN8 DE Discovery agent
DMDI98B ID DMDI98B
DMDI98B DN 2-(2-Methoxy-phenyl)-1-methyl-ethylamine
DMDI98B HS Investigative
DMDI98B SN 1-(2-methoxyphenyl)propan-2-amine; 15402-84-3; N-Desmethylmethoxyphenamine; 2-Methoxyamphetamine; o-Methoxyamphetamine; NDMP; 2-(2-Methoxy-phenyl)-1-methyl-ethylamine; CHEMBL16451; Benzeneethanamine, 2-methoxy-alpha-methyl-; Benzeneethanamine,2-methoxy--methyl-; 1-(2-METHOXYPHENYL)-2-PROPYLAMINE; AC1L4MFB; AC1Q57OA; AC1Q45CZ; (d,l)-2-Methoxyamphetamine; Methoxyphenamine, N-desmethyl; SCHEMBL266563; o-Methoxy(phenylisopropyl)amine; AMBZ0414; AC1Q45D0; 2-Methoxy(phenylisopropyl)amine; o-Methoxy-a-methylphenethylamine
DMDI98B DT Small molecular drug
DMDI98B PC 159755
DMDI98B MW 165.23
DMDI98B FM C10H15NO
DMDI98B IC InChI=1S/C10H15NO/c1-8(11)7-9-5-3-4-6-10(9)12-2/h3-6,8H,7,11H2,1-2H3
DMDI98B CS CC(CC1=CC=CC=C1OC)N
DMDI98B IK VBAHFEPKESUPDE-UHFFFAOYSA-N
DMDI98B IU 1-(2-methoxyphenyl)propan-2-amine
DMDI98B CA CAS 15402-84-3
DMDI98B DE Discovery agent
DMPVCDN ID DMPVCDN
DMPVCDN DN 2-(2-Methoxy-phenyl)-6-methyl-chromen-4-one
DMPVCDN HS Investigative
DMPVCDN SN 89112-85-6; 2-(2-methoxyphenyl)-6-methyl-4H-chromen-4-one; CHEMBL334355; 2-(2-methoxyphenyl)-6-methylchromen-4-one; 4H-1-Benzopyran-4-one, 2-(2-methoxyphenyl)-6-methyl-; F3139-0622; ACMC-20lhvv; AC1LIFWU; 2'-Methoxy-6-methylflavone; CTK3A1211; DTXSID40358996; QEIHFNZSIRWEBX-UHFFFAOYSA-N; MolPort-000-450-861; ZINC521727; STK788037; AKOS002182005; MCULE-9515838114; NCGC00339312-01; ST4146766
DMPVCDN DT Small molecular drug
DMPVCDN PC 930492
DMPVCDN MW 266.29
DMPVCDN FM C17H14O3
DMPVCDN IC InChI=1S/C17H14O3/c1-11-7-8-16-13(9-11)14(18)10-17(20-16)12-5-3-4-6-15(12)19-2/h3-10H,1-2H3
DMPVCDN CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3OC
DMPVCDN IK QEIHFNZSIRWEBX-UHFFFAOYSA-N
DMPVCDN IU 2-(2-methoxyphenyl)-6-methylchromen-4-one
DMPVCDN CA CAS 89112-85-6
DMPVCDN DE Discovery agent
DMXVCL0 ID DMXVCL0
DMXVCL0 DN 2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMXVCL0 HS Investigative
DMXVCL0 SN CHEMBL105256; 2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3538816; BDBM50132363; 2-Morpholino-6-(2-methoxyphenyl)-4H-pyran-4-one
DMXVCL0 DT Small molecular drug
DMXVCL0 PC 21106400
DMXVCL0 MW 287.31
DMXVCL0 FM C16H17NO4
DMXVCL0 IC InChI=1S/C16H17NO4/c1-19-14-5-3-2-4-13(14)15-10-12(18)11-16(21-15)17-6-8-20-9-7-17/h2-5,10-11H,6-9H2,1H3
DMXVCL0 CS COC1=CC=CC=C1C2=CC(=O)C=C(O2)N3CCOCC3
DMXVCL0 IK ZDNMYLJFYAXNHH-UHFFFAOYSA-N
DMXVCL0 IU 2-(2-methoxyphenyl)-6-morpholin-4-ylpyran-4-one
DMXVCL0 CA CAS 155906-26-6
DMXVCL0 DE Discovery agent
DM4GN0E ID DM4GN0E
DM4GN0E DN 2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione
DM4GN0E HS Investigative
DM4GN0E SN CHEMBL355470; 2-(2-Methylbenzoyl)cyclohexane-1,3-dione; 2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione; SCHEMBL10191381
DM4GN0E DT Small molecular drug
DM4GN0E PC 14301714
DM4GN0E MW 230.26
DM4GN0E FM C14H14O3
DM4GN0E IC InChI=1S/C14H14O3/c1-9-5-2-3-6-10(9)14(17)13-11(15)7-4-8-12(13)16/h2-3,5-6,13H,4,7-8H2,1H3
DM4GN0E CS CC1=CC=CC=C1C(=O)C2C(=O)CCCC2=O
DM4GN0E IK ZGPNNJNODAAWSM-UHFFFAOYSA-N
DM4GN0E IU 2-(2-methylbenzoyl)cyclohexane-1,3-dione
DM4GN0E DE Discovery agent
DM7HN4Z ID DM7HN4Z
DM7HN4Z DN 2-(2'-methyl-biphenyl-3-yl)-ethylamine
DM7HN4Z HS Investigative
DM7HN4Z SN CHEMBL234885; ZINC28821767; BDBM50210124; AKOS022255130; 2-(2''-methyl-biphenyl-3-yl)-ethylamine
DM7HN4Z DT Small molecular drug
DM7HN4Z PC 35985234
DM7HN4Z MW 211.3
DM7HN4Z FM C15H17N
DM7HN4Z IC InChI=1S/C15H17N/c1-12-5-2-3-8-15(12)14-7-4-6-13(11-14)9-10-16/h2-8,11H,9-10,16H2,1H3
DM7HN4Z CS CC1=CC=CC=C1C2=CC=CC(=C2)CCN
DM7HN4Z IK KQRAKUVQYREATE-UHFFFAOYSA-N
DM7HN4Z IU 2-[3-(2-methylphenyl)phenyl]ethanamine
DM7HN4Z DE Discovery agent
DMAHZR9 ID DMAHZR9
DMAHZR9 DN 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one
DMAHZR9 HS Investigative
DMAHZR9 SN CHEMBL435507; 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one; SCHEMBL3545107
DMAHZR9 DT Small molecular drug
DMAHZR9 PC 10017389
DMAHZR9 MW 295.3
DMAHZR9 FM C18H17NO3
DMAHZR9 IC InChI=1S/C18H17NO3/c1-12-11-19(8-9-21-12)17-10-16(20)15-7-6-13-4-2-3-5-14(13)18(15)22-17/h2-7,10,12H,8-9,11H2,1H3
DMAHZR9 CS CC1CN(CCO1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMAHZR9 IK RFWCIJWQGHFULK-UHFFFAOYSA-N
DMAHZR9 IU 2-(2-methylmorpholin-4-yl)benzo[h]chromen-4-one
DMAHZR9 DE Discovery agent
DMPH63G ID DMPH63G
DMPH63G DN 2-(2-Methylpropanoyl)-1,3,5-benzenetriol
DMPH63G HS Investigative
DMPH63G SN Phlorisobutyrophenone; 35458-21-0; 2-(2-Methylpropanoyl)-1,3,5-benzenetriol; 1-Propanone, 2-methyl-1-(2,4,6-trihydroxyphenyl)-; CHEMBL20038; 2-methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one; 2-Methyl-1-(2,4,6-trihydroxyphenyl)-1-propanone; phlorisobutanophenone; phloroisobutyrophenone; AC1NS0BJ; 2-isobutyrylphloroglucinol; 2-isobutanoylphloroglucinol; SCHEMBL2150396; CTK1B6928; DTXSID60416108; MolPort-022-379-188; BNEBXEZRBLYBCZ-UHFFFAOYSA-N; CHEBI:133419; ZINC13650343; BDBM50005639; 1-isobutyryl-2,4,6-trihydroxybenzene
DMPH63G DT Small molecular drug
DMPH63G PC 5326317
DMPH63G MW 196.2
DMPH63G FM C10H12O4
DMPH63G IC InChI=1S/C10H12O4/c1-5(2)10(14)9-7(12)3-6(11)4-8(9)13/h3-5,11-13H,1-2H3
DMPH63G CS CC(C)C(=O)C1=C(C=C(C=C1O)O)O
DMPH63G IK BNEBXEZRBLYBCZ-UHFFFAOYSA-N
DMPH63G IU 2-methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one
DMPH63G CA CAS 35458-21-0
DMPH63G CB CHEBI:133419
DMPH63G DE Discovery agent
DMW75IF ID DMW75IF
DMW75IF DN 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide
DMW75IF HS Investigative
DMW75IF SN CHEMBL594511; 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide
DMW75IF DT Small molecular drug
DMW75IF PC 44596230
DMW75IF MW 291.3
DMW75IF FM C18H17N3O
DMW75IF IC InChI=1S/C18H17N3O/c1-13-11-17(15-9-5-6-10-16(15)20-13)19-12-18(22)21-14-7-3-2-4-8-14/h2-11H,12H2,1H3,(H,19,20)(H,21,22)
DMW75IF CS CC1=NC2=CC=CC=C2C(=C1)NCC(=O)NC3=CC=CC=C3
DMW75IF IK HRXVDSHQRNNGBO-UHFFFAOYSA-N
DMW75IF IU 2-[(2-methylquinolin-4-yl)amino]-N-phenylacetamide
DMW75IF DE Discovery agent
DMENUIH ID DMENUIH
DMENUIH DN 2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH HS Investigative
DMENUIH SN CHEMBL434585; 2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH DT Small molecular drug
DMENUIH PC 44432671
DMENUIH MW 244.29
DMENUIH FM C17H12N2
DMENUIH IC InChI=1S/C17H12N2/c1-12-6-7-13-8-9-14(10-17(13)19-12)16-5-3-2-4-15(16)11-18/h2-10H,1H3
DMENUIH CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC=C3C#N
DMENUIH IK MUNVAMLSVBEAIR-UHFFFAOYSA-N
DMENUIH IU 2-(2-methylquinolin-7-yl)benzonitrile
DMENUIH DE Discovery agent
DMIHTL0 ID DMIHTL0
DMIHTL0 DN 2-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMIHTL0 HS Investigative
DMIHTL0 SN CHEMBL65022; 2-(2-Methyl-thiazol-4-ylethynyl)-pyridine; SCHEMBL15049682; BDBM50122757
DMIHTL0 DT Small molecular drug
DMIHTL0 PC 11063448
DMIHTL0 MW 200.26
DMIHTL0 FM C11H8N2S
DMIHTL0 IC InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)6-5-10-4-2-3-7-12-10/h2-4,7-8H,1H3
DMIHTL0 CS CC1=NC(=CS1)C#CC2=CC=CC=N2
DMIHTL0 IK BQDSXKBRSCMFRW-UHFFFAOYSA-N
DMIHTL0 IU 2-methyl-4-(2-pyridin-2-ylethynyl)-1,3-thiazole
DMIHTL0 DE Discovery agent
DMN176Y ID DMN176Y
DMN176Y DN 2-(2-naphthamido)benzoic acid
DMN176Y HS Investigative
DMN176Y SN 2-(2-naphthamido)benzoic acid; SCHEMBL8044197; CHEMBL200536; BDBM16098; 2-(naphthalene-2-amido)benzoic acid; AKOS000132452; 2-[(naphthalen-2-ylcarbonyl)amino]benzoic acid
DMN176Y DT Small molecular drug
DMN176Y PC 13707619
DMN176Y MW 291.3
DMN176Y FM C18H13NO3
DMN176Y IC InChI=1S/C18H13NO3/c20-17(19-16-8-4-3-7-15(16)18(21)22)14-10-9-12-5-1-2-6-13(12)11-14/h1-11H,(H,19,20)(H,21,22)
DMN176Y CS C1=CC=C2C=C(C=CC2=C1)C(=O)NC3=CC=CC=C3C(=O)O
DMN176Y IK BBJZKXXWFJLNRR-UHFFFAOYSA-N
DMN176Y IU 2-(naphthalene-2-carbonylamino)benzoic acid
DMN176Y DE Discovery agent
DMUJQX1 ID DMUJQX1
DMUJQX1 DN 2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione
DMUJQX1 HS Investigative
DMUJQX1 SN CHEMBL169696; 2-(2-nitrobenzoyl)cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(2-nitrobenzoyl)-; 104206-60-2; 2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione; ACMC-20m705; SCHEMBL7275303; CTK0G6513; DTXSID90553792; ZZJZBPYZTKGWTD-UHFFFAOYSA-N; 2-nitrobenzoylcyclohexane-1,3-dione; BDBM50088793; 2-(2-nitrobenzoyl)-1 ,3-cyclohexanedione
DMUJQX1 DT Small molecular drug
DMUJQX1 PC 13983070
DMUJQX1 MW 261.23
DMUJQX1 FM C13H11NO5
DMUJQX1 IC InChI=1S/C13H11NO5/c15-10-6-3-7-11(16)12(10)13(17)8-4-1-2-5-9(8)14(18)19/h1-2,4-5,12H,3,6-7H2
DMUJQX1 CS C1CC(=O)C(C(=O)C1)C(=O)C2=CC=CC=C2[N+](=O)[O-]
DMUJQX1 IK ZZJZBPYZTKGWTD-UHFFFAOYSA-N
DMUJQX1 IU 2-(2-nitrobenzoyl)cyclohexane-1,3-dione
DMUJQX1 CA CAS 104206-60-2
DMUJQX1 DE Discovery agent
DM5NLQE ID DM5NLQE
DM5NLQE DN 2-(2-phenethylphenyl)isoindoline-1,3-dione
DM5NLQE HS Investigative
DM5NLQE SN CHEMBL246144; PP2P; SCHEMBL2464969; BDBM23840; N-(2-Phenethylphenyl)phthalimide
DM5NLQE DT Small molecular drug
DM5NLQE PC 10616182
DM5NLQE MW 327.4
DM5NLQE FM C22H17NO2
DM5NLQE IC InChI=1S/C22H17NO2/c24-21-18-11-5-6-12-19(18)22(25)23(21)20-13-7-4-10-17(20)15-14-16-8-2-1-3-9-16/h1-13H,14-15H2
DM5NLQE CS C1=CC=C(C=C1)CCC2=CC=CC=C2N3C(=O)C4=CC=CC=C4C3=O
DM5NLQE IK XGSWAPNRKGOSKD-UHFFFAOYSA-N
DM5NLQE IU 2-[2-(2-phenylethyl)phenyl]isoindole-1,3-dione
DM5NLQE DE Discovery agent
DME0HPA ID DME0HPA
DME0HPA DN 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid
DME0HPA HS Investigative
DME0HPA SN 4-anilinopyrimidine 6g; CHEMBL244626; BDBM15985; 2-[(2-phenoxypyrimidin-4-yl)amino]benzoic acid
DME0HPA DT Small molecular drug
DME0HPA PC 23647245
DME0HPA MW 307.3
DME0HPA FM C17H13N3O3
DME0HPA IC InChI=1S/C17H13N3O3/c21-16(22)13-8-4-5-9-14(13)19-15-10-11-18-17(20-15)23-12-6-2-1-3-7-12/h1-11H,(H,21,22)(H,18,19,20)
DME0HPA CS C1=CC=C(C=C1)OC2=NC=CC(=N2)NC3=CC=CC=C3C(=O)O
DME0HPA IK MQQUMLXYIRSXSZ-UHFFFAOYSA-N
DME0HPA IU 2-[(2-phenoxypyrimidin-4-yl)amino]benzoic acid
DME0HPA DE Discovery agent
DM1K0U5 ID DM1K0U5
DM1K0U5 DN 2-(2-Phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide
DM1K0U5 HS Investigative
DM1K0U5 SN CHEMBL327286; 2-(2-phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide; BDBM50045857
DM1K0U5 DT Small molecular drug
DM1K0U5 PC 10449567
DM1K0U5 MW 334.5
DM1K0U5 FM C22H26N2O
DM1K0U5 IC InChI=1S/C22H26N2O/c1-3-14-24(15-4-2)21(25)16-19-18-12-8-9-13-20(18)23-22(19)17-10-6-5-7-11-17/h5-13,23H,3-4,14-16H2,1-2H3
DM1K0U5 CS CCCN(CCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DM1K0U5 IK VEAFPKIMCGYMFZ-UHFFFAOYSA-N
DM1K0U5 IU 2-(2-phenyl-1H-indol-3-yl)-N,N-dipropylacetamide
DM1K0U5 DE Discovery agent
DMO9SP1 ID DMO9SP1
DMO9SP1 DN 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DMO9SP1 HS Investigative
DMO9SP1 SN CHEMBL213035; 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DMO9SP1 DT Small molecular drug
DMO9SP1 PC 44414735
DMO9SP1 MW 291.4
DMO9SP1 FM C19H21N3
DMO9SP1 IC InChI=1S/C19H21N3/c20-15-18-9-5-4-8-17(18)14-19(16-6-2-1-3-7-16)22-12-10-21-11-13-22/h1-9,19,21H,10-14H2
DMO9SP1 CS C1CN(CCN1)C(CC2=CC=CC=C2C#N)C3=CC=CC=C3
DMO9SP1 IK FCHUPCOGZXEFDS-UHFFFAOYSA-N
DMO9SP1 IU 2-(2-phenyl-2-piperazin-1-ylethyl)benzonitrile
DMO9SP1 DE Discovery agent
DMQM6IA ID DMQM6IA
DMQM6IA DN 2-(2-Phosphonooxy-ethyl)-pentanedioic acid
DMQM6IA HS Investigative
DMQM6IA SN CHEMBL58232; 2-(2-Phosphonooxy-ethyl)-pentanedioic acid; SCHEMBL8060048
DMQM6IA DT Small molecular drug
DMQM6IA PC 10879227
DMQM6IA MW 240.15
DMQM6IA FM C7H13O7P
DMQM6IA IC InChI=1S/C7H13O7P/c8-6(9)2-1-5(7(10)11)3-4-15(12,13)14/h5H,1-4H2,(H,8,9)(H,10,11)(H2,12,13,14)
DMQM6IA CS C(CC(=O)O)C(CCP(=O)(O)O)C(=O)O
DMQM6IA IK NKKKETAADLKALP-UHFFFAOYSA-N
DMQM6IA IU 2-(2-phosphonoethyl)pentanedioic acid
DMQM6IA DE Discovery agent
DMGVCKZ ID DMGVCKZ
DMGVCKZ DN 2-(2-propoxypyrimidin-4-ylamino)benzoic acid
DMGVCKZ HS Investigative
DMGVCKZ SN 4-anilinopyrimidine 6b; CHEMBL242489; BDBM15980; 2-[(2-propoxypyrimidin-4-yl)amino]benzoic acid
DMGVCKZ DT Small molecular drug
DMGVCKZ PC 23647240
DMGVCKZ MW 273.29
DMGVCKZ FM C14H15N3O3
DMGVCKZ IC InChI=1S/C14H15N3O3/c1-2-9-20-14-15-8-7-12(17-14)16-11-6-4-3-5-10(11)13(18)19/h3-8H,2,9H2,1H3,(H,18,19)(H,15,16,17)
DMGVCKZ CS CCCOC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMGVCKZ IK NZLCVQSIEXQTHO-UHFFFAOYSA-N
DMGVCKZ IU 2-[(2-propoxypyrimidin-4-yl)amino]benzoic acid
DMGVCKZ DE Discovery agent
DMB4W68 ID DMB4W68
DMB4W68 DN 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid
DMB4W68 HS Investigative
DMB4W68 SN CHEMBL242702
DMB4W68 DT Small molecular drug
DMB4W68 PC 44427133
DMB4W68 MW 287.31
DMB4W68 FM C15H17N3O3
DMB4W68 IC InChI=1S/C15H17N3O3/c1-3-10(2)21-15-16-9-8-13(18-15)17-12-7-5-4-6-11(12)14(19)20/h4-10H,3H2,1-2H3,(H,19,20)(H,16,17,18)
DMB4W68 CS CCC(C)OC1=NC=CC(=N1)NC2=CC=CC=C2C(=O)O
DMB4W68 IK XCPPZXZCQFKXQJ-UHFFFAOYSA-N
DMB4W68 IU 2-[(2-butan-2-yloxypyrimidin-4-yl)amino]benzoic acid
DMB4W68 DE Discovery agent
DMRL65E ID DMRL65E
DMRL65E DN 2-(2-thiazolyl)ethanamine
DMRL65E HS Investigative
DMRL65E SN 2-thiazoleethanamine; 2-thiazolylethylamine; 2-(2-aminoethyl)thiazole
DMRL65E DT Small molecular drug
DMRL65E PC 87653
DMRL65E MW 128.199
DMRL65E FM C5H8N2S
DMRL65E IC InChI=1S/C5H8N2S/c6-2-1-5-7-3-4-8-5/h3-4H,1-2,6H2
DMRL65E CS C1=CSC(=N1)CCN
DMRL65E IK TWZOYAWHWDRMEZ-UHFFFAOYSA-N
DMRL65E IU 2-(1,3-thiazol-2-yl)ethanamine
DMRL65E CA CAS 18453-07-1
DMRL65E CB CHEBI:81388
DMRL65E DE Discovery agent
DMLJH92 ID DMLJH92
DMLJH92 DN 2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile
DMLJH92 HS Investigative
DMLJH92 SN CHEMBL267839; 2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile
DMLJH92 DT Small molecular drug
DMLJH92 PC 44432658
DMLJH92 MW 258.3
DMLJH92 FM C18H14N2
DMLJH92 IC InChI=1S/C18H14N2/c1-13-5-6-15-7-8-17(12-18(15)20-13)16-4-2-3-14(11-16)9-10-19/h2-8,11-12H,9H2,1H3
DMLJH92 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)CC#N
DMLJH92 IK XNAOGJHXZYYKMV-UHFFFAOYSA-N
DMLJH92 IU 2-[3-(2-methylquinolin-7-yl)phenyl]acetonitrile
DMLJH92 DE Discovery agent
DMM9WB0 ID DMM9WB0
DMM9WB0 DN 2-(3-(3,5-dichlorophenyl)ureido)benzoic acid
DMM9WB0 HS Investigative
DMM9WB0 SN CHEMBL1088742; 2-{[(3,5-dichlorophenyl)carbamoyl]amino}benzoic acid; 2-(3-(3,5-dichlorophenyl)ureido)benzoic acid; SCHEMBL11983339; MolPort-011-309-281; BDBM50313600; AKOS012857299
DMM9WB0 DT Small molecular drug
DMM9WB0 PC 44631845
DMM9WB0 MW 325.1
DMM9WB0 FM C14H10Cl2N2O3
DMM9WB0 IC InChI=1S/C14H10Cl2N2O3/c15-8-5-9(16)7-10(6-8)17-14(21)18-12-4-2-1-3-11(12)13(19)20/h1-7H,(H,19,20)(H2,17,18,21)
DMM9WB0 CS C1=CC=C(C(=C1)C(=O)O)NC(=O)NC2=CC(=CC(=C2)Cl)Cl
DMM9WB0 IK PIWYMPXOKMFVER-UHFFFAOYSA-N
DMM9WB0 IU 2-[(3,5-dichlorophenyl)carbamoylamino]benzoic acid
DMM9WB0 DE Discovery agent
DMRX4HM ID DMRX4HM
DMRX4HM DN 2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid
DMRX4HM HS Investigative
DMRX4HM SN CHEMBL154700; 2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid; SCHEMBL6431740; ZINC1491954; BDBM50137125; AKOS012857302; 2-[3-(3-Bromo-phenyl)-ureido]-4-chloro-benzoic acid
DMRX4HM DT Small molecular drug
DMRX4HM PC 9799478
DMRX4HM MW 369.6
DMRX4HM FM C14H10BrClN2O3
DMRX4HM IC InChI=1S/C14H10BrClN2O3/c15-8-2-1-3-10(6-8)17-14(21)18-12-7-9(16)4-5-11(12)13(19)20/h1-7H,(H,19,20)(H2,17,18,21)
DMRX4HM CS C1=CC(=CC(=C1)Br)NC(=O)NC2=C(C=CC(=C2)Cl)C(=O)O
DMRX4HM IK QRRARWFCZGWJJY-UHFFFAOYSA-N
DMRX4HM IU 2-[(3-bromophenyl)carbamoylamino]-4-chlorobenzoic acid
DMRX4HM DE Discovery agent
DM1VSOK ID DM1VSOK
DM1VSOK DN 2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine
DM1VSOK HS Investigative
DM1VSOK SN CHEMBL212018; 2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine; SCHEMBL5698315
DM1VSOK DT Small molecular drug
DM1VSOK PC 11299421
DM1VSOK MW 239.27
DM1VSOK FM C15H13NO2
DM1VSOK IC InChI=1S/C15H13NO2/c1-17-14-8-4-9-15(12-14)18-11-5-7-13-6-2-3-10-16-13/h2-4,6,8-10,12H,11H2,1H3
DM1VSOK CS COC1=CC(=CC=C1)OCC#CC2=CC=CC=N2
DM1VSOK IK NUGIZDIFZXSZAH-UHFFFAOYSA-N
DM1VSOK IU 2-[3-(3-methoxyphenoxy)prop-1-ynyl]pyridine
DM1VSOK DE Discovery agent
DMXRHOY ID DMXRHOY
DMXRHOY DN 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine
DMXRHOY HS Investigative
DMXRHOY SN CHEMBL434377; BDBM50208797
DMXRHOY DT Small molecular drug
DMXRHOY PC 16203543
DMXRHOY MW 505.3
DMXRHOY FM C20H21BrN6O5
DMXRHOY IC InChI=1S/C20H21BrN6O5/c21-10-2-1-3-11-13(10)9(6-23-11)4-5-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)12(7-28)32-19/h1-3,6,8,12,15-16,19,23,28-30H,4-5,7H2,(H2,22,25,26)/t12-,15-,16-,19-/m1/s1
DMXRHOY CS C1=CC2=C(C(=C1)Br)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMXRHOY IK GBCVNJCVWVIDED-BGIGGGFGSA-N
DMXRHOY IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(4-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMXRHOY DE Discovery agent
DMR8PGZ ID DMR8PGZ
DMR8PGZ DN 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ HS Investigative
DMR8PGZ SN CHEMBL222194; MRS-3854; BDBM50208783; 2-(3''''-(5''''-bromo-indolyl)ethyloxy)adenosine
DMR8PGZ DT Small molecular drug
DMR8PGZ PC 16203540
DMR8PGZ MW 505.3
DMR8PGZ FM C20H21BrN6O5
DMR8PGZ IC InChI=1S/C20H21BrN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMR8PGZ CS C1=CC2=C(C=C1Br)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMR8PGZ IK ZUYSJPWNKBPSJB-NVQRDWNXSA-N
DMR8PGZ IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(5-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMR8PGZ DE Discovery agent
DMD8Q3E ID DMD8Q3E
DMD8Q3E DN 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E HS Investigative
DMD8Q3E SN CHEMBL222442; BDBM50208782; 2-(3''''(5''''-chloro-indolyl)ethyloxy)adenosine
DMD8Q3E DT Small molecular drug
DMD8Q3E PC 16202725
DMD8Q3E MW 460.9
DMD8Q3E FM C20H21ClN6O5
DMD8Q3E IC InChI=1S/C20H21ClN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMD8Q3E CS C1=CC2=C(C=C1Cl)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMD8Q3E IK RBLGZQGAVZQMSY-NVQRDWNXSA-N
DMD8Q3E IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(5-chloro-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMD8Q3E DE Discovery agent
DME3IN1 ID DME3IN1
DME3IN1 DN 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1 HS Investigative
DME3IN1 SN CHEMBL373478; BDBM50208809; 2-(3''''-(5''''-fluoro-indolyl)ethyloxy)adenosine
DME3IN1 DT Small molecular drug
DME3IN1 PC 16203539
DME3IN1 MW 444.4
DME3IN1 FM C20H21FN6O5
DME3IN1 IC InChI=1S/C20H21FN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DME3IN1 CS C1=CC2=C(C=C1F)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DME3IN1 IK VEJNLHIDLOHNST-NVQRDWNXSA-N
DME3IN1 IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(5-fluoro-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DME3IN1 DE Discovery agent
DM6BIOP ID DM6BIOP
DM6BIOP DN 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP HS Investigative
DM6BIOP SN CHEMBL222500; BDBM50208785; 2-(3''''-(5''''-hydroxyindolyl)ethyloxy)adenosine
DM6BIOP DT Small molecular drug
DM6BIOP PC 16202841
DM6BIOP MW 442.4
DM6BIOP FM C20H22N6O6
DM6BIOP IC InChI=1S/C20H22N6O6/c21-17-14-18(26(8-23-14)19-16(30)15(29)13(7-27)32-19)25-20(24-17)31-4-3-9-6-22-12-2-1-10(28)5-11(9)12/h1-2,5-6,8,13,15-16,19,22,27-30H,3-4,7H2,(H2,21,24,25)/t13-,15-,16-,19-/m1/s1
DM6BIOP CS C1=CC2=C(C=C1O)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DM6BIOP IK CPKNPTKTLVLFFU-NVQRDWNXSA-N
DM6BIOP IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(5-hydroxy-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM6BIOP DE Discovery agent
DMFP0IW ID DMFP0IW
DMFP0IW DN 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW HS Investigative
DMFP0IW SN CHEMBL222748; BDBM50208791; 2-(3''''-(5''''-iodo-indolyl)ethyloxy)adenosine
DMFP0IW DT Small molecular drug
DMFP0IW PC 16202726
DMFP0IW MW 552.3
DMFP0IW FM C20H21IN6O5
DMFP0IW IC InChI=1S/C20H21IN6O5/c21-10-1-2-12-11(5-10)9(6-23-12)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMFP0IW CS C1=CC2=C(C=C1I)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMFP0IW IK RPHVWFYWABZLPJ-NVQRDWNXSA-N
DMFP0IW IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(5-iodo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMFP0IW DE Discovery agent
DMWA0MN ID DMWA0MN
DMWA0MN DN 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN HS Investigative
DMWA0MN SN CHEMBL374028; BDBM50208796; 2-(3''''-(5''''-methoxy-indolyl)ethyloxy)adenosine
DMWA0MN DT Small molecular drug
DMWA0MN PC 16203665
DMWA0MN MW 456.5
DMWA0MN FM C21H24N6O6
DMWA0MN IC InChI=1S/C21H24N6O6/c1-31-11-2-3-13-12(6-11)10(7-23-13)4-5-32-21-25-18(22)15-19(26-21)27(9-24-15)20-17(30)16(29)14(8-28)33-20/h2-3,6-7,9,14,16-17,20,23,28-30H,4-5,8H2,1H3,(H2,22,25,26)/t14-,16-,17-,20-/m1/s1
DMWA0MN CS COC1=CC2=C(C=C1)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMWA0MN IK HIDGDYNRSPJOMR-WVSUBDOOSA-N
DMWA0MN IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(5-methoxy-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMWA0MN DE Discovery agent
DMGRC24 ID DMGRC24
DMGRC24 DN 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine
DMGRC24 HS Investigative
DMGRC24 SN CHEMBL225459; MRS-3997; BDBM50208794; 2-(3''''-(6''''-bromo-indolyl)ethyloxy)adenosine
DMGRC24 DT Small molecular drug
DMGRC24 PC 16203542
DMGRC24 MW 505.3
DMGRC24 FM C20H21BrN6O5
DMGRC24 IC InChI=1S/C20H21BrN6O5/c21-10-1-2-11-9(6-23-12(11)5-10)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DMGRC24 CS C1=CC2=C(C=C1Br)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMGRC24 IK OXLUZSPXALFOBX-NVQRDWNXSA-N
DMGRC24 IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(6-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMGRC24 DE Discovery agent
DML39UW ID DML39UW
DML39UW DN 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine
DML39UW HS Investigative
DML39UW SN CHEMBL222907; BDBM50208786; 2-(3''''-(6''''-chloro-indolyl)ethyloxy)adenosine
DML39UW DT Small molecular drug
DML39UW PC 16202727
DML39UW MW 460.9
DML39UW FM C20H21ClN6O5
DML39UW IC InChI=1S/C20H21ClN6O5/c21-10-1-2-11-9(6-23-12(11)5-10)3-4-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)13(7-28)32-19/h1-2,5-6,8,13,15-16,19,23,28-30H,3-4,7H2,(H2,22,25,26)/t13-,15-,16-,19-/m1/s1
DML39UW CS C1=CC2=C(C=C1Cl)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DML39UW IK QEBJMUICJFPGLR-NVQRDWNXSA-N
DML39UW IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(6-chloro-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DML39UW DE Discovery agent
DMITEND ID DMITEND
DMITEND DN 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine
DMITEND HS Investigative
DMITEND SN CHEMBL223729; BDBM50208814
DMITEND DT Small molecular drug
DMITEND PC 16202728
DMITEND MW 505.3
DMITEND FM C20H21BrN6O5
DMITEND IC InChI=1S/C20H21BrN6O5/c21-11-3-1-2-10-9(6-23-13(10)11)4-5-31-20-25-17(22)14-18(26-20)27(8-24-14)19-16(30)15(29)12(7-28)32-19/h1-3,6,8,12,15-16,19,23,28-30H,4-5,7H2,(H2,22,25,26)/t12-,15-,16-,19-/m1/s1
DMITEND CS C1=CC2=C(C(=C1)Br)NC=C2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMITEND IK DKKUXTZYGGOBFU-BGIGGGFGSA-N
DMITEND IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(7-bromo-1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMITEND DE Discovery agent
DMLDOH6 ID DMLDOH6
DMLDOH6 DN 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine
DMLDOH6 HS Investigative
DMLDOH6 SN CHEMBL221363; BDBM50208818
DMLDOH6 DT Small molecular drug
DMLDOH6 PC 16203666
DMLDOH6 MW 427.4
DMLDOH6 FM C19H21N7O5
DMLDOH6 IC InChI=1S/C19H21N7O5/c20-16-13-17(26(9-22-13)18-15(29)14(28)12(7-27)31-18)24-19(23-16)30-6-5-25-8-21-10-3-1-2-4-11(10)25/h1-4,8-9,12,14-15,18,27-29H,5-7H2,(H2,20,23,24)/t12-,14-,15-,18-/m1/s1
DMLDOH6 CS C1=CC=C2C(=C1)N=CN2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMLDOH6 IK KTEOQJBVVWABJA-SCFUHWHPSA-N
DMLDOH6 IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(benzimidazol-1-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMLDOH6 DE Discovery agent
DM1KCUV ID DM1KCUV
DM1KCUV DN 2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine
DM1KCUV HS Investigative
DM1KCUV SN CHEMBL374737; BDBM50208808
DM1KCUV DT Small molecular drug
DM1KCUV PC 16202842
DM1KCUV MW 428.4
DM1KCUV FM C18H20N8O5
DM1KCUV IC InChI=1S/C18H20N8O5/c19-15-12-16(25(8-20-12)17-14(29)13(28)11(7-27)31-17)22-18(21-15)30-6-5-26-10-4-2-1-3-9(10)23-24-26/h1-4,8,11,13-14,17,27-29H,5-7H2,(H2,19,21,22)/t11-,13-,14-,17-/m1/s1
DM1KCUV CS C1=CC=C2C(=C1)N=NN2CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DM1KCUV IK DNLYYBHYIBDUCX-LSCFUAHRSA-N
DM1KCUV IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(benzotriazol-1-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM1KCUV DE Discovery agent
DM0R5U6 ID DM0R5U6
DM0R5U6 DN 2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione
DM0R5U6 HS Investigative
DM0R5U6 SN CHEMBL205391; N-(3-BENZYLOXYPHENYL)PHTHALIMIDE; 2-(3-phenylmethoxyphenyl)isoindole-1,3-dione; 2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione; AC1MO1I5; ZINC4826839; BDBM50181082; AKOS003508151
DM0R5U6 DT Small molecular drug
DM0R5U6 PC 3361967
DM0R5U6 MW 329.3
DM0R5U6 FM C21H15NO3
DM0R5U6 IC InChI=1S/C21H15NO3/c23-20-18-11-4-5-12-19(18)21(24)22(20)16-9-6-10-17(13-16)25-14-15-7-2-1-3-8-15/h1-13H,14H2
DM0R5U6 CS C1=CC=C(C=C1)COC2=CC=CC(=C2)N3C(=O)C4=CC=CC=C4C3=O
DM0R5U6 IK KEXVEOJPANROJT-UHFFFAOYSA-N
DM0R5U6 IU 2-(3-phenylmethoxyphenyl)isoindole-1,3-dione
DM0R5U6 DE Discovery agent
DMKEY9V ID DMKEY9V
DMKEY9V DN 2-(3-(naphthalen-2-yl)propanamido)benzoic acid
DMKEY9V HS Investigative
DMKEY9V SN CHEMBL235740; SCHEMBL5623042; BDBM23518; Biaryl Anthranilide Analogue, 1b; TUCHRHOVXUFQLY-UHFFFAOYSA-N; 2-[3-(naphthalen-2-yl)propanamido]benzoic acid; 2-{[3-(2-naphthalenyl)propanoyl]amino}benzoic acid
DMKEY9V DT Small molecular drug
DMKEY9V PC 11594881
DMKEY9V MW 319.4
DMKEY9V FM C20H17NO3
DMKEY9V IC InChI=1S/C20H17NO3/c22-19(21-18-8-4-3-7-17(18)20(23)24)12-10-14-9-11-15-5-1-2-6-16(15)13-14/h1-9,11,13H,10,12H2,(H,21,22)(H,23,24)
DMKEY9V CS C1=CC=C2C=C(C=CC2=C1)CCC(=O)NC3=CC=CC=C3C(=O)O
DMKEY9V IK TUCHRHOVXUFQLY-UHFFFAOYSA-N
DMKEY9V IU 2-(3-naphthalen-2-ylpropanoylamino)benzoic acid
DMKEY9V DE Discovery agent
DM94B7N ID DM94B7N
DM94B7N DN 2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine
DM94B7N HS Investigative
DM94B7N SN CHEMBL188182; 2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine; SCHEMBL5787166; BDBM50155140
DM94B7N DT Small molecular drug
DM94B7N PC 10017687
DM94B7N MW 300.4
DM94B7N FM C16H16N2O2S
DM94B7N IC InChI=1S/C16H16N2O2S/c17-10-11-18-12-16(14-8-4-5-9-15(14)18)21(19,20)13-6-2-1-3-7-13/h1-9,12H,10-11,17H2
DM94B7N CS C1=CC=C(C=C1)S(=O)(=O)C2=CN(C3=CC=CC=C32)CCN
DM94B7N IK AIHYRVVMMSIZRM-UHFFFAOYSA-N
DM94B7N IU 2-[3-(benzenesulfonyl)indol-1-yl]ethanamine
DM94B7N DE Discovery agent
DM1I6SO ID DM1I6SO
DM1I6SO DN 2-(3,4,5-Trihydroxy-benzylidene)-malononitrile
DM1I6SO HS Investigative
DM1I6SO SN Tyrphostin A25; Tyrphostin 25; 118409-58-8; Tyrphostin-25; (3,4,5-Trihydroxybenzylidene)-malononitrile; NSC 676484; 2-(3,4,5-Trihydroxybenzylidene)malononitrile; alpha-Cyano-(3,4,5-trihydroxy)cinnamonitrile; AG 82; ((3,4,5-Trihydroxyphenyl)methylene)propanedinitrile; NSC676484; 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile; NCGC00016046-02; RG-50875; 158129-55-6; Propanedinitrile, ((3,4,5-trihydroxyphenyl)methylene)-; Propanedinitrile,2-[(3,4,5-trihydroxyphenyl)methylene]-; Tyrphostin A 25
DM1I6SO DT Small molecular drug
DM1I6SO PC 2061
DM1I6SO MW 202.17
DM1I6SO FM C10H6N2O3
DM1I6SO IC InChI=1S/C10H6N2O3/c11-4-7(5-12)1-6-2-8(13)10(15)9(14)3-6/h1-3,13-15H
DM1I6SO CS C1=C(C=C(C(=C1O)O)O)C=C(C#N)C#N
DM1I6SO IK YZOFLYUAQDJWKV-UHFFFAOYSA-N
DM1I6SO IU 2-[(3,4,5-trihydroxyphenyl)methylidene]propanedinitrile
DM1I6SO CA CAS 118409-58-8
DM1I6SO CB CHEBI:92063
DM1I6SO DE Discovery agent
DMJKVZ3 ID DMJKVZ3
DMJKVZ3 DN 2-(3,4-Difluorophenyl)-2,2-diphenylacetamide
DMJKVZ3 HS Investigative
DMJKVZ3 SN CHEMBL272040; SCHEMBL14437487
DMJKVZ3 DT Small molecular drug
DMJKVZ3 PC 20684857
DMJKVZ3 MW 323.3
DMJKVZ3 FM C20H15F2NO
DMJKVZ3 IC InChI=1S/C20H15F2NO/c21-17-12-11-16(13-18(17)22)20(19(23)24,14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13H,(H2,23,24)
DMJKVZ3 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC(=C(C=C3)F)F)C(=O)N
DMJKVZ3 IK ADMJNOLCZZLSIA-UHFFFAOYSA-N
DMJKVZ3 IU 2-(3,4-difluorophenyl)-2,2-diphenylacetamide
DMJKVZ3 DE Discovery agent
DMAOD0K ID DMAOD0K
DMAOD0K DN 2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one
DMAOD0K HS Investigative
DMAOD0K SN CHEMBL56890; 2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one; ZINC13797584; BDBM50077314
DMAOD0K DT Small molecular drug
DMAOD0K PC 10636768
DMAOD0K MW 284.26
DMAOD0K FM C16H12O5
DMAOD0K IC InChI=1S/C16H12O5/c17-10-2-3-12-14(19)8-11(21-16(12)7-10)5-9-1-4-13(18)15(20)6-9/h1-4,6-8,17-18,20H,5H2
DMAOD0K CS C1=CC(=C(C=C1CC2=CC(=O)C3=C(O2)C=C(C=C3)O)O)O
DMAOD0K IK AERADEZJMNEWMZ-UHFFFAOYSA-N
DMAOD0K IU 2-[(3,4-dihydroxyphenyl)methyl]-7-hydroxychromen-4-one
DMAOD0K DE Discovery agent
DM5MKEI ID DM5MKEI
DM5MKEI DN 2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one
DM5MKEI HS Investigative
DM5MKEI SN 7,3',4'-Trihydroxyflavone; 2150-11-0; 2-(3,4-dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one; 3',4',7-Trihydroxyflavone; BRN 0253031; CHEMBL301624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-hydroxy-; Flavone, 7,3',4'-trihydroxy-; 2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one; Q-100553; 4hlf; AC1NT15U; 3',4',7-Trihydroxyflavon; SCHEMBL34405; 7, 3',4'-Trihydroxyflavone; 3'',4'',7-trihydroxyflavon; trihydroxyflavone, 7
DM5MKEI DT Small molecular drug
DM5MKEI PC 5322065
DM5MKEI MW 270.24
DM5MKEI FM C15H10O5
DM5MKEI IC InChI=1S/C15H10O5/c16-9-2-3-10-12(18)7-14(20-15(10)6-9)8-1-4-11(17)13(19)5-8/h1-7,16-17,19H
DM5MKEI CS C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C=C(C=C3)O)O)O
DM5MKEI IK PVFGJHYLIHMCQD-UHFFFAOYSA-N
DM5MKEI IU 2-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one
DM5MKEI CA CAS 2150-11-0
DM5MKEI DE Discovery agent
DMSZ0H9 ID DMSZ0H9
DMSZ0H9 DN 2-(3,4-Dihydroxyphenyl)Acetic Acid
DMSZ0H9 HS Investigative
DMSZ0H9 SN 3,4-Dihydroxyphenylacetic acid; 102-32-9; Dopac; Homoprotocatechuic acid; 2-(3,4-DIHYDROXYPHENYL)ACETIC ACID; Dopacetic acid; Benzeneacetic acid, 3,4-dihydroxy-; 3,4-Dihydroxybenzeneacetic acid; Dihydroxyphenylacetic acid; 4-Carboxymethylcatechol; (3,4-DIHYDROXYPHENYL)ACETIC ACID; Homoprotocatechuate; 3,4-Dihydroxy-phenylacetic acid; Acetic acid, (3,4-dihydroxyphenyl)-; BA 2773; UNII-KEX5N0R4N5; CCRIS 3765; 3,4-dihydroxyphenylacetate; Lopac-D-9128; EINECS 203-024-1; NSC 73191; BRN 2211017; KEX5N0R4N5; 3,4-DHPOP; MLS001056737
DMSZ0H9 DT Small molecular drug
DMSZ0H9 PC 547
DMSZ0H9 MW 168.15
DMSZ0H9 FM C8H8O4
DMSZ0H9 IC InChI=1S/C8H8O4/c9-6-2-1-5(3-7(6)10)4-8(11)12/h1-3,9-10H,4H2,(H,11,12)
DMSZ0H9 CS C1=CC(=C(C=C1CC(=O)O)O)O
DMSZ0H9 IK CFFZDZCDUFSOFZ-UHFFFAOYSA-N
DMSZ0H9 IU 2-(3,4-dihydroxyphenyl)acetic acid
DMSZ0H9 CA CAS 102-32-9
DMSZ0H9 CB CHEBI:41941
DMSZ0H9 DE Discovery agent
DM3S26I ID DM3S26I
DM3S26I DN 2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide
DM3S26I HS Investigative
DM3S26I SN 2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide; CHEMBL210622; MolPort-003-062-950; ZINC4275736; AC1N3474; BDBM50185082; AKOS024605336; MCULE-1480938066; SR-01000011723; SR-01000011723-1; F1358-0295; 2-[(3,4-dimethoxybenzoyl)amino]thiophene-3-carboxamide
DM3S26I DT Small molecular drug
DM3S26I PC 4106590
DM3S26I MW 306.34
DM3S26I FM C14H14N2O4S
DM3S26I IC InChI=1S/C14H14N2O4S/c1-19-10-4-3-8(7-11(10)20-2)13(18)16-14-9(12(15)17)5-6-21-14/h3-7H,1-2H3,(H2,15,17)(H,16,18)
DM3S26I CS COC1=C(C=C(C=C1)C(=O)NC2=C(C=CS2)C(=O)N)OC
DM3S26I IK LORRZRFBMUDPOE-UHFFFAOYSA-N
DM3S26I IU 2-[(3,4-dimethoxybenzoyl)amino]thiophene-3-carboxamide
DM3S26I DE Discovery agent
DMLOX0Y ID DMLOX0Y
DMLOX0Y DN 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole
DMLOX0Y HS Investigative
DMLOX0Y SN 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole; CHEMBL503049; 192988-59-3; SCHEMBL9575182; DTXSID80571566; BDBM50265991; ZINC34530543; AKOS022491775; 2-(3,4-Dimethoxyphenyl)-2-imidazoline
DMLOX0Y DT Small molecular drug
DMLOX0Y PC 15327588
DMLOX0Y MW 206.24
DMLOX0Y FM C11H14N2O2
DMLOX0Y IC InChI=1S/C11H14N2O2/c1-14-9-4-3-8(7-10(9)15-2)11-12-5-6-13-11/h3-4,7H,5-6H2,1-2H3,(H,12,13)
DMLOX0Y CS COC1=C(C=C(C=C1)C2=NCCN2)OC
DMLOX0Y IK NXHHUAOYFMCRFK-UHFFFAOYSA-N
DMLOX0Y IU 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole
DMLOX0Y CA CAS 192988-59-3
DMLOX0Y DE Discovery agent
DMDGRWM ID DMDGRWM
DMDGRWM DN 2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM HS Investigative
DMDGRWM SN CHEMBL235398; 2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM DT Small molecular drug
DMDGRWM PC 44434720
DMDGRWM MW 234.29
DMDGRWM FM C16H14N2
DMDGRWM IC InChI=1S/C16H14N2/c1-11-5-6-14(10-12(11)2)15-8-7-13-4-3-9-17-16(13)18-15/h3-10H,1-2H3
DMDGRWM CS CC1=C(C=C(C=C1)C2=NC3=C(C=CC=N3)C=C2)C
DMDGRWM IK HNJUUHIKQMSRFO-UHFFFAOYSA-N
DMDGRWM IU 2-(3,4-dimethylphenyl)-1,8-naphthyridine
DMDGRWM DE Discovery agent
DM8KM1Q ID DM8KM1Q
DM8KM1Q DN 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q HS Investigative
DM8KM1Q SN CHEMBL393049; 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q DT Small molecular drug
DM8KM1Q PC 44435041
DM8KM1Q MW 276.12
DM8KM1Q FM C13H7Cl2N3
DM8KM1Q IC InChI=1S/C13H7Cl2N3/c14-10-4-9(5-11(15)6-10)13-17-7-8-2-1-3-16-12(8)18-13/h1-7H
DM8KM1Q CS C1=CC2=CN=C(N=C2N=C1)C3=CC(=CC(=C3)Cl)Cl
DM8KM1Q IK UDWGFUUPZLVQFW-UHFFFAOYSA-N
DM8KM1Q IU 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine
DM8KM1Q DE Discovery agent
DMGJPYO ID DMGJPYO
DMGJPYO DN 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO HS Investigative
DMGJPYO SN CHEMBL235838; 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO DT Small molecular drug
DMGJPYO PC 44434736
DMGJPYO MW 256.25
DMGJPYO FM C15H10F2N2
DMGJPYO IC InChI=1S/C15H10F2N2/c1-9-2-3-10-4-5-14(19-15(10)18-9)11-6-12(16)8-13(17)7-11/h2-8H,1H3
DMGJPYO CS CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC(=C3)F)F
DMGJPYO IK ODEYWYKLTXXLRT-UHFFFAOYSA-N
DMGJPYO IU 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine
DMGJPYO DE Discovery agent
DMIEB8R ID DMIEB8R
DMIEB8R DN 2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine
DMIEB8R HS Investigative
DMIEB8R SN CHEMBL465866; 207740-42-9; Phenescaline; 2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine; DTXSID00659517; BDBM50251265
DMIEB8R DT Small molecular drug
DMIEB8R PC 44567543
DMIEB8R MW 301.4
DMIEB8R FM C18H23NO3
DMIEB8R IC InChI=1S/C18H23NO3/c1-20-16-12-15(8-10-19)13-17(21-2)18(16)22-11-9-14-6-4-3-5-7-14/h3-7,12-13H,8-11,19H2,1-2H3
DMIEB8R CS COC1=CC(=CC(=C1OCCC2=CC=CC=C2)OC)CCN
DMIEB8R IK FKXBCTFKCKEDNI-UHFFFAOYSA-N
DMIEB8R IU 2-[3,5-dimethoxy-4-(2-phenylethoxy)phenyl]ethanamine
DMIEB8R CA CAS 207740-42-9
DMIEB8R DE Discovery agent
DMKND0T ID DMKND0T
DMKND0T DN 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T HS Investigative
DMKND0T SN CHEMBL391755; 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T DT Small molecular drug
DMKND0T PC 44434719
DMKND0T MW 266.29
DMKND0T FM C16H14N2O2
DMKND0T IC InChI=1S/C16H14N2O2/c1-19-13-8-12(9-14(10-13)20-2)15-6-5-11-4-3-7-17-16(11)18-15/h3-10H,1-2H3
DMKND0T CS COC1=CC(=CC(=C1)C2=NC3=C(C=CC=N3)C=C2)OC
DMKND0T IK JUMXQELSAJZAIP-UHFFFAOYSA-N
DMKND0T IU 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine
DMKND0T DE Discovery agent
DMJ2NPY ID DMJ2NPY
DMJ2NPY DN 2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one
DMJ2NPY HS Investigative
DMJ2NPY SN CHEMBL223436; 2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one
DMJ2NPY DT Small molecular drug
DMJ2NPY PC 16203469
DMJ2NPY MW 299.32
DMJ2NPY FM C17H17NO4
DMJ2NPY IC InChI=1S/C17H17NO4/c1-12(19)13-3-2-4-14(9-13)16-10-15(20)11-17(22-16)18-5-7-21-8-6-18/h2-4,9-11H,5-8H2,1H3
DMJ2NPY CS CC(=O)C1=CC=CC(=C1)C2=CC(=O)C=C(O2)N3CCOCC3
DMJ2NPY IK MUGFHNCVHGYLEQ-UHFFFAOYSA-N
DMJ2NPY IU 2-(3-acetylphenyl)-6-morpholin-4-ylpyran-4-one
DMJ2NPY DE Discovery agent
DMAGFUH ID DMAGFUH
DMAGFUH DN 2-(3'-Allyl-biphenyl-4-yl)-propionic acid
DMAGFUH HS Investigative
DMAGFUH SN CHEMBL325787; BDBM50074936; 2-(3''-Allyl-biphenyl-4-yl)-propionic acid
DMAGFUH DT Small molecular drug
DMAGFUH PC 44336367
DMAGFUH MW 266.3
DMAGFUH FM C18H18O2
DMAGFUH IC InChI=1S/C18H18O2/c1-3-5-14-6-4-7-17(12-14)16-10-8-15(9-11-16)13(2)18(19)20/h3-4,6-13H,1,5H2,2H3,(H,19,20)
DMAGFUH CS CC(C1=CC=C(C=C1)C2=CC=CC(=C2)CC=C)C(=O)O
DMAGFUH IK NOUUHOHFFJKTMS-UHFFFAOYSA-N
DMAGFUH IU 2-[4-(3-prop-2-enylphenyl)phenyl]propanoic acid
DMAGFUH DE Discovery agent
DMC6E8R ID DMC6E8R
DMC6E8R DN 2-(3-aminophenoxy)-5-hexylphenol
DMC6E8R HS Investigative
DMC6E8R SN CHEMBL404984
DMC6E8R DT Small molecular drug
DMC6E8R PC 44450095
DMC6E8R MW 285.4
DMC6E8R FM C18H23NO2
DMC6E8R IC InChI=1S/C18H23NO2/c1-2-3-4-5-7-14-10-11-18(17(20)12-14)21-16-9-6-8-15(19)13-16/h6,8-13,20H,2-5,7,19H2,1H3
DMC6E8R CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC(=C2)N)O
DMC6E8R IK ZRRRBQYWHBBQGE-UHFFFAOYSA-N
DMC6E8R IU 2-(3-aminophenoxy)-5-hexylphenol
DMC6E8R DE Discovery agent
DMQB9SC ID DMQB9SC
DMQB9SC DN 2-(3-aminophenyl)-3-mercaptopropanoic acid
DMQB9SC HS Investigative
DMQB9SC SN 2-(3-aminophenyl)-3-mercaptopropanoic acid; CHEMBL246595; 607832-91-7; SCHEMBL2352530; BDBM50201431
DMQB9SC DT Small molecular drug
DMQB9SC PC 10214451
DMQB9SC MW 197.26
DMQB9SC FM C9H11NO2S
DMQB9SC IC InChI=1S/C9H11NO2S/c10-7-3-1-2-6(4-7)8(5-13)9(11)12/h1-4,8,13H,5,10H2,(H,11,12)
DMQB9SC CS C1=CC(=CC(=C1)N)C(CS)C(=O)O
DMQB9SC IK WOYCAJIRNXWVLG-UHFFFAOYSA-N
DMQB9SC IU 2-(3-aminophenyl)-3-sulfanylpropanoic acid
DMQB9SC DE Discovery agent
DMAP37I ID DMAP37I
DMAP37I DN 2-(3-Amino-phenyl)-6-methyl-chromen-4-one
DMAP37I HS Investigative
DMAP37I SN CHEMBL132423; ZINC13491189; AKOS022269929; 468060-72-2; KB-191922
DMAP37I DT Small molecular drug
DMAP37I PC 10977911
DMAP37I MW 251.28
DMAP37I FM C16H13NO2
DMAP37I IC InChI=1S/C16H13NO2/c1-10-5-6-15-13(7-10)14(18)9-16(19-15)11-3-2-4-12(17)8-11/h2-9H,17H2,1H3
DMAP37I CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)N
DMAP37I IK JDDRGOPANADJMA-UHFFFAOYSA-N
DMAP37I IU 2-(3-aminophenyl)-6-methylchromen-4-one
DMAP37I DE Discovery agent
DM3FBLT ID DM3FBLT
DM3FBLT DN 2-(3-benzenesulfonyl)phenyl-1-aminoethane
DM3FBLT HS Investigative
DM3FBLT SN CHEMBL209383; 2-(3-benzenesulfonyl)phenyl-1-aminoethane; ZINC36093365
DM3FBLT DT Small molecular drug
DM3FBLT PC 11849199
DM3FBLT MW 261.339
DM3FBLT FM C14H15NO2S
DM3FBLT IC InChI=1S/C14H15NO2S/c15-10-9-12-5-4-8-14(11-12)18(16,17)13-6-2-1-3-7-13/h1-8,11H,9-10,15H2
DM3FBLT CS C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC(=C2)CCN
DM3FBLT IK PXOKRWBUDGQCDL-UHFFFAOYSA-N
DM3FBLT IU 2-[3-(benzenesulfonyl)phenyl]ethanamine
DM3FBLT DE Discovery agent
DMDB4LZ ID DMDB4LZ
DMDB4LZ DN 2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid
DMDB4LZ HS Investigative
DMDB4LZ SN CHEMBL93723; 2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid; 3-benzoylpyrrole-1-acetic acid; BDBM50146187; 3-Benzoyl-1H-pyrrole-1-acetic acid; (3-Benzoyl-pyrrol-1-yl)-acetic acid
DMDB4LZ DT Small molecular drug
DMDB4LZ PC 10398922
DMDB4LZ MW 229.23
DMDB4LZ FM C13H11NO3
DMDB4LZ IC InChI=1S/C13H11NO3/c15-12(16)9-14-7-6-11(8-14)13(17)10-4-2-1-3-5-10/h1-8H,9H2,(H,15,16)
DMDB4LZ CS C1=CC=C(C=C1)C(=O)C2=CN(C=C2)CC(=O)O
DMDB4LZ IK NFEXRSVGIRNYEZ-UHFFFAOYSA-N
DMDB4LZ IU 2-(3-benzoylpyrrol-1-yl)acetic acid
DMDB4LZ DE Discovery agent
DMWMFTJ ID DMWMFTJ
DMWMFTJ DN 2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE
DMWMFTJ HS Investigative
DMWMFTJ SN SB-543668; 2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE; N-[2-(3-benzoylphenoxy)ethyl]-N-hydroxyformamide; SB8; AC1NRD38; SCHEMBL6245513; BDBM21684; DB08524
DMWMFTJ DT Small molecular drug
DMWMFTJ PC 5289330
DMWMFTJ MW 285.29
DMWMFTJ FM C16H15NO4
DMWMFTJ IC InChI=1S/C16H15NO4/c18-12-17(20)9-10-21-15-8-4-7-14(11-15)16(19)13-5-2-1-3-6-13/h1-8,11-12,20H,9-10H2
DMWMFTJ CS C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)OCCN(C=O)O
DMWMFTJ IK ZHFKBNAHHTUQBH-UHFFFAOYSA-N
DMWMFTJ IU N-[2-(3-benzoylphenoxy)ethyl]-N-hydroxyformamide
DMWMFTJ DE Discovery agent
DM6V91D ID DM6V91D
DM6V91D DN 2-(3-benzylquinoxalin-2-ylamino)ethanol
DM6V91D HS Investigative
DM6V91D SN CHEMBL203892; 2-(3-benzylquinoxalin-2-ylamino)ethanol
DM6V91D DT Small molecular drug
DM6V91D PC 44409443
DM6V91D MW 279.34
DM6V91D FM C17H17N3O
DM6V91D IC InChI=1S/C17H17N3O/c21-11-10-18-17-16(12-13-6-2-1-3-7-13)19-14-8-4-5-9-15(14)20-17/h1-9,21H,10-12H2,(H,18,20)
DM6V91D CS C1=CC=C(C=C1)CC2=NC3=CC=CC=C3N=C2NCCO
DM6V91D IK SNVOYVYEVPVVNG-UHFFFAOYSA-N
DM6V91D IU 2-[(3-benzylquinoxalin-2-yl)amino]ethanol
DM6V91D DE Discovery agent
DMY60K3 ID DMY60K3
DMY60K3 DN 2-(3-biphenyl-4-yl-propionylamino)-benzoic acid
DMY60K3 HS Investigative
DMY60K3 SN CHEMBL235741; SCHEMBL12671515; BDBM23519; Biaryl Anthranilide Analogue, 1c; 2-[3-(4-phenylphenyl)propanamido]benzoic acid
DMY60K3 DT Small molecular drug
DMY60K3 PC 11617151
DMY60K3 MW 345.4
DMY60K3 FM C22H19NO3
DMY60K3 IC InChI=1S/C22H19NO3/c24-21(23-20-9-5-4-8-19(20)22(25)26)15-12-16-10-13-18(14-11-16)17-6-2-1-3-7-17/h1-11,13-14H,12,15H2,(H,23,24)(H,25,26)
DMY60K3 CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)NC3=CC=CC=C3C(=O)O
DMY60K3 IK CAYOKBAXZPGNTO-UHFFFAOYSA-N
DMY60K3 IU 2-[3-(4-phenylphenyl)propanoylamino]benzoic acid
DMY60K3 DE Discovery agent
DMX4DUR ID DMX4DUR
DMX4DUR DN 2-(3-bromobenzoylamino)-4-chlorobenzoic acid
DMX4DUR HS Investigative
DMX4DUR SN 827325-60-0; 2-[(3-bromobenzoyl)amino]-4-chlorobenzoic acid; CHEMBL225612; 2-(3-Bromobenzamido)-4-chlorobenzoic acid; Benzoic acid, 2-[(3-bromobenzoyl)amino]-4-chloro-; 2-(3-bromobenzoylamino)-4-chlorobenzoic acid; AC1N8QX1; SCHEMBL14075271; CTK3D6918; KS-00003MRF; DTXSID50401927; MolPort-002-885-931; ZINC4104976; ZX-AN021268; ALBB-022752; BDBM50158557; AKOS005107642; MCULE-7998531013; MS-0095; R4909; SR-01000309735; SR-01000309735-1; 2-[(3-bromobenzoyl)amino]-4-chlorobenzenecarboxylic acid
DMX4DUR DT Small molecular drug
DMX4DUR PC 4323128
DMX4DUR MW 354.58
DMX4DUR FM C14H9BrClNO3
DMX4DUR IC InChI=1S/C14H9BrClNO3/c15-9-3-1-2-8(6-9)13(18)17-12-7-10(16)4-5-11(12)14(19)20/h1-7H,(H,17,18)(H,19,20)
DMX4DUR CS C1=CC(=CC(=C1)Br)C(=O)NC2=C(C=CC(=C2)Cl)C(=O)O
DMX4DUR IK NKUSVNRZDILGSG-UHFFFAOYSA-N
DMX4DUR IU 2-[(3-bromobenzoyl)amino]-4-chlorobenzoic acid
DMX4DUR CA CAS 827325-60-0
DMX4DUR DE Discovery agent
DM9G7B6 ID DM9G7B6
DM9G7B6 DN 2-(3-Bromo-phenyl)-6-methyl-chromen-4-one
DM9G7B6 HS Investigative
DM9G7B6 SN CHEMBL334427; 2-(3-Bromo-phenyl)-6-methyl-chromen-4-one; AC1LFCVT; BAS 01121887; 3'-Bromo-6-methylflavone; 6-Methyl-3''-bromoflavone; Oprea1_370713; Oprea1_120869; MolPort-001-955-842; ZINC265292; BDBM50118406; AKOS000603553
DM9G7B6 DT Small molecular drug
DM9G7B6 PC 776059
DM9G7B6 MW 315.16
DM9G7B6 FM C16H11BrO2
DM9G7B6 IC InChI=1S/C16H11BrO2/c1-10-5-6-15-13(7-10)14(18)9-16(19-15)11-3-2-4-12(17)8-11/h2-9H,1H3
DM9G7B6 CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)Br
DM9G7B6 IK NGKYRJKVRCEDNG-UHFFFAOYSA-N
DM9G7B6 IU 2-(3-bromophenyl)-6-methylchromen-4-one
DM9G7B6 DE Discovery agent
DM9RAYC ID DM9RAYC
DM9RAYC DN 2-(3-Bromo-phenyl)-6-nitro-chromen-4-one
DM9RAYC HS Investigative
DM9RAYC SN CHEMBL64792; 3'-Bromo-6-nitroflavone
DM9RAYC DT Small molecular drug
DM9RAYC PC 9841153
DM9RAYC MW 346.13
DM9RAYC FM C15H8BrNO4
DM9RAYC IC InChI=1S/C15H8BrNO4/c16-10-3-1-2-9(6-10)15-8-13(18)12-7-11(17(19)20)4-5-14(12)21-15/h1-8H
DM9RAYC CS C1=CC(=CC(=C1)Br)C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-]
DM9RAYC IK IOYFMBZXVIRMNX-UHFFFAOYSA-N
DM9RAYC IU 2-(3-bromophenyl)-6-nitrochromen-4-one
DM9RAYC DE Discovery agent
DMYSM9L ID DMYSM9L
DMYSM9L DN 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L HS Investigative
DMYSM9L SN CHEMBL237906; 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L DT Small molecular drug
DMYSM9L PC 44434745
DMYSM9L MW 299.16
DMYSM9L FM C15H11BrN2
DMYSM9L IC InChI=1S/C15H11BrN2/c1-10-5-6-11-7-8-14(18-15(11)17-10)12-3-2-4-13(16)9-12/h2-9H,1H3
DMYSM9L CS CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC=C3)Br
DMYSM9L IK YAOUIVOXDAAEBA-UHFFFAOYSA-N
DMYSM9L IU 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
DMYSM9L DE Discovery agent
DMANS5X ID DMANS5X
DMANS5X DN 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X HS Investigative
DMANS5X SN CHEMBL396346; 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X DT Small molecular drug
DMANS5X PC 44435028
DMANS5X MW 300.15
DMANS5X FM C14H10BrN3
DMANS5X IC InChI=1S/C14H10BrN3/c1-9-5-6-11-8-16-13(18-14(11)17-9)10-3-2-4-12(15)7-10/h2-8H,1H3
DMANS5X CS CC1=NC2=NC(=NC=C2C=C1)C3=CC(=CC=C3)Br
DMANS5X IK QTHPZWOJWWROSA-UHFFFAOYSA-N
DMANS5X IU 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine
DMANS5X DE Discovery agent
DM7XDLO ID DM7XDLO
DM7XDLO DN 2-(3-Bromo-phenyl)-chromen-4-one
DM7XDLO HS Investigative
DM7XDLO SN 3'-Bromoflavone; CHEMBL55148; 2-(3-bromophenyl)chromen-4-one; 2-(3-Bromo-phenyl)-chromen-4-one; AC1LAQPY; SCHEMBL6654321; MolPort-001-904-025; ZINC265291; AKOS000603552; BAS 01121885; 4H-1-Benzopyran-4-one, 2-(3-bromophenyl)-
DM7XDLO DT Small molecular drug
DM7XDLO PC 493373
DM7XDLO MW 301.13
DM7XDLO FM C15H9BrO2
DM7XDLO IC InChI=1S/C15H9BrO2/c16-11-5-3-4-10(8-11)15-9-13(17)12-6-1-2-7-14(12)18-15/h1-9H
DM7XDLO CS C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC(=CC=C3)Br
DM7XDLO IK YFEZLTPSCJWVHI-UHFFFAOYSA-N
DM7XDLO IU 2-(3-bromophenyl)chromen-4-one
DM7XDLO DE Discovery agent
DM260RG ID DM260RG
DM260RG DN 2-(3-bromophenyl)histamine
DM260RG HS Investigative
DM260RG SN 2-(3-Bromophenyl)histamine; CHEMBL26116; GTPL1194; SCHEMBL15974857; BDBM22863; PDSP2_001292; PDSP1_001308; AKOS022562838; AKOS023977997; 2-(3-Bromophenyl)-1H-imidazole-4-(ethanamine); 2-[2-(3-bromophenyl)-3H-imidazol-4-yl]ethanamine
DM260RG DT Small molecular drug
DM260RG PC 23786499
DM260RG MW 266.14
DM260RG FM C11H12BrN3
DM260RG IC InChI=1S/C11H12BrN3/c12-9-3-1-2-8(6-9)11-14-7-10(15-11)4-5-13/h1-3,6-7H,4-5,13H2,(H,14,15)
DM260RG CS C1=CC(=CC(=C1)Br)C2=NC=C(N2)CCN
DM260RG IK VSKJPAMQPJDPLL-UHFFFAOYSA-N
DM260RG IU 2-[2-(3-bromophenyl)-1H-imidazol-5-yl]ethanamine
DM260RG DE Discovery agent
DMVA4XC ID DMVA4XC
DMVA4XC DN 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC HS Investigative
DMVA4XC SN CHEMBL239197; 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC DT Small molecular drug
DMVA4XC PC 44435039
DMVA4XC MW 286.13
DMVA4XC FM C13H8BrN3
DMVA4XC IC InChI=1S/C13H8BrN3/c14-11-5-1-3-9(7-11)12-16-8-10-4-2-6-15-13(10)17-12/h1-8H
DMVA4XC CS C1=CC(=CC(=C1)Br)C2=NC=C3C=CC=NC3=N2
DMVA4XC IK KOBJRMNXIZSOES-UHFFFAOYSA-N
DMVA4XC IU 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine
DMVA4XC DE Discovery agent
DMFETRH ID DMFETRH
DMFETRH DN 2-(3-Bromophenylthio)-N,N-dimethylethanamine
DMFETRH HS Investigative
DMFETRH SN 2-(3-Bromophenylthio)-N,N-dimethylethanamine; CHEMBL609323; 144085-61-0; BDBM50307505
DMFETRH DT Small molecular drug
DMFETRH PC 46233484
DMFETRH MW 260.2
DMFETRH FM C10H14BrNS
DMFETRH IC InChI=1S/C10H14BrNS/c1-12(2)6-7-13-10-5-3-4-9(11)8-10/h3-5,8H,6-7H2,1-2H3
DMFETRH CS CN(C)CCSC1=CC(=CC=C1)Br
DMFETRH IK LIEFSMJAVJRLBQ-UHFFFAOYSA-N
DMFETRH IU 2-(3-bromophenyl)sulfanyl-N,N-dimethylethanamine
DMFETRH DE Discovery agent
DMJM5VW ID DMJM5VW
DMJM5VW DN 2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol
DMJM5VW HS Investigative
DMJM5VW DT Small molecular drug
DMJM5VW PC 135454786
DMJM5VW MW 299.32
DMJM5VW FM C17H17NO4
DMJM5VW IC InChI=1S/C17H17NO4/c1-2-3-8-21-16-9-11(4-7-14(16)20)17-18-13-6-5-12(19)10-15(13)22-17/h4-7,9-10,19-20H,2-3,8H2,1H3
DMJM5VW CS CCCCOC1=C(C=CC(=C1)C2=NC3=C(O2)C=C(C=C3)O)O
DMJM5VW IK BJVMSZRSXULFSB-UHFFFAOYSA-N
DMJM5VW IU 2-(3-butoxy-4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DMJM5VW DE Discovery agent
DMSZT9G ID DMSZT9G
DMSZT9G DN 2-(3-Butoxy-phenyl)-6-methyl-chromen-4-one
DMSZT9G HS Investigative
DMSZT9G SN CHEMBL131928
DMSZT9G DT Small molecular drug
DMSZT9G PC 11012278
DMSZT9G MW 308.4
DMSZT9G FM C20H20O3
DMSZT9G IC InChI=1S/C20H20O3/c1-3-4-10-22-16-7-5-6-15(12-16)20-13-18(21)17-11-14(2)8-9-19(17)23-20/h5-9,11-13H,3-4,10H2,1-2H3
DMSZT9G CS CCCCOC1=CC=CC(=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C
DMSZT9G IK CFRCJBWAEQSCHB-UHFFFAOYSA-N
DMSZT9G IU 2-(3-butoxyphenyl)-6-methylchromen-4-one
DMSZT9G DE Discovery agent
DMHXVNZ ID DMHXVNZ
DMHXVNZ DN 2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
DMHXVNZ HS Investigative
DMHXVNZ SN Thiol-Based Inhibitor, 20; CHEMBL206885; BDBM17773; 2-[(3-carbamoylphenyl)methyl]-5-sulfanylpentanoic acid
DMHXVNZ DT Small molecular drug
DMHXVNZ PC 11601420
DMHXVNZ MW 267.35
DMHXVNZ FM C13H17NO3S
DMHXVNZ IC InChI=1S/C13H17NO3S/c14-12(15)10-4-1-3-9(7-10)8-11(13(16)17)5-2-6-18/h1,3-4,7,11,18H,2,5-6,8H2,(H2,14,15)(H,16,17)
DMHXVNZ CS C1=CC(=CC(=C1)C(=O)N)CC(CCCS)C(=O)O
DMHXVNZ IK AGWUXZTVEYUITF-UHFFFAOYSA-N
DMHXVNZ IU 2-[(3-carbamoylphenyl)methyl]-5-sulfanylpentanoic acid
DMHXVNZ DE Discovery agent
DMI6AZ5 ID DMI6AZ5
DMI6AZ5 DN 2-(3-carboxybenzyl)succinic acid
DMI6AZ5 HS Investigative
DMI6AZ5 SN 2-(3-carboxybenzyl)succinic acid; carboxylate, 39; 2-[(3-carboxyphenyl)methyl]butanedioic Acid; Butanedioic acid, 2-[(3-carboxyphenyl)methyl]-; CHEMBL209190; BDBM17782
DMI6AZ5 DT Small molecular drug
DMI6AZ5 PC 11499788
DMI6AZ5 MW 252.22
DMI6AZ5 FM C12H12O6
DMI6AZ5 IC InChI=1S/C12H12O6/c13-10(14)6-9(12(17)18)5-7-2-1-3-8(4-7)11(15)16/h1-4,9H,5-6H2,(H,13,14)(H,15,16)(H,17,18)
DMI6AZ5 CS C1=CC(=CC(=C1)C(=O)O)CC(CC(=O)O)C(=O)O
DMI6AZ5 IK WCLWDNBZTFVGIR-UHFFFAOYSA-N
DMI6AZ5 IU 2-[(3-carboxyphenyl)methyl]butanedioic acid
DMI6AZ5 DE Discovery agent
DMBONUV ID DMBONUV
DMBONUV DN 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMBONUV HS Investigative
DMBONUV DT Small molecular drug
DMBONUV PC 135443280
DMBONUV MW 261.66
DMBONUV FM C13H8ClNO3
DMBONUV IC InChI=1S/C13H8ClNO3/c14-9-5-7(1-3-11(9)17)13-15-10-6-8(16)2-4-12(10)18-13/h1-6,16-17H
DMBONUV CS C1=CC(=C(C=C1C2=NC3=C(O2)C=CC(=C3)O)Cl)O
DMBONUV IK XCJCSWQYKSCDIH-UHFFFAOYSA-N
DMBONUV IU 2-(3-chloro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMBONUV DE Discovery agent
DM3B6IN ID DM3B6IN
DM3B6IN DN 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM3B6IN HS Investigative
DM3B6IN DT Small molecular drug
DM3B6IN PC 135496133
DM3B6IN MW 261.66
DM3B6IN FM C13H8ClNO3
DM3B6IN IC InChI=1S/C13H8ClNO3/c14-9-5-7(1-4-11(9)17)13-15-10-3-2-8(16)6-12(10)18-13/h1-6,16-17H
DM3B6IN CS C1=CC(=C(C=C1C2=NC3=C(O2)C=C(C=C3)O)Cl)O
DM3B6IN IK YWMCWMCSJCYHBX-UHFFFAOYSA-N
DM3B6IN IU 2-(3-chloro-4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DM3B6IN DE Discovery agent
DM1VDC3 ID DM1VDC3
DM1VDC3 DN 2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile
DM1VDC3 HS Investigative
DM1VDC3 SN CHEMBL202908; 2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile; SCHEMBL4292772; BDBM50181075
DM1VDC3 DT Small molecular drug
DM1VDC3 PC 44409846
DM1VDC3 MW 279.12
DM1VDC3 FM C13H8Cl2N2O
DM1VDC3 IC InChI=1S/C13H8Cl2N2O/c14-11-3-1-2-9(4-11)8-18-13-6-10(7-16)5-12(15)17-13/h1-6H,8H2
DM1VDC3 CS C1=CC(=CC(=C1)Cl)COC2=NC(=CC(=C2)C#N)Cl
DM1VDC3 IK MGYAMTJNJZZLMV-UHFFFAOYSA-N
DM1VDC3 IU 2-chloro-6-[(3-chlorophenyl)methoxy]pyridine-4-carbonitrile
DM1VDC3 DE Discovery agent
DMK6CD9 ID DMK6CD9
DMK6CD9 DN 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one
DMK6CD9 HS Investigative
DMK6CD9 SN CHEMBL45677; NSC679034; AC1L8S0S; 1, 2-(3-chlorophenyl)-; 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one; SCHEMBL7920166; CTK8C9853; ZINC5541496; BDBM50059959; NSC-679034; NCI60_028233; 2-(3-chlorophenyl)-1H-1,8-naphthyridin-4-one; 2-(3-Chlorophenyl)-1,8-naphthyridin-4(1H)-one; 1,8-Naphthyridin-4(1H)-one, 2-(3-chlorophenyl)-
DMK6CD9 DT Small molecular drug
DMK6CD9 PC 386586
DMK6CD9 MW 256.68
DMK6CD9 FM C14H9ClN2O
DMK6CD9 IC InChI=1S/C14H9ClN2O/c15-10-4-1-3-9(7-10)12-8-13(18)11-5-2-6-16-14(11)17-12/h1-8H,(H,16,17,18)
DMK6CD9 CS C1=CC(=CC(=C1)Cl)C2=CC(=O)C3=C(N2)N=CC=C3
DMK6CD9 IK HZSAAZXBYZMFJN-UHFFFAOYSA-N
DMK6CD9 IU 2-(3-chlorophenyl)-1H-1,8-naphthyridin-4-one
DMK6CD9 DE Discovery agent
DMYQBSV ID DMYQBSV
DMYQBSV DN 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide
DMYQBSV HS Investigative
DMYQBSV SN CHEMBL1094953; 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2265628
DMYQBSV DT Small molecular drug
DMYQBSV PC 44549374
DMYQBSV MW 271.7
DMYQBSV FM C14H10ClN3O
DMYQBSV IC InChI=1S/C14H10ClN3O/c15-10-4-2-5-11(7-10)18-8-9-3-1-6-12(14(16)19)13(9)17-18/h1-8H,(H2,16,19)
DMYQBSV CS C1=CC(=CC(=C1)Cl)N2C=C3C=CC=C(C3=N2)C(=O)N
DMYQBSV IK HWNODZACISEDHJ-UHFFFAOYSA-N
DMYQBSV IU 2-(3-chlorophenyl)indazole-7-carboxamide
DMYQBSV DE Discovery agent
DM7BC50 ID DM7BC50
DM7BC50 DN 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50 HS Investigative
DM7BC50 SN CHEMBL397551; 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50 DT Small molecular drug
DM7BC50 PC 44434741
DM7BC50 MW 254.71
DM7BC50 FM C15H11ClN2
DM7BC50 IC InChI=1S/C15H11ClN2/c1-10-5-6-11-7-8-14(18-15(11)17-10)12-3-2-4-13(16)9-12/h2-9H,1H3
DM7BC50 CS CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC=C3)Cl
DM7BC50 IK LLSDDUWUZVPZOE-UHFFFAOYSA-N
DM7BC50 IU 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine
DM7BC50 DE Discovery agent
DML83DM ID DML83DM
DML83DM DN 2-(3-Chloro-phenyl)-chromen-4-one
DML83DM HS Investigative
DML83DM SN CHEMBL56414; 2-(3-chlorophenyl)chromen-4-one; 1849-61-2; 4h-1-benzopyran-4-one,2-(3-chlorophenyl)-; AC1LAD8B; 2-(3-CHLOROPHENYL)-4H-CHROMEN-4-ONE; SCHEMBL6655676; ZINC6583548; MB10491; 2-(3'-chlorophenyl)-4h-chromen-4-one
DML83DM DT Small molecular drug
DML83DM PC 466272
DML83DM MW 256.68
DML83DM FM C15H9ClO2
DML83DM IC InChI=1S/C15H9ClO2/c16-11-5-3-4-10(8-11)15-9-13(17)12-6-1-2-7-14(12)18-15/h1-9H
DML83DM CS C1=CC=C2C(=C1)C(=O)C=C(O2)C3=CC(=CC=C3)Cl
DML83DM IK JWTQJUQJIRWZLA-UHFFFAOYSA-N
DML83DM IU 2-(3-chlorophenyl)chromen-4-one
DML83DM DE Discovery agent
DMO0Y79 ID DMO0Y79
DMO0Y79 DN 2-(3-chlorophenyl)histamine
DMO0Y79 HS Investigative
DMO0Y79 SN 2-(3-chlorophenyl)histamine; 2-(3-chlorophenyl)-histamine; SCHEMBL3028276; GTPL1195; CHEMBL287052; BDBM86172; PDSP1_001307; PDSP2_001291; AKOS022543464; AKOS023903196; 133118-40-8
DMO0Y79 DT Small molecular drug
DMO0Y79 PC 14827778
DMO0Y79 MW 221.68
DMO0Y79 FM C11H12ClN3
DMO0Y79 IC InChI=1S/C11H12ClN3/c12-9-3-1-2-8(6-9)11-14-7-10(15-11)4-5-13/h1-3,6-7H,4-5,13H2,(H,14,15)
DMO0Y79 CS C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN
DMO0Y79 IK DHGUFKPZDMQBED-UHFFFAOYSA-N
DMO0Y79 IU 2-[2-(3-chlorophenyl)-1H-imidazol-5-yl]ethanamine
DMO0Y79 DE Discovery agent
DMVB5U0 ID DMVB5U0
DMVB5U0 DN 2-(3-cyanobenzyl)-5-mercaptopentanoic acid
DMVB5U0 HS Investigative
DMVB5U0 SN Thiol-Based Inhibitor, 22; CHEMBL207899; BDBM17774; 2-[(3-cyanophenyl)methyl]-5-sulfanylpentanoic acid
DMVB5U0 DT Small molecular drug
DMVB5U0 PC 11715765
DMVB5U0 MW 249.33
DMVB5U0 FM C13H15NO2S
DMVB5U0 IC InChI=1S/C13H15NO2S/c14-9-11-4-1-3-10(7-11)8-12(13(15)16)5-2-6-17/h1,3-4,7,12,17H,2,5-6,8H2,(H,15,16)
DMVB5U0 CS C1=CC(=CC(=C1)C#N)CC(CCCS)C(=O)O
DMVB5U0 IK PCFBGUNMCCWACH-UHFFFAOYSA-N
DMVB5U0 IU 2-[(3-cyanophenyl)methyl]-5-sulfanylpentanoic acid
DMVB5U0 DE Discovery agent
DMPLN58 ID DMPLN58
DMPLN58 DN 2-(3'-Ethyl-biphenyl-4-yl)-propionic acid
DMPLN58 HS Investigative
DMPLN58 SN CHEMBL106203; BDBM50074929; 2-(3'-Ethyl-4-biphenylyl)propanoic acid; 2-(3''-Ethyl-biphenyl-4-yl)-propionic acid
DMPLN58 DT Small molecular drug
DMPLN58 PC 44336344
DMPLN58 MW 254.32
DMPLN58 FM C17H18O2
DMPLN58 IC InChI=1S/C17H18O2/c1-3-13-5-4-6-16(11-13)15-9-7-14(8-10-15)12(2)17(18)19/h4-12H,3H2,1-2H3,(H,18,19)
DMPLN58 CS CCC1=CC(=CC=C1)C2=CC=C(C=C2)C(C)C(=O)O
DMPLN58 IK NXNPVWSOBXWFAA-UHFFFAOYSA-N
DMPLN58 IU 2-[4-(3-ethylphenyl)phenyl]propanoic acid
DMPLN58 DE Discovery agent
DMPGYDA ID DMPGYDA
DMPGYDA DN 2-(3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid
DMPGYDA HS Investigative
DMPGYDA SN CHEMBL107938; BDBM50074924; 2-(3'-Ethylthio-4-biphenylyl)propanoic acid; 2-(3''-Ethylsulfanyl-biphenyl-4-yl)-propionic acid
DMPGYDA DT Small molecular drug
DMPGYDA PC 9817355
DMPGYDA MW 286.4
DMPGYDA FM C17H18O2S
DMPGYDA IC InChI=1S/C17H18O2S/c1-3-20-16-6-4-5-15(11-16)14-9-7-13(8-10-14)12(2)17(18)19/h4-12H,3H2,1-2H3,(H,18,19)
DMPGYDA CS CCSC1=CC=CC(=C1)C2=CC=C(C=C2)C(C)C(=O)O
DMPGYDA IK QGKUCOODYMVNGO-UHFFFAOYSA-N
DMPGYDA IU 2-[4-(3-ethylsulfanylphenyl)phenyl]propanoic acid
DMPGYDA DE Discovery agent
DMNTHK5 ID DMNTHK5
DMNTHK5 DN 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol
DMNTHK5 HS Investigative
DMNTHK5 DT Small molecular drug
DMNTHK5 PC 135528620
DMNTHK5 MW 245.21
DMNTHK5 FM C13H8FNO3
DMNTHK5 IC InChI=1S/C13H8FNO3/c14-9-5-7(1-3-11(9)17)13-15-10-6-8(16)2-4-12(10)18-13/h1-6,16-17H
DMNTHK5 CS C1=CC(=C(C=C1C2=NC3=C(O2)C=CC(=C3)O)F)O
DMNTHK5 IK GOGMBKCQZDIOLM-UHFFFAOYSA-N
DMNTHK5 IU 2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMNTHK5 DE Discovery agent
DM50FW1 ID DM50FW1
DM50FW1 DN 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol
DM50FW1 HS Investigative
DM50FW1 DT Small molecular drug
DM50FW1 PC 135528621
DM50FW1 MW 245.21
DM50FW1 FM C13H8FNO3
DM50FW1 IC InChI=1S/C13H8FNO3/c14-9-5-7(1-4-11(9)17)13-15-10-3-2-8(16)6-12(10)18-13/h1-6,16-17H
DM50FW1 CS C1=CC(=C(C=C1C2=NC3=C(O2)C=C(C=C3)O)F)O
DM50FW1 IK LMARQOUQPBAFEB-UHFFFAOYSA-N
DM50FW1 IU 2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DM50FW1 DE Discovery agent
DMNYWAT ID DMNYWAT
DMNYWAT DN 2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one
DMNYWAT HS Investigative
DMNYWAT SN CHEMBL436080; 652138-30-2; 2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one; CTK1J8219; DTXSID70467020; BDBM50159673; 4H-Naphtho[1,2-b]pyran-4-one, 2-(3-fluorophenyl)-
DMNYWAT DT Small molecular drug
DMNYWAT PC 11471812
DMNYWAT MW 290.3
DMNYWAT FM C19H11FO2
DMNYWAT IC InChI=1S/C19H11FO2/c20-14-6-3-5-13(10-14)18-11-17(21)16-9-8-12-4-1-2-7-15(12)19(16)22-18/h1-11H
DMNYWAT CS C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC(=CC=C4)F
DMNYWAT IK PJCRQJRMDLDKLR-UHFFFAOYSA-N
DMNYWAT IU 2-(3-fluorophenyl)benzo[h]chromen-4-one
DMNYWAT CA CAS 652138-30-2
DMNYWAT DE Discovery agent
DMZX2GE ID DMZX2GE
DMZX2GE DN 2-(3-guanidinophenyl)-3-mercaptopropanoic acid
DMZX2GE HS Investigative
DMZX2GE SN 2-(3-GUANIDINOPHENYL)-3-MERCAPTOPROPANOIC ACID; (2R)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-SULFANYLPROPANOIC ACID; L98; AC1NA0C3; ZINC16051731; DB04723; (2R)-2-(3-carbamimidamidophenyl)-3-sulfanylpropanoic acid; (2R)-2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid; (2R)-2-{3-[(diaminomethylidene)amino]phenyl}-3-sulfanylpropanoic acid
DMZX2GE DT Small molecular drug
DMZX2GE PC 4369579
DMZX2GE MW 239.3
DMZX2GE FM C10H13N3O2S
DMZX2GE IC InChI=1S/C10H13N3O2S/c11-10(12)13-7-3-1-2-6(4-7)8(5-16)9(14)15/h1-4,8,16H,5H2,(H,14,15)(H4,11,12,13)/t8-/m1/s1
DMZX2GE CS C1=CC(=CC(=C1)N=C(N)N)[C@@H](CS)C(=O)O
DMZX2GE IK YHBCRXAIIVZWEW-MRVPVSSYSA-N
DMZX2GE IU (2R)-2-[3-(diaminomethylideneamino)phenyl]-3-sulfanylpropanoic acid
DMZX2GE DE Discovery agent
DMFVITM ID DMFVITM
DMFVITM DN 2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid
DMFVITM HS Investigative
DMFVITM SN CHEMBL433298; 2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid; SCHEMBL13996819; BDBM50129199; 2-[4-Oxo-4-(hydroxyamino)butyl]pentanedioic acid
DMFVITM DT Small molecular drug
DMFVITM PC 20778204
DMFVITM MW 233.22
DMFVITM FM C9H15NO6
DMFVITM IC InChI=1S/C9H15NO6/c11-7(10-16)3-1-2-6(9(14)15)4-5-8(12)13/h6,16H,1-5H2,(H,10,11)(H,12,13)(H,14,15)
DMFVITM CS C(CC(CCC(=O)O)C(=O)O)CC(=O)NO
DMFVITM IK SFUVFBUNWNKLJH-UHFFFAOYSA-N
DMFVITM IU 2-[4-(hydroxyamino)-4-oxobutyl]pentanedioic acid
DMFVITM DE Discovery agent
DMZCE18 ID DMZCE18
DMZCE18 DN 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMZCE18 HS Investigative
DMZCE18 SN CHEMBL24950; SCHEMBL6286195; BDBM50123206; 2-(3-hydroxyphenyl)-1,2''-spirobi[1H-indene]-5-ol
DMZCE18 DT Small molecular drug
DMZCE18 PC 9901869
DMZCE18 MW 326.4
DMZCE18 FM C23H18O2
DMZCE18 IC InChI=1S/C23H18O2/c24-19-7-3-6-15(10-19)22-12-18-11-20(25)8-9-21(18)23(22)13-16-4-1-2-5-17(16)14-23/h1-12,24-25H,13-14H2
DMZCE18 CS C1C2=CC=CC=C2CC13C4=C(C=C(C=C4)O)C=C3C5=CC(=CC=C5)O
DMZCE18 IK NBNSBPOETAKHET-UHFFFAOYSA-N
DMZCE18 IU 2'-(3-hydroxyphenyl)spiro[1,3-dihydroindene-2,1'-indene]-5'-ol
DMZCE18 DE Discovery agent
DMIGXRJ ID DMIGXRJ
DMIGXRJ DN 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol
DMIGXRJ HS Investigative
DMIGXRJ SN CHEMBL144431; SCHEMBL6283932; BDBM50123207; 2-(3-hydroxyphenyl)-1,2''-spirobi[1H-indene]-6-ol
DMIGXRJ DT Small molecular drug
DMIGXRJ PC 10131379
DMIGXRJ MW 326.4
DMIGXRJ FM C23H18O2
DMIGXRJ IC InChI=1S/C23H18O2/c24-19-7-3-6-15(10-19)21-11-16-8-9-20(25)12-22(16)23(21)13-17-4-1-2-5-18(17)14-23/h1-12,24-25H,13-14H2
DMIGXRJ CS C1C2=CC=CC=C2CC13C(=CC4=C3C=C(C=C4)O)C5=CC(=CC=C5)O
DMIGXRJ IK GWRXSPPQGAVBCP-UHFFFAOYSA-N
DMIGXRJ IU 2'-(3-hydroxyphenyl)spiro[1,3-dihydroindene-2,3'-indene]-5'-ol
DMIGXRJ DE Discovery agent
DM40RS3 ID DM40RS3
DM40RS3 DN 2-(3-Hydroxy-phenyl)-6-methyl-chromen-4-one
DM40RS3 HS Investigative
DM40RS3 SN 3'-HYDROXY-6-METHYLFLAVONE; 468060-75-5; SCHEMBL5424662; CHEMBL336559; CTK6C0232; BNOQFZSTTRNHCN-UHFFFAOYSA-N; ZINC13491192; 3'-hydroxy-6-methylflavone, AldrichCPR; RT-008155; 4H-1-Benzopyran-4-one, 2-(3-hydroxyphenyl)-6-methyl-
DM40RS3 DT Small molecular drug
DM40RS3 PC 11075942
DM40RS3 MW 252.26
DM40RS3 FM C16H12O3
DM40RS3 IC InChI=1S/C16H12O3/c1-10-5-6-15-13(7-10)14(18)9-16(19-15)11-3-2-4-12(17)8-11/h2-9,17H,1H3
DM40RS3 CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)O
DM40RS3 IK BNOQFZSTTRNHCN-UHFFFAOYSA-N
DM40RS3 IU 2-(3-hydroxyphenyl)-6-methylchromen-4-one
DM40RS3 DE Discovery agent
DMAH0ZG ID DMAH0ZG
DMAH0ZG DN 2-(3-hydroxyphenyl)-7-methoxychroman-4-one
DMAH0ZG HS Investigative
DMAH0ZG SN CHEMBL256407; 32274-72-9; CTK1B9323; DTXSID30438650; BDBM50374258; AKOS030552772; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(3-hydroxyphenyl)-7-methoxy-
DMAH0ZG DT Small molecular drug
DMAH0ZG PC 10355761
DMAH0ZG MW 270.28
DMAH0ZG FM C16H14O4
DMAH0ZG IC InChI=1S/C16H14O4/c1-19-12-5-6-13-14(18)9-15(20-16(13)8-12)10-3-2-4-11(17)7-10/h2-8,15,17H,9H2,1H3
DMAH0ZG CS COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC(=CC=C3)O
DMAH0ZG IK YETISVQJYRETIF-UHFFFAOYSA-N
DMAH0ZG IU 2-(3-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMAH0ZG CA CAS 32274-72-9
DMAH0ZG DE Discovery agent
DMV9M57 ID DMV9M57
DMV9M57 DN 2-(3-hydroxyphenyl)quinolin-6-ol
DMV9M57 HS Investigative
DMV9M57 SN 2-(3-hydroxyphenyl)quinolin-6-ol; CHEMBL260459; SCHEMBL3007819
DMV9M57 DT Small molecular drug
DMV9M57 PC 25069444
DMV9M57 MW 237.25
DMV9M57 FM C15H11NO2
DMV9M57 IC InChI=1S/C15H11NO2/c17-12-3-1-2-10(8-12)14-6-4-11-9-13(18)5-7-15(11)16-14/h1-9,17-18H
DMV9M57 CS C1=CC(=CC(=C1)O)C2=NC3=C(C=C2)C=C(C=C3)O
DMV9M57 IK KVSLALXAPWSPAG-UHFFFAOYSA-N
DMV9M57 IU 2-(3-hydroxyphenyl)quinolin-6-ol
DMV9M57 CA CAS 87741-96-6
DMV9M57 DE Discovery agent
DMXRAE3 ID DMXRAE3
DMXRAE3 DN 2-(3''-indolylethyloxy)adenosine
DMXRAE3 HS Investigative
DMXRAE3 SN CHEMBL223366; SCHEMBL8111144; 2-(3'-Indolylethyloxy)Adenosine; BDBM50208804; 2-(3''''-indolylethyloxy)adenosine; 2-[2-(1H-Indol-3-yl)ethoxy]adenosine
DMXRAE3 DT Small molecular drug
DMXRAE3 PC 16203429
DMXRAE3 MW 426.4
DMXRAE3 FM C20H22N6O5
DMXRAE3 IC InChI=1S/C20H22N6O5/c21-17-14-18(26(9-23-14)19-16(29)15(28)13(8-27)31-19)25-20(24-17)30-6-5-10-7-22-12-4-2-1-3-11(10)12/h1-4,7,9,13,15-16,19,22,27-29H,5-6,8H2,(H2,21,24,25)/t13-,15-,16-,19-/m1/s1
DMXRAE3 CS C1=CC=C2C(=C1)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O)N
DMXRAE3 IK UIPASAROPWUJRQ-NVQRDWNXSA-N
DMXRAE3 IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-indol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMXRAE3 DE Discovery agent
DMML0VP ID DMML0VP
DMML0VP DN 2-(3-iodophenyl)histamine
DMML0VP HS Investigative
DMML0VP SN 2-(3-iodophenyl)histamine; 2-[2-(3-iodophenyl)-3H-imidazol-4-yl]ethanamine; CHEMBL287367; GTPL1196; BDBM86173; PDSP2_001293; PDSP1_001309
DMML0VP DT Small molecular drug
DMML0VP PC 10245039
DMML0VP MW 313.14
DMML0VP FM C11H12IN3
DMML0VP IC InChI=1S/C11H12IN3/c12-9-3-1-2-8(6-9)11-14-7-10(15-11)4-5-13/h1-3,6-7H,4-5,13H2,(H,14,15)
DMML0VP CS C1=CC(=CC(=C1)I)C2=NC=C(N2)CCN
DMML0VP IK OPICWPJAKDPOOB-UHFFFAOYSA-N
DMML0VP IU 2-[2-(3-iodophenyl)-1H-imidazol-5-yl]ethanamine
DMML0VP DE Discovery agent
DM59VBG ID DM59VBG
DM59VBG DN 2-(3-Isobutyl-phenyl)-propionic acid
DM59VBG HS Investigative
DM59VBG SN 66622-47-7; 2-(3-isobutylphenyl)propanoic acid; m-Isobutyl Ibuprofen; 2-[3-(2-methylpropyl)phenyl]propanoic Acid; 2-(3-Isobutylphenyl)propionic Acid; (2RS)-2-(3-(2-Methylpropyl)phenyl)propanoic acid; (2RS)-2-[3-(2-Methylpropyl)phenyl]propanoic Acid; Ibuprofen specified impurity A [EP]; Ibuprofen Impurity A; alpha-(3-Isobutylphenyl)propionic acid; SCHEMBL66534; alpha-Methyl-3-(2-methylpropyl)phenylacetic acid; CHEMBL187556; Benzeneacetic acid, alpha-methyl-3-(2-methylpropyl)-; CTK5C4963; MolPort-029-294-062; AKOS023890981
DM59VBG DT Small molecular drug
DM59VBG PC 11424295
DM59VBG MW 206.28
DM59VBG FM C13H18O2
DM59VBG IC InChI=1S/C13H18O2/c1-9(2)7-11-5-4-6-12(8-11)10(3)13(14)15/h4-6,8-10H,7H2,1-3H3,(H,14,15)
DM59VBG CS CC(C)CC1=CC(=CC=C1)C(C)C(=O)O
DM59VBG IK SFVKLYXPBKITCE-UHFFFAOYSA-N
DM59VBG IU 2-[3-(2-methylpropyl)phenyl]propanoic acid
DM59VBG CA CAS 66622-47-7
DM59VBG DE Discovery agent
DMUOWNE ID DMUOWNE
DMUOWNE DN 2-(3-Isopropyl-phenyl)-propionic acid
DMUOWNE HS Investigative
DMUOWNE SN Benzeneacetic acid, alpha-methyl-3-(1-methylethyl)-; CHEMBL191103; SCHEMBL1345333; DHFSUPPYOBITGY-UHFFFAOYSA-N; 2-(3-isopropylphenyl)propanoic acid; AKOS022699991; 2-[(3'-isopropyl)phenyl]propionic acid
DMUOWNE DT Small molecular drug
DMUOWNE PC 10307922
DMUOWNE MW 192.25
DMUOWNE FM C12H16O2
DMUOWNE IC InChI=1S/C12H16O2/c1-8(2)10-5-4-6-11(7-10)9(3)12(13)14/h4-9H,1-3H3,(H,13,14)
DMUOWNE CS CC(C)C1=CC(=CC=C1)C(C)C(=O)O
DMUOWNE IK DHFSUPPYOBITGY-UHFFFAOYSA-N
DMUOWNE IU 2-(3-propan-2-ylphenyl)propanoic acid
DMUOWNE DE Discovery agent
DMMDNA8 ID DMMDNA8
DMMDNA8 DN 2-(3-Mercapto-propyl)-pentanedioic acid
DMMDNA8 HS Investigative
DMMDNA8 SN 2-(3-mercaptopropyl)pentanedioic acid; 2-MPPA; 2-(3-sulfanylpropyl)pentanedioic Acid; 254737-29-6; CHEMBL303352; Pentanedioic acid, 2-(3-mercaptopropyl)-; 2-[3-mercaptopropyl]pentanedioic acid; GPI 5693; SCHEMBL787800; CTK0J4030; BDBM17755; FNLNSQHJKVQCBP-UHFFFAOYSA-N; MolPort-035-765-922; pentanedioic acid analogue, (RS)-3; AKOS024458465
DMMDNA8 DT Small molecular drug
DMMDNA8 PC 10198171
DMMDNA8 MW 206.26
DMMDNA8 FM C8H14O4S
DMMDNA8 IC InChI=1S/C8H14O4S/c9-7(10)4-3-6(8(11)12)2-1-5-13/h6,13H,1-5H2,(H,9,10)(H,11,12)
DMMDNA8 CS C(CC(CCC(=O)O)C(=O)O)CS
DMMDNA8 IK FNLNSQHJKVQCBP-UHFFFAOYSA-N
DMMDNA8 IU 2-(3-sulfanylpropyl)pentanedioic acid
DMMDNA8 CA CAS 254737-29-6
DMMDNA8 DE Discovery agent
DM21MAU ID DM21MAU
DM21MAU DN 2-(3-methoxybenzylthio)-2-phenylacetic acid
DM21MAU HS Investigative
DM21MAU SN MLS003115376; 2-(3-methoxybenzylthio)-2-phenylacetic acid; CHEMBL493464; 7037-33-4; NSC268685; AC1L82IK; 2-[(3-methoxyphenyl)methylsulfanyl]-2-phenylacetic acid; DTXSID20313306; BDBM50253013; NSC-268685
DM21MAU DT Small molecular drug
DM21MAU PC 320577
DM21MAU MW 288.4
DM21MAU FM C16H16O3S
DM21MAU IC InChI=1S/C16H16O3S/c1-19-14-9-5-6-12(10-14)11-20-15(16(17)18)13-7-3-2-4-8-13/h2-10,15H,11H2,1H3,(H,17,18)
DM21MAU CS COC1=CC=CC(=C1)CSC(C2=CC=CC=C2)C(=O)O
DM21MAU IK DCWDBUYRVFMPPL-UHFFFAOYSA-N
DM21MAU IU 2-[(3-methoxyphenyl)methylsulfanyl]-2-phenylacetic acid
DM21MAU CA CAS 7037-33-4
DM21MAU DE Discovery agent
DMCDGAU ID DMCDGAU
DMCDGAU DN 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
DMCDGAU HS Investigative
DMCDGAU SN 2-(3'-methoxyphenyl) benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide; CHEMBL134022; BZC; 1efy; AC1L1BMO; SCHEMBL4321727; CTK7A9229; NVVWVYYHTKCIAE-UHFFFAOYSA-N; ZINC11565446; BDBM50093373; DB04010; 2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide; 2-(3-methoxyphenyl)-1H-1,3-benzodiazole-4-carboxamide; 2-(3''-METHOXYPHENYL) BENZIMIDAZOLE-4-CARBOXAMIDE; 2-(3-Methoxy-phenyl)-1H-benzoimidazole-4-carboxylic acid amide
DMCDGAU DT Small molecular drug
DMCDGAU PC 1511
DMCDGAU MW 267.28
DMCDGAU FM C15H13N3O2
DMCDGAU IC InChI=1S/C15H13N3O2/c1-20-10-5-2-4-9(8-10)15-17-12-7-3-6-11(14(16)19)13(12)18-15/h2-8H,1H3,(H2,16,19)(H,17,18)
DMCDGAU CS COC1=CC=CC(=C1)C2=NC3=C(C=CC=C3N2)C(=O)N
DMCDGAU IK NVVWVYYHTKCIAE-UHFFFAOYSA-N
DMCDGAU IU 2-(3-methoxyphenyl)-1H-benzimidazole-4-carboxamide
DMCDGAU DE Discovery agent
DM4C9H2 ID DM4C9H2
DM4C9H2 DN 2-(3-Methoxy-phenyl)-1-methyl-ethylamine
DM4C9H2 HS Investigative
DM4C9H2 SN 3-Methoxyamphetamine; 1-(3-methoxyphenyl)propan-2-amine; 17862-85-0; Benzeneethanamine, 3-methoxy-alpha-methyl-; CHEMBL16247; VEJWNIYARKAHFI-UHFFFAOYSA-N; 2-(3-Methoxyphenyl)-1-methylethylamine; 17862-91-8; meta-Methoxyamphetamine; 3-methoxyamphetamine -; 2-(3-Methoxy-phenyl)-1-methyl-ethylamine; AC1L47YE; NCIOpen2_006073; SCHEMBL269071; CTK0H8604; 1-(3-methoxyphenyl)-2-propylamine; BDBM50024211; AKOS000157039; AKOS022196418; MCULE-6670391418; MB01562; 1-(3-Methoxyphenyl)-2-propanamine #; NCI60_042089
DM4C9H2 DT Small molecular drug
DM4C9H2 PC 152234
DM4C9H2 MW 165.23
DM4C9H2 FM C10H15NO
DM4C9H2 IC InChI=1S/C10H15NO/c1-8(11)6-9-4-3-5-10(7-9)12-2/h3-5,7-8H,6,11H2,1-2H3
DM4C9H2 CS CC(CC1=CC(=CC=C1)OC)N
DM4C9H2 IK VEJWNIYARKAHFI-UHFFFAOYSA-N
DM4C9H2 IU 1-(3-methoxyphenyl)propan-2-amine
DM4C9H2 CA CAS 17862-85-0
DM4C9H2 DE Discovery agent
DMBGVEK ID DMBGVEK
DMBGVEK DN 2-(3-Methoxy-phenyl)-6-methyl-chromen-4-one
DMBGVEK HS Investigative
DMBGVEK SN 3'-METHOXY-6-METHYLFLAVONE; CHEMBL131632; 4H-1-Benzopyran-4-one, 2-(3-methoxyphenyl)-6-methyl-; 88952-72-1; ACMC-20lfb9; AC1LVOZ6; CTK3A4546; DTXSID50364725; GPLWNAUILJELBH-UHFFFAOYSA-N; ZINC1933195; AKOS002387234; MB03835; 3'-methoxy-6-methylflavone, AldrichCPR
DMBGVEK DT Small molecular drug
DMBGVEK PC 1659443
DMBGVEK MW 266.29
DMBGVEK FM C17H14O3
DMBGVEK IC InChI=1S/C17H14O3/c1-11-6-7-16-14(8-11)15(18)10-17(20-16)12-4-3-5-13(9-12)19-2/h3-10H,1-2H3
DMBGVEK CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC(=CC=C3)OC
DMBGVEK IK GPLWNAUILJELBH-UHFFFAOYSA-N
DMBGVEK IU 2-(3-methoxyphenyl)-6-methylchromen-4-one
DMBGVEK CA CAS 88952-72-1
DMBGVEK DE Discovery agent
DMASH36 ID DMASH36
DMASH36 DN 2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMASH36 HS Investigative
DMASH36 SN CHEMBL106543; 2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3538409; BDBM50132356; 2-Morpholino-6-(3-methoxyphenyl)-4H-pyran-4-one
DMASH36 DT Small molecular drug
DMASH36 PC 21106405
DMASH36 MW 287.31
DMASH36 FM C16H17NO4
DMASH36 IC InChI=1S/C16H17NO4/c1-19-14-4-2-3-12(9-14)15-10-13(18)11-16(21-15)17-5-7-20-8-6-17/h2-4,9-11H,5-8H2,1H3
DMASH36 CS COC1=CC=CC(=C1)C2=CC(=O)C=C(O2)N3CCOCC3
DMASH36 IK OLIONIBTYZDPMY-UHFFFAOYSA-N
DMASH36 IU 2-(3-methoxyphenyl)-6-morpholin-4-ylpyran-4-one
DMASH36 DE Discovery agent
DME09J2 ID DME09J2
DME09J2 DN 2-(3-Methyl-3H-imidazol-4-yl)-ethylamine
DME09J2 HS Investigative
DME09J2 SN 3-Methylhistamine; Tau-methylhistamine; 644-42-8; Imidazole, 5-(2-aminoethyl)-1-methyl-; L-histamine deriv. 1; 2-(1-methyl-1H-imidazol-5-yl)ethan-1-amine; 1H-Imidazole-5-ethanamine, 1-methyl-; CHEMBL14722; 2-(1-methyl-1H-imidazol-5-yl)ethanamine; CPAGZVLINCPJEH-UHFFFAOYSA-N; 2-(3-methylimidazol-4-yl)ethanamine; 3-Methyl Histamine Dihydrochloride; (r)-a-methylhistamine; AC1Q4WNL; SCHEMBL946729; BDBM7967; AC1L2C25; CTK5C1256; DTXSID10214651; ZINC403074; AKOS006340201; 1H-Imidazole-5-ethanamine,1-methyl-
DME09J2 DT Small molecular drug
DME09J2 PC 69520
DME09J2 MW 125.17
DME09J2 FM C6H11N3
DME09J2 IC InChI=1S/C6H11N3/c1-9-5-8-4-6(9)2-3-7/h4-5H,2-3,7H2,1H3
DME09J2 CS CN1C=NC=C1CCN
DME09J2 IK CPAGZVLINCPJEH-UHFFFAOYSA-N
DME09J2 IU 2-(3-methylimidazol-4-yl)ethanamine
DME09J2 CA CAS 644-42-8
DME09J2 DE Discovery agent
DMFOA6R ID DMFOA6R
DMFOA6R DN 2-(3-Methyl-indole-1-sulfonyl)-benzoic acid
DMFOA6R HS Investigative
DMFOA6R SN CHEMBL361251; 2-(3-Methyl-indole-1-sulfonyl)-benzoic acid
DMFOA6R DT Small molecular drug
DMFOA6R PC 44393556
DMFOA6R MW 315.3
DMFOA6R FM C16H13NO4S
DMFOA6R IC InChI=1S/C16H13NO4S/c1-11-10-17(14-8-4-2-6-12(11)14)22(20,21)15-9-5-3-7-13(15)16(18)19/h2-10H,1H3,(H,18,19)
DMFOA6R CS CC1=CN(C2=CC=CC=C12)S(=O)(=O)C3=CC=CC=C3C(=O)O
DMFOA6R IK FBAOKNXTXGWCMO-UHFFFAOYSA-N
DMFOA6R IU 2-(3-methylindol-1-yl)sulfonylbenzoic acid
DMFOA6R DE Discovery agent
DM1J4MT ID DM1J4MT
DM1J4MT DN 2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline
DM1J4MT HS Investigative
DM1J4MT SN CHEMBL43526; 2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline; Quinoline,2-(3-methyl-1-piperazinyl)-6-nitro-; SCHEMBL6365197; WIRIBEHWECMIRC-UHFFFAOYSA-N; BDBM50090211; AKOS011768382; 2-(3-Methylpiperazino)-6-nitroquinoline; 296759-20-1
DM1J4MT DT Small molecular drug
DM1J4MT PC 44286607
DM1J4MT MW 272.3
DM1J4MT FM C14H16N4O2
DM1J4MT IC InChI=1S/C14H16N4O2/c1-10-9-17(7-6-15-10)14-5-2-11-8-12(18(19)20)3-4-13(11)16-14/h2-5,8,10,15H,6-7,9H2,1H3
DM1J4MT CS CC1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)[N+](=O)[O-]
DM1J4MT IK WIRIBEHWECMIRC-UHFFFAOYSA-N
DM1J4MT IU 2-(3-methylpiperazin-1-yl)-6-nitroquinoline
DM1J4MT DE Discovery agent
DM4D1UT ID DM4D1UT
DM4D1UT DN 2-(3-Methylsulfanyl-propyl)-pentanedioic acid
DM4D1UT HS Investigative
DM4D1UT SN CHEMBL61882; 2-(3-Methylsulfanyl-propyl)-pentanedioic acid
DM4D1UT DT Small molecular drug
DM4D1UT PC 11790725
DM4D1UT MW 220.29
DM4D1UT FM C9H16O4S
DM4D1UT IC InChI=1S/C9H16O4S/c1-14-6-2-3-7(9(12)13)4-5-8(10)11/h7H,2-6H2,1H3,(H,10,11)(H,12,13)
DM4D1UT CS CSCCCC(CCC(=O)O)C(=O)O
DM4D1UT IK AXRGKFNGKGNVEI-UHFFFAOYSA-N
DM4D1UT IU 2-(3-methylsulfanylpropyl)pentanedioic acid
DM4D1UT DE Discovery agent
DMMYQ9R ID DMMYQ9R
DMMYQ9R DN 2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole
DMMYQ9R HS Investigative
DMMYQ9R SN 2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole; 31659-42-4; 1h-imidazole, 4,5-dihydro-2-(3-nitrophenyl)-; CHEMBL457101; 4,5-Dihydro-2-(3-nitrophenyl)-1H-imidazole; EINECS 250-754-1; AC1LEYVJ; AC1Q1ZUC; 2-(m-nitrophenyl)imidazoline; IMI021; SCHEMBL12643294; CTK4G7541; DTXSID30185551; MolPort-006-126-327; ZINC121568; 2-(3-Nitrophenyl)-2-imidazoline; STK367845; BDBM50266032; BBL001160; AKOS005444754; MCULE-9494328291; T7684
DMMYQ9R DT Small molecular drug
DMMYQ9R PC 720241
DMMYQ9R MW 191.19
DMMYQ9R FM C9H9N3O2
DMMYQ9R IC InChI=1S/C9H9N3O2/c13-12(14)8-3-1-2-7(6-8)9-10-4-5-11-9/h1-3,6H,4-5H2,(H,10,11)
DMMYQ9R CS C1CN=C(N1)C2=CC(=CC=C2)[N+](=O)[O-]
DMMYQ9R IK YSCJJOXSVFNSPY-UHFFFAOYSA-N
DMMYQ9R IU 2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole
DMMYQ9R CA CAS 31659-42-4
DMMYQ9R DE Discovery agent
DM6GLEA ID DM6GLEA
DM6GLEA DN 2-(3-Phenoxy-benzoylamino)-benzoic acid
DM6GLEA HS Investigative
DM6GLEA SN CHEMBL178465; BDBM23579; 2-(3-Phenoxybenzamido)Benzoic Acid; 2-(3-phenoxybenzoylamino)benzoic acid; 2-[(3-phenoxybenzene)amido]benzoic acid; (3-Phenoxybenzoylamino)benzoic acid deriv., 15
DM6GLEA DT Small molecular drug
DM6GLEA PC 11325072
DM6GLEA MW 333.3
DM6GLEA FM C20H15NO4
DM6GLEA IC InChI=1S/C20H15NO4/c22-19(21-18-12-5-4-11-17(18)20(23)24)14-7-6-10-16(13-14)25-15-8-2-1-3-9-15/h1-13H,(H,21,22)(H,23,24)
DM6GLEA CS C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O
DM6GLEA IK MIKJQLWATXBRIP-UHFFFAOYSA-N
DM6GLEA IU 2-[(3-phenoxybenzoyl)amino]benzoic acid
DM6GLEA DE Discovery agent
DMIQBXD ID DMIQBXD
DMIQBXD DN 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one
DMIQBXD HS Investigative
DMIQBXD SN CHEMBL3144578; CHEMBL8053; 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one; BDBM50009009; ZINC138045856
DMIQBXD DT Small molecular drug
DMIQBXD PC 14898717
DMIQBXD MW 252.31
DMIQBXD FM C16H16N2O
DMIQBXD IC InChI=1S/C16H16N2O/c19-16-14-10-4-5-11-15(14)17-18(16)12-6-9-13-7-2-1-3-8-13/h1-5,7-8,10-11,17H,6,9,12H2
DMIQBXD CS C1=CC=C(C=C1)CCCN2C(=O)C3=CC=CC=C3N2
DMIQBXD IK ZTUNGCGUHQENHO-UHFFFAOYSA-N
DMIQBXD IU 2-(3-phenylpropyl)-1H-indazol-3-one
DMIQBXD DE Discovery agent
DM4WOT6 ID DM4WOT6
DM4WOT6 DN 2-(3-phenylthio)phenyl)-1-aminoethane
DM4WOT6 HS Investigative
DM4WOT6 SN CHEMBL211688; 2-(3-phenylthio)phenyl)-1-aminoethane; 2-(3-(Phenylthio)Phenyl)Ethanamine; BDBM50193470
DM4WOT6 DT Small molecular drug
DM4WOT6 PC 11849796
DM4WOT6 MW 229.34
DM4WOT6 FM C14H15NS
DM4WOT6 IC InChI=1S/C14H15NS/c15-10-9-12-5-4-8-14(11-12)16-13-6-2-1-3-7-13/h1-8,11H,9-10,15H2
DM4WOT6 CS C1=CC=C(C=C1)SC2=CC=CC(=C2)CCN
DM4WOT6 IK FJLQSSVQBNJTEU-UHFFFAOYSA-N
DM4WOT6 IU 2-(3-phenylsulfanylphenyl)ethanamine
DM4WOT6 DE Discovery agent
DMZ5H8O ID DMZ5H8O
DMZ5H8O DN 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one
DMZ5H8O HS Investigative
DMZ5H8O DT Small molecular drug
DMZ5H8O PC 135508369
DMZ5H8O MW 271.36
DMZ5H8O FM C16H21N3O
DMZ5H8O IC InChI=1S/C16H21N3O/c20-16-13-7-2-3-8-14(13)17-15(18-16)9-6-12-19-10-4-1-5-11-19/h2-3,7-8H,1,4-6,9-12H2,(H,17,18,20)
DMZ5H8O CS C1CCN(CC1)CCCC2=NC3=CC=CC=C3C(=O)N2
DMZ5H8O IK HDVNQQSSIKDDKS-UHFFFAOYSA-N
DMZ5H8O IU 2-(3-piperidin-1-ylpropyl)-3H-quinazolin-4-one
DMZ5H8O DE Discovery agent
DMNCP8Y ID DMNCP8Y
DMNCP8Y DN 2-(3''-pyrrolylethyloxy)adenosine
DMNCP8Y HS Investigative
DMNCP8Y SN CHEMBL222945; 2-(3'-Pyrrolylethyloxy)Adenosine; BDBM50208806; 2-(3''''-pyrrolylethyloxy)adenosine
DMNCP8Y DT Small molecular drug
DMNCP8Y PC 16204411
DMNCP8Y MW 376.37
DMNCP8Y FM C16H20N6O5
DMNCP8Y IC InChI=1S/C16H20N6O5/c17-13-10-14(21-16(20-13)26-4-2-8-1-3-18-5-8)22(7-19-10)15-12(25)11(24)9(6-23)27-15/h1,3,5,7,9,11-12,15,18,23-25H,2,4,6H2,(H2,17,20,21)/t9-,11-,12-,15-/m1/s1
DMNCP8Y CS C1=CNC=C1CCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMNCP8Y IK OBDCLFIHFXHMSJ-SDBHATRESA-N
DMNCP8Y IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-pyrrol-3-yl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMNCP8Y DE Discovery agent
DM7NGV1 ID DM7NGV1
DM7NGV1 DN 2-(3'-Vinyl-biphenyl-4-yl)-propionic acid
DM7NGV1 HS Investigative
DM7NGV1 SN CHEMBL432782; BDBM50074925; 2-(3'-Vinyl-4-biphenylyl)propanoic acid; 2-(3''-Vinyl-biphenyl-4-yl)-propionic acid
DM7NGV1 DT Small molecular drug
DM7NGV1 PC 44336157
DM7NGV1 MW 252.31
DM7NGV1 FM C17H16O2
DM7NGV1 IC InChI=1S/C17H16O2/c1-3-13-5-4-6-16(11-13)15-9-7-14(8-10-15)12(2)17(18)19/h3-12H,1H2,2H3,(H,18,19)
DM7NGV1 CS CC(C1=CC=C(C=C1)C2=CC=CC(=C2)C=C)C(=O)O
DM7NGV1 IK VRFXYYPKWQXDFK-UHFFFAOYSA-N
DM7NGV1 IU 2-[4-(3-ethenylphenyl)phenyl]propanoic acid
DM7NGV1 DE Discovery agent
DM27CQJ ID DM27CQJ
DM27CQJ DN 2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine
DM27CQJ HS Investigative
DM27CQJ SN CHEMBL213001; 2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine; SCHEMBL4293064; 2-[4-(3-chlorophenyl)but-1-yn-1-yl]-6-methylpyridine; BDBM50191127
DM27CQJ DT Small molecular drug
DM27CQJ PC 11379837
DM27CQJ MW 255.74
DM27CQJ FM C16H14ClN
DM27CQJ IC InChI=1S/C16H14ClN/c1-13-6-4-11-16(18-13)10-3-2-7-14-8-5-9-15(17)12-14/h4-6,8-9,11-12H,2,7H2,1H3
DM27CQJ CS CC1=NC(=CC=C1)C#CCCC2=CC(=CC=C2)Cl
DM27CQJ IK PLDMRMLBISIHNX-UHFFFAOYSA-N
DM27CQJ IU 2-[4-(3-chlorophenyl)but-1-ynyl]-6-methylpyridine
DM27CQJ DE Discovery agent
DMOYT8I ID DMOYT8I
DMOYT8I DN 2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DMOYT8I HS Investigative
DMOYT8I SN CHEMBL551839; 2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DMOYT8I DT Small molecular drug
DMOYT8I PC 45270433
DMOYT8I MW 284.3
DMOYT8I FM C15H12N2O2S
DMOYT8I IC InChI=1S/C15H12N2O2S/c18-11-7-5-10(6-8-11)13-9-20-15(17-13)16-12-3-1-2-4-14(12)19/h1-9,18-19H,(H,16,17)
DMOYT8I CS C1=CC=C(C(=C1)NC2=NC(=CS2)C3=CC=C(C=C3)O)O
DMOYT8I IK HXSHJTRADFDFMA-UHFFFAOYSA-N
DMOYT8I IU 2-[[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino]phenol
DMOYT8I DE Discovery agent
DMDAO5T ID DMDAO5T
DMDAO5T DN 2-(4-(benzenesulfonyl)phenyl)-1-aminoethane
DMDAO5T HS Investigative
DMDAO5T SN CHEMBL213589; 2-(4-(benzenesulfonyl)phenyl)-1-aminoethane; BDBM50193459
DMDAO5T DT Small molecular drug
DMDAO5T PC 44414681
DMDAO5T MW 261.339
DMDAO5T FM C14H15NO2S
DMDAO5T IC InChI=1S/C14H15NO2S/c15-11-10-12-6-8-14(9-7-12)18(16,17)13-4-2-1-3-5-13/h1-9H,10-11,15H2
DMDAO5T CS C1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)CCN
DMDAO5T IK YNFGKNGJUDQMQL-UHFFFAOYSA-N
DMDAO5T IU 2-[4-(benzenesulfonyl)phenyl]ethanamine
DMDAO5T DE Discovery agent
DMFNQZS ID DMFNQZS
DMFNQZS DN 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol
DMFNQZS HS Investigative
DMFNQZS SN 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol; 566169-93-5; UNII-K6396E6G8G; CHEMBL93124; K6396E6G8G; AK-87409; 2-[4'-(methylamino)phenyl]-6-hydroxybenzothiazole; Pittsburgh compound B unlabelled; 2-(4'-methylaminophenyl)-6-hydroxybenzothiazole; SCHEMBL912744; ZQAQXZBSGZUUNL-UHFFFAOYSA-N; MolPort-028-616-384; ZINC3816332; BDBM50129793; AKOS022184240; FC-3012; 4-methylamino-phenyl)-benzothiazol-6-ol; AJ-45711; PIB authentic (6-OH-BTA-1) free base; 2-(4-Methylamino-phenyl)-benzothiazol-6-ol
DMFNQZS DT Small molecular drug
DMFNQZS PC 10171487
DMFNQZS MW 256.32
DMFNQZS FM C14H12N2OS
DMFNQZS IC InChI=1S/C14H12N2OS/c1-15-10-4-2-9(3-5-10)14-16-12-7-6-11(17)8-13(12)18-14/h2-8,15,17H,1H3
DMFNQZS CS CNC1=CC=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O
DMFNQZS IK ZQAQXZBSGZUUNL-UHFFFAOYSA-N
DMFNQZS IU 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
DMFNQZS CA CAS 566169-93-5
DMFNQZS DE Discovery agent
DMVD6HE ID DMVD6HE
DMVD6HE DN 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline
DMVD6HE HS Investigative
DMVD6HE SN CHEMBL598330; 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline
DMVD6HE DT Small molecular drug
DMVD6HE PC 46232132
DMVD6HE MW 359.4
DMVD6HE FM C22H17NO2S
DMVD6HE IC InChI=1S/C22H17NO2S/c1-26(24,25)19-13-11-17(12-14-19)22-20(16-7-3-2-4-8-16)15-18-9-5-6-10-21(18)23-22/h2-15H,1H3
DMVD6HE CS CS(=O)(=O)C1=CC=C(C=C1)C2=NC3=CC=CC=C3C=C2C4=CC=CC=C4
DMVD6HE IK OPLJPOZQZWTQDV-UHFFFAOYSA-N
DMVD6HE IU 2-(4-methylsulfonylphenyl)-3-phenylquinoline
DMVD6HE DE Discovery agent
DM1TZNK ID DM1TZNK
DM1TZNK DN 2-(4-(methylsulfonyl)phenyl)pyridine
DM1TZNK HS Investigative
DM1TZNK SN 2-(4-(methylsulfonyl)phenyl)pyridine; CHEMBL1240924; 2-[4-(Methylsulfonyl)phenyl]pyridine; SCHEMBL8229590
DM1TZNK DT Small molecular drug
DM1TZNK PC 46937403
DM1TZNK MW 233.29
DM1TZNK FM C12H11NO2S
DM1TZNK IC InChI=1S/C12H11NO2S/c1-16(14,15)11-7-5-10(6-8-11)12-4-2-3-9-13-12/h2-9H,1H3
DM1TZNK CS CS(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=N2
DM1TZNK IK PCRZBBOIGHSIEX-UHFFFAOYSA-N
DM1TZNK IU 2-(4-methylsulfonylphenyl)pyridine
DM1TZNK DE Discovery agent
DM4X0SJ ID DM4X0SJ
DM4X0SJ DN 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline
DM4X0SJ HS Investigative
DM4X0SJ SN BU 224; 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline; CHEMBL13698; 2-(4,5-Dihydroimidaz-2-yl)-Quinoline; BU-224; NCGC00015130-01; Tocris-0725; Lopac-B-154; AC1L1DPZ; Lopac0_000167; SCHEMBL1526637; CHEBI:92967; CTK5J7405; ZINC2565858; BDBM50240365; CCG-204262; NCGC00024750-02; NCGC00015130-02; NCGC00024750-01; NCGC00015130-03; NCGC00015130-04; 2-(4,5-Dihydro-1H-imidazol-2-yl)-quinoline
DM4X0SJ DT Small molecular drug
DM4X0SJ PC 2457
DM4X0SJ MW 197.24
DM4X0SJ FM C12H11N3
DM4X0SJ IC InChI=1S/C12H11N3/c1-2-4-10-9(3-1)5-6-11(15-10)12-13-7-8-14-12/h1-6H,7-8H2,(H,13,14)
DM4X0SJ CS C1CN=C(N1)C2=NC3=CC=CC=C3C=C2
DM4X0SJ IK OSUVWJGCKQEMHK-UHFFFAOYSA-N
DM4X0SJ IU 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline
DM4X0SJ CA CAS 187173-05-3
DM4X0SJ CB CHEBI:92967
DM4X0SJ DE Discovery agent
DM4BFHR ID DM4BFHR
DM4BFHR DN 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile
DM4BFHR HS Investigative
DM4BFHR SN (4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile
DM4BFHR DT Small molecular drug
DM4BFHR PC 5328755
DM4BFHR MW 212.2
DM4BFHR FM C12H8N2O2
DM4BFHR IC InChI=1S/C12H8N2O2/c13-5-7(6-14)8-1-2-10-9(8)3-4-11(15)12(10)16/h3-4,15-16H,1-2H2
DM4BFHR CS C1CC(=C(C#N)C#N)C2=C1C(=C(C=C2)O)O
DM4BFHR IK QNMCUDUCYPYEQM-UHFFFAOYSA-N
DM4BFHR IU 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile
DM4BFHR DE Discovery agent
DM1UBGQ ID DM1UBGQ
DM1UBGQ DN 2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol
DM1UBGQ HS Investigative
DM1UBGQ SN CHEMBL258933
DM1UBGQ DT Small molecular drug
DM1UBGQ PC 44450157
DM1UBGQ MW 332.4
DM1UBGQ FM C18H24N2O4
DM1UBGQ IC InChI=1S/C18H24N2O4/c1-4-5-6-7-8-13-9-10-15(14(21)11-13)24-18-19-16(22-2)12-17(20-18)23-3/h9-12,21H,4-8H2,1-3H3
DM1UBGQ CS CCCCCCC1=CC(=C(C=C1)OC2=NC(=CC(=N2)OC)OC)O
DM1UBGQ IK YNAUOGCPBHCMDN-UHFFFAOYSA-N
DM1UBGQ IU 2-(4,6-dimethoxypyrimidin-2-yl)oxy-5-hexylphenol
DM1UBGQ DE Discovery agent
DMUANX1 ID DMUANX1
DMUANX1 DN 2-(4-amino-2-chlorophenoxy)-5-chlorophenol
DMUANX1 HS Investigative
DMUANX1 SN 2-(4-AMINO-2-CHLOROPHENOXY)-5-CHLOROPHENOL; CHEMBL383166; TN5; AC1OA9T5
DMUANX1 DT Small molecular drug
DMUANX1 PC 6852148
DMUANX1 MW 270.11
DMUANX1 FM C12H9Cl2NO2
DMUANX1 IC InChI=1S/C12H9Cl2NO2/c13-7-1-3-12(10(16)5-7)17-11-4-2-8(15)6-9(11)14/h1-6,16H,15H2
DMUANX1 CS C1=CC(=C(C=C1N)Cl)OC2=C(C=C(C=C2)Cl)O
DMUANX1 IK MCYCMAVHVQGDNE-UHFFFAOYSA-N
DMUANX1 IU 2-(4-amino-2-chlorophenoxy)-5-chlorophenol
DMUANX1 DE Discovery agent
DMSHPCW ID DMSHPCW
DMSHPCW DN 2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol
DMSHPCW HS Investigative
DMSHPCW SN CHEMBL350283; SCHEMBL6770087; ITEDDYPYHIHWHC-UHFFFAOYSA-N; BDBM50110507; 2-[2-Amino-5-(3-chlorophenyl)phenyl]-2-propanol; (4-amino-3'-chloro-biphenyl-3-yl)-dimethyl-methanol; 2-(4-Amino-3''-chloro-biphenyl-3-yl)-propan-2-ol
DMSHPCW DT Small molecular drug
DMSHPCW PC 15908132
DMSHPCW MW 261.74
DMSHPCW FM C15H16ClNO
DMSHPCW IC InChI=1S/C15H16ClNO/c1-15(2,18)13-9-11(6-7-14(13)17)10-4-3-5-12(16)8-10/h3-9,18H,17H2,1-2H3
DMSHPCW CS CC(C)(C1=C(C=CC(=C1)C2=CC(=CC=C2)Cl)N)O
DMSHPCW IK ITEDDYPYHIHWHC-UHFFFAOYSA-N
DMSHPCW IU 2-[2-amino-5-(3-chlorophenyl)phenyl]propan-2-ol
DMSHPCW DE Discovery agent
DMP0GI8 ID DMP0GI8
DMP0GI8 DN 2-(4-aminophenoxy)-5-hexylphenol
DMP0GI8 HS Investigative
DMP0GI8 SN CHEMBL264175
DMP0GI8 DT Small molecular drug
DMP0GI8 PC 44450091
DMP0GI8 MW 285.4
DMP0GI8 FM C18H23NO2
DMP0GI8 IC InChI=1S/C18H23NO2/c1-2-3-4-5-6-14-7-12-18(17(20)13-14)21-16-10-8-15(19)9-11-16/h7-13,20H,2-6,19H2,1H3
DMP0GI8 CS CCCCCCC1=CC(=C(C=C1)OC2=CC=C(C=C2)N)O
DMP0GI8 IK ZURCHSRLJXKILX-UHFFFAOYSA-N
DMP0GI8 IU 2-(4-aminophenoxy)-5-hexylphenol
DMP0GI8 DE Discovery agent
DMGQHBU ID DMGQHBU
DMGQHBU DN 2-(4-Amino-phenyl)-6-methyl-chromen-4-one
DMGQHBU HS Investigative
DMGQHBU SN CHEMBL132422; 468060-73-3; CTK1D1882; DTXSID00451376; ZINC13491190; AKOS022269882; KB-191927; 4h-1-benzopyran-4-one,2-(4-aminophenyl)-6-methyl-; 4H-1-Benzopyran-4-one, 2-(4-aminophenyl)-6-methyl-
DMGQHBU DT Small molecular drug
DMGQHBU PC 10999496
DMGQHBU MW 251.28
DMGQHBU FM C16H13NO2
DMGQHBU IC InChI=1S/C16H13NO2/c1-10-2-7-15-13(8-10)14(18)9-16(19-15)11-3-5-12(17)6-4-11/h2-9H,17H2,1H3
DMGQHBU CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=C(C=C3)N
DMGQHBU IK BCMMIAHCWHQZDZ-UHFFFAOYSA-N
DMGQHBU IU 2-(4-aminophenyl)-6-methylchromen-4-one
DMGQHBU CA CAS 468060-73-3
DMGQHBU DE Discovery agent
DM7LBEG ID DM7LBEG
DM7LBEG DN 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one
DM7LBEG HS Investigative
DM7LBEG DT Small molecular drug
DM7LBEG PC 135471356
DM7LBEG MW 253.26
DM7LBEG FM C14H11N3O2
DM7LBEG IC InChI=1S/C14H11N3O2/c15-9-6-4-8(5-7-9)13-16-12-10(14(19)17-13)2-1-3-11(12)18/h1-7,18H,15H2,(H,16,17,19)
DM7LBEG CS C1=CC2=C(C(=C1)O)N=C(NC2=O)C3=CC=C(C=C3)N
DM7LBEG IK FNYTYXJFOSRUTI-UHFFFAOYSA-N
DM7LBEG IU 2-(4-aminophenyl)-8-hydroxy-3H-quinazolin-4-one
DM7LBEG DE Discovery agent
DMJRDAQ ID DMJRDAQ
DMJRDAQ DN 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one
DMJRDAQ HS Investigative
DMJRDAQ DT Small molecular drug
DMJRDAQ PC 135463623
DMJRDAQ MW 251.28
DMJRDAQ FM C15H13N3O
DMJRDAQ IC InChI=1S/C15H13N3O/c1-9-3-2-4-12-13(9)17-14(18-15(12)19)10-5-7-11(16)8-6-10/h2-8H,16H2,1H3,(H,17,18,19)
DMJRDAQ CS CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)N
DMJRDAQ IK RFMIZKCQNUDSTO-UHFFFAOYSA-N
DMJRDAQ IU 2-(4-aminophenyl)-8-methyl-3H-quinazolin-4-one
DMJRDAQ DE Discovery agent
DM2P9L5 ID DM2P9L5
DM2P9L5 DN 2-(4-Amino-phenyl)-benzo[h]chromen-4-one
DM2P9L5 HS Investigative
DM2P9L5 SN CHEMBL179276; 2-(4-Amino-phenyl)-benzo[h]chromen-4-one; BDBM50159660
DM2P9L5 DT Small molecular drug
DM2P9L5 PC 11471732
DM2P9L5 MW 287.3
DM2P9L5 FM C19H13NO2
DM2P9L5 IC InChI=1S/C19H13NO2/c20-14-8-5-13(6-9-14)18-11-17(21)16-10-7-12-3-1-2-4-15(12)19(16)22-18/h1-11H,20H2
DM2P9L5 CS C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CC=C(C=C4)N
DM2P9L5 IK JXHKSKYNJHBJDZ-UHFFFAOYSA-N
DM2P9L5 IU 2-(4-aminophenyl)benzo[h]chromen-4-one
DM2P9L5 DE Discovery agent
DMMU2BZ ID DMMU2BZ
DMMU2BZ DN 2-(4-aminophenylsulfonamido)acetic acid
DMMU2BZ HS Investigative
DMMU2BZ SN 5616-30-8; (4-Amino-benzenesulfonylamino)-acetic acid; 2-(4-aminophenylsulfonamido)acetic acid; 2-[(4-aminophenyl)sulfonylamino]acetic acid; CHEMBL285053; (4-aminophenylsulfonylamino)acetic acid; Glycine, N-[(4-aminophenyl)sulfonyl]-; 2-(4-aminobenzenesulfonylamino)ethanoic acid; Sulfanilamidoacetic acid; 2-(4-aminophenylsulfonamido)aceticacid; AC1L92ZE; SCHEMBL1228868; N-4-aminobenzenesulfonyl glycine; CTK1F5176; DTXSID30328582; ((4-aminophenyl)sulfonyl)glycine; BPJUMYMTQYMSFZ-UHFFFAOYSA-N; ZINC1670307
DMMU2BZ DT Small molecular drug
DMMU2BZ PC 412201
DMMU2BZ MW 230.24
DMMU2BZ FM C8H10N2O4S
DMMU2BZ IC InChI=1S/C8H10N2O4S/c9-6-1-3-7(4-2-6)15(13,14)10-5-8(11)12/h1-4,10H,5,9H2,(H,11,12)
DMMU2BZ CS C1=CC(=CC=C1N)S(=O)(=O)NCC(=O)O
DMMU2BZ IK BPJUMYMTQYMSFZ-UHFFFAOYSA-N
DMMU2BZ IU 2-[(4-aminophenyl)sulfonylamino]acetic acid
DMMU2BZ CA CAS 5616-30-8
DMMU2BZ DE Discovery agent
DM2JG49 ID DM2JG49
DM2JG49 DN 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one
DM2JG49 HS Investigative
DM2JG49 DT Small molecular drug
DM2JG49 PC 135547083
DM2JG49 MW 293.28
DM2JG49 FM C15H11N5O2
DM2JG49 IC InChI=1S/C15H11N5O2/c1-22-12-4-2-3-11-13(12)17-14(18-15(11)21)9-5-7-10(8-6-9)19-20-16/h2-8H,1H3,(H,17,18,21)
DM2JG49 CS COC1=CC=CC2=C1N=C(NC2=O)C3=CC=C(C=C3)N=[N+]=[N-]
DM2JG49 IK BLVUCZJFMHXSJA-UHFFFAOYSA-N
DM2JG49 IU 2-(4-azidophenyl)-8-methoxy-3H-quinazolin-4-one
DM2JG49 DE Discovery agent
DMJA5Y4 ID DMJA5Y4
DMJA5Y4 DN 2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide
DMJA5Y4 HS Investigative
DMJA5Y4 SN CHEMBL568131; 2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide
DMJA5Y4 DT Small molecular drug
DMJA5Y4 PC 45487374
DMJA5Y4 MW 316.4
DMJA5Y4 FM C15H16N4O2S
DMJA5Y4 IC InChI=1S/C15H16N4O2S/c16-13(20)12-10-17-15(22-12)19-8-6-18(7-9-19)14(21)11-4-2-1-3-5-11/h1-5,10H,6-9H2,(H2,16,20)
DMJA5Y4 CS C1CN(CCN1C2=NC=C(S2)C(=O)N)C(=O)C3=CC=CC=C3
DMJA5Y4 IK NYHCFTYRFCRXPO-UHFFFAOYSA-N
DMJA5Y4 IU 2-(4-benzoylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
DMJA5Y4 DE Discovery agent
DMGMZV9 ID DMGMZV9
DMGMZV9 DN 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid
DMGMZV9 HS Investigative
DMGMZV9 SN CHEMBL571233; 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid; ASN 06584077; AC1LSF7A; HMS1695L15; ZINC1336805; BDBM50296427; AKOS000753095; SR-01000350200; 2-(4-Benzoyl-piperidine-1-carbonyl)-benzoic acid
DMGMZV9 DT Small molecular drug
DMGMZV9 PC 1438175
DMGMZV9 MW 337.4
DMGMZV9 FM C20H19NO4
DMGMZV9 IC InChI=1S/C20H19NO4/c22-18(14-6-2-1-3-7-14)15-10-12-21(13-11-15)19(23)16-8-4-5-9-17(16)20(24)25/h1-9,15H,10-13H2,(H,24,25)
DMGMZV9 CS C1CN(CCC1C(=O)C2=CC=CC=C2)C(=O)C3=CC=CC=C3C(=O)O
DMGMZV9 IK JLSQZICREOKKAN-UHFFFAOYSA-N
DMGMZV9 IU 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid
DMGMZV9 DE Discovery agent
DM6R4MG ID DM6R4MG
DM6R4MG DN 2-(4-benzylphenoxy)ethanamine
DM6R4MG HS Investigative
DM6R4MG SN 2-(4-benzylphenoxy)ethanamine; CHEMBL163807; 2-(4-benzylphenoxy)ethylamine; SCHEMBL7138354; MJTXDDKAEQAMNA-UHFFFAOYSA-N; 2-(4-Benzyl-phenoxy)-ethylamine; BDBM50085290
DM6R4MG DT Small molecular drug
DM6R4MG PC 10609349
DM6R4MG MW 227.3
DM6R4MG FM C15H17NO
DM6R4MG IC InChI=1S/C15H17NO/c16-10-11-17-15-8-6-14(7-9-15)12-13-4-2-1-3-5-13/h1-9H,10-12,16H2
DM6R4MG CS C1=CC=C(C=C1)CC2=CC=C(C=C2)OCCN
DM6R4MG IK MJTXDDKAEQAMNA-UHFFFAOYSA-N
DM6R4MG IU 2-(4-benzylphenoxy)ethanamine
DM6R4MG DE Discovery agent
DM1V7EF ID DM1V7EF
DM1V7EF DN 2-(4-Benzyl-piperazin-1-yl)-benzothiazole
DM1V7EF HS Investigative
DM1V7EF SN 2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; 2-(4-Benzyl-piperazin-1-yl)-benzothiazole; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191
DM1V7EF DT Small molecular drug
DM1V7EF PC 1484933
DM1V7EF MW 309.4
DM1V7EF FM C18H19N3S
DM1V7EF IC InChI=1S/C18H19N3S/c1-2-6-15(7-3-1)14-20-10-12-21(13-11-20)18-19-16-8-4-5-9-17(16)22-18/h1-9H,10-14H2
DM1V7EF CS C1CN(CCN1CC2=CC=CC=C2)C3=NC4=CC=CC=C4S3
DM1V7EF IK SNRZSONRAFJJSB-UHFFFAOYSA-N
DM1V7EF IU 2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole
DM1V7EF CA CAS 35463-75-3
DM1V7EF DE Discovery agent
DMFGCS1 ID DMFGCS1
DMFGCS1 DN 2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol
DMFGCS1 HS Investigative
DMFGCS1 SN CHEMBL220775; 2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol
DMFGCS1 DT Small molecular drug
DMFGCS1 PC 16110268
DMFGCS1 MW 320.4
DMFGCS1 FM C21H24N2O
DMFGCS1 IC InChI=1S/C21H24N2O/c24-20-7-6-18-13-19(22-21(18)14-20)15-23-10-8-17(9-11-23)12-16-4-2-1-3-5-16/h1-7,13-14,17,22,24H,8-12,15H2
DMFGCS1 CS C1CN(CCC1CC2=CC=CC=C2)CC3=CC4=C(N3)C=C(C=C4)O
DMFGCS1 IK XCBFDMFJYYJHAL-UHFFFAOYSA-N
DMFGCS1 IU 2-[(4-benzylpiperidin-1-yl)methyl]-1H-indol-6-ol
DMFGCS1 CA CAS 933474-38-5
DMFGCS1 DE Discovery agent
DMID9YA ID DMID9YA
DMID9YA DN 2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMID9YA HS Investigative
DMID9YA SN CHEMBL179397; 2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMID9YA DT Small molecular drug
DMID9YA PC 11245709
DMID9YA MW 335.4
DMID9YA FM C22H25NO2
DMID9YA IC InChI=1S/C22H25NO2/c24-21-15-19(25-22-9-5-4-8-20(21)22)16-23-12-10-18(11-13-23)14-17-6-2-1-3-7-17/h1-9,18-19H,10-16H2
DMID9YA CS C1CN(CCC1CC2=CC=CC=C2)CC3CC(=O)C4=CC=CC=C4O3
DMID9YA IK SVALPNADURCFPN-UHFFFAOYSA-N
DMID9YA IU 2-[(4-benzylpiperidin-1-yl)methyl]-2,3-dihydrochromen-4-one
DMID9YA DE Discovery agent
DM7QK5C ID DM7QK5C
DM7QK5C DN 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid
DM7QK5C HS Investigative
DM7QK5C SN CHEMBL214655; 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid; 2-[4-bromo-2-(hydroxymethyl)phenoxy]acetic acid; AC1LHWL0; AH-487/41804565; SCHEMBL3201339; MolPort-002-091-532; ZINC470785; HMS1590C02; BDBM50200250; MCULE-6729250214; SR-01000266540
DM7QK5C DT Small molecular drug
DM7QK5C PC 894151
DM7QK5C MW 261.07
DM7QK5C FM C9H9BrO4
DM7QK5C IC InChI=1S/C9H9BrO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-3,11H,4-5H2,(H,12,13)
DM7QK5C CS C1=CC(=C(C=C1Br)CO)OCC(=O)O
DM7QK5C IK QMNTWAAGYOSTJK-UHFFFAOYSA-N
DM7QK5C IU 2-[4-bromo-2-(hydroxymethyl)phenoxy]acetic acid
DM7QK5C DE Discovery agent
DM6I1NQ ID DM6I1NQ
DM6I1NQ DN 2-(4-bromo-2-cyclohexylphenoxy)acetic acid
DM6I1NQ HS Investigative
DM6I1NQ SN CHEMBL246311; (4-bromo-2-cyclohexylphenoxy)acetic acid; 2-(4-bromo-2-cyclohexylphenoxy)acetic acid; SCHEMBL4882946; BDBM50213922
DM6I1NQ DT Small molecular drug
DM6I1NQ PC 11500603
DM6I1NQ MW 313.19
DM6I1NQ FM C14H17BrO3
DM6I1NQ IC InChI=1S/C14H17BrO3/c15-11-6-7-13(18-9-14(16)17)12(8-11)10-4-2-1-3-5-10/h6-8,10H,1-5,9H2,(H,16,17)
DM6I1NQ CS C1CCC(CC1)C2=C(C=CC(=C2)Br)OCC(=O)O
DM6I1NQ IK ZWQTTYNQLIMKNE-UHFFFAOYSA-N
DM6I1NQ IU 2-(4-bromo-2-cyclohexylphenoxy)acetic acid
DM6I1NQ DE Discovery agent
DMQVUZP ID DMQVUZP
DMQVUZP DN 2-(4-bromo-2-formylphenoxy)acetic acid
DMQVUZP HS Investigative
DMQVUZP SN 2-(4-bromo-2-formylphenoxy)acetic acid; 24589-89-7; (4-bromo-2-formylphenoxy)acetic acid; CHEMBL385009; AC1LJ5IQ; bromoformylphenoxyaceticacid; Oprea1_723931; AC1Q764A; SCHEMBL2879909; KS-00000LHU; CTK1A1564; DTXSID80359528; MolPort-000-886-040; KXRYNWDCFUKVNN-UHFFFAOYSA-N; ZINC586295; SP656; 4-bromo-2-formylphenoxyacetic acid; ALBB-007850; 4-bromo-2-formylphenoxy acetic acid; 2-formyl-4-bromophenoxy acetic acid; STK201324; SBB020100; BDBM50200251; BBL023190; 8265AD; AKOS000113320; MCULE-3263948503; AC-0818; RP14657; ACN-052850
DMQVUZP DT Small molecular drug
DMQVUZP PC 968879
DMQVUZP MW 259.05
DMQVUZP FM C9H7BrO4
DMQVUZP IC InChI=1S/C9H7BrO4/c10-7-1-2-8(6(3-7)4-11)14-5-9(12)13/h1-4H,5H2,(H,12,13)
DMQVUZP CS C1=CC(=C(C=C1Br)C=O)OCC(=O)O
DMQVUZP IK KXRYNWDCFUKVNN-UHFFFAOYSA-N
DMQVUZP IU 2-(4-bromo-2-formylphenoxy)acetic acid
DMQVUZP CA CAS 24589-89-7
DMQVUZP DE Discovery agent
DM79JVK ID DM79JVK
DM79JVK DN 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine
DM79JVK HS Investigative
DM79JVK SN CHEMBL60146; 99632-51-6; 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine; Benzeneethanamine, 4-bromo-2-methoxy-alpha-methyl-; BDBM50005262; AKOS023456739
DM79JVK DT Small molecular drug
DM79JVK PC 13547422
DM79JVK MW 244.13
DM79JVK FM C10H14BrNO
DM79JVK IC InChI=1S/C10H14BrNO/c1-7(12)5-8-3-4-9(11)6-10(8)13-2/h3-4,6-7H,5,12H2,1-2H3
DM79JVK CS CC(CC1=C(C=C(C=C1)Br)OC)N
DM79JVK IK YWONMRKCBJPFCM-UHFFFAOYSA-N
DM79JVK IU 1-(4-bromo-2-methoxyphenyl)propan-2-amine
DM79JVK DE Discovery agent
DMXAQZ0 ID DMXAQZ0
DMXAQZ0 DN 2-(4-bromo-2-tert-butylphenoxy)acetic acid
DMXAQZ0 HS Investigative
DMXAQZ0 SN 2-[4-BROMO-2-(TERT-BUTYL)PHENOXY]ACETIC ACID; 425372-86-7; 2-(4-bromo-2-tert-butylphenoxy)acetic acid; (4-bromo-2-tert-butylphenoxy)acetic acid; CHEMBL386348; 2-(4-bromo-2-(tert-butyl)phenoxy)acetic acid; 2-[2-(tert-butyl)-4-bromophenoxy]acetic acid; CBMicro_046462; AC1LEXUE; Oprea1_645612; Oprea1_576852; ARONIS011292; SCHEMBL12478128; CTK7J5471; BBB/316; MolPort-000-651-933; GCBNGPDJYUPSBS-UHFFFAOYSA-N; ZINC120478; KS-000042GS; ZX-AS003555; ZX-AL002245; SBB043460; STK948100; BDBM50200269; 3158AE; AKOS000273807; MCULE-9342897788
DMXAQZ0 DT Small molecular drug
DMXAQZ0 PC 719761
DMXAQZ0 MW 287.15
DMXAQZ0 FM C12H15BrO3
DMXAQZ0 IC InChI=1S/C12H15BrO3/c1-12(2,3)9-6-8(13)4-5-10(9)16-7-11(14)15/h4-6H,7H2,1-3H3,(H,14,15)
DMXAQZ0 CS CC(C)(C)C1=C(C=CC(=C1)Br)OCC(=O)O
DMXAQZ0 IK GCBNGPDJYUPSBS-UHFFFAOYSA-N
DMXAQZ0 IU 2-(4-bromo-2-tert-butylphenoxy)acetic acid
DMXAQZ0 DE Discovery agent
DMY8GZP ID DMY8GZP
DMY8GZP DN 2-(4-Bromo-3-phenoxy-benzoylamino)-benzoic acid
DMY8GZP HS Investigative
DMY8GZP SN CHEMBL178585; BDBM23581; 2-(4-bromo-3-phenoxybenzoylamino)benzoic acid; 2-[(4-bromo-3-phenoxybenzene)amido]benzoic acid; (3-Phenoxybenzoylamino)benzoic acid deriv., 23b
DMY8GZP DT Small molecular drug
DMY8GZP PC 11441298
DMY8GZP MW 412.2
DMY8GZP FM C20H14BrNO4
DMY8GZP IC InChI=1S/C20H14BrNO4/c21-16-11-10-13(12-18(16)26-14-6-2-1-3-7-14)19(23)22-17-9-5-4-8-15(17)20(24)25/h1-12H,(H,22,23)(H,24,25)
DMY8GZP CS C1=CC=C(C=C1)OC2=C(C=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O)Br
DMY8GZP IK XOENRMSDPFHAEO-UHFFFAOYSA-N
DMY8GZP IU 2-[(4-bromo-3-phenoxybenzoyl)amino]benzoic acid
DMY8GZP DE Discovery agent
DMB49UP ID DMB49UP
DMB49UP DN 2-(4-Bromo-phenyl)-1-methyl-ethylamine
DMB49UP HS Investigative
DMB49UP SN 1-(4-bromophenyl)propan-2-amine; 13235-83-1; 4-bromoamphetamine; Para-Bromoamphetamine; BRN 3240553; Benzeneethanamine, 4-bromo-alpha-methyl-, (+-)-; 2-(4-Bromo-phenyl)-1-methyl-ethylamine; CHEMBL61355; (+-)-4-Bromo-alpha-methylbenzeneethanamine; 18455-37-3; 1-(4-Bromobenzyl)ethylamine; 4-Ba; AC1L4F4G; 3-12-00-02675 (Beilstein Handbook Reference); SCHEMBL164716; CTK0I1684; SMNXUMMCCOZPPN-UHFFFAOYSA-N; 1-(4-bromophenyl)propane-2-amine; BDBM50005252; AKOS022180693; AKOS000160383; 1-Methyl-2-(4-bromophenyl)ethanamine
DMB49UP DT Small molecular drug
DMB49UP PC 205668
DMB49UP MW 214.1
DMB49UP FM C9H12BrN
DMB49UP IC InChI=1S/C9H12BrN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3
DMB49UP CS CC(CC1=CC=C(C=C1)Br)N
DMB49UP IK SMNXUMMCCOZPPN-UHFFFAOYSA-N
DMB49UP IU 1-(4-bromophenyl)propan-2-amine
DMB49UP CA CAS 13235-83-1
DMB49UP DE Discovery agent
DMY5STK ID DMY5STK
DMY5STK DN 2-(4-bromophenylsulfonamido)-N-hydroxyacetamide
DMY5STK HS Investigative
DMY5STK SN 2-(4-bromophenylsulfonamido)-N-hydroxyacetamide; CHEMBL1090283; 1218922-39-4; SCHEMBL7413923
DMY5STK DT Small molecular drug
DMY5STK PC 22004198
DMY5STK MW 309.14
DMY5STK FM C8H9BrN2O4S
DMY5STK IC InChI=1S/C8H9BrN2O4S/c9-6-1-3-7(4-2-6)16(14,15)10-5-8(12)11-13/h1-4,10,13H,5H2,(H,11,12)
DMY5STK CS C1=CC(=CC=C1S(=O)(=O)NCC(=O)NO)Br
DMY5STK IK AKOBMMAQXVKOJR-UHFFFAOYSA-N
DMY5STK IU 2-[(4-bromophenyl)sulfonylamino]-N-hydroxyacetamide
DMY5STK DE Discovery agent
DMG32HQ ID DMG32HQ
DMG32HQ DN 2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide
DMG32HQ HS Investigative
DMG32HQ SN CHEMBL175410; 2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide; Acetamide, 2-(4-butoxyphenoxy)-N-hydroxy-; BDBM50015105
DMG32HQ DT Small molecular drug
DMG32HQ PC 44387190
DMG32HQ MW 239.27
DMG32HQ FM C12H17NO4
DMG32HQ IC InChI=1S/C12H17NO4/c1-2-3-8-16-10-4-6-11(7-5-10)17-9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
DMG32HQ CS CCCCOC1=CC=C(C=C1)OCC(=O)NO
DMG32HQ IK UJAGRYRJVJSNJC-UHFFFAOYSA-N
DMG32HQ IU 2-(4-butoxyphenoxy)-N-hydroxyacetamide
DMG32HQ DE Discovery agent
DMEKNZW ID DMEKNZW
DMEKNZW DN 2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide
DMEKNZW HS Investigative
DMEKNZW SN CHEMBL178065; 2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide
DMEKNZW DT Small molecular drug
DMEKNZW PC 44386556
DMEKNZW MW 253.29
DMEKNZW FM C13H19NO4
DMEKNZW IC InChI=1S/C13H19NO4/c1-3-4-9-17-11-5-7-12(8-6-11)18-10-13(15)14(2)16/h5-8,16H,3-4,9-10H2,1-2H3
DMEKNZW CS CCCCOC1=CC=C(C=C1)OCC(=O)N(C)O
DMEKNZW IK QJXRKNPTYVKBQZ-UHFFFAOYSA-N
DMEKNZW IU 2-(4-butoxyphenoxy)-N-hydroxy-N-methylacetamide
DMEKNZW DE Discovery agent
DMO5IM0 ID DMO5IM0
DMO5IM0 DN 2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide
DMO5IM0 HS Investigative
DMO5IM0 SN CHEMBL177422; 2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide
DMO5IM0 DT Small molecular drug
DMO5IM0 PC 44386557
DMO5IM0 MW 253.29
DMO5IM0 FM C13H19NO4
DMO5IM0 IC InChI=1S/C13H19NO4/c1-3-4-9-17-11-5-7-12(8-6-11)18-10(2)13(15)14-16/h5-8,10,16H,3-4,9H2,1-2H3,(H,14,15)
DMO5IM0 CS CCCCOC1=CC=C(C=C1)OC(C)C(=O)NO
DMO5IM0 IK PBEZWGMLOHXFDA-UHFFFAOYSA-N
DMO5IM0 IU 2-(4-butoxyphenoxy)-N-hydroxypropanamide
DMO5IM0 DE Discovery agent
DMP7CF8 ID DMP7CF8
DMP7CF8 DN 2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide
DMP7CF8 HS Investigative
DMP7CF8 SN CHEMBL368604; 2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide; KUC110092N; ZINC28096255; BDBM50015186; KSC-229-6-1
DMP7CF8 DT Small molecular drug
DMP7CF8 PC 44386193
DMP7CF8 MW 237.29
DMP7CF8 FM C13H19NO3
DMP7CF8 IC InChI=1S/C13H19NO3/c1-3-4-9-17-12-7-5-11(6-8-12)10-13(15)14(2)16/h5-8,16H,3-4,9-10H2,1-2H3
DMP7CF8 CS CCCCOC1=CC=C(C=C1)CC(=O)N(C)O
DMP7CF8 IK JGCLGKCTJPLHOR-UHFFFAOYSA-N
DMP7CF8 IU 2-(4-butoxyphenyl)-N-hydroxy-N-methylacetamide
DMP7CF8 DE Discovery agent
DM2XFGJ ID DM2XFGJ
DM2XFGJ DN 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
DM2XFGJ HS Investigative
DM2XFGJ SN 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE; DB08192; 5-isopropyl-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]-1,3-thiazole-4-carboxylic acid; 5-(1-methylethyl)-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]-1,3-thiazole-4-carboxylic acid
DM2XFGJ DT Small molecular drug
DM2XFGJ PC 46937131
DM2XFGJ MW 302.4
DM2XFGJ FM C16H18N2O2S
DM2XFGJ IC InChI=1S/C16H18N2O2S/c1-9(2)14-13(16(19)20)18-15(21-14)12-7-10-5-3-4-6-11(10)8-17-12/h3-6,9,12,17H,7-8H2,1-2H3,(H,19,20)/t12-/m0/s1
DM2XFGJ CS CC(C)C1=C(N=C(S1)[C@@H]2CC3=CC=CC=C3CN2)C(=O)O
DM2XFGJ IK HCUGCUQZFBURHR-LBPRGKRZSA-N
DM2XFGJ IU 5-propan-2-yl-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]-1,3-thiazole-4-carboxylic acid
DM2XFGJ DE Discovery agent
DM7BHYS ID DM7BHYS
DM7BHYS DN 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM7BHYS HS Investigative
DM7BHYS SN CHEMBL426297; 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM7BHYS DT Small molecular drug
DM7BHYS PC 11500124
DM7BHYS MW 280.71
DM7BHYS FM C15H9ClN4
DM7BHYS IC InChI=1S/C15H9ClN4/c16-9-4-3-7-12-14(9)20-15(19-12)13-8-17-10-5-1-2-6-11(10)18-13/h1-8H,(H,19,20)
DM7BHYS CS C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=CC=C4Cl
DM7BHYS IK KBVMQLRZERGALQ-UHFFFAOYSA-N
DM7BHYS IU 2-(4-chloro-1H-benzimidazol-2-yl)quinoxaline
DM7BHYS DE Discovery agent
DM15YM7 ID DM15YM7
DM15YM7 DN 2-(4-chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7 HS Investigative
DM15YM7 SN CHEMBL398126; 2-(4-chloro-2-cycloheptylphenoxy)acetic acid; SCHEMBL4875122; JEPDINCGXLHLDF-UHFFFAOYSA-N; BDBM50213919; (4-Chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7 DT Small molecular drug
DM15YM7 PC 11514705
DM15YM7 MW 282.76
DM15YM7 FM C15H19ClO3
DM15YM7 IC InChI=1S/C15H19ClO3/c16-12-7-8-14(19-10-15(17)18)13(9-12)11-5-3-1-2-4-6-11/h7-9,11H,1-6,10H2,(H,17,18)
DM15YM7 CS C1CCCC(CC1)C2=C(C=CC(=C2)Cl)OCC(=O)O
DM15YM7 IK JEPDINCGXLHLDF-UHFFFAOYSA-N
DM15YM7 IU 2-(4-chloro-2-cycloheptylphenoxy)acetic acid
DM15YM7 DE Discovery agent
DMGYZ8D ID DMGYZ8D
DMGYZ8D DN 2-(4-chloro-2-cyclohexylphenoxy)acetic acid
DMGYZ8D HS Investigative
DMGYZ8D SN 2-(4-chloro-2-cyclohexylphenoxy)acetic acid; (4-chloro-2-cyclohexylphenoxy)acetic acid; 19774-97-1; MLS002639096; CHEMBL245908; NSC26127; AC1L5KDG; AC1Q3LV0; SCHEMBL4888054; CTK7J5481; DTXSID10282496; MolPort-004-296-406; HMS3089F12; ZINC1628222; AC1Q7647; BDBM50213909; NSC-26127; AKOS000132678; NE44164; MCULE-7136939287; AS-9826; 4-chloro-2-cyclohexylphenoxy-acetic acid; SMR001548547
DMGYZ8D DT Small molecular drug
DMGYZ8D PC 230826
DMGYZ8D MW 268.73
DMGYZ8D FM C14H17ClO3
DMGYZ8D IC InChI=1S/C14H17ClO3/c15-11-6-7-13(18-9-14(16)17)12(8-11)10-4-2-1-3-5-10/h6-8,10H,1-5,9H2,(H,16,17)
DMGYZ8D CS C1CCC(CC1)C2=C(C=CC(=C2)Cl)OCC(=O)O
DMGYZ8D IK OGVODSDQXYUSDP-UHFFFAOYSA-N
DMGYZ8D IU 2-(4-chloro-2-cyclohexylphenoxy)acetic acid
DMGYZ8D CA CAS 19774-97-1
DMGYZ8D DE Discovery agent
DMA6KQU ID DMA6KQU
DMA6KQU DN 2-(4-chloro-2-cyclopentylphenoxy)acetic acid
DMA6KQU HS Investigative
DMA6KQU SN CHEMBL397842; 2-(4-chloro-2-cyclopentylphenoxy)acetic acid; SCHEMBL4879219
DMA6KQU DT Small molecular drug
DMA6KQU PC 44441193
DMA6KQU MW 254.71
DMA6KQU FM C13H15ClO3
DMA6KQU IC InChI=1S/C13H15ClO3/c14-10-5-6-12(17-8-13(15)16)11(7-10)9-3-1-2-4-9/h5-7,9H,1-4,8H2,(H,15,16)
DMA6KQU CS C1CCC(C1)C2=C(C=CC(=C2)Cl)OCC(=O)O
DMA6KQU IK GOFMJZFPLZWDOU-UHFFFAOYSA-N
DMA6KQU IU 2-(4-chloro-2-cyclopentylphenoxy)acetic acid
DMA6KQU DE Discovery agent
DMBHFIM ID DMBHFIM
DMBHFIM DN 2-(4-chloro-2-hydroxyphenoxy)benzenaminium
DMBHFIM HS Investigative
DMBHFIM SN 2-(2-aminophenoxy)-5-chlorophenol; CHEMBL206178; 832734-14-2; 2-(4-chloro-2-hydroxyphenoxy)benzenaminium; CTK3D3158; DTXSID60658783; BDBM50182380; Phenol, 2-(2-aminophenoxy)-5-chloro-
DMBHFIM DT Small molecular drug
DMBHFIM PC 44410251
DMBHFIM MW 235.66
DMBHFIM FM C12H10ClNO2
DMBHFIM IC InChI=1S/C12H10ClNO2/c13-8-5-6-12(10(15)7-8)16-11-4-2-1-3-9(11)14/h1-7,15H,14H2
DMBHFIM CS C1=CC=C(C(=C1)N)OC2=C(C=C(C=C2)Cl)O
DMBHFIM IK HJXYQHRZHJFAGC-UHFFFAOYSA-N
DMBHFIM IU 2-(2-aminophenoxy)-5-chlorophenol
DMBHFIM CA CAS 832734-14-2
DMBHFIM DE Discovery agent
DMOH2YC ID DMOH2YC
DMOH2YC DN 2-(4-Chlorobenzylidene)cyclopentanone
DMOH2YC HS Investigative
DMOH2YC SN CHEMBL562352; 2-(4-Chlorobenzylidene)cyclopentanone; E-2-(4-chlorobenzylidene)cyclopentanone; BDBM50293435; AKOS027461656; 134791-44-9; (E)-2-(4-Chlorobenzylidene)cyclopentanone
DMOH2YC DT Small molecular drug
DMOH2YC PC 11009103
DMOH2YC MW 206.67
DMOH2YC FM C12H11ClO
DMOH2YC IC InChI=1S/C12H11ClO/c13-11-6-4-9(5-7-11)8-10-2-1-3-12(10)14/h4-8H,1-3H2/b10-8+
DMOH2YC CS C1C/C(=C\\C2=CC=C(C=C2)Cl)/C(=O)C1
DMOH2YC IK WUMOJUUCPXEEQL-CSKARUKUSA-N
DMOH2YC IU (2E)-2-[(4-chlorophenyl)methylidene]cyclopentan-1-one
DMOH2YC DE Discovery agent
DMFE93N ID DMFE93N
DMFE93N DN 2-(4-chlorobenzylidene)cyclopentyl ethyl ether
DMFE93N HS Investigative
DMFE93N SN CHEMBL538612; 2-(4-chlorobenzylidene)cyclopentyl ethyl ether
DMFE93N DT Small molecular drug
DMFE93N PC 44126813
DMFE93N MW 236.73
DMFE93N FM C14H17ClO
DMFE93N IC InChI=1S/C14H17ClO/c1-2-16-14-5-3-4-12(14)10-11-6-8-13(15)9-7-11/h6-10,14H,2-5H2,1H3/b12-10+
DMFE93N CS CCOC\\1CCC/C1=C\\C2=CC=C(C=C2)Cl
DMFE93N IK VORGMCXCJIDOMV-ZRDIBKRKSA-N
DMFE93N IU 1-chloro-4-[(E)-(2-ethoxycyclopentylidene)methyl]benzene
DMFE93N DE Discovery agent
DMTW9B7 ID DMTW9B7
DMTW9B7 DN 2-(4-chlorobenzylidene)cyclopentylmethyl ether
DMTW9B7 HS Investigative
DMTW9B7 SN CHEMBL540746; 2-(4-chlorobenzylidene)cyclopentylmethyl ether
DMTW9B7 DT Small molecular drug
DMTW9B7 PC 44126812
DMTW9B7 MW 222.71
DMTW9B7 FM C13H15ClO
DMTW9B7 IC InChI=1S/C13H15ClO/c1-15-13-4-2-3-11(13)9-10-5-7-12(14)8-6-10/h5-9,13H,2-4H2,1H3/b11-9+
DMTW9B7 CS COC\\1CCC/C1=C\\C2=CC=C(C=C2)Cl
DMTW9B7 IK HTHFNFRVDYWDQC-PKNBQFBNSA-N
DMTW9B7 IU 1-chloro-4-[(E)-(2-methoxycyclopentylidene)methyl]benzene
DMTW9B7 DE Discovery agent
DM1JKWL ID DM1JKWL
DM1JKWL DN 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL HS Investigative
DM1JKWL SN CHEMBL227566; 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide
DM1JKWL DT Small molecular drug
DM1JKWL PC 44423684
DM1JKWL MW 230.65
DM1JKWL FM C9H11ClN2O3
DM1JKWL IC InChI=1S/C9H11ClN2O3/c10-8-3-1-7(2-4-8)6-15-11-5-9(13)12-14/h1-4,11,14H,5-6H2,(H,12,13)
DM1JKWL CS C1=CC(=CC=C1CONCC(=O)NO)Cl
DM1JKWL IK DSHAKCWOEUEDGY-UHFFFAOYSA-N
DM1JKWL IU 2-[(4-chlorophenyl)methoxyamino]-N-hydroxyacetamide
DM1JKWL DE Discovery agent
DMFGQ7K ID DMFGQ7K
DMFGQ7K DN 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K HS Investigative
DMFGQ7K SN CHEMBL388309; 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide
DMFGQ7K DT Small molecular drug
DMFGQ7K PC 44423687
DMFGQ7K MW 286.75
DMFGQ7K FM C13H19ClN2O3
DMFGQ7K IC InChI=1S/C13H19ClN2O3/c1-2-3-4-12(13(17)15-18)16-19-9-10-5-7-11(14)8-6-10/h5-8,12,16,18H,2-4,9H2,1H3,(H,15,17)
DMFGQ7K CS CCCCC(C(=O)NO)NOCC1=CC=C(C=C1)Cl
DMFGQ7K IK SUZRJMQBDIHWSQ-UHFFFAOYSA-N
DMFGQ7K IU 2-[(4-chlorophenyl)methoxyamino]-N-hydroxyhexanamide
DMFGQ7K DE Discovery agent
DMRADWB ID DMRADWB
DMRADWB DN 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB HS Investigative
DMRADWB SN CHEMBL228229; 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide
DMRADWB DT Small molecular drug
DMRADWB PC 44423685
DMRADWB MW 244.67
DMRADWB FM C10H13ClN2O3
DMRADWB IC InChI=1S/C10H13ClN2O3/c1-7(10(14)12-15)13-16-6-8-2-4-9(11)5-3-8/h2-5,7,13,15H,6H2,1H3,(H,12,14)
DMRADWB CS CC(C(=O)NO)NOCC1=CC=C(C=C1)Cl
DMRADWB IK JNDVWCINXNIDOF-UHFFFAOYSA-N
DMRADWB IU 2-[(4-chlorophenyl)methoxyamino]-N-hydroxypropanamide
DMRADWB DE Discovery agent
DMQAVM4 ID DMQAVM4
DMQAVM4 DN 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid
DMQAVM4 HS Investigative
DMQAVM4 SN CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid
DMQAVM4 DT Small molecular drug
DMQAVM4 PC 44411812
DMQAVM4 MW 352.8
DMQAVM4 FM C17H17ClO4S
DMQAVM4 IC InChI=1S/C17H17ClO4S/c1-2-3-16(17(19)20)23(21,22)15-10-6-13(7-11-15)12-4-8-14(18)9-5-12/h4-11,16H,2-3H2,1H3,(H,19,20)
DMQAVM4 CS CCCC(C(=O)O)S(=O)(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)Cl
DMQAVM4 IK JGNJABZIGHTRNB-UHFFFAOYSA-N
DMQAVM4 IU 2-[4-(4-chlorophenyl)phenyl]sulfonylpentanoic acid
DMQAVM4 DE Discovery agent
DM6Z9U4 ID DM6Z9U4
DM6Z9U4 DN 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide
DM6Z9U4 HS Investigative
DM6Z9U4 SN CHEMBL1099295; 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide; SCHEMBL2264064
DM6Z9U4 DT Small molecular drug
DM6Z9U4 PC 44549375
DM6Z9U4 MW 271.7
DM6Z9U4 FM C14H10ClN3O
DM6Z9U4 IC InChI=1S/C14H10ClN3O/c15-10-4-6-11(7-5-10)18-8-9-2-1-3-12(14(16)19)13(9)17-18/h1-8H,(H2,16,19)
DM6Z9U4 CS C1=CC2=CN(N=C2C(=C1)C(=O)N)C3=CC=C(C=C3)Cl
DM6Z9U4 IK ZUUTWXXAMVQOFT-UHFFFAOYSA-N
DM6Z9U4 IU 2-(4-chlorophenyl)indazole-7-carboxamide
DM6Z9U4 DE Discovery agent
DMSB0JA ID DMSB0JA
DMSB0JA DN 2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline
DMSB0JA HS Investigative
DMSB0JA SN CHEMBL316782; SCHEMBL10771178; ZINC13756970
DMSB0JA DT Small molecular drug
DMSB0JA PC 10540663
DMSB0JA MW 279.72
DMSB0JA FM C16H10ClN3
DMSB0JA IC InChI=1S/C16H10ClN3/c17-11-7-5-10(6-8-11)16-19-14-9-18-13-4-2-1-3-12(13)15(14)20-16/h1-9H,(H,19,20)
DMSB0JA CS C1=CC=C2C(=C1)C3=C(C=N2)NC(=N3)C4=CC=C(C=C4)Cl
DMSB0JA IK CGBRMMMHBXSYHH-UHFFFAOYSA-N
DMSB0JA IU 2-(4-chlorophenyl)-3H-imidazo[4,5-c]quinoline
DMSB0JA DE Discovery agent
DMFQI4C ID DMFQI4C
DMFQI4C DN 2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole
DMFQI4C HS Investigative
DMFQI4C SN 2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole; 13623-52-4; CHEMBL448710; 1H-Imidazole,2-(4-chlorophenyl)-4,5-dihydro-; NSC129258; AC1L5PGD; AC1Q3R0Q; AC1Q3IU9; 1h-imidazole, 2-(4-chlorophenyl)-4,5-dihydro-; SCHEMBL523059; CTK4C0220; DTXSID90299300; XUMWMBLBTZAVLW-UHFFFAOYSA-N; MolPort-005-311-522; ZINC608390; 2-(4-chlorophenyl)-2-imidazoline; 2-(4-Chlorophenyl)-1-imidazoline; BDBM50266028; STK367850; AKOS005444786; NE32890; NSC-129258; MCULE-4125153952; 2-Imidazoline, 2-(p-chloro-phenyl)-; DB-063124; FT-0766187; EN300-29599
DMFQI4C DT Small molecular drug
DMFQI4C PC 279088
DMFQI4C MW 180.63
DMFQI4C FM C9H9ClN2
DMFQI4C IC InChI=1S/C9H9ClN2/c10-8-3-1-7(2-4-8)9-11-5-6-12-9/h1-4H,5-6H2,(H,11,12)
DMFQI4C CS C1CN=C(N1)C2=CC=C(C=C2)Cl
DMFQI4C IK XUMWMBLBTZAVLW-UHFFFAOYSA-N
DMFQI4C IU 2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole
DMFQI4C CA CAS 13623-52-4
DMFQI4C DE Discovery agent
DMYGRS9 ID DMYGRS9
DMYGRS9 DN 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one
DMYGRS9 HS Investigative
DMYGRS9 SN CHEMBL203853
DMYGRS9 DT Small molecular drug
DMYGRS9 PC 11543610
DMYGRS9 MW 271.7
DMYGRS9 FM C15H10ClNO2
DMYGRS9 IC InChI=1S/C15H10ClNO2/c16-12-6-8-13(9-7-12)17-15(18)10-14(19-17)11-4-2-1-3-5-11/h1-10H
DMYGRS9 CS C1=CC=C(C=C1)C2=CC(=O)N(O2)C3=CC=C(C=C3)Cl
DMYGRS9 IK DWRJXWOCTFGHCE-UHFFFAOYSA-N
DMYGRS9 IU 2-(4-chlorophenyl)-5-phenyl-1,2-oxazol-3-one
DMYGRS9 DE Discovery agent
DM9SGBO ID DM9SGBO
DM9SGBO DN 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
DM9SGBO HS Investigative
DM9SGBO SN 3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE; 2-(4-CHLOROPHENYL)-5-QUINOXALINECARBOXAMIDE; 4tju; 1wok; AC1LCVX7; quinoxaline analogue, 3b; SCHEMBL424209; 3-(4-chloro-phenyl)-quinoxaline-5-carboxylic acid amide; CTK8F4675; BDBM27720; ZINC1489510; DB03509; 489457-67-2
DM9SGBO DT Small molecular drug
DM9SGBO PC 657038
DM9SGBO MW 283.71
DM9SGBO FM C15H10ClN3O
DM9SGBO IC InChI=1S/C15H10ClN3O/c16-10-6-4-9(5-7-10)13-8-18-12-3-1-2-11(15(17)20)14(12)19-13/h1-8H,(H2,17,20)
DM9SGBO CS C1=CC(=C2C(=C1)N=CC(=N2)C3=CC=C(C=C3)Cl)C(=O)N
DM9SGBO IK FLYGLPYJEQPCFY-UHFFFAOYSA-N
DM9SGBO IU 3-(4-chlorophenyl)quinoxaline-5-carboxamide
DM9SGBO DE Discovery agent
DM7EUOX ID DM7EUOX
DM7EUOX DN 2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one
DM7EUOX HS Investigative
DM7EUOX SN CHEMBL105612; 2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3535601; BDBM50132355; 2-Morpholino-6-(4-chlorophenyl)-4H-pyran-4-one
DM7EUOX DT Small molecular drug
DM7EUOX PC 10062895
DM7EUOX MW 291.73
DM7EUOX FM C15H14ClNO3
DM7EUOX IC InChI=1S/C15H14ClNO3/c16-12-3-1-11(2-4-12)14-9-13(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8H2
DM7EUOX CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)Cl
DM7EUOX IK VYDDKZSYMMZLQU-UHFFFAOYSA-N
DM7EUOX IU 2-(4-chlorophenyl)-6-morpholin-4-ylpyran-4-one
DM7EUOX DE Discovery agent
DMAPWNR ID DMAPWNR
DMAPWNR DN 2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR HS Investigative
DMAPWNR SN CHEMBL205586; 2-(4-chlorophenyl)-6-phenyl-9H-purine
DMAPWNR DT Small molecular drug
DMAPWNR PC 11529627
DMAPWNR MW 306.7
DMAPWNR FM C17H11ClN4
DMAPWNR IC InChI=1S/C17H11ClN4/c18-13-8-6-12(7-9-13)16-21-14(11-4-2-1-3-5-11)15-17(22-16)20-10-19-15/h1-10H,(H,19,20,21,22)
DMAPWNR CS C1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=C(C=C4)Cl)N=CN3
DMAPWNR IK FPWZFVSRIINTRB-UHFFFAOYSA-N
DMAPWNR IU 2-(4-chlorophenyl)-6-phenyl-7H-purine
DMAPWNR DE Discovery agent
DMJORCV ID DMJORCV
DMJORCV DN 2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol
DMJORCV HS Investigative
DMJORCV SN CHEMBL460104; 2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol
DMJORCV DT Small molecular drug
DMJORCV PC 25154759
DMJORCV MW 334.8
DMJORCV FM C16H11ClO4S
DMJORCV IC InChI=1S/C16H11ClO4S/c17-10-5-7-11(8-6-10)22(20,21)15-9-14(18)12-3-1-2-4-13(12)16(15)19/h1-9,18-19H
DMJORCV CS C1=CC=C2C(=C1)C(=CC(=C2O)S(=O)(=O)C3=CC=C(C=C3)Cl)O
DMJORCV IK SXWUEZFUYNUEML-UHFFFAOYSA-N
DMJORCV IU 2-(4-chlorophenyl)sulfonylnaphthalene-1,4-diol
DMJORCV DE Discovery agent
DM4XFJI ID DM4XFJI
DM4XFJI DN 2-(4-cyano-2-cyclohexylphenoxy)acetic acid
DM4XFJI HS Investigative
DM4XFJI SN CHEMBL245700; (4-Cyano-2-cyclohexylphenoxy)acetic acid; 2-(4-cyano-2-cyclohexylphenoxy)acetic acid; SCHEMBL4881986; BDBM50213915
DM4XFJI DT Small molecular drug
DM4XFJI PC 11586961
DM4XFJI MW 259.3
DM4XFJI FM C15H17NO3
DM4XFJI IC InChI=1S/C15H17NO3/c16-9-11-6-7-14(19-10-15(17)18)13(8-11)12-4-2-1-3-5-12/h6-8,12H,1-5,10H2,(H,17,18)
DM4XFJI CS C1CCC(CC1)C2=C(C=CC(=C2)C#N)OCC(=O)O
DM4XFJI IK YLYPWLBTNPRZEM-UHFFFAOYSA-N
DM4XFJI IU 2-(4-cyano-2-cyclohexylphenoxy)acetic acid
DM4XFJI DE Discovery agent
DMOH46C ID DMOH46C
DMOH46C DN 2-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMOH46C HS Investigative
DMOH46C DT Small molecular drug
DMOH46C PC 135676207
DMOH46C MW 277.39
DMOH46C FM C14H19N3OS
DMOH46C IC InChI=1S/C14H19N3OS/c18-13-9-5-4-6-11(13)10-15-17-14(19)16-12-7-2-1-3-8-12/h4-6,9-10,12,18H,1-3,7-8H2,(H2,16,17,19)/b15-10+
DMOH46C CS C1CCC(CC1)NC(=S)N/N=C/C2=CC=CC=C2O
DMOH46C IK QEQOERHFAIIFBC-XNTDXEJSSA-N
DMOH46C IU 1-cyclohexyl-3-[(E)-(2-hydroxyphenyl)methylideneamino]thiourea
DMOH46C DE Discovery agent
DM6VQEO ID DM6VQEO
DM6VQEO DN 2-(4-Cyclopentyl-piperazin-1-yl)-quinoline
DM6VQEO HS Investigative
DM6VQEO SN CHEMBL178608; 2-(4-Cyclopentyl-piperazin-1-yl)-quinoline; SCHEMBL3970736
DM6VQEO DT Small molecular drug
DM6VQEO PC 11337173
DM6VQEO MW 281.4
DM6VQEO FM C18H23N3
DM6VQEO IC InChI=1S/C18H23N3/c1-4-8-17-15(5-1)9-10-18(19-17)21-13-11-20(12-14-21)16-6-2-3-7-16/h1,4-5,8-10,16H,2-3,6-7,11-14H2
DM6VQEO CS C1CCC(C1)N2CCN(CC2)C3=NC4=CC=CC=C4C=C3
DM6VQEO IK JGCMOVVEQUHZRT-UHFFFAOYSA-N
DM6VQEO IU 2-(4-cyclopentylpiperazin-1-yl)quinoline
DM6VQEO DE Discovery agent
DMPU90E ID DMPU90E
DMPU90E DN 2-(4-Cyclopropyl-piperazin-1-yl)-quinoline
DMPU90E HS Investigative
DMPU90E SN CHEMBL179578; 2-(4-Cyclopropyl-piperazin-1-yl)-quinoline; SCHEMBL13648831; BDBM50159109
DMPU90E DT Small molecular drug
DMPU90E PC 11324846
DMPU90E MW 253.34
DMPU90E FM C16H19N3
DMPU90E IC InChI=1S/C16H19N3/c1-2-4-15-13(3-1)5-8-16(17-15)19-11-9-18(10-12-19)14-6-7-14/h1-5,8,14H,6-7,9-12H2
DMPU90E CS C1CC1N2CCN(CC2)C3=NC4=CC=CC=C4C=C3
DMPU90E IK HOMYCGKCEABFJF-UHFFFAOYSA-N
DMPU90E IU 2-(4-cyclopropylpiperazin-1-yl)quinoline
DMPU90E DE Discovery agent
DM823CD ID DM823CD
DM823CD DN 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione
DM823CD HS Investigative
DM823CD SN CHEMBL176400; F2147-1072; 7351-91-9; 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione; SCHEMBL14676513; MolPort-023-212-106; DEWGBLHKQDVWLX-UHFFFAOYSA-N; BDBM50291598; ZINC28090831; AKOS024627738; MCULE-2799628954; 2-(4-(diethylamino)but-2-yn-1-yl)isoindoline-1,3-dione
DM823CD DT Small molecular drug
DM823CD PC 44385509
DM823CD MW 270.33
DM823CD FM C16H18N2O2
DM823CD IC InChI=1S/C16H18N2O2/c1-3-17(4-2)11-7-8-12-18-15(19)13-9-5-6-10-14(13)16(18)20/h5-6,9-10H,3-4,11-12H2,1-2H3
DM823CD CS CCN(CC)CC#CCN1C(=O)C2=CC=CC=C2C1=O
DM823CD IK DEWGBLHKQDVWLX-UHFFFAOYSA-N
DM823CD IU 2-[4-(diethylamino)but-2-ynyl]isoindole-1,3-dione
DM823CD DE Discovery agent
DMXH0FO ID DMXH0FO
DMXH0FO DN 2-(4-Dipropylamino-cyclohexylidene)-malononitrile
DMXH0FO HS Investigative
DMXH0FO SN CHEMBL164950; 2-(4-Dipropylamino-cyclohexylidene)-malononitrile; ZINC13805533
DMXH0FO DT Small molecular drug
DMXH0FO PC 10705550
DMXH0FO MW 245.36
DMXH0FO FM C15H23N3
DMXH0FO IC InChI=1S/C15H23N3/c1-3-9-18(10-4-2)15-7-5-13(6-8-15)14(11-16)12-17/h15H,3-10H2,1-2H3
DMXH0FO CS CCCN(CCC)C1CCC(=C(C#N)C#N)CC1
DMXH0FO IK FGVSZVRUGNMGKP-UHFFFAOYSA-N
DMXH0FO IU 2-[4-(dipropylamino)cyclohexylidene]propanedinitrile
DMXH0FO DE Discovery agent
DMTAVU5 ID DMTAVU5
DMTAVU5 DN 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline
DMTAVU5 HS Investigative
DMTAVU5 SN CHEMBL198008; benzimidazole-quinoxaline, C2; BDBM21216; 2-[4-(ethylsulfanyl)-1H-benzimidazol-2-yl]quinoxaline
DMTAVU5 DT Small molecular drug
DMTAVU5 PC 11688103
DMTAVU5 MW 306.4
DMTAVU5 FM C17H14N4S
DMTAVU5 IC InChI=1S/C17H14N4S/c1-2-22-15-9-5-8-13-16(15)21-17(20-13)14-10-18-11-6-3-4-7-12(11)19-14/h3-10H,2H2,1H3,(H,20,21)
DMTAVU5 CS CCSC1=CC=CC2=C1N=C(N2)C3=NC4=CC=CC=C4N=C3
DMTAVU5 IK IHVQPVYBIZVMSJ-UHFFFAOYSA-N
DMTAVU5 IU 2-(4-ethylsulfanyl-1H-benzimidazol-2-yl)quinoxaline
DMTAVU5 DE Discovery agent
DMGLEX5 ID DMGLEX5
DMGLEX5 DN 2-(4-Fluoro-3-phenoxy-benzoylamino)-benzoic acid
DMGLEX5 HS Investigative
DMGLEX5 SN CHEMBL180428; BDBM23580; 2-(4-fluoro-3-phenoxybenzoylamino)benzoic acid; (3-Phenoxybenzoylamino)benzoic acid deriv., 23a; 2-[(4-fluoro-3-phenoxybenzene)amido]benzoic acid
DMGLEX5 DT Small molecular drug
DMGLEX5 PC 11233439
DMGLEX5 MW 351.3
DMGLEX5 FM C20H14FNO4
DMGLEX5 IC InChI=1S/C20H14FNO4/c21-16-11-10-13(12-18(16)26-14-6-2-1-3-7-14)19(23)22-17-9-5-4-8-15(17)20(24)25/h1-12H,(H,22,23)(H,24,25)
DMGLEX5 CS C1=CC=C(C=C1)OC2=C(C=CC(=C2)C(=O)NC3=CC=CC=C3C(=O)O)F
DMGLEX5 IK OPLSSBDEHIIFAG-UHFFFAOYSA-N
DMGLEX5 IU 2-[(4-fluoro-3-phenoxybenzoyl)amino]benzoic acid
DMGLEX5 DE Discovery agent
DMZSHDR ID DMZSHDR
DMZSHDR DN 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione
DMZSHDR HS Investigative
DMZSHDR SN 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione; CHEMBL203552; SCHEMBL13442861; Isoquinoline-1,3,4-trione 2f; CTK7C0409; BDBM10253; AKOS015966191; 2-(4-FLUORO-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE
DMZSHDR DT Small molecular drug
DMZSHDR PC 11680763
DMZSHDR MW 283.25
DMZSHDR FM C16H10FNO3
DMZSHDR IC InChI=1S/C16H10FNO3/c17-11-7-5-10(6-8-11)9-18-15(20)13-4-2-1-3-12(13)14(19)16(18)21/h1-8H,9H2
DMZSHDR CS C1=CC=C2C(=C1)C(=O)C(=O)N(C2=O)CC3=CC=C(C=C3)F
DMZSHDR IK XFTAXSAPJPVWNZ-UHFFFAOYSA-N
DMZSHDR IU 2-[(4-fluorophenyl)methyl]isoquinoline-1,3,4-trione
DMZSHDR DE Discovery agent
DMKFIEY ID DMKFIEY
DMKFIEY DN 2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid
DMKFIEY HS Investigative
DMKFIEY SN CHEMBL362888; 2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid
DMKFIEY DT Small molecular drug
DMKFIEY PC 44393638
DMKFIEY MW 319.3
DMKFIEY FM C15H10FNO4S
DMKFIEY IC InChI=1S/C15H10FNO4S/c16-12-5-3-6-13-10(12)8-9-17(13)22(20,21)14-7-2-1-4-11(14)15(18)19/h1-9H,(H,18,19)
DMKFIEY CS C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)N2C=CC3=C2C=CC=C3F
DMKFIEY IK YQOPLEXTOUMMNP-UHFFFAOYSA-N
DMKFIEY IU 2-(4-fluoroindol-1-yl)sulfonylbenzoic acid
DMKFIEY DE Discovery agent
DMECX8S ID DMECX8S
DMECX8S DN 2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one
DMECX8S HS Investigative
DMECX8S SN CHEMBL105521; 2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3537099; BDBM50132370; 2-Morpholino-6-(4-fluorophenyl)-4H-pyran-4-one
DMECX8S DT Small molecular drug
DMECX8S PC 10912743
DMECX8S MW 275.27
DMECX8S FM C15H14FNO3
DMECX8S IC InChI=1S/C15H14FNO3/c16-12-3-1-11(2-4-12)14-9-13(18)10-15(20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8H2
DMECX8S CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)F
DMECX8S IK PERAFXFTWFWDNO-UHFFFAOYSA-N
DMECX8S IU 2-(4-fluorophenyl)-6-morpholin-4-ylpyran-4-one
DMECX8S DE Discovery agent
DMZDGB3 ID DMZDGB3
DMZDGB3 DN 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one
DMZDGB3 HS Investigative
DMZDGB3 SN CHEMBL344504; 4'-Fluoro-7-methoxyflavone; 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one; SCHEMBL9142214; ZINC27557271; BDBM50310198
DMZDGB3 DT Small molecular drug
DMZDGB3 PC 10378415
DMZDGB3 MW 270.25
DMZDGB3 FM C16H11FO3
DMZDGB3 IC InChI=1S/C16H11FO3/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-9H,1H3
DMZDGB3 CS COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=C(C=C3)F
DMZDGB3 IK FQRUARKLFVTIIK-UHFFFAOYSA-N
DMZDGB3 IU 2-(4-fluorophenyl)-7-methoxychromen-4-one
DMZDGB3 DE Discovery agent
DM0CDRP ID DM0CDRP
DM0CDRP DN 2-(4-fluorophenylsulfonamido)-1-naphthoic acid
DM0CDRP HS Investigative
DM0CDRP SN sulfonamide compound, 10; CHEMBL212006; SCHEMBL3982656; BDBM17604; 2-[(4-fluorobenzene)sulfonamido]naphthalene-1-carboxylic acid
DM0CDRP DT Small molecular drug
DM0CDRP PC 10427648
DM0CDRP MW 345.3
DM0CDRP FM C17H12FNO4S
DM0CDRP IC InChI=1S/C17H12FNO4S/c18-12-6-8-13(9-7-12)24(22,23)19-15-10-5-11-3-1-2-4-14(11)16(15)17(20)21/h1-10,19H,(H,20,21)
DM0CDRP CS C1=CC=C2C(=C1)C=CC(=C2C(=O)O)NS(=O)(=O)C3=CC=C(C=C3)F
DM0CDRP IK KIYWIXCUCALPGQ-UHFFFAOYSA-N
DM0CDRP IU 2-[(4-fluorophenyl)sulfonylamino]naphthalene-1-carboxylic acid
DM0CDRP DE Discovery agent
DM05HBC ID DM05HBC
DM05HBC DN 2-(4-hexyl-2-methoxyphenoxy)pyrimidine
DM05HBC HS Investigative
DM05HBC SN CHEMBL429332
DM05HBC DT Small molecular drug
DM05HBC PC 44450125
DM05HBC MW 286.37
DM05HBC FM C17H22N2O2
DM05HBC IC InChI=1S/C17H22N2O2/c1-3-4-5-6-8-14-9-10-15(16(13-14)20-2)21-17-18-11-7-12-19-17/h7,9-13H,3-6,8H2,1-2H3
DM05HBC CS CCCCCCC1=CC(=C(C=C1)OC2=NC=CC=N2)OC
DM05HBC IK UIFANQCPIJLKBV-UHFFFAOYSA-N
DM05HBC IU 2-(4-hexyl-2-methoxyphenoxy)pyrimidine
DM05HBC DE Discovery agent
DMCPN7V ID DMCPN7V
DMCPN7V DN 2-(4-hydroxybenzylideneamino)ethanesulfonamide
DMCPN7V HS Investigative
DMCPN7V DT Small molecular drug
DMCPN7V PC 136123546
DMCPN7V MW 228.27
DMCPN7V FM C9H12N2O3S
DMCPN7V IC InChI=1S/C9H12N2O3S/c10-15(13,14)6-5-11-7-8-1-3-9(12)4-2-8/h1-4,7,12H,5-6H2,(H2,10,13,14)
DMCPN7V CS C1=CC(=CC=C1C=NCCS(=O)(=O)N)O
DMCPN7V IK IDKQYIBAMQLGRT-UHFFFAOYSA-N
DMCPN7V IU 2-[(4-hydroxyphenyl)methylideneamino]ethanesulfonamide
DMCPN7V DE Discovery agent
DMM4S1R ID DMM4S1R
DMM4S1R DN 2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa)
DMM4S1R HS Investigative
DMM4S1R SN ZINC34018202; (E)-alpha-(4-Hydroxyphenyl)-3,5-dihydroxycinnamic acid
DMM4S1R DT Small molecular drug
DMM4S1R PC 9900145
DMM4S1R MW 272.25
DMM4S1R FM C15H12O5
DMM4S1R IC InChI=1S/C15H12O5/c16-11-3-1-10(2-4-11)14(15(19)20)7-9-5-12(17)8-13(18)6-9/h1-8,16-18H,(H,19,20)/b14-7+
DMM4S1R CS C1=CC(=CC=C1/C(=C\\C2=CC(=CC(=C2)O)O)/C(=O)O)O
DMM4S1R IK LGVSCQYCQUYTOK-VGOFMYFVSA-N
DMM4S1R IU (E)-3-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)prop-2-enoic acid
DMM4S1R DE Discovery agent
DMUGHF6 ID DMUGHF6
DMUGHF6 DN 2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMUGHF6 HS Investigative
DMUGHF6 DT Small molecular drug
DMUGHF6 PC 135503567
DMUGHF6 MW 277.27
DMUGHF6 FM C17H11NO3
DMUGHF6 IC InChI=1S/C17H11NO3/c19-10-5-7-14-16(9-10)21-17(18-14)13-6-8-15(20)12-4-2-1-3-11(12)13/h1-9,19-20H
DMUGHF6 CS C1=CC=C2C(=C1)C(=CC=C2O)C3=NC4=C(O3)C=C(C=C4)O
DMUGHF6 IK JOCGYNKOMBFRII-UHFFFAOYSA-N
DMUGHF6 IU 2-(4-hydroxynaphthalen-1-yl)-1,3-benzoxazol-6-ol
DMUGHF6 DE Discovery agent
DM1C864 ID DM1C864
DM1C864 DN 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine
DM1C864 HS Investigative
DM1C864 SN CHEMBL219888; 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine; SCHEMBL4381152
DM1C864 DT Small molecular drug
DM1C864 PC 11740439
DM1C864 MW 379.37
DM1C864 FM C16H21N5O6
DM1C864 IC InChI=1S/C16H21N5O6/c1-8(23)4-3-5-10-18-14(20-26-2)11-15(19-10)21(7-17-11)16-13(25)12(24)9(6-22)27-16/h7-9,12-13,16,22-25H,4,6H2,1-2H3,(H,18,19,20)/t8?,9-,12-,13-,16-/m1/s1
DM1C864 CS CC(CC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NOC)O
DM1C864 IK MVQXWIPZMVHVNF-WTBWQYLWSA-N
DM1C864 IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[2-(4-hydroxypent-1-ynyl)-6-(methoxyamino)purin-9-yl]oxolane-3,4-diol
DM1C864 DE Discovery agent
DMW6L38 ID DMW6L38
DMW6L38 DN 2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol
DMW6L38 HS Investigative
DMW6L38 SN CHEMBL281499; SCHEMBL6286186; BDBM50123205; 2-(4-hydroxyphenyl)-1,2''-spirobi[1H-indene]-5-ol
DMW6L38 DT Small molecular drug
DMW6L38 PC 9945207
DMW6L38 MW 326.4
DMW6L38 FM C23H18O2
DMW6L38 IC InChI=1S/C23H18O2/c24-19-7-5-15(6-8-19)22-12-18-11-20(25)9-10-21(18)23(22)13-16-3-1-2-4-17(16)14-23/h1-12,24-25H,13-14H2
DMW6L38 CS C1C2=CC=CC=C2CC13C4=C(C=C(C=C4)O)C=C3C5=CC=C(C=C5)O
DMW6L38 IK NRJDKQAGGSKGKV-UHFFFAOYSA-N
DMW6L38 IU 2'-(4-hydroxyphenyl)spiro[1,3-dihydroindene-2,1'-indene]-5'-ol
DMW6L38 DE Discovery agent
DMBIV8F ID DMBIV8F
DMBIV8F DN 2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol
DMBIV8F HS Investigative
DMBIV8F SN CHEMBL197188; 2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol
DMBIV8F DT Small molecular drug
DMBIV8F PC 11716633
DMBIV8F MW 314.4
DMBIV8F FM C22H18O2
DMBIV8F IC InChI=1S/C22H18O2/c1-14-2-4-16(5-3-14)22-20-11-10-19(24)12-17(20)13-21(22)15-6-8-18(23)9-7-15/h2-12,23-24H,13H2,1H3
DMBIV8F CS CC1=CC=C(C=C1)C2=C(CC3=C2C=CC(=C3)O)C4=CC=C(C=C4)O
DMBIV8F IK YIFNILRPNDYIBP-UHFFFAOYSA-N
DMBIV8F IU 2-(4-hydroxyphenyl)-1-(4-methylphenyl)-3H-inden-5-ol
DMBIV8F DE Discovery agent
DMNGW1A ID DMNGW1A
DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile
DMNGW1A HS Investigative
DMNGW1A SN CHEMBL305128
DMNGW1A DT Small molecular drug
DMNGW1A PC 14537253
DMNGW1A MW 297.3
DMNGW1A FM C21H15NO
DMNGW1A IC InChI=1S/C21H15NO/c22-15-20(16-11-13-19(23)14-12-16)21(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-14,23H
DMNGW1A CS C1=CC=C(C=C1)C(=C(C#N)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMNGW1A IK IMMSDZNZGPJVRN-UHFFFAOYSA-N
DMNGW1A IU 2-(4-hydroxyphenyl)-3,3-diphenylprop-2-enenitrile
DMNGW1A DE Discovery agent
DM4N0LB ID DM4N0LB
DM4N0LB DN 2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol
DM4N0LB HS Investigative
DM4N0LB DT Small molecular drug
DM4N0LB PC 135424609
DM4N0LB MW 267.28
DM4N0LB FM C16H13NO3
DM4N0LB IC InChI=1S/C16H13NO3/c1-20-16-9-15(10-2-4-11(18)5-3-10)17-14-7-6-12(19)8-13(14)16/h2-9,18-19H,1H3
DM4N0LB CS COC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DM4N0LB IK IOTUBGYZUXLZPC-UHFFFAOYSA-N
DM4N0LB IU 2-(4-hydroxyphenyl)-4-methoxyquinolin-6-ol
DM4N0LB DE Discovery agent
DM81G2U ID DM81G2U
DM81G2U DN 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol
DM81G2U HS Investigative
DM81G2U SN 2-(4-hydroxyphenyl)-4-vinylquinolin-6-ol
DM81G2U PC 135409729
DM81G2U MW 263.29
DM81G2U FM C17H13NO2
DM81G2U IC InChI=1S/C17H13NO2/c1-2-11-9-17(12-3-5-13(19)6-4-12)18-16-8-7-14(20)10-15(11)16/h2-10,19-20H,1H2
DM81G2U CS C=CC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DM81G2U IK MPGOJACGGLDRIE-UHFFFAOYSA-N
DM81G2U IU 4-ethenyl-2-(4-hydroxyphenyl)quinolin-6-ol
DM81G2U DE Discovery agent
DMFWOMY ID DMFWOMY
DMFWOMY DN 2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol
DMFWOMY HS Investigative
DMFWOMY DT Small molecular drug
DMFWOMY PC 135442595
DMFWOMY MW 269.29
DMFWOMY FM C16H15NO3
DMFWOMY IC InChI=1S/C16H15NO3/c1-9(2)13-7-12(19)8-14-15(13)20-16(17-14)10-3-5-11(18)6-4-10/h3-9,18-19H,1-2H3
DMFWOMY CS CC(C)C1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMFWOMY IK XMPVRZGJAQOXGV-UHFFFAOYSA-N
DMFWOMY IU 2-(4-hydroxyphenyl)-7-propan-2-yl-1,3-benzoxazol-5-ol
DMFWOMY DE Discovery agent
DMY0I8P ID DMY0I8P
DMY0I8P DN 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol
DMY0I8P HS Investigative
DMY0I8P SN CHEMBL361226; 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol; SCHEMBL3928011; KEWMBPCQWDVBAS-UHFFFAOYSA-N
DMY0I8P DT Small molecular drug
DMY0I8P PC 10286022
DMY0I8P MW 256.25
DMY0I8P FM C15H12O4
DMY0I8P IC InChI=1S/C15H12O4/c1-18-14-8-12(17)6-10-7-13(19-15(10)14)9-2-4-11(16)5-3-9/h2-8,16-17H,1H3
DMY0I8P CS COC1=C2C(=CC(=C1)O)C=C(O2)C3=CC=C(C=C3)O
DMY0I8P IK KEWMBPCQWDVBAS-UHFFFAOYSA-N
DMY0I8P IU 2-(4-hydroxyphenyl)-7-methoxy-1-benzofuran-5-ol
DMY0I8P DE Discovery agent
DMCNITS ID DMCNITS
DMCNITS DN 2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol
DMCNITS HS Investigative
DMCNITS DT Small molecular drug
DMCNITS PC 135409725
DMCNITS MW 257.24
DMCNITS FM C14H11NO4
DMCNITS IC InChI=1S/C14H11NO4/c1-18-12-7-10(17)6-11-13(12)19-14(15-11)8-2-4-9(16)5-3-8/h2-7,16-17H,1H3
DMCNITS CS COC1=CC(=CC2=C1OC(=N2)C3=CC=C(C=C3)O)O
DMCNITS IK RJJQKEPGOIGNSZ-UHFFFAOYSA-N
DMCNITS IU 2-(4-hydroxyphenyl)-7-methoxy-1,3-benzoxazol-5-ol
DMCNITS DE Discovery agent
DMT847Y ID DMT847Y
DMT847Y DN 2-(4-hydroxyphenyl)-7-methoxychroman-4-one
DMT847Y HS Investigative
DMT847Y SN Methyl-liquiritigenin; CHEMBL402970; 4'-hydroxy-7-methoxyflavanone; 32274-71-8; 7-Methylliquiritigenin; CTK1B9324; DTXSID80437613; LMPK12140062; BDBM50374257; AKOS030552775; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-(4-hydroxyphenyl)-7-methoxy-
DMT847Y DT Small molecular drug
DMT847Y PC 10265122
DMT847Y MW 270.28
DMT847Y FM C16H14O4
DMT847Y IC InChI=1S/C16H14O4/c1-19-12-6-7-13-14(18)9-15(20-16(13)8-12)10-2-4-11(17)5-3-10/h2-8,15,17H,9H2,1H3
DMT847Y CS COC1=CC2=C(C=C1)C(=O)CC(O2)C3=CC=C(C=C3)O
DMT847Y IK OJOSVTQXBSSCMQ-UHFFFAOYSA-N
DMT847Y IU 2-(4-hydroxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
DMT847Y CA CAS 32274-71-8
DMT847Y DE Discovery agent
DMQ2KPI ID DMQ2KPI
DMQ2KPI DN 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol
DMQ2KPI HS Investigative
DMQ2KPI SN CHEMBL365290; 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol; SCHEMBL1119325; FUWUZPRNKPGRGX-UHFFFAOYSA-N
DMQ2KPI DT Small molecular drug
DMQ2KPI PC 10285954
DMQ2KPI MW 240.25
DMQ2KPI FM C15H12O3
DMQ2KPI IC InChI=1S/C15H12O3/c1-9-6-13(17)7-11-8-14(18-15(9)11)10-2-4-12(16)5-3-10/h2-8,16-17H,1H3
DMQ2KPI CS CC1=CC(=CC2=C1OC(=C2)C3=CC=C(C=C3)O)O
DMQ2KPI IK FUWUZPRNKPGRGX-UHFFFAOYSA-N
DMQ2KPI IU 2-(4-hydroxyphenyl)-7-methyl-1-benzofuran-5-ol
DMQ2KPI DE Discovery agent
DMUB7KH ID DMUB7KH
DMUB7KH DN 2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol
DMUB7KH HS Investigative
DMUB7KH DT Small molecular drug
DMUB7KH PC 135409756
DMUB7KH MW 303.3
DMUB7KH FM C19H13NO3
DMUB7KH IC InChI=1S/C19H13NO3/c21-14-8-6-13(7-9-14)19-20-17-11-15(22)10-16(18(17)23-19)12-4-2-1-3-5-12/h1-11,21-22H
DMUB7KH CS C1=CC=C(C=C1)C2=C3C(=CC(=C2)O)N=C(O3)C4=CC=C(C=C4)O
DMUB7KH IK OMOPCSHWHZVQPY-UHFFFAOYSA-N
DMUB7KH IU 2-(4-hydroxyphenyl)-7-phenyl-1,3-benzoxazol-5-ol
DMUB7KH DE Discovery agent
DMND63Z ID DMND63Z
DMND63Z DN 2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol
DMND63Z HS Investigative
DMND63Z DT Small molecular drug
DMND63Z PC 136048731
DMND63Z MW 267.28
DMND63Z FM C16H13NO3
DMND63Z IC InChI=1S/C16H13NO3/c1-2-3-11-8-13(19)9-14-15(11)20-16(17-14)10-4-6-12(18)7-5-10/h2-9,18-19H,1H3/b3-2-
DMND63Z CS C/C=C\\C1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMND63Z IK GBNLUWROABYNBX-IHWYPQMZSA-N
DMND63Z IU 2-(4-hydroxyphenyl)-7-[(Z)-prop-1-enyl]-1,3-benzoxazol-5-ol
DMND63Z DE Discovery agent
DMONT2D ID DMONT2D
DMONT2D DN 2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol
DMONT2D HS Investigative
DMONT2D DT Small molecular drug
DMONT2D PC 135519317
DMONT2D MW 269.29
DMONT2D FM C16H15NO3
DMONT2D IC InChI=1S/C16H15NO3/c1-2-3-11-8-13(19)9-14-15(11)20-16(17-14)10-4-6-12(18)7-5-10/h4-9,18-19H,2-3H2,1H3
DMONT2D CS CCCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMONT2D IK VHUQNFQIHPMAAE-UHFFFAOYSA-N
DMONT2D IU 2-(4-hydroxyphenyl)-7-propyl-1,3-benzoxazol-5-ol
DMONT2D DE Discovery agent
DM2F6U3 ID DM2F6U3
DM2F6U3 DN 2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol
DM2F6U3 HS Investigative
DM2F6U3 DT Small molecular drug
DM2F6U3 PC 135494488
DM2F6U3 MW 253.25
DM2F6U3 FM C15H11NO3
DM2F6U3 IC InChI=1S/C15H11NO3/c1-2-9-7-12(18)8-13-14(9)19-15(16-13)10-3-5-11(17)6-4-10/h2-8,17-18H,1H2
DM2F6U3 CS C=CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DM2F6U3 IK DNOMWUYUDHLCAY-UHFFFAOYSA-N
DM2F6U3 IU 7-ethenyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DM2F6U3 DE Discovery agent
DMVHQM9 ID DMVHQM9
DMVHQM9 DN 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one
DMVHQM9 HS Investigative
DMVHQM9 DT Small molecular drug
DMVHQM9 PC 135471354
DMVHQM9 MW 252.27
DMVHQM9 FM C15H12N2O2
DMVHQM9 IC InChI=1S/C15H12N2O2/c1-9-3-2-4-12-13(9)16-14(17-15(12)19)10-5-7-11(18)8-6-10/h2-8,18H,1H3,(H,16,17,19)
DMVHQM9 CS CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)O
DMVHQM9 IK NIPIEXNSQBQPML-UHFFFAOYSA-N
DMVHQM9 IU 2-(4-hydroxyphenyl)-8-methyl-3H-quinazolin-4-one
DMVHQM9 DE Discovery agent
DMN6S3F ID DMN6S3F
DMN6S3F DN 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
DMN6S3F HS Investigative
DMN6S3F SN 2-(4-Hydroxy-phenyl)benzofuran-5-OL; 2-(4-Hydroxy-phenyl)-benzofuran-5-ol; 2-(4-hydroxyphenyl)-1-benzofuran-5-ol; CHEMBL367588; 52814-86-5; 2-(4-Hydroxyphenyl)benzofuran-5-ol; AC1LCVQT; 1u9e; SCHEMBL3922677; CTK1G1983; DTXSID60349669; SNNNDCMXZYWCCI-UHFFFAOYSA-N; ZINC3816519; BDBM50152627; SBB096959; AKOS030555876; DB07032; 2-(4-hydroxyphenyl)benzo[b]furan-5-ol; 5-Benzofuranol,
DMN6S3F DT Small molecular drug
DMN6S3F PC 656936
DMN6S3F MW 226.23
DMN6S3F FM C14H10O3
DMN6S3F IC InChI=1S/C14H10O3/c15-11-3-1-9(2-4-11)14-8-10-7-12(16)5-6-13(10)17-14/h1-8,15-16H
DMN6S3F CS C1=CC(=CC=C1C2=CC3=C(O2)C=CC(=C3)O)O
DMN6S3F IK SNNNDCMXZYWCCI-UHFFFAOYSA-N
DMN6S3F IU 2-(4-hydroxyphenyl)-1-benzofuran-5-ol
DMN6S3F CA CAS 52814-86-5
DMN6S3F DE Discovery agent
DMMUNA7 ID DMMUNA7
DMMUNA7 DN 2-(4-Hydroxy-phenyl)-benzooxazol-5-ol
DMMUNA7 HS Investigative
DMMUNA7 DT Small molecular drug
DMMUNA7 PC 135405741
DMMUNA7 MW 227.21
DMMUNA7 FM C13H9NO3
DMMUNA7 IC InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-14-11-7-10(16)5-6-12(11)17-13/h1-7,15-16H
DMMUNA7 CS C1=CC(=CC=C1C2=NC3=C(O2)C=CC(=C3)O)O
DMMUNA7 IK DPAMLAKLEWYMGF-UHFFFAOYSA-N
DMMUNA7 IU 2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMMUNA7 CA CAS 142629-43-4
DMMUNA7 DE Discovery agent
DM31MY0 ID DM31MY0
DM31MY0 DN 2-(4-Hydroxy-phenyl)-benzooxazol-6-ol
DM31MY0 HS Investigative
DM31MY0 DT Small molecular drug
DM31MY0 PC 135471161
DM31MY0 MW 227.21
DM31MY0 FM C13H9NO3
DM31MY0 IC InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-14-11-6-5-10(16)7-12(11)17-13/h1-7,15-16H
DM31MY0 CS C1=CC(=CC=C1C2=NC3=C(O2)C=C(C=C3)O)O
DM31MY0 IK PDCFEVXISBNCNF-UHFFFAOYSA-N
DM31MY0 IU 2-(4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DM31MY0 DE Discovery agent
DMCWFUZ ID DMCWFUZ
DMCWFUZ DN 2-(4-Hydroxy-phenyl)-quinolin-6-ol
DMCWFUZ HS Investigative
DMCWFUZ DT Small molecular drug
DMCWFUZ PC 135987619
DMCWFUZ MW 237.25
DMCWFUZ FM C15H11NO2
DMCWFUZ IC InChI=1S/C15H11NO2/c17-12-4-1-10(2-5-12)14-7-3-11-9-13(18)6-8-15(11)16-14/h1-9,17-18H
DMCWFUZ CS C1=CC(=CC=C1C2=NC3=C(C=C2)C=C(C=C3)O)O
DMCWFUZ IK SEKOFPJLRLFURL-UHFFFAOYSA-N
DMCWFUZ IU 2-(4-hydroxyphenyl)quinolin-6-ol
DMCWFUZ DE Discovery agent
DM8GBH4 ID DM8GBH4
DM8GBH4 DN 2-(4-hydroxystyryl)quinolin-8-ol
DM8GBH4 HS Investigative
DM8GBH4 DT Small molecular drug
DM8GBH4 PC 135500760
DM8GBH4 MW 263.29
DM8GBH4 FM C17H13NO2
DM8GBH4 IC InChI=1S/C17H13NO2/c19-15-10-5-12(6-11-15)4-8-14-9-7-13-2-1-3-16(20)17(13)18-14/h1-11,19-20H/b8-4+
DM8GBH4 CS C1=CC2=C(C(=C1)O)N=C(C=C2)/C=C/C3=CC=C(C=C3)O
DM8GBH4 IK YMSHSKJZBZKCOR-XBXARRHUSA-N
DM8GBH4 IU 2-[(E)-2-(4-hydroxyphenyl)ethenyl]quinolin-8-ol
DM8GBH4 DE Discovery agent
DMUIVS9 ID DMUIVS9
DMUIVS9 DN 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine
DMUIVS9 HS Investigative
DMUIVS9 SN CHEMBL112592; 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine; SCHEMBL14129997; BDBM50138232
DMUIVS9 DT Small molecular drug
DMUIVS9 PC 44341428
DMUIVS9 MW 251.28
DMUIVS9 FM C15H13N3O
DMUIVS9 IC InChI=1S/C15H13N3O/c1-2-8-17-13(3-1)11-19-15-6-4-14(5-7-15)18-10-9-16-12-18/h1-10,12H,11H2
DMUIVS9 CS C1=CC=NC(=C1)COC2=CC=C(C=C2)N3C=CN=C3
DMUIVS9 IK IMJROXJEYNKELD-UHFFFAOYSA-N
DMUIVS9 IU 2-[(4-imidazol-1-ylphenoxy)methyl]pyridine
DMUIVS9 DE Discovery agent
DMSH4WP ID DMSH4WP
DMSH4WP DN 2-(4-Isopropyl-piperazin-1-yl)-quinoline
DMSH4WP HS Investigative
DMSH4WP SN CHEMBL360253; 2-(4-Isopropyl-piperazin-1-yl)-quinoline; SCHEMBL13648771
DMSH4WP DT Small molecular drug
DMSH4WP PC 11393294
DMSH4WP MW 255.36
DMSH4WP FM C16H21N3
DMSH4WP IC InChI=1S/C16H21N3/c1-13(2)18-9-11-19(12-10-18)16-8-7-14-5-3-4-6-15(14)17-16/h3-8,13H,9-12H2,1-2H3
DMSH4WP CS CC(C)N1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMSH4WP IK WICRMWNIFYTKBK-UHFFFAOYSA-N
DMSH4WP IU 2-(4-propan-2-ylpiperazin-1-yl)quinoline
DMSH4WP DE Discovery agent
DMXPJF3 ID DMXPJF3
DMXPJF3 DN 2-(4-Mercapto-butyl)-pentanedioic acid
DMXPJF3 HS Investigative
DMXPJF3 SN CHEMBL60317; 2-(4-Mercapto-butyl)-pentanedioic acid; SCHEMBL6383425
DMXPJF3 DT Small molecular drug
DMXPJF3 PC 10130679
DMXPJF3 MW 220.29
DMXPJF3 FM C9H16O4S
DMXPJF3 IC InChI=1S/C9H16O4S/c10-8(11)5-4-7(9(12)13)3-1-2-6-14/h7,14H,1-6H2,(H,10,11)(H,12,13)
DMXPJF3 CS C(CCS)CC(CCC(=O)O)C(=O)O
DMXPJF3 IK QFKHEJQVTSTWPJ-UHFFFAOYSA-N
DMXPJF3 IU 2-(4-sulfanylbutyl)pentanedioic acid
DMXPJF3 DE Discovery agent
DMHAE31 ID DMHAE31
DMHAE31 DN 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione
DMHAE31 HS Investigative
DMHAE31 SN 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione; CHEMBL205983; SCHEMBL13442854; Isoquinoline-1,3,4-trione 2e; CTK7A3832; BDBM10252; AKOS015966190; 2-(4-METHOXY-BENZYL)-ISOQUINOLINE-1,3,4-TRIONE
DMHAE31 DT Small molecular drug
DMHAE31 PC 11522185
DMHAE31 MW 295.29
DMHAE31 FM C17H13NO4
DMHAE31 IC InChI=1S/C17H13NO4/c1-22-12-8-6-11(7-9-12)10-18-16(20)14-5-3-2-4-13(14)15(19)17(18)21/h2-9H,10H2,1H3
DMHAE31 CS COC1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3C(=O)C2=O
DMHAE31 IK UJBONJNKVPTSPR-UHFFFAOYSA-N
DMHAE31 IU 2-[(4-methoxyphenyl)methyl]isoquinoline-1,3,4-trione
DMHAE31 DE Discovery agent
DMZNPMQ ID DMZNPMQ
DMZNPMQ DN 2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol
DMZNPMQ HS Investigative
DMZNPMQ DT Small molecular drug
DMZNPMQ PC 716696
DMZNPMQ DE Discovery agent
DMTEQU8 ID DMTEQU8
DMTEQU8 DN 2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde
DMTEQU8 HS Investigative
DMTEQU8 SN 2-(4-methoxyphenyl)-1H-indole-3-carbaldehyde; 76195-80-7; AC1MY4K3; CHEMBL144222; SCHEMBL15332438; CTK2G8075; DTXSID90396949; MolPort-006-701-191; IAL-1620; ZX-BK002979; ZINC3675784; KM5032; STK894724; BBL022005; AKOS005143919; MCULE-1940549514; 1H-Indole-3-carboxaldehyde, 2-(4-methoxyphenyl)-
DMTEQU8 DT Small molecular drug
DMTEQU8 PC 3826063
DMTEQU8 MW 251.28
DMTEQU8 FM C16H13NO2
DMTEQU8 IC InChI=1S/C16H13NO2/c1-19-12-8-6-11(7-9-12)16-14(10-18)13-4-2-3-5-15(13)17-16/h2-10,17H,1H3
DMTEQU8 CS COC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C=O
DMTEQU8 IK QIMWZVMNUAWWSJ-UHFFFAOYSA-N
DMTEQU8 IU 2-(4-methoxyphenyl)-1H-indole-3-carbaldehyde
DMTEQU8 CA CAS 76195-80-7
DMTEQU8 DE Discovery agent
DM0KUMX ID DM0KUMX
DM0KUMX DN 2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole
DM0KUMX HS Investigative
DM0KUMX SN 2-(4-Methoxyphenyl)-4,5-dihydro-1H-imidazole; 6302-84-7; 4,5-Dihydro-2-(4-methoxyphenyl)-1H-Imidazole; 2-Imidazoline, 2-(p-methoxyphenyl)-; 1H-Imidazole, 4,5-dihydro-2-(4-methoxyphenyl)-; CHEMBL13633; NSC41538; AC1L5ZGN; 2-(p-Anisyl)-1-imidazoline; SCHEMBL9575256; AC1Q580G; CTK5B7166; DTXSID40285359; LPRQSQCAHSRGRZ-UHFFFAOYSA-N; ZINC1672770; BDBM50240364; NSC-41538; AKOS022491172; MCULE-4518622050; 1-(2-imidazolin-2-yl)-4-methoxybenzene; 2-(P-METHOXY-PHENYL)-IMIDAZOLINE; DB-073247; KB-222983; ST50998435; FT-0712566
DM0KUMX DT Small molecular drug
DM0KUMX PC 237746
DM0KUMX MW 176.21
DM0KUMX FM C10H12N2O
DM0KUMX IC InChI=1S/C10H12N2O/c1-13-9-4-2-8(3-5-9)10-11-6-7-12-10/h2-5H,6-7H2,1H3,(H,11,12)
DM0KUMX CS COC1=CC=C(C=C1)C2=NCCN2
DM0KUMX IK LPRQSQCAHSRGRZ-UHFFFAOYSA-N
DM0KUMX IU 2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole
DM0KUMX CA CAS 6302-84-7
DM0KUMX DE Discovery agent
DMIDXTR ID DMIDXTR
DMIDXTR DN 2-(4-methoxyphenyl)-4H-chromene-4-thione
DMIDXTR HS Investigative
DMIDXTR SN CHEMBL607571; 2-(4-methoxyphenyl)chromene-4-thione; AC1LO0PS; 2-(4-methoxyphenyl)-4H-chromene-4-thione; MolPort-019-767-607; ZINC1011200; BDBM50310182
DMIDXTR DT Small molecular drug
DMIDXTR PC 1231330
DMIDXTR MW 268.3
DMIDXTR FM C16H12O2S
DMIDXTR IC InChI=1S/C16H12O2S/c1-17-12-8-6-11(7-9-12)15-10-16(19)13-4-2-3-5-14(13)18-15/h2-10H,1H3
DMIDXTR CS COC1=CC=C(C=C1)C2=CC(=S)C3=CC=CC=C3O2
DMIDXTR IK VNYCDMLKRQOQKQ-UHFFFAOYSA-N
DMIDXTR IU 2-(4-methoxyphenyl)chromene-4-thione
DMIDXTR DE Discovery agent
DMZ9A6U ID DMZ9A6U
DMZ9A6U DN 2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol
DMZ9A6U HS Investigative
DMZ9A6U SN CHEMBL65940; 2-(4-Methoxyphenyl)-5-phenylthiazol-4-ol; 2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol; Oprea1_607545; SCHEMBL9629437; YQAKORGQQCUKEJ-UHFFFAOYSA-N; BDBM50012392
DMZ9A6U DT Small molecular drug
DMZ9A6U PC 14425906
DMZ9A6U MW 283.3
DMZ9A6U FM C16H13NO2S
DMZ9A6U IC InChI=1S/C16H13NO2S/c1-19-13-9-7-12(8-10-13)16-17-15(18)14(20-16)11-5-3-2-4-6-11/h2-10,18H,1H3
DMZ9A6U CS COC1=CC=C(C=C1)C2=NC(=C(S2)C3=CC=CC=C3)O
DMZ9A6U IK YQAKORGQQCUKEJ-UHFFFAOYSA-N
DMZ9A6U IU 2-(4-methoxyphenyl)-5-phenyl-1,3-thiazol-4-ol
DMZ9A6U DE Discovery agent
DMVQU1M ID DMVQU1M
DMVQU1M DN 2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one
DMVQU1M HS Investigative
DMVQU1M SN CHEMBL319261; 2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one; SCHEMBL3545199; BDBM50132361; 2-(4-methoxyphenyl)-6-morpholin-4-ylpyran-4-one; 2-Morpholino-6-(4-methoxyphenyl)-4H-pyran-4-one; 2-(4-Methoxy-phenyl)-6-morpholin-4-yl-pyran-4-one
DMVQU1M DT Small molecular drug
DMVQU1M PC 16745325
DMVQU1M MW 287.31
DMVQU1M FM C16H17NO4
DMVQU1M IC InChI=1S/C16H17NO4/c1-19-14-4-2-12(3-5-14)15-10-13(18)11-16(21-15)17-6-8-20-9-7-17/h2-5,10-11H,6-9H2,1H3
DMVQU1M CS COC1=CC=C(C=C1)C2=CC(=O)C=C(O2)N3CCOCC3
DMVQU1M IK QJIHTEXMXZZXDS-UHFFFAOYSA-N
DMVQU1M IU 2-(4-methoxyphenyl)-6-morpholin-4-ylpyran-4-one
DMVQU1M DE Discovery agent
DMXTHOV ID DMXTHOV
DMXTHOV DN 2-(4-methoxyphenyl)-6-phenyl-9H-purine
DMXTHOV HS Investigative
DMXTHOV SN CHEMBL207760; 2-(4-methoxyphenyl)-6-phenyl-9H-purine
DMXTHOV DT Small molecular drug
DMXTHOV PC 11536774
DMXTHOV MW 302.3
DMXTHOV FM C18H14N4O
DMXTHOV IC InChI=1S/C18H14N4O/c1-23-14-9-7-13(8-10-14)17-21-15(12-5-3-2-4-6-12)16-18(22-17)20-11-19-16/h2-11H,1H3,(H,19,20,21,22)
DMXTHOV CS COC1=CC=C(C=C1)C2=NC(=C3C(=N2)N=CN3)C4=CC=CC=C4
DMXTHOV IK COPIEKYOHOQDKK-UHFFFAOYSA-N
DMXTHOV IU 2-(4-methoxyphenyl)-6-phenyl-7H-purine
DMXTHOV DE Discovery agent
DMS572H ID DMS572H
DMS572H DN 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one
DMS572H HS Investigative
DMS572H DT Small molecular drug
DMS572H PC 135407310
DMS572H MW 266.29
DMS572H FM C16H14N2O2
DMS572H IC InChI=1S/C16H14N2O2/c1-10-4-3-5-13-14(10)17-15(18-16(13)19)11-6-8-12(20-2)9-7-11/h3-9H,1-2H3,(H,17,18,19)
DMS572H CS CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)OC
DMS572H IK HTLUBFSSIMOABR-UHFFFAOYSA-N
DMS572H IU 2-(4-methoxyphenyl)-8-methyl-3H-quinazolin-4-one
DMS572H DE Discovery agent
DM1N08O ID DM1N08O
DM1N08O DN 2-(4-methoxyphenyl)-N-(thiazol-2-yl)acetamide
DM1N08O HS Investigative
DM1N08O SN 2-(4-methoxyphenyl)-N-(1,3-thiazol-2-yl)acetamide; AC1LGGXP; Cambridge id 5286247; Oprea1_702537; Oprea1_294245; CHEMBL227898; MolPort-001-026-371; ZINC253385; STL503574; AKOS000673322; MCULE-3731631352; BAS 00626097; KB-115460; ST50912475; 2-(4-Methoxy-phenyl)-N-thiazol-2-yl-acetamide; 2-(4-methoxyphenyl)-N-1,3-thiazol-2-ylacetamide; Z28173731
DM1N08O DT Small molecular drug
DM1N08O PC 770967
DM1N08O MW 248.3
DM1N08O FM C12H12N2O2S
DM1N08O IC InChI=1S/C12H12N2O2S/c1-16-10-4-2-9(3-5-10)8-11(15)14-12-13-6-7-17-12/h2-7H,8H2,1H3,(H,13,14,15)
DM1N08O CS COC1=CC=C(C=C1)CC(=O)NC2=NC=CS2
DM1N08O IK SPAPWVUPZKTBMH-UHFFFAOYSA-N
DM1N08O IU 2-(4-methoxyphenyl)-N-(1,3-thiazol-2-yl)acetamide
DM1N08O DE Discovery agent
DMBRETS ID DMBRETS
DMBRETS DN 2-(4-methoxyphenyl)quinoline-8-carboxamide
DMBRETS HS Investigative
DMBRETS SN 2-(4-methoxyphenyl)quinoline-8-carboxamide; CHEMBL481591; 655222-47-2; CTK1J6622; DTXSID70649086; BDBM50255383; AKOS030560276; 8-Quinolinecarboxamide, 2-(4-methoxyphenyl)-
DMBRETS DT Small molecular drug
DMBRETS PC 25209058
DMBRETS MW 278.3
DMBRETS FM C17H14N2O2
DMBRETS IC InChI=1S/C17H14N2O2/c1-21-13-8-5-11(6-9-13)15-10-7-12-3-2-4-14(17(18)20)16(12)19-15/h2-10H,1H3,(H2,18,20)
DMBRETS CS COC1=CC=C(C=C1)C2=NC3=C(C=CC=C3C(=O)N)C=C2
DMBRETS IK HJJCORRFLXJIBM-UHFFFAOYSA-N
DMBRETS IU 2-(4-methoxyphenyl)quinoline-8-carboxamide
DMBRETS CA CAS 655222-47-2
DMBRETS DE Discovery agent
DMDXIN1 ID DMDXIN1
DMDXIN1 DN 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline
DMDXIN1 HS Investigative
DMDXIN1 SN CHEMBL198779; benzimidazole-quinoxaline, C3; SCHEMBL12834347; BDBM21217; ZINC13678106
DMDXIN1 DT Small molecular drug
DMDXIN1 PC 11521761
DMDXIN1 MW 260.29
DMDXIN1 FM C16H12N4
DMDXIN1 IC InChI=1S/C16H12N4/c1-10-5-4-8-13-15(10)20-16(19-13)14-9-17-11-6-2-3-7-12(11)18-14/h2-9H,1H3,(H,19,20)
DMDXIN1 CS CC1=C2C(=CC=C1)NC(=N2)C3=NC4=CC=CC=C4N=C3
DMDXIN1 IK HQNVISKJTIKRQJ-UHFFFAOYSA-N
DMDXIN1 IU 2-(4-methyl-1H-benzimidazol-2-yl)quinoxaline
DMDXIN1 DE Discovery agent
DM943YL ID DM943YL
DM943YL DN 2-(4-Methyl-indole-1-sulfonyl)-benzoic acid
DM943YL HS Investigative
DM943YL SN CHEMBL184195; 2-(4-Methyl-indole-1-sulfonyl)-benzoic acid
DM943YL DT Small molecular drug
DM943YL PC 44393606
DM943YL MW 315.3
DM943YL FM C16H13NO4S
DM943YL IC InChI=1S/C16H13NO4S/c1-11-5-4-7-14-12(11)9-10-17(14)22(20,21)15-8-3-2-6-13(15)16(18)19/h2-10H,1H3,(H,18,19)
DM943YL CS CC1=C2C=CN(C2=CC=C1)S(=O)(=O)C3=CC=CC=C3C(=O)O
DM943YL IK FSVUAMOXCTUQEP-UHFFFAOYSA-N
DM943YL IU 2-(4-methylindol-1-yl)sulfonylbenzoic acid
DM943YL DE Discovery agent
DMDHFU9 ID DMDHFU9
DMDHFU9 DN 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine
DMDHFU9 HS Investigative
DMDHFU9 SN CHEMBL45158; 159692-85-0; 2-(4-methylpiperazin-1-yl)-4-phenylpyrimidine; 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine; SCHEMBL1275203; CTK0B0099; DTXSID80438281; QHOBPFOGFURKFZ-UHFFFAOYSA-N; BDBM50289600; 1-(4-Phenylpyrimidin-2-yl)-4-methylpiperazine; Pyrimidine, 2-(4-methyl-1-piperazinyl)-4-phenyl-
DMDHFU9 DT Small molecular drug
DMDHFU9 PC 10332554
DMDHFU9 MW 254.33
DMDHFU9 FM C15H18N4
DMDHFU9 IC InChI=1S/C15H18N4/c1-18-9-11-19(12-10-18)15-16-8-7-14(17-15)13-5-3-2-4-6-13/h2-8H,9-12H2,1H3
DMDHFU9 CS CN1CCN(CC1)C2=NC=CC(=N2)C3=CC=CC=C3
DMDHFU9 IK QHOBPFOGFURKFZ-UHFFFAOYSA-N
DMDHFU9 IU 2-(4-methylpiperazin-1-yl)-4-phenylpyrimidine
DMDHFU9 CA CAS 159692-85-0
DMDHFU9 DE Discovery agent
DMB8OY6 ID DMB8OY6
DMB8OY6 DN 2-(4-Methyl-piperazin-1-yl)-quinoline
DMB8OY6 HS Investigative
DMB8OY6 SN N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; 2-(4-Methyl-piperazin-1-yl)-quinoline; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080
DMB8OY6 DT Small molecular drug
DMB8OY6 PC 5013
DMB8OY6 MW 227.3
DMB8OY6 FM C14H17N3
DMB8OY6 IC InChI=1S/C14H17N3/c1-16-8-10-17(11-9-16)14-7-6-12-4-2-3-5-13(12)15-14/h2-7H,8-11H2,1H3
DMB8OY6 CS CN1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMB8OY6 IK HOMWNUXPSJQSSU-UHFFFAOYSA-N
DMB8OY6 IU 2-(4-methylpiperazin-1-yl)quinoline
DMB8OY6 CA CAS 28614-26-8
DMB8OY6 CB CHEBI:64164
DMB8OY6 DE Discovery agent
DMBJICP ID DMBJICP
DMBJICP DN 2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline
DMBJICP HS Investigative
DMBJICP SN CHEMBL198060; 2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline
DMBJICP DT Small molecular drug
DMBJICP PC 11565524
DMBJICP MW 291.26
DMBJICP FM C15H9N5O2
DMBJICP IC InChI=1S/C15H9N5O2/c21-20(22)13-7-3-6-11-14(13)19-15(18-11)12-8-16-9-4-1-2-5-10(9)17-12/h1-8H,(H,18,19)
DMBJICP CS C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=CC=C4[N+](=O)[O-]
DMBJICP IK RDSFCGCNTCJZOD-UHFFFAOYSA-N
DMBJICP IU 2-(4-nitro-1H-benzimidazol-2-yl)quinoxaline
DMBJICP DE Discovery agent
DMX8U32 ID DMX8U32
DMX8U32 DN 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene
DMX8U32 HS Investigative
DMX8U32 SN CHEMBL205403; 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene
DMX8U32 DT Small molecular drug
DMX8U32 PC 10425576
DMX8U32 MW 311.4
DMX8U32 FM C17H13NO3S
DMX8U32 IC InChI=1S/C17H13NO3S/c1-21-15-8-4-13(5-9-15)17-11-10-16(22-17)12-2-6-14(7-3-12)18(19)20/h2-11H,1H3
DMX8U32 CS COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)[N+](=O)[O-]
DMX8U32 IK JNOACYJDBPZIMJ-UHFFFAOYSA-N
DMX8U32 IU 2-(4-methoxyphenyl)-5-(4-nitrophenyl)thiophene
DMX8U32 DE Discovery agent
DMR54SW ID DMR54SW
DMR54SW DN 2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide
DMR54SW HS Investigative
DMR54SW SN CHEMBL260464
DMR54SW DT Small molecular drug
DMR54SW PC 44450365
DMR54SW MW 282.4
DMR54SW FM C18H22N2O
DMR54SW IC InChI=1S/C18H22N2O/c1-2-3-4-6-15-8-10-16(11-9-15)13-18(21)20-17-7-5-12-19-14-17/h5,7-12,14H,2-4,6,13H2,1H3,(H,20,21)
DMR54SW CS CCCCCC1=CC=C(C=C1)CC(=O)NC2=CN=CC=C2
DMR54SW IK VYJQGHFNPZKVTQ-UHFFFAOYSA-N
DMR54SW IU 2-(4-pentylphenyl)-N-pyridin-3-ylacetamide
DMR54SW DE Discovery agent
DM65IF1 ID DM65IF1
DM65IF1 DN 2-(4-Phenoxy-benzyl)-1H-benzoimidazole
DM65IF1 HS Investigative
DM65IF1 SN CHEMBL67249; SCHEMBL7510229
DM65IF1 DT Small molecular drug
DM65IF1 PC 9817808
DM65IF1 MW 300.4
DM65IF1 FM C20H16N2O
DM65IF1 IC InChI=1S/C20H16N2O/c1-2-6-16(7-3-1)23-17-12-10-15(11-13-17)14-20-21-18-8-4-5-9-19(18)22-20/h1-13H,14H2,(H,21,22)
DM65IF1 CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=CC=CC=C4N3
DM65IF1 IK HWTRVTWTEQIXOY-UHFFFAOYSA-N
DM65IF1 IU 2-[(4-phenoxyphenyl)methyl]-1H-benzimidazole
DM65IF1 DE Discovery agent
DM3HANW ID DM3HANW
DM3HANW DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol
DM3HANW HS Investigative
DM3HANW SN CHEMBL63924
DM3HANW DT Small molecular drug
DM3HANW PC 9796984
DM3HANW MW 316.4
DM3HANW FM C20H16N2O2
DM3HANW IC InChI=1S/C20H16N2O2/c23-18-8-4-7-17-20(18)22-19(21-17)13-14-9-11-16(12-10-14)24-15-5-2-1-3-6-15/h1-12,23H,13H2,(H,21,22)
DM3HANW CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=CC=C4O
DM3HANW IK MRBKMMZUVLPGTA-UHFFFAOYSA-N
DM3HANW IU 2-[(4-phenoxyphenyl)methyl]-1H-benzimidazol-4-ol
DM3HANW DE Discovery agent
DMFO19B ID DMFO19B
DMFO19B DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol
DMFO19B HS Investigative
DMFO19B SN CHEMBL63200; SCHEMBL7453649
DMFO19B DT Small molecular drug
DMFO19B PC 9839919
DMFO19B MW 316.4
DMFO19B FM C20H16N2O2
DMFO19B IC InChI=1S/C20H16N2O2/c23-15-8-11-18-19(13-15)22-20(21-18)12-14-6-9-17(10-7-14)24-16-4-2-1-3-5-16/h1-11,13,23H,12H2,(H,21,22)
DMFO19B CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=C(C=C4)O
DMFO19B IK LVCCXJOSNNQODU-UHFFFAOYSA-N
DMFO19B IU 2-[(4-phenoxyphenyl)methyl]-3H-benzimidazol-5-ol
DMFO19B DE Discovery agent
DMJSBFU ID DMJSBFU
DMJSBFU DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine
DMJSBFU HS Investigative
DMJSBFU SN CHEMBL65119
DMJSBFU DT Small molecular drug
DMJSBFU PC 9883372
DMJSBFU MW 315.4
DMJSBFU FM C20H17N3O
DMJSBFU IC InChI=1S/C20H17N3O/c21-15-8-11-18-19(13-15)23-20(22-18)12-14-6-9-17(10-7-14)24-16-4-2-1-3-5-16/h1-11,13H,12,21H2,(H,22,23)
DMJSBFU CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=C(C=C4)N
DMJSBFU IK KVTYWLATLSZWKO-UHFFFAOYSA-N
DMJSBFU IU 2-[(4-phenoxyphenyl)methyl]-3H-benzimidazol-5-amine
DMJSBFU DE Discovery agent
DM7TBUJ ID DM7TBUJ
DM7TBUJ DN 2-(4-phenoxyphenoxy)ethanamine
DM7TBUJ HS Investigative
DM7TBUJ SN 2-(4-phenoxyphenoxy)ethanamine; CHEMBL472386; 2-(4-Phenoxyphenoxy)Ethylamine; 72490-14-3; SCHEMBL9486899; SCHEMBL4653229; CTK2H2396; DTXSID40452640; FBLANPWAVFBRNS-UHFFFAOYSA-N; 2-[(p-phenoxy)phenoxy]ethylamine; Ethanamine, 2-(4-phenoxyphenoxy)-; ZINC11945831; BDBM50246062
DM7TBUJ DT Small molecular drug
DM7TBUJ PC 11031651
DM7TBUJ MW 229.27
DM7TBUJ FM C14H15NO2
DM7TBUJ IC InChI=1S/C14H15NO2/c15-10-11-16-12-6-8-14(9-7-12)17-13-4-2-1-3-5-13/h1-9H,10-11,15H2
DM7TBUJ CS C1=CC=C(C=C1)OC2=CC=C(C=C2)OCCN
DM7TBUJ IK FBLANPWAVFBRNS-UHFFFAOYSA-N
DM7TBUJ IU 2-(4-phenoxyphenoxy)ethanamine
DM7TBUJ CA CAS 72490-14-3
DM7TBUJ DE Discovery agent
DMSPOAT ID DMSPOAT
DMSPOAT DN 2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine
DMSPOAT HS Investigative
DMSPOAT SN CHEMBL179383; 2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine
DMSPOAT DT Small molecular drug
DMSPOAT PC 11407345
DMSPOAT MW 301.3
DMSPOAT FM C19H15N3O
DMSPOAT IC InChI=1S/C19H15N3O/c20-14-8-11-17-18(12-14)22-19(21-17)13-6-9-16(10-7-13)23-15-4-2-1-3-5-15/h1-12H,20H2,(H,21,22)
DMSPOAT CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)N
DMSPOAT IK YDXHPXOLZYGIGV-UHFFFAOYSA-N
DMSPOAT IU 2-(4-phenoxyphenyl)-3H-benzimidazol-5-amine
DMSPOAT DE Discovery agent
DMEQ063 ID DMEQ063
DMEQ063 DN 2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one
DMEQ063 HS Investigative
DMEQ063 SN CHEMBL3144714; 2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one; CHEMBL269654; BDBM50009016
DMEQ063 DT Small molecular drug
DMEQ063 PC 14898718
DMEQ063 MW 266.34
DMEQ063 FM C17H18N2O
DMEQ063 IC InChI=1S/C17H18N2O/c20-17-15-11-4-5-12-16(15)18-19(17)13-7-6-10-14-8-2-1-3-9-14/h1-5,8-9,11-12,18H,6-7,10,13H2
DMEQ063 CS C1=CC=C(C=C1)CCCCN2C(=O)C3=CC=CC=C3N2
DMEQ063 IK VMGHZFARQGLROM-UHFFFAOYSA-N
DMEQ063 IU 2-(4-phenylbutyl)-1H-indazol-3-one
DMEQ063 DE Discovery agent
DMNJAV1 ID DMNJAV1
DMNJAV1 DN 2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3H)-one
DMNJAV1 HS Investigative
DMNJAV1 DT Small molecular drug
DMNJAV1 PC 135899247
DMNJAV1 MW 279.34
DMNJAV1 FM C17H17N3O
DMNJAV1 IC InChI=1S/C17H17N3O/c21-17-14-10-6-12-18-16(14)19-15(20-17)11-5-4-9-13-7-2-1-3-8-13/h1-3,6-8,10,12H,4-5,9,11H2,(H,18,19,20,21)
DMNJAV1 CS C1=CC=C(C=C1)CCCCC2=NC3=C(C=CC=N3)C(=O)N2
DMNJAV1 IK KGCFTSWBCFAQQI-UHFFFAOYSA-N
DMNJAV1 IU 2-(4-phenylbutyl)-3H-pyrido[2,3-d]pyrimidin-4-one
DMNJAV1 DE Discovery agent
DM98WVL ID DM98WVL
DM98WVL DN 2-(4-Piperidin-1-ylmethylphenoxy)benzothiazole
DM98WVL HS Investigative
DM98WVL SN Benzthiazole compound, 33b; SCHEMBL4689016; CHEMBL454760; BDBM24231
DM98WVL DT Small molecular drug
DM98WVL PC 11472798
DM98WVL MW 324.4
DM98WVL FM C19H20N2OS
DM98WVL IC InChI=1S/C19H20N2OS/c1-4-12-21(13-5-1)14-15-8-10-16(11-9-15)22-19-20-17-6-2-3-7-18(17)23-19/h2-3,6-11H,1,4-5,12-14H2
DM98WVL CS C1CCN(CC1)CC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DM98WVL IK JNKRNJIZLGLIJG-UHFFFAOYSA-N
DM98WVL IU 2-[4-(piperidin-1-ylmethyl)phenoxy]-1,3-benzothiazole
DM98WVL DE Discovery agent
DMXC20R ID DMXC20R
DMXC20R DN 2-(4-propylphenylsulfonyl)naphthalene-1,4-diol
DMXC20R HS Investigative
DMXC20R SN CHEMBL445555; 2-(4-propylphenylsulfonyl)naphthalene-1,4-diol; BDBM50245880; J3.494.437G
DMXC20R DT Small molecular drug
DMXC20R PC 44562692
DMXC20R MW 342.4
DMXC20R FM C19H18O4S
DMXC20R IC InChI=1S/C19H18O4S/c1-2-5-13-8-10-14(11-9-13)24(22,23)18-12-17(20)15-6-3-4-7-16(15)19(18)21/h3-4,6-12,20-21H,2,5H2,1H3
DMXC20R CS CCCC1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC=CC=C3C(=C2)O)O
DMXC20R IK BCECDLBGKYFWCS-UHFFFAOYSA-N
DMXC20R IU 2-(4-propylphenyl)sulfonylnaphthalene-1,4-diol
DMXC20R DE Discovery agent
DMWPM9L ID DMWPM9L
DMWPM9L DN 2-(4-Propyl-piperazin-1-yl)-quinoline
DMWPM9L HS Investigative
DMWPM9L SN CHEMBL180478; 2-(4-Propyl-piperazin-1-yl)-quinoline; Oprea1_188953; SCHEMBL3970431; 2-(4-Ethylpiperazino)quinoline; HEWVIFVVKWCRML-UHFFFAOYSA-N; BDBM50159120
DMWPM9L DT Small molecular drug
DMWPM9L PC 11370427
DMWPM9L MW 241.33
DMWPM9L FM C15H19N3
DMWPM9L IC InChI=1S/C15H19N3/c1-2-17-9-11-18(12-10-17)15-8-7-13-5-3-4-6-14(13)16-15/h3-8H,2,9-12H2,1H3
DMWPM9L CS CCN1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMWPM9L IK HEWVIFVVKWCRML-UHFFFAOYSA-N
DMWPM9L IU 2-(4-ethylpiperazin-1-yl)quinoline
DMWPM9L DE Discovery agent
DMIOW3D ID DMIOW3D
DMIOW3D DN 2-(4-tert-butylbenzylideneamino)ethanesulfonamide
DMIOW3D HS Investigative
DMIOW3D SN CHEMBL575785; 2-(4-tert-butylbenzylideneamino)ethanesulfonamide
DMIOW3D DT Small molecular drug
DMIOW3D PC 45483187
DMIOW3D MW 268.38
DMIOW3D FM C13H20N2O2S
DMIOW3D IC InChI=1S/C13H20N2O2S/c1-13(2,3)12-6-4-11(5-7-12)10-15-8-9-18(14,16)17/h4-7,10H,8-9H2,1-3H3,(H2,14,16,17)
DMIOW3D CS CC(C)(C)C1=CC=C(C=C1)C=NCCS(=O)(=O)N
DMIOW3D IK KYYQVPLISNAOAE-UHFFFAOYSA-N
DMIOW3D IU 2-[(4-tert-butylphenyl)methylideneamino]ethanesulfonamide
DMIOW3D DE Discovery agent
DM1A4BS ID DM1A4BS
DM1A4BS DN 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole
DM1A4BS HS Investigative
DM1A4BS SN CHEMBL276868; 67277-66-1; 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole; SCHEMBL8229695; CTK1J3678; DTXSID50658095; ZINC13806045; BDBM50151704; AKOS022538449; 2-(4-tert-Butylphenyl)-4,5-dihydro-1H-imidazole; 1H-Imidazole, 2-[4-(1,1-dimethylethyl)phenyl]-4,5-dihydro-
DM1A4BS DT Small molecular drug
DM1A4BS PC 44269078
DM1A4BS MW 202.3
DM1A4BS FM C13H18N2
DM1A4BS IC InChI=1S/C13H18N2/c1-13(2,3)11-6-4-10(5-7-11)12-14-8-9-15-12/h4-7H,8-9H2,1-3H3,(H,14,15)
DM1A4BS CS CC(C)(C)C1=CC=C(C=C1)C2=NCCN2
DM1A4BS IK JRUYKUSXUFPDNO-UHFFFAOYSA-N
DM1A4BS IU 2-(4-tert-butylphenyl)-4,5-dihydro-1H-imidazole
DM1A4BS CA CAS 67277-66-1
DM1A4BS DE Discovery agent
DMED9FL ID DMED9FL
DMED9FL DN 2-(4-tosylpiperazin-1-yl)nicotinonitrile
DMED9FL HS Investigative
DMED9FL SN arylsulfonylpiperazine, 27; CHEMBL404148; BDBM32555; MolPort-005-568-142; ZINC23996035; AKOS029603555; MCULE-2636718919; AB00772161-01; Z31097483; 2-[4-(4-methylbenzenesulfonyl)piperazin-1-yl]pyridine-3-carbonitrile
DMED9FL DT Small molecular drug
DMED9FL PC 16267445
DMED9FL MW 342.4
DMED9FL FM C17H18N4O2S
DMED9FL IC InChI=1S/C17H18N4O2S/c1-14-4-6-16(7-5-14)24(22,23)21-11-9-20(10-12-21)17-15(13-18)3-2-8-19-17/h2-8H,9-12H2,1H3
DMED9FL CS CC1=CC=C(C=C1)S(=O)(=O)N2CCN(CC2)C3=C(C=CC=N3)C#N
DMED9FL IK NYLACAAEFWBUQQ-UHFFFAOYSA-N
DMED9FL IU 2-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]pyridine-3-carbonitrile
DMED9FL DE Discovery agent
DMTC5Y9 ID DMTC5Y9
DMTC5Y9 DN 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile
DMTC5Y9 HS Investigative
DMTC5Y9 SN 133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile
DMTC5Y9 DT Small molecular drug
DMTC5Y9 PC 5328753
DMTC5Y9 MW 212.2
DMTC5Y9 FM C12H8N2O2
DMTC5Y9 IC InChI=1S/C12H8N2O2/c13-5-8(6-14)9-2-1-7-3-11(15)12(16)4-10(7)9/h3-4,15-16H,1-2H2
DMTC5Y9 CS C1CC(=C(C#N)C#N)C2=CC(=C(C=C21)O)O
DMTC5Y9 IK CDYLNUVNFDZTEB-UHFFFAOYSA-N
DMTC5Y9 IU 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile
DMTC5Y9 CA CAS 133550-11-5
DMTC5Y9 DE Discovery agent
DMXRYDL ID DMXRYDL
DMXRYDL DN 2-(5-Bromo-indole-1-sulfonyl)-benzoic acid
DMXRYDL HS Investigative
DMXRYDL SN CHEMBL184005; 2-(5-Bromo-indole-1-sulfonyl)-benzoic acid
DMXRYDL DT Small molecular drug
DMXRYDL PC 44393643
DMXRYDL MW 380.2
DMXRYDL FM C15H10BrNO4S
DMXRYDL IC InChI=1S/C15H10BrNO4S/c16-11-5-6-13-10(9-11)7-8-17(13)22(20,21)14-4-2-1-3-12(14)15(18)19/h1-9H,(H,18,19)
DMXRYDL CS C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)N2C=CC3=C2C=CC(=C3)Br
DMXRYDL IK RGZDWZUMVMDEAG-UHFFFAOYSA-N
DMXRYDL IU 2-(5-bromoindol-1-yl)sulfonylbenzoic acid
DMXRYDL DE Discovery agent
DM0ZB89 ID DM0ZB89
DM0ZB89 DN 2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM0ZB89 HS Investigative
DM0ZB89 SN CHEMBL198673; 2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline
DM0ZB89 DT Small molecular drug
DM0ZB89 PC 11652061
DM0ZB89 MW 280.71
DM0ZB89 FM C15H9ClN4
DM0ZB89 IC InChI=1S/C15H9ClN4/c16-9-5-6-12-13(7-9)20-15(19-12)14-8-17-10-3-1-2-4-11(10)18-14/h1-8H,(H,19,20)
DM0ZB89 CS C1=CC=C2C(=C1)N=CC(=N2)C3=NC4=C(N3)C=C(C=C4)Cl
DM0ZB89 IK SOUPHJBGFDZRAD-UHFFFAOYSA-N
DM0ZB89 IU 2-(6-chloro-1H-benzimidazol-2-yl)quinoxaline
DM0ZB89 DE Discovery agent
DMSIJ17 ID DMSIJ17
DMSIJ17 DN 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17 HS Investigative
DMSIJ17 SN CHEMBL375619; 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine
DMSIJ17 DT Small molecular drug
DMSIJ17 PC 16115752
DMSIJ17 MW 388.4
DMSIJ17 FM C17H20N6O5
DMSIJ17 IC InChI=1S/C17H20N6O5/c1-27-22-15-12-16(21-11(20-15)6-4-2-3-5-7-18)23(9-19-12)17-14(26)13(25)10(8-24)28-17/h9-10,13-14,17,24-26H,2-3,5,8H2,1H3,(H,20,21,22)/t10-,13-,14-,17-/m1/s1
DMSIJ17 CS CONC1=C2C(=NC(=N1)C#CCCCC#N)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMSIJ17 IK SNWMEUXNYSKHNP-IWCJZZDYSA-N
DMSIJ17 IU 6-[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methoxyamino)purin-2-yl]hex-5-ynenitrile
DMSIJ17 DE Discovery agent
DMHW5FT ID DMHW5FT
DMHW5FT DN 2-(5-fluoro-1H-indol-3-yl)ethanamine
DMHW5FT HS Investigative
DMHW5FT SN 5-Fluorotryptamine; 576-16-9; 3-(2-Aminoethyl)-5-fluoro-1H-indole; 1H-Indole-3-ethanamine, 5-fluoro-; 2-(5-FLUORO-1H-INDOL-3-YL)ETHAN-1-AMINE; 2-(5-Fluoro-1H-indol-3-yl)ethylamine; CHEMBL275628; 2-(5-Fluoro-1H-indol-3-yl)-ethylamine; 2-(5-fluoroindol-3-yl)ethylamine; PubChem1926; PubChem13384; ChemDiv2_003993; AC1L4V8Y; AC1Q4NE7; Oprea1_696214; GTPL146; SCHEMBL387663; 5-fluorotryptamine, AldrichCPR; cid_197774; CTK5A7173; ZINC77278; BDBM30853; DTXSID20206229; ZKIORVIXEWIOGB-UHFFFAOYSA-N; 5-fluorotryptamine
DMHW5FT DT Small molecular drug
DMHW5FT PC 164682
DMHW5FT MW 178.21
DMHW5FT FM C10H11FN2
DMHW5FT IC InChI=1S/C10H11FN2/c11-8-1-2-10-9(5-8)7(3-4-12)6-13-10/h1-2,5-6,13H,3-4,12H2
DMHW5FT CS C1=CC2=C(C=C1F)C(=CN2)CCN
DMHW5FT IK ZKIORVIXEWIOGB-UHFFFAOYSA-N
DMHW5FT IU 2-(5-fluoro-1H-indol-3-yl)ethanamine
DMHW5FT CA CAS 576-16-9
DMHW5FT DE Discovery agent
DMB3JG0 ID DMB3JG0
DMB3JG0 DN 2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DMB3JG0 HS Investigative
DMB3JG0 DT Small molecular drug
DMB3JG0 PC 4369550
DMB3JG0 MW 277.27
DMB3JG0 FM C17H11NO3
DMB3JG0 IC InChI=1S/C17H11NO3/c19-10-7-8-14-16(9-10)21-17(18-14)13-5-1-4-12-11(13)3-2-6-15(12)20/h1-9,19-20H
DMB3JG0 CS C1=CC2=C(C=CC=C2O)C(=C1)C3=NC4=C(O3)C=C(C=C4)O
DMB3JG0 IK JHOZVRGNIYFYHE-UHFFFAOYSA-N
DMB3JG0 IU 2-(5-hydroxynaphthalen-1-yl)-1,3-benzoxazol-6-ol
DMB3JG0 DE Discovery agent
DM0P6A3 ID DM0P6A3
DM0P6A3 DN 2-(5-Mercapto-pentyl)-pentanedioic acid
DM0P6A3 HS Investigative
DM0P6A3 SN CHEMBL61067; 2-(5-Mercapto-pentyl)-pentanedioic acid; Pentanedioic acid, 2-(5-mercaptopentyl)-; BDBM50127621
DM0P6A3 DT Small molecular drug
DM0P6A3 PC 10955499
DM0P6A3 MW 234.31
DM0P6A3 FM C10H18O4S
DM0P6A3 IC InChI=1S/C10H18O4S/c11-9(12)6-5-8(10(13)14)4-2-1-3-7-15/h8,15H,1-7H2,(H,11,12)(H,13,14)
DM0P6A3 CS C(CCC(CCC(=O)O)C(=O)O)CCS
DM0P6A3 IK RHHNRXAIWMGSRF-UHFFFAOYSA-N
DM0P6A3 IU 2-(5-sulfanylpentyl)pentanedioic acid
DM0P6A3 DE Discovery agent
DM1O0JD ID DM1O0JD
DM1O0JD DN 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine
DM1O0JD HS Investigative
DM1O0JD SN 5-methoxy-alpha-methyltryptamine
DM1O0JD PC 36906
DM1O0JD MW 204.27
DM1O0JD FM C12H16N2O
DM1O0JD IC InChI=1S/C12H16N2O/c1-8(13)5-9-7-14-12-4-3-10(15-2)6-11(9)12/h3-4,6-8,14H,5,13H2,1-2H3
DM1O0JD CS CC(CC1=CNC2=C1C=C(C=C2)OC)N
DM1O0JD IK OGNJZVNNKBZFRM-UHFFFAOYSA-N
DM1O0JD IU 1-(5-methoxy-1H-indol-3-yl)propan-2-amine
DM1O0JD CA CAS 1137-04-8
DM1O0JD CB CHEBI:125422
DM1O0JD DE Discovery agent
DM2TU6W ID DM2TU6W
DM2TU6W DN 2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine
DM2TU6W HS Investigative
DM2TU6W SN 5-Nonyloxytryptamine; 5-(Nonyloxy)tryptamine; O-nonylserotonin; 5-(Nonyloxy)-1H-indole-3-ethanamine; 157798-12-4; 2-(5-nonoxy-1H-indol-3-yl)ethanamine; CHEMBL97450; CHEBI:64149; 3-(2-aminoethyl)-5-nonyloxyindole; 1H-Indole-3-ethanamine,5-(nonyloxy)-; 2-[5-(nonyloxy)-1H-indol-3-yl]ethanamine; 5-(Nonyloxy)-tryptamine; Tocris-0901; NCGC00024858-01; Biomol-NT_000115; AC1L1C9C; GTPL106; SCHEMBL2335932; BPBio1_000133; AC1Q56M5; DTXSID4058653; CTK4C9475; ZINC1541570; BDBM50039947; AKOS030238973; 5-(nonyloxy)-tryptamine
DM2TU6W DT Small molecular drug
DM2TU6W PC 1797
DM2TU6W MW 302.5
DM2TU6W FM C19H30N2O
DM2TU6W IC InChI=1S/C19H30N2O/c1-2-3-4-5-6-7-8-13-22-17-9-10-19-18(14-17)16(11-12-20)15-21-19/h9-10,14-15,21H,2-8,11-13,20H2,1H3
DM2TU6W CS CCCCCCCCCOC1=CC2=C(C=C1)NC=C2CCN
DM2TU6W IK YHSMSRREJYOGQJ-UHFFFAOYSA-N
DM2TU6W IU 2-(5-nonoxy-1H-indol-3-yl)ethanamine
DM2TU6W CA CAS 157798-12-4
DM2TU6W CB CHEBI:64149
DM2TU6W DE Discovery agent
DMDZ9RK ID DMDZ9RK
DMDZ9RK DN 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole
DMDZ9RK HS Investigative
DMDZ9RK SN furaline; CHEMBL213439; SCHEMBL11783413
DMDZ9RK DT Small molecular drug
DMDZ9RK PC 16082793
DMDZ9RK MW 212.25
DMDZ9RK FM C13H12N2O
DMDZ9RK IC InChI=1S/C13H12N2O/c1-2-4-10(5-3-1)11-6-7-12(16-11)13-14-8-9-15-13/h1-7H,8-9H2,(H,14,15)
DMDZ9RK CS C1CN=C(N1)C2=CC=C(O2)C3=CC=CC=C3
DMDZ9RK IK HNPLGLAMYJQFOS-UHFFFAOYSA-N
DMDZ9RK IU 2-(5-phenylfuran-2-yl)-4,5-dihydro-1H-imidazole
DMDZ9RK DE Discovery agent
DMX6QMT ID DMX6QMT
DMX6QMT DN 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMX6QMT HS Investigative
DMX6QMT SN 2-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile; 2-Anilino-5-aryloxazole 8; AC1NS7QZ; CHEMBL193912; BDBM5847; N-(2-Cyanophenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMX6QMT DT Small molecular drug
DMX6QMT PC 5329843
DMX6QMT MW 261.279
DMX6QMT FM C16H11N3O
DMX6QMT IC InChI=1S/C16H11N3O/c17-10-13-8-4-5-9-14(13)19-16-18-11-15(20-16)12-6-2-1-3-7-12/h1-9,11H,(H,18,19)
DMX6QMT CS C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC=C3C#N
DMX6QMT IK FPMCYJLZCOBPEC-UHFFFAOYSA-N
DMX6QMT IU 2-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile
DMX6QMT DE Discovery agent
DM1AEK4 ID DM1AEK4
DM1AEK4 DN 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine
DM1AEK4 HS Investigative
DM1AEK4 SN CHEMBL355517; 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine; SCHEMBL8686120; BDBM50088863; AKOS022550938; 3-(2-Aminoethyl)-5-(2-thienyl)-1H-indole
DM1AEK4 DT Small molecular drug
DM1AEK4 PC 10198700
DM1AEK4 MW 242.34
DM1AEK4 FM C14H14N2S
DM1AEK4 IC InChI=1S/C14H14N2S/c15-6-5-11-9-16-13-4-3-10(8-12(11)13)14-2-1-7-17-14/h1-4,7-9,16H,5-6,15H2
DM1AEK4 CS C1=CSC(=C1)C2=CC3=C(C=C2)NC=C3CCN
DM1AEK4 IK KULFBKTWESBCBG-UHFFFAOYSA-N
DM1AEK4 IU 2-(5-thiophen-2-yl-1H-indol-3-yl)ethanamine
DM1AEK4 DE Discovery agent
DMRBX1D ID DMRBX1D
DMRBX1D DN 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol
DMRBX1D HS Investigative
DMRBX1D SN CHEMBL474058; 43047-77-4; 8-Bromo-9-(2-hydroxyethyl)-9H-adenine; 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol; SCHEMBL987368; CTK1C8207; DTXSID50659527; HPCQLQBYCLLETI-UHFFFAOYSA-N; BDBM50257051; AKOS030562477; 9H-Purine-9-ethanol, 6-amino-8-bromo-; 2-(6-amino-8-bromo-purin-9-yl)ethanol; 6-amino-8-bromo-9-(2-hydroxyethyl)-9H-purine
DMRBX1D DT Small molecular drug
DMRBX1D PC 44572469
DMRBX1D MW 258.079
DMRBX1D FM C7H8BrN5O
DMRBX1D IC InChI=1S/C7H8BrN5O/c8-7-12-4-5(9)10-3-11-6(4)13(7)1-2-14/h3,14H,1-2H2,(H2,9,10,11)
DMRBX1D CS C1=NC(=C2C(=N1)N(C(=N2)Br)CCO)N
DMRBX1D IK HPCQLQBYCLLETI-UHFFFAOYSA-N
DMRBX1D IU 2-(6-amino-8-bromopurin-9-yl)ethanol
DMRBX1D CA CAS 43047-77-4
DMRBX1D DE Discovery agent
DMTI1VO ID DMTI1VO
DMTI1VO DN 2-(6-Cyclopentylamino-purin-9-yl)-ethanol
DMTI1VO HS Investigative
DMTI1VO SN CHEMBL320370; 2-(6-Cyclopentylamino-purin-9-yl)-ethanol; BDBM50009691
DMTI1VO DT Small molecular drug
DMTI1VO PC 15693950
DMTI1VO MW 247.3
DMTI1VO FM C12H17N5O
DMTI1VO IC InChI=1S/C12H17N5O/c18-6-5-17-8-15-10-11(13-7-14-12(10)17)16-9-3-1-2-4-9/h7-9,18H,1-6H2,(H,13,14,16)
DMTI1VO CS C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)CCO
DMTI1VO IK XVKHXAUTWLZBQD-UHFFFAOYSA-N
DMTI1VO IU 2-[6-(cyclopentylamino)purin-9-yl]ethanol
DMTI1VO DE Discovery agent
DMXAVHT ID DMXAVHT
DMXAVHT DN 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol
DMXAVHT HS Investigative
DMXAVHT SN CHEMBL183367; 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol; SCHEMBL3933889; GLVGKXBQPYTMGJ-UHFFFAOYSA-N; ZINC3817709; BDBM50154056; 2-(6-hydroxynaphthalen-1-yl)benzo[d]oxazol-5-ol
DMXAVHT DT Small molecular drug
DMXAVHT PC 9993627
DMXAVHT MW 277.27
DMXAVHT FM C17H11NO3
DMXAVHT IC InChI=1S/C17H11NO3/c19-11-4-6-13-10(8-11)2-1-3-14(13)17-18-15-9-12(20)5-7-16(15)21-17/h1-9,19-20H
DMXAVHT CS C1=CC2=C(C=CC(=C2)O)C(=C1)C3=NC4=C(O3)C=CC(=C4)O
DMXAVHT IK GLVGKXBQPYTMGJ-UHFFFAOYSA-N
DMXAVHT IU 2-(6-hydroxynaphthalen-1-yl)-1,3-benzoxazol-5-ol
DMXAVHT DE Discovery agent
DM3GQN2 ID DM3GQN2
DM3GQN2 DN 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol
DM3GQN2 HS Investigative
DM3GQN2 SN CHEMBL189077; 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol; 2-(6-hydroxynaphthalen-1-yl)benzo[d]oxazol-6-ol; SCHEMBL3926798; ZRGCERZQAHMXNC-UHFFFAOYSA-N; BDBM50154135; 595566-69-1; 6-Benzoxazolol,2-(6-hydroxy-1-naphthalenyl)-
DM3GQN2 DT Small molecular drug
DM3GQN2 PC 10062042
DM3GQN2 MW 277.27
DM3GQN2 FM C17H11NO3
DM3GQN2 IC InChI=1S/C17H11NO3/c19-11-4-6-13-10(8-11)2-1-3-14(13)17-18-15-7-5-12(20)9-16(15)21-17/h1-9,19-20H
DM3GQN2 CS C1=CC2=C(C=CC(=C2)O)C(=C1)C3=NC4=C(O3)C=C(C=C4)O
DM3GQN2 IK ZRGCERZQAHMXNC-UHFFFAOYSA-N
DM3GQN2 IU 2-(6-hydroxynaphthalen-1-yl)-1,3-benzoxazol-6-ol
DM3GQN2 DE Discovery agent
DM715EC ID DM715EC
DM715EC DN 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol
DM715EC HS Investigative
DM715EC DT Small molecular drug
DM715EC PC 135492380
DM715EC MW 277.27
DM715EC FM C17H11NO3
DM715EC IC InChI=1S/C17H11NO3/c19-13-4-3-10-7-12(2-1-11(10)8-13)17-18-15-9-14(20)5-6-16(15)21-17/h1-9,19-20H
DM715EC CS C1=CC2=C(C=CC(=C2)O)C=C1C3=NC4=C(O3)C=CC(=C4)O
DM715EC IK PRBSKPRGLMJEEA-UHFFFAOYSA-N
DM715EC IU 2-(6-hydroxynaphthalen-2-yl)-1,3-benzoxazol-5-ol
DM715EC DE Discovery agent
DMANHOT ID DMANHOT
DMANHOT DN 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol
DMANHOT HS Investigative
DMANHOT DT Small molecular drug
DMANHOT PC 135449109
DMANHOT MW 277.27
DMANHOT FM C17H11NO3
DMANHOT IC InChI=1S/C17H11NO3/c19-13-4-3-10-7-12(2-1-11(10)8-13)17-18-15-6-5-14(20)9-16(15)21-17/h1-9,19-20H
DMANHOT CS C1=CC2=C(C=CC(=C2)O)C=C1C3=NC4=C(O3)C=C(C=C4)O
DMANHOT IK PZIKVWJRAOMJDU-UHFFFAOYSA-N
DMANHOT IU 2-(6-hydroxynaphthalen-2-yl)-1,3-benzoxazol-6-ol
DMANHOT CA CAS 595566-71-5
DMANHOT DE Discovery agent
DMKI6GQ ID DMKI6GQ
DMKI6GQ DN 2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione
DMKI6GQ HS Investigative
DMKI6GQ SN CHEMBL167372; 2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione
DMKI6GQ DT Small molecular drug
DMKI6GQ PC 13580026
DMKI6GQ MW 297.35
DMKI6GQ FM C17H19N3O2
DMKI6GQ IC InChI=1S/C17H19N3O2/c21-16-14-7-3-4-8-15(14)17(22)20(16)11-6-2-1-5-10-19-12-9-18-13-19/h3-4,7-9,12-13H,1-2,5-6,10-11H2
DMKI6GQ CS C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCCN3C=CN=C3
DMKI6GQ IK CGDDIOSGLRENCV-UHFFFAOYSA-N
DMKI6GQ IU 2-(6-imidazol-1-ylhexyl)isoindole-1,3-dione
DMKI6GQ DE Discovery agent
DM41UYN ID DM41UYN
DM41UYN DN 2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid
DM41UYN HS Investigative
DM41UYN SN CHEMBL365508; 2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid
DM41UYN DT Small molecular drug
DM41UYN PC 44393683
DM41UYN MW 331.3
DM41UYN FM C16H13NO5S
DM41UYN IC InChI=1S/C16H13NO5S/c1-22-12-7-6-11-8-9-17(14(11)10-12)23(20,21)15-5-3-2-4-13(15)16(18)19/h2-10H,1H3,(H,18,19)
DM41UYN CS COC1=CC2=C(C=C1)C=CN2S(=O)(=O)C3=CC=CC=C3C(=O)O
DM41UYN IK HQQRNJVZOJLXOO-UHFFFAOYSA-N
DM41UYN IU 2-(6-methoxyindol-1-yl)sulfonylbenzoic acid
DM41UYN DE Discovery agent
DMZDNHQ ID DMZDNHQ
DMZDNHQ DN 2-(6-morpholino-9H-purin-2-yl)phenol
DMZDNHQ HS Investigative
DMZDNHQ DT Small molecular drug
DMZDNHQ PC 135955185
DMZDNHQ MW 297.31
DMZDNHQ FM C15H15N5O2
DMZDNHQ IC InChI=1S/C15H15N5O2/c21-11-4-2-1-3-10(11)13-18-14-12(16-9-17-14)15(19-13)20-5-7-22-8-6-20/h1-4,9,21H,5-8H2,(H,16,17,18,19)
DMZDNHQ CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=CC=C4O
DMZDNHQ IK SWYYAXGUDZLFKO-UHFFFAOYSA-N
DMZDNHQ IU 2-(6-morpholin-4-yl-7H-purin-2-yl)phenol
DMZDNHQ DE Discovery agent
DMR3Z1D ID DMR3Z1D
DMR3Z1D DN 2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3H)-one
DMR3Z1D HS Investigative
DMR3Z1D DT Small molecular drug
DMR3Z1D PC 135899263
DMR3Z1D MW 307.4
DMR3Z1D FM C19H21N3O
DMR3Z1D IC InChI=1S/C19H21N3O/c23-19-16-12-8-14-20-18(16)21-17(22-19)13-7-2-1-4-9-15-10-5-3-6-11-15/h3,5-6,8,10-12,14H,1-2,4,7,9,13H2,(H,20,21,22,23)
DMR3Z1D CS C1=CC=C(C=C1)CCCCCCC2=NC3=C(C=CC=N3)C(=O)N2
DMR3Z1D IK WWIOUCLIAKKTPW-UHFFFAOYSA-N
DMR3Z1D IU 2-(6-phenylhexyl)-3H-pyrido[2,3-d]pyrimidin-4-one
DMR3Z1D DE Discovery agent
DMD2QVO ID DMD2QVO
DMD2QVO DN 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine
DMD2QVO HS Investigative
DMD2QVO SN 7-Benzyloxytryptamine; 31677-75-5; 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine; CHEMBL460302; 2-[7-(benzyloxy)-1h-indol-3-yl]ethanamine; JOYGWYISRWPUIM-UHFFFAOYSA-N; 3-(2-AMINOETHYL)-7-BENZYLOXYINDOLE; 1H-Indole-3-ethanamine,7-(phenylmethoxy)-; B-2160; NSC92541; 7-Benzyloxytriptamine; AC1Q57HL; SCHEMBL5167328; AC1L63X1; CTK4G7564; ZINC39096; 7-Benzyloxytryptamine, free base; DTXSID60293835; 6038AH; NSC-92541; BDBM50247069; AKOS024282335; 7-(Benzyloxy)-1H-indole-3-ethanamine; MCULE-8072963757; ACM31677755; ST055630
DMD2QVO DT Small molecular drug
DMD2QVO PC 260806
DMD2QVO MW 266.34
DMD2QVO FM C17H18N2O
DMD2QVO IC InChI=1S/C17H18N2O/c18-10-9-14-11-19-17-15(14)7-4-8-16(17)20-12-13-5-2-1-3-6-13/h1-8,11,19H,9-10,12,18H2
DMD2QVO CS C1=CC=C(C=C1)COC2=CC=CC3=C2NC=C3CCN
DMD2QVO IK JOYGWYISRWPUIM-UHFFFAOYSA-N
DMD2QVO IU 2-(7-phenylmethoxy-1H-indol-3-yl)ethanamine
DMD2QVO CA CAS 31677-75-5
DMD2QVO DE Discovery agent
DMJAEZ8 ID DMJAEZ8
DMJAEZ8 DN 2-(7-phenylheptanoyl)oxazole-4-carbaldehyde
DMJAEZ8 HS Investigative
DMJAEZ8 SN CHEMBL461315; 2-(7-phenylheptanoyl)oxazole-4-carbaldehyde; SCHEMBL2162538
DMJAEZ8 DT Small molecular drug
DMJAEZ8 PC 44554445
DMJAEZ8 MW 285.34
DMJAEZ8 FM C17H19NO3
DMJAEZ8 IC InChI=1S/C17H19NO3/c19-12-15-13-21-17(18-15)16(20)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,12-13H,1-2,4,7-8,11H2
DMJAEZ8 CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C=O
DMJAEZ8 IK CLWIISIKUDVYMX-UHFFFAOYSA-N
DMJAEZ8 IU 2-(7-phenylheptanoyl)-1,3-oxazole-4-carbaldehyde
DMJAEZ8 DE Discovery agent
DMVSL49 ID DMVSL49
DMVSL49 DN 2-(7-phenylheptanoyl)oxazole-4-carbonitrile
DMVSL49 HS Investigative
DMVSL49 SN CHEMBL462423; 2-(7-phenylheptanoyl)oxazole-4-carbonitrile; SCHEMBL2162448; IGDLMZPDBOKHRJ-UHFFFAOYSA-N
DMVSL49 DT Small molecular drug
DMVSL49 PC 25147546
DMVSL49 MW 282.34
DMVSL49 FM C17H18N2O2
DMVSL49 IC InChI=1S/C17H18N2O2/c18-12-15-13-21-17(19-15)16(20)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,13H,1-2,4,7-8,11H2
DMVSL49 CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C#N
DMVSL49 IK IGDLMZPDBOKHRJ-UHFFFAOYSA-N
DMVSL49 IU 2-(7-phenylheptanoyl)-1,3-oxazole-4-carbonitrile
DMVSL49 DE Discovery agent
DM9JMF2 ID DM9JMF2
DM9JMF2 DN 2-(7-phenylheptanoyl)oxazole-4-carboxamide
DM9JMF2 HS Investigative
DM9JMF2 SN 2-(7-phenylheptanoyl)oxazole-4-carboxamide; CHEMBL460492; SCHEMBL2162480; ZOLDFPZCQMAAPD-UHFFFAOYSA-N
DM9JMF2 DT Small molecular drug
DM9JMF2 PC 44554616
DM9JMF2 MW 300.35
DM9JMF2 FM C17H20N2O3
DM9JMF2 IC InChI=1S/C17H20N2O3/c18-16(21)14-12-22-17(19-14)15(20)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2,(H2,18,21)
DM9JMF2 CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C(=O)N
DM9JMF2 IK ZOLDFPZCQMAAPD-UHFFFAOYSA-N
DM9JMF2 IU 2-(7-phenylheptanoyl)-1,3-oxazole-4-carboxamide
DM9JMF2 DE Discovery agent
DM9BE2S ID DM9BE2S
DM9BE2S DN 2-(7-phenylheptanoyl)oxazole-4-carboxylic acid
DM9BE2S HS Investigative
DM9BE2S SN CHEMBL460317; 2-(7-phenylheptanoyl)oxazole-4-carboxylic acid; SCHEMBL2162839; UJGLCAJZAMDFHN-UHFFFAOYSA-N
DM9BE2S DT Small molecular drug
DM9BE2S PC 44554615
DM9BE2S MW 301.34
DM9BE2S FM C17H19NO4
DM9BE2S IC InChI=1S/C17H19NO4/c19-15(16-18-14(12-22-16)17(20)21)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2,(H,20,21)
DM9BE2S CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C(=O)O
DM9BE2S IK UJGLCAJZAMDFHN-UHFFFAOYSA-N
DM9BE2S IU 2-(7-phenylheptanoyl)-1,3-oxazole-4-carboxylic acid
DM9BE2S DE Discovery agent
DM89RYN ID DM89RYN
DM89RYN DN 2-(7-phenylheptanoyl)oxazole-5-carbonitrile
DM89RYN HS Investigative
DM89RYN SN CHEMBL220770; 2-(7-phenylheptanoyl)oxazole-5-carbonitrile; 2-(7-phenylheptanoyl)-1,3-oxazole-5-carbonitrile; SCHEMBL3144301; JOWNZAGZZQQDKI-UHFFFAOYSA-N
DM89RYN DT Small molecular drug
DM89RYN PC 11991895
DM89RYN MW 282.34
DM89RYN FM C17H18N2O2
DM89RYN IC InChI=1S/C17H18N2O2/c18-12-15-13-19-17(21-15)16(20)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,13H,1-2,4,7-8,11H2
DM89RYN CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C#N
DM89RYN IK JOWNZAGZZQQDKI-UHFFFAOYSA-N
DM89RYN IU 2-(7-phenylheptanoyl)-1,3-oxazole-5-carbonitrile
DM89RYN DE Discovery agent
DMB53ML ID DMB53ML
DMB53ML DN 2-(7-phenylheptanoyl)oxazole-5-carboxylic acid
DMB53ML HS Investigative
DMB53ML SN CHEMBL220729; 2-(7-phenylheptanoyl)oxazole-5-carboxylic acid; SCHEMBL1471352; 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic Acid; YYZORCCDLMGZTQ-UHFFFAOYSA-N
DMB53ML DT Small molecular drug
DMB53ML PC 11991892
DMB53ML MW 301.34
DMB53ML FM C17H19NO4
DMB53ML IC InChI=1S/C17H19NO4/c19-14(16-18-12-15(22-16)17(20)21)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2,(H,20,21)
DMB53ML CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C(=O)O
DMB53ML IK YYZORCCDLMGZTQ-UHFFFAOYSA-N
DMB53ML IU 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylic acid
DMB53ML DE Discovery agent
DMLQ9WD ID DMLQ9WD
DMLQ9WD DN 2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione
DMLQ9WD HS Investigative
DMLQ9WD SN CHEMBL166834; 2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione; SCHEMBL10839307; UYNFUMGZMJRXFD-UHFFFAOYSA-N; BDBM50024111
DMLQ9WD DT Small molecular drug
DMLQ9WD PC 13580028
DMLQ9WD MW 325.4
DMLQ9WD FM C19H23N3O2
DMLQ9WD IC InChI=1S/C19H23N3O2/c23-18-16-9-5-6-10-17(16)19(24)22(18)13-8-4-2-1-3-7-12-21-14-11-20-15-21/h5-6,9-11,14-15H,1-4,7-8,12-13H2
DMLQ9WD CS C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCCCCN3C=CN=C3
DMLQ9WD IK UYNFUMGZMJRXFD-UHFFFAOYSA-N
DMLQ9WD IU 2-(8-imidazol-1-yloctyl)isoindole-1,3-dione
DMLQ9WD DE Discovery agent
DMRW475 ID DMRW475
DMRW475 DN 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
DMRW475 HS Investigative
DMRW475 SN CHEMBL595158; BDBM35924; 9,10-dihydroanthracene(DHA), 2b
DMRW475 DT Small molecular drug
DMRW475 PC 44521012
DMRW475 MW 237.34
DMRW475 FM C17H19N
DMRW475 IC InChI=1S/C17H19N/c1-18-11-10-17-15-8-4-2-6-13(15)12-14-7-3-5-9-16(14)17/h2-9,17-18H,10-12H2,1H3
DMRW475 CS CNCCC1C2=CC=CC=C2CC3=CC=CC=C13
DMRW475 IK PVWQFOKNAQZORV-UHFFFAOYSA-N
DMRW475 IU 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine
DMRW475 DE Discovery agent
DMPJ0O6 ID DMPJ0O6
DMPJ0O6 DN 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol
DMPJ0O6 HS Investigative
DMPJ0O6 SN MLS000083858; AC1LDHLL; CHEMBL7291; MolPort-002-645-925; HMS2407L21; ZINC2352774; STL140995; AKOS005714812; MCULE-9452123598; 2-[(9-benzylpurin-6-yl)amino]ethanol; SMR000048556; 112089-01-7
DMPJ0O6 DT Small molecular drug
DMPJ0O6 PC 667207
DMPJ0O6 MW 269.3
DMPJ0O6 FM C14H15N5O
DMPJ0O6 IC InChI=1S/C14H15N5O/c20-7-6-15-13-12-14(17-9-16-13)19(10-18-12)8-11-4-2-1-3-5-11/h1-5,9-10,20H,6-8H2,(H,15,16,17)
DMPJ0O6 CS C1=CC=C(C=C1)CN2C=NC3=C(N=CN=C32)NCCO
DMPJ0O6 IK ZOVSVHTVIDXQPS-UHFFFAOYSA-N
DMPJ0O6 IU 2-[(9-benzylpurin-6-yl)amino]ethanol
DMPJ0O6 DE Discovery agent
DMOUG6Y ID DMOUG6Y
DMOUG6Y DN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose
DMOUG6Y HS Investigative
DMOUG6Y SN Beta-N-Acetylglucosamine; betaGlcNAc; GlcNAc-beta; CHEBI:28009; UNII-8P59336F68; 2-Acetamido-2-deoxy-beta-D-glucose; AI3-51898; 8P59336F68; N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]acetamide; Cheon shim bo yun
DMOUG6Y DT Small molecular drug
DMOUG6Y PC 82313
DMOUG6Y MW 221.21
DMOUG6Y FM C8H15NO6
DMOUG6Y IC InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8+/m1/s1
DMOUG6Y CS CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O
DMOUG6Y IK OVRNDRQMDRJTHS-PVFLNQBWSA-N
DMOUG6Y IU N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMOUG6Y CA CAS 10036-64-3
DMOUG6Y CB CHEBI:44278
DMOUG6Y DE Discovery agent
DMB3YXG ID DMB3YXG
DMB3YXG DN 2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one
DMB3YXG HS Investigative
DMB3YXG DT Small molecular drug
DMB3YXG PC 135950102
DMB3YXG MW 290.4
DMB3YXG FM C17H26N2O2
DMB3YXG IC InChI=1S/C17H26N2O2/c1-3-17(4-2)14(20)18-15(21-17)19-16-8-11-5-12(9-16)7-13(6-11)10-16/h11-13H,3-10H2,1-2H3,(H,18,19,20)
DMB3YXG CS CCC1(C(=O)NC(=NC23CC4CC(C2)CC(C4)C3)O1)CC
DMB3YXG IK RHBIZJSBQCBDJJ-UHFFFAOYSA-N
DMB3YXG IU 2-(1-adamantylimino)-5,5-diethyl-1,3-oxazolidin-4-one
DMB3YXG DE Discovery agent
DM6P20R ID DM6P20R
DM6P20R DN 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide
DM6P20R HS Investigative
DM6P20R SN CHEMBL402719; 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide; SCHEMBL8150833
DM6P20R DT Small molecular drug
DM6P20R PC 25065931
DM6P20R MW 320.4
DM6P20R FM C17H24N2O4
DM6P20R IC InChI=1S/C17H24N2O4/c1-2-13-23-15(11-7-4-8-12-16(20)19-22)17(21)18-14-9-5-3-6-10-14/h2-3,5-6,9-10,15,22H,1,4,7-8,11-13H2,(H,18,21)(H,19,20)
DM6P20R CS C=CCOC(CCCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DM6P20R IK KPKWEJNZWZGOID-UHFFFAOYSA-N
DM6P20R IU N'-hydroxy-N-phenyl-2-prop-2-enoxyoctanediamide
DM6P20R DE Discovery agent
DMU4MIC ID DMU4MIC
DMU4MIC DN 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran
DMU4MIC HS Investigative
DMU4MIC SN CHEMBL511163; SCHEMBL4615998; BDBM50276460
DMU4MIC DT Small molecular drug
DMU4MIC PC 11514389
DMU4MIC MW 255.35
DMU4MIC FM C17H21NO
DMU4MIC IC InChI=1S/C17H21NO/c18-12-16-11-10-15(19-16)9-8-14-6-3-5-13-4-1-2-7-17(13)14/h1-7,15-16H,8-12,18H2
DMU4MIC CS C1CC(OC1CCC2=CC=CC3=CC=CC=C32)CN
DMU4MIC IK QLXIMJBRAWACSR-UHFFFAOYSA-N
DMU4MIC IU [5-(2-naphthalen-1-ylethyl)oxolan-2-yl]methanamine
DMU4MIC DE Discovery agent
DMCUTY9 ID DMCUTY9
DMCUTY9 DN 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran
DMCUTY9 HS Investigative
DMCUTY9 SN CHEMBL456638; SCHEMBL2689095; BDBM50276458
DMCUTY9 DT Small molecular drug
DMCUTY9 PC 11572135
DMCUTY9 MW 227.3
DMCUTY9 FM C15H17NO
DMCUTY9 IC InChI=1S/C15H17NO/c16-10-12-8-9-15(17-12)14-7-3-5-11-4-1-2-6-13(11)14/h1-7,12,15H,8-10,16H2
DMCUTY9 CS C1CC(OC1CN)C2=CC=CC3=CC=CC=C32
DMCUTY9 IK HDLNQDARKJUPIY-UHFFFAOYSA-N
DMCUTY9 IU (5-naphthalen-1-yloxolan-2-yl)methanamine
DMCUTY9 DE Discovery agent
DM157SO ID DM157SO
DM157SO DN 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran
DM157SO HS Investigative
DM157SO SN CHEMBL504028; SCHEMBL2690271; BDBM50276457
DM157SO DT Small molecular drug
DM157SO PC 11637187
DM157SO MW 227.3
DM157SO FM C15H17NO
DM157SO IC InChI=1S/C15H17NO/c16-10-14-7-8-15(17-14)13-6-5-11-3-1-2-4-12(11)9-13/h1-6,9,14-15H,7-8,10,16H2
DM157SO CS C1CC(OC1CN)C2=CC3=CC=CC=C3C=C2
DM157SO IK BVTKYAZPIRQNNS-UHFFFAOYSA-N
DM157SO IU (5-naphthalen-2-yloxolan-2-yl)methanamine
DM157SO DE Discovery agent
DMEZ7O2 ID DMEZ7O2
DMEZ7O2 DN 2-(Aminomethyl)-5-phenethyltetrahydrofuran
DMEZ7O2 HS Investigative
DMEZ7O2 SN CHEMBL456639; 2-(Aminomethyl)-5-phenethyltetrahydrofuran; SCHEMBL2691411
DMEZ7O2 DT Small molecular drug
DMEZ7O2 PC 11506691
DMEZ7O2 MW 205.3
DMEZ7O2 FM C13H19NO
DMEZ7O2 IC InChI=1S/C13H19NO/c14-10-13-9-8-12(15-13)7-6-11-4-2-1-3-5-11/h1-5,12-13H,6-10,14H2
DMEZ7O2 CS C1CC(OC1CCC2=CC=CC=C2)CN
DMEZ7O2 IK LKTJWDXCFJJUGY-UHFFFAOYSA-N
DMEZ7O2 IU [5-(2-phenylethyl)oxolan-2-yl]methanamine
DMEZ7O2 DE Discovery agent
DMO3G6Q ID DMO3G6Q
DMO3G6Q DN 2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one
DMO3G6Q HS Investigative
DMO3G6Q SN CHEMBL222545; 2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one
DMO3G6Q DT Small molecular drug
DMO3G6Q PC 16204045
DMO3G6Q MW 297.3
DMO3G6Q FM C17H15NO4
DMO3G6Q IC InChI=1S/C17H15NO4/c19-13-10-16(15-9-12-3-1-2-4-14(12)21-15)22-17(11-13)18-5-7-20-8-6-18/h1-4,9-11H,5-8H2
DMO3G6Q CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC4=CC=CC=C4O3
DMO3G6Q IK FFDIMOCTDZWGJB-UHFFFAOYSA-N
DMO3G6Q IU 2-(1-benzofuran-2-yl)-6-morpholin-4-ylpyran-4-one
DMO3G6Q DE Discovery agent
DMW27AC ID DMW27AC
DMW27AC DN 2-(benzylamino)-5,5-diethyloxazol-4(5H)-one
DMW27AC HS Investigative
DMW27AC DT Small molecular drug
DMW27AC PC 135950109
DMW27AC MW 246.3
DMW27AC FM C14H18N2O2
DMW27AC IC InChI=1S/C14H18N2O2/c1-3-14(4-2)12(17)16-13(18-14)15-10-11-8-6-5-7-9-11/h5-9H,3-4,10H2,1-2H3,(H,15,16,17)
DMW27AC CS CCC1(C(=O)NC(=NCC2=CC=CC=C2)O1)CC
DMW27AC IK UYIBORRFWIVHQJ-UHFFFAOYSA-N
DMW27AC IU 2-benzylimino-5,5-diethyl-1,3-oxazolidin-4-one
DMW27AC DE Discovery agent
DM4X6I9 ID DM4X6I9
DM4X6I9 DN 2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine
DM4X6I9 HS Investigative
DM4X6I9 SN CHEMBL199800; 2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine
DM4X6I9 DT Small molecular drug
DM4X6I9 PC 11631107
DM4X6I9 MW 318.4
DM4X6I9 FM C19H18N4O
DM4X6I9 IC InChI=1S/C19H18N4O/c1-14(24)22-17-9-5-8-16(10-17)18-12-20-13-19(23-18)21-11-15-6-3-2-4-7-15/h2-10,12-13H,11H2,1H3,(H,21,23)(H,22,24)
DM4X6I9 CS CC(=O)NC1=CC=CC(=C1)C2=CN=CC(=N2)NCC3=CC=CC=C3
DM4X6I9 IK APNYMHFAZCCZRG-UHFFFAOYSA-N
DM4X6I9 IU N-[3-[6-(benzylamino)pyrazin-2-yl]phenyl]acetamide
DM4X6I9 DE Discovery agent
DM3VJLZ ID DM3VJLZ
DM3VJLZ DN 2-(benzylideneamino)ethanesulfonamide
DM3VJLZ HS Investigative
DM3VJLZ SN 2-(benzylideneamino)ethanesulfonamide; CHEMBL574337
DM3VJLZ DT Small molecular drug
DM3VJLZ PC 45483186
DM3VJLZ MW 212.27
DM3VJLZ FM C9H12N2O2S
DM3VJLZ IC InChI=1S/C9H12N2O2S/c10-14(12,13)7-6-11-8-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,10,12,13)
DM3VJLZ CS C1=CC=C(C=C1)C=NCCS(=O)(=O)N
DM3VJLZ IK TZIDZFKPPIWVBP-UHFFFAOYSA-N
DM3VJLZ IU 2-(benzylideneamino)ethanesulfonamide
DM3VJLZ DE Discovery agent
DM48C7G ID DM48C7G
DM48C7G DN 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide
DM48C7G HS Investigative
DM48C7G SN CHEMBL402718; 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide; SCHEMBL8152458
DM48C7G DT Small molecular drug
DM48C7G PC 25065925
DM48C7G MW 356.4
DM48C7G FM C20H24N2O4
DM48C7G IC InChI=1S/C20H24N2O4/c23-19(22-25)14-8-7-13-18(26-15-16-9-3-1-4-10-16)20(24)21-17-11-5-2-6-12-17/h1-6,9-12,18,25H,7-8,13-15H2,(H,21,24)(H,22,23)
DM48C7G CS C1=CC=C(C=C1)COC(CCCCC(=O)NO)C(=O)NC2=CC=CC=C2
DM48C7G IK DGQYQVJKMZAQBV-UHFFFAOYSA-N
DM48C7G IU N'-hydroxy-N-phenyl-2-phenylmethoxyheptanediamide
DM48C7G DE Discovery agent
DME50RZ ID DME50RZ
DME50RZ DN 2-(benzyloxy)naphthalene
DME50RZ HS Investigative
DME50RZ SN Benzyl 2-naphthyl ether; 613-62-7; 2-(benzyloxy)naphthalene; 2-Benzyloxynaphthalene; Naphthalene, 2-(phenylmethoxy)-; 2-(phenylmethoxy)naphthalene; 2-Benzyloxy-naphthalene; 2-phenylmethoxynaphthalene; CHEMBL146439; Q-200695; 2-(Phenylmethoxy)-naphthalene; Benzyl2-naphthylether; 2-Phenylmethoxy naphthalenen; b-naphthylbenzyl ether; ss-Naphtholbenzylaether; benzyl-2-naphthylether; ACMC-209mru; AI3-00945; AC1L3VTE; beta-naphthyl benzyl ether; EC 405-490-3; SCHEMBL51460; KSC493E6R; CTK3J3268; DTXSID80210201; MolPort-002-476-516
DME50RZ DT Small molecular drug
DME50RZ PC 123080
DME50RZ MW 234.29
DME50RZ FM C17H14O
DME50RZ IC InChI=1S/C17H14O/c1-2-6-14(7-3-1)13-18-17-11-10-15-8-4-5-9-16(15)12-17/h1-12H,13H2
DME50RZ CS C1=CC=C(C=C1)COC2=CC3=CC=CC=C3C=C2
DME50RZ IK WLTCCDHHWYAMCG-UHFFFAOYSA-N
DME50RZ IU 2-phenylmethoxynaphthalene
DME50RZ CA CAS 613-62-7
DME50RZ DE Discovery agent
DMSNCOW ID DMSNCOW
DMSNCOW DN 2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide
DMSNCOW HS Investigative
DMSNCOW SN CHEMBL228231; 2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide
DMSNCOW DT Small molecular drug
DMSNCOW PC 16721024
DMSNCOW MW 252.31
DMSNCOW FM C13H20N2O3
DMSNCOW IC InChI=1S/C13H20N2O3/c1-3-10(2)12(13(16)14-17)15-18-9-11-7-5-4-6-8-11/h4-8,10,12,15,17H,3,9H2,1-2H3,(H,14,16)
DMSNCOW CS CCC(C)C(C(=O)NO)NOCC1=CC=CC=C1
DMSNCOW IK OISVGEVVTLNTBZ-UHFFFAOYSA-N
DMSNCOW IU N-hydroxy-3-methyl-2-(phenylmethoxyamino)pentanamide
DMSNCOW DE Discovery agent
DMHZJXG ID DMHZJXG
DMHZJXG DN 2-(benzyloxyamino)-N-hydroxyacetamide
DMHZJXG HS Investigative
DMHZJXG SN CHEMBL226149; 2-(benzyloxyamino)-N-hydroxyacetamide
DMHZJXG DT Small molecular drug
DMHZJXG PC 44423683
DMHZJXG MW 196.2
DMHZJXG FM C9H12N2O3
DMHZJXG IC InChI=1S/C9H12N2O3/c12-9(11-13)6-10-14-7-8-4-2-1-3-5-8/h1-5,10,13H,6-7H2,(H,11,12)
DMHZJXG CS C1=CC=C(C=C1)CONCC(=O)NO
DMHZJXG IK PMVJGZGFFBJYLQ-UHFFFAOYSA-N
DMHZJXG IU N-hydroxy-2-(phenylmethoxyamino)acetamide
DMHZJXG DE Discovery agent
DMOUKTH ID DMOUKTH
DMOUKTH DN 2-(benzyloxyamino)-N-hydroxyhexanamide
DMOUKTH HS Investigative
DMOUKTH SN CHEMBL228230; 2-(benzyloxyamino)-N-hydroxyhexanamide
DMOUKTH DT Small molecular drug
DMOUKTH PC 44423686
DMOUKTH MW 252.31
DMOUKTH FM C13H20N2O3
DMOUKTH IC InChI=1S/C13H20N2O3/c1-2-3-9-12(13(16)14-17)15-18-10-11-7-5-4-6-8-11/h4-8,12,15,17H,2-3,9-10H2,1H3,(H,14,16)
DMOUKTH CS CCCCC(C(=O)NO)NOCC1=CC=CC=C1
DMOUKTH IK MTXWGHZYBWXADO-UHFFFAOYSA-N
DMOUKTH IU N-hydroxy-2-(phenylmethoxyamino)hexanamide
DMOUKTH DE Discovery agent
DM0C5O3 ID DM0C5O3
DM0C5O3 DN 2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine
DM0C5O3 HS Investigative
DM0C5O3 SN CHEMBL20666; N,N-dimethyl-2-(2-phenylphenoxy)ethanamine; 2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine; AC1LHJ83; ZINC4913607; BDBM50307494; MCULE-6428005896
DM0C5O3 DT Small molecular drug
DM0C5O3 PC 888197
DM0C5O3 MW 241.33
DM0C5O3 FM C16H19NO
DM0C5O3 IC InChI=1S/C16H19NO/c1-17(2)12-13-18-16-11-7-6-10-15(16)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3
DM0C5O3 CS CN(C)CCOC1=CC=CC=C1C2=CC=CC=C2
DM0C5O3 IK HEGXUUYKFGNKJB-UHFFFAOYSA-N
DM0C5O3 IU N,N-dimethyl-2-(2-phenylphenoxy)ethanamine
DM0C5O3 DE Discovery agent
DM9XZSC ID DM9XZSC
DM9XZSC DN 2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine
DM9XZSC HS Investigative
DM9XZSC SN CHEMBL607584; 2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine; ZINC45387798
DM9XZSC DT Small molecular drug
DM9XZSC PC 46233381
DM9XZSC MW 257.399
DM9XZSC FM C16H19NS
DM9XZSC IC InChI=1S/C16H19NS/c1-17(2)12-13-18-16-11-7-6-10-15(16)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3
DM9XZSC CS CN(C)CCSC1=CC=CC=C1C2=CC=CC=C2
DM9XZSC IK CIOXNSHCQPHJOE-UHFFFAOYSA-N
DM9XZSC IU N,N-dimethyl-2-(2-phenylphenyl)sulfanylethanamine
DM9XZSC DE Discovery agent
DMU0GDY ID DMU0GDY
DMU0GDY DN 2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine
DMU0GDY HS Investigative
DMU0GDY SN CHEMBL597981; 2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine
DMU0GDY DT Small molecular drug
DMU0GDY PC 46233485
DMU0GDY MW 257.399
DMU0GDY FM C16H19NS
DMU0GDY IC InChI=1S/C16H19NS/c1-17(2)11-12-18-16-10-6-9-15(13-16)14-7-4-3-5-8-14/h3-10,13H,11-12H2,1-2H3
DMU0GDY CS CN(C)CCSC1=CC=CC(=C1)C2=CC=CC=C2
DMU0GDY IK NDJKJLMJAGRKRK-UHFFFAOYSA-N
DMU0GDY IU N,N-dimethyl-2-(3-phenylphenyl)sulfanylethanamine
DMU0GDY DE Discovery agent
DMRQOKB ID DMRQOKB
DMRQOKB DN 2-(biphenyl-4-yl)vinylboronic acid
DMRQOKB HS Investigative
DMRQOKB SN 352530-23-5; trans-2-(4-Biphenyl)vinylboronic acid; (2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid; (E)-(2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid; AC1O0CFW; Alkenylboronic Acid, 22; 4-Phenylstyrylboronic acid; CHEMBL453758; SCHEMBL2910475; SCHEMBL12260418; C14H13BO2; BDBM26143; DTXSID30421729; ZINC169870786; AKOS015893176; FCH5518572; AB21449; RTR-014581; KB-61854; BBV-43957496; ACM352530235; OR360465; AX8240126; [(E)-2-(4-phenylphenyl)ethenyl]boranediol; V5431; [(E)-2-(4-phenylphenyl)ethenyl]boronic acid; B-4710; I04-2357
DMRQOKB DT Small molecular drug
DMRQOKB PC 6011033
DMRQOKB MW 224.06
DMRQOKB FM C14H13BO2
DMRQOKB IC InChI=1S/C14H13BO2/c16-15(17)11-10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-11,16-17H/b11-10+
DMRQOKB CS B(/C=C/C1=CC=C(C=C1)C2=CC=CC=C2)(O)O
DMRQOKB IK NTRGFVQIGQYKIL-ZHACJKMWSA-N
DMRQOKB IU [(E)-2-(4-phenylphenyl)ethenyl]boronic acid
DMRQOKB CA CAS 352530-23-5
DMRQOKB DE Discovery agent
DM3PWK7 ID DM3PWK7
DM3PWK7 DN 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide
DM3PWK7 HS Investigative
DM3PWK7 SN CHEMBL550148; 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide; 3f17; BDBM50294120
DM3PWK7 DT Small molecular drug
DM3PWK7 PC 25049753
DM3PWK7 MW 306.34
DM3PWK7 FM C14H14N2O4S
DM3PWK7 IC InChI=1S/C14H14N2O4S/c17-14(16-18)10-15-21(19,20)13-8-6-12(7-9-13)11-4-2-1-3-5-11/h1-9,15,18H,10H2,(H,16,17)
DM3PWK7 CS C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NCC(=O)NO
DM3PWK7 IK NKGRTRASISLCCZ-UHFFFAOYSA-N
DM3PWK7 IU N-hydroxy-2-[(4-phenylphenyl)sulfonylamino]acetamide
DM3PWK7 DE Discovery agent
DMH3YBR ID DMH3YBR
DMH3YBR DN 2-(biphenyl-4-ylsulfonamido)pentanedioic acid
DMH3YBR HS Investigative
DMH3YBR SN CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; 2-(biphenyl-4-ylsulfonamido)pentanedioic acid; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid
DMH3YBR DT Small molecular drug
DMH3YBR PC 644601
DMH3YBR MW 363.4
DMH3YBR FM C17H17NO6S
DMH3YBR IC InChI=1S/C17H17NO6S/c19-16(20)11-10-15(17(21)22)18-25(23,24)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9,15,18H,10-11H2,(H,19,20)(H,21,22)
DMH3YBR CS C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NC(CCC(=O)O)C(=O)O
DMH3YBR IK IQGHPUPMOUUHPP-UHFFFAOYSA-N
DMH3YBR IU 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid
DMH3YBR CA CAS 193808-18-3
DMH3YBR CB CHEBI:91838
DMH3YBR DE Discovery agent
DMCNV5J ID DMCNV5J
DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J HS Investigative
DMCNV5J SN CHEMBL574589; 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide
DMCNV5J DT Small molecular drug
DMCNV5J PC 44478925
DMCNV5J MW 353.4
DMCNV5J FM C19H15NO4S
DMCNV5J IC InChI=1S/C19H15NO4S/c21-19(20-22)17-8-4-5-9-18(17)25(23,24)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,22H,(H,20,21)
DMCNV5J CS C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3C(=O)NO
DMCNV5J IK WQRJSSRVHCJAKB-UHFFFAOYSA-N
DMCNV5J IU N-hydroxy-2-(4-phenylphenyl)sulfonylbenzamide
DMCNV5J DE Discovery agent
DMFO7CH ID DMFO7CH
DMFO7CH DN 2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one
DMFO7CH HS Investigative
DMFO7CH SN CHEMBL1269398; 204503-10-6; 2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one; CTK0J0428; DTXSID10680655; BDBM50330110; AKOS030554091; 4H-Pyran-4-one, 2-[(butylthio)methyl]-5-hydroxy-
DMFO7CH DT Small molecular drug
DMFO7CH PC 52943048
DMFO7CH MW 214.28
DMFO7CH FM C10H14O3S
DMFO7CH IC InChI=1S/C10H14O3S/c1-2-3-4-14-7-8-5-9(11)10(12)6-13-8/h5-6,12H,2-4,7H2,1H3
DMFO7CH CS CCCCSCC1=CC(=O)C(=CO1)O
DMFO7CH IK PJEUFTMKXABORH-UHFFFAOYSA-N
DMFO7CH IU 2-(butylsulfanylmethyl)-5-hydroxypyran-4-one
DMFO7CH CA CAS 204503-10-6
DMFO7CH DE Discovery agent
DMA6P4J ID DMA6P4J
DMA6P4J DN 2-(Carbazole-9-sulfonyl)-benzoic acid
DMA6P4J HS Investigative
DMA6P4J SN CHEMBL364141; 2-(Carbazole-9-sulfonyl)-benzoic acid
DMA6P4J DT Small molecular drug
DMA6P4J PC 44393734
DMA6P4J MW 351.4
DMA6P4J FM C19H13NO4S
DMA6P4J IC InChI=1S/C19H13NO4S/c21-19(22)15-9-3-6-12-18(15)25(23,24)20-16-10-4-1-7-13(16)14-8-2-5-11-17(14)20/h1-12H,(H,21,22)
DMA6P4J CS C1=CC=C2C(=C1)C3=CC=CC=C3N2S(=O)(=O)C4=CC=CC=C4C(=O)O
DMA6P4J IK WVHKYPINALNKJJ-UHFFFAOYSA-N
DMA6P4J IU 2-carbazol-9-ylsulfonylbenzoic acid
DMA6P4J DE Discovery agent
DMQ2SNL ID DMQ2SNL
DMQ2SNL DN 2-(carboxymethylamino)-2-oxoacetic acid
DMQ2SNL HS Investigative
DMQ2SNL SN N-Oxalylglycine; 5262-39-5; Oxalylglycine; Oxaloglycine; 2-((Carboxymethyl)amino)-2-oxoacetic acid; UNII-VVW38EB8YS; N-(carboxycarbonyl)glycine; N-OXALYOLGLYCINE; VVW38EB8YS; 2-oxo-3-azaglutaric acid; CHEMBL90852; Glycine, N-(carboxycarbonyl)-; CHEBI:44482; OGA; C4H5NO5; 4idz; 4nrp; 2xml; 3hqr; N-oxalyl glycine, 1a; 2oq6; 1h2k; AC1MIVD0; Glycine,N-(carboxycarbonyl)-; SCHEMBL435820; BDBM26106; CTK8F0807; DTXSID20200601; MolPort-000-141-021; ZINC1534133; N-Oxalylglycine, > 4958AE
DMQ2SNL DT Small molecular drug
DMQ2SNL PC 3080614
DMQ2SNL MW 147.09
DMQ2SNL FM C4H5NO5
DMQ2SNL IC InChI=1S/C4H5NO5/c6-2(7)1-5-3(8)4(9)10/h1H2,(H,5,8)(H,6,7)(H,9,10)
DMQ2SNL CS C(C(=O)O)NC(=O)C(=O)O
DMQ2SNL IK BIMZLRFONYSTPT-UHFFFAOYSA-N
DMQ2SNL IU 2-(carboxymethylamino)-2-oxoacetic acid
DMQ2SNL CA CAS 5262-39-5
DMQ2SNL CB CHEBI:44482
DMQ2SNL DE Discovery agent
DM0PA6I ID DM0PA6I
DM0PA6I DN 2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3H)-one
DM0PA6I HS Investigative
DM0PA6I DT Small molecular drug
DM0PA6I PC 136127015
DM0PA6I MW 279.29
DM0PA6I FM C16H13N3O2
DM0PA6I IC InChI=1S/C16H13N3O2/c20-15-13-9-4-10-17-14(13)18-16(19-15)21-11-5-8-12-6-2-1-3-7-12/h1-10H,11H2,(H,17,18,19,20)/b8-5+
DM0PA6I CS C1=CC=C(C=C1)/C=C/COC2=NC3=C(C=CC=N3)C(=O)N2
DM0PA6I IK FROKBSNKSJMXTH-VMPITWQZSA-N
DM0PA6I IU 2-[(E)-3-phenylprop-2-enoxy]-3H-pyrido[2,3-d]pyrimidin-4-one
DM0PA6I DE Discovery agent
DMQ9ODG ID DMQ9ODG
DMQ9ODG DN 2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate
DMQ9ODG HS Investigative
DMQ9ODG SN CHEMBL550694; AC1P0KT3; MLS002166893; 2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate; MolPort-004-113-473; HMS3049I09; ZINC25561600; BDBM50295159; AKOS033614947; MCULE-1392821852; SMR001249231; SR-01000074735; SR-01000074735-1; Z18385694; (cycloheptylcarbamoyl)methyl 2-aminopyridine-3-carboxylate; [2-(cycloheptylamino)-2-oxoethyl] 2-aminopyridine-3-carboxylate
DMQ9ODG DT Small molecular drug
DMQ9ODG PC 8147464
DMQ9ODG MW 291.35
DMQ9ODG FM C15H21N3O3
DMQ9ODG IC InChI=1S/C15H21N3O3/c16-14-12(8-5-9-17-14)15(20)21-10-13(19)18-11-6-3-1-2-4-7-11/h5,8-9,11H,1-4,6-7,10H2,(H2,16,17)(H,18,19)
DMQ9ODG CS C1CCCC(CC1)NC(=O)COC(=O)C2=C(N=CC=C2)N
DMQ9ODG IK YLZFUORCIVHHHD-UHFFFAOYSA-N
DMQ9ODG IU [2-(cycloheptylamino)-2-oxoethyl] 2-aminopyridine-3-carboxylate
DMQ9ODG DE Discovery agent
DMPT0MB ID DMPT0MB
DMPT0MB DN 2-(cyclohexylamino)benzoic acid
DMPT0MB HS Investigative
DMPT0MB SN 2-(cyclohexylamino)benzoic acid; 10286-53-0; 2-CYCLOHEXYLAMINO-BENZOIC ACID; Oprea1_006076; SCHEMBL3274851; DTXSID60600368; MolPort-005-940-199; KS-00003TL8; ZINC21999434; AKOS009313819; DB07038; TS-03143; AJ-80046; Z1945984208
DMPT0MB DT Small molecular drug
DMPT0MB PC 19826721
DMPT0MB MW 219.28
DMPT0MB FM C13H17NO2
DMPT0MB IC InChI=1S/C13H17NO2/c15-13(16)11-8-4-5-9-12(11)14-10-6-2-1-3-7-10/h4-5,8-10,14H,1-3,6-7H2,(H,15,16)
DMPT0MB CS C1CCC(CC1)NC2=CC=CC=C2C(=O)O
DMPT0MB IK JSXMFCCPQQJLCR-UHFFFAOYSA-N
DMPT0MB IU 2-(cyclohexylamino)benzoic acid
DMPT0MB CA CAS 10286-53-0
DMPT0MB DE Discovery agent
DM2CAI1 ID DM2CAI1
DM2CAI1 DN 2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM2CAI1 HS Investigative
DM2CAI1 SN CHEMBL1269426; 2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM2CAI1 DT Small molecular drug
DM2CAI1 PC 23274383
DM2CAI1 MW 240.32
DM2CAI1 FM C12H16O3S
DM2CAI1 IC InChI=1S/C12H16O3S/c13-11-6-9(15-7-12(11)14)8-16-10-4-2-1-3-5-10/h6-7,10,14H,1-5,8H2
DM2CAI1 CS C1CCC(CC1)SCC2=CC(=O)C(=CO2)O
DM2CAI1 IK QOQLSVLZCVJKQA-UHFFFAOYSA-N
DM2CAI1 IU 2-(cyclohexylsulfanylmethyl)-5-hydroxypyran-4-one
DM2CAI1 DE Discovery agent
DMAPW5K ID DMAPW5K
DMAPW5K DN 2-(cyclooctylamino)-5,5-diethyloxazol-4(5H)-one
DMAPW5K HS Investigative
DMAPW5K DT Small molecular drug
DMAPW5K PC 135950111
DMAPW5K MW 266.38
DMAPW5K FM C15H26N2O2
DMAPW5K IC InChI=1S/C15H26N2O2/c1-3-15(4-2)13(18)17-14(19-15)16-12-10-8-6-5-7-9-11-12/h12H,3-11H2,1-2H3,(H,16,17,18)
DMAPW5K CS CCC1(C(=O)NC(=NC2CCCCCCC2)O1)CC
DMAPW5K IK RCJPILQMNSKTFG-UHFFFAOYSA-N
DMAPW5K IU 2-cyclooctylimino-5,5-diethyl-1,3-oxazolidin-4-one
DMAPW5K DE Discovery agent
DMZVMDO ID DMZVMDO
DMZVMDO DN 2-(difluoromethyl)-9H-carbazole
DMZVMDO HS Investigative
DMZVMDO SN CHEMBL1170284; 2-(difluoromethyl)-9H-carbazole
DMZVMDO DT Small molecular drug
DMZVMDO PC 46855212
DMZVMDO MW 217.21
DMZVMDO FM C13H9F2N
DMZVMDO IC InChI=1S/C13H9F2N/c14-13(15)8-5-6-10-9-3-1-2-4-11(9)16-12(10)7-8/h1-7,13,16H
DMZVMDO CS C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)C(F)F
DMZVMDO IK JHTSEXLNQMISRI-UHFFFAOYSA-N
DMZVMDO IU 2-(difluoromethyl)-9H-carbazole
DMZVMDO DE Discovery agent
DMS7WQD ID DMS7WQD
DMS7WQD DN 2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid
DMS7WQD HS Investigative
DMS7WQD SN 2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid; 138731-14-3; 2-(ethoxycarbonyl)indole-5-carboxylic acid; 1H-INDOLE-2,5-DICARBOXYLIC ACID 2-ETHYL ESTER; CHEMBL503643; CAVYPAYXEMVXMS-UHFFFAOYSA-N; 2-ETHOXYCABONYL-5-INDOLE CARBOXYLIC ACID; 2-ethoxycarbonyl-1H-indole-5-carboxylic acid; SCHEMBL1306748; AC1Q34A5; CTK6F6093; DTXSID70592508; MolPort-004-323-750; KS-00000BY1; STK695496; SBB019411; 1264AJ; ZINC14985904; BDBM50268451; AKOS000161198; MCULE-3298585220; AB49136; NCGC00341253-01; BS-14093; SY043081; AJ-66467
DMS7WQD DT Small molecular drug
DMS7WQD PC 18071365
DMS7WQD MW 233.22
DMS7WQD FM C12H11NO4
DMS7WQD IC InChI=1S/C12H11NO4/c1-2-17-12(16)10-6-8-5-7(11(14)15)3-4-9(8)13-10/h3-6,13H,2H2,1H3,(H,14,15)
DMS7WQD CS CCOC(=O)C1=CC2=C(N1)C=CC(=C2)C(=O)O
DMS7WQD IK CAVYPAYXEMVXMS-UHFFFAOYSA-N
DMS7WQD IU 2-ethoxycarbonyl-1H-indole-5-carboxylic acid
DMS7WQD CA CAS 138731-14-3
DMS7WQD DE Discovery agent
DM8GJCU ID DM8GJCU
DM8GJCU DN 2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM8GJCU HS Investigative
DM8GJCU SN CHEMBL1269349; 2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM8GJCU DT Small molecular drug
DM8GJCU PC 52944229
DM8GJCU MW 186.23
DM8GJCU FM C8H10O3S
DM8GJCU IC InChI=1S/C8H10O3S/c1-2-12-5-6-3-7(9)8(10)4-11-6/h3-4,10H,2,5H2,1H3
DM8GJCU CS CCSCC1=CC(=O)C(=CO1)O
DM8GJCU IK BOZGBIVLELURMD-UHFFFAOYSA-N
DM8GJCU IU 2-(ethylsulfanylmethyl)-5-hydroxypyran-4-one
DM8GJCU DE Discovery agent
DM6BHUF ID DM6BHUF
DM6BHUF DN 2-(furan-2-yl)-6-morpholino-4H-pyran-4-one
DM6BHUF HS Investigative
DM6BHUF SN CHEMBL223775; 2-(furan-2-yl)-6-morpholino-4H-pyran-4-one
DM6BHUF DT Small molecular drug
DM6BHUF PC 16203943
DM6BHUF MW 247.25
DM6BHUF FM C13H13NO4
DM6BHUF IC InChI=1S/C13H13NO4/c15-10-8-12(11-2-1-5-17-11)18-13(9-10)14-3-6-16-7-4-14/h1-2,5,8-9H,3-4,6-7H2
DM6BHUF CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CO3
DM6BHUF IK AHAIOLWQJGMAQA-UHFFFAOYSA-N
DM6BHUF IU 2-(furan-2-yl)-6-morpholin-4-ylpyran-4-one
DM6BHUF DE Discovery agent
DM490BL ID DM490BL
DM490BL DN 2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM490BL HS Investigative
DM490BL SN CHEMBL1269401; 2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM490BL DT Small molecular drug
DM490BL PC 52949129
DM490BL MW 256.36
DM490BL FM C13H20O3S
DM490BL IC InChI=1S/C13H20O3S/c1-2-3-4-5-6-7-17-10-11-8-12(14)13(15)9-16-11/h8-9,15H,2-7,10H2,1H3
DM490BL CS CCCCCCCSCC1=CC(=O)C(=CO1)O
DM490BL IK ZRHZWPMLQKIVHQ-UHFFFAOYSA-N
DM490BL IU 2-(heptylsulfanylmethyl)-5-hydroxypyran-4-one
DM490BL DE Discovery agent
DM7YLTS ID DM7YLTS
DM7YLTS DN 2-(hex-1-ynyl)-N6-methoxyadenosine
DM7YLTS HS Investigative
DM7YLTS SN CHEMBL220889; 2-(hex-1-ynyl)-N6-methoxyadenosine; SCHEMBL4384408
DM7YLTS DT Small molecular drug
DM7YLTS PC 10045125
DM7YLTS MW 377.4
DM7YLTS FM C17H23N5O5
DM7YLTS IC InChI=1S/C17H23N5O5/c1-3-4-5-6-7-11-19-15(21-26-2)12-16(20-11)22(9-18-12)17-14(25)13(24)10(8-23)27-17/h9-10,13-14,17,23-25H,3-5,8H2,1-2H3,(H,19,20,21)/t10-,13-,14-,17-/m1/s1
DM7YLTS CS CCCCC#CC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NOC
DM7YLTS IK NIZLYCJGSQRCLN-IWCJZZDYSA-N
DM7YLTS IU (2R,3R,4S,5R)-2-[2-hex-1-ynyl-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM7YLTS DE Discovery agent
DM235Q4 ID DM235Q4
DM235Q4 DN 2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one
DM235Q4 HS Investigative
DM235Q4 SN 2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one; CHEMBL1269400; 1257846-10-8
DM235Q4 DT Small molecular drug
DM235Q4 PC 50899743
DM235Q4 MW 242.34
DM235Q4 FM C12H18O3S
DM235Q4 IC InChI=1S/C12H18O3S/c1-2-3-4-5-6-16-9-10-7-11(13)12(14)8-15-10/h7-8,14H,2-6,9H2,1H3
DM235Q4 CS CCCCCCSCC1=CC(=O)C(=CO1)O
DM235Q4 IK TWEMRPGKBWBOSQ-UHFFFAOYSA-N
DM235Q4 IU 2-(hexylsulfanylmethyl)-5-hydroxypyran-4-one
DM235Q4 DE Discovery agent
DMOVYXT ID DMOVYXT
DMOVYXT DN 2-(indolin-1yl)-melatonin
DMOVYXT HS Investigative
DMOVYXT SN CHEMBL514415; 2-(indolin-1yl)-melatonin; GTPL7782; BDBM50266430; N-(2-{5-Methoxy-2-[(2,3-dihydro-1H-indol-1yl)methyl)]-1H-indol-3-yl}ethyl)acetamide
DMOVYXT DT Small molecular drug
DMOVYXT PC 25210130
DMOVYXT MW 363.5
DMOVYXT FM C22H25N3O2
DMOVYXT IC InChI=1S/C22H25N3O2/c1-15(26)23-11-9-18-19-13-17(27-2)7-8-20(19)24-21(18)14-25-12-10-16-5-3-4-6-22(16)25/h3-8,13,24H,9-12,14H2,1-2H3,(H,23,26)
DMOVYXT CS CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CN3CCC4=CC=CC=C43
DMOVYXT IK WPMBIMXWTHXWHN-UHFFFAOYSA-N
DMOVYXT IU N-[2-[2-(2,3-dihydroindol-1-ylmethyl)-5-methoxy-1H-indol-3-yl]ethyl]acetamide
DMOVYXT DE Discovery agent
DM1SIQD ID DM1SIQD
DM1SIQD DN 2-(methylsulfonyl)naphthalene-1,4-diol
DM1SIQD HS Investigative
DM1SIQD SN CHEMBL491752; 2-(methylsulfonyl)naphthalene-1,4-diol
DM1SIQD DT Small molecular drug
DM1SIQD PC 44562639
DM1SIQD MW 238.26
DM1SIQD FM C11H10O4S
DM1SIQD IC InChI=1S/C11H10O4S/c1-16(14,15)10-6-9(12)7-4-2-3-5-8(7)11(10)13/h2-6,12-13H,1H3
DM1SIQD CS CS(=O)(=O)C1=C(C2=CC=CC=C2C(=C1)O)O
DM1SIQD IK LDKPKJBNGZYJSR-UHFFFAOYSA-N
DM1SIQD IU 2-methylsulfonylnaphthalene-1,4-diol
DM1SIQD DE Discovery agent
DMM52D3 ID DMM52D3
DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate
DMM52D3 HS Investigative
DMM52D3 SN CHEMBL271677; 2-(methylsulfonylthio)ethyl 2-propylpentanoate; SCHEMBL4156413
DMM52D3 DT Small molecular drug
DMM52D3 PC 24759251
DMM52D3 MW 282.4
DMM52D3 FM C11H22O4S2
DMM52D3 IC InChI=1S/C11H22O4S2/c1-4-6-10(7-5-2)11(12)15-8-9-16-17(3,13)14/h10H,4-9H2,1-3H3
DMM52D3 CS CCCC(CCC)C(=O)OCCSS(=O)(=O)C
DMM52D3 IK ZHKBCGORMGLCBI-UHFFFAOYSA-N
DMM52D3 IU 2-methylsulfonylsulfanylethyl 2-propylpentanoate
DMM52D3 DE Discovery agent
DM15BA7 ID DM15BA7
DM15BA7 DN 2-(m-tolylethynyl)pyrimidine
DM15BA7 HS Investigative
DM15BA7 SN 2-(m-tolylethynyl)pyrimidine; CHEMBL496882
DM15BA7 DT Small molecular drug
DM15BA7 PC 44190040
DM15BA7 MW 194.23
DM15BA7 FM C13H10N2
DM15BA7 IC InChI=1S/C13H10N2/c1-11-4-2-5-12(10-11)6-7-13-14-8-3-9-15-13/h2-5,8-10H,1H3
DM15BA7 CS CC1=CC(=CC=C1)C#CC2=NC=CC=N2
DM15BA7 IK GHGMWMJKRGZKMW-UHFFFAOYSA-N
DM15BA7 IU 2-[2-(3-methylphenyl)ethynyl]pyrimidine
DM15BA7 DE Discovery agent
DMRNOM6 ID DMRNOM6
DMRNOM6 DN 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid
DMRNOM6 HS Investigative
DMRNOM6 SN CHEMBL398087; 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid
DMRNOM6 DT Small molecular drug
DMRNOM6 PC 44434501
DMRNOM6 MW 219.21
DMRNOM6 FM C12H10FNO2
DMRNOM6 IC InChI=1S/C12H10FNO2/c13-10-3-1-2-4-11(10)14-6-5-9(8-14)7-12(15)16/h1-6,8H,7H2,(H,15,16)
DMRNOM6 CS C1=CC=C(C(=C1)N2C=CC(=C2)CC(=O)O)F
DMRNOM6 IK FBDSYHLMZKXXBC-UHFFFAOYSA-N
DMRNOM6 IU 2-[1-(2-fluorophenyl)pyrrol-3-yl]acetic acid
DMRNOM6 DE Discovery agent
DMCL9E6 ID DMCL9E6
DMCL9E6 DN 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid
DMCL9E6 HS Investigative
DMCL9E6 SN CHEMBL236238; 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid; BDBM50213563
DMCL9E6 DT Small molecular drug
DMCL9E6 PC 44434500
DMCL9E6 MW 219.21
DMCL9E6 FM C12H10FNO2
DMCL9E6 IC InChI=1S/C12H10FNO2/c13-10-5-1-2-6-11(10)14-7-3-4-9(14)8-12(15)16/h1-7H,8H2,(H,15,16)
DMCL9E6 CS C1=CC=C(C(=C1)N2C=CC=C2CC(=O)O)F
DMCL9E6 IK XOJPIEDVJHMQEJ-UHFFFAOYSA-N
DMCL9E6 IU 2-[1-(2-fluorophenyl)pyrrol-2-yl]acetic acid
DMCL9E6 DE Discovery agent
DMVR248 ID DMVR248
DMVR248 DN 2-(N,N-Diethylamino)-3'-chloropropiophenone
DMVR248 HS Investigative
DMVR248 SN CHEMBL578815; SCHEMBL634022; BDBM50302915; AKOS009048034
DMVR248 DT Small molecular drug
DMVR248 PC 43227726
DMVR248 MW 239.74
DMVR248 FM C13H18ClNO
DMVR248 IC InChI=1S/C13H18ClNO/c1-4-15(5-2)10(3)13(16)11-7-6-8-12(14)9-11/h6-10H,4-5H2,1-3H3
DMVR248 CS CCN(CC)C(C)C(=O)C1=CC(=CC=C1)Cl
DMVR248 IK TZRAZPTWNAPWGU-UHFFFAOYSA-N
DMVR248 IU 1-(3-chlorophenyl)-2-(diethylamino)propan-1-one
DMVR248 DE Discovery agent
DMHYKR8 ID DMHYKR8
DMHYKR8 DN 2-(N''-Acetyl-hydrazino)-benzenesulfonamide
DMHYKR8 HS Investigative
DMHYKR8 SN hydrazide deriv. 19; CHEMBL175652; BDBM12164; 2-acetohydrazidobenzene-1-sulfonamide
DMHYKR8 DT Small molecular drug
DMHYKR8 PC 11160546
DMHYKR8 MW 229.26
DMHYKR8 FM C8H11N3O3S
DMHYKR8 IC InChI=1S/C8H11N3O3S/c1-6(12)10-11-7-4-2-3-5-8(7)15(9,13)14/h2-5,11H,1H3,(H,10,12)(H2,9,13,14)
DMHYKR8 CS CC(=O)NNC1=CC=CC=C1S(=O)(=O)N
DMHYKR8 IK NGNPYNHOTNXXJP-UHFFFAOYSA-N
DMHYKR8 IU 2-(2-acetylhydrazinyl)benzenesulfonamide
DMHYKR8 DE Discovery agent
DMKY71Z ID DMKY71Z
DMKY71Z DN 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole
DMKY71Z HS Investigative
DMKY71Z SN CHEMBL266155; 2-(2-Naphthyl)-1-imidazoline; 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole; 2-naphthalen-2-yl-4,5-dihydro-1H-imidazole; 113698-36-5; SCHEMBL9575180; DTXSID8048442; BGWRJAXPPYHIRG-UHFFFAOYSA-N; ZINC13805903
DMKY71Z DT Small molecular drug
DMKY71Z PC 11769428
DMKY71Z MW 196.25
DMKY71Z FM C13H12N2
DMKY71Z IC InChI=1S/C13H12N2/c1-2-4-11-9-12(6-5-10(11)3-1)13-14-7-8-15-13/h1-6,9H,7-8H2,(H,14,15)
DMKY71Z CS C1CN=C(N1)C2=CC3=CC=CC=C3C=C2
DMKY71Z IK BGWRJAXPPYHIRG-UHFFFAOYSA-N
DMKY71Z IU 2-naphthalen-2-yl-4,5-dihydro-1H-imidazole
DMKY71Z DE Discovery agent
DMEXBUF ID DMEXBUF
DMEXBUF DN 2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol
DMEXBUF HS Investigative
DMEXBUF SN CHEMBL462374; 2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol
DMEXBUF DT Small molecular drug
DMEXBUF PC 44562747
DMEXBUF MW 350.4
DMEXBUF FM C20H14O4S
DMEXBUF IC InChI=1S/C20H14O4S/c21-18-12-19(20(22)17-8-4-3-7-16(17)18)25(23,24)15-10-9-13-5-1-2-6-14(13)11-15/h1-12,21-22H
DMEXBUF CS C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)C3=C(C4=CC=CC=C4C(=C3)O)O
DMEXBUF IK NEXUTBMTXKQNMP-UHFFFAOYSA-N
DMEXBUF IU 2-naphthalen-2-ylsulfonylnaphthalene-1,4-diol
DMEXBUF DE Discovery agent
DML4GHA ID DML4GHA
DML4GHA DN 2-(N-Cyclopentylamino)-3'-bromopropiophenone
DML4GHA HS Investigative
DML4GHA SN CHEMBL599846; BDBM50308113
DML4GHA DT Small molecular drug
DML4GHA PC 45141380
DML4GHA MW 296.2
DML4GHA FM C14H18BrNO
DML4GHA IC InChI=1S/C14H18BrNO/c1-10(16-13-7-2-3-8-13)14(17)11-5-4-6-12(15)9-11/h4-6,9-10,13,16H,2-3,7-8H2,1H3
DML4GHA CS CC(C(=O)C1=CC(=CC=C1)Br)NC2CCCC2
DML4GHA IK ZZWUEOYQVWAKCJ-UHFFFAOYSA-N
DML4GHA IU 1-(3-bromophenyl)-2-(cyclopentylamino)propan-1-one
DML4GHA DE Discovery agent
DMP68CE ID DMP68CE
DMP68CE DN 2-(N-Cyclopentylamino)-3'-chloropropiophenone
DMP68CE HS Investigative
DMP68CE SN CHEMBL566618; SCHEMBL633829; BDBM50302916; 2-(N-Cyclopentylamino)-3''-chloropropiophenone
DMP68CE DT Small molecular drug
DMP68CE PC 44543272
DMP68CE MW 251.75
DMP68CE FM C14H18ClNO
DMP68CE IC InChI=1S/C14H18ClNO/c1-10(16-13-7-2-3-8-13)14(17)11-5-4-6-12(15)9-11/h4-6,9-10,13,16H,2-3,7-8H2,1H3
DMP68CE CS CC(C(=O)C1=CC(=CC=C1)Cl)NC2CCCC2
DMP68CE IK RPHSTODYKZLNFU-UHFFFAOYSA-N
DMP68CE IU 1-(3-chlorophenyl)-2-(cyclopentylamino)propan-1-one
DMP68CE DE Discovery agent
DMH6FKX ID DMH6FKX
DMH6FKX DN 2-(N-Cyclopentylamino)-3'-fluoropropiophenone
DMH6FKX HS Investigative
DMH6FKX SN CHEMBL605501; BDBM50308112
DMH6FKX DT Small molecular drug
DMH6FKX PC 45141379
DMH6FKX MW 235.3
DMH6FKX FM C14H18FNO
DMH6FKX IC InChI=1S/C14H18FNO/c1-10(16-13-7-2-3-8-13)14(17)11-5-4-6-12(15)9-11/h4-6,9-10,13,16H,2-3,7-8H2,1H3
DMH6FKX CS CC(C(=O)C1=CC(=CC=C1)F)NC2CCCC2
DMH6FKX IK CFVHNYYHCCJXDK-UHFFFAOYSA-N
DMH6FKX IU 2-(cyclopentylamino)-1-(3-fluorophenyl)propan-1-one
DMH6FKX DE Discovery agent
DMVN1UI ID DMVN1UI
DMVN1UI DN 2-(N-Cyclopentylamino)-3'-methoxypropiophenone
DMVN1UI HS Investigative
DMVN1UI SN CHEMBL589250; BDBM50308121
DMVN1UI DT Small molecular drug
DMVN1UI PC 45141608
DMVN1UI MW 247.33
DMVN1UI FM C15H21NO2
DMVN1UI IC InChI=1S/C15H21NO2/c1-11(16-13-7-3-4-8-13)15(17)12-6-5-9-14(10-12)18-2/h5-6,9-11,13,16H,3-4,7-8H2,1-2H3
DMVN1UI CS CC(C(=O)C1=CC(=CC=C1)OC)NC2CCCC2
DMVN1UI IK ZMRXSORFBXMBCB-UHFFFAOYSA-N
DMVN1UI IU 2-(cyclopentylamino)-1-(3-methoxyphenyl)propan-1-one
DMVN1UI DE Discovery agent
DMG87RK ID DMG87RK
DMG87RK DN 2-(N-Cyclopentylamino)-3'-methylpropiophenone
DMG87RK HS Investigative
DMG87RK SN CHEMBL592854; BDBM50308114
DMG87RK DT Small molecular drug
DMG87RK PC 45141381
DMG87RK MW 231.33
DMG87RK FM C15H21NO
DMG87RK IC InChI=1S/C15H21NO/c1-11-6-5-7-13(10-11)15(17)12(2)16-14-8-3-4-9-14/h5-7,10,12,14,16H,3-4,8-9H2,1-2H3
DMG87RK CS CC1=CC(=CC=C1)C(=O)C(C)NC2CCCC2
DMG87RK IK VLLKJTHFWNJPCE-UHFFFAOYSA-N
DMG87RK IU 2-(cyclopentylamino)-1-(3-methylphenyl)propan-1-one
DMG87RK DE Discovery agent
DMNMES3 ID DMNMES3
DMNMES3 DN 2-(N-Cyclopropylamino)-3-chloropropiophenone
DMNMES3 HS Investigative
DMNMES3 SN CHEMBL569700; 2-(N-Cyclopropylamino)-3-chloropropiophenone; 2-(N-cyclopropylamino)-3'-chloropropiophenone; SCHEMBL634169; BDBM50302907
DMNMES3 DT Small molecular drug
DMNMES3 PC 44543271
DMNMES3 MW 223.7
DMNMES3 FM C12H14ClNO
DMNMES3 IC InChI=1S/C12H14ClNO/c1-8(14-11-5-6-11)12(15)9-3-2-4-10(13)7-9/h2-4,7-8,11,14H,5-6H2,1H3
DMNMES3 CS CC(C(=O)C1=CC(=CC=C1)Cl)NC2CC2
DMNMES3 IK YKOZIWZLLJVPPD-UHFFFAOYSA-N
DMNMES3 IU 1-(3-chlorophenyl)-2-(cyclopropylamino)propan-1-one
DMNMES3 DE Discovery agent
DMCK7SV ID DMCK7SV
DMCK7SV DN 2-(N-Isopropylamino)-3'-chloropropiophenone
DMCK7SV HS Investigative
DMCK7SV SN CHEMBL565397; 2-(N-Isopropylamino)-3'-chloropropiophenone; 130839-36-0; AC1MHRAR; SCHEMBL770155; 1-(3-chlorophenyl)-2-(propan-2-ylamino)propan-1-one; BDBM50302920
DMCK7SV DT Small molecular drug
DMCK7SV PC 3031077
DMCK7SV MW 225.71
DMCK7SV FM C12H16ClNO
DMCK7SV IC InChI=1S/C12H16ClNO/c1-8(2)14-9(3)12(15)10-5-4-6-11(13)7-10/h4-9,14H,1-3H3
DMCK7SV CS CC(C)NC(C)C(=O)C1=CC(=CC=C1)Cl
DMCK7SV IK WHPARCHZPIKXEX-UHFFFAOYSA-N
DMCK7SV IU 1-(3-chlorophenyl)-2-(propan-2-ylamino)propan-1-one
DMCK7SV DE Discovery agent
DMZVHSB ID DMZVHSB
DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid
DMZVHSB HS Investigative
DMZVHSB SN Jsp003925
DMZVHSB DT Small molecular drug
DMZVHSB PC 4478249
DMZVHSB MW 195.24
DMZVHSB FM C6H13NO4S
DMZVHSB IC InChI=1S/C6H13NO4S/c8-12(9,10)6-3-7-1-4-11-5-2-7/h1-6H2,(H,8,9,10)
DMZVHSB CS C1COCC[NH+]1CCS(=O)(=O)[O-]
DMZVHSB IK SXGZJKUKBWWHRA-UHFFFAOYSA-N
DMZVHSB IU 2-morpholin-4-ium-4-ylethanesulfonate
DMZVHSB CA CAS 4432-31-9
DMZVHSB CB CHEBI:39408
DMZVHSB DE Discovery agent
DM85ZCW ID DM85ZCW
DM85ZCW DN 2-(N-Pyrrolidinyl)-3'-bromopropiophenone
DM85ZCW HS Investigative
DM85ZCW SN CHEMBL599230; BDBM50308117
DM85ZCW DT Small molecular drug
DM85ZCW PC 45141806
DM85ZCW MW 296.2
DM85ZCW FM C14H18BrNO
DM85ZCW IC InChI=1S/C14H18BrNO/c1-11(16-8-3-2-4-9-16)14(17)12-6-5-7-13(15)10-12/h5-7,10-11H,2-4,8-9H2,1H3
DM85ZCW CS CC(C(=O)C1=CC(=CC=C1)Br)N2CCCCC2
DM85ZCW IK DNVMLFGJFSQQDE-UHFFFAOYSA-N
DM85ZCW IU 1-(3-bromophenyl)-2-piperidin-1-ylpropan-1-one
DM85ZCW DE Discovery agent
DMYPOC5 ID DMYPOC5
DMYPOC5 DN 2-(N-Pyrrolidinyl)-3'-fluoropropiophenone
DMYPOC5 HS Investigative
DMYPOC5 SN CHEMBL599028; BDBM50308116
DMYPOC5 DT Small molecular drug
DMYPOC5 PC 45141805
DMYPOC5 MW 235.3
DMYPOC5 FM C14H18FNO
DMYPOC5 IC InChI=1S/C14H18FNO/c1-11(16-8-3-2-4-9-16)14(17)12-6-5-7-13(15)10-12/h5-7,10-11H,2-4,8-9H2,1H3
DMYPOC5 CS CC(C(=O)C1=CC(=CC=C1)F)N2CCCCC2
DMYPOC5 IK UDGISDAHRCDXMV-UHFFFAOYSA-N
DMYPOC5 IU 1-(3-fluorophenyl)-2-piperidin-1-ylpropan-1-one
DMYPOC5 DE Discovery agent
DM1W3L9 ID DM1W3L9
DM1W3L9 DN 2-(N-Pyrrolidinyl)-3'-methoxypropiophenone
DM1W3L9 HS Investigative
DM1W3L9 SN CHEMBL580143; BDBM50308119
DM1W3L9 DT Small molecular drug
DM1W3L9 PC 45141808
DM1W3L9 MW 247.33
DM1W3L9 FM C15H21NO2
DM1W3L9 IC InChI=1S/C15H21NO2/c1-12(16-9-4-3-5-10-16)15(17)13-7-6-8-14(11-13)18-2/h6-8,11-12H,3-5,9-10H2,1-2H3
DM1W3L9 CS CC(C(=O)C1=CC(=CC=C1)OC)N2CCCCC2
DM1W3L9 IK VIWKHXNVEIOPSC-UHFFFAOYSA-N
DM1W3L9 IU 1-(3-methoxyphenyl)-2-piperidin-1-ylpropan-1-one
DM1W3L9 DE Discovery agent
DMGKXOI ID DMGKXOI
DMGKXOI DN 2-(N-Pyrrolidinyl)-3'-methylpropiophenone
DMGKXOI HS Investigative
DMGKXOI SN CHEMBL589494; BDBM50308118
DMGKXOI DT Small molecular drug
DMGKXOI PC 45141807
DMGKXOI MW 231.33
DMGKXOI FM C15H21NO
DMGKXOI IC InChI=1S/C15H21NO/c1-12-7-6-8-14(11-12)15(17)13(2)16-9-4-3-5-10-16/h6-8,11,13H,3-5,9-10H2,1-2H3
DMGKXOI CS CC1=CC(=CC=C1)C(=O)C(C)N2CCCCC2
DMGKXOI IK VMEDIUSDIYRUSA-UHFFFAOYSA-N
DMGKXOI IU 1-(3-methylphenyl)-2-piperidin-1-ylpropan-1-one
DMGKXOI DE Discovery agent
DM1I9LQ ID DM1I9LQ
DM1I9LQ DN 2-(N-Pyrrolidinyl)-3'-nitropropiophenone
DM1I9LQ HS Investigative
DM1I9LQ SN CHEMBL599233; SCHEMBL6055564; BDBM50308120
DM1I9LQ DT Small molecular drug
DM1I9LQ PC 45141809
DM1I9LQ MW 262.3
DM1I9LQ FM C14H18N2O3
DM1I9LQ IC InChI=1S/C14H18N2O3/c1-11(15-8-3-2-4-9-15)14(17)12-6-5-7-13(10-12)16(18)19/h5-7,10-11H,2-4,8-9H2,1H3
DM1I9LQ CS CC(C(=O)C1=CC(=CC=C1)[N+](=O)[O-])N2CCCCC2
DM1I9LQ IK LTLFRBMKBHQUTH-UHFFFAOYSA-N
DM1I9LQ IU 1-(3-nitrophenyl)-2-piperidin-1-ylpropan-1-one
DM1I9LQ DE Discovery agent
DMKIEVP ID DMKIEVP
DMKIEVP DN 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone
DMKIEVP HS Investigative
DMKIEVP SN CHEMBL568140; SCHEMBL770039; BDBM50302918; AKOS022330446; 2-(N-tert-Butylamino)-3'',4''-dichloropropiophenone
DMKIEVP DT Small molecular drug
DMKIEVP PC 45487890
DMKIEVP MW 274.18
DMKIEVP FM C13H17Cl2NO
DMKIEVP IC InChI=1S/C13H17Cl2NO/c1-8(16-13(2,3)4)12(17)9-5-6-10(14)11(15)7-9/h5-8,16H,1-4H3
DMKIEVP CS CC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C
DMKIEVP IK MXUDEADPGZWZCH-UHFFFAOYSA-N
DMKIEVP IU 2-(tert-butylamino)-1-(3,4-dichlorophenyl)propan-1-one
DMKIEVP CA CAS 1193779-34-8
DMKIEVP DE Discovery agent
DMY2PBO ID DMY2PBO
DMY2PBO DN 2-(N-tert-Butylamino)-3'-chloroheptanophenone
DMY2PBO HS Investigative
DMY2PBO SN CHEMBL565382; SCHEMBL769133; BDBM50302921
DMY2PBO DT Small molecular drug
DMY2PBO PC 44542656
DMY2PBO MW 295.8
DMY2PBO FM C17H26ClNO
DMY2PBO IC InChI=1S/C17H26ClNO/c1-5-6-7-11-15(19-17(2,3)4)16(20)13-9-8-10-14(18)12-13/h8-10,12,15,19H,5-7,11H2,1-4H3
DMY2PBO CS CCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMY2PBO IK OROOSQVGDDDAFY-UHFFFAOYSA-N
DMY2PBO IU 2-(tert-butylamino)-1-(3-chlorophenyl)heptan-1-one
DMY2PBO DE Discovery agent
DMPO3CJ ID DMPO3CJ
DMPO3CJ DN 2-(N-tert-Butylamino)-3'-chlorohexanophenone
DMPO3CJ HS Investigative
DMPO3CJ SN CHEMBL576622; SCHEMBL634045; BDBM50302931
DMPO3CJ DT Small molecular drug
DMPO3CJ PC 44543267
DMPO3CJ MW 281.82
DMPO3CJ FM C16H24ClNO
DMPO3CJ IC InChI=1S/C16H24ClNO/c1-5-6-10-14(18-16(2,3)4)15(19)12-8-7-9-13(17)11-12/h7-9,11,14,18H,5-6,10H2,1-4H3
DMPO3CJ CS CCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMPO3CJ IK WSLDIWPVDFGUNH-UHFFFAOYSA-N
DMPO3CJ IU 2-(tert-butylamino)-1-(3-chlorophenyl)hexan-1-one
DMPO3CJ DE Discovery agent
DMW47VA ID DMW47VA
DMW47VA DN 2-(N-tert-Butylamino)-3'-chlorooctanophenone
DMW47VA HS Investigative
DMW47VA SN CHEMBL565593; 2-(N-tert-Butylamino)-3'-chlorooctanophenone; SCHEMBL633368; HHZNTCLXZVSLGW-UHFFFAOYSA-N; BDBM50302909
DMW47VA DT Small molecular drug
DMW47VA PC 44543268
DMW47VA MW 309.9
DMW47VA FM C18H28ClNO
DMW47VA IC InChI=1S/C18H28ClNO/c1-5-6-7-8-12-16(20-18(2,3)4)17(21)14-10-9-11-15(19)13-14/h9-11,13,16,20H,5-8,12H2,1-4H3
DMW47VA CS CCCCCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMW47VA IK HHZNTCLXZVSLGW-UHFFFAOYSA-N
DMW47VA IU 2-(tert-butylamino)-1-(3-chlorophenyl)octan-1-one
DMW47VA DE Discovery agent
DMTZ540 ID DMTZ540
DMTZ540 DN 2-(N-tert-Butylamino)-3'-chloropentanophenone
DMTZ540 HS Investigative
DMTZ540 SN CHEMBL569465; 2-(tert-butylamino)-1-(3-chlorophenyl)pentan-1-one; AC1MHOFP; SCHEMBL769847; BDBM50302927
DMTZ540 DT Small molecular drug
DMTZ540 PC 3029724
DMTZ540 MW 267.79
DMTZ540 FM C15H22ClNO
DMTZ540 IC InChI=1S/C15H22ClNO/c1-5-7-13(17-15(2,3)4)14(18)11-8-6-9-12(16)10-11/h6,8-10,13,17H,5,7H2,1-4H3
DMTZ540 CS CCCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMTZ540 IK PREYWAJYVTVVPE-UHFFFAOYSA-N
DMTZ540 IU 2-(tert-butylamino)-1-(3-chlorophenyl)pentan-1-one
DMTZ540 DE Discovery agent
DME1SP4 ID DME1SP4
DME1SP4 DN 2-(N-tert-Butylamino)-4'-chloropropiophenone
DME1SP4 HS Investigative
DME1SP4 SN CHEMBL566000; 2-(tert-butylamino)-1-(4-chlorophenyl)propan-1-one; AC1MHR9U; SCHEMBL770391; BDBM50302911; AKOS022330116; 4'-Chloro-alpha-(tert-butylamino)propiophenone
DME1SP4 DT Small molecular drug
DME1SP4 PC 3031066
DME1SP4 MW 239.74
DME1SP4 FM C13H18ClNO
DME1SP4 IC InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-5-7-11(14)8-6-10/h5-9,15H,1-4H3
DME1SP4 CS CC(C(=O)C1=CC=C(C=C1)Cl)NC(C)(C)C
DME1SP4 IK IELBAACIVCODPI-UHFFFAOYSA-N
DME1SP4 IU 2-(tert-butylamino)-1-(4-chlorophenyl)propan-1-one
DME1SP4 DE Discovery agent
DM9E5LT ID DM9E5LT
DM9E5LT DN 2-(N-tert-Butylamino)propiophenone
DM9E5LT HS Investigative
DM9E5LT SN 2-(N-tert-Butylamino)propiophenone; CHEMBL569699; AC1MIL82; SCHEMBL769768; JQNSRSIGKZYQAA-UHFFFAOYSA-N; alpha-(tert-Butylamino)propiophenone; BDBM50302912; AKOS022329747
DM9E5LT DT Small molecular drug
DM9E5LT PC 3047299
DM9E5LT MW 205.3
DM9E5LT FM C13H19NO
DM9E5LT IC InChI=1S/C13H19NO/c1-10(14-13(2,3)4)12(15)11-8-6-5-7-9-11/h5-10,14H,1-4H3
DM9E5LT CS CC(C(=O)C1=CC=CC=C1)NC(C)(C)C
DM9E5LT IK JQNSRSIGKZYQAA-UHFFFAOYSA-N
DM9E5LT IU 2-(tert-butylamino)-1-phenylpropan-1-one
DM9E5LT CA CAS 34509-36-9
DM9E5LT DE Discovery agent
DM3RCA9 ID DM3RCA9
DM3RCA9 DN 2-(o-toluidino)-5-ethylthiazol-4(5H)-one
DM3RCA9 HS Investigative
DM3RCA9 DT Small molecular drug
DM3RCA9 PC 135450677
DM3RCA9 MW 234.32
DM3RCA9 FM C12H14N2OS
DM3RCA9 IC InChI=1S/C12H14N2OS/c1-3-10-11(15)14-12(16-10)13-9-7-5-4-6-8(9)2/h4-7,10H,3H2,1-2H3,(H,13,14,15)
DM3RCA9 CS CCC1C(=O)NC(=NC2=CC=CC=C2C)S1
DM3RCA9 IK CWOSTWNWVJUZID-UHFFFAOYSA-N
DM3RCA9 IU 5-ethyl-2-(2-methylphenyl)imino-1,3-thiazolidin-4-one
DM3RCA9 DE Discovery agent
DMYTJX4 ID DMYTJX4
DMYTJX4 DN 2-(o-toluidino)-5-isopropylthiazol-4(5H)-one
DMYTJX4 HS Investigative
DMYTJX4 DT Small molecular drug
DMYTJX4 PC 91253621
DMYTJX4 MW 248.35
DMYTJX4 FM C13H16N2OS
DMYTJX4 IC InChI=1S/C13H16N2OS/c1-8(2)11-12(16)15-13(17-11)14-10-7-5-4-6-9(10)3/h4-8,16H,1-3H3,(H,14,15)
DMYTJX4 CS CC1=CC=CC=C1NC2=NC(=C(S2)C(C)C)O
DMYTJX4 IK CSOPFNOFIZHDML-UHFFFAOYSA-N
DMYTJX4 IU 2-(2-methylanilino)-5-propan-2-yl-1,3-thiazol-4-ol
DMYTJX4 DE Discovery agent
DM7LOHK ID DM7LOHK
DM7LOHK DN 2-(Oxalyl-Amino)-Benzoic Acid
DM7LOHK HS Investigative
DM7LOHK SN 2-(oxaloamino)benzoic acid; 2-(OXALYL-AMINO)-BENZOIC ACID; CHEMBL139050; CHEBI:44493; 2-[(carboxycarbonyl)amino]benzoic acid; OBA; 2-oxaloaminobenzoic acid; AC1L9GUO; SCHEMBL4315667; 2-(Carboxyformamido)Benzoic Acid; 1c85; ZINC2007905; BDBM50118789; AKOS022649621; DB02622; SC-57508; 5651-01-4; BENZOIC ACID,2[(CARBOXYCARBONYL)AMINO]-
DM7LOHK DT Small molecular drug
DM7LOHK PC 444764
DM7LOHK MW 209.16
DM7LOHK FM C9H7NO5
DM7LOHK IC InChI=1S/C9H7NO5/c11-7(9(14)15)10-6-4-2-1-3-5(6)8(12)13/h1-4H,(H,10,11)(H,12,13)(H,14,15)
DM7LOHK CS C1=CC=C(C(=C1)C(=O)O)NC(=O)C(=O)O
DM7LOHK IK QBYNNSFEMMNINN-UHFFFAOYSA-N
DM7LOHK IU 2-(oxaloamino)benzoic acid
DM7LOHK CB CHEBI:44493
DM7LOHK DE Discovery agent
DMPUARE ID DMPUARE
DMPUARE DN 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine
DMPUARE HS Investigative
DMPUARE SN CHEMBL425576; 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine; SCHEMBL1122285
DMPUARE DT Small molecular drug
DMPUARE PC 11515006
DMPUARE MW 304.3
DMPUARE FM C18H16N4O
DMPUARE IC InChI=1S/C18H16N4O/c1-13(23)20-16-9-5-6-14(10-16)17-11-19-12-18(22-17)21-15-7-3-2-4-8-15/h2-12H,1H3,(H,20,23)(H,21,22)
DMPUARE CS CC(=O)NC1=CC=CC(=C1)C2=CN=CC(=N2)NC3=CC=CC=C3
DMPUARE IK MKRMZWIJCMWBDU-UHFFFAOYSA-N
DMPUARE IU N-[3-(6-anilinopyrazin-2-yl)phenyl]acetamide
DMPUARE DE Discovery agent
DMRIFCW ID DMRIFCW
DMRIFCW DN 2-(phenylethynyl)pyrimidine
DMRIFCW HS Investigative
DMRIFCW SN 2-(phenylethynyl)pyrimidine; CHEMBL450465; phenylethynylpyrimidine; SCHEMBL13841597; ZINC39236614; BDBM50278929
DMRIFCW DT Small molecular drug
DMRIFCW PC 12490583
DMRIFCW MW 180.2
DMRIFCW FM C12H8N2
DMRIFCW IC InChI=1S/C12H8N2/c1-2-5-11(6-3-1)7-8-12-13-9-4-10-14-12/h1-6,9-10H
DMRIFCW CS C1=CC=C(C=C1)C#CC2=NC=CC=N2
DMRIFCW IK JGGFEZRQOSIEGG-UHFFFAOYSA-N
DMRIFCW IU 2-(2-phenylethynyl)pyrimidine
DMRIFCW DE Discovery agent
DMFBTM2 ID DMFBTM2
DMFBTM2 DN 2-(phenylsulfonamido)-1-naphthoic acid
DMFBTM2 HS Investigative
DMFBTM2 SN 1-Naphthalenecarboxylic acid, 2-[(phenylsulfonyl)amino]-; 677290-81-2; sulfonamide compound, 9; SCHEMBL3986500; CHEMBL377198; CTK1H6801; BDBM17603; DTXSID20471157; CXPIFTCBANXJNX-UHFFFAOYSA-N; AKOS030618475; 2-[(phenylsulfonyl)amino]-1-naphthoic acid; 2-benzenesulfonamidonaphthalene-1-carboxylic acid
DMFBTM2 DT Small molecular drug
DMFBTM2 PC 11723962
DMFBTM2 MW 327.4
DMFBTM2 FM C17H13NO4S
DMFBTM2 IC InChI=1S/C17H13NO4S/c19-17(20)16-14-9-5-4-6-12(14)10-11-15(16)18-23(21,22)13-7-2-1-3-8-13/h1-11,18H,(H,19,20)
DMFBTM2 CS C1=CC=C(C=C1)S(=O)(=O)NC2=C(C3=CC=CC=C3C=C2)C(=O)O
DMFBTM2 IK CXPIFTCBANXJNX-UHFFFAOYSA-N
DMFBTM2 IU 2-(benzenesulfonamido)naphthalene-1-carboxylic acid
DMFBTM2 CA CAS 677290-81-2
DMFBTM2 DE Discovery agent
DMDGAHO ID DMDGAHO
DMDGAHO DN 2-(phenylsulfonamido)-5-propylbenzoic acid
DMDGAHO HS Investigative
DMDGAHO SN 2-benzenesulfonamido-5-propylbenzoic acid; sulfonamide compound, 7; SCHEMBL3984242; CHEMBL209071; BDBM17601; MolPort-009-343-156; ZINC14965014; AKOS034553679; MCULE-3140792066; Z738155172
DMDGAHO DT Small molecular drug
DMDGAHO PC 10018850
DMDGAHO MW 319.4
DMDGAHO FM C16H17NO4S
DMDGAHO IC InChI=1S/C16H17NO4S/c1-2-6-12-9-10-15(14(11-12)16(18)19)17-22(20,21)13-7-4-3-5-8-13/h3-5,7-11,17H,2,6H2,1H3,(H,18,19)
DMDGAHO CS CCCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DMDGAHO IK LZDCSXYOKAIIJO-UHFFFAOYSA-N
DMDGAHO IU 2-(benzenesulfonamido)-5-propylbenzoic acid
DMDGAHO DE Discovery agent
DMMSI67 ID DMMSI67
DMMSI67 DN 2-(Phenylsulfonamido)acetic Acid
DMMSI67 HS Investigative
DMMSI67 SN 2-(Phenylsulfonamido)acetic Acid; 5398-96-9; Benzenesulfonylamino-acetic acid; n-(phenylsulfonyl)glycine; 2-benzenesulfonamidoacetic acid; CHEMBL37054; 2-(benzenesulfonamido)acetic acid; 2-[(phenylsulfonyl)amino]acetic acid; n-benzenesulfonylglycine; N-benzenesulfonyl-glycine; ChemDiv3_006100; CBChromo1_000178; AC1Q6W5M; Oprea1_227014; Oprea1_645532; CBDivE_002981; SCHEMBL359770; AC1Q763K; NSC3682; MolPort-000-182-647; WTSZSAHZIMPSDM-UHFFFAOYSA-N; ZINC187388; HMS1490F06; NSC-3682; AC1L5954; NSC121986; STL477593; SBB015317
DMMSI67 DT Small molecular drug
DMMSI67 PC 220662
DMMSI67 MW 215.23
DMMSI67 FM C8H9NO4S
DMMSI67 IC InChI=1S/C8H9NO4S/c10-8(11)6-9-14(12,13)7-4-2-1-3-5-7/h1-5,9H,6H2,(H,10,11)
DMMSI67 CS C1=CC=C(C=C1)S(=O)(=O)NCC(=O)O
DMMSI67 IK WTSZSAHZIMPSDM-UHFFFAOYSA-N
DMMSI67 IU 2-(benzenesulfonamido)acetic acid
DMMSI67 CA CAS 5398-96-9
DMMSI67 DE Discovery agent
DMCF75U ID DMCF75U
DMCF75U DN 2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone
DMCF75U HS Investigative
DMCF75U SN CHEMBL238851; 2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone; BDBM50212533
DMCF75U DT Small molecular drug
DMCF75U PC 44437618
DMCF75U MW 266.3
DMCF75U FM C12H10O3S2
DMCF75U IC InChI=1S/C12H10O3S2/c13-12(10-6-7-16-8-10)9-17(14,15)11-4-2-1-3-5-11/h1-8H,9H2
DMCF75U CS C1=CC=C(C=C1)S(=O)(=O)CC(=O)C2=CSC=C2
DMCF75U IK CBJGWEVSYFKKBK-UHFFFAOYSA-N
DMCF75U IU 2-(benzenesulfonyl)-1-thiophen-3-ylethanone
DMCF75U DE Discovery agent
DM93XJT ID DM93XJT
DM93XJT DN 2-(phenylsulfonyl)-1-p-tolylethanone
DM93XJT HS Investigative
DM93XJT SN 38488-14-1; CHEMBL392808; Ethanone, 1-(4-methylphenyl)-2-(phenylsulfonyl)-; 2-(phenylsulfonyl)-1-p-tolylethanone; 4-Methylphenacylphenyl sulfone; SCHEMBL6202982; CTK1A8876; DTXSID20575987; BDBM50212530; ZINC28874639; AKOS008967833; 1-p-Tolyl-2-(phenylsulphonyl)ethanone; 1-(4-methylphenyl)-2-(phenylsulfonyl)ethanone; 2-(Benzenesulfonyl)-1-(4-methylphenyl)ethan-1-one
DM93XJT DT Small molecular drug
DM93XJT PC 15627039
DM93XJT MW 274.3
DM93XJT FM C15H14O3S
DM93XJT IC InChI=1S/C15H14O3S/c1-12-7-9-13(10-8-12)15(16)11-19(17,18)14-5-3-2-4-6-14/h2-10H,11H2,1H3
DM93XJT CS CC1=CC=C(C=C1)C(=O)CS(=O)(=O)C2=CC=CC=C2
DM93XJT IK DITVWQPTRBYVRP-UHFFFAOYSA-N
DM93XJT IU 2-(benzenesulfonyl)-1-(4-methylphenyl)ethanone
DM93XJT CA CAS 38488-14-1
DM93XJT DE Discovery agent
DMAKR2E ID DMAKR2E
DMAKR2E DN 2-(phenylsulfonyl)naphthalene-1,4-diol
DMAKR2E HS Investigative
DMAKR2E SN 2-(phenylsulfonyl)naphthalene-1,4-diol; CHEMBL462205; SCHEMBL9717678; YEDZIHZPRGSAMI-UHFFFAOYSA-N; BDBM50245877
DMAKR2E DT Small molecular drug
DMAKR2E PC 15657226
DMAKR2E MW 300.3
DMAKR2E FM C16H12O4S
DMAKR2E IC InChI=1S/C16H12O4S/c17-14-10-15(16(18)13-9-5-4-8-12(13)14)21(19,20)11-6-2-1-3-7-11/h1-10,17-18H
DMAKR2E CS C1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC=CC=C3C(=C2)O)O
DMAKR2E IK YEDZIHZPRGSAMI-UHFFFAOYSA-N
DMAKR2E IU 2-(benzenesulfonyl)naphthalene-1,4-diol
DMAKR2E DE Discovery agent
DM4V2ZO ID DM4V2ZO
DM4V2ZO DN 2-(Phosphonooxy)Butanoic Acid
DM4V2ZO HS Investigative
DM4V2ZO SN 2-(PHOSPHONOOXY)BUTANOIC ACID; AC1NRCQI; 2-phosphonooxybutanoic acid; SCHEMBL4318695; (2R)-2-(phosphonooxy)butanoic acid
DM4V2ZO DT Small molecular drug
DM4V2ZO PC 17754119
DM4V2ZO MW 184.08
DM4V2ZO FM C4H9O6P
DM4V2ZO IC InChI=1S/C4H9O6P/c1-2-3(4(5)6)10-11(7,8)9/h3H,2H2,1H3,(H,5,6)(H2,7,8,9)/t3-/m1/s1
DM4V2ZO CS CC[C@H](C(=O)O)OP(=O)(O)O
DM4V2ZO IK OETAGSCBSKODFW-GSVOUGTGSA-N
DM4V2ZO IU (2R)-2-phosphonooxybutanoic acid
DM4V2ZO DE Discovery agent
DML6HSE ID DML6HSE
DML6HSE DN 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline
DML6HSE HS Investigative
DML6HSE SN 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline; CHEMBL593547; 1207671-23-5; ZINC45354604; BDBM50304820; AKOS023594147
DML6HSE DT Small molecular drug
DML6HSE PC 46228433
DML6HSE MW 217.31
DML6HSE FM C13H19N3
DML6HSE IC InChI=1S/C13H19N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h5-6,14H,1-4,7-10H2
DML6HSE CS C1CCC2=C(C1)C=CC(=N2)N3CCNCC3
DML6HSE IK OHJFBSROVXQKFQ-UHFFFAOYSA-N
DML6HSE IU 2-piperazin-1-yl-5,6,7,8-tetrahydroquinoline
DML6HSE DE Discovery agent
DMGQX1I ID DMGQX1I
DMGQX1I DN 2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one
DMGQX1I HS Investigative
DMGQX1I SN K 12212; BRN 0415699; 4H-Naphtho(1,2-b)pyran-4-one, 2-(1-piperidinyl)-; CHEMBL367468; 2-(1-Piperidinyl)-4H-naphtho(1,2-b)pyran-4-one; 2-(N-Piperidil)-4-oxo-4H-nafto(1,2-b)pirano [Italian]; 61035-05-0; AC1MIJ0F; 2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one; 2-(N-Piperidil)-4-oxo-4H-nafto(1,2-b)pirano; SCHEMBL3538224; DTXSID60209911; BDBM50159645; 2-piperidin-1-ylbenzo[h]chromen-4-one; LS-95581
DMGQX1I DT Small molecular drug
DMGQX1I PC 3045697
DMGQX1I MW 279.3
DMGQX1I FM C18H17NO2
DMGQX1I IC InChI=1S/C18H17NO2/c20-16-12-17(19-10-4-1-5-11-19)21-18-14-7-3-2-6-13(14)8-9-15(16)18/h2-3,6-9,12H,1,4-5,10-11H2
DMGQX1I CS C1CCN(CC1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMGQX1I IK MAIHLQWUOLIOEP-UHFFFAOYSA-N
DMGQX1I IU 2-piperidin-1-ylbenzo[h]chromen-4-one
DMGQX1I CA CAS 61035-05-0
DMGQX1I DE Discovery agent
DMLT635 ID DMLT635
DMLT635 DN 2-(p-Methylsulfonylbenzoyl)furan
DMLT635 HS Investigative
DMLT635 SN 2-(p-Methylsulfonylbenzoyl)furan; CHEMBL1240887; SCHEMBL7814046; BDBM50326535
DMLT635 DT Small molecular drug
DMLT635 PC 12701751
DMLT635 MW 250.27
DMLT635 FM C12H10O4S
DMLT635 IC InChI=1S/C12H10O4S/c1-17(14,15)10-6-4-9(5-7-10)12(13)11-3-2-8-16-11/h2-8H,1H3
DMLT635 CS CS(=O)(=O)C1=CC=C(C=C1)C(=O)C2=CC=CO2
DMLT635 IK CWRZECMEZICAFW-UHFFFAOYSA-N
DMLT635 IU furan-2-yl-(4-methylsulfonylphenyl)methanone
DMLT635 DE Discovery agent
DM27YTF ID DM27YTF
DM27YTF DN 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF HS Investigative
DM27YTF SN CHEMBL233874; 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF DT Small molecular drug
DM27YTF PC 44430881
DM27YTF MW 286.3
DM27YTF FM C18H14N4
DM27YTF IC InChI=1S/C18H14N4/c1-13-7-9-16(10-8-13)21-18-20-12-15(11-19)17(22-18)14-5-3-2-4-6-14/h2-10,12H,1H3,(H,20,21,22)
DM27YTF CS CC1=CC=C(C=C1)NC2=NC=C(C(=N2)C3=CC=CC=C3)C#N
DM27YTF IK OBWJJSHWDHTFAP-UHFFFAOYSA-N
DM27YTF IU 2-(4-methylanilino)-4-phenylpyrimidine-5-carbonitrile
DM27YTF DE Discovery agent
DMON1A5 ID DMON1A5
DMON1A5 DN 2-(p-tolylthio)naphthalene-1,4-dione
DMON1A5 HS Investigative
DMON1A5 SN CHEMBL501551; 89478-03-5; 1,4-Naphthalenedione, 2-[(4-methylphenyl)thio]-; 2-(p-tolylthio)naphthalene-1,4-dione; ACMC-20lmns; CTK2J5214; DTXSID70567231; BDBM50245831; AKOS030617287; 2-(4-Methylphenylthio)-1,4-naphthoquinone
DMON1A5 DT Small molecular drug
DMON1A5 PC 15032092
DMON1A5 MW 280.3
DMON1A5 FM C17H12O2S
DMON1A5 IC InChI=1S/C17H12O2S/c1-11-6-8-12(9-7-11)20-16-10-15(18)13-4-2-3-5-14(13)17(16)19/h2-10H,1H3
DMON1A5 CS CC1=CC=C(C=C1)SC2=CC(=O)C3=CC=CC=C3C2=O
DMON1A5 IK IHRGUZGBIGODSC-UHFFFAOYSA-N
DMON1A5 IU 2-(4-methylphenyl)sulfanylnaphthalene-1,4-dione
DMON1A5 CA CAS 89478-03-5
DMON1A5 DE Discovery agent
DMST2LX ID DMST2LX
DMST2LX DN 2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine
DMST2LX HS Investigative
DMST2LX SN 55396-63-9; CHEMBL199925; 2-(pyridin-2-yl)-1H-1,3-benzodiazol-5-amine; MLS000528495; 2-Pyridin-2-yl-1H-benzoimidazol-5-ylamine; 2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine; ITFXYBZUPPBWEC-UHFFFAOYSA-N; SMR000121070; 2-pyridin-2-yl-3H-benzimidazol-5-amine; 1H-Benzimidazol-5-amine, 2-(2-pyridinyl)-; 2-(Pyridin-2-yl)-1H-1,3-benzodiazol-6-amine; AC1LBVAV; 1H-Benzimidazol-6-amine, 2-(2-pyridinyl)-; AC1Q52EP; SCHEMBL8556415; SCHEMBL4371835; cid_542828; BDBM62926; CTK1F6864; DTXSID50337459; MolPort-006-709-925; MolPort-001-815-306
DMST2LX DT Small molecular drug
DMST2LX PC 542828
DMST2LX MW 210.23
DMST2LX FM C12H10N4
DMST2LX IC InChI=1S/C12H10N4/c13-8-4-5-9-11(7-8)16-12(15-9)10-3-1-2-6-14-10/h1-7H,13H2,(H,15,16)
DMST2LX CS C1=CC=NC(=C1)C2=NC3=C(N2)C=C(C=C3)N
DMST2LX IK ITFXYBZUPPBWEC-UHFFFAOYSA-N
DMST2LX IU 2-pyridin-2-yl-3H-benzimidazol-5-amine
DMST2LX CA CAS 55396-63-9
DMST2LX DE Discovery agent
DMRUTDY ID DMRUTDY
DMRUTDY DN 2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMRUTDY HS Investigative
DMRUTDY SN 2-(2-Pyridyl)benzimidazole; 1137-68-4; 2-(pyridin-2-yl)-1H-benzo[d]imidazole; 2-pyridin-2-yl-1H-benzimidazole; 2-Pyridin-2-yl-1H-benzoimidazole; 2-(pyridin-2-yl)-1H-benzimidazole; NSC 32814; NSC 110942; CHEMBL72683; YNFBMDWHEHETJW-UHFFFAOYSA-N; 1H-Benzimidazole, 2-(pyridinyl)-; 1H-Benzimidazole, 2-(2-pyridinyl)-; 2-(pyridin-2-yl)-1H-1,3-benzodiazole; 2-(2-Pyridyl)benzimidazole, 99%; EINECS 214-508-7; ACMC-20aime; AC1L2EXP; 2(2-Pyridyl)benzimidazole; 2-(2'-Pyrido)benzimidazole; MLS000554415; 2-(2-pyridyl) benzimidazole
DMRUTDY DT Small molecular drug
DMRUTDY PC 70821
DMRUTDY MW 195.22
DMRUTDY FM C12H9N3
DMRUTDY IC InChI=1S/C12H9N3/c1-2-6-10-9(5-1)14-12(15-10)11-7-3-4-8-13-11/h1-8H,(H,14,15)
DMRUTDY CS C1=CC=C2C(=C1)NC(=N2)C3=CC=CC=N3
DMRUTDY IK YNFBMDWHEHETJW-UHFFFAOYSA-N
DMRUTDY IU 2-pyridin-2-yl-1H-benzimidazole
DMRUTDY CA CAS 1137-68-4
DMRUTDY DE Discovery agent
DMHFGMQ ID DMHFGMQ
DMHFGMQ DN 2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine
DMHFGMQ HS Investigative
DMHFGMQ SN CHEMBL202826; 14060-62-9; 2-(2-Pyridinyl)-1H-imidazo[4,5-c]pyridine; AC1LJB5G; 2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine; 3H-Imidazo[4,5-c]pyridine, 2-(2-pyridinyl)-; Oprea1_672867; SCHEMBL11397558; 2-pyridylimidazo[4,5-c]pyridine; MolPort-002-623-631; ZINC5819379; BDBM50180747; STL346357; AKOS022141602; AKOS012572462; MCULE-6118149650; NCGC00375714-01; NCGC00375714-02; 2-pyridin-2-yl-3H-imidazo[4,5-c]pyridine
DMHFGMQ DT Small molecular drug
DMHFGMQ PC 947740
DMHFGMQ MW 196.21
DMHFGMQ FM C11H8N4
DMHFGMQ IC InChI=1S/C11H8N4/c1-2-5-13-9(3-1)11-14-8-4-6-12-7-10(8)15-11/h1-7H,(H,14,15)
DMHFGMQ CS C1=CC=NC(=C1)C2=NC3=C(N2)C=NC=C3
DMHFGMQ IK RCQLXXHLXWNHOU-UHFFFAOYSA-N
DMHFGMQ IU 2-pyridin-2-yl-3H-imidazo[4,5-c]pyridine
DMHFGMQ DE Discovery agent
DM3EBYD ID DM3EBYD
DM3EBYD DN 2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine
DM3EBYD HS Investigative
DM3EBYD SN 2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine; CHEMBL208730; SCHEMBL6512812; BDBM50182815
DM3EBYD DT Small molecular drug
DM3EBYD PC 11460152
DM3EBYD MW 279.4
DM3EBYD FM C16H13N3S
DM3EBYD IC InChI=1S/C16H13N3S/c1-12-5-4-6-13(11-12)20-15-8-10-18-16(19-15)14-7-2-3-9-17-14/h2-11H,1H3
DM3EBYD CS CC1=CC(=CC=C1)SC2=NC(=NC=C2)C3=CC=CC=N3
DM3EBYD IK LUFGLBRBPWCPQS-UHFFFAOYSA-N
DM3EBYD IU 4-(3-methylphenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DM3EBYD DE Discovery agent
DMET46L ID DMET46L
DMET46L DN 2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile
DMET46L HS Investigative
DMET46L SN CHEMBL202748; 2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile; SCHEMBL5889065
DMET46L DT Small molecular drug
DMET46L PC 21934605
DMET46L MW 203.23
DMET46L FM C8H5N5S
DMET46L IC InChI=1S/C8H5N5S/c9-3-6-4-11-8(14-6)13-7-1-2-10-5-12-7/h1-2,4-5H,(H,10,11,12,13)
DMET46L CS C1=CN=CN=C1NC2=NC=C(S2)C#N
DMET46L IK SMNGUXOKYVUIRA-UHFFFAOYSA-N
DMET46L IU 2-(pyrimidin-4-ylamino)-1,3-thiazole-5-carbonitrile
DMET46L CA CAS 436852-19-6
DMET46L DE Discovery agent
DM5CEG8 ID DM5CEG8
DM5CEG8 DN 2-(Sulfanylmethyl)phenylphosphonic acid
DM5CEG8 HS Investigative
DM5CEG8 SN 2-(Sulfanylmethyl)phenylphosphonic acid; CHEMBL1173338
DM5CEG8 DT Small molecular drug
DM5CEG8 PC 46855907
DM5CEG8 MW 204.19
DM5CEG8 FM C7H9O3PS
DM5CEG8 IC InChI=1S/C7H9O3PS/c8-11(9,10)7-4-2-1-3-6(7)5-12/h1-4,12H,5H2,(H2,8,9,10)
DM5CEG8 CS C1=CC=C(C(=C1)CS)P(=O)(O)O
DM5CEG8 IK MVLYXNMBKWWFNE-UHFFFAOYSA-N
DM5CEG8 IU [2-(sulfanylmethyl)phenyl]phosphonic acid
DM5CEG8 DE Discovery agent
DMI457Y ID DMI457Y
DMI457Y DN 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y HS Investigative
DMI457Y SN CHEMBL566886; 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one; AC1MHKA5; SCHEMBL770048; BDBM50302929
DMI457Y DT Small molecular drug
DMI457Y PC 3027752
DMI457Y MW 253.77
DMI457Y FM C14H20ClNO
DMI457Y IC InChI=1S/C14H20ClNO/c1-5-12(16-14(2,3)4)13(17)10-7-6-8-11(15)9-10/h6-9,12,16H,5H2,1-4H3
DMI457Y CS CCC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
DMI457Y IK PGTPXIBBHIHMQS-UHFFFAOYSA-N
DMI457Y IU 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one
DMI457Y DE Discovery agent
DM6PV4W ID DM6PV4W
DM6PV4W DN 2-(tert-butylamino)-1-m-tolylpropan-1-one
DM6PV4W HS Investigative
DM6PV4W SN CHEMBL566832; 2-(tert-butylamino)-1-m-tolylpropan-1-one; SCHEMBL769882; BDBM50302942
DM6PV4W DT Small molecular drug
DM6PV4W PC 44543118
DM6PV4W MW 219.32
DM6PV4W FM C14H21NO
DM6PV4W IC InChI=1S/C14H21NO/c1-10-7-6-8-12(9-10)13(16)11(2)15-14(3,4)5/h6-9,11,15H,1-5H3
DM6PV4W CS CC1=CC(=CC=C1)C(=O)C(C)NC(C)(C)C
DM6PV4W IK YDGOUEKZXBLUDG-UHFFFAOYSA-N
DM6PV4W IU 2-(tert-butylamino)-1-(3-methylphenyl)propan-1-one
DM6PV4W DE Discovery agent
DMYFQDT ID DMYFQDT
DMYFQDT DN 2-(tert-butylamino)-1-p-tolylpropan-1-one
DMYFQDT HS Investigative
DMYFQDT SN CHEMBL566207; 2-(tert-butylamino)-1-p-tolylpropan-1-one; SCHEMBL769850; BDBM50302941; AKOS022329818; 4'-Methyl-alpha-(tert-butylamino)propiophenone
DMYFQDT DT Small molecular drug
DMYFQDT PC 45487941
DMYFQDT MW 219.32
DMYFQDT FM C14H21NO
DMYFQDT IC InChI=1S/C14H21NO/c1-10-6-8-12(9-7-10)13(16)11(2)15-14(3,4)5/h6-9,11,15H,1-5H3
DMYFQDT CS CC1=CC=C(C=C1)C(=O)C(C)NC(C)(C)C
DMYFQDT IK BMWDQBTXNBGORC-UHFFFAOYSA-N
DMYFQDT IU 2-(tert-butylamino)-1-(4-methylphenyl)propan-1-one
DMYFQDT DE Discovery agent
DMOJK8Y ID DMOJK8Y
DMOJK8Y DN 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone
DMOJK8Y HS Investigative
DMOJK8Y SN CHEMBL566208; SCHEMBL634229; BDBM50302914; 2-(tert-Butylamino)-3'',4''-dichlorobutyrophenone
DMOJK8Y DT Small molecular drug
DMOJK8Y PC 44542809
DMOJK8Y MW 288.2
DMOJK8Y FM C14H19Cl2NO
DMOJK8Y IC InChI=1S/C14H19Cl2NO/c1-5-12(17-14(2,3)4)13(18)9-6-7-10(15)11(16)8-9/h6-8,12,17H,5H2,1-4H3
DMOJK8Y CS CCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C
DMOJK8Y IK JYBXLCIZWPNCMU-UHFFFAOYSA-N
DMOJK8Y IU 2-(tert-butylamino)-1-(3,4-dichlorophenyl)butan-1-one
DMOJK8Y DE Discovery agent
DMMUDQ7 ID DMMUDQ7
DMMUDQ7 DN 2-(tert-Butylamino)-3',4'-dichloropentanophenone
DMMUDQ7 HS Investigative
DMMUDQ7 SN CHEMBL566050; SCHEMBL769423; BDBM50302924; J3.628.916C; 3',4'-Dichloro-alpha-(tert-butylamino)valerophenone; 2-(tert-Butylamino)-3'',4''-dichloropentanophenone
DMMUDQ7 DT Small molecular drug
DMMUDQ7 PC 44543273
DMMUDQ7 MW 302.2
DMMUDQ7 FM C15H21Cl2NO
DMMUDQ7 IC InChI=1S/C15H21Cl2NO/c1-5-6-13(18-15(2,3)4)14(19)10-7-8-11(16)12(17)9-10/h7-9,13,18H,5-6H2,1-4H3
DMMUDQ7 CS CCCC(C(=O)C1=CC(=C(C=C1)Cl)Cl)NC(C)(C)C
DMMUDQ7 IK VBQDZZHUUPHQGQ-UHFFFAOYSA-N
DMMUDQ7 IU 2-(tert-butylamino)-1-(3,4-dichlorophenyl)pentan-1-one
DMMUDQ7 DE Discovery agent
DMH3QLF ID DMH3QLF
DMH3QLF DN 2-(tert-Butylamino)-3',5'-difluoropropiophenone
DMH3QLF HS Investigative
DMH3QLF SN CHEMBL577501; SCHEMBL634113; BDBM50302939
DMH3QLF DT Small molecular drug
DMH3QLF PC 44543266
DMH3QLF MW 241.28
DMH3QLF FM C13H17F2NO
DMH3QLF IC InChI=1S/C13H17F2NO/c1-8(16-13(2,3)4)12(17)9-5-10(14)7-11(15)6-9/h5-8,16H,1-4H3
DMH3QLF CS CC(C(=O)C1=CC(=CC(=C1)F)F)NC(C)(C)C
DMH3QLF IK CXFKXPAAWKFBPJ-UHFFFAOYSA-N
DMH3QLF IU 2-(tert-butylamino)-1-(3,5-difluorophenyl)propan-1-one
DMH3QLF DE Discovery agent
DM5YJP3 ID DM5YJP3
DM5YJP3 DN 2-(tert-Butylamino)-3'-fluoropropiophenone
DM5YJP3 HS Investigative
DM5YJP3 SN 2-(tert-butylamino)-1-(3-fluorophenyl)propan-1-one; CHEMBL576063; AC1Q5DGH; AC1L4Y0Z; 2-(tert-butylamino)-1-(3-fluorphenyl)propan-1-on; 34841-40-2; SCHEMBL770228; CTK8I3431; BDBM50302925; TL8002592
DM5YJP3 DT Small molecular drug
DM5YJP3 PC 215051
DM5YJP3 MW 223.29
DM5YJP3 FM C13H18FNO
DM5YJP3 IC InChI=1S/C13H18FNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3
DM5YJP3 CS CC(C(=O)C1=CC(=CC=C1)F)NC(C)(C)C
DM5YJP3 IK CCGVLNAUEKVICK-UHFFFAOYSA-N
DM5YJP3 IU 2-(tert-butylamino)-1-(3-fluorophenyl)propan-1-one
DM5YJP3 DE Discovery agent
DMH4IRP ID DMH4IRP
DMH4IRP DN 2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine
DMH4IRP HS Investigative
DMH4IRP SN 1H-Benzimidazol-5-amine, 2-(4-thiazolyl)-; CHEMBL370420; 25893-06-5; 5-Aminothiabendazole; 5-amino-2-(thiazol-4-yl)-1H-benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazol-5-amine; AC1Q4XVD; 2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine; AC1L35H8; SCHEMBL4367564; CTK7D8516; CUDHOGCHOXYXRZ-UHFFFAOYSA-N; MolPort-004-293-518; ZINC13679482; BDBM50180749; AKOS000129404; MCULE-2929987645; 5-amino-2-thiazol-4-yl-1H-benzoimidazole; 2-Thiazol-4-yl-3H-benzoimidazol-5-ylamine; 2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-amine
DMH4IRP DT Small molecular drug
DMH4IRP PC 134912
DMH4IRP MW 216.26
DMH4IRP FM C10H8N4S
DMH4IRP IC InChI=1S/C10H8N4S/c11-6-1-2-7-8(3-6)14-10(13-7)9-4-15-5-12-9/h1-5H,11H2,(H,13,14)
DMH4IRP CS C1=CC2=C(C=C1N)NC(=N2)C3=CSC=N3
DMH4IRP IK CUDHOGCHOXYXRZ-UHFFFAOYSA-N
DMH4IRP IU 2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-amine
DMH4IRP CA CAS 25893-06-5
DMH4IRP DE Discovery agent
DMDL8KY ID DMDL8KY
DMDL8KY DN 2-(trifluoromethoxy)-9H-carbazole
DMDL8KY HS Investigative
DMDL8KY SN CHEMBL1171980; 2-(trifluoromethoxy)-9H-carbazole
DMDL8KY DT Small molecular drug
DMDL8KY PC 46855213
DMDL8KY MW 251.2
DMDL8KY FM C13H8F3NO
DMDL8KY IC InChI=1S/C13H8F3NO/c14-13(15,16)18-8-5-6-10-9-3-1-2-4-11(9)17-12(10)7-8/h1-7,17H
DMDL8KY CS C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)OC(F)(F)F
DMDL8KY IK AKPHYUFLAWJLFA-UHFFFAOYSA-N
DMDL8KY IU 2-(trifluoromethoxy)-9H-carbazole
DMDL8KY DE Discovery agent
DM7M6T3 ID DM7M6T3
DM7M6T3 DN 2-(trifluoromethyl)-9H-carbazole
DM7M6T3 HS Investigative
DM7M6T3 SN 2-(trifluoromethyl)-9H-carbazole; 2285-35-0; CHEMBL1173704; 2-TRIFLUOROMETHYL-9H-CARBAZOLE; SCHEMBL4126997; C13H8F3N; CTK4F0330; DTXSID40479099; HWUDQSLQFQHKSV-UHFFFAOYSA-N; 9H-Carbazole,2-(trifluoromethyl)-; BDBM50322579; 9H-Carbazole, 2-(trifluoromethyl)-; ZINC22003772; AKOS015967072; ACM2285350
DM7M6T3 DT Small molecular drug
DM7M6T3 PC 12169809
DM7M6T3 MW 235.2
DM7M6T3 FM C13H8F3N
DM7M6T3 IC InChI=1S/C13H8F3N/c14-13(15,16)8-5-6-10-9-3-1-2-4-11(9)17-12(10)7-8/h1-7,17H
DM7M6T3 CS C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)C(F)(F)F
DM7M6T3 IK HWUDQSLQFQHKSV-UHFFFAOYSA-N
DM7M6T3 IU 2-(trifluoromethyl)-9H-carbazole
DM7M6T3 CA CAS 2285-35-0
DM7M6T3 DE Discovery agent
DMWAKFM ID DMWAKFM
DMWAKFM DN 2-(trifluoromethyl)benzaldehyde thiosemicarbazone
DMWAKFM HS Investigative
DMWAKFM SN 3-Bromobenzaldehyde thiosemicarbazone; CHEMBL91844; (E)-2-(3-bromobenzylidene)hydrazinecarbothioamide; 1346145-39-8; [(E)-(3-bromophenyl)methylideneamino]thiourea; AC1OR2L9; MLS000679007; SCHEMBL8443935; MolPort-000-665-235; MolPort-000-517-617; FGGWIXJNLRDBPW-VZUCSPMQSA-N; MolPort-020-322-421; HMS1608D07; STK409371; SBB015558; ITH000389; BDBM50114665; AKOS002349799; AKOS000304365; 3-Bromobenzaldehyde thiosemicarbazone #; FCH4917890; FCH3689419; SMR000323398; BBV-39869959; [(E)-(3-bromophenyl)methyleneamino]thiourea; ST50169421
DMWAKFM DT Small molecular drug
DMWAKFM PC 5561401
DMWAKFM MW 247.24
DMWAKFM FM C9H8F3N3S
DMWAKFM IC InChI=1S/C9H8F3N3S/c10-9(11,12)7-4-2-1-3-6(7)5-14-15-8(13)16/h1-5H,(H3,13,15,16)/b14-5-
DMWAKFM CS C1=CC=C(C(=C1)/C=N\\NC(=S)N)C(F)(F)F
DMWAKFM IK IVJQRNPGHXNEJE-RZNTYIFUSA-N
DMWAKFM IU [(Z)-[2-(trifluoromethyl)phenyl]methylideneamino]thiourea
DMWAKFM DE Discovery agent
DMBLXOG ID DMBLXOG
DMBLXOG DN 2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX)
DMBLXOG HS Investigative
DMBLXOG SN SCHEMBL4280142; CHEMBL1095541; BDBM50316555; 2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX); 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethan-1-ol
DMBLXOG DT Small molecular drug
DMBLXOG PC 46888391
DMBLXOG MW 404.3
DMBLXOG FM C21H13F5N2O
DMBLXOG IC InChI=1S/C21H13F5N2O/c22-16-4-1-14(2-5-16)20(29,21(24,25)26)15-3-10-19-13(11-15)12-27-28(19)18-8-6-17(23)7-9-18/h1-12,29H
DMBLXOG CS C1=CC(=CC=C1C(C2=CC3=C(C=C2)N(N=C3)C4=CC=C(C=C4)F)(C(F)(F)F)O)F
DMBLXOG IK KMBFENZTPAWDBF-UHFFFAOYSA-N
DMBLXOG IU 2,2,2-trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)indazol-5-yl]ethanol
DMBLXOG DE Discovery agent
DMG4ITB ID DMG4ITB
DMG4ITB DN 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide
DMG4ITB HS Investigative
DMG4ITB SN 2,2,2-trifluoro-N-(4-sulfamoylphenyl)acetamide; CHEMBL417648; NSC36432; AC1L5TZB; AC1Q6VD0; N-[4-(aminosulfonyl)phenyl]-2,2,2-trifluoroacetamide; aromatic sulfonamide compound 9; SCHEMBL16057183; BDBM16644; acetamide, n-[4-(aminosulfonyl)phenyl]-2,2,2-trifluoro-; MolPort-001-023-586; KYCGMLPXHVMDAN-UHFFFAOYSA-N; ZINC993502; HMS1580F07; STK413007; NSC-36432; 4-Trifluoroacetamido-benzenesulfonamide; AKOS001720753; MCULE-7425586358; SDCCGMLS-0064722.P001; ST45139606; EU-0050996; AB00079123-01; SR-01000408197; AK-968/10112031
DMG4ITB DT Small molecular drug
DMG4ITB PC 235259
DMG4ITB MW 268.22
DMG4ITB FM C8H7F3N2O3S
DMG4ITB IC InChI=1S/C8H7F3N2O3S/c9-8(10,11)7(14)13-5-1-3-6(4-2-5)17(12,15)16/h1-4H,(H,13,14)(H2,12,15,16)
DMG4ITB CS C1=CC(=CC=C1NC(=O)C(F)(F)F)S(=O)(=O)N
DMG4ITB IK KYCGMLPXHVMDAN-UHFFFAOYSA-N
DMG4ITB IU 2,2,2-trifluoro-N-(4-sulfamoylphenyl)acetamide
DMG4ITB CA CAS 6275-99-6
DMG4ITB DE Discovery agent
DMJXAF7 ID DMJXAF7
DMJXAF7 DN 2,2,2-tris-(3-fluorophenyl)-acetamide
DMJXAF7 HS Investigative
DMJXAF7 SN CHEMBL260736; SCHEMBL13950949
DMJXAF7 DT Small molecular drug
DMJXAF7 PC 20684851
DMJXAF7 MW 341.3
DMJXAF7 FM C20H14F3NO
DMJXAF7 IC InChI=1S/C20H14F3NO/c21-16-7-1-4-13(10-16)20(19(24)25,14-5-2-8-17(22)11-14)15-6-3-9-18(23)12-15/h1-12H,(H2,24,25)
DMJXAF7 CS C1=CC(=CC(=C1)F)C(C2=CC(=CC=C2)F)(C3=CC(=CC=C3)F)C(=O)N
DMJXAF7 IK NYTZBODQYAXXMZ-UHFFFAOYSA-N
DMJXAF7 IU 2,2,2-tris(3-fluorophenyl)acetamide
DMJXAF7 DE Discovery agent
DMCZHEN ID DMCZHEN
DMCZHEN DN 2,2,2-tris-(4-fluorophenyl)-acetamide
DMCZHEN HS Investigative
DMCZHEN SN CHEMBL270704; 2,2,2-tris(4-fluorophenyl)acetamide; SCHEMBL2338402
DMCZHEN DT Small molecular drug
DMCZHEN PC 9884397
DMCZHEN MW 341.3
DMCZHEN FM C20H14F3NO
DMCZHEN IC InChI=1S/C20H14F3NO/c21-16-7-1-13(2-8-16)20(19(24)25,14-3-9-17(22)10-4-14)15-5-11-18(23)12-6-15/h1-12H,(H2,24,25)
DMCZHEN CS C1=CC(=CC=C1C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N)F
DMCZHEN IK NEYVEJOLUVXNDA-UHFFFAOYSA-N
DMCZHEN IU 2,2,2-tris(4-fluorophenyl)acetamide
DMCZHEN DE Discovery agent
DMG7EPF ID DMG7EPF
DMG7EPF DN 2,2',3-Tribromo-4,4',5,5'-tetrahydroxybibenzyl
DMG7EPF HS Investigative
DMG7EPF SN CHEMBL1270043; SCHEMBL15511567; BDBM50329699; 2,2'',3-Tribromo-4,4'',5,5''-tetrahydroxybibenzyl
DMG7EPF DT Small molecular drug
DMG7EPF PC 52945885
DMG7EPF MW 482.95
DMG7EPF FM C14H11Br3O4
DMG7EPF IC InChI=1S/C14H11Br3O4/c15-8-5-10(19)9(18)3-6(8)1-2-7-4-11(20)14(21)13(17)12(7)16/h3-5,18-21H,1-2H2
DMG7EPF CS C1=C(C(=CC(=C1O)O)Br)CCC2=CC(=C(C(=C2Br)Br)O)O
DMG7EPF IK NFQMJMJFBMIAAK-UHFFFAOYSA-N
DMG7EPF IU 3,4-dibromo-5-[2-(2-bromo-4,5-dihydroxyphenyl)ethyl]benzene-1,2-diol
DMG7EPF DE Discovery agent
DMAYXUR ID DMAYXUR
DMAYXUR DN 2,2',4,4',6'-pentahydroxychalcone
DMAYXUR HS Investigative
DMAYXUR SN CHEMBL244249; 2,2',4,4',6'-pentahydroxychalcone; BDBM50203986
DMAYXUR DT Small molecular drug
DMAYXUR PC 16721049
DMAYXUR MW 288.25
DMAYXUR FM C15H12O6
DMAYXUR IC InChI=1S/C15H12O6/c16-9-3-1-8(12(19)5-9)2-4-11(18)15-13(20)6-10(17)7-14(15)21/h1-7,16-17,19-21H/b4-2+
DMAYXUR CS C1=CC(=C(C=C1O)O)/C=C/C(=O)C2=C(C=C(C=C2O)O)O
DMAYXUR IK MDRJIGPMMMALHB-DUXPYHPUSA-N
DMAYXUR IU (E)-3-(2,4-dihydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one
DMAYXUR DE Discovery agent
DMMJ613 ID DMMJ613
DMMJ613 DN 2,2',4,4'-tetrahydroxy-6'-methoxychalcone
DMMJ613 HS Investigative
DMMJ613 SN CHEMBL244248; BDBM50203987
DMMJ613 DT Small molecular drug
DMMJ613 PC 44428616
DMMJ613 MW 302.28
DMMJ613 FM C16H14O6
DMMJ613 IC InChI=1S/C16H14O6/c1-22-15-8-11(18)7-14(21)16(15)12(19)5-3-9-2-4-10(17)6-13(9)20/h2-8,17-18,20-21H,1H3/b5-3+
DMMJ613 CS COC1=CC(=CC(=C1C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)O
DMMJ613 IK NNOIQNQJIKZQCN-HWKANZROSA-N
DMMJ613 IU (E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMMJ613 DE Discovery agent
DMM6KBD ID DMM6KBD
DMM6KBD DN 2,2',4,4'-tetrahydroxychalcone
DMM6KBD HS Investigative
DMM6KBD SN 2,4,2',4'-Tetrahydroxychalcone; 2,2',4,4'-tetrahydroxychalcone; CHEMBL394855; SCHEMBL675094; 2,4,2'',4''-tetrahydroxychalcone; LMPK12120128; 2,2'',4,4''-tetrahydroxychalcone; BDBM50203985
DMM6KBD DT Small molecular drug
DMM6KBD PC 10107266
DMM6KBD MW 272.25
DMM6KBD FM C15H12O5
DMM6KBD IC InChI=1S/C15H12O5/c16-10-3-1-9(14(19)7-10)2-6-13(18)12-5-4-11(17)8-15(12)20/h1-8,16-17,19-20H/b6-2+
DMM6KBD CS C1=CC(=C(C=C1O)O)/C=C/C(=O)C2=C(C=C(C=C2)O)O
DMM6KBD IK ZWTDXYUDJYDHJR-QHHAFSJGSA-N
DMM6KBD IU (E)-1,3-bis(2,4-dihydroxyphenyl)prop-2-en-1-one
DMM6KBD DE Discovery agent
DMP9ECK ID DMP9ECK
DMP9ECK DN 2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline
DMP9ECK HS Investigative
DMP9ECK SN Santoflex B; UNII-UT9B2V4JD4; USAF B-29; 2,2,4-Trimethyl-6-phenyl-1,2-dihydroquinoline; 3562-69-4; BRN 0185528; UT9B2V4JD4; CHEMBL93463; 6-Phenyl-2,2,4-trimethyldihydroquinoline; 1,2-Dihydro-2,2,4-trimethyl-6-phenylquinoline; Quinoline, 1,2-dihydro-2,2,4-trimethyl-6-phenyl-; 2,2,4-trimethyl-6-phenyl-1H-quinoline; AC1L2SCX; 2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline; 4-20-00-04116 (Beilstein Handbook Reference); SCHEMBL311413; DTXSID30189094; ZINC5315096; BDBM50066527; ACM3562694; LS-141859
DMP9ECK DT Small molecular drug
DMP9ECK PC 77098
DMP9ECK MW 249.3
DMP9ECK FM C18H19N
DMP9ECK IC InChI=1S/C18H19N/c1-13-12-18(2,3)19-17-10-9-15(11-16(13)17)14-7-5-4-6-8-14/h4-12,19H,1-3H3
DMP9ECK CS CC1=CC(NC2=C1C=C(C=C2)C3=CC=CC=C3)(C)C
DMP9ECK IK XKBGEVHKVFIMLY-UHFFFAOYSA-N
DMP9ECK IU 2,2,4-trimethyl-6-phenyl-1H-quinoline
DMP9ECK CA CAS 3562-69-4
DMP9ECK DE Discovery agent
DMPMOHQ ID DMPMOHQ
DMPMOHQ DN 2,2'-bi(1,3,4-thiadiazole)-5,5'(4H,4'H)-dithione
DMPMOHQ HS Investigative
DMPMOHQ SN CHEMBL1163927; BDBM50320719
DMPMOHQ DT Small molecular drug
DMPMOHQ PC 21790441
DMPMOHQ MW 234.4
DMPMOHQ FM C4H2N4S4
DMPMOHQ IC InChI=1S/C4H2N4S4/c9-3-7-5-1(11-3)2-6-8-4(10)12-2/h(H,7,9)(H,8,10)
DMPMOHQ CS C1(=NNC(=S)S1)C2=NNC(=S)S2
DMPMOHQ IK DAHNZAVSTBXUBS-UHFFFAOYSA-N
DMPMOHQ IU 5-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)-3H-1,3,4-thiadiazole-2-thione
DMPMOHQ DE Discovery agent
DMDIX40 ID DMDIX40
DMDIX40 DN 2,2-bis-(2-fluorophenyl)-2-phenylacetamide
DMDIX40 HS Investigative
DMDIX40 SN CHEMBL261606; SCHEMBL2332073
DMDIX40 DT Small molecular drug
DMDIX40 PC 9880246
DMDIX40 MW 323.3
DMDIX40 FM C20H15F2NO
DMDIX40 IC InChI=1S/C20H15F2NO/c21-17-12-6-4-10-15(17)20(19(23)24,14-8-2-1-3-9-14)16-11-5-7-13-18(16)22/h1-13H,(H2,23,24)
DMDIX40 CS C1=CC=C(C=C1)C(C2=CC=CC=C2F)(C3=CC=CC=C3F)C(=O)N
DMDIX40 IK JYLGTXBPFRKVJO-UHFFFAOYSA-N
DMDIX40 IU 2,2-bis(2-fluorophenyl)-2-phenylacetamide
DMDIX40 DE Discovery agent
DM6ICRJ ID DM6ICRJ
DM6ICRJ DN 2,2-bis-(3-fluorophenyl)-2-phenylacetamide
DM6ICRJ HS Investigative
DM6ICRJ SN CHEMBL261828; SCHEMBL13950934
DM6ICRJ DT Small molecular drug
DM6ICRJ PC 20684855
DM6ICRJ MW 323.3
DM6ICRJ FM C20H15F2NO
DM6ICRJ IC InChI=1S/C20H15F2NO/c21-17-10-4-8-15(12-17)20(19(23)24,14-6-2-1-3-7-14)16-9-5-11-18(22)13-16/h1-13H,(H2,23,24)
DM6ICRJ CS C1=CC=C(C=C1)C(C2=CC(=CC=C2)F)(C3=CC(=CC=C3)F)C(=O)N
DM6ICRJ IK WBCHZEIUTRPOCM-UHFFFAOYSA-N
DM6ICRJ IU 2,2-bis(3-fluorophenyl)-2-phenylacetamide
DM6ICRJ DE Discovery agent
DMTODR2 ID DMTODR2
DMTODR2 DN 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide
DMTODR2 HS Investigative
DMTODR2 SN CHEMBL574594; 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide; SCHEMBL4536216
DMTODR2 DT Small molecular drug
DMTODR2 PC 45482630
DMTODR2 MW 263.24
DMTODR2 FM C14H11F2NO2
DMTODR2 IC InChI=1S/C14H11F2NO2/c15-11-5-1-3-9(7-11)13(14(18)17-19)10-4-2-6-12(16)8-10/h1-8,13,19H,(H,17,18)
DMTODR2 CS C1=CC(=CC(=C1)F)C(C2=CC(=CC=C2)F)C(=O)NO
DMTODR2 IK OCJJUBQJPOHGBE-UHFFFAOYSA-N
DMTODR2 IU 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide
DMTODR2 DE Discovery agent
DM2RKD6 ID DM2RKD6
DM2RKD6 DN 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide
DM2RKD6 HS Investigative
DM2RKD6 SN CHEMBL572805; 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide; SCHEMBL2848402
DM2RKD6 DT Small molecular drug
DM2RKD6 PC 45482643
DM2RKD6 MW 296.1
DM2RKD6 FM C14H11Cl2NO2
DM2RKD6 IC InChI=1S/C14H11Cl2NO2/c15-11-5-1-9(2-6-11)13(14(18)17-19)10-3-7-12(16)8-4-10/h1-8,13,19H,(H,17,18)
DM2RKD6 CS C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(=O)NO)Cl
DM2RKD6 IK MITRLTIJDHOUFN-UHFFFAOYSA-N
DM2RKD6 IU 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide
DM2RKD6 DE Discovery agent
DM5PWQM ID DM5PWQM
DM5PWQM DN 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide
DM5PWQM HS Investigative
DM5PWQM SN CHEMBL573190; 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide; SCHEMBL2841871
DM5PWQM DT Small molecular drug
DM5PWQM PC 45482672
DM5PWQM MW 263.24
DM5PWQM FM C14H11F2NO2
DM5PWQM IC InChI=1S/C14H11F2NO2/c15-11-5-1-9(2-6-11)13(14(18)17-19)10-3-7-12(16)8-4-10/h1-8,13,19H,(H,17,18)
DM5PWQM CS C1=CC(=CC=C1C(C2=CC=C(C=C2)F)C(=O)NO)F
DM5PWQM IK HHJNWMNXSDYVHL-UHFFFAOYSA-N
DM5PWQM IU 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide
DM5PWQM DE Discovery agent
DMFPYU8 ID DMFPYU8
DMFPYU8 DN 2,2-Dibenzylcyclopentanol
DMFPYU8 HS Investigative
DMFPYU8 SN 2,2-Dibenzylcyclopentanol
DMFPYU8 DT Small molecular drug
DMFPYU8 PC 10468150
DMFPYU8 MW 266.4
DMFPYU8 FM C19H22O
DMFPYU8 IC InChI=1S/C19H22O/c20-18-12-7-13-19(18,14-16-8-3-1-4-9-16)15-17-10-5-2-6-11-17/h1-6,8-11,18,20H,7,12-15H2
DMFPYU8 CS C1CC(C(C1)(CC2=CC=CC=C2)CC3=CC=CC=C3)O
DMFPYU8 IK MSJGQZXPPBXPBA-UHFFFAOYSA-N
DMFPYU8 IU 2,2-dibenzylcyclopentan-1-ol
DMFPYU8 DE Discovery agent
DMKXFDA ID DMKXFDA
DMKXFDA DN 2,2-difluoromevalonate 5-diphosphate
DMKXFDA HS Investigative
DMKXFDA SN 2,2-difluoromevalonate 5-diphosphate; GTPL3213; CHEMBL1162018; 2,2-difluoro-3-hydroxy-5-(hydroxy-phosphonooxyphosphoryl)oxy-3-methylpentanoic acid
DMKXFDA DT Small molecular drug
DMKXFDA PC 24779755
DMKXFDA MW 344.1
DMKXFDA FM C6H12F2O10P2
DMKXFDA IC InChI=1S/C6H12F2O10P2/c1-5(11,6(7,8)4(9)10)2-3-17-20(15,16)18-19(12,13)14/h11H,2-3H2,1H3,(H,9,10)(H,15,16)(H2,12,13,14)
DMKXFDA CS CC(CCOP(=O)(O)OP(=O)(O)O)(C(C(=O)O)(F)F)O
DMKXFDA IK TYAGFMDNISQMRJ-UHFFFAOYSA-N
DMKXFDA IU 2,2-difluoro-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMKXFDA DE Discovery agent
DMPX642 ID DMPX642
DMPX642 DN 2,2-diMeBut-RYYRIK-NH2
DMPX642 HS Investigative
DMPX642 SN CHEMBL403588
DMPX642 DT Small molecular drug
DMPX642 PC 44456216
DMPX642 MW 979.2
DMPX642 FM C48H78N14O8
DMPX642 IC InChI=1S/C48H78N14O8/c1-6-29(3)38(44(69)57-33(39(50)64)17-11-12-24-49)62-41(66)34(18-13-25-55-46(51)52)58-42(67)37(28-31-20-22-32(63)23-21-31)60-43(68)36(27-30-15-9-8-10-16-30)59-40(65)35(19-14-26-56-47(53)54)61-45(70)48(4,5)7-2/h8-10,15-16,20-23,29,33-38,63H,6-7,11-14,17-19,24-28,49H2,1-5H3,(H2,50,64)(H,57,69)(H,58,67)(H,59,65)(H,60,68)(H,61,70)(H,62,66)(H4,51,52,55)(H4,53,54,56)/t29-,33-,34-,35-,36-,37-,38-/m0/s1
DMPX642 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)(C)CC
DMPX642 IK JOZALXQUIMQHHA-AVTNSMPVSA-N
DMPX642 IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2,2-dimethylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMPX642 DE Discovery agent
DM34IX5 ID DM34IX5
DM34IX5 DN 2,2-Dimethoxy-1,2-diphenyl-ethanone
DM34IX5 HS Investigative
DM34IX5 SN 24650-42-8; 2,2-Dimethoxy-2-phenylacetophenone; 2,2-Dimethoxy-1,2-diphenylethanone; Benzil dimethyl ketal; Kayacure BDMK; Irgacure 651; Ethanone, 2,2-dimethoxy-1,2-diphenyl-; Lucirin BDK; Photomer 51; Esacure KB 1; Irgacure 641; Irgacure 621; Irgacure I 651; Irgacure E 651; Benzil Dimethylketal; Irgacure 951; Benzil mono(dimethyl ketal); 2,2-Dimethoxy-1,2-diphenylethan-1-one; Benzil mono(dimethyl acetal); Benzil dimethyl acetal; alpha,alpha-Dimethoxy-alpha-phenylacetophenone; KB 1; 2,2-Dimethoxy-1,2-diphenyl-ethanone
DM34IX5 DT Small molecular drug
DM34IX5 PC 90571
DM34IX5 MW 256.3
DM34IX5 FM C16H16O3
DM34IX5 IC InChI=1S/C16H16O3/c1-18-16(19-2,14-11-7-4-8-12-14)15(17)13-9-5-3-6-10-13/h3-12H,1-2H3
DM34IX5 CS COC(C1=CC=CC=C1)(C(=O)C2=CC=CC=C2)OC
DM34IX5 IK KWVGIHKZDCUPEU-UHFFFAOYSA-N
DM34IX5 IU 2,2-dimethoxy-1,2-diphenylethanone
DM34IX5 CA CAS 24650-42-8
DM34IX5 DE Discovery agent
DMQYCFI ID DMQYCFI
DMQYCFI DN 2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
DMQYCFI HS Investigative
DMQYCFI SN Xyloidone; Dehydro-alpha-lapachone; 15297-92-4; Dehydrolapachone; DEHYDROPLAPACHONE; Dehydro-.alpha.-lapachol; Dehydro-.alpha.-lapacone; NSC106453; NSC629748; 2,2-Dimethyl-2H-benzo[g]chromene-5,10-dione; Dehydro-.alpha.-lapachone; NSC 629748; NSC 106453; UNII-305WY61CUF; .alpha.-Lapachone, dehydro-; 2H-Naphtho[2,3-b]pyran-5,10-dione, 2,2-dimethyl-; 305WY61CUF; 2,2-dimethylbenzo[g]chromene-5,10-dione; 2H-Naphtho[2,3-b]pyran-5,10-dione,2,2-dimethyl-; 2,2-dimethyl-2H,5H,10H-benzo[g]chromene-5,10-dione; Xyloidone (VAN)
DMQYCFI DT Small molecular drug
DMQYCFI PC 72734
DMQYCFI MW 240.25
DMQYCFI FM C15H12O3
DMQYCFI IC InChI=1S/C15H12O3/c1-15(2)8-7-11-12(16)9-5-3-4-6-10(9)13(17)14(11)18-15/h3-8H,1-2H3
DMQYCFI CS CC1(C=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O)C
DMQYCFI IK OWFHAMHRUCUSRM-UHFFFAOYSA-N
DMQYCFI IU 2,2-dimethylbenzo[g]chromene-5,10-dione
DMQYCFI CA CAS 15297-92-4
DMQYCFI DE Discovery agent
DM7BL04 ID DM7BL04
DM7BL04 DN 2,2-dimethyl-3-methyleneheptadecane
DM7BL04 HS Investigative
DM7BL04 SN CHEMBL270375; 2-Propanone, 3-(dodecylthio)-1,1,1-trifluoro-; 92682-28-5; ACMC-20lwey; CTK3F7670; DTXSID90467547; BDBM50371972
DM7BL04 DT Small molecular drug
DM7BL04 PC 11493344
DM7BL04 MW 312.4
DM7BL04 FM C15H27F3OS
DM7BL04 IC InChI=1S/C15H27F3OS/c1-2-3-4-5-6-7-8-9-10-11-12-20-13-14(19)15(16,17)18/h2-13H2,1H3
DM7BL04 CS CCCCCCCCCCCCSCC(=O)C(F)(F)F
DM7BL04 IK NACMLRDTSWENRZ-UHFFFAOYSA-N
DM7BL04 IU 3-dodecylsulfanyl-1,1,1-trifluoropropan-2-one
DM7BL04 CA CAS 92682-28-5
DM7BL04 DE Discovery agent
DMATB8H ID DMATB8H
DMATB8H DN 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide
DMATB8H HS Investigative
DMATB8H SN CHEMBL23285; 2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide; 103826-87-5; AC1MBHEI; Oprea1_396828; p-pivaloylaminobenzenesulfonamide; Propanamide, N-[4-(aminosulfonyl)phenyl]-2,2-dimethyl-; N-(4-Sulfamoylphenyl)Pivalamide; SCHEMBL10603454; ZINC73524; BDBM16649; aromatic sulfonamide compound 14; CCG-916; KGBTVIQRHXYTRQ-UHFFFAOYSA-N; 4-Pivaloylamido-benzenesulfonamide; MolPort-002-912-681; AKOS003441276; MCULE-2674794031; BRD-K77020128-001-01-6
DMATB8H DT Small molecular drug
DMATB8H PC 2725651
DMATB8H MW 256.32
DMATB8H FM C11H16N2O3S
DMATB8H IC InChI=1S/C11H16N2O3S/c1-11(2,3)10(14)13-8-4-6-9(7-5-8)17(12,15)16/h4-7H,1-3H3,(H,13,14)(H2,12,15,16)
DMATB8H CS CC(C)(C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMATB8H IK KGBTVIQRHXYTRQ-UHFFFAOYSA-N
DMATB8H IU 2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide
DMATB8H DE Discovery agent
DMTBAUG ID DMTBAUG
DMTBAUG DN 2,2-Diphenyl-ethylamine
DMTBAUG HS Investigative
DMTBAUG SN 2,2-Diphenylethylamine; 3963-62-0; 2,2-Diphenylethanamine; 2,2-Diphenyl-ethylamine; 1-Amino-2,2-diphenylethane; 2,2-Diphenylethan-1-Amine; CHEMBL10780; 2,2-Diphenylethylamine, 96%; RXMTUVIKZRXSSM-UHFFFAOYSA-N; NSC27209; EINECS 223-565-7; PubChem7986; ACMC-1CSWZ; 2,2-diphenylethyl-amine; 2,2- diphenylethylamine; AC1L2TCM; beta-phenylbenzeneethanamine; 2,2-diphenyl-ethyl-amine; 2,2-diphenyl ethyl amine; 2,2-di(phenyl)ethanamine; 2,2-Diphenylethanamine #; 2,2-bis-phenyl-ethylamine; AC1Q53LU; Benzeneethanamine, b-phenyl-
DMTBAUG DT Small molecular drug
DMTBAUG PC 77575
DMTBAUG MW 197.27
DMTBAUG FM C14H15N
DMTBAUG IC InChI=1S/C14H15N/c15-11-14(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,14H,11,15H2
DMTBAUG CS C1=CC=C(C=C1)C(CN)C2=CC=CC=C2
DMTBAUG IK RXMTUVIKZRXSSM-UHFFFAOYSA-N
DMTBAUG IU 2,2-diphenylethanamine
DMTBAUG CA CAS 3963-62-0
DMTBAUG DE Discovery agent
DMOQDBA ID DMOQDBA
DMOQDBA DN 2,2'-pyridylisatogen tosylate
DMOQDBA HS Investigative
DMOQDBA SN 2,2'-Pyridylisatogen tosylate; 56583-49-4; PIT; 2-(2-pyridinyl)-(3h)-indol-3-one-1-oxide 4-methylbenzenesulfonate; 4-methylbenzenesulfonic acid; 1-oxido-2-pyridin-2-ylindol-1-ium-3-one; Tocris-1682; AC1L3Y9P; AC1Q6WM2; GTPL1729; CHEMBL1364808; CTK1H0971; MolPort-023-276-189; HMS3268O03; AKOS024456745; 2-(pyridin-2-yl)-3h-indol-3-one 1-oxide 4-methylbenzenesulfonate(1:1); NCGC00025378-01; KB-221271; B6827; SR-01000597767; SR-01000597767-1; 4-methylbenzenesulfonic acid
DMOQDBA DT Small molecular drug
DMOQDBA PC 124333
DMOQDBA MW 396.4
DMOQDBA FM C20H16N2O5S
DMOQDBA IC InChI=1S/C13H8N2O2.C7H8O3S/c16-13-9-5-1-2-7-11(9)15(17)12(13)10-6-3-4-8-14-10;1-6-2-4-7(5-3-6)11(8,9)10/h1-8H;2-5H,1H3,(H,8,9,10)
DMOQDBA CS CC1=CC=C(C=C1)S(=O)(=O)O.C1=CC=C2C(=C1)C(=O)C(=[N+]2[O-])C3=CC=CC=N3
DMOQDBA IK MMPTYEXNPWSTOR-UHFFFAOYSA-N
DMOQDBA IU 4-methylbenzenesulfonic acid;1-oxido-2-pyridin-2-ylindol-1-ium-3-one
DMOQDBA DE Discovery agent
DM7H34U ID DM7H34U
DM7H34U DN 2,3,3-Triphenyl-acrylonitrile
DM7H34U HS Investigative
DM7H34U SN Triphenylacrylonitrile; 2,3,3-Triphenylacrylonitrile; Triphenylcyanoethylene; 6304-33-2; Acrylonitrile, triphenyl-; 2,3,3-triphenylprop-2-enenitrile; 2,3,3-Triphenyl-acrylonitrile; alpha,beta-Diphenylcinnamonitrile; ACRYLONITRILE, 2,3,3-TRIPHENYL-; EINECS 228-610-4; NSC 42900; 2,3,3-Trifenylakrylonitril [Czech]; BRN 1980289; alpha-(Diphenylmethylene)benzeneacetic acid; AI3-63069; MLS002608486; CHEBI:34217; Benzeneacetic acid, alpha-(diphenylmethylene)-; NSC42900; Benzeneacetonitrile, .alpha.-(diphenylmethylene)-
DM7H34U DT Small molecular drug
DM7H34U PC 22743
DM7H34U MW 281.3
DM7H34U FM C21H15N
DM7H34U IC InChI=1S/C21H15N/c22-16-20(17-10-4-1-5-11-17)21(18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15H
DM7H34U CS C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=CC=C3)C#N
DM7H34U IK OPACMJHTQWVSKW-UHFFFAOYSA-N
DM7H34U IU 2,3,3-triphenylprop-2-enenitrile
DM7H34U CA CAS 6304-33-2
DM7H34U CB CHEBI:34217
DM7H34U DE Discovery agent
DMV1CX0 ID DMV1CX0
DMV1CX0 DN 2,3,4,11-tetrahydro-1H-benzo[a]carbazole
DMV1CX0 HS Investigative
DMV1CX0 SN CHEMBL1173621; Tetrahydrobenzcarbazol; 2,3,4,11-tetrahydro-1H-benzo[a]carbazole; SCHEMBL17775042; BDBM50322598
DMV1CX0 DT Small molecular drug
DMV1CX0 PC 11593764
DMV1CX0 MW 221.3
DMV1CX0 FM C16H15N
DMV1CX0 IC InChI=1S/C16H15N/c1-2-6-12-11(5-1)9-10-14-13-7-3-4-8-15(13)17-16(12)14/h3-4,7-10,17H,1-2,5-6H2
DMV1CX0 CS C1CCC2=C(C1)C=CC3=C2NC4=CC=CC=C34
DMV1CX0 IK OOCBASGHISDDOY-UHFFFAOYSA-N
DMV1CX0 IU 2,3,4,11-tetrahydro-1H-benzo[a]carbazole
DMV1CX0 DE Discovery agent
DMK4LTB ID DMK4LTB
DMK4LTB DN 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol
DMK4LTB HS Investigative
DMK4LTB SN CHEMBL362761; Phenol, 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)-; 111863-67-3; ACMC-20meye; 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol; 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol; CTK0G1675; DTXSID50433647; BDBM50150785; 2,2',3,4,4',5-Hexabromo-6-hydroxydiphenyl ether; 2,3,4,5-tetrabromo-6-(2',4'-dibromophenoxy)phenol; 2-(2'',4''-dibromophenoxy-3,4,5,6-tetrabromophenol
DMK4LTB DT Small molecular drug
DMK4LTB PC 9986835
DMK4LTB MW 659.6
DMK4LTB FM C12H4Br6O2
DMK4LTB IC InChI=1S/C12H4Br6O2/c13-4-1-2-6(5(14)3-4)20-12-10(18)8(16)7(15)9(17)11(12)19/h1-3,19H
DMK4LTB CS C1=CC(=C(C=C1Br)Br)OC2=C(C(=C(C(=C2Br)Br)Br)Br)O
DMK4LTB IK LDMKXEGTHGJWLG-UHFFFAOYSA-N
DMK4LTB IU 2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
DMK4LTB CA CAS 111863-67-3
DMK4LTB DE Discovery agent
DMGQE4B ID DMGQE4B
DMGQE4B DN 2,3,4,5-Tetrafluoro-6-pentafluorophenylazo-phenol
DMGQE4B HS Investigative
DMGQE4B DT Small molecular drug
DMGQE4B PC 125381
DMGQE4B MW 360.13
DMGQE4B FM C12HF9N2O
DMGQE4B IC InChI=1S/C12HF9N2O/c13-1-2(14)6(18)10(7(19)3(1)15)22-23-11-8(20)4(16)5(17)9(21)12(11)24/h24H
DMGQE4B CS C1(=C(C(=C(C(=C1F)F)F)F)O)N=NC2=C(C(=C(C(=C2F)F)F)F)F
DMGQE4B IK VNLIKHWBADHUKM-UHFFFAOYSA-N
DMGQE4B IU 2,3,4,5-tetrafluoro-6-[(2,3,4,5,6-pentafluorophenyl)diazenyl]phenol
DMGQE4B CA CAS 129520-55-4
DMGQE4B DE Discovery agent
DM1RE9Q ID DM1RE9Q
DM1RE9Q DN 2,3,4,5-Tetrahydro-1H-benzo[c]azepine
DM1RE9Q HS Investigative
DM1RE9Q SN 2,3,4,5-Tetrahydro-1H-benzo[c]azepine; 7216-22-0; 2,3,4,5-tetrahydro-1H-2-benzazepine; 1H-2-Benzazepine, 2,3,4,5-tetrahydro-; CHEMBL118310; SCHEMBL233066; ARK042; CTK2H2810; DTXSID00440260; SIQBPWRTJNBBER-UHFFFAOYSA-N; MolPort-020-016-004; BDBM50052883; ANW-49031; ZINC13516868; AKOS005264678; MCULE-2809792553; AB49623; 2,3,4,5-tetrahydro 1H-2-benzazepine; BS-13541; BR-76361; AJ-64016; TC-137776; DB-074526; W8089; ST24021451; FT-0707305; 4CH-000440; S-5095; 2,3,4,5-tetrahydro-1H-benzo[c]azepine, AldrichCPR
DM1RE9Q DT Small molecular drug
DM1RE9Q PC 10464472
DM1RE9Q MW 147.22
DM1RE9Q FM C10H13N
DM1RE9Q IC InChI=1S/C10H13N/c1-2-5-10-8-11-7-3-6-9(10)4-1/h1-2,4-5,11H,3,6-8H2
DM1RE9Q CS C1CC2=CC=CC=C2CNC1
DM1RE9Q IK SIQBPWRTJNBBER-UHFFFAOYSA-N
DM1RE9Q IU 2,3,4,5-tetrahydro-1H-2-benzazepine
DM1RE9Q CA CAS 7216-22-0
DM1RE9Q DE Discovery agent
DM4EZOB ID DM4EZOB
DM4EZOB DN 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine
DM4EZOB HS Investigative
DM4EZOB SN 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine; 5946-39-4; 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine; CHEMBL323692; 1H-1,4-Benzodiazepine, 2,3,4,5-tetrahydro-; 2,3,4,5-tetrahydro-(1h)-1,4-benzodiazepine; 2,3,4,5-tetrahydro-1h benzo[e][1,4]diazepine; AC1MCKFZ; PubChem14772; ACMC-1ANOK; tetrahydrobenzo[1,4]diazepine; SCHEMBL379799; BEN206; BEN025; AC1Q1I93; KS-00001OTC; CTK1G9067; DTXSID20378071; MolPort-000-006-540; MLXBHOCKBUILHN-UHFFFAOYSA-N; ZINC2511438; STL554215; CT-889; BDBM50052888; MFCD03789577; BBL100421; AKOS005254212
DM4EZOB DT Small molecular drug
DM4EZOB PC 2771762
DM4EZOB MW 148.2
DM4EZOB FM C9H12N2
DM4EZOB IC InChI=1S/C9H12N2/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10-11H,5-7H2
DM4EZOB CS C1CNC2=CC=CC=C2CN1
DM4EZOB IK MLXBHOCKBUILHN-UHFFFAOYSA-N
DM4EZOB IU 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine
DM4EZOB CA CAS 5946-39-4
DM4EZOB DE Discovery agent
DMX8NYD ID DMX8NYD
DMX8NYD DN 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole
DMX8NYD HS Investigative
DMX8NYD SN 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole; 6208-60-2; 2,3,4,5-Tetrahydro-1h-pyrido[4,3,b]indole; 1H,2H,3H,4H,5H-pyrido[4,3-b]indole; 1H-Pyrido[4,3-b]indole, 2,3,4,5-tetrahydro-; MLS001198355; 1,2,3,4-tetrahydropyridino[4,3-b]indole; SMR000559186; SR-01000530765; PubChem2433; BAS 00107381; AC1Q1GJA; AC1LF5C1; Oprea1_367545; SCHEMBL169954; CHEMBL269074; AC1Q1H88; CTK5B4311; BDBM73071; DTXSID50352329; cid_11572011; MolPort-000-928-989; RPROHCOBMVQVIV-UHFFFAOYSA-N; ALBB-007677; KS-00000E6L; STK500458; BBL010407; ANW-57714; ZINC19228212
DMX8NYD DT Small molecular drug
DMX8NYD PC 723230
DMX8NYD MW 172.23
DMX8NYD FM C11H12N2
DMX8NYD IC InChI=1S/C11H12N2/c1-2-4-10-8(3-1)9-7-12-6-5-11(9)13-10/h1-4,12-13H,5-7H2
DMX8NYD CS C1CNCC2=C1NC3=CC=CC=C23
DMX8NYD IK RPROHCOBMVQVIV-UHFFFAOYSA-N
DMX8NYD IU 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
DMX8NYD CA CAS 6208-60-2
DMX8NYD DE Discovery agent
DMOFG4M ID DMOFG4M
DMOFG4M DN 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine
DMOFG4M HS Investigative
DMOFG4M SN 17775-01-8; 2,3,4,5-Tetrahydrobenzo[f][1,4]oxazepine; 2,3,4,5-tetrahydro-1,4-benzoxazepine; 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine; CHEMBL118420; 1,4-Benzoxazepine, 2,3,4,5-tetrahydro-; 2.3.4.5-tetrahydro-benzo[f][1,4]oxazepine; 1,4-Benzoxazepine, 2,3,4,5-tetrahydro-, hydrochloride; AC1Q1IB5; AC1Q1IB6; SCHEMBL400964; CTK4D6590; DTXSID90619367; HDVHFHONOKCUHQ-UHFFFAOYSA-N; MolPort-001-792-633; KS-00000I8M; ALBB-011885; CT-115; BDBM50052890; ZINC11802711; ANW-65610; STK897763; AKOS005173482; MCULE-4987146186; CS-W007152; BS-12101
DMOFG4M DT Small molecular drug
DMOFG4M PC 21882775
DMOFG4M MW 149.19
DMOFG4M FM C9H11NO
DMOFG4M IC InChI=1S/C9H11NO/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10H,5-7H2
DMOFG4M CS C1COC2=CC=CC=C2CN1
DMOFG4M IK HDVHFHONOKCUHQ-UHFFFAOYSA-N
DMOFG4M IU 2,3,4,5-tetrahydro-1,4-benzoxazepine
DMOFG4M CA CAS 17775-01-8
DMOFG4M DE Discovery agent
DMXAS25 ID DMXAS25
DMXAS25 DN 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMXAS25 HS Investigative
DMXAS25 SN 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; CHEMBL112265; 352549-39-4; CBMicro_001045; Cambridge id 5870454; AC1N6ME3; Oprea1_743470; SCHEMBL251128; CTK1B0687; DTXSID20401358; MolPort-000-735-346; HMS1632P07; SMSF0008851; STL525366; BDBM50178767; carboxamido-1,2,3-tetrahydrocarbazole; AKOS004917884; CB02357; BIM-0000968.P001; SR-01000154363; SR-01000154363-1; 1H-Carbazole-1-carboxamide, 2,3,4,9-tetrahydro-
DMXAS25 DT Small molecular drug
DMXAS25 PC 4262314
DMXAS25 MW 214.26
DMXAS25 FM C13H14N2O
DMXAS25 IC InChI=1S/C13H14N2O/c14-13(16)10-6-3-5-9-8-4-1-2-7-11(8)15-12(9)10/h1-2,4,7,10,15H,3,5-6H2,(H2,14,16)
DMXAS25 CS C1CC(C2=C(C1)C3=CC=CC=C3N2)C(=O)N
DMXAS25 IK YMLOFDJHJSQCSN-UHFFFAOYSA-N
DMXAS25 IU 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
DMXAS25 CA CAS 352549-39-4
DMXAS25 DE Discovery agent
DMQYEZP ID DMQYEZP
DMQYEZP DN 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol
DMQYEZP HS Investigative
DMQYEZP SN CHEMBL462942; 80246-24-8; 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol; SCHEMBL5531128; CTK3E5867; DTXSID70475089; 2-OH-BDE-123; ZINC44386786; BDBM50292444; 2-hydroxy-2',3,4,4',5-pentabromodiphenyl ether; Phenol, 2,3,4-tribromo-6-(2,4-dibromophenoxy)-
DMQYEZP DT Small molecular drug
DMQYEZP PC 11978695
DMQYEZP MW 580.7
DMQYEZP FM C12H5Br5O2
DMQYEZP IC InChI=1S/C12H5Br5O2/c13-5-1-2-8(6(14)3-5)19-9-4-7(15)10(16)11(17)12(9)18/h1-4,18H
DMQYEZP CS C1=CC(=C(C=C1Br)Br)OC2=CC(=C(C(=C2O)Br)Br)Br
DMQYEZP IK FSIJSYKTNOYMTQ-UHFFFAOYSA-N
DMQYEZP IU 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol
DMQYEZP CA CAS 80246-24-8
DMQYEZP DE Discovery agent
DMCAZ32 ID DMCAZ32
DMCAZ32 DN 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide
DMCAZ32 HS Investigative
DMCAZ32 SN CHEMBL214839; 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide; BDBM50196033
DMCAZ32 DT Small molecular drug
DMCAZ32 PC 16090303
DMCAZ32 MW 287.31
DMCAZ32 FM C16H17NO4
DMCAZ32 IC InChI=1S/C16H17NO4/c1-9(2)11-8-12(14(19)15(20)13(11)18)16(21)17-10-6-4-3-5-7-10/h3-9,18-20H,1-2H3,(H,17,21)
DMCAZ32 CS CC(C)C1=CC(=C(C(=C1O)O)O)C(=O)NC2=CC=CC=C2
DMCAZ32 IK HMVKMSUSFWLQLX-UHFFFAOYSA-N
DMCAZ32 IU 2,3,4-trihydroxy-N-phenyl-5-propan-2-ylbenzamide
DMCAZ32 DE Discovery agent
DMWHK35 ID DMWHK35
DMWHK35 DN 2,3,4-trihydroxybenzoic acid
DMWHK35 HS Investigative
DMWHK35 SN 2,3,4-TRIHYDROXYBENZOIC ACID; 610-02-6; 4-Pyrogallolcarboxylic acid; Pyrogallolcarboxylic acid; 2,3,4-Trihydroxybenzoate; Pyrogallol-4-carboxylic acid; UNII-AD1ID2JF5O; Benzoic acid, trihydroxy-; Benzoic acid, 2,3,4-trihydroxy-; 2,3,4-Trihydroxybenzene carboxylic acid; EINECS 210-205-9; NSC 27436; AD1ID2JF5O; BRN 2210807; CHEMBL220779; CHEBI:88714; 2,3,4-Trihydroxybenzoic acid, 97%; AK-94172; W-105210; pyrogallolcarboxylate; trihydroxybenzoic acid; 2,4-Trihydroxybenzoate; AC1L1YC0; 2,4-Trihydroxybenzoic acid; Oprea1_870375
DMWHK35 DT Small molecular drug
DMWHK35 PC 11874
DMWHK35 MW 170.12
DMWHK35 FM C7H6O5
DMWHK35 IC InChI=1S/C7H6O5/c8-4-2-1-3(7(11)12)5(9)6(4)10/h1-2,8-10H,(H,11,12)
DMWHK35 CS C1=CC(=C(C(=C1C(=O)O)O)O)O
DMWHK35 IK BRRSNXCXLSVPFC-UHFFFAOYSA-N
DMWHK35 IU 2,3,4-trihydroxybenzoic acid
DMWHK35 CA CAS 610-02-6
DMWHK35 CB CHEBI:88714
DMWHK35 DE Discovery agent
DMPRF1X ID DMPRF1X
DMPRF1X DN 2,3,4-Trimethoxy-4'-amino-trans-stilbene
DMPRF1X HS Investigative
DMPRF1X SN CHEMBL1173067; BDBM50322053
DMPRF1X DT Small molecular drug
DMPRF1X PC 49799652
DMPRF1X MW 285.34
DMPRF1X FM C17H19NO3
DMPRF1X IC InChI=1S/C17H19NO3/c1-19-15-11-8-13(16(20-2)17(15)21-3)7-4-12-5-9-14(18)10-6-12/h4-11H,18H2,1-3H3/b7-4+
DMPRF1X CS COC1=C(C(=C(C=C1)/C=C/C2=CC=C(C=C2)N)OC)OC
DMPRF1X IK YLCPSZLMRABQDV-QPJJXVBHSA-N
DMPRF1X IU 4-[(E)-2-(2,3,4-trimethoxyphenyl)ethenyl]aniline
DMPRF1X DE Discovery agent
DM592YS ID DM592YS
DM592YS DN 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide
DM592YS HS Investigative
DM592YS SN 2,3,5,6-TETRAFLUORO-4-METHOXY-BENZAMIDE; 2,3,5,6-tetrafluoro-4-methoxybenzamide; C8H5F4NO2; BEK; AC1LCVZS; SCHEMBL1002032; ZINC12501151; AKOS000299242
DM592YS DT Small molecular drug
DM592YS PC 657081
DM592YS MW 223.12
DM592YS FM C8H5F4NO2
DM592YS IC InChI=1S/C8H5F4NO2/c1-15-7-5(11)3(9)2(8(13)14)4(10)6(7)12/h1H3,(H2,13,14)
DM592YS CS COC1=C(C(=C(C(=C1F)F)C(=O)N)F)F
DM592YS IK JTXPTSGPUNTKSM-UHFFFAOYSA-N
DM592YS IU 2,3,5,6-tetrafluoro-4-methoxybenzamide
DM592YS DE Discovery agent
DMRVYKQ ID DMRVYKQ
DMRVYKQ DN 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol
DMRVYKQ HS Investigative
DMRVYKQ DT Small molecular drug
DMRVYKQ PC 168394
DMRVYKQ MW 360.13
DMRVYKQ FM C12HF9N2O
DMRVYKQ IC InChI=1S/C12HF9N2O/c13-1-2(14)4(16)10(5(17)3(1)15)22-23-11-6(18)8(20)12(24)9(21)7(11)19/h24H
DMRVYKQ CS C1(=C(C(=C(C(=C1F)F)O)F)F)N=NC2=C(C(=C(C(=C2F)F)F)F)F
DMRVYKQ IK JYNSAKFWNZEUTH-UHFFFAOYSA-N
DMRVYKQ IU 2,3,5,6-tetrafluoro-4-[(2,3,4,5,6-pentafluorophenyl)diazenyl]phenol
DMRVYKQ CA CAS 25593-03-7
DMRVYKQ DE Discovery agent
DMLI5UT ID DMLI5UT
DMLI5UT DN 2,3,5-Trimethoxy-4'-amino-trans-stilbene
DMLI5UT HS Investigative
DMLI5UT SN CHEMBL1170663; BDBM50322054
DMLI5UT DT Small molecular drug
DMLI5UT PC 49799657
DMLI5UT MW 285.34
DMLI5UT FM C17H19NO3
DMLI5UT IC InChI=1S/C17H19NO3/c1-19-15-10-13(17(21-3)16(11-15)20-2)7-4-12-5-8-14(18)9-6-12/h4-11H,18H2,1-3H3/b7-4+
DMLI5UT CS COC1=CC(=C(C(=C1)OC)OC)/C=C/C2=CC=C(C=C2)N
DMLI5UT IK SRZFJBWGNUYOJJ-QPJJXVBHSA-N
DMLI5UT IU 4-[(E)-2-(2,3,5-trimethoxyphenyl)ethenyl]aniline
DMLI5UT DE Discovery agent
DMCKO6T ID DMCKO6T
DMCKO6T DN 2,3,7-trichloro-5-nitroquinoxaline (TNQX)
DMCKO6T HS Investigative
DMCKO6T SN 5-nitro-2,3,7-trichloroquinoxaline; 72558-70-4; 2,3,7-trichloro-5-nitroquinoxaline
DMCKO6T DT Small molecular drug
DMCKO6T PC 10378848
DMCKO6T MW 278.5
DMCKO6T FM C8H2Cl3N3O2
DMCKO6T IC InChI=1S/C8H2Cl3N3O2/c9-3-1-4-6(5(2-3)14(15)16)13-8(11)7(10)12-4/h1-2H
DMCKO6T CS C1=C(C=C(C2=C1N=C(C(=N2)Cl)Cl)[N+](=O)[O-])Cl
DMCKO6T IK DUBINERALUDRHX-UHFFFAOYSA-N
DMCKO6T IU 2,3,7-trichloro-5-nitroquinoxaline
DMCKO6T DE Discovery agent
DMOB7P6 ID DMOB7P6
DMOB7P6 DN 2',3'-ddATP
DMOB7P6 HS Investigative
DMOB7P6 SN 2',3'-Dideoxyadenosine triphosphate; ddATP; UNII-9MCI2H1EJ6; 2',3'-dideoxyadenosine-5'-triphosphate; 24027-80-3; dideoxyadenosine triphosphate; CHEMBL1383; 9MCI2H1EJ6; 2',3'-DIDEOXYADENOSINE 5'-TRIPHOSPHATE; Adenosine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy-; 2',3'-Dideoxy-ATP; ddA-TP; ATP,2',3'-dideoxy; SCHEMBL79815; GTPL1709; AC1L230G; DTXSID90178767; MolPort-044-561-436; ZINC12501706; BDBM50164644; AKOS030589611; 2'',3''-dideoxyadenosine triphosphate; DB02189; 2',3'-Dideoxyadenosine-5-triphosphate; 2',3'-Dideoxyadenosine Triphosphate (Ddatp)
DMOB7P6 DT Small molecular drug
DMOB7P6 PC 65304
DMOB7P6 MW 475.18
DMOB7P6 FM C10H16N5O11P3
DMOB7P6 IC InChI=1S/C10H16N5O11P3/c11-9-8-10(13-4-12-9)15(5-14-8)7-2-1-6(24-7)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h4-7H,1-3H2,(H,19,20)(H,21,22)(H2,11,12,13)(H2,16,17,18)/t6-,7+/m0/s1
DMOB7P6 CS C1C[C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=NC3=C(N=CN=C32)N
DMOB7P6 IK OAKPWEUQDVLTCN-NKWVEPMBSA-N
DMOB7P6 IU [[(2S,5R)-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMOB7P6 CA CAS 24027-80-3
DMOB7P6 DE Discovery agent
DM2UWDR ID DM2UWDR
DM2UWDR DN 2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene
DM2UWDR HS Investigative
DM2UWDR SN SCHEMBL4220471
DM2UWDR DT Small molecular drug
DM2UWDR PC 16090839
DM2UWDR MW 330.4
DM2UWDR FM C18H22N2O4
DM2UWDR IC InChI=1S/C18H22N2O4/c1-21-14-8-6-11(9-13(14)19)5-7-12-10-15(22-2)17(23-3)18(24-4)16(12)20/h5-10H,19-20H2,1-4H3/b7-5-
DM2UWDR CS COC1=C(C=C(C=C1)/C=C\\C2=CC(=C(C(=C2N)OC)OC)OC)N
DM2UWDR IK ONFPNROXTUMLBU-ALCCZGGFSA-N
DM2UWDR IU 6-[(Z)-2-(3-amino-4-methoxyphenyl)ethenyl]-2,3,4-trimethoxyaniline
DM2UWDR DE Discovery agent
DMPCGSD ID DMPCGSD
DMPCGSD DN 2,3-dichloro-1,4-naphthoquinone
DMPCGSD HS Investigative
DMPCGSD SN 2,3-Dichloro-1,4-naphthoquinone; 117-80-6; DICHLONE; 2,3-dichloronaphthalene-1,4-dione; Diclone; 2,3-Dichloronaphthoquinone; Phygon; Uniroyal; Sanquinon; Algistat; Phygon paste; Dichloronaphthoquinone; Phygon XL; Quintar; Compound 604; 1,4-Naphthalenedione, 2,3-dichloro-; Phygon seed protectant; U.s. rubber 604; Quintar 540F; Dichlon; USR 604; 2,3-Dichloro-1,4-naphthaquinone; 2,3-Dichloro-1,4-naphthalenedione; Caswell No. 298; ENT 3,776; 1,4-Naphthoquinone, 2,3-dichloro-; US Rubber 604; Latka 604; Dichlone [BSI:ISO]; Latka 604 [Czech]
DMPCGSD DT Small molecular drug
DMPCGSD PC 8342
DMPCGSD MW 227.04
DMPCGSD FM C10H4Cl2O2
DMPCGSD IC InChI=1S/C10H4Cl2O2/c11-7-8(12)10(14)6-4-2-1-3-5(6)9(7)13/h1-4H
DMPCGSD CS C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)Cl
DMPCGSD IK SVPKNMBRVBMTLB-UHFFFAOYSA-N
DMPCGSD IU 2,3-dichloronaphthalene-1,4-dione
DMPCGSD CA CAS 117-80-6
DMPCGSD DE Discovery agent
DM6SBPI ID DM6SBPI
DM6SBPI DN 2,3-Didehydroalanine
DM6SBPI HS Investigative
DM6SBPI SN dehydroalanine; 2-aminoacrylic acid; 2-Aminoacrylate; 2,3-DIDEHYDROALANINE; 1948-56-7; alpha,beta-Dehydroalanine; alpha-Aminoacrylate; 2-aminoprop-2-enoic acid; 2-aminoprop-2-enoate; UNII-98RA387EKY; 2-AMINO-ACRYLIC ACID; 98RA387EKY; a-b-di-dehydroalanine; 2-ammonioprop-2-enoate; AC1L3XOY; alpha-beta-di-dehydroalanine; 2-Propenoic acid,2-amino-; 2-Propenoic acid, 2-amino-; CHEBI:76565; CHEBI:17123; CTK4E1639; DTXSID90173131; UQBOJOOOTLPNST-UHFFFAOYSA-N; (alpha)-(beta)-di-dehydroalanine; anhydroserine 2-aminopropenoic acid
DM6SBPI DT Small molecular drug
DM6SBPI PC 123991
DM6SBPI MW 87.08
DM6SBPI FM C3H5NO2
DM6SBPI IC InChI=1S/C3H5NO2/c1-2(4)3(5)6/h1,4H2,(H,5,6)
DM6SBPI CS C=C(C(=O)O)N
DM6SBPI IK UQBOJOOOTLPNST-UHFFFAOYSA-N
DM6SBPI IU 2-aminoprop-2-enoic acid
DM6SBPI CA CAS 1948-56-7
DM6SBPI CB CHEBI:17123
DM6SBPI DE Discovery agent
DMCXR4M ID DMCXR4M
DMCXR4M DN 2',3'-Dideoxycytidine-5'-Monophosphate
DMCXR4M HS Investigative
DMCXR4M SN 104086-76-2; ((2S,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate; 5'-Cytidylic acid, 2',3'-dideoxy-; ddCMP; 2',3'-DIDEOXYCYTIDINE-5'-MONOPHOSPHATE; BRN 0556994; 2',3'-Dideoxycytidine 5'-monophosphate; CHEMBL1232305; C9H14N3O6P; [(2S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate; AC1L9JZG; SCHEMBL454264; dideoxycytidine 5'-monophosphate; ZINC1611080; 0954AA; BDBM50349537; AKOS016009455; DB02883; LS-59086; AJ-28234; AK112219; KB-204945; AX8123167
DMCXR4M DT Small molecular drug
DMCXR4M PC 446696
DMCXR4M MW 291.2
DMCXR4M FM C9H14N3O6P
DMCXR4M IC InChI=1S/C9H14N3O6P/c10-7-3-4-12(9(13)11-7)8-2-1-6(18-8)5-17-19(14,15)16/h3-4,6,8H,1-2,5H2,(H2,10,11,13)(H2,14,15,16)/t6-,8+/m0/s1
DMCXR4M CS C1C[C@@H](O[C@@H]1COP(=O)(O)O)N2C=CC(=NC2=O)N
DMCXR4M IK RAJMXAZJKUGYGW-POYBYMJQSA-N
DMCXR4M IU [(2S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMCXR4M CA CAS 104086-76-2
DMCXR4M DE Discovery agent
DMEQXUD ID DMEQXUD
DMEQXUD DN 2',3'-Dideoxythymidine-5'-Monophosphate
DMEQXUD HS Investigative
DMEQXUD SN ddTMP; 5'-Thymidylic acid, 3'-deoxy-; 2',3'-DIDEOXYTHYMIDINE-5'-MONOPHOSPHATE; 3'-DEOXYTHYMIDINE-5'-MONOPHOSPHATE; [(2s,5r)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate; 3715-64-8; 2DT; 3'-Deoxy-5'-thymidylic acid; AC1Q69EO; AC1L4W6C; 3-Deoxy-5-thymidylic acid; SCHEMBL8883; deoxy-thymidine monophosphate; CHEMBL1229914; CTK4H7825; DTXSID20190634; ZINC1610269; DB03150; 2',3'-Dideoxythymidine-5'-monophosphate disodium salt
DMEQXUD DT Small molecular drug
DMEQXUD PC 165151
DMEQXUD MW 306.21
DMEQXUD FM C10H15N2O7P
DMEQXUD IC InChI=1S/C10H15N2O7P/c1-6-4-12(10(14)11-9(6)13)8-3-2-7(19-8)5-18-20(15,16)17/h4,7-8H,2-3,5H2,1H3,(H,11,13,14)(H2,15,16,17)/t7-,8+/m0/s1
DMEQXUD CS CC1=CN(C(=O)NC1=O)[C@H]2CC[C@H](O2)COP(=O)(O)O
DMEQXUD IK WVNRRNJFRREKAR-JGVFFNPUSA-N
DMEQXUD IU [(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMEQXUD CA CAS 3715-64-8
DMEQXUD DE Discovery agent
DMJB7W1 ID DMJB7W1
DMJB7W1 DN 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide
DMJB7W1 HS Investigative
DMJB7W1 SN 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide; GTPL3486; SCHEMBL10948770; 5,6-Dihydro-1,4-dithiin-1,1,4,4-tetraoxide; 2,3-dihydro-1,4-dithiine 1,1,4,4-tetraoxide
DMJB7W1 DT Small molecular drug
DMJB7W1 PC 20549618
DMJB7W1 MW 182.2
DMJB7W1 FM C4H6O4S2
DMJB7W1 IC InChI=1S/C4H6O4S2/c5-9(6)1-2-10(7,8)4-3-9/h1-2H,3-4H2
DMJB7W1 CS C1CS(=O)(=O)C=CS1(=O)=O
DMJB7W1 IK YNEKVCMDWXAQGQ-UHFFFAOYSA-N
DMJB7W1 IU 2,3-dihydro-1,4-dithiine 1,1,4,4-tetraoxide
DMJB7W1 DE Discovery agent
DMB3WI8 ID DMB3WI8
DMB3WI8 DN 2,3-dihydro-1H-benzo[de]isoquinolin-1-one
DMB3WI8 HS Investigative
DMB3WI8 SN CHEMBL594596; 2,3-dihydro-benzo[de]isoquinolin-1-one; 2,3-dihydro-1H-benzo[de]isoquinolin-1-one; SCHEMBL832168; ZINC24216; BDBM50306285; FCH1866210
DMB3WI8 DT Small molecular drug
DMB3WI8 PC 10130246
DMB3WI8 MW 183.21
DMB3WI8 FM C12H9NO
DMB3WI8 IC InChI=1S/C12H9NO/c14-12-10-6-2-4-8-3-1-5-9(7-13-12)11(8)10/h1-6H,7H2,(H,13,14)
DMB3WI8 CS C1C2=CC=CC3=C2C(=CC=C3)C(=O)N1
DMB3WI8 IK QGJHNXPHHOCUAH-UHFFFAOYSA-N
DMB3WI8 IU 2,3-dihydrobenzo[de]isoquinolin-1-one
DMB3WI8 DE Discovery agent
DM46MKY ID DM46MKY
DM46MKY DN 2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY HS Investigative
DM46MKY SN Indane-5-sulfonamide; indane-5-sulfonamide; 35203-93-1; Indan-5-sulphonamide; Indan-5-sulfonic acid amide; 5-Indansulfonamide; CHEMBL364869; 2,3-dihydro-5-indenylsulfonamide; 2qoa; 5-indanesulfonamide; NSC91508; EINECS 252-432-6; indan-5-sulfonamide; AC1L3XER; AC1Q6UJV; AC1Q55FD; AC1Q55FC; SCHEMBL2011443; CTK7F2159; DTXSID40188710; MolPort-001-845-197; XVQJTFMKKZBBSX-UHFFFAOYSA-N; ZINC394620; HMS3604H17; 1295AE; NSC-91508; BDBM50155556; AKOS000141119; AS-8808; MCULE-2518558267; DB08165; NE29982; Indan-5-sulfonic acid amide
DM46MKY DT Small molecular drug
DM46MKY PC 96876
DM46MKY MW 197.26
DM46MKY FM C9H11NO2S
DM46MKY IC InChI=1S/C9H11NO2S/c10-13(11,12)9-5-4-7-2-1-3-8(7)6-9/h4-6H,1-3H2,(H2,10,11,12)
DM46MKY CS C1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DM46MKY IK XVQJTFMKKZBBSX-UHFFFAOYSA-N
DM46MKY IU 2,3-dihydro-1H-indene-5-sulfonamide
DM46MKY CA CAS 35203-93-1
DM46MKY DE Discovery agent
DM3URJG ID DM3URJG
DM3URJG DN 2,3-Dihydro-1H-indol-5-ol
DM3URJG HS Investigative
DM3URJG SN Indolin-5-ol; 172078-33-0; 2,3-dihydro-1H-indol-5-ol; 2,3-Dihydroindol-5-ol; 1H-Indol-5-ol,2,3-dihydro-; CHEMBL19331; AK-60844; 5-Indolinol; 5-hydroxyindoline; SCHEMBL59263; 2,3-Dihydro-1H-indole-5-ol; 2,3-dihydro-1 H-indol-5-ol; CTK4D4118; DTXSID40434426; MolPort-000-003-182; MPCXQPXCYDDJSR-UHFFFAOYSA-N; 1H-Indol-5-ol, 2,3-dihydro-; 5-hydroxy-2,3-dihydro-1H-indole; KS-00000ML8; ZINC13462664; FCH845722; 8845AA; BDBM50291681; ANW-58857; AKOS006279674; CS-W007244; CHM0007709; AJ-63836; SC-26235; 1H-INDOL-5-OL,2,3-DIHYDRO-,; KB-12380
DM3URJG DT Small molecular drug
DM3URJG PC 10034684
DM3URJG MW 135.16
DM3URJG FM C8H9NO
DM3URJG IC InChI=1S/C8H9NO/c10-7-1-2-8-6(5-7)3-4-9-8/h1-2,5,9-10H,3-4H2
DM3URJG CS C1CNC2=C1C=C(C=C2)O
DM3URJG IK MPCXQPXCYDDJSR-UHFFFAOYSA-N
DM3URJG IU 2,3-dihydro-1H-indol-5-ol
DM3URJG CA CAS 172078-33-0
DM3URJG DE Discovery agent
DMWI9XS ID DMWI9XS
DMWI9XS DN 2,3-Dihydro-1H-isoindole
DMWI9XS HS Investigative
DMWI9XS SN Isoindoline; 496-12-8; 2,3-dihydro-1H-isoindole; 1H-Isoindole, 2,3-dihydro-; Isoindoline, 97%; CHEMBL118475; GWVMLCQWXVFZCN-UHFFFAOYSA-N; iso-indoline; 2-Azaindan; 1,3-dihydroisoindole; 1,2-dihydroisoindole; PubChem16248; ACMC-1AM9E; AC1Q1IE0; AC1L9MF9; 1,3-dihydro-2H-isoindole; SCHEMBL10612; KSC222C5F; SCHEMBL2764305; CTK1C2152; MolPort-000-165-448; KS-000013BD; BCP01139; ACN-S003606; ZINC4111883; ACN-S001460; ANW-30800; STK077165; BDBM50052887; AN-716; BBL000565; AKOS000283835; TRA0077123; RTC-060566; CM10320; MB01342
DMWI9XS DT Small molecular drug
DMWI9XS PC 422478
DMWI9XS MW 119.16
DMWI9XS FM C8H9N
DMWI9XS IC InChI=1S/C8H9N/c1-2-4-8-6-9-5-7(8)3-1/h1-4,9H,5-6H2
DMWI9XS CS C1C2=CC=CC=C2CN1
DMWI9XS IK GWVMLCQWXVFZCN-UHFFFAOYSA-N
DMWI9XS IU 2,3-dihydro-1H-isoindole
DMWI9XS CA CAS 496-12-8
DMWI9XS DE Discovery agent
DMUW94S ID DMUW94S
DMUW94S DN 2,3-dihydrobenzo[d]thiazole-2-thiol
DMUW94S HS Investigative
DMUW94S SN CHEMBL570797; 2,3-dihydrobenzothiazole-2-thiol; 2,3-dihydrobenzo[d]thiazole-2-thiol; 2,3-dihydro-1,3-benzothiazole-2-thiol; AC1MMT8Q; 2-benzo[d]thiazolinethiol; 2(3H)-Benzothiazolethiol; SCHEMBL1405549; BDBM50303907; AKOS006278847; 94495-79-1
DMUW94S DT Small molecular drug
DMUW94S PC 3266369
DMUW94S MW 169.3
DMUW94S FM C7H7NS2
DMUW94S IC InChI=1S/C7H7NS2/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4,7-9H
DMUW94S CS C1=CC=C2C(=C1)NC(S2)S
DMUW94S IK PYVUUPVBIDIYPY-UHFFFAOYSA-N
DMUW94S IU 2,3-dihydro-1,3-benzothiazole-2-thiol
DMUW94S DE Discovery agent
DMYHFUO ID DMYHFUO
DMYHFUO DN 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine
DMYHFUO HS Investigative
DMYHFUO SN CHEMBL214856; 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine; SCHEMBL3385589; Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 2,3-dihydro-; BDBM50194096; 745837-16-5
DMYHFUO DT Small molecular drug
DMYHFUO PC 21094663
DMYHFUO MW 185.22
DMYHFUO FM C11H11N3
DMYHFUO IC InChI=1S/C11H11N3/c12-11-8-4-1-2-5-9(8)13-10-6-3-7-14(10)11/h1-2,4-5,12H,3,6-7H2
DMYHFUO CS C1CC2=NC3=CC=CC=C3C(=N)N2C1
DMYHFUO IK AOSPPBURKIEYRC-UHFFFAOYSA-N
DMYHFUO IU 2,3-dihydro-1H-pyrrolo[2,1-b]quinazolin-9-imine
DMYHFUO DE Discovery agent
DMOWNB4 ID DMOWNB4
DMOWNB4 DN 2,3-dihydroxypropanal
DMOWNB4 HS Investigative
DMOWNB4 SN DL-Glyceraldehyde; glyceraldehyde; 2,3-Dihydroxypropanal; Glyceric aldehyde; Glycerose; Glycerinaldehyde; Glycerinformal; 56-82-6; Propanal, 2,3-dihydroxy-; 2,3-Dihydroxypropionaldehyde; DL-GLYC; Aldotriose; alpha,beta-dihydroxypropionaldehyde; 367-47-5; Glyceraldehyde, (+-)-; Propionaldehyde, 2,3-dihydroxy-; aldose; U 1188; D,L-glyceraldehyde; NSC 67934; BRN 0635844; AI3-24475; (+/-)-Glyceraldehyde; EINECS 206-695-9; EINECS 200-290-0; DLG; .alpha.,.beta.-Dihydroxypropionaldehyde; 2,3-dihydroxy-propionaldehyde; CHEBI:5445
DMOWNB4 DT Small molecular drug
DMOWNB4 PC 751
DMOWNB4 MW 90.08
DMOWNB4 FM C3H6O3
DMOWNB4 IC InChI=1S/C3H6O3/c4-1-3(6)2-5/h1,3,5-6H,2H2
DMOWNB4 CS C(C(C=O)O)O
DMOWNB4 IK MNQZXJOMYWMBOU-UHFFFAOYSA-N
DMOWNB4 IU 2,3-dihydroxypropanal
DMOWNB4 CA CAS 56-82-6
DMOWNB4 CB CHEBI:5445
DMOWNB4 DE Discovery agent
DML92OK ID DML92OK
DML92OK DN 2,3-dimethoxy-2'-hydroxychalcone
DML92OK HS Investigative
DML92OK SN 2'-HYDROXY-2,3-DIMETHOXYCHALCONE; AC1NQ7LG; CTK4I5873; CTK1B1409; 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; MCULE-6103350400; FT-0772376; 2-Propen-1-one, 3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)-, (2E)-
DML92OK DT Small molecular drug
DML92OK PC 6296545
DML92OK MW 284.31
DML92OK FM C17H16O4
DML92OK IC InChI=1S/C17H16O4/c1-20-16-9-5-6-12(17(16)21-2)10-11-15(19)13-7-3-4-8-14(13)18/h3-11,18H,1-2H3/b11-10+
DML92OK CS COC1=CC=CC(=C1OC)/C=C/C(=O)C2=CC=CC=C2O
DML92OK IK HKKXNGSRSNONCJ-ZHACJKMWSA-N
DML92OK IU (E)-3-(2,3-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DML92OK DE Discovery agent
DM9C0YZ ID DM9C0YZ
DM9C0YZ DN 2,3-Dimethoxy-4'-amino-trans-stilbene
DM9C0YZ HS Investigative
DM9C0YZ SN CHEMBL1173700; BDBM50322050
DM9C0YZ DT Small molecular drug
DM9C0YZ PC 49799640
DM9C0YZ MW 255.31
DM9C0YZ FM C16H17NO2
DM9C0YZ IC InChI=1S/C16H17NO2/c1-18-15-5-3-4-13(16(15)19-2)9-6-12-7-10-14(17)11-8-12/h3-11H,17H2,1-2H3/b9-6+
DM9C0YZ CS COC1=CC=CC(=C1OC)/C=C/C2=CC=C(C=C2)N
DM9C0YZ IK WSPBGPLITZFWJL-RMKNXTFCSA-N
DM9C0YZ IU 4-[(E)-2-(2,3-dimethoxyphenyl)ethenyl]aniline
DM9C0YZ DE Discovery agent
DMEB47J ID DMEB47J
DMEB47J DN 2,3-Dimethoxybenzo[i]phenanthridines
DMEB47J HS Investigative
DMEB47J DT Small molecular drug
DMEB47J PC 56603740
DMEB47J DE Discovery agent
DMGXVBA ID DMGXVBA
DMGXVBA DN 2,3-DIMETHYL-1,4-NAPHTHOQUINONE
DMGXVBA HS Investigative
DMGXVBA SN 2,3-Dimethyl-1,4-naphthoquinone; 2,3-Dimethylnaphthoquinone; USAF SN-29; 2197-57-1; 1,4-Naphthalenedione, 2,3-dimethyl-; 2,3-dimethylnaphthalene-1,4-dione; UNII-SY9IO0B44O; SY9IO0B44O; 1,4-NAPHTHOQUINONE, 2,3-DIMETHYL-; NSC 36460; BRN 2044697; AI3-16112; 2,3-dimethyl-1,4-dihydronaphthalene-1,4-dione; AC1L28BU; AC1Q2DM1; SCHEMBL571026; CHEMBL354201; CTK4E8092; DTXSID50176380; MolPort-001-817-681; LGFDNUSAWCHVJN-UHFFFAOYSA-N; HMS1666O12; NSC36460; ZINC3063275; WLN: L66 BV EVJ C1 D1; 2,3-Dimethyl-[1,4]naphthoquinone; NSC-36460
DMGXVBA DT Small molecular drug
DMGXVBA PC 16615
DMGXVBA MW 186.21
DMGXVBA FM C12H10O2
DMGXVBA IC InChI=1S/C12H10O2/c1-7-8(2)12(14)10-6-4-3-5-9(10)11(7)13/h3-6H,1-2H3
DMGXVBA CS CC1=C(C(=O)C2=CC=CC=C2C1=O)C
DMGXVBA IK LGFDNUSAWCHVJN-UHFFFAOYSA-N
DMGXVBA IU 2,3-dimethylnaphthalene-1,4-dione
DMGXVBA CA CAS 2197-57-1
DMGXVBA DE Discovery agent
DMKV9EZ ID DMKV9EZ
DMKV9EZ DN 2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione
DMKV9EZ HS Investigative
DMKV9EZ SN 2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione; 89986-91-4; Naphtho[2,3-f]quinoxaline-7,12-dione, 2,3-dimethyl-; ACMC-20lsfz; SCHEMBL3505034; CHEMBL604342; CTK2I7956; DTXSID80658048
DMKV9EZ DT Small molecular drug
DMKV9EZ PC 44251290
DMKV9EZ MW 288.3
DMKV9EZ FM C18H12N2O2
DMKV9EZ IC InChI=1S/C18H12N2O2/c1-9-10(2)20-16-14(19-9)8-7-13-15(16)18(22)12-6-4-3-5-11(12)17(13)21/h3-8H,1-2H3
DMKV9EZ CS CC1=C(N=C2C(=N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O)C
DMKV9EZ IK WDHCRURNPCZZII-UHFFFAOYSA-N
DMKV9EZ IU 2,3-dimethylnaphtho[3,2-f]quinoxaline-7,12-dione
DMKV9EZ CA CAS 89986-91-4
DMKV9EZ DE Discovery agent
DM8C43L ID DM8C43L
DM8C43L DN 2,3-dioxoindoline-7-carboxylic acid
DM8C43L HS Investigative
DM8C43L SN 2,3-dioxoindoline-7-carboxylic acid; 25128-35-2; Isatin-7-carboxylic acid; 2,3-DIOXO-2,3-DIHYDRO-1H-INDOLE-7-CARBOXYLIC ACID; 2,3-dioxo-1H-indole-7-carboxylic Acid; CHEMBL375078; 1H-INDOLE-7-CARBOXYLIC ACID, 2,3-DIHYDRO-2,3-DIOXO-; 2,3-dioxo-1H-benzo[d]azolidine-7-carboxylic acid; 2,3-Dioxoindoline-7-carboxylicacid; 7-isatincarboxylic acid; PubChem24310; AC1MCVF6; Isatin-based compound, 46; AC1Q72QN; SCHEMBL1742133; BDBM22826; CTK1A1532; DTXSID00381427; ROODQCZSWXEDJL-UHFFFAOYSA-N; MolPort-000-144-864; ZINC2496760; KS-00000FO0
DM8C43L DT Small molecular drug
DM8C43L PC 2779383
DM8C43L MW 191.14
DM8C43L FM C9H5NO4
DM8C43L IC InChI=1S/C9H5NO4/c11-7-4-2-1-3-5(9(13)14)6(4)10-8(7)12/h1-3H,(H,13,14)(H,10,11,12)
DM8C43L CS C1=CC2=C(C(=C1)C(=O)O)NC(=O)C2=O
DM8C43L IK ROODQCZSWXEDJL-UHFFFAOYSA-N
DM8C43L IU 2,3-dioxo-1H-indole-7-carboxylic acid
DM8C43L CA CAS 25128-35-2
DM8C43L DE Discovery agent
DMC3UYH ID DMC3UYH
DMC3UYH DN 2,3-diphenyl-1H-indole
DMC3UYH HS Investigative
DMC3UYH SN 2,3-Diphenylindole; 2,3-Diphenyl-1H-indole; 3469-20-3; 1H-Indole, 2,3-diphenyl-; CHEMBL200719; GYGKJNGSQQORRG-UHFFFAOYSA-N; Indole, 2,3-diphenyl-; NSC17363; EINECS 222-432-0; Indole,3-diphenyl-; Cyto5A2; AC1Q1HUE; 1H-Indole,3-diphenyl-; AC1Q4W1P; AC1L2S6L; Oprea1_738570; 2,3-Diphenyl-1H-indole #; SCHEMBL3864662; CTK1C3291; KS-00000FNK; DTXSID50188241; MolPort-001-804-408; ZINC1036850; STK080838; BDBM50175411; RW3400; NSC-17363; CCG-46312; AKOS001022174; ACM3469203; MCULE-8938765915; VI30149; ACN-036136; 7J-655S; QC-2111; CC-07034; AK-81890
DMC3UYH DT Small molecular drug
DMC3UYH PC 77020
DMC3UYH MW 269.3
DMC3UYH FM C20H15N
DMC3UYH IC InChI=1S/C20H15N/c1-3-9-15(10-4-1)19-17-13-7-8-14-18(17)21-20(19)16-11-5-2-6-12-16/h1-14,21H
DMC3UYH CS C1=CC=C(C=C1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMC3UYH IK GYGKJNGSQQORRG-UHFFFAOYSA-N
DMC3UYH IU 2,3-diphenyl-1H-indole
DMC3UYH CA CAS 3469-20-3
DMC3UYH DE Discovery agent
DMI2PY7 ID DMI2PY7
DMI2PY7 DN 2,4,3',5'-tetrahydroxybibenzyl
DMI2PY7 HS Investigative
DMI2PY7 SN CHEMBL221291; 2,4,3',5'-tetrahydroxybibenzyl; SCHEMBL19433107; BDBM50193667; 2,4,3'',5''-tetrahydroxybibenzyl; 4-[2-(3,5-dihydroxyphenyl)ethyl]benzene-1,3-diol
DMI2PY7 DT Small molecular drug
DMI2PY7 PC 16126762
DMI2PY7 MW 246.26
DMI2PY7 FM C14H14O4
DMI2PY7 IC InChI=1S/C14H14O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h3-8,15-18H,1-2H2
DMI2PY7 CS C1=CC(=C(C=C1O)O)CCC2=CC(=CC(=C2)O)O
DMI2PY7 IK IEOZKGCYMAJAHS-UHFFFAOYSA-N
DMI2PY7 IU 4-[2-(3,5-dihydroxyphenyl)ethyl]benzene-1,3-diol
DMI2PY7 DE Discovery agent
DMS8I1E ID DMS8I1E
DMS8I1E DN 2,4,4-triphenylimidazoline
DMS8I1E HS Investigative
DMS8I1E SN 2,4,4-triphenylimidazoline; CHEMBL493970; SCHEMBL4463957; BDBM50257786
DMS8I1E DT Small molecular drug
DMS8I1E PC 22054806
DMS8I1E MW 298.4
DMS8I1E FM C21H18N2
DMS8I1E IC InChI=1S/C21H18N2/c1-4-10-17(11-5-1)20-22-16-21(23-20,18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15H,16H2,(H,22,23)
DMS8I1E CS C1C(NC(=N1)C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMS8I1E IK KXSXOHNHKQJMNF-UHFFFAOYSA-N
DMS8I1E IU 2,5,5-triphenyl-1,4-dihydroimidazole
DMS8I1E DE Discovery agent
DMSJBEH ID DMSJBEH
DMSJBEH DN 2,4,5-Triarylimidazole analogue
DMSJBEH HS Investigative
DMSJBEH SN CHEMBL16925; 2,4,5-Triarylimidazole analogue; SCHEMBL5137478; JVMAHSCWJIZBJE-UHFFFAOYSA-N; BDBM50284516; N-Hydroxy-N-[1-[4-[4-(4-fluorophenyl)-5-(4-pyridyl)-1H-imidazol-2-yl]phenyl]ethyl]urea
DMSJBEH DT Small molecular drug
DMSJBEH PC 18771543
DMSJBEH MW 417.4
DMSJBEH FM C23H20FN5O2
DMSJBEH IC InChI=1S/C23H20FN5O2/c1-14(29(31)23(25)30)15-2-4-18(5-3-15)22-27-20(16-6-8-19(24)9-7-16)21(28-22)17-10-12-26-13-11-17/h2-14,31H,1H3,(H2,25,30)(H,27,28)
DMSJBEH CS CC(C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)N(C(=O)N)O
DMSJBEH IK JVMAHSCWJIZBJE-UHFFFAOYSA-N
DMSJBEH IU 1-[1-[4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenyl]ethyl]-1-hydroxyurea
DMSJBEH DE Discovery agent
DMTA152 ID DMTA152
DMTA152 DN 2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea
DMTA152 HS Investigative
DMTA152 DT Small molecular drug
DMTA152 PC 56603741
DMTA152 MW 507.2
DMTA152 FM C11H12Cl2N6O11S
DMTA152 IC InChI=1S/C6H3N3O9S.C5H9Cl2N3O2/c10-7(11)3-1-4(8(12)13)6(19(16,17)18)5(2-3)9(14)15;6-1-3-8-5(11)10(9-12)4-2-7/h1-2H,(H,16,17,18);1-4H2,(H,8,11)
DMTA152 CS C1=C(C=C(C(=C1[N+](=O)[O-])S(=O)(=O)[O-])[N+](=O)[O-])[N+](=O)[O-].C(CCl)[NH2+]C(=O)N(CCCl)N=O
DMTA152 IK LMBKFJAIRIBNHB-UHFFFAOYSA-N
DMTA152 IU 2-chloroethyl-[2-chloroethyl(nitroso)carbamoyl]azanium;2,4,6-trinitrobenzenesulfonate
DMTA152 DE Discovery agent
DMTVL9N ID DMTVL9N
DMTVL9N DN 2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide
DMTVL9N HS Investigative
DMTVL9N SN CHEMBL175532; 2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide; Benzamide, 2,4,6-trihydroxy-3-nitro-N-tridecyl-; 126395-25-3; ACMC-20mryy; RD34082; AC1LA66U; SCHEMBL12902000; CTK0F6648; DTXSID50333097; BDBM50158817; AKOS030576830; RD-3-4082
DMTVL9N DT Small molecular drug
DMTVL9N PC 482191
DMTVL9N MW 396.5
DMTVL9N FM C20H32N2O6
DMTVL9N IC InChI=1S/C20H32N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-21-20(26)17-15(23)14-16(24)18(19(17)25)22(27)28/h14,23-25H,2-13H2,1H3,(H,21,26)
DMTVL9N CS CCCCCCCCCCCCCNC(=O)C1=C(C(=C(C=C1O)O)[N+](=O)[O-])O
DMTVL9N IK MSWMANFKQVMQAR-UHFFFAOYSA-N
DMTVL9N IU 2,4,6-trihydroxy-3-nitro-N-tridecylbenzamide
DMTVL9N CA CAS 126395-25-3
DMTVL9N DE Discovery agent
DM90TSI ID DM90TSI
DM90TSI DN 2,4-bis-docosanoylamino-benzenesulfonate
DM90TSI HS Investigative
DM90TSI SN CHEMBL96329
DM90TSI DT Small molecular drug
DM90TSI PC 44327149
DM90TSI MW 855.3
DM90TSI FM C50H91N2NaO5S
DM90TSI IC InChI=1S/C50H92N2O5S.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-41-49(53)51-46-43-44-48(58(55,56)57)47(45-46)52-50(54)42-40-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h43-45H,3-42H2,1-2H3,(H,51,53)(H,52,54)(H,55,56,57);/q;+1/p-1
DM90TSI CS CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=CC(=C(C=C1)S(=O)(=O)[O-])NC(=O)CCCCCCCCCCCCCCCCCCCCC.[Na+]
DM90TSI IK IXCBRSKAYDVLLF-UHFFFAOYSA-M
DM90TSI IU sodium;2,4-bis(docosanoylamino)benzenesulfonate
DM90TSI DE Discovery agent
DMZO0EI ID DMZO0EI
DMZO0EI DN 2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid
DMZO0EI HS Investigative
DMZO0EI SN 2,4-DEOXY-4-GUANIDINO-5-N-ACETYL-NEURAMINIC ACID; AC1NRBJW; 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid; 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-erythro-L-manno-nononic acid; (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMZO0EI DT Small molecular drug
DMZO0EI PC 46936668
DMZO0EI MW 334.33
DMZO0EI FM C12H22N4O7
DMZO0EI IC InChI=1S/C12H22N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h5-10,17,19-20H,2-3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,7-,8+,9-,10-/m1/s1
DMZO0EI CS CC(=O)N[C@H]1[C@@H](C[C@@H](O[C@H]1[C@@H]([C@H](CO)O)O)C(=O)O)N=C(N)N
DMZO0EI IK DAAUVSVERFXBSX-WHSUVHHGSA-N
DMZO0EI IU (2R,4R,5S,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2S)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMZO0EI DE Discovery agent
DMVPWML ID DMVPWML
DMVPWML DN 2,4'-Diacetoxy-5,3'-di-(2-propenyl)-biphenyl
DMVPWML HS Investigative
DMVPWML SN CHEMBL570311; Diacetylhonokiol; SCHEMBL18313888; BDBM50295922
DMVPWML DT Small molecular drug
DMVPWML PC 45269978
DMVPWML MW 350.4
DMVPWML FM C22H22O4
DMVPWML IC InChI=1S/C22H22O4/c1-5-7-17-9-11-22(26-16(4)24)20(13-17)18-10-12-21(25-15(3)23)19(14-18)8-6-2/h5-6,9-14H,1-2,7-8H2,3-4H3
DMVPWML CS CC(=O)OC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)OC(=O)C)CC=C
DMVPWML IK XNFZWGDLKCJOLJ-UHFFFAOYSA-N
DMVPWML IU [4-(2-acetyloxy-5-prop-2-enylphenyl)-2-prop-2-enylphenyl] acetate
DMVPWML DE Discovery agent
DMQPKWM ID DMQPKWM
DMQPKWM DN 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
DMQPKWM HS Investigative
DMQPKWM SN 2,4-diamino-6-phenyl-5,6,7,8,-tetrahydropteridine; (6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine; AC1L9HFU
DMQPKWM DT Small molecular drug
DMQPKWM PC 445109
DMQPKWM MW 242.28
DMQPKWM FM C12H14N6
DMQPKWM IC InChI=1S/C12H14N6/c13-10-9-11(18-12(14)17-10)15-6-8(16-9)7-4-2-1-3-5-7/h1-5,8,16H,6H2,(H5,13,14,15,17,18)/t8-/m0/s1
DMQPKWM CS C1[C@H](NC2=C(N=C(N=C2N1)N)N)C3=CC=CC=C3
DMQPKWM IK VEKRIXRQADJFAG-QMMMGPOBSA-N
DMQPKWM IU (6R)-6-phenyl-5,6,7,8-tetrahydropteridine-2,4-diamine
DMQPKWM DE Discovery agent
DMAOGBP ID DMAOGBP
DMAOGBP DN 2,4-Diamino-butyric acid(GABA)
DMAOGBP HS Investigative
DMAOGBP SN 2,4-Diaminobutanoic acid; 2,4-Diaminobutyric acid; 305-62-4; 2,4-Diamino-butyric acid; alpha,gamma-Diaminobutyric acid; 2,4-diamino-butanoic acid; DL-2,4-Diaminobutyric acid; Butanoic acid, 2,4-diamino-; CHEBI:64307; EINECS 206-166-2; Butyric acid, 2,4-diamino-; CHEMBL307931; OGNSCSPNOLGXSM-UHFFFAOYSA-N; Butanoic acid, 2,4-diamino-, (+)-; Butanoic acid, 2,4-diamino-, dihydrochloride; 6970-28-1; 2,4-Diaminobutyrate; 2,4-Diaminobutanoate; NSC41117; 2,4-diamino-butanoate; DL-2,4-Diaminobutanoate; AC1Q28UL; SCHEMBL34705
DMAOGBP DT Small molecular drug
DMAOGBP PC 470
DMAOGBP MW 118.13
DMAOGBP FM C4H10N2O2
DMAOGBP IC InChI=1S/C4H10N2O2/c5-2-1-3(6)4(7)8/h3H,1-2,5-6H2,(H,7,8)
DMAOGBP CS C(CN)C(C(=O)O)N
DMAOGBP IK OGNSCSPNOLGXSM-UHFFFAOYSA-N
DMAOGBP IU 2,4-diaminobutanoic acid
DMAOGBP CA CAS 305-62-4
DMAOGBP CB CHEBI:64307
DMAOGBP DE Discovery agent
DMS1YXL ID DMS1YXL
DMS1YXL DN 2,4-diaminoquinozalines and quinoxaline-2,3-diones
DMS1YXL HS Investigative
DMS1YXL DE Discovery agent
DMQ385U ID DMQ385U
DMQ385U DN 2,4-Dibenzylamino-6-isopentylpyrimidine
DMQ385U HS Investigative
DMQ385U SN CHEMBL494121; 2,4-Dibenzylamino-6-isopentylpyrimidine
DMQ385U DT Small molecular drug
DMQ385U PC 25128804
DMQ385U MW 360.5
DMQ385U FM C23H28N4
DMQ385U IC InChI=1S/C23H28N4/c1-18(2)13-14-21-15-22(24-16-19-9-5-3-6-10-19)27-23(26-21)25-17-20-11-7-4-8-12-20/h3-12,15,18H,13-14,16-17H2,1-2H3,(H2,24,25,26,27)
DMQ385U CS CC(C)CCC1=CC(=NC(=N1)NCC2=CC=CC=C2)NCC3=CC=CC=C3
DMQ385U IK HEIDJEFGBUXABK-UHFFFAOYSA-N
DMQ385U IU 2-N,4-N-dibenzyl-6-(3-methylbutyl)pyrimidine-2,4-diamine
DMQ385U DE Discovery agent
DM4EY5S ID DM4EY5S
DM4EY5S DN 2,4-dichloro-5-sulfamoylbenzoic acid
DM4EY5S HS Investigative
DM4EY5S SN 2,4-Dichloro-5-sulfamoylbenzoic acid; 2736-23-4; Lasamide; 5-(Aminosulfonyl)-2,4-dichlorobenzoic acid; 2,4-Dichloro-5-sulfamoyl-benzoic acid; 2,4-Dichloro-5-sulphamoylbenzoic acid; UNII-LEG53TF0SN; 2,4-Dichloro-5-sulfamylbenzoic acid; Benzoic acid, 5-(aminosulfonyl)-2,4-dichloro-; EINECS 220-358-3; LEG53TF0SN; 3-Sulfamoyl-4,6-dichlorobenzoic acid; BENZOIC ACID, 2,4-DICHLORO-5-SULFAMOYL-; BRN 2219046; 5-Carboxy-2,4-dichlorobenzenesulfonamide; 5-Aminosulfonyl-2,4-dichlorobenzoic acid; M 12325
DM4EY5S DT Small molecular drug
DM4EY5S PC 17655
DM4EY5S MW 270.09
DM4EY5S FM C7H5Cl2NO4S
DM4EY5S IC InChI=1S/C7H5Cl2NO4S/c8-4-2-5(9)6(15(10,13)14)1-3(4)7(11)12/h1-2H,(H,11,12)(H2,10,13,14)
DM4EY5S CS C1=C(C(=CC(=C1S(=O)(=O)N)Cl)Cl)C(=O)O
DM4EY5S IK ZSHHRBYVHTVRFK-UHFFFAOYSA-N
DM4EY5S IU 2,4-dichloro-5-sulfamoylbenzoic acid
DM4EY5S CA CAS 2736-23-4
DM4EY5S DE Discovery agent
DMR5DYK ID DMR5DYK
DMR5DYK DN 2,4-Dichlorobenzenemethanethiol
DMR5DYK HS Investigative
DMR5DYK SN 2,4-Dichlorobenzyl mercaptan; 59293-67-3; (2,4-Dichlorophenyl)methanethiol; 2,4-Dichlorobenzylmercaptan; 2,4-dichlorophenylmethanethiol; 2,4-Dichlorobenzenemethanethiol; 2,4-Dichloro-alpha-toluenethiol; 2,4-Dichlorotoluene-alpha-thiol; Benzenemethanethiol, 2,4-dichloro-; CHEMBL1224561; ZSPXTTVUJDSRNJ-UHFFFAOYSA-N; NSC33218; EINECS 261-687-2; AI3-31458; AC1Q3MDQ; ACMC-1B9KZ; AC1L3V0Z; SCHEMBL1802752; 2,4-Dichlorothiobenzyl Alcohol; ZSPXTTVUJDSRNJ-UHFFFAOYSA-; CTK5A9733; DTXSID70208016; MolPort-004-354-551
DMR5DYK DT Small molecular drug
DMR5DYK PC 95756
DMR5DYK MW 193.09
DMR5DYK FM C7H6Cl2S
DMR5DYK IC InChI=1S/C7H6Cl2S/c8-6-2-1-5(4-10)7(9)3-6/h1-3,10H,4H2
DMR5DYK CS C1=CC(=C(C=C1Cl)Cl)CS
DMR5DYK IK ZSPXTTVUJDSRNJ-UHFFFAOYSA-N
DMR5DYK IU (2,4-dichlorophenyl)methanethiol
DMR5DYK CA CAS 59293-67-3
DMR5DYK DE Discovery agent
DMO4FSH ID DMO4FSH
DMO4FSH DN 2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMO4FSH HS Investigative
DMO4FSH SN CHEMBL61381; 2,4-Dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; 260790-88-3; (Z)-2,4-dichloro-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; 5307-12-0; AC1LCD3F; CBMicro_016815; Oprea1_161519; 2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide; ARONIS019647; KS-00004BJV; DTXSID00344799; MolPort-001-620-431; MWSDOEQEOIKHRL-UHFFFAOYSA-N; MolPort-003-009-221; ZINC4696587; CCG-5657; STK048438; BDBM50101786; AKOS000486711; AKOS024573981; MCULE-1720813827; ST036566; BIM-0016665.P001; N-(4-Phenyl-2-thiazolyl)-2,4-dichlorobenzamide
DMO4FSH DT Small molecular drug
DMO4FSH PC 599553
DMO4FSH MW 349.2
DMO4FSH FM C16H10Cl2N2OS
DMO4FSH IC InChI=1S/C16H10Cl2N2OS/c17-11-6-7-12(13(18)8-11)15(21)20-16-19-14(9-22-16)10-4-2-1-3-5-10/h1-9H,(H,19,20,21)
DMO4FSH CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=C(C=C(C=C3)Cl)Cl
DMO4FSH IK MWSDOEQEOIKHRL-UHFFFAOYSA-N
DMO4FSH IU 2,4-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMO4FSH CA CAS 5307-12-0
DMO4FSH DE Discovery agent
DM4QDZV ID DM4QDZV
DM4QDZV DN 2',4'-dicyanobiphenyl-4-yl sulfamate
DM4QDZV HS Investigative
DM4QDZV SN CHEMBL592320; SCHEMBL4667745; BDBM50307888; 2'',4''-dicyanobiphenyl-4-yl sulfamate
DM4QDZV DT Small molecular drug
DM4QDZV PC 9861093
DM4QDZV MW 299.31
DM4QDZV FM C14H9N3O3S
DM4QDZV IC InChI=1S/C14H9N3O3S/c15-8-10-1-6-14(12(7-10)9-16)11-2-4-13(5-3-11)20-21(17,18)19/h1-7H,(H2,17,18,19)
DM4QDZV CS C1=CC(=CC=C1C2=C(C=C(C=C2)C#N)C#N)OS(=O)(=O)N
DM4QDZV IK VQTYXLRQENRZOV-UHFFFAOYSA-N
DM4QDZV IU [4-(2,4-dicyanophenyl)phenyl] sulfamate
DM4QDZV DE Discovery agent
DM75TJ1 ID DM75TJ1
DM75TJ1 DN 2,4-difluorophenyl 4-butoxybenzylcarbamate
DM75TJ1 HS Investigative
DM75TJ1 SN 2,4-difluorophenyl 4-butoxybenzylcarbamate; CHEMBL596875; SCHEMBL5222747
DM75TJ1 DT Small molecular drug
DM75TJ1 PC 20872684
DM75TJ1 MW 335.3
DM75TJ1 FM C18H19F2NO3
DM75TJ1 IC InChI=1S/C18H19F2NO3/c1-2-3-10-23-15-7-4-13(5-8-15)12-21-18(22)24-17-9-6-14(19)11-16(17)20/h4-9,11H,2-3,10,12H2,1H3,(H,21,22)
DM75TJ1 CS CCCCOC1=CC=C(C=C1)CNC(=O)OC2=C(C=C(C=C2)F)F
DM75TJ1 IK OHKUODJKULFCPB-UHFFFAOYSA-N
DM75TJ1 IU (2,4-difluorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DM75TJ1 DE Discovery agent
DM0URFY ID DM0URFY
DM0URFY DN 2,4-diisobutylamino-6-isopentylpyrimidine
DM0URFY HS Investigative
DM0URFY SN CHEMBL347927; 2,4-diisobutylamino-6-isopentylpyrimidine; ZINC13559143; BDBM50138886
DM0URFY DT Small molecular drug
DM0URFY PC 9994500
DM0URFY MW 292.5
DM0URFY FM C17H32N4
DM0URFY IC InChI=1S/C17H32N4/c1-12(2)7-8-15-9-16(18-10-13(3)4)21-17(20-15)19-11-14(5)6/h9,12-14H,7-8,10-11H2,1-6H3,(H2,18,19,20,21)
DM0URFY CS CC(C)CCC1=CC(=NC(=N1)NCC(C)C)NCC(C)C
DM0URFY IK FELVKNQXOFEZOY-UHFFFAOYSA-N
DM0URFY IU 6-(3-methylbutyl)-2-N,4-N-bis(2-methylpropyl)pyrimidine-2,4-diamine
DM0URFY DE Discovery agent
DMP9BZU ID DMP9BZU
DMP9BZU DN 2,4-dimethoxy-2'-hydroxychalcone
DMP9BZU HS Investigative
DMP9BZU SN 3-(2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; 36685-63-9; AC1L5NE0; NCIOpen2_004691; CTK1C4388
DMP9BZU DT Small molecular drug
DMP9BZU PC 6041429
DMP9BZU MW 284.31
DMP9BZU FM C17H16O4
DMP9BZU IC InChI=1S/C17H16O4/c1-20-13-9-7-12(17(11-13)21-2)8-10-16(19)14-5-3-4-6-15(14)18/h3-11,18H,1-2H3/b10-8+
DMP9BZU CS COC1=CC(=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O)OC
DMP9BZU IK ORIBPRISLKRPRQ-CSKARUKUSA-N
DMP9BZU IU (E)-3-(2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DMP9BZU DE Discovery agent
DMHSLXI ID DMHSLXI
DMHSLXI DN 2,4-Dimethoxy-3'-amino-trans-stilbene
DMHSLXI HS Investigative
DMHSLXI SN CHEMBL1173641; BDBM50322048
DMHSLXI DT Small molecular drug
DMHSLXI PC 49799639
DMHSLXI MW 255.31
DMHSLXI FM C16H17NO2
DMHSLXI IC InChI=1S/C16H17NO2/c1-18-15-9-8-13(16(11-15)19-2)7-6-12-4-3-5-14(17)10-12/h3-11H,17H2,1-2H3/b7-6+
DMHSLXI CS COC1=CC(=C(C=C1)/C=C/C2=CC(=CC=C2)N)OC
DMHSLXI IK YTHARJUESQVNDD-VOTSOKGWSA-N
DMHSLXI IU 3-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]aniline
DMHSLXI DE Discovery agent
DMMZ643 ID DMMZ643
DMMZ643 DN 2,4-Dimethoxy-4'-amino-trans-stilbene
DMMZ643 HS Investigative
DMMZ643 SN CHEMBL1170662; BDBM50322047
DMMZ643 DT Small molecular drug
DMMZ643 PC 49799655
DMMZ643 MW 255.31
DMMZ643 FM C16H17NO2
DMMZ643 IC InChI=1S/C16H17NO2/c1-18-15-10-7-13(16(11-15)19-2)6-3-12-4-8-14(17)9-5-12/h3-11H,17H2,1-2H3/b6-3+
DMMZ643 CS COC1=CC(=C(C=C1)/C=C/C2=CC=C(C=C2)N)OC
DMMZ643 IK CPBHGSOSBBDXHN-ZZXKWVIFSA-N
DMMZ643 IU 4-[(E)-2-(2,4-dimethoxyphenyl)ethenyl]aniline
DMMZ643 DE Discovery agent
DMWNJ84 ID DMWNJ84
DMWNJ84 DN 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl
DMWNJ84 HS Investigative
DMWNJ84 SN CHEMBL89828; 68592-18-7; NSC293102; AC1L6VMD; HONOKIOL DIMETHYL ETHER; SCHEMBL13978616; CTK2F6825; DTXSID00315202; ZINC1566148; BDBM50295927; 3',5-diallyl-2,4'-dimethoxybiphenyl; NSC-293102; 5,3''-Diallyl-2,4''-dimethoxy-biphenyl; 3,3'-Diallyl-4',6-dimethoxy-1,1'-biphenyl; 2,4''-Dimethoxy-5,3''-di-(2-propenyl)-biphenyl; 1-methoxy-2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylbenzene
DMWNJ84 DT Small molecular drug
DMWNJ84 PC 325144
DMWNJ84 MW 294.4
DMWNJ84 FM C20H22O2
DMWNJ84 IC InChI=1S/C20H22O2/c1-5-7-15-9-11-20(22-4)18(13-15)16-10-12-19(21-3)17(14-16)8-6-2/h5-6,9-14H,1-2,7-8H2,3-4H3
DMWNJ84 CS COC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)OC)CC=C
DMWNJ84 IK GDCJELDNRAWYTE-UHFFFAOYSA-N
DMWNJ84 IU 1-methoxy-2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylbenzene
DMWNJ84 CA CAS 68592-18-7
DMWNJ84 DE Discovery agent
DM94NM7 ID DM94NM7
DM94NM7 DN 2,4'-Dimethoxy-5,3'-dipropyl-biphenyl
DM94NM7 HS Investigative
DM94NM7 SN CHEMBL560262; BDBM50295928
DM94NM7 DT Small molecular drug
DM94NM7 PC 45267390
DM94NM7 MW 298.4
DM94NM7 FM C20H26O2
DM94NM7 IC InChI=1S/C20H26O2/c1-5-7-15-9-11-20(22-4)18(13-15)16-10-12-19(21-3)17(14-16)8-6-2/h9-14H,5-8H2,1-4H3
DM94NM7 CS CCCC1=CC(=C(C=C1)OC)C2=CC(=C(C=C2)OC)CCC
DM94NM7 IK GLDMMYBVNSMLGE-UHFFFAOYSA-N
DM94NM7 IU 1-methoxy-2-(4-methoxy-3-propylphenyl)-4-propylbenzene
DM94NM7 DE Discovery agent
DM2AW0Z ID DM2AW0Z
DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline
DM2AW0Z HS Investigative
DM2AW0Z SN 654-62-6; 4-Amino-6-(trifluoromethyl)benzene-1,3-disulfonamide; 2-amino-4-trifluoromethyl-1,5-benzendisulfonamide; 2,4-Disulfamyl-5-trifluoromethylaniline; UNII-YBN90877RI; CHEMBL418; YBN90877RI; 1,3-Benzenedisulfonamide, 4-amino-6-(trifluoromethyl)-; 5-Amino-alpha,alpha,alpha-trifluorotoluene-2,4-disulfonamide; 5-Amino-alpha,alpha,alpha-trifluorotoluene-2,4-disulphonamide; C7H8F3N3O4S2; 2pow; EINECS 211-506-8; NSC 44625; 2,4-DISULFAMYLTRIFLUOROMETHYLANILINE; AC1Q6TRC; AC1L2C5H; SCHEMBL3863705; BDBM10866; CTK5C2741
DM2AW0Z DT Small molecular drug
DM2AW0Z PC 69561
DM2AW0Z MW 319.3
DM2AW0Z FM C7H8F3N3O4S2
DM2AW0Z IC InChI=1S/C7H8F3N3O4S2/c8-7(9,10)3-1-4(11)6(19(13,16)17)2-5(3)18(12,14)15/h1-2H,11H2,(H2,12,14,15)(H2,13,16,17)
DM2AW0Z CS C1=C(C(=CC(=C1N)S(=O)(=O)N)S(=O)(=O)N)C(F)(F)F
DM2AW0Z IK KRVABEGPNKGLOT-UHFFFAOYSA-N
DM2AW0Z IU 4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide
DM2AW0Z CA CAS 654-62-6
DM2AW0Z DE Discovery agent
DMZRY0Q ID DMZRY0Q
DMZRY0Q DN 2,4-epi-neodysiherbaine
DMZRY0Q HS Investigative
DMZRY0Q SN 2,4-epi-neoDH
DMZRY0Q DT Small molecular drug
DMZRY0Q PC 73755077
DMZRY0Q MW 290.25
DMZRY0Q FM C11H16NO8-
DMZRY0Q IC InChI=1S/C11H17NO8/c12-4(9(15)16)1-11(10(17)18)2-6-8(20-11)7(14)5(13)3-19-6/h4-8,13-14H,1-3,12H2,(H,15,16)(H,17,18)/p-1/t4-,5+,6?,7+,8?,11-/m1/s1
DMZRY0Q CS C1[C@@H]([C@@H](C2C(O1)C[C@](O2)(C[C@H](C(=O)[O-])[NH3+])C(=O)[O-])O)O
DMZRY0Q IK NRTJEXLNSCGBJU-LUHIGIFZSA-M
DMZRY0Q IU (2R,6S,7S)-2-[(2R)-2-azaniumyl-2-carboxylatoethyl]-6,7-dihydroxy-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylate
DMZRY0Q DE Discovery agent
DMLDHMB ID DMLDHMB
DMLDHMB DN 2,5-Anhydroglucitol-1,6-Biphosphate
DMLDHMB HS Investigative
DMLDHMB SN 2,5-Anhydroglucitol-1,6-Biphosphate; 2,5-Anhydro-D-glucitol-1,6-diphosphate; 2,5-Anhydro-D-glucitol 1,6-diphosphate; 4429-47-4; AHG; 2,5-Anhydroglucitol 1,6-Bisphosphate; AC1L9I6X; SCHEMBL20154711; ZINC3870733; AKOS032954084; DB02778; 2,5-anhydro-1,6-di-O-phosphono-D-glucitol; 2,5-Anhydro-D-glucitol 1,6-bisphosphoric acid; W-202770; [(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
DMLDHMB DT Small molecular drug
DMLDHMB PC 445555
DMLDHMB MW 324.12
DMLDHMB FM C6H14O11P2
DMLDHMB IC InChI=1S/C6H14O11P2/c7-5-3(1-15-18(9,10)11)17-4(6(5)8)2-16-19(12,13)14/h3-8H,1-2H2,(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6-/m1/s1
DMLDHMB CS C([C@@H]1[C@H]([C@@H]([C@@H](O1)COP(=O)(O)O)O)O)OP(=O)(O)O
DMLDHMB IK WSMBXSQDFPTODV-JGWLITMVSA-N
DMLDHMB IU [(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
DMLDHMB DE Discovery agent
DMU5GKN ID DMU5GKN
DMU5GKN DN 2,5-bis(2-methoxyphenyl)thiophene
DMU5GKN HS Investigative
DMU5GKN SN 2,5-bis(2-methoxyphenyl)thiophene; CHEMBL204873; SCHEMBL12973253
DMU5GKN DT Small molecular drug
DMU5GKN PC 44408693
DMU5GKN MW 296.4
DMU5GKN FM C18H16O2S
DMU5GKN IC InChI=1S/C18H16O2S/c1-19-15-9-5-3-7-13(15)17-11-12-18(21-17)14-8-4-6-10-16(14)20-2/h3-12H,1-2H3
DMU5GKN CS COC1=CC=CC=C1C2=CC=C(S2)C3=CC=CC=C3OC
DMU5GKN IK VXQDFBRKMXPIGY-UHFFFAOYSA-N
DMU5GKN IU 2,5-bis(2-methoxyphenyl)thiophene
DMU5GKN DE Discovery agent
DMH6RDL ID DMH6RDL
DMH6RDL DN 2,5-Bis-(3,4-dimethoxy-phenyl)-furan
DMH6RDL HS Investigative
DMH6RDL SN CHEMBL110937; 2,5-Bis-(3,4-dimethoxy-phenyl)-furan
DMH6RDL DT Small molecular drug
DMH6RDL PC 16038022
DMH6RDL MW 340.4
DMH6RDL FM C20H20O5
DMH6RDL IC InChI=1S/C20H20O5/c1-21-17-7-5-13(11-19(17)23-3)15-9-10-16(25-15)14-6-8-18(22-2)20(12-14)24-4/h5-12H,1-4H3
DMH6RDL CS COC1=C(C=C(C=C1)C2=CC=C(O2)C3=CC(=C(C=C3)OC)OC)OC
DMH6RDL IK ZESHRVUYCRWWFA-UHFFFAOYSA-N
DMH6RDL IU 2,5-bis(3,4-dimethoxyphenyl)furan
DMH6RDL DE Discovery agent
DM28GQS ID DM28GQS
DM28GQS DN 2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan
DM28GQS HS Investigative
DM28GQS SN CHEMBL111506; 2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan
DM28GQS DT Small molecular drug
DM28GQS PC 44339586
DM28GQS MW 448.5
DM28GQS FM C28H32O5
DM28GQS IC InChI=1S/C28H32O5/c1-29-25-13-11-19(17-27(25)31-21-7-3-4-8-21)23-15-16-24(33-23)20-12-14-26(30-2)28(18-20)32-22-9-5-6-10-22/h11-18,21-22H,3-10H2,1-2H3
DM28GQS CS COC1=C(C=C(C=C1)C2=CC=C(O2)C3=CC(=C(C=C3)OC)OC4CCCC4)OC5CCCC5
DM28GQS IK VJENKFARFHFXFG-UHFFFAOYSA-N
DM28GQS IU 2,5-bis(3-cyclopentyloxy-4-methoxyphenyl)furan
DM28GQS DE Discovery agent
DMOQPHK ID DMOQPHK
DMOQPHK DN 2,5-bis(4-hydroxybenzylidene)cyclopentanone
DMOQPHK HS Investigative
DMOQPHK SN 2,5-Bis(4-hydroxybenzylidene)cyclopentanone; NSC666766; CHEMBL452101; AC1LVVMV; SCHEMBL14473242; MolPort-000-640-539; ZINC5955757; BDBM50264922; AKOS001331259; NSC-666766; 2,5-Bis[(E)-4-hydroxybenzylidene]cyclopentanone; (2E,5E)-2,5-bis[(4-hydroxyphenyl)methylene]cyclopentanone
DMOQPHK DT Small molecular drug
DMOQPHK PC 1712706
DMOQPHK MW 292.3
DMOQPHK FM C19H16O3
DMOQPHK IC InChI=1S/C19H16O3/c20-17-7-1-13(2-8-17)11-15-5-6-16(19(15)22)12-14-3-9-18(21)10-4-14/h1-4,7-12,20-21H,5-6H2/b15-11+,16-12+
DMOQPHK CS C1/C(=C\\C2=CC=C(C=C2)O)/C(=O)/C(=C/C3=CC=C(C=C3)O)/C1
DMOQPHK IK YSEMBYWAAKOCKW-JOBJLJCHSA-N
DMOQPHK IU (2E,5E)-2,5-bis[(4-hydroxyphenyl)methylidene]cyclopentan-1-one
DMOQPHK DE Discovery agent
DMNQIGZ ID DMNQIGZ
DMNQIGZ DN 2,5-bis(4-Hydroxyphenyl)thiophene
DMNQIGZ HS Investigative
DMNQIGZ SN CHEMBL204010; 2,5-bis(4-Hydroxyphenyl)thiophene; SCHEMBL1181642; BDBM25849; ZINC28571224; 4,4'-(Thiophene-2,5-diyl)bisphenol; hydroxyphenyl substituted thiophene, 21
DMNQIGZ DT Small molecular drug
DMNQIGZ PC 14905189
DMNQIGZ MW 268.3
DMNQIGZ FM C16H12O2S
DMNQIGZ IC InChI=1S/C16H12O2S/c17-13-5-1-11(2-6-13)15-9-10-16(19-15)12-3-7-14(18)8-4-12/h1-10,17-18H
DMNQIGZ CS C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)O)O
DMNQIGZ IK KZMOBYGIRBRCFV-UHFFFAOYSA-N
DMNQIGZ IU 4-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMNQIGZ DE Discovery agent
DM30RNY ID DM30RNY
DM30RNY DN 2,5-bis(4-methoxyphenyl)thiophene
DM30RNY HS Investigative
DM30RNY SN 2,5-bis(4-methoxyphenyl)thiophene; CHEMBL378797; 55827-09-3; AC1MS3AA; SCHEMBL1181273; CTK1F5890; DTXSID30393578; SNVBIBDQUGLRIV-UHFFFAOYSA-N; ZINC405078; BDBM50178543; AKOS024342405; MCULE-5357210093; Thiophene, 2,5-bis(4-methoxyphenyl)-
DM30RNY DT Small molecular drug
DM30RNY PC 3552928
DM30RNY MW 296.4
DM30RNY FM C18H16O2S
DM30RNY IC InChI=1S/C18H16O2S/c1-19-15-7-3-13(4-8-15)17-11-12-18(21-17)14-5-9-16(20-2)10-6-14/h3-12H,1-2H3
DM30RNY CS COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)OC
DM30RNY IK SNVBIBDQUGLRIV-UHFFFAOYSA-N
DM30RNY IU 2,5-bis(4-methoxyphenyl)thiophene
DM30RNY CA CAS 55827-09-3
DM30RNY DE Discovery agent
DM3USOR ID DM3USOR
DM3USOR DN 2,5-bis(4-nitrophenyl)thiophene
DM3USOR HS Investigative
DM3USOR SN 2,5-bis(4-nitrophenyl)thiophene; CHEMBL202898; AC1NA972; SCHEMBL12491620; ZINC3107517; BDBM50178545; 70010-47-8
DM3USOR DT Small molecular drug
DM3USOR PC 4373578
DM3USOR MW 326.3
DM3USOR FM C16H10N2O4S
DM3USOR IC InChI=1S/C16H10N2O4S/c19-17(20)13-5-1-11(2-6-13)15-9-10-16(23-15)12-3-7-14(8-4-12)18(21)22/h1-10H
DM3USOR CS C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)[N+](=O)[O-])[N+](=O)[O-]
DM3USOR IK FBNOZEYGTWFASC-UHFFFAOYSA-N
DM3USOR IU 2,5-bis(4-nitrophenyl)thiophene
DM3USOR DE Discovery agent
DMMESIU ID DMMESIU
DMMESIU DN 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine
DMMESIU HS Investigative
DMMESIU SN CHEMBL477445; BDBM50267394; 2,5''-dichloro-5''-deoxy-N6-cyclopentyladenosine
DMMESIU DT Small molecular drug
DMMESIU PC 44582613
DMMESIU MW 388.2
DMMESIU FM C15H19Cl2N5O3
DMMESIU IC InChI=1S/C15H19Cl2N5O3/c16-5-8-10(23)11(24)14(25-8)22-6-18-9-12(19-7-3-1-2-4-7)20-15(17)21-13(9)22/h6-8,10-11,14,23-24H,1-5H2,(H,19,20,21)/t8-,10-,11-,14-/m1/s1
DMMESIU CS C1CCC(C1)NC2=C3C(=NC(=N2)Cl)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CCl)O)O
DMMESIU IK GWUOJELSUSGGDU-IDTAVKCVSA-N
DMMESIU IU (2R,3R,4S,5S)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
DMMESIU DE Discovery agent
DM9PK1R ID DM9PK1R
DM9PK1R DN 2,5-dichloro-N-phenylthiophene-3-sulfonamide
DM9PK1R HS Investigative
DM9PK1R SN CHEMBL1171971; 2,5-dichloro-N-phenylthiophene-3-sulfonamide; SCHEMBL7579927; BDBM50321450
DM9PK1R DT Small molecular drug
DM9PK1R PC 29098931
DM9PK1R MW 308.2
DM9PK1R FM C10H7Cl2NO2S2
DM9PK1R IC InChI=1S/C10H7Cl2NO2S2/c11-9-6-8(10(12)16-9)17(14,15)13-7-4-2-1-3-5-7/h1-6,13H
DM9PK1R CS C1=CC=C(C=C1)NS(=O)(=O)C2=C(SC(=C2)Cl)Cl
DM9PK1R IK ILXABJHIVUDACG-UHFFFAOYSA-N
DM9PK1R IU 2,5-dichloro-N-phenylthiophene-3-sulfonamide
DM9PK1R DE Discovery agent
DMU5J8Y ID DMU5J8Y
DMU5J8Y DN 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y HS Investigative
DMU5J8Y SN CHEMBL1171972; 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide
DMU5J8Y DT Small molecular drug
DMU5J8Y PC 49798484
DMU5J8Y MW 322.2
DMU5J8Y FM C11H9Cl2NO2S2
DMU5J8Y IC InChI=1S/C11H9Cl2NO2S2/c1-7-2-4-8(5-3-7)14-18(15,16)9-6-10(12)17-11(9)13/h2-6,14H,1H3
DMU5J8Y CS CC1=CC=C(C=C1)NS(=O)(=O)C2=C(SC(=C2)Cl)Cl
DMU5J8Y IK OQWXAWNHXDPWGS-UHFFFAOYSA-N
DMU5J8Y IU 2,5-dichloro-N-(4-methylphenyl)thiophene-3-sulfonamide
DMU5J8Y DE Discovery agent
DMI1O54 ID DMI1O54
DMI1O54 DN 2,5-dideoxy-2,5-imino-D-altritol
DMI1O54 HS Investigative
DMI1O54 SN CHEMBL469844; 172823-15-3; CHEMBL10437; SCHEMBL2435520; CTK0A7803; DTXSID40437432; ZINC5766623; 2,5-Imino-2,5-dideoxy-D-altritol; BDBM50241865; BDBM50099008; (2R,3S,4S)-2,5-Bis-hydroxymethyl-pyrrolidine-3,4-diol; 2,5-Pyrrolidinedimethanol, 3,4-dihydroxy-, (2R,3R,4S,5R)-
DMI1O54 DT Small molecular drug
DMI1O54 PC 10261406
DMI1O54 MW 163.17
DMI1O54 FM C6H13NO4
DMI1O54 IC InChI=1S/C6H13NO4/c8-1-3-5(10)6(11)4(2-9)7-3/h3-11H,1-2H2/t3-,4-,5-,6+/m1/s1
DMI1O54 CS C([C@@H]1[C@H]([C@H]([C@H](N1)CO)O)O)O
DMI1O54 IK PFYHYHZGDNWFIF-KAZBKCHUSA-N
DMI1O54 IU (2R,3S,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol
DMI1O54 CA CAS 172823-15-3
DMI1O54 DE Discovery agent
DMKP7O0 ID DMKP7O0
DMKP7O0 DN 2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol
DMKP7O0 HS Investigative
DMKP7O0 SN CHEMBL456077; 2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol; 2,5-dideoxy-2,5-imino-D-glycero-D-manno-heptitol; SCHEMBL5851667; BDBM50242071
DMKP7O0 DT Small molecular drug
DMKP7O0 PC 13005892
DMKP7O0 MW 193.2
DMKP7O0 FM C7H15NO5
DMKP7O0 IC InChI=1S/C7H15NO5/c9-1-3-6(12)7(13)5(8-3)4(11)2-10/h3-13H,1-2H2/t3-,4?,5-,6-,7-/m1/s1
DMKP7O0 CS C([C@@H]1[C@H]([C@@H]([C@H](N1)C(CO)O)O)O)O
DMKP7O0 IK ZJRUOSSQTZGFJV-UHEPRFFZSA-N
DMKP7O0 IU (2R,3R,4R,5R)-2-(1,2-dihydroxyethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
DMKP7O0 DE Discovery agent
DMGQVF5 ID DMGQVF5
DMGQVF5 DN 2,5-Dideoxy-2,5-imino-D-mannitol
DMGQVF5 HS Investigative
DMGQVF5 SN 59920-31-9; (2R,3R,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol; 2,5-Dihydroxymethyl-3,4-dihydroxypyrrolidine; CHEBI:4289; CHEMBL312653; NSC624987; NSC613239; 2(r),5(r)-bis(hydroxymethyl)-3(r),4(r)-dihydroxypyrrolidine; 2,5-Anhydro-2,5-imino-D-mannitol; DQQ; 2,5-dideoxy-2,5-imino-L-mannitol; NSC 624987; AC1L3YWM; AC1Q59GS; SCHEMBL466574; ZINC1492230; 2,5-Pyrrolidinedimethanol, 3,4-dihydroxy-, (2R,3R,4R,5R)-
DMGQVF5 DT Small molecular drug
DMGQVF5 PC 124702
DMGQVF5 MW 163.17
DMGQVF5 FM C6H13NO4
DMGQVF5 IC InChI=1S/C6H13NO4/c8-1-3-5(10)6(11)4(2-9)7-3/h3-11H,1-2H2/t3-,4-,5-,6-/m1/s1
DMGQVF5 CS C([C@@H]1[C@H]([C@@H]([C@H](N1)CO)O)O)O
DMGQVF5 IK PFYHYHZGDNWFIF-KVTDHHQDSA-N
DMGQVF5 IU (2R,3R,4R,5R)-2,5-bis(hydroxymethyl)pyrrolidine-3,4-diol
DMGQVF5 CA CAS 59920-31-9
DMGQVF5 CB CHEBI:4289
DMGQVF5 DE Discovery agent
DM5OYWF ID DM5OYWF
DM5OYWF DN 2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE
DM5OYWF HS Investigative
DM5OYWF SN 2',5'-dideoxy-adenosine 3'-monophosphate; 2',5'-Dideoxyadenosine 3'-monophosphate; AC1L9H2O; SCHEMBL1920523; CTK8E3534; 2',5'-dideoxy-3'-adenylic acid; 2,5-Dideoxyadenosine 3-monophosphate; AKOS025394264; DB06843; 121878-11-3; RT-018381; 2',5'-Dideoxyadenosine 3'-phosphoric acid; [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl]oxyphosphonic acid; [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] dihydrogen phosphate
DM5OYWF DT Small molecular drug
DM5OYWF PC 444894
DM5OYWF MW 315.22
DM5OYWF FM C10H14N5O5P
DM5OYWF IC InChI=1S/C10H14N5O5P/c1-5-6(20-21(16,17)18)2-7(19-5)15-4-14-8-9(11)12-3-13-10(8)15/h3-7H,2H2,1H3,(H2,11,12,13)(H2,16,17,18)/t5-,6+,7-/m1/s1
DM5OYWF CS C[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)OP(=O)(O)O
DM5OYWF IK NFGZMOICZSFFLB-DSYKOEDSSA-N
DM5OYWF IU [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] dihydrogen phosphate
DM5OYWF DE Discovery agent
DM5CWM0 ID DM5CWM0
DM5CWM0 DN 2,5-didesoxy-3-ATP
DM5CWM0 HS Investigative
DM5CWM0 SN 2',5'-DD-3'-ATP; 2',5'-Dideoxyadenosine 3'-(Tetrahydrogen Triphosphate); ZDA; SCHEMBL375553; CHEMBL1162355; ZINC13829365; 2',5'-Dideoxyadenosine 3'-triphosphate; 2',5'-Dideoxyadenosine 3'-triphosphoric acid; (2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-methyltetrahydrofuran-3-yl tetrahydrogen triphosphate
DM5CWM0 DT Small molecular drug
DM5CWM0 PC 9934622
DM5CWM0 MW 475.18
DM5CWM0 FM C10H16N5O11P3
DM5CWM0 IC InChI=1S/C10H16N5O11P3/c1-5-6(24-28(19,20)26-29(21,22)25-27(16,17)18)2-7(23-5)15-4-14-8-9(11)12-3-13-10(8)15/h3-7H,2H2,1H3,(H,19,20)(H,21,22)(H2,11,12,13)(H2,16,17,18)/t5-,6+,7-/m1/s1
DM5CWM0 CS C[C@@H]1[C@H](C[C@@H](O1)N2C=NC3=C(N=CN=C32)N)OP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM5CWM0 IK ZJGUOEYCABTFNH-DSYKOEDSSA-N
DM5CWM0 IU [(2R,3S,5R)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-yl] [hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate
DM5CWM0 DE Discovery agent
DMIGFX6 ID DMIGFX6
DMIGFX6 DN 2,5-difluorophenol
DMIGFX6 HS Investigative
DMIGFX6 SN 2,5-Difluorophenol; 2713-31-7; Phenol, 2,5-difluoro-; 1,4-Difluoro-2-hydroxybenzene; Phenol,2,5-difluoro-; INXKVYFOWNAVMU-UHFFFAOYSA-N; 2,5-difluorphenol; MFCD00042501; 2,5-Difluorophenol;2,5-Difluorophenol;; NSC10288; PubChem3464; phenol derivative, 5; 2,5-difluoro-phenol; 2,5-difluoro phenol; ACMC-209gva; 2,5-Difluorophenol 97%; AC1Q78DB; SCHEMBL70273; 2,5-Difluorophenol, 95%; KSC493C1H; CHEMBL261219; AC1L3T96; INXKVYFOWNAVMU-UHFFFAOYSA-; BDBM26191; CTK3J3113; DTXSID90181594; MolPort-000-154-447; ZINC409280; CS-D1368; JRD-0251
DMIGFX6 DT Small molecular drug
DMIGFX6 PC 94952
DMIGFX6 MW 130.09
DMIGFX6 FM C6H4F2O
DMIGFX6 IC InChI=1S/C6H4F2O/c7-4-1-2-5(8)6(9)3-4/h1-3,9H
DMIGFX6 CS C1=CC(=C(C=C1F)O)F
DMIGFX6 IK INXKVYFOWNAVMU-UHFFFAOYSA-N
DMIGFX6 IU 2,5-difluorophenol
DMIGFX6 CA CAS 2713-31-7
DMIGFX6 DE Discovery agent
DMV0UIR ID DMV0UIR
DMV0UIR DN 2,5-Dimethoxy-4'-amino-trans-stilbene
DMV0UIR HS Investigative
DMV0UIR SN BRN 2855929; 4-(2,5-Dimethoxy)stilbenamine; 4'-Stilbenamine, 2,5-dimethoxy-; 4-(2,5-Dimethoxyphenethyl)aniline; 2,5-Dimethoxy-4'-aminostilbene(trans); 4'-AMINO-2,5-DIMETHOXY STILBENE; CHEMBL1173699; 4-(2-(2,5-Dimethoxyphenyl)ethyl)benzenamine; Stilbenamine, 2',5'-dimethoxy-; 2',5'-Dimethoxy-4-stilbenamine; 23435-31-6; 4-[(E)-2-(2,5-Dimethoxyphenyl)ethenyl]aniline; 32180-65-7; 4-[2-(2,5-dimethoxyphenyl)vinyl]aniline; 4-[2-(2,5-dimethoxyphenyl)ethenyl]aniline; 2,5-Dimethoxy-4'-aminostilbene; 5803-51-0; DMBAS; AC1NTB1S
DMV0UIR DT Small molecular drug
DMV0UIR PC 5377410
DMV0UIR MW 255.31
DMV0UIR FM C16H17NO2
DMV0UIR IC InChI=1S/C16H17NO2/c1-18-15-9-10-16(19-2)13(11-15)6-3-12-4-7-14(17)8-5-12/h3-11H,17H2,1-2H3/b6-3+
DMV0UIR CS COC1=CC(=C(C=C1)OC)/C=C/C2=CC=C(C=C2)N
DMV0UIR IK OZGXSMOLBWHIQA-ZZXKWVIFSA-N
DMV0UIR IU 4-[(E)-2-(2,5-dimethoxyphenyl)ethenyl]aniline
DMV0UIR CA CAS 23435-31-6
DMV0UIR DE Discovery agent
DM50ZQP ID DM50ZQP
DM50ZQP DN 2,5-dimethoxy-4-bromophenethylamine
DM50ZQP HS Investigative
DM50ZQP SN 2,5-Dimethoxy-4-bromophenethylamine; 4-Bromo-2,5-dimethoxyphenethylamine; 66142-81-2; BDMPEA; 2-(4-Bromo-2,5-dimethoxyphenyl)ethylamine; 2C-B; 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine; Nexus; 4-Bromo-2,5-dimethoxyphenylethylamine; UNII-V77772N32H; Benzeneethanamine, 4-bromo-2,5-dimethoxy-; CHEMBL292821; 2-CB; CHEBI:189669; V77772N32H; Eros [Street Name]; Venus [Street Name]; Nexus [Street Name]; Nexus (pharmaceutical); Spectrum [Street Name]; NCGC00168259-02; Toonies [Street Name]dd; DEA No. 7392
DM50ZQP DT Small molecular drug
DM50ZQP PC 98527
DM50ZQP MW 260.13
DM50ZQP FM C10H14BrNO2
DM50ZQP IC InChI=1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3
DM50ZQP CS COC1=CC(=C(C=C1CCN)OC)Br
DM50ZQP IK YMHOBZXQZVXHBM-UHFFFAOYSA-N
DM50ZQP IU 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine
DM50ZQP CA CAS 66142-81-2
DM50ZQP CB CHEBI:189669
DM50ZQP DE Discovery agent
DM5IJSW ID DM5IJSW
DM5IJSW DN 2,5-imino-2,5,6-trideoxy-D-manno-heptitol
DM5IJSW HS Investigative
DM5IJSW SN CHEMBL407337; 6-deoxyhomoDMDP; 2,5-imino-2,5,6-trideoxy-D-manno-heptitol; SCHEMBL2437378; BDBM50234571; 2alpha-Hydroxymethyl-3beta,4alpha-dihydroxypyrrolidine 5beta-ethanol
DM5IJSW DT Small molecular drug
DM5IJSW PC 10374978
DM5IJSW MW 177.2
DM5IJSW FM C7H15NO4
DM5IJSW IC InChI=1S/C7H15NO4/c9-2-1-4-6(11)7(12)5(3-10)8-4/h4-12H,1-3H2/t4-,5-,6-,7-/m1/s1
DM5IJSW CS C(CO)[C@@H]1[C@H]([C@@H]([C@H](N1)CO)O)O
DM5IJSW IK AGFACLQFIYFFOI-DBRKOABJSA-N
DM5IJSW IU (2R,3R,4R,5R)-2-(2-hydroxyethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
DM5IJSW DE Discovery agent
DM4IFPQ ID DM4IFPQ
DM4IFPQ DN 2,6,8-triphenyl-9H-purine
DM4IFPQ HS Investigative
DM4IFPQ SN CHEMBL378959; 2,6,8-triphenyl-9H-purine
DM4IFPQ DT Small molecular drug
DM4IFPQ PC 11462181
DM4IFPQ MW 348.4
DM4IFPQ FM C23H16N4
DM4IFPQ IC InChI=1S/C23H16N4/c1-4-10-16(11-5-1)19-20-23(26-21(24-19)17-12-6-2-7-13-17)27-22(25-20)18-14-8-3-9-15-18/h1-15H,(H,24,25,26,27)
DM4IFPQ CS C1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=C(N3)C5=CC=CC=C5
DM4IFPQ IK UHWGSYGCZUMSMO-UHFFFAOYSA-N
DM4IFPQ IU 2,6,8-triphenyl-7H-purine
DM4IFPQ DE Discovery agent
DMYQNK0 ID DMYQNK0
DMYQNK0 DN 2,6-bis(4-chlorophenyl)-9H-purine
DMYQNK0 HS Investigative
DMYQNK0 SN CHEMBL426497; 2,6-bis(4-chlorophenyl)-9H-purine
DMYQNK0 DT Small molecular drug
DMYQNK0 PC 11660141
DMYQNK0 MW 341.2
DMYQNK0 FM C17H10Cl2N4
DMYQNK0 IC InChI=1S/C17H10Cl2N4/c18-12-5-1-10(2-6-12)14-15-17(21-9-20-15)23-16(22-14)11-3-7-13(19)8-4-11/h1-9H,(H,20,21,22,23)
DMYQNK0 CS C1=CC(=CC=C1C2=C3C(=NC(=N2)C4=CC=C(C=C4)Cl)N=CN3)Cl
DMYQNK0 IK WDBFJNSPOHEOFN-UHFFFAOYSA-N
DMYQNK0 IU 2,6-bis(4-chlorophenyl)-7H-purine
DMYQNK0 DE Discovery agent
DMC2N80 ID DMC2N80
DMC2N80 DN 2,6-bis(4-methoxyphenyl)-9H-purine
DMC2N80 HS Investigative
DMC2N80 SN CHEMBL437123; 889673-61-4; 2,6-bis(4-methoxyphenyl)-9H-purine; CTK3A4136; DTXSID00467553; BDBM50186600; 1H-Purine, 2,6-bis(4-methoxyphenyl)-
DMC2N80 DT Small molecular drug
DMC2N80 PC 11493677
DMC2N80 MW 332.4
DMC2N80 FM C19H16N4O2
DMC2N80 IC InChI=1S/C19H16N4O2/c1-24-14-7-3-12(4-8-14)16-17-19(21-11-20-17)23-18(22-16)13-5-9-15(25-2)10-6-13/h3-11H,1-2H3,(H,20,21,22,23)
DMC2N80 CS COC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=C(C=C4)OC)N=CN3
DMC2N80 IK ZGJSQGNKCRURQW-UHFFFAOYSA-N
DMC2N80 IU 2,6-bis(4-methoxyphenyl)-7H-purine
DMC2N80 CA CAS 889673-61-4
DMC2N80 DE Discovery agent
DM41RZX ID DM41RZX
DM41RZX DN 2,6-bis(4-tolyl)-9H-purine
DM41RZX HS Investigative
DM41RZX SN CHEMBL205192; 2,6-bis(4-tolyl)-9H-purine; BDBM50186598
DM41RZX DT Small molecular drug
DM41RZX PC 11709210
DM41RZX MW 300.4
DM41RZX FM C19H16N4
DM41RZX IC InChI=1S/C19H16N4/c1-12-3-7-14(8-4-12)16-17-19(21-11-20-17)23-18(22-16)15-9-5-13(2)6-10-15/h3-11H,1-2H3,(H,20,21,22,23)
DM41RZX CS CC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=C(C=C4)C)N=CN3
DM41RZX IK DEIRTPFLGXETKT-UHFFFAOYSA-N
DM41RZX IU 2,6-bis(4-methylphenyl)-7H-purine
DM41RZX DE Discovery agent
DMREF31 ID DMREF31
DMREF31 DN 2,6-diamino-5-nitropyrimidin-4(3H)-one
DMREF31 HS Investigative
DMREF31 DT Small molecular drug
DMREF31 PC 135461662
DMREF31 MW 171.11
DMREF31 FM C4H5N5O3
DMREF31 IC InChI=1S/C4H5N5O3/c5-2-1(9(11)12)3(10)8-4(6)7-2/h(H5,5,6,7,8,10)
DMREF31 CS C1(=C(N=C(NC1=O)N)N)[N+](=O)[O-]
DMREF31 IK XNFGVBWYGFPSDN-UHFFFAOYSA-N
DMREF31 IU 2,4-diamino-5-nitro-1H-pyrimidin-6-one
DMREF31 CA CAS 3346-23-4
DMREF31 DE Discovery agent
DM4RS9N ID DM4RS9N
DM4RS9N DN 2,6-diamino-5-nitrosopyrimidin-4(3H)-one
DM4RS9N HS Investigative
DM4RS9N DT Small molecular drug
DM4RS9N PC 135408762
DM4RS9N MW 155.12
DM4RS9N FM C4H5N5O2
DM4RS9N IC InChI=1S/C4H5N5O2/c5-2-1(9-11)3(10)8-4(6)7-2/h(H5,5,6,7,8,10)
DM4RS9N CS C1(=C(N=C(NC1=O)N)N)N=O
DM4RS9N IK HVMRLFSFHWCUCG-UHFFFAOYSA-N
DM4RS9N IU 2,4-diamino-5-nitroso-1H-pyrimidin-6-one
DM4RS9N CA CAS 2387-48-6
DM4RS9N DE Discovery agent
DM8JFNU ID DM8JFNU
DM8JFNU DN 2,6-DICARBOXYNAPHTHALENE
DM8JFNU HS Investigative
DM8JFNU SN 2,6-Naphthalenedicarboxylic acid; naphthalene-2,6-dicarboxylic acid; 1141-38-4; 2,6-NAPHTHALIC ACID; 2,6-DICARBOXYNAPHTHALENE; UNII-K3C4DYZ29O; 2,6-naphthalene dicarboxylic acid; EINECS 214-527-0; NSC 96410; K3C4DYZ29O; CHEBI:44460; RXOHFPCZGPKIRD-UHFFFAOYSA-N; MFCD00004105; FR-1318; W-108606; DSSTox_CID_9211; ACMC-2099kj; AC1Q73RL; NCIOpen2_007124; DSSTox_RID_78711; DSSTox_GSID_29211; SCHEMBL18758; AC1L23O7; 2,6-Naphthalenedicarboxylicacid; 2,6-Naphthalendicarboxylic acid; Jsp001070; CHEMBL1205452; DTXSID5029211; CTK0H6341
DM8JFNU DT Small molecular drug
DM8JFNU PC 14357
DM8JFNU MW 216.19
DM8JFNU FM C12H8O4
DM8JFNU IC InChI=1S/C12H8O4/c13-11(14)9-3-1-7-5-10(12(15)16)4-2-8(7)6-9/h1-6H,(H,13,14)(H,15,16)
DM8JFNU CS C1=CC2=C(C=CC(=C2)C(=O)O)C=C1C(=O)O
DM8JFNU IK RXOHFPCZGPKIRD-UHFFFAOYSA-N
DM8JFNU IU naphthalene-2,6-dicarboxylic acid
DM8JFNU CA CAS 1141-38-4
DM8JFNU CB CHEBI:44460
DM8JFNU DE Discovery agent
DMGEYAK ID DMGEYAK
DMGEYAK DN 2,6-Difluorobenzenesulfonamide
DMGEYAK HS Investigative
DMGEYAK SN 2,6-DIFLUOROBENZENESULFONAMIDE; 60230-37-7; 2,6-difluorobenzenesulphonamide; 2,6-difluorobenzene-1-sulfonamide; Benzenesulfonamide, 2,6-difluoro-; FBT; 2,6-Difluorophenylsulphonylamide; PubChem11779; ACMC-209vki; AC1L9JF9; KSC495S1R; SCHEMBL677588; 2,6-difluorobenzenesulfon-amide; 2,6-difluoro-benzenesulfonamide; CTK3J5918; CHEBI:42429; DTXSID60332218; MolPort-000-154-262; RVVVGGCOFWWDEL-UHFFFAOYSA-N; ZINC404039; KS-000010UU; WT2099; STL554304; SBB091559; WT1897; BBL100510; ANW-45184; 2,6-Difluorobenzenesulfonamide, 97%
DMGEYAK DT Small molecular drug
DMGEYAK PC 446274
DMGEYAK MW 193.17
DMGEYAK FM C6H5F2NO2S
DMGEYAK IC InChI=1S/C6H5F2NO2S/c7-4-2-1-3-5(8)6(4)12(9,10)11/h1-3H,(H2,9,10,11)
DMGEYAK CS C1=CC(=C(C(=C1)F)S(=O)(=O)N)F
DMGEYAK IK RVVVGGCOFWWDEL-UHFFFAOYSA-N
DMGEYAK IU 2,6-difluorobenzenesulfonamide
DMGEYAK CA CAS 60230-37-7
DMGEYAK CB CHEBI:42429
DMGEYAK DE Discovery agent
DMDN12L ID DMDN12L
DMDN12L DN 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
DMDN12L HS Investigative
DMDN12L SN Anthra[1,9-cd]pyrazol-6(2H)-one; 129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra-1,9-pyrazol-6-none; SP-600125; CI 70300; 2H-Dibenzo[cd,g]indazol-6-one; JNK Inhibitor II; SAPK Inhibitor II; NSC 75890; UNII-1TW30Y2766; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; EINECS 204-955-6; 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE; BRN 0746890; CHEMBL7064; MLS002693964; CHEBI:90695; ACPOUJIDANTYHO-UHFFFAOYSA-N; 1TW30Y2766
DMDN12L DT Small molecular drug
DMDN12L PC 8515
DMDN12L MW 220.23
DMDN12L FM C14H8N2O
DMDN12L IC InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)
DMDN12L CS C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O
DMDN12L IK ACPOUJIDANTYHO-UHFFFAOYSA-N
DMDN12L IU 14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
DMDN12L CA CAS 129-56-6
DMDN12L CB CHEBI:90695
DMDN12L DE Discovery agent
DM5QEUC ID DM5QEUC
DM5QEUC DN 2,6-dihydroxy-1,7-dimethoxyxanthone
DM5QEUC HS Investigative
DM5QEUC SN calophymembranol A; 2,6-dihydroxy-1,7-dimethoxyxanthone; CHEMBL463769; AC1NRZXJ; BDBM50269644; 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one
DM5QEUC DT Small molecular drug
DM5QEUC PC 5326145
DM5QEUC MW 288.25
DM5QEUC FM C15H12O6
DM5QEUC IC InChI=1S/C15H12O6/c1-19-12-5-7-11(6-9(12)17)21-10-4-3-8(16)15(20-2)13(10)14(7)18/h3-6,16-17H,1-2H3
DM5QEUC CS COC1=C(C=C2C(=C1)C(=O)C3=C(O2)C=CC(=C3OC)O)O
DM5QEUC IK SROSPGQNFCAFNO-UHFFFAOYSA-N
DM5QEUC IU 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one
DM5QEUC DE Discovery agent
DMD51I4 ID DMD51I4
DMD51I4 DN 2,6-Diisopropyl-4-nitro-phenol
DMD51I4 HS Investigative
DMD51I4 SN 2,6-Diisopropyl-4-nitrophenol; 4-Nitro Propofol; 1576-14-3; Phenol, 2,6-bis(1-methylethyl)-4-nitro-; 4-Nitro-2,6-diisopropylphenol; SCHEMBL6978784; CHEMBL299111; DTXSID20443430; BDOVQBSHXBPOLJ-UHFFFAOYSA-N; ZINC13779578; 2,6-bis(1-methylethyl)-4-nitrophenol; 2,6-Bis(1-methylethyl)-4-nitro-phenol; FT-0672927
DMD51I4 DT Small molecular drug
DMD51I4 PC 10680603
DMD51I4 MW 223.27
DMD51I4 FM C12H17NO3
DMD51I4 IC InChI=1S/C12H17NO3/c1-7(2)10-5-9(13(15)16)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DMD51I4 CS CC(C)C1=CC(=CC(=C1O)C(C)C)[N+](=O)[O-]
DMD51I4 IK BDOVQBSHXBPOLJ-UHFFFAOYSA-N
DMD51I4 IU 4-nitro-2,6-di(propan-2-yl)phenol
DMD51I4 CA CAS 1576-14-3
DMD51I4 DE Discovery agent
DMRZJU5 ID DMRZJU5
DMRZJU5 DN 2,6-dimethyl-8-ethyl-1-deazapurine
DMRZJU5 HS Investigative
DMRZJU5 SN 133240-06-9; 2-Ethyl-5,7-dimethyl-1H-imidazo[4,5-b]pyridine; 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine; CHEMBL221579; 3H-Imidazo[4,5-b]pyridine,2-ethyl-5,7-dimethyl-; 5,7-Dimethyl-2-ethylimidazo[4,5-b]pyridine; 3H-Imidazo[4,5-b]pyridine, 2-ethyl-5,7-dimethyl-; 2,6-dimethyl-8-ethyl-1-deazapurine; ACMC-20dzbe; SCHEMBL1918476; CTK4B8431; DTXSID40431137; XWWJWZJOSWSJQV-UHFFFAOYSA-N; ZINC22058897; BDBM50205288; ANW-72022; AKOS000278272; AKOS015904384; RTX-011778; FCH1411209; AM803160; SC-21701; KB-23752; AJ-80864; TC-160767
DMRZJU5 DT Small molecular drug
DMRZJU5 PC 9815374
DMRZJU5 MW 175.23
DMRZJU5 FM C10H13N3
DMRZJU5 IC InChI=1S/C10H13N3/c1-4-8-12-9-6(2)5-7(3)11-10(9)13-8/h5H,4H2,1-3H3,(H,11,12,13)
DMRZJU5 CS CCC1=NC2=C(N1)C(=CC(=N2)C)C
DMRZJU5 IK XWWJWZJOSWSJQV-UHFFFAOYSA-N
DMRZJU5 IU 2-ethyl-5,7-dimethyl-1H-imidazo[4,5-b]pyridine
DMRZJU5 CA CAS 133240-06-9
DMRZJU5 DE Discovery agent
DMW2VZ1 ID DMW2VZ1
DMW2VZ1 DN 2,6-diphenyl-1-deazapurine
DMW2VZ1 HS Investigative
DMW2VZ1 SN CHEMBL220535; 2,6-diphenyl-1-deazapurine; ZINC34800849
DMW2VZ1 DT Small molecular drug
DMW2VZ1 PC 16109423
DMW2VZ1 MW 271.3
DMW2VZ1 FM C18H13N3
DMW2VZ1 IC InChI=1S/C18H13N3/c1-3-7-13(8-4-1)15-11-16(14-9-5-2-6-10-14)21-18-17(15)19-12-20-18/h1-12H,(H,19,20,21)
DMW2VZ1 CS C1=CC=C(C=C1)C2=CC(=NC3=C2NC=N3)C4=CC=CC=C4
DMW2VZ1 IK JRQCVLBKLGJDMI-UHFFFAOYSA-N
DMW2VZ1 IU 5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMW2VZ1 DE Discovery agent
DMY3C78 ID DMY3C78
DMY3C78 DN 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78 HS Investigative
DMY3C78 SN CHEMBL385109; 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine
DMY3C78 DT Small molecular drug
DMY3C78 PC 16109429
DMY3C78 MW 341.4
DMY3C78 FM C23H23N3
DMY3C78 IC InChI=1S/C23H23N3/c1-3-16(4-2)22-25-21-19(17-11-7-5-8-12-17)15-20(24-23(21)26-22)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,24,25,26)
DMY3C78 CS CCC(CC)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMY3C78 IK GPQRSDCKVYJMOH-UHFFFAOYSA-N
DMY3C78 IU 2-pentan-3-yl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMY3C78 DE Discovery agent
DM0C8BW ID DM0C8BW
DM0C8BW DN 2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW HS Investigative
DM0C8BW SN CHEMBL222130; 2,6-diphenyl-8-ethyl-1-deazapurine
DM0C8BW DT Small molecular drug
DM0C8BW PC 16109432
DM0C8BW MW 299.4
DM0C8BW FM C20H17N3
DM0C8BW IC InChI=1S/C20H17N3/c1-2-18-22-19-16(14-9-5-3-6-10-14)13-17(21-20(19)23-18)15-11-7-4-8-12-15/h3-13H,2H2,1H3,(H,21,22,23)
DM0C8BW CS CCC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DM0C8BW IK PMDYRFYZMJGDQY-UHFFFAOYSA-N
DM0C8BW IU 2-ethyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DM0C8BW DE Discovery agent
DMI79FV ID DMI79FV
DMI79FV DN 2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV HS Investigative
DMI79FV SN CHEMBL220587; 2,6-diphenyl-8-methyl-1-deazapurine
DMI79FV DT Small molecular drug
DMI79FV PC 16109426
DMI79FV MW 285.3
DMI79FV FM C19H15N3
DMI79FV IC InChI=1S/C19H15N3/c1-13-20-18-16(14-8-4-2-5-9-14)12-17(22-19(18)21-13)15-10-6-3-7-11-15/h2-12H,1H3,(H,20,21,22)
DMI79FV CS CC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMI79FV IK HKDKOLLILMBGNN-UHFFFAOYSA-N
DMI79FV IU 2-methyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMI79FV DE Discovery agent
DM6D1BQ ID DM6D1BQ
DM6D1BQ DN 2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ HS Investigative
DM6D1BQ SN CHEMBL220053; 2,6-diphenyl-8-tButyl-1-deazapurine
DM6D1BQ DT Small molecular drug
DM6D1BQ PC 16109434
DM6D1BQ MW 327.4
DM6D1BQ FM C22H21N3
DM6D1BQ IC InChI=1S/C22H21N3/c1-22(2,3)21-24-19-17(15-10-6-4-7-11-15)14-18(23-20(19)25-21)16-12-8-5-9-13-16/h4-14H,1-3H3,(H,23,24,25)
DM6D1BQ CS CC(C)(C)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DM6D1BQ IK LYZUCUIUVUYBJL-UHFFFAOYSA-N
DM6D1BQ IU 2-tert-butyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DM6D1BQ DE Discovery agent
DM5SXYI ID DM5SXYI
DM5SXYI DN 2,6-diphenyl-9H-purine
DM5SXYI HS Investigative
DM5SXYI SN 2,6-diphenyl-9H-purine; 1H-Purine, 2,6-diphenyl-; CHEMBL381729; 889673-58-9; CTK3A4137; DTXSID90468791
DM5SXYI DT Small molecular drug
DM5SXYI PC 11572592
DM5SXYI MW 272.3
DM5SXYI FM C17H12N4
DM5SXYI IC InChI=1S/C17H12N4/c1-3-7-12(8-4-1)14-15-17(19-11-18-15)21-16(20-14)13-9-5-2-6-10-13/h1-11H,(H,18,19,20,21)
DM5SXYI CS C1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=CN3
DM5SXYI IK WNVFFQZYOFELQA-UHFFFAOYSA-N
DM5SXYI IU 2,6-diphenyl-7H-purine
DM5SXYI CA CAS 889673-58-9
DM5SXYI DE Discovery agent
DM3JURW ID DM3JURW
DM3JURW DN 2,6-Diphenyl-pyrimidin-4-ylamine
DM3JURW HS Investigative
DM3JURW SN 4-Amino-2,6-diphenylpyrimidine; 2,6-diphenylpyrimidin-4-amine; CHEMBL406788; PLXFRDQUOPPVHF-UHFFFAOYSA-N; 2,6-Diphenyl-4-pyrimidinamine; AC1LDIB7; SCHEMBL1490059; 2,6-Diphenyl-4-pyrimidinamine #; ZINC29062470; BDBM50375487; AKOS011055092; (2,6-diphenyl-pyrimidin-4-yl)-amine
DM3JURW DT Small molecular drug
DM3JURW PC 619020
DM3JURW MW 247.29
DM3JURW FM C16H13N3
DM3JURW IC InChI=1S/C16H13N3/c17-15-11-14(12-7-3-1-4-8-12)18-16(19-15)13-9-5-2-6-10-13/h1-11H,(H2,17,18,19)
DM3JURW CS C1=CC=C(C=C1)C2=CC(=NC(=N2)C3=CC=CC=C3)N
DM3JURW IK PLXFRDQUOPPVHF-UHFFFAOYSA-N
DM3JURW IU 2,6-diphenylpyrimidin-4-amine
DM3JURW DE Discovery agent
DMY8LDT ID DMY8LDT
DMY8LDT DN 2,6-di-t-butylphenol
DMY8LDT HS Investigative
DMY8LDT SN 2,6-DI-TERT-BUTYLPHENOL; 128-39-2; 2,6-Di-t-butylphenol; 2,6-Bis(tert-butyl)phenol; 2,6-Bis(1,1-dimethylethyl)phenol; Phenol, 2,6-bis(1,1-dimethylethyl)-; 2,6-ditert-butylphenol; 2,6 Di-tert-butylphenol; Ethanox 701; Isonox 103; Ethyl 701; Ethyl AN 701; Hitec 4701; Phenol, 2,6-di-tert-butyl-; 2,6-Bis(t-butyl)phenol; NSC 49175; AN 701; CCRIS 5828; UNII-21294V58PF; HSDB 5616; 2,6-(1,1-Dimethylethyl)phenol; EINECS 204-884-0; MFCD00008820; 2,6-di-tert.-butylphenol; 2,6-Di-tert-butyl-phenol; AI3-26293; CHEMBL281071
DMY8LDT DT Small molecular drug
DMY8LDT PC 31405
DMY8LDT MW 206.32
DMY8LDT FM C14H22O
DMY8LDT IC InChI=1S/C14H22O/c1-13(2,3)10-8-7-9-11(12(10)15)14(4,5)6/h7-9,15H,1-6H3
DMY8LDT CS CC(C)(C)C1=C(C(=CC=C1)C(C)(C)C)O
DMY8LDT IK DKCPKDPYUFEZCP-UHFFFAOYSA-N
DMY8LDT IU 2,6-ditert-butylphenol
DMY8LDT CA CAS 128-39-2
DMY8LDT CB CHEBI:131421
DMY8LDT DE Discovery agent
DMFO1H2 ID DMFO1H2
DMFO1H2 DN 2,6-di-tert-butyl-4-methoxyphenol
DMFO1H2 HS Investigative
DMFO1H2 SN 2,6-DI-TERT-BUTYL-4-METHOXYPHENOL; 489-01-0; 3,5-Di-tert-butyl-4-hydroxyanisole; Topanol 354; Phenol, 2,6-bis(1,1-dimethylethyl)-4-methoxy-; 3,5-di-t-Butyl-4-hydroxyanisole; UNII-616072TMXY; CCRIS 5219; 2,6-Bis(1,1-dimethylethyl)-4-methoxyphenol; EINECS 207-693-0; NSC 14451; Phenol, 2,6-di-tert-butyl-4-methoxy-; CHEMBL98253; 2,6-di-t-butyl-4-methoxyphenol; SLUKQUGVTITNSY-UHFFFAOYSA-N; 2,6-ditert-butyl-4-methoxyphenol; 616072TMXY; 2,6-bis(tert-butyl)-4-methoxyphenol; 2,6-Di-tert-butyl-4-methoxyphenol, 97%; DTBHA; ACMC-1ALDH
DMFO1H2 DT Small molecular drug
DMFO1H2 PC 10269
DMFO1H2 MW 236.35
DMFO1H2 FM C15H24O2
DMFO1H2 IC InChI=1S/C15H24O2/c1-14(2,3)11-8-10(17-7)9-12(13(11)16)15(4,5)6/h8-9,16H,1-7H3
DMFO1H2 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)OC
DMFO1H2 IK SLUKQUGVTITNSY-UHFFFAOYSA-N
DMFO1H2 IU 2,6-ditert-butyl-4-methoxyphenol
DMFO1H2 CA CAS 489-01-0
DMFO1H2 DE Discovery agent
DM8F9KO ID DM8F9KO
DM8F9KO DN 2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO HS Investigative
DM8F9KO SN CHEMBL376648; 2,6-dphenyl-8-propyl-1-deazapurine
DM8F9KO DT Small molecular drug
DM8F9KO PC 16109427
DM8F9KO MW 313.4
DM8F9KO FM C21H19N3
DM8F9KO IC InChI=1S/C21H19N3/c1-2-9-19-23-20-17(15-10-5-3-6-11-15)14-18(22-21(20)24-19)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,22,23,24)
DM8F9KO CS CCCC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DM8F9KO IK DBBRCPJIWFJBPI-UHFFFAOYSA-N
DM8F9KO IU 5,7-diphenyl-2-propyl-1H-imidazo[4,5-b]pyridine
DM8F9KO DE Discovery agent
DMT9JHV ID DMT9JHV
DMT9JHV DN 2,7-Bis(3-chloropropionamido)anthraquinone
DMT9JHV HS Investigative
DMT9JHV SN 2,7-Bis(3-chloropropionamido)anthraquinone; SCHEMBL4294857; CHEMBL494457
DMT9JHV DT Small molecular drug
DMT9JHV PC 10669736
DMT9JHV MW 419.3
DMT9JHV FM C20H16Cl2N2O4
DMT9JHV IC InChI=1S/C20H16Cl2N2O4/c21-7-5-17(25)23-11-1-3-13-15(9-11)20(28)16-10-12(24-18(26)6-8-22)2-4-14(16)19(13)27/h1-4,9-10H,5-8H2,(H,23,25)(H,24,26)
DMT9JHV CS C1=CC2=C(C=C1NC(=O)CCCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCCl
DMT9JHV IK ZOTZWUALAZOEAF-UHFFFAOYSA-N
DMT9JHV IU 3-chloro-N-[7-(3-chloropropanoylamino)-9,10-dioxoanthracen-2-yl]propanamide
DMT9JHV DE Discovery agent
DM8VWQ2 ID DM8VWQ2
DM8VWQ2 DN 2,7-Bis(4-chlorobutyramido)anthraquinone
DM8VWQ2 HS Investigative
DM8VWQ2 SN 2,7-Bis(4-chlorobutyramido)anthraquinone; SCHEMBL4293006
DM8VWQ2 DT Small molecular drug
DM8VWQ2 PC 44242844
DM8VWQ2 MW 447.3
DM8VWQ2 FM C22H20Cl2N2O4
DM8VWQ2 IC InChI=1S/C22H20Cl2N2O4/c23-9-1-3-19(27)25-13-5-7-15-17(11-13)22(30)18-12-14(6-8-16(18)21(15)29)26-20(28)4-2-10-24/h5-8,11-12H,1-4,9-10H2,(H,25,27)(H,26,28)
DM8VWQ2 CS C1=CC2=C(C=C1NC(=O)CCCCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCCCl
DM8VWQ2 IK OWZXQHSZHVLBPE-UHFFFAOYSA-N
DM8VWQ2 IU 4-chloro-N-[7-(4-chlorobutanoylamino)-9,10-dioxoanthracen-2-yl]butanamide
DM8VWQ2 DE Discovery agent
DM2EPM4 ID DM2EPM4
DM2EPM4 DN 2,7-Bis(acetamido)anthraquinone
DM2EPM4 HS Investigative
DM2EPM4 SN 2,7-Bis(acetamido)anthraquinone; CHEMBL481175; SCHEMBL4291944
DM2EPM4 DT Small molecular drug
DM2EPM4 PC 44568336
DM2EPM4 MW 322.3
DM2EPM4 FM C18H14N2O4
DM2EPM4 IC InChI=1S/C18H14N2O4/c1-9(21)19-11-3-5-13-15(7-11)18(24)16-8-12(20-10(2)22)4-6-14(16)17(13)23/h3-8H,1-2H3,(H,19,21)(H,20,22)
DM2EPM4 CS CC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)C
DM2EPM4 IK SNSGXIQBZKNIJT-UHFFFAOYSA-N
DM2EPM4 IU N-(7-acetamido-9,10-dioxoanthracen-2-yl)acetamide
DM2EPM4 DE Discovery agent
DMEQC4X ID DMEQC4X
DMEQC4X DN 2,7-Bis(benzoamido)anthraquinone
DMEQC4X HS Investigative
DMEQC4X SN 2,7-Bis(benzoamido)anthraquinone; SCHEMBL4289564
DMEQC4X DT Small molecular drug
DMEQC4X PC 44243461
DMEQC4X MW 446.5
DMEQC4X FM C28H18N2O4
DMEQC4X IC InChI=1S/C28H18N2O4/c31-25-21-13-11-19(29-27(33)17-7-3-1-4-8-17)15-23(21)26(32)24-16-20(12-14-22(24)25)30-28(34)18-9-5-2-6-10-18/h1-16H,(H,29,33)(H,30,34)
DMEQC4X CS C1=CC=C(C=C1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5=CC=CC=C5
DMEQC4X IK IJKYLKHKCJTQGH-UHFFFAOYSA-N
DMEQC4X IU N-(7-benzamido-9,10-dioxoanthracen-2-yl)benzamide
DMEQC4X DE Discovery agent
DM9S8LY ID DM9S8LY
DM9S8LY DN 2,7-Bis(butyramido)anthraquinone
DM9S8LY HS Investigative
DM9S8LY SN 2,7-Bis(butyramido)anthraquinone; SCHEMBL4298269; CHEMBL480780
DM9S8LY DT Small molecular drug
DM9S8LY PC 44243462
DM9S8LY MW 378.4
DM9S8LY FM C22H22N2O4
DM9S8LY IC InChI=1S/C22H22N2O4/c1-3-5-19(25)23-13-7-9-15-17(11-13)22(28)18-12-14(24-20(26)6-4-2)8-10-16(18)21(15)27/h7-12H,3-6H2,1-2H3,(H,23,25)(H,24,26)
DM9S8LY CS CCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCC
DM9S8LY IK WKZCLVUWGOTILL-UHFFFAOYSA-N
DM9S8LY IU N-[7-(butanoylamino)-9,10-dioxoanthracen-2-yl]butanamide
DM9S8LY DE Discovery agent
DM4MYAR ID DM4MYAR
DM4MYAR DN 2,7-Bis(chloroacetamido)anthraquinone
DM4MYAR HS Investigative
DM4MYAR SN 2,7-Bis(chloroacetamido)anthraquinone; SCHEMBL4294197; CHEMBL492429
DM4MYAR DT Small molecular drug
DM4MYAR PC 44243423
DM4MYAR MW 391.2
DM4MYAR FM C18H12Cl2N2O4
DM4MYAR IC InChI=1S/C18H12Cl2N2O4/c19-7-15(23)21-9-1-3-11-13(5-9)18(26)14-6-10(22-16(24)8-20)2-4-12(14)17(11)25/h1-6H,7-8H2,(H,21,23)(H,22,24)
DM4MYAR CS C1=CC2=C(C=C1NC(=O)CCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCl
DM4MYAR IK MKVRAGYBTIZOIV-UHFFFAOYSA-N
DM4MYAR IU 2-chloro-N-[7-[(2-chloroacetyl)amino]-9,10-dioxoanthracen-2-yl]acetamide
DM4MYAR DE Discovery agent
DMTPZ8D ID DMTPZ8D
DMTPZ8D DN 2,7-Bis(cyclohexanecarbonamido)anthraquinone
DMTPZ8D HS Investigative
DMTPZ8D SN 2,7-Bis(cyclohexanecarbonamido)anthraquinone; CHEMBL479981
DMTPZ8D DT Small molecular drug
DMTPZ8D PC 44243425
DMTPZ8D MW 458.5
DMTPZ8D FM C28H30N2O4
DMTPZ8D IC InChI=1S/C28H30N2O4/c31-25-21-13-11-19(29-27(33)17-7-3-1-4-8-17)15-23(21)26(32)24-16-20(12-14-22(24)25)30-28(34)18-9-5-2-6-10-18/h11-18H,1-10H2,(H,29,33)(H,30,34)
DMTPZ8D CS C1CCC(CC1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5CCCCC5
DMTPZ8D IK ISUCEGSINPVOBA-UHFFFAOYSA-N
DMTPZ8D IU N-[7-(cyclohexanecarbonylamino)-9,10-dioxoanthracen-2-yl]cyclohexanecarboxamide
DMTPZ8D DE Discovery agent
DMP3EZ8 ID DMP3EZ8
DMP3EZ8 DN 2,7-Bis(cyclopentanecarbonamido)anthraquinone
DMP3EZ8 HS Investigative
DMP3EZ8 SN 2,7-Bis(cyclopentanecarbonamido)anthraquinone; CHEMBL480939; SCHEMBL4293737
DMP3EZ8 DT Small molecular drug
DMP3EZ8 PC 44568364
DMP3EZ8 MW 430.5
DMP3EZ8 FM C26H26N2O4
DMP3EZ8 IC InChI=1S/C26H26N2O4/c29-23-19-11-9-17(27-25(31)15-5-1-2-6-15)13-21(19)24(30)22-14-18(10-12-20(22)23)28-26(32)16-7-3-4-8-16/h9-16H,1-8H2,(H,27,31)(H,28,32)
DMP3EZ8 CS C1CCC(C1)C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5CCCC5
DMP3EZ8 IK IYTIDEOSIOFBPE-UHFFFAOYSA-N
DMP3EZ8 IU N-[7-(cyclopentanecarbonylamino)-9,10-dioxoanthracen-2-yl]cyclopentanecarboxamide
DMP3EZ8 DE Discovery agent
DMY3V2B ID DMY3V2B
DMY3V2B DN 2,7-Bis(cyclopropanecarbonamido)anthraquinone
DMY3V2B HS Investigative
DMY3V2B SN 2,7-Bis(cyclopropanecarbonamido)anthraquinone; CHEMBL520920; SCHEMBL4296357
DMY3V2B DT Small molecular drug
DMY3V2B PC 44243459
DMY3V2B MW 374.4
DMY3V2B FM C22H18N2O4
DMY3V2B IC InChI=1S/C22H18N2O4/c25-19-15-7-5-13(23-21(27)11-1-2-11)9-17(15)20(26)18-10-14(6-8-16(18)19)24-22(28)12-3-4-12/h5-12H,1-4H2,(H,23,27)(H,24,28)
DMY3V2B CS C1CC1C(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)C5CC5
DMY3V2B IK SCYQIQINYUMLPD-UHFFFAOYSA-N
DMY3V2B IU N-[7-(cyclopropanecarbonylamino)-9,10-dioxoanthracen-2-yl]cyclopropanecarboxamide
DMY3V2B DE Discovery agent
DMEVIBT ID DMEVIBT
DMEVIBT DN 2,7-Bis(phenylacetamido)anthraquinone
DMEVIBT HS Investigative
DMEVIBT SN 2,7-Bis(phenylacetamido)anthraquinone; CHEMBL480771
DMEVIBT DT Small molecular drug
DMEVIBT PC 44232525
DMEVIBT MW 474.5
DMEVIBT FM C30H22N2O4
DMEVIBT IC InChI=1S/C30H22N2O4/c33-27(15-19-7-3-1-4-8-19)31-21-11-13-23-25(17-21)30(36)26-18-22(12-14-24(26)29(23)35)32-28(34)16-20-9-5-2-6-10-20/h1-14,17-18H,15-16H2,(H,31,33)(H,32,34)
DMEVIBT CS C1=CC=C(C=C1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CC5=CC=CC=C5
DMEVIBT IK YFLLPGICLQVMIU-UHFFFAOYSA-N
DMEVIBT IU N-[9,10-dioxo-7-[(2-phenylacetyl)amino]anthracen-2-yl]-2-phenylacetamide
DMEVIBT DE Discovery agent
DMDKXEY ID DMDKXEY
DMDKXEY DN 2,7-Bis(phenylpropionamido)anthraquinone
DMDKXEY HS Investigative
DMDKXEY SN 2,7-Bis(phenylpropionamido)anthraquinone; SCHEMBL4296330
DMDKXEY DT Small molecular drug
DMDKXEY PC 44243460
DMDKXEY MW 502.6
DMDKXEY FM C32H26N2O4
DMDKXEY IC InChI=1S/C32H26N2O4/c35-29(17-11-21-7-3-1-4-8-21)33-23-13-15-25-27(19-23)32(38)28-20-24(14-16-26(28)31(25)37)34-30(36)18-12-22-9-5-2-6-10-22/h1-10,13-16,19-20H,11-12,17-18H2,(H,33,35)(H,34,36)
DMDKXEY CS C1=CC=C(C=C1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCC5=CC=CC=C5
DMDKXEY IK SZRGPNHLVDLPHX-UHFFFAOYSA-N
DMDKXEY IU N-[9,10-dioxo-7-(3-phenylpropanoylamino)anthracen-2-yl]-3-phenylpropanamide
DMDKXEY DE Discovery agent
DM2D1EJ ID DM2D1EJ
DM2D1EJ DN 2,7-Bis(propionamido)anthraquinone
DM2D1EJ HS Investigative
DM2D1EJ SN 2,7-Bis(propionamido)anthraquinone; SCHEMBL4299908; CHEMBL481176
DM2D1EJ DT Small molecular drug
DM2D1EJ PC 44568337
DM2D1EJ MW 350.4
DM2D1EJ FM C20H18N2O4
DM2D1EJ IC InChI=1S/C20H18N2O4/c1-3-17(23)21-11-5-7-13-15(9-11)20(26)16-10-12(22-18(24)4-2)6-8-14(16)19(13)25/h5-10H,3-4H2,1-2H3,(H,21,23)(H,22,24)
DM2D1EJ CS CCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CC
DM2D1EJ IK FNUQOQZYSRMGQN-UHFFFAOYSA-N
DM2D1EJ IU N-[9,10-dioxo-7-(propanoylamino)anthracen-2-yl]propanamide
DM2D1EJ DE Discovery agent
DM3GTV0 ID DM3GTV0
DM3GTV0 DN 2,7-Bis[2-(butylamino)acetamido]anthraquinone
DM3GTV0 HS Investigative
DM3GTV0 SN 2,7-Bis[2-(butylamino)acetamido]anthraquinone; SCHEMBL4294896; CHEMBL494076
DM3GTV0 DT Small molecular drug
DM3GTV0 PC 44568666
DM3GTV0 MW 464.6
DM3GTV0 FM C26H32N4O4
DM3GTV0 IC InChI=1S/C26H32N4O4/c1-3-5-11-27-15-23(31)29-17-7-9-19-21(13-17)26(34)22-14-18(8-10-20(22)25(19)33)30-24(32)16-28-12-6-4-2/h7-10,13-14,27-28H,3-6,11-12,15-16H2,1-2H3,(H,29,31)(H,30,32)
DM3GTV0 CS CCCCNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCCCC
DM3GTV0 IK FYPZVYMKSUFNRS-UHFFFAOYSA-N
DM3GTV0 IU 2-(butylamino)-N-[7-[[2-(butylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DM3GTV0 DE Discovery agent
DMKDSGE ID DMKDSGE
DMKDSGE DN 2,7-Bis[2-(diethylamino)acetamido]anthraquinone
DMKDSGE HS Investigative
DMKDSGE SN 2,7-Bis[2-(diethylamino)acetamido]anthraquinone; SCHEMBL4305307; CHEMBL493878
DMKDSGE DT Small molecular drug
DMKDSGE PC 44243424
DMKDSGE MW 464.6
DMKDSGE FM C26H32N4O4
DMKDSGE IC InChI=1S/C26H32N4O4/c1-5-29(6-2)15-23(31)27-17-9-11-19-21(13-17)26(34)22-14-18(10-12-20(22)25(19)33)28-24(32)16-30(7-3)8-4/h9-14H,5-8,15-16H2,1-4H3,(H,27,31)(H,28,32)
DMKDSGE CS CCN(CC)CC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CN(CC)CC
DMKDSGE IK ZNVJTQUBGZVROG-UHFFFAOYSA-N
DMKDSGE IU 2-(diethylamino)-N-[7-[[2-(diethylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMKDSGE DE Discovery agent
DMNW5PL ID DMNW5PL
DMNW5PL DN 2,7-Bis[2-(dimethylamino)acetamido]anthraquinone
DMNW5PL HS Investigative
DMNW5PL SN 2,7-Bis[2-(dimethylamino)acetamido]anthraquinone; SCHEMBL4291524; CHEMBL494283; BQUQDCVNESTXAU-UHFFFAOYSA-N
DMNW5PL DT Small molecular drug
DMNW5PL PC 44568710
DMNW5PL MW 408.4
DMNW5PL FM C22H24N4O4
DMNW5PL IC InChI=1S/C22H24N4O4/c1-25(2)11-19(27)23-13-5-7-15-17(9-13)22(30)18-10-14(6-8-16(18)21(15)29)24-20(28)12-26(3)4/h5-10H,11-12H2,1-4H3,(H,23,27)(H,24,28)
DMNW5PL CS CN(C)CC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CN(C)C
DMNW5PL IK BQUQDCVNESTXAU-UHFFFAOYSA-N
DMNW5PL IU 2-(dimethylamino)-N-[7-[[2-(dimethylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMNW5PL DE Discovery agent
DMZ7EAC ID DMZ7EAC
DMZ7EAC DN 2,7-Bis[2-(ethylamino)acetamido]anthraquinone
DMZ7EAC HS Investigative
DMZ7EAC SN 2,7-Bis[2-(ethylamino)acetamido]anthraquinone; SCHEMBL4291481; CHEMBL494482
DMZ7EAC DT Small molecular drug
DMZ7EAC PC 44568712
DMZ7EAC MW 408.4
DMZ7EAC FM C22H24N4O4
DMZ7EAC IC InChI=1S/C22H24N4O4/c1-3-23-11-19(27)25-13-5-7-15-17(9-13)22(30)18-10-14(6-8-16(18)21(15)29)26-20(28)12-24-4-2/h5-10,23-24H,3-4,11-12H2,1-2H3,(H,25,27)(H,26,28)
DMZ7EAC CS CCNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCC
DMZ7EAC IK DJJHCFWUEPEODX-UHFFFAOYSA-N
DMZ7EAC IU 2-(ethylamino)-N-[7-[[2-(ethylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMZ7EAC DE Discovery agent
DMM4T1Q ID DMM4T1Q
DMM4T1Q DN 2,7-Bis[2-(isobutylamino)acetamido]anthraquinone
DMM4T1Q HS Investigative
DMM4T1Q SN 2,7-Bis[2-(isobutylamino)acetamido]anthraquinone; SCHEMBL4298304; CHEMBL494456
DMM4T1Q DT Small molecular drug
DMM4T1Q PC 44568765
DMM4T1Q MW 464.6
DMM4T1Q FM C26H32N4O4
DMM4T1Q IC InChI=1S/C26H32N4O4/c1-15(2)11-27-13-23(31)29-17-5-7-19-21(9-17)26(34)22-10-18(6-8-20(22)25(19)33)30-24(32)14-28-12-16(3)4/h5-10,15-16,27-28H,11-14H2,1-4H3,(H,29,31)(H,30,32)
DMM4T1Q CS CC(C)CNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCC(C)C
DMM4T1Q IK BTABHVPIAAKKHL-UHFFFAOYSA-N
DMM4T1Q IU 2-(2-methylpropylamino)-N-[7-[[2-(2-methylpropylamino)acetyl]amino]-9,10-dioxoanthracen-2-yl]acetamide
DMM4T1Q DE Discovery agent
DMRQGWX ID DMRQGWX
DMRQGWX DN 2,7-Bis[2-(isopropylamino)acetamido]anthraquinone
DMRQGWX HS Investigative
DMRQGWX SN 2,7-Bis[2-(isopropylamino)acetamido]anthraquinone; SCHEMBL4300462; CHEMBL494259
DMRQGWX DT Small molecular drug
DMRQGWX PC 44568764
DMRQGWX MW 436.5
DMRQGWX FM C24H28N4O4
DMRQGWX IC InChI=1S/C24H28N4O4/c1-13(2)25-11-21(29)27-15-5-7-17-19(9-15)24(32)20-10-16(6-8-18(20)23(17)31)28-22(30)12-26-14(3)4/h5-10,13-14,25-26H,11-12H2,1-4H3,(H,27,29)(H,28,30)
DMRQGWX CS CC(C)NCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNC(C)C
DMRQGWX IK DKNQCGLIKICHPF-UHFFFAOYSA-N
DMRQGWX IU N-[9,10-dioxo-7-[[2-(propan-2-ylamino)acetyl]amino]anthracen-2-yl]-2-(propan-2-ylamino)acetamide
DMRQGWX DE Discovery agent
DMPE8GX ID DMPE8GX
DMPE8GX DN 2,7-Bis[2-(piperazino)acetamido]anthraquinone
DMPE8GX HS Investigative
DMPE8GX SN 2,7-Bis[2-(piperazino)acetamido]anthraquinone; SCHEMBL4291737; CHEMBL495308
DMPE8GX DT Small molecular drug
DMPE8GX PC 44568763
DMPE8GX MW 490.6
DMPE8GX FM C26H30N6O4
DMPE8GX IC InChI=1S/C26H30N6O4/c33-23(15-31-9-5-27-6-10-31)29-17-1-3-19-21(13-17)26(36)22-14-18(2-4-20(22)25(19)35)30-24(34)16-32-11-7-28-8-12-32/h1-4,13-14,27-28H,5-12,15-16H2,(H,29,33)(H,30,34)
DMPE8GX CS C1CN(CCN1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CN5CCNCC5
DMPE8GX IK OBWFXMCXHJYGRS-UHFFFAOYSA-N
DMPE8GX IU N-[9,10-dioxo-7-[(2-piperazin-1-ylacetyl)amino]anthracen-2-yl]-2-piperazin-1-ylacetamide
DMPE8GX DE Discovery agent
DMITF0P ID DMITF0P
DMITF0P DN 2,7-Bis[2-(piperidino)acetamido]anthraquinone
DMITF0P HS Investigative
DMITF0P SN 2,7-Bis[2-(piperidino)acetamido]anthraquinone; SCHEMBL4299285; CHEMBL492640
DMITF0P DT Small molecular drug
DMITF0P PC 44568668
DMITF0P MW 488.6
DMITF0P FM C28H32N4O4
DMITF0P IC InChI=1S/C28H32N4O4/c33-25(17-31-11-3-1-4-12-31)29-19-7-9-21-23(15-19)28(36)24-16-20(8-10-22(24)27(21)35)30-26(34)18-32-13-5-2-6-14-32/h7-10,15-16H,1-6,11-14,17-18H2,(H,29,33)(H,30,34)
DMITF0P CS C1CCN(CC1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CN5CCCCC5
DMITF0P IK IOHQNFPYEZQWLH-UHFFFAOYSA-N
DMITF0P IU N-[9,10-dioxo-7-[(2-piperidin-1-ylacetyl)amino]anthracen-2-yl]-2-piperidin-1-ylacetamide
DMITF0P DE Discovery agent
DMH89TO ID DMH89TO
DMH89TO DN 2,7-Bis[2-(propylamino)acetamido]anthraquinone
DMH89TO HS Investigative
DMH89TO SN 2,7-Bis[2-(propylamino)acetamido]anthraquinone; SCHEMBL4297885; CHEMBL494284
DMH89TO DT Small molecular drug
DMH89TO PC 44568711
DMH89TO MW 436.5
DMH89TO FM C24H28N4O4
DMH89TO IC InChI=1S/C24H28N4O4/c1-3-9-25-13-21(29)27-15-5-7-17-19(11-15)24(32)20-12-16(6-8-18(20)23(17)31)28-22(30)14-26-10-4-2/h5-8,11-12,25-26H,3-4,9-10,13-14H2,1-2H3,(H,27,29)(H,28,30)
DMH89TO CS CCCNCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CNCCC
DMH89TO IK OBGMWZLARFADCF-UHFFFAOYSA-N
DMH89TO IU N-[9,10-dioxo-7-[[2-(propylamino)acetyl]amino]anthracen-2-yl]-2-(propylamino)acetamide
DMH89TO DE Discovery agent
DMHVKIJ ID DMHVKIJ
DMHVKIJ DN 2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone
DMHVKIJ HS Investigative
DMHVKIJ SN 2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone; SCHEMBL4297878; CHEMBL522685
DMHVKIJ DT Small molecular drug
DMHVKIJ PC 44568667
DMHVKIJ MW 460.5
DMHVKIJ FM C26H28N4O4
DMHVKIJ IC InChI=1S/C26H28N4O4/c31-23(15-29-9-1-2-10-29)27-17-5-7-19-21(13-17)26(34)22-14-18(6-8-20(22)25(19)33)28-24(32)16-30-11-3-4-12-30/h5-8,13-14H,1-4,9-12,15-16H2,(H,27,31)(H,28,32)
DMHVKIJ CS C1CCN(C1)CC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CN5CCCC5
DMHVKIJ IK CJLKYQVGOOCWAC-UHFFFAOYSA-N
DMHVKIJ IU N-[9,10-dioxo-7-[(2-pyrrolidin-1-ylacetyl)amino]anthracen-2-yl]-2-pyrrolidin-1-ylacetamide
DMHVKIJ DE Discovery agent
DM4V63W ID DM4V63W
DM4V63W DN 2,7-Bis[3-(butylamino)propionamido]anthraquinone
DM4V63W HS Investigative
DM4V63W SN 2,7-Bis[3-(butylamino)propionamido]anthraquinone; SCHEMBL4289808; CHEMBL479984
DM4V63W DT Small molecular drug
DM4V63W PC 44568189
DM4V63W MW 492.6
DM4V63W FM C28H36N4O4
DM4V63W IC InChI=1S/C28H36N4O4/c1-3-5-13-29-15-11-25(33)31-19-7-9-21-23(17-19)28(36)24-18-20(8-10-22(24)27(21)35)32-26(34)12-16-30-14-6-4-2/h7-10,17-18,29-30H,3-6,11-16H2,1-2H3,(H,31,33)(H,32,34)
DM4V63W CS CCCCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCCCC
DM4V63W IK WKRXVGOZDDYFGG-UHFFFAOYSA-N
DM4V63W IU 3-(butylamino)-N-[7-[3-(butylamino)propanoylamino]-9,10-dioxoanthracen-2-yl]propanamide
DM4V63W DE Discovery agent
DMC537F ID DMC537F
DMC537F DN 2,7-Bis[3-(ethylamino)propionamido]anthraquinone
DMC537F HS Investigative
DMC537F SN 2,7-Bis[3-(ethylamino)propionamido]anthraquinone; CHEMBL481161; SCHEMBL4291487
DMC537F DT Small molecular drug
DMC537F PC 44242847
DMC537F MW 436.5
DMC537F FM C24H28N4O4
DMC537F IC InChI=1S/C24H28N4O4/c1-3-25-11-9-21(29)27-15-5-7-17-19(13-15)24(32)20-14-16(6-8-18(20)23(17)31)28-22(30)10-12-26-4-2/h5-8,13-14,25-26H,3-4,9-12H2,1-2H3,(H,27,29)(H,28,30)
DMC537F CS CCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCC
DMC537F IK HJVRZEPJBMFCNQ-UHFFFAOYSA-N
DMC537F IU 3-(ethylamino)-N-[7-[3-(ethylamino)propanoylamino]-9,10-dioxoanthracen-2-yl]propanamide
DMC537F DE Discovery agent
DMOZEKQ ID DMOZEKQ
DMOZEKQ DN 2,7-Bis[3-(piperazino)propionamido]anthraquinone
DMOZEKQ HS Investigative
DMOZEKQ SN 2,7-Bis[3-(piperazino)propionamido]anthraquinone; SCHEMBL4302435; CHEMBL520095
DMOZEKQ DT Small molecular drug
DMOZEKQ PC 44242845
DMOZEKQ MW 518.6
DMOZEKQ FM C28H34N6O4
DMOZEKQ IC InChI=1S/C28H34N6O4/c35-25(5-11-33-13-7-29-8-14-33)31-19-1-3-21-23(17-19)28(38)24-18-20(2-4-22(24)27(21)37)32-26(36)6-12-34-15-9-30-10-16-34/h1-4,17-18,29-30H,5-16H2,(H,31,35)(H,32,36)
DMOZEKQ CS C1CN(CCN1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCN5CCNCC5
DMOZEKQ IK NXAKQSOMJQXBST-UHFFFAOYSA-N
DMOZEKQ IU N-[9,10-dioxo-7-(3-piperazin-1-ylpropanoylamino)anthracen-2-yl]-3-piperazin-1-ylpropanamide
DMOZEKQ DE Discovery agent
DMET693 ID DMET693
DMET693 DN 2,7-Bis[3-(piperidino)propionamido]anthraquinone
DMET693 HS Investigative
DMET693 SN 2,7-Bis[3-(piperidino)propionamido]anthraquinone; CHEMBL89250; SCHEMBL4300594; OFUHVIUIKBRCMP-UHFFFAOYSA-N; BDBM50068321
DMET693 DT Small molecular drug
DMET693 PC 9809446
DMET693 MW 516.6
DMET693 FM C30H36N4O4
DMET693 IC InChI=1S/C30H36N4O4/c35-27(11-17-33-13-3-1-4-14-33)31-21-7-9-23-25(19-21)30(38)26-20-22(8-10-24(26)29(23)37)32-28(36)12-18-34-15-5-2-6-16-34/h7-10,19-20H,1-6,11-18H2,(H,31,35)(H,32,36)
DMET693 CS C1CCN(CC1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCN5CCCCC5
DMET693 IK OFUHVIUIKBRCMP-UHFFFAOYSA-N
DMET693 IU N-[9,10-dioxo-7-(3-piperidin-1-ylpropanoylamino)anthracen-2-yl]-3-piperidin-1-ylpropanamide
DMET693 DE Discovery agent
DM6I90F ID DM6I90F
DM6I90F DN 2,7-Bis[3-(propylamino)propionamido]anthraquinone
DM6I90F HS Investigative
DM6I90F SN 2,7-Bis[3-(propylamino)propionamido]anthraquinone; SCHEMBL4298186; CHEMBL481160
DM6I90F DT Small molecular drug
DM6I90F PC 44242848
DM6I90F MW 464.6
DM6I90F FM C26H32N4O4
DM6I90F IC InChI=1S/C26H32N4O4/c1-3-11-27-13-9-23(31)29-17-5-7-19-21(15-17)26(34)22-16-18(6-8-20(22)25(19)33)30-24(32)10-14-28-12-4-2/h5-8,15-16,27-28H,3-4,9-14H2,1-2H3,(H,29,31)(H,30,32)
DM6I90F CS CCCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCCC
DM6I90F IK JELVSCOBEUHNBV-UHFFFAOYSA-N
DM6I90F IU N-[9,10-dioxo-7-[3-(propylamino)propanoylamino]anthracen-2-yl]-3-(propylamino)propanamide
DM6I90F DE Discovery agent
DMD6ZV5 ID DMD6ZV5
DMD6ZV5 DN 2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone
DMD6ZV5 HS Investigative
DMD6ZV5 SN 2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone; CHEMBL144757; SCHEMBL4298492; CUZAYOMYKDAXQR-UHFFFAOYSA-N; BDBM50068320; N,N'-(9,10-Dihydro-9,10-dioxoanthracene-2,7-diyl)bis[3-(pyrrolidine-1-yl)propanamide]
DMD6ZV5 DT Small molecular drug
DMD6ZV5 PC 10719801
DMD6ZV5 MW 488.6
DMD6ZV5 FM C28H32N4O4
DMD6ZV5 IC InChI=1S/C28H32N4O4/c33-25(9-15-31-11-1-2-12-31)29-19-5-7-21-23(17-19)28(36)24-18-20(6-8-22(24)27(21)35)30-26(34)10-16-32-13-3-4-14-32/h5-8,17-18H,1-4,9-16H2,(H,29,33)(H,30,34)
DMD6ZV5 CS C1CCN(C1)CCC(=O)NC2=CC3=C(C=C2)C(=O)C4=C(C3=O)C=C(C=C4)NC(=O)CCN5CCCC5
DMD6ZV5 IK CUZAYOMYKDAXQR-UHFFFAOYSA-N
DMD6ZV5 IU N-[9,10-dioxo-7-(3-pyrrolidin-1-ylpropanoylamino)anthracen-2-yl]-3-pyrrolidin-1-ylpropanamide
DMD6ZV5 DE Discovery agent
DME0TZU ID DME0TZU
DME0TZU DN 2,7-diaminoanthraquinone
DME0TZU HS Investigative
DME0TZU SN 2,7-Diaminoanthraquinone; 2,7-Diaminoanthrachinon; BRN 2809381; 605-44-7; 2,7-Diaminoanthrachinon [Czech]; 2,7-diaminoanthracene-9,10-dione; 9,10-Anthracenedione, 2,7-diamino- (9CI); ANTHRAQUINONE, 2,7-DIAMINO-; 9,10-Anthracenedione, 2,7-diamino-; AC1L1Y5O; SCHEMBL3135129; CHEMBL454957; CTK5B1667; DTXSID20209235; KJNHYKBXQOSFJR-UHFFFAOYSA-N; ZINC31483469; 9,10-Anthracenedione,2,7-diamino-; AKOS030561506
DME0TZU DT Small molecular drug
DME0TZU PC 11798
DME0TZU MW 238.24
DME0TZU FM C14H10N2O2
DME0TZU IC InChI=1S/C14H10N2O2/c15-7-1-3-9-11(5-7)14(18)12-6-8(16)2-4-10(12)13(9)17/h1-6H,15-16H2
DME0TZU CS C1=CC2=C(C=C1N)C(=O)C3=C(C2=O)C=CC(=C3)N
DME0TZU IK KJNHYKBXQOSFJR-UHFFFAOYSA-N
DME0TZU IU 2,7-diaminoanthracene-9,10-dione
DME0TZU CA CAS 605-44-7
DME0TZU DE Discovery agent
DMN56VM ID DMN56VM
DMN56VM DN 2,7-Dinitroantraquinone
DMN56VM HS Investigative
DMN56VM SN 2,7-Dinitroanthraquinone; 605-28-7; 2,7-Dinitroantraquinone; EINECS 210-084-2; 2,7-dinitro-9,10-anthraquinone; 2,7- Dinitroanthrachinon; AC1L2B0Y; SCHEMBL2772220; CHEMBL493255; AC1Q21I1; CTK5B1648; DTXSID00209233; XFLONXIGNOXKCG-UHFFFAOYSA-N; ZINC5845160; 2,7-dinitroanthracene-9,10-dione
DMN56VM DT Small molecular drug
DMN56VM PC 69057
DMN56VM MW 298.21
DMN56VM FM C14H6N2O6
DMN56VM IC InChI=1S/C14H6N2O6/c17-13-9-3-1-7(15(19)20)5-11(9)14(18)12-6-8(16(21)22)2-4-10(12)13/h1-6H
DMN56VM CS C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C3=C(C2=O)C=CC(=C3)[N+](=O)[O-]
DMN56VM IK XFLONXIGNOXKCG-UHFFFAOYSA-N
DMN56VM IU 2,7-dinitroanthracene-9,10-dione
DMN56VM CA CAS 605-28-7
DMN56VM DE Discovery agent
DMAKZ43 ID DMAKZ43
DMAKZ43 DN 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one
DMAKZ43 HS Investigative
DMAKZ43 SN 2,8-dimethyl-1-oxa-8-azaspiro[4.5]decan-3-one; CHEMBL40121; 123319-03-9; ARL-14995; 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one; SCHEMBL1326512; 1-Oxa-8-azaspiro[4.5]decan-3-one, 2,8-dimethyl-; MolPort-039-242-339; OODDNJQTVFMGCF-UHFFFAOYSA-N; BDBM50034651; AKOS033633463; 2,8-dimethyl-1-oxa-8-azaspiro[4,5]decan-3-one; L010200; 2,8-dimethyl-1-oxa-8-azaspiro[4.5]-decan-3-one; 2,8-dimethyl-1-oxa-8-azaspiro[4,5]-decan-3-one
DMAKZ43 DT Small molecular drug
DMAKZ43 PC 10176401
DMAKZ43 MW 183.25
DMAKZ43 FM C10H17NO2
DMAKZ43 IC InChI=1S/C10H17NO2/c1-8-9(12)7-10(13-8)3-5-11(2)6-4-10/h8H,3-7H2,1-2H3
DMAKZ43 CS CC1C(=O)CC2(O1)CCN(CC2)C
DMAKZ43 IK OODDNJQTVFMGCF-UHFFFAOYSA-N
DMAKZ43 IU 2,8-dimethyl-1-oxa-8-azaspiro[4.5]decan-3-one
DMAKZ43 DE Discovery agent
DMU2EFH ID DMU2EFH
DMU2EFH DN 2,8-Dimethyl-3H-quinazolin-4-one
DMU2EFH HS Investigative
DMU2EFH DT Small molecular drug
DMU2EFH PC 135463574
DMU2EFH MW 174.2
DMU2EFH FM C10H10N2O
DMU2EFH IC InChI=1S/C10H10N2O/c1-6-4-3-5-8-9(6)11-7(2)12-10(8)13/h3-5H,1-2H3,(H,11,12,13)
DMU2EFH CS CC1=C2C(=CC=C1)C(=O)NC(=N2)C
DMU2EFH IK CJXMJXBJIWEHRP-UHFFFAOYSA-N
DMU2EFH IU 2,8-dimethyl-3H-quinazolin-4-one
DMU2EFH CA CAS 172462-90-7
DMU2EFH DE Discovery agent
DMVSTG7 ID DMVSTG7
DMVSTG7 DN 2-[(2,2-diphenylacetyl)amino]benzoic acid
DMVSTG7 HS Investigative
DMVSTG7 SN 2-[(2,2-diphenylacetyl)amino]benzoic Acid; CHEMBL196755; 2-[(diphenylacetyl)amino]benzoic acid; Oprea1_593830; Oprea1_339985; MLS001143352; AC1N2C22; MolPort-001-015-645; HMS2781B19; ZINC3466236; BDBM50174204; STK004896; AKOS003244646; MCULE-3235692188; 2-(2,2-diphenylacetylamino)benzoic acid; SMR000473187
DMVSTG7 DT Small molecular drug
DMVSTG7 PC 4044373
DMVSTG7 MW 331.4
DMVSTG7 FM C21H17NO3
DMVSTG7 IC InChI=1S/C21H17NO3/c23-20(22-18-14-8-7-13-17(18)21(24)25)19(15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14,19H,(H,22,23)(H,24,25)
DMVSTG7 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC3=CC=CC=C3C(=O)O
DMVSTG7 IK NDZQPXFPOCTXEF-UHFFFAOYSA-N
DMVSTG7 IU 2-[(2,2-diphenylacetyl)amino]benzoic acid
DMVSTG7 DE Discovery agent
DMR4LJY ID DMR4LJY
DMR4LJY DN 2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL
DMR4LJY HS Investigative
DMR4LJY SN TF5
DMR4LJY DT Small molecular drug
DMR4LJY PC 46937163
DMR4LJY MW 268.23
DMR4LJY FM C14H11F3O2
DMR4LJY IC InChI=1S/C14H11F3O2/c15-11-6-5-10(13(16)14(11)17)9-3-1-2-4-12(9)19-8-7-18/h1-6,18H,7-8H2
DMR4LJY CS C1=CC=C(C(=C1)C2=C(C(=C(C=C2)F)F)F)OCCO
DMR4LJY IK AGXPXFPIOHNDAN-UHFFFAOYSA-N
DMR4LJY IU 2-[2-(2,3,4-trifluorophenyl)phenoxy]ethanol
DMR4LJY DE Discovery agent
DMXA1LK ID DMXA1LK
DMXA1LK DN 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
DMXA1LK HS Investigative
DMXA1LK SN 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine; SCHEMBL12409072; DB07427
DMXA1LK DT Small molecular drug
DMXA1LK PC 44129642
DMXA1LK MW 229.27
DMXA1LK FM C14H15NO2
DMXA1LK IC InChI=1S/C14H15NO2/c1-11-6-7-13(16-2)14(9-11)17-10-12-5-3-4-8-15-12/h3-9H,10H2,1-2H3
DMXA1LK CS CC1=CC(=C(C=C1)OC)OCC2=CC=CC=N2
DMXA1LK IK AVXQTLSOXWQOHO-UHFFFAOYSA-N
DMXA1LK IU 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
DMXA1LK DE Discovery agent
DM75WN4 ID DM75WN4
DM75WN4 DN 2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine
DM75WN4 HS Investigative
DM75WN4 SN CHEMBL371884; 2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine; SCHEMBL4154142
DM75WN4 DT Small molecular drug
DM75WN4 PC 11608117
DM75WN4 MW 201.25
DM75WN4 FM C10H7N3S
DM75WN4 IC InChI=1S/C10H7N3S/c1-8-13-10(7-14-8)3-2-9-6-11-4-5-12-9/h4-7H,1H3
DM75WN4 CS CC1=NC(=CS1)C#CC2=NC=CN=C2
DM75WN4 IK TZWSJNFDGNIKAZ-UHFFFAOYSA-N
DM75WN4 IU 2-methyl-4-(2-pyrazin-2-ylethynyl)-1,3-thiazole
DM75WN4 DE Discovery agent
DMKC1GI ID DMKC1GI
DMKC1GI DN 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine
DMKC1GI HS Investigative
DMKC1GI SN CHEMBL385770; 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine; SCHEMBL4383259
DMKC1GI DT Small molecular drug
DMKC1GI PC 11743895
DMKC1GI MW 439.4
DMKC1GI FM C21H21N5O6
DMKC1GI IC InChI=1S/C21H21N5O6/c1-11(28)13-6-3-12(4-7-13)5-8-15-23-19(25-31-2)16-20(24-15)26(10-22-16)21-18(30)17(29)14(9-27)32-21/h3-4,6-7,10,14,17-18,21,27,29-30H,9H2,1-2H3,(H,23,24,25)/t14-,17-,18-,21-/m1/s1
DMKC1GI CS CC(=O)C1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DMKC1GI IK MPFGTODTMYCUJG-HAXDFEGKSA-N
DMKC1GI IU 1-[4-[2-[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methoxyamino)purin-2-yl]ethynyl]phenyl]ethanone
DMKC1GI DE Discovery agent
DMTNQZU ID DMTNQZU
DMTNQZU DN 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine
DMTNQZU HS Investigative
DMTNQZU SN CHEMBL223739; 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine; SCHEMBL4381150
DMTNQZU DT Small molecular drug
DMTNQZU PC 10454501
DMTNQZU MW 415.4
DMTNQZU FM C19H18FN5O5
DMTNQZU IC InChI=1S/C19H18FN5O5/c1-29-24-17-14-18(23-13(22-17)7-4-10-2-5-11(20)6-3-10)25(9-21-14)19-16(28)15(27)12(8-26)30-19/h2-3,5-6,9,12,15-16,19,26-28H,8H2,1H3,(H,22,23,24)/t12-,15-,16-,19-/m1/s1
DMTNQZU CS CONC1=C2C(=NC(=N1)C#CC3=CC=C(C=C3)F)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMTNQZU IK IEVVENMHWBPFQV-BGIGGGFGSA-N
DMTNQZU IU (2R,3R,4S,5R)-2-[2-[2-(4-fluorophenyl)ethynyl]-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMTNQZU DE Discovery agent
DMDT7SK ID DMDT7SK
DMDT7SK DN 2-[(biphenyl-4-carbonyl)-amino]-benzoic acid
DMDT7SK HS Investigative
DMDT7SK SN 2-[(biphenyl-4-ylcarbonyl)amino]benzoic acid; 94578-69-5; AC1LIZYF; 2-[(4-phenylbenzoyl)amino]benzoic Acid; Oprea1_107922; CHEMBL370865; SCHEMBL14075233; BDBM16094; MolPort-000-468-692; ZINC499675; STK068761; BBL015607; AKOS002229873; MCULE-9626131737; 2-[(4-phenylbenzene)amido]benzoic acid; ST50103720; H3372; 2-[(4-phenylphenyl)carbonylamino]benzoic acid
DMDT7SK DT Small molecular drug
DMDT7SK PC 914489
DMDT7SK MW 317.3
DMDT7SK FM C20H15NO3
DMDT7SK IC InChI=1S/C20H15NO3/c22-19(21-18-9-5-4-8-17(18)20(23)24)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13H,(H,21,22)(H,23,24)
DMDT7SK CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NC3=CC=CC=C3C(=O)O
DMDT7SK IK WXLRBDMDGLLZRS-UHFFFAOYSA-N
DMDT7SK IU 2-[(4-phenylbenzoyl)amino]benzoic acid
DMDT7SK DE Discovery agent
DMVSI6R ID DMVSI6R
DMVSI6R DN 2-[(Dioxidophosphino)Oxy]Benzoate
DMVSI6R HS Investigative
DMVSI6R SN 2-[(DIOXIDOPHOSPHINO)OXY]BENZOATE; 2-phosphooxybenzoate; 2-(phosphooxy)benzoate; AC1NR9RL; AC1O4QG1; 2-oxidophosphonoyloxybenzoate; 2-[(dioxidophosphanyl)oxy]benzoate; 2-[(Dioxidophosphoranyl)oxy]benzoate
DMVSI6R DT Small molecular drug
DMVSI6R PC 6398365
DMVSI6R MW 199.08
DMVSI6R FM C7H4O5P-
DMVSI6R IC InChI=1S/C7H5O5P/c8-7(9)5-3-1-2-4-6(5)12-13(10)11/h1-4H,(H,8,9)/p-1
DMVSI6R CS C1=CC=C(C(=C1)C(=O)[O-])OP(=O)=O
DMVSI6R IK CEHNRTFNHMGQGW-UHFFFAOYSA-M
DMVSI6R DE Discovery agent
DMSW89U ID DMSW89U
DMSW89U DN 2-[1-(2-Chloro-phenyl)-1H-pyrrol-2-yl]-ethylamine
DMSW89U HS Investigative
DMSW89U SN CHEMBL360277
DMSW89U DT Small molecular drug
DMSW89U PC 44388886
DMSW89U MW 220.7
DMSW89U FM C12H13ClN2
DMSW89U IC InChI=1S/C12H13ClN2/c13-11-5-1-2-6-12(11)15-9-3-4-10(15)7-8-14/h1-6,9H,7-8,14H2
DMSW89U CS C1=CC=C(C(=C1)N2C=CC=C2CCN)Cl
DMSW89U IK QDZRUXBRYDSOHU-UHFFFAOYSA-N
DMSW89U IU 2-[1-(2-chlorophenyl)pyrrol-2-yl]ethanamine
DMSW89U DE Discovery agent
DMUZDSC ID DMUZDSC
DMUZDSC DN 2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL
DMUZDSC HS Investigative
DMUZDSC SN 2-[1-(4-chlorophenyl)ethyl]-4,6-dinitrophenol; DNP-19; AC1MRP5X; CHEBI:74325; 2-[1-(p-chlorophenyl)ethyl]-4,6-dinitrophenol; 2-[1-(p-chlorophenyl)ethyl] 4,6-dinitrophenol
DMUZDSC DT Small molecular drug
DMUZDSC PC 446716
DMUZDSC MW 322.7
DMUZDSC FM C14H11ClN2O5
DMUZDSC IC InChI=1S/C14H11ClN2O5/c1-8(9-2-4-10(15)5-3-9)12-6-11(16(19)20)7-13(14(12)18)17(21)22/h2-8,18H,1H3/t8-/m1/s1
DMUZDSC CS C[C@H](C1=CC=C(C=C1)Cl)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O
DMUZDSC IK MOZUMFSUQQHSCO-MRVPVSSYSA-N
DMUZDSC IU 2-[(1R)-1-(4-chlorophenyl)ethyl]-4,6-dinitrophenol
DMUZDSC DE Discovery agent
DMEA2SR ID DMEA2SR
DMEA2SR DN 2-[1,4]Diazepan-1-yl-6-nitro-quinoline
DMEA2SR HS Investigative
DMEA2SR SN CHEMBL43139; 2-[1,4]Diazepan-1-yl-6-nitro-quinoline; BDBM50090215; AKOS009510173
DMEA2SR DT Small molecular drug
DMEA2SR PC 10445930
DMEA2SR MW 272.3
DMEA2SR FM C14H16N4O2
DMEA2SR IC InChI=1S/C14H16N4O2/c19-18(20)12-3-4-13-11(10-12)2-5-14(16-13)17-8-1-6-15-7-9-17/h2-5,10,15H,1,6-9H2
DMEA2SR CS C1CNCCN(C1)C2=NC3=C(C=C2)C=C(C=C3)[N+](=O)[O-]
DMEA2SR IK DKLQZCAIKFJPKG-UHFFFAOYSA-N
DMEA2SR IU 2-(1,4-diazepan-1-yl)-6-nitroquinoline
DMEA2SR DE Discovery agent
DMC8IEM ID DMC8IEM
DMC8IEM DN 2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
DMC8IEM HS Investigative
DMC8IEM SN CHEMBL367141; 2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one
DMC8IEM DT Small molecular drug
DMC8IEM PC 11208656
DMC8IEM MW 295.3
DMC8IEM FM C18H17NO3
DMC8IEM IC InChI=1S/C18H17NO3/c20-16-12-17(19-8-3-10-21-11-9-19)22-18-14-5-2-1-4-13(14)6-7-15(16)18/h1-2,4-7,12H,3,8-11H2
DMC8IEM CS C1CN(CCOC1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMC8IEM IK NVGTWFCMXLHRJF-UHFFFAOYSA-N
DMC8IEM IU 2-(1,4-oxazepan-4-yl)benzo[h]chromen-4-one
DMC8IEM DE Discovery agent
DMFJOHG ID DMFJOHG
DMFJOHG DN 2-[125I]melatonin
DMFJOHG HS Investigative
DMFJOHG SN 2-(125I)Iodomelatonin; 2[125I]iodomelatonin; 2-iodo-[125I]-melatonin
DMFJOHG DT Small molecular drug
DMFJOHG PC 644212
DMFJOHG MW 356.17
DMFJOHG FM C13H15IN2O2
DMFJOHG IC InChI=1S/C13H15IN2O2/c1-8(17)15-6-5-10-11-7-9(18-2)3-4-12(11)16-13(10)14/h3-4,7,16H,5-6H2,1-2H3,(H,15,17)/i14-2
DMFJOHG CS CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)[125I]
DMFJOHG IK FJDDSMSDZHURBJ-XSBOKVBDSA-N
DMFJOHG IU N-[2-(2-(125I)iodanyl-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMFJOHG CA CAS 140671-15-4
DMFJOHG DE Discovery agent
DMKEZ5G ID DMKEZ5G
DMKEZ5G DN 2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine
DMKEZ5G HS Investigative
DMKEZ5G SN CHEMBL60716; 2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine; SCHEMBL1443461; BDBM50127610; AKOS027413644; (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane
DMKEZ5G DT Small molecular drug
DMKEZ5G PC 10154137
DMKEZ5G MW 151.21
DMKEZ5G FM C8H13N3
DMKEZ5G IC InChI=1S/C8H13N3/c9-2-1-6-3-7(6)8-4-10-5-11-8/h4-7H,1-3,9H2,(H,10,11)/t6-,7+/m1/s1
DMKEZ5G CS C1[C@H]([C@H]1C2=CN=CN2)CCN
DMKEZ5G IK OTBYLNCJHFPRTL-RQJHMYQMSA-N
DMKEZ5G IU 2-[(1S,2S)-2-(1H-imidazol-5-yl)cyclopropyl]ethanamine
DMKEZ5G DE Discovery agent
DMX1TIU ID DMX1TIU
DMX1TIU DN 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene
DMX1TIU HS Investigative
DMX1TIU SN CHEMBL42428; 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene; SCHEMBL7042974; SCHEMBL7042968; ZINC13471769; BDBM50108048; AKOS015967551; (E)-2-(3,5-dimethoxystyryl)thiophene; 2-[(E)-3,5-Dimethoxystyryl]thiophene
DMX1TIU DT Small molecular drug
DMX1TIU PC 9834747
DMX1TIU MW 246.33
DMX1TIU FM C14H14O2S
DMX1TIU IC InChI=1S/C14H14O2S/c1-15-12-8-11(9-13(10-12)16-2)5-6-14-4-3-7-17-14/h3-10H,1-2H3/b6-5+
DMX1TIU CS COC1=CC(=CC(=C1)/C=C/C2=CC=CS2)OC
DMX1TIU IK URRYDXXEGGXDQJ-AATRIKPKSA-N
DMX1TIU IU 2-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]thiophene
DMX1TIU DE Discovery agent
DMDT9KG ID DMDT9KG
DMDT9KG DN 2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid
DMDT9KG HS Investigative
DMDT9KG SN SCHEMBL1345633; CHEMBL189037; Benzeneacetic acid, 3-(1-hydroxypropyl)-alpha-methyl-; AKOS023891992
DMDT9KG DT Small molecular drug
DMDT9KG PC 9964424
DMDT9KG MW 208.25
DMDT9KG FM C12H16O3
DMDT9KG IC InChI=1S/C12H16O3/c1-3-11(13)10-6-4-5-9(7-10)8(2)12(14)15/h4-8,11,13H,3H2,1-2H3,(H,14,15)
DMDT9KG CS CCC(C1=CC=CC(=C1)C(C)C(=O)O)O
DMDT9KG IK HTWFANVWNDWYRH-UHFFFAOYSA-N
DMDT9KG IU 2-[3-(1-hydroxypropyl)phenyl]propanoic acid
DMDT9KG DE Discovery agent
DMWIUR0 ID DMWIUR0
DMWIUR0 DN 2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid
DMWIUR0 HS Investigative
DMWIUR0 SN SCHEMBL3630168
DMWIUR0 DT Small molecular drug
DMWIUR0 PC 11299790
DMWIUR0 MW 254.32
DMWIUR0 FM C17H18O2
DMWIUR0 IC InChI=1S/C17H18O2/c1-12(14-7-4-3-5-8-14)15-9-6-10-16(11-15)13(2)17(18)19/h3-13H,1-2H3,(H,18,19)
DMWIUR0 CS CC(C1=CC=CC=C1)C2=CC(=CC=C2)C(C)C(=O)O
DMWIUR0 IK WHCCIVDFHWZGFN-UHFFFAOYSA-N
DMWIUR0 IU 2-[3-(1-phenylethyl)phenyl]propanoic acid
DMWIUR0 DE Discovery agent
DMKSDT4 ID DMKSDT4
DMKSDT4 DN 2-[3-(2-Methyl-butyl)-phenyl]-propionic acid
DMKSDT4 HS Investigative
DMKSDT4 SN CHEMBL190956
DMKSDT4 DT Small molecular drug
DMKSDT4 PC 44398456
DMKSDT4 MW 220.31
DMKSDT4 FM C14H20O2
DMKSDT4 IC InChI=1S/C14H20O2/c1-4-10(2)8-12-6-5-7-13(9-12)11(3)14(15)16/h5-7,9-11H,4,8H2,1-3H3,(H,15,16)
DMKSDT4 CS CCC(C)CC1=CC(=CC=C1)C(C)C(=O)O
DMKSDT4 IK MKEVMCJZLHDVPO-UHFFFAOYSA-N
DMKSDT4 IU 2-[3-(2-methylbutyl)phenyl]propanoic acid
DMKSDT4 DE Discovery agent
DM8A3NI ID DM8A3NI
DM8A3NI DN 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM8A3NI HS Investigative
DM8A3NI SN CHEMBL115876; 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine; SCHEMBL14129965; BDBM50138233
DM8A3NI DT Small molecular drug
DM8A3NI PC 44341234
DM8A3NI MW 279.34
DM8A3NI FM C17H17N3O
DM8A3NI IC InChI=1S/C17H17N3O/c1-2-10-19-15(4-1)5-3-13-21-17-8-6-16(7-9-17)20-12-11-18-14-20/h1-2,4,6-12,14H,3,5,13H2
DM8A3NI CS C1=CC=NC(=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3
DM8A3NI IK UGLPVHLKYTWQRV-UHFFFAOYSA-N
DM8A3NI IU 2-[3-(4-imidazol-1-ylphenoxy)propyl]pyridine
DM8A3NI DE Discovery agent
DM5ETL9 ID DM5ETL9
DM5ETL9 DN 2-[3-(Pyridin-4-yloxy)-benzoylamino]-benzoic acid
DM5ETL9 HS Investigative
DM5ETL9 SN 2-[3-(Pyridin-4-yloxy)benzoylamino]benzoic acid; CHEMBL438975; BDBM23613; 2-benzoylamino benzoic acid deriv., 28g; 2-{[3-(pyridin-4-yloxy)benzene]amido}benzoic acid
DM5ETL9 DT Small molecular drug
DM5ETL9 PC 11209825
DM5ETL9 MW 334.3
DM5ETL9 FM C19H14N2O4
DM5ETL9 IC InChI=1S/C19H14N2O4/c22-18(21-17-7-2-1-6-16(17)19(23)24)13-4-3-5-15(12-13)25-14-8-10-20-11-9-14/h1-12H,(H,21,22)(H,23,24)
DM5ETL9 CS C1=CC=C(C(=C1)C(=O)O)NC(=O)C2=CC(=CC=C2)OC3=CC=NC=C3
DM5ETL9 IK YATZGUOENCNURV-UHFFFAOYSA-N
DM5ETL9 IU 2-[(3-pyridin-4-yloxybenzoyl)amino]benzoic acid
DM5ETL9 DE Discovery agent
DMUH526 ID DMUH526
DMUH526 DN 2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline
DMUH526 HS Investigative
DMUH526 SN CHEMBL360156; 2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline; SCHEMBL3971032
DMUH526 DT Small molecular drug
DMUH526 PC 11314275
DMUH526 MW 283.4
DMUH526 FM C18H25N3
DMUH526 IC InChI=1S/C18H25N3/c1-3-16(4-2)20-11-13-21(14-12-20)18-10-9-15-7-5-6-8-17(15)19-18/h5-10,16H,3-4,11-14H2,1-2H3
DMUH526 CS CCC(CC)N1CCN(CC1)C2=NC3=CC=CC=C3C=C2
DMUH526 IK FNSKLNDKQPXTIL-UHFFFAOYSA-N
DMUH526 IU 2-(4-pentan-3-ylpiperazin-1-yl)quinoline
DMUH526 DE Discovery agent
DMUHECR ID DMUHECR
DMUHECR DN 2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid
DMUHECR HS Investigative
DMUHECR SN CHEMBL104592; 2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid; BDBM50074934; 2-[4-(1H-Indole-5-yl)phenyl]propanoic acid
DMUHECR DT Small molecular drug
DMUHECR PC 44336354
DMUHECR MW 265.31
DMUHECR FM C17H15NO2
DMUHECR IC InChI=1S/C17H15NO2/c1-11(17(19)20)12-2-4-13(5-3-12)14-6-7-16-15(10-14)8-9-18-16/h2-11,18H,1H3,(H,19,20)
DMUHECR CS CC(C1=CC=C(C=C1)C2=CC3=C(C=C2)NC=C3)C(=O)O
DMUHECR IK NSKFZVRZALCZND-UHFFFAOYSA-N
DMUHECR IU 2-[4-(1H-indol-5-yl)phenyl]propanoic acid
DMUHECR DE Discovery agent
DMWXI06 ID DMWXI06
DMWXI06 DN 2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid
DMWXI06 HS Investigative
DMWXI06 SN Diclofop; 40843-25-2; Diclofop acid; DICHLORFOP ACID; Caswell No. 328B; 2-(4-(2,4-Dichlorophenoxy)phenoxy)propanoic acid; Diclofop [ANSI:BSI:ISO]; 2-[4-(2,4-Dichlorophenoxy)phenoxy]propanoic acid; HOE 21079; BRN 2338390; CHEBI:81909; OOLBCHYXZDXLDS-UHFFFAOYSA-N; Methyl 2-(4-(2,4-Dichlorophenyoxy)phenoxy)propanoate; HOE-021079; (RS)-2-(4-(2,4-Dichlorophenoxy)phenoxy)propionic acid; Methyl (RS)-2-(4-(2,4-Dichlorophenoxy)phenoxy)propionate; Propanoic acid, 2-(4-(2,4-dichlorophenoxy)phenoxy)-; Propanoic acid, 2-[4-(2,4-dichloro
DMWXI06 DT Small molecular drug
DMWXI06 PC 38687
DMWXI06 MW 327.2
DMWXI06 FM C15H12Cl2O4
DMWXI06 IC InChI=1S/C15H12Cl2O4/c1-9(15(18)19)20-11-3-5-12(6-4-11)21-14-7-2-10(16)8-13(14)17/h2-9H,1H3,(H,18,19)
DMWXI06 CS CC(C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl
DMWXI06 IK OOLBCHYXZDXLDS-UHFFFAOYSA-N
DMWXI06 IU 2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid
DMWXI06 CA CAS 40843-25-2
DMWXI06 CB CHEBI:81909
DMWXI06 DE Discovery agent
DMDMK5V ID DMDMK5V
DMDMK5V DN 2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzooxazole
DMDMK5V HS Investigative
DMDMK5V SN Benzoxazole compound, 10c; SCHEMBL2168424; CHEMBL482254; BDBM24206; ZINC40919149
DMDMK5V DT Small molecular drug
DMDMK5V PC 11416868
DMDMK5V MW 352.4
DMDMK5V FM C21H24N2O3
DMDMK5V IC InChI=1S/C21H24N2O3/c1-2-6-14-23(13-5-1)15-16-24-17-9-11-18(12-10-17)25-21-22-19-7-3-4-8-20(19)26-21/h3-4,7-12H,1-2,5-6,13-16H2
DMDMK5V CS C1CCCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3
DMDMK5V IK RUOSQGLZVMYCMI-UHFFFAOYSA-N
DMDMK5V IU 2-[4-[2-(azepan-1-yl)ethoxy]phenoxy]-1,3-benzoxazole
DMDMK5V DE Discovery agent
DM923WK ID DM923WK
DM923WK DN 2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzothiazole
DM923WK HS Investigative
DM923WK SN Benzthiazole compound, 11c; SCHEMBL2168218; CHEMBL520120; BDBM24207; ZINC40919150
DM923WK DT Small molecular drug
DM923WK PC 11257168
DM923WK MW 368.5
DM923WK FM C21H24N2O2S
DM923WK IC InChI=1S/C21H24N2O2S/c1-2-6-14-23(13-5-1)15-16-24-17-9-11-18(12-10-17)25-21-22-19-7-3-4-8-20(19)26-21/h3-4,7-12H,1-2,5-6,13-16H2
DM923WK CS C1CCCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DM923WK IK JDZUDVCYJPNUKO-UHFFFAOYSA-N
DM923WK IU 2-[4-[2-(azepan-1-yl)ethoxy]phenoxy]-1,3-benzothiazole
DM923WK DE Discovery agent
DMECQB4 ID DMECQB4
DMECQB4 DN 2-[4-(2-Morpholin-4-ylethoxy)phenoxy]benzooxazole
DMECQB4 HS Investigative
DMECQB4 SN Benzoxazole compound, 10d; SCHEMBL2168507; CHEMBL482256; BDBM24209
DMECQB4 DT Small molecular drug
DMECQB4 PC 24901582
DMECQB4 MW 340.4
DMECQB4 FM C19H20N2O4
DMECQB4 IC InChI=1S/C19H20N2O4/c1-2-4-18-17(3-1)20-19(25-18)24-16-7-5-15(6-8-16)23-14-11-21-9-12-22-13-10-21/h1-8H,9-14H2
DMECQB4 CS C1COCCN1CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3
DMECQB4 IK NVSWCWWHQRVUDU-UHFFFAOYSA-N
DMECQB4 IU 2-[4-(2-morpholin-4-ylethoxy)phenoxy]-1,3-benzoxazole
DMECQB4 DE Discovery agent
DMMYJ3R ID DMMYJ3R
DMMYJ3R DN 2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole
DMMYJ3R HS Investigative
DMMYJ3R SN Benzthiazole compound, 27b; SCHEMBL2168381; CHEMBL470753; BDBM24223
DMMYJ3R DT Small molecular drug
DMMYJ3R PC 11427736
DMMYJ3R MW 338.5
DMMYJ3R FM C20H22N2OS
DMMYJ3R IC InChI=1S/C20H22N2OS/c1-4-13-22(14-5-1)15-12-16-8-10-17(11-9-16)23-20-21-18-6-2-3-7-19(18)24-20/h2-3,6-11H,1,4-5,12-15H2
DMMYJ3R CS C1CCN(CC1)CCC2=CC=C(C=C2)OC3=NC4=CC=CC=C4S3
DMMYJ3R IK DHHMVJVCMLXZBO-UHFFFAOYSA-N
DMMYJ3R IU 2-[4-(2-piperidin-1-ylethyl)phenoxy]-1,3-benzothiazole
DMMYJ3R DE Discovery agent
DM6R1XH ID DM6R1XH
DM6R1XH DN 2-[4-(2-Thienyl)phenyl]-4-methylmorpholin-2-ol
DM6R1XH HS Investigative
DM6R1XH SN CHEMBL449619; GTPL3081; BDBM50253901; compound 5 [PMID: 18754614]
DM6R1XH DT Small molecular drug
DM6R1XH PC 25108103
DM6R1XH MW 275.4
DM6R1XH FM C15H17NO2S
DM6R1XH IC InChI=1S/C15H17NO2S/c1-16-8-9-18-15(17,11-16)13-6-4-12(5-7-13)14-3-2-10-19-14/h2-7,10,17H,8-9,11H2,1H3
DM6R1XH CS CN1CCOC(C1)(C2=CC=C(C=C2)C3=CC=CS3)O
DM6R1XH IK KXFMAIULBLABNA-UHFFFAOYSA-N
DM6R1XH IU 4-methyl-2-(4-thiophen-2-ylphenyl)morpholin-2-ol
DM6R1XH DE Discovery agent
DMZFKDW ID DMZFKDW
DMZFKDW DN 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
DMZFKDW HS Investigative
DMZFKDW SN CHEMBL574419; 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
DMZFKDW DT Small molecular drug
DMZFKDW PC 44541904
DMZFKDW MW 309.3
DMZFKDW FM C18H15NO4
DMZFKDW IC InChI=1S/C18H15NO4/c19-17(20)8-13-9-18(21)23-16-10-14(6-7-15(13)16)22-11-12-4-2-1-3-5-12/h1-7,9-10H,8,11H2,(H2,19,20)
DMZFKDW CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)C(=CC(=O)O3)CC(=O)N
DMZFKDW IK XAUATGLGKLEUAX-UHFFFAOYSA-N
DMZFKDW IU 2-(2-oxo-7-phenylmethoxychromen-4-yl)acetamide
DMZFKDW DE Discovery agent
DM1PSRQ ID DM1PSRQ
DM1PSRQ DN 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DM1PSRQ HS Investigative
DM1PSRQ SN CHEMBL216198; 2-((2-phenethylphenoxy)methyl)pyridine; 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DM1PSRQ DT Small molecular drug
DM1PSRQ PC 11973809
DM1PSRQ MW 289.4
DM1PSRQ FM C20H19NO
DM1PSRQ IC InChI=1S/C20H19NO/c1-2-8-17(9-3-1)13-14-18-10-4-5-12-20(18)22-16-19-11-6-7-15-21-19/h1-12,15H,13-14,16H2
DM1PSRQ CS C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CC=CC=N3
DM1PSRQ IK XVQTWFFAIBVICX-UHFFFAOYSA-N
DM1PSRQ IU 2-[[2-(2-phenylethyl)phenoxy]methyl]pyridine
DM1PSRQ DE Discovery agent
DM9TCWA ID DM9TCWA
DM9TCWA DN 2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol
DM9TCWA HS Investigative
DM9TCWA SN CHEMBL516151; BDBM50251329
DM9TCWA DT Small molecular drug
DM9TCWA PC 44567596
DM9TCWA MW 371.4
DM9TCWA FM C21H25NO5
DM9TCWA IC InChI=1S/C21H25NO5/c1-22-5-4-14-10-15(27-9-8-26-7-6-23)12-16-19(14)17(22)11-13-2-3-18(24)21(25)20(13)16/h2-3,10,12,17,23-25H,4-9,11H2,1H3/t17-/m1/s1
DM9TCWA CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCOCCO)C(=C(C=C4)O)O
DM9TCWA IK LUIRUBNQVJTQKP-QGZVFWFLSA-N
DM9TCWA IU (6aR)-2-[2-(2-hydroxyethoxy)ethoxy]-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM9TCWA DE Discovery agent
DM5BAJ9 ID DM5BAJ9
DM5BAJ9 DN 20-HETE
DM5BAJ9 HS Investigative
DM5BAJ9 SN 20-hydroxyeicosatetraenoic acid
DM5BAJ9 DT Small molecular drug
DM5BAJ9 PC 5283157
DM5BAJ9 MW 320.5
DM5BAJ9 FM C20H32O3
DM5BAJ9 IC InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-
DM5BAJ9 CS C(CC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O)CCO
DM5BAJ9 IK NNDIXBJHNLFJJP-DTLRTWKJSA-N
DM5BAJ9 IU (5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoic acid
DM5BAJ9 CA CAS 79551-86-3
DM5BAJ9 CB CHEBI:34306
DM5BAJ9 DE Discovery agent
DM84GAQ ID DM84GAQ
DM84GAQ DN 20-hydroxy-LTB4
DM84GAQ HS Investigative
DM84GAQ SN 20-Hydroxy-leukotriene B4; 20-hydroxy-LTB4; 20-hydroxy LTB4; 20-OH-LTB4; 20-OH-Leukotriene B4; (5S,6Z,8E,10E,12R,14Z)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid; CHEBI:15646; 79516-82-8; 5S,12R,20-trihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; 20-hydroxyleukotriene B4; (5S,12R)-5,12,20-Trihydroxy-(6Z,8E,10E,14Z)-eicosatetraenoic acid; (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate; (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyeicosa-6,8,10,14-tetraenoate; 5,12,20-Trihete; w-Hydroxy-LTB4
DM84GAQ DT Small molecular drug
DM84GAQ PC 5280745
DM84GAQ MW 352.5
DM84GAQ FM C20H32O5
DM84GAQ IC InChI=1S/C20H32O5/c21-17-10-6-2-1-3-7-12-18(22)13-8-4-5-9-14-19(23)15-11-16-20(24)25/h3-5,7-9,13-14,18-19,21-23H,1-2,6,10-12,15-17H2,(H,24,25)/b5-4+,7-3-,13-8+,14-9-/t18-,19-/m1/s1
DM84GAQ CS C(CC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O)CCO
DM84GAQ IK PTJFJXLGRSTECQ-PSPARDEHSA-N
DM84GAQ IU (5S,6Z,8E,10E,12R,14Z)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoic acid
DM84GAQ CA CAS 79516-82-8
DM84GAQ CB CHEBI:15646
DM84GAQ DE Discovery agent
DMHJM0F ID DMHJM0F
DMHJM0F DN 227Th-rituximab
DMHJM0F HS Investigative
DMHJM0F SN Thorium-227-rituximab (cancer), Algeta
DMHJM0F CP Algeta ASA
DMHJM0F DT Antibody
DMHJM0F DE Solid tumour/cancer
DME8273 ID DME8273
DME8273 DN 22R-hydroxycholesterol
DME8273 HS Investigative
DME8273 SN 22beta-hydroxycholesterol; 22R-OHC
DME8273 DT Small molecular drug
DME8273 PC 167685
DME8273 MW 402.7
DME8273 FM C27H46O2
DME8273 IC InChI=1S/C27H46O2/c1-17(2)6-11-25(29)18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20-,21-,22+,23-,24-,25+,26-,27+/m0/s1
DME8273 CS C[C@@H]([C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)[C@@H](CCC(C)C)O
DME8273 IK RZPAXNJLEKLXNO-GFKLAVDKSA-N
DME8273 IU (3S,8S,9S,10R,13S,14S,17R)-17-[(2S,3R)-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DME8273 CA CAS 17954-98-2
DME8273 CB CHEBI:67237
DME8273 DE Discovery agent
DM74X5O ID DM74X5O
DM74X5O DN 2'-3'-dideoxy-7-deaza-guaninetriphosphate
DM74X5O HS Investigative
DM74X5O SN CHEMBL195111; BDBM50164639
DM74X5O DT Small molecular drug
DM74X5O PC 44400853
DM74X5O MW 490.19
DM74X5O FM C11H17N4O12P3
DM74X5O IC InChI=1S/C11H17N4O12P3/c12-11-10(16)9-7(3-13-11)15(5-14-9)8-2-1-6(25-8)4-24-29(20,21)27-30(22,23)26-28(17,18)19/h5-6,8H,1-4H2,(H2,12,13)(H,20,21)(H,22,23)(H2,17,18,19)/t6-,8+/m0/s1
DM74X5O CS C1C[C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=NC3=C2CN=C(C3=O)N
DM74X5O IK UOKJOXGBXPVQIX-POYBYMJQSA-N
DM74X5O IU [[(2S,5R)-5-(6-amino-7-oxo-4H-imidazo[4,5-c]pyridin-3-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM74X5O DE Discovery agent
DM27GH0 ID DM27GH0
DM27GH0 DN 23-hydroxybetulinic acid
DM27GH0 HS Investigative
DM27GH0 SN 85999-40-2; CHEBI:69580; 3,23-dihydroxy-20(29)-lupen-28-oic acid; Anemosapogenin; 23-Hydroxybetulinicacid; 23-hydroxy betulic acid; CHEMBL251308; 23-Hydroxybetulinic Acid, 25; BDBM23209; MolPort-039-338-114; HXWLKAXCQLXHML-WGOZWDAUSA-N; HY-N0566; EBD870843; ZINC14980302; AKOS032944876; CS-5686; SC-72875; 23-Hydroxybetulinic acid, > 3I(2),23-dihydroxylup-20(29)-en-28-oic acid
DM27GH0 DT Small molecular drug
DM27GH0 PC 21672692
DM27GH0 MW 472.7
DM27GH0 FM C30H48O4
DM27GH0 IC InChI=1S/C30H48O4/c1-18(2)19-9-14-30(25(33)34)16-15-28(5)20(24(19)30)7-8-22-26(3)12-11-23(32)27(4,17-31)21(26)10-13-29(22,28)6/h19-24,31-32H,1,7-17H2,2-6H3,(H,33,34)/t19-,20+,21+,22+,23-,24+,26-,27-,28+,29+,30-/m0/s1
DM27GH0 CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H]([C@@]([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)CO)O)C)C(=O)O
DM27GH0 IK HXWLKAXCQLXHML-WGOZWDAUSA-N
DM27GH0 IU (1R,3aS,5aR,5bR,7aR,8R,9S,11aR,11bR,13aR,13bR)-9-hydroxy-8-(hydroxymethyl)-5a,5b,8,11a-tetramethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
DM27GH0 CA CAS 85999-40-2
DM27GH0 CB CHEBI:69580
DM27GH0 DE Discovery agent
DMW2KI5 ID DMW2KI5
DMW2KI5 DN 24(S), 25-epoxycholesterol
DMW2KI5 HS Investigative
DMW2KI5 SN 24,25-epoxy-cholesterol
DMW2KI5 DT Small molecular drug
DMW2KI5 PC 3247059
DMW2KI5 MW 400.6
DMW2KI5 FM C27H44O2
DMW2KI5 IC InChI=1S/C27H44O2/c1-17(6-11-24-25(2,3)29-24)21-9-10-22-20-8-7-18-16-19(28)12-14-26(18,4)23(20)13-15-27(21,22)5/h7,17,19-24,28H,6,8-16H2,1-5H3/t17-,19+,20+,21-,22+,23+,24+,26+,27-/m1/s1
DMW2KI5 CS C[C@H](CC[C@H]1C(O1)(C)C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)O)C)C
DMW2KI5 IK OSENKJZWYQXHBN-XVYZBDJZSA-N
DMW2KI5 IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-4-[(2S)-3,3-dimethyloxiran-2-yl]butan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMW2KI5 CA CAS 77058-74-3
DMW2KI5 CB CHEBI:41633
DMW2KI5 DE Discovery agent
DMGMWA6 ID DMGMWA6
DMGMWA6 DN 24(S)-hydroxycholesterol
DMGMWA6 HS Investigative
DMGMWA6 SN 24s-OHC
DMGMWA6 DT Small molecular drug
DMGMWA6 PC 121948
DMGMWA6 MW 402.7
DMGMWA6 FM C27H46O2
DMGMWA6 IC InChI=1S/C27H46O2/c1-17(2)25(29)11-6-18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20+,21+,22-,23+,24+,25+,26+,27-/m1/s1
DMGMWA6 CS C[C@H](CC[C@@H](C(C)C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMGMWA6 IK IOWMKBFJCNLRTC-XWXSNNQWSA-N
DMGMWA6 IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5S)-5-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMGMWA6 CA CAS 474-73-7
DMGMWA6 CB CHEBI:34310
DMGMWA6 DE Discovery agent
DMZIQ56 ID DMZIQ56
DMZIQ56 DN 24-ethylcholest-6-ene-3,5-diol
DMZIQ56 HS Investigative
DMZIQ56 SN CHEMBL201866; 24-ethylcholest-6-ene-3,5-diol
DMZIQ56 DT Small molecular drug
DMZIQ56 PC 44407138
DMZIQ56 MW 430.7
DMZIQ56 FM C29H50O2
DMZIQ56 IC InChI=1S/C29H50O2/c1-7-21(19(2)3)9-8-20(4)24-10-11-25-23-13-17-29(31)18-22(30)12-16-28(29,6)26(23)14-15-27(24,25)5/h13,17,19-26,30-31H,7-12,14-16,18H2,1-6H3/t20-,21?,22+,23+,24-,25+,26+,27-,28-,29?/m1/s1
DMZIQ56 CS CCC(CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=CC4([C@@]3(CC[C@@H](C4)O)C)O)C)C(C)C
DMZIQ56 IK CIZGZRCBMJRIFK-VRGDKWBFSA-N
DMZIQ56 IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-3,5-diol
DMZIQ56 DE Discovery agent
DMQSTYZ ID DMQSTYZ
DMQSTYZ DN 24-ethyl-cholest-7-ene-3,5,6-triol
DMQSTYZ HS Investigative
DMQSTYZ SN CHEMBL201951; 24-ethyl-cholest-7-ene-3,5,6-triol
DMQSTYZ DT Small molecular drug
DMQSTYZ PC 44407137
DMQSTYZ MW 446.7
DMQSTYZ FM C29H50O3
DMQSTYZ IC InChI=1S/C29H50O3/c1-7-20(18(2)3)9-8-19(4)23-10-11-24-22-16-26(31)29(32)17-21(30)12-15-28(29,6)25(22)13-14-27(23,24)5/h16,18-21,23-26,30-32H,7-15,17H2,1-6H3/t19-,20?,21+,23-,24+,25+,26?,27-,28-,29?/m1/s1
DMQSTYZ CS CCC(CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3C2=CC(C4([C@@]3(CC[C@@H](C4)O)C)O)O)C)C(C)C
DMQSTYZ IK OZIAZQBXQMKSLA-XMWGPCPVSA-N
DMQSTYZ IU (3S,9S,10R,13R,14R,17R)-17-[(2R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,6,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-3,5,6-triol
DMQSTYZ DE Discovery agent
DMVY271 ID DMVY271
DMVY271 DN 24-hydroxyursolic acid
DMVY271 HS Investigative
DMVY271 SN 24-hydroxyursolic acid; CHEMBL522373; BDBM50253075; 3beta,24-Dihydroxyurs-12-en-28-oic acid
DMVY271 DT Small molecular drug
DMVY271 PC 44568920
DMVY271 MW 472.7
DMVY271 FM C30H48O4
DMVY271 IC InChI=1S/C30H48O4/c1-18-9-14-30(25(33)34)16-15-28(5)20(24(30)19(18)2)7-8-22-26(3)12-11-23(32)27(4,17-31)21(26)10-13-29(22,28)6/h7,18-19,21-24,31-32H,8-17H2,1-6H3,(H,33,34)/t18-,19+,21-,22-,23+,24+,26+,27-,28-,29-,30+/m1/s1
DMVY271 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H]([C@]5(C)CO)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMVY271 IK NZCULBURCGAPSF-OQCQIIONSA-N
DMVY271 IU (1S,2R,4aS,6aR,6aS,6bR,8aR,9S,10S,12aR,14bS)-10-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMVY271 DE Discovery agent
DM90IRW ID DM90IRW
DM90IRW DN 24-thiacycloartanol
DM90IRW HS Investigative
DM90IRW SN CHEMBL238349; 24-thiacycloartanol
DM90IRW DT Small molecular drug
DM90IRW PC 44434253
DM90IRW MW 446.8
DM90IRW FM C29H50OS
DM90IRW IC InChI=1S/C29H50OS/c1-19(2)31-17-12-20(3)21-10-13-27(7)23-9-8-22-25(4,5)24(30)11-14-28(22)18-29(23,28)16-15-26(21,27)6/h19-24,30H,8-18H2,1-7H3/t20-,21-,22+,23+,24+,26-,27+,28?,29?/m1/s1
DM90IRW CS C[C@H](CCSC(C)C)[C@H]1CC[C@@]2([C@@]1(CCC34[C@H]2CC[C@@H]5C3(C4)CC[C@@H](C5(C)C)O)C)C
DM90IRW IK RCCUSRZZXQUAQP-VMZLNZKESA-N
DM90IRW IU (6S,8R,11S,12S,15R,16R)-7,7,12,16-tetramethyl-15-[(2R)-4-propan-2-ylsulfanylbutan-2-yl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-6-ol
DM90IRW DE Discovery agent
DM6P3Z8 ID DM6P3Z8
DM6P3Z8 DN 2'-5'dideoxyuridine
DM6P3Z8 HS Investigative
DM6P3Z8 SN 2',5'-Dideoxyuridine; 2'-5'dideoxyuridine; 35959-50-3; AC1L9G4G; Uridine, 2',5'-dideoxy-; SCHEMBL2919639; CTK1C1122; DTXSID00332151; FDCFKLBIAIKUKB-GKROBHDKSA-N; ZINC3870698; DB03274
DM6P3Z8 DT Small molecular drug
DM6P3Z8 PC 444320
DM6P3Z8 MW 212.2
DM6P3Z8 FM C9H12N2O4
DM6P3Z8 IC InChI=1S/C9H12N2O4/c1-5-6(12)4-8(15-5)11-3-2-7(13)10-9(11)14/h2-3,5-6,8,12H,4H2,1H3,(H,10,13,14)/t5-,6+,8-/m1/s1
DM6P3Z8 CS C[C@@H]1[C@H](C[C@@H](O1)N2C=CC(=O)NC2=O)O
DM6P3Z8 IK FDCFKLBIAIKUKB-GKROBHDKSA-N
DM6P3Z8 IU 1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]pyrimidine-2,4-dione
DM6P3Z8 CA CAS 35959-50-3
DM6P3Z8 DE Discovery agent
DMCHAQ7 ID DMCHAQ7
DMCHAQ7 DN 25-hydroxycholesterol
DMCHAQ7 HS Investigative
DMCHAQ7 SN 25-OHC
DMCHAQ7 DT Small molecular drug
DMCHAQ7 PC 65094
DMCHAQ7 MW 402.7
DMCHAQ7 FM C27H46O2
DMCHAQ7 IC InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t18-,20+,21+,22-,23+,24+,26+,27-/m1/s1
DMCHAQ7 CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMCHAQ7 IK INBGSXNNRGWLJU-ZHHJOTBYSA-N
DMCHAQ7 IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMCHAQ7 CA CAS 2140-46-7
DMCHAQ7 CB CHEBI:42977
DMCHAQ7 DE Discovery agent
DM2L6OZ ID DM2L6OZ
DM2L6OZ DN 27-hydroxycholesterol
DM2L6OZ HS Investigative
DM2L6OZ SN 27-OHC; 26-hydroxycholesterol
DM2L6OZ DT Small molecular drug
DM2L6OZ PC 123976
DM2L6OZ MW 402.7
DM2L6OZ FM C27H46O2
DM2L6OZ IC InChI=1S/C27H46O2/c1-18(17-28)6-5-7-19(2)23-10-11-24-22-9-8-20-16-21(29)12-14-26(20,3)25(22)13-15-27(23,24)4/h8,18-19,21-25,28-29H,5-7,9-17H2,1-4H3/t18-,19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DM2L6OZ CS C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CO
DM2L6OZ IK FYHRJWMENCALJY-YSQMORBQSA-N
DM2L6OZ IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM2L6OZ CA CAS 20380-11-4
DM2L6OZ CB CHEBI:76591
DM2L6OZ DE Discovery agent
DMUQAP7 ID DMUQAP7
DMUQAP7 DN 29-methylidene-2,3-oxidosqualene
DMUQAP7 HS Investigative
DMUQAP7 SN 29-Mos; 29-Methylidene-2,3-oxidosqualene; 2,2-dimethyl-3-[(3E,7E,11E,15E,19Z)-3,7,12-trimethyl-16-prop-2-enylhenicosa-3,7,11,15,19-pentaenyl]oxirane; AC1O5QC1; (3H)29-Mos; GTPL6719; Oxirane, 3-(16-ethenyl-3,7,12,20-tetramethyl-3,7,11,15,19-heneicosapentaenyl)-2,2-dimethyl-, (S-(all-E))-
DMUQAP7 DT Small molecular drug
DMUQAP7 PC 6438780
DMUQAP7 MW 438.7
DMUQAP7 FM C31H50O
DMUQAP7 IC InChI=1S/C31H50O/c1-8-10-11-22-29(16-9-2)23-15-21-27(4)18-13-12-17-26(3)19-14-20-28(5)24-25-30-31(6,7)32-30/h8-10,17-18,20,23,30H,2,11-16,19,21-22,24-25H2,1,3-7H3/b10-8-,26-17+,27-18+,28-20+,29-23-
DMUQAP7 CS C/C=C\\CC/C(=C\\CC/C(=C/CC/C=C(\\C)/CC/C=C(\\C)/CCC1C(O1)(C)C)/C)/CC=C
DMUQAP7 IK DOTTUEYUTNVWMJ-KSTFQPQISA-N
DMUQAP7 IU 2,2-dimethyl-3-[(3E,7E,11E,15E,19Z)-3,7,12-trimethyl-16-prop-2-enylhenicosa-3,7,11,15,19-pentaenyl]oxirane
DMUQAP7 CA CAS 145919-42-2
DMUQAP7 DE Discovery agent
DMIQM4O ID DMIQM4O
DMIQM4O DN 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O HS Investigative
DMIQM4O SN CHEMBL454461; CHEMBL363489; BDBM50155551; 2-Acetylamino-indan-5-sulfonic acid
DMIQM4O DT Small molecular drug
DMIQM4O PC 44395768
DMIQM4O MW 255.29
DMIQM4O FM C11H13NO4S
DMIQM4O IC InChI=1S/C11H13NO4S/c1-7(13)12-10-4-8-2-3-11(17(14,15)16)6-9(8)5-10/h2-3,6,10H,4-5H2,1H3,(H,12,13)(H,14,15,16)
DMIQM4O CS CC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)O
DMIQM4O IK YEEWPYLDOKFULS-UHFFFAOYSA-N
DMIQM4O IU 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid
DMIQM4O DE Discovery agent
DMPKBVR ID DMPKBVR
DMPKBVR DN 2-acetamido-5-sulfonamidoindane
DMPKBVR HS Investigative
DMPKBVR SN CHEMBL184674; N-(5-Sulfamoyl-indan-2-yl)-acetamide; 2-acetamido-5-sulfonamidoindane; Indanesulfonamide Derivative 6; SCHEMBL1971499; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)acetamide; BDBM11029; CTK6A0685; RVPDXKXWYPPTAL-UHFFFAOYSA-N; N-acetyl-5-sulfamyl-2-indanamine; Acetamide, N-[5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-; AKOS015966079; 74124-93-9
DMPKBVR DT Small molecular drug
DMPKBVR PC 11414131
DMPKBVR MW 254.31
DMPKBVR FM C11H14N2O3S
DMPKBVR IC InChI=1S/C11H14N2O3S/c1-7(14)13-10-4-8-2-3-11(17(12,15)16)6-9(8)5-10/h2-3,6,10H,4-5H2,1H3,(H,13,14)(H2,12,15,16)
DMPKBVR CS CC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMPKBVR IK RVPDXKXWYPPTAL-UHFFFAOYSA-N
DMPKBVR IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)acetamide
DMPKBVR CA CAS 74124-93-9
DMPKBVR DE Discovery agent
DMRKYD6 ID DMRKYD6
DMRKYD6 DN 2-acetyl-3-hydroxycyclohex-2-enone
DMRKYD6 HS Investigative
DMRKYD6 SN CHEMBL73025; 37514-00-4; SCHEMBL5628771; CTK1B5605; DTXSID50472617; YKOOMGHHVDVJAY-UHFFFAOYSA-N; 2-Acetyl-3-hydroxy-cyclohex-2-enone; 2-Acetyl-3-hydroxy-2-cyclohexen-1-one; 2-Cyclohexen-1-one, 2-acetyl-3-hydroxy-
DMRKYD6 DT Small molecular drug
DMRKYD6 PC 11788412
DMRKYD6 MW 154.16
DMRKYD6 FM C8H10O3
DMRKYD6 IC InChI=1S/C8H10O3/c1-5(9)8-6(10)3-2-4-7(8)11/h10H,2-4H2,1H3
DMRKYD6 CS CC(=O)C1=C(CCCC1=O)O
DMRKYD6 IK YKOOMGHHVDVJAY-UHFFFAOYSA-N
DMRKYD6 IU 2-acetyl-3-hydroxycyclohex-2-en-1-one
DMRKYD6 CA CAS 37514-00-4
DMRKYD6 DE Discovery agent
DM9ZOX4 ID DM9ZOX4
DM9ZOX4 DN 2-Acetylaminoethyl 18-methoxycoronaridinate
DM9ZOX4 HS Investigative
DM9ZOX4 SN 2-Acetylaminoethyl 18-methoxycoronaridinate
DM9ZOX4 DT Small molecular drug
DM9ZOX4 PC 46877890
DM9ZOX4 MW 439.5
DM9ZOX4 FM C25H33N3O4
DM9ZOX4 IC InChI=1S/C25H33N3O4/c1-16(29)26-9-12-32-24(30)25-14-17-13-18(8-11-31-2)23(25)28(15-17)10-7-20-19-5-3-4-6-21(19)27-22(20)25/h3-6,17-18,23,27H,7-15H2,1-2H3,(H,26,29)/t17?,18-,23-,25+/m0/s1
DM9ZOX4 CS CC(=O)NCCOC(=O)[C@@]12CC3C[C@@H]([C@@H]1N(C3)CCC4=C2NC5=CC=CC=C45)CCOC
DM9ZOX4 IK PIPDTENSRZRDNA-BJASRFDRSA-N
DM9ZOX4 IU 2-acetamidoethyl (1S,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DM9ZOX4 DE Discovery agent
DMEQKIU ID DMEQKIU
DMEQKIU DN 2-Acetylamino-indan-5-sulfonic acid hydrate
DMEQKIU HS Investigative
DMEQKIU DE Discovery agent
DM0NJYZ ID DM0NJYZ
DM0NJYZ DN 2-acetylaminoquinazoline-4-carboxyanilide
DM0NJYZ HS Investigative
DM0NJYZ SN CHEMBL239193; 2-acetylaminoquinazoline-4-carboxyanilide
DM0NJYZ DT Small molecular drug
DM0NJYZ PC 24749707
DM0NJYZ MW 306.32
DM0NJYZ FM C17H14N4O2
DM0NJYZ IC InChI=1S/C17H14N4O2/c1-11(22)18-17-20-14-10-6-5-9-13(14)15(21-17)16(23)19-12-7-3-2-4-8-12/h2-10H,1H3,(H,19,23)(H,18,20,21,22)
DM0NJYZ CS CC(=O)NC1=NC2=CC=CC=C2C(=N1)C(=O)NC3=CC=CC=C3
DM0NJYZ IK BQZOPXKHGPNWQR-UHFFFAOYSA-N
DM0NJYZ IU 2-acetamido-N-phenylquinazoline-4-carboxamide
DM0NJYZ DE Discovery agent
DMN8TVB ID DMN8TVB
DMN8TVB DN 2-Acetyl-cyclohexane-1,3-dione
DMN8TVB HS Investigative
DMN8TVB SN 2-Acetyl-1,3-cyclohexanedione; 4056-73-9; 2-acetylcyclohexane-1,3-dione; 2-Acetyl-cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-acetyl-; CHEMBL167675; CHNXDYRMRBQOEF-UHFFFAOYSA-N; ACMC-1CTSA; AC1L3C2Y; 2-acetyl1,3-cyclohexanedione; 2-acetyl-1,3-cyclohexadione; SCHEMBL170644; 1-acetyl-2,6-dioxocyclohexane; CTK4I3348; 1,3-Cyclohexanedione,2-acetyl-; DTXSID50193577; BDBM50088797; AKOS015906528; ZINC100068139; 2-Acetyl-1,3-cyclohexanedione, 98%; MCULE-5567869384; TC-171004; ST50997553; X3265; CS-0060856; Z-8544
DMN8TVB DT Small molecular drug
DMN8TVB PC 138104
DMN8TVB MW 154.16
DMN8TVB FM C8H10O3
DMN8TVB IC InChI=1S/C8H10O3/c1-5(9)8-6(10)3-2-4-7(8)11/h8H,2-4H2,1H3
DMN8TVB CS CC(=O)C1C(=O)CCCC1=O
DMN8TVB IK CHNXDYRMRBQOEF-UHFFFAOYSA-N
DMN8TVB IU 2-acetylcyclohexane-1,3-dione
DMN8TVB CA CAS 4056-73-9
DMN8TVB DE Discovery agent
DMJAUH0 ID DMJAUH0
DMJAUH0 DN 2-Adamantan-1-yl-N-decyl-acetamide
DMJAUH0 HS Investigative
DMJAUH0 SN CHEMBL192549; 2-Adamantan-1-yl-N-decyl-acetamide; SCHEMBL12931880
DMJAUH0 DT Small molecular drug
DMJAUH0 PC 11382033
DMJAUH0 MW 333.6
DMJAUH0 FM C22H39NO
DMJAUH0 IC InChI=1S/C22H39NO/c1-2-3-4-5-6-7-8-9-10-23-21(24)17-22-14-18-11-19(15-22)13-20(12-18)16-22/h18-20H,2-17H2,1H3,(H,23,24)
DMJAUH0 CS CCCCCCCCCCNC(=O)CC12CC3CC(C1)CC(C3)C2
DMJAUH0 IK CIOJRKYNUJJCLZ-UHFFFAOYSA-N
DMJAUH0 IU 2-(1-adamantyl)-N-decylacetamide
DMJAUH0 DE Discovery agent
DMXG029 ID DMXG029
DMXG029 DN 2-Adamantan-2-ylidenemethyl-benzooxazol-6-ol
DMXG029 HS Investigative
DMXG029 SN CHEMBL187900
DMXG029 DT Small molecular drug
DMXG029 PC 22733402
DMXG029 MW 281.3
DMXG029 FM C18H19NO2
DMXG029 IC InChI=1S/C18H19NO2/c20-14-1-2-16-17(8-14)21-18(19-16)9-15-12-4-10-3-11(6-12)7-13(15)5-10/h1-2,8-13,20H,3-7H2
DMXG029 CS C1C2CC3CC1CC(C2)C3=CC4=NC5=C(O4)C=C(C=C5)O
DMXG029 IK CEAARYLECHJRSD-UHFFFAOYSA-N
DMXG029 IU 2-(2-adamantylidenemethyl)-1,3-benzoxazol-6-ol
DMXG029 DE Discovery agent
DM3DE9Z ID DM3DE9Z
DM3DE9Z DN 2-allylisoquinoline-1,3,4-trione
DM3DE9Z HS Investigative
DM3DE9Z SN 807334-89-0; 1,3,4(2H)-Isoquinolinetrione, 2-(2-propenyl)-; 2-allylisoquinoline-1,3,4-trione; CHEMBL381777; Isoquinoline-1,3,4-trione 2b; SCHEMBL13442855; CTK2I7309; BDBM10249; DTXSID20469711; ZINC13683126; AKOS015966148
DM3DE9Z DT Small molecular drug
DM3DE9Z PC 11629882
DM3DE9Z MW 215.2
DM3DE9Z FM C12H9NO3
DM3DE9Z IC InChI=1S/C12H9NO3/c1-2-7-13-11(15)9-6-4-3-5-8(9)10(14)12(13)16/h2-6H,1,7H2
DM3DE9Z CS C=CCN1C(=O)C2=CC=CC=C2C(=O)C1=O
DM3DE9Z IK RFPACNBGGYBCGT-UHFFFAOYSA-N
DM3DE9Z IU 2-prop-2-enylisoquinoline-1,3,4-trione
DM3DE9Z CA CAS 807334-89-0
DM3DE9Z DE Discovery agent
DMTO1EJ ID DMTO1EJ
DMTO1EJ DN 2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one
DMTO1EJ HS Investigative
DMTO1EJ SN CHEMBL1092451; 2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one
DMTO1EJ DT Small molecular drug
DMTO1EJ PC 46886486
DMTO1EJ MW 353.4
DMTO1EJ FM C18H15N3O3S
DMTO1EJ IC InChI=1S/C18H15N3O3S/c1-2-10-25-18-19-16-9-8-14(21(23)24)11-15(16)17(22)20(18)12-13-6-4-3-5-7-13/h2-9,11H,1,10,12H2
DMTO1EJ CS C=CCSC1=NC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N1CC3=CC=CC=C3
DMTO1EJ IK BDDASWRESYMCMC-UHFFFAOYSA-N
DMTO1EJ IU 3-benzyl-6-nitro-2-prop-2-enylsulfanylquinazolin-4-one
DMTO1EJ DE Discovery agent
DMBWGCX ID DMBWGCX
DMBWGCX DN 2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one
DMBWGCX HS Investigative
DMBWGCX SN CHEMBL1093491; 2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one
DMBWGCX DT Small molecular drug
DMBWGCX PC 46886512
DMBWGCX MW 323.4
DMBWGCX FM C18H17N3OS
DMBWGCX IC InChI=1S/C18H17N3OS/c1-2-10-23-18-20-16-9-8-14(19)11-15(16)17(22)21(18)12-13-6-4-3-5-7-13/h2-9,11H,1,10,12,19H2
DMBWGCX CS C=CCSC1=NC2=C(C=C(C=C2)N)C(=O)N1CC3=CC=CC=C3
DMBWGCX IK FKQLYAVUAISVGO-UHFFFAOYSA-N
DMBWGCX IU 6-amino-3-benzyl-2-prop-2-enylsulfanylquinazolin-4-one
DMBWGCX DE Discovery agent
DMHY2RA ID DMHY2RA
DMHY2RA DN 2alpha-Hydroxyolean-12-en-28-oic acid
DMHY2RA HS Investigative
DMHY2RA SN CHEMBL1077726; 2alpha-Hydroxyolean-12-en-28-oic acid; BDBM50310519; 2alpha-Hydroxyoleana-12-ene-28-oic acid
DMHY2RA DT Small molecular drug
DMHY2RA PC 44254077
DMHY2RA MW 456.7
DMHY2RA FM C30H48O3
DMHY2RA IC InChI=1S/C30H48O3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31)16-26(3,4)22(27)10-11-29(23,28)7/h8,19,21-23,31H,9-18H2,1-7H3,(H,32,33)/t19-,21-,22-,23+,27-,28+,29+,30-/m0/s1
DMHY2RA CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H](CC3(C)C)O)C
DMHY2RA IK UODITNOILLXLOO-DBWGAYEVSA-N
DMHY2RA IU (4aS,6aR,6aS,6bR,8aS,11S,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMHY2RA DE Discovery agent
DM1RSCP ID DM1RSCP
DM1RSCP DN 2alpha-Hydroxyurs-12-en-28-oic acid
DM1RSCP HS Investigative
DM1RSCP SN CHEMBL1078844; 2alpha-Hydroxyurs-12-en-28-oic acid
DM1RSCP DT Small molecular drug
DM1RSCP PC 44254078
DM1RSCP MW 456.7
DM1RSCP FM C30H48O3
DM1RSCP IC InChI=1S/C30H48O3/c1-18-10-13-30(25(32)33)15-14-28(6)21(24(30)19(18)2)8-9-23-27(5)17-20(31)16-26(3,4)22(27)11-12-29(23,28)7/h8,18-20,22-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,20+,22+,23-,24+,27+,28-,29-,30+/m1/s1
DM1RSCP CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H](CC5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM1RSCP IK DDHYEJNMSYDDTH-ZWHPGZRZSA-N
DM1RSCP IU (1S,2R,4aS,6aR,6aS,6bR,8aS,11S,12aS,14bS)-11-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM1RSCP DE Discovery agent
DM73FWA ID DM73FWA
DM73FWA DN 2-Amino-1-(4-ethylthiophenyl)butane
DM73FWA HS Investigative
DM73FWA SN 2-Amino-1-(4-ethylthiophenyl)butane; CHEMBL1077883; 1204749-31-4; BDBM50310840
DM73FWA DT Small molecular drug
DM73FWA PC 44613455
DM73FWA MW 209.35
DM73FWA FM C12H19NS
DM73FWA IC InChI=1S/C12H19NS/c1-3-11(13)9-10-5-7-12(8-6-10)14-4-2/h5-8,11H,3-4,9,13H2,1-2H3
DM73FWA CS CCC(CC1=CC=C(C=C1)SCC)N
DM73FWA IK PCPVEGXNPCSDGS-UHFFFAOYSA-N
DM73FWA IU 1-(4-ethylsulfanylphenyl)butan-2-amine
DM73FWA DE Discovery agent
DMS5LKR ID DMS5LKR
DMS5LKR DN 2-Amino-1-(4-ethylthiophenyl)propane
DMS5LKR HS Investigative
DMS5LKR SN CHEMBL193309; 2-Amino-1-(4-ethylthiophenyl)propane; 4-ethylthioamphetamine; BDBM50164327; AKOS013148908
DMS5LKR DT Small molecular drug
DMS5LKR PC 44399737
DMS5LKR MW 195.33
DMS5LKR FM C11H17NS
DMS5LKR IC InChI=1S/C11H17NS/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3
DMS5LKR CS CCSC1=CC=C(C=C1)CC(C)N
DMS5LKR IK WOBAXWXQKSIHCH-UHFFFAOYSA-N
DMS5LKR IU 1-(4-ethylsulfanylphenyl)propan-2-amine
DMS5LKR DE Discovery agent
DMW7N3H ID DMW7N3H
DMW7N3H DN 2-Amino-1-(4-methylthiophenyl)butane
DMW7N3H HS Investigative
DMW7N3H SN 2-Amino-1-(4-methylthiophenyl)butane; CHEMBL1078352; 634607-37-7; BDBM50310844
DMW7N3H DT Small molecular drug
DMW7N3H PC 43565977
DMW7N3H MW 195.33
DMW7N3H FM C11H17NS
DMW7N3H IC InChI=1S/C11H17NS/c1-3-10(12)8-9-4-6-11(13-2)7-5-9/h4-7,10H,3,8,12H2,1-2H3
DMW7N3H CS CCC(CC1=CC=C(C=C1)SC)N
DMW7N3H IK DTEDVKORISMLCH-UHFFFAOYSA-N
DMW7N3H IU 1-(4-methylsulfanylphenyl)butan-2-amine
DMW7N3H DE Discovery agent
DMJ2Z9G ID DMJ2Z9G
DMJ2Z9G DN 2-Amino-1-(4-methylthiophenyl)propane
DMJ2Z9G HS Investigative
DMJ2Z9G SN 1-(6-(methylthio)naphthalen-2-yl)propan-2-amine
DMJ2Z9G DT Small molecular drug
DMJ2Z9G PC 151900
DMJ2Z9G MW 181.3
DMJ2Z9G FM C10H15NS
DMJ2Z9G IC InChI=1S/C10H15NS/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3
DMJ2Z9G CS CC(CC1=CC=C(C=C1)SC)N
DMJ2Z9G IK OLEWMKVPSUCNLG-UHFFFAOYSA-N
DMJ2Z9G IU 1-(4-methylsulfanylphenyl)propan-2-amine
DMJ2Z9G CA CAS 14116-06-4
DMJ2Z9G DE Discovery agent
DMNQL17 ID DMNQL17
DMNQL17 DN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
DMNQL17 HS Investigative
DMNQL17 SN PhIP; 105650-23-5; 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; 1-methyl-6-phenyl-1H-imidazo[4,5-b]pyridin-2-amine; 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; UNII-909C6UN66T; CHEBI:76290; 909C6UN66T; 1-Methyl-6-phenyl-1H-imidazo(4,5-b)pyridin-2-amine; PIQ; 2-AMINO-1-METHYL-6-PHENYL-IMIDAZO [4,5-b] PYRIDINE; 1H-Imidazo(4,5-b)pyridin-2-amine, 1-methyl-6-phenyl- (9CI); CCRIS 2954; HSDB 7768; BRN 5951264; ACMC-1BRGI; AC1Q4WMI; (3H)PhIP; AC1L1BO3; SCHEMBL151718; CHEMBL1213271; DTXSID3037628; CTK0I0185
DMNQL17 DT Small molecular drug
DMNQL17 PC 1530
DMNQL17 MW 224.26
DMNQL17 FM C13H12N4
DMNQL17 IC InChI=1S/C13H12N4/c1-17-11-7-10(9-5-3-2-4-6-9)8-15-12(11)16-13(17)14/h2-8H,1H3,(H2,14,15,16)
DMNQL17 CS CN1C2=C(N=CC(=C2)C3=CC=CC=C3)N=C1N
DMNQL17 IK UQVKZNNCIHJZLS-UHFFFAOYSA-N
DMNQL17 IU 1-methyl-6-phenylimidazo[4,5-b]pyridin-2-amine
DMNQL17 CA CAS 105650-23-5
DMNQL17 CB CHEBI:76290
DMNQL17 DE Discovery agent
DMWDENZ ID DMWDENZ
DMWDENZ DN 2-amino-2-(2,3-difluorophenyl)acetic acid
DMWDENZ HS Investigative
DMWDENZ SN 2-amino-2-(2,3-difluorophenyl)acetic Acid; 237424-16-7; 2,3-Difluoro-DL-phenylglycine; 2,3-DIFLUOR-DL-PHENYLGLYCINE; CHEMBL204804; AC1MC6PF; MolPort-000-165-847; JRD-0494; SBB090537; BDBM50179717; amino(2,3-difluorophenyl)acetic acid; AKOS012977999; AB26703; PS-11465; alpha-Amino-2,3-difluoro-benzeneacetic acid
DMWDENZ DT Small molecular drug
DMWDENZ PC 2737049
DMWDENZ MW 187.14
DMWDENZ FM C8H7F2NO2
DMWDENZ IC InChI=1S/C8H7F2NO2/c9-5-3-1-2-4(6(5)10)7(11)8(12)13/h1-3,7H,11H2,(H,12,13)
DMWDENZ CS C1=CC(=C(C(=C1)F)F)C(C(=O)O)N
DMWDENZ IK DNWOZEQWCCXGRU-UHFFFAOYSA-N
DMWDENZ IU 2-amino-2-(2,3-difluorophenyl)acetic acid
DMWDENZ DE Discovery agent
DMSAFUK ID DMSAFUK
DMSAFUK DN 2-amino-2-(2,4-difluorophenyl)acetic acid
DMSAFUK HS Investigative
DMSAFUK SN 2-amino-2-(2,4-difluorophenyl)acetic Acid; 240409-02-3; 2,4-DIFLUORO-DL-PHENYLGLYCINE; amino(2,4-difluorophenyl)acetic acid; CHEMBL382622; Amino-(2,4-difluoro-phenyl)-acetic acid; alpha-Amino-2,4-difluorobenzeneacetic acid; AC1MC6PH; SCHEMBL1115280; CTK7I4174; DTXSID70371799; MolPort-000-165-848; COIWYFIMAXMSKX-UHFFFAOYSA-N; AC1Q5058; KS-00003QV7; BDBM50179695; SBB090539; AKOS016051288; AKOS000170674; PS-6697; QC-3701; AB11996; RP03495; SC-59456; FT-0691426; BB 0249675; 2-aMino-2-(2;4-difluorophenyl)acetic acid; Y8397; EN300-88022
DMSAFUK DT Small molecular drug
DMSAFUK PC 2737050
DMSAFUK MW 187.14
DMSAFUK FM C8H7F2NO2
DMSAFUK IC InChI=1S/C8H7F2NO2/c9-4-1-2-5(6(10)3-4)7(11)8(12)13/h1-3,7H,11H2,(H,12,13)
DMSAFUK CS C1=CC(=C(C=C1F)F)C(C(=O)O)N
DMSAFUK IK COIWYFIMAXMSKX-UHFFFAOYSA-N
DMSAFUK IU 2-amino-2-(2,4-difluorophenyl)acetic acid
DMSAFUK CA CAS 240409-02-3
DMSAFUK DE Discovery agent
DMLXOHE ID DMLXOHE
DMLXOHE DN 2-amino-2-(2-fluorophenyl)acetic acid
DMLXOHE HS Investigative
DMLXOHE SN 84145-28-8; Amino(2-fluorophenyl)acetic acid; Amino-(2-fluoro-phenyl)-acetic acid; 2-(2-FLUOROPHENYL)GLYCINE; CHEMBL383715; DL-2-FLUOROPHENYLGLYCINE; CGNMJIBUVDGMIY-UHFFFAOYSA-N; Bionet2_000821; dl-O-Fluorophenylglycine; AC1LBC1Z; 2-fluoro-dl-phenylglycine; 2-(o-fluorophenyl)glycine; AC1Q4O3E; dl-(2-Fluorophenyl)-glycine; 2-fluoro-dl-; SCHEMBL2628067; AC1Q505A; 2-Fluoro-dl-alpha-phenylglycine; CTK8D0864; MolPort-000-000-424; HMS1366F07; 2-Fluoro-dl-.alpha.-phenylglycine
DMLXOHE DT Small molecular drug
DMLXOHE PC 580073
DMLXOHE MW 169.15
DMLXOHE FM C8H8FNO2
DMLXOHE IC InChI=1S/C8H8FNO2/c9-6-4-2-1-3-5(6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)
DMLXOHE CS C1=CC=C(C(=C1)C(C(=O)O)N)F
DMLXOHE IK CGNMJIBUVDGMIY-UHFFFAOYSA-N
DMLXOHE IU 2-amino-2-(2-fluorophenyl)acetic acid
DMLXOHE CA CAS 84145-28-8
DMLXOHE DE Discovery agent
DMEX6AM ID DMEX6AM
DMEX6AM DN 2-amino-2-(3-bromophenyl)acetic acid
DMEX6AM HS Investigative
DMEX6AM SN 2-amino-2-(3-bromophenyl)acetic Acid; 79422-73-4; Amino(3-bromophenyl)acetic acid; 3-Bromo-DL-phenylglycine; CHEMBL382371; 150174-93-9; Amino-(3-bromo-phenyl)-acetic acid; Benzeneacetic acid, a-amino-3-bromo-; 3-Bromo-L-phenylglycine; (+)-2-Amino-2-(3-bromophenyl)acetic acid; (S)-2-(3-BROMOPHENYL)GLYCINE; AC1MXE2V; 2-(3-Bromophenyl)glycine; SCHEMBL2927725; AMGLY00125; AC1Q505E; CTK5E6784; KS-00000MGC; DTXSID80396791; MolPort-000-000-540; MJPMYLPJAVQUQA-UHFFFAOYSA-N; N-(3-BROMOPHENYL)-GLYCINE; ANW-43657; MFCD00665358; BDBM50179696
DMEX6AM DT Small molecular drug
DMEX6AM PC 3814142
DMEX6AM MW 230.06
DMEX6AM FM C8H8BrNO2
DMEX6AM IC InChI=1S/C8H8BrNO2/c9-6-3-1-2-5(4-6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)
DMEX6AM CS C1=CC(=CC(=C1)Br)C(C(=O)O)N
DMEX6AM IK MJPMYLPJAVQUQA-UHFFFAOYSA-N
DMEX6AM IU 2-amino-2-(3-bromophenyl)acetic acid
DMEX6AM CA CAS 79422-73-4
DMEX6AM DE Discovery agent
DMMU1CQ ID DMMU1CQ
DMMU1CQ DN 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid
DMMU1CQ HS Investigative
DMMU1CQ SN 261762-99-6; 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid; 3-Chloro-4-fluoro-DL-phenylglycine; C8H7ClFNO2; CHEMBL203905; amino(3-chloro-4-fluorophenyl)acetic acid; AC1MCND8; SCHEMBL8196588; KS-00000ZXX; CTK8F0591; DTXSID40378674; MolPort-000-153-073; JRD-1093; SBB093187; BDBM50179692; 8653AD; 2-(3-Chloro-4-fluorophenyl)glycine; MFCD01631397; AKOS032962888; AKOS015907725; MCULE-4108995551; RTR-011871; PS-6305; SY044823; TR-011871; ST51041478; FT-0676194; MFCD01631397 (95%); C-5924
DMMU1CQ DT Small molecular drug
DMMU1CQ PC 2773727
DMMU1CQ MW 203.6
DMMU1CQ FM C8H7ClFNO2
DMMU1CQ IC InChI=1S/C8H7ClFNO2/c9-5-3-4(1-2-6(5)10)7(11)8(12)13/h1-3,7H,11H2,(H,12,13)
DMMU1CQ CS C1=CC(=C(C=C1C(C(=O)O)N)Cl)F
DMMU1CQ IK DVSWHHQDQJPPBH-UHFFFAOYSA-N
DMMU1CQ IU 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid
DMMU1CQ CA CAS 261762-99-6
DMMU1CQ DE Discovery agent
DMPZX8U ID DMPZX8U
DMPZX8U DN 2-amino-2-(3-chlorophenyl)acetic acid
DMPZX8U HS Investigative
DMPZX8U SN 7292-71-9; 2-amino-2-(3-chlorophenyl)acetic acid; Amino-(3-chloro-phenyl)-acetic acid; amino(3-chlorophenyl)acetic acid; dl-3-chlorophenylglycine; 3-chlorophenylglycine; amino-(3-chlorophenyl)acetic acid; DL-(3-Chlorophenyl)glycine; DL-2-(3-Chlorophenyl)glycine; CHEMBL204655; amino(3-chloro-phenyl)acetic acid; (R)-2-(3-Chlorophenyl)glycine; NSC154922; Benzeneacetic acid, a-amino-3-chloro-, (aS)-; PubChem20741; ACMC-20en3l; (3-chlorophenyl)glycine; AC1L6EDK; 3-Chloro-DL-phenylglycine; AC1Q3M3E; 2-(3-Chlorophenyl)glycine
DMPZX8U DT Small molecular drug
DMPZX8U PC 290730
DMPZX8U MW 185.61
DMPZX8U FM C8H8ClNO2
DMPZX8U IC InChI=1S/C8H8ClNO2/c9-6-3-1-2-5(4-6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)
DMPZX8U CS C1=CC(=CC(=C1)Cl)C(C(=O)O)N
DMPZX8U IK MGOUENCSVMAGSE-UHFFFAOYSA-N
DMPZX8U IU 2-amino-2-(3-chlorophenyl)acetic acid
DMPZX8U CA CAS 29884-14-8
DMPZX8U DE Discovery agent
DMHQNZD ID DMHQNZD
DMHQNZD DN 2-amino-2-(thiophen-2-yl)acetic acid
DMHQNZD HS Investigative
DMHQNZD SN 21124-40-3; AMINO-THIOPHEN-2-YL-ACETIC ACID; 2-amino-2-(thiophen-2-yl)acetic acid; Amino(2-thienyl)acetic acid; DL-alpha-Amino-2-thiopheneacetic acid; 2-(2-thienyl)glycine; 4052-59-9; 2-amino-2-(2-thienyl)acetic acid; CHEMBL382570; amino(thiophen-2-yl)acetic acid; 2-Thiopheneacetic acid, alpha-amino-, (-)-; XLMSKXASROPJNG-UHFFFAOYSA-N; (-)-2-Thienylglycine; EINECS 223-758-6; ACMC-20altb; (-)-alpha-Amino-2-thiopheneacetic acid; alpha-(2-Thienyl)glycine; DL-2-(2-Thienyl)glycine; AC1Q5S3H; 2-(Thiophen-2-yl)glycine; AC1L3HV3
DMHQNZD DT Small molecular drug
DMHQNZD PC 89435
DMHQNZD MW 157.19
DMHQNZD FM C6H7NO2S
DMHQNZD IC InChI=1S/C6H7NO2S/c7-5(6(8)9)4-2-1-3-10-4/h1-3,5H,7H2,(H,8,9)
DMHQNZD CS C1=CSC(=C1)C(C(=O)O)N
DMHQNZD IK XLMSKXASROPJNG-UHFFFAOYSA-N
DMHQNZD IU 2-amino-2-thiophen-2-ylacetic acid
DMHQNZD CA CAS 21124-40-3
DMHQNZD DE Discovery agent
DMQOCAY ID DMQOCAY
DMQOCAY DN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY HS Investigative
DMQOCAY SN CHEMBL457996; CHEMBL559179; 5-sulfamyl-2-indanamine; 2-amino-2,3-dihydro-1H-indene-5-sulfonamide; SCHEMBL11452177; FVWXUWAWIYLUJG-UHFFFAOYSA-N; BDBM50155553; 2-Amino-indan-5-sulfonic acid amide; AKOS015921614; 52069-27-9; 2-Amino-indan-5-sulfonic acid amide
DMQOCAY DT Small molecular drug
DMQOCAY PC 20347846
DMQOCAY MW 212.27
DMQOCAY FM C9H12N2O2S
DMQOCAY IC InChI=1S/C9H12N2O2S/c10-8-3-6-1-2-9(14(11,12)13)5-7(6)4-8/h1-2,5,8H,3-4,10H2,(H2,11,12,13)
DMQOCAY CS C1C(CC2=C1C=CC(=C2)S(=O)(=O)N)N
DMQOCAY IK FVWXUWAWIYLUJG-UHFFFAOYSA-N
DMQOCAY IU 2-amino-2,3-dihydro-1H-indene-5-sulfonamide
DMQOCAY DE Discovery agent
DM14HCY ID DM14HCY
DM14HCY DN 2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM14HCY HS Investigative
DM14HCY SN CHEMBL1090816; 2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM14HCY DT Small molecular drug
DM14HCY PC 46885586
DM14HCY MW 291.3
DM14HCY FM C18H17N3O
DM14HCY IC InChI=1S/C18H17N3O/c19-17(14-6-2-1-3-7-14)18(22,15-8-4-10-20-12-15)16-9-5-11-21-13-16/h1-13,17,22H,19H2
DM14HCY CS C1=CC=C(C=C1)C(C(C2=CN=CC=C2)(C3=CN=CC=C3)O)N
DM14HCY IK BBACDJSPZTWBIB-UHFFFAOYSA-N
DM14HCY IU 2-amino-2-phenyl-1,1-dipyridin-3-ylethanol
DM14HCY DE Discovery agent
DMQKGL3 ID DMQKGL3
DMQKGL3 DN 2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX)
DMQKGL3 HS Investigative
DMQKGL3 SN CHEMBL1094129; BDBM50318264
DMQKGL3 DT Small molecular drug
DMQKGL3 PC 46237944
DMQKGL3 MW 173.13
DMQKGL3 FM C5H7N3O4
DMQKGL3 IC InChI=1S/C5H7N3O4/c6-2(5(10)11)1-3-4(9)8-12-7-3/h2H,1,6H2,(H,8,9)(H,10,11)
DMQKGL3 CS C(C1=NONC1=O)C(C(=O)O)N
DMQKGL3 IK LSAPTLMISILBOS-UHFFFAOYSA-N
DMQKGL3 IU 2-amino-3-(4-oxo-1,2,5-oxadiazol-3-yl)propanoic acid
DMQKGL3 DE Discovery agent
DM2GJZE ID DM2GJZE
DM2GJZE DN 2-amino-3-(m-tolylamino)naphthalene-1,4-dione
DM2GJZE HS Investigative
DM2GJZE SN CHEMBL598551; 2-amino-3-(m-tolylamino)naphthalene-1,4-dione; MolPort-007-563-584; ZINC27548840; BDBM50306786; AKOS001660486; MCULE-4833073664; EU-0076855
DM2GJZE DT Small molecular drug
DM2GJZE PC 11976150
DM2GJZE MW 278.3
DM2GJZE FM C17H14N2O2
DM2GJZE IC InChI=1S/C17H14N2O2/c1-10-5-4-6-11(9-10)19-15-14(18)16(20)12-7-2-3-8-13(12)17(15)21/h2-9,19H,18H2,1H3
DM2GJZE CS CC1=CC(=CC=C1)NC2=C(C(=O)C3=CC=CC=C3C2=O)N
DM2GJZE IK REWOWOXSGLQOHC-UHFFFAOYSA-N
DM2GJZE IU 2-amino-3-(3-methylanilino)naphthalene-1,4-dione
DM2GJZE DE Discovery agent
DMUYZA8 ID DMUYZA8
DMUYZA8 DN 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene
DMUYZA8 HS Investigative
DMUYZA8 SN CHEMBL217041; SCHEMBL5071915; ZINC38145012; BDBM50147364; J3.552.112G
DMUYZA8 DT Small molecular drug
DMUYZA8 PC 11988330
DMUYZA8 MW 315.4
DMUYZA8 FM C18H21NO4
DMUYZA8 IC InChI=1S/C18H21NO4/c1-20-14-8-7-13(15(19)11-14)6-5-12-9-16(21-2)18(23-4)17(10-12)22-3/h5-11H,19H2,1-4H3/b6-5-
DMUYZA8 CS COC1=CC(=C(C=C1)/C=C\\C2=CC(=C(C(=C2)OC)OC)OC)N
DMUYZA8 IK XMMNPPLYAJJFPL-WAYWQWQTSA-N
DMUYZA8 IU 5-methoxy-2-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline
DMUYZA8 DE Discovery agent
DMMZ2LI ID DMMZ2LI
DMMZ2LI DN 2-amino-3,4',5-trimethoxy-(Z)-stillbene
DMMZ2LI HS Investigative
DMMZ2LI SN CHEMBL216433; SCHEMBL4224804
DMMZ2LI DT Small molecular drug
DMMZ2LI PC 16090836
DMMZ2LI MW 285.34
DMMZ2LI FM C17H19NO3
DMMZ2LI IC InChI=1S/C17H19NO3/c1-19-14-8-5-12(6-9-14)4-7-13-10-15(20-2)11-16(21-3)17(13)18/h4-11H,18H2,1-3H3/b7-4-
DMMZ2LI CS COC1=CC=C(C=C1)/C=C\\C2=C(C(=CC(=C2)OC)OC)N
DMMZ2LI IK WCORNZIRKFTEOF-DAXSKMNVSA-N
DMMZ2LI IU 2,4-dimethoxy-6-[(Z)-2-(4-methoxyphenyl)ethenyl]aniline
DMMZ2LI DE Discovery agent
DM6AYDL ID DM6AYDL
DM6AYDL DN 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
DM6AYDL HS Investigative
DM6AYDL SN CHEMBL16709; 54124-67-3; AC1NBNWM; 2-amino-3-methyl-1-(1-pyrrolidinyl)-1-Butanone; SCHEMBL1951493; CTK8J1465; MolPort-004-338-106; ALBB-022686; BDBM50118952; AKOS016347010; AKOS000180650; 1-Pyrrolizino-2-amino-3-methyl-1-butanone; DB-071796; FT-0723537; 2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one; F2147-1598; [(1S)-2-methyl-1-(pyrrolidin-1-ylcarbonyl)propyl]amine; 3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-amine hydrochloride; [2-Methyl-1-(pyrrolidin-1-ylcarbonyl)propyl]amine hydrochloride
DM6AYDL DT Small molecular drug
DM6AYDL PC 447256
DM6AYDL MW 170.25
DM6AYDL FM C9H18N2O
DM6AYDL IC InChI=1S/C9H18N2O/c1-7(2)8(10)9(12)11-5-3-4-6-11/h7-8H,3-6,10H2,1-2H3/t8-/m0/s1
DM6AYDL CS CC(C)[C@@H](C(=O)N1CCCC1)N
DM6AYDL IK IHBAVXVTGLANPI-QMMMGPOBSA-N
DM6AYDL IU (2S)-2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one
DM6AYDL CA CAS 54164-07-7
DM6AYDL DE Discovery agent
DMXLZUA ID DMXLZUA
DMXLZUA DN 2-Amino-3-Oxo-4-Sulfo-Butyric Acid
DMXLZUA HS Investigative
DMXLZUA DT Small molecular drug
DMXLZUA PC 46936475
DMXLZUA MW 199.14
DMXLZUA FM C3H5NO7S
DMXLZUA IC InChI=1S/C3H5NO7S/c4-1(2(5)6)3(7)11-12(8,9)10/h1H,4H2,(H,5,6)(H,8,9,10)/t1-/m0/s1
DMXLZUA CS [C@H](C(=O)O)(C(=O)OS(=O)(=O)O)N
DMXLZUA IK RZIKAUMRZOEFET-SFOWXEAESA-N
DMXLZUA IU (2S)-2-amino-3-oxo-3-sulfooxypropanoic acid
DMXLZUA DE Discovery agent
DMTP3LD ID DMTP3LD
DMTP3LD DN 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMTP3LD HS Investigative
DMTP3LD SN CHEMBL234897; BDBM50213173
DMTP3LD DT Small molecular drug
DMTP3LD PC 44431964
DMTP3LD MW 311.5
DMTP3LD FM C21H29NO
DMTP3LD IC InChI=1S/C21H29NO/c1-4-5-6-9-14-21(2,3)16-12-13-18(20(23)15-16)17-10-7-8-11-19(17)22/h7-8,10-13,15,23H,4-6,9,14,22H2,1-3H3
DMTP3LD CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC=CC=C2N)O
DMTP3LD IK QCCUOHALIFFEGL-UHFFFAOYSA-N
DMTP3LD IU 2-(2-aminophenyl)-5-(2-methyloctan-2-yl)phenol
DMTP3LD DE Discovery agent
DMULSNQ ID DMULSNQ
DMULSNQ DN 2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid
DMULSNQ HS Investigative
DMULSNQ SN CHEMBL203743; 2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid; BDBM50179732
DMULSNQ DT Small molecular drug
DMULSNQ PC 44408323
DMULSNQ MW 239.34
DMULSNQ FM C12H17NO2S
DMULSNQ IC InChI=1S/C12H17NO2S/c1-9-4-2-3-5-10(9)8-16-7-6-11(13)12(14)15/h2-5,11H,6-8,13H2,1H3,(H,14,15)
DMULSNQ CS CC1=CC=CC=C1CSCCC(C(=O)O)N
DMULSNQ IK FWEMQWXSSVUTGP-UHFFFAOYSA-N
DMULSNQ IU 2-amino-4-[(2-methylphenyl)methylsulfanyl]butanoic acid
DMULSNQ DE Discovery agent
DMVN0EC ID DMVN0EC
DMVN0EC DN 2-Amino-4,6-di-furan-2-yl-nicotinonitrile
DMVN0EC HS Investigative
DMVN0EC SN CHEMBL506250; AC1MDUVT; 2-Amino-4,6-di-furan-2-yl-nicotinonitrile; SCHEMBL6252357; MolPort-002-903-619; ZINC20432232; BDBM50262441; MCULE-1490383880; SR-01000003798; SR-01000003798-1
DMVN0EC DT Small molecular drug
DMVN0EC PC 2817165
DMVN0EC MW 251.24
DMVN0EC FM C14H9N3O2
DMVN0EC IC InChI=1S/C14H9N3O2/c15-8-10-9(12-3-1-5-18-12)7-11(17-14(10)16)13-4-2-6-19-13/h1-7H,(H2,16,17)
DMVN0EC CS C1=COC(=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CO3
DMVN0EC IK BDULELAUBSFJFH-UHFFFAOYSA-N
DMVN0EC IU 2-amino-4,6-bis(furan-2-yl)pyridine-3-carbonitrile
DMVN0EC DE Discovery agent
DMVJXQ9 ID DMVJXQ9
DMVJXQ9 DN 2-amino-4,6-dimethylpyridine
DMVJXQ9 HS Investigative
DMVJXQ9 SN 2-AMINO-4,6-DIMETHYLPYRIDINE; 5407-87-4; 4,6-dimethylpyridin-2-amine; 6-Amino-2,4-lutidine; 2-Pyridinamine, 4,6-dimethyl-; 4,6-Dimethyl-2-pyridinamine; 4,6-Dimethyl-2-pyridylamine; Pyridine, 2-amino-4,6-dimethyl-; 2,4-Lutidine, 6-amino-; NSC 10731; 2-Amino-4,6-dimehtylpyridine; EINECS 226-470-9; UNII-7NVZ9DW9Q5; BRN 0002048; 7NVZ9DW9Q5; CHEMBL59925; 4,6-Dimethyl-2-aminopyridine; 2-amino-4,6-dimethyl pyridine; 4,6-Dimethyl-pyridin-2-ylamine; BRBUBVKGJRPRRD-UHFFFAOYSA-N; 2-Amino-4,6-dimethylpyridine, 99%; PubChem19956; AC1Q2ICQ
DMVJXQ9 DT Small molecular drug
DMVJXQ9 PC 21507
DMVJXQ9 MW 122.17
DMVJXQ9 FM C7H10N2
DMVJXQ9 IC InChI=1S/C7H10N2/c1-5-3-6(2)9-7(8)4-5/h3-4H,1-2H3,(H2,8,9)
DMVJXQ9 CS CC1=CC(=NC(=C1)N)C
DMVJXQ9 IK BRBUBVKGJRPRRD-UHFFFAOYSA-N
DMVJXQ9 IU 4,6-dimethylpyridin-2-amine
DMVJXQ9 CA CAS 5407-87-4
DMVJXQ9 DE Discovery agent
DMO69TS ID DMO69TS
DMO69TS DN 2-Amino-4,6-diphenyl-nicotinonitrile
DMO69TS HS Investigative
DMO69TS SN 2-amino-4,6-diphenylpyridine-3-carbonitrile; 2-Amino-4,6-diphenyl-nicotinonitrile; CHEMBL467387; 4604-06-2; CBDivE_000439; AC1LDJG4; TimTec1_000178; SCHEMBL4911494; CTK1D2047; DTXSID70349897; YFQVSTNNJZZYLY-UHFFFAOYSA-N; MolPort-000-994-643; HMS1534I02; C18H13N3; 2-amino-4,6-diphenylnicotinonitrile; ZINC18995588; STK831928; BDBM50262323; AKOS000286699; MCULE-4409959472; NCGC00175390-01; ST001238; EU-0034185; 2-Amino-4,6-diphenyl-3-pyridinecarbonitrile; 3-Pyridinecarbonitrile, 2-amino-4,6-diphenyl-; SR-01000395192; SR-01000395192-1
DMO69TS DT Small molecular drug
DMO69TS PC 668105
DMO69TS MW 271.3
DMO69TS FM C18H13N3
DMO69TS IC InChI=1S/C18H13N3/c19-12-16-15(13-7-3-1-4-8-13)11-17(21-18(16)20)14-9-5-2-6-10-14/h1-11H,(H2,20,21)
DMO69TS CS C1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CC=C3
DMO69TS IK YFQVSTNNJZZYLY-UHFFFAOYSA-N
DMO69TS IU 2-amino-4,6-diphenylpyridine-3-carbonitrile
DMO69TS CA CAS 4604-06-2
DMO69TS DE Discovery agent
DM1MOB9 ID DM1MOB9
DM1MOB9 DN 2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile
DM1MOB9 HS Investigative
DM1MOB9 SN CHEMBL259736; SCHEMBL6440910; JMXZSEAMWCKILY-UHFFFAOYSA-N; ZINC29063803; BDBM50375505; 2-amino-4,6-diphenylpyrimidine-5-carbonitrile
DM1MOB9 DT Small molecular drug
DM1MOB9 PC 18507264
DM1MOB9 MW 272.3
DM1MOB9 FM C17H12N4
DM1MOB9 IC InChI=1S/C17H12N4/c18-11-14-15(12-7-3-1-4-8-12)20-17(19)21-16(14)13-9-5-2-6-10-13/h1-10H,(H2,19,20,21)
DM1MOB9 CS C1=CC=C(C=C1)C2=C(C(=NC(=N2)N)C3=CC=CC=C3)C#N
DM1MOB9 IK JMXZSEAMWCKILY-UHFFFAOYSA-N
DM1MOB9 IU 2-amino-4,6-diphenylpyrimidine-5-carbonitrile
DM1MOB9 DE Discovery agent
DMI9YGU ID DMI9YGU
DMI9YGU DN 2-Amino-4,6-diphenyl-pyrimidine
DMI9YGU HS Investigative
DMI9YGU SN 4,6-diphenylpyrimidin-2-amine; 40230-24-8; 2-Amino-4,6-diphenylpyrimidine; 4,6-diphenyl-2- Pyrimidinamine; 4,6-Diphenyl-2-pyrimidinamine; CHEMBL261185; KZUCBEYDRUCBCS-UHFFFAOYSA-N; 2-Pyrimidinamine, 4,6-diphenyl-; AK136264; AC1LDIBD; Cambridge id 5109412; AC1Q52JN; CBDivE_006411; MLS001162904; SCHEMBL4904514; 4,6-Diphenylpyrimidine-2-amine; CTK1D4711; DTXSID20347207; MolPort-001-847-654; HMS2833A20; HMS1577A06; 4,6-Diphenyl-2-pyrimidinamine #; ZINC295268; KS-00001N3D; BDBM50375490; AKOS010263933; (4,6-diphenyl-pyrimidin-2-yl)-amine
DMI9YGU DT Small molecular drug
DMI9YGU PC 619024
DMI9YGU MW 247.29
DMI9YGU FM C16H13N3
DMI9YGU IC InChI=1S/C16H13N3/c17-16-18-14(12-7-3-1-4-8-12)11-15(19-16)13-9-5-2-6-10-13/h1-11H,(H2,17,18,19)
DMI9YGU CS C1=CC=C(C=C1)C2=CC(=NC(=N2)N)C3=CC=CC=C3
DMI9YGU IK KZUCBEYDRUCBCS-UHFFFAOYSA-N
DMI9YGU IU 4,6-diphenylpyrimidin-2-amine
DMI9YGU CA CAS 40230-24-8
DMI9YGU DE Discovery agent
DM53T8Q ID DM53T8Q
DM53T8Q DN 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile
DM53T8Q HS Investigative
DM53T8Q SN CHEMBL455264; 2-amino-4,6-di(2-thienyl)nicotinonitrile; AC1MDUJS; Maybridge3_002859; 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile; AK-245/12665006; MolPort-002-818-186; HMS1439B21; CCG-51878; BDBM50262435; ZINC19815853; MCULE-1768454862; IDI1_014246; SR-01000003726; SR-01000003726-1; 2-amino-4,6-dithiophen-2-ylpyridine-3-carbonitrile; SR-01000003726-2
DM53T8Q DT Small molecular drug
DM53T8Q PC 2817024
DM53T8Q MW 283.4
DM53T8Q FM C14H9N3S2
DM53T8Q IC InChI=1S/C14H9N3S2/c15-8-10-9(12-3-1-5-18-12)7-11(17-14(10)16)13-4-2-6-19-13/h1-7H,(H2,16,17)
DM53T8Q CS C1=CSC(=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CS3
DM53T8Q IK NMMNXFUCSNOZLW-UHFFFAOYSA-N
DM53T8Q IU 2-amino-4,6-dithiophen-2-ylpyridine-3-carbonitrile
DM53T8Q DE Discovery agent
DMP4NHD ID DMP4NHD
DMP4NHD DN 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile
DMP4NHD HS Investigative
DMP4NHD SN CHEMBL447192; 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile; 2-amino-4-(furan-2-yl)-6-phenylpyridine-3-carbonitrile; BAS 02565128; AC1LEWZ0; Oprea1_555020; SCHEMBL6250225; MolPort-001-022-735; HMS1617K16; STL308426; ZINC19608452; BDBM50262388; AKOS000670186; MCULE-4659467081; ST50302441; 2-amino-4-(2-furyl)-6-phenylnicotinonitrile; 2-amino-4-(2-furyl)-6-phenylpyridine-3-carbonitrile
DMP4NHD DT Small molecular drug
DMP4NHD PC 743242
DMP4NHD MW 261.279
DMP4NHD FM C16H11N3O
DMP4NHD IC InChI=1S/C16H11N3O/c17-10-13-12(15-7-4-8-20-15)9-14(19-16(13)18)11-5-2-1-3-6-11/h1-9H,(H2,18,19)
DMP4NHD CS C1=CC=C(C=C1)C2=NC(=C(C(=C2)C3=CC=CO3)C#N)N
DMP4NHD IK UPNSGUUFOFSFEZ-UHFFFAOYSA-N
DMP4NHD IU 2-amino-4-(furan-2-yl)-6-phenylpyridine-3-carbonitrile
DMP4NHD DE Discovery agent
DM1OED2 ID DM1OED2
DM1OED2 DN 2-amino-4-methylpyridine
DM1OED2 HS Investigative
DM1OED2 SN 2-Amino-4-methylpyridine; 4-METHYLPYRIDIN-2-AMINE; 695-34-1; 2-Amino-4-picoline; Ascensil; 2-Pyridinamine, 4-methyl-; 4-Methyl-2-pyridinamine; 4-Methyl-2-aminopyridine; 4-Methyl-2-pyridylamine; W 45 Raschig; 4-PICOLINE, 2-AMINO-; Methyl-4 amino-2-pyridine; 4M2AP; Pyridine, 2-amino-4-methyl-; 4-methylpyridin-2-ylamine; 2-amino-4-methyl pyridine; RA 1226; alpha-Amino-gamma-picoline; NSC 6972; NSC 1490; VMI 20-4; UNII-394N1Z644H; EINECS 211-780-9; 4-Methyl-pyridin-2-ylamine; BRN 0107066; W 45; CHEMBL40833; AI3-23984; C6H8N2; 4-methylpyridin-2-amine
DM1OED2 DT Small molecular drug
DM1OED2 PC 1533
DM1OED2 MW 108.14
DM1OED2 FM C6H8N2
DM1OED2 IC InChI=1S/C6H8N2/c1-5-2-3-8-6(7)4-5/h2-4H,1H3,(H2,7,8)
DM1OED2 CS CC1=CC(=NC=C1)N
DM1OED2 IK ORLGLBZRQYOWNA-UHFFFAOYSA-N
DM1OED2 IU 4-methylpyridin-2-amine
DM1OED2 CA CAS 695-34-1
DM1OED2 DE Discovery agent
DMRVTJ1 ID DMRVTJ1
DMRVTJ1 DN 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile
DMRVTJ1 HS Investigative
DMRVTJ1 SN CHEMBL476308; 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile; SCHEMBL6251249
DMRVTJ1 DT Small molecular drug
DMRVTJ1 PC 10423637
DMRVTJ1 MW 277.3
DMRVTJ1 FM C16H11N3S
DMRVTJ1 IC InChI=1S/C16H11N3S/c17-10-13-12(11-5-2-1-3-6-11)9-14(19-16(13)18)15-7-4-8-20-15/h1-9H,(H2,18,19)
DMRVTJ1 CS C1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CS3
DMRVTJ1 IK CMOAUWPKTBSUQT-UHFFFAOYSA-N
DMRVTJ1 IU 2-amino-4-phenyl-6-thiophen-2-ylpyridine-3-carbonitrile
DMRVTJ1 DE Discovery agent
DMOIZY1 ID DMOIZY1
DMOIZY1 DN 2-Amino-4-phosphono-butyric acid
DMOIZY1 HS Investigative
DMOIZY1 SN 2-amino-4-phosphonobutanoic acid; 6323-99-5; DL-AP4; 20263-07-4; DL-2-Amino-4-phosphonobutyric acid; Butanoic acid, 2-amino-4-phosphono-; BRN 5255932; CHEMBL285843; BUTYRIC ACID, 2-AMINO-4-PHOSPHONO-; MFCD00013999; L-2-amino-4-phosphonobutyrate; Abu(P); SR-01000075414; L-2-amino-4-phosphobutyric acid; L-AP4 cpd, butyric; AC1Q6RPJ; 4-Amino Phosphonobutyrate
DMOIZY1 DT Small molecular drug
DMOIZY1 PC 2207
DMOIZY1 MW 183.1
DMOIZY1 FM C4H10NO5P
DMOIZY1 IC InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)
DMOIZY1 CS C(CP(=O)(O)O)C(C(=O)O)N
DMOIZY1 IK DDOQBQRIEWHWBT-UHFFFAOYSA-N
DMOIZY1 IU 2-amino-4-phosphonobutanoic acid
DMOIZY1 CA CAS 6323-99-5
DMOIZY1 DE Discovery agent
DMDUZ2H ID DMDUZ2H
DMDUZ2H DN 2-Amino-5-(N-nitro-guanidino)-pentanoic acid
DMDUZ2H HS Investigative
DMDUZ2H SN CHEMBL353794; N-nitro-l-arg; KSC911C9L; SCHEMBL5271958; CTK8B1195; BDBM50049252; ANW-24471; ZINC27740002
DMDUZ2H DT Small molecular drug
DMDUZ2H PC 10198326
DMDUZ2H MW 219.2
DMDUZ2H FM C6H13N5O4
DMDUZ2H IC InChI=1S/C6H13N5O4/c7-4(5(12)13)2-1-3-10(6(8)9)11(14)15/h4H,1-3,7H2,(H3,8,9)(H,12,13)/t4-/m0/s1
DMDUZ2H CS C(C[C@@H](C(=O)O)N)CN(C(=N)N)[N+](=O)[O-]
DMDUZ2H IK ZXGQUZOHXHNDPE-BYPYZUCNSA-N
DMDUZ2H IU (2S)-2-amino-5-[carbamimidoyl(nitro)amino]pentanoic acid
DMDUZ2H DE Discovery agent
DMA7ZOW ID DMA7ZOW
DMA7ZOW DN 2-Amino-5-Hydroxy-Benzimidazole
DMA7ZOW HS Investigative
DMA7ZOW DT Small molecular drug
DMA7ZOW PC 162636
DMA7ZOW MW 149.15
DMA7ZOW FM C7H7N3O
DMA7ZOW IC InChI=1S/C7H7N3O/c8-7-9-5-2-1-4(11)3-6(5)10-7/h1-3,11H,(H3,8,9,10)
DMA7ZOW CS C1=CC2=C(C=C1O)NC(=N2)N
DMA7ZOW IK FNSYWIPPPFVBAV-UHFFFAOYSA-N
DMA7ZOW IU 2-amino-3H-benzimidazol-5-ol
DMA7ZOW CA CAS 51276-85-8
DMA7ZOW DE Discovery agent
DMOQ2R8 ID DMOQ2R8
DMOQ2R8 DN 2-amino-5-phenylthiophene-3-carboxamide
DMOQ2R8 HS Investigative
DMOQ2R8 SN 2-amino-5-phenylthiophene-3-carboxamide; 4815-35-4; 2-Amino-5-phenyl-thiophene-3-carboxylic acid amide; CHEMBL382565; 2-AMINO-5-PHENYL-3-THIOPHENECARBOXAMIDE; EN300-04586; AC1LDZKQ; ACMC-209kch; 3-thiophenecarboxamide, 2-amino-5-phenyl-; AC1Q5DNT; CBMicro_037044; Cambridge id 5914467; AC1Q4Z6N; Oprea1_326775; Oprea1_445444; SCHEMBL3510525; ZINC87504; CTK4J0691; DTXSID60351580; UHEGYTDIDBFUJD-UHFFFAOYSA-N; MolPort-000-223-057; HMS1757A19; ZX-AL001522; ANW-30639; STK346852; SBB015475; BDBM50186655; AKOS000274130; ACM4815354
DMOQ2R8 DT Small molecular drug
DMOQ2R8 PC 703965
DMOQ2R8 MW 218.28
DMOQ2R8 FM C11H10N2OS
DMOQ2R8 IC InChI=1S/C11H10N2OS/c12-10(14)8-6-9(15-11(8)13)7-4-2-1-3-5-7/h1-6H,13H2,(H2,12,14)
DMOQ2R8 CS C1=CC=C(C=C1)C2=CC(=C(S2)N)C(=O)N
DMOQ2R8 IK UHEGYTDIDBFUJD-UHFFFAOYSA-N
DMOQ2R8 IU 2-amino-5-phenylthiophene-3-carboxamide
DMOQ2R8 CA CAS 4815-35-4
DMOQ2R8 DE Discovery agent
DM3VJEZ ID DM3VJEZ
DM3VJEZ DN 2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile
DM3VJEZ HS Investigative
DM3VJEZ SN AC1LA8EL; 2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile; BDBM1791; CHEMBL293780; CTK7C6578; ZINC5933963; 2-Amino-6-arylthiobenzonitrile deriv. 3k; 2-(2-Bromophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-bromophenyl)sulfonylbenzonitrile; 2-amino-6-(2-bromophenyl)sulfonyl-benzonitrile; 2-amino-6-[(2-bromophenyl)sulfonyl]benzonitrile
DM3VJEZ DT Small molecular drug
DM3VJEZ PC 483455
DM3VJEZ MW 337.19
DM3VJEZ FM C13H9BrN2O2S
DM3VJEZ IC InChI=1S/C13H9BrN2O2S/c14-10-4-1-2-6-13(10)19(17,18)12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DM3VJEZ CS C1=CC=C(C(=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N)Br
DM3VJEZ IK WBNCALTXWWEQQV-UHFFFAOYSA-N
DM3VJEZ IU 2-amino-6-(2-bromophenyl)sulfonylbenzonitrile
DM3VJEZ DE Discovery agent
DMFW9D3 ID DMFW9D3
DMFW9D3 DN 2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile
DMFW9D3 HS Investigative
DMFW9D3 SN AC1LA8EC; 2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile; BDBM1788; CHEMBL301086; CTK7C6580; ZINC5933964; 2-Amino-6-arylthiobenzonitrile deriv. 3h; 2-amino-6-(2-chlorophenyl)sulfonylbenzonitrile; 2-(2-Chlorophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-chlorophenyl)sulfonyl-benzonitrile; 2-amino-6-[(2-chlorophenyl)sulfonyl]benzonitrile
DMFW9D3 DT Small molecular drug
DMFW9D3 PC 483452
DMFW9D3 MW 292.74
DMFW9D3 FM C13H9ClN2O2S
DMFW9D3 IC InChI=1S/C13H9ClN2O2S/c14-10-4-1-2-6-13(10)19(17,18)12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DMFW9D3 CS C1=CC=C(C(=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N)Cl
DMFW9D3 IK NXUSIYJXPBRFJT-UHFFFAOYSA-N
DMFW9D3 IU 2-amino-6-(2-chlorophenyl)sulfonylbenzonitrile
DMFW9D3 DE Discovery agent
DM7391H ID DM7391H
DM7391H DN 2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile
DM7391H HS Investigative
DM7391H SN 6-Amino-2-(2-chlorophenylthio)benzenecarbonitrile; AC1LAE0H; CHEMBL300757; BDBM1738; CTK7C6441; ZINC5933966; 2-Amino-6-arylthiobenzonitrile deriv. 1h; 2-Amino-6-[(2-chlorophenyl)thio]benzonitrile; 2-amino-6-(2-chlorophenyl)sulfanylbenzonitrile; 2-amino-6-(2-chlorophenyl)sulfanyl-benzonitrile
DM7391H DT Small molecular drug
DM7391H PC 486313
DM7391H MW 260.74
DM7391H FM C13H9ClN2S
DM7391H IC InChI=1S/C13H9ClN2S/c14-10-4-1-2-6-13(10)17-12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DM7391H CS C1=CC=C(C(=C1)SC2=CC=CC(=C2C#N)N)Cl
DM7391H IK ICAGMNDXSMYTTM-UHFFFAOYSA-N
DM7391H IU 2-amino-6-(2-chlorophenyl)sulfanylbenzonitrile
DM7391H DE Discovery agent
DM8O6AC ID DM8O6AC
DM8O6AC DN 2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile
DM8O6AC HS Investigative
DM8O6AC SN CHEMBL294212; 6-Amino-2-[(2-cyanophenyl)sulfinyl]benzenecarbonitrile; AC1LAE2N; BDBM1765; CTK7C8877; 6-Amino[2,2'-sulfinylbisbenzonitrile]; 2-Amino-6-arylthiobenzonitrile deriv. 2j; 2-amino-6-(2-cyanophenyl)sulfinylbenzonitrile; 2-amino-6-(2-cyanophenyl)sulfinyl-benzonitrile
DM8O6AC DT Small molecular drug
DM8O6AC PC 486339
DM8O6AC MW 267.31
DM8O6AC FM C14H9N3OS
DM8O6AC IC InChI=1S/C14H9N3OS/c15-8-10-4-1-2-6-13(10)19(18)14-7-3-5-12(17)11(14)9-16/h1-7H,17H2
DM8O6AC CS C1=CC=C(C(=C1)C#N)S(=O)C2=CC=CC(=C2C#N)N
DM8O6AC IK SAAMTBNDGHUYAE-UHFFFAOYSA-N
DM8O6AC IU 2-amino-6-(2-cyanophenyl)sulfinylbenzonitrile
DM8O6AC DE Discovery agent
DMRKQLV ID DMRKQLV
DMRKQLV DN 2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile
DMRKQLV HS Investigative
DMRKQLV SN 6-Amino-2-[(2-cyanophenyl)sulfonyl]benzenecarbonitrile; AC1LA8F0; CHEMBL298823; BDBM1796; CTK7C8868; ZINC5933865; 2-Amino-6-arylthiobenzonitrile deriv. 3p; 2-amino-6-(2-cyanophenyl)sulfonylbenzonitrile; 2-(2-Cyanophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-cyanophenyl)sulfonyl-benzonitrile
DMRKQLV DT Small molecular drug
DMRKQLV PC 483460
DMRKQLV MW 283.31
DMRKQLV FM C14H9N3O2S
DMRKQLV IC InChI=1S/C14H9N3O2S/c15-8-10-4-1-2-6-13(10)20(18,19)14-7-3-5-12(17)11(14)9-16/h1-7H,17H2
DMRKQLV CS C1=CC=C(C(=C1)C#N)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMRKQLV IK QVEQBYNJIDMTHN-UHFFFAOYSA-N
DMRKQLV IU 2-amino-6-(2-cyanophenyl)sulfonylbenzonitrile
DMRKQLV DE Discovery agent
DM8UQD5 ID DM8UQD5
DM8UQD5 DN 2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile
DM8UQD5 HS Investigative
DM8UQD5 SN 6-Amino-2-(2-cyanophenylthio)benzenecarbonitrile; AC1LAE0Z; CHEMBL59586; BDBM1744; CTK7C8878; ZINC5933866; 2-Amino-6-arylthiobenzonitrile deriv. 1n; 2-amino-6-(2-cyanophenyl)sulfanylbenzonitrile; 2-amino-6-(2-cyanophenyl)sulfanyl-benzonitrile
DM8UQD5 DT Small molecular drug
DM8UQD5 PC 486319
DM8UQD5 MW 251.31
DM8UQD5 FM C14H9N3S
DM8UQD5 IC InChI=1S/C14H9N3S/c15-8-10-4-1-2-6-13(10)18-14-7-3-5-12(17)11(14)9-16/h1-7H,17H2
DM8UQD5 CS C1=CC=C(C(=C1)C#N)SC2=CC=CC(=C2C#N)N
DM8UQD5 IK HZXBXUYNSPXXOH-UHFFFAOYSA-N
DM8UQD5 IU 2-amino-6-(2-cyanophenyl)sulfanylbenzonitrile
DM8UQD5 DE Discovery agent
DMBMK8S ID DMBMK8S
DMBMK8S DN 2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile
DMBMK8S HS Investigative
DMBMK8S SN AC1LA8EU; 2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile; CHEMBL53684; BDBM1794; CTK7C6581; ZINC5933932; 2-Amino-6-arylthiobenzonitrile deriv. 3n; 2-(2-Fluorophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-fluorophenyl)sulfonylbenzonitrile; 2-amino-6-(2-fluorophenyl)sulfonyl-benzonitrile; 2-amino-6-[(2-fluorophenyl)sulfonyl]benzonitrile
DMBMK8S DT Small molecular drug
DMBMK8S PC 483458
DMBMK8S MW 276.29
DMBMK8S FM C13H9FN2O2S
DMBMK8S IC InChI=1S/C13H9FN2O2S/c14-10-4-1-2-6-13(10)19(17,18)12-7-3-5-11(16)9(12)8-15/h1-7H,16H2
DMBMK8S CS C1=CC=C(C(=C1)F)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMBMK8S IK MBHOZDSUDFTYGO-UHFFFAOYSA-N
DMBMK8S IU 2-amino-6-(2-fluorophenyl)sulfonylbenzonitrile
DMBMK8S DE Discovery agent
DM0N5J4 ID DM0N5J4
DM0N5J4 DN 2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile
DM0N5J4 HS Investigative
DM0N5J4 SN 6-Amino-2-(2-methoxyphenylthio)benzenecarbonitrile; AC1LADZB; BDBM1732; CHEMBL292464; CTK7B1781; ZINC5929241; 2-Amino-6-arylthiobenzonitrile deriv. 1b; 2-Amino-6-[(2-methoxyphenyl)thio]benzonitrile; 2-amino-6-(2-methoxyphenyl)sulfanylbenzonitrile; 2-amino-6-[(2-methoxyphenyl)sulfanyl]benzonitrile
DM0N5J4 DT Small molecular drug
DM0N5J4 PC 486297
DM0N5J4 MW 256.32
DM0N5J4 FM C14H12N2OS
DM0N5J4 IC InChI=1S/C14H12N2OS/c1-17-12-6-2-3-7-14(12)18-13-8-4-5-11(16)10(13)9-15/h2-8H,16H2,1H3
DM0N5J4 CS COC1=CC=CC=C1SC2=CC=CC(=C2C#N)N
DM0N5J4 IK NZXQIIPHDSINPY-UHFFFAOYSA-N
DM0N5J4 IU 2-amino-6-(2-methoxyphenyl)sulfanylbenzonitrile
DM0N5J4 DE Discovery agent
DM6R98Y ID DM6R98Y
DM6R98Y DN 2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile
DM6R98Y HS Investigative
DM6R98Y SN CHEMBL55998; 6-Amino-2-[(3-bromophenyl)sulfinyl]benzenecarbonitrile; AC1LAE2H; BDBM1763; CTK7C6587; 2-Amino-6-arylthiobenzonitrile deriv. 2h; 2-amino-6-(3-bromophenyl)sulfinylbenzonitrile; 2-amino-6-(3-bromophenyl)sulfinyl-benzonitrile
DM6R98Y DT Small molecular drug
DM6R98Y PC 486337
DM6R98Y MW 321.19
DM6R98Y FM C13H9BrN2OS
DM6R98Y IC InChI=1S/C13H9BrN2OS/c14-9-3-1-4-10(7-9)18(17)13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DM6R98Y CS C1=CC(=CC(=C1)Br)S(=O)C2=CC=CC(=C2C#N)N
DM6R98Y IK JNNOSSLVLGASPM-UHFFFAOYSA-N
DM6R98Y IU 2-amino-6-(3-bromophenyl)sulfinylbenzonitrile
DM6R98Y DE Discovery agent
DMTUM78 ID DMTUM78
DMTUM78 DN 2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile
DMTUM78 HS Investigative
DMTUM78 SN AC1LA8EO; 2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile; CHEMBL293989; SCHEMBL2641656; BDBM1792; CTK7C6572; ZINC20483; 2-Amino-6-arylthiobenzonitrile deriv. 3l; 2-amino-6-(3-bromophenyl)sulfonylbenzonitrile; 2-(3-Bromophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(3-bromophenyl)sulfonyl-benzonitrile; 2-amino-6-[(3-bromophenyl)sulfonyl]benzonitrile
DMTUM78 DT Small molecular drug
DMTUM78 PC 483456
DMTUM78 MW 337.19
DMTUM78 FM C13H9BrN2O2S
DMTUM78 IC InChI=1S/C13H9BrN2O2S/c14-9-3-1-4-10(7-9)19(17,18)13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMTUM78 CS C1=CC(=CC(=C1)Br)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMTUM78 IK YZHGYTBCSXZBDO-UHFFFAOYSA-N
DMTUM78 IU 2-amino-6-(3-bromophenyl)sulfonylbenzonitrile
DMTUM78 DE Discovery agent
DMH4TRD ID DMH4TRD
DMH4TRD DN 2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile
DMH4TRD HS Investigative
DMH4TRD SN 6-Amino-2-(3-bromophenylthio)benzenecarbonitrile; AC1LAE0T; CHEMBL56465; BDBM1742; SCHEMBL2638192; ZINC20478; CTK7C6433; 2-Amino-6-arylthiobenzonitrile deriv. 1l; 2-amino-6-(3-bromophenyl)sulfanylbenzonitrile; 2-amino-6-(3-bromophenyl)sulfanyl-benzonitrile
DMH4TRD DT Small molecular drug
DMH4TRD PC 486317
DMH4TRD MW 305.19
DMH4TRD FM C13H9BrN2S
DMH4TRD IC InChI=1S/C13H9BrN2S/c14-9-3-1-4-10(7-9)17-13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMH4TRD CS C1=CC(=CC(=C1)Br)SC2=CC=CC(=C2C#N)N
DMH4TRD IK DAHSRCREKZVLOW-UHFFFAOYSA-N
DMH4TRD IU 2-amino-6-(3-bromophenyl)sulfanylbenzonitrile
DMH4TRD DE Discovery agent
DM9XKJQ ID DM9XKJQ
DM9XKJQ DN 2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile
DM9XKJQ HS Investigative
DM9XKJQ SN AC1LA8EF; 2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile; BDBM1789; CHEMBL291532; CTK7C6575; ZINC5933077; 2-Amino-6-arylthiobenzonitrile deriv. 3i; 2-amino-6-(3-chlorophenyl)sulfonylbenzonitrile; 2-(3-Chlorophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(3-chlorophenyl)sulfonyl-benzonitrile; 2-amino-6-[(3-chlorophenyl)sulfonyl]benzonitrile
DM9XKJQ DT Small molecular drug
DM9XKJQ PC 483453
DM9XKJQ MW 292.74
DM9XKJQ FM C13H9ClN2O2S
DM9XKJQ IC InChI=1S/C13H9ClN2O2S/c14-9-3-1-4-10(7-9)19(17,18)13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DM9XKJQ CS C1=CC(=CC(=C1)Cl)S(=O)(=O)C2=CC=CC(=C2C#N)N
DM9XKJQ IK AJPMQLQIJVLDJP-UHFFFAOYSA-N
DM9XKJQ IU 2-amino-6-(3-chlorophenyl)sulfonylbenzonitrile
DM9XKJQ DE Discovery agent
DMT3KP0 ID DMT3KP0
DMT3KP0 DN 2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile
DMT3KP0 HS Investigative
DMT3KP0 SN 6-Amino-2-(3-chlorophenylthio)benzenecarbonitrile; AC1LAE0K; CHEMBL55599; SCHEMBL2637932; BDBM1739; ZINC20476; CTK7C6436; 2-Amino-6-arylthiobenzonitrile deriv. 1i; 2-amino-6-(3-chlorophenyl)sulfanylbenzonitrile; 2-amino-6-(3-chlorophenyl)sulfanyl-benzonitrile
DMT3KP0 DT Small molecular drug
DMT3KP0 PC 486314
DMT3KP0 MW 260.74
DMT3KP0 FM C13H9ClN2S
DMT3KP0 IC InChI=1S/C13H9ClN2S/c14-9-3-1-4-10(7-9)17-13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMT3KP0 CS C1=CC(=CC(=C1)Cl)SC2=CC=CC(=C2C#N)N
DMT3KP0 IK IQGAOZOACGWEAI-UHFFFAOYSA-N
DMT3KP0 IU 2-amino-6-(3-chlorophenyl)sulfanylbenzonitrile
DMT3KP0 DE Discovery agent
DM9GQ1U ID DM9GQ1U
DM9GQ1U DN 2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile
DM9GQ1U HS Investigative
DM9GQ1U SN 6-Amino-2-[(3-cyanophenyl)sulfonyl]benzenecarbonitrile; AC1LA8F3; CHEMBL299271; BDBM1797; CTK7C8628; ZINC5933126; 2-Amino-6-arylthiobenzonitrile deriv. 3q; 2-amino-6-(3-cyanophenyl)sulfonylbenzonitrile; 2-(3-Cyanophenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(3-cyanophenyl)sulfonyl-benzonitrile
DM9GQ1U DT Small molecular drug
DM9GQ1U PC 483461
DM9GQ1U MW 283.31
DM9GQ1U FM C14H9N3O2S
DM9GQ1U IC InChI=1S/C14H9N3O2S/c15-8-10-3-1-4-11(7-10)20(18,19)14-6-2-5-13(17)12(14)9-16/h1-7H,17H2
DM9GQ1U CS C1=CC(=CC(=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N)C#N
DM9GQ1U IK PZWWWGPTXCTXOT-UHFFFAOYSA-N
DM9GQ1U IU 2-amino-6-(3-cyanophenyl)sulfonylbenzonitrile
DM9GQ1U DE Discovery agent
DM2MCK1 ID DM2MCK1
DM2MCK1 DN 2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile
DM2MCK1 HS Investigative
DM2MCK1 SN 6-Amino-2-(3-cyanophenylthio)benzenecarbonitrile; AC1LAE12; BDBM1745; CHEMBL293806; CTK7C8632; ZINC5933129; 6-Amino[2,3'-thiobisbenzonitrile]; 2-Amino-6-arylthiobenzonitrile deriv. 1o; 2-amino-6-(3-cyanophenyl)sulfanylbenzonitrile; 2-amino-6-(3-cyanophenyl)sulfanyl-benzonitrile
DM2MCK1 DT Small molecular drug
DM2MCK1 PC 486320
DM2MCK1 MW 251.31
DM2MCK1 FM C14H9N3S
DM2MCK1 IC InChI=1S/C14H9N3S/c15-8-10-3-1-4-11(7-10)18-14-6-2-5-13(17)12(14)9-16/h1-7H,17H2
DM2MCK1 CS C1=CC(=CC(=C1)SC2=CC=CC(=C2C#N)N)C#N
DM2MCK1 IK LZFWQHZSIBNMAA-UHFFFAOYSA-N
DM2MCK1 IU 2-amino-6-(3-cyanophenyl)sulfanylbenzonitrile
DM2MCK1 DE Discovery agent
DMG7HP2 ID DMG7HP2
DMG7HP2 DN 2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile
DMG7HP2 HS Investigative
DMG7HP2 SN 6-Amino-2-(3-fluorophenylthio)benzenecarbonitrile; AC1LAE0W; SCHEMBL2639266; BDBM1743; CHEMBL449041; CTK7C6437; ZINC20475; 2-Amino-6-arylthiobenzonitrile deriv. 1m; 2-amino-6-(3-fluorophenyl)sulfanylbenzonitrile; 2-amino-6-(3-fluorophenyl)sulfanyl-benzonitrile
DMG7HP2 DT Small molecular drug
DMG7HP2 PC 486318
DMG7HP2 MW 244.29
DMG7HP2 FM C13H9FN2S
DMG7HP2 IC InChI=1S/C13H9FN2S/c14-9-3-1-4-10(7-9)17-13-6-2-5-12(16)11(13)8-15/h1-7H,16H2
DMG7HP2 CS C1=CC(=CC(=C1)SC2=CC=CC(=C2C#N)N)F
DMG7HP2 IK ZJXCBXBCZFLMTP-UHFFFAOYSA-N
DMG7HP2 IU 2-amino-6-(3-fluorophenyl)sulfanylbenzonitrile
DMG7HP2 DE Discovery agent
DMACYWZ ID DMACYWZ
DMACYWZ DN 2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile
DMACYWZ HS Investigative
DMACYWZ SN 6-Amino-2-(3-methoxyphenylthio)benzenecarbonitrile; AC1LAE02; CHEMBL51738; BDBM1733; SCHEMBL8640275; ZINC20465; CTK7A9945; 2-Amino-6-arylthiobenzonitrile deriv. 1c; 2-amino-6-(3-methoxyphenyl)sulfanylbenzonitrile; 2-amino-6-(3-methoxyphenyl)sulfanyl-benzonitrile
DMACYWZ DT Small molecular drug
DMACYWZ PC 486308
DMACYWZ MW 256.32
DMACYWZ FM C14H12N2OS
DMACYWZ IC InChI=1S/C14H12N2OS/c1-17-10-4-2-5-11(8-10)18-14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DMACYWZ CS COC1=CC(=CC=C1)SC2=CC=CC(=C2C#N)N
DMACYWZ IK SHCOEGYZJNZDIW-UHFFFAOYSA-N
DMACYWZ IU 2-amino-6-(3-methoxyphenyl)sulfanylbenzonitrile
DMACYWZ DE Discovery agent
DML6EFV ID DML6EFV
DML6EFV DN 2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile
DML6EFV HS Investigative
DML6EFV SN 6-Amino-2-(4-chlorophenylthio)benzenecarbonitrile; AC1LAE0N; CHEMBL55747; BDBM1740; CTK7C6432; ZINC5932913; 2-Amino-6-arylthiobenzonitrile deriv. 1j; 2-amino-6-(4-chlorophenyl)sulfanylbenzonitrile; 2-amino-6-(4-chlorophenyl)sulfanyl-benzonitrile
DML6EFV DT Small molecular drug
DML6EFV PC 486315
DML6EFV MW 260.74
DML6EFV FM C13H9ClN2S
DML6EFV IC InChI=1S/C13H9ClN2S/c14-9-4-6-10(7-5-9)17-13-3-1-2-12(16)11(13)8-15/h1-7H,16H2
DML6EFV CS C1=CC(=C(C(=C1)SC2=CC=C(C=C2)Cl)C#N)N
DML6EFV IK GYICYNRXLTUTRB-UHFFFAOYSA-N
DML6EFV IU 2-amino-6-(4-chlorophenyl)sulfanylbenzonitrile
DML6EFV DE Discovery agent
DMECHD0 ID DMECHD0
DMECHD0 DN 2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one
DMECHD0 HS Investigative
DMECHD0 DT Small molecular drug
DMECHD0 PC 136044111
DMECHD0 MW 242.28
DMECHD0 FM C13H14N4O
DMECHD0 IC InChI=1S/C13H14N4O/c14-13-16-11(7-12(18)17-13)15-10-5-4-8-2-1-3-9(8)6-10/h4-7H,1-3H2,(H4,14,15,16,17,18)
DMECHD0 CS C1CC2=C(C1)C=C(C=C2)NC3=CC(=O)NC(=N3)N
DMECHD0 IK YUPQFUXJUXRXOG-UHFFFAOYSA-N
DMECHD0 IU 2-amino-4-(2,3-dihydro-1H-inden-5-ylamino)-1H-pyrimidin-6-one
DMECHD0 DE Discovery agent
DMXPWHF ID DMXPWHF
DMXPWHF DN 2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile
DMXPWHF HS Investigative
DMXPWHF SN CHEMBL297956; BDBM50422688; ZINC12354034
DMXPWHF DT Small molecular drug
DMXPWHF PC 10852315
DMXPWHF MW 308.4
DMXPWHF FM C17H12N2O2S
DMXPWHF IC InChI=1S/C17H12N2O2S/c18-11-14-15(19)8-4-10-17(14)22(20,21)16-9-3-6-12-5-1-2-7-13(12)16/h1-10H,19H2
DMXPWHF CS C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)C3=CC=CC(=C3C#N)N
DMXPWHF IK BMSIRAVUGDDUKN-UHFFFAOYSA-N
DMXPWHF IU 2-amino-6-naphthalen-1-ylsulfonylbenzonitrile
DMXPWHF DE Discovery agent
DMMKJYG ID DMMKJYG
DMMKJYG DN 2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile
DMMKJYG HS Investigative
DMMKJYG SN 2-Amino-6-arylthiobenzonitrile deriv. 3ff; AC1NS2PK; CHEMBL53043; BDBM1778; ZINC12354040; 2-(2-Naphthylsulfonyl)-6-aminobenzonitrile; 2-amino-6-naphthalen-2-ylsulfonylbenzonitrile
DMMKJYG DT Small molecular drug
DMMKJYG PC 5327619
DMMKJYG MW 308.4
DMMKJYG FM C17H12N2O2S
DMMKJYG IC InChI=1S/C17H12N2O2S/c18-11-15-16(19)6-3-7-17(15)22(20,21)14-9-8-12-4-1-2-5-13(12)10-14/h1-10H,19H2
DMMKJYG CS C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)C3=CC=CC(=C3C#N)N
DMMKJYG IK SSBDRFPTUIJDHD-UHFFFAOYSA-N
DMMKJYG IU 2-amino-6-naphthalen-2-ylsulfonylbenzonitrile
DMMKJYG DE Discovery agent
DMWGE3U ID DMWGE3U
DMWGE3U DN 2-Amino-6-(toluene-2-sulfonyl)-benzonitrile
DMWGE3U HS Investigative
DMWGE3U SN AC1LA8DU; 2-Amino-6-(toluene-2-sulfonyl)-benzonitrile; CHEMBL54444; BDBM1785; CTK7C6579; ZINC5931403; 2-amino-6-(o-tolylsulfonyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3e; 2-(2-Methylphenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-(2-methylphenyl)sulfonylbenzonitrile; 2-amino-6-[(2-methylbenzene)sulfonyl]benzonitrile
DMWGE3U DT Small molecular drug
DMWGE3U PC 483446
DMWGE3U MW 272.32
DMWGE3U FM C14H12N2O2S
DMWGE3U IC InChI=1S/C14H12N2O2S/c1-10-5-2-3-7-13(10)19(17,18)14-8-4-6-12(16)11(14)9-15/h2-8H,16H2,1H3
DMWGE3U CS CC1=CC=CC=C1S(=O)(=O)C2=CC=CC(=C2C#N)N
DMWGE3U IK YJZJHTMOZPILRK-UHFFFAOYSA-N
DMWGE3U IU 2-amino-6-(2-methylphenyl)sulfonylbenzonitrile
DMWGE3U DE Discovery agent
DMJXWH0 ID DMJXWH0
DMJXWH0 DN 2-Amino-6-(toluene-3-sulfinyl)-benzonitrile
DMJXWH0 HS Investigative
DMJXWH0 SN CHEMBL53893; 6-Amino-2-[(3-methylphenyl)sulfinyl]benzenecarbonitrile; AC1LAE28; BDBM1760; CTK7C6588; 2-amino-6-(m-tolylsulfinyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 2e; 2-amino-6-(3-methylphenyl)sulfinylbenzonitrile
DMJXWH0 DT Small molecular drug
DMJXWH0 PC 486334
DMJXWH0 MW 256.32
DMJXWH0 FM C14H12N2OS
DMJXWH0 IC InChI=1S/C14H12N2OS/c1-10-4-2-5-11(8-10)18(17)14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DMJXWH0 CS CC1=CC(=CC=C1)S(=O)C2=CC=CC(=C2C#N)N
DMJXWH0 IK VIFDNSNSPURBMX-UHFFFAOYSA-N
DMJXWH0 IU 2-amino-6-(3-methylphenyl)sulfinylbenzonitrile
DMJXWH0 DE Discovery agent
DM1EGP9 ID DM1EGP9
DM1EGP9 DN 2-Amino-6-(toluene-3-sulfonyl)-benzonitrile
DM1EGP9 HS Investigative
DM1EGP9 SN AC1LA8DX; 2-Amino-6-(toluene-3-sulfonyl)-benzonitrile; CHEMBL54600; BDBM1786; CTK7C6573; ZINC5931254; 2-amino-6-(m-tolylsulfonyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3f; 2-amino-6-(3-methylphenyl)sulfonylbenzonitrile; 2-(3-Methylphenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-[(3-methylphenyl)sulfonyl]benzonitrile
DM1EGP9 DT Small molecular drug
DM1EGP9 PC 483447
DM1EGP9 MW 272.32
DM1EGP9 FM C14H12N2O2S
DM1EGP9 IC InChI=1S/C14H12N2O2S/c1-10-4-2-5-11(8-10)19(17,18)14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DM1EGP9 CS CC1=CC(=CC=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N
DM1EGP9 IK KWHGWXMLBAGGOE-UHFFFAOYSA-N
DM1EGP9 IU 2-amino-6-(3-methylphenyl)sulfonylbenzonitrile
DM1EGP9 DE Discovery agent
DMB7415 ID DMB7415
DMB7415 DN 2-Amino-6-(toluene-4-sulfonyl)-benzonitrile
DMB7415 HS Investigative
DMB7415 SN 2-Amino-6-(toluene-4-sulfonyl)-benzonitrile; AC1LA8E0; CHEMBL53896; BDBM1787; CTK7C6568; ZINC5930941; 2-amino-6-(p-tolylsulfonyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3g; 2-amino-6-(4-methylphenyl)sulfonylbenzonitrile; 2-(4-Methylphenylsulfonyl)-6-aminobenzonitrile; 2-amino-6-[(4-methylbenzene)sulfonyl]benzonitrile
DMB7415 DT Small molecular drug
DMB7415 PC 483448
DMB7415 MW 272.32
DMB7415 FM C14H12N2O2S
DMB7415 IC InChI=1S/C14H12N2O2S/c1-10-5-7-11(8-6-10)19(17,18)14-4-2-3-13(16)12(14)9-15/h2-8H,16H2,1H3
DMB7415 CS CC1=CC=C(C=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMB7415 IK RDGYQSLTDBICQU-UHFFFAOYSA-N
DMB7415 IU 2-amino-6-(4-methylphenyl)sulfonylbenzonitrile
DMB7415 DE Discovery agent
DMJ4H9F ID DMJ4H9F
DMJ4H9F DN 2-Amino-6-benzenesulfonyl-benzonitrile
DMJ4H9F HS Investigative
DMJ4H9F SN 2-amino-6-(benzenesulfonyl)benzonitrile; 6-Amino-2-(phenylsulfonyl)benzenecarbonitrile; AC1LAE3B; CHEMBL55271; BDBM1781; CTK7C6577; ZINC5939149; 2-(Phenylsulfonyl)-6-aminobenzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 3a
DMJ4H9F DT Small molecular drug
DMJ4H9F PC 486347
DMJ4H9F MW 258.3
DMJ4H9F FM C13H10N2O2S
DMJ4H9F IC InChI=1S/C13H10N2O2S/c14-9-11-12(15)7-4-8-13(11)18(16,17)10-5-2-1-3-6-10/h1-8H,15H2
DMJ4H9F CS C1=CC=C(C=C1)S(=O)(=O)C2=CC=CC(=C2C#N)N
DMJ4H9F IK HVMPJKPAYPLWJZ-UHFFFAOYSA-N
DMJ4H9F IU 2-amino-6-(benzenesulfonyl)benzonitrile
DMJ4H9F DE Discovery agent
DMJVG30 ID DMJVG30
DMJVG30 DN 2-Amino-6-Chloropyrazine
DMJVG30 HS Investigative
DMJVG30 SN 2-AMINO-6-CHLOROPYRAZINE; 33332-28-4; 6-chloropyrazin-2-amine; 2-chloro-6-aminopyrazine; Pyrazinamine, 6-chloro-; 2-Pyrazinamine, 6-chloro-; 6-Chloro-pyrazin-2-ylamine; 6-chloropyrazin-2-ylamine; 2-amino-6-chloro-pyrazine; CHEMBL191632; 6-CHLORO-2-PYRAZINAMINE; CIG; 6-chlorpyrazin-2-amin; 1wcc; PubChem8543; zlchem 1337; AI3-61778; AC1Q3PRB; AC1L3MZH; ACMC-209i0e; 6-chloropyrazine-2-ylamine; SCHEMBL67803; 6-chloro-pyrazin-2-yl-amine; 6-chloropyrazin-2-amine, 5; KSC222G6J; AC1Q52Q1; Jsp006119; DTXSID0067761; CTK1C2364; BDBM24626; ZLE0115
DMJVG30 DT Small molecular drug
DMJVG30 PC 118458
DMJVG30 MW 129.55
DMJVG30 FM C4H4ClN3
DMJVG30 IC InChI=1S/C4H4ClN3/c5-3-1-7-2-4(6)8-3/h1-2H,(H2,6,8)
DMJVG30 CS C1=C(N=C(C=N1)Cl)N
DMJVG30 IK JTPXVCKCLBROOJ-UHFFFAOYSA-N
DMJVG30 IU 6-chloropyrazin-2-amine
DMJVG30 CA CAS 33332-28-4
DMJVG30 DE Discovery agent
DMUYTXS ID DMUYTXS
DMUYTXS DN 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile
DMUYTXS HS Investigative
DMUYTXS SN CHEMBL468370; 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile; SCHEMBL6254165
DMUYTXS DT Small molecular drug
DMUYTXS PC 24950370
DMUYTXS MW 261.279
DMUYTXS FM C16H11N3O
DMUYTXS IC InChI=1S/C16H11N3O/c17-10-13-12(11-5-2-1-3-6-11)9-14(19-16(13)18)15-7-4-8-20-15/h1-9H,(H2,18,19)
DMUYTXS CS C1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CO3
DMUYTXS IK ABFMBAYHWWNULS-UHFFFAOYSA-N
DMUYTXS IU 2-amino-6-(furan-2-yl)-4-phenylpyridine-3-carbonitrile
DMUYTXS DE Discovery agent
DMQF9H1 ID DMQF9H1
DMQF9H1 DN 2-Amino-6-m-tolylsulfanyl-benzonitrile
DMQF9H1 HS Investigative
DMQF9H1 SN 6-Amino-2-(3-methylphenylthio)benzenecarbonitrile; AC1LAE0B; CHEMBL296376; BDBM1736; SCHEMBL8641894; CTK7C6434; ZINC20466; 2-amino-6-(m-tolylsulfanyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 1f; 2-amino-6-(3-methylphenyl)sulfanylbenzonitrile
DMQF9H1 DT Small molecular drug
DMQF9H1 PC 486311
DMQF9H1 MW 240.33
DMQF9H1 FM C14H12N2S
DMQF9H1 IC InChI=1S/C14H12N2S/c1-10-4-2-5-11(8-10)17-14-7-3-6-13(16)12(14)9-15/h2-8H,16H2,1H3
DMQF9H1 CS CC1=CC(=CC=C1)SC2=CC=CC(=C2C#N)N
DMQF9H1 IK VGPLRZAJQWYFDD-UHFFFAOYSA-N
DMQF9H1 IU 2-amino-6-(3-methylphenyl)sulfanylbenzonitrile
DMQF9H1 DE Discovery agent
DMAXESK ID DMAXESK
DMAXESK DN 2-amino-6-phenyl-4-p-tolylnicotinonitrile
DMAXESK HS Investigative
DMAXESK SN CHEMBL376920; 2-amino-4-(4-methylphenyl)-6-phenylpyridine-3-carbonitrile; AC1LEZMJ; BAS 00789881; 2-amino-6-phenyl-4-p-tolylnicotinonitrile; MolPort-000-994-656; ZINC19818501; STK696423; BDBM50194811; AKOS000286711; MCULE-7406561707; ST4039142; 2-Amino-6-phenyl-4-p-tolyl-nicotinonitrile; SR-01000520248; SR-01000520248-1; 2-amino-3-cyano-4-(4-methylphenyl)-6-phenylpyridine; 2-amino-4-(4-methylphenyl)-6-phenyl-3-pyridyl cyanide; A1811/0076551
DMAXESK DT Small molecular drug
DMAXESK PC 695136
DMAXESK MW 285.3
DMAXESK FM C19H15N3
DMAXESK IC InChI=1S/C19H15N3/c1-13-7-9-14(10-8-13)16-11-18(15-5-3-2-4-6-15)22-19(21)17(16)12-20/h2-11H,1H3,(H2,21,22)
DMAXESK CS CC1=CC=C(C=C1)C2=CC(=NC(=C2C#N)N)C3=CC=CC=C3
DMAXESK IK ADSZRHDJWBZORK-UHFFFAOYSA-N
DMAXESK IU 2-amino-4-(4-methylphenyl)-6-phenylpyridine-3-carbonitrile
DMAXESK DE Discovery agent
DM7M9CL ID DM7M9CL
DM7M9CL DN 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile
DM7M9CL HS Investigative
DM7M9CL SN CHEMBL476298; AC1MNMTO; 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile; ZINC33468133; BDBM50262440; AKOS000286735
DM7M9CL DT Small molecular drug
DM7M9CL PC 3355253
DM7M9CL MW 277.3
DM7M9CL FM C16H11N3S
DM7M9CL IC InChI=1S/C16H11N3S/c17-10-13-12(15-7-4-8-20-15)9-14(19-16(13)18)11-5-2-1-3-6-11/h1-9H,(H2,18,19)
DM7M9CL CS C1=CC=C(C=C1)C2=NC(=C(C(=C2)C3=CC=CS3)C#N)N
DM7M9CL IK WFWGQLLRRFDTHC-UHFFFAOYSA-N
DM7M9CL IU 2-amino-6-phenyl-4-thiophen-2-ylpyridine-3-carbonitrile
DM7M9CL DE Discovery agent
DMMBGK0 ID DMMBGK0
DMMBGK0 DN 2-Amino-6-phenylsulfanyl-benzonitrile
DMMBGK0 HS Investigative
DMMBGK0 SN Benzonitrile, 2-amino-6-(phenylthio)-; 123241-49-6; 2-amino-6-phenylsulfanylbenzonitrile; 2-Amino-6-phenylsulfanyl-benzonitrile; AC1LADY2; ACMC-20b9p7; CHEMBL52068; SCHEMBL1772509; BDBM1731; CTK0C2943; DTXSID80333141; MPKFSGFZCBOCIQ-UHFFFAOYSA-N; ZINC5939158; 2-Amino-6-(phenylthio)benzonitrile; 6-Amino-2-phenylthiobenzenecarbonitrile; 2-amino-6-(phenylsulfanyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 1a
DMMBGK0 DT Small molecular drug
DMMBGK0 PC 486276
DMMBGK0 MW 226.3
DMMBGK0 FM C13H10N2S
DMMBGK0 IC InChI=1S/C13H10N2S/c14-9-11-12(15)7-4-8-13(11)16-10-5-2-1-3-6-10/h1-8H,15H2
DMMBGK0 CS C1=CC=C(C=C1)SC2=CC=CC(=C2C#N)N
DMMBGK0 IK MPKFSGFZCBOCIQ-UHFFFAOYSA-N
DMMBGK0 IU 2-amino-6-phenylsulfanylbenzonitrile
DMMBGK0 CA CAS 123241-49-6
DMMBGK0 DE Discovery agent
DM4BQ1W ID DM4BQ1W
DM4BQ1W DN 2-Amino-6-p-tolylsulfanyl-benzonitrile
DM4BQ1W HS Investigative
DM4BQ1W SN Benzonitrile, 2-amino-6-[(4-methylphenyl)thio]-; 168910-27-8; AC1LAE0E; 2-amino-6-(4-methylphenyl)sulfanylbenzonitrile; CHEMBL51912; BDBM1737; CTK0A8438; DTXSID00333143; ZINC5930943; 2-Amino-6-(p-tolylthio)benzonitrile; 2-amino-6-(p-tolylsulfanyl)benzonitrile; 2-Amino-6-arylthiobenzonitrile deriv. 1g; 2-amino-6-[(4-methylphenyl)sulfanyl]benzonitrile
DM4BQ1W DT Small molecular drug
DM4BQ1W PC 486312
DM4BQ1W MW 240.33
DM4BQ1W FM C14H12N2S
DM4BQ1W IC InChI=1S/C14H12N2S/c1-10-5-7-11(8-6-10)17-14-4-2-3-13(16)12(14)9-15/h2-8H,16H2,1H3
DM4BQ1W CS CC1=CC=C(C=C1)SC2=CC=CC(=C2C#N)N
DM4BQ1W IK NLGYCJNCIXKPHK-UHFFFAOYSA-N
DM4BQ1W IU 2-amino-6-(4-methylphenyl)sulfanylbenzonitrile
DM4BQ1W CA CAS 168910-27-8
DM4BQ1W DE Discovery agent
DMRSGC5 ID DMRSGC5
DMRSGC5 DN 2-amino-8-methyl-7,8-dihydropteridin-4(3H)-one
DMRSGC5 HS Investigative
DMRSGC5 DE Discovery agent
DMEMANH ID DMEMANH
DMEMANH DN 2-Amino-benzenesulfonamide
DMEMANH HS Investigative
DMEMANH SN 2-aminobenzenesulfonamide
DMEMANH DT Small molecular drug
DMEMANH PC 72894
DMEMANH MW 172.21
DMEMANH FM C6H8N2O2S
DMEMANH IC InChI=1S/C6H8N2O2S/c7-5-3-1-2-4-6(5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DMEMANH CS C1=CC=C(C(=C1)N)S(=O)(=O)N
DMEMANH IK YAZSBRQTAHVVGE-UHFFFAOYSA-N
DMEMANH IU 2-aminobenzenesulfonamide
DMEMANH CA CAS 3306-62-5
DMEMANH CB CHEBI:94579
DMEMANH DE Discovery agent
DM2OE1W ID DM2OE1W
DM2OE1W DN 2-Aminoethanimidic Acid
DM2OE1W HS Investigative
DM2OE1W SN 2-AMINOETHANIMIDIC ACID; 2-iminoethanamine; 2-aminoethylimine; 2-Aminoethanimine; AC1NBQ0B; (2E)-2-iminoethanamine; AKOS006363845
DM2OE1W DT Small molecular drug
DM2OE1W PC 4471892
DM2OE1W MW 58.08
DM2OE1W FM C2H6N2
DM2OE1W IC InChI=1S/C2H6N2/c3-1-2-4/h1,3H,2,4H2
DM2OE1W CS C(C=N)N
DM2OE1W IK AXQVKDQRBAXYBP-UHFFFAOYSA-N
DM2OE1W IU 2-iminoethanamine
DM2OE1W DE Discovery agent
DMUJC2E ID DMUJC2E
DMUJC2E DN 2'-aminoimidazolylmethyluracils
DMUJC2E HS Investigative
DMUJC2E DT Small molecular drug
DMUJC2E PC 56603742
DMUJC2E MW 243.65
DMUJC2E FM C8H10ClN5O2
DMUJC2E IC InChI=1S/C8H10ClN5O2/c9-5-4(12-8(16)13-6(5)15)3-14-2-1-11-7(14)10/h1-2,7,11H,3,10H2,(H2,12,13,15,16)
DMUJC2E CS C1=CN(C(N1)N)CC2=C(C(=O)NC(=O)N2)Cl
DMUJC2E IK VDNGDZIPDSUEKT-UHFFFAOYSA-N
DMUJC2E IU 6-[(2-amino-1,2-dihydroimidazol-3-yl)methyl]-5-chloro-1H-pyrimidine-2,4-dione
DMUJC2E DE Discovery agent
DMCUSH1 ID DMCUSH1
DMCUSH1 DN 2-Amino-indan-5-sulfonic acid
DMCUSH1 HS Investigative
DMCUSH1 SN 2-amino-2,3-dihydro-1H-indene-5-sulfonic acid
DMCUSH1 PC 44395769
DMCUSH1 MW 213.26
DMCUSH1 FM C9H11NO3S
DMCUSH1 IC InChI=1S/C9H11NO3S/c10-8-3-6-1-2-9(14(11,12)13)5-7(6)4-8/h1-2,5,8H,3-4,10H2,(H,11,12,13)
DMCUSH1 CS C1C(CC2=C1C=CC(=C2)S(=O)(=O)O)N
DMCUSH1 IK NVRZETXANFNFEF-UHFFFAOYSA-N
DMCUSH1 IU 2-amino-2,3-dihydro-1H-indene-5-sulfonic acid
DMCUSH1 DE Discovery agent
DMCJUWK ID DMCJUWK
DMCJUWK DN 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran
DMCJUWK HS Investigative
DMCJUWK SN CHEMBL461268; 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran; SCHEMBL2689197
DMCJUWK DT Small molecular drug
DMCJUWK PC 11644566
DMCJUWK MW 256.14
DMCJUWK FM C11H14BrNO
DMCJUWK IC InChI=1S/C11H14BrNO/c12-9-3-1-8(2-4-9)11-6-5-10(7-13)14-11/h1-4,10-11H,5-7,13H2
DMCJUWK CS C1CC(OC1CN)C2=CC=C(C=C2)Br
DMCJUWK IK NZCDMSTWUUULEH-UHFFFAOYSA-N
DMCJUWK IU [5-(4-bromophenyl)oxolan-2-yl]methanamine
DMCJUWK DE Discovery agent
DM3OTZY ID DM3OTZY
DM3OTZY DN 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran
DM3OTZY HS Investigative
DM3OTZY SN CHEMBL447825; [5-(4-chlorophenyl)oxolan-2-yl]methanamine; 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran; SCHEMBL2689896
DM3OTZY DT Small molecular drug
DM3OTZY PC 11506733
DM3OTZY MW 211.69
DM3OTZY FM C11H14ClNO
DM3OTZY IC InChI=1S/C11H14ClNO/c12-9-3-1-8(2-4-9)11-6-5-10(7-13)14-11/h1-4,10-11H,5-7,13H2
DM3OTZY CS C1CC(OC1CN)C2=CC=C(C=C2)Cl
DM3OTZY IK KHKLNHSDQIKVSU-UHFFFAOYSA-N
DM3OTZY IU [5-(4-chlorophenyl)oxolan-2-yl]methanamine
DM3OTZY DE Discovery agent
DM413ZB ID DM413ZB
DM413ZB DN 2-Aminomethyl-5-(phenyl)tetrahydrofuran
DM413ZB HS Investigative
DM413ZB SN (5-phenyloxolan-2-yl)methanamine; CHEMBL458639; 878661-56-4; 2-Aminomethyl-5-(phenyl)tetrahydrofuran; SCHEMBL2690113; MolPort-035-929-309
DM413ZB DT Small molecular drug
DM413ZB PC 11571886
DM413ZB MW 177.24
DM413ZB FM C11H15NO
DM413ZB IC InChI=1S/C11H15NO/c12-8-10-6-7-11(13-10)9-4-2-1-3-5-9/h1-5,10-11H,6-8,12H2
DM413ZB CS C1CC(OC1CN)C2=CC=CC=C2
DM413ZB IK IAIACGGIZWXQIK-UHFFFAOYSA-N
DM413ZB IU (5-phenyloxolan-2-yl)methanamine
DM413ZB DE Discovery agent
DMDG8FL ID DMDG8FL
DMDG8FL DN 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran
DMDG8FL HS Investigative
DMDG8FL SN CHEMBL451652; 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran; SCHEMBL2689310
DMDG8FL DT Small molecular drug
DMDG8FL PC 11658526
DMDG8FL MW 207.27
DMDG8FL FM C12H17NO2
DMDG8FL IC InChI=1S/C12H17NO2/c1-14-10-4-2-9(3-5-10)12-7-6-11(8-13)15-12/h2-5,11-12H,6-8,13H2,1H3
DMDG8FL CS COC1=CC=C(C=C1)C2CCC(O2)CN
DMDG8FL IK SUAFTJAVJHXARK-UHFFFAOYSA-N
DMDG8FL IU [5-(4-methoxyphenyl)oxolan-2-yl]methanamine
DMDG8FL DE Discovery agent
DME4P7K ID DME4P7K
DME4P7K DN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran
DME4P7K HS Investigative
DME4P7K SN CHEMBL447750; 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran; SCHEMBL2690807
DME4P7K DT Small molecular drug
DME4P7K PC 11651575
DME4P7K MW 233.35
DME4P7K FM C15H23NO
DME4P7K IC InChI=1S/C15H23NO/c1-15(2,3)12-6-4-11(5-7-12)14-9-8-13(10-16)17-14/h4-7,13-14H,8-10,16H2,1-3H3
DME4P7K CS CC(C)(C)C1=CC=C(C=C1)C2CCC(O2)CN
DME4P7K IK OOZOQFAQHUVOAM-UHFFFAOYSA-N
DME4P7K IU [5-(4-tert-butylphenyl)oxolan-2-yl]methanamine
DME4P7K DE Discovery agent
DMAN8EH ID DMAN8EH
DMAN8EH DN 2-Aminomethyl-pyrrolidine-3,4-diol
DMAN8EH HS Investigative
DMAN8EH SN CHEMBL79727; 2-Aminomethyl-pyrrolidine-3,4-diol
DMAN8EH DT Small molecular drug
DMAN8EH PC 11852460
DMAN8EH MW 132.16
DMAN8EH FM C5H12N2O2
DMAN8EH IC InChI=1S/C5H12N2O2/c6-1-3-5(9)4(8)2-7-3/h3-5,7-9H,1-2,6H2
DMAN8EH CS C1C(C(C(N1)CN)O)O
DMAN8EH IK PTUICKYMXFZVGV-UHFFFAOYSA-N
DMAN8EH IU 2-(aminomethyl)pyrrolidine-3,4-diol
DMAN8EH DE Discovery agent
DMESFTW ID DMESFTW
DMESFTW DN 2-amino-N-(quinolin-8-yl)benzenesulfonamide
DMESFTW HS Investigative
DMESFTW SN 2-Amino-N-quinolin-8-yl-benzenesulfonamide; 16082-64-7; CHEMBL256062; QBS; 2-amino-N-quinolin-8-ylbenzenesulfonamide; AC1LLN9A; Cambridge id 5175136; Oprea1_584159; CBDivE_007127; SCHEMBL460773; CTK4D0607; DTXSID90360049; NIOOKXAMJQVDGB-UHFFFAOYSA-N; ZINC758699; DNDI1417207; CCG-15219; BDBM50372507; MFCD00168987; AKOS000154013; NCGC00161683-02; NCGC00161683-01; NCGC00161683-04; NCGC00161683-03; 2-amino-n-quinoline-8-yl-benzenesulfonamide; AB00074880-01; 2-AMINO-N-QUINOLINE-8-YL-BENZENESULFONAM
DMESFTW DT Small molecular drug
DMESFTW PC 1070159
DMESFTW MW 299.3
DMESFTW FM C15H13N3O2S
DMESFTW IC InChI=1S/C15H13N3O2S/c16-12-7-1-2-9-14(12)21(19,20)18-13-8-3-5-11-6-4-10-17-15(11)13/h1-10,18H,16H2
DMESFTW CS C1=CC=C(C(=C1)N)S(=O)(=O)NC2=CC=CC3=C2N=CC=C3
DMESFTW IK NIOOKXAMJQVDGB-UHFFFAOYSA-N
DMESFTW IU 2-amino-N-quinolin-8-ylbenzenesulfonamide
DMESFTW CA CAS 16082-64-7
DMESFTW DE Discovery agent
DM3YI9P ID DM3YI9P
DM3YI9P DN 2-Amino-N,3,3-Trimethylbutanamide
DM3YI9P HS Investigative
DM3YI9P SN 2-AMINO-N,3,3-TRIMETHYLBUTANAMIDE; AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241
DM3YI9P DT Small molecular drug
DM3YI9P PC 3496445
DM3YI9P MW 144.21
DM3YI9P FM C7H16N2O
DM3YI9P IC InChI=1S/C7H16N2O/c1-7(2,3)5(8)6(10)9-4/h5H,8H2,1-4H3,(H,9,10)
DM3YI9P CS CC(C)(C)C(C(=O)NC)N
DM3YI9P IK BPKJNEIOHOEWLO-UHFFFAOYSA-N
DM3YI9P IU 2-amino-N,3,3-trimethylbutanamide
DM3YI9P CA CAS 515140-27-9
DM3YI9P DE Discovery agent
DMRY06D ID DMRY06D
DMRY06D DN 2-Amino-N-[4-(phenylmethoxy)phenyl]-acetamide
DMRY06D HS Investigative
DMRY06D SN N-[4-(Benzyloxy)phenyl]glycinamide; N-[4-(benzyloxy)phenyl]glycinamide; CHEMBL479960; Amino acid analog, 2; BDBM24243; MolPort-003-787-576; HMS3604F07; ZINC11957004; STL183976; BBL019466; AKOS008945725; DB07099; 2-amino-N-[4-(benzyloxy)phenyl]acetamide; 2-Amino-N-(4-benzyloxy-phenyl)-acetamide; T8777; 347A389
DMRY06D DT Small molecular drug
DMRY06D PC 22690393
DMRY06D MW 256.3
DMRY06D FM C15H16N2O2
DMRY06D IC InChI=1S/C15H16N2O2/c16-10-15(18)17-13-6-8-14(9-7-13)19-11-12-4-2-1-3-5-12/h1-9H,10-11,16H2,(H,17,18)
DMRY06D CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CN
DMRY06D IK YJPUATSIKWOSST-UHFFFAOYSA-N
DMRY06D IU 2-amino-N-(4-phenylmethoxyphenyl)acetamide
DMRY06D DE Discovery agent
DMQ30UY ID DMQ30UY
DMQ30UY DN 2-amino-N1-benzyl-N3-hydroxymalonamide
DMQ30UY HS Investigative
DMQ30UY SN CHEMBL219940
DMQ30UY DT Small molecular drug
DMQ30UY PC 16115628
DMQ30UY MW 223.23
DMQ30UY FM C10H13N3O3
DMQ30UY IC InChI=1S/C10H13N3O3/c11-8(10(15)13-16)9(14)12-6-7-4-2-1-3-5-7/h1-5,8,16H,6,11H2,(H,12,14)(H,13,15)
DMQ30UY CS C1=CC=C(C=C1)CNC(=O)C(C(=O)NO)N
DMQ30UY IK HVTWOBIOCPYSGH-UHFFFAOYSA-N
DMQ30UY IU 2-amino-N-benzyl-N'-hydroxypropanediamide
DMQ30UY DE Discovery agent
DM320RW ID DM320RW
DM320RW DN 2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide
DM320RW HS Investigative
DM320RW SN CHEMBL259164
DM320RW DT Small molecular drug
DM320RW PC 44449523
DM320RW MW 344.4
DM320RW FM C19H16N6O
DM320RW IC InChI=1S/C19H16N6O/c20-18-23-15(14-9-5-2-6-10-14)16-17(24-18)25(12-22-16)19(26)21-11-13-7-3-1-4-8-13/h1-10,12H,11H2,(H,21,26)(H2,20,23,24)
DM320RW CS C1=CC=C(C=C1)CNC(=O)N2C=NC3=C(N=C(N=C32)N)C4=CC=CC=C4
DM320RW IK MNONTGDJIJLFPU-UHFFFAOYSA-N
DM320RW IU 2-amino-N-benzyl-6-phenylpurine-9-carboxamide
DM320RW DE Discovery agent
DMBVGAO ID DMBVGAO
DMBVGAO DN 2-aminophenoxazine-3-one
DMBVGAO HS Investigative
DMBVGAO SN Questiomycin A; 2-Amino-3H-phenoxazin-3-one; 2-Aminophenoxazin-3-one; 1916-59-2; 2-Aminophenoxazon; 2-Aminophenoxazone; 3-Aminophenoxazone; 2-Amino-3-phenoxazone; 3H-Phenoxazin-3-one, 2-amino-; Isophenoxazine; 2-amino-phenoxazin-3-one; NSC 94945; MLS000736964; CHEBI:17293; SMR000528446; BRN 0014215; Questinomycine A; 3H-Phenoxazin-3-one,2-amino-; AV toxin C; 2-Aminophenoxazinone; Phx-3 cpd; Phx-3; 2-amino-3-phenoxazinone; 2-azanylphenoxazin-3-one; Acrospermum viticola toxin C; NCIOpen2_006212; 4-27-00-05519 (Beilstein Handbook Reference); cid_72725; CHEMBL146710; SCHEMBL2609261; BDBM76155; DTXSID60172691; HMS2270F19; NSC94945; ZINC4095812; MFCD00207317; NSC-94945; 2-acetylamino-(3h)-phenoxazin-3-one; AKOS027339724; NCGC00246903-01; AS-47041; C02161; J-012388; BRD-K66640612-001-05-8; Q15424786
DMBVGAO DT Small molecular drug
DMBVGAO PC 72725
DMBVGAO MW 212.2
DMBVGAO FM C12H8N2O2
DMBVGAO IC InChI=1S/C12H8N2O2/c13-7-5-9-12(6-10(7)15)16-11-4-2-1-3-8(11)14-9/h1-6H,13H2
DMBVGAO CS C1=CC=C2C(=C1)N=C3C=C(C(=O)C=C3O2)N
DMBVGAO IK RDJXPXHQENRCNG-UHFFFAOYSA-N
DMBVGAO IU 2-aminophenoxazin-3-one
DMBVGAO CA CAS 1916-59-2
DMBVGAO CB CHEBI:17293
DMBVGAO DE T-cell leukaemia
DMQIC3L ID DMQIC3L
DMQIC3L DN 2-aminopyridine
DMQIC3L HS Investigative
DMQIC3L SN 2-AMINOPYRIDINE; 504-29-0; pyridin-2-amine; 2-Pyridinamine; 2-Pyridylamine; Aminopyridine; Pyridinamine; o-Aminopyridine; 2-aminopyridin; 2-Aminopryidine; Amino-2 pyridine; Pyridine, 2-amino-; 1,2-Dihydro-2-iminopyridine; alpha-Pyridylamine; alpha-Pyridinamine; 2-Pyridinylnitrene; alpha-Aminopyridine; Pyridin-2-ylamine; NSC 431; UNII-WSX981HEWU; 2-pyridinylamine; 2-amino pyridine; Pyridine, amino-; pyridin-2-yl-amine; .beta.-Pyridylamine; .alpha.-Pyridylamine; .alpha.-Pyridinamine; CCRIS 4747; .alpha.-Aminopyridine; 26445-05-6; HSDB 206
DMQIC3L DT Small molecular drug
DMQIC3L PC 10439
DMQIC3L MW 94.11
DMQIC3L FM C5H6N2
DMQIC3L IC InChI=1S/C5H6N2/c6-5-3-1-2-4-7-5/h1-4H,(H2,6,7)
DMQIC3L CS C1=CC=NC(=C1)N
DMQIC3L IK ICSNLGPSRYBMBD-UHFFFAOYSA-N
DMQIC3L IU pyridin-2-amine
DMQIC3L CA CAS 504-29-0
DMQIC3L DE Discovery agent
DMJW4CS ID DMJW4CS
DMJW4CS DN 2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide
DMJW4CS HS Investigative
DMJW4CS SN CHEMBL235988; 2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide
DMJW4CS DT Small molecular drug
DMJW4CS PC 24749595
DMJW4CS MW 343.18
DMJW4CS FM C15H11BrN4O
DMJW4CS IC InChI=1S/C15H11BrN4O/c16-9-5-7-10(8-6-9)18-14(21)13-11-3-1-2-4-12(11)19-15(17)20-13/h1-8H,(H,18,21)(H2,17,19,20)
DMJW4CS CS C1=CC=C2C(=C1)C(=NC(=N2)N)C(=O)NC3=CC=C(C=C3)Br
DMJW4CS IK DYTZVUGMYADHJM-UHFFFAOYSA-N
DMJW4CS IU 2-amino-N-(4-bromophenyl)quinazoline-4-carboxamide
DMJW4CS DE Discovery agent
DMQJYX7 ID DMQJYX7
DMQJYX7 DN 2-aminoquinazoline-4-carboxyanilide
DMQJYX7 HS Investigative
DMQJYX7 SN CHEMBL238091; 2-aminoquinazoline-4-carboxyanilide; SCHEMBL3086622
DMQJYX7 DT Small molecular drug
DMQJYX7 PC 24749831
DMQJYX7 MW 264.28
DMQJYX7 FM C15H12N4O
DMQJYX7 IC InChI=1S/C15H12N4O/c16-15-18-12-9-5-4-8-11(12)13(19-15)14(20)17-10-6-2-1-3-7-10/h1-9H,(H,17,20)(H2,16,18,19)
DMQJYX7 CS C1=CC=C(C=C1)NC(=O)C2=NC(=NC3=CC=CC=C32)N
DMQJYX7 IK FXATZDLBKVHWOG-UHFFFAOYSA-N
DMQJYX7 IU 2-amino-N-phenylquinazoline-4-carboxamide
DMQJYX7 DE Discovery agent
DME4856 ID DME4856
DME4856 DN 2-amino-quinoline-3-carboxylic acid amide
DME4856 HS Investigative
DME4856 SN 2-aminoquinoline-3-carboxamide; 31407-28-0; 3-Quinolinecarboxamide, 2-amino-; 2-amino-quinoline-3-carboxylic acid amide; 2-amino-3-quinolinecarboxamide; CHEMBL206956; GXZOXGRLLFZVGF-UHFFFAOYSA-N; ZERO/004541; AC1NP94V; SCHEMBL30837; CTK7D2638; MolPort-002-742-881; ZX-AN021879; ALBB-023365; STK735522; BDBM50186621; SBB012747; ZINC19890815; FCH854771; AKOS003368785; MCULE-6676169786; NCGC00340196-01; 2-Aminoquinoline-3-carboxylic acid amide; OR346178; KB-118564; 2-amino-3-quinolinecarboxamide, AldrichCPR; ST4128359; R9463
DME4856 DT Small molecular drug
DME4856 PC 5200228
DME4856 MW 187.2
DME4856 FM C10H9N3O
DME4856 IC InChI=1S/C10H9N3O/c11-9-7(10(12)14)5-6-3-1-2-4-8(6)13-9/h1-5H,(H2,11,13)(H2,12,14)
DME4856 CS C1=CC=C2C(=C1)C=C(C(=N2)N)C(=O)N
DME4856 IK GXZOXGRLLFZVGF-UHFFFAOYSA-N
DME4856 IU 2-aminoquinoline-3-carboxamide
DME4856 CA CAS 31407-28-0
DME4856 DE Discovery agent
DM9YCAH ID DM9YCAH
DM9YCAH DN 2-Aminothiazoline
DM9YCAH HS Investigative
DM9YCAH SN 2-Amino-2-thiazoline; 1779-81-3; 4,5-dihydrothiazol-2-amine; 2-Iminothiazolidine; 2-Thiazolidinimine; 2-Thiazolamine, 4,5-dihydro-; 2-Amino-4,5-dihydrothiazole; 2-Thiazoline, 2-amino-; 4,5-Dihydro-1,3-thiazol-2-amine; USAF PD-57; 2-Amino-4,5-dihydrothiazoline; 4,5-DIHYDRO-2-THIAZOLAMINE; 2-Thiazolin-2-ylamine; 2-Aminothiazoline (VAN); UNII-5JC2YZG56Q; NSC 3110; NSC 24626; Thiazolidin-(2E)-ylideneamine; 2-Amino-DELTA2-thiazoline; EINECS 217-224-1; 5JC2YZG56Q; CHEMBL362148; 2-Amino-2-thiazoline, 97%
DM9YCAH DT Small molecular drug
DM9YCAH PC 15689
DM9YCAH MW 102.16
DM9YCAH FM C3H6N2S
DM9YCAH IC InChI=1S/C3H6N2S/c4-3-5-1-2-6-3/h1-2H2,(H2,4,5)
DM9YCAH CS C1CSC(=N1)N
DM9YCAH IK REGFWZVTTFGQOJ-UHFFFAOYSA-N
DM9YCAH IU 4,5-dihydro-1,3-thiazol-2-amine
DM9YCAH CA CAS 1779-81-3
DM9YCAH CB CHEBI:40889
DM9YCAH DE Discovery agent
DMO792L ID DMO792L
DMO792L DN 2-amino-uridine-5'-monophosphate
DMO792L HS Investigative
DMO792L SN iso-CMP; compound 13g [PMID: 21417463]
DMO792L DT Small molecular drug
DMO792L PC 49867142
DMO792L MW 323.2
DMO792L FM C9H14N3O8P
DMO792L IC InChI=1S/C9H14N3O8P/c10-9-11-5(13)1-2-12(9)8-7(15)6(14)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,14-15H,3H2,(H2,10,11,13)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMO792L CS C1=CN(C(=NC1=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DMO792L IK ONSQLDCEJIIUJS-XVFCMESISA-N
DMO792L IU [(2R,3S,4R,5R)-5-(2-amino-4-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMO792L DE Discovery agent
DMFNEZW ID DMFNEZW
DMFNEZW DN 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
DMFNEZW HS Investigative
DMFNEZW SN 2-Anilino-6-cyclohexylmethoxypurine; 2-anilino-6-cyclohexylmethoxypurine; 6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine; CHEMBL122264; 444722-80-9; 2A6; NU-6094; 1h1q; AC1L1BOU; SCHEMBL6791643; BDBM5530; CTK1D2421; DTXSID30274313; XWWRLKIBRPJQJX-UHFFFAOYSA-N; O6-Cyclohexylmethylguanine deriv 2; AKOS030619892; DB06948; N-Phenyl-6-(cyclohexylmethoxy)-9H-purine-2-amine; 6-(cyclohexylmethoxy)-N-phenyl-9H-purin-2-amine; 1H-Purin-2-amine,
DMFNEZW DT Small molecular drug
DMFNEZW PC 1540
DMFNEZW MW 323.4
DMFNEZW FM C18H21N5O
DMFNEZW IC InChI=1S/C18H21N5O/c1-3-7-13(8-4-1)11-24-17-15-16(20-12-19-15)22-18(23-17)21-14-9-5-2-6-10-14/h2,5-6,9-10,12-13H,1,3-4,7-8,11H2,(H2,19,20,21,22,23)
DMFNEZW CS C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=CC=C4
DMFNEZW IK XWWRLKIBRPJQJX-UHFFFAOYSA-N
DMFNEZW IU 6-(cyclohexylmethoxy)-N-phenyl-7H-purin-2-amine
DMFNEZW CA CAS 444722-80-9
DMFNEZW DE Discovery agent
DM9AKVR ID DM9AKVR
DM9AKVR DN 2-APB
DM9AKVR HS Investigative
DM9AKVR SN 2-aminoethoxydiphenyl borate; 2-aminoethoxydiphenylborane
DM9AKVR DT Small molecular drug
DM9AKVR PC 1598
DM9AKVR MW 225.1
DM9AKVR FM C14H16BNO
DM9AKVR IC InChI=1S/C14H16BNO/c16-11-12-17-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10H,11-12,16H2
DM9AKVR CS B(C1=CC=CC=C1)(C2=CC=CC=C2)OCCN
DM9AKVR IK BLZVCIGGICSWIG-UHFFFAOYSA-N
DM9AKVR IU 2-diphenylboranyloxyethanamine
DM9AKVR CA CAS 524-95-8
DM9AKVR CB CHEBI:131184
DM9AKVR DE Discovery agent
DMM0KOJ ID DMM0KOJ
DMM0KOJ DN 2-arachidonoylglycerol
DMM0KOJ HS Investigative
DMM0KOJ SN 2-arachidonoylglycerol; 2-AG; 2-Arachidonylglycerol; 2-Arachidonyl-glycerol; 53847-30-6; 2-Arachidonoyl-glycerol; 2-Arachidonoyl Glycerol; 2-Ara-Gl; 2-Monoarachidonoylglycerol; UNII-8D239QDW64; 1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate; CHEMBL122972; CHEBI:52392; RCRCTBLIHCHWDZ-DOFZRALJSA-N; 8D239QDW64; MG(20:4); MG(0:0/20:4(5Z,8Z,11Z,14Z)/0:0); 5,8,11,14-Eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester, (5Z,8Z,11Z,14Z)-; 5,8,11,14-Eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethy
DMM0KOJ DT Small molecular drug
DMM0KOJ PC 5282280
DMM0KOJ MW 378.5
DMM0KOJ FM C23H38O4
DMM0KOJ IC InChI=1S/C23H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)27-22(20-24)21-25/h6-7,9-10,12-13,15-16,22,24-25H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMM0KOJ CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)OC(CO)CO
DMM0KOJ IK RCRCTBLIHCHWDZ-DOFZRALJSA-N
DMM0KOJ IU 1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
DMM0KOJ CA CAS 53847-30-6
DMM0KOJ CB CHEBI:52392
DMM0KOJ DE Discovery agent
DMICOL3 ID DMICOL3
DMICOL3 DN 2-arachidonoylglycerolphosphoinositol
DMICOL3 HS Investigative
DMICOL3 SN 2-arachidonoyl-glycerol-phosphoinositol; arachidonoyl LPI
DMICOL3 DT Small molecular drug
DMICOL3 PC 73755068
DMICOL3 MW 619.7
DMICOL3 FM C29H48O12P-
DMICOL3 IC InChI=1S/C29H49O12P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(31)40-22(20-30)21-39-42(37,38)41-29-27(35)25(33)24(32)26(34)28(29)36/h6-7,9-10,12-13,15-16,22,24-30,32-36H,2-5,8,11,14,17-21H2,1H3,(H,37,38)/p-1/b7-6-,10-9-,13-12-,16-15-
DMICOL3 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)OC(CO)COP(=O)([O-])OC1C(C(C(C(C1O)O)O)O)O
DMICOL3 IK OKEQUIXTUXJQNT-DOFZRALJSA-M
DMICOL3 IU [3-hydroxy-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxypropyl] (2,3,4,5,6-pentahydroxycyclohexyl) phosphate
DMICOL3 DE Discovery agent
DM2H8TV ID DM2H8TV
DM2H8TV DN 2-arachidonyl glyceryl ether
DM2H8TV HS Investigative
DM2H8TV SN Noladin ether; HU 310; 2-AG ether; 2-arachidonylglyceryl ether
DM2H8TV DT Small molecular drug
DM2H8TV PC 6483057
DM2H8TV MW 364.6
DM2H8TV FM C23H40O3
DM2H8TV IC InChI=1S/C23H40O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26-23(21-24)22-25/h6-7,9-10,12-13,15-16,23-25H,2-5,8,11,14,17-22H2,1H3/b7-6-,10-9-,13-12-,16-15-
DM2H8TV CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCOC(CO)CO
DM2H8TV IK CUJUUWXZAQHCNC-DOFZRALJSA-N
DM2H8TV IU 2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoxy]propane-1,3-diol
DM2H8TV CA CAS 222723-55-9
DM2H8TV CB CHEBI:75913
DM2H8TV DE Discovery agent
DMBSDIV ID DMBSDIV
DMBSDIV DN 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine
DMBSDIV HS Investigative
DMBSDIV SN CHEMBL384425; 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine
DMBSDIV DT Small molecular drug
DMBSDIV PC 16094571
DMBSDIV MW 322.28
DMBSDIV FM C11H14N8O4
DMBSDIV IC InChI=1S/C11H14N8O4/c1-13-8-5-9(16-11(15-8)17-18-12)19(3-14-5)10-7(22)6(21)4(2-20)23-10/h3-4,6-7,10,20-22H,2H2,1H3,(H,13,15,16)/t4-,6-,7-,10-/m1/s1
DMBSDIV CS CNC1=C2C(=NC(=N1)N=[N+]=[N-])N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMBSDIV IK CAQREKOGAXNCLL-KQYNXXCUSA-N
DMBSDIV IU (2R,3R,4S,5R)-2-[2-azido-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMBSDIV DE Discovery agent
DMXZ1HL ID DMXZ1HL
DMXZ1HL DN 2-Benzhydryl-7-hydroxy-chromen-4-one
DMXZ1HL HS Investigative
DMXZ1HL SN CHEMBL292697; 2-benzhydryl-7-hydroxy-chromen-4-one; 2-Benzhydryl-7-hydroxychromone
DMXZ1HL DT Small molecular drug
DMXZ1HL PC 10711364
DMXZ1HL MW 328.4
DMXZ1HL FM C22H16O3
DMXZ1HL IC InChI=1S/C22H16O3/c23-17-11-12-18-19(24)14-21(25-20(18)13-17)22(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-14,22-23H
DMXZ1HL CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=CC(=O)C4=C(O3)C=C(C=C4)O
DMXZ1HL IK VVMXRAGTHNZYRJ-UHFFFAOYSA-N
DMXZ1HL IU 2-benzhydryl-7-hydroxychromen-4-one
DMXZ1HL DE Discovery agent
DMQX9PD ID DMQX9PD
DMQX9PD DN 2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMQX9PD HS Investigative
DMQX9PD SN CHEMBL1098228; 2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMQX9PD DT Small molecular drug
DMQX9PD PC 46888005
DMQX9PD MW 350.4
DMQX9PD FM C24H18N2O
DMQX9PD IC InChI=1S/C24H18N2O/c1-17-7-8-19-9-10-21(14-23(19)26-17)20-11-12-24(22(13-20)15-25)27-16-18-5-3-2-4-6-18/h2-14H,16H2,1H3
DMQX9PD CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(C=C3)OCC4=CC=CC=C4)C#N
DMQX9PD IK INOCIGKWKFGOCI-UHFFFAOYSA-N
DMQX9PD IU 5-(2-methylquinolin-7-yl)-2-phenylmethoxybenzonitrile
DMQX9PD DE Discovery agent
DMO97FR ID DMO97FR
DMO97FR DN 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile
DMO97FR HS Investigative
DMO97FR SN Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
DMO97FR DT Small molecular drug
DMO97FR PC 5328763
DMO97FR MW 265.26
DMO97FR FM C16H11NO3
DMO97FR IC InChI=1S/C16H11NO3/c17-10-13(16(20)12-4-2-1-3-5-12)8-11-6-7-14(18)15(19)9-11/h1-9,18-19H/b13-8+
DMO97FR CS C1=CC=C(C=C1)C(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N
DMO97FR IK QBKFKKGORMOFFU-MDWZMJQESA-N
DMO97FR IU (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
DMO97FR DE Discovery agent
DMGEFQP ID DMGEFQP
DMGEFQP DN 2-benzoylaminoquinazoline-4-carboxyanilide
DMGEFQP HS Investigative
DMGEFQP SN CHEMBL239194; 2-benzoylaminoquinazoline-4-carboxyanilide
DMGEFQP DT Small molecular drug
DMGEFQP PC 24749708
DMGEFQP MW 368.4
DMGEFQP FM C22H16N4O2
DMGEFQP IC InChI=1S/C22H16N4O2/c27-20(15-9-3-1-4-10-15)26-22-24-18-14-8-7-13-17(18)19(25-22)21(28)23-16-11-5-2-6-12-16/h1-14H,(H,23,28)(H,24,25,26,27)
DMGEFQP CS C1=CC=C(C=C1)C(=O)NC2=NC3=CC=CC=C3C(=N2)C(=O)NC4=CC=CC=C4
DMGEFQP IK RQQPFMNLXURQFV-UHFFFAOYSA-N
DMGEFQP IU 2-benzamido-N-phenylquinazoline-4-carboxamide
DMGEFQP DE Discovery agent
DM1CB5J ID DM1CB5J
DM1CB5J DN 2-Benzyl-1,2-dihydro-indazol-3-one
DM1CB5J HS Investigative
DM1CB5J SN 2-Benzyl-1,2-dihydro-indazol-3-one; 1848-46-0; CHEMBL1984519; NSC34822; 2-benzyl-1H-indazol-3-one; SCHEMBL9645952; CHEMBL267523; AC1L91I6; CTK4D8835; DTXSID40328538; 2-Benzyl-1H-indazol-3(2H)-one; ZINC1667231; NSC-34822; BDBM50009000; AKOS015963502; FCH2821694; ACM1848460; NCI60_003094
DM1CB5J DT Small molecular drug
DM1CB5J PC 411523
DM1CB5J MW 224.26
DM1CB5J FM C14H12N2O
DM1CB5J IC InChI=1S/C14H12N2O/c17-14-12-8-4-5-9-13(12)15-16(14)10-11-6-2-1-3-7-11/h1-9,15H,10H2
DM1CB5J CS C1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3N2
DM1CB5J IK IBMDKBAGSDBZIJ-UHFFFAOYSA-N
DM1CB5J IU 2-benzyl-1H-indazol-3-one
DM1CB5J CA CAS 1848-46-0
DM1CB5J DE Discovery agent
DMV7IWE ID DMV7IWE
DMV7IWE DN 2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one
DMV7IWE HS Investigative
DMV7IWE SN CHEMBL573922
DMV7IWE DT Small molecular drug
DMV7IWE PC 54736441
DMV7IWE MW 306.4
DMV7IWE FM C20H18O3
DMV7IWE IC InChI=1S/C20H18O3/c21-19-16(12-13-6-2-1-3-7-13)20(22)23-17-11-10-14-8-4-5-9-15(14)18(17)19/h1-3,6-7,10-11,21H,4-5,8-9,12H2
DMV7IWE CS C1CCC2=C(C1)C=CC3=C2C(=C(C(=O)O3)CC4=CC=CC=C4)O
DMV7IWE IK VVGMGNIOZFKXQQ-UHFFFAOYSA-N
DMV7IWE IU 2-benzyl-1-hydroxy-7,8,9,10-tetrahydrobenzo[f]chromen-3-one
DMV7IWE DE Discovery agent
DMPYB93 ID DMPYB93
DMPYB93 DN 2-Benzyl-2H-indazole-7-carboxamide
DMPYB93 HS Investigative
DMPYB93 SN CHEMBL1094951; 2-Benzyl-2H-indazole-7-carboxamide; SCHEMBL2268172
DMPYB93 DT Small molecular drug
DMPYB93 PC 44549372
DMPYB93 MW 251.28
DMPYB93 FM C15H13N3O
DMPYB93 IC InChI=1S/C15H13N3O/c16-15(19)13-8-4-7-12-10-18(17-14(12)13)9-11-5-2-1-3-6-11/h1-8,10H,9H2,(H2,16,19)
DMPYB93 CS C1=CC=C(C=C1)CN2C=C3C=CC=C(C3=N2)C(=O)N
DMPYB93 IK FCHCPSCDAOGWGQ-UHFFFAOYSA-N
DMPYB93 IU 2-benzylindazole-7-carboxamide
DMPYB93 DE Discovery agent
DM6E04T ID DM6E04T
DM6E04T DN 2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM6E04T HS Investigative
DM6E04T SN CHEMBL242205; 2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM6E04T DT Small molecular drug
DM6E04T PC 10636110
DM6E04T MW 275.3
DM6E04T FM C17H13N3O
DM6E04T IC InChI=1S/C17H13N3O/c21-17-16-14(13-8-4-5-9-15(13)18-17)11-20(19-16)10-12-6-2-1-3-7-12/h1-9,11H,10H2,(H,18,21)
DM6E04T CS C1=CC=C(C=C1)CN2C=C3C4=CC=CC=C4NC(=O)C3=N2
DM6E04T IK XJRYZVBNFXKWFF-UHFFFAOYSA-N
DM6E04T IU 2-benzyl-5H-pyrazolo[3,4-c]quinolin-4-one
DM6E04T DE Discovery agent
DMANTCY ID DMANTCY
DMANTCY DN 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole
DMANTCY HS Investigative
DMANTCY SN 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole; SCHEMBL1407219; CHEMBL464189; BDBM26064; LGRUCHCYEMOENE-UHFFFAOYSA-N; 2-benzyl-3-aryl-7-trifluoromethylindazole, 5
DMANTCY DT Small molecular drug
DMANTCY PC 25137977
DMANTCY MW 352.4
DMANTCY FM C21H15F3N2
DMANTCY IC InChI=1S/C21H15F3N2/c22-21(23,24)18-13-7-12-17-19(18)25-26(14-15-8-3-1-4-9-15)20(17)16-10-5-2-6-11-16/h1-13H,14H2
DMANTCY CS C1=CC=C(C=C1)CN2C(=C3C=CC=C(C3=N2)C(F)(F)F)C4=CC=CC=C4
DMANTCY IK LGRUCHCYEMOENE-UHFFFAOYSA-N
DMANTCY IU 2-benzyl-3-phenyl-7-(trifluoromethyl)indazole
DMANTCY DE Discovery agent
DMH76SO ID DMH76SO
DMH76SO DN 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione
DMH76SO HS Investigative
DMH76SO SN CHEMBL11516; 63586-13-0; 2-Benzyl-4,5,6,7-tetrachloro-isoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione; AC1LK1ZO; Oprea1_023833; 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione; SCHEMBL10675358; CTK2A8819; DTXSID60359687; MolPort-001-020-850; ZINC630019; STK246502; BDBM50088678; AKOS003243470; MCULE-7798575308; N-Benzyl-3,4,5,6-tetrachlorophthalimide; ST50854964; AK-918/11423009; 4,5,6,7-tetrachloro-2-benzylbenzo[c]azolidine-1,3-dione
DMH76SO DT Small molecular drug
DMH76SO PC 983732
DMH76SO MW 375
DMH76SO FM C15H7Cl4NO2
DMH76SO IC InChI=1S/C15H7Cl4NO2/c16-10-8-9(11(17)13(19)12(10)18)15(22)20(14(8)21)6-7-4-2-1-3-5-7/h1-5H,6H2
DMH76SO CS C1=CC=C(C=C1)CN2C(=O)C3=C(C2=O)C(=C(C(=C3Cl)Cl)Cl)Cl
DMH76SO IK MQFQHWBPMPPVNJ-UHFFFAOYSA-N
DMH76SO IU 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione
DMH76SO CA CAS 63586-13-0
DMH76SO DE Discovery agent
DMYGKW5 ID DMYGKW5
DMYGKW5 DN 2-Benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5 HS Investigative
DMYGKW5 SN CHEMBL578411; 2-Benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5 DT Small molecular drug
DMYGKW5 PC 45488131
DMYGKW5 MW 292.4
DMYGKW5 FM C18H20N4
DMYGKW5 IC InChI=1S/C18H20N4/c1-2-5-14(6-3-1)13-17-20-15-7-4-8-16(18(15)21-17)22-11-9-19-10-12-22/h1-8,19H,9-13H2,(H,20,21)
DMYGKW5 CS C1CN(CCN1)C2=CC=CC3=C2N=C(N3)CC4=CC=CC=C4
DMYGKW5 IK YTVICZASURPPDE-UHFFFAOYSA-N
DMYGKW5 IU 2-benzyl-4-piperazin-1-yl-1H-benzimidazole
DMYGKW5 DE Discovery agent
DM3I7EL ID DM3I7EL
DM3I7EL DN 2-benzyl-5-mercaptopentanoic acid
DM3I7EL HS Investigative
DM3I7EL SN Thiol-Based Inhibitor, 6a; Benzenepropanoic acid, alpha-(3-mercaptopropyl)-; CHEMBL383676; SCHEMBL5054359; CTK8A8855; BDBM17760; 2-benzyl-5-sulfanylpentanoic acid; AKOS015966158; 378242-19-4; 2-BENZYL-5-MERCAPTO-PENTANOIC ACID
DM3I7EL DT Small molecular drug
DM3I7EL PC 9920926
DM3I7EL MW 224.32
DM3I7EL FM C12H16O2S
DM3I7EL IC InChI=1S/C12H16O2S/c13-12(14)11(7-4-8-15)9-10-5-2-1-3-6-10/h1-3,5-6,11,15H,4,7-9H2,(H,13,14)
DM3I7EL CS C1=CC=C(C=C1)CC(CCCS)C(=O)O
DM3I7EL IK QTCRNIDSGWSKLN-UHFFFAOYSA-N
DM3I7EL IU 2-benzyl-5-sulfanylpentanoic acid
DM3I7EL DE Discovery agent
DMGWRID ID DMGWRID
DMGWRID DN 2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole
DMGWRID HS Investigative
DMGWRID SN CHEMBL281635; 2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole; SCHEMBL5831606; BDBM50126015
DMGWRID DT Small molecular drug
DMGWRID PC 22238481
DMGWRID MW 304.3
DMGWRID FM C19H16N2O2
DMGWRID IC InChI=1S/C19H16N2O2/c1-22-18-10-17-14(9-16(18)19-11-20-12-23-19)8-15(21-17)7-13-5-3-2-4-6-13/h2-6,8-12,21H,7H2,1H3
DMGWRID CS COC1=C(C=C2C=C(NC2=C1)CC3=CC=CC=C3)C4=CN=CO4
DMGWRID IK HWRLJNBXLQMWKB-UHFFFAOYSA-N
DMGWRID IU 5-(2-benzyl-6-methoxy-1H-indol-5-yl)-1,3-oxazole
DMGWRID DE Discovery agent
DMAX5TC ID DMAX5TC
DMAX5TC DN 2-Benzyl-7-hydroxy-chromen-4-one
DMAX5TC HS Investigative
DMAX5TC SN 2-benzyl-7-hydroxy-chromen-4-one; CHEMBL56346; 2-Benzyl-7-hydroxychromone; ZINC12343959
DMAX5TC DT Small molecular drug
DMAX5TC PC 10705949
DMAX5TC MW 252.26
DMAX5TC FM C16H12O3
DMAX5TC IC InChI=1S/C16H12O3/c17-12-6-7-14-15(18)10-13(19-16(14)9-12)8-11-4-2-1-3-5-11/h1-7,9-10,17H,8H2
DMAX5TC CS C1=CC=C(C=C1)CC2=CC(=O)C3=C(O2)C=C(C=C3)O
DMAX5TC IK BQFDTKDYOCJBGZ-UHFFFAOYSA-N
DMAX5TC IU 2-benzyl-7-hydroxychromen-4-one
DMAX5TC DE Discovery agent
DM6EMGJ ID DM6EMGJ
DM6EMGJ DN 2-Benzylaminomethyl-3-hydroxymorphinan
DM6EMGJ HS Investigative
DM6EMGJ SN CHEMBL578173; 2-Benzylaminomethyl-3-hydroxymorphinan
DM6EMGJ DT Small molecular drug
DM6EMGJ PC 44626544
DM6EMGJ MW 376.5
DM6EMGJ FM C25H32N2O
DM6EMGJ IC InChI=1S/C25H32N2O/c1-27-12-11-25-10-6-5-9-21(25)23(27)14-19-13-20(24(28)15-22(19)25)17-26-16-18-7-3-2-4-8-18/h2-4,7-8,13,15,21,23,26,28H,5-6,9-12,14,16-17H2,1H3/t21-,23+,25+/m0/s1
DM6EMGJ CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=CC(=C(C=C34)O)CNCC5=CC=CC=C5
DM6EMGJ IK BGGKLNVUQJUZIE-QQKQFIJSSA-N
DM6EMGJ IU (1R,9R,10R)-5-[(benzylamino)methyl]-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol
DM6EMGJ DE Discovery agent
DMM48L6 ID DMM48L6
DMM48L6 DN 2-Benzylbenzo[f]chromen-3-one
DMM48L6 HS Investigative
DMM48L6 SN CHEMBL513763; 2-Benzylbenzo[f]chromen-3-one; SCHEMBL15398169; BDBM50278257
DMM48L6 DT Small molecular drug
DMM48L6 PC 10731937
DMM48L6 MW 286.3
DMM48L6 FM C20H14O2
DMM48L6 IC InChI=1S/C20H14O2/c21-20-16(12-14-6-2-1-3-7-14)13-18-17-9-5-4-8-15(17)10-11-19(18)22-20/h1-11,13H,12H2
DMM48L6 CS C1=CC=C(C=C1)CC2=CC3=C(C=CC4=CC=CC=C43)OC2=O
DMM48L6 IK OOALWLFUSOVWMV-UHFFFAOYSA-N
DMM48L6 IU 2-benzylbenzo[f]chromen-3-one
DMM48L6 DE Discovery agent
DME7SAV ID DME7SAV
DME7SAV DN 2-benzylisoquinoline-1,3,4-trione
DME7SAV HS Investigative
DME7SAV SN 21640-35-7; 2-benzylisoquinoline-1,3,4-trione; 2-BENZYL-ISOQUINOLINE-1,3,4-TRIONE; CHEMBL382859; SCHEMBL13442853; Isoquinoline-1,3,4-trione 2c; BDBM10250; CTK4E7388; DTXSID80463477; ZINC13683129; AKOS015966149; FCH2821819; ACM21640357; 2-Benzylisoquinoline-1,3,4(2H)-trione; 2-Benzylisoquinoline-1,3,4(2H,4H)-trione; 1,3,4(2H)-Isoquinolinetrione,2-(phenylmethyl)-
DME7SAV DT Small molecular drug
DME7SAV PC 11357566
DME7SAV MW 265.26
DME7SAV FM C16H11NO3
DME7SAV IC InChI=1S/C16H11NO3/c18-14-12-8-4-5-9-13(12)15(19)17(16(14)20)10-11-6-2-1-3-7-11/h1-9H,10H2
DME7SAV CS C1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3C(=O)C2=O
DME7SAV IK MCRWFXGWJMDFON-UHFFFAOYSA-N
DME7SAV IU 2-benzylisoquinoline-1,3,4-trione
DME7SAV CA CAS 21640-35-7
DME7SAV DE Discovery agent
DMF5MGQ ID DMF5MGQ
DMF5MGQ DN 2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide
DMF5MGQ HS Investigative
DMF5MGQ SN CHEMBL331784; 2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide; SCHEMBL7357043; BDBM50062453
DMF5MGQ DT Small molecular drug
DMF5MGQ PC 10592233
DMF5MGQ MW 326.4
DMF5MGQ FM C19H22N2O3
DMF5MGQ IC InChI=1S/C19H22N2O3/c22-18(20-13-7-12-15-8-3-1-4-9-15)17(19(23)21-24)14-16-10-5-2-6-11-16/h1-6,8-11,17,24H,7,12-14H2,(H,20,22)(H,21,23)
DMF5MGQ CS C1=CC=C(C=C1)CCCNC(=O)C(CC2=CC=CC=C2)C(=O)NO
DMF5MGQ IK CQGGQNFRJIAPHA-UHFFFAOYSA-N
DMF5MGQ IU 2-benzyl-N-hydroxy-N'-(3-phenylpropyl)propanediamide
DMF5MGQ DE Discovery agent
DMRVA94 ID DMRVA94
DMRVA94 DN 2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide
DMRVA94 HS Investigative
DMRVA94 SN CHEMBL220996; 2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide; BDBM50197497
DMRVA94 DT Small molecular drug
DMRVA94 PC 16115012
DMRVA94 MW 340.4
DMRVA94 FM C20H24N2O3
DMRVA94 IC InChI=1S/C20H24N2O3/c23-19(21-14-8-7-11-16-9-3-1-4-10-16)18(20(24)22-25)15-17-12-5-2-6-13-17/h1-6,9-10,12-13,18,25H,7-8,11,14-15H2,(H,21,23)(H,22,24)
DMRVA94 CS C1=CC=C(C=C1)CCCCNC(=O)C(CC2=CC=CC=C2)C(=O)NO
DMRVA94 IK WBIXUIDQAJRMSZ-UHFFFAOYSA-N
DMRVA94 IU 2-benzyl-N-hydroxy-N'-(4-phenylbutyl)propanediamide
DMRVA94 DE Discovery agent
DM2BPIN ID DM2BPIN
DM2BPIN DN 2-benzyl-N1-hydroxy-N3-phenethylmalonamide
DM2BPIN HS Investigative
DM2BPIN SN CHEMBL220434; 2-benzyl-N1-hydroxy-N3-phenethylmalonamide; BDBM50206544
DM2BPIN DT Small molecular drug
DM2BPIN PC 16114889
DM2BPIN MW 312.4
DM2BPIN FM C18H20N2O3
DM2BPIN IC InChI=1S/C18H20N2O3/c21-17(19-12-11-14-7-3-1-4-8-14)16(18(22)20-23)13-15-9-5-2-6-10-15/h1-10,16,23H,11-13H2,(H,19,21)(H,20,22)
DM2BPIN CS C1=CC=C(C=C1)CCNC(=O)C(CC2=CC=CC=C2)C(=O)NO
DM2BPIN IK GJBWQDWUWPUOOP-UHFFFAOYSA-N
DM2BPIN IU 2-benzyl-N-hydroxy-N'-(2-phenylethyl)propanediamide
DM2BPIN DE Discovery agent
DMCLAXG ID DMCLAXG
DMCLAXG DN 2-benzyloxy-7,8-dihydro-6H-quinolin-5-one
DMCLAXG HS Investigative
DMCLAXG SN CHEMBL400104; 2-benzyloxy-7,8-dihydro-6H-quinolin-5-one; SCHEMBL4275594; 2-(BENZYLOXY)-7,8-DIHYDROQUINOLIN-5(6H)-ONE; VGMBEUFDLPGOMH-UHFFFAOYSA-N; BDBM50231740; ZINC28967402; AB68928; 143232-64-8; 2-Benzyloxy-7,8-dihydroquinolin-5(6H)-one; 5,6,7,8-tetrahydro-2-(phenylmethoxy)-5-oxoquinoline; 5,6,7,8-Tetrahydro-5-oxo-2-(phenylmethoxy)quinoline
DMCLAXG DT Small molecular drug
DMCLAXG PC 10444977
DMCLAXG MW 253.29
DMCLAXG FM C16H15NO2
DMCLAXG IC InChI=1S/C16H15NO2/c18-15-8-4-7-14-13(15)9-10-16(17-14)19-11-12-5-2-1-3-6-12/h1-3,5-6,9-10H,4,7-8,11H2
DMCLAXG CS C1CC2=C(C=CC(=N2)OCC3=CC=CC=C3)C(=O)C1
DMCLAXG IK VGMBEUFDLPGOMH-UHFFFAOYSA-N
DMCLAXG IU 2-phenylmethoxy-7,8-dihydro-6H-quinolin-5-one
DMCLAXG CA CAS 143232-64-8
DMCLAXG DE Discovery agent
DM6F0C4 ID DM6F0C4
DM6F0C4 DN 2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine
DM6F0C4 HS Investigative
DM6F0C4 SN 4-Amino-2-(benzylthio)-6-chloropyrimidine; 99983-92-3; CHEMBL124578; U-31,355; 2-benzylmercapto-4-amino-6-chloropyrimidine; 2-(benzylthio)-6-chloropyrimidin-4-amine; 2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine; AC1Q3RY2; AC1L3VC9; U 31355; SCHEMBL489860; 4-Pyrimidinamine, 6-chloro-2-((phenylmethyl)thio)-; U 31,355; CTK5I0853; ZINC21246; DTXSID20244368; LGTXUPUULSWTNA-UHFFFAOYSA-N; BDBM50066933; AKOS030548304; KB-239927; 2-benzylsulfanyl-6-chloropyrimidin-4-amine; 2-benzylsulfanyl-6-chloro-pyrimidin-4-amine
DM6F0C4 DT Small molecular drug
DM6F0C4 PC 122830
DM6F0C4 MW 251.74
DM6F0C4 FM C11H10ClN3S
DM6F0C4 IC InChI=1S/C11H10ClN3S/c12-9-6-10(13)15-11(14-9)16-7-8-4-2-1-3-5-8/h1-6H,7H2,(H2,13,14,15)
DM6F0C4 CS C1=CC=C(C=C1)CSC2=NC(=CC(=N2)Cl)N
DM6F0C4 IK LGTXUPUULSWTNA-UHFFFAOYSA-N
DM6F0C4 IU 2-benzylsulfanyl-6-chloropyrimidin-4-amine
DM6F0C4 CA CAS 99983-92-3
DM6F0C4 DE Discovery agent
DMV4OY2 ID DMV4OY2
DMV4OY2 DN 2beta,3alpha-dihydroxyolean-12-en-28-oic acid
DMV4OY2 HS Investigative
DMV4OY2 SN bredemolic acid; CHEMBL577380; 5957-40-4; ZINC8952016; BDBM50346696
DMV4OY2 DT Small molecular drug
DMV4OY2 PC 25156878
DMV4OY2 MW 472.7
DMV4OY2 FM C30H48O4
DMV4OY2 IC InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20-,21-,22+,23+,27-,28+,29+,30-/m0/s1
DMV4OY2 CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@H](C3(C)C)O)O)C
DMV4OY2 IK MDZKJHQSJHYOHJ-SXISEVPCSA-N
DMV4OY2 IU (4aS,6aR,6aS,6bR,8aR,10S,11S,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMV4OY2 DE Discovery agent
DMU4Q8C ID DMU4Q8C
DMU4Q8C DN 2beta,3alpha-dihydroxyurs-12-en-28-oic acid
DMU4Q8C HS Investigative
DMU4Q8C SN CHEMBL574993; SCHEMBL4456541; (2beta,3alpha)-2,3-Dihydroxy-urs-12-en-28-oic acid; BDBM50346702; ZINC49708319; 856012-03-8; 2beta,3alpha-Dihydroxyurs-12-ene-28-oic acid; 012A038; Adbeta,3a)-2,3-dihydroxy-urs-12-en-28-oic acid
DMU4Q8C DT Small molecular drug
DMU4Q8C PC 45481653
DMU4Q8C MW 472.7
DMU4Q8C FM C30H48O4
DMU4Q8C IC InChI=1S/C30H48O4/c1-17-10-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h8,17-18,20-24,31-32H,9-16H2,1-7H3,(H,33,34)/t17-,18+,20+,21+,22-,23+,24-,27+,28-,29-,30+/m1/s1
DMU4Q8C CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H]([C@H](C5(C)C)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMU4Q8C IK HFGSQOYIOKBQOW-FEZPFBHMSA-N
DMU4Q8C IU (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,11S,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMU4Q8C DE Discovery agent
DMWZ4KN ID DMWZ4KN
DMWZ4KN DN 2beta-methoxy-2-deethoxyphantomolin
DMWZ4KN HS Investigative
DMWZ4KN DT Small molecular drug
DMWZ4KN PC 70697849
DMWZ4KN MW 360.4
DMWZ4KN FM C20H24O6
DMWZ4KN IC InChI=1S/C20H24O6/c1-10(2)18(21)24-14-7-11(3)8-20(23-6)9-12(4)16(26-20)17-15(14)13(5)19(22)25-17/h8-9,14-17H,1,5,7H2,2-4,6H3/b11-8+/t14-,15+,16-,17-,20-/m0/s1
DMWZ4KN CS C/C/1=C\\[C@]2(C=C([C@H](O2)[C@@H]3[C@@H]([C@H](C1)OC(=O)C(=C)C)C(=C)C(=O)O3)C)OC
DMWZ4KN IK CSIBMGLPBAXXSG-FWTBDAJASA-N
DMWZ4KN IU [(1S,2S,6R,7S,9E,11S)-11-methoxy-9,13-dimethyl-5-methylidene-4-oxo-3,14-dioxatricyclo[9.2.1.02,6]tetradeca-9,12-dien-7-yl] 2-methylprop-2-enoate
DMWZ4KN CB CHEBI:65835
DMWZ4KN DE Discovery agent
DMFAW4R ID DMFAW4R
DMFAW4R DN 2-BFi
DMFAW4R HS Investigative
DMFAW4R SN 2-Benzofuran-2-yl-4,5-dihydro-1H-imidazole
DMFAW4R DT Small molecular drug
DMFAW4R PC 3080926
DMFAW4R MW 186.21
DMFAW4R FM C11H10N2O
DMFAW4R IC InChI=1S/C11H10N2O/c1-2-4-9-8(3-1)7-10(14-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)
DMFAW4R CS C1CN=C(N1)C2=CC3=CC=CC=C3O2
DMFAW4R IK YTJOHEUHUVBKSB-UHFFFAOYSA-N
DMFAW4R IU 2-(1-benzofuran-2-yl)-4,5-dihydro-1H-imidazole
DMFAW4R CA CAS 72583-92-7
DMFAW4R CB CHEBI:103964
DMFAW4R DE Discovery agent
DMHS3N6 ID DMHS3N6
DMHS3N6 DN 2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone
DMHS3N6 HS Investigative
DMHS3N6 SN CHEMBL240469; 2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone
DMHS3N6 DT Small molecular drug
DMHS3N6 PC 44435201
DMHS3N6 MW 393.5
DMHS3N6 FM C26H19NOS
DMHS3N6 IC InChI=1S/C26H19NOS/c28-26(18-19-14-16-21(17-15-19)20-8-2-1-3-9-20)27-22-10-4-6-12-24(22)29-25-13-7-5-11-23(25)27/h1-17H,18H2
DMHS3N6 CS C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DMHS3N6 IK HQYQYXMOSDNQPG-UHFFFAOYSA-N
DMHS3N6 IU 1-phenothiazin-10-yl-2-(4-phenylphenyl)ethanone
DMHS3N6 DE Discovery agent
DML1W5Z ID DML1W5Z
DML1W5Z DN 2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one
DML1W5Z HS Investigative
DML1W5Z SN CHEMBL426894; 2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one
DML1W5Z DT Small molecular drug
DML1W5Z PC 16203714
DML1W5Z MW 333.4
DML1W5Z FM C21H19NO3
DML1W5Z IC InChI=1S/C21H19NO3/c23-19-14-20(25-21(15-19)22-10-12-24-13-11-22)18-8-6-17(7-9-18)16-4-2-1-3-5-16/h1-9,14-15H,10-13H2
DML1W5Z CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)C4=CC=CC=C4
DML1W5Z IK MIZPDLBPZZKHCN-UHFFFAOYSA-N
DML1W5Z IU 2-morpholin-4-yl-6-(4-phenylphenyl)pyran-4-one
DML1W5Z DE Discovery agent
DMWOJ5N ID DMWOJ5N
DMWOJ5N DN 2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide
DMWOJ5N HS Investigative
DMWOJ5N SN CHEMBL174051; 2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide; BDBM50015169
DMWOJ5N DT Small molecular drug
DMWOJ5N PC 13670400
DMWOJ5N MW 241.28
DMWOJ5N FM C15H15NO2
DMWOJ5N IC InChI=1S/C15H15NO2/c1-16(18)15(17)11-12-7-9-14(10-8-12)13-5-3-2-4-6-13/h2-10,18H,11H2,1H3
DMWOJ5N CS CN(C(=O)CC1=CC=C(C=C1)C2=CC=CC=C2)O
DMWOJ5N IK OKCNSKAFTYDWAP-UHFFFAOYSA-N
DMWOJ5N IU N-hydroxy-N-methyl-2-(4-phenylphenyl)acetamide
DMWOJ5N DE Discovery agent
DMCM01R ID DMCM01R
DMCM01R DN 2-bromo-4-(3-fluorophenylethynyl)thiazole
DMCM01R HS Investigative
DMCM01R SN 2-bromo-4-(3-fluorophenylethynyl)thiazole; CHEMBL382491; 878018-74-7; SCHEMBL4145773; CTK2I2017; DTXSID80468225; ZINC13680939; BDBM50181781; AKOS015965444; KB-228728; Thiazole, 2-bromo-4-[(3-fluorophenyl)ethynyl]-
DMCM01R DT Small molecular drug
DMCM01R PC 11536470
DMCM01R MW 282.13
DMCM01R FM C11H5BrFNS
DMCM01R IC InChI=1S/C11H5BrFNS/c12-11-14-10(7-15-11)5-4-8-2-1-3-9(13)6-8/h1-3,6-7H
DMCM01R CS C1=CC(=CC(=C1)F)C#CC2=CSC(=N2)Br
DMCM01R IK XPOUXVRKZDTDJY-UHFFFAOYSA-N
DMCM01R IU 2-bromo-4-[2-(3-fluorophenyl)ethynyl]-1,3-thiazole
DMCM01R CA CAS 878018-74-7
DMCM01R DE Discovery agent
DMJ0368 ID DMJ0368
DMJ0368 DN 2-bromo-4-methylphenyl 2-nitrobenzoate
DMJ0368 HS Investigative
DMJ0368 SN 2-bromo-4-methylphenyl 2-nitrobenzoate; CHEMBL549456; AC1LDUV8; Oprea1_572597; Oprea1_573870; ARONIS001613; ZINC38499; MolPort-001-525-391; KS-00003V1E; STK096466; BDBM50297528; AKOS000491705; MCULE-5867447196; ST054603; (2-bromo-4-methylphenyl) 2-nitrobenzoate
DMJ0368 DT Small molecular drug
DMJ0368 PC 675658
DMJ0368 MW 336.14
DMJ0368 FM C14H10BrNO4
DMJ0368 IC InChI=1S/C14H10BrNO4/c1-9-6-7-13(11(15)8-9)20-14(17)10-4-2-3-5-12(10)16(18)19/h2-8H,1H3
DMJ0368 CS CC1=CC(=C(C=C1)OC(=O)C2=CC=CC=C2[N+](=O)[O-])Br
DMJ0368 IK GWWHSLCVPYBDPI-UHFFFAOYSA-N
DMJ0368 IU (2-bromo-4-methylphenyl) 2-nitrobenzoate
DMJ0368 DE Discovery agent
DMIHJSA ID DMIHJSA
DMIHJSA DN 2-Bromoacetyl Group
DMIHJSA HS Investigative
DMIHJSA SN BROMOACETIC ACID; 2-Bromoacetic acid; 79-08-3; Monobromoacetic acid; Bromoethanoic acid; Acetic acid, bromo-; To NTU; Bromoacetate ion; Acide bromacetique; 2-bromoethanoic acid; 2-Bromoacetyl Group; Monobromessigsaeure; Acetic acid, 2-bromo-; Bromo-acetic acid; Kyselina bromoctova; alpha-Bromoacetic acid; Caswell No. 112A; NSC 141; .alpha.-Bromoacetic acid; Acide bromacetique [French]; Kyselina bromoctova [Czech]; Monobromessigsaeure [German]; CCRIS 7886; UNII-2B3HS32431; Acetic acid, bromo-, (solution); alpha-Bromoethanoic acid
DMIHJSA DT Small molecular drug
DMIHJSA PC 6227
DMIHJSA MW 138.95
DMIHJSA FM C2H3BrO2
DMIHJSA IC InChI=1S/C2H3BrO2/c3-1-2(4)5/h1H2,(H,4,5)
DMIHJSA CS C(C(=O)O)Br
DMIHJSA IK KDPAWGWELVVRCH-UHFFFAOYSA-N
DMIHJSA IU 2-bromoacetic acid
DMIHJSA CA CAS 79-08-3
DMIHJSA DE Discovery agent
DMOYCWU ID DMOYCWU
DMOYCWU DN 2-bromo-LSD
DMOYCWU HS Investigative
DMOYCWU SN 2-bromolysergic acid diethylamide; 2-br-LSD; bromolysergide
DMOYCWU DT Small molecular drug
DMOYCWU PC 10171
DMOYCWU MW 402.3
DMOYCWU FM C20H24BrN3O
DMOYCWU IC InChI=1S/C20H24BrN3O/c1-4-24(5-2)20(25)12-9-14-13-7-6-8-16-18(13)15(19(21)22-16)10-17(14)23(3)11-12/h6-9,12,17,22H,4-5,10-11H2,1-3H3/t12-,17-/m1/s1
DMOYCWU CS CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C
DMOYCWU IK VKRAXSZEDRWLAG-SJKOYZFVSA-N
DMOYCWU IU (6aR,9R)-5-bromo-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMOYCWU CA CAS 478-84-2
DMOYCWU DE Discovery agent
DMYCENM ID DMYCENM
DMYCENM DN 2-Bromo-N-(2-morpholinoethyl)nicotinamide
DMYCENM HS Investigative
DMYCENM SN 2-Bromo-N-(2-morpholinoethyl)nicotinamide; CHEMBL607864; BDBM50307208
DMYCENM DT Small molecular drug
DMYCENM PC 46233338
DMYCENM MW 314.18
DMYCENM FM C12H16BrN3O2
DMYCENM IC InChI=1S/C12H16BrN3O2/c13-11-10(2-1-3-14-11)12(17)15-4-5-16-6-8-18-9-7-16/h1-3H,4-9H2,(H,15,17)
DMYCENM CS C1COCCN1CCNC(=O)C2=C(N=CC=C2)Br
DMYCENM IK FKGFLJZEVNCAEZ-UHFFFAOYSA-N
DMYCENM IU 2-bromo-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMYCENM DE Discovery agent
DM9NMIO ID DM9NMIO
DM9NMIO DN 2-Bromo-N-(3-morpholinopropyl)nicotinamide
DM9NMIO HS Investigative
DM9NMIO SN CHEMBL598373; 2-Bromo-N-(3-morpholinopropyl)nicotinamide
DM9NMIO DT Small molecular drug
DM9NMIO PC 46233404
DM9NMIO MW 328.2
DM9NMIO FM C13H18BrN3O2
DM9NMIO IC InChI=1S/C13H18BrN3O2/c14-12-11(3-1-4-15-12)13(18)16-5-2-6-17-7-9-19-10-8-17/h1,3-4H,2,5-10H2,(H,16,18)
DM9NMIO CS C1COCCN1CCCNC(=O)C2=C(N=CC=C2)Br
DM9NMIO IK ZMORGFKKKAMCBI-UHFFFAOYSA-N
DM9NMIO IU 2-bromo-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DM9NMIO DE Discovery agent
DM6JDIY ID DM6JDIY
DM6JDIY DN 2-bromophenol
DM6JDIY HS Investigative
DM6JDIY SN 2-BROMOPHENOL; 95-56-7; o-Bromophenol; Phenol, 2-bromo-; BROMOPHENOL; 2-Bromfenol; 2-Bromo-phenol; Phenol, o-bromo-; o-bromo-phenol; 2-bromo phenol; Phenol, bromo-; 2-Bromfenol [Czech]; NSC 6970; bromophenol, 2-; UNII-A0UB206YF0; 2-Bromophenol, 98%; EINECS 202-432-7; 1-Bromo-2-hydroxybenzene; BRN 1905115; CHEMBL186007; A0UB206YF0; 2-BROMO-1-HYDROXYBENZENE; VADKRMSMGWJZCF-UHFFFAOYSA-N; MFCD00002146; 32762-51-9; ortho-bromophenol; 2BR; bromphenol; bromo-phenol; bromo phenol; 2-bromanylphenol; HSDB 7648; ortho-bromo-phenol; EINECS 251-200-1
DM6JDIY DT Small molecular drug
DM6JDIY PC 7244
DM6JDIY MW 173.01
DM6JDIY FM C6H5BrO
DM6JDIY IC InChI=1S/C6H5BrO/c7-5-3-1-2-4-6(5)8/h1-4,8H
DM6JDIY CS C1=CC=C(C(=C1)O)Br
DM6JDIY IK VADKRMSMGWJZCF-UHFFFAOYSA-N
DM6JDIY IU 2-bromophenol
DM6JDIY CA CAS 95-56-7
DM6JDIY CB CHEBI:34264
DM6JDIY DE Discovery agent
DMY7RM8 ID DMY7RM8
DMY7RM8 DN 2-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione
DMY7RM8 HS Investigative
DMY7RM8 SN CHEMBL593752
DMY7RM8 DT Small molecular drug
DMY7RM8 PC 44251145
DMY7RM8 MW 304.3
DMY7RM8 FM C19H16N2O2
DMY7RM8 IC InChI=1S/C19H16N2O2/c1-2-3-8-15-20-14-10-9-13-16(17(14)21-15)19(23)12-7-5-4-6-11(12)18(13)22/h4-7,9-10H,2-3,8H2,1H3,(H,20,21)
DMY7RM8 CS CCCCC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMY7RM8 IK DSPOAQONKLYCKM-UHFFFAOYSA-N
DMY7RM8 IU 2-butyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMY7RM8 DE Discovery agent
DML9MCU ID DML9MCU
DML9MCU DN 2-butylamido-5-sulfonamidoindane
DML9MCU HS Investigative
DML9MCU SN CHEMBL208531; 2-butylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12f; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)pentanamide
DML9MCU DT Small molecular drug
DML9MCU PC 11529486
DML9MCU MW 296.39
DML9MCU FM C14H20N2O3S
DML9MCU IC InChI=1S/C14H20N2O3S/c1-2-3-4-14(17)16-12-7-10-5-6-13(20(15,18)19)9-11(10)8-12/h5-6,9,12H,2-4,7-8H2,1H3,(H,16,17)(H2,15,18,19)
DML9MCU CS CCCCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DML9MCU IK VPKYLHQTQYEJLJ-UHFFFAOYSA-N
DML9MCU IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)pentanamide
DML9MCU DE Discovery agent
DMG5SAQ ID DMG5SAQ
DMG5SAQ DN 2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone
DMG5SAQ HS Investigative
DMG5SAQ SN 2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone; 945414-11-9; alpha-ketooxazole, 14f; SCHEMBL710273; CHEMBL229323; BDBM23135; MKVLXIACPLGLLP-UHFFFAOYSA-N; ZINC14980143; DA-40252; FT-0713758
DMG5SAQ DT Small molecular drug
DMG5SAQ PC 16735859
DMG5SAQ MW 222.63
DMG5SAQ FM C10H7ClN2O2
DMG5SAQ IC InChI=1S/C10H7ClN2O2/c11-5-8(14)10-13-6-9(15-10)7-3-1-2-4-12-7/h1-4,6H,5H2
DMG5SAQ CS C1=CC=NC(=C1)C2=CN=C(O2)C(=O)CCl
DMG5SAQ IK MKVLXIACPLGLLP-UHFFFAOYSA-N
DMG5SAQ IU 2-chloro-1-(5-pyridin-2-yl-1,3-oxazol-2-yl)ethanone
DMG5SAQ DE Discovery agent
DMD3ZNP ID DMD3ZNP
DMD3ZNP DN 2-chloro-2'-C-methyl-tecadenoson
DMD3ZNP HS Investigative
DMD3ZNP SN CHEMBL400782; 2-chloro-2''-C-methyl-tecadenoson
DMD3ZNP DT Small molecular drug
DMD3ZNP PC 44447548
DMD3ZNP MW 385.8
DMD3ZNP FM C15H20ClN5O5
DMD3ZNP IC InChI=1S/C15H20ClN5O5/c1-15(24)10(23)8(4-22)26-13(15)21-6-17-9-11(18-7-2-3-25-5-7)19-14(16)20-12(9)21/h6-8,10,13,22-24H,2-5H2,1H3,(H,18,19,20)/t7-,8-,10-,13-,15-/m1/s1
DMD3ZNP CS C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N[C@@H]4CCOC4)CO)O)O
DMD3ZNP IK PKAKDOUFCOQHOJ-RAPCHXAISA-N
DMD3ZNP IU (2R,3R,4R,5R)-2-[2-chloro-6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
DMD3ZNP DE Discovery agent
DMTPKU8 ID DMTPKU8
DMTPKU8 DN 2-chloro-4-(o-tolyloxy)benzonitrile
DMTPKU8 HS Investigative
DMTPKU8 SN CHEMBL470204; 2-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4175953; BDBM50278226
DMTPKU8 DT Small molecular drug
DMTPKU8 PC 11507014
DMTPKU8 MW 243.69
DMTPKU8 FM C14H10ClNO
DMTPKU8 IC InChI=1S/C14H10ClNO/c1-10-4-2-3-5-14(10)17-12-7-6-11(9-16)13(15)8-12/h2-8H,1H3
DMTPKU8 CS CC1=CC=CC=C1OC2=CC(=C(C=C2)C#N)Cl
DMTPKU8 IK NOLQETBWRAYXMF-UHFFFAOYSA-N
DMTPKU8 IU 2-chloro-4-(2-methylphenoxy)benzonitrile
DMTPKU8 DE Discovery agent
DMPCRLY ID DMPCRLY
DMPCRLY DN 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMPCRLY HS Investigative
DMPCRLY SN CHEMBL260773; 2-Chloro-4-(2-thiazolyl)thieno[3,2-d]pyrimidine; 443148-15-0; SCHEMBL3679573; GWBPGRWRSLAHEX-UHFFFAOYSA-N
DMPCRLY DT Small molecular drug
DMPCRLY PC 44449565
DMPCRLY MW 253.7
DMPCRLY FM C9H4ClN3S2
DMPCRLY IC InChI=1S/C9H4ClN3S2/c10-9-12-5-1-3-14-7(5)6(13-9)8-11-2-4-15-8/h1-4H
DMPCRLY CS C1=CSC2=C1N=C(N=C2C3=NC=CS3)Cl
DMPCRLY IK GWBPGRWRSLAHEX-UHFFFAOYSA-N
DMPCRLY IU 2-chloro-4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidine
DMPCRLY DE Discovery agent
DMC5OQ3 ID DMC5OQ3
DMC5OQ3 DN 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMC5OQ3 HS Investigative
DMC5OQ3 SN CHEMBL253753; Thieno[3,2-d]pyrimidine, 2-chloro-4-(2-thienyl)-; SCHEMBL3682427; BDBM50377508
DMC5OQ3 DT Small molecular drug
DMC5OQ3 PC 44449257
DMC5OQ3 MW 252.7
DMC5OQ3 FM C10H5ClN2S2
DMC5OQ3 IC InChI=1S/C10H5ClN2S2/c11-10-12-6-3-5-15-9(6)8(13-10)7-2-1-4-14-7/h1-5H
DMC5OQ3 CS C1=CSC(=C1)C2=NC(=NC3=C2SC=C3)Cl
DMC5OQ3 IK GFDPXLUZWJSHBL-UHFFFAOYSA-N
DMC5OQ3 IU 2-chloro-4-thiophen-2-ylthieno[3,2-d]pyrimidine
DMC5OQ3 DE Discovery agent
DM5KR4B ID DM5KR4B
DM5KR4B DN 2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile
DM5KR4B HS Investigative
DM5KR4B SN CHEMBL1096196; 2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile
DM5KR4B DT Small molecular drug
DM5KR4B PC 46888088
DM5KR4B MW 279.72
DM5KR4B FM C16H10ClN3
DM5KR4B IC InChI=1S/C16H10ClN3/c1-10-2-3-11-4-5-12(7-15(11)20-10)14-6-13(8-18)16(17)19-9-14/h2-7,9H,1H3
DM5KR4B CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(N=C3)Cl)C#N
DM5KR4B IK FCXAJLFDBPZDJD-UHFFFAOYSA-N
DM5KR4B IU 2-chloro-5-(2-methylquinolin-7-yl)pyridine-3-carbonitrile
DM5KR4B DE Discovery agent
DMUGQIV ID DMUGQIV
DMUGQIV DN 2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV HS Investigative
DMUGQIV SN 2-Chloro-5-nitro-N-phenylbenzamide; GW9662; 22978-25-2; GW 9662; 2-Chloro-5-nitrobenzanilide; GW-9662; MLS001056751; CHEBI:79993; 2-Chloro-5-nitro-N-phenyl-benzamide; 2-Chloro-5-nitro-N-4-phenylbenzamide; benzamide, 2-chloro-5-nitro-N-phenyl-; SMR000326735; (2-chloro-5-nitrophenyl)-N-benzamide; SR-01000075999; Tocris-1508; Spectrum5_001989; Lopac-M-6191; AC1LD8S0; DSSTox_RID_79570; DSSTox_CID_20723; DSSTox_GSID_40723; Lopac0_000798; KBioGR_000361; KBioSS_000361; BSPBio_001021; SCHEMBL420231; CHEMBL375270; GTPL3442; cid_644213
DMUGQIV DT Small molecular drug
DMUGQIV PC 644213
DMUGQIV MW 276.67
DMUGQIV FM C13H9ClN2O3
DMUGQIV IC InChI=1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)
DMUGQIV CS C1=CC=C(C=C1)NC(=O)C2=C(C=CC(=C2)[N+](=O)[O-])Cl
DMUGQIV IK DNTSIBUQMRRYIU-UHFFFAOYSA-N
DMUGQIV IU 2-chloro-5-nitro-N-phenylbenzamide
DMUGQIV CA CAS 22978-25-2
DMUGQIV CB CHEBI:79993
DMUGQIV DE Discovery agent
DML0S8M ID DML0S8M
DML0S8M DN 2-chloro-6(methylamino)purine
DML0S8M HS Investigative
DML0S8M SN 2-Chloro-6(methylamino)purine; 82499-02-3; 2-CHLORO-N-METHYL-9H-PURIN-6-AMINE; 2-chloro-N-methyl-7H-purin-6-amine; CHEMBL446449; 2-Chloro-6-(methylamino)purine; 2-CHLORO-6-(N-METHYLAMINO)-9H-PURINE; ACMC-20anyt; PubChem9784; 2-chloro-6-methylaminopurine; SCHEMBL130696; AC1NE105; CTK5E9746; DTXSID00404544; RIAVUEFUPHOGJY-UHFFFAOYSA-N; 2-Chloro-6-methylamino-9H-purine; NSC15416; ZINC4429067; NSC-15416; BDBM50208873; AKOS006283488; AKOS015894684; 2-Chloro-6(methylamino)purine, 97%; AB44277; TC-170732
DML0S8M DT Small molecular drug
DML0S8M PC 4584789
DML0S8M MW 183.6
DML0S8M FM C6H6ClN5
DML0S8M IC InChI=1S/C6H6ClN5/c1-8-4-3-5(10-2-9-3)12-6(7)11-4/h2H,1H3,(H2,8,9,10,11,12)
DML0S8M CS CNC1=NC(=NC2=C1NC=N2)Cl
DML0S8M IK RIAVUEFUPHOGJY-UHFFFAOYSA-N
DML0S8M IU 2-chloro-N-methyl-7H-purin-6-amine
DML0S8M CA CAS 82499-02-3
DML0S8M DE Discovery agent
DMYPQEW ID DMYPQEW
DMYPQEW DN 2-chloroadenosine
DMYPQEW HS Investigative
DMYPQEW SN 2Cl-Ado; CADO
DMYPQEW DT Small molecular drug
DMYPQEW PC 8974
DMYPQEW MW 301.69
DMYPQEW FM C10H12ClN5O4
DMYPQEW IC InChI=1S/C10H12ClN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6-,9-/m1/s1
DMYPQEW CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)Cl)N
DMYPQEW IK BIXYYZIIJIXVFW-UUOKFMHZSA-N
DMYPQEW IU (2R,3R,4S,5R)-2-(6-amino-2-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMYPQEW CA CAS 146-77-0
DMYPQEW CB CHEBI:125640
DMYPQEW DE Discovery agent
DMQUDA9 ID DMQUDA9
DMQUDA9 DN 2-chloroadenosine-5-triphosphate
DMQUDA9 HS Investigative
DMQUDA9 SN 2-chloro-ATP
DMQUDA9 DT Small molecular drug
DMQUDA9 PC 162565
DMQUDA9 MW 541.62
DMQUDA9 FM C10H15ClN5O13P3
DMQUDA9 IC InChI=1S/C10H15ClN5O13P3/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(27-9)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2-3,5-6,9,17-18H,1H2,(H,22,23)(H,24,25)(H2,12,14,15)(H2,19,20,21)/t3-,5-,6-,9-/m1/s1
DMQUDA9 CS C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)Cl)N
DMQUDA9 IK RNGCVFCOKZEZFL-UUOKFMHZSA-N
DMQUDA9 IU [[(2R,3S,4R,5R)-5-(6-amino-2-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMQUDA9 CA CAS 49564-60-5
DMQUDA9 DE Discovery agent
DMI89RL ID DMI89RL
DMI89RL DN 2-Chlorobenzenemethanethiol
DMI89RL HS Investigative
DMI89RL SN 2-Chlorobenzenemethanethiol; 39718-00-8; (2-Chlorophenyl)methanethiol; 2-Chlorobenzyl mercaptan; 2-Chlorobenzylmercaptan; 2-Chloro benzyl mercaptan; Benzenemethanethiol, 2-chloro-; CHEMBL1224556; WWFIIZLHSNBNTC-UHFFFAOYSA-N; 2-Chlorobenzyl mercaptan, 98%; o-chlorobenzylmercaptan; PubChem6836; AC1Q3PHW; AC1LBDF6; 2-chlorophenylmethanethiol; 2-chlorophenyl-methanethiol; 2-chloro-alpha-toluenethiol; ACMC-1CT33; SCHEMBL646102; (2-Chlorophenyl)methanethiol #; o-chlorotoluene-α-thiol; CTK3J1402
DMI89RL DT Small molecular drug
DMI89RL PC 580759
DMI89RL MW 158.65
DMI89RL FM C7H7ClS
DMI89RL IC InChI=1S/C7H7ClS/c8-7-4-2-1-3-6(7)5-9/h1-4,9H,5H2
DMI89RL CS C1=CC=C(C(=C1)CS)Cl
DMI89RL IK WWFIIZLHSNBNTC-UHFFFAOYSA-N
DMI89RL IU (2-chlorophenyl)methanethiol
DMI89RL CA CAS 39718-00-8
DMI89RL DE Discovery agent
DMR8M36 ID DMR8M36
DMR8M36 DN 2-Chloro-N-(2-morpholinoethyl)nicotinamide
DMR8M36 HS Investigative
DMR8M36 SN 2-Chloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL598814; 551901-48-5; 2-CHLORO-N-[2-(MORPHOLIN-4-YL)ETHYL]PYRIDINE-3-CARBOXAMIDE; AC1MRDK5; CTK7F9629; 2-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide; MolPort-003-989-877; ZINC19387520; BDBM50307207; AKOS000160265
DMR8M36 DT Small molecular drug
DMR8M36 PC 3466480
DMR8M36 MW 269.73
DMR8M36 FM C12H16ClN3O2
DMR8M36 IC InChI=1S/C12H16ClN3O2/c13-11-10(2-1-3-14-11)12(17)15-4-5-16-6-8-18-9-7-16/h1-3H,4-9H2,(H,15,17)
DMR8M36 CS C1COCCN1CCNC(=O)C2=C(N=CC=C2)Cl
DMR8M36 IK DSNJJTFFMQNNPE-UHFFFAOYSA-N
DMR8M36 IU 2-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMR8M36 DE Discovery agent
DM2W71L ID DM2W71L
DM2W71L DN 2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide
DM2W71L HS Investigative
DM2W71L SN CHEMBL1088311; 2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide
DM2W71L DT Small molecular drug
DM2W71L PC 45375908
DM2W71L MW 385.2
DM2W71L FM C20H14Cl2N2O2
DM2W71L IC InChI=1S/C20H14Cl2N2O2/c21-14-6-3-5-13(11-14)19(25)23-15-7-4-8-16(12-15)24-20(26)17-9-1-2-10-18(17)22/h1-12H,(H,23,25)(H,24,26)
DM2W71L CS C1=CC=C(C(=C1)C(=O)NC2=CC=CC(=C2)NC(=O)C3=CC(=CC=C3)Cl)Cl
DM2W71L IK IKCXGGCLQZZTJZ-UHFFFAOYSA-N
DM2W71L IU 2-chloro-N-[3-[(3-chlorobenzoyl)amino]phenyl]benzamide
DM2W71L DE Discovery agent
DM5S1DW ID DM5S1DW
DM5S1DW DN 2-Chloro-N-(3-morpholinopropyl)nicotinamide
DM5S1DW HS Investigative
DM5S1DW SN CHEMBL608436; 2-Chloro-N-(3-morpholinopropyl)nicotinamide; AC1N46O7; 2-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide; ZINC23379340; BDBM50307194; AKOS003849609; KB-120077
DM5S1DW DT Small molecular drug
DM5S1DW PC 4124566
DM5S1DW MW 283.75
DM5S1DW FM C13H18ClN3O2
DM5S1DW IC InChI=1S/C13H18ClN3O2/c14-12-11(3-1-4-15-12)13(18)16-5-2-6-17-7-9-19-10-8-17/h1,3-4H,2,5-10H2,(H,16,18)
DM5S1DW CS C1COCCN1CCCNC(=O)C2=C(N=CC=C2)Cl
DM5S1DW IK YLZONZBOTGMALV-UHFFFAOYSA-N
DM5S1DW IU 2-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DM5S1DW DE Discovery agent
DMBKVM4 ID DMBKVM4
DMBKVM4 DN 2-chloro-N-(6-cyanopyridin-3-yl)propanamide
DMBKVM4 HS Investigative
DMBKVM4 SN 2-chloro-N-(6-cyanopyridin-3-yl)propanamide; 1112994-35-0; SCHEMBL1483919; CHEMBL446834; VFOLQYOVUCHHET-UHFFFAOYSA-N
DMBKVM4 DT Small molecular drug
DMBKVM4 PC 25141337
DMBKVM4 MW 209.63
DMBKVM4 FM C9H8ClN3O
DMBKVM4 IC InChI=1S/C9H8ClN3O/c1-6(10)9(14)13-8-3-2-7(4-11)12-5-8/h2-3,5-6H,1H3,(H,13,14)
DMBKVM4 CS CC(C(=O)NC1=CN=C(C=C1)C#N)Cl
DMBKVM4 IK VFOLQYOVUCHHET-UHFFFAOYSA-N
DMBKVM4 IU 2-chloro-N-(6-cyanopyridin-3-yl)propanamide
DMBKVM4 DE Discovery agent
DMLDQ6I ID DMLDQ6I
DMLDQ6I DN 2-chloro-N-(o-tolylcarbamoyl)benzamide
DMLDQ6I HS Investigative
DMLDQ6I SN CHEMBL1169825; 2-chloro-N-(o-tolylcarbamoyl)benzamide
DMLDQ6I DT Small molecular drug
DMLDQ6I PC 15740307
DMLDQ6I MW 288.73
DMLDQ6I FM C15H13ClN2O2
DMLDQ6I IC InChI=1S/C15H13ClN2O2/c1-10-6-2-5-9-13(10)17-15(20)18-14(19)11-7-3-4-8-12(11)16/h2-9H,1H3,(H2,17,18,19,20)
DMLDQ6I CS CC1=CC=CC=C1NC(=O)NC(=O)C2=CC=CC=C2Cl
DMLDQ6I IK BXURYJIVZUMNBL-UHFFFAOYSA-N
DMLDQ6I IU 2-chloro-N-[(2-methylphenyl)carbamoyl]benzamide
DMLDQ6I DE Discovery agent
DM2E3X5 ID DM2E3X5
DM2E3X5 DN 2-Chlorophenol
DM2E3X5 HS Investigative
DM2E3X5 SN 2-CHLOROPHENOL; o-Chlorophenol; 95-57-8; Phenol, 2-chloro-; 2-Hydroxychlorobenzene; o-Chlorphenol; o-Chlorophenic acid; Phenol, o-chloro-; 2-Chloro-1-hydroxybenzene; CHLOROPHENOL; Septi-Kleen; 2-chloro-phenol; RCRA waste number U048; Pine-O Disinfectant; Caswell No. 203; o-Chlorphenol [German]; UNII-K9KAV4K6BN; Phenol, chloro-; NSC 2870; CCRIS 640; HSDB 1415; EINECS 202-433-2; K9KAV4K6BN; RCRA waste no. U048; 1-Chloro-2-hydroxybenzene; EPA Pesticide Chemical Code 062204; AI3-09060; CHEBI:47083; ISPYQTSUDJAMAB-UHFFFAOYSA-N
DM2E3X5 DT Small molecular drug
DM2E3X5 PC 7245
DM2E3X5 MW 128.55
DM2E3X5 FM C6H5ClO
DM2E3X5 IC InChI=1S/C6H5ClO/c7-5-3-1-2-4-6(5)8/h1-4,8H
DM2E3X5 CS C1=CC=C(C(=C1)O)Cl
DM2E3X5 IK ISPYQTSUDJAMAB-UHFFFAOYSA-N
DM2E3X5 IU 2-chlorophenol
DM2E3X5 CA CAS 95-57-8
DM2E3X5 CB CHEBI:47083
DM2E3X5 DE Discovery agent
DMXYTGU ID DMXYTGU
DMXYTGU DN 2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide
DMXYTGU HS Investigative
DMXYTGU SN CHEMBL594848; 2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide
DMXYTGU DT Small molecular drug
DMXYTGU PC 46228282
DMXYTGU MW 389.5
DMXYTGU FM C21H31N3O4
DMXYTGU IC InChI=1S/C21H31N3O4/c1-2-3-4-5-6-10-15-22-20(26)16-18(21(27)24-28)23-19(25)14-13-17-11-8-7-9-12-17/h7-9,11-14,18,28H,2-6,10,15-16H2,1H3,(H,22,26)(H,23,25)(H,24,27)/b14-13+/t18-/m1/s1
DMXYTGU CS CCCCCCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DMXYTGU IK TYVAVCSSCPJBHI-KAUXGEHWSA-N
DMXYTGU IU (2R)-N-hydroxy-N'-octyl-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DMXYTGU DE Discovery agent
DMI6FZN ID DMI6FZN
DMI6FZN DN 2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide
DMI6FZN HS Investigative
DMI6FZN SN CHEMBL596560; 2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide
DMI6FZN DT Small molecular drug
DMI6FZN PC 45257111
DMI6FZN MW 347.4
DMI6FZN FM C18H25N3O4
DMI6FZN IC InChI=1S/C18H25N3O4/c1-2-3-7-12-19-17(23)13-15(18(24)21-25)20-16(22)11-10-14-8-5-4-6-9-14/h4-6,8-11,15,25H,2-3,7,12-13H2,1H3,(H,19,23)(H,20,22)(H,21,24)/b11-10+/t15-/m1/s1
DMI6FZN CS CCCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DMI6FZN IK GEWJSTSZXRZGCY-AUECHBEKSA-N
DMI6FZN IU (2R)-N-hydroxy-N'-pentyl-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DMI6FZN DE Discovery agent
DMRNGK7 ID DMRNGK7
DMRNGK7 DN 2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide
DMRNGK7 HS Investigative
DMRNGK7 SN CHEMBL595209; 2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide
DMRNGK7 DT Small molecular drug
DMRNGK7 PC 46228278
DMRNGK7 MW 361.4
DMRNGK7 FM C19H27N3O4
DMRNGK7 IC InChI=1S/C19H27N3O4/c1-2-3-4-8-13-20-18(24)14-16(19(25)22-26)21-17(23)12-11-15-9-6-5-7-10-15/h5-7,9-12,16,26H,2-4,8,13-14H2,1H3,(H,20,24)(H,21,23)(H,22,25)/b12-11+/t16-/m1/s1
DMRNGK7 CS CCCCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DMRNGK7 IK AOIMNHYQILMKAB-LPQFERQCSA-N
DMRNGK7 IU (2R)-N'-hexyl-N-hydroxy-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DMRNGK7 DE Discovery agent
DM4235F ID DM4235F
DM4235F DN 2-Cl-ADP(alpha-BH3)
DM4235F HS Investigative
DM4235F SN 2-Cl-ADP(alpha-BH3); GTPL8447; CHEMBL2386491; BDBM50435011
DM4235F DT Small molecular drug
DM4235F PC 71733822
DM4235F MW 455.45
DM4235F FM C10H13BClN5O9P2-
DM4235F IC InChI=1S/C10H13BClN5O9P2/c11-27(20,26-28(21,22)23)24-1-3-5(18)6(19)9(25-3)17-2-14-4-7(13)15-10(12)16-8(4)17/h2-3,5-6,9,18-19H,1H2,(H2,13,15,16)(H2,21,22,23)/q-1/t3-,5-,6-,9-,27-/m1/s1
DM4235F CS [B-][P@@](=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)N)O)O)OP(=O)(O)O
DM4235F IK XLTJNJOUVKOQCW-MWZJDIDNSA-N
DM4235F DE Discovery agent
DMCN6PY ID DMCN6PY
DMCN6PY DN 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide
DMCN6PY HS Investigative
DMCN6PY SN Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR
DMCN6PY DT Small molecular drug
DMCN6PY PC 5328768
DMCN6PY MW 204.18
DMCN6PY FM C10H8N2O3
DMCN6PY IC InChI=1S/C10H8N2O3/c11-5-7(10(12)15)3-6-1-2-8(13)9(14)4-6/h1-4,13-14H,(H2,12,15)/b7-3+
DMCN6PY CS C1=CC(=C(C=C1/C=C(\\C#N)/C(=O)N)O)O
DMCN6PY IK USOXQZNJFMKTKJ-XVNBXDOJSA-N
DMCN6PY IU (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
DMCN6PY CA CAS 118409-59-9
DMCN6PY DE Discovery agent
DM2U1N5 ID DM2U1N5
DM2U1N5 DN 2-Cyclohex-1-enylethynyl-pyridine
DM2U1N5 HS Investigative
DM2U1N5 SN CHEMBL196643; 2-Cyclohex-1-enylethynyl-pyridine; 2-(1-Cyclohexenyl)ethynylpyridine
DM2U1N5 DT Small molecular drug
DM2U1N5 PC 12811063
DM2U1N5 MW 183.25
DM2U1N5 FM C13H13N
DM2U1N5 IC InChI=1S/C13H13N/c1-2-6-12(7-3-1)9-10-13-8-4-5-11-14-13/h4-6,8,11H,1-3,7H2
DM2U1N5 CS C1CCC(=CC1)C#CC2=CC=CC=N2
DM2U1N5 IK ZWQFPYQWWDBORG-UHFFFAOYSA-N
DM2U1N5 IU 2-[2-(cyclohexen-1-yl)ethynyl]pyridine
DM2U1N5 DE Discovery agent
DMS1T0V ID DMS1T0V
DMS1T0V DN 2-Cyclohexylacetic acidbiphenyl-3-yl ester
DMS1T0V HS Investigative
DMS1T0V SN CHEMBL505895; 2-Cyclohexylacetic acidbiphenyl-3-yl ester
DMS1T0V DT Small molecular drug
DMS1T0V PC 24881867
DMS1T0V MW 294.4
DMS1T0V FM C20H22O2
DMS1T0V IC InChI=1S/C20H22O2/c21-20(14-16-8-3-1-4-9-16)22-19-13-7-12-18(15-19)17-10-5-2-6-11-17/h2,5-7,10-13,15-16H,1,3-4,8-9,14H2
DMS1T0V CS C1CCC(CC1)CC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMS1T0V IK VBMZBWIWRKLCHP-UHFFFAOYSA-N
DMS1T0V IU (3-phenylphenyl) 2-cyclohexylacetate
DMS1T0V DE Discovery agent
DMFBD3K ID DMFBD3K
DMFBD3K DN 2-cyclohexylamido-5-sulfonamidoindane
DMFBD3K HS Investigative
DMFBD3K SN CHEMBL204990; 2-cyclohexylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12b; BDBM11033
DMFBD3K DT Small molecular drug
DMFBD3K PC 11623958
DMFBD3K MW 322.4
DMFBD3K FM C16H22N2O3S
DMFBD3K IC InChI=1S/C16H22N2O3S/c17-22(20,21)15-7-6-12-8-14(9-13(12)10-15)18-16(19)11-4-2-1-3-5-11/h6-7,10-11,14H,1-5,8-9H2,(H,18,19)(H2,17,20,21)
DMFBD3K CS C1CCC(CC1)C(=O)NC2CC3=C(C2)C=C(C=C3)S(=O)(=O)N
DMFBD3K IK PUAFUZDTMVHXBP-UHFFFAOYSA-N
DMFBD3K IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)cyclohexanecarboxamide
DMFBD3K DE Discovery agent
DMFMZRB ID DMFMZRB
DMFMZRB DN 2-cyclohexylamino-pyridine-2-carbonitrile
DMFMZRB HS Investigative
DMFMZRB SN 2-Cyano-pyridine, 8; 2-Pyridinecarbonitrile, 6-(cyclohexylamino)-; CHEMBL218522; BDBM19747; AKOS013783092; 927176-95-2
DMFMZRB DT Small molecular drug
DMFMZRB PC 16108897
DMFMZRB MW 201.27
DMFMZRB FM C12H15N3
DMFMZRB IC InChI=1S/C12H15N3/c13-9-11-7-4-8-12(15-11)14-10-5-2-1-3-6-10/h4,7-8,10H,1-3,5-6H2,(H,14,15)
DMFMZRB CS C1CCC(CC1)NC2=CC=CC(=N2)C#N
DMFMZRB IK IBXQOGXYFIMECI-UHFFFAOYSA-N
DMFMZRB IU 6-(cyclohexylamino)pyridine-2-carbonitrile
DMFMZRB DE Discovery agent
DMMIGXO ID DMMIGXO
DMMIGXO DN 2-cyclohexylamino-pyrimidine-4-carbonitrile
DMMIGXO HS Investigative
DMMIGXO SN 4-Cyano-pyrimidine, 9; 2-(cyclohexylamino)pyrimidine-4-carbonitrile; CHEMBL221804; BDBM19748; 927176-96-3; 4-Pyrimidinecarbonitrile, 2-(cyclohexylamino)-
DMMIGXO DT Small molecular drug
DMMIGXO PC 16108885
DMMIGXO MW 202.26
DMMIGXO FM C11H14N4
DMMIGXO IC InChI=1S/C11H14N4/c12-8-10-6-7-13-11(15-10)14-9-4-2-1-3-5-9/h6-7,9H,1-5H2,(H,13,14,15)
DMMIGXO CS C1CCC(CC1)NC2=NC=CC(=N2)C#N
DMMIGXO IK SOIZAJGZULPDSF-UHFFFAOYSA-N
DMMIGXO IU 2-(cyclohexylamino)pyrimidine-4-carbonitrile
DMMIGXO DE Discovery agent
DM2JZ84 ID DM2JZ84
DM2JZ84 DN 2-Cyclohexylethynyl-pyridine
DM2JZ84 HS Investigative
DM2JZ84 SN 2-Cyclohexylethynyl-pyridine; CHEMBL195965; 2-(Cyclohexylethynyl)pyridine
DM2JZ84 DT Small molecular drug
DM2JZ84 PC 44403640
DM2JZ84 MW 185.26
DM2JZ84 FM C13H15N
DM2JZ84 IC InChI=1S/C13H15N/c1-2-6-12(7-3-1)9-10-13-8-4-5-11-14-13/h4-5,8,11-12H,1-3,6-7H2
DM2JZ84 CS C1CCC(CC1)C#CC2=CC=CC=N2
DM2JZ84 IK WDQDPHLOSGNFKP-UHFFFAOYSA-N
DM2JZ84 IU 2-(2-cyclohexylethynyl)pyridine
DM2JZ84 DE Discovery agent
DMF6PMU ID DMF6PMU
DMF6PMU DN 2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide
DMF6PMU HS Investigative
DMF6PMU SN CHEMBL192523; 2-cyclohexyl-N-(4-methoxyphenyl)acetamide; CBMicro_031991; AC1LH2YD; 2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide; Oprea1_584438; SCHEMBL12931990; MolPort-002-194-789; ZINC451523; STL384380; BDBM50167041; AKOS001067578; MCULE-9916735458; BIM-0031907.P001; SR-01000232787
DMF6PMU DT Small molecular drug
DMF6PMU PC 880925
DMF6PMU MW 247.33
DMF6PMU FM C15H21NO2
DMF6PMU IC InChI=1S/C15H21NO2/c1-18-14-9-7-13(8-10-14)16-15(17)11-12-5-3-2-4-6-12/h7-10,12H,2-6,11H2,1H3,(H,16,17)
DMF6PMU CS COC1=CC=C(C=C1)NC(=O)CC2CCCCC2
DMF6PMU IK SCFJMQSXUCFKPS-UHFFFAOYSA-N
DMF6PMU IU 2-cyclohexyl-N-(4-methoxyphenyl)acetamide
DMF6PMU DE Discovery agent
DM89CLH ID DM89CLH
DM89CLH DN 2-Cyclohexyl-N-phenethyl-acetamide
DM89CLH HS Investigative
DM89CLH SN CHEMBL193019; 2-cyclohexyl-N-phenethyl-acetamide; AC1LM26R; Oprea1_260865; SCHEMBL12932020; 2-cyclohexyl-N-phenethylacetamide; MolPort-002-220-431; ZINC858629; STK222764; BDBM50167042; AKOS003337086; MCULE-6211391975
DM89CLH DT Small molecular drug
DM89CLH PC 1121089
DM89CLH MW 245.36
DM89CLH FM C16H23NO
DM89CLH IC InChI=1S/C16H23NO/c18-16(13-15-9-5-2-6-10-15)17-12-11-14-7-3-1-4-8-14/h1,3-4,7-8,15H,2,5-6,9-13H2,(H,17,18)
DM89CLH CS C1CCC(CC1)CC(=O)NCCC2=CC=CC=C2
DM89CLH IK BDWDBZQULOREPW-UHFFFAOYSA-N
DM89CLH IU 2-cyclohexyl-N-(2-phenylethyl)acetamide
DM89CLH DE Discovery agent
DMBJUP5 ID DMBJUP5
DMBJUP5 DN 2-Cyclohexyl-N-phenyl-acetamide
DMBJUP5 HS Investigative
DMBJUP5 SN 2-cyclohexyl-N-phenylacetamide; CHEMBL191663; 2-Cyclohexyl-N-phenyl-acetamide; 4-Cyclohexylacetanilide; CBMicro_047799; AC1LH2Y4; Cambridge id 6369179; SCHEMBL3822162; WIFWWZGKYZCASF-UHFFFAOYSA-N; MolPort-002-194-779; ZINC451519; BDBM50167040; STL384376; AKOS008916535; BIM-0047893.P001; SR-01000232777
DMBJUP5 DT Small molecular drug
DMBJUP5 PC 880922
DMBJUP5 MW 217.31
DMBJUP5 FM C14H19NO
DMBJUP5 IC InChI=1S/C14H19NO/c16-14(11-12-7-3-1-4-8-12)15-13-9-5-2-6-10-13/h2,5-6,9-10,12H,1,3-4,7-8,11H2,(H,15,16)
DMBJUP5 CS C1CCC(CC1)CC(=O)NC2=CC=CC=C2
DMBJUP5 IK WIFWWZGKYZCASF-UHFFFAOYSA-N
DMBJUP5 IU 2-cyclohexyl-N-phenylacetamide
DMBJUP5 DE Discovery agent
DMVP6CW ID DMVP6CW
DMVP6CW DN 2-Cyclopent-1-enylethynyl-pyridine
DMVP6CW HS Investigative
DMVP6CW SN CHEMBL443487; 2-Cyclopent-1-enylethynyl-pyridine; 2-(cyclopent-1-enyl-ethynyl)-pyridine; BDBM50172132
DMVP6CW DT Small molecular drug
DMVP6CW PC 12811064
DMVP6CW MW 169.22
DMVP6CW FM C12H11N
DMVP6CW IC InChI=1S/C12H11N/c1-2-6-11(5-1)8-9-12-7-3-4-10-13-12/h3-5,7,10H,1-2,6H2
DMVP6CW CS C1CC=C(C1)C#CC2=CC=CC=N2
DMVP6CW IK PJMNINJICZHJJV-UHFFFAOYSA-N
DMVP6CW IU 2-[2-(cyclopenten-1-yl)ethynyl]pyridine
DMVP6CW DE Discovery agent
DM6CZAN ID DM6CZAN
DM6CZAN DN 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DM6CZAN HS Investigative
DM6CZAN SN CHEMBL19970; 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine; ZINC13821060; BDBM50011595
DM6CZAN DT Small molecular drug
DM6CZAN PC 14896621
DM6CZAN MW 252.31
DM6CZAN FM C15H16N4
DM6CZAN IC InChI=1S/C15H16N4/c16-14-13-12(10-7-3-4-8-11(10)17-14)18-15(19-13)9-5-1-2-6-9/h3-4,7-9H,1-2,5-6H2,(H2,16,17)(H,18,19)
DM6CZAN CS C1CCC(C1)C2=NC3=C(N2)C(=NC4=CC=CC=C43)N
DM6CZAN IK KPONPDGMNFNBFA-UHFFFAOYSA-N
DM6CZAN IU 2-cyclopentyl-3H-imidazo[4,5-c]quinolin-4-amine
DM6CZAN DE Discovery agent
DMS947W ID DMS947W
DMS947W DN 2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol
DMS947W HS Investigative
DMS947W SN CHEMBL84940; 2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol
DMS947W DT Small molecular drug
DMS947W PC 44462095
DMS947W MW 200.28
DMS947W FM C10H20N2O2
DMS947W IC InChI=1S/C10H20N2O2/c13-9-6-12-8(10(9)14)5-11-7-3-1-2-4-7/h7-14H,1-6H2
DMS947W CS C1CCC(C1)NCC2C(C(CN2)O)O
DMS947W IK CAYLVMUUXWDLQS-UHFFFAOYSA-N
DMS947W IU 2-[(cyclopentylamino)methyl]pyrrolidine-3,4-diol
DMS947W DE Discovery agent
DMRS6LH ID DMRS6LH
DMRS6LH DN 2-Cyclopropanecarbonyl-cyclohexane-1,3-dione
DMRS6LH HS Investigative
DMRS6LH SN CHEMBL355709; 288258-62-8; 2-Cyclopropanecarbonyl-cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(cyclopropylcarbonyl)-; SCHEMBL10192859; BDBM50088792; 2-cyclopropanecarbonylcyclohexane-1,3-dione
DMRS6LH DT Small molecular drug
DMRS6LH PC 44380695
DMRS6LH MW 180.2
DMRS6LH FM C10H12O3
DMRS6LH IC InChI=1S/C10H12O3/c11-7-2-1-3-8(12)9(7)10(13)6-4-5-6/h6,9H,1-5H2
DMRS6LH CS C1CC(=O)C(C(=O)C1)C(=O)C2CC2
DMRS6LH IK DYVQTUZCXQZYGL-UHFFFAOYSA-N
DMRS6LH IU 2-(cyclopropanecarbonyl)cyclohexane-1,3-dione
DMRS6LH DE Discovery agent
DM0W2QB ID DM0W2QB
DM0W2QB DN 2-Cyclopropylmethylenepropanal
DM0W2QB HS Investigative
DM0W2QB SN 2-Cyclopropylmethylenepropanal; AC1NRALT; (2S)-3-cyclopropyl-2-methylpropanal
DM0W2QB DT Small molecular drug
DM0W2QB PC 5287974
DM0W2QB MW 112.17
DM0W2QB FM C7H12O
DM0W2QB IC InChI=1S/C7H12O/c1-6(5-8)4-7-2-3-7/h5-7H,2-4H2,1H3/t6-/m0/s1
DM0W2QB CS C[C@@H](CC1CC1)C=O
DM0W2QB IK NOQCSSAEKDLHCI-LURJTMIESA-N
DM0W2QB IU (2S)-3-cyclopropyl-2-methylpropanal
DM0W2QB DE Discovery agent
DMIAM5L ID DMIAM5L
DMIAM5L DN 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid
DMIAM5L HS Investigative
DMIAM5L SN 24967-27-9; Neu5Ac2en; 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid; N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid; 2-deoxy-2,3-dehydro-n-acetyl-neuraminic acid; 2,3-Dehydro-2-deoxy-N-acetylneuraminic acid; N-Acetyl-2,3-didehydro-2-deoxyneuraminic acid; EINECS 246-550-7; CHEMBL96712; CHEBI:28062; C11H17NO8; (2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 1,3-Dehydro-2-deoxy-N-acetylneuraminic acid
DMIAM5L DT Small molecular drug
DMIAM5L PC 65309
DMIAM5L MW 291.25
DMIAM5L FM C11H17NO8
DMIAM5L IC InChI=1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1
DMIAM5L CS CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)O
DMIAM5L IK JINJZWSZQKHCIP-UFGQHTETSA-N
DMIAM5L IU (2R,3R,4S)-3-acetamido-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMIAM5L CA CAS 24967-27-9
DMIAM5L CB CHEBI:28062
DMBMK4T ID DMBMK4T
DMBMK4T DN 2-Deoxy-2-Amino Glucitol-6-Phosphate
DMBMK4T HS Investigative
DMBMK4T SN 2-Deoxy-2-Amino Glucitol-6-Phosphate; AGP; 2-amino-2-deoxy-D-glucitol 6-phosphate; 2-amino-2-deoxy-6-O-phosphono-D-glucitol; AC1L9J4R; SCHEMBL2847976; CHEMBL396380; DB02445; 2-amino-2-deoxy-d-glucitol-6-phosphate; D-Glucitol, 2-amino-2-deoxy-, 6-(dihydrogen phosphate); [(2R,3S,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexyl] dihydrogen phosphate; [(2R,3S,4R,5S)-5-amino-2,3,4,6-tetrahydroxy-hexyl] dihydrogen phosphate
DMBMK4T DT Small molecular drug
DMBMK4T PC 446113
DMBMK4T MW 261.17
DMBMK4T FM C6H16NO8P
DMBMK4T IC InChI=1S/C6H16NO8P/c7-3(1-8)5(10)6(11)4(9)2-15-16(12,13)14/h3-6,8-11H,1-2,7H2,(H2,12,13,14)/t3-,4+,5+,6+/m0/s1
DMBMK4T CS C([C@@H]([C@H]([C@@H]([C@@H](COP(=O)(O)O)O)O)O)N)O
DMBMK4T IK LBNVXZROMBUNNQ-SLPGGIOYSA-N
DMBMK4T IU [(2R,3S,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexyl] dihydrogen phosphate
DMBMK4T DE Discovery agent
DMMC8IG ID DMMC8IG
DMMC8IG DN 2-Deoxy-2fluoro-Glucose
DMMC8IG HS Investigative
DMMC8IG SN 2-deoxy-2-fluoro-beta-D-glucopyranose; 2-DEOXY-2FLUORO-GLUCOSE; UNII-41XAV5II5H; 41XAV5II5H; CHEBI:49128; 2-deoxy-2-fluoro-beta-D-glucose; NSC-240588; AC1NRBA5; beta-D-Fludeoxyglucopyranose; SCHEMBL4323343; CHEMBL1235932; ZINC4329335; G2F; 2-Fluoro-2-deoxy-beta-D-glucopyranose; beta-D-Glucopyranose, 2-deoxy-2-fluoro-; WURCS=2.0/1,1,0/[a2122h-1b_1-5_2*F]/1/
DMMC8IG DT Small molecular drug
DMMC8IG PC 5288324
DMMC8IG MW 182.15
DMMC8IG FM C6H11FO5
DMMC8IG IC InChI=1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2/t2-,3-,4-,5-,6-/m1/s1
DMMC8IG CS C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)F)O)O)O
DMMC8IG IK ZCXUVYAZINUVJD-QZABAPFNSA-N
DMMC8IG IU (2R,3R,4S,5S,6R)-3-fluoro-6-(hydroxymethyl)oxane-2,4,5-triol
DMMC8IG CA CAS 38711-37-4
DMMC8IG CB CHEBI:49128
DMMC8IG DE Discovery agent
DMG7CAU ID DMG7CAU
DMG7CAU DN 2'-Deoxycytidine-5'-Monophosphate
DMG7CAU HS Investigative
DMG7CAU SN 1032-65-1; dCMP; deoxycytidylic acid; 2'-Deoxycytidine-5'-monophosphoric acid; deoxycytidine monophosphate; 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE; 5'-Cytidylic acid, 2'-deoxy-; 2'-Deoxycytidine 5'-monophosphate; Deoxycytidine-5'-monophosphoric acid; Deoxycytidylate; Polydeoxycytidylic acid; UNII-W7A9174XQL; 2'-deoxy-5'-cytidylic acid; W7A9174XQL; CHEBI:15918; NCMVOABPESMRCP-SHYZEUOFSA-N; deoxycytidine-phosphate; 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE FREE ACID
DMG7CAU DT Small molecular drug
DMG7CAU PC 13945
DMG7CAU MW 307.2
DMG7CAU FM C9H14N3O7P
DMG7CAU IC InChI=1S/C9H14N3O7P/c10-7-1-2-12(9(14)11-7)8-3-5(13)6(19-8)4-18-20(15,16)17/h1-2,5-6,8,13H,3-4H2,(H2,10,11,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMG7CAU CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(O)O)O
DMG7CAU IK NCMVOABPESMRCP-SHYZEUOFSA-N
DMG7CAU IU [(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMG7CAU CA CAS 1032-65-1
DMG7CAU CB CHEBI:15918
DMG7CAU DE Discovery agent
DMMPL3D ID DMMPL3D
DMMPL3D DN 2-Deoxy-Glucose-6-Phosphate
DMMPL3D HS Investigative
DMMPL3D SN D6G; 2-Deoxy-6-O-Phosphono-Alpha-D-Arabino-Hexopyranose; 2pri; AC1L9N1X; ZINC4097095; 2-deoxy-alpha-D-glucopyranose 6-phosphate; [(2R,3S,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMMPL3D DT Small molecular drug
DMMPL3D PC 46936435
DMMPL3D MW 244.14
DMMPL3D FM C6H13O8P
DMMPL3D IC InChI=1S/C6H13O8P/c7-3-1-5(8)14-4(6(3)9)2-13-15(10,11)12/h3-9H,1-2H2,(H2,10,11,12)/t3-,4-,5-,6+/m1/s1
DMMPL3D CS C1[C@H]([C@@H]([C@H](O[C@H]1O)COP(=O)(O)O)O)O
DMMPL3D IK UQJFZAAGZAYVKZ-KAZBKCHUSA-N
DMMPL3D IU [(2R,3S,4R,6R)-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMMPL3D DE Discovery agent
DMY9FDT ID DMY9FDT
DMY9FDT DN 2'-Deoxyguanosine-5'-Monophosphate
DMY9FDT HS Investigative
DMY9FDT SN Deoxyguanylic acid; Deoxy-GMP; 2'-Deoxyguanylic acid; Deoxyguanylate; Deoxyguanosine 5'-monophosphate; dGMP; 2'-Deoxy-GMP; 2'-dGMP; Deoxyguanosine monophosphate; Deoxyguanosine 5'-phosphate; 2'-Deoxyguanosine 5'-phosphate; 2'-Deoxy-5'-guanylic acid; 2'-deoxyguanosine 5'-monophosphate; 5'-DGMP; 5'-Deoxyguanylic acid; Deoxy GMP; 2'-Deoxyguanosine 5'MP; 902-04-5; deoxyguanosine-phosphate; 5'-Guanylic acid, 2'-deoxy-; 2'-dG-5'-MP; 2'-Deoxy-5'-GMP; UNII-7EAM4TG712; 2'-Deoxyguanosine 5'-phosphoric; 5'-dGMP
DMY9FDT DT Small molecular drug
DMY9FDT PC 135398597
DMY9FDT MW 347.22
DMY9FDT FM C10H14N5O7P
DMY9FDT IC InChI=1S/C10H14N5O7P/c11-10-13-8-7(9(17)14-10)12-3-15(8)6-1-4(16)5(22-6)2-21-23(18,19)20/h3-6,16H,1-2H2,(H2,18,19,20)(H3,11,13,14,17)/t4-,5+,6+/m0/s1
DMY9FDT CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)O)O
DMY9FDT IK LTFMZDNNPPEQNG-KVQBGUIXSA-N
DMY9FDT IU [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMY9FDT CA CAS 902-04-5
DMY9FDT CB CHEBI:16192
DMY9FDT DE Discovery agent
DM9OEJT ID DM9OEJT
DM9OEJT DN 2'-deoxythymidine triphosphate
DM9OEJT HS Investigative
DM9OEJT SN Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 2'-Deoxythymidine triphosphate; 5'-TTP; THYMIDINE-5'-TRIPHOSPHATE; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE; Thymidine-5'-Triphosphate
DM9OEJT DT Small molecular drug
DM9OEJT PC 64968
DM9OEJT MW 482.17
DM9OEJT FM C10H17N2O14P3
DM9OEJT IC InChI=1S/C10H17N2O14P3/c1-5-3-12(10(15)11-9(5)14)8-2-6(13)7(24-8)4-23-28(19,20)26-29(21,22)25-27(16,17)18/h3,6-8,13H,2,4H2,1H3,(H,19,20)(H,21,22)(H,11,14,15)(H2,16,17,18)/t6-,7+,8+/m0/s1
DM9OEJT CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
DM9OEJT IK NHVNXKFIZYSCEB-XLPZGREQSA-N
DM9OEJT IU [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate
DM9OEJT CA CAS 365-08-2
DM9OEJT CB CHEBI:18077
DM9OEJT DE Discovery agent
DM1HMWA ID DM1HMWA
DM1HMWA DN 2'-Deoxyuridine
DM1HMWA HS Investigative
DM1HMWA SN 2'-DEOXYURIDINE; 951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615; DEOXYURIDINE
DM1HMWA DT Small molecular drug
DM1HMWA PC 13712
DM1HMWA MW 228.2
DM1HMWA FM C9H12N2O5
DM1HMWA IC InChI=1S/C9H12N2O5/c12-4-6-5(13)3-8(16-6)11-2-1-7(14)10-9(11)15/h1-2,5-6,8,12-13H,3-4H2,(H,10,14,15)/t5-,6+,8+/m0/s1
DM1HMWA CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O
DM1HMWA IK MXHRCPNRJAMMIM-SHYZEUOFSA-N
DM1HMWA IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM1HMWA CA CAS 951-78-0
DM1HMWA CB CHEBI:16450
DM1HMWA DE Discovery agent
DMXV27U ID DMXV27U
DMXV27U DN 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate
DMXV27U HS Investigative
DMXV27U SN 2'-DEOXYURIDINE 5'-ALPHA,BETA-IMIDO-DIPHOSPHATE; DUN; AC1L9MQ3; 2,4(1H,3H)-PYRIMIDINEDIONE, 1-[2-DEOXY-5-O-[HYDROXY(PHOSPHONOAMINO)PHOSPHINYL]-BETA-D-ERYTHRO-PENTOFURANOSYL]-; DB03641; [(2'-Deoxy-5'-uridylyl)amino]phosphonic acid; 2'-deoxy-5'-O-[(R)-hydroxy(phosphonoamino)phosphoryl]uridine; 1-[2-DEOXY-5-O-[HYDROXY(PHOSPHONOAMINO)PHOSPHINYL]-BETA-D-ERYTHRO-PENTOFURANOSYL]-; [[[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]amino]phosphonic acid
DMXV27U DT Small molecular drug
DMXV27U PC 449098
DMXV27U MW 387.18
DMXV27U FM C9H15N3O10P2
DMXV27U IC InChI=1S/C9H15N3O10P2/c13-5-3-8(12-2-1-7(14)10-9(12)15)22-6(5)4-21-24(19,20)11-23(16,17)18/h1-2,5-6,8,13H,3-4H2,(H,10,14,15)(H4,11,16,17,18,19,20)/t5-,6+,8+/m0/s1
DMXV27U CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(NP(=O)(O)O)O)O
DMXV27U IK COFNIXBQVWFHTR-SHYZEUOFSA-N
DMXV27U IU [[[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]amino]phosphonic acid
DMXV27U CA CAS 178809-71-7
DMXV27U DE Discovery agent
DMOHABR ID DMOHABR
DMOHABR DN 2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate
DMOHABR HS Investigative
DMOHABR SN 2'-DEOXYURIDINE 5'-ALPHA,BETA-IMIDO-TRIPHOSPHATE; CHEMBL1232397; DUP; alpha,beta-Imino-dUTP; AC1L9LWH; BDBM50386619; DB01965; 2'-deoxy-5'-O-[(S)-hydroxy{[(R)-hydroxy(phosphonooxy)phosphoryl]amino}phosphoryl]uridine; [(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-N-[hydroxy(phosphonooxy)phosphoryl]phosphonamidic acid
DMOHABR DT Small molecular drug
DMOHABR PC 448381
DMOHABR MW 467.16
DMOHABR FM C9H16N3O13P3
DMOHABR IC InChI=1S/C9H16N3O13P3/c13-5-3-8(12-2-1-7(14)10-9(12)15)24-6(5)4-23-26(16,17)11-27(18,19)25-28(20,21)22/h1-2,5-6,8,13H,3-4H2,(H,10,14,15)(H2,20,21,22)(H3,11,16,17,18,19)/t5-,6+,8+/m0/s1
DMOHABR CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(NP(=O)(O)OP(=O)(O)O)O)O
DMOHABR IK XZLLMTSKYYYJLH-SHYZEUOFSA-N
DMOHABR IU [(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-N-[hydroxy(phosphonooxy)phosphoryl]phosphonamidic acid
DMOHABR DE Discovery agent
DMPV1LU ID DMPV1LU
DMPV1LU DN 2'-deoxyuridylic acid
DMPV1LU HS Investigative
DMPV1LU SN dUMP; 2'-deoxyuridylic acid; Deoxyuridine monophosphate; Deoxyuridylic acid; 2'-Deoxyuridine 5'-monophosphate; 2'-deoxy-5'-uridylic acid; Deoxyuridine 5'-phosphate; 2'-Deoxyuridine 5'-phosphate; Deoxy-UMP; 2'-Deoxyuridylate; 964-26-1; 2'-DEOXYURIDINE-5'-MONOPHOSPHATE; Deoxyuridine 5'-monophosphate; 5'-Uridylic acid, 2'-deoxy-; deoxyuridylate; Uridine, 2'-deoxy-, 5'-phosphate; EINECS 213-518-9; Uridine, 2'-deoxy-, 5'-(dihydrogen phosphate); BRN 0042143; CHEMBL211312; CHEBI:17622; JSRLJPSBLDHEIO-SHYZEUOFSA-N; 42155-08-8; 1tsy; 1tsv
DMPV1LU DT Small molecular drug
DMPV1LU PC 65063
DMPV1LU MW 308.18
DMPV1LU FM C9H13N2O8P
DMPV1LU IC InChI=1S/C9H13N2O8P/c12-5-3-8(11-2-1-7(13)10-9(11)14)19-6(5)4-18-20(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMPV1LU CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)O)O
DMPV1LU IK JSRLJPSBLDHEIO-SHYZEUOFSA-N
DMPV1LU IU [(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMPV1LU CA CAS 964-26-1
DMPV1LU CB CHEBI:17622
DMPV1LU DE Discovery agent
DM4A527 ID DM4A527
DM4A527 DN 2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one
DM4A527 HS Investigative
DM4A527 SN CHEMBL373979; 2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one; SCHEMBL13113941
DM4A527 DT Small molecular drug
DM4A527 PC 16204050
DM4A527 MW 347.4
DM4A527 FM C21H17NO4
DM4A527 IC InChI=1S/C21H17NO4/c23-14-12-19(25-20(13-14)22-8-10-24-11-9-22)17-6-3-5-16-15-4-1-2-7-18(15)26-21(16)17/h1-7,12-13H,8-11H2
DM4A527 CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=C3OC5=CC=CC=C45
DM4A527 IK YREPYLIFIQVESI-UHFFFAOYSA-N
DM4A527 IU 2-dibenzofuran-4-yl-6-morpholin-4-ylpyran-4-one
DM4A527 DE Discovery agent
DMF50YH ID DMF50YH
DMF50YH DN 2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol
DMF50YH HS Investigative
DMF50YH SN CHEMBL62297; 2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol
DMF50YH DT Small molecular drug
DMF50YH PC 44304339
DMF50YH MW 297.4
DMF50YH FM C20H27NO
DMF50YH IC InChI=1S/C20H27NO/c1-3-11-21(12-4-2)17-10-9-16-13-15-7-5-6-8-18(15)20(22)19(16)14-17/h5-8,13,17,22H,3-4,9-12,14H2,1-2H3
DMF50YH CS CCCN(CCC)C1CCC2=CC3=CC=CC=C3C(=C2C1)O
DMF50YH IK TXKDLYBWCJNMHU-UHFFFAOYSA-N
DMF50YH IU 2-(dipropylamino)-1,2,3,4-tetrahydroanthracen-9-ol
DMF50YH DE Discovery agent
DM2PDGO ID DM2PDGO
DM2PDGO DN 2-EPI-2-THIOSALVINORIN A
DM2PDGO HS Investigative
DM2PDGO SN 2-epi-2-thiosalvinorin A; CHEMBL231537
DM2PDGO DT Small molecular drug
DM2PDGO PC 44425462
DM2PDGO MW 448.5
DM2PDGO FM C23H28O7S
DM2PDGO IC InChI=1S/C23H28O7S/c1-12(24)31-17-9-15(20(26)28-4)22(2)7-5-14-21(27)30-16(13-6-8-29-11-13)10-23(14,3)19(22)18(17)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17+,19-,22-,23-/m0/s1
DM2PDGO CS CC(=O)S[C@@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DM2PDGO IK SIUXIXPAKGOVLQ-KWMFLVSKSA-N
DM2PDGO IU methyl (2S,4aR,6aR,7R,9R,10aS,10bR)-9-acetylsulfanyl-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM2PDGO DE Discovery agent
DMZXIW0 ID DMZXIW0
DMZXIW0 DN 2-EPI-2-THIOSALVINORIN B
DMZXIW0 HS Investigative
DMZXIW0 SN 2-epi-2-thiosalvinorin B; CHEMBL231638
DMZXIW0 DT Small molecular drug
DMZXIW0 PC 44425463
DMZXIW0 MW 406.5
DMZXIW0 FM C21H26O6S
DMZXIW0 IC InChI=1S/C21H26O6S/c1-20-6-4-12-19(24)27-14(11-5-7-26-10-11)9-21(12,2)17(20)16(22)15(28)8-13(20)18(23)25-3/h5,7,10,12-15,17,28H,4,6,8-9H2,1-3H3/t12-,13-,14-,15+,17-,20-,21-/m0/s1
DMZXIW0 CS C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@@H](C[C@H]2C(=O)OC)S)C)C4=COC=C4
DMZXIW0 IK NGNBKFTYZQINBO-ZNKMMSAYSA-N
DMZXIW0 IU methyl (2S,4aR,6aR,7R,9R,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-sulfanyl-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMZXIW0 DE Discovery agent
DMNVJY0 ID DMNVJY0
DMNVJY0 DN 2'-epi-guianin
DMNVJY0 HS Investigative
DMNVJY0 SN CHEMBL570978; 2'-epi-guianin; 2''-epi-guianin
DMNVJY0 DT Small molecular drug
DMNVJY0 PC 45487149
DMNVJY0 MW 352.4
DMNVJY0 FM C22H24O4
DMNVJY0 IC InChI=1S/C22H24O4/c1-4-6-15-11-22(9-5-2)13(3)18(19(20(15)23)21(22)24)14-7-8-16-17(10-14)26-12-25-16/h4-5,7-8,10-11,13,18-19,21,24H,1-2,6,9,12H2,3H3/t13-,18+,19?,21+,22+/m1/s1
DMNVJY0 CS C[C@@H]1[C@H](C2[C@@H]([C@]1(C=C(C2=O)CC=C)CC=C)O)C3=CC4=C(C=C3)OCO4
DMNVJY0 IK IELYWLBCFOCUNW-KUXMWZRESA-N
DMNVJY0 IU (5R,6R,7R,8S)-7-(1,3-benzodioxol-5-yl)-8-hydroxy-6-methyl-3,5-bis(prop-2-enyl)bicyclo[3.2.1]oct-3-en-2-one
DMNVJY0 DE Discovery agent
DMGRA3T ID DMGRA3T
DMGRA3T DN 2-ethoxy-5-(m-tolylethynyl)pyrimidine
DMGRA3T HS Investigative
DMGRA3T SN CHEMBL496874; 2-ethoxy-5-(m-tolylethynyl)pyrimidine; Pyrimidine,2-ethoxy-5-[2-(3-methylphenyl)ethynyl]-; BDBM50278923
DMGRA3T DT Small molecular drug
DMGRA3T PC 44190034
DMGRA3T MW 238.28
DMGRA3T FM C15H14N2O
DMGRA3T IC InChI=1S/C15H14N2O/c1-3-18-15-16-10-14(11-17-15)8-7-13-6-4-5-12(2)9-13/h4-6,9-11H,3H2,1-2H3
DMGRA3T CS CCOC1=NC=C(C=N1)C#CC2=CC=CC(=C2)C
DMGRA3T IK LZJPKUYOMGXTBK-UHFFFAOYSA-N
DMGRA3T IU 2-ethoxy-5-[2-(3-methylphenyl)ethynyl]pyrimidine
DMGRA3T DE Discovery agent
DM0BHKM ID DM0BHKM
DM0BHKM DN 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine
DM0BHKM HS Investigative
DM0BHKM SN CHEMBL265695; SCHEMBL3677848
DM0BHKM DT Small molecular drug
DM0BHKM PC 44449741
DM0BHKM MW 230.29
DM0BHKM FM C12H10N2OS
DM0BHKM IC InChI=1S/C12H10N2OS/c1-2-10-13-8-5-7-16-12(8)11(14-10)9-4-3-6-15-9/h3-7H,2H2,1H3
DM0BHKM CS CCC1=NC2=C(C(=N1)C3=CC=CO3)SC=C2
DM0BHKM IK UPHUXPVSRYTEBO-UHFFFAOYSA-N
DM0BHKM IU 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine
DM0BHKM DE Discovery agent
DMR0IEK ID DMR0IEK
DMR0IEK DN 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine
DMR0IEK HS Investigative
DMR0IEK SN CHEMBL259338; SCHEMBL3684676
DMR0IEK DT Small molecular drug
DMR0IEK PC 44449709
DMR0IEK MW 230.29
DMR0IEK FM C12H10N2OS
DMR0IEK IC InChI=1S/C12H10N2OS/c1-2-10-13-9-4-6-16-12(9)11(14-10)8-3-5-15-7-8/h3-7H,2H2,1H3
DMR0IEK CS CCC1=NC2=C(C(=N1)C3=COC=C3)SC=C2
DMR0IEK IK XVRNMWQROQLUBA-UHFFFAOYSA-N
DMR0IEK IU 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine
DMR0IEK DE Discovery agent
DMWFR16 ID DMWFR16
DMWFR16 DN 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine
DMWFR16 HS Investigative
DMWFR16 SN CHEMBL259337; SCHEMBL3684919
DMWFR16 DT Small molecular drug
DMWFR16 PC 9964781
DMWFR16 MW 241.31
DMWFR16 FM C13H11N3S
DMWFR16 IC InChI=1S/C13H11N3S/c1-2-11-15-10-6-8-17-13(10)12(16-11)9-5-3-4-7-14-9/h3-8H,2H2,1H3
DMWFR16 CS CCC1=NC2=C(C(=N1)C3=CC=CC=N3)SC=C2
DMWFR16 IK RJLBQJZGTPMDPY-UHFFFAOYSA-N
DMWFR16 IU 2-ethyl-4-pyridin-2-ylthieno[3,2-d]pyrimidine
DMWFR16 DE Discovery agent
DMWCGE8 ID DMWCGE8
DMWCGE8 DN 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8 HS Investigative
DMWCGE8 SN CHEMBL407650; 2-ethyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine; 443148-33-2; SCHEMBL3674131
DMWCGE8 DT Small molecular drug
DMWCGE8 PC 9834769
DMWCGE8 MW 247.3
DMWCGE8 FM C11H9N3S2
DMWCGE8 IC InChI=1S/C11H9N3S2/c1-2-8-13-7-3-5-15-10(7)9(14-8)11-12-4-6-16-11/h3-6H,2H2,1H3
DMWCGE8 CS CCC1=NC2=C(C(=N1)C3=NC=CS3)SC=C2
DMWCGE8 IK YNBYJWXOQPYWEM-UHFFFAOYSA-N
DMWCGE8 IU 2-ethyl-4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidine
DMWCGE8 DE Discovery agent
DMIRSQO ID DMIRSQO
DMIRSQO DN 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine
DMIRSQO HS Investigative
DMIRSQO SN CHEMBL402817; SCHEMBL3677642
DMIRSQO DT Small molecular drug
DMIRSQO PC 44449258
DMIRSQO MW 246.4
DMIRSQO FM C12H10N2S2
DMIRSQO IC InChI=1S/C12H10N2S2/c1-2-10-13-8-5-7-16-12(8)11(14-10)9-4-3-6-15-9/h3-7H,2H2,1H3
DMIRSQO CS CCC1=NC2=C(C(=N1)C3=CC=CS3)SC=C2
DMIRSQO IK HTDFKCHXFHIXPU-UHFFFAOYSA-N
DMIRSQO IU 2-ethyl-4-thiophen-2-ylthieno[3,2-d]pyrimidine
DMIRSQO DE Discovery agent
DMLC8OB ID DMLC8OB
DMLC8OB DN 2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole
DMLC8OB HS Investigative
DMLC8OB SN CHEMBL194412; 1h-indole,2-ethyl-5-methoxy-3-(4-piperidinyl)-; 866404-90-2; 2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole; ZINC28526364; BDBM50171247
DMLC8OB DT Small molecular drug
DMLC8OB PC 44403334
DMLC8OB MW 258.36
DMLC8OB FM C16H22N2O
DMLC8OB IC InChI=1S/C16H22N2O/c1-3-14-16(11-6-8-17-9-7-11)13-10-12(19-2)4-5-15(13)18-14/h4-5,10-11,17-18H,3,6-9H2,1-2H3
DMLC8OB CS CCC1=C(C2=C(N1)C=CC(=C2)OC)C3CCNCC3
DMLC8OB IK UMTBQNCFQQORNJ-UHFFFAOYSA-N
DMLC8OB IU 2-ethyl-5-methoxy-3-piperidin-4-yl-1H-indole
DMLC8OB DE Discovery agent
DMN8W1H ID DMN8W1H
DMN8W1H DN 2-ethyl-9H-carbazole
DMN8W1H HS Investigative
DMN8W1H SN 2-ethyl-9H-carbazole; 9H-Carbazole, 2-ethyl-; CHEMBL1171435; 106551-62-6; SCHEMBL278610; AC1L3D11; BDBM50322582
DMN8W1H DT Small molecular drug
DMN8W1H PC 138537
DMN8W1H MW 195.26
DMN8W1H FM C14H13N
DMN8W1H IC InChI=1S/C14H13N/c1-2-10-7-8-12-11-5-3-4-6-13(11)15-14(12)9-10/h3-9,15H,2H2,1H3
DMN8W1H CS CCC1=CC2=C(C=C1)C3=CC=CC=C3N2
DMN8W1H IK MLTJHZTUKWUPTG-UHFFFAOYSA-N
DMN8W1H IU 2-ethyl-9H-carbazole
DMN8W1H CA CAS 5599-49-5
DMN8W1H DE Discovery agent
DMDY3JQ ID DMDY3JQ
DMDY3JQ DN 2-ethylamido-5-sulfonamidoindane
DMDY3JQ HS Investigative
DMDY3JQ SN CHEMBL204740; 2-ethylamido-5-sulfonamidoindane; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)propanamide; Indanesulfonamide Derivative 12d
DMDY3JQ DT Small molecular drug
DMDY3JQ PC 11543564
DMDY3JQ MW 268.33
DMDY3JQ FM C12H16N2O3S
DMDY3JQ IC InChI=1S/C12H16N2O3S/c1-2-12(15)14-10-5-8-3-4-11(18(13,16)17)7-9(8)6-10/h3-4,7,10H,2,5-6H2,1H3,(H,14,15)(H2,13,16,17)
DMDY3JQ CS CCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMDY3JQ IK PFHQSNAQKZORAY-UHFFFAOYSA-N
DMDY3JQ IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)propanamide
DMDY3JQ DE Discovery agent
DMC10DR ID DMC10DR
DMC10DR DN 2-ethylestradiol 3,17-O,O-bis-sulfamate
DMC10DR HS Investigative
DMC10DR SN 2-ethylestradiol-3,17-O,O-bis-sulfamate; CHEMBL425287; (9beta,13alpha,14beta,17alpha)-2-Ethylestra-1(10),2,4-Triene-3,17-Diyl Disulfamate; 2-ethyloestradiol-bis-sulfamate; 3oik; WZB; 2x7t; 2-EbM; SCHEMBL3690812; BDBM50200941; LS-193106; 2-Ethyl-3,17beta-bis(sulfamoyloxy)estra-1,3,5(10)-triene; Estra-1,3,5(10)-triene-3,17-diol, 2-ethyl-, disulfamate, (17beta)-
DMC10DR DT Small molecular drug
DMC10DR PC 11583423
DMC10DR MW 458.6
DMC10DR FM C20H30N2O6S2
DMC10DR IC InChI=1S/C20H30N2O6S2/c1-3-12-10-16-13(11-18(12)27-29(21,23)24)4-5-15-14(16)8-9-20(2)17(15)6-7-19(20)28-30(22,25)26/h10-11,14-15,17,19H,3-9H2,1-2H3,(H2,21,23,24)(H2,22,25,26)/t14-,15+,17-,19-,20-/m0/s1
DMC10DR CS CCC1=C(C=C2CC[C@@H]3[C@@H](C2=C1)CC[C@]4([C@H]3CC[C@@H]4OS(=O)(=O)N)C)OS(=O)(=O)N
DMC10DR IK LDOGEZTUWBORPG-SSGANFLRSA-N
DMC10DR IU [(8R,9S,13S,14S,17S)-2-ethyl-13-methyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMC10DR CA CAS 556813-12-8
DMC10DR DE Discovery agent
DMKR47X ID DMKR47X
DMKR47X DN 2-ethylquinoline-8-carboxamide
DMKR47X HS Investigative
DMKR47X SN CHEMBL526128; 2-ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-ethyl-; BDBM50255330
DMKR47X DT Small molecular drug
DMKR47X PC 25208752
DMKR47X MW 200.24
DMKR47X FM C12H12N2O
DMKR47X IC InChI=1S/C12H12N2O/c1-2-9-7-6-8-4-3-5-10(12(13)15)11(8)14-9/h3-7H,2H2,1H3,(H2,13,15)
DMKR47X CS CCC1=NC2=C(C=CC=C2C(=O)N)C=C1
DMKR47X IK DFEARBGMUARFKD-UHFFFAOYSA-N
DMKR47X IU 2-ethylquinoline-8-carboxamide
DMKR47X DE Discovery agent
DME6VKS ID DME6VKS
DME6VKS DN 2-ethynyl-4-(3-fluorophenylethynyl)thiazole
DME6VKS HS Investigative
DME6VKS SN CHEMBL201939; 2-ethynyl-4-(3-fluorophenylethynyl)thiazole; SCHEMBL4138461; Thiazole, 2-ethynyl-4-[2-(3-fluorophenyl)ethynyl]-; BDBM50181773
DME6VKS DT Small molecular drug
DME6VKS PC 11550377
DME6VKS MW 227.26
DME6VKS FM C13H6FNS
DME6VKS IC InChI=1S/C13H6FNS/c1-2-13-15-12(9-16-13)7-6-10-4-3-5-11(14)8-10/h1,3-5,8-9H
DME6VKS CS C#CC1=NC(=CS1)C#CC2=CC(=CC=C2)F
DME6VKS IK SECGPKGEFXVRQQ-UHFFFAOYSA-N
DME6VKS IU 2-ethynyl-4-[2-(3-fluorophenyl)ethynyl]-1,3-thiazole
DME6VKS DE Discovery agent
DM2D78W ID DM2D78W
DM2D78W DN 2-ethynyl-N6-methoxyadenosine
DM2D78W HS Investigative
DM2D78W SN CHEMBL374019; 2-ethynyl-N6-methoxyadenosine; SCHEMBL4389749
DM2D78W DT Small molecular drug
DM2D78W PC 16115754
DM2D78W MW 321.29
DM2D78W FM C13H15N5O5
DM2D78W IC InChI=1S/C13H15N5O5/c1-3-7-15-11(17-22-2)8-12(16-7)18(5-14-8)13-10(21)9(20)6(4-19)23-13/h1,5-6,9-10,13,19-21H,4H2,2H3,(H,15,16,17)/t6-,9-,10-,13-/m1/s1
DM2D78W CS CONC1=C2C(=NC(=N1)C#C)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DM2D78W IK DPDYWTZJFUXIEE-ZRFIDHNTSA-N
DM2D78W IU (2R,3R,4S,5R)-2-[2-ethynyl-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM2D78W DE Discovery agent
DMNOAJG ID DMNOAJG
DMNOAJG DN 2ewy
DMNOAJG HS Investigative
DMNOAJG SN 2ewy; N-{(1s,2r)-1-Benzyl-2-Hydroxy-3-[(3-Methylbenzyl)amino]propyl}dibenzo[b,F]oxepine-10-Carboxamide; GTPL8688; DBO; hydroxyethylamine transition-state inhibitor 1; N-[(2S,3R)-3-hydroxy-4-[(3-methylphenyl)methylamino]-1-phenylbutan-2-yl]benzo[b][1]benzoxepine-6-carboxamide
DMNOAJG DT Small molecular drug
DMNOAJG PC 11963503
DMNOAJG MW 504.6
DMNOAJG FM C33H32N2O3
DMNOAJG IC InChI=1S/C33H32N2O3/c1-23-10-9-13-25(18-23)21-34-22-30(36)29(19-24-11-3-2-4-12-24)35-33(37)28-20-26-14-5-7-16-31(26)38-32-17-8-6-15-27(28)32/h2-18,20,29-30,34,36H,19,21-22H2,1H3,(H,35,37)/t29-,30+/m0/s1
DMNOAJG CS CC1=CC(=CC=C1)CNC[C@H]([C@H](CC2=CC=CC=C2)NC(=O)C3=CC4=CC=CC=C4OC5=CC=CC=C53)O
DMNOAJG IK BNWZCXDHHPBQOX-XZWHSSHBSA-N
DMNOAJG IU N-[(2S,3R)-3-hydroxy-4-[(3-methylphenyl)methylamino]-1-phenylbutan-2-yl]benzo[b][1]benzoxepine-5-carboxamide
DMNOAJG DE Discovery agent
DMUGAT8 ID DMUGAT8
DMUGAT8 DN 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol
DMUGAT8 HS Investigative
DMUGAT8 SN CHEMBL577338; 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol; SCHEMBL1180589
DMUGAT8 DT Small molecular drug
DMUGAT8 PC 25192477
DMUGAT8 MW 286.3
DMUGAT8 FM C16H11FO2S
DMUGAT8 IC InChI=1S/C16H11FO2S/c17-13-9-11(4-5-14(13)19)16-7-6-15(20-16)10-2-1-3-12(18)8-10/h1-9,18-19H
DMUGAT8 CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)O)F
DMUGAT8 IK NRSWHXCLBQLBRC-UHFFFAOYSA-N
DMUGAT8 IU 2-fluoro-4-[5-(3-hydroxyphenyl)thiophen-2-yl]phenol
DMUGAT8 DE Discovery agent
DMGBEFY ID DMGBEFY
DMGBEFY DN 2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol
DMGBEFY HS Investigative
DMGBEFY SN CHEMBL570110; 2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol
DMGBEFY DT Small molecular drug
DMGBEFY PC 44543255
DMGBEFY MW 286.3
DMGBEFY FM C16H11FO2S
DMGBEFY IC InChI=1S/C16H11FO2S/c17-14-7-10(4-5-15(14)19)12-8-16(20-9-12)11-2-1-3-13(18)6-11/h1-9,18-19H
DMGBEFY CS C1=CC(=CC(=C1)O)C2=CC(=CS2)C3=CC(=C(C=C3)O)F
DMGBEFY IK MOBQDOLSPUFHFF-UHFFFAOYSA-N
DMGBEFY IU 2-fluoro-4-[5-(3-hydroxyphenyl)thiophen-3-yl]phenol
DMGBEFY DE Discovery agent
DMCGI1S ID DMCGI1S
DMCGI1S DN 2-fluoro-5-(3-methylthiophen-2-yl)pyridine
DMCGI1S HS Investigative
DMCGI1S SN 2-fluoro-5-(3-methylthiophen-2-yl)pyridine; CHEMBL179621; 837376-37-1; Pyridine, 2-fluoro-5-(3-methyl-2-thienyl)-; SCHEMBL957977; BDBM12354; CTK3D1374; DTXSID90456895; RYGQGRAICBWYPW-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 7; US8609708,10
DMCGI1S DT Small molecular drug
DMCGI1S PC 11148236
DMCGI1S MW 193.24
DMCGI1S FM C10H8FNS
DMCGI1S IC InChI=1S/C10H8FNS/c1-7-4-5-13-10(7)8-2-3-9(11)12-6-8/h2-6H,1H3
DMCGI1S CS CC1=C(SC=C1)C2=CN=C(C=C2)F
DMCGI1S IK RYGQGRAICBWYPW-UHFFFAOYSA-N
DMCGI1S IU 2-fluoro-5-(3-methylthiophen-2-yl)pyridine
DMCGI1S CA CAS 837376-37-1
DMCGI1S DE Discovery agent
DMKOUCM ID DMKOUCM
DMKOUCM DN 2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMKOUCM HS Investigative
DMKOUCM SN CHEMBL570595; 2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMKOUCM DT Small molecular drug
DMKOUCM PC 44542049
DMKOUCM MW 286.3
DMKOUCM FM C16H11FO2S
DMKOUCM IC InChI=1S/C16H11FO2S/c17-13-6-3-11(9-14(13)19)16-8-7-15(20-16)10-1-4-12(18)5-2-10/h1-9,18-19H
DMKOUCM CS C1=CC(=CC=C1C2=CC=C(S2)C3=CC(=C(C=C3)F)O)O
DMKOUCM IK QFKIHVDWWIPQTB-UHFFFAOYSA-N
DMKOUCM IU 2-fluoro-5-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMKOUCM DE Discovery agent
DMP8OXL ID DMP8OXL
DMP8OXL DN 2-Fluoro-6-(3-phenoxy-benzoylamino)-benzoic acid
DMP8OXL HS Investigative
DMP8OXL SN CHEMBL426645; BDBM23611; 3-Phenoxybenzoylamino deriv., 28e; 2-fluoro-6-(3-phenoxybenzoylamino)benzoic acid; 2-fluoro-6-[(3-phenoxybenzene)amido]benzoic acid
DMP8OXL DT Small molecular drug
DMP8OXL PC 11772508
DMP8OXL MW 351.3
DMP8OXL FM C20H14FNO4
DMP8OXL IC InChI=1S/C20H14FNO4/c21-16-10-5-11-17(18(16)20(24)25)22-19(23)13-6-4-9-15(12-13)26-14-7-2-1-3-8-14/h1-12H,(H,22,23)(H,24,25)
DMP8OXL CS C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NC3=C(C(=CC=C3)F)C(=O)O
DMP8OXL IK MUCVEZAGZUMXAG-UHFFFAOYSA-N
DMP8OXL IU 2-fluoro-6-[(3-phenoxybenzoyl)amino]benzoic acid
DMP8OXL DE Discovery agent
DMEQRHY ID DMEQRHY
DMEQRHY DN 2-fluoromevalonate 5-diphosphate
DMEQRHY HS Investigative
DMEQRHY SN 2-fluoromevalonate 5-diphosphate; GTPL3204; 2-fluoro-3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylpentanoic acid
DMEQRHY DT Small molecular drug
DMEQRHY PC 56947015
DMEQRHY MW 326.11
DMEQRHY FM C6H13FO10P2
DMEQRHY IC InChI=1S/C6H13FO10P2/c1-6(10,4(7)5(8)9)2-3-16-19(14,15)17-18(11,12)13/h4,10H,2-3H2,1H3,(H,8,9)(H,14,15)(H2,11,12,13)
DMEQRHY CS CC(CCOP(=O)(O)OP(=O)(O)O)(C(C(=O)O)F)O
DMEQRHY IK WPXHWHACORBSDS-UHFFFAOYSA-N
DMEQRHY IU 2-fluoro-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylpentanoic acid
DMEQRHY DE Discovery agent
DMX34TL ID DMX34TL
DMX34TL DN 2-fluoronorepinehprine
DMX34TL HS Investigative
DMX34TL SN CHEMBL40317; Lopac-B-012; AC1O7G01; CTK2G6131; BDBM50087513; NCGC00015118-01; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-5-fluoro-; 4-[(1R)-2-amino-1-hydroxyethyl]-5-fluorobenzene-1,2-diol; (R)4-(2-Amino-1-hydroxy-ethyl)-5-fluoro-benzene-1,2-diol
DMX34TL DT Small molecular drug
DMX34TL PC 6603724
DMX34TL MW 187.17
DMX34TL FM C8H10FNO3
DMX34TL IC InChI=1S/C8H10FNO3/c9-5-2-7(12)6(11)1-4(5)8(13)3-10/h1-2,8,11-13H,3,10H2/t8-/m0/s1
DMX34TL CS C1=C(C(=CC(=C1O)O)F)[C@H](CN)O
DMX34TL IK SBUQBFTXTZSRMH-QMMMGPOBSA-N
DMX34TL IU 4-[(1R)-2-amino-1-hydroxyethyl]-5-fluorobenzene-1,2-diol
DMX34TL DE Discovery agent
DM5OW91 ID DM5OW91
DM5OW91 DN 2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate
DM5OW91 HS Investigative
DM5OW91 SN CHEMBL597030; 2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate; SCHEMBL5216198
DM5OW91 DT Small molecular drug
DM5OW91 PC 20872688
DM5OW91 MW 345.4
DM5OW91 FM C20H24FNO3
DM5OW91 IC InChI=1S/C20H24FNO3/c1-3-5-14-24-16-12-10-15(11-13-16)18(4-2)22-20(23)25-19-9-7-6-8-17(19)21/h6-13,18H,3-5,14H2,1-2H3,(H,22,23)
DM5OW91 CS CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=CC=C2F
DM5OW91 IK GDLJXVIFSNBWKP-UHFFFAOYSA-N
DM5OW91 IU (2-fluorophenyl) N-[1-(4-butoxyphenyl)propyl]carbamate
DM5OW91 DE Discovery agent
DMSFQAZ ID DMSFQAZ
DMSFQAZ DN 2-fluorophenyl 4-(decyloxy)phenylcarbamate
DMSFQAZ HS Investigative
DMSFQAZ SN 2-fluorophenyl 4-(decyloxy)phenylcarbamate; CHEMBL591825; SCHEMBL5218224
DMSFQAZ DT Small molecular drug
DMSFQAZ PC 20872692
DMSFQAZ MW 387.5
DMSFQAZ FM C23H30FNO3
DMSFQAZ IC InChI=1S/C23H30FNO3/c1-2-3-4-5-6-7-8-11-18-27-20-16-14-19(15-17-20)25-23(26)28-22-13-10-9-12-21(22)24/h9-10,12-17H,2-8,11,18H2,1H3,(H,25,26)
DMSFQAZ CS CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMSFQAZ IK PWZMFAZZDZNTOQ-UHFFFAOYSA-N
DMSFQAZ IU (2-fluorophenyl) N-(4-decoxyphenyl)carbamate
DMSFQAZ DE Discovery agent
DMCEGZU ID DMCEGZU
DMCEGZU DN 2-fluorophenyl 4-(dodecyloxy)phenylcarbamate
DMCEGZU HS Investigative
DMCEGZU SN CHEMBL599488; 2-fluorophenyl 4-(dodecyloxy)phenylcarbamate
DMCEGZU DT Small molecular drug
DMCEGZU PC 20872693
DMCEGZU MW 415.5
DMCEGZU FM C25H34FNO3
DMCEGZU IC InChI=1S/C25H34FNO3/c1-2-3-4-5-6-7-8-9-10-13-20-29-22-18-16-21(17-19-22)27-25(28)30-24-15-12-11-14-23(24)26/h11-12,14-19H,2-10,13,20H2,1H3,(H,27,28)
DMCEGZU CS CCCCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMCEGZU IK WEDCHEHVZVVAIL-UHFFFAOYSA-N
DMCEGZU IU (2-fluorophenyl) N-(4-dodecoxyphenyl)carbamate
DMCEGZU DE Discovery agent
DMLM2WU ID DMLM2WU
DMLM2WU DN 2-fluorophenyl 4-(heptyloxy)phenylcarbamate
DMLM2WU HS Investigative
DMLM2WU SN 2-fluorophenyl 4-(heptyloxy)phenylcarbamate; CHEMBL610774
DMLM2WU DT Small molecular drug
DMLM2WU PC 20872694
DMLM2WU MW 345.4
DMLM2WU FM C20H24FNO3
DMLM2WU IC InChI=1S/C20H24FNO3/c1-2-3-4-5-8-15-24-17-13-11-16(12-14-17)22-20(23)25-19-10-7-6-9-18(19)21/h6-7,9-14H,2-5,8,15H2,1H3,(H,22,23)
DMLM2WU CS CCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMLM2WU IK SHLSOZYYUDUBRA-UHFFFAOYSA-N
DMLM2WU IU (2-fluorophenyl) N-(4-heptoxyphenyl)carbamate
DMLM2WU DE Discovery agent
DM854ED ID DM854ED
DM854ED DN 2-fluorophenyl 4-(hexyloxy)phenylcarbamate
DM854ED HS Investigative
DM854ED SN 2-fluorophenyl 4-(hexyloxy)phenylcarbamate; CHEMBL590243
DM854ED DT Small molecular drug
DM854ED PC 20872695
DM854ED MW 331.4
DM854ED FM C19H22FNO3
DM854ED IC InChI=1S/C19H22FNO3/c1-2-3-4-7-14-23-16-12-10-15(11-13-16)21-19(22)24-18-9-6-5-8-17(18)20/h5-6,8-13H,2-4,7,14H2,1H3,(H,21,22)
DM854ED CS CCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DM854ED IK ASBZIVYPMZQHBL-UHFFFAOYSA-N
DM854ED IU (2-fluorophenyl) N-(4-hexoxyphenyl)carbamate
DM854ED DE Discovery agent
DM81J0O ID DM81J0O
DM81J0O DN 2-fluorophenyl 4-(octyloxy)phenylcarbamate
DM81J0O HS Investigative
DM81J0O SN 2-fluorophenyl 4-(octyloxy)phenylcarbamate; CHEMBL597029; SCHEMBL5216564
DM81J0O DT Small molecular drug
DM81J0O PC 20872696
DM81J0O MW 359.4
DM81J0O FM C21H26FNO3
DM81J0O IC InChI=1S/C21H26FNO3/c1-2-3-4-5-6-9-16-25-18-14-12-17(13-15-18)23-21(24)26-20-11-8-7-10-19(20)22/h7-8,10-15H,2-6,9,16H2,1H3,(H,23,24)
DM81J0O CS CCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DM81J0O IK PHBVHSXINCCZDW-UHFFFAOYSA-N
DM81J0O IU (2-fluorophenyl) N-(4-octoxyphenyl)carbamate
DM81J0O DE Discovery agent
DMTYX5G ID DMTYX5G
DMTYX5G DN 2-fluorophenyl 4-(undecyloxy)phenylcarbamate
DMTYX5G HS Investigative
DMTYX5G SN CHEMBL609024; 2-fluorophenyl 4-(undecyloxy)phenylcarbamate
DMTYX5G DT Small molecular drug
DMTYX5G PC 20872698
DMTYX5G MW 401.5
DMTYX5G FM C24H32FNO3
DMTYX5G IC InChI=1S/C24H32FNO3/c1-2-3-4-5-6-7-8-9-12-19-28-21-17-15-20(16-18-21)26-24(27)29-23-14-11-10-13-22(23)25/h10-11,13-18H,2-9,12,19H2,1H3,(H,26,27)
DMTYX5G CS CCCCCCCCCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMTYX5G IK PDDXKUNCGFODGC-UHFFFAOYSA-N
DMTYX5G IU (2-fluorophenyl) N-(4-undecoxyphenyl)carbamate
DMTYX5G DE Discovery agent
DM4EIQ3 ID DM4EIQ3
DM4EIQ3 DN 2-fluorophenyl 4-butoxybenzylcarbamate
DM4EIQ3 HS Investigative
DM4EIQ3 SN 2-fluorophenyl 4-butoxybenzylcarbamate; CHEMBL596876; SCHEMBL5223902
DM4EIQ3 DT Small molecular drug
DM4EIQ3 PC 20872691
DM4EIQ3 MW 317.4
DM4EIQ3 FM C18H20FNO3
DM4EIQ3 IC InChI=1S/C18H20FNO3/c1-2-3-12-22-15-10-8-14(9-11-15)13-20-18(21)23-17-7-5-4-6-16(17)19/h4-11H,2-3,12-13H2,1H3,(H,20,21)
DM4EIQ3 CS CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC=CC=C2F
DM4EIQ3 IK XSSVFUMMMRTXER-UHFFFAOYSA-N
DM4EIQ3 IU (2-fluorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DM4EIQ3 DE Discovery agent
DMYJ1M4 ID DMYJ1M4
DMYJ1M4 DN 2-fluorophenyl 4-butoxyphenylcarbamate
DMYJ1M4 HS Investigative
DMYJ1M4 SN 2-fluorophenyl 4-butoxyphenylcarbamate; CHEMBL597924
DMYJ1M4 DT Small molecular drug
DMYJ1M4 PC 20872690
DMYJ1M4 MW 303.33
DMYJ1M4 FM C17H18FNO3
DMYJ1M4 IC InChI=1S/C17H18FNO3/c1-2-3-12-21-14-10-8-13(9-11-14)19-17(20)22-16-7-5-4-6-15(16)18/h4-11H,2-3,12H2,1H3,(H,19,20)
DMYJ1M4 CS CCCCOC1=CC=C(C=C1)NC(=O)OC2=CC=CC=C2F
DMYJ1M4 IK IDOBASBUNMSFTC-UHFFFAOYSA-N
DMYJ1M4 IU (2-fluorophenyl) N-(4-butoxyphenyl)carbamate
DMYJ1M4 DE Discovery agent
DMGIKWA ID DMGIKWA
DMGIKWA DN 2-fluorophenyl 4'-ethylbiphenyl-4-ylcarbamate
DMGIKWA HS Investigative
DMGIKWA SN CHEMBL599180; BDBM50309731; 2-fluorophenyl 4''-ethylbiphenyl-4-ylcarbamate
DMGIKWA DT Small molecular drug
DMGIKWA PC 20872689
DMGIKWA MW 335.4
DMGIKWA FM C21H18FNO2
DMGIKWA IC InChI=1S/C21H18FNO2/c1-2-15-7-9-16(10-8-15)17-11-13-18(14-12-17)23-21(24)25-20-6-4-3-5-19(20)22/h3-14H,2H2,1H3,(H,23,24)
DMGIKWA CS CCC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)OC3=CC=CC=C3F
DMGIKWA IK XHWBLLJZJZYEES-UHFFFAOYSA-N
DMGIKWA IU (2-fluorophenyl) N-[4-(4-ethylphenyl)phenyl]carbamate
DMGIKWA DE Discovery agent
DMSMDQC ID DMSMDQC
DMSMDQC DN 2-fluorophenyl 4-phenoxyphenylcarbamate
DMSMDQC HS Investigative
DMSMDQC SN 2-fluorophenyl 4-phenoxyphenylcarbamate; CHEMBL599179; BDBM50309730
DMSMDQC DT Small molecular drug
DMSMDQC PC 20872697
DMSMDQC MW 323.3
DMSMDQC FM C19H14FNO3
DMSMDQC IC InChI=1S/C19H14FNO3/c20-17-8-4-5-9-18(17)24-19(22)21-14-10-12-16(13-11-14)23-15-6-2-1-3-7-15/h1-13H,(H,21,22)
DMSMDQC CS C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)OC3=CC=CC=C3F
DMSMDQC IK KFKCZSDVVBTNPG-UHFFFAOYSA-N
DMSMDQC IU (2-fluorophenyl) N-(4-phenoxyphenyl)carbamate
DMSMDQC DE Discovery agent
DMNPGXA ID DMNPGXA
DMNPGXA DN 2-fluorophenyl-2,2-diphenylacetamide
DMNPGXA HS Investigative
DMNPGXA SN CHEMBL270071; SCHEMBL1784375
DMNPGXA DT Small molecular drug
DMNPGXA PC 9814995
DMNPGXA MW 305.3
DMNPGXA FM C20H16FNO
DMNPGXA IC InChI=1S/C20H16FNO/c21-18-14-8-7-13-17(18)20(19(22)23,15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14H,(H2,22,23)
DMNPGXA CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3F)C(=O)N
DMNPGXA IK YDVJKRJJBXTMCW-UHFFFAOYSA-N
DMNPGXA IU 2-(2-fluorophenyl)-2,2-diphenylacetamide
DMNPGXA DE Discovery agent
DMXPFYZ ID DMXPFYZ
DMXPFYZ DN 2-fluorophenylboronic acid
DMXPFYZ HS Investigative
DMXPFYZ SN 2-Fluorophenylboronic acid; 1993-03-9; (2-fluorophenyl)boronic acid; 2-Fluorobenzeneboronic Acid; (2-fluorophenyl)boranediol; Boronic acid, B-(2-fluorophenyl)-; o-fluorophenylboronic acid; 2-fluorophenyl boronic acid; 2-fluoro-phenyl-boronic acid; BORONIC ACID, (2-FLUOROPHENYL)-; MFCD00674013; 2-Fluorophenylboronic acid, 98%; 34-03-7; PubChem1856; 2-Fluorophenylboronicacid; o-fluorobenzeneboronic acid; ACMC-1BR1I; o -Fluorophenylboronic acid; 2-fluoro-phenylboronic acid; AC1MC0Y0; 2-fluoro phenylboronic acid
DMXPFYZ DT Small molecular drug
DMXPFYZ PC 2734354
DMXPFYZ MW 139.92
DMXPFYZ FM C6H6BFO2
DMXPFYZ IC InChI=1S/C6H6BFO2/c8-6-4-2-1-3-5(6)7(9)10/h1-4,9-10H
DMXPFYZ CS B(C1=CC=CC=C1F)(O)O
DMXPFYZ IK QCSLIRFWJPOENV-UHFFFAOYSA-N
DMXPFYZ IU (2-fluorophenyl)boronic acid
DMXPFYZ DE Discovery agent
DM28XTE ID DM28XTE
DM28XTE DN 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one
DM28XTE HS Investigative
DM28XTE SN CHEMBL180336; 2-(furan-2-yl)-3-phenethylquinazolin-4-one; AC1LEB94; 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one; Oprea1_070906; 2-(2-furyl)-3-(2-phenylethyl)-4(3H)-quinazolinone; ZINC49416; NPS-53574; BDBM50162542; STK674065; AKOS005593239; MCULE-4160039246; ST008066; J3.621.250K; 2-(2-furyl)-3-phenethyl-4(3H)-quinazolinone; AG-205/11559428; SR-01000416527; SR-01000416527-1; 2-(2-furyl)-3-(2-phenylethyl)-3-hydroquinazolin-4-one; 2-(furan-2-yl)-3-(2-phenylethyl)quinazolin-4(3H)-one; A1715/0073151
DM28XTE DT Small molecular drug
DM28XTE PC 683379
DM28XTE MW 316.4
DM28XTE FM C20H16N2O2
DM28XTE IC InChI=1S/C20H16N2O2/c23-20-16-9-4-5-10-17(16)21-19(18-11-6-14-24-18)22(20)13-12-15-7-2-1-3-8-15/h1-11,14H,12-13H2
DM28XTE CS C1=CC=C(C=C1)CCN2C(=NC3=CC=CC=C3C2=O)C4=CC=CO4
DM28XTE IK ZFIMKOHGGKYLGR-UHFFFAOYSA-N
DM28XTE IU 2-(furan-2-yl)-3-(2-phenylethyl)quinazolin-4-one
DM28XTE DE Discovery agent
DMQIFJ9 ID DMQIFJ9
DMQIFJ9 DN 2-Furan-2-yl-4,5-dihydro-1H-imidazole
DMQIFJ9 HS Investigative
DMQIFJ9 SN 2-Furan-2-yl-4,5-dihydro-1H-imidazole; 2-(furan-2-yl)-4,5-dihydro-1H-imidazole; 40029-93-4; CHEMBL14410; 2-(2-furyl)-4,5-dihydro-1H-imidazole; AC1LHNFC; BAS 00087895; 2-(2-furyl)imidazoline; 2-(2-imidazolin-2-yl)furan; 2-(1-Imidazoline-2-yl)furan; CTK5J7407; DTXSID40357040; MolPort-001-914-212; HMS1698J05; ZINC4992560; BDBM50138501; 2536AE; AKOS000301450; MCULE-8474767921; ST072486; TR-043590
DMQIFJ9 DT Small molecular drug
DMQIFJ9 PC 840808
DMQIFJ9 MW 136.15
DMQIFJ9 FM C7H8N2O
DMQIFJ9 IC InChI=1S/C7H8N2O/c1-2-6(10-5-1)7-8-3-4-9-7/h1-2,5H,3-4H2,(H,8,9)
DMQIFJ9 CS C1CN=C(N1)C2=CC=CO2
DMQIFJ9 IK IOTMYJAUZMRWCJ-UHFFFAOYSA-N
DMQIFJ9 IU 2-(furan-2-yl)-4,5-dihydro-1H-imidazole
DMQIFJ9 CA CAS 40029-93-4
DMQIFJ9 DE Discovery agent
DMHT80R ID DMHT80R
DMHT80R DN 2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMHT80R HS Investigative
DMHT80R DT Small molecular drug
DMHT80R PC 135511822
DMHT80R MW 251.24
DMHT80R FM C14H9N3O2
DMHT80R IC InChI=1S/C14H9N3O2/c18-14-15-10-5-2-1-4-9(10)12-8-11(16-17(12)14)13-6-3-7-19-13/h1-8H,(H,15,18)
DMHT80R CS C1=CC=C2C(=C1)C3=CC(=NN3C(=O)N2)C4=CC=CO4
DMHT80R IK HWHAANIZIAJOCF-UHFFFAOYSA-N
DMHT80R IU 2-(furan-2-yl)-6H-pyrazolo[1,5-c]quinazolin-5-one
DMHT80R DE Discovery agent
DMD8ZUH ID DMD8ZUH
DMD8ZUH DN 2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one
DMD8ZUH HS Investigative
DMD8ZUH SN 9008-02-0; CHEMBL130391
DMD8ZUH DT Small molecular drug
DMD8ZUH PC 13285535
DMD8ZUH MW 226.23
DMD8ZUH FM C13H10N2O2
DMD8ZUH IC InChI=1S/C13H10N2O2/c1-8-4-5-9-11(16)7-10(15-13(9)14-8)12-3-2-6-17-12/h2-7H,1H3,(H,14,15,16)
DMD8ZUH CS CC1=NC2=C(C=C1)C(=O)C=C(N2)C3=CC=CO3
DMD8ZUH IK INGWEZCOABYORO-UHFFFAOYSA-N
DMD8ZUH IU 2-(furan-2-yl)-7-methyl-1H-1,8-naphthyridin-4-one
DMD8ZUH CA CAS 9008-02-0
DMD8ZUH DE Discovery agent
DMQIRY7 ID DMQIRY7
DMQIRY7 DN 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one
DMQIRY7 HS Investigative
DMQIRY7 SN CHEMBL3144716; 1,2-dihydro-2-(2-furylmethyl)-3H-indazol-3-one; 120273-74-7; 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL268738; BDBM50009008; AKOS023543910
DMQIRY7 DT Small molecular drug
DMQIRY7 PC 14898715
DMQIRY7 MW 214.22
DMQIRY7 FM C12H10N2O2
DMQIRY7 IC InChI=1S/C12H10N2O2/c15-12-10-5-1-2-6-11(10)13-14(12)8-9-4-3-7-16-9/h1-7,13H,8H2
DMQIRY7 CS C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=CO3
DMQIRY7 IK FFYKZUMLEJLSIN-UHFFFAOYSA-N
DMQIRY7 IU 2-(furan-2-ylmethyl)-1H-indazol-3-one
DMQIRY7 DE Discovery agent
DMET6FO ID DMET6FO
DMET6FO DN 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione
DMET6FO HS Investigative
DMET6FO SN CHEMBL611665; 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione; chromeno[2,3-d]pyrimidine-2,4-dione; AC1LQMEG; 5-Deaza-10-oxaflavin; SCHEMBL11333239; BFMCRAXOACCPEL-UHFFFAOYSA-; ZINC1280587; STK236511; BDBM50309832; AKOS000428551; MCULE-3496773034; ST50987740; 3-hydrochromeno[2,3-d]pyrimidine-2,4-dione; 2H,3H,4H-chromeno[2,3-d]pyrimidine-2,4-dione; 2H-[1]Benzopyrano[2,3-d]pyrimidine-2,4(3H)-dione; InChI=1/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)
DMET6FO DT Small molecular drug
DMET6FO PC 1403654
DMET6FO MW 214.18
DMET6FO FM C11H6N2O3
DMET6FO IC InChI=1S/C11H6N2O3/c14-9-7-5-6-3-1-2-4-8(6)16-10(7)13-11(15)12-9/h1-5H,(H,12,14,15)
DMET6FO CS C1=CC=C2C(=C1)C=C3C(=O)NC(=O)N=C3O2
DMET6FO IK BFMCRAXOACCPEL-UHFFFAOYSA-N
DMET6FO IU chromeno[2,3-d]pyrimidine-2,4-dione
DMET6FO DE Discovery agent
DMX45WE ID DMX45WE
DMX45WE DN 2-Heptyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione
DMX45WE HS Investigative
DMX45WE SN CHEMBL596063
DMX45WE DT Small molecular drug
DMX45WE PC 44251211
DMX45WE MW 346.4
DMX45WE FM C22H22N2O2
DMX45WE IC InChI=1S/C22H22N2O2/c1-2-3-4-5-6-11-18-23-17-13-12-16-19(20(17)24-18)22(26)15-10-8-7-9-14(15)21(16)25/h7-10,12-13H,2-6,11H2,1H3,(H,23,24)
DMX45WE CS CCCCCCCC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMX45WE IK VJUQZYULXGTXCN-UHFFFAOYSA-N
DMX45WE IU 2-heptyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMX45WE DE Discovery agent
DMJ3ATL ID DMJ3ATL
DMJ3ATL DN 2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE
DMJ3ATL HS Investigative
DMJ3ATL SN HQNO; HOQNO; 2-heptyl-4-hydroxyquinoline n-oxide; 341-88-8; 2-heptylquinolin-4-ol 1-oxide; 2-Heptyl-4-quinolinol 1-oxide; 2-HEPTYL-4-HYDROXYQUINOLINE-1-OXIDE; 2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE; 2-(n-Heptyl)-4-hydroxyquinoline N-oxide; CHEBI:28362; 2-Heptyl-4-hydroxyquinoline-N-oxide; 2-n-heptyl-4-hydroxyquinoline-N-oxide; 2-HEPTYL-1-OXY-QUINOLIN-4-OL; Pyo II; UNII-1FU5S5CG6A; 2-Heptyl-4-hydroxyquinoline oxide; KF 8940; BRN 1466419; AC1L1BQL; 1FU5S5CG6A; SCHEMBL429766; CHEMBL1233401; 1-hydroxy-2-heptyl-4-quinolone; CTK4H1880
DMJ3ATL DT Small molecular drug
DMJ3ATL PC 1561
DMJ3ATL MW 259.339
DMJ3ATL FM C16H21NO2
DMJ3ATL IC InChI=1S/C16H21NO2/c1-2-3-4-5-6-9-13-12-16(18)14-10-7-8-11-15(14)17(13)19/h7-8,10-12,19H,2-6,9H2,1H3
DMJ3ATL CS CCCCCCCC1=CC(=O)C2=CC=CC=C2N1O
DMJ3ATL IK ICTVCUOZYWNYHM-UHFFFAOYSA-N
DMJ3ATL IU 2-heptyl-1-hydroxyquinolin-4-one
DMJ3ATL CA CAS 341-88-8
DMJ3ATL CB CHEBI:28362
DMJ3ATL DE Discovery agent
DMRXW3U ID DMRXW3U
DMRXW3U DN 2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole
DMRXW3U HS Investigative
DMRXW3U SN CHEMBL14196; 2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole; AC1LBGT2; 2-(1-Non-8-enyl)-5-(1-hex-5-enyl)-pyrroline; CTK5J4228; JRNMZRPLKGPMHB-UHFFFAOYSA-N; BDBM50284426; 2-(5-Hexenyl)-5-(8-nonenyl)-3,4-dihydro-2H-pyrrole #; 2-(1-Non-8-enyl)-5-(1-hex-5-enyl).delta.1--pyrroline
DMRXW3U DT Small molecular drug
DMRXW3U PC 557705
DMRXW3U MW 275.5
DMRXW3U FM C19H33N
DMRXW3U IC InChI=1S/C19H33N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h3-4,18H,1-2,5-17H2
DMRXW3U CS C=CCCCCCCCC1=NC(CC1)CCCCC=C
DMRXW3U IK JRNMZRPLKGPMHB-UHFFFAOYSA-N
DMRXW3U IU 2-hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole
DMRXW3U DE Discovery agent
DM7KDQV ID DM7KDQV
DM7KDQV DN 2-Hex-5-enyl-5-non-8-enyl-pyrrolidine
DM7KDQV HS Investigative
DM7KDQV SN 2-Hex-5-enyl-5-non-8-enyl-pyrrolidine; CHEMBL14599; 2-(5-Hexenyl)-5-(8-nonenyl)pyrrolidine; 100594-86-3; 2-Hex-5-enyl-5-non-8-enylpyr; ACMC-20m3ob; Pyrrolidine, 2-(5-hexenyl)-5-(8-nonenyl)-; CTK0I4208; YCQNSAJAZIVRFR-UHFFFAOYSA-N; AC1L4819; BDBM50284428
DM7KDQV DT Small molecular drug
DM7KDQV PC 180889
DM7KDQV MW 277.5
DM7KDQV FM C19H35N
DM7KDQV IC InChI=1S/C19H35N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h3-4,18-20H,1-2,5-17H2
DM7KDQV CS C=CCCCCCCCC1CCC(N1)CCCCC=C
DM7KDQV IK YCQNSAJAZIVRFR-UHFFFAOYSA-N
DM7KDQV IU 2-hex-5-enyl-5-non-8-enylpyrrolidine
DM7KDQV CA CAS 100594-86-3
DM7KDQV DE Discovery agent
DMIBRYM ID DMIBRYM
DMIBRYM DN 2-Hex-5-enyl-5-nonyl-pyrrolidine
DMIBRYM HS Investigative
DMIBRYM SN 2-hex-5-enyl-5-nonylpyrrolidine; CHEMBL417618; 100594-88-5; 2-hex-5-enyl-5-nonyl-pyrrolidine; Pyrrolidine, 2-(5-hexenyl)-5-nonyl-; AC1L481F; 2-(5-hexenyl)-5-nonylpyrrolidine; BDBM50284429
DMIBRYM DT Small molecular drug
DMIBRYM PC 180891
DMIBRYM MW 279.5
DMIBRYM FM C19H37N
DMIBRYM IC InChI=1S/C19H37N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h4,18-20H,2-3,5-17H2,1H3
DMIBRYM CS CCCCCCCCCC1CCC(N1)CCCCC=C
DMIBRYM IK VJYHAIYEEJOCLT-UHFFFAOYSA-N
DMIBRYM IU 2-hex-5-enyl-5-nonylpyrrolidine
DMIBRYM CA CAS 100594-88-5
DMIBRYM DE Discovery agent
DMTFIPZ ID DMTFIPZ
DMTFIPZ DN 2-Hexadecynoic acid
DMTFIPZ HS Investigative
DMTFIPZ SN 2-Hexadecynoic acid; hexadec-2-ynoic acid; 2834-03-9; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494
DMTFIPZ DT Small molecular drug
DMTFIPZ PC 151047
DMTFIPZ MW 252.39
DMTFIPZ FM C16H28O2
DMTFIPZ IC InChI=1S/C16H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-13H2,1H3,(H,17,18)
DMTFIPZ CS CCCCCCCCCCCCCC#CC(=O)O
DMTFIPZ IK MECFGCCEVOFCNS-UHFFFAOYSA-N
DMTFIPZ IU hexadec-2-ynoic acid
DMTFIPZ CA CAS 2834-03-9
DMTFIPZ DE Discovery agent
DM94PBL ID DM94PBL
DM94PBL DN 2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole
DM94PBL HS Investigative
DM94PBL SN CHEMBL331942; SCHEMBL4812369
DM94PBL DT Small molecular drug
DM94PBL PC 9795821
DM94PBL MW 284.4
DM94PBL FM C19H28N2
DM94PBL IC InChI=1S/C19H28N2/c1-4-5-6-7-8-19-20-14-18(21-19)17-11-9-16(10-12-17)13-15(2)3/h9-12,14-15H,4-8,13H2,1-3H3,(H,20,21)
DM94PBL CS CCCCCCC1=NC=C(N1)C2=CC=C(C=C2)CC(C)C
DM94PBL IK DJDWXDSQUIVYCH-UHFFFAOYSA-N
DM94PBL IU 2-hexyl-5-[4-(2-methylpropyl)phenyl]-1H-imidazole
DM94PBL CA CAS 478869-61-3
DM94PBL DE Discovery agent
DMKORTS ID DMKORTS
DMKORTS DN 2-Hexyloxy-5-imidazol-1-yl-pyridine
DMKORTS HS Investigative
DMKORTS SN CHEMBL320105; 2-Hexyloxy-5-imidazol-1-yl-pyridine; SCHEMBL14129948; BDBM50138236
DMKORTS DT Small molecular drug
DMKORTS PC 44341439
DMKORTS MW 245.32
DMKORTS FM C14H19N3O
DMKORTS IC InChI=1S/C14H19N3O/c1-2-3-4-5-10-18-14-7-6-13(11-16-14)17-9-8-15-12-17/h6-9,11-12H,2-5,10H2,1H3
DMKORTS CS CCCCCCOC1=NC=C(C=C1)N2C=CN=C2
DMKORTS IK DCDHWTNKKCKJLQ-UHFFFAOYSA-N
DMKORTS IU 2-hexoxy-5-imidazol-1-ylpyridine
DMKORTS DE Discovery agent
DMTD0IG ID DMTD0IG
DMTD0IG DN 2-hexylphenyl acrylate
DMTD0IG HS Investigative
DMTD0IG SN 2-hexylphenyl acrylate; SCHEMBL4475068
DMTD0IG DT Small molecular drug
DMTD0IG PC 44435789
DMTD0IG MW 232.32
DMTD0IG FM C15H20O2
DMTD0IG IC InChI=1S/C15H20O2/c1-3-5-6-7-10-13-11-8-9-12-14(13)17-15(16)4-2/h4,8-9,11-12H,2-3,5-7,10H2,1H3
DMTD0IG CS CCCCCCC1=CC=CC=C1OC(=O)C=C
DMTD0IG IK MADYBBZSBQFZRP-UHFFFAOYSA-N
DMTD0IG IU (2-hexylphenyl) prop-2-enoate
DMTD0IG DE Discovery agent
DMHR1UE ID DMHR1UE
DMHR1UE DN 2H-Isoquinolin-1-one
DMHR1UE HS Investigative
DMHR1UE SN 1-Hydroxyisoquinoline; 491-30-5; Isoquinolin-1(2H)-one; isoquinolin-1-ol; 1-Isoquinolinol; 2H-Isoquinolin-1-one; Isocarbostyril; 1(2H)-ISOQUINOLINONE; Isoquinolin-1-one; 489453-23-8; 1(2H)-Isoquinolone; 1,2-dihydroisoquinolin-1-one; 1-hydroxyisoquinolin; isoquinolinol; 87602-67-3; 1(2H)-ISOQUINILONE; Isocarbostyril, 98%; UNII-95EG3HGG1P; 95EG3HGG1P; Isoquinolinone; CHEMBL339695; CHEBI:18350; VDBNYAPERZTOOF-UHFFFAOYSA-N; 1-isoquinolone; oxidoisoquinolinium; EINECS 207-732-1; Isocarbostyril(1-hydroxyisoquinoline); NSC 27273
DMHR1UE DT Small molecular drug
DMHR1UE PC 10284
DMHR1UE MW 145.16
DMHR1UE FM C9H7NO
DMHR1UE IC InChI=1S/C9H7NO/c11-9-8-4-2-1-3-7(8)5-6-10-9/h1-6H,(H,10,11)
DMHR1UE CS C1=CC=C2C(=C1)C=CNC2=O
DMHR1UE IK VDBNYAPERZTOOF-UHFFFAOYSA-N
DMHR1UE IU 2H-isoquinolin-1-one
DMHR1UE CA CAS 491-30-5
DMHR1UE CB CHEBI:18350
DMHR1UE DE Discovery agent
DMOT1LQ ID DMOT1LQ
DMOT1LQ DN 2-Hydrazino-3-methyl-4(3H)-quinazolinone
DMOT1LQ HS Investigative
DMOT1LQ SN 2-hydrazino-3-methylquinazolin-4(3H)-one; 61507-80-0; 2-Hydrazino-3-methyl-3H-quinazolin-4-one; 2-Hydrazino-3-methyl-4(3H)-quinazolinone; NSC657432; CHEMBL503552; 2-hydrazinyl-3-methylquinazolin-4(3H)-one; 2-hydrazinyl-3-methylquinazolin-4-one; BAS 00718750; 4(3H)-Quinazolinone,2-hydrazinyl-3-methyl-; 2-hydrazinyl-3-methyl-3,4-dihydroquinazolin-4-one; 2-hydrazino-3-methyl-3-hydroquinazolin-4-one; AC1Q6DRE; AC1L8CIY; AC1Q3XQM; 2-Hydrazino-3-methyl-3 H -quinazolin-4-one; Oprea1_318278; Oprea1_401830; MLS000713036; CTK5B3345
DMOT1LQ DT Small molecular drug
DMOT1LQ PC 376484
DMOT1LQ MW 190.2
DMOT1LQ FM C9H10N4O
DMOT1LQ IC InChI=1S/C9H10N4O/c1-13-8(14)6-4-2-3-5-7(6)11-9(13)12-10/h2-5H,10H2,1H3,(H,11,12)
DMOT1LQ CS CN1C(=O)C2=CC=CC=C2N=C1NN
DMOT1LQ IK BQDOAXFBKRUNTF-UHFFFAOYSA-N
DMOT1LQ IU 2-hydrazinyl-3-methylquinazolin-4-one
DMOT1LQ CA CAS 61507-80-0
DMOT1LQ DE Discovery agent
DMG78U2 ID DMG78U2
DMG78U2 DN 2-Hydrazinocarbonyl-benzenesulfonamide
DMG78U2 HS Investigative
DMG78U2 SN 102169-52-8; 2-(hydrazinecarbonyl)benzenesulfonamide; 2-(hydrazinocarbonyl)benzenesulfonamide; 2-Hydrazinocarbonyl-benzenesulfonamide; 2-(hydrazinecarbonyl)benzene-1-sulfonamide; Benzoic acid,2-(aminosulfonyl)-, hydrazide; hydrazide deriv. 6; AC1M8OJR; ACMC-1BW2D; AC1Q54UM; Oprea1_607731; CHEMBL361191; CTK4A0755; BDBM12153; DTXSID30368807; HMS1788K01; ZX-AN012798; ZINC3372954; ALBB-014056; 7604AC; STL301522; AKOS000116142; FCH1317207; MCULE-6758898279; 2-(hydrazinylcarbonyl)benzenesulfonamide; BBV-40193034; Benzoic acid, 2-(aminosul
DMG78U2 DT Small molecular drug
DMG78U2 PC 2490720
DMG78U2 MW 215.23
DMG78U2 FM C7H9N3O3S
DMG78U2 IC InChI=1S/C7H9N3O3S/c8-10-7(11)5-3-1-2-4-6(5)14(9,12)13/h1-4H,8H2,(H,10,11)(H2,9,12,13)
DMG78U2 CS C1=CC=C(C(=C1)C(=O)NN)S(=O)(=O)N
DMG78U2 IK YWPOXIABDFDDSR-UHFFFAOYSA-N
DMG78U2 IU 2-(hydrazinecarbonyl)benzenesulfonamide
DMG78U2 CA CAS 102169-52-8
DMG78U2 DE Discovery agent
DMCNXZM ID DMCNXZM
DMCNXZM DN 2-hydrazinylbenzenesulfonamide
DMCNXZM HS Investigative
DMCNXZM SN 2-Hydrazino-benzenesulfonamide
DMCNXZM DT Small molecular drug
DMCNXZM PC 11206245
DMCNXZM MW 187.22
DMCNXZM FM C6H9N3O2S
DMCNXZM IC InChI=1S/C6H9N3O2S/c7-9-5-3-1-2-4-6(5)12(8,10)11/h1-4,9H,7H2,(H2,8,10,11)
DMCNXZM CS C1=CC=C(C(=C1)NN)S(=O)(=O)N
DMCNXZM IK CTEZEDIMFASQNI-UHFFFAOYSA-N
DMCNXZM IU 2-hydrazinylbenzenesulfonamide
DMCNXZM CA CAS 90824-33-2
DMCNXZM DE Discovery agent
DMJAN52 ID DMJAN52
DMJAN52 DN 2-hydroxy capric acid
DMJAN52 HS Investigative
DMJAN52 SN 2-hydroxy-decanoic acid; 2-OH-C10
DMJAN52 DT Small molecular drug
DMJAN52 PC 21488
DMJAN52 MW 188.26
DMJAN52 FM C10H20O3
DMJAN52 IC InChI=1S/C10H20O3/c1-2-3-4-5-6-7-8-9(11)10(12)13/h9,11H,2-8H2,1H3,(H,12,13)
DMJAN52 CS CCCCCCCCC(C(=O)O)O
DMJAN52 IK GHPVDCPCKSNJDR-UHFFFAOYSA-N
DMJAN52 IU 2-hydroxydecanoic acid
DMJAN52 CA CAS 5393-81-7
DMJAN52 CB CHEBI:133172
DMJAN52 DE Discovery agent
DMM9Z0B ID DMM9Z0B
DMM9Z0B DN 2-hydroxy-17beta-estradiol
DMM9Z0B HS Investigative
DMM9Z0B SN 2-Hydroxyestradiol; 2-OH-Estradiol; 362-05-0; 2-hydroxy-estradiol; 2-OH-E2; (17beta)-Estra-1,3,5(10)-triene-2,3,17-triol; UNII-AYU2L67YUU; Estra-1,3,5(10)-triene-2,3,17beta-triol; CHEBI:28744; NSC 61711; AYU2L67YUU; 2-Hydroxy-17; MLS000069506; CHEMBL467987; DILDHNKDVHLEQB-XSSYPUMDSA-N; ESTRA-1,3,5(10)-TRIENE-2,3,17-beta-TRIOL; SMR000058615; ECS; CCRIS 8709; 2bw7
DMM9Z0B DT Small molecular drug
DMM9Z0B PC 247304
DMM9Z0B MW 288.4
DMM9Z0B FM C18H24O3
DMM9Z0B IC InChI=1S/C18H24O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,17,19-21H,2-7H2,1H3/t11-,12+,14-,17-,18-/m0/s1
DMM9Z0B CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=C(C=C34)O)O
DMM9Z0B IK DILDHNKDVHLEQB-XSSYPUMDSA-N
DMM9Z0B IU (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,17-triol
DMM9Z0B CA CAS 362-05-0
DMM9Z0B CB CHEBI:28744
DMM9Z0B DE Discovery agent
DM2GPF6 ID DM2GPF6
DM2GPF6 DN 2-Hydroxy-2-phenyl-nonanoic acid amide
DM2GPF6 HS Investigative
DM2GPF6 SN CHEMBL287713
DM2GPF6 DT Small molecular drug
DM2GPF6 PC 10131164
DM2GPF6 MW 249.35
DM2GPF6 FM C15H23NO2
DM2GPF6 IC InChI=1S/C15H23NO2/c1-2-3-4-5-9-12-15(18,14(16)17)13-10-7-6-8-11-13/h6-8,10-11,18H,2-5,9,12H2,1H3,(H2,16,17)
DM2GPF6 CS CCCCCCCC(C1=CC=CC=C1)(C(=O)N)O
DM2GPF6 IK FXKCDILPUXRDAT-UHFFFAOYSA-N
DM2GPF6 IU 2-hydroxy-2-phenylnonanamide
DM2GPF6 DE Discovery agent
DM5ACNU ID DM5ACNU
DM5ACNU DN 2'-hydroxy-3,4,5-trimethoxychalcone
DM5ACNU HS Investigative
DM5ACNU SN Crotaoprostrin; 2'-hydroxy-3,4,5-trimethoxychalcone; CHEMBL521653; 2'-Hydroxy-3,4,5-methoxychalcone; (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (2E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; 59817-22-0; 142955-68-8; NSC331924; AC1NWOUH; MLS001049027; SCHEMBL5423339; MolPort-000-450-785; SRSBUHVXNLHWHU-CMDGGOBGSA-N; HMS2268N22; ZINC4042476; ZX-AT026929; LMPK12120198; STK888527; BDBM50257726; AKOS002181958; NSC-331924; NSC 331924; 2''-hydroxy-3,4,5-trimethoxychalcone; SMR000387055
DM5ACNU DT Small molecular drug
DM5ACNU PC 5709436
DM5ACNU MW 314.3
DM5ACNU FM C18H18O5
DM5ACNU IC InChI=1S/C18H18O5/c1-21-16-10-12(11-17(22-2)18(16)23-3)8-9-15(20)13-6-4-5-7-14(13)19/h4-11,19H,1-3H3/b9-8+
DM5ACNU CS COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)C2=CC=CC=C2O
DM5ACNU IK SRSBUHVXNLHWHU-CMDGGOBGSA-N
DM5ACNU IU (E)-1-(2-hydroxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
DM5ACNU CA CAS 59817-22-0
DM5ACNU DE Discovery agent
DMDOHRF ID DMDOHRF
DMDOHRF DN 2-HYDROXY-3,5-DIIODOBENZOIC ACID
DMDOHRF HS Investigative
DMDOHRF SN 3,5-DIIODOSALICYLIC ACID; 133-91-5; 2-Hydroxy-3,5-diiodobenzoic acid; 3,5-Diiodo-2-hydroxybenzoic acid; Benzoic acid, 2-hydroxy-3,5-diiodo-; 2-Hydroxy-3,5-diiodobenzoate; 3,5-Diiodosalicylate; 2-Hydroxy-3,5-diiodobenzenecarboxylic acid; 2-HYDROXY-3,5-DIIODO-BENZOIC ACID; Salicylic acid, 3,5-diiodo-; NSC 6303; Benzoic acid, 3,5-diiodo-2-hydroxy-; UNII-1496OH15B6; 3,5-Diiodosalicylicacid; EINECS 205-124-0; BRN 2615358; AI3-33355; NSC6303; DHZVWQPHNWDCFS-UHFFFAOYSA-N; MFCD00002444; 1496OH15B6; DIU; rarechem al be 0656; ACMC-1BPSO
DMDOHRF DT Small molecular drug
DMDOHRF PC 8631
DMDOHRF MW 389.91
DMDOHRF FM C7H4I2O3
DMDOHRF IC InChI=1S/C7H4I2O3/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,10H,(H,11,12)
DMDOHRF CS C1=C(C=C(C(=C1C(=O)O)O)I)I
DMDOHRF IK DHZVWQPHNWDCFS-UHFFFAOYSA-N
DMDOHRF IU 2-hydroxy-3,5-diiodobenzoic acid
DMDOHRF CA CAS 133-91-5
DMDOHRF DE Discovery agent
DMK8WUR ID DMK8WUR
DMK8WUR DN 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one
DMK8WUR HS Investigative
DMK8WUR SN 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-3-(1-methylethyl)-; 1946-74-3; CHEMBL1275969; a-thujaplicine; thujaplicin; .alpha.-Thujaplicin; AC1Q6BZY; SCHEMBL355645; 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one; AC1L2Z64; CTK1B5134; DTXSID70173098; TUFYVOCKVJOUIR-UHFFFAOYSA-N; ZINC2041733; BDBM50330793; AKOS025402371; AC-8489; LS-56188; 2-hydroxy-3-isopropyl-cyclohepta-2,4,6-trien-1-one; 2-hydroxy-3-propan-2-ylcyclohepta-2,4,6-trien-1-one; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy(1-methylethyl)-; 38094-79-0
DMK8WUR DT Small molecular drug
DMK8WUR PC 80297
DMK8WUR MW 164.2
DMK8WUR FM C10H12O2
DMK8WUR IC InChI=1S/C10H12O2/c1-7(2)8-5-3-4-6-9(11)10(8)12/h3-7H,1-2H3,(H,11,12)
DMK8WUR CS CC(C)C1=C(C(=O)C=CC=C1)O
DMK8WUR IK TUFYVOCKVJOUIR-UHFFFAOYSA-N
DMK8WUR IU 2-hydroxy-3-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMK8WUR CA CAS 1946-74-3
DMK8WUR DE Discovery agent
DM5QV19 ID DM5QV19
DM5QV19 DN 2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile
DM5QV19 HS Investigative
DM5QV19 SN diarylphenol, 5b; CHEMBL503575; BDBM25431
DM5QV19 DT Small molecular drug
DM5QV19 PC 25093227
DM5QV19 MW 225.24
DM5QV19 FM C14H11NO2
DM5QV19 IC InChI=1S/C14H11NO2/c1-17-14-8-10(6-7-11(14)9-15)12-4-2-3-5-13(12)16/h2-8,16H,1H3
DM5QV19 CS COC1=C(C=CC(=C1)C2=CC=CC=C2O)C#N
DM5QV19 IK LZGNSWNEFCSNST-UHFFFAOYSA-N
DM5QV19 IU 4-(2-hydroxyphenyl)-2-methoxybenzonitrile
DM5QV19 DE Discovery agent
DMSDYZQ ID DMSDYZQ
DMSDYZQ DN 2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one
DMSDYZQ HS Investigative
DMSDYZQ SN gamma-Thujaplicin; 5-Isopropyltropolone; 672-76-4; gamma-Thujaplicine; THUJAPLICIN, ALPHA; .gamma.-Thujaplicin; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-5-(1-methylethyl)-; NSC43338; .gamma.-Thujaplicine; 2-Hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one; NSC402794; NSC 43338; NSC 18805; NSC 402794; BRN 2044323; AI3-28399; MLS002608534; MLS002702822; CHEMBL1275999; CHEBI:10578; NSC18805; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-5-isopropyl-; 2-hydroxy-5-isopropyl-cyclohepta-2,4,6-trien-1-one; WLN: L7VJ BQ EY1& SMR001527281
DMSDYZQ DT Small molecular drug
DMSDYZQ PC 12649
DMSDYZQ MW 164.2
DMSDYZQ FM C10H12O2
DMSDYZQ IC InChI=1S/C10H12O2/c1-7(2)8-3-5-9(11)10(12)6-4-8/h3-7H,1-2H3,(H,11,12)
DMSDYZQ CS CC(C)C1=CC=C(C(=O)C=C1)O
DMSDYZQ IK WKEWHSLZDDZONF-UHFFFAOYSA-N
DMSDYZQ IU 2-hydroxy-5-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMSDYZQ CA CAS 672-76-4
DMSDYZQ CB CHEBI:10578
DMSDYZQ DE Discovery agent
DMB3Y8H ID DMB3Y8H
DMB3Y8H DN 2-Hydroxy-6-(3-phenoxy-benzoylamino)-benzoic acid
DMB3Y8H HS Investigative
DMB3Y8H SN CHEMBL193840; BDBM23612; 3-Phenoxybenzoylamino deriv., 28f; 2-hydroxy-6-(3-phenoxybenzoylamino)benzoic acid; 2-hydroxy-6-[(3-phenoxybenzene)amido]benzoic acid
DMB3Y8H DT Small molecular drug
DMB3Y8H PC 11302521
DMB3Y8H MW 349.3
DMB3Y8H FM C20H15NO5
DMB3Y8H IC InChI=1S/C20H15NO5/c22-17-11-5-10-16(18(17)20(24)25)21-19(23)13-6-4-9-15(12-13)26-14-7-2-1-3-8-14/h1-12,22H,(H,21,23)(H,24,25)
DMB3Y8H CS C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NC3=C(C(=CC=C3)O)C(=O)O
DMB3Y8H IK QXBHJJXXAXXUEZ-UHFFFAOYSA-N
DMB3Y8H IU 2-hydroxy-6-[(3-phenoxybenzoyl)amino]benzoic acid
DMB3Y8H DE Discovery agent
DMOT6V7 ID DMOT6V7
DMOT6V7 DN 2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID
DMOT6V7 HS Investigative
DMOT6V7 SN AC1L1BQO; SCHEMBL1458463; CINIOMOBGSHXRK-UHFFFAOYSA-N
DMOT6V7 DT Small molecular drug
DMOT6V7 PC 1562
DMOT6V7 MW 175.18
DMOT6V7 FM C7H13NO4
DMOT6V7 IC InChI=1S/C7H13NO4/c1-4(2)3-5(7(10)11)6(9)8-12/h4-5,12H,3H2,1-2H3,(H,8,9)(H,10,11)
DMOT6V7 CS CC(C)CC(C(=O)NO)C(=O)O
DMOT6V7 IK CINIOMOBGSHXRK-UHFFFAOYSA-N
DMOT6V7 IU 2-(hydroxycarbamoyl)-4-methylpentanoic acid
DMOT6V7 DE Discovery agent
DMA8DZT ID DMA8DZT
DMA8DZT DN 2-Hydroxycarbamoylmethyl-pentanedioic acid
DMA8DZT HS Investigative
DMA8DZT SN CHEMBL65043; hydroxamate, 41; 2-Hydroxycarbamoylmethyl-pentanedioic acid; SCHEMBL1373534; BDBM17779; 2-[(hydroxycarbamoyl)methyl]pentanedioic acid; 2-[2-Oxo-2-(hydroxyamino)ethyl]pentanedioic acid
DMA8DZT DT Small molecular drug
DMA8DZT PC 10219893
DMA8DZT MW 205.17
DMA8DZT FM C7H11NO6
DMA8DZT IC InChI=1S/C7H11NO6/c9-5(8-14)3-4(7(12)13)1-2-6(10)11/h4,14H,1-3H2,(H,8,9)(H,10,11)(H,12,13)
DMA8DZT CS C(CC(=O)O)C(CC(=O)NO)C(=O)O
DMA8DZT IK PILHIJIJVLWKNF-UHFFFAOYSA-N
DMA8DZT IU 2-[2-(hydroxyamino)-2-oxoethyl]pentanedioic acid
DMA8DZT DE Discovery agent
DM412RI ID DM412RI
DM412RI DN 2-Hydroxycarbamoyl-pentanedioic acid
DM412RI HS Investigative
DM412RI SN 2-Hydroxycarbamoyl-pentanedioic acid; CHEMBL432726; SCHEMBL13996815; BDBM50129193; 2-(Hydroxycarbamoyl)pentanedioic acid
DM412RI DT Small molecular drug
DM412RI PC 20778210
DM412RI MW 191.14
DM412RI FM C6H9NO6
DM412RI IC InChI=1S/C6H9NO6/c8-4(9)2-1-3(6(11)12)5(10)7-13/h3,13H,1-2H2,(H,7,10)(H,8,9)(H,11,12)
DM412RI CS C(CC(=O)O)C(C(=O)NO)C(=O)O
DM412RI IK FSDICXJFWIWOEV-UHFFFAOYSA-N
DM412RI IU 2-(hydroxycarbamoyl)pentanedioic acid
DM412RI DE Discovery agent
DM8RTBS ID DM8RTBS
DM8RTBS DN 2'-Hydroxychalcone
DM8RTBS HS Investigative
DM8RTBS SN 6'-hydroxychalcone; ACMC-1BLFY; 2-HYDROXY CHALCONE; 2-Propen-1-one, 1-(hydroxyphenyl)-3-phenyl-; SCHEMBL126857; CHEMBL1867065; CTK1E5803; CTK4B2371; MolPort-006-109-326; AETKQQBRKSELEL-UHFFFAOYSA-N; AC1L2476; ACT07806; CMLD2_000189; ANW-17633; MCULE-2929659613; TRA0032483; AN-6742; NCGC00017803-05; NCGC00017803-04; DB-021203; FT-0669974; FT-0612588; 2-Propen-1-one,1-(2-hydroxyphenyl)-3-phenyl-; 1-(2-hydroxyphenyl)-3-phenyl-prop-2-en-1-one
DM8RTBS DT Small molecular drug
DM8RTBS PC 638276
DM8RTBS MW 224.25
DM8RTBS FM C15H12O2
DM8RTBS IC InChI=1S/C15H12O2/c16-14-9-5-4-8-13(14)15(17)11-10-12-6-2-1-3-7-12/h1-11,16H/b11-10+
DM8RTBS CS C1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O
DM8RTBS IK AETKQQBRKSELEL-ZHACJKMWSA-N
DM8RTBS IU (E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one
DM8RTBS CA CAS 888-12-0
DM8RTBS CB CHEBI:27916
DM8RTBS DE Discovery agent
DM86HTZ ID DM86HTZ
DM86HTZ DN 2-Hydroxycinnamic acid
DM86HTZ HS Investigative
DM86HTZ SN 2-Hydroxy Cinnamic Acid; 3-(2-hydroxyphenyl)prop-2-enoic acid; Orthocumarsaure; ACMC-1BBQC; AC1L1YJR; 2-HYDROXYCINNAMICACID; CTK1F7842; CTK1H2007; CTK1B5135; PMOWTIHVNWZYFI-UHFFFAOYSA-N; MolPort-006-109-312; HMS3604C08; KS-00000X9C; EINECS 209-500-5; AKOS026677434; MCULE-7485332494; SY048367; FT-0612592; FT-0612591; MFCD00004379 (97%); 2-Propenoic acid, 3-(hydroxyphenyl)-, (Z)-; 2-Propenoic acid, 3-(hydroxyphenyl)-, (2E)-; 38094-41-6
DM86HTZ DT Small molecular drug
DM86HTZ PC 637540
DM86HTZ MW 164.16
DM86HTZ FM C9H8O3
DM86HTZ IC InChI=1S/C9H8O3/c10-8-4-2-1-3-7(8)5-6-9(11)12/h1-6,10H,(H,11,12)/b6-5+
DM86HTZ CS C1=CC=C(C(=C1)/C=C/C(=O)O)O
DM86HTZ IK PMOWTIHVNWZYFI-AATRIKPKSA-N
DM86HTZ IU (E)-3-(2-hydroxyphenyl)prop-2-enoic acid
DM86HTZ CA CAS 614-60-8
DM86HTZ CB CHEBI:18125
DM86HTZ DE Discovery agent
DMT6APV ID DMT6APV
DMT6APV DN 2-Hydroxyethyl 18-methoxycoronaridinate
DMT6APV HS Investigative
DMT6APV SN 2-Hydroxyethyl 18-methoxycoronaridinate
DMT6APV DT Small molecular drug
DMT6APV PC 46877886
DMT6APV MW 398.5
DMT6APV FM C23H30N2O4
DMT6APV IC InChI=1S/C23H30N2O4/c1-28-10-7-16-12-15-13-23(22(27)29-11-9-26)20-18(6-8-25(14-15)21(16)23)17-4-2-3-5-19(17)24-20/h2-5,15-16,21,24,26H,6-14H2,1H3/t15?,16-,21-,23+/m0/s1
DMT6APV CS COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OCCO
DMT6APV IK VOCSICAFSPBNRT-NVVKDKPXSA-N
DMT6APV IU 2-hydroxyethyl (1S,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMT6APV DE Discovery agent
DM5E1DC ID DM5E1DC
DM5E1DC DN 2-hydroxygarveatin E
DM5E1DC HS Investigative
DM5E1DC SN 2-hydroxygarveatin E
DM5E1DC DT Small molecular drug
DM5E1DC PC 16091656
DM5E1DC MW 356.4
DM5E1DC FM C20H20O6
DM5E1DC IC InChI=1S/C20H20O6/c1-6-9-8(2)14(21)10-7-11-13(16(23)12(10)15(9)22)17(24)20(5,26)18(25)19(11,3)4/h7,23,26H,6H2,1-5H3
DM5E1DC CS CCC1=C(C(=O)C2=CC3=C(C(=C2C1=O)O)C(=O)C(C(=O)C3(C)C)(C)O)C
DM5E1DC IK MEDXQZJJCUKMBX-UHFFFAOYSA-N
DM5E1DC IU 7-ethyl-2,9-dihydroxy-2,4,4,6-tetramethylanthracene-1,3,5,8-tetrone
DM5E1DC DE Discovery agent
DMK96BL ID DMK96BL
DMK96BL DN 2-HYDROXYGARVIN A
DMK96BL HS Investigative
DMK96BL SN 2-hydroxygarvin A; CHEMBL465623; SCHEMBL3076542
DMK96BL DT Small molecular drug
DMK96BL PC 21609882
DMK96BL MW 414.4
DMK96BL FM C23H26O7
DMK96BL IC InChI=1S/C23H26O7/c1-7-8-12-15-11(10-14(29-5)16(12)20(26)30-6)9-13-17(18(15)24)19(25)23(4,28)21(27)22(13,2)3/h9-10,24,28H,7-8H2,1-6H3
DMK96BL CS CCCC1=C(C(=CC2=CC3=C(C(=C21)O)C(=O)C(C(=O)C3(C)C)(C)O)OC)C(=O)OC
DMK96BL IK PRAZMVBMBFPZFN-UHFFFAOYSA-N
DMK96BL IU methyl 7,9-dihydroxy-3-methoxy-5,5,7-trimethyl-6,8-dioxo-1-propylanthracene-2-carboxylate
DMK96BL DE Discovery agent
DMNXV2I ID DMNXV2I
DMNXV2I DN 2-Hydroxyiminoolean-12-en-28-oic acid
DMNXV2I HS Investigative
DMNXV2I DT Small molecular drug
DMNXV2I PC 91937014
DMNXV2I MW 469.7
DMNXV2I FM C30H47NO3
DMNXV2I IC InChI=1S/C30H47NO3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31-34)16-26(3,4)22(27)10-11-29(23,28)7/h8,19,21-23H,9-18H2,1-7H3,(H,32,33)/t19?,21-,22-,23+,27-,28+,29+,30-/m0/s1
DMNXV2I CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(CC(CC3(C)C)N=O)C
DMNXV2I IK XTPUMPBRCGZOFP-VVLRTUPLSA-N
DMNXV2I IU (4aS,6aR,6aS,6bR,8aS,12aS,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-11-nitroso-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMNXV2I DE Discovery agent
DMDKF03 ID DMDKF03
DMDKF03 DN 2-Hydroxyiminours-12-en-28-oic acid
DMDKF03 HS Investigative
DMDKF03 SN 2-(Hydroxyimino)-19beta-methyl-30-noroleana-12-ene-28-oic acid
DMDKF03 DT Small molecular drug
DMDKF03 PC 91937016
DMDKF03 MW 469.7
DMDKF03 FM C30H47NO3
DMDKF03 IC InChI=1S/C30H47NO3/c1-18-10-13-30(25(32)33)15-14-28(6)21(24(30)19(18)2)8-9-23-27(5)17-20(31-34)16-26(3,4)22(27)11-12-29(23,28)7/h8,18-20,22-24H,9-17H2,1-7H3,(H,32,33)/t18-,19+,20?,22+,23-,24+,27+,28-,29-,30+/m1/s1
DMDKF03 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC(CC5(C)C)N=O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMDKF03 IK YUEQLEDAPGIQNH-POPBXVHQSA-N
DMDKF03 IU (1S,2R,4aS,6aR,6aS,6bR,8aS,12aS,14bS)-1,2,6a,6b,9,9,12a-heptamethyl-11-nitroso-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMDKF03 DE Discovery agent
DMTLYDS ID DMTLYDS
DMTLYDS DN 2-hydroxyisoquinoline-1,3(2H,4H)-dione
DMTLYDS HS Investigative
DMTLYDS SN 2-hydroxyisoquinoline-1,3(2H,4H)-dione; 6890-08-0; CHEMBL16755; 2-Hydroxy-4H-isoquinoline-1,3-dione; 1,3(2H,4H)-Isoquinolinedione, 2-hydroxy-; 2-hydroxy-1,2,3,4-tetrahydroisoquinoline-1,3-dione; 0N7; AC1LAHYL; N-hydroxyisoquinolinedione, 2; SCHEMBL3358267; BDBM33410; DTXSID70333610; ZINC3626195; 0637AC; AKOS016011468; FCH1154656; ACN-049309; AJ-45130; 2-Hydroxy-1,3(2H,4H)-isoquinolinedione; KB-230940; AX8246098
DMTLYDS DT Small molecular drug
DMTLYDS PC 514100
DMTLYDS MW 177.16
DMTLYDS FM C9H7NO3
DMTLYDS IC InChI=1S/C9H7NO3/c11-8-5-6-3-1-2-4-7(6)9(12)10(8)13/h1-4,13H,5H2
DMTLYDS CS C1C2=CC=CC=C2C(=O)N(C1=O)O
DMTLYDS IK ZXAICCBFIBBVAR-UHFFFAOYSA-N
DMTLYDS IU 2-hydroxy-4H-isoquinoline-1,3-dione
DMTLYDS CA CAS 6890-08-0
DMTLYDS DE Discovery agent
DMCNW3M ID DMCNW3M
DMCNW3M DN 2-hydroxylauric acid
DMCNW3M HS Investigative
DMCNW3M SN 2-OH-C12; 2-hydroxy lauric acid
DMCNW3M DT Small molecular drug
DMCNW3M PC 97783
DMCNW3M MW 216.32
DMCNW3M FM C12H24O3
DMCNW3M IC InChI=1S/C12H24O3/c1-2-3-4-5-6-7-8-9-10-11(13)12(14)15/h11,13H,2-10H2,1H3,(H,14,15)
DMCNW3M CS CCCCCCCCCCC(C(=O)O)O
DMCNW3M IK YDZIJQXINJLRLL-UHFFFAOYSA-N
DMCNW3M IU 2-hydroxydodecanoic acid
DMCNW3M CB CHEBI:36211
DMCNW3M DE Discovery agent
DM4LMPD ID DM4LMPD
DM4LMPD DN 2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD HS Investigative
DM4LMPD SN CHEMBL570449; 2-Hydroxymethyl-3-hydroxymorphinan
DM4LMPD DT Small molecular drug
DM4LMPD PC 44626540
DM4LMPD MW 287.4
DM4LMPD FM C18H25NO2
DM4LMPD IC InChI=1S/C18H25NO2/c1-19-7-6-18-5-3-2-4-14(18)16(19)9-12-8-13(11-20)17(21)10-15(12)18/h8,10,14,16,20-21H,2-7,9,11H2,1H3/t14-,16+,18+/m0/s1
DM4LMPD CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=CC(=C(C=C34)O)CO
DM4LMPD IK BPBSRBFSNMZXSP-YXJHDRRASA-N
DM4LMPD IU (1R,9R,10R)-5-(hydroxymethyl)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol
DM4LMPD DE Discovery agent
DM7MUZ1 ID DM7MUZ1
DM7MUZ1 DN 2-Hydroxymethyl-Pyrrolidine-3,4-Diol
DM7MUZ1 HS Investigative
DM7MUZ1 SN 2-(Hydroxymethyl)-[2R-(2a,3b,4b)]-3,4-Pyrrolidinediol; 2-(Hydroxymethyl)-(2R-(2a,3b,4b))-3,4-Pyrrolidinediol; ACMC-20m9e3; ACMC-20m1d3; ACMC-20m9e4; 3,4-Pyrrolidinediol,2-(hydroxymethyl)-, (2S,3S,4R)-; 3,4-Pyrrolidinediol,2-(hydroxymethyl)-, (2R,3R,4S)-; AC1L1B8Z; 3,4-Pyrrolidinediol, 2-(hydroxymethyl)-, (2R,3S,4S)-; SCHEMBL981088; CTK8A3364; 1,4-dideoxy-1,4-iminopentitol; OQEBIHBLFRADNM-UHFFFAOYSA-N; HMS3373I18; IMR; 97058-12-3
DM7MUZ1 DT Small molecular drug
DM7MUZ1 PC 127716
DM7MUZ1 MW 133.15
DM7MUZ1 FM C5H11NO3
DM7MUZ1 IC InChI=1S/C5H11NO3/c7-2-3-5(9)4(8)1-6-3/h3-9H,1-2H2/t3-,4-,5-/m0/s1
DM7MUZ1 CS C1[C@@H]([C@H]([C@@H](N1)CO)O)O
DM7MUZ1 IK OQEBIHBLFRADNM-YUPRTTJUSA-N
DM7MUZ1 IU (2S,3S,4S)-2-(hydroxymethyl)pyrrolidine-3,4-diol
DM7MUZ1 CA CAS 100937-53-9
DM7MUZ1 DE Discovery agent
DMWSR13 ID DMWSR13
DMWSR13 DN 2-Hydroxy-N-(3-phenyl-propyl)-benzamide
DMWSR13 HS Investigative
DMWSR13 SN 2-hydroxy-N-(3-phenylpropyl)benzamide; CHEMBL290426; 153810-66-3; MLS000112389; 2-Hydroxy-N-(3-phenyl-propyl)-benzamide; AC1M4REE; Cambridge id 6816004; cid_2287872; MolPort-001-028-867; HMS2472G06; ZINC2989649; AC1Q7881; BDBM50282105; AKOS008913729; NE30179; MCULE-4556826159; JJ-3297; ST069062; SMR000108303; EN300-70444; AB00120250-01; (2-hydroxyphenyl)-N-(3-phenylpropyl)carboxamide; SR-01000522099; SR-01000522099-1
DMWSR13 DT Small molecular drug
DMWSR13 PC 2287872
DMWSR13 MW 255.31
DMWSR13 FM C16H17NO2
DMWSR13 IC InChI=1S/C16H17NO2/c18-15-11-5-4-10-14(15)16(19)17-12-6-9-13-7-2-1-3-8-13/h1-5,7-8,10-11,18H,6,9,12H2,(H,17,19)
DMWSR13 CS C1=CC=C(C=C1)CCCNC(=O)C2=CC=CC=C2O
DMWSR13 IK NCGDIICSZWHCQX-UHFFFAOYSA-N
DMWSR13 IU 2-hydroxy-N-(3-phenylpropyl)benzamide
DMWSR13 DE Discovery agent
DMQ0F96 ID DMQ0F96
DMQ0F96 DN 2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide
DMQ0F96 HS Investigative
DMQ0F96 SN 2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide; SCHEMBL3009043; CHEMBL511606
DMQ0F96 DT Small molecular drug
DMQ0F96 PC 24950386
DMQ0F96 MW 371.4
DMQ0F96 FM C23H17NO4
DMQ0F96 IC InChI=1S/C23H17NO4/c25-18-5-1-3-14(12-18)15-7-9-20-16(11-15)8-10-21(27)22(20)23(28)24-17-4-2-6-19(26)13-17/h1-13,25-27H,(H,24,28)
DMQ0F96 CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=C(C=C3)O)C(=O)NC4=CC(=CC=C4)O
DMQ0F96 IK JFOMBBOIWCMHKV-UHFFFAOYSA-N
DMQ0F96 IU 2-hydroxy-N,6-bis(3-hydroxyphenyl)naphthalene-1-carboxamide
DMQ0F96 DE Discovery agent
DMMILJS ID DMMILJS
DMMILJS DN 2-hydroxyoctanoic acid
DMMILJS HS Investigative
DMMILJS SN 2-Hydroxyoctanoic acid; 617-73-2; 2-Hydroxycaprylic acid; 2-Hydroxy-n-octanoic Acid; hydroxycaprylic acid; 2-hydroxy caprylic acid; Hydroxyoctanoate; 2-hydroxy-octanoic acid; Octanoic acid, hydroxy-; alpha-Hydroxycaprylic acid; 2-Hydroxyoctanoate; alpha-Hydroxyoctanoic acid; (+/-)-2-Hydroxyoctanoic acid; JKRDADVRIYVCCY-UHFFFAOYSA-N; MFCD00014410; 2-Hydroxycaprylate; alpha-Hydroxyoctanoate; alpha-Hydroxycaprylate; 2-hydroxyoctans; Octanoic acid, 2-hydroxy-; a-Hydroxycaprylate; a-Hydroxyoctanoate; EINECS 210-524-3; NSC 189703
DMMILJS DT Small molecular drug
DMMILJS PC 94180
DMMILJS MW 160.21
DMMILJS FM C8H16O3
DMMILJS IC InChI=1S/C8H16O3/c1-2-3-4-5-6-7(9)8(10)11/h7,9H,2-6H2,1H3,(H,10,11)
DMMILJS CS CCCCCCC(C(=O)O)O
DMMILJS IK JKRDADVRIYVCCY-UHFFFAOYSA-N
DMMILJS IU 2-hydroxyoctanoic acid
DMMILJS CA CAS 617-73-2
DMMILJS CB CHEBI:86543
DMMILJS DE Discovery agent
DMHK2NQ ID DMHK2NQ
DMHK2NQ DN 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMHK2NQ HS Investigative
DMHK2NQ SN CHEMBL399354; 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate; Gallic acid 2-hydroxyphenethyl ester
DMHK2NQ DT Small molecular drug
DMHK2NQ PC 24180556
DMHK2NQ MW 290.27
DMHK2NQ FM C15H14O6
DMHK2NQ IC InChI=1S/C15H14O6/c16-11-4-2-1-3-9(11)5-6-21-15(20)10-7-12(17)14(19)13(18)8-10/h1-4,7-8,16-19H,5-6H2
DMHK2NQ CS C1=CC=C(C(=C1)CCOC(=O)C2=CC(=C(C(=C2)O)O)O)O
DMHK2NQ IK BFCLPURLRKZMCC-UHFFFAOYSA-N
DMHK2NQ IU 2-(2-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate
DMHK2NQ DE Discovery agent
DMHO8KQ ID DMHO8KQ
DMHO8KQ DN 2-hydroxy-saclofen
DMHO8KQ HS Investigative
DMHO8KQ SN 2-hydroxy-s-(-)-saclofen; 2-OH-saclofen; 2-hydroxysaclofen
DMHO8KQ DT Small molecular drug
DMHO8KQ PC 1564
DMHO8KQ MW 265.71
DMHO8KQ FM C9H12ClNO4S
DMHO8KQ IC InChI=1S/C9H12ClNO4S/c10-8-3-1-7(2-4-8)9(12,5-11)6-16(13,14)15/h1-4,12H,5-6,11H2,(H,13,14,15)
DMHO8KQ CS C1=CC(=CC=C1C(CN)(CS(=O)(=O)O)O)Cl
DMHO8KQ IK WBSMZVIMANOCNX-UHFFFAOYSA-N
DMHO8KQ IU 3-amino-2-(4-chlorophenyl)-2-hydroxypropane-1-sulfonic acid
DMHO8KQ CA CAS 117354-64-0
DMHO8KQ CB CHEBI:111179
DMHO8KQ DE Discovery agent
DM261B0 ID DM261B0
DM261B0 DN 2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one
DM261B0 HS Investigative
DM261B0 SN CHEMBL192306; azole isoflavone analog 2a; BDBM9891; 2-(1H-imidazol-1-yl)-7-methoxy-3-phenyl-4H-chromen-4-one; 2-(1H-Imidazol-1-yl)-7-methoxy-3-phenyl-4H-1-benzopyran4-one; 2-(1h-imidazol-1-yl)-7-methoxy-3-phenyl-4h-1-benzo pyran-4-one
DM261B0 DT Small molecular drug
DM261B0 PC 23644623
DM261B0 MW 318.3
DM261B0 FM C19H14N2O3
DM261B0 IC InChI=1S/C19H14N2O3/c1-23-14-7-8-15-16(11-14)24-19(21-10-9-20-12-21)17(18(15)22)13-5-3-2-4-6-13/h2-12H,1H3
DM261B0 CS COC1=CC2=C(C=C1)C(=O)C(=C(O2)N3C=CN=C3)C4=CC=CC=C4
DM261B0 IK XDJIKPUCOXIQTJ-UHFFFAOYSA-N
DM261B0 IU 2-imidazol-1-yl-7-methoxy-3-phenylchromen-4-one
DM261B0 DE Discovery agent
DM2GUDZ ID DM2GUDZ
DM2GUDZ DN 2-Imidazol-1-ylmethylxanthen-9-one
DM2GUDZ HS Investigative
DM2GUDZ SN CHEMBL1083354; 2-Imidazol-1-ylmethylxanthen-9-one
DM2GUDZ DT Small molecular drug
DM2GUDZ PC 46867544
DM2GUDZ MW 276.29
DM2GUDZ FM C17H12N2O2
DM2GUDZ IC InChI=1S/C17H12N2O2/c20-17-13-3-1-2-4-15(13)21-16-6-5-12(9-14(16)17)10-19-8-7-18-11-19/h1-9,11H,10H2
DM2GUDZ CS C1=CC=C2C(=C1)C(=O)C3=C(O2)C=CC(=C3)CN4C=CN=C4
DM2GUDZ IK FWPREHSGJHCERR-UHFFFAOYSA-N
DM2GUDZ IU 2-(imidazol-1-ylmethyl)xanthen-9-one
DM2GUDZ DE Discovery agent
DMSEIUP ID DMSEIUP
DMSEIUP DN 2-iodo-melatonin
DMSEIUP HS Investigative
DMSEIUP SN 2-Iodomelatonin; 93515-00-5; n-[2-(2-iodo-5-methoxy-1h-indol-3-yl)ethyl]acetamide; CHEMBL289233; N-(2-(2-Iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide; acetamide,n-[2-(2-iodo-5-methoxy-1h-indol-3-yl)ethyl]-; Acetamide, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)-, (3beta)-; Acetamide, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)-; SR-01000075935; 2-I-MLT; Melatonin,2-Iodo; ML2; Tocris-0737; Lopac-I-1899; AC1L3GZ8; AC1Q5P6Z; Lopac0_000610; SCHEMBL163451; GTPL1343; BDBM29611; CTK8F4316; DTXSID30239462; 2-iodomelatonin; IODOMELATONIN
DMSEIUP DT Small molecular drug
DMSEIUP PC 115348
DMSEIUP MW 358.17
DMSEIUP FM C13H15IN2O2
DMSEIUP IC InChI=1S/C13H15IN2O2/c1-8(17)15-6-5-10-11-7-9(18-2)3-4-12(11)16-13(10)14/h3-4,7,16H,5-6H2,1-2H3,(H,15,17)
DMSEIUP CS CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)I
DMSEIUP IK FJDDSMSDZHURBJ-UHFFFAOYSA-N
DMSEIUP IU N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMSEIUP CA CAS 93515-00-5
DMSEIUP CB CHEBI:109558
DMSEIUP DE Discovery agent
DMOVRX7 ID DMOVRX7
DMOVRX7 DN 2-isooleanolic acid
DMOVRX7 HS Investigative
DMOVRX7 SN 2-isooleanolic acid; CHEMBL1080965; BDBM50310507; 2beta-Hydroxyoleana-12-ene-28-oic acid
DMOVRX7 DT Small molecular drug
DMOVRX7 PC 46883487
DMOVRX7 MW 456.7
DMOVRX7 FM C30H48O3
DMOVRX7 IC InChI=1S/C30H48O3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31)16-26(3,4)22(27)10-11-29(23,28)7/h8,19,21-23,31H,9-18H2,1-7H3,(H,32,33)/t19-,21+,22+,23-,27+,28-,29-,30+/m1/s1
DMOVRX7 CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H](CC3(C)C)O)C
DMOVRX7 IK UODITNOILLXLOO-VGWDZYRESA-N
DMOVRX7 IU (4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMOVRX7 DE Discovery agent
DMSLMAN ID DMSLMAN
DMSLMAN DN 2-isopropyl-9H-carbazole
DMSLMAN HS Investigative
DMSLMAN SN 2-isopropyl-9H-carbazole; CHEMBL1170460; SCHEMBL10892550
DMSLMAN DT Small molecular drug
DMSLMAN PC 20228010
DMSLMAN MW 209.29
DMSLMAN FM C15H15N
DMSLMAN IC InChI=1S/C15H15N/c1-10(2)11-7-8-13-12-5-3-4-6-14(12)16-15(13)9-11/h3-10,16H,1-2H3
DMSLMAN CS CC(C)C1=CC2=C(C=C1)C3=CC=CC=C3N2
DMSLMAN IK AMSCTVXMVALTQJ-UHFFFAOYSA-N
DMSLMAN IU 2-propan-2-yl-9H-carbazole
DMSLMAN DE Discovery agent
DMEZFKS ID DMEZFKS
DMEZFKS DN 2-isoursolic acid
DMEZFKS HS Investigative
DMEZFKS SN 2-isoursolic acid; CHEMBL1080966
DMEZFKS DT Small molecular drug
DMEZFKS PC 46883488
DMEZFKS MW 456.7
DMEZFKS FM C30H48O3
DMEZFKS IC InChI=1S/C30H48O3/c1-18-10-13-30(25(32)33)15-14-28(6)21(24(30)19(18)2)8-9-23-27(5)17-20(31)16-26(3,4)22(27)11-12-29(23,28)7/h8,18-20,22-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19-,20+,22-,23+,24-,27-,28+,29+,30-/m0/s1
DMEZFKS CS C[C@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H](CC5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMEZFKS IK DDHYEJNMSYDDTH-JJKIWFBPSA-N
DMEZFKS IU (1S,2S,4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMEZFKS DE Discovery agent
DM1F4TN ID DM1F4TN
DM1F4TN DN 2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline
DM1F4TN HS Investigative
DM1F4TN DT Small molecular drug
DM1F4TN PC 10561772
DM1F4TN DE Discovery agent
DMD2ZNA ID DMD2ZNA
DMD2ZNA DN 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline
DMD2ZNA HS Investigative
DMD2ZNA DT Small molecular drug
DMD2ZNA PC 10513958
DMD2ZNA DE Discovery agent
DMZD348 ID DMZD348
DMZD348 DN 2LM20-4
DMZD348 HS Investigative
DMZD348 SN Anti-CD20 SMIP (autoimmune disease), Pfizer; Anti-CD20 small modular immunopharmaceutical (autoimmune disease), Pfizer
DMZD348 CP Pfizer Inc
DMZD348 DE Autoimmune diabetes
DMPJT1C ID DMPJT1C
DMPJT1C DN 2MD
DMPJT1C HS Investigative
DMPJT1C SN VDZ; 2-methylene-19-nor-(20S)-1 alpha,25-dihydroxy-vitamin D3
DMPJT1C DT Small molecular drug
DMPJT1C PC 5289549
DMPJT1C MW 416.6
DMPJT1C FM C27H44O3
DMPJT1C IC InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)22-12-13-23-21(9-7-15-27(22,23)5)11-10-20-16-24(28)19(2)25(29)17-20/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b21-11+/t18-,22+,23-,24+,25+,27+/m0/s1
DMPJT1C CS C[C@@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C3C[C@H](C(=C)[C@@H](C3)O)O)C
DMPJT1C IK UHMPCVGLSKFXHR-NAQZCRMNSA-N
DMPJT1C IU (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2S)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol
DMPJT1C DE Discovery agent
DMDFPGB ID DMDFPGB
DMDFPGB DN 2'-Me-CCPA
DMDFPGB HS Investigative
DMDFPGB SN 2'methyl-2-chloro-N6-cyclopentyladenosine
DMDFPGB DT Small molecular drug
DMDFPGB PC 10475082
DMDFPGB MW 383.8
DMDFPGB FM C16H22ClN5O4
DMDFPGB IC InChI=1S/C16H22ClN5O4/c1-16(25)11(24)9(6-23)26-14(16)22-7-18-10-12(19-8-4-2-3-5-8)20-15(17)21-13(10)22/h7-9,11,14,23-25H,2-6H2,1H3,(H,19,20,21)/t9-,11-,14-,16-/m1/s1
DMDFPGB CS C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)NC4CCCC4)CO)O)O
DMDFPGB IK MMPAUXMIDJWGFO-ROMFRFKVSA-N
DMDFPGB IU (2R,3R,4R,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
DMDFPGB CA CAS 205171-12-6
DMDFPGB DE Discovery agent
DMDZTU3 ID DMDZTU3
DMDZTU3 DN 2-MePen-RYYRIK-NH2
DMDZTU3 HS Investigative
DMDZTU3 SN CHEMBL437601
DMDZTU3 DT Small molecular drug
DMDZTU3 PC 44456298
DMDZTU3 MW 979.2
DMDZTU3 FM C48H78N14O8
DMDZTU3 IC InChI=1S/C48H78N14O8/c1-5-14-30(4)41(65)58-35(18-12-25-55-47(51)52)42(66)60-37(27-31-15-8-7-9-16-31)45(69)61-38(28-32-20-22-33(63)23-21-32)44(68)59-36(19-13-26-56-48(53)54)43(67)62-39(29(3)6-2)46(70)57-34(40(50)64)17-10-11-24-49/h7-9,15-16,20-23,29-30,34-39,63H,5-6,10-14,17-19,24-28,49H2,1-4H3,(H2,50,64)(H,57,70)(H,58,65)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t29-,30?,34-,35-,36-,37-,38-,39-/m0/s1
DMDZTU3 CS CCCC(C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DMDZTU3 IK TYNKFZNKNQQZMB-GUICQBDJSA-N
DMDZTU3 IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-methylpentanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMDZTU3 DE Discovery agent
DMHK25N ID DMHK25N
DMHK25N DN 2-Mercaptomethyl-pentanedioic acid
DMHK25N HS Investigative
DMHK25N SN 2-Mercaptomethylglutaric acid; 2-Mercaptomethyl-pentanedioic acid; CHEMBL60941; 106146-19-4; Pentanedioic acid,2-(mercaptomethyl)-; 2-Mmga; 2-(sulfanylmethyl)pentanedioic acid; ACMC-1BUG7; AC1L2VT3; 2-mer-captomethylglutaric acid; SCHEMBL1278279; CTK4A4424; Glutaric acid, 2-mercaptomethyl-; LDFDXRPEWZHIML-UHFFFAOYSA-N; NSC613827; BDBM50127614
DMHK25N DT Small molecular drug
DMHK25N PC 129558
DMHK25N MW 178.21
DMHK25N FM C6H10O4S
DMHK25N IC InChI=1S/C6H10O4S/c7-5(8)2-1-4(3-11)6(9)10/h4,11H,1-3H2,(H,7,8)(H,9,10)
DMHK25N CS C(CC(=O)O)C(CS)C(=O)O
DMHK25N IK LDFDXRPEWZHIML-UHFFFAOYSA-N
DMHK25N IU 2-(sulfanylmethyl)pentanedioic acid
DMHK25N CA CAS 109333-27-9
DMHK25N DE Discovery agent
DMXEUDM ID DMXEUDM
DMXEUDM DN 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide
DMXEUDM HS Investigative
DMXEUDM SN N-[4-(Aminosulfonyl)phenyl]-2-Mercaptobenzamide; N-(4-sulfamoylphenyl)-2-sulfanylbenzamide; CHEMBL386049; reduced thio H5a; 2hd6; AC1LA75B; SCHEMBL6227210; BDBM11053; reduced monomeric thio of compound 5a; DB07476; BOS; N-(4-sulfamoylphenyl)-2-sulfanyl-benzamide; 4-(2-mercaptophenylcarboxamido)benzenesulfonamide; N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE
DMXEUDM DT Small molecular drug
DMXEUDM PC 462919
DMXEUDM MW 308.4
DMXEUDM FM C13H12N2O3S2
DMXEUDM IC InChI=1S/C13H12N2O3S2/c14-20(17,18)10-7-5-9(6-8-10)15-13(16)11-3-1-2-4-12(11)19/h1-8,19H,(H,15,16)(H2,14,17,18)
DMXEUDM CS C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)N)S
DMXEUDM IK MRLVIVXGUGNENL-UHFFFAOYSA-N
DMXEUDM IU N-(4-sulfamoylphenyl)-2-sulfanylbenzamide
DMXEUDM DE Discovery agent
DMRVBCI ID DMRVBCI
DMRVBCI DN 2-Mercapto-pentanedioic acid
DMRVBCI HS Investigative
DMRVBCI SN Pentanedioic acid, 2-mercapto-; 2-Mercapto-pentanedioic acid; CHEMBL304885; 36303-63-6; 2-Mercaptoglutaric acid; SCHEMBL1204501; CTK1B0110; DTXSID20436307
DMRVBCI DT Small molecular drug
DMRVBCI PC 10171263
DMRVBCI MW 164.18
DMRVBCI FM C5H8O4S
DMRVBCI IC InChI=1S/C5H8O4S/c6-4(7)2-1-3(10)5(8)9/h3,10H,1-2H2,(H,6,7)(H,8,9)
DMRVBCI CS C(CC(=O)O)C(C(=O)O)S
DMRVBCI IK HWPIVZNZHAFMNA-UHFFFAOYSA-N
DMRVBCI IU 2-sulfanylpentanedioic acid
DMRVBCI CA CAS 36303-63-6
DMRVBCI DE Discovery agent
DM8HSBT ID DM8HSBT
DM8HSBT DN 2-mercaptophenylphosphonic acid
DM8HSBT HS Investigative
DM8HSBT SN 2-mercaptophenylphosphonic acid; CHEMBL1173336; SCHEMBL108541; (2-Mercaptophenyl)phosphonic acid
DM8HSBT DT Small molecular drug
DM8HSBT PC 15738646
DM8HSBT MW 190.16
DM8HSBT FM C6H7O3PS
DM8HSBT IC InChI=1S/C6H7O3PS/c7-10(8,9)5-3-1-2-4-6(5)11/h1-4,11H,(H2,7,8,9)
DM8HSBT CS C1=CC=C(C(=C1)P(=O)(O)O)S
DM8HSBT IK XUDMIKRWJYMQKD-UHFFFAOYSA-N
DM8HSBT IU (2-sulfanylphenyl)phosphonic acid
DM8HSBT DE Discovery agent
DMGADQ1 ID DMGADQ1
DMGADQ1 DN 2MeSADP
DMGADQ1 HS Investigative
DMGADQ1 SN 2-Methylthio-adenosine-5'-diphosphate; 2-MeSADP; 2-methylthio-ADP; 2-Mes-ADP; 2-methylthio-adenosine-5'-diphosphate; CHEMBL435402; 2-(methylsulfanyl)adenosine 5'-(trihydrogen diphosphate); methylthio-ADP; [(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate; 2-(Methylthio)adenosine 5'-diphosphate; [3H]2-methylthio-ADP; [3H]2MeSADP; (3H)2-Mes-ADP; AC1L3TRY; SCHEMBL195864; GTPL1763; GTPL1710; AC1Q6S18; adenosine, 2-(methylthio)-, 5'-(trihydrogen diphosphate); 2-(Methylthio)-Adenosinediphosphate; 2-methylthio-ADP
DMGADQ1 DT Small molecular drug
DMGADQ1 PC 121990
DMGADQ1 MW 473.3
DMGADQ1 FM C11H17N5O10P2S
DMGADQ1 IC InChI=1S/C11H17N5O10P2S/c1-29-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(25-10)2-24-28(22,23)26-27(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMGADQ1 CS CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N
DMGADQ1 IK WLMZTKAZJUWXCB-KQYNXXCUSA-N
DMGADQ1 IU [(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMGADQ1 CA CAS 34983-48-7
DMGADQ1 DE Discovery agent
DMBO2DC ID DMBO2DC
DMBO2DC DN 2MeSAMP
DMBO2DC HS Investigative
DMBO2DC SN 2-methylthio-AMP; poly(2'-methylthioadenylic acid)
DMBO2DC DT Small molecular drug
DMBO2DC PC 189762
DMBO2DC MW 393.32
DMBO2DC FM C11H16N5O7PS
DMBO2DC IC InChI=1S/C11H16N5O7PS/c1-25-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(23-10)2-22-24(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMBO2DC CS CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DMBO2DC IK XVTFTCNRRAQHEQ-KQYNXXCUSA-N
DMBO2DC IU [(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMBO2DC CA CAS 70804-88-5
DMBO2DC DE Discovery agent
DMUE0W6 ID DMUE0W6
DMUE0W6 DN 2MeSATP
DMUE0W6 HS Investigative
DMUE0W6 SN 2-methylthio-ATP; 2-MeSATP; 2-methylthio-adenosine-5'-triphosphate
DMUE0W6 DT Small molecular drug
DMUE0W6 PC 5310983
DMUE0W6 MW 553.28
DMUE0W6 FM C11H18N5O13P3S
DMUE0W6 IC InChI=1S/C11H18N5O13P3S/c1-33-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(27-10)2-26-31(22,23)29-32(24,25)28-30(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H,24,25)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMUE0W6 CS CSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DMUE0W6 IK XNOBOKJVOTYSJV-KQYNXXCUSA-N
DMUE0W6 IU [[(2R,3S,4R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMUE0W6 CA CAS 43170-89-4
DMUE0W6 DE Discovery agent
DMY2GXT ID DMY2GXT
DMY2GXT DN 2'-Me-tecadenoson
DMY2GXT HS Investigative
DMY2GXT SN CHEMBL400190; 2'-Me-tecadenoson; 2''-Me-tecadenoson
DMY2GXT DT Small molecular drug
DMY2GXT PC 44447542
DMY2GXT MW 351.36
DMY2GXT FM C15H21N5O5
DMY2GXT IC InChI=1S/C15H21N5O5/c1-15(23)11(22)9(4-21)25-14(15)20-7-18-10-12(16-6-17-13(10)20)19-8-2-3-24-5-8/h6-9,11,14,21-23H,2-5H2,1H3,(H,16,17,19)/t8-,9-,11-,14-,15-/m1/s1
DMY2GXT CS C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N[C@@H]4CCOC4)CO)O)O
DMY2GXT IK BPEIIXZHZSYVFH-LVSZHXFLSA-N
DMY2GXT IU (2R,3R,4R,5R)-5-(hydroxymethyl)-3-methyl-2-[6-[[(3R)-oxolan-3-yl]amino]purin-9-yl]oxolane-3,4-diol
DMY2GXT DE Discovery agent
DMA5Q4T ID DMA5Q4T
DMA5Q4T DN 2-methoxy-1,4-naphthoquinone
DMA5Q4T HS Investigative
DMA5Q4T SN 2-Methoxy-1,4-naphthoquinone; 2348-82-5; 2-Methoxynaphthoquinone; 2-methoxynaphthalene-1,4-dione; 2-Methoxy-p-naphthoquinone; 1,4-Naphthalenedione, 2-methoxy-; 1,4-NAPHTHOQUINONE, 2-METHOXY-; UNII-39020BUT1D; 2-Methoxy-1,4-naphthalenedione; NSC 31530; AI3-17893; CHEMBL106562; 2-Methoxy-[1,4]naphthoquinone; CHEBI:69522; OBGBGHKYJAOXRR-UHFFFAOYSA-N; 39020BUT1D; 2-methoxy-1,4-dihydronaphthalene-1,4-dione; ACMC-20ans6; AC1L28UU; MLS002472995; 2-methoxy-1,4-napthoquinone; SCHEMBL571061; AC1Q483I; DTXSID1062338; CTK4F1565
DMA5Q4T DT Small molecular drug
DMA5Q4T PC 16871
DMA5Q4T MW 188.18
DMA5Q4T FM C11H8O3
DMA5Q4T IC InChI=1S/C11H8O3/c1-14-10-6-9(12)7-4-2-3-5-8(7)11(10)13/h2-6H,1H3
DMA5Q4T CS COC1=CC(=O)C2=CC=CC=C2C1=O
DMA5Q4T IK OBGBGHKYJAOXRR-UHFFFAOYSA-N
DMA5Q4T IU 2-methoxynaphthalene-1,4-dione
DMA5Q4T CA CAS 2348-82-5
DMA5Q4T CB CHEBI:69522
DMA5Q4T DE Discovery agent
DMH76C5 ID DMH76C5
DMH76C5 DN 2-methoxy-1-naphthaldehyde thiosemicarbazone
DMH76C5 HS Investigative
DMH76C5 SN CHEMBL90867; 2-methoxy-1-naphthaldehyde thiosemicarbazone; 65110-22-7; NSC525522; AC1OBL0Z; ARONIS022059; SCHEMBL13954727; DTXSID80425959; MolPort-009-657-950; MolPort-001-023-825; ZINC4483101; BDBM50114597; STK028739; AKOS000488676; NSC-525522; KB-94431; ST035230; BB0276319; AN-329/40200631; [(E)-(2-methoxynaphthalen-1-yl)methylideneamino]thiourea; {[(1E)-2-(2-methoxynaphthyl)-1-azavinyl]amino}aminomethane-1-thione
DMH76C5 DT Small molecular drug
DMH76C5 PC 6875577
DMH76C5 MW 259.329
DMH76C5 FM C13H13N3OS
DMH76C5 IC InChI=1S/C13H13N3OS/c1-17-12-7-6-9-4-2-3-5-10(9)11(12)8-15-16-13(14)18/h2-8H,1H3,(H3,14,16,18)/b15-8+
DMH76C5 CS COC1=C(C2=CC=CC=C2C=C1)/C=N/NC(=S)N
DMH76C5 IK DXTYDDVJOBCCHE-OVCLIPMQSA-N
DMH76C5 IU [(E)-(2-methoxynaphthalen-1-yl)methylideneamino]thiourea
DMH76C5 CA CAS 65110-22-7
DMH76C5 DE Discovery agent
DM93DYT ID DM93DYT
DM93DYT DN 2-methoxy-3,4-methylenedioxybenzophenone
DM93DYT HS Investigative
DM93DYT SN 872881-74-8; (4-methoxybenzo[d][1,3]dioxol-5-yl)(phenyl)methanone; 2-methoxy-3,4-methylenedioxybenzophenone; CHEMBL497717; CTK3C4926; SUKAEERDMQPLMM-UHFFFAOYSA-; DTXSID20475539; AKOS027335527; 4-Methoxy-5-benzoyl-1,3-benzodioxole; Methanone, (4-methoxy-1,3-benzodioxol-5-yl)phenyl-
DM93DYT DT Small molecular drug
DM93DYT PC 11999967
DM93DYT MW 256.25
DM93DYT FM C15H12O4
DM93DYT IC InChI=1S/C15H12O4/c1-17-14-11(7-8-12-15(14)19-9-18-12)13(16)10-5-3-2-4-6-10/h2-8H,9H2,1H3
DM93DYT CS COC1=C(C=CC2=C1OCO2)C(=O)C3=CC=CC=C3
DM93DYT IK SUKAEERDMQPLMM-UHFFFAOYSA-N
DM93DYT IU (4-methoxy-1,3-benzodioxol-5-yl)-phenylmethanone
DM93DYT CA CAS 872881-74-8
DM93DYT DE Discovery agent
DMF8E5L ID DMF8E5L
DMF8E5L DN 2-methoxy-4-(2-methoxyphenylthio)benzonitrile
DMF8E5L HS Investigative
DMF8E5L SN CHEMBL510145; 2-methoxy-4-(2-methoxyphenylthio)benzonitrile
DMF8E5L DT Small molecular drug
DMF8E5L PC 44565206
DMF8E5L MW 271.3
DMF8E5L FM C15H13NO2S
DMF8E5L IC InChI=1S/C15H13NO2S/c1-17-13-5-3-4-6-15(13)19-12-8-7-11(10-16)14(9-12)18-2/h3-9H,1-2H3
DMF8E5L CS COC1=CC=CC=C1SC2=CC(=C(C=C2)C#N)OC
DMF8E5L IK WQGGJJSMEMAVIF-UHFFFAOYSA-N
DMF8E5L IU 2-methoxy-4-(2-methoxyphenyl)sulfanylbenzonitrile
DMF8E5L DE Discovery agent
DMEAVD2 ID DMEAVD2
DMEAVD2 DN 2-methoxy-4-(2-nitrovinyl)phenol
DMEAVD2 HS Investigative
DMEAVD2 SN 2-methoxy-4-(2-nitrovinyl)phenol; 6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924
DMEAVD2 DT Small molecular drug
DMEAVD2 PC 638439
DMEAVD2 MW 195.17
DMEAVD2 FM C9H9NO4
DMEAVD2 IC InChI=1S/C9H9NO4/c1-14-9-6-7(2-3-8(9)11)4-5-10(12)13/h2-6,11H,1H3/b5-4+
DMEAVD2 CS COC1=C(C=CC(=C1)/C=C/[N+](=O)[O-])O
DMEAVD2 IK XVXCSPJSXIUNQJ-SNAWJCMRSA-N
DMEAVD2 IU 2-methoxy-4-[(E)-2-nitroethenyl]phenol
DMEAVD2 CA CAS 22568-51-0
DMEAVD2 DE Discovery agent
DM1MGQ6 ID DM1MGQ6
DM1MGQ6 DN 2-methoxy-4-(m-tolyloxy)benzonitrile
DM1MGQ6 HS Investigative
DM1MGQ6 SN CHEMBL490957; 2-methoxy-4-(m-tolyloxy)benzonitrile
DM1MGQ6 DT Small molecular drug
DM1MGQ6 PC 44565104
DM1MGQ6 MW 239.27
DM1MGQ6 FM C15H13NO2
DM1MGQ6 IC InChI=1S/C15H13NO2/c1-11-4-3-5-13(8-11)18-14-7-6-12(10-16)15(9-14)17-2/h3-9H,1-2H3
DM1MGQ6 CS CC1=CC(=CC=C1)OC2=CC(=C(C=C2)C#N)OC
DM1MGQ6 IK NXORRFHUCGSBOI-UHFFFAOYSA-N
DM1MGQ6 IU 2-methoxy-4-(3-methylphenoxy)benzonitrile
DM1MGQ6 DE Discovery agent
DMT7YR3 ID DMT7YR3
DMT7YR3 DN 2-methoxy-4-(o-tolyloxy)benzonitrile
DMT7YR3 HS Investigative
DMT7YR3 SN CHEMBL491493; 2-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4178171
DMT7YR3 DT Small molecular drug
DMT7YR3 PC 11715659
DMT7YR3 MW 239.27
DMT7YR3 FM C15H13NO2
DMT7YR3 IC InChI=1S/C15H13NO2/c1-11-5-3-4-6-14(11)18-13-8-7-12(10-16)15(9-13)17-2/h3-9H,1-2H3
DMT7YR3 CS CC1=CC=CC=C1OC2=CC(=C(C=C2)C#N)OC
DMT7YR3 IK QZFFCZYDLZAYFR-UHFFFAOYSA-N
DMT7YR3 IU 2-methoxy-4-(2-methylphenoxy)benzonitrile
DMT7YR3 DE Discovery agent
DMXGP2I ID DMXGP2I
DMXGP2I DN 2-methoxy-4-(propylthio)benzonitrile
DMXGP2I HS Investigative
DMXGP2I SN CHEMBL443970; 2-methoxy-4-(propylthio)benzonitrile
DMXGP2I DT Small molecular drug
DMXGP2I PC 44564581
DMXGP2I MW 207.29
DMXGP2I FM C11H13NOS
DMXGP2I IC InChI=1S/C11H13NOS/c1-3-6-14-10-5-4-9(8-12)11(7-10)13-2/h4-5,7H,3,6H2,1-2H3
DMXGP2I CS CCCSC1=CC(=C(C=C1)C#N)OC
DMXGP2I IK SYEDQZDHJDTUDG-UHFFFAOYSA-N
DMXGP2I IU 2-methoxy-4-propylsulfanylbenzonitrile
DMXGP2I DE Discovery agent
DMR5YZG ID DMR5YZG
DMR5YZG DN 2-methoxy-4-(p-tolyloxy)benzonitrile
DMR5YZG HS Investigative
DMR5YZG SN CHEMBL501649; 2-methoxy-4-(p-tolyloxy)benzonitrile; SCHEMBL17354615
DMR5YZG DT Small molecular drug
DMR5YZG PC 44565150
DMR5YZG MW 239.27
DMR5YZG FM C15H13NO2
DMR5YZG IC InChI=1S/C15H13NO2/c1-11-3-6-13(7-4-11)18-14-8-5-12(10-16)15(9-14)17-2/h3-9H,1-2H3
DMR5YZG CS CC1=CC=C(C=C1)OC2=CC(=C(C=C2)C#N)OC
DMR5YZG IK UIOZKPIEPDRGOC-UHFFFAOYSA-N
DMR5YZG IU 2-methoxy-4-(4-methylphenoxy)benzonitrile
DMR5YZG DE Discovery agent
DMCGID6 ID DMCGID6
DMCGID6 DN 2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol
DMCGID6 HS Investigative
DMCGID6 SN CHEMBL10121; 2-methoxy-5-(3,4,5-trimethoxybenzyl)phenol; NSC648581; Neuro_000355; AC1Q56F6; AC1L85N6; CTK6J6605; ZINC1630963; BDBM50212289; NSC-648581; NCI60_016862
DMCGID6 DT Small molecular drug
DMCGID6 PC 372869
DMCGID6 MW 304.34
DMCGID6 FM C17H20O5
DMCGID6 IC InChI=1S/C17H20O5/c1-19-14-6-5-11(8-13(14)18)7-12-9-15(20-2)17(22-4)16(10-12)21-3/h5-6,8-10,18H,7H2,1-4H3
DMCGID6 CS COC1=C(C=C(C=C1)CC2=CC(=C(C(=C2)OC)OC)OC)O
DMCGID6 IK JFZDWXGLUXEEAY-UHFFFAOYSA-N
DMCGID6 IU 2-methoxy-5-[(3,4,5-trimethoxyphenyl)methyl]phenol
DMCGID6 DE Discovery agent
DM6CAYV ID DM6CAYV
DM6CAYV DN 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol
DM6CAYV HS Investigative
DM6CAYV SN CHEMBL356370; 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol; BDBM50095326
DM6CAYV DT Small molecular drug
DM6CAYV PC 44367275
DM6CAYV MW 306.31
DM6CAYV FM C16H18O6
DM6CAYV IC InChI=1S/C16H18O6/c1-18-13-6-5-10(7-12(13)17)22-11-8-14(19-2)16(21-4)15(9-11)20-3/h5-9,17H,1-4H3
DM6CAYV CS COC1=C(C=C(C=C1)OC2=CC(=C(C(=C2)OC)OC)OC)O
DM6CAYV IK OJRSPUQFMNDPAN-UHFFFAOYSA-N
DM6CAYV IU 2-methoxy-5-(3,4,5-trimethoxyphenoxy)phenol
DM6CAYV DE Discovery agent
DM9LY0Z ID DM9LY0Z
DM9LY0Z DN 2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol
DM9LY0Z HS Investigative
DM9LY0Z SN CHEMBL131684
DM9LY0Z DT Small molecular drug
DM9LY0Z PC 10336746
DM9LY0Z MW 330.4
DM9LY0Z FM C19H22O5
DM9LY0Z IC InChI=1S/C19H22O5/c1-21-15-8-6-11(9-14(15)20)13-7-5-12-10-16(22-2)18(23-3)19(24-4)17(12)13/h6,8-10,13,20H,5,7H2,1-4H3
DM9LY0Z CS COC1=C(C=C(C=C1)C2CCC3=CC(=C(C(=C23)OC)OC)OC)O
DM9LY0Z IK QYUAUFKQRRPTIK-UHFFFAOYSA-N
DM9LY0Z IU 2-methoxy-5-(5,6,7-trimethoxy-2,3-dihydro-1H-inden-1-yl)phenol
DM9LY0Z DE Discovery agent
DMXCAKO ID DMXCAKO
DMXCAKO DN 2-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMXCAKO HS Investigative
DMXCAKO SN CHEMBL497157; 2-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264949
DMXCAKO DT Small molecular drug
DMXCAKO PC 44580317
DMXCAKO MW 239.31
DMXCAKO FM C16H17NO
DMXCAKO IC InChI=1S/C16H17NO/c1-18-13-7-6-12-8-11-4-2-3-5-14(11)16(10-17)15(12)9-13/h2-7,9,16H,8,10,17H2,1H3
DMXCAKO CS COC1=CC2=C(CC3=CC=CC=C3C2CN)C=C1
DMXCAKO IK UKAGNBPAZOMJAO-UHFFFAOYSA-N
DMXCAKO IU (2-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMXCAKO DE Discovery agent
DM4G3FS ID DM4G3FS
DM4G3FS DN 2-methoxy-alpha,beta-didehydro-agomelatine
DM4G3FS HS Investigative
DM4G3FS SN CHEMBL2314259; 2-methoxy-alpha,beta-didehydro-agomelatine; GTPL7775; BDBM50425202
DM4G3FS DT Small molecular drug
DM4G3FS PC 71533431
DM4G3FS MW 271.31
DM4G3FS FM C16H17NO3
DM4G3FS IC InChI=1S/C16H17NO3/c1-11(18)17-9-8-14-15-10-13(19-2)6-4-12(15)5-7-16(14)20-3/h4-10H,1-3H3,(H,17,18)/b9-8+
DM4G3FS CS CC(=O)N/C=C/C1=C(C=CC2=C1C=C(C=C2)OC)OC
DM4G3FS IK HMYFXYOFPXZULT-CMDGGOBGSA-N
DM4G3FS IU N-[(E)-2-(2,7-dimethoxynaphthalen-1-yl)ethenyl]acetamide
DM4G3FS DE Discovery agent
DMPG0V7 ID DMPG0V7
DMPG0V7 DN 2-methoxyapomorphine
DMPG0V7 HS Investigative
DMPG0V7 SN 2-Methoxyapomorphine; CHEMBL53445; 126874-79-1; (6ar)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol; SCHEMBL8097389; AC1L503G; (R)-(-)-2-methoxyapomorphine; CTK4B5400; 4H-Dibenzo[de,g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-2-methoxy-6-methyl-, (6aR)-; 2-Methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; AC1Q5802; BDBM50010697; (R)-2-Methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol; (6aR)-5,6,6abeta,7-Tetrahydro-2-methoxy-6-methyl 4H-dibenzo
DMPG0V7 DT Small molecular drug
DMPG0V7 PC 195499
DMPG0V7 MW 297.3
DMPG0V7 FM C18H19NO3
DMPG0V7 IC InChI=1S/C18H19NO3/c1-19-6-5-11-7-12(22-2)9-13-16(11)14(19)8-10-3-4-15(20)18(21)17(10)13/h3-4,7,9,14,20-21H,5-6,8H2,1-2H3/t14-/m1/s1
DMPG0V7 CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=C(C=C4)O)O
DMPG0V7 IK QGJWYJSOGNAUCY-CQSZACIVSA-N
DMPG0V7 IU (6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMPG0V7 CA CAS 126874-79-1
DMPG0V7 DE Discovery agent
DMIBKNZ ID DMIBKNZ
DMIBKNZ DN 2-methoxyestradiol-17-O-sulfamate
DMIBKNZ HS Investigative
DMIBKNZ SN CHEMBL374721; 2-methoxyestradiol 17-O-sulfamate; (13alpha,14beta,17alpha)-3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-Yl Sulfamate; 2-methoxyestradiol-17-O-sulfamate; 2x7s; BDBM50200940
DMIBKNZ DT Small molecular drug
DMIBKNZ PC 16098578
DMIBKNZ MW 381.5
DMIBKNZ FM C19H27NO5S
DMIBKNZ IC InChI=1S/C19H27NO5S/c1-19-8-7-12-13(15(19)5-6-18(19)25-26(20,22)23)4-3-11-9-16(21)17(24-2)10-14(11)12/h9-10,12-13,15,18,21H,3-8H2,1-2H3,(H2,20,22,23)/t12-,13+,15-,18-,19-/m0/s1
DMIBKNZ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=CC(=C(C=C34)OC)O
DMIBKNZ IK AOEHUXLJSHGXHN-SSTWWWIQSA-N
DMIBKNZ IU [(8R,9S,13S,14S,17S)-3-hydroxy-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMIBKNZ DE Discovery agent
DMD6L7C ID DMD6L7C
DMD6L7C DN 2-methoxyestrrone-3-O-sulfamate
DMD6L7C HS Investigative
DMD6L7C SN CHEMBL372231; 2-MeOEMATE; 2-methoxyestrrone-3-O-sulfamate; 2-methoxyestrone sulfamate; SCHEMBL307890; BTQHAWWINOTNQQ-QPWUGHHJSA-N; BDBM50171450; 2-methoxy-17-oxo-estra-1,3,5(10)-trien-3-yl sulfamate; (8R,9S,13S,14S)-2-Methoxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3-sulfonic acid amide
DMD6L7C DT Small molecular drug
DMD6L7C PC 9842809
DMD6L7C MW 379.5
DMD6L7C FM C19H25NO5S
DMD6L7C IC InChI=1S/C19H25NO5S/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-17(25-26(20,22)23)16(24-2)10-14(11)12/h9-10,12-13,15H,3-8H2,1-2H3,(H2,20,22,23)/t12-,13+,15-,19-/m0/s1
DMD6L7C CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=C(C=C34)OC)OS(=O)(=O)N
DMD6L7C IK BTQHAWWINOTNQQ-QPWUGHHJSA-N
DMD6L7C IU [(8R,9S,13S,14S)-2-methoxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfamate
DMD6L7C DE Discovery agent
DM6X8GN ID DM6X8GN
DM6X8GN DN 2-Methoxyethyl 18-methoxycoronaridinate
DM6X8GN HS Investigative
DM6X8GN SN CHEMBL607152; 2-Methoxyethyl 18-methoxycoronaridinate
DM6X8GN DT Small molecular drug
DM6X8GN PC 46877895
DM6X8GN MW 412.5
DM6X8GN FM C24H32N2O4
DM6X8GN IC InChI=1S/C24H32N2O4/c1-28-10-8-17-13-16-14-24(23(27)30-12-11-29-2)21-19(7-9-26(15-16)22(17)24)18-5-3-4-6-20(18)25-21/h3-6,16-17,22,25H,7-15H2,1-2H3/t16?,17-,22-,24+/m0/s1
DM6X8GN CS COCC[C@H]1CC2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OCCOC
DM6X8GN IK OLFXZBDPKBSIPG-SAJNPJMVSA-N
DM6X8GN IU 2-methoxyethyl (1S,17R,18S)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DM6X8GN DE Discovery agent
DM31E6J ID DM31E6J
DM31E6J DN 2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide
DM31E6J HS Investigative
DM31E6J SN CHEMBL16450; 2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide
DM31E6J DT Small molecular drug
DM31E6J PC 44270882
DM31E6J MW 297.4
DM31E6J FM C19H23NO2
DM31E6J IC InChI=1S/C19H23NO2/c1-14(2)17(15-9-5-4-6-10-15)13-20-19(21)16-11-7-8-12-18(16)22-3/h4-12,14,17H,13H2,1-3H3,(H,20,21)
DM31E6J CS CC(C)C(CNC(=O)C1=CC=CC=C1OC)C2=CC=CC=C2
DM31E6J IK XVFLGHVOMBWJAC-UHFFFAOYSA-N
DM31E6J IU 2-methoxy-N-(3-methyl-2-phenylbutyl)benzamide
DM31E6J DE Discovery agent
DMQS8VE ID DMQS8VE
DMQS8VE DN 2-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMQS8VE HS Investigative
DMQS8VE SN CHEMBL481525; 2-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMQS8VE DT Small molecular drug
DMQS8VE PC 24905595
DMQS8VE MW 349.4
DMQS8VE FM C20H15NO3S
DMQS8VE IC InChI=1S/C20H15NO3S/c1-23-16-10-4-5-11-17(16)24-20(22)21-14-8-2-6-12-18(14)25-19-13-7-3-9-15(19)21/h2-13H,1H3
DMQS8VE CS COC1=CC=CC=C1OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMQS8VE IK KQZJYFLCWHHHIK-UHFFFAOYSA-N
DMQS8VE IU (2-methoxyphenyl) phenothiazine-10-carboxylate
DMQS8VE DE Discovery agent
DML5PE9 ID DML5PE9
DML5PE9 DN 2-methoxyphenylboronic acid
DML5PE9 HS Investigative
DML5PE9 SN 2-Methoxyphenylboronic acid; 5720-06-9; 2-Methoxybenzeneboronic acid; (2-methoxyphenyl)boronic Acid; 2-methoxyphenyl boronic acid; o-Methoxyphenylboronic acid; 2-boronoanisole; (2-methoxyphenyl)boranediol; MFCD00236047; o-methoxyphenyl boronic acid; 2-methoxy phenylboronic acid; 2-methoxybenzene boronic acid; Boronic acid, (2-methoxyphenyl)-; 2-methoxypenylboronic acid; 2-Methoxybenzeneboronicacid; PubChem1865; ACMC-1AZDE; 2-methoxypbenylboronic acid; AC1Q44YL; AC1MC01Q; 2-methyoxyphenylboronic acid; 2-methoxyphenyl-boronic aci
DML5PE9 DT Small molecular drug
DML5PE9 PC 2733958
DML5PE9 MW 151.96
DML5PE9 FM C7H9BO3
DML5PE9 IC InChI=1S/C7H9BO3/c1-11-7-5-3-2-4-6(7)8(9)10/h2-5,9-10H,1H3
DML5PE9 CS B(C1=CC=CC=C1OC)(O)O
DML5PE9 IK ROEQGIFOWRQYHD-UHFFFAOYSA-N
DML5PE9 IU (2-methoxyphenyl)boronic acid
DML5PE9 CA CAS 5720-06-9
DML5PE9 DE Discovery agent
DMX1IC4 ID DMX1IC4
DMX1IC4 DN 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMX1IC4 HS Investigative
DMX1IC4 SN CHEMBL187008; 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155783
DMX1IC4 DT Small molecular drug
DMX1IC4 PC 18721719
DMX1IC4 MW 144.24
DMX1IC4 FM C6H12N2S
DMX1IC4 IC InChI=1S/C6H12N2S/c1-5-4-8-6(7)2-3-9-5/h5H,2-4H2,1H3,(H2,7,8)
DMX1IC4 CS CC1CN=C(CCS1)N
DMX1IC4 IK FACIWFABQIDLEA-UHFFFAOYSA-N
DMX1IC4 IU 2-methyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMX1IC4 DE Discovery agent
DMKTQB2 ID DMKTQB2
DMKTQB2 DN 2-Methyl-1(3)H-anthrasimidazole-6,11-dione
DMKTQB2 HS Investigative
DMKTQB2 SN AC1MZY8L; CHEMBL594892; SCHEMBL17702673; MolPort-002-517-242; MolPort-000-752-121; ZINC9353066; AKOS030496241; MCULE-7367469235; 2-methyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMKTQB2 DT Small molecular drug
DMKTQB2 PC 3908369
DMKTQB2 MW 262.26
DMKTQB2 FM C16H10N2O2
DMKTQB2 IC InChI=1S/C16H10N2O2/c1-8-17-12-7-6-11-13(14(12)18-8)16(20)10-5-3-2-4-9(10)15(11)19/h2-7H,1H3,(H,17,18)
DMKTQB2 CS CC1=NC2=C(N1)C=CC3=C2C(=O)C4=CC=CC=C4C3=O
DMKTQB2 IK IXPPRTBZHPTQCM-UHFFFAOYSA-N
DMKTQB2 IU 2-methyl-3H-naphtho[3,2-e]benzimidazole-6,11-dione
DMKTQB2 DE Discovery agent
DMRWOQH ID DMRWOQH
DMRWOQH DN 2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime
DMRWOQH HS Investigative
DMRWOQH SN SCHEMBL4299298
DMRWOQH DT Small molecular drug
DMRWOQH PC 91933437
DMRWOQH MW 190.24
DMRWOQH FM C11H14N2O
DMRWOQH IC InChI=1S/C11H14N2O/c1-3-11(13-14)9(2)7-10-5-4-6-12-8-10/h4-8,11H,3H2,1-2H3/b9-7+
DMRWOQH CS CCC(/C(=C/C1=CN=CC=C1)/C)N=O
DMRWOQH IK ZJNKUZQXZJOGMM-VQHVLOKHSA-N
DMRWOQH IU 3-[(E)-2-methyl-3-nitrosopent-1-enyl]pyridine
DMRWOQH DE Discovery agent
DMTQ4FV ID DMTQ4FV
DMTQ4FV DN 2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime
DMTQ4FV HS Investigative
DMTQ4FV DT Small molecular drug
DMTQ4FV PC 91933438
DMTQ4FV MW 190.24
DMTQ4FV FM C11H14N2O
DMTQ4FV IC InChI=1S/C11H14N2O/c1-3-11(13-14)9(2)8-10-4-6-12-7-5-10/h4-8,11H,3H2,1-2H3/b9-8+
DMTQ4FV CS CCC(/C(=C/C1=CC=NC=C1)/C)N=O
DMTQ4FV IK GOJJWAOCMJUGEU-CMDGGOBGSA-N
DMTQ4FV IU 4-[(E)-2-methyl-3-nitrosopent-1-enyl]pyridine
DMTQ4FV DE Discovery agent
DMLTJDR ID DMLTJDR
DMLTJDR DN 2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime
DMLTJDR HS Investigative
DMLTJDR SN SCHEMBL4299802
DMLTJDR DT Small molecular drug
DMLTJDR PC 91933434
DMLTJDR MW 195.28
DMLTJDR FM C10H13NOS
DMLTJDR IC InChI=1S/C10H13NOS/c1-3-10(11-12)8(2)7-9-5-4-6-13-9/h4-7,10H,3H2,1-2H3/b8-7+
DMLTJDR CS CCC(/C(=C/C1=CC=CS1)/C)N=O
DMLTJDR IK KWDFITPUCBENQZ-BQYQJAHWSA-N
DMLTJDR IU 2-[(E)-2-methyl-3-nitrosopent-1-enyl]thiophene
DMLTJDR DE Discovery agent
DMQJKSV ID DMQJKSV
DMQJKSV DN 2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime
DMQJKSV HS Investigative
DMQJKSV SN SCHEMBL3671471
DMQJKSV DT Small molecular drug
DMQJKSV PC 91933436
DMQJKSV MW 195.28
DMQJKSV FM C10H13NOS
DMQJKSV IC InChI=1S/C10H13NOS/c1-3-10(11-12)8(2)6-9-4-5-13-7-9/h4-7,10H,3H2,1-2H3/b8-6+
DMQJKSV CS CCC(/C(=C/C1=CSC=C1)/C)N=O
DMQJKSV IK MTERIVIYUVDTBU-SOFGYWHQSA-N
DMQJKSV IU 3-[(E)-2-methyl-3-nitrosopent-1-enyl]thiophene
DMQJKSV DE Discovery agent
DMDJHFQ ID DMDJHFQ
DMDJHFQ DN 2-Methyl-1,2-dihydro-indazol-3-one
DMDJHFQ HS Investigative
DMDJHFQ SN 1848-40-4; 1,2-Dihydro-2-methyl-3H-indazol-3-one; 2-methyl-1H-indazol-3(2H)-one; 3H-Indazol-3-one, 1,2-dihydro-2-methyl-; CHEMBL3144583; FPNXGZRMUROVNY-UHFFFAOYSA-N; 2-methyl-1,2-dihydroindazol-3-one; 3-Indazolinone, 2-methyl-; 2-methyl-1H-indazol-3-one; 2-Methyl-1,2-dihydro-indazol-3-one; AC1LBX43; CHEMBL8364; SCHEMBL2673327; CTK0E2434; DTXSID30343553; MolPort-028-748-594; BDBM50009002; ZINC13820683; AKOS023543896; MB14910; CM10169; 2-Methyl-1,2-dihydro-3H-indazol-3-one #; 2-METHYL-2,3-DIHYDRO-1H-INDAZOL-3-ONE; INDAZOL-3-ONE, 1,
DMDJHFQ DT Small molecular drug
DMDJHFQ PC 590513
DMDJHFQ MW 148.16
DMDJHFQ FM C8H8N2O
DMDJHFQ IC InChI=1S/C8H8N2O/c1-10-8(11)6-4-2-3-5-7(6)9-10/h2-5,9H,1H3
DMDJHFQ CS CN1C(=O)C2=CC=CC=C2N1
DMDJHFQ IK FPNXGZRMUROVNY-UHFFFAOYSA-N
DMDJHFQ IU 2-methyl-1H-indazol-3-one
DMDJHFQ CA CAS 1848-40-4
DMDJHFQ DE Discovery agent
DMIWX21 ID DMIWX21
DMIWX21 DN 2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane
DMIWX21 HS Investigative
DMIWX21 SN CHEMBL55488; 87372-73-4; 2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane; CTK3C4531; DTXSID00658227; BDBM50028161; 3,3'-(1-Methoxy-2-methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(2-methoxy-1,1-dimethyl-1,2-ethanediyl)bis-
DMIWX21 DT Small molecular drug
DMIWX21 PC 44299128
DMIWX21 MW 242.32
DMIWX21 FM C15H18N2O
DMIWX21 IC InChI=1S/C15H18N2O/c1-15(2,13-7-5-9-17-11-13)14(18-3)12-6-4-8-16-10-12/h4-11,14H,1-3H3
DMIWX21 CS CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)OC
DMIWX21 IK NIZJKWCUCWIETQ-UHFFFAOYSA-N
DMIWX21 IU 3-(1-methoxy-2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DMIWX21 CA CAS 87372-73-4
DMIWX21 DE Discovery agent
DMB0NEL ID DMB0NEL
DMB0NEL DN 2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime
DMB0NEL HS Investigative
DMB0NEL DT Small molecular drug
DMB0NEL PC 53724392
DMB0NEL MW 241.29
DMB0NEL FM C14H15N3O
DMB0NEL IC InChI=1S/C14H15N3O/c1-14(2,12-6-4-8-16-10-12)13(17-18)11-5-3-7-15-9-11/h3-10,13H,1-2H3
DMB0NEL CS CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)N=O
DMB0NEL IK CJLBATLINTYVRN-UHFFFAOYSA-N
DMB0NEL IU 3-(2-methyl-1-nitroso-1-pyridin-3-ylpropan-2-yl)pyridine
DMB0NEL DE Discovery agent
DMC3ET2 ID DMC3ET2
DMC3ET2 DN 2-Methyl-1,2-di-pyridin-3-yl-propane
DMC3ET2 HS Investigative
DMC3ET2 SN CHEMBL54171; 87372-71-2; 2-Methyl-1,2-di-pyridin-3-yl-propane; CTK3C4533; DTXSID60658228; ZINC29551986; BDBM50028165; 3,3'-(2-Methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(1,1-dimethyl-1,2-ethanediyl)bis-
DMC3ET2 DT Small molecular drug
DMC3ET2 PC 44299129
DMC3ET2 MW 212.29
DMC3ET2 FM C14H16N2
DMC3ET2 IC InChI=1S/C14H16N2/c1-14(2,13-6-4-8-16-11-13)9-12-5-3-7-15-10-12/h3-8,10-11H,9H2,1-2H3
DMC3ET2 CS CC(C)(CC1=CN=CC=C1)C2=CN=CC=C2
DMC3ET2 IK PKJNPGGSGKBGGS-UHFFFAOYSA-N
DMC3ET2 IU 3-(2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DMC3ET2 CA CAS 87372-71-2
DMC3ET2 DE Discovery agent
DMQHM7R ID DMQHM7R
DMQHM7R DN 2-Methyl-1,2-di-pyridin-3-yl-propylchloride
DMQHM7R HS Investigative
DMQHM7R SN CHEMBL300127; 87372-70-1; 2-Methyl-1,2-di-pyridin-3-yl-propylchloride; CTK3C4534; DTXSID60658223; BDBM50028167; 3,3'-(1-Chloro-2-methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(2-chloro-1,1-dimethyl-1,2-ethanediyl)bis-
DMQHM7R DT Small molecular drug
DMQHM7R PC 44299093
DMQHM7R MW 246.73
DMQHM7R FM C14H15ClN2
DMQHM7R IC InChI=1S/C14H15ClN2/c1-14(2,12-6-4-8-17-10-12)13(15)11-5-3-7-16-9-11/h3-10,13H,1-2H3
DMQHM7R CS CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)Cl
DMQHM7R IK VVJXUKVBHKTNGD-UHFFFAOYSA-N
DMQHM7R IU 3-(1-chloro-2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DMQHM7R CA CAS 87372-70-1
DMQHM7R DE Discovery agent
DM561MH ID DM561MH
DM561MH DN 2-Methyl-1,2-di-pyridin-3-yl-propyliodide
DM561MH HS Investigative
DM561MH SN CHEMBL55678; 87372-72-3; 2-Methyl-1,2-di-pyridin-3-yl-propyliodide; CTK3C4532; DTXSID20658224; BDBM50028168; 3,3'-(1-Iodo-2-methylpropane-1,2-diyl)dipyridine; Pyridine, 3,3'-(2-iodo-1,1-dimethyl-1,2-ethanediyl)bis-
DM561MH DT Small molecular drug
DM561MH PC 44299094
DM561MH MW 338.19
DM561MH FM C14H15IN2
DM561MH IC InChI=1S/C14H15IN2/c1-14(2,12-6-4-8-17-10-12)13(15)11-5-3-7-16-9-11/h3-10,13H,1-2H3
DM561MH CS CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)I
DM561MH IK BPACVLBDZBTCAO-UHFFFAOYSA-N
DM561MH IU 3-(1-iodo-2-methyl-1-pyridin-3-ylpropan-2-yl)pyridine
DM561MH CA CAS 87372-72-3
DM561MH DE Discovery agent
DMLX9RG ID DMLX9RG
DMLX9RG DN 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol
DMLX9RG HS Investigative
DMLX9RG SN CHEMBL55378; 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol
DMLX9RG DT Small molecular drug
DMLX9RG PC 44299143
DMLX9RG MW 227.3
DMLX9RG FM C15H17NO
DMLX9RG IC InChI=1S/C15H17NO/c1-15(2,13-9-6-10-16-11-13)14(17)12-7-4-3-5-8-12/h3-11,14,17H,1-2H3
DMLX9RG CS CC(C)(C1=CN=CC=C1)C(C2=CC=CC=C2)O
DMLX9RG IK LCRMYPGRORRMNU-UHFFFAOYSA-N
DMLX9RG IU 2-methyl-1-phenyl-2-pyridin-3-ylpropan-1-ol
DMLX9RG DE Discovery agent
DMZY72I ID DMZY72I
DMZY72I DN 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one
DMZY72I HS Investigative
DMZY72I SN 87372-75-6; 2-Methyl-1-phenyl-2-(3-pyridinyl)-1-propanone; CHEMBL294460; 2-Mppp; 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one; AC1L37C5; SCHEMBL12260655; CTK5F8302; DTXSID50236312; ZINC5138212; BDBM50028170; KB-231336; 2-methyl-1-phenyl-2-pyridin-3-ylpropan-1-one
DMZY72I DT Small molecular drug
DMZY72I PC 135918
DMZY72I MW 225.28
DMZY72I FM C15H15NO
DMZY72I IC InChI=1S/C15H15NO/c1-15(2,13-9-6-10-16-11-13)14(17)12-7-4-3-5-8-12/h3-11H,1-2H3
DMZY72I CS CC(C)(C1=CN=CC=C1)C(=O)C2=CC=CC=C2
DMZY72I IK GWWVZTFGCNLAOV-UHFFFAOYSA-N
DMZY72I IU 2-methyl-1-phenyl-2-pyridin-3-ylpropan-1-one
DMZY72I CA CAS 87372-75-6
DMZY72I DE Discovery agent
DMD45CU ID DMD45CU
DMD45CU DN 2-Methyl-2,4-Pentanediol
DMD45CU HS Investigative
DMD45CU SN 2-METHYL-2,4-PENTANEDIOL; 107-41-5; 2-Methylpentane-2,4-diol; Pinakon; 2,4-Dihydroxy-2-methylpentane; 2,4-Pentanediol, 2-methyl-; Diolane; Isol; 4-Methyl-2,4-pentanediol; 1,1,3-Trimethyltrimethylenediol; 2-Methyl pentane-2,4-diol; 2-Methyl-2,4-pentandiol; Caswell No. 574; alpha,alpha,alpha'-Trimethyltrimethylene glycol; 1,3-dimethyl-3-hydroxybutanol; Hexylene glycol [NF]; HSDB 1126; 1,3,3-trimethyl-1,3-propanediol; (+-)-2-Methyl-2,4-pentanediol; NSC 8098; EINECS 203-489-0; EPA Pesticide Chemical Code 068601; BRN
DMD45CU DT Small molecular drug
DMD45CU PC 7870
DMD45CU MW 118.17
DMD45CU FM C6H14O2
DMD45CU IC InChI=1S/C6H14O2/c1-5(7)4-6(2,3)8/h5,7-8H,4H2,1-3H3
DMD45CU CS CC(CC(C)(C)O)O
DMD45CU IK SVTBMSDMJJWYQN-UHFFFAOYSA-N
DMD45CU IU 2-methylpentane-2,4-diol
DMD45CU CA CAS 107-41-5
DMD45CU CB CHEBI:62995
DMD45CU DE Discovery agent
DMHM5GJ ID DMHM5GJ
DMHM5GJ DN 2-Methyl-2-Propanol
DMHM5GJ HS Investigative
DMHM5GJ SN tert-Butanol; tert-Butyl alcohol; 2-Methyl-2-propanol; 2-Methylpropan-2-ol; 75-65-0; t-Butanol; t-Butyl hydroxide; 1,1-Dimethylethanol; Trimethylcarbinol; Trimethyl methanol; 2-Propanol, 2-methyl-; Tertiary-Butyl Alcohol; T-BUTYL ALCOHOL; Trimethylmethanol; tert-butylalcohol; Butanol tertiaire; Trimethyl carbinol; Dimethylethanol; tertiary-Butanol; Alcool butylique tertiaire; Methanol, trimethyl-; Arconol; tertiary Butyl Alcohol; tert.-butanol; tert- butyl alcohol; Caswell No. 124A; t-butylalcohol; tertiary butanol; NCI-C55367; tBuOH
DMHM5GJ DT Small molecular drug
DMHM5GJ PC 6386
DMHM5GJ MW 74.12
DMHM5GJ FM C4H10O
DMHM5GJ IC InChI=1S/C4H10O/c1-4(2,3)5/h5H,1-3H3
DMHM5GJ CS CC(C)(C)O
DMHM5GJ IK DKGAVHZHDRPRBM-UHFFFAOYSA-N
DMHM5GJ IU 2-methylpropan-2-ol
DMHM5GJ CA CAS 75-65-0
DMHM5GJ CB CHEBI:45895
DMHM5GJ DE Discovery agent
DM3DNFQ ID DM3DNFQ
DM3DNFQ DN 2-Methyl-3-(2-Aminothiazolo)Propanal
DM3DNFQ HS Investigative
DM3DNFQ SN 2-Methyl-3-(2-Aminothiazolo)propanal; (2S)-3-(2-amino-1,3-thiazol-4-yl)-2-methylpropanal; AC1NRBOT; DB03024
DM3DNFQ DT Small molecular drug
DM3DNFQ PC 5288557
DM3DNFQ MW 170.23
DM3DNFQ FM C7H10N2OS
DM3DNFQ IC InChI=1S/C7H10N2OS/c1-5(3-10)2-6-4-11-7(8)9-6/h3-5H,2H2,1H3,(H2,8,9)/t5-/m0/s1
DM3DNFQ CS C[C@@H](CC1=CSC(=N1)N)C=O
DM3DNFQ IK KFMAJVLZSDMFBV-YFKPBYRVSA-N
DM3DNFQ IU (2S)-3-(2-amino-1,3-thiazol-4-yl)-2-methylpropanal
DM3DNFQ DE Discovery agent
DMV8YIZ ID DMV8YIZ
DMV8YIZ DN 2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine
DMV8YIZ HS Investigative
DMV8YIZ SN CHEMBL207502; 2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine
DMV8YIZ DT Small molecular drug
DMV8YIZ PC 44410708
DMV8YIZ MW 223.27
DMV8YIZ FM C14H13N3
DMV8YIZ IC InChI=1S/C14H13N3/c1-9-14(10-4-6-16-7-5-10)12-3-2-11(15)8-13(12)17-9/h2-8,17H,15H2,1H3
DMV8YIZ CS CC1=C(C2=C(N1)C=C(C=C2)N)C3=CC=NC=C3
DMV8YIZ IK AAIHLDQORIUJKB-UHFFFAOYSA-N
DMV8YIZ IU 2-methyl-3-pyridin-4-yl-1H-indol-6-amine
DMV8YIZ DE Discovery agent
DM8N54C ID DM8N54C
DM8N54C DN 2-methyl-3-(pyridin-4-yl)-1H-indole
DM8N54C HS Investigative
DM8N54C SN CHEMBL207501; 2-methyl-3-(pyridin-4-yl)-1H-indole; ZINC36338566
DM8N54C DT Small molecular drug
DM8N54C PC 11962095
DM8N54C MW 208.26
DM8N54C FM C14H12N2
DM8N54C IC InChI=1S/C14H12N2/c1-10-14(11-6-8-15-9-7-11)12-4-2-3-5-13(12)16-10/h2-9,16H,1H3
DM8N54C CS CC1=C(C2=CC=CC=C2N1)C3=CC=NC=C3
DM8N54C IK NMPHKIHQOKMIKF-UHFFFAOYSA-N
DM8N54C IU 2-methyl-3-pyridin-4-yl-1H-indole
DM8N54C DE Discovery agent
DMHYA7G ID DMHYA7G
DMHYA7G DN 2-methyl-3-phenethyl-3H-pyrimidin-4-one
DMHYA7G HS Investigative
DMHYA7G SN compound 2H [PMID: 15863312]
DMHYA7G DT Small molecular drug
DMHYA7G PC 135515453
DMHYA7G MW 352.4
DMHYA7G FM C21H21FN2O2
DMHYA7G IC InChI=1S/C21H21FN2O2/c1-3-16-14(2)23-20(17-9-5-7-11-19(17)25)24(21(16)26)13-12-15-8-4-6-10-18(15)22/h4-11,25H,3,12-13H2,1-2H3
DMHYA7G CS CCC1=C(N=C(N(C1=O)CCC2=CC=CC=C2F)C3=CC=CC=C3O)C
DMHYA7G IK JYFJNCCRKBBRKZ-UHFFFAOYSA-N
DMHYA7G IU 5-ethyl-3-[2-(2-fluorophenyl)ethyl]-2-(2-hydroxyphenyl)-6-methylpyrimidin-4-one
DMHYA7G DE Discovery agent
DMAFPE7 ID DMAFPE7
DMAFPE7 DN 2-methyl-4-(2-thienylethynyl)thiazole
DMAFPE7 HS Investigative
DMAFPE7 SN CHEMBL202331; 2-methyl-4-(2-thienylethynyl)thiazole; Thiazole, 2-methyl-4-[2-(2-thienyl)ethynyl]-; SCHEMBL4151041; BDBM50181768; 878018-56-5
DMAFPE7 DT Small molecular drug
DMAFPE7 PC 11535796
DMAFPE7 MW 205.3
DMAFPE7 FM C10H7NS2
DMAFPE7 IC InChI=1S/C10H7NS2/c1-8-11-9(7-13-8)4-5-10-3-2-6-12-10/h2-3,6-7H,1H3
DMAFPE7 CS CC1=NC(=CS1)C#CC2=CC=CS2
DMAFPE7 IK SSSIEHWNKPXIHQ-UHFFFAOYSA-N
DMAFPE7 IU 2-methyl-4-(2-thiophen-2-ylethynyl)-1,3-thiazole
DMAFPE7 DE Discovery agent
DMK4A0J ID DMK4A0J
DMK4A0J DN 2-methyl-4-(3-thienylethynyl)thiazole
DMK4A0J HS Investigative
DMK4A0J SN CHEMBL202610; 2-methyl-4-(3-thienylethynyl)thiazole; Thiazole, 2-methyl-4-[2-(3-thienyl)ethynyl]-; SCHEMBL4144709; BDBM50181788
DMK4A0J DT Small molecular drug
DMK4A0J PC 11658509
DMK4A0J MW 205.3
DMK4A0J FM C10H7NS2
DMK4A0J IC InChI=1S/C10H7NS2/c1-8-11-10(7-13-8)3-2-9-4-5-12-6-9/h4-7H,1H3
DMK4A0J CS CC1=NC(=CS1)C#CC2=CSC=C2
DMK4A0J IK DWHLLFJNQYENJN-UHFFFAOYSA-N
DMK4A0J IU 2-methyl-4-(2-thiophen-3-ylethynyl)-1,3-thiazole
DMK4A0J DE Discovery agent
DM4P3CW ID DM4P3CW
DM4P3CW DN 2-methyl-4-(m-tolylethynyl)thiazole
DM4P3CW HS Investigative
DM4P3CW SN CHEMBL182950; 2-methyl-4-(m-tolylethynyl)thiazole; SCHEMBL4150883; 2-Methyl-4-m-tolylethynyl-thiazole; ZINC13680880
DM4P3CW DT Small molecular drug
DM4P3CW PC 11579392
DM4P3CW MW 213.3
DM4P3CW FM C13H11NS
DM4P3CW IC InChI=1S/C13H11NS/c1-10-4-3-5-12(8-10)6-7-13-9-15-11(2)14-13/h3-5,8-9H,1-2H3
DM4P3CW CS CC1=CC(=CC=C1)C#CC2=CSC(=N2)C
DM4P3CW IK LYHRSGPNRBPYDG-UHFFFAOYSA-N
DM4P3CW IU 2-methyl-4-[2-(3-methylphenyl)ethynyl]-1,3-thiazole
DM4P3CW DE Discovery agent
DMKFBVS ID DMKFBVS
DMKFBVS DN 2-Methyl-4-o-tolylethynyl-thiazole
DMKFBVS HS Investigative
DMKFBVS SN CHEMBL181915; 2-Methyl-4-o-tolylethynyl-thiazole; Thiazole, 2-methyl-4-[2-(2-methylphenyl)ethynyl]-; BDBM50149797
DMKFBVS DT Small molecular drug
DMKFBVS PC 44393020
DMKFBVS MW 213.3
DMKFBVS FM C13H11NS
DMKFBVS IC InChI=1S/C13H11NS/c1-10-5-3-4-6-12(10)7-8-13-9-15-11(2)14-13/h3-6,9H,1-2H3
DMKFBVS CS CC1=CC=CC=C1C#CC2=CSC(=N2)C
DMKFBVS IK XDQBEOSJZSBVGG-UHFFFAOYSA-N
DMKFBVS IU 2-methyl-4-[2-(2-methylphenyl)ethynyl]-1,3-thiazole
DMKFBVS DE Discovery agent
DMRC60A ID DMRC60A
DMRC60A DN 2-Methyl-4-phenylethynyl-thiazole
DMRC60A HS Investigative
DMRC60A SN CHEMBL63042; 2-Methyl-4-phenylethynyl-thiazole; Thiazole, 2-methyl-4-(2-phenylethynyl)-; SCHEMBL5653485; NZHWBWVBWDOSJY-UHFFFAOYSA-N; 2-Methyl-4-(phenylethynyl)thiazole; BDBM50122759; 329203-01-2
DMRC60A DT Small molecular drug
DMRC60A PC 10921526
DMRC60A MW 199.27
DMRC60A FM C12H9NS
DMRC60A IC InChI=1S/C12H9NS/c1-10-13-12(9-14-10)8-7-11-5-3-2-4-6-11/h2-6,9H,1H3
DMRC60A CS CC1=NC(=CS1)C#CC2=CC=CC=C2
DMRC60A IK NZHWBWVBWDOSJY-UHFFFAOYSA-N
DMRC60A IU 2-methyl-4-(2-phenylethynyl)-1,3-thiazole
DMRC60A DE Discovery agent
DMWRCFY ID DMWRCFY
DMWRCFY DN 2-Methyl-4-p-tolylethynyl-thiazole
DMWRCFY HS Investigative
DMWRCFY SN CHEMBL185813; 2-Methyl-4-p-tolylethynyl-thiazole; Thiazole, 2-methyl-4-[2-(4-methylphenyl)ethynyl]-; SCHEMBL4456131; BDBM50149803
DMWRCFY DT Small molecular drug
DMWRCFY PC 44393040
DMWRCFY MW 213.3
DMWRCFY FM C13H11NS
DMWRCFY IC InChI=1S/C13H11NS/c1-10-3-5-12(6-4-10)7-8-13-9-15-11(2)14-13/h3-6,9H,1-2H3
DMWRCFY CS CC1=CC=C(C=C1)C#CC2=CSC(=N2)C
DMWRCFY IK AIMMPGMZHVMWCT-UHFFFAOYSA-N
DMWRCFY IU 2-methyl-4-[2-(4-methylphenyl)ethynyl]-1,3-thiazole
DMWRCFY DE Discovery agent
DM1S5CB ID DM1S5CB
DM1S5CB DN 2-methyl-5-HT
DM1S5CB HS Investigative
DM1S5CB SN 2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin
DM1S5CB DT Small molecular drug
DM1S5CB PC 1574
DM1S5CB MW 190.24
DM1S5CB FM C11H14N2O
DM1S5CB IC InChI=1S/C11H14N2O/c1-7-9(4-5-12)10-6-8(14)2-3-11(10)13-7/h2-3,6,13-14H,4-5,12H2,1H3
DM1S5CB CS CC1=C(C2=C(N1)C=CC(=C2)O)CCN
DM1S5CB IK WYWNEDARFVJQSG-UHFFFAOYSA-N
DM1S5CB IU 3-(2-aminoethyl)-2-methyl-1H-indol-5-ol
DM1S5CB CA CAS 78263-90-8
DM1S5CB CB CHEBI:31085
DM536IA ID DM536IA
DM536IA DN 2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine
DM536IA HS Investigative
DM536IA SN CHEMBL214874; 2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine; 2-methyl-6-[3-(phenylthio)prop-1-yn-1-yl]pyridine; SCHEMBL5703368; BDBM50191120
DM536IA DT Small molecular drug
DM536IA PC 11333903
DM536IA MW 239.3
DM536IA FM C15H13NS
DM536IA IC InChI=1S/C15H13NS/c1-13-7-5-8-14(16-13)9-6-12-17-15-10-3-2-4-11-15/h2-5,7-8,10-11H,12H2,1H3
DM536IA CS CC1=NC(=CC=C1)C#CCSC2=CC=CC=C2
DM536IA IK QPGKAVMWBQPWGX-UHFFFAOYSA-N
DM536IA IU 2-methyl-6-(3-phenylsulfanylprop-1-ynyl)pyridine
DM536IA DE Discovery agent
DMGPDYE ID DMGPDYE
DMGPDYE DN 2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine
DMGPDYE HS Investigative
DMGPDYE SN CHEMBL212130; 2-methyl-6-(3-p-tolyloxy-prop-1-ynyl)pyridine; 2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine; SCHEMBL5698271; BDBM50191151
DMGPDYE DT Small molecular drug
DMGPDYE PC 11481793
DMGPDYE MW 237.3
DMGPDYE FM C16H15NO
DMGPDYE IC InChI=1S/C16H15NO/c1-13-8-10-16(11-9-13)18-12-4-7-15-6-3-5-14(2)17-15/h3,5-6,8-11H,12H2,1-2H3
DMGPDYE CS CC1=CC=C(C=C1)OCC#CC2=CC=CC(=N2)C
DMGPDYE IK GMIZGDGVYPBQCS-UHFFFAOYSA-N
DMGPDYE IU 2-methyl-6-[3-(4-methylphenoxy)prop-1-ynyl]pyridine
DMGPDYE DE Discovery agent
DM1YK7M ID DM1YK7M
DM1YK7M DN 2-methyl-6-(4-phenylbut-1-ynyl)pyridine
DM1YK7M HS Investigative
DM1YK7M SN CHEMBL214542; 2-methyl-6-(4-phenylbut-1-ynyl)pyridine; 2-methyl-6-(4-phenylbut-1-yn-1-yl)pyridine; SCHEMBL5703352; BDBM50191117
DM1YK7M DT Small molecular drug
DM1YK7M PC 11424570
DM1YK7M MW 221.3
DM1YK7M FM C16H15N
DM1YK7M IC InChI=1S/C16H15N/c1-14-8-7-13-16(17-14)12-6-5-11-15-9-3-2-4-10-15/h2-4,7-10,13H,5,11H2,1H3
DM1YK7M CS CC1=NC(=CC=C1)C#CCCC2=CC=CC=C2
DM1YK7M IK YWQJYKCSHSTIRB-UHFFFAOYSA-N
DM1YK7M IU 2-methyl-6-(4-phenylbut-1-ynyl)pyridine
DM1YK7M DE Discovery agent
DM0UNM1 ID DM0UNM1
DM0UNM1 DN 2-methyl-6-(4-phenylpent-1-ynyl)pyridine
DM0UNM1 HS Investigative
DM0UNM1 SN CHEMBL212834; 2-methyl-6-(4-phenylpent-1-ynyl)pyridine; 2-methyl-6-(4-phenylpent-1-yn-1-yl)pyridine; SCHEMBL5703254; BDBM50191124
DM0UNM1 DT Small molecular drug
DM0UNM1 PC 11736483
DM0UNM1 MW 235.32
DM0UNM1 FM C17H17N
DM0UNM1 IC InChI=1S/C17H17N/c1-14(16-10-4-3-5-11-16)8-6-12-17-13-7-9-15(2)18-17/h3-5,7,9-11,13-14H,8H2,1-2H3
DM0UNM1 CS CC1=NC(=CC=C1)C#CCC(C)C2=CC=CC=C2
DM0UNM1 IK QVXDBDKPSMNGHQ-UHFFFAOYSA-N
DM0UNM1 IU 2-methyl-6-(4-phenylpent-1-ynyl)pyridine
DM0UNM1 DE Discovery agent
DMDVO7Z ID DMDVO7Z
DMDVO7Z DN 2-methyl-6-(5-phenylpent-1-ynyl)pyridine
DMDVO7Z HS Investigative
DMDVO7Z SN CHEMBL378040; 2-methyl-6-(5-phenylpent-1-ynyl)pyridine; 2-methyl-6-(5-phenylpent-1-yn-1-yl)pyridine; SCHEMBL5703524; BDBM50191123
DMDVO7Z DT Small molecular drug
DMDVO7Z PC 44416004
DMDVO7Z MW 235.32
DMDVO7Z FM C17H17N
DMDVO7Z IC InChI=1S/C17H17N/c1-15-9-8-14-17(18-15)13-7-3-6-12-16-10-4-2-5-11-16/h2,4-5,8-11,14H,3,6,12H2,1H3
DMDVO7Z CS CC1=NC(=CC=C1)C#CCCCC2=CC=CC=C2
DMDVO7Z IK NJJSTWRJIALOHE-UHFFFAOYSA-N
DMDVO7Z IU 2-methyl-6-(5-phenylpent-1-ynyl)pyridine
DMDVO7Z DE Discovery agent
DMVQK4Y ID DMVQK4Y
DMVQK4Y DN 2-methyl-6-(phenylethynyl)pyridine
DMVQK4Y HS Investigative
DMVQK4Y SN 2-Methyl-6-(phenylethynyl)pyridine; MPEP; 96206-92-7; 6-Methyl-2-(phenylethynyl)pyridine; 2-methyl-6-(2-phenylethynyl)pyridine; UNII-7VC0YVI27Y; 7VC0YVI27Y; CHEMBL66654; CHEBI:64159; Pyridine, 2-methyl-6-(phenylethynyl)-; Tocris-1212; AC1MHGB1; Lopac-M-5435; Lopac0_000738; MLS006011229; SCHEMBL103061; 2-Picoline, 6-phenylethynyl-; GTPL1426; DTXSID9043982; MolPort-003-958-770; HMS3651F13; 2-Methyl-6-phenylethynyl-pyridine; ZINC2581406; BCP05962; ZX-AN014840; 2-methyl-6-(phenylethynyl)-pyridine; s2809; HY-14609A; 2151AH
DMVQK4Y DT Small molecular drug
DMVQK4Y PC 3025961
DMVQK4Y MW 193.24
DMVQK4Y FM C14H11N
DMVQK4Y IC InChI=1S/C14H11N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-9H,1H3
DMVQK4Y CS CC1=NC(=CC=C1)C#CC2=CC=CC=C2
DMVQK4Y IK NEWKHUASLBMWRE-UHFFFAOYSA-N
DMVQK4Y IU 2-methyl-6-(2-phenylethynyl)pyridine
DMVQK4Y CA CAS 96206-92-7
DMVQK4Y CB CHEBI:64159
DMVQK4Y DE Discovery agent
DMJYSF3 ID DMJYSF3
DMJYSF3 DN 2-methyl-6-(trifluoromethyl)-9H-carbazole
DMJYSF3 HS Investigative
DMJYSF3 SN 2-methyl-6-(trifluoromethyl)-9H-carbazole; CHEMBL1170659; SCHEMBL13772410
DMJYSF3 DT Small molecular drug
DMJYSF3 PC 24741169
DMJYSF3 MW 249.23
DMJYSF3 FM C14H10F3N
DMJYSF3 IC InChI=1S/C14H10F3N/c1-8-2-4-10-11-7-9(14(15,16)17)3-5-12(11)18-13(10)6-8/h2-7,18H,1H3
DMJYSF3 CS CC1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(F)(F)F
DMJYSF3 IK QYXUJSGMFDAAAV-UHFFFAOYSA-N
DMJYSF3 IU 2-methyl-6-(trifluoromethyl)-9H-carbazole
DMJYSF3 DE Discovery agent
DM8EV4A ID DM8EV4A
DM8EV4A DN 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime
DM8EV4A HS Investigative
DM8EV4A DT Small molecular drug
DM8EV4A PC 91934662
DM8EV4A MW 194.27
DM8EV4A FM C11H18N2O
DM8EV4A IC InChI=1S/C11H18N2O/c1-11(10-12-14)6-2-3-7-13-8-4-5-9-13/h11H,4-10H2,1H3
DM8EV4A CS CC(CC#CCN1CCCC1)CN=O
DM8EV4A IK GMFWCDSZRLSMRO-UHFFFAOYSA-N
DM8EV4A IU 1-(5-methyl-6-nitrosohex-2-ynyl)pyrrolidine
DM8EV4A DE Discovery agent
DM9FZ0B ID DM9FZ0B
DM9FZ0B DN 2-methyl-7-(pyridin-3-yl)quinoline
DM9FZ0B HS Investigative
DM9FZ0B SN CHEMBL231763; 2-methyl-7-(pyridin-3-yl)quinoline
DM9FZ0B DT Small molecular drug
DM9FZ0B PC 44432659
DM9FZ0B MW 220.27
DM9FZ0B FM C15H12N2
DM9FZ0B IC InChI=1S/C15H12N2/c1-11-4-5-12-6-7-13(9-15(12)17-11)14-3-2-8-16-10-14/h2-10H,1H3
DM9FZ0B CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CN=CC=C3
DM9FZ0B IK MALXWWORFUKTKQ-UHFFFAOYSA-N
DM9FZ0B IU 2-methyl-7-pyridin-3-ylquinoline
DM9FZ0B DE Discovery agent
DMMFKOH ID DMMFKOH
DMMFKOH DN 2-methyl-7-m-tolyl-1,6-naphthyridine
DMMFKOH HS Investigative
DMMFKOH SN CHEMBL236431; 2-methyl-7-m-tolyl-1,6-naphthyridine
DMMFKOH DT Small molecular drug
DMMFKOH PC 44434750
DMMFKOH MW 234.29
DMMFKOH FM C16H14N2
DMMFKOH IC InChI=1S/C16H14N2/c1-11-4-3-5-13(8-11)15-9-16-14(10-17-15)7-6-12(2)18-16/h3-10H,1-2H3
DMMFKOH CS CC1=CC(=CC=C1)C2=NC=C3C=CC(=NC3=C2)C
DMMFKOH IK RXRAEDHCPCFPLI-UHFFFAOYSA-N
DMMFKOH IU 2-methyl-7-(3-methylphenyl)-1,6-naphthyridine
DMMFKOH DE Discovery agent
DMZFK4R ID DMZFK4R
DMZFK4R DN 2-methyl-7-m-tolyl-1,8-naphthyridine
DMZFK4R HS Investigative
DMZFK4R SN CHEMBL235629; 2-methyl-7-m-tolyl-1,8-naphthyridine
DMZFK4R DT Small molecular drug
DMZFK4R PC 44434735
DMZFK4R MW 234.29
DMZFK4R FM C16H14N2
DMZFK4R IC InChI=1S/C16H14N2/c1-11-4-3-5-14(10-11)15-9-8-13-7-6-12(2)17-16(13)18-15/h3-10H,1-2H3
DMZFK4R CS CC1=CC(=CC=C1)C2=NC3=C(C=CC(=N3)C)C=C2
DMZFK4R IK RJHUNTTZZMJQOV-UHFFFAOYSA-N
DMZFK4R IU 2-methyl-7-(3-methylphenyl)-1,8-naphthyridine
DMZFK4R DE Discovery agent
DMC02TI ID DMC02TI
DMC02TI DN 2-methyl-7-m-tolylquinoline
DMC02TI HS Investigative
DMC02TI SN CHEMBL231765; 2-methyl-7-m-tolylquinoline
DMC02TI DT Small molecular drug
DMC02TI PC 44432662
DMC02TI MW 233.31
DMC02TI FM C17H15N
DMC02TI IC InChI=1S/C17H15N/c1-12-4-3-5-15(10-12)16-9-8-14-7-6-13(2)18-17(14)11-16/h3-11H,1-2H3
DMC02TI CS CC1=CC(=CC=C1)C2=CC3=C(C=CC(=N3)C)C=C2
DMC02TI IK LRWHLTHMQZJGQD-UHFFFAOYSA-N
DMC02TI IU 2-methyl-7-(3-methylphenyl)quinoline
DMC02TI DE Discovery agent
DM8RV5X ID DM8RV5X
DM8RV5X DN 2-methyl-7-phenyl-1,8-naphthyridine
DM8RV5X HS Investigative
DM8RV5X SN 2-methyl-7-phenyl-1,8-naphthyridine; CHEMBL97344; BDBM50090686; 7-Methyl-2-phenyl-1,8-naphthyridine; 2-Methyl-7-phenyl-[1,8]naphthyridine
DM8RV5X DT Small molecular drug
DM8RV5X PC 12431922
DM8RV5X MW 220.27
DM8RV5X FM C15H12N2
DM8RV5X IC InChI=1S/C15H12N2/c1-11-7-8-13-9-10-14(17-15(13)16-11)12-5-3-2-4-6-12/h2-10H,1H3
DM8RV5X CS CC1=NC2=C(C=C1)C=CC(=N2)C3=CC=CC=C3
DM8RV5X IK BGLSJWRWFABGNC-UHFFFAOYSA-N
DM8RV5X IU 2-methyl-7-phenyl-1,8-naphthyridine
DM8RV5X DE Discovery agent
DMT7MVD ID DMT7MVD
DMT7MVD DN 2-methyl-7-phenylquinoline
DMT7MVD HS Investigative
DMT7MVD SN CHEMBL244418; 2-methyl-7-phenylquinoline; 7-Phenylchinaldin
DMT7MVD DT Small molecular drug
DMT7MVD PC 44427376
DMT7MVD MW 219.28
DMT7MVD FM C16H13N
DMT7MVD IC InChI=1S/C16H13N/c1-12-7-8-14-9-10-15(11-16(14)17-12)13-5-3-2-4-6-13/h2-11H,1H3
DMT7MVD CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC=C3
DMT7MVD IK FGRQGIBMKYGMEX-UHFFFAOYSA-N
DMT7MVD IU 2-methyl-7-phenylquinoline
DMT7MVD DE Discovery agent
DMY65CX ID DMY65CX
DMY65CX DN 2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline
DMY65CX HS Investigative
DMY65CX SN AC1MHU5K; 2-methyl-8-phenyl-3,4-dihydro-1H-isoquinoline; CHEMBL13101; SCHEMBL11488388; Isoquinoline, 1,2,3,4-tetrahydro-2-methyl-8-phenyl-
DMY65CX DT Small molecular drug
DMY65CX PC 3057770
DMY65CX MW 223.31
DMY65CX FM C16H17N
DMY65CX IC InChI=1S/C16H17N/c1-17-11-10-14-8-5-9-15(16(14)12-17)13-6-3-2-4-7-13/h2-9H,10-12H2,1H3
DMY65CX CS CN1CCC2=C(C1)C(=CC=C2)C3=CC=CC=C3
DMY65CX IK XBKQADUXVZAYDY-UHFFFAOYSA-N
DMY65CX IU 2-methyl-8-phenyl-3,4-dihydro-1H-isoquinoline
DMY65CX DE Discovery agent
DM06TZN ID DM06TZN
DM06TZN DN 2-methyl-9H-carbazole
DM06TZN HS Investigative
DM06TZN SN 2-METHYLCARBAZOLE; 2-Methyl-9H-carbazole; 9H-Carbazole, 2-methyl-; 3652-91-3; 2-Methyldibenzopyrrole; Carbazole, 2-methyl-; UNII-7MWG08F2MG; 7MWG08F2MG; CHEMBL1173640; PWJYOTPKLOICJK-UHFFFAOYSA-N; 2-methyl carbazole; NSC10153; EINECS 222-894-3; NSC 10153; 2-methyl-9H-carbazol; ACMC-1AHNQ; AC1L2DUH; 2-Methyl-9H-carbazole #; SCHEMBL607346; Carbazole, 2-methyl- (8CI); DTXSID9073963; CTK1C3104; MolPort-006-115-551; ZINC1706058; 9H-Carbazole, 2-methyl- (9CI); FCH838910; NSC-10153; BDBM50322581; AKOS006274371; ACM3652913; KB-25102; OR340083
DM06TZN DT Small molecular drug
DM06TZN PC 19290
DM06TZN MW 181.23
DM06TZN FM C13H11N
DM06TZN IC InChI=1S/C13H11N/c1-9-6-7-11-10-4-2-3-5-12(10)14-13(11)8-9/h2-8,14H,1H3
DM06TZN CS CC1=CC2=C(C=C1)C3=CC=CC=C3N2
DM06TZN IK PWJYOTPKLOICJK-UHFFFAOYSA-N
DM06TZN IU 2-methyl-9H-carbazole
DM06TZN CA CAS 3652-91-3
DM06TZN DE Discovery agent
DMEVFJW ID DMEVFJW
DMEVFJW DN 2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
DMEVFJW HS Investigative
DMEVFJW SN 2-methyl-9H-indeno[2,1-d]pyrimidin-9-one; 9H-Indeno[2,1-d]pyrimidin-9-one, 2-methyl-; CHEMBL392622; Aza-heterocyclic Derivative, 2a; BDBM19174
DMEVFJW DT Small molecular drug
DMEVFJW PC 23636012
DMEVFJW MW 196.2
DMEVFJW FM C12H8N2O
DMEVFJW IC InChI=1S/C12H8N2O/c1-7-13-6-10-8-4-2-3-5-9(8)12(15)11(10)14-7/h2-6H,1H3
DMEVFJW CS CC1=NC=C2C3=CC=CC=C3C(=O)C2=N1
DMEVFJW IK QMXCHNWJZQMLGG-UHFFFAOYSA-N
DMEVFJW IU 2-methylindeno[2,1-d]pyrimidin-9-one
DMEVFJW DE Discovery agent
DMKP6BM ID DMKP6BM
DMKP6BM DN 2-Methylamino-succinic acid(NMDA)
DMKP6BM HS Investigative
DMKP6BM SN N-Methyl-D-aspartic acid; N-methyl-D-aspartic acid; NMDA; 6384-92-5; N-Methyl-D-aspartate; N-Methylaspartate; D-Aspartic acid, N-methyl-; N-Me-D-Asp-OH; (R)-2-(Methylamino)succinic acid; NMDA (N-Methyl-D-aspartic acid); Methyl aspartic acid; n-methyl-d-aspartic acid (nmda); UNII-1903B9Q6PI; N-Methyl aspartic acid; (2R)-2-(methylamino)butanedioic acid; 2-Methylamino-succinic acid; BRN 1724431; CHEMBL291278; CHEBI:31882; HOKKHZGPKSLGJE-GSVOUGTGSA-N; 1903B9Q6PI; N-Methyl-D-aspartic Acid, Hydrate; AK-44365; W-203368; N-Methyl-D-aspartic acid, 98%
DMKP6BM DT Small molecular drug
DMKP6BM PC 22880
DMKP6BM MW 147.13
DMKP6BM FM C5H9NO4
DMKP6BM IC InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)/t3-/m1/s1
DMKP6BM CS CN[C@H](CC(=O)O)C(=O)O
DMKP6BM IK HOKKHZGPKSLGJE-GSVOUGTGSA-N
DMKP6BM IU (2R)-2-(methylamino)butanedioic acid
DMKP6BM CA CAS 6384-92-5
DMKP6BM CB CHEBI:31882
DMKP6BM DE Discovery agent
DMQBF7J ID DMQBF7J
DMQBF7J DN 2-Methyl-beta-carboline-2-ium iodide
DMQBF7J HS Investigative
DMQBF7J SN 2-methylnorharmane iodide; CHEMBL455600; MolPort-001-815-824; AKOS024332881
DMQBF7J DT Small molecular drug
DMQBF7J PC 3036890
DMQBF7J MW 183.23
DMQBF7J FM C12H11N2+
DMQBF7J IC InChI=1S/C12H10N2/c1-14-7-6-10-9-4-2-3-5-11(9)13-12(10)8-14/h2-8H,1H3/p+1
DMQBF7J CS C[N+]1=CC2=C(C=C1)C3=CC=CC=C3N2
DMQBF7J IK UDHBHTHWWOQPBW-UHFFFAOYSA-O
DMQBF7J IU 2-methyl-9H-pyrido[3,4-b]indol-2-ium
DMQBF7J CA CAS 17994-14-8
DMQBF7J DE Discovery agent
DMKB2P8 ID DMKB2P8
DMKB2P8 DN 2-methylbut-3-yn-2-yl 4-methoxybenzoate
DMKB2P8 HS Investigative
DMKB2P8 SN 2-methylbut-3-yn-2-yl 4-methoxybenzoate; 294619-87-7; 1,1-dimethyl-2-propyn-1-yl 4-methoxybenzoate; ZERO/003209; AC1LE8OG; ARONIS020757; CHEMBL244918; ZINC96414; BDBM23726; KS-00004CEK; MolPort-001-510-482; BBL014263; STK001780; AKOS000487782; MCULE-8443375339; ST036671; 1,1-dimethylprop-2-ynyl 4-methoxybenzoate; BB0275130; 1,1-dimethyl-2-propynyl 4-methoxybenzoate; H2604; EU-0085447; SR-01000525786; AG-205/12908103; SR-01000525786-1; 1,1-dimethylprop-2-yn-1-yl 4-methoxybenzoate, 10; 4-Methoxybenzoic acid 1,1-dimethyl-2-propynyl es
DMKB2P8 DT Small molecular drug
DMKB2P8 PC 708205
DMKB2P8 MW 218.25
DMKB2P8 FM C13H14O3
DMKB2P8 IC InChI=1S/C13H14O3/c1-5-13(2,3)16-12(14)10-6-8-11(15-4)9-7-10/h1,6-9H,2-4H3
DMKB2P8 CS CC(C)(C#C)OC(=O)C1=CC=C(C=C1)OC
DMKB2P8 IK WRGOVRZCLGHFFF-UHFFFAOYSA-N
DMKB2P8 IU 2-methylbut-3-yn-2-yl 4-methoxybenzoate
DMKB2P8 DE Discovery agent
DMD8CQS ID DMD8CQS
DMD8CQS DN 2-methylhistamine
DMD8CQS HS Investigative
DMD8CQS SN 56975-07-6; Tetrahydro-5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-1,3,5-triazine-2(1H)-thione; 5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-1,3,5-triazinane-2-thione; EINECS 260-494-0; AC1L3OH4; GTPL1268; AC1Q7F21; CTK5A6094; DTXSID70205580; 1,3,5-Triazine-2(1H)-thione,tetrahydro-5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-
DMD8CQS DT Small molecular drug
DMD8CQS PC 91613
DMD8CQS MW 125.17
DMD8CQS FM C6H11N3
DMD8CQS IC InChI=1S/C6H11N3/c1-5-8-4-6(9-5)2-3-7/h4H,2-3,7H2,1H3,(H,8,9)
DMD8CQS CS CC1=NC=C(N1)CCN
DMD8CQS IK XDKYTXBAVJELDQ-UHFFFAOYSA-N
DMD8CQS IU 2-(2-methyl-1H-imidazol-5-yl)ethanamine
DMD8CQS CA CAS 34392-54-6
DMD8CQS CB CHEBI:74761
DMD8CQS DE Discovery agent
DMHW9GL ID DMHW9GL
DMHW9GL DN 2-methylisoquinoline-1,3,4-trione
DMHW9GL HS Investigative
DMHW9GL SN 2-methylisoquinoline-1,3,4(2H)-trione; 21640-33-5; 2-methyl-isoquinoline-1,3,4-trione; 2-methylisoquinoline-1,3,4-trione; 2-methyl-1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; N-methylphthalonimide; AC1LVZDH; AC1Q3XNZ; 1,3,4(2H)-Isoquinolinetrione, 2-methyl-; CHEMBL381480; SCHEMBL13442852; Isoquinoline-1,3,4-trione 2a; CTK4E7387; BDBM10248; DTXSID90364926; MolPort-001-798-932; ZINC2030689; CS-D0370; FCH830488; STK368698; AKOS005444509; MCULE-7985115369; ACM21640335; 2-methyl-1,3,4(2H)-isoquinolinetrione; AK325966
DMHW9GL DT Small molecular drug
DMHW9GL PC 1714901
DMHW9GL MW 189.17
DMHW9GL FM C10H7NO3
DMHW9GL IC InChI=1S/C10H7NO3/c1-11-9(13)7-5-3-2-4-6(7)8(12)10(11)14/h2-5H,1H3
DMHW9GL CS CN1C(=O)C2=CC=CC=C2C(=O)C1=O
DMHW9GL IK LSVJISCDJHIYOW-UHFFFAOYSA-N
DMHW9GL IU 2-methylisoquinoline-1,3,4-trione
DMHW9GL CA CAS 21640-33-5
DMHW9GL DE Discovery agent
DMUN3LV ID DMUN3LV
DMUN3LV DN 2-Methylquinoline-8-carboxamide
DMUN3LV HS Investigative
DMUN3LV SN CHEMBL471966; 2-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 2-methyl-; SCHEMBL422282; BDBM50255329; AKOS022882220
DMUN3LV DT Small molecular drug
DMUN3LV PC 21195867
DMUN3LV MW 186.21
DMUN3LV FM C11H10N2O
DMUN3LV IC InChI=1S/C11H10N2O/c1-7-5-6-8-3-2-4-9(11(12)14)10(8)13-7/h2-6H,1H3,(H2,12,14)
DMUN3LV CS CC1=NC2=C(C=CC=C2C(=O)N)C=C1
DMUN3LV IK FKDAECIKJPVBCN-UHFFFAOYSA-N
DMUN3LV IU 2-methylquinoline-8-carboxamide
DMUN3LV DE Discovery agent
DMM4HXK ID DMM4HXK
DMM4HXK DN 2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate
DMM4HXK HS Investigative
DMM4HXK SN CHEMBL219273; 2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate
DMM4HXK DT Small molecular drug
DMM4HXK PC 16098588
DMM4HXK MW 476.6
DMM4HXK FM C19H28N2O6S3
DMM4HXK IC InChI=1S/C19H28N2O6S3/c1-19-8-7-12-13(15(19)5-6-18(19)27-30(21,24)25)4-3-11-9-16(26-29(20,22)23)17(28-2)10-14(11)12/h9-10,12-13,15,18H,3-8H2,1-2H3,(H2,20,22,23)(H2,21,24,25)/t12-,13+,15-,18-,19-/m0/s1
DMM4HXK CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=CC(=C(C=C34)SC)OS(=O)(=O)N
DMM4HXK IK DWVUBFTWKROFPD-SSTWWWIQSA-N
DMM4HXK IU [(8R,9S,13S,14S,17S)-13-methyl-2-methylsulfanyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMM4HXK DE Discovery agent
DM4IJXW ID DM4IJXW
DM4IJXW DN 2-MOE phosphorothioate gapmers
DM4IJXW HS Investigative
DM4IJXW SN Oligo445236; Oligo445238
DM4IJXW CP Genzyme Corp
DM4IJXW DT Antisense drug
DM4IJXW DE Myotonic dystrophy
DME9S8M ID DME9S8M
DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose
DME9S8M HS Investigative
DME9S8M SN 53-59-8; Cozymase II; Codehydrogenase II; TPN (nucleotide); Codehydrase II; Nadide phosphate; NAD phosphate; EINECS 200-178-1; BRN 3885115; nicotinamide adenine dinucleotide phosphate; CHEBI:44409; beta-NADP; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; beta-TPN; TPN-ox; nadp nicotinamide-adenine-dinucleotide phosphate; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen p
DME9S8M DT Small molecular drug
DME9S8M PC 46936685
DME9S8M MW 743.4
DME9S8M FM C21H28N7O17P3
DME9S8M IC InChI=1S/C21H28N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1-4,7-8,10-11,13-16,20-21,29-31H,5-6H2,(H7-,22,23,24,25,32,33,34,35,36,37,38,39)/t10-,11-,13-,14-,15+,16+,20+,21+/m0/s1
DME9S8M CS C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@H]([C@@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@H]3[C@@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)N
DME9S8M IK XJLXINKUBYWONI-XCSFTKGKSA-N
DME9S8M IU [[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
DME9S8M DE Discovery agent
DMDYRNF ID DMDYRNF
DMDYRNF DN 2'-Monophosphoadenosine-5'-Diphosphate
DMDYRNF HS Investigative
DMDYRNF SN 2'-MONOPHOSPHOADENOSINE-5'-DIPHOSPHATE; adenosine 2'-(dihydrogen phosphate) 5'-(trihydrogen diphosphate); 2-Phospho-adenosine diphosphate; 1afl; AC1L4WBL; phosphoadenosine diphosphate; AC1Q6S1C; 2'P-ADP; SCHEMBL905455; 5'-Diphosphoadenosine 2'-phosphate; DB02363; Adenosine 2'-phosphoric acid 5'-diphosphoric acid; Adenosine 5'-(trihydrogen diphorphate), 2'-(dihydrogen phosphate); [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMDYRNF DT Small molecular drug
DMDYRNF PC 165230
DMDYRNF MW 507.18
DMDYRNF FM C10H16N5O13P3
DMDYRNF IC InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(27-29(17,18)19)6(16)4(26-10)1-25-31(23,24)28-30(20,21)22/h2-4,6-7,10,16H,1H2,(H,23,24)(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DMDYRNF CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)OP(=O)(O)O)N
DMDYRNF IK YPTPYQSAVGGMFN-KQYNXXCUSA-N
DMDYRNF IU [(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMDYRNF CA CAS 4457-01-6
DMDYRNF DE Discovery agent
DMCVF7R ID DMCVF7R
DMCVF7R DN 2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one
DMCVF7R HS Investigative
DMCVF7R SN CHEMBL276746; 2-morpholino-6-phenyl-4H-thiopyran-4-one; 2-morpholin-4-yl-6-phenyl-thiopyran-4-one; 2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one; SCHEMBL5842568
DMCVF7R DT Small molecular drug
DMCVF7R PC 9965345
DMCVF7R MW 273.4
DMCVF7R FM C15H15NO2S
DMCVF7R IC InChI=1S/C15H15NO2S/c17-13-10-14(12-4-2-1-3-5-12)19-15(11-13)16-6-8-18-9-7-16/h1-5,10-11H,6-9H2
DMCVF7R CS C1COCCN1C2=CC(=O)C=C(S2)C3=CC=CC=C3
DMCVF7R IK ZRGAPZKMQHRLTD-UHFFFAOYSA-N
DMCVF7R IU 2-morpholin-4-yl-6-phenylthiopyran-4-one
DMCVF7R DE Discovery agent
DMTB1KV ID DMTB1KV
DMTB1KV DN 2-Morpholin-4-yl-6-phenyl-chromen-4-one
DMTB1KV HS Investigative
DMTB1KV SN CHEMBL369146; 2-morpholin-4-yl-6-phenyl-chromen-4-one; SCHEMBL3542251
DMTB1KV DT Small molecular drug
DMTB1KV PC 11358716
DMTB1KV MW 307.3
DMTB1KV FM C19H17NO3
DMTB1KV IC InChI=1S/C19H17NO3/c21-17-13-19(20-8-10-22-11-9-20)23-18-7-6-15(12-16(17)18)14-4-2-1-3-5-14/h1-7,12-13H,8-11H2
DMTB1KV CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=CC=C4
DMTB1KV IK FGDAUGYDQLYAKT-UHFFFAOYSA-N
DMTB1KV IU 2-morpholin-4-yl-6-phenylchromen-4-one
DMTB1KV DE Discovery agent
DMC1TWI ID DMC1TWI
DMC1TWI DN 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI HS Investigative
DMC1TWI SN CHEMBL200340; 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI DT Small molecular drug
DMC1TWI PC 11660428
DMC1TWI MW 357.4
DMC1TWI FM C23H19NO3
DMC1TWI IC InChI=1S/C23H19NO3/c25-21-15-22(24-10-12-26-13-11-24)27-23-19(6-3-7-20(21)23)18-9-8-16-4-1-2-5-17(16)14-18/h1-9,14-15H,10-13H2
DMC1TWI CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC5=CC=CC=C5C=C4
DMC1TWI IK OYLGZUQUTITVHN-UHFFFAOYSA-N
DMC1TWI IU 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one
DMC1TWI DE Discovery agent
DMVN38H ID DMVN38H
DMVN38H DN 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H HS Investigative
DMVN38H SN CHEMBL197551; 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H DT Small molecular drug
DMVN38H PC 11502854
DMVN38H MW 429.5
DMVN38H FM C25H19NO4S
DMVN38H IC InChI=1S/C25H19NO4S/c27-19-15-23(26-11-13-28-14-12-26)30-24-16(5-3-7-18(19)24)17-6-4-10-22-25(17)29-20-8-1-2-9-21(20)31-22/h1-10,15H,11-14H2
DMVN38H CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=C5C(=CC=C4)SC6=CC=CC=C6O5
DMVN38H IK IAMQVMPIHMBYSY-UHFFFAOYSA-N
DMVN38H IU 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one
DMVN38H DE Discovery agent
DMNKHOI ID DMNKHOI
DMNKHOI DN 2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one
DMNKHOI HS Investigative
DMNKHOI SN 2-morpholino-8-(2-phenylethynyl)-4H-chromen-4-one
DMNKHOI PC 10359339
DMNKHOI MW 331.4
DMNKHOI FM C21H17NO3
DMNKHOI IC InChI=1S/C21H17NO3/c23-19-15-20(22-11-13-24-14-12-22)25-21-17(7-4-8-18(19)21)10-9-16-5-2-1-3-6-16/h1-8,15H,11-14H2
DMNKHOI CS C1COCCN1C2=CC(=O)C3=CC=CC(=C3O2)C#CC4=CC=CC=C4
DMNKHOI IK FVCZHPDXMMYSDW-UHFFFAOYSA-N
DMNKHOI IU 2-morpholin-4-yl-8-(2-phenylethynyl)chromen-4-one
DMNKHOI DE Discovery agent
DMNHYQ0 ID DMNHYQ0
DMNHYQ0 DN 2-morpholin-4-yl-8-styrylchromen-4-one
DMNHYQ0 HS Investigative
DMNHYQ0 SN CHEMBL198476; 2-morpholin-4-yl-8-styrylchromen-4-one; SCHEMBL6357331
DMNHYQ0 DT Small molecular drug
DMNHYQ0 PC 11709748
DMNHYQ0 MW 333.4
DMNHYQ0 FM C21H19NO3
DMNHYQ0 IC InChI=1S/C21H19NO3/c23-19-15-20(22-11-13-24-14-12-22)25-21-17(7-4-8-18(19)21)10-9-16-5-2-1-3-6-16/h1-10,15H,11-14H2/b10-9+
DMNHYQ0 CS C1COCCN1C2=CC(=O)C3=CC=CC(=C3O2)/C=C/C4=CC=CC=C4
DMNHYQ0 IK OLQGOHPEAUHNBE-MDZDMXLPSA-N
DMNHYQ0 IU 2-morpholin-4-yl-8-[(E)-2-phenylethenyl]chromen-4-one
DMNHYQ0 DE Discovery agent
DM5JHT6 ID DM5JHT6
DM5JHT6 DN 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one
DM5JHT6 HS Investigative
DM5JHT6 SN CHEMBL362729; 503468-86-8; 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one; 2-morpholin-4-yl-8-thiophen-2-yl-chromen-4-one; CTK1G6919; DTXSID30469303; BDBM50156496; AKOS030552940; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-(2-thienyl)-
DM5JHT6 DT Small molecular drug
DM5JHT6 PC 11602076
DM5JHT6 MW 313.4
DM5JHT6 FM C17H15NO3S
DM5JHT6 IC InChI=1S/C17H15NO3S/c19-14-11-16(18-6-8-20-9-7-18)21-17-12(14)3-1-4-13(17)15-5-2-10-22-15/h1-5,10-11H,6-9H2
DM5JHT6 CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CS4
DM5JHT6 IK FEOKXELSWFEHJU-UHFFFAOYSA-N
DM5JHT6 IU 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one
DM5JHT6 CA CAS 503468-86-8
DM5JHT6 DE Discovery agent
DMCY4EP ID DMCY4EP
DMCY4EP DN 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one
DMCY4EP HS Investigative
DMCY4EP SN CHEMBL360183; 503468-85-7; 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one; 2-morpholin-4-yl-8-thiophen-3-yl-chromen-4-one; CTK1G6920; DTXSID30469641; BDBM50156502; AKOS030552941; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-(3-thienyl)-
DMCY4EP DT Small molecular drug
DMCY4EP PC 11623802
DMCY4EP MW 313.4
DMCY4EP FM C17H15NO3S
DMCY4EP IC InChI=1S/C17H15NO3S/c19-15-10-16(18-5-7-20-8-6-18)21-17-13(2-1-3-14(15)17)12-4-9-22-11-12/h1-4,9-11H,5-8H2
DMCY4EP CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CSC=C4
DMCY4EP IK MHMBRJOWOVNUNC-UHFFFAOYSA-N
DMCY4EP IU 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one
DMCY4EP CA CAS 503468-85-7
DMCY4EP DE Discovery agent
DM3ZWNI ID DM3ZWNI
DM3ZWNI DN 2-Morpholin-4-yl-benzo[h]chromene-4-thione
DM3ZWNI HS Investigative
DM3ZWNI SN CHEMBL176233; 2-Morpholin-4-yl-benzo[h]chromene-4-thione; SCHEMBL13346492
DM3ZWNI DT Small molecular drug
DM3ZWNI PC 11426483
DM3ZWNI MW 297.4
DM3ZWNI FM C17H15NO2S
DM3ZWNI IC InChI=1S/C17H15NO2S/c21-15-11-16(18-7-9-19-10-8-18)20-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
DM3ZWNI CS C1COCCN1C2=CC(=S)C3=C(O2)C4=CC=CC=C4C=C3
DM3ZWNI IK VNZKDSHSVFSENH-UHFFFAOYSA-N
DM3ZWNI IU 2-morpholin-4-ylbenzo[h]chromene-4-thione
DM3ZWNI DE Discovery agent
DMDTRZ2 ID DMDTRZ2
DMDTRZ2 DN 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide
DMDTRZ2 HS Investigative
DMDTRZ2 SN 91533-01-6; 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide; CHEMBL180943; Sulfanilamide, N4-(alpha-morpholinoacetyl)-; 2-(morpholin-4-yl)-N-(4-sulfamoylphenyl)acetamide; N4-(alpha-Morpholinoacetyl)sulfanilamide; AE-848/36321029; 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide; AC1L47H0; SCHEMBL15798186; DTXSID70238616; MolPort-000-225-319; BDBM50157946; ZINC19901027; STL294445; AKOS001028531; MCULE-6306887577; ST086382; SR-01000467406; SR-01000467406-1; Z46180370; 4-Morpholineacetamide, N-(4-(aminosulfonyl)phenyl)-
DMDTRZ2 DT Small molecular drug
DMDTRZ2 PC 180598
DMDTRZ2 MW 299.35
DMDTRZ2 FM C12H17N3O4S
DMDTRZ2 IC InChI=1S/C12H17N3O4S/c13-20(17,18)11-3-1-10(2-4-11)14-12(16)9-15-5-7-19-8-6-15/h1-4H,5-9H2,(H,14,16)(H2,13,17,18)
DMDTRZ2 CS C1COCCN1CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMDTRZ2 IK ZKUIDNFBWWVULC-UHFFFAOYSA-N
DMDTRZ2 IU 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide
DMDTRZ2 CA CAS 91533-01-6
DMDTRZ2 DE Discovery agent
DMCKSX7 ID DMCKSX7
DMCKSX7 DN 2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
DMCKSX7 HS Investigative
DMCKSX7 SN CHEMBL179043; 2-(morpholin-4-yl)-4h-pyrido[1,2-a]pyrimidin-4-one; 17326-31-7; NSC110390; AC1Q6IJU; AC1L6MD6; 2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one; 2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one; SCHEMBL4544196; CTK4D4568; DTXSID80296606; ZINC1702791; BDBM50159642; AKOS024361168; NSC-110390; MCULE-7092692912; ST50991317
DMCKSX7 DT Small molecular drug
DMCKSX7 PC 269395
DMCKSX7 MW 231.25
DMCKSX7 FM C12H13N3O2
DMCKSX7 IC InChI=1S/C12H13N3O2/c16-12-9-11(14-5-7-17-8-6-14)13-10-3-1-2-4-15(10)12/h1-4,9H,5-8H2
DMCKSX7 CS C1COCCN1C2=CC(=O)N3C=CC=CC3=N2
DMCKSX7 IK VDMRPNTZWKDYBB-UHFFFAOYSA-N
DMCKSX7 IU 2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one
DMCKSX7 CA CAS 17326-31-7
DMCKSX7 DE Discovery agent
DM79ZOV ID DM79ZOV
DM79ZOV DN 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one
DM79ZOV HS Investigative
DM79ZOV SN Compound 401; 168425-64-7; 2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one; 2-(morpholin-4-yl)pyrimido[2,1-a]isoquinolin-4-one; CHEMBL179242; 2-(4-MORPHOLINYL)-4H-PYRIMIDO[2,1-A]ISOQUINOLIN-4-ONE; Compound401; 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one; SCHEMBL10092321; KS-00001DEG; CTK4D2994; DTXSID20434626; MolPort-023-276-726; HMS3229D15; EX-A1016; BCP04303; BDBM50159620; ZINC13608047; AKOS016369524; CS-5624; NCGC00378805-02; HY-19341; KB-224235; M2537; B7337; S-7713; J-010456
DM79ZOV DT Small molecular drug
DM79ZOV PC 10039361
DM79ZOV MW 281.31
DM79ZOV FM C16H15N3O2
DM79ZOV IC InChI=1S/C16H15N3O2/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2
DM79ZOV CS C1COCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=N2
DM79ZOV IK BVRDQVRQVGRNHG-UHFFFAOYSA-N
DM79ZOV IU 2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one
DM79ZOV CA CAS 168425-64-7
DM79ZOV DE Discovery agent
DMFHTEG ID DMFHTEG
DMFHTEG DN 2-morpholino-1,1,2-triphenylethanol
DMFHTEG HS Investigative
DMFHTEG SN CHEMBL1091863; 2-morpholino-1,1,2-triphenylethanol
DMFHTEG DT Small molecular drug
DMFHTEG PC 46885513
DMFHTEG MW 359.5
DMFHTEG FM C24H25NO2
DMFHTEG IC InChI=1S/C24H25NO2/c26-24(21-12-6-2-7-13-21,22-14-8-3-9-15-22)23(20-10-4-1-5-11-20)25-16-18-27-19-17-25/h1-15,23,26H,16-19H2
DMFHTEG CS C1COCCN1C(C2=CC=CC=C2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
DMFHTEG IK HOPDHEHFNMVVFR-UHFFFAOYSA-N
DMFHTEG IU 2-morpholin-4-yl-1,1,2-triphenylethanol
DMFHTEG DE Discovery agent
DMH89O5 ID DMH89O5
DMH89O5 DN 2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol
DMH89O5 HS Investigative
DMH89O5 SN CHEMBL1088803; 2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol; SCHEMBL1242083
DMH89O5 DT Small molecular drug
DMH89O5 PC 11588169
DMH89O5 MW 341.4
DMH89O5 FM C20H27N3O2
DMH89O5 IC InChI=1S/C20H27N3O2/c1-2-3-8-19(23-11-13-25-14-12-23)20(24,17-6-4-9-21-15-17)18-7-5-10-22-16-18/h4-7,9-10,15-16,19,24H,2-3,8,11-14H2,1H3
DMH89O5 CS CCCCC(C(C1=CN=CC=C1)(C2=CN=CC=C2)O)N3CCOCC3
DMH89O5 IK MHMGSQRAIMZTJJ-UHFFFAOYSA-N
DMH89O5 IU 2-morpholin-4-yl-1,1-dipyridin-3-ylhexan-1-ol
DMH89O5 DE Discovery agent
DMDMVA1 ID DMDMVA1
DMDMVA1 DN 2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol
DMDMVA1 HS Investigative
DMDMVA1 SN CHEMBL1088804; 2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol; SCHEMBL1242942
DMDMVA1 DT Small molecular drug
DMDMVA1 PC 11646379
DMDMVA1 MW 369.5
DMDMVA1 FM C22H31N3O2
DMDMVA1 IC InChI=1S/C22H31N3O2/c1-2-3-4-5-10-21(25-13-15-27-16-14-25)22(26,19-8-6-11-23-17-19)20-9-7-12-24-18-20/h6-9,11-12,17-18,21,26H,2-5,10,13-16H2,1H3
DMDMVA1 CS CCCCCCC(C(C1=CN=CC=C1)(C2=CN=CC=C2)O)N3CCOCC3
DMDMVA1 IK PUFFDHPIZWKLSX-UHFFFAOYSA-N
DMDMVA1 IU 2-morpholin-4-yl-1,1-dipyridin-3-yloctan-1-ol
DMDMVA1 DE Discovery agent
DM3V5AB ID DM3V5AB
DM3V5AB DN 2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol
DM3V5AB HS Investigative
DM3V5AB SN CHEMBL1090794; 2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol; SCHEMBL1240366
DM3V5AB DT Small molecular drug
DM3V5AB PC 11710246
DM3V5AB MW 361.4
DM3V5AB FM C22H23N3O2
DM3V5AB IC InChI=1S/C22H23N3O2/c26-22(19-8-4-10-23-16-19,20-9-5-11-24-17-20)21(18-6-2-1-3-7-18)25-12-14-27-15-13-25/h1-11,16-17,21,26H,12-15H2
DM3V5AB CS C1COCCN1C(C2=CC=CC=C2)C(C3=CN=CC=C3)(C4=CN=CC=C4)O
DM3V5AB IK WPLZJOHYEBBPRT-UHFFFAOYSA-N
DM3V5AB IU 2-morpholin-4-yl-2-phenyl-1,1-dipyridin-3-ylethanol
DM3V5AB DE Discovery agent
DM5J6IT ID DM5J6IT
DM5J6IT DN 2-morpholino-4H-benzo[g]chromen-4-one
DM5J6IT HS Investigative
DM5J6IT SN CHEMBL175883; 503467-97-8; 2-morpholino-4H-benzo[g]chromen-4-one; SCHEMBL3536668; CTK1G6923; DTXSID10465904; BDBM50159668; 2-Morpholin-4-yl-benzo[g]chromen-4-one; 4H-Naphtho[2,3-b]pyran-4-one, 2-(4-morpholinyl)-
DM5J6IT DT Small molecular drug
DM5J6IT PC 11437483
DM5J6IT MW 281.3
DM5J6IT FM C17H15NO3
DM5J6IT IC InChI=1S/C17H15NO3/c19-15-11-17(18-5-7-20-8-6-18)21-16-10-13-4-2-1-3-12(13)9-14(15)16/h1-4,9-11H,5-8H2
DM5J6IT CS C1COCCN1C2=CC(=O)C3=CC4=CC=CC=C4C=C3O2
DM5J6IT IK FKURMCWOGPDJSJ-UHFFFAOYSA-N
DM5J6IT IU 2-morpholin-4-ylbenzo[g]chromen-4-one
DM5J6IT CA CAS 503467-97-8
DM5J6IT DE Discovery agent
DMZL6Q1 ID DMZL6Q1
DMZL6Q1 DN 2-morpholino-6-(naphthalen-1-yl)-4H-chromen-4-one
DMZL6Q1 HS Investigative
DMZL6Q1 SN CHEMBL197475
DMZL6Q1 DT Small molecular drug
DMZL6Q1 PC 11646132
DMZL6Q1 MW 357.4
DMZL6Q1 FM C23H19NO3
DMZL6Q1 IC InChI=1S/C23H19NO3/c25-21-15-23(24-10-12-26-13-11-24)27-22-9-8-17(14-20(21)22)19-7-3-5-16-4-1-2-6-18(16)19/h1-9,14-15H,10-13H2
DMZL6Q1 CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=CC5=CC=CC=C54
DMZL6Q1 IK ALYIMYTWUBXFRH-UHFFFAOYSA-N
DMZL6Q1 IU 2-morpholin-4-yl-6-naphthalen-1-ylchromen-4-one
DMZL6Q1 DE Discovery agent
DMEOI0V ID DMEOI0V
DMEOI0V DN 2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one
DMEOI0V HS Investigative
DMEOI0V SN CHEMBL225608; 2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one
DMEOI0V DT Small molecular drug
DMEOI0V PC 16204046
DMEOI0V MW 307.3
DMEOI0V FM C19H17NO3
DMEOI0V IC InChI=1S/C19H17NO3/c21-15-12-18(23-19(13-15)20-8-10-22-11-9-20)17-7-3-5-14-4-1-2-6-16(14)17/h1-7,12-13H,8-11H2
DMEOI0V CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=CC=CC=C43
DMEOI0V IK VSXKSTFHVOSHSV-UHFFFAOYSA-N
DMEOI0V IU 2-morpholin-4-yl-6-naphthalen-1-ylpyran-4-one
DMEOI0V DE Discovery agent
DMO7QCN ID DMO7QCN
DMO7QCN DN 2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one
DMO7QCN HS Investigative
DMO7QCN SN CHEMBL225609; 2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one
DMO7QCN DT Small molecular drug
DMO7QCN PC 16204047
DMO7QCN MW 307.3
DMO7QCN FM C19H17NO3
DMO7QCN IC InChI=1S/C19H17NO3/c21-17-12-18(23-19(13-17)20-7-9-22-10-8-20)16-6-5-14-3-1-2-4-15(14)11-16/h1-6,11-13H,7-10H2
DMO7QCN CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC4=CC=CC=C4C=C3
DMO7QCN IK FNMVAZNGFWLDOQ-UHFFFAOYSA-N
DMO7QCN IU 2-morpholin-4-yl-6-naphthalen-2-ylpyran-4-one
DMO7QCN DE Discovery agent
DMTBRLK ID DMTBRLK
DMTBRLK DN 2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one
DMTBRLK HS Investigative
DMTBRLK SN CHEMBL223041; 2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one
DMTBRLK DT Small molecular drug
DMTBRLK PC 16204049
DMTBRLK MW 308.3
DMTBRLK FM C18H16N2O3
DMTBRLK IC InChI=1S/C18H16N2O3/c21-14-11-16(23-17(12-14)20-7-9-22-10-8-20)15-5-1-3-13-4-2-6-19-18(13)15/h1-6,11-12H,7-10H2
DMTBRLK CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC4=C3N=CC=C4
DMTBRLK IK GJFZIARIYRYNDJ-UHFFFAOYSA-N
DMTBRLK IU 2-morpholin-4-yl-6-quinolin-8-ylpyran-4-one
DMTBRLK DE Discovery agent
DMATVZB ID DMATVZB
DMATVZB DN 2-morpholino-6-(thianthren-1-yl)-4H-chromen-4-one
DMATVZB HS Investigative
DMATVZB SN CHEMBL200824
DMATVZB DT Small molecular drug
DMATVZB PC 11583137
DMATVZB MW 445.6
DMATVZB FM C25H19NO3S2
DMATVZB IC InChI=1S/C25H19NO3S2/c27-19-15-24(26-10-12-28-13-11-26)29-20-9-8-16(14-18(19)20)17-4-3-7-23-25(17)31-22-6-2-1-5-21(22)30-23/h1-9,14-15H,10-13H2
DMATVZB CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=C5C(=CC=C4)SC6=CC=CC=C6S5
DMATVZB IK NXGBJPCXFKHQKN-UHFFFAOYSA-N
DMATVZB IU 2-morpholin-4-yl-6-thianthren-1-ylchromen-4-one
DMATVZB DE Discovery agent
DMTWJMN ID DMTWJMN
DMTWJMN DN 2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one
DMTWJMN HS Investigative
DMTWJMN SN CHEMBL374133; 2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one
DMTWJMN DT Small molecular drug
DMTWJMN PC 16203941
DMTWJMN MW 263.31
DMTWJMN FM C13H13NO3S
DMTWJMN IC InChI=1S/C13H13NO3S/c15-10-8-11(12-2-1-7-18-12)17-13(9-10)14-3-5-16-6-4-14/h1-2,7-9H,3-6H2
DMTWJMN CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CS3
DMTWJMN IK MEBJAUWWCSKYMY-UHFFFAOYSA-N
DMTWJMN IU 2-morpholin-4-yl-6-thiophen-2-ylpyran-4-one
DMTWJMN DE Discovery agent
DMF3NPW ID DMF3NPW
DMF3NPW DN 2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one
DMF3NPW HS Investigative
DMF3NPW SN CHEMBL223381; 2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one
DMF3NPW DT Small molecular drug
DMF3NPW PC 16203942
DMF3NPW MW 263.31
DMF3NPW FM C13H13NO3S
DMF3NPW IC InChI=1S/C13H13NO3S/c15-11-7-12(10-1-6-18-9-10)17-13(8-11)14-2-4-16-5-3-14/h1,6-9H,2-5H2
DMF3NPW CS C1COCCN1C2=CC(=O)C=C(O2)C3=CSC=C3
DMF3NPW IK LICYALMZYZNUAP-UHFFFAOYSA-N
DMF3NPW IU 2-morpholin-4-yl-6-thiophen-3-ylpyran-4-one
DMF3NPW DE Discovery agent
DMMC0ZP ID DMMC0ZP
DMMC0ZP DN 2-morpholino-6-phenyl-4H-pyran-4-one
DMMC0ZP HS Investigative
DMMC0ZP SN 2-morpholino-6-phenyl-4H-pyran-4-one; CHEMBL105613; 2-morpholin-4-yl-6-phenyl-pyran-4-one; SCHEMBL3540014
DMMC0ZP DT Small molecular drug
DMMC0ZP PC 10923175
DMMC0ZP MW 257.279
DMMC0ZP FM C15H15NO3
DMMC0ZP IC InChI=1S/C15H15NO3/c17-13-10-14(12-4-2-1-3-5-12)19-15(11-13)16-6-8-18-9-7-16/h1-5,10-11H,6-9H2
DMMC0ZP CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC=C3
DMMC0ZP IK QQHMBGBSWORRAG-UHFFFAOYSA-N
DMMC0ZP IU 2-morpholin-4-yl-6-phenylpyran-4-one
DMMC0ZP DE Discovery agent
DM8ZPJI ID DM8ZPJI
DM8ZPJI DN 2-morpholino-6-styryl-4H-pyran-4-one
DM8ZPJI HS Investigative
DM8ZPJI SN CHEMBL223559; 2-morpholino-6-styryl-4H-pyran-4-one; SCHEMBL13435577
DM8ZPJI DT Small molecular drug
DM8ZPJI PC 16203255
DM8ZPJI MW 283.32
DM8ZPJI FM C17H17NO3
DM8ZPJI IC InChI=1S/C17H17NO3/c19-15-12-16(7-6-14-4-2-1-3-5-14)21-17(13-15)18-8-10-20-11-9-18/h1-7,12-13H,8-11H2/b7-6+
DM8ZPJI CS C1COCCN1C2=CC(=O)C=C(O2)/C=C/C3=CC=CC=C3
DM8ZPJI IK ZJOMZZQTJIYOSC-VOTSOKGWSA-N
DM8ZPJI IU 2-morpholin-4-yl-6-[(E)-2-phenylethenyl]pyran-4-one
DM8ZPJI DE Discovery agent
DM4XKYN ID DM4XKYN
DM4XKYN DN 2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one
DM4XKYN HS Investigative
DM4XKYN SN CHEMBL95923
DM4XKYN DT Small molecular drug
DM4XKYN PC 44328640
DM4XKYN MW 331.4
DM4XKYN FM C21H17NO3
DM4XKYN IC InChI=1S/C21H17NO3/c23-19-15-21(22-10-12-24-13-11-22)25-20-14-17(8-9-18(19)20)7-6-16-4-2-1-3-5-16/h1-5,8-9,14-15H,10-13H2
DM4XKYN CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)C#CC4=CC=CC=C4
DM4XKYN IK INSPUQMNGZSNFZ-UHFFFAOYSA-N
DM4XKYN IU 2-morpholin-4-yl-7-(2-phenylethynyl)chromen-4-one
DM4XKYN DE Discovery agent
DMK7WON ID DMK7WON
DMK7WON DN 2-morpholino-7-phenyl-4H-chromen-4-one
DMK7WON HS Investigative
DMK7WON SN CHEMBL95309
DMK7WON DT Small molecular drug
DMK7WON PC 23586694
DMK7WON MW 307.3
DMK7WON FM C19H17NO3
DMK7WON IC InChI=1S/C19H17NO3/c21-17-13-19(20-8-10-22-11-9-20)23-18-12-15(6-7-16(17)18)14-4-2-1-3-5-14/h1-7,12-13H,8-11H2
DMK7WON CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)C4=CC=CC=C4
DMK7WON IK RWIGISKNQAMRJZ-UHFFFAOYSA-N
DMK7WON IU 2-morpholin-4-yl-7-phenylchromen-4-one
DMK7WON DE Discovery agent
DMYP0UI ID DMYP0UI
DMYP0UI DN 2-morpholinobenzo[h]quinolin-4(1H)-one
DMYP0UI HS Investigative
DMYP0UI SN CHEMBL198675; 2-morpholinobenzo[h]quinolin-4(1H)-one
DMYP0UI DT Small molecular drug
DMYP0UI PC 25817490
DMYP0UI MW 282.32
DMYP0UI FM C16H16N3O2+
DMYP0UI IC InChI=1S/C16H15N3O2/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2/p+1
DMYP0UI CS C1COCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=[NH+]2
DMYP0UI IK BVRDQVRQVGRNHG-UHFFFAOYSA-O
DMYP0UI IU 2-morpholin-4-ylpyrimido[2,1-a]isoquinolin-1-ium-4-one
DMYP0UI DE Discovery agent
DMIQYWM ID DMIQYWM
DMIQYWM DN 2-morpholino-N-phenethylpyrimidin-4-amine
DMIQYWM HS Investigative
DMIQYWM SN CHEMBL1085505; 2-morpholino-N-phenethylpyrimidin-4-amine; BDBM50319974
DMIQYWM DT Small molecular drug
DMIQYWM PC 46891060
DMIQYWM MW 284.36
DMIQYWM FM C16H20N4O
DMIQYWM IC InChI=1S/C16H20N4O/c1-2-4-14(5-3-1)6-8-17-15-7-9-18-16(19-15)20-10-12-21-13-11-20/h1-5,7,9H,6,8,10-13H2,(H,17,18,19)
DMIQYWM CS C1COCCN1C2=NC=CC(=N2)NCCC3=CC=CC=C3
DMIQYWM IK QCZVHPUPIBZBLH-UHFFFAOYSA-N
DMIQYWM IU 2-morpholin-4-yl-N-(2-phenylethyl)pyrimidin-4-amine
DMIQYWM DE Discovery agent
DMBWDXH ID DMBWDXH
DMBWDXH DN 2-m-tolyl-1,8-naphthyridine
DMBWDXH HS Investigative
DMBWDXH SN CHEMBL395902; 2-m-tolyl-1,8-naphthyridine
DMBWDXH DT Small molecular drug
DMBWDXH PC 44434718
DMBWDXH MW 220.27
DMBWDXH FM C15H12N2
DMBWDXH IC InChI=1S/C15H12N2/c1-11-4-2-5-13(10-11)14-8-7-12-6-3-9-16-15(12)17-14/h2-10H,1H3
DMBWDXH CS CC1=CC(=CC=C1)C2=NC3=C(C=CC=N3)C=C2
DMBWDXH IK VOPUZVINSLDWHQ-UHFFFAOYSA-N
DMBWDXH IU 2-(3-methylphenyl)-1,8-naphthyridine
DMBWDXH DE Discovery agent
DM9ZVHJ ID DM9ZVHJ
DM9ZVHJ DN 2-m-Tolyl-1H-[1,8]naphthyridin-4-one
DM9ZVHJ HS Investigative
DM9ZVHJ SN CHEMBL299979; 2-(3-methylphenyl)-1,8-naphthyridin-4(1h)-one; NSC676185; 2-m-Tolyl-1H-[1,8]naphthyridin-4-one; AC1L8OZI; SCHEMBL7922307; CTK8D2142; ZINC5504118; BDBM50059970; NSC-676185; NCI60_026912
DM9ZVHJ DT Small molecular drug
DM9ZVHJ PC 385181
DM9ZVHJ MW 236.27
DM9ZVHJ FM C15H12N2O
DM9ZVHJ IC InChI=1S/C15H12N2O/c1-10-4-2-5-11(8-10)13-9-14(18)12-6-3-7-16-15(12)17-13/h2-9H,1H3,(H,16,17,18)
DM9ZVHJ CS CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=CC=C3
DM9ZVHJ IK IZFIIAGLKAXALT-UHFFFAOYSA-N
DM9ZVHJ IU 2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DM9ZVHJ DE Discovery agent
DM3AFXM ID DM3AFXM
DM3AFXM DN 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM3AFXM HS Investigative
DM3AFXM SN CHEMBL387592; 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one; BDBM50218914; 2-m-Tolyl-2,5-dihydro-pyrazolo[3,4-c]quinolin-4-one
DM3AFXM DT Small molecular drug
DM3AFXM PC 10588437
DM3AFXM MW 275.3
DM3AFXM FM C17H13N3O
DM3AFXM IC InChI=1S/C17H13N3O/c1-11-5-4-6-12(9-11)20-10-14-13-7-2-3-8-15(13)18-17(21)16(14)19-20/h2-10H,1H3,(H,18,21)
DM3AFXM CS CC1=CC(=CC=C1)N2C=C3C4=CC=CC=C4NC(=O)C3=N2
DM3AFXM IK KHYUWCCULSYNJP-UHFFFAOYSA-N
DM3AFXM IU 2-(3-methylphenyl)-5H-pyrazolo[3,4-c]quinolin-4-one
DM3AFXM DE Discovery agent
DMIMRCH ID DMIMRCH
DMIMRCH DN 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DMIMRCH HS Investigative
DMIMRCH SN CHEMBL107446; 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine; BDBM50091130; 2-m-Tolyl-2H-pyrazolo[3,4-c]quinolin-4-ylamine
DMIMRCH DT Small molecular drug
DMIMRCH PC 10612371
DMIMRCH MW 274.32
DMIMRCH FM C17H14N4
DMIMRCH IC InChI=1S/C17H14N4/c1-11-5-4-6-12(9-11)21-10-14-13-7-2-3-8-15(13)19-17(18)16(14)20-21/h2-10H,1H3,(H2,18,19)
DMIMRCH CS CC1=CC(=CC=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
DMIMRCH IK NJFGXLMDWIXVEW-UHFFFAOYSA-N
DMIMRCH IU 2-(3-methylphenyl)pyrazolo[3,4-c]quinolin-4-amine
DMIMRCH DE Discovery agent
DM0PT8R ID DM0PT8R
DM0PT8R DN 2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane
DM0PT8R HS Investigative
DM0PT8R SN CHEMBL1077899; 2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane
DM0PT8R DT Small molecular drug
DM0PT8R PC 44613578
DM0PT8R MW 237.41
DM0PT8R FM C14H23NS
DM0PT8R IC InChI=1S/C14H23NS/c1-5-13(15-11(2)3)10-12-6-8-14(16-4)9-7-12/h6-9,11,13,15H,5,10H2,1-4H3
DM0PT8R CS CCC(CC1=CC=C(C=C1)SC)NC(C)C
DM0PT8R IK JPJSEWJNHDIYAS-UHFFFAOYSA-N
DM0PT8R IU 1-(4-methylsulfanylphenyl)-N-propan-2-ylbutan-2-amine
DM0PT8R DE Discovery agent
DMLJ30O ID DMLJ30O
DMLJ30O DN 2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane
DMLJ30O HS Investigative
DMLJ30O SN CHEMBL1077898; 2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane
DMLJ30O DT Small molecular drug
DMLJ30O PC 44613577
DMLJ30O MW 237.41
DMLJ30O FM C14H23NS
DMLJ30O IC InChI=1S/C14H23NS/c1-4-10-15-13(5-2)11-12-6-8-14(16-3)9-7-12/h6-9,13,15H,4-5,10-11H2,1-3H3
DMLJ30O CS CCCNC(CC)CC1=CC=C(C=C1)SC
DMLJ30O IK BVNCGPDTVNALJQ-UHFFFAOYSA-N
DMLJ30O IU 1-(4-methylsulfanylphenyl)-N-propylbutan-2-amine
DMLJ30O DE Discovery agent
DMKSUVH ID DMKSUVH
DMKSUVH DN 2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane
DMKSUVH HS Investigative
DMKSUVH SN CHEMBL1078835; 2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane; NFRBJBFYUNQIQP-UHFFFAOYSA-N; BDBM50310863; N,N-Dimethyl-1-[4-(methylthio)phenyl]-2-propaneamine
DMKSUVH DT Small molecular drug
DMKSUVH PC 46882974
DMKSUVH MW 209.35
DMKSUVH FM C12H19NS
DMKSUVH IC InChI=1S/C12H19NS/c1-10(13(2)3)9-11-5-7-12(14-4)8-6-11/h5-8,10H,9H2,1-4H3
DMKSUVH CS CC(CC1=CC=C(C=C1)SC)N(C)C
DMKSUVH IK NFRBJBFYUNQIQP-UHFFFAOYSA-N
DMKSUVH IU N,N-dimethyl-1-(4-methylsulfanylphenyl)propan-2-amine
DMKSUVH DE Discovery agent
DM5S0BY ID DM5S0BY
DM5S0BY DN 2-N-Allylamino-1-(4-methylthiophenyl)propan
DM5S0BY HS Investigative
DM5S0BY SN CHEMBL1079254; 2-N-Allylamino-1-(4-methylthiophenyl)propan
DM5S0BY DT Small molecular drug
DM5S0BY PC 44613067
DM5S0BY MW 221.36
DM5S0BY FM C13H19NS
DM5S0BY IC InChI=1S/C13H19NS/c1-4-9-14-11(2)10-12-5-7-13(15-3)8-6-12/h4-8,11,14H,1,9-10H2,2-3H3
DM5S0BY CS CC(CC1=CC=C(C=C1)SC)NCC=C
DM5S0BY IK QEAUILQRYNKCJK-UHFFFAOYSA-N
DM5S0BY IU 1-(4-methylsulfanylphenyl)-N-prop-2-enylpropan-2-amine
DM5S0BY DE Discovery agent
DM2FTIC ID DM2FTIC
DM2FTIC DN 2-NAP
DM2FTIC HS Investigative
DM2FTIC SN N-(2-Naphthylsulfonyl)-L-aspartic acid 2-phenylethylamide sodium salt
DM2FTIC DT Small molecular drug
DM2FTIC PC 9867157
DM2FTIC MW 426.5
DM2FTIC FM C22H22N2O5S
DM2FTIC IC InChI=1S/C22H22N2O5S/c25-21(26)15-20(22(27)23-13-12-16-6-2-1-3-7-16)24-30(28,29)19-11-10-17-8-4-5-9-18(17)14-19/h1-11,14,20,24H,12-13,15H2,(H,23,27)(H,25,26)/t20-/m0/s1
DM2FTIC CS C1=CC=C(C=C1)CCNC(=O)[C@H](CC(=O)O)NS(=O)(=O)C2=CC3=CC=CC=C3C=C2
DM2FTIC IK VMYREBYTVVSDDK-FQEVSTJZSA-N
DM2FTIC IU (3S)-3-(naphthalen-2-ylsulfonylamino)-4-oxo-4-(2-phenylethylamino)butanoic acid
DM2FTIC CA CAS 141577-40-4
DM2FTIC DE Gastrointestinal disease
DMTSF6A ID DMTSF6A
DMTSF6A DN 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one
DMTSF6A HS Investigative
DMTSF6A SN CHEMBL423845; NSC676180; AC1L8OZ9; 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one; SCHEMBL7925077; CTK8D2144; ZINC5647446; BDBM50059969; NSC-676180; NCI60_026907; 2-(1-Naphthyl)-1,8-naphthyridin-4(1H)-one; 2-naphthalen-1-yl-1H-1,8-naphthyridin-4-one
DMTSF6A DT Small molecular drug
DMTSF6A PC 385176
DMTSF6A MW 272.3
DMTSF6A FM C18H12N2O
DMTSF6A IC InChI=1S/C18H12N2O/c21-17-11-16(20-18-15(17)9-4-10-19-18)14-8-3-6-12-5-1-2-7-13(12)14/h1-11H,(H,19,20,21)
DMTSF6A CS C1=CC=C2C(=C1)C=CC=C2C3=CC(=O)C4=C(N3)N=CC=C4
DMTSF6A IK PPEYNRXCXSJVHV-UHFFFAOYSA-N
DMTSF6A IU 2-naphthalen-1-yl-1H-1,8-naphthyridin-4-one
DMTSF6A DE Discovery agent
DMBI6U9 ID DMBI6U9
DMBI6U9 DN 2-Naphthalen-1-yl-benzooxazol-6-ol
DMBI6U9 HS Investigative
DMBI6U9 SN CHEMBL188527; 2-Naphthalen-1-yl-benzooxazol-6-ol; 2-(naphthalen-1-yl)benzo[d]oxazol-6-ol; SCHEMBL6311736; LYJKLNQQSXCGDI-UHFFFAOYSA-N; BDBM50154077; ZINC12353755
DMBI6U9 DT Small molecular drug
DMBI6U9 PC 10244394
DMBI6U9 MW 261.269
DMBI6U9 FM C17H11NO2
DMBI6U9 IC InChI=1S/C17H11NO2/c19-12-8-9-15-16(10-12)20-17(18-15)14-7-3-5-11-4-1-2-6-13(11)14/h1-10,19H
DMBI6U9 CS C1=CC=C2C(=C1)C=CC=C2C3=NC4=C(O3)C=C(C=C4)O
DMBI6U9 IK LYJKLNQQSXCGDI-UHFFFAOYSA-N
DMBI6U9 IU 2-naphthalen-1-yl-1,3-benzoxazol-6-ol
DMBI6U9 DE Discovery agent
DMIDGNB ID DMIDGNB
DMIDGNB DN 2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one
DMIDGNB HS Investigative
DMIDGNB SN CHEMBL3144719; 2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL273743; SCHEMBL9646265; SXKBSXCUDSHBDF-UHFFFAOYSA-N; BDBM50008985; 2-[(1-Naphthalenyl)methyl]-1H-indazol-3(2H)-one
DMIDGNB DT Small molecular drug
DMIDGNB PC 14898710
DMIDGNB MW 274.3
DMIDGNB FM C18H14N2O
DMIDGNB IC InChI=1S/C18H14N2O/c21-18-16-10-3-4-11-17(16)19-20(18)12-14-8-5-7-13-6-1-2-9-15(13)14/h1-11,19H,12H2
DMIDGNB CS C1=CC=C2C(=C1)C=CC=C2CN3C(=O)C4=CC=CC=C4N3
DMIDGNB IK SXKBSXCUDSHBDF-UHFFFAOYSA-N
DMIDGNB IU 2-(naphthalen-1-ylmethyl)-1H-indazol-3-one
DMIDGNB DE Discovery agent
DM12YH4 ID DM12YH4
DM12YH4 DN 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one
DM12YH4 HS Investigative
DM12YH4 SN CHEMBL298328; NSC679017; AC1L8RZV; 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one; SCHEMBL7913593; CTK8D2145; ZINC5541468; BDBM50059980; NSC-679017; NCI60_028216; 2-(2-Naphthyl)-1,8-naphthyridin-4(1H)-one; 2-naphthalen-2-yl-1H-1,8-naphthyridin-4-one
DM12YH4 DT Small molecular drug
DM12YH4 PC 386569
DM12YH4 MW 272.3
DM12YH4 FM C18H12N2O
DM12YH4 IC InChI=1S/C18H12N2O/c21-17-11-16(20-18-15(17)6-3-9-19-18)14-8-7-12-4-1-2-5-13(12)10-14/h1-11H,(H,19,20,21)
DM12YH4 CS C1=CC=C2C=C(C=CC2=C1)C3=CC(=O)C4=C(N3)N=CC=C4
DM12YH4 IK SIAZQYUZGIPPRX-UHFFFAOYSA-N
DM12YH4 IU 2-naphthalen-2-yl-1H-1,8-naphthyridin-4-one
DM12YH4 DE Discovery agent
DM1EJ6W ID DM1EJ6W
DM1EJ6W DN 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM1EJ6W HS Investigative
DM1EJ6W SN CHEMBL3144577; CHEMBL8355; 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one; SCHEMBL9645961; BDBM50009006
DM1EJ6W DT Small molecular drug
DM1EJ6W PC 14898720
DM1EJ6W MW 274.3
DM1EJ6W FM C18H14N2O
DM1EJ6W IC InChI=1S/C18H14N2O/c21-18-16-7-3-4-8-17(16)19-20(18)12-13-9-10-14-5-1-2-6-15(14)11-13/h1-11,19H,12H2
DM1EJ6W CS C1=CC=C2C=C(C=CC2=C1)CN3C(=O)C4=CC=CC=C4N3
DM1EJ6W IK UVPPFCAMTBSDRP-UHFFFAOYSA-N
DM1EJ6W IU 2-(naphthalen-2-ylmethyl)-1H-indazol-3-one
DM1EJ6W DE Discovery agent
DMNMEPB ID DMNMEPB
DMNMEPB DN 2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole
DMNMEPB HS Investigative
DMNMEPB SN CHEMBL441948; 2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole; DSSTox_RID_82756; DSSTox_CID_28423; DSSTox_GSID_48449; 2-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole; CAS-835-31-4; SMR000054538; Lopac-N-5504; AC1LD21I; Lopac0_000828; CBDivE_007782; MLS000104605; SCHEMBL953099; cid_610682; DTXSID3048449; VIXRKFBKWOHVBR-UHFFFAOYSA-N; MolPort-001-896-776; HMS2287I17; ZINC2472262; CCG-2426; Tox21_113058; Tox21_113645; BDBM50057120; MCULE-4581148654; NCGC00015743-03; NCGC00015743-02; NCGC00015743-01; BAS 00364529; AB00076191-01
DMNMEPB DT Small molecular drug
DMNMEPB PC 610682
DMNMEPB MW 210.27
DMNMEPB FM C14H14N2
DMNMEPB IC InChI=1S/C14H14N2/c1-2-4-13-9-11(5-6-12(13)3-1)10-14-15-7-8-16-14/h1-6,9H,7-8,10H2,(H,15,16)
DMNMEPB CS C1CN=C(N1)CC2=CC3=CC=CC=C3C=C2
DMNMEPB IK VIXRKFBKWOHVBR-UHFFFAOYSA-N
DMNMEPB IU 2-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole
DMNMEPB DE Discovery agent
DMZ4LJ7 ID DMZ4LJ7
DMZ4LJ7 DN 2-NAPHTHALENESULFONIC ACID
DMZ4LJ7 HS Investigative
DMZ4LJ7 SN 120-18-3; beta-Naphthylsulfonic acid; beta-Naphthalenesulfonic acid; Naphthalene-2-sulphonic acid; 2-Naphthalene Sulfonic Acid; Kyselina 2-naftalensulfonova; UNII-O9S4K2S25E; 2-Naphthylsulfonic acid; EINECS 204-375-3; Kyselina 2-naftalensulfonova [Czech]; BRN 1955756; AI3-18435; O9S4K2S25E; CHEBI:44229; KVBGVZZKJNLNJU-UHFFFAOYSA-N; MFCD00004089; 2-Naphthalenesulfonic acid, monohydrate; W-109067; 2-Sulfonaphthalene; 2-Naphthalenesulfonic; PubChem19963; AC1L1QYN; AC1Q6WYB
DMZ4LJ7 DT Small molecular drug
DMZ4LJ7 PC 8420
DMZ4LJ7 MW 208.24
DMZ4LJ7 FM C10H8O3S
DMZ4LJ7 IC InChI=1S/C10H8O3S/c11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10/h1-7H,(H,11,12,13)
DMZ4LJ7 CS C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)O
DMZ4LJ7 IK KVBGVZZKJNLNJU-UHFFFAOYSA-N
DMZ4LJ7 IU naphthalene-2-sulfonic acid
DMZ4LJ7 CA CAS 120-18-3
DMZ4LJ7 CB CHEBI:44229
DMZ4LJ7 DE Discovery agent
DMFXKN1 ID DMFXKN1
DMFXKN1 DN 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine
DMFXKN1 HS Investigative
DMFXKN1 SN (S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE; 2gv6; AC1OA9XW; CHEMBL210771; SCHEMBL12960819; BDBM23902; 3-amidinophenylalanine deriv., 8; 3-[(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-(naphthalene-2-sulfonamido)-3-oxopropyl]benzene-1-carboximidamide; 3-{(2S)-3-[4-(2-carbamimidamidoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}benzenecarboximidamide
DMFXKN1 DT Small molecular drug
DMFXKN1 PC 6852210
DMFXKN1 MW 549.7
DMFXKN1 FM C28H35N7O3S
DMFXKN1 IC InChI=1S/C28H35N7O3S/c29-26(30)23-7-3-4-20(16-23)17-25(27(36)35-14-11-19(12-15-35)10-13-33-28(31)32)34-39(37,38)24-9-8-21-5-1-2-6-22(21)18-24/h1-9,16,18-19,25,34H,10-15,17H2,(H3,29,30)(H4,31,32,33)/t25-/m0/s1
DMFXKN1 CS C1CN(CCC1CCN=C(N)N)C(=O)[C@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DMFXKN1 IK BKOKSJAQZJNVPN-VWLOTQADSA-N
DMFXKN1 IU 3-[(2S)-3-[4-[2-(diaminomethylideneamino)ethyl]piperidin-1-yl]-2-(naphthalen-2-ylsulfonylamino)-3-oxopropyl]benzenecarboximidamide
DMFXKN1 DE Discovery agent
DMS0NW3 ID DMS0NW3
DMS0NW3 DN 2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane
DMS0NW3 HS Investigative
DMS0NW3 SN CHEMBL1078818; 2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane
DMS0NW3 DT Small molecular drug
DMS0NW3 PC 44613579
DMS0NW3 MW 235.39
DMS0NW3 FM C14H21NS
DMS0NW3 IC InChI=1S/C14H21NS/c1-3-12(15-13-6-7-13)10-11-4-8-14(16-2)9-5-11/h4-5,8-9,12-13,15H,3,6-7,10H2,1-2H3
DMS0NW3 CS CCC(CC1=CC=C(C=C1)SC)NC2CC2
DMS0NW3 IK WWIGSCWWTFIJCJ-UHFFFAOYSA-N
DMS0NW3 IU N-[1-(4-methylsulfanylphenyl)butan-2-yl]cyclopropanamine
DMS0NW3 DE Discovery agent
DMCYVS0 ID DMCYVS0
DMCYVS0 DN 2-N-Ethylamino-1-(4-ethylthiophenyl)butane
DMCYVS0 HS Investigative
DMCYVS0 SN CHEMBL1077884; 2-N-Ethylamino-1-(4-ethylthiophenyl)butane
DMCYVS0 DT Small molecular drug
DMCYVS0 PC 44613456
DMCYVS0 MW 237.41
DMCYVS0 FM C14H23NS
DMCYVS0 IC InChI=1S/C14H23NS/c1-4-13(15-5-2)11-12-7-9-14(10-8-12)16-6-3/h7-10,13,15H,4-6,11H2,1-3H3
DMCYVS0 CS CCC(CC1=CC=C(C=C1)SCC)NCC
DMCYVS0 IK FXAXBZLCZVSQJT-UHFFFAOYSA-N
DMCYVS0 IU N-ethyl-1-(4-ethylsulfanylphenyl)butan-2-amine
DMCYVS0 DE Discovery agent
DM64093 ID DM64093
DM64093 DN 2-N-Ethylamino-1-(4-ethylthiophenyl)propane
DM64093 HS Investigative
DM64093 SN CHEMBL1077873; 2-N-Ethylamino-1-(4-ethylthiophenyl)propane
DM64093 DT Small molecular drug
DM64093 PC 44613452
DM64093 MW 223.38
DM64093 FM C13H21NS
DM64093 IC InChI=1S/C13H21NS/c1-4-14-11(3)10-12-6-8-13(9-7-12)15-5-2/h6-9,11,14H,4-5,10H2,1-3H3
DM64093 CS CCNC(C)CC1=CC=C(C=C1)SCC
DM64093 IK UKMQZNZTCNFILP-UHFFFAOYSA-N
DM64093 IU N-ethyl-1-(4-ethylsulfanylphenyl)propan-2-amine
DM64093 DE Discovery agent
DMKA3V2 ID DMKA3V2
DMKA3V2 DN 2-N-Ethylamino-1-(4-methylthiophenyl)butane
DMKA3V2 HS Investigative
DMKA3V2 SN CHEMBL1077897; 2-N-Ethylamino-1-(4-methylthiophenyl)butane
DMKA3V2 DT Small molecular drug
DMKA3V2 PC 44613576
DMKA3V2 MW 223.38
DMKA3V2 FM C13H21NS
DMKA3V2 IC InChI=1S/C13H21NS/c1-4-12(14-5-2)10-11-6-8-13(15-3)9-7-11/h6-9,12,14H,4-5,10H2,1-3H3
DMKA3V2 CS CCC(CC1=CC=C(C=C1)SC)NCC
DMKA3V2 IK DVPCSQHSLVMBEG-UHFFFAOYSA-N
DMKA3V2 IU N-ethyl-1-(4-methylsulfanylphenyl)butan-2-amine
DMKA3V2 DE Discovery agent
DM6O1SY ID DM6O1SY
DM6O1SY DN 2-N-Ethylamino-1-(4-methylthiophenyl)propane
DM6O1SY HS Investigative
DM6O1SY SN 2-N-Ethylamino-1-(4-methylthiophenyl)propane; CHEMBL1078039; 634607-27-5; LAWDOCPCCFOXQO-UHFFFAOYSA-N; BDBM50310856
DM6O1SY DT Small molecular drug
DM6O1SY PC 21978439
DM6O1SY MW 209.35
DM6O1SY FM C12H19NS
DM6O1SY IC InChI=1S/C12H19NS/c1-4-13-10(2)9-11-5-7-12(14-3)8-6-11/h5-8,10,13H,4,9H2,1-3H3
DM6O1SY CS CCNC(C)CC1=CC=C(C=C1)SC
DM6O1SY IK LAWDOCPCCFOXQO-UHFFFAOYSA-N
DM6O1SY IU N-ethyl-1-(4-methylsulfanylphenyl)propan-2-amine
DM6O1SY DE Discovery agent
DM2MH6J ID DM2MH6J
DM2MH6J DN 2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane
DM2MH6J HS Investigative
DM2MH6J SN 2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane; CHEMBL1077983; 1204749-43-8
DM2MH6J DT Small molecular drug
DM2MH6J PC 44613458
DM2MH6J MW 225.35
DM2MH6J FM C12H19NOS
DM2MH6J IC InChI=1S/C12H19NOS/c1-3-11(13-14)9-10-5-7-12(8-6-10)15-4-2/h5-8,11,13-14H,3-4,9H2,1-2H3
DM2MH6J CS CCC(CC1=CC=C(C=C1)SCC)NO
DM2MH6J IK HZILCAQYLMPMJC-UHFFFAOYSA-N
DM2MH6J IU N-[1-(4-ethylsulfanylphenyl)butan-2-yl]hydroxylamine
DM2MH6J DE Discovery agent
DMIQGWK ID DMIQGWK
DMIQGWK DN 2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane
DMIQGWK HS Investigative
DMIQGWK SN 2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane; CHEMBL1077874; 1204749-41-6
DMIQGWK DT Small molecular drug
DMIQGWK PC 44613453
DMIQGWK MW 211.33
DMIQGWK FM C11H17NOS
DMIQGWK IC InChI=1S/C11H17NOS/c1-3-14-11-6-4-10(5-7-11)8-9(2)12-13/h4-7,9,12-13H,3,8H2,1-2H3
DMIQGWK CS CCSC1=CC=C(C=C1)CC(C)NO
DMIQGWK IK JDIRZPZVUPWDQO-UHFFFAOYSA-N
DMIQGWK IU N-[1-(4-ethylsulfanylphenyl)propan-2-yl]hydroxylamine
DMIQGWK DE Discovery agent
DME41NR ID DME41NR
DME41NR DN 2-N-Hydroxyamino-1-(4-methylthiophenyl)butane
DME41NR HS Investigative
DME41NR SN 2-N-Hydroxyamino-1-(4-methylthiophenyl)butane; CHEMBL1078920; 1204749-75-6
DME41NR DT Small molecular drug
DME41NR PC 44613690
DME41NR MW 211.33
DME41NR FM C11H17NOS
DME41NR IC InChI=1S/C11H17NOS/c1-3-10(12-13)8-9-4-6-11(14-2)7-5-9/h4-7,10,12-13H,3,8H2,1-2H3
DME41NR CS CCC(CC1=CC=C(C=C1)SC)NO
DME41NR IK HJFQUPKLSAEIPC-UHFFFAOYSA-N
DME41NR IU N-[1-(4-methylsulfanylphenyl)butan-2-yl]hydroxylamine
DME41NR DE Discovery agent
DMZDYCW ID DMZDYCW
DMZDYCW DN 2-N-Hydroxyamino-1-(4-methylthiophenyl)propane
DMZDYCW HS Investigative
DMZDYCW SN 2-N-Hydroxyamino-1-(4-methylthiophenyl)propane; CHEMBL1077857; 1204749-10-9; hydroxy-4-methylthioamphetamine
DMZDYCW DT Small molecular drug
DMZDYCW PC 44613192
DMZDYCW MW 197.3
DMZDYCW FM C10H15NOS
DMZDYCW IC InChI=1S/C10H15NOS/c1-8(11-12)7-9-3-5-10(13-2)6-4-9/h3-6,8,11-12H,7H2,1-2H3
DMZDYCW CS CC(CC1=CC=C(C=C1)SC)NO
DMZDYCW IK WSDWYDJPBFHVDU-UHFFFAOYSA-N
DMZDYCW IU N-[1-(4-methylsulfanylphenyl)propan-2-yl]hydroxylamine
DMZDYCW DE Discovery agent
DM2NX4K ID DM2NX4K
DM2NX4K DN 2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide
DM2NX4K HS Investigative
DM2NX4K SN CHEMBL177084; BDBM50015162; ZINC28086552; 2''-Nitro-biphenyl-4-carboxylic acid hydroxyamide
DM2NX4K DT Small molecular drug
DM2NX4K PC 44386824
DM2NX4K MW 258.23
DM2NX4K FM C13H10N2O4
DM2NX4K IC InChI=1S/C13H10N2O4/c16-13(14-17)10-7-5-9(6-8-10)11-3-1-2-4-12(11)15(18)19/h1-8,17H,(H,14,16)
DM2NX4K CS C1=CC=C(C(=C1)C2=CC=C(C=C2)C(=O)NO)[N+](=O)[O-]
DM2NX4K IK MDYLSZYFKUGXHL-UHFFFAOYSA-N
DM2NX4K IU N-hydroxy-4-(2-nitrophenyl)benzamide
DM2NX4K DE Discovery agent
DMRZK9A ID DMRZK9A
DMRZK9A DN 2-nitro-N-(2,4,5-trichlorophenyl)benzamide
DMRZK9A HS Investigative
DMRZK9A SN 2-nitro-N-(2,4,5-trichlorophenyl)benzamide; CHEMBL570080; AC1LEFM1; CBMicro_048760; Oprea1_298416; MolPort-001-513-202; ZINC103157; STL255954; BDBM50297534; AKOS003265549; MCULE-2760222088; ST011169; BIM-0048873.P001
DMRZK9A DT Small molecular drug
DMRZK9A PC 711434
DMRZK9A MW 345.6
DMRZK9A FM C13H7Cl3N2O3
DMRZK9A IC InChI=1S/C13H7Cl3N2O3/c14-8-5-10(16)11(6-9(8)15)17-13(19)7-3-1-2-4-12(7)18(20)21/h1-6H,(H,17,19)
DMRZK9A CS C1=CC=C(C(=C1)C(=O)NC2=CC(=C(C=C2Cl)Cl)Cl)[N+](=O)[O-]
DMRZK9A IK IWLWJYOQIYGDKH-UHFFFAOYSA-N
DMRZK9A IU 2-nitro-N-(2,4,5-trichlorophenyl)benzamide
DMRZK9A DE Discovery agent
DM4Z56O ID DM4Z56O
DM4Z56O DN 2-nitro-N-(quinolin-8-yl)benzenesulfonamide
DM4Z56O HS Investigative
DM4Z56O SN MLS001123640; SMR000658615; 2-nitro-N-quinolin-8-ylbenzenesulfonamide; 2-Nitro-N-quinolin-8-yl-benzenesulfonamide; AC1LEORR; CBKinase1_000077; CBKinase1_012477; Cambridge id 5175135; Oprea1_237550; CBDivE_007245; cid_739449; CHEMBL270605; SCHEMBL11973295; BDBM60287; MolPort-002-134-446; YCXUFEOBLVZNAP-UHFFFAOYSA-N; ZINC175212; AKOS033118464; MCULE-3457699063; NCGC00161682-02; NCGC00161682-01; NCGC00161682-03; 2-nitro-N-(8-quinolyl)benzenesulfonamide; N-(8-Quinolyl)-2-nitrobenzenesulfonamide
DM4Z56O DT Small molecular drug
DM4Z56O PC 739449
DM4Z56O MW 329.3
DM4Z56O FM C15H11N3O4S
DM4Z56O IC InChI=1S/C15H11N3O4S/c19-18(20)13-8-1-2-9-14(13)23(21,22)17-12-7-3-5-11-6-4-10-16-15(11)12/h1-10,17H
DM4Z56O CS C1=CC=C(C(=C1)[N+](=O)[O-])S(=O)(=O)NC2=CC=CC3=C2N=CC=C3
DM4Z56O IK YCXUFEOBLVZNAP-UHFFFAOYSA-N
DM4Z56O IU 2-nitro-N-quinolin-8-ylbenzenesulfonamide
DM4Z56O DE Discovery agent
DMHCVKJ ID DMHCVKJ
DMHCVKJ DN 2-N-Methoxyamino-1-(4-methylthiophenyl)propane
DMHCVKJ HS Investigative
DMHCVKJ SN 2-N-Methoxyamino-1-(4-methylthiophenyl)propane; CHEMBL1077961; 1204749-12-1
DMHCVKJ DT Small molecular drug
DMHCVKJ PC 44613193
DMHCVKJ MW 211.33
DMHCVKJ FM C11H17NOS
DMHCVKJ IC InChI=1S/C11H17NOS/c1-9(12-13-2)8-10-4-6-11(14-3)7-5-10/h4-7,9,12H,8H2,1-3H3
DMHCVKJ CS CC(CC1=CC=C(C=C1)SC)NOC
DMHCVKJ IK BWEGTFZAQIVRFB-UHFFFAOYSA-N
DMHCVKJ IU N-methoxy-1-(4-methylsulfanylphenyl)propan-2-amine
DMHCVKJ DE Discovery agent
DM1X5RY ID DM1X5RY
DM1X5RY DN 2-N-Methylamino-1-(4-ethylthiophenyl)propane
DM1X5RY HS Investigative
DM1X5RY SN 2-N-Methylamino-1-(4-ethylthiophenyl)propane; CHEMBL1077872; 1204749-25-6
DM1X5RY DT Small molecular drug
DM1X5RY PC 44613451
DM1X5RY MW 209.35
DM1X5RY FM C12H19NS
DM1X5RY IC InChI=1S/C12H19NS/c1-4-14-12-7-5-11(6-8-12)9-10(2)13-3/h5-8,10,13H,4,9H2,1-3H3
DM1X5RY CS CCSC1=CC=C(C=C1)CC(C)NC
DM1X5RY IK LCGABASJFJNHGF-UHFFFAOYSA-N
DM1X5RY IU 1-(4-ethylsulfanylphenyl)-N-methylpropan-2-amine
DM1X5RY DE Discovery agent
DMCR49K ID DMCR49K
DMCR49K DN 2-N-Methylamino-1-(4-methylthiophenyl)butane
DMCR49K HS Investigative
DMCR49K SN 2-N-Methylamino-1-(4-methylthiophenyl)butane; CHEMBL1078440; 1204749-45-0
DMCR49K DT Small molecular drug
DMCR49K PC 44613575
DMCR49K MW 209.35
DMCR49K FM C12H19NS
DMCR49K IC InChI=1S/C12H19NS/c1-4-11(13-2)9-10-5-7-12(14-3)8-6-10/h5-8,11,13H,4,9H2,1-3H3
DMCR49K CS CCC(CC1=CC=C(C=C1)SC)NC
DMCR49K IK JMLCRWOWZIZAEU-UHFFFAOYSA-N
DMCR49K IU N-methyl-1-(4-methylsulfanylphenyl)butan-2-amine
DMCR49K DE Discovery agent
DMVLX1T ID DMVLX1T
DMVLX1T DN 2-N-Methylamino-1-(4-methylthiophenyl)propane
DMVLX1T HS Investigative
DMVLX1T SN CHEMBL1078038; WWHIYWVWPXXBTC-UHFFFAOYSA-N; BDBM50310855
DMVLX1T DT Small molecular drug
DMVLX1T PC 46882957
DMVLX1T MW 195.33
DMVLX1T FM C11H17NS
DMVLX1T IC InChI=1S/C11H17NS/c1-9(12-2)8-10-4-6-11(13-3)7-5-10/h4-7,9,12H,8H2,1-3H3
DMVLX1T CS CC(CC1=CC=C(C=C1)SC)NC
DMVLX1T IK WWHIYWVWPXXBTC-UHFFFAOYSA-N
DMVLX1T IU N-methyl-1-(4-methylsulfanylphenyl)propan-2-amine
DMVLX1T DE Discovery agent
DMQWR69 ID DMQWR69
DMQWR69 DN 2-NONYL-4-HYDROXYQUINOLINE N-OXIDE
DMQWR69 HS Investigative
DMQWR69 SN QNO; AC1O4QJA
DMQWR69 DT Small molecular drug
DMQWR69 PC 130804
DMQWR69 MW 287.4
DMQWR69 FM C18H25NO2
DMQWR69 IC InChI=1S/C18H25NO2/c1-2-3-4-5-6-7-8-11-15-14-18(20)16-12-9-10-13-17(16)19(15)21/h9-10,12-14,21H,2-8,11H2,1H3
DMQWR69 CS CCCCCCCCCC1=CC(=O)C2=CC=CC=C2N1O
DMQWR69 IK JYFNTDPGDPZMCM-UHFFFAOYSA-N
DMQWR69 IU 1-hydroxy-2-nonylquinolin-4-one
DMQWR69 CA CAS 316-66-5
DMQWR69 DE Discovery agent
DMOGWIK ID DMOGWIK
DMOGWIK DN 2-nonylamido-5-sulfonamidoindane
DMOGWIK HS Investigative
DMOGWIK SN CHEMBL208532; 2-nonylamido-5-sulfonamidoindane; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)decanamide; Indanesulfonamide Derivative 12g
DMOGWIK DT Small molecular drug
DMOGWIK PC 11660633
DMOGWIK MW 366.5
DMOGWIK FM C19H30N2O3S
DMOGWIK IC InChI=1S/C19H30N2O3S/c1-2-3-4-5-6-7-8-9-19(22)21-17-12-15-10-11-18(25(20,23)24)14-16(15)13-17/h10-11,14,17H,2-9,12-13H2,1H3,(H,21,22)(H2,20,23,24)
DMOGWIK CS CCCCCCCCCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMOGWIK IK CWOKTKYGRFERNA-UHFFFAOYSA-N
DMOGWIK IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)decanamide
DMOGWIK DE Discovery agent
DMRXDS2 ID DMRXDS2
DMRXDS2 DN 2np8
DMRXDS2 HS Investigative
DMRXDS2 SN Aurora Kinase Inhibitor III; 879127-16-9; 2np8; N-{3-[(4-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}cyclopropanecarboxamide; CHEMBL383899; Cyclopropanecarboxylic acid-(3-(4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino)-phenyl)-amide; N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide; Anilinopyrimidine1; SCHEMBL676556; GTPL5931; CTK8E9807; DTXSID20429557; MolPort-029-945-855; HMS3229O19; HMS3229A22; K00603a; ZINC13831338; MFCD09265250; IN1527; BDBM50200392
DMRXDS2 DT Small molecular drug
DMRXDS2 PC 9549303
DMRXDS2 MW 413.4
DMRXDS2 FM C21H18F3N5O
DMRXDS2 IC InChI=1S/C21H18F3N5O/c22-21(23,24)14-3-1-4-15(11-14)26-18-9-10-25-20(29-18)28-17-6-2-5-16(12-17)27-19(30)13-7-8-13/h1-6,9-13H,7-8H2,(H,27,30)(H2,25,26,28,29)
DMRXDS2 CS C1CC1C(=O)NC2=CC=CC(=C2)NC3=NC=CC(=N3)NC4=CC=CC(=C4)C(F)(F)F
DMRXDS2 IK RDTDWGQDFJPTPD-UHFFFAOYSA-N
DMRXDS2 IU N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide
DMRXDS2 CA CAS 879127-16-9
DMRXDS2 DE Discovery agent
DMLZCOU ID DMLZCOU
DMLZCOU DN 2-N-Propargylamino-1-(4-methylthiophenyl)butane
DMLZCOU HS Investigative
DMLZCOU SN CHEMBL1077900; 2-N-Propargylamino-1-(4-methylthiophenyl)butane
DMLZCOU DT Small molecular drug
DMLZCOU PC 44613580
DMLZCOU MW 233.37
DMLZCOU FM C14H19NS
DMLZCOU IC InChI=1S/C14H19NS/c1-4-10-15-13(5-2)11-12-6-8-14(16-3)9-7-12/h1,6-9,13,15H,5,10-11H2,2-3H3
DMLZCOU CS CCC(CC1=CC=C(C=C1)SC)NCC#C
DMLZCOU IK LQQBIFPYEKWTOI-UHFFFAOYSA-N
DMLZCOU IU 1-(4-methylsulfanylphenyl)-N-prop-2-ynylbutan-2-amine
DMLZCOU DE Discovery agent
DM9HPG1 ID DM9HPG1
DM9HPG1 DN 2-N-Propargylamino-1-(4-methylthiophenyl)propane
DM9HPG1 HS Investigative
DM9HPG1 SN CHEMBL1079255; 2-N-Propargylamino-1-(4-methylthiophenyl)propane
DM9HPG1 DT Small molecular drug
DM9HPG1 PC 44613068
DM9HPG1 MW 219.35
DM9HPG1 FM C13H17NS
DM9HPG1 IC InChI=1S/C13H17NS/c1-4-9-14-11(2)10-12-5-7-13(15-3)8-6-12/h1,5-8,11,14H,9-10H2,2-3H3
DM9HPG1 CS CC(CC1=CC=C(C=C1)SC)NCC#C
DM9HPG1 IK UPHGABWYFBVICE-UHFFFAOYSA-N
DM9HPG1 IU 1-(4-methylsulfanylphenyl)-N-prop-2-ynylpropan-2-amine
DM9HPG1 DE Discovery agent
DMZK0JV ID DMZK0JV
DMZK0JV DN 2-O-ethyl-PAF C-16
DMZK0JV HS Investigative
DMZK0JV SN 2-O-ethyl-platelet-activating factor C-16
DMZK0JV DT Small molecular drug
DMZK0JV PC 9546625
DMZK0JV MW 510.7
DMZK0JV FM C26H57NO6P+
DMZK0JV IC InChI=1S/C26H56NO6P/c1-6-8-9-10-11-12-13-14-15-16-17-18-19-20-22-30-24-26(31-7-2)25-33-34(28,29)32-23-21-27(3,4)5/h26H,6-25H2,1-5H3/p+1
DMZK0JV CS CCCCCCCCCCCCCCCCOCC(COP(=O)(O)OCC[N+](C)(C)C)OCC
DMZK0JV IK LPHUUVMLQFHHQG-UHFFFAOYSA-O
DMZK0JV IU 2-[(2-ethoxy-3-hexadecoxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
DMZK0JV DE Discovery agent
DM5PXQU ID DM5PXQU
DM5PXQU DN 2-oleoyl glycerol
DM5PXQU HS Investigative
DM5PXQU SN 2-monoolein; 2-oleoyl-glycerol; 2-oleoylglycerol (2OG)
DM5PXQU DT Small molecular drug
DM5PXQU PC 5319879
DM5PXQU MW 356.5
DM5PXQU FM C21H40O4
DM5PXQU IC InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-20(18-22)19-23/h9-10,20,22-23H,2-8,11-19H2,1H3/b10-9-
DM5PXQU CS CCCCCCCC/C=C\\CCCCCCCC(=O)OC(CO)CO
DM5PXQU IK UPWGQKDVAURUGE-KTKRTIGZSA-N
DM5PXQU IU 1,3-dihydroxypropan-2-yl (Z)-octadec-9-enoate
DM5PXQU CA CAS 3443-84-3
DM5PXQU CB CHEBI:73990
DM5PXQU DE Discovery agent
DMN9OS1 ID DMN9OS1
DMN9OS1 DN 2-oleoyl-LPA
DMN9OS1 HS Investigative
DMN9OS1 SN 2-acyl-1LPA; 2Acyl-LPA
DMN9OS1 DT Small molecular drug
DMN9OS1 PC 56947016
DMN9OS1 MW 436.5
DMN9OS1 FM C21H41O7P
DMN9OS1 IC InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)28-20(18-22)19-27-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-
DMN9OS1 CS CCCCCCCC/C=C\\CCCCCCCC(=O)OC(CO)COP(=O)(O)O
DMN9OS1 IK ZOOLJLSXNRZLDH-KTKRTIGZSA-N
DMN9OS1 IU (1-hydroxy-3-phosphonooxypropan-2-yl) (Z)-octadec-9-enoate
DMN9OS1 DE Discovery agent
DMO6JRW ID DMO6JRW
DMO6JRW DN 2'-O-Methyl G-Clamp Containing Oligonucleotides
DMO6JRW HS Investigative
DMO6JRW DE Discovery agent
DME7K64 ID DME7K64
DME7K64 DN 2-O-methyl-PAF C-18
DME7K64 HS Investigative
DME7K64 SN 2-O-methyl-platelet-activating factor C-18; 2-methyl-C18-PAF; 2-methyloctadecyl PAF
DME7K64 DT Small molecular drug
DME7K64 PC 132181
DME7K64 MW 565.8
DME7K64 FM C29H60NO7P
DME7K64 IC InChI=1S/C29H60NO7P/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(2)24-34-25-29(37-28(3)31)26-36-38(32,33)35-23-22-30(4,5)6/h27,29H,7-26H2,1-6H3
DME7K64 CS CCCCCCCCCCCCCCCCC(C)COCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C
DME7K64 IK CIVAIADZNGBFHP-UHFFFAOYSA-N
DME7K64 IU [2-acetyloxy-3-(2-methyloctadecoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
DME7K64 CA CAS 138852-22-9
DME7K64 DE Discovery agent
DM2NEX4 ID DM2NEX4
DM2NEX4 DN 2-Oxa-spiro[4.4]nonan-1-one
DM2NEX4 HS Investigative
DM2NEX4 SN 2-Oxaspiro[4.4]nonan-1-one; 5732-98-9; 2-oxaspiro[4,4]nonan-1-one; CHEMBL330370; SCHEMBL11055887; CTK1H4141; DTXSID90574422; MolPort-028-950-793; ZINC13734068
DM2NEX4 DT Small molecular drug
DM2NEX4 PC 15566992
DM2NEX4 MW 140.18
DM2NEX4 FM C8H12O2
DM2NEX4 IC InChI=1S/C8H12O2/c9-7-8(5-6-10-7)3-1-2-4-8/h1-6H2
DM2NEX4 CS C1CCC2(C1)CCOC2=O
DM2NEX4 IK PBZONIMHAVOWHW-UHFFFAOYSA-N
DM2NEX4 IU 2-oxaspiro[4.4]nonan-1-one
DM2NEX4 CA CAS 5732-98-9
DM2NEX4 DE Discovery agent
DMFN769 ID DMFN769
DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid
DMFN769 HS Investigative
DMFN769 SN Coumarin-3-carboxylic acid; 531-81-7; 2-Oxo-2H-chromene-3-carboxylic acid; 3-Carboxycoumarin; 2-Oxochromene-3-carboxylic acid; 2-Oxobenzopyran-3-carboxylic acid; G 1 (rodenticide); 2H-1-BENZOPYRAN-3-CARBOXYLIC ACID, 2-OXO-; 2-Oxo-2H-1-benzopyran-3-carboxylic acid; UNII-V85UOV8788; G 1 (VAN); G 1 (The rodenticide) (VAN); EINECS 208-518-0; NSC 14797; NSC 53239; BRN 0154276; CHEMBL83294; Malonic acid, salicylidene-, delta-lactone; AI3-36066; ACMLKANOGIVEPB-UHFFFAOYSA-N; V85UOV8788; NSC53239; MFCD00006852; G 1 (The rodenticide); WLN:
DMFN769 DT Small molecular drug
DMFN769 PC 10752
DMFN769 MW 190.15
DMFN769 FM C10H6O4
DMFN769 IC InChI=1S/C10H6O4/c11-9(12)7-5-6-3-1-2-4-8(6)14-10(7)13/h1-5H,(H,11,12)
DMFN769 CS C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)O
DMFN769 IK ACMLKANOGIVEPB-UHFFFAOYSA-N
DMFN769 IU 2-oxochromene-3-carboxylic acid
DMFN769 CA CAS 531-81-7
DMFN769 DE Discovery agent
DMZTCOM ID DMZTCOM
DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid
DMZTCOM HS Investigative
DMZTCOM SN 2-oxo-2H-thiochromene-3-carboxylic acid; CHEMBL571519; 66253-08-5; SCHEMBL7679158
DMZTCOM DT Small molecular drug
DMZTCOM PC 12394434
DMZTCOM MW 206.22
DMZTCOM FM C10H6O3S
DMZTCOM IC InChI=1S/C10H6O3S/c11-9(12)7-5-6-3-1-2-4-8(6)14-10(7)13/h1-5H,(H,11,12)
DMZTCOM CS C1=CC=C2C(=C1)C=C(C(=O)S2)C(=O)O
DMZTCOM IK CIMFYGICTNZOPT-UHFFFAOYSA-N
DMZTCOM IU 2-oxothiochromene-3-carboxylic acid
DMZTCOM DE Discovery agent
DM3UY74 ID DM3UY74
DM3UY74 DN 2-oxoguaia-1,4(15), 11(13)-trien-12,8beta-olide
DM3UY74 HS Investigative
DM3UY74 SN CHEMBL189428
DM3UY74 DT Small molecular drug
DM3UY74 PC 44398330
DM3UY74 MW 244.28
DM3UY74 FM C15H16O3
DM3UY74 IC InChI=1S/C15H16O3/c1-7-4-14-12(9(3)15(17)18-14)5-11-8(2)13(16)6-10(7)11/h6-7,11-12,14H,2-5H2,1H3/t7-,11-,12+,14-/m0/s1
DM3UY74 CS C[C@H]1C[C@H]2[C@H](C[C@@H]3C1=CC(=O)C3=C)C(=C)C(=O)O2
DM3UY74 IK RVBPAMCSEVHKLO-MZZAWFPRSA-N
DM3UY74 IU (3aS,5S,8aR,9aR)-5-methyl-1,8-dimethylidene-3a,4,5,8a,9,9a-hexahydroazuleno[6,5-b]furan-2,7-dione
DM3UY74 DE Discovery agent
DM23WOV ID DM23WOV
DM23WOV DN 2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide
DM23WOV HS Investigative
DM23WOV SN CHEMBL191179
DM23WOV DT Small molecular drug
DM23WOV PC 44398347
DM23WOV MW 244.28
DM23WOV FM C15H16O3
DM23WOV IC InChI=1S/C15H16O3/c1-7-4-14-12(9(3)15(17)18-14)5-11-8(2)13(16)6-10(7)11/h6-7,11-12,14H,2-5H2,1H3/t7-,11-,12+,14+/m0/s1
DM23WOV CS C[C@H]1C[C@@H]2[C@H](C[C@@H]3C1=CC(=O)C3=C)C(=C)C(=O)O2
DM23WOV IK RVBPAMCSEVHKLO-LWZBDFBTSA-N
DM23WOV IU (3aR,5S,8aR,9aR)-5-methyl-1,8-dimethylidene-3a,4,5,8a,9,9a-hexahydroazuleno[6,5-b]furan-2,7-dione
DM23WOV DE Discovery agent
DMDKSZ0 ID DMDKSZ0
DMDKSZ0 DN 2-oxo-N-m-tolyl-2H-chromene-3-carboxamide
DMDKSZ0 HS Investigative
DMDKSZ0 SN 1846-99-7; 2-oxo-N-(m-tolyl)-2H-chromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid m-tolylamide; N-(3-Methylphenyl)-2-oxo-2H-chromene-3-carboxamide; AC1LCCPQ; BAS 00837918; AC1Q2NKJ; 3-carboxamido coumarin, 8; TimTec1_006709; Oprea1_808053; Oprea1_256730; CBDivE_000076; MLS001209245; CHEMBL445184; SCHEMBL6228552; BDBM29158; 2h-1-benzopyran-3-carboxamide,n-(3-methylphenyl)-2-oxo-; MolPort-000-375-220; XUNAVIWFCXQWCJ-UHFFFAOYSA-N; HMS2825F09; HMS1553A21; ZINC130233; N-(m-Tolyl)-3-coumarincarboxamide; STK408207
DMDKSZ0 DT Small molecular drug
DMDKSZ0 PC 599289
DMDKSZ0 MW 279.29
DMDKSZ0 FM C17H13NO3
DMDKSZ0 IC InChI=1S/C17H13NO3/c1-11-5-4-7-13(9-11)18-16(19)14-10-12-6-2-3-8-15(12)21-17(14)20/h2-10H,1H3,(H,18,19)
DMDKSZ0 CS CC1=CC(=CC=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMDKSZ0 IK XUNAVIWFCXQWCJ-UHFFFAOYSA-N
DMDKSZ0 IU N-(3-methylphenyl)-2-oxochromene-3-carboxamide
DMDKSZ0 DE Discovery agent
DMH8QWY ID DMH8QWY
DMH8QWY DN 2-oxo-N-phenyl-2H-chromene-3-carboxamide
DMH8QWY HS Investigative
DMH8QWY SN 2-oxo-N-phenyl-2H-chromene-3-carboxamide; NSC375104; 2-oxo-N-phenylchromene-3-carboxamide; 54396-25-7; AC1L7UQ9; Oprea1_247443; Oprea1_472798; CBDivE_011982; JMC521935 Compound 6; SCHEMBL831792; IFLab1_001129; CHEMBL494795; NIOSH/DJ2267500; Coumarin, 3-(anilinocarbonyl)-; BDBM23543; ZINC42178; DTXSID80321427; MolPort-000-375-218; HMS1415D07; (2-oxochromen-3-yl)-N-benzamide; 3-Carboxamide-coumarin deriv., 18; STK337557; AKOS000511884; 2-oxo-N-phenyl-chromene-3-carboxamide; NSC-375104; MCULE-7275389335; IDI1_008996
DMH8QWY DT Small molecular drug
DMH8QWY PC 341782
DMH8QWY MW 265.26
DMH8QWY FM C16H11NO3
DMH8QWY IC InChI=1S/C16H11NO3/c18-15(17-12-7-2-1-3-8-12)13-10-11-6-4-5-9-14(11)20-16(13)19/h1-10H,(H,17,18)
DMH8QWY CS C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMH8QWY IK IMFBGZCBLOPVCJ-UHFFFAOYSA-N
DMH8QWY IU 2-oxo-N-phenylchromene-3-carboxamide
DMH8QWY CA CAS 54396-25-7
DMH8QWY DE Discovery agent
DMWXI6C ID DMWXI6C
DMWXI6C DN 2-oxo-N-p-tolyl-2H-chromene-3-carboxamide
DMWXI6C HS Investigative
DMWXI6C SN 1847-00-3; N-(4-Methylphenyl)-2-oxo-2H-chromene-3-carboxamide; AC1LCCPS; BAS 00837919; Oprea1_724223; Oprea1_384928; 3-carboxamido coumarin, 12; CBDivE_000120; CHEMBL512843; AC1Q2M91; ZINC59647; BDBM29162; 2h-1-benzopyran-3-carboxamide,n-(4-methylphenyl)-2-oxo-; MolPort-000-375-219; RYYPYTSGWXNKDU-UHFFFAOYSA-N; N-(p-Tolyl)coumarin-3-carboxamide; N-(p-Tolyl)-3-coumarincarboxamide; STK709419; AKOS000533534; MCULE-3147355051; ST4011307; KB-284700; EU-0034745; 2-oxo-N-(p-tolyl)-2H-chromene-3-carboxamide
DMWXI6C DT Small molecular drug
DMWXI6C PC 599290
DMWXI6C MW 279.29
DMWXI6C FM C17H13NO3
DMWXI6C IC InChI=1S/C17H13NO3/c1-11-6-8-13(9-7-11)18-16(19)14-10-12-4-2-3-5-15(12)21-17(14)20/h2-10H,1H3,(H,18,19)
DMWXI6C CS CC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMWXI6C IK RYYPYTSGWXNKDU-UHFFFAOYSA-N
DMWXI6C IU N-(4-methylphenyl)-2-oxochromene-3-carboxamide
DMWXI6C DE Discovery agent
DMDMK81 ID DMDMK81
DMDMK81 DN 2-Oxoolean-12-en-28-oic acid
DMDMK81 HS Investigative
DMDMK81 SN CHEMBL1081876; 2-Oxoolean-12-en-28-oic acid; 2-Oxooleana-12-ene-28-oic acid
DMDMK81 DT Small molecular drug
DMDMK81 PC 44254075
DMDMK81 MW 454.7
DMDMK81 FM C30H46O3
DMDMK81 IC InChI=1S/C30H46O3/c1-25(2)12-14-30(24(32)33)15-13-28(6)20(21(30)18-25)8-9-23-27(5)17-19(31)16-26(3,4)22(27)10-11-29(23,28)7/h8,21-23H,9-18H2,1-7H3,(H,32,33)/t21-,22-,23+,27-,28+,29+,30-/m0/s1
DMDMK81 CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(CC(=O)CC3(C)C)C
DMDMK81 IK RHPBUWJZKONKCT-CDNBJWEZSA-N
DMDMK81 IU (4aS,6aR,6aS,6bR,8aS,12aS,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-11-oxo-3,4,5,6,6a,7,8,8a,10,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
DMDMK81 DE Discovery agent
DMZ9NCA ID DMZ9NCA
DMZ9NCA DN 2-pentafluorophenylamido-5-sulfonamidoindane
DMZ9NCA HS Investigative
DMZ9NCA SN CHEMBL184361; 2-pentafluorophenylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12c; BDBM11035
DMZ9NCA DT Small molecular drug
DMZ9NCA PC 11718391
DMZ9NCA MW 406.3
DMZ9NCA FM C16H11F5N2O3S
DMZ9NCA IC InChI=1S/C16H11F5N2O3S/c17-11-10(12(18)14(20)15(21)13(11)19)16(24)23-8-3-6-1-2-9(27(22,25)26)5-7(6)4-8/h1-2,5,8H,3-4H2,(H,23,24)(H2,22,25,26)
DMZ9NCA CS C1C(CC2=C1C=CC(=C2)S(=O)(=O)N)NC(=O)C3=C(C(=C(C(=C3F)F)F)F)F
DMZ9NCA IK DTWDCDSAKWSSGY-UHFFFAOYSA-N
DMZ9NCA IU 2,3,4,5,6-pentafluoro-N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)benzamide
DMZ9NCA DE Discovery agent
DM032YM ID DM032YM
DM032YM DN 2-pentenal
DM032YM HS Investigative
DM032YM SN trans-2-Pentenal; 2-PENTENAL; 1576-87-0; (E)-2-Pentenal; (E)-pent-2-enal; 3-Ethylacrolein; 764-39-6; pent-2-enal; 2-Pentenal, (E)-; 2-(E)-Pentenal; 3-Ethyl-2-propenal; (E)-Pent-2-en-1-al; gamma-Methylcrotonaldehyde; 2-Penten-1-al; trans-2-Penten-1-al; UNII-7A4R3CQA2T; FEMA No. 3218; CCRIS 3514; CCRIS 4564; Pentenal, (E)-; 2-Ethylacrylic aldehyde; (E)-2-penten-1-al; EINECS 212-120-2; EINECS 216-414-1; BRN 1719742; 7A4R3CQA2T; CHEMBL256368; DTCCTIQRPGSLPT-ONEGZZNKSA-N; MFCD00009615; trans-2-Pentenal, 97%; Propylidenacetaldehyd
DM032YM DT Small molecular drug
DM032YM PC 5364752
DM032YM MW 84.12
DM032YM FM C5H8O
DM032YM IC InChI=1S/C5H8O/c1-2-3-4-5-6/h3-5H,2H2,1H3/b4-3+
DM032YM CS CC/C=C/C=O
DM032YM IK DTCCTIQRPGSLPT-ONEGZZNKSA-N
DM032YM IU (E)-pent-2-enal
DM032YM CA CAS 1576-87-0
DM032YM CB CHEBI:61722
DM032YM DE Discovery agent
DM0WMBC ID DM0WMBC
DM0WMBC DN 2-Phenethyl-1,2-dihydro-indazol-3-one
DM0WMBC HS Investigative
DM0WMBC SN CHEMBL3144586; 2-Phenethyl-1,2-dihydro-indazol-3-one; CHEMBL8415; BDBM50009007; ZINC138045731
DM0WMBC DT Small molecular drug
DM0WMBC PC 14898714
DM0WMBC MW 238.28
DM0WMBC FM C15H14N2O
DM0WMBC IC InChI=1S/C15H14N2O/c18-15-13-8-4-5-9-14(13)16-17(15)11-10-12-6-2-1-3-7-12/h1-9,16H,10-11H2
DM0WMBC CS C1=CC=C(C=C1)CCN2C(=O)C3=CC=CC=C3N2
DM0WMBC IK HCKFBGZZOSOLAC-UHFFFAOYSA-N
DM0WMBC IU 2-(2-phenylethyl)-1H-indazol-3-one
DM0WMBC DE Discovery agent
DM4H6PC ID DM4H6PC
DM4H6PC DN 2-Phenethyl-4,5-dihydro-1H-imidazole
DM4H6PC HS Investigative
DM4H6PC SN beta-Phenylethylimidazoline; 2-Phenethyl-2-imidazoline; 2-IMIDAZOLINE, 2-PHENETHYL-; BRN 0129593; 1H-Imidazole, 4,5-dihydro-2-(2-phenylethyl)-; 26038-62-0; 2-Phenethyl-4,5-dihydro-1H-imidazole; CHEMBL14210; 2-(beta-Phenylaethyl)imidazolin [German]; Phenyzoline; 2-(beta-Phenylaethyl)imidazolin; 2-Phenethyl-1-imidazoline; AC1L1PA8; 5-23-07-00011 (Beilstein Handbook Reference); SCHEMBL3172677; DTXSID30180682; BDBM50138499; AKOS022535828; LS-79674
DM4H6PC DT Small molecular drug
DM4H6PC PC 33273
DM4H6PC MW 174.24
DM4H6PC FM C11H14N2
DM4H6PC IC InChI=1S/C11H14N2/c1-2-4-10(5-3-1)6-7-11-12-8-9-13-11/h1-5H,6-9H2,(H,12,13)
DM4H6PC CS C1CN=C(N1)CCC2=CC=CC=C2
DM4H6PC IK CPMMXSDLEOJRHI-UHFFFAOYSA-N
DM4H6PC IU 2-(2-phenylethyl)-4,5-dihydro-1H-imidazole
DM4H6PC CA CAS 26038-62-0
DM4H6PC DE Discovery agent
DMPWG21 ID DMPWG21
DMPWG21 DN 2-phenethylisoquinoline-1,3,4-trione
DMPWG21 HS Investigative
DMPWG21 SN 2-phenethylisoquinoline-1,3,4-trione; CHEMBL382860; SCHEMBL13442858; Isoquinoline-1,3,4-trione 2d; BDBM10251; CTK7H5068; AKOS015966189; 2-PHENETHYL-ISOQUINOLINE-1,3,4-TRIONE
DMPWG21 DT Small molecular drug
DMPWG21 PC 11652039
DMPWG21 MW 279.29
DMPWG21 FM C17H13NO3
DMPWG21 IC InChI=1S/C17H13NO3/c19-15-13-8-4-5-9-14(13)16(20)18(17(15)21)11-10-12-6-2-1-3-7-12/h1-9H,10-11H2
DMPWG21 CS C1=CC=C(C=C1)CCN2C(=O)C3=CC=CC=C3C(=O)C2=O
DMPWG21 IK QORWHUYLLGKESS-UHFFFAOYSA-N
DMPWG21 IU 2-(2-phenylethyl)isoquinoline-1,3,4-trione
DMPWG21 DE Discovery agent
DMQX7FW ID DMQX7FW
DMQX7FW DN 2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone
DMQX7FW HS Investigative
DMQX7FW SN CHEMBL217530
DMQX7FW DT Small molecular drug
DMQX7FW PC 44418202
DMQX7FW MW 313.4
DMQX7FW FM C18H19NO2S
DMQX7FW IC InChI=1S/C18H19NO2S/c1-14-7-9-15(10-8-14)18-19(11-12-22-18)17(20)13-21-16-5-3-2-4-6-16/h2-10,18H,11-13H2,1H3
DMQX7FW CS CC1=CC=C(C=C1)C2N(CCS2)C(=O)COC3=CC=CC=C3
DMQX7FW IK MHEJSTGXKATLNP-UHFFFAOYSA-N
DMQX7FW IU 1-[2-(4-methylphenyl)-1,3-thiazolidin-3-yl]-2-phenoxyethanone
DMQX7FW DE Discovery agent
DM6JNT5 ID DM6JNT5
DM6JNT5 DN 2-phenoxy-3-(piperidin-4-yl)pyridine
DM6JNT5 HS Investigative
DM6JNT5 SN CHEMBL608148; 2-phenoxy-3-(piperidin-4-yl)pyridine; SCHEMBL4013368
DM6JNT5 DT Small molecular drug
DM6JNT5 PC 44133490
DM6JNT5 MW 254.33
DM6JNT5 FM C16H18N2O
DM6JNT5 IC InChI=1S/C16H18N2O/c1-2-5-14(6-3-1)19-16-15(7-4-10-18-16)13-8-11-17-12-9-13/h1-7,10,13,17H,8-9,11-12H2
DM6JNT5 CS C1CNCCC1C2=C(N=CC=C2)OC3=CC=CC=C3
DM6JNT5 IK LKVOLTSPLLAMPJ-UHFFFAOYSA-N
DM6JNT5 IU 2-phenoxy-3-piperidin-4-ylpyridine
DM6JNT5 DE Discovery agent
DM5E74G ID DM5E74G
DM5E74G DN 2-Phenoxymethyl-4,5-dihydro-1H-imidazole
DM5E74G HS Investigative
DM5E74G SN 2-(phenoxymethyl)-4,5-dihydro-1H-imidazole; CHEMBL14640; 43111-36-0; SCHEMBL546875; 2-(Phenoxymethyl)-2-imidazoline; BDBM50179395; AKOS006278066; 1H-Imidazole, 4,5-dihydro-2-(phenoxymethyl)-
DM5E74G DT Small molecular drug
DM5E74G PC 10442227
DM5E74G MW 176.21
DM5E74G FM C10H12N2O
DM5E74G IC InChI=1S/C10H12N2O/c1-2-4-9(5-3-1)13-8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)
DM5E74G CS C1CN=C(N1)COC2=CC=CC=C2
DM5E74G IK GRMJZZBFHKTYDJ-UHFFFAOYSA-N
DM5E74G IU 2-(phenoxymethyl)-4,5-dihydro-1H-imidazole
DM5E74G CA CAS 43111-36-0
DM5E74G DE Discovery agent
DMERNSK ID DMERNSK
DMERNSK DN 2-phenyl-1,1-di(pyridin-3-yl)ethanol
DMERNSK HS Investigative
DMERNSK SN CHEMBL1088805; 2-phenyl-1,1-di(pyridin-3-yl)ethanol; SCHEMBL4336663
DMERNSK DT Small molecular drug
DMERNSK PC 46885546
DMERNSK MW 276.3
DMERNSK FM C18H16N2O
DMERNSK IC InChI=1S/C18H16N2O/c21-18(16-8-4-10-19-13-16,17-9-5-11-20-14-17)12-15-6-2-1-3-7-15/h1-11,13-14,21H,12H2
DMERNSK CS C1=CC=C(C=C1)CC(C2=CN=CC=C2)(C3=CN=CC=C3)O
DMERNSK IK ISJDJRMNDVLGMU-UHFFFAOYSA-N
DMERNSK IU 2-phenyl-1,1-dipyridin-3-ylethanol
DMERNSK DE Discovery agent
DM28CLZ ID DM28CLZ
DM28CLZ DN 2-Phenyl-1,2-dihydro-indazol-3-one
DM28CLZ HS Investigative
DM28CLZ SN 3-Indazolinone, 2-phenyl-; 2-phenyl-1H-indazol-3-one; 17049-65-9; MLS-0315919.0001; CHEMBL412902; 2-phenylindazolone; NSC34813; 2-Phenyl-1,2-dihydro-indazol-3-one; 2-phenylindazolin-3-one; 3H-Indazol-3-one, 1,2-dihydro-2-phenyl-; AC1L91HU; cid_411519; SCHEMBL2438599; CHEMBL1719803; BDBM46671; DTXSID20328536; CFNJFZDGHGYAMU-UHFFFAOYSA-N; NSC-34813; ZINC84460115; AKOS023543908; 3H-Indazol-3-one,2-dihydro-2-phenyl-; 1,2-Dihydro-2-phenyl-3H-indazol-3-one; 2-Phenyl-1,2-dihydro-3H-indazol-3-one #
DM28CLZ DT Small molecular drug
DM28CLZ PC 411519
DM28CLZ MW 210.23
DM28CLZ FM C13H10N2O
DM28CLZ IC InChI=1S/C13H10N2O/c16-13-11-8-4-5-9-12(11)14-15(13)10-6-2-1-3-7-10/h1-9,14H
DM28CLZ CS C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3N2
DM28CLZ IK CFNJFZDGHGYAMU-UHFFFAOYSA-N
DM28CLZ IU 2-phenyl-1H-indazol-3-one
DM28CLZ CA CAS 17049-65-9
DM28CLZ DE Discovery agent
DMP8G3C ID DMP8G3C
DMP8G3C DN 2-phenyl-1,2'-spirobi[1H-indene]-5'-ol
DMP8G3C HS Investigative
DMP8G3C SN CHEMBL439806; SCHEMBL6283895; BDBM50123212; 2-phenyl-1,2''-spirobi[1H-indene]-5''-ol
DMP8G3C DT Small molecular drug
DMP8G3C PC 12133211
DMP8G3C MW 310.4
DMP8G3C FM C23H18O
DMP8G3C IC InChI=1S/C23H18O/c24-20-11-10-18-14-23(15-19(18)12-20)21-9-5-4-8-17(21)13-22(23)16-6-2-1-3-7-16/h1-13,24H,14-15H2
DMP8G3C CS C1C2=C(CC13C4=CC=CC=C4C=C3C5=CC=CC=C5)C=C(C=C2)O
DMP8G3C IK SGBUUCIHANKAQI-UHFFFAOYSA-N
DMP8G3C IU 2'-phenylspiro[1,3-dihydroindene-2,1'-indene]-5-ol
DMP8G3C DE Discovery agent
DM3WOHI ID DM3WOHI
DM3WOHI DN 2-phenyl-1,8-naphthyridine
DM3WOHI HS Investigative
DM3WOHI SN 2-phenyl-1,8-naphthyridine; CHEMBL235396; SKVWGHJCDNDXAG-UHFFFAOYSA-N; SCHEMBL5309600; 1,8-Naphthyridine, 2-phenyl-; ZINC28826013
DM3WOHI DT Small molecular drug
DM3WOHI PC 12333592
DM3WOHI MW 206.24
DM3WOHI FM C14H10N2
DM3WOHI IC InChI=1S/C14H10N2/c1-2-5-11(6-3-1)13-9-8-12-7-4-10-15-14(12)16-13/h1-10H
DM3WOHI CS C1=CC=C(C=C1)C2=NC3=C(C=CC=N3)C=C2
DM3WOHI IK SKVWGHJCDNDXAG-UHFFFAOYSA-N
DM3WOHI IU 2-phenyl-1,8-naphthyridine
DM3WOHI DE Discovery agent
DMDC6XP ID DMDC6XP
DMDC6XP DN 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine
DMDC6XP HS Investigative
DMDC6XP SN CHEMBL276138; 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine; ZINC13821064; BDBM50011597
DMDC6XP DT Small molecular drug
DMDC6XP PC 14896622
DMDC6XP MW 260.29
DMDC6XP FM C16H12N4
DMDC6XP IC InChI=1S/C16H12N4/c17-15-14-13(11-8-4-5-9-12(11)18-15)19-16(20-14)10-6-2-1-3-7-10/h1-9H,(H2,17,18)(H,19,20)
DMDC6XP CS C1=CC=C(C=C1)C2=NC3=C(N2)C(=NC4=CC=CC=C43)N
DMDC6XP IK IBRIUJBAFMFSDF-UHFFFAOYSA-N
DMDC6XP IU 2-phenyl-3H-imidazo[4,5-c]quinolin-4-amine
DMDC6XP DE Discovery agent
DMZI7O1 ID DMZI7O1
DMZI7O1 DN 2-phenyl-1H-imidazole-4-carboxylic acid
DMZI7O1 HS Investigative
DMZI7O1 SN 2-Phenyl-1H-imidazole-4-carboxylic acid; 77498-98-7; 2-phenyl-1H-imidazole-5-carboxylic acid; 1H-Imidazole-5-carboxylic acid, 2-phenyl-; CHEMBL1232889; 1H-Imidazole-4-carboxylic acid, 2-phenyl-; UNII-HGH57KDY8T; HGH57KDY8T; 2-phenylimidazole-4-carboxylic acid; G14; 2-phenyl-3H-imidazole-4-carboxylic Acid; AC1MC8EL; SCHEMBL1080850; CTK4I4538; CTK2I0991; XCAXKZJNJCKTQH-UHFFFAOYSA-N; MolPort-000-146-264; HMS3604D08; ZINC164985; CS-D0591; ALBB-012261; CP-011; BDBM50329857; STK897779; ANW-57703; AKOS007930827; AKOS005173647; NE61009
DMZI7O1 DT Small molecular drug
DMZI7O1 PC 2738139
DMZI7O1 MW 188.18
DMZI7O1 FM C10H8N2O2
DMZI7O1 IC InChI=1S/C10H8N2O2/c13-10(14)8-6-11-9(12-8)7-4-2-1-3-5-7/h1-6H,(H,11,12)(H,13,14)
DMZI7O1 CS C1=CC=C(C=C1)C2=NC=C(N2)C(=O)O
DMZI7O1 IK XCAXKZJNJCKTQH-UHFFFAOYSA-N
DMZI7O1 IU 2-phenyl-1H-imidazole-5-carboxylic acid
DMZI7O1 CA CAS 77498-98-7
DMZI7O1 DE Discovery agent
DMRNZ4X ID DMRNZ4X
DMRNZ4X DN 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one
DMRNZ4X HS Investigative
DMRNZ4X SN ALPHA-NAPHTHOFLAVANONE; 2-phenyl-2H-benzo[h]chromen-4(3H)-one; CHEMBL404225; 6051-86-1; 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one; SCHEMBL14027636; BDBM50345186; FT-0758804; 2-Phenyl-2H-naphtho[1,2-b]pyran-4(3H)-one
DMRNZ4X DT Small molecular drug
DMRNZ4X PC 9898204
DMRNZ4X MW 274.3
DMRNZ4X FM C19H14O2
DMRNZ4X IC InChI=1S/C19H14O2/c20-17-12-18(14-7-2-1-3-8-14)21-19-15-9-5-4-6-13(15)10-11-16(17)19/h1-11,18H,12H2
DMRNZ4X CS C1C(OC2=C(C1=O)C=CC3=CC=CC=C32)C4=CC=CC=C4
DMRNZ4X IK QEVIKVQRCYXXSA-UHFFFAOYSA-N
DMRNZ4X IU 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one
DMRNZ4X DE Discovery agent
DMTSBJL ID DMTSBJL
DMTSBJL DN 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide
DMTSBJL HS Investigative
DMTSBJL SN CHEMBL1096560; 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide; SCHEMBL2265205
DMTSBJL DT Small molecular drug
DMTSBJL PC 44549505
DMTSBJL MW 238.24
DMTSBJL FM C13H10N4O
DMTSBJL IC InChI=1S/C13H10N4O/c14-13(18)10-7-4-8-11-12(10)16-17(15-11)9-5-2-1-3-6-9/h1-8H,(H2,14,18)
DMTSBJL CS C1=CC=C(C=C1)N2N=C3C=CC=C(C3=N2)C(=O)N
DMTSBJL IK LALFCNWFYNSGHS-UHFFFAOYSA-N
DMTSBJL IU 2-phenylbenzotriazole-4-carboxamide
DMTSBJL DE Discovery agent
DM8HSMU ID DM8HSMU
DM8HSMU DN 2-phenyl-2H-indazole-7-carboxamide
DM8HSMU HS Investigative
DM8HSMU SN 2-phenyl-2H-indazole-7-carboxamide; CHEMBL594298; SCHEMBL1422404; BDBM50306166
DM8HSMU DT Small molecular drug
DM8HSMU PC 44549251
DM8HSMU MW 237.26
DM8HSMU FM C14H11N3O
DM8HSMU IC InChI=1S/C14H11N3O/c15-14(18)12-8-4-5-10-9-17(16-13(10)12)11-6-2-1-3-7-11/h1-9H,(H2,15,18)
DM8HSMU CS C1=CC=C(C=C1)N2C=C3C=CC=C(C3=N2)C(=O)N
DM8HSMU IK MWXFYWRQDSMARJ-UHFFFAOYSA-N
DM8HSMU IU 2-phenylindazole-7-carboxamide
DM8HSMU DE Discovery agent
DMFE2R1 ID DMFE2R1
DMFE2R1 DN 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DMFE2R1 HS Investigative
DMFE2R1 SN 2-phenyl-2,5-dihydro-4H-pyrazolo[3,4-c]quinolin-4-one; 109740-09-2; CHEMBL241987; 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one; 2-phenyl-2H,4H,5H-pyrazolo[3,4-c]quinolin-4-one; AC1NLR9L; AC1Q6GQQ; 2-phenyl-5H-pyrazolo[3,4-c]quinolin-4-one; MLS001176701; SCHEMBL728937; cid_4962866; CTK7H0251; DTXSID10407182; ISMLHIIGSRUCOQ-UHFFFAOYSA-N; MolPort-002-469-503; HMS2920J03; HMS1784C01; ZINC3888482; BDBM50218922; AKOS027391050; NE38059; MCULE-7237346858; SMR000595674; EN300-14160; SR-01000074278; SR-01000074278-1; J-002324
DMFE2R1 DT Small molecular drug
DMFE2R1 PC 4962866
DMFE2R1 MW 261.279
DMFE2R1 FM C16H11N3O
DMFE2R1 IC InChI=1S/C16H11N3O/c20-16-15-13(12-8-4-5-9-14(12)17-16)10-19(18-15)11-6-2-1-3-7-11/h1-10H,(H,17,20)
DMFE2R1 CS C1=CC=C(C=C1)N2C=C3C4=CC=CC=C4NC(=O)C3=N2
DMFE2R1 IK ISMLHIIGSRUCOQ-UHFFFAOYSA-N
DMFE2R1 IU 2-phenyl-5H-pyrazolo[3,4-c]quinolin-4-one
DMFE2R1 CA CAS 109740-09-2
DMFE2R1 DE Discovery agent
DM5WOSM ID DM5WOSM
DM5WOSM DN 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM5WOSM HS Investigative
DM5WOSM SN CHEMBL320805; 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine; BDBM50091117; 2-Phenyl-2H-pyrazolo[3,4-c]quinoline-4-amine
DM5WOSM DT Small molecular drug
DM5WOSM PC 10491577
DM5WOSM MW 260.29
DM5WOSM FM C16H12N4
DM5WOSM IC InChI=1S/C16H12N4/c17-16-15-13(12-8-4-5-9-14(12)18-16)10-20(19-15)11-6-2-1-3-7-11/h1-10H,(H2,17,18)
DM5WOSM CS C1=CC=C(C=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
DM5WOSM IK MVHJGGYPZDDBQV-UHFFFAOYSA-N
DM5WOSM IU 2-phenylpyrazolo[3,4-c]quinolin-4-amine
DM5WOSM DE Discovery agent
DMAHI7G ID DMAHI7G
DMAHI7G DN 2-Phenyl-2H-pyrazolo[4,3-c]quinoline
DMAHI7G HS Investigative
DMAHI7G SN 2-Phenyl-2H-pyrazolo[4,3-c]quinoline; CHEMBL190111; ZINC13648697
DMAHI7G DT Small molecular drug
DMAHI7G PC 11470612
DMAHI7G MW 245.28
DMAHI7G FM C16H11N3
DMAHI7G IC InChI=1S/C16H11N3/c1-2-6-13(7-3-1)19-11-12-10-17-15-9-5-4-8-14(15)16(12)18-19/h1-11H
DMAHI7G CS C1=CC=C(C=C1)N2C=C3C=NC4=CC=CC=C4C3=N2
DMAHI7G IK GUVLEBBZKMQLIY-UHFFFAOYSA-N
DMAHI7G IU 2-phenylpyrazolo[4,3-c]quinoline
DMAHI7G DE Discovery agent
DMQXCIK ID DMQXCIK
DMQXCIK DN 2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
DMQXCIK HS Investigative
DMQXCIK DT Small molecular drug
DMQXCIK PC 135911551
DMQXCIK MW 212.21
DMQXCIK FM C11H8N4O
DMQXCIK IC InChI=1S/C11H8N4O/c16-11-10-9(12-7-13-11)6-15(14-10)8-4-2-1-3-5-8/h1-7H,(H,12,13,16)
DMQXCIK CS C1=CC=C(C=C1)N2C=C3C(=N2)C(=O)NC=N3
DMQXCIK IK OQHWVAQCLKFQMO-UHFFFAOYSA-N
DMQXCIK IU 2-phenyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
DMQXCIK DE Discovery agent
DMNXI6D ID DMNXI6D
DMNXI6D DN 2-Phenyl-3-(1-phenyl-ethoxy)-piperidine
DMNXI6D HS Investigative
DMNXI6D SN CHEMBL103657; 2-Phenyl-3-(1-phenyl-ethoxy)-piperidine
DMNXI6D DT Small molecular drug
DMNXI6D PC 44331715
DMNXI6D MW 281.4
DMNXI6D FM C19H23NO
DMNXI6D IC InChI=1S/C19H23NO/c1-15(16-9-4-2-5-10-16)21-18-13-8-14-20-19(18)17-11-6-3-7-12-17/h2-7,9-12,15,18-20H,8,13-14H2,1H3/t15-,18+,19+/m1/s1
DMNXI6D CS C[C@H](C1=CC=CC=C1)O[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMNXI6D IK FFKDZHIKRMLWQT-MNEFBYGVSA-N
DMNXI6D IU (2S,3S)-2-phenyl-3-[(1R)-1-phenylethoxy]piperidine
DMNXI6D DE Discovery agent
DM5YC2K ID DM5YC2K
DM5YC2K DN 2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole
DM5YC2K HS Investigative
DM5YC2K SN CHEMBL91205; 2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole; SCHEMBL7645809; BDBM50095028; 2-Phenyl-3-(2-piperidinoethyl)-1H-indole
DM5YC2K DT Small molecular drug
DM5YC2K PC 9817960
DM5YC2K MW 304.4
DM5YC2K FM C21H24N2
DM5YC2K IC InChI=1S/C21H24N2/c1-3-9-17(10-4-1)21-19(13-16-23-14-7-2-8-15-23)18-11-5-6-12-20(18)22-21/h1,3-6,9-12,22H,2,7-8,13-16H2
DM5YC2K CS C1CCN(CC1)CCC2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DM5YC2K IK FKIIRAHSARSGPF-UHFFFAOYSA-N
DM5YC2K IU 2-phenyl-3-(2-piperidin-1-ylethyl)-1H-indole
DM5YC2K DE Discovery agent
DML9DJP ID DML9DJP
DML9DJP DN 2-Phenyl-3H-imidazo[4,5-c]quinoline
DML9DJP HS Investigative
DML9DJP SN 2-Phenyl-3H-imidazo[4,5-c]quinoline; 3H-Imidazo[4,5-c]quinoline,2-phenyl-; CHEMBL95085; SCHEMBL1423662
DML9DJP DT Small molecular drug
DML9DJP PC 10824264
DML9DJP MW 245.28
DML9DJP FM C16H11N3
DML9DJP IC InChI=1S/C16H11N3/c1-2-6-11(7-3-1)16-18-14-10-17-13-9-5-4-8-12(13)15(14)19-16/h1-10H,(H,18,19)
DML9DJP CS C1=CC=C(C=C1)C2=NC3=C(N2)C=NC4=CC=CC=C43
DML9DJP IK ZGICTZVKFFYIEA-UHFFFAOYSA-N
DML9DJP IU 2-phenyl-3H-imidazo[4,5-c]quinoline
DML9DJP DE Discovery agent
DMY6NIT ID DMY6NIT
DMY6NIT DN 2-Phenyl-3-piperidin-3-yl-1H-indole
DMY6NIT HS Investigative
DMY6NIT SN CHEMBL42557; 2-Phenyl-3-piperidin-3-yl-1H-indole; 2-phenyl-3-(3-piperidinyl)-1H-Indole; SCHEMBL8525019; BDBM50099262; AKOS022450446; 3-(3-Piperidinyl)-2-phenyl-1H-indole; 244086-74-6; 3-(Piperidin-3-yl)-2-phenyl-1H-indole; DA-07759
DMY6NIT DT Small molecular drug
DMY6NIT PC 9795587
DMY6NIT MW 276.4
DMY6NIT FM C19H20N2
DMY6NIT IC InChI=1S/C19H20N2/c1-2-7-14(8-3-1)19-18(15-9-6-12-20-13-15)16-10-4-5-11-17(16)21-19/h1-5,7-8,10-11,15,20-21H,6,9,12-13H2
DMY6NIT CS C1CC(CNC1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMY6NIT IK FYHCOUIJWCQUMZ-UHFFFAOYSA-N
DMY6NIT IU 2-phenyl-3-piperidin-3-yl-1H-indole
DMY6NIT DE Discovery agent
DMEXZQ5 ID DMEXZQ5
DMEXZQ5 DN 2-Phenyl-3-piperidin-4-yl-1H-indole
DMEXZQ5 HS Investigative
DMEXZQ5 SN 221109-26-8; 2-PHENYL-3-(PIPERIDIN-4-YL)-1H-INDOLE; 2-Phenyl-3-(4-piperidinyl)-1H-indole; 2-Phenyl-3-piperidin-4-yl-1H-indole; CHEMBL295559; SCHEMBL7962369; CTK4E8621; DTXSID60432328; FWPAVENSJPMGJO-UHFFFAOYSA-N; ZINC2580888; CP-220; ANW-46494; BDBM50095050; AKOS015898489; AJ-42917; 3-(Piperidin-4-yl)-2-phenyl-1H-indole; 1H-Indole,2-phenyl-3-(4-piperidinyl)-; TC-135239; ST2404535; KB-231980; AX8078102; W4568; FT-0707553; AM20030371; P13451
DMEXZQ5 DT Small molecular drug
DMEXZQ5 PC 9882067
DMEXZQ5 MW 276.4
DMEXZQ5 FM C19H20N2
DMEXZQ5 IC InChI=1S/C19H20N2/c1-2-6-15(7-3-1)19-18(14-10-12-20-13-11-14)16-8-4-5-9-17(16)21-19/h1-9,14,20-21H,10-13H2
DMEXZQ5 CS C1CNCCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMEXZQ5 IK FWPAVENSJPMGJO-UHFFFAOYSA-N
DMEXZQ5 IU 2-phenyl-3-piperidin-4-yl-1H-indole
DMEXZQ5 CA CAS 221109-26-8
DMEXZQ5 DE Discovery agent
DMKCOS2 ID DMKCOS2
DMKCOS2 DN 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one
DMKCOS2 HS Investigative
DMKCOS2 SN CHEMBL10072; 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one; AC1O1A27; BDBM50111271; 3-[(Z)-4-Pyridinylmethylene]flavanone
DMKCOS2 DT Small molecular drug
DMKCOS2 PC 6116651
DMKCOS2 MW 313.3
DMKCOS2 FM C21H15NO2
DMKCOS2 IC InChI=1S/C21H15NO2/c23-20-17-8-4-5-9-19(17)24-21(16-6-2-1-3-7-16)18(20)14-15-10-12-22-13-11-15/h1-14,21H/b18-14+
DMKCOS2 CS C1=CC=C(C=C1)C2/C(=C/C3=CC=NC=C3)/C(=O)C4=CC=CC=C4O2
DMKCOS2 IK YQBABXZFWNTIHJ-NBVRZTHBSA-N
DMKCOS2 IU (3Z)-2-phenyl-3-(pyridin-4-ylmethylidene)chromen-4-one
DMKCOS2 DE Discovery agent
DMEXYSP ID DMEXYSP
DMEXYSP DN 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol
DMEXYSP HS Investigative
DMEXYSP SN CHEMBL187185; 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol
DMEXYSP DT Small molecular drug
DMEXYSP PC 44394887
DMEXYSP MW 293.32
DMEXYSP FM C17H15N3O2
DMEXYSP IC InChI=1S/C17H15N3O2/c21-13-6-7-14-15(20-11-18-10-19-20)9-16(22-17(14)8-13)12-4-2-1-3-5-12/h1-8,10-11,15-16,21H,9H2
DMEXYSP CS C1C(C2=C(C=C(C=C2)O)OC1C3=CC=CC=C3)N4C=NC=N4
DMEXYSP IK FDEHVWXURCBTAP-UHFFFAOYSA-N
DMEXYSP IU 2-phenyl-4-(1,2,4-triazol-1-yl)-3,4-dihydro-2H-chromen-7-ol
DMEXYSP DE Discovery agent
DM7A3GO ID DM7A3GO
DM7A3GO DN 2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine
DM7A3GO HS Investigative
DM7A3GO SN CHEMBL184995; 2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine; SCHEMBL7419236; BDBM50149801
DM7A3GO DT Small molecular drug
DM7A3GO PC 44392990
DM7A3GO MW 276.4
DM7A3GO FM C17H12N2S
DM7A3GO IC InChI=1S/C17H12N2S/c1-13-19-16(12-20-13)9-7-14-8-10-17(18-11-14)15-5-3-2-4-6-15/h2-6,8,10-12H,1H3
DM7A3GO CS CC1=NC(=CS1)C#CC2=CN=C(C=C2)C3=CC=CC=C3
DM7A3GO IK OUYHNXKLIHUODF-UHFFFAOYSA-N
DM7A3GO IU 2-methyl-4-[2-(6-phenylpyridin-3-yl)ethynyl]-1,3-thiazole
DM7A3GO DE Discovery agent
DMUIYZB ID DMUIYZB
DMUIYZB DN 2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline
DMUIYZB HS Investigative
DMUIYZB DT Small molecular drug
DMUIYZB PC 10681942
DMUIYZB DE Discovery agent
DMMDS2T ID DMMDS2T
DMMDS2T DN 2-phenyl-5H-indeno[1,2-d]pyrimidine
DMMDS2T HS Investigative
DMMDS2T SN 2-phenyl-5H-indeno[1,2-d]pyrimidine; CHEMBL241206; Aza-heterocyclic Derivative, 3b; SCHEMBL18015923; BDBM19179
DMMDS2T DT Small molecular drug
DMMDS2T PC 10728986
DMMDS2T MW 244.29
DMMDS2T FM C17H12N2
DMMDS2T IC InChI=1S/C17H12N2/c1-2-6-12(7-3-1)17-18-11-14-10-13-8-4-5-9-15(13)16(14)19-17/h1-9,11H,10H2
DMMDS2T CS C1C2=CC=CC=C2C3=NC(=NC=C31)C4=CC=CC=C4
DMMDS2T IK GOMPLLCNQNCUNU-UHFFFAOYSA-N
DMMDS2T IU 2-phenyl-5H-indeno[1,2-d]pyrimidine
DMMDS2T DE Discovery agent
DMA1RHE ID DMA1RHE
DMA1RHE DN 2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMA1RHE HS Investigative
DMA1RHE DT Small molecular drug
DMA1RHE PC 10659062
DMA1RHE DE Discovery agent
DMY9ERA ID DMY9ERA
DMY9ERA DN 2-Phenyl-6-propyl-chromen-4-one
DMY9ERA HS Investigative
DMY9ERA SN CHEMBL134539
DMY9ERA DT Small molecular drug
DMY9ERA PC 10858340
DMY9ERA MW 264.3
DMY9ERA FM C18H16O2
DMY9ERA IC InChI=1S/C18H16O2/c1-2-6-13-9-10-17-15(11-13)16(19)12-18(20-17)14-7-4-3-5-8-14/h3-5,7-12H,2,6H2,1H3
DMY9ERA CS CCCC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMY9ERA IK PKMXZOUCSSZIGB-UHFFFAOYSA-N
DMY9ERA IU 2-phenyl-6-propylchromen-4-one
DMY9ERA DE Discovery agent
DMMHSYV ID DMMHSYV
DMMHSYV DN 2-phenyl-9H-indeno[2,1-d]pyrimidine
DMMHSYV HS Investigative
DMMHSYV SN CHEMBL241205
DMMHSYV DT Small molecular drug
DMMHSYV PC 91895927
DMMHSYV MW 244.29
DMMHSYV FM C17H12N2
DMMHSYV IC InChI=1S/C17H12N2/c1-2-6-12(7-3-1)17-18-11-15-14-9-5-4-8-13(14)10-16(15)19-17/h1-11H,(H,18,19)
DMMHSYV CS C1=CC=C(C=C1)C2=NC=C3C4=CC=CC=C4C=C3N2
DMMHSYV IK INQKEQXZMUIZGI-UHFFFAOYSA-N
DMMHSYV IU 2-phenyl-1H-indeno[2,1-d]pyrimidine
DMMHSYV DE Discovery agent
DM60AJ2 ID DM60AJ2
DM60AJ2 DN 2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE
DM60AJ2 HS Investigative
DM60AJ2 SN 31609-42-4; 2-Phenylamino-4-Methyl-5-Acetyl Thiazole; 5-acetyl-4-methyl-2-(phenylamino)thiazole; 2-phenylamino-4-methyl-5-acetylthiazole; CHEMBL1235108; 1-(4-Methyl-2-(phenylamino)thiazol-5-yl)ethanone; 5-Acetyl-4-methyl-2-(phenylamino)-1,3-thiazole; 1-(2-anilino-4-methyl-1,3-thiazol-5-yl)ethanone; Ethanone,1-[4-methyl-2-(phenylamino)-5-thiazolyl]-; 1-[4-methyl-2-(phenylamino)-1,3-thiazol-5-yl]ethanone; 1-[4-methyl-2-(phenylamino)-1,3-thiazol-5-yl]ethan-1-one; 5-acetyl-4-methyl-2-phenylamino-thiazole; 2vba; AC1LEGRW
DM60AJ2 DT Small molecular drug
DM60AJ2 PC 735838
DM60AJ2 MW 232.3
DM60AJ2 FM C12H12N2OS
DM60AJ2 IC InChI=1S/C12H12N2OS/c1-8-11(9(2)15)16-12(13-8)14-10-6-4-3-5-7-10/h3-7H,1-2H3,(H,13,14)
DM60AJ2 CS CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)C
DM60AJ2 IK UIIUOFPGDKBCEZ-UHFFFAOYSA-N
DM60AJ2 IU 1-(2-anilino-4-methyl-1,3-thiazol-5-yl)ethanone
DM60AJ2 CA CAS 31609-42-4
DM60AJ2 DE Discovery agent
DMW0M14 ID DMW0M14
DMW0M14 DN 2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine
DMW0M14 HS Investigative
DMW0M14 DT Small molecular drug
DMW0M14 PC 448110
DMW0M14 DE Discovery agent
DMUGH6J ID DMUGH6J
DMUGH6J DN 2-Phenyl-cyclopropylamine hydrochloride
DMUGH6J HS Investigative
DMUGH6J DE Discovery agent
DMW3F5C ID DMW3F5C
DMW3F5C DN 2-phenylethylyl-adenosine derivative
DMW3F5C HS Investigative
DMW3F5C SN CHEMBL574602; 2-phenylethylyl-adenosine derivative; GTPL5600; BDBM50299701; N6-Methyl-2-phenylethynyl-5''-N-methylcarboxamidoadenosine
DMW3F5C DT Small molecular drug
DMW3F5C PC 44598833
DMW3F5C MW 408.4
DMW3F5C FM C20H20N6O4
DMW3F5C IC InChI=1S/C20H20N6O4/c1-21-17-13-18(25-12(24-17)9-8-11-6-4-3-5-7-11)26(10-23-13)20-15(28)14(27)16(30-20)19(29)22-2/h3-7,10,14-16,20,27-28H,1-2H3,(H,22,29)(H,21,24,25)/t14-,15+,16-,20+/m0/s1
DMW3F5C CS CNC1=C2C(=NC(=N1)C#CC3=CC=CC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)C(=O)NC)O)O
DMW3F5C IK PAFSPMXSTBOTSN-KSVNGYGVSA-N
DMW3F5C IU (2S,3S,4R,5R)-3,4-dihydroxy-N-methyl-5-[6-(methylamino)-2-(2-phenylethynyl)purin-9-yl]oxolane-2-carboxamide
DMW3F5C DE Discovery agent
DMNYOH5 ID DMNYOH5
DMNYOH5 DN 2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol
DMNYOH5 HS Investigative
DMNYOH5 SN CHEMBL253157; 2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol
DMNYOH5 DT Small molecular drug
DMNYOH5 PC 24777189
DMNYOH5 MW 249.31
DMNYOH5 FM C17H15NO
DMNYOH5 IC InChI=1S/C17H15NO/c19-17-8-4-7-16-15(17)12-11-14(18-16)10-9-13-5-2-1-3-6-13/h1-3,5-6,11-12,17,19H,4,7-8H2
DMNYOH5 CS C1CC(C2=C(C1)N=C(C=C2)C#CC3=CC=CC=C3)O
DMNYOH5 IK VUDNTKZUIAXLLZ-UHFFFAOYSA-N
DMNYOH5 IU 2-(2-phenylethynyl)-5,6,7,8-tetrahydroquinolin-5-ol
DMNYOH5 DE Discovery agent
DM4LCRS ID DM4LCRS
DM4LCRS DN 2-phenylethynyl-5,6,7,8-tetrahydro-quinoline
DM4LCRS HS Investigative
DM4LCRS SN CHEMBL253160; 2-phenylethynyl-5,6,7,8-tetrahydro-quinoline
DM4LCRS DT Small molecular drug
DM4LCRS PC 24777940
DM4LCRS MW 233.31
DM4LCRS FM C17H15N
DM4LCRS IC InChI=1S/C17H15N/c1-2-6-14(7-3-1)10-12-16-13-11-15-8-4-5-9-17(15)18-16/h1-3,6-7,11,13H,4-5,8-9H2
DM4LCRS CS C1CCC2=C(C1)C=CC(=N2)C#CC3=CC=CC=C3
DM4LCRS IK WGJNWKPVRLKAIF-UHFFFAOYSA-N
DM4LCRS IU 2-(2-phenylethynyl)-5,6,7,8-tetrahydroquinoline
DM4LCRS DE Discovery agent
DMFRQJ3 ID DMFRQJ3
DMFRQJ3 DN 2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one
DMFRQJ3 HS Investigative
DMFRQJ3 SN 864224-08-8; 2-(PHENYLETHYNYL)-7,8-DIHYDROQUINOLIN-5(6H)-ONE; CHEMBL252956; 2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one; 5(6H)-Quinolinone, 7,8-dihydro-2-(phenylethynyl)-; SCHEMBL4325876; 2-(2-phenylethynyl)-7,8-dihydro-6H-quinolin-5-one; CTK3C7284; DTXSID10464098; XOUDFZJCSDKXLG-UHFFFAOYSA-N; ZINC28967975; BDBM50231741; AKOS025146642; SC-68865; AK164588; AS-41243; 2-(Phenylethynyl)-7,8-dihydroquinolin-5(6H)-one, 98%
DMFRQJ3 DT Small molecular drug
DMFRQJ3 PC 11379626
DMFRQJ3 MW 247.29
DMFRQJ3 FM C17H13NO
DMFRQJ3 IC InChI=1S/C17H13NO/c19-17-8-4-7-16-15(17)12-11-14(18-16)10-9-13-5-2-1-3-6-13/h1-3,5-6,11-12H,4,7-8H2
DMFRQJ3 CS C1CC2=C(C=CC(=N2)C#CC3=CC=CC=C3)C(=O)C1
DMFRQJ3 IK XOUDFZJCSDKXLG-UHFFFAOYSA-N
DMFRQJ3 IU 2-(2-phenylethynyl)-7,8-dihydro-6H-quinolin-5-one
DMFRQJ3 CA CAS 864224-08-8
DMFRQJ3 DE Discovery agent
DMPIQTE ID DMPIQTE
DMPIQTE DN 2-Phenylheme
DMPIQTE HS Investigative
DMPIQTE DT Small molecular drug
DMPIQTE PC 17753777
DMPIQTE MW 692.6
DMPIQTE FM C40H36FeN4O4
DMPIQTE IC InChI=1S/C40H38N4O4.Fe/c1-7-26-21(3)30-18-32-23(5)28(14-16-36(45)46)39(43-32)38(25-12-10-9-11-13-25)40-29(15-17-37(47)48)24(6)33(44-40)20-35-27(8-2)22(4)31(42-35)19-34(26)41-30;/h7-13,18-20H,1-2,14-17H2,3-6H3,(H4,41,42,43,44,45,46,47,48);/q;+2/p-2
DMPIQTE CS CC1=C(C2=C(C3=NC(=CC4=C(C(=C([N-]4)C=C5C(=C(C(=N5)C=C1[N-]2)C=C)C)C=C)C)C(=C3CCC(=O)O)C)C6=CC=CC=C6)CCC(=O)O.[Fe+2]
DMPIQTE IK FQZJPOQXUNESIK-UHFFFAOYSA-L
DMPIQTE IU 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethyl-20-phenylporphyrin-21,23-diid-2-yl]propanoic acid;iron(2+)
DMPIQTE DE Discovery agent
DMFC3B5 ID DMFC3B5
DMFC3B5 DN 2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide
DMFC3B5 HS Investigative
DMFC3B5 SN 2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide; AC1LGHTG; CHEMBL225956; MolPort-002-561-993; MolPort-000-823-043; ZINC17043968; STK536010; AKOS002254375; MCULE-9751182652; 84954-79-0; ST50752086; Benzeneacetamide, N-1,3,4-thiadiazol-2-yl-
DMFC3B5 DT Small molecular drug
DMFC3B5 PC 821620
DMFC3B5 MW 219.27
DMFC3B5 FM C10H9N3OS
DMFC3B5 IC InChI=1S/C10H9N3OS/c14-9(12-10-13-11-7-15-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H,12,13,14)
DMFC3B5 CS C1=CC=C(C=C1)CC(=O)NC2=NN=CS2
DMFC3B5 IK VRCPUIHHVMQIHP-UHFFFAOYSA-N
DMFC3B5 IU 2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide
DMFC3B5 DE Discovery agent
DMNOE0V ID DMNOE0V
DMNOE0V DN 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide
DMNOE0V HS Investigative
DMNOE0V SN CHEMBL274763; 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide; AC1ME6SQ; Oprea1_279909; SCHEMBL4477684; MolPort-001-501-804; IEDWYQQEMKCMSQ-UHFFFAOYSA-N; BDBM50074822; STK047893; AKOS022078440; AKOS003267625; MCULE-5320435270; ST45002516; 2-phenyl-N-(1-phenylethyl)-4-quinolinecarboxamide; (2-phenyl(4-quinolyl))-N-(phenylethyl)carboxamide; 2-Phenyl-quinoline-4-carboxylic acid (1-phenyl-ethyl)amide; 2-Phenyl-quinoline-4-carboxylic acid (1-phenyl-ethyl)-amide
DMNOE0V DT Small molecular drug
DMNOE0V PC 2849628
DMNOE0V MW 352.4
DMNOE0V FM C24H20N2O
DMNOE0V IC InChI=1S/C24H20N2O/c1-17(18-10-4-2-5-11-18)25-24(27)21-16-23(19-12-6-3-7-13-19)26-22-15-9-8-14-20(21)22/h2-17H,1H3,(H,25,27)
DMNOE0V CS CC(C1=CC=CC=C1)NC(=O)C2=CC(=NC3=CC=CC=C32)C4=CC=CC=C4
DMNOE0V IK IEDWYQQEMKCMSQ-UHFFFAOYSA-N
DMNOE0V IU 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide
DMNOE0V DE Discovery agent
DMEFOV6 ID DMEFOV6
DMEFOV6 DN 2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine
DMEFOV6 HS Investigative
DMEFOV6 SN CHEMBL564660; 2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine; AC1O5DWY; SCHEMBL412953; QGWNGFYEPGNYNY-UHFFFAOYSA-N; MolPort-002-121-406; BDBM50293513; ZINC13633702; STL388203; AKOS003232028; AKOS002341780; MCULE-2242877238; 4-(4-pyridylamino)-2-penyl quinazoline; 4-(4-Pyridvlamino)-2-Phenyl Quinazoline; 4-(4-pyridylamino)-2-phenyl quinazoline
DMEFOV6 DT Small molecular drug
DMEFOV6 PC 6456587
DMEFOV6 MW 298.3
DMEFOV6 FM C19H14N4
DMEFOV6 IC InChI=1S/C19H14N4/c1-2-6-14(7-3-1)18-22-17-9-5-4-8-16(17)19(23-18)21-15-10-12-20-13-11-15/h1-13H,(H,20,21,22,23)
DMEFOV6 CS C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC=NC=C4
DMEFOV6 IK QGWNGFYEPGNYNY-UHFFFAOYSA-N
DMEFOV6 IU 2-phenyl-N-pyridin-4-ylquinazolin-4-amine
DMEFOV6 DE Discovery agent
DMP0NW3 ID DMP0NW3
DMP0NW3 DN 2-phenyl-N-(thiazol-2-yl)acetamide
DMP0NW3 HS Investigative
DMP0NW3 SN 2-Phenyl-N-(1,3-thiazol-2-yl)acetamide; 2-Phenyl-N-thiazol-2-yl-acetamide; 292051-66-2; Benzeneacetamide, N-2-thiazolyl-; BAS 15431504; ChemDiv2_003476; AC1LBQ73; MLS001211116; CHEMBL227897; SCHEMBL4687548; ZINC29573; HYRZQLIFVQELLP-UHFFFAOYSA-N; MolPort-001-012-138; HMS2829M16; HMS1378N22; STK012295; AKOS000714854; MCULE-4931151694; ST042627; SMR000516648; 2-Phenyl-N-(1,3-thiazol-2-yl)acetamide #; 2-phenyl-N~1~-(1,3-thiazol-2-yl)acetamide; SR-01000415900; SR-01000415900-1; BRD-K98487211-001-07-7; Z28173686
DMP0NW3 DT Small molecular drug
DMP0NW3 PC 562362
DMP0NW3 MW 218.28
DMP0NW3 FM C11H10N2OS
DMP0NW3 IC InChI=1S/C11H10N2OS/c14-10(13-11-12-6-7-15-11)8-9-4-2-1-3-5-9/h1-7H,8H2,(H,12,13,14)
DMP0NW3 CS C1=CC=C(C=C1)CC(=O)NC2=NC=CS2
DMP0NW3 IK HYRZQLIFVQELLP-UHFFFAOYSA-N
DMP0NW3 IU 2-phenyl-N-(1,3-thiazol-2-yl)acetamide
DMP0NW3 DE Discovery agent
DMMJENF ID DMMJENF
DMMJENF DN 2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine
DMMJENF HS Investigative
DMMJENF SN CHEMBL398687; AC1MRYJJ; 2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine; BDBM50232470
DMMJENF DT Small molecular drug
DMMJENF PC 3575822
DMMJENF MW 393.6
DMMJENF FM C24H27NS2
DMMJENF IC InChI=1S/C24H27NS2/c1-20-10-6-8-14-23(20)26-18-25(17-16-22-12-4-3-5-13-22)19-27-24-15-9-7-11-21(24)2/h3-15H,16-19H2,1-2H3
DMMJENF CS CC1=CC=CC=C1SCN(CCC2=CC=CC=C2)CSC3=CC=CC=C3C
DMMJENF IK XPJBCYSDRUCTBK-UHFFFAOYSA-N
DMMJENF IU N,N-bis[(2-methylphenyl)sulfanylmethyl]-2-phenylethanamine
DMMJENF DE Discovery agent
DM7OHSX ID DM7OHSX
DM7OHSX DN 2-phenylpiperidine hydrochloride
DM7OHSX HS Investigative
DM7OHSX SN 2-Phenylpiperidine; 3466-80-6; 2-phenyl-piperidine; Piperidine, 2-phenyl-; 2-phenyl piperidine; EINECS 222-422-6; PubChem8019; (Piperidin-2-yl)benzene; ACMC-1AG1G; AC1L2U2P; AC1Q1H0F; SCHEMBL938781; SCHEMBL11523711; CTK1C4792; MolPort-000-147-784; WGIAUTGOUJDVEI-UHFFFAOYSA-N; KS-00000N7T; ALBB-006245; SBB022661; STK312087; BBL022420; AKOS000184053; AKOS016344001; FS-1688; MCULE-8351203351; ACN-027346; KB-84880; AM803744; SC-48762; TR-014336; ST2404539; AB0089977; ST45091094; P2005; BB 0254270; A6090; FT-0656912; CS-0028391; K-7884; J-019700
DM7OHSX DT Small molecular drug
DM7OHSX PC 17814274
DM7OHSX MW 197.7
DM7OHSX FM C11H16ClN
DM7OHSX IC InChI=1S/C11H15N.ClH/c1-2-6-10(7-3-1)11-8-4-5-9-12-11;/h1-3,6-7,11-12H,4-5,8-9H2;1H
DM7OHSX CS C1CCNC(C1)C2=CC=CC=C2.Cl
DM7OHSX IK YNQTWZUWWFUKSN-UHFFFAOYSA-N
DM7OHSX IU 2-phenylpiperidine;hydrochloride
DM7OHSX CA CAS 3466-81-7
DM7OHSX DE Discovery agent
DMZQCEP ID DMZQCEP
DMZQCEP DN 2-phenylpropoxyadenosine
DMZQCEP HS Investigative
DMZQCEP SN 2-phenylpropoxyadenosine; CHEMBL374151; Adenosine, 2-(3-phenylpropoxy)-; SCHEMBL8110831; 2-(3-Phenylpropyloxy)adenosine; CTK0C0845; 131865-80-0; BDBM50208810
DMZQCEP DT Small molecular drug
DMZQCEP PC 14842885
DMZQCEP MW 401.4
DMZQCEP FM C19H23N5O5
DMZQCEP IC InChI=1S/C19H23N5O5/c20-16-13-17(24(10-21-13)18-15(27)14(26)12(9-25)29-18)23-19(22-16)28-8-4-7-11-5-2-1-3-6-11/h1-3,5-6,10,12,14-15,18,25-27H,4,7-9H2,(H2,20,22,23)/t12-,14-,15-,18-/m1/s1
DMZQCEP CS C1=CC=C(C=C1)CCCOC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMZQCEP IK UDWLAWJOABGYPL-SCFUHWHPSA-N
DMZQCEP IU (2R,3R,4S,5R)-2-[6-amino-2-(3-phenylpropoxy)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMZQCEP DE Discovery agent
DM64JE8 ID DM64JE8
DM64JE8 DN 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide
DM64JE8 HS Investigative
DM64JE8 SN 2-phenylpyrazolo[1,5-a]pyridine-7-carboxamide; 1196713-16-2; ZINC64337832; DA-47424
DM64JE8 DT Small molecular drug
DM64JE8 PC 49799912
DM64JE8 MW 243.3
DM64JE8 FM C14H17N3O
DM64JE8 IC InChI=1S/C14H17N3O/c15-14(18)13-8-4-7-11-9-12(16-17(11)13)10-5-2-1-3-6-10/h4,7-10H,1-3,5-6H2,(H2,15,18)
DM64JE8 CS C1CCC(CC1)C2=NN3C(=C2)C=CC=C3C(=O)N
DM64JE8 IK YQKBVCBRJDUULG-UHFFFAOYSA-N
DM64JE8 IU 2-cyclohexylpyrazolo[1,5-a]pyridine-7-carboxamide
DM64JE8 DE Discovery agent
DMAENRQ ID DMAENRQ
DMAENRQ DN 2-phenylquinoline-8-carboxamide
DMAENRQ HS Investigative
DMAENRQ SN 2-phenylquinoline-8-carboxamide; CHEMBL480429; SCHEMBL6442515; ZINC3939668
DMAENRQ DT Small molecular drug
DMAENRQ PC 44156952
DMAENRQ MW 248.28
DMAENRQ FM C16H12N2O
DMAENRQ IC InChI=1S/C16H12N2O/c17-16(19)13-8-4-7-12-9-10-14(18-15(12)13)11-5-2-1-3-6-11/h1-10H,(H2,17,19)
DMAENRQ CS C1=CC=C(C=C1)C2=NC3=C(C=CC=C3C(=O)N)C=C2
DMAENRQ IK BNQJEMTZUOVMLM-UHFFFAOYSA-N
DMAENRQ IU 2-phenylquinoline-8-carboxamide
DMAENRQ DE Discovery agent
DMX6GH5 ID DMX6GH5
DMX6GH5 DN 2-Phosphoglyceric Acid
DMX6GH5 HS Investigative
DMX6GH5 SN 2-Phospho-D-Glyceric Acid; D-Glycerate 2-phosphate; 2-phospho-D-glycerate; 2-phosphoglyceric acid; (2R)-3-hydroxy-2-(phosphonooxy)propanoic acid; 3-D-Hydroxy-2-phosphonooxy-propanoic acid; 2-phospho-(R)-glycerate; Glyceric acid-2-phosphate; D(+)2-Phosphoglyceric acid; SCHEMBL2726719; CTK1B7706; CHEBI:17835; GXIURPTVHJPJLF-UWTATZPHSA-N; 1-Carboxy-2-hydroxyethyl phosphate; AC1L9718; ZINC3869232; 3443-57-0; 2PG; 3-D-Hydroxy-2-phosphonooxy-propanoate; DB01709; (2R)-3-hydroxy-2-(phosphonooxy)propanoate
DMX6GH5 DT Small molecular drug
DMX6GH5 PC 59
DMX6GH5 MW 186.06
DMX6GH5 FM C3H7O7P
DMX6GH5 IC InChI=1S/C3H7O7P/c4-1-2(3(5)6)10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)
DMX6GH5 CS C(C(C(=O)O)OP(=O)(O)O)O
DMX6GH5 IK GXIURPTVHJPJLF-UHFFFAOYSA-N
DMX6GH5 IU 3-hydroxy-2-phosphonooxypropanoic acid
DMX6GH5 CA CAS 2553-59-5
DMX6GH5 CB CHEBI:24344
DMX6GH5 DE Discovery agent
DMO14NH ID DMO14NH
DMO14NH DN 2-Phosphoglycolic Acid
DMO14NH HS Investigative
DMO14NH SN Phosphoglycolic acid; 2-Phosphoglycolic Acid; phosphoglycolate; (Phosphonooxy)acetic acid; 13147-57-4; Glycophosphoric acid; acetic acid, (phosphonooxy)-; UNII-H8593JOP13; 2-phosphoglycolate; Glycolic acid phosphate; CHEBI:17150; H8593JOP13; 2-phosphonatoglycolate; (phosphonooxy)essigs; Glycophosphorate; 1hti; 1lyx; 1egh; 2ypi; 1pdz; 1lzo; EINECS 236-084-2; (Phosphonooxy)acetate; Phosphonooxyacetic acid; (phosphonooxy)-acetate; 1kv5; 1ml1; 1aw1; 2-phosphonooxyacetic acid; Glycolic acid-2-phosphate; (phosphonooxy)-acetic acid; AC1Q6RY7
DMO14NH DT Small molecular drug
DMO14NH PC 529
DMO14NH MW 156.03
DMO14NH FM C2H5O6P
DMO14NH IC InChI=1S/C2H5O6P/c3-2(4)1-8-9(5,6)7/h1H2,(H,3,4)(H2,5,6,7)
DMO14NH CS C(C(=O)O)OP(=O)(O)O
DMO14NH IK ASCFNMCAHFUBCO-UHFFFAOYSA-N
DMO14NH IU 2-phosphonooxyacetic acid
DMO14NH CA CAS 13147-57-4
DMO14NH CB CHEBI:17150
DMO14NH DE Discovery agent
DMM05AO ID DMM05AO
DMM05AO DN 2-Phosphonooxy-pentanedioic acid
DMM05AO HS Investigative
DMM05AO SN 2-Phosphonooxy-pentanedioic acid; CHEMBL302413; 2-phosphonopentanedioic Acid; SCHEMBL2201753; BDBM50127620
DMM05AO DT Small molecular drug
DMM05AO PC 11020196
DMM05AO MW 212.09
DMM05AO FM C5H9O7P
DMM05AO IC InChI=1S/C5H9O7P/c6-4(7)2-1-3(5(8)9)13(10,11)12/h3H,1-2H2,(H,6,7)(H,8,9)(H2,10,11,12)
DMM05AO CS C(CC(=O)O)C(C(=O)O)P(=O)(O)O
DMM05AO IK HHRBAERKINHBJK-UHFFFAOYSA-N
DMM05AO IU 2-phosphonopentanedioic acid
DMM05AO DE Discovery agent
DM742IJ ID DM742IJ
DM742IJ DN 2-Piperazin-1-yl-benzonitrile
DM742IJ HS Investigative
DM742IJ SN 1-(2-Cyanophenyl)piperazine; 111373-03-6; 2-(piperazin-1-yl)benzonitrile; 2-piperazin-1-ylbenzonitrile; 2-(1-Piperazino)benzonitrile; Benzonitrile, 2-(1-piperazinyl)-; 2-Piperazin-1-yl-benzonitrile; 1-(2-Cyanophenyl)-piperazine; 2-(1-piperazinyl)benzonitrile; CHEMBL275943; 2-piperazinylbenzenecarbonitrile; PubChem9347; 2-Piperazinobenzonitrile; AC1MC4BA; AC1Q4R0F; (2-cyano-phenyl)-piperazine; KSC491G1H; SCHEMBL233169; 1-(2-cyanophenyl) piperazine; ACMC-20999f; 1-(2-cyano phenyl) piperazine; Jsp000853
DM742IJ DT Small molecular drug
DM742IJ PC 2735875
DM742IJ MW 187.24
DM742IJ FM C11H13N3
DM742IJ IC InChI=1S/C11H13N3/c12-9-10-3-1-2-4-11(10)14-7-5-13-6-8-14/h1-4,13H,5-8H2
DM742IJ CS C1CN(CCN1)C2=CC=CC=C2C#N
DM742IJ IK FRICBZWJFIRJOB-UHFFFAOYSA-N
DM742IJ IU 2-piperazin-1-ylbenzonitrile
DM742IJ CA CAS 111373-03-6
DM742IJ DE Discovery agent
DMQT9OK ID DMQT9OK
DMQT9OK DN 2-Piperazin-1-yl-phenol
DMQT9OK HS Investigative
DMQT9OK SN 1011-17-2; 2-(piperazin-1-yl)phenol; 1-(2-Hydroxyphenyl)piperazine; 2-(1-piperazinyl)phenol; 2-(1-Piperazino)phenol; 2-piperazin-1-ylphenol; Phenol, 2-(1-piperazinyl)-; o-(1-Piperazinyl)phenol; 2-Piperazin-1-yl-phenol; n-(2-hydroxyphenyl)piperazine; 1-(2-Hydroxyphenyl)-piperazine; CHEMBL266250; 2-piperazinylphenol; EINECS 213-782-5; 2-Piperazinophenol; rarechem ah ck 0117; ACMC-209v6m; 2-(1-piperazinyl) phenol; AC1L2EA8; AC1Q7AO1; 2-(piperazine-1-yl)phenol; Oprea1_446736; labotest-bb lt01596124; SCHEMBL531748; AC1Q788T
DMQT9OK DT Small molecular drug
DMQT9OK PC 70530
DMQT9OK MW 178.23
DMQT9OK FM C10H14N2O
DMQT9OK IC InChI=1S/C10H14N2O/c13-10-4-2-1-3-9(10)12-7-5-11-6-8-12/h1-4,11,13H,5-8H2
DMQT9OK CS C1CN(CCN1)C2=CC=CC=C2O
DMQT9OK IK UORNTHBBLYBAJJ-UHFFFAOYSA-N
DMQT9OK IU 2-piperazin-1-ylphenol
DMQT9OK CA CAS 1011-17-2
DMQT9OK DE Discovery agent
DM27GZC ID DM27GZC
DM27GZC DN 2-PMPA
DM27GZC HS Investigative
DM27GZC SN 2-(Phosphonomethyl)pentanedioic acid; 2-(phosphonomethyl)pentanedioic acid; 173039-10-6; PMPA (NAALADase inhibitor); CHEMBL47009; 2-(PHOSPHONOMETHYL)-PENTANEDIOIC ACID; PMPA(NAALADaseinhibitor); 2-PMPA(NAALADaseinhibitor); SCHEMBL383173; BDBM17659; KS-00001CPM; CTK0E4395; DTXSID90436036; MolPort-023-276-085; ISEYJGQFXSTPMQ-UHFFFAOYSA-N; HMS3267D10; 2-Phosphonomethyl-pentanedioic acid; EX-A1248; pentanedioic acid analogue, (RS)-1; ANW-62579; AKOS016004257; API0001123; 2-PMPA, > MP-2042; CS-6202; Pentanedioic acid, 2-(phosphonomethyl)-
DM27GZC DT Small molecular drug
DM27GZC PC 10130754
DM27GZC MW 226.12
DM27GZC FM C6H11O7P
DM27GZC IC InChI=1S/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(11,12)13/h4H,1-3H2,(H,7,8)(H,9,10)(H2,11,12,13)
DM27GZC CS C(CC(=O)O)C(CP(=O)(O)O)C(=O)O
DM27GZC IK ISEYJGQFXSTPMQ-UHFFFAOYSA-N
DM27GZC IU 2-(phosphonomethyl)pentanedioic acid
DM27GZC CA CAS 173039-10-6
DM27GZC DE Discovery agent
DML5O0H ID DML5O0H
DML5O0H DN 2-Propanol, Isopropanol
DML5O0H HS Investigative
DML5O0H SN Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand; Isopropyl Alcohol
DML5O0H DT Small molecular drug
DML5O0H PC 3776
DML5O0H MW 60.1
DML5O0H FM C3H8O
DML5O0H IC InChI=1S/C3H8O/c1-3(2)4/h3-4H,1-2H3
DML5O0H CS CC(C)O
DML5O0H IK KFZMGEQAYNKOFK-UHFFFAOYSA-N
DML5O0H IU propan-2-ol
DML5O0H CA CAS 67-63-0
DML5O0H CB CHEBI:17824
DML5O0H DE Discovery agent
DMORG3D ID DMORG3D
DMORG3D DN 2-Propionyl-1H-indole-6-carboxamidine
DMORG3D HS Investigative
DMORG3D SN CHEMBL321960; 2-Propionyl-1H-indole-6-carboxamidine
DMORG3D DT Small molecular drug
DMORG3D PC 44331573
DMORG3D MW 215.25
DMORG3D FM C12H13N3O
DMORG3D IC InChI=1S/C12H13N3O/c1-2-11(16)10-5-7-3-4-8(12(13)14)6-9(7)15-10/h3-6,15H,2H2,1H3,(H3,13,14)
DMORG3D CS CCC(=O)C1=CC2=C(N1)C=C(C=C2)C(=N)N
DMORG3D IK MUIPXQPVWYRDNF-UHFFFAOYSA-N
DMORG3D IU 2-propanoyl-1H-indole-6-carboximidamide
DMORG3D DE Discovery agent
DMP8J7E ID DMP8J7E
DMP8J7E DN 2-Propionyl-cyclohexane-1,3-dione
DMP8J7E HS Investigative
DMP8J7E SN CHEMBL166694; 104775-30-6; 2-Propionyl-cyclohexane-1,3-dione; 1,3-Cyclohexanedione, 2-(1-oxopropyl)-; SCHEMBL8639644; DTXSID50448337; DVLHCJHTXAHANV-UHFFFAOYSA-N; 2-Propanoyl-1,3-cyclohexanedione; 2-propionylcyclohexane-1,3-dione; BDBM50088802; AKOS006243102
DMP8J7E DT Small molecular drug
DMP8J7E PC 10920903
DMP8J7E MW 168.19
DMP8J7E FM C9H12O3
DMP8J7E IC InChI=1S/C9H12O3/c1-2-6(10)9-7(11)4-3-5-8(9)12/h9H,2-5H2,1H3
DMP8J7E CS CCC(=O)C1C(=O)CCCC1=O
DMP8J7E IK DVLHCJHTXAHANV-UHFFFAOYSA-N
DMP8J7E IU 2-propanoylcyclohexane-1,3-dione
DMP8J7E CA CAS 104775-30-6
DMP8J7E DE Discovery agent
DMG0I25 ID DMG0I25
DMG0I25 DN 2-propylamido-5-sulfonamidoindane
DMG0I25 HS Investigative
DMG0I25 SN CHEMBL205743; 2-propylamido-5-sulfonamidoindane; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)butanamide; Indanesulfonamide Derivative 12e
DMG0I25 DT Small molecular drug
DMG0I25 PC 11536481
DMG0I25 MW 282.36
DMG0I25 FM C13H18N2O3S
DMG0I25 IC InChI=1S/C13H18N2O3S/c1-2-3-13(16)15-11-6-9-4-5-12(19(14,17)18)8-10(9)7-11/h4-5,8,11H,2-3,6-7H2,1H3,(H,15,16)(H2,14,17,18)
DMG0I25 CS CCCC(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DMG0I25 IK ZTRWXFFYFBYLJU-UHFFFAOYSA-N
DMG0I25 IU N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)butanamide
DMG0I25 DE Discovery agent
DMBW6GA ID DMBW6GA
DMBW6GA DN 2-Propyl-beta-carboline-2-ium iodide
DMBW6GA HS Investigative
DMBW6GA SN CHEMBL1088723
DMBW6GA DT Small molecular drug
DMBW6GA PC 44725473
DMBW6GA MW 211.28
DMBW6GA FM C14H15N2+
DMBW6GA IC InChI=1S/C14H14N2/c1-2-8-16-9-7-12-11-5-3-4-6-13(11)15-14(12)10-16/h3-7,9-10H,2,8H2,1H3/p+1
DMBW6GA CS CCC[N+]1=CC2=C(C=C1)C3=CC=CC=C3N2
DMBW6GA IK SFUAYJFEBSOZSQ-UHFFFAOYSA-O
DMBW6GA IU 2-propyl-9H-pyrido[3,4-b]indol-2-ium
DMBW6GA DE Discovery agent
DM1L7PN ID DM1L7PN
DM1L7PN DN 2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester
DM1L7PN HS Investigative
DM1L7PN SN CHEMBL107722; 2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester; BDBM50108587; ZINC13471991; 2-Propylvaleric acid 4-sulfamoylbenzyl ester
DM1L7PN DT Small molecular drug
DM1L7PN PC 10881548
DM1L7PN MW 313.4
DM1L7PN FM C15H23NO4S
DM1L7PN IC InChI=1S/C15H23NO4S/c1-3-5-13(6-4-2)15(17)20-11-12-7-9-14(10-8-12)21(16,18)19/h7-10,13H,3-6,11H2,1-2H3,(H2,16,18,19)
DM1L7PN CS CCCC(CCC)C(=O)OCC1=CC=C(C=C1)S(=O)(=O)N
DM1L7PN IK MSITXBOMUACCFV-UHFFFAOYSA-N
DM1L7PN IU (4-sulfamoylphenyl)methyl 2-propylpentanoate
DM1L7PN DE Discovery agent
DMVWUME ID DMVWUME
DMVWUME DN 2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide
DMVWUME HS Investigative
DMVWUME SN CHEMBL432626; 4-(Valproylamide)-Benzyl Sulfonamide; 2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide; ZINC13471978; BDBM50108562
DMVWUME DT Small molecular drug
DMVWUME PC 10946908
DMVWUME MW 312.4
DMVWUME FM C15H24N2O3S
DMVWUME IC InChI=1S/C15H24N2O3S/c1-3-5-13(6-4-2)15(18)17-11-12-7-9-14(10-8-12)21(16,19)20/h7-10,13H,3-6,11H2,1-2H3,(H,17,18)(H2,16,19,20)
DMVWUME CS CCCC(CCC)C(=O)NCC1=CC=C(C=C1)S(=O)(=O)N
DMVWUME IK VQEFALSVKDRQBJ-UHFFFAOYSA-N
DMVWUME IU 2-propyl-N-[(4-sulfamoylphenyl)methyl]pentanamide
DMVWUME DE Discovery agent
DM1NK2M ID DM1NK2M
DM1NK2M DN 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one
DM1NK2M HS Investigative
DM1NK2M SN CHEMBL242202; 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one; BDBM50218920; 2-p-Tolyl-2,5-dihydro-pyrazolo[3,4-c]quinolin-4-one
DM1NK2M DT Small molecular drug
DM1NK2M PC 10731097
DM1NK2M MW 275.3
DM1NK2M FM C17H13N3O
DM1NK2M IC InChI=1S/C17H13N3O/c1-11-6-8-12(9-7-11)20-10-14-13-4-2-3-5-15(13)18-17(21)16(14)19-20/h2-10H,1H3,(H,18,21)
DM1NK2M CS CC1=CC=C(C=C1)N2C=C3C4=CC=CC=C4NC(=O)C3=N2
DM1NK2M IK KTONIIHJBREXRC-UHFFFAOYSA-N
DM1NK2M IU 2-(4-methylphenyl)-5H-pyrazolo[3,4-c]quinolin-4-one
DM1NK2M DE Discovery agent
DM9MIC5 ID DM9MIC5
DM9MIC5 DN 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
DM9MIC5 HS Investigative
DM9MIC5 SN CHEMBL106346; 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine; BDBM50091144; 2-p-Tolyl-2H-pyrazolo[3,4-c]quinolin-4-ylamine
DM9MIC5 DT Small molecular drug
DM9MIC5 PC 10754789
DM9MIC5 MW 274.32
DM9MIC5 FM C17H14N4
DM9MIC5 IC InChI=1S/C17H14N4/c1-11-6-8-12(9-7-11)21-10-14-13-4-2-3-5-15(13)19-17(18)16(14)20-21/h2-10H,1H3,(H2,18,19)
DM9MIC5 CS CC1=CC=C(C=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
DM9MIC5 IK XVEJYBYRDZTECS-UHFFFAOYSA-N
DM9MIC5 IU 2-(4-methylphenyl)pyrazolo[3,4-c]quinolin-4-amine
DM9MIC5 DE Discovery agent
DM37S5C ID DM37S5C
DM37S5C DN 2-p-tolyl-4,5-dihydro-1H-imidazole
DM37S5C HS Investigative
DM37S5C DE Discovery agent
DMFWA9Y ID DMFWA9Y
DMFWA9Y DN 2-p-tolyl-4H-chromen-4-one
DMFWA9Y HS Investigative
DMFWA9Y SN 4'-Methylflavone; 2-(4-methylphenyl)-4H-chromen-4-one; 2-(4-methylphenyl)chromen-4-one; 2-p-Tolyl-chromen-4-one; CHEMBL16861; 2-p-tolyl-4H-chromen-4-one; 4'-Methylflavon; 4hlk; AC1LEMVU; Maybridge3_003060; Oprea1_528340; Oprea1_754899; 2-(p-tolyl)-chromen-4-one; SCHEMBL7593917; ZINC57876; MolPort-000-648-141; OPHKKQQCOYMLPW-UHFFFAOYSA-N; HMS1439L02; BDBM50310190; AKOS000603601; MCULE-3669298263; IDI1_014447; 41255-30-5; ST093690; BAS 01121718; NS-00120; 4H-1-Benzopyran-4-one, 2-(4-methylphenyl)-; AG-690/13115015
DMFWA9Y DT Small molecular drug
DMFWA9Y PC 688829
DMFWA9Y MW 236.26
DMFWA9Y FM C16H12O2
DMFWA9Y IC InChI=1S/C16H12O2/c1-11-6-8-12(9-7-11)16-10-14(17)13-4-2-3-5-15(13)18-16/h2-10H,1H3
DMFWA9Y CS CC1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2
DMFWA9Y IK OPHKKQQCOYMLPW-UHFFFAOYSA-N
DMFWA9Y IU 2-(4-methylphenyl)chromen-4-one
DMFWA9Y DE Discovery agent
DM2HKCM ID DM2HKCM
DM2HKCM DN 2-p-tolyl-4H-chromene-4-thione
DM2HKCM HS Investigative
DM2HKCM SN CHEMBL582494; 2-p-tolyl-4H-chromene-4-thione; 4'-methylthioflavone; BDBM50310183
DM2HKCM DT Small molecular drug
DM2HKCM PC 15352647
DM2HKCM MW 252.3
DM2HKCM FM C16H12OS
DM2HKCM IC InChI=1S/C16H12OS/c1-11-6-8-12(9-7-11)15-10-16(18)13-4-2-3-5-14(13)17-15/h2-10H,1H3
DM2HKCM CS CC1=CC=C(C=C1)C2=CC(=S)C3=CC=CC=C3O2
DM2HKCM IK PUUXSOGZGHKVIT-UHFFFAOYSA-N
DM2HKCM IU 2-(4-methylphenyl)chromene-4-thione
DM2HKCM DE Discovery agent
DMJIVL3 ID DMJIVL3
DMJIVL3 DN 2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMJIVL3 HS Investigative
DMJIVL3 DT Small molecular drug
DMJIVL3 PC 135504122
DMJIVL3 MW 275.3
DMJIVL3 FM C17H13N3O
DMJIVL3 IC InChI=1S/C17H13N3O/c1-11-6-8-12(9-7-11)15-10-16-13-4-2-3-5-14(13)18-17(21)20(16)19-15/h2-10H,1H3,(H,18,21)
DMJIVL3 CS CC1=CC=C(C=C1)C2=NN3C(=C2)C4=CC=CC=C4NC3=O
DMJIVL3 IK MEMISOHEHYPPHH-UHFFFAOYSA-N
DMJIVL3 IU 2-(4-methylphenyl)-6H-pyrazolo[1,5-c]quinazolin-5-one
DMJIVL3 DE Discovery agent
DMLCDZN ID DMLCDZN
DMLCDZN DN 2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMLCDZN HS Investigative
DMLCDZN DT Small molecular drug
DMLCDZN PC 135433795
DMLCDZN MW 262.27
DMLCDZN FM C15H10N4O
DMLCDZN IC InChI=1S/C15H10N4O/c20-15-17-11-6-2-1-5-10(11)14-9-13(18-19(14)15)12-7-3-4-8-16-12/h1-9H,(H,17,20)
DMLCDZN CS C1=CC=C2C(=C1)C3=CC(=NN3C(=O)N2)C4=CC=CC=N4
DMLCDZN IK YUDPHONPFGCUGC-UHFFFAOYSA-N
DMLCDZN IU 2-pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one
DMLCDZN DE Discovery agent
DMAS46B ID DMAS46B
DMAS46B DN 2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one
DMAS46B HS Investigative
DMAS46B SN CHEMBL3144580; CHEMBL8231; 2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one; BDBM50009010; ZINC107084651; AKOS023543918
DMAS46B DT Small molecular drug
DMAS46B PC 14898722
DMAS46B MW 225.25
DMAS46B FM C13H11N3O
DMAS46B IC InChI=1S/C13H11N3O/c17-13-11-6-1-2-7-12(11)15-16(13)9-10-5-3-4-8-14-10/h1-8,15H,9H2
DMAS46B CS C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=CC=N3
DMAS46B IK NZOJCPNWISMMAJ-UHFFFAOYSA-N
DMAS46B IU 2-(pyridin-2-ylmethyl)-1H-indazol-3-one
DMAS46B DE Discovery agent
DM7RUNT ID DM7RUNT
DM7RUNT DN 2-Pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane
DM7RUNT HS Investigative
DM7RUNT SN CHEMBL56817; deschloroepibatidine; SCHEMBL8047370; BDBM50100717; AKOS023808321; 2-(3-Pyridyl)-7-azabicyclo[2.2.1]heptane
DM7RUNT DT Small molecular drug
DM7RUNT PC 10154265
DM7RUNT MW 174.24
DM7RUNT FM C11H14N2
DM7RUNT IC InChI=1S/C11H14N2/c1-2-8(7-12-5-1)10-6-9-3-4-11(10)13-9/h1-2,5,7,9-11,13H,3-4,6H2
DM7RUNT CS C1CC2C(CC1N2)C3=CN=CC=C3
DM7RUNT IK GYACOUGJSVTBRX-UHFFFAOYSA-N
DM7RUNT IU 2-pyridin-3-yl-7-azabicyclo[2.2.1]heptane
DM7RUNT DE Discovery agent
DMT21UX ID DMT21UX
DMT21UX DN 2-Pyridin-3-yl-benzo[h]chromen-4-one
DMT21UX HS Investigative
DMT21UX SN MLS000757116; CHEMBL177938; 1939-53-3; 2-(pyridin-3-yl)-4H-benzo[h]chromen-4-one; NSC283845; 2-pyridin-3-ylbenzo[h]chromen-4-one; 2-Pyridin-3-yl-benzo[h]chromen-4-one; AC1L88Q3; CTK0E1147; DTXSID00314472; ZINC13143019; BDBM50159611; NSC-283845; SMR000449783; TX-011635; 4H-Naphtho[1,2-b]pyran-4-one, 2-(3-pyridinyl)-
DMT21UX DT Small molecular drug
DMT21UX PC 323484
DMT21UX MW 273.3
DMT21UX FM C18H11NO2
DMT21UX IC InChI=1S/C18H11NO2/c20-16-10-17(13-5-3-9-19-11-13)21-18-14-6-2-1-4-12(14)7-8-15(16)18/h1-11H
DMT21UX CS C1=CC=C2C(=C1)C=CC3=C2OC(=CC3=O)C4=CN=CC=C4
DMT21UX IK RURRJHXFMININK-UHFFFAOYSA-N
DMT21UX IU 2-pyridin-3-ylbenzo[h]chromen-4-one
DMT21UX CA CAS 1939-53-3
DMT21UX DE Discovery agent
DMJYI0P ID DMJYI0P
DMJYI0P DN 2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one
DMJYI0P HS Investigative
DMJYI0P SN 2-(3-Pyridylmethyl)indazolinone; ICI-207968; 120273-58-7; CHEMBL3144579; AC1L2UZT; CHEMBL8337; SCHEMBL9596545; DTXSID90152784; BDBM50008992; ZINC100091041; AKOS023543919; 3H-Indazol-3-one,; ICI 207968
DMJYI0P DT Small molecular drug
DMJYI0P PC 129095
DMJYI0P MW 225.25
DMJYI0P FM C13H11N3O
DMJYI0P IC InChI=1S/C13H11N3O/c17-13-11-5-1-2-6-12(11)15-16(13)9-10-4-3-7-14-8-10/h1-8,15H,9H2
DMJYI0P CS C1=CC=C2C(=C1)C(=O)N(N2)CC3=CN=CC=C3
DMJYI0P IK SKZAIZCDZYPCRF-UHFFFAOYSA-N
DMJYI0P IU 2-(pyridin-3-ylmethyl)-1H-indazol-3-one
DMJYI0P CA CAS 120273-58-7
DMJYI0P DE Discovery agent
DM5D09Q ID DM5D09Q
DM5D09Q DN 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
DM5D09Q HS Investigative
DM5D09Q SN CHEMBL51594; 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL6441852; CIOBWNSCGKJAQU-UHFFFAOYSA-N; ZINC13489832; BDBM50127824; AKOS027557951
DM5D09Q DT Small molecular drug
DM5D09Q PC 9877750
DM5D09Q MW 210.27
DM5D09Q FM C14H14N2
DM5D09Q IC InChI=1S/C14H14N2/c1-2-4-13-11-16(10-7-12(13)3-1)14-5-8-15-9-6-14/h1-6,8-9H,7,10-11H2
DM5D09Q CS C1CN(CC2=CC=CC=C21)C3=CC=NC=C3
DM5D09Q IK CIOBWNSCGKJAQU-UHFFFAOYSA-N
DM5D09Q IU 2-pyridin-4-yl-3,4-dihydro-1H-isoquinoline
DM5D09Q DE Discovery agent
DMGB1QU ID DMGB1QU
DMGB1QU DN 2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one
DMGB1QU HS Investigative
DMGB1QU SN CHEMBL3144718; 2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL274331; BDBM50008994; ZINC107084657; AKOS023543920
DMGB1QU DT Small molecular drug
DMGB1QU PC 14898716
DMGB1QU MW 225.25
DMGB1QU FM C13H11N3O
DMGB1QU IC InChI=1S/C13H11N3O/c17-13-11-3-1-2-4-12(11)15-16(13)9-10-5-7-14-8-6-10/h1-8,15H,9H2
DMGB1QU CS C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=NC=C3
DMGB1QU IK CCCUFFBZCPVPFV-UHFFFAOYSA-N
DMGB1QU IU 2-(pyridin-4-ylmethyl)-1H-indazol-3-one
DMGB1QU DE Discovery agent
DMVAQOZ ID DMVAQOZ
DMVAQOZ DN 2-Pyridinethiol
DMVAQOZ HS Investigative
DMVAQOZ SN 2-Mercaptopyridine; Pyridine-2-thiol; 2-Pyridinethiol; 2637-34-5; 2-Thiopyridine; Pyrid-2-thione; 2(1H)-PYRIDINETHIONE; Pyridinethione; 1H-pyridine-2-thione; 73018-10-7; 2-pyridylthiol; 2-Thiopyridone; 2-Pyridinethione; 2-Mercapto pyridine; 2-Pyridyl mercaptan; 1,2-dihydropyridine-2-thione; Thiopyridone-2 [French]; 2-pyridinylthiol; Alrithiol-2; NSC 41337; UNII-EE982KT952; CHEBI:45223; EINECS 220-131-9; WHMDPDGBKYUEMW-UHFFFAOYSA-N; EE982KT952; 29468-20-0; 2-Mercaptopyridine, 98%; Thiopyridone-2; PYS; Pyridinethiol; mercaptopyridine
DMVAQOZ DT Small molecular drug
DMVAQOZ PC 2723698
DMVAQOZ MW 111.17
DMVAQOZ FM C5H5NS
DMVAQOZ IC InChI=1S/C5H5NS/c7-5-3-1-2-4-6-5/h1-4H,(H,6,7)
DMVAQOZ CS C1=CC(=S)NC=C1
DMVAQOZ IK WHMDPDGBKYUEMW-UHFFFAOYSA-N
DMVAQOZ IU 1H-pyridine-2-thione
DMVAQOZ CA CAS 73018-10-7
DMVAQOZ CB CHEBI:45223
DMVAQOZ DE Discovery agent
DMN516S ID DMN516S
DMN516S DN 2-pyridylethylamine
DMN516S HS Investigative
DMN516S SN 2-(2-Aminoethyl)pyridine; 2706-56-1; 2-Pyridylethylamine; 2-(pyridin-2-yl)ethanamine; 2-(2-Pyridyl)ethylamine; 2-Pyridineethanamine; 2-pyridin-2-ylethanamine; Demethylbetahistine; alpha-Pyridylethylamine; 2-(pyridin-2-yl)ethan-1-amine; Lilly 04432; Pyridine, 2-(2-aminoethyl)-; UNII-ATW1AH7OJ5; Pyridineethanamine; 2-(2'-Aminoethyl)pyridine; NSC 71989; .alpha.-Pyridylethylamine; EINECS 220-295-1; ATW1AH7OJ5; 2-AMINOETHYLPYRIDINE; 2-(2-Pyridinyl)ethanamine; 2-(2-aminoethyl)-pyridine; 2-(2-aminoethyl) pyridine
DMN516S DT Small molecular drug
DMN516S PC 75919
DMN516S MW 122.17
DMN516S FM C7H10N2
DMN516S IC InChI=1S/C7H10N2/c8-5-4-7-3-1-2-6-9-7/h1-3,6H,4-5,8H2
DMN516S CS C1=CC=NC(=C1)CCN
DMN516S IK XPQIPUZPSLAZDV-UHFFFAOYSA-N
DMN516S IU 2-pyridin-2-ylethanamine
DMN516S CA CAS 2706-56-1
DMN516S CB CHEBI:74024
DMN516S DE Discovery agent
DMBJXCF ID DMBJXCF
DMBJXCF DN 2pyrrolidin-1-yl-1-phenylpentan-1-one
DMBJXCF HS Investigative
DMBJXCF SN 14530-33-7; alpha-PVP; 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one; alpha-pyrrolidinovalerophenone; Desmethyl pyrovalerone; Alpha-Pyrrolidinopentiophenone; CHEMBL205082; 1-Pentanone, 1-phenyl-2-(1-pyrrolidinyl)-; Flakka; beta-Ketone-prolintane; Prolintanone; Gravel; beta-Keto-prolintane; a-PVP; 2pyrrolidin-1-yl-1-phenylpentan-1-one; 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone; a-Pyrrolidinopentiophenone; O-2387; SCHEMBL4936204; DTXSID70456954; YDIIDRWHPFMLGR-UHFFFAOYSA-N; MFCD24386810; BDBM50182584; alpha-Pyrrolidinopentiophenone, a-PVP
DMBJXCF DT Small molecular drug
DMBJXCF PC 11148955
DMBJXCF MW 231.33
DMBJXCF FM C15H21NO
DMBJXCF IC InChI=1S/C15H21NO/c1-2-8-14(16-11-6-7-12-16)15(17)13-9-4-3-5-10-13/h3-5,9-10,14H,2,6-8,11-12H2,1H3
DMBJXCF CS CCCC(C(=O)C1=CC=CC=C1)N2CCCC2
DMBJXCF IK YDIIDRWHPFMLGR-UHFFFAOYSA-N
DMBJXCF IU 1-phenyl-2-pyrrolidin-1-ylpentan-1-one
DMBJXCF CA CAS 14530-33-7
DMBJXCF DE Discovery agent
DMGPI0C ID DMGPI0C
DMGPI0C DN 2-Pyrrolidin-1-yl-benzo[h]chromen-4-one
DMGPI0C HS Investigative
DMGPI0C SN K 12344; BRN 0412624; 4H-Naphtho(1,2-b)pyran-4-one, 2-(1-pyrrolidinyl)-; CHEMBL179914; 2-(1-Pyrrolidinyl)-4H-naphtho(1,2-b)pyran-4-one; 2-(N-Pirrolidil)-4-oxo-4H-nafto(1,2-b)pirano [Italian]; 61035-04-9; 2-Pyrrolidin-1-yl-benzo[h]chromen-4-one; AC1MIJ0D; 2-(N-Pirrolidil)-4-oxo-4H-nafto(1,2-b)pirano; SCHEMBL3535232; DTXSID00209910; BDBM50159631; 2-pyrrolidin-1-ylbenzo[h]chromen-4-one
DMGPI0C DT Small molecular drug
DMGPI0C PC 3045696
DMGPI0C MW 265.31
DMGPI0C FM C17H15NO2
DMGPI0C IC InChI=1S/C17H15NO2/c19-15-11-16(18-9-3-4-10-18)20-17-13-6-2-1-5-12(13)7-8-14(15)17/h1-2,5-8,11H,3-4,9-10H2
DMGPI0C CS C1CCN(C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMGPI0C IK CYNBNMZZLAYOIM-UHFFFAOYSA-N
DMGPI0C IU 2-pyrrolidin-1-ylbenzo[h]chromen-4-one
DMGPI0C CA CAS 61035-04-9
DMGPI0C DE Discovery agent
DMNU1YR ID DMNU1YR
DMNU1YR DN 2S,4R-4-METHYLGLUTAMATE
DMNU1YR HS Investigative
DMNU1YR SN (2S,4R)-4-Methylglutamic acid; 31137-74-3; (2S,4R)-2-amino-4-methylpentanedioic acid; 2S,4R-4-Methylglutamate; CHEMBL288166; 4-Methylglutamic acid; 4-Methylglutamate; (4r)-4-methyl-l-glutamic acid; threo-gamma-Methylglutamate; 2-Amino-4-methyl-pentanedioic acid; 14561-55-8; 59685-03-9; NSC 41355; Tocris-0903; AC1L3VAT; SYM; Biomol-NT_000218; AC1Q5QI2; SCHEMBL594187; BPBio1_001308; CTK5B0310; KRKRAOXTGDJWNI-DMTCNVIQSA-N; MolPort-003-848-893; ZINC896091; Glutamic acid, 4-methyl- (VAN); (2S,4R)-4-methyl gluta
DMNU1YR DT Small molecular drug
DMNU1YR PC 95883
DMNU1YR MW 161.16
DMNU1YR FM C6H11NO4
DMNU1YR IC InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)/t3-,4+/m1/s1
DMNU1YR CS C[C@H](C[C@@H](C(=O)O)N)C(=O)O
DMNU1YR IK KRKRAOXTGDJWNI-DMTCNVIQSA-N
DMNU1YR IU (2S,4R)-2-amino-4-methylpentanedioic acid
DMNU1YR CA CAS 77842-39-8
DMNU1YR DE Discovery agent
DMAO7DS ID DMAO7DS
DMAO7DS DN 2-Sulfamoyl-benzoic acid methyl ester
DMAO7DS HS Investigative
DMAO7DS SN 57683-71-3; Methyl 2-(aminosulfonyl)benzoate; methyl 2-sulfamoylbenzoate; 2-Carbomethoxybenzenesulfonamide; (2-Methoxycarbonyl)benzene sulfonamide; 2-Sulfamoylbenzoic acid methyl ester; Methyl o-sulphamoylbenzoate; Benzoic acid, 2-(aminosulfonyl)-, methyl ester; EINECS 260-903-2; BENZOIC ACID, 2-SULFAMOYL-, METHYL ESTER; BRN 2728611; 2-aminosulfonyl-benzoic acid methyl ester; CHEMBL148680; CHEBI:83512; 2-methoxycarbonylphenylsulfonamide; VSOOBQALJVLTBH-UHFFFAOYSA-N; MFCD00009808; 2-(methoxycarbonyl)benzenesulphonamide
DMAO7DS DT Small molecular drug
DMAO7DS PC 42546
DMAO7DS MW 215.23
DMAO7DS FM C8H9NO4S
DMAO7DS IC InChI=1S/C8H9NO4S/c1-13-8(10)6-4-2-3-5-7(6)14(9,11)12/h2-5H,1H3,(H2,9,11,12)
DMAO7DS CS COC(=O)C1=CC=CC=C1S(=O)(=O)N
DMAO7DS IK VSOOBQALJVLTBH-UHFFFAOYSA-N
DMAO7DS IU methyl 2-sulfamoylbenzoate
DMAO7DS CA CAS 57683-71-3
DMAO7DS CB CHEBI:83512
DMAO7DS DE Discovery agent
DMJBO3D ID DMJBO3D
DMJBO3D DN 2-Sulfhydryl-Ethanol
DMJBO3D HS Investigative
DMJBO3D SN beta-Mercaptoethanol; 2-mercaptoethanol; 60-24-2; Thioglycol; Mercaptoethanol; Beta-Mercaptoethanol; Ethanol, 2-mercapto-; 2-Sulfanylethanol; 2-Thioethanol; Thioethylene glycol; 2-Hydroxyethanethiol; 2-Hydroxyethyl mercaptan; 2-Hydroxy-1-ethanethiol; Thiomonoglycol; Monothioglycol; 2-Mercapto-1-ethanol; 1-Ethanol-2-thiol; Hydroxyethyl mercaptan; Monothioethylene glycol; 2-Mercaptoethyl alcohol; 2-ME; Mercaptoetanol; Ethylene glycol, monothio-; 1-Hydroxy-2-mercaptoethane; 1-Mercapto-2-hydroxyethane; 2-Hydroxyethylmercaptan; Emery 5791; USAF EK-4196
DMJBO3D DT Small molecular drug
DMJBO3D PC 1567
DMJBO3D MW 78.14
DMJBO3D FM C2H6OS
DMJBO3D IC InChI=1S/C2H6OS/c3-1-2-4/h3-4H,1-2H2
DMJBO3D CS C(CS)O
DMJBO3D IK DGVVWUTYPXICAM-UHFFFAOYSA-N
DMJBO3D IU 2-sulfanylethanol
DMJBO3D CA CAS 60-24-2
DMJBO3D CB CHEBI:41218
DMJBO3D DE Discovery agent
DM26NKG ID DM26NKG
DM26NKG DN 2-tert-butoxy-9H-carbazole
DM26NKG HS Investigative
DM26NKG SN CHEMBL1170845; 2-tert-butoxy-9H-carbazole; SCHEMBL13064179
DM26NKG DT Small molecular drug
DM26NKG PC 46855214
DM26NKG MW 239.31
DM26NKG FM C16H17NO
DM26NKG IC InChI=1S/C16H17NO/c1-16(2,3)18-11-8-9-13-12-6-4-5-7-14(12)17-15(13)10-11/h4-10,17H,1-3H3
DM26NKG CS CC(C)(C)OC1=CC2=C(C=C1)C3=CC=CC=C3N2
DM26NKG IK VSDPUTYQQKWFAG-UHFFFAOYSA-N
DM26NKG IU 2-[(2-methylpropan-2-yl)oxy]-9H-carbazole
DM26NKG DE Discovery agent
DMJBQD8 ID DMJBQD8
DMJBQD8 DN 2-tert-butyl-7-(trifluoromethyl)-9H-carbazole
DMJBQD8 HS Investigative
DMJBQD8 SN CHEMBL1171079; 2-tert-butyl-7-(trifluoromethyl)-9H-carbazole; ZINC53230612
DMJBQD8 DT Small molecular drug
DMJBQD8 PC 46855216
DMJBQD8 MW 291.31
DMJBQD8 FM C17H16F3N
DMJBQD8 IC InChI=1S/C17H16F3N/c1-16(2,3)10-4-6-12-13-7-5-11(17(18,19)20)9-15(13)21-14(12)8-10/h4-9,21H,1-3H3
DMJBQD8 CS CC(C)(C)C1=CC2=C(C=C1)C3=C(N2)C=C(C=C3)C(F)(F)F
DMJBQD8 IK XAQHCEWJSXOCDT-UHFFFAOYSA-N
DMJBQD8 IU 2-tert-butyl-7-(trifluoromethyl)-9H-carbazole
DMJBQD8 DE Discovery agent
DM6M8Y3 ID DM6M8Y3
DM6M8Y3 DN 2-tert-butyl-9H-carbazole
DM6M8Y3 HS Investigative
DM6M8Y3 SN 2-TERT-BUTYL-9H-CARBAZOLE; 69386-36-3; CHEMBL1173703; 2-(tert-Butyl)-9H-carbazole; 2-Tert-butylcarbazole; SCHEMBL10312973; CTK2F2146; DTXSID90499227; MolPort-005-941-197; ZINC22003756; BDBM50322580; AKOS015967050
DM6M8Y3 DT Small molecular drug
DM6M8Y3 PC 12462654
DM6M8Y3 MW 223.31
DM6M8Y3 FM C16H17N
DM6M8Y3 IC InChI=1S/C16H17N/c1-16(2,3)11-8-9-13-12-6-4-5-7-14(12)17-15(13)10-11/h4-10,17H,1-3H3
DM6M8Y3 CS CC(C)(C)C1=CC2=C(C=C1)C3=CC=CC=C3N2
DM6M8Y3 IK FUFORZIUGGNDKM-UHFFFAOYSA-N
DM6M8Y3 IU 2-tert-butyl-9H-carbazole
DM6M8Y3 CA CAS 69386-36-3
DM6M8Y3 DE Discovery agent
DMNXI1E ID DMNXI1E
DMNXI1E DN 2-tert-butylbenzene-1,4-diol
DMNXI1E HS Investigative
DMNXI1E SN Tert-Butylhydroquinone; tert-Butylhydroquinone; 1948-33-0; TBHQ; 2-tert-Butylhydroquinone; T-BUTYLHYDROQUINONE; MTBHQ; t-Butyl hydroquinone; 2-tert-Butyl-1,4-benzenediol; 2-t-Butylhydroquinone; Mono-tert-butylhydroquinone; Sustane; Tenox TBHQ; tert-Butyl-1,4-benzenediol; Mono-tertiarybutylhydroquinone; Hydroquinone, tert-butyl-; Banox 20BA; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; tertiary-Butylhydroquinone; 2-(1,1-Dimethylethyl)-1,4-benzenediol; 2-tert-Butyl(1,4)hydroquinone; 2-(tert-butyl)benzene-1,4-diol
DMNXI1E DT Small molecular drug
DMNXI1E PC 16043
DMNXI1E MW 166.22
DMNXI1E FM C10H14O2
DMNXI1E IC InChI=1S/C10H14O2/c1-10(2,3)8-6-7(11)4-5-9(8)12/h4-6,11-12H,1-3H3
DMNXI1E CS CC(C)(C)C1=C(C=CC(=C1)O)O
DMNXI1E IK BGNXCDMCOKJUMV-UHFFFAOYSA-N
DMNXI1E IU 2-tert-butylbenzene-1,4-diol
DMNXI1E CA CAS 1948-33-0
DMNXI1E CB CHEBI:78886
DMNXI1E DE Discovery agent
DMFAV5R ID DMFAV5R
DMFAV5R DN 2-tert-Butyldimethylsilyloxylycorine
DMFAV5R HS Investigative
DMFAV5R SN 2-tert-Butyldimethylsilyloxylycorine; CHEMBL558873; SCHEMBL12270994; BDBM50293600
DMFAV5R DT Small molecular drug
DMFAV5R PC 44191462
DMFAV5R MW 401.6
DMFAV5R FM C22H31NO4Si
DMFAV5R IC InChI=1S/C22H31NO4Si/c1-22(2,3)28(4,5)27-18-8-13-6-7-23-11-14-9-16-17(26-12-25-16)10-15(14)19(20(13)23)21(18)24/h8-10,18-21,24H,6-7,11-12H2,1-5H3/t18-,19-,20+,21+/m0/s1
DMFAV5R CS CC(C)(C)[Si](C)(C)O[C@H]1C=C2CCN3[C@H]2[C@@H]([C@@H]1O)C4=CC5=C(C=C4C3)OCO5
DMFAV5R IK RLYPONLPAHPYMG-UWHLTILDSA-N
DMFAV5R IU (1S,17S,18S,19S)-17-[tert-butyl(dimethyl)silyl]oxy-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraen-18-ol
DMFAV5R DE Discovery agent
DM35JQS ID DM35JQS
DM35JQS DN 2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one
DM35JQS HS Investigative
DM35JQS SN 2-(Thiazol-5-ylmethyl)-1H-indazol-3(2H)-one; 120273-62-3; CHEMBL3144715; 1,2-dihydro-2-(5-thiazolylmethyl)-3H-indazol-3-one; 2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL267524; SCHEMBL16160907; BDBM50008996; ZINC100161259; AKOS022188370; AJ-64420; AJ-64421; AX8285840
DM35JQS DT Small molecular drug
DM35JQS PC 14898745
DM35JQS MW 231.28
DM35JQS FM C11H9N3OS
DM35JQS IC InChI=1S/C11H9N3OS/c15-11-9-3-1-2-4-10(9)13-14(11)6-8-5-12-7-16-8/h1-5,7,13H,6H2
DM35JQS CS C1=CC=C2C(=C1)C(=O)N(N2)CC3=CN=CS3
DM35JQS IK KPXSUQVYEHMEMW-UHFFFAOYSA-N
DM35JQS IU 2-(1,3-thiazol-5-ylmethyl)-1H-indazol-3-one
DM35JQS DE Discovery agent
DMEY9T2 ID DMEY9T2
DMEY9T2 DN 2-Thioethenamine
DMEY9T2 HS Investigative
DMEY9T2 SN AC1NXIBI; (E)-2-aminoethenethiol
DMEY9T2 DT Small molecular drug
DMEY9T2 PC 5806800
DMEY9T2 MW 75.14
DMEY9T2 FM C2H5NS
DMEY9T2 IC InChI=1S/C2H5NS/c3-1-2-4/h1-2,4H,3H2/b2-1+
DMEY9T2 CS C(=C/S)\\N
DMEY9T2 IK JLZMZFJVTNYDOT-OWOJBTEDSA-N
DMEY9T2 IU (E)-2-aminoethenethiol
DMEY9T2 CA CAS 676992-63-5
DMEY9T2 DE Discovery agent
DMCEK6N ID DMCEK6N
DMCEK6N DN 2-Thiomethyl-3-Phenylpropanoic Acid
DMCEK6N HS Investigative
DMCEK6N SN 2-Thiomethyl-3-phenylpropanoic acid; 2-THIOMETHYL-3-PHENYLPROPANOIC ACID; CHEMBL90403; (2S)-2-benzyl-3-sulfanylpropanoic acid; S-BMPA; AC1NRAFB; GTPL8676; SCHEMBL1464853; BDBM50281176; DB02953; (S)-2-Mercaptomethyl-3-phenyl-propionic acid; (S)-alpha-(Mercaptomethyl)benzenepropionic acid; (2S)-2-(phenylmethyl)-3-sulfanylpropanoic
DMCEK6N DT Small molecular drug
DMCEK6N PC 5287850
DMCEK6N MW 196.27
DMCEK6N FM C10H12O2S
DMCEK6N IC InChI=1S/C10H12O2S/c11-10(12)9(7-13)6-8-4-2-1-3-5-8/h1-5,9,13H,6-7H2,(H,11,12)/t9-/m1/s1
DMCEK6N CS C1=CC=C(C=C1)C[C@H](CS)C(=O)O
DMCEK6N IK ZUEBVBPVXLQMQR-SECBINFHSA-N
DMCEK6N IU (2S)-2-benzyl-3-sulfanylpropanoic acid
DMCEK6N DE Discovery agent
DMSKNBA ID DMSKNBA
DMSKNBA DN 2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one
DMSKNBA HS Investigative
DMSKNBA SN CHEMBL179168; 2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one; SCHEMBL3540143
DMSKNBA DT Small molecular drug
DMSKNBA PC 11289486
DMSKNBA MW 297.4
DMSKNBA FM C16H15N3OS
DMSKNBA IC InChI=1S/C16H15N3OS/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2
DMSKNBA CS C1CSCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=N2
DMSKNBA IK LGFZVFQIQUWUBJ-UHFFFAOYSA-N
DMSKNBA IU 2-thiomorpholin-4-ylpyrimido[2,1-a]isoquinolin-4-one
DMSKNBA DE Discovery agent
DMFXG2E ID DMFXG2E
DMFXG2E DN 2-thiomorpholino-4H-benzo[h]chromen-4-one
DMFXG2E HS Investigative
DMFXG2E SN CHEMBL360038; 2-thiomorpholino-4H-benzo[h]chromen-4-one; SCHEMBL3537842; BDBM50159639
DMFXG2E DT Small molecular drug
DMFXG2E PC 11174002
DMFXG2E MW 297.4
DMFXG2E FM C17H15NO2S
DMFXG2E IC InChI=1S/C17H15NO2S/c19-15-11-16(18-7-9-21-10-8-18)20-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
DMFXG2E CS C1CSCCN1C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMFXG2E IK IIWOVJPSKUAWDA-UHFFFAOYSA-N
DMFXG2E IU 2-thiomorpholin-4-ylbenzo[h]chromen-4-one
DMFXG2E DE Discovery agent
DMPF598 ID DMPF598
DMPF598 DN 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598 HS Investigative
DMPF598 SN CHEMBL319249; ZINC13756973
DMPF598 DT Small molecular drug
DMPF598 PC 10705898
DMPF598 MW 251.31
DMPF598 FM C14H9N3S
DMPF598 IC InChI=1S/C14H9N3S/c1-2-5-10-9(4-1)13-11(8-15-10)16-14(17-13)12-6-3-7-18-12/h1-8H,(H,16,17)
DMPF598 CS C1=CC=C2C(=C1)C3=C(C=N2)NC(=N3)C4=CC=CS4
DMPF598 IK APVZAVOHLAQECW-UHFFFAOYSA-N
DMPF598 IU 2-thiophen-2-yl-3H-imidazo[4,5-c]quinoline
DMPF598 DE Discovery agent
DM4J8B9 ID DM4J8B9
DM4J8B9 DN 2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one
DM4J8B9 HS Investigative
DM4J8B9 SN CHEMBL3144717; 1,2-dihydro-2-(2-thienylmethyl)-3H-indazol-3-one; 120273-89-4; 2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one; CHEMBL269658; BDBM50008989
DM4J8B9 DT Small molecular drug
DM4J8B9 PC 14898713
DM4J8B9 MW 230.29
DM4J8B9 FM C12H10N2OS
DM4J8B9 IC InChI=1S/C12H10N2OS/c15-12-10-5-1-2-6-11(10)13-14(12)8-9-4-3-7-16-9/h1-7,13H,8H2
DM4J8B9 CS C1=CC=C2C(=C1)C(=O)N(N2)CC3=CC=CS3
DM4J8B9 IK JGPURYLHMLRGGI-UHFFFAOYSA-N
DM4J8B9 IU 2-(thiophen-2-ylmethyl)-1H-indazol-3-one
DM4J8B9 DE Discovery agent
DMIEGF4 ID DMIEGF4
DMIEGF4 DN 2-THIOSALVINORIN B
DMIEGF4 HS Investigative
DMIEGF4 SN 2-thiosalvinorin B; CHEMBL231536; SCHEMBL13415898
DMIEGF4 DT Small molecular drug
DMIEGF4 PC 17747979
DMIEGF4 MW 406.5
DMIEGF4 FM C21H26O6S
DMIEGF4 IC InChI=1S/C21H26O6S/c1-20-6-4-12-19(24)27-14(11-5-7-26-10-11)9-21(12,2)17(20)16(22)15(28)8-13(20)18(23)25-3/h5,7,10,12-15,17,28H,4,6,8-9H2,1-3H3/t12-,13-,14-,15-,17-,20-,21-/m0/s1
DMIEGF4 CS C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)S)C)C4=COC=C4
DMIEGF4 IK NGNBKFTYZQINBO-CEFSSPBYSA-N
DMIEGF4 IU methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-sulfanyl-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMIEGF4 DE Discovery agent
DM84R6C ID DM84R6C
DM84R6C DN 2-thio-UDP
DM84R6C HS Investigative
DM84R6C SN CHEMBL216011; 2-thio-UDP; thiouridine 5'-diphosphate; GTPL6202; SCHEMBL9397187; BDBM50194160; [(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate; (2R,3R,4S,5R)-1-(3,4-dihydroxy-5-(diphosphoryloxymethyl)-tetrahydrofuran-2-yl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one ammonium salt
DM84R6C DT Small molecular drug
DM84R6C PC 16082712
DM84R6C MW 420.23
DM84R6C FM C9H14N2O11P2S
DM84R6C IC InChI=1S/C9H14N2O11P2S/c12-5-1-2-11(9(25)10-5)8-7(14)6(13)4(21-8)3-20-24(18,19)22-23(15,16)17/h1-2,4,6-8,13-14H,3H2,(H,18,19)(H,10,12,25)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DM84R6C CS C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O
DM84R6C IK BMJOHSBBMARQHC-XVFCMESISA-N
DM84R6C IU [(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
DM84R6C DE Discovery agent
DMJZ5V0 ID DMJZ5V0
DMJZ5V0 DN 2-thioUTP
DMJZ5V0 HS Investigative
DMJZ5V0 SN 2-thio-UTP
DMJZ5V0 DT Small molecular drug
DMJZ5V0 PC 10174453
DMJZ5V0 MW 500.21
DMJZ5V0 FM C9H15N2O14P3S
DMJZ5V0 IC InChI=1S/C9H15N2O14P3S/c12-5-1-2-11(9(29)10-5)8-7(14)6(13)4(23-8)3-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,4,6-8,13-14H,3H2,(H,18,19)(H,20,21)(H,10,12,29)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DMJZ5V0 CS C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMJZ5V0 IK KHYOUGAATNYCAZ-XVFCMESISA-N
DMJZ5V0 IU [[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMJZ5V0 DE Discovery agent
DM1HABS ID DM1HABS
DM1HABS DN 2-tolyl-6-phenyl-9H-purine
DM1HABS HS Investigative
DM1HABS SN CHEMBL205194; 2-tolyl-6-phenyl-9H-purine
DM1HABS DT Small molecular drug
DM1HABS PC 11652153
DM1HABS MW 286.3
DM1HABS FM C18H14N4
DM1HABS IC InChI=1S/C18H14N4/c1-12-7-9-14(10-8-12)17-21-15(13-5-3-2-4-6-13)16-18(22-17)20-11-19-16/h2-11H,1H3,(H,19,20,21,22)
DM1HABS CS CC1=CC=C(C=C1)C2=NC(=C3C(=N2)N=CN3)C4=CC=CC=C4
DM1HABS IK OPFZHJCGZXEIRY-UHFFFAOYSA-N
DM1HABS IU 2-(4-methylphenyl)-6-phenyl-7H-purine
DM1HABS DE Discovery agent
DMOFDVE ID DMOFDVE
DMOFDVE DN 2-tosylanthracene-1,4-diol
DMOFDVE HS Investigative
DMOFDVE SN CHEMBL451059; 2-tosylanthracene-1,4-diol
DMOFDVE DT Small molecular drug
DMOFDVE PC 44562748
DMOFDVE MW 364.4
DMOFDVE FM C21H16O4S
DMOFDVE IC InChI=1S/C21H16O4S/c1-13-6-8-16(9-7-13)26(24,25)20-12-19(22)17-10-14-4-2-3-5-15(14)11-18(17)21(20)23/h2-12,22-23H,1H3
DMOFDVE CS CC1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC4=CC=CC=C4C=C3C(=C2)O)O
DMOFDVE IK DKOISANXNBXJMG-UHFFFAOYSA-N
DMOFDVE IU 2-(4-methylphenyl)sulfonylanthracene-1,4-diol
DMOFDVE DE Discovery agent
DM8LS6H ID DM8LS6H
DM8LS6H DN 2-tosylbenzene-1,4-diol
DM8LS6H HS Investigative
DM8LS6H SN 2-tosylbenzene-1,4-diol; 2-Tosylhydroquinone; 30958-16-8; CHEMBL462375; 2-(4-Methylbenzenesulfonyl)benzene-1,4-diol; 2-[(4-methylphenyl)sulfonyl]benzene-1,4-diol; AC1LDN5E; CBMicro_029952; Cambridge id 5869439; Oprea1_104843; Oprea1_717162; SCHEMBL10489221; ZINC36613; MolPort-015-161-937; JDVLOEPBUIGUKP-UHFFFAOYSA-N; MolPort-000-279-703; BDBM50245925; STK739706; AKOS000727738; MCULE-7472387969; BAS 00095777; ST001815; BIM-0030021.P001; 2-(Toluene-4-sulfonyl)-benzene-1,4-diol; 2-(4-methylphenyl)sulfonylbenzene-1,4-diol
DM8LS6H DT Small molecular drug
DM8LS6H PC 621969
DM8LS6H MW 264.3
DM8LS6H FM C13H12O4S
DM8LS6H IC InChI=1S/C13H12O4S/c1-9-2-5-11(6-3-9)18(16,17)13-8-10(14)4-7-12(13)15/h2-8,14-15H,1H3
DM8LS6H CS CC1=CC=C(C=C1)S(=O)(=O)C2=C(C=CC(=C2)O)O
DM8LS6H IK JDVLOEPBUIGUKP-UHFFFAOYSA-N
DM8LS6H IU 2-(4-methylphenyl)sulfonylbenzene-1,4-diol
DM8LS6H CA CAS 30958-16-8
DM8LS6H DE Discovery agent
DM2OUG0 ID DM2OUG0
DM2OUG0 DN 2-tosylnaphthalene
DM2OUG0 HS Investigative
DM2OUG0 SN 2-tosylnaphthalene; 2-Naphthyl-p-tolyl sulfone; CHEMBL462553; AC1LAR2N; SCHEMBL9587829; UOUHDIZYOCFQKG-UHFFFAOYSA-N; 4-methylphenyl 2-naphthyl sulfone; ZINC32149231; BDBM50245927; 2-(4-methylphenyl)sulfonylnaphthalene; 2-[(4-Methylphenyl)sulfonyl]naphthalene; 2-[(4-Methylphenyl)sulfonyl]naphthalene #
DM2OUG0 DT Small molecular drug
DM2OUG0 PC 518736
DM2OUG0 MW 282.4
DM2OUG0 FM C17H14O2S
DM2OUG0 IC InChI=1S/C17H14O2S/c1-13-6-9-16(10-7-13)20(18,19)17-11-8-14-4-2-3-5-15(14)12-17/h2-12H,1H3
DM2OUG0 CS CC1=CC=C(C=C1)S(=O)(=O)C2=CC3=CC=CC=C3C=C2
DM2OUG0 IK UOUHDIZYOCFQKG-UHFFFAOYSA-N
DM2OUG0 IU 2-(4-methylphenyl)sulfonylnaphthalene
DM2OUG0 DE Discovery agent
DM5FHO4 ID DM5FHO4
DM5FHO4 DN 2-Tosylnaphthalene-1,4-diol
DM5FHO4 HS Investigative
DM5FHO4 SN CHEMBL509952; 2-Tosylnaphthalene-1,4-diol; 4-Tolyl-2-[1,4-dihydroxynaphthyl]sulfone; AC1LC4IM; CYYDOKQRZQTSOL-UHFFFAOYSA-N; BDBM50245828; 2-(4-methylphenyl)sulfonylnaphthalene-1,4-diol; 2-[(4-Methylphenyl)sulfonyl]-1,4-naphthalenediol #
DM5FHO4 DT Small molecular drug
DM5FHO4 PC 594215
DM5FHO4 MW 314.4
DM5FHO4 FM C17H14O4S
DM5FHO4 IC InChI=1S/C17H14O4S/c1-11-6-8-12(9-7-11)22(20,21)16-10-15(18)13-4-2-3-5-14(13)17(16)19/h2-10,18-19H,1H3
DM5FHO4 CS CC1=CC=C(C=C1)S(=O)(=O)C2=C(C3=CC=CC=C3C(=C2)O)O
DM5FHO4 IK CYYDOKQRZQTSOL-UHFFFAOYSA-N
DM5FHO4 IU 2-(4-methylphenyl)sulfonylnaphthalene-1,4-diol
DM5FHO4 DE Discovery agent
DMK9OYM ID DMK9OYM
DMK9OYM DN 2-tosylnaphthalene-1,4-dione
DMK9OYM HS Investigative
DMK9OYM SN 2-[4-Toluenesulfonyl]-1,4-naphthoquinone; CHEMBL454282; 2-(4-methylphenyl)sulfonylnaphthalene-1,4-dione; 40852-77-5; 2-tosylnaphthalene-1,4-dione; NSC124929; AC1L5KCI; AC1Q6TN2; CTK4I3907; DTXSID00298642; UCFUGRHGHVYUOA-UHFFFAOYSA-N; ZINC1714192; BDBM50245928; NSC-124929; 2-(p-Tolylsulfonyl)-1,4-naphthoquinone; 2-[(4-Methylphenyl)sulfonyl]naphthoquinone #
DMK9OYM DT Small molecular drug
DMK9OYM PC 276683
DMK9OYM MW 312.3
DMK9OYM FM C17H12O4S
DMK9OYM IC InChI=1S/C17H12O4S/c1-11-6-8-12(9-7-11)22(20,21)16-10-15(18)13-4-2-3-5-14(13)17(16)19/h2-10H,1H3
DMK9OYM CS CC1=CC=C(C=C1)S(=O)(=O)C2=CC(=O)C3=CC=CC=C3C2=O
DMK9OYM IK UCFUGRHGHVYUOA-UHFFFAOYSA-N
DMK9OYM IU 2-(4-methylphenyl)sulfonylnaphthalene-1,4-dione
DMK9OYM CA CAS 40852-77-5
DMK9OYM DE Discovery agent
DMVJORE ID DMVJORE
DMVJORE DN 2-trityl-4,5-dihydrooxazole
DMVJORE HS Investigative
DMVJORE SN CHEMBL271167
DMVJORE DT Small molecular drug
DMVJORE PC 24799664
DMVJORE MW 313.4
DMVJORE FM C22H19NO
DMVJORE IC InChI=1S/C22H19NO/c1-4-10-18(11-5-1)22(21-23-16-17-24-21,19-12-6-2-7-13-19)20-14-8-3-9-15-20/h1-15H,16-17H2
DMVJORE CS C1COC(=N1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
DMVJORE IK PHFOYYZFWZIUBU-UHFFFAOYSA-N
DMVJORE IU 2-trityl-4,5-dihydro-1,3-oxazole
DMVJORE DE Discovery agent
DM8XSE3 ID DM8XSE3
DM8XSE3 DN 2-valproylamido-5-sulfonamidoindane
DM8XSE3 HS Investigative
DM8XSE3 SN CHEMBL381730; 2-valproylamido-5-sulfonamidoindane; Indanesulfonamide Derivative 12a; BDBM11031
DM8XSE3 DT Small molecular drug
DM8XSE3 PC 11537386
DM8XSE3 MW 338.5
DM8XSE3 FM C17H26N2O3S
DM8XSE3 IC InChI=1S/C17H26N2O3S/c1-3-5-12(6-4-2)17(20)19-15-9-13-7-8-16(23(18,21)22)11-14(13)10-15/h7-8,11-12,15H,3-6,9-10H2,1-2H3,(H,19,20)(H2,18,21,22)
DM8XSE3 CS CCCC(CCC)C(=O)NC1CC2=C(C1)C=C(C=C2)S(=O)(=O)N
DM8XSE3 IK XBYJCVDSFWJBSM-UHFFFAOYSA-N
DM8XSE3 IU 2-propyl-N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)pentanamide
DM8XSE3 DE Discovery agent
DMOAY8R ID DMOAY8R
DMOAY8R DN 3 9-DIHYDRO-N-DESMETHYL-N-ISOPROPYLERYTHROMYCIN A
DMOAY8R HS Investigative
DMOAY8R SN CHEMBL584549; 3 9-dihydro-N-desmethyl-N-isopropylerythromycin A; SCHEMBL13681692
DMOAY8R DT Small molecular drug
DMOAY8R PC 44542667
DMOAY8R MW 764
DMOAY8R FM C39H73NO13
DMOAY8R IC InChI=1S/C39H73NO13/c1-15-27-39(12,47)32(43)22(6)29(41)20(4)17-37(10,46)34(53-36-30(42)26(16-21(5)49-36)40(13)19(2)3)23(7)31(24(8)35(45)51-27)52-28-18-38(11,48-14)33(44)25(9)50-28/h19-34,36,41-44,46-47H,15-18H2,1-14H3/t20-,21-,22+,23+,24-,25+,26+,27-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39-/m1/s1
DMOAY8R CS CC[C@@H]1[C@@]([C@@H]([C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C(C)C)O)(C)O)C)O)C)O)(C)O
DMOAY8R IK RXJCJWPPKSQMAS-IRNFSOKPSA-N
DMOAY8R IU (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ethyl-7,10,12,13-tetrahydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-6-[(2S,3R,4S,6R)-3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
DMOAY8R DE Discovery agent
DM1L5IJ ID DM1L5IJ
DM1L5IJ DN 3 beta-O-acetyloleanolic acid
DM1L5IJ HS Investigative
DM1L5IJ SN 3 beta-O-acetyloleanolic acid; CHEMBL503071
DM1L5IJ DT Small molecular drug
DM1L5IJ PC 44583799
DM1L5IJ MW 498.7
DM1L5IJ FM C32H50O4
DM1L5IJ IC InChI=1S/C32H50O4/c1-27(2)15-17-32(26(34)35)18-16-30(6)20(22(32)19-27)9-10-24-29(5)13-11-21(25(33)36-8)28(3,4)23(29)12-14-31(24,30)7/h9,21-24H,10-19H2,1-8H3,(H,34,35)/t21-,22+,23+,24-,29+,30-,31-,32+/m1/s1
DM1L5IJ CS C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)C(=O)OC
DM1L5IJ IK HDWYAPCZHCDUNP-JVZQWSIASA-N
DM1L5IJ IU (4aS,6aR,6aS,6bR,8aS,10S,12aS,14bS)-10-methoxycarbonyl-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM1L5IJ DE Discovery agent
DM491YV ID DM491YV
DM491YV DN 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one
DM491YV HS Investigative
DM491YV SN CHEMBL350922; 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one; BDBM50097364; 3-Imidazol-1-ylmethyl-xanthen-9-one
DM491YV DT Small molecular drug
DM491YV PC 10588478
DM491YV MW 276.29
DM491YV FM C17H12N2O2
DM491YV IC InChI=1S/C17H12N2O2/c20-17-13-3-1-2-4-15(13)21-16-9-12(5-6-14(16)17)10-19-8-7-18-11-19/h1-9,11H,10H2
DM491YV CS C1=CC=C2C(=C1)C(=O)C3=C(O2)C=C(C=C3)CN4C=CN=C4
DM491YV IK GFCUIFVKCOEHQN-UHFFFAOYSA-N
DM491YV IU 3-(imidazol-1-ylmethyl)xanthen-9-one
DM491YV DE Discovery agent
DMZ9L6Q ID DMZ9L6Q
DMZ9L6Q DN 3-((1H-imidazol-1-yl)methyl)aniline
DMZ9L6Q HS Investigative
DMZ9L6Q SN 3-(1H-imidazol-1-ylmethyl)aniline; 120107-85-9; 3-((1H-imidazol-1-yl)methyl)aniline; 3-(1-Imidazolylmethyl)aniline; 3-(imidazol-1-ylmethyl)aniline; Benzenamine, 3-(1H-imidazol-1-ylmethyl)-; 3-Imidazol-1-ylmethyl-phenylamine; Benzenamine,3-(1H-imidazol-1-ylmethyl)-; CHEMBL597369; 3-(imidazolylmethyl)phenylamine; 3-[(1H-Imidazol-1-yl)methyl]aniline; ACMC-20e0av; AC1Q51NE; 1-(3-aminobenzyl)imidazole; SCHEMBL860653; 3-(Imidazo-1-ylmethyl)aniline; AC1O5C89; CTK4B1687; DTXSID20424305; MolPort-000-143-257
DMZ9L6Q DT Small molecular drug
DMZ9L6Q PC 6481821
DMZ9L6Q MW 173.21
DMZ9L6Q FM C10H11N3
DMZ9L6Q IC InChI=1S/C10H11N3/c11-10-3-1-2-9(6-10)7-13-5-4-12-8-13/h1-6,8H,7,11H2
DMZ9L6Q CS C1=CC(=CC(=C1)N)CN2C=CN=C2
DMZ9L6Q IK HOZXQBSHRUITCX-UHFFFAOYSA-N
DMZ9L6Q IU 3-(imidazol-1-ylmethyl)aniline
DMZ9L6Q CA CAS 120107-85-9
DMZ9L6Q DE Discovery agent
DMJ6O43 ID DMJ6O43
DMJ6O43 DN 3-((1H-imidazol-4-yl)methyl)pyridine
DMJ6O43 HS Investigative
DMJ6O43 SN CHEMBL78838; 3-((1H-imidazol-4-yl)methyl)pyridine; BDBM50326297
DMJ6O43 DT Small molecular drug
DMJ6O43 PC 9812843
DMJ6O43 MW 159.19
DMJ6O43 FM C9H9N3
DMJ6O43 IC InChI=1S/C9H9N3/c1-2-8(5-10-3-1)4-9-6-11-7-12-9/h1-3,5-7H,4H2,(H,11,12)
DMJ6O43 CS C1=CC(=CN=C1)CC2=CN=CN2
DMJ6O43 IK IQMRECYOUIKYGG-UHFFFAOYSA-N
DMJ6O43 IU 3-(1H-imidazol-5-ylmethyl)pyridine
DMJ6O43 DE Discovery agent
DMSGX7V ID DMSGX7V
DMSGX7V DN 3-((2-Pyrrolidine-1-yl)-ethyl)uracil
DMSGX7V HS Investigative
DMSGX7V SN CHEMBL1275720; 3-((2-pyrrolidin-1-yl)ethyl)uracil; 1254329-95-7; 3-((2-Pyrrolidine-1-yl)-ethyl)uracil
DMSGX7V DT Small molecular drug
DMSGX7V PC 49845542
DMSGX7V MW 209.24
DMSGX7V FM C10H15N3O2
DMSGX7V IC InChI=1S/C10H15N3O2/c14-9-3-4-11-10(15)13(9)8-7-12-5-1-2-6-12/h3-4H,1-2,5-8H2,(H,11,15)
DMSGX7V CS C1CCN(C1)CCN2C(=O)C=CNC2=O
DMSGX7V IK XKWFMZHWDROEIH-UHFFFAOYSA-N
DMSGX7V IU 3-(2-pyrrolidin-1-ylethyl)-1H-pyrimidine-2,4-dione
DMSGX7V DE Discovery agent
DMJZK40 ID DMJZK40
DMJZK40 DN 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
DMJZK40 HS Investigative
DMJZK40 DT Small molecular drug
DMJZK40 PC 9964499
DMJZK40 DE Discovery agent
DME3079 ID DME3079
DME3079 DN 3-((3-bromothiophen-2-yl)methylene)indolin-2-one
DME3079 HS Investigative
DME3079 SN CHEMBL230414; 3-((3-bromothiophen-2-yl)methylene)indolin-2-one
DME3079 DT Small molecular drug
DME3079 PC 22394620
DME3079 MW 306.18
DME3079 FM C13H8BrNOS
DME3079 IC InChI=1S/C13H8BrNOS/c14-10-5-6-17-12(10)7-9-8-3-1-2-4-11(8)15-13(9)16/h1-7H,(H,15,16)/b9-7+
DME3079 CS C1=CC=C2C(=C1)/C(=C\\C3=C(C=CS3)Br)/C(=O)N2
DME3079 IK ZGCKMTQNGWQKEN-VQHVLOKHSA-N
DME3079 IU (3E)-3-[(3-bromothiophen-2-yl)methylidene]-1H-indol-2-one
DME3079 DE Discovery agent
DM37X04 ID DM37X04
DM37X04 DN 3-((4-aminophenyl)diazenyl)benzenesulfonamide
DM37X04 HS Investigative
DM37X04 SN 3-(4'-Aminophenyl)diazenylbenzenesulfonamide
DM37X04 DT Small molecular drug
DM37X04 PC 44246267
DM37X04 MW 276.32
DM37X04 FM C12H12N4O2S
DM37X04 IC InChI=1S/C12H12N4O2S/c13-9-4-6-10(7-5-9)15-16-11-2-1-3-12(8-11)19(14,17)18/h1-8H,13H2,(H2,14,17,18)
DM37X04 CS C1=CC(=CC(=C1)S(=O)(=O)N)N=NC2=CC=C(C=C2)N
DM37X04 IK VAOWCMBATGAWIO-UHFFFAOYSA-N
DM37X04 IU 3-[(4-aminophenyl)diazenyl]benzenesulfonamide
DM37X04 DE Discovery agent
DMAPZQW ID DMAPZQW
DMAPZQW DN 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DMAPZQW HS Investigative
DMAPZQW DT Small molecular drug
DMAPZQW PC 135932620
DMAPZQW MW 277.3
DMAPZQW FM C12H11N3O3S
DMAPZQW IC InChI=1S/C12H11N3O3S/c13-19(17,18)12-3-1-2-10(8-12)15-14-9-4-6-11(16)7-5-9/h1-8,16H,(H2,13,17,18)
DMAPZQW CS C1=CC(=CC(=C1)S(=O)(=O)N)N=NC2=CC=C(C=C2)O
DMAPZQW IK HJVKSSWMWPZDOV-UHFFFAOYSA-N
DMAPZQW IU 3-[(4-hydroxyphenyl)diazenyl]benzenesulfonamide
DMAPZQW DE Discovery agent
DMAO64J ID DMAO64J
DMAO64J DN 3-((E)-Styryl)-quinoline
DMAO64J HS Investigative
DMAO64J SN CHEMBL65858; 3-((E)-Styryl)-quinoline; (e)-3-styrylquinoline; 3-[(E)-Styryl]quinoline; SCHEMBL3164863; ZINC3832235; BDBM50039053
DMAO64J DT Small molecular drug
DMAO64J PC 10243001
DMAO64J MW 231.29
DMAO64J FM C17H13N
DMAO64J IC InChI=1S/C17H13N/c1-2-6-14(7-3-1)10-11-15-12-16-8-4-5-9-17(16)18-13-15/h1-13H/b11-10+
DMAO64J CS C1=CC=C(C=C1)/C=C/C2=CC3=CC=CC=C3N=C2
DMAO64J IK OHHPAEZEBAYVPW-ZHACJKMWSA-N
DMAO64J IU 3-[(E)-2-phenylethenyl]quinoline
DMAO64J DE Discovery agent
DMZU74I ID DMZU74I
DMZU74I DN 3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine
DMZU74I HS Investigative
DMZU74I SN CHEMBL55138; 3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine
DMZU74I DT Small molecular drug
DMZU74I PC 44297909
DMZU74I MW 276.07
DMZU74I FM C8H9IN2O
DMZU74I IC InChI=1S/C8H9IN2O/c9-6-3-7(5-10-4-6)12-8-1-2-11-8/h3-5,8,11H,1-2H2/t8-/m0/s1
DMZU74I CS C1CN[C@H]1OC2=CC(=CN=C2)I
DMZU74I IK KSOZTGQWGPTPSV-QMMMGPOBSA-N
DMZU74I IU 3-[(2S)-azetidin-2-yl]oxy-5-iodopyridine
DMZU74I DE Discovery agent
DM57ZMJ ID DM57ZMJ
DM57ZMJ DN 3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine
DM57ZMJ HS Investigative
DM57ZMJ SN CHEMBL440299; 87372-78-9; 3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine; CTK3C4529; DTXSID20658229; ZINC29556563; BDBM50028169; 3-(2-Methyl-1-phenylpropan-2-yl)pyridine; Pyridine, 3-(1,1-dimethyl-2-phenylethyl)-
DM57ZMJ DT Small molecular drug
DM57ZMJ PC 44299138
DM57ZMJ MW 211.3
DM57ZMJ FM C15H17N
DM57ZMJ IC InChI=1S/C15H17N/c1-15(2,14-9-6-10-16-12-14)11-13-7-4-3-5-8-13/h3-10,12H,11H2,1-2H3
DM57ZMJ CS CC(C)(CC1=CC=CC=C1)C2=CN=CC=C2
DM57ZMJ IK MSUUKPGKCBHOAJ-UHFFFAOYSA-N
DM57ZMJ IU 3-(2-methyl-1-phenylpropan-2-yl)pyridine
DM57ZMJ CA CAS 87372-78-9
DM57ZMJ DE Discovery agent
DMTDB62 ID DMTDB62
DMTDB62 DN 3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole
DMTDB62 HS Investigative
DMTDB62 SN 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole; 65347-55-9; 38620-69-8; MLS000093715; SMR000029333; CHEMBL27811; 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole; 3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole; 3-(4-1,2,5,6-tetrahydropyridyl)indole; THPindole; ChemDiv2_002931; AC1Q1GX4; SCHEMBL653742; AC1MC402; CTK5C2597; cid_2761023; BDBM31023; DTXSID20375484; CIRSPTXGPFAXRE-UHFFFAOYSA-N; MolPort-000-159-541; HMS1377F05; ZINC154399; STK801496; 2202AE; SBB092334; BBL010213; MFCD03695471; AKOS000505683; FS-1743; NE12559; CCG-139909
DMTDB62 DT Small molecular drug
DMTDB62 PC 2761023
DMTDB62 MW 198.26
DMTDB62 FM C13H14N2
DMTDB62 IC InChI=1S/C13H14N2/c1-2-4-13-11(3-1)12(9-15-13)10-5-7-14-8-6-10/h1-5,9,14-15H,6-8H2
DMTDB62 CS C1CNCC=C1C2=CNC3=CC=CC=C32
DMTDB62 IK CIRSPTXGPFAXRE-UHFFFAOYSA-N
DMTDB62 IU 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
DMTDB62 CA CAS 65347-55-9
DMTDB62 DE Discovery agent
DM5UL3F ID DM5UL3F
DM5UL3F DN 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine
DM5UL3F HS Investigative
DM5UL3F SN 3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
DM5UL3F DT Small molecular drug
DM5UL3F PC 452142
DM5UL3F MW 293.28
DM5UL3F FM C12H15N5O4
DM5UL3F IC InChI=1S/C12H15N5O4/c1-7-5-16(12(20)14-11(7)19)10-4-8(9(6-18)21-10)17-3-2-13-15-17/h2-3,5,8-10,18H,4,6H2,1H3,(H,14,19,20)/t8-,9+,10+/m0/s1
DM5UL3F CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N3C=CN=N3
DM5UL3F IK CPWUCLYZTKEZPT-IVZWLZJFSA-N
DM5UL3F IU 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DM5UL3F CA CAS 122370-58-5
DM5UL3F DE Discovery agent
DMXZBQL ID DMXZBQL
DMXZBQL DN 3-(1,2-dihydroacenaphthylen-3-yl)pyridine
DMXZBQL HS Investigative
DMXZBQL SN acenaphthene derivative A; 3-(1,2-dihydroacenaphthylen-3-yl)pyridine; CHEMBL372747; SCHEMBL4225082
DMXZBQL DT Small molecular drug
DMXZBQL PC 11586681
DMXZBQL MW 231.29
DMXZBQL FM C17H13N
DMXZBQL IC InChI=1S/C17H13N/c1-3-12-6-8-15(14-5-2-10-18-11-14)16-9-7-13(4-1)17(12)16/h1-6,8,10-11H,7,9H2
DMXZBQL CS C1CC2=C(C=CC3=C2C1=CC=C3)C4=CN=CC=C4
DMXZBQL IK CKORXOPHZBFEPV-UHFFFAOYSA-N
DMXZBQL IU 3-(1,2-dihydroacenaphthylen-3-yl)pyridine
DMXZBQL DE Discovery agent
DMHB4PA ID DMHB4PA
DMHB4PA DN 3-(1,2-dihydroacenaphthylen-5-yl)pyridine
DMHB4PA HS Investigative
DMHB4PA SN acenaphthene derivative B; 3-(1,2-dihydroacenaphthylen-5-yl)pyridine; CHEMBL199683
DMHB4PA DT Small molecular drug
DMHB4PA PC 23644953
DMHB4PA MW 231.29
DMHB4PA FM C17H13N
DMHB4PA IC InChI=1S/C17H13N/c1-3-12-6-7-13-8-9-15(16(5-1)17(12)13)14-4-2-10-18-11-14/h1-5,8-11H,6-7H2
DMHB4PA CS C1CC2=CC=C(C3=CC=CC1=C23)C4=CN=CC=C4
DMHB4PA IK BWVFIMXEVGYZOM-UHFFFAOYSA-N
DMHB4PA IU 3-(1,2-dihydroacenaphthylen-5-yl)pyridine
DMHB4PA DE Discovery agent
DMQC168 ID DMQC168
DMQC168 DN 3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid
DMQC168 HS Investigative
DMQC168 SN 4-[3-(Dodeca-1,3-diyn-1-yl)oxiran-2-yl]butanoic acid; CHEMBL483819; FA(18:4)(Ep,cyclo); GTPL2958; LMFA01070030; BDBM50292404; 5,6-Epoxyoctadeca-7,9-diynoic acid; 5,6-epoxy-7,9-octadecadiynoic acid; compound 9a [Patil et al, 1989]; 4-[3-(dodeca-1,3-diyn-1-yl)oxiran-2-yl]butanoic; compound 9a (Patil et al., 1989)
DMQC168 DT Small molecular drug
DMQC168 PC 14309407
DMQC168 MW 290.4
DMQC168 FM C18H26O3
DMQC168 IC InChI=1S/C18H26O3/c1-2-3-4-5-6-7-8-9-10-11-13-16-17(21-16)14-12-15-18(19)20/h16-17H,2-8,12,14-15H2,1H3,(H,19,20)
DMQC168 CS CCCCCCCCC#CC#CC1C(O1)CCCC(=O)O
DMQC168 IK XLDNBXDVNANPCY-UHFFFAOYSA-N
DMQC168 IU 4-(3-dodeca-1,3-diynyloxiran-2-yl)butanoic acid
DMQC168 DE Discovery agent
DM24BG6 ID DM24BG6
DM24BG6 DN 3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6 HS Investigative
DM24BG6 SN CHEMBL394718; 3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6 DT Small molecular drug
DM24BG6 PC 44434729
DM24BG6 MW 231.25
DM24BG6 FM C15H9N3
DM24BG6 IC InChI=1S/C15H9N3/c16-9-11-3-1-4-12(7-11)13-8-15-14(18-10-13)5-2-6-17-15/h1-8,10H
DM24BG6 CS C1=CC(=CC(=C1)C2=CC3=C(C=CC=N3)N=C2)C#N
DM24BG6 IK GOWMBIHHRVFADP-UHFFFAOYSA-N
DM24BG6 IU 3-(1,5-naphthyridin-3-yl)benzonitrile
DM24BG6 DE Discovery agent
DMSP4N5 ID DMSP4N5
DMSP4N5 DN 3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5 HS Investigative
DMSP4N5 SN CHEMBL235397; 3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5 DT Small molecular drug
DMSP4N5 PC 44434717
DMSP4N5 MW 231.25
DMSP4N5 FM C15H9N3
DMSP4N5 IC InChI=1S/C15H9N3/c16-10-11-3-1-4-13(9-11)14-7-6-12-5-2-8-17-15(12)18-14/h1-9H
DMSP4N5 CS C1=CC(=CC(=C1)C2=NC3=C(C=CC=N3)C=C2)C#N
DMSP4N5 IK ANJYTIPEHJCPPM-UHFFFAOYSA-N
DMSP4N5 IU 3-(1,8-naphthyridin-2-yl)benzonitrile
DMSP4N5 DE Discovery agent
DMSZLNE ID DMSZLNE
DMSZLNE DN 3'-(1-Benzothien-2-yl)biphenyl-3-ol
DMSZLNE HS Investigative
DMSZLNE SN CHEMBL1097016; BDBM50318420
DMSZLNE DT Small molecular drug
DMSZLNE PC 46887555
DMSZLNE MW 302.4
DMSZLNE FM C20H14OS
DMSZLNE IC InChI=1S/C20H14OS/c21-18-9-4-7-15(12-18)14-6-3-8-16(11-14)20-13-17-5-1-2-10-19(17)22-20/h1-13,21H
DMSZLNE CS C1=CC=C2C(=C1)C=C(S2)C3=CC=CC(=C3)C4=CC(=CC=C4)O
DMSZLNE IK BQKUVAJYBNSSNI-UHFFFAOYSA-N
DMSZLNE IU 3-[3-(1-benzothiophen-2-yl)phenyl]phenol
DMSZLNE DE Discovery agent
DMGYDEK ID DMGYDEK
DMGYDEK DN 3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol
DMGYDEK HS Investigative
DMGYDEK SN CHEMBL610794; 3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol
DMGYDEK DT Small molecular drug
DMGYDEK PC 45103805
DMGYDEK MW 216.28
DMGYDEK FM C13H16N2O
DMGYDEK IC InChI=1S/C13H16N2O/c16-8-4-7-13-9-14-11-15(13)10-12-5-2-1-3-6-12/h1-3,5-6,9,11,16H,4,7-8,10H2
DMGYDEK CS C1=CC=C(C=C1)CN2C=NC=C2CCCO
DMGYDEK IK TZVJUMCHCPZGTM-UHFFFAOYSA-N
DMGYDEK IU 3-(3-benzylimidazol-4-yl)propan-1-ol
DMGYDEK CA CAS 1000540-66-8
DMGYDEK DE Discovery agent
DMGDN93 ID DMGDN93
DMGDN93 DN 3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole
DMGDN93 HS Investigative
DMGDN93 SN CHEMBL46523; 3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole; SCHEMBL8524973; BDBM50099274
DMGDN93 DT Small molecular drug
DMGDN93 PC 9842124
DMGDN93 MW 366.5
DMGDN93 FM C26H26N2
DMGDN93 IC InChI=1S/C26H26N2/c1-3-10-20(11-4-1)18-28-17-9-14-22(19-28)25-23-15-7-8-16-24(23)27-26(25)21-12-5-2-6-13-21/h1-8,10-13,15-16,22,27H,9,14,17-19H2
DMGDN93 CS C1CC(CN(C1)CC2=CC=CC=C2)C3=C(NC4=CC=CC=C43)C5=CC=CC=C5
DMGDN93 IK RXGPCIHYSMKIRI-UHFFFAOYSA-N
DMGDN93 IU 3-(1-benzylpiperidin-3-yl)-2-phenyl-1H-indole
DMGDN93 DE Discovery agent
DMWP0VK ID DMWP0VK
DMWP0VK DN 3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole
DMWP0VK HS Investigative
DMWP0VK SN CHEMBL327169; 3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole; SCHEMBL7955758; BDBM50095051; L018754
DMWP0VK DT Small molecular drug
DMWP0VK PC 18354719
DMWP0VK MW 366.5
DMWP0VK FM C26H26N2
DMWP0VK IC InChI=1S/C26H26N2/c1-3-9-20(10-4-1)19-28-17-15-21(16-18-28)25-23-13-7-8-14-24(23)27-26(25)22-11-5-2-6-12-22/h1-14,21,27H,15-19H2
DMWP0VK CS C1CN(CCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4)CC5=CC=CC=C5
DMWP0VK IK DGLKVJXUWHYMSL-UHFFFAOYSA-N
DMWP0VK IU 3-(1-benzylpiperidin-4-yl)-2-phenyl-1H-indole
DMWP0VK DE Discovery agent
DM2YKHI ID DM2YKHI
DM2YKHI DN 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI HS Investigative
DM2YKHI SN CHEMBL210770; 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole; SCHEMBL14280723; NRIVFQIOYWIUPX-UHFFFAOYSA-N; BDBM50185792
DM2YKHI DT Small molecular drug
DM2YKHI PC 44413409
DM2YKHI MW 324.8
DM2YKHI FM C20H21ClN2
DM2YKHI IC InChI=1S/C20H21ClN2/c21-17-6-7-20-18(12-17)19(13-22-20)16-8-10-23(11-9-16)14-15-4-2-1-3-5-15/h1-7,12-13,16,22H,8-11,14H2
DM2YKHI CS C1CN(CCC1C2=CNC3=C2C=C(C=C3)Cl)CC4=CC=CC=C4
DM2YKHI IK NRIVFQIOYWIUPX-UHFFFAOYSA-N
DM2YKHI IU 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole
DM2YKHI DE Discovery agent
DMG3A4Z ID DMG3A4Z
DMG3A4Z DN 3-(1-benzylpiperidin-4-yloxy)benzamide
DMG3A4Z HS Investigative
DMG3A4Z SN 3-((1-Benzylpiperidin-4-yl)oxy)benzamide; 1254475-25-6; CHEMBL1257457; 3-[(1-Benzylpiperidin-4-yl)oxy]benzamide; 3-(1-benzylpiperidin-4-yloxy)benzamide; DTXSID90680658; ZINC64548741; BDBM50327259; AKOS022176132; AJ-114866
DMG3A4Z DT Small molecular drug
DMG3A4Z PC 52946209
DMG3A4Z MW 310.4
DMG3A4Z FM C19H22N2O2
DMG3A4Z IC InChI=1S/C19H22N2O2/c20-19(22)16-7-4-8-18(13-16)23-17-9-11-21(12-10-17)14-15-5-2-1-3-6-15/h1-8,13,17H,9-12,14H2,(H2,20,22)
DMG3A4Z CS C1CN(CCC1OC2=CC=CC(=C2)C(=O)N)CC3=CC=CC=C3
DMG3A4Z IK IDSIUINGWBNUFD-UHFFFAOYSA-N
DMG3A4Z IU 3-(1-benzylpiperidin-4-yl)oxybenzamide
DMG3A4Z CA CAS 1254475-25-6
DMG3A4Z DE Discovery agent
DMOMSTN ID DMOMSTN
DMOMSTN DN 3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP)
DMOMSTN HS Investigative
DMOMSTN DE Discovery agent
DMHPYWM ID DMHPYWM
DMHPYWM DN 3-(1-carboxy-4-mercaptobutoxy)benzoic acid
DMHPYWM HS Investigative
DMHPYWM SN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-; Thiol-Based Inhibitor, 26a; CHEMBL207350; SCHEMBL5053092; BDBM17775; KUHQPVJMGPHXPD-UHFFFAOYSA-N; 378242-30-9; 3-(1-carboxy-4-sulfanylbutoxy)benzoic acid; 3-(l-carboxy-4-mercaptobutoxy)-benzoic acid; 3-(1-Carboxy-4-mercaptobutoxy)-benzoic Acid
DMHPYWM DT Small molecular drug
DMHPYWM PC 9900104
DMHPYWM MW 270.3
DMHPYWM FM C12H14O5S
DMHPYWM IC InChI=1S/C12H14O5S/c13-11(14)8-3-1-4-9(7-8)17-10(12(15)16)5-2-6-18/h1,3-4,7,10,18H,2,5-6H2,(H,13,14)(H,15,16)
DMHPYWM CS C1=CC(=CC(=C1)OC(CCCS)C(=O)O)C(=O)O
DMHPYWM IK KUHQPVJMGPHXPD-UHFFFAOYSA-N
DMHPYWM IU 3-(1-carboxy-4-sulfanylbutoxy)benzoic acid
DMHPYWM DE Discovery agent
DMLH7YI ID DMLH7YI
DMLH7YI DN 3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine
DMLH7YI HS Investigative
DMLH7YI SN SCHEMBL4517614; BDBM8913; CHEMBL371430; Pyridine-substituted naphthalene 14; ZINC13674470; 3-(1-chloro-7-methoxy-2-naphthyl)pyridine; 3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine
DMLH7YI DT Small molecular drug
DMLH7YI PC 11680597
DMLH7YI MW 269.72
DMLH7YI FM C16H12ClNO
DMLH7YI IC InChI=1S/C16H12ClNO/c1-19-13-6-4-11-5-7-14(16(17)15(11)9-13)12-3-2-8-18-10-12/h2-10H,1H3
DMLH7YI CS COC1=CC2=C(C=C1)C=CC(=C2Cl)C3=CN=CC=C3
DMLH7YI IK KRLGQBXIHBDUPS-UHFFFAOYSA-N
DMLH7YI IU 3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine
DMLH7YI DE Discovery agent
DMR7M82 ID DMR7M82
DMR7M82 DN 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMR7M82 HS Investigative
DMR7M82 SN 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 7; AC1O70HD; 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine; CHEMBL205503; BDBM8893; SCHEMBL4505824; CTK6D0393; ZINC13684518; AKOS015965702
DMR7M82 DT Small molecular drug
DMR7M82 PC 6540051
DMR7M82 MW 235.32
DMR7M82 FM C17H17N
DMR7M82 IC InChI=1S/C17H17N/c1-2-15-16-8-4-3-6-13(16)9-10-17(15)14-7-5-11-18-12-14/h3-8,11-12H,2,9-10H2,1H3
DMR7M82 CS CCC1=C(CCC2=CC=CC=C21)C3=CN=CC=C3
DMR7M82 IK ZKPVULIWDZEZIT-UHFFFAOYSA-N
DMR7M82 IU 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMR7M82 DE Discovery agent
DMERZHK ID DMERZHK
DMERZHK DN 3-(1H-Imidazol-4-yl)benzenethiol
DMERZHK HS Investigative
DMERZHK SN 3-(1H-Imidazol-4-yl)benzenethiol; 1048983-24-9; CHEMBL446387; SCHEMBL1501883; BDBM24665; 3-(1H-imidazol-4-yl)benzene-1-thiol; 3-(1H-imidazol-4-yl)benzenethiol, 17
DMERZHK DT Small molecular drug
DMERZHK PC 24971327
DMERZHK MW 176.24
DMERZHK FM C9H8N2S
DMERZHK IC InChI=1S/C9H8N2S/c12-8-3-1-2-7(4-8)9-5-10-6-11-9/h1-6,12H,(H,10,11)
DMERZHK CS C1=CC(=CC(=C1)S)C2=CN=CN2
DMERZHK IK GZDISEVTMUIDGB-UHFFFAOYSA-N
DMERZHK IU 3-(1H-imidazol-5-yl)benzenethiol
DMERZHK DE Discovery agent
DM9ZDIK ID DM9ZDIK
DM9ZDIK DN 3-(1H-inden-2-yl)pyridine
DM9ZDIK HS Investigative
DM9ZDIK SN 3-(1H-inden-2-yl)pyridine; indene 1; SCHEMBL4504698; CHEMBL205782; BDBM8888; AC1O70H3
DM9ZDIK DT Small molecular drug
DM9ZDIK PC 6540046
DM9ZDIK MW 193.24
DM9ZDIK FM C14H11N
DM9ZDIK IC InChI=1S/C14H11N/c1-2-5-12-9-14(8-11(12)4-1)13-6-3-7-15-10-13/h1-8,10H,9H2
DM9ZDIK CS C1C2=CC=CC=C2C=C1C3=CN=CC=C3
DM9ZDIK IK NNEAKBWZBQOQDH-UHFFFAOYSA-N
DM9ZDIK IU 3-(1H-inden-2-yl)pyridine
DM9ZDIK DE Discovery agent
DMLV80B ID DMLV80B
DMLV80B DN 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine
DMLV80B HS Investigative
DMLV80B SN CHEMBL453838; SCHEMBL2074980; 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine; VDFAJYFMKVKZLC-UHFFFAOYSA-N; BDBM50245797
DMLV80B DT Small molecular drug
DMLV80B PC 44593439
DMLV80B MW 264.4
DMLV80B FM C18H20N2
DMLV80B IC InChI=1S/C18H20N2/c1-19-13-11-18(15-7-3-2-4-8-15)20-14-12-16-9-5-6-10-17(16)20/h2-10,12,14,18-19H,11,13H2,1H3
DMLV80B CS CNCCC(C1=CC=CC=C1)N2C=CC3=CC=CC=C32
DMLV80B IK VDFAJYFMKVKZLC-UHFFFAOYSA-N
DMLV80B IU 3-indol-1-yl-N-methyl-3-phenylpropan-1-amine
DMLV80B DE Discovery agent
DMS3JCN ID DMS3JCN
DMS3JCN DN 3-(1H-Indol-2-yl)-1H-quinolin-2-one
DMS3JCN HS Investigative
DMS3JCN SN 3-(1H-indol-2-yl)quinolin-2(1H)-one
DMS3JCN DT Small molecular drug
DMS3JCN PC 5329371
DMS3JCN MW 260.29
DMS3JCN FM C17H12N2O
DMS3JCN IC InChI=1S/C17H12N2O/c20-17-13(9-11-5-1-4-8-15(11)19-17)16-10-12-6-2-3-7-14(12)18-16/h1-10,18H,(H,19,20)
DMS3JCN CS C1=CC=C2C(=C1)C=C(C(=O)N2)C3=CC4=CC=CC=C4N3
DMS3JCN IK OSFGHYZLBDAJTP-UHFFFAOYSA-N
DMS3JCN IU 3-(1H-indol-2-yl)-1H-quinolin-2-one
DMS3JCN DE Discovery agent
DMP0RYB ID DMP0RYB
DMP0RYB DN 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione
DMP0RYB HS Investigative
DMP0RYB SN CHEMBL183310; 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione; SCHEMBL7840920; 1H-Pyrrole-2,5-dione,3-(1H-indol-3-yl)-4-(phenylamino)-; BDBM50153450; 257878-66-3
DMP0RYB DT Small molecular drug
DMP0RYB PC 17814743
DMP0RYB MW 303.3
DMP0RYB FM C18H13N3O2
DMP0RYB IC InChI=1S/C18H13N3O2/c22-17-15(13-10-19-14-9-5-4-8-12(13)14)16(18(23)21-17)20-11-6-2-1-3-7-11/h1-10,19H,(H2,20,21,22,23)
DMP0RYB CS C1=CC=C(C=C1)NC2=C(C(=O)NC2=O)C3=CNC4=CC=CC=C43
DMP0RYB IK WEKZVKNLORTLQV-UHFFFAOYSA-N
DMP0RYB IU 3-anilino-4-(1H-indol-3-yl)pyrrole-2,5-dione
DMP0RYB DE Discovery agent
DMSGCKU ID DMSGCKU
DMSGCKU DN 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline
DMSGCKU HS Investigative
DMSGCKU SN CHEMBL302545; 3-(1H-indol-3-yl)-6,7-dimethoxy-quinoline; SCHEMBL8172242
DMSGCKU DT Small molecular drug
DMSGCKU PC 9972296
DMSGCKU MW 304.3
DMSGCKU FM C19H16N2O2
DMSGCKU IC InChI=1S/C19H16N2O2/c1-22-18-8-12-7-13(10-20-17(12)9-19(18)23-2)15-11-21-16-6-4-3-5-14(15)16/h3-11,21H,1-2H3
DMSGCKU CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CNC4=CC=CC=C43
DMSGCKU IK CTHPHODXZDFNPE-UHFFFAOYSA-N
DMSGCKU IU 3-(1H-indol-3-yl)-6,7-dimethoxyquinoline
DMSGCKU DE Discovery agent
DM6Y2XK ID DM6Y2XK
DM6Y2XK DN 3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine
DM6Y2XK HS Investigative
DM6Y2XK SN NSC88622; 3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine; NSC-88622; 13117-35-6; CHEMBL360575; AC1Q3WPU; NCIStruc2_000554; NCIStruc1_000767; AC1L1D58; SCHEMBL3957606; N,N-DIMETHYLHOMOTRYPTAMINE; DTXSID00275574; ZINC393884; NCI88622; NCGC00013925; BDBM50162709; CCG-38332; AKOS024323101; MCULE-7123094039; NCGC00097034-01; NCGC00013925-02; NCI60_041964; [3-(1H-indol-3-yl)propyl]dimethylamine; [3-(1H-Indol-3-yl)-propyl]-dimethyl-amine
DM6Y2XK DT Small molecular drug
DM6Y2XK PC 52549
DM6Y2XK MW 202.3
DM6Y2XK FM C13H18N2
DM6Y2XK IC InChI=1S/C13H18N2/c1-15(2)9-5-6-11-10-14-13-8-4-3-7-12(11)13/h3-4,7-8,10,14H,5-6,9H2,1-2H3
DM6Y2XK CS CN(C)CCCC1=CNC2=CC=CC=C21
DM6Y2XK IK QHNWPRMHGXRBAO-UHFFFAOYSA-N
DM6Y2XK IU 3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine
DM6Y2XK CA CAS 13117-35-6
DM6Y2XK DE Discovery agent
DMEV6Q2 ID DMEV6Q2
DMEV6Q2 DN 3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine
DMEV6Q2 HS Investigative
DMEV6Q2 SN CHEMBL487763; 3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine; SCHEMBL2074218; HYXMIUGYZHSSJS-UHFFFAOYSA-N; BDBM50275378
DMEV6Q2 DT Small molecular drug
DMEV6Q2 PC 44589528
DMEV6Q2 MW 264.4
DMEV6Q2 FM C18H20N2
DMEV6Q2 IC InChI=1S/C18H20N2/c1-19-12-11-15(14-7-3-2-4-8-14)17-13-20-18-10-6-5-9-16(17)18/h2-10,13,15,19-20H,11-12H2,1H3
DMEV6Q2 CS CNCCC(C1=CC=CC=C1)C2=CNC3=CC=CC=C32
DMEV6Q2 IK HYXMIUGYZHSSJS-UHFFFAOYSA-N
DMEV6Q2 IU 3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine
DMEV6Q2 DE Discovery agent
DMW7XN5 ID DMW7XN5
DMW7XN5 DN 3-(1H-Indol-3-yl)-quinoline
DMW7XN5 HS Investigative
DMW7XN5 SN 3-(1H-indol-3-yl)quinoline; CHEMBL309116; 3-(1H-Indol-3-yl)-quinoline; 3-(3-Quinolyl)-1H-indole; SCHEMBL8171583; ZINC13737696; BDBM50039096
DMW7XN5 DT Small molecular drug
DMW7XN5 PC 10243546
DMW7XN5 MW 244.29
DMW7XN5 FM C17H12N2
DMW7XN5 IC InChI=1S/C17H12N2/c1-3-7-16-12(5-1)9-13(10-18-16)15-11-19-17-8-4-2-6-14(15)17/h1-11,19H
DMW7XN5 CS C1=CC=C2C(=C1)C=C(C=N2)C3=CNC4=CC=CC=C43
DMW7XN5 IK BJQHKICYZOBROI-UHFFFAOYSA-N
DMW7XN5 IU 3-(1H-indol-3-yl)quinoline
DMW7XN5 DE Discovery agent
DMKFGDI ID DMKFGDI
DMKFGDI DN 3-(1H-pyrazol-3-yl)benzoic acid
DMKFGDI HS Investigative
DMKFGDI SN 3-(1H-pyrazol-5-yl)benzoic acid; 850375-11-0; 3-(1H-pyrazol-3-yl)benzoic acid; 3-(2H-pyrazol-3-yl)benzoic Acid; Benzoic acid, 3-(1H-pyrazol-3-yl)-; CHEMBL497801; 5-(3-Carboxyphenyl)-1H-pyrazole; PubChem22748; AC1MDTM0; buttpark 44\01-87; 3-pyrazol-5-ylbenzoic acid; 3-pyrazol-3-ylbenzoic acid; SCHEMBL939810; CTK5F3854; CTK7I8615; DTXSID80383762; MolPort-000-142-934; RXZRBZWATRFHCS-UHFFFAOYSA-N; MolPort-009-196-824; 3-(2h-pyrazol-3-yl)-benzoicacid; KS-00002A0D; ZX-AT019147; ZINC4200665; 3-(1H-Pyrazole-3-yl)benzoic acid
DMKFGDI DT Small molecular drug
DMKFGDI PC 2795542
DMKFGDI MW 188.18
DMKFGDI FM C10H8N2O2
DMKFGDI IC InChI=1S/C10H8N2O2/c13-10(14)8-3-1-2-7(6-8)9-4-5-11-12-9/h1-6H,(H,11,12)(H,13,14)
DMKFGDI CS C1=CC(=CC(=C1)C(=O)O)C2=CC=NN2
DMKFGDI IK RXZRBZWATRFHCS-UHFFFAOYSA-N
DMKFGDI IU 3-(1H-pyrazol-5-yl)benzoic acid
DMKFGDI CA CAS 850375-11-0
DMKFGDI DE Discovery agent
DMCKJ27 ID DMCKJ27
DMCKJ27 DN 3-(1H-Pyrrol-3-yl)-propionamide
DMCKJ27 HS Investigative
DMCKJ27 SN 1H-Pyrrole-3-propanamide; CHEMBL277776; 152509-75-6; 3-(1H-Pyrrol-3-yl)-propionamide; ACMC-20n6gu; CTK0I3006; DTXSID90435928; BDBM50287316
DMCKJ27 DT Small molecular drug
DMCKJ27 PC 10129992
DMCKJ27 MW 138.17
DMCKJ27 FM C7H10N2O
DMCKJ27 IC InChI=1S/C7H10N2O/c8-7(10)2-1-6-3-4-9-5-6/h3-5,9H,1-2H2,(H2,8,10)
DMCKJ27 CS C1=CNC=C1CCC(=O)N
DMCKJ27 IK TWGRVIPCCGRSNM-UHFFFAOYSA-N
DMCKJ27 IU 3-(1H-pyrrol-3-yl)propanamide
DMCKJ27 CA CAS 152509-75-6
DMCKJ27 DE Discovery agent
DMU5HMC ID DMU5HMC
DMU5HMC DN 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine
DMU5HMC HS Investigative
DMU5HMC SN 3614-50-4; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 6; 2-yl)-pyridine; 3-(1-Methyl-3,4-dihydro-naphthalen-; AC1O70HB; 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine; SCHEMBL4514804; CHEMBL206283; BDBM8892; CTK4H5985; DTXSID90424897; ZINC13684515; AKOS015965701; ACM3614504; AC-20696; KB-232450
DMU5HMC DT Small molecular drug
DMU5HMC PC 6540050
DMU5HMC MW 221.3
DMU5HMC FM C16H15N
DMU5HMC IC InChI=1S/C16H15N/c1-12-15-7-3-2-5-13(15)8-9-16(12)14-6-4-10-17-11-14/h2-7,10-11H,8-9H2,1H3
DMU5HMC CS CC1=C(CCC2=CC=CC=C12)C3=CN=CC=C3
DMU5HMC IK WBEMJRFRGOAAJI-UHFFFAOYSA-N
DMU5HMC IU 3-(1-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMU5HMC CA CAS 3614-50-4
DMU5HMC DE Discovery agent
DMK8LHB ID DMK8LHB
DMK8LHB DN 3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole
DMK8LHB HS Investigative
DMK8LHB SN CHEMBL43697; 3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole; BDBM50099263
DMK8LHB DT Small molecular drug
DMK8LHB PC 10493741
DMK8LHB MW 290.4
DMK8LHB FM C20H22N2
DMK8LHB IC InChI=1S/C20H22N2/c1-22-14-8-7-13-18(22)19-16-11-5-6-12-17(16)21-20(19)15-9-3-2-4-10-15/h2-6,9-12,18,21H,7-8,13-14H2,1H3
DMK8LHB CS CN1CCCCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DMK8LHB IK YKKPUIDGSXNPRO-UHFFFAOYSA-N
DMK8LHB IU 3-(1-methylpiperidin-2-yl)-2-phenyl-1H-indole
DMK8LHB DE Discovery agent
DM4UD8C ID DM4UD8C
DM4UD8C DN 3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C HS Investigative
DM4UD8C SN CHEMBL43819; 3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole; SCHEMBL8525408; BDBM50099264; 3-(1-methylpiperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C DT Small molecular drug
DM4UD8C PC 9838960
DM4UD8C MW 290.4
DM4UD8C FM C20H22N2
DM4UD8C IC InChI=1S/C20H22N2/c1-22-13-7-10-16(14-22)19-17-11-5-6-12-18(17)21-20(19)15-8-3-2-4-9-15/h2-6,8-9,11-12,16,21H,7,10,13-14H2,1H3
DM4UD8C CS CN1CCCC(C1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DM4UD8C IK JRFXDRYERZNJFJ-UHFFFAOYSA-N
DM4UD8C IU 3-(1-methylpiperidin-3-yl)-2-phenyl-1H-indole
DM4UD8C DE Discovery agent
DM6R5HU ID DM6R5HU
DM6R5HU DN 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole
DM6R5HU HS Investigative
DM6R5HU SN CHEMBL91667; 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole; SCHEMBL7959758; UBCVYEFSXHCFPK-UHFFFAOYSA-N; BDBM50095055; 3-(1-methylpiperidin-4-yl)-2-phenyl-1H-indole; L018753
DM6R5HU DT Small molecular drug
DM6R5HU PC 9838958
DM6R5HU MW 290.4
DM6R5HU FM C20H22N2
DM6R5HU IC InChI=1S/C20H22N2/c1-22-13-11-15(12-14-22)19-17-9-5-6-10-18(17)21-20(19)16-7-3-2-4-8-16/h2-10,15,21H,11-14H2,1H3
DM6R5HU CS CN1CCC(CC1)C2=C(NC3=CC=CC=C32)C4=CC=CC=C4
DM6R5HU IK UBCVYEFSXHCFPK-UHFFFAOYSA-N
DM6R5HU IU 3-(1-methylpiperidin-4-yl)-2-phenyl-1H-indole
DM6R5HU DE Discovery agent
DMXMBEF ID DMXMBEF
DMXMBEF DN 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
DMXMBEF HS Investigative
DMXMBEF SN 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE; 3-(naphthalen-1-ylmethoxy)pyridin-2-amine; 2-amino-3-(1-naphthylmethyloxy)pyridine; LI4; 1wbw; CHEMBL195393; AC1NS185; SCHEMBL6080116; BDBM13340; AKOS009255557; DB08093; Pyridine derived fragment based inhibitor 5
DMXMBEF DT Small molecular drug
DMXMBEF PC 5326871
DMXMBEF MW 250.29
DMXMBEF FM C16H14N2O
DMXMBEF IC InChI=1S/C16H14N2O/c17-16-15(9-4-10-18-16)19-11-13-7-3-6-12-5-1-2-8-14(12)13/h1-10H,11H2,(H2,17,18)
DMXMBEF CS C1=CC=C2C(=C1)C=CC=C2COC3=C(N=CC=C3)N
DMXMBEF IK SZANYTFSQVBOBA-UHFFFAOYSA-N
DMXMBEF IU 3-(naphthalen-1-ylmethoxy)pyridin-2-amine
DMXMBEF DE Discovery agent
DMOQ4ER ID DMOQ4ER
DMOQ4ER DN 3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole
DMOQ4ER HS Investigative
DMOQ4ER SN CHEMBL44310; 3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole; SCHEMBL8525084; BDBM50099267
DMOQ4ER DT Small molecular drug
DMOQ4ER PC 9821248
DMOQ4ER MW 380.5
DMOQ4ER FM C27H28N2
DMOQ4ER IC InChI=1S/C27H28N2/c1-3-10-21(11-4-1)17-19-29-18-9-14-23(20-29)26-24-15-7-8-16-25(24)28-27(26)22-12-5-2-6-13-22/h1-8,10-13,15-16,23,28H,9,14,17-20H2
DMOQ4ER CS C1CC(CN(C1)CCC2=CC=CC=C2)C3=C(NC4=CC=CC=C43)C5=CC=CC=C5
DMOQ4ER IK HQXCPXHVSRWLFR-UHFFFAOYSA-N
DMOQ4ER IU 2-phenyl-3-[1-(2-phenylethyl)piperidin-3-yl]-1H-indole
DMOQ4ER DE Discovery agent
DM8TH2N ID DM8TH2N
DM8TH2N DN 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole
DM8TH2N HS Investigative
DM8TH2N SN CHEMBL40584; 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole; SCHEMBL7948313; BDBM50095049; L018755; 3-(1-phenethylpiperidin-4-yl)-2-phenyl-1H-indole
DM8TH2N DT Small molecular drug
DM8TH2N PC 10091189
DM8TH2N MW 380.5
DM8TH2N FM C27H28N2
DM8TH2N IC InChI=1S/C27H28N2/c1-3-9-21(10-4-1)15-18-29-19-16-22(17-20-29)26-24-13-7-8-14-25(24)28-27(26)23-11-5-2-6-12-23/h1-14,22,28H,15-20H2
DM8TH2N CS C1CN(CCC1C2=C(NC3=CC=CC=C32)C4=CC=CC=C4)CCC5=CC=CC=C5
DM8TH2N IK MONKRYYJEIHBRU-UHFFFAOYSA-N
DM8TH2N IU 2-phenyl-3-[1-(2-phenylethyl)piperidin-4-yl]-1H-indole
DM8TH2N DE Discovery agent
DM4QRV9 ID DM4QRV9
DM4QRV9 DN 3-(1-Propyl-pyrrolidin-3-yl)-phenol
DM4QRV9 HS Investigative
DM4QRV9 SN CHEMBL81675; 3-(1-Propyl-pyrrolidin-3-yl)-phenol; SCHEMBL7316143
DM4QRV9 DT Small molecular drug
DM4QRV9 PC 11074524
DM4QRV9 MW 205.3
DM4QRV9 FM C13H19NO
DM4QRV9 IC InChI=1S/C13H19NO/c1-2-7-14-8-6-12(10-14)11-4-3-5-13(15)9-11/h3-5,9,12,15H,2,6-8,10H2,1H3
DM4QRV9 CS CCCN1CCC(C1)C2=CC(=CC=C2)O
DM4QRV9 IK WPYVGSUSOOZONM-UHFFFAOYSA-N
DM4QRV9 IU 3-(1-propylpyrrolidin-3-yl)phenol
DM4QRV9 DE Discovery agent
DMTD7VE ID DMTD7VE
DMTD7VE DN 3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile
DMTD7VE HS Investigative
DMTD7VE SN CHEMBL182771; 3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile; SCHEMBL3922673; LQROCYQCXGUXNA-UHFFFAOYSA-N; ZINC13582316; BDBM50151902
DMTD7VE DT Small molecular drug
DMTD7VE PC 10236192
DMTD7VE MW 246.27
DMTD7VE FM C15H10N4
DMTD7VE IC InChI=1S/C15H10N4/c16-11-12-4-3-5-13(10-12)14-7-9-19(18-14)15-6-1-2-8-17-15/h1-10H
DMTD7VE CS C1=CC=NC(=C1)N2C=CC(=N2)C3=CC=CC(=C3)C#N
DMTD7VE IK LQROCYQCXGUXNA-UHFFFAOYSA-N
DMTD7VE IU 3-(1-pyridin-2-ylpyrazol-3-yl)benzonitrile
DMTD7VE DE Discovery agent
DMWI37C ID DMWI37C
DMWI37C DN 3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile
DMWI37C HS Investigative
DMWI37C SN CHEMBL182973; 3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile; SCHEMBL3923401; WCEMBGUJGXXYCF-UHFFFAOYSA-N; BDBM50151912; ZINC13582322
DMWI37C DT Small molecular drug
DMWI37C PC 10308060
DMWI37C MW 246.27
DMWI37C FM C15H10N4
DMWI37C IC InChI=1S/C15H10N4/c16-9-12-4-3-5-13(8-12)14-10-18-19(11-14)15-6-1-2-7-17-15/h1-8,10-11H
DMWI37C CS C1=CC=NC(=C1)N2C=C(C=N2)C3=CC=CC(=C3)C#N
DMWI37C IK WCEMBGUJGXXYCF-UHFFFAOYSA-N
DMWI37C IU 3-(1-pyridin-2-ylpyrazol-4-yl)benzonitrile
DMWI37C DE Discovery agent
DMJ9LRE ID DMJ9LRE
DMJ9LRE DN 3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile
DMJ9LRE HS Investigative
DMJ9LRE SN CHEMBL361120; 3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile; SCHEMBL5104615; GXXRNNGNWUNPKZ-UHFFFAOYSA-N; BDBM50151899; ZINC13582310
DMJ9LRE DT Small molecular drug
DMJ9LRE PC 10131083
DMJ9LRE MW 245.28
DMJ9LRE FM C16H11N3
DMJ9LRE IC InChI=1S/C16H11N3/c17-11-13-4-3-5-14(10-13)15-7-9-19(12-15)16-6-1-2-8-18-16/h1-10,12H
DMJ9LRE CS C1=CC=NC(=C1)N2C=CC(=C2)C3=CC=CC(=C3)C#N
DMJ9LRE IK GXXRNNGNWUNPKZ-UHFFFAOYSA-N
DMJ9LRE IU 3-(1-pyridin-2-ylpyrrol-3-yl)benzonitrile
DMJ9LRE CA CAS 566931-83-7
DMJ9LRE DE Discovery agent
DM8P26J ID DM8P26J
DM8P26J DN 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid
DM8P26J HS Investigative
DM8P26J DT Small molecular drug
DM8P26J PC 52947851
DM8P26J MW 528.6
DM8P26J FM C36H32O4
DM8P26J IC InChI=1S/2C18H16O2/c2*19-18(20)14-13-17-11-5-4-10-16(17)12-6-9-15-7-2-1-3-8-15/h1-8,10-14H,9H2,(H,19,20);1-11,13-14H,12H2,(H,19,20)/b12-6+,14-13+;9-6+,14-13+
DM8P26J CS C1=CC=C(C=C1)C/C=C/C2=CC=CC=C2/C=C/C(=O)O.C1=CC=C(C=C1)/C=C/CC2=CC=CC=C2/C=C/C(=O)O
DM8P26J IK QRLAGHDTOFFHIC-UMYPGWKJSA-N
DM8P26J IU (E)-3-[2-[(E)-3-phenylprop-1-enyl]phenyl]prop-2-enoic acid;(E)-3-[2-[(E)-3-phenylprop-2-enyl]phenyl]prop-2-enoic acid
DM8P26J DE Discovery agent
DM61CHU ID DM61CHU
DM61CHU DN 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU HS Investigative
DM61CHU SN CHEMBL219590; 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid
DM61CHU DT Small molecular drug
DM61CHU PC 44419388
DM61CHU MW 294.3
DM61CHU FM C19H18O3
DM61CHU IC InChI=1S/C19H18O3/c1-22-18-12-9-15(10-13-18)5-4-8-16-6-2-3-7-17(16)11-14-19(20)21/h2-7,9-14H,8H2,1H3,(H,20,21)/b5-4+,14-11+
DM61CHU CS COC1=CC=C(C=C1)/C=C/CC2=CC=CC=C2/C=C/C(=O)O
DM61CHU IK UIMOCAMZLBHNCQ-CTLAPNPFSA-N
DM61CHU IU (E)-3-[2-[(E)-3-(4-methoxyphenyl)prop-2-enyl]phenyl]prop-2-enoic acid
DM61CHU DE Discovery agent
DM9O5CH ID DM9O5CH
DM9O5CH DN 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid
DM9O5CH HS Investigative
DM9O5CH SN CHEMBL423815; 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid; SCHEMBL7922112; SCHEMBL7922115; BDBM50097792; 2-(2-Naphthylmethyl)benzeneacrylic acid; (E)-3-(2-Naphthalen-2-ylmethyl-phenyl)-acrylic acid
DM9O5CH DT Small molecular drug
DM9O5CH PC 9817405
DM9O5CH MW 288.3
DM9O5CH FM C20H16O2
DM9O5CH IC InChI=1S/C20H16O2/c21-20(22)12-11-17-6-2-4-8-19(17)14-15-9-10-16-5-1-3-7-18(16)13-15/h1-13H,14H2,(H,21,22)/b12-11+
DM9O5CH CS C1=CC=C2C=C(C=CC2=C1)CC3=CC=CC=C3/C=C/C(=O)O
DM9O5CH IK MOLQZQYMXCCLHS-VAWYXSNFSA-N
DM9O5CH IU (E)-3-[2-(naphthalen-2-ylmethyl)phenyl]prop-2-enoic acid
DM9O5CH DE Discovery agent
DMSCIP2 ID DMSCIP2
DMSCIP2 DN 3-(2,2-Dimethyl-propoxy)-9H-beta-carboline
DMSCIP2 HS Investigative
DMSCIP2 SN 3-(Neopentyloxy)-9H-pyrido[3,4-b]indole; CHEMBL128348
DMSCIP2 DT Small molecular drug
DMSCIP2 PC 10402001
DMSCIP2 MW 254.33
DMSCIP2 FM C16H18N2O
DMSCIP2 IC InChI=1S/C16H18N2O/c1-16(2,3)10-19-15-8-12-11-6-4-5-7-13(11)18-14(12)9-17-15/h4-9,18H,10H2,1-3H3
DMSCIP2 CS CC(C)(C)COC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMSCIP2 IK YABCOKXBPACNCE-UHFFFAOYSA-N
DMSCIP2 IU 3-(2,2-dimethylpropoxy)-9H-pyrido[3,4-b]indole
DMSCIP2 DE Discovery agent
DMCPOQ9 ID DMCPOQ9
DMCPOQ9 DN 3-(2,2-Diphenyl-vinyl)-pyridine
DMCPOQ9 HS Investigative
DMCPOQ9 SN 3-(2,2-diphenylethenyl)pyridine; 3-Pyridylmethylene 33; BDBM8638; CHEMBL370317; 3-(2,2-Diphenylvinyl)Pyridine
DMCPOQ9 DT Small molecular drug
DMCPOQ9 PC 6539811
DMCPOQ9 MW 257.3
DMCPOQ9 FM C19H15N
DMCPOQ9 IC InChI=1S/C19H15N/c1-3-9-17(10-4-1)19(18-11-5-2-6-12-18)14-16-8-7-13-20-15-16/h1-15H
DMCPOQ9 CS C1=CC=C(C=C1)C(=CC2=CN=CC=C2)C3=CC=CC=C3
DMCPOQ9 IK GOQNCJGTIMHWGO-UHFFFAOYSA-N
DMCPOQ9 IU 3-(2,2-diphenylethenyl)pyridine
DMCPOQ9 DE Discovery agent
DMTS4YD ID DMTS4YD
DMTS4YD DN 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine
DMTS4YD HS Investigative
DMTS4YD SN CHEMBL462092; 1092522-84-3; 3-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)pyridine; 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine; 3-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-pyridine; ZINC40873967; BDBM50273702
DMTS4YD DT Small molecular drug
DMTS4YD PC 25180306
DMTS4YD MW 213.23
DMTS4YD FM C13H11NO2
DMTS4YD IC InChI=1S/C13H11NO2/c1-2-11(9-14-5-1)10-3-4-12-13(8-10)16-7-6-15-12/h1-5,8-9H,6-7H2
DMTS4YD CS C1COC2=C(O1)C=CC(=C2)C3=CN=CC=C3
DMTS4YD IK WBKBSDQNOSGKCC-UHFFFAOYSA-N
DMTS4YD IU 3-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridine
DMTS4YD DE Discovery agent
DM0ZRDV ID DM0ZRDV
DM0ZRDV DN 3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine
DM0ZRDV HS Investigative
DM0ZRDV SN CHEMBL341825; 3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068421
DM0ZRDV DT Small molecular drug
DM0ZRDV PC 10609576
DM0ZRDV MW 231.38
DM0ZRDV FM C16H25N
DM0ZRDV IC InChI=1S/C16H25N/c1-4-10-17-11-6-8-15(12-17)16-9-5-7-13(2)14(16)3/h5,7,9,15H,4,6,8,10-12H2,1-3H3
DM0ZRDV CS CCCN1CCCC(C1)C2=CC=CC(=C2C)C
DM0ZRDV IK AORDKZRSVBDZJZ-UHFFFAOYSA-N
DM0ZRDV IU 3-(2,3-dimethylphenyl)-1-propylpiperidine
DM0ZRDV DE Discovery agent
DMEFKJD ID DMEFKJD
DMEFKJD DN 3-(2,3-Dimethyl-phenyl)-piperidine
DMEFKJD HS Investigative
DMEFKJD SN 3-(2,3-dimethylphenyl)piperidine; CHEMBL144019; 219703-97-6; 3-(2,3-Dimethyl-phenyl)-piperidine; 3-(dimethylphenyl) piperidine; SCHEMBL9310414; BDBM50068426; AKOS006308927
DMEFKJD DT Small molecular drug
DMEFKJD PC 10679213
DMEFKJD MW 189.3
DMEFKJD FM C13H19N
DMEFKJD IC InChI=1S/C13H19N/c1-10-5-3-7-13(11(10)2)12-6-4-8-14-9-12/h3,5,7,12,14H,4,6,8-9H2,1-2H3
DMEFKJD CS CC1=C(C(=CC=C1)C2CCCNC2)C
DMEFKJD IK TXQGNZXKUWJMKW-UHFFFAOYSA-N
DMEFKJD IU 3-(2,3-dimethylphenyl)piperidine
DMEFKJD DE Discovery agent
DMXQROU ID DMXQROU
DMXQROU DN 3-(2,4-dihydroxyphenyl)propionic acid
DMXQROU HS Investigative
DMXQROU SN 5631-68-5; 3-(2,4-dihydroxyphenyl)propanoic acid; 3-(2,4-Dihydroxyphenyl)propionic acid; Hydroumbellic acid; Benzenepropanoic acid, 2,4-dihydroxy-; CHEMBL228155; 2,4-Dihydroxybenzenepropanoic acid; AI3-13072; AC1L3WC8; AC1Q5VW7; NCIOpen2_000618; SCHEMBL490491; ACMC-1B046; 2,4-Dihydroxyhydrocinnamic acid; CTK5A4966; DTXSID50204854; MolPort-000-877-529; HMCMTJPPXSGYJY-UHFFFAOYSA-N; ZINC388556; NSC71551; KS-00000N9R; NSC-71551; BDBM50211056; STL034241; SBB068271; BBL028276; Benzenepropanoic acid,2,4-dihydroxy-
DMXQROU DT Small molecular drug
DMXQROU PC 96384
DMXQROU MW 182.17
DMXQROU FM C9H10O4
DMXQROU IC InChI=1S/C9H10O4/c10-7-3-1-6(8(11)5-7)2-4-9(12)13/h1,3,5,10-11H,2,4H2,(H,12,13)
DMXQROU CS C1=CC(=C(C=C1O)O)CCC(=O)O
DMXQROU IK HMCMTJPPXSGYJY-UHFFFAOYSA-N
DMXQROU IU 3-(2,4-dihydroxyphenyl)propanoic acid
DMXQROU CA CAS 5631-68-5
DMXQROU DE Discovery agent
DMB71FZ ID DMB71FZ
DMB71FZ DN 3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine
DMB71FZ HS Investigative
DMB71FZ SN CHEMBL144302; 3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068425
DMB71FZ DT Small molecular drug
DMB71FZ PC 10633305
DMB71FZ MW 231.38
DMB71FZ FM C16H25N
DMB71FZ IC InChI=1S/C16H25N/c1-4-9-17-10-5-6-15(12-17)16-8-7-13(2)11-14(16)3/h7-8,11,15H,4-6,9-10,12H2,1-3H3
DMB71FZ CS CCCN1CCCC(C1)C2=C(C=C(C=C2)C)C
DMB71FZ IK XMWBOCKXCDCQOT-UHFFFAOYSA-N
DMB71FZ IU 3-(2,4-dimethylphenyl)-1-propylpiperidine
DMB71FZ CA CAS 219704-01-5
DMB71FZ DE Discovery agent
DMUDW1J ID DMUDW1J
DMUDW1J DN 3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid
DMUDW1J HS Investigative
DMUDW1J SN 3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid; 26180-28-9; 3-(2,5-dimethylpyrrol-1-yl)benzoic acid; 3-(2,5-Dimethyl-pyrrol-1-yl)-benzoic acid; MLS000053036; Benzoic acid, m-(2,5-dimethylpyrrol-1-yl)-; SMR000068999; m-(2,5-Dimethylpyrrol-1-yl)benzoic acid; Benzoic acid,3-(2,5-dimethyl-1H-pyrrol-1-yl)-; 3-(2,5-dimethylpyrrolyl)benzoic acid; SR-01000430237; 3-(2,5-dimethylpyrrol-1-yl) benzoic acd; benzoic acid, 3-(2,5-dimethyl-1h-pyrrol-1-yl)-; BAS 00687694; AC1L4UOW; Probes2_000222; Probes2_000239; Probes1_000276
DMUDW1J DT Small molecular drug
DMUDW1J PC 213329
DMUDW1J MW 215.25
DMUDW1J FM C13H13NO2
DMUDW1J IC InChI=1S/C13H13NO2/c1-9-6-7-10(2)14(9)12-5-3-4-11(8-12)13(15)16/h3-8H,1-2H3,(H,15,16)
DMUDW1J CS CC1=CC=C(N1C2=CC=CC(=C2)C(=O)O)C
DMUDW1J IK NJPUZFUOUGTNOV-UHFFFAOYSA-N
DMUDW1J IU 3-(2,5-dimethylpyrrol-1-yl)benzoic acid
DMUDW1J CA CAS 26180-28-9
DMUDW1J DE Discovery agent
DM974E5 ID DM974E5
DM974E5 DN 3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine
DM974E5 HS Investigative
DM974E5 SN CHEMBL280491; 3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068420
DM974E5 DT Small molecular drug
DM974E5 PC 10847137
DM974E5 MW 231.38
DM974E5 FM C16H25N
DM974E5 IC InChI=1S/C16H25N/c1-4-9-17-10-5-6-15(12-17)16-11-13(2)7-8-14(16)3/h7-8,11,15H,4-6,9-10,12H2,1-3H3
DM974E5 CS CCCN1CCCC(C1)C2=C(C=CC(=C2)C)C
DM974E5 IK SSDVDUAQCIGPNR-UHFFFAOYSA-N
DM974E5 IU 3-(2,5-dimethylphenyl)-1-propylpiperidine
DM974E5 DE Discovery agent
DM6JTNW ID DM6JTNW
DM6JTNW DN 3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid
DM6JTNW HS Investigative
DM6JTNW SN 3-(2,5-dioxopyrrolidin-1-yl)benzoic acid; 60693-31-4; 3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid; 3-(2,5-dioxo-1-pyrrolidinyl)benzoic acid; 3-(2,5-dioxoazolidinyl)benzoic acid; AC1LETYJ; BAS 16153444; Enamine_005131; 3-succinimidobenzoic acid; 3-Succinimidylbenzoic acid; Cambridge id 5631823; AC1Q5U3M; AC1Q73IP; Oprea1_343380; Oprea1_386853; MLS000061625; SCHEMBL20053775; ZINC63844; CTK5B2080; DTXSID80351143; MolPort-000-385-168; HMS1408J05; ANW-46498; STK155926; SBB011404; AKOS000112869; MCULE-3726251625; IDI1_007718; SMR000069955
DM6JTNW DT Small molecular drug
DM6JTNW PC 692331
DM6JTNW MW 219.19
DM6JTNW FM C11H9NO4
DM6JTNW IC InChI=1S/C11H9NO4/c13-9-4-5-10(14)12(9)8-3-1-2-7(6-8)11(15)16/h1-3,6H,4-5H2,(H,15,16)
DM6JTNW CS C1CC(=O)N(C1=O)C2=CC=CC(=C2)C(=O)O
DM6JTNW IK BEQRYKGDEGNALQ-UHFFFAOYSA-N
DM6JTNW IU 3-(2,5-dioxopyrrolidin-1-yl)benzoic acid
DM6JTNW CA CAS 60693-31-4
DM6JTNW DE Discovery agent
DMPSAQW ID DMPSAQW
DMPSAQW DN 3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine
DMPSAQW HS Investigative
DMPSAQW SN CHEMBL144501; 3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068424
DMPSAQW DT Small molecular drug
DMPSAQW PC 10561522
DMPSAQW MW 231.38
DMPSAQW FM C16H25N
DMPSAQW IC InChI=1S/C16H25N/c1-4-10-17-11-6-9-15(12-17)16-13(2)7-5-8-14(16)3/h5,7-8,15H,4,6,9-12H2,1-3H3
DMPSAQW CS CCCN1CCCC(C1)C2=C(C=CC=C2C)C
DMPSAQW IK HBTLGWNZDLWXQJ-UHFFFAOYSA-N
DMPSAQW IU 3-(2,6-dimethylphenyl)-1-propylpiperidine
DMPSAQW DE Discovery agent
DMDYW4J ID DMDYW4J
DMDYW4J DN 3-(2,6-diphenylpyridin-4-yl)phenol
DMDYW4J HS Investigative
DMDYW4J SN CHEMBL1096032
DMDYW4J DT Small molecular drug
DMDYW4J PC 46887217
DMDYW4J MW 323.4
DMDYW4J FM C23H17NO
DMDYW4J IC InChI=1S/C23H17NO/c25-21-13-7-12-19(14-21)20-15-22(17-8-3-1-4-9-17)24-23(16-20)18-10-5-2-6-11-18/h1-16,25H
DMDYW4J CS C1=CC=C(C=C1)C2=CC(=CC(=N2)C3=CC=CC=C3)C4=CC(=CC=C4)O
DMDYW4J IK JTTGRNWIRRFPKZ-UHFFFAOYSA-N
DMDYW4J IU 3-(2,6-diphenylpyridin-4-yl)phenol
DMDYW4J DE Discovery agent
DMS98WA ID DMS98WA
DMS98WA DN 3-(2-adamantyl) pyrrolidine
DMS98WA HS Investigative
DMS98WA SN 3-(2-adamantyl)pyrrolidine; AC1MHVT3; CHEMBL67992; SCHEMBL587443; AKOS023848508; Pyrrolidine, 3-tricyclo[3.3.1.13,7]dec-2-yl-
DMS98WA DT Small molecular drug
DMS98WA PC 3012268
DMS98WA MW 205.34
DMS98WA FM C14H23N
DMS98WA IC InChI=1S/C14H23N/c1-2-15-8-11(1)14-12-4-9-3-10(6-12)7-13(14)5-9/h9-15H,1-8H2
DMS98WA CS C1CNCC1C2C3CC4CC(C3)CC2C4
DMS98WA IK IULGEPJXNLPTSZ-UHFFFAOYSA-N
DMS98WA IU 3-(2-adamantyl)pyrrolidine
DMS98WA DE Discovery agent
DMQXPM3 ID DMQXPM3
DMQXPM3 DN 3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid
DMQXPM3 HS Investigative
DMQXPM3 SN 3-(2-AMINOETHYL)-4-(AMINOMETHYL)HEPTANEDIOIC ACID; (3R,4S)-3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid; AC1NRCOO
DMQXPM3 DT Small molecular drug
DMQXPM3 PC 5289108
DMQXPM3 MW 232.28
DMQXPM3 FM C10H20N2O4
DMQXPM3 IC InChI=1S/C10H20N2O4/c11-4-3-7(5-10(15)16)8(6-12)1-2-9(13)14/h7-8H,1-6,11-12H2,(H,13,14)(H,15,16)/t7-,8-/m1/s1
DMQXPM3 CS C(CC(=O)O)[C@H](CN)[C@H](CCN)CC(=O)O
DMQXPM3 IK QMRGRIXXWLVLTR-HTQZYQBOSA-N
DMQXPM3 IU (3R,4S)-3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid
DMQXPM3 DE Discovery agent
DM95R6O ID DM95R6O
DM95R6O DN 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane
DM95R6O HS Investigative
DM95R6O SN CHEMBL89735; 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane; SCHEMBL8551346; BDBM50104651
DM95R6O DT Small molecular drug
DM95R6O PC 44323014
DM95R6O MW 157.21
DM95R6O FM C7H15N3O
DM95R6O IC InChI=1S/C7H15N3O/c8-3-1-6-5-11-4-2-7(9)10-6/h6H,1-5,8H2,(H2,9,10)
DM95R6O CS C1COCC(N=C1N)CCN
DM95R6O IK ZPHRNAHMHZVACD-UHFFFAOYSA-N
DM95R6O IU 3-(2-aminoethyl)-2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DM95R6O DE Discovery agent
DMQPNUM ID DMQPNUM
DMQPNUM DN 3-(2-Amino-propyl)-1H-indol-5-ol
DMQPNUM HS Investigative
DMQPNUM SN 5-hydroxy-alpha-methyltryptamine
DMQPNUM DE Discovery agent
DMZCTGF ID DMZCTGF
DMZCTGF DN 3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF HS Investigative
DMZCTGF SN CHEMBL64508; 3-[2-(benzylamino)ethoxy]phenol; 3-(2-Benzylamino-ethoxy)-phenol
DMZCTGF DT Small molecular drug
DMZCTGF PC 11776546
DMZCTGF MW 243.3
DMZCTGF FM C15H17NO2
DMZCTGF IC InChI=1S/C15H17NO2/c17-14-7-4-8-15(11-14)18-10-9-16-12-13-5-2-1-3-6-13/h1-8,11,16-17H,9-10,12H2
DMZCTGF CS C1=CC=C(C=C1)CNCCOC2=CC=CC(=C2)O
DMZCTGF IK VBTFJGYCISLKEQ-UHFFFAOYSA-N
DMZCTGF IU 3-[2-(benzylamino)ethoxy]phenol
DMZCTGF CA CAS 129689-29-8
DMZCTGF DE Discovery agent
DMH6I4E ID DMH6I4E
DMH6I4E DN 3-(2-Bromophenyl)-2-thioxo-(1H )-quinazolin-4-one
DMH6I4E HS Investigative
DMH6I4E SN CHEMBL496735; SCHEMBL18239972
DMH6I4E DT Small molecular drug
DMH6I4E PC 11427575
DMH6I4E MW 333.2
DMH6I4E FM C14H9BrN2OS
DMH6I4E IC InChI=1S/C14H9BrN2OS/c15-10-6-2-4-8-12(10)17-13(18)9-5-1-3-7-11(9)16-14(17)19/h1-8H,(H,16,19)
DMH6I4E CS C1=CC=C2C(=C1)C(=O)N(C(=S)N2)C3=CC=CC=C3Br
DMH6I4E IK FHKTYFZUNGXFGS-UHFFFAOYSA-N
DMH6I4E IU 3-(2-bromophenyl)-2-sulfanylidene-1H-quinazolin-4-one
DMH6I4E DE Discovery agent
DMDM0R6 ID DMDM0R6
DMDM0R6 DN 3-(2-Bromophenyl)-6-methylcoumarin
DMDM0R6 HS Investigative
DMDM0R6 SN CHEMBL1221929; 3-(2-Bromophenyl)-6-methylcoumarin
DMDM0R6 DT Small molecular drug
DMDM0R6 PC 49864488
DMDM0R6 MW 315.16
DMDM0R6 FM C16H11BrO2
DMDM0R6 IC InChI=1S/C16H11BrO2/c1-10-6-7-15-11(8-10)9-13(16(18)19-15)12-4-2-3-5-14(12)17/h2-9H,1H3
DMDM0R6 CS CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC=CC=C3Br
DMDM0R6 IK AEOXYENOHINSQF-UHFFFAOYSA-N
DMDM0R6 IU 3-(2-bromophenyl)-6-methylchromen-2-one
DMDM0R6 DE Discovery agent
DMNOKR3 ID DMNOKR3
DMNOKR3 DN 3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
DMNOKR3 HS Investigative
DMNOKR3 SN Thiol-Based Inhibitor, 16; CHEMBL377648; CTK8A8852; BDBM17771; AKOS015965622; 3-[2-carbamoyl-2-(3-sulfanylpropyl)ethyl]benzoic acid; 3-(2-CARBAMOYL-5-MERCAPTO-PENTYL)-BENZOIC ACID
DMNOKR3 DT Small molecular drug
DMNOKR3 PC 11694647
DMNOKR3 MW 267.35
DMNOKR3 FM C13H17NO3S
DMNOKR3 IC InChI=1S/C13H17NO3S/c14-12(15)10(5-2-6-18)7-9-3-1-4-11(8-9)13(16)17/h1,3-4,8,10,18H,2,5-7H2,(H2,14,15)(H,16,17)
DMNOKR3 CS C1=CC(=CC(=C1)C(=O)O)CC(CCCS)C(=O)N
DMNOKR3 IK KSGSHIYQUPDDPN-UHFFFAOYSA-N
DMNOKR3 IU 3-(2-carbamoyl-5-sulfanylpentyl)benzoic acid
DMNOKR3 DE Discovery agent
DM67B8S ID DM67B8S
DM67B8S DN 3-(2-carboxy-3-mercaptopropyl)benzoic acid
DM67B8S HS Investigative
DM67B8S SN Thiol-Based Inhibitor, 7a; CHEMBL206699; CTK8A8777; BDBM17764; AKOS015965664; 3-[2-carboxy-2-(sulfanylmethyl)ethyl]benzoic acid; 3-(2-CARBOXY-3-MERCAPTO-PROPYL)-BENZOIC ACID
DM67B8S DT Small molecular drug
DM67B8S PC 11557761
DM67B8S MW 240.28
DM67B8S FM C11H12O4S
DM67B8S IC InChI=1S/C11H12O4S/c12-10(13)8-3-1-2-7(4-8)5-9(6-16)11(14)15/h1-4,9,16H,5-6H2,(H,12,13)(H,14,15)
DM67B8S CS C1=CC(=CC(=C1)C(=O)O)CC(CS)C(=O)O
DM67B8S IK LQVBVNPZOILYPX-UHFFFAOYSA-N
DM67B8S IU 3-(2-carboxy-3-sulfanylpropyl)benzoic acid
DM67B8S DE Discovery agent
DMG5R0N ID DMG5R0N
DMG5R0N DN 3-(2-carboxy-3-phosphonopropyl)benzoic acid
DMG5R0N HS Investigative
DMG5R0N SN phosphonate, 28; CHEMBL207343; BDBM17777; 3-[2-carboxy-2-(phosphonomethyl)ethyl]benzoic acid
DMG5R0N DT Small molecular drug
DMG5R0N PC 11492994
DMG5R0N MW 288.19
DMG5R0N FM C11H13O7P
DMG5R0N IC InChI=1S/C11H13O7P/c12-10(13)8-3-1-2-7(4-8)5-9(11(14)15)6-19(16,17)18/h1-4,9H,5-6H2,(H,12,13)(H,14,15)(H2,16,17,18)
DMG5R0N CS C1=CC(=CC(=C1)C(=O)O)CC(CP(=O)(O)O)C(=O)O
DMG5R0N IK JQOYXWMDISLLFO-UHFFFAOYSA-N
DMG5R0N IU 3-(2-carboxy-3-phosphonopropyl)benzoic acid
DMG5R0N DE Discovery agent
DM6HPYN ID DM6HPYN
DM6HPYN DN 3-(2-carboxy-4-mercaptobutyl)benzoic acid
DM6HPYN HS Investigative
DM6HPYN SN Thiol-Based Inhibitor, 7b; CHEMBL206078; BDBM17765; Benzenepropanoic acid, 3-carboxy-alpha-(2-mercaptoethyl)-; 378241-99-7; 3-[2-carboxy-2-(2-sulfanylethyl)ethyl]benzoic acid
DM6HPYN DT Small molecular drug
DM6HPYN PC 11615808
DM6HPYN MW 254.3
DM6HPYN FM C12H14O4S
DM6HPYN IC InChI=1S/C12H14O4S/c13-11(14)9-3-1-2-8(6-9)7-10(4-5-17)12(15)16/h1-3,6,10,17H,4-5,7H2,(H,13,14)(H,15,16)
DM6HPYN CS C1=CC(=CC(=C1)C(=O)O)CC(CCS)C(=O)O
DM6HPYN IK NTMSKDFHMVZFMA-UHFFFAOYSA-N
DM6HPYN IU 3-(2-carboxy-4-sulfanylbutyl)benzoic acid
DM6HPYN DE Discovery agent
DM6H52B ID DM6H52B
DM6H52B DN 3-(2-carboxy-5-mercaptopentyl)benzoic acid
DM6H52B HS Investigative
DM6H52B SN 3-(2-carboxy-5-mercaptopentyl)benzoic acid; Thiol-Based Inhibitor, 6c; SCHEMBL2058464; CHEMBL382398; CTK8A8854; BDBM17762; JKPYNGWTXQIZFC-UHFFFAOYSA-N; AKOS015966199; 3-[2-carboxy-2-(3-sulfanylpropyl)ethyl]benzoic acid; 3-(2-CARBOXY-5-MERCAPTO-PENTYL)-BENZOIC ACID
DM6H52B DT Small molecular drug
DM6H52B PC 9878510
DM6H52B MW 268.33
DM6H52B FM C13H16O4S
DM6H52B IC InChI=1S/C13H16O4S/c14-12(15)10-4-1-3-9(7-10)8-11(13(16)17)5-2-6-18/h1,3-4,7,11,18H,2,5-6,8H2,(H,14,15)(H,16,17)
DM6H52B CS C1=CC(=CC(=C1)C(=O)O)CC(CCCS)C(=O)O
DM6H52B IK JKPYNGWTXQIZFC-UHFFFAOYSA-N
DM6H52B IU 3-(2-carboxy-5-sulfanylpentyl)benzoic acid
DM6H52B DE Discovery agent
DM870W1 ID DM870W1
DM870W1 DN 3-(2-carboxy-6-mercaptohexyl)benzoic acid
DM870W1 HS Investigative
DM870W1 SN Thiol-Based Inhibitor, 7c; CHEMBL204412; BDBM17766; 3-[2-carboxy-2-(4-sulfanylbutyl)ethyl]benzoic acid
DM870W1 DT Small molecular drug
DM870W1 PC 11666341
DM870W1 MW 282.36
DM870W1 FM C14H18O4S
DM870W1 IC InChI=1S/C14H18O4S/c15-13(16)11(5-1-2-7-19)8-10-4-3-6-12(9-10)14(17)18/h3-4,6,9,11,19H,1-2,5,7-8H2,(H,15,16)(H,17,18)
DM870W1 CS C1=CC(=CC(=C1)C(=O)O)CC(CCCCS)C(=O)O
DM870W1 IK NHGYNJPSUMLAJY-UHFFFAOYSA-N
DM870W1 IU 3-(2-carboxy-6-sulfanylhexyl)benzoic acid
DM870W1 DE Discovery agent
DMDS4Q0 ID DMDS4Q0
DMDS4Q0 DN 3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine
DMDS4Q0 HS Investigative
DMDS4Q0 SN CHEMBL55746; 87372-77-8; 3-(1-Chloro-2-methyl-1-phenylpropan-2-yl)pyridine; 3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine; CTK3C4530; DTXSID30658230; BDBM50028163; Pyridine, 3-(2-chloro-1,1-dimethyl-2-phenylethyl)-
DMDS4Q0 DT Small molecular drug
DMDS4Q0 PC 44299142
DMDS4Q0 MW 245.74
DMDS4Q0 FM C15H16ClN
DMDS4Q0 IC InChI=1S/C15H16ClN/c1-15(2,13-9-6-10-17-11-13)14(16)12-7-4-3-5-8-12/h3-11,14H,1-2H3
DMDS4Q0 CS CC(C)(C1=CN=CC=C1)C(C2=CC=CC=C2)Cl
DMDS4Q0 IK DEEQECRKPXLAOA-UHFFFAOYSA-N
DMDS4Q0 IU 3-(1-chloro-2-methyl-1-phenylpropan-2-yl)pyridine
DMDS4Q0 CA CAS 87372-77-8
DMDS4Q0 DE Discovery agent
DM4XWME ID DM4XWME
DM4XWME DN 3-(2-cinnamylphenyl)acrylic acid
DM4XWME HS Investigative
DM4XWME SN 3-(2-cinnamylphenyl)acrylic acid; CHEMBL376282; SCHEMBL585953
DM4XWME DT Small molecular drug
DM4XWME PC 9813912
DM4XWME MW 264.3
DM4XWME FM C18H16O2
DM4XWME IC InChI=1S/C18H16O2/c19-18(20)14-13-17-11-5-4-10-16(17)12-6-9-15-7-2-1-3-8-15/h1-11,13-14H,12H2,(H,19,20)/b9-6+,14-13+
DM4XWME CS C1=CC=C(C=C1)/C=C/CC2=CC=CC=C2/C=C/C(=O)O
DM4XWME IK LDBYEQVSQBZSEH-BDXQXIFWSA-N
DM4XWME IU (E)-3-[2-[(E)-3-phenylprop-2-enyl]phenyl]prop-2-enoic acid
DM4XWME DE Discovery agent
DMVUK96 ID DMVUK96
DMVUK96 DN 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline
DMVUK96 HS Investigative
DMVUK96 SN CHEMBL66786; 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline; SCHEMBL8166505; HLKSYKUFDFBKPC-UHFFFAOYSA-N; ZINC3834045; BDBM50039049
DMVUK96 DT Small molecular drug
DMVUK96 PC 10040402
DMVUK96 MW 299.4
DMVUK96 FM C19H25NO2
DMVUK96 IC InChI=1S/C19H25NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h10-14H,3-9H2,1-2H3
DMVUK96 CS COC1=CC2=CC(=CN=C2C=C1OC)CCC3CCCCC3
DMVUK96 IK HLKSYKUFDFBKPC-UHFFFAOYSA-N
DMVUK96 IU 3-(2-cyclohexylethyl)-6,7-dimethoxyquinoline
DMVUK96 DE Discovery agent
DM08GRF ID DM08GRF
DM08GRF DN 3-(2-Diethylamino-acetamino)-rutaecarpine
DM08GRF HS Investigative
DM08GRF SN CHEMBL1095603; 3-(2-Diethylamino-acetamino)-rutaecarpine
DM08GRF DT Small molecular drug
DM08GRF PC 44623996
DM08GRF MW 415.5
DM08GRF FM C24H25N5O2
DM08GRF IC InChI=1S/C24H25N5O2/c1-3-28(4-2)14-21(30)25-15-9-10-20-18(13-15)24(31)29-12-11-17-16-7-5-6-8-19(16)26-22(17)23(29)27-20/h5-10,13,26H,3-4,11-12,14H2,1-2H3,(H,25,30)
DM08GRF CS CCN(CC)CC(=O)NC1=CC2=C(C=C1)N=C3C4=C(CCN3C2=O)C5=CC=CC=C5N4
DM08GRF IK IIFLCYXLKCVJJT-UHFFFAOYSA-N
DM08GRF IU 2-(diethylamino)-N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)acetamide
DM08GRF DE Discovery agent
DM1FOIZ ID DM1FOIZ
DM1FOIZ DN 3-(2-Diethylamino-propionamino)-rutaecarpine
DM1FOIZ HS Investigative
DM1FOIZ SN CHEMBL1098295; 3-(2-Diethylamino-propionamino)-rutaecarpine
DM1FOIZ DT Small molecular drug
DM1FOIZ PC 44624062
DM1FOIZ MW 429.5
DM1FOIZ FM C25H27N5O2
DM1FOIZ IC InChI=1S/C25H27N5O2/c1-3-29(4-2)13-12-22(31)26-16-9-10-21-19(15-16)25(32)30-14-11-18-17-7-5-6-8-20(17)27-23(18)24(30)28-21/h5-10,15,27H,3-4,11-14H2,1-2H3,(H,26,31)
DM1FOIZ CS CCN(CC)CCC(=O)NC1=CC2=C(C=C1)N=C3C4=C(CCN3C2=O)C5=CC=CC=C5N4
DM1FOIZ IK XTKDYIOBJOQMHV-UHFFFAOYSA-N
DM1FOIZ IU 3-(diethylamino)-N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)propanamide
DM1FOIZ DE Discovery agent
DM32MIE ID DM32MIE
DM32MIE DN 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol
DM32MIE HS Investigative
DM32MIE SN BRN 0160817; 6-Hydroxy-N,N-dimethyltryptamine; 1476-33-1; INDOL-6-OL, 3-(2-(DIMETHYLAMINO)ETHYL)-; CHEMBL382750; 3-(2-dimethylaminoethyl)-1H-indol-6-ol; 1H-Indol-6-ol, 3-[2-(dimethylamino)ethyl]-; 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol; 5-22-12-00067 (Beilstein Handbook Reference); 6-hydroxy-N-dimethyltryptamine; AC1L257Q; DTXSID70163752; BDBM50171259; AKOS023092717; LS-83678
DM32MIE DT Small molecular drug
DM32MIE PC 15124
DM32MIE MW 204.27
DM32MIE FM C12H16N2O
DM32MIE IC InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-7-10(15)3-4-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
DM32MIE CS CN(C)CCC1=CNC2=C1C=CC(=C2)O
DM32MIE IK WUQMRWPLIMXBDX-UHFFFAOYSA-N
DM32MIE IU 3-[2-(dimethylamino)ethyl]-1H-indol-6-ol
DM32MIE CA CAS 1476-33-1
DM32MIE DE Discovery agent
DMKYZGD ID DMKYZGD
DMKYZGD DN 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol
DMKYZGD HS Investigative
DMKYZGD SN 1-METHYLPSILOCIN; 1465-16-3; 3-[2-(DIMETHYLAMINO)ETHYL]-1-METHYLINDOL-4-OL; CHEMBL197664; 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol; SCHEMBL12558828; CTK4C4996; DTXSID40658761; MolPort-023-276-636; ZINC13985099; BDBM50171261; AKOS024457385; API0007835; B7244; J-008232
DMKYZGD DT Small molecular drug
DMKYZGD PC 44404883
DMKYZGD MW 218.29
DMKYZGD FM C13H18N2O
DMKYZGD IC InChI=1S/C13H18N2O/c1-14(2)8-7-10-9-15(3)11-5-4-6-12(16)13(10)11/h4-6,9,16H,7-8H2,1-3H3
DMKYZGD CS CN1C=C(C2=C1C=CC=C2O)CCN(C)C
DMKYZGD IK MZZRFEIDRWKTKJ-UHFFFAOYSA-N
DMKYZGD IU 3-[2-(dimethylamino)ethyl]-1-methylindol-4-ol
DMKYZGD CA CAS 1465-16-3
DMKYZGD DE Discovery agent
DM9BTLC ID DM9BTLC
DM9BTLC DN 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol
DM9BTLC HS Investigative
DM9BTLC SN CHEMBL370859; 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol
DM9BTLC DT Small molecular drug
DM9BTLC PC 44404892
DM9BTLC MW 218.29
DM9BTLC FM C13H18N2O
DM9BTLC IC InChI=1S/C13H18N2O/c1-9-10(7-8-15(2)3)13-11(14-9)5-4-6-12(13)16/h4-6,14,16H,7-8H2,1-3H3
DM9BTLC CS CC1=C(C2=C(N1)C=CC=C2O)CCN(C)C
DM9BTLC IK HXNGZUVNHQYMKL-UHFFFAOYSA-N
DM9BTLC IU 3-[2-(dimethylamino)ethyl]-2-methyl-1H-indol-4-ol
DM9BTLC DE Discovery agent
DMMJP9D ID DMMJP9D
DMMJP9D DN 3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D HS Investigative
DMMJP9D SN CHEMBL194202; 3-(2-Dimethylamino-propyl)-1H-indol-4-ol
DMMJP9D DT Small molecular drug
DMMJP9D PC 44404906
DMMJP9D MW 218.29
DMMJP9D FM C13H18N2O
DMMJP9D IC InChI=1S/C13H18N2O/c1-9(15(2)3)7-10-8-14-11-5-4-6-12(16)13(10)11/h4-6,8-9,14,16H,7H2,1-3H3
DMMJP9D CS CC(CC1=CNC2=C1C(=CC=C2)O)N(C)C
DMMJP9D IK GRWDWEFPYLWISL-UHFFFAOYSA-N
DMMJP9D IU 3-[2-(dimethylamino)propyl]-1H-indol-4-ol
DMMJP9D DE Discovery agent
DMD24EW ID DMD24EW
DMD24EW DN 3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMD24EW HS Investigative
DMD24EW DT Small molecular drug
DMD24EW PC 135474202
DMD24EW MW 227.21
DMD24EW FM C13H9NO3
DMD24EW IC InChI=1S/C13H9NO3/c15-8-5-6-10-12(7-8)17-14-13(10)9-3-1-2-4-11(9)16/h1-7,15-16H
DMD24EW CS C1=CC=C(C(=C1)C2=NOC3=C2C=CC(=C3)O)O
DMD24EW IK PKKSNVBSDIEUEZ-UHFFFAOYSA-N
DMD24EW IU 3-(2-hydroxyphenyl)-1,2-benzoxazol-6-ol
DMD24EW DE Discovery agent
DM1DQGJ ID DM1DQGJ
DM1DQGJ DN 3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol
DM1DQGJ HS Investigative
DM1DQGJ SN CHEMBL285250; 27107-68-2; 3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol; CTK0I5787; DTXSID80494706; BDBM50000570; AKOS022657931; 3-(2-Methyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol; Phenol, 3-(2-methyl-2-azabicyclo[3.3.1]non-5-yl)-; 2-Methyl-5-(3-hydroxyphenyl)-2-azabicyclo[3.3.1]nonane
DM1DQGJ DT Small molecular drug
DM1DQGJ PC 12368881
DM1DQGJ MW 231.33
DM1DQGJ FM C15H21NO
DM1DQGJ IC InChI=1S/C15H21NO/c1-16-9-8-15(7-3-5-13(16)11-15)12-4-2-6-14(17)10-12/h2,4,6,10,13,17H,3,5,7-9,11H2,1H3
DM1DQGJ CS CN1CCC2(CCCC1C2)C3=CC(=CC=C3)O
DM1DQGJ IK ZQJGRSYDDMBMPJ-UHFFFAOYSA-N
DM1DQGJ IU 3-(2-methyl-2-azabicyclo[3.3.1]nonan-5-yl)phenol
DM1DQGJ CA CAS 27107-68-2
DM1DQGJ DE Discovery agent
DMY782R ID DMY782R
DMY782R DN 3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile
DMY782R HS Investigative
DMY782R SN CHEMBL244585; 3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile
DMY782R DT Small molecular drug
DMY782R PC 44427389
DMY782R MW 250.32
DMY782R FM C15H10N2S
DMY782R IC InChI=1S/C15H10N2S/c1-10-17-14-8-13(5-6-15(14)18-10)12-4-2-3-11(7-12)9-16/h2-8H,1H3
DMY782R CS CC1=NC2=C(S1)C=CC(=C2)C3=CC=CC(=C3)C#N
DMY782R IK QCTQEXSACACMOJ-UHFFFAOYSA-N
DMY782R IU 3-(2-methyl-1,3-benzothiazol-5-yl)benzonitrile
DMY782R DE Discovery agent
DMUPB9H ID DMUPB9H
DMUPB9H DN 3-(2-methylquinolin-7-yl)benzonitrile
DMUPB9H HS Investigative
DMUPB9H SN CHEMBL244796; 3-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4296051
DMUPB9H DT Small molecular drug
DMUPB9H PC 16747725
DMUPB9H MW 244.29
DMUPB9H FM C17H12N2
DMUPB9H IC InChI=1S/C17H12N2/c1-12-5-6-14-7-8-16(10-17(14)19-12)15-4-2-3-13(9-15)11-18/h2-10H,1H3
DMUPB9H CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)C#N
DMUPB9H IK RPEUOKKTGONULE-UHFFFAOYSA-N
DMUPB9H IU 3-(2-methylquinolin-7-yl)benzonitrile
DMUPB9H DE Discovery agent
DM41HMZ ID DM41HMZ
DM41HMZ DN 3-(2-methylquinolin-7-yl)phenol
DM41HMZ HS Investigative
DM41HMZ SN CHEMBL231988; 3-(2-methylquinolin-7-yl)phenol
DM41HMZ DT Small molecular drug
DM41HMZ PC 44432667
DM41HMZ MW 235.28
DM41HMZ FM C16H13NO
DM41HMZ IC InChI=1S/C16H13NO/c1-11-5-6-12-7-8-14(10-16(12)17-11)13-3-2-4-15(18)9-13/h2-10,18H,1H3
DM41HMZ CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)O
DM41HMZ IK ONBWGZNKVDEPCB-UHFFFAOYSA-N
DM41HMZ IU 3-(2-methylquinolin-7-yl)phenol
DM41HMZ DE Discovery agent
DM27HSO ID DM27HSO
DM27HSO DN 3-(2-naphthyl)phenol
DM27HSO HS Investigative
DM27HSO SN 3-(2-naphthyl)phenol; 2-(3-Hydroxyphenyl)naphthalene; 3-(NAPHTHALEN-2-YL)PHENOL; 33104-32-4; CHEMBL258687; 3-Naphthalene-2-ylphenol; 3-naphthalen-2-yl-phenol; SCHEMBL3015094; DTXSID90487649; FQDQJXSIUCYJDC-UHFFFAOYSA-N; BDBM50373033
DM27HSO DT Small molecular drug
DM27HSO PC 12316406
DM27HSO MW 220.26
DM27HSO FM C16H12O
DM27HSO IC InChI=1S/C16H12O/c17-16-7-3-6-14(11-16)15-9-8-12-4-1-2-5-13(12)10-15/h1-11,17H
DM27HSO CS C1=CC=C2C=C(C=CC2=C1)C3=CC(=CC=C3)O
DM27HSO IK FQDQJXSIUCYJDC-UHFFFAOYSA-N
DM27HSO IU 3-naphthalen-2-ylphenol
DM27HSO CA CAS 33104-32-4
DM27HSO DE Discovery agent
DMYXQ7L ID DMYXQ7L
DMYXQ7L DN 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine
DMYXQ7L HS Investigative
DMYXQ7L SN CHEMBL314727; 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine; SCHEMBL8550044; BDBM50104648
DMYXQ7L DT Small molecular drug
DMYXQ7L PC 44322572
DMYXQ7L MW 187.2
DMYXQ7L FM C7H13N3O3
DMYXQ7L IC InChI=1S/C7H13N3O3/c8-7-2-4-13-5-6(9-7)1-3-10(11)12/h6H,1-5H2,(H2,8,9)
DMYXQ7L CS C1COCC(N=C1N)CC[N+](=O)[O-]
DMYXQ7L IK BWBBVEBIAZILKQ-UHFFFAOYSA-N
DMYXQ7L IU 3-(2-nitroethyl)-2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DMYXQ7L DE Discovery agent
DM3BQO0 ID DM3BQO0
DM3BQO0 DN 3-(2-N-Piperidyl-acetamino)-rutaecarpine
DM3BQO0 HS Investigative
DM3BQO0 SN CHEMBL1097952; 3-(2-N-Piperidyl-acetamino)-rutaecarpine
DM3BQO0 DT Small molecular drug
DM3BQO0 PC 44624061
DM3BQO0 MW 427.5
DM3BQO0 FM C25H25N5O2
DM3BQO0 IC InChI=1S/C25H25N5O2/c31-22(15-29-11-4-1-5-12-29)26-16-8-9-21-19(14-16)25(32)30-13-10-18-17-6-2-3-7-20(17)27-23(18)24(30)28-21/h2-3,6-9,14,27H,1,4-5,10-13,15H2,(H,26,31)
DM3BQO0 CS C1CCN(CC1)CC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DM3BQO0 IK QCNQXHWYZYJQDL-UHFFFAOYSA-N
DM3BQO0 IU N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-2-piperidin-1-ylacetamide
DM3BQO0 DE Discovery agent
DMFEHDY ID DMFEHDY
DMFEHDY DN 3-(2-N-Piperidyl-propionamino)-rutaecarpine
DMFEHDY HS Investigative
DMFEHDY SN CHEMBL1096951; 3-(2-N-Piperidyl-propionamino)-rutaecarpine
DMFEHDY DT Small molecular drug
DMFEHDY PC 44624064
DMFEHDY MW 441.5
DMFEHDY FM C26H27N5O2
DMFEHDY IC InChI=1S/C26H27N5O2/c32-23(11-14-30-12-4-1-5-13-30)27-17-8-9-22-20(16-17)26(33)31-15-10-19-18-6-2-3-7-21(18)28-24(19)25(31)29-22/h2-3,6-9,16,28H,1,4-5,10-15H2,(H,27,32)
DMFEHDY CS C1CCN(CC1)CCC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DMFEHDY IK SJTYFVUMCWQRRK-UHFFFAOYSA-N
DMFEHDY IU N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-3-piperidin-1-ylpropanamide
DMFEHDY DE Discovery agent
DMQ0A8W ID DMQ0A8W
DMQ0A8W DN 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine
DMQ0A8W HS Investigative
DMQ0A8W SN CHEMBL1097951; 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine
DMQ0A8W DT Small molecular drug
DMQ0A8W PC 44624060
DMQ0A8W MW 413.5
DMQ0A8W FM C24H23N5O2
DMQ0A8W IC InChI=1S/C24H23N5O2/c30-21(14-28-10-3-4-11-28)25-15-7-8-20-18(13-15)24(31)29-12-9-17-16-5-1-2-6-19(16)26-22(17)23(29)27-20/h1-2,5-8,13,26H,3-4,9-12,14H2,(H,25,30)
DMQ0A8W CS C1CCN(C1)CC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DMQ0A8W IK WZTWUTJMQXWCQN-UHFFFAOYSA-N
DMQ0A8W IU N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-2-pyrrolidin-1-ylacetamide
DMQ0A8W DE Discovery agent
DM9MRTW ID DM9MRTW
DM9MRTW DN 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine
DM9MRTW HS Investigative
DM9MRTW SN CHEMBL1094633; 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine
DM9MRTW DT Small molecular drug
DM9MRTW PC 44624063
DM9MRTW MW 427.5
DM9MRTW FM C25H25N5O2
DM9MRTW IC InChI=1S/C25H25N5O2/c31-22(10-13-29-11-3-4-12-29)26-16-7-8-21-19(15-16)25(32)30-14-9-18-17-5-1-2-6-20(17)27-23(18)24(30)28-21/h1-2,5-8,15,27H,3-4,9-14H2,(H,26,31)
DM9MRTW CS C1CCN(C1)CCC(=O)NC2=CC3=C(C=C2)N=C4C5=C(CCN4C3=O)C6=CC=CC=C6N5
DM9MRTW IK QEZVUWPDYKSHCV-UHFFFAOYSA-N
DM9MRTW IU N-(14-oxo-3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15(20),16,18-octaen-17-yl)-3-pyrrolidin-1-ylpropanamide
DM9MRTW DE Discovery agent
DM0YEGM ID DM0YEGM
DM0YEGM DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide
DM0YEGM HS Investigative
DM0YEGM SN CHEMBL379536; 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide
DM0YEGM DT Small molecular drug
DM0YEGM PC 44414732
DM0YEGM MW 309.4
DM0YEGM FM C19H23N3O
DM0YEGM IC InChI=1S/C19H23N3O/c20-19(23)17-8-4-5-15(13-17)14-18(16-6-2-1-3-7-16)22-11-9-21-10-12-22/h1-8,13,18,21H,9-12,14H2,(H2,20,23)
DM0YEGM CS C1CN(CCN1)C(CC2=CC(=CC=C2)C(=O)N)C3=CC=CC=C3
DM0YEGM IK AGCDRDCNYZHHKS-UHFFFAOYSA-N
DM0YEGM IU 3-(2-phenyl-2-piperazin-1-ylethyl)benzamide
DM0YEGM DE Discovery agent
DM6YJOU ID DM6YJOU
DM6YJOU DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DM6YJOU HS Investigative
DM6YJOU SN CHEMBL386223; 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile
DM6YJOU DT Small molecular drug
DM6YJOU PC 44414721
DM6YJOU MW 291.4
DM6YJOU FM C19H21N3
DM6YJOU IC InChI=1S/C19H21N3/c20-15-17-6-4-5-16(13-17)14-19(18-7-2-1-3-8-18)22-11-9-21-10-12-22/h1-8,13,19,21H,9-12,14H2
DM6YJOU CS C1CN(CCN1)C(CC2=CC(=CC=C2)C#N)C3=CC=CC=C3
DM6YJOU IK JQQRBSOAFDAWGZ-UHFFFAOYSA-N
DM6YJOU IU 3-(2-phenyl-2-piperazin-1-ylethyl)benzonitrile
DM6YJOU DE Discovery agent
DM6QZTB ID DM6QZTB
DM6QZTB DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol
DM6QZTB HS Investigative
DM6QZTB SN CHEMBL210026; 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol; 61311-64-6; 3-[2-Phenyl-2-(piperazin-1-yl)ethyl]phenol; SCHEMBL8531930; CTK2E2737; DTXSID30552209; VPNYIGJUQBPBMU-UHFFFAOYSA-N; BDBM50188056; Phenol, 3-[2-phenyl-2-(1-piperazinyl)ethyl]-; 1-[1-Phenyl-2-(3-hydroxyphenyl)ethyl]piperazine
DM6QZTB DT Small molecular drug
DM6QZTB PC 13904714
DM6QZTB MW 282.4
DM6QZTB FM C18H22N2O
DM6QZTB IC InChI=1S/C18H22N2O/c21-17-8-4-5-15(13-17)14-18(16-6-2-1-3-7-16)20-11-9-19-10-12-20/h1-8,13,18-19,21H,9-12,14H2
DM6QZTB CS C1CN(CCN1)C(CC2=CC(=CC=C2)O)C3=CC=CC=C3
DM6QZTB IK VPNYIGJUQBPBMU-UHFFFAOYSA-N
DM6QZTB IU 3-(2-phenyl-2-piperazin-1-ylethyl)phenol
DM6QZTB CA CAS 61311-64-6
DM6QZTB DE Discovery agent
DM63T9D ID DM63T9D
DM63T9D DN 3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol
DM63T9D HS Investigative
DM63T9D SN CHEMBL1096659
DM63T9D DT Small molecular drug
DM63T9D PC 46887242
DM63T9D MW 329.4
DM63T9D FM C21H15NOS
DM63T9D IC InChI=1S/C21H15NOS/c23-18-9-4-8-16(12-18)17-13-19(15-6-2-1-3-7-15)22-20(14-17)21-10-5-11-24-21/h1-14,23H
DM63T9D CS C1=CC=C(C=C1)C2=NC(=CC(=C2)C3=CC(=CC=C3)O)C4=CC=CS4
DM63T9D IK VNKCREXUIZRWPF-UHFFFAOYSA-N
DM63T9D IU 3-(2-phenyl-6-thiophen-2-ylpyridin-4-yl)phenol
DM63T9D DE Discovery agent
DMF369N ID DMF369N
DMF369N DN 3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol
DMF369N HS Investigative
DMF369N SN CHEMBL1094745
DMF369N DT Small molecular drug
DMF369N PC 46887243
DMF369N MW 329.4
DMF369N FM C21H15NOS
DMF369N IC InChI=1S/C21H15NOS/c23-19-8-4-7-16(11-19)18-12-20(15-5-2-1-3-6-15)22-21(13-18)17-9-10-24-14-17/h1-14,23H
DMF369N CS C1=CC=C(C=C1)C2=NC(=CC(=C2)C3=CC(=CC=C3)O)C4=CSC=C4
DMF369N IK GWFRFJZJQITLHW-UHFFFAOYSA-N
DMF369N IU 3-(2-phenyl-6-thiophen-3-ylpyridin-4-yl)phenol
DMF369N DE Discovery agent
DMQC9WV ID DMQC9WV
DMQC9WV DN 3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one
DMQC9WV HS Investigative
DMQC9WV SN SCHEMBL5463666; CHEMBL240264; BDBM20859; quinolin-2(1H)-one derivative, 17a
DMQC9WV DT Small molecular drug
DMQC9WV PC 22638512
DMQC9WV MW 304.4
DMQC9WV FM C18H12N2OS
DMQC9WV IC InChI=1S/C18H12N2OS/c21-17-14(10-13-8-4-5-9-15(13)19-17)16-11-22-18(20-16)12-6-2-1-3-7-12/h1-11H,(H,19,21)
DMQC9WV CS C1=CC=C(C=C1)C2=NC(=CS2)C3=CC4=CC=CC=C4NC3=O
DMQC9WV IK OANBFUCSFFQVAU-UHFFFAOYSA-N
DMQC9WV IU 3-(2-phenyl-1,3-thiazol-4-yl)-1H-quinolin-2-one
DMQC9WV DE Discovery agent
DM2IYAP ID DM2IYAP
DM2IYAP DN 3-(2-propyn-1-yl)thymidine
DM2IYAP HS Investigative
DM2IYAP SN 3-(2-propyn-1-yl)thymidine; 3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872
DM2IYAP DT Small molecular drug
DM2IYAP PC 11323459
DM2IYAP MW 280.28
DM2IYAP FM C13H16N2O5
DM2IYAP IC InChI=1S/C13H16N2O5/c1-3-4-14-12(18)8(2)6-15(13(14)19)11-5-9(17)10(7-16)20-11/h1,6,9-11,16-17H,4-5,7H2,2H3/t9-,10+,11+/m0/s1
DM2IYAP CS CC1=CN(C(=O)N(C1=O)CC#C)[C@H]2C[C@@H]([C@H](O2)CO)O
DM2IYAP IK LZHTUGCZNRVCGE-HBNTYKKESA-N
DM2IYAP IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-3-prop-2-ynylpyrimidine-2,4-dione
DM2IYAP DE Discovery agent
DMPWEL8 ID DMPWEL8
DMPWEL8 DN 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile
DMPWEL8 HS Investigative
DMPWEL8 SN CHEMBL366288; 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile; SCHEMBL4703496; ZINC13582347
DMPWEL8 DT Small molecular drug
DMPWEL8 PC 9813637
DMPWEL8 MW 248.24
DMPWEL8 FM C13H8N6
DMPWEL8 IC InChI=1S/C13H8N6/c14-9-10-4-3-5-11(8-10)13-16-18-19(17-13)12-6-1-2-7-15-12/h1-8H
DMPWEL8 CS C1=CC=NC(=C1)N2N=C(N=N2)C3=CC=CC(=C3)C#N
DMPWEL8 IK GHRSDAGWCBAULR-UHFFFAOYSA-N
DMPWEL8 IU 3-(2-pyridin-2-yltetrazol-5-yl)benzonitrile
DMPWEL8 DE Discovery agent
DM7VJPX ID DM7VJPX
DM7VJPX DN 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol
DM7VJPX HS Investigative
DM7VJPX SN CHEMBL364061; 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol; BDBM50171265; AKOS022506696
DM7VJPX DT Small molecular drug
DM7VJPX PC 21854226
DM7VJPX MW 230.31
DM7VJPX FM C14H18N2O
DM7VJPX IC InChI=1S/C14H18N2O/c17-13-5-3-4-12-14(13)11(10-15-12)6-9-16-7-1-2-8-16/h3-5,10,15,17H,1-2,6-9H2
DM7VJPX CS C1CCN(C1)CCC2=CNC3=C2C(=CC=C3)O
DM7VJPX IK XASLPZWIPBCAPF-UHFFFAOYSA-N
DM7VJPX IU 3-(2-pyrrolidin-1-ylethyl)-1H-indol-4-ol
DM7VJPX CA CAS 63097-26-7
DM7VJPX DE Discovery agent
DMKAEUD ID DMKAEUD
DMKAEUD DN 3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine
DMKAEUD HS Investigative
DMKAEUD SN CHEMBL208506; 3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine
DMKAEUD DT Small molecular drug
DMKAEUD PC 44409820
DMKAEUD MW 309.8
DMKAEUD FM C19H16ClNO
DMKAEUD IC InChI=1S/C19H16ClNO/c1-14-8-17(16-5-3-7-21-12-16)11-19(9-14)22-13-15-4-2-6-18(20)10-15/h2-12H,13H2,1H3
DMKAEUD CS CC1=CC(=CC(=C1)OCC2=CC(=CC=C2)Cl)C3=CN=CC=C3
DMKAEUD IK XCVOOHGTUQHYAX-UHFFFAOYSA-N
DMKAEUD IU 3-[3-[(3-chlorophenyl)methoxy]-5-methylphenyl]pyridine
DMKAEUD DE Discovery agent
DMY4VX2 ID DMY4VX2
DMY4VX2 DN 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid
DMY4VX2 HS Investigative
DMY4VX2 SN CHEMBL218226
DMY4VX2 DT Small molecular drug
DMY4VX2 PC 44418282
DMY4VX2 MW 412.4
DMY4VX2 FM C20H20N4O6
DMY4VX2 IC InChI=1S/C20H20N4O6/c25-18(26)4-6-22-19(27)13-7-14(10-17(9-13)24(29)30)20(28)23-16-2-1-12-3-5-21-11-15(12)8-16/h1-2,7-10,21H,3-6,11H2,(H,22,27)(H,23,28)(H,25,26)
DMY4VX2 CS C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC(=CC(=C3)C(=O)NCCC(=O)O)[N+](=O)[O-]
DMY4VX2 IK VGPKJRDGGNBIGH-UHFFFAOYSA-N
DMY4VX2 IU 3-[[3-nitro-5-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzoyl]amino]propanoic acid
DMY4VX2 DE Discovery agent
DM2K51S ID DM2K51S
DM2K51S DN 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid
DM2K51S HS Investigative
DM2K51S SN CHEMBL220128; 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid
DM2K51S DT Small molecular drug
DM2K51S PC 44418281
DM2K51S MW 443.5
DM2K51S FM C26H25N3O4
DM2K51S IC InChI=1S/C26H25N3O4/c30-24(31)15-23(18-5-2-1-3-6-18)29-26(33)20-8-4-7-19(13-20)25(32)28-22-10-9-17-11-12-27-16-21(17)14-22/h1-10,13-14,23,27H,11-12,15-16H2,(H,28,32)(H,29,33)(H,30,31)
DM2K51S CS C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC(=CC=C3)C(=O)NC(CC(=O)O)C4=CC=CC=C4
DM2K51S IK OCNALRIBAIFGLP-UHFFFAOYSA-N
DM2K51S IU 3-phenyl-3-[[3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzoyl]amino]propanoic acid
DM2K51S DE Discovery agent
DM31JAZ ID DM31JAZ
DM31JAZ DN 3-(3-(carbamoyl)benzamido)propanoic acid
DM31JAZ HS Investigative
DM31JAZ SN CHEMBL219603; 3-(3-(carbamoyl)benzamido)propanoic acid
DM31JAZ DT Small molecular drug
DM31JAZ PC 44418280
DM31JAZ MW 367.4
DM31JAZ FM C20H21N3O4
DM31JAZ IC InChI=1S/C20H21N3O4/c24-18(25)7-9-22-19(26)14-2-1-3-15(10-14)20(27)23-17-5-4-13-6-8-21-12-16(13)11-17/h1-5,10-11,21H,6-9,12H2,(H,22,26)(H,23,27)(H,24,25)
DM31JAZ CS C1CNCC2=C1C=CC(=C2)NC(=O)C3=CC=CC(=C3)C(=O)NCCC(=O)O
DM31JAZ IK MPYXISYAFIYYRD-UHFFFAOYSA-N
DM31JAZ IU 3-[[3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzoyl]amino]propanoic acid
DM31JAZ DE Discovery agent
DMSHORK ID DMSHORK
DMSHORK DN 3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile
DMSHORK HS Investigative
DMSHORK SN CHEMBL117187; 3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile; SCHEMBL3518135; BDBM50121164; 3,3-Dimethyl-5-(3-cyanophenyl)indoline-2-one
DMSHORK DT Small molecular drug
DMSHORK PC 9903358
DMSHORK MW 262.3
DMSHORK FM C17H14N2O
DMSHORK IC InChI=1S/C17H14N2O/c1-17(2)14-9-13(6-7-15(14)19-16(17)20)12-5-3-4-11(8-12)10-18/h3-9H,1-2H3,(H,19,20)
DMSHORK CS CC1(C2=C(C=CC(=C2)C3=CC=CC(=C3)C#N)NC1=O)C
DMSHORK IK WZZPSUKZMZKXTQ-UHFFFAOYSA-N
DMSHORK IU 3-(3,3-dimethyl-2-oxo-1H-indol-5-yl)benzonitrile
DMSHORK DE Discovery agent
DMT3AW8 ID DMT3AW8
DMT3AW8 DN 3-(3,4-dichlorophenyl)-2-nortropene
DMT3AW8 HS Investigative
DMT3AW8 SN CHEMBL578130; 3-(3,4-dichlorophenyl)-2-nortropene; SCHEMBL5194296; WNTMTTVEDFGEMS-UHFFFAOYSA-N; BDBM50303309
DMT3AW8 DT Small molecular drug
DMT3AW8 PC 10220657
DMT3AW8 MW 254.15
DMT3AW8 FM C13H13Cl2N
DMT3AW8 IC InChI=1S/C13H13Cl2N/c14-12-4-1-8(7-13(12)15)9-5-10-2-3-11(6-9)16-10/h1,4-5,7,10-11,16H,2-3,6H2
DMT3AW8 CS C1CC2C=C(CC1N2)C3=CC(=C(C=C3)Cl)Cl
DMT3AW8 IK WNTMTTVEDFGEMS-UHFFFAOYSA-N
DMT3AW8 IU 3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene
DMT3AW8 DE Discovery agent
DMEJH13 ID DMEJH13
DMEJH13 DN 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline
DMEJH13 HS Investigative
DMEJH13 SN CHEMBL67702; 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502992; BDBM50039074
DMEJH13 DT Small molecular drug
DMEJH13 PC 10065445
DMEJH13 MW 334.2
DMEJH13 FM C17H13Cl2NO2
DMEJH13 IC InChI=1S/C17H13Cl2NO2/c1-21-16-7-11-5-12(9-20-15(11)8-17(16)22-2)10-3-4-13(18)14(19)6-10/h3-9H,1-2H3
DMEJH13 CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC(=C(C=C3)Cl)Cl
DMEJH13 IK PSUROKVLDMNXCQ-UHFFFAOYSA-N
DMEJH13 IU 3-(3,4-dichlorophenyl)-6,7-dimethoxyquinoline
DMEJH13 DE Discovery agent
DMX3AMB ID DMX3AMB
DMX3AMB DN 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline
DMX3AMB HS Investigative
DMX3AMB SN CHEMBL67424; 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834040
DMX3AMB DT Small molecular drug
DMX3AMB PC 10402592
DMX3AMB MW 301.29
DMX3AMB FM C17H13F2NO2
DMX3AMB IC InChI=1S/C17H13F2NO2/c1-21-16-7-11-5-12(9-20-15(11)8-17(16)22-2)10-3-4-13(18)14(19)6-10/h3-9H,1-2H3
DMX3AMB CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC(=C(C=C3)F)F
DMX3AMB IK RETQZWLIOAJIRM-UHFFFAOYSA-N
DMX3AMB IU 3-(3,4-difluorophenyl)-6,7-dimethoxyquinoline
DMX3AMB DE Discovery agent
DM0VL17 ID DM0VL17
DM0VL17 DN 3-(3,4-dihydronaphthalen-2-yl)pyridine
DM0VL17 HS Investigative
DM0VL17 SN 3-(3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 2; AC1O70H5; BDBM8889; SCHEMBL4508891; CHEMBL205881
DM0VL17 DT Small molecular drug
DM0VL17 PC 6540047
DM0VL17 MW 207.27
DM0VL17 FM C15H13N
DM0VL17 IC InChI=1S/C15H13N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h1-6,9-11H,7-8H2
DM0VL17 CS C1CC(=CC2=CC=CC=C21)C3=CN=CC=C3
DM0VL17 IK AXLDMZNUHQOZFK-UHFFFAOYSA-N
DM0VL17 IU 3-(3,4-dihydronaphthalen-2-yl)pyridine
DM0VL17 DE Discovery agent
DMDU10A ID DMDU10A
DMDU10A DN 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline
DMDU10A HS Investigative
DMDU10A SN CHEMBL66100; 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline; BDBM50039089
DMDU10A DT Small molecular drug
DMDU10A PC 10336427
DMDU10A MW 325.4
DMDU10A FM C19H19NO4
DMDU10A IC InChI=1S/C19H19NO4/c1-21-16-6-5-12(8-17(16)22-2)14-7-13-9-18(23-3)19(24-4)10-15(13)20-11-14/h5-11H,1-4H3
DMDU10A CS COC1=C(C=C(C=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC)OC
DMDU10A IK BWIYMDQJIKNCMK-UHFFFAOYSA-N
DMDU10A IU 3-(3,4-dimethoxyphenyl)-6,7-dimethoxyquinoline
DMDU10A DE Discovery agent
DM9BYVL ID DM9BYVL
DM9BYVL DN 3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one
DM9BYVL HS Investigative
DM9BYVL SN CHEMBL576116; BDBM35551; 4-hydroxy-2H-chromen-2-one core, 28
DM9BYVL DT Small molecular drug
DM9BYVL PC 54736444
DM9BYVL MW 280.3
DM9BYVL FM C18H16O3
DM9BYVL IC InChI=1S/C18H16O3/c1-11-7-8-13(9-12(11)2)10-15-17(19)14-5-3-4-6-16(14)21-18(15)20/h3-9,19H,10H2,1-2H3
DM9BYVL CS CC1=C(C=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O)C
DM9BYVL IK YGMVKOKEKHJHOV-UHFFFAOYSA-N
DM9BYVL IU 3-[(3,4-dimethylphenyl)methyl]-4-hydroxychromen-2-one
DM9BYVL DE Discovery agent
DMULX9O ID DMULX9O
DMULX9O DN 3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O HS Investigative
DMULX9O SN CHEMBL236264; 3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O DT Small molecular drug
DMULX9O PC 44434731
DMULX9O MW 234.29
DMULX9O FM C16H14N2
DMULX9O IC InChI=1S/C16H14N2/c1-11-5-6-13(8-12(11)2)14-9-16-15(18-10-14)4-3-7-17-16/h3-10H,1-2H3
DMULX9O CS CC1=C(C=C(C=C1)C2=CC3=C(C=CC=N3)N=C2)C
DMULX9O IK MGYKFCHFCGICOX-UHFFFAOYSA-N
DMULX9O IU 3-(3,4-dimethylphenyl)-1,5-naphthyridine
DMULX9O DE Discovery agent
DM8W9EO ID DM8W9EO
DM8W9EO DN 3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine
DM8W9EO HS Investigative
DM8W9EO SN CHEMBL72630; 3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine; CTK8F4622; DTXSID60441778; BDBM50068422; 1-Propyl-3-(3,4-dimethylphenyl)piperidine
DM8W9EO DT Small molecular drug
DM8W9EO PC 10561521
DM8W9EO MW 231.38
DM8W9EO FM C16H25N
DM8W9EO IC InChI=1S/C16H25N/c1-4-9-17-10-5-6-16(12-17)15-8-7-13(2)14(3)11-15/h7-8,11,16H,4-6,9-10,12H2,1-3H3
DM8W9EO CS CCCN1CCCC(C1)C2=CC(=C(C=C2)C)C
DM8W9EO IK WKCUEEXFTZSNLI-UHFFFAOYSA-N
DM8W9EO IU 3-(3,4-dimethylphenyl)-1-propylpiperidine
DM8W9EO DE Discovery agent
DMOW0L9 ID DMOW0L9
DMOW0L9 DN 3-(3,4-Dimethyl-phenyl)-piperidine
DMOW0L9 HS Investigative
DMOW0L9 SN 3-(3,4-dimethylphenyl)piperidine; CHEMBL356746; 219703-95-4; 3-(3,4-Dimethyl-phenyl)-piperidine; BDBM50068423; AKOS013783555
DMOW0L9 DT Small molecular drug
DMOW0L9 PC 10103976
DMOW0L9 MW 189.3
DMOW0L9 FM C13H19N
DMOW0L9 IC InChI=1S/C13H19N/c1-10-5-6-12(8-11(10)2)13-4-3-7-14-9-13/h5-6,8,13-14H,3-4,7,9H2,1-2H3
DMOW0L9 CS CC1=C(C=C(C=C1)C2CCCNC2)C
DMOW0L9 IK NDGKSXYKTXZIQO-UHFFFAOYSA-N
DMOW0L9 IU 3-(3,4-dimethylphenyl)piperidine
DMOW0L9 DE Discovery agent
DMDFHCU ID DMDFHCU
DMDFHCU DN 3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid
DMDFHCU HS Investigative
DMDFHCU SN SCHEMBL4895878; CHEMBL195556; BDBM18906; ZINC13643210; 3,5-Dibromo-4-alkoxyphenylalkanoic Acid, 9i; 3-[3,5-dibromo-4-(hexyloxy)phenyl]propanoic acid
DMDFHCU DT Small molecular drug
DMDFHCU PC 11350323
DMDFHCU MW 408.12
DMDFHCU FM C15H20Br2O3
DMDFHCU IC InChI=1S/C15H20Br2O3/c1-2-3-4-5-8-20-15-12(16)9-11(10-13(15)17)6-7-14(18)19/h9-10H,2-8H2,1H3,(H,18,19)
DMDFHCU CS CCCCCCOC1=C(C=C(C=C1Br)CCC(=O)O)Br
DMDFHCU IK FVDRTJXVCUAOCA-UHFFFAOYSA-N
DMDFHCU IU 3-(3,5-dibromo-4-hexoxyphenyl)propanoic acid
DMDFHCU DE Discovery agent
DMSI3V4 ID DMSI3V4
DMSI3V4 DN 3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine
DMSI3V4 HS Investigative
DMSI3V4 SN CHEMBL144114; 3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine; BDBM50068419
DMSI3V4 DT Small molecular drug
DMSI3V4 PC 10775901
DMSI3V4 MW 231.38
DMSI3V4 FM C16H25N
DMSI3V4 IC InChI=1S/C16H25N/c1-4-7-17-8-5-6-15(12-17)16-10-13(2)9-14(3)11-16/h9-11,15H,4-8,12H2,1-3H3
DMSI3V4 CS CCCN1CCCC(C1)C2=CC(=CC(=C2)C)C
DMSI3V4 IK AMPXVBOIQBSQML-UHFFFAOYSA-N
DMSI3V4 IU 3-(3,5-dimethylphenyl)-1-propylpiperidine
DMSI3V4 CA CAS 219704-08-2
DMSI3V4 DE Discovery agent
DMUWKMN ID DMUWKMN
DMUWKMN DN 3-(3,5-Dimethyl-phenyl)-piperidine
DMUWKMN HS Investigative
DMUWKMN SN 3-(3,5-dimethylphenyl)piperidine; CHEMBL342345; 219704-07-1; 3-(3,5-Dimethyl-phenyl)-piperidine; BDBM50068427; AKOS006308924
DMUWKMN DT Small molecular drug
DMUWKMN PC 10035413
DMUWKMN MW 189.3
DMUWKMN FM C13H19N
DMUWKMN IC InChI=1S/C13H19N/c1-10-6-11(2)8-13(7-10)12-4-3-5-14-9-12/h6-8,12,14H,3-5,9H2,1-2H3
DMUWKMN CS CC1=CC(=CC(=C1)C2CCCNC2)C
DMUWKMN IK KCTMOZHTZAFYSJ-UHFFFAOYSA-N
DMUWKMN IU 3-(3,5-dimethylphenyl)piperidine
DMUWKMN DE Discovery agent
DMT0M94 ID DMT0M94
DMT0M94 DN 3-(3-Adamantan-1-yl-ureido)-benzoic acid
DMT0M94 HS Investigative
DMT0M94 SN CHEMBL478320; 3-(3-Adamantan-1-yl-ureido)-benzoic acid; SCHEMBL12932180; BDBM50267173; AKOS029868879; 3-(1-adamantylcarbamoylamino)benzoic acid
DMT0M94 DT Small molecular drug
DMT0M94 PC 44582455
DMT0M94 MW 314.4
DMT0M94 FM C18H22N2O3
DMT0M94 IC InChI=1S/C18H22N2O3/c21-16(22)14-2-1-3-15(7-14)19-17(23)20-18-8-11-4-12(9-18)6-13(5-11)10-18/h1-3,7,11-13H,4-6,8-10H2,(H,21,22)(H2,19,20,23)
DMT0M94 CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=CC(=C4)C(=O)O
DMT0M94 IK IPTYXUOUPSNRTP-UHFFFAOYSA-N
DMT0M94 IU 3-(1-adamantylcarbamoylamino)benzoic acid
DMT0M94 DE Discovery agent
DMLYVPH ID DMLYVPH
DMLYVPH DN 3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol
DMLYVPH HS Investigative
DMLYVPH SN CHEMBL218003; 3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol; Phenol,3-(3-amino-1,2,4-benzotriazin-7-yl)-; SCHEMBL3737100; BDBM50193876
DMLYVPH DT Small molecular drug
DMLYVPH PC 18455703
DMLYVPH MW 238.24
DMLYVPH FM C13H10N4O
DMLYVPH IC InChI=1S/C13H10N4O/c14-13-15-11-5-4-9(7-12(11)16-17-13)8-2-1-3-10(18)6-8/h1-7,18H,(H2,14,15,17)
DMLYVPH CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)N=C(N=N3)N
DMLYVPH IK WCBDDBSMIBIXTG-UHFFFAOYSA-N
DMLYVPH IU 3-(3-amino-1,2,4-benzotriazin-7-yl)phenol
DMLYVPH DE Discovery agent
DMB6SP8 ID DMB6SP8
DMB6SP8 DN 3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile
DMB6SP8 HS Investigative
DMB6SP8 SN CHEMBL1276297; 3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile; SCHEMBL6087331
DMB6SP8 DT Small molecular drug
DMB6SP8 PC 22139473
DMB6SP8 MW 225.29
DMB6SP8 FM C14H15N3
DMB6SP8 IC InChI=1S/C14H15N3/c15-7-9-1-4-14-12(5-9)13(8-17-14)10-2-3-11(16)6-10/h1,4-5,8,10-11,17H,2-3,6,16H2
DMB6SP8 CS C1CC(CC1C2=CNC3=C2C=C(C=C3)C#N)N
DMB6SP8 IK MBZJCLUPDBZVMZ-UHFFFAOYSA-N
DMB6SP8 IU 3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile
DMB6SP8 DE Discovery agent
DMXKL75 ID DMXKL75
DMXKL75 DN 3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid
DMXKL75 HS Investigative
DMXKL75 SN CHEMBL602309; 3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid
DMXKL75 DT Small molecular drug
DMXKL75 PC 46229306
DMXKL75 MW 243.26
DMXKL75 FM C14H13NO3
DMXKL75 IC InChI=1S/C14H13NO3/c16-13(17)7-9-15-8-6-12(10-15)14(18)11-4-2-1-3-5-11/h1-6,8,10H,7,9H2,(H,16,17)
DMXKL75 CS C1=CC=C(C=C1)C(=O)C2=CN(C=C2)CCC(=O)O
DMXKL75 IK SZVSICYEXHCWBP-UHFFFAOYSA-N
DMXKL75 IU 3-(3-benzoylpyrrol-1-yl)propanoic acid
DMXKL75 DE Discovery agent
DM1325C ID DM1325C
DM1325C DN 3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C HS Investigative
DM1325C SN CHEMBL523196; 3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C DT Small molecular drug
DM1325C PC 25129117
DM1325C MW 325.4
DM1325C FM C23H19NO
DM1325C IC InChI=1S/C23H19NO/c1-25-22-10-9-18-15-23(19-8-5-11-24-16-19)21(13-20(18)14-22)12-17-6-3-2-4-7-17/h2-11,13-16H,12H2,1H3
DM1325C CS COC1=CC2=CC(=C(C=C2C=C1)C3=CN=CC=C3)CC4=CC=CC=C4
DM1325C IK OXCXOWFIXPOTGG-UHFFFAOYSA-N
DM1325C IU 3-(3-benzyl-6-methoxynaphthalen-2-yl)pyridine
DM1325C DE Discovery agent
DMYN6Z9 ID DMYN6Z9
DMYN6Z9 DN 3-(3-benzylamino)-piperidin-2-one
DMYN6Z9 HS Investigative
DMYN6Z9 SN CHEMBL223197
DMYN6Z9 DT Small molecular drug
DMYN6Z9 PC 16203227
DMYN6Z9 MW 218.29
DMYN6Z9 FM C13H18N2O
DMYN6Z9 IC InChI=1S/C13H18N2O/c14-9-11-4-1-3-10(7-11)8-12-5-2-6-15-13(12)16/h1,3-4,7,12H,2,5-6,8-9,14H2,(H,15,16)
DMYN6Z9 CS C1CC(C(=O)NC1)CC2=CC(=CC=C2)CN
DMYN6Z9 IK WOUBCSVRQLAOBC-UHFFFAOYSA-N
DMYN6Z9 IU 3-[[3-(aminomethyl)phenyl]methyl]piperidin-2-one
DMYN6Z9 DE Discovery agent
DM9S36A ID DM9S36A
DM9S36A DN 3-(3-Benzylnaphthalen-2-yl)pyridine
DM9S36A HS Investigative
DM9S36A SN CHEMBL493485; 3-(3-Benzylnaphthalen-2-yl)pyridine
DM9S36A DT Small molecular drug
DM9S36A PC 25130517
DM9S36A MW 295.4
DM9S36A FM C22H17N
DM9S36A IC InChI=1S/C22H17N/c1-2-7-17(8-3-1)13-21-14-18-9-4-5-10-19(18)15-22(21)20-11-6-12-23-16-20/h1-12,14-16H,13H2
DM9S36A CS C1=CC=C(C=C1)CC2=CC3=CC=CC=C3C=C2C4=CN=CC=C4
DM9S36A IK RPMMFOVAHREENB-UHFFFAOYSA-N
DM9S36A IU 3-(3-benzylnaphthalen-2-yl)pyridine
DM9S36A DE Discovery agent
DMFPTXO ID DMFPTXO
DMFPTXO DN 3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine
DMFPTXO HS Investigative
DMFPTXO SN CHEMBL390803; 3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine; SCHEMBL4289011; 1,2,4-Triazine, 3-[2-(3-bromophenyl)ethynyl]-5-methyl-; BDBM50215451
DMFPTXO DT Small molecular drug
DMFPTXO PC 16735841
DMFPTXO MW 274.12
DMFPTXO FM C12H8BrN3
DMFPTXO IC InChI=1S/C12H8BrN3/c1-9-8-14-16-12(15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMFPTXO CS CC1=CN=NC(=N1)C#CC2=CC(=CC=C2)Br
DMFPTXO IK ZFPUZPDBHDTJCE-UHFFFAOYSA-N
DMFPTXO IU 3-[2-(3-bromophenyl)ethynyl]-5-methyl-1,2,4-triazine
DMFPTXO DE Discovery agent
DMSJGQE ID DMSJGQE
DMSJGQE DN 3-(3-Carboxy-propionylamino)-benzoic acid
DMSJGQE HS Investigative
DMSJGQE SN CHEMBL296834; 3-(3-carboxypropanamido)benzoic acid; 3-[(3-carboxypropanoyl)amino]benzoic acid; 259222-20-3; IFLab1_001254; 3-(3-carboxypropanoylamino)benzoic acid; 3-(3-Carboxy-propionylamino)-benzoic acid; AC1LFPO3; Oprea1_683242; Oprea1_208346; CTK0J3689; DTXSID30353899; MolPort-000-385-127; HMS1415I22; ZINC216961; STK032065; BDBM50127981; AKOS000112854; MCULE-6483245282; IDI1_009121; ST50036495; 3-(4-Oxo-4-hydroxybutyrylamino)benzoic acid; 3-[(4-hydroxy-4-oxobutanoyl)amino]benzoic acid; SR-01000005669; Benzoic acid, 3-[(3-carbo
DMSJGQE DT Small molecular drug
DMSJGQE PC 757562
DMSJGQE MW 237.21
DMSJGQE FM C11H11NO5
DMSJGQE IC InChI=1S/C11H11NO5/c13-9(4-5-10(14)15)12-8-3-1-2-7(6-8)11(16)17/h1-3,6H,4-5H2,(H,12,13)(H,14,15)(H,16,17)
DMSJGQE CS C1=CC(=CC(=C1)NC(=O)CCC(=O)O)C(=O)O
DMSJGQE IK IKRKGFIXYILHIJ-UHFFFAOYSA-N
DMSJGQE IU 3-(3-carboxypropanoylamino)benzoic acid
DMSJGQE CA CAS 259222-20-3
DMSJGQE DE Discovery agent
DMI2RH1 ID DMI2RH1
DMI2RH1 DN 3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one
DMI2RH1 HS Investigative
DMI2RH1 DT Small molecular drug
DMI2RH1 PC 135407706
DMI2RH1 MW 246.65
DMI2RH1 FM C11H7ClN4O
DMI2RH1 IC InChI=1S/C11H7ClN4O/c12-9-5-8(15-16-9)10-11(17)14-7-4-2-1-3-6(7)13-10/h1-5H,(H,14,17)(H,15,16)
DMI2RH1 CS C1=CC=C2C(=C1)NC(=O)C(=N2)C3=NNC(=C3)Cl
DMI2RH1 IK HKRYFPDYIBYUGZ-UHFFFAOYSA-N
DMI2RH1 IU 3-(5-chloro-1H-pyrazol-3-yl)-1H-quinoxalin-2-one
DMI2RH1 DE Discovery agent
DMD4O6V ID DMD4O6V
DMD4O6V DN 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one
DMD4O6V HS Investigative
DMD4O6V SN CHEMBL7827; SCHEMBL3355884; 62845-10-7; 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy-
DMD4O6V DT Small molecular drug
DMD4O6V PC 10850934
DMD4O6V MW 288.68
DMD4O6V FM C15H9ClO4
DMD4O6V IC InChI=1S/C15H9ClO4/c16-9-3-1-2-8(4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,17-18H
DMD4O6V CS C1=CC(=CC(=C1)Cl)C2=COC3=CC(=CC(=C3C2=O)O)O
DMD4O6V IK NKDPIBPNSMKOPN-UHFFFAOYSA-N
DMD4O6V IU 3-(3-chlorophenyl)-5,7-dihydroxychromen-4-one
DMD4O6V CA CAS 62845-10-7
DMD4O6V DE Discovery agent
DMGJS9N ID DMGJS9N
DMGJS9N DN 3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N HS Investigative
DMGJS9N SN CHEMBL205328; 3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N DT Small molecular drug
DMGJS9N PC 44410465
DMGJS9N MW 290.32
DMGJS9N FM C17H14N4O
DMGJS9N IC InChI=1S/C17H14N4O/c1-21(14-5-3-2-4-6-14)17(22)20-13-7-8-15-12(10-18)11-19-16(15)9-13/h2-9,11,19H,1H3,(H,20,22)
DMGJS9N CS CN(C1=CC=CC=C1)C(=O)NC2=CC3=C(C=C2)C(=CN3)C#N
DMGJS9N IK QBNNBKXETLRTHU-UHFFFAOYSA-N
DMGJS9N IU 3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea
DMGJS9N DE Discovery agent
DM0O2ZB ID DM0O2ZB
DM0O2ZB DN 3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB HS Investigative
DM0O2ZB SN CHEMBL198617; 3-(3-Dimethylamino-propyl)-1H-indol-4-ol
DM0O2ZB DT Small molecular drug
DM0O2ZB PC 44404905
DM0O2ZB MW 218.29
DM0O2ZB FM C13H18N2O
DM0O2ZB IC InChI=1S/C13H18N2O/c1-15(2)8-4-5-10-9-14-11-6-3-7-12(16)13(10)11/h3,6-7,9,14,16H,4-5,8H2,1-2H3
DM0O2ZB CS CN(C)CCCC1=CNC2=C1C(=CC=C2)O
DM0O2ZB IK IBSZSSDQXMYZOZ-UHFFFAOYSA-N
DM0O2ZB IU 3-[3-(dimethylamino)propyl]-1H-indol-4-ol
DM0O2ZB DE Discovery agent
DM0ZHJQ ID DM0ZHJQ
DM0ZHJQ DN 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0ZHJQ HS Investigative
DM0ZHJQ SN CHEMBL302491; 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline; SCHEMBL8502238; ZINC3834024; BDBM50039084
DM0ZHJQ DT Small molecular drug
DM0ZHJQ PC 9971060
DM0ZHJQ MW 283.3
DM0ZHJQ FM C17H14FNO2
DM0ZHJQ IC InChI=1S/C17H14FNO2/c1-20-16-8-12-6-13(11-4-3-5-14(18)7-11)10-19-15(12)9-17(16)21-2/h3-10H,1-2H3
DM0ZHJQ CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC(=CC=C3)F
DM0ZHJQ IK UECRIUGPTSAZMC-UHFFFAOYSA-N
DM0ZHJQ IU 3-(3-fluorophenyl)-6,7-dimethoxyquinoline
DM0ZHJQ DE Discovery agent
DM7FQVC ID DM7FQVC
DM7FQVC DN 3-(3'-furyl)-aniline
DM7FQVC HS Investigative
DM7FQVC SN 936249-46-6; 3-(3-furanyl)-Benzenamine; 3-(furan-3-yl)aniline; Benzenamine, 3-(3-furanyl)-; SCHEMBL1019148; CHEMBL222787; LQDARHFLRKPAMM-UHFFFAOYSA-N
DM7FQVC DT Small molecular drug
DM7FQVC PC 16203332
DM7FQVC MW 159.18
DM7FQVC FM C10H9NO
DM7FQVC IC InChI=1S/C10H9NO/c11-10-3-1-2-8(6-10)9-4-5-12-7-9/h1-7H,11H2
DM7FQVC CS C1=CC(=CC(=C1)N)C2=COC=C2
DM7FQVC IK LQDARHFLRKPAMM-UHFFFAOYSA-N
DM7FQVC IU 3-(furan-3-yl)aniline
DM7FQVC CA CAS 936249-46-6
DM7FQVC DE Discovery agent
DMP0DQE ID DMP0DQE
DMP0DQE DN 3-(3-hydroxyphenyl)quinolin-7-ol
DMP0DQE HS Investigative
DMP0DQE DT Small molecular drug
DMP0DQE PC 135783365
DMP0DQE MW 237.25
DMP0DQE FM C15H11NO2
DMP0DQE IC InChI=1S/C15H11NO2/c17-13-3-1-2-10(7-13)12-6-11-4-5-14(18)8-15(11)16-9-12/h1-9,17-18H
DMP0DQE CS C1=CC(=CC(=C1)O)C2=CN=C3C=C(C=CC3=C2)O
DMP0DQE IK DQXYHOHBSRRAIV-UHFFFAOYSA-N
DMP0DQE IU 3-(3-hydroxyphenyl)quinolin-7-ol
DMP0DQE DE Discovery agent
DMRDS1U ID DMRDS1U
DMRDS1U DN 3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine
DMRDS1U HS Investigative
DMRDS1U SN CHEMBL310745; 3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine
DMRDS1U DT Small molecular drug
DMRDS1U PC 44461148
DMRDS1U MW 267.39
DMRDS1U FM C14H21NO2S
DMRDS1U IC InChI=1S/C14H21NO2S/c1-3-8-15-9-7-13(11-15)12-5-4-6-14(10-12)18(2,16)17/h4-6,10,13H,3,7-9,11H2,1-2H3
DMRDS1U CS CCCN1CCC(C1)C2=CC(=CC=C2)S(=O)(=O)C
DMRDS1U IK RJYDYJIGFDPBRL-UHFFFAOYSA-N
DMRDS1U IU 3-(3-methylsulfonylphenyl)-1-propylpyrrolidine
DMRDS1U DE Discovery agent
DMU53NZ ID DMU53NZ
DMU53NZ DN 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine
DMU53NZ HS Investigative
DMU53NZ SN CHEMBL1231606; 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine; 3c4f; SCHEMBL857805; BDBM50065455; DB07525; 3-(3-Methoxybenzyl)-7-aza-1H-indole; 3-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridine
DMU53NZ DT Small molecular drug
DMU53NZ PC 24180722
DMU53NZ MW 238.28
DMU53NZ FM C15H14N2O
DMU53NZ IC InChI=1S/C15H14N2O/c1-18-13-5-2-4-11(9-13)8-12-10-17-15-14(12)6-3-7-16-15/h2-7,9-10H,8H2,1H3,(H,16,17)
DMU53NZ CS COC1=CC=CC(=C1)CC2=CNC3=C2C=CC=N3
DMU53NZ IK GHQCCHWTDLTMJT-UHFFFAOYSA-N
DMU53NZ IU 3-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridine
DMU53NZ DE Discovery agent
DMZQ2CJ ID DMZQ2CJ
DMZQ2CJ DN 3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one
DMZQ2CJ HS Investigative
DMZQ2CJ SN CHEMBL570731; 3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one; 2H-1-Benzopyran-2-one,3-(3-methoxyphenyl)-6-methyl-; SCHEMBL17857194; BDBM50300895
DMZQ2CJ DT Small molecular drug
DMZQ2CJ PC 44622873
DMZQ2CJ MW 266.29
DMZQ2CJ FM C17H14O3
DMZQ2CJ IC InChI=1S/C17H14O3/c1-11-6-7-16-13(8-11)10-15(17(18)20-16)12-4-3-5-14(9-12)19-2/h3-10H,1-2H3
DMZQ2CJ CS CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC(=CC=C3)OC
DMZQ2CJ IK FXKIDMXANLWDBM-UHFFFAOYSA-N
DMZQ2CJ IU 3-(3-methoxyphenyl)-6-methylchromen-2-one
DMZQ2CJ DE Discovery agent
DM2YLBD ID DM2YLBD
DM2YLBD DN 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DM2YLBD HS Investigative
DM2YLBD SN 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 8; AC1O70HF; SCHEMBL4505804; BDBM8894
DM2YLBD DT Small molecular drug
DM2YLBD PC 6540052
DM2YLBD MW 221.3
DM2YLBD FM C16H15N
DM2YLBD IC InChI=1S/C16H15N/c1-12-9-13-5-2-3-6-14(13)10-16(12)15-7-4-8-17-11-15/h2-8,10-12H,9H2,1H3
DM2YLBD CS CC1CC2=CC=CC=C2C=C1C3=CN=CC=C3
DM2YLBD IK ARDWAGDGUKXSPH-UHFFFAOYSA-N
DM2YLBD IU 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DM2YLBD DE Discovery agent
DMTNCXP ID DMTNCXP
DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline
DMTNCXP HS Investigative
DMTNCXP SN CHEMBL87641; 3-(isopentyloxy)-9H-pyrido[3,4-b]indole; SCHEMBL10644963; BDBM50001483
DMTNCXP DT Small molecular drug
DMTNCXP PC 11779007
DMTNCXP MW 254.33
DMTNCXP FM C16H18N2O
DMTNCXP IC InChI=1S/C16H18N2O/c1-11(2)7-8-19-16-9-13-12-5-3-4-6-14(12)18-15(13)10-17-16/h3-6,9-11,18H,7-8H2,1-2H3
DMTNCXP CS CC(C)CCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMTNCXP IK LGSILYYIMNHYCP-UHFFFAOYSA-N
DMTNCXP IU 3-(3-methylbutoxy)-9H-pyrido[3,4-b]indole
DMTNCXP DE Discovery agent
DMXAD0R ID DMXAD0R
DMXAD0R DN 3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine
DMXAD0R HS Investigative
DMXAD0R SN CHEMBL227200; 3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine; SCHEMBL4298939; ZINC28701667; BDBM50215452
DMXAD0R DT Small molecular drug
DMXAD0R PC 16735840
DMXAD0R MW 209.25
DMXAD0R FM C13H11N3
DMXAD0R IC InChI=1S/C13H11N3/c1-10-4-3-5-12(8-10)6-7-13-15-11(2)9-14-16-13/h3-5,8-9H,1-2H3
DMXAD0R CS CC1=CC(=CC=C1)C#CC2=NC(=CN=N2)C
DMXAD0R IK SGAMWPHZFACGBU-UHFFFAOYSA-N
DMXAD0R IU 5-methyl-3-[2-(3-methylphenyl)ethynyl]-1,2,4-triazine
DMXAD0R DE Discovery agent
DMHU9V5 ID DMHU9V5
DMHU9V5 DN 3-(3-methylthiophen-2-yl)pyridine
DMHU9V5 HS Investigative
DMHU9V5 SN 3-(3-methylthiophen-2-yl)pyridine; CHEMBL179669; Pyridine, 3-(3-methyl-2-thienyl)-; 837376-35-9; SCHEMBL3606167; BDBM12351; CTK3D1375; DTXSID20635313; nicotine 3-heteroaromatic analogue 4; US8609708, 4
DMHU9V5 DT Small molecular drug
DMHU9V5 PC 23646069
DMHU9V5 MW 175.25
DMHU9V5 FM C10H9NS
DMHU9V5 IC InChI=1S/C10H9NS/c1-8-4-6-12-10(8)9-3-2-5-11-7-9/h2-7H,1H3
DMHU9V5 CS CC1=C(SC=C1)C2=CN=CC=C2
DMHU9V5 IK JIOQSJVEVFADJG-UHFFFAOYSA-N
DMHU9V5 IU 3-(3-methylthiophen-2-yl)pyridine
DMHU9V5 CA CAS 837376-35-9
DMHU9V5 DE Discovery agent
DM314ZE ID DM314ZE
DM314ZE DN 3-(3-Phenyl-ureido)-benzenesulfonamide
DM314ZE HS Investigative
DM314ZE SN CHEMBL370526; 3-(3-Phenyl-ureido)-benzenesulfonamide; AC1MDJRG; MLS000850240; SCHEMBL1395590; MolPort-002-901-146; HMS2801K06; ZINC4325112; 3-(3-Phenylureido)benzenesulfonamide; BDBM50174039; 1-phenyl-3-(3-sulfamoylphenyl)urea; AKOS008966131; MCULE-8491785004; SMR000456258
DM314ZE DT Small molecular drug
DM314ZE PC 2812287
DM314ZE MW 291.33
DM314ZE FM C13H13N3O3S
DM314ZE IC InChI=1S/C13H13N3O3S/c14-20(18,19)12-8-4-7-11(9-12)16-13(17)15-10-5-2-1-3-6-10/h1-9H,(H2,14,18,19)(H2,15,16,17)
DM314ZE CS C1=CC=C(C=C1)NC(=O)NC2=CC(=CC=C2)S(=O)(=O)N
DM314ZE IK BXGWKSJDQKSXDR-UHFFFAOYSA-N
DM314ZE IU 1-phenyl-3-(3-sulfamoylphenyl)urea
DM314ZE DE Discovery agent
DMU52WA ID DMU52WA
DMU52WA DN 3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
DMU52WA HS Investigative
DMU52WA SN CHEMBL182558; 3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile; SCHEMBL3922587; FUXJRPCONXOULZ-UHFFFAOYSA-N; BDBM50151895; ZINC13582319
DMU52WA DT Small molecular drug
DMU52WA PC 10192768
DMU52WA MW 246.27
DMU52WA FM C15H10N4
DMU52WA IC InChI=1S/C15H10N4/c16-11-12-4-3-5-13(10-12)19-9-7-15(18-19)14-6-1-2-8-17-14/h1-10H
DMU52WA CS C1=CC=NC(=C1)C2=NN(C=C2)C3=CC=CC(=C3)C#N
DMU52WA IK FUXJRPCONXOULZ-UHFFFAOYSA-N
DMU52WA IU 3-(3-pyridin-2-ylpyrazol-1-yl)benzonitrile
DMU52WA DE Discovery agent
DMZLT24 ID DMZLT24
DMZLT24 DN 3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile
DMZLT24 HS Investigative
DMZLT24 SN CHEMBL361325; 3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile; SCHEMBL5100840; VWIHRRSEESXDSS-UHFFFAOYSA-N; ZINC13582313; BDBM50151897
DMZLT24 DT Small molecular drug
DMZLT24 PC 10332109
DMZLT24 MW 245.28
DMZLT24 FM C16H11N3
DMZLT24 IC InChI=1S/C16H11N3/c17-11-13-4-3-5-15(10-13)19-9-7-14(12-19)16-6-1-2-8-18-16/h1-10,12H
DMZLT24 CS C1=CC=NC(=C1)C2=CN(C=C2)C3=CC=CC(=C3)C#N
DMZLT24 IK VWIHRRSEESXDSS-UHFFFAOYSA-N
DMZLT24 IU 3-(3-pyridin-2-ylpyrrol-1-yl)benzonitrile
DMZLT24 DE Discovery agent
DMQDPHT ID DMQDPHT
DMQDPHT DN 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT HS Investigative
DMQDPHT SN CHEMBL202875; 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid
DMQDPHT DT Small molecular drug
DMQDPHT PC 11609208
DMQDPHT MW 306.4
DMQDPHT FM C20H18O3
DMQDPHT IC InChI=1S/C20H18O3/c1-2-17(14-19(21)22)20(23)18-12-10-16(11-13-18)9-8-15-6-4-3-5-7-15/h3-7,10-13,17H,2,14H2,1H3,(H,21,22)
DMQDPHT CS CCC(CC(=O)O)C(=O)C1=CC=C(C=C1)C#CC2=CC=CC=C2
DMQDPHT IK OQWWYXZJKRAMIK-UHFFFAOYSA-N
DMQDPHT IU 3-[4-(2-phenylethynyl)benzoyl]pentanoic acid
DMQDPHT DE Discovery agent
DM1GVE8 ID DM1GVE8
DM1GVE8 DN 3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol
DM1GVE8 HS Investigative
DM1GVE8 DT Small molecular drug
DM1GVE8 PC 5521244
DM1GVE8 DE Discovery agent
DM8EH07 ID DM8EH07
DM8EH07 DN 3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol
DM8EH07 HS Investigative
DM8EH07 SN CHEMBL552961; 3-{[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino}phenol; 3-[[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino]phenol; AC1MOQ7Z; 3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol; BDBM50293580; STK163120; AKOS005408679; MCULE-5910300038; NCGC00285022-01
DM8EH07 DT Small molecular drug
DM8EH07 PC 3324368
DM8EH07 MW 284.3
DM8EH07 FM C15H12N2O2S
DM8EH07 IC InChI=1S/C15H12N2O2S/c18-12-6-4-10(5-7-12)14-9-20-15(17-14)16-11-2-1-3-13(19)8-11/h1-9,18-19H,(H,16,17)
DM8EH07 CS C1=CC(=CC(=C1)O)NC2=NC(=CS2)C3=CC=C(C=C3)O
DM8EH07 IK SAFZMMTWTRFRQE-UHFFFAOYSA-N
DM8EH07 IU 3-[[4-(4-hydroxyphenyl)-1,3-thiazol-2-yl]amino]phenol
DM8EH07 DE Discovery agent
DM36VA0 ID DM36VA0
DM36VA0 DN 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid
DM36VA0 HS Investigative
DM36VA0 SN benzyl derivative, 8; CHEMBL402713; BDBM18888; 3-[4-(benzyloxy)-3,5-dibromophenyl]propanoic acid
DM36VA0 DT Small molecular drug
DM36VA0 PC 23648092
DM36VA0 MW 414.09
DM36VA0 FM C16H14Br2O3
DM36VA0 IC InChI=1S/C16H14Br2O3/c17-13-8-12(6-7-15(19)20)9-14(18)16(13)21-10-11-4-2-1-3-5-11/h1-5,8-9H,6-7,10H2,(H,19,20)
DM36VA0 CS C1=CC=C(C=C1)COC2=C(C=C(C=C2Br)CCC(=O)O)Br
DM36VA0 IK ZCVQDNGOBFARHQ-UHFFFAOYSA-N
DM36VA0 IU 3-(3,5-dibromo-4-phenylmethoxyphenyl)propanoic acid
DM36VA0 DE Discovery agent
DMX6ZHQ ID DMX6ZHQ
DMX6ZHQ DN 3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide
DMX6ZHQ HS Investigative
DMX6ZHQ SN 2,4-dianilino pyrimidine, 8; CHEMBL400798; BDBM26151
DMX6ZHQ DT Small molecular drug
DMX6ZHQ PC 25138018
DMX6ZHQ MW 319.4
DMX6ZHQ FM C18H17N5O
DMX6ZHQ IC InChI=1S/C18H17N5O/c1-12-5-2-3-8-15(12)22-16-9-10-20-18(23-16)21-14-7-4-6-13(11-14)17(19)24/h2-11H,1H3,(H2,19,24)(H2,20,21,22,23)
DMX6ZHQ CS CC1=CC=CC=C1NC2=NC(=NC=C2)NC3=CC=CC(=C3)C(=O)N
DMX6ZHQ IK ZUJLZMHZCZZHLN-UHFFFAOYSA-N
DMX6ZHQ IU 3-[[4-(2-methylanilino)pyrimidin-2-yl]amino]benzamide
DMX6ZHQ DE Discovery agent
DMGXPJV ID DMGXPJV
DMGXPJV DN 3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol
DMGXPJV HS Investigative
DMGXPJV SN 3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol; 296792-52-4; CHEMBL443007; 3-[4,5-bis(4-phenylphenyl)-1H-imidazol-2-yl]phenol; AC1M4HYZ; AC1Q790A; CTK8A0066; MolPort-001-732-645; ZINC6028400; BDBM50113297; STK758717; AKOS001063669; NE26785; MCULE-4347250395; UPCMLD0ENAT5224754:001; ST4040901; KB-335272; EN300-07381; 3-[4,5-bis(4-phenylphenyl)imidazol-2-yl]phenol; SR-01000521283; J-510645; SR-01000521283-1; Z56935326; 3-[4,5-di(biphenyl-4-yl)-1H-imidazol-2-yl]phenol; 3-(4,5-bis-biphenyl-4-yl-1h-imidazol-2-yl)phenol
DMGXPJV DT Small molecular drug
DMGXPJV PC 2259222
DMGXPJV MW 464.6
DMGXPJV FM C33H24N2O
DMGXPJV IC InChI=1S/C33H24N2O/c36-30-13-7-12-29(22-30)33-34-31(27-18-14-25(15-19-27)23-8-3-1-4-9-23)32(35-33)28-20-16-26(17-21-28)24-10-5-2-6-11-24/h1-22,36H,(H,34,35)
DMGXPJV CS C1=CC=C(C=C1)C2=CC=C(C=C2)C3=C(N=C(N3)C4=CC(=CC=C4)O)C5=CC=C(C=C5)C6=CC=CC=C6
DMGXPJV IK JTVSGRFYVCXWNC-UHFFFAOYSA-N
DMGXPJV IU 3-[4,5-bis(4-phenylphenyl)-1H-imidazol-2-yl]phenol
DMGXPJV DE Discovery agent
DMONSM1 ID DMONSM1
DMONSM1 DN 3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate
DMONSM1 HS Investigative
DMONSM1 SN CHEMBL576381; 3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate; SCHEMBL4751773
DMONSM1 DT Small molecular drug
DMONSM1 PC 44243876
DMONSM1 MW 248.28
DMONSM1 FM C13H16N2O3
DMONSM1 IC InChI=1S/C13H16N2O3/c1-2-6-15-13(16)18-11-5-3-4-10(9-11)12-14-7-8-17-12/h3-5,9H,2,6-8H2,1H3,(H,15,16)
DMONSM1 CS CCCNC(=O)OC1=CC=CC(=C1)C2=NCCO2
DMONSM1 IK JLCYRBIRENXOKD-UHFFFAOYSA-N
DMONSM1 IU [3-(4,5-dihydro-1,3-oxazol-2-yl)phenyl] N-propylcarbamate
DMONSM1 DE Discovery agent
DMS1LDH ID DMS1LDH
DMS1LDH DN 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione
DMS1LDH HS Investigative
DMS1LDH SN CHEMBL357775; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-1-methyl-; 59512-13-9; 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione; CTK1E7233; DTXSID50490593; BDBM50025151; AKOS022647888
DMS1LDH DT Small molecular drug
DMS1LDH PC 12331302
DMS1LDH MW 204.22
DMS1LDH FM C11H12N2O2
DMS1LDH IC InChI=1S/C11H12N2O2/c1-13-10(14)6-9(11(13)15)7-2-4-8(12)5-3-7/h2-5,9H,6,12H2,1H3
DMS1LDH CS CN1C(=O)CC(C1=O)C2=CC=C(C=C2)N
DMS1LDH IK QMQMEAAIWVAXHW-UHFFFAOYSA-N
DMS1LDH IU 3-(4-aminophenyl)-1-methylpyrrolidine-2,5-dione
DMS1LDH CA CAS 59512-13-9
DMS1LDH DE Discovery agent
DMD5YKO ID DMD5YKO
DMD5YKO DN 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione
DMD5YKO HS Investigative
DMD5YKO SN CHEMBL29863; 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione
DMD5YKO DT Small molecular drug
DMD5YKO PC 13660218
DMD5YKO MW 260.329
DMD5YKO FM C15H20N2O2
DMD5YKO IC InChI=1S/C15H20N2O2/c1-2-3-9-15(10-8-13(18)17-14(15)19)11-4-6-12(16)7-5-11/h4-7H,2-3,8-10,16H2,1H3,(H,17,18,19)
DMD5YKO CS CCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMD5YKO IK HECRHMWBGLSDHM-UHFFFAOYSA-N
DMD5YKO IU 3-(4-aminophenyl)-3-butylpiperidine-2,6-dione
DMD5YKO DE Discovery agent
DM3I15D ID DM3I15D
DM3I15D DN 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione
DM3I15D HS Investigative
DM3I15D SN CHEMBL151212; 91567-07-6; 3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione; 3-Apepd; AC1Q6LV5; AC1L3YU4; 3-(4-aminophenyl)-3-ethyl-2,5-Pyrrolidinedione; 3-(4'-Aminophenyl)-3-ethylpyrollidine-2,5-dione; 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione; SCHEMBL9634038; BDBM50025152; DA-01219; FT-0716174; 3-Ethyl-3-(4-aminophenyl)pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-ethyl-
DM3I15D DT Small molecular drug
DM3I15D PC 124662
DM3I15D MW 218.25
DM3I15D FM C12H14N2O2
DM3I15D IC InChI=1S/C12H14N2O2/c1-2-12(7-10(15)14-11(12)16)8-3-5-9(13)6-4-8/h3-6H,2,7,13H2,1H3,(H,14,15,16)
DM3I15D CS CCC1(CC(=O)NC1=O)C2=CC=C(C=C2)N
DM3I15D IK QPJZAHJMZUCFMF-UHFFFAOYSA-N
DM3I15D IU 3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione
DM3I15D CA CAS 91567-07-6
DM3I15D DE Discovery agent
DMZ86CS ID DMZ86CS
DMZ86CS DN 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione
DMZ86CS HS Investigative
DMZ86CS SN CHEMBL29338; 3-(4-aminophenyl)-3-heptylpiperidine-2,6-dione; NSC622730; AC1L7GXY; 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione; AC1Q6G81; CTK6D7912; 2,3-(4-aminophenyl)-3-heptyl-; BDBM50025057; NSC-622730; NCI60_006748; 2,6-piperidinedione, 3-(4-aminophenyl)-3-heptyl-
DMZ86CS DT Small molecular drug
DMZ86CS PC 360578
DMZ86CS MW 302.4
DMZ86CS FM C18H26N2O2
DMZ86CS IC InChI=1S/C18H26N2O2/c1-2-3-4-5-6-12-18(13-11-16(21)20-17(18)22)14-7-9-15(19)10-8-14/h7-10H,2-6,11-13,19H2,1H3,(H,20,21,22)
DMZ86CS CS CCCCCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMZ86CS IK OSRMOQHQZPPFAZ-UHFFFAOYSA-N
DMZ86CS IU 3-(4-aminophenyl)-3-heptylpiperidine-2,6-dione
DMZ86CS DE Discovery agent
DMW62U8 ID DMW62U8
DMW62U8 DN 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione
DMW62U8 HS Investigative
DMW62U8 SN CHEMBL29339; 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione
DMW62U8 DT Small molecular drug
DMW62U8 PC 13660225
DMW62U8 MW 288.4
DMW62U8 FM C17H24N2O2
DMW62U8 IC InChI=1S/C17H24N2O2/c1-2-3-4-5-11-17(12-10-15(20)19-16(17)21)13-6-8-14(18)9-7-13/h6-9H,2-5,10-12,18H2,1H3,(H,19,20,21)
DMW62U8 CS CCCCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DMW62U8 IK VWJXCBZWAWHJLE-UHFFFAOYSA-N
DMW62U8 IU 3-(4-aminophenyl)-3-hexylpiperidine-2,6-dione
DMW62U8 DE Discovery agent
DMITHX5 ID DMITHX5
DMITHX5 DN 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione
DMITHX5 HS Investigative
DMITHX5 SN CHEMBL149238; 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-3-methyl-; SCHEMBL19074638; BDBM50025155
DMITHX5 DT Small molecular drug
DMITHX5 PC 13596072
DMITHX5 MW 204.22
DMITHX5 FM C11H12N2O2
DMITHX5 IC InChI=1S/C11H12N2O2/c1-11(6-9(14)13-10(11)15)7-2-4-8(12)5-3-7/h2-5H,6,12H2,1H3,(H,13,14,15)
DMITHX5 CS CC1(CC(=O)NC1=O)C2=CC=C(C=C2)N
DMITHX5 IK MAUIJSRGENXQBY-UHFFFAOYSA-N
DMITHX5 IU 3-(4-aminophenyl)-3-methylpyrrolidine-2,5-dione
DMITHX5 DE Discovery agent
DM20DXS ID DM20DXS
DM20DXS DN 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione
DM20DXS HS Investigative
DM20DXS SN CHEMBL25735; 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione
DM20DXS DT Small molecular drug
DM20DXS PC 13660221
DM20DXS MW 274.36
DM20DXS FM C16H22N2O2
DM20DXS IC InChI=1S/C16H22N2O2/c1-2-3-4-10-16(11-9-14(19)18-15(16)20)12-5-7-13(17)8-6-12/h5-8H,2-4,9-11,17H2,1H3,(H,18,19,20)
DM20DXS CS CCCCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DM20DXS IK VFLOMQQDKBQIOE-UHFFFAOYSA-N
DM20DXS IU 3-(4-aminophenyl)-3-pentylpiperidine-2,6-dione
DM20DXS DE Discovery agent
DM39XMT ID DM39XMT
DM39XMT DN 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione
DM39XMT HS Investigative
DM39XMT SN CHEMBL29864; 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione; BDBM50025059
DM39XMT DT Small molecular drug
DM39XMT PC 13660216
DM39XMT MW 246.3
DM39XMT FM C14H18N2O2
DM39XMT IC InChI=1S/C14H18N2O2/c1-2-8-14(9-7-12(17)16-13(14)18)10-3-5-11(15)6-4-10/h3-6H,2,7-9,15H2,1H3,(H,16,17,18)
DM39XMT CS CCCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
DM39XMT IK CKRTXCPPNWSZFC-UHFFFAOYSA-N
DM39XMT IU 3-(4-aminophenyl)-3-propylpiperidine-2,6-dione
DM39XMT DE Discovery agent
DMVN0O5 ID DMVN0O5
DMVN0O5 DN 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione
DMVN0O5 HS Investigative
DMVN0O5 SN 32856-49-8; 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione; 3-(4-aminophenyl)pyrrolidine-2,5-dione; 3-(4-Aminophenyl)-2,5-pyrrolidinedione; CHEMBL148903; 2,5-Pyrrolidinedione, 3-(4-aminophenyl)-; WSP-3; 3-(4'-aminophenyl)pyrrolidine-2,5-dione; AC1Q6LVA; 2-(p-aminophenyl) succinimide; SCHEMBL3274268; AC1L4Q15; CTK4G9448; BDBM50025154; FCH920777; AKOS006343465; AB07636; CC-12440; KB-26942; AS-35730; 2,5-Pyrrolidinedione,3-(4-aminophenyl)-; AX8033232; AB0073720; FT-0691904; X-3375; C-33345; 3-(4-amino-phenyl)-pyrrolidine-2,5-dione, AldrichCP
DMVN0O5 DT Small molecular drug
DMVN0O5 PC 161760
DMVN0O5 MW 190.2
DMVN0O5 FM C10H10N2O2
DMVN0O5 IC InChI=1S/C10H10N2O2/c11-7-3-1-6(2-4-7)8-5-9(13)12-10(8)14/h1-4,8H,5,11H2,(H,12,13,14)
DMVN0O5 CS C1C(C(=O)NC1=O)C2=CC=C(C=C2)N
DMVN0O5 IK AFLGSUFOCCZEEZ-UHFFFAOYSA-N
DMVN0O5 IU 3-(4-aminophenyl)pyrrolidine-2,5-dione
DMVN0O5 CA CAS 32856-49-8
DMVN0O5 DE Discovery agent
DM6XTBI ID DM6XTBI
DM6XTBI DN 3-(4-aminophenyl)quinoxaline-5-carboxamide
DM6XTBI HS Investigative
DM6XTBI SN CHEMBL443077; quinoxaline analogue, 3f; 3-(4-aminophenyl)quinoxaline-5-carboxamide; SCHEMBL7112515
DM6XTBI DT Small molecular drug
DM6XTBI PC 25218519
DM6XTBI MW 264.28
DM6XTBI FM C15H12N4O
DM6XTBI IC InChI=1S/C15H12N4O/c16-10-6-4-9(5-7-10)13-8-18-12-3-1-2-11(15(17)20)14(12)19-13/h1-8H,16H2,(H2,17,20)
DM6XTBI CS C1=CC(=C2C(=C1)N=CC(=N2)C3=CC=C(C=C3)N)C(=O)N
DM6XTBI IK JCXJUCVUESBKLT-UHFFFAOYSA-N
DM6XTBI IU 3-(4-aminophenyl)quinoxaline-5-carboxamide
DM6XTBI DE Discovery agent
DM30GV2 ID DM30GV2
DM30GV2 DN 3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine
DM30GV2 HS Investigative
DM30GV2 SN 3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine; CHEMBL231153; 832694-16-3; Kinome_611; SCHEMBL3531281; CTK3D3472; DTXSID50593932; RSUCBZJSTXEGSF-UHFFFAOYSA-N; BDBM50201316; Thieno[3,2-c]pyridin-4-amine, 3-(4-aminophenyl)-
DM30GV2 DT Small molecular drug
DM30GV2 PC 18450753
DM30GV2 MW 241.31
DM30GV2 FM C13H11N3S
DM30GV2 IC InChI=1S/C13H11N3S/c14-9-3-1-8(2-4-9)10-7-17-11-5-6-16-13(15)12(10)11/h1-7H,14H2,(H2,15,16)
DM30GV2 CS C1=CC(=CC=C1C2=CSC3=C2C(=NC=C3)N)N
DM30GV2 IK RSUCBZJSTXEGSF-UHFFFAOYSA-N
DM30GV2 IU 3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine
DM30GV2 CA CAS 832694-16-3
DM30GV2 DE Discovery agent
DMAT7VN ID DMAT7VN
DMAT7VN DN 3-(4-Benzoylpiperazine-1-carbonyl)coumarin
DMAT7VN HS Investigative
DMAT7VN SN CHEMBL453852; 3-(4-Benzoyl-piperazine-1-carbonyl)-chromen-2-one; 3-(4-Benzoylpiperazine-1-carbonyl)coumarin; Oprea1_255077; Oprea1_655896; MLS001221424; MolPort-000-517-247; ZINC887160; HMS2917O18; HMS1690L15; BDBM50244614; AKOS000599038; MCULE-2543571988; SMR000611504; BAS 02911887; ST50014713; 3-{[4-(phenylcarbonyl)piperazinyl]carbonyl}chromen-2-one
DMAT7VN DT Small molecular drug
DMAT7VN PC 1143426
DMAT7VN MW 362.4
DMAT7VN FM C21H18N2O4
DMAT7VN IC InChI=1S/C21H18N2O4/c24-19(15-6-2-1-3-7-15)22-10-12-23(13-11-22)20(25)17-14-16-8-4-5-9-18(16)27-21(17)26/h1-9,14H,10-13H2
DMAT7VN CS C1CN(CCN1C(=O)C2=CC=CC=C2)C(=O)C3=CC4=CC=CC=C4OC3=O
DMAT7VN IK YBJQFYCTDMHHMH-UHFFFAOYSA-N
DMAT7VN IU 3-(4-benzoylpiperazine-1-carbonyl)chromen-2-one
DMAT7VN DE Discovery agent
DMWPB0G ID DMWPB0G
DMWPB0G DN 3-(4-Benzyl-piperazin-1-yl)-phenol
DMWPB0G HS Investigative
DMWPB0G SN CHEMBL88365; 3-(4-Benzyl-piperazin-1-yl)-phenol; SCHEMBL13902706; ZINC26638652; BDBM50069907
DMWPB0G DT Small molecular drug
DMWPB0G PC 10015867
DMWPB0G MW 268.35
DMWPB0G FM C17H20N2O
DMWPB0G IC InChI=1S/C17H20N2O/c20-17-8-4-7-16(13-17)19-11-9-18(10-12-19)14-15-5-2-1-3-6-15/h1-8,13,20H,9-12,14H2
DMWPB0G CS C1CN(CCN1CC2=CC=CC=C2)C3=CC(=CC=C3)O
DMWPB0G IK BISVFNHMXVNVMG-UHFFFAOYSA-N
DMWPB0G IU 3-(4-benzylpiperazin-1-yl)phenol
DMWPB0G DE Discovery agent
DMFVCOP ID DMFVCOP
DMFVCOP DN 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMFVCOP HS Investigative
DMFVCOP SN CHEMBL178519; 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one
DMFVCOP DT Small molecular drug
DMFVCOP PC 11773145
DMFVCOP MW 335.4
DMFVCOP FM C22H25NO2
DMFVCOP IC InChI=1S/C22H25NO2/c24-22-19(16-25-21-9-5-4-8-20(21)22)15-23-12-10-18(11-13-23)14-17-6-2-1-3-7-17/h1-9,18-19H,10-16H2
DMFVCOP CS C1CN(CCC1CC2=CC=CC=C2)CC3COC4=CC=CC=C4C3=O
DMFVCOP IK ODWZSCLUZWGCOH-UHFFFAOYSA-N
DMFVCOP IU 3-[(4-benzylpiperidin-1-yl)methyl]-2,3-dihydrochromen-4-one
DMFVCOP DE Discovery agent
DM7LMD6 ID DM7LMD6
DM7LMD6 DN 3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one
DM7LMD6 HS Investigative
DM7LMD6 SN CHEMBL426958; AC1MDK2H; Oprea1_222683; 3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one; MolPort-045-902-159; BDBM50159007
DM7LMD6 DT Small molecular drug
DM7LMD6 PC 2838196
DM7LMD6 MW 333.4
DM7LMD6 FM C22H23NO2
DM7LMD6 IC InChI=1S/C22H23NO2/c24-22-19(16-25-21-9-5-4-8-20(21)22)15-23-12-10-18(11-13-23)14-17-6-2-1-3-7-17/h1-9,16,18H,10-15H2
DM7LMD6 CS C1CN(CCC1CC2=CC=CC=C2)CC3=COC4=CC=CC=C4C3=O
DM7LMD6 IK WZWRAAKVOATXPL-UHFFFAOYSA-N
DM7LMD6 IU 3-[(4-benzylpiperidin-1-yl)methyl]chromen-4-one
DM7LMD6 DE Discovery agent
DMAKMIJ ID DMAKMIJ
DMAKMIJ DN 3-(4-bromobenzyl)-1,1-dimethylselenourea
DMAKMIJ HS Investigative
DMAKMIJ SN CHEMBL398715; 3-(4-bromobenzyl)-1,1-dimethylselenourea
DMAKMIJ DT Small molecular drug
DMAKMIJ PC 44442159
DMAKMIJ MW 319.09
DMAKMIJ FM C10H12BrN2Se
DMAKMIJ IC InChI=1S/C10H12BrN2Se/c1-13(2)10(14)12-7-8-3-5-9(11)6-4-8/h3-6H,7H2,1-2H3
DMAKMIJ CS CN(C)C(=NCC1=CC=C(C=C1)Br)[Se]
DMAKMIJ IK FFMCEZVYXHAZHZ-UHFFFAOYSA-N
DMAKMIJ DE Discovery agent
DMXMZRE ID DMXMZRE
DMXMZRE DN 3-(4-bromophenyl)-1,1-dimethylthiourea
DMXMZRE HS Investigative
DMXMZRE SN 3-(4-bromophenyl)-1,1-dimethylthiourea; CHEMBL249923; 75105-07-6; 3-(p-Bromophenyl)-1,1-dimethylthiourea; AC1NT9ZG; CTK2G1172; DTXSID30418775; YZPBPTSRPUXFGV-UHFFFAOYSA-N; STL265123; BDBM50223160; AKOS023092916; AKOS009470673; MCULE-1938000461; 1-(4-Bromophenyl)-3,3-dimethylthiourea; N'-(4-Bromophenyl)-N,N-dimethylthiourea #; Thiourea, N'-(4-bromophenyl)-N,N-dimethyl-
DMXMZRE DT Small molecular drug
DMXMZRE PC 5376123
DMXMZRE MW 259.17
DMXMZRE FM C9H11BrN2S
DMXMZRE IC InChI=1S/C9H11BrN2S/c1-12(2)9(13)11-8-5-3-7(10)4-6-8/h3-6H,1-2H3,(H,11,13)
DMXMZRE CS CN(C)C(=S)NC1=CC=C(C=C1)Br
DMXMZRE IK YZPBPTSRPUXFGV-UHFFFAOYSA-N
DMXMZRE IU 3-(4-bromophenyl)-1,1-dimethylthiourea
DMXMZRE CA CAS 75105-07-6
DMXMZRE DE Discovery agent
DM8W3GC ID DM8W3GC
DM8W3GC DN 3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide
DM8W3GC HS Investigative
DM8W3GC SN CHEMBL446362; 3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide; BDBM50015130; (E)-3-[4-Butoxyphenyl]-N-methyl-2-propenehydroxamic acid
DM8W3GC DT Small molecular drug
DM8W3GC PC 44387153
DM8W3GC MW 249.3
DM8W3GC FM C14H19NO3
DM8W3GC IC InChI=1S/C14H19NO3/c1-3-4-11-18-13-8-5-12(6-9-13)7-10-14(16)15(2)17/h5-10,17H,3-4,11H2,1-2H3/b10-7+
DM8W3GC CS CCCCOC1=CC=C(C=C1)/C=C/C(=O)N(C)O
DM8W3GC IK HAQOPUCXUDNSDH-JXMROGBWSA-N
DM8W3GC IU (E)-3-(4-butoxyphenyl)-N-hydroxy-N-methylprop-2-enamide
DM8W3GC DE Discovery agent
DMQ2D09 ID DMQ2D09
DMQ2D09 DN 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid
DMQ2D09 HS Investigative
DMQ2D09 SN CHEMBL247544; 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid; CTK7J4510; BDBM50213910
DMQ2D09 DT Small molecular drug
DMQ2D09 PC 16775011
DMQ2D09 MW 282.76
DMQ2D09 FM C15H19ClO3
DMQ2D09 IC InChI=1S/C15H19ClO3/c16-12-6-7-14(19-9-8-15(17)18)13(10-12)11-4-2-1-3-5-11/h6-7,10-11H,1-5,8-9H2,(H,17,18)
DMQ2D09 CS C1CCC(CC1)C2=C(C=CC(=C2)Cl)OCCC(=O)O
DMQ2D09 IK ZHWIAECJQUFYPY-UHFFFAOYSA-N
DMQ2D09 IU 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid
DMQ2D09 DE Discovery agent
DM71EUO ID DM71EUO
DM71EUO DN 3-(4-Chlorophenyl)-2-nortropene
DM71EUO HS Investigative
DM71EUO SN CHEMBL576508; 189746-53-0; 3-(4-Chlorophenyl)-2-nortropene; SCHEMBL6214667; CTK0A2712; DTXSID10431947; QBSBBGLHCMPGNO-UHFFFAOYSA-N; BDBM50303307; 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-chlorophenyl)-; racemic 3-(4-Chloro-phenyl)-8-aza-bicyclo[3.2.1]oct-2-ene
DM71EUO DT Small molecular drug
DM71EUO PC 9859279
DM71EUO MW 219.71
DM71EUO FM C13H14ClN
DM71EUO IC InChI=1S/C13H14ClN/c14-11-3-1-9(2-4-11)10-7-12-5-6-13(8-10)15-12/h1-4,7,12-13,15H,5-6,8H2
DM71EUO CS C1CC2C=C(CC1N2)C3=CC=C(C=C3)Cl
DM71EUO IK QBSBBGLHCMPGNO-UHFFFAOYSA-N
DM71EUO IU 3-(4-chlorophenyl)-8-azabicyclo[3.2.1]oct-2-ene
DM71EUO CA CAS 189746-53-0
DM71EUO DE Discovery agent
DM23JIY ID DM23JIY
DM23JIY DN 3-(4-cyanophenyl)quinoxaline-5-carboxamide
DM23JIY HS Investigative
DM23JIY SN CHEMBL481603; quinoxaline analogue, 3c; 3-(4-cyanophenyl)quinoxaline-5-carboxamide; SCHEMBL7108289
DM23JIY DT Small molecular drug
DM23JIY PC 25218518
DM23JIY MW 274.28
DM23JIY FM C16H10N4O
DM23JIY IC InChI=1S/C16H10N4O/c17-8-10-4-6-11(7-5-10)14-9-19-13-3-1-2-12(16(18)21)15(13)20-14/h1-7,9H,(H2,18,21)
DM23JIY CS C1=CC(=C2C(=C1)N=CC(=N2)C3=CC=C(C=C3)C#N)C(=O)N
DM23JIY IK WCZAODKSIJSHQD-UHFFFAOYSA-N
DM23JIY IU 3-(4-cyanophenyl)quinoxaline-5-carboxamide
DM23JIY DE Discovery agent
DMGQE8D ID DMGQE8D
DMGQE8D DN 3-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMGQE8D HS Investigative
DMGQE8D SN CHEMBL387708; 3-(4-cyclohexylthiosemicarbazono)methyl-phenol; BDBM50216118; (Z)-3-Hydroxybenzaldehyde 4-cyclohexyl thiosemicarbazone
DMGQE8D DT Small molecular drug
DMGQE8D PC 9729029
DMGQE8D MW 277.39
DMGQE8D FM C14H19N3OS
DMGQE8D IC InChI=1S/C14H19N3OS/c18-13-8-4-5-11(9-13)10-15-17-14(19)16-12-6-2-1-3-7-12/h4-5,8-10,12,18H,1-3,6-7H2,(H2,16,17,19)/b15-10+
DMGQE8D CS C1CCC(CC1)NC(=S)N/N=C/C2=CC(=CC=C2)O
DMGQE8D IK GVMJJZTZCKCYTK-XNTDXEJSSA-N
DMGQE8D IU 1-cyclohexyl-3-[(E)-(3-hydroxyphenyl)methylideneamino]thiourea
DMGQE8D DE Discovery agent
DM6XC0M ID DM6XC0M
DM6XC0M DN 3-(4-dimethylamino-benzylidenyl)-2-indolinone
DM6XC0M HS Investigative
DM6XC0M SN dmbi; 3-(4-Dimethylaminobenzylidenyl)-2-indolinone; CHEMBL296455; (Z)-3-[4-(Dimethylamino)benzylidenyl]indolin-2-one; 3-[4-(dimethylamino)benzylidene]-1,3-dihydro-2H-indol-2-one; SU-4312; Tocris-1459; trans-SU 4312; AC1NS4CN; Lopac-S-8567; AC1Q6J0Q; SCHEMBL644678; GTPL5958; SCHEMBL13394695; ZINC21786; MolPort-019-728-327; MolPort-002-894-447; 3-[[(4-Dimethyl-amino)phenyl]methylene]-1,3-dihydro-2H-indol-2-one, E/Z mixture; HMS3229C19; HSCI1_000057; MFCD00118147; BDBM50111603; AKOS001034409; CCG-206747; NCGC00025170-01
DM6XC0M DT Small molecular drug
DM6XC0M PC 3135
DM6XC0M MW 264.32
DM6XC0M FM C17H16N2O
DM6XC0M IC InChI=1S/C17H16N2O/c1-19(2)13-9-7-12(8-10-13)11-15-14-5-3-4-6-16(14)18-17(15)20/h3-11H,1-2H3,(H,18,20)
DM6XC0M CS CN(C)C1=CC=C(C=C1)C=C2C3=CC=CC=C3NC2=O
DM6XC0M IK UAKWLVYMKBWHMX-UHFFFAOYSA-N
DM6XC0M IU 3-[[4-(dimethylamino)phenyl]methylidene]-1H-indol-2-one
DM6XC0M CA CAS 5812-07-7
DM6XC0M CB CHEBI:92369
DM6XC0M DE Discovery agent
DMM7BQP ID DMM7BQP
DMM7BQP DN 3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMM7BQP HS Investigative
DMM7BQP SN 3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 10; AC1O70HJ; BDBM8896; CHEMBL205250
DMM7BQP DT Small molecular drug
DMM7BQP PC 6540054
DMM7BQP MW 235.32
DMM7BQP FM C17H17N
DMM7BQP IC InChI=1S/C17H17N/c1-2-13-10-16(15-7-5-9-18-12-15)11-14-6-3-4-8-17(13)14/h3-9,11-13H,2,10H2,1H3
DMM7BQP CS CCC1CC(=CC2=CC=CC=C12)C3=CN=CC=C3
DMM7BQP IK FTBOKBNMIAPUAJ-UHFFFAOYSA-N
DMM7BQP IU 3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine
DMM7BQP DE Discovery agent
DM8CK9M ID DM8CK9M
DM8CK9M DN 3-(4-Fluorophenyl)-2-nortropene
DM8CK9M HS Investigative
DM8CK9M SN CHEMBL570638; 3-(4-Fluorophenyl)-2-nortropene; 3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-3-ene; SCHEMBL6993886; LKSXLNMBLGXHQS-UHFFFAOYSA-N; BDBM50303306; 163630-91-9
DM8CK9M DT Small molecular drug
DM8CK9M PC 9815620
DM8CK9M MW 203.25
DM8CK9M FM C13H14FN
DM8CK9M IC InChI=1S/C13H14FN/c14-11-3-1-9(2-4-11)10-7-12-5-6-13(8-10)15-12/h1-4,7,12-13,15H,5-6,8H2
DM8CK9M CS C1CC2C=C(CC1N2)C3=CC=C(C=C3)F
DM8CK9M IK LKSXLNMBLGXHQS-UHFFFAOYSA-N
DM8CK9M IU 3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-2-ene
DM8CK9M DE Discovery agent
DM0POH2 ID DM0POH2
DM0POH2 DN 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline
DM0POH2 HS Investigative
DM0POH2 SN CHEMBL68401; 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline; ZINC3834028
DM0POH2 DT Small molecular drug
DM0POH2 PC 10039460
DM0POH2 MW 283.3
DM0POH2 FM C17H14FNO2
DM0POH2 IC InChI=1S/C17H14FNO2/c1-20-16-8-12-7-13(11-3-5-14(18)6-4-11)10-19-15(12)9-17(16)21-2/h3-10H,1-2H3
DM0POH2 CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)F
DM0POH2 IK UKJTWBAIJVXDSM-UHFFFAOYSA-N
DM0POH2 IU 3-(4-fluorophenyl)-6,7-dimethoxyquinoline
DM0POH2 DE Discovery agent
DMDYS7Q ID DMDYS7Q
DMDYS7Q DN 3-(4-hexylthiosemicarbazono)methyl-benzoic acid
DMDYS7Q HS Investigative
DMDYS7Q SN CHEMBL228317; 3-(4-hexylthiosemicarbazono)methyl-benzoic acid
DMDYS7Q DT Small molecular drug
DMDYS7Q PC 16748617
DMDYS7Q MW 307.4
DMDYS7Q FM C15H21N3O2S
DMDYS7Q IC InChI=1S/C15H21N3O2S/c1-2-3-4-5-9-16-15(21)18-17-11-12-7-6-8-13(10-12)14(19)20/h6-8,10-11H,2-5,9H2,1H3,(H,19,20)(H2,16,18,21)/b17-11+
DMDYS7Q CS CCCCCCNC(=S)N/N=C/C1=CC(=CC=C1)C(=O)O
DMDYS7Q IK WAIVPXALQIYLJU-GZTJUZNOSA-N
DMDYS7Q IU 3-[(E)-(hexylcarbamothioylhydrazinylidene)methyl]benzoic acid
DMDYS7Q DE Discovery agent
DMPS1GW ID DMPS1GW
DMPS1GW DN 3-(4H-Imidazol-4-yl)benzenethiol
DMPS1GW HS Investigative
DMPS1GW PC 25194941
DMPS1GW MW 176.24
DMPS1GW FM C9H8N2S
DMPS1GW IC InChI=1S/C9H8N2S/c12-8-3-1-2-7(4-8)9-5-10-6-11-9/h1-6,9,12H
DMPS1GW CS C1=CC(=CC(=C1)S)C2C=NC=N2
DMPS1GW IK GGVYLSRKJAVBST-UHFFFAOYSA-N
DMPS1GW IU 3-(4H-imidazol-4-yl)benzenethiol
DMPS1GW DE Discovery agent
DME5238 ID DME5238
DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile
DME5238 HS Investigative
DME5238 SN CHEMBL303801
DME5238 DT Small molecular drug
DME5238 PC 14537255
DME5238 MW 297.3
DME5238 FM C21H15NO
DME5238 IC InChI=1S/C21H15NO/c22-15-20(16-7-3-1-4-8-16)21(17-9-5-2-6-10-17)18-11-13-19(23)14-12-18/h1-14,23H/b21-20-
DME5238 CS C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\\C3=CC=C(C=C3)O)/C#N
DME5238 IK ASWQVWZGOMLNRM-MRCUWXFGSA-N
DME5238 IU (E)-3-(4-hydroxyphenyl)-2,3-diphenylprop-2-enenitrile
DME5238 DE Discovery agent
DMN01PI ID DMN01PI
DMN01PI DN 3-(4-Hydroxy-phenyl)-4H-chromen-7-ol
DMN01PI HS Investigative
DMN01PI SN CHEMBL195560; 4h-1-benzopyran-7-ol,3-(4-hydroxyphenyl)-; 232261-61-9; isophenoxodiol; 3-(4-Hydroxy-phenyl)-4H-chromen-7-ol; SCHEMBL3755117; BDBM50166895; ZINC13643803; KB-290777; US8552057, 4
DMN01PI DT Small molecular drug
DMN01PI PC 11356877
DMN01PI MW 240.25
DMN01PI FM C15H12O3
DMN01PI IC InChI=1S/C15H12O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8-9,16-17H,7H2
DMN01PI CS C1C2=C(C=C(C=C2)O)OC=C1C3=CC=C(C=C3)O
DMN01PI IK QCNUDDPWPNUALZ-UHFFFAOYSA-N
DMN01PI IU 3-(4-hydroxyphenyl)-4H-chromen-7-ol
DMN01PI DE Discovery agent
DM3XOVL ID DM3XOVL
DM3XOVL DN 3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one
DM3XOVL HS Investigative
DM3XOVL SN CHEMBL577099; 3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one; ZINC45291389
DM3XOVL DT Small molecular drug
DM3XOVL PC 45485414
DM3XOVL MW 252.26
DM3XOVL FM C16H12O3
DM3XOVL IC InChI=1S/C16H12O3/c1-10-2-7-15-12(8-10)9-14(16(18)19-15)11-3-5-13(17)6-4-11/h2-9,17H,1H3
DM3XOVL CS CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC=C(C=C3)O
DM3XOVL IK JSHUCMRTLUIFTM-UHFFFAOYSA-N
DM3XOVL IU 3-(4-hydroxyphenyl)-6-methylchromen-2-one
DM3XOVL DE Discovery agent
DMS5N6Y ID DMS5N6Y
DMS5N6Y DN 3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one
DMS5N6Y HS Investigative
DMS5N6Y SN SCHEMBL1701136
DMS5N6Y DT Small molecular drug
DMS5N6Y PC 46914766
DMS5N6Y MW 310.3
DMS5N6Y FM C19H18O4
DMS5N6Y IC InChI=1S/C19H18O4/c1-12(2)10-22-15-7-8-16-18(9-15)23-11-17(19(16)21)13-3-5-14(20)6-4-13/h3-9,11-12,20H,10H2,1-2H3
DMS5N6Y CS CC(C)COC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O
DMS5N6Y IK WYYSKWHYOXHLTB-UHFFFAOYSA-N
DMS5N6Y IU 3-(4-hydroxyphenyl)-7-(2-methylpropoxy)chromen-4-one
DMS5N6Y DE Discovery agent
DMH75AO ID DMH75AO
DMH75AO DN 3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one
DMH75AO HS Investigative
DMH75AO SN CHEMBL115109; 97846-18-9; 4H-1-Benzopyran-4-one, 3-(4-hydroxyphenyl)-7-(1-methylethoxy)-; ACMC-20m1ro; 3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one; SCHEMBL1701110; CTK3G8070; DTXSID70440494; 7-Isopropoxy-4'-hydroxyisoflavone; BDBM50104874; ZINC13864225; AKOS030553087; 3-(4-Hydroxy-phenyl)-7-isopropoxy-chromen-4-one
DMH75AO DT Small molecular drug
DMH75AO PC 10469827
DMH75AO MW 296.3
DMH75AO FM C18H16O4
DMH75AO IC InChI=1S/C18H16O4/c1-11(2)22-14-7-8-15-17(9-14)21-10-16(18(15)20)12-3-5-13(19)6-4-12/h3-11,19H,1-2H3
DMH75AO CS CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O
DMH75AO IK DEQMUPGWSXUDKV-UHFFFAOYSA-N
DMH75AO IU 3-(4-hydroxyphenyl)-7-propan-2-yloxychromen-4-one
DMH75AO CA CAS 97846-18-9
DMH75AO DE Discovery agent
DMXZ9T6 ID DMXZ9T6
DMXZ9T6 DN 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol
DMXZ9T6 HS Investigative
DMXZ9T6 DT Small molecular drug
DMXZ9T6 PC 135474625
DMXZ9T6 MW 227.21
DMXZ9T6 FM C13H9NO3
DMXZ9T6 IC InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-11-7-10(16)5-6-12(11)17-14-13/h1-7,15-16H
DMXZ9T6 CS C1=CC(=CC=C1C2=NOC3=C2C=C(C=C3)O)O
DMXZ9T6 IK SSWFRICEKZJJHY-UHFFFAOYSA-N
DMXZ9T6 IU 3-(4-hydroxyphenyl)-1,2-benzoxazol-5-ol
DMXZ9T6 DE Discovery agent
DMYLDFG ID DMYLDFG
DMYLDFG DN 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol
DMYLDFG HS Investigative
DMYLDFG DT Small molecular drug
DMYLDFG PC 135526958
DMYLDFG MW 227.21
DMYLDFG FM C13H9NO3
DMYLDFG IC InChI=1S/C13H9NO3/c15-9-3-1-8(2-4-9)13-11-6-5-10(16)7-12(11)17-14-13/h1-7,15-16H
DMYLDFG CS C1=CC(=CC=C1C2=NOC3=C2C=CC(=C3)O)O
DMYLDFG IK DPKXDXRRZZTHNM-UHFFFAOYSA-N
DMYLDFG IU 3-(4-hydroxyphenyl)-1,2-benzoxazol-6-ol
DMYLDFG DE Discovery agent
DM18MOH ID DM18MOH
DM18MOH DN 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM18MOH HS Investigative
DM18MOH SN 4-((4-aminophenyl)diazenyl)benzenesulfonamide
DM18MOH DT Small molecular drug
DM18MOH PC 405487
DM18MOH MW 276.32
DM18MOH FM C12H12N4O2S
DM18MOH IC InChI=1S/C12H12N4O2S/c13-9-1-3-10(4-2-9)15-16-11-5-7-12(8-6-11)19(14,17)18/h1-8H,13H2,(H2,14,17,18)
DM18MOH CS C1=CC(=CC=C1N)N=NC2=CC=C(C=C2)S(=O)(=O)N
DM18MOH IK JSHXITVMUADQEA-UHFFFAOYSA-N
DM18MOH IU 4-[(4-aminophenyl)diazenyl]benzenesulfonamide
DM18MOH CA CAS 59553-77-4
DM18MOH DE Discovery agent
DMSR2O3 ID DMSR2O3
DMSR2O3 DN 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone
DMSR2O3 HS Investigative
DMSR2O3 SN CHEMBL193856; BDBM22344; ZINC13683316; 1,3-Diarylprop-2-yn-1-one, 13a
DMSR2O3 DT Small molecular drug
DMSR2O3 PC 11231439
DMSR2O3 MW 284.3
DMSR2O3 FM C16H12O3S
DMSR2O3 IC InChI=1S/C16H12O3S/c1-20(18,19)15-10-7-13(8-11-15)9-12-16(17)14-5-3-2-4-6-14/h2-8,10-11H,1H3
DMSR2O3 CS CS(=O)(=O)C1=CC=C(C=C1)C#CC(=O)C2=CC=CC=C2
DMSR2O3 IK OIHHELVXIPDXIK-UHFFFAOYSA-N
DMSR2O3 IU 3-(4-methylsulfonylphenyl)-1-phenylprop-2-yn-1-one
DMSR2O3 DE Discovery agent
DM206M1 ID DM206M1
DM206M1 DN 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol
DM206M1 HS Investigative
DM206M1 SN CHEMBL295066; 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol; SCHEMBL7208466
DM206M1 DT Small molecular drug
DM206M1 PC 19366816
DM206M1 MW 286.4
DM206M1 FM C13H18O3S2
DM206M1 IC InChI=1S/C13H18O3S2/c1-16-10-5-7-12(8-6-10)18(14,15)13-4-2-3-11(17)9-13/h5-8,11,13,17H,2-4,9H2,1H3
DM206M1 CS COC1=CC=C(C=C1)S(=O)(=O)C2CCCC(C2)S
DM206M1 IK CTONTIQKTODDRQ-UHFFFAOYSA-N
DM206M1 IU 3-(4-methoxyphenyl)sulfonylcyclohexane-1-thiol
DM206M1 DE Discovery agent
DMK79U1 ID DMK79U1
DMK79U1 DN 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol
DMK79U1 HS Investigative
DMK79U1 SN CHEMBL51013; 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol
DMK79U1 DT Small molecular drug
DMK79U1 PC 44294636
DMK79U1 MW 272.4
DMK79U1 FM C12H16O3S2
DMK79U1 IC InChI=1S/C12H16O3S2/c1-15-9-2-5-11(6-3-9)17(13,14)12-7-4-10(16)8-12/h2-3,5-6,10,12,16H,4,7-8H2,1H3
DMK79U1 CS COC1=CC=C(C=C1)S(=O)(=O)C2CCC(C2)S
DMK79U1 IK JDPMCWHMTGTQGU-UHFFFAOYSA-N
DMK79U1 IU 3-(4-methoxyphenyl)sulfonylcyclopentane-1-thiol
DMK79U1 DE Discovery agent
DMRLAX8 ID DMRLAX8
DMRLAX8 DN 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol
DMRLAX8 HS Investigative
DMRLAX8 SN CHEMBL175113; 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol; SCHEMBL7212134
DMRLAX8 DT Small molecular drug
DMRLAX8 PC 19366844
DMRLAX8 MW 288.4
DMRLAX8 FM C13H20O3S2
DMRLAX8 IC InChI=1S/C13H20O3S2/c1-3-4-12(9-10-17)18(14,15)13-7-5-11(16-2)6-8-13/h5-8,12,17H,3-4,9-10H2,1-2H3
DMRLAX8 CS CCCC(CCS)S(=O)(=O)C1=CC=C(C=C1)OC
DMRLAX8 IK SHMJSERYBLZGBT-UHFFFAOYSA-N
DMRLAX8 IU 3-(4-methoxyphenyl)sulfonylhexane-1-thiol
DMRLAX8 DE Discovery agent
DM854IG ID DM854IG
DM854IG DN 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol
DM854IG HS Investigative
DM854IG SN CHEMBL368972; 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol; SCHEMBL7207764
DM854IG DT Small molecular drug
DM854IG PC 19366856
DM854IG MW 274.4
DM854IG FM C12H18O3S2
DM854IG IC InChI=1S/C12H18O3S2/c1-3-11(8-9-16)17(13,14)12-6-4-10(15-2)5-7-12/h4-7,11,16H,3,8-9H2,1-2H3
DM854IG CS CCC(CCS)S(=O)(=O)C1=CC=C(C=C1)OC
DM854IG IK PKYBEORBMGUOOP-UHFFFAOYSA-N
DM854IG IU 3-(4-methoxyphenyl)sulfonylpentane-1-thiol
DM854IG DE Discovery agent
DM7B1VT ID DM7B1VT
DM7B1VT DN 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol
DM7B1VT HS Investigative
DM7B1VT SN CHEMBL51638; 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7076532; JIFLEYNNNKKNOQ-UHFFFAOYSA-N; BDBM50076592; 3-(4-Methoxyphenylsulfonyl)propane-1-thiol
DM7B1VT DT Small molecular drug
DM7B1VT PC 18411961
DM7B1VT MW 246.4
DM7B1VT FM C10H14O3S2
DM7B1VT IC InChI=1S/C10H14O3S2/c1-13-9-3-5-10(6-4-9)15(11,12)8-2-7-14/h3-6,14H,2,7-8H2,1H3
DM7B1VT CS COC1=CC=C(C=C1)S(=O)(=O)CCCS
DM7B1VT IK JIFLEYNNNKKNOQ-UHFFFAOYSA-N
DM7B1VT IU 3-(4-methoxyphenyl)sulfonylpropane-1-thiol
DM7B1VT DE Discovery agent
DMFRZGS ID DMFRZGS
DMFRZGS DN 3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one
DMFRZGS HS Investigative
DMFRZGS SN CHEMBL386837; 921611-05-4; 3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one; CTK3H0752; DTXSID80658821; BDBM50198253; AKOS030552092; 4-Thiazolidinone, 3-[(4-methoxyphenyl)methoxy]-2-phenyl-
DMFRZGS DT Small molecular drug
DMFRZGS PC 44418200
DMFRZGS MW 315.4
DMFRZGS FM C17H17NO3S
DMFRZGS IC InChI=1S/C17H17NO3S/c1-20-15-9-7-13(8-10-15)11-21-18-16(19)12-22-17(18)14-5-3-2-4-6-14/h2-10,17H,11-12H2,1H3
DMFRZGS CS COC1=CC=C(C=C1)CON2C(SCC2=O)C3=CC=CC=C3
DMFRZGS IK IUBPXBYZGYCTMU-UHFFFAOYSA-N
DMFRZGS IU 3-[(4-methoxyphenyl)methoxy]-2-phenyl-1,3-thiazolidin-4-one
DMFRZGS CA CAS 921611-05-4
DMFRZGS DE Discovery agent
DMGC7RY ID DMGC7RY
DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione
DMGC7RY HS Investigative
DMGC7RY SN CHEMBL372076; SCHEMBL3822337
DMGC7RY DT Small molecular drug
DMGC7RY PC 11572699
DMGC7RY MW 279.29
DMGC7RY FM C17H13NO3
DMGC7RY IC InChI=1S/C17H13NO3/c1-21-13-9-7-12(8-10-13)15-14(16(19)18-17(15)20)11-5-3-2-4-6-11/h2-10H,1H3,(H,18,19,20)
DMGC7RY CS COC1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CC=CC=C3
DMGC7RY IK PXJXUZZVGCBPLM-UHFFFAOYSA-N
DMGC7RY IU 3-(4-methoxyphenyl)-4-phenylpyrrole-2,5-dione
DMGC7RY DE Discovery agent
DMXKJOC ID DMXKJOC
DMXKJOC DN 3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one
DMXKJOC HS Investigative
DMXKJOC SN CHEMBL572233; 3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one; SCHEMBL17857190; BDBM50300894; 3-(4-methoxyphenyl)-6-methylcoumarin; 113769-77-0; 3-(4-Methoxyphenyl)-6-methyl-3-chromene-2-one
DMXKJOC DT Small molecular drug
DMXKJOC PC 14054762
DMXKJOC MW 266.29
DMXKJOC FM C17H14O3
DMXKJOC IC InChI=1S/C17H14O3/c1-11-3-8-16-13(9-11)10-15(17(18)20-16)12-4-6-14(19-2)7-5-12/h3-10H,1-2H3
DMXKJOC CS CC1=CC2=C(C=C1)OC(=O)C(=C2)C3=CC=C(C=C3)OC
DMXKJOC IK IXPFLPLQVXPBGF-UHFFFAOYSA-N
DMXKJOC IU 3-(4-methoxyphenyl)-6-methylchromen-2-one
DMXKJOC DE Discovery agent
DM7WPQC ID DM7WPQC
DM7WPQC DN 3-(4-methoxyphenyl)quinoxaline-5-carboxamide
DM7WPQC HS Investigative
DM7WPQC SN CHEMBL519443; 3-(4-methoxyphenyl)quinoxaline-5-carboxamide; quinoxaline analogue, 3e; SCHEMBL7045177
DM7WPQC DT Small molecular drug
DM7WPQC PC 9965481
DM7WPQC MW 279.29
DM7WPQC FM C16H13N3O2
DM7WPQC IC InChI=1S/C16H13N3O2/c1-21-11-7-5-10(6-8-11)14-9-18-13-4-2-3-12(16(17)20)15(13)19-14/h2-9H,1H3,(H2,17,20)
DM7WPQC CS COC1=CC=C(C=C1)C2=NC3=C(C=CC=C3N=C2)C(=O)N
DM7WPQC IK XLKSSLKAULIQEE-UHFFFAOYSA-N
DM7WPQC IU 3-(4-methoxyphenyl)quinoxaline-5-carboxamide
DM7WPQC DE Discovery agent
DMDR20P ID DMDR20P
DMDR20P DN 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMDR20P HS Investigative
DMDR20P SN 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 9; AC1O70HH; SCHEMBL4507080; CHEMBL206070
DMDR20P DT Small molecular drug
DMDR20P PC 6540053
DMDR20P MW 221.3
DMDR20P FM C16H15N
DMDR20P IC InChI=1S/C16H15N/c1-12-9-15(14-6-4-8-17-11-14)10-13-5-2-3-7-16(12)13/h2-8,10-12H,9H2,1H3
DMDR20P CS CC1CC(=CC2=CC=CC=C12)C3=CN=CC=C3
DMDR20P IK HIOBIABFPPEMPT-UHFFFAOYSA-N
DMDR20P IU 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine
DMDR20P DE Discovery agent
DM0HYDZ ID DM0HYDZ
DM0HYDZ DN 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole
DM0HYDZ HS Investigative
DM0HYDZ SN 21000-95-3; BRN 0191400; CHEMBL57478; 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole; INDOLE, 3-((4-METHYLPIPERIDINO)METHYL)-; 3-((4-Methylpiperidino)methyl)indole; 3-[(4-methylpiperidin-1-yl)methyl]-1H-indole; AC1L1JK7; AC1Q2R9P; Oprea1_731728; Oprea1_382776; AURORA 16336; SCHEMBL13504100; CTK8H5660; DTXSID30175210; MolPort-001-815-823; ZINC142608; BDBM50050469; STK617550; 3-[(4-methylpiperidyl)methyl]indole; AKOS002266584; MCULE-4620579742; ACM21000953; 3-(4-Methylpiperidinomethyl)-1H-indole; LS-83280; BAS 02946824; ST50190326
DM0HYDZ DT Small molecular drug
DM0HYDZ PC 30438
DM0HYDZ MW 228.33
DM0HYDZ FM C15H20N2
DM0HYDZ IC InChI=1S/C15H20N2/c1-12-6-8-17(9-7-12)11-13-10-16-15-5-3-2-4-14(13)15/h2-5,10,12,16H,6-9,11H2,1H3
DM0HYDZ CS CC1CCN(CC1)CC2=CNC3=CC=CC=C32
DM0HYDZ IK DGCGMYNLCDVYMB-UHFFFAOYSA-N
DM0HYDZ IU 3-[(4-methylpiperidin-1-yl)methyl]-1H-indole
DM0HYDZ CA CAS 21000-95-3
DM0HYDZ DE Discovery agent
DM54MDH ID DM54MDH
DM54MDH DN 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol
DM54MDH HS Investigative
DM54MDH SN CHEMBL541643
DM54MDH DT Small molecular drug
DM54MDH PC 9901372
DM54MDH MW 313.4
DM54MDH FM C16H15N3O2S
DM54MDH IC InChI=1S/C16H15N3O2S/c20-12-3-1-2-11(10-12)15-17-13-4-9-22-14(13)16(18-15)19-5-7-21-8-6-19/h1-4,9-10,20H,5-8H2
DM54MDH CS C1COCCN1C2=NC(=NC3=C2SC=C3)C4=CC(=CC=C4)O
DM54MDH IK XXLAEKOWCYJOKK-UHFFFAOYSA-N
DM54MDH IU 3-(4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol
DM54MDH CA CAS 371943-05-4
DM54MDH DE Discovery agent
DMIBAM2 ID DMIBAM2
DMIBAM2 DN 3-(4-o-Tolylpiperazine-1-carbonyl)coumarin
DMIBAM2 HS Investigative
DMIBAM2 SN CHEMBL509131; AC1PLLS0; 3-(4-o-Tolylpiperazine-1-carbonyl)coumarin; BDBM50244558; AKOS002932058
DMIBAM2 DT Small molecular drug
DMIBAM2 PC 9153545
DMIBAM2 MW 348.4
DMIBAM2 FM C21H20N2O3
DMIBAM2 IC InChI=1S/C21H20N2O3/c1-15-6-2-4-8-18(15)22-10-12-23(13-11-22)20(24)17-14-16-7-3-5-9-19(16)26-21(17)25/h2-9,14H,10-13H2,1H3
DMIBAM2 CS CC1=CC=CC=C1N2CCN(CC2)C(=O)C3=CC4=CC=CC=C4OC3=O
DMIBAM2 IK IVCTUFTWYWRJLW-UHFFFAOYSA-N
DMIBAM2 IU 3-[4-(2-methylphenyl)piperazine-1-carbonyl]chromen-2-one
DMIBAM2 DE Discovery agent
DMBKDZ3 ID DMBKDZ3
DMBKDZ3 DN 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3 HS Investigative
DMBKDZ3 SN CHEMBL48474; 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol
DMBKDZ3 DT Small molecular drug
DMBKDZ3 PC 44294677
DMBKDZ3 MW 348.5
DMBKDZ3 FM C18H20O3S2
DMBKDZ3 IC InChI=1S/C18H20O3S2/c19-23(20,18-8-4-7-16(22)13-18)17-11-9-15(10-12-17)21-14-5-2-1-3-6-14/h1-3,5-6,9-12,16,18,22H,4,7-8,13H2
DMBKDZ3 CS C1CC(CC(C1)S(=O)(=O)C2=CC=C(C=C2)OC3=CC=CC=C3)S
DMBKDZ3 IK XOVSRAFNJNQNRK-UHFFFAOYSA-N
DMBKDZ3 IU 3-(4-phenoxyphenyl)sulfonylcyclohexane-1-thiol
DMBKDZ3 DE Discovery agent
DM2HBGL ID DM2HBGL
DM2HBGL DN 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol
DM2HBGL HS Investigative
DM2HBGL SN CHEMBL301565; 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol; SCHEMBL7208687; BDBM50076589
DM2HBGL DT Small molecular drug
DM2HBGL PC 10267279
DM2HBGL MW 308.4
DM2HBGL FM C15H16O3S2
DM2HBGL IC InChI=1S/C15H16O3S2/c16-20(17,12-4-11-19)15-9-7-14(8-10-15)18-13-5-2-1-3-6-13/h1-3,5-10,19H,4,11-12H2
DM2HBGL CS C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)CCCS
DM2HBGL IK CTVWOVYWOFCAMW-UHFFFAOYSA-N
DM2HBGL IU 3-(4-phenoxyphenyl)sulfonylpropane-1-thiol
DM2HBGL DE Discovery agent
DMO6LID ID DMO6LID
DMO6LID DN 3-(4-Phenoxy-phenyl)-1H-pyrazole
DMO6LID HS Investigative
DMO6LID SN 5-(4-phenoxyphenyl)-1H-pyrazole; CHEMBL41864; 111273-31-5; 1H-Pyrazole, 3-(4-phenoxyphenyl)-; 3-(4-Phenoxy-phenyl)-1H-pyrazole; ACMC-20me6r; AC1MD5RK; Maybridge3_001296; Oprea1_637414; MLS000851363; SCHEMBL3364770; CTK0G1854; DTXSID00384478; MolPort-001-792-591; SGQSMRQYEPPNIA-UHFFFAOYSA-N; 3-(4-phenoxyphenyl)-1H-pyrazole; HMS2799J18; HMS1434K20; BDBM50141064; ZINC13559817; AKOS023552923; MCULE-9803599814; IDI1_012683
DMO6LID DT Small molecular drug
DMO6LID PC 2806138
DMO6LID MW 236.27
DMO6LID FM C15H12N2O
DMO6LID IC InChI=1S/C15H12N2O/c1-2-4-13(5-3-1)18-14-8-6-12(7-9-14)15-10-11-16-17-15/h1-11H,(H,16,17)
DMO6LID CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=CC=NN3
DMO6LID IK SGQSMRQYEPPNIA-UHFFFAOYSA-N
DMO6LID IU 5-(4-phenoxyphenyl)-1H-pyrazole
DMO6LID CA CAS 111273-31-5
DMO6LID DE Discovery agent
DMSZ1VC ID DMSZ1VC
DMSZ1VC DN 3-(4-phenyl-2,4'-bipyridin-6-yl)phenol
DMSZ1VC HS Investigative
DMSZ1VC SN CHEMBL1095650
DMSZ1VC DT Small molecular drug
DMSZ1VC PC 46861757
DMSZ1VC MW 324.4
DMSZ1VC FM C22H16N2O
DMSZ1VC IC InChI=1S/C22H16N2O/c25-20-8-4-7-18(13-20)22-15-19(16-5-2-1-3-6-16)14-21(24-22)17-9-11-23-12-10-17/h1-15,25H
DMSZ1VC CS C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC(=CC=C3)O)C4=CC=NC=C4
DMSZ1VC IK CBYVMWRLWYKHTF-UHFFFAOYSA-N
DMSZ1VC IU 3-(4-phenyl-6-pyridin-4-ylpyridin-2-yl)phenol
DMSZ1VC DE Discovery agent
DM0OF64 ID DM0OF64
DM0OF64 DN 3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol
DM0OF64 HS Investigative
DM0OF64 SN CHEMBL1094819
DM0OF64 DT Small molecular drug
DM0OF64 PC 46887131
DM0OF64 MW 329.4
DM0OF64 FM C21H15NOS
DM0OF64 IC InChI=1S/C21H15NOS/c23-18-9-4-8-16(12-18)19-13-17(15-6-2-1-3-7-15)14-20(22-19)21-10-5-11-24-21/h1-14,23H
DM0OF64 CS C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=CS3)C4=CC(=CC=C4)O
DM0OF64 IK ARUHBJGNLAPWGO-UHFFFAOYSA-N
DM0OF64 IU 3-(4-phenyl-6-thiophen-2-ylpyridin-2-yl)phenol
DM0OF64 DE Discovery agent
DMTR8SZ ID DMTR8SZ
DMTR8SZ DN 3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol
DMTR8SZ HS Investigative
DMTR8SZ SN CHEMBL1095140
DMTR8SZ DT Small molecular drug
DMTR8SZ PC 46887132
DMTR8SZ MW 329.4
DMTR8SZ FM C21H15NOS
DMTR8SZ IC InChI=1S/C21H15NOS/c23-19-8-4-7-16(11-19)20-12-18(15-5-2-1-3-6-15)13-21(22-20)17-9-10-24-14-17/h1-14,23H
DMTR8SZ CS C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CSC=C3)C4=CC(=CC=C4)O
DMTR8SZ IK GZCPVCLLSOKGCF-UHFFFAOYSA-N
DMTR8SZ IU 3-(4-phenyl-6-thiophen-3-ylpyridin-2-yl)phenol
DMTR8SZ DE Discovery agent
DMXL0J5 ID DMXL0J5
DMXL0J5 DN 3-(4-Phenylethynylbenzoyl)nonanoic acid
DMXL0J5 HS Investigative
DMXL0J5 SN 3-(4-Phenylethynylbenzoyl)nonanoic acid; CHEMBL201298
DMXL0J5 DT Small molecular drug
DMXL0J5 PC 11581319
DMXL0J5 MW 362.5
DMXL0J5 FM C24H26O3
DMXL0J5 IC InChI=1S/C24H26O3/c1-2-3-4-8-11-22(18-23(25)26)24(27)21-16-14-20(15-17-21)13-12-19-9-6-5-7-10-19/h5-7,9-10,14-17,22H,2-4,8,11,18H2,1H3,(H,25,26)
DMXL0J5 CS CCCCCCC(CC(=O)O)C(=O)C1=CC=C(C=C1)C#CC2=CC=CC=C2
DMXL0J5 IK RPSYWEPJQQLLJN-UHFFFAOYSA-N
DMXL0J5 IU 3-[4-(2-phenylethynyl)benzoyl]nonanoic acid
DMXL0J5 DE Discovery agent
DMH27E0 ID DMH27E0
DMH27E0 DN 3-(4-Phenylpiperazin-1-carbonyl)coumarin
DMH27E0 HS Investigative
DMH27E0 SN CHEMBL486460; 3-(4-phenylpiperazine-1-carbonyl)-2H-chromen-2-one; 420099-59-8; 3-(4-Phenylpiperazin-1-carbonyl)coumarin; AC1LEC4F; CBMicro_029395; Oprea1_062891; ZINC99797; PEIQALYIIRRQAZ-UHFFFAOYSA-N; MolPort-000-467-605; STK414837; BDBM50244417; AKOS001407600; MCULE-7805538534; NCGC00306822-01; BIM-0029313.P001; ST4080681; AB00094693-01; 3-[(4-phenylpiperazinyl)carbonyl]chromen-2-one; AB00094693-02; 3-(4-phenylpiperazine-1-carbonyl)chromen-2-one; SR-01000218055; Chromen-2-one, 3-(4-phenylpiperazine-1-carbonyl)-
DMH27E0 DT Small molecular drug
DMH27E0 PC 709819
DMH27E0 MW 334.4
DMH27E0 FM C20H18N2O3
DMH27E0 IC InChI=1S/C20H18N2O3/c23-19(17-14-15-6-4-5-9-18(15)25-20(17)24)22-12-10-21(11-13-22)16-7-2-1-3-8-16/h1-9,14H,10-13H2
DMH27E0 CS C1CN(CCN1C2=CC=CC=C2)C(=O)C3=CC4=CC=CC=C4OC3=O
DMH27E0 IK PEIQALYIIRRQAZ-UHFFFAOYSA-N
DMH27E0 IU 3-(4-phenylpiperazine-1-carbonyl)chromen-2-one
DMH27E0 DE Discovery agent
DM17SNR ID DM17SNR
DM17SNR DN 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole
DM17SNR HS Investigative
DM17SNR SN 3-[(4-phenylpiperazino)methyl]-1h-indole; CHEMBL59324; 4281-72-5; 3-[(4-phenylpiperazin-1-yl)methyl]-1H-indole; NSC33115; AC1Q1ILD; 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole; AC1L5R6D; Oprea1_259378; CBDivE_012786; CTK4I6632; MolPort-002-141-505; NSC-33115; CCG-45935; ZINC53151307; BDBM50050464; AKOS030540271; MCULE-7772581256; KB-286915
DM17SNR DT Small molecular drug
DM17SNR PC 233952
DM17SNR MW 291.4
DM17SNR FM C19H21N3
DM17SNR IC InChI=1S/C19H21N3/c1-2-6-17(7-3-1)22-12-10-21(11-13-22)15-16-14-20-19-9-5-4-8-18(16)19/h1-9,14,20H,10-13,15H2
DM17SNR CS C1CN(CCN1CC2=CNC3=CC=CC=C32)C4=CC=CC=C4
DM17SNR IK FDOZNCJWYJMHAG-UHFFFAOYSA-N
DM17SNR IU 3-[(4-phenylpiperazin-1-yl)methyl]-1H-indole
DM17SNR CA CAS 4281-72-5
DM17SNR DE Discovery agent
DMM0WGI ID DMM0WGI
DMM0WGI DN 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole
DMM0WGI HS Investigative
DMM0WGI SN CHEMBL59103; 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole; BDBM50050468; ZINC13755886
DMM0WGI DT Small molecular drug
DMM0WGI PC 10851078
DMM0WGI MW 290.4
DMM0WGI FM C20H22N2
DMM0WGI IC InChI=1S/C20H22N2/c1-2-6-16(7-3-1)17-10-12-22(13-11-17)15-18-14-21-20-9-5-4-8-19(18)20/h1-9,14,17,21H,10-13,15H2
DMM0WGI CS C1CN(CCC1C2=CC=CC=C2)CC3=CNC4=CC=CC=C43
DMM0WGI IK XNXQFTTXHFQTRX-UHFFFAOYSA-N
DMM0WGI IU 3-[(4-phenylpiperidin-1-yl)methyl]-1H-indole
DMM0WGI DE Discovery agent
DMDYVA7 ID DMDYVA7
DMDYVA7 DN 3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile
DMDYVA7 HS Investigative
DMDYVA7 SN CHEMBL363883; 3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile; SCHEMBL5224021; WFXSTBNPVNZJHP-UHFFFAOYSA-N; BDBM50151900; ZINC13582329
DMDYVA7 DT Small molecular drug
DMDYVA7 PC 11242036
DMDYVA7 MW 246.27
DMDYVA7 FM C15H10N4
DMDYVA7 IC InChI=1S/C15H10N4/c16-9-12-4-3-5-13(8-12)19-10-15(18-11-19)14-6-1-2-7-17-14/h1-8,10-11H
DMDYVA7 CS C1=CC=NC(=C1)C2=CN(C=N2)C3=CC=CC(=C3)C#N
DMDYVA7 IK WFXSTBNPVNZJHP-UHFFFAOYSA-N
DMDYVA7 IU 3-(4-pyridin-2-ylimidazol-1-yl)benzonitrile
DMDYVA7 DE Discovery agent
DMTD16H ID DMTD16H
DMTD16H DN 3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile
DMTD16H HS Investigative
DMTD16H SN CHEMBL189389; 546141-91-7; 3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile; SCHEMBL3922456; CTK1F8523; DTXSID40432285; ZINC13582324; BDBM50151901; Benzonitrile, 3-[4-(2-pyridinyl)-1H-pyrazol-1-yl]-
DMTD16H DT Small molecular drug
DMTD16H PC 9881352
DMTD16H MW 246.27
DMTD16H FM C15H10N4
DMTD16H IC InChI=1S/C15H10N4/c16-9-12-4-3-5-14(8-12)19-11-13(10-18-19)15-6-1-2-7-17-15/h1-8,10-11H
DMTD16H CS C1=CC=NC(=C1)C2=CN(N=C2)C3=CC=CC(=C3)C#N
DMTD16H IK SLFBHONCPFNHGU-UHFFFAOYSA-N
DMTD16H IU 3-(4-pyridin-2-ylpyrazol-1-yl)benzonitrile
DMTD16H CA CAS 546141-91-7
DMTD16H DE Discovery agent
DMBDW8P ID DMBDW8P
DMBDW8P DN 3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P HS Investigative
DMBDW8P SN 3-(4-Sulfamoylphenyl)propanoic acid; 90610-69-8; 3-(4-Sulfamoyl-phenyl)-propionic acid; 3-[4-(Aminosulfonyl)phenyl]propanoic Acid; CHEMBL451332; 4-(2-carboxyethyl)-benzenesulfonamide; M28; BAS 12384209; AC1MKR5Y; AC1Q55BB; 4-carboxyethylbenzenesulfonamide; SCHEMBL4964212; CTK7J3040; BDBM29277; MolPort-001-769-253; JUEONDBIBADVGD-UHFFFAOYSA-N; HMS3604J11; ZINC4362893; 4-(Aminosulphonyl)hydrocinnamic acid; STK802680; ANW-44559; SBB011591; BBL002635; 4-(2-Carboxyethyl)benzenesulphonamide; P-CARBOXYETHYLBENZENESULFONAMIDE; 3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID
DMBDW8P DT Small molecular drug
DMBDW8P PC 3161908
DMBDW8P MW 229.26
DMBDW8P FM C9H11NO4S
DMBDW8P IC InChI=1S/C9H11NO4S/c10-15(13,14)8-4-1-7(2-5-8)3-6-9(11)12/h1-2,4-5H,3,6H2,(H,11,12)(H2,10,13,14)
DMBDW8P CS C1=CC(=CC=C1CCC(=O)O)S(=O)(=O)N
DMBDW8P IK JUEONDBIBADVGD-UHFFFAOYSA-N
DMBDW8P IU 3-(4-sulfamoylphenyl)propanoic acid
DMBDW8P DE Discovery agent
DMZB804 ID DMZB804
DMZB804 DN 3-(4-Trifluoromethylphenyl)-2-nortropene
DMZB804 HS Investigative
DMZB804 SN CHEMBL570871; (+/-)-3-(4-trifluoromethylphenyl)-8-azabicyclo(3.2.1]oct-2-ene; (+/-)-3-(4-trifluoromethylphenyl)-8-azabicyclo[3.2.1]oct-2-ene; 3-(4-Trifluoromethylphenyl)-2-nortropene; SCHEMBL6577750; TVAPTTJJXRUWFI-UHFFFAOYSA-N
DMZB804 DT Small molecular drug
DMZB804 PC 9816454
DMZB804 MW 253.26
DMZB804 FM C14H14F3N
DMZB804 IC InChI=1S/C14H14F3N/c15-14(16,17)11-3-1-9(2-4-11)10-7-12-5-6-13(8-10)18-12/h1-4,7,12-13,18H,5-6,8H2
DMZB804 CS C1CC2C=C(CC1N2)C3=CC=C(C=C3)C(F)(F)F
DMZB804 IK TVAPTTJJXRUWFI-UHFFFAOYSA-N
DMZB804 IU 3-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]oct-2-ene
DMZB804 DE Discovery agent
DM6S28U ID DM6S28U
DM6S28U DN 3-(5-((methylthio)methyl)furan-2-yl)pyridine
DM6S28U HS Investigative
DM6S28U SN 3-(5-((methylthio)methyl)furan-2-yl)pyridine; 859239-20-6; Pyridine, 3-[5-[(methylthio)methyl]-2-furanyl]-; SCHEMBL3611062; CHEMBL214990; CTK2I3857; BDBM12361; DTXSID60475412; QSLAHFFHHYZNQL-UHFFFAOYSA-N; nicotine 3-heteroaromatic analogue 15
DM6S28U DT Small molecular drug
DM6S28U PC 11993873
DM6S28U MW 205.28
DM6S28U FM C11H11NOS
DM6S28U IC InChI=1S/C11H11NOS/c1-14-8-10-4-5-11(13-10)9-3-2-6-12-7-9/h2-7H,8H2,1H3
DM6S28U CS CSCC1=CC=C(O1)C2=CN=CC=C2
DM6S28U IK QSLAHFFHHYZNQL-UHFFFAOYSA-N
DM6S28U IU 3-[5-(methylsulfanylmethyl)furan-2-yl]pyridine
DM6S28U CA CAS 859239-20-6
DM6S28U DE Discovery agent
DMTVYLM ID DMTVYLM
DMTVYLM DN 3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine
DMTVYLM HS Investigative
DMTVYLM SN CHEMBL461457; 3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine; SCHEMBL8081400; ZINC40863212
DMTVYLM DT Small molecular drug
DMTVYLM PC 25180303
DMTVYLM MW 209.29
DMTVYLM FM C15H15N
DMTVYLM IC InChI=1S/C15H15N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h3,6-11H,1-2,4-5H2
DMTVYLM CS C1CCC2=C(C1)C=CC(=C2)C3=CN=CC=C3
DMTVYLM IK WGNJGUOGXBTDMP-UHFFFAOYSA-N
DMTVYLM IU 3-(5,6,7,8-tetrahydronaphthalen-2-yl)pyridine
DMTVYLM CA CAS 1092522-77-4
DMTVYLM DE Discovery agent
DMOUNPH ID DMOUNPH
DMOUNPH DN 3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine
DMOUNPH HS Investigative
DMOUNPH SN Pyridine, 3-[5-(1,3-dithiolan-2-yl)-2-furanyl]-; 859239-21-7; 3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine; 3-[5-(1,3-dithiolan-2-yl)furan-2-yl]pyridine; CHEMBL215174; SCHEMBL3608709; CTK2I3856; BDBM12362; DTXSID40475410; nicotine 3-heteroaromatic analogue 17
DMOUNPH DT Small molecular drug
DMOUNPH PC 11993867
DMOUNPH MW 249.4
DMOUNPH FM C12H11NOS2
DMOUNPH IC InChI=1S/C12H11NOS2/c1-2-9(8-13-5-1)10-3-4-11(14-10)12-15-6-7-16-12/h1-5,8,12H,6-7H2
DMOUNPH CS C1CSC(S1)C2=CC=C(O2)C3=CN=CC=C3
DMOUNPH IK UITMTMQMFFBLFB-UHFFFAOYSA-N
DMOUNPH IU 3-[5-(1,3-dithiolan-2-yl)furan-2-yl]pyridine
DMOUNPH CA CAS 859239-21-7
DMOUNPH DE Discovery agent
DMUIXNS ID DMUIXNS
DMUIXNS DN 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine
DMUIXNS HS Investigative
DMUIXNS SN SCHEMBL4508450; CHEMBL196328; BDBM8911; Pyridine-substituted naphthalene 10; ZINC13674462; 3-(5-bromo-6-methoxy-2-naphthyl)pyridine
DMUIXNS DT Small molecular drug
DMUIXNS PC 11616637
DMUIXNS MW 314.18
DMUIXNS FM C16H12BrNO
DMUIXNS IC InChI=1S/C16H12BrNO/c1-19-15-7-5-12-9-11(4-6-14(12)16(15)17)13-3-2-8-18-10-13/h2-10H,1H3
DMUIXNS CS COC1=C(C2=C(C=C1)C=C(C=C2)C3=CN=CC=C3)Br
DMUIXNS IK ZVOWEWSHEFYCIY-UHFFFAOYSA-N
DMUIXNS IU 3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine
DMUIXNS DE Discovery agent
DMM4HF8 ID DMM4HF8
DMM4HF8 DN 3'-(5-Chloro-2-thienyl)biphenyl-3-ol
DMM4HF8 HS Investigative
DMM4HF8 SN CHEMBL1097014; BDBM50318419
DMM4HF8 DT Small molecular drug
DMM4HF8 PC 46844318
DMM4HF8 MW 286.8
DMM4HF8 FM C16H11ClOS
DMM4HF8 IC InChI=1S/C16H11ClOS/c17-16-8-7-15(19-16)13-5-1-3-11(9-13)12-4-2-6-14(18)10-12/h1-10,18H
DMM4HF8 CS C1=CC(=CC(=C1)C2=CC=C(S2)Cl)C3=CC(=CC=C3)O
DMM4HF8 IK IBTNRYGKAUWUJS-UHFFFAOYSA-N
DMM4HF8 IU 3-[3-(5-chlorothiophen-2-yl)phenyl]phenol
DMM4HF8 DE Discovery agent
DM67DVU ID DM67DVU
DM67DVU DN 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine
DM67DVU HS Investigative
DM67DVU SN CHEMBL197576; BDBM8910; SCHEMBL4509209; Pyridine-substituted naphthalene 9; ZINC13674461; 3-(5-chloro-6-methoxy-2-naphthyl)pyridine
DM67DVU DT Small molecular drug
DM67DVU PC 11529133
DM67DVU MW 269.72
DM67DVU FM C16H12ClNO
DM67DVU IC InChI=1S/C16H12ClNO/c1-19-15-7-5-12-9-11(4-6-14(12)16(15)17)13-3-2-8-18-10-13/h2-10H,1H3
DM67DVU CS COC1=C(C2=C(C=C1)C=C(C=C2)C3=CN=CC=C3)Cl
DM67DVU IK BMTHOHYTXCPKJC-UHFFFAOYSA-N
DM67DVU IU 3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine
DM67DVU DE Discovery agent
DMPRBLH ID DMPRBLH
DMPRBLH DN 3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DMPRBLH HS Investigative
DMPRBLH DT Small molecular drug
DMPRBLH PC 135522274
DMPRBLH MW 243.21
DMPRBLH FM C13H9NO4
DMPRBLH IC InChI=1S/C13H9NO4/c15-7-4-5-11-9(6-7)14-13(18-11)8-2-1-3-10(16)12(8)17/h1-6,15-17H
DMPRBLH CS C1=CC(=C(C(=C1)O)O)C2=NC3=C(O2)C=CC(=C3)O
DMPRBLH IK XVMUZRUUMXAORF-UHFFFAOYSA-N
DMPRBLH IU 3-(5-hydroxy-1,3-benzoxazol-2-yl)benzene-1,2-diol
DMPRBLH DE Discovery agent
DMTJXOU ID DMTJXOU
DMTJXOU DN 3-(5-methoxy-1H-inden-2-yl)pyridine
DMTJXOU HS Investigative
DMTJXOU SN 3-(5-methoxy-1H-inden-2-yl)pyridine; indene 3; AC1O70H7; CHEMBL206300; BDBM8890
DMTJXOU DT Small molecular drug
DMTJXOU PC 6540048
DMTJXOU MW 223.27
DMTJXOU FM C15H13NO
DMTJXOU IC InChI=1S/C15H13NO/c1-17-15-5-4-11-7-13(8-14(11)9-15)12-3-2-6-16-10-12/h2-6,8-10H,7H2,1H3
DMTJXOU CS COC1=CC2=C(CC(=C2)C3=CN=CC=C3)C=C1
DMTJXOU IK KPJYOCDWGFDTFR-UHFFFAOYSA-N
DMTJXOU IU 3-(5-methoxy-1H-inden-2-yl)pyridine
DMTJXOU DE Discovery agent
DMXLVG6 ID DMXLVG6
DMXLVG6 DN 3-(5-methoxy-1H-indol-3-yl)propanoic acid
DMXLVG6 HS Investigative
DMXLVG6 SN 3-(5-methoxy-1H-indol-3-yl)propanoic acid; 39547-16-5; 3-(5-Methoxy-1H-indol-3-yl)-propionic acid; 1H-Indole-3-propanoic acid, 5-methoxy-; 3-(5-methoxyindol-3-yl)propanoic acid; CBMicro_030931; ChemDiv2_000435; AC1L48GT; Oprea1_046476; SCHEMBL3024961; CTK1C3093; 5-methoxyindole-3-propionic acid; ZLSZCJIWILJKMR-UHFFFAOYSA-N; MolPort-002-085-835; ZINC195148; HMS3604K06; HMS1370D17; 2429AE; STK984200; SBB028111; AKOS000300418; MCULE-1797370196; DB07723; CCG-108176; DS-3311; AK403360; SC-43672; BIM-0030775.P001; TR-055403; AX8188175
DMXLVG6 DT Small molecular drug
DMXLVG6 PC 181137
DMXLVG6 MW 219.24
DMXLVG6 FM C12H13NO3
DMXLVG6 IC InChI=1S/C12H13NO3/c1-16-9-3-4-11-10(6-9)8(7-13-11)2-5-12(14)15/h3-4,6-7,13H,2,5H2,1H3,(H,14,15)
DMXLVG6 CS COC1=CC2=C(C=C1)NC=C2CCC(=O)O
DMXLVG6 IK ZLSZCJIWILJKMR-UHFFFAOYSA-N
DMXLVG6 IU 3-(5-methoxy-1H-indol-3-yl)propanoic acid
DMXLVG6 CA CAS 39547-16-5
DMXLVG6 DE Discovery agent
DM5NIE7 ID DM5NIE7
DM5NIE7 DN 3-(5-phenyl-2-thienyl)phenol
DM5NIE7 HS Investigative
DM5NIE7 SN SCHEMBL1180118; CHEMBL457438; BDBM25847; 3-(5-phenylthiophen-2-yl)phenol; ZINC40847377; hydroxyphenyl substituted thiophene, 19
DM5NIE7 DT Small molecular drug
DM5NIE7 PC 25093384
DM5NIE7 MW 252.3
DM5NIE7 FM C16H12OS
DM5NIE7 IC InChI=1S/C16H12OS/c17-14-8-4-7-13(11-14)16-10-9-15(18-16)12-5-2-1-3-6-12/h1-11,17H
DM5NIE7 CS C1=CC=C(C=C1)C2=CC=C(S2)C3=CC(=CC=C3)O
DM5NIE7 IK DVGFXRZFDOGHJL-UHFFFAOYSA-N
DM5NIE7 IU 3-(5-phenylthiophen-2-yl)phenol
DM5NIE7 DE Discovery agent
DMPBLM2 ID DMPBLM2
DMPBLM2 DN 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile
DMPBLM2 HS Investigative
DMPBLM2 SN 3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile; GW627834A; 2-Anilino-5-aryloxazole 10; AC1NS7R5; BDBM5849; CHEMBL192413; NCGC00241897-01; AB01092081-01; N-(3-Cyanophenyl)-5-phenyl-1,3-oxazol-2-amine Hydrochloride
DMPBLM2 DT Small molecular drug
DMPBLM2 PC 5329845
DMPBLM2 MW 261.279
DMPBLM2 FM C16H11N3O
DMPBLM2 IC InChI=1S/C16H11N3O/c17-10-12-5-4-8-14(9-12)19-16-18-11-15(20-16)13-6-2-1-3-7-13/h1-9,11H,(H,18,19)
DMPBLM2 CS C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=CC(=C3)C#N
DMPBLM2 IK VZMXZHOJAGFSNF-UHFFFAOYSA-N
DMPBLM2 IU 3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzonitrile
DMPBLM2 DE Discovery agent
DMM1CKZ ID DMM1CKZ
DMM1CKZ DN 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile
DMM1CKZ HS Investigative
DMM1CKZ SN 507268-13-5; CHEMBL365499; 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile; 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]Benzonitrile; 3-(5-(pyridin-2-yl)-2h-tetrazol-2-yl)benzonitrile; 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile; SCHEMBL660355; CTK1G6179; DTXSID70436690; OGIBYDWBTRKAOL-UHFFFAOYSA-N; ZINC3962980; BDBM50151907; AKOS015995227; RP28801; DA-05371; DB-050669; KB-233258; FT-0760671; J-510771; 3-[5-(2-Pyridinyl)-2H-tetrazole-2-yl]benzonitrile; Benzonitrile, 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
DMM1CKZ DT Small molecular drug
DMM1CKZ PC 10198811
DMM1CKZ MW 248.24
DMM1CKZ FM C13H8N6
DMM1CKZ IC InChI=1S/C13H8N6/c14-9-10-4-3-5-11(8-10)19-17-13(16-18-19)12-6-1-2-7-15-12/h1-8H
DMM1CKZ CS C1=CC=NC(=C1)C2=NN(N=N2)C3=CC=CC(=C3)C#N
DMM1CKZ IK OGIBYDWBTRKAOL-UHFFFAOYSA-N
DMM1CKZ IU 3-(5-pyridin-2-yltetrazol-2-yl)benzonitrile
DMM1CKZ CA CAS 507268-13-5
DMM1CKZ DE Discovery agent
DM9LVR5 ID DM9LVR5
DM9LVR5 DN 3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole
DM9LVR5 HS Investigative
DM9LVR5 SN 3-(5-Thien-3-ylpyridin-3-yl)-1Hindole 3a; AC1NS6N5; SCHEMBL7506919; BDBM5318; CHEMBL327518; 3-[5-(3-Thienyl)-3-pyridinyl]-1H-indole; 3-(5-thiophen-3-ylpyridin-3-yl)-1H-indole
DM9LVR5 DT Small molecular drug
DM9LVR5 PC 5329361
DM9LVR5 MW 276.4
DM9LVR5 FM C17H12N2S
DM9LVR5 IC InChI=1S/C17H12N2S/c1-2-4-17-15(3-1)16(10-19-17)14-7-13(8-18-9-14)12-5-6-20-11-12/h1-11,19H
DM9LVR5 CS C1=CC=C2C(=C1)C(=CN2)C3=CN=CC(=C3)C4=CSC=C4
DM9LVR5 IK GDLQJKCZVIUEDN-UHFFFAOYSA-N
DM9LVR5 IU 3-(5-thiophen-3-ylpyridin-3-yl)-1H-indole
DM9LVR5 DE Discovery agent
DMADQCW ID DMADQCW
DMADQCW DN 3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol
DMADQCW HS Investigative
DMADQCW SN CHEMBL1095141
DMADQCW DT Small molecular drug
DMADQCW PC 46887133
DMADQCW MW 313.3
DMADQCW FM C21H15NO2
DMADQCW IC InChI=1S/C21H15NO2/c23-18-9-4-8-16(12-18)19-13-17(15-6-2-1-3-7-15)14-20(22-19)21-10-5-11-24-21/h1-14,23H
DMADQCW CS C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=CO3)C4=CC(=CC=C4)O
DMADQCW IK CYYONTBOQHHDLF-UHFFFAOYSA-N
DMADQCW IU 3-[6-(furan-2-yl)-4-phenylpyridin-2-yl]phenol
DMADQCW DE Discovery agent
DM8WL21 ID DM8WL21
DM8WL21 DN 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile
DM8WL21 HS Investigative
DM8WL21 SN CHEMBL1210236; 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile; BDBM50322829
DM8WL21 DT Small molecular drug
DM8WL21 PC 46894038
DM8WL21 MW 312.3
DM8WL21 FM C18H12N6
DM8WL21 IC InChI=1S/C18H12N6/c19-10-12-5-4-6-13(9-12)16-23-15-17(20-11-21-18(15)24-16)22-14-7-2-1-3-8-14/h1-9,11H,(H2,20,21,22,23,24)
DM8WL21 CS C1=CC=C(C=C1)NC2=NC=NC3=C2NC(=N3)C4=CC=CC(=C4)C#N
DM8WL21 IK JMBXPIFLNLGLKP-UHFFFAOYSA-N
DM8WL21 IU 3-(6-anilino-7H-purin-8-yl)benzonitrile
DM8WL21 DE Discovery agent
DM4DFUS ID DM4DFUS
DM4DFUS DN 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol
DM4DFUS HS Investigative
DM4DFUS SN CHEMBL101389; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol; SCHEMBL6431286; CGIFTRWAYIWEGG-UHFFFAOYSA-N; BDBM50290850
DM4DFUS DT Small molecular drug
DM4DFUS PC 22646527
DM4DFUS MW 297.3
DM4DFUS FM C17H15NO4
DM4DFUS IC InChI=1S/C17H15NO4/c1-20-16-9-13-14(10-17(16)21-2)18-7-6-15(13)22-12-5-3-4-11(19)8-12/h3-10,19H,1-2H3
DM4DFUS CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC(=C3)O
DM4DFUS IK CGIFTRWAYIWEGG-UHFFFAOYSA-N
DM4DFUS IU 3-(6,7-dimethoxyquinolin-4-yl)oxyphenol
DM4DFUS DE Discovery agent
DMAWXV6 ID DMAWXV6
DMAWXV6 DN 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine
DMAWXV6 HS Investigative
DMAWXV6 SN CHEMBL321572; 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine; SCHEMBL7478985; ZINC13859457; BDBM50290846
DMAWXV6 DT Small molecular drug
DMAWXV6 PC 22132655
DMAWXV6 MW 296.32
DMAWXV6 FM C17H16N2O3
DMAWXV6 IC InChI=1S/C17H16N2O3/c1-20-16-9-13-14(10-17(16)21-2)19-7-6-15(13)22-12-5-3-4-11(18)8-12/h3-10H,18H2,1-2H3
DMAWXV6 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC(=C3)N
DMAWXV6 IK KOTHQRYMXOUUHZ-UHFFFAOYSA-N
DMAWXV6 IU 3-(6,7-dimethoxyquinolin-4-yl)oxyaniline
DMAWXV6 DE Discovery agent
DMISL9R ID DMISL9R
DMISL9R DN 3-(6-Amino-purin-9-yl)-4-butoxy-butan-2-ol
DMISL9R HS Investigative
DMISL9R SN CHEMBL606665; ZINC13835548
DMISL9R DT Small molecular drug
DMISL9R PC 44361699
DMISL9R MW 279.34
DMISL9R FM C13H21N5O2
DMISL9R IC InChI=1S/C13H21N5O2/c1-3-4-5-20-6-10(9(2)19)18-8-17-11-12(14)15-7-16-13(11)18/h7-10,19H,3-6H2,1-2H3,(H2,14,15,16)/t9-,10?/m0/s1
DMISL9R CS CCCCOCC([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DMISL9R IK JLZPQJZPCMKWRD-RGURZIINSA-N
DMISL9R IU (2S)-3-(6-aminopurin-9-yl)-4-butoxybutan-2-ol
DMISL9R DE Discovery agent
DMMTU78 ID DMMTU78
DMMTU78 DN 3-(6-Amino-purin-9-yl)-4-phenethyloxy-butan-2-ol
DMMTU78 HS Investigative
DMMTU78 SN CHEMBL606664
DMMTU78 DT Small molecular drug
DMMTU78 PC 44361680
DMMTU78 MW 327.4
DMMTU78 FM C17H21N5O2
DMMTU78 IC InChI=1S/C17H21N5O2/c1-12(23)14(9-24-8-7-13-5-3-2-4-6-13)22-11-21-15-16(18)19-10-20-17(15)22/h2-6,10-12,14,23H,7-9H2,1H3,(H2,18,19,20)/t12-,14?/m0/s1
DMMTU78 CS C[C@@H](C(COCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMMTU78 IK AGLLOYCRAOLWDZ-NBFOIZRFSA-N
DMMTU78 IU (2S)-3-(6-aminopurin-9-yl)-4-(2-phenylethoxy)butan-2-ol
DMMTU78 DE Discovery agent
DMU08A4 ID DMU08A4
DMU08A4 DN 3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol
DMU08A4 HS Investigative
DMU08A4 SN CHEMBL43261; 3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol; SCHEMBL7454006; BDBM50070640; ZINC13835542; (2S,3R)-3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol
DMU08A4 DT Small molecular drug
DMU08A4 PC 10709134
DMU08A4 MW 297.35
DMU08A4 FM C16H19N5O
DMU08A4 IC InChI=1S/C16H19N5O/c1-10-3-5-12(6-4-10)7-13(11(2)22)21-9-20-14-15(17)18-8-19-16(14)21/h3-6,8-9,11,13,22H,7H2,1-2H3,(H2,17,18,19)/t11-,13+/m0/s1
DMU08A4 CS CC1=CC=C(C=C1)C[C@H]([C@H](C)O)N2C=NC3=C(N=CN=C32)N
DMU08A4 IK BHZLBHHOPOAOSL-WCQYABFASA-N
DMU08A4 IU (2S,3R)-3-(6-aminopurin-9-yl)-4-(4-methylphenyl)butan-2-ol
DMU08A4 DE Discovery agent
DMHXI21 ID DMHXI21
DMHXI21 DN 3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol
DMHXI21 HS Investigative
DMHXI21 SN CHEMBL418074; 3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol; SCHEMBL7455950; ZINC13835543; BDBM50070643; (2S,3R)-3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol
DMHXI21 DT Small molecular drug
DMHXI21 PC 10567019
DMHXI21 MW 311.4
DMHXI21 FM C17H21N5O
DMHXI21 IC InChI=1S/C17H21N5O/c1-11-4-3-5-13(8-11)6-7-14(12(2)23)22-10-21-15-16(18)19-9-20-17(15)22/h3-5,8-10,12,14,23H,6-7H2,1-2H3,(H2,18,19,20)/t12-,14+/m0/s1
DMHXI21 CS CC1=CC(=CC=C1)CC[C@H]([C@H](C)O)N2C=NC3=C(N=CN=C32)N
DMHXI21 IK VVISVMDMFZVYMH-GXTWGEPZSA-N
DMHXI21 IU (2S,3R)-3-(6-aminopurin-9-yl)-5-(3-methylphenyl)pentan-2-ol
DMHXI21 DE Discovery agent
DMYIZBK ID DMYIZBK
DMYIZBK DN 3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol
DMYIZBK HS Investigative
DMYIZBK SN CHEMBL42063; 3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol; SCHEMBL7458391; BDBM50070641; (2S,3R)-3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol
DMYIZBK DT Small molecular drug
DMYIZBK PC 9862110
DMYIZBK MW 325.4
DMYIZBK FM C18H23N5O
DMYIZBK IC InChI=1S/C18H23N5O/c1-12-6-3-4-7-14(12)8-5-9-15(13(2)24)23-11-22-16-17(19)20-10-21-18(16)23/h3-4,6-7,10-11,13,15,24H,5,8-9H2,1-2H3,(H2,19,20,21)/t13-,15+/m0/s1
DMYIZBK CS CC1=CC=CC=C1CCC[C@H]([C@H](C)O)N2C=NC3=C(N=CN=C32)N
DMYIZBK IK GLTLCSYYROAISP-DZGCQCFKSA-N
DMYIZBK IU (2S,3R)-3-(6-aminopurin-9-yl)-6-(2-methylphenyl)hexan-2-ol
DMYIZBK DE Discovery agent
DMZT8QX ID DMZT8QX
DMZT8QX DN 3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol
DMZT8QX HS Investigative
DMZT8QX SN CHEMBL295417; 3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol; SCHEMBL7459663; ZINC13835544; BDBM50070642; (2S,3R)-3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol
DMZT8QX DT Small molecular drug
DMZT8QX PC 10543066
DMZT8QX MW 311.4
DMZT8QX FM C17H21N5O
DMZT8QX IC InChI=1S/C17H21N5O/c1-12(23)14(9-5-8-13-6-3-2-4-7-13)22-11-21-15-16(18)19-10-20-17(15)22/h2-4,6-7,10-12,14,23H,5,8-9H2,1H3,(H2,18,19,20)/t12-,14+/m0/s1
DMZT8QX CS C[C@@H]([C@@H](CCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMZT8QX IK KTRFRUCNFHFSAF-GXTWGEPZSA-N
DMZT8QX IU (2S,3R)-3-(6-aminopurin-9-yl)-6-phenylhexan-2-ol
DMZT8QX DE Discovery agent
DMUYELJ ID DMUYELJ
DMUYELJ DN 3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol
DMUYELJ HS Investigative
DMUYELJ SN CHEMBL295003; 3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol; SCHEMBL7458479; BDBM50070646; ZINC13835546; (2S,3R)-3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol
DMUYELJ DT Small molecular drug
DMUYELJ PC 10404061
DMUYELJ MW 325.4
DMUYELJ FM C18H23N5O
DMUYELJ IC InChI=1S/C18H23N5O/c1-13(24)15(10-6-5-9-14-7-3-2-4-8-14)23-12-22-16-17(19)20-11-21-18(16)23/h2-4,7-8,11-13,15,24H,5-6,9-10H2,1H3,(H2,19,20,21)/t13-,15+/m0/s1
DMUYELJ CS C[C@@H]([C@@H](CCCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMUYELJ IK HWARBJPXURXCIU-DZGCQCFKSA-N
DMUYELJ IU (2S,3R)-3-(6-aminopurin-9-yl)-7-phenylheptan-2-ol
DMUYELJ DE Discovery agent
DMAIS1D ID DMAIS1D
DMAIS1D DN 3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol
DMAIS1D HS Investigative
DMAIS1D SN CHEMBL43742; 3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol; SCHEMBL7458088; ZINC13835547; BDBM50070645; (2S,3R)-3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol
DMAIS1D DT Small molecular drug
DMAIS1D PC 10593196
DMAIS1D MW 339.4
DMAIS1D FM C19H25N5O
DMAIS1D IC InChI=1S/C19H25N5O/c1-14(25)16(11-7-3-6-10-15-8-4-2-5-9-15)24-13-23-17-18(20)21-12-22-19(17)24/h2,4-5,8-9,12-14,16,25H,3,6-7,10-11H2,1H3,(H2,20,21,22)/t14-,16+/m0/s1
DMAIS1D CS C[C@@H]([C@@H](CCCCCC1=CC=CC=C1)N2C=NC3=C(N=CN=C32)N)O
DMAIS1D IK JVHQYTUGDFGNES-GOEBONIOSA-N
DMAIS1D IU (2S,3R)-3-(6-aminopurin-9-yl)-8-phenyloctan-2-ol
DMAIS1D DE Discovery agent
DM6FHWZ ID DM6FHWZ
DM6FHWZ DN 3-(6-Amino-purin-9-yl)-non-5-en-2-ol
DM6FHWZ HS Investigative
DM6FHWZ SN CHEMBL81390; 3-(6-Amino-purin-9-yl)-non-5-en-2-ol; BDBM50288072; (Z)-(2S,3R)-3-(6-Amino-purin-9-yl)-non-5-en-2-ol
DM6FHWZ DT Small molecular drug
DM6FHWZ PC 10516542
DM6FHWZ MW 275.35
DM6FHWZ FM C14H21N5O
DM6FHWZ IC InChI=1S/C14H21N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h5-6,8-11,20H,3-4,7H2,1-2H3,(H2,15,16,17)/b6-5+/t10-,11+/m0/s1
DM6FHWZ CS CCC/C=C/C[C@H]([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DM6FHWZ IK QZMKAUPEGUOLDB-PFDYWKIBSA-N
DM6FHWZ IU (E,2S,3R)-3-(6-aminopurin-9-yl)non-5-en-2-ol
DM6FHWZ DE Discovery agent
DM0YOZJ ID DM0YOZJ
DM0YOZJ DN 3-(6-Amino-purin-9-yl)-non-5-yn-2-ol
DM0YOZJ HS Investigative
DM0YOZJ SN CHEMBL311182; 3-(6-Amino-purin-9-yl)-non-5-yn-2-ol; BDBM50288071; (2S,3R)-3-(6-Amino-purin-9-yl)-non-5-yn-2-ol
DM0YOZJ DT Small molecular drug
DM0YOZJ PC 10754736
DM0YOZJ MW 273.33
DM0YOZJ FM C14H19N5O
DM0YOZJ IC InChI=1S/C14H19N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-4,7H2,1-2H3,(H2,15,16,17)/t10-,11+/m0/s1
DM0YOZJ CS CCCC#CC[C@H]([C@H](C)O)N1C=NC2=C(N=CN=C21)N
DM0YOZJ IK GXOXTRCBYSFJKS-WDEREUQCSA-N
DM0YOZJ IU (2S,3R)-3-(6-aminopurin-9-yl)non-5-yn-2-ol
DM0YOZJ DE Discovery agent
DM63BI9 ID DM63BI9
DM63BI9 DN 3-(6-Bromo-naphthalen-2-yl)-pyridine
DM63BI9 HS Investigative
DM63BI9 SN 3-(6-bromonaphthalen-2-yl)pyridine; BDBM8907; SCHEMBL4499954; CHEMBL193534; 3-(6-bromo-2-naphthyl)pyridine; Pyridine-substituted naphthalene 4
DM63BI9 DT Small molecular drug
DM63BI9 PC 11558270
DM63BI9 MW 284.15
DM63BI9 FM C15H10BrN
DM63BI9 IC InChI=1S/C15H10BrN/c16-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-17-10-14/h1-10H
DM63BI9 CS C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)Br
DM63BI9 IK MAIJPIYXFRLIEK-UHFFFAOYSA-N
DM63BI9 IU 3-(6-bromonaphthalen-2-yl)pyridine
DM63BI9 DE Discovery agent
DMUQ0WI ID DMUQ0WI
DMUQ0WI DN 3-(6-Ethoxy-naphthalen-2-yl)-pyridine
DMUQ0WI HS Investigative
DMUQ0WI SN 3-(6-ethoxynaphthalen-2-yl)pyridine; SCHEMBL4511117; BDBM8908; CHEMBL193343; 3-(6-ethoxy-2-naphthyl)pyridine; Pyridine-substituted naphthalene 5
DMUQ0WI DT Small molecular drug
DMUQ0WI PC 11557864
DMUQ0WI MW 249.31
DMUQ0WI FM C17H15NO
DMUQ0WI IC InChI=1S/C17H15NO/c1-2-19-17-8-7-13-10-14(5-6-15(13)11-17)16-4-3-9-18-12-16/h3-12H,2H2,1H3
DMUQ0WI CS CCOC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC=C3
DMUQ0WI IK CQLHDOYGDGBDQA-UHFFFAOYSA-N
DMUQ0WI IU 3-(6-ethoxynaphthalen-2-yl)pyridine
DMUQ0WI DE Discovery agent
DMHJ0SV ID DMHJ0SV
DMHJ0SV DN 3-(6-fluoroquinazolin-4-ylamino)benzonitrile
DMHJ0SV HS Investigative
DMHJ0SV SN CHEMBL1080128; 3-(6-fluoroquinazolin-4-ylamino)benzonitrile; BDBM50311855
DMHJ0SV DT Small molecular drug
DMHJ0SV PC 46879811
DMHJ0SV MW 264.26
DMHJ0SV FM C15H9FN4
DMHJ0SV IC InChI=1S/C15H9FN4/c16-11-4-5-14-13(7-11)15(19-9-18-14)20-12-3-1-2-10(6-12)8-17/h1-7,9H,(H,18,19,20)
DMHJ0SV CS C1=CC(=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)F)C#N
DMHJ0SV IK NWRSWZMZACUZPY-UHFFFAOYSA-N
DMHJ0SV IU 3-[(6-fluoroquinazolin-4-yl)amino]benzonitrile
DMHJ0SV DE Discovery agent
DMTIKF7 ID DMTIKF7
DMTIKF7 DN 3-(6-hydroxy-2-naphthyl)benzoic acid
DMTIKF7 HS Investigative
DMTIKF7 SN SCHEMBL3020903
DMTIKF7 DT Small molecular drug
DMTIKF7 PC 24827299
DMTIKF7 MW 264.27
DMTIKF7 FM C17H12O3
DMTIKF7 IC InChI=1S/C17H12O3/c18-16-7-6-13-8-12(4-5-14(13)10-16)11-2-1-3-15(9-11)17(19)20/h1-10,18H,(H,19,20)
DMTIKF7 CS C1=CC(=CC(=C1)C(=O)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMTIKF7 IK QKQDCOMEKVAYFS-UHFFFAOYSA-N
DMTIKF7 IU 3-(6-hydroxynaphthalen-2-yl)benzoic acid
DMTIKF7 DE Discovery agent
DM5H9QT ID DM5H9QT
DM5H9QT DN 3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM5H9QT HS Investigative
DM5H9QT DT Small molecular drug
DM5H9QT PC 135430305
DM5H9QT MW 243.21
DM5H9QT FM C13H9NO4
DM5H9QT IC InChI=1S/C13H9NO4/c15-7-4-5-9-11(6-7)18-13(14-9)8-2-1-3-10(16)12(8)17/h1-6,15-17H
DM5H9QT CS C1=CC(=C(C(=C1)O)O)C2=NC3=C(O2)C=C(C=C3)O
DM5H9QT IK MRXLNZKXLFWEGB-UHFFFAOYSA-N
DM5H9QT IU 3-(6-hydroxy-1,3-benzoxazol-2-yl)benzene-1,2-diol
DM5H9QT DE Discovery agent
DMAJHXO ID DMAJHXO
DMAJHXO DN 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO HS Investigative
DMAJHXO SN 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine; CHEMBL206351; Dihydronaphthalene 4; AC1O70H9; SCHEMBL4504105; BDBM8891
DMAJHXO DT Small molecular drug
DMAJHXO PC 6540049
DMAJHXO MW 237.3
DMAJHXO FM C16H15NO
DMAJHXO IC InChI=1S/C16H15NO/c1-18-16-7-6-12-9-13(4-5-14(12)10-16)15-3-2-8-17-11-15/h2-3,6-11H,4-5H2,1H3
DMAJHXO CS COC1=CC2=C(C=C1)C=C(CC2)C3=CN=CC=C3
DMAJHXO IK WUTGTMFGCHNUET-UHFFFAOYSA-N
DMAJHXO IU 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DMAJHXO DE Discovery agent
DMISLV4 ID DMISLV4
DMISLV4 DN 3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine
DMISLV4 HS Investigative
DMISLV4 SN CHEMBL499871; 3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine; BDBM50272194
DMISLV4 DT Small molecular drug
DMISLV4 PC 44586852
DMISLV4 MW 249.31
DMISLV4 FM C17H15NO
DMISLV4 IC InChI=1S/C17H15NO/c1-12-8-15-9-16(19-2)6-5-13(15)10-17(12)14-4-3-7-18-11-14/h3-11H,1-2H3
DMISLV4 CS CC1=CC2=C(C=CC(=C2)OC)C=C1C3=CN=CC=C3
DMISLV4 IK YGFDDQOJFLQBKT-UHFFFAOYSA-N
DMISLV4 IU 3-(6-methoxy-3-methylnaphthalen-2-yl)pyridine
DMISLV4 DE Discovery agent
DM0GXFB ID DM0GXFB
DM0GXFB DN 3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine
DM0GXFB HS Investigative
DM0GXFB SN CHEMBL500664; 3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine; ZINC40976977
DM0GXFB DT Small molecular drug
DM0GXFB PC 25034430
DM0GXFB MW 249.31
DM0GXFB FM C17H15NO
DM0GXFB IC InChI=1S/C17H15NO/c1-12-7-8-18-11-17(12)15-4-3-14-10-16(19-2)6-5-13(14)9-15/h3-11H,1-2H3
DM0GXFB CS CC1=C(C=NC=C1)C2=CC3=C(C=C2)C=C(C=C3)OC
DM0GXFB IK DBZOUPBQQHJUKL-UHFFFAOYSA-N
DM0GXFB IU 3-(6-methoxynaphthalen-2-yl)-4-methylpyridine
DM0GXFB DE Discovery agent
DM704R5 ID DM704R5
DM704R5 DN 3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5 HS Investigative
DM704R5 SN CHEMBL500393; 3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5 DT Small molecular drug
DM704R5 PC 25034426
DM704R5 MW 311.4
DM704R5 FM C22H17NO
DM704R5 IC InChI=1S/C22H17NO/c1-24-22-10-9-17-11-18(7-8-19(17)13-22)21-12-20(14-23-15-21)16-5-3-2-4-6-16/h2-15H,1H3
DM704R5 CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC(=C3)C4=CC=CC=C4
DM704R5 IK SQTORKYTOSOTPB-UHFFFAOYSA-N
DM704R5 IU 3-(6-methoxynaphthalen-2-yl)-5-phenylpyridine
DM704R5 DE Discovery agent
DMN75RD ID DMN75RD
DMN75RD DN 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine
DMN75RD HS Investigative
DMN75RD SN CHEMBL453169; 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine; ZINC40835651; BDBM50272248
DMN75RD DT Small molecular drug
DMN75RD PC 25034431
DMN75RD MW 250.29
DMN75RD FM C16H14N2O
DMN75RD IC InChI=1S/C16H14N2O/c1-19-14-5-4-11-8-13(3-2-12(11)9-14)15-10-18-7-6-16(15)17/h2-10H,1H3,(H2,17,18)
DMN75RD CS COC1=CC2=C(C=C1)C=C(C=C2)C3=C(C=CN=C3)N
DMN75RD IK WAIWXNYKRBBVSH-UHFFFAOYSA-N
DMN75RD IU 3-(6-methoxynaphthalen-2-yl)pyridin-4-amine
DMN75RD DE Discovery agent
DMYRJAB ID DMYRJAB
DMYRJAB DN 3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB HS Investigative
DMYRJAB SN CHEMBL362968; 3-(6-methoxynaphthalen-2-yl)pyridine; BDBM8905; SCHEMBL4500403; Pyridine-substituted naphthalene 2; 3-(6-methoxy-2-naphthyl)pyridine
DMYRJAB DT Small molecular drug
DMYRJAB PC 11506923
DMYRJAB MW 235.28
DMYRJAB FM C16H13NO
DMYRJAB IC InChI=1S/C16H13NO/c1-18-16-7-6-12-9-13(4-5-14(12)10-16)15-3-2-8-17-11-15/h2-11H,1H3
DMYRJAB CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC=C3
DMYRJAB IK DCVWYSMRLGKIJB-UHFFFAOYSA-N
DMYRJAB IU 3-(6-methoxynaphthalen-2-yl)pyridine
DMYRJAB DE Discovery agent
DMS9DPO ID DMS9DPO
DMS9DPO DN 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde
DMS9DPO HS Investigative
DMS9DPO SN CHEMBL223437; 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde; SCHEMBL3535188
DMS9DPO DT Small molecular drug
DMS9DPO PC 16203472
DMS9DPO MW 285.29
DMS9DPO FM C16H15NO4
DMS9DPO IC InChI=1S/C16H15NO4/c18-11-12-2-1-3-13(8-12)15-9-14(19)10-16(21-15)17-4-6-20-7-5-17/h1-3,8-11H,4-7H2
DMS9DPO CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC(=C3)C=O
DMS9DPO IK JXTKUJIDCHLXDV-UHFFFAOYSA-N
DMS9DPO IU 3-(6-morpholin-4-yl-4-oxopyran-2-yl)benzaldehyde
DMS9DPO DE Discovery agent
DM2VNLK ID DM2VNLK
DM2VNLK DN 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid
DM2VNLK HS Investigative
DM2VNLK SN CHEMBL222180; 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid; SCHEMBL13435565
DM2VNLK DT Small molecular drug
DM2VNLK PC 16203474
DM2VNLK MW 301.29
DM2VNLK FM C16H15NO5
DM2VNLK IC InChI=1S/C16H15NO5/c18-13-9-14(11-2-1-3-12(8-11)16(19)20)22-15(10-13)17-4-6-21-7-5-17/h1-3,8-10H,4-7H2,(H,19,20)
DM2VNLK CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC(=CC=C3)C(=O)O
DM2VNLK IK DIBMCWVULMJJDM-UHFFFAOYSA-N
DM2VNLK IU 3-(6-morpholin-4-yl-4-oxopyran-2-yl)benzoic acid
DM2VNLK DE Discovery agent
DM2J63V ID DM2J63V
DM2J63V DN 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM2J63V HS Investigative
DM2J63V SN CHEMBL223034; 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM2J63V DT Small molecular drug
DM2J63V PC 16203599
DM2J63V MW 282.29
DM2J63V FM C16H14N2O3
DM2J63V IC InChI=1S/C16H14N2O3/c17-11-12-2-1-3-13(8-12)15-9-14(19)10-16(21-15)18-4-6-20-7-5-18/h1-3,8-10H,4-7H2
DM2J63V CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=CC(=C3)C#N
DM2J63V IK IBXUISQIAHYEGD-UHFFFAOYSA-N
DM2J63V IU 3-(6-morpholin-4-yl-4-oxopyran-2-yl)benzonitrile
DM2J63V DE Discovery agent
DMS2OY9 ID DMS2OY9
DMS2OY9 DN 3-(6-morpholino-9H-purin-2-yl)phenol
DMS2OY9 HS Investigative
DMS2OY9 SN 3-(6-morpholino-9H-purin-2-yl)phenol; CHEMBL593515; SCHEMBL4443377; FUDQNOGEMXSUSQ-UHFFFAOYSA-N
DMS2OY9 DT Small molecular drug
DMS2OY9 PC 16049458
DMS2OY9 MW 297.31
DMS2OY9 FM C15H15N5O2
DMS2OY9 IC InChI=1S/C15H15N5O2/c21-11-3-1-2-10(8-11)13-18-14-12(16-9-17-14)15(19-13)20-4-6-22-7-5-20/h1-3,8-9,21H,4-7H2,(H,16,17,18,19)
DMS2OY9 CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC(=CC=C4)O
DMS2OY9 IK FUDQNOGEMXSUSQ-UHFFFAOYSA-N
DMS2OY9 IU 3-(6-morpholin-4-yl-7H-purin-2-yl)phenol
DMS2OY9 DE Discovery agent
DM8ZUBY ID DM8ZUBY
DM8ZUBY DN 3-(6-phenyl-2,4'-bipyridin-4-yl)phenol
DM8ZUBY HS Investigative
DM8ZUBY SN CHEMBL1094095
DM8ZUBY DT Small molecular drug
DM8ZUBY PC 46887284
DM8ZUBY MW 324.4
DM8ZUBY FM C22H16N2O
DM8ZUBY IC InChI=1S/C22H16N2O/c25-20-8-4-7-18(13-20)19-14-21(16-5-2-1-3-6-16)24-22(15-19)17-9-11-23-12-10-17/h1-15,25H
DM8ZUBY CS C1=CC=C(C=C1)C2=NC(=CC(=C2)C3=CC(=CC=C3)O)C4=CC=NC=C4
DM8ZUBY IK DFVGOMXQSFFZEA-UHFFFAOYSA-N
DM8ZUBY IU 3-(2-phenyl-6-pyridin-4-ylpyridin-4-yl)phenol
DM8ZUBY DE Discovery agent
DMZ53N4 ID DMZ53N4
DMZ53N4 DN 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4 HS Investigative
DMZ53N4 SN CHEMBL235837; 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4 DT Small molecular drug
DMZ53N4 PC 44434734
DMZ53N4 MW 245.28
DMZ53N4 FM C16H11N3
DMZ53N4 IC InChI=1S/C16H11N3/c1-11-5-6-13-7-8-15(19-16(13)18-11)14-4-2-3-12(9-14)10-17/h2-9H,1H3
DMZ53N4 CS CC1=NC2=C(C=C1)C=CC(=N2)C3=CC=CC(=C3)C#N
DMZ53N4 IK LAVFGKYBDJIZSF-UHFFFAOYSA-N
DMZ53N4 IU 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile
DMZ53N4 DE Discovery agent
DMDIQ7H ID DMDIQ7H
DMDIQ7H DN 3-(9-Acridinylamino)-5-(hydroxymethyl)aniline (AHMA)
DMDIQ7H HS Investigative
DMDIQ7H SN CHEMBL321473; NSC666097; 3-(9-acridinylamino)-5-(hydroxymethyl)aniline; 154310-42-6; [3-(acridin-9-ylamino)-5-aminophenyl]methanol; AC1Q7C6S; AC1L8FG4; SCHEMBL1865418; CTK0E7866; DTXSID30327555; GZHHMAFXYHPHBO-UHFFFAOYSA-N; ZINC3799478; AKOS030584742; NCI60_022917; 3-(9-acridinylamino)-5-hydroxymethylaniline; 3-(acridin-9-yl)amino-5-hydroxymethylaniline; Benzenemethanol, 3-(9-acridinylamino)-5-amino-; [3-(acridin-9-ylamino)-5-amino-phenyl]methanol
DMDIQ7H DT Small molecular drug
DMDIQ7H PC 380482
DMDIQ7H MW 315.4
DMDIQ7H FM C20H17N3O
DMDIQ7H IC InChI=1S/C20H17N3O/c21-14-9-13(12-24)10-15(11-14)22-20-16-5-1-3-7-18(16)23-19-8-4-2-6-17(19)20/h1-11,24H,12,21H2,(H,22,23)
DMDIQ7H CS C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)NC4=CC(=CC(=C4)N)CO
DMDIQ7H IK GZHHMAFXYHPHBO-UHFFFAOYSA-N
DMDIQ7H IU [3-(acridin-9-ylamino)-5-aminophenyl]methanol
DMDIQ7H CA CAS 154310-42-6
DMDIQ7H DE Discovery agent
DM5497S ID DM5497S
DM5497S DN 3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM5497S HS Investigative
DM5497S SN CHEMBL382876; 3-aminomethyl-4-furan-2-yl-butyric acid; 311803-95-9; 3-(aminomethyl)-4-(furan-2-yl)butanoic acid; SCHEMBL6375245; BDBM50171795
DM5497S DT Small molecular drug
DM5497S PC 10130245
DM5497S MW 183.2
DM5497S FM C9H13NO3
DM5497S IC InChI=1S/C9H13NO3/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)
DM5497S CS C1=COC(=C1)CC(CC(=O)O)CN
DM5497S IK JASKMEUWYOXVFB-UHFFFAOYSA-N
DM5497S IU 3-(aminomethyl)-4-(furan-2-yl)butanoic acid
DM5497S DE Discovery agent
DMG3FPJ ID DMG3FPJ
DMG3FPJ DN 3-(aminomethyl)-4-(furan-3-yl)butanoic acid
DMG3FPJ HS Investigative
DMG3FPJ SN CHEMBL381742; 3-aminomethyl-4-(furan-3-yl)butyric acid; 311804-13-4; 3-(aminomethyl)-4-(furan-3-yl)butanoic acid; SCHEMBL6376423
DMG3FPJ DT Small molecular drug
DMG3FPJ PC 9794064
DMG3FPJ MW 183.2
DMG3FPJ FM C9H13NO3
DMG3FPJ IC InChI=1S/C9H13NO3/c10-5-8(4-9(11)12)3-7-1-2-13-6-7/h1-2,6,8H,3-5,10H2,(H,11,12)
DMG3FPJ CS C1=COC=C1CC(CC(=O)O)CN
DMG3FPJ IK CZUZSIQSURACNQ-UHFFFAOYSA-N
DMG3FPJ IU 3-(aminomethyl)-4-(furan-3-yl)butanoic acid
DMG3FPJ DE Discovery agent
DMT72FB ID DMT72FB
DMT72FB DN 3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid
DMT72FB HS Investigative
DMT72FB SN CHEMBL208302; 3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid; SCHEMBL6377686; BDBM50171789
DMT72FB DT Small molecular drug
DMT72FB PC 10198102
DMT72FB MW 199.27
DMT72FB FM C9H13NO2S
DMT72FB IC InChI=1S/C9H13NO2S/c10-6-7(5-9(11)12)4-8-2-1-3-13-8/h1-3,7H,4-6,10H2,(H,11,12)
DMT72FB CS C1=CSC(=C1)CC(CC(=O)O)CN
DMT72FB IK BSTBHLRENZEVEM-UHFFFAOYSA-N
DMT72FB IU 3-(aminomethyl)-4-thiophen-2-ylbutanoic acid
DMT72FB DE Discovery agent
DMWO1Z7 ID DMWO1Z7
DMWO1Z7 DN 3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid
DMWO1Z7 HS Investigative
DMWO1Z7 SN CHEMBL382417; 3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid; SCHEMBL6376202
DMWO1Z7 DT Small molecular drug
DMWO1Z7 PC 10198101
DMWO1Z7 MW 199.27
DMWO1Z7 FM C9H13NO2S
DMWO1Z7 IC InChI=1S/C9H13NO2S/c10-5-8(4-9(11)12)3-7-1-2-13-6-7/h1-2,6,8H,3-5,10H2,(H,11,12)
DMWO1Z7 CS C1=CSC=C1CC(CC(=O)O)CN
DMWO1Z7 IK DZFWQAKTRWBNFX-UHFFFAOYSA-N
DMWO1Z7 IU 3-(aminomethyl)-4-thiophen-3-ylbutanoic acid
DMWO1Z7 DE Discovery agent
DMPFH15 ID DMPFH15
DMPFH15 DN 3-(Aminooxy)propan-1-amine hydrochloride
DMPFH15 HS Investigative
DMPFH15 SN CHEMBL1209776
DMPFH15 DT Small molecular drug
DMPFH15 PC 49862725
DMPFH15 MW 126.58
DMPFH15 FM C3H11ClN2O
DMPFH15 IC InChI=1S/C3H10N2O.ClH/c4-2-1-3-6-5;/h1-5H2;1H
DMPFH15 CS C(CN)CON.Cl
DMPFH15 IK KJXCRFUWQRHVMV-UHFFFAOYSA-N
DMPFH15 IU O-(3-aminopropyl)hydroxylamine;hydrochloride
DMPFH15 DE Discovery agent
DM58GRA ID DM58GRA
DM58GRA DN 3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine
DM58GRA HS Investigative
DM58GRA SN CHEMBL486537; 3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine; SCHEMBL984632; VVROCSNBKQTQEO-UHFFFAOYSA-N; BDBM50275440
DM58GRA DT Small molecular drug
DM58GRA PC 44231007
DM58GRA MW 293.4
DM58GRA FM C19H19NS
DM58GRA IC InChI=1S/C19H19NS/c1-2-4-15(5-3-1)13-19(9-10-20-14-19)17-6-7-18-16(12-17)8-11-21-18/h1-8,11-12,20H,9-10,13-14H2
DM58GRA CS C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)SC=C4
DM58GRA IK VVROCSNBKQTQEO-UHFFFAOYSA-N
DM58GRA IU 3-(1-benzothiophen-5-yl)-3-benzylpyrrolidine
DM58GRA DE Discovery agent
DMPFH8U ID DMPFH8U
DMPFH8U DN 3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
DMPFH8U HS Investigative
DMPFH8U SN CHEMBL573871; 3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate
DMPFH8U DT Small molecular drug
DMPFH8U PC 44244229
DMPFH8U MW 296.32
DMPFH8U FM C17H16N2O3
DMPFH8U IC InChI=1S/C17H16N2O3/c1-2-10-18-17(20)21-13-7-5-6-12(11-13)16-19-14-8-3-4-9-15(14)22-16/h3-9,11H,2,10H2,1H3,(H,18,20)
DMPFH8U CS CCCNC(=O)OC1=CC=CC(=C1)C2=NC3=CC=CC=C3O2
DMPFH8U IK VWTFAQPOTOAJGW-UHFFFAOYSA-N
DMPFH8U IU [3-(1,3-benzoxazol-2-yl)phenyl] N-propylcarbamate
DMPFH8U DE Discovery agent
DMD4WHN ID DMD4WHN
DMD4WHN DN 3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one
DMD4WHN HS Investigative
DMD4WHN SN CHEMBL217096; 921611-01-0; 3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one; CTK3H0755; DTXSID50658813; BDBM50198243; AKOS030551987; 4-Thiazolidinone, 2-(4-chlorophenyl)-3-(phenylmethoxy)-
DMD4WHN DT Small molecular drug
DMD4WHN PC 44418147
DMD4WHN MW 319.8
DMD4WHN FM C16H14ClNO2S
DMD4WHN IC InChI=1S/C16H14ClNO2S/c17-14-8-6-13(7-9-14)16-18(15(19)11-21-16)20-10-12-4-2-1-3-5-12/h1-9,16H,10-11H2
DMD4WHN CS C1C(=O)N(C(S1)C2=CC=C(C=C2)Cl)OCC3=CC=CC=C3
DMD4WHN IK HYDHJKJHWORBLX-UHFFFAOYSA-N
DMD4WHN IU 2-(4-chlorophenyl)-3-phenylmethoxy-1,3-thiazolidin-4-one
DMD4WHN CA CAS 921611-01-0
DMD4WHN DE Discovery agent
DMDNEKR ID DMDNEKR
DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole
DMDNEKR HS Investigative
DMDNEKR SN CHEMBL87331; 3-Benzyloxy-9H-beta-carboline; SCHEMBL10641576; BDBM50001481; ZINC13728535
DMDNEKR DT Small molecular drug
DMDNEKR PC 10335601
DMDNEKR MW 274.3
DMDNEKR FM C18H14N2O
DMDNEKR IC InChI=1S/C18H14N2O/c1-2-6-13(7-3-1)12-21-18-10-15-14-8-4-5-9-16(14)20-17(15)11-19-18/h1-11,20H,12H2
DMDNEKR CS C1=CC=C(C=C1)COC2=NC=C3C(=C2)C4=CC=CC=C4N3
DMDNEKR IK ZROLETFFKMIVMZ-UHFFFAOYSA-N
DMDNEKR IU 3-phenylmethoxy-9H-pyrido[3,4-b]indole
DMDNEKR DE Discovery agent
DM35VEI ID DM35VEI
DM35VEI DN 3-(Benzyloxy)Pyridin-2-Amine
DM35VEI HS Investigative
DM35VEI SN 2-Amino-3-benzyloxypyridine; 24016-03-3; 3-(BENZYLOXY)PYRIDIN-2-AMINE; 3-Benzyloxy-2-pyridylamine; 2-Pyridinamine, 3-(phenylmethoxy)-; 3-benzyloxypyridin-2-amine; 3-Benzyloxy-2-aminopyridine; 2-amino-3-benzyloxy pyridine; 3-phenylmethoxypyridin-2-amine; 2-Amino-3-(benzyloxy)pyridine; 3-(phenylmethoxy)-2-pyridinamine; MFCD00006316; 3IP; 3-(phenylmethoxy)-2-pyridylamine; 2-Amino-3-benzyloxypyridine, 98.5%; 3-(benzyloxy)pyridin-2-amin; 3fty; EINECS 245-983-9; PubChem2575; 1w7h; ACMC-1COKO; AC1L3JRI; Maybridge1_001801; AC1Q52WQ
DM35VEI DT Small molecular drug
DM35VEI PC 90334
DM35VEI MW 200.24
DM35VEI FM C12H12N2O
DM35VEI IC InChI=1S/C12H12N2O/c13-12-11(7-4-8-14-12)15-9-10-5-2-1-3-6-10/h1-8H,9H2,(H2,13,14)
DM35VEI CS C1=CC=C(C=C1)COC2=C(N=CC=C2)N
DM35VEI IK NMCBWICNRJLKKM-UHFFFAOYSA-N
DM35VEI IU 3-phenylmethoxypyridin-2-amine
DM35VEI CA CAS 24016-03-3
DM35VEI DE Discovery agent
DM4GWJO ID DM4GWJO
DM4GWJO DN 3-(biphenyl-4-yl)-1-(oxazol-2-yl)propan-1-one
DM4GWJO HS Investigative
DM4GWJO SN CHEMBL261172
DM4GWJO DT Small molecular drug
DM4GWJO PC 24801394
DM4GWJO MW 277.3
DM4GWJO FM C18H15NO2
DM4GWJO IC InChI=1S/C18H15NO2/c20-17(18-19-12-13-21-18)11-8-14-6-9-16(10-7-14)15-4-2-1-3-5-15/h1-7,9-10,12-13H,8,11H2
DM4GWJO CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)C3=NC=CO3
DM4GWJO IK RKXYRLSZCAAEPX-UHFFFAOYSA-N
DM4GWJO IU 1-(1,3-oxazol-2-yl)-3-(4-phenylphenyl)propan-1-one
DM4GWJO DE Discovery agent
DM8PM0E ID DM8PM0E
DM8PM0E DN 3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one
DM8PM0E HS Investigative
DM8PM0E SN CHEMBL403288
DM8PM0E DT Small molecular drug
DM8PM0E PC 44455868
DM8PM0E MW 216.22
DM8PM0E FM C7H11F3O2S
DM8PM0E IC InChI=1S/C7H11F3O2S/c1-2-3-4-13(12)5-6(11)7(8,9)10/h2-5H2,1H3
DM8PM0E CS CCCCS(=O)CC(=O)C(F)(F)F
DM8PM0E IK MFTBLUCHUFLEGX-UHFFFAOYSA-N
DM8PM0E IU 3-butylsulfinyl-1,1,1-trifluoropropan-2-one
DM8PM0E DE Discovery agent
DM8T2OX ID DM8T2OX
DM8T2OX DN 3-(butylthio)-1,1,1-trifluoropropan-2-one
DM8T2OX HS Investigative
DM8T2OX SN 3-Butylsulfanyl-1,1,1-trifluoropropan-2-one; 34509-08-5; CHEMBL402615; 3-(butylthio)-1,1,1-trifluoropropan-2-one; AC1L4AHE; 3-butylsulfanyl-1,1,1-trifluoro-propan-2-one; CTK1C3366; DTXSID90188068; BDBM50371973
DM8T2OX DT Small molecular drug
DM8T2OX PC 182197
DM8T2OX MW 200.22
DM8T2OX FM C7H11F3OS
DM8T2OX IC InChI=1S/C7H11F3OS/c1-2-3-4-12-5-6(11)7(8,9)10/h2-5H2,1H3
DM8T2OX CS CCCCSCC(=O)C(F)(F)F
DM8T2OX IK PEBSSHOGFAFMQB-UHFFFAOYSA-N
DM8T2OX IU 3-butylsulfanyl-1,1,1-trifluoropropan-2-one
DM8T2OX CA CAS 34509-08-5
DM8T2OX DE Discovery agent
DMWJ6UD ID DMWJ6UD
DMWJ6UD DN 3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one
DMWJ6UD HS Investigative
DMWJ6UD SN CHEMBL269931
DMWJ6UD DT Small molecular drug
DMWJ6UD PC 44455842
DMWJ6UD MW 300.38
DMWJ6UD FM C13H23F3O2S
DMWJ6UD IC InChI=1S/C13H23F3O2S/c1-2-3-4-5-6-7-8-9-10-19(18)11-12(17)13(14,15)16/h2-11H2,1H3
DMWJ6UD CS CCCCCCCCCCS(=O)CC(=O)C(F)(F)F
DMWJ6UD IK PWWCYKIIRMNUAY-UHFFFAOYSA-N
DMWJ6UD IU 3-decylsulfinyl-1,1,1-trifluoropropan-2-one
DMWJ6UD DE Discovery agent
DMF27YT ID DMF27YT
DMF27YT DN 3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one
DMF27YT HS Investigative
DMF27YT SN CHEMBL272075
DMF27YT DT Small molecular drug
DMF27YT PC 44455838
DMF27YT MW 316.38
DMF27YT FM C13H23F3O3S
DMF27YT IC InChI=1S/C13H23F3O3S/c1-2-3-4-5-6-7-8-9-10-20(18,19)11-12(17)13(14,15)16/h2-11H2,1H3
DMF27YT CS CCCCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMF27YT IK QTDVUUSBCIIYIV-UHFFFAOYSA-N
DMF27YT IU 3-decylsulfonyl-1,1,1-trifluoropropan-2-one
DMF27YT DE Discovery agent
DM1Y6L8 ID DM1Y6L8
DM1Y6L8 DN 3-(decylthio)-1,1,1-trifluoropropan-2-one
DM1Y6L8 HS Investigative
DM1Y6L8 SN 3-decylsulfanyl-1,1,1-trifluoropropan-2-one; CHEMBL270374; 92682-26-3; AC1L4GC5; decyl-thio-trifluoropropanone; CTK5H1583; DTXSID50239101; BDBM50371969; 2-propanone, 3-(decylthio)-1,1,1-trifluoro-
DM1Y6L8 DT Small molecular drug
DM1Y6L8 PC 185195
DM1Y6L8 MW 284.38
DM1Y6L8 FM C13H23F3OS
DM1Y6L8 IC InChI=1S/C13H23F3OS/c1-2-3-4-5-6-7-8-9-10-18-11-12(17)13(14,15)16/h2-11H2,1H3
DM1Y6L8 CS CCCCCCCCCCSCC(=O)C(F)(F)F
DM1Y6L8 IK PGAJDYUDVRIKCP-UHFFFAOYSA-N
DM1Y6L8 IU 3-decylsulfanyl-1,1,1-trifluoropropan-2-one
DM1Y6L8 CA CAS 92682-26-3
DM1Y6L8 DE Discovery agent
DM2JBQI ID DM2JBQI
DM2JBQI DN 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one
DM2JBQI HS Investigative
DM2JBQI SN beta-Aminophenylketone, 3g; 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one; CHEMBL396086; SCHEMBL15862326; BDBM18820
DM2JBQI DT Small molecular drug
DM2JBQI PC 23635364
DM2JBQI MW 345.6
DM2JBQI FM C23H39NO
DM2JBQI IC InChI=1S/C23H39NO/c1-4-7-10-11-12-21-13-15-22(16-14-21)23(25)17-20-24(18-8-5-2)19-9-6-3/h13-16H,4-12,17-20H2,1-3H3
DM2JBQI CS CCCCCCC1=CC=C(C=C1)C(=O)CCN(CCCC)CCCC
DM2JBQI IK UMFRWWULZNWTFF-UHFFFAOYSA-N
DM2JBQI IU 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one
DM2JBQI DE Discovery agent
DMG5VMH ID DMG5VMH
DMG5VMH DN 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH HS Investigative
DMG5VMH SN CHEMBL561850; 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH DT Small molecular drug
DMG5VMH PC 21653696
DMG5VMH MW 275.4
DMG5VMH FM C18H29NO
DMG5VMH IC InChI=1S/C18H29NO/c1-4-5-6-7-8-9-16-10-12-17(13-11-16)18(20)14-15-19(2)3/h10-13H,4-9,14-15H2,1-3H3
DMG5VMH CS CCCCCCCC1=CC=C(C=C1)C(=O)CCN(C)C
DMG5VMH IK ANCSLKGKDIAGLN-UHFFFAOYSA-N
DMG5VMH IU 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one
DMG5VMH DE Discovery agent
DMJYCHG ID DMJYCHG
DMJYCHG DN 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one
DMJYCHG HS Investigative
DMJYCHG SN 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one; BAS 00130047; AC1MJHY9; beta-Aminophenylketone, 3h; CHEMBL236033; BDBM18821; ZINC3065713; NCGC00168202-01; 4'-Hexyl-beta-(dimethylamino)propiophenone
DMJYCHG DT Small molecular drug
DMJYCHG PC 3092218
DMJYCHG MW 261.399
DMJYCHG FM C17H27NO
DMJYCHG IC InChI=1S/C17H27NO/c1-4-5-6-7-8-15-9-11-16(12-10-15)17(19)13-14-18(2)3/h9-12H,4-8,13-14H2,1-3H3
DMJYCHG CS CCCCCCC1=CC=C(C=C1)C(=O)CCN(C)C
DMJYCHG IK KDBREDBLOZXWHK-UHFFFAOYSA-N
DMJYCHG IU 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one
DMJYCHG DE Discovery agent
DMM05G2 ID DMM05G2
DMM05G2 DN 3-(dimethylamino)phenyl phenylcarbamate
DMM05G2 HS Investigative
DMM05G2 SN 3-(dimethylamino)phenyl phenylcarbamate; CHEMBL1171854; AC1L2FAU; AC1Q61FO; YNGSTYODGGYXSA-UHFFFAOYSA-N; BDBM50321912; AKOS029953756; [3-(dimethylamino)phenyl] N-phenylcarbamate; phenol, 3-(dimethylamino)-, phenylcarbamate (ester)
DMM05G2 DT Small molecular drug
DMM05G2 PC 46080
DMM05G2 MW 256.3
DMM05G2 FM C15H16N2O2
DMM05G2 IC InChI=1S/C15H16N2O2/c1-17(2)13-9-6-10-14(11-13)19-15(18)16-12-7-4-3-5-8-12/h3-11H,1-2H3,(H,16,18)
DMM05G2 CS CN(C)C1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2
DMM05G2 IK YNGSTYODGGYXSA-UHFFFAOYSA-N
DMM05G2 IU [3-(dimethylamino)phenyl] N-phenylcarbamate
DMM05G2 DE Discovery agent
DM7AG6Y ID DM7AG6Y
DM7AG6Y DN 3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one
DM7AG6Y HS Investigative
DM7AG6Y SN CHEMBL273138
DM7AG6Y DT Small molecular drug
DM7AG6Y PC 44455839
DM7AG6Y MW 328.4
DM7AG6Y FM C15H27F3O2S
DM7AG6Y IC InChI=1S/C15H27F3O2S/c1-2-3-4-5-6-7-8-9-10-11-12-21(20)13-14(19)15(16,17)18/h2-13H2,1H3
DM7AG6Y CS CCCCCCCCCCCCS(=O)CC(=O)C(F)(F)F
DM7AG6Y IK HIQQJIUOQKSANW-UHFFFAOYSA-N
DM7AG6Y IU 3-dodecylsulfinyl-1,1,1-trifluoropropan-2-one
DM7AG6Y DE Discovery agent
DMPRCS0 ID DMPRCS0
DMPRCS0 DN 3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one
DMPRCS0 HS Investigative
DMPRCS0 SN CHEMBL257071
DMPRCS0 DT Small molecular drug
DMPRCS0 PC 44455814
DMPRCS0 MW 344.4
DMPRCS0 FM C15H27F3O3S
DMPRCS0 IC InChI=1S/C15H27F3O3S/c1-2-3-4-5-6-7-8-9-10-11-12-22(20,21)13-14(19)15(16,17)18/h2-13H2,1H3
DMPRCS0 CS CCCCCCCCCCCCS(=O)(=O)CC(=O)C(F)(F)F
DMPRCS0 IK JUVLUOYDHJEJIQ-UHFFFAOYSA-N
DMPRCS0 IU 3-dodecylsulfonyl-1,1,1-trifluoropropan-2-one
DMPRCS0 DE Discovery agent
DM71EMN ID DM71EMN
DM71EMN DN 3-(ethoxycarbonyl)phenylboronic acid
DM71EMN HS Investigative
DM71EMN SN 3-Ethoxycarbonylphenylboronic acid; 4334-87-6; 3-(Ethoxycarbonyl)phenylboronic acid; (3-ethoxycarbonylphenyl)boronic Acid; 3-carbethoxyphenylboronic acid; (3-(ethoxycarbonyl)phenyl)boronic acid; m-ethoxycarbonylphenylboronic acid; 3-Ethoxycarbonylbenzeneboronic acid; Ethyl 3-(Dihydroxyboranyl)Benzoate; MFCD02179444; [3-(ethoxycarbonyl)phenyl]boronic acid; 3-(ethoxycarbonyl)benzeneboronic acid; 3-(ethoxycarbonyl)phenyl boronic acid; Akos Brn-0097; BENZOIC ACID, 3-BORONO-, 1-ETHYL ESTER; PubChem6092; Phenylboronic Acid, 2
DM71EMN DT Small molecular drug
DM71EMN PC 3249312
DM71EMN MW 193.99
DM71EMN FM C9H11BO4
DM71EMN IC InChI=1S/C9H11BO4/c1-2-14-9(11)7-4-3-5-8(6-7)10(12)13/h3-6,12-13H,2H2,1H3
DM71EMN CS B(C1=CC(=CC=C1)C(=O)OCC)(O)O
DM71EMN IK REHVCPNQQBDOJJ-UHFFFAOYSA-N
DM71EMN IU (3-ethoxycarbonylphenyl)boronic acid
DM71EMN CA CAS 4334-87-6
DM71EMN DE Discovery agent
DMM2AR3 ID DMM2AR3
DMM2AR3 DN 3-(furan-3-yl)-1H-indole
DMM2AR3 HS Investigative
DMM2AR3 SN CHEMBL381132; 155440-58-7; 3-(3-furyl)indole; 3-(furan-3-yl)-1H-indole; 3-(3-Furanyl)-1H-indole; BDBM50182886
DMM2AR3 DT Small molecular drug
DMM2AR3 PC 10607518
DMM2AR3 MW 183.21
DMM2AR3 FM C12H9NO
DMM2AR3 IC InChI=1S/C12H9NO/c1-2-4-12-10(3-1)11(7-13-12)9-5-6-14-8-9/h1-8,13H
DMM2AR3 CS C1=CC=C2C(=C1)C(=CN2)C3=COC=C3
DMM2AR3 IK AFKNGDFJVAPDNN-UHFFFAOYSA-N
DMM2AR3 IU 3-(furan-3-yl)-1H-indole
DMM2AR3 DE Discovery agent
DM6L4J8 ID DM6L4J8
DM6L4J8 DN 3-(furan-3-yl)-1-methyl-1H-indole
DM6L4J8 HS Investigative
DM6L4J8 SN CHEMBL207375; 3-(furan-3-yl)-1-methyl-1H-indole; 1H-Indole, 3-(3-furanyl)-1-methyl-; BDBM50182882
DM6L4J8 DT Small molecular drug
DM6L4J8 PC 44410800
DM6L4J8 MW 197.23
DM6L4J8 FM C13H11NO
DM6L4J8 IC InChI=1S/C13H11NO/c1-14-8-12(10-6-7-15-9-10)11-4-2-3-5-13(11)14/h2-9H,1H3
DM6L4J8 CS CN1C=C(C2=CC=CC=C21)C3=COC=C3
DM6L4J8 IK UFMJKAKKDCGNEF-UHFFFAOYSA-N
DM6L4J8 IU 3-(furan-3-yl)-1-methylindole
DM6L4J8 DE Discovery agent
DMQZU9G ID DMQZU9G
DMQZU9G DN 3-(heptyloxy)benzoic acid
DMQZU9G HS Investigative
DMQZU9G SN 3-(Heptyloxy)benzoic Acid; 3-(heptyloxy)benzoate; 3-heptyloxybenzoate; 3-heptyloxybenzoic acid; 3-n-Heptyloxybenzoic acid; SCHEMBL7047692; CHEMBL1161949; FOFZVIUYGPBWLV-UHFFFAOYSA-N; ZINC14980578; AKOS005288423; AS01084; DB07355
DMQZU9G DT Small molecular drug
DMQZU9G PC 14368760
DMQZU9G MW 236.31
DMQZU9G FM C14H20O3
DMQZU9G IC InChI=1S/C14H20O3/c1-2-3-4-5-6-10-17-13-9-7-8-12(11-13)14(15)16/h7-9,11H,2-6,10H2,1H3,(H,15,16)
DMQZU9G CS CCCCCCCOC1=CC=CC(=C1)C(=O)O
DMQZU9G IK FOFZVIUYGPBWLV-UHFFFAOYSA-N
DMQZU9G IU 3-heptoxybenzoic acid
DMQZU9G DE Discovery agent
DMKHNTY ID DMKHNTY
DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY HS Investigative
DMKHNTY SN CHEMBL1269094; 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole
DMKHNTY DT Small molecular drug
DMKHNTY PC 52945666
DMKHNTY MW 264.32
DMKHNTY FM C17H16N2O
DMKHNTY IC InChI=1S/C17H16N2O/c1-2-3-4-7-10-20-17-11-14-13-8-5-6-9-15(13)19-16(14)12-18-17/h3-12,19H,2H2,1H3/b4-3+,10-7+
DMKHNTY CS CC/C=C/C=C/OC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMKHNTY IK PUUXLLSHSWLAML-YZQQHVNFSA-N
DMKHNTY IU 3-[(1E,3E)-hexa-1,3-dienoxy]-9H-pyrido[3,4-b]indole
DMKHNTY DE Discovery agent
DMM52LC ID DMM52LC
DMM52LC DN 3-(imidazolylmethyl)-4'-methoxyflavone
DMM52LC HS Investigative
DMM52LC SN CHEMBL212473; BDBM50191600; 3-(imidazolylmethyl)-4''-methoxyflavone
DMM52LC DT Small molecular drug
DMM52LC PC 11847320
DMM52LC MW 332.4
DMM52LC FM C20H16N2O3
DMM52LC IC InChI=1S/C20H16N2O3/c1-24-15-8-6-14(7-9-15)20-17(12-22-11-10-21-13-22)19(23)16-4-2-3-5-18(16)25-20/h2-11,13H,12H2,1H3
DMM52LC CS COC1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)CN4C=CN=C4
DMM52LC IK GMZSVBKZQWIFKJ-UHFFFAOYSA-N
DMM52LC IU 3-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)chromen-4-one
DMM52LC DE Discovery agent
DMX2LT5 ID DMX2LT5
DMX2LT5 DN 3-(imidazolylmethyl)-4'-nitroflavone
DMX2LT5 HS Investigative
DMX2LT5 SN CHEMBL213588; BDBM50191598; 3-(imidazolylmethyl)-4''-nitroflavone
DMX2LT5 DT Small molecular drug
DMX2LT5 PC 11847317
DMX2LT5 MW 347.3
DMX2LT5 FM C19H13N3O4
DMX2LT5 IC InChI=1S/C19H13N3O4/c23-18-15-3-1-2-4-17(15)26-19(16(18)11-21-10-9-20-12-21)13-5-7-14(8-6-13)22(24)25/h1-10,12H,11H2
DMX2LT5 CS C1=CC=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])CN4C=CN=C4
DMX2LT5 IK QRPSGPSYOIPDIF-UHFFFAOYSA-N
DMX2LT5 IU 3-(imidazol-1-ylmethyl)-2-(4-nitrophenyl)chromen-4-one
DMX2LT5 DE Discovery agent
DML63MX ID DML63MX
DML63MX DN 3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone
DML63MX HS Investigative
DML63MX SN CHEMBL212168; BDBM50191603; 3-(imidazolylmethyl)-7-methoxy-4''-nitroflavone
DML63MX DT Small molecular drug
DML63MX PC 11847169
DML63MX MW 377.3
DML63MX FM C20H15N3O5
DML63MX IC InChI=1S/C20H15N3O5/c1-27-15-6-7-16-18(10-15)28-20(13-2-4-14(5-3-13)23(25)26)17(19(16)24)11-22-9-8-21-12-22/h2-10,12H,11H2,1H3
DML63MX CS COC1=CC2=C(C=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])CN4C=CN=C4
DML63MX IK DTEZOESXMOWJRN-UHFFFAOYSA-N
DML63MX IU 3-(imidazol-1-ylmethyl)-7-methoxy-2-(4-nitrophenyl)chromen-4-one
DML63MX DE Discovery agent
DMLI7F4 ID DMLI7F4
DMLI7F4 DN 3-(imidazolylmethyl)flavone
DMLI7F4 HS Investigative
DMLI7F4 SN 3-(imidazolylmethyl)flavone; CHEMBL213587; BDBM50191599
DMLI7F4 DT Small molecular drug
DMLI7F4 PC 11847316
DMLI7F4 MW 302.3
DMLI7F4 FM C19H14N2O2
DMLI7F4 IC InChI=1S/C19H14N2O2/c22-18-15-8-4-5-9-17(15)23-19(14-6-2-1-3-7-14)16(18)12-21-11-10-20-13-21/h1-11,13H,12H2
DMLI7F4 CS C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)CN4C=CN=C4
DMLI7F4 IK CAKKGEJFZFTSEV-UHFFFAOYSA-N
DMLI7F4 IU 3-(imidazol-1-ylmethyl)-2-phenylchromen-4-one
DMLI7F4 DE Discovery agent
DM3EV9N ID DM3EV9N
DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione
DM3EV9N HS Investigative
DM3EV9N SN CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide
DM3EV9N DT Small molecular drug
DM3EV9N PC 15422868
DM3EV9N MW 288.3
DM3EV9N FM C18H12N2O2
DM3EV9N IC InChI=1S/C18H12N2O2/c21-17-15(11-6-2-1-3-7-11)16(18(22)20-17)13-10-19-14-9-5-4-8-12(13)14/h1-10,19H,(H,20,21,22)
DM3EV9N CS C1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CNC4=CC=CC=C43
DM3EV9N IK HVQJGNALTWNDMX-UHFFFAOYSA-N
DM3EV9N IU 3-(1H-indol-3-yl)-4-phenylpyrrole-2,5-dione
DM3EV9N DE Discovery agent
DMJDG9C ID DMJDG9C
DMJDG9C DN 3-(N-alkylamino) propylphosphonic acid derivative
DMJDG9C HS Investigative
DMJDG9C SN CHEMBL1161691
DMJDG9C DT Small molecular drug
DMJDG9C PC 46905530
DMJDG9C MW 388.5
DMJDG9C FM C19H35NO5P+
DMJDG9C IC InChI=1S/C19H35NO5P/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-25-26(22,23)24/h9-12,21-24H,2-8,13-16,20H2,1H3/q+1
DMJDG9C CS CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO[P+](O)(O)O)N
DMJDG9C IK CGCGFGUOJDITDE-UHFFFAOYSA-N
DMJDG9C IU [2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butoxy]-trihydroxyphosphanium
DMJDG9C DE Discovery agent
DMJRBT1 ID DMJRBT1
DMJRBT1 DN 3-(naphthalen-2-yl)pyridine
DMJRBT1 HS Investigative
DMJRBT1 SN 3-(2-naphthyl)pyridine; CHEMBL365735; 3-(naphthalen-2-yl)pyridine; 2-(3-pyridyl)-naphthalene; SCHEMBL4510935; BDBM8904; Pyridine-substituted naphthalene 1
DMJRBT1 DT Small molecular drug
DMJRBT1 PC 11845485
DMJRBT1 MW 205.25
DMJRBT1 FM C15H11N
DMJRBT1 IC InChI=1S/C15H11N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h1-11H
DMJRBT1 CS C1=CC=C2C=C(C=CC2=C1)C3=CN=CC=C3
DMJRBT1 IK JVWGLICJXUMGHN-UHFFFAOYSA-N
DMJRBT1 IU 3-naphthalen-2-ylpyridine
DMJRBT1 DE Discovery agent
DM6OCU5 ID DM6OCU5
DM6OCU5 DN 3-(N-propylpiperidin-4-yl)phenol
DM6OCU5 HS Investigative
DM6OCU5 SN CHEMBL592618; 3-(N-propylpiperidin-4-yl)phenol; SCHEMBL3454031; HPUYFCNUROWQBG-UHFFFAOYSA-N; BDBM50308024
DM6OCU5 DT Small molecular drug
DM6OCU5 PC 12988959
DM6OCU5 MW 219.32
DM6OCU5 FM C14H21NO
DM6OCU5 IC InChI=1S/C14H21NO/c1-2-8-15-9-6-12(7-10-15)13-4-3-5-14(16)11-13/h3-5,11-12,16H,2,6-10H2,1H3
DM6OCU5 CS CCCN1CCC(CC1)C2=CC(=CC=C2)O
DM6OCU5 IK HPUYFCNUROWQBG-UHFFFAOYSA-N
DM6OCU5 IU 3-(1-propylpiperidin-4-yl)phenol
DM6OCU5 CA CAS 346688-61-7
DM6OCU5 DE Discovery agent
DMJRNI7 ID DMJRNI7
DMJRNI7 DN 3-(Octahydro-indolizin-8-yl)-phenol
DMJRNI7 HS Investigative
DMJRNI7 SN CHEMBL268240; 3-(Octahydro-indolizin-8-yl)-phenol; SCHEMBL9406084; BDBM50010616; AKOS022652621; (-)-3-(Octahydro-indolizin-8-yl)-phenol; (+)-3-(Octahydro-indolizin-8-yl)-phenol; isomer-13-(Octahydro-indolizin-8-yl)-phenol
DMJRNI7 DT Small molecular drug
DMJRNI7 PC 13720757
DMJRNI7 MW 217.31
DMJRNI7 FM C14H19NO
DMJRNI7 IC InChI=1S/C14H19NO/c16-12-5-1-4-11(10-12)13-6-2-8-15-9-3-7-14(13)15/h1,4-5,10,13-14,16H,2-3,6-9H2/t13-,14?/m1/s1
DMJRNI7 CS C1C[C@@H](C2CCCN2C1)C3=CC(=CC=C3)O
DMJRNI7 IK WOXUXMJHVREOKX-KWCCSABGSA-N
DMJRNI7 IU 3-[(8R)-1,2,3,5,6,7,8,8a-octahydroindolizin-8-yl]phenol
DMJRNI7 DE Discovery agent
DMU1SGX ID DMU1SGX
DMU1SGX DN 3-(Octahydro-quinolizin-1-yl)-phenol
DMU1SGX HS Investigative
DMU1SGX SN CHEMBL7381; 3-(Octahydro-quinolizin-1-yl)-phenol; SCHEMBL7351093; BDBM50010614; AKOS022657925; 3-[(Octahydro-4H-quinolizin)-1-yl]phenol; isomer-23-(Octahydro-quinolizin-1-yl)-phenol
DMU1SGX DT Small molecular drug
DMU1SGX PC 13720739
DMU1SGX MW 231.33
DMU1SGX FM C15H21NO
DMU1SGX IC InChI=1S/C15H21NO/c17-13-6-3-5-12(11-13)14-7-4-10-16-9-2-1-8-15(14)16/h3,5-6,11,14-15,17H,1-2,4,7-10H2
DMU1SGX CS C1CCN2CCCC(C2C1)C3=CC(=CC=C3)O
DMU1SGX IK RUTLNJGVITWMQE-UHFFFAOYSA-N
DMU1SGX IU 3-(2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-yl)phenol
DMU1SGX DE Discovery agent
DM01BKR ID DM01BKR
DM01BKR DN 3-(Octahydro-quinolizin-3-yl)-phenol
DM01BKR HS Investigative
DM01BKR SN CHEMBL8120
DM01BKR DT Small molecular drug
DM01BKR PC 13720748
DM01BKR MW 231.33
DM01BKR FM C15H21NO
DM01BKR IC InChI=1S/C15H21NO/c17-15-6-3-4-12(10-15)13-7-8-14-5-1-2-9-16(14)11-13/h3-4,6,10,13-14,17H,1-2,5,7-9,11H2
DM01BKR CS C1CCN2CC(CCC2C1)C3=CC(=CC=C3)O
DM01BKR IK GBPVZNJTTUIKKY-UHFFFAOYSA-N
DM01BKR IU 3-(2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-3-yl)phenol
DM01BKR DE Discovery agent
DMMRV1N ID DMMRV1N
DMMRV1N DN 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
DMMRV1N HS Investigative
DMMRV1N SN 3-(oxalyl-amino)-naphthalene-2-carboxylic acid; CHEMBL383570; 3-[(carboxycarbonyl)amino]naphthalene-2-carboxylic acid; AC1L1BVL; SCHEMBL4311266; CTK7I3794; 1c84; ZINC2007904; BDBM50416040; DB01734; N-(3-Carboxy-2-naphthyl)oxamidic acid; 3-(oxaloamino)naphthalene-2-carboxylic acid; 3-(carboxyformamido)naphthalene-2-carboxylic acid
DMMRV1N DT Small molecular drug
DMMRV1N PC 1628
DMMRV1N MW 259.209
DMMRV1N FM C13H9NO5
DMMRV1N IC InChI=1S/C13H9NO5/c15-11(13(18)19)14-10-6-8-4-2-1-3-7(8)5-9(10)12(16)17/h1-6H,(H,14,15)(H,16,17)(H,18,19)
DMMRV1N CS C1=CC=C2C=C(C(=CC2=C1)C(=O)O)NC(=O)C(=O)O
DMMRV1N IK DQBLKSRRWDWNKQ-UHFFFAOYSA-N
DMMRV1N IU 3-(oxaloamino)naphthalene-2-carboxylic acid
DMMRV1N DE Discovery agent
DM2UPQG ID DM2UPQG
DM2UPQG DN 3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
DM2UPQG HS Investigative
DM2UPQG SN 3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one; CHEMBL239282; Aza-heterocyclic Derivative, 1e
DM2UPQG DT Small molecular drug
DM2UPQG PC 23635754
DM2UPQG MW 288.3
DM2UPQG FM C18H12N2O2
DM2UPQG IC InChI=1S/C18H12N2O2/c21-18-15-9-5-4-8-14(15)17-16(18)10-12(19-20-17)11-22-13-6-2-1-3-7-13/h1-10H,11H2
DM2UPQG CS C1=CC=C(C=C1)OCC2=CC3=C(C4=CC=CC=C4C3=O)N=N2
DM2UPQG IK FYSBXMGLLLBKBR-UHFFFAOYSA-N
DM2UPQG IU 3-(phenoxymethyl)indeno[1,2-c]pyridazin-5-one
DM2UPQG DE Discovery agent
DMSRHLC ID DMSRHLC
DMSRHLC DN 3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole
DMSRHLC HS Investigative
DMSRHLC SN CHEMBL1076583; 651335-52-3; 3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole; SCHEMBL4077273; CTK1J9031; DTXSID60434701; BDBM50313130; 1H-Indole, 3-(phenylsulfonyl)-1-(3-piperidinyl)-
DMSRHLC DT Small molecular drug
DMSRHLC PC 10042892
DMSRHLC MW 340.4
DMSRHLC FM C19H20N2O2S
DMSRHLC IC InChI=1S/C19H20N2O2S/c22-24(23,16-8-2-1-3-9-16)19-14-21(15-7-6-12-20-13-15)18-11-5-4-10-17(18)19/h1-5,8-11,14-15,20H,6-7,12-13H2
DMSRHLC CS C1CC(CNC1)N2C=C(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DMSRHLC IK QAYPUMLPFJDPQW-UHFFFAOYSA-N
DMSRHLC IU 3-(benzenesulfonyl)-1-piperidin-3-ylindole
DMSRHLC CA CAS 651335-52-3
DMSRHLC DE Discovery agent
DM9QB0X ID DM9QB0X
DM9QB0X DN 3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole
DM9QB0X HS Investigative
DM9QB0X SN CHEMBL1080574; 651335-50-1; 3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole; SCHEMBL4077678; CTK1J9032; DTXSID00437312; BDBM50313128; 1H-Indole, 3-(phenylsulfonyl)-1-(4-piperidinyl)-
DM9QB0X DT Small molecular drug
DM9QB0X PC 10246639
DM9QB0X MW 340.4
DM9QB0X FM C19H20N2O2S
DM9QB0X IC InChI=1S/C19H20N2O2S/c22-24(23,16-6-2-1-3-7-16)19-14-21(15-10-12-20-13-11-15)18-9-5-4-8-17(18)19/h1-9,14-15,20H,10-13H2
DM9QB0X CS C1CNCCC1N2C=C(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DM9QB0X IK VDJWPWVFSZYDTQ-UHFFFAOYSA-N
DM9QB0X IU 3-(benzenesulfonyl)-1-piperidin-4-ylindole
DM9QB0X CA CAS 651335-50-1
DM9QB0X DE Discovery agent
DMVKO5N ID DMVKO5N
DMVKO5N DN 3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole
DMVKO5N HS Investigative
DMVKO5N SN CHEMBL1076665; 651335-54-5; 3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole; SCHEMBL4067463; CTK1J9030; DTXSID20431690; BDBM50313139; 1H-Indole, 3-(phenylsulfonyl)-1-(3-pyrrolidinyl)-
DMVKO5N DT Small molecular drug
DMVKO5N PC 9840311
DMVKO5N MW 326.4
DMVKO5N FM C18H18N2O2S
DMVKO5N IC InChI=1S/C18H18N2O2S/c21-23(22,15-6-2-1-3-7-15)18-13-20(14-10-11-19-12-14)17-9-5-4-8-16(17)18/h1-9,13-14,19H,10-12H2
DMVKO5N CS C1CNCC1N2C=C(C3=CC=CC=C32)S(=O)(=O)C4=CC=CC=C4
DMVKO5N IK RLICEYAZXFQQMC-UHFFFAOYSA-N
DMVKO5N IU 3-(benzenesulfonyl)-1-pyrrolidin-3-ylindole
DMVKO5N CA CAS 651335-54-5
DMVKO5N DE Discovery agent
DMN1DWF ID DMN1DWF
DMN1DWF DN 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
DMN1DWF HS Investigative
DMN1DWF SN 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine; CHEMBL538932; 633303-90-9; SCHEMBL3889418; CTK2A9458; DTXSID00621754; XIVJYIWQYBHEBJ-UHFFFAOYSA-N; BDBM50295740; 3-(Benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine; 1H-Pyrrolo[2,3-b]pyridine, 3-(phenylsulfonyl)-
DMN1DWF DT Small molecular drug
DMN1DWF PC 22028181
DMN1DWF MW 258.3
DMN1DWF FM C13H10N2O2S
DMN1DWF IC InChI=1S/C13H10N2O2S/c16-18(17,10-5-2-1-3-6-10)12-9-15-13-11(12)7-4-8-14-13/h1-9H,(H,14,15)
DMN1DWF CS C1=CC=C(C=C1)S(=O)(=O)C2=CNC3=C2C=CC=N3
DMN1DWF IK XIVJYIWQYBHEBJ-UHFFFAOYSA-N
DMN1DWF IU 3-(benzenesulfonyl)-1H-pyrrolo[2,3-b]pyridine
DMN1DWF CA CAS 633303-90-9
DMN1DWF DE Discovery agent
DM2ETXB ID DM2ETXB
DM2ETXB DN 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB HS Investigative
DM2ETXB SN CHEMBL596714; 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine
DM2ETXB DT Small molecular drug
DM2ETXB PC 46230706
DM2ETXB MW 268.35
DM2ETXB FM C17H20N2O
DM2ETXB IC InChI=1S/C17H20N2O/c1-13-5-2-3-7-16(13)20-17-15(6-4-10-19-17)14-8-11-18-12-9-14/h2-7,10,14,18H,8-9,11-12H2,1H3
DM2ETXB CS CC1=CC=CC=C1OC2=C(C=CC=N2)C3CCNCC3
DM2ETXB IK BLKKGRNFYMEBJN-UHFFFAOYSA-N
DM2ETXB IU 2-(2-methylphenoxy)-3-piperidin-4-ylpyridine
DM2ETXB DE Discovery agent
DMMOE40 ID DMMOE40
DMMOE40 DN 3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol
DMMOE40 HS Investigative
DMMOE40 SN 3-(prop-2-ene-1-sulfinyl)-propene-1-thiol; AJ3; DB02895; (1E)-3-[(R)-prop-2-ene-1-sulfinyl]prop-1-ene-1-thiol
DMMOE40 DT Small molecular drug
DMMOE40 PC 9543424
DMMOE40 MW 162.3
DMMOE40 FM C6H10OS2
DMMOE40 IC InChI=1S/C6H10OS2/c1-2-5-9(7)6-3-4-8/h2-4,8H,1,5-6H2/b4-3+/t9-/m1/s1
DMMOE40 CS C=CC[S@@](=O)C/C=C/S
DMMOE40 IK HSVQDVSVQIMRSS-CDAZIORVSA-N
DMMOE40 IU (E)-3-[(R)-prop-2-enylsulfinyl]prop-1-ene-1-thiol
DMMOE40 DE Discovery agent
DM3EDQ1 ID DM3EDQ1
DM3EDQ1 DN 3-(pyridin-3-yl)prop-2-yn-1-amine
DM3EDQ1 HS Investigative
DM3EDQ1 SN 3-(pyridin-3-yl)prop-2-yn-1-amine; 777856-62-9; 2-PROPYN-1-AMINE, 3-(3-PYRIDINYL)-; CHEMBL360541; SCHEMBL3603698; CTK2G6074; BDBM12348; DTXSID90460412; MolPort-014-472-743; BGKUWZFWNZFRMO-UHFFFAOYSA-N; ZINC13607158; nicotine 3-heteroaromatic analogue 3a; AKOS010148504; MCULE-3042424640; NE58716; US8609708, 3; Z1333761438
DM3EDQ1 DT Small molecular drug
DM3EDQ1 PC 11263510
DM3EDQ1 MW 132.16
DM3EDQ1 FM C8H8N2
DM3EDQ1 IC InChI=1S/C8H8N2/c9-5-1-3-8-4-2-6-10-7-8/h2,4,6-7H,5,9H2
DM3EDQ1 CS C1=CC(=CN=C1)C#CCN
DM3EDQ1 IK BGKUWZFWNZFRMO-UHFFFAOYSA-N
DM3EDQ1 IU 3-pyridin-3-ylprop-2-yn-1-amine
DM3EDQ1 CA CAS 777856-62-9
DM3EDQ1 DE Discovery agent
DMZARSD ID DMZARSD
DMZARSD DN 3-(pyridin-4-yl)-1H-indol-6-amine
DMZARSD HS Investigative
DMZARSD SN 3-(pyridin-4-yl)-1H-indol-6-amine; CHEMBL207612; 887615-80-7; CTK3A6374; DTXSID00658787; BDBM50182874; AKOS030619478; 1H-Indol-6-amine, 3-(4-pyridinyl)-
DMZARSD DT Small molecular drug
DMZARSD PC 44410928
DMZARSD MW 209.25
DMZARSD FM C13H11N3
DMZARSD IC InChI=1S/C13H11N3/c14-10-1-2-11-12(8-16-13(11)7-10)9-3-5-15-6-4-9/h1-8,16H,14H2
DMZARSD CS C1=CC2=C(C=C1N)NC=C2C3=CC=NC=C3
DMZARSD IK NUDVKMUJCFEKEL-UHFFFAOYSA-N
DMZARSD IU 3-pyridin-4-yl-1H-indol-6-amine
DMZARSD CA CAS 887615-80-7
DMZARSD DE Discovery agent
DMRFPNE ID DMRFPNE
DMRFPNE DN 3-(pyridin-4-yl)-1H-indol-7-amine
DMRFPNE HS Investigative
DMRFPNE SN CHEMBL207262; 3-(pyridin-4-yl)-1H-indol-7-amine; SCHEMBL3500355
DMRFPNE DT Small molecular drug
DMRFPNE PC 44410707
DMRFPNE MW 209.25
DMRFPNE FM C13H11N3
DMRFPNE IC InChI=1S/C13H11N3/c14-12-3-1-2-10-11(8-16-13(10)12)9-4-6-15-7-5-9/h1-8,16H,14H2
DMRFPNE CS C1=CC2=C(C(=C1)N)NC=C2C3=CC=NC=C3
DMRFPNE IK NVYSWJKBWRBXSR-UHFFFAOYSA-N
DMRFPNE IU 3-pyridin-4-yl-1H-indol-7-amine
DMRFPNE DE Discovery agent
DMNA6LF ID DMNA6LF
DMNA6LF DN 3-(tetradecylamino)propylphosphonic acid
DMNA6LF HS Investigative
DMNA6LF SN 3-(tetradecylamino)propylphosphonic acid; CHEMBL334213; 725724-60-7; CTK2H2323; DTXSID50658353; BDBM50148403; (3-Tetradecylamino-propyl)-phosphonic acid; [3-(Tetradecylamino)propyl]phosphonic acid; Phosphonic acid, [3-(tetradecylamino)propyl]-
DMNA6LF DT Small molecular drug
DMNA6LF PC 44344193
DMNA6LF MW 335.5
DMNA6LF FM C17H38NO3P
DMNA6LF IC InChI=1S/C17H38NO3P/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-16-14-17-22(19,20)21/h18H,2-17H2,1H3,(H2,19,20,21)
DMNA6LF CS CCCCCCCCCCCCCCNCCCP(=O)(O)O
DMNA6LF IK ROTPOJPBVJTWLI-UHFFFAOYSA-N
DMNA6LF IU 3-(tetradecylamino)propylphosphonic acid
DMNA6LF CA CAS 725724-60-7
DMNA6LF DE Discovery agent
DMMI0UC ID DMMI0UC
DMMI0UC DN 3-(thiophen-3-yl)-1H-indol-6-amine
DMMI0UC HS Investigative
DMMI0UC SN CHEMBL206475; 3-(thiophen-3-yl)-1H-indol-6-amine; SCHEMBL20561548
DMMI0UC DT Small molecular drug
DMMI0UC PC 44410875
DMMI0UC MW 214.29
DMMI0UC FM C12H10N2S
DMMI0UC IC InChI=1S/C12H10N2S/c13-9-1-2-10-11(6-14-12(10)5-9)8-3-4-15-7-8/h1-7,14H,13H2
DMMI0UC CS C1=CC2=C(C=C1N)NC=C2C3=CSC=C3
DMMI0UC IK QEKXSCXVUJXAFF-UHFFFAOYSA-N
DMMI0UC IU 3-thiophen-3-yl-1H-indol-6-amine
DMMI0UC DE Discovery agent
DMWX4L5 ID DMWX4L5
DMWX4L5 DN 3-(trifluoromethyl)-9H-carbazole
DMWX4L5 HS Investigative
DMWX4L5 SN 3-(trifluoromethyl)-9H-carbazole; 2467-83-6; CHEMBL1170444; 3-trifluoromethyl-9H-carbazole; SCHEMBL4130017; JGFJDDMRCMCZMU-UHFFFAOYSA-N; CS-B1171; 9H-Carbazole, 3-(trifluoromethyl)-; BDBM50322575; ZINC53243063
DMWX4L5 DT Small molecular drug
DMWX4L5 PC 42611896
DMWX4L5 MW 235.2
DMWX4L5 FM C13H8F3N
DMWX4L5 IC InChI=1S/C13H8F3N/c14-13(15,16)8-5-6-12-10(7-8)9-3-1-2-4-11(9)17-12/h1-7,17H
DMWX4L5 CS C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)C(F)(F)F
DMWX4L5 IK JGFJDDMRCMCZMU-UHFFFAOYSA-N
DMWX4L5 IU 3-(trifluoromethyl)-9H-carbazole
DMWX4L5 DE Discovery agent
DM2YVA1 ID DM2YVA1
DM2YVA1 DN 3-(trifluoromethyl)benzaldehyde thiosemicarbazone
DM2YVA1 HS Investigative
DM2YVA1 SN CHEMBL90688; 3-(trifluoromethyl)benzaldehyde thiosemicarbazone; (2E)-2-[3-(trifluoromethyl)benzylidene]hydrazinecarbothioamide; 264148-89-2; MolPort-002-925-405; HMS1669J15; STK179777; BDBM50114639; AKOS005411111; CCG-254652; MS-7103
DM2YVA1 DT Small molecular drug
DM2YVA1 PC 9580972
DM2YVA1 MW 247.24
DM2YVA1 FM C9H8F3N3S
DM2YVA1 IC InChI=1S/C9H8F3N3S/c10-9(11,12)7-3-1-2-6(4-7)5-14-15-8(13)16/h1-5H,(H3,13,15,16)/b14-5+
DM2YVA1 CS C1=CC(=CC(=C1)C(F)(F)F)/C=N/NC(=S)N
DM2YVA1 IK GDIMOASDCOFPTD-LHHJGKSTSA-N
DM2YVA1 IU [(E)-[3-(trifluoromethyl)phenyl]methylideneamino]thiourea
DM2YVA1 DE Discovery agent
DMH7K0N ID DMH7K0N
DMH7K0N DN 3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate
DMH7K0N HS Investigative
DMH7K0N SN CHEMBL597272; 3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate
DMH7K0N DT Small molecular drug
DMH7K0N PC 46230998
DMH7K0N MW 367.4
DMH7K0N FM C19H20F3NO3
DMH7K0N IC InChI=1S/C19H20F3NO3/c1-2-3-11-25-16-9-7-14(8-10-16)13-23-18(24)26-17-6-4-5-15(12-17)19(20,21)22/h4-10,12H,2-3,11,13H2,1H3,(H,23,24)
DMH7K0N CS CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC=CC(=C2)C(F)(F)F
DMH7K0N IK ULJSSIFMAROIAL-UHFFFAOYSA-N
DMH7K0N IU [3-(trifluoromethyl)phenyl] N-[(4-butoxyphenyl)methyl]carbamate
DMH7K0N DE Discovery agent
DM4B5JY ID DM4B5JY
DM4B5JY DN 3-(trifluoromethyl)phenylboronic acid
DM4B5JY HS Investigative
DM4B5JY SN 1423-26-3; 3-(Trifluoromethyl)phenylboronic acid; 3-Trifluoromethylphenylboronic acid; (3-(Trifluoromethyl)phenyl)boronic acid; [3-(trifluoromethyl)phenyl]boronic Acid; 3-(Trifluoromethyl)benzeneboronic acid; 3-(Trifluoromethyl)phenylbornic acid; m-(trifluoromethyl)phenylboronic acid; CHEMBL336239; 3-trifluoromethylphenyl boronic acid; MFCD00151854; [3-(Trifluoromethyl)Phenyl]Boranediol; 3-(trifluoromethyl)benzene boronic acid; Boronic acid, [3-(trifluoromethyl)phenyl]-; Boronic acid, B-[3-(trifluoromethyl)phenyl]-
DM4B5JY DT Small molecular drug
DM4B5JY PC 2734388
DM4B5JY MW 189.93
DM4B5JY FM C7H6BF3O2
DM4B5JY IC InChI=1S/C7H6BF3O2/c9-7(10,11)5-2-1-3-6(4-5)8(12)13/h1-4,12-13H
DM4B5JY CS B(C1=CC(=CC=C1)C(F)(F)F)(O)O
DM4B5JY IK WOAORAPRPVIATR-UHFFFAOYSA-N
DM4B5JY IU [3-(trifluoromethyl)phenyl]boronic acid
DM4B5JY CA CAS 1423-26-3
DM4B5JY DE Discovery agent
DMR9WF7 ID DMR9WF7
DMR9WF7 DN 3,14-DIDEHYDROGINKGOLIDE A
DMR9WF7 HS Investigative
DMR9WF7 SN 3,14-didehydroginkgolide A; CHEMBL373969
DMR9WF7 DT Small molecular drug
DMR9WF7 PC 44420886
DMR9WF7 MW 390.4
DMR9WF7 FM C20H22O8
DMR9WF7 IC InChI=1S/C20H22O8/c1-7-11-9(25-13(7)22)6-18-8-5-10(17(2,3)4)19(18)12(21)15(24)26-16(19)28-20(11,18)27-14(8)23/h8-10,12,16,21H,5-6H2,1-4H3/t8-,9-,10-,12-,16-,18-,19-,20+/m0/s1
DMR9WF7 CS CC1=C2[C@H](C[C@@]34[C@]25O[C@H]6[C@]3([C@@H](C[C@H]4C(=O)O5)C(C)(C)C)[C@H](C(=O)O6)O)OC1=O
DMR9WF7 IK KQXWWKYPPREDFP-VETRYGRWSA-N
DMR9WF7 IU (1R,3R,6R,7S,8S,10R,11S,13S)-8-tert-butyl-6-hydroxy-16-methyl-2,4,14,18-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadec-16-ene-5,15,19-trione
DMR9WF7 DE Discovery agent
DMD0Z3U ID DMD0Z3U
DMD0Z3U DN 3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile
DMD0Z3U HS Investigative
DMD0Z3U SN CHEMBL396656; BDBM50220379; 582293-27-4; 3,2''-bis-trifluoromethyl-biphenyl-4-carbonitrile
DMD0Z3U DT Small molecular drug
DMD0Z3U PC 44434099
DMD0Z3U MW 315.21
DMD0Z3U FM C15H7F6N
DMD0Z3U IC InChI=1S/C15H7F6N/c16-14(17,18)12-4-2-1-3-11(12)9-5-6-10(8-22)13(7-9)15(19,20)21/h1-7H
DMD0Z3U CS C1=CC=C(C(=C1)C2=CC(=C(C=C2)C#N)C(F)(F)F)C(F)(F)F
DMD0Z3U IK LVFYAAITUNIVMI-UHFFFAOYSA-N
DMD0Z3U IU 2-(trifluoromethyl)-4-[2-(trifluoromethyl)phenyl]benzonitrile
DMD0Z3U DE Discovery agent
DM9GO8Y ID DM9GO8Y
DM9GO8Y DN 3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol
DM9GO8Y HS Investigative
DM9GO8Y SN 3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol; MLS002706401; 71123-38-1; 3-[6-(3-hydroxyphenyl)-1,2,4,5-tetrazin-3-yl]phenol; NSC111295; AC1Q4XDI; AC1L6N8F; SCHEMBL1180643; cid_269792; CHEMBL457636; CTK5D3544; BDBM25867; DTXSID10296755; YDADTNARCJIMQM-UHFFFAOYSA-N; ZINC1703222; AKOS030537993; NSC-111295; hydroxyphenyl substituted tetrazine, 39
DM9GO8Y DT Small molecular drug
DM9GO8Y PC 269792
DM9GO8Y MW 266.25
DM9GO8Y FM C14H10N4O2
DM9GO8Y IC InChI=1S/C14H10N4O2/c19-11-5-1-3-9(7-11)13-15-17-14(18-16-13)10-4-2-6-12(20)8-10/h1-8,19-20H
DM9GO8Y CS C1=CC(=CC(=C1)O)C2=NN=C(N=N2)C3=CC(=CC=C3)O
DM9GO8Y IK YDADTNARCJIMQM-UHFFFAOYSA-N
DM9GO8Y IU 3-[6-(3-hydroxyphenyl)-1,2,4,5-tetrazin-3-yl]phenol
DM9GO8Y CA CAS 71123-38-1
DM9GO8Y DE Discovery agent
DM4O2VC ID DM4O2VC
DM4O2VC DN 3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol
DM4O2VC HS Investigative
DM4O2VC SN 3,3'-(1,3,4-Thiadiazole-2,5-diyl)diphenol; 155877-54-6; CHEMBL450189; SCHEMBL1180710; BDBM25837; CTK0E7552; DTXSID00618942; KZZBPNSRBQBVII-UHFFFAOYSA-N; hydroxyphenyl substituted thiadiazole, 9; 2,5-Bis(3-hydroxyphenyl)-1,3,4-thiadiazole; Phenol, 3,3'-(1,3,4-thiadiazole-2,5-diyl)bis-
DM4O2VC DT Small molecular drug
DM4O2VC PC 21861202
DM4O2VC MW 270.31
DM4O2VC FM C14H10N2O2S
DM4O2VC IC InChI=1S/C14H10N2O2S/c17-11-5-1-3-9(7-11)13-15-16-14(19-13)10-4-2-6-12(18)8-10/h1-8,17-18H
DM4O2VC CS C1=CC(=CC(=C1)O)C2=NN=C(S2)C3=CC(=CC=C3)O
DM4O2VC IK KZZBPNSRBQBVII-UHFFFAOYSA-N
DM4O2VC IU 3-[5-(3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl]phenol
DM4O2VC CA CAS 155877-54-6
DM4O2VC DE Discovery agent
DMC34UW ID DMC34UW
DMC34UW DN 3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol
DMC34UW HS Investigative
DMC34UW SN CHEMBL503399; SCHEMBL12871356; BDBM25839; hydroxyphenyl substituted thiadiazole, 11
DMC34UW DT Small molecular drug
DMC34UW PC 25093379
DMC34UW MW 270.31
DMC34UW FM C14H10N2O2S
DMC34UW IC InChI=1S/C14H10N2O2S/c17-11-5-1-3-9(7-11)13-15-14(19-16-13)10-4-2-6-12(18)8-10/h1-8,17-18H
DMC34UW CS C1=CC(=CC(=C1)O)C2=NSC(=N2)C3=CC(=CC=C3)O
DMC34UW IK OYXDKVOVGLCIIZ-UHFFFAOYSA-N
DMC34UW IU 3-[5-(3-hydroxyphenyl)-1,2,4-thiadiazol-3-yl]phenol
DMC34UW DE Discovery agent
DM9AJNW ID DM9AJNW
DM9AJNW DN 3,3'-(1,3-Thiazol-2,4-diyl)diphenol
DM9AJNW HS Investigative
DM9AJNW SN CHEMBL512196; SCHEMBL1180078; BDBM25836; WSUUHCNQLBCNOV-UHFFFAOYSA-N; hydroxyphenyl substituted thiazole, 8; 3,3'-(1,3-Thiazole-2,4-diyl)diphenol
DM9AJNW DT Small molecular drug
DM9AJNW PC 25093377
DM9AJNW MW 269.3
DM9AJNW FM C15H11NO2S
DM9AJNW IC InChI=1S/C15H11NO2S/c17-12-5-1-3-10(7-12)14-9-19-15(16-14)11-4-2-6-13(18)8-11/h1-9,17-18H
DM9AJNW CS C1=CC(=CC(=C1)O)C2=CSC(=N2)C3=CC(=CC=C3)O
DM9AJNW IK WSUUHCNQLBCNOV-UHFFFAOYSA-N
DM9AJNW IU 3-[2-(3-hydroxyphenyl)-1,3-thiazol-4-yl]phenol
DM9AJNW DE Discovery agent
DMQY50A ID DMQY50A
DMQY50A DN 3,3-(1,3-Thiazole-2,5-diyl)diphenol
DMQY50A HS Investigative
DMQY50A SN CHEMBL456379; SCHEMBL1181184; BDBM25832; hydroxyphenyl substituted thiazole, 4
DMQY50A DT Small molecular drug
DMQY50A PC 25093374
DMQY50A MW 269.3
DMQY50A FM C15H11NO2S
DMQY50A IC InChI=1S/C15H11NO2S/c17-12-5-1-3-10(7-12)14-9-16-15(19-14)11-4-2-6-13(18)8-11/h1-9,17-18H
DMQY50A CS C1=CC(=CC(=C1)O)C2=CN=C(S2)C3=CC(=CC=C3)O
DMQY50A IK OYFRXCWZMBHNHW-UHFFFAOYSA-N
DMQY50A IU 3-[2-(3-hydroxyphenyl)-1,3-thiazol-5-yl]phenol
DMQY50A DE Discovery agent
DM40SNY ID DM40SNY
DM40SNY DN 3,3'-(3-Methylthiene-2,5-diyl]diphenol
DM40SNY HS Investigative
DM40SNY SN CHEMBL572171; BDBM50299646
DM40SNY DT Small molecular drug
DM40SNY PC 44543261
DM40SNY MW 282.4
DM40SNY FM C17H14O2S
DM40SNY IC InChI=1S/C17H14O2S/c1-11-8-16(12-4-2-6-14(18)9-12)20-17(11)13-5-3-7-15(19)10-13/h2-10,18-19H,1H3
DM40SNY CS CC1=C(SC(=C1)C2=CC(=CC=C2)O)C3=CC(=CC=C3)O
DM40SNY IK LRHCSXOEZSEMIF-UHFFFAOYSA-N
DM40SNY IU 3-[5-(3-hydroxyphenyl)-4-methylthiophen-2-yl]phenol
DM40SNY DE Discovery agent
DMUK1VX ID DMUK1VX
DMUK1VX DN 3,3'-(3-Phenylthiene-2,5-diyl)diphenol
DMUK1VX HS Investigative
DMUK1VX SN CHEMBL569885; BDBM50299649
DMUK1VX DT Small molecular drug
DMUK1VX PC 44542047
DMUK1VX MW 344.4
DMUK1VX FM C22H16O2S
DMUK1VX IC InChI=1S/C22H16O2S/c23-18-10-4-8-16(12-18)21-14-20(15-6-2-1-3-7-15)22(25-21)17-9-5-11-19(24)13-17/h1-14,23-24H
DMUK1VX CS C1=CC=C(C=C1)C2=C(SC(=C2)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMUK1VX IK ZQUCGOXYEIRCOX-UHFFFAOYSA-N
DMUK1VX IU 3-[5-(3-hydroxyphenyl)-4-phenylthiophen-2-yl]phenol
DMUK1VX DE Discovery agent
DMJVKMO ID DMJVKMO
DMJVKMO DN 3,3'-(4-phenylpyridine-2,6-diyl)diphenol
DMJVKMO HS Investigative
DMJVKMO SN CHEMBL1095114
DMJVKMO DT Small molecular drug
DMJVKMO PC 46887181
DMJVKMO MW 339.4
DMJVKMO FM C23H17NO2
DMJVKMO IC InChI=1S/C23H17NO2/c25-20-10-4-8-17(12-20)22-14-19(16-6-2-1-3-7-16)15-23(24-22)18-9-5-11-21(26)13-18/h1-15,25-26H
DMJVKMO CS C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMJVKMO IK DLUFNTXHXJNUFJ-UHFFFAOYSA-N
DMJVKMO IU 3-[6-(3-hydroxyphenyl)-4-phenylpyridin-2-yl]phenol
DMJVKMO DE Discovery agent
DMH7A32 ID DMH7A32
DMH7A32 DN 3,3',3''-Thiene-2,3,5-triyltriphenol
DMH7A32 HS Investigative
DMH7A32 SN CHEMBL576682; BDBM50299657
DMH7A32 DT Small molecular drug
DMH7A32 PC 44542800
DMH7A32 MW 360.4
DMH7A32 FM C22H16O3S
DMH7A32 IC InChI=1S/C22H16O3S/c23-17-7-1-4-14(10-17)20-13-21(15-5-2-8-18(24)11-15)26-22(20)16-6-3-9-19(25)12-16/h1-13,23-25H
DMH7A32 CS C1=CC(=CC(=C1)O)C2=CC(=C(S2)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMH7A32 IK ZBWIOPSLXQDYEV-UHFFFAOYSA-N
DMH7A32 IU 3-[4,5-bis(3-hydroxyphenyl)thiophen-2-yl]phenol
DMH7A32 DE Discovery agent
DMBFY4H ID DMBFY4H
DMBFY4H DN 3,3,3-tris(4-chlorophenyl)propanoic acid
DMBFY4H HS Investigative
DMBFY4H SN 3,3,3-Tris(4-chlorophenyl)propionic acid; 2168-06-1; 3,3,3-Tris(4-chlorophenyl)propanoic acid; 3,3,3-Tris(p-chlorophenyl)propionic acid; CHEMBL201593; AK-23664; 3,3,3-tris-(4-Chlorophenyl)propionic acid; 3,3,3-TRIS(4-CHLOROPHENYL)PROPIONIS ACID; W-107531; rarechem al bo 1263; AC1Q3NC9; ACMC-1CB39; SCHEMBL503944; C21H15Cl3O2; AC1L2O20; LHIVWYJOCNGZRI-UHFFFAOYSA-; CTK4E7478; DTXSID30176065; LHIVWYJOCNGZRI-UHFFFAOYSA-N; MolPort-003-928-967; 3,3,3-tris-(4-chlorophenyl)-pr; ZINC4529217; KS-00000NC6; EINECS 218-509-3; CT-098
DMBFY4H DT Small molecular drug
DMBFY4H PC 75107
DMBFY4H MW 405.7
DMBFY4H FM C21H15Cl3O2
DMBFY4H IC InChI=1S/C21H15Cl3O2/c22-17-7-1-14(2-8-17)21(13-20(25)26,15-3-9-18(23)10-4-15)16-5-11-19(24)12-6-16/h1-12H,13H2,(H,25,26)
DMBFY4H CS C1=CC(=CC=C1C(CC(=O)O)(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)Cl
DMBFY4H IK LHIVWYJOCNGZRI-UHFFFAOYSA-N
DMBFY4H IU 3,3,3-tris(4-chlorophenyl)propanoic acid
DMBFY4H CA CAS 2168-06-1
DMBFY4H DE Discovery agent
DMO51QG ID DMO51QG
DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile
DMO51QG HS Investigative
DMO51QG SN 3,3-bis(4-hydroxyphenyl)-2-phenylprop-2-enenitrile; CHEMBL65053
DMO51QG DT Small molecular drug
DMO51QG PC 14537247
DMO51QG MW 313.3
DMO51QG FM C21H15NO2
DMO51QG IC InChI=1S/C21H15NO2/c22-14-20(15-4-2-1-3-5-15)21(16-6-10-18(23)11-7-16)17-8-12-19(24)13-9-17/h1-13,23-24H
DMO51QG CS C1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C#N
DMO51QG IK PMKMHLVHNOXPOY-UHFFFAOYSA-N
DMO51QG IU 3,3-bis(4-hydroxyphenyl)-2-phenylprop-2-enenitrile
DMO51QG DE Discovery agent
DMZPYN2 ID DMZPYN2
DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile
DMZPYN2 HS Investigative
DMZPYN2 SN CHEMBL304867
DMZPYN2 DT Small molecular drug
DMZPYN2 PC 14537244
DMZPYN2 MW 341.4
DMZPYN2 FM C23H19NO2
DMZPYN2 IC InChI=1S/C23H19NO2/c1-25-20-12-8-18(9-13-20)23(19-10-14-21(26-2)15-11-19)22(16-24)17-6-4-3-5-7-17/h3-15H,1-2H3
DMZPYN2 CS COC1=CC=C(C=C1)C(=C(C#N)C2=CC=CC=C2)C3=CC=C(C=C3)OC
DMZPYN2 IK RQZZPWWADAMYCL-UHFFFAOYSA-N
DMZPYN2 IU 3,3-bis(4-methoxyphenyl)-2-phenylprop-2-enenitrile
DMZPYN2 DE Discovery agent
DMK9BN0 ID DMK9BN0
DMK9BN0 DN 3,3-di(pent-4-enyl)azetidin-2-one
DMK9BN0 HS Investigative
DMK9BN0 SN CHEMBL487447; 3,3-di(pent-4-enyl)azetidin-2-one
DMK9BN0 DT Small molecular drug
DMK9BN0 PC 44560664
DMK9BN0 MW 207.31
DMK9BN0 FM C13H21NO
DMK9BN0 IC InChI=1S/C13H21NO/c1-3-5-7-9-13(10-8-6-4-2)11-14-12(13)15/h3-4H,1-2,5-11H2,(H,14,15)
DMK9BN0 CS C=CCCCC1(CNC1=O)CCCC=C
DMK9BN0 IK RZYCKKZEBQDDLK-UHFFFAOYSA-N
DMK9BN0 IU 3,3-bis(pent-4-enyl)azetidin-2-one
DMK9BN0 DE Discovery agent
DMWFD5C ID DMWFD5C
DMWFD5C DN 3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione
DMWFD5C HS Investigative
DMWFD5C SN 3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione; CHEMBL566906; BDBM50303356
DMWFD5C DT Small molecular drug
DMWFD5C PC 44626811
DMWFD5C MW 218.25
DMWFD5C FM C12H14N2O2
DMWFD5C IC InChI=1S/C12H14N2O2/c1-3-12(4-2)10(15)14(11(12)16)9-6-5-7-13-8-9/h5-8H,3-4H2,1-2H3
DMWFD5C CS CCC1(C(=O)N(C1=O)C2=CN=CC=C2)CC
DMWFD5C IK OHEZXQVPDSACCJ-UHFFFAOYSA-N
DMWFD5C IU 3,3-diethyl-1-pyridin-3-ylazetidine-2,4-dione
DMWFD5C DE Discovery agent
DMY8S94 ID DMY8S94
DMY8S94 DN 3,3-Diethyl-1-o-tolylazetidine-2,4-dione
DMY8S94 HS Investigative
DMY8S94 SN CHEMBL566918; 3,3-Diethyl-1-o-tolylazetidine-2,4-dione
DMY8S94 DT Small molecular drug
DMY8S94 PC 44626810
DMY8S94 MW 231.29
DMY8S94 FM C14H17NO2
DMY8S94 IC InChI=1S/C14H17NO2/c1-4-14(5-2)12(16)15(13(14)17)11-9-7-6-8-10(11)3/h6-9H,4-5H2,1-3H3
DMY8S94 CS CCC1(C(=O)N(C1=O)C2=CC=CC=C2C)CC
DMY8S94 IK QNAKQLGCEYBHNC-UHFFFAOYSA-N
DMY8S94 IU 3,3-diethyl-1-(2-methylphenyl)azetidine-2,4-dione
DMY8S94 DE Discovery agent
DMCFJIP ID DMCFJIP
DMCFJIP DN 3,3-diethyl-1-phenylazetidine-2,4-dione
DMCFJIP HS Investigative
DMCFJIP SN 3,3-diethyl-1-phenylazetidine-2,4-dione; CHEMBL272413; 2,4-Azetidinedione, 3,3-diethyl-1-phenyl-; 15745-94-5; 3,3-Diethyl-1-phenylazetidin-2,4-dione; AC1L3FYP; DTXSID30166264; KDXSTYUPRNLDGW-UHFFFAOYSA-N; BDBM50235613; 1-Phenyl-3,3-diethylazetidine-2,4-dione
DMCFJIP DT Small molecular drug
DMCFJIP PC 139973
DMCFJIP MW 217.26
DMCFJIP FM C13H15NO2
DMCFJIP IC InChI=1S/C13H15NO2/c1-3-13(4-2)11(15)14(12(13)16)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3
DMCFJIP CS CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC
DMCFJIP IK KDXSTYUPRNLDGW-UHFFFAOYSA-N
DMCFJIP IU 3,3-diethyl-1-phenylazetidine-2,4-dione
DMCFJIP CA CAS 15745-94-5
DMCFJIP DE Discovery agent
DMFJ9N0 ID DMFJ9N0
DMFJ9N0 DN 3,3-Diethyl-dihydro-furan-2-one
DMFJ9N0 HS Investigative
DMFJ9N0 SN 2(3H)-Furanone, 3,3-diethyldihydro-; 50994-87-1; SCHEMBL576533; CHEMBL286415; dihydro-3,3-diethyl-2(3h)-furanone
DMFJ9N0 DT Small molecular drug
DMFJ9N0 PC 14872649
DMFJ9N0 MW 142.2
DMFJ9N0 FM C8H14O2
DMFJ9N0 IC InChI=1S/C8H14O2/c1-3-8(4-2)5-6-10-7(8)9/h3-6H2,1-2H3
DMFJ9N0 CS CCC1(CCOC1=O)CC
DMFJ9N0 IK OKKTUDVXPHANCU-UHFFFAOYSA-N
DMFJ9N0 IU 3,3-diethyloxolan-2-one
DMFJ9N0 DE Discovery agent
DMGMJWL ID DMGMJWL
DMGMJWL DN 3,3'-difluorobenzaldazine
DMGMJWL HS Investigative
DMGMJWL SN 3,3'-Difluorobenzaldazine; DFB; 15332-10-2; CHEMBL371811; 1,2-Bis(3-Fluorobenzylidene)Hydrazine; AC1O7H0M; SCHEMBL12017614; SCHEMBL12497017; bis(3-fluorobenzylidene)hydrazine; CHEBI:92414; MolPort-003-940-930; HMS3262J07; Tox21_500843; DFB, > MFCD03653615; BDBM50156074; ZINC13719901; AKOS024456711; VZ25360; CCG-222147; NCGC00261528-01; NCGC00025238-05; NCGC00025238-02; NCGC00025238-03; NCGC00025238-04; KB-76455; SR-01000597595; C-14798; J-009001; SR-01000597595-1; 3,3 inverted exclamation marka-Difluorobenzaldazine
DMGMJWL DT Small molecular drug
DMGMJWL PC 6604893
DMGMJWL MW 244.24
DMGMJWL FM C14H10F2N2
DMGMJWL IC InChI=1S/C14H10F2N2/c15-13-5-1-3-11(7-13)9-17-18-10-12-4-2-6-14(16)8-12/h1-10H/b17-9+,18-10+
DMGMJWL CS C1=CC(=CC(=C1)F)/C=N/N=C/C2=CC(=CC=C2)F
DMGMJWL IK YYMCVDNIIFNDJK-BEQMOXJMSA-N
DMGMJWL IU (E)-1-(3-fluorophenyl)-N-[(E)-(3-fluorophenyl)methylideneamino]methanimine
DMGMJWL CB CHEBI:92414
DMGMJWL DE Discovery agent
DMIFUDG ID DMIFUDG
DMIFUDG DN 3,3-Diisopropyl-dihydro-furan-2-one
DMIFUDG HS Investigative
DMIFUDG SN CHEMBL34879; 2(3H)-Furanone, dihydro-3,3-bis(1-methylethyl)-; SCHEMBL10358026; 132462-12-5
DMIFUDG DT Small molecular drug
DMIFUDG PC 10352121
DMIFUDG MW 170.25
DMIFUDG FM C10H18O2
DMIFUDG IC InChI=1S/C10H18O2/c1-7(2)10(8(3)4)5-6-12-9(10)11/h7-8H,5-6H2,1-4H3
DMIFUDG CS CC(C)C1(CCOC1=O)C(C)C
DMIFUDG IK HBNIKFYZKDWFNE-UHFFFAOYSA-N
DMIFUDG IU 3,3-di(propan-2-yl)oxolan-2-one
DMIFUDG DE Discovery agent
DMUS0A4 ID DMUS0A4
DMUS0A4 DN 3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one
DMUS0A4 HS Investigative
DMUS0A4 SN CHEMBL566982; SCHEMBL4421269; 3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one; IQXQUXAACBOTRO-UHFFFAOYSA-N; ZINC45245855; BDBM50299884
DMUS0A4 DT Small molecular drug
DMUS0A4 PC 45483822
DMUS0A4 MW 250.3
DMUS0A4 FM C18H18O
DMUS0A4 IC InChI=1S/C18H18O/c1-12-5-4-6-13(9-12)14-7-8-15-16(10-14)18(2,3)11-17(15)19/h4-10H,11H2,1-3H3
DMUS0A4 CS CC1=CC(=CC=C1)C2=CC3=C(C=C2)C(=O)CC3(C)C
DMUS0A4 IK IQXQUXAACBOTRO-UHFFFAOYSA-N
DMUS0A4 IU 3,3-dimethyl-5-(3-methylphenyl)-2H-inden-1-one
DMUS0A4 DE Discovery agent
DM09LY4 ID DM09LY4
DM09LY4 DN 3,3-Dimethyl-dihydro-furan-2-one
DM09LY4 HS Investigative
DM09LY4 SN 3709-08-8; alpha,alpha-Dimethyl-gamma-butyrolactone; 3,3-dimethyldihydrofuran-2(3h)-one; 3,3-dimethyloxolan-2-one; 2(3H)-Furanone, dihydro-3,3-dimethyl-; Dihydro-3,3-dimethyl-2(3H)-furanone; 2,2-Dimethyl-4-butyrolactone; UPVAIJPDWVTFKT-UHFFFAOYSA-N; Butyric acid, 2,2-dimethyl-4-hydroxy-, g-lactone; Dimethylbutanolid; alpha-DMgBL; NSC1094; AC1L3STF; AC1Q6HQD; 2,2-dimethylbutyrolactone; Furanone, dihydrodimethyl-; a,a-Dimethyl- -butyrolactone; SCHEMBL149596; CHEMBL33962; CTK2A6366; DTXSID30190584; MolPort-009-198-442
DM09LY4 DT Small molecular drug
DM09LY4 PC 94746
DM09LY4 MW 114.14
DM09LY4 FM C6H10O2
DM09LY4 IC InChI=1S/C6H10O2/c1-6(2)3-4-8-5(6)7/h3-4H2,1-2H3
DM09LY4 CS CC1(CCOC1=O)C
DM09LY4 IK UPVAIJPDWVTFKT-UHFFFAOYSA-N
DM09LY4 IU 3,3-dimethyloxolan-2-one
DM09LY4 CA CAS 3709-08-8
DM09LY4 DE Discovery agent
DMNOUSV ID DMNOUSV
DMNOUSV DN 3,3-diphenylpropan-1-amine
DMNOUSV HS Investigative
DMNOUSV SN 3,3-Diphenylpropylamine; 5586-73-2; 3,3-diphenylpropan-1-amine; UNII-C31E561S64; KISZTEOELCMZPY-UHFFFAOYSA-N; Benzenepropanamine, .gamma.-phenyl-; MFCD00008202; C31E561S64; 3-3-Diphenylpropylamine; 3,3-diphenylpropylamine e; 3,3-diphenylpropan-1-amin; EINECS 226-984-3; NSC137832; NSC 137832; ACMC-209lpx; 3.3-diphenylpropylamine; 3,3 Diphenylpropylamine; 3,3-diphenyl-propylamine; 3,3-diphenyl propylamine; EC 226-984-3; (3,3-diphenylpropyl)amine; AC1Q1HZ2; AC1L2XY3; TimTec1_004202; 3,3-Diphenyl-1-propanamine; Propylamine, 3,3-dipheny
DMNOUSV DT Small molecular drug
DMNOUSV PC 79698
DMNOUSV MW 211.3
DMNOUSV FM C15H17N
DMNOUSV IC InChI=1S/C15H17N/c16-12-11-15(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,15H,11-12,16H2
DMNOUSV CS C1=CC=C(C=C1)C(CCN)C2=CC=CC=C2
DMNOUSV IK KISZTEOELCMZPY-UHFFFAOYSA-N
DMNOUSV IU 3,3-diphenylpropan-1-amine
DMNOUSV CA CAS 5586-73-2
DMNOUSV DE Discovery agent
DMZTIPJ ID DMZTIPJ
DMZTIPJ DN 3,3'-pyrazine-2,5-diyldiphenol
DMZTIPJ HS Investigative
DMZTIPJ SN SCHEMBL1180306; CHEMBL450256; BDBM25866; ZINC40835319; hydroxyphenyl substituted pyrazine, 38
DMZTIPJ DT Small molecular drug
DMZTIPJ PC 25093399
DMZTIPJ MW 264.28
DMZTIPJ FM C16H12N2O2
DMZTIPJ IC InChI=1S/C16H12N2O2/c19-13-5-1-3-11(7-13)15-9-18-16(10-17-15)12-4-2-6-14(20)8-12/h1-10,19-20H
DMZTIPJ CS C1=CC(=CC(=C1)O)C2=CN=C(C=N2)C3=CC(=CC=C3)O
DMZTIPJ IK NBGGRQZLXLTPFA-UHFFFAOYSA-N
DMZTIPJ IU 3-[5-(3-hydroxyphenyl)pyrazin-2-yl]phenol
DMZTIPJ DE Discovery agent
DMZILNC ID DMZILNC
DMZILNC DN 3,3'-Pyridine-2,5-diyldiphenol
DMZILNC HS Investigative
DMZILNC SN SCHEMBL1181050; CHEMBL460182; BDBM25865; 3,3'-(2,5-Pyridinediyl)bisphenol; ZINC40865361; hydroxyphenyl substituted pyridine, 37
DMZILNC DT Small molecular drug
DMZILNC PC 25093398
DMZILNC MW 263.29
DMZILNC FM C17H13NO2
DMZILNC IC InChI=1S/C17H13NO2/c19-15-5-1-3-12(9-15)14-7-8-17(18-11-14)13-4-2-6-16(20)10-13/h1-11,19-20H
DMZILNC CS C1=CC(=CC(=C1)O)C2=CN=C(C=C2)C3=CC(=CC=C3)O
DMZILNC IK GWBPLTAHNKSFLG-UHFFFAOYSA-N
DMZILNC IU 3-[6-(3-hydroxyphenyl)pyridin-3-yl]phenol
DMZILNC DE Discovery agent
DMW7XFQ ID DMW7XFQ
DMW7XFQ DN 3,3'-Thiene-2,4-diyldiphenol
DMW7XFQ HS Investigative
DMW7XFQ SN 3,3'-Thiene-2,4-diyldiphenol; SCHEMBL1180152; CHEMBL461027; BDBM25856; FIVXNZZSAFLVFQ-UHFFFAOYSA-N; ZINC40391436; hydroxyphenyl substituted thiophene, 28
DMW7XFQ DT Small molecular drug
DMW7XFQ PC 25093392
DMW7XFQ MW 268.3
DMW7XFQ FM C16H12O2S
DMW7XFQ IC InChI=1S/C16H12O2S/c17-14-5-1-3-11(7-14)13-9-16(19-10-13)12-4-2-6-15(18)8-12/h1-10,17-18H
DMW7XFQ CS C1=CC(=CC(=C1)O)C2=CC(=CS2)C3=CC(=CC=C3)O
DMW7XFQ IK FIVXNZZSAFLVFQ-UHFFFAOYSA-N
DMW7XFQ IU 3-[4-(3-hydroxyphenyl)thiophen-2-yl]phenol
DMW7XFQ DE Discovery agent
DMWH0ER ID DMWH0ER
DMWH0ER DN 3,3'-thiene-2,5-diyldiphenol
DMWH0ER HS Investigative
DMWH0ER SN 3,3'-Thiene-2,5-diyldiphenol; SCHEMBL1181010; CHEMBL511530; BDBM25851; SVBBCXVMACPXGW-UHFFFAOYSA-N; ZINC40393198; hydroxyphenyl substituted thiophene, 23
DMWH0ER DT Small molecular drug
DMWH0ER PC 25093387
DMWH0ER MW 268.3
DMWH0ER FM C16H12O2S
DMWH0ER IC InChI=1S/C16H12O2S/c17-13-5-1-3-11(9-13)15-7-8-16(19-15)12-4-2-6-14(18)10-12/h1-10,17-18H
DMWH0ER CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=CC=C3)O
DMWH0ER IK SVBBCXVMACPXGW-UHFFFAOYSA-N
DMWH0ER IU 3-[5-(3-hydroxyphenyl)thiophen-2-yl]phenol
DMWH0ER DE Discovery agent
DMQDKYI ID DMQDKYI
DMQDKYI DN 3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine
DMQDKYI HS Investigative
DMQDKYI SN CHEMBL1077387; 36770-51-1; 1H-3-(3-pyridyl)-5-(4-pyridyl)-1,2,4-triazole; AC1LJ7ET; SCHEMBL11592234; MolPort-002-889-160; BDBM50311281; STL442012; CCG-42398; ZINC18164784; AKOS002669464; AKOS005228430; AKOS002732698; MCULE-6941572691; FT-0749446; 3,4''-(1H-1,2,4-triazole-3,5-diyl)dipyridine; SR-01000632401-1; 3-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine; 3-(3-Pyridyl)-5-(4-pyridyl)-1H-1,2,4-triazole
DMQDKYI DT Small molecular drug
DMQDKYI PC 918281
DMQDKYI MW 223.23
DMQDKYI FM C12H9N5
DMQDKYI IC InChI=1S/C12H9N5/c1-2-10(8-14-5-1)12-15-11(16-17-12)9-3-6-13-7-4-9/h1-8H,(H,15,16,17)
DMQDKYI CS C1=CC(=CN=C1)C2=NNC(=N2)C3=CC=NC=C3
DMQDKYI IK WIHUWTSKKGOEGI-UHFFFAOYSA-N
DMQDKYI IU 3-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine
DMQDKYI CA CAS 36770-51-1
DMQDKYI DE Discovery agent
DMFM60H ID DMFM60H
DMFM60H DN 3,4'-(Ethane-1,2-diyl)dibenzenamine
DMFM60H HS Investigative
DMFM60H SN CHEMBL1172396; 3,4'-Ethylenedianiline; BDBM50322062
DMFM60H DT Small molecular drug
DMFM60H PC 13580711
DMFM60H MW 212.29
DMFM60H FM C14H16N2
DMFM60H IC InChI=1S/C14H16N2/c15-13-8-6-11(7-9-13)4-5-12-2-1-3-14(16)10-12/h1-3,6-10H,4-5,15-16H2
DMFM60H CS C1=CC(=CC(=C1)N)CCC2=CC=C(C=C2)N
DMFM60H IK INOLZHNXGZQKJJ-UHFFFAOYSA-N
DMFM60H IU 3-[2-(4-aminophenyl)ethyl]aniline
DMFM60H DE Discovery agent
DMEN9T4 ID DMEN9T4
DMEN9T4 DN 3,4'-(thiophene-2,4-diyl)diphenol
DMEN9T4 HS Investigative
DMEN9T4 SN SCHEMBL1180505; CHEMBL505523; BDBM25855; VPHQUMICJYAMAM-UHFFFAOYSA-N; ZINC40835480; 3,4'-(2,4-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 27; 3-[4-(4-Hydroxyphenyl)-2-thienyl]phenol
DMEN9T4 DT Small molecular drug
DMEN9T4 PC 25093391
DMEN9T4 MW 268.3
DMEN9T4 FM C16H12O2S
DMEN9T4 IC InChI=1S/C16H12O2S/c17-14-6-4-11(5-7-14)13-9-16(19-10-13)12-2-1-3-15(18)8-12/h1-10,17-18H
DMEN9T4 CS C1=CC(=CC(=C1)O)C2=CC(=CS2)C3=CC=C(C=C3)O
DMEN9T4 IK VPHQUMICJYAMAM-UHFFFAOYSA-N
DMEN9T4 IU 3-[4-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMEN9T4 DE Discovery agent
DMSN814 ID DMSN814
DMSN814 DN 3,4,4',5-tetramethoxy-(Z)-stilbene
DMSN814 HS Investigative
DMSN814 SN CHEMBL47426; 134029-49-5; 1-Mtpe; NSC638499; Deoxycombretastatin A4; AC1NTUK5; ZINC5900; SCHEMBL3834841; (Z)-1,2,3-Trimethoxy-5-(2-(4-methoxyphenyl)ethenyl)benzene; cis-3,4,5,4'-tetramethoxystilbene; BDBM50006677; 10Z-3,4,4',5-tetramethoxystilbene; AKOS027382909; NSC-638499; 10Z-3,4,4'',5-tetramethoxystilbene; 3,4,4'',5-tetramethoxy-(Z)-stilbene; (Z) 3,4',5-TETRAMETHOXYSTILBENE; 5-(4-methoxystyryl)-1,2,3-trimethoxybenzene; (Z)-1,2,3-Trimethoxy-5-(4-methoxystyryl)benzene
DMSN814 DT Small molecular drug
DMSN814 PC 5388779
DMSN814 MW 300.3
DMSN814 FM C18H20O4
DMSN814 IC InChI=1S/C18H20O4/c1-19-15-9-7-13(8-10-15)5-6-14-11-16(20-2)18(22-4)17(12-14)21-3/h5-12H,1-4H3/b6-5-
DMSN814 CS COC1=CC=C(C=C1)/C=C\\C2=CC(=C(C(=C2)OC)OC)OC
DMSN814 IK GGFQQRXTLIJXNY-WAYWQWQTSA-N
DMSN814 IU 1,2,3-trimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMSN814 CA CAS 134029-49-5
DMSN814 DE Discovery agent
DMSV6K5 ID DMSV6K5
DMSV6K5 DN 3,4,5,6-Tetrachloro-[1,2]benzoquinone
DMSV6K5 HS Investigative
DMSV6K5 SN o-Chloranil; 2435-53-2; Tetrachloro-O-benzoquinone; 3,4,5,6-tetrachlorocyclohexa-3,5-diene-1,2-dione; 3,4,5,6-Tetrachloro-1,2-benzoquinone; Tetrachloro-o-quinone; 2-Chloranil; Tetrachloro-1,2-benzoquinone; o-Chloroanil; Isochloranil; 3,5-Cyclohexadiene-1,2-dione, 3,4,5,6-tetrachloro-; ortho-Chloranil; UNII-QN2NZL16NG; 3,4,5,6-Tetrachloro-o-benzoquinone; QN2NZL16NG; NSC 403503; o-Benzoquinone, 3,4,5,6-tetrachloro-; 3,4,5,6-Tetrachloro-3,5-cyclohexadiene-1,2-dione; MLS003171542; VRGCYEIGVVTZCC-UHFFFAOYSA-N
DMSV6K5 DT Small molecular drug
DMSV6K5 PC 73252
DMSV6K5 MW 245.9
DMSV6K5 FM C6Cl4O2
DMSV6K5 IC InChI=1S/C6Cl4O2/c7-1-2(8)4(10)6(12)5(11)3(1)9
DMSV6K5 CS C1(=C(C(=O)C(=O)C(=C1Cl)Cl)Cl)Cl
DMSV6K5 IK VRGCYEIGVVTZCC-UHFFFAOYSA-N
DMSV6K5 IU 3,4,5,6-tetrachlorocyclohexa-3,5-diene-1,2-dione
DMSV6K5 CA CAS 2435-53-2
DMSV6K5 DE Discovery agent
DMKOE9I ID DMKOE9I
DMKOE9I DN 3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one
DMKOE9I HS Investigative
DMKOE9I SN CHEMBL99448; 3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one; SCHEMBL6940070; LNTWPSKEEYNUKK-UHFFFAOYSA-N; BDBM50072192; 4,4a,5,6-Tetrahydro-pyrido[1,2-a]quinolin-3-one; 4,4a,5,6-Tetrahydro-3H-benzo[c]quinolizine-3-one
DMKOE9I DT Small molecular drug
DMKOE9I PC 10442752
DMKOE9I MW 199.25
DMKOE9I FM C13H13NO
DMKOE9I IC InChI=1S/C13H13NO/c15-12-7-8-14-11(9-12)6-5-10-3-1-2-4-13(10)14/h1-4,7-8,11H,5-6,9H2
DMKOE9I CS C1CC2=CC=CC=C2N3C1CC(=O)C=C3
DMKOE9I IK LNTWPSKEEYNUKK-UHFFFAOYSA-N
DMKOE9I IU 4,4a,5,6-tetrahydrobenzo[f]quinolizin-3-one
DMKOE9I DE Discovery agent
DMS42CA ID DMS42CA
DMS42CA DN 3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol
DMS42CA HS Investigative
DMS42CA SN CHEMBL464577; CHEBI:68326; 3,4,5-tribromo-2-(2,4-dibromophenoxy)phenol; 35162-01-7; Dysidea substance A; 6-hydroxy-2,2',3,4,4'-pentabromodiphenyl ether; SCHEMBL5527228; CTK1B7172; DTXSID60474586; BDBM50292443; ACM35162017; 3,4,5-tribromo-2-(2',4'-dibromophenoxy)phenol; Phenol, 3,4,5-tribromo-2-(2,4-dibromophenoxy)-; 3,4,5-tribromo-2-(2'', 4''-dibromo-phenoxy)phenol
DMS42CA DT Small molecular drug
DMS42CA PC 11952901
DMS42CA MW 580.7
DMS42CA FM C12H5Br5O2
DMS42CA IC InChI=1S/C12H5Br5O2/c13-5-1-2-9(6(14)3-5)19-12-8(18)4-7(15)10(16)11(12)17/h1-4,18H
DMS42CA CS C1=CC(=C(C=C1Br)Br)OC2=C(C(=C(C=C2O)Br)Br)Br
DMS42CA IK LNZHBUPVHNJGJG-UHFFFAOYSA-N
DMS42CA IU 3,4,5-tribromo-2-(2,4-dibromophenoxy)phenol
DMS42CA CA CAS 35162-01-7
DMS42CA CB CHEBI:68326
DMS42CA DE Discovery agent
DMYHC3S ID DMYHC3S
DMYHC3S DN 3,4',5-trimethoxy-(Z)-stilbene
DMYHC3S HS Investigative
DMYHC3S SN (Z)-3,5,4'-TRIMETHOXYSTILBENE; cis-trismethoxy Resveratrol; 94608-23-8; CHEMBL311636; (Z)-3,4',5-trimethoxystilbene; cis-Trismethoxyresveratrol; cis-Stilbene Derivative, 5a; SCHEMBL1006207; ZINC9252; 8Z-3,4',5-trimethoxystilbene; BDBM23940; MolPort-009-018-268; GDHNBPHYVRHYCC-PLNGDYQASA-N; (Z)-3,5,40-Trimethoxystilbene; HMS3648G16; 1101AH; AKOS025401671; AC-24237; DB-079973; 608T238; SR-01000946368; SR-01000946368-1; I14-7426; 1,3-dimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMYHC3S DT Small molecular drug
DMYHC3S PC 9878556
DMYHC3S MW 270.32
DMYHC3S FM C17H18O3
DMYHC3S IC InChI=1S/C17H18O3/c1-18-15-8-6-13(7-9-15)4-5-14-10-16(19-2)12-17(11-14)20-3/h4-12H,1-3H3/b5-4-
DMYHC3S CS COC1=CC=C(C=C1)/C=C\\C2=CC(=CC(=C2)OC)OC
DMYHC3S IK GDHNBPHYVRHYCC-PLNGDYQASA-N
DMYHC3S IU 1,3-dimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMYHC3S CA CAS 94608-23-8
DMYHC3S DE Discovery agent
DMCA7XU ID DMCA7XU
DMCA7XU DN 3,4,5-Trimethoxy-3'-amino-trans-stilbene
DMCA7XU HS Investigative
DMCA7XU SN CHEMBL1173065; SCHEMBL17236642; BDBM50322052
DMCA7XU DT Small molecular drug
DMCA7XU PC 49799650
DMCA7XU MW 285.34
DMCA7XU FM C17H19NO3
DMCA7XU IC InChI=1S/C17H19NO3/c1-19-15-10-13(11-16(20-2)17(15)21-3)8-7-12-5-4-6-14(18)9-12/h4-11H,18H2,1-3H3/b8-7+
DMCA7XU CS COC1=CC(=CC(=C1OC)OC)/C=C/C2=CC(=CC=C2)N
DMCA7XU IK KHIQMXWOBUJQMV-BQYQJAHWSA-N
DMCA7XU IU 3-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline
DMCA7XU DE Discovery agent
DMDBOJ5 ID DMDBOJ5
DMDBOJ5 DN 3,4,5-Trimethoxy-4'-amino-trans-stilbene
DMDBOJ5 HS Investigative
DMDBOJ5 SN CHEMBL87477; SCHEMBL4263050; MWXBWYJFAGYFKS-SNAWJCMRSA-N; ZINC26575008; BDBM50322046; (E)-4'-Amino-3,4,5-trimethoxystilbene; 3,4,5-Trimethoxy-4''-amino-trans-stilbene; 4-[2-(3,4,5-Trimethoxy-phenyl)-vinyl]-phenylamine
DMDBOJ5 DT Small molecular drug
DMDBOJ5 PC 15696376
DMDBOJ5 MW 285.34
DMDBOJ5 FM C17H19NO3
DMDBOJ5 IC InChI=1S/C17H19NO3/c1-19-15-10-13(11-16(20-2)17(15)21-3)5-4-12-6-8-14(18)9-7-12/h4-11H,18H2,1-3H3/b5-4+
DMDBOJ5 CS COC1=CC(=CC(=C1OC)OC)/C=C/C2=CC=C(C=C2)N
DMDBOJ5 IK MWXBWYJFAGYFKS-SNAWJCMRSA-N
DMDBOJ5 IU 4-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline
DMDBOJ5 DE Discovery agent
DMU5NRA ID DMU5NRA
DMU5NRA DN 3,4,5-trimethoxy-N-(thiazol-2-yl)benzamide
DMU5NRA HS Investigative
DMU5NRA SN 3,4,5-Trimethoxy-N-(1,3-thiazol-2-yl)benzamide; 50591-71-4; AC1LCU6P; Cambridge id 5149479; Oprea1_821264; MLS000027375; CHEMBL225354; ZINC45264; XSAYHNGEJLPKEX-UHFFFAOYSA-N; MolPort-000-653-421; HMS2331F23; STK731712; AKOS001625155; MCULE-9743171840; NCGC00018998-01; NCGC00018998-02; ST067007; SMR000034190; Benzamide, 3,4,5-trimethoxy-N-2-thiazolyl-; Thiazole, 2-(3,4,5-trimethoxybenzoylamino)-; 3,4,5-trimethoxy-N-1,3-thiazol-2-ylbenzamide; SR-01000000944; SR-01000000944-2; Z28173733
DMU5NRA DT Small molecular drug
DMU5NRA PC 606801
DMU5NRA MW 294.33
DMU5NRA FM C13H14N2O4S
DMU5NRA IC InChI=1S/C13H14N2O4S/c1-17-9-6-8(7-10(18-2)11(9)19-3)12(16)15-13-14-4-5-20-13/h4-7H,1-3H3,(H,14,15,16)
DMU5NRA CS COC1=CC(=CC(=C1OC)OC)C(=O)NC2=NC=CS2
DMU5NRA IK XSAYHNGEJLPKEX-UHFFFAOYSA-N
DMU5NRA IU 3,4,5-trimethoxy-N-(1,3-thiazol-2-yl)benzamide
DMU5NRA DE Discovery agent
DMO34LJ ID DMO34LJ
DMO34LJ DN 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol
DMO34LJ HS Investigative
DMO34LJ SN CHEMBL186098; 6-hydroxy-2,2',3,4',5-pentabromodiphenyl ether; 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol; ZINC95606620; BDBM50150782; 497069-29-1; 2-(2,4-Dibromophenoxy)-3,4,6-tribromophenol
DMO34LJ DT Small molecular drug
DMO34LJ PC 11093078
DMO34LJ MW 580.7
DMO34LJ FM C12H5Br5O2
DMO34LJ IC InChI=1S/C12H5Br5O2/c13-5-1-2-9(6(14)3-5)19-12-10(17)7(15)4-8(16)11(12)18/h1-4,18H
DMO34LJ CS C1=CC(=C(C=C1Br)Br)OC2=C(C(=CC(=C2Br)Br)Br)O
DMO34LJ IK FAGFPLJEMPQMRV-UHFFFAOYSA-N
DMO34LJ IU 3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
DMO34LJ DE Discovery agent
DM3MAEQ ID DM3MAEQ
DM3MAEQ DN 3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one
DM3MAEQ HS Investigative
DM3MAEQ DT Small molecular drug
DM3MAEQ PC 10308184
DM3MAEQ MW 270.24
DM3MAEQ FM C15H10O5
DM3MAEQ IC InChI=1S/C15H10O5/c16-8-3-1-7(2-4-8)12-14(19)10-5-9(17)6-11(18)13(10)15(12)20/h1-6,12,16-18H
DM3MAEQ CS C1=CC(=CC=C1C2C(=O)C3=C(C2=O)C(=CC(=C3)O)O)O
DM3MAEQ IK GXKXWCKNQMYETG-UHFFFAOYSA-N
DM3MAEQ IU 4,6-dihydroxy-2-(4-hydroxyphenyl)indene-1,3-dione
DM3MAEQ DE Discovery agent
DMN4Z27 ID DMN4Z27
DMN4Z27 DN 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin
DMN4Z27 HS Investigative
DMN4Z27 SN CHEMBL487235; 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin
DMN4Z27 DT Small molecular drug
DMN4Z27 PC 25139469
DMN4Z27 MW 345.2
DMN4Z27 FM C17H13BrO3
DMN4Z27 IC InChI=1S/C17H13BrO3/c1-10(18)9-20-15-8-7-13-12-5-3-4-6-14(12)17(19)21-16(13)11(15)2/h3-8H,1,9H2,2H3
DMN4Z27 CS CC1=C(C=CC2=C1OC(=O)C3=CC=CC=C23)OCC(=C)Br
DMN4Z27 IK GGTNLZBSSNHXRY-UHFFFAOYSA-N
DMN4Z27 IU 3-(2-bromoprop-2-enoxy)-4-methylbenzo[c]chromen-6-one
DMN4Z27 DE Discovery agent
DM1MC06 ID DM1MC06
DM1MC06 DN 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
DM1MC06 HS Investigative
DM1MC06 SN CHEMBL520061; 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
DM1MC06 DT Small molecular drug
DM1MC06 PC 25139473
DM1MC06 MW 298.29
DM1MC06 FM C17H14O5
DM1MC06 IC InChI=1S/C17H14O5/c1-10(18)9-21-14-8-7-12-11-5-3-4-6-13(11)17(19)22-15(12)16(14)20-2/h3-8H,9H2,1-2H3
DM1MC06 CS CC(=O)COC1=C(C2=C(C=C1)C3=CC=CC=C3C(=O)O2)OC
DM1MC06 IK KXJLOTAAVRETIT-UHFFFAOYSA-N
DM1MC06 IU 4-methoxy-3-(2-oxopropoxy)benzo[c]chromen-6-one
DM1MC06 DE Discovery agent
DMKC6L8 ID DMKC6L8
DMKC6L8 DN 3,4-Benzo-7-acetonyloxy-8-methylcoumarin
DMKC6L8 HS Investigative
DMKC6L8 SN 4-Methyl-3-(2-oxopropoxy)-6H-benzo[c]chromen-6-one; 307551-49-1; CHEMBL488072; CHEMBRDG-BB 6146055; CBMicro_001512; AC1LDVAV; 3,4-Benzo-7-acetonyloxy-8-methylcoumarin; ZINC83619; MolPort-000-689-004; ZX-CM016545; SMSF0015505; STL457381; BDBM50246269; AKOS002377781; MCULE-6636508935; CB03255; ACM307551491; AJ-10649; BIM-0001590.P001; W-9060; 4-methyl-3-(2-oxopropoxy)benzo[c]chromen-6-one; SR-01000229085
DMKC6L8 DT Small molecular drug
DMKC6L8 PC 701990
DMKC6L8 MW 282.29
DMKC6L8 FM C17H14O4
DMKC6L8 IC InChI=1S/C17H14O4/c1-10(18)9-20-15-8-7-13-12-5-3-4-6-14(12)17(19)21-16(13)11(15)2/h3-8H,9H2,1-2H3
DMKC6L8 CS CC1=C(C=CC2=C1OC(=O)C3=CC=CC=C23)OCC(=O)C
DMKC6L8 IK VNVLPLZRLNYOQH-UHFFFAOYSA-N
DMKC6L8 IU 4-methyl-3-(2-oxopropoxy)benzo[c]chromen-6-one
DMKC6L8 DE Discovery agent
DM91W2K ID DM91W2K
DM91W2K DN 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one
DM91W2K HS Investigative
DM91W2K SN CHEMBL1098382; 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one
DM91W2K DT Small molecular drug
DM91W2K PC 11760063
DM91W2K MW 356.4
DM91W2K FM C20H20O6
DM91W2K IC InChI=1S/C20H20O6/c1-22-15-7-5-12(9-17(15)24-3)14-11-26-20(21)19(14)13-6-8-16(23-2)18(10-13)25-4/h5-10H,11H2,1-4H3
DM91W2K CS COC1=C(C=C(C=C1)C2=C(C(=O)OC2)C3=CC(=C(C=C3)OC)OC)OC
DM91W2K IK FGMQIGBHXSBGMS-UHFFFAOYSA-N
DM91W2K IU 3,4-bis(3,4-dimethoxyphenyl)-2H-furan-5-one
DM91W2K DE Discovery agent
DMEQ1HC ID DMEQ1HC
DMEQ1HC DN 3,4-bis(indol-3-yl)maleimide derivative
DMEQ1HC HS Investigative
DMEQ1HC SN CHEMBL7364
DMEQ1HC DT Small molecular drug
DMEQ1HC PC 10033891
DMEQ1HC MW 971.2
DMEQ1HC FM C49H66N10O9S
DMEQ1HC IC InChI=1S/C49H66N10O9S/c1-31(60)54-39(49(66)59-21-11-18-41(59)46(63)56-38(16-8-10-20-51)45(62)55-37(44(61)52-2)15-7-9-19-50)30-69-27-26-68-25-24-67-23-22-58-29-35(33-13-4-6-17-40(33)58)43-42(47(64)57-48(43)65)34-28-53-36-14-5-3-12-32(34)36/h3-6,12-14,17,28-29,37-39,41,53H,7-11,15-16,18-27,30,50-51H2,1-2H3,(H,52,61)(H,54,60)(H,55,62)(H,56,63)(H,57,64,65)/t37-,38-,39-,41-/m0/s1
DMEQ1HC CS CC(=O)N[C@@H](CSCCOCCOCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NC
DMEQ1HC IK HOAREJUGBLUUJD-MJSJRNKMSA-N
DMEQ1HC IU (2S)-1-[(2R)-2-acetamido-3-[2-[2-[2-[3-[4-(1H-indol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]ethoxy]ethoxy]ethylsulfanyl]propanoyl]-N-[(2S)-6-amino-1-[[(2S)-6-amino-1-(methylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DMEQ1HC DE Discovery agent
DMDO175 ID DMDO175
DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione
DMDO175 HS Investigative
DMDO175 SN 1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388
DMDO175 DT Small molecular drug
DMDO175 PC 10946795
DMDO175 MW 309.3
DMDO175 FM C18H15NO4
DMDO175 IC InChI=1S/C18H15NO4/c1-22-13-7-3-11(4-8-13)15-16(18(21)19-17(15)20)12-5-9-14(23-2)10-6-12/h3-10H,1-2H3,(H,19,20,21)
DMDO175 CS COC1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CC=C(C=C3)OC
DMDO175 IK WRDXDCMVUJADCC-UHFFFAOYSA-N
DMDO175 IU 3,4-bis(4-methoxyphenyl)pyrrole-2,5-dione
DMDO175 CA CAS 108774-82-9
DMDO175 DE Discovery agent
DM8R03D ID DM8R03D
DM8R03D DN 3,4-diarylpyrazoline derivative
DM8R03D HS Investigative
DM8R03D DE Discovery agent
DMBUT8A ID DMBUT8A
DMBUT8A DN 3,4-dibenzyloxy-2'-hydroxychalcone
DMBUT8A HS Investigative
DMBUT8A SN CHEMBL492554; SCHEMBL17509393; SCHEMBL17509394; LHMDXKJKKAITQJ-BMRADRMJSA-N; BDBM50257724; 3,4-dibenzyloxy-2''-hydroxychalcone
DMBUT8A DT Small molecular drug
DMBUT8A PC 25256831
DMBUT8A MW 436.5
DMBUT8A FM C29H24O4
DMBUT8A IC InChI=1S/C29H24O4/c30-26-14-8-7-13-25(26)27(31)17-15-22-16-18-28(32-20-23-9-3-1-4-10-23)29(19-22)33-21-24-11-5-2-6-12-24/h1-19,30H,20-21H2/b17-15+
DMBUT8A CS C1=CC=C(C=C1)COC2=C(C=C(C=C2)/C=C/C(=O)C3=CC=CC=C3O)OCC4=CC=CC=C4
DMBUT8A IK LHMDXKJKKAITQJ-BMRADRMJSA-N
DMBUT8A IU (E)-3-[3,4-bis(phenylmethoxy)phenyl]-1-(2-hydroxyphenyl)prop-2-en-1-one
DMBUT8A DE Discovery agent
DMXQVRD ID DMXQVRD
DMXQVRD DN 3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol
DMXQVRD HS Investigative
DMXQVRD SN CHEMBL187472; 3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol; Phenol, 3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)-; BDBM50150781; 741285-19-8; 5,5',6-Tribromo-2,2'-dihydroxydiphenyl ether
DMXQVRD DT Small molecular drug
DMXQVRD PC 44396194
DMXQVRD MW 438.89
DMXQVRD FM C12H7Br3O3
DMXQVRD IC InChI=1S/C12H7Br3O3/c13-6-1-3-8(16)10(5-6)18-12-9(17)4-2-7(14)11(12)15/h1-5,16-17H
DMXQVRD CS C1=CC(=C(C=C1Br)OC2=C(C=CC(=C2Br)Br)O)O
DMXQVRD IK MQTQEJZMDKSDNZ-UHFFFAOYSA-N
DMXQVRD IU 3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
DMXQVRD DE Discovery agent
DMS1QIJ ID DMS1QIJ
DMS1QIJ DN 3',4'-dichloroacetophenonethiosemicarbazone
DMS1QIJ HS Investigative
DMS1QIJ SN CHEMBL90512; 3',4'-dichloroacetophenonethiosemicarbazone; HMS544L20; MolPort-000-519-093; 18087-41-7; BDBM50114653; AKOS002268894; CCG-244059; ST50170879; [(E)-1-(3,4-dichlorophenyl)ethylideneamino]thiourea; 1-(3,4-DICHLOROPHENYL)ETHANONE THIOSEMICARBAZONE; (1E)-1-(3,4-dichlorophenyl)ethan-1-one thiosemicarbazone
DMS1QIJ DT Small molecular drug
DMS1QIJ PC 9583002
DMS1QIJ MW 262.16
DMS1QIJ FM C9H9Cl2N3S
DMS1QIJ IC InChI=1S/C9H9Cl2N3S/c1-5(13-14-9(12)15)6-2-3-7(10)8(11)4-6/h2-4H,1H3,(H3,12,14,15)/b13-5+
DMS1QIJ CS C/C(=N\\NC(=S)N)/C1=CC(=C(C=C1)Cl)Cl
DMS1QIJ IK WLYQLQVFJXFMJD-WLRTZDKTSA-N
DMS1QIJ IU [(E)-1-(3,4-dichlorophenyl)ethylideneamino]thiourea
DMS1QIJ DE Discovery agent
DMUSPIC ID DMUSPIC
DMUSPIC DN 3,4-dichlorobenzaldehyde thiosemicarbazone
DMUSPIC HS Investigative
DMUSPIC SN 3,4-Dichlorobenzaldehyde thiosemicarbazone; CHEMBL415311; 6292-74-6; 2-(3,4-dichlorobenzylidene)hydrazine-1-carbothioamide; NSC9937; AC1OR2L6; HMS556D17; DTXSID30428879; OMVGKAWQTXZISA-UUILKARUSA-N; MolPort-002-909-527; NSC-9937; BDBM50114648; ZINC20164022; AKOS008939634; CCG-247690; KB-279883
DMUSPIC DT Small molecular drug
DMUSPIC PC 7695053
DMUSPIC MW 248.13
DMUSPIC FM C8H7Cl2N3S
DMUSPIC IC InChI=1S/C8H7Cl2N3S/c9-6-2-1-5(3-7(6)10)4-12-13-8(11)14/h1-4H,(H3,11,13,14)/b12-4+
DMUSPIC CS C1=CC(=C(C=C1/C=N/NC(=S)N)Cl)Cl
DMUSPIC IK OMVGKAWQTXZISA-UUILKARUSA-N
DMUSPIC IU [(E)-(3,4-dichlorophenyl)methylideneamino]thiourea
DMUSPIC CA CAS 6292-74-6
DMUSPIC DE Discovery agent
DMN61Q5 ID DMN61Q5
DMN61Q5 DN 3,4-Dichlorobenzenemethanethiol
DMN61Q5 HS Investigative
DMN61Q5 SN 3,4-Dichlorobenzyl mercaptan; 36480-40-7; 3,4-Dichlorobenzenemethanethiol; (3,4-Dichlorophenyl)methanethiol; 3,4-Dichlorotoluene-alpha-thiol; CHEMBL1224626; CEGBRSQPRQXALB-UHFFFAOYSA-N; Benzenemethanethiol, 3,4-dichloro-; EINECS 253-054-4; AC1L3NZT; ACMC-1AEX5; AC1Q3O9X; 3,4-dichlorobenzylmercaptan; SCHEMBL232137; CTK3J7596; 3,4-Dichloro-alpha-toluenethiol; DTXSID50189990; MolPort-002-498-119; ZINC4802670; (3,4-Dichlorophenyl)methanethiol #; (3,4-Dichloro-phenyl)-methanethiol; BDBM50325571; MFCD00039651; GEO-00980
DMN61Q5 DT Small molecular drug
DMN61Q5 PC 118986
DMN61Q5 MW 193.09
DMN61Q5 FM C7H6Cl2S
DMN61Q5 IC InChI=1S/C7H6Cl2S/c8-6-2-1-5(4-10)3-7(6)9/h1-3,10H,4H2
DMN61Q5 CS C1=CC(=C(C=C1CS)Cl)Cl
DMN61Q5 IK CEGBRSQPRQXALB-UHFFFAOYSA-N
DMN61Q5 IU (3,4-dichlorophenyl)methanethiol
DMN61Q5 CA CAS 36480-40-7
DMN61Q5 DE Discovery agent
DMOZCDK ID DMOZCDK
DMOZCDK DN 3,4-dichloroisocoumarin
DMOZCDK HS Investigative
DMOZCDK SN 3,4-dichloroisocoumarin; 51050-59-0; 3,4-Dcl; 3,4-Dichloro-1H-isochromen-1-one; 1H-2-Benzopyran-1-one,3,4-dichloro-; 3,4-DCI; 3,4 dichloroisocoumarin; 3,4-Dichloro-1H-2-benzopyran-1-one; 1H-2-Benzopyran-1-one, 3,4-dichloro-; CHEMBL24983; 3,4-dichloroisochromen-1-one; 3,4-Dichloro-2-benzopyran-1-one; C9H4Cl2O2; Lopac-D-7910; cid_1609; AC1Q3H9V; AC1L1BU9; Lopac0_000442; KBioGR_000269; KBioSS_000269; BSPBio_001549; MLS002153325; SCHEMBL106901; 3,4-Dichloro-isochromen-1-one; KBio3_000538; KBio2_002837; CTK4J3543; KBio2_005405
DMOZCDK DT Small molecular drug
DMOZCDK PC 1609
DMOZCDK MW 215.03
DMOZCDK FM C9H4Cl2O2
DMOZCDK IC InChI=1S/C9H4Cl2O2/c10-7-5-3-1-2-4-6(5)9(12)13-8(7)11/h1-4H
DMOZCDK CS C1=CC=C2C(=C1)C(=C(OC2=O)Cl)Cl
DMOZCDK IK SUGXUUGGLDCZKB-UHFFFAOYSA-N
DMOZCDK IU 3,4-dichloroisochromen-1-one
DMOZCDK CA CAS 51050-59-0
DMOZCDK CB CHEBI:109540
DMOZCDK DE Discovery agent
DMMZURL ID DMMZURL
DMMZURL DN 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL HS Investigative
DMMZURL SN CHEMBL1254552; 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL DT Small molecular drug
DMMZURL PC 46947643
DMMZURL MW 319.2
DMMZURL FM C16H12Cl2N2O
DMMZURL IC InChI=1S/C16H12Cl2N2O/c1-9-6-11-7-12(3-5-15(11)19-9)20-16(21)10-2-4-13(17)14(18)8-10/h2-8,19H,1H3,(H,20,21)
DMMZURL CS CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3=CC(=C(C=C3)Cl)Cl
DMMZURL IK ICMYUZJRKLEKDA-UHFFFAOYSA-N
DMMZURL IU 3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMMZURL DE Discovery agent
DMWOMVF ID DMWOMVF
DMWOMVF DN 3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide
DMWOMVF HS Investigative
DMWOMVF SN CHEMBL8893; 3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide; BDBM50005468
DMWOMVF DT Small molecular drug
DMWOMVF PC 44265913
DMWOMVF MW 382.3
DMWOMVF FM C22H17Cl2NO
DMWOMVF IC InChI=1S/C22H17Cl2NO/c23-20-12-11-18(15-21(20)24)22(26)25-14-13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-13,15H,14H2,(H,25,26)
DMWOMVF CS C1=CC=C(C=C1)C(=CCNC(=O)C2=CC(=C(C=C2)Cl)Cl)C3=CC=CC=C3
DMWOMVF IK OYXWUVAZLKNOAB-UHFFFAOYSA-N
DMWOMVF IU 3,4-dichloro-N-(3,3-diphenylprop-2-enyl)benzamide
DMWOMVF DE Discovery agent
DM4RNOE ID DM4RNOE
DM4RNOE DN 3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DM4RNOE HS Investigative
DM4RNOE SN CHEMBL293437; 3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide; 3,4-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; AC1LF45X; Oprea1_772660; Oprea1_724335; ZINC73690; CCG-993; MolPort-001-949-151; BDBM50101784; STK017434; AKOS000519164; MCULE-6935310530; BAS 00860111; ST50005447; N-(4-Phenyl-2-thiazolyl)-3,4-dichlorobenzamide; Z27772110; (3,4-dichlorophenyl)-N-(4-phenyl(1,3-thiazol-2-yl))carboxamide
DM4RNOE DT Small molecular drug
DM4RNOE PC 697363
DM4RNOE MW 349.2
DM4RNOE FM C16H10Cl2N2OS
DM4RNOE IC InChI=1S/C16H10Cl2N2OS/c17-12-7-6-11(8-13(12)18)15(21)20-16-19-14(9-22-16)10-4-2-1-3-5-10/h1-9H,(H,19,20,21)
DM4RNOE CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC(=C(C=C3)Cl)Cl
DM4RNOE IK AYVXSTQWLPUGKB-UHFFFAOYSA-N
DM4RNOE IU 3,4-dichloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DM4RNOE DE Discovery agent
DMFV3Y9 ID DMFV3Y9
DMFV3Y9 DN 3,4-difluorobenzaldehyde O-benzoyloxime
DMFV3Y9 HS Investigative
DMFV3Y9 SN 3,4-difluorobenzaldehyde O-benzoyloxime; CHEMBL178450; SCHEMBL3226311; SCHEMBL3226318
DMFV3Y9 DT Small molecular drug
DMFV3Y9 PC 11470979
DMFV3Y9 MW 261.22
DMFV3Y9 FM C14H9F2NO2
DMFV3Y9 IC InChI=1S/C14H9F2NO2/c15-12-7-6-10(8-13(12)16)9-17-19-14(18)11-4-2-1-3-5-11/h1-9H/b17-9+
DMFV3Y9 CS C1=CC=C(C=C1)C(=O)O/N=C/C2=CC(=C(C=C2)F)F
DMFV3Y9 IK HOHACQRGFZUDCD-RQZCQDPDSA-N
DMFV3Y9 IU [(E)-(3,4-difluorophenyl)methylideneamino] benzoate
DMFV3Y9 DE Discovery agent
DM0I6UT ID DM0I6UT
DM0I6UT DN 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine
DM0I6UT HS Investigative
DM0I6UT SN CHEMBL6656; 2-amino-3,4-dihydroquinoline; 1,2,3,4-tetrahydroquinolin-2-imine; AC1N2ULT; 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine; 3,4-dihydroquinolin-2-amine; SCHEMBL2075410; RREBANHDFAXBEZ-UHFFFAOYSA-N; MolPort-005-905-447; HMS1726J17; 3,4-Dihydroquinolin-2(1H)-imine; ZINC13014981; BDBM50062129; AKOS006221851; AKOS008024789; MCULE-1322063466; 3,4-Dihydro-1H-quinolin-(2Z)-ylideneamine
DM0I6UT DT Small molecular drug
DM0I6UT PC 4102304
DM0I6UT MW 146.19
DM0I6UT FM C9H10N2
DM0I6UT IC InChI=1S/C9H10N2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-4H,5-6H2,(H2,10,11)
DM0I6UT CS C1CC(=NC2=CC=CC=C21)N
DM0I6UT IK RREBANHDFAXBEZ-UHFFFAOYSA-N
DM0I6UT IU 3,4-dihydroquinolin-2-amine
DM0I6UT DE Discovery agent
DMUOXHP ID DMUOXHP
DMUOXHP DN 3,4-dihydroquinazolin-2-amine hydrobromide
DMUOXHP HS Investigative
DMUOXHP SN CHEMBL557381; SCHEMBL2386507; RXCXYMVUYRKQAO-UHFFFAOYSA-N; 1,4-dihydro-quinazolin-2-ylamine monohydrobromide
DMUOXHP DT Small molecular drug
DMUOXHP PC 45263885
DMUOXHP MW 228.09
DMUOXHP FM C8H10BrN3
DMUOXHP IC InChI=1S/C8H9N3.BrH/c9-8-10-5-6-3-1-2-4-7(6)11-8;/h1-4H,5H2,(H3,9,10,11);1H
DMUOXHP CS C1C2=CC=CC=C2NC(=N1)N.Br
DMUOXHP IK RXCXYMVUYRKQAO-UHFFFAOYSA-N
DMUOXHP IU 1,4-dihydroquinazolin-2-amine;hydrobromide
DMUOXHP DE Discovery agent
DMG4NR3 ID DMG4NR3
DMG4NR3 DN 3,4-Dihydroxy-10H-anthracen-9-one
DMG4NR3 HS Investigative
DMG4NR3 SN CHEMBL121693; 3,4-Dihydroxy-10H-anthracen-9-one; 1,2-dihydroxy-10-anthrone; SCHEMBL5034789; KBOKOYAHHLPGSJ-UHFFFAOYSA-N; BDBM50060872; ZINC13606495; 3,4-Dihydroxyanthracen-9(10H)-one
DMG4NR3 DT Small molecular drug
DMG4NR3 PC 12976294
DMG4NR3 MW 226.23
DMG4NR3 FM C14H10O3
DMG4NR3 IC InChI=1S/C14H10O3/c15-12-6-5-10-11(14(12)17)7-8-3-1-2-4-9(8)13(10)16/h1-6,15,17H,7H2
DMG4NR3 CS C1C2=CC=CC=C2C(=O)C3=C1C(=C(C=C3)O)O
DMG4NR3 IK KBOKOYAHHLPGSJ-UHFFFAOYSA-N
DMG4NR3 IU 3,4-dihydroxy-10H-anthracen-9-one
DMG4NR3 DE Discovery agent
DMZJ4VL ID DMZJ4VL
DMZJ4VL DN 3,4-dihydroxybenzaldehyde-O-ethyloxime
DMZJ4VL HS Investigative
DMZJ4VL DT Small molecular drug
DMZJ4VL PC 136180746
DMZJ4VL MW 181.19
DMZJ4VL FM C9H11NO3
DMZJ4VL IC InChI=1S/C9H11NO3/c1-2-13-10-6-7-3-4-8(11)9(12)5-7/h3-6,11-12H,2H2,1H3/b10-6-
DMZJ4VL CS CCO/N=C\\C1=CC(=C(C=C1)O)O
DMZJ4VL IK XMXAPNDTHZRELH-POHAHGRESA-N
DMZJ4VL IU 4-[(Z)-ethoxyiminomethyl]benzene-1,2-diol
DMZJ4VL DE Discovery agent
DM7N3MX ID DM7N3MX
DM7N3MX DN 3,4-dihydroxyphenylacetaldehyde
DM7N3MX HS Investigative
DM7N3MX SN DOPAL
DM7N3MX DT Small molecular drug
DM7N3MX PC 119219
DM7N3MX MW 152.15
DM7N3MX FM C8H8O3
DM7N3MX IC InChI=1S/C8H8O3/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,4-5,10-11H,3H2
DM7N3MX CS C1=CC(=C(C=C1CC=O)O)O
DM7N3MX IK IADQVXRMSNIUEL-UHFFFAOYSA-N
DM7N3MX IU 2-(3,4-dihydroxyphenyl)acetaldehyde
DM7N3MX CA CAS 5707-55-1
DM7N3MX CB CHEBI:27978
DM7N3MX DE Discovery agent
DMTQX92 ID DMTQX92
DMTQX92 DN 3,4-dihydroxyxanthone
DMTQX92 HS Investigative
DMTQX92 SN 3,4-Dihydroxyxanthone; 3,4-Dihydroxy-xanthone; 3,4-dihydroxyxanthen-9-one; CHEMBL446323; 39731-48-1; AC1NX8OR; SCHEMBL133422; 3,4-dihydroxy-xanthen-9-one; CTK4I1796; DTXSID20192815; YFVCSEXMOBEPQB-UHFFFAOYSA-N; 3,4-dihydroxy-9H-xanthen-9-one; 9H-Xanthen-9-one,3,4-dihydroxy-; ZINC15119047; BDBM50269645; 9H-Xanthen-9-one, 3,4-dihydroxy-
DMTQX92 DT Small molecular drug
DMTQX92 PC 5748382
DMTQX92 MW 228.2
DMTQX92 FM C13H8O4
DMTQX92 IC InChI=1S/C13H8O4/c14-9-6-5-8-11(15)7-3-1-2-4-10(7)17-13(8)12(9)16/h1-6,14,16H
DMTQX92 CS C1=CC=C2C(=C1)C(=O)C3=C(O2)C(=C(C=C3)O)O
DMTQX92 IK YFVCSEXMOBEPQB-UHFFFAOYSA-N
DMTQX92 IU 3,4-dihydroxyxanthen-9-one
DMTQX92 CA CAS 39731-48-1
DMTQX92 DE Discovery agent
DMVDZCE ID DMVDZCE
DMVDZCE DN 3,4-Dimethoxy-4'-amino-trans-stilbene
DMVDZCE HS Investigative
DMVDZCE SN CHEMBL1172937; BDBM50322051
DMVDZCE DT Small molecular drug
DMVDZCE PC 49799648
DMVDZCE MW 255.31
DMVDZCE FM C16H17NO2
DMVDZCE IC InChI=1S/C16H17NO2/c1-18-15-10-7-13(11-16(15)19-2)4-3-12-5-8-14(17)9-6-12/h3-11H,17H2,1-2H3/b4-3+
DMVDZCE CS COC1=C(C=C(C=C1)/C=C/C2=CC=C(C=C2)N)OC
DMVDZCE IK JZZHXIPQAWDZPC-ONEGZZNKSA-N
DMVDZCE IU 4-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]aniline
DMVDZCE DE Discovery agent
DMMO6QI ID DMMO6QI
DMMO6QI DN 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMMO6QI HS Investigative
DMMO6QI SN CHEMBL185161; 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine; 3,4-dimethylpyrrolidin-2-on imine; BDBM50150928
DMMO6QI DT Small molecular drug
DMMO6QI PC 19049163
DMMO6QI MW 112.17
DMMO6QI FM C6H12N2
DMMO6QI IC InChI=1S/C6H12N2/c1-4-3-8-6(7)5(4)2/h4-5H,3H2,1-2H3,(H2,7,8)
DMMO6QI CS CC1CN=C(C1C)N
DMMO6QI IK YVPMIGCVKYQACC-UHFFFAOYSA-N
DMMO6QI IU 3,4-dimethyl-3,4-dihydro-2H-pyrrol-5-amine
DMMO6QI DE Discovery agent
DMPK6YT ID DMPK6YT
DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione
DMPK6YT HS Investigative
DMPK6YT SN 2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; 3,4-diphenyl-1H-pyrrole-2,5-dione; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556
DMPK6YT DT Small molecular drug
DMPK6YT PC 2752461
DMPK6YT MW 249.26
DMPK6YT FM C16H11NO2
DMPK6YT IC InChI=1S/C16H11NO2/c18-15-13(11-7-3-1-4-8-11)14(16(19)17-15)12-9-5-2-6-10-12/h1-10H,(H,17,18,19)
DMPK6YT CS C1=CC=C(C=C1)C2=C(C(=O)NC2=O)C3=CC=CC=C3
DMPK6YT IK WADCPEMKIBAJHH-UHFFFAOYSA-N
DMPK6YT IU 3,4-diphenylpyrrole-2,5-dione
DMPK6YT CA CAS 31295-36-0
DMPK6YT DE Discovery agent
DM8BJPU ID DM8BJPU
DM8BJPU DN 3,4-epoxydehydroleucodin
DM8BJPU HS Investigative
DM8BJPU SN 3,4-epoxydehydroleucodin; Eminensin A
DM8BJPU DT Small molecular drug
DM8BJPU PC 10422717
DM8BJPU MW 260.279
DM8BJPU FM C15H16O4
DM8BJPU IC InChI=1S/C15H16O4/c1-6-4-5-8-7(2)14(17)18-12(8)10-9(6)11(16)13-15(10,3)19-13/h8,10,12-13H,2,4-5H2,1,3H3/t8-,10-,12-,13+,15-/m0/s1
DM8BJPU CS CC1=C2[C@@H]([C@@H]3[C@@H](CC1)C(=C)C(=O)O3)[C@]4([C@@H](C2=O)O4)C
DM8BJPU IK IQFFYNSHANWLIR-FJKOOJNLSA-N
DM8BJPU IU (1S,2S,6S,12S,14S)-9,14-dimethyl-5-methylidene-3,13-dioxatetracyclo[8.4.0.02,6.012,14]tetradec-9-ene-4,11-dione
DM8BJPU DE Discovery agent
DMLIG3X ID DMLIG3X
DMLIG3X DN 3,5 DIBROMOTYROSINE
DMLIG3X HS Investigative
DMLIG3X SN 3,5-DIBROMOTYROSINE; 2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid; 537-24-6; 3,5-Dibromo-tyrosine; NSC210786; 3,5-Dibromo-DL-tyrosine; Bromotiren; CHEMBL1253341; CHEBI:80912; L-Tyrosine,5-dibromo-; Tyrosine,5-dibromo-, L-; Dibromotirina; Biotiren; NSC-210786; EINECS 208-661-9; Tyrosine,5-dibromo-; .beta.-(3,5-Dibromo-4-hydroxyphenyl)alanine; ACMC-209hco; AC1L1W1Q; SCHEMBL145218; CTK7I4423; MolPort-002-887-590; NSC97935; ZX-AN012875; NSC39452; ALBB-014135; NSC-97935; NSC-39452; BDBM50326563; AKOS005109959; MS-3024
DMLIG3X DT Small molecular drug
DMLIG3X PC 67532
DMLIG3X MW 338.98
DMLIG3X FM C9H9Br2NO3
DMLIG3X IC InChI=1S/C9H9Br2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)/t7-/m0/s1
DMLIG3X CS C1=C(C=C(C(=C1Br)O)Br)C[C@@H](C(=O)O)N
DMLIG3X IK COESHZUDRKCEPA-ZETCQYMHSA-N
DMLIG3X IU (2S)-2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid
DMLIG3X CA CAS 300-38-9
DMLIG3X CB CHEBI:28335
DMLIG3X DE Discovery agent
DMAU80W ID DMAU80W
DMAU80W DN 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
DMAU80W HS Investigative
DMAU80W SN 1,3,5,6,8-Pentamethyl-1,10-phenanthrolinium; 1,3,5,6,8-pentamethyl-1,10-phenanthrolin-1-ium; 55247-91-1; AC1Q4YDA; 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium; AC1L519F; CTK5A3287; 23624-78-4 (iodide); DB02310; 3,4,6,8-Tetramethyl-N-methyl phenanthrolinium
DMAU80W DT Small molecular drug
DMAU80W PC 168131
DMAU80W MW 251.35
DMAU80W FM C17H19N2+
DMAU80W IC InChI=1S/C17H19N2/c1-10-6-14-12(3)13(4)15-7-11(2)9-19(5)17(15)16(14)18-8-10/h6-9H,1-5H3/q+1
DMAU80W CS CC1=CC2=C(C3=C(C=C(C=[N+]3C)C)C(=C2C)C)N=C1
DMAU80W IK FQTUZNACZKILMC-UHFFFAOYSA-N
DMAU80W IU 1,3,5,6,8-pentamethyl-1,10-phenanthrolin-1-ium
DMAU80W CA CAS 55247-91-1
DMAU80W DE Discovery agent
DMV859W ID DMV859W
DMV859W DN 3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole
DMV859W HS Investigative
DMV859W SN CHEMBL1079001; 3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole; SCHEMBL11589338
DMV859W DT Small molecular drug
DMV859W PC 20309751
DMV859W MW 251.29
DMV859W FM C14H13N5
DMV859W IC InChI=1S/C14H13N5/c1-9-7-11(3-5-15-9)13-17-14(19-18-13)12-4-6-16-10(2)8-12/h3-8H,1-2H3,(H,17,18,19)
DMV859W CS CC1=NC=CC(=C1)C2=NC(=NN2)C3=CC(=NC=C3)C
DMV859W IK VTUBKJFCLVZEFR-UHFFFAOYSA-N
DMV859W IU 2-methyl-4-[3-(2-methylpyridin-4-yl)-1H-1,2,4-triazol-5-yl]pyridine
DMV859W DE Discovery agent
DMFEQ6S ID DMFEQ6S
DMFEQ6S DN 3,5-DHPG
DMFEQ6S HS Investigative
DMFEQ6S SN 3,5-dihydroxyphenylglycine
DMFEQ6S DT Small molecular drug
DMFEQ6S PC 108001
DMFEQ6S MW 183.16
DMFEQ6S FM C8H9NO4
DMFEQ6S IC InChI=1S/C8H9NO4/c9-7(8(12)13)4-1-5(10)3-6(11)2-4/h1-3,7,10-11H,9H2,(H,12,13)
DMFEQ6S CS C1=C(C=C(C=C1O)O)C(C(=O)O)N
DMFEQ6S IK HOOWCUZPEFNHDT-UHFFFAOYSA-N
DMFEQ6S IU 2-amino-2-(3,5-dihydroxyphenyl)acetic acid
DMFEQ6S CA CAS 146255-66-5
DMFEQ6S CB CHEBI:93822
DMFEQ6S DE Discovery agent
DM6CBTE ID DM6CBTE
DM6CBTE DN 3,5-di(pyridin-4-yl)-1H-1,2,4-triazole
DM6CBTE HS Investigative
DM6CBTE SN 4329-78-6; CHEMBL1078978; 4,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine; 3,5-DI(4-pyridyl)-1,2,4-triazole; 3,5-bis(pyridin-4-yl)-1,2,4-triazole; AC1M7KCV; 3,5-di(pyridin-4-yl)-1H-1,2,4-triazole; MLS000999673; 4-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)pyridine; SCHEMBL10000033; CTK1D2724; QUKGHTHKDNHSOX-UHFFFAOYSA-; DTXSID00368692; QUKGHTHKDNHSOX-UHFFFAOYSA-N; MolPort-000-263-064; ZINC8048404; BDBM50311280; STK246494; AKOS002269457; AKOS001080808; MCULE-5677308017; 3,5-bis(4-pyridyl)-1,2,4-triazole; SMR000498789; ST092086
DM6CBTE DT Small molecular drug
DM6CBTE PC 2443499
DM6CBTE MW 223.23
DM6CBTE FM C12H9N5
DM6CBTE IC InChI=1S/C12H9N5/c1-5-13-6-2-9(1)11-15-12(17-16-11)10-3-7-14-8-4-10/h1-8H,(H,15,16,17)
DM6CBTE CS C1=CN=CC=C1C2=NC(=NN2)C3=CC=NC=C3
DM6CBTE IK QUKGHTHKDNHSOX-UHFFFAOYSA-N
DM6CBTE IU 4-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)pyridine
DM6CBTE CA CAS 4329-78-6
DM6CBTE DE Discovery agent
DMEXPIJ ID DMEXPIJ
DMEXPIJ DN 3,5-Diacetoxy-4'-amino-trans-stilbene
DMEXPIJ HS Investigative
DMEXPIJ SN CHEMBL1172400; BDBM50322065
DMEXPIJ DT Small molecular drug
DMEXPIJ PC 49798801
DMEXPIJ MW 311.3
DMEXPIJ FM C18H17NO4
DMEXPIJ IC InChI=1S/C18H17NO4/c1-12(20)22-17-9-15(10-18(11-17)23-13(2)21)4-3-14-5-7-16(19)8-6-14/h3-11H,19H2,1-2H3/b4-3+
DMEXPIJ CS CC(=O)OC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)N)OC(=O)C
DMEXPIJ IK QERWBDJMMUMFOT-ONEGZZNKSA-N
DMEXPIJ IU [3-acetyloxy-5-[(E)-2-(4-aminophenyl)ethenyl]phenyl] acetate
DMEXPIJ DE Discovery agent
DMK9JCA ID DMK9JCA
DMK9JCA DN 3,5-Diamino-4'-amino-trans-stilbene
DMK9JCA HS Investigative
DMK9JCA SN CHEMBL1171091; BDBM50322064
DMK9JCA DT Small molecular drug
DMK9JCA PC 49798900
DMK9JCA MW 225.29
DMK9JCA FM C14H15N3
DMK9JCA IC InChI=1S/C14H15N3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9H,15-17H2/b2-1+
DMK9JCA CS C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)N)N)N
DMK9JCA IK QRFAISVLMWANDO-OWOJBTEDSA-N
DMK9JCA IU 5-[(E)-2-(4-aminophenyl)ethenyl]benzene-1,3-diamine
DMK9JCA DE Discovery agent
DMCEY6O ID DMCEY6O
DMCEY6O DN 3,5-dibromo-2-(2,4-dibromophenoxy)phenol
DMCEY6O HS Investigative
DMCEY6O SN 3,5-Dibromo-2-(2,4-dibromophenoxy)phenol; CHEMBL258224; 79755-43-4; BPE-5; AC1MJ5LD; AC1Q78K6; 6-OH-BDE47; DTXSID60229856; ZINC14676777; SR-1-1; BDBM50232491; 6-Hydroxy-2,2,4,4-tetrabromodiphenyl ether; 6-hydroxy-2,2',4,4'-tetrabromodiphenylether; 3,5-dibromo-2-(2'',4''-dibromophenoxy)phenol; Phenol, 3,5-dibromo-2-(2,4-dibromophenoxy)-
DMCEY6O DT Small molecular drug
DMCEY6O PC 3086109
DMCEY6O MW 501.79
DMCEY6O FM C12H6Br4O2
DMCEY6O IC InChI=1S/C12H6Br4O2/c13-6-1-2-11(8(15)3-6)18-12-9(16)4-7(14)5-10(12)17/h1-5,17H
DMCEY6O CS C1=CC(=C(C=C1Br)Br)OC2=C(C=C(C=C2Br)Br)O
DMCEY6O IK SNCQITRZEBFIRW-UHFFFAOYSA-N
DMCEY6O IU 3,5-dibromo-2-(2,4-dibromophenoxy)phenol
DMCEY6O CA CAS 79755-43-4
DMCEY6O DE Discovery agent
DMPVI9W ID DMPVI9W
DMPVI9W DN 3,5-dichlorobenzaldehyde thiosemicarbazone
DMPVI9W HS Investigative
DMPVI9W SN 3,5-Dichlorobenzaldehyde thiosemicarbazone; CHEMBL421363; NSC109597; AC1NSHS0; ZINC33848878; BDBM50114607; AKOS014545904; NSC-109597
DMPVI9W DT Small molecular drug
DMPVI9W PC 5363470
DMPVI9W MW 248.13
DMPVI9W FM C8H7Cl2N3S
DMPVI9W IC InChI=1S/C8H7Cl2N3S/c9-6-1-5(2-7(10)3-6)4-12-13-8(11)14/h1-4H,(H3,11,13,14)/b12-4+
DMPVI9W CS C1=C(C=C(C=C1Cl)Cl)/C=N/NC(=S)N
DMPVI9W IK OTKIBPHYGDDNDE-UUILKARUSA-N
DMPVI9W IU [(E)-(3,5-dichlorophenyl)methylideneamino]thiourea
DMPVI9W DE Discovery agent
DMQ45WH ID DMQ45WH
DMQ45WH DN 3,5-dichlorosalicylic acid
DMQ45WH HS Investigative
DMQ45WH SN 3,5-DICHLOROSALICYLIC ACID; 3,5-Dichloro-2-hydroxybenzoic acid; 320-72-9; Benzoic acid, 3,5-dichloro-2-hydroxy-; Salicylic acid, 3,5-dichloro-; USAF DO-68; 2-Hydroxy-3,5-dichlorobenzoic acid; 3,5-Dichlorosalicylicacid; UNII-O6PXR32G3V; 3,5-Dichlorosalicyclic acid; HSDB 5562; EINECS 206-281-8; NSC 30109; 3,5-dichloro-2-hydroxy-benzoic acid; BRN 2210803; O6PXR32G3V; AI3-22601; CHEMBL449129; CNJGWCQEGROXEE-UHFFFAOYSA-N; C2U; ACMC-1CUK7; Salicylic acid,5-dichloro-; AC1Q3M9M; WLN: QVR BQ CG EG; DSSTox_RID_80582; DSSTox_CID_24914
DMQ45WH DT Small molecular drug
DMQ45WH PC 9445
DMQ45WH MW 207.01
DMQ45WH FM C7H4Cl2O3
DMQ45WH IC InChI=1S/C7H4Cl2O3/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,10H,(H,11,12)
DMQ45WH CS C1=C(C=C(C(=C1C(=O)O)O)Cl)Cl
DMQ45WH IK CNJGWCQEGROXEE-UHFFFAOYSA-N
DMQ45WH IU 3,5-dichloro-2-hydroxybenzoic acid
DMQ45WH CA CAS 320-72-9
DMQ45WH CB CHEBI:165214
DMQ45WH DE Discovery agent
DMET46F ID DMET46F
DMET46F DN 3,5-Difluorobenzenesulfonamide
DMET46F HS Investigative
DMET46F SN 3,5-DIFLUOROBENZENESULFONAMIDE; 140480-89-3; 3,5-Difluorobenzenesulphonamide; Benzenesulfonamide, 3,5-difluoro-; 3,5-difluorobenzene-1-sulfonamide; Buttpark 27\07-04; FBU; PubChem11783; ACMC-20ai3d; AC1L9JFC; KSC493S5P; SCHEMBL602631; CHEBI:42566; CTK3J3957; DTXSID20332219; MKQPOVUFDWKPNO-UHFFFAOYSA-N; MolPort-000-150-739; ZINC2576766; JRD-1790; MFCD02091379; BBL100443; 6828AA; STL554237; ANW-74375; SBB091558; 3,5-Difluorobenzenesulfonamide, 97%; AKOS000148222; DB02087; VZ25762; TRA0083487; PS-8315; MCULE-4003409613; RTR-005258; CJ-10108
DMET46F DT Small molecular drug
DMET46F PC 446275
DMET46F MW 193.17
DMET46F FM C6H5F2NO2S
DMET46F IC InChI=1S/C6H5F2NO2S/c7-4-1-5(8)3-6(2-4)12(9,10)11/h1-3H,(H2,9,10,11)
DMET46F CS C1=C(C=C(C=C1F)S(=O)(=O)N)F
DMET46F IK MKQPOVUFDWKPNO-UHFFFAOYSA-N
DMET46F IU 3,5-difluorobenzenesulfonamide
DMET46F CA CAS 140480-89-3
DMET46F CB CHEBI:42566
DMET46F DE Discovery agent
DM4VT0Q ID DM4VT0Q
DM4VT0Q DN 3,5-difluorophenol
DM4VT0Q HS Investigative
DM4VT0Q SN 3,5-Difluorophenol; 2713-34-0; Phenol, 3,5-difluoro-; 3,5-difluoro phenol; 3,5-difluoro-phenol; Phenol,3,5-difluoro-; HJSSBIMVTMYKPD-UHFFFAOYSA-N; MFCD00002255; 3,5difluorophenol; 3,5-difluorphenol; 3.5-difluorophenol; PubChem1496; phenol derivative, 6; ACMC-209gvc; AC1Q4NDO; AC1L2PTJ; 3,5-Difluorophenol, 99%; KSC203O5T; SCHEMBL156265; AC1Q78L9; CHEMBL259068; CTK1A3759; BDBM26192; HJSSBIMVTMYKPD-UHFFFAOYSA-; DTXSID10181596; ABLOCK AB-12-1639; MolPort-000-154-449; ZINC406989; ACT11666; JRD-0083; CS-D1731; SBB085756; ANW-26134
DM4VT0Q DT Small molecular drug
DM4VT0Q PC 75928
DM4VT0Q MW 130.09
DM4VT0Q FM C6H4F2O
DM4VT0Q IC InChI=1S/C6H4F2O/c7-4-1-5(8)3-6(9)2-4/h1-3,9H
DM4VT0Q CS C1=C(C=C(C=C1F)F)O
DM4VT0Q IK HJSSBIMVTMYKPD-UHFFFAOYSA-N
DM4VT0Q IU 3,5-difluorophenol
DM4VT0Q CA CAS 2713-34-0
DM4VT0Q DE Discovery agent
DM04N7I ID DM04N7I
DM04N7I DN 3,5-dihydroxybenzoic acid
DM04N7I HS Investigative
DM04N7I SN NSC 22948; alpha-resorcylic acid; 5-carboxyresorcinol
DM04N7I DT Small molecular drug
DM04N7I PC 7424
DM04N7I MW 154.12
DM04N7I FM C7H6O4
DM04N7I IC InChI=1S/C7H6O4/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3,8-9H,(H,10,11)
DM04N7I CS C1=C(C=C(C=C1O)O)C(=O)O
DM04N7I IK UYEMGAFJOZZIFP-UHFFFAOYSA-N
DM04N7I IU 3,5-dihydroxybenzoic acid
DM04N7I CA CAS 99-10-5
DM04N7I CB CHEBI:39912
DM04N7I DE Discovery agent
DMQ9TNB ID DMQ9TNB
DMQ9TNB DN 3,5-Dihydroxyl-4'-amino-trans-stilbene
DMQ9TNB HS Investigative
DMQ9TNB SN CHEMBL1172402; Stilbene derivative, 3; SCHEMBL2516281; CHEBI:125141; (E)-4'-Aminostilbene-3,5-diol; BDBM50322066; 3,5-Dihydroxyl-4''-amino-trans-stilbene
DMQ9TNB DT Small molecular drug
DMQ9TNB PC 46191176
DMQ9TNB MW 227.26
DMQ9TNB FM C14H13NO2
DMQ9TNB IC InChI=1S/C14H13NO2/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,16-17H,15H2/b2-1+
DMQ9TNB CS C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)N
DMQ9TNB IK MDUTXYLPODCITG-OWOJBTEDSA-N
DMQ9TNB IU 5-[(E)-2-(4-aminophenyl)ethenyl]benzene-1,3-diol
DMQ9TNB CB CHEBI:125141
DMQ9TNB DE Discovery agent
DMRY2ZC ID DMRY2ZC
DMRY2ZC DN 3'',5''-dimethoxy-[1,1':2',1'']-terphenyl-4-ol
DMRY2ZC HS Investigative
DMRY2ZC SN CHEMBL207240; ZINC35929342; BDBM50186755
DMRY2ZC DT Small molecular drug
DMRY2ZC PC 11609210
DMRY2ZC MW 306.4
DMRY2ZC FM C20H18O3
DMRY2ZC IC InChI=1S/C20H18O3/c1-22-17-11-15(12-18(13-17)23-2)20-6-4-3-5-19(20)14-7-9-16(21)10-8-14/h3-13,21H,1-2H3
DMRY2ZC CS COC1=CC(=CC(=C1)C2=CC=CC=C2C3=CC=C(C=C3)O)OC
DMRY2ZC IK WBVVLROKTBXXTP-UHFFFAOYSA-N
DMRY2ZC IU 4-[2-(3,5-dimethoxyphenyl)phenyl]phenol
DMRY2ZC DE Discovery agent
DMXCZAK ID DMXCZAK
DMXCZAK DN 3'',5''-dimethoxy-[1,1':3',1'']-terphenyl-4-ol
DMXCZAK HS Investigative
DMXCZAK SN CHEMBL381164; BDBM50186750; ZINC40763401
DMXCZAK DT Small molecular drug
DMXCZAK PC 11493254
DMXCZAK MW 306.4
DMXCZAK FM C20H18O3
DMXCZAK IC InChI=1S/C20H18O3/c1-22-19-11-17(12-20(13-19)23-2)16-5-3-4-15(10-16)14-6-8-18(21)9-7-14/h3-13,21H,1-2H3
DMXCZAK CS COC1=CC(=CC(=C1)C2=CC=CC(=C2)C3=CC=C(C=C3)O)OC
DMXCZAK IK MWVCWBDXUJZBEC-UHFFFAOYSA-N
DMXCZAK IU 4-[3-(3,5-dimethoxyphenyl)phenyl]phenol
DMXCZAK DE Discovery agent
DMC3917 ID DMC3917
DMC3917 DN 3,5-Dimethoxy-4'-amino-trans-stilbene
DMC3917 HS Investigative
DMC3917 SN CHEMBL324290; SCHEMBL3359253; BDBM50131692; ZINC27107058; AKOS030581623; trans-3,5-dimethoxyl-4''-aminostilbene; 3,5-Dimethoxy-4''-amino-trans-stilbene; (e)-1-(4'-aminostyryl)-3,5-dimethoxybenzene; 4-[2-(3,5-Dimethoxyphenyl)ethenyl]benzeneamine
DMC3917 DT Small molecular drug
DMC3917 PC 18785180
DMC3917 MW 255.31
DMC3917 FM C16H17NO2
DMC3917 IC InChI=1S/C16H17NO2/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11H,17H2,1-2H3/b4-3+
DMC3917 CS COC1=CC(=CC(=C1)/C=C/C2=CC=C(C=C2)N)OC
DMC3917 IK LGVZJSLFOMGJOS-ONEGZZNKSA-N
DMC3917 IU 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]aniline
DMC3917 DE Discovery agent
DM3E98I ID DM3E98I
DM3E98I DN 3,5-dimethyl PPP
DM3E98I HS Investigative
DM3E98I SN 3,5-DMPPP
DM3E98I DT Small molecular drug
DM3E98I PC 11722867
DM3E98I MW 309.4
DM3E98I FM C17H27NO4
DM3E98I IC InChI=1S/C17H27NO4/c1-8-9-21-16(20)14-10(2)13(11(3)18-14)15(19)22-12(4)17(5,6)7/h12,18H,8-9H2,1-7H3
DM3E98I CS CCCOC(=O)C1=C(C(=C(N1)C)C(=O)OC(C)C(C)(C)C)C
DM3E98I IK DOYZAIRDDZPMQZ-UHFFFAOYSA-N
DM3E98I IU 4-O-(3,3-dimethylbutan-2-yl) 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate
DM3E98I DE Discovery agent
DMAQ6OM ID DMAQ6OM
DMAQ6OM DN 3,5-dimethyl-2-(phenylsulfonamido)benzoic acid
DMAQ6OM HS Investigative
DMAQ6OM SN sulfonamide compound, 5; CHEMBL209317; SCHEMBL10116990; BDBM17599; AKOS012072515; 2-benzenesulfonamido-3,5-dimethylbenzoic acid
DMAQ6OM DT Small molecular drug
DMAQ6OM PC 23647758
DMAQ6OM MW 305.4
DMAQ6OM FM C15H15NO4S
DMAQ6OM IC InChI=1S/C15H15NO4S/c1-10-8-11(2)14(13(9-10)15(17)18)16-21(19,20)12-6-4-3-5-7-12/h3-9,16H,1-2H3,(H,17,18)
DMAQ6OM CS CC1=CC(=C(C(=C1)C(=O)O)NS(=O)(=O)C2=CC=CC=C2)C
DMAQ6OM IK ORCGTMODRHXXRZ-UHFFFAOYSA-N
DMAQ6OM IU 2-(benzenesulfonamido)-3,5-dimethylbenzoic acid
DMAQ6OM DE Discovery agent
DMBGSHD ID DMBGSHD
DMBGSHD DN 3,5-Dinitrocatechol
DMBGSHD HS Investigative
DMBGSHD SN 3,5-dinitrocatechol; 3,5-dinitrobenzene-1,2-diol; 7659-29-2; 3,5-Dinitro-1,2-benzenediol; OR-486; 3,5-Dinitropyrocatechol; OR486; UNII-VK0VA22GY2; Pyrocatechol, 3,5-dinitro-; 1,2-Benzenediol, 3,5-dinitro-; BRN 2217246; VK0VA22GY2; 3,5-DINITROCATECHOL (OR-486); CHEMBL168276; 3,5-DINITRO-BENZENE-1,2-DIOL; DNC; SR-01000075610; OR 486; Ro 12812; Ro 01-2812; Tocris-0483; Spectrum_000187; Lopac-D-131; AC1MZC4M; Spectrum4_000747; Spectrum2_001109; Spectrum5_001163; Entacapone EP Impurity E; 3,5-Dinitrocatechol, solid; Lopac0_000477
DMBGSHD DT Small molecular drug
DMBGSHD PC 3870203
DMBGSHD MW 200.11
DMBGSHD FM C6H4N2O6
DMBGSHD IC InChI=1S/C6H4N2O6/c9-5-2-3(7(11)12)1-4(6(5)10)8(13)14/h1-2,9-10H
DMBGSHD CS C1=C(C=C(C(=C1[N+](=O)[O-])O)O)[N+](=O)[O-]
DMBGSHD IK VDCDWNDTNSWDFJ-UHFFFAOYSA-N
DMBGSHD IU 3,5-dinitrobenzene-1,2-diol
DMBGSHD CA CAS 7659-29-2
DMBGSHD DE Discovery agent
DMWOB7Q ID DMWOB7Q
DMWOB7Q DN 3,5-Di-tert-butyl-[1,2]benzoquinone
DMWOB7Q HS Investigative
DMWOB7Q SN 3383-21-9; 3,5-Di-tert-butyl-o-benzoquinone; 3,5-Di-tert-butyl-1,2-benzoquinone; 3,5-di(tert-butyl)benzo-1,2-quinone; 3,5-Cyclohexadiene-1,2-dione, 3,5-bis(1,1-dimethylethyl)-; 3,5-di-tert-butylcyclohexa-3,5-diene-1,2-dione; o-Benzoquinone, 3,5-di-tert-butyl-; 3,5-di-tert-butylbenzo-1,2-quinone; NOUZOVBGCDDMSX-UHFFFAOYSA-N; 3,5-di-t-butyl-1,2-benzoquinone; 3,5-Ditert-butylbenzo-1,2-quinone; MFCD00001647; 3,5-bis(tert-butyl)cyclohexa-3,5-diene-1,2-dione; Benzil-related compound, 54; EINECS 222-189-0; NSC 149061; AC1Q6BRK
DMWOB7Q DT Small molecular drug
DMWOB7Q PC 76915
DMWOB7Q MW 220.31
DMWOB7Q FM C14H20O2
DMWOB7Q IC InChI=1S/C14H20O2/c1-13(2,3)9-7-10(14(4,5)6)12(16)11(15)8-9/h7-8H,1-6H3
DMWOB7Q CS CC(C)(C)C1=CC(=O)C(=O)C(=C1)C(C)(C)C
DMWOB7Q IK NOUZOVBGCDDMSX-UHFFFAOYSA-N
DMWOB7Q IU 3,5-ditert-butylcyclohexa-3,5-diene-1,2-dione
DMWOB7Q CA CAS 3383-21-9
DMWOB7Q DE Discovery agent
DMM632N ID DMM632N
DMM632N DN 3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol
DMM632N HS Investigative
DMM632N SN Spongiadioxin C; CHEMBL185753; 3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol; 3,6,8-tribromooxanthren-1-ol; dibenzo[b,e][1,4]dioxin-1-ol, 3,6,8-tribromo-; 3,6,8-tribromodibenzo[b,e][1,4]dioxin-1-ol; AC1LCT04; BDBM50150791; 3,6,8-tribromodibenzo-p-dioxin-1-ol; 460092-06-2
DMM632N DT Small molecular drug
DMM632N PC 636835
DMM632N MW 436.88
DMM632N FM C12H5Br3O3
DMM632N IC InChI=1S/C12H5Br3O3/c13-5-1-7(15)11-9(3-5)18-12-8(16)2-6(14)4-10(12)17-11/h1-4,16H
DMM632N CS C1=C(C=C2C(=C1O)OC3=C(O2)C(=CC(=C3)Br)Br)Br
DMM632N IK XZPITRJUKODSMI-UHFFFAOYSA-N
DMM632N IU 3,6,8-tribromodibenzo-p-dioxin-1-ol
DMM632N DE Discovery agent
DMY26JI ID DMY26JI
DMY26JI DN 3,6,9,12,15,18-HEXAOXAICOSANE
DMY26JI HS Investigative
DMY26JI SN 3,6,9,12,15,18-Hexaoxaicosane; 3,6,9,12,15,18-Hexaoxaeicosane; 23601-39-0; 1-ethoxy-2-[2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethoxy]ethane; EINECS 245-774-2; AC1L3JHX; SCHEMBL987828; DTXSID1041473; CHEBI:39576; CTK1A3907; DB06867
DMY26JI DT Small molecular drug
DMY26JI PC 90206
DMY26JI MW 294.38
DMY26JI FM C14H30O6
DMY26JI IC InChI=1S/C14H30O6/c1-3-15-5-7-17-9-11-19-13-14-20-12-10-18-8-6-16-4-2/h3-14H2,1-2H3
DMY26JI CS CCOCCOCCOCCOCCOCCOCC
DMY26JI IK IXFAFGFZFQHRLB-UHFFFAOYSA-N
DMY26JI IU 1-ethoxy-2-[2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethoxy]ethane
DMY26JI CA CAS 23601-39-0
DMY26JI CB CHEBI:39576
DMY26JI DE Discovery agent
DMY8IOP ID DMY8IOP
DMY8IOP DN 3,6,9,12,15-Pentaoxaheptadecane
DMY8IOP HS Investigative
DMY8IOP SN 3,6,9,12,15-Pentaoxaheptadecane; Diethoxytetraethylene glycol; Tetraethylene glycol diethyl ether; 4353-28-0; Glycol, diethoxytetraethylene; Ether, bis(2-(2-ethoxyethoxy)ethyl); Diethylether tetraethylenglykolu; EINECS 224-423-7; Diethylether tetraethylenglykolu [Czech]; BRN 1767873; bis(2-(2-ethoxyethoxy)ethyl) ether; P3G; 1-ethoxy-2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethane; AC1Q58NT; AC1L2UE6; SCHEMBL216926; tetraethyleneglycol diethyl ether; DTXSID0052099; CTK3I9254; CHEBI:44751; HYDWALOBQJFOMS-UHFFFAOYSA-N; ZINC5650744
DMY8IOP DT Small molecular drug
DMY8IOP PC 78057
DMY8IOP MW 250.33
DMY8IOP FM C12H26O5
DMY8IOP IC InChI=1S/C12H26O5/c1-3-13-5-7-15-9-11-17-12-10-16-8-6-14-4-2/h3-12H2,1-2H3
DMY8IOP CS CCOCCOCCOCCOCCOCC
DMY8IOP IK HYDWALOBQJFOMS-UHFFFAOYSA-N
DMY8IOP IU 1-ethoxy-2-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]ethane
DMY8IOP CA CAS 4353-28-0
DMY8IOP CB CHEBI:44751
DMY8IOP DE Discovery agent
DMMVL5P ID DMMVL5P
DMMVL5P DN 3,6,9,12,15-PENTAOXATRICOSAN-1-OL
DMMVL5P HS Investigative
DMMVL5P SN 3,6,9,12,15-Pentaoxatricosan-1-ol; n-Octylpentaoxyethylene; 19327-40-3; PENTAETHYLENE GLYCOL MONOOCTYL ETHER; Pentaoxyethylene monooctyl ether; polyoxyethylene 5 octyl ether; C;Pentaethyleneglycolmonooctylether; 2-[2-[2-[2-(2-octoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol; Octylpentaglycol; N8E; C18H38O6; AC1L4MMQ; SCHEMBL61744; C8E5; Octyl pentaethylene glycol ether; DTXSID6075192; CTK0H9802; Pentaethylene glycol, octyl ether; MJELOWOAIAAUJT-UHFFFAOYSA-N; AC1Q5919; ZINC16051619; 7571AH; MFCD00043032; AKOS027320404; DB08249; LS-102023
DMMVL5P DT Small molecular drug
DMMVL5P PC 159866
DMMVL5P MW 350.5
DMMVL5P FM C18H38O6
DMMVL5P IC InChI=1S/C18H38O6/c1-2-3-4-5-6-7-9-20-11-13-22-15-17-24-18-16-23-14-12-21-10-8-19/h19H,2-18H2,1H3
DMMVL5P CS CCCCCCCCOCCOCCOCCOCCOCCO
DMMVL5P IK MJELOWOAIAAUJT-UHFFFAOYSA-N
DMMVL5P IU 2-[2-[2-[2-(2-octoxyethoxy)ethoxy]ethoxy]ethoxy]ethanol
DMMVL5P CA CAS 19327-40-3
DMMVL5P DE Discovery agent
DMWTP7Y ID DMWTP7Y
DMWTP7Y DN 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone
DMWTP7Y HS Investigative
DMWTP7Y SN CHEMBL373668; 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone
DMWTP7Y DT Small molecular drug
DMWTP7Y PC 44405182
DMWTP7Y MW 953.2
DMWTP7Y FM C55H68N8O7
DMWTP7Y IC InChI=1S/C55H68N8O7/c1-32-22-41(64)23-33(2)43(32)28-45(56)54(69)62-30-39-16-8-6-14-37(39)26-49(62)52(67)58-20-12-10-18-47-36(5)60-48(51(66)61-47)19-11-13-21-59-53(68)50-27-38-15-7-9-17-40(38)31-63(50)55(70)46(57)29-44-34(3)24-42(65)25-35(44)4/h6-9,14-17,22-25,45-46,49-50,64-65H,10-13,18-21,26-31,56-57H2,1-5H3,(H,58,67)(H,59,68)(H,61,66)/t45-,46-,49?,50?/m0/s1
DMWTP7Y CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCC4=C(N=C(C(=O)N4)CCCCNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DMWTP7Y IK HHTSJHJHPFGARW-RFLUKDKXSA-N
DMWTP7Y IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[4-[5-[4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]butyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]butyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMWTP7Y DE Discovery agent
DM2Y4A6 ID DM2Y4A6
DM2Y4A6 DN 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone
DM2Y4A6 HS Investigative
DM2Y4A6 SN CHEMBL198800; 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone
DM2Y4A6 DT Small molecular drug
DM2Y4A6 PC 44405192
DM2Y4A6 MW 897.1
DM2Y4A6 FM C51H60N8O7
DM2Y4A6 IC InChI=1S/C51H60N8O7/c1-28-18-37(60)19-29(2)39(28)24-41(52)50(65)58-26-35-12-8-6-10-33(35)22-45(58)48(63)54-16-14-43-32(5)56-44(47(62)57-43)15-17-55-49(64)46-23-34-11-7-9-13-36(34)27-59(46)51(66)42(53)25-40-30(3)20-38(61)21-31(40)4/h6-13,18-21,41-42,45-46,60-61H,14-17,22-27,52-53H2,1-5H3,(H,54,63)(H,55,64)(H,57,62)/t41-,42-,45?,46?/m0/s1
DM2Y4A6 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCC4=C(N=C(C(=O)N4)CCNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DM2Y4A6 IK OOTASVYBVWGNJP-KJLUANBESA-N
DM2Y4A6 IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-[5-[2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]ethyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM2Y4A6 DE Discovery agent
DMJR983 ID DMJR983
DMJR983 DN 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
DMJR983 HS Investigative
DMJR983 SN CHEMBL200890; 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone
DMJR983 DT Small molecular drug
DMJR983 PC 44405233
DMJR983 MW 869
DMJR983 FM C49H56N8O7
DMJR983 IC InChI=1S/C49H56N8O7/c1-26-14-35(58)15-27(2)37(26)20-39(50)48(63)56-24-33-12-8-6-10-31(33)18-43(56)46(61)52-22-41-30(5)54-42(45(60)55-41)23-53-47(62)44-19-32-11-7-9-13-34(32)25-57(44)49(64)40(51)21-38-28(3)16-36(59)17-29(38)4/h6-17,39-40,43-44,58-59H,18-25,50-51H2,1-5H3,(H,52,61)(H,53,62)(H,55,60)/t39-,40-,43?,44?/m0/s1
DMJR983 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCC4=C(N=C(C(=O)N4)CNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DMJR983 IK BOYVBTQTUISOKQ-XQIDWOBFSA-N
DMJR983 IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[[5-[[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]methyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]methyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMJR983 DE Discovery agent
DMEQBS3 ID DMEQBS3
DMEQBS3 DN 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone
DMEQBS3 HS Investigative
DMEQBS3 SN CHEMBL381874; 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone
DMEQBS3 DT Small molecular drug
DMEQBS3 PC 44405208
DMEQBS3 MW 925.1
DMEQBS3 FM C53H64N8O7
DMEQBS3 IC InChI=1S/C53H64N8O7/c1-30-20-39(62)21-31(2)41(30)26-43(54)52(67)60-28-37-14-8-6-12-35(37)24-47(60)50(65)56-18-10-16-45-34(5)58-46(49(64)59-45)17-11-19-57-51(66)48-25-36-13-7-9-15-38(36)29-61(48)53(68)44(55)27-42-32(3)22-40(63)23-33(42)4/h6-9,12-15,20-23,43-44,47-48,62-63H,10-11,16-19,24-29,54-55H2,1-5H3,(H,56,65)(H,57,66)(H,59,64)/t43-,44-,47?,48?/m0/s1
DMEQBS3 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCC4=C(N=C(C(=O)N4)CCCNC(=O)C5CC6=CC=CC=C6CN5C(=O)[C@H](CC7=C(C=C(C=C7C)O)C)N)C)N)C)O
DMEQBS3 IK NATWHSVYZBCLOS-OYVXWBFTSA-N
DMEQBS3 IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[3-[5-[3-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]propyl]-3-methyl-6-oxo-1H-pyrazin-2-yl]propyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMEQBS3 DE Discovery agent
DMUH4OV ID DMUH4OV
DMUH4OV DN 3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one
DMUH4OV HS Investigative
DMUH4OV DT Small molecular drug
DMUH4OV PC 10308089
DMUH4OV MW 254.24
DMUH4OV FM C15H10O4
DMUH4OV IC InChI=1S/C15H10O4/c16-9-3-1-8(2-4-9)13-14(18)11-6-5-10(17)7-12(11)15(13)19/h1-7,13,16-17H
DMUH4OV CS C1=CC(=CC=C1C2C(=O)C3=C(C2=O)C=C(C=C3)O)O
DMUH4OV IK QKHHOGHOHPKHGS-UHFFFAOYSA-N
DMUH4OV IU 5-hydroxy-2-(4-hydroxyphenyl)indene-1,3-dione
DMUH4OV DE Discovery agent
DM7AORH ID DM7AORH
DM7AORH DN 3,6-Dihydroxy-Xanthene-9-Propionic Acid
DM7AORH HS Investigative
DM7AORH SN 3,6-DIHYDROXY-XANTHENE-9-PROPIONIC ACID; HXP; 3-(3,6-dihydroxy-9H-xanthen-9-yl)propanoic acid; AC1L9MSN; SCHEMBL4315610
DM7AORH DT Small molecular drug
DM7AORH PC 449159
DM7AORH MW 286.28
DM7AORH FM C16H14O5
DM7AORH IC InChI=1S/C16H14O5/c17-9-1-3-12-11(5-6-16(19)20)13-4-2-10(18)8-15(13)21-14(12)7-9/h1-4,7-8,11,17-18H,5-6H2,(H,19,20)
DM7AORH CS C1=CC2=C(C=C1O)OC3=C(C2CCC(=O)O)C=CC(=C3)O
DM7AORH IK PFQGLFBMMPZYEU-UHFFFAOYSA-N
DM7AORH IU 3-(3,6-dihydroxy-9H-xanthen-9-yl)propanoic acid
DM7AORH DE Discovery agent
DMEOBNJ ID DMEOBNJ
DMEOBNJ DN 3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane
DMEOBNJ HS Investigative
DMEOBNJ DT Small molecular drug
DMEOBNJ PC 44324916
DMEOBNJ MW 293.4
DMEOBNJ FM C20H23NO
DMEOBNJ IC InChI=1S/C20H23NO/c1-3-8-16(9-4-1)18-14-20(22-15-18)12-7-13-21-19(20)17-10-5-2-6-11-17/h1-6,8-11,18-19,21H,7,12-15H2/t18-,19?,20?/m1/s1
DMEOBNJ CS C1CC2(C[C@H](CO2)C3=CC=CC=C3)C(NC1)C4=CC=CC=C4
DMEOBNJ IK WJRYRJACQITXQC-XEVCZEQESA-N
DMEOBNJ IU (3S)-3,10-diphenyl-1-oxa-9-azaspiro[4.5]decane
DMEOBNJ DE Discovery agent
DMNV0EZ ID DMNV0EZ
DMNV0EZ DN 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
DMNV0EZ HS Investigative
DMNV0EZ SN pyrazolo[1,5-a]pyrimidine 1a; AC1NS6UW; CHEMBL92279; BDBM5417; 3,6-dipyridin-4-ylpyrazolo[1,5-a]pyrimidine; 3,6-Bis(4-pyridyl)pyrazolo[1,5-a]pyrimidine
DMNV0EZ DT Small molecular drug
DMNV0EZ PC 5329454
DMNV0EZ MW 273.29
DMNV0EZ FM C16H11N5
DMNV0EZ IC InChI=1S/C16H11N5/c1-5-17-6-2-12(1)14-9-19-16-15(10-20-21(16)11-14)13-3-7-18-8-4-13/h1-11H
DMNV0EZ CS C1=CN=CC=C1C2=CN3C(=C(C=N3)C4=CC=NC=C4)N=C2
DMNV0EZ IK ZLISHOMLHVNDJG-UHFFFAOYSA-N
DMNV0EZ IU 3,6-dipyridin-4-ylpyrazolo[1,5-a]pyrimidine
DMNV0EZ DE Discovery agent
DMES906 ID DMES906
DMES906 DN 3,7,3',4'-TETRAHYDROXYFLAVONE
DMES906 HS Investigative
DMES906 SN Fisetin; 528-48-3; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; 5-Desoxyquercetin; Fustel; Cotinin; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fustet; Fietin; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Zante fustic; Young fustic; Superfustel K; Ungarisches gelbholz; CI Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; CI 75620; NSC 407010; NSC 656275; 5-Deoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Natural Brown 1; FISETIN
DMES906 DT Small molecular drug
DMES906 PC 5281614
DMES906 MW 286.24
DMES906 FM C15H10O6
DMES906 IC InChI=1S/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20H
DMES906 CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O
DMES906 IK XHEFDIBZLJXQHF-UHFFFAOYSA-N
DMES906 IU 2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one
DMES906 CA CAS 528-48-3
DMES906 CB CHEBI:42567
DMES906 DE Discovery agent
DMQADXL ID DMQADXL
DMQADXL DN 3,7-Bis(2-hydroxyethyl)icaritin
DMQADXL HS Investigative
DMQADXL SN 3,7-Bis(2-hydroxyethyl)icaritin; UNII-5U58D99D1L; CHEMBL498486; 5U58D99D1L; SCHEMBL18533069; BDBM50272529; 3,7-Bis(2-hydroxyethoxy)-5-hydroxy-4'-methoxy-8-(3-methyl-2-butenyl)flavone; 1067198-74-6; 4H-1-Benzopyran-4-one, 5-hydroxy-3,7-bis(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-
DMQADXL DT Small molecular drug
DMQADXL PC 25058047
DMQADXL MW 456.5
DMQADXL FM C25H28O8
DMQADXL IC InChI=1S/C25H28O8/c1-15(2)4-9-18-20(31-12-10-26)14-19(28)21-22(29)25(32-13-11-27)23(33-24(18)21)16-5-7-17(30-3)8-6-16/h4-8,14,26-28H,9-13H2,1-3H3
DMQADXL CS CC(=CCC1=C(C=C(C2=C1OC(=C(C2=O)OCCO)C3=CC=C(C=C3)OC)O)OCCO)C
DMQADXL IK WTJGVHRGWYENBZ-UHFFFAOYSA-N
DMQADXL IU 5-hydroxy-3,7-bis(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DMQADXL CA CAS 1067198-74-6
DMQADXL DE Discovery agent
DMBIRC6 ID DMBIRC6
DMBIRC6 DN 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM
DMBIRC6 HS Investigative
DMBIRC6 SN Methylene Blue cation; 3,7-bis(dimethylamino)phenothiazin-5-ium; UNII-ZMZ79891ZH; N-[7-(dimethylamino)-3H-phenothiazin-3-ylidene]-N-methylmethanaminium; ZMZ79891ZH; CHEBI:43830; azul de metileno; Methylthionine HCl; Methylthionine chloride; CHEMBL405110; NSC3089; NSC617593; NSC215213; NCGC00167496-03; NCGC00167496-01; C.I. 52015; Methylthioninium; Methylene Blue parent; AI3-52463; cid_6099; AC1Q4UZ6; AC1L1HI1; SCHEMBL109755; CHEMBL191083; DTXSID3047009; NOCAS_47009; RBTBFTRPCNLSDE-UHFFFAOYSA-N; MolPort-003-700-760
DMBIRC6 DT Small molecular drug
DMBIRC6 PC 4139
DMBIRC6 MW 284.4
DMBIRC6 FM C16H18N3S+
DMBIRC6 IC InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1
DMBIRC6 CS CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2
DMBIRC6 IK RBTBFTRPCNLSDE-UHFFFAOYSA-N
DMBIRC6 IU [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium
DMBIRC6 CA CAS 7060-82-4
DMBIRC6 CB CHEBI:43830
DMBIRC6 DE Discovery agent
DMH04P7 ID DMH04P7
DMH04P7 DN 3,7-dihydroxy-flavone
DMH04P7 HS Investigative
DMH04P7 SN 3,7-dihydroxyflavone; 7-Hydroxyflavonol; 492-00-2; 3,7-dihydroxy-2-phenyl-4H-chromen-4-one; 5-Deoxygalangin; 4H-1-Benzopyran-4-one, 3,7-dihydroxy-2-phenyl-; UNII-O948D0K9BQ; O948D0K9BQ; CHEMBL210276; 3,7-dihydroxy-2-phenylchromen-4-one; 3,7-dihydroxy-flavone; 7,3'-dihydroxyflavonol; SR-01000314616; Resogalangin; SPBio_001803; Spectrum_001462; SpecPlus_000778; AC1NU2BD; Spectrum4_001767; Spectrum3_001623; Spectrum2_001652; Spectrum5_000353; 3,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; Oprea1_793720; KBioSS_001942; KBioGR_002253
DMH04P7 DT Small molecular drug
DMH04P7 PC 5393152
DMH04P7 MW 254.24
DMH04P7 FM C15H10O4
DMH04P7 IC InChI=1S/C15H10O4/c16-10-6-7-11-12(8-10)19-15(14(18)13(11)17)9-4-2-1-3-5-9/h1-8,16,18H
DMH04P7 CS C1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O
DMH04P7 IK UWQJWDYDYIJWKY-UHFFFAOYSA-N
DMH04P7 IU 3,7-dihydroxy-2-phenylchromen-4-one
DMH04P7 CA CAS 492-00-2
DMH04P7 CB CHEBI:109535
DMH04P7 DE Discovery agent
DMJ0654 ID DMJ0654
DMJ0654 DN 3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID
DMJ0654 HS Investigative
DMJ0654 SN 3,7-DIHYDROXY-2-NAPHTHOIC ACID; 83511-07-3; 2,6-Dihydroxy-3-Naphthoic acid; 3,7-Dihydroxy-2-naphthalenecarboxylic Acid; CHEMBL1231350; 2,6-DIOXYNAPHTHALENE-3-CARBOXYLIC ACID; PubChem9419; ACMC-209psi; AC1LEHT6; AC1Q5UP9; AC1Q72HK; SCHEMBL124773; 3,7-dihydroxy-2-naphtoic acid; KS-00000GHV; CTK3E8003; DTXSID30352988; QMWOUSYSNFCKAZ-UHFFFAOYSA-N; MolPort-001-790-958; ZINC156898; STL426758; BDBM50379183; BBL034659; ANW-37696; SBB037881; AKOS015856275; VZ22995; MCULE-9133006477; CD-1291
DMJ0654 DT Small molecular drug
DMJ0654 PC 736299
DMJ0654 MW 204.18
DMJ0654 FM C11H8O4
DMJ0654 IC InChI=1S/C11H8O4/c12-8-2-1-6-5-10(13)9(11(14)15)4-7(6)3-8/h1-5,12-13H,(H,14,15)
DMJ0654 CS C1=CC(=CC2=CC(=C(C=C21)O)C(=O)O)O
DMJ0654 IK QMWOUSYSNFCKAZ-UHFFFAOYSA-N
DMJ0654 IU 3,7-dihydroxynaphthalene-2-carboxylic acid
DMJ0654 CA CAS 83511-07-3
DMJ0654 DE Discovery agent
DM23CEI ID DM23CEI
DM23CEI DN 3,8-dibromoboldine
DM23CEI HS Investigative
DM23CEI SN 3,8-dibromoboldine; CHEMBL388564
DM23CEI DT Small molecular drug
DM23CEI PC 10480509
DM23CEI MW 485.2
DM23CEI FM C19H19Br2NO4
DM23CEI IC InChI=1S/C19H19Br2NO4/c1-22-5-4-8-13-11(22)6-10-9(7-12(25-2)17(23)16(10)21)14(13)19(26-3)18(24)15(8)20/h7,11,23-24H,4-6H2,1-3H3/t11-/m0/s1
DM23CEI CS CN1CCC2=C3[C@@H]1CC4=C(C(=C(C=C4C3=C(C(=C2Br)O)OC)OC)O)Br
DM23CEI IK FTUCKVYWXINSAK-NSHDSACASA-N
DM23CEI IU (6aS)-3,8-dibromo-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM23CEI DE Discovery agent
DMIFJRS ID DMIFJRS
DMIFJRS DN 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMIFJRS HS Investigative
DMIFJRS SN CHEMBL206600; 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one; SCHEMBL6828078
DMIFJRS DT Small molecular drug
DMIFJRS PC 10331951
DMIFJRS MW 242.23
DMIFJRS FM C14H10O4
DMIFJRS IC InChI=1S/C14H10O4/c1-7-12(16)5-4-10-9-3-2-8(15)6-11(9)14(17)18-13(7)10/h2-6,15-16H,1H3
DMIFJRS CS CC1=C(C=CC2=C1OC(=O)C3=C2C=CC(=C3)O)O
DMIFJRS IK JVSYWKIVBHXUKB-UHFFFAOYSA-N
DMIFJRS IU 3,8-dihydroxy-4-methylbenzo[c]chromen-6-one
DMIFJRS DE Discovery agent
DMW0B4H ID DMW0B4H
DMW0B4H DN 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one
DMW0B4H HS Investigative
DMW0B4H SN CHEMBL206226; 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one
DMW0B4H DT Small molecular drug
DMW0B4H PC 44408971
DMW0B4H MW 242.23
DMW0B4H FM C14H10O4
DMW0B4H IC InChI=1S/C14H10O4/c1-7-11(16)5-4-10-9-3-2-8(15)6-12(9)18-14(17)13(7)10/h2-6,15-16H,1H3
DMW0B4H CS CC1=C(C=CC2=C1C(=O)OC3=C2C=CC(=C3)O)O
DMW0B4H IK UQGMRVBIHYSKJN-UHFFFAOYSA-N
DMW0B4H IU 3,8-dihydroxy-7-methylbenzo[c]chromen-6-one
DMW0B4H DE Discovery agent
DMXZ8RJ ID DMXZ8RJ
DMXZ8RJ DN 3,9-dihydroxy-2,10-diprenylpterocap-6a-ene
DMXZ8RJ HS Investigative
DMXZ8RJ SN Erycristagallin; CHEMBL462699; 3,9-Dihydroxy-2,10-diprenylpterocarpene; Erycrystagallin; 3,9-dihydroxy-2,10-diprenylpterocap-6a-ene; SCHEMBL571693; BDBM50292388; LMPK12070146
DMXZ8RJ DT Small molecular drug
DMXZ8RJ PC 10362969
DMXZ8RJ MW 390.5
DMXZ8RJ FM C25H26O4
DMXZ8RJ IC InChI=1S/C25H26O4/c1-14(2)5-7-16-11-19-23(12-22(16)27)28-13-20-17-9-10-21(26)18(8-6-15(3)4)24(17)29-25(19)20/h5-6,9-12,26-27H,7-8,13H2,1-4H3
DMXZ8RJ CS CC(=CCC1=CC2=C(C=C1O)OCC3=C2OC4=C3C=CC(=C4CC=C(C)C)O)C
DMXZ8RJ IK VNTSSLCFFUCTNP-UHFFFAOYSA-N
DMXZ8RJ IU 2,10-bis(3-methylbut-2-enyl)-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMXZ8RJ CA CAS 92533-56-7
DMXZ8RJ DE Discovery agent
DMK53AT ID DMK53AT
DMK53AT DN 3,9-Dihydroxy-4-prenyl-[6aR,11aR]pterocarpan
DMK53AT HS Investigative
DMK53AT SN CHEMBL1087027; BDBM50311578
DMK53AT DT Small molecular drug
DMK53AT PC 46880035
DMK53AT MW 324.4
DMK53AT FM C20H20O4
DMK53AT IC InChI=1S/C20H20O4/c1-11(2)3-5-14-17(22)8-7-15-19(14)23-10-16-13-6-4-12(21)9-18(13)24-20(15)16/h3-4,6-9,16,20-22H,5,10H2,1-2H3/t16-,20-/m0/s1
DMK53AT CS CC(=CCC1=C(C=CC2=C1OC[C@@H]3[C@H]2OC4=C3C=CC(=C4)O)O)C
DMK53AT IK QKYUTKLCEVEMIE-JXFKEZNVSA-N
DMK53AT IU (6aR,11aR)-4-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMK53AT DE Discovery agent
DMLSET4 ID DMLSET4
DMLSET4 DN 3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
DMLSET4 HS Investigative
DMLSET4 SN Thiol-Based Inhibitor, 26b; CHEMBL207288; SCHEMBL9965357; Benzoic acid, 3-[(1-carboxy-4-mercaptobutyl)thio]-; BDBM17776; 378242-58-1; 3-[(1-carboxy-4-sulfanylbutyl)sulfanyl]benzoic acid
DMLSET4 DT Small molecular drug
DMLSET4 PC 11666386
DMLSET4 MW 286.4
DMLSET4 FM C12H14O4S2
DMLSET4 IC InChI=1S/C12H14O4S2/c13-11(14)8-3-1-4-9(7-8)18-10(12(15)16)5-2-6-17/h1,3-4,7,10,17H,2,5-6H2,(H,13,14)(H,15,16)
DMLSET4 CS C1=CC(=CC(=C1)SC(CCCS)C(=O)O)C(=O)O
DMLSET4 IK QIPLUMAHVZVCQB-UHFFFAOYSA-N
DMLSET4 IU 3-(1-carboxy-4-sulfanylbutyl)sulfanylbenzoic acid
DMLSET4 DE Discovery agent
DM2KXFS ID DM2KXFS
DM2KXFS DN 3-[(1s)-1-(Dimethylamino)Ethyl]Phenol
DM2KXFS HS Investigative
DM2KXFS SN 139306-10-8; (S)-3-(1-(dimethylamino)ethyl)phenol; 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL; 3-[(1S)-1-(Dimethylaminoethyl)]phenol; (s)-3-[1-(dimethylamino)ethyl]phenol; 3-((S)-1-Dimethylamino-ethyl)-phenol; UNII-1608PLR9ZO; (S)-3-1(-Dimethylamino)ethylphenol; NAP-226-90; (S)-3-1(- Dimethylamino)ethylphenol; NAP 226-90; 1608PLR9ZO; (S)-3-(1-DIMETHYLAMINOETHYL)PHENOL; Phenol, 3-[(1S)-1-(dimethylamino)ethyl]-; AK-51758; 3-((1S)-1-(Dimethylamino)ethyl)phenol; Phenol, 3-((1S)-1-(dimethylamino)ethyl)-; SAF; A1-00312; W-205531
DM2KXFS DT Small molecular drug
DM2KXFS PC 445892
DM2KXFS MW 165.23
DM2KXFS FM C10H15NO
DM2KXFS IC InChI=1S/C10H15NO/c1-8(11(2)3)9-5-4-6-10(12)7-9/h4-8,12H,1-3H3/t8-/m0/s1
DM2KXFS CS C[C@@H](C1=CC(=CC=C1)O)N(C)C
DM2KXFS IK GQZXRLWUYONVCP-QMMMGPOBSA-N
DM2KXFS IU 3-[(1S)-1-(dimethylamino)ethyl]phenol
DM2KXFS CA CAS 139306-10-8
DM2KXFS DE Discovery agent
DMBAHRJ ID DMBAHRJ
DMBAHRJ DN 3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine
DMBAHRJ HS Investigative
DMBAHRJ SN CHEMBL201857; 3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine; SCHEMBL4149620
DMBAHRJ DT Small molecular drug
DMBAHRJ PC 11615445
DMBAHRJ MW 214.29
DMBAHRJ FM C12H10N2S
DMBAHRJ IC InChI=1S/C12H10N2S/c1-9-12(14-10(2)15-9)6-5-11-4-3-7-13-8-11/h3-4,7-8H,1-2H3
DMBAHRJ CS CC1=C(N=C(S1)C)C#CC2=CN=CC=C2
DMBAHRJ IK JDFSJBMBMZRXML-UHFFFAOYSA-N
DMBAHRJ IU 2,5-dimethyl-4-(2-pyridin-3-ylethynyl)-1,3-thiazole
DMBAHRJ DE Discovery agent
DMZ78WB ID DMZ78WB
DMZ78WB DN 3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine
DMZ78WB HS Investigative
DMZ78WB SN CHEMBL202307; 3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine; SCHEMBL4160862; BDBM50181753; ZINC13680962; US8609852, 78
DMZ78WB DT Small molecular drug
DMZ78WB PC 11608287
DMZ78WB MW 226.3
DMZ78WB FM C13H10N2S
DMZ78WB IC InChI=1S/C13H10N2S/c1-3-11-6-12(8-14-7-11)4-5-13-9-16-10(2)15-13/h3,6-9H,1H2,2H3
DMZ78WB CS CC1=NC(=CS1)C#CC2=CN=CC(=C2)C=C
DMZ78WB IK BZJCMXLEGBDDGI-UHFFFAOYSA-N
DMZ78WB IU 4-[2-(5-ethenylpyridin-3-yl)ethynyl]-2-methyl-1,3-thiazole
DMZ78WB DE Discovery agent
DMMLDOZ ID DMMLDOZ
DMMLDOZ DN 3-[(2-methyl-4-thiazolyl)ethynyl]benzamide
DMMLDOZ HS Investigative
DMMLDOZ SN CHEMBL414673; 3-[(2-methyl-4-thiazolyl)ethynyl]benzamide; Benzamide, 3-[2-(2-methyl-4-thiazolyl)ethynyl]-; SCHEMBL4157102; BDBM50181774
DMMLDOZ DT Small molecular drug
DMMLDOZ PC 11586785
DMMLDOZ MW 242.3
DMMLDOZ FM C13H10N2OS
DMMLDOZ IC InChI=1S/C13H10N2OS/c1-9-15-12(8-17-9)6-5-10-3-2-4-11(7-10)13(14)16/h2-4,7-8H,1H3,(H2,14,16)
DMMLDOZ CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)C(=O)N
DMMLDOZ IK WCIRCOOMYHNZHE-UHFFFAOYSA-N
DMMLDOZ IU 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]benzamide
DMMLDOZ DE Discovery agent
DMQUDR1 ID DMQUDR1
DMQUDR1 DN 3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile
DMQUDR1 HS Investigative
DMQUDR1 SN 3-[(2-Methyl-4-thiazolyl)ethynyl]benzonitrile; CHEMBL201943; MTEB; SCHEMBL4153877; Benzonitrile, 3-[2-(2-methyl-4-thiazolyl)ethynyl]-; GTPL1428; 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile; BDBM50181745
DMQUDR1 DT Small molecular drug
DMQUDR1 PC 11535913
DMQUDR1 MW 224.28
DMQUDR1 FM C13H8N2S
DMQUDR1 IC InChI=1S/C13H8N2S/c1-10-15-13(9-16-10)6-5-11-3-2-4-12(7-11)8-14/h2-4,7,9H,1H3
DMQUDR1 CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)C#N
DMQUDR1 IK GRUPMMBRLDBTDD-UHFFFAOYSA-N
DMQUDR1 IU 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]benzonitrile
DMQUDR1 DE Discovery agent
DMF0QM2 ID DMF0QM2
DMF0QM2 DN 3-[(2-methyl-4-thiazolyl)ethynyl]phenol
DMF0QM2 HS Investigative
DMF0QM2 SN CHEMBL201974; 3-[(2-methyl-4-thiazolyl)ethynyl]phenol; SCHEMBL4152997; BDBM50181784
DMF0QM2 DT Small molecular drug
DMF0QM2 PC 11708325
DMF0QM2 MW 215.27
DMF0QM2 FM C12H9NOS
DMF0QM2 IC InChI=1S/C12H9NOS/c1-9-13-11(8-15-9)6-5-10-3-2-4-12(14)7-10/h2-4,7-8,14H,1H3
DMF0QM2 CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)O
DMF0QM2 IK HMWLZOIKORRPSN-UHFFFAOYSA-N
DMF0QM2 IU 3-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]phenol
DMF0QM2 DE Discovery agent
DMHISM2 ID DMHISM2
DMHISM2 DN 3-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMHISM2 HS Investigative
DMHISM2 SN CHEMBL1215663; BDBM50324610
DMHISM2 DT Small molecular drug
DMHISM2 PC 49864180
DMHISM2 MW 277.3
DMHISM2 FM C18H15NO2
DMHISM2 IC InChI=1S/C18H15NO2/c20-17-9-7-14(8-10-17)13-3-5-15(6-4-13)18(21)16-2-1-11-19-12-16/h1-12,18,20-21H
DMHISM2 CS C1=CC(=CN=C1)C(C2=CC=C(C=C2)C3=CC=C(C=C3)O)O
DMHISM2 IK ZSARFSCMOGDZTE-UHFFFAOYSA-N
DMHISM2 IU 4-[4-[hydroxy(pyridin-3-yl)methyl]phenyl]phenol
DMHISM2 DE Discovery agent
DM9OI2R ID DM9OI2R
DM9OI2R DN 3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine
DM9OI2R HS Investigative
DM9OI2R SN CHEMBL202277; 3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine; SCHEMBL4151649
DM9OI2R DT Small molecular drug
DM9OI2R PC 11572145
DM9OI2R MW 228.31
DM9OI2R FM C13H12N2S
DM9OI2R IC InChI=1S/C13H12N2S/c1-3-13-12(15-10(2)16-13)7-6-11-5-4-8-14-9-11/h4-5,8-9H,3H2,1-2H3
DM9OI2R CS CCC1=C(N=C(S1)C)C#CC2=CN=CC=C2
DM9OI2R IK SJJSHLRFCBWELS-UHFFFAOYSA-N
DM9OI2R IU 5-ethyl-2-methyl-4-(2-pyridin-3-ylethynyl)-1,3-thiazole
DM9OI2R DE Discovery agent
DMH5329 ID DMH5329
DMH5329 DN 3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile
DMH5329 HS Investigative
DMH5329 SN CHEMBL181483; 3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile; SCHEMBL4711543; FKODYULBKPINFM-UHFFFAOYSA-N; BDBM50160632; ZINC28362342; 3-(6-Methyl-pyridin-2-ylethynyl)-benzonitrile
DMH5329 DT Small molecular drug
DMH5329 PC 11378977
DMH5329 MW 218.25
DMH5329 FM C15H10N2
DMH5329 IC InChI=1S/C15H10N2/c1-12-4-2-7-15(17-12)9-8-13-5-3-6-14(10-13)11-16/h2-7,10H,1H3
DMH5329 CS CC1=NC(=CC=C1)C#CC2=CC(=CC=C2)C#N
DMH5329 IK FKODYULBKPINFM-UHFFFAOYSA-N
DMH5329 IU 3-[2-(6-methylpyridin-2-yl)ethynyl]benzonitrile
DMH5329 DE Discovery agent
DMNPKZ6 ID DMNPKZ6
DMNPKZ6 DN 3-[(Z)-2-phenylvinyl]pyridine
DMNPKZ6 HS Investigative
DMNPKZ6 SN pyridine,3-(2-phenylethenyl)-,(z)-; 3-[(Z)-2-phenylethenyl]pyridine; 5097-90-5; Styrylpyridine 16; 3-[(Z)-2-phenylvinyl]pyridine; cis-3-styrylpyridine; 3-[(Z)-Styryl]pyridine; AC1O70HN; BDBM8900; CHEMBL206125; ZINC13684559; AKOS024262946
DMNPKZ6 DT Small molecular drug
DMNPKZ6 PC 6540056
DMNPKZ6 MW 181.23
DMNPKZ6 FM C13H11N
DMNPKZ6 IC InChI=1S/C13H11N/c1-2-5-12(6-3-1)8-9-13-7-4-10-14-11-13/h1-11H/b9-8-
DMNPKZ6 CS C1=CC=C(C=C1)/C=C\\C2=CN=CC=C2
DMNPKZ6 IK RMSGACVDMOLUPL-HJWRWDBZSA-N
DMNPKZ6 IU 3-[(Z)-2-phenylethenyl]pyridine
DMNPKZ6 DE Discovery agent
DM7URMW ID DM7URMW
DM7URMW DN 3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol
DM7URMW HS Investigative
DM7URMW SN CHEMBL598810; SCHEMBL3823053; 3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol; HNOJMJNDVRPLSW-UHFFFAOYSA-N; BDBM50307229; 1-p-Bromobenzyl-5-(3-hydroxypropyl)-1H-imidazole
DM7URMW DT Small molecular drug
DM7URMW PC 22466877
DM7URMW MW 295.17
DM7URMW FM C13H15BrN2O
DM7URMW IC InChI=1S/C13H15BrN2O/c14-12-5-3-11(4-6-12)9-16-10-15-8-13(16)2-1-7-17/h3-6,8,10,17H,1-2,7,9H2
DM7URMW CS C1=CC(=CC=C1CN2C=NC=C2CCCO)Br
DM7URMW IK HNOJMJNDVRPLSW-UHFFFAOYSA-N
DM7URMW IU 3-[3-[(4-bromophenyl)methyl]imidazol-4-yl]propan-1-ol
DM7URMW DE Discovery agent
DM63IKF ID DM63IKF
DM63IKF DN 3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol
DM63IKF HS Investigative
DM63IKF SN CHEMBL598399; SCHEMBL3822518; 3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol; ACOYOVQVLSTOMH-UHFFFAOYSA-N; ZINC34123980; BDBM50307226; AKOS027324260; 1-p-Cyanophenylmethyl-5-(3-hydroxypropyl)-1H-imidazole; 1-(p-cyanophenylmethyl)-5-(3-hydroxypropyl)-1H-imidazole; 1-(p-Cyanophenylmethyl)-5-(3-hydroxypropyl) -1H-imidazole
DM63IKF DT Small molecular drug
DM63IKF PC 13688208
DM63IKF MW 241.29
DM63IKF FM C14H15N3O
DM63IKF IC InChI=1S/C14H15N3O/c15-8-12-3-5-13(6-4-12)10-17-11-16-9-14(17)2-1-7-18/h3-6,9,11,18H,1-2,7,10H2
DM63IKF CS C1=CC(=CC=C1CN2C=NC=C2CCCO)C#N
DM63IKF IK ACOYOVQVLSTOMH-UHFFFAOYSA-N
DM63IKF IU 4-[[5-(3-hydroxypropyl)imidazol-1-yl]methyl]benzonitrile
DM63IKF DE Discovery agent
DMIHWAJ ID DMIHWAJ
DMIHWAJ DN 3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene
DMIHWAJ HS Investigative
DMIHWAJ SN CHEMBL453439; 3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene; BDBM50270321; 3-[1''-{4''-(Benzyloxy)-phenyl}]-quinuclidine-2-ene
DMIHWAJ DT Small molecular drug
DMIHWAJ PC 23653492
DMIHWAJ MW 291.4
DMIHWAJ FM C20H21NO
DMIHWAJ IC InChI=1S/C20H21NO/c1-2-4-16(5-3-1)15-22-19-8-6-17(7-9-19)20-14-21-12-10-18(20)11-13-21/h1-9,14,18H,10-13,15H2
DMIHWAJ CS C1CN2CCC1C(=C2)C3=CC=C(C=C3)OCC4=CC=CC=C4
DMIHWAJ IK OKNMXSHKBLYYKN-UHFFFAOYSA-N
DMIHWAJ IU 3-(4-phenylmethoxyphenyl)-1-azabicyclo[2.2.2]oct-2-ene
DMIHWAJ DE Discovery agent
DMBHUP3 ID DMBHUP3
DMBHUP3 DN 3-[10-(benzylmethylamino)decyloxy]xanthen-9-one
DMBHUP3 HS Investigative
DMBHUP3 SN CHEMBL390598; 3-[10-(benzylmethylamino)decyloxy]xanthen-9-one
DMBHUP3 DT Small molecular drug
DMBHUP3 PC 44421959
DMBHUP3 MW 471.6
DMBHUP3 FM C31H37NO3
DMBHUP3 IC InChI=1S/C31H37NO3/c1-32(24-25-15-9-8-10-16-25)21-13-6-4-2-3-5-7-14-22-34-26-19-20-28-30(23-26)35-29-18-12-11-17-27(29)31(28)33/h8-12,15-20,23H,2-7,13-14,21-22,24H2,1H3
DMBHUP3 CS CN(CCCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMBHUP3 IK YOTLTNQICYMZSI-UHFFFAOYSA-N
DMBHUP3 IU 3-[10-[benzyl(methyl)amino]decoxy]xanthen-9-one
DMBHUP3 DE Discovery agent
DM287UO ID DM287UO
DM287UO DN 3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one
DM287UO HS Investigative
DM287UO SN CHEMBL224347; 3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one
DM287UO DT Small molecular drug
DM287UO PC 44421960
DM287UO MW 485.7
DM287UO FM C32H39NO3
DM287UO IC InChI=1S/C32H39NO3/c1-33(25-26-16-10-9-11-17-26)22-14-7-5-3-2-4-6-8-15-23-35-27-20-21-29-31(24-27)36-30-19-13-12-18-28(30)32(29)34/h9-13,16-21,24H,2-8,14-15,22-23,25H2,1H3
DM287UO CS CN(CCCCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM287UO IK GQHNOERJFAPKTD-UHFFFAOYSA-N
DM287UO IU 3-[11-[benzyl(methyl)amino]undecoxy]xanthen-9-one
DM287UO DE Discovery agent
DM9KVHQ ID DM9KVHQ
DM9KVHQ DN 3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one
DM9KVHQ HS Investigative
DM9KVHQ SN CHEMBL224555; 3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one
DM9KVHQ DT Small molecular drug
DM9KVHQ PC 16066832
DM9KVHQ MW 499.7
DM9KVHQ FM C33H41NO3
DM9KVHQ IC InChI=1S/C33H41NO3/c1-34(26-27-17-11-10-12-18-27)23-15-8-6-4-2-3-5-7-9-16-24-36-28-21-22-30-32(25-28)37-31-20-14-13-19-29(31)33(30)35/h10-14,17-22,25H,2-9,15-16,23-24,26H2,1H3
DM9KVHQ CS CN(CCCCCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM9KVHQ IK JLVUWPGHBWDHKA-UHFFFAOYSA-N
DM9KVHQ IU 3-[12-[benzyl(methyl)amino]dodecoxy]xanthen-9-one
DM9KVHQ DE Discovery agent
DMPTI1Z ID DMPTI1Z
DMPTI1Z DN 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol
DMPTI1Z HS Investigative
DMPTI1Z SN Metahexes trol; 3,3'-Hexestrol; Metahexestrol; 3,3'-Hes; 68266-24-0; meso-3,4-Bis(3'-hydroxyphenyl)hexane; BRN 3971661; NSC-297,170; meso-3,3'-(1,2-Diethylethylene)diphenol; NSC-297170; (R*,S*)-3,3'-(1,2-Diethyl-1,2-ethanediyl)bisphenol; Phenol, 3,3'-(1,2-diethyl-1,2-ethanediyl)bis-, (R*,S*)-; Phenol, 3,3'-((1R,2S)-1,2-diethyl-1,2-ethanediyl)bis-, rel-; UNII-DSF584X94B; DSF584X94B; NSC 297170; 3-[4-(3-hydroxyphenyl)hexan-3-yl]phenol; AC1L2OPY; 1,2-Diethyl-1,2-bis(3'-hydroxyphenyl)ethane; AC1Q79WV; CHEMBL18268; SCHEMBL5014485
DMPTI1Z DT Small molecular drug
DMPTI1Z PC 100424
DMPTI1Z MW 270.4
DMPTI1Z FM C18H22O2
DMPTI1Z IC InChI=1S/C18H22O2/c1-3-17(13-7-5-9-15(19)11-13)18(4-2)14-8-6-10-16(20)12-14/h5-12,17-20H,3-4H2,1-2H3
DMPTI1Z CS CCC(C1=CC(=CC=C1)O)C(CC)C2=CC(=CC=C2)O
DMPTI1Z IK KUJAWCSIKNKXLL-UHFFFAOYSA-N
DMPTI1Z IU 3-[4-(3-hydroxyphenyl)hexan-3-yl]phenol
DMPTI1Z CA CAS 68266-24-0
DMPTI1Z DE Discovery agent
DME1UNY ID DME1UNY
DME1UNY DN 3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole
DME1UNY HS Investigative
DME1UNY SN CHEMBL92958; SCHEMBL6989630; 3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole; BDBM50039720
DME1UNY DT Small molecular drug
DME1UNY PC 9996081
DME1UNY MW 319.4
DME1UNY FM C21H25N3
DME1UNY IC InChI=1S/C21H25N3/c1-2-6-18(7-3-1)16-24-14-12-17(13-15-24)10-11-21-19-8-4-5-9-20(19)22-23-21/h1-9,17H,10-16H2,(H,22,23)
DME1UNY CS C1CN(CCC1CCC2=C3C=CC=CC3=NN2)CC4=CC=CC=C4
DME1UNY IK NPZKLBFCTYVTBS-UHFFFAOYSA-N
DME1UNY IU 3-[2-(1-benzylpiperidin-4-yl)ethyl]-2H-indazole
DME1UNY DE Discovery agent
DMXE1LC ID DMXE1LC
DMXE1LC DN 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan
DMXE1LC HS Investigative
DMXE1LC SN CHEMBL43396; 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan; SCHEMBL7047273; SCHEMBL7047277; 3-[(E)-3,5-Dimethoxystyryl]furan; ZINC13471767; BDBM50108047; AKOS015967552
DMXE1LC DT Small molecular drug
DMXE1LC PC 10105252
DMXE1LC MW 230.26
DMXE1LC FM C14H14O3
DMXE1LC IC InChI=1S/C14H14O3/c1-15-13-7-12(8-14(9-13)16-2)4-3-11-5-6-17-10-11/h3-10H,1-2H3/b4-3+
DMXE1LC CS COC1=CC(=CC(=C1)/C=C/C2=COC=C2)OC
DMXE1LC IK UUOXVOMLPNADJK-ONEGZZNKSA-N
DMXE1LC IU 3-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]furan
DMXE1LC DE Discovery agent
DM5EJLD ID DM5EJLD
DM5EJLD DN 3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol
DM5EJLD HS Investigative
DM5EJLD SN CHEMBL1096026; 3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol
DM5EJLD DT Small molecular drug
DM5EJLD PC 46887579
DM5EJLD MW 287.8
DM5EJLD FM C15H10ClNOS
DM5EJLD IC InChI=1S/C15H10ClNOS/c16-15-5-4-14(19-15)13-9-11(6-7-17-13)10-2-1-3-12(18)8-10/h1-9,18H
DM5EJLD CS C1=CC(=CC(=C1)O)C2=CC(=NC=C2)C3=CC=C(S3)Cl
DM5EJLD IK IJRUJPYMZCIXQJ-UHFFFAOYSA-N
DM5EJLD IU 3-[2-(5-chlorothiophen-2-yl)pyridin-4-yl]phenol
DM5EJLD DE Discovery agent
DMJB1KL ID DMJB1KL
DMJB1KL DN 3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine
DMJB1KL HS Investigative
DMJB1KL SN CHEMBL345732; BDBM50135703; 3-[2-(Trimethylaminio)ethoxy]pyridine; Trimethyl-[2-(pyridin-3-yloxy)-ethyl]-ammonium
DMJB1KL DT Small molecular drug
DMJB1KL PC 9794401
DMJB1KL MW 181.25
DMJB1KL FM C10H17N2O+
DMJB1KL IC InChI=1S/C10H17N2O/c1-12(2,3)7-8-13-10-5-4-6-11-9-10/h4-6,9H,7-8H2,1-3H3/q+1
DMJB1KL CS C[N+](C)(C)CCOC1=CN=CC=C1
DMJB1KL IK WBRKKKJHXQZXEM-UHFFFAOYSA-N
DMJB1KL IU trimethyl(2-pyridin-3-yloxyethyl)azanium
DMJB1KL DE Discovery agent
DMLX9SI ID DMLX9SI
DMLX9SI DN 3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one
DMLX9SI HS Investigative
DMLX9SI SN CHEMBL97218; AC1OCFMJ; 3-[3-(2-hydroxyethoxy)phenyl]-1H-quinolin-2-one; 3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one; ZINC13584303; BDBM50105767
DMLX9SI DT Small molecular drug
DMLX9SI PC 6918599
DMLX9SI MW 281.3
DMLX9SI FM C17H15NO3
DMLX9SI IC InChI=1S/C17H15NO3/c19-8-9-21-14-6-3-5-12(10-14)15-11-13-4-1-2-7-16(13)18-17(15)20/h1-7,10-11,19H,8-9H2,(H,18,20)
DMLX9SI CS C1=CC=C2C(=C1)C=C(C(=O)N2)C3=CC(=CC=C3)OCCO
DMLX9SI IK CAPTUZLISRNFKN-UHFFFAOYSA-N
DMLX9SI IU 3-[3-(2-hydroxyethoxy)phenyl]-1H-quinolin-2-one
DMLX9SI DE Discovery agent
DM60YGF ID DM60YGF
DM60YGF DN 3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
DM60YGF HS Investigative
DM60YGF SN CHEMBL201394; 3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide; BDBM50181479; 3-[(3-benzyloxy-2-pyridyl)carbamoylamino]benzamide; Benzamide, 3-[[[[3-(phenylmethoxy)-2-pyridinyl]amino]carbonyl]amino]-
DM60YGF DT Small molecular drug
DM60YGF PC 11639129
DM60YGF MW 362.4
DM60YGF FM C20H18N4O3
DM60YGF IC InChI=1S/C20H18N4O3/c21-18(25)15-8-4-9-16(12-15)23-20(26)24-19-17(10-5-11-22-19)27-13-14-6-2-1-3-7-14/h1-12H,13H2,(H2,21,25)(H2,22,23,24,26)
DM60YGF CS C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=CC(=C3)C(=O)N
DM60YGF IK RLBJUMUHKDTSCO-UHFFFAOYSA-N
DM60YGF IU 3-[(3-phenylmethoxypyridin-2-yl)carbamoylamino]benzamide
DM60YGF DE Discovery agent
DMNC6W9 ID DMNC6W9
DMNC6W9 DN 3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol
DMNC6W9 HS Investigative
DMNC6W9 DT Small molecular drug
DMNC6W9 PC 135855877
DMNC6W9 MW 253.25
DMNC6W9 FM C15H11NO3
DMNC6W9 IC InChI=1S/C15H11NO3/c17-12-6-4-10(5-7-12)14-9-15(19-16-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DMNC6W9 CS C1=CC(=CC(=C1)O)C2=CC(=NO2)C3=CC=C(C=C3)O
DMNC6W9 IK ZYSCCHLCNRGGTO-UHFFFAOYSA-N
DMNC6W9 IU 3-[3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]phenol
DMNC6W9 DE Discovery agent
DMTLJMF ID DMTLJMF
DMTLJMF DN 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DMTLJMF HS Investigative
DMTLJMF SN CHEMBL262968; 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine; SCHEMBL14130000; BDBM50138237
DMTLJMF DT Small molecular drug
DMTLJMF PC 44341278
DMTLJMF MW 279.34
DMTLJMF FM C17H17N3O
DMTLJMF IC InChI=1S/C17H17N3O/c1-3-15(13-18-9-1)4-2-12-21-17-7-5-16(6-8-17)20-11-10-19-14-20/h1,3,5-11,13-14H,2,4,12H2
DMTLJMF CS C1=CC(=CN=C1)CCCOC2=CC=C(C=C2)N3C=CN=C3
DMTLJMF IK GCRYIIOKZWQWIH-UHFFFAOYSA-N
DMTLJMF IU 3-[3-(4-imidazol-1-ylphenoxy)propyl]pyridine
DMTLJMF CA CAS 742691-87-8
DMTLJMF DE Discovery agent
DM8NRJQ ID DM8NRJQ
DM8NRJQ DN 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
DM8NRJQ HS Investigative
DM8NRJQ SN CHEMBL493082; 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine
DM8NRJQ DT Small molecular drug
DM8NRJQ PC 25130848
DM8NRJQ MW 325.4
DM8NRJQ FM C23H19NO
DM8NRJQ IC InChI=1S/C23H19NO/c1-25-22-10-8-17(9-11-22)13-21-14-18-5-2-3-6-19(18)15-23(21)20-7-4-12-24-16-20/h2-12,14-16H,13H2,1H3
DM8NRJQ CS COC1=CC=C(C=C1)CC2=CC3=CC=CC=C3C=C2C4=CN=CC=C4
DM8NRJQ IK GOGQHVZGANJJDF-UHFFFAOYSA-N
DM8NRJQ IU 3-[3-[(4-methoxyphenyl)methyl]naphthalen-2-yl]pyridine
DM8NRJQ DE Discovery agent
DMPVXTB ID DMPVXTB
DMPVXTB DN 3-[3-(benzylmethylamino)propoxy]xanthen-9-one
DMPVXTB HS Investigative
DMPVXTB SN CHEMBL225610; 3-[3-(benzylmethylamino)propoxy]xanthen-9-one
DMPVXTB DT Small molecular drug
DMPVXTB PC 44421937
DMPVXTB MW 373.4
DMPVXTB FM C24H23NO3
DMPVXTB IC InChI=1S/C24H23NO3/c1-25(17-18-8-3-2-4-9-18)14-7-15-27-19-12-13-21-23(16-19)28-22-11-6-5-10-20(22)24(21)26/h2-6,8-13,16H,7,14-15,17H2,1H3
DMPVXTB CS CN(CCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMPVXTB IK OTLLABLRJBVBHD-UHFFFAOYSA-N
DMPVXTB IU 3-[3-[benzyl(methyl)amino]propoxy]xanthen-9-one
DMPVXTB DE Discovery agent
DMDS8UJ ID DMDS8UJ
DMDS8UJ DN 3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMDS8UJ HS Investigative
DMDS8UJ SN (3-Pyridylmethylene)indane 36a; CHEMBL195688; AC1O707D; BDBM8646; SCHEMBL13877113; 3-[(E)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMDS8UJ DT Small molecular drug
DMDS8UJ PC 6539817
DMDS8UJ MW 221.3
DMDS8UJ FM C16H15N
DMDS8UJ IC InChI=1S/C16H15N/c1-12-9-14(10-13-5-4-8-17-11-13)16-7-3-2-6-15(12)16/h2-8,10-12H,9H2,1H3/b14-10+
DMDS8UJ CS CC1C/C(=C\\C2=CN=CC=C2)/C3=CC=CC=C13
DMDS8UJ IK KMRIBBKLCIMDTB-GXDHUFHOSA-N
DMDS8UJ IU 3-[(E)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMDS8UJ DE Discovery agent
DMTF520 ID DMTF520
DMTF520 DN 3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMTF520 HS Investigative
DMTF520 SN CHEMBL373074; AC1O707F; BDBM8647; (3-Pyridylmethylene)indane 36b; 3-[(Z)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMTF520 DT Small molecular drug
DMTF520 PC 6539818
DMTF520 MW 221.3
DMTF520 FM C16H15N
DMTF520 IC InChI=1S/C16H15N/c1-12-9-14(10-13-5-4-8-17-11-13)16-7-3-2-6-15(12)16/h2-8,10-12H,9H2,1H3/b14-10-
DMTF520 CS CC1C/C(=C/C2=CN=CC=C2)/C3=CC=CC=C13
DMTF520 IK KMRIBBKLCIMDTB-UVTDQMKNSA-N
DMTF520 IU 3-[(Z)-(3-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMTF520 DE Discovery agent
DMYEWA4 ID DMYEWA4
DMYEWA4 DN 3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine
DMYEWA4 HS Investigative
DMYEWA4 SN (3-Pyridylmethylene)indane 37a; BDBM8648; AC1O707H; CHEMBL193555; 3-[(E)-(3-phenyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYEWA4 DT Small molecular drug
DMYEWA4 PC 6539819
DMYEWA4 MW 283.4
DMYEWA4 FM C21H17N
DMYEWA4 IC InChI=1S/C21H17N/c1-2-8-17(9-3-1)21-14-18(13-16-7-6-12-22-15-16)19-10-4-5-11-20(19)21/h1-13,15,21H,14H2/b18-13+
DMYEWA4 CS C\\1C(C2=CC=CC=C2/C1=C/C3=CN=CC=C3)C4=CC=CC=C4
DMYEWA4 IK ADQBWRCDKUIPFI-QGOAFFKASA-N
DMYEWA4 IU 3-[(E)-(3-phenyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYEWA4 DE Discovery agent
DME86OK ID DME86OK
DME86OK DN 3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole
DME86OK HS Investigative
DME86OK SN CHEMBL38031; 3-[4-(4-Fluorophenoxy)phenyl]-1H-pyrazole; 3-(4-(4-Fluorophenoxy)phenyl)-1H-pyrazole; 3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole; SCHEMBL1385301; CTK7C0984; CGMPMLHCCFCLQL-UHFFFAOYSA-N; BDBM50141066; ZINC13559818
DME86OK DT Small molecular drug
DME86OK PC 9816478
DME86OK MW 254.26
DME86OK FM C15H11FN2O
DME86OK IC InChI=1S/C15H11FN2O/c16-12-3-7-14(8-4-12)19-13-5-1-11(2-6-13)15-9-10-17-18-15/h1-10H,(H,17,18)
DME86OK CS C1=CC(=CC=C1C2=CC=NN2)OC3=CC=C(C=C3)F
DME86OK IK CGMPMLHCCFCLQL-UHFFFAOYSA-N
DME86OK IU 5-[4-(4-fluorophenoxy)phenyl]-1H-pyrazole
DME86OK DE Discovery agent
DMIM5WE ID DMIM5WE
DMIM5WE DN 3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DMIM5WE HS Investigative
DMIM5WE SN CHEMBL529446; 3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol; SCHEMBL1180107; BDBM50271078
DMIM5WE DT Small molecular drug
DMIM5WE PC 25192184
DMIM5WE MW 253.25
DMIM5WE FM C15H11NO3
DMIM5WE IC InChI=1S/C15H11NO3/c17-12-6-4-10(5-7-12)14-9-19-15(16-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DMIM5WE CS C1=CC(=CC(=C1)O)C2=NC(=CO2)C3=CC=C(C=C3)O
DMIM5WE IK NOWYSMIMXQPTPC-UHFFFAOYSA-N
DMIM5WE IU 3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DMIM5WE DE Discovery agent
DM75F1Q ID DM75F1Q
DM75F1Q DN 3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid
DM75F1Q HS Investigative
DM75F1Q SN CHEMBL201425; 3-[4-(4-phenoxybenzoyl)phenyl]propanoic Acid
DM75F1Q DT Small molecular drug
DM75F1Q PC 11515759
DM75F1Q MW 346.4
DM75F1Q FM C22H18O4
DM75F1Q IC InChI=1S/C22H18O4/c23-21(24)15-8-16-6-9-17(10-7-16)22(25)18-11-13-20(14-12-18)26-19-4-2-1-3-5-19/h1-7,9-14H,8,15H2,(H,23,24)
DM75F1Q CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)CCC(=O)O
DM75F1Q IK FYPQECPTVJQSOG-UHFFFAOYSA-N
DM75F1Q IU 3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid
DM75F1Q DE Discovery agent
DMZCO83 ID DMZCO83
DMZCO83 DN 3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMZCO83 HS Investigative
DMZCO83 SN CHEMBL1096375; 3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMZCO83 DT Small molecular drug
DMZCO83 PC 46887581
DMZCO83 MW 287.8
DMZCO83 FM C15H10ClNOS
DMZCO83 IC InChI=1S/C15H10ClNOS/c16-15-5-4-14(19-15)11-6-7-17-13(9-11)10-2-1-3-12(18)8-10/h1-9,18H
DMZCO83 CS C1=CC(=CC(=C1)O)C2=NC=CC(=C2)C3=CC=C(S3)Cl
DMZCO83 IK MOVQEDAJQOEYIC-UHFFFAOYSA-N
DMZCO83 IU 3-[4-(5-chlorothiophen-2-yl)pyridin-2-yl]phenol
DMZCO83 DE Discovery agent
DMZPULH ID DMZPULH
DMZPULH DN 3-[4-(benzylmethylamino)butoxy]xanthen-9-one
DMZPULH HS Investigative
DMZPULH SN CHEMBL225611; 3-[4-(benzylmethylamino)butoxy]xanthen-9-one
DMZPULH DT Small molecular drug
DMZPULH PC 44421938
DMZPULH MW 387.5
DMZPULH FM C25H25NO3
DMZPULH IC InChI=1S/C25H25NO3/c1-26(18-19-9-3-2-4-10-19)15-7-8-16-28-20-13-14-22-24(17-20)29-23-12-6-5-11-21(23)25(22)27/h2-6,9-14,17H,7-8,15-16,18H2,1H3
DMZPULH CS CN(CCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMZPULH IK VUBALVZUDJIWHQ-UHFFFAOYSA-N
DMZPULH IU 3-[4-[benzyl(methyl)amino]butoxy]xanthen-9-one
DMZPULH DE Discovery agent
DM0XD6T ID DM0XD6T
DM0XD6T DN 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM0XD6T HS Investigative
DM0XD6T SN AC1O705J; SCHEMBL4231098; SCHEMBL4231088; CHEMBL176287; BDBM8608; (3-Pyridylmethylene)indane 25a; 3-[(E)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM0XD6T DT Small molecular drug
DM0XD6T PC 6539784
DM0XD6T MW 241.71
DM0XD6T FM C15H12ClN
DM0XD6T IC InChI=1S/C15H12ClN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9+
DM0XD6T CS C\\1CC2=C(/C1=C/C3=CN=CC=C3)C=CC=C2Cl
DM0XD6T IK OAISOHCDZRMGCP-FMIVXFBMSA-N
DM0XD6T IU 3-[(E)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM0XD6T DE Discovery agent
DMMDIB9 ID DMMDIB9
DMMDIB9 DN 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMMDIB9 HS Investigative
DMMDIB9 SN (3-Pyridylmethylene)indane 25b; CHEMBL369623; SCHEMBL4231092; BDBM8609; AC1O705L; 3-[(Z)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMDIB9 DT Small molecular drug
DMMDIB9 PC 6539785
DMMDIB9 MW 241.71
DMMDIB9 FM C15H12ClN
DMMDIB9 IC InChI=1S/C15H12ClN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9-
DMMDIB9 CS C\\1CC2=C(/C1=C\\C3=CN=CC=C3)C=CC=C2Cl
DMMDIB9 IK OAISOHCDZRMGCP-XFXZXTDPSA-N
DMMDIB9 IU 3-[(Z)-(4-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMDIB9 DE Discovery agent
DMZS20Y ID DMZS20Y
DMZS20Y DN 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMZS20Y HS Investigative
DMZS20Y SN (3-Pyridylmethylene)indane 24a; SCHEMBL4221248; SCHEMBL4221241; AC1O705H; CHEMBL366490; BDBM8607; 3-[(E)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZS20Y DT Small molecular drug
DMZS20Y PC 6539783
DMZS20Y MW 225.26
DMZS20Y FM C15H12FN
DMZS20Y IC InChI=1S/C15H12FN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9+
DMZS20Y CS C\\1CC2=C(/C1=C/C3=CN=CC=C3)C=CC=C2F
DMZS20Y IK JKDSUQNXZNYUED-FMIVXFBMSA-N
DMZS20Y IU 3-[(E)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZS20Y DE Discovery agent
DMPS340 ID DMPS340
DMPS340 DN 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMPS340 HS Investigative
DMPS340 SN CHEMBL176076; AC1O705X; BDBM8617; SCHEMBL4221244; (3-Pyridylmethylene)indane 24b; 3-[(Z)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMPS340 DT Small molecular drug
DMPS340 PC 6539791
DMPS340 MW 225.26
DMPS340 FM C15H12FN
DMPS340 IC InChI=1S/C15H12FN/c16-15-5-1-4-13-12(6-7-14(13)15)9-11-3-2-8-17-10-11/h1-5,8-10H,6-7H2/b12-9-
DMPS340 CS C\\1CC2=C(/C1=C\\C3=CN=CC=C3)C=CC=C2F
DMPS340 IK JKDSUQNXZNYUED-XFXZXTDPSA-N
DMPS340 IU 3-[(Z)-(4-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMPS340 DE Discovery agent
DMJN93U ID DMJN93U
DMJN93U DN 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMJN93U HS Investigative
DMJN93U SN SCHEMBL4224799; BDBM8599; CHEMBL368305; SCHEMBL4224793; (3-Pyridylmethylene)indane 23a; AC1O7051; 3-[(E)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMJN93U DT Small molecular drug
DMJN93U PC 6539775
DMJN93U MW 221.3
DMJN93U FM C16H15N
DMJN93U IC InChI=1S/C16H15N/c1-12-4-2-6-16-14(7-8-15(12)16)10-13-5-3-9-17-11-13/h2-6,9-11H,7-8H2,1H3/b14-10+
DMJN93U CS CC1=C2CC/C(=C\\C3=CN=CC=C3)/C2=CC=C1
DMJN93U IK ORCOWTSQEFCEFC-GXDHUFHOSA-N
DMJN93U IU 3-[(E)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMJN93U DE Discovery agent
DMNILXG ID DMNILXG
DMNILXG DN 3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMNILXG HS Investigative
DMNILXG SN (3-Pyridylmethylene)indane 23b; AC1O705F; SCHEMBL4224796; BDBM8606; CHEMBL176009; 3-[(Z)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMNILXG DT Small molecular drug
DMNILXG PC 6539782
DMNILXG MW 221.3
DMNILXG FM C16H15N
DMNILXG IC InChI=1S/C16H15N/c1-12-4-2-6-16-14(7-8-15(12)16)10-13-5-3-9-17-11-13/h2-6,9-11H,7-8H2,1H3/b14-10-
DMNILXG CS CC1=C2CC/C(=C/C3=CN=CC=C3)/C2=CC=C1
DMNILXG IK ORCOWTSQEFCEFC-UVTDQMKNSA-N
DMNILXG IU 3-[(Z)-(4-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMNILXG DE Discovery agent
DMYZIG3 ID DMYZIG3
DMYZIG3 DN 3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol
DMYZIG3 HS Investigative
DMYZIG3 SN CHEMBL566521; 3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol
DMYZIG3 DT Small molecular drug
DMYZIG3 PC 44542795
DMYZIG3 MW 288.3
DMYZIG3 FM C16H10F2OS
DMYZIG3 IC InChI=1S/C16H10F2OS/c17-13-5-4-11(9-14(13)18)16-7-6-15(20-16)10-2-1-3-12(19)8-10/h1-9,19H
DMYZIG3 CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)F)F
DMYZIG3 IK PKUPEZBIFLWEBN-UHFFFAOYSA-N
DMYZIG3 IU 3-[5-(3,4-difluorophenyl)thiophen-2-yl]phenol
DMYZIG3 DE Discovery agent
DMD5QOW ID DMD5QOW
DMD5QOW DN 3-[5-(3-Fluorophenyl)-2-thienyl]phenol
DMD5QOW HS Investigative
DMD5QOW SN CHEMBL576318; 3-[5-(3-Fluorophenyl)-2-thienyl]phenol; SCHEMBL1179817
DMD5QOW DT Small molecular drug
DMD5QOW PC 25192480
DMD5QOW MW 270.3
DMD5QOW FM C16H11FOS
DMD5QOW IC InChI=1S/C16H11FOS/c17-13-5-1-3-11(9-13)15-7-8-16(19-15)12-4-2-6-14(18)10-12/h1-10,18H
DMD5QOW CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=CC=C3)F
DMD5QOW IK BZEWIGQYBSBQAI-UHFFFAOYSA-N
DMD5QOW IU 3-[5-(3-fluorophenyl)thiophen-2-yl]phenol
DMD5QOW DE Discovery agent
DM1QKNU ID DM1QKNU
DM1QKNU DN 3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid
DM1QKNU HS Investigative
DM1QKNU SN 3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid; 53N; DB07139; 3-[5-(3-nitrophenyl)thiophen-2-yl] propanoic acid
DM1QKNU DT Small molecular drug
DM1QKNU PC 25210476
DM1QKNU MW 277.3
DM1QKNU FM C13H11NO4S
DM1QKNU IC InChI=1S/C13H11NO4S/c15-13(16)7-5-11-4-6-12(19-11)9-2-1-3-10(8-9)14(17)18/h1-4,6,8H,5,7H2,(H,15,16)
DM1QKNU CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(S2)CCC(=O)O
DM1QKNU IK IHKCOKRMJRDWAL-UHFFFAOYSA-N
DM1QKNU IU 3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid
DM1QKNU DE Discovery agent
DMYZ2U0 ID DMYZ2U0
DMYZ2U0 DN 3-[5-(4-Fluorophenyl)-2-thienyl]phenol
DMYZ2U0 HS Investigative
DMYZ2U0 SN CHEMBL570368; 3-[5-(4-Fluorophenyl)-2-thienyl]phenol; SCHEMBL1180762
DMYZ2U0 DT Small molecular drug
DMYZ2U0 PC 25192620
DMYZ2U0 MW 270.3
DMYZ2U0 FM C16H11FOS
DMYZ2U0 IC InChI=1S/C16H11FOS/c17-13-6-4-11(5-7-13)15-8-9-16(19-15)12-2-1-3-14(18)10-12/h1-10,18H
DMYZ2U0 CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC=C(C=C3)F
DMYZ2U0 IK LBERAJGCBDGPHK-UHFFFAOYSA-N
DMYZ2U0 IU 3-[5-(4-fluorophenyl)thiophen-2-yl]phenol
DMYZ2U0 DE Discovery agent
DM4TFMA ID DM4TFMA
DM4TFMA DN 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DM4TFMA HS Investigative
DM4TFMA SN CHEMBL488752; 3-[5-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol; SCHEMBL1180391
DM4TFMA DT Small molecular drug
DM4TFMA PC 24857878
DM4TFMA MW 253.25
DM4TFMA FM C15H11NO3
DM4TFMA IC InChI=1S/C15H11NO3/c17-12-6-4-10(5-7-12)14-9-16-15(19-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DM4TFMA CS C1=CC(=CC(=C1)O)C2=NC=C(O2)C3=CC=C(C=C3)O
DM4TFMA IK QWBAQAYKEITCRE-UHFFFAOYSA-N
DM4TFMA IU 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
DM4TFMA DE Discovery agent
DM2IXO0 ID DM2IXO0
DM2IXO0 DN 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol
DM2IXO0 HS Investigative
DM2IXO0 SN SCHEMBL1180532; CHEMBL458727; BDBM25831; WBUPCNHALRFMCB-UHFFFAOYSA-N; hydroxyphenyl substituted thiazole, 3; 3-[5-(4-Hydroxyphenyl)-1,3-thiazole-2-yl]phenol
DM2IXO0 DT Small molecular drug
DM2IXO0 PC 25093373
DM2IXO0 MW 269.3
DM2IXO0 FM C15H11NO2S
DM2IXO0 IC InChI=1S/C15H11NO2S/c17-12-6-4-10(5-7-12)14-9-16-15(19-14)11-2-1-3-13(18)8-11/h1-9,17-18H
DM2IXO0 CS C1=CC(=CC(=C1)O)C2=NC=C(S2)C3=CC=C(C=C3)O
DM2IXO0 IK WBUPCNHALRFMCB-UHFFFAOYSA-N
DM2IXO0 IU 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol
DM2IXO0 DE Discovery agent
DMAMOJE ID DMAMOJE
DMAMOJE DN 3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol
DMAMOJE HS Investigative
DMAMOJE SN CHEMBL583519; 3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol; SCHEMBL1180575
DMAMOJE DT Small molecular drug
DMAMOJE PC 25192619
DMAMOJE MW 282.4
DMAMOJE FM C17H14O2S
DMAMOJE IC InChI=1S/C17H14O2S/c1-11-8-13(10-15(19)9-11)17-7-6-16(20-17)12-2-4-14(18)5-3-12/h2-10,18-19H,1H3
DMAMOJE CS CC1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC=C(C=C3)O
DMAMOJE IK NWLAWEHHCISQCM-UHFFFAOYSA-N
DMAMOJE IU 3-[5-(4-hydroxyphenyl)thiophen-2-yl]-5-methylphenol
DMAMOJE DE Discovery agent
DMSFW9T ID DMSFW9T
DMSFW9T DN 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMSFW9T HS Investigative
DMSFW9T SN 3-[5-(4-Hydroxyphenyl)-2-thienyl]phenol; SCHEMBL1180468; CHEMBL457323; BDBM25850; PKHBRBMFZXTMIS-UHFFFAOYSA-N; ZINC40847645; 4,3'-(2,5-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 22
DMSFW9T DT Small molecular drug
DMSFW9T PC 25093386
DMSFW9T MW 268.3
DMSFW9T FM C16H12O2S
DMSFW9T IC InChI=1S/C16H12O2S/c17-13-6-4-11(5-7-13)15-8-9-16(19-15)12-2-1-3-14(18)10-12/h1-10,17-18H
DMSFW9T CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC=C(C=C3)O
DMSFW9T IK PKHBRBMFZXTMIS-UHFFFAOYSA-N
DMSFW9T IU 3-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMSFW9T DE Discovery agent
DM40GJ8 ID DM40GJ8
DM40GJ8 DN 3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol
DM40GJ8 HS Investigative
DM40GJ8 SN CHEMBL462513; SCHEMBL1180467; BDBM25853; ZINC40393334; 4,3'-(2,4-Thiophenediyl)bisphenol; hydroxyphenyl substituted thiophene, 25
DM40GJ8 DT Small molecular drug
DM40GJ8 PC 25093389
DM40GJ8 MW 268.3
DM40GJ8 FM C16H12O2S
DM40GJ8 IC InChI=1S/C16H12O2S/c17-14-6-4-11(5-7-14)16-9-13(10-19-16)12-2-1-3-15(18)8-12/h1-10,17-18H
DM40GJ8 CS C1=CC(=CC(=C1)O)C2=CSC(=C2)C3=CC=C(C=C3)O
DM40GJ8 IK JECPEAXUEYTRPA-UHFFFAOYSA-N
DM40GJ8 IU 3-[5-(4-hydroxyphenyl)thiophen-3-yl]phenol
DM40GJ8 DE Discovery agent
DMQZ0A7 ID DMQZ0A7
DMQZ0A7 DN 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one
DMQZ0A7 HS Investigative
DMQZ0A7 SN CHEMBL427249; 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one
DMQZ0A7 DT Small molecular drug
DMQZ0A7 PC 44421943
DMQZ0A7 MW 401.5
DMQZ0A7 FM C26H27NO3
DMQZ0A7 IC InChI=1S/C26H27NO3/c1-27(19-20-10-4-2-5-11-20)16-8-3-9-17-29-21-14-15-23-25(18-21)30-24-13-7-6-12-22(24)26(23)28/h2,4-7,10-15,18H,3,8-9,16-17,19H2,1H3
DMQZ0A7 CS CN(CCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMQZ0A7 IK NDUSIOVFIPORBY-UHFFFAOYSA-N
DMQZ0A7 IU 3-[5-[benzyl(methyl)amino]pentoxy]xanthen-9-one
DMQZ0A7 DE Discovery agent
DMUEVAQ ID DMUEVAQ
DMUEVAQ DN 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMUEVAQ HS Investigative
DMUEVAQ SN (3-Pyridylmethylene)indane 9a; SCHEMBL4231367; BDBM8590; SCHEMBL4231363; AC1O704L; CHEMBL194440; 3-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMUEVAQ DT Small molecular drug
DMUEVAQ PC 6539767
DMUEVAQ MW 286.17
DMUEVAQ FM C15H12BrN
DMUEVAQ IC InChI=1S/C15H12BrN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8+
DMUEVAQ CS C1C/C(=C\\C2=CN=CC=C2)/C3=C1C=C(C=C3)Br
DMUEVAQ IK QWAFSKBCSGIDRF-XYOKQWHBSA-N
DMUEVAQ IU 3-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMUEVAQ DE Discovery agent
DMCXSIH ID DMCXSIH
DMCXSIH DN 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMCXSIH HS Investigative
DMCXSIH SN (3-Pyridylmethylene)indane 9b; BDBM8591; AC1O704N; CHEMBL176118; SCHEMBL4231365; 3-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMCXSIH DT Small molecular drug
DMCXSIH PC 6539768
DMCXSIH MW 286.17
DMCXSIH FM C15H12BrN
DMCXSIH IC InChI=1S/C15H12BrN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8-
DMCXSIH CS C1C/C(=C/C2=CN=CC=C2)/C3=C1C=C(C=C3)Br
DMCXSIH IK QWAFSKBCSGIDRF-WQLSENKSSA-N
DMCXSIH IU 3-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMCXSIH DE Discovery agent
DM8TWLO ID DM8TWLO
DM8TWLO DN 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DM8TWLO HS Investigative
DM8TWLO SN (3-Pyridylmethylene)indane 7a; CHEMBL383807; SCHEMBL4220789; AC1O704H; SCHEMBL4220782; BDBM8588; ZINC13610774; 3-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM8TWLO DT Small molecular drug
DM8TWLO PC 6539765
DM8TWLO MW 241.71
DM8TWLO FM C15H12ClN
DM8TWLO IC InChI=1S/C15H12ClN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8+
DM8TWLO CS C1C/C(=C\\C2=CN=CC=C2)/C3=C1C=C(C=C3)Cl
DM8TWLO IK GQENGHZHJWXFLG-XYOKQWHBSA-N
DM8TWLO IU 3-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM8TWLO DE Discovery agent
DMN60YG ID DMN60YG
DMN60YG DN 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DMN60YG HS Investigative
DMN60YG SN (3-Pyridylmethylene)indane 7b; AC1O704J; CHEMBL193652; BDBM8589; SCHEMBL4220785; ZINC13610777; 3-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN60YG DT Small molecular drug
DMN60YG PC 6539766
DMN60YG MW 241.71
DMN60YG FM C15H12ClN
DMN60YG IC InChI=1S/C15H12ClN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8-
DMN60YG CS C1C/C(=C/C2=CN=CC=C2)/C3=C1C=C(C=C3)Cl
DMN60YG IK GQENGHZHJWXFLG-WQLSENKSSA-N
DMN60YG IU 3-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN60YG DE Discovery agent
DMLJQZS ID DMLJQZS
DMLJQZS DN 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine
DMLJQZS HS Investigative
DMLJQZS SN (3-Pyridylmethylene)indane 19a; SCHEMBL4226312; CHEMBL425323; SCHEMBL4226322; BDBM8597; AC1O704X; 3-[(E)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLJQZS DT Small molecular drug
DMLJQZS PC 6539773
DMLJQZS MW 251.32
DMLJQZS FM C17H17NO
DMLJQZS IC InChI=1S/C17H17NO/c1-2-19-16-7-8-17-14(5-6-15(17)11-16)10-13-4-3-9-18-12-13/h3-4,7-12H,2,5-6H2,1H3/b14-10+
DMLJQZS CS CCOC1=CC2=C(C=C1)/C(=C/C3=CN=CC=C3)/CC2
DMLJQZS IK PXXLKRIIKURDBT-GXDHUFHOSA-N
DMLJQZS IU 3-[(E)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLJQZS DE Discovery agent
DMMTUON ID DMMTUON
DMMTUON DN 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMMTUON HS Investigative
DMMTUON SN CHEMBL176886; SCHEMBL4226316; BDBM8598; AC1O704Z; (3-Pyridylmethylene)indane 19b; 3-[(Z)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMTUON DT Small molecular drug
DMMTUON PC 6539774
DMMTUON MW 251.32
DMMTUON FM C17H17NO
DMMTUON IC InChI=1S/C17H17NO/c1-2-19-16-7-8-17-14(5-6-15(17)11-16)10-13-4-3-9-18-12-13/h3-4,7-12H,2,5-6H2,1H3/b14-10-
DMMTUON CS CCOC1=CC2=C(C=C1)/C(=C\\C3=CN=CC=C3)/CC2
DMMTUON IK PXXLKRIIKURDBT-UVTDQMKNSA-N
DMMTUON IU 3-[(Z)-(5-ethoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMMTUON DE Discovery agent
DMWSFIR ID DMWSFIR
DMWSFIR DN 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMWSFIR HS Investigative
DMWSFIR SN (3-Pyridylmethylene)indane 5a; SCHEMBL4220971; AC1O704D; CHEMBL193997; BDBM8586; SCHEMBL4220959; ZINC13610768; 3-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMWSFIR DT Small molecular drug
DMWSFIR PC 6539763
DMWSFIR MW 225.26
DMWSFIR FM C15H12FN
DMWSFIR IC InChI=1S/C15H12FN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8+
DMWSFIR CS C1C/C(=C\\C2=CN=CC=C2)/C3=C1C=C(C=C3)F
DMWSFIR IK WLUDJBASYYHRDC-XYOKQWHBSA-N
DMWSFIR IU 3-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMWSFIR DE Discovery agent
DMN42I5 ID DMN42I5
DMN42I5 DN 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMN42I5 HS Investigative
DMN42I5 SN (3-Pyridylmethylene)indane 5b; BDBM8587; CHEMBL383806; AC1O704F; SCHEMBL4220962; ZINC13610771; 3-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN42I5 DT Small molecular drug
DMN42I5 PC 6539764
DMN42I5 MW 225.26
DMN42I5 FM C15H12FN
DMN42I5 IC InChI=1S/C15H12FN/c16-14-5-6-15-12(3-4-13(15)9-14)8-11-2-1-7-17-10-11/h1-2,5-10H,3-4H2/b12-8-
DMN42I5 CS C1C/C(=C/C2=CN=CC=C2)/C3=C1C=C(C=C3)F
DMN42I5 IK WLUDJBASYYHRDC-WQLSENKSSA-N
DMN42I5 IU 3-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMN42I5 DE Discovery agent
DM9AW5U ID DM9AW5U
DM9AW5U DN 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM9AW5U HS Investigative
DM9AW5U SN CHEMBL176609; AC1O704P; SCHEMBL4226031; SCHEMBL4226036; BDBM8593; (3-Pyridylmethylene)indane 11a; 3-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM9AW5U DT Small molecular drug
DM9AW5U PC 6539769
DM9AW5U MW 237.3
DM9AW5U FM C16H15NO
DM9AW5U IC InChI=1S/C16H15NO/c1-18-15-6-7-16-13(4-5-14(16)10-15)9-12-3-2-8-17-11-12/h2-3,6-11H,4-5H2,1H3/b13-9+
DM9AW5U CS COC1=CC2=C(C=C1)/C(=C/C3=CN=CC=C3)/CC2
DM9AW5U IK HVRLSDXXVKSVBR-UKTHLTGXSA-N
DM9AW5U IU 3-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM9AW5U DE Discovery agent
DMB3XYE ID DMB3XYE
DMB3XYE DN 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMB3XYE HS Investigative
DMB3XYE SN (3-Pyridylmethylene)indane 11b; AC1O704R; SCHEMBL4226034; CHEMBL176101; BDBM8594; 3-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMB3XYE DT Small molecular drug
DMB3XYE PC 6539770
DMB3XYE MW 237.3
DMB3XYE FM C16H15NO
DMB3XYE IC InChI=1S/C16H15NO/c1-18-15-6-7-16-13(4-5-14(16)10-15)9-12-3-2-8-17-11-12/h2-3,6-11H,4-5H2,1H3/b13-9-
DMB3XYE CS COC1=CC2=C(C=C1)/C(=C\\C3=CN=CC=C3)/CC2
DMB3XYE IK HVRLSDXXVKSVBR-LCYFTJDESA-N
DMB3XYE IU 3-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMB3XYE DE Discovery agent
DMLTZ5F ID DMLTZ5F
DMLTZ5F DN 3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMLTZ5F HS Investigative
DMLTZ5F SN CHEMBL1096027; 3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol
DMLTZ5F DT Small molecular drug
DMLTZ5F PC 46887580
DMLTZ5F MW 287.8
DMLTZ5F FM C15H10ClNOS
DMLTZ5F IC InChI=1S/C15H10ClNOS/c16-15-8-7-14(19-15)13-6-2-5-12(17-13)10-3-1-4-11(18)9-10/h1-9,18H
DMLTZ5F CS C1=CC(=CC(=C1)O)C2=NC(=CC=C2)C3=CC=C(S3)Cl
DMLTZ5F IK IYXPXDBFKHBESO-UHFFFAOYSA-N
DMLTZ5F IU 3-[6-(5-chlorothiophen-2-yl)pyridin-2-yl]phenol
DMLTZ5F DE Discovery agent
DM89RN3 ID DM89RN3
DM89RN3 DN 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one
DM89RN3 HS Investigative
DM89RN3 SN CHEMBL390737; 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one
DM89RN3 DT Small molecular drug
DM89RN3 PC 44421948
DM89RN3 MW 415.5
DM89RN3 FM C27H29NO3
DM89RN3 IC InChI=1S/C27H29NO3/c1-28(20-21-11-5-4-6-12-21)17-9-2-3-10-18-30-22-15-16-24-26(19-22)31-25-14-8-7-13-23(25)27(24)29/h4-8,11-16,19H,2-3,9-10,17-18,20H2,1H3
DM89RN3 CS CN(CCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM89RN3 IK NKJXMWCNCBVIAA-UHFFFAOYSA-N
DM89RN3 IU 3-[6-[benzyl(methyl)amino]hexoxy]xanthen-9-one
DM89RN3 DE Discovery agent
DMHT6FX ID DMHT6FX
DMHT6FX DN 3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMHT6FX HS Investigative
DMHT6FX SN (3-Pyridylmethylene)indane 15a; CHEMBL366772; BDBM8601; AC1O7055; 3-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHT6FX DT Small molecular drug
DMHT6FX PC 6539777
DMHT6FX MW 237.3
DMHT6FX FM C16H15NO
DMHT6FX IC InChI=1S/C16H15NO/c1-18-15-7-6-13-4-5-14(16(13)10-15)9-12-3-2-8-17-11-12/h2-3,6-11H,4-5H2,1H3/b14-9+
DMHT6FX CS COC1=CC\\2=C(CC/C2=C\\C3=CN=CC=C3)C=C1
DMHT6FX IK NDEGTMIIOPDVPA-NTEUORMPSA-N
DMHT6FX IU 3-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHT6FX DE Discovery agent
DMG76LS ID DMG76LS
DMG76LS DN 3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMG76LS HS Investigative
DMG76LS SN CHEMBL175550; BDBM8604; AC1O705B; (3-Pyridylmethylene)indane 21a; 3-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMG76LS DT Small molecular drug
DMG76LS PC 6539780
DMG76LS MW 221.3
DMG76LS FM C16H15N
DMG76LS IC InChI=1S/C16H15N/c1-12-4-5-14-6-7-15(16(14)9-12)10-13-3-2-8-17-11-13/h2-5,8-11H,6-7H2,1H3/b15-10+
DMG76LS CS CC1=CC\\2=C(CC/C2=C\\C3=CN=CC=C3)C=C1
DMG76LS IK INXZXCKRUCKCJE-XNTDXEJSSA-N
DMG76LS IU 3-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMG76LS DE Discovery agent
DMKOB2T ID DMKOB2T
DMKOB2T DN 3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DMKOB2T HS Investigative
DMKOB2T SN (3-Pyridylmethylene)indane 21b; CHEMBL366570; BDBM8605; AC1O705D; 3-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMKOB2T DT Small molecular drug
DMKOB2T PC 6539781
DMKOB2T MW 221.3
DMKOB2T FM C16H15N
DMKOB2T IC InChI=1S/C16H15N/c1-12-4-5-14-6-7-15(16(14)9-12)10-13-3-2-8-17-11-13/h2-5,8-11H,6-7H2,1H3/b15-10-
DMKOB2T CS CC1=CC\\2=C(CC/C2=C/C3=CN=CC=C3)C=C1
DMKOB2T IK INXZXCKRUCKCJE-GDNBJRDFSA-N
DMKOB2T IU 3-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMKOB2T DE Discovery agent
DMMD3G6 ID DMMD3G6
DMMD3G6 DN 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one
DMMD3G6 HS Investigative
DMMD3G6 SN CHEMBL224433; 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one
DMMD3G6 DT Small molecular drug
DMMD3G6 PC 44421953
DMMD3G6 MW 429.5
DMMD3G6 FM C28H31NO3
DMMD3G6 IC InChI=1S/C28H31NO3/c1-29(21-22-12-6-5-7-13-22)18-10-3-2-4-11-19-31-23-16-17-25-27(20-23)32-26-15-9-8-14-24(26)28(25)30/h5-9,12-17,20H,2-4,10-11,18-19,21H2,1H3
DMMD3G6 CS CN(CCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMMD3G6 IK JUEPMIFCYDBLJZ-UHFFFAOYSA-N
DMMD3G6 IU 3-[7-[benzyl(methyl)amino]heptoxy]xanthen-9-one
DMMD3G6 DE Discovery agent
DM7IHUK ID DM7IHUK
DM7IHUK DN 3-[7'-(Methoxy)-napht-2'-yl]-quinuclidine-2-ene
DM7IHUK HS Investigative
DM7IHUK SN CHEMBL478981; SCHEMBL2422138; KZWBNNXTWZPPPP-UHFFFAOYSA-N; BDBM50270302; 3-[7''-(Methoxy)-napht-2''-yl]-quinuclidine-2-ene; 3-(6-methoxy-2-naphthyl)-1-azabicyclo[2.2.2]oct-2-ene
DM7IHUK DT Small molecular drug
DM7IHUK PC 11550718
DM7IHUK MW 265.3
DM7IHUK FM C18H19NO
DM7IHUK IC InChI=1S/C18H19NO/c1-20-17-5-4-14-10-16(3-2-15(14)11-17)18-12-19-8-6-13(18)7-9-19/h2-5,10-13H,6-9H2,1H3
DM7IHUK CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CN4CCC3CC4
DM7IHUK IK KZWBNNXTWZPPPP-UHFFFAOYSA-N
DM7IHUK IU 3-(6-methoxynaphthalen-2-yl)-1-azabicyclo[2.2.2]oct-2-ene
DM7IHUK CA CAS 894079-46-0
DM7IHUK DE Discovery agent
DMVWIQ2 ID DMVWIQ2
DMVWIQ2 DN 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DMVWIQ2 HS Investigative
DMVWIQ2 SN (3-Pyridylmethylene)indane 26a; SCHEMBL4221327; SCHEMBL4221321; CHEMBL175791; BDBM8600; AC1O7053; 3-[(E)-(7-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMVWIQ2 DT Small molecular drug
DMVWIQ2 PC 6539776
DMVWIQ2 MW 237.3
DMVWIQ2 FM C16H15NO
DMVWIQ2 IC InChI=1S/C16H15NO/c1-18-15-6-2-5-13-7-8-14(16(13)15)10-12-4-3-9-17-11-12/h2-6,9-11H,7-8H2,1H3/b14-10+
DMVWIQ2 CS COC1=CC=CC2=C1/C(=C/C3=CN=CC=C3)/CC2
DMVWIQ2 IK VTCRFWNOJMKNRS-GXDHUFHOSA-N
DMVWIQ2 IU 3-[(E)-(7-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMVWIQ2 DE Discovery agent
DM31WYF ID DM31WYF
DM31WYF DN 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one
DM31WYF HS Investigative
DM31WYF SN CHEMBL224469; 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one
DM31WYF DT Small molecular drug
DM31WYF PC 44421954
DM31WYF MW 443.6
DM31WYF FM C29H33NO3
DM31WYF IC InChI=1S/C29H33NO3/c1-30(22-23-13-7-6-8-14-23)19-11-4-2-3-5-12-20-32-24-17-18-26-28(21-24)33-27-16-10-9-15-25(27)29(26)31/h6-10,13-18,21H,2-5,11-12,19-20,22H2,1H3
DM31WYF CS CN(CCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DM31WYF IK QDZBIUGFNUHGNM-UHFFFAOYSA-N
DM31WYF IU 3-[8-[benzyl(methyl)amino]octoxy]xanthen-9-one
DM31WYF DE Discovery agent
DMZSBU5 ID DMZSBU5
DMZSBU5 DN 3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one
DMZSBU5 HS Investigative
DMZSBU5 SN CHEMBL427090; 3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one
DMZSBU5 DT Small molecular drug
DMZSBU5 PC 44421955
DMZSBU5 MW 457.6
DMZSBU5 FM C30H35NO3
DMZSBU5 IC InChI=1S/C30H35NO3/c1-31(23-24-14-8-7-9-15-24)20-12-5-3-2-4-6-13-21-33-25-18-19-27-29(22-25)34-28-17-11-10-16-26(28)30(27)32/h7-11,14-19,22H,2-6,12-13,20-21,23H2,1H3
DMZSBU5 CS CN(CCCCCCCCCOC1=CC2=C(C=C1)C(=O)C3=CC=CC=C3O2)CC4=CC=CC=C4
DMZSBU5 IK QDYNPKJXQNLYFL-UHFFFAOYSA-N
DMZSBU5 IU 3-[9-[benzyl(methyl)amino]nonoxy]xanthen-9-one
DMZSBU5 DE Discovery agent
DMLZ5F1 ID DMLZ5F1
DMLZ5F1 DN 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DMLZ5F1 HS Investigative
DMLZ5F1 SN CHEMBL217425; 3-((2-phenethylphenoxy)methyl)pyridine; 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine
DMLZ5F1 DT Small molecular drug
DMLZ5F1 PC 11973810
DMLZ5F1 MW 289.4
DMLZ5F1 FM C20H19NO
DMLZ5F1 IC InChI=1S/C20H19NO/c1-2-7-17(8-3-1)12-13-19-10-4-5-11-20(19)22-16-18-9-6-14-21-15-18/h1-11,14-15H,12-13,16H2
DMLZ5F1 CS C1=CC=C(C=C1)CCC2=CC=CC=C2OCC3=CN=CC=C3
DMLZ5F1 IK WUVSQVHZKKJEHX-UHFFFAOYSA-N
DMLZ5F1 IU 3-[[2-(2-phenylethyl)phenoxy]methyl]pyridine
DMLZ5F1 DE Discovery agent
DMUH9PF ID DMUH9PF
DMUH9PF DN 3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMUH9PF HS Investigative
DMUH9PF SN CHEMBL65204; 3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMUH9PF DT Small molecular drug
DMUH9PF PC 44306774
DMUH9PF MW 372.4
DMUH9PF FM C13H12N2O7S2
DMUH9PF IC InChI=1S/C13H12N2O7S2/c14-23(17,18)21-11-5-1-3-9(7-11)13(16)10-4-2-6-12(8-10)22-24(15,19)20/h1-8H,(H2,14,17,18)(H2,15,19,20)
DMUH9PF CS C1=CC(=CC(=C1)OS(=O)(=O)N)C(=O)C2=CC(=CC=C2)OS(=O)(=O)N
DMUH9PF IK YKEGOWCJKMPGLE-UHFFFAOYSA-N
DMUH9PF IU [3-(3-sulfamoyloxybenzoyl)phenyl] sulfamate
DMUH9PF DE Discovery agent
DMGS2X7 ID DMGS2X7
DMGS2X7 DN 3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMGS2X7 HS Investigative
DMGS2X7 SN CHEMBL65211; 3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMGS2X7 DT Small molecular drug
DMGS2X7 PC 44306753
DMGS2X7 MW 372.4
DMGS2X7 FM C13H12N2O7S2
DMGS2X7 IC InChI=1S/C13H12N2O7S2/c14-23(17,18)21-11-6-4-9(5-7-11)13(16)10-2-1-3-12(8-10)22-24(15,19)20/h1-8H,(H2,14,17,18)(H2,15,19,20)
DMGS2X7 CS C1=CC(=CC(=C1)OS(=O)(=O)N)C(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMGS2X7 IK NEMACRXQAFHGPF-UHFFFAOYSA-N
DMGS2X7 IU [3-(4-sulfamoyloxybenzoyl)phenyl] sulfamate
DMGS2X7 DE Discovery agent
DMT80IF ID DMT80IF
DMT80IF DN 3570-0208
DMT80IF HS Investigative
DMT80IF SN [6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxochromen-7-yl] acetate; UNM000003536701; AC1MJIQD; BAS 00135206; Oprea1_681432; Oprea1_151337; MLS001242385; GTPL5828; CHEMBL1329101; cid_3092570; CHEBI:92290; BDBM40404; ML048; HMS2231A24; HMS3372G14; ZINC4247033; STK922580; AKOS000525202; MCULE-3542011334; SMR000686159; ST50330694; EU-0040874; SR-01000456743; SR-01000456743-1; 3570-0208 [PMID:19807662]; 2-methyl-3-(1-methyl-2-benzimidazolyl)-6-ethyl-7-acetoxychromone
DMT80IF DT Small molecular drug
DMT80IF PC 3092570
DMT80IF MW 376.4
DMT80IF FM C22H20N2O4
DMT80IF IC InChI=1S/C22H20N2O4/c1-5-14-10-15-19(11-18(14)28-13(3)25)27-12(2)20(21(15)26)22-23-16-8-6-7-9-17(16)24(22)4/h6-11H,5H2,1-4H3
DMT80IF CS CCC1=CC2=C(C=C1OC(=O)C)OC(=C(C2=O)C3=NC4=CC=CC=C4N3C)C
DMT80IF IK HTTVYKXJCQENKW-UHFFFAOYSA-N
DMT80IF IU [6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxochromen-7-yl] acetate
DMT80IF CB CHEBI:92290
DMT80IF DE Discovery agent
DMGO2D7 ID DMGO2D7
DMGO2D7 DN 3-acetyl-11-keto-beta-boswellic acid
DMGO2D7 HS Investigative
DMGO2D7 SN AKBA; 67416-61-9; 3-O-Acetyl-11-keto-beta-Boswellic Acid; AKbetaBA; UNII-BS16QT99Q1; Acetyl-11-keto-beta-boswellic acid; CHEMBL237111; BS16QT99Q1; Acetyl-11-keto--boswellic acid; AKBA cpd; Acetyl-11-keto-b-boswellic acid; acetyl-11-ketoboswellic acid; Acetyl-11-keto-beta-Boswellic Acid, Boswellia serrata; 3-Acetyl-11-keto-; 3alpha-acetoxy-11-keto-beta-boswellic acid; Curator_000001; MolPort-020-005-785; HMMGKOVEOFBCAU-BCDBGHSCSA-N
DMGO2D7 DT Small molecular drug
DMGO2D7 PC 11168203
DMGO2D7 MW 512.7
DMGO2D7 FM C32H48O5
DMGO2D7 IC InChI=1S/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
DMGO2D7 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C
DMGO2D7 IK HMMGKOVEOFBCAU-BCDBGHSCSA-N
DMGO2D7 IU (3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14aR,14bS)-3-acetyloxy-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4a,5,6,7,8,9,10,11,12,12a,14a-tetradecahydropicene-4-carboxylic acid
DMGO2D7 CA CAS 67416-61-9
DMGO2D7 CB CHEBI:166842
DMGO2D7 DE Discovery agent
DMHRZ2V ID DMHRZ2V
DMHRZ2V DN 3-acetyl-11-keto-ursolic acid
DMHRZ2V HS Investigative
DMHRZ2V SN 11-OXOURSOLIC ACID ACETATE; CHEMBL601891; 3-acetyl-11-keto-ursolic acid; NSC33403; AC1L5RI4; 3-O-acetyl-11-oxoursolic acid; MolPort-044-649-591; NSC-33403; BDBM50307109; AKOS016036264; 35959-01-4; (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-acetyloxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
DMHRZ2V DT Small molecular drug
DMHRZ2V PC 234102
DMHRZ2V MW 512.7
DMHRZ2V FM C32H48O5
DMHRZ2V IC InChI=1S/C32H48O5/c1-18-9-14-32(27(35)36)16-15-30(7)21(25(32)19(18)2)17-22(34)26-29(6)12-11-24(37-20(3)33)28(4,5)23(29)10-13-31(26,30)8/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23+,24+,25+,26-,29+,30-,31-,32+/m1/s1
DMHRZ2V CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMHRZ2V IK XDHCWTUZCOFKRH-CIKBGXLUSA-N
DMHRZ2V IU (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bS)-10-acetyloxy-1,2,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,5,6,6a,7,8,8a,10,11,12,14b-tetradecahydropicene-4a-carboxylic acid
DMHRZ2V CA CAS 35959-01-4
DMHRZ2V DE Discovery agent
DM01WBD ID DM01WBD
DM01WBD DN 3-acetyl-7-hydroxy-2H-chromen-2-one
DM01WBD HS Investigative
DM01WBD SN 3-acetyl-7-hydroxy-2H-chromen-2-one; 10441-27-7; 3-Acetyl-7-hydroxy-chromen-2-one; 3-Acetyl-umbelliferone; 3-acetylumbelliferone; CHEMBL153064; 2H-1-Benzopyran-2-one, 3-acetyl-7-hydroxy-; BRQZHMHHZLRXOO-UHFFFAOYSA-N; 3-acetyl-7-hydroxy-2-oxochromene; 3-acetyl-7-hydroxychromen-2-one; 3-Acetyl-7-Hydroxy-1H-Chromen-2-One; 3-acethyl-umbelliferone; AC1NU0NR; 3-Acetyl-7-hydroxycoumarin; CBDivE_005922; MLS000777662; SCHEMBL592707; ZINC47516; cid_5392139; ASIS-0097; CTK4A3026; DTXSID20419817; MolPort-000-820-976; BB_NC-01216; STK365153
DM01WBD DT Small molecular drug
DM01WBD PC 5392139
DM01WBD MW 204.18
DM01WBD FM C11H8O4
DM01WBD IC InChI=1S/C11H8O4/c1-6(12)9-4-7-2-3-8(13)5-10(7)15-11(9)14/h2-5,13H,1H3
DM01WBD CS CC(=O)C1=CC2=C(C=C(C=C2)O)OC1=O
DM01WBD IK BRQZHMHHZLRXOO-UHFFFAOYSA-N
DM01WBD IU 3-acetyl-7-hydroxychromen-2-one
DM01WBD CA CAS 10441-27-7
DM01WBD DE Discovery agent
DMCNX34 ID DMCNX34
DMCNX34 DN 3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane
DMCNX34 HS Investigative
DMCNX34 SN CHEMBL593963; BDBM50304334
DMCNX34 DT Small molecular drug
DMCNX34 PC 46226590
DMCNX34 MW 298.4
DMCNX34 FM C18H22N2O2
DMCNX34 IC InChI=1S/C18H22N2O2/c1-19-13-7-8-14(19)11-15(10-13)22-18(21)17-9-12-5-3-4-6-16(12)20(17)2/h3-6,9,13-15H,7-8,10-11H2,1-2H3/t13-,14-/m1/s1
DMCNX34 CS CN1[C@@H]2CC[C@@H]1CC(C2)OC(=O)C3=CC4=CC=CC=C4N3C
DMCNX34 IK WGAYVVNWRFPKMG-ZIAGYGMSSA-N
DMCNX34 IU [(1R,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1-methylindole-2-carboxylate
DMCNX34 DE Discovery agent
DM3BRYJ ID DM3BRYJ
DM3BRYJ DN 3alpha-(2'-Indolecarbonyloxy)-nortropane
DM3BRYJ HS Investigative
DM3BRYJ SN CHEMBL596256; BDBM50304333
DM3BRYJ DT Small molecular drug
DM3BRYJ PC 46226582
DM3BRYJ MW 270.33
DM3BRYJ FM C16H18N2O2
DM3BRYJ IC InChI=1S/C16H18N2O2/c19-16(15-7-10-3-1-2-4-14(10)18-15)20-13-8-11-5-6-12(9-13)17-11/h1-4,7,11-13,17-18H,5-6,8-9H2/t11-,12-/m1/s1
DM3BRYJ CS C1C[C@@H]2CC(C[C@@H]1N2)OC(=O)C3=CC4=CC=CC=C4N3
DM3BRYJ IK JTIOAVUBNSKIPD-VXGBXAGGSA-N
DM3BRYJ IU [(1R,5R)-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-2-carboxylate
DM3BRYJ DE Discovery agent
DMBUZWQ ID DMBUZWQ
DMBUZWQ DN 3alpha-(bis-chloro-phenylmethoxy)tropane
DMBUZWQ HS Investigative
DMBUZWQ SN CHEMBL119664; CHEMBL541825; SCHEMBL1152029; BDBM50039177; 3-[Bis(4-chlorophenyl)methoxy]tropane; 3-[Bis-(4-chloro-phenyl)-methoxy]-8-methyl-8-aza-bicyclo[3.2.1]octane
DMBUZWQ DT Small molecular drug
DMBUZWQ PC 10068100
DMBUZWQ MW 376.3
DMBUZWQ FM C21H23Cl2NO
DMBUZWQ IC InChI=1S/C21H23Cl2NO/c1-24-18-10-11-19(24)13-20(12-18)25-21(14-2-6-16(22)7-3-14)15-4-8-17(23)9-5-15/h2-9,18-21H,10-13H2,1H3
DMBUZWQ CS CN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl
DMBUZWQ IK DAAKBMHWKLVSKY-UHFFFAOYSA-N
DMBUZWQ IU 3-[bis(4-chlorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane
DMBUZWQ DE Discovery agent
DM3ZR7A ID DM3ZR7A
DM3ZR7A DN 3alpha,24-dihydroxyolean-12-en-27-oic acid
DM3ZR7A HS Investigative
DM3ZR7A SN CHEMBL207657; 3alpha,24-dihydroxyolean-12-en-27-oic acid
DM3ZR7A DT Small molecular drug
DM3ZR7A PC 44411959
DM3ZR7A MW 472.7
DM3ZR7A FM C30H48O4
DM3ZR7A IC InChI=1S/C30H48O4/c1-25(2)13-14-26(3)15-16-30(24(33)34)19(20(26)17-25)7-8-22-27(4)11-10-23(32)28(5,18-31)21(27)9-12-29(22,30)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21?,22+,23+,26+,27-,28+,29+,30+/m0/s1
DM3ZR7A CS C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@H]([C@]5(C)CO)O)C)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DM3ZR7A IK HQGWITLOHQUPBL-NFHCHMPHSA-N
DM3ZR7A IU (4aR,6aR,6aR,6bR,9S,10R,12aR,14bR)-10-hydroxy-9-(hydroxymethyl)-2,2,4a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DM3ZR7A DE Discovery agent
DMV6OPB ID DMV6OPB
DMV6OPB DN 3alpha-Hydroxyurs-12-en-28-oic Acid
DMV6OPB HS Investigative
DMV6OPB SN 989-30-0; CHEMBL491715; AC1OG92I; SCHEMBL19714770; MolPort-039-338-864; ZINC12890906; BDBM50346612; 9.89E+302; (1S,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMV6OPB DT Small molecular drug
DMV6OPB PC 7163177
DMV6OPB MW 456.7
DMV6OPB FM C30H48O3
DMV6OPB IC InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23-,24+,27+,28-,29-,30+/m1/s1
DMV6OPB CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMV6OPB IK WCGUUGGRBIKTOS-XHINXETDSA-N
DMV6OPB IU (1S,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMV6OPB DE Discovery agent
DM4M6LR ID DM4M6LR
DM4M6LR DN 3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid
DM4M6LR HS Investigative
DM4M6LR SN CHEMBL494656; 3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid
DM4M6LR DT Small molecular drug
DM4M6LR PC 44566339
DM4M6LR MW 454.6
DM4M6LR FM C28H38O5
DM4M6LR IC InChI=1S/C28H38O5/c1-18(17-26(30)31)5-12-22-19(2)6-14-24-23(22)13-15-25(28(24,3)4)33-27(32)16-9-20-7-10-21(29)11-8-20/h6-11,16,18,22-25,29H,5,12-15,17H2,1-4H3,(H,30,31)/b16-9+/t18-,22-,23+,24+,25-/m0/s1
DM4M6LR CS CC1=CC[C@@H]2[C@@H]([C@H]1CC[C@H](C)CC(=O)O)CC[C@@H](C2(C)C)OC(=O)/C=C/C3=CC=C(C=C3)O
DM4M6LR IK ZSKLTPLHCIUPKA-LOWUFNJHSA-N
DM4M6LR IU (3S)-5-[(1R,4aR,6S,8aR)-6-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy-2,5,5-trimethyl-4,4a,6,7,8,8a-hexahydro-1H-naphthalen-1-yl]-3-methylpentanoic acid
DM4M6LR DE Discovery agent
DMO5IJA ID DMO5IJA
DMO5IJA DN 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane
DMO5IJA HS Investigative
DMO5IJA SN 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane; CHEMBL566837
DMO5IJA DT Small molecular drug
DMO5IJA PC 45488086
DMO5IJA MW 293.4
DMO5IJA FM C20H23NO
DMO5IJA IC InChI=1S/C20H23NO/c1-3-7-16(8-4-1)15-22-20(17-9-5-2-6-10-17)13-18-11-12-19(14-20)21-18/h1-10,18-19,21H,11-15H2
DMO5IJA CS C1CC2CC(CC1N2)(C3=CC=CC=C3)OCC4=CC=CC=C4
DMO5IJA IK DFUGHSKLQQMYID-UHFFFAOYSA-N
DMO5IJA IU 3-phenyl-3-phenylmethoxy-8-azabicyclo[3.2.1]octane
DMO5IJA DE Discovery agent
DMKGIQ1 ID DMKGIQ1
DMKGIQ1 DN 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one
DMKGIQ1 HS Investigative
DMKGIQ1 SN CHEMBL156974; 5-Methoxykynuramine
DMKGIQ1 DT Small molecular drug
DMKGIQ1 PC 44372211
DMKGIQ1 MW 194.23
DMKGIQ1 FM C10H14N2O2
DMKGIQ1 IC InChI=1S/C10H14N2O2/c1-14-7-2-3-9(12)8(6-7)10(13)4-5-11/h2-3,6H,4-5,11-12H2,1H3
DMKGIQ1 CS COC1=CC(=C(C=C1)N)C(=O)CCN
DMKGIQ1 IK DFZXDYZPSYJYBU-UHFFFAOYSA-N
DMKGIQ1 IU 3-amino-1-(2-amino-5-methoxyphenyl)propan-1-one
DMKGIQ1 DE Discovery agent
DMF3DBE ID DMF3DBE
DMF3DBE DN 3-amino-2-(benzylideneamino)-5-mercaptophenol
DMF3DBE HS Investigative
DMF3DBE SN CHEMBL468589; 3-amino-2-(benzylideneamino)-5-mercaptophenol
DMF3DBE DT Small molecular drug
DMF3DBE PC 44577786
DMF3DBE MW 244.31
DMF3DBE FM C13H12N2OS
DMF3DBE IC InChI=1S/C13H12N2OS/c14-11-6-10(17)7-12(16)13(11)15-8-9-4-2-1-3-5-9/h1-8,16-17H,14H2
DMF3DBE CS C1=CC=C(C=C1)C=NC2=C(C=C(C=C2O)S)N
DMF3DBE IK ZHJMODAVTYPZRG-UHFFFAOYSA-N
DMF3DBE IU 3-amino-2-(benzylideneamino)-5-sulfanylphenol
DMF3DBE DE Discovery agent
DMV4XGT ID DMV4XGT
DMV4XGT DN 3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid
DMV4XGT HS Investigative
DMV4XGT SN CHEMBL541497
DMV4XGT DT Small molecular drug
DMV4XGT PC 49797638
DMV4XGT MW 241.62
DMV4XGT FM C7H12ClNO6
DMV4XGT IC InChI=1S/C7H11NO6.ClH/c1-14-6(13)7(8,2-4(9)10)3-5(11)12;/h2-3,8H2,1H3,(H,9,10)(H,11,12);1H
DMV4XGT CS COC(=O)C(CC(=O)O)(CC(=O)O)N.Cl
DMV4XGT IK SQNZWVALOOOEKW-UHFFFAOYSA-N
DMV4XGT IU 3-amino-3-methoxycarbonylpentanedioic acid;hydrochloride
DMV4XGT DE Discovery agent
DM60K7H ID DM60K7H
DM60K7H DN 3-amino-3-demethoxythiocolchicine
DM60K7H HS Investigative
DM60K7H SN SCHEMBL8239297
DM60K7H DT Small molecular drug
DM60K7H PC 16081784
DM60K7H MW 400.5
DM60K7H FM C21H24N2O4S
DM60K7H IC InChI=1S/C21H24N2O4S/c1-11(24)23-16-7-5-12-9-15(22)20(26-2)21(27-3)19(12)13-6-8-18(28-4)17(25)10-14(13)16/h6,8-10,16H,5,7,22H2,1-4H3,(H,23,24)/t16-/m0/s1
DM60K7H CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)N
DM60K7H IK HGWINWYVDWEKKX-INIZCTEOSA-N
DM60K7H IU N-[(7S)-3-amino-1,2-dimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM60K7H DE Discovery agent
DMJ7Y3H ID DMJ7Y3H
DMJ7Y3H DN 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMJ7Y3H HS Investigative
DMJ7Y3H SN CHEMBL237897; BDBM50213160
DMJ7Y3H DT Small molecular drug
DMJ7Y3H PC 44431966
DMJ7Y3H MW 311.5
DMJ7Y3H FM C21H29NO
DMJ7Y3H IC InChI=1S/C21H29NO/c1-4-5-6-7-13-21(2,3)17-11-12-19(20(23)15-17)16-9-8-10-18(22)14-16/h8-12,14-15,23H,4-7,13,22H2,1-3H3
DMJ7Y3H CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC(=CC=C2)N)O
DMJ7Y3H IK GWRWPRMABCQODZ-UHFFFAOYSA-N
DMJ7Y3H IU 2-(3-aminophenyl)-5-(2-methyloctan-2-yl)phenol
DMJ7Y3H DE Discovery agent
DMIS3LN ID DMIS3LN
DMIS3LN DN 3-Amino-4'-amino-trans-stilbene
DMIS3LN HS Investigative
DMIS3LN SN 3,4'-Diaminostilbene; CCRIS 6786; CHEMBL1171628; BRN 3129972; 3-(2-(4-Aminophenyl)ethenyl)benzenamine; Benzenamine, 3-(2-(4-aminophenyl)ethenyl)-; 79305-82-1; 3-[2-(4-aminophenyl)ethenyl]aniline; AC1NYYMC; Stilbene-3,4'-diamine; AC1Q51YO; (E)-Stilbene-3,4'-diamine; SCHEMBL2774636; SCHEMBL2774639; 3-Amino-4''-amino-trans-stilbene; ZINC5161777; BDBM50322063; AKOS030582755; LS-28069; 3-[(E)-2-(4-aminophenyl)ethenyl]aniline; 3-13-00-00512 (Beilstein Handbook Reference)
DMIS3LN DT Small molecular drug
DMIS3LN PC 5844100
DMIS3LN MW 210.27
DMIS3LN FM C14H14N2
DMIS3LN IC InChI=1S/C14H14N2/c15-13-8-6-11(7-9-13)4-5-12-2-1-3-14(16)10-12/h1-10H,15-16H2/b5-4+
DMIS3LN CS C1=CC(=CC(=C1)N)/C=C/C2=CC=C(C=C2)N
DMIS3LN IK IXGDBTKLQUHIAX-SNAWJCMRSA-N
DMIS3LN IU 3-[(E)-2-(4-aminophenyl)ethenyl]aniline
DMIS3LN CA CAS 79305-82-1
DMIS3LN DE Discovery agent
DM5Z0O6 ID DM5Z0O6
DM5Z0O6 DN 3-Amino-4-Oxybenzyl-2-Butanone
DM5Z0O6 HS Investigative
DM5Z0O6 SN 3-AMINO-4-OXYBENZYL-2-BUTANONE; AC1NRD4M; SCHEMBL15172323; CHEMBL1235900; DB02148
DM5Z0O6 DT Small molecular drug
DM5Z0O6 PC 5289348
DM5Z0O6 MW 193.24
DM5Z0O6 FM C11H15NO2
DM5Z0O6 IC InChI=1S/C11H15NO2/c1-9(13)11(12)8-14-7-10-5-3-2-4-6-10/h2-6,11H,7-8,12H2,1H3/t11-/m0/s1
DM5Z0O6 CS CC(=O)[C@H](COCC1=CC=CC=C1)N
DM5Z0O6 IK ISLRAQPEXPIKDJ-NSHDSACASA-N
DM5Z0O6 IU (3S)-3-amino-4-phenylmethoxybutan-2-one
DM5Z0O6 DE Discovery agent
DM2U9RY ID DM2U9RY
DM2U9RY DN 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide
DM2U9RY HS Investigative
DM2U9RY SN 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide; 175137-05-0; CHEMBL444884; 515142-45-7; 2-Thiophenecarboxamide,3-amino-5-(4-chlorophenyl)-; AC1MBTGN; 3-amino-5-(4-chlorophenyl)-2-thiophenecarboxamide; SCHEMBL4097325; CTK4D5319; DTXSID90373351; MQYJPACEBWKWEH-UHFFFAOYSA-N; MolPort-000-150-990; ZX-AT016871; ZINC2556119; SBB101177; BDBM50186632; 5704AD; AKOS022181810; AJ-39853; ACM175137050; RT-019539; FT-0704094; 3-Amino-5-(4-chloro-phenyl)-thiophene-2-carboxylic acid amide
DM2U9RY DT Small molecular drug
DM2U9RY PC 2756390
DM2U9RY MW 252.72
DM2U9RY FM C11H9ClN2OS
DM2U9RY IC InChI=1S/C11H9ClN2OS/c12-7-3-1-6(2-4-7)9-5-8(13)10(16-9)11(14)15/h1-5H,13H2,(H2,14,15)
DM2U9RY CS C1=CC(=CC=C1C2=CC(=C(S2)C(=O)N)N)Cl
DM2U9RY IK MQYJPACEBWKWEH-UHFFFAOYSA-N
DM2U9RY IU 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide
DM2U9RY CA CAS 175137-05-0
DM2U9RY DE Discovery agent
DMONHFR ID DMONHFR
DMONHFR DN 3-amino-5-(4-octylphenyl)pentanoic acid
DMONHFR HS Investigative
DMONHFR SN CHEMBL326346; 3-amino-5-(4-octylphenyl)pentanoic Acid; SCHEMBL5464250; BDBM50147707; 3-Amino-5-(4-octyl-phenyl)-pentanoic acid
DMONHFR DT Small molecular drug
DMONHFR PC 10149595
DMONHFR MW 305.5
DMONHFR FM C19H31NO2
DMONHFR IC InChI=1S/C19H31NO2/c1-2-3-4-5-6-7-8-16-9-11-17(12-10-16)13-14-18(20)15-19(21)22/h9-12,18H,2-8,13-15,20H2,1H3,(H,21,22)
DMONHFR CS CCCCCCCCC1=CC=C(C=C1)CCC(CC(=O)O)N
DMONHFR IK UDEAYIGFOWYIGY-UHFFFAOYSA-N
DMONHFR IU 3-amino-5-(4-octylphenyl)pentanoic acid
DMONHFR DE Discovery agent
DM6Y2KW ID DM6Y2KW
DM6Y2KW DN 3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile
DM6Y2KW HS Investigative
DM6Y2KW SN 3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile; CHEMBL577938; SMR000054390; AC1LCDQ5; Cambridge id 5105969; MLS000104455; cid_625239; ZINC28097; SLQVQKSDEBBOSA-UHFFFAOYSA-N; MolPort-000-475-780; HMS1700M17; BDBM50303384; STK831931; AKOS000663950; MCULE-3002689151; BAS 13070166; ST001263; AB00073722-01; 3-Amino-5-furan-2-yl-biphenyl-2,4-dicarbonitrile; 2-amino-6-(2-furyl)-4-phenylbenzene-1,3-dicarbonitrile; 1,1'-Biphenyl-2,4-dicarbonitrile, 3-amino-5-(2-furyl)-; 3-Amino-5-(2-furyl)[1,1'-biphenyl]-2,4-dicarbonitrile #
DM6Y2KW DT Small molecular drug
DM6Y2KW PC 625239
DM6Y2KW MW 285.3
DM6Y2KW FM C18H11N3O
DM6Y2KW IC InChI=1S/C18H11N3O/c19-10-15-13(12-5-2-1-3-6-12)9-14(16(11-20)18(15)21)17-7-4-8-22-17/h1-9H,21H2
DM6Y2KW CS C1=CC=C(C=C1)C2=CC(=C(C(=C2C#N)N)C#N)C3=CC=CO3
DM6Y2KW IK SLQVQKSDEBBOSA-UHFFFAOYSA-N
DM6Y2KW IU 2-amino-4-(furan-2-yl)-6-phenylbenzene-1,3-dicarbonitrile
DM6Y2KW DE Discovery agent
DMP2K1A ID DMP2K1A
DMP2K1A DN 3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one
DMP2K1A HS Investigative
DMP2K1A DT Small molecular drug
DMP2K1A PC 135838221
DMP2K1A MW 213.23
DMP2K1A FM C12H11N3O
DMP2K1A IC InChI=1S/C12H11N3O/c13-12-14-9-6-5-7-3-1-2-4-8(7)10(9)11(16)15-12/h1-4H,5-6H2,(H3,13,14,15,16)
DMP2K1A CS C1CC2=C(C3=CC=CC=C31)C(=O)NC(=N2)N
DMP2K1A IK VXKOVZZJDGUSEF-UHFFFAOYSA-N
DMP2K1A IU 3-amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one
DMP2K1A CA CAS 33987-08-5
DMP2K1A DE Discovery agent
DMHDFZE ID DMHDFZE
DMHDFZE DN 3-Amino-5-Phenylpentane
DMHDFZE HS Investigative
DMHDFZE SN SCHEMBL7412184
DMHDFZE DT Small molecular drug
DMHDFZE PC 46936513
DMHDFZE MW 303.4
DMHDFZE FM C17H21NO2S
DMHDFZE IC InChI=1S/C17H21NO2S/c18-16(12-11-15-7-3-1-4-8-15)13-14-21(19,20)17-9-5-2-6-10-17/h1-10,16H,11-14,18H2/t16-/m0/s1
DMHDFZE CS C1=CC=C(C=C1)CC[C@@H](CCS(=O)(=O)C2=CC=CC=C2)N
DMHDFZE IK WQRZZKAHRWPIFX-INIZCTEOSA-N
DMHDFZE IU (3S)-1-(benzenesulfonyl)-5-phenylpentan-3-amine
DMHDFZE DE Discovery agent
DM0GJZM ID DM0GJZM
DM0GJZM DN 3-aminoacetamido-4'-methylfuro[3,2-g]coumarin
DM0GJZM HS Investigative
DM0GJZM SN CHEMBL202017; BDBM50181852
DM0GJZM DT Small molecular drug
DM0GJZM PC 11492774
DM0GJZM MW 272.26
DM0GJZM FM C14H12N2O4
DM0GJZM IC InChI=1S/C14H12N2O4/c1-7-6-19-12-4-11-8(2-9(7)12)3-10(14(18)20-11)16-13(17)5-15/h2-4,6H,5,15H2,1H3,(H,16,17)
DM0GJZM CS CC1=COC2=C1C=C3C=C(C(=O)OC3=C2)NC(=O)CN
DM0GJZM IK MNKUYMIFZBIEPU-UHFFFAOYSA-N
DM0GJZM IU 2-amino-N-(3-methyl-7-oxofuro[3,2-g]chromen-6-yl)acetamide
DM0GJZM DE Discovery agent
DM5073T ID DM5073T
DM5073T DN 3-AMINO-AZACYCLOTRIDECAN-2-ONE
DM5073T HS Investigative
DM5073T SN 3-AMINO-AZACYCLOTRIDECAN-2-ONE; RIN; AC1L9JYK; (3S)-3-aminoazacyclotridecan-2-one; (3S)-3-amino-azacyclotridecan-2-one; DB08476
DM5073T DT Small molecular drug
DM5073T PC 446676
DM5073T MW 212.33
DM5073T FM C12H24N2O
DM5073T IC InChI=1S/C12H24N2O/c13-11-9-7-5-3-1-2-4-6-8-10-14-12(11)15/h11H,1-10,13H2,(H,14,15)/t11-/m0/s1
DM5073T CS C1CCCCCNC(=O)[C@H](CCCC1)N
DM5073T IK CQZLEYBEPASILI-NSHDSACASA-N
DM5073T IU (3S)-3-amino-azacyclotridecan-2-one
DM5073T DE Discovery agent
DM7P3IZ ID DM7P3IZ
DM7P3IZ DN 3-aminobenzamide
DM7P3IZ HS Investigative
DM7P3IZ SN 3-Aminobenzamide; 3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde
DM7P3IZ DT Small molecular drug
DM7P3IZ PC 1645
DM7P3IZ MW 136.15
DM7P3IZ FM C7H8N2O
DM7P3IZ IC InChI=1S/C7H8N2O/c8-6-3-1-2-5(4-6)7(9)10/h1-4H,8H2,(H2,9,10)
DM7P3IZ CS C1=CC(=CC(=C1)N)C(=O)N
DM7P3IZ IK GSCPDZHWVNUUFI-UHFFFAOYSA-N
DM7P3IZ IU 3-aminobenzamide
DM7P3IZ CA CAS 3544-24-9
DM7P3IZ CB CHEBI:64042
DM7P3IZ DE Discovery agent
DME0TNA ID DME0TNA
DME0TNA DN 3-Amino-benzenesulfonamide
DME0TNA HS Investigative
DME0TNA SN 3-AMINOBENZENESULFONAMIDE; 98-18-0; Metanilamide; m-Aminobenzenesulfonamide; Benzenesulfonamide, 3-amino-; m-Sulfamoylaniline; 3-Aminobenzene-1-Sulfonamide; Benzenesulfonamide, m-amino-; m-Aminobenzenesulphonamide; Metaniilamide; 3-Aminosulfonylaniline; 3-Amino-benzenesulfonamide; NSC 7542; EINECS 202-646-0; BRN 0511851; CHEMBL6852; JPVKCHIPRSQDKL-UHFFFAOYSA-N; MFCD00035781; 3-Sulfanilamide; m-sulfamylaniline; NSC7542; 3-sulfamoyl-aniline; 3-sulfamoyl-phenylamine; 3-aminobenzensulfonamide; AC1Q6UKN; AC1L1OMG
DME0TNA DT Small molecular drug
DME0TNA PC 7377
DME0TNA MW 172.21
DME0TNA FM C6H8N2O2S
DME0TNA IC InChI=1S/C6H8N2O2S/c7-5-2-1-3-6(4-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)
DME0TNA CS C1=CC(=CC(=C1)S(=O)(=O)N)N
DME0TNA IK JPVKCHIPRSQDKL-UHFFFAOYSA-N
DME0TNA IU 3-aminobenzenesulfonamide
DME0TNA CA CAS 98-18-0
DME0TNA DE Discovery agent
DMWOTD3 ID DMWOTD3
DMWOTD3 DN 3-amino-benzo[b]thiophene-2-carboxylic acid amide
DMWOTD3 HS Investigative
DMWOTD3 SN 3-amino-1-benzothiophene-2-carboxamide; 37839-59-1; 3-Aminobenzo[b]thiophene-2-carboxamide; CHEMBL211002; Benzo[b]thiophene-2-carboxamide, 3-amino-; 3-aminobenzo[b]thiophene-2-carboxylic acid amide; AC1LGIJV; 3-amino-benzo[b]thiophene-2-carboxylic acid amide; SCHEMBL6609258; CTK1B5350; DTXSID80356350; MolPort-002-798-643; ZINC339150; STL134701; BDBM50186634; AKOS001782516; CCG-127335; MCULE-9206749194; NE38914; EN300-88534
DMWOTD3 DT Small molecular drug
DMWOTD3 PC 821974
DMWOTD3 MW 192.24
DMWOTD3 FM C9H8N2OS
DMWOTD3 IC InChI=1S/C9H8N2OS/c10-7-5-3-1-2-4-6(5)13-8(7)9(11)12/h1-4H,10H2,(H2,11,12)
DMWOTD3 CS C1=CC=C2C(=C1)C(=C(S2)C(=O)N)N
DMWOTD3 IK LTNWICBPQWPXDK-UHFFFAOYSA-N
DMWOTD3 IU 3-amino-1-benzothiophene-2-carboxamide
DMWOTD3 CA CAS 37839-59-1
DMWOTD3 DE Discovery agent
DML2UCP ID DML2UCP
DML2UCP DN 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one
DML2UCP HS Investigative
DML2UCP SN CHEMBL106154; 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one; Benzo[c]-1,5-naphthyridin-6(5H)-one, 3-amino-; SCHEMBL12750402; BDBM50130580; 433726-73-9
DML2UCP DT Small molecular drug
DML2UCP PC 16221809
DML2UCP MW 211.22
DML2UCP FM C12H9N3O
DML2UCP IC InChI=1S/C12H9N3O/c13-7-5-10-11(14-6-7)8-3-1-2-4-9(8)12(16)15-10/h1-6H,13H2,(H,15,16)
DML2UCP CS C1=CC=C2C(=C1)C3=C(C=C(C=N3)N)NC2=O
DML2UCP IK PSWYPUADRXNJGE-UHFFFAOYSA-N
DML2UCP IU 3-amino-5H-benzo[c][1,5]naphthyridin-6-one
DML2UCP DE Discovery agent
DMTYXH1 ID DMTYXH1
DMTYXH1 DN 3-Aminomethyl-5-methyl-hexanoic acid
DMTYXH1 HS Investigative
DMTYXH1 SN 3-(aminomethyl)-5-methylhexanoic acid; 128013-69-4; 130912-52-6; rac-Pregabalin; 3-(Aminomethyl)-5-methylhexanoicacid; 3-(aminomethyl)-5-methyl-hexanoic acid; Hexanoic acid,3-(aminomethyl)-5-methyl-; Hexanoic acid, 3-(aminomethyl)-5-methyl-; AYXYPKUFHZROOJ-UHFFFAOYSA-N; NCGC00095186-01; AC1NFWUF; PubChem15652; ACMC-20p1cu; ACMC-1CF05; SCHEMBL15497; CHEMBL88034; PHARMA-0589; KS-00000AKV; CTK4B5836; BCP17115; BCP05685; BBL100350; CA-452; FC0023; ANW-51583; STK894330
DMTYXH1 DT Small molecular drug
DMTYXH1 PC 4715169
DMTYXH1 MW 159.23
DMTYXH1 FM C8H17NO2
DMTYXH1 IC InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)
DMTYXH1 CS CC(C)CC(CC(=O)O)CN
DMTYXH1 IK AYXYPKUFHZROOJ-UHFFFAOYSA-N
DMTYXH1 IU 3-(aminomethyl)-5-methylhexanoic acid
DMTYXH1 DE Discovery agent
DM5SQVC ID DM5SQVC
DM5SQVC DN 3-ammoniopropane-1-sulfinate
DM5SQVC HS Investigative
DM5SQVC SN Homohypotaurine; 3-aminopropane-1-sulfinic acid; 25346-09-2; CHEMBL32102; 1-Propanesulfinic acid,3-amino-; 3-ammoniopropane-1-sulfinate; AC1L4VIZ; AC1Q6YOU; 3-aminopropylsulfinic acid; 3-Aminopropansulfinic acid; 3-amino-propane sulfinic acid; SCHEMBL341598; CTK4F5523; DTXSID30179995; NPGXQDBNBFXJKB-UHFFFAOYSA-N; MolPort-028-749-783; ZINC5410694; BDBM50087276; AKOS006338176; NE49789; 3-Amino-propane-1-sulfinic acid (Homohypotaurine)
DM5SQVC DT Small molecular drug
DM5SQVC PC 193060
DM5SQVC MW 123.18
DM5SQVC FM C3H9NO2S
DM5SQVC IC InChI=1S/C3H9NO2S/c4-2-1-3-7(5)6/h1-4H2,(H,5,6)
DM5SQVC CS C(CN)CS(=O)O
DM5SQVC IK NPGXQDBNBFXJKB-UHFFFAOYSA-N
DM5SQVC IU 3-aminopropane-1-sulfinic acid
DM5SQVC CA CAS 25346-09-2
DM5SQVC DE Discovery agent
DM3VYNJ ID DM3VYNJ
DM3VYNJ DN 3-anilino-5-benzylthio-1,2,4-triazole
DM3VYNJ HS Investigative
DM3VYNJ SN 3-anilino-5-benzylthio-1,2,4-triazole; CHEMBL243303; SCHEMBL5376882; 1,2,4-Triazole Compound, 6; BDBM17352; QBUZLNWDECJZMT-UHFFFAOYSA-N
DM3VYNJ DT Small molecular drug
DM3VYNJ PC 9838682
DM3VYNJ MW 282.4
DM3VYNJ FM C15H14N4S
DM3VYNJ IC InChI=1S/C15H14N4S/c1-3-7-12(8-4-1)11-20-15-17-14(18-19-15)16-13-9-5-2-6-10-13/h1-10H,11H2,(H2,16,17,18,19)
DM3VYNJ CS C1=CC=C(C=C1)CSC2=NNC(=N2)NC3=CC=CC=C3
DM3VYNJ IK QBUZLNWDECJZMT-UHFFFAOYSA-N
DM3VYNJ IU 3-benzylsulfanyl-N-phenyl-1H-1,2,4-triazol-5-amine
DM3VYNJ DE Discovery agent
DM6KNMB ID DM6KNMB
DM6KNMB DN 3-azageranylgeranyl diphosphate
DM6KNMB HS Investigative
DM6KNMB SN 3-Azageranylgeranyl diphosphate; CHEMBL71360; 2-[METHYL-(5-GERANYL-4-METHYL-PENT-3-ENYL)-AMINO]-ETHYL-DIPHOSPHATE; MGM; 150942-60-2; AC1L9KO8; GTPL3199; DTXSID70332249; BDBM50113289; 3-aza-geranylgeranyl diphosphoric acid; DB08180; 3-aza-geranylgeranyl pyrophosphoric acid; Diphosphoric acid, mono[2-[methyl[(3E,7E)-4,8,12-trimethyl-3,7,11-tridecatrienyl]amino]ethyl] ester (9CI); 2-[methyl-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-amino]-ethyl trihydrogendiphosphate(3-aza-GGPP)
DM6KNMB DT Small molecular drug
DM6KNMB PC 447278
DM6KNMB MW 453.4
DM6KNMB FM C19H37NO7P2
DM6KNMB IC InChI=1S/C19H37NO7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13H,6-8,10,12,14-16H2,1-5H3,(H,24,25)(H2,21,22,23)/b18-11+,19-13+
DM6KNMB CS CC(=CCC/C(=C/CC/C(=C/CCN(C)CCOP(=O)(O)OP(=O)(O)O)/C)/C)C
DM6KNMB IK OEMBPHBKZPOPBN-NWLVNBMCSA-N
DM6KNMB IU 2-[methyl-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]amino]ethyl phosphono hydrogen phosphate
DM6KNMB CA CAS 150942-60-2
DM6KNMB DE Discovery agent
DMU08MN ID DMU08MN
DMU08MN DN 3'-Azido-3'-Deoxythymidine-5'-Monophosphate
DMU08MN HS Investigative
DMU08MN SN AZTMP; Zidovudine 5'-monophosphate; UNII-97YMU05VPJ; ZDVMP; AZT-MP; 3'-azido-3'-deoxythymidine-5'-monophosphate; 97YMU05VPJ; Zidovudine monophosphate; 3'-Azido-3'-deoxythymidine 5'-phosphate; 29706-85-2; 5'-Thymidylic acid, 3'-azido-3'-deoxy-; Zdv 5'-monophosphate; AzddTMP; 3'-azido-3'-deoxythymidine monophosphate; AZT-monophosphate; 3'-Azido-2',3'-deoxythymidine 5'-monophosphate; NSC742230; 3'-Azido-3'-deoxythymidine 5'phosphate; AC1Q6RVL; [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methyl d
DMU08MN DT Small molecular drug
DMU08MN PC 65374
DMU08MN MW 347.22
DMU08MN FM C10H14N5O7P
DMU08MN IC InChI=1S/C10H14N5O7P/c1-5-3-15(10(17)12-9(5)16)8-2-6(13-14-11)7(22-8)4-21-23(18,19)20/h3,6-8H,2,4H2,1H3,(H,12,16,17)(H2,18,19,20)/t6-,7+,8+/m0/s1
DMU08MN CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)N=[N+]=[N-]
DMU08MN IK OIFWQOKDSPDILA-XLPZGREQSA-N
DMU08MN IU [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMU08MN CA CAS 29706-85-2
DMU08MN DE Discovery agent
DMQXD0N ID DMQXD0N
DMQXD0N DN 3-Benzenesulfinyl-heptanoic acid hydroxyamide
DMQXD0N HS Investigative
DMQXD0N SN CHEMBL75433; 3-Benzenesulfinyl-heptanoic acid hydroxyamide; BDBM50089197
DMQXD0N DT Small molecular drug
DMQXD0N PC 9816867
DMQXD0N MW 269.36
DMQXD0N FM C13H19NO3S
DMQXD0N IC InChI=1S/C13H19NO3S/c1-2-3-7-12(10-13(15)14-16)18(17)11-8-5-4-6-9-11/h4-6,8-9,12,16H,2-3,7,10H2,1H3,(H,14,15)
DMQXD0N CS CCCCC(CC(=O)NO)S(=O)C1=CC=CC=C1
DMQXD0N IK SQIUCETXNXHTSW-UHFFFAOYSA-N
DMQXD0N IU 3-(benzenesulfinyl)-N-hydroxyheptanamide
DMQXD0N DE Discovery agent
DM7XDCF ID DM7XDCF
DM7XDCF DN 3-Benzenesulfonyl-heptanoic acid hydroxyamide
DM7XDCF HS Investigative
DM7XDCF SN CHEMBL263501; 3-Benzenesulfonyl-heptanoic acid hydroxyamide; BDBM50089196
DM7XDCF DT Small molecular drug
DM7XDCF PC 9838786
DM7XDCF MW 285.36
DM7XDCF FM C13H19NO4S
DM7XDCF IC InChI=1S/C13H19NO4S/c1-2-3-7-12(10-13(15)14-16)19(17,18)11-8-5-4-6-9-11/h4-6,8-9,12,16H,2-3,7,10H2,1H3,(H,14,15)
DM7XDCF CS CCCCC(CC(=O)NO)S(=O)(=O)C1=CC=CC=C1
DM7XDCF IK TUUMURVUDGZZQZ-UHFFFAOYSA-N
DM7XDCF IU 3-(benzenesulfonyl)-N-hydroxyheptanamide
DM7XDCF DE Discovery agent
DMQXJA1 ID DMQXJA1
DMQXJA1 DN 3-Benzimidazol-2-ylhydroquinolin-2-one
DMQXJA1 HS Investigative
DMQXJA1 DT Small molecular drug
DMQXJA1 PC 5329370
DMQXJA1 DE Discovery agent
DMWLIK1 ID DMWLIK1
DMWLIK1 DN 3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile
DMWLIK1 HS Investigative
DMWLIK1 DE Glioma; Melanoma
DMHXRQL ID DMHXRQL
DMHXRQL DN 3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one
DMHXRQL HS Investigative
DMHXRQL SN CHEMBL237166; 3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one; BDBM50224060
DMHXRQL DT Small molecular drug
DMHXRQL PC 44436068
DMHXRQL MW 319.4
DMHXRQL FM C21H21NO2
DMHXRQL IC InChI=1S/C21H21NO2/c1-2-3-9-14-22-15-18(20(23)16-10-5-4-6-11-16)21(24)17-12-7-8-13-19(17)22/h4-8,10-13,15H,2-3,9,14H2,1H3
DMHXRQL CS CCCCCN1C=C(C(=O)C2=CC=CC=C21)C(=O)C3=CC=CC=C3
DMHXRQL IK IEVKXDBTVSPAJD-UHFFFAOYSA-N
DMHXRQL IU 3-benzoyl-1-pentylquinolin-4-one
DMHXRQL DE Discovery agent
DMAH4DG ID DMAH4DG
DMAH4DG DN 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one
DMAH4DG HS Investigative
DMAH4DG DT Small molecular drug
DMAH4DG PC 54696209
DMAH4DG DE Discovery agent
DM25K86 ID DM25K86
DM25K86 DN 3-Benzoyl-N-hydroxy-benzamide
DM25K86 HS Investigative
DM25K86 SN CHEMBL175908; 3-Benzoyl-N-hydroxy-benzamide; 3-Benzoylbenzohydroximic acid; SCHEMBL14880296; ZINC28108876
DM25K86 DT Small molecular drug
DM25K86 PC 44386957
DM25K86 MW 241.24
DM25K86 FM C14H11NO3
DM25K86 IC InChI=1S/C14H11NO3/c16-13(10-5-2-1-3-6-10)11-7-4-8-12(9-11)14(17)15-18/h1-9,18H,(H,15,17)
DM25K86 CS C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)C(=O)NO
DM25K86 IK LAZDNRBVPKMJSY-UHFFFAOYSA-N
DM25K86 IU 3-benzoyl-N-hydroxybenzamide
DM25K86 DE Discovery agent
DMNG0TY ID DMNG0TY
DMNG0TY DN 3-benzyl-1-cyclohexylpyrrolidin-2-one
DMNG0TY HS Investigative
DMNG0TY SN CHEMBL218285; 3-benzyl-1-cyclohexylpyrrolidin-2-one; 3-benzyl-1-cyclohexyl-pyrrolidin-2-one; SCHEMBL2986964; DGGDICYTCJZLPW-UHFFFAOYSA-N
DMNG0TY DT Small molecular drug
DMNG0TY PC 11673314
DMNG0TY MW 257.37
DMNG0TY FM C17H23NO
DMNG0TY IC InChI=1S/C17H23NO/c19-17-15(13-14-7-3-1-4-8-14)11-12-18(17)16-9-5-2-6-10-16/h1,3-4,7-8,15-16H,2,5-6,9-13H2
DMNG0TY CS C1CCC(CC1)N2CCC(C2=O)CC3=CC=CC=C3
DMNG0TY IK DGGDICYTCJZLPW-UHFFFAOYSA-N
DMNG0TY IU 3-benzyl-1-cyclohexylpyrrolidin-2-one
DMNG0TY DE Discovery agent
DMQ13Z8 ID DMQ13Z8
DMQ13Z8 DN 3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one
DMQ13Z8 HS Investigative
DMQ13Z8 SN CHEMBL1092690; 3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one
DMQ13Z8 DT Small molecular drug
DMQ13Z8 PC 46886465
DMQ13Z8 MW 341.4
DMQ13Z8 FM C17H15N3O3S
DMQ13Z8 IC InChI=1S/C17H15N3O3S/c1-2-24-17-18-15-9-8-13(20(22)23)10-14(15)16(21)19(17)11-12-6-4-3-5-7-12/h3-10H,2,11H2,1H3
DMQ13Z8 CS CCSC1=NC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)N1CC3=CC=CC=C3
DMQ13Z8 IK XLPYZVKSRJZTGS-UHFFFAOYSA-N
DMQ13Z8 IU 3-benzyl-2-ethylsulfanyl-6-nitroquinazolin-4-one
DMQ13Z8 DE Discovery agent
DM4GWAH ID DM4GWAH
DM4GWAH DN 3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one
DM4GWAH HS Investigative
DM4GWAH SN CHEMBL1093884; 3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one; BDBM50316110
DM4GWAH DT Small molecular drug
DM4GWAH PC 46886435
DM4GWAH MW 313.3
DM4GWAH FM C15H11N3O3S
DM4GWAH IC InChI=1S/C15H11N3O3S/c19-14-12-8-11(18(20)21)6-7-13(12)16-15(22)17(14)9-10-4-2-1-3-5-10/h1-8H,9H2,(H,16,22)
DM4GWAH CS C1=CC=C(C=C1)CN2C(=O)C3=C(C=CC(=C3)[N+](=O)[O-])NC2=S
DM4GWAH IK CAFCJNRLHXPRGN-UHFFFAOYSA-N
DM4GWAH IU 3-benzyl-6-nitro-2-sulfanylidene-1H-quinazolin-4-one
DM4GWAH DE Discovery agent
DMDAO28 ID DMDAO28
DMDAO28 DN 3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28 HS Investigative
DMDAO28 SN CHEMBL578583; 3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28 DT Small molecular drug
DMDAO28 PC 44626901
DMDAO28 MW 279.3
DMDAO28 FM C18H17NO2
DMDAO28 IC InChI=1S/C18H17NO2/c1-2-18(13-14-9-5-3-6-10-14)16(20)19(17(18)21)15-11-7-4-8-12-15/h3-12H,2,13H2,1H3
DMDAO28 CS CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC3=CC=CC=C3
DMDAO28 IK FWZVCEYFFJOHOK-UHFFFAOYSA-N
DMDAO28 IU 3-benzyl-3-ethyl-1-phenylazetidine-2,4-dione
DMDAO28 DE Discovery agent
DMHINWF ID DMHINWF
DMHINWF DN 3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF HS Investigative
DMHINWF SN CHEMBL567138; 3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF DT Small molecular drug
DMHINWF PC 44626902
DMHINWF MW 265.31
DMHINWF FM C17H15NO2
DMHINWF IC InChI=1S/C17H15NO2/c1-17(12-13-8-4-2-5-9-13)15(19)18(16(17)20)14-10-6-3-7-11-14/h2-11H,12H2,1H3
DMHINWF CS CC1(C(=O)N(C1=O)C2=CC=CC=C2)CC3=CC=CC=C3
DMHINWF IK ZFHCQEMYYXRUAS-UHFFFAOYSA-N
DMHINWF IU 3-benzyl-3-methyl-1-phenylazetidine-2,4-dione
DMHINWF DE Discovery agent
DMA5EHC ID DMA5EHC
DMA5EHC DN 3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one
DMA5EHC HS Investigative
DMA5EHC SN CHEMBL576081
DMA5EHC DT Small molecular drug
DMA5EHC PC 54736438
DMA5EHC MW 306.4
DMA5EHC FM C20H18O3
DMA5EHC IC InChI=1S/C20H18O3/c21-18-16-11-10-14-8-4-5-9-15(14)19(16)23-20(22)17(18)12-13-6-2-1-3-7-13/h1-3,6-7,10-11,21H,4-5,8-9,12H2
DMA5EHC CS C1CCC2=C(C1)C=CC3=C2OC(=O)C(=C3O)CC4=CC=CC=C4
DMA5EHC IK AGXYLUCTDKGDGR-UHFFFAOYSA-N
DMA5EHC IU 3-benzyl-4-hydroxy-7,8,9,10-tetrahydrobenzo[h]chromen-2-one
DMA5EHC DE Discovery agent
DM3BFX0 ID DM3BFX0
DM3BFX0 DN 3-Benzyl-4-hydroxy-2H-chromen-2-one
DM3BFX0 HS Investigative
DM3BFX0 SN 4-Hydroxy-3-benzylcoumarin; 15074-18-7; 3-Benzyl-4-hydroxy-2H-chromen-2-one; 3-Benzyl-4-hydroxy-chromen-2-one; 3-benzyl-4-hydroxycoumarin; 3-benzyl-4-hydroxy-2h-1-benzopyran-2-one; 3Bz-4OHBzpyran2one; 4-hydroxy-coumarin 8; CBMicro_020160; AC1L9T1B; 3-Benzyl-4-hydroxy-cumarin; Oprea1_155335; 3-benzyl-4-hydroxy-coumarin; Oprea1_579559; 3-benzyl-4 -hydroxycoumarin; SCHEMBL1648186; CHEMBL574145; BDBM2566; JMC527142 Compound 27; 3-benzyl-2-hydroxychromen-4-one; DTXSID60715769; 4-hydroxy-3-benzylchromen-2-one; MolPort-001-017-230
DM3BFX0 DT Small molecular drug
DM3BFX0 PC 54686112
DM3BFX0 MW 252.26
DM3BFX0 FM C16H12O3
DM3BFX0 IC InChI=1S/C16H12O3/c17-15-12-8-4-5-9-14(12)19-16(18)13(15)10-11-6-2-1-3-7-11/h1-9,17H,10H2
DM3BFX0 CS C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O
DM3BFX0 IK AEIVRFFWQSJCAR-UHFFFAOYSA-N
DM3BFX0 IU 3-benzyl-4-hydroxychromen-2-one
DM3BFX0 CA CAS 15074-18-7
DM3BFX0 DE Discovery agent
DML0ME9 ID DML0ME9
DML0ME9 DN 3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one
DML0ME9 HS Investigative
DML0ME9 SN CHEMBL573693; BDBM35542; 4-hydroxy-2H-chromen-2-one core, 18
DML0ME9 DT Small molecular drug
DML0ME9 PC 54736428
DML0ME9 MW 280.3
DML0ME9 FM C18H16O3
DML0ME9 IC InChI=1S/C18H16O3/c1-11-8-14-16(9-12(11)2)21-18(20)15(17(14)19)10-13-6-4-3-5-7-13/h3-9,19H,10H2,1-2H3
DML0ME9 CS CC1=CC2=C(C=C1C)OC(=O)C(=C2O)CC3=CC=CC=C3
DML0ME9 IK XYLBSWJPINWPSC-UHFFFAOYSA-N
DML0ME9 IU 3-benzyl-4-hydroxy-6,7-dimethylchromen-2-one
DML0ME9 DE Discovery agent
DMZ85NC ID DMZ85NC
DMZ85NC DN 3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one
DMZ85NC HS Investigative
DMZ85NC SN CHEMBL1256370; 3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one; SCHEMBL18805702
DMZ85NC DT Small molecular drug
DMZ85NC PC 52942744
DMZ85NC MW 243.23
DMZ85NC FM C14H10FNO2
DMZ85NC IC InChI=1S/C14H10FNO2/c15-11-6-7-13-12(8-11)16(14(17)18-13)9-10-4-2-1-3-5-10/h1-8H,9H2
DMZ85NC CS C1=CC=C(C=C1)CN2C3=C(C=CC(=C3)F)OC2=O
DMZ85NC IK YYEOCYSVLLWJQE-UHFFFAOYSA-N
DMZ85NC IU 3-benzyl-5-fluoro-1,3-benzoxazol-2-one
DMZ85NC DE Discovery agent
DMKZDYP ID DMKZDYP
DMKZDYP DN 3-Benzyl-5-isopropyl-8-methylchromen-2-one
DMKZDYP HS Investigative
DMKZDYP SN CHEMBL470224; 3-Benzyl-5-isopropyl-8-methylchromen-2-one
DMKZDYP DT Small molecular drug
DMKZDYP PC 16066912
DMKZDYP MW 292.4
DMKZDYP FM C20H20O2
DMKZDYP IC InChI=1S/C20H20O2/c1-13(2)17-10-9-14(3)19-18(17)12-16(20(21)22-19)11-15-7-5-4-6-8-15/h4-10,12-13H,11H2,1-3H3
DMKZDYP CS CC1=C2C(=C(C=C1)C(C)C)C=C(C(=O)O2)CC3=CC=CC=C3
DMKZDYP IK PFSLDHWSUPFZPK-UHFFFAOYSA-N
DMKZDYP IU 3-benzyl-8-methyl-5-propan-2-ylchromen-2-one
DMKZDYP DE Discovery agent
DMF04YH ID DMF04YH
DMF04YH DN 3-Benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH HS Investigative
DMF04YH SN CHEMBL470199; 3-Benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH DT Small molecular drug
DMF04YH PC 16067266
DMF04YH MW 280.3
DMF04YH FM C18H16O3
DMF04YH IC InChI=1S/C18H16O3/c1-12-8-16(20-2)15-11-14(18(19)21-17(15)9-12)10-13-6-4-3-5-7-13/h3-9,11H,10H2,1-2H3
DMF04YH CS CC1=CC2=C(C=C(C(=O)O2)CC3=CC=CC=C3)C(=C1)OC
DMF04YH IK AOPKGUPAQXHRKK-UHFFFAOYSA-N
DMF04YH IU 3-benzyl-5-methoxy-7-methylchromen-2-one
DMF04YH DE Discovery agent
DMSIAMN ID DMSIAMN
DMSIAMN DN 3-Benzyl-5-methoxychromen-2-one
DMSIAMN HS Investigative
DMSIAMN SN CHEMBL471247; 3-Benzyl-5-methoxychromen-2-one
DMSIAMN DT Small molecular drug
DMSIAMN PC 16067269
DMSIAMN MW 266.29
DMSIAMN FM C17H14O3
DMSIAMN IC InChI=1S/C17H14O3/c1-19-15-8-5-9-16-14(15)11-13(17(18)20-16)10-12-6-3-2-4-7-12/h2-9,11H,10H2,1H3
DMSIAMN CS COC1=CC=CC2=C1C=C(C(=O)O2)CC3=CC=CC=C3
DMSIAMN IK XJSXZFXFKVCTQS-UHFFFAOYSA-N
DMSIAMN IU 3-benzyl-5-methoxychromen-2-one
DMSIAMN DE Discovery agent
DMHYQ3Z ID DMHYQ3Z
DMHYQ3Z DN 3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one
DMHYQ3Z HS Investigative
DMHYQ3Z SN 3-Benzyl-5-methyl-3H-benzooxazol-2-one; CHEMBL523238; 3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one; F1633-0044; 107235-17-6; AC1LLOHB; BAS 07089306; MLS001205717; SCHEMBL10874258; MolPort-000-473-697; ZINC806272; HMS2816L07; BDBM50265523; ZINC 00806272; AKOS000649124; MCULE-9514588723; CCG-142613; SMR000523953; 3-benzyl-5-methyl-1,3-benzoxazol-2-one; 5-methyl-3-benzyl-3-hydrobenzoxazol-2-one
DMHYQ3Z DT Small molecular drug
DMHYQ3Z PC 1087842
DMHYQ3Z MW 239.27
DMHYQ3Z FM C15H13NO2
DMHYQ3Z IC InChI=1S/C15H13NO2/c1-11-7-8-14-13(9-11)16(15(17)18-14)10-12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMHYQ3Z CS CC1=CC2=C(C=C1)OC(=O)N2CC3=CC=CC=C3
DMHYQ3Z IK OHZOKKGTLRVETE-UHFFFAOYSA-N
DMHYQ3Z IU 3-benzyl-5-methyl-1,3-benzoxazol-2-one
DMHYQ3Z DE Discovery agent
DMGPKIY ID DMGPKIY
DMGPKIY DN 3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one
DMGPKIY HS Investigative
DMGPKIY SN CHEMBL1256155; 3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one; SCHEMBL243468; HYWGUCHKPHXSGZ-UHFFFAOYSA-N; BDBM50327347
DMGPKIY DT Small molecular drug
DMGPKIY PC 52950186
DMGPKIY MW 239.27
DMGPKIY FM C15H13NO2
DMGPKIY IC InChI=1S/C15H13NO2/c1-11-7-8-13-14(9-11)18-15(17)16(13)10-12-5-3-2-4-6-12/h2-9H,10H2,1H3
DMGPKIY CS CC1=CC2=C(C=C1)N(C(=O)O2)CC3=CC=CC=C3
DMGPKIY IK HYWGUCHKPHXSGZ-UHFFFAOYSA-N
DMGPKIY IU 3-benzyl-6-methyl-1,3-benzoxazol-2-one
DMGPKIY DE Discovery agent
DMHQ467 ID DMHQ467
DMHQ467 DN 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol
DMHQ467 HS Investigative
DMHQ467 SN CHEMBL198760; 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol; BDBM50171758; 3-benzyl-7-methyl-1H-1,8-naphthyridin-4-one
DMHQ467 DT Small molecular drug
DMHQ467 PC 15557795
DMHQ467 MW 250.29
DMHQ467 FM C16H14N2O
DMHQ467 IC InChI=1S/C16H14N2O/c1-11-7-8-14-15(19)13(10-17-16(14)18-11)9-12-5-3-2-4-6-12/h2-8,10H,9H2,1H3,(H,17,18,19)
DMHQ467 CS CC1=NC2=C(C=C1)C(=O)C(=CN2)CC3=CC=CC=C3
DMHQ467 IK QRUPNIJLOWMQBO-UHFFFAOYSA-N
DMHQ467 IU 3-benzyl-7-methyl-1H-1,8-naphthyridin-4-one
DMHQ467 DE Discovery agent
DM12RH3 ID DM12RH3
DM12RH3 DN 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol
DM12RH3 HS Investigative
DM12RH3 SN CHEMBL427178; 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol
DM12RH3 DT Small molecular drug
DM12RH3 PC 44403594
DM12RH3 MW 266.4
DM12RH3 FM C16H14N2S
DM12RH3 IC InChI=1S/C16H14N2S/c1-11-7-8-14-15(19)13(10-17-16(14)18-11)9-12-5-3-2-4-6-12/h2-8,10H,9H2,1H3,(H,17,18,19)
DM12RH3 CS CC1=NC2=C(C=C1)C(=S)C(=CN2)CC3=CC=CC=C3
DM12RH3 IK JNNOALSYCGYTDY-UHFFFAOYSA-N
DM12RH3 IU 3-benzyl-7-methyl-1H-1,8-naphthyridine-4-thione
DM12RH3 DE Discovery agent
DMB4WP5 ID DMB4WP5
DMB4WP5 DN 3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one
DMB4WP5 HS Investigative
DMB4WP5 SN CHEMBL86064; 3-(benzylamino)-5-ethyl-6-methyl-1H-pyridin-2-one; AC1L9RKU; 2-pyridinone deriv. 28; BDBM1298; ZINC5887250; 3-Aminopyridin-2(1H)-one analogue 18; 3-(Benzylamino)-5-ethyl-6-methyl-2(1H)-pyridinone; 3-(Benzylamino)-5-ethyl-6-methylpyridin-2(1H)-one
DMB4WP5 DT Small molecular drug
DMB4WP5 PC 454349
DMB4WP5 MW 242.32
DMB4WP5 FM C15H18N2O
DMB4WP5 IC InChI=1S/C15H18N2O/c1-3-13-9-14(15(18)17-11(13)2)16-10-12-7-5-4-6-8-12/h4-9,16H,3,10H2,1-2H3,(H,17,18)
DMB4WP5 CS CCC1=C(NC(=O)C(=C1)NCC2=CC=CC=C2)C
DMB4WP5 IK HEQCOEDABQUKBA-UHFFFAOYSA-N
DMB4WP5 IU 3-(benzylamino)-5-ethyl-6-methyl-1H-pyridin-2-one
DMB4WP5 DE Discovery agent
DMZIOJS ID DMZIOJS
DMZIOJS DN 3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine
DMZIOJS HS Investigative
DMZIOJS SN CHEMBL206465; 3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine
DMZIOJS DT Small molecular drug
DMZIOJS PC 11624425
DMZIOJS MW 348.4
DMZIOJS FM C21H24N4O
DMZIOJS IC InChI=1S/C21H24N4O/c1-2-6-17(7-3-1)16-20-21(22-10-11-25-12-14-26-15-13-25)24-19-9-5-4-8-18(19)23-20/h1-9H,10-16H2,(H,22,24)
DMZIOJS CS C1COCCN1CCNC2=NC3=CC=CC=C3N=C2CC4=CC=CC=C4
DMZIOJS IK JEKWAIMSNCODJF-UHFFFAOYSA-N
DMZIOJS IU 3-benzyl-N-(2-morpholin-4-ylethyl)quinoxalin-2-amine
DMZIOJS DE Discovery agent
DM94K83 ID DM94K83
DM94K83 DN 3-Benzyloxy-2-phenyl-piperidine
DM94K83 HS Investigative
DM94K83 SN CHEMBL100178; 3-Benzyloxy-2-phenyl-piperidine; SCHEMBL9023808
DM94K83 DT Small molecular drug
DM94K83 PC 44331794
DM94K83 MW 267.4
DM94K83 FM C18H21NO
DM94K83 IC InChI=1S/C18H21NO/c1-3-8-15(9-4-1)14-20-17-12-7-13-19-18(17)16-10-5-2-6-11-16/h1-6,8-11,17-19H,7,12-14H2/t17-,18-/m0/s1
DM94K83 CS C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)OCC3=CC=CC=C3
DM94K83 IK VPMJRXBIGDTSRT-ROUUACIJSA-N
DM94K83 IU (2S,3S)-2-phenyl-3-phenylmethoxypiperidine
DM94K83 DE Discovery agent
DMKD874 ID DMKD874
DMKD874 DN 3-benzyloxy-4-methoxy-2'-hydroxychalcone
DMKD874 HS Investigative
DMKD874 SN CHEMBL437006
DMKD874 DT Small molecular drug
DMKD874 PC 12681944
DMKD874 MW 360.4
DMKD874 FM C23H20O4
DMKD874 IC InChI=1S/C23H20O4/c1-26-22-14-12-17(11-13-21(25)19-9-5-6-10-20(19)24)15-23(22)27-16-18-7-3-2-4-8-18/h2-15,24H,16H2,1H3/b13-11+
DMKD874 CS COC1=C(C=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O)OCC3=CC=CC=C3
DMKD874 IK QYADGBNDKLLFIV-ACCUITESSA-N
DMKD874 IU (E)-1-(2-hydroxyphenyl)-3-(4-methoxy-3-phenylmethoxyphenyl)prop-2-en-1-one
DMKD874 DE Discovery agent
DMPG315 ID DMPG315
DMPG315 DN 3-Benzyloxy-6,7-dimethoxy-quinoline
DMPG315 HS Investigative
DMPG315 SN CHEMBL66932; 3-Benzyloxy-6,7-dimethoxy-quinoline; SCHEMBL8172572; ZJIOVLLLFWQBKA-UHFFFAOYSA-N; 3-benzyloxy-6,7-dimethoxyquinoline; ZINC3834031
DMPG315 DT Small molecular drug
DMPG315 PC 10085863
DMPG315 MW 295.3
DMPG315 FM C18H17NO3
DMPG315 IC InChI=1S/C18H17NO3/c1-20-17-9-14-8-15(11-19-16(14)10-18(17)21-2)22-12-13-6-4-3-5-7-13/h3-11H,12H2,1-2H3
DMPG315 CS COC1=CC2=CC(=CN=C2C=C1OC)OCC3=CC=CC=C3
DMPG315 IK ZJIOVLLLFWQBKA-UHFFFAOYSA-N
DMPG315 IU 6,7-dimethoxy-3-phenylmethoxyquinoline
DMPG315 DE Discovery agent
DMLEXWC ID DMLEXWC
DMLEXWC DN 3beta,6beta-dihydroxyolean-12-en-27-oic acid
DMLEXWC HS Investigative
DMLEXWC SN CHEMBL377760; 3beta,6beta-dihydroxyolean-12-en-27-oic acid
DMLEXWC DT Small molecular drug
DMLEXWC PC 44411962
DMLEXWC MW 472.7
DMLEXWC FM C30H48O4
DMLEXWC IC InChI=1S/C30H48O4/c1-25(2)12-13-27(5)14-15-30(24(33)34)18(19(27)16-25)8-9-21-28(6)11-10-22(32)26(3,4)23(28)20(31)17-29(21,30)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20+,21+,22-,23?,27+,28+,29+,30+/m0/s1
DMLEXWC CS C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(C[C@H](C5[C@@]4(CC[C@@H](C5(C)C)O)C)O)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DMLEXWC IK LUJTWDWEYNWTBP-ULYQHCOQSA-N
DMLEXWC IU (4aR,6aR,6aR,6bR,8R,10S,12aR,14bR)-8,10-dihydroxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DMLEXWC DE Discovery agent
DMOZAHB ID DMOZAHB
DMOZAHB DN 3beta-acetoxyolean-12-en-27-oic acid
DMOZAHB HS Investigative
DMOZAHB SN CHEMBL208639; 3beta-acetoxyolean-12-en-27-oic acid
DMOZAHB DT Small molecular drug
DMOZAHB PC 44411975
DMOZAHB MW 498.7
DMOZAHB FM C32H50O4
DMOZAHB IC InChI=1S/C32H50O4/c1-20(33)36-25-12-13-30(7)23(28(25,4)5)11-14-31(8)24(30)10-9-21-22-19-27(2,3)15-16-29(22,6)17-18-32(21,31)26(34)35/h9,22-25H,10-19H2,1-8H3,(H,34,35)/t22-,23?,24+,25-,29+,30-,31+,32+/m0/s1
DMOZAHB CS CC(=O)O[C@H]1CC[C@@]2([C@H]3CC=C4[C@@H]5CC(CC[C@@]5(CC[C@]4([C@@]3(CCC2C1(C)C)C)C(=O)O)C)(C)C)C
DMOZAHB IK IQYUEJTVDLHZDJ-PVLVPSCMSA-N
DMOZAHB IU (4aR,6aR,6aR,6bR,10S,12aR,14bR)-10-acetyloxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DMOZAHB DE Discovery agent
DMF6VGK ID DMF6VGK
DMF6VGK DN 3beta-hydroxyolean-12-en-27-oic acid
DMF6VGK HS Investigative
DMF6VGK SN CHEMBL210970; 3beta-hydroxyolean-12-en-27-oic acid
DMF6VGK DT Small molecular drug
DMF6VGK PC 44411858
DMF6VGK MW 456.7
DMF6VGK FM C30H48O3
DMF6VGK IC InChI=1S/C30H48O3/c1-25(2)14-15-27(5)16-17-30(24(32)33)19(20(27)18-25)8-9-22-28(6)12-11-23(31)26(3,4)21(28)10-13-29(22,30)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)/t20-,21?,22+,23-,27+,28-,29+,30+/m0/s1
DMF6VGK CS C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DMF6VGK IK QGOSJBZFTWGWDU-ROOBTRRZSA-N
DMF6VGK IU (4aR,6aR,6aR,6bR,10S,12aR,14bR)-10-hydroxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylic acid
DMF6VGK DE Discovery agent
DML8NY0 ID DML8NY0
DML8NY0 DN 3beta-hydroxyrus-12,19(29)-dien-28-oic acid
DML8NY0 HS Investigative
DML8NY0 SN CHEMBL517522; 3beta-hydroxyrus-12,19(29)-dien-28-oic acid; BDBM50259781; 3beta-Hydroxyurs-12,19(29)-diene-28-oic acid
DML8NY0 DT Small molecular drug
DML8NY0 PC 21670092
DML8NY0 MW 454.7
DML8NY0 FM C30H46O3
DML8NY0 IC InChI=1S/C30H46O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18,21-24,31H,2,9-17H2,1,3-7H3,(H,32,33)/t18-,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
DML8NY0 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2C1=C)C)C(=O)O
DML8NY0 IK VPMTUSRUIJFRMW-XCYSCKFXSA-N
DML8NY0 IU (2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,6a,6b,9,9,12a-hexamethyl-1-methylidene-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DML8NY0 DE Discovery agent
DMKL59W ID DMKL59W
DMKL59W DN 3beta-hydroxyrus-18,20(30)-dien-28-oic acid
DMKL59W HS Investigative
DMKL59W SN CHEMBL479472; 3beta-hydroxyrus-18,20(30)-dien-28-oic acid; BDBM50259782; 3beta-Hydroxyurs-18,20(30)-diene-28-oic acid
DMKL59W DT Small molecular drug
DMKL59W PC 10718553
DMKL59W MW 454.7
DMKL59W FM C30H46O3
DMKL59W IC InChI=1S/C30H46O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h20-23,31H,1,8-17H2,2-7H3,(H,32,33)/t20-,21+,22-,23+,27+,28-,29-,30+/m1/s1
DMKL59W CS CC1=C2[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC[C@]2(CCC1=C)C(=O)O)C)C)(C)C)O)C
DMKL59W IK DZVARQVBYAEZFI-JZQYXDLISA-N
DMKL59W IU (4aS,6aR,6aR,6bR,8aR,10S,12aR,14aS)-10-hydroxy-1,6a,6b,9,9,12a-hexamethyl-2-methylidene-3,4,5,6,6a,7,8,8a,10,11,12,13,14,14a-tetradecahydropicene-4a-carboxylic acid
DMKL59W DE Discovery agent
DM6NFO0 ID DM6NFO0
DM6NFO0 DN 3beta-hydroxyurs-12-en-27-oic acid
DM6NFO0 HS Investigative
DM6NFO0 SN CHEMBL380467; 3beta-hydroxyurs-12-en-27-oic acid
DM6NFO0 DT Small molecular drug
DM6NFO0 PC 179431
DM6NFO0 MW 456.7
DM6NFO0 FM C30H48O3
DM6NFO0 IC InChI=1S/C30H48O3/c1-18-10-13-27(5)16-17-30(25(32)33)20(24(27)19(18)2)8-9-22-28(6)14-12-23(31)26(3,4)21(28)11-15-29(22,30)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21?,22-,23+,24-,27-,28+,29-,30-/m1/s1
DM6NFO0 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@H]2[C@H]1C)C(=O)O)C
DM6NFO0 IK RXVRYAUOTRSYDU-RKQWDYETSA-N
DM6NFO0 IU (1S,2R,4aR,6aR,6aR,6bR,10S,12aR,14bS)-10-hydroxy-1,2,4a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-6a-carboxylic acid
DM6NFO0 CA CAS 24778-49-2
DM6NFO0 DE Discovery agent
DMZ8WMA ID DMZ8WMA
DMZ8WMA DN 3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol
DMZ8WMA HS Investigative
DMZ8WMA SN 1,2-benzenediol,3-bicyclo[2.2.1]hept-2-yl-; 462606-73-1; AC1MXF8P; 3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol; Oprea1_604715; GTPL2569; CTK8I7953; AKOS027407656; KB-148826; 3-(3-bicyclo[2.2.1]heptanyl)benzene-1,2-diol
DMZ8WMA DT Small molecular drug
DMZ8WMA PC 3764681
DMZ8WMA MW 204.26
DMZ8WMA FM C13H16O2
DMZ8WMA IC InChI=1S/C13H16O2/c14-12-3-1-2-10(13(12)15)11-7-8-4-5-9(11)6-8/h1-3,8-9,11,14-15H,4-7H2
DMZ8WMA CS C1CC2CC1CC2C3=C(C(=CC=C3)O)O
DMZ8WMA IK DWWJNUSFHLSDSW-UHFFFAOYSA-N
DMZ8WMA IU 3-(2-bicyclo[2.2.1]heptanyl)benzene-1,2-diol
DMZ8WMA DE Discovery agent
DMHSAOQ ID DMHSAOQ
DMHSAOQ DN 3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide
DMHSAOQ HS Investigative
DMHSAOQ SN CHEMBL177549; 3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide; SCHEMBL10876301; BDBM50015161; (E)-3-[3-Phenylphenyl]-N-methyl-2-propenehydroxamic acid
DMHSAOQ DT Small molecular drug
DMHSAOQ PC 13746841
DMHSAOQ MW 253.29
DMHSAOQ FM C16H15NO2
DMHSAOQ IC InChI=1S/C16H15NO2/c1-17(19)16(18)11-10-13-6-5-9-15(12-13)14-7-3-2-4-8-14/h2-12,19H,1H3/b11-10+
DMHSAOQ CS CN(C(=O)/C=C/C1=CC(=CC=C1)C2=CC=CC=C2)O
DMHSAOQ IK CXMSWAWAJRLYBE-ZHACJKMWSA-N
DMHSAOQ IU (E)-N-hydroxy-N-methyl-3-(3-phenylphenyl)prop-2-enamide
DMHSAOQ DE Discovery agent
DMMC2Q9 ID DMMC2Q9
DMMC2Q9 DN 3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine
DMMC2Q9 HS Investigative
DMMC2Q9 SN CHEMBL226831; 3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine
DMMC2Q9 DT Small molecular drug
DMMC2Q9 PC 16735659
DMMC2Q9 MW 271.3
DMMC2Q9 FM C18H13N3
DMMC2Q9 IC InChI=1S/C18H13N3/c1-14-13-19-21-18(20-14)12-9-15-7-10-17(11-8-15)16-5-3-2-4-6-16/h2-8,10-11,13H,1H3
DMMC2Q9 CS CC1=CN=NC(=N1)C#CC2=CC=C(C=C2)C3=CC=CC=C3
DMMC2Q9 IK OXVAGVMMJCNKRK-UHFFFAOYSA-N
DMMC2Q9 IU 5-methyl-3-[2-(4-phenylphenyl)ethynyl]-1,2,4-triazine
DMMC2Q9 DE Discovery agent
DMKBRIM ID DMKBRIM
DMKBRIM DN 3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide
DMKBRIM HS Investigative
DMKBRIM SN CHEMBL178053; 3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide; ZINC28103871; BDBM50015167; (E)-3-[4-Phenylphenyl]-N-methyl-2-propenehydroxamic acid
DMKBRIM DT Small molecular drug
DMKBRIM PC 13746840
DMKBRIM MW 253.29
DMKBRIM FM C16H15NO2
DMKBRIM IC InChI=1S/C16H15NO2/c1-17(19)16(18)12-9-13-7-10-15(11-8-13)14-5-3-2-4-6-14/h2-12,19H,1H3/b12-9+
DMKBRIM CS CN(C(=O)/C=C/C1=CC=C(C=C1)C2=CC=CC=C2)O
DMKBRIM IK TUEHLNCQVBWQNV-FMIVXFBMSA-N
DMKBRIM IU (E)-N-hydroxy-N-methyl-3-(4-phenylphenyl)prop-2-enamide
DMKBRIM DE Discovery agent
DMRCJW0 ID DMRCJW0
DMRCJW0 DN 3-boronobenzoic acid
DMRCJW0 HS Investigative
DMRCJW0 SN 3-Carboxyphenylboronic acid; 25487-66-5; 3-Boronobenzoic acid; 3-(dihydroxyboranyl)benzoic acid; 3-Carboxybenzeneboronic Acid; m-Carboxyphenylboronic acid; Benzoic acid, 3-borono-; 3-(dihydroxyborane)benzoic acid; 3-Carboxyphenylboronicacid; 3-(DIHYDROXYBORYL)BENZOIC ACID; 3-phenyl ester boronic acid; 3-carboxy-phenyl-boronic acid; (3-carboxyphenyl)boronic acid; CHEMBL421765; MFCD00036833; 3-Carboxyphenylboronic acid, 97%; zlchem 425; PubChem1773; 3-borono-benzoic acid; ACMC-1CMDG; 3-carboxyphenyboronic acid; AC1MC01N
DMRCJW0 DT Small molecular drug
DMRCJW0 PC 2733957
DMRCJW0 MW 165.94
DMRCJW0 FM C7H7BO4
DMRCJW0 IC InChI=1S/C7H7BO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4,11-12H,(H,9,10)
DMRCJW0 CS B(C1=CC(=CC=C1)C(=O)O)(O)O
DMRCJW0 IK DBVFWZMQJQMJCB-UHFFFAOYSA-N
DMRCJW0 IU 3-boronobenzoic acid
DMRCJW0 CA CAS 25487-66-5
DMRCJW0 DE Discovery agent
DM03ROH ID DM03ROH
DM03ROH DN 3-bromo-1-(4-hexylphenyl)propan-1-one
DM03ROH HS Investigative
DM03ROH SN beta-bromo ketone, 8e; 3-bromo-1-(4-hexylphenyl)propan-1-one; CHEMBL395602; BDBM18857; ZINC14969063
DM03ROH DT Small molecular drug
DM03ROH PC 23635858
DM03ROH MW 297.23
DM03ROH FM C15H21BrO
DM03ROH IC InChI=1S/C15H21BrO/c1-2-3-4-5-6-13-7-9-14(10-8-13)15(17)11-12-16/h7-10H,2-6,11-12H2,1H3
DM03ROH CS CCCCCCC1=CC=C(C=C1)C(=O)CCBr
DM03ROH IK IKJXBCMGQCDIDG-UHFFFAOYSA-N
DM03ROH IU 3-bromo-1-(4-hexylphenyl)propan-1-one
DM03ROH DE Discovery agent
DMZGWL2 ID DMZGWL2
DMZGWL2 DN 3-Bromo-1H-indazole-7-carbonitrile
DMZGWL2 HS Investigative
DMZGWL2 SN 3-Bromo-1H-indazole-7-carbonitrile; 945762-00-5; CHEMBL451541; 1H-Indazole-7-carbonitrile,3-bromo-; AK-27881; CTK8B8302; KS-00000HFF; DTXSID00659577; MolPort-009-197-290; 3-bromo-2H-indazole-7-carbonitrile; ZINC40448363; BDBM50270530; ANW-59984; AKOS015898261; FCH1406736; VI20021; RP05214; SC-35603; QC-11297; KB-70485; DS-11111; CJ-20125; TC-148729; ST2417498; AX8158454; AB0037522; AJ-102668; AJ-102669; FT-0646755; Y4808; 4CH-016057; A15929; J-511797
DMZGWL2 DT Small molecular drug
DMZGWL2 PC 44585510
DMZGWL2 MW 222.04
DMZGWL2 FM C8H4BrN3
DMZGWL2 IC InChI=1S/C8H4BrN3/c9-8-6-3-1-2-5(4-10)7(6)11-12-8/h1-3H,(H,11,12)
DMZGWL2 CS C1=CC2=C(NN=C2C(=C1)C#N)Br
DMZGWL2 IK MRGZUAUMTMLMTE-UHFFFAOYSA-N
DMZGWL2 IU 3-bromo-2H-indazole-7-carbonitrile
DMZGWL2 CA CAS 945762-00-5
DMZGWL2 DE Discovery agent
DM1BALV ID DM1BALV
DM1BALV DN 3-Bromo-2'-hydroxy-4-methoxychalcone
DM1BALV HS Investigative
DM1BALV SN AC1ORO2M; CHEMBL492941; MolPort-000-648-211; ZINC5549056; STL192121; AKOS025268524; (E)-3-(3-bromo-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DM1BALV DT Small molecular drug
DM1BALV PC 7729032
DM1BALV MW 333.18
DM1BALV FM C16H13BrO3
DM1BALV IC InChI=1S/C16H13BrO3/c1-20-16-9-7-11(10-13(16)17)6-8-15(19)12-4-2-3-5-14(12)18/h2-10,18H,1H3/b8-6+
DM1BALV CS COC1=C(C=C(C=C1)/C=C/C(=O)C2=CC=CC=C2O)Br
DM1BALV IK KXSKRIQLDQIBNJ-SOFGYWHQSA-N
DM1BALV IU (E)-3-(3-bromo-4-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
DM1BALV DE Discovery agent
DMPZ4M8 ID DMPZ4M8
DMPZ4M8 DN 3-bromo-4,4',5-trimethoxy-(Z)-stilbene
DMPZ4M8 HS Investigative
DMPZ4M8 SN SCHEMBL4219422; CHEMBL424885
DMPZ4M8 DT Small molecular drug
DMPZ4M8 PC 16090832
DMPZ4M8 MW 349.2
DMPZ4M8 FM C17H17BrO3
DMPZ4M8 IC InChI=1S/C17H17BrO3/c1-19-14-8-6-12(7-9-14)4-5-13-10-15(18)17(21-3)16(11-13)20-2/h4-11H,1-3H3/b5-4-
DMPZ4M8 CS COC1=CC=C(C=C1)/C=C\\C2=CC(=C(C(=C2)Br)OC)OC
DMPZ4M8 IK HORVHXITWDPZBG-PLNGDYQASA-N
DMPZ4M8 IU 1-bromo-2,3-dimethoxy-5-[(Z)-2-(4-methoxyphenyl)ethenyl]benzene
DMPZ4M8 DE Discovery agent
DMPQOS2 ID DMPQOS2
DMPQOS2 DN 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2 HS Investigative
DMPQOS2 SN CHEMBL396177; 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2 DT Small molecular drug
DMPQOS2 PC 44432681
DMPQOS2 MW 323.2
DMPQOS2 FM C17H11BrN2
DMPQOS2 IC InChI=1S/C17H11BrN2/c1-11-2-3-13-4-5-14(9-17(13)20-11)15-6-12(10-19)7-16(18)8-15/h2-9H,1H3
DMPQOS2 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)Br
DMPQOS2 IK UCLWCGCRIQDNMD-UHFFFAOYSA-N
DMPQOS2 IU 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile
DMPQOS2 DE Discovery agent
DMOXY78 ID DMOXY78
DMOXY78 DN 3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine
DMOXY78 HS Investigative
DMOXY78 SN 3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine; CHEMBL202116; 329204-97-9; SCHEMBL4144716; SLLMZMSYBFFSLX-UHFFFAOYSA-N; BDBM50181777; 2-Methyl-4-(5-bromo-3-pyridylethynyl)thiazole
DMOXY78 DT Small molecular drug
DMOXY78 PC 11701860
DMOXY78 MW 279.16
DMOXY78 FM C11H7BrN2S
DMOXY78 IC InChI=1S/C11H7BrN2S/c1-8-14-11(7-15-8)3-2-9-4-10(12)6-13-5-9/h4-7H,1H3
DMOXY78 CS CC1=NC(=CS1)C#CC2=CC(=CN=C2)Br
DMOXY78 IK SLLMZMSYBFFSLX-UHFFFAOYSA-N
DMOXY78 IU 4-[2-(5-bromopyridin-3-yl)ethynyl]-2-methyl-1,3-thiazole
DMOXY78 DE Discovery agent
DMZTDCL ID DMZTDCL
DMZTDCL DN 3-Bromo-5-phenylsalicylc acid
DMZTDCL HS Investigative
DMZTDCL SN 4906-68-7; CHEMBL387536; 3-bromo-5-phenylsalicylic acid; 3-bromo-5-phenylsalicyclic acid; 5-bromo-4-hydroxybiphenyl-3-carboxylic acid; 5-Bromo-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; 3-bromo-2-hydroxy-5-phenylbenzoic acid; 3-Bromo-5-phenylsalicylc acid; NSC109116; [1,1'-biphenyl]-3-carboxylic acid, 5-bromo-4-hydroxy-; AC1L6KWF; AC1Q25S5; SCHEMBL18319714; KS-00002WWQ; CTK1D8664; 3-bromo-5-phenyl-Salicylic Acid; DTXSID70296397; MolPort-018-496-593; XVZSXNULHSIRCQ-UHFFFAOYSA-N; ZINC1701218; BDBM50219490; AKOS005151372
DMZTDCL DT Small molecular drug
DMZTDCL PC 268734
DMZTDCL MW 293.11
DMZTDCL FM C13H9BrO3
DMZTDCL IC InChI=1S/C13H9BrO3/c14-11-7-9(8-4-2-1-3-5-8)6-10(12(11)15)13(16)17/h1-7,15H,(H,16,17)
DMZTDCL CS C1=CC=C(C=C1)C2=CC(=C(C(=C2)Br)O)C(=O)O
DMZTDCL IK XVZSXNULHSIRCQ-UHFFFAOYSA-N
DMZTDCL IU 3-bromo-2-hydroxy-5-phenylbenzoic acid
DMZTDCL CA CAS 4906-68-7
DMZTDCL DE Discovery agent
DMXZB5C ID DMXZB5C
DMXZB5C DN 3-Bromo-6-nitro-2-piperazin-1-yl-quinoline
DMXZB5C HS Investigative
DMXZB5C SN CHEMBL290523; 3-bromo-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6365221; MPHPQAKQQDLIGK-UHFFFAOYSA-N; BDBM50090214; 2-Piperazino-3-bromo-6-nitroquinoline
DMXZB5C DT Small molecular drug
DMXZB5C PC 10246440
DMXZB5C MW 337.17
DMXZB5C FM C13H13BrN4O2
DMXZB5C IC InChI=1S/C13H13BrN4O2/c14-11-8-9-7-10(18(19)20)1-2-12(9)16-13(11)17-5-3-15-4-6-17/h1-2,7-8,15H,3-6H2
DMXZB5C CS C1CN(CCN1)C2=C(C=C3C=C(C=CC3=N2)[N+](=O)[O-])Br
DMXZB5C IK MPHPQAKQQDLIGK-UHFFFAOYSA-N
DMXZB5C IU 3-bromo-6-nitro-2-piperazin-1-ylquinoline
DMXZB5C DE Discovery agent
DMM7DHB ID DMM7DHB
DMM7DHB DN 3-bromo-7-nitro-1H-indazole
DMM7DHB HS Investigative
DMM7DHB SN 3-Bromo-7-nitroindazole; 3-Bromo-7-nitro-1H-indazole; 3-bromo-7-nitroindazole; 74209-34-0; 1H-Indazole,3-bromo-7-nitro-; 3-bromo-7-nitro-2H-indazole; CHEMBL479014; NFSTZPMYAZRZPC-UHFFFAOYSA-N; MFCD00159910; AK-27879; SR-01000075708; 3-bromo-7NI; Tocris-0735; 3-Br-7-Nitroindazole; AC1L1BXC; Lopac-B-2050; 3-Br-7NI; Lopac0_000161; BSPBio_002434; BSPBio_001502; KBioGR_000222; KBioSS_000222; SPECTRUM1505105; SCHEMBL499422; SCHEMBL499421; GTPL5113; KBio3_000444; KBio3_000443; KBio2_002790; CTK5D9545; BCBcMAP01_000129; KBio2_005358; KBio2_000222; DTXSID90274319; OR6862T; 3-Bromo-7-Nitroindazole
DMM7DHB DT Small molecular drug
DMM7DHB PC 1649
DMM7DHB MW 242.03
DMM7DHB FM C7H4BrN3O2
DMM7DHB IC InChI=1S/C7H4BrN3O2/c8-7-4-2-1-3-5(11(12)13)6(4)9-10-7/h1-3H,(H,9,10)
DMM7DHB CS C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br
DMM7DHB IK NFSTZPMYAZRZPC-UHFFFAOYSA-N
DMM7DHB IU 3-bromo-7-nitro-2H-indazole
DMM7DHB CA CAS 74209-34-0
DMM7DHB DE Discovery agent
DMPF7O2 ID DMPF7O2
DMPF7O2 DN 3-bromoboldine
DMPF7O2 HS Investigative
DMPF7O2 SN 3-bromoboldine; CHEMBL225853; BDBM50202340
DMPF7O2 DT Small molecular drug
DMPF7O2 PC 10409038
DMPF7O2 MW 406.3
DMPF7O2 FM C19H20BrNO4
DMPF7O2 IC InChI=1S/C19H20BrNO4/c1-21-5-4-10-15-12(21)6-9-7-13(22)14(24-2)8-11(9)16(15)19(25-3)18(23)17(10)20/h7-8,12,22-23H,4-6H2,1-3H3/t12-/m0/s1
DMPF7O2 CS CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2Br)O)OC)OC)O
DMPF7O2 IK ORZPHDSNVICTTE-LBPRGKRZSA-N
DMPF7O2 IU (6aS)-3-bromo-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DMPF7O2 DE Discovery agent
DM62Y1S ID DM62Y1S
DM62Y1S DN 3-bromo-N-(6-methylpyridin-2-yl)benzamide
DM62Y1S HS Investigative
DM62Y1S SN 3-bromo-N-(6-methylpyridin-2-yl)benzamide; CHEMBL377195; 188747-28-6; AC1LCNCE; TimTec1_002275; Oprea1_606042; CTK0A3803; DTXSID30345279; MolPort-002-316-872; BOCBDQIZNZCOPX-UHFFFAOYSA-N; HMS1540H09; ZINC138486; STK182187; BDBM50186324; AKOS000204447; MCULE-1961959863; ST031112; 3-bromo-N~1~-(6-methyl-2-pyridyl)benzamide; 3-Bromo-N-(6-methyl-pyridin-2-yl)-benzamide; 3-Bromo-N-(6-methyl-2-pyridinyl)benzamide #; Benzamide, 3-bromo-N-(6-methyl-2-pyridinyl)-; Z57716131; (3-bromophenyl)-N-(6-methyl(2-pyridyl))carboxamide
DM62Y1S DT Small molecular drug
DM62Y1S PC 603306
DM62Y1S MW 291.14
DM62Y1S FM C13H11BrN2O
DM62Y1S IC InChI=1S/C13H11BrN2O/c1-9-4-2-7-12(15-9)16-13(17)10-5-3-6-11(14)8-10/h2-8H,1H3,(H,15,16,17)
DM62Y1S CS CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)Br
DM62Y1S IK BOCBDQIZNZCOPX-UHFFFAOYSA-N
DM62Y1S IU 3-bromo-N-(6-methylpyridin-2-yl)benzamide
DM62Y1S CA CAS 188747-28-6
DM62Y1S DE Discovery agent
DMXZW3R ID DMXZW3R
DMXZW3R DN 3-bromophenyl-difluoromethanesulfonamide
DMXZW3R HS Investigative
DMXZW3R SN 3-bromophenyl-difluoromethanesulfonamide; CHEMBL200673; BDBM50175006
DMXZW3R DT Small molecular drug
DMXZW3R PC 11687831
DMXZW3R MW 286.1
DMXZW3R FM C7H6BrF2NO2S
DMXZW3R IC InChI=1S/C7H6BrF2NO2S/c8-6-3-1-2-5(4-6)7(9,10)14(11,12)13/h1-4H,(H2,11,12,13)
DMXZW3R CS C1=CC(=CC(=C1)Br)C(F)(F)S(=O)(=O)N
DMXZW3R IK RXNVOIIGCVXUGN-UHFFFAOYSA-N
DMXZW3R IU (3-bromophenyl)-difluoromethanesulfonamide
DMXZW3R DE Discovery agent
DMK7D8N ID DMK7D8N
DMK7D8N DN 3'-bromopropiophenonethiosemicarbazone
DMK7D8N HS Investigative
DMK7D8N SN CHEMBL313679; (1E)-1-(3-bromophenyl)propan-1-one thiosemicarbazone; 3'-bromopropiophenonethiosemicarbazone; SCHEMBL6338417; BDBM50114613; 3'-Bromopropiophenone Thiosemicarbazone
DMK7D8N DT Small molecular drug
DMK7D8N PC 10356636
DMK7D8N MW 286.19
DMK7D8N FM C10H12BrN3S
DMK7D8N IC InChI=1S/C10H12BrN3S/c1-2-9(13-14-10(12)15)7-4-3-5-8(11)6-7/h3-6H,2H2,1H3,(H3,12,14,15)/b13-9+
DMK7D8N CS CC/C(=N\\NC(=S)N)/C1=CC(=CC=C1)Br
DMK7D8N IK WBIKZQWGHHXZTG-UKTHLTGXSA-N
DMK7D8N IU [(E)-1-(3-bromophenyl)propylideneamino]thiourea
DMK7D8N DE Discovery agent
DMYL3ST ID DMYL3ST
DMYL3ST DN 3-bromopyruvate
DMYL3ST HS Investigative
DMYL3ST SN bromopyruvate; 3-bromo-2-oxopropanoate; AC1ODWIN; 3-bromo-2-oxo-propionate; GTPL4517; CHEBI:131592; PRRZDZJYSJLDBS-UHFFFAOYSA-M
DMYL3ST DT Small molecular drug
DMYL3ST PC 6994776
DMYL3ST MW 165.95
DMYL3ST FM C3H2BrO3-
DMYL3ST IC InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)/p-1
DMYL3ST CS C(C(=O)C(=O)[O-])Br
DMYL3ST IK PRRZDZJYSJLDBS-UHFFFAOYSA-M
DMYL3ST IU 3-bromo-2-oxopropanoate
DMYL3ST CA CAS 68-38-2
DMYL3ST CB CHEBI:131592
DMYL3ST DE Discovery agent
DMQ8H74 ID DMQ8H74
DMQ8H74 DN 3-Butoxy-9H-beta-carboline
DMQ8H74 HS Investigative
DMQ8H74 SN CHEMBL66902; 3-butoxy-9H-pyrido[3,4-b]indole; AC1NFSYC; 3-Butoxy-beta-carboline; CHEMBL458012; SCHEMBL10644773; ZINC6869004
DMQ8H74 DT Small molecular drug
DMQ8H74 PC 4713436
DMQ8H74 MW 240.3
DMQ8H74 FM C15H16N2O
DMQ8H74 IC InChI=1S/C15H16N2O/c1-2-3-8-18-15-9-12-11-6-4-5-7-13(11)17-14(12)10-16-15/h4-7,9-10,17H,2-3,8H2,1H3
DMQ8H74 CS CCCCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMQ8H74 IK UARMCWOWRLFTFP-UHFFFAOYSA-N
DMQ8H74 IU 3-butoxy-9H-pyrido[3,4-b]indole
DMQ8H74 DE Discovery agent
DMRF2Q8 ID DMRF2Q8
DMRF2Q8 DN 3-butoxycarbonyl-4-quinolone
DMRF2Q8 HS Investigative
DMRF2Q8 SN CHEMBL205456; AKOS017354707; 4-Hydroxyquinoline-3-carboxylic acid butyl ester
DMRF2Q8 DT Small molecular drug
DMRF2Q8 PC 11630136
DMRF2Q8 MW 245.27
DMRF2Q8 FM C14H15NO3
DMRF2Q8 IC InChI=1S/C14H15NO3/c1-2-3-8-18-14(17)11-9-15-12-7-5-4-6-10(12)13(11)16/h4-7,9H,2-3,8H2,1H3,(H,15,16)
DMRF2Q8 CS CCCCOC(=O)C1=CNC2=CC=CC=C2C1=O
DMRF2Q8 IK LKWHYYPRQAIKDW-UHFFFAOYSA-N
DMRF2Q8 IU butyl 4-oxo-1H-quinoline-3-carboxylate
DMRF2Q8 DE Discovery agent
DMD6PMZ ID DMD6PMZ
DMD6PMZ DN 3-butoxycarbonyl-6-ethyl-4-quinolone
DMD6PMZ HS Investigative
DMD6PMZ SN CHEMBL206591
DMD6PMZ DT Small molecular drug
DMD6PMZ PC 11587151
DMD6PMZ MW 273.33
DMD6PMZ FM C16H19NO3
DMD6PMZ IC InChI=1S/C16H19NO3/c1-3-5-8-20-16(19)13-10-17-14-7-6-11(4-2)9-12(14)15(13)18/h6-7,9-10H,3-5,8H2,1-2H3,(H,17,18)
DMD6PMZ CS CCCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMD6PMZ IK CJTBJWFADVNZQZ-UHFFFAOYSA-N
DMD6PMZ IU butyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMD6PMZ DE Discovery agent
DMRI503 ID DMRI503
DMRI503 DN 3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine
DMRI503 HS Investigative
DMRI503 SN CHEMBL89282; 3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine; SCHEMBL8550109; BDBM50104656
DMRI503 DT Small molecular drug
DMRI503 PC 44322997
DMRI503 MW 170.25
DMRI503 FM C9H18N2O
DMRI503 IC InChI=1S/C9H18N2O/c1-2-3-4-8-7-12-6-5-9(10)11-8/h8H,2-7H2,1H3,(H2,10,11)
DMRI503 CS CCCCC1COCCC(=N1)N
DMRI503 IK YXURWRQCUHZROM-UHFFFAOYSA-N
DMRI503 IU 3-butyl-2,3,6,7-tetrahydro-1,4-oxazepin-5-amine
DMRI503 DE Discovery agent
DM6A80U ID DM6A80U
DM6A80U DN 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine
DM6A80U HS Investigative
DM6A80U SN CHEMBL186091; 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7679025
DM6A80U DT Small molecular drug
DM6A80U PC 22617750
DM6A80U MW 186.32
DM6A80U FM C9H18N2S
DM6A80U IC InChI=1S/C9H18N2S/c1-2-3-4-8-7-12-6-5-9(10)11-8/h8H,2-7H2,1H3,(H2,10,11)
DM6A80U CS CCCCC1CSCCC(=N1)N
DM6A80U IK FGUKFZPUKNZRSR-UHFFFAOYSA-N
DM6A80U IU 3-butyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DM6A80U DE Discovery agent
DMXF8M0 ID DMXF8M0
DMXF8M0 DN 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine
DMXF8M0 HS Investigative
DMXF8M0 SN CHEMBL234615; 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine
DMXF8M0 DT Small molecular drug
DMXF8M0 PC 44431763
DMXF8M0 MW 282.4
DMXF8M0 FM C19H26N2
DMXF8M0 IC InChI=1S/C19H26N2/c1-2-3-7-16-14-21(13-12-18(16)20)19-11-6-9-15-8-4-5-10-17(15)19/h4-6,8-11,16,18H,2-3,7,12-14,20H2,1H3
DMXF8M0 CS CCCCC1CN(CCC1N)C2=CC=CC3=CC=CC=C32
DMXF8M0 IK CPKGFALQFTVZTA-UHFFFAOYSA-N
DMXF8M0 IU 3-butyl-1-naphthalen-1-ylpiperidin-4-amine
DMXF8M0 DE Discovery agent
DMDOPVM ID DMDOPVM
DMDOPVM DN 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMDOPVM HS Investigative
DMDOPVM SN CHEMBL132112; 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol; ZINC13728506; BDBM50003343
DMDOPVM DT Small molecular drug
DMDOPVM PC 10376148
DMDOPVM MW 219.32
DMDOPVM FM C14H21NO
DMDOPVM IC InChI=1S/C14H21NO/c1-2-3-9-15-10-7-12-5-4-6-14(16)13(12)8-11-15/h4-6,16H,2-3,7-11H2,1H3
DMDOPVM CS CCCCN1CCC2=C(CC1)C(=CC=C2)O
DMDOPVM IK LLOMAHVTVGHSNN-UHFFFAOYSA-N
DMDOPVM IU 3-butyl-1,2,4,5-tetrahydro-3-benzazepin-6-ol
DMDOPVM DE Discovery agent
DMOGZUK ID DMOGZUK
DMOGZUK DN 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione
DMOGZUK HS Investigative
DMOGZUK SN CHEMBL566476; 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione; SCHEMBL10952562; BDBM50303373
DMOGZUK DT Small molecular drug
DMOGZUK PC 20283207
DMOGZUK MW 245.32
DMOGZUK FM C15H19NO2
DMOGZUK IC InChI=1S/C15H19NO2/c1-3-5-11-15(4-2)13(17)16(14(15)18)12-9-7-6-8-10-12/h6-10H,3-5,11H2,1-2H3
DMOGZUK CS CCCCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC
DMOGZUK IK OMJBWYRKWVXDDX-UHFFFAOYSA-N
DMOGZUK IU 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione
DMOGZUK DE Discovery agent
DM95XWR ID DM95XWR
DM95XWR DN 3-butylaminocarbonyl-6-ethyl-4-quinolone
DM95XWR HS Investigative
DM95XWR SN CHEMBL205536
DM95XWR DT Small molecular drug
DM95XWR PC 11673471
DM95XWR MW 272.34
DM95XWR FM C16H20N2O2
DM95XWR IC InChI=1S/C16H20N2O2/c1-3-5-8-17-16(20)13-10-18-14-7-6-11(4-2)9-12(14)15(13)19/h6-7,9-10H,3-5,8H2,1-2H3,(H,17,20)(H,18,19)
DM95XWR CS CCCCNC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DM95XWR IK QHHMSXBSEWIFOB-UHFFFAOYSA-N
DM95XWR IU N-butyl-6-ethyl-4-oxo-1H-quinoline-3-carboxamide
DM95XWR DE Discovery agent
DMP6TLY ID DMP6TLY
DMP6TLY DN 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid
DMP6TLY HS Investigative
DMP6TLY SN CHEMBL42415; 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid; BDBM50280277; 6-Chloro-3-carbamoyl-1H-indole-2-carboxylic acid
DMP6TLY DT Small molecular drug
DMP6TLY PC 44289108
DMP6TLY MW 238.63
DMP6TLY FM C10H7ClN2O3
DMP6TLY IC InChI=1S/C10H7ClN2O3/c11-4-1-2-5-6(3-4)13-8(10(15)16)7(5)9(12)14/h1-3,13H,(H2,12,14)(H,15,16)
DMP6TLY CS C1=CC2=C(C=C1Cl)NC(=C2C(=O)N)C(=O)O
DMP6TLY IK UVIJBMMICWJDAD-UHFFFAOYSA-N
DMP6TLY IU 3-carbamoyl-6-chloro-1H-indole-2-carboxylic acid
DMP6TLY DE Discovery agent
DM530OW ID DM530OW
DM530OW DN 3'-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate
DM530OW HS Investigative
DM530OW SN CHEMBL451909; 887264-44-0; C26H28N2O3; JP83; MolPort-009-019-196; HMS3650I04; BDBM50275301; 1384AH; ZINC27646193; AKOS027282688; 3'-Carbamoyl-biphenyl-3-yl-hexylphenylcarbamate; SR-01000946289; 3''-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate
DM530OW DT Small molecular drug
DM530OW PC 35027739
DM530OW MW 416.5
DM530OW FM C26H28N2O3
DM530OW IC InChI=1S/C26H28N2O3/c27-25(29)23-15-8-13-21(18-23)22-14-9-16-24(19-22)31-26(30)28-17-7-2-1-4-10-20-11-5-3-6-12-20/h3,5-6,8-9,11-16,18-19H,1-2,4,7,10,17H2,(H2,27,29)(H,28,30)
DM530OW CS C1=CC=C(C=C1)CCCCCCNC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N
DM530OW IK JMLPLSJWSHVJLP-UHFFFAOYSA-N
DM530OW IU [3-(3-carbamoylphenyl)phenyl] N-(6-phenylhexyl)carbamate
DM530OW DE Discovery agent
DMHUBT5 ID DMHUBT5
DMHUBT5 DN 3-Carbazol-9-yl-propionic acid
DMHUBT5 HS Investigative
DMHUBT5 SN 6622-54-4; 3-(9H-carbazol-9-yl)propanoic acid; 3-carbazol-9-ylpropanoic acid; CHEMBL184817; Carbazole-9-propionic acid; NSC400; Carbazol-N-propionsaure; AC1Q75LO; AC1Q5WE7; TimTec1_004366; Oprea1_037143; Oprea1_183633; SCHEMBL150033; 9H-Carbazole-9-propionic acid; AC1L56H9; DTXSID30277021; 3-(carbazol-9-yl)propanoic acid; NSC-400; MolPort-000-474-043; 3-(Carbazol-9-yl)propionic acid; HMS1546G10; NSC54636; ZINC1841595; STK387004; BDBM50152856; 7615AE; BBL007862; SBB010078
DMHUBT5 DT Small molecular drug
DMHUBT5 PC 219301
DMHUBT5 MW 239.27
DMHUBT5 FM C15H13NO2
DMHUBT5 IC InChI=1S/C15H13NO2/c17-15(18)9-10-16-13-7-3-1-5-11(13)12-6-2-4-8-14(12)16/h1-8H,9-10H2,(H,17,18)
DMHUBT5 CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCC(=O)O
DMHUBT5 IK ZAJJJOMMWPVJMH-UHFFFAOYSA-N
DMHUBT5 IU 3-carbazol-9-ylpropanoic acid
DMHUBT5 CA CAS 6622-54-4
DMHUBT5 DE Discovery agent
DMRUX93 ID DMRUX93
DMRUX93 DN 3-carboxy-6-ethyl-4-quinolone
DMRUX93 HS Investigative
DMRUX93 SN 6-ethyl-4-hydroxyquinoline-3-carboxylic acid; 6-Ethyl-4-hydroxy-quinoline-3-carboxylic acid; 103802-41-1; 35128-00-8; 111185-85-4; BAS 02168017; CBMicro_031482; AC1LF0Z6; Cambridge id 6145909; Oprea1_555463; Oprea1_768752; SCHEMBL396402; CHEMBL206122; 3-Quinolinecarboxylic acid, 6-ethyl-1,4-dihydro-4-oxo-; SCHEMBL10032038; CTK6D1895; CTK8F7130; DTXSID70352225; MolPort-000-653-081; MolPort-015-116-184; ZINC3677328; STL229952; 1251AE; SBB015438; AKOS000273237; AKOS009582526; CCG-108136; AB11572; MCULE-1628369792; OR309458
DMRUX93 DT Small molecular drug
DMRUX93 PC 721200
DMRUX93 MW 217.22
DMRUX93 FM C12H11NO3
DMRUX93 IC InChI=1S/C12H11NO3/c1-2-7-3-4-10-8(5-7)11(14)9(6-13-10)12(15)16/h3-6H,2H2,1H3,(H,13,14)(H,15,16)
DMRUX93 CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)O
DMRUX93 IK RESVKOSPFKHQBK-UHFFFAOYSA-N
DMRUX93 IU 6-ethyl-4-oxo-1H-quinoline-3-carboxylic acid
DMRUX93 CA CAS 103802-41-1
DMRUX93 DE Discovery agent
DM9OGNE ID DM9OGNE
DM9OGNE DN 3-chloro-1-(4-hydroxyphenyl)propan-1-one
DM9OGNE HS Investigative
DM9OGNE SN 3-chloro-1-(4-hydroxyphenyl)propan-1-one; 7182-38-9; 3-Chloro-4'-hydroxypropiophenone; CHEMBL500579; NSC46501; AC1Q5ECM; SCHEMBL2392675; AC1L650T; CTK5D5119; DTXSID20286561; QRXBKSZGQHXBDO-UHFFFAOYSA-N; MolPort-022-892-113; ZINC1678195; BDBM50255245; NSC-46501; AKOS022516648; KS-000009D4; SY028371; CS-11693; 1-Propanone,3-chloro-1-(4-hydroxyphenyl)-; MFCD18393259 (97%); 3-Chloro-4 inverted exclamation mark -hydroxypropiophenone
DM9OGNE DT Small molecular drug
DM9OGNE PC 240358
DM9OGNE MW 184.62
DM9OGNE FM C9H9ClO2
DM9OGNE IC InChI=1S/C9H9ClO2/c10-6-5-9(12)7-1-3-8(11)4-2-7/h1-4,11H,5-6H2
DM9OGNE CS C1=CC(=CC=C1C(=O)CCCl)O
DM9OGNE IK QRXBKSZGQHXBDO-UHFFFAOYSA-N
DM9OGNE IU 3-chloro-1-(4-hydroxyphenyl)propan-1-one
DM9OGNE CA CAS 7182-38-9
DM9OGNE DE Discovery agent
DM3R8OM ID DM3R8OM
DM3R8OM DN 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
DM3R8OM HS Investigative
DM3R8OM SN 3-chloro-2-(4-hydroxyphenyl)-2H-indazol-5-ol; 848142-62-1; 3-chloro-2-(4-hydroxyphenyl)indazol-5-ol; CHEMBL180071; CTK2I5101; DTXSID40463812; Indazole-Cl, > ZINC13609473; AKOS030536245; DB07708; 2-(p-Hydroxyphenyl)-3-chloro-2H-indazole-5-ol; 2H-Indazol-5-ol, 3-chloro-2-(4-hydroxyphenyl)-
DM3R8OM DT Small molecular drug
DM3R8OM PC 11368987
DM3R8OM MW 260.67
DM3R8OM FM C13H9ClN2O2
DM3R8OM IC InChI=1S/C13H9ClN2O2/c14-13-11-7-10(18)5-6-12(11)15-16(13)8-1-3-9(17)4-2-8/h1-7,17-18H
DM3R8OM CS C1=CC(=CC=C1N2C(=C3C=C(C=CC3=N2)O)Cl)O
DM3R8OM IK ZNHQDSBJVFFIAK-UHFFFAOYSA-N
DM3R8OM IU 3-chloro-2-(4-hydroxyphenyl)indazol-5-ol
DM3R8OM CA CAS 848142-62-1
DM3R8OM DE Discovery agent
DMZ5JFG ID DMZ5JFG
DMZ5JFG DN 3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG HS Investigative
DMZ5JFG SN CHEMBL198887; 3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG DT Small molecular drug
DMZ5JFG PC 44405331
DMZ5JFG MW 298.12
DMZ5JFG FM C13H9Cl2NO3
DMZ5JFG IC InChI=1S/C13H9Cl2NO3/c14-8-2-4-12(10(17)6-8)19-11-3-1-7(13(16)18)5-9(11)15/h1-6,17H,(H2,16,18)
DMZ5JFG CS C1=CC(=C(C=C1C(=O)N)Cl)OC2=C(C=C(C=C2)Cl)O
DMZ5JFG IK XMCNGTFAEHHMRY-UHFFFAOYSA-N
DMZ5JFG IU 3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
DMZ5JFG DE Discovery agent
DMER4U1 ID DMER4U1
DMER4U1 DN 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime
DMER4U1 HS Investigative
DMER4U1 DT Small molecular drug
DMER4U1 PC 91066436
DMER4U1 MW 263.67
DMER4U1 FM C13H10ClNO3
DMER4U1 IC InChI=1S/C13H10ClNO3/c14-12-11(8-1-4-10(16)5-2-8)6-3-9(7-15-18)13(12)17/h1-6,16-17H,7H2
DMER4U1 CS C1=CC(=CC=C1C2=C(C(=C(C=C2)CN=O)O)Cl)O
DMER4U1 IK CIYDFCOZUPKHFA-UHFFFAOYSA-N
DMER4U1 IU 2-chloro-3-(4-hydroxyphenyl)-6-(nitrosomethyl)phenol
DMER4U1 DE Discovery agent
DMNQF03 ID DMNQF03
DMNQF03 DN 3-chloro-4-(o-tolyloxy)benzonitrile
DMNQF03 HS Investigative
DMNQF03 SN CHEMBL490955; 3-chloro-4-(o-tolyloxy)benzonitrile; SCHEMBL4168825; BDBM50248505
DMNQF03 DT Small molecular drug
DMNQF03 PC 11673174
DMNQF03 MW 243.69
DMNQF03 FM C14H10ClNO
DMNQF03 IC InChI=1S/C14H10ClNO/c1-10-4-2-3-5-13(10)17-14-7-6-11(9-16)8-12(14)15/h2-8H,1H3
DMNQF03 CS CC1=CC=CC=C1OC2=C(C=C(C=C2)C#N)Cl
DMNQF03 IK LMZHFUQMQDTSFO-UHFFFAOYSA-N
DMNQF03 IU 3-chloro-4-(2-methylphenoxy)benzonitrile
DMNQF03 DE Discovery agent
DM6Z3I8 ID DM6Z3I8
DM6Z3I8 DN 3-chloro-4-(o-tolylthio)benzonitrile
DM6Z3I8 HS Investigative
DM6Z3I8 SN CHEMBL490956; 3-chloro-4-(o-tolylthio)benzonitrile; BDBM50248506
DM6Z3I8 DT Small molecular drug
DM6Z3I8 PC 44565102
DM6Z3I8 MW 259.8
DM6Z3I8 FM C14H10ClNS
DM6Z3I8 IC InChI=1S/C14H10ClNS/c1-10-4-2-3-5-13(10)17-14-7-6-11(9-16)8-12(14)15/h2-8H,1H3
DM6Z3I8 CS CC1=CC=CC=C1SC2=C(C=C(C=C2)C#N)Cl
DM6Z3I8 IK XNDBEERQWNGTKH-UHFFFAOYSA-N
DM6Z3I8 IU 3-chloro-4-(2-methylphenyl)sulfanylbenzonitrile
DM6Z3I8 DE Discovery agent
DMSB5IQ ID DMSB5IQ
DMSB5IQ DN 3-Chloro-4-hydrazino-benzenesulfonamide
DMSB5IQ HS Investigative
DMSB5IQ SN 3-chloro-4-hydrazino-benzenesulphonamide; 776281-37-9; hydrazide deriv. 16; SCHEMBL3952309; CHEMBL176203; CTK2G6221; BDBM12161; DTXSID30461261; MIIRMBFCBFPOKU-UHFFFAOYSA-N; 4-Hydrazino-3-chlorobenzenesulfonamide; AKOS030585345; Benzenesulfonamide, 3-chloro-4-hydrazino-
DMSB5IQ DT Small molecular drug
DMSB5IQ PC 11287480
DMSB5IQ MW 221.67
DMSB5IQ FM C6H8ClN3O2S
DMSB5IQ IC InChI=1S/C6H8ClN3O2S/c7-5-3-4(13(9,11)12)1-2-6(5)10-8/h1-3,10H,8H2,(H2,9,11,12)
DMSB5IQ CS C1=CC(=C(C=C1S(=O)(=O)N)Cl)NN
DMSB5IQ IK MIIRMBFCBFPOKU-UHFFFAOYSA-N
DMSB5IQ IU 3-chloro-4-hydrazinylbenzenesulfonamide
DMSB5IQ CA CAS 776281-37-9
DMSB5IQ DE Discovery agent
DMBMH96 ID DMBMH96
DMBMH96 DN 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile
DMBMH96 HS Investigative
DMBMH96 SN CHEMBL396135; 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4297824
DMBMH96 DT Small molecular drug
DMBMH96 PC 44432675
DMBMH96 MW 278.7
DMBMH96 FM C17H11ClN2
DMBMH96 IC InChI=1S/C17H11ClN2/c1-11-2-3-13-4-5-14(9-17(13)20-11)15-6-12(10-19)7-16(18)8-15/h2-9H,1H3
DMBMH96 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)Cl
DMBMH96 IK NJKOTXYVFGIDOL-UHFFFAOYSA-N
DMBMH96 IU 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile
DMBMH96 DE Discovery agent
DMCD901 ID DMCD901
DMCD901 DN 3-Chloro-9H-beta-carboline
DMCD901 HS Investigative
DMCD901 SN 3-chloro-9H-pyrido[3,4-b]indole; CHEMBL298561; 91985-80-7; 3-Chloro-9H-beta-carboline; 3-chloro-b-carboline; 3-Chloro-beta-carboline; AC1O2G3D; CHEMBL496742; SCHEMBL10642293; BDBM50013805; 9H-Pyrido[3,4-b]indole, 3-chloro-
DMCD901 DT Small molecular drug
DMCD901 PC 6198020
DMCD901 MW 202.64
DMCD901 FM C11H7ClN2
DMCD901 IC InChI=1S/C11H7ClN2/c12-11-5-8-7-3-1-2-4-9(7)14-10(8)6-13-11/h1-6,14H
DMCD901 CS C1=CC=C2C(=C1)C3=CC(=NC=C3N2)Cl
DMCD901 IK JDYLMOJCIKYTGV-UHFFFAOYSA-N
DMCD901 IU 3-chloro-9H-pyrido[3,4-b]indole
DMCD901 DE Discovery agent
DM5J1TX ID DM5J1TX
DM5J1TX DN 3-Chloroboldine
DM5J1TX HS Investigative
DM5J1TX SN 3-Chloroboldine; CHEMBL524439
DM5J1TX DT Small molecular drug
DM5J1TX PC 10406315
DM5J1TX MW 361.8
DM5J1TX FM C19H20ClNO4
DM5J1TX IC InChI=1S/C19H20ClNO4/c1-21-5-4-10-15-12(21)6-9-7-13(22)14(24-2)8-11(9)16(15)19(25-3)18(23)17(10)20/h7-8,12,22-23H,4-6H2,1-3H3/t12-/m0/s1
DM5J1TX CS CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2Cl)O)OC)OC)O
DM5J1TX IK HRPJZDTZANKXQI-LBPRGKRZSA-N
DM5J1TX IU (6aS)-3-chloro-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM5J1TX DE Discovery agent
DMIEZGD ID DMIEZGD
DMIEZGD DN 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMIEZGD HS Investigative
DMIEZGD SN CHEMBL1253604; 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide; BDBM50326843
DMIEZGD DT Small molecular drug
DMIEZGD PC 24219273
DMIEZGD MW 284.74
DMIEZGD FM C16H13ClN2O
DMIEZGD IC InChI=1S/C16H13ClN2O/c1-10-7-12-9-14(5-6-15(12)18-10)19-16(20)11-3-2-4-13(17)8-11/h2-9,18H,1H3,(H,19,20)
DMIEZGD CS CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3=CC(=CC=C3)Cl
DMIEZGD IK SSPHXZNBIVJTMG-UHFFFAOYSA-N
DMIEZGD IU 3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
DMIEZGD DE Discovery agent
DMV8TNO ID DMV8TNO
DMV8TNO DN 3-chloro-N-(3-isobutyramidophenyl)benzamide
DMV8TNO HS Investigative
DMV8TNO SN CHEMBL1081896; 3-chloro-N-[3-(isobutyrylamino)phenyl]benzamide; 3-chloro-N-(3-isobutyramidophenyl)benzamide; AC1LR77A; Oprea1_474979; 3-chloro-N-[3-(2-methylpropanoylamino)phenyl]benzamide; MolPort-003-001-488; ZINC1207329; BDBM50312135; STK319961; AKOS000471367; MCULE-7229085520; AP-970/13572856
DMV8TNO DT Small molecular drug
DMV8TNO PC 1363600
DMV8TNO MW 316.8
DMV8TNO FM C17H17ClN2O2
DMV8TNO IC InChI=1S/C17H17ClN2O2/c1-11(2)16(21)19-14-7-4-8-15(10-14)20-17(22)12-5-3-6-13(18)9-12/h3-11H,1-2H3,(H,19,21)(H,20,22)
DMV8TNO CS CC(C)C(=O)NC1=CC=CC(=C1)NC(=O)C2=CC(=CC=C2)Cl
DMV8TNO IK ZXAGKBUSUTVPML-UHFFFAOYSA-N
DMV8TNO IU 3-chloro-N-[3-(2-methylpropanoylamino)phenyl]benzamide
DMV8TNO DE Discovery agent
DMBVCLY ID DMBVCLY
DMBVCLY DN 3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide
DMBVCLY HS Investigative
DMBVCLY SN CHEMBL566920; 3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide; 3-chloro-N-[4-(phenyldiazenyl)phenyl]benzamide; AC1MEGAF; MLS000571688; CHEMBL1585037; MolPort-002-176-797; HMS2431J18; ZINC18006916; BDBM50303375; AKOS002249913; MCULE-8045658796; SMR000193697; 3-chloro-N-(4-phenyldiazenylphenyl)benzamide; ST50752429
DMBVCLY DT Small molecular drug
DMBVCLY PC 2877914
DMBVCLY MW 335.8
DMBVCLY FM C19H14ClN3O
DMBVCLY IC InChI=1S/C19H14ClN3O/c20-15-6-4-5-14(13-15)19(24)21-16-9-11-18(12-10-16)23-22-17-7-2-1-3-8-17/h1-13H,(H,21,24)
DMBVCLY CS C1=CC=C(C=C1)N=NC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)Cl
DMBVCLY IK BVHXJXQDOFAUQY-UHFFFAOYSA-N
DMBVCLY IU 3-chloro-N-(4-phenyldiazenylphenyl)benzamide
DMBVCLY DE Discovery agent
DM4EL6M ID DM4EL6M
DM4EL6M DN 3-chloro-N-(4-methylthiazol-2-yl)benzamide
DM4EL6M HS Investigative
DM4EL6M SN 3-chloro-N-(4-methyl-1,3-thiazol-2-yl)benzamide; CHEMBL212529; 3-chloro-N-(4-methylthiazol-2-yl)benzamide; AC1LI75J; MolPort-003-812-188; ZINC477397; BDBM50186320; AKOS003848769; MCULE-7000942763
DM4EL6M DT Small molecular drug
DM4EL6M PC 899301
DM4EL6M MW 252.72
DM4EL6M FM C11H9ClN2OS
DM4EL6M IC InChI=1S/C11H9ClN2OS/c1-7-6-16-11(13-7)14-10(15)8-3-2-4-9(12)5-8/h2-6H,1H3,(H,13,14,15)
DM4EL6M CS CC1=CSC(=N1)NC(=O)C2=CC(=CC=C2)Cl
DM4EL6M IK MXGUAAMFCPDOEZ-UHFFFAOYSA-N
DM4EL6M IU 3-chloro-N-(4-methyl-1,3-thiazol-2-yl)benzamide
DM4EL6M DE Discovery agent
DMAWC7S ID DMAWC7S
DMAWC7S DN 3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMAWC7S HS Investigative
DMAWC7S SN 3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide; CHEMBL61222; AC1LFIX3; Oprea1_263322; Oprea1_095427; SCHEMBL2754070; 2-[(3-chlorophenyl)carboxamido]-4-phenyl-1,3-thiazole; OHXHEHNTSIBWMV-UHFFFAOYSA-N; MolPort-001-997-617; ZINC208080; BDBM50101789; AKOS000651093; MCULE-4878334658; BAS 04456777; 50591-72-5; N-(4-Phenyl-2-thiazolyl)-3-chlorobenzamide
DMAWC7S DT Small molecular drug
DMAWC7S PC 754492
DMAWC7S MW 314.8
DMAWC7S FM C16H11ClN2OS
DMAWC7S IC InChI=1S/C16H11ClN2OS/c17-13-8-4-7-12(9-13)15(20)19-16-18-14(10-21-16)11-5-2-1-3-6-11/h1-10H,(H,18,19,20)
DMAWC7S CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC(=CC=C3)Cl
DMAWC7S IK OHXHEHNTSIBWMV-UHFFFAOYSA-N
DMAWC7S IU 3-chloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMAWC7S DE Discovery agent
DMLC2I6 ID DMLC2I6
DMLC2I6 DN 3-chloro-N-(6-chloropyridin-2-yl)benzamide
DMLC2I6 HS Investigative
DMLC2I6 SN CHEMBL208976; 3-chloro-N-(6-chloropyridin-2-yl)benzamide; BDBM50186322
DMLC2I6 DT Small molecular drug
DMLC2I6 PC 44412923
DMLC2I6 MW 267.11
DMLC2I6 FM C12H8Cl2N2O
DMLC2I6 IC InChI=1S/C12H8Cl2N2O/c13-9-4-1-3-8(7-9)12(17)16-11-6-2-5-10(14)15-11/h1-7H,(H,15,16,17)
DMLC2I6 CS C1=CC(=CC(=C1)Cl)C(=O)NC2=NC(=CC=C2)Cl
DMLC2I6 IK FCJWDXAXERKUEZ-UHFFFAOYSA-N
DMLC2I6 IU 3-chloro-N-(6-chloropyridin-2-yl)benzamide
DMLC2I6 DE Discovery agent
DMLJGF1 ID DMLJGF1
DMLJGF1 DN 3-chloro-N-(6-methylpyridin-2-yl)benzamide
DMLJGF1 HS Investigative
DMLJGF1 SN 3-chloro-N-(6-methylpyridin-2-yl)benzamide; CHEMBL377829; AC1LHBCW; Oprea1_422679; ZINC361715; BDBM50186323; STK028098; AKOS003227907; MCULE-3037986633; ST51016900
DMLJGF1 DT Small molecular drug
DMLJGF1 PC 835261
DMLJGF1 MW 246.69
DMLJGF1 FM C13H11ClN2O
DMLJGF1 IC InChI=1S/C13H11ClN2O/c1-9-4-2-7-12(15-9)16-13(17)10-5-3-6-11(14)8-10/h2-8H,1H3,(H,15,16,17)
DMLJGF1 CS CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)Cl
DMLJGF1 IK HNLLGNJHYQMYEI-UHFFFAOYSA-N
DMLJGF1 IU 3-chloro-N-(6-methylpyridin-2-yl)benzamide
DMLJGF1 DE Discovery agent
DMQCVKO ID DMQCVKO
DMQCVKO DN 3-chlorophenyl 10H-phenothiazine-10-carboxylate
DMQCVKO HS Investigative
DMQCVKO SN CHEMBL481529; 3-chlorophenyl 10H-phenothiazine-10-carboxylate
DMQCVKO DT Small molecular drug
DMQCVKO PC 24905653
DMQCVKO MW 353.8
DMQCVKO FM C19H12ClNO2S
DMQCVKO IC InChI=1S/C19H12ClNO2S/c20-13-6-5-7-14(12-13)23-19(22)21-15-8-1-3-10-17(15)24-18-11-4-2-9-16(18)21/h1-12H
DMQCVKO CS C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)OC4=CC(=CC=C4)Cl
DMQCVKO IK IXZXEECBRFSNPQ-UHFFFAOYSA-N
DMQCVKO IU (3-chlorophenyl) phenothiazine-10-carboxylate
DMQCVKO DE Discovery agent
DMZ0F7E ID DMZ0F7E
DMZ0F7E DN 3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate
DMZ0F7E HS Investigative
DMZ0F7E SN CHEMBL199203; SCHEMBL7682509; 2-Oxo-2H-1-benzopyran-3-carboxylic acid 3-chlorophenyl ester
DMZ0F7E DT Small molecular drug
DMZ0F7E PC 11616411
DMZ0F7E MW 300.69
DMZ0F7E FM C16H9ClO4
DMZ0F7E IC InChI=1S/C16H9ClO4/c17-11-5-3-6-12(9-11)20-15(18)13-8-10-4-1-2-7-14(10)21-16(13)19/h1-9H
DMZ0F7E CS C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)OC3=CC(=CC=C3)Cl
DMZ0F7E IK HDIMJBWUBWTFNJ-UHFFFAOYSA-N
DMZ0F7E IU (3-chlorophenyl) 2-oxochromene-3-carboxylate
DMZ0F7E DE Discovery agent
DMJ2SZ1 ID DMJ2SZ1
DMJ2SZ1 DN 3-chlorophenyl 4-butoxybenzylcarbamate
DMJ2SZ1 HS Investigative
DMJ2SZ1 SN 3-chlorophenyl 4-butoxybenzylcarbamate; CHEMBL596874; SCHEMBL5222756
DMJ2SZ1 DT Small molecular drug
DMJ2SZ1 PC 20872705
DMJ2SZ1 MW 333.8
DMJ2SZ1 FM C18H20ClNO3
DMJ2SZ1 IC InChI=1S/C18H20ClNO3/c1-2-3-11-22-16-9-7-14(8-10-16)13-20-18(21)23-17-6-4-5-15(19)12-17/h4-10,12H,2-3,11,13H2,1H3,(H,20,21)
DMJ2SZ1 CS CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC(=CC=C2)Cl
DMJ2SZ1 IK RFAALCRYXIMHGO-UHFFFAOYSA-N
DMJ2SZ1 IU (3-chlorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DMJ2SZ1 DE Discovery agent
DMJ4SDM ID DMJ4SDM
DMJ4SDM DN 3-chlorotyrosine
DMJ4SDM HS Investigative
DMJ4SDM SN Monochlorotyrosine; Tyrosine, 3-chloro-; 3-Chloro-DL-tyrosine; C9H10ClNO3; 2-amino-3-(3-chloro-4-hydroxyphenyl)propanoic acid; 7298-90-0; AC1L3OFH; AC1Q3M6L; SCHEMBL157442; L-(8CI)-3-chloro-Tyrosine; GTPL5114; CTK7I4440; ACWBBAGYTKWBCD-UHFFFAOYSA-N; AKOS009158821; VZ26714; MCULE-5698335509; KB-31251; LS-177012; A838069; 2-azanyl-3-(3-chloranyl-4-oxidanyl-phenyl)propanoic acid
DMJ4SDM DT Small molecular drug
DMJ4SDM PC 110992
DMJ4SDM MW 215.63
DMJ4SDM FM C9H10ClNO3
DMJ4SDM IC InChI=1S/C9H10ClNO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1
DMJ4SDM CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)Cl)O
DMJ4SDM IK ACWBBAGYTKWBCD-ZETCQYMHSA-N
DMJ4SDM IU (2S)-2-amino-3-(3-chloro-4-hydroxyphenyl)propanoic acid
DMJ4SDM CA CAS 7423-93-0
DMJ4SDM CB CHEBI:53678
DMJ4SDM DE Discovery agent
DM78FWG ID DM78FWG
DM78FWG DN 3-cis-p-coumaroyl maslinic acid
DM78FWG HS Investigative
DM78FWG SN CHEMBL463995; 3-cis-p-coumaroyl maslinic acid
DM78FWG DT Small molecular drug
DM78FWG PC 16664518
DM78FWG MW 602.8
DM78FWG FM C39H54O5
DM78FWG IC InChI=1S/C39H54O5/c1-34(2)19-21-39(33(42)43)22-20-37(6)26(27(39)23-34)14-15-30-36(5)24-28(40)32(35(3,4)29(36)17-18-38(30,37)7)44-31(41)16-13-25-11-9-8-10-12-25/h8-14,16,27-30,32,40H,15,17-24H2,1-7H3,(H,42,43)/b16-13-/t27-,28+,29-,30+,32-,36-,37+,38+,39-/m0/s1
DM78FWG CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)OC(=O)/C=C\\C6=CC=CC=C6)O)C
DM78FWG IK QYNZDAXHBDWWFS-GZOAODGCSA-N
DM78FWG IU (4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(Z)-3-phenylprop-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM78FWG DE Discovery agent
DMF1PIW ID DMF1PIW
DMF1PIW DN 3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW HS Investigative
DMF1PIW SN CHEMBL1209394; 3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW DT Small molecular drug
DMF1PIW PC 49862433
DMF1PIW MW 258.22
DMF1PIW FM C14H8F2N2O
DMF1PIW IC InChI=1S/C14H8F2N2O/c15-11-2-1-3-13(7-11)18-14(19)10-4-9(8-17)5-12(16)6-10/h1-7H,(H,18,19)
DMF1PIW CS C1=CC(=CC(=C1)F)NC(=O)C2=CC(=CC(=C2)C#N)F
DMF1PIW IK PXKKWNKVXLXAEB-UHFFFAOYSA-N
DMF1PIW IU 3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide
DMF1PIW DE Discovery agent
DMBA4XN ID DMBA4XN
DMBA4XN DN 3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide
DMBA4XN HS Investigative
DMBA4XN SN CHEMBL1209204; 3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide
DMBA4XN DT Small molecular drug
DMBA4XN PC 49862277
DMBA4XN MW 241.22
DMBA4XN FM C13H8FN3O
DMBA4XN IC InChI=1S/C13H8FN3O/c14-11-6-9(8-15)5-10(7-11)13(18)17-12-3-1-2-4-16-12/h1-7H,(H,16,17,18)
DMBA4XN CS C1=CC=NC(=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMBA4XN IK QSQNDNOCUDDTAZ-UHFFFAOYSA-N
DMBA4XN IU 3-cyano-5-fluoro-N-pyridin-2-ylbenzamide
DMBA4XN DE Discovery agent
DMF097H ID DMF097H
DMF097H DN 3-cyano-5-fluoro-N-m-tolylbenzamide
DMF097H HS Investigative
DMF097H SN CHEMBL1209203; 3-cyano-5-fluoro-N-m-tolylbenzamide
DMF097H DT Small molecular drug
DMF097H PC 49862276
DMF097H MW 254.26
DMF097H FM C15H11FN2O
DMF097H IC InChI=1S/C15H11FN2O/c1-10-3-2-4-14(5-10)18-15(19)12-6-11(9-17)7-13(16)8-12/h2-8H,1H3,(H,18,19)
DMF097H CS CC1=CC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMF097H IK JHLDQKUSWAUHCQ-UHFFFAOYSA-N
DMF097H IU 3-cyano-5-fluoro-N-(3-methylphenyl)benzamide
DMF097H DE Discovery agent
DMIZ8RC ID DMIZ8RC
DMIZ8RC DN 3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC HS Investigative
DMIZ8RC SN CHEMBL1209392; 3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC DT Small molecular drug
DMIZ8RC PC 49862431
DMIZ8RC MW 240.23
DMIZ8RC FM C14H9FN2O
DMIZ8RC IC InChI=1S/C14H9FN2O/c15-12-7-10(9-16)6-11(8-12)14(18)17-13-4-2-1-3-5-13/h1-8H,(H,17,18)
DMIZ8RC CS C1=CC=C(C=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMIZ8RC IK MCCCAUONCIKYRV-UHFFFAOYSA-N
DMIZ8RC IU 3-cyano-5-fluoro-N-phenylbenzamide
DMIZ8RC DE Discovery agent
DMH7FC9 ID DMH7FC9
DMH7FC9 DN 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMH7FC9 HS Investigative
DMH7FC9 SN 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; CDPPB; 781652-57-1; mGluR5 Ligand, CDPPB; CHEMBL190270; GTPL1422; SCHEMBL1823352; CTK5E5464; DTXSID80459996; MolPort-009-199-287; ZINC3986698; BDBM50156071; IN1239; AKOS024457497; RTC-070344; NCGC00370800-01; KB-75992; EN002594; TC-070344; DB-075421; FT-0763465; B7324; A9858; 3-cyano-N-[2,5-di(phenyl)pyrazol-3-yl]benzamide; 3-Cyano-N-1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMH7FC9 DT Small molecular drug
DMH7FC9 PC 11245456
DMH7FC9 MW 364.4
DMH7FC9 FM C23H16N4O
DMH7FC9 IC InChI=1S/C23H16N4O/c24-16-17-8-7-11-19(14-17)23(28)25-22-15-21(18-9-3-1-4-10-18)26-27(22)20-12-5-2-6-13-20/h1-15H,(H,25,28)
DMH7FC9 CS C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=CC(=C3)C#N)C4=CC=CC=C4
DMH7FC9 IK BKUIZWILNWHFHD-UHFFFAOYSA-N
DMH7FC9 IU 3-cyano-N-(2,5-diphenylpyrazol-3-yl)benzamide
DMH7FC9 CA CAS 781652-57-1
DMH7FC9 DE Discovery agent
DM3EIWC ID DM3EIWC
DM3EIWC DN 3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DM3EIWC HS Investigative
DM3EIWC SN CHEMBL210488; 3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DM3EIWC DT Small molecular drug
DM3EIWC PC 11494297
DM3EIWC MW 364.4
DM3EIWC FM C23H16N4O
DM3EIWC IC InChI=1S/C23H16N4O/c24-15-17-8-7-11-19(14-17)23(28)26-22-21(18-9-3-1-4-10-18)16-25-27(22)20-12-5-2-6-13-20/h1-14,16H,(H,26,28)
DM3EIWC CS C1=CC=C(C=C1)C2=C(N(N=C2)C3=CC=CC=C3)NC(=O)C4=CC=CC(=C4)C#N
DM3EIWC IK ZNMCOYKAPQGPBZ-UHFFFAOYSA-N
DM3EIWC IU 3-cyano-N-(2,4-diphenylpyrazol-3-yl)benzamide
DM3EIWC DE Discovery agent
DMRD8VM ID DMRD8VM
DMRD8VM DN 3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM HS Investigative
DMRD8VM SN CHEMBL1209548; 3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM DT Small molecular drug
DMRD8VM PC 49862542
DMRD8VM MW 265.24
DMRD8VM FM C15H8FN3O
DMRD8VM IC InChI=1S/C15H8FN3O/c16-13-5-11(9-18)4-12(7-13)15(20)19-14-3-1-2-10(6-14)8-17/h1-7H,(H,19,20)
DMRD8VM CS C1=CC(=CC(=C1)NC(=O)C2=CC(=CC(=C2)C#N)F)C#N
DMRD8VM IK YKPYRZLWZZAYPC-UHFFFAOYSA-N
DMRD8VM IU 3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide
DMRD8VM DE Discovery agent
DMFUT57 ID DMFUT57
DMFUT57 DN 3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57 HS Investigative
DMFUT57 SN CHEMBL1209550; 3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57 DT Small molecular drug
DMFUT57 PC 49862544
DMFUT57 MW 268.28
DMFUT57 FM C16H13FN2O
DMFUT57 IC InChI=1S/C16H13FN2O/c1-2-11-4-3-5-15(8-11)19-16(20)13-6-12(10-18)7-14(17)9-13/h3-9H,2H2,1H3,(H,19,20)
DMFUT57 CS CCC1=CC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMFUT57 IK FGYATISUHIGFJB-UHFFFAOYSA-N
DMFUT57 IU 3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide
DMFUT57 DE Discovery agent
DM9FEMV ID DM9FEMV
DM9FEMV DN 3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV HS Investigative
DM9FEMV SN CHEMBL1209549; 3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV DT Small molecular drug
DM9FEMV PC 49862543
DM9FEMV MW 264.25
DM9FEMV FM C16H9FN2O
DM9FEMV IC InChI=1S/C16H9FN2O/c1-2-11-4-3-5-15(8-11)19-16(20)13-6-12(10-18)7-14(17)9-13/h1,3-9H,(H,19,20)
DM9FEMV CS C#CC1=CC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DM9FEMV IK WPLAMCXDNWYUEU-UHFFFAOYSA-N
DM9FEMV IU 3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide
DM9FEMV DE Discovery agent
DMUB9XW ID DMUB9XW
DMUB9XW DN 3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW HS Investigative
DMUB9XW SN CHEMBL1209330; 3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW DT Small molecular drug
DMUB9XW PC 49862385
DMUB9XW MW 269.27
DMUB9XW FM C15H12FN3O
DMUB9XW IC InChI=1S/C15H12FN3O/c1-2-13-4-3-5-14(18-13)19-15(20)11-6-10(9-17)7-12(16)8-11/h3-8H,2H2,1H3,(H,18,19,20)
DMUB9XW CS CCC1=NC(=CC=C1)NC(=O)C2=CC(=CC(=C2)C#N)F
DMUB9XW IK LBPUNEZWEHBQQO-UHFFFAOYSA-N
DMUB9XW IU 3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide
DMUB9XW DE Discovery agent
DMTDEYL ID DMTDEYL
DMTDEYL DN 3-cyano-N-(6-methylpyridin-2-yl)benzamide
DMTDEYL HS Investigative
DMTDEYL SN 3-cyano-N-(6-methylpyridin-2-yl)benzamide; CHEMBL208927; 900801-18-5; benzamide,3-cyano-n-(6-methyl-2-pyridinyl)-; MolPort-004-359-738; ZINC12545036; BDBM50186330; AKOS000205559; MCULE-1984522308; SC-60782; KB-270891
DMTDEYL DT Small molecular drug
DMTDEYL PC 16007001
DMTDEYL MW 237.26
DMTDEYL FM C14H11N3O
DMTDEYL IC InChI=1S/C14H11N3O/c1-10-4-2-7-13(16-10)17-14(18)12-6-3-5-11(8-12)9-15/h2-8H,1H3,(H,16,17,18)
DMTDEYL CS CC1=NC(=CC=C1)NC(=O)C2=CC=CC(=C2)C#N
DMTDEYL IK HRIDAJBBAATPGT-UHFFFAOYSA-N
DMTDEYL IU 3-cyano-N-(6-methylpyridin-2-yl)benzamide
DMTDEYL DE Discovery agent
DMPWR90 ID DMPWR90
DMPWR90 DN 3-cyanophenylboronic acid
DMPWR90 HS Investigative
DMPWR90 SN 3-Cyanophenylboronic acid; 150255-96-2; (3-cyanophenyl)boronic Acid; 3-Cyanobenzeneboronic Acid; 3-Boronobenzonitrile; 3-(dihydroxyboranyl)benzonitrile; 3-cyanophenyl boronic acid; 3-cyanobenzene boronic acid; 3-cyano-phenyl-boronic acid; Boronic acid, B-(3-cyanophenyl)-; MFCD01318967; BORONIC ACID, (3-CYANOPHENYL)-; PubChem1804; Phenylboronic Acid, 4; m-cyanophenyl boronic acid; 3-cyano-phenylboronic acid; 3-cyano phenylboronic acid; 3-cyanophenyl-boronic acid; 3-Cyanophenylboronic acid; 3-Cyanophenylboronic acid,
DMPWR90 DT Small molecular drug
DMPWR90 PC 2734325
DMPWR90 MW 146.94
DMPWR90 FM C7H6BNO2
DMPWR90 IC InChI=1S/C7H6BNO2/c9-5-6-2-1-3-7(4-6)8(10)11/h1-4,10-11H
DMPWR90 CS B(C1=CC(=CC=C1)C#N)(O)O
DMPWR90 IK XDBHWPLGGBLUHH-UHFFFAOYSA-N
DMPWR90 IU (3-cyanophenyl)boronic acid
DMPWR90 CA CAS 150255-96-2
DMPWR90 DE Discovery agent
DMJSOTE ID DMJSOTE
DMJSOTE DN 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE HS Investigative
DMJSOTE SN CHEMBL77258; 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide
DMJSOTE DT Small molecular drug
DMJSOTE PC 10565532
DMJSOTE MW 291.41
DMJSOTE FM C13H25NO4S
DMJSOTE IC InChI=1S/C13H25NO4S/c1-2-3-7-12(10-13(15)14-16)19(17,18)11-8-5-4-6-9-11/h11-12,16H,2-10H2,1H3,(H,14,15)
DMJSOTE CS CCCCC(CC(=O)NO)S(=O)(=O)C1CCCCC1
DMJSOTE IK LUHJAOVICRNTRC-UHFFFAOYSA-N
DMJSOTE IU 3-cyclohexylsulfonyl-N-hydroxyheptanamide
DMJSOTE DE Discovery agent
DMWMFZ3 ID DMWMFZ3
DMWMFZ3 DN 3-Cyclohexyl-1-propyl-piperidine hydrochloride
DMWMFZ3 HS Investigative
DMWMFZ3 DE Discovery agent
DMCQ6J8 ID DMCQ6J8
DMCQ6J8 DN 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline
DMCQ6J8 HS Investigative
DMCQ6J8 SN CHEMBL63575; 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline; SCHEMBL8172563; MBQNQJQVMOFJOD-UHFFFAOYSA-N; ZINC8552727; BDBM50039040
DMCQ6J8 DT Small molecular drug
DMCQ6J8 PC 10402251
DMCQ6J8 MW 295.4
DMCQ6J8 FM C19H21NO2
DMCQ6J8 IC InChI=1S/C19H21NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h10-14H,3-7H2,1-2H3
DMCQ6J8 CS COC1=CC2=CC(=CN=C2C=C1OC)C#CC3CCCCC3
DMCQ6J8 IK MBQNQJQVMOFJOD-UHFFFAOYSA-N
DMCQ6J8 IU 3-(2-cyclohexylethynyl)-6,7-dimethoxyquinoline
DMCQ6J8 DE Discovery agent
DM1FSZM ID DM1FSZM
DM1FSZM DN 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline
DM1FSZM HS Investigative
DM1FSZM SN CHEMBL66618; 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline; ZINC8079; SCHEMBL4364039; BDBM50039090
DM1FSZM DT Small molecular drug
DM1FSZM PC 10083699
DM1FSZM MW 255.31
DM1FSZM FM C16H17NO2
DM1FSZM IC InChI=1S/C16H17NO2/c1-18-15-8-12-7-13(11-5-3-4-6-11)10-17-14(12)9-16(15)19-2/h5,7-10H,3-4,6H2,1-2H3
DM1FSZM CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CCCC3
DM1FSZM IK DVMMSUYWABLYCR-UHFFFAOYSA-N
DM1FSZM IU 3-(cyclopenten-1-yl)-6,7-dimethoxyquinoline
DM1FSZM DE Discovery agent
DMEL8S5 ID DMEL8S5
DMEL8S5 DN 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone
DMEL8S5 HS Investigative
DMEL8S5 SN CHEMBL202724
DMEL8S5 DT Small molecular drug
DMEL8S5 PC 11565450
DMEL8S5 MW 285.34
DMEL8S5 FM C17H19NO3
DMEL8S5 IC InChI=1S/C17H19NO3/c1-2-11-7-8-15-13(9-11)16(19)14(10-18-15)17(20)21-12-5-3-4-6-12/h7-10,12H,2-6H2,1H3,(H,18,19)
DMEL8S5 CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OC3CCCC3
DMEL8S5 IK XLRFFZMGTKMUJJ-UHFFFAOYSA-N
DMEL8S5 IU cyclopentyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMEL8S5 DE Discovery agent
DMS7B6T ID DMS7B6T
DMS7B6T DN 3-Cyclopentyl-6,7-dimethoxy-quinoline
DMS7B6T HS Investigative
DMS7B6T SN CHEMBL66785; 3-cyclopentyl-6,7-dimethoxy-quinoline; SCHEMBL8801444; ZINC3834044
DMS7B6T DT Small molecular drug
DMS7B6T PC 10422592
DMS7B6T MW 257.329
DMS7B6T FM C16H19NO2
DMS7B6T IC InChI=1S/C16H19NO2/c1-18-15-8-12-7-13(11-5-3-4-6-11)10-17-14(12)9-16(15)19-2/h7-11H,3-6H2,1-2H3
DMS7B6T CS COC1=CC2=CC(=CN=C2C=C1OC)C3CCCC3
DMS7B6T IK BYQWDMZNUPGMNG-UHFFFAOYSA-N
DMS7B6T IU 3-cyclopentyl-6,7-dimethoxyquinoline
DMS7B6T DE Discovery agent
DMLQJ64 ID DMLQJ64
DMLQJ64 DN 3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one
DMLQJ64 HS Investigative
DMLQJ64 SN CHEMBL7958; 3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one; SCHEMBL10337595
DMLQJ64 DT Small molecular drug
DMLQJ64 PC 54736658
DMLQJ64 MW 392.6
DMLQJ64 FM C24H40O4
DMLQJ64 IC InChI=1S/C24H40O4/c1-3-5-7-9-11-13-15-17-20-19-22(26)23(24(27)28-20)21(25)18-16-14-12-10-8-6-4-2/h19,26H,3-18H2,1-2H3
DMLQJ64 CS CCCCCCCCCC1=CC(=C(C(=O)O1)C(=O)CCCCCCCCC)O
DMLQJ64 IK FFXYZCMDXPBYIG-UHFFFAOYSA-N
DMLQJ64 IU 3-decanoyl-4-hydroxy-6-nonylpyran-2-one
DMLQJ64 DE Discovery agent
DMID7TC ID DMID7TC
DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine
DMID7TC HS Investigative
DMID7TC SN CHEMBL438794
DMID7TC DT Small molecular drug
DMID7TC PC 16043015
DMID7TC MW 562.6
DMID7TC FM C27H34N2O9S
DMID7TC IC InChI=1S/C27H34N2O9S/c1-12(31)28-16-7-5-13-9-17(29-27-24(35)23(34)22(33)19(11-30)38-27)25(36-2)26(37-3)21(13)14-6-8-20(39-4)18(32)10-15(14)16/h6,8-10,16,19,22-24,27,29-30,33-35H,5,7,11H2,1-4H3,(H,28,31)/t16-,19+,22+,23-,24+,27?/m0/s1
DMID7TC CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)NC4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMID7TC IK FPOIHQLRIKBTGP-DCWZWRKFSA-N
DMID7TC IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMID7TC DE Discovery agent
DME8VPC ID DME8VPC
DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine
DME8VPC HS Investigative
DME8VPC SN CHEMBL215655
DME8VPC DT Small molecular drug
DME8VPC PC 16043019
DME8VPC MW 532.6
DME8VPC FM C26H32N2O8S
DME8VPC IC InChI=1S/C26H32N2O8S/c1-12(29)27-16-7-5-13-9-17(28-26-23(33)22(32)19(31)11-36-26)24(34-2)25(35-3)21(13)14-6-8-20(37-4)18(30)10-15(14)16/h6,8-10,16,19,22-23,26,28,31-33H,5,7,11H2,1-4H3,(H,27,29)/t16-,19+,22-,23-,26?/m0/s1
DME8VPC CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)NC4[C@H]([C@H]([C@@H](CO4)O)O)O
DME8VPC IK MCKYAFJMJJFRCX-NFKHFCJPSA-N
DME8VPC IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(3S,4S,5R)-3,4,5-trihydroxyoxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DME8VPC DE Discovery agent
DMALMGH ID DMALMGH
DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine
DMALMGH HS Investigative
DMALMGH SN CHEMBL214305
DMALMGH DT Small molecular drug
DMALMGH PC 16081752
DMALMGH MW 562.6
DMALMGH FM C27H34N2O9S
DMALMGH IC InChI=1S/C27H34N2O9S/c1-12(31)28-16-7-5-13-9-17(29-27-24(35)23(34)22(33)19(11-30)38-27)25(36-2)26(37-3)21(13)14-6-8-20(39-4)18(32)10-15(14)16/h6,8-10,16,19,22-24,27,29-30,33-35H,5,7,11H2,1-4H3,(H,28,31)/t16-,19+,22+,23-,24-,27+/m0/s1
DMALMGH CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)N[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
DMALMGH IK FPOIHQLRIKBTGP-LMOMQKJLSA-N
DMALMGH IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMALMGH DE Discovery agent
DMXFVD1 ID DMXFVD1
DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine
DMXFVD1 HS Investigative
DMXFVD1 SN CHEMBL213312
DMXFVD1 DT Small molecular drug
DMXFVD1 PC 12001016
DMXFVD1 MW 532.6
DMXFVD1 FM C26H32N2O8S
DMXFVD1 IC InChI=1S/C26H32N2O8S/c1-12(29)27-16-7-5-13-9-17(28-26-23(33)22(32)19(31)11-36-26)24(34-2)25(35-3)21(13)14-6-8-20(37-4)18(30)10-15(14)16/h6,8-10,16,19,22-23,26,28,31-33H,5,7,11H2,1-4H3,(H,27,29)/t16-,19+,22-,23+,26?/m0/s1
DMXFVD1 CS CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)NC4[C@@H]([C@H]([C@@H](CO4)O)O)O
DMXFVD1 IK MCKYAFJMJJFRCX-PXSUQPJVSA-N
DMXFVD1 IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DMXFVD1 DE Discovery agent
DM4ERYF ID DM4ERYF
DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine
DM4ERYF HS Investigative
DM4ERYF SN CHEMBL214151
DM4ERYF DT Small molecular drug
DM4ERYF PC 16082784
DM4ERYF MW 546.6
DM4ERYF FM C27H34N2O8S
DM4ERYF IC InChI=1S/C27H34N2O8S/c1-12-22(32)23(33)24(34)27(37-12)29-18-10-14-6-8-17(28-13(2)30)16-11-19(31)20(38-5)9-7-15(16)21(14)26(36-4)25(18)35-3/h7,9-12,17,22-24,27,29,32-34H,6,8H2,1-5H3,(H,28,30)/t12-,17-,22+,23+,24-,27+/m0/s1
DM4ERYF CS C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)NC2=C(C(=C3C(=C2)CC[C@@H](C4=CC(=O)C(=CC=C43)SC)NC(=O)C)OC)OC)O)O)O
DM4ERYF IK ZYVFSIDQHJSZKV-MPHDHXMWSA-N
DM4ERYF IU N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]amino]-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
DM4ERYF DE Discovery agent
DMFQUGE ID DMFQUGE
DMFQUGE DN 3-Deoxyguanosine
DMFQUGE HS Investigative
DMFQUGE DT Small molecular drug
DMFQUGE PC 135440068
DMFQUGE MW 267.24
DMFQUGE FM C10H13N5O4
DMFQUGE IC InChI=1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)/t4-,5+,9+/m0/s1
DMFQUGE CS C1[C@H](O[C@H]([C@@H]1O)N2C=NC3=C2N=C(NC3=O)N)CO
DMFQUGE IK OROIAVZITJBGSM-OBXARNEKSA-N
DMFQUGE IU 2-amino-9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMFQUGE CA CAS 3608-58-0
DMFQUGE DE Discovery agent
DMBNA0V ID DMBNA0V
DMBNA0V DN 3-desoxy-3-carboxamidonaltrexone
DMBNA0V HS Investigative
DMBNA0V SN CHEMBL56695; 3-desoxy-3-carboxamidonaltrexone; SCHEMBL2785528; QAICPHMNUHNDMC-WUHBCXKYSA-N; BDBM50128411; 6-Oxo-17-(cyclopropylmethyl)-14-hydroxy-4,5alpha-epoxymorphinan-3-carboxamide; (5a)-17-(cyclopropylmethyl)-14-hydroxy-6-oxo-4,5-epoxymorphinan-3-carboxamide
DMBNA0V DT Small molecular drug
DMBNA0V PC 10021946
DMBNA0V MW 368.4
DMBNA0V FM C21H24N2O4
DMBNA0V IC InChI=1S/C21H24N2O4/c22-19(25)13-4-3-12-9-15-21(26)6-5-14(24)18-20(21,16(12)17(13)27-18)7-8-23(15)10-11-1-2-11/h3-4,11,15,18,26H,1-2,5-10H2,(H2,22,25)/t15-,18+,20+,21-/m1/s1
DMBNA0V CS C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)C(=O)N)O5)O
DMBNA0V IK QAICPHMNUHNDMC-WUHBCXKYSA-N
DMBNA0V IU (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-9-carboxamide
DMBNA0V DE Discovery agent
DMSJUOH ID DMSJUOH
DMSJUOH DN 3-Dimethylaminomethyl-1H-indol-4-ol
DMSJUOH HS Investigative
DMSJUOH SN CHEMBL194588; 3-Dimethylaminomethyl-1H-indol-4-ol; BDBM50171272
DMSJUOH DT Small molecular drug
DMSJUOH PC 44404899
DMSJUOH MW 190.24
DMSJUOH FM C11H14N2O
DMSJUOH IC InChI=1S/C11H14N2O/c1-13(2)7-8-6-12-9-4-3-5-10(14)11(8)9/h3-6,12,14H,7H2,1-2H3
DMSJUOH CS CN(C)CC1=CNC2=C1C(=CC=C2)O
DMSJUOH IK YJJMKVPZBCHYHD-UHFFFAOYSA-N
DMSJUOH IU 3-[(dimethylamino)methyl]-1H-indol-4-ol
DMSJUOH DE Discovery agent
DMDOIJM ID DMDOIJM
DMDOIJM DN 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM HS Investigative
DMDOIJM SN CHEMBL370221; 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol
DMDOIJM DT Small molecular drug
DMDOIJM PC 44404904
DMDOIJM MW 204.27
DMDOIJM FM C12H16N2O
DMDOIJM IC InChI=1S/C12H16N2O/c1-13(2)7-9-8-14(3)10-5-4-6-11(15)12(9)10/h4-6,8,15H,7H2,1-3H3
DMDOIJM CS CN1C=C(C2=C1C=CC=C2O)CN(C)C
DMDOIJM IK QOWUCENJFGRMQC-UHFFFAOYSA-N
DMDOIJM IU 3-[(dimethylamino)methyl]-1-methylindol-4-ol
DMDOIJM DE Discovery agent
DMVHQB8 ID DMVHQB8
DMVHQB8 DN 3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE
DMVHQB8 HS Investigative
DMVHQB8 SN CHEMBL303950; MR2; 3,3-Bis-(4-hydroxy-phenyl)-6-nitro-3H-benzo[de]isochromen-1-one; 1tsm; AC1L9MC8; bis(4-hydroxyphenyl)-nitro-[ ]one; BDBM50077849; DB08204; 3,3-bis(4-hydroxyphenyl)-6-nitro-1H,3H-benzo[de]isochromen-1-one; 3,3-Bis(4-hydroxyphenyl)-6-nitro-1H,3H-naphtho[1,8-cd]pyran-1-one
DMVHQB8 DT Small molecular drug
DMVHQB8 PC 448781
DMVHQB8 MW 413.4
DMVHQB8 FM C24H15NO6
DMVHQB8 IC InChI=1S/C24H15NO6/c26-16-8-4-14(5-9-16)24(15-6-10-17(27)11-7-15)20-12-13-21(25(29)30)18-2-1-3-19(22(18)20)23(28)31-24/h1-13,26-27H
DMVHQB8 CS C1=CC2=C(C=CC3=C2C(=C1)C(=O)OC3(C4=CC=C(C=C4)O)C5=CC=C(C=C5)O)[N+](=O)[O-]
DMVHQB8 IK FLWABCQDXUKNQY-UHFFFAOYSA-N
DMVHQB8 IU 4,4-bis(4-hydroxyphenyl)-8-nitro-3-oxatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaen-2-one
DMVHQB8 DE Discovery agent
DMO5EBI ID DMO5EBI
DMO5EBI DN 3-dodecyl-1,1-dimethylthiourea
DMO5EBI HS Investigative
DMO5EBI SN CHEMBL251521; 3-dodecyl-1,1-dimethylthiourea
DMO5EBI DT Small molecular drug
DMO5EBI PC 44442157
DMO5EBI MW 272.5
DMO5EBI FM C15H32N2S
DMO5EBI IC InChI=1S/C15H32N2S/c1-4-5-6-7-8-9-10-11-12-13-14-16-15(18)17(2)3/h4-14H2,1-3H3,(H,16,18)
DMO5EBI CS CCCCCCCCCCCCNC(=S)N(C)C
DMO5EBI IK ZZKLRJUYYVBOIF-UHFFFAOYSA-N
DMO5EBI IU 3-dodecyl-1,1-dimethylthiourea
DMO5EBI DE Discovery agent
DMQ8VIU ID DMQ8VIU
DMQ8VIU DN 3-epicorosolic acid methyl ester
DMQ8VIU HS Investigative
DMQ8VIU SN 3-epicorosolic acid methyl ester; CHEMBL604538; BDBM50307106; 2alpha,3alpha-Dihydroxyurs-12-en-28-oic acid methyl ester
DMQ8VIU DT Small molecular drug
DMQ8VIU PC 21672621
DMQ8VIU MW 486.7
DMQ8VIU FM C31H50O4
DMQ8VIU IC InChI=1S/C31H50O4/c1-18-11-14-31(26(34)35-8)16-15-29(6)20(24(31)19(18)2)9-10-23-28(5)17-21(32)25(33)27(3,4)22(28)12-13-30(23,29)7/h9,18-19,21-25,32-33H,10-17H2,1-8H3/t18-,19+,21-,22+,23-,24+,25-,28+,29-,30-,31+/m1/s1
DMQ8VIU CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@H](C5(C)C)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)OC
DMQ8VIU IK BRZWXKGDPAZBLF-ZLSCOBDWSA-N
DMQ8VIU IU methyl (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,11R,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylate
DMQ8VIU CA CAS 52213-28-2
DMQ8VIU DE Discovery agent
DM1UOWB ID DM1UOWB
DM1UOWB DN 3-epi-masilinic acid
DM1UOWB HS Investigative
DM1UOWB SN 3-epimaslinic acid; epi-Maslinic acid; 3-epi-masilinic acid; 3-epi-maslinic acid; CHEMBL383749; CHEBI:66683; 26563-68-8; (2alpha,3alpha)-2,3-dihydroxyolean-12-en-28-oic acid; 2alpha,3alpha-Dihydroxyolean-12-en-28-oic acid; Epimaslinic acid; SCHEMBL5797455; MolPort-039-338-353; BDBM50175873; ZINC12868514; LMPR0106150030
DM1UOWB DT Small molecular drug
DM1UOWB PC 25564831
DM1UOWB MW 472.7
DM1UOWB FM C30H48O4
DM1UOWB IC InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20+,21-,22+,23+,27-,28+,29+,30-/m0/s1
DM1UOWB CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@H](C3(C)C)O)O)C
DM1UOWB IK MDZKJHQSJHYOHJ-HFYZCPLSSA-N
DM1UOWB IU (4aS,6aR,6aS,6bR,8aR,10S,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DM1UOWB CA CAS 26563-68-8
DM1UOWB CB CHEBI:66683
DM1UOWB DE Discovery agent
DMTKQNU ID DMTKQNU
DMTKQNU DN 3-Ethenylquinoline-8-carboxamide
DMTKQNU HS Investigative
DMTKQNU SN CHEMBL481793; 3-Ethenylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethenyl-; BDBM50255270
DMTKQNU DT Small molecular drug
DMTKQNU PC 25208747
DMTKQNU MW 198.22
DMTKQNU FM C12H10N2O
DMTKQNU IC InChI=1S/C12H10N2O/c1-2-8-6-9-4-3-5-10(12(13)15)11(9)14-7-8/h2-7H,1H2,(H2,13,15)
DMTKQNU CS C=CC1=CN=C2C(=C1)C=CC=C2C(=O)N
DMTKQNU IK CODIVOZOEAWHDX-UHFFFAOYSA-N
DMTKQNU IU 3-ethenylquinoline-8-carboxamide
DMTKQNU DE Discovery agent
DMSK6EM ID DMSK6EM
DMSK6EM DN 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM HS Investigative
DMSK6EM SN CHEMBL233358; 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM DT Small molecular drug
DMSK6EM PC 44432682
DMSK6EM MW 288.3
DMSK6EM FM C19H16N2O
DMSK6EM IC InChI=1S/C19H16N2O/c1-3-22-18-9-14(12-20)8-17(10-18)16-7-6-15-5-4-13(2)21-19(15)11-16/h4-11H,3H2,1-2H3
DMSK6EM CS CCOC1=CC(=CC(=C1)C2=CC3=C(C=CC(=N3)C)C=C2)C#N
DMSK6EM IK QGNKITVJGNCQSU-UHFFFAOYSA-N
DMSK6EM IU 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMSK6EM DE Discovery agent
DMWZDA1 ID DMWZDA1
DMWZDA1 DN 3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1 HS Investigative
DMWZDA1 SN CHEMBL445259; 3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1 DT Small molecular drug
DMWZDA1 PC 25034346
DMWZDA1 MW 279.3
DMWZDA1 FM C18H17NO2
DMWZDA1 IC InChI=1S/C18H17NO2/c1-3-21-18-10-16(11-19-12-18)14-4-5-15-9-17(20-2)7-6-13(15)8-14/h4-12H,3H2,1-2H3
DMWZDA1 CS CCOC1=CN=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)OC
DMWZDA1 IK YYDLHEYJRYMTMO-UHFFFAOYSA-N
DMWZDA1 IU 3-ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMWZDA1 DE Discovery agent
DM6K7BI ID DM6K7BI
DM6K7BI DN 3-Ethoxy-9H-beta-carboline
DM6K7BI HS Investigative
DM6K7BI SN 3-Ethoxy-beta-carboline; 3-ethoxy-9H-pyrido[3,4-b]indole; CHEMBL498936; CHEMBL299250; 3-ethoxy-9h-; AC1Q4YMX; AC1L3YI4; SCHEMBL9531510; FNNPSIGQQWCKKB-UHFFFAOYSA-N; ZINC5139892; BDBM50001475; PDSP2_001734; BDBM50244034; PDSP1_001751; 3-Ethoxy-9H-beta-carboline(3-EBC); 9H-Pyrido(3,4-b)indole, 3-ethoxy-
DM6K7BI DT Small molecular drug
DM6K7BI PC 124477
DM6K7BI MW 212.25
DM6K7BI FM C13H12N2O
DM6K7BI IC InChI=1S/C13H12N2O/c1-2-16-13-7-10-9-5-3-4-6-11(9)15-12(10)8-14-13/h3-8,15H,2H2,1H3
DM6K7BI CS CCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DM6K7BI IK FNNPSIGQQWCKKB-UHFFFAOYSA-N
DM6K7BI IU 3-ethoxy-9H-pyrido[3,4-b]indole
DM6K7BI CA CAS 91985-81-8
DM6K7BI DE Discovery agent
DMY4VOI ID DMY4VOI
DMY4VOI DN 3-ethoxycarbonyl-4-quinolone
DMY4VOI HS Investigative
DMY4VOI SN ethyl 4-hydroxyquinoline-3-carboxylate; 26892-90-0; 52980-28-6; 4-Hydroxyquinoline-3-carboxylic acid ethyl ester; Ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate; Ethyl 4-oxo-1,4-dihydro-3-quinolinecarboxylate; ethyl 1,4-dihydro-4-oxoquinoline-3-carboxylate; 3-Quinolinecarboxylic acid, 1,4-dihydro-4-oxo-, ethyl ester; ethyl 4-oxohydroquinoline-3-carboxylate; ethyl 4-oxo-1H-quinoline-3-carboxylate; 4-HYDROXY-QUINOLINE-3-CARBOXYLIC ACID METHYL ESTER; 4-Oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester
DMY4VOI DT Small molecular drug
DMY4VOI PC 220876
DMY4VOI MW 217.22
DMY4VOI FM C12H11NO3
DMY4VOI IC InChI=1S/C12H11NO3/c1-2-16-12(15)9-7-13-10-6-4-3-5-8(10)11(9)14/h3-7H,2H2,1H3,(H,13,14)
DMY4VOI CS CCOC(=O)C1=CNC2=CC=CC=C2C1=O
DMY4VOI IK YBEOYBKKSWUSBR-UHFFFAOYSA-N
DMY4VOI IU ethyl 4-oxo-1H-quinoline-3-carboxylate
DMY4VOI CA CAS 52980-28-6
DMY4VOI DE Discovery agent
DMMDOI4 ID DMMDOI4
DMMDOI4 DN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone
DMMDOI4 HS Investigative
DMMDOI4 SN CHEMBL205159
DMMDOI4 DT Small molecular drug
DMMDOI4 PC 11521754
DMMDOI4 MW 259.3
DMMDOI4 FM C15H17NO3
DMMDOI4 IC InChI=1S/C15H17NO3/c1-4-10-6-7-12-11(8-10)14(17)13(9(3)16-12)15(18)19-5-2/h6-8H,4-5H2,1-3H3,(H,16,17)
DMMDOI4 CS CCC1=CC2=C(C=C1)NC(=C(C2=O)C(=O)OCC)C
DMMDOI4 IK RYTCQLITPWABMH-UHFFFAOYSA-N
DMMDOI4 IU ethyl 6-ethyl-2-methyl-4-oxo-1H-quinoline-3-carboxylate
DMMDOI4 DE Discovery agent
DM1E5QZ ID DM1E5QZ
DM1E5QZ DN 3-ethoxycarbonyl-6-propyl-4-quinolone
DM1E5QZ HS Investigative
DM1E5QZ SN CHEMBL381491
DM1E5QZ DT Small molecular drug
DM1E5QZ PC 11572455
DM1E5QZ MW 259.3
DM1E5QZ FM C15H17NO3
DM1E5QZ IC InChI=1S/C15H17NO3/c1-3-5-10-6-7-13-11(8-10)14(17)12(9-16-13)15(18)19-4-2/h6-9H,3-5H2,1-2H3,(H,16,17)
DM1E5QZ CS CCCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC
DM1E5QZ IK GLVXKESFOXDNRX-UHFFFAOYSA-N
DM1E5QZ IU ethyl 4-oxo-6-propyl-1H-quinoline-3-carboxylate
DM1E5QZ DE Discovery agent
DM4YL5Q ID DM4YL5Q
DM4YL5Q DN 3-ethoxycarbonylpyroglutamate
DM4YL5Q HS Investigative
DM4YL5Q SN 3-ethoxycarbonylpyroglutamate
DM4YL5Q DT Small molecular drug
DM4YL5Q PC 45272996
DM4YL5Q MW 229.23
DM4YL5Q FM C10H15NO5
DM4YL5Q IC InChI=1S/C10H15NO5/c1-3-15-9(13)6-5-7(12)11-8(6)10(14)16-4-2/h6,8H,3-5H2,1-2H3,(H,11,12)
DM4YL5Q CS CCOC(=O)C1CC(=O)NC1C(=O)OCC
DM4YL5Q IK OUZUMLMSKXXOLI-UHFFFAOYSA-N
DM4YL5Q IU diethyl 5-oxopyrrolidine-2,3-dicarboxylate
DM4YL5Q DE Discovery agent
DMX2JKQ ID DMX2JKQ
DMX2JKQ DN 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ HS Investigative
DMX2JKQ SN CHEMBL185833; 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine
DMX2JKQ DT Small molecular drug
DMX2JKQ PC 18721724
DMX2JKQ MW 158.27
DMX2JKQ FM C7H14N2S
DMX2JKQ IC InChI=1S/C7H14N2S/c1-2-6-5-10-4-3-7(8)9-6/h6H,2-5H2,1H3,(H2,8,9)
DMX2JKQ CS CCC1CSCCC(=N1)N
DMX2JKQ IK BJFMNSRYUNDINA-UHFFFAOYSA-N
DMX2JKQ IU 3-ethyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMX2JKQ DE Discovery agent
DMEWAVM ID DMEWAVM
DMEWAVM DN 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
DMEWAVM HS Investigative
DMEWAVM SN 3-ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol; CHEMBL180517
DMEWAVM DT Small molecular drug
DMEWAVM PC 11149479
DMEWAVM MW 254.28
DMEWAVM FM C15H14N2O2
DMEWAVM IC InChI=1S/C15H14N2O2/c1-2-15-13-9-12(19)7-8-14(13)16-17(15)10-3-5-11(18)6-4-10/h3-9,18-19H,2H2,1H3
DMEWAVM CS CCC1=C2C=C(C=CC2=NN1C3=CC=C(C=C3)O)O
DMEWAVM IK XBMVVMYGKMGLJX-UHFFFAOYSA-N
DMEWAVM IU 3-ethyl-2-(4-hydroxyphenyl)indazol-5-ol
DMEWAVM DE Discovery agent
DMN8C93 ID DMN8C93
DMN8C93 DN 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol
DMN8C93 HS Investigative
DMN8C93 SN CHEMBL129249; 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol; 1H-3-Benzazepin-6-ol, 3-ethyl-2,3,4,5-tetrahydro-; BDBM50003341; 143620-42-2
DMN8C93 DT Small molecular drug
DMN8C93 PC 10261961
DMN8C93 MW 191.27
DMN8C93 FM C12H17NO
DMN8C93 IC InChI=1S/C12H17NO/c1-2-13-8-6-10-4-3-5-12(14)11(10)7-9-13/h3-5,14H,2,6-9H2,1H3
DMN8C93 CS CCN1CCC2=C(CC1)C(=CC=C2)O
DMN8C93 IK HTCXSPINZBVTNI-UHFFFAOYSA-N
DMN8C93 IU 3-ethyl-1,2,4,5-tetrahydro-3-benzazepin-6-ol
DMN8C93 DE Discovery agent
DMB8Q7T ID DMB8Q7T
DMB8Q7T DN 3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione
DMB8Q7T HS Investigative
DMB8Q7T SN CHEMBL566475; 3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione
DMB8Q7T DT Small molecular drug
DMB8Q7T PC 44626814
DMB8Q7T MW 245.32
DMB8Q7T FM C15H19NO2
DMB8Q7T IC InChI=1S/C15H19NO2/c1-4-15(10-11(2)3)13(17)16(14(15)18)12-8-6-5-7-9-12/h5-9,11H,4,10H2,1-3H3
DMB8Q7T CS CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC(C)C
DMB8Q7T IK IDCYZOAEGDFOSJ-UHFFFAOYSA-N
DMB8Q7T IU 3-ethyl-3-(2-methylpropyl)-1-phenylazetidine-2,4-dione
DMB8Q7T DE Discovery agent
DMZK13I ID DMZK13I
DMZK13I DN 3-Ethyl-3-isopropyl-dihydro-furan-2-one
DMZK13I HS Investigative
DMZK13I SN CHEMBL95665
DMZK13I DT Small molecular drug
DMZK13I PC 10261321
DMZK13I MW 156.22
DMZK13I FM C9H16O2
DMZK13I IC InChI=1S/C9H16O2/c1-4-9(7(2)3)5-6-11-8(9)10/h7H,4-6H2,1-3H3
DMZK13I CS CCC1(CCOC1=O)C(C)C
DMZK13I IK RQXMJDAZNMCZLO-UHFFFAOYSA-N
DMZK13I IU 3-ethyl-3-propan-2-yloxolan-2-one
DMZK13I DE Discovery agent
DM1VTFU ID DM1VTFU
DM1VTFU DN 3-Ethyl-3-methyl-dihydro-furan-2-one
DM1VTFU HS Investigative
DM1VTFU SN alpha-Emgbl; 2-Ethyl-2-methyl-4-butyrolactone; 3-ethyl-3-methyldihydrofuran-2(3h)-one; 31004-76-9; AC1Q6HQE; CHEBI:35057; 2(3H)-Furanone, 3-ethyldihydro-3-methyl-; alpha-Ethyl-alpha-methyl-gamma-butyrolactone; SureCN132980; C13714; AC1L53DL; SCHEMBL132980; CHEMBL285171; 3-ethyl-3-methyloxolan-2-one; CTK4G6275; 3-ethyl-3-methyl-tetrahydrofuran-2-one
DM1VTFU DT Small molecular drug
DM1VTFU PC 169232
DM1VTFU MW 128.169
DM1VTFU FM C7H12O2
DM1VTFU IC InChI=1S/C7H12O2/c1-3-7(2)4-5-9-6(7)8/h3-5H2,1-2H3
DM1VTFU CS CCC1(CCOC1=O)C
DM1VTFU IK DRTXQTMTWPIHLI-UHFFFAOYSA-N
DM1VTFU IU 3-ethyl-3-methyloxolan-2-one
DM1VTFU CA CAS 31004-76-9
DM1VTFU CB CHEBI:35057
DM1VTFU DE Discovery agent
DMGPRBE ID DMGPRBE
DMGPRBE DN 3-Ethylquinoline-8-carboxamide
DMGPRBE HS Investigative
DMGPRBE SN CHEMBL453989; 3-Ethylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethyl-; BDBM50255269
DMGPRBE DT Small molecular drug
DMGPRBE PC 25208904
DMGPRBE MW 200.24
DMGPRBE FM C12H12N2O
DMGPRBE IC InChI=1S/C12H12N2O/c1-2-8-6-9-4-3-5-10(12(13)15)11(9)14-7-8/h3-7H,2H2,1H3,(H2,13,15)
DMGPRBE CS CCC1=CN=C2C(=C1)C=CC=C2C(=O)N
DMGPRBE IK ACADFMJVXMCIFY-UHFFFAOYSA-N
DMGPRBE IU 3-ethylquinoline-8-carboxamide
DMGPRBE DE Discovery agent
DMS4JGT ID DMS4JGT
DMS4JGT DN 3-Ethynylquinoline-8-carboxamide
DMS4JGT HS Investigative
DMS4JGT SN CHEMBL501330; 3-Ethynylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-ethynyl-; BDBM50255268
DMS4JGT DT Small molecular drug
DMS4JGT PC 25208746
DMS4JGT MW 196.2
DMS4JGT FM C12H8N2O
DMS4JGT IC InChI=1S/C12H8N2O/c1-2-8-6-9-4-3-5-10(12(13)15)11(9)14-7-8/h1,3-7H,(H2,13,15)
DMS4JGT CS C#CC1=CN=C2C(=C1)C=CC=C2C(=O)N
DMS4JGT IK FVYCGVPNXRWDOH-UHFFFAOYSA-N
DMS4JGT IU 3-ethynylquinoline-8-carboxamide
DMS4JGT DE Discovery agent
DMR29IQ ID DMR29IQ
DMR29IQ DN 3-Fluoren-9-ylidenemethyl-pyridine
DMR29IQ HS Investigative
DMR29IQ SN 3-(9h-fluoren-9-ylidenemethyl)pyridine; 3-(fluoren-9-ylidenemethyl)pyridine; 3239-00-7; NSC83320; AC1Q4YVX; AC1L5UM9; NCIOpen2_004633; CHEMBL194928; BDBM8637; SCHEMBL8276088; CTK1C4120; (3-Pyridylmethylene)fluorene 32; DTXSID10292510; NSC-83320; ZINC13283158; AKOS030540073; 3-(9H-Fluorene-9-ylidenemethyl)pyridine
DMR29IQ DT Small molecular drug
DMR29IQ PC 139138079
DMR29IQ MW 510.6
DMR29IQ FM C38H26N2
DMR29IQ IC InChI=1S/2C19H13N/c2*1-3-9-17-15(7-1)16-8-2-4-10-18(16)19(17)12-14-6-5-11-20-13-14/h2*1-13H
DMR29IQ CS C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CN=CC=C4.C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CN=CC=C4
DMR29IQ IK QQJHSQKNTSNWIQ-UHFFFAOYSA-N
DMR29IQ IU 3-(fluoren-9-ylidenemethyl)pyridine
DMR29IQ DE Discovery agent
DMTY92S ID DMTY92S
DMTY92S DN 3-Fluoro-2-(Phosphonooxy)Propanoic Acid
DMTY92S HS Investigative
DMTY92S SN 3-FLUORO-2-(PHOSPHONOOXY)PROPANOIC ACID; AC1NRB38; DB03113; (2R)-3-fluoro-2-phosphonooxypropanoic acid; (2R)-3-fluoro-2-(phosphonooxy)propanoic acid
DMTY92S DT Small molecular drug
DMTY92S PC 5288237
DMTY92S MW 188.05
DMTY92S FM C3H6FO6P
DMTY92S IC InChI=1S/C3H6FO6P/c4-1-2(3(5)6)10-11(7,8)9/h2H,1H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1
DMTY92S CS C([C@@H](C(=O)O)OP(=O)(O)O)F
DMTY92S IK BNOCDEBUFVJMQI-REOHCLBHSA-N
DMTY92S IU (2R)-3-fluoro-2-phosphonooxypropanoic acid
DMTY92S DE Discovery agent
DM4PLSU ID DM4PLSU
DM4PLSU DN 3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol
DM4PLSU HS Investigative
DM4PLSU SN CHEMBL1173261; SCHEMBL18770414; BDBM50322797
DM4PLSU DT Small molecular drug
DM4PLSU PC 46854606
DM4PLSU MW 307.4
DM4PLSU FM C20H18FNO
DM4PLSU IC InChI=1S/C20H18FNO/c1-2-18(16-9-11-22-12-10-16)15-5-3-14(4-6-15)17-7-8-20(23)19(21)13-17/h3-13,18,23H,2H2,1H3
DM4PLSU CS CCC(C1=CC=C(C=C1)C2=CC(=C(C=C2)O)F)C3=CC=NC=C3
DM4PLSU IK MSZSUMNJIMRHDP-UHFFFAOYSA-N
DM4PLSU IU 2-fluoro-4-[4-(1-pyridin-4-ylpropyl)phenyl]phenol
DM4PLSU DE Discovery agent
DMJ3WNP ID DMJ3WNP
DMJ3WNP DN 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol
DMJ3WNP HS Investigative
DMJ3WNP SN CHEMBL1173260; SCHEMBL18770351; BDBM50322791
DMJ3WNP DT Small molecular drug
DMJ3WNP PC 46901611
DMJ3WNP MW 279.3
DMJ3WNP FM C18H14FNO
DMJ3WNP IC InChI=1S/C18H14FNO/c19-17-12-16(5-6-18(17)21)15-3-1-13(2-4-15)11-14-7-9-20-10-8-14/h1-10,12,21H,11H2
DMJ3WNP CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)F
DMJ3WNP IK SFFLHOMUFWFHRI-UHFFFAOYSA-N
DMJ3WNP IU 2-fluoro-4-[4-(pyridin-4-ylmethyl)phenyl]phenol
DMJ3WNP DE Discovery agent
DMLG69R ID DMLG69R
DMLG69R DN 3-Fluoro-4-hydrazino-benzenesulfonamide
DMLG69R HS Investigative
DMLG69R SN 3-Fluoro-4-hydrazino-benzenesulfonamide; 606126-17-4; 3-fluoro-4-hydrazinobenzenesulfonamide; hydrazide deriv. 15; SCHEMBL1244816; CHEMBL176180; CTK2E9801; BDBM12160; DTXSID90448811; IDSRHQBHQWPDNY-UHFFFAOYSA-N; AKOS013645919; 4-Hydrazino-3-fluorobenzenesulfonamide; Benzenesulfonamide, 3-fluoro-4-hydrazino-; TC-063144; 3-fluoro-4-hydrazinylbenzene-1-sulfonamide; 144147-EP2287165A2; 144147-EP2292620A2
DMLG69R DT Small molecular drug
DMLG69R PC 10932611
DMLG69R MW 205.21
DMLG69R FM C6H8FN3O2S
DMLG69R IC InChI=1S/C6H8FN3O2S/c7-5-3-4(13(9,11)12)1-2-6(5)10-8/h1-3,10H,8H2,(H2,9,11,12)
DMLG69R CS C1=CC(=C(C=C1S(=O)(=O)N)F)NN
DMLG69R IK IDSRHQBHQWPDNY-UHFFFAOYSA-N
DMLG69R IU 3-fluoro-4-hydrazinylbenzenesulfonamide
DMLG69R CA CAS 606126-17-4
DMLG69R DE Discovery agent
DMH9VLF ID DMH9VLF
DMH9VLF DN 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF HS Investigative
DMH9VLF SN CHEMBL238390; 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF DT Small molecular drug
DMH9VLF PC 44434724
DMH9VLF MW 249.24
DMH9VLF FM C15H8FN3
DMH9VLF IC InChI=1S/C15H8FN3/c16-13-5-10(8-17)4-12(6-13)15-7-14-11(9-19-15)2-1-3-18-14/h1-7,9H
DMH9VLF CS C1=CC2=CN=C(C=C2N=C1)C3=CC(=CC(=C3)C#N)F
DMH9VLF IK PSQNPPVCWZBHDY-UHFFFAOYSA-N
DMH9VLF IU 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile
DMH9VLF DE Discovery agent
DM2V45Z ID DM2V45Z
DM2V45Z DN 3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile
DM2V45Z HS Investigative
DM2V45Z SN 3-Fluoro-5-(2-methylquinolin-7-yl)benzonitrile; CHEMBL232188; GTPL6444; SCHEMBL4303163; BDBM50216746; compound 23 [PMID:; compound 23
DM2V45Z DT Small molecular drug
DM2V45Z PC 23661671
DM2V45Z MW 262.28
DM2V45Z FM C17H11FN2
DM2V45Z IC InChI=1S/C17H11FN2/c1-11-2-3-13-4-5-14(9-17(13)20-11)15-6-12(10-19)7-16(18)8-15/h2-9H,1H3
DM2V45Z CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)F
DM2V45Z IK SDOLISUYGVMVBK-UHFFFAOYSA-N
DM2V45Z IU 3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile
DM2V45Z DE Discovery agent
DMDPY9N ID DMDPY9N
DMDPY9N DN 3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMDPY9N HS Investigative
DMDPY9N SN CHEMBL583520; 3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol
DMDPY9N DT Small molecular drug
DMDPY9N PC 44542048
DMDPY9N MW 286.3
DMDPY9N FM C16H11FO2S
DMDPY9N IC InChI=1S/C16H11FO2S/c17-12-7-11(8-14(19)9-12)16-6-5-15(20-16)10-1-3-13(18)4-2-10/h1-9,18-19H
DMDPY9N CS C1=CC(=CC=C1C2=CC=C(S2)C3=CC(=CC(=C3)F)O)O
DMDPY9N IK OWTLTMXTNPNZPH-UHFFFAOYSA-N
DMDPY9N IU 3-fluoro-5-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
DMDPY9N DE Discovery agent
DMDPUC7 ID DMDPUC7
DMDPUC7 DN 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline
DMDPUC7 HS Investigative
DMDPUC7 SN CHEMBL121531; 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline; Isoquinoline, 3-(fluoromethyl)-1,2,3,4-tetrahydro-; SCHEMBL6847135; BDBM50080517; AKOS024125792
DMDPUC7 DT Small molecular drug
DMDPUC7 PC 10654599
DMDPUC7 MW 165.21
DMDPUC7 FM C10H12FN
DMDPUC7 IC InChI=1S/C10H12FN/c11-6-10-5-8-3-1-2-4-9(8)7-12-10/h1-4,10,12H,5-7H2
DMDPUC7 CS C1C(NCC2=CC=CC=C21)CF
DMDPUC7 IK SLBKHMRNZGCZIO-UHFFFAOYSA-N
DMDPUC7 IU 3-(fluoromethyl)-1,2,3,4-tetrahydroisoquinoline
DMDPUC7 DE Discovery agent
DMECBLA ID DMECBLA
DMECBLA DN 3-fluorovinylglycine
DMECBLA HS Investigative
DMECBLA SN Fluorovinylglycine; 3-Fluorovinylglycine; FVGly; ACMC-20melc; 3-Butenoic acid, 2-amino-3-fluoro-, (S)-; AC1MIW53; 2-amino-3-fluorobut-3-enoic acid; 2-Amino-3-fluoro-3-butenoic acid; 111687-18-4; AKOS006361808; 3-Butenoic acid, 2-amino-3-fluoro-, (+-)-
DMECBLA DT Small molecular drug
DMECBLA PC 3081008
DMECBLA MW 119.09
DMECBLA FM C4H6FNO2
DMECBLA IC InChI=1S/C4H6FNO2/c1-2(5)3(6)4(7)8/h3H,1,6H2,(H,7,8)
DMECBLA CS C=C(C(C(=O)O)N)F
DMECBLA IK HMOXWHQSNHKKFM-UHFFFAOYSA-N
DMECBLA IU 2-amino-3-fluorobut-3-enoic acid
DMECBLA CA CAS 111581-52-3
DMECBLA DE Discovery agent
DM8RY7G ID DM8RY7G
DM8RY7G DN 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide
DM8RY7G HS Investigative
DM8RY7G SN CHEMBL567637; 135733-34-5; 1,2,5-Oxadiazole-3-carboxaldehyde, 4-phenyl-, 2-oxide; 3-formyl-4-phenyl-1,2,5-oxadiazole n2-oxide; ACMC-20mvvi; 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide; CTK0F4054; DTXSID00438521; 3-Formyl-4-phenylfurazan 2-oxide; BDBM50300756
DM8RY7G DT Small molecular drug
DM8RY7G PC 10352496
DM8RY7G MW 190.16
DM8RY7G FM C9H6N2O3
DM8RY7G IC InChI=1S/C9H6N2O3/c12-6-8-9(10-14-11(8)13)7-4-2-1-3-5-7/h1-6H
DM8RY7G CS C1=CC=C(C=C1)C2=NO[N+](=C2C=O)[O-]
DM8RY7G IK MNNADPGXJASGIU-UHFFFAOYSA-N
DM8RY7G IU 2-oxido-4-phenyl-1,2,5-oxadiazol-2-ium-3-carbaldehyde
DM8RY7G CA CAS 135733-34-5
DM8RY7G DE Discovery agent
DMBFCTZ ID DMBFCTZ
DMBFCTZ DN 3h-Indole-5,6-Diol
DMBFCTZ HS Investigative
DMBFCTZ SN 5,6-Dihydroxyindole; 3131-52-0; 1H-Indole-5,6-diol; Dopamine lutine; 3H-INDOLE-5,6-DIOL; dhi; UNII-Z3OC8499KG; 5,6-DihydroxyindoleI; C8H7NO2; CHEMBL92636; Z3OC8499KG; CHEBI:27404; AK-25753; D-3560; 3ID; 5,6-Dihydroxy-1H-indole; indole-5,6-diol; 5,6-dihydroxy indole; AC1L3FSK; EC 412-130-9; SCHEMBL48994; AC1Q7A19; CTK1C3371; DTXSID20185242; SGNZYJXNUURYCH-UHFFFAOYSA-N; MolPort-001-782-232; ZINC895800; BCP02562; ACT06797; EBD26988; ZX-AT011826; KS-00000J9K; CD-595; BDBM50028548; BBL102959; ANW-44822; STL556768; MFCD00798933; FCH834612
DMBFCTZ DT Small molecular drug
DMBFCTZ PC 114683
DMBFCTZ MW 149.15
DMBFCTZ FM C8H7NO2
DMBFCTZ IC InChI=1S/C8H7NO2/c10-7-3-5-1-2-9-6(5)4-8(7)11/h1-4,9-11H
DMBFCTZ CS C1=CNC2=CC(=C(C=C21)O)O
DMBFCTZ IK SGNZYJXNUURYCH-UHFFFAOYSA-N
DMBFCTZ IU 1H-indole-5,6-diol
DMBFCTZ CA CAS 3131-52-0
DMBFCTZ CB CHEBI:27404
DMBFCTZ DE Discovery agent
DMLB2W5 ID DMLB2W5
DMLB2W5 DN 3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol
DMLB2W5 HS Investigative
DMLB2W5 DT Small molecular drug
DMLB2W5 PC 135403816
DMLB2W5 MW 136.11
DMLB2W5 FM C5H4N4O
DMLB2W5 IC InChI=1S/C5H4N4O/c10-5-4-3(1-8-9-4)6-2-7-5/h2H,1H2,(H,6,7,10)
DMLB2W5 CS C1C2=C(C(=O)NC=N2)N=N1
DMLB2W5 IK OGCXIHWGXUQTCQ-UHFFFAOYSA-N
DMLB2W5 IU 3,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
DMLB2W5 CA CAS 161746-78-7
DMLB2W5 CB CHEBI:44995
DMLB2W5 DE Discovery agent
DMC70P1 ID DMC70P1
DMC70P1 DN 3-hydroxy capric acid
DMC70P1 HS Investigative
DMC70P1 SN 3-OH-C10; 3-hydroxy-decanoic acid
DMC70P1 DT Small molecular drug
DMC70P1 PC 26612
DMC70P1 MW 188.26
DMC70P1 FM C10H20O3
DMC70P1 IC InChI=1S/C10H20O3/c1-2-3-4-5-6-7-9(11)8-10(12)13/h9,11H,2-8H2,1H3,(H,12,13)
DMC70P1 CS CCCCCCCC(CC(=O)O)O
DMC70P1 IK FYSSBMZUBSBFJL-UHFFFAOYSA-N
DMC70P1 IU 3-hydroxydecanoic acid
DMC70P1 CA CAS 14292-26-3
DMC70P1 CB CHEBI:132983
DMC70P1 DE Discovery agent
DMZSOPU ID DMZSOPU
DMZSOPU DN 3-Hydroxy-1H-benzo[b]azepine-2,5-dione
DMZSOPU HS Investigative
DMZSOPU SN 3-hydroxy-1H-1-benzazepine-2,5-dione; CHEMBL91742; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-; 52280-64-5; 3-Hydroxy-1H-benzo[b]azepine-2,5-dione; SCHEMBL2639080; CTK1E4553; DTXSID10618296; BDBM50054638; 5-hydroxy-1H-1-benzazepine-2,3-dione
DMZSOPU DT Small molecular drug
DMZSOPU PC 21812299
DMZSOPU MW 189.17
DMZSOPU FM C10H7NO3
DMZSOPU IC InChI=1S/C10H7NO3/c12-8-5-9(13)10(14)11-7-4-2-1-3-6(7)8/h1-5,12H,(H,11,13,14)
DMZSOPU CS C1=CC=C2C(=C1)C(=CC(=O)C(=O)N2)O
DMZSOPU IK LRWDJVXXZACNEV-UHFFFAOYSA-N
DMZSOPU IU 5-hydroxy-1H-1-benzazepine-2,3-dione
DMZSOPU CA CAS 52280-64-5
DMZSOPU DE Discovery agent
DM4758S ID DM4758S
DM4758S DN 3hydroxy-1-methyl-1-phenylurea
DM4758S HS Investigative
DM4758S SN CHEMBL262340; N'-hydroxy-N-methyl-N-phenylurea; 13262-41-4; 1-Methyl-1-phenyl-3-hydroxyurea; BDBM50377110
DM4758S DT Small molecular drug
DM4758S PC 11672724
DM4758S MW 166.18
DM4758S FM C8H10N2O2
DM4758S IC InChI=1S/C8H10N2O2/c1-10(8(11)9-12)7-5-3-2-4-6-7/h2-6,12H,1H3,(H,9,11)
DM4758S CS CN(C1=CC=CC=C1)C(=O)NO
DM4758S IK UDJKPENTLREIMW-UHFFFAOYSA-N
DM4758S IU 3-hydroxy-1-methyl-1-phenylurea
DM4758S DE Discovery agent
DMI785L ID DMI785L
DMI785L DN 3-hydroxy-2-methoxybenzaldehyde
DMI785L HS Investigative
DMI785L SN 3-hydroxy-2-methoxybenzaldehyde; 66495-88-3; CHEMBL507918; 3-hydroxy-2-methoxy-benzaldehyde; hydroxy-methoxy-benzaldehyde; SCHEMBL470709; 2-methoxy-3-hydroxybenzaldehyde; CTK1J4694; DTXSID70473025; GRIWJVSWLJHHEM-UHFFFAOYSA-N; MolPort-002-462-004; Benzaldehyde,3-hydroxy-2-methoxy-; KS-00000B2L; Benzaldehyde, 3-hydroxy-2-methoxy-; ZINC12505037; BDBM50266963; 5891AJ; AKOS000119267; MB03871; SY025931; CS-11591; KB-236283; MFCD06656119 (95%)
DMI785L DT Small molecular drug
DMI785L PC 11804953
DMI785L MW 152.15
DMI785L FM C8H8O3
DMI785L IC InChI=1S/C8H8O3/c1-11-8-6(5-9)3-2-4-7(8)10/h2-5,10H,1H3
DMI785L CS COC1=C(C=CC=C1O)C=O
DMI785L IK GRIWJVSWLJHHEM-UHFFFAOYSA-N
DMI785L IU 3-hydroxy-2-methoxybenzaldehyde
DMI785L CA CAS 66495-88-3
DMI785L DE Discovery agent
DMIVDFW ID DMIVDFW
DMIVDFW DN 3-hydroxy-2-phenylquinoline-4-carboxylic acid
DMIVDFW HS Investigative
DMIVDFW SN Oxycinchophen; 485-89-2; Oxinofen; Chinoxone; Fenidrone; 3-hydroxy-2-phenylquinoline-4-carboxylic acid; Hydroxycinchophene; Sintofene; Magnofenyl; Reumartril; Magnophenyl; 3-Hydroxy-2-phenylcinchoninic acid; 3-Hydroxycinchophen; oxicinchophen; Oxicinchophenum; Oxycinchophen [INN:BAN]; Oxicincofeno [INN-Spanish]; UNII-UK6392GD5W; Oxycinchophene [INN-French]; Oxycinchophenum [INN-Latin]; 3-Hydroxy-2-phenyl-4-quinolinecarboxylic acid; 3-Hydroxy-2-phenyl-chinchoninsaeure; EINECS 207-624-4; NSC 41784; BRN 0224526; CHEMBL219376
DMIVDFW DT Small molecular drug
DMIVDFW PC 10239
DMIVDFW MW 265.26
DMIVDFW FM C16H11NO3
DMIVDFW IC InChI=1S/C16H11NO3/c18-15-13(16(19)20)11-8-4-5-9-12(11)17-14(15)10-6-2-1-3-7-10/h1-9,18H,(H,19,20)
DMIVDFW CS C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2O)C(=O)O
DMIVDFW IK XAPRFLSJBSXESP-UHFFFAOYSA-N
DMIVDFW IU 3-hydroxy-2-phenylquinoline-4-carboxylic acid
DMIVDFW CA CAS 485-89-2
DMIVDFW CB CHEBI:135094
DMIVDFW DE Discovery agent
DMEK9DH ID DMEK9DH
DMEK9DH DN 3-hydroxy-2-propionylcyclohex-2-enone
DMEK9DH HS Investigative
DMEK9DH SN CHEMBL308796; 62847-90-9; AC1LBQYE; 2-(1-hydroxypropylidene)cyclohexane-1,3-dione; CTK2B1414; DTXSID40343105; ROVGIVWUAMEQQN-UHFFFAOYSA-N; ZINC4786244; 2-Cyclohexen-3-ol-1-one, 2-propioyl-; 2-Propionyl-3-hydroxy-2-cyclohexene-1-one; 3-Hydroxy-2-propionyl-2-cyclohexen-1-one #; 2-Cyclohexen-1-one, 3-hydroxy-2-(1-oxopropyl)-
DMEK9DH DT Small molecular drug
DMEK9DH PC 587484
DMEK9DH MW 168.19
DMEK9DH FM C9H12O3
DMEK9DH IC InChI=1S/C9H12O3/c1-2-6(10)9-7(11)4-3-5-8(9)12/h10H,2-5H2,1H3
DMEK9DH CS CCC(=C1C(=O)CCCC1=O)O
DMEK9DH IK KIXYWPAKWURPPK-UHFFFAOYSA-N
DMEK9DH IU 2-(1-hydroxypropylidene)cyclohexane-1,3-dione
DMEK9DH CA CAS 62847-90-9
DMEK9DH DE Discovery agent
DM3YO72 ID DM3YO72
DM3YO72 DN 3-hydroxy-3-methyl-6-phosphohexanoic acid
DM3YO72 HS Investigative
DM3YO72 SN 3-hydroxy-3-methyl-6-phosphonohexanoic acid; 63370-13-8; GTPL3202; SCHEMBL11310701; CTK2A9401; DTXSID80634286; Hexanoic acid, 3-hydroxy-3-methyl-6-phosphono-
DM3YO72 DT Small molecular drug
DM3YO72 PC 23452327
DM3YO72 MW 226.16
DM3YO72 FM C7H15O6P
DM3YO72 IC InChI=1S/C7H15O6P/c1-7(10,5-6(8)9)3-2-4-14(11,12)13/h10H,2-5H2,1H3,(H,8,9)(H2,11,12,13)
DM3YO72 CS CC(CCCP(=O)(O)O)(CC(=O)O)O
DM3YO72 IK XRCIRZGXKWCWNQ-UHFFFAOYSA-N
DM3YO72 IU 3-hydroxy-3-methyl-6-phosphonohexanoic acid
DM3YO72 CA CAS 63370-13-8
DM3YO72 DE Discovery agent
DMJD0UV ID DMJD0UV
DMJD0UV DN 3-Hydroxy-3-Methyl-Glutaric Acid
DMJD0UV HS Investigative
DMJD0UV SN Meglutol; MEGLUTOL; 3-Hydroxy-3-methylglutaric acid; 503-49-1; Dicrotalic acid; 3-Hydroxy-3-methylpentanedioic acid; Lipoglutaren; Medroglutaric acid; 3-hydroxy-3-methyl-glutaric acid; HMGA; beta-Hydroxy-beta-methylglutaric acid; Meglutolum; Meglutol [USAN:INN]; Meglutolum [INN-Latin]; Pentanedioic acid, 3-hydroxy-3-methyl-; CB-337; CB 337; UNII-CLA99KCD53; 3-Hydroxy-3-methylglutarate; Glutaric acid, 3-hydroxy-3-methyl-; EINECS 207-971-1; NSC 361411; 3-Hydroxymethylglutaric acid; BRN 1769194; CLA99KCD53; CHEMBL50444; CHEBI:16831
DMJD0UV DT Small molecular drug
DMJD0UV PC 1662
DMJD0UV MW 162.14
DMJD0UV FM C6H10O5
DMJD0UV IC InChI=1S/C6H10O5/c1-6(11,2-4(7)8)3-5(9)10/h11H,2-3H2,1H3,(H,7,8)(H,9,10)
DMJD0UV CS CC(CC(=O)O)(CC(=O)O)O
DMJD0UV IK NPOAOTPXWNWTSH-UHFFFAOYSA-N
DMJD0UV IU 3-hydroxy-3-methylpentanedioic acid
DMJD0UV CA CAS 503-49-1
DMJD0UV CB CHEBI:16831
DMJD0UV DE Discovery agent
DMEJQTA ID DMEJQTA
DMEJQTA DN 3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one
DMEJQTA HS Investigative
DMEJQTA SN CHEMBL205988; 3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one; SCHEMBL6828383
DMEJQTA DT Small molecular drug
DMEJQTA PC 10082995
DMEJQTA MW 240.25
DMEJQTA FM C15H12O3
DMEJQTA IC InChI=1S/C15H12O3/c1-8-4-3-5-11-13(8)10-6-7-12(16)9(2)14(10)18-15(11)17/h3-7,16H,1-2H3
DMEJQTA CS CC1=C2C3=C(C(=C(C=C3)O)C)OC(=O)C2=CC=C1
DMEJQTA IK PSZUCXJKMVSZSN-UHFFFAOYSA-N
DMEJQTA IU 3-hydroxy-4,10-dimethylbenzo[c]chromen-6-one
DMEJQTA DE Discovery agent
DMUME74 ID DMUME74
DMUME74 DN 3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one
DMUME74 HS Investigative
DMUME74 SN CHEMBL204959; 3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one; BDBM50180476
DMUME74 DT Small molecular drug
DMUME74 PC 10399376
DMUME74 MW 240.25
DMUME74 FM C15H12O3
DMUME74 IC InChI=1S/C15H12O3/c1-8-4-3-5-10-11-6-7-12(16)9(2)14(11)18-15(17)13(8)10/h3-7,16H,1-2H3
DMUME74 CS CC1=C2C(=CC=C1)C3=C(C(=C(C=C3)O)C)OC2=O
DMUME74 IK BSCZPVUHFUQDQP-UHFFFAOYSA-N
DMUME74 IU 3-hydroxy-4,7-dimethylbenzo[c]chromen-6-one
DMUME74 DE Discovery agent
DMDBJCY ID DMDBJCY
DMDBJCY DN 3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one
DMDBJCY HS Investigative
DMDBJCY SN 3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one; 3-hydroxy-4-methylbenzo[c]chromen-6-one; CHEMBL203519; 76244-77-4; CBMicro_031406; AC1NT8BO; AC1Q2GPY; Oprea1_200366; SCHEMBL6825266; MolPort-000-688-996; ALBB-015456; ZINC5921519; BDBM50180504; STL466134; AKOS002377900; MCULE-5900160059; NS-02841; BIM-0031475.P001; R5445; 4-Methyl-3-hydroxy-6H-dibenzo[b,d]pyran-6-one; SR-01000229483; SR-01000229483-1; 6H-Dibenzo[b,d]pyran-6-one, 3-hydroxy-4-methyl-
DMDBJCY DT Small molecular drug
DMDBJCY PC 5348729
DMDBJCY MW 226.23
DMDBJCY FM C14H10O3
DMDBJCY IC InChI=1S/C14H10O3/c1-8-12(15)7-6-10-9-4-2-3-5-11(9)14(16)17-13(8)10/h2-7,15H,1H3
DMDBJCY CS CC1=C(C=CC2=C1OC(=O)C3=CC=CC=C23)O
DMDBJCY IK LAVHXGNOROFSCU-UHFFFAOYSA-N
DMDBJCY IU 3-hydroxy-4-methylbenzo[c]chromen-6-one
DMDBJCY DE Discovery agent
DM5QZDL ID DM5QZDL
DM5QZDL DN 3-Hydroxy-4-phenyl-5H-furan-2-one
DM5QZDL HS Investigative
DM5QZDL SN CHEMBL295478; 6362-76-1; 3-Hydroxy-4-phenylfuran-2(5H)-one; CTK2A8725; DTXSID60446001; 3-hydroxy-4-phenyl-2(5h)-furanone; 2(5H)-Furanone, 3-hydroxy-4-phenyl-
DM5QZDL DT Small molecular drug
DM5QZDL PC 10103675
DM5QZDL MW 176.17
DM5QZDL FM C10H8O3
DM5QZDL IC InChI=1S/C10H8O3/c11-9-8(6-13-10(9)12)7-4-2-1-3-5-7/h1-5,8H,6H2
DM5QZDL CS C1C(C(=O)C(=O)O1)C2=CC=CC=C2
DM5QZDL IK WYGILTLZANOLBZ-UHFFFAOYSA-N
DM5QZDL IU 4-phenyloxolane-2,3-dione
DM5QZDL DE Discovery agent
DMZS4P7 ID DMZS4P7
DMZS4P7 DN 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7 HS Investigative
DMZS4P7 SN CHEMBL233618; 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7 DT Small molecular drug
DMZS4P7 PC 44432687
DMZS4P7 MW 260.29
DMZS4P7 FM C17H12N2O
DMZS4P7 IC InChI=1S/C17H12N2O/c1-11-2-3-13-4-5-14(9-17(13)19-11)15-6-12(10-18)7-16(20)8-15/h2-9,20H,1H3
DMZS4P7 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)O
DMZS4P7 IK DYISJDYQAJMMQY-UHFFFAOYSA-N
DMZS4P7 IU 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile
DMZS4P7 DE Discovery agent
DMYR350 ID DMYR350
DMYR350 DN 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione
DMYR350 HS Investigative
DMYR350 SN 3-Hydroxy-6-methyl-1H-1-benzazepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-6-methyl-; SCHEMBL8580170; CHEMBL143225; LPRUKTXSSXGABW-UHFFFAOYSA-N
DMYR350 DT Small molecular drug
DMYR350 PC 10655753
DMYR350 MW 203.19
DMYR350 FM C11H9NO3
DMYR350 IC InChI=1S/C11H9NO3/c1-6-3-2-4-7-10(6)8(13)5-9(14)11(15)12-7/h2-5,13H,1H3,(H,12,14,15)
DMYR350 CS CC1=C2C(=CC=C1)NC(=O)C(=O)C=C2O
DMYR350 IK SFRUZUUPMLUZHX-UHFFFAOYSA-N
DMYR350 IU 5-hydroxy-6-methyl-1H-1-benzazepine-2,3-dione
DMYR350 DE Discovery agent
DM3SOFX ID DM3SOFX
DM3SOFX DN 3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile
DM3SOFX HS Investigative
DM3SOFX SN 3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile; CHEMBL508693; SCHEMBL3015500; PBXARVUJEROSCH-UHFFFAOYSA-N
DM3SOFX DT Small molecular drug
DM3SOFX PC 24950552
DM3SOFX MW 261.269
DM3SOFX FM C17H11NO2
DM3SOFX IC InChI=1S/C17H11NO2/c18-10-14-8-16(20)7-13-5-4-12(9-17(13)14)11-2-1-3-15(19)6-11/h1-9,19-20H
DM3SOFX CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C(C=C3C=C2)O)C#N
DM3SOFX IK PBXARVUJEROSCH-UHFFFAOYSA-N
DM3SOFX IU 3-hydroxy-7-(3-hydroxyphenyl)naphthalene-1-carbonitrile
DM3SOFX DE Discovery agent
DMTEJOY ID DMTEJOY
DMTEJOY DN 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione
DMTEJOY HS Investigative
DMTEJOY SN SCHEMBL9389021
DMTEJOY DT Small molecular drug
DMTEJOY PC 10633414
DMTEJOY MW 234.16
DMTEJOY FM C10H6N2O5
DMTEJOY IC InChI=1S/C10H6N2O5/c13-8-4-9(14)10(15)11-7-2-1-5(12(16)17)3-6(7)8/h1-4,13H,(H,11,14,15)
DMTEJOY CS C1=CC2=C(C=C1[N+](=O)[O-])C(=CC(=O)C(=O)N2)O
DMTEJOY IK QIUGYFFOPLNZSP-UHFFFAOYSA-N
DMTEJOY IU 5-hydroxy-7-nitro-1H-1-benzazepine-2,3-dione
DMTEJOY DE Discovery agent
DM3H56L ID DM3H56L
DM3H56L DN 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one
DM3H56L HS Investigative
DM3H56L SN CHEMBL380720; 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one
DM3H56L DT Small molecular drug
DM3H56L PC 44408769
DM3H56L MW 240.25
DM3H56L FM C15H12O3
DM3H56L IC InChI=1S/C15H12O3/c1-8-5-9(2)14-11-4-3-10(16)7-13(11)18-15(17)12(14)6-8/h3-7,16H,1-2H3
DM3H56L CS CC1=CC(=C2C3=C(C=C(C=C3)O)OC(=O)C2=C1)C
DM3H56L IK LTZNXKCOWADUFT-UHFFFAOYSA-N
DM3H56L IU 3-hydroxy-8,10-dimethylbenzo[c]chromen-6-one
DM3H56L DE Discovery agent
DM7HKIF ID DM7HKIF
DM7HKIF DN 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione
DM7HKIF HS Investigative
DM7HKIF SN 144040-48-2; 2,5-Dihydro-2,5-dioxo-3-hydroxy-8-methyl-1H-benzazepine; 8-Me-Ddhb; AC1L2QYL; 5-hydroxy-8-methyl-1H-1-benzazepine-2,3-dione; 1H-1-Benzazepine-2,5-dione, 3-hydroxy-8-methyl-; CHEMBL143519; SCHEMBL9387738; CTK4C3913; 8-Methyl-3-hydroxy-1H-1-benzazepine-2,5-dione; 1H-1-Benzaepine-2,5-dione, 3-hydroxy-8-methyl-
DM7HKIF DT Small molecular drug
DM7HKIF PC 126810
DM7HKIF MW 203.19
DM7HKIF FM C11H9NO3
DM7HKIF IC InChI=1S/C11H9NO3/c1-6-2-3-7-8(4-6)12-11(15)10(14)5-9(7)13/h2-5,13H,1H3,(H,12,14,15)
DM7HKIF CS CC1=CC2=C(C=C1)C(=CC(=O)C(=O)N2)O
DM7HKIF IK HJKATLKAMYKFOH-UHFFFAOYSA-N
DM7HKIF IU 5-hydroxy-8-methyl-1H-1-benzazepine-2,3-dione
DM7HKIF CA CAS 144040-48-2
DM7HKIF DE Discovery agent
DMNV1P3 ID DMNV1P3
DMNV1P3 DN 3-Hydroxy-benzamide
DMNV1P3 HS Investigative
DMNV1P3 SN 3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; 3-Hydroxy-benzamide; CHEMBL419424; 3-Hydroxy benzamide; NSC379289; 3-hydroxybenzenecarboxamide; AC1Q4ZB3; AC1L7W2U; ACMC-1B71B; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; CTK2F7291; DTXSID90321635; NGMMGKYJUWYIIG-UHFFFAOYSA-N; MolPort-001-791-593; ZINC1590754; KM0548; BDBM50068769; 9282AB; ANW-33964; 3-HYDROXY-BENZOIC ACID,AMIDE; SBB079277; AKOS000207073; VZ26952; NSC-379289; MB00281; MCULE-9599926365; NCGC00323509-01; KB-32185; CJ-25437; AJ-27681; CJ-05592; SC-47787
DMNV1P3 DT Small molecular drug
DMNV1P3 PC 342403
DMNV1P3 MW 137.14
DMNV1P3 FM C7H7NO2
DMNV1P3 IC InChI=1S/C7H7NO2/c8-7(10)5-2-1-3-6(9)4-5/h1-4,9H,(H2,8,10)
DMNV1P3 CS C1=CC(=CC(=C1)O)C(=O)N
DMNV1P3 IK NGMMGKYJUWYIIG-UHFFFAOYSA-N
DMNV1P3 IU 3-hydroxybenzamide
DMNV1P3 CA CAS 618-49-5
DMNV1P3 DE Discovery agent
DMNUM4K ID DMNUM4K
DMNUM4K DN 3-hydroxybenzylhydrazine
DMNUM4K HS Investigative
DMNUM4K SN 3-hydroxybenzylhydrazine; 3-(hydrazinylmethyl)phenol; 637-33-2; 3-(Hydrazinomethyl)phenol; Nsd 1015; m-Hydroxybenzyl hydrazine; UNII-A27K5Q85R2; 3-Hydrazinomethyl-phenol; BRN 1841459; HYDRAZINE, 1-(3-HYDROXYBENZYL)-; CHEMBL352205; NSD-1015; A27K5Q85R2; 3-hydroxy-benzylhydrazine; C7H10N2O; m-hydroxybenzylhydrazine; Phenol,3-(hydrazinylmethyl)-; Spectrum_000313; SpecPlus_000785; AC1L1BYI; Spectrum4_001209; Spectrum5_001883; Spectrum3_000726; Lopac-H-9382; Lopac0_000597; BSPBio_002252; KBioGR_001618; 3-(Hydrazinomethyl)phenol #
DMNUM4K DT Small molecular drug
DMNUM4K PC 1663
DMNUM4K MW 138.17
DMNUM4K FM C7H10N2O
DMNUM4K IC InChI=1S/C7H10N2O/c8-9-5-6-2-1-3-7(10)4-6/h1-4,9-10H,5,8H2
DMNUM4K CS C1=CC(=CC(=C1)O)CNN
DMNUM4K IK OFKWWALNMPEOSZ-UHFFFAOYSA-N
DMNUM4K IU 3-(hydrazinylmethyl)phenol
DMNUM4K CA CAS 637-33-2
DMNUM4K CB CHEBI:104133
DMNUM4K DE Discovery agent
DM5T6AM ID DM5T6AM
DM5T6AM DN 3-hydroxydesaminokynurenine
DM5T6AM HS Investigative
DM5T6AM DT Small molecular drug
DM5T6AM PC 56603743
DM5T6AM MW 223.22
DM5T6AM FM C11H13NO4
DM5T6AM IC InChI=1S/C11H13NO4/c1-11(12,10(15)16)6-9(14)7-3-2-4-8(13)5-7/h2-5,13H,6,12H2,1H3,(H,15,16)
DM5T6AM CS CC(CC(=O)C1=CC(=CC=C1)O)(C(=O)O)N
DM5T6AM IK DVMCGTUZEKNSGK-UHFFFAOYSA-N
DM5T6AM IU 2-amino-4-(3-hydroxyphenyl)-2-methyl-4-oxobutanoic acid
DM5T6AM DE Discovery agent
DM2LBFW ID DM2LBFW
DM2LBFW DN 3-Hydroxyhippuric acid
DM2LBFW HS Investigative
DM2LBFW SN 3-hydroxyhippuric acid; m-Hydroxyhippuric acid; 1637-75-8; (3-Hydroxybenzoylamino)acetic acid; 2-[(3-hydroxyphenyl)formamido]acetic acid; Glycine, N-(3-hydroxybenzoyl)-; UNII-17HCX0HNRT; N-m-Hydroxylbenzoylglycine; 3-Hydroxybenzoylglycine; 17HCX0HNRT; CHEMBL447627; Glycine,N-(3-hydroxybenzoyl)-; (3-hydroxybenzamido)acetic acid; CHEBI:70824; m-Hydroxyhippurate; 3-Hydroxyhippurate; AC1L9OTS; (3-hydroxybenzoyl)glycine; AC1Q75XZ; N-(3-hydroxybenzoyl)glycine; SCHEMBL600772; CTK4D1647; DTXSID30167650; MolPort-004-292-678
DM2LBFW DT Small molecular drug
DM2LBFW PC 450268
DM2LBFW MW 195.17
DM2LBFW FM C9H9NO4
DM2LBFW IC InChI=1S/C9H9NO4/c11-7-3-1-2-6(4-7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)
DM2LBFW CS C1=CC(=CC(=C1)O)C(=O)NCC(=O)O
DM2LBFW IK XDOFWFNMYJRHEW-UHFFFAOYSA-N
DM2LBFW IU 2-[(3-hydroxybenzoyl)amino]acetic acid
DM2LBFW CA CAS 1637-75-8
DM2LBFW CB CHEBI:70824
DM2LBFW DE Discovery agent
DMKLZXV ID DMKLZXV
DMKLZXV DN 3-Hydroxyisoxazole-4-Carboxylic Acid
DMKLZXV HS Investigative
DMKLZXV SN 3-HYDROXYISOXAZOLE-4-CARBOXYLIC ACID; 178316-78-4; GAG; AC1L9M6X; 3-isoxazolol carboxylic acid; SCHEMBL353410; CHEMBL1232960; CTK0H1143; BDBM23242; DTXSID30332285; 1,2(1,5)-Isoxazole, IOA1; AKOS022719234; AKOS006383552; 3-oxo-1,2-oxazole-4-carboxylic acid; DB02111; 3-hydroxy-1,2-oxazole-4-carboxylic acid; 3-oxo-2,3-dihydroisoxazole-4-carboxylic acid; 2429-EP2311823A1; 2429-EP2308960A1; 4-Isoxazolecarboxylicacid, 2,3-dihydro-3-oxo-
DMKLZXV DT Small molecular drug
DMKLZXV PC 448651
DMKLZXV MW 129.07
DMKLZXV FM C4H3NO4
DMKLZXV IC InChI=1S/C4H3NO4/c6-3-2(4(7)8)1-9-5-3/h1H,(H,5,6)(H,7,8)
DMKLZXV CS C1=C(C(=O)NO1)C(=O)O
DMKLZXV IK JLPHBZYAQYOJND-UHFFFAOYSA-N
DMKLZXV IU 3-oxo-1,2-oxazole-4-carboxylic acid
DMKLZXV CA CAS 178316-78-4
DMKLZXV DE Discovery agent
DMNMB6V ID DMNMB6V
DMNMB6V DN 3-hydroxylauric acid
DMNMB6V HS Investigative
DMNMB6V SN 3-hydroxy lauric acid
DMNMB6V DT Small molecular drug
DMNMB6V PC 94216
DMNMB6V MW 216.32
DMNMB6V FM C12H24O3
DMNMB6V IC InChI=1S/C12H24O3/c1-2-3-4-5-6-7-8-9-11(13)10-12(14)15/h11,13H,2-10H2,1H3,(H,14,15)
DMNMB6V CS CCCCCCCCCC(CC(=O)O)O
DMNMB6V IK MUCMKTPAZLSKTL-UHFFFAOYSA-N
DMNMB6V IU 3-hydroxydodecanoic acid
DMNMB6V CA CAS 1883-13-2
DMNMB6V CB CHEBI:36206
DMNMB6V DE Discovery agent
DMFJLWO ID DMFJLWO
DMFJLWO DN 3-Hydroxy-Myristic Acid
DMFJLWO HS Investigative
DMFJLWO SN 3-hydroxymyristate; 3-hydroxytetradecanoate; beta-hydroxymyristate; 3-hydroxy myristic acid; 3-hydroxytetradecanoate(1-)
DMFJLWO DT Small molecular drug
DMFJLWO PC 5288266
DMFJLWO MW 244.37
DMFJLWO FM C14H28O3
DMFJLWO IC InChI=1S/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-13(15)12-14(16)17/h13,15H,2-12H2,1H3,(H,16,17)/t13-/m1/s1
DMFJLWO CS CCCCCCCCCCC[C@H](CC(=O)O)O
DMFJLWO IK ATRNZOYKSNPPBF-CYBMUJFWSA-N
DMFJLWO IU (3R)-3-hydroxytetradecanoic acid
DMFJLWO CA CAS 28715-21-1
DMFJLWO CB CHEBI:42539
DMFJLWO DE Discovery agent
DMXO98C ID DMXO98C
DMXO98C DN 3-hydroxy-N,N,N-trimethylbenzenaminium iodide
DMXO98C HS Investigative
DMXO98C SN TMPH; 3-(Trimethylammonio)phenol iodide; m-(Dimethylamino)phenol methiodide; 3-Hydroxy-N,N,N-trimethylbenzenaminium iodide; 3-Oxyphenyl trimethylammonium iodide; (m-Hydroxyphenyl)trimethylammonium iodide; CHEMBL37773; AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, IODIDE; 2498-27-3; 3483-84-9 (Parent); 3-Hydroxyphenyltrimethylammonium Iodide; AC1L29MQ; Benzenaminium, 3-hydroxy-N,N,N-trimethyl-, iodide; KNPHMCQIKGHPRU-UHFFFAOYSA-N; m-hydroxyphenyltrimethylammonium iodide; LS-18453; (3-hydroxyphenyl)-trimethylazanium iodide
DMXO98C DT Small molecular drug
DMXO98C PC 17250
DMXO98C MW 279.12
DMXO98C FM C9H14INO
DMXO98C IC InChI=1S/C9H13NO.HI/c1-10(2,3)8-5-4-6-9(11)7-8;/h4-7H,1-3H3;1H
DMXO98C CS C[N+](C)(C)C1=CC(=CC=C1)O.[I-]
DMXO98C IK KNPHMCQIKGHPRU-UHFFFAOYSA-N
DMXO98C IU (3-hydroxyphenyl)-trimethylazanium;iodide
DMXO98C CA CAS 2498-27-3
DMXO98C DE Discovery agent
DMS658R ID DMS658R
DMS658R DN 3-hydroxyoctanoic acid
DMS658R HS Investigative
DMS658R SN 3-hydroxyoctanoate; 3-OH-octanoic acid
DMS658R DT Small molecular drug
DMS658R PC 26613
DMS658R MW 160.21
DMS658R FM C8H16O3
DMS658R IC InChI=1S/C8H16O3/c1-2-3-4-5-7(9)6-8(10)11/h7,9H,2-6H2,1H3,(H,10,11)
DMS658R CS CCCCCC(CC(=O)O)O
DMS658R IK NDPLAKGOSZHTPH-UHFFFAOYSA-N
DMS658R IU 3-hydroxyoctanoic acid
DMS658R CA CAS 14292-27-4
DMS658R CB CHEBI:37098
DMS658R DE Discovery agent
DMMAK83 ID DMMAK83
DMMAK83 DN 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMMAK83 HS Investigative
DMMAK83 SN CHEMBL246622; 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate; Gallic acid 3-hydroxyphenethyl ester
DMMAK83 DT Small molecular drug
DMMAK83 PC 24180539
DMMAK83 MW 290.27
DMMAK83 FM C15H14O6
DMMAK83 IC InChI=1S/C15H14O6/c16-11-3-1-2-9(6-11)4-5-21-15(20)10-7-12(17)14(19)13(18)8-10/h1-3,6-8,16-19H,4-5H2
DMMAK83 CS C1=CC(=CC(=C1)O)CCOC(=O)C2=CC(=C(C(=C2)O)O)O
DMMAK83 IK VXELBUJPXRMMLF-UHFFFAOYSA-N
DMMAK83 IU 2-(3-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate
DMMAK83 DE Discovery agent
DM5OR96 ID DM5OR96
DM5OR96 DN 3-Hydroxy-piperidine-4-carboxylic acid
DM5OR96 HS Investigative
DM5OR96 SN CHEMBL16132; BDBM50223877
DM5OR96 DT Small molecular drug
DM5OR96 PC 44270790
DM5OR96 MW 145.16
DM5OR96 FM C6H11NO3
DM5OR96 IC InChI=1S/C6H11NO3/c8-5-3-7-2-1-4(5)6(9)10/h4-5,7-8H,1-3H2,(H,9,10)/t4-,5+/m1/s1
DM5OR96 CS C1CNC[C@@H]([C@@H]1C(=O)O)O
DM5OR96 IK ASDFUVTYTVOHPL-UHNVWZDZSA-N
DM5OR96 IU (3R,4R)-3-hydroxypiperidine-4-carboxylic acid
DM5OR96 DE Discovery agent
DM67QDT ID DM67QDT
DM67QDT DN 3-Hydroxypyruvic Acid
DM67QDT HS Investigative
DM67QDT SN 3-Hydroxypyruvic acid; hydroxypyruvic acid; 3-Hydroxy-2-oxopropanoic acid; hydroxypyruvate; 1113-60-6; beta-Hydroxypyruvate; UNII-934B2KHY0S; 3-hydroxypyruvate; 934B2KHY0S; OH-pyruvate; OH-pyr; 3PY; 4mfe; beta-Hydoxypyruvic acid; beta-Hydroxypyruvic acid; AC1L1AFB; SCHEMBL60708; CTK8A1122; CHEBI:30841; DTXSID40149588; MolPort-006-168-729; ZINC1532558; AKOS006378194; DB02951; HY-113013; CS-0059352; C00168; J-002568; beta-Hydroxypyruvic acid, >=95.0% (dry substance, T)
DM67QDT DT Small molecular drug
DM67QDT PC 964
DM67QDT MW 104.06
DM67QDT FM C3H4O4
DM67QDT IC InChI=1S/C3H4O4/c4-1-2(5)3(6)7/h4H,1H2,(H,6,7)
DM67QDT CS C(C(=O)C(=O)O)O
DM67QDT IK HHDDCCUIIUWNGJ-UHFFFAOYSA-N
DM67QDT IU 3-hydroxy-2-oxopropanoic acid
DM67QDT CA CAS 1113-60-6
DM67QDT CB CHEBI:30841
DM67QDT DE Discovery agent
DMCXZ9L ID DMCXZ9L
DMCXZ9L DN 3-hydroxyquinazoline-2,4(1H,3H)-dione
DMCXZ9L HS Investigative
DMCXZ9L SN 3-hydroxyquinazoline-2,4(1H,3H)-dione; 3-hydroxy-quinazoline-2,4-dione; CHEMBL183852; 5329-43-1; NSC2552; AC1Q6JF3; AC1L58DP; N-hydroxy quinazolinedione, 4; SCHEMBL1520708; 3-hydroxyquinazoline-2,4-dione; CTK4J7468; BDBM33412; DTXSID00277492; ZINC1640999; NSC-2552; 3-hydroxy-1H-quinazoline-2,4-dione; 3-HYDROXY-2,3H)-QUINAZOLINEDIONE
DMCXZ9L DT Small molecular drug
DMCXZ9L PC 220188
DMCXZ9L MW 178.14
DMCXZ9L FM C8H6N2O3
DMCXZ9L IC InChI=1S/C8H6N2O3/c11-7-5-3-1-2-4-6(5)9-8(12)10(7)13/h1-4,13H,(H,9,12)
DMCXZ9L CS C1=CC=C2C(=C1)C(=O)N(C(=O)N2)O
DMCXZ9L IK TZZSQUATPYDROZ-UHFFFAOYSA-N
DMCXZ9L IU 3-hydroxy-1H-quinazoline-2,4-dione
DMCXZ9L CA CAS 5329-43-1
DMCXZ9L DE Discovery agent
DMBZ60O ID DMBZ60O
DMBZ60O DN 3-Imidazol-1-ylmethyl-1H-indole
DMBZ60O HS Investigative
DMBZ60O SN CHEMBL116794; 3-Imidazol-1-ylmethyl-1H-indole; 1H-Indole, 3-(1H-imidazol-1-ylmethyl)-; 19714-15-9; MLS000105265; AC1LGCIB; Cambridge id 5261471; CBDivE_013805; SCHEMBL9214699; 3-(imidazol-1-ylmethyl)indole; CTK0E0809; DTXSID40355147; FRADTKAUXQUOIJ-UHFFFAOYSA-N; MolPort-001-788-875; HMS2390H20; ZINC293947; 3-(imidazol-1-ylmethyl)-1H-indole; BDBM50022120; AKOS030489795; MCULE-1147695503; 3-(1H-imidazol-1-ylmethyl)-1H-Indole; BAS 01027138; 1-(1H-Indole-3-ylmethyl)-1H-imidazole
DMBZ60O DT Small molecular drug
DMBZ60O PC 792486
DMBZ60O MW 197.24
DMBZ60O FM C12H11N3
DMBZ60O IC InChI=1S/C12H11N3/c1-2-4-12-11(3-1)10(7-14-12)8-15-6-5-13-9-15/h1-7,9,14H,8H2
DMBZ60O CS C1=CC=C2C(=C1)C(=CN2)CN3C=CN=C3
DMBZ60O IK FRADTKAUXQUOIJ-UHFFFAOYSA-N
DMBZ60O IU 3-(imidazol-1-ylmethyl)-1H-indole
DMBZ60O CA CAS 19714-15-9
DMBZ60O DE Discovery agent
DMAQOL0 ID DMAQOL0
DMAQOL0 DN 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole
DMAQOL0 HS Investigative
DMAQOL0 SN 72818-36-1; UK 34787; UK-34787; CHEMBL284356; 3-(1h-imidazol-1-ylmethyl)-2-(propan-2-yl)-1h-indole; 3-(imidazol-1-ylmethyl)-2-propan-2-yl-1H-indole; 3-Isopropyl-3-(1-imidazolylmethyl)indole; AC1L4YBG; 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole; AC1Q4X5Y; SCHEMBL11346119; CTK5D6874; DTXSID00223136; NZXGMVRYQLENHC-UHFFFAOYSA-N; BDBM50022121; NSC342229; AKOS030539398; NSC-342229; 3-(imidazol-1-ylmethyl)-2-isopropylindole; 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole(UK-34787); 1H-Indole, 3-(1H-imidazol-1-ylmethyl)-2-(1-methylethy
DMAQOL0 DT Small molecular drug
DMAQOL0 PC 194468
DMAQOL0 MW 239.32
DMAQOL0 FM C15H17N3
DMAQOL0 IC InChI=1S/C15H17N3/c1-11(2)15-13(9-18-8-7-16-10-18)12-5-3-4-6-14(12)17-15/h3-8,10-11,17H,9H2,1-2H3
DMAQOL0 CS CC(C)C1=C(C2=CC=CC=C2N1)CN3C=CN=C3
DMAQOL0 IK NZXGMVRYQLENHC-UHFFFAOYSA-N
DMAQOL0 IU 3-(imidazol-1-ylmethyl)-2-propan-2-yl-1H-indole
DMAQOL0 CA CAS 72818-36-1
DMAQOL0 DE Discovery agent
DMVF6OQ ID DMVF6OQ
DMVF6OQ DN 3-Imidazol-1-yl-quinoline
DMVF6OQ HS Investigative
DMVF6OQ SN 3-Imidazol-1-yl-quinoline; MLS003269485; SCHEMBL4514468; CHEMBL193556; BDBM8919; 3-(1h-imidazol-1-yl)quinoline; 3-(1H-Imidazole-1-yl)quinoline; Imidazole-substituted quinoline 26; ZINC13674486; Quinoline, 3-(1H-imidazol-1-yl)-; 63822-85-5
DMVF6OQ DT Small molecular drug
DMVF6OQ PC 12354256
DMVF6OQ MW 195.22
DMVF6OQ FM C12H9N3
DMVF6OQ IC InChI=1S/C12H9N3/c1-2-4-12-10(3-1)7-11(8-14-12)15-6-5-13-9-15/h1-9H
DMVF6OQ CS C1=CC=C2C(=C1)C=C(C=N2)N3C=CN=C3
DMVF6OQ IK SRUVTPIFNUPTIR-UHFFFAOYSA-N
DMVF6OQ IU 3-imidazol-1-ylquinoline
DMVF6OQ DE Discovery agent
DMYH6A2 ID DMYH6A2
DMYH6A2 DN 3-Indan-(1E)-ylidenemethyl-pyridine
DMYH6A2 HS Investigative
DMYH6A2 SN (3-Pyridylmethylene)indane 1a; SCHEMBL4221377; SCHEMBL4221371; CHEMBL364080; BDBM8581; AC1O7046; 3-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride
DMYH6A2 DT Small molecular drug
DMYH6A2 PC 6539759
DMYH6A2 MW 207.27
DMYH6A2 FM C15H13N
DMYH6A2 IC InChI=1S/C15H13N/c1-2-6-15-13(5-1)7-8-14(15)10-12-4-3-9-16-11-12/h1-6,9-11H,7-8H2/b14-10+
DMYH6A2 CS C1C/C(=C\\C2=CN=CC=C2)/C3=CC=CC=C31
DMYH6A2 IK WDSJJUYCBHIJRT-GXDHUFHOSA-N
DMYH6A2 IU 3-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DMYH6A2 DE Discovery agent
DMTQERW ID DMTQERW
DMTQERW DN 3-Indan-(1Z)-ylidenemethyl-pyridine
DMTQERW HS Investigative
DMTQERW SN (3-Pyridylmethylene)indane 1b; BDBM8583; SCHEMBL4221374; CHEMBL363621; AC1O7048; 3-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 3-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 3-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Hydrochloride
DMTQERW DT Small molecular drug
DMTQERW PC 6539760
DMTQERW MW 207.27
DMTQERW FM C15H13N
DMTQERW IC InChI=1S/C15H13N/c1-2-6-15-13(5-1)7-8-14(15)10-12-4-3-9-16-11-12/h1-6,9-11H,7-8H2/b14-10-
DMTQERW CS C1C/C(=C/C2=CN=CC=C2)/C3=CC=CC=C31
DMTQERW IK WDSJJUYCBHIJRT-UVTDQMKNSA-N
DMTQERW IU 3-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DMTQERW DE Discovery agent
DM890WJ ID DM890WJ
DM890WJ DN 3-Iodoboldine
DM890WJ HS Investigative
DM890WJ SN 3-Iodoboldine; CHEMBL256075; BDBM50202337
DM890WJ DT Small molecular drug
DM890WJ PC 10004036
DM890WJ MW 453.3
DM890WJ FM C19H20INO4
DM890WJ IC InChI=1S/C19H20INO4/c1-21-5-4-10-15-12(21)6-9-7-13(22)14(24-2)8-11(9)16(15)19(25-3)18(23)17(10)20/h7-8,12,22-23H,4-6H2,1-3H3/t12-/m0/s1
DM890WJ CS CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2I)O)OC)OC)O
DM890WJ IK YCBIBKGMUXWRRT-LBPRGKRZSA-N
DM890WJ IU (6aS)-3-iodo-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DM890WJ DE Discovery agent
DMDSJ0O ID DMDSJ0O
DMDSJ0O DN 3-iodo-N-(6-methylpyridin-2-yl)benzamide
DMDSJ0O HS Investigative
DMDSJ0O SN 3-iodo-N-(6-methylpyridin-2-yl)benzamide; CHEMBL210550; AC1MPEXW; Oprea1_504239; BDBM50186325
DMDSJ0O DT Small molecular drug
DMDSJ0O PC 3410100
DMDSJ0O MW 338.14
DMDSJ0O FM C13H11IN2O
DMDSJ0O IC InChI=1S/C13H11IN2O/c1-9-4-2-7-12(15-9)16-13(17)10-5-3-6-11(14)8-10/h2-8H,1H3,(H,15,16,17)
DMDSJ0O CS CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)I
DMDSJ0O IK YFGDUEHHLUXXKH-UHFFFAOYSA-N
DMDSJ0O IU 3-iodo-N-(6-methylpyridin-2-yl)benzamide
DMDSJ0O DE Discovery agent
DM3L0F8 ID DM3L0F8
DM3L0F8 DN 3-iodothyronamine
DM3L0F8 HS Investigative
DM3L0F8 SN CHEMBL201002; 3'-iodothyronamine; 3''-iodothyronamine; GTPL2145; SCHEMBL13886595; BDBM50181801; 4-[4-(2-aminoethyl)phenoxy]-2-iodophenol
DM3L0F8 DT Small molecular drug
DM3L0F8 PC 9950514
DM3L0F8 MW 355.17
DM3L0F8 FM C14H14INO2
DM3L0F8 IC InChI=1S/C14H14INO2/c15-13-9-10(7-8-16)1-6-14(13)18-12-4-2-11(17)3-5-12/h1-6,9,17H,7-8,16H2
DM3L0F8 CS C1=CC(=CC=C1O)OC2=C(C=C(C=C2)CCN)I
DM3L0F8 IK XIINYOJWNGOUPF-UHFFFAOYSA-N
DM3L0F8 IU 4-[4-(2-aminoethyl)-2-iodophenoxy]phenol
DM3L0F8 CA CAS 712349-95-6
DM3L0F8 CB CHEBI:89700
DM3L0F8 DE Discovery agent
DMNZMH6 ID DMNZMH6
DMNZMH6 DN 3-iodotyrosine
DMNZMH6 HS Investigative
DMNZMH6 SN 2-amino-3-(4-hydroxy-3-iodophenyl)propanoic acid; 3078-39-5; 3-Iodo-DL-tyrosine; C9H10INO3; 3-iodo-l-tyr; AC1Q4PGG; ACMC-209og3; SCHEMBL159411; AC1L1M60; GTPL5117; CTK7I4445; UQTZMGFTRHFAAM-UHFFFAOYSA-N; MolPort-006-167-934; NSC210787; AKOS022187633; S(-)-3-Iodo-4-hydroxy- phenylamine; TRA0009499; MCULE-7084802066; AN-8912; NSC-210787; FCH1320103; SC-11023; KB-32311; AX8285033; Z5788; 2-Amino-3-(3-iodo-4-hydroxyphenyl)propionic acid; 2-Amino-3-(4-hydroxy-3-iodophenyl)propionic acid; 2-amino-3-(4-hydroxy-3-iodo-phenyl)propanoic acid
DMNZMH6 DT Small molecular drug
DMNZMH6 PC 439744
DMNZMH6 MW 307.08
DMNZMH6 FM C9H10INO3
DMNZMH6 IC InChI=1S/C9H10INO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1
DMNZMH6 CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)I)O
DMNZMH6 IK UQTZMGFTRHFAAM-ZETCQYMHSA-N
DMNZMH6 IU (2S)-2-amino-3-(4-hydroxy-3-iodophenyl)propanoic acid
DMNZMH6 CA CAS 70-78-0
DMNZMH6 CB CHEBI:27847
DMNZMH6 DE Discovery agent
DMJSLVT ID DMJSLVT
DMJSLVT DN 3-Iodyl-benzoic acid
DMJSLVT HS Investigative
DMJSLVT SN 3-Iodyl-benzoic acid; 3-iodylbenzoic Acid; CHEMBL332161; 64297-65-0; m-iodoxybenzoic acid; AC1MTEHD; Benzoic acid, 3-iodyl-; SCHEMBL752292; CTK2A6346; DTXSID40393544
DMJSLVT DT Small molecular drug
DMJSLVT PC 3549290
DMJSLVT MW 280.02
DMJSLVT FM C7H5IO4
DMJSLVT IC InChI=1S/C7H5IO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4H,(H,9,10)
DMJSLVT CS C1=CC(=CC(=C1)I(=O)=O)C(=O)O
DMJSLVT IK PXGYMLKSIXWMJW-UHFFFAOYSA-N
DMJSLVT IU 3-iodylbenzoic acid
DMJSLVT CA CAS 64297-65-0
DMJSLVT DE Discovery agent
DMWP0LZ ID DMWP0LZ
DMWP0LZ DN 3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ HS Investigative
DMWP0LZ SN CHEMBL413487; 3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ DT Small molecular drug
DMWP0LZ PC 44432689
DMWP0LZ MW 316.4
DMWP0LZ FM C21H20N2O
DMWP0LZ IC InChI=1S/C21H20N2O/c1-14(2)13-24-20-9-16(12-22)8-19(10-20)18-7-6-17-5-4-15(3)23-21(17)11-18/h4-11,14H,13H2,1-3H3
DMWP0LZ CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)OCC(C)C
DMWP0LZ IK HPDNDHJWHRZLDU-UHFFFAOYSA-N
DMWP0LZ IU 3-(2-methylpropoxy)-5-(2-methylquinolin-7-yl)benzonitrile
DMWP0LZ DE Discovery agent
DM6X5TZ ID DM6X5TZ
DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline
DM6X5TZ HS Investigative
DM6X5TZ SN CHEMBL87334; CHEMBL1269093; ZINC13728526; BDBM50001470; 3-isobutoxy-9H-pyrido[3,4-b]indole
DM6X5TZ DT Small molecular drug
DM6X5TZ PC 10333698
DM6X5TZ MW 240.3
DM6X5TZ FM C15H16N2O
DM6X5TZ IC InChI=1S/C15H16N2O/c1-10(2)9-18-15-7-12-11-5-3-4-6-13(11)17-14(12)8-16-15/h3-8,10,17H,9H2,1-2H3
DM6X5TZ CS CC(C)COC1=NC=C2C(=C1)C3=CC=CC=C3N2
DM6X5TZ IK KWHWSXISOMCUPZ-UHFFFAOYSA-N
DM6X5TZ IU 3-(2-methylpropoxy)-9H-pyrido[3,4-b]indole
DM6X5TZ DE Discovery agent
DMQXP7C ID DMQXP7C
DMQXP7C DN 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine
DMQXP7C HS Investigative
DMQXP7C SN CHEMBL185919; 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine
DMQXP7C DT Small molecular drug
DMQXP7C PC 18721725
DMQXP7C MW 186.32
DMQXP7C FM C9H18N2S
DMQXP7C IC InChI=1S/C9H18N2S/c1-7(2)5-8-6-12-4-3-9(10)11-8/h7-8H,3-6H2,1-2H3,(H2,10,11)
DMQXP7C CS CC(C)CC1CSCCC(=N1)N
DMQXP7C IK KMFANDQFKVBAJW-UHFFFAOYSA-N
DMQXP7C IU 3-(2-methylpropyl)-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMQXP7C DE Discovery agent
DM9GM1H ID DM9GM1H
DM9GM1H DN 3-isobutyl-8-pyrrolidinoxanthine
DM9GM1H HS Investigative
DM9GM1H SN 3-isobutyl-8-pyrrolidinoxanthine; IPDX; GTPL447; SCHEMBL2954176; KHQOTPZSYMSVHB-UHFFFAOYSA-N
DM9GM1H DT Small molecular drug
DM9GM1H PC 10221256
DM9GM1H MW 277.32
DM9GM1H FM C13H19N5O2
DM9GM1H IC InChI=1S/C13H19N5O2/c1-8(2)7-18-10-9(11(19)16-13(18)20)14-12(15-10)17-5-3-4-6-17/h8H,3-7H2,1-2H3,(H,14,15)(H,16,19,20)
DM9GM1H CS CC(C)CN1C2=C(C(=O)NC1=O)NC(=N2)N3CCCC3
DM9GM1H IK KHQOTPZSYMSVHB-UHFFFAOYSA-N
DM9GM1H IU 3-(2-methylpropyl)-8-pyrrolidin-1-yl-7H-purine-2,6-dione
DM9GM1H DE Discovery agent
DM7PHO4 ID DM7PHO4
DM7PHO4 DN 3-Isopropoxy-9H-beta-carboline
DM7PHO4 HS Investigative
DM7PHO4 SN CHEMBL67421; 3-Isopropoxy-9H-beta-carboline; AC1NFSY9; 3-Isopropyloxy-beta-carboline; CHEMBL458006; SCHEMBL10642443; ZINC6858948; BDBM50001471
DM7PHO4 DT Small molecular drug
DM7PHO4 PC 4713435
DM7PHO4 MW 226.27
DM7PHO4 FM C14H14N2O
DM7PHO4 IC InChI=1S/C14H14N2O/c1-9(2)17-14-7-11-10-5-3-4-6-12(10)16-13(11)8-15-14/h3-9,16H,1-2H3
DM7PHO4 CS CC(C)OC1=NC=C2C(=C1)C3=CC=CC=C3N2
DM7PHO4 IK AKHQVIZELNFWSQ-UHFFFAOYSA-N
DM7PHO4 IU 3-propan-2-yloxy-9H-pyrido[3,4-b]indole
DM7PHO4 DE Discovery agent
DMYKVRF ID DMYKVRF
DMYKVRF DN 3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione
DMYKVRF HS Investigative
DMYKVRF SN 3-isopropyl-1-methylxanthine; CHEMBL26119; 102284-72-0; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(1-methylethyl)-; ACMC-20m5ap; 1-Methyl-3-isopropylxanthine; 3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione; 3-isopropyl-1-methyl xanthine; CTK0D9143; DTXSID50436895; BDBM50025581
DMYKVRF DT Small molecular drug
DMYKVRF PC 10219934
DMYKVRF MW 208.22
DMYKVRF FM C9H12N4O2
DMYKVRF IC InChI=1S/C9H12N4O2/c1-5(2)13-7-6(10-4-11-7)8(14)12(3)9(13)15/h4-5H,1-3H3,(H,10,11)
DMYKVRF CS CC(C)N1C2=C(C(=O)N(C1=O)C)NC=N2
DMYKVRF IK ZBQTVZYXBOKEMJ-UHFFFAOYSA-N
DMYKVRF IU 1-methyl-3-propan-2-yl-7H-purine-2,6-dione
DMYKVRF CA CAS 102284-72-0
DMYKVRF DE Discovery agent
DMSLPGZ ID DMSLPGZ
DMSLPGZ DN 3-Isopropyl-3-methyl-dihydro-furan-2-one
DMSLPGZ HS Investigative
DMSLPGZ SN 132462-11-4; alpha-Imgbl; 2(3H)-Furanone, dihydro-3-methyl-3-(1-methylethyl)-; 3-methyl-3-propan-2-yloxolan-2-one; alpha-Isopropyl-alpha-methyl-gamma-butyrolactone; AC1L2ZBI; CHEMBL35007; SCHEMBL10171772
DMSLPGZ DT Small molecular drug
DMSLPGZ PC 131516
DMSLPGZ MW 142.2
DMSLPGZ FM C8H14O2
DMSLPGZ IC InChI=1S/C8H14O2/c1-6(2)8(3)4-5-10-7(8)9/h6H,4-5H2,1-3H3
DMSLPGZ CS CC(C)C1(CCOC1=O)C
DMSLPGZ IK NUQBWYMPMSPNQT-UHFFFAOYSA-N
DMSLPGZ IU 3-methyl-3-propan-2-yloxolan-2-one
DMSLPGZ CA CAS 132462-11-4
DMSLPGZ DE Discovery agent
DMHAJ6W ID DMHAJ6W
DMHAJ6W DN 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione
DMHAJ6W HS Investigative
DMHAJ6W SN CHEMBL204939; 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione
DMHAJ6W DT Small molecular drug
DMHAJ6W PC 44409841
DMHAJ6W MW 291.3
DMHAJ6W FM C19H17NO2
DMHAJ6W IC InChI=1S/C19H17NO2/c1-12(2)16-17(20-13-8-4-3-5-9-13)14-10-6-7-11-15(14)18(21)19(16)22/h3-12,20H,1-2H3
DMHAJ6W CS CC(C)C1=C(C2=CC=CC=C2C(=O)C1=O)NC3=CC=CC=C3
DMHAJ6W IK HHIYZEJIOLXXOB-UHFFFAOYSA-N
DMHAJ6W IU 4-anilino-3-propan-2-ylnaphthalene-1,2-dione
DMHAJ6W DE Discovery agent
DMJZEMB ID DMJZEMB
DMJZEMB DN 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB HS Investigative
DMJZEMB SN CHEMBL205381; 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione
DMJZEMB DT Small molecular drug
DMJZEMB PC 44409669
DMJZEMB MW 308.4
DMJZEMB FM C19H16O2S
DMJZEMB IC InChI=1S/C19H16O2S/c1-12(2)16-18(21)17(20)14-10-6-7-11-15(14)19(16)22-13-8-4-3-5-9-13/h3-12H,1-2H3
DMJZEMB CS CC(C)C1=C(C2=CC=CC=C2C(=O)C1=O)SC3=CC=CC=C3
DMJZEMB IK VHVWQYNOEGPBOE-UHFFFAOYSA-N
DMJZEMB IU 4-phenylsulfanyl-3-propan-2-ylnaphthalene-1,2-dione
DMJZEMB DE Discovery agent
DMYZCWX ID DMYZCWX
DMYZCWX DN 3-isopropyl-4-phenylnaphthalene-1,2-dione
DMYZCWX HS Investigative
DMYZCWX SN CHEMBL207833; 3-isopropyl-4-phenylnaphthalene-1,2-dione
DMYZCWX DT Small molecular drug
DMYZCWX PC 44409685
DMYZCWX MW 276.3
DMYZCWX FM C19H16O2
DMYZCWX IC InChI=1S/C19H16O2/c1-12(2)16-17(13-8-4-3-5-9-13)14-10-6-7-11-15(14)18(20)19(16)21/h3-12H,1-2H3
DMYZCWX CS CC(C)C1=C(C2=CC=CC=C2C(=O)C1=O)C3=CC=CC=C3
DMYZCWX IK ZMFOKOSZYNMITK-UHFFFAOYSA-N
DMYZCWX IU 4-phenyl-3-propan-2-ylnaphthalene-1,2-dione
DMYZCWX DE Discovery agent
DM46ID2 ID DM46ID2
DM46ID2 DN 3-isopropylnaphthalene-1,2-dione
DM46ID2 HS Investigative
DM46ID2 SN CHEMBL44166; 3-Isopropyl-[1,2]naphthoquinone; 3-isopropylnaphthalene-1,2-dione; 3-Isopropyl-1,2-naphthoquinone; BDBM50009207; ZINC13821901
DM46ID2 DT Small molecular drug
DM46ID2 PC 14828129
DM46ID2 MW 200.23
DM46ID2 FM C13H12O2
DM46ID2 IC InChI=1S/C13H12O2/c1-8(2)11-7-9-5-3-4-6-10(9)12(14)13(11)15/h3-8H,1-2H3
DM46ID2 CS CC(C)C1=CC2=CC=CC=C2C(=O)C1=O
DM46ID2 IK KGCDZSGUSQQVKL-UHFFFAOYSA-N
DM46ID2 IU 3-propan-2-ylnaphthalene-1,2-dione
DM46ID2 DE Discovery agent
DMZPGBT ID DMZPGBT
DMZPGBT DN 3-isopr-sal-cyclosal-d4TMP
DMZPGBT HS Investigative
DMZPGBT SN CHEMBL375636; 3-isopr-sal-cyclosal-d4TMP; (Sp)-3-isopr-sal-cyclosal-d4TMP; (Rp)-3-isopr-sal-cyclosal-d4TMP; BDBM50206632; 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-5-[[[8-(2,2-dimethyl-4H-1,3-benzodioxin-8-yl)-2-oxido-4H-1,3,2-benzodioxaphosphorin-2-yl]oxy]methyl]-2,5-dihydro-2-furanyl]-5-methyl-
DMZPGBT DT Small molecular drug
DMZPGBT PC 16728608
DMZPGBT MW 554.5
DMZPGBT FM C27H27N2O9P
DMZPGBT IC InChI=1S/C27H27N2O9P/c1-16-12-29(26(31)28-25(16)30)22-11-10-19(36-22)15-35-39(32)34-14-18-7-5-9-21(24(18)38-39)20-8-4-6-17-13-33-27(2,3)37-23(17)20/h4-12,19,22H,13-15H2,1-3H3,(H,28,30,31)/t19-,22+,39?/m0/s1
DMZPGBT CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC6=C5OC(OC6)(C)C
DMZPGBT IK CCBOYGOTQIYLJA-CATCILLUSA-N
DMZPGBT IU 1-[(2R,5S)-5-[[8-(2,2-dimethyl-4H-1,3-benzodioxin-8-yl)-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DMZPGBT DE Discovery agent
DM9LEWH ID DM9LEWH
DM9LEWH DN 3-Isothiocyanato-9H-beta-carboline
DM9LEWH HS Investigative
DM9LEWH SN CHEMBL53651; 3-Isothiocyanato-9H-beta-carboline; 9H-Pyrido[3,4-b]indole, 3-isothiocyanato-; CHEMBL2262044; beta-Carbolin-3-yl isothiocyanate; BDBM50013788
DM9LEWH DT Small molecular drug
DM9LEWH PC 14146437
DM9LEWH MW 225.27
DM9LEWH FM C12H7N3S
DM9LEWH IC InChI=1S/C12H7N3S/c16-7-14-12-5-9-8-3-1-2-4-10(8)15-11(9)6-13-12/h1-6,15H
DM9LEWH CS C1=CC=C2C(=C1)C3=CC(=NC=C3N2)N=C=S
DM9LEWH IK NEOUOHDNZDRDNJ-UHFFFAOYSA-N
DM9LEWH IU 3-isothiocyanato-9H-pyrido[3,4-b]indole
DM9LEWH DE Discovery agent
DM5LUED ID DM5LUED
DM5LUED DN 3-keto-lithocholic acid
DM5LUED HS Investigative
DM5LUED SN dehydrolithocholic acid; 3-keto-LCA
DM5LUED DT Small molecular drug
DM5LUED PC 5283906
DM5LUED MW 374.6
DM5LUED FM C24H38O3
DM5LUED IC InChI=1S/C24H38O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-16,18-21H,4-14H2,1-3H3,(H,26,27)/t15-,16-,18+,19-,20+,21+,23+,24-/m1/s1
DM5LUED CS C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CCC(=O)C4)C)C
DM5LUED IK KIQFUORWRVZTHT-OPTMKGCMSA-N
DM5LUED IU (4R)-4-[(5R,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
DM5LUED CA CAS 1553-56-6
DM5LUED CB CHEBI:17639
DM5LUED DE Discovery agent
DMRMF13 ID DMRMF13
DMRMF13 DN 3-MATIDA
DMRMF13 HS Investigative
DMRMF13 SN alpha-amino-5-carboxy-3-methyl-2-thiopheneacetic acid
DMRMF13 DT Small molecular drug
DMRMF13 PC 10398360
DMRMF13 MW 215.23
DMRMF13 FM C8H9NO4S
DMRMF13 IC InChI=1S/C8H9NO4S/c1-3-2-4(7(10)11)14-6(3)5(9)8(12)13/h2,5H,9H2,1H3,(H,10,11)(H,12,13)
DMRMF13 CS CC1=C(SC(=C1)C(=O)O)C(C(=O)O)N
DMRMF13 IK KOMWRBFEDDEWEP-UHFFFAOYSA-N
DMRMF13 IU 5-[amino(carboxy)methyl]-4-methylthiophene-2-carboxylic acid
DMRMF13 CA CAS 518357-51-2
DMRMF13 CB CHEBI:93911
DMRMF13 DE Discovery agent
DMPJBNC ID DMPJBNC
DMPJBNC DN 3-mercapto-2-(piperidin-3-yl)propanoic acid
DMPJBNC HS Investigative
DMPJBNC SN CHEMBL245591; 3-mercapto-2-(piperidin-3-yl)propanoic acid; SCHEMBL2354438
DMPJBNC DT Small molecular drug
DMPJBNC PC 10214441
DMPJBNC MW 189.28
DMPJBNC FM C8H15NO2S
DMPJBNC IC InChI=1S/C8H15NO2S/c10-8(11)7(5-12)6-2-1-3-9-4-6/h6-7,9,12H,1-5H2,(H,10,11)
DMPJBNC CS C1CC(CNC1)C(CS)C(=O)O
DMPJBNC IK ZEKJYPSRDZCIDP-UHFFFAOYSA-N
DMPJBNC IU 2-piperidin-3-yl-3-sulfanylpropanoic acid
DMPJBNC DE Discovery agent
DMYQG7A ID DMYQG7A
DMYQG7A DN 3-mercapto-2-(piperidin-4-yl)propanoic acid
DMYQG7A HS Investigative
DMYQG7A SN CHEMBL246978; 3-mercapto-2-(piperidin-4-yl)propanoic acid; SCHEMBL2353967
DMYQG7A DT Small molecular drug
DMYQG7A PC 10192614
DMYQG7A MW 189.28
DMYQG7A FM C8H15NO2S
DMYQG7A IC InChI=1S/C8H15NO2S/c10-8(11)7(5-12)6-1-3-9-4-2-6/h6-7,9,12H,1-5H2,(H,10,11)
DMYQG7A CS C1CNCCC1C(CS)C(=O)O
DMYQG7A IK AYOUKDACKXEDFA-UHFFFAOYSA-N
DMYQG7A IU 2-piperidin-4-yl-3-sulfanylpropanoic acid
DMYQG7A DE Discovery agent
DMQ09J8 ID DMQ09J8
DMQ09J8 DN 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide
DMQ09J8 HS Investigative
DMQ09J8 SN reduced thio H2a; CHEMBL214201; SCHEMBL5805803; BDBM11041; reduced monomeric thio of compound 2a; AKOS023511640
DMQ09J8 DT Small molecular drug
DMQ09J8 PC 23645365
DMQ09J8 MW 260.3
DMQ09J8 FM C9H12N2O3S2
DMQ09J8 IC InChI=1S/C9H12N2O3S2/c10-16(13,14)8-3-1-7(2-4-8)11-9(12)5-6-15/h1-4,15H,5-6H2,(H,11,12)(H2,10,13,14)
DMQ09J8 CS C1=CC(=CC=C1NC(=O)CCS)S(=O)(=O)N
DMQ09J8 IK QGPJKQACZFKJBW-UHFFFAOYSA-N
DMQ09J8 IU N-(4-sulfamoylphenyl)-3-sulfanylpropanamide
DMQ09J8 DE Discovery agent
DMX3ANZ ID DMX3ANZ
DMX3ANZ DN 3-Mercuri-4-Aminobenzenesulfonamide
DMX3ANZ HS Investigative
DMX3ANZ SN 3-Mercuri-4-Aminobenzenesulfonamide; (2-amino-5-sulfamoylphenyl)mercury; AC1L4WFQ; SCHEMBL678556; CTK7D7985; CHEBI:49484; [2-amino-5-(sulfamoyl)phenyl]mercury; DB04203
DMX3ANZ DT Small molecular drug
DMX3ANZ PC 193512
DMX3ANZ MW 371.79
DMX3ANZ FM C6H7HgN2O2S
DMX3ANZ IC InChI=1S/C6H7N2O2S.Hg/c7-5-1-3-6(4-2-5)11(8,9)10;/h1,3-4H,7H2,(H2,8,9,10);
DMX3ANZ CS C1=CC(=C(C=C1S(=O)(=O)N)[Hg])N
DMX3ANZ IK KGGLGSZFQPTPPT-UHFFFAOYSA-N
DMX3ANZ IU (2-amino-5-sulfamoylphenyl)mercury
DMX3ANZ CB CHEBI:49484
DMX3ANZ DE Discovery agent
DMAWEQH ID DMAWEQH
DMAWEQH DN 3-MeSO2-DDE
DMAWEQH HS Investigative
DMAWEQH SN 1-Chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene; Meso2-dde; 62938-14-1; 3-Methylsulfonyl-dde; 3-Meso(2)-dde; AC1Q3QDJ; AC1L3O8E; CTK2F6395; DTXSID20212143; 5-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)vinyl]phenyl methyl sulfone; 2-(2-methylsulphonyl-4-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethene; Benzene, 4-chloro-1-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-2-(methylsulfonyl)-
DMAWEQH DT Small molecular drug
DMAWEQH PC 119115
DMAWEQH MW 396.1
DMAWEQH FM C15H10Cl4O2S
DMAWEQH IC InChI=1S/C15H10Cl4O2S/c1-22(20,21)13-8-11(17)6-7-12(13)14(15(18)19)9-2-4-10(16)5-3-9/h2-8H,1H3
DMAWEQH CS CS(=O)(=O)C1=C(C=CC(=C1)Cl)C(=C(Cl)Cl)C2=CC=C(C=C2)Cl
DMAWEQH IK YQCQEXWXRQQMAR-UHFFFAOYSA-N
DMAWEQH IU 4-chloro-1-[2,2-dichloro-1-(4-chlorophenyl)ethenyl]-2-methylsulfonylbenzene
DMAWEQH CA CAS 62938-14-1
DMAWEQH DE Discovery agent
DM2QD45 ID DM2QD45
DM2QD45 DN 3-methoxy-4-(m-tolyloxy)benzonitrile
DM2QD45 HS Investigative
DM2QD45 SN CHEMBL447604; 3-methoxy-4-(m-tolyloxy)benzonitrile
DM2QD45 DT Small molecular drug
DM2QD45 PC 44565151
DM2QD45 MW 239.27
DM2QD45 FM C15H13NO2
DM2QD45 IC InChI=1S/C15H13NO2/c1-11-4-3-5-13(8-11)18-14-7-6-12(10-16)9-15(14)17-2/h3-9H,1-2H3
DM2QD45 CS CC1=CC(=CC=C1)OC2=C(C=C(C=C2)C#N)OC
DM2QD45 IK XMFGJPOABFQKTB-UHFFFAOYSA-N
DM2QD45 IU 3-methoxy-4-(3-methylphenoxy)benzonitrile
DM2QD45 DE Discovery agent
DMEGF58 ID DMEGF58
DMEGF58 DN 3-methoxy-4-(o-tolyloxy)benzonitrile
DMEGF58 HS Investigative
DMEGF58 SN CHEMBL449867; 3-methoxy-4-(o-tolyloxy)benzonitrile; SCHEMBL4183144
DMEGF58 DT Small molecular drug
DMEGF58 PC 11557752
DMEGF58 MW 239.27
DMEGF58 FM C15H13NO2
DMEGF58 IC InChI=1S/C15H13NO2/c1-11-5-3-4-6-13(11)18-14-8-7-12(10-16)9-15(14)17-2/h3-9H,1-2H3
DMEGF58 CS CC1=CC=CC=C1OC2=C(C=C(C=C2)C#N)OC
DMEGF58 IK VDMHQBDHJWOOTF-UHFFFAOYSA-N
DMEGF58 IU 3-methoxy-4-(2-methylphenoxy)benzonitrile
DMEGF58 DE Discovery agent
DMKUM4L ID DMKUM4L
DMKUM4L DN 3-methoxy-4-(oxazol-5-yl)aniline
DMKUM4L HS Investigative
DMKUM4L SN 3-methoxy-4-(oxazol-5-yl)aniline; 198821-79-3; 3-METHOXY-4-(1,3-OXAZOL-5-YL)ANILINE; Benzenamine, 3-methoxy-4-(5-oxazolyl)-; 3-methoxy-4-(5-oxazolyl)aniline; CHEMBL45870; 5-(4-amino-2-methoxyphenyl)oxazole; AK116113; A1-00139; SCHEMBL1353846; CTK4E2632; KS-00000NNJ; DTXSID80572997; MolPort-006-666-066; KYCMMXMEXWSPCV-UHFFFAOYSA-N; ZINC2518269; FCH848314; 3-methoxy-4-(oxazol-5-yl) aniline; BDBM50127715; 3-Methoxy-4-oxazol-5-yl-phenylamine; AKOS006278384; CS-W005501; MP-1879; DS-2798; 3-methoxy-4-(oxazol-5-yl)benzenamine; AJ-37081
DMKUM4L DT Small molecular drug
DMKUM4L PC 15462732
DMKUM4L MW 190.2
DMKUM4L FM C10H10N2O2
DMKUM4L IC InChI=1S/C10H10N2O2/c1-13-9-4-7(11)2-3-8(9)10-5-12-6-14-10/h2-6H,11H2,1H3
DMKUM4L CS COC1=C(C=CC(=C1)N)C2=CN=CO2
DMKUM4L IK KYCMMXMEXWSPCV-UHFFFAOYSA-N
DMKUM4L IU 3-methoxy-4-(1,3-oxazol-5-yl)aniline
DMKUM4L CA CAS 198821-79-3
DMKUM4L DE Discovery agent
DM37QE8 ID DM37QE8
DM37QE8 DN 3-methoxy-4-(p-tolyloxy)benzonitrile
DM37QE8 HS Investigative
DM37QE8 SN CHEMBL464929; 3-methoxy-4-(p-tolyloxy)benzonitrile
DM37QE8 DT Small molecular drug
DM37QE8 PC 44565152
DM37QE8 MW 239.27
DM37QE8 FM C15H13NO2
DM37QE8 IC InChI=1S/C15H13NO2/c1-11-3-6-13(7-4-11)18-14-8-5-12(10-16)9-15(14)17-2/h3-9H,1-2H3
DM37QE8 CS CC1=CC=C(C=C1)OC2=C(C=C(C=C2)C#N)OC
DM37QE8 IK YKRUICLEGSVULK-UHFFFAOYSA-N
DM37QE8 IU 3-methoxy-4-(4-methylphenoxy)benzonitrile
DM37QE8 DE Discovery agent
DMG1T6H ID DMG1T6H
DMG1T6H DN 3'-Methoxy-4'Hydroxyclomiphene
DMG1T6H HS Investigative
DMG1T6H SN CHEMBL955; 3-Methoxy-4-hydroxyclomiphene; 3'-METHOXY-4'HYDROXYCLOMIPHENE; AC1MIWC3; SCHEMBL20193223; 3''-Methoxy-4''Hydroxyclomiphene; BDBM50020285; 4-{2-Chloro-1-[4-(2-diethylamino-ethoxy)-phenyl]-2-phenyl-vinyl}-2-methoxy-phenol; Phenol, 4-(2-chloro-1-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylethenyl)-2-methoxy-; 4-[(Z)-2-chloro-1-[4-(2-diethylaminoethyloxy)phenyl]-2-phenylethenyl]-2-methoxyphenol; 4-(2-Chloro-1-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylethenyl)-2-methoxyphenol
DMG1T6H DT Small molecular drug
DMG1T6H PC 3081117
DMG1T6H MW 452
DMG1T6H FM C27H30ClNO3
DMG1T6H IC InChI=1S/C27H30ClNO3/c1-4-29(5-2)17-18-32-23-14-11-20(12-15-23)26(27(28)21-9-7-6-8-10-21)22-13-16-24(30)25(19-22)31-3/h6-16,19,30H,4-5,17-18H2,1-3H3/b27-26-
DMG1T6H CS CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\\C2=CC=CC=C2)/Cl)/C3=CC(=C(C=C3)O)OC
DMG1T6H IK QRVWKOHAAHLWBP-RQZHXJHFSA-N
DMG1T6H IU 4-[(Z)-2-chloro-1-[4-[2-(diethylamino)ethoxy]phenyl]-2-phenylethenyl]-2-methoxyphenol
DMG1T6H CA CAS 117095-59-7
DMG1T6H DE Discovery agent
DMAL1CP ID DMAL1CP
DMAL1CP DN 3-methoxy-4-hydroxylonchocarpin
DMAL1CP HS Investigative
DMAL1CP SN Pongachalcone II; 3-methoxy-4-hydroxylonchocarpin; CHEMBL463206; Polyarvin; LMPK12120083
DMAL1CP DT Small molecular drug
DMAL1CP PC 10712965
DMAL1CP MW 352.4
DMAL1CP FM C21H20O5
DMAL1CP IC InChI=1S/C21H20O5/c1-21(2)11-10-15-18(26-21)9-6-14(20(15)24)16(22)7-4-13-5-8-17(23)19(12-13)25-3/h4-12,23-24H,1-3H3/b7-4+
DMAL1CP CS CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)/C=C/C3=CC(=C(C=C3)O)OC)C
DMAL1CP IK WNUBZQVPFKTBOZ-QPJJXVBHSA-N
DMAL1CP IU (E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
DMAL1CP DE Discovery agent
DMHYRES ID DMHYRES
DMHYRES DN 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES HS Investigative
DMHYRES SN CHEMBL397617; 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES DT Small molecular drug
DMHYRES PC 44434733
DMHYRES MW 261.279
DMHYRES FM C16H11N3O
DMHYRES IC InChI=1S/C16H11N3O/c1-20-14-6-11(9-17)5-12(7-14)13-8-16-15(19-10-13)3-2-4-18-16/h2-8,10H,1H3
DMHYRES CS COC1=CC(=CC(=C1)C2=CC3=C(C=CC=N3)N=C2)C#N
DMHYRES IK KPRNNBVYUUWBLA-UHFFFAOYSA-N
DMHYRES IU 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile
DMHYRES DE Discovery agent
DMKHJ8G ID DMKHJ8G
DMKHJ8G DN 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G HS Investigative
DMKHJ8G SN CHEMBL395122; 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G DT Small molecular drug
DMKHJ8G PC 44434727
DMKHJ8G MW 261.279
DMKHJ8G FM C16H11N3O
DMKHJ8G IC InChI=1S/C16H11N3O/c1-20-14-6-11(9-17)5-13(7-14)16-8-15-12(10-19-16)3-2-4-18-15/h2-8,10H,1H3
DMKHJ8G CS COC1=CC(=CC(=C1)C2=NC=C3C=CC=NC3=C2)C#N
DMKHJ8G IK YBYSMAYSUKEUHM-UHFFFAOYSA-N
DMKHJ8G IU 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile
DMKHJ8G DE Discovery agent
DMRMZLV ID DMRMZLV
DMRMZLV DN 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMRMZLV HS Investigative
DMRMZLV SN CHEMBL233417; 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4296310
DMRMZLV DT Small molecular drug
DMRMZLV PC 44432680
DMRMZLV MW 274.3
DMRMZLV FM C18H14N2O
DMRMZLV IC InChI=1S/C18H14N2O/c1-12-3-4-14-5-6-15(10-18(14)20-12)16-7-13(11-19)8-17(9-16)21-2/h3-10H,1-2H3
DMRMZLV CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)OC
DMRMZLV IK UYKOUDWFOWHINO-UHFFFAOYSA-N
DMRMZLV IU 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile
DMRMZLV DE Discovery agent
DMF2IW8 ID DMF2IW8
DMF2IW8 DN 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMF2IW8 HS Investigative
DMF2IW8 SN CHEMBL447591; 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine; SCHEMBL3004402; SEXSHORPOJSDHK-UHFFFAOYSA-N; BDBM50272250; ZINC40979781
DMF2IW8 DT Small molecular drug
DMF2IW8 PC 24827305
DMF2IW8 MW 265.31
DMF2IW8 FM C17H15NO2
DMF2IW8 IC InChI=1S/C17H15NO2/c1-19-16-6-5-12-7-13(3-4-14(12)8-16)15-9-17(20-2)11-18-10-15/h3-11H,1-2H3
DMF2IW8 CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)OC
DMF2IW8 IK SEXSHORPOJSDHK-UHFFFAOYSA-N
DMF2IW8 IU 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine
DMF2IW8 DE Discovery agent
DMO2N56 ID DMO2N56
DMO2N56 DN 3-methoxy-9-aminomethyl-9,10-dihydroanthracene
DMO2N56 HS Investigative
DMO2N56 SN 3-METHOXY-9-AMINOMETHYL-9,10-DIHYDROANTHRACENE; CHEMBL83081; 1075741-20-6; DTXSID10648836; BDBM50131086; 3-Methoxy-9,10-dihydroanthracene-9-methanamine; 1-(3-Methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMO2N56 DT Small molecular drug
DMO2N56 PC 25138699
DMO2N56 MW 239.31
DMO2N56 FM C16H17NO
DMO2N56 IC InChI=1S/C16H17NO/c1-18-13-6-7-15-12(9-13)8-11-4-2-3-5-14(11)16(15)10-17/h2-7,9,16H,8,10,17H2,1H3
DMO2N56 CS COC1=CC2=C(C=C1)C(C3=CC=CC=C3C2)CN
DMO2N56 IK DTEPCKRLYVEVEM-UHFFFAOYSA-N
DMO2N56 IU (3-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DMO2N56 CA CAS 1075741-20-6
DMO2N56 DE Discovery agent
DMTBX0D ID DMTBX0D
DMTBX0D DN 3-Methoxy-9H-beta-carboline
DMTBX0D HS Investigative
DMTBX0D SN 3-methoxy-9H-pyrido[3,4-b]indole; NSC627681; 91985-82-9; 9H-Pyrido[3,4-b]indole, 3-methoxy-; AC1Q4YMW; 3-Methoxy-beta-carboline; AC1L7M1C; 3-Methoxy-9H-; CHEMBL54228; CHEMBL496741; 3-Methoxy-9H-.beta.-carboline; SCHEMBL10646617; NSC-627681; 9H-.Beta.-Carbolin-3-yl methyl ether
DMTBX0D DT Small molecular drug
DMTBX0D PC 363113
DMTBX0D MW 198.22
DMTBX0D FM C12H10N2O
DMTBX0D IC InChI=1S/C12H10N2O/c1-15-12-6-9-8-4-2-3-5-10(8)14-11(9)7-13-12/h2-7,14H,1H3
DMTBX0D CS COC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMTBX0D IK UFGGNIMGPVLCJZ-UHFFFAOYSA-N
DMTBX0D IU 3-methoxy-9H-pyrido[3,4-b]indole
DMTBX0D DE Discovery agent
DM245AB ID DM245AB
DM245AB DN 3-Methoxybenzamide
DM245AB HS Investigative
DM245AB SN 3-Methoxybenzamide; 5813-86-5; m-Methoxybenzamide; m-Anisamide; 3-Methoxy-benzamide; Benzamide, 3-methoxy-; UNII-M8502TLK98; EINECS 227-379-7; NSC 28589; NSC 209527; BRN 2206857; CHEMBL123978; VKPLPDIMEREJJF-UHFFFAOYSA-N; M8502TLK98; 3MB; 3pax; 5-methoxybenzamide; 3-methoxy-benzamid; ACMC-1ASRE; AC1Q5DMC; M-METHOXY BENZAMIDE; bmse000775; 3-Methoxybenzamide, 97%; Oprea1_695428; MLS001066418; 4-10-00-00326 (Beilstein Handbook Reference); cid_98487; SCHEMBL283787; AC1L407F; KS-00000VVU; CTK1H2082; VKPLPDIMEREJJF-UHFFFAOYSA-; DTXSID00206848
DM245AB DT Small molecular drug
DM245AB PC 98487
DM245AB MW 151.16
DM245AB FM C8H9NO2
DM245AB IC InChI=1S/C8H9NO2/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5H,1H3,(H2,9,10)
DM245AB CS COC1=CC=CC(=C1)C(=O)N
DM245AB IK VKPLPDIMEREJJF-UHFFFAOYSA-N
DM245AB IU 3-methoxybenzamide
DM245AB CA CAS 5813-86-5
DM245AB DE Discovery agent
DMQMT1A ID DMQMT1A
DMQMT1A DN 3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium
DMQMT1A HS Investigative
DMQMT1A SN CHEMBL97741
DMQMT1A DT Small molecular drug
DMQMT1A PC 15630152
DMQMT1A MW 241.26
DMQMT1A FM C14H13N2O2+
DMQMT1A IC InChI=1S/C14H12N2O2/c1-16-8-12-10(7-13(16)14(17)18-2)9-5-3-4-6-11(9)15-12/h3-8H,1-2H3/p+1
DMQMT1A CS C[N+]1=C(C=C2C3=CC=CC=C3NC2=C1)C(=O)OC
DMQMT1A IK UUMQQVGTICTWCW-UHFFFAOYSA-O
DMQMT1A IU methyl 2-methyl-9H-pyrido[3,4-b]indol-2-ium-3-carboxylate
DMQMT1A DE Discovery agent
DMHVIK3 ID DMHVIK3
DMHVIK3 DN 3-methoxydesaminokynurenine
DMHVIK3 HS Investigative
DMHVIK3 DT Small molecular drug
DMHVIK3 PC 56603744
DMHVIK3 MW 237.25
DMHVIK3 FM C12H15NO4
DMHVIK3 IC InChI=1S/C12H15NO4/c1-12(13,11(15)16)7-10(14)8-4-3-5-9(6-8)17-2/h3-6H,7,13H2,1-2H3,(H,15,16)
DMHVIK3 CS CC(CC(=O)C1=CC(=CC=C1)OC)(C(=O)O)N
DMHVIK3 IK WRBHWPHQKJOLHX-UHFFFAOYSA-N
DMHVIK3 IU 2-amino-4-(3-methoxyphenyl)-2-methyl-4-oxobutanoic acid
DMHVIK3 DE Discovery agent
DMWNO4D ID DMWNO4D
DMWNO4D DN 3-Methoxyl-4'-amino-trans-stilbene
DMWNO4D HS Investigative
DMWNO4D SN 4-Amino-3'-methoxystilbene; CCRIS 6787; CHEMBL1173573; 4-(2-(3-Methoxyphenyl)ethenyl)benzenamine; Benzenamine, 4-(2-(3-methoxyphenyl)ethenyl)-; 154028-32-7; AC1O5THI; 3'-Methoxystilben-4-amine; SCHEMBL3365675; SCHEMBL3365670; KQIPLUOUWQXDOT-AATRIKPKSA-N; BDBM50322058; 3-Methoxyl-4''-amino-trans-stilbene; AKOS030582815; LS-28359; 4-[(E)-2-(3-methoxyphenyl)ethenyl]aniline
DMWNO4D DT Small molecular drug
DMWNO4D PC 6440384
DMWNO4D MW 225.28
DMWNO4D FM C15H15NO
DMWNO4D IC InChI=1S/C15H15NO/c1-17-15-4-2-3-13(11-15)6-5-12-7-9-14(16)10-8-12/h2-11H,16H2,1H3/b6-5+
DMWNO4D CS COC1=CC=CC(=C1)/C=C/C2=CC=C(C=C2)N
DMWNO4D IK KQIPLUOUWQXDOT-AATRIKPKSA-N
DMWNO4D IU 4-[(E)-2-(3-methoxyphenyl)ethenyl]aniline
DMWNO4D CA CAS 154028-32-7
DMWNO4D DE Discovery agent
DMH1RX6 ID DMH1RX6
DMH1RX6 DN 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline
DMH1RX6 HS Investigative
DMH1RX6 SN CHEMBL294562; Isoquinoline, 1,2,3,4-tetrahydro-3-(methoxymethyl)-; 245125-98-8; 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline; 3-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline; SCHEMBL7585285
DMH1RX6 DT Small molecular drug
DMH1RX6 PC 10797392
DMH1RX6 MW 177.24
DMH1RX6 FM C11H15NO
DMH1RX6 IC InChI=1S/C11H15NO/c1-13-8-11-6-9-4-2-3-5-10(9)7-12-11/h2-5,11-12H,6-8H2,1H3
DMH1RX6 CS COCC1CC2=CC=CC=C2CN1
DMH1RX6 IK IDSUOIGUQHWCCU-UHFFFAOYSA-N
DMH1RX6 IU 3-(methoxymethyl)-1,2,3,4-tetrahydroisoquinoline
DMH1RX6 DE Discovery agent
DMFEL39 ID DMFEL39
DMFEL39 DN 3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39 HS Investigative
DMFEL39 SN 3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide; ASN 03033124; AC1N2XQD; Oprea1_831715; CHEMBL388817; MolPort-000-015-090; HMS1702F08; ZINC4167694; STK237517; AKOS000648965; MCULE-6144605851; ST064843; 3-Methoxy-N-[1,3,4]thiadiazol-2-yl-benzamide; 3-methoxy-N~1~-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39 DT Small molecular drug
DMFEL39 PC 4055929
DMFEL39 MW 235.26
DMFEL39 FM C10H9N3O2S
DMFEL39 IC InChI=1S/C10H9N3O2S/c1-15-8-4-2-3-7(5-8)9(14)12-10-13-11-6-16-10/h2-6H,1H3,(H,12,13,14)
DMFEL39 CS COC1=CC=CC(=C1)C(=O)NC2=NN=CS2
DMFEL39 IK UMVWXZHHIZNLAO-UHFFFAOYSA-N
DMFEL39 IU 3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide
DMFEL39 DE Discovery agent
DM4WJX3 ID DM4WJX3
DM4WJX3 DN 3-methoxy-N-(4-methylthiazol-2-yl)benzamide
DM4WJX3 HS Investigative
DM4WJX3 SN CHEMBL211740; 477516-34-0; 3-methoxy-N-(4-methyl-1,3-thiazol-2-yl)benzamide; SMR000155061; AC1MAGB1; 3-methoxy-N-(4-methylthiazol-2-yl)benzamide; Oprea1_281072; Oprea1_273858; MLS000569675; CTK4J0236; cid_2679292; DTXSID80369021; MolPort-000-631-036; CHEBI:114888; HMS2341M09; ZINC3562014; BDBM50186332; AKOS001313290; MCULE-7375167923; KB-288021; BENZAMIDE, 3-METHOXY-N-(4-METHYL-2-THIAZOLYL)-
DM4WJX3 DT Small molecular drug
DM4WJX3 PC 2679292
DM4WJX3 MW 248.3
DM4WJX3 FM C12H12N2O2S
DM4WJX3 IC InChI=1S/C12H12N2O2S/c1-8-7-17-12(13-8)14-11(15)9-4-3-5-10(6-9)16-2/h3-7H,1-2H3,(H,13,14,15)
DM4WJX3 CS CC1=CSC(=N1)NC(=O)C2=CC(=CC=C2)OC
DM4WJX3 IK PAGPVSQZNPBQLP-UHFFFAOYSA-N
DM4WJX3 IU 3-methoxy-N-(4-methyl-1,3-thiazol-2-yl)benzamide
DM4WJX3 CA CAS 477516-34-0
DM4WJX3 CB CHEBI:114888
DM4WJX3 DE Discovery agent
DMSFJNE ID DMSFJNE
DMSFJNE DN 3-methoxy-N-(6-methylpyridin-2-yl)benzamide
DMSFJNE HS Investigative
DMSFJNE SN 3-methoxy-N-(6-methylpyridin-2-yl)benzamide; CHEMBL211801; AC1LBN1X; TimTec1_005849; Oprea1_873046; Oprea1_343584; ZINC92708; RGDXTZSZZQXINX-UHFFFAOYSA-N; MolPort-002-713-956; HMS1550J19; BDBM50186321; STK696160; AKOS003855494; MCULE-9890451107; NCGC00173451-01; ST090431; EU-0053201; 3-Methoxy-N-(6-methyl-2-pyridinyl)benzamide #; 3-Methoxy-N-(6-methyl-pyridin-2-yl)-benzamide; (3-methoxyphenyl)-N-(6-methyl(2-pyridyl))carboxamide
DMSFJNE DT Small molecular drug
DMSFJNE PC 585532
DMSFJNE MW 242.27
DMSFJNE FM C14H14N2O2
DMSFJNE IC InChI=1S/C14H14N2O2/c1-10-5-3-8-13(15-10)16-14(17)11-6-4-7-12(9-11)18-2/h3-9H,1-2H3,(H,15,16,17)
DMSFJNE CS CC1=NC(=CC=C1)NC(=O)C2=CC(=CC=C2)OC
DMSFJNE IK RGDXTZSZZQXINX-UHFFFAOYSA-N
DMSFJNE IU 3-methoxy-N-(6-methylpyridin-2-yl)benzamide
DMSFJNE DE Discovery agent
DMZ9MQ5 ID DMZ9MQ5
DMZ9MQ5 DN 3-methoxy-N',2-diphenylquinoline-4-carbohydrazide
DMZ9MQ5 HS Investigative
DMZ9MQ5 SN CHEMBL218717; SCHEMBL3963611; WQHSKTAHWLQAGK-UHFFFAOYSA-N; BDBM50194593; 3-methyloxy-N',2-diphenyl-4-quinolinecarbohydrazide
DMZ9MQ5 DT Small molecular drug
DMZ9MQ5 PC 44419758
DMZ9MQ5 MW 369.4
DMZ9MQ5 FM C23H19N3O2
DMZ9MQ5 IC InChI=1S/C23H19N3O2/c1-28-22-20(23(27)26-25-17-12-6-3-7-13-17)18-14-8-9-15-19(18)24-21(22)16-10-4-2-5-11-16/h2-15,25H,1H3,(H,26,27)
DMZ9MQ5 CS COC1=C(C2=CC=CC=C2N=C1C3=CC=CC=C3)C(=O)NNC4=CC=CC=C4
DMZ9MQ5 IK WQHSKTAHWLQAGK-UHFFFAOYSA-N
DMZ9MQ5 IU 3-methoxy-N',2-diphenylquinoline-4-carbohydrazide
DMZ9MQ5 DE Discovery agent
DMKHVGJ ID DMKHVGJ
DMKHVGJ DN 3-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMKHVGJ HS Investigative
DMKHVGJ SN CHEMBL481871; 3-methoxyphenyl 10H-phenothiazine-10-carboxylate
DMKHVGJ DT Small molecular drug
DMKHVGJ PC 24905596
DMKHVGJ MW 349.4
DMKHVGJ FM C20H15NO3S
DMKHVGJ IC InChI=1S/C20H15NO3S/c1-23-14-7-6-8-15(13-14)24-20(22)21-16-9-2-4-11-18(16)25-19-12-5-3-10-17(19)21/h2-13H,1H3
DMKHVGJ CS COC1=CC(=CC=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMKHVGJ IK UVKJOYFYOPXYID-UHFFFAOYSA-N
DMKHVGJ IU (3-methoxyphenyl) phenothiazine-10-carboxylate
DMKHVGJ DE Discovery agent
DMHJTLW ID DMHJTLW
DMHJTLW DN 3-methoxyphenylboronic acid
DMHJTLW HS Investigative
DMHJTLW SN 3-Methoxyphenylboronic acid; 10365-98-7; (3-methoxyphenyl)boronic acid; 3-Methoxybenzeneboronic acid; 3-methoxyphenyl boronic acid; (3-Methoxyphenyl)Boranediol; 3-Boronoanisole; 3-methoxypenylboronic acid; m-methoxyphenylboronic acid; boronic acid, (3-methoxyphenyl)-; 3-methoxy phenylboronic acid; 3-Methoxyphenylboronic acid, 97%; 3-methoxyphenylboronicacid; 3-boronanisole; Phenylboronic Acid, 6; AC1MC0ZC; ACMC-1BR3R; 3-methoxyphenylbornoic acid; m-methoxy phenylboronic acid; 3-methoxylphenylboronic acid; SCHEMBL5140
DMHJTLW DT Small molecular drug
DMHJTLW PC 2734370
DMHJTLW MW 151.96
DMHJTLW FM C7H9BO3
DMHJTLW IC InChI=1S/C7H9BO3/c1-11-7-4-2-3-6(5-7)8(9)10/h2-5,9-10H,1H3
DMHJTLW CS B(C1=CC(=CC=C1)OC)(O)O
DMHJTLW IK NLLGFYPSWCMUIV-UHFFFAOYSA-N
DMHJTLW IU (3-methoxyphenyl)boronic acid
DMHJTLW CA CAS 10365-98-7
DMHJTLW DE Discovery agent
DMCOH46 ID DMCOH46
DMCOH46 DN 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMCOH46 HS Investigative
DMCOH46 SN CHEMBL364999; 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine; BDBM50155779
DMCOH46 DT Small molecular drug
DMCOH46 PC 18721726
DMCOH46 MW 144.24
DMCOH46 FM C6H12N2S
DMCOH46 IC InChI=1S/C6H12N2S/c1-5-4-9-3-2-6(7)8-5/h5H,2-4H2,1H3,(H2,7,8)
DMCOH46 CS CC1CSCCC(=N1)N
DMCOH46 IK XAKJYXSNTIZTRW-UHFFFAOYSA-N
DMCOH46 IU 3-methyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMCOH46 DE Discovery agent
DMIWQ7G ID DMIWQ7G
DMIWQ7G DN 3-Methyl-1,2,3,4-tetrahydro-isoquinoline
DMIWQ7G HS Investigative
DMIWQ7G SN 3-Methyl-1,2,3,4-tetrahydroisoquinoline; 29726-60-1; 1,2,3,4-Tetrahydro-3-methylisoquinoline; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-; 3-Methyl-1,2,3,4-tetrahydro-isoquinoline; CHEMBL60434; UEKQPSAKUNXFHL-UHFFFAOYSA-N; BAS 03334621; AC1Q1HKS; AC1LC3M2; SCHEMBL1011182; SCHEMBL15334650; KS-00000JVD; MolPort-001-990-837; HMS1698C16; BDBM50023304; ANW-75096; AKOS016843414; AKOS000650337; AB30586; NE31770; MCULE-3517571472; NCGC00184271-01; DA-07231; KB-70931; BS-13528; TC-163841; ST24042290; FT-0729461; EN300-86328
DMIWQ7G DT Small molecular drug
DMIWQ7G PC 568974
DMIWQ7G MW 147.22
DMIWQ7G FM C10H13N
DMIWQ7G IC InChI=1S/C10H13N/c1-8-6-9-4-2-3-5-10(9)7-11-8/h2-5,8,11H,6-7H2,1H3
DMIWQ7G CS CC1CC2=CC=CC=C2CN1
DMIWQ7G IK UEKQPSAKUNXFHL-UHFFFAOYSA-N
DMIWQ7G IU 3-methyl-1,2,3,4-tetrahydroisoquinoline
DMIWQ7G DE Discovery agent
DMKOX0N ID DMKOX0N
DMKOX0N DN 3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide
DMKOX0N HS Investigative
DMKOX0N SN CHEMBL198022; 3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide; SCHEMBL15514276
DMKOX0N DT Small molecular drug
DMKOX0N PC 44405988
DMKOX0N MW 181.22
DMKOX0N FM C7H7N3OS
DMKOX0N IC InChI=1S/C7H7N3OS/c1-3-4-2-5(6(8)11)12-7(4)10-9-3/h2H,1H3,(H2,8,11)(H,9,10)
DMKOX0N CS CC1=C2C=C(SC2=NN1)C(=O)N
DMKOX0N IK MELHJKUYOBXOER-UHFFFAOYSA-N
DMKOX0N IU 3-methyl-2H-thieno[2,3-c]pyrazole-5-carboxamide
DMKOX0N DE Discovery agent
DMKYPUW ID DMKYPUW
DMKYPUW DN 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione
DMKYPUW HS Investigative
DMKYPUW SN CHEMBL67228; 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione
DMKYPUW DT Small molecular drug
DMKYPUW PC 10869347
DMKYPUW MW 270.29
DMKYPUW FM C14H14N4O2
DMKYPUW IC InChI=1S/C14H14N4O2/c1-17-12-11(15-9-16-12)13(19)18(14(17)20)8-7-10-5-3-2-4-6-10/h2-6,9H,7-8H2,1H3,(H,15,16)
DMKYPUW CS CN1C2=C(C(=O)N(C1=O)CCC3=CC=CC=C3)NC=N2
DMKYPUW IK FVUNKKIGHICYFX-UHFFFAOYSA-N
DMKYPUW IU 3-methyl-1-(2-phenylethyl)-7H-purine-2,6-dione
DMKYPUW DE Discovery agent
DMTM6B0 ID DMTM6B0
DMTM6B0 DN 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one
DMTM6B0 HS Investigative
DMTM6B0 SN CHEMBL412610; AC1MDPHC; BDBM50026583; 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-one
DMTM6B0 DT Small molecular drug
DMTM6B0 PC 2793709
DMTM6B0 MW 276.29
DMTM6B0 FM C17H12N2O2
DMTM6B0 IC InChI=1S/C17H12N2O2/c1-11-15-16(19(18-11)12-7-3-2-4-8-12)13-9-5-6-10-14(13)21-17(15)20/h2-10H,1H3
DMTM6B0 CS CC1=NN(C2=C1C(=O)OC3=CC=CC=C32)C4=CC=CC=C4
DMTM6B0 IK XQVHTRBZHCYIDD-UHFFFAOYSA-N
DMTM6B0 IU 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4-one
DMTM6B0 DE Discovery agent
DMHVNQM ID DMHVNQM
DMHVNQM DN 3-methyl-2(1H)-thioxo-4(3H)-quinazolinone
DMHVNQM HS Investigative
DMHVNQM SN 1705-09-5; 2-mercapto-3-methylquinazolin-4(3H)-one; 2-Mercapto-3-methyl-3H-quinazolin-4-one; CHEMBL460734; 3-methyl-2-sulfanylidene-1H-quinazolin-4-one; 2-mercapto-3-methyl-3,4-dihydroquinazolin-4-one; 3-methyl-2-thioxo-2,3-dihydroquinazolin-4(1H)-one; 3-Methyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one; 4(1H)-Quinazolinone, 2,3-dihydro-3-methyl-2-thioxo-; 3-methyl-2-thioxo-1H-quinazolin-4-one; 3-methyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone; 3-methyl-2-sulfanylquinazolin-4(3H)-one
DMHVNQM DT Small molecular drug
DMHVNQM PC 747056
DMHVNQM MW 192.24
DMHVNQM FM C9H8N2OS
DMHVNQM IC InChI=1S/C9H8N2OS/c1-11-8(12)6-4-2-3-5-7(6)10-9(11)13/h2-5H,1H3,(H,10,13)
DMHVNQM CS CN1C(=O)C2=CC=CC=C2NC1=S
DMHVNQM IK NVINMHFLRZHVKS-UHFFFAOYSA-N
DMHVNQM IU 3-methyl-2-sulfanylidene-1H-quinazolin-4-one
DMHVNQM CA CAS 1705-09-5
DMHVNQM DE Discovery agent
DMFC0H5 ID DMFC0H5
DMFC0H5 DN 3-Methyl-2H-benzo[f]quinazolin-1-one
DMFC0H5 HS Investigative
DMFC0H5 DT Small molecular drug
DMFC0H5 PC 135838247
DMFC0H5 MW 210.23
DMFC0H5 FM C13H10N2O
DMFC0H5 IC InChI=1S/C13H10N2O/c1-8-14-11-7-6-9-4-2-3-5-10(9)12(11)13(16)15-8/h2-7H,1H3,(H,14,15,16)
DMFC0H5 CS CC1=NC2=C(C3=CC=CC=C3C=C2)C(=O)N1
DMFC0H5 IK HVULCQPSGYYROI-UHFFFAOYSA-N
DMFC0H5 IU 3-methyl-2H-benzo[f]quinazolin-1-one
DMFC0H5 DE Discovery agent
DMKWAV6 ID DMKWAV6
DMKWAV6 DN 3-methyl-2-morpholino-1,1-diphenylbutan-1-ol
DMKWAV6 HS Investigative
DMKWAV6 SN CHEMBL1090793; 3-methyl-2-morpholino-1,1-diphenylbutan-1-ol
DMKWAV6 DT Small molecular drug
DMKWAV6 PC 46885515
DMKWAV6 MW 325.4
DMKWAV6 FM C21H27NO2
DMKWAV6 IC InChI=1S/C21H27NO2/c1-17(2)20(22-13-15-24-16-14-22)21(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17,20,23H,13-16H2,1-2H3
DMKWAV6 CS CC(C)C(C(C1=CC=CC=C1)(C2=CC=CC=C2)O)N3CCOCC3
DMKWAV6 IK DKXSPARARMBTSS-UHFFFAOYSA-N
DMKWAV6 IU 3-methyl-2-morpholin-4-yl-1,1-diphenylbutan-1-ol
DMKWAV6 DE Discovery agent
DM870UV ID DM870UV
DM870UV DN 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one
DM870UV HS Investigative
DM870UV SN 86100-07-4; CHEMBL102071; CTK2I3740; DTXSID80574491; AKOS030534429; 3-Methyl-2-phenyl[1]benzopyrano[4,3-c]pyrazol-4(2H)-one; [1]Benzopyrano[4,3-c]pyrazol-4(2H)-one, 3-methyl-2-phenyl-
DM870UV DT Small molecular drug
DM870UV PC 15569045
DM870UV MW 276.29
DM870UV FM C17H12N2O2
DM870UV IC InChI=1S/C17H12N2O2/c1-11-15-16(18-19(11)12-7-3-2-4-8-12)13-9-5-6-10-14(13)21-17(15)20/h2-10H,1H3
DM870UV CS CC1=C2C(=NN1C3=CC=CC=C3)C4=CC=CC=C4OC2=O
DM870UV IK VJSRCIFAUSKZHJ-UHFFFAOYSA-N
DM870UV IU 3-methyl-2-phenylchromeno[4,3-c]pyrazol-4-one
DM870UV CA CAS 86100-07-4
DM870UV DE Discovery agent
DM0WVTF ID DM0WVTF
DM0WVTF DN 3-Methyl-4-phenylbut-3-en-2-one oxime
DM0WVTF HS Investigative
DM0WVTF SN 5460-65-1; AC1L5FRS; Maybridge4_003045; CTK1H3786; MCULE-8988176310; 4-Phenyl-3-methyl-3-buten-2-on-oxim; N-(3-methyl-4-phenylbut-3-en-2-ylidene)hydroxylamine
DM0WVTF DT Small molecular drug
DM0WVTF PC 91934004
DM0WVTF MW 175.23
DM0WVTF FM C11H13NO
DM0WVTF IC InChI=1S/C11H13NO/c1-9(10(2)12-13)8-11-6-4-3-5-7-11/h3-8,10H,1-2H3/b9-8+
DM0WVTF CS CC(/C(=C/C1=CC=CC=C1)/C)N=O
DM0WVTF IK LZZIRBNCATZAGX-CMDGGOBGSA-N
DM0WVTF IU [(E)-2-methyl-3-nitrosobut-1-enyl]benzene
DM0WVTF DE Discovery agent
DMM3RNV ID DMM3RNV
DMM3RNV DN 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile
DMM3RNV HS Investigative
DMM3RNV SN CHEMBL232189; 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile; SCHEMBL4291326
DMM3RNV DT Small molecular drug
DMM3RNV PC 44432676
DMM3RNV MW 258.3
DMM3RNV FM C18H14N2
DMM3RNV IC InChI=1S/C18H14N2/c1-12-7-14(11-19)9-17(8-12)16-6-5-15-4-3-13(2)20-18(15)10-16/h3-10H,1-2H3
DMM3RNV CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)C
DMM3RNV IK FSRORMXGJWDWBA-UHFFFAOYSA-N
DMM3RNV IU 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile
DMM3RNV DE Discovery agent
DM3BL45 ID DM3BL45
DM3BL45 DN 3-methyl-6-(trifluoromethyl)-9H-carbazole
DM3BL45 HS Investigative
DM3BL45 SN CHEMBL1172905; 3-methyl-6-(trifluoromethyl)-9H-carbazole; SCHEMBL10253400
DM3BL45 DT Small molecular drug
DM3BL45 PC 46855064
DM3BL45 MW 249.23
DM3BL45 FM C14H10F3N
DM3BL45 IC InChI=1S/C14H10F3N/c1-8-2-4-12-10(6-8)11-7-9(14(15,16)17)3-5-13(11)18-12/h2-7,18H,1H3
DM3BL45 CS CC1=CC2=C(C=C1)NC3=C2C=C(C=C3)C(F)(F)F
DM3BL45 IK KIKCAVCUKRAGJM-UHFFFAOYSA-N
DM3BL45 IU 3-methyl-6-(trifluoromethyl)-9H-carbazole
DM3BL45 DE Discovery agent
DMZY6VX ID DMZY6VX
DMZY6VX DN 3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline
DMZY6VX HS Investigative
DMZY6VX SN CHEMBL59719; 3-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline; 3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline; SCHEMBL7512740; Isoquinoline, 1,2,3,4-tetrahydro-3-methyl-7-nitro-; OTVSEAHLIUCIKT-UHFFFAOYSA-N; BDBM50077543
DMZY6VX DT Small molecular drug
DMZY6VX PC 15407445
DMZY6VX MW 192.21
DMZY6VX FM C10H12N2O2
DMZY6VX IC InChI=1S/C10H12N2O2/c1-7-4-8-2-3-10(12(13)14)5-9(8)6-11-7/h2-3,5,7,11H,4,6H2,1H3
DMZY6VX CS CC1CC2=C(CN1)C=C(C=C2)[N+](=O)[O-]
DMZY6VX IK OTVSEAHLIUCIKT-UHFFFAOYSA-N
DMZY6VX IU 3-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline
DMZY6VX DE Discovery agent
DME81U3 ID DME81U3
DME81U3 DN 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3 HS Investigative
DME81U3 SN CHEMBL353023; 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one
DME81U3 DT Small molecular drug
DME81U3 PC 15685977
DME81U3 MW 193.28
DME81U3 FM C12H19NO
DME81U3 IC InChI=1S/C12H19NO/c1-11(12(2)14)7-3-4-8-13-9-5-6-10-13/h11H,5-10H2,1-2H3
DME81U3 CS CC(CC#CCN1CCCC1)C(=O)C
DME81U3 IK FFWLTEFDRQBMQC-UHFFFAOYSA-N
DME81U3 IU 3-methyl-7-pyrrolidin-1-ylhept-5-yn-2-one
DME81U3 DE Discovery agent
DMEJKZN ID DMEJKZN
DMEJKZN DN 3-Methyl-9H-beta-carboline
DMEJKZN HS Investigative
DMEJKZN SN 3-methyl-beta-carboline; 3-Methyl-9h-pyrido[3,4-b]indole; CHEMBL344859; 18203-06-0; 3-Methyl-9H-beta-carboline; 3-methyl-b-carboline; SCHEMBL3333771; XOHBPUCYRSORIZ-UHFFFAOYSA-N; BDBM50035527
DMEJKZN DT Small molecular drug
DMEJKZN PC 13315103
DMEJKZN MW 182.22
DMEJKZN FM C12H10N2
DMEJKZN IC InChI=1S/C12H10N2/c1-8-6-10-9-4-2-3-5-11(9)14-12(10)7-13-8/h2-7,14H,1H3
DMEJKZN CS CC1=CC2=C(C=N1)NC3=CC=CC=C32
DMEJKZN IK XOHBPUCYRSORIZ-UHFFFAOYSA-N
DMEJKZN IU 3-methyl-9H-pyrido[3,4-b]indole
DMEJKZN DE Discovery agent
DMX71N9 ID DMX71N9
DMX71N9 DN 3-Methylfentanyl
DMX71N9 HS Investigative
DMX71N9 SN Mefentanyl; 3-METHYLFENTANYL; 3-MF; 42045-86-3; N-(3-Methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide; F 7209; DEA No. 9813; Propanamide, N-(3-methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-; CHEBI:61092; N-(3-Methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide; N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide; 3-methyl-fentanyl; C23H30N2O; 3-Methylfentanil; AC1L1WAM; Epitope ID:153511; AC1Q5I8R; SCHEMBL2337401; HSDB 8379; CTK1D6517; MLQRZXNZHAOCHQ-UHFFFAOYSA-N; DB01571; LS-119344; R-26800
DMX71N9 DT Small molecular drug
DMX71N9 PC 61996
DMX71N9 MW 350.5
DMX71N9 FM C23H30N2O
DMX71N9 IC InChI=1S/C23H30N2O/c1-3-23(26)25(21-12-8-5-9-13-21)22-15-17-24(18-19(22)2)16-14-20-10-6-4-7-11-20/h4-13,19,22H,3,14-18H2,1-2H3
DMX71N9 CS CCC(=O)N(C1CCN(CC1C)CCC2=CC=CC=C2)C3=CC=CC=C3
DMX71N9 IK MLQRZXNZHAOCHQ-UHFFFAOYSA-N
DMX71N9 IU N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide
DMX71N9 CA CAS 42045-86-3
DMX71N9 CB CHEBI:61092
DMX71N9 DE Discovery agent
DMRNMKG ID DMRNMKG
DMRNMKG DN 3-methyl-N-(6-methylpyridin-2-yl)benzamide
DMRNMKG HS Investigative
DMRNMKG SN 3-methyl-N-(6-methylpyridin-2-yl)benzamide; CHEMBL212724; AC1LJ0IB; Oprea1_323038; Oprea1_123319; SCHEMBL8557860; MolPort-003-351-883; ZINC579315; BDBM50186319; AKOS001316653; MCULE-8428043810; 346720-66-9; ST51016902; N-(6-methyl(2-pyridyl))(3-methylphenyl)carboxamide
DMRNMKG DT Small molecular drug
DMRNMKG PC 966005
DMRNMKG MW 226.27
DMRNMKG FM C14H14N2O
DMRNMKG IC InChI=1S/C14H14N2O/c1-10-5-3-7-12(9-10)14(17)16-13-8-4-6-11(2)15-13/h3-9H,1-2H3,(H,15,16,17)
DMRNMKG CS CC1=CC(=CC=C1)C(=O)NC2=CC=CC(=N2)C
DMRNMKG IK AKCGNQRHTCXVRF-UHFFFAOYSA-N
DMRNMKG IU 3-methyl-N-(6-methylpyridin-2-yl)benzamide
DMRNMKG DE Discovery agent
DMQOI5X ID DMQOI5X
DMQOI5X DN 3-Methylphenylalanine
DMQOI5X HS Investigative
DMQOI5X SN 5472-70-8; 2-Amino-3-(m-tolyl)propanoic acid; 2-amino-3-m-tolyl-propionic acid; 3-Methy-DL-Phenylalanine; DL-3-ME-PHE-OH; 2-amino-3-(3-methylphenyl)propanoic acid; 3-METHYLPHENYLALANINE; 3-Methylphe; NSC14793; AC1L5E1A; SCHEMBL42906; AC1Q5S51; ss-m-Tolyl-a-amino-propionsaure; CTK8E3667; KS-00000JHC; 3-METHYL-DL-PHENYLALANINE; MolPort-003-990-079; 2-amino-3-(m-tolyl)propionic acid; 2283-42-3; NSC29447; NSC-29447; NSC-14793; AKOS016843161; AKOS000174493; MCULE-1997175050; AM83420; AB21660; 2-AMINO-3-M-TOLYLPROPANOIC ACID
DMQOI5X DT Small molecular drug
DMQOI5X PC 2761494
DMQOI5X MW 179.22
DMQOI5X FM C10H13NO2
DMQOI5X IC InChI=1S/C10H13NO2/c1-7-3-2-4-8(5-7)6-9(11)10(12)13/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
DMQOI5X CS CC1=CC(=CC=C1)C[C@@H](C(=O)O)N
DMQOI5X IK JZRBSTONIYRNRI-VIFPVBQESA-N
DMQOI5X IU (2S)-2-amino-3-(3-methylphenyl)propanoic acid
DMQOI5X CA CAS 114926-37-3
DMQOI5X DE Discovery agent
DMF3JHM ID DMF3JHM
DMF3JHM DN 3-Methylpyridine
DMF3JHM HS Investigative
DMF3JHM SN 3-METHYLPYRIDINE; 3-Picoline; 108-99-6; beta-Picoline; Pyridine, 3-methyl-; m-Picoline; m-Methylpyridine; B-Picoline; beta-Methylpyridine; 3-Methyl pyridine; .beta.-Methylpyridine; NSC 18251; .beta.-Picoline; meta-Methylpyridine; UNII-B083J4KF7F; 3-Mepy; CCRIS 1722; HSDB 4254; EINECS 203-636-9; AI3-24110; B083J4KF7F; 3-Methylpyridin; CHEBI:39922; ITQTTZVARXURQS-UHFFFAOYSA-N; 3-Picoline, 99%; DSSTox_CID_1897; DSSTox_RID_76391; DSSTox_GSID_21897; CAS-108-99-6; bpicolin; 3-methypyridine; 5-methylpyridine; 3-methyl-pyridin; 3-methyl pyridin
DMF3JHM DT Small molecular drug
DMF3JHM PC 7970
DMF3JHM MW 93.13
DMF3JHM FM C6H7N
DMF3JHM IC InChI=1S/C6H7N/c1-6-3-2-4-7-5-6/h2-5H,1H3
DMF3JHM CS CC1=CN=CC=C1
DMF3JHM IK ITQTTZVARXURQS-UHFFFAOYSA-N
DMF3JHM IU 3-methylpyridine
DMF3JHM CB CHEBI:39922
DMF3JHM DE Discovery agent
DMHVUF8 ID DMHVUF8
DMHVUF8 DN 3-Methyl-pyrrolidin-(2Z)-ylideneamine
DMHVUF8 HS Investigative
DMHVUF8 SN CHEMBL359703; CHEMBL545291; 3-Methylpyrrolidine-2-imine; BDBM50066781; AKOS006353988; 3-Methyl-pyrrolidin-(2E)-ylideneamine
DMHVUF8 DT Small molecular drug
DMHVUF8 PC 9942127
DMHVUF8 MW 98.15
DMHVUF8 FM C5H10N2
DMHVUF8 IC InChI=1S/C5H10N2/c1-4-2-3-7-5(4)6/h4H,2-3H2,1H3,(H2,6,7)
DMHVUF8 CS CC1CCN=C1N
DMHVUF8 IK IIZNRRGQKIIKRY-UHFFFAOYSA-N
DMHVUF8 IU 4-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMHVUF8 DE Discovery agent
DMQZULR ID DMQZULR
DMQZULR DN 3-Methylquinoline-8-carboxamide
DMQZULR HS Investigative
DMQZULR SN CHEMBL504998; 3-Methylquinoline-8-carboxamide; 8-Quinolinecarboxamide, 3-methyl-; BDBM50255267
DMQZULR DT Small molecular drug
DMQZULR PC 25208598
DMQZULR MW 186.21
DMQZULR FM C11H10N2O
DMQZULR IC InChI=1S/C11H10N2O/c1-7-5-8-3-2-4-9(11(12)14)10(8)13-6-7/h2-6H,1H3,(H2,12,14)
DMQZULR CS CC1=CC2=C(C(=CC=C2)C(=O)N)N=C1
DMQZULR IK BRQFPNHEOMCVCI-UHFFFAOYSA-N
DMQZULR IU 3-methylquinoline-8-carboxamide
DMQZULR DE Discovery agent
DMC153X ID DMC153X
DMC153X DN 3-Methylthiofentanyl
DMC153X HS Investigative
DMC153X SN 3-Methylthiofentanyl; 3-Methyl-thiofentanyl; UNII-C9C204973M; 86052-04-2; CHEBI:53763; N-(3-Methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide; C9C204973M; Propanamide, N-(3-methyl-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-; N-{3-methyl-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide; DEA No. 9833; 3-Methylthiofentanil; Epitope ID:153515; AC1Q5I8I; AC1L1WU2; SCHEMBL1742151; CHEMBL2365680; DB01439; FT-0672232
DMC153X DT Small molecular drug
DMC153X PC 62296
DMC153X MW 356.5
DMC153X FM C21H28N2OS
DMC153X IC InChI=1S/C21H28N2OS/c1-3-21(24)23(18-8-5-4-6-9-18)20-12-14-22(16-17(20)2)13-11-19-10-7-15-25-19/h4-10,15,17,20H,3,11-14,16H2,1-2H3
DMC153X CS CCC(=O)N(C1CCN(CC1C)CCC2=CC=CS2)C3=CC=CC=C3
DMC153X IK SRARDYUHGVMEQI-UHFFFAOYSA-N
DMC153X IU N-[3-methyl-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
DMC153X CA CAS 86052-04-2
DMC153X CB CHEBI:53763
DMC153X DE Discovery agent
DM0YS25 ID DM0YS25
DM0YS25 DN 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one
DM0YS25 HS Investigative
DM0YS25 SN CHEMBL194535; 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one
DM0YS25 DT Small molecular drug
DM0YS25 PC 44403357
DM0YS25 MW 294.3
DM0YS25 FM C18H18N2O2
DM0YS25 IC InChI=1S/C18H18N2O2/c21-18-16-4-2-1-3-14(16)15-6-5-13(11-17(15)19-18)12-20-7-9-22-10-8-20/h1-6,11H,7-10,12H2,(H,19,21)
DM0YS25 CS C1COCCN1CC2=CC3=C(C=C2)C4=CC=CC=C4C(=O)N3
DM0YS25 IK YRZWAGRTCFCAAG-UHFFFAOYSA-N
DM0YS25 IU 3-(morpholin-4-ylmethyl)-5H-phenanthridin-6-one
DM0YS25 DE Discovery agent
DMGWH0E ID DMGWH0E
DMGWH0E DN 3-morpholino-1H-benzo[f]chromen-1-one
DMGWH0E HS Investigative
DMGWH0E SN CHEMBL367537; 3-morpholino-1H-benzo[f]chromen-1-one; SCHEMBL13346489; BDBM50159678; 3-Morpholin-4-yl-benzo[f]chromen-1-one
DMGWH0E DT Small molecular drug
DMGWH0E PC 11437484
DMGWH0E MW 281.3
DMGWH0E FM C17H15NO3
DMGWH0E IC InChI=1S/C17H15NO3/c19-14-11-16(18-7-9-20-10-8-18)21-15-6-5-12-3-1-2-4-13(12)17(14)15/h1-6,11H,7-10H2
DMGWH0E CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43
DMGWH0E IK UEWQIWVPOFKCFX-UHFFFAOYSA-N
DMGWH0E IU 3-morpholin-4-ylbenzo[f]chromen-1-one
DMGWH0E DE Discovery agent
DMCDLG4 ID DMCDLG4
DMCDLG4 DN 3-MPPTS
DMCDLG4 HS Investigative
DMCDLG4 SN 2,2,2-Trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(3-pyridinylmethyl)-ethanesulfonamide; 3-MPPTS; SCHEMBL6732943; GTPL1401; GJWZEUKWBMFOAA-UHFFFAOYSA-N; 2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMCDLG4 DT Small molecular drug
DMCDLG4 PC 10275802
DMCDLG4 MW 452.4
DMCDLG4 FM C21H19F3N2O4S
DMCDLG4 IC InChI=1S/C21H19F3N2O4S/c1-29-19-9-2-3-10-20(19)30-18-8-4-7-17(12-18)26(14-16-6-5-11-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3
DMCDLG4 CS COC1=CC=CC=C1OC2=CC=CC(=C2)N(CC3=CN=CC=C3)S(=O)(=O)CC(F)(F)F
DMCDLG4 IK GJWZEUKWBMFOAA-UHFFFAOYSA-N
DMCDLG4 IU 2,2,2-trifluoro-N-[3-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMCDLG4 DE Discovery agent
DMMFA4N ID DMMFA4N
DMMFA4N DN 3-m-tolyl-1,5-naphthyridine
DMMFA4N HS Investigative
DMMFA4N SN CHEMBL236263; 3-m-tolyl-1,5-naphthyridine
DMMFA4N DT Small molecular drug
DMMFA4N PC 44434730
DMMFA4N MW 220.27
DMMFA4N FM C15H12N2
DMMFA4N IC InChI=1S/C15H12N2/c1-11-4-2-5-12(8-11)13-9-15-14(17-10-13)6-3-7-16-15/h2-10H,1H3
DMMFA4N CS CC1=CC(=CC=C1)C2=CC3=C(C=CC=N3)N=C2
DMMFA4N IK OICHXALTVOUDOG-UHFFFAOYSA-N
DMMFA4N IU 3-(3-methylphenyl)-1,5-naphthyridine
DMMFA4N DE Discovery agent
DMNZI9R ID DMNZI9R
DMNZI9R DN 3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R HS Investigative
DMNZI9R SN CHEMBL82485; 3-Naphthalen-1-yl-1-propyl-pyrrolidine
DMNZI9R DT Small molecular drug
DMNZI9R PC 44460743
DMNZI9R MW 239.35
DMNZI9R FM C17H21N
DMNZI9R IC InChI=1S/C17H21N/c1-2-11-18-12-10-15(13-18)17-9-5-7-14-6-3-4-8-16(14)17/h3-9,15H,2,10-13H2,1H3
DMNZI9R CS CCCN1CCC(C1)C2=CC=CC3=CC=CC=C32
DMNZI9R IK JPGGRFYDEHKZFB-UHFFFAOYSA-N
DMNZI9R IU 3-naphthalen-1-yl-1-propylpyrrolidine
DMNZI9R DE Discovery agent
DMCW7F5 ID DMCW7F5
DMCW7F5 DN 3-Naphthalen-1-yl-pyrrolidine
DMCW7F5 HS Investigative
DMCW7F5 SN 3-(1-NAPHTHYL)PYRROLIDINE; 178483-14-2; 3-(naphthalen-1-yl)pyrrolidine; CHEMBL311972; 3-Naphthalen-1-yl-pyrrolidine; SCHEMBL8878356; CTK5J7733; BDBM50290933; 5967AD; AKOS011343953
DMCW7F5 DT Small molecular drug
DMCW7F5 PC 10584082
DMCW7F5 MW 197.27
DMCW7F5 FM C14H15N
DMCW7F5 IC InChI=1S/C14H15N/c1-2-6-13-11(4-1)5-3-7-14(13)12-8-9-15-10-12/h1-7,12,15H,8-10H2
DMCW7F5 CS C1CNCC1C2=CC=CC3=CC=CC=C32
DMCW7F5 IK KTMCVZGLGDBGJZ-UHFFFAOYSA-N
DMCW7F5 IU 3-naphthalen-1-ylpyrrolidine
DMCW7F5 DE Discovery agent
DMZRNOT ID DMZRNOT
DMZRNOT DN 3-Nitro-4'-nitro-trans-stilbene
DMZRNOT HS Investigative
DMZRNOT SN (E)-3,4'-Dinitrostilbene; 3,4'-Dinitrostilbene; CHEMBL1173131; (E)-1-Nitro-3-(2-(4-nitrophenyl)ethenyl)benzene; 51042-51-4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-, (E)-; Stilbene, 3,4'-dinitro-; CCRIS 8545; AC1NTBW4; Benzene, 1-nitro-3-(2-(4-nitrophenyl)ethenyl)-; WMOGPQFWQAXCTI-SNAWJCMRSA-N; 3-Nitro-4''-nitro-trans-stilbene; ZINC6092536; BDBM50322057; 27892-99-5; LS-30911; 1-Nitro-3-[2-[4-nitrophenyl]ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene; 1-Nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene #
DMZRNOT DT Small molecular drug
DMZRNOT PC 5377857
DMZRNOT MW 270.24
DMZRNOT FM C14H10N2O4
DMZRNOT IC InChI=1S/C14H10N2O4/c17-15(18)13-8-6-11(7-9-13)4-5-12-2-1-3-14(10-12)16(19)20/h1-10H/b5-4+
DMZRNOT CS C1=CC(=CC(=C1)[N+](=O)[O-])/C=C/C2=CC=C(C=C2)[N+](=O)[O-]
DMZRNOT IK WMOGPQFWQAXCTI-SNAWJCMRSA-N
DMZRNOT IU 1-nitro-3-[(E)-2-(4-nitrophenyl)ethenyl]benzene
DMZRNOT CA CAS 27892-99-5
DMZRNOT DE Discovery agent
DM08V9W ID DM08V9W
DM08V9W DN 3-Nitro-9H-beta-carboline
DM08V9W HS Investigative
DM08V9W SN 9H-Pyrido[3,4-b]indole, 3-nitro-; AC1NFSZR; 3-Nitro-beta-carboline; CHEMBL53229; CHEMBL487006; 3-nitro-9H-pyrido[3,4-b]indole
DM08V9W DT Small molecular drug
DM08V9W PC 4713455
DM08V9W MW 213.19
DM08V9W FM C11H7N3O2
DM08V9W IC InChI=1S/C11H7N3O2/c15-14(16)11-5-8-7-3-1-2-4-9(7)13-10(8)6-12-11/h1-6,13H
DM08V9W CS C1=CC=C2C(=C1)C3=CC(=NC=C3N2)[N+](=O)[O-]
DM08V9W IK XQNOYQREYCKAIN-UHFFFAOYSA-N
DM08V9W IU 3-nitro-9H-pyrido[3,4-b]indole
DM08V9W DE Discovery agent
DMAY4OZ ID DMAY4OZ
DMAY4OZ DN 3-Nitro-benzenesulfonamide
DMAY4OZ HS Investigative
DMAY4OZ SN 3-Nitrobenzenesulfonamide; 121-52-8; Benzenesulfonamide, 3-nitro-; m-Nitrobenzenesulfonamide; 3-Nitrobenzolesulfamide; m-Nitrobenzenesulphonamide; 3-nitrobenzenesulphonamide; 3-Nitro-benzenesulfonamide; Benzenesulfonamide, m-nitro-; 3-nitrobenzene-1-sulfonamide; CHEMBL367035; TXTQURPQLVHJRE-UHFFFAOYSA-N; EINECS 204-477-8; NSC 407487; m-nitrobenzolsulfonamid; 3-nitrophenylsulfonamide; AI3-50018; AC1Q1GYY; 3-nitro-benzenesulfonamid; m-Nitrobenzene sulfonamide; 3-nitrophenyl sulphonamide; 3-nitrobenzene sulfonamide; AC1L26XH
DMAY4OZ DT Small molecular drug
DMAY4OZ PC 67138
DMAY4OZ MW 202.19
DMAY4OZ FM C6H6N2O4S
DMAY4OZ IC InChI=1S/C6H6N2O4S/c7-13(11,12)6-3-1-2-5(4-6)8(9)10/h1-4H,(H2,7,11,12)
DMAY4OZ CS C1=CC(=CC(=C1)S(=O)(=O)N)[N+](=O)[O-]
DMAY4OZ IK TXTQURPQLVHJRE-UHFFFAOYSA-N
DMAY4OZ IU 3-nitrobenzenesulfonamide
DMAY4OZ CA CAS 121-52-8
DMAY4OZ DE Discovery agent
DMIZJ9G ID DMIZJ9G
DMIZJ9G DN 3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMIZJ9G HS Investigative
DMIZJ9G SN CHEMBL381264; 3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMIZJ9G DT Small molecular drug
DMIZJ9G PC 11625160
DMIZJ9G MW 384.4
DMIZJ9G FM C22H16N4O3
DMIZJ9G IC InChI=1S/C22H16N4O3/c27-22(17-10-7-13-19(14-17)26(28)29)23-21-15-20(16-8-3-1-4-9-16)24-25(21)18-11-5-2-6-12-18/h1-15H,(H,23,27)
DMIZJ9G CS C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-])C4=CC=CC=C4
DMIZJ9G IK NTGZFLVYBRAVEA-UHFFFAOYSA-N
DMIZJ9G IU N-(2,5-diphenylpyrazol-3-yl)-3-nitrobenzamide
DMIZJ9G DE Discovery agent
DMPMX8R ID DMPMX8R
DMPMX8R DN 3-Nitrophenylboronic Acid
DMPMX8R HS Investigative
DMPMX8R SN 3-nitrophenylboronic acid; 13331-27-6; (3-nitrophenyl)boronic acid; 3-Nitrobenzeneboronic acid; m-Nitrophenylboronic acid; Boronic acid, (3-nitrophenyl)-; Benzeneboronic acid, m-nitro-; m-Nitrobenzeneboronic acid; 3-Nitrophenyl boronic acid; Boronic acid, B-(3-nitrophenyl)-; m-nitophenyl boronic acid; NSC 59739; BRN 2938638; 3-nitro-phenyl boronic acid; CHEMBL20945; AI3-60393; MFCD00007193; WLN: WNR CBQQ; 3-Nitrophenylboronic acid, 97%; zlchem 233; PubChem6366; AC1L1BZL; (3-nitrophenyl)boranediol; 3-nitropenyl boronic acid
DMPMX8R DT Small molecular drug
DMPMX8R PC 1677
DMPMX8R MW 166.93
DMPMX8R FM C6H6BNO4
DMPMX8R IC InChI=1S/C6H6BNO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4,9-10H
DMPMX8R CS B(C1=CC(=CC=C1)[N+](=O)[O-])(O)O
DMPMX8R IK ZNRGSYUVFVNSAW-UHFFFAOYSA-N
DMPMX8R IU (3-nitrophenyl)boronic acid
DMPMX8R CA CAS 13331-27-6
DMPMX8R DE Discovery agent
DMH798G ID DMH798G
DMH798G DN 3-nitropropionate
DMH798G HS Investigative
DMH798G SN 3-Nitropropanoate; 3-nitro-1-propionate; CHEMBL451226; 3-nitropropanoate anion; 3-nitropropionate anion; 3-nitropropanoate(1-); 3-nitropropionate(1-); AC1ODZ5Z; SCHEMBL3292643; CHEBI:59899; BDBM50274515
DMH798G DT Small molecular drug
DMH798G PC 1678
DMH798G MW 119.08
DMH798G FM C3H5NO4
DMH798G IC InChI=1S/C3H5NO4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)
DMH798G CS C(C[N+](=O)[O-])C(=O)O
DMH798G IK WBLZUCOIBUDNBV-UHFFFAOYSA-N
DMH798G IU 3-nitropropanoic acid
DMH798G CA CAS 504-88-1
DMH798G CB CHEBI:16348
DMH798G DE Discovery agent
DMFHYAE ID DMFHYAE
DMFHYAE DN 3-noradamantyl-1,3-dipropylxanthine
DMFHYAE HS Investigative
DMFHYAE DT Small molecular drug
DMFHYAE PC 129846038
DMFHYAE MW 356.5
DMFHYAE FM C20H28N4O2
DMFHYAE IC InChI=1S/C20H28N4O2/c1-3-5-22-18-17(19(25)23(6-4-2)20(22)26)24(11-21-18)16-14-8-12-7-13(10-14)15(16)9-12/h11-16H,3-10H2,1-2H3
DMFHYAE CS CCCN1C2=C(C(=O)N(C1=O)CCC)N(C=N2)C3C4CC5CC(C4)C3C5
DMFHYAE IK CTRHINADNBPODV-UHFFFAOYSA-N
DMFHYAE IU 1,3-dipropyl-7-(2-tricyclo[3.3.1.03,7]nonanyl)purine-2,6-dione
DMFHYAE DE Discovery agent
DMVIZ1S ID DMVIZ1S
DMVIZ1S DN 3-O-METHYLQUERCETIN
DMVIZ1S HS Investigative
DMVIZ1S SN 1486-70-0; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-4H-chromen-4-one; Quercetin 3-O-methyl ether; 3-Methylquercetol; NSC 154016; Quercetin-3-O-methyl ether; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-4H-1-benzopyran-4-one; UNII-7J92C373RH; CHEMBL163316; CHEBI:16860; 7J92C373RH; NSC-154016; 3-Methoxy-5,7,3',4'-tetrahydroxyflavone; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxy-
DMVIZ1S DT Small molecular drug
DMVIZ1S PC 5280681
DMVIZ1S MW 316.26
DMVIZ1S FM C16H12O7
DMVIZ1S IC InChI=1S/C16H12O7/c1-22-16-14(21)13-11(20)5-8(17)6-12(13)23-15(16)7-2-3-9(18)10(19)4-7/h2-6,17-20H,1H3
DMVIZ1S CS COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O
DMVIZ1S IK WEPBGSIAWZTEJR-UHFFFAOYSA-N
DMVIZ1S IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxychromen-4-one
DMVIZ1S CA CAS 1486-70-0
DMVIZ1S CB CHEBI:16860
DMVIZ1S DE Discovery agent
DMVIRLX ID DMVIRLX
DMVIRLX DN 3-Oximo-olean-12-en-29-oic acid
DMVIRLX HS Investigative
DMVIRLX SN 3-(Hydroxyimino)oleana-12-ene-29-oic acid
DMVIRLX DT Small molecular drug
DMVIRLX PC 91935881
DMVIRLX MW 469.7
DMVIRLX FM C30H47NO3
DMVIRLX IC InChI=1S/C30H47NO3/c1-25(2)21-10-13-30(7)22(28(21,5)12-11-23(25)31-34)9-8-19-20-18-27(4,24(32)33)15-14-26(20,3)16-17-29(19,30)6/h8,20-23H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,23?,26+,27+,28-,29+,30+/m0/s1
DMVIRLX CS C[C@]12CC[C@@](C[C@H]1C3=CC[C@@H]4[C@]5(CCC(C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)N=O)C)(C)C(=O)O
DMVIRLX IK WINMXRJYKUPMJI-DEXHSINNSA-N
DMVIRLX IU (2R,4aS,6aR,6aS,6bR,8aR,12aR,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-nitroso-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-2-carboxylic acid
DMVIRLX DE Discovery agent
DM47ZWK ID DM47ZWK
DM47ZWK DN 3'-Oxo-Adenosine
DM47ZWK HS Investigative
DM47ZWK SN 3'-OXO-ADENOSINE; ADY; AC1L9K4U; DB03273; 9-beta-D-erythro-pentofuranosyl-3-ulose-9H-purin-6-amine
DM47ZWK DT Small molecular drug
DM47ZWK PC 446824
DM47ZWK MW 265.23
DM47ZWK FM C10H11N5O4
DM47ZWK IC InChI=1S/C10H11N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,7,10,16,18H,1H2,(H2,11,12,13)/t4-,7-,10-/m1/s1
DM47ZWK CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H](C(=O)[C@H](O3)CO)O)N
DM47ZWK IK MIAZJCOESMXYNJ-XMRAEQSQSA-N
DM47ZWK IU (2R,4S,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-one
DM47ZWK DE Discovery agent
DM6JYWQ ID DM6JYWQ
DM6JYWQ DN 3-oxoolean-12-en-27-oic acid
DM6JYWQ HS Investigative
DM6JYWQ DT Small molecular drug
DM6JYWQ PC 44411850
DM6JYWQ MW 454.7
DM6JYWQ FM C30H46O3
DM6JYWQ IC InChI=1S/C30H46O3/c1-25(2)14-15-27(5)16-17-30(24(32)33)19(20(27)18-25)8-9-22-28(6)12-11-23(31)26(3,4)21(28)10-13-29(22,30)7/h8,20-22H,9-18H2,1-7H3,(H,32,33)/t20-,21?,22+,27+,28-,29+,30+/m0/s1
DM6JYWQ CS C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CCC(=O)C5(C)C)C)C)[C@@H]1CC(CC2)(C)C)C(=O)O
DM6JYWQ IK DQHMTWAVBRLUSK-YHNOYPSGSA-N
DM6JYWQ IU (4aR,6aR,6aR,6bR,12aR,14bR)-2,2,4a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-6a-carboxylic acid
DM6JYWQ DE Discovery agent
DMOLZ65 ID DMOLZ65
DMOLZ65 DN 3-phenacyl-UDP
DMOLZ65 HS Investigative
DMOLZ65 SN phenacyl-UDP
DMOLZ65 DT Small molecular drug
DMOLZ65 PC 11994011
DMOLZ65 MW 522.299
DMOLZ65 FM C17H20N2O13P2
DMOLZ65 IC InChI=1S/C17H20N2O13P2/c20-11(10-4-2-1-3-5-10)8-19-13(21)6-7-18(17(19)24)16-15(23)14(22)12(31-16)9-30-34(28,29)32-33(25,26)27/h1-7,12,14-16,22-23H,8-9H2,(H,28,29)(H2,25,26,27)/t12-,14-,15-,16-/m1/s1
DMOLZ65 CS C1=CC=C(C=C1)C(=O)CN2C(=O)C=CN(C2=O)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O
DMOLZ65 IK SEUHNFHNNANEAJ-DTZQCDIJSA-N
DMOLZ65 IU [(2R,3S,4R,5R)-5-(2,4-dioxo-3-phenacylpyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMOLZ65 DE Discovery agent
DM7RWQT ID DM7RWQT
DM7RWQT DN 3-Phenanthren-9-yl-pyridine
DM7RWQT HS Investigative
DM7RWQT SN 3-(9-phenanthryl)pyridine; 3-(phenanthren-9-yl)pyridine; SCHEMBL4508899; BDBM8915; CHEMBL194277; Pyridine-substituted phenanthryl 22
DM7RWQT DT Small molecular drug
DM7RWQT PC 11687499
DM7RWQT MW 255.3
DM7RWQT FM C19H13N
DM7RWQT IC InChI=1S/C19H13N/c1-2-8-16-14(6-1)12-19(15-7-5-11-20-13-15)18-10-4-3-9-17(16)18/h1-13H
DM7RWQT CS C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)C4=CN=CC=C4
DM7RWQT IK PNVGXPZDAYDCKZ-UHFFFAOYSA-N
DM7RWQT IU 3-phenanthren-9-ylpyridine
DM7RWQT DE Discovery agent
DMVSQFI ID DMVSQFI
DMVSQFI DN 3-Phenethyl-2-phenyl-3H-quinazolin-4-one
DMVSQFI HS Investigative
DMVSQFI SN 3-Phenethyl-2-phenyl-3H-quinazolin-4-one; CHEMBL180391; AC1LJAK1; Oprea1_440152; SCHEMBL5777984; MolPort-002-576-141; KANHEDFPOIQKTH-UHFFFAOYSA-N; ZINC546443; BDBM50162540; STL361550; 3-phenethyl-2-phenylquinazolin-4-one; AKOS003179499; MCULE-6975064033; 3-Phenethyl-2-phenylquinazoline-4(3H)-one; 2-phenyl-3-(2-phenylethyl)quinazolin-4(3H)-one
DMVSQFI DT Small molecular drug
DMVSQFI PC 947434
DMVSQFI MW 326.4
DMVSQFI FM C22H18N2O
DMVSQFI IC InChI=1S/C22H18N2O/c25-22-19-13-7-8-14-20(19)23-21(18-11-5-2-6-12-18)24(22)16-15-17-9-3-1-4-10-17/h1-14H,15-16H2
DMVSQFI CS C1=CC=C(C=C1)CCN2C(=NC3=CC=CC=C3C2=O)C4=CC=CC=C4
DMVSQFI IK KANHEDFPOIQKTH-UHFFFAOYSA-N
DMVSQFI IU 2-phenyl-3-(2-phenylethyl)quinazolin-4-one
DMVSQFI DE Discovery agent
DMGPOZE ID DMGPOZE
DMGPOZE DN 3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene
DMGPOZE HS Investigative
DMGPOZE SN CHEMBL365403; 3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene; BDBM50149798
DMGPOZE DT Small molecular drug
DMGPOZE PC 44392958
DMGPOZE MW 275.4
DMGPOZE FM C18H13NS
DMGPOZE IC InChI=1S/C18H13NS/c1-14-19-18(13-20-14)11-10-15-6-5-9-17(12-15)16-7-3-2-4-8-16/h2-9,12-13H,1H3
DMGPOZE CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)C3=CC=CC=C3
DMGPOZE IK JWWDWRFQBGXCEK-UHFFFAOYSA-N
DMGPOZE IU 2-methyl-4-[2-(3-phenylphenyl)ethynyl]-1,3-thiazole
DMGPOZE DE Discovery agent
DMU9WGT ID DMU9WGT
DMU9WGT DN 3-Phenyl-1,2-Propandiol
DMU9WGT HS Investigative
DMU9WGT SN 3-phenylpropane-1,2-diol; 17131-14-5; 3-phenyl-1,2-propanediol; AC1L59FY; AC1Q77AE; SCHEMBL25158; 1,2-Propanediol,3-phenyl-; CTK4D3895; NSC4322; DTXSID80277814; NSC-4322; AKOS017514819; DA-09349
DMU9WGT DT Small molecular drug
DMU9WGT PC 446127
DMU9WGT MW 152.19
DMU9WGT FM C9H12O2
DMU9WGT IC InChI=1S/C9H12O2/c10-7-9(11)6-8-4-2-1-3-5-8/h1-5,9-11H,6-7H2/t9-/m0/s1
DMU9WGT CS C1=CC=C(C=C1)C[C@@H](CO)O
DMU9WGT IK JHWQMXKQJVAWKI-VIFPVBQESA-N
DMU9WGT IU (2S)-3-phenylpropane-1,2-diol
DMU9WGT CA CAS 61475-32-9
DMU9WGT DE Discovery agent
DMD0OZ8 ID DMD0OZ8
DMD0OZ8 DN 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole
DMD0OZ8 HS Investigative
DMD0OZ8 SN 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole; CHEMBL215971; SCHEMBL6968182; NZNCUNCNFCUBOK-UHFFFAOYSA-N; BDBM50188284; ZINC36338882
DMD0OZ8 DT Small molecular drug
DMD0OZ8 PC 12043829
DMD0OZ8 MW 232.28
DMD0OZ8 FM C16H12N2
DMD0OZ8 IC InChI=1S/C16H12N2/c1-2-6-11(7-3-1)15-14-10-12-8-4-5-9-13(12)16(14)18-17-15/h1-9H,10H2,(H,17,18)
DMD0OZ8 CS C1C2=CC=CC=C2C3=C1C(=NN3)C4=CC=CC=C4
DMD0OZ8 IK NZNCUNCNFCUBOK-UHFFFAOYSA-N
DMD0OZ8 IU 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole
DMD0OZ8 DE Discovery agent
DM568CK ID DM568CK
DM568CK DN 3-Phenyl-1-propyl-piperidine hydrochloride
DM568CK HS Investigative
DM568CK DE Discovery agent
DMJ0SVB ID DMJ0SVB
DMJ0SVB DN 3-Phenyl-1-propyl-pyrrolidine
DMJ0SVB HS Investigative
DMJ0SVB SN CHEMBL82541; 3-Phenyl-1-propyl-pyrrolidine; SCHEMBL1546830
DMJ0SVB DT Small molecular drug
DMJ0SVB PC 12101308
DMJ0SVB MW 189.3
DMJ0SVB FM C13H19N
DMJ0SVB IC InChI=1S/C13H19N/c1-2-9-14-10-8-13(11-14)12-6-4-3-5-7-12/h3-7,13H,2,8-11H2,1H3
DMJ0SVB CS CCCN1CCC(C1)C2=CC=CC=C2
DMJ0SVB IK SUMWVMTWESCBLU-UHFFFAOYSA-N
DMJ0SVB IU 3-phenyl-1-propylpyrrolidine
DMJ0SVB DE Discovery agent
DMEG3YX ID DMEG3YX
DMEG3YX DN 3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione
DMEG3YX HS Investigative
DMEG3YX SN 3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione; CHEMBL479747; MolPort-002-665-959; ZINC6670445; STK789842; BDBM50251664; AKOS003747776; MCULE-9417936038
DMEG3YX DT Small molecular drug
DMEG3YX PC 17067759
DMEG3YX MW 280.32
DMEG3YX FM C17H16N2O2
DMEG3YX IC InChI=1S/C17H16N2O2/c1-2-12-18-15-11-7-6-10-14(15)16(20)19(17(18)21)13-8-4-3-5-9-13/h3-11H,2,12H2,1H3
DMEG3YX CS CCCN1C2=CC=CC=C2C(=O)N(C1=O)C3=CC=CC=C3
DMEG3YX IK HDWMSIFMWUKWBC-UHFFFAOYSA-N
DMEG3YX IU 3-phenyl-1-propylquinazoline-2,4-dione
DMEG3YX DE Discovery agent
DMAJMU6 ID DMAJMU6
DMAJMU6 DN 3-Phenyl-2-nortropene
DMAJMU6 HS Investigative
DMAJMU6 SN CHEMBL576092; 3-Phenyl-2-nortropene; SCHEMBL2881954; BDBM50303305; 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene
DMAJMU6 DT Small molecular drug
DMAJMU6 PC 10154356
DMAJMU6 MW 185.26
DMAJMU6 FM C13H15N
DMAJMU6 IC InChI=1S/C13H15N/c1-2-4-10(5-3-1)11-8-12-6-7-13(9-11)14-12/h1-5,8,12-14H,6-7,9H2
DMAJMU6 CS C1CC2C=C(CC1N2)C3=CC=CC=C3
DMAJMU6 IK VHBRUQHAUJNUAM-UHFFFAOYSA-N
DMAJMU6 IU 3-phenyl-8-azabicyclo[3.2.1]oct-2-ene
DMAJMU6 CA CAS 36769-07-0
DMAJMU6 DE Discovery agent
DM6T5K4 ID DM6T5K4
DM6T5K4 DN 3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione
DM6T5K4 HS Investigative
DM6T5K4 SN SKF-62604; 4-arylmaleimide deriv. 6a; phenyl anilino-maleimide; AC1O6ZNQ; BDBM8218; SCHEMBL5682682; CHEMBL346551; HMS3303J01; HMS3305A03; 2-(Phenylamino)-3-phenylmaleimide; 3-anilino-4-phenylpyrrole-2,5-dione; NCGC00241898-01; AB01092118-01
DM6T5K4 DT Small molecular drug
DM6T5K4 PC 6539451
DM6T5K4 MW 264.28
DM6T5K4 FM C16H12N2O2
DM6T5K4 IC InChI=1S/C16H12N2O2/c19-15-13(11-7-3-1-4-8-11)14(16(20)18-15)17-12-9-5-2-6-10-12/h1-10H,(H2,17,18,19,20)
DM6T5K4 CS C1=CC=C(C=C1)C2=C(C(=O)NC2=O)NC3=CC=CC=C3
DM6T5K4 IK ACQZMAJVOPRMQJ-UHFFFAOYSA-N
DM6T5K4 IU 3-anilino-4-phenylpyrrole-2,5-dione
DM6T5K4 DE Discovery agent
DM2C9X8 ID DM2C9X8
DM2C9X8 DN 3-phenyl-4-hydroxyquinolin-2(1H)-one
DM2C9X8 HS Investigative
DM2C9X8 SN 14933-29-0; 3-Phenyl-2,4-quinolinediol; 3-phenyl-4-hydroxyquinolin-2(1H)-one; 2,4-Dihydroxy-3-phenylquinoline; NSC16582; UNII-98SFL4LU2U; 98SFL4LU2U; 3-phenylquinoline-2,4-diol; CHEMBL324519; 4-hydroxy-3-phenylquinolin-2(1H)-one; 4-Hydroxy-3-phenyl-1H-quinolin-2-one; 2,4-quinolinediol, 3-phenyl-; NSC 16582; Maybridge1_005460; AC1L5EN7; Oprea1_589873; MLS000850648; DivK1c_001748; SCHEMBL625364; AC1Q6B83; HMS557A04; CTK4C6143; DTXSID90164221; MolPort-002-043-580; MolPort-000-808-473; HMS2269O16; NSC-16582; BDBM50001260; STK587488
DM2C9X8 DT Small molecular drug
DM2C9X8 PC 54677756
DM2C9X8 MW 237.25
DM2C9X8 FM C15H11NO2
DM2C9X8 IC InChI=1S/C15H11NO2/c17-14-11-8-4-5-9-12(11)16-15(18)13(14)10-6-2-1-3-7-10/h1-9H,(H2,16,17,18)
DM2C9X8 CS C1=CC=C(C=C1)C2=C(C3=CC=CC=C3NC2=O)O
DM2C9X8 IK WNISVGSZMGXKHE-UHFFFAOYSA-N
DM2C9X8 IU 4-hydroxy-3-phenyl-1H-quinolin-2-one
DM2C9X8 CA CAS 14933-29-0
DM2C9X8 DE Discovery agent
DM43CIK ID DM43CIK
DM43CIK DN 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK HS Investigative
DM43CIK SN CHEMBL512633; 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK DT Small molecular drug
DM43CIK PC 44574267
DM43CIK MW 315.3
DM43CIK FM C15H13N3O3S
DM43CIK IC InChI=1S/C15H13N3O3S/c16-15(19)14-13(9-4-2-1-3-5-9)11-8-10(22(17,20)21)6-7-12(11)18-14/h1-8,18H,(H2,16,19)(H2,17,20,21)
DM43CIK CS C1=CC=C(C=C1)C2=C(NC3=C2C=C(C=C3)S(=O)(=O)N)C(=O)N
DM43CIK IK QMGMALTZHHCWGS-UHFFFAOYSA-N
DM43CIK IU 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide
DM43CIK DE Discovery agent
DM830FW ID DM830FW
DM830FW DN 3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
DM830FW HS Investigative
DM830FW SN CHEMBL399620; Aza-heterocyclic Derivative, 4a; BDBM19181; AC1O4770; 3-phenylindeno[1,2-e][1,2,4]triazin-9-one
DM830FW DT Small molecular drug
DM830FW PC 6401016
DM830FW MW 259.26
DM830FW FM C16H9N3O
DM830FW IC InChI=1S/C16H9N3O/c20-15-12-9-5-4-8-11(12)13-14(15)18-19-16(17-13)10-6-2-1-3-7-10/h1-9H
DM830FW CS C1=CC=C(C=C1)C2=NC3=C(C(=O)C4=CC=CC=C43)N=N2
DM830FW IK OERHOWFXDDHRBP-UHFFFAOYSA-N
DM830FW IU 3-phenylindeno[1,2-e][1,2,4]triazin-9-one
DM830FW DE Discovery agent
DMQZJYS ID DMQZJYS
DMQZJYS DN 3-phenyl-CPP
DMQZJYS HS Investigative
DMQZJYS SN 3-phenyl-CPP; GTPL4104; SCHEMBL20553475; 2-(4-chlorophenoxy)-3-phenylpropanoic acid; 2-(p-chlorophenoxy)-3-phenylpropionic acid
DMQZJYS DT Small molecular drug
DMQZJYS PC 10356116
DMQZJYS MW 276.71
DMQZJYS FM C15H13ClO3
DMQZJYS IC InChI=1S/C15H13ClO3/c16-12-6-8-13(9-7-12)19-14(15(17)18)10-11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)
DMQZJYS CS C1=CC=C(C=C1)CC(C(=O)O)OC2=CC=C(C=C2)Cl
DMQZJYS IK CPBLTMSKPQDJPW-UHFFFAOYSA-N
DMQZJYS IU 2-(4-chlorophenoxy)-3-phenylpropanoic acid
DMQZJYS DE Discovery agent
DMJOD1T ID DMJOD1T
DMJOD1T DN 3-Phenylcyclopentanecarboxylic acid
DMJOD1T HS Investigative
DMJOD1T SN 3-Phenylcyclopentanecarboxylic acid; 91495-75-9; 3-phenylcyclopentane-1-carboxylic acid; CHEMBL554283; 3-phenyl-cyclopentanecarboxylic acid; SCHEMBL1073107; CTK3I5725; DTXSID80605012; MolPort-020-002-441; BDBM50293437; CP-858; Cyclopentanecarboxylicacid, 3-phenyl-; 3-phenyl-1-cyclopentanecarboxylic acid; AKOS022536861; A843950
DMJOD1T DT Small molecular drug
DMJOD1T PC 20313173
DMJOD1T MW 190.24
DMJOD1T FM C12H14O2
DMJOD1T IC InChI=1S/C12H14O2/c13-12(14)11-7-6-10(8-11)9-4-2-1-3-5-9/h1-5,10-11H,6-8H2,(H,13,14)
DMJOD1T CS C1CC(CC1C2=CC=CC=C2)C(=O)O
DMJOD1T IK IWOLSKRVZNXDNU-UHFFFAOYSA-N
DMJOD1T IU 3-phenylcyclopentane-1-carboxylic acid
DMJOD1T CA CAS 91495-75-9
DMJOD1T DE Discovery agent
DM3LM6B ID DM3LM6B
DM3LM6B DN 3-phenyl-cyclosal-d4TMP
DM3LM6B HS Investigative
DM3LM6B SN CHEMBL221156; 3-phenyl-cyclosal-d4TMP; AC1LAXDT; BDBM50206640; 5-methyl-1-[(2R,5S)-5-[(2-oxo-8-phenyl-4H-1,3,2; 5-Methyl-1-[(2R,5S)-5-(2-oxo-8-phenyl-4H-2.lambda. 5-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione; 5-Methyl-1-[(2R,5S)-5-(2-oxo-8-phenyl-4H-2lambda*5*-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione
DM3LM6B DT Small molecular drug
DM3LM6B PC 497286
DM3LM6B MW 468.4
DM3LM6B FM C23H21N2O7P
DM3LM6B IC InChI=1S/C23H21N2O7P/c1-15-12-25(23(27)24-22(15)26)20-11-10-18(31-20)14-30-33(28)29-13-17-8-5-9-19(21(17)32-33)16-6-3-2-4-7-16/h2-12,18,20H,13-14H2,1H3,(H,24,26,27)/t18-,20+,33?/m0/s1
DM3LM6B CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC=C5
DM3LM6B IK OQMPUIYQXGGVDT-GQODUDPDSA-N
DM3LM6B IU 5-methyl-1-[(2R,5S)-5-[(2-oxo-8-phenyl-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DM3LM6B DE Discovery agent
DMIJN9E ID DMIJN9E
DMIJN9E DN 3-phenylprop-1-enylboronic acid
DMIJN9E HS Investigative
DMIJN9E SN 129423-29-6; trans-3-phenylpropen-1-yl-boronic acid; trans-3-Phenyl-1-propen-1-ylboronic acid; (3-Phenylprop-1-en-1-yl)boronic acid; CHEMBL539140; Boronic acid, (3-phenyl-1-propenyl)-, (E)-; 3-phenylprop-1-enylboronic acid; SCHEMBL2207331; 3-Phenyl-1-propenylboronic acid; GMGWFDHLFMBIDS-XBXARRHUSA-N; 214907-30-9; BDBM50294581; (e)-3-phenylprop-1-enylboronic acid; Trans-3-phenylpropen-1-ylboronic acid; (E)-3-Phenyl-1-propenylboronic acid; ZINC169877170; AKOS015840563; (E)-3-phenylpropen-1-yl-boronic acid; RTR-004066
DMIJN9E DT Small molecular drug
DMIJN9E PC 11041016
DMIJN9E MW 162
DMIJN9E FM C9H11BO2
DMIJN9E IC InChI=1S/C9H11BO2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-6,8,11-12H,7H2/b8-4+
DMIJN9E CS B(/C=C/CC1=CC=CC=C1)(O)O
DMIJN9E IK GMGWFDHLFMBIDS-XBXARRHUSA-N
DMIJN9E IU [(E)-3-phenylprop-1-enyl]boronic acid
DMIJN9E DE Discovery agent
DMBTDZL ID DMBTDZL
DMBTDZL DN 3-Phenyl-pyrrolidine
DMBTDZL HS Investigative
DMBTDZL SN 3-Phenylpyrrolidine; 936-44-7; 3-Phenyl-pyrrolidine; Pyrrolidine, 3-phenyl-; (Pyrrolidin-3-yl)benzene; CHEMBL75207; PRRFFTYUBPGHLE-UHFFFAOYSA-N; F2189-0088; 3-phenyl-pyrolidine; 3-phenyl-pyrollidine; 4-phenyl-pyrrolidine; PubChem22374; BAS 03334576; AC1MK0OA; SCHEMBL4122; AC1Q1H4Y; (+/-)-3-phenyl-pyrrolidine; 3-phenylpyrrolidine, AldrichCPR; KS-00001OYR; CTK3I6515; DTXSID60389848; MolPort-000-006-168; HMS1704P05; 3AAX-0-0; BBL008865; ANW-54854; SBB010168; KM3208; BDBM50144660; STK006609; AKOS000674061; AKOS016051772; MCULE-5600189216
DMBTDZL DT Small molecular drug
DMBTDZL PC 3146743
DMBTDZL MW 147.22
DMBTDZL FM C10H13N
DMBTDZL IC InChI=1S/C10H13N/c1-2-4-9(5-3-1)10-6-7-11-8-10/h1-5,10-11H,6-8H2
DMBTDZL CS C1CNCC1C2=CC=CC=C2
DMBTDZL IK PRRFFTYUBPGHLE-UHFFFAOYSA-N
DMBTDZL IU 3-phenylpyrrolidine
DMBTDZL CA CAS 936-44-7
DMBTDZL DE Discovery agent
DM12SKU ID DM12SKU
DM12SKU DN 3-Phenylquinoline-8-carboxamide
DM12SKU HS Investigative
DM12SKU SN CHEMBL450259; 3-Phenylquinoline-8-carboxamide; BDBM50255264
DM12SKU DT Small molecular drug
DM12SKU PC 25208596
DM12SKU MW 248.28
DM12SKU FM C16H12N2O
DM12SKU IC InChI=1S/C16H12N2O/c17-16(19)14-8-4-7-12-9-13(10-18-15(12)14)11-5-2-1-3-6-11/h1-10H,(H2,17,19)
DM12SKU CS C1=CC=C(C=C1)C2=CN=C3C(=C2)C=CC=C3C(=O)N
DM12SKU IK DFGJDJRADWQKAW-UHFFFAOYSA-N
DM12SKU IU 3-phenylquinoline-8-carboxamide
DM12SKU DE Discovery agent
DMRNHXE ID DMRNHXE
DMRNHXE DN 3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine
DMRNHXE HS Investigative
DMRNHXE SN CHEMBL141548; 3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine
DMRNHXE DT Small molecular drug
DMRNHXE PC 44362450
DMRNHXE MW 282.4
DMRNHXE FM C15H14N4S
DMRNHXE IC InChI=1S/C15H14N4S/c16-10-6-13(17)15-14(7-10)18-8-11(19-15)9-20-12-4-2-1-3-5-12/h1-8H,9,16-17H2
DMRNHXE CS C1=CC=C(C=C1)SCC2=NC3=C(C=C(C=C3N=C2)N)N
DMRNHXE IK PBRHNJQCRCVADQ-UHFFFAOYSA-N
DMRNHXE IU 3-(phenylsulfanylmethyl)quinoxaline-5,7-diamine
DMRNHXE DE Discovery agent
DMIK9VO ID DMIK9VO
DMIK9VO DN 3-Phosphoglyceric Acid
DMIK9VO HS Investigative
DMIK9VO SN 3-phospho-D-glycerate; 3-phosphoglycerate; 3-phosphoglyceric acid; D-Glycerate 3-phosphate; 3-phospho-(R)-glycerate; CHEBI:17794; 3-phospho-D-glyceric acid; (2R)-2-hydroxy-3-(phosphonooxy)propanoic acid; 2-D-Hydroxy-3-phosphonooxy-propanoic acid; 3443-58-1; 3PG; (2R)-2-hydroxy-3-(phosphonatooxy)propanoate; 1iih; 820-11-1; bmse000007; SCHEMBL2497743; AC1L96U5; CHEMBL1160563; CTK1B7705; OSJPPGNTCRNQQC-UWTATZPHSA-N; ZINC3869934; BDBM50216218; DB04510; (2R)-2-hydroxy-3-phosphonooxypropanoic acid; C00197; Propanoic acid, 2-hydroxy-3-(ph
DMIK9VO DT Small molecular drug
DMIK9VO PC 439183
DMIK9VO MW 186.06
DMIK9VO FM C3H7O7P
DMIK9VO IC InChI=1S/C3H7O7P/c4-2(3(5)6)1-10-11(7,8)9/h2,4H,1H2,(H,5,6)(H2,7,8,9)/t2-/m1/s1
DMIK9VO CS C([C@H](C(=O)O)O)OP(=O)(O)O
DMIK9VO IK OSJPPGNTCRNQQC-UWTATZPHSA-N
DMIK9VO IU (2R)-2-hydroxy-3-phosphonooxypropanoic acid
DMIK9VO CA CAS 820-11-1
DMIK9VO CB CHEBI:17794
DMIK9VO DE Discovery agent
DM9BDV2 ID DM9BDV2
DM9BDV2 DN 3-Phosphoglycerol
DM9BDV2 HS Investigative
DM9BDV2 SN L-Glycerol 1-phosphate; sn-glycerol-1-phosphate; sn-Glycerol 1-phosphate; UNII-196623779E; 5746-57-6; D-(glycerol 3-phosphate); L-(glycerol 1-phosphate); 3-phosphoglycerol; (2S)-2,3-dihydroxypropyl dihydrogen phosphate; sn-glycerol 1-(dihydrogen phosphate); sn-Gro-1-P; 196623779E; L-alpha-glycerophosphate; 1GP; L-alpha-Glycerol phosphate; Glyceryl 1-phosphate, (S)-; L-alpha-Glycerophosphoric acid; 6tim; g3p; Glycerophosphoric acid L-alpha-form [MI]; SCHEMBL7341
DM9BDV2 DT Small molecular drug
DM9BDV2 PC 439276
DM9BDV2 MW 172.07
DM9BDV2 FM C3H9O6P
DM9BDV2 IC InChI=1S/C3H9O6P/c4-1-3(5)2-9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)/t3-/m0/s1
DM9BDV2 CS C([C@@H](COP(=O)(O)O)O)O
DM9BDV2 IK AWUCVROLDVIAJX-VKHMYHEASA-N
DM9BDV2 IU [(2S)-2,3-dihydroxypropyl] dihydrogen phosphate
DM9BDV2 CA CAS 5746-57-6
DM9BDV2 CB CHEBI:16221
DM9BDV2 DE Discovery agent
DMPF5OX ID DMPF5OX
DMPF5OX DN 3PO
DMPF5OX HS Investigative
DMPF5OX SN 18550-98-6; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3PO; 13309-08-5; CHEMBL3105848; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one; (E)-3-(Pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; SCHEMBL196639; 3-PO; (E)-3PO;3PO; CHEBI:144367; BCP34641; ZINC3997313; BDBM50445948; s7639; 3PO, >=98% (HPLC); AKOS025142053; CCG-266648; CS-5491; SB17190; NCGC00386709-03; AS-55969; HY-19824; AB00079158-01; SR-01000203323; SR-01000203323-1; 2-Propen-1-one, 3-(3-pyridinyl)-1-(4-pyridinyl)-; 3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (2E)-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one (3PO); (2E)-3-(PYRIDIN-3-YL)-1-(PYRIDIN-4-YL)PROP-2-EN-1-ONE
DMPF5OX DT Small molecular drug
DMPF5OX PC 5720233
DMPF5OX MW 210.23
DMPF5OX FM C13H10N2O
DMPF5OX IC InChI=1S/C13H10N2O/c16-13(12-5-8-14-9-6-12)4-3-11-2-1-7-15-10-11/h1-10H/b4-3+
DMPF5OX CS C1=CC(=CN=C1)/C=C/C(=O)C2=CC=NC=C2
DMPF5OX IK UOWGYMNWMDNSTL-ONEGZZNKSA-N
DMPF5OX IU (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one
DMPF5OX CB CHEBI:144367
DMPF5OX DE Pulmonary fibrosis
DM23I8E ID DM23I8E
DM23I8E DN 3-Prop-1-ynylquinoline-8-carboxamide
DM23I8E HS Investigative
DM23I8E SN CHEMBL504903; 3-Prop-1-ynylquinoline-8-carboxamide; ZINC40829471
DM23I8E DT Small molecular drug
DM23I8E PC 25208905
DM23I8E MW 210.23
DM23I8E FM C13H10N2O
DM23I8E IC InChI=1S/C13H10N2O/c1-2-4-9-7-10-5-3-6-11(13(14)16)12(10)15-8-9/h3,5-8H,1H3,(H2,14,16)
DM23I8E CS CC#CC1=CN=C2C(=C1)C=CC=C2C(=O)N
DM23I8E IK IUUKYHUSWYCGAA-UHFFFAOYSA-N
DM23I8E IU 3-prop-1-ynylquinoline-8-carboxamide
DM23I8E DE Discovery agent
DMDEV64 ID DMDEV64
DMDEV64 DN 3-Propoxy-9H-beta-carboline
DMDEV64 HS Investigative
DMDEV64 SN 3-Propoxy-9H-pyrido[3,4-b]indole; 3-propoxy-9H-pyrido[3,4-b]indole; 3-propyloxy-beta-carboline; CHEMBL52750; CHEMBL499814; AC1NFSYF; 3-propoxy-beta-carboline; SCHEMBL2347434; LPAODQAWVMEXKR-UHFFFAOYSA-N; ZINC6869122; BDBM50001473; PDSP1_001752; BDBM50244037; PDSP2_001735
DMDEV64 DT Small molecular drug
DMDEV64 PC 4713437
DMDEV64 MW 226.27
DMDEV64 FM C14H14N2O
DMDEV64 IC InChI=1S/C14H14N2O/c1-2-7-17-14-8-11-10-5-3-4-6-12(10)16-13(11)9-15-14/h3-6,8-9,16H,2,7H2,1H3
DMDEV64 CS CCCOC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMDEV64 IK LPAODQAWVMEXKR-UHFFFAOYSA-N
DMDEV64 IU 3-propoxy-9H-pyrido[3,4-b]indole
DMDEV64 DE Discovery agent
DMYACO7 ID DMYACO7
DMYACO7 DN 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine
DMYACO7 HS Investigative
DMYACO7 SN CHEMBL186969; 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7675949
DMYACO7 DT Small molecular drug
DMYACO7 PC 15463449
DMYACO7 MW 172.29
DMYACO7 FM C8H16N2S
DMYACO7 IC InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)
DMYACO7 CS CCCC1CSCCC(=N1)N
DMYACO7 IK SWOQAUBWIBZBLQ-UHFFFAOYSA-N
DMYACO7 IU 3-propyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMYACO7 DE Discovery agent
DM0872E ID DM0872E
DM0872E DN 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane
DM0872E HS Investigative
DM0872E SN CHEMBL80262; 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane; SCHEMBL15961866; 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester
DM0872E DT Small molecular drug
DM0872E PC 10106631
DM0872E MW 259.339
DM0872E FM C16H21NO2
DM0872E IC InChI=1S/C16H21NO2/c1-10-3-5-11(6-4-10)13-9-12-7-8-14(17-12)15(13)16(18)19-2/h3-6,12-15,17H,7-9H2,1-2H3
DM0872E CS CC1=CC=C(C=C1)C2CC3CCC(C2C(=O)OC)N3
DM0872E IK YUMUSCBAOZYAIX-UHFFFAOYSA-N
DM0872E IU methyl 3-(4-methylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DM0872E DE Discovery agent
DM60Q1B ID DM60Q1B
DM60Q1B DN 3-Pyridin-3-yl-quinoline-6,7-diol
DM60Q1B HS Investigative
DM60Q1B DT Small molecular drug
DM60Q1B PC 135453851
DM60Q1B MW 238.24
DM60Q1B FM C14H10N2O2
DM60Q1B IC InChI=1S/C14H10N2O2/c17-13-5-10-4-11(9-2-1-3-15-7-9)8-16-12(10)6-14(13)18/h1-8,17-18H
DM60Q1B CS C1=CC(=CN=C1)C2=CN=C3C=C(C(=CC3=C2)O)O
DM60Q1B IK QQQXEUOUDIWAIJ-UHFFFAOYSA-N
DM60Q1B IU 3-pyridin-3-ylquinoline-6,7-diol
DM60Q1B DE Discovery agent
DM0SEL5 ID DM0SEL5
DM0SEL5 DN 3-Pyridin-4-yl-quinolin-7-ol
DM0SEL5 HS Investigative
DM0SEL5 DT Small molecular drug
DM0SEL5 PC 135449022
DM0SEL5 MW 222.24
DM0SEL5 FM C14H10N2O
DM0SEL5 IC InChI=1S/C14H10N2O/c17-13-2-1-11-7-12(9-16-14(11)8-13)10-3-5-15-6-4-10/h1-9,17H
DM0SEL5 CS C1=CC(=CC2=NC=C(C=C21)C3=CC=NC=C3)O
DM0SEL5 IK NYQMESYHKIIFEI-UHFFFAOYSA-N
DM0SEL5 IU 3-pyridin-4-ylquinolin-7-ol
DM0SEL5 CA CAS 156909-26-1
DM0SEL5 DE Discovery agent
DM6U074 ID DM6U074
DM6U074 DN 3-Pyridin-4-yl-quinoline
DM6U074 HS Investigative
DM6U074 SN 3-(4-Pyridinyl)quinoline; CHEMBL89550; 3-Pyridin-4-yl-quinoline; 3-(pyridin-4-yl)quinoline; SCHEMBL2346887; QYCONSXONLLGHQ-UHFFFAOYSA-N; BDBM50039658
DM6U074 DT Small molecular drug
DM6U074 PC 10081720
DM6U074 MW 206.24
DM6U074 FM C14H10N2
DM6U074 IC InChI=1S/C14H10N2/c1-2-4-14-12(3-1)9-13(10-16-14)11-5-7-15-8-6-11/h1-10H
DM6U074 CS C1=CC=C2C(=C1)C=C(C=N2)C3=CC=NC=C3
DM6U074 IK QYCONSXONLLGHQ-UHFFFAOYSA-N
DM6U074 IU 3-pyridin-4-ylquinoline
DM6U074 DE Discovery agent
DMPCT0A ID DMPCT0A
DMPCT0A DN 3-Pyridin-4-yl-quinoline-5,7-diol
DMPCT0A HS Investigative
DMPCT0A DT Small molecular drug
DMPCT0A PC 135474209
DMPCT0A MW 238.24
DMPCT0A FM C14H10N2O2
DMPCT0A IC InChI=1S/C14H10N2O2/c17-11-6-13-12(14(18)7-11)5-10(8-16-13)9-1-3-15-4-2-9/h1-8,17-18H
DMPCT0A CS C1=CN=CC=C1C2=CC3=C(C=C(C=C3O)O)N=C2
DMPCT0A IK QYWQBBCHWNMFSG-UHFFFAOYSA-N
DMPCT0A IU 3-pyridin-4-ylquinoline-5,7-diol
DMPCT0A DE Discovery agent
DME1TUK ID DME1TUK
DME1TUK DN 3-Pyridin-4-yl-quinoline-6,7-diol
DME1TUK HS Investigative
DME1TUK DT Small molecular drug
DME1TUK PC 135469328
DME1TUK MW 238.24
DME1TUK FM C14H10N2O2
DME1TUK IC InChI=1S/C14H10N2O2/c17-13-6-10-5-11(9-1-3-15-4-2-9)8-16-12(10)7-14(13)18/h1-8,17-18H
DME1TUK CS C1=CN=CC=C1C2=CN=C3C=C(C(=CC3=C2)O)O
DME1TUK IK PWPSIWFFYVGDHO-UHFFFAOYSA-N
DME1TUK IU 3-pyridin-4-ylquinoline-6,7-diol
DME1TUK DE Discovery agent
DMAGXMJ ID DMAGXMJ
DMAGXMJ DN 3-pyridine-acetic acid
DMAGXMJ HS Investigative
DMAGXMJ SN lessterol; lioxone; minedil; 3-pyridineacetic acid; piridil; toneon; Piristerol
DMAGXMJ DT Small molecular drug
DMAGXMJ PC 108
DMAGXMJ MW 137.14
DMAGXMJ FM C7H7NO2
DMAGXMJ IC InChI=1S/C7H7NO2/c9-7(10)4-6-2-1-3-8-5-6/h1-3,5H,4H2,(H,9,10)
DMAGXMJ CS C1=CC(=CN=C1)CC(=O)O
DMAGXMJ IK WGNUNYPERJMVRM-UHFFFAOYSA-N
DMAGXMJ IU 2-pyridin-3-ylacetic acid
DMAGXMJ CA CAS 501-81-5
DMAGXMJ CB CHEBI:86390
DMAGXMJ DE Discovery agent
DM2KEW6 ID DM2KEW6
DM2KEW6 DN 3R14S-OCHRATOXIN A
DM2KEW6 HS Investigative
DM2KEW6 SN Ochratoxin A; OCHRATOXIN A; Antibiotic 9663; 303-47-9; Phenylalanine - ochratoxin A; NCI-C56586; C20H18ClNO6; CHEBI:7719; RWQKHEORZBHNRI-BMIGLBTASA-N; Ochratoxin A, aspergillus ochraceus; Ochratoxin A-BSA conjugate from Aspergillus ochraceus; N-(((3R)-5-Chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenyl-L-alanine; (-)-N-((5-Chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenylalanine; NSC 201422; UNII-1779SX6LUY; OTA; ochratoxin A
DM2KEW6 DT Small molecular drug
DM2KEW6 PC 442530
DM2KEW6 MW 403.8
DM2KEW6 FM C20H18ClNO6
DM2KEW6 IC InChI=1S/C20H18ClNO6/c1-10-7-12-14(21)9-13(17(23)16(12)20(27)28-10)18(24)22-15(19(25)26)8-11-5-3-2-4-6-11/h2-6,9-10,15,23H,7-8H2,1H3,(H,22,24)(H,25,26)/t10-,15+/m1/s1
DM2KEW6 CS C[C@@H]1CC2=C(C=C(C(=C2C(=O)O1)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)Cl
DM2KEW6 IK RWQKHEORZBHNRI-BMIGLBTASA-N
DM2KEW6 IU (2S)-2-[[(3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydroisochromene-7-carbonyl]amino]-3-phenylpropanoic acid
DM2KEW6 CA CAS 303-47-9
DM2KEW6 CB CHEBI:7719
DM2KEW6 DE Discovery agent
DMV1HMX ID DMV1HMX
DMV1HMX DN 3r-Hydroxydecanoyl-Coa
DMV1HMX HS Investigative
DMV1HMX SN 3R-HYDROXYDECANOYL-COA; 3R-HYDROXYDECANOYL-COENZYME A; (R)-3-hydroxydecanoyl-CoA; AC1L9LCA; CHEBI:74405; (R)-3-hydroxydecanoyl-coenzyme A; DB03192; S-{(9R,13S,15R)-17-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl]-9,13,15-trihydroxy-10,10-dimethyl-13,15-dioxido-4,8-dioxo-12,14,16-trioxa-3,7-diaza-13,15-diphosphaheptadec-1-yl} (3R)-3-hydroxydecanethioate (non-preferred name)
DMV1HMX DT Small molecular drug
DMV1HMX PC 447877
DMV1HMX MW 937.8
DMV1HMX FM C31H54N7O18P3S
DMV1HMX IC InChI=1S/C31H54N7O18P3S/c1-4-5-6-7-8-9-19(39)14-22(41)60-13-12-33-21(40)10-11-34-29(44)26(43)31(2,3)16-53-59(50,51)56-58(48,49)52-15-20-25(55-57(45,46)47)24(42)30(54-20)38-18-37-23-27(32)35-17-36-28(23)38/h17-20,24-26,30,39,42-43H,4-16H2,1-3H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t19-,20-,24-,25-,26+,30-/m1/s1
DMV1HMX CS CCCCCCC[C@H](CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O
DMV1HMX IK HIVSMYZAMUNFKZ-PDQACDDGSA-N
DMV1HMX IU S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (3R)-3-hydroxydecanethioate
DMV1HMX CB CHEBI:74405
DMV1HMX DE Discovery agent
DMVGDSM ID DMVGDSM
DMVGDSM DN 3S,4R-293B
DMVGDSM HS Investigative
DMVGDSM DT Small molecular drug
DMVGDSM PC 6604863
DMVGDSM MW 324.4
DMVGDSM FM C15H20N2O4S
DMVGDSM IC InChI=1S/C15H20N2O4S/c1-5-22(19,20)17(4)13-11-8-10(9-16)6-7-12(11)21-15(2,3)14(13)18/h6-8,13-14,18H,5H2,1-4H3/t13-,14+/m1/s1
DMVGDSM CS CCS(=O)(=O)N(C)[C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O
DMVGDSM IK HVSJHHXUORMCGK-KGLIPLIRSA-N
DMVGDSM IU N-[(3S,4R)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
DMVGDSM CA CAS 163163-25-5
DMVGDSM DE Discovery agent
DMCD4GR ID DMCD4GR
DMCD4GR DN 3-sal-cyclosal-d4TMP
DMCD4GR HS Investigative
DMCD4GR SN CHEMBL373537; 3-sal-cyclosal-d4TMP; (Sp)-3-sal-cyclosal-d4TMP; (Rp)-3-sal-cyclosal-d4TMP
DMCD4GR DT Small molecular drug
DMCD4GR PC 44420671
DMCD4GR MW 514.4
DMCD4GR FM C24H23N2O9P
DMCD4GR IC InChI=1S/C24H23N2O9P/c1-14-10-26(24(30)25-23(14)29)20-9-8-17(34-20)13-33-36(31)32-12-16-5-3-7-19(22(16)35-36)18-6-2-4-15(11-27)21(18)28/h2-10,17,20,27-28H,11-13H2,1H3,(H,25,29,30)/t17-,20+,36?/m0/s1
DMCD4GR CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC(=C5O)CO
DMCD4GR IK ONCMROQDJNEQJX-AVINKISOSA-N
DMCD4GR IU 1-[(2R,5S)-5-[[8-[2-hydroxy-3-(hydroxymethyl)phenyl]-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
DMCD4GR DE Discovery agent
DMNP8DQ ID DMNP8DQ
DMNP8DQ DN 3-sec-Butoxy-9H-beta-carboline
DMNP8DQ HS Investigative
DMNP8DQ SN CHEMBL86231; 3-sec-Butoxy-9H-beta-carboline; BDBM50001480
DMNP8DQ DT Small molecular drug
DMNP8DQ PC 11778239
DMNP8DQ MW 240.3
DMNP8DQ FM C15H16N2O
DMNP8DQ IC InChI=1S/C15H16N2O/c1-3-10(2)18-15-8-12-11-6-4-5-7-13(11)17-14(12)9-16-15/h4-10,17H,3H2,1-2H3
DMNP8DQ CS CCC(C)OC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMNP8DQ IK JKWXAXMOLXCXJS-UHFFFAOYSA-N
DMNP8DQ IU 3-butan-2-yloxy-9H-pyrido[3,4-b]indole
DMNP8DQ DE Discovery agent
DMILTRN ID DMILTRN
DMILTRN DN 3-Sulfinoalanine
DMILTRN HS Investigative
DMILTRN SN 2-amino-3-sulfinopropanoic acid; 2381-08-0; Alanine 3-sulfinic acid; Cysteine hydrogen sulfite ester; L-Cysteinesulfinic acid monohydrate; Alanine, 3-sulfino-; UNII-56X032NVQL; 56X032NVQL; Cysteinesulfinic acid, L-; AC1Q5S9C; MLS000859909; SCHEMBL443654; AC1L18I0; GTPL4695; CHEMBL1702607; 2-Amino-3-sulfinopropionic acid; BDBM86194; NSC_109; CAS_109; ADVPTQAUNPRNPO-UHFFFAOYSA-N; HMS3369H02; HMS3266C09; HMS2235M21; EINECS 214-228-5; AKOS022145786; SMR000326770; ST45022126; 207121-48-0
DMILTRN DT Small molecular drug
DMILTRN PC 1549098
DMILTRN MW 153.16
DMILTRN FM C3H7NO4S
DMILTRN IC InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/t2-/m0/s1
DMILTRN CS C([C@@H](C(=O)O)N)S(=O)O
DMILTRN IK ADVPTQAUNPRNPO-REOHCLBHSA-N
DMILTRN IU (2R)-2-amino-3-sulfinopropanoic acid
DMILTRN CA CAS 1115-65-7
DMILTRN CB CHEBI:16345
DMKSUV9 ID DMKSUV9
DMKSUV9 DN 3-tapap
DMKSUV9 HS Investigative
DMKSUV9 SN 3-Tapap; TAPAP; AC1Q5K4B; AC1L2Q7B; Nalpha-Tosyl-(3-amidinophenyl)alanine piperidide; N(alpha)-(4-Toluenesulfonyl)-3-amidinophenylalanylpiperidine; CHEMBL384295; 80457-09-6; 3-[2-{[(4-methylphenyl)sulfonyl]amino}-3-oxo-3-(piperidin-1-yl)propyl]benzenecarboximidamide; 1-(3-(3-(Aminoiminomethyl)phenyl)-2-(((4-methylphenyl)sulfonyl)amino)-1-oxopropyl)piperidine; Piperidine, 1-(3-(3-(aminoiminomethyl)phenyl)-2-(((4-methylphenyl)sulfonyl)amino)-1-oxopropyl)-; 73438-63-8; N(alpha)-Tosyl-(3-amidinophenyl)alanine piperidide
DMKSUV9 DT Small molecular drug
DMKSUV9 PC 126363
DMKSUV9 MW 428.5
DMKSUV9 FM C22H28N4O3S
DMKSUV9 IC InChI=1S/C22H28N4O3S/c1-16-8-10-19(11-9-16)30(28,29)25-20(22(27)26-12-3-2-4-13-26)15-17-6-5-7-18(14-17)21(23)24/h5-11,14,20,25H,2-4,12-13,15H2,1H3,(H3,23,24)
DMKSUV9 CS CC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CC(=CC=C2)C(=N)N)C(=O)N3CCCCC3
DMKSUV9 IK RNNMXTSTLVYYQG-UHFFFAOYSA-N
DMKSUV9 IU 3-[2-[(4-methylphenyl)sulfonylamino]-3-oxo-3-piperidin-1-ylpropyl]benzenecarboximidamide
DMKSUV9 CA CAS 73438-63-8
DMKSUV9 DE Discovery agent
DMGDT8V ID DMGDT8V
DMGDT8V DN 3-tert-Butyl-3-ethyl-dihydro-furan-2-one
DMGDT8V HS Investigative
DMGDT8V SN CHEMBL97749; 2(3H)-Furanone, 3-(1,1-dimethylethyl)-3-ethyldihydro-; 153579-88-5
DMGDT8V DT Small molecular drug
DMGDT8V PC 10261531
DMGDT8V MW 170.25
DMGDT8V FM C10H18O2
DMGDT8V IC InChI=1S/C10H18O2/c1-5-10(9(2,3)4)6-7-12-8(10)11/h5-7H2,1-4H3
DMGDT8V CS CCC1(CCOC1=O)C(C)(C)C
DMGDT8V IK LHTNJLBXDQITGL-UHFFFAOYSA-N
DMGDT8V IU 3-tert-butyl-3-ethyloxolan-2-one
DMGDT8V DE Discovery agent
DMY57CV ID DMY57CV
DMY57CV DN 3-tert-butyl-9H-carbazole
DMY57CV HS Investigative
DMY57CV SN 3-(tert-Butyl)-9H-carbazole; 3-tert-butyl-9H-carbazole; 22401-74-7; CHEMBL1170621; SCHEMBL10090582; CTK0J6436; DTXSID30477842; MolPort-044-724-355; KS-000017WT; BDBM50322591; AKOS030561970; 9H-Carbazole, 3-(1,1-dimethylethyl)-
DMY57CV DT Small molecular drug
DMY57CV PC 12117342
DMY57CV MW 223.31
DMY57CV FM C16H17N
DMY57CV IC InChI=1S/C16H17N/c1-16(2,3)11-8-9-15-13(10-11)12-6-4-5-7-14(12)17-15/h4-10,17H,1-3H3
DMY57CV CS CC(C)(C)C1=CC2=C(C=C1)NC3=CC=CC=C32
DMY57CV IK TYXSZNGDCCGIBO-UHFFFAOYSA-N
DMY57CV IU 3-tert-butyl-9H-carbazole
DMY57CV CA CAS 22401-74-7
DMY57CV DE Discovery agent
DMIH6JU ID DMIH6JU
DMIH6JU DN 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane
DMIH6JU HS Investigative
DMIH6JU SN CHEMBL23563; SCHEMBL8430767; AMJXIOSRIOJUEM-UHFFFAOYSA-N; BDBM50229667
DMIH6JU DT Small molecular drug
DMIH6JU PC 15663667
DMIH6JU MW 179.22
DMIH6JU FM C8H13N5
DMIH6JU IC InChI=1S/C8H13N5/c1-3-12-4-2-7(1)8(5-12)13-10-6-9-11-13/h6-8H,1-5H2
DMIH6JU CS C1CN2CCC1C(C2)N3N=CN=N3
DMIH6JU IK AMJXIOSRIOJUEM-UHFFFAOYSA-N
DMIH6JU IU 3-(tetrazol-2-yl)-1-azabicyclo[2.2.2]octane
DMIH6JU DE Discovery agent
DM2K59V ID DM2K59V
DM2K59V DN 3'thiacytidine
DM2K59V HS Investigative
DM2K59V DT Small molecular drug
DM2K59V PC 9825995
DM2K59V MW 470.6
DM2K59V FM C29H34N4O2
DM2K59V IC InChI=1S/C19H20N2O2.C10H14N2/c1-22-17-8-7-14(18(12-17)23-2)11-15-5-4-10-21-19(15)16-6-3-9-20-13-16;1-11-7-3-2-5-10-6-4-8-12-9-10/h3,6-9,11-13H,4-5,10H2,1-2H3;2,4-6,8-9,11H,3,7H2,1H3/b15-11+;5-2+
DM2K59V CS CNCC/C=C/C1=CN=CC=C1.COC1=CC(=C(C=C1)/C=C/2\\CCCN=C2C3=CN=CC=C3)OC
DM2K59V IK MILFUDCXGDJQOI-ZSPSLKEUSA-N
DM2K59V IU 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine;(E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine
DM2K59V DE Discovery agent
DM9MFZ1 ID DM9MFZ1
DM9MFZ1 DN 3-Thiophen-3-yl-quinoline
DM9MFZ1 HS Investigative
DM9MFZ1 SN 3-(3-Thienyl)quinoline; 56421-85-3; 3-(Thiophen-3-yl)quinoline; CHEMBL304310; 3-thiophen-3-ylquinoline; 3-Thiophen-3-yl-quinoline; 3-(3-thiophenyl)quinoline; SCHEMBL19180724; ZINC2392505; BDBM50039081; AKOS004118779; BB 0223675
DM9MFZ1 DT Small molecular drug
DM9MFZ1 PC 10242258
DM9MFZ1 MW 211.28
DM9MFZ1 FM C13H9NS
DM9MFZ1 IC InChI=1S/C13H9NS/c1-2-4-13-10(3-1)7-12(8-14-13)11-5-6-15-9-11/h1-9H
DM9MFZ1 CS C1=CC=C2C(=C1)C=C(C=N2)C3=CSC=C3
DM9MFZ1 IK ZWOOWBWBVMAYGL-UHFFFAOYSA-N
DM9MFZ1 IU 3-thiophen-3-ylquinoline
DM9MFZ1 DE Discovery agent
DM5SM8X ID DM5SM8X
DM5SM8X DN 3'-THIO-THYMIDINE-5'-PHOSPHATE
DM5SM8X HS Investigative
DM5SM8X SN 3'-THIO-THYMIDINE-5'-PHOSPHATE; DB08651; 3'-thiothymidine 5'-(dihydrogen phosphate); 3'-Mercapto-3'-deoxythymidine 5'-phosphoric acid; [(2R,3S,5R)-5-(5-methyl-2,4-dioxo-3H-pyrimidin-1-yl)-3-sulfanyloxolan-2-yl]methoxyphosphonic acid
DM5SM8X DT Small molecular drug
DM5SM8X PC 46937170
DM5SM8X MW 338.28
DM5SM8X FM C10H15N2O7PS
DM5SM8X IC InChI=1S/C10H15N2O7PS/c1-5-3-12(10(14)11-9(5)13)8-2-7(21)6(19-8)4-18-20(15,16)17/h3,6-8,21H,2,4H2,1H3,(H,11,13,14)(H2,15,16,17)/t6-,7+,8-/m1/s1
DM5SM8X CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)O)S
DM5SM8X IK BORVFKJZAOEGOO-GJMOJQLCSA-N
DM5SM8X IU [(2R,3S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-3-sulfanyloxolan-2-yl]methyl dihydrogen phosphate
DM5SM8X DE Discovery agent
DMOQWDS ID DMOQWDS
DMOQWDS DN 3-trans-p-coumaroyl maslinic acid
DMOQWDS HS Investigative
DMOQWDS SN CHEMBL453751; 3-trans-p-coumaroyl maslinic acid
DMOQWDS DT Small molecular drug
DMOQWDS PC 16664517
DMOQWDS MW 602.8
DMOQWDS FM C39H54O5
DMOQWDS IC InChI=1S/C39H54O5/c1-34(2)19-21-39(33(42)43)22-20-37(6)26(27(39)23-34)14-15-30-36(5)24-28(40)32(35(3,4)29(36)17-18-38(30,37)7)44-31(41)16-13-25-11-9-8-10-12-25/h8-14,16,27-30,32,40H,15,17-24H2,1-7H3,(H,42,43)/b16-13+/t27-,28+,29-,30+,32-,36-,37+,38+,39-/m0/s1
DMOQWDS CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)OC(=O)/C=C/C6=CC=CC=C6)O)C
DMOQWDS IK QYNZDAXHBDWWFS-BECYFJCGSA-N
DMOQWDS IU (4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-[(E)-3-phenylprop-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMOQWDS DE Discovery agent
DMI15VQ ID DMI15VQ
DMI15VQ DN 4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate
DMI15VQ HS Investigative
DMI15VQ SN CHEMBL224828; 4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate; BDBM50158415; 4-(1-Imidazolyl)retinoic acid methyl ester
DMI15VQ DT Small molecular drug
DMI15VQ PC 10786043
DMI15VQ MW 380.5
DMI15VQ FM C24H32N2O2
DMI15VQ IC InChI=1S/C24H32N2O2/c1-18(8-7-9-19(2)16-23(27)28-6)10-11-21-20(3)22(12-13-24(21,4)5)26-15-14-25-17-26/h7-11,14-17,22H,12-13H2,1-6H3/b9-7+,11-10+,18-8+,19-16+
DMI15VQ CS CC1=C(C(CCC1N2C=CN=C2)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)OC)/C)/C
DMI15VQ IK LEOKNFOQHCUMCU-PFLBVIONSA-N
DMI15VQ IU methyl (2E,4E,6E,8E)-9-(3-imidazol-1-yl-2,6,6-trimethylcyclohexen-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoate
DMI15VQ DE Discovery agent
DMKYB4D ID DMKYB4D
DMKYB4D DN 4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid
DMKYB4D HS Investigative
DMKYB4D SN CHEMBL57765; 4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid; SCHEMBL1234027; 4-(1-Imidazolyl)retinoic acid; BDBM50091698; (2E,4E,6E,8E)-9-(3-Imidazol-1-yl-2,6,6-trimethyl-cyclohex-1-enyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid
DMKYB4D DT Small molecular drug
DMKYB4D PC 9951075
DMKYB4D MW 366.5
DMKYB4D FM C23H30N2O2
DMKYB4D IC InChI=1S/C23H30N2O2/c1-17(7-6-8-18(2)15-22(26)27)9-10-20-19(3)21(11-12-23(20,4)5)25-14-13-24-16-25/h6-10,13-16,21H,11-12H2,1-5H3,(H,26,27)/b8-6+,10-9+,17-7+,18-15+
DMKYB4D CS CC1=C(C(CCC1N2C=CN=C2)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DMKYB4D IK MRFBVQCSZMKBFY-UBFIAYEVSA-N
DMKYB4D IU (2E,4E,6E,8E)-9-(3-imidazol-1-yl-2,6,6-trimethylcyclohexen-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
DMKYB4D DE Discovery agent
DMDHV0N ID DMDHV0N
DMDHV0N DN 4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
DMDHV0N HS Investigative
DMDHV0N SN CHEMBL427247; 2H-1-Benzopyran-2-one, 4-(1H-imidazol-1-ylmethyl)-; 828265-54-9; Coumarin deriv. 19; BDBM9470; CTK3D6009; DTXSID40460922; ZINC13586713
DMDHV0N DT Small molecular drug
DMDHV0N PC 11276192
DMDHV0N MW 226.23
DMDHV0N FM C13H10N2O2
DMDHV0N IC InChI=1S/C13H10N2O2/c16-13-7-10(8-15-6-5-14-9-15)11-3-1-2-4-12(11)17-13/h1-7,9H,8H2
DMDHV0N CS C1=CC=C2C(=C1)C(=CC(=O)O2)CN3C=CN=C3
DMDHV0N IK SOWQJCOJWDYZNR-UHFFFAOYSA-N
DMDHV0N IU 4-(imidazol-1-ylmethyl)chromen-2-one
DMDHV0N CA CAS 828265-54-9
DMDHV0N DE Discovery agent
DMFUBRC ID DMFUBRC
DMFUBRC DN 4-((1H-imidazol-1-yl)methyl)benzonitrile
DMFUBRC HS Investigative
DMFUBRC SN 1-(4-Cyanobenzyl)-1H-imidazole; 4-Imidazol-1-ylmethyl-benzonitrile
DMFUBRC PC 1236449
DMFUBRC MW 183.21
DMFUBRC FM C11H9N3
DMFUBRC IC InChI=1S/C11H9N3/c12-7-10-1-3-11(4-2-10)8-14-6-5-13-9-14/h1-6,9H,8H2
DMFUBRC CS C1=CC(=CC=C1CN2C=CN=C2)C#N
DMFUBRC IK LUSFCTSUDCCYLQ-UHFFFAOYSA-N
DMFUBRC IU 4-(imidazol-1-ylmethyl)benzonitrile
DMFUBRC CA CAS 112809-54-8
DMFUBRC DE Discovery agent
DMYDGH4 ID DMYDGH4
DMYDGH4 DN 4-((1H-imidazol-1-yl)methyl)phenol
DMYDGH4 HS Investigative
DMYDGH4 SN 4-(1h-imidazol-1-ylmethyl)phenol; 1-(4-Hydroxybenzyl)imidazole; 41833-17-4; 4-((1H-imidazol-1-yl)methyl)phenol; Phenol, 4-(1H-imidazol-1-ylmethyl)-; CHEMBL166845; ZEFROCQEWXHIEP-UHFFFAOYSA-N; 4-(imidazolylmethyl)phenol; 4-Hobi; n-p-hydroxybenzylimidazole; AC1L4X2E; AC1Q7A8C; 4-Imidazol-1-ylmethyl-phenol; 4-(1h-imidazolylmethyl)phenol; 4-(imidazol-1-ylmethyl)phenol; SCHEMBL6323414; 4-[(1-imidazolyl)methyl]phenol; CTK4I5281; DTXSID30194643; MolPort-006-827-429; 1-(4-Hydroxybenzyl)-1H-imidazole; ZINC13549136; SBB051635
DMYDGH4 DT Small molecular drug
DMYDGH4 PC 193822
DMYDGH4 MW 174.2
DMYDGH4 FM C10H10N2O
DMYDGH4 IC InChI=1S/C10H10N2O/c13-10-3-1-9(2-4-10)7-12-6-5-11-8-12/h1-6,8,13H,7H2
DMYDGH4 CS C1=CC(=CC=C1CN2C=CN=C2)O
DMYDGH4 IK ZEFROCQEWXHIEP-UHFFFAOYSA-N
DMYDGH4 IU 4-(imidazol-1-ylmethyl)phenol
DMYDGH4 CA CAS 41833-17-4
DMYDGH4 DE Discovery agent
DMX2QD5 ID DMX2QD5
DMX2QD5 DN 4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine
DMX2QD5 HS Investigative
DMX2QD5 SN CHEMBL424847; 4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine
DMX2QD5 DT Small molecular drug
DMX2QD5 PC 44406484
DMX2QD5 MW 263.42
DMX2QD5 FM C16H29N3
DMX2QD5 IC InChI=1S/C16H29N3/c1-2-3-4-5-6-9-19-10-7-15(8-11-19)12-16-13-17-14-18-16/h13-15H,2-12H2,1H3,(H,17,18)
DMX2QD5 CS CCCCCCCN1CCC(CC1)CC2=CN=CN2
DMX2QD5 IK PKTDABXMBJERIM-UHFFFAOYSA-N
DMX2QD5 IU 1-heptyl-4-(1H-imidazol-5-ylmethyl)piperidine
DMX2QD5 DE Discovery agent
DMRYWSN ID DMRYWSN
DMRYWSN DN 4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine
DMRYWSN HS Investigative
DMRYWSN SN CHEMBL1171443; 4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine
DMRYWSN DT Small molecular drug
DMRYWSN PC 49799252
DMRYWSN MW 241.33
DMRYWSN FM C15H19N3
DMRYWSN IC InChI=1S/C15H19N3/c1-2-4-15(5-3-1)18-8-6-13(7-9-18)10-14-11-16-12-17-14/h1-5,11-13H,6-10H2,(H,16,17)
DMRYWSN CS C1CN(CCC1CC2=CN=CN2)C3=CC=CC=C3
DMRYWSN IK DKJLGZJEDGFKIC-UHFFFAOYSA-N
DMRYWSN IU 4-(1H-imidazol-5-ylmethyl)-1-phenylpiperidine
DMRYWSN DE Discovery agent
DMLV59R ID DMLV59R
DMLV59R DN 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol
DMLV59R HS Investigative
DMLV59R SN CHEMBL1240676; 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol; BDBM50326004
DMLV59R DT Small molecular drug
DMLV59R PC 43743432
DMLV59R MW 255.27
DMLV59R FM C14H13N3O2
DMLV59R IC InChI=1S/C14H13N3O2/c18-13-4-1-9(5-14(13)19)7-15-11-3-2-10-8-16-17-12(10)6-11/h1-6,8,15,18-19H,7H2,(H,16,17)
DMLV59R CS C1=CC(=C(C=C1CNC2=CC3=C(C=C2)C=NN3)O)O
DMLV59R IK FOCLURCEJLBSGE-UHFFFAOYSA-N
DMLV59R IU 4-[(1H-indazol-6-ylamino)methyl]benzene-1,2-diol
DMLV59R DE Discovery agent
DMRWZ6T ID DMRWZ6T
DMRWZ6T DN 4-((1H-indol-1-yl)methyl)benzenamine
DMRWZ6T HS Investigative
DMRWZ6T SN CHEMBL247281; 4-((1H-indol-1-yl)methyl)benzenamine; SCHEMBL14338710; BDBM50203132
DMRWZ6T DT Small molecular drug
DMRWZ6T PC 19779451
DMRWZ6T MW 222.28
DMRWZ6T FM C15H14N2
DMRWZ6T IC InChI=1S/C15H14N2/c16-14-7-5-12(6-8-14)11-17-10-9-13-3-1-2-4-15(13)17/h1-10H,11,16H2
DMRWZ6T CS C1=CC=C2C(=C1)C=CN2CC3=CC=C(C=C3)N
DMRWZ6T IK CRNJIXJRSKNGTP-UHFFFAOYSA-N
DMRWZ6T IU 4-(indol-1-ylmethyl)aniline
DMRWZ6T DE Discovery agent
DMCRWTH ID DMCRWTH
DMCRWTH DN 4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol
DMCRWTH HS Investigative
DMCRWTH SN CHEMBL24141; BDBM50086945; 4''-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol; 4''-(2-Butyl-benzofuran-3-ylmethyl)-biphenyl-4-ol
DMCRWTH DT Small molecular drug
DMCRWTH PC 9841650
DMCRWTH MW 356.5
DMCRWTH FM C25H24O2
DMCRWTH IC InChI=1S/C25H24O2/c1-2-3-7-25-23(22-6-4-5-8-24(22)27-25)17-18-9-11-19(12-10-18)20-13-15-21(26)16-14-20/h4-6,8-16,26H,2-3,7,17H2,1H3
DMCRWTH CS CCCCC1=C(C2=CC=CC=C2O1)CC3=CC=C(C=C3)C4=CC=C(C=C4)O
DMCRWTH IK AESGURZHBVMCOS-UHFFFAOYSA-N
DMCRWTH IU 4-[4-[(2-butyl-1-benzofuran-3-yl)methyl]phenyl]phenol
DMCRWTH DE Discovery agent
DMJN2OW ID DMJN2OW
DMJN2OW DN 4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole
DMJN2OW HS Investigative
DMJN2OW SN CHEMBL18735; Immepyr; 4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole; 1H-Imidazole, 4-[(2R,3S)-2-methyl-3-pyrrolidinyl]-; BDBM50034708
DMJN2OW DT Small molecular drug
DMJN2OW PC 9815231
DMJN2OW MW 151.21
DMJN2OW FM C8H13N3
DMJN2OW IC InChI=1S/C8H13N3/c1-6-7(2-3-10-6)8-4-9-5-11-8/h4-7,10H,2-3H2,1H3,(H,9,11)/t6-,7+/m1/s1
DMJN2OW CS C[C@@H]1[C@H](CCN1)C2=CN=CN2
DMJN2OW IK FLOJCNYYPGNYBP-RQJHMYQMSA-N
DMJN2OW IU 5-[(2R,3S)-2-methylpyrrolidin-3-yl]-1H-imidazole
DMJN2OW DE Discovery agent
DM8WCJK ID DM8WCJK
DM8WCJK DN 4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole
DM8WCJK HS Investigative
DM8WCJK SN CHEMBL18980; 4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole; BDBM50034707; 151093-64-0; 1H-Imidazole, 4-[(2S,3R)-2-methyl-3-pyrrolidinyl]-
DM8WCJK DT Small molecular drug
DM8WCJK PC 10329450
DM8WCJK MW 151.21
DM8WCJK FM C8H13N3
DM8WCJK IC InChI=1S/C8H13N3/c1-6-7(2-3-10-6)8-4-9-5-11-8/h4-7,10H,2-3H2,1H3,(H,9,11)/t6-,7+/m0/s1
DM8WCJK CS C[C@H]1[C@@H](CCN1)C2=CN=CN2
DM8WCJK IK FLOJCNYYPGNYBP-NKWVEPMBSA-N
DM8WCJK IU 5-[(2S,3R)-2-methylpyrrolidin-3-yl]-1H-imidazole
DM8WCJK DE Discovery agent
DMHN5OL ID DMHN5OL
DMHN5OL DN 4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine
DMHN5OL HS Investigative
DMHN5OL SN CHEMBL1214660; SCHEMBL18770342; BDBM50324617; ZINC58563870
DMHN5OL DT Small molecular drug
DMHN5OL PC 46901616
DMHN5OL MW 281.3
DMHN5OL FM C18H13F2N
DMHN5OL IC InChI=1S/C18H13F2N/c19-17-6-5-16(12-18(17)20)15-3-1-13(2-4-15)11-14-7-9-21-10-8-14/h1-10,12H,11H2
DMHN5OL CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)F)F
DMHN5OL IK KREPMUWCVWQPGH-UHFFFAOYSA-N
DMHN5OL IU 4-[[4-(3,4-difluorophenyl)phenyl]methyl]pyridine
DMHN5OL DE Discovery agent
DM5EP3V ID DM5EP3V
DM5EP3V DN 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide
DM5EP3V HS Investigative
DM5EP3V SN 4-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide
DM5EP3V DT Small molecular drug
DM5EP3V PC 404195
DM5EP3V MW 277.3
DM5EP3V FM C12H11N3O3S
DM5EP3V IC InChI=1S/C12H11N3O3S/c13-19(17,18)12-7-3-10(4-8-12)15-14-9-1-5-11(16)6-2-9/h1-8,16H,(H2,13,17,18)
DM5EP3V CS C1=CC(=CC=C1N=NC2=CC=C(C=C2)S(=O)(=O)N)O
DM5EP3V IK IPPFWRRJWLCWGK-UHFFFAOYSA-N
DM5EP3V IU 4-[(4-hydroxyphenyl)diazenyl]benzenesulfonamide
DM5EP3V CA CAS 2497-37-2
DM5EP3V DE Discovery agent
DMNAT1D ID DMNAT1D
DMNAT1D DN 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide
DMNAT1D HS Investigative
DMNAT1D SN CHEMBL213267; 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide; 4-[(4-methoxyphenyl)diazenyl]benzenesulfonamide; NSC722840; AC1L8P6K; CTK7A1570; MolPort-002-934-354; ZINC6484196; STK037234; BDBM50190339; AKOS005382697; NSC-722840; MCULE-3486440340; 4-(4-Methoxy-phenylazo)-benzenesulfonamide; 4-[(E)-(4-methoxyphenyl)diazenyl]benzenesulfonamide; benzenesulfonamide, 4-[(e)-2-(4-methoxyphenyl)diazenyl]-
DMNAT1D DT Small molecular drug
DMNAT1D PC 405489
DMNAT1D MW 291.33
DMNAT1D FM C13H13N3O3S
DMNAT1D IC InChI=1S/C13H13N3O3S/c1-19-12-6-2-10(3-7-12)15-16-11-4-8-13(9-5-11)20(14,17)18/h2-9H,1H3,(H2,14,17,18)
DMNAT1D CS COC1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)N
DMNAT1D IK IPDZIIYOQAEWIC-UHFFFAOYSA-N
DMNAT1D IU 4-[(4-methoxyphenyl)diazenyl]benzenesulfonamide
DMNAT1D DE Discovery agent
DM6R43J ID DM6R43J
DM6R43J DN 4-((benzylideneamino)methyl)benzenesulfonamide
DM6R43J HS Investigative
DM6R43J SN CHEMBL582858; 4-((benzylideneamino)methyl)benzenesulfonamide; 4-[(benzylideneamino)methyl]benzenesulfonamide
DM6R43J DT Small molecular drug
DM6R43J PC 45483206
DM6R43J MW 274.34
DM6R43J FM C14H14N2O2S
DM6R43J IC InChI=1S/C14H14N2O2S/c15-19(17,18)14-8-6-13(7-9-14)11-16-10-12-4-2-1-3-5-12/h1-10H,11H2,(H2,15,17,18)
DM6R43J CS C1=CC=C(C=C1)C=NCC2=CC=C(C=C2)S(=O)(=O)N
DM6R43J IK IUUNKBLBYPIGMX-UHFFFAOYSA-N
DM6R43J IU 4-[(benzylideneamino)methyl]benzenesulfonamide
DM6R43J DE Discovery agent
DMDOJ4E ID DMDOJ4E
DMDOJ4E DN 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DMDOJ4E HS Investigative
DMDOJ4E SN CHEMBL102669; ZINC13757203
DMDOJ4E DT Small molecular drug
DMDOJ4E PC 10704862
DMDOJ4E MW 234.29
DMDOJ4E FM C16H14N2
DMDOJ4E IC InChI=1S/C16H14N2/c1-2-13(16-10-17-11-18-16)15-9-5-7-12-6-3-4-8-14(12)15/h2-11H,1H3,(H,17,18)/b13-2+
DMDOJ4E CS C/C=C(\\C1=CC=CC2=CC=CC=C21)/C3=CN=CN3
DMDOJ4E IK VDVBKYMIYSQNPM-XNJYKOPJSA-N
DMDOJ4E IU 5-[(E)-1-naphthalen-1-ylprop-1-enyl]-1H-imidazole
DMDOJ4E DE Discovery agent
DM52Y3Q ID DM52Y3Q
DM52Y3Q DN 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol
DM52Y3Q HS Investigative
DM52Y3Q SN CHEMBL1240677; 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol; BDBM50326006
DM52Y3Q DT Small molecular drug
DM52Y3Q PC 43680262
DM52Y3Q MW 265.31
DM52Y3Q FM C17H15NO2
DM52Y3Q IC InChI=1S/C17H15NO2/c19-16-8-5-12(9-17(16)20)11-18-15-7-6-13-3-1-2-4-14(13)10-15/h1-10,18-20H,11H2
DM52Y3Q CS C1=CC=C2C=C(C=CC2=C1)NCC3=CC(=C(C=C3)O)O
DM52Y3Q IK QYMHAOZLKJHVDJ-UHFFFAOYSA-N
DM52Y3Q IU 4-[(naphthalen-2-ylamino)methyl]benzene-1,2-diol
DM52Y3Q DE Discovery agent
DMIQHYZ ID DMIQHYZ
DMIQHYZ DN 4-((naphthalen-2-yloxy)methyl)piperidine
DMIQHYZ HS Investigative
DMIQHYZ SN 4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 4-((naphthalen-2-yloxy)methyl)piperidine; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158
DMIQHYZ DT Small molecular drug
DMIQHYZ PC 24691160
DMIQHYZ MW 241.33
DMIQHYZ FM C16H19NO
DMIQHYZ IC InChI=1S/C16H19NO/c1-2-4-15-11-16(6-5-14(15)3-1)18-12-13-7-9-17-10-8-13/h1-6,11,13,17H,7-10,12H2
DMIQHYZ CS C1CNCCC1COC2=CC3=CC=CC=C3C=C2
DMIQHYZ IK MUOXAGUZMVATIC-UHFFFAOYSA-N
DMIQHYZ IU 4-(naphthalen-2-yloxymethyl)piperidine
DMIQHYZ DE Discovery agent
DM7X2AY ID DM7X2AY
DM7X2AY DN 4-((pyridin-4-ylthio)methyl)benzene-1,2-diol
DM7X2AY HS Investigative
DM7X2AY SN CHEMBL199691; 4-((pyridin-4-ylthio)methyl)benzene-1,2-diol
DM7X2AY DT Small molecular drug
DM7X2AY PC 44406762
DM7X2AY MW 233.29
DM7X2AY FM C12H11NO2S
DM7X2AY IC InChI=1S/C12H11NO2S/c14-11-2-1-9(7-12(11)15)8-16-10-3-5-13-6-4-10/h1-7,14-15H,8H2
DM7X2AY CS C1=CC(=C(C=C1CSC2=CC=NC=C2)O)O
DM7X2AY IK JVOZIFHFAIJCMB-UHFFFAOYSA-N
DM7X2AY IU 4-(pyridin-4-ylsulfanylmethyl)benzene-1,2-diol
DM7X2AY DE Discovery agent
DM1UK3G ID DM1UK3G
DM1UK3G DN 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole
DM1UK3G HS Investigative
DM1UK3G SN CHEMBL322844; SCHEMBL7919847; ZINC13757204
DM1UK3G DT Small molecular drug
DM1UK3G PC 9991628
DM1UK3G MW 234.29
DM1UK3G FM C16H14N2
DM1UK3G IC InChI=1S/C16H14N2/c1-2-13(16-10-17-11-18-16)15-9-5-7-12-6-3-4-8-14(12)15/h2-11H,1H3,(H,17,18)/b13-2-
DM1UK3G CS C/C=C(/C1=CC=CC2=CC=CC=C21)\\C3=CN=CN3
DM1UK3G IK VDVBKYMIYSQNPM-SILLCRNTSA-N
DM1UK3G IU 5-[(Z)-1-naphthalen-1-ylprop-1-enyl]-1H-imidazole
DM1UK3G DE Discovery agent
DMEW1CP ID DMEW1CP
DMEW1CP DN 4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol
DMEW1CP HS Investigative
DMEW1CP SN CHEMBL1172883; SCHEMBL18770306; BDBM50322795
DMEW1CP DT Small molecular drug
DMEW1CP PC 46854448
DMEW1CP MW 289.4
DMEW1CP FM C20H19NO
DMEW1CP IC InChI=1S/C20H19NO/c1-2-20(17-10-12-21-13-11-17)16-8-6-15(7-9-16)18-4-3-5-19(22)14-18/h3-14,20,22H,2H2,1H3
DMEW1CP CS CCC(C1=CC=C(C=C1)C2=CC(=CC=C2)O)C3=CC=NC=C3
DMEW1CP IK CANWOPWELBFZMH-UHFFFAOYSA-N
DMEW1CP IU 3-[4-(1-pyridin-4-ylpropyl)phenyl]phenol
DMEW1CP DE Discovery agent
DMV4QRF ID DMV4QRF
DMV4QRF DN 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol
DMV4QRF HS Investigative
DMV4QRF SN CHEMBL234678; BDBM50213141
DMV4QRF DT Small molecular drug
DMV4QRF PC 11290338
DMV4QRF MW 326.5
DMV4QRF FM C22H30O2
DMV4QRF IC InChI=1S/C22H30O2/c1-5-6-7-10-15-22(2,3)17-13-14-18(20(23)16-17)19-11-8-9-12-21(19)24-4/h8-9,11-14,16,23H,5-7,10,15H2,1-4H3
DMV4QRF CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC=CC=C2OC)O
DMV4QRF IK WXRCAYBWSXUGLS-UHFFFAOYSA-N
DMV4QRF IU 2-(2-methoxyphenyl)-5-(2-methyloctan-2-yl)phenol
DMV4QRF DE Discovery agent
DMUMD8L ID DMUMD8L
DMUMD8L DN 4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl
DMUMD8L HS Investigative
DMUMD8L SN CHEMBL61038; BDBM50213142
DMUMD8L DT Small molecular drug
DMUMD8L PC 44300692
DMUMD8L MW 308.5
DMUMD8L FM C23H32
DMUMD8L IC InChI=1S/C23H32/c1-6-7-8-9-14-23(4,5)22-12-10-20(11-13-22)21-16-18(2)15-19(3)17-21/h10-13,15-17H,6-9,14H2,1-5H3
DMUMD8L CS CCCCCCC(C)(C)C1=CC=C(C=C1)C2=CC(=CC(=C2)C)C
DMUMD8L IK KOXFWOOFJAOOQK-UHFFFAOYSA-N
DMUMD8L IU 1,3-dimethyl-5-[4-(2-methyloctan-2-yl)phenyl]benzene
DMUMD8L DE Discovery agent
DM5BN41 ID DM5BN41
DM5BN41 DN 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol
DM5BN41 HS Investigative
DM5BN41 SN CHEMBL234845; BDBM50213171
DM5BN41 DT Small molecular drug
DM5BN41 PC 44431961
DM5BN41 MW 326.5
DM5BN41 FM C22H30O2
DM5BN41 IC InChI=1S/C22H30O2/c1-5-6-7-8-14-22(2,3)18-12-13-20(21(23)16-18)17-10-9-11-19(15-17)24-4/h9-13,15-16,23H,5-8,14H2,1-4H3
DM5BN41 CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC(=CC=C2)OC)O
DM5BN41 IK XKFBIUKAHKJONV-UHFFFAOYSA-N
DM5BN41 IU 2-(3-methoxyphenyl)-5-(2-methyloctan-2-yl)phenol
DM5BN41 DE Discovery agent
DMG4HO3 ID DMG4HO3
DMG4HO3 DN 4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate
DMG4HO3 HS Investigative
DMG4HO3 SN CHEMBL551567; AC1MCABO; 4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate; MolPort-002-920-365; HMS1668O20; ZINC3119736; BDBM50295657; MCULE-2085974247; CCG-245837; [4-(thiadiazol-4-yl)phenyl] N-butylcarbamate
DMG4HO3 DT Small molecular drug
DMG4HO3 PC 2739381
DMG4HO3 MW 277.34
DMG4HO3 FM C13H15N3O2S
DMG4HO3 IC InChI=1S/C13H15N3O2S/c1-2-3-8-14-13(17)18-11-6-4-10(5-7-11)12-9-19-16-15-12/h4-7,9H,2-3,8H2,1H3,(H,14,17)
DMG4HO3 CS CCCCNC(=O)OC1=CC=C(C=C1)C2=CSN=N2
DMG4HO3 IK XVFSPFDRDOHQIV-UHFFFAOYSA-N
DMG4HO3 IU [4-(thiadiazol-4-yl)phenyl] N-butylcarbamate
DMG4HO3 DE Discovery agent
DMSFGRI ID DMSFGRI
DMSFGRI DN 4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate
DMSFGRI HS Investigative
DMSFGRI SN CHEMBL550587; 4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate
DMSFGRI DT Small molecular drug
DMSFGRI PC 42645847
DMSFGRI MW 305.4
DMSFGRI FM C15H19N3O2S
DMSFGRI IC InChI=1S/C15H19N3O2S/c1-2-3-4-5-10-16-15(19)20-13-8-6-12(7-9-13)14-11-21-18-17-14/h6-9,11H,2-5,10H2,1H3,(H,16,19)
DMSFGRI CS CCCCCCNC(=O)OC1=CC=C(C=C1)C2=CSN=N2
DMSFGRI IK KWDYSOZHSAWBCY-UHFFFAOYSA-N
DMSFGRI IU [4-(thiadiazol-4-yl)phenyl] N-hexylcarbamate
DMSFGRI DE Discovery agent
DMJDW50 ID DMJDW50
DMJDW50 DN 4-(1,2-Diphenyl-but-1-enyl)-phenol
DMJDW50 HS Investigative
DMJDW50 SN CHEMBL50995; 4-(1,2-Diphenyl-1-butenyl)phenol; Monophenoltamoxifen; 4-(1,2-Diphenyl-but-1-enyl)-phenol; 4-[(Z)-1,2-diphenylbut-1-enyl]phenol; AC1O4GB8; SCHEMBL5354173; BDBM50121319; ZINC29469549; 69967-80-2; LS-104581
DMJDW50 DT Small molecular drug
DMJDW50 PC 6366969
DMJDW50 MW 300.4
DMJDW50 FM C22H20O
DMJDW50 IC InChI=1S/C22H20O/c1-2-21(17-9-5-3-6-10-17)22(18-11-7-4-8-12-18)19-13-15-20(23)16-14-19/h3-16,23H,2H2,1H3/b22-21-
DMJDW50 CS CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)O)/C3=CC=CC=C3
DMJDW50 IK YJVFSITVRZYTHO-DQRAZIAOSA-N
DMJDW50 IU 4-[(Z)-1,2-diphenylbut-1-enyl]phenol
DMJDW50 DE Discovery agent
DM1SP36 ID DM1SP36
DM1SP36 DN 4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine
DM1SP36 HS Investigative
DM1SP36 SN CHEMBL348459; 4-(10H-anthracen-9-ylidene)-1-methyl-piperidine; SCHEMBL13921290; BDBM50097218
DM1SP36 DT Small molecular drug
DM1SP36 PC 10468648
DM1SP36 MW 275.4
DM1SP36 FM C20H21N
DM1SP36 IC InChI=1S/C20H21N/c1-21-12-10-15(11-13-21)20-18-8-4-2-6-16(18)14-17-7-3-5-9-19(17)20/h2-9H,10-14H2,1H3
DM1SP36 CS CN1CCC(=C2C3=CC=CC=C3CC4=CC=CC=C42)CC1
DM1SP36 IK ZOARGTMABFXNDY-UHFFFAOYSA-N
DM1SP36 IU 4-(10H-anthracen-9-ylidene)-1-methylpiperidine
DM1SP36 DE Discovery agent
DMNV9H5 ID DMNV9H5
DMNV9H5 DN 4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol
DMNV9H5 HS Investigative
DMNV9H5 DT Small molecular drug
DMNV9H5 PC 135503667
DMNV9H5 MW 334.8
DMNV9H5 FM C20H15ClN2O
DMNV9H5 IC InChI=1S/C20H15ClN2O/c21-18-8-4-7-17-19(15-9-11-16(24)12-10-15)22-23(20(17)18)13-14-5-2-1-3-6-14/h1-12,24H,13H2
DMNV9H5 CS C1=CC=C(C=C1)CN2C3=C(C=CC=C3Cl)C(=N2)C4=CC=C(C=C4)O
DMNV9H5 IK DPRKSCQCEZRMAF-UHFFFAOYSA-N
DMNV9H5 IU 4-(1-benzyl-7-chloroindazol-3-yl)phenol
DMNV9H5 CA CAS 680613-14-3
DMNV9H5 DE Discovery agent
DMS1OYA ID DMS1OYA
DMS1OYA DN 4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol
DMS1OYA HS Investigative
DMS1OYA DT Small molecular drug
DMS1OYA PC 135458016
DMS1OYA MW 300.8
DMS1OYA FM C17H17ClN2O
DMS1OYA IC InChI=1S/C17H17ClN2O/c1-2-3-11-20-17-14(5-4-6-15(17)18)16(19-20)12-7-9-13(21)10-8-12/h4-10,21H,2-3,11H2,1H3
DMS1OYA CS CCCCN1C2=C(C=CC=C2Cl)C(=N1)C3=CC=C(C=C3)O
DMS1OYA IK NPAAZPFDWTWFDL-UHFFFAOYSA-N
DMS1OYA IU 4-(1-butyl-7-chloroindazol-3-yl)phenol
DMS1OYA CA CAS 680613-52-9
DMS1OYA DE Discovery agent
DM3NEYB ID DM3NEYB
DM3NEYB DN 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol
DM3NEYB HS Investigative
DM3NEYB DT Small molecular drug
DM3NEYB PC 135524867
DM3NEYB MW 296.3
DM3NEYB FM C18H17FN2O
DM3NEYB IC InChI=1S/C18H17FN2O/c19-16-7-3-6-15-17(12-8-10-14(22)11-9-12)20-21(18(15)16)13-4-1-2-5-13/h3,6-11,13,22H,1-2,4-5H2
DM3NEYB CS C1CCC(C1)N2C3=C(C=CC=C3F)C(=N2)C4=CC=C(C=C4)O
DM3NEYB IK IYPUUNMLLKLEOH-UHFFFAOYSA-N
DM3NEYB IU 4-(1-cyclopentyl-7-fluoroindazol-3-yl)phenol
DM3NEYB CA CAS 680611-78-3
DM3NEYB DE Discovery agent
DMFWVJI ID DMFWVJI
DMFWVJI DN 4-(1H-1,2,3-triazol-5-yl)pyridine
DMFWVJI HS Investigative
DMFWVJI SN (4-pyridyl)triazole; 4-(1H-1,2,3-triazol-5-yl)pyridine; SCHEMBL4806159; CHEMBL364898; ZINC27317; BDBM17472; 1,2,3-triazole analogue, 28; AKOS027406024
DMFWVJI DT Small molecular drug
DMFWVJI PC 9942176
DMFWVJI MW 146.15
DMFWVJI FM C7H6N4
DMFWVJI IC InChI=1S/C7H6N4/c1-3-8-4-2-6(1)7-5-9-11-10-7/h1-5H,(H,9,10,11)
DMFWVJI CS C1=CN=CC=C1C2=NNN=C2
DMFWVJI IK KEFBRERBEDJOQZ-UHFFFAOYSA-N
DMFWVJI IU 4-(2H-triazol-4-yl)pyridine
DMFWVJI DE Discovery agent
DM5JDYO ID DM5JDYO
DM5JDYO DN 4-(1H-IMIDAZOL-1-YL)PHENOL
DM5JDYO HS Investigative
DM5JDYO SN 4-(Imidazol-1-yl)phenol; 10041-02-8; 4-(1h-imidazol-1-yl)phenol; 4-Imidazol-1-yl-phenol; 4-(1-Imidazolyl)Phenol; Phenol, 4-(1H-imidazol-1-yl)-; 1-(p-Hydroxyphenyl)imidazole; 1-(4-Hydroxyphenyl)imidazole; p-(1-imidazolyl)phenol; CYKCUAPYWQDIKR-UHFFFAOYSA-N; 4-imidazolylphenol; (1H& imidazol& 1& yl)phenol (Compound 1); EINECS 233-121-4; 4-imidazol-1-ylphenol; 4m5r; p-(Imidazol-1-yl)phenol; ACMC-209vy5; AC1Q78RW; AC1Q4YG7; 4-(1H-imidazol-yl)phenol; 4(1H-imidazol-1-yl)phenol
DM5JDYO DT Small molecular drug
DM5JDYO PC 82315
DM5JDYO MW 160.17
DM5JDYO FM C9H8N2O
DM5JDYO IC InChI=1S/C9H8N2O/c12-9-3-1-8(2-4-9)11-6-5-10-7-11/h1-7,12H
DM5JDYO CS C1=CC(=CC=C1N2C=CN=C2)O
DM5JDYO IK CYKCUAPYWQDIKR-UHFFFAOYSA-N
DM5JDYO IU 4-imidazol-1-ylphenol
DM5JDYO CA CAS 10041-02-8
DM5JDYO DE Discovery agent
DMMJI4R ID DMMJI4R
DMMJI4R DN 4-(1H-Inden-1-ylmethyl)-phenylamine
DMMJI4R HS Investigative
DMMJI4R SN CHEMBL193637; 4-(1H-Inden-1-ylmethyl)-phenylamine
DMMJI4R DT Small molecular drug
DMMJI4R PC 44401550
DMMJI4R MW 221.3
DMMJI4R FM C16H15N
DMMJI4R IC InChI=1S/C16H15N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-10,14H,11,17H2
DMMJI4R CS C1=CC=C2C(C=CC2=C1)CC3=CC=C(C=C3)N
DMMJI4R IK CTQZYHBDQGUTCI-UHFFFAOYSA-N
DMMJI4R IU 4-(1H-inden-1-ylmethyl)aniline
DMMJI4R DE Discovery agent
DMY5QBF ID DMY5QBF
DMY5QBF DN 4-(1H-indol-1-ylsulfonyl)benzenamine
DMY5QBF HS Investigative
DMY5QBF SN CHEMBL372109; BDBM34151; N-arenesulfonylindole antagonist, 10
DMY5QBF DT Small molecular drug
DMY5QBF PC 44263491
DMY5QBF MW 272.32
DMY5QBF FM C14H12N2O2S
DMY5QBF IC InChI=1S/C14H12N2O2S/c15-12-5-7-13(8-6-12)19(17,18)16-10-9-11-3-1-2-4-14(11)16/h1-10H,15H2
DMY5QBF CS C1=CC=C2C(=C1)C=CN2S(=O)(=O)C3=CC=C(C=C3)N
DMY5QBF IK FLNRELDLHZADER-UHFFFAOYSA-N
DMY5QBF IU 4-indol-1-ylsulfonylaniline
DMY5QBF DE Discovery agent
DM9FKSM ID DM9FKSM
DM9FKSM DN 4-(1H-indol-3-yl)-1-morpholinobutan-1-one
DM9FKSM HS Investigative
DM9FKSM SN CHEMBL395709; 4-(1H-indol-3-yl)-1-(morpholin-4-yl)butan-1-one; AC1LDAKL; 4-(1H-indol-3-yl)-1-morpholinobutan-1-one; Oprea1_287687; MLS000073378; SCHEMBL14882056; MolPort-001-888-170; ZINC280650; HMS2314G24; BDBM50207035; STK110153; AKOS000614077; MCULE-8725603794; SMR000013452; 313532-54-6; ST50900693; 4-indol-3-yl-1-morpholin-4-ylbutan-1-one; 4-(1H-indol-3-yl)-1-morpholin-4-ylbutan-1-one; SR-01000362492; 4-(1H-Indol-3-yl)-1-morpholin-4-yl-butan-1-one; SR-01000362492-1
DM9FKSM DT Small molecular drug
DM9FKSM PC 645040
DM9FKSM MW 272.34
DM9FKSM FM C16H20N2O2
DM9FKSM IC InChI=1S/C16H20N2O2/c19-16(18-8-10-20-11-9-18)7-3-4-13-12-17-15-6-2-1-5-14(13)15/h1-2,5-6,12,17H,3-4,7-11H2
DM9FKSM CS C1COCCN1C(=O)CCCC2=CNC3=CC=CC=C32
DM9FKSM IK YFXYLXOHDNYDNC-UHFFFAOYSA-N
DM9FKSM IU 4-(1H-indol-3-yl)-1-morpholin-4-ylbutan-1-one
DM9FKSM DE Discovery agent
DM7Y1ZD ID DM7Y1ZD
DM7Y1ZD DN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD HS Investigative
DM7Y1ZD SN CHEMBL231809; 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine
DM7Y1ZD DT Small molecular drug
DM7Y1ZD PC 44430859
DM7Y1ZD MW 240.34
DM7Y1ZD FM C16H20N2
DM7Y1ZD IC InChI=1S/C16H20N2/c1-18(2)13-9-7-12(8-10-13)15-11-17-16-6-4-3-5-14(15)16/h3-7,11,13,17H,8-10H2,1-2H3
DM7Y1ZD CS CN(C)C1CCC(=CC1)C2=CNC3=CC=CC=C32
DM7Y1ZD IK OLBSGDZXLHSPOR-UHFFFAOYSA-N
DM7Y1ZD IU 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-en-1-amine
DM7Y1ZD DE Discovery agent
DMK5CJO ID DMK5CJO
DMK5CJO DN 4-(1H-Indol-3-ylmethyl)-phenylamine
DMK5CJO HS Investigative
DMK5CJO SN Benzenamine, 4-(1H-indol-3-ylmethyl)-; CHEMBL364248; 134627-70-6; 4-(1H-indol-3-ylmethyl)aniline; ACMC-20mvfl; 4-(1H-Indol-3-ylmethyl)-phenylamine; AC1N7FQI; SCHEMBL4224120; CTK0F4358; DTXSID30401708; 4-[(1H-Indol-3-yl)methyl]aniline; BDBM50164747
DMK5CJO DT Small molecular drug
DMK5CJO PC 4301799
DMK5CJO MW 222.28
DMK5CJO FM C15H14N2
DMK5CJO IC InChI=1S/C15H14N2/c16-13-7-5-11(6-8-13)9-12-10-17-15-4-2-1-3-14(12)15/h1-8,10,17H,9,16H2
DMK5CJO CS C1=CC=C2C(=C1)C(=CN2)CC3=CC=C(C=C3)N
DMK5CJO IK KDXYOBVEKNURNB-UHFFFAOYSA-N
DMK5CJO IU 4-(1H-indol-3-ylmethyl)aniline
DMK5CJO CA CAS 134627-70-6
DMK5CJO DE Discovery agent
DMQVOSU ID DMQVOSU
DMQVOSU DN 4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol
DMQVOSU HS Investigative
DMQVOSU SN CHEMBL412022; 4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol
DMQVOSU DT Small molecular drug
DMQVOSU PC 44433256
DMQVOSU MW 262.35
DMQVOSU FM C15H22N2O2
DMQVOSU IC InChI=1S/C15H22N2O2/c1-11(2)17-10-12(18)7-9-19-15-5-3-4-14-13(15)6-8-16-14/h3-6,8,11-12,16-18H,7,9-10H2,1-2H3
DMQVOSU CS CC(C)NCC(CCOC1=CC=CC2=C1C=CN2)O
DMQVOSU IK DJWOTJGQRBWXIN-UHFFFAOYSA-N
DMQVOSU IU 4-(1H-indol-4-yloxy)-1-(propan-2-ylamino)butan-2-ol
DMQVOSU DE Discovery agent
DMAU0SF ID DMAU0SF
DMAU0SF DN 4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile
DMAU0SF HS Investigative
DMAU0SF SN CHEMBL579201; 4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile; SCHEMBL2935239
DMAU0SF DT Small molecular drug
DMAU0SF PC 45485012
DMAU0SF MW 336.4
DMAU0SF FM C22H16N4
DMAU0SF IC InChI=1S/C22H16N4/c23-13-19-15-24-14-18(7-6-16-4-2-1-3-5-16)22(19)26-20-8-9-21-17(12-20)10-11-25-21/h1-12,14-15,25H,(H,24,26)/b7-6+
DMAU0SF CS C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2NC3=CC4=C(C=C3)NC=C4)C#N
DMAU0SF IK GLBDOEWDGNREFF-VOTSOKGWSA-N
DMAU0SF IU 4-(1H-indol-5-ylamino)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMAU0SF DE Discovery agent
DMH360U ID DMH360U
DMH360U DN 4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile
DMH360U HS Investigative
DMH360U SN CHEMBL568973; 4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile; SCHEMBL2935007
DMH360U DT Small molecular drug
DMH360U PC 45484993
DMH360U MW 337.4
DMH360U FM C22H15N3O
DMH360U IC InChI=1S/C22H15N3O/c23-13-19-15-24-14-18(7-6-16-4-2-1-3-5-16)22(19)26-20-8-9-21-17(12-20)10-11-25-21/h1-12,14-15,25H/b7-6+
DMH360U CS C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2OC3=CC4=C(C=C3)NC=C4)C#N
DMH360U IK IMMBFBPNPIRCBR-VOTSOKGWSA-N
DMH360U IU 4-(1H-indol-5-yloxy)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMH360U DE Discovery agent
DMB07TU ID DMB07TU
DMB07TU DN 4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile
DMB07TU HS Investigative
DMB07TU SN CHEMBL578348; 4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile; SCHEMBL2935272
DMB07TU DT Small molecular drug
DMB07TU PC 45485036
DMB07TU MW 336.4
DMB07TU FM C22H16N4
DMB07TU IC InChI=1S/C22H16N4/c23-13-19-15-24-14-18(7-6-16-4-2-1-3-5-16)22(19)26-20-9-8-17-10-11-25-21(17)12-20/h1-12,14-15,25H,(H,24,26)/b7-6+
DMB07TU CS C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2NC3=CC4=C(C=C3)C=CN4)C#N
DMB07TU IK DDIZHXIEUONSME-VOTSOKGWSA-N
DMB07TU IU 4-(1H-indol-6-ylamino)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMB07TU DE Discovery agent
DM9MPHF ID DM9MPHF
DM9MPHF DN 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM9MPHF HS Investigative
DM9MPHF SN CHEMBL1089985; 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine; SCHEMBL2239177; 1H-Pyrrolo[2,3-b]pyridine, 4-(1H-pyrazol-4-yl)-; BDBM50315770
DM9MPHF DT Small molecular drug
DM9MPHF PC 46885627
DM9MPHF MW 184.2
DM9MPHF FM C10H8N4
DM9MPHF IC InChI=1S/C10H8N4/c1-3-11-10-9(2-4-12-10)8(1)7-5-13-14-6-7/h1-6H,(H,11,12)(H,13,14)
DM9MPHF CS C1=CNC2=NC=CC(=C21)C3=CNN=C3
DM9MPHF IK FATFDRYYCYZBQB-UHFFFAOYSA-N
DM9MPHF IU 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
DM9MPHF DE Discovery agent
DM08963 ID DM08963
DM08963 DN 4-(1-Imidazol-1-yl-vinyl)-benzonitrile
DM08963 HS Investigative
DM08963 SN CHEMBL31760; Benzonitrile, 4-[1-(1H-imidazol-1-yl)ethenyl]-; 112809-36-6; 4-(1-Imidazol-1-yl-vinyl)-benzonitrile; SCHEMBL1507802; BDBM50047259; 4-(1-(1H-imidazol-1-yl)vinyl)benzonitrile
DM08963 DT Small molecular drug
DM08963 PC 11819989
DM08963 MW 195.22
DM08963 FM C12H9N3
DM08963 IC InChI=1S/C12H9N3/c1-10(15-7-6-14-9-15)12-4-2-11(8-13)3-5-12/h2-7,9H,1H2
DM08963 CS C=C(C1=CC=C(C=C1)C#N)N2C=CN=C2
DM08963 IK FUFISTOVGRWOOB-UHFFFAOYSA-N
DM08963 IU 4-(1-imidazol-1-ylethenyl)benzonitrile
DM08963 DE Discovery agent
DMFYBLH ID DMFYBLH
DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole
DMFYBLH HS Investigative
DMFYBLH SN CHEMBL306751; 1H-Imidazole, 4-[1-(1-naphthalenyl)ethyl]-; 137967-87-4; ACMC-20mx1j; 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole; AC1L30EQ; SCHEMBL1551477; CTK0F3329; DTXSID60276325; BDBM50036910; 4-[1-(1-Naphthyl)ethyl]-1H-imidazole; 5-(1-naphthalen-1-ylethyl)-1H-imidazole; 4-(1-(naphthalene-1-yl) ethyl)-1h-imidazole
DMFYBLH DT Small molecular drug
DMFYBLH PC 132111
DMFYBLH MW 222.28
DMFYBLH FM C15H14N2
DMFYBLH IC InChI=1S/C15H14N2/c1-11(15-9-16-10-17-15)13-8-4-6-12-5-2-3-7-14(12)13/h2-11H,1H3,(H,16,17)
DMFYBLH CS CC(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
DMFYBLH IK DZSQSLQSMKNVBV-UHFFFAOYSA-N
DMFYBLH IU 5-(1-naphthalen-1-ylethyl)-1H-imidazole
DMFYBLH CA CAS 137967-87-4
DMFYBLH DE Discovery agent
DM64THP ID DM64THP
DM64THP DN 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole
DM64THP HS Investigative
DM64THP SN SCHEMBL2104730; CHEMBL102076
DM64THP DT Small molecular drug
DM64THP PC 10657471
DM64THP MW 236.31
DM64THP FM C16H16N2
DM64THP IC InChI=1S/C16H16N2/c1-2-13(16-10-17-11-18-16)15-9-5-7-12-6-3-4-8-14(12)15/h3-11,13H,2H2,1H3,(H,17,18)
DM64THP CS CCC(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
DM64THP IK LDZDVSZUAUUBGV-UHFFFAOYSA-N
DM64THP IU 5-(1-naphthalen-1-ylpropyl)-1H-imidazole
DM64THP DE Discovery agent
DM49PR1 ID DM49PR1
DM49PR1 DN 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole
DM49PR1 HS Investigative
DM49PR1 SN 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole; CHEMBL105487; SCHEMBL3751615; RADFITYEEZIPNJ-UHFFFAOYSA-N; ZINC13757201
DM49PR1 DT Small molecular drug
DM49PR1 PC 10632725
DM49PR1 MW 220.27
DM49PR1 FM C15H12N2
DM49PR1 IC InChI=1S/C15H12N2/c1-11(15-9-16-10-17-15)13-8-4-6-12-5-2-3-7-14(12)13/h2-10H,1H2,(H,16,17)
DM49PR1 CS C=C(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
DM49PR1 IK RADFITYEEZIPNJ-UHFFFAOYSA-N
DM49PR1 IU 5-(1-naphthalen-1-ylethenyl)-1H-imidazole
DM49PR1 DE Discovery agent
DMJ9CNA ID DMJ9CNA
DMJ9CNA DN 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA HS Investigative
DMJ9CNA SN CHEMBL573766; 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine
DMJ9CNA DT Small molecular drug
DMJ9CNA PC 45483528
DMJ9CNA MW 285.4
DMJ9CNA FM C18H20FNO
DMJ9CNA IC InChI=1S/C18H20FNO/c19-16-5-3-6-17(12-16)21-13-15-4-1-2-7-18(15)14-8-10-20-11-9-14/h1-7,12,14,20H,8-11,13H2
DMJ9CNA CS C1CNCCC1C2=CC=CC=C2COC3=CC(=CC=C3)F
DMJ9CNA IK LGSKMJOUAMVJKK-UHFFFAOYSA-N
DMJ9CNA IU 4-[2-[(3-fluorophenoxy)methyl]phenyl]piperidine
DMJ9CNA DE Discovery agent
DM0MWVU ID DM0MWVU
DM0MWVU DN 4-(2-((dimethylamino)methyl)phenoxy)benzonitrile
DM0MWVU HS Investigative
DM0MWVU SN CHEMBL481941; 4-(2-((dimethylamino)methyl)phenoxy)benzonitrile
DM0MWVU DT Small molecular drug
DM0MWVU PC 44568213
DM0MWVU MW 252.31
DM0MWVU FM C16H16N2O
DM0MWVU IC InChI=1S/C16H16N2O/c1-18(2)12-14-5-3-4-6-16(14)19-15-9-7-13(11-17)8-10-15/h3-10H,12H2,1-2H3
DM0MWVU CS CN(C)CC1=CC=CC=C1OC2=CC=C(C=C2)C#N
DM0MWVU IK RQDOQYXVLGVVBA-UHFFFAOYSA-N
DM0MWVU IU 4-[2-[(dimethylamino)methyl]phenoxy]benzonitrile
DM0MWVU DE Discovery agent
DM1043B ID DM1043B
DM1043B DN 4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one
DM1043B HS Investigative
DM1043B SN CHEMBL225178; 2H-1-Benzopyran-2-one, 4-[2-(1H-imidazol-1-yl)ethoxy]-; 828265-57-2; Coumarin deriv. 22; BDBM9473; CTK3D6006; DTXSID60462004
DM1043B DT Small molecular drug
DM1043B PC 11311402
DM1043B MW 256.26
DM1043B FM C14H12N2O3
DM1043B IC InChI=1S/C14H12N2O3/c17-14-9-13(11-3-1-2-4-12(11)19-14)18-8-7-16-6-5-15-10-16/h1-6,9-10H,7-8H2
DM1043B CS C1=CC=C2C(=C1)C(=CC(=O)O2)OCCN3C=CN=C3
DM1043B IK MXJNKMWQNZHBOE-UHFFFAOYSA-N
DM1043B IU 4-(2-imidazol-1-ylethoxy)chromen-2-one
DM1043B CA CAS 828265-57-2
DM1043B DE Discovery agent
DMTJGBL ID DMTJGBL
DMTJGBL DN 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine
DMTJGBL HS Investigative
DMTJGBL SN CHEMBL611630; 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine
DMTJGBL DT Small molecular drug
DMTJGBL PC 46225260
DMTJGBL MW 320.3
DMTJGBL FM C17H16N6O
DMTJGBL IC InChI=1S/C17H16N6O/c1-2-12(9-13-11(1)3-4-18-13)15-21-16-14(19-10-20-16)17(22-15)23-5-7-24-8-6-23/h1-4,9-10,18H,5-8H2,(H,19,20,21,22)
DMTJGBL CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC5=C(C=C4)C=CN5
DMTJGBL IK LYJKHCYTQHFQLX-UHFFFAOYSA-N
DMTJGBL IU 4-[2-(1H-indol-6-yl)-7H-purin-6-yl]morpholine
DMTJGBL DE Discovery agent
DM9UA0N ID DM9UA0N
DM9UA0N DN 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N HS Investigative
DM9UA0N SN CHEMBL583332; 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine
DM9UA0N DT Small molecular drug
DM9UA0N PC 45483409
DM9UA0N MW 285.4
DM9UA0N FM C18H20FNO
DM9UA0N IC InChI=1S/C18H20FNO/c1-13-6-7-16(19)18(12-13)21-17-5-3-2-4-15(17)14-8-10-20-11-9-14/h2-7,12,14,20H,8-11H2,1H3
DM9UA0N CS CC1=CC(=C(C=C1)F)OC2=CC=CC=C2C3CCNCC3
DM9UA0N IK QPPDVPUFQFPJKK-UHFFFAOYSA-N
DM9UA0N IU 4-[2-(2-fluoro-5-methylphenoxy)phenyl]piperidine
DM9UA0N DE Discovery agent
DMCR3VM ID DMCR3VM
DMCR3VM DN 4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM HS Investigative
DMCR3VM SN CHEMBL573897; 4-(2-(2-fluorobenzyloxy)phenyl)piperidine
DMCR3VM DT Small molecular drug
DMCR3VM PC 45483400
DMCR3VM MW 285.4
DMCR3VM FM C18H20FNO
DMCR3VM IC InChI=1S/C18H20FNO/c19-17-7-3-1-5-15(17)13-21-18-8-4-2-6-16(18)14-9-11-20-12-10-14/h1-8,14,20H,9-13H2
DMCR3VM CS C1CNCCC1C2=CC=CC=C2OCC3=CC=CC=C3F
DMCR3VM IK CDVPUDLPRZVZHB-UHFFFAOYSA-N
DMCR3VM IU 4-[2-[(2-fluorophenyl)methoxy]phenyl]piperidine
DMCR3VM DE Discovery agent
DMKZ6JW ID DMKZ6JW
DMKZ6JW DN 4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole
DMKZ6JW HS Investigative
DMKZ6JW SN CHEMBL1097658; 4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole
DMKZ6JW DT Small molecular drug
DMKZ6JW PC 46222044
DMKZ6JW MW 215.29
DMKZ6JW FM C13H17N3
DMKZ6JW IC InChI=1S/C13H17N3/c1-10-3-4-12(7-11(10)2)15-6-5-13-8-14-9-16-13/h3-4,7-9,15H,5-6H2,1-2H3,(H,14,16)
DMKZ6JW CS CC1=C(C=C(C=C1)NCCC2=CN=CN2)C
DMKZ6JW IK GHCPLWBMALOXTM-UHFFFAOYSA-N
DMKZ6JW IU N-[2-(1H-imidazol-5-yl)ethyl]-3,4-dimethylaniline
DMKZ6JW DE Discovery agent
DM0IT5E ID DM0IT5E
DM0IT5E DN 4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E HS Investigative
DM0IT5E SN CHEMBL575290; 4-(2-(3-chlorophenoxy)phenyl)piperidine
DM0IT5E DT Small molecular drug
DM0IT5E PC 45483512
DM0IT5E MW 287.8
DM0IT5E FM C17H18ClNO
DM0IT5E IC InChI=1S/C17H18ClNO/c18-14-4-3-5-15(12-14)20-17-7-2-1-6-16(17)13-8-10-19-11-9-13/h1-7,12-13,19H,8-11H2
DM0IT5E CS C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)Cl
DM0IT5E IK QHHWSRAVBLCPAI-UHFFFAOYSA-N
DM0IT5E IU 4-[2-(3-chlorophenoxy)phenyl]piperidine
DM0IT5E DE Discovery agent
DMEPB9L ID DMEPB9L
DMEPB9L DN 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L HS Investigative
DMEPB9L SN CHEMBL573898; 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine
DMEPB9L DT Small molecular drug
DMEPB9L PC 45483408
DMEPB9L MW 285.4
DMEPB9L FM C18H20FNO
DMEPB9L IC InChI=1S/C18H20FNO/c1-13-5-6-17(14-7-9-20-10-8-14)18(11-13)21-16-4-2-3-15(19)12-16/h2-6,11-12,14,20H,7-10H2,1H3
DMEPB9L CS CC1=CC(=C(C=C1)C2CCNCC2)OC3=CC(=CC=C3)F
DMEPB9L IK BBYFZRZFESDGLZ-UHFFFAOYSA-N
DMEPB9L IU 4-[2-(3-fluorophenoxy)-4-methylphenyl]piperidine
DMEPB9L DE Discovery agent
DMZMEOG ID DMZMEOG
DMZMEOG DN 4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG HS Investigative
DMZMEOG SN CHEMBL583752; 4-(2-(3-fluorophenoxy)phenyl)piperidine
DMZMEOG DT Small molecular drug
DMZMEOG PC 45375937
DMZMEOG MW 271.33
DMZMEOG FM C17H18FNO
DMZMEOG IC InChI=1S/C17H18FNO/c18-14-4-3-5-15(12-14)20-17-7-2-1-6-16(17)13-8-10-19-11-9-13/h1-7,12-13,19H,8-11H2
DMZMEOG CS C1CNCCC1C2=CC=CC=C2OC3=CC(=CC=C3)F
DMZMEOG IK WLJMFBUPVRQPDQ-UHFFFAOYSA-N
DMZMEOG IU 4-[2-(3-fluorophenoxy)phenyl]piperidine
DMZMEOG DE Discovery agent
DMRDWUT ID DMRDWUT
DMRDWUT DN 4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole
DMRDWUT HS Investigative
DMRDWUT SN CHEMBL202323; 4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole; SCHEMBL4145662
DMRDWUT DT Small molecular drug
DMRDWUT PC 11557579
DMRDWUT MW 217.26
DMRDWUT FM C12H8FNS
DMRDWUT IC InChI=1S/C12H8FNS/c1-9-14-12(8-15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMRDWUT CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)F
DMRDWUT IK SCVDCVQUJSBAAM-UHFFFAOYSA-N
DMRDWUT IU 4-[2-(3-fluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMRDWUT DE Discovery agent
DMP1LY4 ID DMP1LY4
DMP1LY4 DN 4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole
DMP1LY4 HS Investigative
DMP1LY4 SN CHEMBL1096517; 4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole
DMP1LY4 DT Small molecular drug
DMP1LY4 PC 46222046
DMP1LY4 MW 243.35
DMP1LY4 FM C15H21N3
DMP1LY4 IC InChI=1S/C15H21N3/c1-15(2,3)12-5-4-6-13(9-12)17-8-7-14-10-16-11-18-14/h4-6,9-11,17H,7-8H2,1-3H3,(H,16,18)
DMP1LY4 CS CC(C)(C)C1=CC(=CC=C1)NCCC2=CN=CN2
DMP1LY4 IK LRIVTYQQFCXAFC-UHFFFAOYSA-N
DMP1LY4 IU 3-tert-butyl-N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMP1LY4 DE Discovery agent
DMN97TC ID DMN97TC
DMN97TC DN 4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine
DMN97TC HS Investigative
DMN97TC SN CHEMBL391379; Morpholine, 4-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]-; 851546-84-4; 4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine; SCHEMBL5699765; CTK3C9230; DTXSID80458181; 4-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]morpholine
DMN97TC DT Small molecular drug
DMN97TC PC 11188669
DMN97TC MW 396.7
DMN97TC FM C18H19BrClNO2
DMN97TC IC InChI=1S/C18H19BrClNO2/c19-16-3-6-18(23-13-14-1-4-17(20)5-2-14)15(11-16)12-21-7-9-22-10-8-21/h1-6,11H,7-10,12-13H2
DMN97TC CS C1COCCN1CC2=C(C=CC(=C2)Br)OCC3=CC=C(C=C3)Cl
DMN97TC IK JUKUHNUKMFGLIK-UHFFFAOYSA-N
DMN97TC IU 4-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]morpholine
DMN97TC CA CAS 851546-84-4
DMN97TC DE Discovery agent
DMM8CU2 ID DMM8CU2
DMM8CU2 DN 4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole
DMM8CU2 HS Investigative
DMM8CU2 SN CHEMBL1098229; 4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole
DMM8CU2 DT Small molecular drug
DMM8CU2 PC 46222047
DMM8CU2 MW 269.4
DMM8CU2 FM C17H23N3
DMM8CU2 IC InChI=1S/C17H23N3/c1-2-4-14(5-3-1)15-6-8-16(9-7-15)19-11-10-17-12-18-13-20-17/h6-9,12-14,19H,1-5,10-11H2,(H,18,20)
DMM8CU2 CS C1CCC(CC1)C2=CC=C(C=C2)NCCC3=CN=CN3
DMM8CU2 IK GEYDSVZUDGXVCV-UHFFFAOYSA-N
DMM8CU2 IU 4-cyclohexyl-N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMM8CU2 DE Discovery agent
DM29QLG ID DM29QLG
DM29QLG DN 4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG HS Investigative
DM29QLG SN CHEMBL573531; 4-(2-(4-fluorobenzyloxy)phenyl)piperidine
DM29QLG DT Small molecular drug
DM29QLG PC 45483407
DM29QLG MW 285.4
DM29QLG FM C18H20FNO
DM29QLG IC InChI=1S/C18H20FNO/c19-16-7-5-14(6-8-16)13-21-18-4-2-1-3-17(18)15-9-11-20-12-10-15/h1-8,15,20H,9-13H2
DM29QLG CS C1CNCCC1C2=CC=CC=C2OCC3=CC=C(C=C3)F
DM29QLG IK QJRQNVRAJVCSDH-UHFFFAOYSA-N
DM29QLG IU 4-[2-[(4-fluorophenyl)methoxy]phenyl]piperidine
DM29QLG DE Discovery agent
DMJNB8C ID DMJNB8C
DMJNB8C DN 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C HS Investigative
DMJNB8C SN CHEMBL574347; 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine
DMJNB8C DT Small molecular drug
DMJNB8C PC 45483520
DMJNB8C MW 285.4
DMJNB8C FM C18H20FNO
DMJNB8C IC InChI=1S/C18H20FNO/c1-13-2-7-17(14-8-10-20-11-9-14)18(12-13)21-16-5-3-15(19)4-6-16/h2-7,12,14,20H,8-11H2,1H3
DMJNB8C CS CC1=CC(=C(C=C1)C2CCNCC2)OC3=CC=C(C=C3)F
DMJNB8C IK MUPPOMFFBLBAKT-UHFFFAOYSA-N
DMJNB8C IU 4-[2-(4-fluorophenoxy)-4-methylphenyl]piperidine
DMJNB8C DE Discovery agent
DMFQT9O ID DMFQT9O
DMFQT9O DN 4-(2-(4-fluorophenoxy)phenyl)piperidine
DMFQT9O HS Investigative
DMFQT9O SN CHEMBL584173; 4-(2-(4-fluorophenoxy)phenyl)piperidine; SCHEMBL3040991; BDBM50299806
DMFQT9O DT Small molecular drug
DMFQT9O PC 22599992
DMFQT9O MW 271.33
DMFQT9O FM C17H18FNO
DMFQT9O IC InChI=1S/C17H18FNO/c18-14-5-7-15(8-6-14)20-17-4-2-1-3-16(17)13-9-11-19-12-10-13/h1-8,13,19H,9-12H2
DMFQT9O CS C1CNCCC1C2=CC=CC=C2OC3=CC=C(C=C3)F
DMFQT9O IK BXXRQIARNFYYBC-UHFFFAOYSA-N
DMFQT9O IU 4-[2-(4-fluorophenoxy)phenyl]piperidine
DMFQT9O DE Discovery agent
DMOX40J ID DMOX40J
DMOX40J DN 4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole
DMOX40J HS Investigative
DMOX40J SN CHEMBL202125; 4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole; SCHEMBL4146642
DMOX40J DT Small molecular drug
DMOX40J PC 11550292
DMOX40J MW 217.26
DMOX40J FM C12H8FNS
DMOX40J IC InChI=1S/C12H8FNS/c1-9-14-12(8-15-9)7-4-10-2-5-11(13)6-3-10/h2-3,5-6,8H,1H3
DMOX40J CS CC1=NC(=CS1)C#CC2=CC=C(C=C2)F
DMOX40J IK UUKQDEMVLZEXPO-UHFFFAOYSA-N
DMOX40J IU 4-[2-(4-fluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMOX40J DE Discovery agent
DMFCS8G ID DMFCS8G
DMFCS8G DN 4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole
DMFCS8G HS Investigative
DMFCS8G SN CHEMBL1098527; 4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole
DMFCS8G DT Small molecular drug
DMFCS8G PC 46888007
DMFCS8G MW 234.32
DMFCS8G FM C12H14N2OS
DMFCS8G IC InChI=1S/C12H14N2OS/c1-15-11-2-4-12(5-3-11)16-7-6-10-8-13-9-14-10/h2-5,8-9H,6-7H2,1H3,(H,13,14)
DMFCS8G CS COC1=CC=C(C=C1)SCCC2=CN=CN2
DMFCS8G IK MFQHSSADNRVZAE-UHFFFAOYSA-N
DMFCS8G IU 5-[2-(4-methoxyphenyl)sulfanylethyl]-1H-imidazole
DMFCS8G DE Discovery agent
DMYM72T ID DMYM72T
DMYM72T DN 4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole
DMYM72T HS Investigative
DMYM72T SN 4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole; CHEMBL1096515; BDBM50317870
DMYM72T DT Small molecular drug
DMYM72T PC 46222043
DMYM72T MW 201.27
DMYM72T FM C12H15N3
DMYM72T IC InChI=1S/C12H15N3/c1-10-2-4-11(5-3-10)14-7-6-12-8-13-9-15-12/h2-5,8-9,14H,6-7H2,1H3,(H,13,15)
DMYM72T CS CC1=CC=C(C=C1)NCCC2=CN=CN2
DMYM72T IK OOTAMYWJHGNDAH-UHFFFAOYSA-N
DMYM72T IU N-[2-(1H-imidazol-5-yl)ethyl]-4-methylaniline
DMYM72T DE Discovery agent
DMK8ROX ID DMK8ROX
DMK8ROX DN 4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole
DMK8ROX HS Investigative
DMK8ROX SN CHEMBL1096516; 4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole
DMK8ROX DT Small molecular drug
DMK8ROX PC 46222045
DMK8ROX MW 243.35
DMK8ROX FM C15H21N3
DMK8ROX IC InChI=1S/C15H21N3/c1-15(2,3)12-4-6-13(7-5-12)17-9-8-14-10-16-11-18-14/h4-7,10-11,17H,8-9H2,1-3H3,(H,16,18)
DMK8ROX CS CC(C)(C)C1=CC=C(C=C1)NCCC2=CN=CN2
DMK8ROX IK CAUIWLDBMLQRJD-UHFFFAOYSA-N
DMK8ROX IU 4-tert-butyl-N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMK8ROX DE Discovery agent
DMUYPMO ID DMUYPMO
DMUYPMO DN 4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol
DMUYPMO HS Investigative
DMUYPMO SN CHEMBL234581; 4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol
DMUYPMO DT Small molecular drug
DMUYPMO PC 44430036
DMUYPMO MW 296.4
DMUYPMO FM C19H24N2O
DMUYPMO IC InChI=1S/C19H24N2O/c20-14-17-8-4-5-9-18(17)19(22)10-12-21(13-11-19)15-16-6-2-1-3-7-16/h1-9,22H,10-15,20H2
DMUYPMO CS C1CN(CCC1(C2=CC=CC=C2CN)O)CC3=CC=CC=C3
DMUYPMO IK RPBRGKBDJGSAFB-UHFFFAOYSA-N
DMUYPMO IU 4-[2-(aminomethyl)phenyl]-1-benzylpiperidin-4-ol
DMUYPMO DE Discovery agent
DMM2NHZ ID DMM2NHZ
DMM2NHZ DN 4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ HS Investigative
DMM2NHZ SN CHEMBL583750; 4-(2-(benzyloxy)-3-fluorophenyl)piperidine
DMM2NHZ DT Small molecular drug
DMM2NHZ PC 45483405
DMM2NHZ MW 285.4
DMM2NHZ FM C18H20FNO
DMM2NHZ IC InChI=1S/C18H20FNO/c19-17-8-4-7-16(15-9-11-20-12-10-15)18(17)21-13-14-5-2-1-3-6-14/h1-8,15,20H,9-13H2
DMM2NHZ CS C1CNCCC1C2=C(C(=CC=C2)F)OCC3=CC=CC=C3
DMM2NHZ IK ONPYWJJNTLFDAR-UHFFFAOYSA-N
DMM2NHZ IU 4-(3-fluoro-2-phenylmethoxyphenyl)piperidine
DMM2NHZ DE Discovery agent
DMF3S50 ID DMF3S50
DMF3S50 DN 4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50 HS Investigative
DMF3S50 SN CHEMBL575930; 4-(2-(benzyloxy)-6-fluorophenyl)piperidine
DMF3S50 DT Small molecular drug
DMF3S50 PC 45483406
DMF3S50 MW 285.4
DMF3S50 FM C18H20FNO
DMF3S50 IC InChI=1S/C18H20FNO/c19-16-7-4-8-17(18(16)15-9-11-20-12-10-15)21-13-14-5-2-1-3-6-14/h1-8,15,20H,9-13H2
DMF3S50 CS C1CNCCC1C2=C(C=CC=C2F)OCC3=CC=CC=C3
DMF3S50 IK WEBWNOZIRPUGTR-UHFFFAOYSA-N
DMF3S50 IU 4-(2-fluoro-6-phenylmethoxyphenyl)piperidine
DMF3S50 DE Discovery agent
DMOC7PY ID DMOC7PY
DMOC7PY DN 4-(2-(benzyloxy)phenyl)piperidine
DMOC7PY HS Investigative
DMOC7PY SN 4-(2-(benzyloxy)phenyl)piperidine; CHEMBL573769
DMOC7PY DT Small molecular drug
DMOC7PY PC 45483529
DMOC7PY MW 267.4
DMOC7PY FM C18H21NO
DMOC7PY IC InChI=1S/C18H21NO/c1-2-6-15(7-3-1)14-20-18-9-5-4-8-17(18)16-10-12-19-13-11-16/h1-9,16,19H,10-14H2
DMOC7PY CS C1CNCCC1C2=CC=CC=C2OCC3=CC=CC=C3
DMOC7PY IK XJJHPGZYVOFINN-UHFFFAOYSA-N
DMOC7PY IU 4-(2-phenylmethoxyphenyl)piperidine
DMOC7PY DE Discovery agent
DM1MP96 ID DM1MP96
DM1MP96 DN 4-(2-(Cyclohexylamino)ethyl)-1H-imidazole
DM1MP96 HS Investigative
DM1MP96 SN CHEMBL1096513; 4-(2-(Cyclohexylamino)ethyl)-1H-imidazole; BDBM50317872
DM1MP96 DT Small molecular drug
DM1MP96 PC 12647300
DM1MP96 MW 193.29
DM1MP96 FM C11H19N3
DM1MP96 IC InChI=1S/C11H19N3/c1-2-4-10(5-3-1)13-7-6-11-8-12-9-14-11/h8-10,13H,1-7H2,(H,12,14)
DM1MP96 CS C1CCC(CC1)NCCC2=CN=CN2
DM1MP96 IK OKJFYIHINPOKMF-UHFFFAOYSA-N
DM1MP96 IU N-[2-(1H-imidazol-5-yl)ethyl]cyclohexanamine
DM1MP96 DE Discovery agent
DMRQ8T9 ID DMRQ8T9
DMRQ8T9 DN 4-(2-(diethylamino)ethylamino)-1-naphthol
DMRQ8T9 HS Investigative
DMRQ8T9 SN CHEMBL576113; Kinome_2771; 4-(2-(diethylamino)ethylamino)-1-naphthol; SCHEMBL12649369
DMRQ8T9 DT Small molecular drug
DMRQ8T9 PC 44466196
DMRQ8T9 MW 258.36
DMRQ8T9 FM C16H22N2O
DMRQ8T9 IC InChI=1S/C16H22N2O/c1-3-18(4-2)12-11-17-15-9-10-16(19)14-8-6-5-7-13(14)15/h5-10,17,19H,3-4,11-12H2,1-2H3
DMRQ8T9 CS CCN(CC)CCNC1=CC=C(C2=CC=CC=C21)O
DMRQ8T9 IK LVUBFHBEMVTCJQ-UHFFFAOYSA-N
DMRQ8T9 IU 4-[2-(diethylamino)ethylamino]naphthalen-1-ol
DMRQ8T9 DE Discovery agent
DM0OFRQ ID DM0OFRQ
DM0OFRQ DN 4-(2-(phenoxymethyl)phenyl)piperidine
DM0OFRQ HS Investigative
DM0OFRQ SN 4-(2-(phenoxymethyl)phenyl)piperidine; CHEMBL574348; SCHEMBL12965384
DM0OFRQ DT Small molecular drug
DM0OFRQ PC 45483527
DM0OFRQ MW 267.4
DM0OFRQ FM C18H21NO
DM0OFRQ IC InChI=1S/C18H21NO/c1-2-7-17(8-3-1)20-14-16-6-4-5-9-18(16)15-10-12-19-13-11-15/h1-9,15,19H,10-14H2
DM0OFRQ CS C1CNCCC1C2=CC=CC=C2COC3=CC=CC=C3
DM0OFRQ IK SYLMRMITUMFBTA-UHFFFAOYSA-N
DM0OFRQ IU 4-[2-(phenoxymethyl)phenyl]piperidine
DM0OFRQ DE Discovery agent
DMX1HKU ID DMX1HKU
DMX1HKU DN 4-(2-(Phenylamino)ethyl)-1H-imidazole
DMX1HKU HS Investigative
DMX1HKU SN 4-(2-(Phenylamino)ethyl)-1H-imidazole; CHEMBL1096514; 51720-84-4; phenylhistamine; BDBM50317871; ZINC49088978
DMX1HKU DT Small molecular drug
DMX1HKU PC 46222042
DMX1HKU MW 187.24
DMX1HKU FM C11H13N3
DMX1HKU IC InChI=1S/C11H13N3/c1-2-4-10(5-3-1)13-7-6-11-8-12-9-14-11/h1-5,8-9,13H,6-7H2,(H,12,14)
DMX1HKU CS C1=CC=C(C=C1)NCCC2=CN=CN2
DMX1HKU IK JNHQUQHJWWFGKK-UHFFFAOYSA-N
DMX1HKU IU N-[2-(1H-imidazol-5-yl)ethyl]aniline
DMX1HKU DE Discovery agent
DMHWD2C ID DMHWD2C
DMHWD2C DN 4-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMHWD2C HS Investigative
DMHWD2C SN 67580-65-8; 4-[2-(pyrrolidin-1-yl)ethyl]pyridine; 4-(2-Tetrahydro-1H-pyrrol-1-ylethyl)pyridine; 4-(2-pyrrolidin-1-ylethyl)pyridine; MLS000737070; CHEMBL405070; 4-(2-(pyrrolidin-1-yl)ethyl)pyridine; 4-(2-pyrrolidin-1-yl-ethyl)-pyridine; NSC42776; AC1Q4WU8; AC1Q28PY; AC1L60Z5; SCHEMBL3993201; 4-(2-pyrrolidinylethyl)pyridine; CTK2F7988; DTXSID30285782; MolPort-000-145-638; ZINC163336; HMS2752A23; SBB089201; BDBM50372345; STL324986; NSC-42776; AKOS006227946; VP14627; MCULE-2911571696; 4-(2-PYRROLIDINOETHYL)PYRIDINE; SMR000038089
DMHWD2C DT Small molecular drug
DMHWD2C PC 238432
DMHWD2C MW 176.26
DMHWD2C FM C11H16N2
DMHWD2C IC InChI=1S/C11H16N2/c1-2-9-13(8-1)10-5-11-3-6-12-7-4-11/h3-4,6-7H,1-2,5,8-10H2
DMHWD2C CS C1CCN(C1)CCC2=CC=NC=C2
DMHWD2C IK GNJYGFKCUMGKOY-UHFFFAOYSA-N
DMHWD2C IU 4-(2-pyrrolidin-1-ylethyl)pyridine
DMHWD2C CA CAS 67580-65-8
DMHWD2C DE Discovery agent
DMWN1CM ID DMWN1CM
DMWN1CM DN 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine
DMWN1CM HS Investigative
DMWN1CM SN CHEMBL604876; 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine; SCHEMBL4439490
DMWN1CM DT Small molecular drug
DMWN1CM PC 25074311
DMWN1CM MW 287.34
DMWN1CM FM C13H13N5OS
DMWN1CM IC InChI=1S/C13H13N5OS/c1-2-9(20-7-1)11-16-12-10(14-8-15-12)13(17-11)18-3-5-19-6-4-18/h1-2,7-8H,3-6H2,(H,14,15,16,17)
DMWN1CM CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=CS4
DMWN1CM IK WKJDCMFOOMWIQG-UHFFFAOYSA-N
DMWN1CM IU 4-(2-thiophen-2-yl-7H-purin-6-yl)morpholine
DMWN1CM DE Discovery agent
DMAO6X9 ID DMAO6X9
DMAO6X9 DN 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine
DMAO6X9 HS Investigative
DMAO6X9 SN CHEMBL608095; 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine; SCHEMBL4438208
DMAO6X9 DT Small molecular drug
DMAO6X9 PC 25074312
DMAO6X9 MW 287.34
DMAO6X9 FM C13H13N5OS
DMAO6X9 IC InChI=1S/C13H13N5OS/c1-6-20-7-9(1)11-16-12-10(14-8-15-12)13(17-11)18-2-4-19-5-3-18/h1,6-8H,2-5H2,(H,14,15,16,17)
DMAO6X9 CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CSC=C4
DMAO6X9 IK SQTGJTBXJLFTBF-UHFFFAOYSA-N
DMAO6X9 IU 4-(2-thiophen-3-yl-7H-purin-6-yl)morpholine
DMAO6X9 DE Discovery agent
DMIL45X ID DMIL45X
DMIL45X DN 4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole
DMIL45X HS Investigative
DMIL45X SN CHEMBL1224520; BDBM50325802
DMIL45X DT Small molecular drug
DMIL45X PC 11324184
DMIL45X MW 305.25
DMIL45X FM C16H10F3NO2
DMIL45X IC InChI=1S/C16H10F3NO2/c17-16(18,19)22-15-7-2-1-6-13(15)11-4-3-5-12(8-11)14-9-21-10-20-14/h1-10H
DMIL45X CS C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=COC=N3)OC(F)(F)F
DMIL45X IK QUFLMZRMQIORDK-UHFFFAOYSA-N
DMIL45X IU 4-[3-[2-(trifluoromethoxy)phenyl]phenyl]-1,3-oxazole
DMIL45X DE Discovery agent
DM3R2D1 ID DM3R2D1
DM3R2D1 DN 4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole
DM3R2D1 HS Investigative
DM3R2D1 SN CHEMBL1224656; BDBM50325809
DM3R2D1 DT Small molecular drug
DM3R2D1 PC 11427214
DM3R2D1 MW 321.3
DM3R2D1 FM C16H10F3NOS
DM3R2D1 IC InChI=1S/C16H10F3NOS/c17-16(18,19)21-15-7-2-1-6-13(15)11-4-3-5-12(8-11)14-9-22-10-20-14/h1-10H
DM3R2D1 CS C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=CSC=N3)OC(F)(F)F
DM3R2D1 IK AJYWSJBYBSJCBJ-UHFFFAOYSA-N
DM3R2D1 IU 4-[3-[2-(trifluoromethoxy)phenyl]phenyl]-1,3-thiazole
DM3R2D1 DE Discovery agent
DMXC5S0 ID DMXC5S0
DMXC5S0 DN 4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole
DMXC5S0 HS Investigative
DMXC5S0 SN CHEMBL1224519; BDBM50325801
DMXC5S0 DT Small molecular drug
DMXC5S0 PC 11460438
DMXC5S0 MW 289.25
DMXC5S0 FM C16H10F3NO
DMXC5S0 IC InChI=1S/C16H10F3NO/c17-16(18,19)14-7-2-1-6-13(14)11-4-3-5-12(8-11)15-9-21-10-20-15/h1-10H
DMXC5S0 CS C1=CC=C(C(=C1)C2=CC(=CC=C2)C3=COC=N3)C(F)(F)F
DMXC5S0 IK SRZDIBWHWBVAAW-UHFFFAOYSA-N
DMXC5S0 IU 4-[3-[2-(trifluoromethyl)phenyl]phenyl]-1,3-oxazole
DMXC5S0 DE Discovery agent
DMRZY0B ID DMRZY0B
DMRZY0B DN 4-(2,2'-bithiophen-5-ylmethyleneamino)phenol
DMRZY0B HS Investigative
DMRZY0B SN MLS000106248; SMR000103217; CHEMBL504791; 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol; AC1LGKRK; cid_796420; BDBM29642; HMS2448D05; MCULE-1982148585; SR-01000609337; SR-01000609337-2; 4-[[5-(2-thienyl)-2-thienyl]methyleneamino]phenol
DMRZY0B DT Small molecular drug
DMRZY0B PC 796420
DMRZY0B MW 285.4
DMRZY0B FM C15H11NOS2
DMRZY0B IC InChI=1S/C15H11NOS2/c17-12-5-3-11(4-6-12)16-10-13-7-8-15(19-13)14-2-1-9-18-14/h1-10,17H
DMRZY0B CS C1=CSC(=C1)C2=CC=C(S2)C=NC3=CC=C(C=C3)O
DMRZY0B IK UMPJRGAFFRSXRX-UHFFFAOYSA-N
DMRZY0B IU 4-[(5-thiophen-2-ylthiophen-2-yl)methylideneamino]phenol
DMRZY0B DE Discovery agent
DMI638K ID DMI638K
DMI638K DN 4-(2,2-Diphenyl-vinyl)-pyridine
DMI638K HS Investigative
DMI638K SN 4-(2,2-diphenylethenyl)pyridine; 4-Pyridylmethylene 35; AC1NEND1; CHEMBL381194; BDBM8645; SCHEMBL16946606
DMI638K DT Small molecular drug
DMI638K PC 4594970
DMI638K MW 257.3
DMI638K FM C19H15N
DMI638K IC InChI=1S/C19H15N/c1-3-7-17(8-4-1)19(18-9-5-2-6-10-18)15-16-11-13-20-14-12-16/h1-15H
DMI638K CS C1=CC=C(C=C1)C(=CC2=CC=NC=C2)C3=CC=CC=C3
DMI638K IK QSVVYMBWQOGDNI-UHFFFAOYSA-N
DMI638K IU 4-(2,2-diphenylethenyl)pyridine
DMI638K CA CAS 15814-97-8
DMI638K DE Discovery agent
DMGOHSF ID DMGOHSF
DMGOHSF DN 4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid
DMGOHSF HS Investigative
DMGOHSF SN CHEMBL413572; 4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid
DMGOHSF DT Small molecular drug
DMGOHSF PC 44408224
DMGOHSF MW 294.2
DMGOHSF FM C11H13Cl2NO2S
DMGOHSF IC InChI=1S/C11H13Cl2NO2S/c12-8-3-1-2-7(10(8)13)6-17-5-4-9(14)11(15)16/h1-3,9H,4-6,14H2,(H,15,16)
DMGOHSF CS C1=CC(=C(C(=C1)Cl)Cl)CSCCC(C(=O)O)N
DMGOHSF IK IHFPLLZGLBOAJJ-UHFFFAOYSA-N
DMGOHSF IU 2-amino-4-[(2,3-dichlorophenyl)methylsulfanyl]butanoic acid
DMGOHSF DE Discovery agent
DMVIQ7F ID DMVIQ7F
DMVIQ7F DN 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F HS Investigative
DMVIQ7F SN CHEMBL105328; 178556-61-1; CTK0A6889; DTXSID50441101; 4-[(2,3-Dihydro-1H-phenalen)-1-yl]-1H-imidazole; 1H-Imidazole, 4-(2,3-dihydro-1H-phenalen-1-yl)-
DMVIQ7F DT Small molecular drug
DMVIQ7F PC 10513867
DMVIQ7F MW 234.29
DMVIQ7F FM C16H14N2
DMVIQ7F IC InChI=1S/C16H14N2/c1-3-11-5-2-6-14-13(15-9-17-10-18-15)8-7-12(4-1)16(11)14/h1-6,9-10,13H,7-8H2,(H,17,18)
DMVIQ7F CS C1CC2=CC=CC3=C2C(=CC=C3)C1C4=CN=CN4
DMVIQ7F IK KFGFWNKBPWPCKX-UHFFFAOYSA-N
DMVIQ7F IU 5-(2,3-dihydro-1H-phenalen-1-yl)-1H-imidazole
DMVIQ7F CA CAS 178556-61-1
DMVIQ7F DE Discovery agent
DM6PMFJ ID DM6PMFJ
DM6PMFJ DN 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM6PMFJ HS Investigative
DM6PMFJ SN CHEMBL98155; 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM6PMFJ DT Small molecular drug
DM6PMFJ PC 44331261
DM6PMFJ MW 341.4
DM6PMFJ FM C19H19NO5
DM6PMFJ IC InChI=1S/C19H19NO5/c1-21-15-6-5-7-16(19(15)24-4)25-14-8-9-20-13-11-18(23-3)17(22-2)10-12(13)14/h5-11H,1-4H3
DM6PMFJ CS COC1=C(C(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC
DM6PMFJ IK NQWDTJUCVNPURX-UHFFFAOYSA-N
DM6PMFJ IU 4-(2,3-dimethoxyphenoxy)-6,7-dimethoxyquinoline
DM6PMFJ DE Discovery agent
DMPKE6G ID DMPKE6G
DMPKE6G DN 4-(2,4-dichloro-phenoxy)-2'-methyl-biphenyl-3-ol
DMPKE6G HS Investigative
DMPKE6G SN 4-(2,4-Dichlorophenoxy)-2'-Methylbiphenyl-3-Ol; Triclosan derivative, 15; CHEMBL261708; BDBM25414; 2-(2,4-dichlorophenoxy)-5-(2-methylphenyl)phenol
DMPKE6G DT Small molecular drug
DMPKE6G PC 15942656
DMPKE6G MW 345.2
DMPKE6G FM C19H14Cl2O2
DMPKE6G IC InChI=1S/C19H14Cl2O2/c1-12-4-2-3-5-15(12)13-6-8-19(17(22)10-13)23-18-9-7-14(20)11-16(18)21/h2-11,22H,1H3
DMPKE6G CS CC1=CC=CC=C1C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMPKE6G IK VDWAWADVXJMBAA-UHFFFAOYSA-N
DMPKE6G IU 2-(2,4-dichlorophenoxy)-5-(2-methylphenyl)phenol
DMPKE6G DE Discovery agent
DMS7POY ID DMS7POY
DMS7POY DN 4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile
DMS7POY HS Investigative
DMS7POY SN Triclosan derivative, 4; SCHEMBL3365482; CHEMBL260168; BDBM25403; QYLRCMQANMWAOJ-UHFFFAOYSA-N; ZINC29059641; 4-(2,4-dichlorophenoxy)-3-hydroxy-benzonitrile; hydroxybenzonitrile (19)
DMS7POY DT Small molecular drug
DMS7POY PC 25023955
DMS7POY MW 280.1
DMS7POY FM C13H7Cl2NO2
DMS7POY IC InChI=1S/C13H7Cl2NO2/c14-9-2-4-12(10(15)6-9)18-13-3-1-8(7-16)5-11(13)17/h1-6,17H
DMS7POY CS C1=CC(=C(C=C1C#N)O)OC2=C(C=C(C=C2)Cl)Cl
DMS7POY IK QYLRCMQANMWAOJ-UHFFFAOYSA-N
DMS7POY IU 4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile
DMS7POY DE Discovery agent
DMY6GWF ID DMY6GWF
DMY6GWF DN 4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol
DMY6GWF HS Investigative
DMY6GWF SN Triclosan derivative, 17; CHEMBL260978; BDBM25416; 2-(2,4-dichlorophenoxy)-5-(m-tolyl)phenol
DMY6GWF DT Small molecular drug
DMY6GWF PC 25023966
DMY6GWF MW 345.2
DMY6GWF FM C19H14Cl2O2
DMY6GWF IC InChI=1S/C19H14Cl2O2/c1-12-3-2-4-13(9-12)14-5-7-19(17(22)10-14)23-18-8-6-15(20)11-16(18)21/h2-11,22H,1H3
DMY6GWF CS CC1=CC(=CC=C1)C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMY6GWF IK GFJKNHKOZLFIJW-UHFFFAOYSA-N
DMY6GWF IU 2-(2,4-dichlorophenoxy)-5-(3-methylphenyl)phenol
DMY6GWF DE Discovery agent
DMAK789 ID DMAK789
DMAK789 DN 4-(2,4-dichloro-phenoxy)-4'-fluoro-biphenyl-3-ol
DMAK789 HS Investigative
DMAK789 SN 2-(2,4-dichlorophenoxy)-5-(4-fluorophenyl)phenol; Triclosan derivative, 19; CHEMBL260979
DMAK789 DT Small molecular drug
DMAK789 PC 25023968
DMAK789 MW 349.2
DMAK789 FM C18H11Cl2FO2
DMAK789 IC InChI=1S/C18H11Cl2FO2/c19-13-4-8-17(15(20)10-13)23-18-7-3-12(9-16(18)22)11-1-5-14(21)6-2-11/h1-10,22H
DMAK789 CS C1=CC(=CC=C1C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O)F
DMAK789 IK LFNMTUYVBXAAKI-UHFFFAOYSA-N
DMAK789 IU 2-(2,4-dichlorophenoxy)-5-(4-fluorophenyl)phenol
DMAK789 DE Discovery agent
DMRPVO3 ID DMRPVO3
DMRPVO3 DN 4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol
DMRPVO3 HS Investigative
DMRPVO3 SN Triclosan derivative, 18; CHEMBL408744; BDBM25417; 2-(2,4-dichlorophenoxy)-5-(p-tolyl)phenol
DMRPVO3 DT Small molecular drug
DMRPVO3 PC 25023967
DMRPVO3 MW 345.2
DMRPVO3 FM C19H14Cl2O2
DMRPVO3 IC InChI=1S/C19H14Cl2O2/c1-12-2-4-13(5-3-12)14-6-8-19(17(22)10-14)23-18-9-7-15(20)11-16(18)21/h2-11,22H,1H3
DMRPVO3 CS CC1=CC=C(C=C1)C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMRPVO3 IK MJKDRJABBJYCNP-UHFFFAOYSA-N
DMRPVO3 IU 2-(2,4-dichlorophenoxy)-5-(4-methylphenyl)phenol
DMRPVO3 DE Discovery agent
DMB96SY ID DMB96SY
DMB96SY DN 4-(2,4-dichloro-phenoxy)-biphenyl-3-ol
DMB96SY HS Investigative
DMB96SY SN Triclosan derivative, 3; CHEMBL258772; BDBM25402; 2-(2,4-dichlorophenoxy)-5-phenylphenol
DMB96SY DT Small molecular drug
DMB96SY PC 25023954
DMB96SY MW 331.2
DMB96SY FM C18H12Cl2O2
DMB96SY IC InChI=1S/C18H12Cl2O2/c19-14-7-9-17(15(20)11-14)22-18-8-6-13(10-16(18)21)12-4-2-1-3-5-12/h1-11,21H
DMB96SY CS C1=CC=C(C=C1)C2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DMB96SY IK NOKHJANPMHROFU-UHFFFAOYSA-N
DMB96SY IU 2-(2,4-dichlorophenoxy)-5-phenylphenol
DMB96SY DE Discovery agent
DMCGOPQ ID DMCGOPQ
DMCGOPQ DN 4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine
DMCGOPQ HS Investigative
DMCGOPQ SN CHEMBL396300
DMCGOPQ DT Small molecular drug
DMCGOPQ PC 44440632
DMCGOPQ MW 307.2
DMCGOPQ FM C16H16Cl2N2
DMCGOPQ IC InChI=1S/C16H16Cl2N2/c17-11-6-7-13(15(18)8-11)14-9-20(10-16(14)19)12-4-2-1-3-5-12/h1-8,14,16H,9-10,19H2
DMCGOPQ CS C1C(C(CN1C2=CC=CC=C2)N)C3=C(C=C(C=C3)Cl)Cl
DMCGOPQ IK KQIXDQQTPCBRIX-UHFFFAOYSA-N
DMCGOPQ IU 4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine
DMCGOPQ DE Discovery agent
DMRMAOI ID DMRMAOI
DMRMAOI DN 4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine
DMRMAOI HS Investigative
DMRMAOI SN CHEMBL245552
DMRMAOI DT Small molecular drug
DMRMAOI PC 44440628
DMRMAOI MW 385.3
DMRMAOI FM C17H18Cl2N2O2S
DMRMAOI IC InChI=1S/C17H18Cl2N2O2S/c1-11-2-5-13(6-3-11)24(22,23)21-9-15(17(20)10-21)14-7-4-12(18)8-16(14)19/h2-8,15,17H,9-10,20H2,1H3
DMRMAOI CS CC1=CC=C(C=C1)S(=O)(=O)N2CC(C(C2)N)C3=C(C=C(C=C3)Cl)Cl
DMRMAOI IK XFWVFJXNYYSICX-UHFFFAOYSA-N
DMRMAOI IU 4-(2,4-dichlorophenyl)-1-(4-methylphenyl)sulfonylpyrrolidin-3-amine
DMRMAOI DE Discovery agent
DMBLAI1 ID DMBLAI1
DMBLAI1 DN 4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile
DMBLAI1 HS Investigative
DMBLAI1 SN CHEMBL1084705; 4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile
DMBLAI1 DT Small molecular drug
DMBLAI1 PC 46889764
DMBLAI1 MW 240.3
DMBLAI1 FM C15H16N2O
DMBLAI1 IC InChI=1S/C15H16N2O/c1-3-12-10-17-14(4-2)15(12)18-13-7-5-11(9-16)6-8-13/h5-8,10,17H,3-4H2,1-2H3
DMBLAI1 CS CCC1=CNC(=C1OC2=CC=C(C=C2)C#N)CC
DMBLAI1 IK XXYHXMUPGLKKGE-UHFFFAOYSA-N
DMBLAI1 IU 4-[(2,4-diethyl-1H-pyrrol-3-yl)oxy]benzonitrile
DMBLAI1 DE Discovery agent
DME8BLW ID DME8BLW
DME8BLW DN 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
DME8BLW HS Investigative
DME8BLW SN 364334-94-1; 4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-amine; 4-(2,4-DIMETHYL-1,3-THIAZOL-5-YL)PYRIMIDIN-2-AMINE; 4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE; CTFDMGIBHFQWKB-UHFFFAOYSA-N; 4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-ylamine; CK2; 4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine; 1pxj; 2c5o; AC1L9LFI; Maybridge3_001247; CHEMBL47302; CS12; SCHEMBL4314069; BDBM8037; CTK4H6460; DTXSID70332264; MolPort-002-896-655; HMS1434I15; ZINC141286; HMS3604E21; ANW-58550; 4623AB; AKOS013063215; MCULE-3137548628; DB02091; CCG-243780
DME8BLW DT Small molecular drug
DME8BLW PC 447956
DME8BLW MW 206.27
DME8BLW FM C9H10N4S
DME8BLW IC InChI=1S/C9H10N4S/c1-5-8(14-6(2)12-5)7-3-4-11-9(10)13-7/h3-4H,1-2H3,(H2,10,11,13)
DME8BLW CS CC1=C(SC(=N1)C)C2=NC(=NC=C2)N
DME8BLW IK CTFDMGIBHFQWKB-UHFFFAOYSA-N
DME8BLW IU 4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine
DME8BLW CA CAS 364334-94-1
DME8BLW DE Discovery agent
DM3D8OK ID DM3D8OK
DM3D8OK DN 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL
DM3D8OK HS Investigative
DM3D8OK SN AC1NBQIC
DM3D8OK DT Small molecular drug
DM3D8OK PC 46937065
DM3D8OK MW 210.27
DM3D8OK FM C11H18N2O2
DM3D8OK IC InChI=1S/C11H18N2O2/c12-9(3-6-11(13)15)7-8-1-4-10(14)5-2-8/h1-2,4-5,9,11,14-15H,3,6-7,12-13H2/t9-,11+/m1/s1
DM3D8OK CS C1=CC(=CC=C1C[C@@H](CC[C@@H](N)O)N)O
DM3D8OK IK VTBBVHAOBBELOH-KOLCDFICSA-N
DM3D8OK IU 4-[(2R,5S)-2,5-diamino-5-hydroxypentyl]phenol
DM3D8OK DE Discovery agent
DMKVH90 ID DMKVH90
DMKVH90 DN 4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid
DMKVH90 HS Investigative
DMKVH90 SN CHEMBL205126; 4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid; BDBM50179736
DMKVH90 DT Small molecular drug
DMKVH90 PC 44408335
DMKVH90 MW 294.2
DMKVH90 FM C11H13Cl2NO2S
DMKVH90 IC InChI=1S/C11H13Cl2NO2S/c12-8-1-2-9(13)7(5-8)6-17-4-3-10(14)11(15)16/h1-2,5,10H,3-4,6,14H2,(H,15,16)
DMKVH90 CS C1=CC(=C(C=C1Cl)CSCCC(C(=O)O)N)Cl
DMKVH90 IK TYFOZYAERVGDAT-UHFFFAOYSA-N
DMKVH90 IU 2-amino-4-[(2,5-dichlorophenyl)methylsulfanyl]butanoic acid
DMKVH90 DE Discovery agent
DMVYALJ ID DMVYALJ
DMVYALJ DN 4-(2,5-Diphenyl-furan-3-yl)-morpholine
DMVYALJ HS Investigative
DMVYALJ SN CHEMBL323451; 4-(2,5-Diphenyl-furan-3-yl)-morpholine; 2,5-Diphenyl-3-morpholinofuran
DMVYALJ DT Small molecular drug
DMVYALJ PC 10990391
DMVYALJ MW 305.4
DMVYALJ FM C20H19NO2
DMVYALJ IC InChI=1S/C20H19NO2/c1-3-7-16(8-4-1)19-15-18(21-11-13-22-14-12-21)20(23-19)17-9-5-2-6-10-17/h1-10,15H,11-14H2
DMVYALJ CS C1COCCN1C2=C(OC(=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMVYALJ IK UIZBMSXOYPJXSV-UHFFFAOYSA-N
DMVYALJ IU 4-(2,5-diphenylfuran-3-yl)morpholine
DMVYALJ DE Discovery agent
DMH3TBQ ID DMH3TBQ
DMH3TBQ DN 4-(2,6-diamino-9H-purin-8-yl)-2,6-dimethoxyphenol
DMH3TBQ HS Investigative
DMH3TBQ DT Small molecular drug
DMH3TBQ PC 457716
DMH3TBQ MW 302.29
DMH3TBQ FM C13H14N6O3
DMH3TBQ IC InChI=1S/C13H14N6O3/c1-21-6-3-5(4-7(22-2)9(6)20)11-16-8-10(14)17-13(15)19-12(8)18-11/h3-4,20H,1-2H3,(H5,14,15,16,17,18,19)
DMH3TBQ CS COC1=CC(=CC(=C1O)OC)C2=NC3=NC(=NC(=C3N2)N)N
DMH3TBQ IK TWOVCAQBEASXFN-UHFFFAOYSA-N
DMH3TBQ IU 4-(2,6-diamino-7H-purin-8-yl)-2,6-dimethoxyphenol
DMH3TBQ DE Discovery agent
DMPLG9Q ID DMPLG9Q
DMPLG9Q DN 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile
DMPLG9Q HS Investigative
DMPLG9Q SN CHEMBL448454; 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile
DMPLG9Q DT Small molecular drug
DMPLG9Q PC 44157041
DMPLG9Q MW 269.4
DMPLG9Q FM C16H15NOS
DMPLG9Q IC InChI=1S/C16H15NOS/c1-11-5-4-6-12(2)16(11)19-14-8-7-13(10-17)15(9-14)18-3/h4-9H,1-3H3
DMPLG9Q CS CC1=C(C(=CC=C1)C)SC2=CC(=C(C=C2)C#N)OC
DMPLG9Q IK AAYYOXKEPZBTIZ-UHFFFAOYSA-N
DMPLG9Q IU 4-(2,6-dimethylphenyl)sulfanyl-2-methoxybenzonitrile
DMPLG9Q DE Discovery agent
DMH5CAQ ID DMH5CAQ
DMH5CAQ DN 4-(2-amino-1,3-thiazol-4-yl)phenol
DMH5CAQ HS Investigative
DMH5CAQ SN 4-(2-Amino-1,3-thiazol-4-yl)phenol; 57634-55-6; 4-(2-amino-4-thiazolyl)phenol; 4-(2-Amino-thiazol-4-yl)-phenol; 4-(2-aminothiazol-4-yl)phenol; CHEMBL483790; QGSJYYIRAFRPIT-UHFFFAOYSA-N; Phenol, 4-(2-amino-4-thiazolyl)-; 2-amino-4-(4-hydroxyphenyl)-thiazole; NSC405294; 3fu3; Oprea1_415030; SCHEMBL5321407; p-(2-Amino-4-thiazolyl)phenol; CTK5A7198; DTXSID30323956; MolPort-000-141-769; HMS3604B06; Phenol,4-(2-amino-4-thiazolyl)-; AC1L8637; KS-00000A4L; ZINC16951624; STK723345; SBB018017; BDBM50293592; KM0129; 5926AE; 4-(2-Aminothiazol-4-yl)phenol
DMH5CAQ DT Small molecular drug
DMH5CAQ PC 346926
DMH5CAQ MW 192.24
DMH5CAQ FM C9H8N2OS
DMH5CAQ IC InChI=1S/C9H8N2OS/c10-9-11-8(5-13-9)6-1-3-7(12)4-2-6/h1-5,12H,(H2,10,11)
DMH5CAQ CS C1=CC(=CC=C1C2=CSC(=N2)N)O
DMH5CAQ IK QGSJYYIRAFRPIT-UHFFFAOYSA-N
DMH5CAQ IU 4-(2-amino-1,3-thiazol-4-yl)phenol
DMH5CAQ CA CAS 57634-55-6
DMH5CAQ DE Discovery agent
DMWHDRI ID DMWHDRI
DMWHDRI DN 4-(2-Aminoethyl) benzenesulfonyl fluoride
DMWHDRI HS Investigative
DMWHDRI SN 4-(2-Aminoethyl)benzenesulfonyl fluoride; 4-(2-Aminoethyl)benzenesulfonylfluoride; 4-(2-aminoethyl)-benzenesulfonyl fluoride; 4-(2-aminoethyl)benzene-1-sulfonyl fluoride; 4-beta-Aminoethylbenzolsulfofluoride; AC1L1C1L; AC1Q4OX1; AEBSF; AEBSF.HCl; AES; Benzenesulfonyl fluoride, 4-(2-aminoethyl)-; C8H10FNO2S; CHEMBL1256178; Lopac-A-8456; Lopac0_000132; MGSKVZWGBWPBTF-UHFFFAOYSA-N; Pefabloc; SR-01000075690
DMWHDRI DT Small molecular drug
DMWHDRI PC 1701
DMWHDRI MW 203.231
DMWHDRI FM C8H10FNO2S
DMWHDRI IC InChI=1S/C8H10FNO2S/c9-13(11,12)8-3-1-7(2-4-8)5-6-10/h1-4H,5-6,10H2
DMWHDRI CS C1=CC(=CC=C1CCN)S(=O)(=O)F
DMWHDRI IK MGSKVZWGBWPBTF-UHFFFAOYSA-N
DMWHDRI IU 4-(2-aminoethyl)benzenesulfonyl fluoride
DMWHDRI CA CAS 34284-75-8
DMCS538 ID DMCS538
DMCS538 DN 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol
DMCS538 HS Investigative
DMCS538 SN CHEMBL211176; AKOS006351843; 4-(2-Aminoethyl)-1,2,5-oxadiazole-3-ol
DMCS538 DT Small molecular drug
DMCS538 PC 11607975
DMCS538 MW 129.12
DMCS538 FM C4H7N3O2
DMCS538 IC InChI=1S/C4H7N3O2/c5-2-1-3-4(8)7-9-6-3/h1-2,5H2,(H,7,8)
DMCS538 CS C(CN)C1=NONC1=O
DMCS538 IK LGTWAFYEFVSZIU-UHFFFAOYSA-N
DMCS538 IU 4-(2-aminoethyl)-1,2,5-oxadiazol-3-one
DMCS538 DE Discovery agent
DMZSN1Y ID DMZSN1Y
DMZSN1Y DN 4-(2-aminoethyl)-2-cyclohexylphenol
DMZSN1Y HS Investigative
DMZSN1Y SN 4-(2-aminoethyl)-2-cyclohexylphenol; CHEMBL404150; BDBM50372980
DMZSN1Y DT Small molecular drug
DMZSN1Y PC 24748051
DMZSN1Y MW 219.32
DMZSN1Y FM C14H21NO
DMZSN1Y IC InChI=1S/C14H21NO/c15-9-8-11-6-7-14(16)13(10-11)12-4-2-1-3-5-12/h6-7,10,12,16H,1-5,8-9,15H2
DMZSN1Y CS C1CCC(CC1)C2=C(C=CC(=C2)CCN)O
DMZSN1Y IK DOCCSEDGBYCYLS-UHFFFAOYSA-N
DMZSN1Y IU 4-(2-aminoethyl)-2-cyclohexylphenol
DMZSN1Y DE Discovery agent
DMF8D5S ID DMF8D5S
DMF8D5S DN 4-(2-aminoethyl)-2-ethylphenol
DMF8D5S HS Investigative
DMF8D5S SN 4-(2-aminoethyl)-2-ethylphenol; CHEMBL255750; 4-methyl-a-methyl-tyramine; BDBM50372983; DB07346
DMF8D5S DT Small molecular drug
DMF8D5S PC 24748050
DMF8D5S MW 165.23
DMF8D5S FM C10H15NO
DMF8D5S IC InChI=1S/C10H15NO/c1-2-9-7-8(5-6-11)3-4-10(9)12/h3-4,7,12H,2,5-6,11H2,1H3
DMF8D5S CS CCC1=C(C=CC(=C1)CCN)O
DMF8D5S IK LDAFQVRTSOETPE-UHFFFAOYSA-N
DMF8D5S IU 4-(2-aminoethyl)-2-ethylphenol
DMF8D5S DE Discovery agent
DMEK6WX ID DMEK6WX
DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE
DMEK6WX HS Investigative
DMEK6WX SN 4-(2-Aminoethyl)benzenesulfonamide; 35303-76-5; 4-(2-aminoethyl)benzene-1-sulfonamide; 4-(2-Aminoethyl)benzene sulfonamide; 4-(2-Amino-ethyl)-benzenesulfonamide; Benzenesulfonamide, 4-(2-aminoethyl)-; 4-(2-Aminoethyl)benzenesulphonamide; CHEMBL7087; 4-aminoethylbenzenesulfonamide; 2-(4-sulfamoylphenyl)ethylamine; 4-(2-Aminoethyl)benzesulfonamide; FXNSVEQMUYPYJS-UHFFFAOYSA-N; 4-(2-Aminoethyl) Benzenesulfonamide; MFCD00010301; 4-(2-aminoethyl)-benzenesulfonamide hydrochloride; EINECS 252-501-0
DMEK6WX DT Small molecular drug
DMEK6WX PC 169682
DMEK6WX MW 200.26
DMEK6WX FM C8H12N2O2S
DMEK6WX IC InChI=1S/C8H12N2O2S/c9-6-5-7-1-3-8(4-2-7)13(10,11)12/h1-4H,5-6,9H2,(H2,10,11,12)
DMEK6WX CS C1=CC(=CC=C1CCN)S(=O)(=O)N
DMEK6WX IK FXNSVEQMUYPYJS-UHFFFAOYSA-N
DMEK6WX IU 4-(2-aminoethyl)benzenesulfonamide
DMEK6WX CA CAS 35303-76-5
DMEK6WX DE Discovery agent
DMWG706 ID DMWG706
DMWG706 DN 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide
DMWG706 HS Investigative
DMWG706 SN NSC135784; 2153-13-1; 4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide; UNII-1DW8U29X8S; CHEMBL6633; 1DW8U29X8S; 4-((2-amino-4-pyrimidinyl)amino)benzenesulfonamide; NSC-135784; NSC683526; AC1L1KSM; NCIStruc2_000899; NCIStruc1_000852; Oprea1_770349; SCHEMBL3791868; ZINC56465; CTK4E7061; BDBM10873; NCI135784; NCGC00014345; CCG-38281; AKOS030546962; aromatic/heteroaromatic sulfonamide 18; MCULE-1716829198; NCGC00097454-01; NCGC00014345-02; NCI60_000801; EN300-24853; 4-(2-Amino-4-pyrimidinylamino)benzenesulfonamide
DMWG706 DT Small molecular drug
DMWG706 PC 31036
DMWG706 MW 265.29
DMWG706 FM C10H11N5O2S
DMWG706 IC InChI=1S/C10H11N5O2S/c11-10-13-6-5-9(15-10)14-7-1-3-8(4-2-7)18(12,16)17/h1-6H,(H2,12,16,17)(H3,11,13,14,15)
DMWG706 CS C1=CC(=CC=C1NC2=NC(=NC=C2)N)S(=O)(=O)N
DMWG706 IK QOAXQANKSMHFKJ-UHFFFAOYSA-N
DMWG706 IU 4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide
DMWG706 CA CAS 2153-13-1
DMWG706 DE Discovery agent
DMAZ0LV ID DMAZ0LV
DMAZ0LV DN 4-(2-benzenesulfonylphenyl)piperazine
DMAZ0LV HS Investigative
DMAZ0LV SN 4-(2-benzenesulfonylphenyl)piperazine; CHEMBL209893; SCHEMBL3796417
DMAZ0LV DT Small molecular drug
DMAZ0LV PC 11849201
DMAZ0LV MW 302.4
DMAZ0LV FM C16H18N2O2S
DMAZ0LV IC InChI=1S/C16H18N2O2S/c19-21(20,14-6-2-1-3-7-14)16-9-5-4-8-15(16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DMAZ0LV CS C1CN(CCN1)C2=CC=CC=C2S(=O)(=O)C3=CC=CC=C3
DMAZ0LV IK QHMSQHVDMJCBCI-UHFFFAOYSA-N
DMAZ0LV IU 1-[2-(benzenesulfonyl)phenyl]piperazine
DMAZ0LV DE Discovery agent
DMYVD2E ID DMYVD2E
DMYVD2E DN 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one
DMYVD2E HS Investigative
DMYVD2E SN CHEMBL59752; 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one; SCHEMBL7478147; CVWQKEFTSSJDLS-UHFFFAOYSA-N; ZINC1903144; BDBM50077578; 4-[2-(Benzylamino)ethoxy]indoline-2-one
DMYVD2E DT Small molecular drug
DMYVD2E PC 9903877
DMYVD2E MW 282.34
DMYVD2E FM C17H18N2O2
DMYVD2E IC InChI=1S/C17H18N2O2/c20-17-11-14-15(19-17)7-4-8-16(14)21-10-9-18-12-13-5-2-1-3-6-13/h1-8,18H,9-12H2,(H,19,20)
DMYVD2E CS C1C2=C(C=CC=C2OCCNCC3=CC=CC=C3)NC1=O
DMYVD2E IK CVWQKEFTSSJDLS-UHFFFAOYSA-N
DMYVD2E IU 4-[2-(benzylamino)ethoxy]-1,3-dihydroindol-2-one
DMYVD2E DE Discovery agent
DMZ9TSR ID DMZ9TSR
DMZ9TSR DN 4-(2-bromobenzylthio)-2-aminobutanoic acid
DMZ9TSR HS Investigative
DMZ9TSR SN CHEMBL204646; 4-(2-bromobenzylthio)-2-aminobutanoic acid; BDBM50179711
DMZ9TSR DT Small molecular drug
DMZ9TSR PC 44408327
DMZ9TSR MW 304.21
DMZ9TSR FM C11H14BrNO2S
DMZ9TSR IC InChI=1S/C11H14BrNO2S/c12-9-4-2-1-3-8(9)7-16-6-5-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)
DMZ9TSR CS C1=CC=C(C(=C1)CSCCC(C(=O)O)N)Br
DMZ9TSR IK MWUVRUMWNBKYCW-UHFFFAOYSA-N
DMZ9TSR IU 2-amino-4-[(2-bromophenyl)methylsulfanyl]butanoic acid
DMZ9TSR DE Discovery agent
DM2MSEF ID DM2MSEF
DM2MSEF DN 4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol
DM2MSEF HS Investigative
DM2MSEF SN CHEMBL286007; SCHEMBL7499937; JIBMWJCMDPEYQP-UHFFFAOYSA-N; BDBM50086976; 4''-(2-butylbenzofuran-3-yl)biphenyl-4-ol; 4'-(2-Butyl-benzofuran-3-yl)-biphenyl-4-ol; 4''-(2-Butyl-benzofuran-3-yl)-biphenyl-4-ol
DM2MSEF DT Small molecular drug
DM2MSEF PC 10854796
DM2MSEF MW 342.4
DM2MSEF FM C24H22O2
DM2MSEF IC InChI=1S/C24H22O2/c1-2-3-7-23-24(21-6-4-5-8-22(21)26-23)19-11-9-17(10-12-19)18-13-15-20(25)16-14-18/h4-6,8-16,25H,2-3,7H2,1H3
DM2MSEF CS CCCCC1=C(C2=CC=CC=C2O1)C3=CC=C(C=C3)C4=CC=C(C=C4)O
DM2MSEF IK JIBMWJCMDPEYQP-UHFFFAOYSA-N
DM2MSEF IU 4-[4-(2-butyl-1-benzofuran-3-yl)phenyl]phenol
DM2MSEF DE Discovery agent
DM8HLEP ID DM8HLEP
DM8HLEP DN 4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol
DM8HLEP HS Investigative
DM8HLEP SN CHEMBL71254; 4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol; SCHEMBL9129370
DM8HLEP DT Small molecular drug
DM8HLEP PC 15288898
DM8HLEP MW 280.4
DM8HLEP FM C18H20N2O
DM8HLEP IC InChI=1S/C18H20N2O/c1-2-3-8-18-19-16-6-4-5-7-17(16)20(18)13-14-9-11-15(21)12-10-14/h4-7,9-12,21H,2-3,8,13H2,1H3
DM8HLEP CS CCCCC1=NC2=CC=CC=C2N1CC3=CC=C(C=C3)O
DM8HLEP IK SSRIUMAFZMGUFE-UHFFFAOYSA-N
DM8HLEP IU 4-[(2-butylbenzimidazol-1-yl)methyl]phenol
DM8HLEP DE Discovery agent
DM5L4WP ID DM5L4WP
DM5L4WP DN 4-(2-carboxy-5-mercaptopentyl)benzoic acid
DM5L4WP HS Investigative
DM5L4WP SN Thiol-Based Inhibitor, 6d; SCHEMBL5051284; CHEMBL205399; BDBM17763; CTK8A8853; AKOS015966200; 4-[2-carboxy-2-(3-sulfanylpropyl)ethyl]benzoic acid; 4-(2-CARBOXY-5-MERCAPTO-PENTYL)-BENZOIC ACID
DM5L4WP DT Small molecular drug
DM5L4WP PC 9878511
DM5L4WP MW 268.33
DM5L4WP FM C13H16O4S
DM5L4WP IC InChI=1S/C13H16O4S/c14-12(15)10-5-3-9(4-6-10)8-11(13(16)17)2-1-7-18/h3-6,11,18H,1-2,7-8H2,(H,14,15)(H,16,17)
DM5L4WP CS C1=CC(=CC=C1CC(CCCS)C(=O)O)C(=O)O
DM5L4WP IK WDVWCNCIBNEXCG-UHFFFAOYSA-N
DM5L4WP IU 4-(2-carboxy-5-sulfanylpentyl)benzoic acid
DM5L4WP DE Discovery agent
DM82D9N ID DM82D9N
DM82D9N DN 4-(2-cyanobenzylthio)-2-aminobutanoic acid
DM82D9N HS Investigative
DM82D9N SN CHEMBL204479; 4-(2-cyanobenzylthio)-2-aminobutanoic acid; BDBM50179704
DM82D9N DT Small molecular drug
DM82D9N PC 44408228
DM82D9N MW 250.32
DM82D9N FM C12H14N2O2S
DM82D9N IC InChI=1S/C12H14N2O2S/c13-7-9-3-1-2-4-10(9)8-17-6-5-11(14)12(15)16/h1-4,11H,5-6,8,14H2,(H,15,16)
DM82D9N CS C1=CC=C(C(=C1)CSCCC(C(=O)O)N)C#N
DM82D9N IK JVNHJGWGKVBEAG-UHFFFAOYSA-N
DM82D9N IU 2-amino-4-[(2-cyanophenyl)methylsulfanyl]butanoic acid
DM82D9N DE Discovery agent
DMFJW2E ID DMFJW2E
DMFJW2E DN 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine
DMFJW2E HS Investigative
DMFJW2E SN CHEMBL198334; 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine; BDBM50173628
DMFJW2E DT Small molecular drug
DMFJW2E PC 11277481
DMFJW2E MW 280.4
DMFJW2E FM C17H16N2S
DMFJW2E IC InChI=1S/C17H16N2S/c1-3-15-19-16(14-6-4-5-12(2)11-14)17(20-15)13-7-9-18-10-8-13/h4-11H,3H2,1-2H3
DMFJW2E CS CCC1=NC(=C(S1)C2=CC=NC=C2)C3=CC=CC(=C3)C
DMFJW2E IK QUKIIQWKXMTFAE-UHFFFAOYSA-N
DMFJW2E IU 2-ethyl-4-(3-methylphenyl)-5-pyridin-4-yl-1,3-thiazole
DMFJW2E DE Discovery agent
DMQUAP2 ID DMQUAP2
DMQUAP2 DN 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2 HS Investigative
DMQUAP2 SN CHEMBL598346; 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine
DMQUAP2 DT Small molecular drug
DMQUAP2 PC 46230654
DMQUAP2 MW 289.32
DMQUAP2 FM C17H17F2NO
DMQUAP2 IC InChI=1S/C17H17F2NO/c18-13-4-1-2-6-15(13)21-16-7-3-5-14(19)17(16)12-8-10-20-11-9-12/h1-7,12,20H,8-11H2
DMQUAP2 CS C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3F
DMQUAP2 IK ZSIHFDAUAFSTIM-UHFFFAOYSA-N
DMQUAP2 IU 4-[2-fluoro-6-(2-fluorophenoxy)phenyl]piperidine
DMQUAP2 DE Discovery agent
DMUBHRF ID DMUBHRF
DMUBHRF DN 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF HS Investigative
DMUBHRF SN CHEMBL574004; 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine
DMUBHRF DT Small molecular drug
DMUBHRF PC 45375938
DMUBHRF MW 289.32
DMUBHRF FM C17H17F2NO
DMUBHRF IC InChI=1S/C17H17F2NO/c18-13-3-1-4-14(11-13)21-16-6-2-5-15(19)17(16)12-7-9-20-10-8-12/h1-6,11-12,20H,7-10H2
DMUBHRF CS C1CNCCC1C2=C(C=CC=C2F)OC3=CC(=CC=C3)F
DMUBHRF IK IMXJQWVQVSZOKO-UHFFFAOYSA-N
DMUBHRF IU 4-[2-fluoro-6-(3-fluorophenoxy)phenyl]piperidine
DMUBHRF DE Discovery agent
DMJ2GW0 ID DMJ2GW0
DMJ2GW0 DN 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0 HS Investigative
DMJ2GW0 SN CHEMBL574231; 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine
DMJ2GW0 DT Small molecular drug
DMJ2GW0 PC 45483536
DMJ2GW0 MW 289.32
DMJ2GW0 FM C17H17F2NO
DMJ2GW0 IC InChI=1S/C17H17F2NO/c18-13-4-6-14(7-5-13)21-16-3-1-2-15(19)17(16)12-8-10-20-11-9-12/h1-7,12,20H,8-11H2
DMJ2GW0 CS C1CNCCC1C2=C(C=CC=C2F)OC3=CC=C(C=C3)F
DMJ2GW0 IK WPYMMOOTBZOFOZ-UHFFFAOYSA-N
DMJ2GW0 IU 4-[2-fluoro-6-(4-fluorophenoxy)phenyl]piperidine
DMJ2GW0 DE Discovery agent
DMXIGWC ID DMXIGWC
DMXIGWC DN 4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC HS Investigative
DMXIGWC SN CHEMBL574428; 4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC DT Small molecular drug
DMXIGWC PC 45483451
DMXIGWC MW 271.33
DMXIGWC FM C17H18FNO
DMXIGWC IC InChI=1S/C17H18FNO/c18-15-7-4-8-16(20-14-5-2-1-3-6-14)17(15)13-9-11-19-12-10-13/h1-8,13,19H,9-12H2
DMXIGWC CS C1CNCCC1C2=C(C=CC=C2F)OC3=CC=CC=C3
DMXIGWC IK PTVWULKTBHSTNS-UHFFFAOYSA-N
DMXIGWC IU 4-(2-fluoro-6-phenoxyphenyl)piperidine
DMXIGWC DE Discovery agent
DMCWZF6 ID DMCWZF6
DMCWZF6 DN 4-(2-fluorophenylethynyl)-2-methylthiazole
DMCWZF6 HS Investigative
DMCWZF6 SN CHEMBL370453; 4-(2-fluorophenylethynyl)-2-methylthiazole; SCHEMBL4137694
DMCWZF6 DT Small molecular drug
DMCWZF6 PC 11572058
DMCWZF6 MW 217.26
DMCWZF6 FM C12H8FNS
DMCWZF6 IC InChI=1S/C12H8FNS/c1-9-14-11(8-15-9)7-6-10-4-2-3-5-12(10)13/h2-5,8H,1H3
DMCWZF6 CS CC1=NC(=CS1)C#CC2=CC=CC=C2F
DMCWZF6 IK IDJAGQSTASLJRW-UHFFFAOYSA-N
DMCWZF6 IU 4-[2-(2-fluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMCWZF6 DE Discovery agent
DM17QG8 ID DM17QG8
DM17QG8 DN 4-(2-Hydroxyethoxy)-1-naphthol
DM17QG8 HS Investigative
DM17QG8 SN 4-(2-Hydroxyethoxy)-1-naphthol; CHEMBL570066; 83115-56-4; SCHEMBL12599103
DM17QG8 DT Small molecular drug
DM17QG8 PC 45487214
DM17QG8 MW 204.22
DM17QG8 FM C12H12O3
DM17QG8 IC InChI=1S/C12H12O3/c13-7-8-15-12-6-5-11(14)9-3-1-2-4-10(9)12/h1-6,13-14H,7-8H2
DM17QG8 CS C1=CC=C2C(=C1)C(=CC=C2OCCO)O
DM17QG8 IK PABAILNRYWRUQG-UHFFFAOYSA-N
DM17QG8 IU 4-(2-hydroxyethoxy)naphthalen-1-ol
DM17QG8 DE Discovery agent
DM1C5U6 ID DM1C5U6
DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide
DM1C5U6 HS Investigative
DM1C5U6 SN 4-(2-hydroxyethyl)benzenesulfonamide
DM1C5U6 DE Discovery agent
DMB6SNE ID DMB6SNE
DMB6SNE DN 4-(2-Imidazol-1-yl-ethoxy)-benzamide
DMB6SNE HS Investigative
DMB6SNE SN CHEMBL30395; 4-(2-Imidazol-1-yl-ethoxy)-benzamide; SCHEMBL3005716; DVALIYTWWUIPGC-UHFFFAOYSA-N; BDBM50025995; 75912-57-1; 1-[2-(4-carbamoylphenoxy)ethyl]imidazole; 4-(2-(1H-imidazol-1-yl)ethoxy)benzamide; 1-[2-(4-carbamoyl phenoxy)ethyl]imidazole
DMB6SNE DT Small molecular drug
DMB6SNE PC 13569177
DMB6SNE MW 231.25
DMB6SNE FM C12H13N3O2
DMB6SNE IC InChI=1S/C12H13N3O2/c13-12(16)10-1-3-11(4-2-10)17-8-7-15-6-5-14-9-15/h1-6,9H,7-8H2,(H2,13,16)
DMB6SNE CS C1=CC(=CC=C1C(=O)N)OCCN2C=CN=C2
DMB6SNE IK DVALIYTWWUIPGC-UHFFFAOYSA-N
DMB6SNE IU 4-(2-imidazol-1-ylethoxy)benzamide
DMB6SNE DE Discovery agent
DMNSKXR ID DMNSKXR
DMNSKXR DN 4-(2-methoxybenzylthio)-2-aminobutanoic acid
DMNSKXR HS Investigative
DMNSKXR SN CHEMBL204961; 4-(2-methoxybenzylthio)-2-aminobutanoic acid; BDBM50179708
DMNSKXR DT Small molecular drug
DMNSKXR PC 44408324
DMNSKXR MW 255.34
DMNSKXR FM C12H17NO3S
DMNSKXR IC InChI=1S/C12H17NO3S/c1-16-11-5-3-2-4-9(11)8-17-7-6-10(13)12(14)15/h2-5,10H,6-8,13H2,1H3,(H,14,15)
DMNSKXR CS COC1=CC=CC=C1CSCCC(C(=O)O)N
DMNSKXR IK OCNLPBAJIIKAGX-UHFFFAOYSA-N
DMNSKXR IU 2-amino-4-[(2-methoxyphenyl)methylsulfanyl]butanoic acid
DMNSKXR DE Discovery agent
DM9WQOJ ID DM9WQOJ
DM9WQOJ DN 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
DM9WQOJ HS Investigative
DM9WQOJ SN 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidin-2-ylamine; 75435-54-0; 2wi1; AC1MWPG2; pyrimidin-2-amine, 11; CHEMBL538937; SCHEMBL10752783; BDBM33223; CCG-774; VCJHOFUOIQHNBC-UHFFFAOYSA-N; AKOS017529730; DB08786; 2-amino-4-(2-methoxyethoxy)-6-methylpyrimidine; 4-Methyl-6-(2-methoxyethoxy)pyrimidine-2-amine; 4-(2-methoxy-ethoxy)-6-methyl-pyrimidine-2-ylamine
DM9WQOJ DT Small molecular drug
DM9WQOJ PC 3777900
DM9WQOJ MW 183.21
DM9WQOJ FM C8H13N3O2
DM9WQOJ IC InChI=1S/C8H13N3O2/c1-6-5-7(11-8(9)10-6)13-4-3-12-2/h5H,3-4H2,1-2H3,(H2,9,10,11)
DM9WQOJ CS CC1=CC(=NC(=N1)N)OCCOC
DM9WQOJ IK VCJHOFUOIQHNBC-UHFFFAOYSA-N
DM9WQOJ IU 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
DM9WQOJ DE Discovery agent
DMFVYHI ID DMFVYHI
DMFVYHI DN 4-(2-methoxyphenylethynyl)-2-methylthiazole
DMFVYHI HS Investigative
DMFVYHI SN CHEMBL202002; 4-(2-methoxyphenylethynyl)-2-methylthiazole; Thiazole, 4-[2-(2-methoxyphenyl)ethynyl]-2-methyl-; SCHEMBL4291588; BDBM50181749; 878018-34-9
DMFVYHI DT Small molecular drug
DMFVYHI PC 11665793
DMFVYHI MW 229.3
DMFVYHI FM C13H11NOS
DMFVYHI IC InChI=1S/C13H11NOS/c1-10-14-12(9-16-10)8-7-11-5-3-4-6-13(11)15-2/h3-6,9H,1-2H3
DMFVYHI CS CC1=NC(=CS1)C#CC2=CC=CC=C2OC
DMFVYHI IK WOLUACOHPFWBIX-UHFFFAOYSA-N
DMFVYHI IU 4-[2-(2-methoxyphenyl)ethynyl]-2-methyl-1,3-thiazole
DMFVYHI DE Discovery agent
DM6DSNI ID DM6DSNI
DM6DSNI DN 4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol
DM6DSNI HS Investigative
DM6DSNI SN CHEMBL1172559; SCHEMBL18770344; BDBM50322796
DM6DSNI DT Small molecular drug
DM6DSNI PC 46854449
DM6DSNI MW 303.4
DM6DSNI FM C21H21NO
DM6DSNI IC InChI=1S/C21H21NO/c1-15(2)21(18-10-12-22-13-11-18)17-8-6-16(7-9-17)19-4-3-5-20(23)14-19/h3-15,21,23H,1-2H3
DM6DSNI CS CC(C)C(C1=CC=C(C=C1)C2=CC(=CC=C2)O)C3=CC=NC=C3
DM6DSNI IK YNPHCSJZYQIGGU-UHFFFAOYSA-N
DM6DSNI IU 3-[4-(2-methyl-1-pyridin-4-ylpropyl)phenyl]phenol
DM6DSNI DE Discovery agent
DME6DHX ID DME6DHX
DME6DHX DN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX HS Investigative
DME6DHX SN CHEMBL1165071; 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide
DME6DHX DT Small molecular drug
DME6DHX PC 46703923
DME6DHX MW 315.3
DME6DHX FM C15H13N3O3S
DME6DHX IC InChI=1S/C15H13N3O3S/c1-10-5-6-11-3-2-4-13(15(11)18-10)21-12-7-8-17-9-14(12)22(16,19)20/h2-9H,1H3,(H2,16,19,20)
DME6DHX CS CC1=NC2=C(C=CC=C2OC3=C(C=NC=C3)S(=O)(=O)N)C=C1
DME6DHX IK LNNGPAKWWNABIA-UHFFFAOYSA-N
DME6DHX IU 4-(2-methylquinolin-8-yl)oxypyridine-3-sulfonamide
DME6DHX DE Discovery agent
DMEAV9Q ID DMEAV9Q
DMEAV9Q DN 4-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMEAV9Q HS Investigative
DMEAV9Q SN CHEMBL303090; 4-(2-Methyl-thiazol-4-ylethynyl)-pyridine
DMEAV9Q DT Small molecular drug
DMEAV9Q PC 11095641
DMEAV9Q MW 200.26
DMEAV9Q FM C11H8N2S
DMEAV9Q IC InChI=1S/C11H8N2S/c1-9-13-11(8-14-9)3-2-10-4-6-12-7-5-10/h4-8H,1H3
DMEAV9Q CS CC1=NC(=CS1)C#CC2=CC=NC=C2
DMEAV9Q IK WWKCHJLBBNNNCI-UHFFFAOYSA-N
DMEAV9Q IU 2-methyl-4-(2-pyridin-4-ylethynyl)-1,3-thiazole
DMEAV9Q DE Discovery agent
DMC1KEG ID DMC1KEG
DMC1KEG DN 4-(2-nitrobenzylthio)-2-aminobutanoic acid
DMC1KEG HS Investigative
DMC1KEG SN CHEMBL380506; 4-(2-nitrobenzylthio)-2-aminobutanoic acid; BDBM50179699
DMC1KEG DT Small molecular drug
DMC1KEG PC 44408226
DMC1KEG MW 270.31
DMC1KEG FM C11H14N2O4S
DMC1KEG IC InChI=1S/C11H14N2O4S/c12-9(11(14)15)5-6-18-7-8-3-1-2-4-10(8)13(16)17/h1-4,9H,5-7,12H2,(H,14,15)
DMC1KEG CS C1=CC=C(C(=C1)CSCCC(C(=O)O)N)[N+](=O)[O-]
DMC1KEG IK QZOGSZKBBMQKMN-UHFFFAOYSA-N
DMC1KEG IU 2-amino-4-[(2-nitrophenyl)methylsulfanyl]butanoic acid
DMC1KEG DE Discovery agent
DMCHTI0 ID DMCHTI0
DMCHTI0 DN 4-(2-nitroprop-1-enyl)benzene-1,2-diol
DMCHTI0 HS Investigative
DMCHTI0 SN 4-(2-nitroprop-1-enyl)benzene-1,2-diol; 13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192
DMCHTI0 DT Small molecular drug
DMCHTI0 PC 3260632
DMCHTI0 MW 195.17
DMCHTI0 FM C9H9NO4
DMCHTI0 IC InChI=1S/C9H9NO4/c1-6(10(13)14)4-7-2-3-8(11)9(12)5-7/h2-5,11-12H,1H3
DMCHTI0 CS CC(=CC1=CC(=C(C=C1)O)O)[N+](=O)[O-]
DMCHTI0 IK CBBBJLQAIWVLBM-UHFFFAOYSA-N
DMCHTI0 IU 4-(2-nitroprop-1-enyl)benzene-1,2-diol
DMCHTI0 CA CAS 13662-96-9
DMCHTI0 DE Discovery agent
DM62ZRE ID DM62ZRE
DM62ZRE DN 4-(2-nitrovinyl)benzene-1,2-diol
DM62ZRE HS Investigative
DM62ZRE SN SL-1; CHEMBL78224; 108074-44-8; 4-(2-nitrovinyl)benzene-1,2-diol; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)-
DM62ZRE DT Small molecular drug
DM62ZRE PC 6439158
DM62ZRE MW 181.15
DM62ZRE FM C8H7NO4
DM62ZRE IC InChI=1S/C8H7NO4/c10-7-2-1-6(5-8(7)11)3-4-9(12)13/h1-5,10-11H/b4-3+
DM62ZRE CS C1=CC(=C(C=C1/C=C/[N+](=O)[O-])O)O
DM62ZRE IK LLJASJHXECDHOM-ONEGZZNKSA-N
DM62ZRE IU 4-[(E)-2-nitroethenyl]benzene-1,2-diol
DM62ZRE CA CAS 108074-44-8
DM62ZRE DE Discovery agent
DMPTVR2 ID DMPTVR2
DMPTVR2 DN 4-(2-nitrovinyl)phenol
DMPTVR2 HS Investigative
DMPTVR2 SN 4-(2-nitrovinyl)phenol; 3179-08-6; 4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)-
DMPTVR2 DT Small molecular drug
DMPTVR2 PC 638437
DMPTVR2 MW 165.15
DMPTVR2 FM C8H7NO3
DMPTVR2 IC InChI=1S/C8H7NO3/c10-8-3-1-7(2-4-8)5-6-9(11)12/h1-6,10H/b6-5+
DMPTVR2 CS C1=CC(=CC=C1/C=C/[N+](=O)[O-])O
DMPTVR2 IK CTJKRKMPTRJAIT-AATRIKPKSA-N
DMPTVR2 IU 4-[(E)-2-nitroethenyl]phenol
DMPTVR2 CA CAS 22568-49-6
DMPTVR2 DE Discovery agent
DMWIALU ID DMWIALU
DMWIALU DN 4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid
DMWIALU HS Investigative
DMWIALU SN 4-[(2-Oxo-2H-chromene-3-carbonyl)-amino]-benzoic acid; 4-[(2-oxochromen-3-yl)carbonylamino]benzoic acid; 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid; BAS 00518567; AC1MJCO7; 3-carboxamido coumarin, 19; Oprea1_826423; Oprea1_127959; CHEMBL513209; SCHEMBL4389144; BDBM29169; MolPort-000-375-260; ZINC3076649; STL353172; SBB041117; BBL026015; AKOS000269615; MCULE-2534949799; ST50102584; 4-[(2-oxochromene-3-carbonyl)amino]benzoic acid
DMWIALU DT Small molecular drug
DMWIALU PC 3110315
DMWIALU MW 309.27
DMWIALU FM C17H11NO5
DMWIALU IC InChI=1S/C17H11NO5/c19-15(18-12-7-5-10(6-8-12)16(20)21)13-9-11-3-1-2-4-14(11)23-17(13)22/h1-9H,(H,18,19)(H,20,21)
DMWIALU CS C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)NC3=CC=C(C=C3)C(=O)O
DMWIALU IK IMGLCZZPWOJMLB-UHFFFAOYSA-N
DMWIALU IU 4-[(2-oxochromene-3-carbonyl)amino]benzoic acid
DMWIALU DE Discovery agent
DMFPNQ9 ID DMFPNQ9
DMFPNQ9 DN 4-(2-Oxo-2-phenyl-acetyl)-benzoic acid
DMFPNQ9 HS Investigative
DMFPNQ9 SN 4-(2-oxo-2-phenylacetyl)benzoic acid; 72857-25-1; 4-(2-Oxo-2-phenyl-acetyl)-benzoic acid; MLS000775407; SMR000368487; Opera_ID_465; Benzil-based compound, 14; AC1M5V1J; CHEMBL370059; SCHEMBL2156860; 4-(oxophenylacetyl)benzoic acid; BDBM22736; CTK5D6959; DTXSID10368385; MolPort-000-510-282; HMS2753L08; 4-[oxo(phenyl)acetyl]benzoic acid; ZINC3269660; ZX-AL000632; STK246909; SBB039312; AKOS000267727; MCULE-7710064147; Benzoic acid,4-(2-oxo-2-phenylacetyl)-; KB-237683; ST50160330
DMFPNQ9 DT Small molecular drug
DMFPNQ9 PC 2385968
DMFPNQ9 MW 254.24
DMFPNQ9 FM C15H10O4
DMFPNQ9 IC InChI=1S/C15H10O4/c16-13(10-4-2-1-3-5-10)14(17)11-6-8-12(9-7-11)15(18)19/h1-9H,(H,18,19)
DMFPNQ9 CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)C(=O)O
DMFPNQ9 IK MWJHDSAAGSURCA-UHFFFAOYSA-N
DMFPNQ9 IU 4-(2-oxo-2-phenylacetyl)benzoic acid
DMFPNQ9 CA CAS 72857-25-1
DMFPNQ9 DE Discovery agent
DMBMJC5 ID DMBMJC5
DMBMJC5 DN 4-(2-oxohexadecanamido)butanoic acid
DMBMJC5 HS Investigative
DMBMJC5 SN 4-(2-oxohexadecanamido)butanoic acid; CHEMBL95190; SCHEMBL1877382; ZINC36310606; BDBM50149408; 4-(2-Oxo-hexadecanoylamino)-butyric acid; 4-[(1,2-Dioxohexadecyl)amino]butanoic acid
DMBMJC5 DT Small molecular drug
DMBMJC5 PC 9906670
DMBMJC5 MW 355.5
DMBMJC5 FM C20H37NO4
DMBMJC5 IC InChI=1S/C20H37NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18(22)20(25)21-17-14-16-19(23)24/h2-17H2,1H3,(H,21,25)(H,23,24)
DMBMJC5 CS CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)O
DMBMJC5 IK GCTDVJHSYNCJRN-UHFFFAOYSA-N
DMBMJC5 IU 4-(2-oxohexadecanoylamino)butanoic acid
DMBMJC5 DE Discovery agent
DMB5IFA ID DMB5IFA
DMB5IFA DN 4-(2-phenoxyphenyl)piperidine
DMB5IFA HS Investigative
DMB5IFA SN 4-(2-phenoxyphenyl)piperidine; CHEMBL575077; SCHEMBL4699769
DMB5IFA DT Small molecular drug
DMB5IFA PC 23113096
DMB5IFA MW 253.34
DMB5IFA FM C17H19NO
DMB5IFA IC InChI=1S/C17H19NO/c1-2-6-15(7-3-1)19-17-9-5-4-8-16(17)14-10-12-18-13-11-14/h1-9,14,18H,10-13H2
DMB5IFA CS C1CNCCC1C2=CC=CC=C2OC3=CC=CC=C3
DMB5IFA IK YWIYMDPWBAXEKQ-UHFFFAOYSA-N
DMB5IFA IU 4-(2-phenoxyphenyl)piperidine
DMB5IFA DE Discovery agent
DMFQZOI ID DMFQZOI
DMFQZOI DN 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol
DMFQZOI HS Investigative
DMFQZOI SN CHEMBL200483; 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol; SCHEMBL6440186
DMFQZOI DT Small molecular drug
DMFQZOI PC 44405888
DMFQZOI MW 286.3
DMFQZOI FM C19H14N2O
DMFQZOI IC InChI=1S/C19H14N2O/c22-16-12-10-15(11-13-16)21-18-9-5-4-8-17(18)20-19(21)14-6-2-1-3-7-14/h1-13,22H
DMFQZOI CS C1=CC=C(C=C1)C2=NC3=CC=CC=C3N2C4=CC=C(C=C4)O
DMFQZOI IK MXMPRHRVFXJSFN-UHFFFAOYSA-N
DMFQZOI IU 4-(2-phenylbenzimidazol-1-yl)phenol
DMFQZOI DE Discovery agent
DMCPSE9 ID DMCPSE9
DMCPSE9 DN 4-(2-phenyl-1H-indol-3-yl)phenol
DMCPSE9 HS Investigative
DMCPSE9 SN CHEMBL371012; 4-(2-phenyl-1H-indol-3-yl)phenol; SCHEMBL7041571; OITCYCYIUVYFKQ-UHFFFAOYSA-N; BDBM50175419; 4-(2-Phenyl-1H-indol-3-yl)-phenol
DMCPSE9 DT Small molecular drug
DMCPSE9 PC 13896065
DMCPSE9 MW 285.3
DMCPSE9 FM C20H15NO
DMCPSE9 IC InChI=1S/C20H15NO/c22-16-12-10-14(11-13-16)19-17-8-4-5-9-18(17)21-20(19)15-6-2-1-3-7-15/h1-13,21-22H
DMCPSE9 CS C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=C(C=C4)O
DMCPSE9 IK OITCYCYIUVYFKQ-UHFFFAOYSA-N
DMCPSE9 IU 4-(2-phenyl-1H-indol-3-yl)phenol
DMCPSE9 DE Discovery agent
DMZ62L3 ID DMZ62L3
DMZ62L3 DN 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide
DMZ62L3 HS Investigative
DMZ62L3 SN sulfonamide deriv., 7f; CHEMBL574021; BDBM35738
DMZ62L3 DT Small molecular drug
DMZ62L3 PC 44520902
DMZ62L3 MW 369.24
DMZ62L3 FM C14H13BrN2O3S
DMZ62L3 IC InChI=1S/C14H13BrN2O3S/c15-12-9-11(21(16,19)20)6-7-13(12)17-14(18)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H,17,18)(H2,16,19,20)
DMZ62L3 CS C1=CC=C(C=C1)CC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)Br
DMZ62L3 IK LBFJKAVSXZGFAX-UHFFFAOYSA-N
DMZ62L3 IU N-(2-bromo-4-sulfamoylphenyl)-2-phenylacetamide
DMZ62L3 DE Discovery agent
DM9GOTA ID DM9GOTA
DM9GOTA DN 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide
DM9GOTA HS Investigative
DM9GOTA SN BRN 2157920; N-(4-(Aminosulfonyl)-2-chlorophenyl)benzeneacetamide; 3-Chloro-4-phenacetamido-benzenesulfonamide; Benzeneacetamide, N-(4-(aminosulfonyl)-2-chlorophenyl)-; 68252-75-5; AC1MHICQ; sulfonamide deriv., 7e; SCHEMBL8222515; CHEMBL583971; CTK5C7613; BDBM35737; DTXSID70218418; LS-28479; 3-Chloro-4-(phenylacetylamino)benzenesulfonamide
DM9GOTA DT Small molecular drug
DM9GOTA PC 3051968
DM9GOTA MW 324.8
DM9GOTA FM C14H13ClN2O3S
DM9GOTA IC InChI=1S/C14H13ClN2O3S/c15-12-9-11(21(16,19)20)6-7-13(12)17-14(18)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H,17,18)(H2,16,19,20)
DM9GOTA CS C1=CC=C(C=C1)CC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)Cl
DM9GOTA IK PCTUCNXXOLZRTM-UHFFFAOYSA-N
DM9GOTA IU N-(2-chloro-4-sulfamoylphenyl)-2-phenylacetamide
DM9GOTA CA CAS 68252-75-5
DM9GOTA DE Discovery agent
DMCOD4N ID DMCOD4N
DMCOD4N DN 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide
DMCOD4N HS Investigative
DMCOD4N SN sulfonamide deriv., 7d; CHEMBL575660; BDBM35736
DMCOD4N DT Small molecular drug
DMCOD4N PC 44520901
DMCOD4N MW 308.33
DMCOD4N FM C14H13FN2O3S
DMCOD4N IC InChI=1S/C14H13FN2O3S/c15-12-9-11(21(16,19)20)6-7-13(12)17-14(18)8-10-4-2-1-3-5-10/h1-7,9H,8H2,(H,17,18)(H2,16,19,20)
DMCOD4N CS C1=CC=C(C=C1)CC(=O)NC2=C(C=C(C=C2)S(=O)(=O)N)F
DMCOD4N IK NPXJDOTWYYSLEJ-UHFFFAOYSA-N
DMCOD4N IU N-(2-fluoro-4-sulfamoylphenyl)-2-phenylacetamide
DMCOD4N DE Discovery agent
DMFYR6H ID DMFYR6H
DMFYR6H DN 4-(2-Phenylacetamido)benzenesulfonamide
DMFYR6H HS Investigative
DMFYR6H SN 2-phenyl-N-(4-sulfamoylphenyl)acetamide; N-[4-(aminosulfonyl)phenyl]-2-phenylacetamide; 331274-56-7; 3oys; 4-(2-Phenylacetamido)benzenesulfonamide; sulfonamide deriv., 7a; AC1LE45L; Oprea1_842052; CHEMBL574782; ARONIS000876; SCHEMBL13276539; KS-00003UGZ; BDBM35733; MolPort-001-503-086; ZINC142256; STK097687; AKOS000490206; MCULE-4432635286; ST039768; AN-329/10027012; F3145-0673
DMFYR6H DT Small molecular drug
DMFYR6H PC 729977
DMFYR6H MW 290.34
DMFYR6H FM C14H14N2O3S
DMFYR6H IC InChI=1S/C14H14N2O3S/c15-20(18,19)13-8-6-12(7-9-13)16-14(17)10-11-4-2-1-3-5-11/h1-9H,10H2,(H,16,17)(H2,15,18,19)
DMFYR6H CS C1=CC=C(C=C1)CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMFYR6H IK JWDLYKTZCRIGNW-UHFFFAOYSA-N
DMFYR6H IU 2-phenyl-N-(4-sulfamoylphenyl)acetamide
DMFYR6H DE Discovery agent
DM1JL03 ID DM1JL03
DM1JL03 DN 4-(2-Phenylacetamidoethyl)benzenesulfonamide
DM1JL03 HS Investigative
DM1JL03 SN AC1MPEEB; sulfonamide deriv., 7c; 4-(2-Phenylacetamidoethyl)benzenesulfonamide; Oprea1_837732; CHEMBL573859; BDBM35735; AKOS027674184
DM1JL03 DT Small molecular drug
DM1JL03 PC 3433937
DM1JL03 MW 318.4
DM1JL03 FM C16H18N2O3S
DM1JL03 IC InChI=1S/C16H18N2O3S/c17-22(20,21)15-8-6-13(7-9-15)10-11-18-16(19)12-14-4-2-1-3-5-14/h1-9H,10-12H2,(H,18,19)(H2,17,20,21)
DM1JL03 CS C1=CC=C(C=C1)CC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
DM1JL03 IK DIZLDASYQVXHTB-UHFFFAOYSA-N
DM1JL03 IU 2-phenyl-N-[2-(4-sulfamoylphenyl)ethyl]acetamide
DM1JL03 DE Discovery agent
DMDYHXE ID DMDYHXE
DMDYHXE DN 4-(2-Phenylacetamidomethyl)benzenesulfonamide
DMDYHXE HS Investigative
DMDYHXE SN 2-phenyl-N-(4-sulfamoylbenzyl)acetamide; 41352-39-0; 4itp; sulfonamide deriv., 7b; 4-(2-Phenylacetamidomethyl)benzenesulfonamide; AC1N3X6Y; 2-phenyl-N-[(4-sulfamoylphenyl)methyl]acetamide; Oprea1_692071; ARONIS26431; CHEMBL574783; BDBM35734; MolPort-010-990-071; ZINC6864120; STL261373; AKOS003796845; MCULE-9432670742; 4-phenylacetamidomethyl-benzenesulfonamide; BB0294421; 4-(Phenylacetylaminomethyl)benzenesulfonamide; KS-00004825; N-[4-(aminosulfonyl)benzyl]-2-phenylacetamide; Benzeneacetamide, N-[[4-(aminosulfonyl)phenyl]methy
DMDYHXE DT Small molecular drug
DMDYHXE PC 4119643
DMDYHXE MW 304.4
DMDYHXE FM C15H16N2O3S
DMDYHXE IC InChI=1S/C15H16N2O3S/c16-21(19,20)14-8-6-13(7-9-14)11-17-15(18)10-12-4-2-1-3-5-12/h1-9H,10-11H2,(H,17,18)(H2,16,19,20)
DMDYHXE CS C1=CC=C(C=C1)CC(=O)NCC2=CC=C(C=C2)S(=O)(=O)N
DMDYHXE IK FTDLZZRRCJRQAA-UHFFFAOYSA-N
DMDYHXE IU 2-phenyl-N-[(4-sulfamoylphenyl)methyl]acetamide
DMDYHXE DE Discovery agent
DMT9RAC ID DMT9RAC
DMT9RAC DN 4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC HS Investigative
DMT9RAC SN CHEMBL1164486; 4-(2-Propynylthio)pyridine-3-sulfonamide
DMT9RAC DT Small molecular drug
DMT9RAC PC 46907399
DMT9RAC MW 228.3
DMT9RAC FM C8H8N2O2S2
DMT9RAC IC InChI=1S/C8H8N2O2S2/c1-2-5-13-7-3-4-10-6-8(7)14(9,11)12/h1,3-4,6H,5H2,(H2,9,11,12)
DMT9RAC CS C#CCSC1=C(C=NC=C1)S(=O)(=O)N
DMT9RAC IK DGLKDMDQEUWHSZ-UHFFFAOYSA-N
DMT9RAC IU 4-prop-2-ynylsulfanylpyridine-3-sulfonamide
DMT9RAC DE Discovery agent
DM9LKMP ID DM9LKMP
DM9LKMP DN 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide
DM9LKMP HS Investigative
DM9LKMP SN sulfonamide deriv., 7g; CHEMBL582965; BDBM35739
DM9LKMP DT Small molecular drug
DM9LKMP PC 44520903
DM9LKMP MW 291.33
DM9LKMP FM C13H13N3O3S
DM9LKMP IC InChI=1S/C13H13N3O3S/c14-20(18,19)12-6-4-10(5-7-12)16-13(17)9-11-3-1-2-8-15-11/h1-8H,9H2,(H,16,17)(H2,14,18,19)
DM9LKMP CS C1=CC=NC(=C1)CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DM9LKMP IK AVVKIKWNABJSCP-UHFFFAOYSA-N
DM9LKMP IU 2-pyridin-2-yl-N-(4-sulfamoylphenyl)acetamide
DM9LKMP DE Discovery agent
DMD6AYQ ID DMD6AYQ
DMD6AYQ DN 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide
DMD6AYQ HS Investigative
DMD6AYQ SN sulfonamide deriv., 7h; CHEMBL574245
DMD6AYQ DT Small molecular drug
DMD6AYQ PC 44520904
DMD6AYQ MW 291.33
DMD6AYQ FM C13H13N3O3S
DMD6AYQ IC InChI=1S/C13H13N3O3S/c14-20(18,19)12-3-1-11(2-4-12)16-13(17)9-10-5-7-15-8-6-10/h1-8H,9H2,(H,16,17)(H2,14,18,19)
DMD6AYQ CS C1=CC(=CC=C1NC(=O)CC2=CC=NC=C2)S(=O)(=O)N
DMD6AYQ IK CXBVXOMVANONBT-UHFFFAOYSA-N
DMD6AYQ IU 2-pyridin-4-yl-N-(4-sulfamoylphenyl)acetamide
DMD6AYQ DE Discovery agent
DMOSDAN ID DMOSDAN
DMOSDAN DN 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile
DMOSDAN HS Investigative
DMOSDAN SN CHEMBL202518; 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile; SCHEMBL4932714
DMOSDAN DT Small molecular drug
DMOSDAN PC 11550626
DMOSDAN MW 256.339
DMOSDAN FM C16H20N2O
DMOSDAN IC InChI=1S/C16H20N2O/c1-2-5-15(18-10-3-4-11-18)16(19)14-8-6-13(12-17)7-9-14/h6-9,15H,2-5,10-11H2,1H3
DMOSDAN CS CCCC(C(=O)C1=CC=C(C=C1)C#N)N2CCCC2
DMOSDAN IK AQQRGNNYEPRIIF-UHFFFAOYSA-N
DMOSDAN IU 4-(2-pyrrolidin-1-ylpentanoyl)benzonitrile
DMOSDAN DE Discovery agent
DMX681M ID DMX681M
DMX681M DN 4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
DMX681M HS Investigative
DMX681M SN 4-(2-THIENYL)-1-(4-METHYLBENZYL)-1H-IMIDAZOLE; Disubstituted imidazole 1; AC1L9J9C; CHEMBL66526; SCHEMBL4319860; BDBM8738; DB03030; 1-(4-methylbenzyl)-4-(2-thienyl)-1h-imidazole; 1-(4-methylbenzyl)-4-thiophen-2-yl-1H-imidazole; 1-[(4-methylphenyl)methyl]-4-thiophen-2-ylimidazole; 1-[(4-methylphenyl)methyl]-4-(thiophen-2-yl)imidazole
DMX681M DT Small molecular drug
DMX681M PC 446185
DMX681M MW 254.4
DMX681M FM C15H14N2S
DMX681M IC InChI=1S/C15H14N2S/c1-12-4-6-13(7-5-12)9-17-10-14(16-11-17)15-3-2-8-18-15/h2-8,10-11H,9H2,1H3
DMX681M CS CC1=CC=C(C=C1)CN2C=C(N=C2)C3=CC=CS3
DMX681M IK UMOFOLLUKPBVQG-UHFFFAOYSA-N
DMX681M IU 1-[(4-methylphenyl)methyl]-4-thiophen-2-ylimidazole
DMX681M DE Discovery agent
DM4YWQN ID DM4YWQN
DM4YWQN DN 4-(2-thienyl)benzene-1,2-diamine
DM4YWQN HS Investigative
DM4YWQN SN 4-(thiophen-2-yl)benzene-1,2-diamine; 471239-63-1; 4-(2-thienyl)-1,2-Benzenediamine; CHEMBL495702; SCHEMBL2873589; XWTMGMKBRLLEFX-UHFFFAOYSA-N; MolPort-042-605-637; ZINC40977399; AKOS033921192; DA-05644; FT-0738633
DM4YWQN DT Small molecular drug
DM4YWQN PC 13007805
DM4YWQN MW 190.27
DM4YWQN FM C10H10N2S
DM4YWQN IC InChI=1S/C10H10N2S/c11-8-4-3-7(6-9(8)12)10-2-1-5-13-10/h1-6H,11-12H2
DM4YWQN CS C1=CSC(=C1)C2=CC(=C(C=C2)N)N
DM4YWQN IK XWTMGMKBRLLEFX-UHFFFAOYSA-N
DM4YWQN IU 4-thiophen-2-ylbenzene-1,2-diamine
DM4YWQN DE Discovery agent
DMR3T2D ID DMR3T2D
DMR3T2D DN 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol
DMR3T2D HS Investigative
DMR3T2D SN Phenol, 4,4'-indole-2,3-diyldi-; BRN 1541731; 4,4'-Indole-2,3-diyldiphenol; CHEMBL200232; 5890-93-7; 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol; SCHEMBL7037980; AC1L46D4; DTXSID90207642; ZINC3638330; BDBM50175412; LS-104733; 4,4'-[1H-Indole-2,3-diyl]bis(phenol)
DMR3T2D DT Small molecular drug
DMR3T2D PC 201385
DMR3T2D MW 301.3
DMR3T2D FM C20H15NO2
DMR3T2D IC InChI=1S/C20H15NO2/c22-15-9-5-13(6-10-15)19-17-3-1-2-4-18(17)21-20(19)14-7-11-16(23)12-8-14/h1-12,21-23H
DMR3T2D CS C1=CC=C2C(=C1)C(=C(N2)C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
DMR3T2D IK MGOARPQWMKCCSF-UHFFFAOYSA-N
DMR3T2D IU 4-[2-(4-hydroxyphenyl)-1H-indol-3-yl]phenol
DMR3T2D CA CAS 5890-93-7
DMR3T2D DE Discovery agent
DMX5V9T ID DMX5V9T
DMX5V9T DN 4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide
DMX5V9T HS Investigative
DMX5V9T SN CHEMBL561648; 4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide
DMX5V9T DT Small molecular drug
DMX5V9T PC 44186304
DMX5V9T MW 304.4
DMX5V9T FM C18H28N2O2
DMX5V9T IC InChI=1S/C18H28N2O2/c1-4-5-6-7-13-19-18(22)16-10-8-15(9-11-16)17(21)12-14-20(2)3/h8-11H,4-7,12-14H2,1-3H3,(H,19,22)
DMX5V9T CS CCCCCCNC(=O)C1=CC=C(C=C1)C(=O)CCN(C)C
DMX5V9T IK BARBHIHQBFLEIN-UHFFFAOYSA-N
DMX5V9T IU 4-[3-(dimethylamino)propanoyl]-N-hexylbenzamide
DMX5V9T DE Discovery agent
DMNUWK2 ID DMNUWK2
DMNUWK2 DN 4-(3,4,5-Trimethoxyphenethyl)aniline
DMNUWK2 HS Investigative
DMNUWK2 SN CHEMBL86928; 4-(3,4,5-Trimethoxyphenethyl)aniline; 110997-90-5; Benzenamine, 4-[2-(3,4,5-trimethoxyphenyl)ethyl]-; 4-[2-(3,4,5-Trimethoxy-phenyl)-ethyl]-phenylamine; 4-[2-(3,4,5-Trimethoxyphenyl)Ethyl]Aniline; NSC631359; ACMC-20mdvn; AC1L7PCU; AC1Q56FF; SCHEMBL6483085; CTK0G1952; DTXSID30327095; BPIQFCQFIYIISU-UHFFFAOYSA-N; ZINC1622338; BDBM50322061; 4'-Amino-3,4,5-trimethoxybibenzyl; AKOS030581735; NSC-631359; NCI60_010236; 4-[2-(3,5-Trimethoxyphenyl)Ethyl]Aniline; 4-[2-(3,4,5-trimethoxy-phenyl)ethyl]-phenylamine
DMNUWK2 DT Small molecular drug
DMNUWK2 PC 364705
DMNUWK2 MW 287.35
DMNUWK2 FM C17H21NO3
DMNUWK2 IC InChI=1S/C17H21NO3/c1-19-15-10-13(11-16(20-2)17(15)21-3)5-4-12-6-8-14(18)9-7-12/h6-11H,4-5,18H2,1-3H3
DMNUWK2 CS COC1=CC(=CC(=C1OC)OC)CCC2=CC=C(C=C2)N
DMNUWK2 IK BPIQFCQFIYIISU-UHFFFAOYSA-N
DMNUWK2 IU 4-[2-(3,4,5-trimethoxyphenyl)ethyl]aniline
DMNUWK2 CA CAS 110997-90-5
DMNUWK2 DE Discovery agent
DMBEA23 ID DMBEA23
DMBEA23 DN 4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid
DMBEA23 HS Investigative
DMBEA23 SN CHEMBL382682; 4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid; BDBM50179735
DMBEA23 DT Small molecular drug
DMBEA23 PC 44408336
DMBEA23 MW 294.2
DMBEA23 FM C11H13Cl2NO2S
DMBEA23 IC InChI=1S/C11H13Cl2NO2S/c12-8-2-1-7(5-9(8)13)6-17-4-3-10(14)11(15)16/h1-2,5,10H,3-4,6,14H2,(H,15,16)
DMBEA23 CS C1=CC(=C(C=C1CSCCC(C(=O)O)N)Cl)Cl
DMBEA23 IK FCRWKMQNOHHYCO-UHFFFAOYSA-N
DMBEA23 IU 2-amino-4-[(3,4-dichlorophenyl)methylsulfanyl]butanoic acid
DMBEA23 DE Discovery agent
DMIZXYM ID DMIZXYM
DMIZXYM DN 4-(3,4-Diethoxy-benzylamino)-benzamidine
DMIZXYM HS Investigative
DMIZXYM SN benzylamine 5; CHEMBL181265; BDBM13579
DMIZXYM DT Small molecular drug
DMIZXYM PC 23646461
DMIZXYM MW 313.4
DMIZXYM FM C18H23N3O2
DMIZXYM IC InChI=1S/C18H23N3O2/c1-3-22-16-10-5-13(11-17(16)23-4-2)12-21-15-8-6-14(7-9-15)18(19)20/h5-11,21H,3-4,12H2,1-2H3,(H3,19,20)
DMIZXYM CS CCOC1=C(C=C(C=C1)CNC2=CC=C(C=C2)C(=N)N)OCC
DMIZXYM IK KWXVDUACPKJCCN-UHFFFAOYSA-N
DMIZXYM IU 4-[(3,4-diethoxyphenyl)methylamino]benzenecarboximidamide
DMIZXYM DE Discovery agent
DMCOJIL ID DMCOJIL
DMCOJIL DN 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
DMCOJIL HS Investigative
DMCOJIL SN CHEMBL50166; 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline; SCHEMBL6159581; ZINC26870; BDBM50127827
DMCOJIL DT Small molecular drug
DMCOJIL PC 18326767
DMCOJIL MW 260.3
DMCOJIL FM C18H16N2
DMCOJIL IC InChI=1S/C18H16N2/c1-2-6-15-13-20(12-10-14(15)5-1)18-9-11-19-17-8-4-3-7-16(17)18/h1-9,11H,10,12-13H2
DMCOJIL CS C1CN(CC2=CC=CC=C21)C3=CC=NC4=CC=CC=C43
DMCOJIL IK HRDFYQVITWAQGZ-UHFFFAOYSA-N
DMCOJIL IU 4-(3,4-dihydro-1H-isoquinolin-2-yl)quinoline
DMCOJIL DE Discovery agent
DMBI7MS ID DMBI7MS
DMBI7MS DN 4-(3,4-Dimethoxyphenethyl)aniline
DMBI7MS HS Investigative
DMBI7MS SN 4-(3,4-Dimethoxyphenethyl)aniline; CHEMBL1171680; SCHEMBL6481605; MEJNYOQOZUXCOG-UHFFFAOYSA-N; ZINC34258590; BDBM50322060; 4-[2-[3,4-dimethoxyphenyl)ethyl]aniline; 4[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]benzenamine; 4-[2-(3,4-dimethoxyphenyl)ethyl]phenylamine; 4-[2-(3,4-Dimethoxy-phenyl)ethyl]-phenylamine; 4-[2-(3,4-dimethoxy-phenyl)-ethyl]phenylamine
DMBI7MS DT Small molecular drug
DMBI7MS PC 14256024
DMBI7MS MW 257.329
DMBI7MS FM C16H19NO2
DMBI7MS IC InChI=1S/C16H19NO2/c1-18-15-10-7-13(11-16(15)19-2)4-3-12-5-8-14(17)9-6-12/h5-11H,3-4,17H2,1-2H3
DMBI7MS CS COC1=C(C=C(C=C1)CCC2=CC=C(C=C2)N)OC
DMBI7MS IK MEJNYOQOZUXCOG-UHFFFAOYSA-N
DMBI7MS IU 4-[2-(3,4-dimethoxyphenyl)ethyl]aniline
DMBI7MS DE Discovery agent
DMW1H6C ID DMW1H6C
DMW1H6C DN 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMW1H6C HS Investigative
DMW1H6C SN CHEMBL327300; Ki-6783; 6,7-Dimethoxy-4-(3,4-dimethoxyphenoxy)quinoline; SCHEMBL925876; 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline; ZQSHUGGLESWJFP-UHFFFAOYSA-N
DMW1H6C DT Small molecular drug
DMW1H6C PC 9927943
DMW1H6C MW 341.4
DMW1H6C FM C19H19NO5
DMW1H6C IC InChI=1S/C19H19NO5/c1-21-16-6-5-12(9-17(16)22-2)25-15-7-8-20-14-11-19(24-4)18(23-3)10-13(14)15/h5-11H,1-4H3
DMW1H6C CS COC1=C(C=C(C=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC
DMW1H6C IK ZQSHUGGLESWJFP-UHFFFAOYSA-N
DMW1H6C IU 4-(3,4-dimethoxyphenoxy)-6,7-dimethoxyquinoline
DMW1H6C DE Discovery agent
DM5ZTXO ID DM5ZTXO
DM5ZTXO DN 4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid
DM5ZTXO HS Investigative
DM5ZTXO SN CHEMBL204870; 4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid; BDBM50179737
DM5ZTXO DT Small molecular drug
DM5ZTXO PC 44408222
DM5ZTXO MW 253.36
DM5ZTXO FM C13H19NO2S
DM5ZTXO IC InChI=1S/C13H19NO2S/c1-9-3-4-11(7-10(9)2)8-17-6-5-12(14)13(15)16/h3-4,7,12H,5-6,8,14H2,1-2H3,(H,15,16)
DM5ZTXO CS CC1=C(C=C(C=C1)CSCCC(C(=O)O)N)C
DM5ZTXO IK HMCZVDYIAXLHNI-UHFFFAOYSA-N
DM5ZTXO IU 2-amino-4-[(3,4-dimethylphenyl)methylsulfanyl]butanoic acid
DM5ZTXO DE Discovery agent
DMM3F9K ID DMM3F9K
DMM3F9K DN 4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid
DMM3F9K HS Investigative
DMM3F9K SN CHEMBL204818; 4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid
DMM3F9K DT Small molecular drug
DMM3F9K PC 44408337
DMM3F9K MW 294.2
DMM3F9K FM C11H13Cl2NO2S
DMM3F9K IC InChI=1S/C11H13Cl2NO2S/c12-8-3-7(4-9(13)5-8)6-17-2-1-10(14)11(15)16/h3-5,10H,1-2,6,14H2,(H,15,16)
DMM3F9K CS C1=C(C=C(C=C1Cl)Cl)CSCCC(C(=O)O)N
DMM3F9K IK CLPWTUZDSOPCKQ-UHFFFAOYSA-N
DMM3F9K IU 2-amino-4-[(3,5-dichlorophenyl)methylsulfanyl]butanoic acid
DMM3F9K DE Discovery agent
DM48Z5Y ID DM48Z5Y
DM48Z5Y DN 4-(3,5-difluorophenylethynyl)-2-methylthiazole
DM48Z5Y HS Investigative
DM48Z5Y SN CHEMBL202436; 4-(3,5-difluorophenylethynyl)-2-methylthiazole; SCHEMBL4161912
DM48Z5Y DT Small molecular drug
DM48Z5Y PC 11543200
DM48Z5Y MW 235.25
DM48Z5Y FM C12H7F2NS
DM48Z5Y IC InChI=1S/C12H7F2NS/c1-8-15-12(7-16-8)3-2-9-4-10(13)6-11(14)5-9/h4-7H,1H3
DM48Z5Y CS CC1=NC(=CS1)C#CC2=CC(=CC(=C2)F)F
DM48Z5Y IK RIXDIVBFRYYMRM-UHFFFAOYSA-N
DM48Z5Y IU 4-[2-(3,5-difluorophenyl)ethynyl]-2-methyl-1,3-thiazole
DM48Z5Y DE Discovery agent
DM4FC9O ID DM4FC9O
DM4FC9O DN 4-(3,5-Dimethoxyphenethyl)benzenamine
DM4FC9O HS Investigative
DM4FC9O SN 4-(3,5-Dimethoxyphenethyl)benzenamine; CHEMBL1171818; SCHEMBL10384348
DM4FC9O DT Small molecular drug
DM4FC9O PC 14256034
DM4FC9O MW 257.329
DM4FC9O FM C16H19NO2
DM4FC9O IC InChI=1S/C16H19NO2/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h5-11H,3-4,17H2,1-2H3
DM4FC9O CS COC1=CC(=CC(=C1)CCC2=CC=C(C=C2)N)OC
DM4FC9O IK LIBKKCPPEBZEHD-UHFFFAOYSA-N
DM4FC9O IU 4-[2-(3,5-dimethoxyphenyl)ethyl]aniline
DM4FC9O DE Discovery agent
DM5279R ID DM5279R
DM5279R DN 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM5279R HS Investigative
DM5279R SN CHEMBL101733; 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline
DM5279R DT Small molecular drug
DM5279R PC 44330968
DM5279R MW 341.4
DM5279R FM C19H19NO5
DM5279R IC InChI=1S/C19H19NO5/c1-21-12-7-13(22-2)9-14(8-12)25-17-5-6-20-16-11-19(24-4)18(23-3)10-15(16)17/h5-11H,1-4H3
DM5279R CS COC1=CC(=CC(=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC
DM5279R IK RNXKKASQCMYWCJ-UHFFFAOYSA-N
DM5279R IU 4-(3,5-dimethoxyphenoxy)-6,7-dimethoxyquinoline
DM5279R DE Discovery agent
DM9MIQB ID DM9MIQB
DM9MIQB DN 4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid
DM9MIQB HS Investigative
DM9MIQB SN CHEMBL380950; 4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid; BDBM50179702
DM9MIQB DT Small molecular drug
DM9MIQB PC 44408223
DM9MIQB MW 253.36
DM9MIQB FM C13H19NO2S
DM9MIQB IC InChI=1S/C13H19NO2S/c1-9-5-10(2)7-11(6-9)8-17-4-3-12(14)13(15)16/h5-7,12H,3-4,8,14H2,1-2H3,(H,15,16)
DM9MIQB CS CC1=CC(=CC(=C1)CSCCC(C(=O)O)N)C
DM9MIQB IK XBQZUMGAFICQFC-UHFFFAOYSA-N
DM9MIQB IU 2-amino-4-[(3,5-dimethylphenyl)methylsulfanyl]butanoic acid
DM9MIQB DE Discovery agent
DMKUAEY ID DMKUAEY
DMKUAEY DN 4-(3-Adamantan-1-yl-ureido)-benzoic acid
DMKUAEY HS Investigative
DMKUAEY SN CHEMBL478321; 4-(3-Adamantan-1-yl-ureido)-benzoic acid; SCHEMBL12932181; BDBM50267174
DMKUAEY DT Small molecular drug
DMKUAEY PC 44582456
DMKUAEY MW 314.4
DMKUAEY FM C18H22N2O3
DMKUAEY IC InChI=1S/C18H22N2O3/c21-16(22)14-1-3-15(4-2-14)19-17(23)20-18-8-11-5-12(9-18)7-13(6-11)10-18/h1-4,11-13H,5-10H2,(H,21,22)(H2,19,20,23)
DMKUAEY CS C1C2CC3CC1CC(C2)(C3)NC(=O)NC4=CC=C(C=C4)C(=O)O
DMKUAEY IK KBCDTFQYSZRNRK-UHFFFAOYSA-N
DMKUAEY IU 4-(1-adamantylcarbamoylamino)benzoic acid
DMKUAEY DE Discovery agent
DMLVZ6O ID DMLVZ6O
DMLVZ6O DN 4-(3-benzenesulfonamidophenyl)piperazine
DMLVZ6O HS Investigative
DMLVZ6O SN 4-(3-benzenesulfonamidophenyl)piperazine; CHEMBL213586; BDBM50193466
DMLVZ6O DT Small molecular drug
DMLVZ6O PC 11849196
DMLVZ6O MW 317.4
DMLVZ6O FM C16H19N3O2S
DMLVZ6O IC InChI=1S/C16H19N3O2S/c20-22(21,16-7-2-1-3-8-16)18-14-5-4-6-15(13-14)19-11-9-17-10-12-19/h1-8,13,17-18H,9-12H2
DMLVZ6O CS C1CN(CCN1)C2=CC=CC(=C2)NS(=O)(=O)C3=CC=CC=C3
DMLVZ6O IK KUAATZXIILUWMF-UHFFFAOYSA-N
DMLVZ6O IU N-(3-piperazin-1-ylphenyl)benzenesulfonamide
DMLVZ6O DE Discovery agent
DMG4X13 ID DMG4X13
DMG4X13 DN 4-(3-benzenesulfonylphenyl)piperazine
DMG4X13 HS Investigative
DMG4X13 SN 4-(3-benzenesulfonylphenyl)piperazine; CHEMBL212995; SCHEMBL3826873; KDBOZUADFFNYSM-UHFFFAOYSA-N; BDBM50193464
DMG4X13 DT Small molecular drug
DMG4X13 PC 9948345
DMG4X13 MW 302.4
DMG4X13 FM C16H18N2O2S
DMG4X13 IC InChI=1S/C16H18N2O2S/c19-21(20,15-6-2-1-3-7-15)16-8-4-5-14(13-16)18-11-9-17-10-12-18/h1-8,13,17H,9-12H2
DMG4X13 CS C1CN(CCN1)C2=CC(=CC=C2)S(=O)(=O)C3=CC=CC=C3
DMG4X13 IK KDBOZUADFFNYSM-UHFFFAOYSA-N
DMG4X13 IU 1-[3-(benzenesulfonyl)phenyl]piperazine
DMG4X13 DE Discovery agent
DMT0EK8 ID DMT0EK8
DMT0EK8 DN 4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid
DMT0EK8 HS Investigative
DMT0EK8 SN CHEMBL590016; 4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid
DMT0EK8 DT Small molecular drug
DMT0EK8 PC 46229307
DMT0EK8 MW 257.279
DMT0EK8 FM C15H15NO3
DMT0EK8 IC InChI=1S/C15H15NO3/c17-14(18)7-4-9-16-10-8-13(11-16)15(19)12-5-2-1-3-6-12/h1-3,5-6,8,10-11H,4,7,9H2,(H,17,18)
DMT0EK8 CS C1=CC=C(C=C1)C(=O)C2=CN(C=C2)CCCC(=O)O
DMT0EK8 IK DMGGHIOFOITOLX-UHFFFAOYSA-N
DMT0EK8 IU 4-(3-benzoylpyrrol-1-yl)butanoic acid
DMT0EK8 DE Discovery agent
DML3VB7 ID DML3VB7
DML3VB7 DN 4-(3-bromobenzylthio)-2-aminobutanoic acid
DML3VB7 HS Investigative
DML3VB7 SN CHEMBL380929; 4-(3-bromobenzylthio)-2-aminobutanoic acid; BDBM50179727
DML3VB7 DT Small molecular drug
DML3VB7 PC 44408328
DML3VB7 MW 304.21
DML3VB7 FM C11H14BrNO2S
DML3VB7 IC InChI=1S/C11H14BrNO2S/c12-9-3-1-2-8(6-9)7-16-5-4-10(13)11(14)15/h1-3,6,10H,4-5,7,13H2,(H,14,15)
DML3VB7 CS C1=CC(=CC(=C1)Br)CSCCC(C(=O)O)N
DML3VB7 IK NFPJCMSYLUNWCI-UHFFFAOYSA-N
DML3VB7 IU 2-amino-4-[(3-bromophenyl)methylsulfanyl]butanoic acid
DML3VB7 DE Discovery agent
DMNBLQ8 ID DMNBLQ8
DMNBLQ8 DN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
DMNBLQ8 HS Investigative
DMNBLQ8 SN CHEMBL98798; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
DMNBLQ8 DT Small molecular drug
DMNBLQ8 PC 44331231
DMNBLQ8 MW 361.19
DMNBLQ8 FM C16H13BrN2O3
DMNBLQ8 IC InChI=1S/C16H13BrN2O3/c1-20-14-7-12-13(8-15(14)21-2)18-9-19-16(12)22-11-5-3-4-10(17)6-11/h3-9H,1-2H3
DMNBLQ8 CS COC1=C(C=C2C(=C1)C(=NC=N2)OC3=CC(=CC=C3)Br)OC
DMNBLQ8 IK BRHOGFZRGDIAMT-UHFFFAOYSA-N
DMNBLQ8 IU 4-(3-bromophenoxy)-6,7-dimethoxyquinazoline
DMNBLQ8 DE Discovery agent
DMK6JV7 ID DMK6JV7
DMK6JV7 DN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline
DMK6JV7 HS Investigative
DMK6JV7 SN CHEMBL101581; 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline
DMK6JV7 DT Small molecular drug
DMK6JV7 PC 44331083
DMK6JV7 MW 360.2
DMK6JV7 FM C17H14BrNO3
DMK6JV7 IC InChI=1S/C17H14BrNO3/c1-20-16-9-13-14(10-17(16)21-2)19-7-6-15(13)22-12-5-3-4-11(18)8-12/h3-10H,1-2H3
DMK6JV7 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=CC=C3)Br
DMK6JV7 IK OVJMXMWWASQPSL-UHFFFAOYSA-N
DMK6JV7 IU 4-(3-bromophenoxy)-6,7-dimethoxyquinoline
DMK6JV7 DE Discovery agent
DM3LGOT ID DM3LGOT
DM3LGOT DN 4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT HS Investigative
DM3LGOT SN CHEMBL1082103; 4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT DT Small molecular drug
DM3LGOT PC 46879772
DM3LGOT MW 335.58
DM3LGOT FM C14H8BrClN2O
DM3LGOT IC InChI=1S/C14H8BrClN2O/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H
DM3LGOT CS C1=CC(=CC(=C1)Br)OC2=NC=NC3=C2C=C(C=C3)Cl
DM3LGOT IK WAILHPROBXVCQL-UHFFFAOYSA-N
DM3LGOT IU 4-(3-bromophenoxy)-6-chloroquinazoline
DM3LGOT DE Discovery agent
DM1Q5KV ID DM1Q5KV
DM1Q5KV DN 4-(3-Bromo-phenylamino)-quinazoline-6,7-diol
DM1Q5KV HS Investigative
DM1Q5KV DT Small molecular drug
DM1Q5KV PC 5328050
DM1Q5KV DE Discovery agent
DMQBHF2 ID DMQBHF2
DMQBHF2 DN 4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine
DMQBHF2 HS Investigative
DMQBHF2 SN CHEMBL208163; 4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine; SCHEMBL6504580; 4-(3-bromo-phenylsulfanyl)-2-pyridin-2-yl-pyrimidine; BDBM50182817
DMQBHF2 DT Small molecular drug
DMQBHF2 PC 11473392
DMQBHF2 MW 344.2
DMQBHF2 FM C15H10BrN3S
DMQBHF2 IC InChI=1S/C15H10BrN3S/c16-11-4-3-5-12(10-11)20-14-7-9-18-15(19-14)13-6-1-2-8-17-13/h1-10H
DMQBHF2 CS C1=CC=NC(=C1)C2=NC=CC(=N2)SC3=CC(=CC=C3)Br
DMQBHF2 IK GOUWEKQNTSGAGA-UHFFFAOYSA-N
DMQBHF2 IU 4-(3-bromophenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DMQBHF2 DE Discovery agent
DML5NF6 ID DML5NF6
DML5NF6 DN 4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol
DML5NF6 HS Investigative
DML5NF6 SN 4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol; 945376-95-4; CHEMBL1269227; AK-87708; SCHEMBL2813127; CTK8B8546; DTXSID20680661; MolPort-023-331-308; XBHIAJWNXVJSAA-UHFFFAOYSA-N; KS-00000P8Z; ZINC64512573; ANW-60649; 6223AC; AKOS016003310; ACN-048482; QC-10378; DS-18362; ST2405344; KB-237849; AX8219172; AB0098071; DB-079951; TC-149394; AJ-114863; 4CH-017501
DML5NF6 DT Small molecular drug
DML5NF6 PC 52947893
DML5NF6 MW 290.11
DML5NF6 FM C12H8BrN3O
DML5NF6 IC InChI=1S/C12H8BrN3O/c13-11-6-15-16-7-9(5-14-12(11)16)8-1-3-10(17)4-2-8/h1-7,17H
DML5NF6 CS C1=CC(=CC=C1C2=CN3C(=C(C=N3)Br)N=C2)O
DML5NF6 IK XBHIAJWNXVJSAA-UHFFFAOYSA-N
DML5NF6 IU 4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol
DML5NF6 CA CAS 945376-95-4
DML5NF6 DE Discovery agent
DMQVXMZ ID DMQVXMZ
DMQVXMZ DN 4-(3-chlorobenzylthio)-2-aminobutanoic acid
DMQVXMZ HS Investigative
DMQVXMZ SN CHEMBL203616; 4-(3-chlorobenzylthio)-2-aminobutanoic acid; BDBM50179722
DMQVXMZ DT Small molecular drug
DMQVXMZ PC 44408320
DMQVXMZ MW 259.75
DMQVXMZ FM C11H14ClNO2S
DMQVXMZ IC InChI=1S/C11H14ClNO2S/c12-9-3-1-2-8(6-9)7-16-5-4-10(13)11(14)15/h1-3,6,10H,4-5,7,13H2,(H,14,15)
DMQVXMZ CS C1=CC(=CC(=C1)Cl)CSCCC(C(=O)O)N
DMQVXMZ IK CHLGWHKXVGUGBH-UHFFFAOYSA-N
DMQVXMZ IU 2-amino-4-[(3-chlorophenyl)methylsulfanyl]butanoic acid
DMQVXMZ DE Discovery agent
DMDS2LZ ID DMDS2LZ
DMDS2LZ DN 4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline
DMDS2LZ HS Investigative
DMDS2LZ SN CHEMBL135853; 4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline; SCHEMBL6182199; XDUSWBSGDKRQAF-UHFFFAOYSA-N; BDBM50291080
DMDS2LZ DT Small molecular drug
DMDS2LZ PC 9948853
DMDS2LZ MW 316.74
DMDS2LZ FM C16H13ClN2O3
DMDS2LZ IC InChI=1S/C16H13ClN2O3/c1-20-14-7-12-13(8-15(14)21-2)18-9-19-16(12)22-11-5-3-4-10(17)6-11/h3-9H,1-2H3
DMDS2LZ CS COC1=C(C=C2C(=C1)C(=NC=N2)OC3=CC(=CC=C3)Cl)OC
DMDS2LZ IK XDUSWBSGDKRQAF-UHFFFAOYSA-N
DMDS2LZ IU 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline
DMDS2LZ DE Discovery agent
DMDTFKL ID DMDTFKL
DMDTFKL DN 4-(3-chlorophenylethynyl)-2-methylthiazole
DMDTFKL HS Investigative
DMDTFKL SN CHEMBL202124; 4-(3-chlorophenylethynyl)-2-methylthiazole; SCHEMBL4153004
DMDTFKL DT Small molecular drug
DMDTFKL PC 11701423
DMDTFKL MW 233.72
DMDTFKL FM C12H8ClNS
DMDTFKL IC InChI=1S/C12H8ClNS/c1-9-14-12(8-15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMDTFKL CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)Cl
DMDTFKL IK ORFSHDWOPQJKQL-UHFFFAOYSA-N
DMDTFKL IU 4-[2-(3-chlorophenyl)ethynyl]-2-methyl-1,3-thiazole
DMDTFKL DE Discovery agent
DMJH2OE ID DMJH2OE
DMJH2OE DN 4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine
DMJH2OE HS Investigative
DMJH2OE SN 4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine; CHEMBL208781; SCHEMBL6507354; BDBM50182809
DMJH2OE DT Small molecular drug
DMJH2OE PC 11460771
DMJH2OE MW 299.8
DMJH2OE FM C15H10ClN3S
DMJH2OE IC InChI=1S/C15H10ClN3S/c16-11-4-3-5-12(10-11)20-14-7-9-18-15(19-14)13-6-1-2-8-17-13/h1-10H
DMJH2OE CS C1=CC=NC(=C1)C2=NC=CC(=N2)SC3=CC(=CC=C3)Cl
DMJH2OE IK UISOVRMNRPVABO-UHFFFAOYSA-N
DMJH2OE IU 4-(3-chlorophenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DMJH2OE DE Discovery agent
DMSUB8D ID DMSUB8D
DMSUB8D DN 4-(3-cyanobenzylthio)-2-aminobutanoic acid
DMSUB8D HS Investigative
DMSUB8D SN CHEMBL380507; 4-(3-cyanobenzylthio)-2-aminobutanoic acid; BDBM50179730
DMSUB8D DT Small molecular drug
DMSUB8D PC 44408229
DMSUB8D MW 250.32
DMSUB8D FM C12H14N2O2S
DMSUB8D IC InChI=1S/C12H14N2O2S/c13-7-9-2-1-3-10(6-9)8-17-5-4-11(14)12(15)16/h1-3,6,11H,4-5,8,14H2,(H,15,16)
DMSUB8D CS C1=CC(=CC(=C1)C#N)CSCCC(C(=O)O)N
DMSUB8D IK HDBDOMDCBCMSJT-UHFFFAOYSA-N
DMSUB8D IU 2-amino-4-[(3-cyanophenyl)methylsulfanyl]butanoic acid
DMSUB8D DE Discovery agent
DMXFLMK ID DMXFLMK
DMXFLMK DN 4-(3-cyclohexylureido)butanoic acid
DMXFLMK HS Investigative
DMXFLMK SN 4-{[(Cyclohexylamino)carbonyl]amino}butanoic acid; 4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID; 4-[(cyclohexylcarbamoyl)amino]butanoic acid; 511552-46-8; 4-(3-Cyclohexyl-ureido)-butyric acid; CHEMBL219695; 4-([(Cyclohexylamino)carbonyl]amino)butanoic acid; 4-(3-CYCLOHEXYLURIEDO)-BUTYRIC ACID; NC4; 1zd3; AC1O4WJY; AC1Q75I7; SCHEMBL1065092; WSVFRGGLURJIMG-UHFFFAOYSA-N; MolPort-004-290-136; HMS3604L06; ZINC8754389; BDBM50192936; AKOS000125413; 4-(3-cyclohexylur-eido)-butyric acid; NE13821; MCULE-1918218076; DB08257
DMXFLMK DT Small molecular drug
DMXFLMK PC 6420119
DMXFLMK MW 228.29
DMXFLMK FM C11H20N2O3
DMXFLMK IC InChI=1S/C11H20N2O3/c14-10(15)7-4-8-12-11(16)13-9-5-2-1-3-6-9/h9H,1-8H2,(H,14,15)(H2,12,13,16)
DMXFLMK CS C1CCC(CC1)NC(=O)NCCCC(=O)O
DMXFLMK IK WSVFRGGLURJIMG-UHFFFAOYSA-N
DMXFLMK IU 4-(cyclohexylcarbamoylamino)butanoic acid
DMXFLMK DE Discovery agent
DMOQE5W ID DMOQE5W
DMOQE5W DN 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMOQE5W HS Investigative
DMOQE5W SN CHEMBL98169; 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline
DMOQE5W DT Small molecular drug
DMOQE5W PC 44331209
DMOQE5W MW 325.4
DMOQE5W FM C19H19NO4
DMOQE5W IC InChI=1S/C19H19NO4/c1-4-23-13-6-5-7-14(10-13)24-17-8-9-20-16-12-19(22-3)18(21-2)11-15(16)17/h5-12H,4H2,1-3H3
DMOQE5W CS CCOC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMOQE5W IK PKUBIFVLLLNKCO-UHFFFAOYSA-N
DMOQE5W IU 4-(3-ethoxyphenoxy)-6,7-dimethoxyquinoline
DMOQE5W DE Discovery agent
DMFM9SH ID DMFM9SH
DMFM9SH DN 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline
DMFM9SH HS Investigative
DMFM9SH SN CHEMBL100765; 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline
DMFM9SH DT Small molecular drug
DMFM9SH PC 44331127
DMFM9SH MW 309.4
DMFM9SH FM C19H19NO3
DMFM9SH IC InChI=1S/C19H19NO3/c1-4-13-6-5-7-14(10-13)23-17-8-9-20-16-12-19(22-3)18(21-2)11-15(16)17/h5-12H,4H2,1-3H3
DMFM9SH CS CCC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMFM9SH IK BXXFKNUQXUJVKP-UHFFFAOYSA-N
DMFM9SH IU 4-(3-ethylphenoxy)-6,7-dimethoxyquinoline
DMFM9SH DE Discovery agent
DM1C3NZ ID DM1C3NZ
DM1C3NZ DN 4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ HS Investigative
DM1C3NZ SN CHEMBL583751; 4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ DT Small molecular drug
DM1C3NZ PC 45483459
DM1C3NZ MW 271.33
DM1C3NZ FM C17H18FNO
DM1C3NZ IC InChI=1S/C17H18FNO/c18-16-8-4-7-15(13-9-11-19-12-10-13)17(16)20-14-5-2-1-3-6-14/h1-8,13,19H,9-12H2
DM1C3NZ CS C1CNCCC1C2=C(C(=CC=C2)F)OC3=CC=CC=C3
DM1C3NZ IK WWIFVPBPYYVHTD-UHFFFAOYSA-N
DM1C3NZ IU 4-(3-fluoro-2-phenoxyphenyl)piperidine
DM1C3NZ DE Discovery agent
DMXLC94 ID DMXLC94
DMXLC94 DN 4-(3-fluorobenzylthio)-2-aminobutanoic acid
DMXLC94 HS Investigative
DMXLC94 SN CHEMBL204611; 4-(3-fluorobenzylthio)-2-aminobutanoic acid; BDBM50179707
DMXLC94 DT Small molecular drug
DMXLC94 PC 44408322
DMXLC94 MW 243.3
DMXLC94 FM C11H14FNO2S
DMXLC94 IC InChI=1S/C11H14FNO2S/c12-9-3-1-2-8(6-9)7-16-5-4-10(13)11(14)15/h1-3,6,10H,4-5,7,13H2,(H,14,15)
DMXLC94 CS C1=CC(=CC(=C1)F)CSCCC(C(=O)O)N
DMXLC94 IK BWUFBZIPJLPDQV-UHFFFAOYSA-N
DMXLC94 IU 2-amino-4-[(3-fluorophenyl)methylsulfanyl]butanoic acid
DMXLC94 DE Discovery agent
DMER3D9 ID DMER3D9
DMER3D9 DN 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline
DMER3D9 HS Investigative
DMER3D9 SN CHEMBL102191; 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline; SCHEMBL7490337; LQOBRLFNSGKIFO-UHFFFAOYSA-N; BDBM50290841
DMER3D9 DT Small molecular drug
DMER3D9 PC 22132626
DMER3D9 MW 299.3
DMER3D9 FM C17H14FNO3
DMER3D9 IC InChI=1S/C17H14FNO3/c1-20-16-9-13-14(10-17(16)21-2)19-7-6-15(13)22-12-5-3-4-11(18)8-12/h3-10H,1-2H3
DMER3D9 CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=CC=C3)F
DMER3D9 IK LQOBRLFNSGKIFO-UHFFFAOYSA-N
DMER3D9 IU 4-(3-fluorophenoxy)-6,7-dimethoxyquinoline
DMER3D9 DE Discovery agent
DM6RV9L ID DM6RV9L
DM6RV9L DN 4-(3-fluorophenylethynyl)-2-thiazolylamine
DM6RV9L HS Investigative
DM6RV9L SN 4-(3-fluorophenylethynyl)-2-thiazolylamine; CHEMBL370559; 878018-65-6; SCHEMBL4140841
DM6RV9L DT Small molecular drug
DM6RV9L PC 11629906
DM6RV9L MW 218.25
DM6RV9L FM C11H7FN2S
DM6RV9L IC InChI=1S/C11H7FN2S/c12-9-3-1-2-8(6-9)4-5-10-7-15-11(13)14-10/h1-3,6-7H,(H2,13,14)
DM6RV9L CS C1=CC(=CC(=C1)F)C#CC2=CSC(=N2)N
DM6RV9L IK XTUCFPVDIBJRML-UHFFFAOYSA-N
DM6RV9L IU 4-[2-(3-fluorophenyl)ethynyl]-1,3-thiazol-2-amine
DM6RV9L DE Discovery agent
DMZ1TNM ID DMZ1TNM
DMZ1TNM DN 4-(3'-furyl)-aniline
DMZ1TNM HS Investigative
DMZ1TNM SN Benzenamine, 4-(3-furanyl)-; 4-(furan-3-yl)aniline; 4-furan-3-yl-phenylamine; CHEMBL374967; SCHEMBL1016530; NSKKXDBWURWAOW-UHFFFAOYSA-N; AKOS013265082
DMZ1TNM DT Small molecular drug
DMZ1TNM PC 44420988
DMZ1TNM MW 159.18
DMZ1TNM FM C10H9NO
DMZ1TNM IC InChI=1S/C10H9NO/c11-10-3-1-8(2-4-10)9-5-6-12-7-9/h1-7H,11H2
DMZ1TNM CS C1=CC(=CC=C1C2=COC=C2)N
DMZ1TNM IK NSKKXDBWURWAOW-UHFFFAOYSA-N
DMZ1TNM IU 4-(furan-3-yl)aniline
DMZ1TNM CA CAS 936249-47-7
DMZ1TNM DE Discovery agent
DMC5GAW ID DMC5GAW
DMC5GAW DN 4-(3-hexylureido)-N-phenylbenzenesulfonamide
DMC5GAW HS Investigative
DMC5GAW SN CHEMBL1077716; 4-(3-hexylureido)-N-phenylbenzenesulfonamide
DMC5GAW DT Small molecular drug
DMC5GAW PC 46882764
DMC5GAW MW 375.5
DMC5GAW FM C19H25N3O3S
DMC5GAW IC InChI=1S/C19H25N3O3S/c1-2-3-4-8-15-20-19(23)21-16-11-13-18(14-12-16)26(24,25)22-17-9-6-5-7-10-17/h5-7,9-14,22H,2-4,8,15H2,1H3,(H2,20,21,23)
DMC5GAW CS CCCCCCNC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2
DMC5GAW IK ADKICSRVDIFTQJ-UHFFFAOYSA-N
DMC5GAW IU 1-hexyl-3-[4-(phenylsulfamoyl)phenyl]urea
DMC5GAW DE Discovery agent
DM3QJVT ID DM3QJVT
DM3QJVT DN 4-(3H-Inden-1-ylmethyl)-phenylamine
DM3QJVT HS Investigative
DM3QJVT SN CHEMBL371048; 4-(3H-Inden-1-ylmethyl)-phenylamine
DM3QJVT DT Small molecular drug
DM3QJVT PC 44401549
DM3QJVT MW 221.3
DM3QJVT FM C16H15N
DM3QJVT IC InChI=1S/C16H15N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-6,8-10H,7,11,17H2
DM3QJVT CS C1C=C(C2=CC=CC=C21)CC3=CC=C(C=C3)N
DM3QJVT IK IJBWRSORBVHQFX-UHFFFAOYSA-N
DM3QJVT IU 4-(3H-inden-1-ylmethyl)aniline
DM3QJVT DE Discovery agent
DMM8AY5 ID DMM8AY5
DMM8AY5 DN 4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile
DMM8AY5 HS Investigative
DMM8AY5 DT Small molecular drug
DMM8AY5 PC 68447853
DMM8AY5 MW 336.4
DMM8AY5 FM C22H16N4
DMM8AY5 IC InChI=1S/C22H16N4/c23-13-18-15-24-14-17(10-9-16-5-2-1-3-6-16)22(18)26-21-8-4-7-20-19(21)11-12-25-20/h1-12,14-15,25H,(H,24,26)/b10-9+
DMM8AY5 CS C1=CC=C(C=C1)/C=C/C2=CN=CC(=C2NC3=CC=CC4=C3C=CN4)C#N
DMM8AY5 IK HETWGNHMXYNQPB-MDZDMXLPSA-N
DMM8AY5 IU 4-(1H-indol-4-ylamino)-5-[(E)-2-phenylethenyl]pyridine-3-carbonitrile
DMM8AY5 DE Discovery agent
DMY2OVL ID DMY2OVL
DMY2OVL DN 4-(3-hydroxy-benzylideneamino)-benzenesulfonamide
DMY2OVL HS Investigative
DMY2OVL SN CHEMBL270243; 66667-57-0; NSC722923; AC1L8PAB; CBDivE_016053; 4-[(3-hydroxyphenyl)methylideneamino]benzenesulfonamide; CTK1H9643; CTK7J9950; DTXSID20328076; BDBM50371761; AKOS030585458; MCULE-4187647437; NSC-722923; SR-01000199564; SR-01000199564-1; 4-[(3-Hydroxy-benzylidene)-amino]-benzenesulfonamide; Benzenesulfonamide, 4-[[(3-hydroxyphenyl)methylene]amino]-
DMY2OVL DT Small molecular drug
DMY2OVL PC 405560
DMY2OVL MW 276.31
DMY2OVL FM C13H12N2O3S
DMY2OVL IC InChI=1S/C13H12N2O3S/c14-19(17,18)13-6-4-11(5-7-13)15-9-10-2-1-3-12(16)8-10/h1-9,16H,(H2,14,17,18)
DMY2OVL CS C1=CC(=CC(=C1)O)C=NC2=CC=C(C=C2)S(=O)(=O)N
DMY2OVL IK FNUVWCBUDJAFOI-UHFFFAOYSA-N
DMY2OVL IU 4-[(3-hydroxyphenyl)methylideneamino]benzenesulfonamide
DMY2OVL CA CAS 66667-57-0
DMY2OVL DE Discovery agent
DMUQWJZ ID DMUQWJZ
DMUQWJZ DN 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol
DMUQWJZ HS Investigative
DMUQWJZ SN CHEMBL7278; 100112-61-6; 1,2-benzenediol,4-(3-hydroxy-3-piperidinyl)-; 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(3-hydroxy-3-piperidinyl)-; CTK8G4032; BDBM50000496; AKOS022649735; 3-(3,4-Dihydroxyphenyl)piperidin-3-ol
DMUQWJZ DT Small molecular drug
DMUQWJZ PC 11820398
DMUQWJZ MW 209.24
DMUQWJZ FM C11H15NO3
DMUQWJZ IC InChI=1S/C11H15NO3/c13-9-3-2-8(6-10(9)14)11(15)4-1-5-12-7-11/h2-3,6,12-15H,1,4-5,7H2
DMUQWJZ CS C1CC(CNC1)(C2=CC(=C(C=C2)O)O)O
DMUQWJZ IK REBGJGKBMBFBHE-UHFFFAOYSA-N
DMUQWJZ IU 4-(3-hydroxypiperidin-3-yl)benzene-1,2-diol
DMUQWJZ DE Discovery agent
DMO8SQA ID DMO8SQA
DMO8SQA DN 4-(3-methoxy-benzylideneamino)-benzenesulfonamide
DMO8SQA HS Investigative
DMO8SQA SN CHEMBL271930; NSC720589; AC1L8N6O; CTK7A8689; BDBM50371745; NSC-720589; 4-[(3-Methoxy-benzylidene)-amino]-benzenesulfonamide; 4-[(3-methoxyphenyl)methylideneamino]benzenesulfonamide
DMO8SQA DT Small molecular drug
DMO8SQA PC 404378
DMO8SQA MW 290.34
DMO8SQA FM C14H14N2O3S
DMO8SQA IC InChI=1S/C14H14N2O3S/c1-19-13-4-2-3-11(9-13)10-16-12-5-7-14(8-6-12)20(15,17)18/h2-10H,1H3,(H2,15,17,18)
DMO8SQA CS COC1=CC=CC(=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DMO8SQA IK PMXSUWQVMRZMRV-UHFFFAOYSA-N
DMO8SQA IU 4-[(3-methoxyphenyl)methylideneamino]benzenesulfonamide
DMO8SQA DE Discovery agent
DMTPL0C ID DMTPL0C
DMTPL0C DN 4-(3-methoxybenzylthio)-2-aminobutanoic acid
DMTPL0C HS Investigative
DMTPL0C SN CHEMBL204963; 4-(3-methoxybenzylthio)-2-aminobutanoic acid; BDBM50179714
DMTPL0C DT Small molecular drug
DMTPL0C PC 44408325
DMTPL0C MW 255.34
DMTPL0C FM C12H17NO3S
DMTPL0C IC InChI=1S/C12H17NO3S/c1-16-10-4-2-3-9(7-10)8-17-6-5-11(13)12(14)15/h2-4,7,11H,5-6,8,13H2,1H3,(H,14,15)
DMTPL0C CS COC1=CC=CC(=C1)CSCCC(C(=O)O)N
DMTPL0C IK WAUOPBRKRQFQTA-UHFFFAOYSA-N
DMTPL0C IU 2-amino-4-[(3-methoxyphenyl)methylsulfanyl]butanoic acid
DMTPL0C DE Discovery agent
DMSUFJZ ID DMSUFJZ
DMSUFJZ DN 4-(3-Methoxy-phenyl)-isoxazolidine-3,5-dione
DMSUFJZ HS Investigative
DMSUFJZ SN 3,5-Isoxazolidinedione, 4-(3-methoxyphenyl)-; CHEMBL165286
DMSUFJZ DT Small molecular drug
DMSUFJZ PC 12762411
DMSUFJZ MW 207.18
DMSUFJZ FM C10H9NO4
DMSUFJZ IC InChI=1S/C10H9NO4/c1-14-7-4-2-3-6(5-7)8-9(12)11-15-10(8)13/h2-5,8H,1H3,(H,11,12)
DMSUFJZ CS COC1=CC=CC(=C1)C2C(=O)NOC2=O
DMSUFJZ IK GTLJNZXLCZDZRN-UHFFFAOYSA-N
DMSUFJZ IU 4-(3-methoxyphenyl)-1,2-oxazolidine-3,5-dione
DMSUFJZ DE Discovery agent
DMGCPKU ID DMGCPKU
DMGCPKU DN 4-(3-methoxyphenylethynyl)-2-methylthiazole
DMGCPKU HS Investigative
DMGCPKU SN CHEMBL440220; 4-(3-methoxyphenylethynyl)-2-methylthiazole; Thiazole, 4-[2-(3-methoxyphenyl)ethynyl]-2-methyl-; SCHEMBL4150915; BDBM50181739
DMGCPKU DT Small molecular drug
DMGCPKU PC 11564861
DMGCPKU MW 229.3
DMGCPKU FM C13H11NOS
DMGCPKU IC InChI=1S/C13H11NOS/c1-10-14-12(9-16-10)7-6-11-4-3-5-13(8-11)15-2/h3-5,8-9H,1-2H3
DMGCPKU CS CC1=NC(=CS1)C#CC2=CC(=CC=C2)OC
DMGCPKU IK OFMNNPTVFPHRMM-UHFFFAOYSA-N
DMGCPKU IU 4-[2-(3-methoxyphenyl)ethynyl]-2-methyl-1,3-thiazole
DMGCPKU DE Discovery agent
DM67A4U ID DM67A4U
DM67A4U DN 4-(3-Methyl-indole-1-sulfonyl)-phenylamine
DM67A4U HS Investigative
DM67A4U SN CHEMBL328816; SCHEMBL14642142; BDBM34150; n1-(4-aminobenzenesulfonyl)skatole; N-arenesulfonylindole antagonist, 9; 4-(3-methyl-1H-indole-1-sulfonyl)aniline, 8
DM67A4U DT Small molecular drug
DM67A4U PC 10356663
DM67A4U MW 286.4
DM67A4U FM C15H14N2O2S
DM67A4U IC InChI=1S/C15H14N2O2S/c1-11-10-17(15-5-3-2-4-14(11)15)20(18,19)13-8-6-12(16)7-9-13/h2-10H,16H2,1H3
DM67A4U CS CC1=CN(C2=CC=CC=C12)S(=O)(=O)C3=CC=C(C=C3)N
DM67A4U IK ZNRJXSHXWJKTGJ-UHFFFAOYSA-N
DM67A4U IU 4-(3-methylindol-1-yl)sulfonylaniline
DM67A4U DE Discovery agent
DM5I6O2 ID DM5I6O2
DM5I6O2 DN 4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide
DM5I6O2 HS Investigative
DM5I6O2 SN CHEMBL215015; 4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide
DM5I6O2 DT Small molecular drug
DM5I6O2 PC 44416783
DM5I6O2 MW 302.4
DM5I6O2 FM C20H18N2O
DM5I6O2 IC InChI=1S/C20H18N2O/c1-14-5-11-18(12-6-14)22-20(23)17-9-7-16(8-10-17)19-15(2)4-3-13-21-19/h3-13H,1-2H3,(H,22,23)
DM5I6O2 CS CC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=C(C=CC=N3)C
DM5I6O2 IK ACHPKRXTLZWRLG-UHFFFAOYSA-N
DM5I6O2 IU N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)benzamide
DM5I6O2 DE Discovery agent
DMD94OB ID DMD94OB
DMD94OB DN 4-(3-nitro-benzylideneamino)-benzenesulfonamide
DMD94OB HS Investigative
DMD94OB SN CHEMBL404921; BDBM50371766; AKOS003620777
DMD94OB DT Small molecular drug
DMD94OB PC 21177358
DMD94OB MW 305.31
DMD94OB FM C13H11N3O4S
DMD94OB IC InChI=1S/C13H11N3O4S/c14-21(19,20)13-6-4-11(5-7-13)15-9-10-2-1-3-12(8-10)16(17)18/h1-9H,(H2,14,19,20)
DMD94OB CS C1=CC(=CC(=C1)[N+](=O)[O-])C=NC2=CC=C(C=C2)S(=O)(=O)N
DMD94OB IK QDRKXDMYDRNCDI-UHFFFAOYSA-N
DMD94OB IU 4-[(3-nitrophenyl)methylideneamino]benzenesulfonamide
DMD94OB DE Discovery agent
DM4WI0Y ID DM4WI0Y
DM4WI0Y DN 4-(3-nitrobenzylthio)-2-aminobutanoic acid
DM4WI0Y HS Investigative
DM4WI0Y SN CHEMBL204478; 4-(3-nitrobenzylthio)-2-aminobutanoic acid; BDBM50179690
DM4WI0Y DT Small molecular drug
DM4WI0Y PC 44408227
DM4WI0Y MW 270.31
DM4WI0Y FM C11H14N2O4S
DM4WI0Y IC InChI=1S/C11H14N2O4S/c12-10(11(14)15)4-5-18-7-8-2-1-3-9(6-8)13(16)17/h1-3,6,10H,4-5,7,12H2,(H,14,15)
DM4WI0Y CS C1=CC(=CC(=C1)[N+](=O)[O-])CSCCC(C(=O)O)N
DM4WI0Y IK OLFRZJABCSLPAK-UHFFFAOYSA-N
DM4WI0Y IU 2-amino-4-[(3-nitrophenyl)methylsulfanyl]butanoic acid
DM4WI0Y DE Discovery agent
DMEYV1B ID DMEYV1B
DMEYV1B DN 4-(3-Pent-1-ynyl-benzyl)-1H-imidazole
DMEYV1B HS Investigative
DMEYV1B SN CHEMBL451399; BDBM22540; 4-Benzyl-1H-imidazole derivative, 21
DMEYV1B DT Small molecular drug
DMEYV1B PC 24825518
DMEYV1B MW 224.3
DMEYV1B FM C15H16N2
DMEYV1B IC InChI=1S/C15H16N2/c1-2-3-4-6-13-7-5-8-14(9-13)10-15-11-16-12-17-15/h5,7-9,11-12H,2-3,10H2,1H3,(H,16,17)
DMEYV1B CS CCCC#CC1=CC=CC(=C1)CC2=CN=CN2
DMEYV1B IK JAPGJDHRYBFKBD-UHFFFAOYSA-N
DMEYV1B IU 5-[(3-pent-1-ynylphenyl)methyl]-1H-imidazole
DMEYV1B DE Discovery agent
DMSXG23 ID DMSXG23
DMSXG23 DN 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole
DMSXG23 HS Investigative
DMSXG23 SN CHEMBL428206; 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969160; CTK8F9477; BDBM50200766
DMSXG23 DT Small molecular drug
DMSXG23 PC 16216595
DMSXG23 MW 262.27
DMSXG23 FM C15H10N4O
DMSXG23 IC InChI=1S/C15H10N4O/c16-10-14-15(18-19-17-14)11-6-8-13(9-7-11)20-12-4-2-1-3-5-12/h1-9H,(H,17,18,19)
DMSXG23 CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=NNN=C3C#N
DMSXG23 IK LHOBXXROLCTUBM-UHFFFAOYSA-N
DMSXG23 IU 5-(4-phenoxyphenyl)-2H-triazole-4-carbonitrile
DMSXG23 DE Discovery agent
DM5F13I ID DM5F13I
DM5F13I DN 4-(3-Phenoxy-propyl)-1H-imidazole
DM5F13I HS Investigative
DM5F13I SN CHEMBL112951; CHEMBL128923; 4-(3-Phenoxypropyl)-1H-imidazole; BDBM50092833; 4-(3-Phenoxy-propyl)-1H-imidazole with (0.95M)oxalic acid
DM5F13I DT Small molecular drug
DM5F13I PC 10774476
DM5F13I MW 202.25
DM5F13I FM C12H14N2O
DM5F13I IC InChI=1S/C12H14N2O/c1-2-6-12(7-3-1)15-8-4-5-11-9-13-10-14-11/h1-3,6-7,9-10H,4-5,8H2,(H,13,14)
DM5F13I CS C1=CC=C(C=C1)OCCCC2=CN=CN2
DM5F13I IK DOOCQHQHBHNOGX-UHFFFAOYSA-N
DM5F13I IU 5-(3-phenoxypropyl)-1H-imidazole
DM5F13I DE Discovery agent
DMEJF6V ID DMEJF6V
DMEJF6V DN 4-(3-phenyl-1H-indol-2-yl)phenol
DMEJF6V HS Investigative
DMEJF6V SN CHEMBL199766; 4-(3-phenyl-1H-indol-2-yl)phenol; SCHEMBL7040440; BDBM50175418
DMEJF6V DT Small molecular drug
DMEJF6V PC 44405867
DMEJF6V MW 285.3
DMEJF6V FM C20H15NO
DMEJF6V IC InChI=1S/C20H15NO/c22-16-12-10-15(11-13-16)20-19(14-6-2-1-3-7-14)17-8-4-5-9-18(17)21-20/h1-13,21-22H
DMEJF6V CS C1=CC=C(C=C1)C2=C(NC3=CC=CC=C32)C4=CC=C(C=C4)O
DMEJF6V IK HRWBDGGFCFVAHP-UHFFFAOYSA-N
DMEJF6V IU 4-(3-phenyl-1H-indol-2-yl)phenol
DMEJF6V DE Discovery agent
DMS4JVT ID DMS4JVT
DMS4JVT DN 4-(3-Phenylethynyl-benzyl)-1H-imidazole
DMS4JVT HS Investigative
DMS4JVT SN CHEMBL449840; BDBM22538; 4-Benzyl-1H-imidazole derivative, 19
DMS4JVT DT Small molecular drug
DMS4JVT PC 24825516
DMS4JVT MW 258.3
DMS4JVT FM C18H14N2
DMS4JVT IC InChI=1S/C18H14N2/c1-2-5-15(6-3-1)9-10-16-7-4-8-17(11-16)12-18-13-19-14-20-18/h1-8,11,13-14H,12H2,(H,19,20)
DMS4JVT CS C1=CC=C(C=C1)C#CC2=CC=CC(=C2)CC3=CN=CN3
DMS4JVT IK VIPAIZRIFZFESY-UHFFFAOYSA-N
DMS4JVT IU 5-[[3-(2-phenylethynyl)phenyl]methyl]-1H-imidazole
DMS4JVT DE Discovery agent
DMRXKMP ID DMRXKMP
DMRXKMP DN 4-(3-pyridylethynyl)-2-thiazolylamine
DMRXKMP HS Investigative
DMRXKMP SN 4-(3-pyridylethynyl)-2-thiazolylamine; CHEMBL381031; 329205-54-1; SCHEMBL4158461
DMRXKMP DT Small molecular drug
DMRXKMP PC 11564671
DMRXKMP MW 201.25
DMRXKMP FM C10H7N3S
DMRXKMP IC InChI=1S/C10H7N3S/c11-10-13-9(7-14-10)4-3-8-2-1-5-12-6-8/h1-2,5-7H,(H2,11,13)
DMRXKMP CS C1=CC(=CN=C1)C#CC2=CSC(=N2)N
DMRXKMP IK BQUGCIBMYSKXRH-UHFFFAOYSA-N
DMRXKMP IU 4-(2-pyridin-3-ylethynyl)-1,3-thiazol-2-amine
DMRXKMP DE Discovery agent
DML4NJU ID DML4NJU
DML4NJU DN 4-(3-thienyl)benzene-1,2-diamine)
DML4NJU HS Investigative
DML4NJU SN SCHEMBL3568658
DML4NJU DT Small molecular drug
DML4NJU PC 13007806
DML4NJU MW 190.27
DML4NJU FM C10H10N2S
DML4NJU IC InChI=1S/C10H10N2S/c11-9-2-1-7(5-10(9)12)8-3-4-13-6-8/h1-6H,11-12H2
DML4NJU CS C1=CC(=C(C=C1C2=CSC=C2)N)N
DML4NJU IK OZEWMDJTNVDPJN-UHFFFAOYSA-N
DML4NJU IU 4-thiophen-3-ylbenzene-1,2-diamine
DML4NJU DE Discovery agent
DM0QRJ3 ID DM0QRJ3
DM0QRJ3 DN 4-(4-((phenethylamino)methyl)phenoxy)benzamide
DM0QRJ3 HS Investigative
DM0QRJ3 SN CHEMBL238317; 4-(4-((phenethylamino)methyl)phenoxy)benzamide; SCHEMBL3692341; FARQYUHOSNLRKV-UHFFFAOYSA-N; BDBM50219921
DM0QRJ3 DT Small molecular drug
DM0QRJ3 PC 44434950
DM0QRJ3 MW 346.4
DM0QRJ3 FM C22H22N2O2
DM0QRJ3 IC InChI=1S/C22H22N2O2/c23-22(25)19-8-12-21(13-9-19)26-20-10-6-18(7-11-20)16-24-15-14-17-4-2-1-3-5-17/h1-13,24H,14-16H2,(H2,23,25)
DM0QRJ3 CS C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=CC=C(C=C3)C(=O)N
DM0QRJ3 IK FARQYUHOSNLRKV-UHFFFAOYSA-N
DM0QRJ3 IU 4-[4-[(2-phenylethylamino)methyl]phenoxy]benzamide
DM0QRJ3 DE Discovery agent
DMWBVMH ID DMWBVMH
DMWBVMH DN 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid
DMWBVMH HS Investigative
DMWBVMH SN CHEMBL76958; 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid
DMWBVMH DT Small molecular drug
DMWBVMH PC 14862522
DMWBVMH MW 349.3
DMWBVMH FM C15H11NO7S
DMWBVMH IC InChI=1S/C15H11NO7S/c17-15(18)12-3-7-14(8-4-12)24(21,22)23-13-5-1-11(2-6-13)9-10-16(19)20/h1-10H,(H,17,18)/b10-9+
DMWBVMH CS C1=CC(=CC=C1/C=C/[N+](=O)[O-])OS(=O)(=O)C2=CC=C(C=C2)C(=O)O
DMWBVMH IK JJLJZGDGOYIKBT-MDZDMXLPSA-N
DMWBVMH IU 4-[4-[(E)-2-nitroethenyl]phenoxy]sulfonylbenzoic acid
DMWBVMH DE Discovery agent
DMA9TCD ID DMA9TCD
DMA9TCD DN 4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol
DMA9TCD HS Investigative
DMA9TCD SN 4-{[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino}phenol; CHEMBL559270; BDBM91658; ZINC36627530; STL255714; AKOS002279368; MCULE-8884798678; N-aryl-4-aryl-1,3-thiazole-2-amine, 6
DMA9TCD DT Small molecular drug
DMA9TCD PC 16645659
DMA9TCD MW 313.3
DMA9TCD FM C15H11N3O3S
DMA9TCD IC InChI=1S/C15H11N3O3S/c19-13-7-3-11(4-8-13)16-15-17-14(9-22-15)10-1-5-12(6-2-10)18(20)21/h1-9,19H,(H,16,17)
DMA9TCD CS C1=CC(=CC=C1C2=CSC(=N2)NC3=CC=C(C=C3)O)[N+](=O)[O-]
DMA9TCD IK PXYPXTOUOYAWOU-UHFFFAOYSA-N
DMA9TCD IU 4-[[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino]phenol
DMA9TCD DE Discovery agent
DM6KIG0 ID DM6KIG0
DM6KIG0 DN 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid
DM6KIG0 HS Investigative
DM6KIG0 SN CHEMBL373275; 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid; BDBM50180608
DM6KIG0 DT Small molecular drug
DM6KIG0 PC 44406790
DM6KIG0 MW 314.4
DM6KIG0 FM C20H26O3
DM6KIG0 IC InChI=1S/C20H26O3/c1-2-3-4-5-6-7-8-9-10-17-11-13-18(14-12-17)19(21)15-16-20(22)23/h11-14H,2-8,15-16H2,1H3,(H,22,23)
DM6KIG0 CS CCCCCCCCC#CC1=CC=C(C=C1)C(=O)CCC(=O)O
DM6KIG0 IK JJPRJMIBECZYNN-UHFFFAOYSA-N
DM6KIG0 IU 4-(4-dec-1-ynylphenyl)-4-oxobutanoic acid
DM6KIG0 DE Discovery agent
DMYXHUO ID DMYXHUO
DMYXHUO DN 4-(4-(pentyloxy)phenoxy)phenol
DMYXHUO HS Investigative
DMYXHUO SN 4-(4-(pentyloxy)phenoxy)phenol; CHEMBL500079
DMYXHUO DT Small molecular drug
DMYXHUO PC 44562857
DMYXHUO MW 272.34
DMYXHUO FM C17H20O3
DMYXHUO IC InChI=1S/C17H20O3/c1-2-3-4-13-19-15-9-11-17(12-10-15)20-16-7-5-14(18)6-8-16/h5-12,18H,2-4,13H2,1H3
DMYXHUO CS CCCCCOC1=CC=C(C=C1)OC2=CC=C(C=C2)O
DMYXHUO IK JYQOLNAVBLFGQA-UHFFFAOYSA-N
DMYXHUO IU 4-(4-pentoxyphenoxy)phenol
DMYXHUO DE Discovery agent
DMVXJU6 ID DMVXJU6
DMVXJU6 DN 4-(4-(thiophen-2-yl)benzyl)pyridine
DMVXJU6 HS Investigative
DMVXJU6 SN CHEMBL1214736; 4-(4-(thiophen-2-yl)benzyl)pyridine; SCHEMBL18770350
DMVXJU6 DT Small molecular drug
DMVXJU6 PC 46901783
DMVXJU6 MW 251.3
DMVXJU6 FM C16H13NS
DMVXJU6 IC InChI=1S/C16H13NS/c1-2-16(18-11-1)15-5-3-13(4-6-15)12-14-7-9-17-10-8-14/h1-11H,12H2
DMVXJU6 CS C1=CSC(=C1)C2=CC=C(C=C2)CC3=CC=NC=C3
DMVXJU6 IK ORQOALYZYXEWJV-UHFFFAOYSA-N
DMVXJU6 IU 4-[(4-thiophen-2-ylphenyl)methyl]pyridine
DMVXJU6 DE Discovery agent
DM7I21V ID DM7I21V
DM7I21V DN 4-(4-(thiophen-3-yl)benzyl)pyridine
DM7I21V HS Investigative
DM7I21V SN CHEMBL1214735; 4-(4-(thiophen-3-yl)benzyl)pyridine; SCHEMBL18770375
DM7I21V DT Small molecular drug
DM7I21V PC 46901784
DM7I21V MW 251.3
DM7I21V FM C16H13NS
DM7I21V IC InChI=1S/C16H13NS/c1-3-15(16-7-10-18-12-16)4-2-13(1)11-14-5-8-17-9-6-14/h1-10,12H,11H2
DM7I21V CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CSC=C3
DM7I21V IK JZVKRZVTIHAZFG-UHFFFAOYSA-N
DM7I21V IU 4-[(4-thiophen-3-ylphenyl)methyl]pyridine
DM7I21V DE Discovery agent
DMOF0J1 ID DMOF0J1
DMOF0J1 DN 4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate
DMOF0J1 HS Investigative
DMOF0J1 SN CHEMBL457882; AC1MCGW6; 4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate; MolPort-002-923-829; HMS1669K08; ZINC4394394; BDBM50274981; CCG-56239; MCULE-6668458781; SR-01000645209-1; [4-(4,5-dihydro-1,3-thiazol-2-yl)phenyl] N-butylcarbamate
DMOF0J1 DT Small molecular drug
DMOF0J1 PC 2743568
DMOF0J1 MW 278.37
DMOF0J1 FM C14H18N2O2S
DMOF0J1 IC InChI=1S/C14H18N2O2S/c1-2-3-8-16-14(17)18-12-6-4-11(5-7-12)13-15-9-10-19-13/h4-7H,2-3,8-10H2,1H3,(H,16,17)
DMOF0J1 CS CCCCNC(=O)OC1=CC=C(C=C1)C2=NCCS2
DMOF0J1 IK OUBMDYCXTDANEM-UHFFFAOYSA-N
DMOF0J1 IU [4-(4,5-dihydro-1,3-thiazol-2-yl)phenyl] N-butylcarbamate
DMOF0J1 DE Discovery agent
DMI1598 ID DMI1598
DMI1598 DN 4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine
DMI1598 HS Investigative
DMI1598 SN CHEMBL200844; 4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine
DMI1598 DT Small molecular drug
DMI1598 PC 44405257
DMI1598 MW 362.32
DMI1598 FM C14H10N4O6S
DMI1598 IC InChI=1S/C14H10N4O6S/c15-9-1-3-11(4-2-9)25(23,24)16-6-5-12-13(16)7-10(17(19)20)8-14(12)18(21)22/h1-8H,15H2
DMI1598 CS C1=CC(=CC=C1N)S(=O)(=O)N2C=CC3=C2C=C(C=C3[N+](=O)[O-])[N+](=O)[O-]
DMI1598 IK NMGNRDGVTLTPFO-UHFFFAOYSA-N
DMI1598 IU 4-(4,6-dinitroindol-1-yl)sulfonylaniline
DMI1598 DE Discovery agent
DMETK18 ID DMETK18
DMETK18 DN 4-(4,6-diphenylpyridin-2-yl)phenol
DMETK18 HS Investigative
DMETK18 DT Small molecular drug
DMETK18 PC 135838975
DMETK18 MW 323.4
DMETK18 FM C23H17NO
DMETK18 IC InChI=1S/C23H17NO/c25-21-13-11-19(12-14-21)23-16-20(17-7-3-1-4-8-17)15-22(24-23)18-9-5-2-6-10-18/h1-16,25H
DMETK18 CS C1=CC=C(C=C1)C2=CC(=NC(=C2)C3=CC=C(C=C3)O)C4=CC=CC=C4
DMETK18 IK LARDQALKCMOPHD-UHFFFAOYSA-N
DMETK18 IU 4-(4,6-diphenylpyridin-2-yl)phenol
DMETK18 DE Discovery agent
DMGOTYC ID DMGOTYC
DMGOTYC DN 4'-(4-Aminobenzensulfonamide)-4-hydroxychalcone
DMGOTYC HS Investigative
DMGOTYC SN CHEMBL1087578; SCHEMBL3484498; BDBM50316856; 4''-(4-Aminobenzensulfonamide)-4-hydroxychalcone
DMGOTYC DT Small molecular drug
DMGOTYC PC 24989956
DMGOTYC MW 394.4
DMGOTYC FM C21H18N2O4S
DMGOTYC IC InChI=1S/C21H18N2O4S/c22-17-6-12-20(13-7-17)28(26,27)23-18-8-4-16(5-9-18)21(25)14-3-15-1-10-19(24)11-2-15/h1-14,23-24H,22H2/b14-3+
DMGOTYC CS C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)N)O
DMGOTYC IK HMCALLLWIUWUTM-LZWSPWQCSA-N
DMGOTYC IU 4-amino-N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]benzenesulfonamide
DMGOTYC DE Discovery agent
DMK1IWD ID DMK1IWD
DMK1IWD DN 4-(4-aminophenyl)-1H-indazol-3yl-amine
DMK1IWD HS Investigative
DMK1IWD SN 4-(4-aminophenyl)-1H-indazol-3-amine; 819058-89-4; CHEMBL222778; Flt3 Inhibitor IV; 4-(4-aminophenyl)-1H-indazol-3yl-amine; SCHEMBL421242; DTXSID90583110; 3-amino-4-(4-aminophenyl)indazole; BDBM50207472; ZINC35324130; AKOS025401748; QC-1103; AC-25079; 1H-Indazol-3-amine,4-(4-aminophenyl)-
DMK1IWD DT Small molecular drug
DMK1IWD PC 16125106
DMK1IWD MW 224.26
DMK1IWD FM C13H12N4
DMK1IWD IC InChI=1S/C13H12N4/c14-9-6-4-8(5-7-9)10-2-1-3-11-12(10)13(15)17-16-11/h1-7H,14H2,(H3,15,16,17)
DMK1IWD CS C1=CC(=C2C(=C1)NN=C2N)C3=CC=C(C=C3)N
DMK1IWD IK KHQLSBOHZQJRPC-UHFFFAOYSA-N
DMK1IWD IU 4-(4-aminophenyl)-1H-indazol-3-amine
DMK1IWD CA CAS 819058-89-4
DMK1IWD DE Discovery agent
DMP0G1W ID DMP0G1W
DMP0G1W DN 4-(4-benzenesulfonamidophenyl)piperazine
DMP0G1W HS Investigative
DMP0G1W SN 4-(4-benzenesulfonamidophenyl)piperazine; CHEMBL426332; SCHEMBL18553766
DMP0G1W DT Small molecular drug
DMP0G1W PC 11849789
DMP0G1W MW 317.4
DMP0G1W FM C16H19N3O2S
DMP0G1W IC InChI=1S/C16H19N3O2S/c20-22(21,16-4-2-1-3-5-16)18-14-6-8-15(9-7-14)19-12-10-17-11-13-19/h1-9,17-18H,10-13H2
DMP0G1W CS C1CN(CCN1)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=CC=C3
DMP0G1W IK LHOHHFFMBNKDDU-UHFFFAOYSA-N
DMP0G1W IU N-(4-piperazin-1-ylphenyl)benzenesulfonamide
DMP0G1W DE Discovery agent
DM0DZFX ID DM0DZFX
DM0DZFX DN 4-(4-benzenesulfonylphenyl)piperazine
DM0DZFX HS Investigative
DM0DZFX SN 4-(4-benzenesulfonylphenyl)piperazine; CHEMBL211577; 1-[4-(benzenesulfonyl)phenyl]piperazine; AC1NOI8E; SCHEMBL4573254; 4-(1-Piperazinyl)diphenyl sulfone; ZINC3716178; BDBM50193458; AKOS025215167; MCULE-7301402628
DM0DZFX DT Small molecular drug
DM0DZFX PC 5113605
DM0DZFX MW 302.4
DM0DZFX FM C16H18N2O2S
DM0DZFX IC InChI=1S/C16H18N2O2S/c19-21(20,15-4-2-1-3-5-15)16-8-6-14(7-9-16)18-12-10-17-11-13-18/h1-9,17H,10-13H2
DM0DZFX CS C1CN(CCN1)C2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3
DM0DZFX IK SZAOHADKAZDUGT-UHFFFAOYSA-N
DM0DZFX IU 1-[4-(benzenesulfonyl)phenyl]piperazine
DM0DZFX DE Discovery agent
DMT2S9U ID DMT2S9U
DMT2S9U DN 4-(4-benzyl-1H-1,2,3-triazol-1-yl)phenol
DMT2S9U HS Investigative
DMT2S9U SN CHEMBL1288977
DMT2S9U DT Small molecular drug
DMT2S9U PC 52947733
DMT2S9U MW 251.28
DMT2S9U FM C15H13N3O
DMT2S9U IC InChI=1S/C15H13N3O/c19-15-8-6-14(7-9-15)18-11-13(16-17-18)10-12-4-2-1-3-5-12/h1-9,11,19H,10H2
DMT2S9U CS C1=CC=C(C=C1)CC2=CN(N=N2)C3=CC=C(C=C3)O
DMT2S9U IK ZSQDQVRTOOCIEW-UHFFFAOYSA-N
DMT2S9U IU 4-(4-benzyltriazol-1-yl)phenol
DMT2S9U DE Discovery agent
DME3PUT ID DME3PUT
DME3PUT DN 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine
DME3PUT HS Investigative
DME3PUT SN benzylamine 6; CHEMBL179938; BDBM13580
DME3PUT DT Small molecular drug
DME3PUT PC 23646462
DME3PUT MW 361.4
DME3PUT FM C22H23N3O2
DME3PUT IC InChI=1S/C22H23N3O2/c1-26-21-13-17(14-25-19-10-8-18(9-11-19)22(23)24)7-12-20(21)27-15-16-5-3-2-4-6-16/h2-13,25H,14-15H2,1H3,(H3,23,24)
DME3PUT CS COC1=C(C=CC(=C1)CNC2=CC=C(C=C2)C(=N)N)OCC3=CC=CC=C3
DME3PUT IK YPLDWUAEABIXKN-UHFFFAOYSA-N
DME3PUT IU 4-[(3-methoxy-4-phenylmethoxyphenyl)methylamino]benzenecarboximidamide
DME3PUT DE Discovery agent
DMXAEW9 ID DMXAEW9
DMXAEW9 DN 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9 HS Investigative
DMXAEW9 SN CHEMBL88837; 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole
DMXAEW9 DT Small molecular drug
DMXAEW9 PC 44323762
DMXAEW9 MW 292.4
DMXAEW9 FM C18H20N4
DMXAEW9 IC InChI=1S/C18H20N4/c1-2-5-15(6-3-1)13-21-9-11-22(12-10-21)17-8-4-7-16-18(17)20-14-19-16/h1-8,14H,9-13H2,(H,19,20)
DMXAEW9 CS C1CN(CCN1CC2=CC=CC=C2)C3=CC=CC4=C3N=CN4
DMXAEW9 IK ZNBOBGDGUIWKPE-UHFFFAOYSA-N
DMXAEW9 IU 4-(4-benzylpiperazin-1-yl)-1H-benzimidazole
DMXAEW9 DE Discovery agent
DMWR0AS ID DMWR0AS
DMWR0AS DN 4-(4-Benzyl-piperazin-1-yl)-1H-indole
DMWR0AS HS Investigative
DMWR0AS SN 4-(4-Benzyl-piperazin-1-yl)-1H-indole; CHEMBL328051; Maybridge2_000682; AC1MBNW0; Oprea1_014756; SCHEMBL2161609; JLZIBIQTDGMAFZ-UHFFFAOYSA-N; BDBM50071857; ZINC53006914
DMWR0AS DT Small molecular drug
DMWR0AS PC 2728532
DMWR0AS MW 291.4
DMWR0AS FM C19H21N3
DMWR0AS IC InChI=1S/C19H21N3/c1-2-5-16(6-3-1)15-21-11-13-22(14-12-21)19-8-4-7-18-17(19)9-10-20-18/h1-10,20H,11-15H2
DMWR0AS CS C1CN(CCN1CC2=CC=CC=C2)C3=CC=CC4=C3C=CN4
DMWR0AS IK JLZIBIQTDGMAFZ-UHFFFAOYSA-N
DMWR0AS IU 4-(4-benzylpiperazin-1-yl)-1H-indole
DMWR0AS DE Discovery agent
DMZ4237 ID DMZ4237
DMZ4237 DN 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237 HS Investigative
DMZ4237 SN CHEMBL311539; 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
DMZ4237 DT Small molecular drug
DMZ4237 PC 44323978
DMZ4237 MW 325.8
DMZ4237 FM C19H20ClN3
DMZ4237 IC InChI=1S/C19H20ClN3/c20-17-6-7-18-16(8-9-21-18)19(17)23-12-10-22(11-13-23)14-15-4-2-1-3-5-15/h1-9,21H,10-14H2
DMZ4237 CS C1CN(CCN1CC2=CC=CC=C2)C3=C(C=CC4=C3C=CN4)Cl
DMZ4237 IK IRFLVVGRMBDQSJ-UHFFFAOYSA-N
DMZ4237 IU 4-(4-benzylpiperazin-1-yl)-5-chloro-1H-indole
DMZ4237 DE Discovery agent
DMVAB7U ID DMVAB7U
DMVAB7U DN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U HS Investigative
DMVAB7U SN CHEMBL90476; 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole
DMVAB7U DT Small molecular drug
DMVAB7U PC 44323962
DMVAB7U MW 370.3
DMVAB7U FM C19H20BrN3
DMVAB7U IC InChI=1S/C19H20BrN3/c20-17-6-7-18(16-8-9-21-19(16)17)23-12-10-22(11-13-23)14-15-4-2-1-3-5-15/h1-9,21H,10-14H2
DMVAB7U CS C1CN(CCN1CC2=CC=CC=C2)C3=C4C=CNC4=C(C=C3)Br
DMVAB7U IK RBUDKKJLRVBPDA-UHFFFAOYSA-N
DMVAB7U IU 4-(4-benzylpiperazin-1-yl)-7-bromo-1H-indole
DMVAB7U DE Discovery agent
DMHWIMO ID DMHWIMO
DMHWIMO DN 4-(4-bromobenzylthio)-2-aminobutanoic acid
DMHWIMO HS Investigative
DMHWIMO SN CHEMBL203746; 4-(4-bromobenzylthio)-2-aminobutanoic acid; BDBM50179700
DMHWIMO DT Small molecular drug
DMHWIMO PC 44408329
DMHWIMO MW 304.21
DMHWIMO FM C11H14BrNO2S
DMHWIMO IC InChI=1S/C11H14BrNO2S/c12-9-3-1-8(2-4-9)7-16-6-5-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)
DMHWIMO CS C1=CC(=CC=C1CSCCC(C(=O)O)N)Br
DMHWIMO IK XUFONRLUGMPMHQ-UHFFFAOYSA-N
DMHWIMO IU 2-amino-4-[(4-bromophenyl)methylsulfanyl]butanoic acid
DMHWIMO DE Discovery agent
DMFEBCO ID DMFEBCO
DMFEBCO DN 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole
DMFEBCO HS Investigative
DMFEBCO SN 4-(4-BROMOPHENYL)-1H-1,2,3-TRIAZOLE-5-CARBONITRILE; CHEMBL238828; 1119392-12-9; AC1O4QZZ; 5-(4-bromophenyl)-2H-triazole-4-carbonitrile; 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL4105736; CTK7C5822; MolPort-006-755-219; ZINC6448351; BDBM50200765; AKOS022169659; MS-8537; KS-000029L0; 4-(4-Bromophenyl)-1H-1,2,3-triazole-5-carbonitrile, AldrichCPR
DMFEBCO DT Small molecular drug
DMFEBCO PC 6411478
DMFEBCO MW 249.07
DMFEBCO FM C9H5BrN4
DMFEBCO IC InChI=1S/C9H5BrN4/c10-7-3-1-6(2-4-7)9-8(5-11)12-14-13-9/h1-4H,(H,12,13,14)
DMFEBCO CS C1=CC(=CC=C1C2=NNN=C2C#N)Br
DMFEBCO IK SKCRCHJZYFYITH-UHFFFAOYSA-N
DMFEBCO IU 5-(4-bromophenyl)-2H-triazole-4-carbonitrile
DMFEBCO DE Discovery agent
DMI2EM5 ID DMI2EM5
DMI2EM5 DN 4-(4-butoxyphenoxy)phenol
DMI2EM5 HS Investigative
DMI2EM5 SN 4-(4-butoxyphenoxy)phenol; CHEMBL467374
DMI2EM5 DT Small molecular drug
DMI2EM5 PC 44562814
DMI2EM5 MW 258.31
DMI2EM5 FM C16H18O3
DMI2EM5 IC InChI=1S/C16H18O3/c1-2-3-12-18-14-8-10-16(11-9-14)19-15-6-4-13(17)5-7-15/h4-11,17H,2-3,12H2,1H3
DMI2EM5 CS CCCCOC1=CC=C(C=C1)OC2=CC=C(C=C2)O
DMI2EM5 IK WZNRRCAQHKVCHJ-UHFFFAOYSA-N
DMI2EM5 IU 4-(4-butoxyphenoxy)phenol
DMI2EM5 DE Discovery agent
DMNGDOM ID DMNGDOM
DMNGDOM DN 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide
DMNGDOM HS Investigative
DMNGDOM SN CHEMBL197632; 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide
DMNGDOM DT Small molecular drug
DMNGDOM PC 44404521
DMNGDOM MW 265.3
DMNGDOM FM C14H19NO4
DMNGDOM IC InChI=1S/C14H19NO4/c1-2-3-10-19-12-6-4-11(5-7-12)13(16)8-9-14(17)15-18/h4-7,18H,2-3,8-10H2,1H3,(H,15,17)
DMNGDOM CS CCCCOC1=CC=C(C=C1)C(=O)CCC(=O)NO
DMNGDOM IK SFIUVAFWSBUQJK-UHFFFAOYSA-N
DMNGDOM IU 4-(4-butoxyphenyl)-N-hydroxy-4-oxobutanamide
DMNGDOM DE Discovery agent
DMM9X0G ID DMM9X0G
DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one
DMM9X0G HS Investigative
DMM9X0G SN 4-(4-Butylpiperidin-1-yl)-1-o-tolylbutan-1-one; AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one
DMM9X0G DT Small molecular drug
DMM9X0G PC 9948320
DMM9X0G MW 301.5
DMM9X0G FM C20H31NO
DMM9X0G IC InChI=1S/C20H31NO/c1-3-4-9-18-12-15-21(16-13-18)14-7-11-20(22)19-10-6-5-8-17(19)2/h5-6,8,10,18H,3-4,7,9,11-16H2,1-2H3
DMM9X0G CS CCCCC1CCN(CC1)CCCC(=O)C2=CC=CC=C2C
DMM9X0G IK ANTKBACNWQHQJE-UHFFFAOYSA-N
DMM9X0G IU 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one
DMM9X0G DE Discovery agent
DM14I6C ID DM14I6C
DM14I6C DN 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid
DM14I6C HS Investigative
DM14I6C SN CHEMBL394496; 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid; BDBM50213928
DM14I6C DT Small molecular drug
DM14I6C PC 43169594
DM14I6C MW 296.79
DM14I6C FM C16H21ClO3
DM14I6C IC InChI=1S/C16H21ClO3/c17-13-8-9-15(20-10-4-7-16(18)19)14(11-13)12-5-2-1-3-6-12/h8-9,11-12H,1-7,10H2,(H,18,19)
DM14I6C CS C1CCC(CC1)C2=C(C=CC(=C2)Cl)OCCCC(=O)O
DM14I6C IK BDEUQTBTFVDWEA-UHFFFAOYSA-N
DM14I6C IU 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid
DM14I6C DE Discovery agent
DMRBEZD ID DMRBEZD
DMRBEZD DN 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one
DMRBEZD HS Investigative
DMRBEZD SN CHEMBL207277; 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one; BDBM50183665; 2-allyl-4-[(4-chlorophenyl)methyl]phthalazin-1-one; 1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-allyl-
DMRBEZD DT Small molecular drug
DMRBEZD PC 15959119
DMRBEZD MW 310.8
DMRBEZD FM C18H15ClN2O
DMRBEZD IC InChI=1S/C18H15ClN2O/c1-2-11-21-18(22)16-6-4-3-5-15(16)17(20-21)12-13-7-9-14(19)10-8-13/h2-10H,1,11-12H2
DMRBEZD CS C=CCN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl
DMRBEZD IK OHEWOPKEAKDVRX-UHFFFAOYSA-N
DMRBEZD IU 4-[(4-chlorophenyl)methyl]-2-prop-2-enylphthalazin-1-one
DMRBEZD DE Discovery agent
DMNYQGV ID DMNYQGV
DMNYQGV DN 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one
DMNYQGV HS Investigative
DMNYQGV SN CHEMBL67457; 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one; 4-[(4-chlorophenyl)methyl]-2-methyl-phthalazin-1-one; BDBM50131411; 4-(4-Chloro-benzyl)-2-methyl-2H-phthalazin-1-one; 2-Methyl-4-(4-chlorobenzyl)-1,2-dihydrophthalazine-1-one; 1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-methyl-
DMNYQGV DT Small molecular drug
DMNYQGV PC 11522042
DMNYQGV MW 284.74
DMNYQGV FM C16H13ClN2O
DMNYQGV IC InChI=1S/C16H13ClN2O/c1-19-16(20)14-5-3-2-4-13(14)15(18-19)10-11-6-8-12(17)9-7-11/h2-9H,10H2,1H3
DMNYQGV CS CN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl
DMNYQGV IK QZOXWSKLFOUEKD-UHFFFAOYSA-N
DMNYQGV IU 4-[(4-chlorophenyl)methyl]-2-methylphthalazin-1-one
DMNYQGV DE Discovery agent
DM9AEF0 ID DM9AEF0
DM9AEF0 DN 4-(4-chlorobenzyl)phthalazin-1(2H)-one
DM9AEF0 HS Investigative
DM9AEF0 SN 53242-88-9; 4-(4-chlorobenzyl)phthalazin-1(2H)-one; 4-(4-Chloro-benzyl)-2H-phthalazin-1-one; 4-[(4-chlorophenyl)methyl]-2H-phthalazin-1-one; UNII-56DW142LLX; MLS000547504; 4-(4-chlorobenzyl)phthalazin-1-ol; CHEMBL63976; 4-(4-chlorobenzyl)-1(2H)-phthalazinone; 56DW142LLX; 4-[(4-CHLOROPHENYL)METHYL]PHTHALAZIN-1(2H)-ONE; SMR000113649; 4-(4-Chlorobenzyl)-2H-phthalazin-1-one; 4-[(4-Chlorophenyl)methyl]-1(2H)-phthalazinone; 4-((4-Chlorophenyl)methyl)phthalazin-1(2H)-one; W-109042; 4-{[4-chlorophenyl]methyl}-1(2H)-phthalazinone
DM9AEF0 DT Small molecular drug
DM9AEF0 PC 104452
DM9AEF0 MW 270.71
DM9AEF0 FM C15H11ClN2O
DM9AEF0 IC InChI=1S/C15H11ClN2O/c16-11-7-5-10(6-8-11)9-14-12-3-1-2-4-13(12)15(19)18-17-14/h1-8H,9H2,(H,18,19)
DM9AEF0 CS C1=CC=C2C(=C1)C(=NNC2=O)CC3=CC=C(C=C3)Cl
DM9AEF0 IK NLXGCQIEVZYDRS-UHFFFAOYSA-N
DM9AEF0 IU 4-[(4-chlorophenyl)methyl]-2H-phthalazin-1-one
DM9AEF0 CA CAS 53242-88-9
DM9AEF0 DE Discovery agent
DMENLUP ID DMENLUP
DMENLUP DN 4-(4-chlorobenzylthio)-2-aminobutanoic acid
DMENLUP HS Investigative
DMENLUP SN CHEMBL377079; 4-(4-chlorobenzylthio)-2-aminobutanoic acid; BDBM50179703
DMENLUP DT Small molecular drug
DMENLUP PC 44408321
DMENLUP MW 259.75
DMENLUP FM C11H14ClNO2S
DMENLUP IC InChI=1S/C11H14ClNO2S/c12-9-3-1-8(2-4-9)7-16-6-5-10(13)11(14)15/h1-4,10H,5-7,13H2,(H,14,15)
DMENLUP CS C1=CC(=CC=C1CSCCC(C(=O)O)N)Cl
DMENLUP IK ALRMSMDJCRNGNM-UHFFFAOYSA-N
DMENLUP IU 2-amino-4-[(4-chlorophenyl)methylsulfanyl]butanoic acid
DMENLUP DE Discovery agent
DMJI6QH ID DMJI6QH
DMJI6QH DN 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole
DMJI6QH HS Investigative
DMJI6QH SN CHEMBL206705
DMJI6QH DT Small molecular drug
DMJI6QH PC 44408653
DMJI6QH MW 255.7
DMJI6QH FM C14H10ClN3
DMJI6QH IC InChI=1S/C14H10ClN3/c15-13-6-4-11(5-7-13)12-9-17-18(10-12)14-3-1-2-8-16-14/h1-10H
DMJI6QH CS C1=CC=NC(=C1)N2C=C(C=N2)C3=CC=C(C=C3)Cl
DMJI6QH IK NJMIDEUMQUSYDE-UHFFFAOYSA-N
DMJI6QH IU 2-[4-(4-chlorophenyl)pyrazol-1-yl]pyridine
DMJI6QH DE Discovery agent
DMODVGN ID DMODVGN
DMODVGN DN 4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole
DMODVGN HS Investigative
DMODVGN SN CHEMBL522624; 4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole
DMODVGN DT Small molecular drug
DMODVGN PC 44564458
DMODVGN MW 301.8
DMODVGN FM C16H12ClNOS
DMODVGN IC InChI=1S/C16H12ClNOS/c1-19-14-8-4-12(5-9-14)16-15(10-18-20-16)11-2-6-13(17)7-3-11/h2-10H,1H3
DMODVGN CS COC1=CC=C(C=C1)C2=C(C=NS2)C3=CC=C(C=C3)Cl
DMODVGN IK OORIOMOWZWWCHX-UHFFFAOYSA-N
DMODVGN IU 4-(4-chlorophenyl)-5-(4-methoxyphenyl)-1,2-thiazole
DMODVGN DE Discovery agent
DMVN7GC ID DMVN7GC
DMVN7GC DN 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole
DMVN7GC HS Investigative
DMVN7GC SN CHEMBL393014; 5-(4-CHLORO-PHENYL)-3H-[1,2,3]TRIAZOLE-4-CARBONITRILE; 50710-06-0; 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969183; CTK1G7781; BDBM50200758; ZINC22004877; AKOS015967718; FCH1390661; ACM50710060
DMVN7GC DT Small molecular drug
DMVN7GC PC 11183327
DMVN7GC MW 204.61
DMVN7GC FM C9H5ClN4
DMVN7GC IC InChI=1S/C9H5ClN4/c10-7-3-1-6(2-4-7)9-8(5-11)12-14-13-9/h1-4H,(H,12,13,14)
DMVN7GC CS C1=CC(=CC=C1C2=NNN=C2C#N)Cl
DMVN7GC IK KBDVIKMDRWVMPM-UHFFFAOYSA-N
DMVN7GC IU 5-(4-chlorophenyl)-2H-triazole-4-carbonitrile
DMVN7GC DE Discovery agent
DMZBEYO ID DMZBEYO
DMZBEYO DN 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole
DMZBEYO HS Investigative
DMZBEYO SN CHEMBL471171; 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole
DMZBEYO DT Small molecular drug
DMZBEYO PC 24884693
DMZBEYO MW 332.7
DMZBEYO FM C16H12ClNSe
DMZBEYO IC InChI=1S/C16H12ClNSe/c1-11-2-4-13(5-3-11)16-15(10-18-19-16)12-6-8-14(17)9-7-12/h2-10H,1H3
DMZBEYO CS CC1=CC=C(C=C1)C2=C(C=N[Se]2)C3=CC=C(C=C3)Cl
DMZBEYO IK NMKXOVXYAQBXPT-UHFFFAOYSA-N
DMZBEYO IU 4-(4-chlorophenyl)-5-(4-methylphenyl)-1,2-selenazole
DMZBEYO DE Discovery agent
DMVDF9Q ID DMVDF9Q
DMVDF9Q DN 4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one
DMVDF9Q HS Investigative
DMVDF9Q SN CHEMBL504541; 4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one
DMVDF9Q DT Small molecular drug
DMVDF9Q PC 44564004
DMVDF9Q MW 318.8
DMVDF9Q FM C16H11ClOS2
DMVDF9Q IC InChI=1S/C16H11ClOS2/c1-10-2-4-12(5-3-10)15-14(16(18)20-19-15)11-6-8-13(17)9-7-11/h2-9H,1H3
DMVDF9Q CS CC1=CC=C(C=C1)C2=C(C(=O)SS2)C3=CC=C(C=C3)Cl
DMVDF9Q IK NLGIFTIQVVCDPR-UHFFFAOYSA-N
DMVDF9Q IU 4-(4-chlorophenyl)-5-(4-methylphenyl)dithiol-3-one
DMVDF9Q DE Discovery agent
DMMK9RC ID DMMK9RC
DMMK9RC DN 4-(4-Chlorophenyl)-5-p-tolylisothiazole
DMMK9RC HS Investigative
DMMK9RC SN CHEMBL490889; 4-(4-Chlorophenyl)-5-p-tolylisothiazole
DMMK9RC DT Small molecular drug
DMMK9RC PC 44564455
DMMK9RC MW 285.8
DMMK9RC FM C16H12ClNS
DMMK9RC IC InChI=1S/C16H12ClNS/c1-11-2-4-13(5-3-11)16-15(10-18-19-16)12-6-8-14(17)9-7-12/h2-10H,1H3
DMMK9RC CS CC1=CC=C(C=C1)C2=C(C=NS2)C3=CC=C(C=C3)Cl
DMMK9RC IK YLLFNDIXMCYHET-UHFFFAOYSA-N
DMMK9RC IU 4-(4-chlorophenyl)-5-(4-methylphenyl)-1,2-thiazole
DMMK9RC DE Discovery agent
DM9YRHW ID DM9YRHW
DM9YRHW DN 4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine
DM9YRHW HS Investigative
DM9YRHW SN CHEMBL208731; 4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine; 4-[(4-chlorophenyl)thio]-2-pyridin-2-ylpyrimidine; SCHEMBL8280517; BDBM50182822
DM9YRHW DT Small molecular drug
DM9YRHW PC 11381029
DM9YRHW MW 299.8
DM9YRHW FM C15H10ClN3S
DM9YRHW IC InChI=1S/C15H10ClN3S/c16-11-4-6-12(7-5-11)20-14-8-10-18-15(19-14)13-3-1-2-9-17-13/h1-10H
DM9YRHW CS C1=CC=NC(=C1)C2=NC=CC(=N2)SC3=CC=C(C=C3)Cl
DM9YRHW IK GJICJCYMPFHBPO-UHFFFAOYSA-N
DM9YRHW IU 4-(4-chlorophenyl)sulfanyl-2-pyridin-2-ylpyrimidine
DM9YRHW DE Discovery agent
DMNEAJH ID DMNEAJH
DMNEAJH DN 4-(4-Cyanophenoxy)-3-pyridinesulfonamide
DMNEAJH HS Investigative
DMNEAJH SN CHEMBL1164572; 4-(4-Cyanophenoxy)-3-pyridinesulfonamide; BDBM50320503
DMNEAJH DT Small molecular drug
DMNEAJH PC 46703769
DMNEAJH MW 275.29
DMNEAJH FM C12H9N3O3S
DMNEAJH IC InChI=1S/C12H9N3O3S/c13-7-9-1-3-10(4-2-9)18-11-5-6-15-8-12(11)19(14,16)17/h1-6,8H,(H2,14,16,17)
DMNEAJH CS C1=CC(=CC=C1C#N)OC2=C(C=NC=C2)S(=O)(=O)N
DMNEAJH IK SUYXGHCYAUOKRH-UHFFFAOYSA-N
DMNEAJH IU 4-(4-cyanophenoxy)pyridine-3-sulfonamide
DMNEAJH DE Discovery agent
DMSYH8R ID DMSYH8R
DMSYH8R DN 4-(4-cyclohexylthiosemicarbazono)methyl-phenol
DMSYH8R HS Investigative
DMSYH8R DT Small molecular drug
DMSYH8R PC 135562887
DMSYH8R MW 277.39
DMSYH8R FM C14H19N3OS
DMSYH8R IC InChI=1S/C14H19N3OS/c18-13-8-6-11(7-9-13)10-15-17-14(19)16-12-4-2-1-3-5-12/h6-10,12,18H,1-5H2,(H2,16,17,19)/b15-10+
DMSYH8R CS C1CCC(CC1)NC(=S)N/N=C/C2=CC=C(C=C2)O
DMSYH8R IK GRDLPUUYRVMQPX-XNTDXEJSSA-N
DMSYH8R IU 1-cyclohexyl-3-[(E)-(4-hydroxyphenyl)methylideneamino]thiourea
DMSYH8R DE Discovery agent
DMCDKHJ ID DMCDKHJ
DMCDKHJ DN 4-(4-Decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one
DMCDKHJ HS Investigative
DMCDKHJ SN CHEMBL462600
DMCDKHJ DT Small molecular drug
DMCDKHJ PC 25059818
DMCDKHJ MW 358.4
DMCDKHJ FM C20H29F3O2
DMCDKHJ IC InChI=1S/C20H29F3O2/c1-2-3-4-5-6-7-8-9-16-25-18-13-10-17(11-14-18)12-15-19(24)20(21,22)23/h10-11,13-14H,2-9,12,15-16H2,1H3
DMCDKHJ CS CCCCCCCCCCOC1=CC=C(C=C1)CCC(=O)C(F)(F)F
DMCDKHJ IK DJDSHOVBFZKIEK-UHFFFAOYSA-N
DMCDKHJ IU 4-(4-decoxyphenyl)-1,1,1-trifluorobutan-2-one
DMCDKHJ DE Discovery agent
DMA6E28 ID DMA6E28
DMA6E28 DN 4'-(4-Fluorobenzensulfonamide)-4-hydroxychalcone
DMA6E28 HS Investigative
DMA6E28 SN CHEMBL1087448; SCHEMBL3483870; BDBM50316857
DMA6E28 DT Small molecular drug
DMA6E28 PC 24757297
DMA6E28 MW 397.4
DMA6E28 FM C21H16FNO4S
DMA6E28 IC InChI=1S/C21H16FNO4S/c22-17-6-12-20(13-7-17)28(26,27)23-18-8-4-16(5-9-18)21(25)14-3-15-1-10-19(24)11-2-15/h1-14,23-24H/b14-3+
DMA6E28 CS C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)F)O
DMA6E28 IK SRDYAWAEKAHCHN-LZWSPWQCSA-N
DMA6E28 IU 4-fluoro-N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]benzenesulfonamide
DMA6E28 DE Discovery agent
DMW8IN3 ID DMW8IN3
DMW8IN3 DN 4-(4-FLUOROBENZYL)PIPERIDINE
DMW8IN3 HS Investigative
DMW8IN3 SN 4-(4'-Fluorobenzyl)piperidine; 92822-02-1; 4-[(4-fluorophenyl)methyl]piperidine; 4-(4-fluorobenzyl)piperidine; 4-(4-fluoro-benzyl)-piperidine; PIPERIDINE, 4-[(4-FLUOROPHENYL)METHYL]-; CHEMBL144527; piperidine 4; PubChem12570; AC1Q4MDN; chembrdg-bb 4010301; AC1MWI24; SCHEMBL895063; 4-(4-fluorobenzyl)-piperidine; 4-(4'-fluorobenzyl) piperidine; CTK8F5377; BDBM15788; DTXSID30395219; JLAKCHGEEBPDQI-UHFFFAOYSA-N; MolPort-002-053-743; HMS3604B15; 4-(4-flourophenylmethyl)piperidine; ZINC2512916; ALBB-014951; KS-00002B8F
DMW8IN3 DT Small molecular drug
DMW8IN3 PC 3699841
DMW8IN3 MW 193.26
DMW8IN3 FM C12H16FN
DMW8IN3 IC InChI=1S/C12H16FN/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11/h1-4,11,14H,5-9H2
DMW8IN3 CS C1CNCCC1CC2=CC=C(C=C2)F
DMW8IN3 IK JLAKCHGEEBPDQI-UHFFFAOYSA-N
DMW8IN3 IU 4-[(4-fluorophenyl)methyl]piperidine
DMW8IN3 CA CAS 92822-02-1
DMW8IN3 DE Discovery agent
DM4NEOU ID DM4NEOU
DM4NEOU DN 4-(4-Fluoro-benzyl)-piperidine hydrochloride
DM4NEOU HS Investigative
DM4NEOU SN 4-(4-Fluorobenzyl)piperidine hydrochloride; 92822-03-2; 193357-52-7; C12H17ClFN; CHEMBL1204355; 4-(4-Fluoro-benzyl)-piperidine hydrochloride; 4-(4'-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE; Piperidine, 4-[(4-fluorophenyl)methyl]-, hydrochloride; 4-(4-FLUOROBENZYL)PIPERIDINE HCL; AK134910; 4-[(4-fluorophenyl)methyl]piperidine Hydrochloride; 4-(4-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE Salt; SCHEMBL4247331; KS-00000DOL; CTK7C0359; DTXSID30588780; MolPort-001-778-599; OJKWWANXBGLGQN-UHFFFAOYSA-N; 4NPA-Q05-1; ZX-AV000292; ZX-CM003409
DM4NEOU DT Small molecular drug
DM4NEOU PC 17039492
DM4NEOU MW 229.72
DM4NEOU FM C12H17ClFN
DM4NEOU IC InChI=1S/C12H16FN.ClH/c13-12-3-1-10(2-4-12)9-11-5-7-14-8-6-11;/h1-4,11,14H,5-9H2;1H
DM4NEOU CS C1CNCCC1CC2=CC=C(C=C2)F.Cl
DM4NEOU IK OJKWWANXBGLGQN-UHFFFAOYSA-N
DM4NEOU IU 4-[(4-fluorophenyl)methyl]piperidine;hydrochloride
DM4NEOU CA CAS 193357-52-7
DM4NEOU DE Discovery agent
DMRJD75 ID DMRJD75
DMRJD75 DN 4-(4-fluoro-benzylideneamino)-benzenesulfonamide
DMRJD75 HS Investigative
DMRJD75 SN CHEMBL427835; 4-[(4-fluorobenzylidene)amino]benzenesulfonamide; 4-{[(e)-(4-fluorophenyl)methylidene]amino}benzenesulfonamide; NSC720519; AC1L8N2R; SCHEMBL5311683; CTK7B9640; BKZPDMSMFWCHPI-UHFFFAOYSA-N; MolPort-003-705-944; ZINC18102137; BDBM50371768; ZINC95919526; AKOS001613042; ZINC253618202; AKOS016038195; NSC-720519; MCULE-4378033729; ST009698; KB-117288; N-(4-Fluorobenzylidene)-4-sulfamoylaniline; EU-0002043; SR-01000079257; SR-01000079257-1; 4-[(4-Fluoro-benzylidene)-amino]-benzenesulfonamide
DMRJD75 DT Small molecular drug
DMRJD75 PC 404324
DMRJD75 MW 278.3
DMRJD75 FM C13H11FN2O2S
DMRJD75 IC InChI=1S/C13H11FN2O2S/c14-11-3-1-10(2-4-11)9-16-12-5-7-13(8-6-12)19(15,17)18/h1-9H,(H2,15,17,18)
DMRJD75 CS C1=CC(=CC=C1C=NC2=CC=C(C=C2)S(=O)(=O)N)F
DMRJD75 IK BKZPDMSMFWCHPI-UHFFFAOYSA-N
DMRJD75 IU 4-[(4-fluorophenyl)methylideneamino]benzenesulfonamide
DMRJD75 DE Discovery agent
DM52NMU ID DM52NMU
DM52NMU DN 4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine
DM52NMU HS Investigative
DM52NMU SN CHEMBL1215732; BDBM50324616
DM52NMU DT Small molecular drug
DM52NMU PC 49864196
DM52NMU MW 263.3
DM52NMU FM C18H14FN
DM52NMU IC InChI=1S/C18H14FN/c19-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-20-11-9-15/h1-11,13H,12H2
DM52NMU CS C1=CC(=CC(=C1)F)C2=CC=C(C=C2)CC3=CC=NC=C3
DM52NMU IK NDUUGOAGHNLAIZ-UHFFFAOYSA-N
DM52NMU IU 4-[[4-(3-fluorophenyl)phenyl]methyl]pyridine
DM52NMU DE Discovery agent
DMRJLAP ID DMRJLAP
DMRJLAP DN 4-(4-Fluorophenoxy)-3-pyridinesulfonamide
DMRJLAP HS Investigative
DMRJLAP SN 4-(4-Fluorophenoxy)-3-pyridinesulfonamide; CHEMBL1163599; BDBM50320502
DMRJLAP DT Small molecular drug
DMRJLAP PC 46703770
DMRJLAP MW 268.27
DMRJLAP FM C11H9FN2O3S
DMRJLAP IC InChI=1S/C11H9FN2O3S/c12-8-1-3-9(4-2-8)17-10-5-6-14-7-11(10)18(13,15)16/h1-7H,(H2,13,15,16)
DMRJLAP CS C1=CC(=CC=C1OC2=C(C=NC=C2)S(=O)(=O)N)F
DMRJLAP IK AJOXYVWAKWQVRZ-UHFFFAOYSA-N
DMRJLAP IU 4-(4-fluorophenoxy)pyridine-3-sulfonamide
DMRJLAP DE Discovery agent
DMK8DCF ID DMK8DCF
DMK8DCF DN 4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide
DMK8DCF HS Investigative
DMK8DCF SN CHEMBL272622; SCHEMBL5312313; JAKLWQFGJXPTHN-UHFFFAOYSA-N; BDBM50371742
DMK8DCF DT Small molecular drug
DMK8DCF PC 21862753
DMK8DCF MW 278.3
DMK8DCF FM C13H11FN2O2S
DMK8DCF IC InChI=1S/C13H11FN2O2S/c14-11-3-5-12(6-4-11)16-9-10-1-7-13(8-2-10)19(15,17)18/h1-9H,(H2,15,17,18)
DMK8DCF CS C1=CC(=CC=C1C=NC2=CC=C(C=C2)F)S(=O)(=O)N
DMK8DCF IK JAKLWQFGJXPTHN-UHFFFAOYSA-N
DMK8DCF IU 4-[(4-fluorophenyl)iminomethyl]benzenesulfonamide
DMK8DCF DE Discovery agent
DMR9TBW ID DMR9TBW
DMR9TBW DN 4-(4-hexylphenyl)-4-oxobut-2-enoic acid
DMR9TBW HS Investigative
DMR9TBW SN CHEMBL237601; SCHEMBL16227167
DMR9TBW DT Small molecular drug
DMR9TBW PC 53881633
DMR9TBW MW 260.329
DMR9TBW FM C16H20O3
DMR9TBW IC InChI=1S/C16H20O3/c1-2-3-4-5-6-13-7-9-14(10-8-13)15(17)11-12-16(18)19/h7-12H,2-6H2,1H3,(H,18,19)
DMR9TBW CS CCCCCCC1=CC=C(C=C1)C(=O)C=CC(=O)O
DMR9TBW IK HKEVTQICMJNUNY-UHFFFAOYSA-N
DMR9TBW IU 4-(4-hexylphenyl)-4-oxobut-2-enoic acid
DMR9TBW DE Discovery agent
DMNY0I5 ID DMNY0I5
DMNY0I5 DN 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide
DMNY0I5 HS Investigative
DMNY0I5 SN 4-(4-hydroxybenzylideneamino)benzenesulfonamide
DMNY0I5 PC 404202
DMNY0I5 MW 276.31
DMNY0I5 FM C13H12N2O3S
DMNY0I5 IC InChI=1S/C13H12N2O3S/c14-19(17,18)13-7-3-11(4-8-13)15-9-10-1-5-12(16)6-2-10/h1-9,16H,(H2,14,17,18)
DMNY0I5 CS C1=CC(=CC=C1C=NC2=CC=C(C=C2)S(=O)(=O)N)O
DMNY0I5 IK QEZYWFVOEUVTBF-UHFFFAOYSA-N
DMNY0I5 IU 4-[(4-hydroxyphenyl)methylideneamino]benzenesulfonamide
DMNY0I5 CA CAS 66667-58-1
DMNY0I5 DE Discovery agent
DML357W ID DML357W
DML357W DN 4-(4-hydroxybenzylideneamino)benzoic acid
DML357W HS Investigative
DML357W DT Small molecular drug
DML357W PC 2306645
DML357W MW 241.24
DML357W FM C14H11NO3
DML357W IC InChI=1S/C14H11NO3/c16-13-7-1-10(2-8-13)9-15-12-5-3-11(4-6-12)14(17)18/h1-9,16H,(H,17,18)
DML357W CS C1=CC(=CC=C1C=NC2=CC=C(C=C2)C(=O)O)O
DML357W IK HRLVVRLMLAPCBI-UHFFFAOYSA-N
DML357W IU 4-[(4-hydroxyphenyl)methylideneamino]benzoic acid
DML357W CA CAS 60027-82-9
DML357W DE Discovery agent
DMZT6HL ID DMZT6HL
DMZT6HL DN 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
DMZT6HL HS Investigative
DMZT6HL DT Small molecular drug
DMZT6HL PC 135440536
DMZT6HL MW 263.29
DMZT6HL FM C17H13NO2
DMZT6HL IC InChI=1S/C17H13NO2/c19-14-8-5-12(6-9-14)16-10-7-13(11-18-20)15-3-1-2-4-17(15)16/h1-11,19-20H/b18-11+
DMZT6HL CS C1=CC=C2C(=C1)C(=CC=C2C3=CC=C(C=C3)O)/C=N/O
DMZT6HL IK VYQQTWUZKPWPRL-WOJGMQOQSA-N
DMZT6HL IU 4-[4-[(E)-hydroxyiminomethyl]naphthalen-1-yl]phenol
DMZT6HL CA CAS 799765-95-0
DMZT6HL DE Discovery agent
DMC9Z45 ID DMC9Z45
DMC9Z45 DN 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol
DMC9Z45 HS Investigative
DMC9Z45 SN CHEMBL268881; NSC622468; 4-(4-Isopropyl-2-morpholinyl)-1,2-benzenediol hydrochloride; AC1L7GLH; AC1Q7ACF; 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol; BDBM50000499; AKOS022660109; NCI60_006589; 4-(4-isopropylmorpholin-2-yl)benzene-1,2-diol; 4-(4-propan-2-ylmorpholin-2-yl)benzene-1,2-diol; 1,2-benzenediol, 4-[4-(1-methylethyl)-2-morpholinyl]-
DMC9Z45 DT Small molecular drug
DMC9Z45 PC 360400
DMC9Z45 MW 237.29
DMC9Z45 FM C13H19NO3
DMC9Z45 IC InChI=1S/C13H19NO3/c1-9(2)14-5-6-17-13(8-14)10-3-4-11(15)12(16)7-10/h3-4,7,9,13,15-16H,5-6,8H2,1-2H3
DMC9Z45 CS CC(C)N1CCOC(C1)C2=CC(=C(C=C2)O)O
DMC9Z45 IK SUYJAACXNVNFGP-UHFFFAOYSA-N
DMC9Z45 IU 4-(4-propan-2-ylmorpholin-2-yl)benzene-1,2-diol
DMC9Z45 DE Discovery agent
DMRGM21 ID DMRGM21
DMRGM21 DN 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole
DMRGM21 HS Investigative
DMRGM21 SN CHEMBL239895; 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole; SCHEMBL17969081
DMRGM21 DT Small molecular drug
DMRGM21 PC 44437844
DMRGM21 MW 212.25
DMRGM21 FM C12H12N4
DMRGM21 IC InChI=1S/C12H12N4/c1-8(2)9-3-5-10(6-4-9)12-11(7-13)14-16-15-12/h3-6,8H,1-2H3,(H,14,15,16)
DMRGM21 CS CC(C)C1=CC=C(C=C1)C2=NNN=C2C#N
DMRGM21 IK WEMPWGDVLUDOBY-UHFFFAOYSA-N
DMRGM21 IU 5-(4-propan-2-ylphenyl)-2H-triazole-4-carbonitrile
DMRGM21 DE Discovery agent
DMA7LEO ID DMA7LEO
DMA7LEO DN 4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DMA7LEO HS Investigative
DMA7LEO SN CHEMBL379273; 4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DMA7LEO DT Small molecular drug
DMA7LEO PC 44413494
DMA7LEO MW 302.4
DMA7LEO FM C15H14N2O3S
DMA7LEO IC InChI=1S/C15H14N2O3S/c1-20-15-4-2-3-14-13(15)9-10-17(14)21(18,19)12-7-5-11(16)6-8-12/h2-10H,16H2,1H3
DMA7LEO CS COC1=CC=CC2=C1C=CN2S(=O)(=O)C3=CC=C(C=C3)N
DMA7LEO IK ITHFAYACRWTMMR-UHFFFAOYSA-N
DMA7LEO IU 4-(4-methoxyindol-1-yl)sulfonylaniline
DMA7LEO DE Discovery agent
DM5PTB9 ID DM5PTB9
DM5PTB9 DN 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol
DM5PTB9 HS Investigative
DM5PTB9 SN CHEMBL172912; 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol; SCHEMBL7212305
DM5PTB9 DT Small molecular drug
DM5PTB9 PC 15516780
DM5PTB9 MW 260.399
DM5PTB9 FM C11H16O3S2
DM5PTB9 IC InChI=1S/C11H16O3S2/c1-9(15)7-8-16(12,13)11-5-3-10(14-2)4-6-11/h3-6,9,15H,7-8H2,1-2H3
DM5PTB9 CS CC(CCS(=O)(=O)C1=CC=C(C=C1)OC)S
DM5PTB9 IK UXTQFUKVODXBBJ-UHFFFAOYSA-N
DM5PTB9 IU 4-(4-methoxyphenyl)sulfonylbutane-2-thiol
DM5PTB9 DE Discovery agent
DM2OR8E ID DM2OR8E
DM2OR8E DN 4-(4-methoxy-benzylideneamino)-benzenesulfonamide
DM2OR8E HS Investigative
DM2OR8E SN CHEMBL271911; N-(4-Methoxybenzylidene)-4-sulfamoylaniline; 66667-56-9; AC1LCE5G; CBDivE_014997; SCHEMBL1517619; 4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide; CTK1J4463; DTXSID70347792; MolPort-000-519-122; MLUHDVSELBSKPI-UHFFFAOYSA-N; MLUHDVSELBSKPI-MHWRWJLKSA-N; ZINC131008; BDBM50371762; STK790787; AKOS001583663; MCULE-9167737347; MCULE-3795342438; ST016434; 4-(4-Methoxybenzylideneamino)benzenesulfonamide; Benzenesulfonamide, 4-(4-methoxybenzylideneamino)-; 4-((4-METHOXYBENZYLIDENE)AMINO)BENZENESULFONAMIDE
DM2OR8E DT Small molecular drug
DM2OR8E PC 625902
DM2OR8E MW 290.34
DM2OR8E FM C14H14N2O3S
DM2OR8E IC InChI=1S/C14H14N2O3S/c1-19-13-6-2-11(3-7-13)10-16-12-4-8-14(9-5-12)20(15,17)18/h2-10H,1H3,(H2,15,17,18)
DM2OR8E CS COC1=CC=C(C=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DM2OR8E IK MLUHDVSELBSKPI-UHFFFAOYSA-N
DM2OR8E IU 4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide
DM2OR8E CA CAS 66667-56-9
DM2OR8E DE Discovery agent
DMZSQ04 ID DMZSQ04
DMZSQ04 DN 4-(4-methyl-benzylideneamino)-benzenesulfonamide
DMZSQ04 HS Investigative
DMZSQ04 SN CHEMBL429915; AC1LEQSK; SCHEMBL5312741; SOHFVFXITPDEDK-UHFFFAOYSA-N; ZINC95919525; ZINC18036434; BDBM50371763; ZINC253618240; AKOS016038193; AKOS003632590; MCULE-3900521489; ST009696; N-(4-Methylbenzylidene)-4-sulfamoylaniline; J3.552.121F; 4-[[(E)-4-Methylbenzylidene]amino]benzenesulfonamide; 4-[(4-methylphenyl)methylideneamino]benzenesulfonamide; 4-[(1E)-2-(4-methylphenyl)-1-azavinyl]benzenesulfonamide
DMZSQ04 DT Small molecular drug
DMZSQ04 PC 690836
DMZSQ04 MW 274.34
DMZSQ04 FM C14H14N2O2S
DMZSQ04 IC InChI=1S/C14H14N2O2S/c1-11-2-4-12(5-3-11)10-16-13-6-8-14(9-7-13)19(15,17)18/h2-10H,1H3,(H2,15,17,18)
DMZSQ04 CS CC1=CC=C(C=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DMZSQ04 IK SOHFVFXITPDEDK-UHFFFAOYSA-N
DMZSQ04 IU 4-[(4-methylphenyl)methylideneamino]benzenesulfonamide
DMZSQ04 DE Discovery agent
DMYZHXR ID DMYZHXR
DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole
DMYZHXR HS Investigative
DMYZHXR SN SCHEMBL7035172; CHEMBL102763; 1H-Imidazole, 5-(2,3-dihydro-4-methyl-1H-inden-1-yl)-; AKOS006291239; 4-(4-methylindan-1-yl)-1h-imidazole; 192208-31-4; L016358
DMYZHXR DT Small molecular drug
DMYZHXR PC 9990325
DMYZHXR MW 198.26
DMYZHXR FM C13H14N2
DMYZHXR IC InChI=1S/C13H14N2/c1-9-3-2-4-11-10(9)5-6-12(11)13-7-14-8-15-13/h2-4,7-8,12H,5-6H2,1H3,(H,14,15)
DMYZHXR CS CC1=C2CCC(C2=CC=C1)C3=CN=CN3
DMYZHXR IK XXQLSAWUSXSJTK-UHFFFAOYSA-N
DMYZHXR IU 5-(4-methyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole
DMYZHXR DE Discovery agent
DMV0S4U ID DMV0S4U
DMV0S4U DN 4-(4-methyl-phenyliminomethyl)-benzenesulfonamide
DMV0S4U HS Investigative
DMV0S4U SN CHEMBL271962; SCHEMBL5309671; GFCNORPCMFOXDQ-UHFFFAOYSA-N; BDBM50371756
DMV0S4U DT Small molecular drug
DMV0S4U PC 21862824
DMV0S4U MW 274.34
DMV0S4U FM C14H14N2O2S
DMV0S4U IC InChI=1S/C14H14N2O2S/c1-11-2-6-13(7-3-11)16-10-12-4-8-14(9-5-12)19(15,17)18/h2-10H,1H3,(H2,15,17,18)
DMV0S4U CS CC1=CC=C(C=C1)N=CC2=CC=C(C=C2)S(=O)(=O)N
DMV0S4U IK GFCNORPCMFOXDQ-UHFFFAOYSA-N
DMV0S4U IU 4-[(4-methylphenyl)iminomethyl]benzenesulfonamide
DMV0S4U DE Discovery agent
DMS74F2 ID DMS74F2
DMS74F2 DN 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one
DMS74F2 HS Investigative
DMS74F2 SN CHEMBL373210; 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one
DMS74F2 DT Small molecular drug
DMS74F2 PC 44403404
DMS74F2 MW 287.36
DMS74F2 FM C16H21N3O2
DMS74F2 IC InChI=1S/C16H21N3O2/c20-16-14-6-2-1-5-13(14)15(17-18-16)7-3-4-8-19-9-11-21-12-10-19/h1-2,5-6H,3-4,7-12H2,(H,18,20)
DMS74F2 CS C1COCCN1CCCCC2=NNC(=O)C3=CC=CC=C32
DMS74F2 IK BMGFFXOJQJDSQN-UHFFFAOYSA-N
DMS74F2 IU 4-(4-morpholin-4-ylbutyl)-2H-phthalazin-1-one
DMS74F2 DE Discovery agent
DM3KCL1 ID DM3KCL1
DM3KCL1 DN 4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide
DM3KCL1 HS Investigative
DM3KCL1 SN CHEMBL196025; AC1LR1ZB; 4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide; Oprea1_451204; MolPort-002-560-372; MolPort-000-703-859; ZINC1297754; BDBM50173029; STK846512; AKOS030511153; AKOS005626717; MCULE-6513504515; 4-(4-(m-tolylamino)phthalazin-1-yl)benzamide; AB00109646-01; 4-[4-(3-methylanilino)phthalazin-1-yl]benzamide
DM3KCL1 DT Small molecular drug
DM3KCL1 PC 1416247
DM3KCL1 MW 354.4
DM3KCL1 FM C22H18N4O
DM3KCL1 IC InChI=1S/C22H18N4O/c1-14-5-4-6-17(13-14)24-22-19-8-3-2-7-18(19)20(25-26-22)15-9-11-16(12-10-15)21(23)27/h2-13H,1H3,(H2,23,27)(H,24,26)
DM3KCL1 CS CC1=CC(=CC=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
DM3KCL1 IK JBCRRCQSLMCSLQ-UHFFFAOYSA-N
DM3KCL1 IU 4-[4-(3-methylanilino)phthalazin-1-yl]benzamide
DM3KCL1 DE Discovery agent
DMHB1N6 ID DMHB1N6
DMHB1N6 DN 4'-(4-Nitrobenzensulfonamide)-4-hydroxychalcone
DMHB1N6 HS Investigative
DMHB1N6 SN CHEMBL1087324; SCHEMBL3484304; BDBM50316855
DMHB1N6 DT Small molecular drug
DMHB1N6 PC 24989566
DMHB1N6 MW 424.4
DMHB1N6 FM C21H16N2O6S
DMHB1N6 IC InChI=1S/C21H16N2O6S/c24-19-10-1-15(2-11-19)3-14-21(25)16-4-6-17(7-5-16)22-30(28,29)20-12-8-18(9-13-20)23(26)27/h1-14,22,24H/b14-3+
DMHB1N6 CS C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)NS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-])O
DMHB1N6 IK WQIGNJDEMJBAFL-LZWSPWQCSA-N
DMHB1N6 IU N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]-4-nitrobenzenesulfonamide
DMHB1N6 DE Discovery agent
DMM86YK ID DMM86YK
DMM86YK DN 4-(4-nitro-benzylideneamino)-benzenesulfonamide
DMM86YK HS Investigative
DMM86YK SN CHEMBL255175; 66667-60-5; 4-[(1E)-2-(4-nitrophenyl)-1-azavinyl]benzenesulfonamide; AC1LBU0E; 4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide; SCHEMBL12416808; CTK5I3043; CTK1J4461; DTXSID10340363; IJEQJCKQAKELNC-OQLLNIDSSA-N; MolPort-001-818-097; ZINC131032; BDBM50371746; STK790732; SBB006116; AKOS001719928; MCULE-1611993564; MCULE-9098092341; ST016439; EU-0084260; 4-(4-Nitrobenzylideneamino)Benzenesulfonamide; 4-[(4-Nitrobenzylidene)amino]benzenesulfonamide; Benzenesulfonamide, 4-(4-nitrobenzylidenamino)-
DMM86YK DT Small molecular drug
DMM86YK PC 564225
DMM86YK MW 305.31
DMM86YK FM C13H11N3O4S
DMM86YK IC InChI=1S/C13H11N3O4S/c14-21(19,20)13-7-3-11(4-8-13)15-9-10-1-5-12(6-2-10)16(17)18/h1-9H,(H2,14,19,20)
DMM86YK CS C1=CC(=CC=C1C=NC2=CC=C(C=C2)S(=O)(=O)N)[N+](=O)[O-]
DMM86YK IK IJEQJCKQAKELNC-UHFFFAOYSA-N
DMM86YK IU 4-[(4-nitrophenyl)methylideneamino]benzenesulfonamide
DMM86YK CA CAS 66667-60-5
DMM86YK DE Discovery agent
DMGVNE3 ID DMGVNE3
DMGVNE3 DN 4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide
DMGVNE3 HS Investigative
DMGVNE3 SN azo-sulfonamide, 1c; CHEMBL571371; BDBM33268; 4-[(E)-[4-(methylamino)phenyl]azo]benzenesulfonamide
DMGVNE3 DT Small molecular drug
DMGVNE3 PC 44246261
DMGVNE3 MW 290.34
DMGVNE3 FM C13H14N4O2S
DMGVNE3 IC InChI=1S/C13H14N4O2S/c1-15-10-2-4-11(5-3-10)16-17-12-6-8-13(9-7-12)20(14,18)19/h2-9,15H,1H3,(H2,14,18,19)
DMGVNE3 CS CNC1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)N
DMGVNE3 IK RMLHDMTUTOMVIX-UHFFFAOYSA-N
DMGVNE3 IU 4-[[4-(methylamino)phenyl]diazenyl]benzenesulfonamide
DMGVNE3 DE Discovery agent
DMOHB6U ID DMOHB6U
DMOHB6U DN 4-(4-phenoxybenzoyl)benzoic acid
DMOHB6U HS Investigative
DMOHB6U SN 4-(4-phenoxybenzoyl)benzoic Acid; CHEMBL36392; SCHEMBL7822422; BDBM50180894; 4-(4-Phenoxy-benzoyl)-benzoic acid
DMOHB6U DT Small molecular drug
DMOHB6U PC 10087225
DMOHB6U MW 318.3
DMOHB6U FM C20H14O4
DMOHB6U IC InChI=1S/C20H14O4/c21-19(14-6-8-16(9-7-14)20(22)23)15-10-12-18(13-11-15)24-17-4-2-1-3-5-17/h1-13H,(H,22,23)
DMOHB6U CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMOHB6U IK SQQFOBWKPOREAO-UHFFFAOYSA-N
DMOHB6U IU 4-(4-phenoxybenzoyl)benzoic acid
DMOHB6U DE Discovery agent
DMQ0JWZ ID DMQ0JWZ
DMQ0JWZ DN 4-(4-phenoxybenzoyl)phenylacetic acid
DMQ0JWZ HS Investigative
DMQ0JWZ SN 4-(4-phenoxybenzoyl)phenylacetic acid; CHEMBL370016
DMQ0JWZ DT Small molecular drug
DMQ0JWZ PC 11695657
DMQ0JWZ MW 332.3
DMQ0JWZ FM C21H16O4
DMQ0JWZ IC InChI=1S/C21H16O4/c22-20(23)14-15-6-8-16(9-7-15)21(24)17-10-12-19(13-11-17)25-18-4-2-1-3-5-18/h1-13H,14H2,(H,22,23)
DMQ0JWZ CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)CC(=O)O
DMQ0JWZ IK VRBHQDUOTOPSLA-UHFFFAOYSA-N
DMQ0JWZ IU 2-[4-(4-phenoxybenzoyl)phenyl]acetic acid
DMQ0JWZ DE Discovery agent
DMKMH5L ID DMKMH5L
DMKMH5L DN 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
DMKMH5L HS Investigative
DMKMH5L SN 5-(4-Phenoxybutoxy)psoralen; 870653-45-5; UNII-A62C114Q0Q; CHEMBL444449; A62C114Q0Q; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-(4-phenoxybutoxy)-; 4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-(4-phenoxybutoxy)-; C21H18O5; 4-(4-Phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one; 7h-furo[3; 4-(4-phenoxybutoxy)-; 2-g][1]benzopyran-7-one; 5-(4-phenoxybutoxy) psoralen; GTPL2554; SCHEMBL2585454; CTK8F0318; DTXSID80461776; 5-(4-phenoxybutoxy)psoralen
DMKMH5L DT Small molecular drug
DMKMH5L PC 11302540
DMKMH5L MW 350.4
DMKMH5L FM C21H18O5
DMKMH5L IC InChI=1S/C21H18O5/c22-20-9-8-16-19(26-20)14-18-17(10-13-24-18)21(16)25-12-5-4-11-23-15-6-2-1-3-7-15/h1-3,6-10,13-14H,4-5,11-12H2
DMKMH5L CS C1=CC=C(C=C1)OCCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
DMKMH5L IK KINMYBBFQRSVLL-UHFFFAOYSA-N
DMKMH5L IU 4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one
DMKMH5L CA CAS 870653-45-5
DMKMH5L DE Discovery agent
DMBZHUA ID DMBZHUA
DMBZHUA DN 4-(4-propoxyphenoxy)phenol
DMBZHUA HS Investigative
DMBZHUA SN 4-(4-propoxyphenoxy)phenol; CHEMBL472893; SCHEMBL19848981
DMBZHUA DT Small molecular drug
DMBZHUA PC 44562813
DMBZHUA MW 244.28
DMBZHUA FM C15H16O3
DMBZHUA IC InChI=1S/C15H16O3/c1-2-11-17-13-7-9-15(10-8-13)18-14-5-3-12(16)4-6-14/h3-10,16H,2,11H2,1H3
DMBZHUA CS CCCOC1=CC=C(C=C1)OC2=CC=C(C=C2)O
DMBZHUA IK FNAGBMSBTIDLJO-UHFFFAOYSA-N
DMBZHUA IU 4-(4-propoxyphenoxy)phenol
DMBZHUA DE Discovery agent
DM6ESXB ID DM6ESXB
DM6ESXB DN 4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide
DM6ESXB HS Investigative
DM6ESXB SN CHEMBL194747; 4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide; BAS 02999388; AC1LR1JT; Oprea1_289700; Oprea1_093859; SCHEMBL3021915; MolPort-000-702-961; MolPort-001-909-424; ZINC1297142; BDBM50173017; STL148635; STL483208; AKOS005748394; AKOS000665050; MCULE-9763616884; 4-(4-(p-tolylamino)phthalazin-1-yl)benzamide; 4-[4-(4-methylanilino)phthalazin-1-yl]benzamide; 4-{4-[(4-methylphenyl)amino]phthalazin-1-yl}benzamide
DM6ESXB DT Small molecular drug
DM6ESXB PC 1416020
DM6ESXB MW 354.4
DM6ESXB FM C22H18N4O
DM6ESXB IC InChI=1S/C22H18N4O/c1-14-6-12-17(13-7-14)24-22-19-5-3-2-4-18(19)20(25-26-22)15-8-10-16(11-9-15)21(23)27/h2-13H,1H3,(H2,23,27)(H,24,26)
DM6ESXB CS CC1=CC=C(C=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
DM6ESXB IK UTDXGHMGCXLCKT-UHFFFAOYSA-N
DM6ESXB IU 4-[4-(4-methylanilino)phthalazin-1-yl]benzamide
DM6ESXB DE Discovery agent
DMFLH2G ID DMFLH2G
DMFLH2G DN 4-(4-tert-butylbenzylideneamino)benzoic acid
DMFLH2G HS Investigative
DMFLH2G SN CHEMBL567821; 4-(4-tert-butylbenzylideneamino)benzoic acid
DMFLH2G DT Small molecular drug
DMFLH2G PC 45483280
DMFLH2G MW 281.3
DMFLH2G FM C18H19NO2
DMFLH2G IC InChI=1S/C18H19NO2/c1-18(2,3)15-8-4-13(5-9-15)12-19-16-10-6-14(7-11-16)17(20)21/h4-12H,1-3H3,(H,20,21)
DMFLH2G CS CC(C)(C)C1=CC=C(C=C1)C=NC2=CC=C(C=C2)C(=O)O
DMFLH2G IK CZLMLVYXQCJOGH-UHFFFAOYSA-N
DMFLH2G IU 4-[(4-tert-butylphenyl)methylideneamino]benzoic acid
DMFLH2G DE Discovery agent
DMG6DV9 ID DMG6DV9
DMG6DV9 DN 4-(4-tert-butylbenzylthio)-2-aminobutanoic acid
DMG6DV9 HS Investigative
DMG6DV9 SN CHEMBL383441; 4-(4-tert-butylbenzylthio)-2-aminobutanoic acid; BDBM50179698
DMG6DV9 DT Small molecular drug
DMG6DV9 PC 44408220
DMG6DV9 MW 281.4
DMG6DV9 FM C15H23NO2S
DMG6DV9 IC InChI=1S/C15H23NO2S/c1-15(2,3)12-6-4-11(5-7-12)10-19-9-8-13(16)14(17)18/h4-7,13H,8-10,16H2,1-3H3,(H,17,18)
DMG6DV9 CS CC(C)(C)C1=CC=C(C=C1)CSCCC(C(=O)O)N
DMG6DV9 IK BAHGAZBQXUXBJR-UHFFFAOYSA-N
DMG6DV9 IU 2-amino-4-[(4-tert-butylphenyl)methylsulfanyl]butanoic acid
DMG6DV9 DE Discovery agent
DMGHVW7 ID DMGHVW7
DMGHVW7 DN 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol
DMGHVW7 HS Investigative
DMGHVW7 SN CHEMBL205512; 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol
DMGHVW7 DT Small molecular drug
DMGHVW7 PC 44408965
DMGHVW7 MW 281.4
DMGHVW7 FM C17H15NOS
DMGHVW7 IC InChI=1S/C17H15NOS/c1-18-14-6-2-12(3-7-14)16-10-11-17(20-16)13-4-8-15(19)9-5-13/h2-11,18-19H,1H3
DMGHVW7 CS CNC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)O
DMGHVW7 IK CXLILFMFVYDZLM-UHFFFAOYSA-N
DMGHVW7 IU 4-[5-[4-(methylamino)phenyl]thiophen-2-yl]phenol
DMGHVW7 DE Discovery agent
DMOGMJ9 ID DMOGMJ9
DMOGMJ9 DN 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine
DMOGMJ9 HS Investigative
DMOGMJ9 SN CHEMBL382007; 2,5-bis(4-aminophenyl)thiophene; 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine; SCHEMBL6751854; ZINC28571226; BDBM50178547; 70010-49-0
DMOGMJ9 DT Small molecular drug
DMOGMJ9 PC 21788024
DMOGMJ9 MW 266.4
DMOGMJ9 FM C16H14N2S
DMOGMJ9 IC InChI=1S/C16H14N2S/c17-13-5-1-11(2-6-13)15-9-10-16(19-15)12-3-7-14(18)8-4-12/h1-10H,17-18H2
DMOGMJ9 CS C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)N)N
DMOGMJ9 IK QUVIYFJRWXKEKM-UHFFFAOYSA-N
DMOGMJ9 IU 4-[5-(4-aminophenyl)thiophen-2-yl]aniline
DMOGMJ9 DE Discovery agent
DM1UX89 ID DM1UX89
DM1UX89 DN 4-(5-(4-aminophenyl)thiophen-2-yl)phenol
DM1UX89 HS Investigative
DM1UX89 SN CHEMBL205824; 4-(5-(4-aminophenyl)thiophen-2-yl)phenol; SCHEMBL12973258
DM1UX89 DT Small molecular drug
DM1UX89 PC 44408840
DM1UX89 MW 267.3
DM1UX89 FM C16H13NOS
DM1UX89 IC InChI=1S/C16H13NOS/c17-13-5-1-11(2-6-13)15-9-10-16(19-15)12-3-7-14(18)8-4-12/h1-10,18H,17H2
DM1UX89 CS C1=CC(=CC=C1C2=CC=C(S2)C3=CC=C(C=C3)O)N
DM1UX89 IK NTAJNMDKXYZMKZ-UHFFFAOYSA-N
DM1UX89 IU 4-[5-(4-aminophenyl)thiophen-2-yl]phenol
DM1UX89 DE Discovery agent
DMK1ZF2 ID DMK1ZF2
DMK1ZF2 DN 4-(5-(4-Hydroxyphenyl)isothiazol-4-yl)phenol
DMK1ZF2 HS Investigative
DMK1ZF2 DT Small molecular drug
DMK1ZF2 PC 136036233
DMK1ZF2 MW 269.3
DMK1ZF2 FM C15H11NO2S
DMK1ZF2 IC InChI=1S/C15H11NO2S/c17-12-5-1-10(2-6-12)14-9-16-19-15(14)11-3-7-13(18)8-4-11/h1-9,17-18H
DMK1ZF2 CS C1=CC(=CC=C1C2=C(SN=C2)C3=CC=C(C=C3)O)O
DMK1ZF2 IK OCBISDMDUBGFSN-UHFFFAOYSA-N
DMK1ZF2 IU 4-[5-(4-hydroxyphenyl)-1,2-thiazol-4-yl]phenol
DMK1ZF2 DE Discovery agent
DMO9YH0 ID DMO9YH0
DMO9YH0 DN 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine
DMO9YH0 HS Investigative
DMO9YH0 SN CHEMBL203320; 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine; SCHEMBL12973259
DMO9YH0 DT Small molecular drug
DMO9YH0 PC 44408839
DMO9YH0 MW 281.4
DMO9YH0 FM C17H15NOS
DMO9YH0 IC InChI=1S/C17H15NOS/c1-19-15-8-4-13(5-9-15)17-11-10-16(20-17)12-2-6-14(18)7-3-12/h2-11H,18H2,1H3
DMO9YH0 CS COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)N
DMO9YH0 IK JJUWIYUCBOADAD-UHFFFAOYSA-N
DMO9YH0 IU 4-[5-(4-methoxyphenyl)thiophen-2-yl]aniline
DMO9YH0 DE Discovery agent
DMCNLBZ ID DMCNLBZ
DMCNLBZ DN 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol
DMCNLBZ HS Investigative
DMCNLBZ SN CHEMBL381991; 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol
DMCNLBZ DT Small molecular drug
DMCNLBZ PC 44408738
DMCNLBZ MW 282.4
DMCNLBZ FM C17H14O2S
DMCNLBZ IC InChI=1S/C17H14O2S/c1-19-15-8-4-13(5-9-15)17-11-10-16(20-17)12-2-6-14(18)7-3-12/h2-11,18H,1H3
DMCNLBZ CS COC1=CC=C(C=C1)C2=CC=C(S2)C3=CC=C(C=C3)O
DMCNLBZ IK WNCPZRMABGADNX-UHFFFAOYSA-N
DMCNLBZ IU 4-[5-(4-methoxyphenyl)thiophen-2-yl]phenol
DMCNLBZ DE Discovery agent
DMJKUQI ID DMJKUQI
DMJKUQI DN 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine
DMJKUQI HS Investigative
DMJKUQI SN 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine; Meridianin C; 213473-00-8; 2-Pyrimidinamine, 4-(5-bromo-1H-indol-3-yl)-; CHEMBL44541; SCHEMBL1612228; CTK0J7680; BDBM10840; DTXSID50434275; PKQJCYXKRNGUKQ-UHFFFAOYSA-N; AKOS027469387; AS-49872
DMJKUQI DT Small molecular drug
DMJKUQI PC 10017019
DMJKUQI MW 289.13
DMJKUQI FM C12H9BrN4
DMJKUQI IC InChI=1S/C12H9BrN4/c13-7-1-2-10-8(5-7)9(6-16-10)11-3-4-15-12(14)17-11/h1-6,16H,(H2,14,15,17)
DMJKUQI CS C1=CC2=C(C=C1Br)C(=CN2)C3=NC(=NC=C3)N
DMJKUQI IK PKQJCYXKRNGUKQ-UHFFFAOYSA-N
DMJKUQI IU 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine
DMJKUQI CA CAS 213473-00-8
DMJKUQI DE Discovery agent
DMLSGU1 ID DMLSGU1
DMLSGU1 DN 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline
DMLSGU1 HS Investigative
DMLSGU1 SN CHEMBL473320; 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline; SCHEMBL5616932
DMLSGU1 DT Small molecular drug
DMLSGU1 PC 11696664
DMLSGU1 MW 384.2
DMLSGU1 FM C18H14BrN3O2
DMLSGU1 IC InChI=1S/C18H14BrN3O2/c1-23-16-6-12-15(7-17(16)24-2)21-9-22-18(12)13-8-20-14-4-3-10(19)5-11(13)14/h3-9,20H,1-2H3
DMLSGU1 CS COC1=C(C=C2C(=C1)C(=NC=N2)C3=CNC4=C3C=C(C=C4)Br)OC
DMLSGU1 IK MWBJNWJINFGNLQ-UHFFFAOYSA-N
DMLSGU1 IU 4-(5-bromo-1H-indol-3-yl)-6,7-dimethoxyquinazoline
DMLSGU1 DE Discovery agent
DMDYBIC ID DMDYBIC
DMDYBIC DN 4'-(5-Chloro-2-thienyl)biphenyl-3-ol
DMDYBIC HS Investigative
DMDYBIC SN CHEMBL1099312; BDBM50318418
DMDYBIC DT Small molecular drug
DMDYBIC PC 46887551
DMDYBIC MW 286.8
DMDYBIC FM C16H11ClOS
DMDYBIC IC InChI=1S/C16H11ClOS/c17-16-9-8-15(19-16)12-6-4-11(5-7-12)13-2-1-3-14(18)10-13/h1-10,18H
DMDYBIC CS C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC=C(S3)Cl
DMDYBIC IK ABAQWDXYFZGNGR-UHFFFAOYSA-N
DMDYBIC IU 3-[4-(5-chlorothiophen-2-yl)phenyl]phenol
DMDYBIC DE Discovery agent
DM1EANV ID DM1EANV
DM1EANV DN 4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM1EANV HS Investigative
DM1EANV DT Small molecular drug
DM1EANV PC 135486039
DM1EANV MW 243.21
DM1EANV FM C13H9NO4
DM1EANV IC InChI=1S/C13H9NO4/c15-7-2-4-12-10(5-7)14-13(18-12)9-3-1-8(16)6-11(9)17/h1-6,15-17H
DM1EANV CS C1=CC(=C(C=C1O)O)C2=NC3=C(O2)C=CC(=C3)O
DM1EANV IK RGXSSCFRVTXICH-UHFFFAOYSA-N
DM1EANV IU 4-(5-hydroxy-1,3-benzoxazol-2-yl)benzene-1,3-diol
DM1EANV DE Discovery agent
DMIWT60 ID DMIWT60
DMIWT60 DN 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine
DMIWT60 HS Investigative
DMIWT60 SN 5-Substituted 1-Phenylbenzimidazole 22; AC1NS4PO; SCHEMBL7989819; CHEMBL309035; BDBM3933; AKOS023129997; 4-(5-methoxybenzimidazol-1-yl)aniline; 5-Methoxy-1-(4-aminophenyl)-1H-benzimidazole; 4-(5-methoxy-1H-1,3-benzodiazol-1-yl)aniline; 1-(4-aminophenyl)-5-methoxybenzimidazole dihydrochloride
DMIWT60 DT Small molecular drug
DMIWT60 PC 5328512
DMIWT60 MW 239.27
DMIWT60 FM C14H13N3O
DMIWT60 IC InChI=1S/C14H13N3O/c1-18-12-6-7-14-13(8-12)16-9-17(14)11-4-2-10(15)3-5-11/h2-9H,15H2,1H3
DMIWT60 CS COC1=CC2=C(C=C1)N(C=N2)C3=CC=C(C=C3)N
DMIWT60 IK KLJLVCKIKCKKEA-UHFFFAOYSA-N
DMIWT60 IU 4-(5-methoxybenzimidazol-1-yl)aniline
DMIWT60 DE Discovery agent
DMKT20Q ID DMKT20Q
DMKT20Q DN 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q HS Investigative
DMKT20Q SN CHEMBL1163382; 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide
DMKT20Q DT Small molecular drug
DMKT20Q PC 46704077
DMKT20Q MW 240.28
DMKT20Q FM C9H12N4O2S
DMKT20Q IC InChI=1S/C9H12N4O2S/c1-7-2-5-12-13(7)8-3-4-11-6-9(8)16(10,14)15/h3-7H,2H2,1H3,(H2,10,14,15)
DMKT20Q CS CC1CC=NN1C2=C(C=NC=C2)S(=O)(=O)N
DMKT20Q IK LMKCKKHGIIIBOX-UHFFFAOYSA-N
DMKT20Q IU 4-(3-methyl-3,4-dihydropyrazol-2-yl)pyridine-3-sulfonamide
DMKT20Q DE Discovery agent
DMXHIK5 ID DMXHIK5
DMXHIK5 DN 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one
DMXHIK5 HS Investigative
DMXHIK5 SN CHEMBL194684; 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one
DMXHIK5 DT Small molecular drug
DMXHIK5 PC 44403402
DMXHIK5 MW 301.4
DMXHIK5 FM C17H23N3O2
DMXHIK5 IC InChI=1S/C17H23N3O2/c21-17-15-7-4-3-6-14(15)16(18-19-17)8-2-1-5-9-20-10-12-22-13-11-20/h3-4,6-7H,1-2,5,8-13H2,(H,19,21)
DMXHIK5 CS C1COCCN1CCCCCC2=NNC(=O)C3=CC=CC=C32
DMXHIK5 IK OSFRDFHBAQDMGC-UHFFFAOYSA-N
DMXHIK5 IU 4-(5-morpholin-4-ylpentyl)-2H-phthalazin-1-one
DMXHIK5 DE Discovery agent
DMUHQ0J ID DMUHQ0J
DMUHQ0J DN 4-(5-Nitro-indol-1-ylmethyl)-benzamidine
DMUHQ0J HS Investigative
DMUHQ0J SN CHEMBL100296; 4-(5-Nitro-indol-1-ylmethyl)-benzamidine
DMUHQ0J DT Small molecular drug
DMUHQ0J PC 44331823
DMUHQ0J MW 294.31
DMUHQ0J FM C16H14N4O2
DMUHQ0J IC InChI=1S/C16H14N4O2/c17-16(18)12-3-1-11(2-4-12)10-19-8-7-13-9-14(20(21)22)5-6-15(13)19/h1-9H,10H2,(H3,17,18)
DMUHQ0J CS C1=CC(=CC=C1CN2C=CC3=C2C=CC(=C3)[N+](=O)[O-])C(=N)N
DMUHQ0J IK TYZQZZRAPZQXLG-UHFFFAOYSA-N
DMUHQ0J IU 4-[(5-nitroindol-1-yl)methyl]benzenecarboximidamide
DMUHQ0J DE Discovery agent
DM3N9O5 ID DM3N9O5
DM3N9O5 DN 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide
DM3N9O5 HS Investigative
DM3N9O5 SN GW572399X; 4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide; 2-Anilino-5-aryloxazole 15; AC1NS7RK; CHEMBL194062; BDBM5854; HMS3303D13; HMS3305L11; NCGC00242064-01; AB01092072-01
DM3N9O5 DT Small molecular drug
DM3N9O5 PC 5329850
DM3N9O5 MW 315.3
DM3N9O5 FM C15H13N3O3S
DM3N9O5 IC InChI=1S/C15H13N3O3S/c16-22(19,20)13-8-6-12(7-9-13)18-15-17-10-14(21-15)11-4-2-1-3-5-11/h1-10H,(H,17,18)(H2,16,19,20)
DM3N9O5 CS C1=CC=C(C=C1)C2=CN=C(O2)NC3=CC=C(C=C3)S(=O)(=O)N
DM3N9O5 IK OKFOIEMZTIOWQH-UHFFFAOYSA-N
DM3N9O5 IU 4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide
DM3N9O5 DE Discovery agent
DMZ1DW0 ID DMZ1DW0
DMZ1DW0 DN 4-(5-tert-Butyl-[1,3]dithian-2-yl)-benzonitrile
DMZ1DW0 HS Investigative
DMZ1DW0 SN CHEMBL90342; SCHEMBL8950639; ZINC584599047; ZINC584599044
DMZ1DW0 DT Small molecular drug
DMZ1DW0 PC 10039485
DMZ1DW0 MW 277.5
DMZ1DW0 FM C15H19NS2
DMZ1DW0 IC InChI=1S/C15H19NS2/c1-15(2,3)13-9-17-14(18-10-13)12-6-4-11(8-16)5-7-12/h4-7,13-14H,9-10H2,1-3H3
DMZ1DW0 CS CC(C)(C)C1CSC(SC1)C2=CC=C(C=C2)C#N
DMZ1DW0 IK JBVUMTNJGGTVQA-UHFFFAOYSA-N
DMZ1DW0 IU 4-(5-tert-butyl-1,3-dithian-2-yl)benzonitrile
DMZ1DW0 DE Discovery agent
DM8A6UH ID DM8A6UH
DM8A6UH DN 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid
DM8A6UH HS Investigative
DM8A6UH SN CHEMBL66868; 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid; SCHEMBL8172493; ZINC13737718
DM8A6UH DT Small molecular drug
DM8A6UH PC 10244811
DM8A6UH MW 309.3
DM8A6UH FM C18H15NO4
DM8A6UH IC InChI=1S/C18H15NO4/c1-22-16-8-13-7-14(10-19-15(13)9-17(16)23-2)11-3-5-12(6-4-11)18(20)21/h3-10H,1-2H3,(H,20,21)
DM8A6UH CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)C(=O)O
DM8A6UH IK YEEIRSIWKQULLK-UHFFFAOYSA-N
DM8A6UH IU 4-(6,7-dimethoxyquinolin-3-yl)benzoic acid
DM8A6UH DE Discovery agent
DM9RNUX ID DM9RNUX
DM9RNUX DN 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol
DM9RNUX HS Investigative
DM9RNUX SN CHEMBL303704; 4-(6,7-dimethoxyquinolin-3-yl)phenol; 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol; ZINC3834025
DM9RNUX DT Small molecular drug
DM9RNUX PC 11778467
DM9RNUX MW 281.3
DM9RNUX FM C17H15NO3
DM9RNUX IC InChI=1S/C17H15NO3/c1-20-16-8-12-7-13(11-3-5-14(19)6-4-11)10-18-15(12)9-17(16)21-2/h3-10,19H,1-2H3
DM9RNUX CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)O
DM9RNUX IK GVQYSEHILFQSHO-UHFFFAOYSA-N
DM9RNUX IU 4-(6,7-dimethoxyquinolin-3-yl)phenol
DM9RNUX DE Discovery agent
DMPD9GE ID DMPD9GE
DMPD9GE DN 4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole
DMPD9GE HS Investigative
DMPD9GE SN CHEMBL15000; 4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole; SCHEMBL7621912; LATXTZVCBBIDBM-UHFFFAOYSA-N; ZINC2001873; PDSP2_000104; BDBM50070211; PDSP1_000104; GT 2260; GT-2260; 1-[1H-imidazol-4-yl]-6-cyclohexyl-3-hexyne
DMPD9GE DT Small molecular drug
DMPD9GE PC 10220233
DMPD9GE MW 230.35
DMPD9GE FM C15H22N2
DMPD9GE IC InChI=1S/C15H22N2/c1(2-7-11-15-12-16-13-17-15)4-8-14-9-5-3-6-10-14/h12-14H,3-11H2,(H,16,17)
DMPD9GE CS C1CCC(CC1)CCC#CCCC2=CN=CN2
DMPD9GE IK LATXTZVCBBIDBM-UHFFFAOYSA-N
DMPD9GE IU 5-(6-cyclohexylhex-3-ynyl)-1H-imidazole
DMPD9GE DE Discovery agent
DM4EC0J ID DM4EC0J
DM4EC0J DN 4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole
DM4EC0J HS Investigative
DM4EC0J SN CHEMBL274977; 4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole; SCHEMBL7621345; PDSP1_000105; ZINC13795227; BDBM50070220; PDSP2_000105; GT-2286; GT 2286
DM4EC0J DT Small molecular drug
DM4EC0J PC 9794398
DM4EC0J MW 216.32
DM4EC0J FM C14H20N2
DM4EC0J IC InChI=1S/C14H20N2/c1(3-7-13-8-5-6-9-13)2-4-10-14-11-15-12-16-14/h11-13H,3-10H2,(H,15,16)
DM4EC0J CS C1CCC(C1)CCC#CCCC2=CN=CN2
DM4EC0J IK XFHACGZTJUJXHB-UHFFFAOYSA-N
DM4EC0J IU 5-(6-cyclopentylhex-3-ynyl)-1H-imidazole
DM4EC0J DE Discovery agent
DMHGRPB ID DMHGRPB
DMHGRPB DN 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
DMHGRPB HS Investigative
DMHGRPB DT Small molecular drug
DMHGRPB PC 135566322
DMHGRPB MW 242.23
DMHGRPB FM C13H10N2O3
DMHGRPB IC InChI=1S/C13H10N2O3/c16-7-1-3-9-11(5-7)14-15-13(9)10-4-2-8(17)6-12(10)18/h1-6,16-18H,(H,14,15)
DMHGRPB CS C1=CC2=C(C=C1O)NN=C2C3=C(C=C(C=C3)O)O
DMHGRPB IK WLDZDEMGKFWJNR-UHFFFAOYSA-N
DMHGRPB IU 4-(6-hydroxy-1H-indazol-3-yl)benzene-1,3-diol
DMHGRPB CA CAS 117767-16-5
DMHGRPB DE Discovery agent
DM38YZ4 ID DM38YZ4
DM38YZ4 DN 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol
DM38YZ4 HS Investigative
DM38YZ4 DT Small molecular drug
DM38YZ4 PC 135545334
DM38YZ4 MW 243.21
DM38YZ4 FM C13H9NO4
DM38YZ4 IC InChI=1S/C13H9NO4/c15-8-2-3-9-12(6-8)18-13(14-9)7-1-4-10(16)11(17)5-7/h1-6,15-17H
DM38YZ4 CS C1=CC(=C(C=C1C2=NC3=C(O2)C=C(C=C3)O)O)O
DM38YZ4 IK QSWPVNMCVFYCHT-UHFFFAOYSA-N
DM38YZ4 IU 4-(6-hydroxy-1,3-benzoxazol-2-yl)benzene-1,2-diol
DM38YZ4 DE Discovery agent
DM07NT9 ID DM07NT9
DM07NT9 DN 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol
DM07NT9 HS Investigative
DM07NT9 DT Small molecular drug
DM07NT9 PC 135522275
DM07NT9 MW 243.21
DM07NT9 FM C13H9NO4
DM07NT9 IC InChI=1S/C13H9NO4/c15-7-1-3-9(11(17)5-7)13-14-10-4-2-8(16)6-12(10)18-13/h1-6,15-17H
DM07NT9 CS C1=CC(=C(C=C1O)O)C2=NC3=C(O2)C=C(C=C3)O
DM07NT9 IK FLDXQSCXJKEXJF-UHFFFAOYSA-N
DM07NT9 IU 4-(6-hydroxy-1,3-benzoxazol-2-yl)benzene-1,3-diol
DM07NT9 DE Discovery agent
DM4SPV7 ID DM4SPV7
DM4SPV7 DN 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DM4SPV7 HS Investigative
DM4SPV7 SN HS-1793; CHEMBL248499; 927885-00-5; 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol; 4-(6-hydroxy-2-naphthyl)-1,3-benzenediol; AOB4534; BCP17387; ZINC28878526; BDBM50197244
DM4SPV7 DT Small molecular drug
DM4SPV7 PC 16215105
DM4SPV7 MW 252.26
DM4SPV7 FM C16H12O3
DM4SPV7 IC InChI=1S/C16H12O3/c17-13-4-3-10-7-12(2-1-11(10)8-13)15-6-5-14(18)9-16(15)19/h1-9,17-19H
DM4SPV7 CS C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3)O)O
DM4SPV7 IK BXZJBSHLEZAMOP-UHFFFAOYSA-N
DM4SPV7 IU 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DM4SPV7 DE Discovery agent
DM3L5I6 ID DM3L5I6
DM3L5I6 DN 4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DM3L5I6 HS Investigative
DM3L5I6 SN CHEMBL209724; 4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine
DM3L5I6 DT Small molecular drug
DM3L5I6 PC 44413495
DM3L5I6 MW 302.4
DM3L5I6 FM C15H14N2O3S
DM3L5I6 IC InChI=1S/C15H14N2O3S/c1-20-13-5-2-11-8-9-17(15(11)10-13)21(18,19)14-6-3-12(16)4-7-14/h2-10H,16H2,1H3
DM3L5I6 CS COC1=CC2=C(C=C1)C=CN2S(=O)(=O)C3=CC=C(C=C3)N
DM3L5I6 IK DMQUSAAOCWRTQX-UHFFFAOYSA-N
DM3L5I6 IU 4-(6-methoxyindol-1-yl)sulfonylaniline
DM3L5I6 DE Discovery agent
DM3ACVD ID DM3ACVD
DM3ACVD DN 4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DM3ACVD HS Investigative
DM3ACVD SN 4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine; Dihydronaphthalene 11; AC1O70HL; SCHEMBL4513739; CHEMBL425054; BDBM8897
DM3ACVD DT Small molecular drug
DM3ACVD PC 6540055
DM3ACVD MW 237.3
DM3ACVD FM C16H15NO
DM3ACVD IC InChI=1S/C16H15NO/c1-18-16-5-4-14-10-13(2-3-15(14)11-16)12-6-8-17-9-7-12/h4-11H,2-3H2,1H3
DM3ACVD CS COC1=CC2=C(C=C1)C=C(CC2)C3=CC=NC=C3
DM3ACVD IK QCWIENOGGDTTEN-UHFFFAOYSA-N
DM3ACVD IU 4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
DM3ACVD DE Discovery agent
DMRPU0V ID DMRPU0V
DMRPU0V DN 4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V HS Investigative
DMRPU0V SN CHEMBL525785; 4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V DT Small molecular drug
DMRPU0V PC 25034427
DMRPU0V MW 299.4
DMRPU0V FM C21H17NO
DMRPU0V IC InChI=1S/C21H17NO/c1-14-9-17-10-18(23-2)8-7-15(17)11-20(14)21-13-22-12-16-5-3-4-6-19(16)21/h3-13H,1-2H3
DMRPU0V CS CC1=CC2=C(C=CC(=C2)OC)C=C1C3=CN=CC4=CC=CC=C43
DMRPU0V IK PVTDLLYLEPRYDL-UHFFFAOYSA-N
DMRPU0V IU 4-(6-methoxy-3-methylnaphthalen-2-yl)isoquinoline
DMRPU0V DE Discovery agent
DM51XDA ID DM51XDA
DM51XDA DN 4-(6-Methoxynaphthalen-2-yl)isoquinoline
DM51XDA HS Investigative
DM51XDA SN CHEMBL500394; 4-(6-Methoxynaphthalen-2-yl)isoquinoline; BDBM50272368
DM51XDA DT Small molecular drug
DM51XDA PC 24754344
DM51XDA MW 285.3
DM51XDA FM C20H15NO
DM51XDA IC InChI=1S/C20H15NO/c1-22-18-9-8-14-10-16(7-6-15(14)11-18)20-13-21-12-17-4-2-3-5-19(17)20/h2-13H,1H3
DM51XDA CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC4=CC=CC=C43
DM51XDA IK SGBOBLSELUHWRG-UHFFFAOYSA-N
DM51XDA IU 4-(6-methoxynaphthalen-2-yl)isoquinoline
DM51XDA DE Discovery agent
DM4B73F ID DM4B73F
DM4B73F DN 4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol
DM4B73F HS Investigative
DM4B73F SN CHEMBL1097417; BDBM50318417
DM4B73F DT Small molecular drug
DM4B73F PC 46887511
DM4B73F MW 277.3
DM4B73F FM C18H15NO2
DM4B73F IC InChI=1S/C18H15NO2/c1-21-18-10-9-16(12-19-18)14-7-5-13(6-8-14)15-3-2-4-17(20)11-15/h2-12,20H,1H3
DM4B73F CS COC1=NC=C(C=C1)C2=CC=C(C=C2)C3=CC(=CC=C3)O
DM4B73F IK JEDOKEGGMJNKGY-UHFFFAOYSA-N
DM4B73F IU 3-[4-(6-methoxypyridin-3-yl)phenyl]phenol
DM4B73F DE Discovery agent
DM9O8VY ID DM9O8VY
DM9O8VY DN 4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM9O8VY HS Investigative
DM9O8VY SN CHEMBL222765; 4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile
DM9O8VY DT Small molecular drug
DM9O8VY PC 16203359
DM9O8VY MW 282.29
DM9O8VY FM C16H14N2O3
DM9O8VY IC InChI=1S/C16H14N2O3/c17-11-12-1-3-13(4-2-12)15-9-14(19)10-16(21-15)18-5-7-20-8-6-18/h1-4,9-10H,5-8H2
DM9O8VY CS C1COCCN1C2=CC(=O)C=C(O2)C3=CC=C(C=C3)C#N
DM9O8VY IK GGAAWYRRMFPEHA-UHFFFAOYSA-N
DM9O8VY IU 4-(6-morpholin-4-yl-4-oxopyran-2-yl)benzonitrile
DM9O8VY DE Discovery agent
DM1Z3N6 ID DM1Z3N6
DM1Z3N6 DN 4-(6-morpholino-9H-purin-2-yl)phenol
DM1Z3N6 HS Investigative
DM1Z3N6 DT Small molecular drug
DM1Z3N6 PC 135955186
DM1Z3N6 MW 297.31
DM1Z3N6 FM C15H15N5O2
DM1Z3N6 IC InChI=1S/C15H15N5O2/c21-11-3-1-10(2-4-11)13-18-14-12(16-9-17-14)15(19-13)20-5-7-22-8-6-20/h1-4,9,21H,5-8H2,(H,16,17,18,19)
DM1Z3N6 CS C1COCCN1C2=NC(=NC3=C2NC=N3)C4=CC=C(C=C4)O
DM1Z3N6 IK PSGSPCJHCOUEEU-UHFFFAOYSA-N
DM1Z3N6 IU 4-(6-morpholin-4-yl-7H-purin-2-yl)phenol
DM1Z3N6 DE Discovery agent
DMJ81IL ID DMJ81IL
DMJ81IL DN 4-(6-phenyl-2,4'-bipyridin-4-yl)phenol
DMJ81IL HS Investigative
DMJ81IL DT Small molecular drug
DMJ81IL PC 46887286
DMJ81IL DE Discovery agent
DMIY5QU ID DMIY5QU
DMIY5QU DN 4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole
DMIY5QU HS Investigative
DMIY5QU SN CHEMBL280076; 4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole; 1H-Imidazole, 5-(7,7-dimethyl-3-octyn-1-yl)-; SCHEMBL7619037; PDSP1_000108; BDBM50070214; PDSP2_000108; GT 2293; 209599-16-6
DMIY5QU DT Small molecular drug
DMIY5QU PC 10219888
DMIY5QU MW 204.31
DMIY5QU FM C13H20N2
DMIY5QU IC InChI=1S/C13H20N2/c1-13(2,3)9-7-5-4-6-8-12-10-14-11-15-12/h10-11H,6-9H2,1-3H3,(H,14,15)
DMIY5QU CS CC(C)(C)CCC#CCCC1=CN=CN1
DMIY5QU IK CNQBABLURIQXNU-UHFFFAOYSA-N
DMIY5QU IU 5-(7,7-dimethyloct-3-ynyl)-1H-imidazole
DMIY5QU DE Discovery agent
DMUXZOM ID DMUXZOM
DMUXZOM DN 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol
DMUXZOM HS Investigative
DMUXZOM DT Small molecular drug
DMUXZOM PC 135525228
DMUXZOM MW 326.8
DMUXZOM FM C19H19ClN2O
DMUXZOM IC InChI=1S/C19H19ClN2O/c20-17-8-4-7-16-18(13-9-11-15(23)12-10-13)21-22(19(16)17)14-5-2-1-3-6-14/h4,7-12,14,23H,1-3,5-6H2
DMUXZOM CS C1CCC(CC1)N2C3=C(C=CC=C3Cl)C(=N2)C4=CC=C(C=C4)O
DMUXZOM IK JFMIDTYLHCPZPL-UHFFFAOYSA-N
DMUXZOM IU 4-(7-chloro-1-cyclohexylindazol-3-yl)phenol
DMUXZOM CA CAS 680611-05-6
DMUXZOM DE Discovery agent
DM0X5SY ID DM0X5SY
DM0X5SY DN 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol
DM0X5SY HS Investigative
DM0X5SY DT Small molecular drug
DM0X5SY PC 135476471
DM0X5SY MW 312.8
DM0X5SY FM C18H17ClN2O
DM0X5SY IC InChI=1S/C18H17ClN2O/c19-16-7-3-6-15-17(12-8-10-14(22)11-9-12)20-21(18(15)16)13-4-1-2-5-13/h3,6-11,13,22H,1-2,4-5H2
DM0X5SY CS C1CCC(C1)N2C3=C(C=CC=C3Cl)C(=N2)C4=CC=C(C=C4)O
DM0X5SY IK NDUBFDHNGRZGIL-UHFFFAOYSA-N
DM0X5SY IU 4-(7-chloro-1-cyclopentylindazol-3-yl)phenol
DM0X5SY CA CAS 680611-61-4
DM0X5SY DE Discovery agent
DMEYUH0 ID DMEYUH0
DMEYUH0 DN 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol
DMEYUH0 HS Investigative
DMEYUH0 DT Small molecular drug
DMEYUH0 PC 135407148
DMEYUH0 MW 286.75
DMEYUH0 FM C16H15ClN2O
DMEYUH0 IC InChI=1S/C16H15ClN2O/c1-2-10-19-16-13(4-3-5-14(16)17)15(18-19)11-6-8-12(20)9-7-11/h3-9,20H,2,10H2,1H3
DMEYUH0 CS CCCN1C2=C(C=CC=C2Cl)C(=N1)C3=CC=C(C=C3)O
DMEYUH0 IK OEWGFWIYFTVVAZ-UHFFFAOYSA-N
DMEYUH0 IU 4-(7-chloro-1-propylindazol-3-yl)phenol
DMEYUH0 CA CAS 680611-44-3
DMEYUH0 DE Discovery agent
DMX2K8R ID DMX2K8R
DMX2K8R DN 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol
DMX2K8R HS Investigative
DMX2K8R DT Small molecular drug
DMX2K8R PC 135511848
DMX2K8R MW 266.34
DMX2K8R FM C17H18N2O
DMX2K8R IC InChI=1S/C17H18N2O/c1-3-11-19-17-12(2)5-4-6-15(17)16(18-19)13-7-9-14(20)10-8-13/h4-10,20H,3,11H2,1-2H3
DMX2K8R CS CCCN1C2=C(C=CC=C2C(=N1)C3=CC=C(C=C3)O)C
DMX2K8R IK KGNRBLHSFFCQIN-UHFFFAOYSA-N
DMX2K8R IU 4-(7-methyl-1-propylindazol-3-yl)phenol
DMX2K8R CA CAS 680611-32-9
DMX2K8R DE Discovery agent
DMJ86OS ID DMJ86OS
DMJ86OS DN 4-(7-Methyl-oct-3-ynyl)-1H-imidazole
DMJ86OS HS Investigative
DMJ86OS SN CHEMBL14497; 4-(7-Methyl-oct-3-ynyl)-1H-imidazole; 1H-Imidazole, 5-(7-methyl-3-octyn-1-yl)-; SCHEMBL7618441; BDBM50070212; 4-(7-Methyl-3-octynyl)-1H-imidazole
DMJ86OS DT Small molecular drug
DMJ86OS PC 10012754
DMJ86OS MW 190.28
DMJ86OS FM C12H18N2
DMJ86OS IC InChI=1S/C12H18N2/c1-11(2)7-5-3-4-6-8-12-9-13-10-14-12/h9-11H,5-8H2,1-2H3,(H,13,14)
DMJ86OS CS CC(C)CCC#CCCC1=CN=CN1
DMJ86OS IK FGSZNBGTIGFMGN-UHFFFAOYSA-N
DMJ86OS IU 5-(7-methyloct-3-ynyl)-1H-imidazole
DMJ86OS DE Discovery agent
DM27OGL ID DM27OGL
DM27OGL DN 4-(8-Phenyl-oct-3-ynyl)-1H-imidazole
DM27OGL HS Investigative
DM27OGL SN CHEMBL14811; 4-(8-Phenyl-oct-3-ynyl)-1H-imidazole; SCHEMBL7621857; ZINC13795232; BDBM50070216
DM27OGL DT Small molecular drug
DM27OGL PC 9794983
DM27OGL MW 252.35
DM27OGL FM C17H20N2
DM27OGL IC InChI=1S/C17H20N2/c1(2-4-9-13-17-14-18-15-19-17)3-6-10-16-11-7-5-8-12-16/h5,7-8,11-12,14-15H,1,3,6,9-10,13H2,(H,18,19)
DM27OGL CS C1=CC=C(C=C1)CCCCC#CCCC2=CN=CN2
DM27OGL IK MSBRTBBFZFRZEJ-UHFFFAOYSA-N
DM27OGL IU 5-(8-phenyloct-3-ynyl)-1H-imidazole
DM27OGL DE Discovery agent
DMR37FN ID DMR37FN
DMR37FN DN 4-(Acetylamino)-3-Amino Benzoic Acid
DMR37FN HS Investigative
DMR37FN SN 4-(Acetylamino)-3-Amino Benzoic Acid; 3-amino-4-acetamidobenzoic acid; CHEMBL109162; 4-acetylamino-3-aminobenzoic acid; 4-(Acetylamino)-3-aminobenzoic acid; 53484-10-9; ST3; BANA108; AC1L9JL6; BANA-108; SCHEMBL2344997; BANA 108; BDBM5274; 4-acetamido-3-aminobenzoic acid; 4-acetamido-3-amino-benzoic acid; 4-Acetylamino-3-amino-benzoic acid; AKOS012418429
DMR37FN DT Small molecular drug
DMR37FN PC 446367
DMR37FN MW 194.19
DMR37FN FM C9H10N2O3
DMR37FN IC InChI=1S/C9H10N2O3/c1-5(12)11-8-3-2-6(9(13)14)4-7(8)10/h2-4H,10H2,1H3,(H,11,12)(H,13,14)
DMR37FN CS CC(=O)NC1=C(C=C(C=C1)C(=O)O)N
DMR37FN IK MJMLUICFHWSBQZ-UHFFFAOYSA-N
DMR37FN IU 4-acetamido-3-aminobenzoic acid
DMR37FN DE Discovery agent
DM8F0N5 ID DM8F0N5
DM8F0N5 DN 4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID
DM8F0N5 HS Investigative
DM8F0N5 SN 4-acetamido-3-hydroxy-5-nitrobenzoic acid; 162252-45-1; 4-(Acetylamino)-3-hydroxy-5-nitrobenzoic acid; ST1; BANA105; AC1MO7GF; SCHEMBL5571782; CHEMBL324455; BANA-105; CTK8C2119; DTXSID30391837; JIDRTCHFBHJIDG-UHFFFAOYSA-N; ZINC3833968; 8224AA; ANW-67849; AKOS016007095; DB08570; AJ-45807; TC-156594; AX8236797; KB-107355; 4-acetamido-3-hydroxy-5-nitro-benzoic acid; Benzoic acid,4-(acetylamino)-3-hydroxy-5-nitro-
DM8F0N5 DT Small molecular drug
DM8F0N5 PC 3364665
DM8F0N5 MW 240.17
DM8F0N5 FM C9H8N2O6
DM8F0N5 IC InChI=1S/C9H8N2O6/c1-4(12)10-8-6(11(16)17)2-5(9(14)15)3-7(8)13/h2-3,13H,1H3,(H,10,12)(H,14,15)
DM8F0N5 CS CC(=O)NC1=C(C=C(C=C1O)C(=O)O)[N+](=O)[O-]
DM8F0N5 IK JIDRTCHFBHJIDG-UHFFFAOYSA-N
DM8F0N5 IU 4-acetamido-3-hydroxy-5-nitrobenzoic acid
DM8F0N5 CA CAS 162252-45-1
DM8F0N5 DE Discovery agent
DM1DKSV ID DM1DKSV
DM1DKSV DN 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID
DM1DKSV HS Investigative
DM1DKSV SN 4-acetamido-3-amino-5-hydroxybenzoic acid; 162252-46-2; 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID; 4-(Acetylamino)-3-amino-5-hydroxybenzoic acid; ST2; BANA106; AC1L9JL3; CHEMBL109005; BANA-106; SCHEMBL8375025; CTK8H1571; DTXSID70332224; ZINC3581100; 8225AA; AKOS016012208; DB08571; AJ-45035; 3-amino-4-acetamido-5-hydroxybenzoic acid; KB-239845; AX8247088; 4-acetamido-3-amino-5-hydroxy-benzoic acid; 3-Amino-4-(acetylamino)-5-hydroxybenzoic acid
DM1DKSV DT Small molecular drug
DM1DKSV PC 446366
DM1DKSV MW 210.19
DM1DKSV FM C9H10N2O4
DM1DKSV IC InChI=1S/C9H10N2O4/c1-4(12)11-8-6(10)2-5(9(14)15)3-7(8)13/h2-3,13H,10H2,1H3,(H,11,12)(H,14,15)
DM1DKSV CS CC(=O)NC1=C(C=C(C=C1O)C(=O)O)N
DM1DKSV IK CALDTVBHJMBRTM-UHFFFAOYSA-N
DM1DKSV IU 4-acetamido-3-amino-5-hydroxybenzoic acid
DM1DKSV CA CAS 162252-46-2
DM1DKSV DE Discovery agent
DM6MQCI ID DM6MQCI
DM6MQCI DN 4-(Allylamino)-3-pyridinesulfonamide
DM6MQCI HS Investigative
DM6MQCI SN 4-(Allylamino)-3-pyridinesulfonamide; CHEMBL1164966; 76254-81-4; Oprea1_825745
DM6MQCI DT Small molecular drug
DM6MQCI PC 25044690
DM6MQCI MW 213.26
DM6MQCI FM C8H11N3O2S
DM6MQCI IC InChI=1S/C8H11N3O2S/c1-2-4-11-7-3-5-10-6-8(7)14(9,12)13/h2-3,5-6H,1,4H2,(H,10,11)(H2,9,12,13)
DM6MQCI CS C=CCNC1=C(C=NC=C1)S(=O)(=O)N
DM6MQCI IK HYUSVYAJBKXAKB-UHFFFAOYSA-N
DM6MQCI IU 4-(prop-2-enylamino)pyridine-3-sulfonamide
DM6MQCI DE Discovery agent
DMTB80W ID DMTB80W
DMTB80W DN 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
DMTB80W HS Investigative
DMTB80W SN CHEMBL572533; 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
DMTB80W DT Small molecular drug
DMTB80W PC 44542042
DMTB80W MW 281.3
DMTB80W FM C17H15NO3
DMTB80W IC InChI=1S/C17H15NO3/c18-10-13-8-17(19)21-16-9-14(6-7-15(13)16)20-11-12-4-2-1-3-5-12/h1-9H,10-11,18H2
DMTB80W CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)C(=CC(=O)O3)CN
DMTB80W IK XCWHFSADYQMGEA-UHFFFAOYSA-N
DMTB80W IU 4-(aminomethyl)-7-phenylmethoxychromen-2-one
DMTB80W DE Discovery agent
DML2EF4 ID DML2EF4
DML2EF4 DN 4'-(Benzensulfonamide)-4-hydroxychalcone
DML2EF4 HS Investigative
DML2EF4 SN CHEMBL1087322; SCHEMBL3483693; BDBM50316853; 4''-(Benzensulfonamide)-4-hydroxychalcone
DML2EF4 DT Small molecular drug
DML2EF4 PC 15176577
DML2EF4 MW 379.4
DML2EF4 FM C21H17NO4S
DML2EF4 IC InChI=1S/C21H17NO4S/c23-19-13-6-16(7-14-19)8-15-21(24)17-9-11-18(12-10-17)22-27(25,26)20-4-2-1-3-5-20/h1-15,22-23H/b15-8+
DML2EF4 CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)/C=C/C3=CC=C(C=C3)O
DML2EF4 IK CJSVUASMASROSS-OVCLIPMQSA-N
DML2EF4 IU N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]benzenesulfonamide
DML2EF4 DE Discovery agent
DMF6S3X ID DMF6S3X
DMF6S3X DN 4-(Benzylamino)-1-naphthol
DMF6S3X HS Investigative
DMF6S3X SN CHEMBL569096; 4-(Benzylamino)-1-naphthol; SCHEMBL6677663
DMF6S3X DT Small molecular drug
DMF6S3X PC 17937479
DMF6S3X MW 249.31
DMF6S3X FM C17H15NO
DMF6S3X IC InChI=1S/C17H15NO/c19-17-11-10-16(14-8-4-5-9-15(14)17)18-12-13-6-2-1-3-7-13/h1-11,18-19H,12H2
DMF6S3X CS C1=CC=C(C=C1)CNC2=CC=C(C3=CC=CC=C32)O
DMF6S3X IK GXGORQOUKCMHGK-UHFFFAOYSA-N
DMF6S3X IU 4-(benzylamino)naphthalen-1-ol
DMF6S3X DE Discovery agent
DM03BQD ID DM03BQD
DM03BQD DN 4-(benzylideneamino)benzenesulfonamide
DM03BQD HS Investigative
DM03BQD SN 4-benzylideneamino-benzenesulfonamide
DM03BQD DT Small molecular drug
DM03BQD PC 308405
DM03BQD MW 260.31
DM03BQD FM C13H12N2O2S
DM03BQD IC InChI=1S/C13H12N2O2S/c14-18(16,17)13-8-6-12(7-9-13)15-10-11-4-2-1-3-5-11/h1-10H,(H2,14,16,17)
DM03BQD CS C1=CC=C(C=C1)C=NC2=CC=C(C=C2)S(=O)(=O)N
DM03BQD IK OPUFYXLEFFRGSQ-UHFFFAOYSA-N
DM03BQD IU 4-(benzylideneamino)benzenesulfonamide
DM03BQD CA CAS 5877-53-2
DM03BQD DE Discovery agent
DMJM2H1 ID DMJM2H1
DMJM2H1 DN 4-(benzylideneamino)benzoic acid
DMJM2H1 HS Investigative
DMJM2H1 SN 4-(benzylideneamino)benzoic Acid; CHEMBL567820; 820985-82-8; AC1LEKUN; SCHEMBL11027747; SCHEMBL10354517; ZINC56233; CTK3E2373; DTXSID10350765; MolPort-000-420-278; 4-(a-benzylideneamino)benzoic acid; benzylideneaniline-p-carboxylic acid; STK861975; BDBM50299292; AKOS002162184; MCULE-4796916281; 4-((1E)-2-phenyl-1-azavinyl)benzoic acid; ST45187403; 4-{[(E)-phenylmethylidene]amino}benzoic acid; Benzoic acid, 4-[(E)-(phenylmethylene)amino]-
DMJM2H1 DT Small molecular drug
DMJM2H1 PC 687887
DMJM2H1 MW 225.24
DMJM2H1 FM C14H11NO2
DMJM2H1 IC InChI=1S/C14H11NO2/c16-14(17)12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-10H,(H,16,17)
DMJM2H1 CS C1=CC=C(C=C1)C=NC2=CC=C(C=C2)C(=O)O
DMJM2H1 IK MREPJQZHXSDMKL-UHFFFAOYSA-N
DMJM2H1 IU 4-(benzylideneamino)benzoic acid
DMJM2H1 CA CAS 820985-82-8
DMJM2H1 DE Discovery agent
DM1T95Y ID DM1T95Y
DM1T95Y DN 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM1T95Y HS Investigative
DM1T95Y SN CHEMBL223324; 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol; BDBM50208721; J3.502.571E
DM1T95Y DT Small molecular drug
DM1T95Y PC 16203494
DM1T95Y MW 320.4
DM1T95Y FM C20H20N2O2
DM1T95Y IC InChI=1S/C20H20N2O2/c23-20-18(19(24-22-20)15-9-11-21-12-10-15)17-8-4-7-16(13-17)14-5-2-1-3-6-14/h1-8,13,15,21H,9-12H2,(H,22,23)
DM1T95Y CS C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC(=C3)C4=CC=CC=C4
DM1T95Y IK KLKHVLINJXRNBG-UHFFFAOYSA-N
DM1T95Y IU 4-(3-phenylphenyl)-5-piperidin-4-yl-1,2-oxazol-3-one
DM1T95Y DE Discovery agent
DMNE5H7 ID DMNE5H7
DMNE5H7 DN 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide
DMNE5H7 HS Investigative
DMNE5H7 SN CHEMBL601040; 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide
DMNE5H7 DT Small molecular drug
DMNE5H7 PC 46207013
DMNE5H7 MW 351.3
DMNE5H7 FM C18H20Cl2N2O
DMNE5H7 IC InChI=1S/C18H20Cl2N2O/c1-14-2-6-16(7-3-14)21-18(23)15-4-8-17(9-5-15)22(12-10-19)13-11-20/h2-9H,10-13H2,1H3,(H,21,23)
DMNE5H7 CS CC1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)N(CCCl)CCCl
DMNE5H7 IK YUHSPIYJWBBMHU-UHFFFAOYSA-N
DMNE5H7 IU 4-[bis(2-chloroethyl)amino]-N-(4-methylphenyl)benzamide
DMNE5H7 DE Discovery agent
DM3GUFI ID DM3GUFI
DM3GUFI DN 4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide
DM3GUFI HS Investigative
DM3GUFI SN CHEMBL258915; SCHEMBL845760
DM3GUFI DT Small molecular drug
DM3GUFI PC 44450336
DM3GUFI MW 333.4
DM3GUFI FM C21H23N3O
DM3GUFI IC InChI=1S/C21H23N3O/c1-3-4-13-24(2)19-11-9-16(10-12-19)21(25)23-18-14-17-7-5-6-8-20(17)22-15-18/h5-12,14-15H,3-4,13H2,1-2H3,(H,23,25)
DM3GUFI CS CCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM3GUFI IK UYXXRZNAVMFMMG-UHFFFAOYSA-N
DM3GUFI IU 4-[butyl(methyl)amino]-N-quinolin-3-ylbenzamide
DM3GUFI DE Discovery agent
DM6SIA4 ID DM6SIA4
DM6SIA4 DN 4-(butylthio)-2-(trifluoromethyl)benzonitrile
DM6SIA4 HS Investigative
DM6SIA4 SN CHEMBL462665; 4-(butylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247959
DM6SIA4 DT Small molecular drug
DM6SIA4 PC 43615786
DM6SIA4 MW 259.29
DM6SIA4 FM C12H12F3NS
DM6SIA4 IC InChI=1S/C12H12F3NS/c1-2-3-6-17-10-5-4-9(8-16)11(7-10)12(13,14)15/h4-5,7H,2-3,6H2,1H3
DM6SIA4 CS CCCCSC1=CC(=C(C=C1)C#N)C(F)(F)F
DM6SIA4 IK FQVZVSZPULBOJM-UHFFFAOYSA-N
DM6SIA4 IU 4-butylsulfanyl-2-(trifluoromethyl)benzonitrile
DM6SIA4 DE Discovery agent
DMH1AZV ID DMH1AZV
DMH1AZV DN 4-(butylthio)-2-methoxybenzonitrile
DMH1AZV HS Investigative
DMH1AZV SN CHEMBL455566; 4-(butylthio)-2-methoxybenzonitrile
DMH1AZV DT Small molecular drug
DMH1AZV PC 44564582
DMH1AZV MW 221.32
DMH1AZV FM C12H15NOS
DMH1AZV IC InChI=1S/C12H15NOS/c1-3-4-7-15-11-6-5-10(9-13)12(8-11)14-2/h5-6,8H,3-4,7H2,1-2H3
DMH1AZV CS CCCCSC1=CC(=C(C=C1)C#N)OC
DMH1AZV IK RUUKMZBJVWOJEZ-UHFFFAOYSA-N
DMH1AZV IU 4-butylsulfanyl-2-methoxybenzonitrile
DMH1AZV DE Discovery agent
DM12R4M ID DM12R4M
DM12R4M DN 4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M HS Investigative
DM12R4M SN CHEMBL1163376; 4-(carbamoylmethylthio)pyridine-3-sulfonamide; 1078160-11-8; 4-(Carbamolymethylthio)pyridine-3-sulfonamide
DM12R4M DT Small molecular drug
DM12R4M PC 46907400
DM12R4M MW 247.3
DM12R4M FM C7H9N3O3S2
DM12R4M IC InChI=1S/C7H9N3O3S2/c8-7(11)4-14-5-1-2-10-3-6(5)15(9,12)13/h1-3H,4H2,(H2,8,11)(H2,9,12,13)
DM12R4M CS C1=CN=CC(=C1SCC(=O)N)S(=O)(=O)N
DM12R4M IK GMEZLQXYYUCJAQ-UHFFFAOYSA-N
DM12R4M IU 2-(3-sulfamoylpyridin-4-yl)sulfanylacetamide
DM12R4M DE Discovery agent
DMSG9LV ID DMSG9LV
DMSG9LV DN 4-(Carboxyvin-2-Yl)Phenylboronic Acid
DMSG9LV HS Investigative
DMSG9LV SN 159896-15-8; (E)-3-(4-Boronophenyl)acrylic acid; 4-(2-Carboxyvinyl)phenylboronic acid; 3-(4-Boronophenyl)Acrylic Acid; 4-Boronocinnamic acid; 4-(CARBOXYVIN-2-YL)PHENYLBORONIC ACID; 151169-68-5; 4-(E-2-Carboxyvinyl)phenylboronic acid; 4-(2-CARBOXYVINYL)BENZENEBORONIC ACID; C9H9BO4; CHEMBL139928; 4-phenylpropylester boronic acid; (2E)-3-[4-(DIHYDROXYBORANYL)PHENYL]PROP-2-ENOIC ACID; 4-(E-2-Carboxyvinyl)benzeneboronic acid; AC1NRANQ; 3-[4-(dihydroxyboranyl)phenyl]prop-2-enoic acid; MolPort-000-931-601
DMSG9LV DT Small molecular drug
DMSG9LV PC 5288001
DMSG9LV MW 191.98
DMSG9LV FM C9H9BO4
DMSG9LV IC InChI=1S/C9H9BO4/c11-9(12)6-3-7-1-4-8(5-2-7)10(13)14/h1-6,13-14H,(H,11,12)/b6-3+
DMSG9LV CS B(C1=CC=C(C=C1)/C=C/C(=O)O)(O)O
DMSG9LV IK IEMLKNHGGSYOMP-ZZXKWVIFSA-N
DMSG9LV IU (E)-3-(4-boronophenyl)prop-2-enoic acid
DMSG9LV DE Discovery agent
DMZP20H ID DMZP20H
DMZP20H DN 4-(Cyanomethylthio)pyridine-3-sulfonamide
DMZP20H HS Investigative
DMZP20H SN 4-(Cyanomethylthio)pyridine-3-sulfonamide; CHEMBL1164420; 1078160-09-4
DMZP20H DT Small molecular drug
DMZP20H PC 46703932
DMZP20H MW 229.3
DMZP20H FM C7H7N3O2S2
DMZP20H IC InChI=1S/C7H7N3O2S2/c8-2-4-13-6-1-3-10-5-7(6)14(9,11)12/h1,3,5H,4H2,(H2,9,11,12)
DMZP20H CS C1=CN=CC(=C1SCC#N)S(=O)(=O)N
DMZP20H IK JOIYJNZMYUXKRS-UHFFFAOYSA-N
DMZP20H IU 4-(cyanomethylsulfanyl)pyridine-3-sulfonamide
DMZP20H DE Discovery agent
DMR69K2 ID DMR69K2
DMR69K2 DN 4-(cyclobutylmethylthio)-2-methoxybenzonitrile
DMR69K2 HS Investigative
DMR69K2 SN CHEMBL453244; 4-(cyclobutylmethylthio)-2-methoxybenzonitrile
DMR69K2 DT Small molecular drug
DMR69K2 PC 44564584
DMR69K2 MW 233.33
DMR69K2 FM C13H15NOS
DMR69K2 IC InChI=1S/C13H15NOS/c1-15-13-7-12(6-5-11(13)8-14)16-9-10-3-2-4-10/h5-7,10H,2-4,9H2,1H3
DMR69K2 CS COC1=C(C=CC(=C1)SCC2CCC2)C#N
DMR69K2 IK VLNPFRWDACXANC-UHFFFAOYSA-N
DMR69K2 IU 4-(cyclobutylmethylsulfanyl)-2-methoxybenzonitrile
DMR69K2 DE Discovery agent
DMUOQN7 ID DMUOQN7
DMUOQN7 DN 4-(Cyclohexylamino)-1-naphthol
DMUOQN7 HS Investigative
DMUOQN7 SN CHEMBL571437; 4-(Cyclohexylamino)-1-naphthol
DMUOQN7 DT Small molecular drug
DMUOQN7 PC 45487176
DMUOQN7 MW 241.33
DMUOQN7 FM C16H19NO
DMUOQN7 IC InChI=1S/C16H19NO/c18-16-11-10-15(13-8-4-5-9-14(13)16)17-12-6-2-1-3-7-12/h4-5,8-12,17-18H,1-3,6-7H2
DMUOQN7 CS C1CCC(CC1)NC2=CC=C(C3=CC=CC=C32)O
DMUOQN7 IK JNIUFYOCOKGFDL-UHFFFAOYSA-N
DMUOQN7 IU 4-(cyclohexylamino)naphthalen-1-ol
DMUOQN7 DE Discovery agent
DMWELVK ID DMWELVK
DMWELVK DN 4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide
DMWELVK HS Investigative
DMWELVK SN CHEMBL406573; SCHEMBL846014
DMWELVK DT Small molecular drug
DMWELVK PC 44450288
DMWELVK MW 345.4
DMWELVK FM C22H23N3O
DMWELVK IC InChI=1S/C22H23N3O/c26-22(25-20-14-17-6-4-5-9-21(17)23-15-20)16-10-12-19(13-11-16)24-18-7-2-1-3-8-18/h4-6,9-15,18,24H,1-3,7-8H2,(H,25,26)
DMWELVK CS C1CCC(CC1)NC2=CC=C(C=C2)C(=O)NC3=CC4=CC=CC=C4N=C3
DMWELVK IK SWEAAERORIFOIX-UHFFFAOYSA-N
DMWELVK IU 4-(cyclohexylamino)-N-quinolin-3-ylbenzamide
DMWELVK DE Discovery agent
DMWYESB ID DMWYESB
DMWYESB DN 4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB HS Investigative
DMWYESB SN CHEMBL465214; 4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB DT Small molecular drug
DMWYESB PC 44589216
DMWYESB MW 277.31
DMWYESB FM C15H19NO4
DMWYESB IC InChI=1S/C15H19NO4/c17-14(18)12-6-8-13(9-7-12)20-15(19)16-10-11-4-2-1-3-5-11/h6-9,11H,1-5,10H2,(H,16,19)(H,17,18)
DMWYESB CS C1CCC(CC1)CNC(=O)OC2=CC=C(C=C2)C(=O)O
DMWYESB IK UTXJJIRQAYXELZ-UHFFFAOYSA-N
DMWYESB IU 4-(cyclohexylmethylcarbamoyloxy)benzoic acid
DMWYESB DE Discovery agent
DMCDZ7E ID DMCDZ7E
DMCDZ7E DN 4-(cyclohexyloxy)quinazoline
DMCDZ7E HS Investigative
DMCDZ7E SN 4-(cyclohexyloxy)quinazoline; CHEMBL471866
DMCDZ7E DT Small molecular drug
DMCDZ7E PC 44591868
DMCDZ7E MW 228.29
DMCDZ7E FM C14H16N2O
DMCDZ7E IC InChI=1S/C14H16N2O/c1-2-6-11(7-3-1)17-14-12-8-4-5-9-13(12)15-10-16-14/h4-5,8-11H,1-3,6-7H2
DMCDZ7E CS C1CCC(CC1)OC2=NC=NC3=CC=CC=C32
DMCDZ7E IK QNXOLVQGDILPJV-UHFFFAOYSA-N
DMCDZ7E IU 4-cyclohexyloxyquinazoline
DMCDZ7E DE Discovery agent
DM43Z2J ID DM43Z2J
DM43Z2J DN 4-(cyclopropylmethylthio)-2-methoxybenzonitrile
DM43Z2J HS Investigative
DM43Z2J SN CHEMBL504110; 4-(cyclopropylmethylthio)-2-methoxybenzonitrile
DM43Z2J DT Small molecular drug
DM43Z2J PC 44564583
DM43Z2J MW 219.3
DM43Z2J FM C12H13NOS
DM43Z2J IC InChI=1S/C12H13NOS/c1-14-12-6-11(5-4-10(12)7-13)15-8-9-2-3-9/h4-6,9H,2-3,8H2,1H3
DM43Z2J CS COC1=C(C=CC(=C1)SCC2CC2)C#N
DM43Z2J IK KLTYCOFPIFASIE-UHFFFAOYSA-N
DM43Z2J IU 4-(cyclopropylmethylsulfanyl)-2-methoxybenzonitrile
DM43Z2J DE Discovery agent
DM68S9F ID DM68S9F
DM68S9F DN 4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE
DM68S9F HS Investigative
DM68S9F SN 4-(Dimethylamino)butyl carbamimidothioate; F 91488; UNII-1I4LVX494H; SKF 91488; F-91488; SKF-91488; 1I4LVX494H; 68643-23-2; [4-(carbamimidoylsulfanyl)butyl]dimethylamine; Carbamimidothioic acid, 4-(dimethylamino)butyl ester; 4DI; Tocris-0512; Lopac-S-145; AC1L1JVO; AC1Q1UAN; Lopac0_001172; carbamimidothioic acid 4-(dimethylamino)butyl ester; CHEMBL1230270; SCHEMBL12648461; CTK5C8308; ZINC29747245; AKOS006328360; DB07106; CCG-205246; NCGC00024626-01; NCGC00015911-02
DM68S9F DT Small molecular drug
DM68S9F PC 5227
DM68S9F MW 175.3
DM68S9F FM C7H17N3S
DM68S9F IC InChI=1S/C7H17N3S/c1-10(2)5-3-4-6-11-7(8)9/h3-6H2,1-2H3,(H3,8,9)
DM68S9F CS CN(C)CCCCSC(=N)N
DM68S9F IK UFYJLJINUGVUHO-UHFFFAOYSA-N
DM68S9F IU 4-(dimethylamino)butyl carbamimidothioate
DM68S9F CA CAS 68643-23-2
DM68S9F DE Discovery agent
DMJP5YH ID DMJP5YH
DMJP5YH DN 4-(dimethylamino)-N-(thiazol-2-yl)benzamide
DMJP5YH HS Investigative
DMJP5YH SN 4-(dimethylamino)-N-(1,3-thiazol-2-yl)benzamide; AC1M7A6S; CHEMBL425124; MolPort-004-070-500; ZINC3346941; AKOS017059191; MCULE-5265697892; N-(Thiazole-2-yl)-4-(dimethylamino)benzamide; Z28173761
DMJP5YH DT Small molecular drug
DMJP5YH PC 2463677
DMJP5YH MW 247.32
DMJP5YH FM C12H13N3OS
DMJP5YH IC InChI=1S/C12H13N3OS/c1-15(2)10-5-3-9(4-6-10)11(16)14-12-13-7-8-17-12/h3-8H,1-2H3,(H,13,14,16)
DMJP5YH CS CN(C)C1=CC=C(C=C1)C(=O)NC2=NC=CS2
DMJP5YH IK RGXFQNTVZRGDNG-UHFFFAOYSA-N
DMJP5YH IU 4-(dimethylamino)-N-(1,3-thiazol-2-yl)benzamide
DMJP5YH DE Discovery agent
DM14C9V ID DM14C9V
DM14C9V DN 4-(ethylamino)naphthalen-1-ol
DM14C9V HS Investigative
DM14C9V SN CHEMBL577335; 4-(ethylamino)-1-naphthol; 4-(ethylamino)naphthalen-1-ol; SCHEMBL12599061; BDBM50303902; AKOS022516437
DM14C9V DT Small molecular drug
DM14C9V PC 45487209
DM14C9V MW 187.24
DM14C9V FM C12H13NO
DM14C9V IC InChI=1S/C12H13NO/c1-2-13-11-7-8-12(14)10-6-4-3-5-9(10)11/h3-8,13-14H,2H2,1H3
DM14C9V CS CCNC1=CC=C(C2=CC=CC=C21)O
DM14C9V IK SKQYPGROWSDIBN-UHFFFAOYSA-N
DM14C9V IU 4-(ethylamino)naphthalen-1-ol
DM14C9V DE Discovery agent
DM0GCEK ID DM0GCEK
DM0GCEK DN 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK HS Investigative
DM0GCEK SN CHEMBL220445; 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK DT Small molecular drug
DM0GCEK PC 44420099
DM0GCEK MW 232.31
DM0GCEK FM C11H12N4S
DM0GCEK IC InChI=1S/C11H12N4S/c1-2-16-11-14-9(13-10(12)15-11)8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H2,12,13,14,15)
DM0GCEK CS CCSC1=NC(=NC(=N1)N)C2=CC=CC=C2
DM0GCEK IK UMHVGNHYSDRNNN-UHFFFAOYSA-N
DM0GCEK IU 4-ethylsulfanyl-6-phenyl-1,3,5-triazin-2-amine
DM0GCEK DE Discovery agent
DMY7035 ID DMY7035
DMY7035 DN 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
DMY7035 HS Investigative
DMY7035 SN CHEMBL406499; 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamine; 442847-46-3; SCHEMBL4369855; 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine; SCHEMBL13668449; YOPVCNSOKMOXST-UHFFFAOYSA-N; BDBM50239028; J3.571.237B; L021771; 4-(2-Furyl)-7H-pyrrolo[2,3-d]pyrimidine-2-amine
DMY7035 DT Small molecular drug
DMY7035 PC 21976428
DMY7035 MW 200.2
DMY7035 FM C10H8N4O
DMY7035 IC InChI=1S/C10H8N4O/c11-10-13-8(7-2-1-5-15-7)6-3-4-12-9(6)14-10/h1-5H,(H3,11,12,13,14)
DMY7035 CS C1=COC(=C1)C2=C3C=CNC3=NC(=N2)N
DMY7035 IK YOPVCNSOKMOXST-UHFFFAOYSA-N
DMY7035 IU 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
DMY7035 DE Discovery agent
DM7LVKP ID DM7LVKP
DM7LVKP DN 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine
DM7LVKP HS Investigative
DM7LVKP SN CHEMBL406298; Thieno[3,2-d]pyrimidin-2-amine, 4-(2-furanyl)-; SCHEMBL3678073; ARPSUXKIHNZLQL-UHFFFAOYSA-N; BDBM50377489; 443148-30-9
DM7LVKP DT Small molecular drug
DM7LVKP PC 9964493
DM7LVKP MW 217.25
DM7LVKP FM C10H7N3OS
DM7LVKP IC InChI=1S/C10H7N3OS/c11-10-12-6-3-5-15-9(6)8(13-10)7-2-1-4-14-7/h1-5H,(H2,11,12,13)
DM7LVKP CS C1=COC(=C1)C2=NC(=NC3=C2SC=C3)N
DM7LVKP IK ARPSUXKIHNZLQL-UHFFFAOYSA-N
DM7LVKP IU 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine
DM7LVKP DE Discovery agent
DMW4O31 ID DMW4O31
DMW4O31 DN 4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine
DMW4O31 HS Investigative
DMW4O31 SN CHEMBL601911
DMW4O31 DT Small molecular drug
DMW4O31 PC 46224813
DMW4O31 MW 309.4
DMW4O31 FM C17H11NOS2
DMW4O31 IC InChI=1S/C17H11NOS2/c1-3-16(20-7-1)14-9-13(12-5-6-19-11-12)10-15(18-14)17-4-2-8-21-17/h1-11H
DMW4O31 CS C1=CSC(=C1)C2=CC(=CC(=N2)C3=CC=CS3)C4=COC=C4
DMW4O31 IK HCNMYINNCZEXQR-UHFFFAOYSA-N
DMW4O31 IU 4-(furan-3-yl)-2,6-dithiophen-2-ylpyridine
DMW4O31 DE Discovery agent
DM70MRZ ID DM70MRZ
DM70MRZ DN 4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide
DM70MRZ HS Investigative
DM70MRZ SN CHEMBL408637; SCHEMBL846538
DM70MRZ DT Small molecular drug
DM70MRZ PC 44450322
DM70MRZ MW 361.5
DM70MRZ FM C23H27N3O
DM70MRZ IC InChI=1S/C23H27N3O/c1-3-4-5-8-15-26(2)21-13-11-18(12-14-21)23(27)25-20-16-19-9-6-7-10-22(19)24-17-20/h6-7,9-14,16-17H,3-5,8,15H2,1-2H3,(H,25,27)
DM70MRZ CS CCCCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM70MRZ IK FIZXTSXGXVTGKK-UHFFFAOYSA-N
DM70MRZ IU 4-[hexyl(methyl)amino]-N-quinolin-3-ylbenzamide
DM70MRZ DE Discovery agent
DMWJN73 ID DMWJN73
DMWJN73 DN 4-(Hydroxymercury)Benzoic Acid
DMWJN73 HS Investigative
DMWJN73 SN p-hydroxymercuribenzoic acid; p-hydroxymercuribenzoate; (p-carboxyphenyl)hydroxymercury; 4-(HYDROXYMERCURY)BENZOIC ACID; mercury, (p-carboxyphenyl)hydroxy-; (4-carboxyphenyl)(hydroxy)mercury; (4-carboxylatophenyl)hydroxymercurate(1-) hydrogen; 1126-48-3; Sodium p-chloromercuribenzoate; Mercury, sodium salt; Mercury, monosodium salt; Mercurate(1-), sodium; SCHEMBL678164; CHEMBL78771; Mercurate(1-), (4-carboxylatophenyl)hydroxy-, hydrogen; CHEBI:49644; NSC1048; NSC-1048
DMWJN73 DT Small molecular drug
DMWJN73 PC 14309
DMWJN73 MW 339.72
DMWJN73 FM C7H7HgO3
DMWJN73 IC InChI=1S/C7H5O2.Hg.H2O/c8-7(9)6-4-2-1-3-5-6;;/h2-5H,(H,8,9);;1H2
DMWJN73 CS C1=CC(=CC=C1C(=O)O)[Hg].O
DMWJN73 IK NBCQBGBECVUZMK-UHFFFAOYSA-N
DMWJN73 IU (4-carboxyphenyl)mercury;hydrate
DMWJN73 CA CAS 1126-48-3
DMWJN73 CB CHEBI:49644
DMWJN73 DE Discovery agent
DMR6VWL ID DMR6VWL
DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide
DMR6VWL HS Investigative
DMR6VWL SN 4-Hydroxymethyl-benzenesulfonamide
DMR6VWL DT Small molecular drug
DMR6VWL PC 10081162
DMR6VWL MW 187.22
DMR6VWL FM C7H9NO3S
DMR6VWL IC InChI=1S/C7H9NO3S/c8-12(10,11)7-3-1-6(5-9)2-4-7/h1-4,9H,5H2,(H2,8,10,11)
DMR6VWL CS C1=CC(=CC=C1CO)S(=O)(=O)N
DMR6VWL IK UULCVOIRJRJPQS-UHFFFAOYSA-N
DMR6VWL IU 4-(hydroxymethyl)benzenesulfonamide
DMR6VWL CA CAS 67472-44-0
DMR6VWL DE Discovery agent
DMHI50W ID DMHI50W
DMHI50W DN 4-(Indan-1-ylsulfanyl)-phenylamine
DMHI50W HS Investigative
DMHI50W SN CHEMBL191844; 4-(Indan-1-ylsulfanyl)-phenylamine
DMHI50W DT Small molecular drug
DMHI50W PC 44401620
DMHI50W MW 241.4
DMHI50W FM C15H15NS
DMHI50W IC InChI=1S/C15H15NS/c16-12-6-8-13(9-7-12)17-15-10-5-11-3-1-2-4-14(11)15/h1-4,6-9,15H,5,10,16H2
DMHI50W CS C1CC2=CC=CC=C2C1SC3=CC=C(C=C3)N
DMHI50W IK WWGLOFVWIRHNNH-UHFFFAOYSA-N
DMHI50W IU 4-(2,3-dihydro-1H-inden-1-ylsulfanyl)aniline
DMHI50W DE Discovery agent
DM201UM ID DM201UM
DM201UM DN 4-(Indane-1-sulfonyl)-phenylamine
DM201UM HS Investigative
DM201UM SN CHEMBL191972; 4-(Indane-1-sulfonyl)-phenylamine
DM201UM DT Small molecular drug
DM201UM PC 44401621
DM201UM MW 273.4
DM201UM FM C15H15NO2S
DM201UM IC InChI=1S/C15H15NO2S/c16-12-6-8-13(9-7-12)19(17,18)15-10-5-11-3-1-2-4-14(11)15/h1-4,6-9,15H,5,10,16H2
DM201UM CS C1CC2=CC=CC=C2C1S(=O)(=O)C3=CC=C(C=C3)N
DM201UM IK AJRGJBUDLAAWNT-UHFFFAOYSA-N
DM201UM IU 4-(2,3-dihydro-1H-inden-1-ylsulfonyl)aniline
DM201UM DE Discovery agent
DMGSZB2 ID DMGSZB2
DMGSZB2 DN 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile
DMGSZB2 HS Investigative
DMGSZB2 SN CHEMBL503687; 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile
DMGSZB2 DT Small molecular drug
DMGSZB2 PC 44564659
DMGSZB2 MW 273.32
DMGSZB2 FM C13H14F3NS
DMGSZB2 IC InChI=1S/C13H14F3NS/c1-9(2)5-6-18-11-4-3-10(8-17)12(7-11)13(14,15)16/h3-4,7,9H,5-6H2,1-2H3
DMGSZB2 CS CC(C)CCSC1=CC(=C(C=C1)C#N)C(F)(F)F
DMGSZB2 IK JCLWLTZDKYNAQH-UHFFFAOYSA-N
DMGSZB2 IU 4-(3-methylbutylsulfanyl)-2-(trifluoromethyl)benzonitrile
DMGSZB2 DE Discovery agent
DML1G9S ID DML1G9S
DML1G9S DN 4-(isopentylthio)-2-methoxybenzonitrile
DML1G9S HS Investigative
DML1G9S SN CHEMBL462663; 4-(isopentylthio)-2-methoxybenzonitrile
DML1G9S DT Small molecular drug
DML1G9S PC 44564585
DML1G9S MW 235.35
DML1G9S FM C13H17NOS
DML1G9S IC InChI=1S/C13H17NOS/c1-10(2)6-7-16-12-5-4-11(9-14)13(8-12)15-3/h4-5,8,10H,6-7H2,1-3H3
DML1G9S CS CC(C)CCSC1=CC(=C(C=C1)C#N)OC
DML1G9S IK XWPLSLIGOKRGBS-UHFFFAOYSA-N
DML1G9S IU 2-methoxy-4-(3-methylbutylsulfanyl)benzonitrile
DML1G9S DE Discovery agent
DMJFSTX ID DMJFSTX
DMJFSTX DN 4-(Isopropylamino)-1-naphthol
DMJFSTX HS Investigative
DMJFSTX SN CHEMBL578212; 4-(Isopropylamino)-1-naphthol; SCHEMBL12599062
DMJFSTX DT Small molecular drug
DMJFSTX PC 44465702
DMJFSTX MW 201.26
DMJFSTX FM C13H15NO
DMJFSTX IC InChI=1S/C13H15NO/c1-9(2)14-12-7-8-13(15)11-6-4-3-5-10(11)12/h3-9,14-15H,1-2H3
DMJFSTX CS CC(C)NC1=CC=C(C2=CC=CC=C21)O
DMJFSTX IK TWBKFLLEYLZFHH-UHFFFAOYSA-N
DMJFSTX IU 4-(propan-2-ylamino)naphthalen-1-ol
DMJFSTX DE Discovery agent
DMVDHX1 ID DMVDHX1
DMVDHX1 DN 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile
DMVDHX1 HS Investigative
DMVDHX1 SN CHEMBL453740; 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247976
DMVDHX1 DT Small molecular drug
DMVDHX1 PC 44157043
DMVDHX1 MW 245.27
DMVDHX1 FM C11H10F3NS
DMVDHX1 IC InChI=1S/C11H10F3NS/c1-7(2)16-9-4-3-8(6-15)10(5-9)11(12,13)14/h3-5,7H,1-2H3
DMVDHX1 CS CC(C)SC1=CC(=C(C=C1)C#N)C(F)(F)F
DMVDHX1 IK QPFAGTVKCMQHRW-UHFFFAOYSA-N
DMVDHX1 IU 4-propan-2-ylsulfanyl-2-(trifluoromethyl)benzonitrile
DMVDHX1 DE Discovery agent
DMR5HNI ID DMR5HNI
DMR5HNI DN 4-(isopropylthio)-2-methoxybenzonitrile
DMR5HNI HS Investigative
DMR5HNI SN CHEMBL445429; 4-(isopropylthio)-2-methoxybenzonitrile
DMR5HNI DT Small molecular drug
DMR5HNI PC 44157042
DMR5HNI MW 207.29
DMR5HNI FM C11H13NOS
DMR5HNI IC InChI=1S/C11H13NOS/c1-8(2)14-10-5-4-9(7-12)11(6-10)13-3/h4-6,8H,1-3H3
DMR5HNI CS CC(C)SC1=CC(=C(C=C1)C#N)OC
DMR5HNI IK MIAOMCWVGGHYSA-UHFFFAOYSA-N
DMR5HNI IU 2-methoxy-4-propan-2-ylsulfanylbenzonitrile
DMR5HNI DE Discovery agent
DM8LODU ID DM8LODU
DM8LODU DN 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine
DM8LODU HS Investigative
DM8LODU SN CHEMBL202998; 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine; BDBM50179884
DM8LODU DT Small molecular drug
DM8LODU PC 44409436
DM8LODU MW 362.4
DM8LODU FM C24H18N4
DM8LODU IC InChI=1S/C24H18N4/c1-16-6-4-8-18(14-16)26-24-22-10-3-2-9-21(22)23(27-28-24)20-11-5-7-17-15-25-13-12-19(17)20/h2-15H,1H3,(H,26,28)
DM8LODU CS CC1=CC(=CC=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=CC5=C4C=CN=C5
DM8LODU IK KGVVWWXTGNZBAX-UHFFFAOYSA-N
DM8LODU IU 4-isoquinolin-5-yl-N-(3-methylphenyl)phthalazin-1-amine
DM8LODU DE Discovery agent
DMS30HQ ID DMS30HQ
DMS30HQ DN 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine
DMS30HQ HS Investigative
DMS30HQ SN CHEMBL204220; 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine; BDBM50179895
DMS30HQ DT Small molecular drug
DMS30HQ PC 44409370
DMS30HQ MW 362.4
DMS30HQ FM C24H18N4
DMS30HQ IC InChI=1S/C24H18N4/c1-16-7-2-5-12-22(16)26-24-21-10-4-3-9-20(21)23(27-28-24)19-11-6-8-17-15-25-14-13-18(17)19/h2-15H,1H3,(H,26,28)
DMS30HQ CS CC1=CC=CC=C1NC2=NN=C(C3=CC=CC=C32)C4=CC=CC5=C4C=CN=C5
DMS30HQ IK AQWOEJFWZLDYCH-UHFFFAOYSA-N
DMS30HQ IU 4-isoquinolin-5-yl-N-(2-methylphenyl)phthalazin-1-amine
DMS30HQ DE Discovery agent
DMQG57D ID DMQG57D
DMQG57D DN 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile
DMQG57D HS Investigative
DMQG57D SN CHEMBL513768; 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163778
DMQG57D DT Small molecular drug
DMQG57D PC 11587567
DMQG57D MW 305.29
DMQG57D FM C17H14F3NO
DMQG57D IC InChI=1S/C17H14F3NO/c1-10-6-11(2)16(12(3)7-10)22-14-5-4-13(9-21)15(8-14)17(18,19)20/h4-8H,1-3H3
DMQG57D CS CC1=CC(=C(C(=C1)C)OC2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMQG57D IK XMMDWVWTOYZZAJ-UHFFFAOYSA-N
DMQG57D IU 2-(trifluoromethyl)-4-(2,4,6-trimethylphenoxy)benzonitrile
DMQG57D DE Discovery agent
DMAI3NZ ID DMAI3NZ
DMAI3NZ DN 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile
DMAI3NZ HS Investigative
DMAI3NZ SN CHEMBL462234; 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile
DMAI3NZ DT Small molecular drug
DMAI3NZ PC 44565205
DMAI3NZ MW 321.4
DMAI3NZ FM C17H14F3NS
DMAI3NZ IC InChI=1S/C17H14F3NS/c1-10-6-11(2)16(12(3)7-10)22-14-5-4-13(9-21)15(8-14)17(18,19)20/h4-8H,1-3H3
DMAI3NZ CS CC1=CC(=C(C(=C1)C)SC2=CC(=C(C=C2)C#N)C(F)(F)F)C
DMAI3NZ IK ZDVOQQIVWWNKSG-UHFFFAOYSA-N
DMAI3NZ IU 2-(trifluoromethyl)-4-(2,4,6-trimethylphenyl)sulfanylbenzonitrile
DMAI3NZ DE Discovery agent
DM1XK68 ID DM1XK68
DM1XK68 DN 4-(mesitylthio)-2-methoxybenzonitrile
DM1XK68 HS Investigative
DM1XK68 SN CHEMBL462022; 4-(mesitylthio)-2-methoxybenzonitrile
DM1XK68 DT Small molecular drug
DM1XK68 PC 44564580
DM1XK68 MW 283.4
DM1XK68 FM C17H17NOS
DM1XK68 IC InChI=1S/C17H17NOS/c1-11-7-12(2)17(13(3)8-11)20-15-6-5-14(10-18)16(9-15)19-4/h5-9H,1-4H3
DM1XK68 CS CC1=CC(=C(C(=C1)C)SC2=CC(=C(C=C2)C#N)OC)C
DM1XK68 IK YPJRESPHGOONFU-UHFFFAOYSA-N
DM1XK68 IU 2-methoxy-4-(2,4,6-trimethylphenyl)sulfanylbenzonitrile
DM1XK68 DE Discovery agent
DMQCMFU ID DMQCMFU
DMQCMFU DN 4-(methyl(4-phenylthiazol-2-yl)amino)phenol
DMQCMFU HS Investigative
DMQCMFU SN CHEMBL460515; 4-[Methyl-(4-phenyl-thiazol-2-yl)-amino]-phenol; 4-(methyl(4-phenylthiazol-2-yl)amino)phenol; AC1LDK73; MLS000075845; cid_649391; ZINC813364; HMS2534H13; BDBM50247460; AKOS000563578; SMR000014954; BAS 08769335; SR-01000322128; SR-01000322128-1
DMQCMFU DT Small molecular drug
DMQCMFU PC 649391
DMQCMFU MW 282.4
DMQCMFU FM C16H14N2OS
DMQCMFU IC InChI=1S/C16H14N2OS/c1-18(13-7-9-14(19)10-8-13)16-17-15(11-20-16)12-5-3-2-4-6-12/h2-11,19H,1H3
DMQCMFU CS CN(C1=CC=C(C=C1)O)C2=NC(=CS2)C3=CC=CC=C3
DMQCMFU IK XDKOSPFALAXPJO-UHFFFAOYSA-N
DMQCMFU IU 4-[methyl-(4-phenyl-1,3-thiazol-2-yl)amino]phenol
DMQCMFU DE Discovery agent
DM3TF9Y ID DM3TF9Y
DM3TF9Y DN 4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide
DM3TF9Y HS Investigative
DM3TF9Y SN CHEMBL407233; SCHEMBL846831
DM3TF9Y DT Small molecular drug
DM3TF9Y PC 44450300
DM3TF9Y MW 403.6
DM3TF9Y FM C26H33N3O
DM3TF9Y IC InChI=1S/C26H33N3O/c1-3-4-5-6-7-8-11-18-29(2)24-16-14-21(15-17-24)26(30)28-23-19-22-12-9-10-13-25(22)27-20-23/h9-10,12-17,19-20H,3-8,11,18H2,1-2H3,(H,28,30)
DM3TF9Y CS CCCCCCCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM3TF9Y IK KGQMIDBMCJPWMX-UHFFFAOYSA-N
DM3TF9Y IU 4-[methyl(nonyl)amino]-N-quinolin-3-ylbenzamide
DM3TF9Y DE Discovery agent
DM1I0TA ID DM1I0TA
DM1I0TA DN 4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide
DM1I0TA HS Investigative
DM1I0TA SN CHEMBL259017; SCHEMBL846048
DM1I0TA DT Small molecular drug
DM1I0TA PC 44450313
DM1I0TA MW 389.5
DM1I0TA FM C25H31N3O
DM1I0TA IC InChI=1S/C25H31N3O/c1-3-4-5-6-7-10-17-28(2)23-15-13-20(14-16-23)25(29)27-22-18-21-11-8-9-12-24(21)26-19-22/h8-9,11-16,18-19H,3-7,10,17H2,1-2H3,(H,27,29)
DM1I0TA CS CCCCCCCCN(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM1I0TA IK YWPSOIQULJMWIC-UHFFFAOYSA-N
DM1I0TA IU 4-[methyl(octyl)amino]-N-quinolin-3-ylbenzamide
DM1I0TA DE Discovery agent
DMF3O10 ID DMF3O10
DMF3O10 DN 4-(methylamino)naphthalen-1-ol
DMF3O10 HS Investigative
DMF3O10 SN CHEMBL571240; 4-(methylamino)naphthalen-1-ol; SCHEMBL10158309; BDBM50303921
DMF3O10 DT Small molecular drug
DMF3O10 PC 20029042
DMF3O10 MW 173.21
DMF3O10 FM C11H11NO
DMF3O10 IC InChI=1S/C11H11NO/c1-12-10-6-7-11(13)9-5-3-2-4-8(9)10/h2-7,12-13H,1H3
DMF3O10 CS CNC1=CC=C(C2=CC=CC=C21)O
DMF3O10 IK YEJJUWPHXGQPCZ-UHFFFAOYSA-N
DMF3O10 IU 4-(methylamino)naphthalen-1-ol
DMF3O10 DE Discovery agent
DM4BPL1 ID DM4BPL1
DM4BPL1 DN 4-(Methylhydrazino)-3-pyridinesulfonamide
DM4BPL1 HS Investigative
DM4BPL1 SN 4-(Methylhydrazino)-3-pyridinesulfonamide; CHEMBL1164878; BDBM50320511
DM4BPL1 DT Small molecular drug
DM4BPL1 PC 46704078
DM4BPL1 MW 202.24
DM4BPL1 FM C6H10N4O2S
DM4BPL1 IC InChI=1S/C6H10N4O2S/c1-8-10-5-2-3-9-4-6(5)13(7,11)12/h2-4,8H,1H3,(H,9,10)(H2,7,11,12)
DM4BPL1 CS CNNC1=C(C=NC=C1)S(=O)(=O)N
DM4BPL1 IK CKTSHDQZQGLANI-UHFFFAOYSA-N
DM4BPL1 IU 4-(2-methylhydrazinyl)pyridine-3-sulfonamide
DM4BPL1 DE Discovery agent
DM8BWZO ID DM8BWZO
DM8BWZO DN 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile
DM8BWZO HS Investigative
DM8BWZO SN CHEMBL464764; 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248553
DM8BWZO DT Small molecular drug
DM8BWZO PC 43320723
DM8BWZO MW 277.24
DM8BWZO FM C15H10F3NO
DM8BWZO IC InChI=1S/C15H10F3NO/c1-10-3-2-4-12(7-10)20-13-6-5-11(9-19)14(8-13)15(16,17)18/h2-8H,1H3
DM8BWZO CS CC1=CC(=CC=C1)OC2=CC(=C(C=C2)C#N)C(F)(F)F
DM8BWZO IK RKGPWAIQCDEIFV-UHFFFAOYSA-N
DM8BWZO IU 4-(3-methylphenoxy)-2-(trifluoromethyl)benzonitrile
DM8BWZO DE Discovery agent
DMI5XB1 ID DMI5XB1
DMI5XB1 DN 4-(Naphthalene-1-sulfonyl)-phenylamine
DMI5XB1 HS Investigative
DMI5XB1 SN CHEMBL181382; 4-(Naphthalene-1-sulfonyl)-phenylamine; SCHEMBL10775871
DMI5XB1 DT Small molecular drug
DMI5XB1 PC 44390054
DMI5XB1 MW 283.3
DMI5XB1 FM C16H13NO2S
DMI5XB1 IC InChI=1S/C16H13NO2S/c17-13-8-10-14(11-9-13)20(18,19)16-7-3-5-12-4-1-2-6-15(12)16/h1-11H,17H2
DMI5XB1 CS C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)C3=CC=C(C=C3)N
DMI5XB1 IK WJMHQZIDRDGGIY-UHFFFAOYSA-N
DMI5XB1 IU 4-naphthalen-1-ylsulfonylaniline
DMI5XB1 DE Discovery agent
DMADWTI ID DMADWTI
DMADWTI DN 4-(N-Methyl-hydrazino)-benzenesulfonamide
DMADWTI HS Investigative
DMADWTI SN CHEMBL183913; 4-(N-Methyl-hydrazino)-benzenesulfonamide; SCHEMBL13242579
DMADWTI DT Small molecular drug
DMADWTI PC 44392435
DMADWTI MW 201.25
DMADWTI FM C7H11N3O2S
DMADWTI IC InChI=1S/C7H11N3O2S/c1-10(8)6-2-4-7(5-3-6)13(9,11)12/h2-5H,8H2,1H3,(H2,9,11,12)
DMADWTI CS CN(C1=CC=C(C=C1)S(=O)(=O)N)N
DMADWTI IK XGAFGUJHKUYKIM-UHFFFAOYSA-N
DMADWTI IU 4-[amino(methyl)amino]benzenesulfonamide
DMADWTI DE Discovery agent
DMYCV8E ID DMYCV8E
DMYCV8E DN 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E HS Investigative
DMYCV8E SN CHEMBL1165118; 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide
DMYCV8E DT Small molecular drug
DMYCV8E PC 46703924
DMYCV8E MW 283.3
DMYCV8E FM C10H9N3O3S2
DMYCV8E IC InChI=1S/C10H9N3O3S2/c11-18(15,16)9-7-12-5-4-8(9)17-10-3-1-2-6-13(10)14/h1-7H,(H2,11,15,16)
DMYCV8E CS C1=CC=[N+](C(=C1)SC2=C(C=NC=C2)S(=O)(=O)N)[O-]
DMYCV8E IK DQAURQJZVIJAAO-UHFFFAOYSA-N
DMYCV8E IU 4-(1-oxidopyridin-1-ium-2-yl)sulfanylpyridine-3-sulfonamide
DMYCV8E DE Discovery agent
DMP43HI ID DMP43HI
DMP43HI DN 4-(n-propyl)amino-3-nitrobenzoic acid
DMP43HI HS Investigative
DMP43HI SN compound 5c [PMID: 17931863]
DMP43HI DT Small molecular drug
DMP43HI PC 11715556
DMP43HI MW 224.21
DMP43HI FM C10H12N2O4
DMP43HI IC InChI=1S/C10H12N2O4/c1-2-5-11-8-4-3-7(10(13)14)6-9(8)12(15)16/h3-4,6,11H,2,5H2,1H3,(H,13,14)
DMP43HI CS CCCNC1=C(C=C(C=C1)C(=O)O)[N+](=O)[O-]
DMP43HI IK OVDGUTHABMXVMI-UHFFFAOYSA-N
DMP43HI IU 3-nitro-4-(propylamino)benzoic acid
DMP43HI CA CAS 68740-31-8
DMP43HI DE Discovery agent
DM8I4B9 ID DM8I4B9
DM8I4B9 DN 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile
DM8I4B9 HS Investigative
DM8I4B9 SN CHEMBL499137; 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile; SCHEMBL4163678; BDBM50248552
DM8I4B9 DT Small molecular drug
DM8I4B9 PC 11608821
DM8I4B9 MW 277.24
DM8I4B9 FM C15H10F3NO
DM8I4B9 IC InChI=1S/C15H10F3NO/c1-10-4-2-3-5-14(10)20-12-7-6-11(9-19)13(8-12)15(16,17)18/h2-8H,1H3
DM8I4B9 CS CC1=CC=CC=C1OC2=CC(=C(C=C2)C#N)C(F)(F)F
DM8I4B9 IK PEOSULIFVYUPML-UHFFFAOYSA-N
DM8I4B9 IU 4-(2-methylphenoxy)-2-(trifluoromethyl)benzonitrile
DM8I4B9 DE Discovery agent
DM85XP6 ID DM85XP6
DM85XP6 DN 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile
DM85XP6 HS Investigative
DM85XP6 SN CHEMBL462025; 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile; BDBM50248593
DM85XP6 DT Small molecular drug
DM85XP6 PC 44565202
DM85XP6 MW 293.31
DM85XP6 FM C15H10F3NS
DM85XP6 IC InChI=1S/C15H10F3NS/c1-10-4-2-3-5-14(10)20-12-7-6-11(9-19)13(8-12)15(16,17)18/h2-8H,1H3
DM85XP6 CS CC1=CC=CC=C1SC2=CC(=C(C=C2)C#N)C(F)(F)F
DM85XP6 IK RAJQECAXWDTUGF-UHFFFAOYSA-N
DM85XP6 IU 4-(2-methylphenyl)sulfanyl-2-(trifluoromethyl)benzonitrile
DM85XP6 DE Discovery agent
DMHIDY6 ID DMHIDY6
DMHIDY6 DN 4-(Pent-3-ylamino)-1-naphthol
DMHIDY6 HS Investigative
DMHIDY6 SN CHEMBL571980; 4-(Pent-3-ylamino)-1-naphthol; SCHEMBL12649391
DMHIDY6 DT Small molecular drug
DMHIDY6 PC 45487171
DMHIDY6 MW 229.32
DMHIDY6 FM C15H19NO
DMHIDY6 IC InChI=1S/C15H19NO/c1-3-11(4-2)16-14-9-10-15(17)13-8-6-5-7-12(13)14/h5-11,16-17H,3-4H2,1-2H3
DMHIDY6 CS CCC(CC)NC1=CC=C(C2=CC=CC=C21)O
DMHIDY6 IK LZQSUKJAJXHQLF-UHFFFAOYSA-N
DMHIDY6 IU 4-(pentan-3-ylamino)naphthalen-1-ol
DMHIDY6 DE Discovery agent
DM54MOP ID DM54MOP
DM54MOP DN 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine
DM54MOP HS Investigative
DM54MOP DT Small molecular drug
DM54MOP PC 242623
DM54MOP MW 202.22
DM54MOP FM C9H10N6
DM54MOP IC InChI=1S/C9H10N6/c10-8-7(9(11)15-14-8)13-12-6-4-2-1-3-5-6/h1-5H,(H5,10,11,14,15)
DM54MOP CS C1=CC=C(C=C1)N=NC2=C(NN=C2N)N
DM54MOP IK BLXRKDXUWQFGAW-UHFFFAOYSA-N
DM54MOP IU 4-phenyldiazenyl-1H-pyrazole-3,5-diamine
DM54MOP CA CAS 3656-02-8
DM54MOP DE Discovery agent
DMM1RCS ID DMM1RCS
DMM1RCS DN 4-(piperazin-1-yl)-1H-indole
DMM1RCS HS Investigative
DMM1RCS SN 4-(1-Piperazinyl)-1H-indole; 84807-09-0; 4-(piperazin-1-yl)-1H-indole; 4-Piperazino-1H-indole; 1H-Indole, 4-(1-piperazinyl)-; 4-(Piperazino)indole; 4-piperazin-1-yl-1H-indole; 1-(4-indolyl)piperazine; CHEMBL200234; YZKSXUIOKWQABW-UHFFFAOYSA-N; AK-26360; W-206959; 1H-Indole-4-(1-piperazinyl)dihydrochloride; 4-piperazinoindole; 4-piperazino-indole; PubChem22668; AC1LC5AN; 1H-indol-4-ylpiperazine; 4-(1-piperazinyl)indole; 1-(indol-4yl)piperazine; 1-(indol-4yl)-piperazine; 1-(indol-4-yl)piperazine; 1-(4-indolyl)-piperazine
DMM1RCS DT Small molecular drug
DMM1RCS PC 594590
DMM1RCS MW 201.27
DMM1RCS FM C12H15N3
DMM1RCS IC InChI=1S/C12H15N3/c1-2-11-10(4-5-14-11)12(3-1)15-8-6-13-7-9-15/h1-5,13-14H,6-9H2
DMM1RCS CS C1CN(CCN1)C2=CC=CC3=C2C=CN3
DMM1RCS IK YZKSXUIOKWQABW-UHFFFAOYSA-N
DMM1RCS IU 4-piperazin-1-yl-1H-indole
DMM1RCS CA CAS 84807-09-0
DMM1RCS DE Discovery agent
DM1HM3F ID DM1HM3F
DM1HM3F DN 4-(piperazin-1-yl)-3-tosyl-1H-indazole
DM1HM3F HS Investigative
DM1HM3F SN CHEMBL1277834; 4-(piperazin-1-yl)-3-tosyl-1H-indazole
DM1HM3F DT Small molecular drug
DM1HM3F PC 49836506
DM1HM3F MW 356.4
DM1HM3F FM C18H20N4O2S
DM1HM3F IC InChI=1S/C18H20N4O2S/c1-13-5-7-14(8-6-13)25(23,24)18-17-15(20-21-18)3-2-4-16(17)22-11-9-19-10-12-22/h2-8,19H,9-12H2,1H3,(H,20,21)
DM1HM3F CS CC1=CC=C(C=C1)S(=O)(=O)C2=C3C(=NN2)C=CC=C3N4CCNCC4
DM1HM3F IK SJAUEJQIVFASOP-UHFFFAOYSA-N
DM1HM3F IU 3-(4-methylphenyl)sulfonyl-4-piperazin-1-yl-2H-indazole
DM1HM3F DE Discovery agent
DMTNVFZ ID DMTNVFZ
DMTNVFZ DN 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine
DMTNVFZ HS Investigative
DMTNVFZ SN 252722-52-4; 4-(Piperazin-1-yl)-1H-pyrrolo[2,3-d]pyrimidine; 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine; 4-(1-Piperazinyl)-1H-pyrrolo[2,3-d]pyrimidine; CHEMBL595554; 1-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}piperazine; 6J9; SCHEMBL2251760; DTXSID20592472; MolPort-028-913-269; BDBM50304819; AKOS022175220; AKOS016374229; MCULE-3871238079; ACM252722524; NS-02114; DB-067363; AX8159612; KB-186079; AJ-103002
DMTNVFZ DT Small molecular drug
DMTNVFZ PC 18008465
DMTNVFZ MW 203.24
DMTNVFZ FM C10H13N5
DMTNVFZ IC InChI=1S/C10H13N5/c1-2-12-9-8(1)10(14-7-13-9)15-5-3-11-4-6-15/h1-2,7,11H,3-6H2,(H,12,13,14)
DMTNVFZ CS C1CN(CCN1)C2=NC=NC3=C2C=CN3
DMTNVFZ IK LZSXQBNNRGZPES-UHFFFAOYSA-N
DMTNVFZ IU 4-piperazin-1-yl-7H-pyrrolo[2,3-d]pyrimidine
DMTNVFZ CA CAS 252722-52-4
DMTNVFZ DE Discovery agent
DMNM8VY ID DMNM8VY
DMNM8VY DN 4-(piperazin-1-yl)furo[3,2-c]pyridine
DMNM8VY HS Investigative
DMNM8VY SN 4-(piperazin-1-yl)furo[3,2-c]pyridine; 81078-84-4; 4-PIPERAZIN-1-YL-FURO[3,2-C]PYRIDINE; 1-{furo[3,2-c]pyridin-4-yl}piperazine; CHEMBL595555; Furo[3,2-c]pyridine, 4-(1-piperazinyl)-; AK-76639; CHEMBL543969; PubChem17312; AC1MDRY3; SCHEMBL1026755; KS-00000EXO; CTK5E8449; DTXSID10383432; MolPort-000-145-249; LUIZVTKJWSGSPA-UHFFFAOYSA-N; ZINC4287704; 4-piperazinylfurano[3,2-c]pyridine; ANW-49259; BDBM50016972; SBB093149; 4-piperazin-1-ylfuro[3,2-c]pyridine; AKOS015919593; FS-3269; 1-(4-furo[3,2-c]pyridinyl)piperazine
DMNM8VY DT Small molecular drug
DMNM8VY PC 2794808
DMNM8VY MW 203.24
DMNM8VY FM C11H13N3O
DMNM8VY IC InChI=1S/C11H13N3O/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
DMNM8VY CS C1CN(CCN1)C2=NC=CC3=C2C=CO3
DMNM8VY IK LUIZVTKJWSGSPA-UHFFFAOYSA-N
DMNM8VY IU 4-piperazin-1-ylfuro[3,2-c]pyridine
DMNM8VY CA CAS 81078-84-4
DMNM8VY DE Discovery agent
DMNU2RM ID DMNU2RM
DMNU2RM DN 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine
DMNU2RM HS Investigative
DMNU2RM SN 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine; 373356-48-0; 1-{thieno[2,3-d]pyrimidin-4-yl}piperazine; 4-piperazin-1-ylthieno[2,3-d]pyrimidine; CHEMBL596108; 1-(Thieno[2,3-d]pyrimidin-4-yl)piperazine; AC1Q1I4T; SCHEMBL4922800; CTK7D1707; MolPort-001-760-894; ZINC12954996; SBB095996; BDBM50304810; AKOS000123564; MCULE-6714459164; PS-3311; NE24045; KS-000029X0; 4-piperazinylthiopheno[2,3-d]pyrimidine; KB-85055; DA-06355; 4-Piperazin-1-yl-thieno[2,3-d]pyrimidine; KB-243074; FT-0727983; EN300-29445; Thieno[2,3-d]pyrimidine, 4-(1-piperaziny
DMNU2RM DT Small molecular drug
DMNU2RM PC 16768198
DMNU2RM MW 220.3
DMNU2RM FM C10H12N4S
DMNU2RM IC InChI=1S/C10H12N4S/c1-6-15-10-8(1)9(12-7-13-10)14-4-2-11-3-5-14/h1,6-7,11H,2-5H2
DMNU2RM CS C1CN(CCN1)C2=C3C=CSC3=NC=N2
DMNU2RM IK HFGUINASBGDWLY-UHFFFAOYSA-N
DMNU2RM IU 4-piperazin-1-ylthieno[2,3-d]pyrimidine
DMNU2RM CA CAS 373356-48-0
DMNU2RM DE Discovery agent
DMJGTS7 ID DMJGTS7
DMJGTS7 DN 4-(piperazin-1-yl)thieno[3,2-c]pyridine
DMJGTS7 HS Investigative
DMJGTS7 SN 106261-27-2; 4-(piperazin-1-yl)thieno[3,2-c]pyridine; 1-{THIENO[3,2-C]PYRIDIN-4-YL}PIPERAZINE; Thieno[3,2-c]pyridine,4-(1-piperazinyl)-; Thieno[3,2-c]pyridine, 4-(1-piperazinyl)-; 4-Piperazin-1-yl-thieno[3,2-c]pyridine; CHEMBL608135; 4-Piperazin-1-ylthieno[3,2-c]pyridine; CHEMBL552833; 4-(1-piperazinyl)thieno[3,2-c]pyridine; 4-piperazine-1-yl-thieno[3,2-c]pyridine; 4-Piperazine-1-yl-thieno[2,3-c]pyridine hydrochloride; ACMC-1BO03; SCHEMBL616087; CTK4A4454; DTXSID10450113; MolPort-002-500-678; RVGRTFBJOXMFAX-UHFFFAOYSA-N
DMJGTS7 DT Small molecular drug
DMJGTS7 PC 10966027
DMJGTS7 MW 219.31
DMJGTS7 FM C11H13N3S
DMJGTS7 IC InChI=1S/C11H13N3S/c1-3-13-11(9-2-8-15-10(1)9)14-6-4-12-5-7-14/h1-3,8,12H,4-7H2
DMJGTS7 CS C1CN(CCN1)C2=NC=CC3=C2C=CS3
DMJGTS7 IK RVGRTFBJOXMFAX-UHFFFAOYSA-N
DMJGTS7 IU 4-piperazin-1-ylthieno[3,2-c]pyridine
DMJGTS7 CA CAS 106261-27-2
DMJGTS7 DE Discovery agent
DM2KAG5 ID DM2KAG5
DM2KAG5 DN 4-(piperazin-1-yl)thieno[3,2-d]pyrimidine
DM2KAG5 HS Investigative
DM2KAG5 SN 683274-67-1; 4-(piperazin-1-yl)thieno[3,2-d]pyrimidine; 4-Piperazinothieno[3,2-d]pyrimidine; CHEMBL594477; 1-{thieno[3,2-d]pyrimidin-4-yl}piperazine; 1-(thieno[3,2-d]pyrimidin-4-yl)piperazine; AC1MC2NN; SCHEMBL1601613; CTK7D1709; GVNSLBIXJYZCCB-UHFFFAOYSA-N; MolPort-000-158-321; ZINC2513539; SBB095997; KM1197; BDBM50304815; 8099AE; AKOS009377421; FS-1502; MCULE-3522335295; KS-0000257Q; 4-piperazinylthiopheno[3,2-d]pyrimidine; 4-piperazin-1-ylthieno[3,2-d]pyrimidine; KB-86789; KB-193828; 4-piperazin-1-yl-thieno[3,2-d]pyrimidine
DM2KAG5 DT Small molecular drug
DM2KAG5 PC 2760428
DM2KAG5 MW 220.3
DM2KAG5 FM C10H12N4S
DM2KAG5 IC InChI=1S/C10H12N4S/c1-6-15-9-8(1)12-7-13-10(9)14-4-2-11-3-5-14/h1,6-7,11H,2-5H2
DM2KAG5 CS C1CN(CCN1)C2=NC=NC3=C2SC=C3
DM2KAG5 IK GVNSLBIXJYZCCB-UHFFFAOYSA-N
DM2KAG5 IU 4-piperazin-1-ylthieno[3,2-d]pyrimidine
DM2KAG5 DE Discovery agent
DMEAZFJ ID DMEAZFJ
DMEAZFJ DN 4-(propylamino)naphthalen-1-ol
DMEAZFJ HS Investigative
DMEAZFJ SN CHEMBL572064; 4-(propylamino)naphthalen-1-ol; SCHEMBL12599065
DMEAZFJ DT Small molecular drug
DMEAZFJ PC 45487219
DMEAZFJ MW 201.26
DMEAZFJ FM C13H15NO
DMEAZFJ IC InChI=1S/C13H15NO/c1-2-9-14-12-7-8-13(15)11-6-4-3-5-10(11)12/h3-8,14-15H,2,9H2,1H3
DMEAZFJ CS CCCNC1=CC=C(C2=CC=CC=C21)O
DMEAZFJ IK FDQDPQDUXWRNKT-UHFFFAOYSA-N
DMEAZFJ IU 4-(propylamino)naphthalen-1-ol
DMEAZFJ DE Discovery agent
DM8BZQ3 ID DM8BZQ3
DM8BZQ3 DN 4-(propylthio)-2-(trifluoromethyl)benzonitrile
DM8BZQ3 HS Investigative
DM8BZQ3 SN CHEMBL462664; 4-(propylthio)-2-(trifluoromethyl)benzonitrile; BDBM50247958
DM8BZQ3 DT Small molecular drug
DM8BZQ3 PC 43138589
DM8BZQ3 MW 245.27
DM8BZQ3 FM C11H10F3NS
DM8BZQ3 IC InChI=1S/C11H10F3NS/c1-2-5-16-9-4-3-8(7-15)10(6-9)11(12,13)14/h3-4,6H,2,5H2,1H3
DM8BZQ3 CS CCCSC1=CC(=C(C=C1)C#N)C(F)(F)F
DM8BZQ3 IK CUMRETWHEPZEIN-UHFFFAOYSA-N
DM8BZQ3 IU 4-propylsulfanyl-2-(trifluoromethyl)benzonitrile
DM8BZQ3 DE Discovery agent
DM8M0N9 ID DM8M0N9
DM8M0N9 DN 4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone
DM8M0N9 HS Investigative
DM8M0N9 SN CHEMBL199829; Sulfonamide chalcone, 5; SCHEMBL3484418; BDBM50174837; 4''-(p-toluenesulfonamide)-3,4-dihydroxy chalcone
DM8M0N9 DT Small molecular drug
DM8M0N9 PC 11668680
DM8M0N9 MW 409.5
DM8M0N9 FM C22H19NO5S
DM8M0N9 IC InChI=1S/C22H19NO5S/c1-15-2-10-19(11-3-15)29(27,28)23-18-8-6-17(7-9-18)20(24)12-4-16-5-13-21(25)22(26)14-16/h2-14,23,25-26H,1H3/b12-4+
DM8M0N9 CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)/C=C/C3=CC(=C(C=C3)O)O
DM8M0N9 IK XCEAUELSIXURQB-UUILKARUSA-N
DM8M0N9 IU N-[4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]phenyl]-4-methylbenzenesulfonamide
DM8M0N9 DE Discovery agent
DMRFWE1 ID DMRFWE1
DMRFWE1 DN 4'-(p-Toluenesulfonamide)-4-hydroxychalcone
DMRFWE1 HS Investigative
DMRFWE1 SN CHEMBL371723; TSAHC; Sulfonamide chalcone, 4; SCHEMBL3483827; BDBM50174835; 4''-(p-Toluenesulfonamide)-4-hydroxychalcone; 4''-(4-toluenesulfonamido)-4-hydroxychalcone
DMRFWE1 DT Small molecular drug
DMRFWE1 PC 24757213
DMRFWE1 MW 393.5
DMRFWE1 FM C22H19NO4S
DMRFWE1 IC InChI=1S/C22H19NO4S/c1-16-2-13-21(14-3-16)28(26,27)23-19-9-7-18(8-10-19)22(25)15-6-17-4-11-20(24)12-5-17/h2-15,23-24H,1H3/b15-6+
DMRFWE1 CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)/C=C/C3=CC=C(C=C3)O
DMRFWE1 IK KDODYFOOJCIHGK-GIDUJCDVSA-N
DMRFWE1 IU N-[4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]phenyl]-4-methylbenzenesulfonamide
DMRFWE1 DE Discovery agent
DMQA0EJ ID DMQA0EJ
DMQA0EJ DN 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ HS Investigative
DMQA0EJ SN CHEMBL204456; 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione
DMQA0EJ DT Small molecular drug
DMQA0EJ PC 44409922
DMQA0EJ MW 305.4
DMQA0EJ FM C20H19NO2
DMQA0EJ IC InChI=1S/C20H19NO2/c1-12(2)17-18(21-14-10-8-13(3)9-11-14)15-6-4-5-7-16(15)19(22)20(17)23/h4-12,21H,1-3H3
DMQA0EJ CS CC1=CC=C(C=C1)NC2=C(C(=O)C(=O)C3=CC=CC=C32)C(C)C
DMQA0EJ IK JFLZSYUNGPXQEX-UHFFFAOYSA-N
DMQA0EJ IU 4-(4-methylanilino)-3-propan-2-ylnaphthalene-1,2-dione
DMQA0EJ DE Discovery agent
DMIOQJD ID DMIOQJD
DMIOQJD DN 4-(p-Tolyl)spiro[chromene-2,4'-piperidine]
DMIOQJD HS Investigative
DMIOQJD SN CHEMBL492448; SCHEMBL471328; BDBM50252831
DMIOQJD DT Small molecular drug
DMIOQJD PC 25129090
DMIOQJD MW 291.4
DMIOQJD FM C20H21NO
DMIOQJD IC InChI=1S/C20H21NO/c1-15-6-8-16(9-7-15)18-14-20(10-12-21-13-11-20)22-19-5-3-2-4-17(18)19/h2-9,14,21H,10-13H2,1H3
DMIOQJD CS CC1=CC=C(C=C1)C2=CC3(CCNCC3)OC4=CC=CC=C42
DMIOQJD IK YDXKUUFNKUXOBE-UHFFFAOYSA-N
DMIOQJD IU 4-(4-methylphenyl)spiro[chromene-2,4'-piperidine]
DMIOQJD DE Discovery agent
DMXK56P ID DMXK56P
DMXK56P DN 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile
DMXK56P HS Investigative
DMXK56P SN CHEMBL465539; 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile; BDBM50248554
DMXK56P DT Small molecular drug
DMXK56P PC 43138559
DMXK56P MW 277.24
DMXK56P FM C15H10F3NO
DMXK56P IC InChI=1S/C15H10F3NO/c1-10-2-5-12(6-3-10)20-13-7-4-11(9-19)14(8-13)15(16,17)18/h2-8H,1H3
DMXK56P CS CC1=CC=C(C=C1)OC2=CC(=C(C=C2)C#N)C(F)(F)F
DMXK56P IK NLEVNQCHSZMRKR-UHFFFAOYSA-N
DMXK56P IU 4-(4-methylphenoxy)-2-(trifluoromethyl)benzonitrile
DMXK56P DE Discovery agent
DMZ0H5X ID DMZ0H5X
DMZ0H5X DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine
DMZ0H5X HS Investigative
DMZ0H5X SN CHEMBL1173327; SCHEMBL18770336; BDBM50322785
DMZ0H5X DT Small molecular drug
DMZ0H5X PC 46901445
DMZ0H5X MW 275.3
DMZ0H5X FM C18H17N3
DMZ0H5X IC InChI=1S/C18H17N3/c19-17-6-5-16(12-18(17)20)15-3-1-13(2-4-15)11-14-7-9-21-10-8-14/h1-10,12H,11,19-20H2
DMZ0H5X CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)N)N
DMZ0H5X IK SRXFPSNWVWAMBL-UHFFFAOYSA-N
DMZ0H5X IU 4-[4-(pyridin-4-ylmethyl)phenyl]benzene-1,2-diamine
DMZ0H5X DE Discovery agent
DM6Z5EK ID DM6Z5EK
DM6Z5EK DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol
DM6Z5EK HS Investigative
DM6Z5EK SN CHEMBL1172779; SCHEMBL18770369; BDBM50322793
DM6Z5EK DT Small molecular drug
DM6Z5EK PC 46901610
DM6Z5EK MW 277.3
DM6Z5EK FM C18H15NO2
DM6Z5EK IC InChI=1S/C18H15NO2/c20-17-6-5-16(12-18(17)21)15-3-1-13(2-4-15)11-14-7-9-19-10-8-14/h1-10,12,20-21H,11H2
DM6Z5EK CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)O)O
DM6Z5EK IK KOYRCBKCALKGKO-UHFFFAOYSA-N
DM6Z5EK IU 4-[4-(pyridin-4-ylmethyl)phenyl]benzene-1,2-diol
DM6Z5EK DE Discovery agent
DMR8O1B ID DMR8O1B
DMR8O1B DN 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine
DMR8O1B HS Investigative
DMR8O1B SN CHEMBL1171987; SCHEMBL18770411; BDBM50322783
DMR8O1B DT Small molecular drug
DMR8O1B PC 46901444
DMR8O1B MW 260.3
DMR8O1B FM C18H16N2
DMR8O1B IC InChI=1S/C18H16N2/c19-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-20-11-9-15/h1-11,13H,12,19H2
DMR8O1B CS C1=CC(=CC(=C1)N)C2=CC=C(C=C2)CC3=CC=NC=C3
DMR8O1B IK MVDKLMQNQSJYHJ-UHFFFAOYSA-N
DMR8O1B IU 3-[4-(pyridin-4-ylmethyl)phenyl]aniline
DMR8O1B DE Discovery agent
DM8HXYS ID DM8HXYS
DM8HXYS DN 4'-(Pyridin-4-ylmethyl)biphenyl-4-amine
DM8HXYS HS Investigative
DM8HXYS SN CHEMBL1215665; BDBM50324612
DM8HXYS DT Small molecular drug
DM8HXYS PC 46901443
DM8HXYS MW 260.3
DM8HXYS FM C18H16N2
DM8HXYS IC InChI=1S/C18H16N2/c19-18-7-5-17(6-8-18)16-3-1-14(2-4-16)13-15-9-11-20-12-10-15/h1-12H,13,19H2
DM8HXYS CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC=C(C=C3)N
DM8HXYS IK DFRORZVGCQQRJH-UHFFFAOYSA-N
DM8HXYS IU 4-[4-(pyridin-4-ylmethyl)phenyl]aniline
DM8HXYS DE Discovery agent
DMYXMT6 ID DMYXMT6
DMYXMT6 DN 4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide
DMYXMT6 HS Investigative
DMYXMT6 SN CHEMBL1215731; BDBM50324615
DMYXMT6 DT Small molecular drug
DMYXMT6 PC 46901614
DMYXMT6 MW 288.3
DMYXMT6 FM C19H16N2O
DMYXMT6 IC InChI=1S/C19H16N2O/c20-19(22)18-7-5-17(6-8-18)16-3-1-14(2-4-16)13-15-9-11-21-12-10-15/h1-12H,13H2,(H2,20,22)
DMYXMT6 CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC=C(C=C3)C(=O)N
DMYXMT6 IK IYXGEVQAAIDJAA-UHFFFAOYSA-N
DMYXMT6 IU 4-[4-(pyridin-4-ylmethyl)phenyl]benzamide
DMYXMT6 DE Discovery agent
DM4YFU5 ID DM4YFU5
DM4YFU5 DN 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine
DM4YFU5 HS Investigative
DM4YFU5 SN CHEMBL1080666
DM4YFU5 DT Small molecular drug
DM4YFU5 PC 44820377
DM4YFU5 MW 312.4
DM4YFU5 FM C20H16N4
DM4YFU5 IC InChI=1S/C20H16N4/c1-14-6-8-17(9-7-14)23-20-21-11-10-19(24-20)16-12-15-4-2-3-5-18(15)22-13-16/h2-13H,1H3,(H,21,23,24)
DM4YFU5 CS CC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC4=CC=CC=C4N=C3
DM4YFU5 IK DLSCDFDGOMZHSD-UHFFFAOYSA-N
DM4YFU5 IU N-(4-methylphenyl)-4-quinolin-3-ylpyrimidin-2-amine
DM4YFU5 DE Discovery agent
DMDW3SX ID DMDW3SX
DMDW3SX DN 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine
DMDW3SX HS Investigative
DMDW3SX SN CHEMBL1080023
DMDW3SX DT Small molecular drug
DMDW3SX PC 44820374
DMDW3SX MW 312.4
DMDW3SX FM C20H16N4
DMDW3SX IC InChI=1S/C20H16N4/c1-14-6-8-15(9-7-14)23-20-22-13-11-19(24-20)17-10-12-21-18-5-3-2-4-16(17)18/h2-13H,1H3,(H,22,23,24)
DMDW3SX CS CC1=CC=C(C=C1)NC2=NC=CC(=N2)C3=CC=NC4=CC=CC=C34
DMDW3SX IK HFJKLAQBWSUMDJ-UHFFFAOYSA-N
DMDW3SX IU N-(4-methylphenyl)-4-quinolin-4-ylpyrimidin-2-amine
DMDW3SX DE Discovery agent
DMPNXFA ID DMPNXFA
DMPNXFA DN 4-(Quinolinoxy)-3-pyridinesulfonamide
DMPNXFA HS Investigative
DMPNXFA SN CHEMBL1165726; 4-(Quinolinoxy)-3-pyridinesulfonamide; BDBM50320501; NSC743333; NSC-743333
DMPNXFA DT Small molecular drug
DMPNXFA PC 45028568
DMPNXFA MW 301.32
DMPNXFA FM C14H11N3O3S
DMPNXFA IC InChI=1S/C14H11N3O3S/c15-21(18,19)13-9-16-8-6-11(13)20-12-5-1-3-10-4-2-7-17-14(10)12/h1-9H,(H2,15,18,19)
DMPNXFA CS C1=CC2=C(C(=C1)OC3=C(C=NC=C3)S(=O)(=O)N)N=CC=C2
DMPNXFA IK YEXUPIWQHCCQQA-UHFFFAOYSA-N
DMPNXFA IU 4-quinolin-8-yloxypyridine-3-sulfonamide
DMPNXFA DE Discovery agent
DM0XDG6 ID DM0XDG6
DM0XDG6 DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
DM0XDG6 HS Investigative
DM0XDG6 SN CHEMBL550063; SCHEMBL10266987; BDBM50297313
DM0XDG6 DT Small molecular drug
DM0XDG6 PC 44254503
DM0XDG6 MW 320.4
DM0XDG6 FM C20H20N2O2
DM0XDG6 IC InChI=1S/C20H20N2O2/c21-19(23)15-7-5-14(6-8-15)17-13-20(9-11-22-12-10-20)24-18-4-2-1-3-16(17)18/h1-8,13,22H,9-12H2,(H2,21,23)
DM0XDG6 CS C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=C(C=C4)C(=O)N
DM0XDG6 IK QQXCPIPMLCDOFK-UHFFFAOYSA-N
DM0XDG6 IU 4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide
DM0XDG6 DE Discovery agent
DM8ZRAE ID DM8ZRAE
DM8ZRAE DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol
DM8ZRAE HS Investigative
DM8ZRAE SN CHEMBL495074; SCHEMBL471335; BDBM50252834
DM8ZRAE DT Small molecular drug
DM8ZRAE PC 25129433
DM8ZRAE MW 293.4
DM8ZRAE FM C19H19NO2
DM8ZRAE IC InChI=1S/C19H19NO2/c21-15-7-5-14(6-8-15)17-13-19(9-11-20-12-10-19)22-18-4-2-1-3-16(17)18/h1-8,13,20-21H,9-12H2
DM8ZRAE CS C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=C(C=C4)O
DM8ZRAE IK OZOVJRMTVPPLSS-UHFFFAOYSA-N
DM8ZRAE IU 4-spiro[chromene-2,4'-piperidine]-4-ylphenol
DM8ZRAE DE Discovery agent
DMU5A2B ID DMU5A2B
DMU5A2B DN 4-(tert-butylamino)naphthalen-1-ol
DMU5A2B HS Investigative
DMU5A2B SN CHEMBL568767; 4-(tert-butylamino)naphthalen-1-ol; SCHEMBL12599109
DMU5A2B DT Small molecular drug
DMU5A2B PC 44465947
DMU5A2B MW 215.29
DMU5A2B FM C14H17NO
DMU5A2B IC InChI=1S/C14H17NO/c1-14(2,3)15-12-8-9-13(16)11-7-5-4-6-10(11)12/h4-9,15-16H,1-3H3
DMU5A2B CS CC(C)(C)NC1=CC=C(C2=CC=CC=C21)O
DMU5A2B IK YZPHFECVIINFFI-UHFFFAOYSA-N
DMU5A2B IU 4-(tert-butylamino)naphthalen-1-ol
DMU5A2B DE Discovery agent
DMSUM3C ID DMSUM3C
DMSUM3C DN 4-(thiazol-2-yl)phenyl butylcarbamate
DMSUM3C HS Investigative
DMSUM3C SN CHEMBL376748; 4-(thiazol-2-yl)phenyl butylcarbamate
DMSUM3C DT Small molecular drug
DMSUM3C PC 16007307
DMSUM3C MW 276.36
DMSUM3C FM C14H16N2O2S
DMSUM3C IC InChI=1S/C14H16N2O2S/c1-2-3-8-16-14(17)18-12-6-4-11(5-7-12)13-15-9-10-19-13/h4-7,9-10H,2-3,8H2,1H3,(H,16,17)
DMSUM3C CS CCCCNC(=O)OC1=CC=C(C=C1)C2=NC=CS2
DMSUM3C IK HIQUBTZOYOZSPC-UHFFFAOYSA-N
DMSUM3C IU [4-(1,3-thiazol-2-yl)phenyl] N-butylcarbamate
DMSUM3C DE Discovery agent
DMK3J8Q ID DMK3J8Q
DMK3J8Q DN 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine
DMK3J8Q HS Investigative
DMK3J8Q SN CHEMBL259111; 4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine; 443148-62-7; SCHEMBL3684455
DMK3J8Q DT Small molecular drug
DMK3J8Q PC 9813424
DMK3J8Q MW 234.3
DMK3J8Q FM C9H6N4S2
DMK3J8Q IC InChI=1S/C9H6N4S2/c10-9-12-5-1-3-14-7(5)6(13-9)8-11-2-4-15-8/h1-4H,(H2,10,12,13)
DMK3J8Q CS C1=CSC2=C1N=C(N=C2C3=NC=CS3)N
DMK3J8Q IK CLNBBLGSLDNSMF-UHFFFAOYSA-N
DMK3J8Q IU 4-(1,3-thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine
DMK3J8Q DE Discovery agent
DMMWZLC ID DMMWZLC
DMMWZLC DN 4'-(trifluoromethyl)-4-biphenylol
DMMWZLC HS Investigative
DMMWZLC SN 10355-13-2; 4-(4-TRIFLUOROMETHYLPHENYL)PHENOL; 4'-(Trifluoromethyl)[1,1'-biphenyl]-4-ol; CHEMBL244264; 4'-(trifluoromethyl)biphenyl-4-ol; 4'-(Trifluoromethyl)-[1,1'-biphenyl]-4-ol; [1,1'-Biphenyl]-4-ol, 4'-(trifluoromethyl)-; ACMC-1BRC7; SCHEMBL678508; CTK0D8481; DTXSID50573870; 4'-Trifluoromethyl-biphenyl-4-ol; AFPOYLCQXONCPX-UHFFFAOYSA-N; ZINC13840578; BDBM50220207; 4'-(trifluoromethyl) biphenyl-4-ol; 4''-(trifluoromethyl)-4-biphenylol; ANW-14928; AKOS004116417; SEL12447598; 4-hydroxy-4'-(trifluoromethyl)biphenyl; AJ-64481
DMMWZLC DT Small molecular drug
DMMWZLC PC 15541180
DMMWZLC MW 238.2
DMMWZLC FM C13H9F3O
DMMWZLC IC InChI=1S/C13H9F3O/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(17)8-4-10/h1-8,17H
DMMWZLC CS C1=CC(=CC=C1C2=CC=C(C=C2)O)C(F)(F)F
DMMWZLC IK AFPOYLCQXONCPX-UHFFFAOYSA-N
DMMWZLC IU 4-[4-(trifluoromethyl)phenyl]phenol
DMMWZLC CA CAS 10355-13-2
DMMWZLC DE Discovery agent
DMLP67R ID DMLP67R
DMLP67R DN 4'-(trifluoromethyl)-4-biphenylsulfonamide
DMLP67R HS Investigative
DMLP67R SN CHEMBL242783; WWPFVDFIDSAULR-UHFFFAOYSA-N; BDBM50220193; ZINC28711886; AKOS015966248; 4'-Trifluoromethylbiphenyl-4-O-sulfamate; 950500-72-8; 4'-(Trifluoromethyl)-4-biphenylsulfoamide; 4'-(trifluoromethyl)biphenyl-4-sulfonamide
DMLP67R DT Small molecular drug
DMLP67R PC 23625979
DMLP67R MW 301.29
DMLP67R FM C13H10F3NO2S
DMLP67R IC InChI=1S/C13H10F3NO2S/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)20(17,18)19/h1-8H,(H2,17,18,19)
DMLP67R CS C1=CC(=CC=C1C2=CC=C(C=C2)S(=O)(=O)N)C(F)(F)F
DMLP67R IK WWPFVDFIDSAULR-UHFFFAOYSA-N
DMLP67R IU 4-[4-(trifluoromethyl)phenyl]benzenesulfonamide
DMLP67R DE Discovery agent
DMT3BX9 ID DMT3BX9
DMT3BX9 DN 4'-(trifluoromethyl)-4-biphenylyl carbamate
DMT3BX9 HS Investigative
DMT3BX9 SN CHEMBL394512; BDBM50220194; 4''-(trifluoromethyl)-4-biphenylyl carbamate
DMT3BX9 DT Small molecular drug
DMT3BX9 PC 23626139
DMT3BX9 MW 281.23
DMT3BX9 FM C14H10F3NO2
DMT3BX9 IC InChI=1S/C14H10F3NO2/c15-14(16,17)11-5-1-9(2-6-11)10-3-7-12(8-4-10)20-13(18)19/h1-8H,(H2,18,19)
DMT3BX9 CS C1=CC(=CC=C1C2=CC=C(C=C2)OC(=O)N)C(F)(F)F
DMT3BX9 IK ZIARVUIVYFGYIG-UHFFFAOYSA-N
DMT3BX9 IU [4-[4-(trifluoromethyl)phenyl]phenyl] carbamate
DMT3BX9 DE Discovery agent
DM8PTNR ID DM8PTNR
DM8PTNR DN 4'-(trifluoromethyl)-4-biphenylyl sulfamate
DM8PTNR HS Investigative
DM8PTNR SN CHEMBL396794; SCHEMBL4665444; ZINC28711937; BDBM50220172; 4''-(trifluoromethyl)-4-biphenylyl sulfamate
DM8PTNR DT Small molecular drug
DM8PTNR PC 15541181
DM8PTNR MW 317.29
DM8PTNR FM C13H10F3NO3S
DM8PTNR IC InChI=1S/C13H10F3NO3S/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)20-21(17,18)19/h1-8H,(H2,17,18,19)
DM8PTNR CS C1=CC(=CC=C1C2=CC=C(C=C2)OS(=O)(=O)N)C(F)(F)F
DM8PTNR IK CRJUOWWINLUIRE-UHFFFAOYSA-N
DM8PTNR IU [4-[4-(trifluoromethyl)phenyl]phenyl] sulfamate
DM8PTNR DE Discovery agent
DMZ0AKP ID DMZ0AKP
DMZ0AKP DN 4-(trifluoromethyl)biphenyl
DMZ0AKP HS Investigative
DMZ0AKP SN 4-(trifluoromethyl)biphenyl; 398-36-7; 4-trifluoromethylbiphenyl; 4-(Trifluoromethyl)-1,1'-biphenyl; 1-phenyl-4-(trifluoromethyl)benzene; 4-(Trifluoromethyl)-biphenyl; CHEMBL242993; 4-Phenylbenzotrifluoride; p-Trifluoromethylbiphenyl; SCHEMBL163728; CTK4I1963; DTXSID20432208; MolPort-005-937-883; 4-(a,a,a-Trifluoromethyl)biphenyl; ZINC2529931; STL555310; 2494AE; BDBM50220191; BBL101514; 1,1'-Biphenyl,4-(trifluoromethyl)-; AKOS005259545; MCULE-3710616152; AN-44717; DS-11883; AC-18838; AK326586; AB0077698; TR-015900; KB-195437
DMZ0AKP DT Small molecular drug
DMZ0AKP PC 9877863
DMZ0AKP MW 222.2
DMZ0AKP FM C13H9F3
DMZ0AKP IC InChI=1S/C13H9F3/c14-13(15,16)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H
DMZ0AKP CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F
DMZ0AKP IK OUMKBAHMPRLISR-UHFFFAOYSA-N
DMZ0AKP IU 1-phenyl-4-(trifluoromethyl)benzene
DMZ0AKP CA CAS 398-36-7
DMZ0AKP DE Discovery agent
DMADZQ9 ID DMADZQ9
DMADZQ9 DN 4-(trifluoromethyl)phenylboronic acid
DMADZQ9 HS Investigative
DMADZQ9 SN 128796-39-4; 4-(Trifluoromethyl)phenylboronic acid; 4-trifluoromethylphenylboronic acid; 4-(Trifluoromethyl)benzeneboronic acid; (4-(trifluoromethyl)phenyl)boronic acid; [4-(Trifluoromethyl)phenyl]boronic acid; (4-Trifluoromethylphenyl)boronic acid; [4-(trifluoromethyl)phenyl]boranediol; 4-Boronobenzotrifluoride; p-(trifluoromethyl)phenylboronic acid; CHEMBL143654; alpha,alpha,alpha-Trifluoro-p-tolylboronic acid; 4-trifluoromethylphenyl boronic acid; 4-trifluoromethylphenyl-boronic acid; MFCD00151855; Boronic acid, [4-(tr
DMADZQ9 DT Small molecular drug
DMADZQ9 PC 2734389
DMADZQ9 MW 189.93
DMADZQ9 FM C7H6BF3O2
DMADZQ9 IC InChI=1S/C7H6BF3O2/c9-7(10,11)5-1-3-6(4-2-5)8(12)13/h1-4,12-13H
DMADZQ9 CS B(C1=CC=C(C=C1)C(F)(F)F)(O)O
DMADZQ9 IK ALMFIOZYDASRRC-UHFFFAOYSA-N
DMADZQ9 IU [4-(trifluoromethyl)phenyl]boronic acid
DMADZQ9 CA CAS 128796-39-4
DMADZQ9 DE Discovery agent
DM2YAUX ID DM2YAUX
DM2YAUX DN 4(Z)-(5'-Deoxyadenosin-5'-ylidene)butanoic acid
DM2YAUX HS Investigative
DM2YAUX SN CHEMBL525000
DM2YAUX DT Small molecular drug
DM2YAUX PC 44576814
DM2YAUX MW 335.32
DM2YAUX FM C14H17N5O5
DM2YAUX IC InChI=1S/C14H17N5O5/c15-12-9-13(17-5-16-12)19(6-18-9)14-11(23)10(22)7(24-14)3-1-2-4-8(20)21/h1,3,5-7,10-11,14,22-23H,2,4H2,(H,20,21)(H2,15,16,17)/b3-1-/t7-,10-,11-,14-/m1/s1
DM2YAUX CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)/C=C\\CCC(=O)O)O)O)N
DM2YAUX IK ZZPNPWVYLOIHPM-RSPDOVAOSA-N
DM2YAUX IU (Z)-5-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]pent-4-enoic acid
DM2YAUX DE Discovery agent
DMB5RJK ID DMB5RJK
DMB5RJK DN 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol
DMB5RJK HS Investigative
DMB5RJK SN CHEMBL206582; 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6924719
DMB5RJK DT Small molecular drug
DMB5RJK PC 10399473
DMB5RJK MW 242.27
DMB5RJK FM C15H14O3
DMB5RJK IC InChI=1S/C15H14O3/c1-8-5-11(16)6-10-7-18-15-9(2)13(17)4-3-12(15)14(8)10/h3-6,16-17H,7H2,1-2H3
DMB5RJK CS CC1=CC(=CC2=C1C3=C(C(=C(C=C3)O)C)OC2)O
DMB5RJK IK UUVHCOKGCFXIER-UHFFFAOYSA-N
DMB5RJK IU 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol
DMB5RJK DE Discovery agent
DM1XTJC ID DM1XTJC
DM1XTJC DN 4,12,17-dehydroxyriccardin C
DM1XTJC HS Investigative
DM1XTJC SN Deoxyriccardin C; 4,12,17-dehydroxyriccardin C; Riccardin C derivative, 22; CHEMBL410486; BDBM23854
DM1XTJC DT Small molecular drug
DM1XTJC PC 24860516
DM1XTJC MW 376.5
DM1XTJC FM C28H24O
DM1XTJC IC InChI=1S/C28H24O/c1-2-7-28-24(5-1)15-10-22-13-18-26(19-14-22)29-27-6-3-4-23(20-27)9-8-21-11-16-25(28)17-12-21/h1-7,11-14,16-20H,8-10,15H2
DM1XTJC CS C1CC2=CC(=CC=C2)OC3=CC=C(CCC4=CC=CC=C4C5=CC=C1C=C5)C=C3
DM1XTJC IK VHGMCOKOKWHSEA-UHFFFAOYSA-N
DM1XTJC IU 14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaene
DM1XTJC DE Discovery agent
DMIZ0GO ID DMIZ0GO
DMIZ0GO DN 4,17-dehydroxyriccardin C
DMIZ0GO HS Investigative
DMIZ0GO SN 4,17-dehydroxyriccardin C; Riccardin C derivative, 20f; CHEMBL411912; BDBM23853
DMIZ0GO DT Small molecular drug
DMIZ0GO PC 24860515
DMIZ0GO MW 392.5
DMIZ0GO FM C28H24O2
DMIZ0GO IC InChI=1S/C28H24O2/c29-28-19-22-9-8-21-4-3-6-25(18-21)30-24-15-11-20(12-16-24)10-14-23-5-1-2-7-26(23)27(28)17-13-22/h1-7,11-13,15-19,29H,8-10,14H2
DMIZ0GO CS C1CC2=CC=CC=C2C3=C(C=C(CCC4=CC(=CC=C4)OC5=CC=C1C=C5)C=C3)O
DMIZ0GO IK AWANYYTXBZWDHH-UHFFFAOYSA-N
DMIZ0GO IU 14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2,4,6,10(29),11,13(28),15,17,19(27),22,25-dodecaen-24-ol
DMIZ0GO DE Discovery agent
DMBN4G6 ID DMBN4G6
DMBN4G6 DN 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl
DMBN4G6 HS Investigative
DMBN4G6 SN CHEMBL379687; BDBM50186763
DMBN4G6 DT Small molecular drug
DMBN4G6 PC 11537051
DMBN4G6 MW 320.4
DMBN4G6 FM C21H20O3
DMBN4G6 IC InChI=1S/C21H20O3/c1-22-17-10-8-15(9-11-17)20-6-4-5-7-21(20)16-12-18(23-2)14-19(13-16)24-3/h4-14H,1-3H3
DMBN4G6 CS COC1=CC=C(C=C1)C2=CC=CC=C2C3=CC(=CC(=C3)OC)OC
DMBN4G6 IK YTEAKYDIQLKHMB-UHFFFAOYSA-N
DMBN4G6 IU 1,3-dimethoxy-5-[2-(4-methoxyphenyl)phenyl]benzene
DMBN4G6 DE Discovery agent
DM40E1T ID DM40E1T
DM40E1T DN 4,3'',5''-trimethoxy-[1,1':3',1'']-terphenyl
DM40E1T HS Investigative
DM40E1T SN CHEMBL206919; BDBM50186761
DM40E1T DT Small molecular drug
DM40E1T PC 11594901
DM40E1T MW 320.4
DM40E1T FM C21H20O3
DM40E1T IC InChI=1S/C21H20O3/c1-22-19-9-7-15(8-10-19)16-5-4-6-17(11-16)18-12-20(23-2)14-21(13-18)24-3/h4-14H,1-3H3
DM40E1T CS COC1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC(=CC(=C3)OC)OC
DM40E1T IK MDKFFJFTEBNHAN-UHFFFAOYSA-N
DM40E1T IU 1,3-dimethoxy-5-[3-(4-methoxyphenyl)phenyl]benzene
DM40E1T DE Discovery agent
DMJKWFI ID DMJKWFI
DMJKWFI DN 4,4'-(4-phenylpyridine-2,6-diyl)diphenol
DMJKWFI HS Investigative
DMJKWFI DT Small molecular drug
DMJKWFI PC 46887215
DMJKWFI DE Discovery agent
DM1NVEI ID DM1NVEI
DM1NVEI DN 4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol
DM1NVEI HS Investigative
DM1NVEI SN CHEMBL499124; SCHEMBL1397158; GTPL8785; Bibenzyl-2,2',4,4'-tetraol; BDBM50263336; compound 7 [PMID: 21334791]; 4,4''-(ethane-1,2-diyl)dibenzene-1,3-diol
DM1NVEI DT Small molecular drug
DM1NVEI PC 24849532
DM1NVEI MW 246.26
DM1NVEI FM C14H14O4
DM1NVEI IC InChI=1S/C14H14O4/c15-11-5-3-9(13(17)7-11)1-2-10-4-6-12(16)8-14(10)18/h3-8,15-18H,1-2H2
DM1NVEI CS C1=CC(=C(C=C1O)O)CCC2=C(C=C(C=C2)O)O
DM1NVEI IK WKIFTWPZTZUMRN-UHFFFAOYSA-N
DM1NVEI IU 4-[2-(2,4-dihydroxyphenyl)ethyl]benzene-1,3-diol
DM1NVEI DE Discovery agent
DMFGQ02 ID DMFGQ02
DMFGQ02 DN 4,4'-Biphenyldiboronic Acid
DMFGQ02 HS Investigative
DMFGQ02 SN 44'-Biphenyldiboronic acid; SCHEMBL2460602; ZINC199832994; KB-187838; A825578; (1-borono-4-phenyl-1-cyclohexa-2,4-dienyl)boronic acid; [1-(dihydroxyboranyl)-4-phenyl-cyclohexa-2,4-dien-1-yl]boronic acid
DMFGQ02 DT Small molecular drug
DMFGQ02 PC 2734608
DMFGQ02 MW 241.8
DMFGQ02 FM C12H12B2O4
DMFGQ02 IC InChI=1S/C12H12B2O4/c15-13(16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)14(17)18/h1-8,15-18H
DMFGQ02 CS B(C1=CC=C(C=C1)C2=CC=C(C=C2)B(O)O)(O)O
DMFGQ02 IK SLHKDOGTVUCXKX-UHFFFAOYSA-N
DMFGQ02 IU [4-(4-boronophenyl)phenyl]boronic acid
DMFGQ02 CA CAS 4151-80-8
DMFGQ02 DE Discovery agent
DMFPO16 ID DMFPO16
DMFPO16 DN 4',4-Dihydroxychalcone
DMFPO16 HS Investigative
DMFPO16 SN 4,4'-Dihydroxychalcone; UNII-CKY3J88Z94; CKY3J88Z94; CHEMBL145927; 1,3-bis(4-hydroxyphenyl)prop-2-en-1-one; 4',4-Dihydroxychalcone; 3600-61-1; 4,4'-Dihydroxybenzylidene acetophenone; RVC 588 (chalcone); 4,4''-dihydroxychalcone; 4'',4-Dihydroxychalcone; AC1NV3S6; (E)-1,3-bis(4-hydroxyphenyl)prop-2-en-1-one; Trans-4,4'-dihydroxychalcone; SCHEMBL773588; (E)-4,4'-Dihydroxychalcone; 4,4'-Dihydroxychalcone, (E)-; 1,3-bis(4-hydroxyphenyl)propenone; ZINC5843955; NSC652891; LMPK12120193; BDBM50068224; AKOS022660924; NSC-652891
DMFPO16 DT Small molecular drug
DMFPO16 PC 5467477
DMFPO16 MW 240.25
DMFPO16 FM C15H12O3
DMFPO16 IC InChI=1S/C15H12O3/c16-13-6-1-11(2-7-13)3-10-15(18)12-4-8-14(17)9-5-12/h1-10,16-17H/b10-3+
DMFPO16 CS C1=CC(=CC=C1/C=C/C(=O)C2=CC=C(C=C2)O)O
DMFPO16 IK FZQLEXXZAVVCCA-XCVCLJGOSA-N
DMFPO16 IU (E)-1,3-bis(4-hydroxyphenyl)prop-2-en-1-one
DMFPO16 CA CAS 3600-61-1
DMFPO16 DE Discovery agent
DM1ONBT ID DM1ONBT
DM1ONBT DN 4,4'-dihydroxyoctafluoroazobenzene
DM1ONBT HS Investigative
DM1ONBT DT Small molecular drug
DM1ONBT PC 136186019
DM1ONBT MW 358.14
DM1ONBT FM C12H2F8N2O2
DM1ONBT IC InChI=1S/C12H2F8N2O2/c13-1-5(17)11(23)6(18)2(14)9(1)21-22-10-3(15)7(19)12(24)8(20)4(10)16/h23-24H
DM1ONBT CS C1(=C(C(=C(C(=C1F)F)O)F)F)N=NC2=C(C(=C(C(=C2F)F)O)F)F
DM1ONBT IK OLAUREFYJFRAJD-UHFFFAOYSA-N
DM1ONBT IU 2,3,5,6-tetrafluoro-4-[(2,3,5,6-tetrafluoro-4-hydroxyphenyl)diazenyl]phenol
DM1ONBT DE Discovery agent
DMQ0TBX ID DMQ0TBX
DMQ0TBX DN 4,4-Diphenylbutan-1-amine
DMQ0TBX HS Investigative
DMQ0TBX SN 4,4-Diphenylbutylamine; 36765-74-9; EINECS 253-194-6; 4,4-Diphenylbutan-1-amine; diphenylbutylamine; AC1MI1YM; delta-Phenylbenzenebutanamine; Benzenebutanamine, d-phenyl-; SCHEMBL157808; diphenylalkylamine (DPA), 6a; CHEMBL593734; CTK4H7118; BDBM35935; DTXSID10190229; MAAQGZFMFXQVOG-UHFFFAOYSA-N; AKOS030583685
DMQ0TBX DT Small molecular drug
DMQ0TBX PC 3015863
DMQ0TBX MW 225.33
DMQ0TBX FM C16H19N
DMQ0TBX IC InChI=1S/C16H19N/c17-13-7-12-16(14-8-3-1-4-9-14)15-10-5-2-6-11-15/h1-6,8-11,16H,7,12-13,17H2
DMQ0TBX CS C1=CC=C(C=C1)C(CCCN)C2=CC=CC=C2
DMQ0TBX IK MAAQGZFMFXQVOG-UHFFFAOYSA-N
DMQ0TBX IU 4,4-diphenylbutan-1-amine
DMQ0TBX CA CAS 36765-74-9
DMQ0TBX DE Discovery agent
DMM0H9Y ID DMM0H9Y
DMM0H9Y DN 4,4-Diphenyl-N-(pyridin-3-yl)-butyramide
DMM0H9Y HS Investigative
DMM0H9Y SN CHEMBL565028; 4,4-Diphenyl-N-(pyridin-3-yl)-butyramide; SCHEMBL4617484; CEQRPUYSSDGEML-UHFFFAOYSA-N; BDBM50297404
DMM0H9Y DT Small molecular drug
DMM0H9Y PC 11976417
DMM0H9Y MW 316.4
DMM0H9Y FM C21H20N2O
DMM0H9Y IC InChI=1S/C21H20N2O/c24-21(23-19-12-7-15-22-16-19)14-13-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-12,15-16,20H,13-14H2,(H,23,24)
DMM0H9Y CS C1=CC=C(C=C1)C(CCC(=O)NC2=CN=CC=C2)C3=CC=CC=C3
DMM0H9Y IK CEQRPUYSSDGEML-UHFFFAOYSA-N
DMM0H9Y IU 4,4-diphenyl-N-pyridin-3-ylbutanamide
DMM0H9Y DE Discovery agent
DM0K5JM ID DM0K5JM
DM0K5JM DN 4,4'-thiodipyridine-3-sulfonamide
DM0K5JM HS Investigative
DM0K5JM SN 4,4'-thiodipyridine-3-sulfonamide; CHEMBL1164504; 1078160-08-3; NSC743332; BDBM50320519; 4,4''-thiodipyridine-3-sulfonamide; 4,4'-Thiodi(pyridine-3-sulfonamide); NSC-743332
DM0K5JM DT Small molecular drug
DM0K5JM PC 45028567
DM0K5JM MW 346.4
DM0K5JM FM C10H10N4O4S3
DM0K5JM IC InChI=1S/C10H10N4O4S3/c11-20(15,16)9-5-13-3-1-7(9)19-8-2-4-14-6-10(8)21(12,17)18/h1-6H,(H2,11,15,16)(H2,12,17,18)
DM0K5JM CS C1=CN=CC(=C1SC2=C(C=NC=C2)S(=O)(=O)N)S(=O)(=O)N
DM0K5JM IK JYMNSJBFCKCLMB-UHFFFAOYSA-N
DM0K5JM IU 4-(3-sulfamoylpyridin-4-yl)sulfanylpyridine-3-sulfonamide
DM0K5JM DE Discovery agent
DMUE4K3 ID DMUE4K3
DMUE4K3 DN 4,5,6,7-tetrabromo-1H-benzimidazole
DMUE4K3 HS Investigative
DMUE4K3 SN 4,5,6,7-tetrabromobenzimidazole; TBBz; 577779-57-8; 4,5,6,7-Tetrabromo-Benzimidazole; 4,5,6,7-tetrabromo-1H-benzo[d]imidazole; CHEMBL373937; 2oxy; AC1NP4E4; SCHEMBL406945; CTK5I6050; DTXSID80408803; MolPort-003-850-464; LOEIRDBRYBHAJB-UHFFFAOYSA-N; HMS3260K22; ZINC2528524; Tox21_500140; BDBM50156669; TBBz, > MFCD04116202; 4,5,6,7-Tetrabromo-1Hbenzimidazole; LP00140; CCG-221444; NCGC00260825-01; NCGC00165910-02; NCGC00165910-01; RT-009016; FT-0674936
DMUE4K3 DT Small molecular drug
DMUE4K3 PC 5149739
DMUE4K3 MW 433.72
DMUE4K3 FM C7H2Br4N2
DMUE4K3 IC InChI=1S/C7H2Br4N2/c8-2-3(9)5(11)7-6(4(2)10)12-1-13-7/h1H,(H,12,13)
DMUE4K3 CS C1=NC2=C(N1)C(=C(C(=C2Br)Br)Br)Br
DMUE4K3 IK LOEIRDBRYBHAJB-UHFFFAOYSA-N
DMUE4K3 IU 4,5,6,7-tetrabromo-1H-benzimidazole
DMUE4K3 CA CAS 577779-57-8
DMUE4K3 DE Discovery agent
DMN9YOB ID DMN9YOB
DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole
DMN9YOB HS Investigative
DMN9YOB SN 4,5,6,7-tetrabromobenzotriazole
DMN9YOB DT Small molecular drug
DMN9YOB PC 1694
DMN9YOB MW 434.71
DMN9YOB FM C6HBr4N3
DMN9YOB IC InChI=1S/C6HBr4N3/c7-1-2(8)4(10)6-5(3(1)9)11-13-12-6/h(H,11,12,13)
DMN9YOB CS C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br
DMN9YOB IK OMZYUVOATZSGJY-UHFFFAOYSA-N
DMN9YOB IU 4,5,6,7-tetrabromo-2H-benzotriazole
DMN9YOB CA CAS 17374-26-4
DMN9YOB DE Discovery agent
DMTC7J2 ID DMTC7J2
DMTC7J2 DN 4,5,6,7-tetrafluoro-3-methyl-1H-indazole
DMTC7J2 HS Investigative
DMTC7J2 SN 4,5,6,7-tetrafluoro-3-methyl-1H-indazole; 220057-70-5; CHEMBL593307; SCHEMBL13122192; ZINC34415295; AKOS024258260; FCH3137367; AJ-88433; AX8289182
DMTC7J2 DT Small molecular drug
DMTC7J2 PC 10726859
DMTC7J2 MW 204.12
DMTC7J2 FM C8H4F4N2
DMTC7J2 IC InChI=1S/C8H4F4N2/c1-2-3-4(9)5(10)6(11)7(12)8(3)14-13-2/h1H3,(H,13,14)
DMTC7J2 CS CC1=C2C(=C(C(=C(C2=NN1)F)F)F)F
DMTC7J2 IK MEHLPQAUVAMMPE-UHFFFAOYSA-N
DMTC7J2 IU 4,5,6,7-tetrafluoro-3-methyl-2H-indazole
DMTC7J2 DE Discovery agent
DMZEY31 ID DMZEY31
DMZEY31 DN 4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole
DMZEY31 HS Investigative
DMZEY31 SN CHEMBL595197; 4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole; SCHEMBL20472960; BDBM50304151
DMZEY31 DT Small molecular drug
DMZEY31 PC 44622822
DMZEY31 MW 356.15
DMZEY31 FM C13HF9N2
DMZEY31 IC InChI=1S/C13HF9N2/c14-3-1(4(15)7(18)9(20)6(3)17)12-2-5(16)8(19)10(21)11(22)13(2)24-23-12/h(H,23,24)
DMZEY31 CS C12=C(NN=C1C(=C(C(=C2F)F)F)F)C3=C(C(=C(C(=C3F)F)F)F)F
DMZEY31 IK BLRLNVDCKOMIHM-UHFFFAOYSA-N
DMZEY31 IU 4,5,6,7-tetrafluoro-3-(2,3,4,5,6-pentafluorophenyl)-2H-indazole
DMZEY31 DE Discovery agent
DMDQL24 ID DMDQL24
DMDQL24 DN 4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid
DMDQL24 HS Investigative
DMDQL24 SN 4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid; 6076-13-7; 4,5,6,7-Tetrahydro-2H-indazole-3-carboxylic acid; 714255-28-4; CHEMBL338405; LWXNHFZBFJMHGU-UHFFFAOYSA-N; 2H-Indazole-3-carboxylicacid, 4,5,6,7-tetrahydro-; 1H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-; 2H-Indazole-3-carboxylic acid, 4,5,6,7-tetrahydro-; 1H-4,5,6,7-tetrahydroindazole-3-carboxylic acid; MLS000074645; AC1LDJ0A; ChemDiv2_003320; Oprea1_089683; AC1Q748E; SCHEMBL1808017; AC1Q72Q0; CTK2H6469; DTXSID00349466; MolPort-000-767-792; MolPort-000-149-162
DMDQL24 DT Small molecular drug
DMDQL24 PC 648852
DMDQL24 MW 166.18
DMDQL24 FM C8H10N2O2
DMDQL24 IC InChI=1S/C8H10N2O2/c11-8(12)7-5-3-1-2-4-6(5)9-10-7/h1-4H2,(H,9,10)(H,11,12)
DMDQL24 CS C1CCC2=C(C1)C(=NN2)C(=O)O
DMDQL24 IK LWXNHFZBFJMHGU-UHFFFAOYSA-N
DMDQL24 IU 4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid
DMDQL24 CA CAS 6076-13-7
DMDQL24 DE Discovery agent
DMO91EH ID DMO91EH
DMO91EH DN 4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol
DMO91EH HS Investigative
DMO91EH SN THIP hydrochloride; GABOXADOL HYDROCHLORIDE; 85118-33-8; UNII-478RVH3TVD; 478RVH3TVD; 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride; 4,5,6,7-TETRAHYDROISOXAZOLO[5,4-C]PYRIDIN-3-OL HCL, GABOXADOL-HCL; SR-01000075651; EINECS 285-687-7; THIP NIEaNI; THIP HCl; AC1NWAX4; Gaboxadol (hydrochloride); MLS002154080; SPECTRUM1503648; CHEMBL1255746; CTK8G3449; DTXSID90234251; AOB5024; MolPort-006-141-665; MolPort-003-666-496; HMS1571C05; Pharmakon1600-01503648; BCP16610; Tox21_501233; BN0520; NSC759585; CCG-39368
DMO91EH DT Small molecular drug
DMO91EH PC 5702253
DMO91EH MW 176.6
DMO91EH FM C6H9ClN2O2
DMO91EH IC InChI=1S/C6H8N2O2.ClH/c9-6-4-1-2-7-3-5(4)10-8-6;/h7H,1-3H2,(H,8,9);1H
DMO91EH CS C1CNCC2=C1C(=O)NO2.Cl
DMO91EH IK ZDZDSZQYRBZPNN-UHFFFAOYSA-N
DMO91EH IU 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-3-one;hydrochloride
DMO91EH CA CAS 85118-33-8
DMO91EH DE Discovery agent
DMQFTJ7 ID DMQFTJ7
DMQFTJ7 DN 4,5,6-trihydroxy-3-methylphthalide
DMQFTJ7 HS Investigative
DMQFTJ7 SN CHEMBL486813; 4,5,6-trihydroxy-3-methylphthalide; AGUVVAYMPQDJDX-UHFFFAOYSA-; BDBM50242174; 3-methyl-4,5,6-trihydroxy-phthalide; 4,5,6-Trihydroxy-3-methylisobenzofuran-1(3H)-one
DMQFTJ7 DT Small molecular drug
DMQFTJ7 PC 11424128
DMQFTJ7 MW 196.16
DMQFTJ7 FM C9H8O5
DMQFTJ7 IC InChI=1S/C9H8O5/c1-3-6-4(9(13)14-3)2-5(10)7(11)8(6)12/h2-3,10-12H,1H3
DMQFTJ7 CS CC1C2=C(C(=C(C=C2C(=O)O1)O)O)O
DMQFTJ7 IK AGUVVAYMPQDJDX-UHFFFAOYSA-N
DMQFTJ7 IU 4,5,6-trihydroxy-3-methyl-3H-2-benzofuran-1-one
DMQFTJ7 DE Discovery agent
DMXZ9PI ID DMXZ9PI
DMXZ9PI DN 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI HS Investigative
DMXZ9PI SN CHEMBL147690
DMXZ9PI DT Small molecular drug
DMXZ9PI PC 44364737
DMXZ9PI MW 264.5
DMXZ9PI FM C9H4Cl3NO2
DMXZ9PI IC InChI=1S/C9H4Cl3NO2/c10-3-1-4(11)6-5(2-3)13-9(15)8(14)7(6)12/h1-2,14H,(H,13,15)
DMXZ9PI CS C1=C(C=C(C2=C1NC(=O)C(=C2Cl)O)Cl)Cl
DMXZ9PI IK NRMJPXWRZZNIDJ-UHFFFAOYSA-N
DMXZ9PI IU 4,5,7-trichloro-3-hydroxy-1H-quinolin-2-one
DMXZ9PI DE Discovery agent
DM1RM3H ID DM1RM3H
DM1RM3H DN 4',5,7-trihydroxy-6,8-dimethylisoflavone
DM1RM3H HS Investigative
DM1RM3H SN 4',5,7-Trihydroxy-6,8-dimethylisoflavone; CHEMBL512579; AC1LCTEG; SCHEMBL571136; BDBM50250906; 4'',5,7-trihydroxy-6,8-dimethylisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethylchromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethyl-4H-chromen-4-one; 5,7-Dihydroxy-3-(4-hydroxy-phenyl)-6,8-dimethyl-chromen-4-one; 4H-1-benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethyl-
DM1RM3H DT Small molecular drug
DM1RM3H PC 637048
DM1RM3H MW 298.29
DM1RM3H FM C17H14O5
DM1RM3H IC InChI=1S/C17H14O5/c1-8-14(19)9(2)17-13(15(8)20)16(21)12(7-22-17)10-3-5-11(18)6-4-10/h3-7,18-20H,1-2H3
DM1RM3H CS CC1=C(C(=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)C)O
DM1RM3H IK VSEIMGCATUFLSE-UHFFFAOYSA-N
DM1RM3H IU 5,7-dihydroxy-3-(4-hydroxyphenyl)-6,8-dimethylchromen-4-one
DM1RM3H DE Discovery agent
DMIO254 ID DMIO254
DMIO254 DN 4,5-Bis(4-chlorophenyl)-1,2-selenazole
DMIO254 HS Investigative
DMIO254 SN CHEMBL501676; 4,5-Bis(4-chlorophenyl)-1,2-selenazole
DMIO254 DT Small molecular drug
DMIO254 PC 24884694
DMIO254 MW 353.1
DMIO254 FM C15H9Cl2NSe
DMIO254 IC InChI=1S/C15H9Cl2NSe/c16-12-5-1-10(2-6-12)14-9-18-19-15(14)11-3-7-13(17)8-4-11/h1-9H
DMIO254 CS C1=CC(=CC=C1C2=C([Se]N=C2)C3=CC=C(C=C3)Cl)Cl
DMIO254 IK QKBSSPQBZVKIAU-UHFFFAOYSA-N
DMIO254 IU 4,5-bis(4-chlorophenyl)-1,2-selenazole
DMIO254 DE Discovery agent
DMENLFY ID DMENLFY
DMENLFY DN 4,5-Bis(4-chlorophenyl)isothiazole
DMENLFY HS Investigative
DMENLFY SN 4,5-Bis(4-chlorophenyl)isothiazole; CHEMBL491088
DMENLFY DT Small molecular drug
DMENLFY PC 44564456
DMENLFY MW 306.2
DMENLFY FM C15H9Cl2NS
DMENLFY IC InChI=1S/C15H9Cl2NS/c16-12-5-1-10(2-6-12)14-9-18-19-15(14)11-3-7-13(17)8-4-11/h1-9H
DMENLFY CS C1=CC(=CC=C1C2=C(SN=C2)C3=CC=C(C=C3)Cl)Cl
DMENLFY IK FCOMTKBRAKMDNZ-UHFFFAOYSA-N
DMENLFY IU 4,5-bis(4-chlorophenyl)-1,2-thiazole
DMENLFY DE Discovery agent
DMKHD1M ID DMKHD1M
DMKHD1M DN 4,5-Bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M HS Investigative
DMKHD1M SN CHEMBL470304; 4,5-Bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M DT Small molecular drug
DMKHD1M PC 24884690
DMKHD1M MW 344.3
DMKHD1M FM C17H15NO2Se
DMKHD1M IC InChI=1S/C17H15NO2Se/c1-19-14-7-3-12(4-8-14)16-11-18-21-17(16)13-5-9-15(20-2)10-6-13/h3-11H,1-2H3
DMKHD1M CS COC1=CC=C(C=C1)C2=C([Se]N=C2)C3=CC=C(C=C3)OC
DMKHD1M IK QSLNOYIPCSNQKT-UHFFFAOYSA-N
DMKHD1M IU 4,5-bis(4-methoxyphenyl)-1,2-selenazole
DMKHD1M DE Discovery agent
DMI39QT ID DMI39QT
DMI39QT DN 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one
DMI39QT HS Investigative
DMI39QT SN CHEMBL490292; 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one
DMI39QT DT Small molecular drug
DMI39QT PC 13015959
DMI39QT MW 330.4
DMI39QT FM C17H14O3S2
DMI39QT IC InChI=1S/C17H14O3S2/c1-19-13-7-3-11(4-8-13)15-16(21-22-17(15)18)12-5-9-14(20-2)10-6-12/h3-10H,1-2H3
DMI39QT CS COC1=CC=C(C=C1)C2=C(SSC2=O)C3=CC=C(C=C3)OC
DMI39QT IK HXHFMMHFTDDRIF-UHFFFAOYSA-N
DMI39QT IU 4,5-bis(4-methoxyphenyl)dithiol-3-one
DMI39QT DE Discovery agent
DMPW145 ID DMPW145
DMPW145 DN 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione
DMPW145 HS Investigative
DMPW145 SN CHEMBL489899; 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione
DMPW145 DT Small molecular drug
DMPW145 PC 44564508
DMPW145 MW 346.5
DMPW145 FM C17H14O2S3
DMPW145 IC InChI=1S/C17H14O2S3/c1-18-13-7-3-11(4-8-13)15-16(21-22-17(15)20)12-5-9-14(19-2)10-6-12/h3-10H,1-2H3
DMPW145 CS COC1=CC=C(C=C1)C2=C(SSC2=S)C3=CC=C(C=C3)OC
DMPW145 IK CLEJIKNYKPUJCS-UHFFFAOYSA-N
DMPW145 IU 4,5-bis(4-methoxyphenyl)dithiole-3-thione
DMPW145 CA CAS 35564-24-0
DMPW145 DE Discovery agent
DM90DV6 ID DM90DV6
DM90DV6 DN 4,5-Bis(4-methoxyphenyl)isothiazole
DM90DV6 HS Investigative
DM90DV6 SN 4,5-Bis(4-methoxyphenyl)isothiazole; CHEMBL473946
DM90DV6 DT Small molecular drug
DM90DV6 PC 44564415
DM90DV6 MW 297.4
DM90DV6 FM C17H15NO2S
DM90DV6 IC InChI=1S/C17H15NO2S/c1-19-14-7-3-12(4-8-14)16-11-18-21-17(16)13-5-9-15(20-2)10-6-13/h3-11H,1-2H3
DM90DV6 CS COC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)OC
DM90DV6 IK COPANKICKKUPAC-UHFFFAOYSA-N
DM90DV6 IU 4,5-bis(4-methoxyphenyl)-1,2-thiazole
DM90DV6 DE Discovery agent
DMHURXY ID DMHURXY
DMHURXY DN 4,5-dibenzylbenzene-1,2-diol
DMHURXY HS Investigative
DMHURXY SN 4,5-dibenzylbenzene-1,2-diol; 4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154
DMHURXY DT Small molecular drug
DMHURXY PC 379493
DMHURXY MW 290.4
DMHURXY FM C20H18O2
DMHURXY IC InChI=1S/C20H18O2/c21-19-13-17(11-15-7-3-1-4-8-15)18(14-20(19)22)12-16-9-5-2-6-10-16/h1-10,13-14,21-22H,11-12H2
DMHURXY CS C1=CC=C(C=C1)CC2=CC(=C(C=C2CC3=CC=CC=C3)O)O
DMHURXY IK SQDMOCPHIXUCCE-UHFFFAOYSA-N
DMHURXY IU 4,5-dibenzylbenzene-1,2-diol
DMHURXY DE Discovery agent
DMDM9UV ID DMDM9UV
DMDM9UV DN 4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide
DMDM9UV HS Investigative
DMDM9UV SN CHEMBL356164; 34649-20-2; 4,5-dibromopyrrole-2-carboxamide; 4,5-dibromo-1h-pyrrole-2-carboxamide; 4,5-dibromopyrrole-2-carbonamide; 4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide; MLS001250248; 4,5-dibromopyrrole-2-carbamide; CTK1B1045; DTXSID30555154; BDBM50108773; SMR001216076; 1H-Pyrrole-2-carboxamide, 4,5-dibromo-; 4,5-Dibromo-1H-pyrrole-2-carboxylic acid
DMDM9UV DT Small molecular drug
DMDM9UV PC 14056555
DMDM9UV MW 267.91
DMDM9UV FM C5H4Br2N2O
DMDM9UV IC InChI=1S/C5H4Br2N2O/c6-2-1-3(5(8)10)9-4(2)7/h1,9H,(H2,8,10)
DMDM9UV CS C1=C(NC(=C1Br)Br)C(=O)N
DMDM9UV IK VTWHNVAKXBNGFV-UHFFFAOYSA-N
DMDM9UV IU 4,5-dibromo-1H-pyrrole-2-carboxamide
DMDM9UV CA CAS 34649-20-2
DMDM9UV DE Discovery agent
DMX94EK ID DMX94EK
DMX94EK DN 4,5-dichloro-1H-indole-2,3-dione
DMX94EK HS Investigative
DMX94EK SN 4,5-Dichloroisatin; 1677-47-0; 4,5-dichloro-1H-indole-2,3-dione; 4,5-Dichloroindoline-2,3-dione; 1H-Indole-2,3-dione, 4,5-dichloro-; 4,5-dichloro-2,3-dihydro-1H-indole-2,3-dione; 4,5-Dichlorisatin; AC1NOKZI; AC1Q3HQG; Isatin-based compound, 49; SCHEMBL734955; CHEMBL385799; CTK4D2746; BDBM22829; DTXSID90408697; MolPort-001-828-451; WWSWHYAXEFLETD-UHFFFAOYSA-N; ZINC4530445; 8556AA; 4,5-dichloro-1H-indol-2,3-dione; ANW-58782; AKOS015850110; FCH1330653; 1H-Indole-2,3-dione,4,5-dichloro-; QC-9708; MCULE-6649049490; KB-35588; SY030680
DMX94EK DT Small molecular drug
DMX94EK PC 5139980
DMX94EK MW 216.02
DMX94EK FM C8H3Cl2NO2
DMX94EK IC InChI=1S/C8H3Cl2NO2/c9-3-1-2-4-5(6(3)10)7(12)8(13)11-4/h1-2H,(H,11,12,13)
DMX94EK CS C1=CC(=C(C2=C1NC(=O)C2=O)Cl)Cl
DMX94EK IK WWSWHYAXEFLETD-UHFFFAOYSA-N
DMX94EK IU 4,5-dichloro-1H-indole-2,3-dione
DMX94EK CA CAS 1677-47-0
DMX94EK DE Discovery agent
DMG8KRN ID DMG8KRN
DMG8KRN DN 4,5-Dihydroxy-10H-anthracen-9-one
DMG8KRN HS Investigative
DMG8KRN SN CHEMBL124951; Isoanthralin; 4,5-Dihydroxy-10H-anthracen-9-one; 1,8-dihydroxy-10-anthrone; ZINC13606497; BDBM50060858
DMG8KRN DT Small molecular drug
DMG8KRN PC 13379482
DMG8KRN MW 226.23
DMG8KRN FM C14H10O3
DMG8KRN IC InChI=1S/C14H10O3/c15-12-5-1-3-8-10(12)7-11-9(14(8)17)4-2-6-13(11)16/h1-6,15-16H,7H2
DMG8KRN CS C1C2=C(C=CC=C2O)C(=O)C3=C1C(=CC=C3)O
DMG8KRN IK BGECJMUUSSERAU-UHFFFAOYSA-N
DMG8KRN IU 4,5-dihydroxy-10H-anthracen-9-one
DMG8KRN DE Discovery agent
DM34L89 ID DM34L89
DM34L89 DN 4,5-Dimethoxy-10H-anthracen-9-one
DM34L89 HS Investigative
DM34L89 SN 4,5-dimethoxy-10H-anthracen-9-one; CHEMBL125822; 76403-03-7; AC1NRZIP; CTK2G0639; DTXSID90416070; ZINC2540909; BDBM50060856; 4,5-Dimethoxyanthracen-9(10H)-one; 9(10H)-Anthracenone, 4,5-dimethoxy-
DM34L89 DT Small molecular drug
DM34L89 PC 5325945
DM34L89 MW 254.28
DM34L89 FM C16H14O3
DM34L89 IC InChI=1S/C16H14O3/c1-18-14-7-3-5-10-12(14)9-13-11(16(10)17)6-4-8-15(13)19-2/h3-8H,9H2,1-2H3
DM34L89 CS COC1=CC=CC2=C1CC3=C(C2=O)C=CC=C3OC
DM34L89 IK YNXDXUPTUFLKRN-UHFFFAOYSA-N
DM34L89 IU 4,5-dimethoxy-10H-anthracen-9-one
DM34L89 CA CAS 76403-03-7
DM34L89 DE Discovery agent
DMB9CJM ID DMB9CJM
DMB9CJM DN 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine
DMB9CJM HS Investigative
DMB9CJM SN CHEMBL185584; 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150924
DMB9CJM DT Small molecular drug
DMB9CJM PC 10261068
DMB9CJM MW 112.17
DMB9CJM FM C6H12N2
DMB9CJM IC InChI=1S/C6H12N2/c1-4-3-6(7)8-5(4)2/h4-5H,3H2,1-2H3,(H2,7,8)
DMB9CJM CS CC1CC(=NC1C)N
DMB9CJM IK HLFGYTAETWRDBS-UHFFFAOYSA-N
DMB9CJM IU 2,3-dimethyl-3,4-dihydro-2H-pyrrol-5-amine
DMB9CJM DE Discovery agent
DMXNP2W ID DMXNP2W
DMXNP2W DN 4,5-ISOBUDLEIN A
DMXNP2W HS Investigative
DMXNP2W SN 4,5-isobudlein A
DMXNP2W DT Small molecular drug
DMXNP2W PC 44409589
DMXNP2W MW 374.4
DMXNP2W FM C20H22O7
DMXNP2W IC InChI=1S/C20H22O7/c1-6-9(2)18(23)25-13-8-20(5)14(21)7-12(27-20)10(3)16(22)17-15(13)11(4)19(24)26-17/h6-7,13,15-17,22H,3-4,8H2,1-2,5H3/b9-6-/t13-,15-,16+,17+,20-/m1/s1
DMXNP2W CS C/C=C(/C)\\C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)C(=C)[C@@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)C
DMXNP2W IK LEMMNOMGQFFVKL-NPUWKFQTSA-N
DMXNP2W IU [(3S,4S,8R,9R,11R)-3-hydroxy-11-methyl-2,7-dimethylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradec-1(13)-en-9-yl] (Z)-2-methylbut-2-enoate
DMXNP2W DE Discovery agent
DM6N98E ID DM6N98E
DM6N98E DN 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E HS Investigative
DM6N98E SN CHEMBL380362; 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E DT Small molecular drug
DM6N98E PC 11777167
DM6N98E MW 256.3
DM6N98E FM C16H16O3
DM6N98E IC InChI=1S/C16H16O3/c1-8-6-11(17)7-13-10(3)19-16-9(2)14(18)5-4-12(16)15(8)13/h4-7,10,17-18H,1-3H3
DM6N98E CS CC1C2=C(C(=CC(=C2)O)C)C3=C(O1)C(=C(C=C3)O)C
DM6N98E IK ACLQWAFSCNOYRE-UHFFFAOYSA-N
DM6N98E IU 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol
DM6N98E DE Discovery agent
DM14VI3 ID DM14VI3
DM14VI3 DN 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol
DM14VI3 HS Investigative
DM14VI3 SN CHEMBL204025; 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6827956
DM14VI3 DT Small molecular drug
DM14VI3 PC 9993278
DM14VI3 MW 270.32
DM14VI3 FM C17H18O3
DM14VI3 IC InChI=1S/C17H18O3/c1-9-13(18)7-5-11-12-6-8-14(19)10(2)16(12)20-17(3,4)15(9)11/h5-8,18-19H,1-4H3
DM14VI3 CS CC1=C(C=CC2=C1C(OC3=C2C=CC(=C3C)O)(C)C)O
DM14VI3 IK XQLSNCGISMACFD-UHFFFAOYSA-N
DM14VI3 IU 4,6,6,7-tetramethylbenzo[c]chromene-3,8-diol
DM14VI3 DE Discovery agent
DMYN25U ID DMYN25U
DMYN25U DN 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U HS Investigative
DMYN25U SN CHEMBL206584; SCHEMBL6830345; 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U DT Small molecular drug
DMYN25U PC 10061675
DMYN25U MW 270.32
DMYN25U FM C17H18O3
DMYN25U IC InChI=1S/C17H18O3/c1-8-7-14(19)9(2)16-11(4)20-17-10(3)13(18)6-5-12(17)15(8)16/h5-7,11,18-19H,1-4H3
DMYN25U CS CC1C2=C(C(=CC(=C2C)O)C)C3=C(O1)C(=C(C=C3)O)C
DMYN25U IK NXVCUJCNTBPNSZ-UHFFFAOYSA-N
DMYN25U IU 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol
DMYN25U DE Discovery agent
DMFECXI ID DMFECXI
DMFECXI DN 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol
DMFECXI HS Investigative
DMFECXI SN CHEMBL381337; 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6828067
DMFECXI DT Small molecular drug
DMFECXI PC 10060956
DMFECXI MW 256.3
DMFECXI FM C16H16O3
DMFECXI IC InChI=1S/C16H16O3/c1-8-13(17)6-4-11-12-5-7-14(18)9(2)16(12)19-10(3)15(8)11/h4-7,10,17-18H,1-3H3
DMFECXI CS CC1C2=C(C=CC(=C2C)O)C3=C(O1)C(=C(C=C3)O)C
DMFECXI IK SKULOBHFUJYXEB-UHFFFAOYSA-N
DMFECXI IU 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol
DMFECXI DE Discovery agent
DMHBO17 ID DMHBO17
DMHBO17 DN 4,6-dichloro-1H-indole-2,3-dione
DMHBO17 HS Investigative
DMHBO17 SN 4,6-Dichloroisatin; 18711-15-4; 4,6-Dichloro-1H-indole-2,3-dione; 4,6-DICHLOROINDOLINE-2,3-DIONE; 4,6-dichloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione,4,6-dichloro-; CGCVHJCZBIYRQC-UHFFFAOYSA-N; 4,6-dichloro-1H-benzo[d]azoline-2,3-dione; 4,6-dichlorisatin; NSC72897; AC1L5KVQ; AC1Q3MQL; Isatin-based compound, 50; SCHEMBL124586; CHEMBL385800; Jsp003834; BDBM22830; CTK4D9417; 4,6-dichloroindolin-2,3-dione; DTXSID60291058; 4,6-Dichloro-2,3-indolinedione; MolPort-001-969-148; ACT09176; ZINC1698777; ZERO/005650; KS-00000J1A
DMHBO17 DT Small molecular drug
DMHBO17 PC 251908
DMHBO17 MW 216.02
DMHBO17 FM C8H3Cl2NO2
DMHBO17 IC InChI=1S/C8H3Cl2NO2/c9-3-1-4(10)6-5(2-3)11-8(13)7(6)12/h1-2H,(H,11,12,13)
DMHBO17 CS C1=C(C=C(C2=C1NC(=O)C2=O)Cl)Cl
DMHBO17 IK CGCVHJCZBIYRQC-UHFFFAOYSA-N
DMHBO17 IU 4,6-dichloro-1H-indole-2,3-dione
DMHBO17 CA CAS 18711-15-4
DMHBO17 DE Discovery agent
DM62XC3 ID DM62XC3
DM62XC3 DN 4,6-Dichloro-1H-indole-2-carboxylic acid
DM62XC3 HS Investigative
DM62XC3 SN 101861-63-6; 4,6-dichloro-1H-indole-2-carboxylic acid; 4,6-Dichloroindole-2-carboxylic acid; CHEMBL301556; 1H-Indole-2-carboxylicacid, 4,6-dichloro-; 3-(4,6-Dichloro-2-carboxyindol-3-yl)propionic acid; 3-Dccip; KBio2_007460; PubChem7197; Spectrum_001822; SpecPlus_000800; 4,6-Dichloro-1H-indole-2-carboxylicacid; ACMC-1BPUR; AC1Q3MQM; AC1L2SZE; Maybridge1_006804; AC1Q73TA; Oprea1_268024; KBioSS_002327; SCHEMBL727389; DivK1c_006896; KBio2_004892; KBio2_002324; KBio1_001840; CTK0H4782; HMS560N06; DTXSID80144299; MolPort-000-147-351; Mdl-29951
DM62XC3 DT Small molecular drug
DM62XC3 PC 127988
DM62XC3 MW 230.04
DM62XC3 FM C9H5Cl2NO2
DM62XC3 IC InChI=1S/C9H5Cl2NO2/c10-4-1-6(11)5-3-8(9(13)14)12-7(5)2-4/h1-3,12H,(H,13,14)
DM62XC3 CS C1=C(C=C(C2=C1NC(=C2)C(=O)O)Cl)Cl
DM62XC3 IK DHXISZKSSIWRLH-UHFFFAOYSA-N
DM62XC3 IU 4,6-dichloro-1H-indole-2-carboxylic acid
DM62XC3 CA CAS 101861-63-6
DM62XC3 DE Discovery agent
DMBZIG7 ID DMBZIG7
DMBZIG7 DN 4,6-Dideoxy-4-Amino-Alpha-D-Glucose
DMBZIG7 HS Investigative
DMBZIG7 SN 4,6-DIDEOXY-4-AMINO-ALPHA-D-GLUCOSE; AC1L9FSA; SCHEMBL1543515; DB03439; 4-amino-4,6-dideoxy-alpha-d-glucopyranose; AGL; (2S,3R,4S,5S,6R)-5-amino-6-methyloxane-2,3,4-triol
DMBZIG7 DT Small molecular drug
DMBZIG7 PC 444139
DMBZIG7 MW 163.17
DMBZIG7 FM C6H13NO4
DMBZIG7 IC InChI=1S/C6H13NO4/c1-2-3(7)4(8)5(9)6(10)11-2/h2-6,8-10H,7H2,1H3/t2-,3-,4+,5-,6+/m1/s1
DMBZIG7 CS C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)N
DMBZIG7 IK RJKBJEZZABBYBA-DVKNGEFBSA-N
DMBZIG7 IU (2S,3R,4S,5S,6R)-5-amino-6-methyloxane-2,3,4-triol
DMBZIG7 DE Discovery agent
DMP5M9E ID DMP5M9E
DMP5M9E DN 4,6-Dideoxyglucose
DMP5M9E HS Investigative
DMP5M9E SN 4,6-DIDEOXYGLUCOSE; AC1NRBIQ; ZINC12501177; DB01841; 4,6-dideoxy-alpha-D-xylo-hexopyranose
DMP5M9E DT Small molecular drug
DMP5M9E PC 5288437
DMP5M9E MW 148.16
DMP5M9E FM C6H12O4
DMP5M9E IC InChI=1S/C6H12O4/c1-3-2-4(7)5(8)6(9)10-3/h3-9H,2H2,1H3/t3-,4+,5-,6+/m1/s1
DMP5M9E CS C[C@@H]1C[C@@H]([C@H]([C@H](O1)O)O)O
DMP5M9E IK BJBURJZEESAQPG-MOJAZDJTSA-N
DMP5M9E IU (2S,3R,4S,6R)-6-methyloxane-2,3,4-triol
DMP5M9E DE Discovery agent
DMIJ4VZ ID DMIJ4VZ
DMIJ4VZ DN 4,6-Dinitro salicylic acid
DMIJ4VZ HS Investigative
DMIJ4VZ SN 4,6-Dinitro salicylic acid; 4,6-dinitrosalicylic acid; CHEMBL447810; 65841-03-4; SCHEMBL8633874; 6-hydroxy-2,4-dinitrobenzoic acid; 2-Hydroxy-4,6-dinitrobenzoic acid
DMIJ4VZ DT Small molecular drug
DMIJ4VZ PC 13443185
DMIJ4VZ MW 228.12
DMIJ4VZ FM C7H4N2O7
DMIJ4VZ IC InChI=1S/C7H4N2O7/c10-5-2-3(8(13)14)1-4(9(15)16)6(5)7(11)12/h1-2,10H,(H,11,12)
DMIJ4VZ CS C1=C(C=C(C(=C1[N+](=O)[O-])C(=O)O)O)[N+](=O)[O-]
DMIJ4VZ IK AQBLBIVMAAUENI-UHFFFAOYSA-N
DMIJ4VZ IU 2-hydroxy-4,6-dinitrobenzoic acid
DMIJ4VZ DE Discovery agent
DMWDYLR ID DMWDYLR
DMWDYLR DN 4,6-dinitrobenzo[c][1,2,5]thiadiazole
DMWDYLR HS Investigative
DMWDYLR SN 4,6-Dinitro-2,1,3-benzothiadiazole; 4,6-dinitrobenzo[c][1,2,5]thiadiazole; CHEMBL206140; 16408-06-3; NSC202427; AC1L76UW; AC1Q1Y7D; C6H2N4O4S; DTXSID90308123; MolPort-000-820-133; BYLOIWCTRDPRTP-UHFFFAOYSA-N; ZINC1736331; STK744333; BDBM50182130; 5,7-dinitro-2,1,3-benzothiadiazole; AKOS000544790; NSC-202427; MCULE-2301273439; 4,6-dinitrobenzo[c]1,2,5-thiadiazole; 4,6-Dinitro-benzo[1,2,5]thiadiazole; 2,1,3-Benzothiadiazole, 4,6-dinitro-; 4,6-Dinitro-2,1,3-benzothiadiazole #; NCI60_001699; ST032375; BAS 00731156
DMWDYLR DT Small molecular drug
DMWDYLR PC 305451
DMWDYLR MW 226.17
DMWDYLR FM C6H2N4O4S
DMWDYLR IC InChI=1S/C6H2N4O4S/c11-9(12)3-1-4-6(8-15-7-4)5(2-3)10(13)14/h1-2H
DMWDYLR CS C1=C(C=C(C2=NSN=C21)[N+](=O)[O-])[N+](=O)[O-]
DMWDYLR IK BYLOIWCTRDPRTP-UHFFFAOYSA-N
DMWDYLR IU 4,6-dinitro-2,1,3-benzothiadiazole
DMWDYLR CA CAS 16408-06-3
DMWDYLR DE Discovery agent
DMEVK5F ID DMEVK5F
DMEVK5F DN 4,7-dichloro-1H-indole-2,3-dione
DMEVK5F HS Investigative
DMEVK5F SN 4,7-Dichloroisatin; 18711-13-2; 4,7-dichloroindoline-2,3-dione; 4,7-dichloro-1H-indole-2,3-dione; 4,7-dichloro isatin; 4,7-dichloro-isatin; 4,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 4,7-dichloro-; 4,7-dichloroisatin;; 4,7-dichloroisatine;; AC1MC1Y2; Isatin-based compound, 51; ACMC-1C3I3; 4,7-Dichloroisatin, 97%; KSC494I6J; SCHEMBL281619; CHEMBL223039; 4,7-Dichloroindole-2,3-dione; CTK3J4464; BDBM22831; DTXSID90370507; 4,7-Dichloro-2,3-indolinedione; MolPort-001-766-630; 4,7-Dichloroindole-2,3-dione;
DMEVK5F DT Small molecular drug
DMEVK5F PC 2734793
DMEVK5F MW 216.02
DMEVK5F FM C8H3Cl2NO2
DMEVK5F IC InChI=1S/C8H3Cl2NO2/c9-3-1-2-4(10)6-5(3)7(12)8(13)11-6/h1-2H,(H,11,12,13)
DMEVK5F CS C1=CC(=C2C(=C1Cl)C(=O)C(=O)N2)Cl
DMEVK5F IK NUXYYWOWNFEMNH-UHFFFAOYSA-N
DMEVK5F IU 4,7-dichloro-1H-indole-2,3-dione
DMEVK5F CA CAS 18711-13-2
DMEVK5F DE Discovery agent
DM67Z81 ID DM67Z81
DM67Z81 DN 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DM67Z81 HS Investigative
DM67Z81 SN CHEMBL378798; 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6830103
DM67Z81 DT Small molecular drug
DM67Z81 PC 9991961
DM67Z81 MW 242.27
DM67Z81 FM C15H14O3
DM67Z81 IC InChI=1S/C15H14O3/c1-8-12-7-18-15-9(2)14(17)6-4-11(15)10(12)3-5-13(8)16/h3-6,16-17H,7H2,1-2H3
DM67Z81 CS CC1=C(C=CC2=C1COC3=C2C=CC(=C3C)O)O
DM67Z81 IK UCANDFJLKWPIBP-UHFFFAOYSA-N
DM67Z81 IU 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DM67Z81 DE Discovery agent
DML5302 ID DML5302
DML5302 DN 4,7-Dioxosebacic Acid
DML5302 HS Investigative
DML5302 PC 1698
DML5302 MW 230.21
DML5302 FM C10H14O6
DML5302 IC InChI=1S/C10H14O6/c11-7(3-5-9(13)14)1-2-8(12)4-6-10(15)16/h1-6H2,(H,13,14)(H,15,16)
DML5302 CS C(CC(=O)CCC(=O)O)C(=O)CCC(=O)O
DML5302 IK DUAWJQCMZICMIK-UHFFFAOYSA-N
DML5302 IU 4,7-dioxodecanedioic acid
DML5302 DE Discovery agent
DMQNXL1 ID DMQNXL1
DMQNXL1 DN 4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin
DMQNXL1 HS Investigative
DMQNXL1 SN CHEMBL488917; 4,8-dimethyl-7-((2-oxocyclohexyl)oxy)-2H-chromen-2-one; 4,8-dimethyl-7-[(2-oxocyclohexyl)oxy]-2H-chromen-2-one; AC1N8LB1; MLS001213498; MolPort-000-837-574; HMS2863H04; STL528052; BDBM50246220; AKOS030497124; MCULE-3956285825; SMR000540525; 4,8-Dimethyl-7-(2''-oxocyclohexyloxy)coumarin; 4,8-dimethyl-7-(2-oxocyclohexyl)oxychromen-2-one
DMQNXL1 DT Small molecular drug
DMQNXL1 PC 4297278
DMQNXL1 MW 286.32
DMQNXL1 FM C17H18O4
DMQNXL1 IC InChI=1S/C17H18O4/c1-10-9-16(19)21-17-11(2)14(8-7-12(10)17)20-15-6-4-3-5-13(15)18/h7-9,15H,3-6H2,1-2H3
DMQNXL1 CS CC1=CC(=O)OC2=C1C=CC(=C2C)OC3CCCCC3=O
DMQNXL1 IK WRTZCCCOMNOONZ-UHFFFAOYSA-N
DMQNXL1 IU 4,8-dimethyl-7-(2-oxocyclohexyl)oxychromen-2-one
DMQNXL1 DE Discovery agent
DMEKI1B ID DMEKI1B
DMEKI1B DN 4,9-anhydro-tetrodotoxin
DMEKI1B HS Investigative
DMEKI1B SN 4,9-anhydro-TTX; 4,9-ah-TTX
DMEKI1B DT Small molecular drug
DMEKI1B PC 73755148
DMEKI1B MW 302.26
DMEKI1B FM C11H16N3O7+
DMEKI1B IC InChI=1S/C11H15N3O7/c12-8-13-6-2-4-9(17,1-15)5-3(16)10(2,14-8)7(19-6)11(18,20-4)21-5/h2-7,15-18H,1H2,(H3,12,13,14)/p+1
DMEKI1B CS C(C1(C2C3C4[NH+]=C(NC35C(C1OC(C5O4)(O2)O)O)N)O)O
DMEKI1B IK STNXQECXKDMLJK-UHFFFAOYSA-O
DMEKI1B IU 7-amino-2-(hydroxymethyl)-10,13,15-trioxa-6-aza-8-azoniapentacyclo[7.4.1.13,12.05,11.05,14]pentadec-7-ene-2,4,12-triol
DMEKI1B DE Discovery agent
DM27HMT ID DM27HMT
DM27HMT DN 4,9-Dihydro-3H-beta-carboline
DM27HMT HS Investigative
DM27HMT SN 4894-26-2; 4,9-dihydro-3H-Pyrido[3,4-b]indole; 4,9-dihydro-3H-beta-carboline; 3H-Pyrido(3,4-b)indole, 4,9-dihydro-; 3,4-dihydro-beta-carboline; CHEMBL266221; 4,9-Dihydro-3H-pyrido(3,4-b)indole; 3H-Pyrido[3,4-b]indole, 4,9-dihydro-; AC1L3RVU; 3,4-dihydrobeta-carboline; SCHEMBL678673; CTK7D1379; DTXSID20197643; ZINC332024; BDBM50136506; SBB062953; FCH841675; AKOS006272808; ACM4894262; 3H,4H,9H-PYRIDO[3,4-B]INDOLE; TX-010240; FT-0698471
DM27HMT DT Small molecular drug
DM27HMT PC 145772
DM27HMT MW 170.21
DM27HMT FM C11H10N2
DM27HMT IC InChI=1S/C11H10N2/c1-2-4-10-8(3-1)9-5-6-12-7-11(9)13-10/h1-4,7,13H,5-6H2
DM27HMT CS C1CN=CC2=C1C3=CC=CC=C3N2
DM27HMT IK NTYXKFHKVREUMR-UHFFFAOYSA-N
DM27HMT IU 4,9-dihydro-3H-pyrido[3,4-b]indole
DM27HMT CA CAS 4894-26-2
DM27HMT DE Discovery agent
DM8BPTQ ID DM8BPTQ
DM8BPTQ DN 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine
DM8BPTQ HS Investigative
DM8BPTQ SN CHEMBL1269156; 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine; BDBM50330054; AKOS013124194
DM8BPTQ DT Small molecular drug
DM8BPTQ PC 52949342
DM8BPTQ MW 173.21
DM8BPTQ FM C10H11N3
DM8BPTQ IC InChI=1S/C10H11N3/c1-9-12-6-7-13(9)8-10-2-4-11-5-3-10/h2-7H,8H2,1H3
DM8BPTQ CS CC1=NC=CN1CC2=CC=NC=C2
DM8BPTQ IK MNSNMTASPOHKEI-UHFFFAOYSA-N
DM8BPTQ IU 4-[(2-methylimidazol-1-yl)methyl]pyridine
DM8BPTQ DE Discovery agent
DMSKJ1X ID DMSKJ1X
DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol
DMSKJ1X HS Investigative
DMSKJ1X DT Small molecular drug
DMSKJ1X PC 9859248
DMSKJ1X DE Discovery agent
DM04MK7 ID DM04MK7
DM04MK7 DN 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine
DM04MK7 HS Investigative
DM04MK7 SN CHEMBL1172882; SCHEMBL18770302; BDBM50322789; 4''-(pyridin-4-ylmethyl)biphenyl-3-ol
DM04MK7 DT Small molecular drug
DM04MK7 PC 46901446
DM04MK7 MW 261.3
DM04MK7 FM C18H15NO
DM04MK7 IC InChI=1S/C18H15NO/c20-18-3-1-2-17(13-18)16-6-4-14(5-7-16)12-15-8-10-19-11-9-15/h1-11,13,20H,12H2
DM04MK7 CS C1=CC(=CC(=C1)O)C2=CC=C(C=C2)CC3=CC=NC=C3
DM04MK7 IK GFIBJCSJSOCGMM-UHFFFAOYSA-N
DM04MK7 IU 3-[4-(pyridin-4-ylmethyl)phenyl]phenol
DM04MK7 DE Discovery agent
DMIEMWA ID DMIEMWA
DMIEMWA DN 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine
DMIEMWA HS Investigative
DMIEMWA SN CHEMBL1215664; BDBM50324611
DMIEMWA DT Small molecular drug
DMIEMWA PC 49864181
DMIEMWA MW 277.3
DMIEMWA FM C18H15NO2
DMIEMWA IC InChI=1S/C18H15NO2/c20-17-7-5-14(6-8-17)13-1-3-15(4-2-13)18(21)16-9-11-19-12-10-16/h1-12,18,20-21H
DMIEMWA CS C1=CC(=CC=C1C2=CC=C(C=C2)O)C(C3=CC=NC=C3)O
DMIEMWA IK ABUNZHUAYBOXCN-UHFFFAOYSA-N
DMIEMWA IU 4-[4-[hydroxy(pyridin-4-yl)methyl]phenyl]phenol
DMIEMWA DE Discovery agent
DMNMC9O ID DMNMC9O
DMNMC9O DN 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
DMNMC9O HS Investigative
DMNMC9O SN 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine; DB07428
DMNMC9O DT Small molecular drug
DMNMC9O PC 46937073
DMNMC9O MW 229.27
DMNMC9O FM C14H15NO2
DMNMC9O IC InChI=1S/C14H15NO2/c1-11-3-4-13(16-2)9-14(11)17-10-12-5-7-15-8-6-12/h3-9H,10H2,1-2H3
DMNMC9O CS CC1=C(C=C(C=C1)OC)OCC2=CC=NC=C2
DMNMC9O IK MBHBRRBLXCXQKV-UHFFFAOYSA-N
DMNMC9O IU 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
DMNMC9O DE Discovery agent
DMGRWEU ID DMGRWEU
DMGRWEU DN 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
DMGRWEU HS Investigative
DMGRWEU SN 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide; CHEMBL487738; 4-(6-chloropyrazin-2-ylamino)benzenesulfonamide; 642459-21-0; 2vtj; SCHEMBL6659290; BDBM24631; ZINC16052861; DB08134; FT-0723597; 4-[(6-chloropyrazin-2-yl)amino]benzene-1-sulfonamide; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide, 10
DMGRWEU DT Small molecular drug
DMGRWEU PC 9994066
DMGRWEU MW 284.72
DMGRWEU FM C10H9ClN4O2S
DMGRWEU IC InChI=1S/C10H9ClN4O2S/c11-9-5-13-6-10(15-9)14-7-1-3-8(4-2-7)18(12,16)17/h1-6H,(H,14,15)(H2,12,16,17)
DMGRWEU CS C1=CC(=CC=C1NC2=CN=CC(=N2)Cl)S(=O)(=O)N
DMGRWEU IK RSNSGNZRUMHXAY-UHFFFAOYSA-N
DMGRWEU IU 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
DMGRWEU DE Discovery agent
DMT1PM4 ID DMT1PM4
DMT1PM4 DN 4-[(diphenylmethyl)amino]-2-phenylquinazoline
DMT1PM4 HS Investigative
DMT1PM4 SN 4-[(Diphenylmethyl)amino]-2-phenylquinazoline; CHEMBL305876; Benzhydryl-(2-phenyl-quinazolin-4-yl)-amine; SCHEMBL18388787; BDBM50116317
DMT1PM4 DT Small molecular drug
DMT1PM4 PC 9930153
DMT1PM4 MW 387.5
DMT1PM4 FM C27H21N3
DMT1PM4 IC InChI=1S/C27H21N3/c1-4-12-20(13-5-1)25(21-14-6-2-7-15-21)29-27-23-18-10-11-19-24(23)28-26(30-27)22-16-8-3-9-17-22/h1-19,25H,(H,28,29,30)
DMT1PM4 CS C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=N2)NC(C4=CC=CC=C4)C5=CC=CC=C5
DMT1PM4 IK LJIQXEUCYVPWRY-UHFFFAOYSA-N
DMT1PM4 IU N-benzhydryl-2-phenylquinazolin-4-amine
DMT1PM4 DE Discovery agent
DMXKT6M ID DMXKT6M
DMXKT6M DN 4-[(METHYLSULFONYL)AMINO]BENZOIC ACID
DMXKT6M HS Investigative
DMXKT6M SN 4-(Methylsulfonamido)benzoic acid; 7151-76-0; 4-[(methylsulfonyl)amino]benzoic acid; 4-methanesulfonamidobenzoic acid; 4-Methanesulfonylamino-benzoic acid; 4-(METHANESULFONYLAMINO)BENZOIC ACID; Benzoic acid, 4-[(methylsulfonyl)amino]-; 4-(methanesulfonamido)benzoic acid; CHEMBL339996; SROHFTOYGFCJAF-UHFFFAOYSA-N; p-(Methylsulfonamido)benzoic acid; 2hds; methanesulfonamidobenzoicacid; AC1Q6VU0; AC1Q4GQ4; NCIOpen2_003463; Oprea1_337582; Oprea1_072870; SCHEMBL118340; AC1L5I58; 4-methylsulfonylaminobenzoic acid
DMXKT6M DT Small molecular drug
DMXKT6M PC 250653
DMXKT6M MW 215.23
DMXKT6M FM C8H9NO4S
DMXKT6M IC InChI=1S/C8H9NO4S/c1-14(12,13)9-7-4-2-6(3-5-7)8(10)11/h2-5,9H,1H3,(H,10,11)
DMXKT6M CS CS(=O)(=O)NC1=CC=C(C=C1)C(=O)O
DMXKT6M IK SROHFTOYGFCJAF-UHFFFAOYSA-N
DMXKT6M IU 4-(methanesulfonamido)benzoic acid
DMXKT6M CA CAS 7151-76-0
DMXKT6M DE Discovery agent
DMTMLXU ID DMTMLXU
DMTMLXU DN 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol
DMTMLXU HS Investigative
DMTMLXU SN 91221-46-4; 1,1-Bis(4-hydroxyphenyl)-2-phenylbut-1-ene; 1,1-Bis(4-hydroxyphenyl)-2-phenyl-1-butene; 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol; CHEMBL149791; 4,4'-(2-phenylbut-1-ene-1,1-diyl)diphenol; Tamoxifen bis-phenol; 1,1-Bhpe; Tamoxifenbisphenol; AC1L1YAG; SCHEMBL639225; CTK5G9076; DTXSID50238452; BPKSDMHGDYTXLI-UHFFFAOYSA-N; ZINC1849484; BDBM50121317; AKOS030254689; KB-09832; 4,4'-(2-Phenyl-1-butenylidene)bisphenol; B5114; FT-0663304; Phenol, 4,4'-(2-phenyl-1-butenylidene)bis-
DMTMLXU DT Small molecular drug
DMTMLXU PC 63059
DMTMLXU MW 316.4
DMTMLXU FM C22H20O2
DMTMLXU IC InChI=1S/C22H20O2/c1-2-21(16-6-4-3-5-7-16)22(17-8-12-19(23)13-9-17)18-10-14-20(24)15-11-18/h3-15,23-24H,2H2,1H3
DMTMLXU CS CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMTMLXU IK BPKSDMHGDYTXLI-UHFFFAOYSA-N
DMTMLXU IU 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol
DMTMLXU CA CAS 91221-46-4
DMTMLXU DE Discovery agent
DM30421 ID DM30421
DM30421 DN 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421 HS Investigative
DM30421 SN CHEMBL356693; 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421 DT Small molecular drug
DM30421 PC 10871661
DM30421 MW 344.4
DM30421 FM C24H24O2
DM30421 IC InChI=1S/C24H24O2/c1-2-3-9-23(18-7-5-4-6-8-18)24(19-10-14-21(25)15-11-19)20-12-16-22(26)17-13-20/h4-8,10-17,25-26H,2-3,9H2,1H3
DM30421 CS CCCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DM30421 IK LOSAKSLRALRQMY-UHFFFAOYSA-N
DM30421 IU 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol
DM30421 DE Discovery agent
DMWHKLA ID DMWHKLA
DMWHKLA DN 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol
DMWHKLA HS Investigative
DMWHKLA SN CHEMBL357824; 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol; SCHEMBL19158863; BDBM50121321
DMWHKLA DT Small molecular drug
DMWHKLA PC 11782482
DMWHKLA MW 330.4
DMWHKLA FM C23H22O2
DMWHKLA IC InChI=1S/C23H22O2/c1-2-6-22(17-7-4-3-5-8-17)23(18-9-13-20(24)14-10-18)19-11-15-21(25)16-12-19/h3-5,7-16,24-25H,2,6H2,1H3
DMWHKLA CS CCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMWHKLA IK UTLLHWVRVATSPI-UHFFFAOYSA-N
DMWHKLA IU 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol
DMWHKLA DE Discovery agent
DMH1I32 ID DMH1I32
DMH1I32 DN 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol
DMH1I32 HS Investigative
DMH1I32 SN CHEMBL150461; 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol; SCHEMBL18882768
DMH1I32 DT Small molecular drug
DMH1I32 PC 11141183
DMH1I32 MW 302.4
DMH1I32 FM C21H18O2
DMH1I32 IC InChI=1S/C21H18O2/c1-15(16-5-3-2-4-6-16)21(17-7-11-19(22)12-8-17)18-9-13-20(23)14-10-18/h2-14,22-23H,1H3
DMH1I32 CS CC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=CC=C3
DMH1I32 IK VGWVLJXJHQENDY-UHFFFAOYSA-N
DMH1I32 IU 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol
DMH1I32 DE Discovery agent
DM4BFPE ID DM4BFPE
DM4BFPE DN 4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol
DM4BFPE HS Investigative
DM4BFPE SN CHEMBL415864; 1,1-Bis(4-hydroxyphenyl)-2-phenylethylene; 4,4'-(2-Phenylethene-1,1-Diyl)diphenol; 66422-18-2; Bhpe-1,1; 4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol; SCHEMBL641985; AC1MI565; CTK5C4724; 4-(1,2-diphenyl-vinyl)-phenol; BDBM50023749; ZINC13492380; Phenol, 4,4'-(phenylethenylidene)bis-; 1,1-bis(4-hydroxyphenyl)-2-phenylethene; 4-[1-(4-hydroxyphenyl)-2-phenylethenyl]phenol
DM4BFPE DT Small molecular drug
DM4BFPE PC 3017674
DM4BFPE MW 288.3
DM4BFPE FM C20H16O2
DM4BFPE IC InChI=1S/C20H16O2/c21-18-10-6-16(7-11-18)20(14-15-4-2-1-3-5-15)17-8-12-19(22)13-9-17/h1-14,21-22H
DM4BFPE CS C1=CC=C(C=C1)C=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DM4BFPE IK CKNFKDYCAQZYBQ-UHFFFAOYSA-N
DM4BFPE IU 4-[1-(4-hydroxyphenyl)-2-phenylethenyl]phenol
DM4BFPE CA CAS 66422-18-2
DM4BFPE DE Discovery agent
DM8IYG1 ID DM8IYG1
DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol
DM8IYG1 HS Investigative
DM8IYG1 SN Phenol, 4,4'-(3-methyl-1-butenylidene)bis-; 66422-07-9; CHEMBL156843; CTK1J4765; DTXSID70441143; ZINC13650255
DM8IYG1 DT Small molecular drug
DM8IYG1 PC 10515117
DM8IYG1 MW 254.32
DM8IYG1 FM C17H18O2
DM8IYG1 IC InChI=1S/C17H18O2/c1-12(2)11-17(13-3-7-15(18)8-4-13)14-5-9-16(19)10-6-14/h3-12,18-19H,1-2H3
DM8IYG1 CS CC(C)C=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O
DM8IYG1 IK DDEWRRMILVWZOZ-UHFFFAOYSA-N
DM8IYG1 IU 4-[1-(4-hydroxyphenyl)-3-methylbut-1-enyl]phenol
DM8IYG1 CA CAS 66422-07-9
DM8IYG1 DE Discovery agent
DMCEABJ ID DMCEABJ
DMCEABJ DN 4-[1-(4'-Methoxybiphenyl-4-yl)propyl]pyridine
DMCEABJ HS Investigative
DMCEABJ SN CHEMBL1215596; BDBM50324608
DMCEABJ DT Small molecular drug
DMCEABJ PC 46901440
DMCEABJ MW 303.4
DMCEABJ FM C21H21NO
DMCEABJ IC InChI=1S/C21H21NO/c1-3-21(19-12-14-22-15-13-19)18-6-4-16(5-7-18)17-8-10-20(23-2)11-9-17/h4-15,21H,3H2,1-2H3
DMCEABJ CS CCC(C1=CC=C(C=C1)C2=CC=C(C=C2)OC)C3=CC=NC=C3
DMCEABJ IK DURIQWOMVBEIPW-UHFFFAOYSA-N
DMCEABJ IU 4-[1-[4-(4-methoxyphenyl)phenyl]propyl]pyridine
DMCEABJ DE Discovery agent
DMW1IXY ID DMW1IXY
DMW1IXY DN 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol
DMW1IXY HS Investigative
DMW1IXY SN CHEMBL37775
DMW1IXY DT Small molecular drug
DMW1IXY PC 10246180
DMW1IXY MW 332.4
DMW1IXY FM C22H20O3
DMW1IXY IC InChI=1S/C22H20O3/c1-2-21(15-3-9-18(23)10-4-15)22(16-5-11-19(24)12-6-16)17-7-13-20(25)14-8-17/h3-14,23-25H,2H2,1H3
DMW1IXY CS CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMW1IXY IK CUXRGANZEHBODX-UHFFFAOYSA-N
DMW1IXY IU 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]phenol
DMW1IXY DE Discovery agent
DMTL6ES ID DMTL6ES
DMTL6ES DN 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol
DMTL6ES HS Investigative
DMTL6ES SN CHEMBL38222
DMTL6ES DT Small molecular drug
DMTL6ES PC 10948394
DMTL6ES MW 360.4
DMTL6ES FM C24H24O3
DMTL6ES IC InChI=1S/C24H24O3/c1-2-3-4-23(17-5-11-20(25)12-6-17)24(18-7-13-21(26)14-8-18)19-9-15-22(27)16-10-19/h5-16,25-27H,2-4H2,1H3
DMTL6ES CS CCCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMTL6ES IK QMNAADNBEBCAEQ-UHFFFAOYSA-N
DMTL6ES IU 4-[1,1-bis(4-hydroxyphenyl)hex-1-en-2-yl]phenol
DMTL6ES DE Discovery agent
DMTHG0Y ID DMTHG0Y
DMTHG0Y DN 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol
DMTHG0Y HS Investigative
DMTHG0Y SN CHEMBL38266
DMTHG0Y DT Small molecular drug
DMTHG0Y PC 11131781
DMTHG0Y MW 346.4
DMTHG0Y FM C23H22O3
DMTHG0Y IC InChI=1S/C23H22O3/c1-2-3-22(16-4-10-19(24)11-5-16)23(17-6-12-20(25)13-7-17)18-8-14-21(26)15-9-18/h4-15,24-26H,2-3H2,1H3
DMTHG0Y CS CCCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMTHG0Y IK OCRBCWNNWUOJIP-UHFFFAOYSA-N
DMTHG0Y IU 4-[1,1-bis(4-hydroxyphenyl)pent-1-en-2-yl]phenol
DMTHG0Y DE Discovery agent
DMR7GP6 ID DMR7GP6
DMR7GP6 DN 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol
DMR7GP6 HS Investigative
DMR7GP6 SN CHEMBL34709
DMR7GP6 DT Small molecular drug
DMR7GP6 PC 10881256
DMR7GP6 MW 304.3
DMR7GP6 FM C20H16O3
DMR7GP6 IC InChI=1S/C20H16O3/c21-17-7-1-14(2-8-17)13-20(15-3-9-18(22)10-4-15)16-5-11-19(23)12-6-16/h1-13,21-23H
DMR7GP6 CS C1=CC(=CC=C1C=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)O
DMR7GP6 IK LZHPXIZTZSFAAE-UHFFFAOYSA-N
DMR7GP6 IU 4-[2,2-bis(4-hydroxyphenyl)ethenyl]phenol
DMR7GP6 DE Discovery agent
DM08CG7 ID DM08CG7
DM08CG7 DN 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine
DM08CG7 HS Investigative
DM08CG7 SN CHEMBL365697; 4-[2-(2-benzylphenoxy)ethyl]morpholine; AC1MGXJ0; 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine; BDBM50151042
DM08CG7 DT Small molecular drug
DM08CG7 PC 2993172
DM08CG7 MW 297.4
DM08CG7 FM C19H23NO2
DM08CG7 IC InChI=1S/C19H23NO2/c1-2-6-17(7-3-1)16-18-8-4-5-9-19(18)22-15-12-20-10-13-21-14-11-20/h1-9H,10-16H2
DM08CG7 CS C1COCCN1CCOC2=CC=CC=C2CC3=CC=CC=C3
DM08CG7 IK DQESEABEPUDVEZ-UHFFFAOYSA-N
DM08CG7 IU 4-[2-(2-benzylphenoxy)ethyl]morpholine
DM08CG7 DE Discovery agent
DMYESXB ID DMYESXB
DMYESXB DN 4-[2-(2-Thienyl)acetamido]benzenesulfonamide
DMYESXB HS Investigative
DMYESXB SN N-(4-sulfamoylphenyl)-2-(thiophen-2-yl)acetamide; N-(4-Sulfamoyl-phenyl)-2-thiophen-2-yl-acetamide; 4-[2-(2-Thienyl)acetamido]benzenesulfonamide; sulfonamide deriv., 5a; AC1LDN6X; Cambridge id 6617099; Oprea1_255870; Oprea1_090963; MLS001212957; CHEMBL573127; ZINC30817; BDBM35726; MolPort-000-681-412; 3r16; HMS1588L03; HMS2848H14; CCG-19182; STK001094; AKOS000646514; MCULE-6253669570; 349432-97-9; SMR000518066; BAS 03030369; ST043878; N-(4-sulfamoylphenyl)-2-(2-thienyl)acetamide; N-(4-sulfamoylphenyl)-2-thiophen-2-ylacetamide
DMYESXB DT Small molecular drug
DMYESXB PC 670143
DMYESXB MW 296.4
DMYESXB FM C12H12N2O3S2
DMYESXB IC InChI=1S/C12H12N2O3S2/c13-19(16,17)11-5-3-9(4-6-11)14-12(15)8-10-2-1-7-18-10/h1-7H,8H2,(H,14,15)(H2,13,16,17)
DMYESXB CS C1=CSC(=C1)CC(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMYESXB IK ZQWXOBLMDBJRLY-UHFFFAOYSA-N
DMYESXB IU N-(4-sulfamoylphenyl)-2-thiophen-2-ylacetamide
DMYESXB DE Discovery agent
DMH3UPO ID DMH3UPO
DMH3UPO DN 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide
DMH3UPO HS Investigative
DMH3UPO SN ST044176; N-[2-(4-sulfamoylphenyl)ethyl]-2-(2-thienyl)acetamide; N-[2-(4-sulfamoylphenyl)ethyl]-2-(thiophen-2-yl)acetamide; N-[2-(4-Sulfamoyl-phenyl)-ethyl]-2-thiophen-2-yl-acetamide; 6613-83-8; NAPETA; sulfonamide deriv., 5f; AC1LDO3N; Oprea1_814072; Oprea1_120836; MLS001207920; CHEMBL583171; ZINC31727; BDBM35731; DTXSID20350014; MolPort-001-528-371; HMS2823O10; STK091085; AKOS000648562; MCULE-3510388823; BAS 03034092; 349537-90-2; SMR000518099; MLS-0291936.0001; SR-01000476637; SR-01000476637-1; Z30857856
DMH3UPO DT Small molecular drug
DMH3UPO PC 670786
DMH3UPO MW 324.4
DMH3UPO FM C14H16N2O3S2
DMH3UPO IC InChI=1S/C14H16N2O3S2/c15-21(18,19)13-5-3-11(4-6-13)7-8-16-14(17)10-12-2-1-9-20-12/h1-6,9H,7-8,10H2,(H,16,17)(H2,15,18,19)
DMH3UPO CS C1=CSC(=C1)CC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
DMH3UPO IK DWGJCBRJYFGGNR-UHFFFAOYSA-N
DMH3UPO IU N-[2-(4-sulfamoylphenyl)ethyl]-2-thiophen-2-ylacetamide
DMH3UPO CA CAS 6613-83-8
DMH3UPO DE Discovery agent
DM4ENGI ID DM4ENGI
DM4ENGI DN 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine
DM4ENGI HS Investigative
DM4ENGI SN CHEMBL43013; 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine; SCHEMBL7047647; SCHEMBL7047642; BDBM50108054; ZINC13471766; AKOS015967530; 4-[(E)-3,5-Dimethoxystyryl]pyridine
DM4ENGI DT Small molecular drug
DM4ENGI PC 11957947
DM4ENGI MW 241.28
DM4ENGI FM C15H15NO2
DM4ENGI IC InChI=1S/C15H15NO2/c1-17-14-9-13(10-15(11-14)18-2)4-3-12-5-7-16-8-6-12/h3-11H,1-2H3/b4-3+
DM4ENGI CS COC1=CC(=CC(=C1)/C=C/C2=CC=NC=C2)OC
DM4ENGI IK HXJQPOSPRKZPGS-ONEGZZNKSA-N
DM4ENGI IU 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]pyridine
DM4ENGI DE Discovery agent
DM64WSV ID DM64WSV
DM64WSV DN 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol
DM64WSV HS Investigative
DM64WSV SN CHEMBL333339; 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol; SCHEMBL12009648; BDBM50066543; AKOS010487382
DM64WSV DT Small molecular drug
DM64WSV PC 10565541
DM64WSV MW 255.35
DM64WSV FM C17H21NO
DM64WSV IC InChI=1S/C17H21NO/c19-17-10-8-16(9-11-17)12-14-18-13-4-7-15-5-2-1-3-6-15/h1-3,5-6,8-11,18-19H,4,7,12-14H2
DM64WSV CS C1=CC=C(C=C1)CCCNCCC2=CC=C(C=C2)O
DM64WSV IK SJSNYEZWGGSNKY-UHFFFAOYSA-N
DM64WSV IU 4-[2-(3-phenylpropylamino)ethyl]phenol
DM64WSV DE Discovery agent
DMGXM9C ID DMGXM9C
DMGXM9C DN 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide
DMGXM9C HS Investigative
DMGXM9C SN CHEMBL22374; ST50982048; 1-phenyl-3-[2-(4-sulfamoylphenyl)ethyl]urea; 10080-04-3; AC1N65GX; CTK0G8621; aromatic sulfonamide compound 21; BDBM16656; DTXSID80401056; ZINC6344454; AKOS024355000; 1-(4-Sulfamoylphenethyl)-3-phenylurea; MCULE-8492301896; N-(4-aminosulfonylphenylethyl)-N'-phenyl-urea; N-phenyl{[2-(4-sulfamoylphenyl)ethyl]amino}carboxamide; Benzenesulfonamide, 4-[2-[[(phenylamino)carbonyl]amino]ethyl]-
DMGXM9C DT Small molecular drug
DMGXM9C PC 4229592
DMGXM9C MW 319.4
DMGXM9C FM C15H17N3O3S
DMGXM9C IC InChI=1S/C15H17N3O3S/c16-22(20,21)14-8-6-12(7-9-14)10-11-17-15(19)18-13-4-2-1-3-5-13/h1-9H,10-11H2,(H2,16,20,21)(H2,17,18,19)
DMGXM9C CS C1=CC=C(C=C1)NC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)N
DMGXM9C IK CQMWNAHSFVPGJL-UHFFFAOYSA-N
DMGXM9C IU 1-phenyl-3-[2-(4-sulfamoylphenyl)ethyl]urea
DMGXM9C CA CAS 10080-04-3
DMGXM9C DE Discovery agent
DMDI32S ID DMDI32S
DMDI32S DN 4-[2-(4-Benzylphenoxy)ethyl]pyridine
DMDI32S HS Investigative
DMDI32S SN CHEMBL578131; 4-[2-(4-Benzylphenoxy)ethyl]pyridine
DMDI32S DT Small molecular drug
DMDI32S PC 44818625
DMDI32S MW 289.4
DMDI32S FM C20H19NO
DMDI32S IC InChI=1S/C20H19NO/c1-2-4-18(5-3-1)16-19-6-8-20(9-7-19)22-15-12-17-10-13-21-14-11-17/h1-11,13-14H,12,15-16H2
DMDI32S CS C1=CC=C(C=C1)CC2=CC=C(C=C2)OCCC3=CC=NC=C3
DMDI32S IK PHONRHOSBJCBIH-UHFFFAOYSA-N
DMDI32S IU 4-[2-(4-benzylphenoxy)ethyl]pyridine
DMDI32S DE Discovery agent
DM74G6Q ID DM74G6Q
DM74G6Q DN 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol
DM74G6Q HS Investigative
DM74G6Q SN CHEMBL54778; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol; SCHEMBL7402131; BDBM50079386; Co-101071; 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol(Co 101071)
DM74G6Q DT Small molecular drug
DM74G6Q PC 10086803
DM74G6Q MW 311.4
DM74G6Q FM C20H25NO2
DM74G6Q IC InChI=1S/C20H25NO2/c22-19-6-8-20(9-7-19)23-15-14-21-12-10-18(11-13-21)16-17-4-2-1-3-5-17/h1-9,18,22H,10-16H2
DM74G6Q CS C1CN(CCC1CC2=CC=CC=C2)CCOC3=CC=C(C=C3)O
DM74G6Q IK CSOKNRXDEKJUFZ-UHFFFAOYSA-N
DM74G6Q IU 4-[2-(4-benzylpiperidin-1-yl)ethoxy]phenol
DM74G6Q DE Discovery agent
DM9UGO0 ID DM9UGO0
DM9UGO0 DN 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine
DM9UGO0 HS Investigative
DM9UGO0 SN CHEMBL113018; 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine; SCHEMBL14129876; BDBM50138231
DM9UGO0 DT Small molecular drug
DM9UGO0 PC 44341256
DM9UGO0 MW 273.33
DM9UGO0 FM C15H19N3O2
DM9UGO0 IC InChI=1S/C15H19N3O2/c1-3-15(4-2-14(1)18-6-5-16-13-18)20-12-9-17-7-10-19-11-8-17/h1-6,13H,7-12H2
DM9UGO0 CS C1COCCN1CCOC2=CC=C(C=C2)N3C=CN=C3
DM9UGO0 IK PXFGMZGVHWPLCC-UHFFFAOYSA-N
DM9UGO0 IU 4-[2-(4-imidazol-1-ylphenoxy)ethyl]morpholine
DM9UGO0 DE Discovery agent
DML8B3T ID DML8B3T
DML8B3T DN 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol
DML8B3T HS Investigative
DML8B3T SN CHEMBL119100; 4-[2-(4-phenylbutoxy)ethyl]phenol; 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol; BDBM50066548
DML8B3T DT Small molecular drug
DML8B3T PC 10707190
DML8B3T MW 270.4
DML8B3T FM C18H22O2
DML8B3T IC InChI=1S/C18H22O2/c19-18-11-9-17(10-12-18)13-15-20-14-5-4-8-16-6-2-1-3-7-16/h1-3,6-7,9-12,19H,4-5,8,13-15H2
DML8B3T CS C1=CC=C(C=C1)CCCCOCCC2=CC=C(C=C2)O
DML8B3T IK FCGUGQUECVRUCX-UHFFFAOYSA-N
DML8B3T IU 4-[2-(4-phenylbutoxy)ethyl]phenol
DML8B3T DE Discovery agent
DMXLVJW ID DMXLVJW
DMXLVJW DN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol
DMXLVJW HS Investigative
DMXLVJW SN CHEMBL118969; 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol; SCHEMBL7379499; ZINC13781000; BDBM50066539
DMXLVJW DT Small molecular drug
DMXLVJW PC 10707108
DMXLVJW MW 269.4
DMXLVJW FM C18H23NO
DMXLVJW IC InChI=1S/C18H23NO/c20-18-11-9-17(10-12-18)13-15-19-14-5-4-8-16-6-2-1-3-7-16/h1-3,6-7,9-12,19-20H,4-5,8,13-15H2
DMXLVJW CS C1=CC=C(C=C1)CCCCNCCC2=CC=C(C=C2)O
DMXLVJW IK FNRAWMBUHCSCSX-UHFFFAOYSA-N
DMXLVJW IU 4-[2-(4-phenylbutylamino)ethyl]phenol
DMXLVJW DE Discovery agent
DM8JM4Q ID DM8JM4Q
DM8JM4Q DN 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol
DM8JM4Q HS Investigative
DM8JM4Q SN CHEMBL100870; 763907-80-8; 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol; CTK2G7823; DTXSID50445220; BDBM50079384; 4-[2-(4-Phenylpiperidino)ethoxy]phenol; Phenol, 4-[2-(4-phenyl-1-piperidinyl)ethoxy]-
DM8JM4Q DT Small molecular drug
DM8JM4Q PC 10806596
DM8JM4Q MW 297.4
DM8JM4Q FM C19H23NO2
DM8JM4Q IC InChI=1S/C19H23NO2/c21-18-6-8-19(9-7-18)22-15-14-20-12-10-17(11-13-20)16-4-2-1-3-5-16/h1-9,17,21H,10-15H2
DM8JM4Q CS C1CN(CCC1C2=CC=CC=C2)CCOC3=CC=C(C=C3)O
DM8JM4Q IK JRNIKKDZNLWUQY-UHFFFAOYSA-N
DM8JM4Q IU 4-[2-(4-phenylpiperidin-1-yl)ethoxy]phenol
DM8JM4Q CA CAS 763907-80-8
DM8JM4Q DE Discovery agent
DM5J7O8 ID DM5J7O8
DM5J7O8 DN 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol
DM5J7O8 HS Investigative
DM5J7O8 SN CHEMBL119778; 790642-63-6; 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol; CTK2G4587; DTXSID40438363; BDBM50066544; 4-[2-[(5-Phenylpentyl)amino]ethyl]phenol; Phenol, 4-[2-[(5-phenylpentyl)amino]ethyl]-
DM5J7O8 DT Small molecular drug
DM5J7O8 PC 10336113
DM5J7O8 MW 283.4
DM5J7O8 FM C19H25NO
DM5J7O8 IC InChI=1S/C19H25NO/c21-19-12-10-18(11-13-19)14-16-20-15-6-2-5-9-17-7-3-1-4-8-17/h1,3-4,7-8,10-13,20-21H,2,5-6,9,14-16H2
DM5J7O8 CS C1=CC=C(C=C1)CCCCCNCCC2=CC=C(C=C2)O
DM5J7O8 IK GMQWOUOTGDXTNP-UHFFFAOYSA-N
DM5J7O8 IU 4-[2-(5-phenylpentylamino)ethyl]phenol
DM5J7O8 CA CAS 790642-63-6
DM5J7O8 DE Discovery agent
DMLCIJX ID DMLCIJX
DMLCIJX DN 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol
DMLCIJX HS Investigative
DMLCIJX SN CHEMBL420530; 765883-50-9; 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol; CTK2G7588; DTXSID10444870; BDBM50066547; 4-[2-[(6-Phenylhexyl)amino]ethyl]phenol; Phenol, 4-[2-[(6-phenylhexyl)amino]ethyl]-
DMLCIJX DT Small molecular drug
DMLCIJX PC 10782907
DMLCIJX MW 297.4
DMLCIJX FM C20H27NO
DMLCIJX IC InChI=1S/C20H27NO/c22-20-13-11-19(12-14-20)15-17-21-16-7-2-1-4-8-18-9-5-3-6-10-18/h3,5-6,9-14,21-22H,1-2,4,7-8,15-17H2
DMLCIJX CS C1=CC=C(C=C1)CCCCCCNCCC2=CC=C(C=C2)O
DMLCIJX IK GWYOLALPGDHNBU-UHFFFAOYSA-N
DMLCIJX IU 4-[2-(6-phenylhexylamino)ethyl]phenol
DMLCIJX CA CAS 765883-50-9
DMLCIJX DE Discovery agent
DMS0HV6 ID DMS0HV6
DMS0HV6 DN 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol
DMS0HV6 HS Investigative
DMS0HV6 SN Ici-3188; 1,1,2-Tris(4-hydroxyphenyl)prop-1-ene; 68373-13-7; 4-[1,1-bis(4-hydroxyphenyl)prop-1-en-2-yl]phenol; Phenol, 4,4',4''-(1-methyl-1-ethenyl-2-ylidene)tris-; Ici 3188; AC1MJ4DX; CHEMBL38103; CTK2F3093; DTXSID20218504; AKOS030547870
DMS0HV6 DT Small molecular drug
DMS0HV6 PC 3085373
DMS0HV6 MW 318.4
DMS0HV6 FM C21H18O3
DMS0HV6 IC InChI=1S/C21H18O3/c1-14(15-2-8-18(22)9-3-15)21(16-4-10-19(23)11-5-16)17-6-12-20(24)13-7-17/h2-13,22-24H,1H3
DMS0HV6 CS CC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O
DMS0HV6 IK FFGNPMKMQDXQJJ-UHFFFAOYSA-N
DMS0HV6 IU 4-[1,1-bis(4-hydroxyphenyl)prop-1-en-2-yl]phenol
DMS0HV6 CA CAS 68373-13-7
DMS0HV6 DE Discovery agent
DMOPRQ7 ID DMOPRQ7
DMOPRQ7 DN 4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide
DMOPRQ7 HS Investigative
DMOPRQ7 SN CHEMBL201718; 4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide; BDBM50181477; 4-[(3-benzyloxy-2-pyridyl)carbamoylamino]benzamide; Benzamide, 4-[[[[3-(phenylmethoxy)-2-pyridinyl]amino]carbonyl]amino]-
DMOPRQ7 DT Small molecular drug
DMOPRQ7 PC 11574097
DMOPRQ7 MW 362.4
DMOPRQ7 FM C20H18N4O3
DMOPRQ7 IC InChI=1S/C20H18N4O3/c21-18(25)15-8-10-16(11-9-15)23-20(26)24-19-17(7-4-12-22-19)27-13-14-5-2-1-3-6-14/h1-12H,13H2,(H2,21,25)(H2,22,23,24,26)
DMOPRQ7 CS C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=C(C=C3)C(=O)N
DMOPRQ7 IK TWCYUPDQSZQMLM-UHFFFAOYSA-N
DMOPRQ7 IU 4-[(3-phenylmethoxypyridin-2-yl)carbamoylamino]benzamide
DMOPRQ7 DE Discovery agent
DMFKRMG ID DMFKRMG
DMFKRMG DN 4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole
DMFKRMG HS Investigative
DMFKRMG SN CHEMBL419654; 4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole; SCHEMBL7991257; NKIFZJYIQSBUEI-UHFFFAOYSA-N; BDBM50093221; [3-(4-Imidazolyl)propyl](4-butylphenyl) ether; 4-Butylphenyl 3-(1H-imidazol-4-yl)propyl ether
DMFKRMG DT Small molecular drug
DMFKRMG PC 21193574
DMFKRMG MW 258.36
DMFKRMG FM C16H22N2O
DMFKRMG IC InChI=1S/C16H22N2O/c1-2-3-5-14-7-9-16(10-8-14)19-11-4-6-15-12-17-13-18-15/h7-10,12-13H,2-6,11H2,1H3,(H,17,18)
DMFKRMG CS CCCCC1=CC=C(C=C1)OCCCC2=CN=CN2
DMFKRMG IK NKIFZJYIQSBUEI-UHFFFAOYSA-N
DMFKRMG IU 5-[3-(4-butylphenoxy)propyl]-1H-imidazole
DMFKRMG DE Discovery agent
DMJI6AM ID DMJI6AM
DMJI6AM DN 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE
DMJI6AM HS Investigative
DMJI6AM SN 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE; 156336-70-8; 4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]piperidine; CHEMBL75691; 4-(5-(4-chlorophenyl)-1H-pyrazol-3-yl)piperidine; L02; 1way; AC1L9MRB; Bionet2_000947; Oprea1_423246; MLS000706783; SCHEMBL2598428; KS-00001ZEP; MolPort-001-684-207; GELALLNTKKLQLM-UHFFFAOYSA-N; HMS2660H19; HMS1366L01; ZINC5974200; BDBM50059237; AKOS015868501; AKOS023968186; DB08061; MCULE-8931017804; SMR000334280; FT-0741308; 7L-015; 3-(4-Piperidinyl)-5-(4-chlorophenyl)pyrazole
DMJI6AM DT Small molecular drug
DMJI6AM PC 449126
DMJI6AM MW 261.75
DMJI6AM FM C14H16ClN3
DMJI6AM IC InChI=1S/C14H16ClN3/c15-12-3-1-10(2-4-12)13-9-14(18-17-13)11-5-7-16-8-6-11/h1-4,9,11,16H,5-8H2,(H,17,18)
DMJI6AM CS C1CNCCC1C2=CC(=NN2)C3=CC=C(C=C3)Cl
DMJI6AM IK GELALLNTKKLQLM-UHFFFAOYSA-N
DMJI6AM IU 4-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]piperidine
DMJI6AM DE Discovery agent
DMXBEYQ ID DMXBEYQ
DMXBEYQ DN 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole
DMXBEYQ HS Investigative
DMXBEYQ SN CHEMBL309600; 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole; SCHEMBL7987317; FUB-470; BDBM50067472; L018291; 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole (FUB 470)
DMXBEYQ DT Small molecular drug
DMXBEYQ PC 10082417
DMXBEYQ MW 226.27
DMXBEYQ FM C14H14N2O
DMXBEYQ IC InChI=1S/C14H14N2O/c1-2-12-5-7-14(8-6-12)17-9-3-4-13-10-15-11-16-13/h1,5-8,10-11H,3-4,9H2,(H,15,16)
DMXBEYQ CS C#CC1=CC=C(C=C1)OCCCC2=CN=CN2
DMXBEYQ IK LMKPPWNWUJXSAQ-UHFFFAOYSA-N
DMXBEYQ IU 5-[3-(4-ethynylphenoxy)propyl]-1H-imidazole
DMXBEYQ DE Discovery agent
DM7LV5A ID DM7LV5A
DM7LV5A DN 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine
DM7LV5A HS Investigative
DM7LV5A SN CHEMBL113227; 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine; SCHEMBL14130001; BDBM50138238
DM7LV5A DT Small molecular drug
DM7LV5A PC 44341260
DM7LV5A MW 279.34
DM7LV5A FM C17H17N3O
DM7LV5A IC InChI=1S/C17H17N3O/c1(2-15-7-9-18-10-8-15)13-21-17-5-3-16(4-6-17)20-12-11-19-14-20/h3-12,14H,1-2,13H2
DM7LV5A CS C1=CC(=CC=C1N2C=CN=C2)OCCCC3=CC=NC=C3
DM7LV5A IK PFAUOLMRDJNYLJ-UHFFFAOYSA-N
DM7LV5A IU 4-[3-(4-imidazol-1-ylphenoxy)propyl]pyridine
DM7LV5A DE Discovery agent
DM4GU29 ID DM4GU29
DM4GU29 DN 4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole
DM4GU29 HS Investigative
DM4GU29 SN CHEMBL369714; SCHEMBL7987297; DEZXFTGWFMDRDA-UHFFFAOYSA-N; BDBM50092844; 4-[3-(4-Methoxyphenoxy)propyl]-1H-imidazole; 3-(1H-Imidazol-4-yl)propyl 4-methoxyphenyl ether; 4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole; compound with but-2-enedioic acid(0.25M H2O)
DM4GU29 DT Small molecular drug
DM4GU29 PC 10681081
DM4GU29 MW 232.28
DM4GU29 FM C13H16N2O2
DM4GU29 IC InChI=1S/C13H16N2O2/c1-16-12-4-6-13(7-5-12)17-8-2-3-11-9-14-10-15-11/h4-7,9-10H,2-3,8H2,1H3,(H,14,15)
DM4GU29 CS COC1=CC=C(C=C1)OCCCC2=CN=CN2
DM4GU29 IK DEZXFTGWFMDRDA-UHFFFAOYSA-N
DM4GU29 IU 5-[3-(4-methoxyphenoxy)propyl]-1H-imidazole
DM4GU29 DE Discovery agent
DMOF9YN ID DMOF9YN
DMOF9YN DN 4-[3-(4-Phenyl-butylamino)-propyl]-phenol
DMOF9YN HS Investigative
DMOF9YN SN CHEMBL42414; 4-[3-(4-Phenyl-butylamino)-propyl]-phenol; BDBM50066538
DMOF9YN DT Small molecular drug
DMOF9YN PC 10853103
DMOF9YN MW 283.4
DMOF9YN FM C19H25NO
DMOF9YN IC InChI=1S/C19H25NO/c21-19-13-11-18(12-14-19)10-6-16-20-15-5-4-9-17-7-2-1-3-8-17/h1-3,7-8,11-14,20-21H,4-6,9-10,15-16H2
DMOF9YN CS C1=CC=C(C=C1)CCCCNCCCC2=CC=C(C=C2)O
DMOF9YN IK NXJFACHOHAZIMY-UHFFFAOYSA-N
DMOF9YN IU 4-[3-(4-phenylbutylamino)propyl]phenol
DMOF9YN DE Discovery agent
DMKDBHN ID DMKDBHN
DMKDBHN DN 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol
DMKDBHN HS Investigative
DMKDBHN SN CHEMBL334003; 771459-50-8; 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol; CTK2G6876; DTXSID00441232; BDBM50066546; 4-[3-[(5-Phenylpentyl)amino]propyl]phenol; Phenol, 4-[3-[(5-phenylpentyl)amino]propyl]-
DMKDBHN DT Small molecular drug
DMKDBHN PC 10520673
DMKDBHN MW 297.4
DMKDBHN FM C20H27NO
DMKDBHN IC InChI=1S/C20H27NO/c22-20-14-12-19(13-15-20)11-7-17-21-16-6-2-5-10-18-8-3-1-4-9-18/h1,3-4,8-9,12-15,21-22H,2,5-7,10-11,16-17H2
DMKDBHN CS C1=CC=C(C=C1)CCCCCNCCCC2=CC=C(C=C2)O
DMKDBHN IK HCVJFVZXTLAHRT-UHFFFAOYSA-N
DMKDBHN IU 4-[3-(5-phenylpentylamino)propyl]phenol
DMKDBHN CA CAS 771459-50-8
DMKDBHN DE Discovery agent
DMZU23D ID DMZU23D
DMZU23D DN 4-[3-(benzyloxy)benzoyl]benzoic acid
DMZU23D HS Investigative
DMZU23D SN 4-[3-(benzyloxy)benzoyl]benzoic acid; CHEMBL382649
DMZU23D DT Small molecular drug
DMZU23D PC 11702714
DMZU23D MW 332.3
DMZU23D FM C21H16O4
DMZU23D IC InChI=1S/C21H16O4/c22-20(16-9-11-17(12-10-16)21(23)24)18-7-4-8-19(13-18)25-14-15-5-2-1-3-6-15/h1-13H,14H2,(H,23,24)
DMZU23D CS C1=CC=C(C=C1)COC2=CC=CC(=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMZU23D IK UBSDFPUNDIGYKJ-UHFFFAOYSA-N
DMZU23D IU 4-(3-phenylmethoxybenzoyl)benzoic acid
DMZU23D DE Discovery agent
DMTIA27 ID DMTIA27
DMTIA27 DN 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
DMTIA27 HS Investigative
DMTIA27 SN 4-[3-Hydroxyanilino]-6,7-dimethoxyquinazoline; whi-p180; 211555-08-7; 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; WHI-P180, Hydrochloride; JANEX 3; 4-[3-HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE; CHEMBL127907; 3-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol; AK341047; DTQ; 4-(3& -Hydroxyphenyl)amino-6,7-dimethoxyquinazoline, HCl; JANEX-3; 4btk; 1di8; AC1L1KWT; AC1Q4XVE; 3-(6,7-dimethoxyquinazolin-4-ylamino)phenol; Anilinoquinazoline deriv 5; WHI-P180(Janex 3); BDBM4622; SCHEMBL1180103; CTK4E5981; AOB5495; MolPort-000-672-017; BNDYIYYKEIXHNK-UHFFFAOYSA-N; HMS3229P15; WHI-P180
DMTIA27 DT Small molecular drug
DMTIA27 PC 5687
DMTIA27 MW 297.31
DMTIA27 FM C16H15N3O3
DMTIA27 IC InChI=1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-4-3-5-11(20)6-10/h3-9,20H,1-2H3,(H,17,18,19)
DMTIA27 CS COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)O)OC
DMTIA27 IK BNDYIYYKEIXHNK-UHFFFAOYSA-N
DMTIA27 IU 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
DMTIA27 DE Discovery agent
DM62351 ID DM62351
DM62351 DN 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine
DM62351 HS Investigative
DM62351 SN CHEMBL1214738; 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine; SCHEMBL18770313
DM62351 DT Small molecular drug
DM62351 PC 46901928
DM62351 MW 325.4
DM62351 FM C23H19NO
DM62351 IC InChI=1S/C23H19NO/c1-25-23-9-8-21-15-20(6-7-22(21)16-23)19-4-2-17(3-5-19)14-18-10-12-24-13-11-18/h2-13,15-16H,14H2,1H3
DM62351 CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CC=C(C=C3)CC4=CC=NC=C4
DM62351 IK XDUUJWUQYXFHEK-UHFFFAOYSA-N
DM62351 IU 4-[[4-(6-methoxynaphthalen-2-yl)phenyl]methyl]pyridine
DM62351 DE Discovery agent
DM8MVE9 ID DM8MVE9
DM8MVE9 DN 4-[4-(benzhydryloxy)benzoyl]benzoic acid
DM8MVE9 HS Investigative
DM8MVE9 SN 4-[4-(benzhydryloxy)benzoyl]benzoic acid; CHEMBL203352
DM8MVE9 DT Small molecular drug
DM8MVE9 PC 11509747
DM8MVE9 MW 408.4
DM8MVE9 FM C27H20O4
DM8MVE9 IC InChI=1S/C27H20O4/c28-25(19-11-13-23(14-12-19)27(29)30)20-15-17-24(18-16-20)31-26(21-7-3-1-4-8-21)22-9-5-2-6-10-22/h1-18,26H,(H,29,30)
DM8MVE9 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)OC3=CC=C(C=C3)C(=O)C4=CC=C(C=C4)C(=O)O
DM8MVE9 IK RSHGTUVDNJDFHP-UHFFFAOYSA-N
DM8MVE9 IU 4-(4-benzhydryloxybenzoyl)benzoic acid
DM8MVE9 DE Discovery agent
DM5Z64L ID DM5Z64L
DM5Z64L DN 4-[4-(benzhydryloxy)piperidino]butyl benzoate
DM5Z64L HS Investigative
DM5Z64L SN CHEMBL228999; 4-[4-(benzhydryloxy)piperidino]butyl benzoate; SCHEMBL4020166
DM5Z64L DT Small molecular drug
DM5Z64L PC 10275242
DM5Z64L MW 443.6
DM5Z64L FM C29H33NO3
DM5Z64L IC InChI=1S/C29H33NO3/c31-29(26-16-8-3-9-17-26)32-23-11-10-20-30-21-18-27(19-22-30)33-28(24-12-4-1-5-13-24)25-14-6-2-7-15-25/h1-9,12-17,27-28H,10-11,18-23H2
DM5Z64L CS C1CN(CCC1OC(C2=CC=CC=C2)C3=CC=CC=C3)CCCCOC(=O)C4=CC=CC=C4
DM5Z64L IK SUQKPOGAPWZPRM-UHFFFAOYSA-N
DM5Z64L IU 4-(4-benzhydryloxypiperidin-1-yl)butyl benzoate
DM5Z64L DE Discovery agent
DM9VPFL ID DM9VPFL
DM9VPFL DN 4-[4-(benzoylamino)benzoyl]benzoic acid
DM9VPFL HS Investigative
DM9VPFL SN 4-[4-(benzoylamino)benzoyl]benzoic acid
DM9VPFL DT Small molecular drug
DM9VPFL PC 11681722
DM9VPFL MW 345.3
DM9VPFL FM C21H15NO4
DM9VPFL IC InChI=1S/C21H15NO4/c23-19(14-6-8-17(9-7-14)21(25)26)15-10-12-18(13-11-15)22-20(24)16-4-2-1-3-5-16/h1-13H,(H,22,24)(H,25,26)
DM9VPFL CS C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DM9VPFL IK FKMULXSKUTZDBD-UHFFFAOYSA-N
DM9VPFL IU 4-(4-benzamidobenzoyl)benzoic acid
DM9VPFL DE Discovery agent
DMQC5EH ID DMQC5EH
DMQC5EH DN 4-[4-(benzylamino)benzoyl]benzoic acid
DMQC5EH HS Investigative
DMQC5EH SN 4-[4-(benzylamino)benzoyl]benzoic Acid
DMQC5EH DT Small molecular drug
DMQC5EH PC 11602388
DMQC5EH MW 331.4
DMQC5EH FM C21H17NO3
DMQC5EH IC InChI=1S/C21H17NO3/c23-20(16-6-8-18(9-7-16)21(24)25)17-10-12-19(13-11-17)22-14-15-4-2-1-3-5-15/h1-13,22H,14H2,(H,24,25)
DMQC5EH CS C1=CC=C(C=C1)CNC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMQC5EH IK HTOJJEGICHZIJA-UHFFFAOYSA-N
DMQC5EH IU 4-[4-(benzylamino)benzoyl]benzoic acid
DMQC5EH DE Discovery agent
DMTDYHE ID DMTDYHE
DMTDYHE DN 4-[4-(benzyloxy)piperidino]butyl benzoate
DMTDYHE HS Investigative
DMTDYHE SN 4-[4-(benzyloxy)piperidino]butyl benzoate; CHEMBL228950; SCHEMBL4028855
DMTDYHE DT Small molecular drug
DMTDYHE PC 9969234
DMTDYHE MW 367.5
DMTDYHE FM C23H29NO3
DMTDYHE IC InChI=1S/C23H29NO3/c25-23(21-11-5-2-6-12-21)26-18-8-7-15-24-16-13-22(14-17-24)27-19-20-9-3-1-4-10-20/h1-6,9-12,22H,7-8,13-19H2
DMTDYHE CS C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=CC=C3
DMTDYHE IK PIHTVJYRMYAPDJ-UHFFFAOYSA-N
DMTDYHE IU 4-(4-phenylmethoxypiperidin-1-yl)butyl benzoate
DMTDYHE DE Discovery agent
DMIXRCS ID DMIXRCS
DMIXRCS DN 4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate
DMIXRCS HS Investigative
DMIXRCS SN CHEMBL389049; 4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate; SCHEMBL4024650
DMIXRCS DT Small molecular drug
DMIXRCS PC 10222714
DMIXRCS MW 401.9
DMIXRCS FM C23H28ClNO3
DMIXRCS IC InChI=1S/C23H28ClNO3/c24-21-10-6-9-20(17-21)23(26)27-16-5-4-13-25-14-11-22(12-15-25)28-18-19-7-2-1-3-8-19/h1-3,6-10,17,22H,4-5,11-16,18H2
DMIXRCS CS C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC(=CC=C3)Cl
DMIXRCS IK NDGPQNPYSUGIAY-UHFFFAOYSA-N
DMIXRCS IU 4-(4-phenylmethoxypiperidin-1-yl)butyl 3-chlorobenzoate
DMIXRCS DE Discovery agent
DM87AYP ID DM87AYP
DM87AYP DN 4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate
DM87AYP HS Investigative
DM87AYP SN CHEMBL228359; 4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate; SCHEMBL4027386
DM87AYP DT Small molecular drug
DM87AYP PC 10178151
DM87AYP MW 385.5
DM87AYP FM C23H28FNO3
DM87AYP IC InChI=1S/C23H28FNO3/c24-21-10-6-9-20(17-21)23(26)27-16-5-4-13-25-14-11-22(12-15-25)28-18-19-7-2-1-3-8-19/h1-3,6-10,17,22H,4-5,11-16,18H2
DM87AYP CS C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC(=CC=C3)F
DM87AYP IK YJPYLKLJKPTNBQ-UHFFFAOYSA-N
DM87AYP IU 4-(4-phenylmethoxypiperidin-1-yl)butyl 3-fluorobenzoate
DM87AYP DE Discovery agent
DM0V8MA ID DM0V8MA
DM0V8MA DN 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate
DM0V8MA HS Investigative
DM0V8MA SN CHEMBL389048; 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate; SCHEMBL4020282
DM0V8MA DT Small molecular drug
DM0V8MA PC 10135721
DM0V8MA MW 401.9
DM0V8MA FM C23H28ClNO3
DM0V8MA IC InChI=1S/C23H28ClNO3/c24-21-10-8-20(9-11-21)23(26)27-17-5-4-14-25-15-12-22(13-16-25)28-18-19-6-2-1-3-7-19/h1-3,6-11,22H,4-5,12-18H2
DM0V8MA CS C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=C(C=C3)Cl
DM0V8MA IK ZUARKRNDJKGEIT-UHFFFAOYSA-N
DM0V8MA IU 4-(4-phenylmethoxypiperidin-1-yl)butyl 4-chlorobenzoate
DM0V8MA DE Discovery agent
DML7UQ1 ID DML7UQ1
DML7UQ1 DN 4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate
DML7UQ1 HS Investigative
DML7UQ1 SN CHEMBL229105; 4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate; SCHEMBL4026157
DML7UQ1 DT Small molecular drug
DML7UQ1 PC 10221700
DML7UQ1 MW 385.5
DML7UQ1 FM C23H28FNO3
DML7UQ1 IC InChI=1S/C23H28FNO3/c24-21-10-8-20(9-11-21)23(26)27-17-5-4-14-25-15-12-22(13-16-25)28-18-19-6-2-1-3-7-19/h1-3,6-11,22H,4-5,12-18H2
DML7UQ1 CS C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=C(C=C3)F
DML7UQ1 IK WNLQOEBYDOWFBU-UHFFFAOYSA-N
DML7UQ1 IU 4-(4-phenylmethoxypiperidin-1-yl)butyl 4-fluorobenzoate
DML7UQ1 DE Discovery agent
DMNOD2Q ID DMNOD2Q
DMNOD2Q DN 4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate
DMNOD2Q HS Investigative
DMNOD2Q SN CHEMBL228301; 4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate; SCHEMBL4025407
DMNOD2Q DT Small molecular drug
DMNOD2Q PC 10112356
DMNOD2Q MW 412.5
DMNOD2Q FM C23H28N2O5
DMNOD2Q IC InChI=1S/C23H28N2O5/c26-23(20-8-10-21(11-9-20)25(27)28)29-17-5-4-14-24-15-12-22(13-16-24)30-18-19-6-2-1-3-7-19/h1-3,6-11,22H,4-5,12-18H2
DMNOD2Q CS C1CN(CCC1OCC2=CC=CC=C2)CCCCOC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMNOD2Q IK CBYWQHUSTLWEBJ-UHFFFAOYSA-N
DMNOD2Q IU 4-(4-phenylmethoxypiperidin-1-yl)butyl 4-nitrobenzoate
DMNOD2Q DE Discovery agent
DMQ9IN4 ID DMQ9IN4
DMQ9IN4 DN 4-[4-benzyloxy)benzoyl]benzoic acid
DMQ9IN4 HS Investigative
DMQ9IN4 SN CHEMBL202871; 4-[4-benzyloxy)benzoyl]benzoic acid
DMQ9IN4 DT Small molecular drug
DMQ9IN4 PC 11616925
DMQ9IN4 MW 332.3
DMQ9IN4 FM C21H16O4
DMQ9IN4 IC InChI=1S/C21H16O4/c22-20(16-6-8-18(9-7-16)21(23)24)17-10-12-19(13-11-17)25-14-15-4-2-1-3-5-15/h1-13H,14H2,(H,23,24)
DMQ9IN4 CS C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(=O)O
DMQ9IN4 IK ZSVDQQIAIVOVRI-UHFFFAOYSA-N
DMQ9IN4 IU 4-(4-phenylmethoxybenzoyl)benzoic acid
DMQ9IN4 DE Discovery agent
DMK4ICB ID DMK4ICB
DMK4ICB DN 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol
DMK4ICB HS Investigative
DMK4ICB SN 1122660-25-6; 4-(5-(3-Hydroxyphenyl)thiophen-2-yl)-2-methylphenol; 3-(5-(4-hydroxy-3-methylphenyl)thiophen-2-yl)phenol; CHEMBL570596; AK160974; 3-(5-(4-Hydroxy-3-methylphenyl)-thiophen-2-yl)phenol; SCHEMBL1180399; 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol; MolPort-028-616-334; ZINC45254284; BDBM50299633; AKOS024463871; DS-9818; QC-10086; AJ-110394; AX8293985
DMK4ICB DT Small molecular drug
DMK4ICB PC 25192475
DMK4ICB MW 282.4
DMK4ICB FM C17H14O2S
DMK4ICB IC InChI=1S/C17H14O2S/c1-11-9-13(5-6-15(11)19)17-8-7-16(20-17)12-3-2-4-14(18)10-12/h2-10,18-19H,1H3
DMK4ICB CS CC1=C(C=CC(=C1)C2=CC=C(S2)C3=CC(=CC=C3)O)O
DMK4ICB IK ICDRVGLMFQWTDX-UHFFFAOYSA-N
DMK4ICB IU 4-[5-(3-hydroxyphenyl)thiophen-2-yl]-2-methylphenol
DMK4ICB DE Discovery agent
DMZHVFO ID DMZHVFO
DMZHVFO DN 4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol
DMZHVFO HS Investigative
DMZHVFO SN CHEMBL573003; 4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol; SCHEMBL1180066
DMZHVFO DT Small molecular drug
DMZHVFO PC 25192476
DMZHVFO MW 284.3
DMZHVFO FM C16H12O3S
DMZHVFO IC InChI=1S/C16H12O3S/c17-12-3-1-2-10(8-12)15-6-7-16(20-15)11-4-5-13(18)14(19)9-11/h1-9,17-19H
DMZHVFO CS C1=CC(=CC(=C1)O)C2=CC=C(S2)C3=CC(=C(C=C3)O)O
DMZHVFO IK URXFYOORYZACQY-UHFFFAOYSA-N
DMZHVFO IU 4-[5-(3-hydroxyphenyl)thiophen-2-yl]benzene-1,2-diol
DMZHVFO DE Discovery agent
DM7ERYJ ID DM7ERYJ
DM7ERYJ DN 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol
DM7ERYJ HS Investigative
DM7ERYJ SN CHEMBL569862; 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol; SCHEMBL1180208
DM7ERYJ DT Small molecular drug
DM7ERYJ PC 25192621
DM7ERYJ MW 282.4
DM7ERYJ FM C17H14O2S
DM7ERYJ IC InChI=1S/C17H14O2S/c1-11-7-12(5-6-16(11)19)14-9-17(20-10-14)13-3-2-4-15(18)8-13/h2-10,18-19H,1H3
DM7ERYJ CS CC1=C(C=CC(=C1)C2=CSC(=C2)C3=CC(=CC=C3)O)O
DM7ERYJ IK STFVOGWUKNAWOF-UHFFFAOYSA-N
DM7ERYJ IU 4-[5-(3-hydroxyphenyl)thiophen-3-yl]-2-methylphenol
DM7ERYJ DE Discovery agent
DMI7YAQ ID DMI7YAQ
DMI7YAQ DN 4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine
DMI7YAQ HS Investigative
DMI7YAQ SN (4-Pyridylmethylene)indane 10a; CHEMBL366773; BDBM8620; AC1O7063; 4-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMI7YAQ DT Small molecular drug
DMI7YAQ PC 6539794
DMI7YAQ MW 286.17
DMI7YAQ FM C15H12BrN
DMI7YAQ IC InChI=1S/C15H12BrN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9+
DMI7YAQ CS C1C/C(=C\\C2=CC=NC=C2)/C3=C1C=C(C=C3)Br
DMI7YAQ IK MNQUPNOEJZVKRD-FMIVXFBMSA-N
DMI7YAQ IU 4-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMI7YAQ DE Discovery agent
DMQKHXN ID DMQKHXN
DMQKHXN DN 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine
DMQKHXN HS Investigative
DMQKHXN SN CHEMBL179222; BDBM8621; (4-Pyridylmethylene)indane 10b; AC1O7065; 4-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMQKHXN DT Small molecular drug
DMQKHXN PC 6539795
DMQKHXN MW 286.17
DMQKHXN FM C15H12BrN
DMQKHXN IC InChI=1S/C15H12BrN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9-
DMQKHXN CS C1C/C(=C/C2=CC=NC=C2)/C3=C1C=C(C=C3)Br
DMQKHXN IK MNQUPNOEJZVKRD-XFXZXTDPSA-N
DMQKHXN IU 4-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMQKHXN DE Discovery agent
DMZL8KN ID DMZL8KN
DMZL8KN DN 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine
DMZL8KN HS Investigative
DMZL8KN SN (4-Pyridylmethylene)indane 8a; SCHEMBL4231646; CHEMBL175554; BDBM8618; SCHEMBL4231651; AC1O705Z; ZINC13610827; 4-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZL8KN DT Small molecular drug
DMZL8KN PC 6539792
DMZL8KN MW 241.71
DMZL8KN FM C15H12ClN
DMZL8KN IC InChI=1S/C15H12ClN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9+
DMZL8KN CS C1C/C(=C\\C2=CC=NC=C2)/C3=C1C=C(C=C3)Cl
DMZL8KN IK NFCDNDMUSHGWSU-FMIVXFBMSA-N
DMZL8KN IU 4-[(E)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMZL8KN DE Discovery agent
DM1Z3DG ID DM1Z3DG
DM1Z3DG DN 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine
DM1Z3DG HS Investigative
DM1Z3DG SN (4-Pyridylmethylene)indane 8b; SCHEMBL4231649; CHEMBL175799; BDBM8619; AC1O7061; ZINC100056323; 4-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM1Z3DG DT Small molecular drug
DM1Z3DG PC 6539793
DM1Z3DG MW 241.71
DM1Z3DG FM C15H12ClN
DM1Z3DG IC InChI=1S/C15H12ClN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9-
DM1Z3DG CS C1C/C(=C/C2=CC=NC=C2)/C3=C1C=C(C=C3)Cl
DM1Z3DG IK NFCDNDMUSHGWSU-XFXZXTDPSA-N
DM1Z3DG IU 4-[(Z)-(5-chloro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM1Z3DG DE Discovery agent
DMY08FE ID DMY08FE
DMY08FE DN 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine
DMY08FE HS Investigative
DMY08FE SN (4-Pyridylmethylene)indane 6a; BDBM8614; AC1O705R; SCHEMBL4231103; CHEMBL424960; SCHEMBL4231111; ZINC13535834; 4-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMY08FE DT Small molecular drug
DMY08FE PC 6539788
DMY08FE MW 225.26
DMY08FE FM C15H12FN
DMY08FE IC InChI=1S/C15H12FN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9+
DMY08FE CS C1C/C(=C\\C2=CC=NC=C2)/C3=C1C=C(C=C3)F
DMY08FE IK KVRYTKBSTLSXKC-FMIVXFBMSA-N
DMY08FE IU 4-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMY08FE DE Discovery agent
DMHDZUO ID DMHDZUO
DMHDZUO DN 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine
DMHDZUO HS Investigative
DMHDZUO SN (4-Pyridylmethylene)indane 6b; SCHEMBL4231108; CHEMBL179144; AC1O705T; BDBM8615; ZINC100056302; 4-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHDZUO DT Small molecular drug
DMHDZUO PC 6539789
DMHDZUO MW 225.26
DMHDZUO FM C15H12FN
DMHDZUO IC InChI=1S/C15H12FN/c16-14-3-4-15-12(1-2-13(15)10-14)9-11-5-7-17-8-6-11/h3-10H,1-2H2/b12-9-
DMHDZUO CS C1C/C(=C/C2=CC=NC=C2)/C3=C1C=C(C=C3)F
DMHDZUO IK KVRYTKBSTLSXKC-XFXZXTDPSA-N
DMHDZUO IU 4-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMHDZUO DE Discovery agent
DM25GS6 ID DM25GS6
DM25GS6 DN 4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM25GS6 HS Investigative
DM25GS6 SN (4-Pyridylmethylene)indane 12a; CHEMBL359942; BDBM8622; AC1O7067; 4-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM25GS6 DT Small molecular drug
DM25GS6 PC 6539796
DM25GS6 MW 237.3
DM25GS6 FM C16H15NO
DM25GS6 IC InChI=1S/C16H15NO/c1-18-15-4-5-16-13(2-3-14(16)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b13-10+
DM25GS6 CS COC1=CC2=C(C=C1)/C(=C/C3=CC=NC=C3)/CC2
DM25GS6 IK VDGYNVYFCLIMOF-JLHYYAGUSA-N
DM25GS6 IU 4-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM25GS6 DE Discovery agent
DMLBX4Q ID DMLBX4Q
DMLBX4Q DN 4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMLBX4Q HS Investigative
DMLBX4Q SN CHEMBL175609; BDBM8623; (4-Pyridylmethylene)indane 12b; AC1O7069; 4-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLBX4Q DT Small molecular drug
DMLBX4Q PC 6539797
DMLBX4Q MW 237.3
DMLBX4Q FM C16H15NO
DMLBX4Q IC InChI=1S/C16H15NO/c1-18-15-4-5-16-13(2-3-14(16)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b13-10-
DMLBX4Q CS COC1=CC2=C(C=C1)/C(=C\\C3=CC=NC=C3)/CC2
DMLBX4Q IK VDGYNVYFCLIMOF-RAXLEYEMSA-N
DMLBX4Q IU 4-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMLBX4Q DE Discovery agent
DM3IR8Y ID DM3IR8Y
DM3IR8Y DN 4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine
DM3IR8Y HS Investigative
DM3IR8Y SN AC1O706F; CHEMBL365314; BDBM8626; (4-Pyridylmethylene)indane 16a; 4-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM3IR8Y DT Small molecular drug
DM3IR8Y PC 6539800
DM3IR8Y MW 237.3
DM3IR8Y FM C16H15NO
DM3IR8Y IC InChI=1S/C16H15NO/c1-18-15-5-4-13-2-3-14(16(13)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b14-10+
DM3IR8Y CS COC1=CC\\2=C(CC/C2=C\\C3=CC=NC=C3)C=C1
DM3IR8Y IK VFFWGGPPTWJBON-GXDHUFHOSA-N
DM3IR8Y IU 4-[(E)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM3IR8Y DE Discovery agent
DMIBZJC ID DMIBZJC
DMIBZJC DN 4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine
DMIBZJC HS Investigative
DMIBZJC SN (4-Pyridylmethylene)indane 16b; CHEMBL370281; AC1O706H; BDBM8627; 4-[(Z)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMIBZJC DT Small molecular drug
DMIBZJC PC 6539801
DMIBZJC MW 237.3
DMIBZJC FM C16H15NO
DMIBZJC IC InChI=1S/C16H15NO/c1-18-15-5-4-13-2-3-14(16(13)11-15)10-12-6-8-17-9-7-12/h4-11H,2-3H2,1H3/b14-10-
DMIBZJC CS COC1=CC\\2=C(CC/C2=C/C3=CC=NC=C3)C=C1
DMIBZJC IK VFFWGGPPTWJBON-UVTDQMKNSA-N
DMIBZJC IU 4-[(Z)-(6-methoxy-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMIBZJC DE Discovery agent
DMYGN1K ID DMYGN1K
DMYGN1K DN 4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine
DMYGN1K HS Investigative
DMYGN1K SN CHEMBL371742; BDBM8629; AC1O706L; (4-Pyridylmethylene)indane 22a; 4-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYGN1K DT Small molecular drug
DMYGN1K PC 6539803
DMYGN1K MW 221.3
DMYGN1K FM C16H15N
DMYGN1K IC InChI=1S/C16H15N/c1-12-2-3-14-4-5-15(16(14)10-12)11-13-6-8-17-9-7-13/h2-3,6-11H,4-5H2,1H3/b15-11+
DMYGN1K CS CC1=CC\\2=C(CC/C2=C\\C3=CC=NC=C3)C=C1
DMYGN1K IK JRWJGUYEZHCVMC-RVDMUPIBSA-N
DMYGN1K IU 4-[(E)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DMYGN1K DE Discovery agent
DM5VN3D ID DM5VN3D
DM5VN3D DN 4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine
DM5VN3D HS Investigative
DM5VN3D SN (4-Pyridylmethylene)indane 22b; AC1O706N; CHEMBL192077; BDBM8630; 4-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM5VN3D DT Small molecular drug
DM5VN3D PC 6539804
DM5VN3D MW 221.3
DM5VN3D FM C16H15N
DM5VN3D IC InChI=1S/C16H15N/c1-12-2-3-14-4-5-15(16(14)10-12)11-13-6-8-17-9-7-13/h2-3,6-11H,4-5H2,1H3/b15-11-
DM5VN3D CS CC1=CC\\2=C(CC/C2=C/C3=CC=NC=C3)C=C1
DM5VN3D IK JRWJGUYEZHCVMC-PTNGSMBKSA-N
DM5VN3D IU 4-[(Z)-(6-methyl-2,3-dihydroinden-1-ylidene)methyl]pyridine
DM5VN3D DE Discovery agent
DMMGHNA ID DMMGHNA
DMMGHNA DN 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid
DMMGHNA HS Investigative
DMMGHNA SN 4-{2-[(3-NITROBENZOYL)AMINO]PHENOXY}PHTHALIC ACID; CHEMBL326611; 4-[2-[(3-nitrobenzoyl)amino]phenoxy]phthalic acid; 1z6p; AC1LCW3D; SCHEMBL4323472; NAQUAVBNIYTIIS-UHFFFAOYSA-N; BDBM50149303; DB04044; 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid; 4-[2-(3-nitrobenzoylamino)-phenoxy]phthalic acid; 4-[2-(3-nitrobenzoylamino)-phenoxyl]phthalic acid; 4-[2-(3-Nitro-benzoylamino)-phenoxy]-phthalic acid; 4-[2-(3-nitrobenzamido)phenoxy]benzene-1,2-dicarboxylic acid
DMMGHNA DT Small molecular drug
DMMGHNA PC 657140
DMMGHNA MW 422.3
DMMGHNA FM C21H14N2O8
DMMGHNA IC InChI=1S/C21H14N2O8/c24-19(12-4-3-5-13(10-12)23(29)30)22-17-6-1-2-7-18(17)31-14-8-9-15(20(25)26)16(11-14)21(27)28/h1-11H,(H,22,24)(H,25,26)(H,27,28)
DMMGHNA CS C1=CC=C(C(=C1)NC(=O)C2=CC(=CC=C2)[N+](=O)[O-])OC3=CC(=C(C=C3)C(=O)O)C(=O)O
DMMGHNA IK NAQUAVBNIYTIIS-UHFFFAOYSA-N
DMMGHNA IU 4-[2-[(3-nitrobenzoyl)amino]phenoxy]phthalic acid
DMMGHNA DE Discovery agent
DMA21GM ID DMA21GM
DMA21GM DN 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol
DMA21GM HS Investigative
DMA21GM SN CHEMBL327075; 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol; SCHEMBL7374092; BDBM50066540; ZINC13781001
DMA21GM DT Small molecular drug
DMA21GM PC 10685438
DMA21GM MW 297.4
DMA21GM FM C20H27NO
DMA21GM IC InChI=1S/C20H27NO/c1-2-21(17-15-19-11-13-20(22)14-12-19)16-7-6-10-18-8-4-3-5-9-18/h3-5,8-9,11-14,22H,2,6-7,10,15-17H2,1H3
DMA21GM CS CCN(CCCCC1=CC=CC=C1)CCC2=CC=C(C=C2)O
DMA21GM IK CJODMSRSFMFSCO-UHFFFAOYSA-N
DMA21GM IU 4-[2-[ethyl(4-phenylbutyl)amino]ethyl]phenol
DMA21GM DE Discovery agent
DMZUM95 ID DMZUM95
DMZUM95 DN 4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate
DMZUM95 HS Investigative
DMZUM95 SN CHEMBL67175; 4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate; SCHEMBL2501164
DMZUM95 DT Small molecular drug
DMZUM95 PC 9885795
DMZUM95 MW 372.4
DMZUM95 FM C13H12N2O7S2
DMZUM95 IC InChI=1S/C13H12N2O7S2/c14-23(17,18)21-11-5-1-9(2-6-11)13(16)10-3-7-12(8-4-10)22-24(15,19)20/h1-8H,(H2,14,17,18)(H2,15,19,20)
DMZUM95 CS C1=CC(=CC=C1C(=O)C2=CC=C(C=C2)OS(=O)(=O)N)OS(=O)(=O)N
DMZUM95 IK NKZRLSJYBCVOGN-UHFFFAOYSA-N
DMZUM95 IU [4-(4-sulfamoyloxybenzoyl)phenyl] sulfamate
DMZUM95 DE Discovery agent
DMLE0I7 ID DMLE0I7
DMLE0I7 DN 4557W
DMLE0I7 HS Investigative
DMLE0I7 SN EGFR/ErbB-2 Inhibitor; 179248-61-4; 4557W; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine
DMLE0I7 DT Small molecular drug
DMLE0I7 PC 9843206
DMLE0I7 MW 387.4
DMLE0I7 FM C23H21N3O3
DMLE0I7 IC InChI=1S/C23H21N3O3/c1-27-21-12-19-20(13-22(21)28-2)24-15-25-23(19)26-17-8-10-18(11-9-17)29-14-16-6-4-3-5-7-16/h3-13,15H,14H2,1-2H3,(H,24,25,26)
DMLE0I7 CS COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)OCC4=CC=CC=C4)OC
DMLE0I7 IK DNOKYISWMVFYFA-UHFFFAOYSA-N
DMLE0I7 IU 6,7-dimethoxy-N-(4-phenylmethoxyphenyl)quinazolin-4-amine
DMLE0I7 CA CAS 179248-61-4
DMLE0I7 DE Discovery agent
DMN2TMS ID DMN2TMS
DMN2TMS DN 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide
DMN2TMS HS Investigative
DMN2TMS SN CHEMBL200958
DMN2TMS DT Small molecular drug
DMN2TMS PC 44406548
DMN2TMS MW 361.19
DMN2TMS FM C16H13BrN2O3
DMN2TMS IC InChI=1S/C16H13BrN2O3/c1-2-15(21)18-12-6-7-13(14(20)9-12)16(22)19-11-5-3-4-10(17)8-11/h2-9,20H,1H2,(H,18,21)(H,19,22)
DMN2TMS CS C=CC(=O)NC1=CC(=C(C=C1)C(=O)NC2=CC(=CC=C2)Br)O
DMN2TMS IK RVPAGQILSYDDNT-UHFFFAOYSA-N
DMN2TMS IU N-(3-bromophenyl)-2-hydroxy-4-(prop-2-enoylamino)benzamide
DMN2TMS DE Discovery agent
DME24LV ID DME24LV
DME24LV DN 4-adamantyl resorcinol
DME24LV HS Investigative
DME24LV SN 4-adamantyl resorcinol; CHEMBL474953; 4-(adamant-1-yl)resorcin; 4-(1-Adamantyl)resorcinol; SCHEMBL2420330; NAJPJOQCMCYGLX-UHFFFAOYSA-N; 1-(2,4-dihydroxyphenyl)adamantane
DME24LV DT Small molecular drug
DME24LV PC 15105171
DME24LV MW 244.33
DME24LV FM C16H20O2
DME24LV IC InChI=1S/C16H20O2/c17-13-1-2-14(15(18)6-13)16-7-10-3-11(8-16)5-12(4-10)9-16/h1-2,6,10-12,17-18H,3-5,7-9H2
DME24LV CS C1C2CC3CC1CC(C2)(C3)C4=C(C=C(C=C4)O)O
DME24LV IK NAJPJOQCMCYGLX-UHFFFAOYSA-N
DME24LV IU 4-(1-adamantyl)benzene-1,3-diol
DME24LV DE Discovery agent
DM9WT8M ID DM9WT8M
DM9WT8M DN 4-Allyl-6-nitro-2-piperazin-1-yl-quinoline
DM9WT8M HS Investigative
DM9WT8M SN CHEMBL167358; 4-Allyl-6-nitro-2-piperazin-1-yl-quinoline; BDBM50110587
DM9WT8M DT Small molecular drug
DM9WT8M PC 44379686
DM9WT8M MW 298.34
DM9WT8M FM C16H18N4O2
DM9WT8M IC InChI=1S/C16H18N4O2/c1-2-3-12-10-16(19-8-6-17-7-9-19)18-15-5-4-13(20(21)22)11-14(12)15/h2,4-5,10-11,17H,1,3,6-9H2
DM9WT8M CS C=CCC1=CC(=NC2=C1C=C(C=C2)[N+](=O)[O-])N3CCNCC3
DM9WT8M IK MQKUUUQECTZPIV-UHFFFAOYSA-N
DM9WT8M IU 6-nitro-2-piperazin-1-yl-4-prop-2-enylquinoline
DM9WT8M DE Discovery agent
DMGYK25 ID DMGYK25
DMGYK25 DN 4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B
DMGYK25 HS Investigative
DMGYK25 SN CHEMBL464537; 4alpha-(hydroxymethyl)-4alpha-demethylterritrem B; BDBM50292394; 4beta-Hyroxymethyl-4beta-demethylterritrem B
DMGYK25 DT Small molecular drug
DMGYK25 PC 10030248
DMGYK25 MW 542.6
DMGYK25 FM C29H34O10
DMGYK25 IC InChI=1S/C29H34O10/c1-25(15-30)8-7-22(31)27(3)28(25,33)10-9-26(2)29(27,34)14-17-19(39-26)13-18(38-24(17)32)16-11-20(35-4)23(37-6)21(12-16)36-5/h7-8,11-13,30,33-34H,9-10,14-15H2,1-6H3/t25-,26+,27-,28+,29+/m0/s1
DMGYK25 CS C[C@@]12CC[C@]3([C@](C=CC(=O)[C@@]3([C@]1(CC4=C(O2)C=C(OC4=O)C5=CC(=C(C(=C5)OC)OC)OC)O)C)(C)CO)O
DMGYK25 IK PXIKKOJKOBCLTQ-XPLNXOJDSA-N
DMGYK25 IU (1S,2S,6S,7R,10R)-1,7-dihydroxy-6-(hydroxymethyl)-2,6,10-trimethyl-14-(3,4,5-trimethoxyphenyl)-11,15-dioxatetracyclo[8.8.0.02,7.012,17]octadeca-4,12(17),13-triene-3,16-dione
DMGYK25 DE Discovery agent
DMTSPLX ID DMTSPLX
DMTSPLX DN 4alpha-PDD
DMTSPLX HS Investigative
DMTSPLX SN 4alpha-phorbol 12,13-didecanoate; 4alpha-phorbol-didecanoate
DMTSPLX DT Small molecular drug
DMTSPLX PC 452544
DMTSPLX MW 672.9
DMTSPLX FM C40H64O8
DMTSPLX IC InChI=1S/C40H64O8/c1-7-9-11-13-15-17-19-21-32(42)47-36-28(4)39(46)30(24-29(26-41)25-38(45)31(39)23-27(3)35(38)44)34-37(5,6)40(34,36)48-33(43)22-20-18-16-14-12-10-8-2/h23-24,28,30-31,34,36,41,45-46H,7-22,25-26H2,1-6H3/t28-,30+,31-,34-,36-,38+,39-,40-/m1/s1
DMTSPLX CS CCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)CCCCCCCCC)O)C
DMTSPLX IK DGOSGFYDFDYMCW-OEFRVDPMSA-N
DMTSPLX IU [(1S,2S,6S,10S,11R,13S,14R,15R)-13-decanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] decanoate
DMTSPLX CA CAS 27536-56-7
DMTSPLX CB CHEBI:139299
DMTSPLX DE Discovery agent
DMUOLES ID DMUOLES
DMUOLES DN 4alpha-PDH
DMUOLES HS Investigative
DMUOLES SN 4alpha-phorbol 12,13-dihexanoate
DMUOLES DT Small molecular drug
DMUOLES PC 42638006
DMUOLES MW 560.7
DMUOLES FM C32H48O8
DMUOLES IC InChI=1S/C32H48O8/c1-7-9-11-13-24(34)39-28-20(4)31(38)22(16-21(18-33)17-30(37)23(31)15-19(3)27(30)36)26-29(5,6)32(26,28)40-25(35)14-12-10-8-2/h15-16,20,22-23,26,28,33,37-38H,7-14,17-18H2,1-6H3/t20-,22+,23-,26-,28-,30+,31-,32-/m1/s1
DMUOLES CS CCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@@]3([C@H]2C=C(C3=O)C)O)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)CCCCC)O)C
DMUOLES IK XGPRSRGBAHBMAF-QYSBVNMQSA-N
DMUOLES IU [(1S,2S,6S,10S,11R,13S,14R,15R)-13-hexanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] hexanoate
DMUOLES DE Discovery agent
DMYNASR ID DMYNASR
DMYNASR DN 4-AMBA
DMYNASR HS Investigative
DMYNASR SN 4-(Aminomethyl)benzoic acid; 56-91-7; 4-Carboxybenzylamine; Pamba; 4-Aminomethylbenzoic acid; Styptopur; Gumbix; p-Aminomethylbenzoic acid; Aminomethylbenzoic acid; Benzoic acid, 4-(aminomethyl)-; Benzylamine-4-carboxylic acid; alpha-Amino-p-toluic acid; p-(Aminomethyl)benzoic acid; Aminomethyl benzoic acid; UNII-68WG9JKC7L; 4-Aminomethyl-benzoic acid; 4-(Aminomethyl)benzoesaeure; NSC41629; EINECS 200-297-9; NSC 41629; 68WG9JKC7L; .alpha.-Amino-p-toluic acid; CHEMBL328875; p-Toluic acid, .alpha.-amino-
DMYNASR DT Small molecular drug
DMYNASR PC 65526
DMYNASR MW 151.16
DMYNASR FM C8H9NO2
DMYNASR IC InChI=1S/C8H9NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4H,5,9H2,(H,10,11)
DMYNASR CS C1=CC(=CC=C1CN)C(=O)O
DMYNASR IK QCTBMLYLENLHLA-UHFFFAOYSA-N
DMYNASR IU 4-(aminomethyl)benzoic acid
DMYNASR CA CAS 56-91-7
DMYNASR CB CHEBI:134774
DMYNASR DE Discovery agent
DMYX34S ID DMYX34S
DMYX34S DN 4-Amino Hexanoic Acid
DMYX34S HS Investigative
DMYX34S SN 4-Aminohexanoic acid; 5415-99-6; Hexanoic acid, 4-amino-; g-aminocaproic acid; 4-ethyl aminobutyric acid; AC1L3CX4; SCHEMBL900872; CTK1H4537; MolPort-006-169-599; ALBB-018090; NSC11326; NSC-11326; AKOS000277394; AKOS017258812; Hexanoic acid, 4-amino-, hydrochloride
DMYX34S DT Small molecular drug
DMYX34S PC 46936928
DMYX34S MW 131.17
DMYX34S FM C6H13NO2
DMYX34S IC InChI=1S/C6H13NO2/c1-2-5(7)3-4-6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
DMYX34S CS CC[C@@H](CCC(=O)O)N
DMYX34S IK ROFNJLCLYMMXCT-YFKPBYRVSA-N
DMYX34S IU (4S)-4-aminohexanoic acid
DMYX34S CA CAS 1334472-86-4
DMYX34S DE Discovery agent
DMNXSM2 ID DMNXSM2
DMNXSM2 DN 4-amino-1,2,5-oxadiazole-3-carboximidamide
DMNXSM2 HS Investigative
DMNXSM2 DT Small molecular drug
DMNXSM2 PC 45078766
DMNXSM2 MW 127.11
DMNXSM2 FM C3H5N5O
DMNXSM2 IC InChI=1S/C3H5N5O/c4-2(5)1-3(6)8-9-7-1/h(H3,4,5)(H2,6,8)
DMNXSM2 CS C1(=NON=C1N)C(=N)N
DMNXSM2 IK YHIJOLKAHGHVML-UHFFFAOYSA-N
DMNXSM2 IU 4-amino-1,2,5-oxadiazole-3-carboximidamide
DMNXSM2 DE Discovery agent
DMU49H6 ID DMU49H6
DMU49H6 DN 4-amino-1,8-naphthalimide
DMU49H6 HS Investigative
DMU49H6 SN 4-Amino-1,8-naphthalimide; 1742-95-6; 4-Aminonaphthalimide; 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE; 6-Amino-1H-benzo[de]isoquinoline-1,3(2H)-dione; 4-Aminonaphthalene-1,8-dicarboximide; Naphthalimide, 4-amino-; DFP 1; 1H-Benz[de]isoquinoline-1,3(2H)-dione, 6-amino-; EINECS 217-110-1; BRN 0177185; 6-aminobenzo[de]isoquinoline-1,3-dione; PARP Inhibitor V, 4-ANI; CHEMBL338790; CHEBI:40071; SSMIFVHARFVINF-UHFFFAOYSA-N; 6-Amino-1H-benz(de)isoquinoline-1,3(2H)-dione; 4-AMINO-1,8 NAPHTHALIMIDE
DMU49H6 DT Small molecular drug
DMU49H6 PC 1720
DMU49H6 MW 212.2
DMU49H6 FM C12H8N2O2
DMU49H6 IC InChI=1S/C12H8N2O2/c13-9-5-4-8-10-6(9)2-1-3-7(10)11(15)14-12(8)16/h1-5H,13H2,(H,14,15,16)
DMU49H6 CS C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N
DMU49H6 IK SSMIFVHARFVINF-UHFFFAOYSA-N
DMU49H6 IU 6-aminobenzo[de]isoquinoline-1,3-dione
DMU49H6 CA CAS 1742-95-6
DMU49H6 CB CHEBI:40071
DMU49H6 DE Discovery agent
DM7X59V ID DM7X59V
DM7X59V DN 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile
DM7X59V HS Investigative
DM7X59V SN MLS000055002; 4-amino-2,6-diphenylpyrimidine-5-carbonitrile; SMR000065808; 4-amino-2,6-diphenyl-5-pyrimidinecarbonitrile; AC1M4AA8; 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile; CHEMBL260615; BDBM49037; cid_2303947; MolPort-003-996-370; HMS2490H05; ZINC3098930; AKOS003621107; MCULE-1850499298; 20954-77-2; FT-0711858; 4-azanyl-2,6-diphenyl-pyrimidine-5-carbonitrile
DM7X59V DT Small molecular drug
DM7X59V PC 2303947
DM7X59V MW 272.3
DM7X59V FM C17H12N4
DM7X59V IC InChI=1S/C17H12N4/c18-11-14-15(12-7-3-1-4-8-12)20-17(21-16(14)19)13-9-5-2-6-10-13/h1-10H,(H2,19,20,21)
DM7X59V CS C1=CC=C(C=C1)C2=C(C(=NC(=N2)C3=CC=CC=C3)N)C#N
DM7X59V IK RVAUJCJDJMOIOL-UHFFFAOYSA-N
DM7X59V IU 4-amino-2,6-diphenylpyrimidine-5-carbonitrile
DM7X59V DE Discovery agent
DMINUHD ID DMINUHD
DMINUHD DN 4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid
DMINUHD HS Investigative
DMINUHD SN 130525-62-1; 4-amino-2-deoxy-2,3-dehydro-n-neuraminic acid; 4-AM-DANA; CHEMBL52270; 4-Amino-neu5Ac2en; 5-(Acetylamino)-4-amino-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic Acid; 4AM; Zanamivir Amine; (4S,5R,6R)-5-Acetylamino-4-amino-6-((1R,2R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid; (2R,3R,4S)-3-acetamido-4-amino-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMINUHD DT Small molecular drug
DMINUHD PC 445533
DMINUHD MW 290.27
DMINUHD FM C11H18N2O7
DMINUHD IC InChI=1S/C11H18N2O7/c1-4(15)13-8-5(12)2-7(11(18)19)20-10(8)9(17)6(16)3-14/h2,5-6,8-10,14,16-17H,3,12H2,1H3,(H,13,15)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1
DMINUHD CS CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N
DMINUHD IK NKENBBIXEGPQLS-UFGQHTETSA-N
DMINUHD IU (2R,3R,4S)-3-acetamido-4-amino-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DMINUHD CA CAS 130525-62-1
DMINUHD DE Discovery agent
DM3MUF1 ID DM3MUF1
DM3MUF1 DN 4-amino-2H-chromen-2-one
DM3MUF1 HS Investigative
DM3MUF1 SN 4-Amino-chromen-2-one; 4-Aminocoumarin; 53348-92-8; 4-amino-2H-chromen-2-one; 4-Amino-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 4-amino-; UNII-SCI2054E4F; CHEMBL240482; SCI2054E4F; Coumarin, 4-amino-; 4-aminochromen-2-one; AC1LGGAS; Coumarin, 4-amino- (7CI); SCHEMBL4396062; AC1Q69X0; CTK7H2649; DTXSID90201509; MolPort-000-000-981; AHZAKFLOHIRCDU-UHFFFAOYSA-N; ZINC337346; STL371135; BDBM50226833; 4-[Amino]-2H-1-benzopyran-2-one; AKOS004909244; FCH1162846; MCULE-3726196442; MB00371; LS-39436; DB-071668; KB-189290; FT-0740005; A58124
DM3MUF1 DT Small molecular drug
DM3MUF1 PC 820807
DM3MUF1 MW 161.16
DM3MUF1 FM C9H7NO2
DM3MUF1 IC InChI=1S/C9H7NO2/c10-7-5-9(11)12-8-4-2-1-3-6(7)8/h1-5H,10H2
DM3MUF1 CS C1=CC=C2C(=C1)C(=CC(=O)O2)N
DM3MUF1 IK AHZAKFLOHIRCDU-UHFFFAOYSA-N
DM3MUF1 IU 4-aminochromen-2-one
DM3MUF1 CA CAS 53348-92-8
DM3MUF1 DE Discovery agent
DMOJTZD ID DMOJTZD
DMOJTZD DN 4-amino-2-p-tolylisoindoline-1,3-dione
DMOJTZD HS Investigative
DMOJTZD SN 4-Amino-2-p-tolylisoindole-1,3-dione; CHEMBL600405; 20871-07-2; 4-Amino-2-p-tolyl-isoindole-1,3-dione; 4-Amino-2-(p-tolyl)isoindoline-1,3-dione; 4-amino-2-p-tolylisoindoline-1,3-dione; AC1LHA6Z; Oprea1_716953; Oprea1_214378; MolPort-000-151-255; ZINC360744; BDBM50306747; AKOS000727908; MCULE-4928093173; BAS 00084697; KB-189090
DMOJTZD DT Small molecular drug
DMOJTZD PC 834731
DMOJTZD MW 252.27
DMOJTZD FM C15H12N2O2
DMOJTZD IC InChI=1S/C15H12N2O2/c1-9-5-7-10(8-6-9)17-14(18)11-3-2-4-12(16)13(11)15(17)19/h2-8H,16H2,1H3
DMOJTZD CS CC1=CC=C(C=C1)N2C(=O)C3=C(C2=O)C(=CC=C3)N
DMOJTZD IK LTZXDGYVXKFIET-UHFFFAOYSA-N
DMOJTZD IU 4-amino-2-(4-methylphenyl)isoindole-1,3-dione
DMOJTZD CA CAS 20871-07-2
DMOJTZD DE Discovery agent
DMIX81A ID DMIX81A
DMIX81A DN 4-Amino-3-(2-chloro-phenyl)-butyric acid
DMIX81A HS Investigative
DMIX81A SN CHEMBL83245; 28311-34-4; 4-Amino-3-(2-chloro-phenyl)-butyric acid; SCHEMBL349398; BDBM50007121; AKOS015157811; 4-Amino-3-(2-chlorophenyl)butyric acid; 4-amino-3-(2-chlorophenyl)butanoic acid; 4-amino-3-(-chlorophenyl)-butanoic acid; Benzenepropanoic acid, beta-(aminomethyl)-2-chloro-
DMIX81A DT Small molecular drug
DMIX81A PC 21950279
DMIX81A MW 213.66
DMIX81A FM C10H12ClNO2
DMIX81A IC InChI=1S/C10H12ClNO2/c11-9-4-2-1-3-8(9)7(6-12)5-10(13)14/h1-4,7H,5-6,12H2,(H,13,14)
DMIX81A CS C1=CC=C(C(=C1)C(CC(=O)O)CN)Cl
DMIX81A IK RNSIJRUPQJHCBR-UHFFFAOYSA-N
DMIX81A IU 4-amino-3-(2-chlorophenyl)butanoic acid
DMIX81A DE Discovery agent
DMGI0YV ID DMGI0YV
DMGI0YV DN 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid
DMGI0YV HS Investigative
DMGI0YV SN CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729
DMGI0YV DT Small molecular drug
DMGI0YV PC 651854
DMGI0YV MW 293.36
DMGI0YV FM C16H23NO4
DMGI0YV IC InChI=1S/C16H23NO4/c1-2-3-4-5-10-21-13-8-6-12(7-9-13)14(16(17)20)11-15(18)19/h6-9,14H,2-5,10-11H2,1H3,(H2,17,20)(H,18,19)
DMGI0YV CS CCCCCCOC1=CC=C(C=C1)C(CC(=O)O)C(=O)N
DMGI0YV IK RRXQHLQCQYPPMF-UHFFFAOYSA-N
DMGI0YV IU 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid
DMGI0YV DE Discovery agent
DMVKPF1 ID DMVKPF1
DMVKPF1 DN 4-Amino-3-(4-fluoro-phenyl)-butyric acid
DMVKPF1 HS Investigative
DMVKPF1 SN (R)-4-AMINO-3-(4-FLUOROPHENYL)BUTANOIC ACID; 741217-33-4; CHEMBL301492; (3R)-4-amino-3-(4-fluorophenyl)butanoic acid; AK-87533; PubChem18292; SCHEMBL351702; CTK5D9380; KS-00000QGP; DTXSID00557064; MolPort-023-332-505; ZINC6093177; ANW-65813; 1505AC; BDBM50368295; AKOS006325793; LS30154; CA-2040; DS-2490; AC-22391; AJ-55750; TC-154558; AX8236708; KB-210177; ST24020736; (R)-3-(4-Fluorophenyl)-4-aminobutyric acid
DMVKPF1 DT Small molecular drug
DMVKPF1 PC 103611
DMVKPF1 MW 197.21
DMVKPF1 FM C10H12FNO2
DMVKPF1 IC InChI=1S/C10H12FNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)
DMVKPF1 CS C1=CC(=CC=C1C(CC(=O)O)CN)F
DMVKPF1 IK QWHXHLDNSXLAPX-UHFFFAOYSA-N
DMVKPF1 IU 4-amino-3-(4-fluorophenyl)butanoic acid
DMVKPF1 CA CAS 52237-19-1
DMVKPF1 DE Discovery agent
DMTO8NV ID DMTO8NV
DMTO8NV DN 4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid
DMTO8NV HS Investigative
DMTO8NV SN CHEMBL314177; 4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid; SCHEMBL340904; beta-(5-Bromo-2-thienyl)GABA; BDBM50007108; AKOS022983047; 4-amino-3-(5-bromothien-2-yl)butanoic acid
DMTO8NV DT Small molecular drug
DMTO8NV PC 10220920
DMTO8NV MW 264.14
DMTO8NV FM C8H10BrNO2S
DMTO8NV IC InChI=1S/C8H10BrNO2S/c9-7-2-1-6(13-7)5(4-10)3-8(11)12/h1-2,5H,3-4,10H2,(H,11,12)
DMTO8NV CS C1=C(SC(=C1)Br)C(CC(=O)O)CN
DMTO8NV IK AGSZIPFOQSAPON-UHFFFAOYSA-N
DMTO8NV IU 4-amino-3-(5-bromothiophen-2-yl)butanoic acid
DMTO8NV DE Discovery agent
DM415DB ID DM415DB
DM415DB DN 4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid
DM415DB HS Investigative
DM415DB SN 133933-81-0; 4-amino-3-(5-chlorothiophen-2-yl)butanoic acid; CHEMBL87482; 4-AMINO-3- (5-CHLOROTHIEN-2-YL)BUTANOIC ACID; 2-Thiophenepropanoicacid, b-(aminomethyl)-5-chloro-; (+/-)-4-AMINO-3-(5-CHLORO-2-THIENYL)-BUTANOIC ACID; 4-Actba; KBio3_002901; ACMC-20mv5p; AC1L2PFH; Spectrum2_001171; Spectrum3_001889; Spectrum4_000231; Spectrum5_001875; 4-Amino-3-(5-chloro-2-thienyl)butyric acid; Biomol-NT_000250; BSPBio_003398; KBioGR_000921; 4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid; SCHEMBL342009; SPBio_001181; BPBio1_000706
DM415DB DT Small molecular drug
DM415DB PC 125917
DM415DB MW 219.69
DM415DB FM C8H10ClNO2S
DM415DB IC InChI=1S/C8H10ClNO2S/c9-7-2-1-6(13-7)5(4-10)3-8(11)12/h1-2,5H,3-4,10H2,(H,11,12)
DM415DB CS C1=C(SC(=C1)Cl)C(CC(=O)O)CN
DM415DB IK CDFQDLUHBLZCGL-UHFFFAOYSA-N
DM415DB IU 4-amino-3-(5-chlorothiophen-2-yl)butanoic acid
DM415DB CA CAS 151563-54-1
DM415DB DE Discovery agent
DMEDRAX ID DMEDRAX
DMEDRAX DN 4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid
DMEDRAX HS Investigative
DMEDRAX SN 133933-77-4; CHEMBL86144; 4-amino-3-(5-methylthiophen-2-yl)butanoic acid; 4-Amtba; 4-Amino-3-(5-methyl-2-thienyl)butyric acid; AC1L2PFE; ACMC-1C1U4; 4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid; SCHEMBL341475; CTK0H6620; beta-(5-Methyl-2-thienyl)GABA; BDBM50007107; AKOS022919013; 4-amino-3-(5-methylthien-2-yl)butanoic acid; 2-Thiophenepropanoic acid, beta-(aminomethyl)-5-methyl-, (+-)-
DMEDRAX DT Small molecular drug
DMEDRAX PC 125916
DMEDRAX MW 199.27
DMEDRAX FM C9H13NO2S
DMEDRAX IC InChI=1S/C9H13NO2S/c1-6-2-3-8(13-6)7(5-10)4-9(11)12/h2-3,7H,4-5,10H2,1H3,(H,11,12)
DMEDRAX CS CC1=CC=C(S1)C(CC(=O)O)CN
DMEDRAX IK RPNWEWXYTFWDTR-UHFFFAOYSA-N
DMEDRAX IU 4-amino-3-(5-methylthiophen-2-yl)butanoic acid
DMEDRAX CA CAS 133933-77-4
DMEDRAX DE Discovery agent
DMDCQAX ID DMDCQAX
DMDCQAX DN 4-amino-3,5-dibromobenzenesulfonamide
DMDCQAX HS Investigative
DMDCQAX SN 4-amino-3,5-dibromobenzenesulfonamide; 39150-45-3; 3,5-Dibromosulfanilamide; 2,6-Dibromosulfanilamide; 3,5-Dibromosulphanilamide; CHEMBL306195; DLXJPWSYRLLYSV-UHFFFAOYSA-N; AK109126; 4-amino-3,5-dibromobenzene-1-sulfonamide; Benzenesulfonamide, 4-amino-3,5-dibromo-; W-202619; EINECS 254-321-8; 4-Amino-3,5-dibromobenzenesulphonamide; ACMC-209j3o; AC1Q50HX; AC1MJ34Y; halogenosulfanilamide deriv. 12; SCHEMBL11136228; BDBM11611; CTK4I0998; DTXSID20192395; MolPort-001-780-206; ZINC2146706; ALBB-026584; ZX-AN025095; KS-00000NE9; 5104AB
DMDCQAX DT Small molecular drug
DMDCQAX PC 3084733
DMDCQAX MW 330
DMDCQAX FM C6H6Br2N2O2S
DMDCQAX IC InChI=1S/C6H6Br2N2O2S/c7-4-1-3(13(10,11)12)2-5(8)6(4)9/h1-2H,9H2,(H2,10,11,12)
DMDCQAX CS C1=C(C=C(C(=C1Br)N)Br)S(=O)(=O)N
DMDCQAX IK DLXJPWSYRLLYSV-UHFFFAOYSA-N
DMDCQAX IU 4-amino-3,5-dibromobenzenesulfonamide
DMDCQAX CA CAS 39150-45-3
DMDCQAX DE Discovery agent
DM1IHCV ID DM1IHCV
DM1IHCV DN 4-Amino-3-benzofuran-2-yl-butyric acid
DM1IHCV HS Investigative
DM1IHCV SN 121838-28-6; CHEMBL349520; 4-Amino-3-benzo(b)furan-2-ylbutanoic acid; 2-Benzofuranpropanoicacid, b-(aminomethyl)-; 4-amino-3-benzo[b]furan-2-ylbutanoic acid; Bfg-butanoic acid; 4-Amino-3-benzofuran-2-yl-butyric acid; ACMC-20mpq1; AC1L2VQL; 4-amino-3-(1-benzofuran-2-yl)butanoic acid; 2-Benzofuranpropanoic acid, beta-(aminomethyl)-; CTK4B2770; BDBM50021756; AKOS015439841; KB-240006
DM1IHCV DT Small molecular drug
DM1IHCV PC 129512
DM1IHCV MW 219.24
DM1IHCV FM C12H13NO3
DM1IHCV IC InChI=1S/C12H13NO3/c13-7-9(6-12(14)15)11-5-8-3-1-2-4-10(8)16-11/h1-5,9H,6-7,13H2,(H,14,15)
DM1IHCV CS C1=CC=C2C(=C1)C=C(O2)C(CC(=O)O)CN
DM1IHCV IK SRLRWPSSQWUHQC-UHFFFAOYSA-N
DM1IHCV IU 4-amino-3-(1-benzofuran-2-yl)butanoic acid
DM1IHCV CA CAS 121838-28-6
DM1IHCV DE Discovery agent
DMVUCZK ID DMVUCZK
DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide
DMVUCZK HS Investigative
DMVUCZK SN 4-amino-3-bromobenzenesulfonamide
DMVUCZK PC 3526523
DMVUCZK MW 251.1
DMVUCZK FM C6H7BrN2O2S
DMVUCZK IC InChI=1S/C6H7BrN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMVUCZK CS C1=CC(=C(C=C1S(=O)(=O)N)Br)N
DMVUCZK IK KQEVQYJWCZRLTJ-UHFFFAOYSA-N
DMVUCZK IU 4-amino-3-bromobenzenesulfonamide
DMVUCZK CA CAS 53297-69-1
DMVUCZK DE Discovery agent
DMERTQ4 ID DMERTQ4
DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide
DMERTQ4 HS Investigative
DMERTQ4 SN 4-amino-3-chlorobenzenesulfonamide
DMERTQ4 DT Small molecular drug
DMERTQ4 PC 1502014
DMERTQ4 MW 206.65
DMERTQ4 FM C6H7ClN2O2S
DMERTQ4 IC InChI=1S/C6H7ClN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMERTQ4 CS C1=CC(=C(C=C1S(=O)(=O)N)Cl)N
DMERTQ4 IK LFIOFZKZCDMGFG-UHFFFAOYSA-N
DMERTQ4 IU 4-amino-3-chlorobenzenesulfonamide
DMERTQ4 CA CAS 53297-68-0
DMERTQ4 DE Discovery agent
DMR9M6H ID DMR9M6H
DMR9M6H DN 4-amino-3-fluoro-5-iodobenzenesulfonamide
DMR9M6H HS Investigative
DMR9M6H SN CHEMBL69813; 4-amino-3-fluoro-5-iodobenzenesulfonamide; 4-amino-3-fluoro-5-iodobenzene-1-sulfonamide; halogenosulfanilamide deriv. 8
DMR9M6H DT Small molecular drug
DMR9M6H PC 10903168
DMR9M6H MW 316.09
DMR9M6H FM C6H6FIN2O2S
DMR9M6H IC InChI=1S/C6H6FIN2O2S/c7-4-1-3(13(10,11)12)2-5(8)6(4)9/h1-2H,9H2,(H2,10,11,12)
DMR9M6H CS C1=C(C=C(C(=C1F)N)I)S(=O)(=O)N
DMR9M6H IK KDXNVSMWRXCNMY-UHFFFAOYSA-N
DMR9M6H IU 4-amino-3-fluoro-5-iodobenzenesulfonamide
DMR9M6H DE Discovery agent
DMIQ3VR ID DMIQ3VR
DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide
DMIQ3VR HS Investigative
DMIQ3VR SN 4-amino-3-fluorobenzenesulfonamide
DMIQ3VR PC 4687472
DMIQ3VR MW 190.2
DMIQ3VR FM C6H7FN2O2S
DMIQ3VR IC InChI=1S/C6H7FN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMIQ3VR CS C1=CC(=C(C=C1S(=O)(=O)N)F)N
DMIQ3VR IK HVFBADWBKHAPKV-UHFFFAOYSA-N
DMIQ3VR IU 4-amino-3-fluorobenzenesulfonamide
DMIQ3VR CA CAS 2368-84-5
DMIQ3VR DE Discovery agent
DMPY8D3 ID DMPY8D3
DMPY8D3 DN 4-Amino-3-hydroxy-butyric acid
DMPY8D3 HS Investigative
DMPY8D3 SN 4-Amino-3-hydroxybutanoic acid; 924-49-2; 4-Amino-3-hydroxybutyric acid; Gabob; DL-4-Amino-3-hydroxybutyric acid; 3-Hydroxy-GABA; Gamibetal; Gabomade; Gaboril; Idramina; Gaminal; Buksamin; Gabimex; Bogil; 352-21-6; Gamma-amino-beta-hydroxybutyric acid; Butanoic acid, 4-amino-3-hydroxy-; Buxamine; Buxamin; Gabobe; beta-Oxy-gaba; 3-Hydroxy-4-aminobutyric acid; Buxamine (VAN); NSC 40244; gamma-Amino-beta-hydroxybutyrate; beta-Hydroxy-gamma-aminobutyrate; 4-Amino-3-hydroxy-butyric acid; BUTYRIC ACID, 4-AMINO-3-HYDROXY-
DMPY8D3 DT Small molecular drug
DMPY8D3 PC 2149
DMPY8D3 MW 119.12
DMPY8D3 FM C4H9NO3
DMPY8D3 IC InChI=1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)
DMPY8D3 CS C(C(CN)O)C(=O)O
DMPY8D3 IK YQGDEPYYFWUPGO-UHFFFAOYSA-N
DMPY8D3 IU 4-amino-3-hydroxybutanoic acid
DMPY8D3 CA CAS 924-49-2
DMPY8D3 CB CHEBI:16080
DMPY8D3 DE Discovery agent
DMCOYHR ID DMCOYHR
DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide
DMCOYHR HS Investigative
DMCOYHR SN 4-amino-3-iodobenzenesulfonamide
DMCOYHR PC 9861037
DMCOYHR MW 298.1
DMCOYHR FM C6H7IN2O2S
DMCOYHR IC InChI=1S/C6H7IN2O2S/c7-5-3-4(12(9,10)11)1-2-6(5)8/h1-3H,8H2,(H2,9,10,11)
DMCOYHR CS C1=CC(=C(C=C1S(=O)(=O)N)I)N
DMCOYHR IK HCODCRHNVCTCTR-UHFFFAOYSA-N
DMCOYHR IU 4-amino-3-iodobenzenesulfonamide
DMCOYHR CA CAS 60154-06-5
DMCOYHR DE Discovery agent
DMZJS2E ID DMZJS2E
DMZJS2E DN 4-Amino-3-thiophen-2-yl-butyric acid
DMZJS2E HS Investigative
DMZJS2E SN 4-Amino-3-(2-thienyl)butanoic acid; 133933-76-3; CHEMBL315476; 4-amino-3-(thien-2-yl)butanoic acid; 2-Thiophenepropanoicacid, b-(aminomethyl)-; 98593-59-0; 2-BTG; 4-amino-3-thiophen-2-ylbutanoic acid; 4-Amino-3-thiophen-2-yl-butyric acid; beta-(2-Thienyl)-gamma-aminobutyric acid; ACMC-1C0HP; AC1L2ZM2; SCHEMBL341042; CTK4B8884; BDBM50007117; 4-Amino-3-(2-thienyl)butyric acid; 4-amino-3-(2-thienyl) butyric acid; AKOS014313933
DMZJS2E DT Small molecular drug
DMZJS2E PC 131689
DMZJS2E MW 185.25
DMZJS2E FM C8H11NO2S
DMZJS2E IC InChI=1S/C8H11NO2S/c9-5-6(4-8(10)11)7-2-1-3-12-7/h1-3,6H,4-5,9H2,(H,10,11)
DMZJS2E CS C1=CSC(=C1)C(CC(=O)O)CN
DMZJS2E IK QDVRXIPQICAUFK-UHFFFAOYSA-N
DMZJS2E IU 4-amino-3-thiophen-2-ylbutanoic acid
DMZJS2E CA CAS 98593-59-0
DMZJS2E DE Discovery agent
DMQ6EBR ID DMQ6EBR
DMQ6EBR DN 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol
DMQ6EBR HS Investigative
DMQ6EBR SN CHEMBL391136; BDBM50213140
DMQ6EBR DT Small molecular drug
DMQ6EBR PC 44431968
DMQ6EBR MW 311.5
DMQ6EBR FM C21H29NO
DMQ6EBR IC InChI=1S/C21H29NO/c1-4-5-6-7-14-21(2,3)17-10-13-19(20(23)15-17)16-8-11-18(22)12-9-16/h8-13,15,23H,4-7,14,22H2,1-3H3
DMQ6EBR CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CC=C(C=C2)N)O
DMQ6EBR IK SDBAMIYHTMYHHO-UHFFFAOYSA-N
DMQ6EBR IU 2-(4-aminophenyl)-5-(2-methyloctan-2-yl)phenol
DMQ6EBR DE Discovery agent
DM9S5V0 ID DM9S5V0
DM9S5V0 DN 4'-Amino-4-hydroxychalcone
DM9S5V0 HS Investigative
DM9S5V0 SN CHEMBL383563; 1-(4-aminophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 4''-Amino-4-hydroxychalcone; AC1O21K2; SCHEMBL3762443; MolPort-019-723-769; ZINC4099897; SBB099103; BDBM50174839; AN-308/25123008; (2E)-1-(4-aminophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM9S5V0 DT Small molecular drug
DM9S5V0 PC 4525387
DM9S5V0 MW 239.27
DM9S5V0 FM C15H13NO2
DM9S5V0 IC InChI=1S/C15H13NO2/c16-13-6-4-12(5-7-13)15(18)10-3-11-1-8-14(17)9-2-11/h1-10,17H,16H2
DM9S5V0 CS C1=CC(=CC=C1C=CC(=O)C2=CC=C(C=C2)N)O
DM9S5V0 IK GJKSOGFGWQZGRL-UHFFFAOYSA-N
DM9S5V0 IU 1-(4-aminophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM9S5V0 DE Discovery agent
DMZRM0Q ID DMZRM0Q
DMZRM0Q DN 4-amino-6-(4-octylphenyl)hexanoic acid
DMZRM0Q HS Investigative
DMZRM0Q SN CHEMBL325050; 4-amino-6-(4-octylphenyl)hexanoic Acid; SCHEMBL5462898; BDBM50147701; 4-Amino-6-(4-octyl-phenyl)-hexanoic acid
DMZRM0Q DT Small molecular drug
DMZRM0Q PC 10125714
DMZRM0Q MW 319.5
DMZRM0Q FM C20H33NO2
DMZRM0Q IC InChI=1S/C20H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(21)15-16-20(22)23/h9-12,19H,2-8,13-16,21H2,1H3,(H,22,23)
DMZRM0Q CS CCCCCCCCC1=CC=C(C=C1)CCC(CCC(=O)O)N
DMZRM0Q IK UUODWPRHRNIITI-UHFFFAOYSA-N
DMZRM0Q IU 4-amino-6-(4-octylphenyl)hexanoic acid
DMZRM0Q DE Discovery agent
DMIWGZS ID DMIWGZS
DMIWGZS DN 4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS HS Investigative
DMIWGZS SN 121-30-2; 4-Amino-6-chlorobenzene-1,3-disulfonamide; 4-Amino-6-chloro-1,3-benzenedisulfonamide; Chloraminophenamide; Idorese; Salmid; Chloroaminophenamide; 1,3-Benzenedisulfonamide, 4-amino-6-chloro-; 5-Chloro-2,4-disulfamylaniline; 4-Amino-6-chloro-m-benzenedisulfonamide; 3-Chloro-4,6-disulfamoylaniline; 5-Chloro-2,4-disulfamoylaniline; UNII-3A52O8YREJ; Su 5683; 4-Amino-6-Chloro-1,3-Benzendisulfonamide; 3A52O8YREJ; CHEBI:3602; CHEMBL266240; 4-Amino-6-chlorobenzene-1,3-disulphonamide
DMIWGZS DT Small molecular drug
DMIWGZS PC 67136
DMIWGZS MW 285.7
DMIWGZS FM C6H8ClN3O4S2
DMIWGZS IC InChI=1S/C6H8ClN3O4S2/c7-3-1-4(8)6(16(10,13)14)2-5(3)15(9,11)12/h1-2H,8H2,(H2,9,11,12)(H2,10,13,14)
DMIWGZS CS C1=C(C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N)N
DMIWGZS IK IHJCXVZDYSXXFT-UHFFFAOYSA-N
DMIWGZS IU 4-amino-6-chlorobenzene-1,3-disulfonamide
DMIWGZS CA CAS 121-30-2
DMIWGZS CB CHEBI:3602
DMIWGZS DE Discovery agent
DMP2GN7 ID DMP2GN7
DMP2GN7 DN 4-aminobenzoic acid hydrazide
DMP2GN7 HS Investigative
DMP2GN7 SN 4-Aminobenzohydrazide; 5351-17-7; 4-Aminobenzhydrazide; 4-Aminobenzoic acid hydrazide; Amben hydrazide; p-Aminobenzhydrazide; Aminostimil; p-Aminobenzoic acid hydrazide; 4-Aminobenzoylhydrazine; p-Aminobenzoyl hydrazide; Benzoic acid, 4-amino-, hydrazide; p-Aminobenzoic hydrazide; p-Aminobenzoylhydrazine; para-Aminobenzhydrazide; NSC 640; BENZOIC ACID, p-AMINO-, HYDRAZIDE; EINECS 226-324-4; Myeloperoxidase Inhibitor-I; BRN 0639053; AI3-52435; CHEMBL2170241; (4-Aminobenzoyl)hydrazide, 95%; WPBZMCGPFHZRHJ-UHFFFAOYSA-N
DMP2GN7 DT Small molecular drug
DMP2GN7 PC 21450
DMP2GN7 MW 151.17
DMP2GN7 FM C7H9N3O
DMP2GN7 IC InChI=1S/C7H9N3O/c8-6-3-1-5(2-4-6)7(11)10-9/h1-4H,8-9H2,(H,10,11)
DMP2GN7 CS C1=CC(=CC=C1C(=O)NN)N
DMP2GN7 IK WPBZMCGPFHZRHJ-UHFFFAOYSA-N
DMP2GN7 IU 4-aminobenzohydrazide
DMP2GN7 CA CAS 5351-17-7
DMP2GN7 DE Discovery agent
DMHDB70 ID DMHDB70
DMHDB70 DN 4-amino-biphenyl-3-carboxylic acid amide
DMHDB70 HS Investigative
DMHDB70 SN CHEMBL207940; 5-phenylanthranilamide; 2-amino-5-phenylbenzamide; SCHEMBL3781950; Amino-substituted benzamide, 8c; BDBM27462; ZINC13686738
DMHDB70 DT Small molecular drug
DMHDB70 PC 11600944
DMHDB70 MW 212.25
DMHDB70 FM C13H12N2O
DMHDB70 IC InChI=1S/C13H12N2O/c14-12-7-6-10(8-11(12)13(15)16)9-4-2-1-3-5-9/h1-8H,14H2,(H2,15,16)
DMHDB70 CS C1=CC=C(C=C1)C2=CC(=C(C=C2)N)C(=O)N
DMHDB70 IK KLDLPUIJJYDCEE-UHFFFAOYSA-N
DMHDB70 IU 2-amino-5-phenylbenzamide
DMHDB70 DE Discovery agent
DM6PQ5V ID DM6PQ5V
DM6PQ5V DN 4-amino-N-(2-chlorophenyl)benzenesulfonamide
DM6PQ5V HS Investigative
DM6PQ5V SN 19837-85-5; 4-amino-N-(2-chlorophenyl)benzenesulfonamide; 4-amino-N-(2-chlorophenyl)benzene-1-sulfonamide; 4-Amino-N-(2-chloro-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(2-chlorophenyl)-; AC1MP5DG; AC1Q51WZ; SCHEMBL1970942; n1-2-chlorophenylsulphanilamide; CHEMBL227597; CTK4E2501; DTXSID20392191; XZQHDUUDKCHQIL-UHFFFAOYSA-N; MolPort-002-463-078; ZINC3885452; STL420385; BBL034801; AKOS000115492; NE25153; MCULE-7275329899; KB-289984; FT-0719132; N-(2-Chlorophenyl)-4-aminobenzenesulfonamide; EN300-02335
DM6PQ5V DT Small molecular drug
DM6PQ5V PC 3405810
DM6PQ5V MW 282.75
DM6PQ5V FM C12H11ClN2O2S
DM6PQ5V IC InChI=1S/C12H11ClN2O2S/c13-11-3-1-2-4-12(11)15-18(16,17)10-7-5-9(14)6-8-10/h1-8,15H,14H2
DM6PQ5V CS C1=CC=C(C(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)Cl
DM6PQ5V IK XZQHDUUDKCHQIL-UHFFFAOYSA-N
DM6PQ5V IU 4-amino-N-(2-chlorophenyl)benzenesulfonamide
DM6PQ5V CA CAS 19837-85-5
DM6PQ5V DE Discovery agent
DMCUSD4 ID DMCUSD4
DMCUSD4 DN 4-amino-N-(4-chlorophenyl)benzenesulfonamide
DMCUSD4 HS Investigative
DMCUSD4 SN 4-amino-N-(4-chlorophenyl)benzenesulfonamide; 16803-92-2; 4-Amino-N-(4-chloro-phenyl)-benzenesulfonamide; CHEMBL227413; Benzenesulfonamide, 4-amino-N-(4-chlorophenyl)-; 4-amino-n-(4-chlorophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-chlorophenyl)-; [(4-aminophenyl)sulfonyl](4-chlorophenyl)amine; BAS 02102352; AC1Q3REH; AC1LG33E; ARONIS021171; AC1Q51X9; SCHEMBL14093755; KS-00003SYR; CTK4D2850; DTXSID90354963; MolPort-000-164-113; ZINC286765; ALBB-000053; BDBM50197705; 5394AD; BBL037004; SBB009347; STK091555
DMCUSD4 DT Small molecular drug
DMCUSD4 PC 788021
DMCUSD4 MW 282.75
DMCUSD4 FM C12H11ClN2O2S
DMCUSD4 IC InChI=1S/C12H11ClN2O2S/c13-9-1-5-11(6-2-9)15-18(16,17)12-7-3-10(14)4-8-12/h1-8,15H,14H2
DMCUSD4 CS C1=CC(=CC=C1N)S(=O)(=O)NC2=CC=C(C=C2)Cl
DMCUSD4 IK RBJGYDGKXTYSSL-UHFFFAOYSA-N
DMCUSD4 IU 4-amino-N-(4-chlorophenyl)benzenesulfonamide
DMCUSD4 CA CAS 16803-92-2
DMCUSD4 DE Discovery agent
DMN19QP ID DMN19QP
DMN19QP DN 4-amino-N-(4-iodophenyl)benzenesulfonamide
DMN19QP HS Investigative
DMN19QP SN 6965-75-9; NSC63371; 4-amino-N-(4-iodophenyl)benzenesulfonamide; 4-amino-n-(4-iodo-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(4-iodophenyl)-; 4-amino-N-(4-iodophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-iodophenyl)-; NSC 63371; Enamine_003086; AC1Q6VVM; AC1Q51XD; AC1L6LA2; AC1Q51XC; 4-IODOSULFANILANILIDE; CHEMBL227416; CTK5D0764; DTXSID00219913; MolPort-001-833-979; HMS1402M06; ZINC537958; NSC-63371; STK063720; AKOS000115972; NE11209; MCULE-7780071880; KB-290010; EN300-02869; SR-01000033730
DMN19QP DT Small molecular drug
DMN19QP PC 247908
DMN19QP MW 374.2
DMN19QP FM C12H11IN2O2S
DMN19QP IC InChI=1S/C12H11IN2O2S/c13-9-1-5-11(6-2-9)15-18(16,17)12-7-3-10(14)4-8-12/h1-8,15H,14H2
DMN19QP CS C1=CC(=CC=C1N)S(=O)(=O)NC2=CC=C(C=C2)I
DMN19QP IK GNYYVWOTRVNKCO-UHFFFAOYSA-N
DMN19QP IU 4-amino-N-(4-iodophenyl)benzenesulfonamide
DMN19QP CA CAS 6965-75-9
DMN19QP DE Discovery agent
DMJZNX6 ID DMJZNX6
DMJZNX6 DN 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMJZNX6 HS Investigative
DMJZNX6 SN CHEMBL266026; 4-[[(4-aminophenyl)sulfonylamino]methyl]benzenesulfonamide; AC1NA7ER; SCHEMBL3789773; BDBM10871; ZINC6392199; aromatic/heteroaromatic sulfonamide 16; AKOS024362676; MCULE-5136189306; ST50993685; N-(4-Sulfamoylbenzyl)-4-aminobenzenesulfonamide; 4-amino-N-[(4-sulfamoylphenyl)methyl]benzene-1-sulfonamide; 4-({[(4-aminophenyl)sulfonyl]amino}methyl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-[[4-(aminosulfonyl)phenyl]methyl]-
DMJZNX6 DT Small molecular drug
DMJZNX6 PC 4422372
DMJZNX6 MW 341.4
DMJZNX6 FM C13H15N3O4S2
DMJZNX6 IC InChI=1S/C13H15N3O4S2/c14-11-3-7-13(8-4-11)22(19,20)16-9-10-1-5-12(6-2-10)21(15,17)18/h1-8,16H,9,14H2,(H2,15,17,18)
DMJZNX6 CS C1=CC(=CC=C1CNS(=O)(=O)C2=CC=C(C=C2)N)S(=O)(=O)N
DMJZNX6 IK HHCXOFYGBAPOJR-UHFFFAOYSA-N
DMJZNX6 IU 4-[[(4-aminophenyl)sulfonylamino]methyl]benzenesulfonamide
DMJZNX6 DE Discovery agent
DMDX0VP ID DMDX0VP
DMDX0VP DN 4-amino-N-[4-(benzyloxy)phenyl]butanamide
DMDX0VP HS Investigative
DMDX0VP SN 4-Amino-N-[4-(benzyloxy)phenyl]butanamide; CHEMBL478718; Modified amino acid analog, 7a; BDBM24263; AKOS010509844; DB07104; N-[4-(Benzyloxy)phenyl]-4-aminobutanamide; J3603388F; 4-Amino-N-[4-(phenylmethoxy)phenyl]butanamide
DMDX0VP DT Small molecular drug
DMDX0VP PC 22692237
DMDX0VP MW 284.35
DMDX0VP FM C17H20N2O2
DMDX0VP IC InChI=1S/C17H20N2O2/c18-12-4-7-17(20)19-15-8-10-16(11-9-15)21-13-14-5-2-1-3-6-14/h1-3,5-6,8-11H,4,7,12-13,18H2,(H,19,20)
DMDX0VP CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CCCN
DMDX0VP IK QTWBKNVNGVYTNZ-UHFFFAOYSA-N
DMDX0VP IU 4-amino-N-(4-phenylmethoxyphenyl)butanamide
DMDX0VP DE Discovery agent
DMIG82P ID DMIG82P
DMIG82P DN 4-aminonaphthalen-1-ol
DMIG82P HS Investigative
DMIG82P SN 4-Amino-1-naphthol; 2834-90-4; 4-Amino-1-naphthalenol; 1-Naphthalenol, 4-amino-; 1-AMINO-4-NAPHTHOL; UNII-02W29959D9; 4-amino-naphthalen-1-ol; CHEMBL576321; ABJQKDJOYSQVFX-UHFFFAOYSA-N; 4-Amino-1-naphtholhydrochloride; 02W29959D9; PCMD-CC-PAB-253; PC-0685415; 4-amino1-naphthol; 4-amino-1-naphtol; 4-azanylnaphthalen-1-ol; AC1L2AQW; 1-Amino-4-hydroxynaphthalene; SCHEMBL367092; AC1Q523Y; cid_2723858; BDBM43339; DTXSID30182580; 4-amino-1-naphthol; ZINC119431
DMIG82P DT Small molecular drug
DMIG82P PC 17815
DMIG82P MW 159.18
DMIG82P FM C10H9NO
DMIG82P IC InChI=1S/C10H9NO/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6,12H,11H2
DMIG82P CS C1=CC=C2C(=C1)C(=CC=C2O)N
DMIG82P IK ABJQKDJOYSQVFX-UHFFFAOYSA-N
DMIG82P IU 4-aminonaphthalen-1-ol
DMIG82P CA CAS 2834-90-4
DMIG82P DE Discovery agent
DMLW651 ID DMLW651
DMLW651 DN 4-amino-N-p-tolylbenzenesulfonamide
DMLW651 HS Investigative
DMLW651 SN 4-Amino-N-(4-methylphenyl)benzenesulfonamide; 16803-95-5; 4-Amino-N-(p-tolyl)benzenesulfonamide; QXIZWXNTAVXJNC-UHFFFAOYSA-N; Benzenesulfonamide, 4-amino-N-(4-methylphenyl)-; AC1LC9K2; Oprea1_140477; CHEMBL389286; SCHEMBL2240008; CTK0E5316; DTXSID50341293; MolPort-002-788-929; ZINC265634; ALBB-005339; ZX-AN005271; BBL008295; STK288097; 4-Amino-N-p-tolyl-benzenesulfonamide; AKOS000151276; MCULE-6336197788; SEL11434898; TR-041978; TR-058746; AB0221486; ST45130422; R4223; EU-0099855; [(4-aminophenyl)sulfonyl](4-methylphenyl)amine
DMLW651 DT Small molecular drug
DMLW651 PC 572102
DMLW651 MW 262.33
DMLW651 FM C13H14N2O2S
DMLW651 IC InChI=1S/C13H14N2O2S/c1-10-2-6-12(7-3-10)15-18(16,17)13-8-4-11(14)5-9-13/h2-9,15H,14H2,1H3
DMLW651 CS CC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)N
DMLW651 IK QXIZWXNTAVXJNC-UHFFFAOYSA-N
DMLW651 IU 4-amino-N-(4-methylphenyl)benzenesulfonamide
DMLW651 CA CAS 16803-95-5
DMLW651 DE Discovery agent
DMYC1T6 ID DMYC1T6
DMYC1T6 DN 4-AMINOPHENOL
DMYC1T6 HS Investigative
DMYC1T6 SN 4-aminophenol; 123-30-8; p-aminophenol; 4-hydroxyaniline; p-hydroxyaniline; Phenol, 4-amino-; Paranol; Certinal; Citol; Azol; 4-aminobenzenol; Fouramine P; Ursol P Base; Rodinal; p-Hydroxyphenylamine; Benzofur P; Fourrine P Base; Pelagol P Base; Tertral P Base; Ursol P; Furro P Base; Nako Brown R; Durafur Brown RB; 4-Amino-1-hydroxybenzene; Renal AC; Fourrine 84; Phenol, p-amino-; Zoba Brown P Base; 4-AMINO-PHENOL; UNAL; C.I. Oxidation Base 6; 1-Amino-4-hydroxybenzene; Pelagol Grey P Base; BASF Ursol P Base; p-Aminofenol; Para-aminophenol
DMYC1T6 DT Small molecular drug
DMYC1T6 PC 403
DMYC1T6 MW 109.13
DMYC1T6 FM C6H7NO
DMYC1T6 IC InChI=1S/C6H7NO/c7-5-1-3-6(8)4-2-5/h1-4,8H,7H2
DMYC1T6 CS C1=CC(=CC=C1N)O
DMYC1T6 IK PLIKAWJENQZMHA-UHFFFAOYSA-N
DMYC1T6 IU 4-aminophenol
DMYC1T6 CA CAS 123-30-8
DMYC1T6 CB CHEBI:17602
DMYC1T6 DE Discovery agent
DMSE8NU ID DMSE8NU
DMSE8NU DN 4-ANDROSTENE-3-17-DIONE
DMSE8NU HS Investigative
DMSE8NU SN Androstenedione; androstenedione; 4-Androstene-3,17-dione; Androst-4-ene-3,17-dione; 1963/5/8; 4-Androstenedione; Androtex; 3,17-Dioxoandrost-4-ene; delta-4-Androstenedione; SKF 2170; Fecundin; delta-4-Androsten-3,17-dione; delta-4-Androstene-3,17-dione; Androstendione; 4-Androsten-3,17-dione; NSC 9563; delta-(sup4)-Androsten-3,17-dione; delta(sup 4)-Androstene-3,17-dione; UNII-409J2J96VR; 17-Ketotestosterone; d4-androstenedione; CHEBI:16422; Androstenedione [JAN]; HSDB 7335; EINECS 200-554-5; MLS000028510; NSC9563; ANDROSTENEDIONE
DMSE8NU DT Small molecular drug
DMSE8NU PC 6128
DMSE8NU MW 286.4
DMSE8NU FM C19H26O2
DMSE8NU IC InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
DMSE8NU CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C
DMSE8NU IK AEMFNILZOJDQLW-QAGGRKNESA-N
DMSE8NU IU (8R,9S,10R,13S,14S)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMSE8NU CA CAS 63-05-8
DMSE8NU CB CHEBI:16422
DMSE8NU DE Discovery agent
DM1UXHE ID DM1UXHE
DM1UXHE DN 4-APPES
DM1UXHE HS Investigative
DM1UXHE SN 4-APPES; GTPL6258
DM1UXHE DT Small molecular drug
DM1UXHE PC 11281345
DM1UXHE MW 411.5
DM1UXHE FM C21H21N3O4S
DM1UXHE IC InChI=1S/C21H21N3O4S/c1-2-29(26,27)24(15-16-4-3-13-23-14-16)18-7-11-20(12-8-18)28-19-9-5-17(6-10-19)21(22)25/h3-14H,2,15H2,1H3,(H2,22,25)
DM1UXHE CS CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=C(C=C2)OC3=CC=C(C=C3)C(=O)N
DM1UXHE IK VCBPWPYIGXFKDH-UHFFFAOYSA-N
DM1UXHE IU 4-[4-[ethylsulfonyl(pyridin-3-ylmethyl)amino]phenoxy]benzamide
DM1UXHE DE Discovery agent
DM3UE42 ID DM3UE42
DM3UE42 DN 4-arylphthalazin-1(2H)-3,4-Di-F
DM3UE42 HS Investigative
DM3UE42 SN CHEMBL1934835; 4-arylphthalazin-1(2H)-3,4-Di-F; GTPL7753; BDBM50360858
DM3UE42 DT Small molecular drug
DM3UE42 PC 56835134
DM3UE42 MW 516.6
DM3UE42 FM C30H30F2N4O2
DM3UE42 IC InChI=1S/C30H30F2N4O2/c1-20(37)33-24-7-4-6-22(18-24)21-12-16-35(17-13-21)14-5-15-36-30(38)26-9-3-2-8-25(26)29(34-36)23-10-11-27(31)28(32)19-23/h2-4,6-11,18-19,21H,5,12-17H2,1H3,(H,33,37)
DM3UE42 CS CC(=O)NC1=CC=CC(=C1)C2CCN(CC2)CCCN3C(=O)C4=CC=CC=C4C(=N3)C5=CC(=C(C=C5)F)F
DM3UE42 IK YVVMAGRTTSOPEO-UHFFFAOYSA-N
DM3UE42 IU N-[3-[1-[3-[4-(3,4-difluorophenyl)-1-oxophthalazin-2-yl]propyl]piperidin-4-yl]phenyl]acetamide
DM3UE42 DE Discovery agent
DM7EQ06 ID DM7EQ06
DM7EQ06 DN 4-azidobenzenesulfonamide
DM7EQ06 HS Investigative
DM7EQ06 SN 4-azidobenzenesulfonamide; 4-azidobenzene-1-sulfonamide; CHEMBL222837; 36326-86-0; diazosulfanilamide; azide 1; AC1MSFSV; 4-azidophenylsulfonamide; 4-azido-benzenesulfonamide; SCHEMBL15155897; BDBM15222; MolPort-023-499-930; NSC80928; ZINC12410597; NSC-80928
DM7EQ06 DT Small molecular drug
DM7EQ06 PC 3558590
DM7EQ06 MW 198.21
DM7EQ06 FM C6H6N4O2S
DM7EQ06 IC InChI=1S/C6H6N4O2S/c7-10-9-5-1-3-6(4-2-5)13(8,11)12/h1-4H,(H2,8,11,12)
DM7EQ06 CS C1=CC(=CC=C1N=[N+]=[N-])S(=O)(=O)N
DM7EQ06 IK UZEFHQIOSJWWSB-UHFFFAOYSA-N
DM7EQ06 IU 4-azidobenzenesulfonamide
DM7EQ06 CA CAS 36326-86-0
DM7EQ06 DE Discovery agent
DMACRHS ID DMACRHS
DMACRHS DN 4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine
DMACRHS HS Investigative
DMACRHS SN CHEMBL148565; 4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine; BDBM50108708; ZINC13472074; 4-(Phenylsulfonyl)-1-hydrocinnamylpiperidine
DMACRHS DT Small molecular drug
DMACRHS PC 10871642
DMACRHS MW 343.5
DMACRHS FM C20H25NO2S
DMACRHS IC InChI=1S/C20H25NO2S/c22-24(23,19-11-5-2-6-12-19)20-13-16-21(17-14-20)15-7-10-18-8-3-1-4-9-18/h1-6,8-9,11-12,20H,7,10,13-17H2
DMACRHS CS C1CN(CCC1S(=O)(=O)C2=CC=CC=C2)CCCC3=CC=CC=C3
DMACRHS IK PZLOABUPAFZHAF-UHFFFAOYSA-N
DMACRHS IU 4-(benzenesulfonyl)-1-(3-phenylpropyl)piperidine
DMACRHS DE Discovery agent
DMCKT3Q ID DMCKT3Q
DMCKT3Q DN 4-Benzenesulfonyl-1-phenethyl-piperidine
DMCKT3Q HS Investigative
DMCKT3Q SN CHEMBL148280; 4-Benzenesulfonyl-1-phenethyl-piperidine; ZINC13472072; BDBM50108703; 4-(Phenylsulfonyl)-1-phenethylpiperidine
DMCKT3Q DT Small molecular drug
DMCKT3Q PC 10991121
DMCKT3Q MW 329.5
DMCKT3Q FM C19H23NO2S
DMCKT3Q IC InChI=1S/C19H23NO2S/c21-23(22,18-9-5-2-6-10-18)19-12-15-20(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19H,11-16H2
DMCKT3Q CS C1CN(CCC1S(=O)(=O)C2=CC=CC=C2)CCC3=CC=CC=C3
DMCKT3Q IK XFTLHKDSWBEMSE-UHFFFAOYSA-N
DMCKT3Q IU 4-(benzenesulfonyl)-1-(2-phenylethyl)piperidine
DMCKT3Q DE Discovery agent
DMC7HKA ID DMC7HKA
DMC7HKA DN 4-Benzenesulfonylamino-benzenesulfonamide
DMC7HKA HS Investigative
DMC7HKA SN 4-Benzenesulfonylamino-benzenesulfonamide; CHEMBL23796; 4461-11-4; N4-(benzenesulfonyl)sulfanilamide; 4-(benzenesulfonamido)benzenesulfonamide; AC1LGK72; BDBM16658; aromatic sulfonamide compound 23; CTK1D2369; DTXSID20356379; MolPort-001-887-057; ZINC340351; AKOS001088105; 1-N-benzenebenzene-1,4-disulfonamide; MCULE-1421025287; 4-[(Phenylsulfonyl)amino]benzenesulfonamide; Benzenesulfonamide, N-[4-(aminosulfonyl)phenyl]-
DMC7HKA DT Small molecular drug
DMC7HKA PC 822774
DMC7HKA MW 312.4
DMC7HKA FM C12H12N2O4S2
DMC7HKA IC InChI=1S/C12H12N2O4S2/c13-19(15,16)11-8-6-10(7-9-11)14-20(17,18)12-4-2-1-3-5-12/h1-9,14H,(H2,13,15,16)
DMC7HKA CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMC7HKA IK FOOYRJIJNYBGIF-UHFFFAOYSA-N
DMC7HKA IU 4-(benzenesulfonamido)benzenesulfonamide
DMC7HKA CA CAS 4461-11-4
DMC7HKA DE Discovery agent
DMM6UPD ID DMM6UPD
DMM6UPD DN 4-Benzenesulfonylamino-N-hydroxy-benzamide
DMM6UPD HS Investigative
DMM6UPD SN CHEMBL98345; 4-Benzenesulfonylamino-N-hydroxy-benzamide; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid
DMM6UPD DT Small molecular drug
DMM6UPD PC 44328873
DMM6UPD MW 292.31
DMM6UPD FM C13H12N2O4S
DMM6UPD IC InChI=1S/C13H12N2O4S/c16-13(14-17)10-6-8-11(9-7-10)15-20(18,19)12-4-2-1-3-5-12/h1-9,15,17H,(H,14,16)
DMM6UPD CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)C(=O)NO
DMM6UPD IK ZSIKBIFOAPITGF-UHFFFAOYSA-N
DMM6UPD IU 4-(benzenesulfonamido)-N-hydroxybenzamide
DMM6UPD DE Discovery agent
DMVSNPB ID DMVSNPB
DMVSNPB DN 4-benzhydryl-N-butylpiperazine-1-carboxamide
DMVSNPB HS Investigative
DMVSNPB SN 4-benzhydryl-N-butylpiperazine-1-carboxamide; CHEMBL1087032; 681801-59-2; N-butyl-4-(diphenylmethyl)piperazine-1-carboxamide; (4-(DIPHENYLMETHYL)PIPERAZINYL)-N-BUTYLFORMAMIDE; AC1MDDX7; AC1Q2X1X; MLS001181725; MolPort-001-841-442; HMS2858M18; HMS1662P18; KS-000029IQ; BDBM50312580; ZINC19924797; AKOS022169771; MS-8361; MCULE-5902192289
DMVSNPB DT Small molecular drug
DMVSNPB PC 2809754
DMVSNPB MW 351.5
DMVSNPB FM C22H29N3O
DMVSNPB IC InChI=1S/C22H29N3O/c1-2-3-14-23-22(26)25-17-15-24(16-18-25)21(19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,21H,2-3,14-18H2,1H3,(H,23,26)
DMVSNPB CS CCCCNC(=O)N1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
DMVSNPB IK QRGYLEAVFDZUPV-UHFFFAOYSA-N
DMVSNPB IU 4-benzhydryl-N-butylpiperazine-1-carboxamide
DMVSNPB DE Discovery agent
DMASO86 ID DMASO86
DMASO86 DN 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
DMASO86 HS Investigative
DMASO86 SN CHEMBL1086903; 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide; MLS000532882; AC1LQXAP; CBMicro_028883; Oprea1_410069; Oprea1_118265; MolPort-001-490-660; HMS2484B06; STK413461; ZINC13468414; BDBM50312579; AKOS003253125; MCULE-2070823146; SMR000140320; BIM-0028795.P001; ST50914634; N-cyclohexyl-4-(diphenylmethyl)piperazine-1-carboxamide; N-cyclohexyl-4-(diphenylmethyl)-1-piperazinecarboxamide
DMASO86 DT Small molecular drug
DMASO86 PC 1358608
DMASO86 MW 377.5
DMASO86 FM C24H31N3O
DMASO86 IC InChI=1S/C24H31N3O/c28-24(25-22-14-8-3-9-15-22)27-18-16-26(17-19-27)23(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-2,4-7,10-13,22-23H,3,8-9,14-19H2,(H,25,28)
DMASO86 CS C1CCC(CC1)NC(=O)N2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4
DMASO86 IK IRRGBCHOFRYUCB-UHFFFAOYSA-N
DMASO86 IU 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
DMASO86 CA CAS 401578-04-9
DMASO86 DE Discovery agent
DM02Q8N ID DM02Q8N
DM02Q8N DN 4-Benzo[b]thiophen-4-yl-1H-imidazole
DM02Q8N HS Investigative
DM02Q8N SN CHEMBL30534; 4-Benzo[b]thiophen-4-yl-1H-imidazole; 1H-Imidazole, 5-benzo[b]thien-4-yl-; SCHEMBL1502418; BDBM50085681; 4-(1H-Imidazole-4-yl)benzo[b]thiophene
DM02Q8N DT Small molecular drug
DM02Q8N PC 10176567
DM02Q8N MW 200.26
DM02Q8N FM C11H8N2S
DM02Q8N IC InChI=1S/C11H8N2S/c1-2-8(10-6-12-7-13-10)9-4-5-14-11(9)3-1/h1-7H,(H,12,13)
DM02Q8N CS C1=CC(=C2C=CSC2=C1)C3=CN=CN3
DM02Q8N IK QRRRICPYXPJYEH-UHFFFAOYSA-N
DM02Q8N IU 5-(1-benzothiophen-4-yl)-1H-imidazole
DM02Q8N DE Discovery agent
DM1UG2A ID DM1UG2A
DM1UG2A DN 4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol
DM1UG2A HS Investigative
DM1UG2A DT Small molecular drug
DM1UG2A PC 135496123
DM1UG2A MW 227.21
DM1UG2A FM C13H9NO3
DM1UG2A IC InChI=1S/C13H9NO3/c15-8-5-6-9(11(16)7-8)13-10-3-1-2-4-12(10)17-14-13/h1-7,15-16H
DM1UG2A CS C1=CC=C2C(=C1)C(=NO2)C3=C(C=C(C=C3)O)O
DM1UG2A IK JTGLWGSJTQMWBD-UHFFFAOYSA-N
DM1UG2A IU 4-(1,2-benzoxazol-3-yl)benzene-1,3-diol
DM1UG2A DE Discovery agent
DM7AOGD ID DM7AOGD
DM7AOGD DN 4-Benzoimidazol-1-yl-phenylamine
DM7AOGD HS Investigative
DM7AOGD SN 4-(1H-benzimidazol-1-yl)aniline; 52708-36-8; 4-(1H-Benzo[d]imidazol-1-yl)aniline; 4-(1H-1,3-benzodiazol-1-yl)aniline; 4-benzimidazolylphenylamine; AC1NS4KU; 4-(benzimidazol-1-yl)aniline; AC1Q51W1; SCHEMBL1208951; BDBM3829; CHEMBL346870; CTK1H4832; DTXSID80416160; 1-Phenylbenzimidazole deriv. 46; MolPort-000-892-003; ZINC2538824; 7454AB; STK122023; 1-(4-Aminophenyl)-1H-benzimidazole; SBB022485; AKOS000200797; MCULE-3811873515; AJ-38769; DA-18573; Benzenamine, 4-(1H-benzimidazol-1-yl)-; KB-237102; ST45055167; FT-0748937; EN300-14992
DM7AOGD DT Small molecular drug
DM7AOGD PC 5328453
DM7AOGD MW 209.25
DM7AOGD FM C13H11N3
DM7AOGD IC InChI=1S/C13H11N3/c14-10-5-7-11(8-6-10)16-9-15-12-3-1-2-4-13(12)16/h1-9H,14H2
DM7AOGD CS C1=CC=C2C(=C1)N=CN2C3=CC=C(C=C3)N
DM7AOGD IK DWYMPMWWYZEKLQ-UHFFFAOYSA-N
DM7AOGD IU 4-(benzimidazol-1-yl)aniline
DM7AOGD CA CAS 52708-36-8
DM7AOGD DE Discovery agent
DMA9DHE ID DMA9DHE
DMA9DHE DN 4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane
DMA9DHE HS Investigative
DMA9DHE SN CHEMBL611082; 4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862
DMA9DHE DT Small molecular drug
DMA9DHE PC 9794818
DMA9DHE MW 243.3
DMA9DHE FM C14H17N3O
DMA9DHE IC InChI=1S/C14H17N3O/c1-2-4-13-12(3-1)15-14(18-13)17-10-9-16-7-5-11(17)6-8-16/h1-4,11H,5-10H2
DMA9DHE CS C1CN2CCC1N(CC2)C3=NC4=CC=CC=C4O3
DMA9DHE IK CXJLWJAYGMWLRR-UHFFFAOYSA-N
DMA9DHE IU 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1,3-benzoxazole
DMA9DHE DE Discovery agent
DMYBPFS ID DMYBPFS
DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide
DMYBPFS HS Investigative
DMYBPFS SN SCHEMBL673678; CHEMBL191227
DMYBPFS DT Small molecular drug
DMYBPFS PC 11817702
DMYBPFS MW 256.26
DMYBPFS FM C14H12N2O3
DMYBPFS IC InChI=1S/C14H12N2O3/c17-13(10-4-2-1-3-5-10)15-12-8-6-11(7-9-12)14(18)16-19/h1-9,19H,(H,15,17)(H,16,18)
DMYBPFS CS C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMYBPFS IK QXGMQWWJCBVFOF-UHFFFAOYSA-N
DMYBPFS IU 4-benzamido-N-hydroxybenzamide
DMYBPFS DE Discovery agent
DMQZ0D6 ID DMQZ0D6
DMQZ0D6 DN 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine
DMQZ0D6 HS Investigative
DMQZ0D6 SN 4-benzyl-1-(2-phenoxyethyl)piperidine; CHEMBL102659; 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine; AC1LPA49; SCHEMBL5888854; HRBKFQYSVXXYDE-UHFFFAOYSA-N; ZINC1159765
DMQZ0D6 DT Small molecular drug
DMQZ0D6 PC 1328600
DMQZ0D6 MW 295.4
DMQZ0D6 FM C20H25NO
DMQZ0D6 IC InChI=1S/C20H25NO/c1-3-7-18(8-4-1)17-19-11-13-21(14-12-19)15-16-22-20-9-5-2-6-10-20/h1-10,19H,11-17H2
DMQZ0D6 CS C1CN(CCC1CC2=CC=CC=C2)CCOC3=CC=CC=C3
DMQZ0D6 IK HRBKFQYSVXXYDE-UHFFFAOYSA-N
DMQZ0D6 IU 4-benzyl-1-(2-phenoxyethyl)piperidine
DMQZ0D6 DE Discovery agent
DMIX6RG ID DMIX6RG
DMIX6RG DN 4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine
DMIX6RG HS Investigative
DMIX6RG SN CHEMBL513620; 4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine
DMIX6RG DT Small molecular drug
DMIX6RG PC 44563685
DMIX6RG MW 351.5
DMIX6RG FM C24H33NO
DMIX6RG IC InChI=1S/C24H33NO/c1-3-9-22(10-4-1)13-7-19-26-20-8-16-25-17-14-24(15-18-25)21-23-11-5-2-6-12-23/h1-6,9-12,24H,7-8,13-21H2
DMIX6RG CS C1CN(CCC1CC2=CC=CC=C2)CCCOCCCC3=CC=CC=C3
DMIX6RG IK XBQBYNHFYXHMHB-UHFFFAOYSA-N
DMIX6RG IU 4-benzyl-1-[3-(3-phenylpropoxy)propyl]piperidine
DMIX6RG DE Discovery agent
DM6XLZ0 ID DM6XLZ0
DM6XLZ0 DN 4-Benzyl-1-chroman-2-ylmethyl-piperidine
DM6XLZ0 HS Investigative
DM6XLZ0 SN CHEMBL178650; 4-Benzyl-1-chroman-2-ylmethyl-piperidine
DM6XLZ0 DT Small molecular drug
DM6XLZ0 PC 11220953
DM6XLZ0 MW 321.5
DM6XLZ0 FM C22H27NO
DM6XLZ0 IC InChI=1S/C22H27NO/c1-2-6-18(7-3-1)16-19-12-14-23(15-13-19)17-21-11-10-20-8-4-5-9-22(20)24-21/h1-9,19,21H,10-17H2
DM6XLZ0 CS C1CC2=CC=CC=C2OC1CN3CCC(CC3)CC4=CC=CC=C4
DM6XLZ0 IK XIEPNNMDKPLLAY-UHFFFAOYSA-N
DM6XLZ0 IU 4-benzyl-1-(3,4-dihydro-2H-chromen-2-ylmethyl)piperidine
DM6XLZ0 DE Discovery agent
DMAZMPF ID DMAZMPF
DMAZMPF DN 4-Benzyl-1-chroman-3-ylmethyl-piperidine
DMAZMPF HS Investigative
DMAZMPF SN CHEMBL179373; 4-Benzyl-1-chroman-3-ylmethyl-piperidine
DMAZMPF DT Small molecular drug
DMAZMPF PC 11152527
DMAZMPF MW 321.5
DMAZMPF FM C22H27NO
DMAZMPF IC InChI=1S/C22H27NO/c1-2-6-18(7-3-1)14-19-10-12-23(13-11-19)16-20-15-21-8-4-5-9-22(21)24-17-20/h1-9,19-20H,10-17H2
DMAZMPF CS C1CN(CCC1CC2=CC=CC=C2)CC3CC4=CC=CC=C4OC3
DMAZMPF IK SLJXLWDNADHNLA-UHFFFAOYSA-N
DMAZMPF IU 4-benzyl-1-(3,4-dihydro-2H-chromen-3-ylmethyl)piperidine
DMAZMPF DE Discovery agent
DMES9AJ ID DMES9AJ
DMES9AJ DN 4-Benzyl-1-indan-2-ylmethyl-piperidine
DMES9AJ HS Investigative
DMES9AJ SN CHEMBL179145; 4-Benzyl-1-indan-2-ylmethyl-piperidine
DMES9AJ DT Small molecular drug
DMES9AJ PC 11336800
DMES9AJ MW 305.5
DMES9AJ FM C22H27N
DMES9AJ IC InChI=1S/C22H27N/c1-2-6-18(7-3-1)14-19-10-12-23(13-11-19)17-20-15-21-8-4-5-9-22(21)16-20/h1-9,19-20H,10-17H2
DMES9AJ CS C1CN(CCC1CC2=CC=CC=C2)CC3CC4=CC=CC=C4C3
DMES9AJ IK YMEBJHPCSQTYQZ-UHFFFAOYSA-N
DMES9AJ IU 4-benzyl-1-(2,3-dihydro-1H-inden-2-ylmethyl)piperidine
DMES9AJ DE Discovery agent
DMQKCGI ID DMQKCGI
DMQKCGI DN 4-Benzyl-1-methyl-piperidine hydrochloride
DMQKCGI HS Investigative
DMQKCGI DE Discovery agent
DMAI6X2 ID DMAI6X2
DMAI6X2 DN 4-Benzyl-1-phenethyl-piperidine hydrochloride
DMAI6X2 HS Investigative
DMAI6X2 DE Discovery agent
DM2Q0VB ID DM2Q0VB
DM2Q0VB DN 4-benzyl-2,6-diisobutylamino-pyrimidine
DM2Q0VB HS Investigative
DM2Q0VB SN CHEMBL493703; 4-benzyl-2,6-diisobutylamino-pyrimidine
DM2Q0VB DT Small molecular drug
DM2Q0VB PC 25130896
DM2Q0VB MW 327.5
DM2Q0VB FM C19H29N5
DM2Q0VB IC InChI=1S/C19H29N5/c1-14(2)11-20-17-10-18(21-13-16-8-6-5-7-9-16)24-19(23-17)22-12-15(3)4/h5-10,14-15H,11-13H2,1-4H3,(H3,20,21,22,23,24)
DM2Q0VB CS CC(C)CNC1=NC(=NC(=C1)NCC2=CC=CC=C2)NCC(C)C
DM2Q0VB IK ZOQDUFOUNDLFCC-UHFFFAOYSA-N
DM2Q0VB IU 6-N-benzyl-2-N,4-N-bis(2-methylpropyl)pyrimidine-2,4,6-triamine
DM2Q0VB DE Discovery agent
DM8MVU4 ID DM8MVU4
DM8MVU4 DN 4-benzyl-2-methylphthalazin-1(2H)-one
DM8MVU4 HS Investigative
DM8MVU4 SN CHEMBL304747; AC1LDJCK; 4-benzyl-2-methylphthalazin-1(2H)-one; 4-Benzyl-2-methyl-1(2H)-phthalazinone; SCHEMBL8556390; KUTSOIMAOFABLX-UHFFFAOYSA-N; 4-benzyl-2-methylphthalazin-1-one; BDBM50131423; 4-Benzyl-2-methyl-2H-phthalazin-1-one; 4-Benzyl-2-methyl-1(2H)-phthalazinone #; 4-Benzyl-1,2-dihydro-2-methyl-1-oxophthalazine
DM8MVU4 DT Small molecular drug
DM8MVU4 PC 619552
DM8MVU4 MW 250.29
DM8MVU4 FM C16H14N2O
DM8MVU4 IC InChI=1S/C16H14N2O/c1-18-16(19)14-10-6-5-9-13(14)15(17-18)11-12-7-3-2-4-8-12/h2-10H,11H2,1H3
DM8MVU4 CS CN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=CC=C3
DM8MVU4 IK KUTSOIMAOFABLX-UHFFFAOYSA-N
DM8MVU4 IU 4-benzyl-2-methylphthalazin-1-one
DM8MVU4 DE Discovery agent
DMZ18OJ ID DMZ18OJ
DMZ18OJ DN 4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ HS Investigative
DMZ18OJ SN CHEMBL203718; 4-benzyl-5-(4-piperidyl)isothiazol-3-ol
DMZ18OJ DT Small molecular drug
DMZ18OJ PC 11515916
DMZ18OJ MW 274.4
DMZ18OJ FM C15H18N2OS
DMZ18OJ IC InChI=1S/C15H18N2OS/c18-15-13(10-11-4-2-1-3-5-11)14(19-17-15)12-6-8-16-9-7-12/h1-5,12,16H,6-10H2,(H,17,18)
DMZ18OJ CS C1CNCCC1C2=C(C(=O)NS2)CC3=CC=CC=C3
DMZ18OJ IK VUKNNEXTWWCNCW-UHFFFAOYSA-N
DMZ18OJ IU 4-benzyl-5-piperidin-4-yl-1,2-thiazol-3-one
DMZ18OJ DE Discovery agent
DMA4CZK ID DMA4CZK
DMA4CZK DN 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol
DMA4CZK HS Investigative
DMA4CZK SN CHEMBL144364; CHEMBL542896; 439944-86-2; CTK1C8001; DTXSID40440825; ZINC13473970; BDBM50113808; AKOS030538866; 4-Benzyl-5-(4-piperidinyl)isoxazole-3-ol; 3(2H)-Isoxazolone, 4-(phenylmethyl)-5-(4-piperidinyl)-
DMA4CZK DT Small molecular drug
DMA4CZK PC 10491441
DMA4CZK MW 258.32
DMA4CZK FM C15H18N2O2
DMA4CZK IC InChI=1S/C15H18N2O2/c18-15-13(10-11-4-2-1-3-5-11)14(19-17-15)12-6-8-16-9-7-12/h1-5,12,16H,6-10H2,(H,17,18)
DMA4CZK CS C1CNCCC1C2=C(C(=O)NO2)CC3=CC=CC=C3
DMA4CZK IK UQASDRGKIOGECB-UHFFFAOYSA-N
DMA4CZK IU 4-benzyl-5-piperidin-4-yl-1,2-oxazol-3-one
DMA4CZK CA CAS 439944-86-2
DMA4CZK DE Discovery agent
DMOBC0F ID DMOBC0F
DMOBC0F DN 4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline
DMOBC0F HS Investigative
DMOBC0F SN CHEMBL422203; 4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline; BDBM50110580
DMOBC0F DT Small molecular drug
DMOBC0F PC 44379687
DMOBC0F MW 348.4
DMOBC0F FM C20H20N4O2
DMOBC0F IC InChI=1S/C20H20N4O2/c25-24(26)17-6-7-19-18(14-17)16(12-15-4-2-1-3-5-15)13-20(22-19)23-10-8-21-9-11-23/h1-7,13-14,21H,8-12H2
DMOBC0F CS C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)CC4=CC=CC=C4
DMOBC0F IK SOYBGJFHGGERLE-UHFFFAOYSA-N
DMOBC0F IU 4-benzyl-6-nitro-2-piperazin-1-ylquinoline
DMOBC0F DE Discovery agent
DMDC7TL ID DMDC7TL
DMDC7TL DN 4-benzyloxy-2'-hydroxychalcone
DMDC7TL HS Investigative
DMDC7TL SN CHEMBL242078; (E)-3-(4-(benzyloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one; AC1O2DDI; SCHEMBL10768190; 4-benzyloxy-2''-hydroxychalcone; 2'-Hydroxy-4-(benzyloxy)chalcone; ZINC4775332; BDBM50241204; AKOS024335342; (E)-1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one
DMDC7TL DT Small molecular drug
DMDC7TL PC 6172473
DMDC7TL MW 330.4
DMDC7TL FM C22H18O3
DMDC7TL IC InChI=1S/C22H18O3/c23-21-9-5-4-8-20(21)22(24)15-12-17-10-13-19(14-11-17)25-16-18-6-2-1-3-7-18/h1-15,23H,16H2/b15-12+
DMDC7TL CS C1=CC=C(C=C1)COC2=CC=C(C=C2)/C=C/C(=O)C3=CC=CC=C3O
DMDC7TL IK PQZKTWBQDPHGOU-NTCAYCPXSA-N
DMDC7TL IU (E)-1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one
DMDC7TL DE Discovery agent
DM0T1NZ ID DM0T1NZ
DM0T1NZ DN 4-Benzyloxybenzo[b]thiophene-2-carboxamidine
DM0T1NZ HS Investigative
DM0T1NZ SN CHEMBL598191; 4-Benzyloxybenzo[b]thiophene-2-carboxamidine; SCHEMBL13709500
DM0T1NZ DT Small molecular drug
DM0T1NZ PC 24859718
DM0T1NZ MW 282.4
DM0T1NZ FM C16H14N2OS
DM0T1NZ IC InChI=1S/C16H14N2OS/c17-16(18)15-9-12-13(7-4-8-14(12)20-15)19-10-11-5-2-1-3-6-11/h1-9H,10H2,(H3,17,18)
DM0T1NZ CS C1=CC=C(C=C1)COC2=C3C=C(SC3=CC=C2)C(=N)N
DM0T1NZ IK BMADCBRXHDOABZ-UHFFFAOYSA-N
DM0T1NZ IU 4-phenylmethoxy-1-benzothiophene-2-carboximidamide
DM0T1NZ DE Discovery agent
DMA5FEM ID DMA5FEM
DMA5FEM DN 4-benzylphthalazin-1(2H)-one
DMA5FEM HS Investigative
DMA5FEM SN 4-Benzyl-1(2H)-phthalazinone; 4-benzylphthalazin-1(2H)-one; 32003-14-8; 4-Benzyl-2H-phthalazin-1-one; 4-benzyl-1,2-dihydrophthalazin-1-one; CHEMBL66761; JUCCMEHWBGPJKS-UHFFFAOYSA-N; benzylphthalazinone; phthalazinone, 1; 4-benzyl-phthalazone; AC1LDDNC; SMR000135223; AC1Q6GZZ; ChemDiv2_000142; Cambridge id 5241846; Oprea1_151142; Oprea1_623913; CBDivE_015258; MLS000530246; SCHEMBL863462; CTK4G8063; BDBM27660; DTXSID30346948; MolPort-001-796-654; HMS2379K10; HMS1369G10; 4-benzyl-2-hydrophthalazin-1-one; 4-Benzyl-1(2H)-phthalazinone #
DMA5FEM DT Small molecular drug
DMA5FEM PC 616651
DMA5FEM MW 236.27
DMA5FEM FM C15H12N2O
DMA5FEM IC InChI=1S/C15H12N2O/c18-15-13-9-5-4-8-12(13)14(16-17-15)10-11-6-2-1-3-7-11/h1-9H,10H2,(H,17,18)
DMA5FEM CS C1=CC=C(C=C1)CC2=NNC(=O)C3=CC=CC=C32
DMA5FEM IK JUCCMEHWBGPJKS-UHFFFAOYSA-N
DMA5FEM IU 4-benzyl-2H-phthalazin-1-one
DMA5FEM CA CAS 32003-14-8
DMA5FEM DE Discovery agent
DMI1EFY ID DMI1EFY
DMI1EFY DN 4-Benzythiopyridine-3-sulfonamide
DMI1EFY HS Investigative
DMI1EFY SN 4-Benzythiopyridine-3-sulfonamide; CHEMBL1164472; 4-benzylsulfanylpyridine-3-sulfonamide; 4-(benzylsulfanyl)-3-pyridinesulfonamide; AC1LICQ3; Oprea1_561801; AJ-333/13050159; MolPort-002-817-660; ZINC481325; BDBM50320515; MCULE-9875266241
DMI1EFY DT Small molecular drug
DMI1EFY PC 901953
DMI1EFY MW 280.4
DMI1EFY FM C12H12N2O2S2
DMI1EFY IC InChI=1S/C12H12N2O2S2/c13-18(15,16)12-8-14-7-6-11(12)17-9-10-4-2-1-3-5-10/h1-8H,9H2,(H2,13,15,16)
DMI1EFY CS C1=CC=C(C=C1)CSC2=C(C=NC=C2)S(=O)(=O)N
DMI1EFY IK FUJBJSOIYVUFSM-UHFFFAOYSA-N
DMI1EFY IU 4-benzylsulfanylpyridine-3-sulfonamide
DMI1EFY DE Discovery agent
DMDF3KJ ID DMDF3KJ
DMDF3KJ DN 4beta,15-epoxy-miller-9E-enolide
DMDF3KJ HS Investigative
DMDF3KJ SN CHEMBL364742; (4R,5Z,10R,11R)-2,3,3abeta,4,7,8,9,10,11,11aalpha-Decahydro-2-oxo-3-methylene-11-hydroxy-4-(methacryloyloxy)spiro[cyclodeca[b]furan-10,2'-oxirane]-6-carbaldehyde
DMDF3KJ DT Small molecular drug
DMDF3KJ PC 44398301
DMDF3KJ MW 362.4
DMDF3KJ FM C19H22O7
DMDF3KJ IC InChI=1S/C19H22O7/c1-10(2)17(22)25-13-7-12(8-20)5-4-6-19(9-24-19)16(21)15-14(13)11(3)18(23)26-15/h7-8,13-16,21H,1,3-6,9H2,2H3/b12-7+/t13-,14-,15+,16-,19-/m1/s1
DMDF3KJ CS CC(=C)C(=O)O[C@@H]1/C=C(\\CCC[C@@]2(CO2)[C@@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)/C=O
DMDF3KJ IK OGCMEEKAZKEDQP-USTFYIHISA-N
DMDF3KJ IU [(3aR,4R,5E,10R,11R,11aS)-6-formyl-11-hydroxy-3-methylidene-2-oxospiro[4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-10,2'-oxirane]-4-yl] 2-methylprop-2-enoate
DMDF3KJ DE Discovery agent
DMZ01SV ID DMZ01SV
DMZ01SV DN 4beta,15-epoxy-miller-9Z-enolide
DMZ01SV HS Investigative
DMZ01SV SN CHEMBL205620
DMZ01SV DT Small molecular drug
DMZ01SV PC 44409577
DMZ01SV MW 362.4
DMZ01SV FM C19H22O7
DMZ01SV IC InChI=1S/C19H22O7/c1-10(2)17(22)25-13-7-12(8-20)5-4-6-19(9-24-19)16(21)15-14(13)11(3)18(23)26-15/h7-8,13-16,21H,1,3-6,9H2,2H3/b12-7-/t13-,14-,15+,16-,19-/m1/s1
DMZ01SV CS CC(=C)C(=O)O[C@@H]1/C=C(/CCC[C@@]2(CO2)[C@@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)\\C=O
DMZ01SV IK OGCMEEKAZKEDQP-UPZPYLOFSA-N
DMZ01SV IU [(3aR,4R,5Z,10R,11R,11aS)-6-formyl-11-hydroxy-3-methylidene-2-oxospiro[4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-10,2'-oxirane]-4-yl] 2-methylprop-2-enoate
DMZ01SV DE Discovery agent
DM3B2TG ID DM3B2TG
DM3B2TG DN 4-Biphenyl-2-ylethynyl-2-methyl-thiazole
DM3B2TG HS Investigative
DM3B2TG SN CHEMBL183608; 4-Biphenyl-2-ylethynyl-2-methyl-thiazole
DM3B2TG DT Small molecular drug
DM3B2TG PC 44393041
DM3B2TG MW 275.4
DM3B2TG FM C18H13NS
DM3B2TG IC InChI=1S/C18H13NS/c1-14-19-17(13-20-14)12-11-16-9-5-6-10-18(16)15-7-3-2-4-8-15/h2-10,13H,1H3
DM3B2TG CS CC1=NC(=CS1)C#CC2=CC=CC=C2C3=CC=CC=C3
DM3B2TG IK BXIUXCNGUNCOFW-UHFFFAOYSA-N
DM3B2TG IU 2-methyl-4-[2-(2-phenylphenyl)ethynyl]-1,3-thiazole
DM3B2TG DE Discovery agent
DMYUL9J ID DMYUL9J
DMYUL9J DN 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline
DMYUL9J HS Investigative
DMYUL9J SN CHEMBL250924; 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline; BDBM50222419
DMYUL9J DT Small molecular drug
DMYUL9J PC 44442180
DMYUL9J MW 366.4
DMYUL9J FM C24H18N2O2
DMYUL9J IC InChI=1S/C24H18N2O2/c1-27-23-14-20-21(25-16-26-22(20)15-24(23)28-2)13-12-18-10-6-7-11-19(18)17-8-4-3-5-9-17/h3-11,14-16H,1-2H3
DMYUL9J CS COC1=C(C=C2C(=C1)C(=NC=N2)C#CC3=CC=CC=C3C4=CC=CC=C4)OC
DMYUL9J IK ZUBUFJOEYHKFCQ-UHFFFAOYSA-N
DMYUL9J IU 6,7-dimethoxy-4-[2-(2-phenylphenyl)ethynyl]quinazoline
DMYUL9J DE Discovery agent
DML6PTX ID DML6PTX
DML6PTX DN 4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole
DML6PTX HS Investigative
DML6PTX SN CHEMBL332257; SCHEMBL4817122
DML6PTX DT Small molecular drug
DML6PTX PC 10109974
DML6PTX MW 374.6
DML6PTX FM C26H34N2
DML6PTX IC InChI=1S/C26H34N2/c1-3-5-8-14-24(15-9-6-4-2)26-27-20-25(28-26)23-18-16-22(17-19-23)21-12-10-7-11-13-21/h7,10-13,16-20,24H,3-6,8-9,14-15H2,1-2H3,(H,27,28)
DML6PTX CS CCCCCC(CCCCC)C1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DML6PTX IK FAJKZAIMTCYING-UHFFFAOYSA-N
DML6PTX IU 5-(4-phenylphenyl)-2-undecan-6-yl-1H-imidazole
DML6PTX DE Discovery agent
DM2I13S ID DM2I13S
DM2I13S DN 4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole
DM2I13S HS Investigative
DM2I13S SN CHEMBL118682; SCHEMBL4811439
DM2I13S DT Small molecular drug
DM2I13S PC 9923013
DM2I13S MW 318.5
DM2I13S FM C22H26N2
DM2I13S IC InChI=1S/C22H26N2/c1-3-8-20(9-4-2)22-23-16-21(24-22)19-14-12-18(13-15-19)17-10-6-5-7-11-17/h5-7,10-16,20H,3-4,8-9H2,1-2H3,(H,23,24)
DM2I13S CS CCCC(CCC)C1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DM2I13S IK VAJCFLBVVHOAAW-UHFFFAOYSA-N
DM2I13S IU 2-heptan-4-yl-5-(4-phenylphenyl)-1H-imidazole
DM2I13S DE Discovery agent
DMLSUXD ID DMLSUXD
DMLSUXD DN 4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole
DMLSUXD HS Investigative
DMLSUXD SN CHEMBL334104; SCHEMBL4821982
DMLSUXD DT Small molecular drug
DMLSUXD PC 9966703
DMLSUXD MW 316.4
DMLSUXD FM C22H24N2
DMLSUXD IC InChI=1S/C22H24N2/c1-3-7-17(8-4-1)15-22-23-16-21(24-22)20-13-11-19(12-14-20)18-9-5-2-6-10-18/h2,5-6,9-14,16-17H,1,3-4,7-8,15H2,(H,23,24)
DMLSUXD CS C1CCC(CC1)CC2=NC=C(N2)C3=CC=C(C=C3)C4=CC=CC=C4
DMLSUXD IK LAHDQEJNOQBNSA-UHFFFAOYSA-N
DMLSUXD IU 2-(cyclohexylmethyl)-5-(4-phenylphenyl)-1H-imidazole
DMLSUXD DE Discovery agent
DMPIH4L ID DMPIH4L
DMPIH4L DN 4-Biphenyl-4-yl-2-hexyl-1H-imidazole
DMPIH4L HS Investigative
DMPIH4L SN CHEMBL118603; SCHEMBL4814536
DMPIH4L DT Small molecular drug
DMPIH4L PC 9922499
DMPIH4L MW 304.4
DMPIH4L FM C21H24N2
DMPIH4L IC InChI=1S/C21H24N2/c1-2-3-4-8-11-21-22-16-20(23-21)19-14-12-18(13-15-19)17-9-6-5-7-10-17/h5-7,9-10,12-16H,2-4,8,11H2,1H3,(H,22,23)
DMPIH4L CS CCCCCCC1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DMPIH4L IK LLLKBKRUIUYVOU-UHFFFAOYSA-N
DMPIH4L IU 2-hexyl-5-(4-phenylphenyl)-1H-imidazole
DMPIH4L DE Discovery agent
DMNLC2Y ID DMNLC2Y
DMNLC2Y DN 4-Biphenyl-4-yl-2-methyl-1H-imidazole
DMNLC2Y HS Investigative
DMNLC2Y SN CHEMBL330800; SCHEMBL3669956
DMNLC2Y DT Small molecular drug
DMNLC2Y PC 44344607
DMNLC2Y MW 234.29
DMNLC2Y FM C16H14N2
DMNLC2Y IC InChI=1S/C16H14N2/c1-12-17-11-16(18-12)15-9-7-14(8-10-15)13-5-3-2-4-6-13/h2-11H,1H3,(H,17,18)
DMNLC2Y CS CC1=NC=C(N1)C2=CC=C(C=C2)C3=CC=CC=C3
DMNLC2Y IK MBBDOQNKURHTFH-UHFFFAOYSA-N
DMNLC2Y IU 2-methyl-5-(4-phenylphenyl)-1H-imidazole
DMNLC2Y DE Discovery agent
DMCQYKO ID DMCQYKO
DMCQYKO DN 4-Biphenyl-4-ylethynyl-2-methyl-thiazole
DMCQYKO HS Investigative
DMCQYKO SN CHEMBL185078; 4-Biphenyl-4-ylethynyl-2-methyl-thiazole
DMCQYKO DT Small molecular drug
DMCQYKO PC 44392959
DMCQYKO MW 275.4
DMCQYKO FM C18H13NS
DMCQYKO IC InChI=1S/C18H13NS/c1-14-19-18(13-20-14)12-9-15-7-10-17(11-8-15)16-5-3-2-4-6-16/h2-8,10-11,13H,1H3
DMCQYKO CS CC1=NC(=CS1)C#CC2=CC=C(C=C2)C3=CC=CC=C3
DMCQYKO IK DGRLZFWNJWSHOX-UHFFFAOYSA-N
DMCQYKO IU 2-methyl-4-[2-(4-phenylphenyl)ethynyl]-1,3-thiazole
DMCQYKO DE Discovery agent
DMS0JVE ID DMS0JVE
DMS0JVE DN 4BP-TQS
DMS0JVE HS Investigative
DMS0JVE SN 360791-49-7; 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide; AC1MEMT7; ChemDiv1_000271; Cambridge id 5647991; Oprea1_528880; ARONIS25331; GTPL3962; SCHEMBL17458811; HMS587M07; SYN5056; MolPort-002-160-471; STL289206; AKOS003520670; AKOS022133488; MCULE-3388310837; 4BP-TQS, > KS-0000477C; ST042158; AS-16422; BB0293824; KB-268939; AB00091637-01; SR-01000388448; SR-01000388448-1; 4-(4-bromophenyl)-3H,3aH,4H,5H,9bH-cyclopenta[c]quinoline-8-sulfonamide
DMS0JVE DT Small molecular drug
DMS0JVE PC 2857838
DMS0JVE MW 405.3
DMS0JVE FM C18H17BrN2O2S
DMS0JVE IC InChI=1S/C18H17BrN2O2S/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(24(20,22)23)8-9-17(16)21-18/h1-2,4-10,14-15,18,21H,3H2,(H2,20,22,23)
DMS0JVE CS C1C=CC2C1C(NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)Br
DMS0JVE IK YNCXHXYZTLIZTO-UHFFFAOYSA-N
DMS0JVE IU 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide
DMS0JVE DE Discovery agent
DM81D90 ID DM81D90
DM81D90 DN 4-bromo-1H-indazole
DM81D90 HS Investigative
DM81D90 SN 4-bromo-1H-indazole; 186407-74-9; 4-Bromoindazole; 1H-Indazole, 4-bromo-; 4-BROMO (1H)INDAZOLE; 4-Bromo(1H)indazole; CHEMBL246393; 4-bromo-indazole; bromo-1h-indazole; PubChem7834; 4-bromo-2H-indazole; ACMC-1BZDS; 4-bromanyl-1H-indazole; KSC173Q8P; 4-BROMO-7AH-INDAZOLE; SCHEMBL155255; 4-Bromo-1H-indazole, 95%; IND084; AC1Q24I6; Jsp003814; 4-bromo-1h-indazole, 97+%; SCHEMBL16799950; CTK0H3887; HID1021; DTXSID30625169; KJIODOACRIRBPB-UHFFFAOYSA-N; MolPort-022-450-748; MolPort-000-002-423; BCP00013; ACN-S003168; SBB054645; BDBM50209241
DM81D90 DT Small molecular drug
DM81D90 PC 22352548
DM81D90 MW 197.03
DM81D90 FM C7H5BrN2
DM81D90 IC InChI=1S/C7H5BrN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
DM81D90 CS C1=CC2=C(C=NN2)C(=C1)Br
DM81D90 IK KJIODOACRIRBPB-UHFFFAOYSA-N
DM81D90 IU 4-bromo-1H-indazole
DM81D90 CA CAS 186407-74-9
DM81D90 DE Discovery agent
DMMVASI ID DMMVASI
DMMVASI DN 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one
DMMVASI HS Investigative
DMMVASI SN CHEMBL78322; 331684-13-0; 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one; CTK1B8690; DTXSID70440555; BDBM50097370; AKOS030562752; 1-(imidazol-1-ylmethyl)-4-bromo-9h-9-xanthenone; 1-(1H-Imidazole-1-ylmethyl)-4-bromo-9H-xanthene-9-one; 9H-Xanthen-9-one, 4-bromo-1-(1H-imidazol-1-ylmethyl)-
DMMVASI DT Small molecular drug
DMMVASI PC 10473365
DMMVASI MW 355.2
DMMVASI FM C17H11BrN2O2
DMMVASI IC InChI=1S/C17H11BrN2O2/c18-13-6-5-11(9-20-8-7-19-10-20)15-16(21)12-3-1-2-4-14(12)22-17(13)15/h1-8,10H,9H2
DMMVASI CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)Br)CN4C=CN=C4
DMMVASI IK FSWPWGQUEZXZFV-UHFFFAOYSA-N
DMMVASI IU 4-bromo-1-(imidazol-1-ylmethyl)xanthen-9-one
DMMVASI CA CAS 331684-13-0
DMMVASI DE Discovery agent
DMPSRAC ID DMPSRAC
DMPSRAC DN 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMPSRAC HS Investigative
DMPSRAC SN 4-bromo-2-(4-hydroxyphenyl)quinolin-6-ol
DMPSRAC PC 135454802
DMPSRAC MW 316.15
DMPSRAC FM C15H10BrNO2
DMPSRAC IC InChI=1S/C15H10BrNO2/c16-13-8-15(9-1-3-10(18)4-2-9)17-14-6-5-11(19)7-12(13)14/h1-8,18-19H
DMPSRAC CS C1=CC(=CC=C1C2=NC3=C(C=C(C=C3)O)C(=C2)Br)O
DMPSRAC IK XRUZUCBHVAMRMC-UHFFFAOYSA-N
DMPSRAC IU 4-bromo-2-(4-hydroxyphenyl)quinolin-6-ol
DMPSRAC DE Discovery agent
DMY8TLO ID DMY8TLO
DMY8TLO DN 4-Bromo-2,6-diisopropyl-phenol
DMY8TLO HS Investigative
DMY8TLO SN 4-Bromo-2,6-diisopropyl-phenol; 4-BROMO-2,6-DIISOPROPYLPHENOL; CHEMBL54497; 2432-03-3; SCHEMBL3640323; 2,6-Diisopropyl-4-bromophenol; CTK5I6265; 4-bromo-2,6-di-isopropylphenol; MolPort-002-462-054; QNJVELOLCDKQBN-UHFFFAOYSA-N; ZINC13779577; BDBM50064417; AKOS028112327; 4-bromo-2,6-bis(propan-2-yl)phenol; AS-3289; Phenol, 4-bromo-2,6-bis(1-methylethyl)-
DMY8TLO DT Small molecular drug
DMY8TLO PC 10422572
DMY8TLO MW 257.17
DMY8TLO FM C12H17BrO
DMY8TLO IC InChI=1S/C12H17BrO/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DMY8TLO CS CC(C)C1=CC(=CC(=C1O)C(C)C)Br
DMY8TLO IK QNJVELOLCDKQBN-UHFFFAOYSA-N
DMY8TLO IU 4-bromo-2,6-di(propan-2-yl)phenol
DMY8TLO DE Discovery agent
DMK2PBJ ID DMK2PBJ
DMK2PBJ DN 4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone
DMK2PBJ HS Investigative
DMK2PBJ SN CHEMBL209047; BDBM50191596; 4''-bromo-3-(imidazolylmethyl)-7-methoxyflavone
DMK2PBJ DT Small molecular drug
DMK2PBJ PC 11847170
DMK2PBJ MW 411.2
DMK2PBJ FM C20H15BrN2O3
DMK2PBJ IC InChI=1S/C20H15BrN2O3/c1-25-15-6-7-16-18(10-15)26-20(13-2-4-14(21)5-3-13)17(19(16)24)11-23-9-8-22-12-23/h2-10,12H,11H2,1H3
DMK2PBJ CS COC1=CC2=C(C=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)Br)CN4C=CN=C4
DMK2PBJ IK DWMSDWDWUCFTQZ-UHFFFAOYSA-N
DMK2PBJ IU 2-(4-bromophenyl)-3-(imidazol-1-ylmethyl)-7-methoxychromen-4-one
DMK2PBJ DE Discovery agent
DM2V3S8 ID DM2V3S8
DM2V3S8 DN 4'-bromo-3-(imidazolylmethyl)flavone
DM2V3S8 HS Investigative
DM2V3S8 SN CHEMBL377766; BDBM50191597; 4''-bromo-3-(imidazolylmethyl)flavone
DM2V3S8 DT Small molecular drug
DM2V3S8 PC 11847318
DM2V3S8 MW 381.2
DM2V3S8 FM C19H13BrN2O2
DM2V3S8 IC InChI=1S/C19H13BrN2O2/c20-14-7-5-13(6-8-14)19-16(11-22-10-9-21-12-22)18(23)15-3-1-2-4-17(15)24-19/h1-10,12H,11H2
DM2V3S8 CS C1=CC=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)Br)CN4C=CN=C4
DM2V3S8 IK VPZRWXUJDQPWSY-UHFFFAOYSA-N
DM2V3S8 IU 2-(4-bromophenyl)-3-(imidazol-1-ylmethyl)chromen-4-one
DM2V3S8 DE Discovery agent
DMYOCFX ID DMYOCFX
DMYOCFX DN 4-Bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX HS Investigative
DMYOCFX SN 2(1H)-Quinolinone, 4-bromo-3-hydroxy-; CHEMBL146520; SCHEMBL15690621; BSYFERFWIZPSKL-UHFFFAOYSA-N; BDBM247011; 4-Bromo-3-hydroxyquinolin-2(1H)-one; 4-Bromo-3-hydroxyquinoline-2(1H)-one; 176170-14-2; US9701638, 2
DMYOCFX DT Small molecular drug
DMYOCFX PC 44364603
DMYOCFX MW 240.05
DMYOCFX FM C9H6BrNO2
DMYOCFX IC InChI=1S/C9H6BrNO2/c10-7-5-3-1-2-4-6(5)11-9(13)8(7)12/h1-4,12H,(H,11,13)
DMYOCFX CS C1=CC=C2C(=C1)C(=C(C(=O)N2)O)Br
DMYOCFX IK BSYFERFWIZPSKL-UHFFFAOYSA-N
DMYOCFX IU 4-bromo-3-hydroxy-1H-quinolin-2-one
DMYOCFX DE Discovery agent
DM2QJ5A ID DM2QJ5A
DM2QJ5A DN 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A HS Investigative
DM2QJ5A SN CHEMBL147398
DM2QJ5A DT Small molecular drug
DM2QJ5A PC 44364764
DM2QJ5A MW 308.94
DM2QJ5A FM C9H4BrCl2NO2
DM2QJ5A IC InChI=1S/C9H4BrCl2NO2/c10-7-6-4(12)1-3(11)2-5(6)13-9(15)8(7)14/h1-2,14H,(H,13,15)
DM2QJ5A CS C1=C(C=C(C2=C1NC(=O)C(=C2Br)O)Cl)Cl
DM2QJ5A IK HDPAPMXBVVKNAQ-UHFFFAOYSA-N
DM2QJ5A IU 4-bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one
DM2QJ5A DE Discovery agent
DMH6OPI ID DMH6OPI
DMH6OPI DN 4-Bromo-6-nitro-2-piperazin-1-yl-quinoline
DMH6OPI HS Investigative
DMH6OPI SN 4-Bromo-6-nitroquipazine; 143954-73-8; CHEMBL167825; 4-Bromo-6-nitro-2-piperazin-1-yl-quinoline; Quinoline, 4-bromo-6-nitro-2-(1-piperazinyl)-; ACMC-20n3fo; SCHEMBL6364738; AC1L318Y; CTK0I3188; DTXSID50162581; NRCNLRMWSMFETI-UHFFFAOYSA-N; BDBM50110574
DMH6OPI DT Small molecular drug
DMH6OPI PC 132590
DMH6OPI MW 337.17
DMH6OPI FM C13H13BrN4O2
DMH6OPI IC InChI=1S/C13H13BrN4O2/c14-11-8-13(17-5-3-15-4-6-17)16-12-2-1-9(18(19)20)7-10(11)12/h1-2,7-8,15H,3-6H2
DMH6OPI CS C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)Br
DMH6OPI IK NRCNLRMWSMFETI-UHFFFAOYSA-N
DMH6OPI IU 4-bromo-6-nitro-2-piperazin-1-ylquinoline
DMH6OPI CA CAS 143954-73-8
DMH6OPI DE Discovery agent
DMJFY9Z ID DMJFY9Z
DMJFY9Z DN 4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide
DMJFY9Z HS Investigative
DMJFY9Z SN CHEMBL61836; 4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide; 4-bromo-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; AC1LKC2E; Oprea1_799831; SCHEMBL17107249; MolPort-001-934-338; ZINC5775827; BDBM50101783; AKOS000591432; MCULE-9538176345; BAS 00470402; N-(4-Phenyl-2-thiazolyl)-4-bromobenzamide; ST50002847
DMJFY9Z DT Small molecular drug
DMJFY9Z PC 988802
DMJFY9Z MW 359.2
DMJFY9Z FM C16H11BrN2OS
DMJFY9Z IC InChI=1S/C16H11BrN2OS/c17-13-8-6-12(7-9-13)15(20)19-16-18-14(10-21-16)11-4-2-1-3-5-11/h1-10H,(H,18,19,20)
DMJFY9Z CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)Br
DMJFY9Z IK PJMUFKFWQNWHCY-UHFFFAOYSA-N
DMJFY9Z IU 4-bromo-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMJFY9Z DE Discovery agent
DMF38M5 ID DMF38M5
DMF38M5 DN 4-Bromo-N-hydroxy-benzamide
DMF38M5 HS Investigative
DMF38M5 SN 4-Bromo-N-hydroxybenzamide; 4-Bromo-N-hydroxy-benzamide; 1836-27-7; CHEMBL351337; 4-bromobenzenecarbohydroxamic acid; p-Bromobenzohydroxamic acid; AC1LCOKZ; N-Hydroxy-4-bromobenzamide; p-bromophenylhydroxamic acid; 4-Bromo-N-hydroxybenzamide #; SCHEMBL8575405; Benzamide, 4-bromo-N-hydroxy-; CTK0E2598; DTXSID20345349; VESPFSJNQMGUCQ-UHFFFAOYSA-N; MolPort-002-985-506; ZINC5249551; STK249669; BDBM50015106; AKOS000175576; MCULE-4510290140; DA-16649; SC-53612; KB-290158; ST51029575; FT-0708429
DMF38M5 DT Small molecular drug
DMF38M5 PC 603910
DMF38M5 MW 216.03
DMF38M5 FM C7H6BrNO2
DMF38M5 IC InChI=1S/C7H6BrNO2/c8-6-3-1-5(2-4-6)7(10)9-11/h1-4,11H,(H,9,10)
DMF38M5 CS C1=CC(=CC=C1C(=O)NO)Br
DMF38M5 IK VESPFSJNQMGUCQ-UHFFFAOYSA-N
DMF38M5 IU 4-bromo-N-hydroxybenzamide
DMF38M5 CA CAS 1836-27-7
DMF38M5 DE Discovery agent
DM2YN37 ID DM2YN37
DM2YN37 DN 4-bromophenylboronic acid
DM2YN37 HS Investigative
DM2YN37 SN 4-Bromophenylboronic acid; 5467-74-3; (4-Bromophenyl)boronic acid; 4-Bromobenzeneboronic acid; 4-Bromophenylboric acid; p-Bromophenylboronic acid; p-Bromophenylboric acid; p-Bromobenzeneboronic acid; Boronic acid, (4-bromophenyl)-; Benzeneboronic acid, p-bromo-; (p-Bromophenyl)boronic acid; 4-bromo phenyl boronic acid; 4-bromophenyl boronic acid; 4-bromo-phenylboronic acid; Dihydroxy-4-bromophenylborane; EINECS 226-779-9; NSC 25407; 4-bromo phenylboronic acid; BRN 2936347; CHEMBL20866; AI3-32763; Boronic acid,B-(4-romophenyl)
DM2YN37 DT Small molecular drug
DM2YN37 PC 79599
DM2YN37 MW 200.83
DM2YN37 FM C6H6BBrO2
DM2YN37 IC InChI=1S/C6H6BBrO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4,9-10H
DM2YN37 CS B(C1=CC=C(C=C1)Br)(O)O
DM2YN37 IK QBLFZIBJXUQVRF-UHFFFAOYSA-N
DM2YN37 IU (4-bromophenyl)boronic acid
DM2YN37 CA CAS 5467-74-3
DM2YN37 DE Discovery agent
DMMGK2B ID DMMGK2B
DMMGK2B DN 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide
DMMGK2B HS Investigative
DMMGK2B SN CHEMBL371715; 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide
DMMGK2B DT Small molecular drug
DMMGK2B PC 44404479
DMMGK2B MW 266.29
DMMGK2B FM C13H18N2O4
DMMGK2B IC InChI=1S/C13H18N2O4/c1-2-3-8-19-11-6-4-10(5-7-11)13(17)14-9-12(16)15-18/h4-7,18H,2-3,8-9H2,1H3,(H,14,17)(H,15,16)
DMMGK2B CS CCCCOC1=CC=C(C=C1)C(=O)NCC(=O)NO
DMMGK2B IK BFVCLRFRELSADQ-UHFFFAOYSA-N
DMMGK2B IU 4-butoxy-N-[2-(hydroxyamino)-2-oxoethyl]benzamide
DMMGK2B DE Discovery agent
DMFCB7L ID DMFCB7L
DMFCB7L DN 4-Butoxy-N-hydroxy-N-methyl-benzamide
DMFCB7L HS Investigative
DMFCB7L SN CHEMBL177392; 4-Butoxy-N-hydroxy-N-methyl-benzamide; Benzamide, 4-butoxy-N-hydroxy-N-methyl-; BDBM50015090; 4-Butoxy-N-methylbenzohydroxamic acid
DMFCB7L DT Small molecular drug
DMFCB7L PC 44387015
DMFCB7L MW 223.27
DMFCB7L FM C12H17NO3
DMFCB7L IC InChI=1S/C12H17NO3/c1-3-4-9-16-11-7-5-10(6-8-11)12(14)13(2)15/h5-8,15H,3-4,9H2,1-2H3
DMFCB7L CS CCCCOC1=CC=C(C=C1)C(=O)N(C)O
DMFCB7L IK OFVDFLZBUJEGOQ-UHFFFAOYSA-N
DMFCB7L IU 4-butoxy-N-hydroxy-N-methylbenzamide
DMFCB7L DE Discovery agent
DM6ADJM ID DM6ADJM
DM6ADJM DN 4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine
DM6ADJM HS Investigative
DM6ADJM SN CHEMBL460309; 4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine
DM6ADJM DT Small molecular drug
DM6ADJM PC 44563684
DM6ADJM MW 317.5
DM6ADJM FM C21H35NO
DM6ADJM IC InChI=1S/C21H35NO/c1-2-3-9-21-13-16-22(17-14-21)15-8-19-23-18-7-12-20-10-5-4-6-11-20/h4-6,10-11,21H,2-3,7-9,12-19H2,1H3
DM6ADJM CS CCCCC1CCN(CC1)CCCOCCCC2=CC=CC=C2
DM6ADJM IK OFZZAFXTRYWAHX-UHFFFAOYSA-N
DM6ADJM IU 4-butyl-1-[3-(3-phenylpropoxy)propyl]piperidine
DM6ADJM DE Discovery agent
DMZHGP6 ID DMZHGP6
DMZHGP6 DN 4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide
DMZHGP6 HS Investigative
DMZHGP6 SN CHEMBL259601
DMZHGP6 DT Small molecular drug
DMZHGP6 PC 44450356
DMZHGP6 MW 319.4
DMZHGP6 FM C21H21NO2
DMZHGP6 IC InChI=1S/C21H21NO2/c1-2-3-5-15-8-10-17(11-9-15)21(24)22-20-7-4-6-16-12-13-18(23)14-19(16)20/h4,6-14,23H,2-3,5H2,1H3,(H,22,24)
DMZHGP6 CS CCCCC1=CC=C(C=C1)C(=O)NC2=CC=CC3=C2C=C(C=C3)O
DMZHGP6 IK KSWNGABTIMONPN-UHFFFAOYSA-N
DMZHGP6 IU 4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide
DMZHGP6 DE Discovery agent
DMHLQSE ID DMHLQSE
DMHLQSE DN 4-butyl-N-(isoquinolin-5-yl)benzamide
DMHLQSE HS Investigative
DMHLQSE SN CHEMBL407762
DMHLQSE DT Small molecular drug
DMHLQSE PC 44450355
DMHLQSE MW 304.4
DMHLQSE FM C20H20N2O
DMHLQSE IC InChI=1S/C20H20N2O/c1-2-3-5-15-8-10-16(11-9-15)20(23)22-19-7-4-6-17-14-21-13-12-18(17)19/h4,6-14H,2-3,5H2,1H3,(H,22,23)
DMHLQSE CS CCCCC1=CC=C(C=C1)C(=O)NC2=CC=CC3=C2C=CN=C3
DMHLQSE IK FBFHYVLRXNNMSE-UHFFFAOYSA-N
DMHLQSE IU 4-butyl-N-isoquinolin-5-ylbenzamide
DMHLQSE DE Discovery agent
DMGW9XJ ID DMGW9XJ
DMGW9XJ DN 4-butyl-N-(pyridin-3-yl)benzamide
DMGW9XJ HS Investigative
DMGW9XJ SN CHEMBL259396; 4-butyl-N-pyridin-3-ylbenzamide; 4-butyl-N-(pyridin-3-yl)benzamide; AC1N7X0I; Oprea1_505737; MolPort-003-720-572; ZINC3899411; STK493059; BDBM50376254; AKOS001583267; MCULE-4107696507; (4-butylphenyl)-N-(3-pyridyl)carboxamide; ST50859128; SR-01000396349
DMGW9XJ DT Small molecular drug
DMGW9XJ PC 4286311
DMGW9XJ MW 254.33
DMGW9XJ FM C16H18N2O
DMGW9XJ IC InChI=1S/C16H18N2O/c1-2-3-5-13-7-9-14(10-8-13)16(19)18-15-6-4-11-17-12-15/h4,6-12H,2-3,5H2,1H3,(H,18,19)
DMGW9XJ CS CCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMGW9XJ IK KDHOWTVYQKITMO-UHFFFAOYSA-N
DMGW9XJ IU 4-butyl-N-pyridin-3-ylbenzamide
DMGW9XJ DE Discovery agent
DMRMGWF ID DMRMGWF
DMRMGWF DN 4-butyl-N-(quinolin-3-yl)benzamide
DMRMGWF HS Investigative
DMRMGWF SN CHEMBL259385; 4-butyl-N-(quinolin-3-yl)benzamide; AC1LXX0M; Oprea1_455948; SCHEMBL846651; 4-butyl-N-quinolin-3-ylbenzamide; MolPort-002-564-310; ZINC2228626; STL329914; BDBM50376281; AKOS022106211; MCULE-9844265532; ST020606; (4-butylphenyl)-N-(3-quinolyl)carboxamide; SR-01000396347
DMRMGWF DT Small molecular drug
DMRMGWF PC 1860395
DMRMGWF MW 304.4
DMRMGWF FM C20H20N2O
DMRMGWF IC InChI=1S/C20H20N2O/c1-2-3-6-15-9-11-16(12-10-15)20(23)22-18-13-17-7-4-5-8-19(17)21-14-18/h4-5,7-14H,2-3,6H2,1H3,(H,22,23)
DMRMGWF CS CCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMRMGWF IK LEGBMUNFZPMJOG-UHFFFAOYSA-N
DMRMGWF IU 4-butyl-N-quinolin-3-ylbenzamide
DMRMGWF DE Discovery agent
DMIMW1E ID DMIMW1E
DMIMW1E DN 4-butyl-N-phenylbenzamide
DMIMW1E HS Investigative
DMIMW1E SN CHEMBL260465; BDBM50376283
DMIMW1E DT Small molecular drug
DMIMW1E PC 44450366
DMIMW1E MW 253.34
DMIMW1E FM C17H19NO
DMIMW1E IC InChI=1S/C17H19NO/c1-2-3-7-14-10-12-15(13-11-14)17(19)18-16-8-5-4-6-9-16/h4-6,8-13H,2-3,7H2,1H3,(H,18,19)
DMIMW1E CS CCCCC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2
DMIMW1E IK PNJHOPPVHVQWPM-UHFFFAOYSA-N
DMIMW1E IU 4-butyl-N-phenylbenzamide
DMIMW1E DE Discovery agent
DMD9FZW ID DMD9FZW
DMD9FZW DN 4-butylphenylboronic acid
DMD9FZW HS Investigative
DMD9FZW SN 4-Butylphenylboronic acid; 145240-28-4; (4-butylphenyl)boronic Acid; 4-n-Butylphenylboronic acid; 4-Butylphenylboronicacid; 4-Butylbenzeneboronic Acid; 4-N-BUTYLBENZENEBORONIC ACID; (4-Butylphenyl)Boranediol; CHEMBL555064; Boronic acid, (4-butylphenyl)-; MFCD02093926; AK-47631; 4-n-Butylphenylboronic acid, 95%; Boronic acid, B-(4-butylphenyl)-; PubChem18523; ACMC-209cue; AC1N2RDA; 4-Butylphenylboranic acid; 4-n-Butylphenylboronicacid; 4-butylphenyl boronic acid; 4-butyl-phenylboronic acid; AC1Q2VE3; 4-butyl phenyl boronic acid
DMD9FZW DT Small molecular drug
DMD9FZW PC 4100860
DMD9FZW MW 178.04
DMD9FZW FM C10H15BO2
DMD9FZW IC InChI=1S/C10H15BO2/c1-2-3-4-9-5-7-10(8-6-9)11(12)13/h5-8,12-13H,2-4H2,1H3
DMD9FZW CS B(C1=CC=C(C=C1)CCCC)(O)O
DMD9FZW IK UGZUUTHZEATQAM-UHFFFAOYSA-N
DMD9FZW IU (4-butylphenyl)boronic acid
DMD9FZW CA CAS 145240-28-4
DMD9FZW DE Discovery agent
DMKU4TR ID DMKU4TR
DMKU4TR DN 4-Butyl-thiazolidin-(2E)-ylideneamine
DMKU4TR HS Investigative
DMKU4TR SN CHEMBL363049; 4-Butyl-thiazolidin-(2E)-ylideneamine; SCHEMBL7090223
DMKU4TR DT Small molecular drug
DMKU4TR PC 9812839
DMKU4TR MW 158.27
DMKU4TR FM C7H14N2S
DMKU4TR IC InChI=1S/C7H14N2S/c1-2-3-4-6-5-10-7(8)9-6/h6H,2-5H2,1H3,(H2,8,9)
DMKU4TR CS CCCCC1CSC(=N1)N
DMKU4TR IK LRIFCAXPRJKRBE-UHFFFAOYSA-N
DMKU4TR IU 4-butyl-4,5-dihydro-1,3-thiazol-2-amine
DMKU4TR DE Discovery agent
DMRY6B4 ID DMRY6B4
DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide
DMRY6B4 HS Investigative
DMRY6B4 SN CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
DMRY6B4 DT Small molecular drug
DMRY6B4 PC 11287488
DMRY6B4 MW 222.24
DMRY6B4 FM C11H14N2O3
DMRY6B4 IC InChI=1S/C11H14N2O3/c1-2-3-10(14)12-9-6-4-8(5-7-9)11(15)13-16/h4-7,16H,2-3H2,1H3,(H,12,14)(H,13,15)
DMRY6B4 CS CCCC(=O)NC1=CC=C(C=C1)C(=O)NO
DMRY6B4 IK WASGGDMUCRMECJ-UHFFFAOYSA-N
DMRY6B4 IU 4-(butanoylamino)-N-hydroxybenzamide
DMRY6B4 CA CAS 656261-22-2
DMRY6B4 DE Discovery agent
DM74GWO ID DM74GWO
DM74GWO DN 4-Carbazol-9-yl-butyric acid
DM74GWO HS Investigative
DM74GWO SN CARBAZOLE BUTANOIC ACID; 4-(9H-CARBAZOL-9-YL)BUTANOIC ACID; CHEMBL185595; CRZ; 90053-09-1; 4-Carbazol-9-yl-butyric acid; 1tow; AC1L9MBO; 4-carbazol-9-ylbutanoic acid; 9H-Carbazole-9-butanoic acid; SCHEMBL4314440; 4-(N-carbazolyl) butyric acid; CTK3I5050; DTXSID50332287; BDBM50152851; AKOS000153937
DM74GWO DT Small molecular drug
DM74GWO PC 448769
DM74GWO MW 253.29
DM74GWO FM C16H15NO2
DM74GWO IC InChI=1S/C16H15NO2/c18-16(19)10-5-11-17-14-8-3-1-6-12(14)13-7-2-4-9-15(13)17/h1-4,6-9H,5,10-11H2,(H,18,19)
DM74GWO CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCC(=O)O
DM74GWO IK HQAKVYGASUTQHH-UHFFFAOYSA-N
DM74GWO IU 4-carbazol-9-ylbutanoic acid
DM74GWO CA CAS 90053-09-1
DM74GWO DE Discovery agent
DMBIQV3 ID DMBIQV3
DMBIQV3 DN 4-Carboxycinnamic Acid
DMBIQV3 HS Investigative
DMBIQV3 PC 697959
DMBIQV3 MW 192.17
DMBIQV3 FM C10H8O4
DMBIQV3 IC InChI=1S/C10H8O4/c11-9(12)6-3-7-1-4-8(5-2-7)10(13)14/h1-6H,(H,11,12)(H,13,14)/b6-3+
DMBIQV3 CS C1=CC(=CC=C1/C=C/C(=O)O)C(=O)O
DMBIQV3 IK HAEJSGLKJYIYTB-ZZXKWVIFSA-N
DMBIQV3 IU 4-[(E)-2-carboxyethenyl]benzoic acid
DMBIQV3 CA CAS 19675-63-9
DMBIQV3 DE Discovery agent
DM8A2QO ID DM8A2QO
DM8A2QO DN 4-Carboxyphenylboronic Acid
DM8A2QO HS Investigative
DM8A2QO SN 62729-39-9; 4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)benzoic acid; Benzoic acid,4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-; SCHEMBL8083423; CTK5B5787; DTXSID00656960; ZX-AT029551; ZINC169807903; AKOS027380718; FCH2811826; AB29398
DM8A2QO DT Small molecular drug
DM8A2QO PC 312183
DM8A2QO MW 165.94
DM8A2QO FM C7H7BO4
DM8A2QO IC InChI=1S/C7H7BO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4,11-12H,(H,9,10)
DM8A2QO CS B(C1=CC=C(C=C1)C(=O)O)(O)O
DM8A2QO IK SIAVMDKGVRXFAX-UHFFFAOYSA-N
DM8A2QO IU 4-boronobenzoic acid
DM8A2QO CA CAS 14047-29-1
DM8A2QO DE Discovery agent
DMMIA36 ID DMMIA36
DMMIA36 DN 4-chloro-1-guanidino-7-isoquinolinesulphonamide
DMMIA36 HS Investigative
DMMIA36 SN 223671-02-1; 1-GUANIDINO-4-CHLORO-7-SULFAMOYL-ISOQUINOLINE; 4-chloro-1-guanidino-7-isoquinolinesulphonamide; 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine; CHEMBL227782; SCHEMBL6437735; CTK4E9305; BDBM16132; DTXSID90586545; FXVHAOFNNRNCRJ-UHFFFAOYSA-N; AKOS015966420; 1-guanidino-7-sulfonamidoisoquinoline 6; ACM223671021; 4-chloro-1-guanidino-7-sulphamoylisoquinoline
DMMIA36 DT Small molecular drug
DMMIA36 PC 16658353
DMMIA36 MW 299.74
DMMIA36 FM C10H10ClN5O2S
DMMIA36 IC InChI=1S/C10H10ClN5O2S/c11-8-4-15-9(16-10(12)13)7-3-5(19(14,17)18)1-2-6(7)8/h1-4H,(H2,14,17,18)(H4,12,13,15,16)
DMMIA36 CS C1=CC2=C(C=C1S(=O)(=O)N)C(=NC=C2Cl)N=C(N)N
DMMIA36 IK FXVHAOFNNRNCRJ-UHFFFAOYSA-N
DMMIA36 IU 2-(4-chloro-7-sulfamoylisoquinolin-1-yl)guanidine
DMMIA36 CA CAS 223671-02-1
DMMIA36 DE Discovery agent
DMHNSXP ID DMHNSXP
DMHNSXP DN 4-chloro-1H-indazole
DMHNSXP HS Investigative
DMHNSXP SN 4-Chloro-1H-indazole; 13096-96-3; 4-CHLOROINDAZOLE; 1H-Indazole, 4-chloro-; 4-Chloro-2H-indazole; NSC694315; 4-CHLORO(1H)INDAZOLE; CHEMBL246533; MFCD00211065; 4-Chloro-1H-indazole, AldrichCPR; 4-chloro-indazole; zlchem 748; NSC 694315; PubChem21945; AC1Q3RSH; ACMC-1BUW0; AC1L95AW; SCHEMBL476854; 4-Chloro-1H-indazole, 97%; 4-CHLORO (1H)INDAZOLE; CTK0H7106; DTXSID40156818; ZLD0205; CQTGQYVQJOJQCM-UHFFFAOYSA-N; MolPort-001-767-756; 4-CHLORO-3-(1H)INDAZOLE; ACT06078; BCP27008; ZINC5543816; KS-00000O0T; CS-M0440; STL556259; SBB054691; QC-206
DMHNSXP DT Small molecular drug
DMHNSXP PC 393037
DMHNSXP MW 152.58
DMHNSXP FM C7H5ClN2
DMHNSXP IC InChI=1S/C7H5ClN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
DMHNSXP CS C1=CC2=C(C=NN2)C(=C1)Cl
DMHNSXP IK CQTGQYVQJOJQCM-UHFFFAOYSA-N
DMHNSXP IU 4-chloro-1H-indazole
DMHNSXP CA CAS 13096-96-3
DMHNSXP DE Discovery agent
DM9HXPR ID DM9HXPR
DM9HXPR DN 4-chloro-1H-indole-2,3-dione
DM9HXPR HS Investigative
DM9HXPR SN 4-Chloroisatin; 6344-05-4; 4-chloro-1H-indole-2,3-dione; 4-chloroindoline-2,3-dione; 4-chloro-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 4-chloro-; 4-Chloroindole-2,3-dione; 4-Chloro-2,3-indolinedione; Indole-2,3-dione, 4-chloro-; HSYFISNDMZKGRS-UHFFFAOYSA-N; 4-chloro isatin; NSC49794; PubChem13911; AC1Q3HWJ; AC1L3VNL; ACMC-2097je; AC1Q3P5R; Isatin-based compound, 29; AC1Q3KG8; KSC492I4L; SCHEMBL282066; CHEMBL376228; KS-00000DIY; HSYFISNDMZKGRS-UHFFFAOYSA-; CTK3J2445; BDBM22809; DTXSID90212852; MolPort-001-797-339
DM9HXPR DT Small molecular drug
DM9HXPR PC 96047
DM9HXPR MW 181.57
DM9HXPR FM C8H4ClNO2
DM9HXPR IC InChI=1S/C8H4ClNO2/c9-4-2-1-3-5-6(4)7(11)8(12)10-5/h1-3H,(H,10,11,12)
DM9HXPR CS C1=CC2=C(C(=C1)Cl)C(=O)C(=O)N2
DM9HXPR IK HSYFISNDMZKGRS-UHFFFAOYSA-N
DM9HXPR IU 4-chloro-1H-indole-2,3-dione
DM9HXPR CA CAS 6344-05-4
DM9HXPR DE Discovery agent
DMKJ18X ID DMKJ18X
DMKJ18X DN 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMKJ18X HS Investigative
DMKJ18X SN 4-chloro-2-(4-hydroxyphenyl)quinolin-6-ol
DMKJ18X PC 135519319
DMKJ18X MW 271.7
DMKJ18X FM C15H10ClNO2
DMKJ18X IC InChI=1S/C15H10ClNO2/c16-13-8-15(9-1-3-10(18)4-2-9)17-14-6-5-11(19)7-12(13)14/h1-8,18-19H
DMKJ18X CS C1=CC(=CC=C1C2=NC3=C(C=C(C=C3)O)C(=C2)Cl)O
DMKJ18X IK MJJDANHWHHWHME-UHFFFAOYSA-N
DMKJ18X IU 4-chloro-2-(4-hydroxyphenyl)quinolin-6-ol
DMKJ18X DE Discovery agent
DM9VN21 ID DM9VN21
DM9VN21 DN 4-Chloro-2,6-diisopropyl-phenol
DM9VN21 HS Investigative
DM9VN21 SN CHEMBL292402; 2,6-diisopropyl-4-chlorophenol; 91561-75-0; 4-chloro-2,6-diisopropylphenol; 4-Chloro-2,6-diisopropyl-phenol; SCHEMBL4714270; ZINC13779576; BDBM50064419; DA-01221
DM9VN21 DT Small molecular drug
DM9VN21 PC 10059055
DM9VN21 MW 212.71
DM9VN21 FM C12H17ClO
DM9VN21 IC InChI=1S/C12H17ClO/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DM9VN21 CS CC(C)C1=CC(=CC(=C1O)C(C)C)Cl
DM9VN21 IK ZRTAKZQCHCQFAB-UHFFFAOYSA-N
DM9VN21 IU 4-chloro-2,6-di(propan-2-yl)phenol
DM9VN21 DE Discovery agent
DMIYVJX ID DMIYVJX
DMIYVJX DN 4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN
DMIYVJX HS Investigative
DMIYVJX SN 3,3-BIS(3-BROMO-4-HYDROXYPHENYL)-7-CHLORO-1H,3H-BENZO[DE]ISOCHROMEN-1-ONE; 4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN; BDBM18753; DB04696; 4-CHLORO-3',3"-DIBROMOPHENOL-1,8-NAPHTHALEIN; 4,4-bis(3-bromo-4-hydroxyphenyl)-10-chloro-3-oxatricyclo[7.3.1.0;{5,13}]trideca-1(12),5(13),6,8,10-pentaen-2-one
DMIYVJX DT Small molecular drug
DMIYVJX PC 5288329
DMIYVJX MW 560.6
DMIYVJX FM C24H13Br2ClO4
DMIYVJX IC InChI=1S/C24H13Br2ClO4/c25-17-10-12(4-8-20(17)28)24(13-5-9-21(29)18(26)11-13)16-3-1-2-14-19(27)7-6-15(22(14)16)23(30)31-24/h1-11,28-29H
DMIYVJX CS C1=CC2=C(C=CC3=C2C(=C1)C(OC3=O)(C4=CC(=C(C=C4)O)Br)C5=CC(=C(C=C5)O)Br)Cl
DMIYVJX IK GFGZCXHXQCQRFP-UHFFFAOYSA-N
DMIYVJX IU 4,4-bis(3-bromo-4-hydroxyphenyl)-10-chloro-3-oxatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-2-one
DMIYVJX DE Discovery agent
DMMALY3 ID DMMALY3
DMMALY3 DN 4-Chloro-3-hydroxy-1H-quinolin-2-one
DMMALY3 HS Investigative
DMMALY3 DE Discovery agent
DMI580M ID DMI580M
DMI580M DN 4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine
DMI580M HS Investigative
DMI580M SN 4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine; 4-chloro-5,7-diphenylpyrrolo[2,3-d]pyrimidine; 287177-10-0; CHEMBL426229; AC1M1GSW; MolPort-000-510-379; ZINC2455203; BDBM50088916; SBB039474; BBL001718; STL115578; AKOS000267629; MCULE-6403159172; ST45174715; H6707; L-3752
DMI580M DT Small molecular drug
DMI580M PC 2049536
DMI580M MW 305.8
DMI580M FM C18H12ClN3
DMI580M IC InChI=1S/C18H12ClN3/c19-17-16-15(13-7-3-1-4-8-13)11-22(18(16)21-12-20-17)14-9-5-2-6-10-14/h1-12H
DMI580M CS C1=CC=C(C=C1)C2=CN(C3=C2C(=NC=N3)Cl)C4=CC=CC=C4
DMI580M IK INLZGZMAUAHURP-UHFFFAOYSA-N
DMI580M IU 4-chloro-5,7-diphenylpyrrolo[2,3-d]pyrimidine
DMI580M DE Discovery agent
DM04OFE ID DM04OFE
DM04OFE DN 4-Chloro-6-nitro-2-piperazin-1-yl-quinoline
DM04OFE HS Investigative
DM04OFE SN 4-CHLORO-6-NITRO-2-(PIPERAZIN-1-YL)QUINOLINE; 437708-76-4; CHEMBL423269; 4-chloro-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6365676; CTK4I7722; DTXSID00438329; ZINC13439731; BDBM50110578; AKOS027381012; 2-Piperazino-4-chloro-6-nitroquinoline; ACM437708764; KB-334255
DM04OFE DT Small molecular drug
DM04OFE PC 10334554
DM04OFE MW 292.72
DM04OFE FM C13H13ClN4O2
DM04OFE IC InChI=1S/C13H13ClN4O2/c14-11-8-13(17-5-3-15-4-6-17)16-12-2-1-9(18(19)20)7-10(11)12/h1-2,7-8,15H,3-6H2
DM04OFE CS C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)Cl
DM04OFE IK HADJVDJPSUSVPZ-UHFFFAOYSA-N
DM04OFE IU 4-chloro-6-nitro-2-piperazin-1-ylquinoline
DM04OFE CA CAS 437708-76-4
DM04OFE DE Discovery agent
DM16P3N ID DM16P3N
DM16P3N DN 4-chloro-7-methyl-1H-indole-2,3-dione
DM16P3N HS Investigative
DM16P3N SN 61258-72-8; 4-Chloro-7-methyl isatin; 4-Chloro-7-methyl-1H-indole-2,3-dione; 4-chloro-7-methylisatin; 4-chloro-7-methylindoline-2,3-dione; 4-chloro-7-methyl-2,3-dihydro-1H-indole-2,3-dione; 1H-Indole-2,3-dione,4-chloro-7-methyl-; 1H-Indole-2,3-dione, 4-chloro-7-methyl-; AC1LXYLJ; AC1Q2GPB; Isatin-based compound, 55; Cambridge id 5226020; MLS002473344; SCHEMBL950949; CHEMBL373715; CTK5B2947; BDBM22835; DTXSID20365244; MolPort-002-111-842; MWCJCUFHPFXQLS-UHFFFAOYSA-N; HMS2228G20; ZINC2169011; ALBB-024400; SBB066723; BBL005527
DM16P3N DT Small molecular drug
DM16P3N PC 1810509
DM16P3N MW 195.6
DM16P3N FM C9H6ClNO2
DM16P3N IC InChI=1S/C9H6ClNO2/c1-4-2-3-5(10)6-7(4)11-9(13)8(6)12/h2-3H,1H3,(H,11,12,13)
DM16P3N CS CC1=C2C(=C(C=C1)Cl)C(=O)C(=O)N2
DM16P3N IK MWCJCUFHPFXQLS-UHFFFAOYSA-N
DM16P3N IU 4-chloro-7-methyl-1H-indole-2,3-dione
DM16P3N CA CAS 61258-72-8
DM16P3N DE Discovery agent
DM9SVEB ID DM9SVEB
DM9SVEB DN 4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine
DM9SVEB HS Investigative
DM9SVEB SN CHEMBL97778; 4-chloro-7-methyl-2-phenyl-1,8-naphthyridine; 4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine; SCHEMBL1536334; BDBM50090689; ZINC13579501
DM9SVEB DT Small molecular drug
DM9SVEB PC 12431921
DM9SVEB MW 254.71
DM9SVEB FM C15H11ClN2
DM9SVEB IC InChI=1S/C15H11ClN2/c1-10-7-8-12-13(16)9-14(18-15(12)17-10)11-5-3-2-4-6-11/h2-9H,1H3
DM9SVEB CS CC1=NC2=C(C=C1)C(=CC(=N2)C3=CC=CC=C3)Cl
DM9SVEB IK CMSOCFLZPHQUAD-UHFFFAOYSA-N
DM9SVEB IU 4-chloro-7-methyl-2-phenyl-1,8-naphthyridine
DM9SVEB DE Discovery agent
DMKTSPM ID DMKTSPM
DMKTSPM DN 4-Chlorobenzenemethanethiol
DMKTSPM HS Investigative
DMKTSPM SN 4-Chlorobenzyl mercaptan; 6258-66-8; 4-Chlorobenzenemethanethiol; 4-Chlorobenzylmercaptan; (4-Chlorophenyl)methanethiol; p-Chlorobenzyl mercaptan; Benzenemethanethiol, 4-chloro-; p-Chlorotoluene-alpha-thiol; 4-Chloro benzyl mercaptan; 4-chloro-alpha-toluenethiol; CHEMBL1224555; GKQXPTHQTXCXEV-UHFFFAOYSA-N; EINECS 228-395-7; 4-chlor-benzylthiol; 4-chlorobenzyl thiol; p-chlorobenzylmercaptan; PubChem6838; NSC 108735; 4-chloro-benzylmercaptan; AC1L2ZDM; 4-chlorophenylmethanethiol; ACMC-1BE9W; 4-chlorophenyl methanethiol; AC1Q3NX5
DMKTSPM DT Small molecular drug
DMKTSPM PC 80409
DMKTSPM MW 158.65
DMKTSPM FM C7H7ClS
DMKTSPM IC InChI=1S/C7H7ClS/c8-7-3-1-6(5-9)2-4-7/h1-4,9H,5H2
DMKTSPM CS C1=CC(=CC=C1CS)Cl
DMKTSPM IK GKQXPTHQTXCXEV-UHFFFAOYSA-N
DMKTSPM IU (4-chlorophenyl)methanethiol
DMKTSPM CA CAS 6258-66-8
DMKTSPM DE Discovery agent
DMHL9V3 ID DMHL9V3
DMHL9V3 DN 4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide
DMHL9V3 HS Investigative
DMHL9V3 SN 4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide; CHEMBL560605; AC1LEF7J; Oprea1_805046; Oprea1_782408; MolPort-001-927-690; ZINC102805; BDBM50297549; STK201761; AKOS000609413; MCULE-5386572276; 2',4,5'-Trichloro-3-nitrobenzanilide; BAS 00368876; 91822-09-2; ST011043; AG-690/09694020; 4-Chloro-N-(2,5-dichloro-phenyl)-3-nitro-benzamide
DMHL9V3 DT Small molecular drug
DMHL9V3 PC 711259
DMHL9V3 MW 345.6
DMHL9V3 FM C13H7Cl3N2O3
DMHL9V3 IC InChI=1S/C13H7Cl3N2O3/c14-8-2-4-9(15)11(6-8)17-13(19)7-1-3-10(16)12(5-7)18(20)21/h1-6H,(H,17,19)
DMHL9V3 CS C1=CC(=C(C=C1C(=O)NC2=C(C=CC(=C2)Cl)Cl)[N+](=O)[O-])Cl
DMHL9V3 IK FYQHDHBGADAFGF-UHFFFAOYSA-N
DMHL9V3 IU 4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide
DMHL9V3 DE Discovery agent
DMVJ61A ID DMVJ61A
DMVJ61A DN 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide
DMVJ61A HS Investigative
DMVJ61A SN AC1LJL3L; CHEMBL189826; MolPort-000-293-674; ZINC617836; AKOS002786758; MCULE-4723966083; 2-chloro-N-(4-chlorophenyl)sulfonylbenzamide; SR-01000270508
DMVJ61A DT Small molecular drug
DMVJ61A PC 975893
DMVJ61A MW 330.2
DMVJ61A FM C13H9Cl2NO3S
DMVJ61A IC InChI=1S/C13H9Cl2NO3S/c14-9-5-7-10(8-6-9)20(18,19)16-13(17)11-3-1-2-4-12(11)15/h1-8H,(H,16,17)
DMVJ61A CS C1=CC=C(C(=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl)Cl
DMVJ61A IK XWHYBUXHQMUOJE-UHFFFAOYSA-N
DMVJ61A IU 2-chloro-N-(4-chlorophenyl)sulfonylbenzamide
DMVJ61A DE Discovery agent
DM6SI78 ID DM6SI78
DM6SI78 DN 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide
DM6SI78 HS Investigative
DM6SI78 SN CHEMBL187769; MolPort-000-480-083; ZINC16740680; AKOS016874521; MCULE-6213547895; N-(4-chlorobenzenesulfonyl)-2-methylbenzamide; Z56665599
DM6SI78 DT Small molecular drug
DM6SI78 PC 11266872
DM6SI78 MW 309.8
DM6SI78 FM C14H12ClNO3S
DM6SI78 IC InChI=1S/C14H12ClNO3S/c1-10-4-2-3-5-13(10)14(17)16-20(18,19)12-8-6-11(15)7-9-12/h2-9H,1H3,(H,16,17)
DM6SI78 CS CC1=CC=CC=C1C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
DM6SI78 IK JQSONZDJELNSLQ-UHFFFAOYSA-N
DM6SI78 IU N-(4-chlorophenyl)sulfonyl-2-methylbenzamide
DM6SI78 DE Discovery agent
DMVCLP8 ID DMVCLP8
DMVCLP8 DN 4-Chloro-N-(2-morpholinoethyl)nicotinamide
DMVCLP8 HS Investigative
DMVCLP8 SN 4-Chloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL598187; BDBM50307210; AKOS019796958
DMVCLP8 DT Small molecular drug
DMVCLP8 PC 46233361
DMVCLP8 MW 269.73
DMVCLP8 FM C12H16ClN3O2
DMVCLP8 IC InChI=1S/C12H16ClN3O2/c13-11-1-2-14-9-10(11)12(17)15-3-4-16-5-7-18-8-6-16/h1-2,9H,3-8H2,(H,15,17)
DMVCLP8 CS C1COCCN1CCNC(=O)C2=C(C=CN=C2)Cl
DMVCLP8 IK FJZDMBYDDXBLAU-UHFFFAOYSA-N
DMVCLP8 IU 4-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMVCLP8 DE Discovery agent
DMI3OR9 ID DMI3OR9
DMI3OR9 DN 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide
DMI3OR9 HS Investigative
DMI3OR9 SN CHEMBL359783
DMI3OR9 DT Small molecular drug
DMI3OR9 PC 11174891
DMI3OR9 MW 330.2
DMI3OR9 FM C13H9Cl2NO3S
DMI3OR9 IC InChI=1S/C13H9Cl2NO3S/c14-10-4-6-12(7-5-10)20(18,19)16-13(17)9-2-1-3-11(15)8-9/h1-8H,(H,16,17)
DMI3OR9 CS C1=CC(=CC(=C1)Cl)C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
DMI3OR9 IK OPPZHIMBWGDCCT-UHFFFAOYSA-N
DMI3OR9 IU 3-chloro-N-(4-chlorophenyl)sulfonylbenzamide
DMI3OR9 DE Discovery agent
DMM8G6H ID DMM8G6H
DMM8G6H DN 4-Chloro-N-(3-morpholinopropyl)nicotinamide
DMM8G6H HS Investigative
DMM8G6H SN 4-Chloro-N-(3-morpholinopropyl)nicotinamide; CHEMBL598586; SCHEMBL1613255; XYKBQKHBJFXZSH-UHFFFAOYSA-N; BDBM50307197; AKOS019797554
DMM8G6H DT Small molecular drug
DMM8G6H PC 46233458
DMM8G6H MW 283.75
DMM8G6H FM C13H18ClN3O2
DMM8G6H IC InChI=1S/C13H18ClN3O2/c14-12-2-4-15-10-11(12)13(18)16-3-1-5-17-6-8-19-9-7-17/h2,4,10H,1,3,5-9H2,(H,16,18)
DMM8G6H CS C1COCCN1CCCNC(=O)C2=C(C=CN=C2)Cl
DMM8G6H IK XYKBQKHBJFXZSH-UHFFFAOYSA-N
DMM8G6H IU 4-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DMM8G6H DE Discovery agent
DMTDX2S ID DMTDX2S
DMTDX2S DN 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide
DMTDX2S HS Investigative
DMTDX2S SN BAS 00692952; AC1LHFP5; Oprea1_686071; 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide; Oprea1_072837; CHEMBL365275; SCHEMBL10989349; MolPort-000-293-593; ZINC364345; AKOS001022179; MCULE-2798437162; 4-chloro-N-(4-chlorophenyl)sulfonylbenzamide; 4-chloro-N-((4-chlorophenyl)sulfonyl)benzamide; SR-01000319886; SR-01000319886-1
DMTDX2S DT Small molecular drug
DMTDX2S PC 837182
DMTDX2S MW 330.2
DMTDX2S FM C13H9Cl2NO3S
DMTDX2S IC InChI=1S/C13H9Cl2NO3S/c14-10-3-1-9(2-4-10)13(17)16-20(18,19)12-7-5-11(15)6-8-12/h1-8H,(H,16,17)
DMTDX2S CS C1=CC(=CC=C1C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl)Cl
DMTDX2S IK IZIJDUMIQKCMGD-UHFFFAOYSA-N
DMTDX2S IU 4-chloro-N-(4-chlorophenyl)sulfonylbenzamide
DMTDX2S CA CAS 14068-02-1
DMTDX2S DE Discovery agent
DMM0TL6 ID DMM0TL6
DMM0TL6 DN 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide
DMM0TL6 HS Investigative
DMM0TL6 SN CHEMBL436085; 36965-16-9; CTK1A9789; DTXSID10465969; ZINC16740685; AKOS002221762; Benzamide, N-[(4-chlorophenyl)sulfonyl]-4-nitro-
DMM0TL6 DT Small molecular drug
DMM0TL6 PC 11439243
DMM0TL6 MW 340.74
DMM0TL6 FM C13H9ClN2O5S
DMM0TL6 IC InChI=1S/C13H9ClN2O5S/c14-10-3-7-12(8-4-10)22(20,21)15-13(17)9-1-5-11(6-2-9)16(18)19/h1-8H,(H,15,17)
DMM0TL6 CS C1=CC(=CC=C1C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl)[N+](=O)[O-]
DMM0TL6 IK NOPPJNVGKXKZSN-UHFFFAOYSA-N
DMM0TL6 IU N-(4-chlorophenyl)sulfonyl-4-nitrobenzamide
DMM0TL6 CA CAS 36965-16-9
DMM0TL6 DE Discovery agent
DMVKU4L ID DMVKU4L
DMVKU4L DN 4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMVKU4L HS Investigative
DMVKU4L SN 4-chloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; CHEMBL62078; 4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide; 103966-00-3; (Z)-4-chloro-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; AC1LF4A9; Oprea1_546006; SCHEMBL17107148; MolPort-000-422-245; MolPort-003-009-218; CCG-1056; ZINC4693069; STK514420; BDBM50101787; AKOS024573977; AKOS000620846; MCULE-1729549249; BAS 00444248; ST45229639; N-(4-Phenyl-2-thiazolyl)-4-chlorobenzamide; AH-034/06884044; SR-01000394981; SR-01000394981-1; F0013-0438
DMVKU4L DT Small molecular drug
DMVKU4L PC 697415
DMVKU4L MW 314.8
DMVKU4L FM C16H11ClN2OS
DMVKU4L IC InChI=1S/C16H11ClN2OS/c17-13-8-6-12(7-9-13)15(20)19-16-18-14(10-21-16)11-4-2-1-3-5-11/h1-10H,(H,18,19,20)
DMVKU4L CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)Cl
DMVKU4L IK ZLQJUNKKCMQVHA-UHFFFAOYSA-N
DMVKU4L IU 4-chloro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMVKU4L DE Discovery agent
DM5AVG3 ID DM5AVG3
DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DM5AVG3 HS Investigative
DM5AVG3 SN CHEMBL143734; NSC718168; 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid
DM5AVG3 DT Small molecular drug
DM5AVG3 PC 403373
DM5AVG3 MW 284.74
DM5AVG3 FM C13H17ClN2O3
DM5AVG3 IC InChI=1S/C13H17ClN2O3/c14-11-7-5-10(6-8-11)13(18)15-9-3-1-2-4-12(17)16-19/h5-8,19H,1-4,9H2,(H,15,18)(H,16,17)
DM5AVG3 CS C1=CC(=CC=C1C(=O)NCCCCCC(=O)NO)Cl
DM5AVG3 IK YYCQNZBMCNSCKG-UHFFFAOYSA-N
DM5AVG3 IU 4-chloro-N-[6-(hydroxyamino)-6-oxohexyl]benzamide
DM5AVG3 DE Discovery agent
DM2UYCS ID DM2UYCS
DM2UYCS DN 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide
DM2UYCS HS Investigative
DM2UYCS SN CHEMBL364127; 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide; BDBM50155552
DM2UYCS DT Small molecular drug
DM2UYCS PC 44395685
DM2UYCS MW 350.8
DM2UYCS FM C16H15ClN2O3S
DM2UYCS IC InChI=1S/C16H15ClN2O3S/c17-13-4-1-10(2-5-13)16(20)19-14-7-11-3-6-15(23(18,21)22)9-12(11)8-14/h1-6,9,14H,7-8H2,(H,19,20)(H2,18,21,22)
DM2UYCS CS C1C(CC2=C1C=CC(=C2)S(=O)(=O)N)NC(=O)C3=CC=C(C=C3)Cl
DM2UYCS IK BJLRENUWWOPZIL-UHFFFAOYSA-N
DM2UYCS IU 4-chloro-N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)benzamide
DM2UYCS DE Discovery agent
DMPINBR ID DMPINBR
DMPINBR DN 4-chlorophenyl 10H-phenothiazine-10-carboxylate
DMPINBR HS Investigative
DMPINBR SN CHEMBL481530; 4-chlorophenyl 10H-phenothiazine-10-carboxylate; SCHEMBL4442850; ZINC27529769; BDBM50292625; AKOS002279099; 4-chlorophenyl phenothiazine-10-carboxylate
DMPINBR DT Small molecular drug
DMPINBR PC 16645663
DMPINBR MW 353.8
DMPINBR FM C19H12ClNO2S
DMPINBR IC InChI=1S/C19H12ClNO2S/c20-13-9-11-14(12-10-13)23-19(22)21-15-5-1-3-7-17(15)24-18-8-4-2-6-16(18)21/h1-12H
DMPINBR CS C1=CC=C2C(=C1)N(C3=CC=CC=C3S2)C(=O)OC4=CC=C(C=C4)Cl
DMPINBR IK OTLLKYSWTVZPOJ-UHFFFAOYSA-N
DMPINBR IU (4-chlorophenyl) phenothiazine-10-carboxylate
DMPINBR DE Discovery agent
DMWGF9R ID DMWGF9R
DMWGF9R DN 4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone
DMWGF9R HS Investigative
DMWGF9R SN CHEMBL377626; BDBM50191601; 4''-cyano-3-(imidazolylmethyl)-7-methoxyflavone
DMWGF9R DT Small molecular drug
DMWGF9R PC 11847171
DMWGF9R MW 357.4
DMWGF9R FM C21H15N3O3
DMWGF9R IC InChI=1S/C21H15N3O3/c1-26-16-6-7-17-19(10-16)27-21(15-4-2-14(11-22)3-5-15)18(20(17)25)12-24-9-8-23-13-24/h2-10,13H,12H2,1H3
DMWGF9R CS COC1=CC2=C(C=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)C#N)CN4C=CN=C4
DMWGF9R IK MFAAEVRNWGIQOT-UHFFFAOYSA-N
DMWGF9R IU 4-[3-(imidazol-1-ylmethyl)-7-methoxy-4-oxochromen-2-yl]benzonitrile
DMWGF9R DE Discovery agent
DMUJS4R ID DMUJS4R
DMUJS4R DN 4'-cyano-3-(imidazolylmethyl)flavone
DMUJS4R HS Investigative
DMUJS4R SN CHEMBL209731; BDBM50191602; 4''-cyano-3-(imidazolylmethyl)flavone
DMUJS4R DT Small molecular drug
DMUJS4R PC 11847319
DMUJS4R MW 327.3
DMUJS4R FM C20H13N3O2
DMUJS4R IC InChI=1S/C20H13N3O2/c21-11-14-5-7-15(8-6-14)20-17(12-23-10-9-22-13-23)19(24)16-3-1-2-4-18(16)25-20/h1-10,13H,12H2
DMUJS4R CS C1=CC=C2C(=C1)C(=O)C(=C(O2)C3=CC=C(C=C3)C#N)CN4C=CN=C4
DMUJS4R IK IOBDYJIIOAQKGQ-UHFFFAOYSA-N
DMUJS4R IU 4-[3-(imidazol-1-ylmethyl)-4-oxochromen-2-yl]benzonitrile
DMUJS4R DE Discovery agent
DMJ610E ID DMJ610E
DMJ610E DN 4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMJ610E HS Investigative
DMJ610E SN CHEMBL378434; 4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; MLS002153000; SCHEMBL3677412; HMS2198C07; BDBM50187632
DMJ610E DT Small molecular drug
DMJ610E PC 11574130
DMJ610E MW 364.4
DMJ610E FM C23H16N4O
DMJ610E IC InChI=1S/C23H16N4O/c24-16-17-11-13-19(14-12-17)23(28)25-22-15-21(18-7-3-1-4-8-18)26-27(22)20-9-5-2-6-10-20/h1-15H,(H,25,28)
DMJ610E CS C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=C(C=C3)C#N)C4=CC=CC=C4
DMJ610E IK YOQRDFGCIVWWAO-UHFFFAOYSA-N
DMJ610E IU 4-cyano-N-(2,5-diphenylpyrazol-3-yl)benzamide
DMJ610E DE Discovery agent
DMN12EX ID DMN12EX
DMN12EX DN 4-CYANOPHENOL
DMN12EX HS Investigative
DMN12EX SN 4-Hydroxybenzonitrile; 4-Cyanophenol; 767-00-0; p-Hydroxybenzonitrile; P-CYANOPHENOL; Benzonitrile, 4-hydroxy-; Benzonitrile, p-hydroxy-; 4-CYANO PHENOL; 4-Hydroxybenzoic acid nitrile; 4-hydroxy-benzonitrile; 4-Hydroxy benzonitrile; 4-hydroxybenzenecarbonitrile; UNII-1S13529YJU; EINECS 212-175-2; C7H5NO; NSC 400524; AI3-52392; CHEBI:38622; CVNOWLNNPYYEOH-UHFFFAOYSA-N; 1S13529YJU; 4-Cyanophenol, 99%; paracyanophenol; p-cyano-phenol; 4-cyano-phenol; 4 -cyanophenol; para-cyanophenol;; 4-hydroxybezonitrile; p-hydroxybenzo-nitrile
DMN12EX DT Small molecular drug
DMN12EX PC 13019
DMN12EX MW 119.12
DMN12EX FM C7H5NO
DMN12EX IC InChI=1S/C7H5NO/c8-5-6-1-3-7(9)4-2-6/h1-4,9H
DMN12EX CS C1=CC(=CC=C1C#N)O
DMN12EX IK CVNOWLNNPYYEOH-UHFFFAOYSA-N
DMN12EX IU 4-hydroxybenzonitrile
DMN12EX CA CAS 767-00-0
DMN12EX CB CHEBI:38622
DMN12EX DE Discovery agent
DMEP80Q ID DMEP80Q
DMEP80Q DN 4-cyanophenyl ethyl dodecylphosphonate
DMEP80Q HS Investigative
DMEP80Q SN 4-cyanophenyl ethyl dodecylphosphonate; CHEMBL462582
DMEP80Q DT Small molecular drug
DMEP80Q PC 44563662
DMEP80Q MW 379.5
DMEP80Q FM C21H34NO3P
DMEP80Q IC InChI=1S/C21H34NO3P/c1-3-5-6-7-8-9-10-11-12-13-18-26(23,24-4-2)25-21-16-14-20(19-22)15-17-21/h14-17H,3-13,18H2,1-2H3
DMEP80Q CS CCCCCCCCCCCCP(=O)(OCC)OC1=CC=C(C=C1)C#N
DMEP80Q IK FHIBETIKXBGJPS-UHFFFAOYSA-N
DMEP80Q IU 4-[dodecyl(ethoxy)phosphoryl]oxybenzonitrile
DMEP80Q DE Discovery agent
DMOLFHZ ID DMOLFHZ
DMOLFHZ DN 4-cyanophenylboronic acid
DMOLFHZ HS Investigative
DMOLFHZ SN 4-Cyanophenylboronic acid; 126747-14-6; (4-cyanophenyl)boronic Acid; 4-Cyanobenzeneboronic Acid; 4-cyanophenyl boronic acid; 4-cyano-phenyl-boronic acid; 4-Boronobenzonitrile; 4-(dihydroxyboranyl)benzonitrile; p-cyanophenylboronic acid; 4-cyanobenzene boronic acid; (4-cyano-phenyl)boronic acid; CEBAHYWORUOILU-UHFFFAOYSA-N; MFCD01318968; BORONIC ACID, (4-CYANOPHENYL)-; 4-Cyanophenylboronic acid, 97%; ACMC-209bbp; AC1MC0VB; 4-cyanoplienylboronic acid; 4-cyano phenylboronic acid; 4-cyano-phenylboronic acid; 4-cyanophenyl-boronic
DMOLFHZ DT Small molecular drug
DMOLFHZ PC 2734326
DMOLFHZ MW 146.94
DMOLFHZ FM C7H6BNO2
DMOLFHZ IC InChI=1S/C7H6BNO2/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4,10-11H
DMOLFHZ CS B(C1=CC=C(C=C1)C#N)(O)O
DMOLFHZ IK CEBAHYWORUOILU-UHFFFAOYSA-N
DMOLFHZ IU (4-cyanophenyl)boronic acid
DMOLFHZ CA CAS 126747-14-6
DMOLFHZ DE Discovery agent
DMNT5BF ID DMNT5BF
DMNT5BF DN 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
DMNT5BF HS Investigative
DMNT5BF SN CHEMBL1085423; 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile; SCHEMBL5796281
DMNT5BF DT Small molecular drug
DMNT5BF PC 11694425
DMNT5BF MW 243.35
DMNT5BF FM C15H21N3
DMNT5BF IC InChI=1S/C15H21N3/c1-2-7-13-10-14(18-15(11-16)17-13)12-8-5-3-4-6-9-12/h10,12H,2-9H2,1H3
DMNT5BF CS CCCC1=CC(=NC(=N1)C#N)C2CCCCCC2
DMNT5BF IK UOAUUFFKQMFGTJ-UHFFFAOYSA-N
DMNT5BF IU 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile
DMNT5BF DE Discovery agent
DM4LIUC ID DM4LIUC
DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol
DM4LIUC HS Investigative
DM4LIUC SN 4,4'-(Cycloheptylidenemethylene)diphenol; 4,4'-(Cycloheptylidenemethanediyl)diphenol; 14303-48-1; 4-cycloheptyliden(4-hydroxyphenyl)methylphenol; CHEMBL154947; SCHEMBL3468370; CTK0F0060; DTXSID10469043; XVTAYJKFHUKWSR-UHFFFAOYSA-N; 4,4'-(Cycloheptylidenemethylene)bis(phenol); Phenol, 4-[cycloheptylidene(4-hydroxyphenyl)methyl]-
DM4LIUC DT Small molecular drug
DM4LIUC PC 11587420
DM4LIUC MW 294.4
DM4LIUC FM C20H22O2
DM4LIUC IC InChI=1S/C20H22O2/c21-18-11-7-16(8-12-18)20(15-5-3-1-2-4-6-15)17-9-13-19(22)14-10-17/h7-14,21-22H,1-6H2
DM4LIUC CS C1CCCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)CC1
DM4LIUC IK XVTAYJKFHUKWSR-UHFFFAOYSA-N
DM4LIUC IU 4-[cycloheptylidene-(4-hydroxyphenyl)methyl]phenol
DM4LIUC CA CAS 14303-48-1
DM4LIUC DE Discovery agent
DMTFL5J ID DMTFL5J
DMTFL5J DN 4-Cyclohexyl-4-hydroxy-but-2-enoic acid
DMTFL5J HS Investigative
DMTFL5J SN CHEMBL171331; 4-cyclohexyl-4-hydroxybut-2-enoic acid; NSC400155; AC1NTOGK; AC1Q5T8F; BDBM50023573; AKOS022641700; NSC-400155; 4-Cyclohexyl-4-hydroxy-but-2-enoic acid; (E)-4-cyclohexyl-4-hydroxybut-2-enoic acid
DMTFL5J DT Small molecular drug
DMTFL5J PC 5385144
DMTFL5J MW 184.23
DMTFL5J FM C10H16O3
DMTFL5J IC InChI=1S/C10H16O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h6-9,11H,1-5H2,(H,12,13)/b7-6+
DMTFL5J CS C1CCC(CC1)C(/C=C/C(=O)O)O
DMTFL5J IK CGIACWYLNZMXMN-VOTSOKGWSA-N
DMTFL5J IU (E)-4-cyclohexyl-4-hydroxybut-2-enoic acid
DMTFL5J DE Discovery agent
DM10U6S ID DM10U6S
DM10U6S DN 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S HS Investigative
DM10U6S SN CHEMBL1085896; 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S DT Small molecular drug
DM10U6S PC 11622731
DM10U6S MW 229.32
DM10U6S FM C14H19N3
DM10U6S IC InChI=1S/C14H19N3/c1-2-6-12-9-13(17-14(10-15)16-12)11-7-4-3-5-8-11/h9,11H,2-8H2,1H3
DM10U6S CS CCCC1=CC(=NC(=N1)C#N)C2CCCCC2
DM10U6S IK WGTHPYHNMKDPLN-UHFFFAOYSA-N
DM10U6S IU 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
DM10U6S DE Discovery agent
DMGVIXW ID DMGVIXW
DMGVIXW DN 4-cyclohexylamino-pyrimidine-2-carbonitrile
DMGVIXW HS Investigative
DMGVIXW SN 2-Cyano-pyrimidine, 5; 4-(cyclohexylamino)pyrimidine-2-carbonitrile; CHEMBL221591; BDBM19749; 927176-94-1; 2-Pyrimidinecarbonitrile, 4-(cyclohexylamino)-
DMGVIXW DT Small molecular drug
DMGVIXW PC 16108884
DMGVIXW MW 202.26
DMGVIXW FM C11H14N4
DMGVIXW IC InChI=1S/C11H14N4/c12-8-11-13-7-6-10(15-11)14-9-4-2-1-3-5-9/h6-7,9H,1-5H2,(H,13,14,15)
DMGVIXW CS C1CCC(CC1)NC2=NC(=NC=C2)C#N
DMGVIXW IK UWPRHHHJGYCNGK-UHFFFAOYSA-N
DMGVIXW IU 4-(cyclohexylamino)pyrimidine-2-carbonitrile
DMGVIXW DE Discovery agent
DM8BLK2 ID DM8BLK2
DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol
DM8BLK2 HS Investigative
DM8BLK2 SN 4,4'-(cyclohexylidenemethylene)diphenol; 5189-40-2; Cyclofenil diphenol; 4,4'-Cyclohexylidenemethylenediphenol; UNII-00W4083OML; EINECS 225-972-5; BRN 2055864; F 6060; 4-[cyclohexylidene(4-hydroxyphenyl)methyl]phenol; 4-(Cyclohexylidene(4-hydroxyphenyl)methyl)phenol; 00W4083OML; 4,4-Cyclohexylidenemethylenediphenol; Phenol, 4-(cyclohexylidene(4-hydroxyphenyl)methyl)-; alpha-Cyclohexylidene-alpha-(p-hydroxyphenyl)-p-cresol; p-CRESOL, alpha-CYCLOHEXYLIDENE-alpha-(p-HYDROXYPHENYL)-; AC1L2HYB
DM8BLK2 DT Small molecular drug
DM8BLK2 PC 21260
DM8BLK2 MW 280.4
DM8BLK2 FM C19H20O2
DM8BLK2 IC InChI=1S/C19H20O2/c20-17-10-6-15(7-11-17)19(14-4-2-1-3-5-14)16-8-12-18(21)13-9-16/h6-13,20-21H,1-5H2
DM8BLK2 CS C1CCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)CC1
DM8BLK2 IK POEZOFHZEJTFHF-UHFFFAOYSA-N
DM8BLK2 IU 4-[cyclohexylidene-(4-hydroxyphenyl)methyl]phenol
DM8BLK2 CA CAS 5189-40-2
DM8BLK2 DE Discovery agent
DMS42TN ID DMS42TN
DMS42TN DN 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN HS Investigative
DMS42TN SN CHEMBL1077194; 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN DT Small molecular drug
DMS42TN PC 46881498
DMS42TN MW 257.37
DMS42TN FM C16H23N3
DMS42TN IC InChI=1S/C16H23N3/c1-2-8-14-11-15(19-16(12-17)18-14)13-9-6-4-3-5-7-10-13/h11,13H,2-10H2,1H3
DMS42TN CS CCCC1=CC(=NC(=N1)C#N)C2CCCCCCC2
DMS42TN IK AWOXPJKLDJGFMS-UHFFFAOYSA-N
DMS42TN IU 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile
DMS42TN DE Discovery agent
DM7LN53 ID DM7LN53
DM7LN53 DN 4-cyclopentyliden(4-hydroxyphenyl)methylphenol
DM7LN53 HS Investigative
DM7LN53 SN 4-cyclopentyliden(4-hydroxyphenyl)methylphenol; 66422-10-4; SCHEMBL3902681; CHEMBL352015; CTK1J4764; DTXSID00468323; ZINC13650257; bis(4-hydroxyphenyl)methylidenecyclopentane; 4,4'-(Cyclopentylidenemethylene)bis(phenol); Phenol, 4-[cyclopentylidene(4-hydroxyphenyl)methyl]-
DM7LN53 DT Small molecular drug
DM7LN53 PC 11543532
DM7LN53 MW 266.3
DM7LN53 FM C18H18O2
DM7LN53 IC InChI=1S/C18H18O2/c19-16-9-5-14(6-10-16)18(13-3-1-2-4-13)15-7-11-17(20)12-8-15/h5-12,19-20H,1-4H2
DM7LN53 CS C1CCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C1
DM7LN53 IK GIGYKXHGYNZBEN-UHFFFAOYSA-N
DM7LN53 IU 4-[cyclopentylidene-(4-hydroxyphenyl)methyl]phenol
DM7LN53 CA CAS 66422-10-4
DM7LN53 DE Discovery agent
DMZIUQ2 ID DMZIUQ2
DMZIUQ2 DN 4-DAMP
DMZIUQ2 HS Investigative
DMZIUQ2 SN 4-Diphenylacetoxy-1,1-dimethylpiperidinium; CHEMBL168067; 81405-11-0; CHEBI:73467; CHEMBL76897; 4-Damp methobromide; C21H26NO2; Tocris-0482; Lopac-D-104; AC1Q60WY; AC1L1C4C; 4-[(diphenylacetyl)oxy]-1,1-dimethylpiperidinium; Lopac0_000407; GTPL307; SCHEMBL2730650; 1952-15-4 (iodide); CTK3E9884; DTXSID70231086; 4-DAMP(1+); ZINC2555356; BDBM50176065; CCG-204500; NCGC00024611-02; NCGC00015304-04; NCGC00015304-03; NCGC00163244-01; NCGC00024611-01; NCGC00015304-02; NCGC00015304-01; LS-177624; N,N-dimethyl-4-(diphenylacetoxy)piperidinium
DMZIUQ2 DT Small molecular drug
DMZIUQ2 PC 3014059
DMZIUQ2 MW 451.3
DMZIUQ2 FM C21H26INO2
DMZIUQ2 IC InChI=1S/C21H26NO2.HI/c1-22(2)15-13-19(14-16-22)24-21(23)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;/h3-12,19-20H,13-16H2,1-2H3;1H/q+1;/p-1
DMZIUQ2 CS C[N+]1(CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C.[I-]
DMZIUQ2 IK WWJHRSCUAQPFQO-UHFFFAOYSA-M
DMZIUQ2 IU (1,1-dimethylpiperidin-1-ium-4-yl) 2,2-diphenylacetate;iodide
DMZIUQ2 CA CAS 1952-15-4
DMZIUQ2 CB CHEBI:73340
DMZIUQ2 DE Discovery agent
DMGQTF9 ID DMGQTF9
DMGQTF9 DN 4-decyl-N-(pyridin-3-yl)benzamide
DMGQTF9 HS Investigative
DMGQTF9 SN CHEMBL259102
DMGQTF9 DT Small molecular drug
DMGQTF9 PC 44450381
DMGQTF9 MW 338.5
DMGQTF9 FM C22H30N2O
DMGQTF9 IC InChI=1S/C22H30N2O/c1-2-3-4-5-6-7-8-9-11-19-13-15-20(16-14-19)22(25)24-21-12-10-17-23-18-21/h10,12-18H,2-9,11H2,1H3,(H,24,25)
DMGQTF9 CS CCCCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMGQTF9 IK QIODTOXMQFMJNV-UHFFFAOYSA-N
DMGQTF9 IU 4-decyl-N-pyridin-3-ylbenzamide
DMGQTF9 DE Discovery agent
DM93DQG ID DM93DQG
DM93DQG DN 4-dehydroxyriccardin C
DM93DQG HS Investigative
DM93DQG SN 4-dehydroxyriccardin C; Riccardin C derivative, 20d; CHEMBL411246; BDBM23851; 2',4-(Ethylene-1,4-phenylene-oxy-1,3-phenylene-ethylene)-1,1'-biphenyl-2,4'-diol
DM93DQG DT Small molecular drug
DM93DQG PC 24860513
DM93DQG MW 408.5
DM93DQG FM C28H24O3
DM93DQG IC InChI=1S/C28H24O3/c29-23-11-15-26-22(18-23)10-6-19-7-12-24(13-8-19)31-25-3-1-2-20(16-25)4-5-21-9-14-27(26)28(30)17-21/h1-3,7-9,11-18,29-30H,4-6,10H2
DM93DQG CS C1CC2=C(C=CC(=C2)O)C3=C(C=C(CCC4=CC(=CC=C4)OC5=CC=C1C=C5)C=C3)O
DM93DQG IK ZCEPVFMKRVLFDX-UHFFFAOYSA-N
DM93DQG IU 14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-5,24-diol
DM93DQG DE Discovery agent
DMQWHLM ID DMQWHLM
DMQWHLM DN 4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin
DMQWHLM HS Investigative
DMQWHLM SN CHEMBL32083; SCHEMBL4854498; WZTRSUUEQXXWCN-JHQYFNNDSA-N; (5R,5aR,8aS,9S)-9-amino-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5R,5aR,8aS,9S)-9-amino-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one
DMQWHLM DT Small molecular drug
DMQWHLM PC 10927468
DMQWHLM MW 399.4
DMQWHLM FM C21H21NO7
DMQWHLM IC InChI=1S/C21H21NO7/c1-25-15-3-9(4-16(26-2)20(15)23)17-10-5-13-14(29-8-28-13)6-11(10)19(22)12-7-27-21(24)18(12)17/h3-6,12,17-19,23H,7-8,22H2,1-2H3/t12-,17+,18-,19+/m0/s1
DMQWHLM CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)N
DMQWHLM IK WZTRSUUEQXXWCN-JHQYFNNDSA-N
DMQWHLM IU (5S,5aS,8aR,9R)-5-amino-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMQWHLM DE Discovery agent
DMIWX3B ID DMIWX3B
DMIWX3B DN 4'-Demethyl-epipodophyllotoxin
DMIWX3B HS Investigative
DMIWX3B SN 4'-Demethylepipodophyllotoxin; 6559-91-7; 4'-DMEP; 4-Demethylepipodophyllotoxin; UNII-X0S6I23X6L; (-)-4'-Demethylepipodophyllotoxin; BRN 1358259; X0S6I23X6L; CHEBI:74422; C21H20O8; (5R,5aR,8aR,9S)-9-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; (5s,5ar,8ar,9r)-9-(3,5-Dimethoxy-4-Oxidanyl-Phenyl)-5-Oxidanyl-5a,6,8a,9-Tetrahydro-5h-[2]benzofuro[6,5-F][1,3]benzodioxol-8-One; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydrox
DMIWX3B DT Small molecular drug
DMIWX3B PC 122797
DMIWX3B MW 400.4
DMIWX3B FM C21H20O8
DMIWX3B IC InChI=1S/C21H20O8/c1-25-15-3-9(4-16(26-2)20(15)23)17-10-5-13-14(29-8-28-13)6-11(10)19(22)12-7-27-21(24)18(12)17/h3-6,12,17-19,22-23H,7-8H2,1-2H3/t12-,17+,18-,19+/m0/s1
DMIWX3B CS COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O
DMIWX3B IK YVCVYCSAAZQOJI-JHQYFNNDSA-N
DMIWX3B IU (5S,5aR,8aR,9R)-5-hydroxy-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
DMIWX3B CA CAS 6559-91-7
DMIWX3B CB CHEBI:74422
DMIWX3B DE Discovery agent
DMEC1PS ID DMEC1PS
DMEC1PS DN 4-Dimethylamino-2,6-diisopropyl-phenol
DMEC1PS HS Investigative
DMEC1PS SN CHEMBL55136; ZINC13779581
DMEC1PS DT Small molecular drug
DMEC1PS PC 10727719
DMEC1PS MW 221.34
DMEC1PS FM C14H23NO
DMEC1PS IC InChI=1S/C14H23NO/c1-9(2)12-7-11(15(5)6)8-13(10(3)4)14(12)16/h7-10,16H,1-6H3
DMEC1PS CS CC(C)C1=CC(=CC(=C1O)C(C)C)N(C)C
DMEC1PS IK BOEKREBRMTXRRJ-UHFFFAOYSA-N
DMEC1PS IU 4-(dimethylamino)-2,6-di(propan-2-yl)phenol
DMEC1PS DE Discovery agent
DM0M8G5 ID DM0M8G5
DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide
DM0M8G5 HS Investigative
DM0M8G5 SN CHEMBL324126
DM0M8G5 DT Small molecular drug
DM0M8G5 PC 11277483
DM0M8G5 MW 280.4
DM0M8G5 FM C15H24N2OS
DM0M8G5 IC InChI=1S/C15H24N2OS/c1-17(2)14-9-7-13(8-10-14)15(18)16-11-5-3-4-6-12-19/h7-10,19H,3-6,11-12H2,1-2H3,(H,16,18)
DM0M8G5 CS CN(C)C1=CC=C(C=C1)C(=O)NCCCCCCS
DM0M8G5 IK XMUAFOWTSHBASP-UHFFFAOYSA-N
DM0M8G5 IU 4-(dimethylamino)-N-(6-sulfanylhexyl)benzamide
DM0M8G5 DE Discovery agent
DMKEHLD ID DMKEHLD
DMKEHLD DN 4-Dipropylamino-cyclohex-1-enecarbonitrile
DMKEHLD HS Investigative
DMKEHLD SN CHEMBL164631; 4-Dipropylamino-cyclohex-1-enecarbonitrile; SCHEMBL153730
DMKEHLD DT Small molecular drug
DMKEHLD PC 10420539
DMKEHLD MW 206.33
DMKEHLD FM C13H22N2
DMKEHLD IC InChI=1S/C13H22N2/c1-3-9-15(10-4-2)13-7-5-12(11-14)6-8-13/h5,13H,3-4,6-10H2,1-2H3
DMKEHLD CS CCCN(CCC)C1CCC(=CC1)C#N
DMKEHLD IK WKFNOWSGTCBYBL-UHFFFAOYSA-N
DMKEHLD IU 4-(dipropylamino)cyclohexene-1-carbonitrile
DMKEHLD DE Discovery agent
DMD6ROZ ID DMD6ROZ
DMD6ROZ DN 4E2Rcat
DMD6ROZ HS Investigative
DMD6ROZ SN CAS 432499-63-3
DMD6ROZ TC Antiviral Agents
DMD6ROZ DT Small molecular drug
DMD6ROZ PC 2287236
DMD6ROZ MW 455.9
DMD6ROZ FM C22H14ClNO4S2
DMD6ROZ IC InChI=1S/C22H14ClNO4S2/c23-17-8-6-14(10-16(17)21(26)27)18-9-7-15(28-18)11-19-20(25)24(22(29)30-19)12-13-4-2-1-3-5-13/h1-11H,12H2,(H,26,27)/b19-11-
DMD6ROZ CS C1=CC=C(C=C1)CN2C(=O)/C(=C/C3=CC=C(O3)C4=CC(=C(C=C4)Cl)C(=O)O)/SC2=S
DMD6ROZ IK WOBPZFKXPCYOLU-ODLFYWEKSA-N
DMD6ROZ IU 5-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]-2-chlorobenzoic acid
DMD6ROZ DE Coronavirus Disease 2019 (COVID-19)
DM8WAOR ID DM8WAOR
DM8WAOR DN 4-Ethoxy-3-pyridinesulfonamide
DM8WAOR HS Investigative
DM8WAOR SN CHEMBL1165319; 4-Ethoxy-3-pyridinesulfonamide; 4-ethoxypyridine-3-sulfonamide; SCHEMBL20610078; MolPort-038-948-438; BDBM50320504; ZINC49803276
DM8WAOR DT Small molecular drug
DM8WAOR PC 46703768
DM8WAOR MW 202.23
DM8WAOR FM C7H10N2O3S
DM8WAOR IC InChI=1S/C7H10N2O3S/c1-2-12-6-3-4-9-5-7(6)13(8,10)11/h3-5H,2H2,1H3,(H2,8,10,11)
DM8WAOR CS CCOC1=C(C=NC=C1)S(=O)(=O)N
DM8WAOR IK MQJPVIGZIDYFMM-UHFFFAOYSA-N
DM8WAOR IU 4-ethoxypyridine-3-sulfonamide
DM8WAOR CA CAS 1229666-21-0
DM8WAOR DE Discovery agent
DM8642Z ID DM8642Z
DM8642Z DN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one
DM8642Z HS Investigative
DM8642Z SN CHEMBL76874; MRS1066; GTPL396; MRS-1066; BDBM50051338; AKOS030557417
DM8642Z DT Small molecular drug
DM8642Z PC 10806465
DM8642Z MW 332.3
DM8642Z FM C21H16O4
DM8642Z IC InChI=1S/C21H16O4/c1-2-23-21-16-10-11-24-18(16)13-19-20(21)17(22)12-15(25-19)9-8-14-6-4-3-5-7-14/h3-13H,2H2,1H3/b9-8+
DM8642Z CS CCOC1=C2C=COC2=CC3=C1C(=O)C=C(O3)/C=C/C4=CC=CC=C4
DM8642Z IK TZRUAYHMQMKKLT-CMDGGOBGSA-N
DM8642Z IU 4-ethoxy-7-[(E)-2-phenylethenyl]furo[3,2-g]chromen-5-one
DM8642Z DE Discovery agent
DMUN7KC ID DMUN7KC
DMUN7KC DN 4-ethoxynaphthalene-1,2-dione
DMUN7KC HS Investigative
DMUN7KC SN 4-ethoxynaphthalene-1,2-dione; 4-ethoxy-1,2-naphthoquinone; CHEMBL50620; 4-Ethoxy-[1,2]naphthoquinone; 7473-19-0; NSC400247; AC1L7Z1H; 4-Ethoxy-1,2-naphthalenedione; SCHEMBL5595641; DTXSID70322029; XPXODXIULRDWNT-UHFFFAOYSA-N; 1,2-Naphthalenedione, 4-ethoxy-; ZINC1593117; BDBM50099736
DMUN7KC DT Small molecular drug
DMUN7KC PC 343759
DMUN7KC MW 202.21
DMUN7KC FM C12H10O3
DMUN7KC IC InChI=1S/C12H10O3/c1-2-15-11-7-10(13)12(14)9-6-4-3-5-8(9)11/h3-7H,2H2,1H3
DMUN7KC CS CCOC1=CC(=O)C(=O)C2=CC=CC=C21
DMUN7KC IK XPXODXIULRDWNT-UHFFFAOYSA-N
DMUN7KC IU 4-ethoxynaphthalene-1,2-dione
DMUN7KC CA CAS 7473-19-0
DMUN7KC DE Discovery agent
DMTIY89 ID DMTIY89
DMTIY89 DN 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMTIY89 HS Investigative
DMTIY89 SN 4-ethyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMTIY89 PC 135430317
DMTIY89 MW 265.31
DMTIY89 FM C17H15NO2
DMTIY89 IC InChI=1S/C17H15NO2/c1-2-11-9-17(12-3-5-13(19)6-4-12)18-16-8-7-14(20)10-15(11)16/h3-10,19-20H,2H2,1H3
DMTIY89 CS CCC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DMTIY89 IK JHGHNHLKUJDBRE-UHFFFAOYSA-N
DMTIY89 IU 4-ethyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMTIY89 DE Discovery agent
DMHDN25 ID DMHDN25
DMHDN25 DN 4-ethyl-3,4-dihydroquinazolin-2-amine
DMHDN25 HS Investigative
DMHDN25 SN CHEMBL270841
DMHDN25 DT Small molecular drug
DMHDN25 PC 44455986
DMHDN25 MW 175.23
DMHDN25 FM C10H13N3
DMHDN25 IC InChI=1S/C10H13N3/c1-2-8-7-5-3-4-6-9(7)13-10(11)12-8/h3-6,8H,2H2,1H3,(H3,11,12,13)
DMHDN25 CS CCC1C2=CC=CC=C2NC(=N1)N
DMHDN25 IK FUFWGLRRMNVLPD-UHFFFAOYSA-N
DMHDN25 IU 4-ethyl-1,4-dihydroquinazolin-2-amine
DMHDN25 DE Discovery agent
DM5G3NU ID DM5G3NU
DM5G3NU DN 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DM5G3NU HS Investigative
DM5G3NU SN CHEMBL184798; 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150930
DM5G3NU DT Small molecular drug
DM5G3NU PC 19049061
DM5G3NU MW 126.2
DM5G3NU FM C7H14N2
DM5G3NU IC InChI=1S/C7H14N2/c1-3-6-4-9-7(8)5(6)2/h5-6H,3-4H2,1-2H3,(H2,8,9)
DM5G3NU CS CCC1CN=C(C1C)N
DM5G3NU IK BIWSZTWZJHYWGX-UHFFFAOYSA-N
DM5G3NU IU 3-ethyl-4-methyl-3,4-dihydro-2H-pyrrol-5-amine
DM5G3NU DE Discovery agent
DMTM1VD ID DMTM1VD
DMTM1VD DN 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DMTM1VD HS Investigative
DMTM1VD SN CHEMBL260277; 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine; BDBM50237936; AKOS006359116; 4-Ethyl-1,2,5,6-tetrahydropyridine-2-imine
DMTM1VD DT Small molecular drug
DMTM1VD PC 10130105
DMTM1VD MW 124.18
DMTM1VD FM C7H12N2
DMTM1VD IC InChI=1S/C7H12N2/c1-2-6-3-4-9-7(8)5-6/h5H,2-4H2,1H3,(H2,8,9)
DMTM1VD CS CCC1=CC(=NCC1)N
DMTM1VD IK PZWTXXAVOPPTGW-UHFFFAOYSA-N
DMTM1VD IU 4-ethyl-2,3-dihydropyridin-6-amine
DMTM1VD DE Discovery agent
DMOAQ1E ID DMOAQ1E
DMOAQ1E DN 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine
DMOAQ1E HS Investigative
DMOAQ1E SN CHEMBL363477; 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150933
DMOAQ1E DT Small molecular drug
DMOAQ1E PC 19049121
DMOAQ1E MW 126.2
DMOAQ1E FM C7H14N2
DMOAQ1E IC InChI=1S/C7H14N2/c1-3-6-4-7(8)9-5(6)2/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMOAQ1E CS CCC1CC(=NC1C)N
DMOAQ1E IK NMCNOZCNKVOIET-UHFFFAOYSA-N
DMOAQ1E IU 3-ethyl-2-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMOAQ1E DE Discovery agent
DMYO2GP ID DMYO2GP
DMYO2GP DN 4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol
DMYO2GP HS Investigative
DMYO2GP SN CHEMBL143993; 439944-80-6; 3(2H)-Isoxazolone, 4-ethyl-5-(4-piperidinyl)-; CHEMBL543365; 4-ethyl-5-piperidin-4-yl-isoxazol-3-ol; CTK1C8002; DTXSID50445689; BDBM50113809; AKOS030538897; AKOS015904779; 4-ethyl-5-(4-piperidinyl)-3-isoxazolol; 4-Ethyl-5-(4-piperidinyl)isoxazole-3-ol; I14-23452; 4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol
DMYO2GP DT Small molecular drug
DMYO2GP PC 10845560
DMYO2GP MW 196.25
DMYO2GP FM C10H16N2O2
DMYO2GP IC InChI=1S/C10H16N2O2/c1-2-8-9(14-12-10(8)13)7-3-5-11-6-4-7/h7,11H,2-6H2,1H3,(H,12,13)
DMYO2GP CS CCC1=C(ONC1=O)C2CCNCC2
DMYO2GP IK NKLHMQIBLBZVKZ-UHFFFAOYSA-N
DMYO2GP IU 4-ethyl-5-piperidin-4-yl-1,2-oxazol-3-one
DMYO2GP CA CAS 439944-80-6
DMYO2GP DE Discovery agent
DMG0Y3W ID DMG0Y3W
DMG0Y3W DN 4-Ethyl-oxazolidin-(2Z)-ylideneamine
DMG0Y3W HS Investigative
DMG0Y3W SN CHEMBL108788; 4-Ethyl-oxazolidin-(2Z)-ylideneamine; 4-Ethyloxazolidine-2-imine; SCHEMBL10211233; BDBM50138188; AKOS013533141
DMG0Y3W DT Small molecular drug
DMG0Y3W PC 44337211
DMG0Y3W MW 114.15
DMG0Y3W FM C5H10N2O
DMG0Y3W IC InChI=1S/C5H10N2O/c1-2-4-3-8-5(6)7-4/h4H,2-3H2,1H3,(H2,6,7)
DMG0Y3W CS CCC1COC(=N1)N
DMG0Y3W IK JTEWXLMHFCOPAX-UHFFFAOYSA-N
DMG0Y3W IU 4-ethyl-4,5-dihydro-1,3-oxazol-2-amine
DMG0Y3W DE Discovery agent
DMYIWAH ID DMYIWAH
DMYIWAH DN 4-Ethyl-pyrrolidin-(2Z)-ylideneamine
DMYIWAH HS Investigative
DMYIWAH SN CHEMBL360616; CHEMBL543886; 4-Ethylpyrrolidine-2-imine; SCHEMBL7593608; BDBM50066783; AKOS006353400; 4-Ethyl-pyrrolidin-(2E)-ylideneamine
DMYIWAH DT Small molecular drug
DMYIWAH PC 10725313
DMYIWAH MW 112.17
DMYIWAH FM C6H12N2
DMYIWAH IC InChI=1S/C6H12N2/c1-2-5-3-6(7)8-4-5/h5H,2-4H2,1H3,(H2,7,8)
DMYIWAH CS CCC1CC(=NC1)N
DMYIWAH IK YDJLYZDTIUKJQI-UHFFFAOYSA-N
DMYIWAH IU 3-ethyl-3,4-dihydro-2H-pyrrol-5-amine
DMYIWAH DE Discovery agent
DMIF1D6 ID DMIF1D6
DMIF1D6 DN 4-ethynyl benzene sulfonamide
DMIF1D6 HS Investigative
DMIF1D6 SN 4-ethynylbenzenesulfonamide; 1788-08-5; 4-Ethynylbenzene-1-sulfonamide; 4-Ethynybenzenesulfonamide; 4-ethynyl benzene sulfonamide; Benzenesulfonamide, 4-ethynyl-; CHEMBL272881; benzenesulfonamide, 4-ethynyl- (9ci); P-Ethynylbenzenesulfonamide; 4-ethvnylbenzenesulfonamide; 4-ethynylbenzene sulfonamide; 4-ethynyl-benzenesulfonamide; Benzenesulfonamide,4-ethynyl-; SCHEMBL1066580; CTK4D6902; DTXSID80659176; OQPUCENNUFNCQO-UHFFFAOYSA-N; MolPort-004-759-802; KS-00000L2U; ANW-45086; BDBM50236140; ZINC29134554; FC0779; AKOS006308323
DMIF1D6 DT Small molecular drug
DMIF1D6 PC 44457221
DMIF1D6 MW 181.21
DMIF1D6 FM C8H7NO2S
DMIF1D6 IC InChI=1S/C8H7NO2S/c1-2-7-3-5-8(6-4-7)12(9,10)11/h1,3-6H,(H2,9,10,11)
DMIF1D6 CS C#CC1=CC=C(C=C1)S(=O)(=O)N
DMIF1D6 IK OQPUCENNUFNCQO-UHFFFAOYSA-N
DMIF1D6 IU 4-ethynylbenzenesulfonamide
DMIF1D6 CA CAS 1788-08-5
DMIF1D6 DE Discovery agent
DMXLZAT ID DMXLZAT
DMXLZAT DN 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXLZAT HS Investigative
DMXLZAT SN 4-ethynyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMXLZAT PC 135524856
DMXLZAT MW 261.269
DMXLZAT FM C17H11NO2
DMXLZAT IC InChI=1S/C17H11NO2/c1-2-11-9-17(12-3-5-13(19)6-4-12)18-16-8-7-14(20)10-15(11)16/h1,3-10,19-20H
DMXLZAT CS C#CC1=CC(=NC2=C1C=C(C=C2)O)C3=CC=C(C=C3)O
DMXLZAT IK LZRCWCHYOCKNED-UHFFFAOYSA-N
DMXLZAT IU 4-ethynyl-2-(4-hydroxyphenyl)quinolin-6-ol
DMXLZAT DE Discovery agent
DMNDS19 ID DMNDS19
DMNDS19 DN 4-Flourobenzenesulfonamide
DMNDS19 HS Investigative
DMNDS19 SN 4-Fluorobenzenesulfonamide; 402-46-0; p-Fluorobenzenesulfonamide; 4-fluorobenzenesulphonamide; 4-fluorobenzene-1-sulfonamide; p-Fluorobenzenesulphonamide; 4-FLOUROBENZENESULFONAMIDE; EINECS 206-946-2; 4-fluoro-benzenesulfonamide; BRN 2832246; Benzenesulfonamide, p-fluoro-; Benzenesulfonamide, 4-fluoro-; PubChem2167; ACMC-1ACSJ; 4-Fuloro sulfonamide, C; 4-fluorobenzene sulfonamide; Cambridge id 5135296; AC1Q55BS; AC1L3QD2; 4-fluoranylbenzenesulfonamide; 4-fluoro benzene sulfonamide; Benzenesulfonamide,4-fluoro-; 4-11-00-00102 (Be
DMNDS19 DT Small molecular drug
DMNDS19 PC 120231
DMNDS19 MW 175.18
DMNDS19 FM C6H6FNO2S
DMNDS19 IC InChI=1S/C6H6FNO2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,(H2,8,9,10)
DMNDS19 CS C1=CC(=CC=C1F)S(=O)(=O)N
DMNDS19 IK LFLSATHZMYYIAQ-UHFFFAOYSA-N
DMNDS19 IU 4-fluorobenzenesulfonamide
DMNDS19 CA CAS 402-46-0
DMNDS19 DE Discovery agent
DMW9I1X ID DMW9I1X
DMW9I1X DN 4-Fluoren-9-ylidenemethyl-pyridine
DMW9I1X HS Investigative
DMW9I1X SN MLS002694154; 4-(9H-fluoren-9-ylidenemethyl)pyridine; 4-Fluoren-9-ylidenemethyl-pyridine; NSC83319; AC1L5UM6; NCIOpen2_004593; Oprea1_438447; Oprea1_732020; BDBM8644; CHEMBL383145; 9-(4-pyridylmethylene)fluorene; SCHEMBL8276094; CTK7D1435; (4-Pyridylmethylene)fluorene 34; HMS3088F22; 4-(fluoren-9-ylidenemethyl)pyridine; ZINC13283063; NSC-83319; AKOS000634958; Pyridine, 4-(fluoren-9-ylidenemethyl)-; 4-(9H-Fluorene-9-ylidenemethyl)pyridine; SMR001560085; BAS 00004846; SR-01000321373
DMW9I1X DT Small molecular drug
DMW9I1X PC 256445
DMW9I1X MW 255.3
DMW9I1X FM C19H13N
DMW9I1X IC InChI=1S/C19H13N/c1-3-7-17-15(5-1)16-6-2-4-8-18(16)19(17)13-14-9-11-20-12-10-14/h1-13H
DMW9I1X CS C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CC=NC=C4
DMW9I1X IK YVNXZDHQCSSQMR-UHFFFAOYSA-N
DMW9I1X IU 4-(fluoren-9-ylidenemethyl)pyridine
DMW9I1X DE Discovery agent
DM0INZX ID DM0INZX
DM0INZX DN 4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol
DM0INZX HS Investigative
DM0INZX SN CHEMBL570102; BDBM50299654
DM0INZX DT Small molecular drug
DM0INZX PC 44543260
DM0INZX MW 280.3
DM0INZX FM C18H13FO2
DM0INZX IC InChI=1S/C18H13FO2/c19-17-9-8-15(11-18(17)21)13-6-4-12(5-7-13)14-2-1-3-16(20)10-14/h1-11,20-21H
DM0INZX CS C1=CC(=CC(=C1)O)C2=CC=C(C=C2)C3=CC(=C(C=C3)F)O
DM0INZX IK MCDQJOWWXZILHP-UHFFFAOYSA-N
DM0INZX IU 2-fluoro-5-[4-(3-hydroxyphenyl)phenyl]phenol
DM0INZX DE Discovery agent
DMQ1D9A ID DMQ1D9A
DMQ1D9A DN 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
DMQ1D9A HS Investigative
DMQ1D9A SN 5731-10-2; 4-(4-Fluorophenyl)benzoic acid; 4'-Fluoro-biphenyl-4-carboxylic acid; 4'-fluorobiphenyl-4-carboxylic acid; 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID; 4'-Fluoro-biphenyl-4-carboxylic aci; 4'-Fluoro-[1,1'-biphenyl]-4-carboxylic acid; CHEMBL106708; MFCD01631909; 4-(4-Fluorophenyl)benzoic acid, 97%; 4'-fluoro[1,1'-biphenyl]-4-carboxylic acid; 4FC; 4'-fluoro(1,1'-biphenyl)-4-carboxylic acid; 1ysg; 4-Biphenyl-4'-fluoro-carboxylicacid; 4-Biphenyl-4'-fluoro-carboxylic acid; PubChem10277; 1,5-dibenzoyloxybenzene
DMQ1D9A DT Small molecular drug
DMQ1D9A PC 2782689
DMQ1D9A MW 216.21
DMQ1D9A FM C13H9FO2
DMQ1D9A IC InChI=1S/C13H9FO2/c14-12-7-5-10(6-8-12)9-1-3-11(4-2-9)13(15)16/h1-8H,(H,15,16)
DMQ1D9A CS C1=CC(=CC=C1C2=CC=C(C=C2)F)C(=O)O
DMQ1D9A IK LXWNTLBMNCXRQN-UHFFFAOYSA-N
DMQ1D9A IU 4-(4-fluorophenyl)benzoic acid
DMQ1D9A CA CAS 5731-10-2
DMQ1D9A DE Discovery agent
DM2N4BJ ID DM2N4BJ
DM2N4BJ DN 4-fluorobenzaldehyde O-benzoyloxime
DM2N4BJ HS Investigative
DM2N4BJ SN 4-fluorobenzaldehyde O-benzoyloxime; CHEMBL180720; SCHEMBL3225285; SCHEMBL3225274
DM2N4BJ DT Small molecular drug
DM2N4BJ PC 11368513
DM2N4BJ MW 243.23
DM2N4BJ FM C14H10FNO2
DM2N4BJ IC InChI=1S/C14H10FNO2/c15-13-8-6-11(7-9-13)10-16-18-14(17)12-4-2-1-3-5-12/h1-10H/b16-10+
DM2N4BJ CS C1=CC=C(C=C1)C(=O)O/N=C/C2=CC=C(C=C2)F
DM2N4BJ IK DIEBAKUPBFEXAP-MHWRWJLKSA-N
DM2N4BJ IU [(E)-(4-fluorophenyl)methylideneamino] benzoate
DM2N4BJ DE Discovery agent
DMS6RHD ID DMS6RHD
DMS6RHD DN 4-Fluorobenzenemethanethiol
DMS6RHD HS Investigative
DMS6RHD SN 4-Fluorobenzyl mercaptan; 15894-04-9; (4-Fluorophenyl)methanethiol; 4-Fluoro benzyl mercaptan; 4-fluorobenzylmercaptan; 4-Fluorobenzenemethanethiol; p-Fluorotoluene-alpha-thiol; 4-fluorophenylmethanethiol; 4-fluoro-alpha-toluenethiol; Benzenemethanethiol, 4-fluoro-; (4-fluoro-phenyl)-methanethiol; CHEMBL1224558; 4-Fluorobenzyl mercaptan, 96%; RKTRHMNWVZRZJQ-UHFFFAOYSA-N; 4-fluorobenzylthiol; EINECS 240-031-9; 4-fluorobenzyl thiol; PubChem6855; 4-fluorobenzylmercaptane; AC1Q4NST; p-fluorobenzenemethanethiol; ACMC-209dj5
DMS6RHD DT Small molecular drug
DMS6RHD PC 85171
DMS6RHD MW 142.2
DMS6RHD FM C7H7FS
DMS6RHD IC InChI=1S/C7H7FS/c8-7-3-1-6(5-9)2-4-7/h1-4,9H,5H2
DMS6RHD CS C1=CC(=CC=C1CS)F
DMS6RHD IK RKTRHMNWVZRZJQ-UHFFFAOYSA-N
DMS6RHD IU (4-fluorophenyl)methanethiol
DMS6RHD CA CAS 15894-04-9
DMS6RHD DE Discovery agent
DMWD42N ID DMWD42N
DMWD42N DN 4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2
DMWD42N HS Investigative
DMWD42N SN CHEMBL388586; Peptide analogue, 1; SCHEMBL4132720; BDBM26338; FTM-080; N-[(4-fluorophenyl)carbonyl]-L-phenylalanylglycyl-L-leucyl-L-arginyl-L-tryptophanamide
DMWD42N DT Small molecular drug
DMWD42N PC 16735569
DMWD42N MW 798.9
DMWD42N FM C41H51FN10O6
DMWD42N IC InChI=1S/C41H51FN10O6/c1-24(2)19-33(49-35(53)23-48-38(56)34(20-25-9-4-3-5-10-25)52-37(55)26-14-16-28(42)17-15-26)40(58)50-31(13-8-18-46-41(44)45)39(57)51-32(36(43)54)21-27-22-47-30-12-7-6-11-29(27)30/h3-7,9-12,14-17,22,24,31-34,47H,8,13,18-21,23H2,1-2H3,(H2,43,54)(H,48,56)(H,49,53)(H,50,58)(H,51,57)(H,52,55)(H4,44,45,46)/t31-,32-,33-,34-/m0/s1
DMWD42N CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)C4=CC=C(C=C4)F
DMWD42N IK CSDUUNOZBMGMHZ-CUPIEXAXSA-N
DMWD42N IU N-[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-4-fluorobenzamide
DMWD42N DE Discovery agent
DMV6M5U ID DMV6M5U
DMV6M5U DN 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline
DMV6M5U HS Investigative
DMV6M5U SN CHEMBL1240925; 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline
DMV6M5U DT Small molecular drug
DMV6M5U PC 46937407
DMV6M5U MW 265.31
DMV6M5U FM C13H12FNO2S
DMV6M5U IC InChI=1S/C13H12FNO2S/c1-18(16,17)13-8-6-12(7-9-13)15-11-4-2-10(14)3-5-11/h2-9,15H,1H3
DMV6M5U CS CS(=O)(=O)C1=CC=C(C=C1)NC2=CC=C(C=C2)F
DMV6M5U IK QTRCGPBYCSHGJM-UHFFFAOYSA-N
DMV6M5U IU 4-fluoro-N-(4-methylsulfonylphenyl)aniline
DMV6M5U DE Discovery agent
DMGBKN7 ID DMGBKN7
DMGBKN7 DN 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide
DMGBKN7 HS Investigative
DMGBKN7 SN CHEMBL511186; 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide; 4-({[(4-fluorophenyl)sulfonyl]amino}methyl)benzenesulfonamide; 4-[[[(4-Fluorophenyl)sulfonyl]amino]methyl]benzenesulfonamide; BAS 02065178; AC1LG4NC; Cambridge id 6100956; Oprea1_631950; Oprea1_795607; MolPort-001-510-834; ZINC288074; STK396016; BDBM50247721; AKOS000644386; MCULE-1179145360; ST50706913; AB00102538-01; Z45537946; N-[4-(aminosulfonyl)benzyl]-4-fluoro-1-benzenesulfonamide; 4-[[(4-fluorophenyl)sulfonylamino]methyl]benzenesulfonamide
DMGBKN7 DT Small molecular drug
DMGBKN7 PC 788811
DMGBKN7 MW 344.4
DMGBKN7 FM C13H13FN2O4S2
DMGBKN7 IC InChI=1S/C13H13FN2O4S2/c14-11-3-7-13(8-4-11)22(19,20)16-9-10-1-5-12(6-2-10)21(15,17)18/h1-8,16H,9H2,(H2,15,17,18)
DMGBKN7 CS C1=CC(=CC=C1CNS(=O)(=O)C2=CC=C(C=C2)F)S(=O)(=O)N
DMGBKN7 IK RXAAVLURIXEENO-UHFFFAOYSA-N
DMGBKN7 IU 4-[[(4-fluorophenyl)sulfonylamino]methyl]benzenesulfonamide
DMGBKN7 DE Discovery agent
DMZV3MD ID DMZV3MD
DMZV3MD DN 4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate
DMZV3MD HS Investigative
DMZV3MD SN CHEMBL604388; 4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate; SCHEMBL5215965
DMZV3MD DT Small molecular drug
DMZV3MD PC 20872768
DMZV3MD MW 345.4
DMZV3MD FM C20H24FNO3
DMZV3MD IC InChI=1S/C20H24FNO3/c1-3-5-14-24-17-10-6-15(7-11-17)19(4-2)22-20(23)25-18-12-8-16(21)9-13-18/h6-13,19H,3-5,14H2,1-2H3,(H,22,23)
DMZV3MD CS CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=C(C=C2)F
DMZV3MD IK IEKBPHHXDXKATO-UHFFFAOYSA-N
DMZV3MD IU (4-fluorophenyl) N-[1-(4-butoxyphenyl)propyl]carbamate
DMZV3MD DE Discovery agent
DMCRJ54 ID DMCRJ54
DMCRJ54 DN 4-fluorophenyl 4-butoxybenzylcarbamate
DMCRJ54 HS Investigative
DMCRJ54 SN 4-fluorophenyl 4-butoxybenzylcarbamate; CHEMBL607558; SCHEMBL5216504
DMCRJ54 DT Small molecular drug
DMCRJ54 PC 20872770
DMCRJ54 MW 317.4
DMCRJ54 FM C18H20FNO3
DMCRJ54 IC InChI=1S/C18H20FNO3/c1-2-3-12-22-16-8-4-14(5-9-16)13-20-18(21)23-17-10-6-15(19)7-11-17/h4-11H,2-3,12-13H2,1H3,(H,20,21)
DMCRJ54 CS CCCCOC1=CC=C(C=C1)CNC(=O)OC2=CC=C(C=C2)F
DMCRJ54 IK BVPXJSVMJYBIRX-UHFFFAOYSA-N
DMCRJ54 IU (4-fluorophenyl) N-[(4-butoxyphenyl)methyl]carbamate
DMCRJ54 DE Discovery agent
DMI03KV ID DMI03KV
DMI03KV DN 4-fluorophenyl-2,2-diphenylacetamide
DMI03KV HS Investigative
DMI03KV SN CHEMBL258604; SCHEMBL2337394
DMI03KV DT Small molecular drug
DMI03KV PC 9879550
DMI03KV MW 305.3
DMI03KV FM C20H16FNO
DMI03KV IC InChI=1S/C20H16FNO/c21-18-13-11-17(12-14-18)20(19(22)23,15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-14H,(H2,22,23)
DMI03KV CS C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)F)C(=O)N
DMI03KV IK JHPLFDBQYVMFCT-UHFFFAOYSA-N
DMI03KV IU 2-(4-fluorophenyl)-2,2-diphenylacetamide
DMI03KV DE Discovery agent
DMD5LXQ ID DMD5LXQ
DMD5LXQ DN 4-fluorophenylboronic acid
DMD5LXQ HS Investigative
DMD5LXQ SN 4-Fluorophenylboronic acid; 1765-93-1; 4-Fluorobenzeneboronic acid; (4-fluorophenyl)boronic acid; 4-Fluorophenyl boronic acid; (4-fluorophenyl)boranediol; p-fluorophenylboronic acid; 4-fluorophenylbornic acid; 4-Fluorophenylboric acid; (4-FLUOROPHENYL)DIHYDROXYBORON; p-fluorobenzeneboronic acid; 4-fluoro phenylboronic acid; C6H6BFO2; 4-Fluoro Phenyl Boronic Acid; CHEMBL344890; (4-fluorophenyl)dihydroxyborane; CHEBI:48661; Boronic acid, (4-fluorophenyl)-; LBUNNMJLXWQQBY-UHFFFAOYSA-N; (P-FLUOROPHENYL)BORIC ACID
DMD5LXQ DT Small molecular drug
DMD5LXQ PC 285645
DMD5LXQ MW 139.92
DMD5LXQ FM C6H6BFO2
DMD5LXQ IC InChI=1S/C6H6BFO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4,9-10H
DMD5LXQ CS B(C1=CC=C(C=C1)F)(O)O
DMD5LXQ IK LBUNNMJLXWQQBY-UHFFFAOYSA-N
DMD5LXQ IU (4-fluorophenyl)boronic acid
DMD5LXQ CA CAS 1765-93-1
DMD5LXQ CB CHEBI:48661
DMD5LXQ DE Discovery agent
DMRC49E ID DMRC49E
DMRC49E DN 4-fluoroselegiline
DMRC49E HS Investigative
DMRC49E SN CH-175; SR-96516; P-Fluoro-Selegiline; P-Fluoro-Selegiline hydrochloride
DMRC49E CP Chinoin Gyogyszer Es Vegyeszeti
DMRC49E DE Dementia
DM1VNEF ID DM1VNEF
DM1VNEF DN 4-formylphenyl-O-beta-Dglucopyranoside
DM1VNEF HS Investigative
DM1VNEF SN Helicid; 26993-16-8; HELECIN; 4-formylphenyl b-d-glucopyranoside; 4-Formylphenyl beta-D-glucopyranoside; CHEMBL461515; 4-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde; 4-formylphenyl-O-beta-Dglucopyranoside; helicin hydrate; 4'-Formylphenyl-beta-d-glucopyranoside; Gastrodin Impurity 1; AC1OPT9G; SCHEMBL987981; CTK8F5959; MolPort-000-629-575; ZINC5234422; BDBM50245886; AKOS015960450; AC-7974; 4-formylphenyl-O-beta-D-glucopyranoside; 4-(beta-d-glucopyranosyloxy)benzaldehyde
DM1VNEF DT Small molecular drug
DM1VNEF PC 7573800
DM1VNEF MW 284.26
DM1VNEF FM C13H16O7
DM1VNEF IC InChI=1S/C13H16O7/c14-5-7-1-3-8(4-2-7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-5,9-13,15-18H,6H2/t9-,10-,11+,12-,13-/m1/s1
DM1VNEF CS C1=CC(=CC=C1C=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM1VNEF IK OLZAGZCCJJBKNZ-UJPOAAIJSA-N
DM1VNEF IU 4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde
DM1VNEF DE Discovery agent
DM7DW0G ID DM7DW0G
DM7DW0G DN 4-formylphenyl-O-beta-D-ribopyranoside
DM7DW0G HS Investigative
DM7DW0G SN CHEMBL499285; 4-formylphenyl-O-beta-D-ribopyranoside; 4-formylphenyl beta-d-ribopyranoside; BDBM50245887
DM7DW0G DT Small molecular drug
DM7DW0G PC 24796254
DM7DW0G MW 254.24
DM7DW0G FM C12H14O6
DM7DW0G IC InChI=1S/C12H14O6/c13-5-7-1-3-8(4-2-7)18-12-11(16)10(15)9(14)6-17-12/h1-5,9-12,14-16H,6H2/t9-,10-,11-,12+/m1/s1
DM7DW0G CS C1[C@H]([C@H]([C@H]([C@@H](O1)OC2=CC=C(C=C2)C=O)O)O)O
DM7DW0G IK QGBRWWHJQCFYEI-KKOKHZNYSA-N
DM7DW0G IU 4-[(2S,3R,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxybenzaldehyde
DM7DW0G DE Discovery agent
DMKT915 ID DMKT915
DMKT915 DN 4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline
DMKT915 HS Investigative
DMKT915 SN CHEMBL166948; 4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6364878; APJKUNDSNZQZPA-UHFFFAOYSA-N; BDBM50110576; 2-Piperazino-4-(2-furyl)-6-nitroquinoline
DMKT915 DT Small molecular drug
DMKT915 PC 44379696
DMKT915 MW 324.33
DMKT915 FM C17H16N4O3
DMKT915 IC InChI=1S/C17H16N4O3/c22-21(23)12-3-4-15-13(10-12)14(16-2-1-9-24-16)11-17(19-15)20-7-5-18-6-8-20/h1-4,9-11,18H,5-8H2
DMKT915 CS C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)C4=CC=CO4
DMKT915 IK APJKUNDSNZQZPA-UHFFFAOYSA-N
DMKT915 IU 4-(furan-2-yl)-6-nitro-2-piperazin-1-ylquinoline
DMKT915 DE Discovery agent
DMRF9NH ID DMRF9NH
DMRF9NH DN 4'-GALACTOSYLLACTOSE
DMRF9NH HS Investigative
DMRF9NH SN O-beta-D-Galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-D-glucose; 4'-GL
DMRF9NH DT Small molecular drug
DMRF9NH PC 10874809
DMRF9NH MW 504.4
DMRF9NH FM C18H32O16
DMRF9NH IC InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14-,15+,16?,17+,18+/m1/s1
DMRF9NH CS C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)O)O
DMRF9NH IK FYGDTMLNYKFZSV-YXENHOCSSA-N
DMRF9NH IU (2S,3R,4S,5R,6R)-2-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMRF9NH CA CAS 157240-67-0
DMRF9NH CB CHEBI:63141
DMRF9NH DE Hyperlipidaemia
DM5MHO6 ID DM5MHO6
DM5MHO6 DN 4-Hept-3-ynyl-1H-imidazole
DM5MHO6 HS Investigative
DM5MHO6 SN CHEMBL276804; 4-Hept-3-ynyl-1H-imidazole; 1H-Imidazole, 5-(3-heptyn-1-yl)-; SCHEMBL7620435; 4-(3-Heptynyl)-1H-imidazole; BDBM50070215
DM5MHO6 DT Small molecular drug
DM5MHO6 PC 10630835
DM5MHO6 MW 162.23
DM5MHO6 FM C10H14N2
DM5MHO6 IC InChI=1S/C10H14N2/c1-2-3-4-5-6-7-10-8-11-9-12-10/h8-9H,2-3,6-7H2,1H3,(H,11,12)
DM5MHO6 CS CCCC#CCCC1=CN=CN1
DM5MHO6 IK UDXIRDIVFQGLKT-UHFFFAOYSA-N
DM5MHO6 IU 5-hept-3-ynyl-1H-imidazole
DM5MHO6 DE Discovery agent
DMA3MX5 ID DMA3MX5
DMA3MX5 DN 4-heptyl-N-(pyridin-3-yl)benzamide
DMA3MX5 HS Investigative
DMA3MX5 SN CHEMBL263921
DMA3MX5 DT Small molecular drug
DMA3MX5 PC 44450346
DMA3MX5 MW 296.4
DMA3MX5 FM C19H24N2O
DMA3MX5 IC InChI=1S/C19H24N2O/c1-2-3-4-5-6-8-16-10-12-17(13-11-16)19(22)21-18-9-7-14-20-15-18/h7,9-15H,2-6,8H2,1H3,(H,21,22)
DMA3MX5 CS CCCCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMA3MX5 IK XRYFRVDOZOSYGN-UHFFFAOYSA-N
DMA3MX5 IU 4-heptyl-N-pyridin-3-ylbenzamide
DMA3MX5 CA CAS 1029437-48-6
DMA3MX5 DE Discovery agent
DMAHLF6 ID DMAHLF6
DMAHLF6 DN 4-heptyl-N-(quinolin-3-yl)benzamide
DMAHLF6 HS Investigative
DMAHLF6 SN CHEMBL406860; AC1MYO1K; SCHEMBL846864; 4-heptyl-N-quinolin-3-ylbenzamide; BDBM50376279
DMAHLF6 DT Small molecular drug
DMAHLF6 PC 3884807
DMAHLF6 MW 346.5
DMAHLF6 FM C23H26N2O
DMAHLF6 IC InChI=1S/C23H26N2O/c1-2-3-4-5-6-9-18-12-14-19(15-13-18)23(26)25-21-16-20-10-7-8-11-22(20)24-17-21/h7-8,10-17H,2-6,9H2,1H3,(H,25,26)
DMAHLF6 CS CCCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMAHLF6 IK VJFYODCLTPGLMR-UHFFFAOYSA-N
DMAHLF6 IU 4-heptyl-N-quinolin-3-ylbenzamide
DMAHLF6 DE Discovery agent
DMYNTJ0 ID DMYNTJ0
DMYNTJ0 DN 4-Hex-3-ynyl-1H-imidazole
DMYNTJ0 HS Investigative
DMYNTJ0 SN CHEMBL14721; 4-Hex-3-ynyl-1H-imidazole; SCHEMBL7627737; 4-(3-Hexynyl)-1H-imidazole; BDBM50070219
DMYNTJ0 DT Small molecular drug
DMYNTJ0 PC 10749338
DMYNTJ0 MW 148.2
DMYNTJ0 FM C9H12N2
DMYNTJ0 IC InChI=1S/C9H12N2/c1-2-3-4-5-6-9-7-10-8-11-9/h7-8H,2,5-6H2,1H3,(H,10,11)
DMYNTJ0 CS CCC#CCCC1=CN=CN1
DMYNTJ0 IK KXZPBLYVPNSMHH-UHFFFAOYSA-N
DMYNTJ0 IU 5-hex-3-ynyl-1H-imidazole
DMYNTJ0 DE Discovery agent
DM36JUD ID DM36JUD
DM36JUD DN 4-hexyl resorcinol
DM36JUD HS Investigative
DM36JUD SN hexylresorcinol; 4-Hexylresorcinol; 4-hexylbenzene-1,3-diol; 136-77-6; Ascarinol; Antascarin; 4-Hexyl-1,3-benzenediol; Ascaricid; p-Hexylresorcinol; 4-n-Hexylresorcinol; Hidesol; Caprokol; Adrover; Oxana; Crystoids; Prensol; 4-Hexylresorcine; 1,3-Benzenediol, 4-hexyl-; Sucrets; Hexylresorcin; Gelovermin; Ascaryl; 4-Hexyl-1,3-dihydroxybenzene; 4-(1-Hexyl)resorcinol; Cystoids anthelmintic; 1,3-Dihydroxy-4-hexylbenzene; Worm-agen; Resorcinol, 4-hexyl-; Hexylresorzin; Mycoderm; 1,3-Dihydroxy-4-n-hexylbenzene; NCI-C55787
DM36JUD DT Small molecular drug
DM36JUD PC 3610
DM36JUD MW 194.27
DM36JUD FM C12H18O2
DM36JUD IC InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3
DM36JUD CS CCCCCCC1=C(C=C(C=C1)O)O
DM36JUD IK WFJIVOKAWHGMBH-UHFFFAOYSA-N
DM36JUD IU 4-hexylbenzene-1,3-diol
DM36JUD CA CAS 136-77-6
DM36JUD CB CHEBI:93749
DM36JUD DE Discovery agent
DM5E03C ID DM5E03C
DM5E03C DN 4-hexyl-N-(quinolin-3-yl)benzamide
DM5E03C HS Investigative
DM5E03C SN CHEMBL258623; SCHEMBL846650
DM5E03C DT Small molecular drug
DM5E03C PC 44450347
DM5E03C MW 332.4
DM5E03C FM C22H24N2O
DM5E03C IC InChI=1S/C22H24N2O/c1-2-3-4-5-8-17-11-13-18(14-12-17)22(25)24-20-15-19-9-6-7-10-21(19)23-16-20/h6-7,9-16H,2-5,8H2,1H3,(H,24,25)
DM5E03C CS CCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM5E03C IK RTKCLHOLWGNTOT-UHFFFAOYSA-N
DM5E03C IU 4-hexyl-N-quinolin-3-ylbenzamide
DM5E03C DE Discovery agent
DMONZ0Y ID DMONZ0Y
DMONZ0Y DN 4-hexylphenyl propiolate
DMONZ0Y HS Investigative
DMONZ0Y SN 4-hexylphenyl propiolate; 4-hexylphenyl prop-2-ynoate; Propiolic acid derivative, 8b; CHEMBL236338; BDBM18854
DMONZ0Y DT Small molecular drug
DMONZ0Y PC 23635856
DMONZ0Y MW 230.3
DMONZ0Y FM C15H18O2
DMONZ0Y IC InChI=1S/C15H18O2/c1-3-5-6-7-8-13-9-11-14(12-10-13)17-15(16)4-2/h2,9-12H,3,5-8H2,1H3
DMONZ0Y CS CCCCCCC1=CC=C(C=C1)OC(=O)C#C
DMONZ0Y IK IAEVDNHEIHTNJR-UHFFFAOYSA-N
DMONZ0Y IU (4-hexylphenyl) prop-2-ynoate
DMONZ0Y DE Discovery agent
DMSZMQU ID DMSZMQU
DMSZMQU DN 4-Hydrazino-3-pyridinesulfonamide
DMSZMQU HS Investigative
DMSZMQU SN 4-hydrazinylpyridine-3-sulfonamide; 73742-76-4; CHEMBL1164967; 4-Hydrazino-3-pyridinesulfonamide; 4-Hydrazinopyridine-3-sulfonamide; MolPort-004-759-861; 3-pyridinesulfonamide,4-hydrazino-; ZINC39054028; BDBM50320510; AKOS006341241; AJ-97667; 3-Pyridinesulfonamide,4-hydrazino-(9CI); KB-184865; ST24043768; FT-0705130
DMSZMQU DT Small molecular drug
DMSZMQU PC 12554666
DMSZMQU MW 188.21
DMSZMQU FM C5H8N4O2S
DMSZMQU IC InChI=1S/C5H8N4O2S/c6-9-4-1-2-8-3-5(4)12(7,10)11/h1-3H,6H2,(H,8,9)(H2,7,10,11)
DMSZMQU CS C1=CN=CC(=C1NN)S(=O)(=O)N
DMSZMQU IK PTRSDYFZXIJRKG-UHFFFAOYSA-N
DMSZMQU IU 4-hydrazinylpyridine-3-sulfonamide
DMSZMQU DE Discovery agent
DM49B18 ID DM49B18
DM49B18 DN 4-Hydrazino-benzenesulfonamide
DM49B18 HS Investigative
DM49B18 SN 4-hydrazinylbenzenesulfonamide
DM49B18 DT Small molecular drug
DM49B18 PC 78105
DM49B18 MW 187.22
DM49B18 FM C6H9N3O2S
DM49B18 IC InChI=1S/C6H9N3O2S/c7-9-5-1-3-6(4-2-5)12(8,10)11/h1-4,9H,7H2,(H2,8,10,11)
DM49B18 CS C1=CC(=CC=C1NN)S(=O)(=O)N
DM49B18 IK NBJSNAGTUCWQRO-UHFFFAOYSA-N
DM49B18 IU 4-hydrazinylbenzenesulfonamide
DM49B18 CA CAS 4392-54-5
DM49B18 DE Discovery agent
DM8PBEJ ID DM8PBEJ
DM8PBEJ DN 4-Hydrazinocarbonyl-benzenesulfonamide
DM8PBEJ HS Investigative
DM8PBEJ SN 4-(hydrazinecarbonyl)benzenesulfonamide; 35264-29-0; 4-(hydrazinecarbonyl)benzene-1-sulfonamide; JIDAHYHCQJXNTD-UHFFFAOYSA-N; 4-(hydrazinylcarbonyl)benzenesulfonamide; 4- benzenesulfonamide; 4-HYDRAZINOCARBONYL-BENZENE-SULFONAMIDE; hydrazide 2; p-Sulfamylbenzoic acid hydrazide; AC1L7XIP; CHEMBL180323; SCHEMBL4616920; BDBM12136; CTK4H4135; DTXSID60312358; 4-Sulfamoylbenzoic acid hydrazide; MolPort-000-887-192; ZINC1556993; STK349231; SBB021016; 4376AB; NSC252930; AKOS000305291; MCULE-5832659214
DM8PBEJ DT Small molecular drug
DM8PBEJ PC 318174
DM8PBEJ MW 215.23
DM8PBEJ FM C7H9N3O3S
DM8PBEJ IC InChI=1S/C7H9N3O3S/c8-10-7(11)5-1-3-6(4-2-5)14(9,12)13/h1-4H,8H2,(H,10,11)(H2,9,12,13)
DM8PBEJ CS C1=CC(=CC=C1C(=O)NN)S(=O)(=O)N
DM8PBEJ IK JIDAHYHCQJXNTD-UHFFFAOYSA-N
DM8PBEJ IU 4-(hydrazinecarbonyl)benzenesulfonamide
DM8PBEJ CA CAS 35264-29-0
DM8PBEJ DE Discovery agent
DM6WJ4K ID DM6WJ4K
DM6WJ4K DN 4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid
DM6WJ4K HS Investigative
DM6WJ4K SN 4-HYDROXY-1,2,5-OXADIAZOLE-3-CARBOXYLIC ACID; 4-Hydroxy-furazan-3-carboxylic acid; 66313-36-8; OXQ; AC1L9M6V; 1,2,5-oxadiazole, OXD1; SCHEMBL1043406; CTK8F6043; CTK7J1234; BDBM23232; MolPort-002-679-216; ZINC6523895; FCH841687; AKOS030214651; AKOS000301440; DB02401; MCULE-2928095407; ST077901; TR-055247; AX8302019; 4-oxo-1,2,5-oxadiazole-3-carboxylic acid; BB 0257536
DM6WJ4K DT Small molecular drug
DM6WJ4K PC 448650
DM6WJ4K MW 130.06
DM6WJ4K FM C3H2N2O4
DM6WJ4K IC InChI=1S/C3H2N2O4/c6-2-1(3(7)8)4-9-5-2/h(H,5,6)(H,7,8)
DM6WJ4K CS C1(=NONC1=O)C(=O)O
DM6WJ4K IK IBRWUZLLHSXPKL-UHFFFAOYSA-N
DM6WJ4K IU 4-oxo-1,2,5-oxadiazole-3-carboxylic acid
DM6WJ4K CA CAS 66313-36-8
DM6WJ4K DE Discovery agent
DME29PX ID DME29PX
DME29PX DN 4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid
DME29PX HS Investigative
DME29PX SN 4-HYDROXY-1,2,5-THIADIAZOLE-3-CARBOXYLIC ACID; LDHA Inhibitor, 1; 45654-48-6; GBD; AC1L9M6Z; C3H2N2O3S; 1,2,5-Thiadiazole, TDA1; SCHEMBL2573610; CHEMBL1232973; BDBM23251; MolPort-006-168-875; ZINC6523896; AKOS006380523; DB03162; 4-oxo-1,2,5-thiadiazole-3-carboxylic acid; Z2467454497; 4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid
DME29PX DT Small molecular drug
DME29PX PC 448652
DME29PX MW 146.13
DME29PX FM C3H2N2O3S
DME29PX IC InChI=1S/C3H2N2O3S/c6-2-1(3(7)8)4-9-5-2/h(H,5,6)(H,7,8)
DME29PX CS C1(=NSNC1=O)C(=O)O
DME29PX IK FVZITYNLUYJDOE-UHFFFAOYSA-N
DME29PX IU 4-oxo-1,2,5-thiadiazole-3-carboxylic acid
DME29PX CA CAS 45654-48-6
DME29PX DE Discovery agent
DMTZ9G3 ID DMTZ9G3
DMTZ9G3 DN 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone
DMTZ9G3 HS Investigative
DMTZ9G3 PC 285836
DMTZ9G3 MW 323.4
DMTZ9G3 FM C21H25NO2
DMTZ9G3 IC InChI=1S/C21H25NO2/c1-15-4-8-17(9-5-15)20(23)19-14-22(3)13-12-21(19,24)18-10-6-16(2)7-11-18/h4-11,19,24H,12-14H2,1-3H3
DMTZ9G3 CS CC1=CC=C(C=C1)C(=O)C2CN(CCC2(C3=CC=C(C=C3)C)O)C
DMTZ9G3 IK SWFNNRQTSSTAGB-UHFFFAOYSA-N
DMTZ9G3 IU [4-hydroxy-1-methyl-4-(4-methylphenyl)piperidin-3-yl]-(4-methylphenyl)methanone
DMTZ9G3 DE Discovery agent
DM7BQ65 ID DM7BQ65
DM7BQ65 DN 4-Hydroxy-2-Butanone
DM7BQ65 HS Investigative
DM7BQ65 SN 4-Hydroxy-2-butanone; 4-Hydroxybutan-2-one; 590-90-9; 2-Butanone, 4-hydroxy-; Methylolacetone; 3-Oxo-1-butanol; 3-Oxobutanol; 3-Ketobutan-1-ol; Monomethylolacetone; 4-Butanol-2-one; UNII-TCM0BJ44MF; 2-Hydroxyethyl methyl ketone; NSC 41219; TCM0BJ44MF; CH3C(O)CH2CH2OH; LVSQXDHWDCMMRJ-UHFFFAOYSA-N; BUQ; Ketones, C4-6, beta-hydroxy; 3-ketobutanol; 4-hydroxy butanone; EINECS 209-693-6; 1-hydroxy-3-butanone; 4-oxidanylbutan-2-one; 1d7j; 1 -hydroxy-3-butanone; 4-hydroxy-butan-2-one; AI3-11747; EC 209-693-6; ACMC-1B12A
DM7BQ65 DT Small molecular drug
DM7BQ65 PC 111509
DM7BQ65 MW 88.11
DM7BQ65 FM C4H8O2
DM7BQ65 IC InChI=1S/C4H8O2/c1-4(6)2-3-5/h5H,2-3H2,1H3
DM7BQ65 CS CC(=O)CCO
DM7BQ65 IK LVSQXDHWDCMMRJ-UHFFFAOYSA-N
DM7BQ65 IU 4-hydroxybutan-2-one
DM7BQ65 CA CAS 590-90-9
DM7BQ65 CB CHEBI:41268
DM7BQ65 DE Discovery agent
DM2LJFZ ID DM2LJFZ
DM2LJFZ DN 4-hydroxy-2-nonenal
DM2LJFZ HS Investigative
DM2LJFZ SN 4-Hydroxynonenal; 4-Hydroxy-2-nonenal; 4-hydroxynon-2-enal; trans-4-Hydroxy-2-nonenal; 4-Hydroxy-2,3-nonenal; 4-HNE; 75899-68-2; 4-hydroxy-2E-nonenal; (E)-4-hydroxynon-2-enal; CCRIS 9028; CCRIS 1781; 29343-52-0; 128946-65-6; 2-NONENAL, 4-HYDROXY-; HNE; (E)-4-hydroxy-2-nonenal; (2E)-4-hydroxynon-2-enal; (2E)-4-Hydroxy-2-nonenal; CHEMBL454280; CHEBI:58968; C9H16O2; (+/-)4-HYDROXYNON-2-ENAL; NCGC00161254-02; 4-hydroxynonen-2-al; CHEBI:32585; CCRIS 6927; 4 hydroxynonenal; (E)-4-Hydroxynonenal; AC1Q2VOQ; 4HNE; SCHEMBL3920; AC1Q6PP5; AC1NR22M
DM2LJFZ DT Small molecular drug
DM2LJFZ PC 5283344
DM2LJFZ MW 156.22
DM2LJFZ FM C9H16O2
DM2LJFZ IC InChI=1S/C9H16O2/c1-2-3-4-6-9(11)7-5-8-10/h5,7-9,11H,2-4,6H2,1H3/b7-5+
DM2LJFZ CS CCCCCC(/C=C/C=O)O
DM2LJFZ IK JVJFIQYAHPMBBX-FNORWQNLSA-N
DM2LJFZ IU (E)-4-hydroxynon-2-enal
DM2LJFZ CA CAS 75899-68-2
DM2LJFZ CB CHEBI:58968
DM2LJFZ DE Discovery agent
DMY3OHK ID DMY3OHK
DMY3OHK DN 4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one
DMY3OHK HS Investigative
DMY3OHK SN SCHEMBL7353536; CHEMBL582933; BDBM35549; 4-hydroxy-2H-chromen-2-one core, 25
DMY3OHK DT Small molecular drug
DMY3OHK PC 54711585
DMY3OHK MW 302.3
DMY3OHK FM C20H14O3
DMY3OHK IC InChI=1S/C20H14O3/c21-19-16-10-3-4-11-18(16)23-20(22)17(19)12-14-8-5-7-13-6-1-2-9-15(13)14/h1-11,21H,12H2
DMY3OHK CS C1=CC=C2C(=C1)C=CC=C2CC3=C(C4=CC=CC=C4OC3=O)O
DMY3OHK IK PRHLSJVWKOFWSE-UHFFFAOYSA-N
DMY3OHK IU 4-hydroxy-3-(naphthalen-1-ylmethyl)chromen-2-one
DMY3OHK DE Discovery agent
DMM3QPL ID DMM3QPL
DMM3QPL DN 4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one
DMM3QPL HS Investigative
DMM3QPL SN CHEMBL571283; SCHEMBL7354617; BDBM35550; 4-hydroxy-2H-chromen-2-one core, 26
DMM3QPL DT Small molecular drug
DMM3QPL PC 54724899
DMM3QPL MW 302.3
DMM3QPL FM C20H14O3
DMM3QPL IC InChI=1S/C20H14O3/c21-19-16-7-3-4-8-18(16)23-20(22)17(19)12-13-9-10-14-5-1-2-6-15(14)11-13/h1-11,21H,12H2
DMM3QPL CS C1=CC=C2C=C(C=CC2=C1)CC3=C(C4=CC=CC=C4OC3=O)O
DMM3QPL IK UHCUHNQBQRRJOC-UHFFFAOYSA-N
DMM3QPL IU 4-hydroxy-3-(naphthalen-2-ylmethyl)chromen-2-one
DMM3QPL DE Discovery agent
DM2PS89 ID DM2PS89
DM2PS89 DN 4-Hydroxy-3,5-diisopropyl-benzaldehyde
DM2PS89 HS Investigative
DM2PS89 SN 4-hydroxy-3,5-diisopropylbenzaldehyde; 10537-86-7; 4-Hydroxy-3,5-bis(isopropyl)benzaldehyde; 4-hydroxy-3,5-di(propan-2-yl)benzaldehyde; 3,5-diisopropyl-4-hydroxybenzaldehyde; WVGDLTQPAQUBMO-UHFFFAOYSA-N; EINECS 234-111-2; CDS1_003950; CBMicro_017454; Cambridge id 5318853; AC1L33YK; CHEMBL55354; DivK1c_004990; AC1Q6Q36; SCHEMBL2597919; CTK4A3796; DTXSID50147095; MolPort-002-144-464; ZINC297726; CCG-6041; ANW-58021; CD-932; 3,5-diisopropy-4-hydroxylbenzaldehyde; AKOS000100686; MCULE-9155785460; 3,5-diisopropyl-4-hydroxylbenzaldehyde
DM2PS89 DT Small molecular drug
DM2PS89 PC 82712
DM2PS89 MW 206.28
DM2PS89 FM C13H18O2
DM2PS89 IC InChI=1S/C13H18O2/c1-8(2)11-5-10(7-14)6-12(9(3)4)13(11)15/h5-9,15H,1-4H3
DM2PS89 CS CC(C)C1=CC(=CC(=C1O)C(C)C)C=O
DM2PS89 IK WVGDLTQPAQUBMO-UHFFFAOYSA-N
DM2PS89 IU 4-hydroxy-3,5-di(propan-2-yl)benzaldehyde
DM2PS89 CA CAS 10537-86-7
DM2PS89 DE Discovery agent
DMWDBHC ID DMWDBHC
DMWDBHC DN 4-Hydroxy-3-methyl-but-2-enoic acid
DMWDBHC HS Investigative
DMWDBHC SN 44647-19-0; (E)-4-hydroxy-3-methylbut-2-enoic acid; CHEMBL353481; SCHEMBL6282205; SCHEMBL8370948; 4-hydroxy-3-methylcrotonic acid; 3-(Hydroxymethyl)-2-butenoic acid; 4-hydroxy-3-methylbut-2-enoic acid; AKOS013086986; FCH4103824; FCH2609833; BBV-37850347; (E)-4-Hydroxy-3-methyl-2-butenoic acid; (2E)-4-hydroxy-3-methylbut-2-enoic acid
DMWDBHC DT Small molecular drug
DMWDBHC PC 11389379
DMWDBHC MW 116.11
DMWDBHC FM C5H8O3
DMWDBHC IC InChI=1S/C5H8O3/c1-4(3-6)2-5(7)8/h2,6H,3H2,1H3,(H,7,8)/b4-2+
DMWDBHC CS C/C(=C\\C(=O)O)/CO
DMWDBHC IK BERUOTKXCOOJJM-DUXPYHPUSA-N
DMWDBHC IU (E)-4-hydroxy-3-methylbut-2-enoic acid
DMWDBHC DE Discovery agent
DM6AHO4 ID DM6AHO4
DM6AHO4 DN 4-Hydroxy-3-methyl-butyric acid
DM6AHO4 HS Investigative
DM6AHO4 SN 4-Hydroxyisovaleric acid; 4-Hydroxyisovalerate; 4-Hydroxyisopentanoate; 4-Hydroxyisopentanoic acid; 4-hydroxy-3-methylbutanoic acid; 4-hydroxy-isovaleric acid; 77220-86-1; CHEBI:90005; 3-methyl-4-hydroxy-butanoic acid; AC1Q5V9X; AC1Q2B3C; AC1L2ZR2; SCHEMBL43435; CHEMBL353863; CTK5E4050; Butanoic acid,4-hydroxy-3-methyl-; Butanoic acid, 4-hydroxy-3-methyl-; LMFA01050399; AKOS006373039; 4-Hydroxyisovaleric acid sodium salt hydrate, analytical standard
DM6AHO4 DT Small molecular drug
DM6AHO4 PC 131760
DM6AHO4 MW 118.13
DM6AHO4 FM C5H10O3
DM6AHO4 IC InChI=1S/C5H10O3/c1-4(3-6)2-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)
DM6AHO4 CS CC(CC(=O)O)CO
DM6AHO4 IK ZGYGEPZZMAXSKH-UHFFFAOYSA-N
DM6AHO4 IU 4-hydroxy-3-methylbutanoic acid
DM6AHO4 CA CAS 77220-86-1
DM6AHO4 CB CHEBI:90005
DM6AHO4 DE Discovery agent
DMR0S8X ID DMR0S8X
DMR0S8X DN 4-hydroxy-3-nitrobenzaldehyde
DMR0S8X HS Investigative
DMR0S8X SN 4-Hydroxy-3-nitrobenzaldehyde; 3011-34-5; Benzaldehyde, 4-hydroxy-3-nitro-; 3-nitro-4-hydroxybenzaldehyde; CHEMBL378361; 4-hydroxy-3-nitro-benzaldehyde; 4-FORMYL-2-NITROPHENOL; YTHJCZRFJGXPTL-UHFFFAOYSA-N; 4-Hydroxy-3-nitrobenzaldehyde, 97%; EINECS 221-141-6; NSC138267; NSC 138267; PubChem8135; ACMC-1CJNU; AC1L2BHN; 4-hydroxy-3-nitrobenzaldeyde; KSC223K5F; SCHEMBL244093; 4-hydroxyl-3-nitrobenzaldehyde; 4-Hydroxy-3-nitro benzaldehyde; Jsp005694; KS-00000AYN; CTK1C3552; DTXSID80184195; MolPort-000-156-359; ZINC562702; ACT01022
DMR0S8X DT Small molecular drug
DMR0S8X PC 18169
DMR0S8X MW 167.12
DMR0S8X FM C7H5NO4
DMR0S8X IC InChI=1S/C7H5NO4/c9-4-5-1-2-7(10)6(3-5)8(11)12/h1-4,10H
DMR0S8X CS C1=CC(=C(C=C1C=O)[N+](=O)[O-])O
DMR0S8X IK YTHJCZRFJGXPTL-UHFFFAOYSA-N
DMR0S8X IU 4-hydroxy-3-nitrobenzaldehyde
DMR0S8X CA CAS 3011-34-5
DMR0S8X DE Discovery agent
DMDEMV8 ID DMDEMV8
DMDEMV8 DN 4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one
DMDEMV8 HS Investigative
DMDEMV8 SN CHEMBL7816; 4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one; SCHEMBL10337787
DMDEMV8 DT Small molecular drug
DMDEMV8 PC 54737457
DMDEMV8 MW 364.5
DMDEMV8 FM C22H36O4
DMDEMV8 IC InChI=1S/C22H36O4/c1-3-5-7-9-11-13-15-18-17-20(24)21(22(25)26-18)19(23)16-14-12-10-8-6-4-2/h17,24H,3-16H2,1-2H3
DMDEMV8 CS CCCCCCCCC1=CC(=C(C(=O)O1)C(=O)CCCCCCCC)O
DMDEMV8 IK NLATVPVYSKNDRM-UHFFFAOYSA-N
DMDEMV8 IU 4-hydroxy-3-nonanoyl-6-octylpyran-2-one
DMDEMV8 DE Discovery agent
DMIVQGW ID DMIVQGW
DMIVQGW DN 4-Hydroxy-4-phenyl-but-2-enoic acid
DMIVQGW HS Investigative
DMIVQGW SN 4-hydroxy-4-phenylbut-2-enoic acid; 99389-54-5; CHEMBL435474
DMIVQGW DT Small molecular drug
DMIVQGW PC 14168401
DMIVQGW MW 178.18
DMIVQGW FM C10H10O3
DMIVQGW IC InChI=1S/C10H10O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h1-7,9,11H,(H,12,13)/b7-6+
DMIVQGW CS C1=CC=C(C=C1)C(/C=C/C(=O)O)O
DMIVQGW IK JJTRLNDAHGRZGZ-VOTSOKGWSA-N
DMIVQGW IU (E)-4-hydroxy-4-phenylbut-2-enoic acid
DMIVQGW DE Discovery agent
DMDWGS9 ID DMDWGS9
DMDWGS9 DN 4-Hydroxy-4-phenyl-butyric acid
DMDWGS9 HS Investigative
DMDWGS9 SN 4-Hydroxy-4-phenyl-butyric acid; 4-hydroxy-4-phenylbutanoic acid; 34674-93-6; BAS 00281341; AC1O5G7Z; SCHEMBL258372; CHEMBL170514; 4-Hydroxy-4-phenylbutyric acid; gamma-Hydroxybenzenebutanoic acid; CTK7J6414; SBB010649; AKOS016038533; AKOS000301399; MCULE-4325680851; BBV-183857; TR-045028; BB0266635; ST50341916
DMDWGS9 DT Small molecular drug
DMDWGS9 PC 6483718
DMDWGS9 MW 180.2
DMDWGS9 FM C10H12O3
DMDWGS9 IC InChI=1S/C10H12O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h1-5,9,11H,6-7H2,(H,12,13)
DMDWGS9 CS C1=CC=C(C=C1)C(CCC(=O)O)O
DMDWGS9 IK OGQGIKZPOBBMNO-UHFFFAOYSA-N
DMDWGS9 IU 4-hydroxy-4-phenylbutanoic acid
DMDWGS9 DE Discovery agent
DMVFKSX ID DMVFKSX
DMVFKSX DN 4-Hydroxy-5-methoxy-10H-anthracen-9-one
DMVFKSX HS Investigative
DMVFKSX SN CHEMBL123148; 4-hydroxy-5-methoxy-10H-anthracen-9-one; ZINC13606502; BDBM50060871
DMVFKSX DT Small molecular drug
DMVFKSX PC 10776422
DMVFKSX MW 240.25
DMVFKSX FM C15H12O3
DMVFKSX IC InChI=1S/C15H12O3/c1-18-14-7-3-5-10-12(14)8-11-9(15(10)17)4-2-6-13(11)16/h2-7,16H,8H2,1H3
DMVFKSX CS COC1=CC=CC2=C1CC3=C(C2=O)C=CC=C3O
DMVFKSX IK ZLLAABQSJKWBDB-UHFFFAOYSA-N
DMVFKSX IU 4-hydroxy-5-methoxy-10H-anthracen-9-one
DMVFKSX DE Discovery agent
DMT3H2X ID DMT3H2X
DMT3H2X DN 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one
DMT3H2X HS Investigative
DMT3H2X SN CHEMBL414672; 4-hydroxy-5-phenyl-Thieno[2,3-b]pyridin-6(7H)-one; 179337-87-2; SCHEMBL1077245; SCHEMBL16776799; CTK7H0273; ZINC13679983; AKOS015965514; DA-09113; 4-Hydroxy-5-phenyl-7H-thieno[2,3-b]; FT-0762488
DMT3H2X DT Small molecular drug
DMT3H2X PC 54688796
DMT3H2X MW 243.28
DMT3H2X FM C13H9NO2S
DMT3H2X IC InChI=1S/C13H9NO2S/c15-11-9-6-7-17-13(9)14-12(16)10(11)8-4-2-1-3-5-8/h1-7H,(H2,14,15,16)
DMT3H2X CS C1=CC=C(C=C1)C2=C(C3=C(NC2=O)SC=C3)O
DMT3H2X IK LLZJLIULTBEDHM-UHFFFAOYSA-N
DMT3H2X IU 4-hydroxy-5-phenyl-7H-thieno[2,3-b]pyridin-6-one
DMT3H2X DE Discovery agent
DM7PWOL ID DM7PWOL
DM7PWOL DN 4'-hydroxy-6,3',5'-triprenylisoflavonone
DM7PWOL HS Investigative
DM7PWOL SN CHEMBL465773; BDBM50292387; AKOS025289213
DM7PWOL DT Small molecular drug
DM7PWOL PC 129847997
DM7PWOL MW 458.6
DM7PWOL FM C30H34O4
DM7PWOL IC InChI=1S/C30H34O4/c1-18(2)7-10-21-11-14-26-25(15-21)29(32)27(30(33)34-26)24-16-22(12-8-19(3)4)28(31)23(17-24)13-9-20(5)6/h7-9,11,14-17,27,31H,10,12-13H2,1-6H3
DM7PWOL CS CC(=CCC1=CC2=C(C=C1)OC(=O)C(C2=O)C3=CC(=C(C(=C3)CC=C(C)C)O)CC=C(C)C)C
DM7PWOL IK XVMLCODOINIZIF-UHFFFAOYSA-N
DM7PWOL IU 3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-6-(3-methylbut-2-enyl)chromene-2,4-dione
DM7PWOL DE Discovery agent
DMH78QU ID DMH78QU
DMH78QU DN 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one
DMH78QU HS Investigative
DMH78QU SN CHEMBL413773; 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4469573; ZINC36185238; BDBM50189455
DMH78QU DT Small molecular drug
DMH78QU PC 54737894
DMH78QU MW 282.25
DMH78QU FM C15H10N2O4
DMH78QU IC InChI=1S/C15H10N2O4/c18-14-11-8-10(17(20)21)6-7-12(11)16-15(19)13(14)9-4-2-1-3-5-9/h1-8H,(H2,16,18,19)
DMH78QU CS C1=CC=C(C=C1)C2=C(C3=C(C=CC(=C3)[N+](=O)[O-])NC2=O)O
DMH78QU IK FHJYCGCXAYLWFD-UHFFFAOYSA-N
DMH78QU IU 4-hydroxy-6-nitro-3-phenyl-1H-quinolin-2-one
DMH78QU DE Discovery agent
DMD3OV8 ID DMD3OV8
DMD3OV8 DN 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one
DMD3OV8 HS Investigative
DMD3OV8 SN CHEMBL377646; 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one; SCHEMBL4456699; BDBM50189477; 2(1H)-Quinolinone, 4-hydroxy-8-nitro-3-phenyl-
DMD3OV8 DT Small molecular drug
DMD3OV8 PC 54737904
DMD3OV8 MW 282.25
DMD3OV8 FM C15H10N2O4
DMD3OV8 IC InChI=1S/C15H10N2O4/c18-14-10-7-4-8-11(17(20)21)13(10)16-15(19)12(14)9-5-2-1-3-6-9/h1-8H,(H2,16,18,19)
DMD3OV8 CS C1=CC=C(C=C1)C2=C(C3=C(C(=CC=C3)[N+](=O)[O-])NC2=O)O
DMD3OV8 IK XWRIMEVQDODFAZ-UHFFFAOYSA-N
DMD3OV8 IU 4-hydroxy-8-nitro-3-phenyl-1H-quinolin-2-one
DMD3OV8 DE Discovery agent
DMT8L5R ID DMT8L5R
DMT8L5R DN 4-Hydroxy-Aconitate Ion
DMT8L5R HS Investigative
DMT8L5R SN 4-hydroxy-aconitate ion; ATH; AC1NRA5R; DB03964; (E,3R)-3-hydroxyprop-1-ene-1,2,3-tricarboxylate
DMT8L5R DT Small molecular drug
DMT8L5R PC 5287714
DMT8L5R MW 187.08
DMT8L5R FM C6H3O7-3
DMT8L5R IC InChI=1S/C6H6O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h1,4,9H,(H,7,8)(H,10,11)(H,12,13)/p-3/b2-1+/t4-/m1/s1
DMT8L5R CS C(=C(\\[C@H](C(=O)[O-])O)/C(=O)[O-])\\C(=O)[O-]
DMT8L5R IK WUUVSJBKHXDKBS-ROFOPDMZSA-K
DMT8L5R IU (E,3R)-3-hydroxyprop-1-ene-1,2,3-tricarboxylate
DMT8L5R DE Discovery agent
DM7WPGN ID DM7WPGN
DM7WPGN DN 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME
DM7WPGN HS Investigative
DM7WPGN DT Small molecular drug
DM7WPGN PC 135566316
DM7WPGN MW 247.29
DM7WPGN FM C14H17NO3
DM7WPGN IC InChI=1S/C14H17NO3/c16-13-8-6-11(7-9-13)10-15-18-14(17)12-4-2-1-3-5-12/h6-10,12,16H,1-5H2/b15-10-
DM7WPGN CS C1CCC(CC1)C(=O)O/N=C\\C2=CC=C(C=C2)O
DM7WPGN IK YWZBYSBZDQWXGQ-GDNBJRDFSA-N
DM7WPGN IU [(Z)-(4-hydroxyphenyl)methylideneamino] cyclohexanecarboxylate
DM7WPGN DE Discovery agent
DMJVPF0 ID DMJVPF0
DMJVPF0 DN 4-hydroxybenzylamine
DMJVPF0 HS Investigative
DMJVPF0 SN 4-Hydroxybenzylamine; 4-(aminomethyl)phenol; 696-60-6; 4-Aminomethyl-phenol; para-Hydroxybenzylamine; UNII-7J7F85B7BI; 4-aminomethylphenol; CHEMBL202519; 7J7F85B7BI; (4-HYDROXYPHENYL)METHANAMINIUM BROMIDE; 4-Hydroxybenzylamine hydrate, 97%; a-Amino-p-cresol; p-hydroxybenzylamine; 4-hyroxybenzylamine; 4-hydroxylbenzylamine; NSC 125720; 4-hydroxybenzyl amine; 4-hydroxy benzylamine; 4-(amino methyl)phenol; 4-(Aminomethyl)-Phenol; ACMC-1AXW9; Phenol, 4-(aminomethyl)-; AC1Q7A8B; AC1L3YL9; SCHEMBL63123; (4-Hydroxyphenyl)methylamine
DMJVPF0 DT Small molecular drug
DMJVPF0 PC 97472
DMJVPF0 MW 123.15
DMJVPF0 FM C7H9NO
DMJVPF0 IC InChI=1S/C7H9NO/c8-5-6-1-3-7(9)4-2-6/h1-4,9H,5,8H2
DMJVPF0 CS C1=CC(=CC=C1CN)O
DMJVPF0 IK RQJDUEKERVZLLU-UHFFFAOYSA-N
DMJVPF0 IU 4-(aminomethyl)phenol
DMJVPF0 CA CAS 696-60-6
DMJVPF0 DE Discovery agent
DMCA2XQ ID DMCA2XQ
DMCA2XQ DN 4-hydroxy-but-2-enoate
DMCA2XQ HS Investigative
DMCA2XQ SN CHEMBL354804
DMCA2XQ DT Small molecular drug
DMCA2XQ PC 23699047
DMCA2XQ MW 124.07
DMCA2XQ FM C4H5NaO3
DMCA2XQ IC InChI=1S/C4H6O3.Na/c5-3-1-2-4(6)7;/h1-2,5H,3H2,(H,6,7);/q;+1/p-1/b2-1+;
DMCA2XQ CS C(/C=C/C(=O)[O-])O.[Na+]
DMCA2XQ IK PUAFPEZXZZJTBR-TYYBGVCCSA-M
DMCA2XQ IU sodium;(E)-4-hydroxybut-2-enoate
DMCA2XQ DE Discovery agent
DM36PHM ID DM36PHM
DM36PHM DN 4-hydroxylonchocarpin
DM36PHM HS Investigative
DM36PHM SN Isobavachromene; 4-Hydroxylonchocarpin; 56083-03-5; CHEMBL362378; 4-Hydroxylonchocharpin; AC1NYR2W; SCHEMBL19960679; MolPort-003-804-213; BDBM50240945; ZINC14557836; LMPK12120077; 52801-22-6; 1-(5-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)-3-(4-hydroxy-phenyl)-propenone; (E)-1-(5-hydroxy-2,2-dimethyl-2H-chromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(5-hydroxy-2,2-dimethyl-chromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM36PHM DT Small molecular drug
DM36PHM PC 5889042
DM36PHM MW 322.4
DM36PHM FM C20H18O4
DM36PHM IC InChI=1S/C20H18O4/c1-20(2)12-11-16-18(24-20)10-8-15(19(16)23)17(22)9-5-13-3-6-14(21)7-4-13/h3-12,21,23H,1-2H3/b9-5+
DM36PHM CS CC1(C=CC2=C(O1)C=CC(=C2O)C(=O)/C=C/C3=CC=C(C=C3)O)C
DM36PHM IK IQHPDUUSMBMDGN-WEVVVXLNSA-N
DM36PHM IU (E)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)-3-(4-hydroxyphenyl)prop-2-en-1-one
DM36PHM DE Discovery agent
DMULOHZ ID DMULOHZ
DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide
DMULOHZ HS Investigative
DMULOHZ SN CHEMBL167455
DMULOHZ DT Small molecular drug
DMULOHZ PC 11086699
DMULOHZ MW 266.29
DMULOHZ FM C13H18N2O4
DMULOHZ IC InChI=1S/C13H18N2O4/c16-11-7-5-10(6-8-11)13(18)14-9-3-1-2-4-12(17)15-19/h5-8,16,19H,1-4,9H2,(H,14,18)(H,15,17)
DMULOHZ CS C1=CC(=CC=C1C(=O)NCCCCCC(=O)NO)O
DMULOHZ IK JORFILXLFWALBT-UHFFFAOYSA-N
DMULOHZ IU 4-hydroxy-N-[6-(hydroxyamino)-6-oxohexyl]benzamide
DMULOHZ DE Discovery agent
DMXPQ5H ID DMXPQ5H
DMXPQ5H DN 4-hydroxy-N,N-diphenylbenzenesulfonamide
DMXPQ5H HS Investigative
DMXPQ5H SN CHEMBL203061; 4-hydroxy-N,N-diphenylbenzenesulfonamide; SCHEMBL2114599
DMXPQ5H DT Small molecular drug
DMXPQ5H PC 23582387
DMXPQ5H MW 325.4
DMXPQ5H FM C18H15NO3S
DMXPQ5H IC InChI=1S/C18H15NO3S/c20-17-11-13-18(14-12-17)23(21,22)19(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-14,20H
DMXPQ5H CS C1=CC=C(C=C1)N(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)O
DMXPQ5H IK KLZORRIEDRGOHR-UHFFFAOYSA-N
DMXPQ5H IU 4-hydroxy-N,N-diphenylbenzenesulfonamide
DMXPQ5H DE Discovery agent
DMVAP9U ID DMVAP9U
DMVAP9U DN 4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide
DMVAP9U HS Investigative
DMVAP9U SN CHEMBL204664; 4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide
DMVAP9U DT Small molecular drug
DMVAP9U PC 44407886
DMVAP9U MW 291.4
DMVAP9U FM C15H17NO3S
DMVAP9U IC InChI=1S/C15H17NO3S/c1-12(2)16(13-6-4-3-5-7-13)20(18,19)15-10-8-14(17)9-11-15/h3-12,17H,1-2H3
DMVAP9U CS CC(C)N(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMVAP9U IK QYGYTGVIRJYHLA-UHFFFAOYSA-N
DMVAP9U IU 4-hydroxy-N-phenyl-N-propan-2-ylbenzenesulfonamide
DMVAP9U DE Discovery agent
DM8XOJC ID DM8XOJC
DM8XOJC DN 4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide
DM8XOJC HS Investigative
DM8XOJC SN CHEMBL203515; 4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide
DM8XOJC DT Small molecular drug
DM8XOJC PC 44407806
DM8XOJC MW 319.4
DM8XOJC FM C17H21NO3S
DM8XOJC IC InChI=1S/C17H21NO3S/c1-17(2,3)13-18(14-7-5-4-6-8-14)22(20,21)16-11-9-15(19)10-12-16/h4-12,19H,13H2,1-3H3
DM8XOJC CS CC(C)(C)CN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DM8XOJC IK QKNCIALYEAWCOU-UHFFFAOYSA-N
DM8XOJC IU N-(2,2-dimethylpropyl)-4-hydroxy-N-phenylbenzenesulfonamide
DM8XOJC DE Discovery agent
DM5TU98 ID DM5TU98
DM5TU98 DN 4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98 HS Investigative
DM5TU98 SN CHEMBL205070; 4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98 DT Small molecular drug
DM5TU98 PC 44407885
DM5TU98 MW 291.4
DM5TU98 FM C15H17NO3S
DM5TU98 IC InChI=1S/C15H17NO3S/c1-2-12-16(13-6-4-3-5-7-13)20(18,19)15-10-8-14(17)9-11-15/h3-11,17H,2,12H2,1H3
DM5TU98 CS CCCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DM5TU98 IK VUUWGEGTDFUSTR-UHFFFAOYSA-N
DM5TU98 IU 4-hydroxy-N-phenyl-N-propylbenzenesulfonamide
DM5TU98 DE Discovery agent
DMNMJDL ID DMNMJDL
DMNMJDL DN 4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN
DMNMJDL HS Investigative
DMNMJDL SN 4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN; AC1NUV4X; DB08480; (1R)-1-(prop-2-enylideneamino)-2,3-dihydro-1H-inden-4-ol; (1R)-1-[(E)-prop-2-en-1-ylideneamino]-2,3-dihydro-1H-inden-4-ol
DMNMJDL DT Small molecular drug
DMNMJDL PC 5494443
DMNMJDL MW 187.24
DMNMJDL FM C12H13NO
DMNMJDL IC InChI=1S/C12H13NO/c1-2-8-13-11-7-6-10-9(11)4-3-5-12(10)14/h2-5,8,11,14H,1,6-7H2/t11-/m1/s1
DMNMJDL CS C=CC=N[C@@H]1CCC2=C1C=CC=C2O
DMNMJDL IK OFWOPQIDDNCCLL-LLVKDONJSA-N
DMNMJDL IU (1R)-1-(prop-2-enylideneamino)-2,3-dihydro-1H-inden-4-ol
DMNMJDL DE Discovery agent
DM5ZQK1 ID DM5ZQK1
DM5ZQK1 DN 4-Hydroxy-pent-2-enoic acid
DM5ZQK1 HS Investigative
DM5ZQK1 SN CHEMBL171595; (E)-4-hydroxypent-2-enoic acid; YANJKPZKTWMMOF-NSCUHMNNSA-N; 4-Hydroxy-pent-2-enoic acid; trans-4-hydroxypent-2-enoic acid; AC1NSI5H; 4-hydroxy-2-pentenoic acid; SCHEMBL166635; 2-Pentenoic acid, 4-hydroxy-; BDBM50023574; (2E)-4-Hydroxy-2-pentenoic acid #; AKOS022632862
DM5ZQK1 DT Small molecular drug
DM5ZQK1 PC 5363658
DM5ZQK1 MW 116.11
DM5ZQK1 FM C5H8O3
DM5ZQK1 IC InChI=1S/C5H8O3/c1-4(6)2-3-5(7)8/h2-4,6H,1H3,(H,7,8)/b3-2+
DM5ZQK1 CS CC(/C=C/C(=O)O)O
DM5ZQK1 IK YANJKPZKTWMMOF-NSCUHMNNSA-N
DM5ZQK1 IU (E)-4-hydroxypent-2-enoic acid
DM5ZQK1 DE Discovery agent
DMDGKFV ID DMDGKFV
DMDGKFV DN 4-Hydroxy-pentanoic acid
DMDGKFV HS Investigative
DMDGKFV SN 4-Hydroxypentanoic acid; 4-Hydroxyvaleric acid; 4-hydroxy-pentanoic acid; gamma-Hydroxyvaleric acid; 13532-37-1; 4-hydroxy-valeric acid; Pentanoic acid, 4-hydroxy-; 103712-26-1; Pentanoic acid, 4-hydroxy-, (S)-; EINECS 236-884-1; ACMC-20m6jh; AC1Q5VUF; Pentanoic acid,4-hydroxy-; AC1L3FK5; AC1Q2BV5; SCHEMBL27394; CHEMBL169219; CTK4B9757; FMHKPLXYWVCLME-UHFFFAOYSA-N; MolPort-006-120-502; LMFA01050009; AKOS008148154; MCULE-6352217997; TX-017030
DMDGKFV DT Small molecular drug
DMDGKFV PC 114539
DMDGKFV MW 118.13
DMDGKFV FM C5H10O3
DMDGKFV IC InChI=1S/C5H10O3/c1-4(6)2-3-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)
DMDGKFV CS CC(CCC(=O)O)O
DMDGKFV IK FMHKPLXYWVCLME-UHFFFAOYSA-N
DMDGKFV IU 4-hydroxypentanoic acid
DMDGKFV CA CAS 13532-37-1
DMDGKFV DE Discovery agent
DMJ7G0E ID DMJ7G0E
DMJ7G0E DN 4-hydroxyphenethyl 3,4,5-trihydroxybenzoate
DMJ7G0E HS Investigative
DMJ7G0E SN CHEMBL147069; 4-hydroxyphenethyl 3,4,5-trihydroxybenzoate; 2-(4-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate; AC1NQOM4; SCHEMBL4738028; Gallic acid 4-hydroxyphenethyl ester; BDBM50109690; 2-(4-hydroxyphenyl) ethyl 3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxy-benzoic acid 2-(4-hydroxy-phenyl)-ethyl ester; Benzoic acid, 3,4,5-trihydroxy-, 2-(4-hydroxyphenyl)ethyl ester
DMJ7G0E DT Small molecular drug
DMJ7G0E PC 5276405
DMJ7G0E MW 290.27
DMJ7G0E FM C15H14O6
DMJ7G0E IC InChI=1S/C15H14O6/c16-11-3-1-9(2-4-11)5-6-21-15(20)10-7-12(17)14(19)13(18)8-10/h1-4,7-8,16-19H,5-6H2
DMJ7G0E CS C1=CC(=CC=C1CCOC(=O)C2=CC(=C(C(=C2)O)O)O)O
DMJ7G0E IK WSPSAXWXELZFQI-UHFFFAOYSA-N
DMJ7G0E IU 2-(4-hydroxyphenyl)ethyl 3,4,5-trihydroxybenzoate
DMJ7G0E DE Discovery agent
DM0564K ID DM0564K
DM0564K DN 4-hydroxyphenylpyruvic acid
DM0564K HS Investigative
DM0564K SN 4-Hydroxyphenylpyruvic acid; 156-39-8; 3-(4-Hydroxyphenyl)-2-oxopropanoic acid; Testacid; p-Hydroxyphenylpyruvic acid; 4-hydroxyphenylpyruvate; Testacide; 3-(4-Hydroxyphenyl)pyruvic acid; (P-HYDROXYPHENYL)PYRUVIC ACID; 3-(p-Hydroxyphenyl)pyruvic acid; 3-(p-Hydroxyphenyl)-2-oxopropanoic acid; 3-(4-HYDROXY-PHENYL)PYRUVIC ACID; (p-hydroxyphenyl)-pyruvic acid; Pyruvic acid, p-hydroxyphenyl-; NSC 100738; 4-Hydroxy alpha-oxobenzenepropanoic acid; Pyruvic acid, (p-hydroxyphenyl)-; p-hydroxyphenylpyruvate; 4-hydroxyphenylpyruvate
DM0564K DT Small molecular drug
DM0564K PC 979
DM0564K MW 180.16
DM0564K FM C9H8O4
DM0564K IC InChI=1S/C9H8O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,10H,5H2,(H,12,13)
DM0564K CS C1=CC(=CC=C1CC(=O)C(=O)O)O
DM0564K IK KKADPXVIOXHVKN-UHFFFAOYSA-N
DM0564K IU 3-(4-hydroxyphenyl)-2-oxopropanoic acid
DM0564K CA CAS 156-39-8
DM0564K CB CHEBI:15999
DM0564K DE Discovery agent
DM9VQ0T ID DM9VQ0T
DM9VQ0T DN 4-Hydroxy-piperidine-3-carboxylic acid
DM9VQ0T HS Investigative
DM9VQ0T SN CHEMBL277372; SCHEMBL5426302; ZINC26898692; BDBM50223874; AKOS006353852; (3S)-4alpha-Hydroxypiperidine-3alpha-carboxylic acid
DM9VQ0T DT Small molecular drug
DM9VQ0T PC 21125089
DM9VQ0T MW 145.16
DM9VQ0T FM C6H11NO3
DM9VQ0T IC InChI=1S/C6H11NO3/c8-5-1-2-7-3-4(5)6(9)10/h4-5,7-8H,1-3H2,(H,9,10)/t4-,5+/m0/s1
DM9VQ0T CS C1CNC[C@@H]([C@@H]1O)C(=O)O
DM9VQ0T IK DAMFVOCECLPLSI-CRCLSJGQSA-N
DM9VQ0T IU (3S,4R)-4-hydroxypiperidine-3-carboxylic acid
DM9VQ0T DE Discovery agent
DMPIV6J ID DMPIV6J
DMPIV6J DN 4-hydroxysaprothoquinone
DMPIV6J HS Investigative
DMPIV6J SN 4-hydroxysaprothoquinone; CHEMBL453303; 4-Hydroxysaprorthoquinone; AC1NRZ82; BDBM50242319; 8-(4-hydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
DMPIV6J DT Small molecular drug
DMPIV6J PC 5325817
DMPIV6J MW 314.4
DMPIV6J FM C20H26O3
DMPIV6J IC InChI=1S/C20H26O3/c1-12(2)16-11-14-9-8-13(3)15(7-6-10-20(4,5)23)17(14)19(22)18(16)21/h8-9,11-12,23H,6-7,10H2,1-5H3
DMPIV6J CS CC1=C(C2=C(C=C1)C=C(C(=O)C2=O)C(C)C)CCCC(C)(C)O
DMPIV6J IK QJYXXTULLNTAEX-UHFFFAOYSA-N
DMPIV6J IU 8-(4-hydroxy-4-methylpentyl)-7-methyl-3-propan-2-ylnaphthalene-1,2-dione
DMPIV6J DE Discovery agent
DMJKF17 ID DMJKF17
DMJKF17 DN 4-Imidazol-1-yl-2-phenyl-chroman-7-ol
DMJKF17 HS Investigative
DMJKF17 SN CHEMBL95919; 4-imidazol-1-yl-2-phenyl-chroman-7-ol
DMJKF17 DT Small molecular drug
DMJKF17 PC 11779089
DMJKF17 MW 292.3
DMJKF17 FM C18H16N2O2
DMJKF17 IC InChI=1S/C18H16N2O2/c21-14-6-7-15-16(20-9-8-19-12-20)11-17(22-18(15)10-14)13-4-2-1-3-5-13/h1-10,12,16-17,21H,11H2
DMJKF17 CS C1C(C2=C(C=C(C=C2)O)OC1C3=CC=CC=C3)N4C=CN=C4
DMJKF17 IK ZVMPYRSCCMHXRC-UHFFFAOYSA-N
DMJKF17 IU 4-imidazol-1-yl-2-phenyl-3,4-dihydro-2H-chromen-7-ol
DMJKF17 DE Discovery agent
DM28DEU ID DM28DEU
DM28DEU DN 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one
DM28DEU HS Investigative
DM28DEU SN CHEMBL1083665; 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one
DM28DEU DT Small molecular drug
DM28DEU PC 46867540
DM28DEU MW 337.4
DM28DEU FM C17H11N3O3S
DM28DEU IC InChI=1S/C17H11N3O3S/c21-16-12-3-1-2-4-14(12)24-17-11(9-19-8-7-18-10-19)5-6-13(15(16)17)20(22)23/h1-8,10H,9H2
DM28DEU CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3S2)CN4C=CN=C4)[N+](=O)[O-]
DM28DEU IK OCFFNJCKSSDREB-UHFFFAOYSA-N
DM28DEU IU 4-(imidazol-1-ylmethyl)-1-nitrothioxanthen-9-one
DM28DEU DE Discovery agent
DMZLVIF ID DMZLVIF
DMZLVIF DN 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one
DMZLVIF HS Investigative
DMZLVIF SN aromatase inhibitor i; CHEMBL159073; 4-(Imidazolylmethyl)-1-nitro-9H-9-xanthenone; 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one; AC1L1D8C; CTK5I3006; BDBM50097366; 4-(imidazol-1-ylmethyl)-1-nitroxanthen-9-one; 4-(1H-imidazol-1-ylmethyl)-1-nitro-9H-xanthen-9-one; 4-((1H-imidazol-1-yl)methyl)-1-nitro-9H-xanthen-9-one; 1-Nitro-4-(1H-imidazole-1-ylmethyl)-9H-xanthene-9-one
DMZLVIF DT Small molecular drug
DMZLVIF PC 2238
DMZLVIF MW 321.29
DMZLVIF FM C17H11N3O4
DMZLVIF IC InChI=1S/C17H11N3O4/c21-16-12-3-1-2-4-14(12)24-17-11(9-19-8-7-18-10-19)5-6-13(15(16)17)20(22)23/h1-8,10H,9H2
DMZLVIF CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3O2)CN4C=CN=C4)[N+](=O)[O-]
DMZLVIF IK JLTNBMDVMUSXHQ-UHFFFAOYSA-N
DMZLVIF IU 4-(imidazol-1-ylmethyl)-1-nitroxanthen-9-one
DMZLVIF DE Discovery agent
DM6FMO1 ID DM6FMO1
DM6FMO1 DN 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one
DM6FMO1 HS Investigative
DM6FMO1 SN CHEMBL1083663; 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one
DM6FMO1 DT Small molecular drug
DM6FMO1 PC 46867416
DM6FMO1 MW 321.29
DM6FMO1 FM C17H11N3O4
DM6FMO1 IC InChI=1S/C17H11N3O4/c21-16-13-3-1-2-4-15(13)24-17-11(9-19-6-5-18-10-19)7-12(20(22)23)8-14(16)17/h1-8,10H,9H2
DM6FMO1 CS C1=CC=C2C(=C1)C(=O)C3=CC(=CC(=C3O2)CN4C=CN=C4)[N+](=O)[O-]
DM6FMO1 IK FTWURRJWFIOKBA-UHFFFAOYSA-N
DM6FMO1 IU 4-(imidazol-1-ylmethyl)-2-nitroxanthen-9-one
DM6FMO1 DE Discovery agent
DM8KZQN ID DM8KZQN
DM8KZQN DN 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one
DM8KZQN HS Investigative
DM8KZQN SN CHEMBL1083664; 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one
DM8KZQN DT Small molecular drug
DM8KZQN PC 46867417
DM8KZQN MW 321.29
DM8KZQN FM C17H11N3O4
DM8KZQN IC InChI=1S/C17H11N3O4/c21-16-11-3-1-2-4-15(11)24-17-12(16)5-6-14(20(22)23)13(17)9-19-8-7-18-10-19/h1-8,10H,9H2
DM8KZQN CS C1=CC=C2C(=C1)C(=O)C3=C(O2)C(=C(C=C3)[N+](=O)[O-])CN4C=CN=C4
DM8KZQN IK SRBZAHSXFAWSRK-UHFFFAOYSA-N
DM8KZQN IU 4-(imidazol-1-ylmethyl)-3-nitroxanthen-9-one
DM8KZQN DE Discovery agent
DMVUSMP ID DMVUSMP
DMVUSMP DN 4-Imidazol-1-ylmethylthioxanthen-9-one
DMVUSMP HS Investigative
DMVUSMP SN CHEMBL1083353; 4-Imidazol-1-ylmethylthioxanthen-9-one
DMVUSMP DT Small molecular drug
DMVUSMP PC 46867543
DMVUSMP MW 292.4
DMVUSMP FM C17H12N2OS
DMVUSMP IC InChI=1S/C17H12N2OS/c20-16-13-5-1-2-7-15(13)21-17-12(4-3-6-14(16)17)10-19-9-8-18-11-19/h1-9,11H,10H2
DMVUSMP CS C1=CC=C2C(=C1)C(=O)C3=CC=CC(=C3S2)CN4C=CN=C4
DMVUSMP IK QHPHZBRQVQYOFQ-UHFFFAOYSA-N
DMVUSMP IU 4-(imidazol-1-ylmethyl)thioxanthen-9-one
DMVUSMP DE Discovery agent
DMM8HK0 ID DMM8HK0
DMM8HK0 DN 4-Imidazol-1-ylmethylxanthen-9-one
DMM8HK0 HS Investigative
DMM8HK0 SN CHEMBL1083971; 4-Imidazol-1-ylmethylxanthen-9-one
DMM8HK0 DT Small molecular drug
DMM8HK0 PC 46867542
DMM8HK0 MW 276.29
DMM8HK0 FM C17H12N2O2
DMM8HK0 IC InChI=1S/C17H12N2O2/c20-16-13-5-1-2-7-15(13)21-17-12(4-3-6-14(16)17)10-19-9-8-18-11-19/h1-9,11H,10H2
DMM8HK0 CS C1=CC=C2C(=C1)C(=O)C3=CC=CC(=C3O2)CN4C=CN=C4
DMM8HK0 IK SWNOXHJBMDOXFE-UHFFFAOYSA-N
DMM8HK0 IU 4-(imidazol-1-ylmethyl)xanthen-9-one
DMM8HK0 DE Discovery agent
DMFRCQS ID DMFRCQS
DMFRCQS DN 4-Indan-(1E)-ylidenemethyl-pyridine
DMFRCQS HS Investigative
DMFRCQS SN (4-Pyridylmethylene)indane 2a; SCHEMBL4230787; BDBM8616; CHEMBL175962; SCHEMBL4230798; AC1O705V; ZINC13610822; 4-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1E)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate
DMFRCQS DT Small molecular drug
DMFRCQS PC 6539790
DMFRCQS MW 207.27
DMFRCQS FM C15H13N
DMFRCQS IC InChI=1S/C15H13N/c1-2-4-15-13(3-1)5-6-14(15)11-12-7-9-16-10-8-12/h1-4,7-11H,5-6H2/b14-11+
DMFRCQS CS C1C/C(=C\\C2=CC=NC=C2)/C3=CC=CC=C31
DMFRCQS IK ZHGWOEHABOMOSV-SDNWHVSQSA-N
DMFRCQS IU 4-[(E)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DMFRCQS DE Discovery agent
DM25DR7 ID DM25DR7
DM25DR7 DN 4-Indan-(1Z)-ylidenemethyl-pyridine
DM25DR7 HS Investigative
DM25DR7 SN (4-Pyridylmethylene)indane 2b; SCHEMBL4230792; CHEMBL179149; BDBM8612; AC1O705N; 4-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine; 4-[(1Z)-2,3-dihydro-1H-inden-1-ylidenemethyl]pyridine; 4-[(Z)-2,3-Dihydro-1H-inden-1-ylidenemethyl]pyridine Oxalate
DM25DR7 DT Small molecular drug
DM25DR7 PC 6539786
DM25DR7 MW 207.27
DM25DR7 FM C15H13N
DM25DR7 IC InChI=1S/C15H13N/c1-2-4-15-13(3-1)5-6-14(15)11-12-7-9-16-10-8-12/h1-4,7-11H,5-6H2/b14-11-
DM25DR7 CS C1C/C(=C/C2=CC=NC=C2)/C3=CC=CC=C31
DM25DR7 IK ZHGWOEHABOMOSV-KAMYIIQDSA-N
DM25DR7 IU 4-[(Z)-2,3-dihydroinden-1-ylidenemethyl]pyridine
DM25DR7 DE Discovery agent
DM6YON7 ID DM6YON7
DM6YON7 DN 4-Indan-1-ylmethyl-phenylamine
DM6YON7 HS Investigative
DM6YON7 SN CHEMBL364089; 4-Indan-1-ylmethyl-phenylamine
DM6YON7 DT Small molecular drug
DM6YON7 PC 44401390
DM6YON7 MW 223.31
DM6YON7 FM C16H17N
DM6YON7 IC InChI=1S/C16H17N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-6,9-10,14H,7-8,11,17H2
DM6YON7 CS C1CC2=CC=CC=C2C1CC3=CC=C(C=C3)N
DM6YON7 IK IFNMCDJEFWXUCT-UHFFFAOYSA-N
DM6YON7 IU 4-(2,3-dihydro-1H-inden-1-ylmethyl)aniline
DM6YON7 DE Discovery agent
DM23E0R ID DM23E0R
DM23E0R DN 4-Inden-(1E)-ylidenemethyl-phenylamine
DM23E0R HS Investigative
DM23E0R SN 4-(1H-Inden-1-ylidenemethyl)aniline; NSC83092; 4-[(E)-inden-1-ylidenemethyl]aniline; CHEMBL193376; 487-61-6; 1-(4-Aminobenzylidene)indene; p-Toluidine, .alpha.-inden-1-ylidene-; 4-(1H-Inden-1-ylidenemethyl)phenylamine; Benzenamine, 4-(1H-inden-1-ylidenemethyl)-; MLS002694146; WLN: L56 BYJ BU1R DZ; 4-Inden-(1E)-ylidenemethyl-phenylamine; AC1O53IW; AC1Q1HQ2; cid_98148; BDBM50164749; NSC-83092; AKOS030547084; ZINC100425076; NCGC00186285-13; NCGC00186285-07; NCGC00186285-06; NCGC00186285-01; NCGC00186285-11; NCGC00186285-09
DM23E0R DT Small molecular drug
DM23E0R PC 6476992
DM23E0R MW 219.28
DM23E0R FM C16H13N
DM23E0R IC InChI=1S/C16H13N/c17-15-9-5-12(6-10-15)11-14-8-7-13-3-1-2-4-16(13)14/h1-11H,17H2/b14-11+
DM23E0R CS C1=CC=C\\2C(=C1)C=C/C2=C\\C3=CC=C(C=C3)N
DM23E0R IK GISMNWZLKDONAA-SDNWHVSQSA-N
DM23E0R IU 4-[(E)-inden-1-ylidenemethyl]aniline
DM23E0R CA CAS 487-61-6
DM23E0R DE Discovery agent
DMG9JSK ID DMG9JSK
DMG9JSK DN 4-Indol-1-ylmethyl-benzamidine
DMG9JSK HS Investigative
DMG9JSK SN 1-(4-Amidinobenzyl)indole; 83783-25-9; CHEMBL100569; 4-ABI; 4-Indol-1-ylmethyl-benzamidine; 4-(1h-indol-1-ylmethyl)benzenecarboximidamide; AC1L34FF; AC1Q1U95; CTK5F1124; DTXSID50232637; ZINC5162918; BDBM50027305; AKOS030584119; 4-((1h-indol-1-yl)methyl)benzimidamide; 4-(indol-1-ylmethyl)benzenecarboximidamide; KB-214170; Benzenecarboximidamide,4-(1H-indol-1-ylmethyl)-; Benzenecarboximidamide, 4-(1H-indol-1-ylmethyl)-
DMG9JSK DT Small molecular drug
DMG9JSK PC 134348
DMG9JSK MW 249.31
DMG9JSK FM C16H15N3
DMG9JSK IC InChI=1S/C16H15N3/c17-16(18)14-7-5-12(6-8-14)11-19-10-9-13-3-1-2-4-15(13)19/h1-10H,11H2,(H3,17,18)
DMG9JSK CS C1=CC=C2C(=C1)C=CN2CC3=CC=C(C=C3)C(=N)N
DMG9JSK IK VKEKMIKRPJWXHO-UHFFFAOYSA-N
DMG9JSK IU 4-(indol-1-ylmethyl)benzenecarboximidamide
DMG9JSK CA CAS 83783-25-9
DMG9JSK DE Discovery agent
DMKZQ3I ID DMKZQ3I
DMKZQ3I DN 4-iodo-1H-indazole
DMKZQ3I HS Investigative
DMKZQ3I SN 4-iodo-1H-indazole; 885522-11-2; 4-Iodoindazole; 4-IODO (1H)INDAZOLE; CHEMBL246534; zlchem 1146; PubChem21944; SCHEMBL358061; 4-Iodo-1H-indazole, 95%; 4-IODO-(1H)-iNDAZOLE; 1H-INDAZOLE, 4-IODO-; CTK8B7170; ZLD0614; DTXSID10646276; MolPort-009-197-588; CJQXSPSUIGJNJX-UHFFFAOYSA-N; ZX-RL006042; BCP26449; ZINC14983484; BDBM50209235; ANW-56585; CI-483; AKOS015853740; FCH1325887; VI20042; QC-2871; PB27826; RP05951; AS-50534; AJ-65949; EN002531; KB-39256; OR308061; AK-27887; TC-062829; DB-023141; AB0037276; ST1100625; AX8158792; Y4536; AM20041322
DMKZQ3I DT Small molecular drug
DMKZQ3I PC 24728219
DMKZQ3I MW 244.03
DMKZQ3I FM C7H5IN2
DMKZQ3I IC InChI=1S/C7H5IN2/c8-6-2-1-3-7-5(6)4-9-10-7/h1-4H,(H,9,10)
DMKZQ3I CS C1=CC2=C(C=NN2)C(=C1)I
DMKZQ3I IK CJQXSPSUIGJNJX-UHFFFAOYSA-N
DMKZQ3I IU 4-iodo-1H-indazole
DMKZQ3I CA CAS 885522-11-2
DMKZQ3I DE Discovery agent
DMIPENJ ID DMIPENJ
DMIPENJ DN 4-Iodo-2,6-diisopropyl-phenol
DMIPENJ HS Investigative
DMIPENJ SN 4-Iodopropofol; 169255-48-5; 4-IODO-2,6-BIS(ISOPROPYL)PHENOL; CHEMBL53267; 4-Iodo-2,6-diisopropyl-phenol; Bobel 4; Phenol, 4-iodo-2,6-bis(1-methylethyl)-; 4-Iodo-2,6-diisopropylphenol; ZINC8678; SCHEMBL1163939; DTXSID10432353; MolPort-009-677-266; ZX-AT014004; BDBM50064424; 2,6-Bis(prop-2-yl)-4-iodophenol; AKOS025310281; OR54368; FCH1363142; 2,6-Bis(isopropyl)-4-iodophenol 97%
DMIPENJ DT Small molecular drug
DMIPENJ PC 9882905
DMIPENJ MW 304.17
DMIPENJ FM C12H17IO
DMIPENJ IC InChI=1S/C12H17IO/c1-7(2)10-5-9(13)6-11(8(3)4)12(10)14/h5-8,14H,1-4H3
DMIPENJ CS CC(C)C1=CC(=CC(=C1O)C(C)C)I
DMIPENJ IK JMJHJCFWTNRPEI-UHFFFAOYSA-N
DMIPENJ IU 4-iodo-2,6-di(propan-2-yl)phenol
DMIPENJ CA CAS 169255-48-5
DMIPENJ DE Discovery agent
DMC8D4R ID DMC8D4R
DMC8D4R DN 4-Iodo-6-nitro-2-piperazin-1-yl-quinoline
DMC8D4R HS Investigative
DMC8D4R SN CHEMBL167475; 4-Iodo-6-nitro-2-piperazin-1-yl-quinoline; SCHEMBL6365240; BDBM50110579
DMC8D4R DT Small molecular drug
DMC8D4R PC 44379433
DMC8D4R MW 384.17
DMC8D4R FM C13H13IN4O2
DMC8D4R IC InChI=1S/C13H13IN4O2/c14-11-8-13(17-5-3-15-4-6-17)16-12-2-1-9(18(19)20)7-10(11)12/h1-2,7-8,15H,3-6H2
DMC8D4R CS C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)I
DMC8D4R IK ABNBXDNNSDJWKN-UHFFFAOYSA-N
DMC8D4R IU 4-iodo-6-nitro-2-piperazin-1-ylquinoline
DMC8D4R DE Discovery agent
DMYNVLZ ID DMYNVLZ
DMYNVLZ DN 4-iodo-6-phenylpyrimidine
DMYNVLZ HS Investigative
DMYNVLZ SN 41270-96-6; CHEMBL497802; AC-907/25004997; AC1LG8ZQ; SCHEMBL244108; CHEBI:91213; CTK7C3610; MolPort-003-800-888; ZINC331218; BDBM50265608; AKOS005266491; FCH1331127; 4-IPP, >
DMYNVLZ DT Small molecular drug
DMYNVLZ PC 817368
DMYNVLZ MW 282.08
DMYNVLZ FM C10H7IN2
DMYNVLZ IC InChI=1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
DMYNVLZ CS C1=CC=C(C=C1)C2=CC(=NC=N2)I
DMYNVLZ IK ZTCJXHNJVLUUMR-UHFFFAOYSA-N
DMYNVLZ IU 4-iodo-6-phenylpyrimidine
DMYNVLZ CB CHEBI:91213
DMYNVLZ DE Solid tumour/cancer
DMFSH2I ID DMFSH2I
DMFSH2I DN 4-iodo-acetamido phenylboronic acid
DMFSH2I HS Investigative
DMFSH2I SN 4-IODO-ACETAMIDO PHENYLBORONIC ACID; Boronic acid, [3-[(iodoacetyl)amino]phenyl]-; 87199-19-7; AC1NE0SC; [3-[(2-iodoacetyl)amino]phenyl]boronic acid; C8H9BINO3; SCHEMBL7744399; CTK2I2732; DTXSID90405045; AKOS030568788; DB02122; {3-[(iodoacetyl)amino]phenyl}boronic acid
DMFSH2I DT Small molecular drug
DMFSH2I PC 4634714
DMFSH2I MW 304.88
DMFSH2I FM C8H9BINO3
DMFSH2I IC InChI=1S/C8H9BINO3/c10-5-8(12)11-7-3-1-2-6(4-7)9(13)14/h1-4,13-14H,5H2,(H,11,12)
DMFSH2I CS B(C1=CC(=CC=C1)NC(=O)CI)(O)O
DMFSH2I IK LMHXPDZPXBIIEX-UHFFFAOYSA-N
DMFSH2I IU [3-[(2-iodoacetyl)amino]phenyl]boronic acid
DMFSH2I CA CAS 87199-19-7
DMFSH2I DE Discovery agent
DMXAEGF ID DMXAEGF
DMXAEGF DN 4-iodobenzo[b]thiophene 2-carboxamidine
DMXAEGF HS Investigative
DMXAEGF SN amino(4-iodo-1-benzothiophen-2-yl)methaniminium; ESI; AC1L1C5C; CTK7C3490; BDBM14169; APC-6860; CRA-6860; DB03136; [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium
DMXAEGF DT Small molecular drug
DMXAEGF PC 1746
DMXAEGF MW 303.14
DMXAEGF FM C9H8IN2S+
DMXAEGF IC InChI=1S/C9H7IN2S/c10-6-2-1-3-7-5(6)4-8(13-7)9(11)12/h1-4H,(H3,11,12)/p+1
DMXAEGF CS C1=CC2=C(C=C(S2)C(=[NH2+])N)C(=C1)I
DMXAEGF IK YERQOXAYAFWFEJ-UHFFFAOYSA-O
DMXAEGF IU [amino-(4-iodo-1-benzothiophen-2-yl)methylidene]azanium
DMJMOAI ID DMJMOAI
DMJMOAI DN 4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine
DMJMOAI HS Investigative
DMJMOAI SN SCHEMBL3260399; CHEMBL199881; BDBM11116; 4-substituted phenylalanine cyano-(S)-pyrrolidine deriv. 3
DMJMOAI DT Small molecular drug
DMJMOAI PC 23645372
DMJMOAI MW 369.2
DMJMOAI FM C14H16IN3O
DMJMOAI IC InChI=1S/C14H16IN3O/c15-11-5-3-10(4-6-11)8-13(17)14(19)18-7-1-2-12(18)9-16/h3-6,12-13H,1-2,7-8,17H2/t12-,13-/m0/s1
DMJMOAI CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)I)N)C#N
DMJMOAI IK PQFUJTFHVDWNOF-STQMWFEESA-N
DMJMOAI IU (2S)-1-[(2S)-2-amino-3-(4-iodophenyl)propanoyl]pyrrolidine-2-carbonitrile
DMJMOAI DE Discovery agent
DMF3CLX ID DMF3CLX
DMF3CLX DN 4-Iodopyrazole
DMF3CLX HS Investigative
DMF3CLX SN 4-Iodopyrazole; 4-Iodo-1H-pyrazole; 3469-69-0; 1H-Pyrazole, 4-iodo-; 4-iodo-pyrazole; Pyrazole, 4-iodo; LLNQWPTUJJYTTE-UHFFFAOYSA-N; 4-Iodopyrazole, 98%; 4-iod-1h-pyrazol; 4-iodo pyrazole; sFtHCQVILimKP@; zlchem 55; EINECS 222-434-1; 4-iodo-1H-pyrazol; PubChem13295; ACMC-1CSZW; 4-Iodopyrazole, 99%; AC1Q4PAD; AC1L2S6R; AC1Q1GT3; SCHEMBL71959; AMTH001; KSC225I2F; Jsp006281; LLNQWPTUJJYTTE-UHFFFAOYSA-; CTK1C5422; CHEBI:45260; ZLB0042; DTXSID30188244; MolPort-000-156-497; BM019; KS-000004PJ; ALBB-013400; ACT01776; ZINC2046962; ACN-P000781
DMF3CLX DT Small molecular drug
DMF3CLX PC 77022
DMF3CLX MW 193.97
DMF3CLX FM C3H3IN2
DMF3CLX IC InChI=1S/C3H3IN2/c4-3-1-5-6-2-3/h1-2H,(H,5,6)
DMF3CLX CS C1=C(C=NN1)I
DMF3CLX IK LLNQWPTUJJYTTE-UHFFFAOYSA-N
DMF3CLX IU 4-iodo-1H-pyrazole
DMF3CLX CA CAS 3469-69-0
DMF3CLX CB CHEBI:45260
DMF3CLX DE Discovery agent
DMQ95EG ID DMQ95EG
DMQ95EG DN 4-Iodyl-benzoic acid
DMQ95EG HS Investigative
DMQ95EG SN 4-iodylbenzoic Acid; 4-Iodyl-benzoic acid; CHEMBL119805; AC1MW5HG; SCHEMBL3123027
DMQ95EG DT Small molecular drug
DMQ95EG PC 3718733
DMQ95EG MW 280.02
DMQ95EG FM C7H5IO4
DMQ95EG IC InChI=1S/C7H5IO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4H,(H,9,10)
DMQ95EG CS C1=CC(=CC=C1C(=O)O)I(=O)=O
DMQ95EG IK OCPGBAXIXDSOBI-UHFFFAOYSA-N
DMQ95EG IU 4-iodylbenzoic acid
DMQ95EG DE Discovery agent
DM7F38J ID DM7F38J
DM7F38J DN 4-isopropyl-2-(phenoxymethyl)morpholine
DM7F38J HS Investigative
DM7F38J SN CHEMBL510654; 4-isopropyl-2-(phenoxymethyl)morpholine; BDBM50293194
DM7F38J DT Small molecular drug
DM7F38J PC 12226582
DM7F38J MW 235.32
DM7F38J FM C14H21NO2
DM7F38J IC InChI=1S/C14H21NO2/c1-12(2)15-8-9-16-14(10-15)11-17-13-6-4-3-5-7-13/h3-7,12,14H,8-11H2,1-2H3
DM7F38J CS CC(C)N1CCOC(C1)COC2=CC=CC=C2
DM7F38J IK WCHHCBBPGSWTOB-UHFFFAOYSA-N
DM7F38J IU 2-(phenoxymethyl)-4-propan-2-ylmorpholine
DM7F38J DE Discovery agent
DMW1T93 ID DMW1T93
DMW1T93 DN 4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine
DMW1T93 HS Investigative
DMW1T93 SN CHEMBL207589; 4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine; SCHEMBL14433285
DMW1T93 DT Small molecular drug
DMW1T93 PC 9814022
DMW1T93 MW 268.4
DMW1T93 FM C16H16N2S
DMW1T93 IC InChI=1S/C16H16N2S/c1-11(2)15-10-19-16(18-15)17-14-9-5-7-12-6-3-4-8-13(12)14/h3-11H,1-2H3,(H,17,18)
DMW1T93 CS CC(C)C1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMW1T93 IK UZYASSJTIRFKFN-UHFFFAOYSA-N
DMW1T93 IU N-naphthalen-1-yl-4-propan-2-yl-1,3-thiazol-2-amine
DMW1T93 DE Discovery agent
DMMDGR2 ID DMMDGR2
DMMDGR2 DN 4-ISOPROPYLPHENSERINE
DMMDGR2 HS Investigative
DMMDGR2 SN Cymserine; cymserinetartaric acid; 145209-39-8; CHEMBL129837; BDBM10960; DTXSID10432696; 4-Isopropylphenylcarbamic acid (3aS)-1,3aalpha,8-trimethyl-1,2,3,3a,8,8aalpha-hexahydropyrrolo[2,3-b]indole-5-yl ester; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl
DMMDGR2 DT Small molecular drug
DMMDGR2 PC 9907847
DMMDGR2 MW 379.5
DMMDGR2 FM C23H29N3O2
DMMDGR2 IC InChI=1S/C23H29N3O2/c1-15(2)16-6-8-17(9-7-16)24-22(27)28-18-10-11-20-19(14-18)23(3)12-13-25(4)21(23)26(20)5/h6-11,14-15,21H,12-13H2,1-5H3,(H,24,27)/t21-,23+/m1/s1
DMMDGR2 CS CC(C)C1=CC=C(C=C1)NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN4C)C)C
DMMDGR2 IK NKJRRVBTMYRXRB-GGAORHGYSA-N
DMMDGR2 IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(4-propan-2-ylphenyl)carbamate
DMMDGR2 CA CAS 145209-39-8
DMMDGR2 DE Discovery agent
DMVTEOQ ID DMVTEOQ
DMVTEOQ DN 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine
DMVTEOQ HS Investigative
DMVTEOQ SN CHEMBL365637; 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine; SCHEMBL7598537; SCHEMBL10077978; BDBM50150914
DMVTEOQ DT Small molecular drug
DMVTEOQ PC 18983431
DMVTEOQ MW 126.2
DMVTEOQ FM C7H14N2
DMVTEOQ IC InChI=1S/C7H14N2/c1-5(2)6-3-7(8)9-4-6/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMVTEOQ CS CC(C)C1CC(=NC1)N
DMVTEOQ IK PUOKLNVZFQOPOS-UHFFFAOYSA-N
DMVTEOQ IU 3-propan-2-yl-3,4-dihydro-2H-pyrrol-5-amine
DMVTEOQ DE Discovery agent
DMBK67H ID DMBK67H
DMBK67H DN 4-isothiocyanatobenzenesulfonamide
DMBK67H HS Investigative
DMBK67H SN 4-Isothiocyanatobenzenesulfonamide; 51908-29-3; 4-isothiocyanatobenzene-1-sulfonamide; 4-Isothiocyanato-benzenesulfonamide; Benzenesulfonamide, 4-isothiocyanato-; CHEMBL144818; IMDUFDNFSJWYQT-UHFFFAOYSA-N; 4-Isothiocyanatobenzene sulfonamide; 4-Icsa; AC1LAVHK; SCHEMBL1476527; CTK4J5100; DTXSID90199871; MolPort-000-156-692; KS-00000HK9; ZINC2571868; ALBB-003064; 4-(Isothiocyanato)benzenesulfonamide; Benzenesulfonamide,4-isothiocyanato-; GEO-03379; BDBM50094812; ANW-51072; STK501629; 4-(aminosulfonyl)phenylisothiocyanate; SBB046978
DMBK67H DT Small molecular drug
DMBK67H PC 521359
DMBK67H MW 214.3
DMBK67H FM C7H6N2O2S2
DMBK67H IC InChI=1S/C7H6N2O2S2/c8-13(10,11)7-3-1-6(2-4-7)9-5-12/h1-4H,(H2,8,10,11)
DMBK67H CS C1=CC(=CC=C1N=C=S)S(=O)(=O)N
DMBK67H IK IMDUFDNFSJWYQT-UHFFFAOYSA-N
DMBK67H IU 4-isothiocyanatobenzenesulfonamide
DMBK67H CA CAS 51908-29-3
DMBK67H DE Discovery agent
DMNCVIP ID DMNCVIP
DMNCVIP DN 4-MA
DMNCVIP HS Investigative
DMNCVIP SN 4-Methylbenzoic acid; P-TOLUIC ACID; 99-94-5; 4-Toluic acid; Crithminic acid; p-Methylbenzoic acid; p-Toluylic acid; Benzoic acid, 4-methyl-; p-Carboxytoluene; para-Toluic acid; 4-Methyl-Benzoic Acid; Toluate; Toluenecarboxylic acid; p-Toluate; UNII-A26GBX5SSV; para toluic acid; NSC 2215; p-Toluic acid, 98%; EINECS 202-803-3; A26GBX5SSV; BRN 0507600; AI3-15627; CHEBI:36635; 2420-97-5 (cadmium salt); LPNBBFKOUUSUDB-UHFFFAOYSA-N; p-toluicacid; 4MA; Crithmic acid; rho-toluic acid; 4-Carboxytoluene; 4-MethylbenzoicAcid; 4-methylbenzic acid
DMNCVIP DT Small molecular drug
DMNCVIP PC 6917653
DMNCVIP MW 388.6
DMNCVIP FM C24H40N2O2
DMNCVIP IC InChI=1S/C24H40N2O2/c1-6-26(7-2)22(28)19-10-9-17-16-8-11-20-24(4,15-13-21(27)25(20)5)18(16)12-14-23(17,19)3/h16-20H,6-15H2,1-5H3/t16-,17-,18-,19+,20+,23-,24+/m0/s1
DMNCVIP CS CCN(CC)C(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(=O)N4C)C)C
DMNCVIP IK GNWBLLYJQXKPIP-ZOGIJGBBSA-N
DMNCVIP IU (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
DMNCVIP CA CAS 73671-86-0
DMNCVIP DE Discovery agent
DMPH4C8 ID DMPH4C8
DMPH4C8 DN 4-Methanesulfonylamino-benzenesulfonamide
DMPH4C8 HS Investigative
DMPH4C8 SN 4-Methanesulfonylamino-benzenesulfonamide; 4-(methanesulfonamido)benzenesulfonamide; CHEMBL193648; 4426-90-8; 4-[(methylsulfonyl)amino]benzenesulfonamide; AC1MDJCY; Oprea1_082411; SCHEMBL6401783; DTXSID60385527; MolPort-001-489-118; ZINC3191876; BDBM50174035; STK416772; BBL020042; AKOS002973885; MCULE-3544784326; 4-(Methylsulfonylamino)benzenesulfonamide
DMPH4C8 DT Small molecular drug
DMPH4C8 PC 2837872
DMPH4C8 MW 250.3
DMPH4C8 FM C7H10N2O4S2
DMPH4C8 IC InChI=1S/C7H10N2O4S2/c1-14(10,11)9-6-2-4-7(5-3-6)15(8,12)13/h2-5,9H,1H3,(H2,8,12,13)
DMPH4C8 CS CS(=O)(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMPH4C8 IK KPLRLDFXFOARQY-UHFFFAOYSA-N
DMPH4C8 IU 4-(methanesulfonamido)benzenesulfonamide
DMPH4C8 CA CAS 4426-90-8
DMPH4C8 DE Discovery agent
DM97B2G ID DM97B2G
DM97B2G DN 4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline
DM97B2G HS Investigative
DM97B2G SN CHEMBL188052; 4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline
DM97B2G DT Small molecular drug
DM97B2G PC 11196622
DM97B2G MW 275.3
DM97B2G FM C17H13N3O
DM97B2G IC InChI=1S/C17H13N3O/c1-21-17-14-11-20(12-7-3-2-4-8-12)19-16(14)13-9-5-6-10-15(13)18-17/h2-11H,1H3
DM97B2G CS COC1=NC2=CC=CC=C2C3=NN(C=C31)C4=CC=CC=C4
DM97B2G IK LBRDTSFKAURCRO-UHFFFAOYSA-N
DM97B2G IU 4-methoxy-2-phenylpyrazolo[4,3-c]quinoline
DM97B2G DE Discovery agent
DMJIX7H ID DMJIX7H
DMJIX7H DN 4-Methoxy-3-pyridinesulfonamide
DMJIX7H HS Investigative
DMJIX7H SN CHEMBL1165321; 4-Methoxy-3-pyridinesulfonamide
DMJIX7H DT Small molecular drug
DMJIX7H PC 46703766
DMJIX7H MW 188.21
DMJIX7H FM C6H8N2O3S
DMJIX7H IC InChI=1S/C6H8N2O3S/c1-11-5-2-3-8-4-6(5)12(7,9)10/h2-4H,1H3,(H2,7,9,10)
DMJIX7H CS COC1=C(C=NC=C1)S(=O)(=O)N
DMJIX7H IK YLDUTJXETDRGDZ-UHFFFAOYSA-N
DMJIX7H IU 4-methoxypyridine-3-sulfonamide
DMJIX7H DE Discovery agent
DM5FRV2 ID DM5FRV2
DM5FRV2 DN 4'-Methoxy-5,3'-dipropyl-biphenyl-2ol
DM5FRV2 HS Investigative
DM5FRV2 SN CHEMBL555297; Magreth-1; ZINC42966087; BDBM50295920
DM5FRV2 DT Small molecular drug
DM5FRV2 PC 45267389
DM5FRV2 MW 284.4
DM5FRV2 FM C19H24O2
DM5FRV2 IC InChI=1S/C19H24O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h8-13,20H,4-7H2,1-3H3
DM5FRV2 CS CCCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)OC)CCC
DM5FRV2 IK HFEJJSAHPYKAPW-UHFFFAOYSA-N
DM5FRV2 IU 2-(4-methoxy-3-propylphenyl)-4-propylphenol
DM5FRV2 DE Discovery agent
DMID40H ID DMID40H
DMID40H DN 4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene
DMID40H HS Investigative
DMID40H SN CHEMBL142639; 4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene; ZINC13603872; BDBM50029753
DMID40H DT Small molecular drug
DMID40H PC 10494803
DMID40H MW 305.4
DMID40H FM C19H15NOS
DMID40H IC InChI=1S/C19H15NOS/c1-21-18-16-11-7-13-20(16)15-10-5-6-12-17(15)22-19(18)14-8-3-2-4-9-14/h2-13H,1H3
DMID40H CS COC1=C(SC2=CC=CC=C2N3C1=CC=C3)C4=CC=CC=C4
DMID40H IK AWMKYXNZIQHXIW-UHFFFAOYSA-N
DMID40H IU 7-methoxy-6-phenylpyrrolo[2,1-d][1,5]benzothiazepine
DMID40H DE Discovery agent
DM54A3W ID DM54A3W
DM54A3W DN 4-methoxy-9-aminomethyl-9,10-dihydroanthracene
DM54A3W HS Investigative
DM54A3W SN CHEMBL454491; 4-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264950
DM54A3W DT Small molecular drug
DM54A3W PC 44580318
DM54A3W MW 239.31
DM54A3W FM C16H17NO
DM54A3W IC InChI=1S/C16H17NO/c1-18-16-8-4-7-13-14(16)9-11-5-2-3-6-12(11)15(13)10-17/h2-8,15H,9-10,17H2,1H3
DM54A3W CS COC1=CC=CC2=C1CC3=CC=CC=C3C2CN
DM54A3W IK ZJILWLYMMRQWLR-UHFFFAOYSA-N
DM54A3W IU (4-methoxy-9,10-dihydroanthracen-9-yl)methanamine
DM54A3W DE Discovery agent
DMVFLCM ID DMVFLCM
DMVFLCM DN 4-Methoxybenzenemethanethiol
DMVFLCM HS Investigative
DMVFLCM SN 6258-60-2; 4-Methoxy-alpha-toluenethiol; 4-Methoxybenzyl mercaptan; 4-methoxybenzylmercaptan; (4-Methoxyphenyl)methanethiol; 4-Methoxy Benzylmercaptan; Benzenemethanethiol, 4-methoxy-; p-Methoxybenzyl Mercaptan; 4-Methoxy benzyl mercaptan; 4-Methoxy-; p-Methoxybenzylthiol; p-Methoxybenzylmercaptan; p-Methoxy-.alpha.-toluenethiol; 4-Methoxy-.alpha.-toluenethiol; CHEMBL1224560; PTDVPWWJRCOIIO-UHFFFAOYSA-N; 4-Methoxy-alpha-toluenethiol, 95%; 4-methoxybenzylthiol; EINECS 228-393-6
DMVFLCM DT Small molecular drug
DMVFLCM PC 80407
DMVFLCM MW 154.23
DMVFLCM FM C8H10OS
DMVFLCM IC InChI=1S/C8H10OS/c1-9-8-4-2-7(6-10)3-5-8/h2-5,10H,6H2,1H3
DMVFLCM CS COC1=CC=C(C=C1)CS
DMVFLCM IK PTDVPWWJRCOIIO-UHFFFAOYSA-N
DMVFLCM IU (4-methoxyphenyl)methanethiol
DMVFLCM CA CAS 6258-60-2
DMVFLCM DE Discovery agent
DMCS83F ID DMCS83F
DMCS83F DN 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline
DMCS83F HS Investigative
DMCS83F SN CHEMBL83581; 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline
DMCS83F DT Small molecular drug
DMCS83F PC 10711377
DMCS83F MW 328.4
DMCS83F FM C19H24N2O3
DMCS83F IC InChI=1S/C19H24N2O3/c1-4-8-23-13-6-7-16-14(10-13)18-15(12-22-3)19(24-9-5-2)20-11-17(18)21-16/h6-7,10-11,21H,4-5,8-9,12H2,1-3H3
DMCS83F CS CCCOC1=CC2=C(C=C1)NC3=CN=C(C(=C23)COC)OCCC
DMCS83F IK BTCRVOSPHNKQGJ-UHFFFAOYSA-N
DMCS83F IU 4-(methoxymethyl)-3,6-dipropoxy-9H-pyrido[3,4-b]indole
DMCS83F DE Discovery agent
DMF079L ID DMF079L
DMF079L DN 4-methoxy-N'-(2-phenylacetyl)benzohydrazide
DMF079L HS Investigative
DMF079L SN 4-methoxy-N'-(phenylacetyl)benzohydrazide; 4-methoxy-N'-(2-phenylacetyl)benzohydrazide; benzohydrazide, 15; AC1LEZHC; CHEMBL244921; ARONIS002261; BDBM23731; ZINC68809; KS-00003VJE; MolPort-000-681-545; STK056698; AKOS000492246; MCULE-6943344531; ST040019; 4-methoxy-N -(phenylacetyl)benzohydrazide; KB-115318; 4-methoxy-N''-(2-phenylacetyl)benzohydrazide
DMF079L DT Small molecular drug
DMF079L PC 695069
DMF079L MW 284.31
DMF079L FM C16H16N2O3
DMF079L IC InChI=1S/C16H16N2O3/c1-21-14-9-7-13(8-10-14)16(20)18-17-15(19)11-12-5-3-2-4-6-12/h2-10H,11H2,1H3,(H,17,19)(H,18,20)
DMF079L CS COC1=CC=C(C=C1)C(=O)NNC(=O)CC2=CC=CC=C2
DMF079L IK BJVRKPCYZSFHDT-UHFFFAOYSA-N
DMF079L IU 4-methoxy-N'-(2-phenylacetyl)benzohydrazide
DMF079L DE Discovery agent
DMFKN1M ID DMFKN1M
DMFKN1M DN 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide
DMFKN1M HS Investigative
DMFKN1M SN CHEMBL62075; 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide; BDBM50097446
DMFKN1M DT Small molecular drug
DMFKN1M PC 10760609
DMFKN1M MW 354.4
DMFKN1M FM C23H18N2O2
DMFKN1M IC InChI=1S/C23H18N2O2/c1-27-19-13-11-17(12-14-19)23(26)25-22-20-10-6-5-9-18(20)15-21(24-22)16-7-3-2-4-8-16/h2-15H,1H3,(H,24,25,26)
DMFKN1M CS COC1=CC=C(C=C1)C(=O)NC2=NC(=CC3=CC=CC=C32)C4=CC=CC=C4
DMFKN1M IK MJZBWCOZBVDNSM-UHFFFAOYSA-N
DMFKN1M IU 4-methoxy-N-(3-phenylisoquinolin-1-yl)benzamide
DMFKN1M DE Discovery agent
DMPQKGY ID DMPQKGY
DMPQKGY DN 4-methoxy-N-(thiazol-2-yl)benzamide
DMPQKGY HS Investigative
DMPQKGY SN 4-Methoxy-N-thiazol-2-yl-benzamide; 4-methoxy-N-1,3-thiazol-2-ylbenzamide; 4-methoxy-benzoic acid thiazol-2-ylamide; 4-methoxy-N-(1,3-thiazol-2-yl)benzamide; 303122-55-6; BAS 00626024; Oprea1_481467; Oprea1_830630; MLS001209223; ARONIS023447; CHEMBL387618; AC1Q49Y5; AC1LF170; MolPort-001-004-838; ZINC123532; HMS2848F19; STK031490; AKOS001320075; MCULE-9448418356; KS-0000469Q; ST089107; SMR000514833; KB-115289; 4-methoxy-N~1~-(1,3-thiazol-2-yl)benzamide
DMPQKGY DT Small molecular drug
DMPQKGY PC 721308
DMPQKGY MW 234.28
DMPQKGY FM C11H10N2O2S
DMPQKGY IC InChI=1S/C11H10N2O2S/c1-15-9-4-2-8(3-5-9)10(14)13-11-12-6-7-16-11/h2-7H,1H3,(H,12,13,14)
DMPQKGY CS COC1=CC=C(C=C1)C(=O)NC2=NC=CS2
DMPQKGY IK PPERAEKJEHRHOY-UHFFFAOYSA-N
DMPQKGY IU 4-methoxy-N-(1,3-thiazol-2-yl)benzamide
DMPQKGY DE Discovery agent
DMBS61O ID DMBS61O
DMBS61O DN 4-methoxynaphthalen-1-amine
DMBS61O HS Investigative
DMBS61O SN 4-methoxynaphthalen-1-amine; 16430-99-2; 1-Naphthalenamine, 4-methoxy-; 1-amino-4-methoxynaphthalene; CHEMBL572058; JVMUPDOMGALPOW-UHFFFAOYSA-N; F2146-0572; 4-methoxy naphthylamine; ACMC-209dqv; 4-methoxy-1-naphthalenamine; 1-methoxy-4-naphthalenamine; SCHEMBL331453; 1 -amino-4-methoxy-naphthalene; CTK8B0935; DTXSID80454284; ZINC11919966; BDBM50303938; ANW-22085; AKOS009236876; MCULE-9788991699; 4-methoxynaphthalen-1-amine, AldrichCPR; CJ-13724; AJ-60498; TC-110830; FT-0750226
DMBS61O DT Small molecular drug
DMBS61O PC 11074644
DMBS61O MW 173.21
DMBS61O FM C11H11NO
DMBS61O IC InChI=1S/C11H11NO/c1-13-11-7-6-10(12)8-4-2-3-5-9(8)11/h2-7H,12H2,1H3
DMBS61O CS COC1=CC=C(C2=CC=CC=C21)N
DMBS61O IK JVMUPDOMGALPOW-UHFFFAOYSA-N
DMBS61O IU 4-methoxynaphthalen-1-amine
DMBS61O CA CAS 16430-99-2
DMBS61O DE Discovery agent
DM739SQ ID DM739SQ
DM739SQ DN 4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate
DM739SQ HS Investigative
DM739SQ SN CHEMBL591447; 4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate; SCHEMBL5214948
DM739SQ DT Small molecular drug
DM739SQ PC 20872773
DM739SQ MW 357.4
DM739SQ FM C21H27NO4
DM739SQ IC InChI=1S/C21H27NO4/c1-4-6-15-25-18-9-7-16(8-10-18)20(5-2)22-21(23)26-19-13-11-17(24-3)12-14-19/h7-14,20H,4-6,15H2,1-3H3,(H,22,23)
DM739SQ CS CCCCOC1=CC=C(C=C1)C(CC)NC(=O)OC2=CC=C(C=C2)OC
DM739SQ IK SOBJGOKNEOSMPL-UHFFFAOYSA-N
DM739SQ IU (4-methoxyphenyl) N-[1-(4-butoxyphenyl)propyl]carbamate
DM739SQ DE Discovery agent
DM3L76R ID DM3L76R
DM3L76R DN 4-methoxyphenyl 10H-phenothiazine-10-carboxylate
DM3L76R HS Investigative
DM3L76R SN CHEMBL481872; 4-methoxyphenyl 10H-phenothiazine-10-carboxylate; SCHEMBL4453079; MolPort-004-877-802; BDBM50292614; STK354315; ZINC20085903; AKOS005442135
DM3L76R DT Small molecular drug
DM3L76R PC 24905597
DM3L76R MW 349.4
DM3L76R FM C20H15NO3S
DM3L76R IC InChI=1S/C20H15NO3S/c1-23-14-10-12-15(13-11-14)24-20(22)21-16-6-2-4-8-18(16)25-19-9-5-3-7-17(19)21/h2-13H,1H3
DM3L76R CS COC1=CC=C(C=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM3L76R IK OFQHJDQONOGHGC-UHFFFAOYSA-N
DM3L76R IU (4-methoxyphenyl) phenothiazine-10-carboxylate
DM3L76R DE Discovery agent
DMP5YFQ ID DMP5YFQ
DMP5YFQ DN 4-methoxyphenylboronic acid
DMP5YFQ HS Investigative
DMP5YFQ SN 4-Methoxyphenylboronic acid; 5720-07-0; (4-Methoxyphenyl)boronic acid; 4-Methoxybenzeneboronic acid; 4-Methoxyphenyl boronic acid; p-Anisylboronic acid; p-Methoxyphenylboronic acid; 45713-46-0; p-Methoxybenzeneboronic acid; (4-Methoxyphenyl)Boranediol; Benzeneboronic acid, p-methoxy-; 4-Boronoanisole; Boronic acid, p-methoxyphenyl-; 4-methoxy boronic acid; BRN 2936912; CHEMBL21427; BORONIC ACID, (4-METHOXYPHENYL)-; 4-methoxy-phenyl-boronic acid; AI3-61385; (4-METHOXYPHENYL)BORANE; MFCD00039139; 4-Methoxyphenylboronic acid, 97%
DMP5YFQ DT Small molecular drug
DMP5YFQ PC 201262
DMP5YFQ MW 151.96
DMP5YFQ FM C7H9BO3
DMP5YFQ IC InChI=1S/C7H9BO3/c1-11-7-4-2-6(3-5-7)8(9)10/h2-5,9-10H,1H3
DMP5YFQ CS B(C1=CC=C(C=C1)OC)(O)O
DMP5YFQ IK VOAAEKKFGLPLLU-UHFFFAOYSA-N
DMP5YFQ IU (4-methoxyphenyl)boronic acid
DMP5YFQ CA CAS 5720-07-0
DMP5YFQ DE Discovery agent
DMVW8KN ID DMVW8KN
DMVW8KN DN 4-methoxyphenylsulfamide
DMVW8KN HS Investigative
DMVW8KN SN 4-methoxyphenylsulfamide; N-(4-methoxyphenyl)sulfamide; CHEMBL165878; 10539-83-0; (4-methoxylphenyl)sulfamide; SCHEMBL1645328; CTK8G5045; N-(4-methoxyphenyl)sulfuric diamide; BDBM50124171; ZINC13488096; 1-methoxy-4-(sulfamoylamino)-benzene; AKOS027393897; DA-48085; KB-299500; FT-0726752; 79495-EP2305698A2; 79495-EP2305697A2; 79495-EP2305696A2
DMVW8KN DT Small molecular drug
DMVW8KN PC 12033284
DMVW8KN MW 202.23
DMVW8KN FM C7H10N2O3S
DMVW8KN IC InChI=1S/C7H10N2O3S/c1-12-7-4-2-6(3-5-7)9-13(8,10)11/h2-5,9H,1H3,(H2,8,10,11)
DMVW8KN CS COC1=CC=C(C=C1)NS(=O)(=O)N
DMVW8KN IK ICWBFSCBEZAOCT-UHFFFAOYSA-N
DMVW8KN IU 1-methoxy-4-(sulfamoylamino)benzene
DMVW8KN DE Discovery agent
DM2IZA3 ID DM2IZA3
DM2IZA3 DN 4-Methyl-1,1':4',1''-terphenyl-3,4''-diol
DM2IZA3 HS Investigative
DM2IZA3 SN CHEMBL568945; BDBM50299638
DM2IZA3 DT Small molecular drug
DM2IZA3 PC 44543257
DM2IZA3 MW 276.3
DM2IZA3 FM C19H16O2
DM2IZA3 IC InChI=1S/C19H16O2/c1-13-11-17(9-10-19(13)21)15-7-5-14(6-8-15)16-3-2-4-18(20)12-16/h2-12,20-21H,1H3
DM2IZA3 CS CC1=C(C=CC(=C1)C2=CC=C(C=C2)C3=CC(=CC=C3)O)O
DM2IZA3 IK NXOBKCKXSAATAY-UHFFFAOYSA-N
DM2IZA3 IU 4-[4-(3-hydroxyphenyl)phenyl]-2-methylphenol
DM2IZA3 DE Discovery agent
DMKRHQ3 ID DMKRHQ3
DMKRHQ3 DN 4-methyl-2H-benzofuro[3,2-g]chromen-2-one
DMKRHQ3 HS Investigative
DMKRHQ3 SN CHEMBL201777; 105290-13-9; 2H-Benzofuro(3,2-g)-1-benzopyran-2-one, 4-methyl-; 4-Methyl-(1)benzofuro(3,2-g)chromen-2-one; 2H-Benzofuro[3,2-g]-1-benzopyran-2-one, 4-methyl-; 4-methyl-[1]benzofuro[3,2-g]chromen-2-one; 4-methyl-2H-benzofuro[3,2-g]chromen-2-one; ACMC-20c6p3; AC1Q6A2V; AC1L4EY2; 4-methyl-2h-[1]benzofuro[3,2-g]chromen-2-one; CTK0G5617; DTXSID00147060; ZINC6069630; BDBM50181850
DMKRHQ3 DT Small molecular drug
DMKRHQ3 PC 184462
DMKRHQ3 MW 250.25
DMKRHQ3 FM C16H10O3
DMKRHQ3 IC InChI=1S/C16H10O3/c1-9-6-16(17)19-14-8-15-12(7-11(9)14)10-4-2-3-5-13(10)18-15/h2-8H,1H3
DMKRHQ3 CS CC1=CC(=O)OC2=CC3=C(C=C12)C4=CC=CC=C4O3
DMKRHQ3 IK MOTTUNALIBKKNF-UHFFFAOYSA-N
DMKRHQ3 IU 4-methyl-[1]benzofuro[3,2-g]chromen-2-one
DMKRHQ3 CA CAS 105290-13-9
DMKRHQ3 DE Discovery agent
DMH6QZO ID DMH6QZO
DMH6QZO DN 4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid
DMH6QZO HS Investigative
DMH6QZO SN CHEMBL124880; 88072-24-6; 4-Methyl-3-(2-oxoazetidin-1-yl)benzoic acid; 4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid; CTK3B8559; DTXSID20539468; BDBM50022785; Benzoic acid, 4-methyl-3-(2-oxo-1-azetidinyl)-
DMH6QZO DT Small molecular drug
DMH6QZO PC 13400034
DMH6QZO MW 205.21
DMH6QZO FM C11H11NO3
DMH6QZO IC InChI=1S/C11H11NO3/c1-7-2-3-8(11(14)15)6-9(7)12-5-4-10(12)13/h2-3,6H,4-5H2,1H3,(H,14,15)
DMH6QZO CS CC1=C(C=C(C=C1)C(=O)O)N2CCC2=O
DMH6QZO IK XLQAIEGAEHIXRJ-UHFFFAOYSA-N
DMH6QZO IU 4-methyl-3-(2-oxoazetidin-1-yl)benzoic acid
DMH6QZO CA CAS 88072-24-6
DMH6QZO DE Discovery agent
DM5FWYG ID DM5FWYG
DM5FWYG DN 4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DM5FWYG HS Investigative
DM5FWYG SN AKOS006358726
DM5FWYG DT Small molecular drug
DM5FWYG PC 44313256
DM5FWYG MW 110.16
DM5FWYG FM C6H10N2
DM5FWYG IC InChI=1S/C6H10N2/c1-5-2-3-8-6(7)4-5/h2H,3-4H2,1H3,(H2,7,8)
DM5FWYG CS CC1=CCN=C(C1)N
DM5FWYG IK ZOKOWWYVKANQNJ-UHFFFAOYSA-N
DM5FWYG IU 4-methyl-2,5-dihydropyridin-6-amine
DM5FWYG DE Discovery agent
DMV19HC ID DMV19HC
DMV19HC DN 4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC HS Investigative
DMV19HC SN CHEMBL204110; 4-Methyl-5-(4-piperidyl)isothiazol-3-ol
DMV19HC DT Small molecular drug
DMV19HC PC 11507406
DMV19HC MW 198.29
DMV19HC FM C9H14N2OS
DMV19HC IC InChI=1S/C9H14N2OS/c1-6-8(13-11-9(6)12)7-2-4-10-5-3-7/h7,10H,2-5H2,1H3,(H,11,12)
DMV19HC CS CC1=C(SNC1=O)C2CCNCC2
DMV19HC IK TVYLWJFICSYNFD-UHFFFAOYSA-N
DMV19HC IU 4-methyl-5-piperidin-4-yl-1,2-thiazol-3-one
DMV19HC DE Discovery agent
DMUP8NS ID DMUP8NS
DMUP8NS DN 4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine
DMUP8NS HS Investigative
DMUP8NS SN CHEMBL75304; 479668-33-2; 5,6-dihydro-4-methyl-2-Pyridinamine; ZINC2002913; BDBM50116666; AKOS006359115; FCH1123804; ACM479668332; DB-070901; FT-0749169; 2-Pyridinamine,5,6-dihydro-4-methyl-(9CI)
DMUP8NS DT Small molecular drug
DMUP8NS PC 9793827
DMUP8NS MW 110.16
DMUP8NS FM C6H10N2
DMUP8NS IC InChI=1S/C6H10N2/c1-5-2-3-8-6(7)4-5/h4H,2-3H2,1H3,(H2,7,8)
DMUP8NS CS CC1=CC(=NCC1)N
DMUP8NS IK SRTDZDDEFUNXJL-UHFFFAOYSA-N
DMUP8NS IU 4-methyl-2,3-dihydropyridin-6-amine
DMUP8NS DE Discovery agent
DM7LPON ID DM7LPON
DM7LPON DN 4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one
DM7LPON HS Investigative
DM7LPON SN CHEMBL124849; 4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one; SCHEMBL6942608; ZINC27211803
DM7LPON DT Small molecular drug
DM7LPON PC 12969973
DM7LPON MW 211.26
DM7LPON FM C14H13NO
DM7LPON IC InChI=1S/C14H13NO/c1-10-12-7-6-11-4-2-3-5-13(11)15(12)9-8-14(10)16/h2-5,8-9H,6-7H2,1H3
DM7LPON CS CC1=C2CCC3=CC=CC=C3N2C=CC1=O
DM7LPON IK POEIHRYHSHOMRL-UHFFFAOYSA-N
DM7LPON IU 4-methyl-5,6-dihydrobenzo[f]quinolizin-3-one
DM7LPON DE Discovery agent
DM0ZA7T ID DM0ZA7T
DM0ZA7T DN 4-Methyl-5-piperidin-4-yl-isoxazol-3-ol
DM0ZA7T HS Investigative
DM0ZA7T SN CHEMBL144416; CHEMBL553129; 439944-42-0; 3(2H)-Isoxazolone, 4-methyl-5-(4-piperidinyl)-; BDBM50113803; BDBM50020029; AKOS022705739; 4-Methyl-5-(4-piperidinyl)isoxazole-3-ol; 4-Methyl-5-piperidin-4-yl-isoxazol-3-ol
DM0ZA7T DT Small molecular drug
DM0ZA7T PC 10797510
DM0ZA7T MW 182.22
DM0ZA7T FM C9H14N2O2
DM0ZA7T IC InChI=1S/C9H14N2O2/c1-6-8(13-11-9(6)12)7-2-4-10-5-3-7/h7,10H,2-5H2,1H3,(H,11,12)
DM0ZA7T CS CC1=C(ONC1=O)C2CCNCC2
DM0ZA7T IK PACUXLHRGQUIQZ-UHFFFAOYSA-N
DM0ZA7T IU 4-methyl-5-piperidin-4-yl-1,2-oxazol-3-one
DM0ZA7T DE Discovery agent
DMN8Z3C ID DMN8Z3C
DMN8Z3C DN 4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine
DMN8Z3C HS Investigative
DMN8Z3C SN CHEMBL186142; CHEMBL541081; BDBM50066785; AKOS006377665; 4-Methyl-5-propyl-pyrrolidin-(2E)-ylideneamine
DMN8Z3C DT Small molecular drug
DMN8Z3C PC 19049123
DMN8Z3C MW 140.23
DMN8Z3C FM C8H16N2
DMN8Z3C IC InChI=1S/C8H16N2/c1-3-4-7-6(2)5-8(9)10-7/h6-7H,3-5H2,1-2H3,(H2,9,10)
DMN8Z3C CS CCCC1C(CC(=N1)N)C
DMN8Z3C IK TYAICJLSMGBRPT-UHFFFAOYSA-N
DMN8Z3C IU 3-methyl-2-propyl-3,4-dihydro-2H-pyrrol-5-amine
DMN8Z3C DE Discovery agent
DMW7YHS ID DMW7YHS
DMW7YHS DN 4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine
DMW7YHS HS Investigative
DMW7YHS SN 4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine; CHEMBL464556; 1146620-61-2; SCHEMBL13040624
DMW7YHS DT Small molecular drug
DMW7YHS PC 42625621
DMW7YHS MW 162.23
DMW7YHS FM C10H14N2
DMW7YHS IC InChI=1S/C10H14N2/c1-7(2)4-9-5-8(3)6-10(11)12-9/h4-6H,1-3H3,(H2,11,12)
DMW7YHS CS CC1=CC(=NC(=C1)N)C=C(C)C
DMW7YHS IK BHPPONCQQUIFAK-UHFFFAOYSA-N
DMW7YHS IU 4-methyl-6-(2-methylprop-1-enyl)pyridin-2-amine
DMW7YHS DE Discovery agent
DMY04D1 ID DMY04D1
DMY04D1 DN 4-methyl-6-propylpyridin-2-amine
DMY04D1 HS Investigative
DMY04D1 SN 4-Methyl-6-propylpyridin-2-amine; CHEMBL302657; 2-amino-4-methyl-6-propylpyridine; 179555-24-9; SCHEMBL7051196; QGCCHDIBMYPTPX-UHFFFAOYSA-N; BDBM50091817; 4-Methyl-6-propyl-pyridin-2-ylamine; 2-Pyridinamine, 4-methyl-6-propyl-; AKOS027400844; 4-Methyl-6-propylpyridin-2-amine, 7
DMY04D1 DT Small molecular drug
DMY04D1 PC 9855524
DMY04D1 MW 150.22
DMY04D1 FM C9H14N2
DMY04D1 IC InChI=1S/C9H14N2/c1-3-4-8-5-7(2)6-9(10)11-8/h5-6H,3-4H2,1-2H3,(H2,10,11)
DMY04D1 CS CCCC1=NC(=CC(=C1)C)N
DMY04D1 IK QGCCHDIBMYPTPX-UHFFFAOYSA-N
DMY04D1 IU 4-methyl-6-propylpyridin-2-amine
DMY04D1 DE Discovery agent
DM9K7CQ ID DM9K7CQ
DM9K7CQ DN 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one
DM9K7CQ HS Investigative
DM9K7CQ SN CHEMBL372943; 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one; CTK7H3804; BDBM50181856; AKOS015965448; 4-Methyl-7-(2-oxo-cyclopentyloxy)-c
DM9K7CQ DT Small molecular drug
DM9K7CQ PC 44407281
DM9K7CQ MW 258.269
DM9K7CQ FM C15H14O4
DM9K7CQ IC InChI=1S/C15H14O4/c1-9-7-15(17)19-14-8-10(5-6-11(9)14)18-13-4-2-3-12(13)16/h5-8,13H,2-4H2,1H3
DM9K7CQ CS CC1=CC(=O)OC2=C1C=CC(=C2)OC3CCCC3=O
DM9K7CQ IK UDCMJKJFGCMHHR-UHFFFAOYSA-N
DM9K7CQ IU 4-methyl-7-(2-oxocyclopentyl)oxychromen-2-one
DM9K7CQ DE Discovery agent
DM5XMI9 ID DM5XMI9
DM5XMI9 DN 4-Methylamino-benzenesulfonamide
DM5XMI9 HS Investigative
DM5XMI9 SN 4-(Methylamino)Benzenesulfonamide; 4-(methylamino)benzene-1-sulfonamide; 16891-79-5; 4-Methylamino-benzenesulfonamide; CHEMBL174847; AC1Q40XN; SCHEMBL3521509; p-methylaminobenzene sulphonamide; CTK4D3153; DTXSID40562172; FJVAYUUWTJKKNC-UHFFFAOYSA-N; MolPort-004-759-881; Benzenesulfonamide,4-(methylamino)-; ZINC28098746; BDBM50160668; Benzenesulfonamide, 4-(methylamino)-; AKOS009323835; MCULE-7909074599; NE62186; DA-09438; KB-289209; FT-0749810; EN300-58198
DM5XMI9 DT Small molecular drug
DM5XMI9 PC 14612854
DM5XMI9 MW 186.23
DM5XMI9 FM C7H10N2O2S
DM5XMI9 IC InChI=1S/C7H10N2O2S/c1-9-6-2-4-7(5-3-6)12(8,10)11/h2-5,9H,1H3,(H2,8,10,11)
DM5XMI9 CS CNC1=CC=C(C=C1)S(=O)(=O)N
DM5XMI9 IK FJVAYUUWTJKKNC-UHFFFAOYSA-N
DM5XMI9 IU 4-(methylamino)benzenesulfonamide
DM5XMI9 CA CAS 16891-79-5
DM5XMI9 DE Discovery agent
DMI1L6Q ID DMI1L6Q
DMI1L6Q DN 4-methylaminomethyl-7-methoxycoumarin
DMI1L6Q HS Investigative
DMI1L6Q SN 4-Methylaminomethyl-7-methoxycoumarin; AC1PGYCB; 7-methoxy-4-(methylaminomethyl)chromen-2-one; SCHEMBL5022816; CHEMBL1080339; BDBM26482; GWMGUFTYUOYYQV-UHFFFAOYSA-N; 4-(Methylaminomethyl)-7-methoxycoumarin; 7-Methoxy-4-(methylaminomethyl)coumarin
DMI1L6Q DT Small molecular drug
DMI1L6Q PC 8931837
DMI1L6Q MW 219.24
DMI1L6Q FM C12H13NO3
DMI1L6Q IC InChI=1S/C12H13NO3/c1-13-7-8-5-12(14)16-11-6-9(15-2)3-4-10(8)11/h3-6,13H,7H2,1-2H3
DMI1L6Q CS CNCC1=CC(=O)OC2=C1C=CC(=C2)OC
DMI1L6Q IK GWMGUFTYUOYYQV-UHFFFAOYSA-N
DMI1L6Q IU 7-methoxy-4-(methylaminomethyl)chromen-2-one
DMI1L6Q DE Discovery agent
DM3S2P8 ID DM3S2P8
DM3S2P8 DN 4-Methylbenzenemethanethiol
DM3S2P8 HS Investigative
DM3S2P8 SN 4498-99-1; 4-Methylbenzyl Mercaptan; (4-Methylphenyl)methanethiol; p-Xylene-alpha-thiol; alpha-Mercapto-p-xylene; 4-Methylbenzenemethanethiol; 4-Methylbenzylmercaptan; Benzenemethanethiol, 4-methyl-; CHEMBL1224559; AGFYZLVFPSGUIX-UHFFFAOYSA-N; P-Xylyl Mercaptan; (4-methylphenyl)methane-1-thiol; p-tolylmethanethiol; NSC79870; EINECS 224-796-6; AC1L2UTO; AC1Q7GOJ; ACMC-1AQT2; 4-Methyl-alpha-toluenethiol; SCHEMBL385561; PARA-XYLENE-ALPHA-THIOL; (4-Methylphenyl)methanethiol #; CTK3J1384; DTXSID30196349; MolPort-000-146-954
DM3S2P8 DT Small molecular drug
DM3S2P8 PC 78252
DM3S2P8 MW 138.23
DM3S2P8 FM C8H10S
DM3S2P8 IC InChI=1S/C8H10S/c1-7-2-4-8(6-9)5-3-7/h2-5,9H,6H2,1H3
DM3S2P8 CS CC1=CC=C(C=C1)CS
DM3S2P8 IK AGFYZLVFPSGUIX-UHFFFAOYSA-N
DM3S2P8 IU (4-methylphenyl)methanethiol
DM3S2P8 CA CAS 4498-99-1
DM3S2P8 DE Discovery agent
DMABMPQ ID DMABMPQ
DMABMPQ DN 4-methylhistamine
DMABMPQ HS Investigative
DMABMPQ SN 4-Methylhistamine; 5-Methylhistamine; 36507-31-0; 5(4)-Methylhistamine; 1H-Imidazole-4-ethanamine, 5-methyl-; 2-(5-methyl-1H-imidazol-4-yl)ethanamine; UNII-54ST71P9EE; 1H-Imidazo-4-ethanamine, 5-methyl-; 54ST71P9EE; CHEBI:74760; IMIDAZOLE, 4-(2-AMINOETHYL)-5-METHYL-; 2-(5-Methyl-4-imidazolyl)ethylamine; 2-(4-METHYL-1H-IMIDAZOL-5-YL)ETHANAMINE; p-methylhistamine; Methylhistamine-4; 5-(2-Aminoethyl)-4-methylimidazole; AC1L1XS2; SCHEMBL606803; CHEMBL275443; GTPL1269; SCHEMBL11452941; BDBM22880; UGYXPZQILZRKJJ-UHFFFAOYSA-N
DMABMPQ DT Small molecular drug
DMABMPQ PC 37463
DMABMPQ MW 125.17
DMABMPQ FM C6H11N3
DMABMPQ IC InChI=1S/C6H11N3/c1-5-6(2-3-7)9-4-8-5/h4H,2-3,7H2,1H3,(H,8,9)
DMABMPQ CS CC1=C(N=CN1)CCN
DMABMPQ IK UGYXPZQILZRKJJ-UHFFFAOYSA-N
DMABMPQ IU 2-(5-methyl-1H-imidazol-4-yl)ethanamine
DMABMPQ CA CAS 36507-31-0
DMABMPQ CB CHEBI:74760
DMABMPQ DE Discovery agent
DM45N6U ID DM45N6U
DM45N6U DN 4-Methylimidazole
DM45N6U HS Investigative
DM45N6U SN 4-Methylimidazole; 4-Methyl-1H-imidazole; 822-36-6; 5-Methyl-1H-imidazole; 1H-Imidazole, 4-methyl-; 4(5)-Methylimidazole; 4-Me-i; 5-Methylimidazole; IMIDAZOLE, 4-METHYL-; 4(or 5)-Methylimidazole; 4-MEI; 4-methylimidazol; UNII-Q64GF9FV4I; 1H-Imidazole, 5-methyl-; 4-methyl imidazole; EINECS 212-497-3; NSC 40744; Q64GF9FV4I; AI3-08274; CHEBI:40035; XLSZMDLNRCVEIJ-UHFFFAOYSA-N; 4-Methylimidazole, 98%; 4-Methyl-d3-imidazole; 88054-16-4; 4MI; 4MZ; InChI=1/C4H6N2/c1-4-2-5-3-6-4/h2-3H,1H3,(H,5,6; CCRIS 8912; HSDB 7757; 4-methyl-imidazole
DM45N6U DT Small molecular drug
DM45N6U PC 13195
DM45N6U MW 82.1
DM45N6U FM C4H6N2
DM45N6U IC InChI=1S/C4H6N2/c1-4-2-5-3-6-4/h2-3H,1H3,(H,5,6)
DM45N6U CS CC1=CN=CN1
DM45N6U IK XLSZMDLNRCVEIJ-UHFFFAOYSA-N
DM45N6U IU 5-methyl-1H-imidazole
DM45N6U CA CAS 822-36-6
DM45N6U CB CHEBI:40035
DM45N6U DE Discovery agent
DMSF5DR ID DMSF5DR
DMSF5DR DN 4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide
DMSF5DR HS Investigative
DMSF5DR SN 4-Methyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; CHEMBL294175; 4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide; NERONVMZIDSIRT-UHFFFAOYSA-N; 87614-00-4; (Z)-4-methyl-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; AC1Q2JVA; AC1LB6OY; Oprea1_598164; Oprea1_751162; Oprea1_000114; SCHEMBL233522; ARONIS019641; 2-[(4-methylphenyl)carboxamido]-4-phenyl-1,3-thiazole; KS-00004BJP; MolPort-003-009-217; MolPort-001-029-741; ZINC4031557; BDBM50101781; STK084905; AKOS024573976; AKOS000486758; MCULE-8350259880; ST036564
DMSF5DR DT Small molecular drug
DMSF5DR PC 577347
DMSF5DR MW 294.4
DMSF5DR FM C17H14N2OS
DMSF5DR IC InChI=1S/C17H14N2OS/c1-12-7-9-14(10-8-12)16(20)19-17-18-15(11-21-17)13-5-3-2-4-6-13/h2-11H,1H3,(H,18,19,20)
DMSF5DR CS CC1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DMSF5DR IK NERONVMZIDSIRT-UHFFFAOYSA-N
DMSF5DR IU 4-methyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMSF5DR DE Discovery agent
DMFRASQ ID DMFRASQ
DMFRASQ DN 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine
DMFRASQ HS Investigative
DMFRASQ SN CHEMBL383736; AC1LEV1N; Maybridge1_006094; 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine; SCHEMBL14433296; HMS558M22; CCG-716; MolPort-000-432-043; ZINC5730833; BDBM50183094; AKOS002285219; MCULE-5807523116; ST50046832; (4-methyl(1,3-thiazol-2-yl))naphthylamine
DMFRASQ DT Small molecular drug
DMFRASQ PC 692856
DMFRASQ MW 240.33
DMFRASQ FM C14H12N2S
DMFRASQ IC InChI=1S/C14H12N2S/c1-10-9-17-14(15-10)16-13-8-4-6-11-5-2-3-7-12(11)13/h2-9H,1H3,(H,15,16)
DMFRASQ CS CC1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMFRASQ IK QNKLFDFMOINNIW-UHFFFAOYSA-N
DMFRASQ IU 4-methyl-N-naphthalen-1-yl-1,3-thiazol-2-amine
DMFRASQ DE Discovery agent
DMN45EH ID DMN45EH
DMN45EH DN 4-methyl-N-propyl-3,4-dihydroquinazolin-2-amine
DMN45EH HS Investigative
DMN45EH DT Small molecular drug
DMN45EH PC 44456463
DMN45EH DE Discovery agent
DME7W0Q ID DME7W0Q
DME7W0Q DN 4-Methyl-oxazolidin-(2Z)-ylideneamine
DME7W0Q HS Investigative
DME7W0Q SN CHEMBL105823; 4-methyl-4,5-dihydro-1,3-oxazol-2-amine; 68210-17-3; 4-Methyl-oxazolidin-(2Z)-ylideneamine; 4-Methyloxazolidine-2-imine; SCHEMBL6593982; SCHEMBL11825446; MolPort-004-802-126; BDBM50138202; AKOS006363611; NE17732
DME7W0Q DT Small molecular drug
DME7W0Q PC 18376830
DME7W0Q MW 100.12
DME7W0Q FM C4H8N2O
DME7W0Q IC InChI=1S/C4H8N2O/c1-3-2-7-4(5)6-3/h3H,2H2,1H3,(H2,5,6)
DME7W0Q CS CC1COC(=N1)N
DME7W0Q IK PIXPFRMNXPKTFS-UHFFFAOYSA-N
DME7W0Q IU 4-methyl-4,5-dihydro-1,3-oxazol-2-amine
DME7W0Q DE Discovery agent
DMR5NLM ID DMR5NLM
DMR5NLM DN 4-methylphenyl-difluoromethanesulfonamide
DMR5NLM HS Investigative
DMR5NLM SN 4-methylphenyl-difluoromethanesulfonamide; CHEMBL199464; 803728-11-2; CTK5E7727; DTXSID60658763; BDBM50175011; AKOS027416710; Benzenemethanesulfonamide,a,a-difluoro-4-methyl-; 1,1-Difluoro-1-(4-methylphenyl)methanesulfonamide
DMR5NLM DT Small molecular drug
DMR5NLM PC 44405177
DMR5NLM MW 221.23
DMR5NLM FM C8H9F2NO2S
DMR5NLM IC InChI=1S/C8H9F2NO2S/c1-6-2-4-7(5-3-6)8(9,10)14(11,12)13/h2-5H,1H3,(H2,11,12,13)
DMR5NLM CS CC1=CC=C(C=C1)C(F)(F)S(=O)(=O)N
DMR5NLM IK QPMHTUPJLAWJAW-UHFFFAOYSA-N
DMR5NLM IU difluoro-(4-methylphenyl)methanesulfonamide
DMR5NLM CA CAS 803728-11-2
DMR5NLM DE Discovery agent
DMNMXCE ID DMNMXCE
DMNMXCE DN 4-Methyl-piperidin-(2E)-ylideneamine
DMNMXCE HS Investigative
DMNMXCE SN CHEMBL6808; 2-imino-4-methylpiperidine; 2-PYRIDINAMINE, 3,4,5,6-TETRAHYDRO-4-METHYL-; 165383-71-1; 4-Methyl-piperidin-(2E)-ylideneamine; AC1MMWW1; 4-methylpiperidin-2-imine; 4-methyl-3,4,5,6-tetrahydropyridin-2-amine; 4-Methyl-2-piperidinimine; SCHEMBL4103569; CTK0A9019; DTXSID00390857; BDBM50062133; 4-Methyl-piperidin-(2Z)-ylideneamine; AKOS006348873; FT-0722141; 4-methyl-2,3,4,5-tetrahydropyridin-6-amine
DMNMXCE DT Small molecular drug
DMNMXCE PC 3268009
DMNMXCE MW 112.17
DMNMXCE FM C6H12N2
DMNMXCE IC InChI=1S/C6H12N2/c1-5-2-3-8-6(7)4-5/h5H,2-4H2,1H3,(H2,7,8)
DMNMXCE CS CC1CCN=C(C1)N
DMNMXCE IK GGDLOMFAKKVDPT-UHFFFAOYSA-N
DMNMXCE IU 4-methyl-2,3,4,5-tetrahydropyridin-6-amine
DMNMXCE CA CAS 165383-71-1
DMNMXCE DE Discovery agent
DME6UOM ID DME6UOM
DME6UOM DN 4-Methyl-pyridine
DME6UOM HS Investigative
DME6UOM SN 4-METHYLPYRIDINE; 4-Picoline; 108-89-4; Pyridine, 4-methyl-; p-Picoline; gamma-Picoline; p-Methylpyridine; 4-methyl-pyridine; gamma-Methylpyridine; Ba 35846; UNII-TJD6V9SSO7; .gamma.-Picoline; NSC 18252; 4-Mepy; CCRIS 1723; .gamma.-Methylpyridine; HSDB 5386; EINECS 203-626-4; TJD6V9SSO7; AI3-24111; CHEBI:32547; FKNQCJSGGFJEIZ-UHFFFAOYSA-N; 4-Picoline, 99%; DSSTox_CID_1892; DSSTox_RID_76389; DSSTox_GSID_21892; 4-methyl pyridine; CAS-108-89-4; gamma-picolin; 4-Pyridylmethyl; 4-pi-coline; para-Methylpyridine; Methyl, 4-pyridinyl-; 4-Picoline
DME6UOM DT Small molecular drug
DME6UOM PC 7963
DME6UOM MW 93.13
DME6UOM FM C6H7N
DME6UOM IC InChI=1S/C6H7N/c1-6-2-4-7-5-3-6/h2-5H,1H3
DME6UOM CS CC1=CC=NC=C1
DME6UOM IK FKNQCJSGGFJEIZ-UHFFFAOYSA-N
DME6UOM IU 4-methylpyridine
DME6UOM CA CAS 108-89-4
DME6UOM CB CHEBI:32547
DME6UOM DE Discovery agent
DM0YS36 ID DM0YS36
DM0YS36 DN 4-Methyl-pyrrolidin-(2Z)-ylideneamine
DM0YS36 HS Investigative
DM0YS36 SN CHEMBL183012; CHEMBL541090; 4-Methylpyrrolidine-2-imine; BDBM50066780; AKOS006351281; 4-Methyl-pyrrolidin-(2E)-ylideneamine
DM0YS36 DT Small molecular drug
DM0YS36 PC 15887953
DM0YS36 MW 98.15
DM0YS36 FM C5H10N2
DM0YS36 IC InChI=1S/C5H10N2/c1-4-2-5(6)7-3-4/h4H,2-3H2,1H3,(H2,6,7)
DM0YS36 CS CC1CC(=NC1)N
DM0YS36 IK IAGJRVCMUDBZSN-UHFFFAOYSA-N
DM0YS36 IU 3-methyl-3,4-dihydro-2H-pyrrol-5-amine
DM0YS36 DE Discovery agent
DMVMHBL ID DMVMHBL
DMVMHBL DN 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMVMHBL HS Investigative
DMVMHBL SN CHEMBL380940; 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5828673
DMVMHBL DT Small molecular drug
DMVMHBL PC 44407566
DMVMHBL MW 250.25
DMVMHBL FM C15H10N2O2
DMVMHBL IC InChI=1S/C15H10N2O2/c1-7-6-10-12(8-4-2-3-5-9(8)16-10)13-11(7)14(18)17-15(13)19/h2-6,16H,1H3,(H,17,18,19)
DMVMHBL CS CC1=CC2=C(C3=CC=CC=C3N2)C4=C1C(=O)NC4=O
DMVMHBL IK DSCSSQAANWCYAP-UHFFFAOYSA-N
DMVMHBL IU 4-methyl-6H-pyrrolo[3,4-c]carbazole-1,3-dione
DMVMHBL DE Discovery agent
DMW0Y29 ID DMW0Y29
DMW0Y29 DN 4-methylstyrylboronic acid
DMW0Y29 HS Investigative
DMW0Y29 SN 72316-17-7; trans-2-(4-Methylphenyl)vinylboronic acid; 4-methylstyrylboronic acid; (4-Methylstyryl)boronic acid; (E)-(4-Methylstyryl)boronic acid; CHEMBL551649; AK-96341; AC1O0LYH; AC1Q2JL5; SCHEMBL350162; JJOBVKVXRDHVRP-VOTSOKGWSA-N; [(E)-4-Methylstyryl]boronic acid; 1219AC; BDBM50294579; ZINC169876972; AKOS015893172; AB15070; FCH1119774; FCH4624789; OR360466; KB-61861; BBV-43860393; AX8240132; TX-012607; TC-143527; (E)-2-(4-methylphenyl)ethenylboronic acid; [(E)-2-(4-methylphenyl)ethenyl]boranediol
DMW0Y29 DT Small molecular drug
DMW0Y29 PC 6019835
DMW0Y29 MW 162
DMW0Y29 FM C9H11BO2
DMW0Y29 IC InChI=1S/C9H11BO2/c1-8-2-4-9(5-3-8)6-7-10(11)12/h2-7,11-12H,1H3/b7-6+
DMW0Y29 CS B(/C=C/C1=CC=C(C=C1)C)(O)O
DMW0Y29 IK JJOBVKVXRDHVRP-VOTSOKGWSA-N
DMW0Y29 IU [(E)-2-(4-methylphenyl)ethenyl]boronic acid
DMW0Y29 CA CAS 214907-11-6
DMW0Y29 DE Discovery agent
DMEB5XP ID DMEB5XP
DMEB5XP DN 4-Methylthiopyridine-3-sulfonamide
DMEB5XP HS Investigative
DMEB5XP SN 4-Methylthiopyridine-3-sulfonamide; CHEMBL1165117; 1078160-10-7
DMEB5XP DT Small molecular drug
DMEB5XP PC 46703929
DMEB5XP MW 204.3
DMEB5XP FM C6H8N2O2S2
DMEB5XP IC InChI=1S/C6H8N2O2S2/c1-11-5-2-3-8-4-6(5)12(7,9)10/h2-4H,1H3,(H2,7,9,10)
DMEB5XP CS CSC1=C(C=NC=C1)S(=O)(=O)N
DMEB5XP IK PLOUCIVACOBALV-UHFFFAOYSA-N
DMEB5XP IU 4-methylsulfanylpyridine-3-sulfonamide
DMEB5XP DE Discovery agent
DM049QO ID DM049QO
DM049QO DN 4-Morpholin-2-yl-benzene-1,2-diol
DM049QO HS Investigative
DM049QO SN 4-(2-Morpholinyl)pyrocatechol; 1,2-Benzenediol, 4-(2-morpholinyl)-; BRN 0170116; Pyrocatechol, 4-(2-morpholinyl)-; CHEMBL7681; 54826-84-5; 2-(3,4-Dioxyphenyl)tetrahydro-1,4-oxazin [German]; 4-Morpholin-2-yl-benzene-1,2-diol; AC1MIECG; 2-(3,4-Dioxyphenyl)tetrahydro-1,4-oxazin; 3,4-Dioxyphenyl-Morpholin; SCHEMBL17632965; CTK5A2632; 4-morpholin-2-ylbenzene-1,2-diol; BDBM50000502; AKOS022644999; UK-42620; LS-136459
DM049QO DT Small molecular drug
DM049QO PC 3042920
DM049QO MW 195.21
DM049QO FM C10H13NO3
DM049QO IC InChI=1S/C10H13NO3/c12-8-2-1-7(5-9(8)13)10-6-11-3-4-14-10/h1-2,5,10-13H,3-4,6H2
DM049QO CS C1COC(CN1)C2=CC(=C(C=C2)O)O
DM049QO IK GYJRRQRGZZEHEB-UHFFFAOYSA-N
DM049QO IU 4-morpholin-2-ylbenzene-1,2-diol
DM049QO CA CAS 54826-84-5
DM049QO DE Discovery agent
DMEJ6G9 ID DMEJ6G9
DMEJ6G9 DN 4-Morpholin-4-yl-benzo[g]chromen-2-one
DMEJ6G9 HS Investigative
DMEJ6G9 SN CHEMBL177279; 4-Morpholin-4-yl-benzo[g]chromen-2-one
DMEJ6G9 DT Small molecular drug
DMEJ6G9 PC 11346540
DMEJ6G9 MW 281.3
DMEJ6G9 FM C17H15NO3
DMEJ6G9 IC InChI=1S/C17H15NO3/c19-17-11-15(18-5-7-20-8-6-18)14-9-12-3-1-2-4-13(12)10-16(14)21-17/h1-4,9-11H,5-8H2
DMEJ6G9 CS C1COCCN1C2=CC(=O)OC3=CC4=CC=CC=C4C=C23
DMEJ6G9 IK NEEAOCHOCYXDSE-UHFFFAOYSA-N
DMEJ6G9 IU 4-morpholin-4-ylbenzo[g]chromen-2-one
DMEJ6G9 DE Discovery agent
DMW2MRP ID DMW2MRP
DMW2MRP DN 4-Morpholin-4-yl-benzo[h]chromen-2-one
DMW2MRP HS Investigative
DMW2MRP SN CHEMBL179641; 4-Morpholin-4-yl-benzo[h]chromen-2-one; BDBM50159617
DMW2MRP DT Small molecular drug
DMW2MRP PC 11471539
DMW2MRP MW 281.3
DMW2MRP FM C17H15NO3
DMW2MRP IC InChI=1S/C17H15NO3/c19-16-11-15(18-7-9-20-10-8-18)14-6-5-12-3-1-2-4-13(12)17(14)21-16/h1-6,11H,7-10H2
DMW2MRP CS C1COCCN1C2=CC(=O)OC3=C2C=CC4=CC=CC=C43
DMW2MRP IK QPPKEHFJUVBRAD-UHFFFAOYSA-N
DMW2MRP IU 4-morpholin-4-ylbenzo[h]chromen-2-one
DMW2MRP DE Discovery agent
DM7T3CU ID DM7T3CU
DM7T3CU DN 4-Morpholin-4-yl-chromen-2-one
DM7T3CU HS Investigative
DM7T3CU SN 4-Morpholin-4-yl-chromen-2-one; 4-morpholin-4-ylchromen-2-one; CHEMBL367262; 65625-83-4; 4-morpholinyl coumarin; SMR000116476; AC1LFJN6; CBMicro_022351; Oprea1_628619; Oprea1_860966; MLS000526002; SCHEMBL11450752; 4-morpholino-2H-chromen-2-one; CTK1I2254; DTXSID30355510; MolPort-001-959-554; ZINC312514; HMS2490I17; CCG-9410; BDBM50159613; AKOS000639877; 4-(4-morpholinyl)-2H-chromen-2-one; MCULE-8859511318; BAS 01256112; BIM-0022285.P001; ST50008215; 2H-1-Benzopyran-2-one, 4-(4-morpholinyl)-; SR-01000312410; AI-204/31682008
DM7T3CU DT Small molecular drug
DM7T3CU PC 804048
DM7T3CU MW 231.25
DM7T3CU FM C13H13NO3
DM7T3CU IC InChI=1S/C13H13NO3/c15-13-9-11(14-5-7-16-8-6-14)10-3-1-2-4-12(10)17-13/h1-4,9H,5-8H2
DM7T3CU CS C1COCCN1C2=CC(=O)OC3=CC=CC=C32
DM7T3CU IK YJXJQEJDZPLPTQ-UHFFFAOYSA-N
DM7T3CU IU 4-morpholin-4-ylchromen-2-one
DM7T3CU CA CAS 65625-83-4
DM7T3CU DE Discovery agent
DM8QPTJ ID DM8QPTJ
DM8QPTJ DN 4-morpholino-6-phenyl-2H-pyran-2-one
DM8QPTJ HS Investigative
DM8QPTJ SN CHEMBL221409; 4-morpholino-6-phenyl-2H-pyran-2-one; SCHEMBL3542543
DM8QPTJ DT Small molecular drug
DM8QPTJ PC 21106428
DM8QPTJ MW 257.279
DM8QPTJ FM C15H15NO3
DM8QPTJ IC InChI=1S/C15H15NO3/c17-15-11-13(16-6-8-18-9-7-16)10-14(19-15)12-4-2-1-3-5-12/h1-5,10-11H,6-9H2
DM8QPTJ CS C1COCCN1C2=CC(=O)OC(=C2)C3=CC=CC=C3
DM8QPTJ IK VKOGCIIARBRLEC-UHFFFAOYSA-N
DM8QPTJ IU 4-morpholin-4-yl-6-phenylpyran-2-one
DM8QPTJ DE Discovery agent
DM4E6HW ID DM4E6HW
DM4E6HW DN 4-MPPTS
DM4E6HW HS Investigative
DM4E6HW SN LY487379; LY-487379
DM4E6HW DT Small molecular drug
DM4E6HW PC 9825084
DM4E6HW MW 452.4
DM4E6HW FM C21H19F3N2O4S
DM4E6HW IC InChI=1S/C21H19F3N2O4S/c1-29-19-6-2-3-7-20(19)30-18-10-8-17(9-11-18)26(14-16-5-4-12-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3
DM4E6HW CS COC1=CC=CC=C1OC2=CC=C(C=C2)N(CC3=CN=CC=C3)S(=O)(=O)CC(F)(F)F
DM4E6HW IK ALMACYDZFBMGOR-UHFFFAOYSA-N
DM4E6HW IU 2,2,2-trifluoro-N-[4-(2-methoxyphenoxy)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DM4E6HW CA CAS 353231-17-1
DM4E6HW DE Discovery agent
DMEIA3L ID DMEIA3L
DMEIA3L DN 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol
DMEIA3L HS Investigative
DMEIA3L SN CHEMBL370714; 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol; BDBM50159229
DMEIA3L DT Small molecular drug
DMEIA3L PC 11303367
DMEIA3L MW 294.3
DMEIA3L FM C18H18N2O2
DMEIA3L IC InChI=1S/C18H18N2O2/c21-18-16(17(22-20-18)13-8-10-19-11-9-13)15-7-3-5-12-4-1-2-6-14(12)15/h1-7,13,19H,8-11H2,(H,20,21)
DMEIA3L CS C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC4=CC=CC=C43
DMEIA3L IK WDMOSRJVOUIQMD-UHFFFAOYSA-N
DMEIA3L IU 4-naphthalen-1-yl-5-piperidin-4-yl-1,2-oxazol-3-one
DMEIA3L DE Discovery agent
DM9O8UM ID DM9O8UM
DM9O8UM DN 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol
DM9O8UM HS Investigative
DM9O8UM SN CHEMBL382320; 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol; BDBM50159237; J3.626.536A; 4-(naphthalen-2-yl)-5-(piperidin-4-yl)isoxazol-3-ol
DM9O8UM DT Small molecular drug
DM9O8UM PC 11303369
DM9O8UM MW 294.3
DM9O8UM FM C18H18N2O2
DM9O8UM IC InChI=1S/C18H18N2O2/c21-18-16(17(22-20-18)13-7-9-19-10-8-13)15-6-5-12-3-1-2-4-14(12)11-15/h1-6,11,13,19H,7-10H2,(H,20,21)
DM9O8UM CS C1CNCCC1C2=C(C(=O)NO2)C3=CC4=CC=CC=C4C=C3
DM9O8UM IK PWDALQSYHZMANN-UHFFFAOYSA-N
DM9O8UM IU 4-naphthalen-2-yl-5-piperidin-4-yl-1,2-oxazol-3-one
DM9O8UM DE Discovery agent
DMKPNSH ID DMKPNSH
DMKPNSH DN 4-Naphthalen-2-yl-phenol
DMKPNSH HS Investigative
DMKPNSH SN 4-(naphthalen-2-yl)phenol; 6336-82-9; 4-Naphthalen-2-yl-phenol; 4-(2-Naphthyl)phenol; 4-naphthalen-2-ylphenol; CHEMBL194772; NSC-39892; 2-(4-HYDROXYPHENYL)NAPHTHALENE; NSC39892; AC1L5XK9; AC1Q7B9I; SCHEMBL234529; KS-00000ORV; CTK5B8841; DTXSID70284931; NIRHUNSXEDESLN-UHFFFAOYSA-N; MolPort-015-145-553; ZINC1671629; MFCD18312886; KM0737; BDBM50168385; ANW-73541; AKOS016007751; IMED1575423883; KB-40006; AK-50357; AJ-29221; TC-162286; AX8212912; 4CH-024303
DMKPNSH DT Small molecular drug
DMKPNSH PC 236868
DMKPNSH MW 220.26
DMKPNSH FM C16H12O
DMKPNSH IC InChI=1S/C16H12O/c17-16-9-7-13(8-10-16)15-6-5-12-3-1-2-4-14(12)11-15/h1-11,17H
DMKPNSH CS C1=CC=C2C=C(C=CC2=C1)C3=CC=C(C=C3)O
DMKPNSH IK NIRHUNSXEDESLN-UHFFFAOYSA-N
DMKPNSH IU 4-naphthalen-2-ylphenol
DMKPNSH CA CAS 6336-82-9
DMKPNSH DE Discovery agent
DMZY8UW ID DMZY8UW
DMZY8UW DN 4-Nitro-benzenesulfonamide
DMZY8UW HS Investigative
DMZY8UW SN 4-NITROBENZENESULFONAMIDE; 6325-93-5; Benzenesulfonamide, 4-nitro-; p-Nitrobenzenesulfonamide; 4-Nitrobenzolesulfamide; p-Nitrophenylsulfonamide; 4-Nitrobenzenesulphonamide; Benzenesulfonamide, p-nitro-; 4-Nitro-benzenesulfonamide; UNII-TUF52O8Y8B; EINECS 228-691-6; NSC 31148; BRN 2214218; TUF52O8Y8B; CHEMBL282157; 4-Nitrobenzenesulfonamide, 97%; QWKKYJLAUWFPDB-UHFFFAOYSA-N; NsNH2; 4-nitrophenylsulfonamid; 3m8t; 4-Nitrobenzolsulfonamide; p-nitrophenyl sulfonamide; WLN: ZSWR DNW; p-nitrobenzene sulphonamide; AC1Q55AA; Cambridge id 5
DMZY8UW DT Small molecular drug
DMZY8UW PC 22784
DMZY8UW MW 202.19
DMZY8UW FM C6H6N2O4S
DMZY8UW IC InChI=1S/C6H6N2O4S/c7-13(11,12)6-3-1-5(2-4-6)8(9)10/h1-4H,(H2,7,11,12)
DMZY8UW CS C1=CC(=CC=C1[N+](=O)[O-])S(=O)(=O)N
DMZY8UW IK QWKKYJLAUWFPDB-UHFFFAOYSA-N
DMZY8UW IU 4-nitrobenzenesulfonamide
DMZY8UW CA CAS 6325-93-5
DMZY8UW DE Discovery agent
DMKZJ1V ID DMKZJ1V
DMKZJ1V DN 4-nitrobenzo[c][1,2,5]thiadiazole
DMKZJ1V HS Investigative
DMKZJ1V SN 4-Nitro-2,1,3-benzothiadiazole; 6583-06-8; 4-nitrobenzo[c][1,2,5]thiadiazole; 4-Nitropiazthiole; 2,1,3-Benzothiadiazole, 4-nitro-; NSC404747; CHEMBL383084; 4-Nitro-1,2,3-benzothiadiazole; 4-Nitro-benzo[1,2,5]thiadiazole; 4-nitrobenzo[c]1,2,5-thiadiazole; ACMC-1B59L; Oprea1_370043; 4-Bromo-2,8-dimethylphenol; C6H3N3O2S; 4-Nitro-2,3-benzothiadiazole; SCHEMBL2213406; AC1Q202C; AC1L30J9; CTK5C3163; DTXSID10216019; 4-nitrobenzo-2,1,3-thiadiazole; MolPort-004-288-376; IWQKAMJGVIHECB-UHFFFAOYSA-N; MolPort-001-779-862
DMKZJ1V DT Small molecular drug
DMKZJ1V PC 81062
DMKZJ1V MW 181.17
DMKZJ1V FM C6H3N3O2S
DMKZJ1V IC InChI=1S/C6H3N3O2S/c10-9(11)5-3-1-2-4-6(5)8-12-7-4/h1-3H
DMKZJ1V CS C1=CC2=NSN=C2C(=C1)[N+](=O)[O-]
DMKZJ1V IK IWQKAMJGVIHECB-UHFFFAOYSA-N
DMKZJ1V IU 4-nitro-2,1,3-benzothiadiazole
DMKZJ1V CA CAS 6583-06-8
DMKZJ1V DE Discovery agent
DMKZUWY ID DMKZUWY
DMKZUWY DN 4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide
DMKZUWY HS Investigative
DMKZUWY SN 4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide; CHEMBL60027; 4-nitro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; AC1LEVE1; Oprea1_616019; Oprea1_578616; Oprea1_274027; MolPort-001-016-564; ZINC1506439; BDBM50101782; STK401913; AKOS000523323; MCULE-9071819567; BAS 00417263; N-(4-Phenyl-2-thiazolyl)-4-nitrobenzamide; ST50002539; SR-01000394982; SR-01000394982-1
DMKZUWY DT Small molecular drug
DMKZUWY PC 718622
DMKZUWY MW 325.3
DMKZUWY FM C16H11N3O3S
DMKZUWY IC InChI=1S/C16H11N3O3S/c20-15(12-6-8-13(9-7-12)19(21)22)18-16-17-14(10-23-16)11-4-2-1-3-5-11/h1-10H,(H,17,18,20)
DMKZUWY CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMKZUWY IK LLSUVHOZHQEGJS-UHFFFAOYSA-N
DMKZUWY IU 4-nitro-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMKZUWY DE Discovery agent
DMLJDU5 ID DMLJDU5
DMLJDU5 DN 4-nitro-N-(quinolin-8-yl)benzenesulfonamide
DMLJDU5 HS Investigative
DMLJDU5 SN CHEMBL540966; 33757-62-9; AC1NAKSM; SCHEMBL13485922; CTK1B1556; DTXSID90403445; MolPort-007-041-512; ZINC5681580; BDBM50372514; AKOS024374275; MCULE-8526334160; NCGC00161718-01; 4-nitro-N-quinolin-8-ylbenzenesulfonamide; N-(8-Quinolyl)-4-nitrobenzenesulfonamide; 4-nitro-N-(8-quinolyl)benzenesulfonamide; [(4-nitrophenyl)sulfonyl]-8-quinolylamine; ST51013795; Benzenesulfonamide, 4-nitro-N-8-quinolinyl-; 4-nitro-N-(quinolin-8-yl)benzene-1-sulfonamide; CU-00000000141-1
DMLJDU5 DT Small molecular drug
DMLJDU5 PC 4453505
DMLJDU5 MW 329.3
DMLJDU5 FM C15H11N3O4S
DMLJDU5 IC InChI=1S/C15H11N3O4S/c19-18(20)12-6-8-13(9-7-12)23(21,22)17-14-5-1-3-11-4-2-10-16-15(11)14/h1-10,17H
DMLJDU5 CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-])N=CC=C2
DMLJDU5 IK HXWOKTOKXJLLRZ-UHFFFAOYSA-N
DMLJDU5 IU 4-nitro-N-quinolin-8-ylbenzenesulfonamide
DMLJDU5 CA CAS 33757-62-9
DMLJDU5 DE Discovery agent
DMTJ3F9 ID DMTJ3F9
DMTJ3F9 DN 4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate
DMTJ3F9 HS Investigative
DMTJ3F9 SN CHEMBL597700; 4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate; SCHEMBL12794615
DMTJ3F9 DT Small molecular drug
DMTJ3F9 PC 45104861
DMTJ3F9 MW 341.4
DMTJ3F9 FM C18H19N3O4
DMTJ3F9 IC InChI=1S/C18H19N3O4/c22-18(25-17-8-6-16(7-9-17)21(23)24)20-12-10-19(11-13-20)14-15-4-2-1-3-5-15/h1-9H,10-14H2
DMTJ3F9 CS C1CN(CCN1CC2=CC=CC=C2)C(=O)OC3=CC=C(C=C3)[N+](=O)[O-]
DMTJ3F9 IK HNIDATBYDXCKRE-UHFFFAOYSA-N
DMTJ3F9 IU (4-nitrophenyl) 4-benzylpiperazine-1-carboxylate
DMTJ3F9 DE Discovery agent
DMBX4UJ ID DMBX4UJ
DMBX4UJ DN 4-nitrophenyl phosphate
DMBX4UJ HS Investigative
DMBX4UJ SN 4-nitrophenyl phosphate; 4-Nitrophenyl dihydrogen phosphate; 330-13-2; Nitrophenylphosphate; Phosphoric acid, mono(4-nitrophenyl) ester; p-nitrophenyl phosphate; p-Nitrophenyl dihydrogen phosphate; p-Nitrophenol phosphate; p-Nitrophenylphosphate; (4-nitrophenyl) dihydrogen phosphate; PNPP; NSC 404086; Phenol, p-nitro-, dihydrogen phosphate; CHEMBL24231; (4-nitrophenoxy)phosphonic acid; CHEBI:17440; XZKIHKMTEMTJQX-UHFFFAOYSA-N; pNPP Alkaline Phosphatase Substrate; Phosphoric acid, mono(p-nitrophenyl) ester (8CI); Phosphoric ac
DMBX4UJ DT Small molecular drug
DMBX4UJ PC 378
DMBX4UJ MW 219.09
DMBX4UJ FM C6H6NO6P
DMBX4UJ IC InChI=1S/C6H6NO6P/c8-7(9)5-1-3-6(4-2-5)13-14(10,11)12/h1-4H,(H2,10,11,12)
DMBX4UJ CS C1=CC(=CC=C1[N+](=O)[O-])OP(=O)(O)O
DMBX4UJ IK XZKIHKMTEMTJQX-UHFFFAOYSA-N
DMBX4UJ IU (4-nitrophenyl) dihydrogen phosphate
DMBX4UJ CA CAS 330-13-2
DMBX4UJ CB CHEBI:17440
DMBX4UJ DE Discovery agent
DMO6XK2 ID DMO6XK2
DMO6XK2 DN 4-nitrophenylboronic acid
DMO6XK2 HS Investigative
DMO6XK2 SN 4-Nitrophenylboronic acid; 24067-17-2; (4-nitrophenyl)boronic Acid; 4-Nitrobenzeneboronic acid; p-nitrophenylboronic acid; 4-Nitrophenyl boronic acid; p-nitrophenyl boronic acid; 4-Nitro phenyl boronic acid; Boronic acid, (4-nitrophenyl)-; MFCD00161360; 4-Nitrophenylboronic acid, 97%; 4-Nitrophenylboronicacid; 4-Borononitrobenzene; PubChem24079; 4-nitrobenzenboronic acid; (4-nitrophenyl)boranediol; 4-nitro-phenylboronic acid; ACMC-209g8k; para-nitrophenylboronic acid; 4-nitrobenzene boronic acid; AC1MCN49; SCHEMBL5993
DMO6XK2 DT Small molecular drug
DMO6XK2 PC 2773552
DMO6XK2 MW 166.93
DMO6XK2 FM C6H6BNO4
DMO6XK2 IC InChI=1S/C6H6BNO4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4,9-10H
DMO6XK2 CS B(C1=CC=C(C=C1)[N+](=O)[O-])(O)O
DMO6XK2 IK NSFJAFZHYOAMHL-UHFFFAOYSA-N
DMO6XK2 IU (4-nitrophenyl)boronic acid
DMO6XK2 CA CAS 24067-17-2
DMO6XK2 DE Discovery agent
DM9ETMD ID DM9ETMD
DM9ETMD DN 4-nitrophenyl-difluoromethanesulfonamide
DM9ETMD HS Investigative
DM9ETMD SN 4-nitrophenyl-difluoromethanesulfonamide; CHEMBL370159; BDBM50175001
DM9ETMD DT Small molecular drug
DM9ETMD PC 44405178
DM9ETMD MW 252.2
DM9ETMD FM C7H6F2N2O4S
DM9ETMD IC InChI=1S/C7H6F2N2O4S/c8-7(9,16(10,14)15)5-1-3-6(4-2-5)11(12)13/h1-4H,(H2,10,14,15)
DM9ETMD CS C1=CC(=CC=C1C(F)(F)S(=O)(=O)N)[N+](=O)[O-]
DM9ETMD IK WUEDWPOZFNFODO-UHFFFAOYSA-N
DM9ETMD IU difluoro-(4-nitrophenyl)methanesulfonamide
DM9ETMD DE Discovery agent
DM47IFL ID DM47IFL
DM47IFL DN 4-nitrophenylsulfamide
DM47IFL HS Investigative
DM47IFL SN 4-nitrophenylsulfamide; N-(4-Nitrophenyl)sulfamide; CHEMBL168778; 70466-80-7; AC1LD5GZ; N-(4-Nitrophenyl)sulfamide #; Sulphamide, N-(4-nitrophenyl)-; RAXPQAODVUNKFW-UHFFFAOYSA-N; 1-nitro-4-(sulfamoylamino)benzene; BDBM50124157
DM47IFL DT Small molecular drug
DM47IFL PC 612414
DM47IFL MW 217.21
DM47IFL FM C6H7N3O4S
DM47IFL IC InChI=1S/C6H7N3O4S/c7-14(12,13)8-5-1-3-6(4-2-5)9(10)11/h1-4,8H,(H2,7,12,13)
DM47IFL CS C1=CC(=CC=C1NS(=O)(=O)N)[N+](=O)[O-]
DM47IFL IK RAXPQAODVUNKFW-UHFFFAOYSA-N
DM47IFL IU 1-nitro-4-(sulfamoylamino)benzene
DM47IFL DE Discovery agent
DMOW8TM ID DMOW8TM
DMOW8TM DN 4-nonyl-N-(quinolin-3-yl)benzamide
DMOW8TM HS Investigative
DMOW8TM SN CHEMBL261848; AC1N8TZO; SCHEMBL846134; 4-nonyl-N-quinolin-3-ylbenzamide
DMOW8TM DT Small molecular drug
DMOW8TM PC 4375060
DMOW8TM MW 374.5
DMOW8TM FM C25H30N2O
DMOW8TM IC InChI=1S/C25H30N2O/c1-2-3-4-5-6-7-8-11-20-14-16-21(17-15-20)25(28)27-23-18-22-12-9-10-13-24(22)26-19-23/h9-10,12-19H,2-8,11H2,1H3,(H,27,28)
DMOW8TM CS CCCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMOW8TM IK LTHZASJBAIGTJL-UHFFFAOYSA-N
DMOW8TM IU 4-nonyl-N-quinolin-3-ylbenzamide
DMOW8TM DE Discovery agent
DMBF5KW ID DMBF5KW
DMBF5KW DN 4-nonylphenylboronic acid
DMBF5KW HS Investigative
DMBF5KW SN 256383-45-6; 4-N-Nonylphenylboronic acid; 4-Nonylphenylboronic acid; (4-nonylphenyl)boronic Acid; 4-N-NONYLBENZENEBORONIC ACID; 4-N-Nonylphenylboronicacid; VONVJOGSLHAKOX-UHFFFAOYSA-N; AC1NEAO1; (4-nonylphenyl)boranediol; 4-nonylbenzene boronic acid; B-(4-Nonylphenyl)boronic acid; SCHEMBL3405525; CHEMBL485946; 4-(n-Nonyl)benzeneboronic Acid; BDBM26134; CTK8B1318; 1-Borono-4-(non-1-yl)benzene; DTXSID10404611; MolPort-000-931-545; Boronic acid,B-(4-nonylphenyl)-; 4-(Non-1-yl)benzeneboronic acid; ZX-AT001529; OR7244; CN-219
DMBF5KW DT Small molecular drug
DMBF5KW PC 4589192
DMBF5KW MW 248.17
DMBF5KW FM C15H25BO2
DMBF5KW IC InChI=1S/C15H25BO2/c1-2-3-4-5-6-7-8-9-14-10-12-15(13-11-14)16(17)18/h10-13,17-18H,2-9H2,1H3
DMBF5KW CS B(C1=CC=C(C=C1)CCCCCCCCC)(O)O
DMBF5KW IK VONVJOGSLHAKOX-UHFFFAOYSA-N
DMBF5KW IU (4-nonylphenyl)boronic acid
DMBF5KW CA CAS 256383-45-6
DMBF5KW DE Discovery agent
DMNSU1H ID DMNSU1H
DMNSU1H DN 4-octyl-N-(pyridin-3-yl)benzamide
DMNSU1H HS Investigative
DMNSU1H SN CHEMBL405990
DMNSU1H DT Small molecular drug
DMNSU1H PC 44450380
DMNSU1H MW 310.4
DMNSU1H FM C20H26N2O
DMNSU1H IC InChI=1S/C20H26N2O/c1-2-3-4-5-6-7-9-17-11-13-18(14-12-17)20(23)22-19-10-8-15-21-16-19/h8,10-16H,2-7,9H2,1H3,(H,22,23)
DMNSU1H CS CCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMNSU1H IK ONPWXUJVJZCKSY-UHFFFAOYSA-N
DMNSU1H IU 4-octyl-N-pyridin-3-ylbenzamide
DMNSU1H DE Discovery agent
DMOGM3H ID DMOGM3H
DMOGM3H DN 4-octyl-N-(quinolin-3-yl)benzamide
DMOGM3H HS Investigative
DMOGM3H SN CHEMBL406859; AC1MZP51; SCHEMBL846096; 4-octyl-N-quinolin-3-ylbenzamide; BDBM50376278
DMOGM3H DT Small molecular drug
DMOGM3H PC 3904199
DMOGM3H MW 360.5
DMOGM3H FM C24H28N2O
DMOGM3H IC InChI=1S/C24H28N2O/c1-2-3-4-5-6-7-10-19-13-15-20(16-14-19)24(27)26-22-17-21-11-8-9-12-23(21)25-18-22/h8-9,11-18H,2-7,10H2,1H3,(H,26,27)
DMOGM3H CS CCCCCCCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DMOGM3H IK QXGPHMISVLJYDS-UHFFFAOYSA-N
DMOGM3H IU 4-octyl-N-quinolin-3-ylbenzamide
DMOGM3H DE Discovery agent
DM7GW4P ID DM7GW4P
DM7GW4P DN 4-oxo-4H-chromene-3-carboxylic acid
DM7GW4P HS Investigative
DM7GW4P SN Chromone-3-carboxylic acid; 39079-62-4; 4-oxo-4H-chromene-3-carboxylic acid; 4-Oxo-4H-1-benzopyran-3-carboxylic acid; 4-oxochromene-3-carboxylic acid; CHEMBL315361; PCIITXGDSHXTSN-UHFFFAOYSA-N; MFCD00017338; Maybridge1_005842; 3-carboxychromone; ACMC-1AD65; SCHEMBL1253672; AC1L49D2; CTK1C4919; ZINC57725; HMS558B12; DTXSID90192327; MolPort-000-145-536; 4-oxo-chromene-3-carboxylic acid; Chromone-3-carboxylic acid, 97%; CC-721; BDBM50131081; 4H-Chromen-4-one-3-carboxylic acid; SBB017525; AKOS001044083; CS-W015906; VZ31583
DM7GW4P DT Small molecular drug
DM7GW4P PC 181620
DM7GW4P MW 190.15
DM7GW4P FM C10H6O4
DM7GW4P IC InChI=1S/C10H6O4/c11-9-6-3-1-2-4-8(6)14-5-7(9)10(12)13/h1-5H,(H,12,13)
DM7GW4P CS C1=CC=C2C(=C1)C(=O)C(=CO2)C(=O)O
DM7GW4P IK PCIITXGDSHXTSN-UHFFFAOYSA-N
DM7GW4P IU 4-oxochromene-3-carboxylic acid
DM7GW4P CA CAS 39079-62-4
DM7GW4P CB CHEBI:166522
DM7GW4P DE Discovery agent
DMPX1J9 ID DMPX1J9
DMPX1J9 DN 4-oxo-nonenal
DMPX1J9 HS Investigative
DMPX1J9 SN 4-oxo-2E-nonenal
DMPX1J9 DT Small molecular drug
DMPX1J9 PC 6445537
DMPX1J9 MW 154.21
DMPX1J9 FM C9H14O2
DMPX1J9 IC InChI=1S/C9H14O2/c1-2-3-4-6-9(11)7-5-8-10/h5,7-8H,2-4,6H2,1H3/b7-5+
DMPX1J9 CS CCCCCC(=O)/C=C/C=O
DMPX1J9 IK SEPPVOUBHWNCAW-FNORWQNLSA-N
DMPX1J9 IU (E)-4-oxonon-2-enal
DMPX1J9 CA CAS 103560-62-9
DMPX1J9 CB CHEBI:58972
DMPX1J9 DE Discovery agent
DMADSUY ID DMADSUY
DMADSUY DN 4-Oxosebacic Acid
DMADSUY HS Investigative
DMADSUY SN 4-OXOSEBACIC ACID; Decanedioic acid, 4-oxo-; 3-Oxo-1,8-octanedicarboxylic acid; AC1L1C60; SCHEMBL1053787; CTK7G1425; XTQIBFVBYWIHIP-UHFFFAOYSA-N; ZINC3074811; AKOS024339724; DB02260; MCULE-8689766454
DMADSUY DT Small molecular drug
DMADSUY PC 1755
DMADSUY MW 216.23
DMADSUY FM C10H16O5
DMADSUY IC InChI=1S/C10H16O5/c11-8(6-7-10(14)15)4-2-1-3-5-9(12)13/h1-7H2,(H,12,13)(H,14,15)
DMADSUY CS C(CCC(=O)CCC(=O)O)CCC(=O)O
DMADSUY IK XTQIBFVBYWIHIP-UHFFFAOYSA-N
DMADSUY IU 4-oxodecanedioic acid
DMADSUY DE Discovery agent
DMN1XMK ID DMN1XMK
DMN1XMK DN 4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid
DMN1XMK HS Investigative
DMN1XMK SN CHEMBL16979; 4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid; ZINC36222955
DMN1XMK DT Small molecular drug
DMN1XMK PC 14632697
DMN1XMK MW 324.5
DMN1XMK FM C19H32O2S
DMN1XMK IC InChI=1S/C19H32O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-22-18-15-16-19(20)21/h9-10,12-14,17H,2-8,11,15-16,18H2,1H3,(H,20,21)/b10-9-,13-12-,17-14+
DMN1XMK CS CCCCCCCC/C=C\\C/C=C\\C=C\\SCCCC(=O)O
DMN1XMK IK YRBDHTFMZHCRCL-MPAZIYIRSA-N
DMN1XMK IU 4-[(1E,3Z,6Z)-pentadeca-1,3,6-trienyl]sulfanylbutanoic acid
DMN1XMK DE Discovery agent
DMW198G ID DMW198G
DMW198G DN 4-pentyl-N-pyridin-3-yl benzamide
DMW198G HS Investigative
DMW198G SN CHEMBL321932; 4-pentyl-N-pyridin-3-yl benzamide; AC1MDVHQ; 4-pentyl-N-pyridin-3-ylbenzamide; MolPort-002-889-076; ZINC3128742; 4-Pentyl-N-pyridin-3-yl-benzamide; BDBM50147079
DMW198G DT Small molecular drug
DMW198G PC 2796370
DMW198G MW 268.35
DMW198G FM C17H20N2O
DMW198G IC InChI=1S/C17H20N2O/c1-2-3-4-6-14-8-10-15(11-9-14)17(20)19-16-7-5-12-18-13-16/h5,7-13H,2-4,6H2,1H3,(H,19,20)
DMW198G CS CCCCCC1=CC=C(C=C1)C(=O)NC2=CN=CC=C2
DMW198G IK DZLXEBWNAFQZQI-UHFFFAOYSA-N
DMW198G IU 4-pentyl-N-pyridin-3-ylbenzamide
DMW198G DE Discovery agent
DMIPQTW ID DMIPQTW
DMIPQTW DN 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
DMIPQTW HS Investigative
DMIPQTW SN 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE; CHEMBL199237; CHEBI:41135; 4-phenoxy-N-[(pyridin-2-yl)methyl]benzamide; BI5; 1zyj; AC1M5EGY; Oprea1_773674; MolPort-004-000-036; HMS3604L15; BDBM50174097; ZINC13284470; AKOS027682522; MCULE-5005773275; DB07459; Z30166389
DMIPQTW DT Small molecular drug
DMIPQTW PC 2352168
DMIPQTW MW 304.3
DMIPQTW FM C19H16N2O2
DMIPQTW IC InChI=1S/C19H16N2O2/c22-19(21-14-16-6-4-5-13-20-16)15-9-11-18(12-10-15)23-17-7-2-1-3-8-17/h1-13H,14H2,(H,21,22)
DMIPQTW CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=CC=N3
DMIPQTW IK HVLSCZSVTCNAQX-UHFFFAOYSA-N
DMIPQTW IU 4-phenoxy-N-(pyridin-2-ylmethyl)benzamide
DMIPQTW CB CHEBI:41135
DMIPQTW DE Discovery agent
DMMWYI9 ID DMMWYI9
DMMWYI9 DN 4-phenoxyphenylboronic acid
DMMWYI9 HS Investigative
DMMWYI9 SN 4-Phenoxyphenylboronic acid; 51067-38-0; (4-phenoxyphenyl)boronic acid; 4-Phenoxybenzeneboronic acid; (4-Phenoxyphenyl)Boranediol; CHEMBL459151; Boronic acid, (4-phenoxyphenyl)-; MFCD00093312; 4-Phenoxyphenylboronic acid, 95+%; 4-phenoxyphenyl boronic acid; PubChem7890; phenoxyphenylboronic acid; ACMC-209krn; AC1MC0ZX; SCHEMBL9285; 4-phenyoxyphenylboronic acid; 4-phenoxy-phenylboronic acid; 4-Phenoxyphenyl-boronic acid; KSC489K8J; 4-phenoxy-phenyl boronic acid; AC1Q715Q; (4-phenoxyphenyl) boronic acid
DMMWYI9 DT Small molecular drug
DMMWYI9 PC 2734377
DMMWYI9 MW 214.03
DMMWYI9 FM C12H11BO3
DMMWYI9 IC InChI=1S/C12H11BO3/c14-13(15)10-6-8-12(9-7-10)16-11-4-2-1-3-5-11/h1-9,14-15H
DMMWYI9 CS B(C1=CC=C(C=C1)OC2=CC=CC=C2)(O)O
DMMWYI9 IK KFXUHRXGLWUOJT-UHFFFAOYSA-N
DMMWYI9 IU (4-phenoxyphenyl)boronic acid
DMMWYI9 CA CAS 51067-38-0
DMMWYI9 DE Discovery agent
DMVCIJB ID DMVCIJB
DMVCIJB DN 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB HS Investigative
DMVCIJB SN CHEMBL230145; 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB DT Small molecular drug
DMVCIJB PC 44426807
DMVCIJB MW 309.4
DMVCIJB FM C21H27NO
DMVCIJB IC InChI=1S/C21H27NO/c1-2-9-20(18-10-5-3-6-11-18)22-16-14-21(23,15-17-22)19-12-7-4-8-13-19/h3-8,10-13,20,23H,2,9,14-17H2,1H3
DMVCIJB CS CCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMVCIJB IK HVKSQGJIDXVAKX-UHFFFAOYSA-N
DMVCIJB IU 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol
DMVCIJB DE Discovery agent
DM6EFLV ID DM6EFLV
DM6EFLV DN 4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV HS Investigative
DM6EFLV SN CHEMBL230249; 4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV DT Small molecular drug
DM6EFLV PC 9925737
DM6EFLV MW 281.4
DM6EFLV FM C19H23NO
DM6EFLV IC InChI=1S/C19H23NO/c1-16(17-8-4-2-5-9-17)20-14-12-19(21,13-15-20)18-10-6-3-7-11-18/h2-11,16,21H,12-15H2,1H3
DM6EFLV CS CC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DM6EFLV IK PKTJCXJTMHJHNK-UHFFFAOYSA-N
DM6EFLV IU 4-phenyl-1-(1-phenylethyl)piperidin-4-ol
DM6EFLV DE Discovery agent
DMISTXQ ID DMISTXQ
DMISTXQ DN 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ HS Investigative
DMISTXQ SN CHEMBL231607; 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ DT Small molecular drug
DMISTXQ PC 44426812
DMISTXQ MW 351.5
DMISTXQ FM C24H33NO
DMISTXQ IC InChI=1S/C24H33NO/c1-2-3-4-11-16-23(21-12-7-5-8-13-21)25-19-17-24(26,18-20-25)22-14-9-6-10-15-22/h5-10,12-15,23,26H,2-4,11,16-20H2,1H3
DMISTXQ CS CCCCCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMISTXQ IK VSTFKYJXYVRGDG-UHFFFAOYSA-N
DMISTXQ IU 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol
DMISTXQ DE Discovery agent
DM1GRWY ID DM1GRWY
DM1GRWY DN 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY HS Investigative
DM1GRWY SN CHEMBL230253; 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY DT Small molecular drug
DM1GRWY PC 44426810
DM1GRWY MW 337.5
DM1GRWY FM C23H31NO
DM1GRWY IC InChI=1S/C23H31NO/c1-2-3-6-15-22(20-11-7-4-8-12-20)24-18-16-23(25,17-19-24)21-13-9-5-10-14-21/h4-5,7-14,22,25H,2-3,6,15-19H2,1H3
DM1GRWY CS CCCCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DM1GRWY IK AHZUGQDNSYDLNN-UHFFFAOYSA-N
DM1GRWY IU 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol
DM1GRWY DE Discovery agent
DMZQ7DP ID DMZQ7DP
DMZQ7DP DN 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP HS Investigative
DMZQ7DP SN CHEMBL390882; 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP DT Small molecular drug
DMZQ7DP PC 44426808
DMZQ7DP MW 323.5
DMZQ7DP FM C22H29NO
DMZQ7DP IC InChI=1S/C22H29NO/c1-2-3-14-21(19-10-6-4-7-11-19)23-17-15-22(24,16-18-23)20-12-8-5-9-13-20/h4-13,21,24H,2-3,14-18H2,1H3
DMZQ7DP CS CCCCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMZQ7DP IK WQECIXIOLXNRTH-UHFFFAOYSA-N
DMZQ7DP IU 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol
DMZQ7DP DE Discovery agent
DM491FJ ID DM491FJ
DM491FJ DN 4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol
DM491FJ HS Investigative
DM491FJ SN CHEMBL230140
DM491FJ DT Small molecular drug
DM491FJ PC 44426805
DM491FJ MW 295.4
DM491FJ FM C20H25NO
DM491FJ IC InChI=1S/C20H25NO/c1-17(16-18-8-4-2-5-9-18)21-14-12-20(22,13-15-21)19-10-6-3-7-11-19/h2-11,17,22H,12-16H2,1H3
DM491FJ CS CC(CC1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DM491FJ IK DBTIAPBSTRWDLH-UHFFFAOYSA-N
DM491FJ IU 4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol
DM491FJ DE Discovery agent
DMALIQ8 ID DMALIQ8
DMALIQ8 DN 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8 HS Investigative
DMALIQ8 SN CHEMBL433814; 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol; SCHEMBL9520650
DMALIQ8 DT Small molecular drug
DMALIQ8 PC 44426806
DMALIQ8 MW 295.4
DMALIQ8 FM C20H25NO
DMALIQ8 IC InChI=1S/C20H25NO/c1-2-19(17-9-5-3-6-10-17)21-15-13-20(22,14-16-21)18-11-7-4-8-12-18/h3-12,19,22H,2,13-16H2,1H3
DMALIQ8 CS CCC(C1=CC=CC=C1)N2CCC(CC2)(C3=CC=CC=C3)O
DMALIQ8 IK YUOJNJIUXXIUHY-UHFFFAOYSA-N
DMALIQ8 IU 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol
DMALIQ8 DE Discovery agent
DMM8O1X ID DMM8O1X
DMM8O1X DN 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol
DMM8O1X HS Investigative
DMM8O1X SN CHEMBL115508; 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol; SCHEMBL8096481; BDBM50007398
DMM8O1X DT Small molecular drug
DMM8O1X PC 15723894
DMM8O1X MW 295.4
DMM8O1X FM C20H25NO
DMM8O1X IC InChI=1S/C20H25NO/c22-20(19-11-5-2-6-12-19)13-16-21(17-14-20)15-7-10-18-8-3-1-4-9-18/h1-6,8-9,11-12,22H,7,10,13-17H2
DMM8O1X CS C1CN(CCC1(C2=CC=CC=C2)O)CCCC3=CC=CC=C3
DMM8O1X IK ZZUJERGWKSXINO-UHFFFAOYSA-N
DMM8O1X IU 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol
DMM8O1X DE Discovery agent
DMFV0JC ID DMFV0JC
DMFV0JC DN 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC HS Investigative
DMFV0JC SN CHEMBL390279; 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol
DMFV0JC DT Small molecular drug
DMFV0JC PC 44426827
DMFV0JC MW 357.5
DMFV0JC FM C25H27NO
DMFV0JC IC InChI=1S/C25H27NO/c1-20-9-8-12-22(19-20)24(21-10-4-2-5-11-21)26-17-15-25(27,16-18-26)23-13-6-3-7-14-23/h2-14,19,24,27H,15-18H2,1H3
DMFV0JC CS CC1=CC(=CC=C1)C(C2=CC=CC=C2)N3CCC(CC3)(C4=CC=CC=C4)O
DMFV0JC IK ODFDCTDNLNJAAY-UHFFFAOYSA-N
DMFV0JC IU 1-[(3-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
DMFV0JC DE Discovery agent
DM2MPWC ID DM2MPWC
DM2MPWC DN 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC HS Investigative
DM2MPWC SN CHEMBL388123; 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol
DM2MPWC DT Small molecular drug
DM2MPWC PC 9863568
DM2MPWC MW 357.5
DM2MPWC FM C25H27NO
DM2MPWC IC InChI=1S/C25H27NO/c1-20-10-8-9-15-23(20)24(21-11-4-2-5-12-21)26-18-16-25(27,17-19-26)22-13-6-3-7-14-22/h2-15,24,27H,16-19H2,1H3
DM2MPWC CS CC1=CC=CC=C1C(C2=CC=CC=C2)N3CCC(CC3)(C4=CC=CC=C4)O
DM2MPWC IK GBDUIWBXAKZJPC-UHFFFAOYSA-N
DM2MPWC IU 1-[(2-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
DM2MPWC DE Discovery agent
DM5R6T4 ID DM5R6T4
DM5R6T4 DN 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4 HS Investigative
DM5R6T4 SN CHEMBL228793; 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol
DM5R6T4 DT Small molecular drug
DM5R6T4 PC 44426828
DM5R6T4 MW 357.5
DM5R6T4 FM C25H27NO
DM5R6T4 IC InChI=1S/C25H27NO/c1-20-12-14-22(15-13-20)24(21-8-4-2-5-9-21)26-18-16-25(27,17-19-26)23-10-6-3-7-11-23/h2-15,24,27H,16-19H2,1H3
DM5R6T4 CS CC1=CC=C(C=C1)C(C2=CC=CC=C2)N3CCC(CC3)(C4=CC=CC=C4)O
DM5R6T4 IK RKHFFYFBKRWGAL-UHFFFAOYSA-N
DM5R6T4 IU 1-[(4-methylphenyl)-phenylmethyl]-4-phenylpiperidin-4-ol
DM5R6T4 DE Discovery agent
DMV6WC4 ID DMV6WC4
DMV6WC4 DN 4-phenyl-1,2,3,6-tetrahydropyridine
DMV6WC4 HS Investigative
DMV6WC4 SN 4-Phenyl-1,2,3,6-tetrahydropyridine; 10338-69-9; 4-Phenyl-1,2,3,6-tetrahydro-pyridine; 1,2,3,6-tetrahydro-4-phenyl-pyridine; 1,2,3,6-Tetrahydro-4-phenylpyridine; Pyridine, 1,2,3,6-tetrahydro-4-phenyl-; CHEMBL6224; OMPXTQYWYRWWPH-UHFFFAOYSA-N; 4-phenyl-1,2,3,6-tetrahydro pyridine; Oprea1_874761; NSC 54451; AC1Q1IN6; AC1L33NE; AC1Q1GX2; SCHEMBL415545; DTXSID2065040; CTK4A2038; MolPort-001-794-494; 43064-12-6 (hydrochloride); ZINC1295150; NSC54451; 4-Phenyl-1,3,6-tetrahydropyridine; STK535809; NSC-54451; BDBM50036718; BBL027886
DMV6WC4 DT Small molecular drug
DMV6WC4 PC 82553
DMV6WC4 MW 159.23
DMV6WC4 FM C11H13N
DMV6WC4 IC InChI=1S/C11H13N/c1-2-4-10(5-3-1)11-6-8-12-9-7-11/h1-6,12H,7-9H2
DMV6WC4 CS C1CNCC=C1C2=CC=CC=C2
DMV6WC4 IK OMPXTQYWYRWWPH-UHFFFAOYSA-N
DMV6WC4 IU 4-phenyl-1,2,3,6-tetrahydropyridine
DMV6WC4 CA CAS 10338-69-9
DMV6WC4 DE Discovery agent
DMONKDQ ID DMONKDQ
DMONKDQ DN 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile
DMONKDQ HS Investigative
DMONKDQ SN CHEMBL411829; 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile; SCHEMBL6033918
DMONKDQ DT Small molecular drug
DMONKDQ PC 18516979
DMONKDQ MW 272.3
DMONKDQ FM C17H12N4
DMONKDQ IC InChI=1S/C17H12N4/c18-11-14-12-19-17(20-15-9-5-2-6-10-15)21-16(14)13-7-3-1-4-8-13/h1-10,12H,(H,19,20,21)
DMONKDQ CS C1=CC=C(C=C1)C2=NC(=NC=C2C#N)NC3=CC=CC=C3
DMONKDQ IK KLNVGLIZGCKXCE-UHFFFAOYSA-N
DMONKDQ IU 2-anilino-4-phenylpyrimidine-5-carbonitrile
DMONKDQ DE Discovery agent
DMPY4G1 ID DMPY4G1
DMPY4G1 DN 4-phenyl-4-[1H-imidazol-2-yl]-piperidine
DMPY4G1 HS Investigative
DMPY4G1 SN CHEMBL382326; 4-phenyl-4-[1H-imidazol-2-yl]-piperidine; SCHEMBL14173644
DMPY4G1 DT Small molecular drug
DMPY4G1 PC 44406272
DMPY4G1 MW 436.5
DMPY4G1 FM C28H28N4O
DMPY4G1 IC InChI=1S/C28H28N4O/c33-27(30-25-14-8-3-9-15-25)31-19-16-28(17-20-31,24-12-6-2-7-13-24)26-29-18-21-32(26)22-23-10-4-1-5-11-23/h1-15,18,21H,16-17,19-20,22H2,(H,30,33)
DMPY4G1 CS C1CN(CCC1(C2=CC=CC=C2)C3=NC=CN3CC4=CC=CC=C4)C(=O)NC5=CC=CC=C5
DMPY4G1 IK SSXWGBNGZDJNOZ-UHFFFAOYSA-N
DMPY4G1 IU 4-(1-benzylimidazol-2-yl)-N,4-diphenylpiperidine-1-carboxamide
DMPY4G1 DE Discovery agent
DM7E4JU ID DM7E4JU
DM7E4JU DN 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol
DM7E4JU HS Investigative
DM7E4JU SN 4-phenyl-5-(4-piperidyl)-3-isoxazolol
DM7E4JU PC 11404581
DM7E4JU MW 244.29
DM7E4JU FM C14H16N2O2
DM7E4JU IC InChI=1S/C14H16N2O2/c17-14-12(10-4-2-1-3-5-10)13(18-16-14)11-6-8-15-9-7-11/h1-5,11,15H,6-9H2,(H,16,17)
DM7E4JU CS C1CNCCC1C2=C(C(=O)NO2)C3=CC=CC=C3
DM7E4JU IK QTEBXBALJGPXEP-UHFFFAOYSA-N
DM7E4JU IU 4-phenyl-5-piperidin-4-yl-1,2-oxazol-3-one
DM7E4JU DE Discovery agent
DMMIB0R ID DMMIB0R
DMMIB0R DN 4-phenyl-6-propylpyrimidine-2-carbonitrile
DMMIB0R HS Investigative
DMMIB0R SN CHEMBL1077366; 4-phenyl-6-propylpyrimidine-2-carbonitrile; SCHEMBL4442260
DMMIB0R DT Small molecular drug
DMMIB0R PC 46882093
DMMIB0R MW 223.27
DMMIB0R FM C14H13N3
DMMIB0R IC InChI=1S/C14H13N3/c1-2-6-12-9-13(17-14(10-15)16-12)11-7-4-3-5-8-11/h3-5,7-9H,2,6H2,1H3
DMMIB0R CS CCCC1=CC(=NC(=N1)C#N)C2=CC=CC=C2
DMMIB0R IK IUPDRSKJKKTVKP-UHFFFAOYSA-N
DMMIB0R IU 4-phenyl-6-propylpyrimidine-2-carbonitrile
DMMIB0R DE Discovery agent
DMLZSH1 ID DMLZSH1
DMLZSH1 DN 4-Phenyl-benzo[b]thiophene-2-carboxamidine
DMLZSH1 HS Investigative
DMLZSH1 SN CHEMBL591931; 4-Phenyl-benzo[b]thiophene-2-carboxamidine; SCHEMBL13709464
DMLZSH1 DT Small molecular drug
DMLZSH1 PC 15230353
DMLZSH1 MW 252.3
DMLZSH1 FM C15H12N2S
DMLZSH1 IC InChI=1S/C15H12N2S/c16-15(17)14-9-12-11(7-4-8-13(12)18-14)10-5-2-1-3-6-10/h1-9H,(H3,16,17)
DMLZSH1 CS C1=CC=C(C=C1)C2=C3C=C(SC3=CC=C2)C(=N)N
DMLZSH1 IK HKXOXDHVUZHJFV-UHFFFAOYSA-N
DMLZSH1 IU 4-phenyl-1-benzothiophene-2-carboximidamide
DMLZSH1 DE Discovery agent
DM871ZE ID DM871ZE
DM871ZE DN 4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester
DM871ZE HS Investigative
DM871ZE SN CHEMBL486492; 4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester
DM871ZE DT Small molecular drug
DM871ZE PC 24881743
DM871ZE MW 345.4
DM871ZE FM C23H23NO2
DM871ZE IC InChI=1S/C23H23NO2/c25-23(24-17-8-7-12-19-10-3-1-4-11-19)26-22-16-9-15-21(18-22)20-13-5-2-6-14-20/h1-6,9-11,13-16,18H,7-8,12,17H2,(H,24,25)
DM871ZE CS C1=CC=C(C=C1)CCCCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM871ZE IK WZSGWNPOHRAUQO-UHFFFAOYSA-N
DM871ZE IU (3-phenylphenyl) N-(4-phenylbutyl)carbamate
DM871ZE DE Discovery agent
DMCZKN7 ID DMCZKN7
DMCZKN7 DN 4-Phenylbutyrohydroxamic acid
DMCZKN7 HS Investigative
DMCZKN7 SN N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; 4-Phenylbutyrohydroxamic acid; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596
DMCZKN7 DT Small molecular drug
DMCZKN7 PC 279980
DMCZKN7 MW 179.22
DMCZKN7 FM C10H13NO2
DMCZKN7 IC InChI=1S/C10H13NO2/c12-10(11-13)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,13H,4,7-8H2,(H,11,12)
DMCZKN7 CS C1=CC=C(C=C1)CCCC(=O)NO
DMCZKN7 IK UPHXPXYRKPCXHK-UHFFFAOYSA-N
DMCZKN7 IU N-hydroxy-4-phenylbutanamide
DMCZKN7 CA CAS 32153-46-1
DMCZKN7 DE Discovery agent
DM5UNBW ID DM5UNBW
DM5UNBW DN 4-Phenylimidazole
DM5UNBW HS Investigative
DM5UNBW SN 4-Phenylimidazole; 670-95-1; 4-PHENYL-1H-IMIDAZOLE; 5-Phenyl-1H-imidazole; 4(5)-Phenylimidazole; 1H-Imidazole, 4-phenyl-; Imidazole, 4-phenyl-; 5-phenylimidazole; 4-PHENYL IMIDAZOLE; CHEMBL14145; XHLKOHSAWQPOFO-UHFFFAOYSA-N; MFCD00005197; NSC-195337; F1918-0054; PIM; 4-phenyl-1h-imidazol; 4-phenyl-imidazole; EINECS 211-580-1; PubChem7224; NSC 195337; ACMC-209nxp; 4-phenylimidazole, 4-PI; 4-Phenylimidazole, 97%; 1H-Imidazole, 5-phenyl-; AC1L2C7W; AC1Q4YD1; SCHEMBL37563; KSC696A2D; Imidazole, 4-phenyl- (8CI); AMBZ0133; CTK5J6021
DM5UNBW DT Small molecular drug
DM5UNBW PC 69590
DM5UNBW MW 144.17
DM5UNBW FM C9H8N2
DM5UNBW IC InChI=1S/C9H8N2/c1-2-4-8(5-3-1)9-6-10-7-11-9/h1-7H,(H,10,11)
DM5UNBW CS C1=CC=C(C=C1)C2=CN=CN2
DM5UNBW IK XHLKOHSAWQPOFO-UHFFFAOYSA-N
DM5UNBW IU 5-phenyl-1H-imidazole
DM5UNBW CA CAS 670-95-1
DM5UNBW DE Discovery agent
DM9J5TZ ID DM9J5TZ
DM9J5TZ DN 4-phenyliminomethyl-benzenesulfonamide
DM9J5TZ HS Investigative
DM9J5TZ SN 4-phenyliminomethyl-benzenesulfonamide; CHEMBL407019; SCHEMBL5311443
DM9J5TZ DT Small molecular drug
DM9J5TZ PC 44456679
DM9J5TZ MW 260.31
DM9J5TZ FM C13H12N2O2S
DM9J5TZ IC InChI=1S/C13H12N2O2S/c14-18(16,17)13-8-6-11(7-9-13)10-15-12-4-2-1-3-5-12/h1-10H,(H2,14,16,17)
DM9J5TZ CS C1=CC=C(C=C1)N=CC2=CC=C(C=C2)S(=O)(=O)N
DM9J5TZ IK XUMZYVTUPBUWOY-UHFFFAOYSA-N
DM9J5TZ IU 4-(phenyliminomethyl)benzenesulfonamide
DM9J5TZ DE Discovery agent
DMW46K7 ID DMW46K7
DMW46K7 DN 4-Phenylspiro[chromene-2,4'-piperidine]
DMW46K7 HS Investigative
DMW46K7 SN CHEMBL492447; SCHEMBL467151; BDBM50252830
DMW46K7 DT Small molecular drug
DMW46K7 PC 25129089
DMW46K7 MW 277.4
DMW46K7 FM C19H19NO
DMW46K7 IC InChI=1S/C19H19NO/c1-2-6-15(7-3-1)17-14-19(10-12-20-13-11-19)21-18-9-5-4-8-16(17)18/h1-9,14,20H,10-13H2
DMW46K7 CS C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=CC=C4
DMW46K7 IK AWYPHZMWGAOGIC-UHFFFAOYSA-N
DMW46K7 IU 4-phenylspiro[chromene-2,4'-piperidine]
DMW46K7 DE Discovery agent
DMHANXD ID DMHANXD
DMHANXD DN 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
DMHANXD HS Investigative
DMHANXD SN 4-(Phenylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine; 736142-84-0; 7h-pyrrolo[2,3-d]pyrimidine,4-(phenylthio)-; SCHEMBL191691; CHEMBL360302; TUBUPSQEQADRHY-UHFFFAOYSA-N; ZINC13608572; KB-270401; 7H-Pyrrolo[2,3-d]pyrimidine, 4-(phenylthio)-
DMHANXD DT Small molecular drug
DMHANXD PC 11481564
DMHANXD MW 227.29
DMHANXD FM C12H9N3S
DMHANXD IC InChI=1S/C12H9N3S/c1-2-4-9(5-3-1)16-12-10-6-7-13-11(10)14-8-15-12/h1-8H,(H,13,14,15)
DMHANXD CS C1=CC=C(C=C1)SC2=NC=NC3=C2C=CN3
DMHANXD IK TUBUPSQEQADRHY-UHFFFAOYSA-N
DMHANXD IU 4-phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine
DMHANXD DE Discovery agent
DM3B1CE ID DM3B1CE
DM3B1CE DN 4-phenylthiazole-2-thiol
DM3B1CE HS Investigative
DM3B1CE SN 4-Phenylthiazole-2-thiol; 2103-88-0; 2-Mercapto-4-phenylthiazole; 4-Phenyl-2-thiazolethiol; 4-Phenyl-1,3-thiazole-2-thiol; 2(3H)-Thiazolethione, 4-phenyl-; 4-Phenyl-2-mercaptothiazole; 4-Thiazoline-2-thione, 4-phenyl-; 2-Thiazolethiol, 4-phenyl-; 4-phenyl-thiazole-2-thiol; CHEMBL571436; 4-Phenylthiazole-2(3H)-thione; NSC 678; CYCKHTAVNBPQDB-UHFFFAOYSA-N; EINECS 218-274-7; 4-phenyl-3H-1,3-thiazole-2-thione; NSC678; zlchem 830; AC1MHDCC; ACMC-1CJ8W; 2-mercapto-4-phenylthiazol; MLS001006837; SCHEMBL178051; SCHEMBL11460891
DM3B1CE DT Small molecular drug
DM3B1CE PC 3000729
DM3B1CE MW 193.3
DM3B1CE FM C9H7NS2
DM3B1CE IC InChI=1S/C9H7NS2/c11-9-10-8(6-12-9)7-4-2-1-3-5-7/h1-6H,(H,10,11)
DM3B1CE CS C1=CC=C(C=C1)C2=CSC(=S)N2
DM3B1CE IK CYCKHTAVNBPQDB-UHFFFAOYSA-N
DM3B1CE IU 4-phenyl-3H-1,3-thiazole-2-thione
DM3B1CE CA CAS 2103-88-0
DM3B1CE CB CHEBI:109516
DM3B1CE DE Discovery agent
DMW4KXQ ID DMW4KXQ
DMW4KXQ DN 4-phospho-D-erythronate
DMW4KXQ HS Investigative
DMW4KXQ SN 4-Phospho-D-erythronate; 4-phosphoerythronate; 4-phospho-D-erythronic acid; 4-Phospho D-Erythronate; 57229-25-1; CHEBI:49003; 4-O-phosphono-D-erythronic acid; (2R,3R)-2,3-dihydroxy-4-(phosphonooxy)butanoic acid; 2bet; AC1L9MYX; SCHEMBL420471; CHEMBL1160945; CTK1E1186; DTXSID70332305; ZINC3869897; DER; AKOS030570437; DB03108; FT-0673861; C03393; (2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid; [R-(R*,R*)]-2,3-Dihydroxy-4-(phosphonooxy)butanoic Acid; Butanoic acid, 2,3-dihydroxy-4-(phosphonooxy)-, (2R,3R)-
DMW4KXQ DT Small molecular drug
DMW4KXQ PC 449304
DMW4KXQ MW 216.08
DMW4KXQ FM C4H9O8P
DMW4KXQ IC InChI=1S/C4H9O8P/c5-2(3(6)4(7)8)1-12-13(9,10)11/h2-3,5-6H,1H2,(H,7,8)(H2,9,10,11)/t2-,3-/m1/s1
DMW4KXQ CS C([C@H]([C@H](C(=O)O)O)O)OP(=O)(O)O
DMW4KXQ IK ZCZXOHUILRHRQJ-PWNYCUMCSA-N
DMW4KXQ IU (2R,3R)-2,3-dihydroxy-4-phosphonooxybutanoic acid
DMW4KXQ CA CAS 57229-25-1
DMW4KXQ CB CHEBI:49003
DMW4KXQ DE Discovery agent
DMJ0A4Z ID DMJ0A4Z
DMJ0A4Z DN 4'-Phosphopantetheine
DMJ0A4Z HS Investigative
DMJ0A4Z SN 4'-phosphopantetheine; Phosphopantetheine; Psh-4'-P; Pantetheine-4'-phosphate; D-Pantetheine 4'-phosphate; UNII-NM39WU8OFM; 2226-71-3; NM39WU8OFM; O(4)-phosphono-D-pantethein; (2R)-2-Hydroxy-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethyl-4-(phosphonooxy)butanamide; PNS; N(3)-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-N-(2-sulfanylethyl)-beta-alaninamide; P-PantSH; AC1L3GTE; SCHEMBL106050; CHEBI:4222; JDMUPRLRUUMCTL-VIFPVBQESA-N; AKOS027326509; DB03912; C01134; Butanamide, 2-hydroxy-N-(3-((2-mercaptoethyl)a
DMJ0A4Z DT Small molecular drug
DMJ0A4Z PC 115254
DMJ0A4Z MW 358.35
DMJ0A4Z FM C11H23N2O7PS
DMJ0A4Z IC InChI=1S/C11H23N2O7PS/c1-11(2,7-20-21(17,18)19)9(15)10(16)13-4-3-8(14)12-5-6-22/h9,15,22H,3-7H2,1-2H3,(H,12,14)(H,13,16)(H2,17,18,19)/t9-/m0/s1
DMJ0A4Z CS CC(C)(COP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O
DMJ0A4Z IK JDMUPRLRUUMCTL-VIFPVBQESA-N
DMJ0A4Z IU [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] dihydrogen phosphate
DMJ0A4Z CA CAS 2226-71-3
DMJ0A4Z CB CHEBI:4222
DMJ0A4Z DE Discovery agent
DMOHDRS ID DMOHDRS
DMOHDRS DN 4-Piperidin-1-yl-chromen-2-one
DMOHDRS HS Investigative
DMOHDRS SN 4-Piperidin-1-yl-chromen-2-one; CHEMBL176114; 4-piperidinocoumarin; AC1LEH6J; 4-piperidylchromen-2-one; Oprea1_207466; Oprea1_800231; MLS000711082; 4-piperidin-1-ylchromen-2-one; ZINC53303; HMS2627L16; BDBM50159626; AKOS003620982; MCULE-1716733202; 4-(1-piperidinyl)-2H-chromen-2-one; BAS 01052429; SMR000280849; ST50993947; EU-0085678; SR-01000527828
DMOHDRS DT Small molecular drug
DMOHDRS PC 686127
DMOHDRS MW 229.27
DMOHDRS FM C14H15NO2
DMOHDRS IC InChI=1S/C14H15NO2/c16-14-10-12(15-8-4-1-5-9-15)11-6-2-3-7-13(11)17-14/h2-3,6-7,10H,1,4-5,8-9H2
DMOHDRS CS C1CCN(CC1)C2=CC(=O)OC3=CC=CC=C32
DMOHDRS IK AZAXRUNIGYYEKS-UHFFFAOYSA-N
DMOHDRS IU 4-piperidin-1-ylchromen-2-one
DMOHDRS DE Discovery agent
DMONGDX ID DMONGDX
DMONGDX DN 4-Piperidino-Piperidine
DMONGDX HS Investigative
DMONGDX SN 4-Piperidinopiperidine; 4897-50-1; 1,4'-Bipiperidine; 4-PIPERIDINO-PIPERIDINE; 1,4'-Bipiperidyl; 1,4-Bipiperidine; [1,4']BIPIPERIDINYL; 4-(1-piperidinyl)piperidine; 1-(piperidin-4-yl)piperidine; 4-(piperidin-1-yl)piperidine; 4-Piperidino piperidine; 4-piperidin-1-ylpiperidine; 1-(4-PIPERIDYL)PIPERIDINE; CHEMBL174391; CHEBI:40117; QDVBKXJMLILLLB-UHFFFAOYSA-N; N-(4-PIPERIDINO)PIPERIDINE; MFCD00006475; 4-piperidylpiperidine; {1,4'}bipiperidinyl; 4PN; 1,4'-bipiperidin; 4-Piperidinopiperidine, 95%, tech.
DMONGDX DT Small molecular drug
DMONGDX PC 78607
DMONGDX MW 168.28
DMONGDX FM C10H20N2
DMONGDX IC InChI=1S/C10H20N2/c1-2-8-12(9-3-1)10-4-6-11-7-5-10/h10-11H,1-9H2
DMONGDX CS C1CCN(CC1)C2CCNCC2
DMONGDX IK QDVBKXJMLILLLB-UHFFFAOYSA-N
DMONGDX IU 1-piperidin-4-ylpiperidine
DMONGDX CA CAS 4897-50-1
DMONGDX CB CHEBI:40117
DMONGDX DE Discovery agent
DMEMN0W ID DMEMN0W
DMEMN0W DN 4P-PDOT
DMEMN0W HS Investigative
DMEMN0W SN N-(4-phenyltetralin-2-yl)propanamide; 4-phenyl-2-propionamidotetraline
DMEMN0W DT Small molecular drug
DMEMN0W PC 3976006
DMEMN0W MW 279.4
DMEMN0W FM C19H21NO
DMEMN0W IC InChI=1S/C19H21NO/c1-2-19(21)20-16-12-15-10-6-7-11-17(15)18(13-16)14-8-4-3-5-9-14/h3-11,16,18H,2,12-13H2,1H3,(H,20,21)
DMEMN0W CS CCC(=O)NC1CC(C2=CC=CC=C2C1)C3=CC=CC=C3
DMEMN0W IK RCYLUNPFECYGDW-UHFFFAOYSA-N
DMEMN0W IU N-(4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
DMEMN0W CA CAS 134865-74-0
DMEMN0W CB CHEBI:110160
DMEMN0W DE Discovery agent
DMDBC1K ID DMDBC1K
DMDBC1K DN 4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine
DMDBC1K HS Investigative
DMDBC1K SN CHEMBL462598; 4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine
DMDBC1K DT Small molecular drug
DMDBC1K PC 44563683
DMDBC1K MW 303.5
DMDBC1K FM C20H33NO
DMDBC1K IC InChI=1S/C20H33NO/c1-2-8-19-12-15-21(16-13-19)14-7-18-22-17-6-11-20-9-4-3-5-10-20/h3-5,9-10,19H,2,6-8,11-18H2,1H3
DMDBC1K CS CCCC1CCN(CC1)CCCOCCCC2=CC=CC=C2
DMDBC1K IK STTDWMNBHHXZBO-UHFFFAOYSA-N
DMDBC1K IU 1-[3-(3-phenylpropoxy)propyl]-4-propylpiperidine
DMDBC1K DE Discovery agent
DMRYCL6 ID DMRYCL6
DMRYCL6 DN 4-propyl-3,4-dihydroquinazolin-2-amine
DMRYCL6 HS Investigative
DMRYCL6 SN CHEMBL270840
DMRYCL6 DT Small molecular drug
DMRYCL6 PC 44455983
DMRYCL6 MW 189.26
DMRYCL6 FM C11H15N3
DMRYCL6 IC InChI=1S/C11H15N3/c1-2-5-9-8-6-3-4-7-10(8)14-11(12)13-9/h3-4,6-7,9H,2,5H2,1H3,(H3,12,13,14)
DMRYCL6 CS CCCC1C2=CC=CC=C2NC(=N1)N
DMRYCL6 IK GMMVLHFFOQJVPH-UHFFFAOYSA-N
DMRYCL6 IU 4-propyl-1,4-dihydroquinazolin-2-amine
DMRYCL6 DE Discovery agent
DMNM4GE ID DMNM4GE
DMNM4GE DN 4-propyl-6-m-tolylpyrimidine-2-carbonitrile
DMNM4GE HS Investigative
DMNM4GE SN CHEMBL1082859; 4-propyl-6-m-tolylpyrimidine-2-carbonitrile; SCHEMBL4453859
DMNM4GE DT Small molecular drug
DMNM4GE PC 46881451
DMNM4GE MW 237.3
DMNM4GE FM C15H15N3
DMNM4GE IC InChI=1S/C15H15N3/c1-3-5-13-9-14(18-15(10-16)17-13)12-7-4-6-11(2)8-12/h4,6-9H,3,5H2,1-2H3
DMNM4GE CS CCCC1=CC(=NC(=N1)C#N)C2=CC=CC(=C2)C
DMNM4GE IK LWTLVKKUNGVFHE-UHFFFAOYSA-N
DMNM4GE IU 4-(3-methylphenyl)-6-propylpyrimidine-2-carbonitrile
DMNM4GE DE Discovery agent
DM4FLK6 ID DM4FLK6
DM4FLK6 DN 4-propyl-N-(quinolin-3-yl)benzamide
DM4FLK6 HS Investigative
DM4FLK6 SN CHEMBL259600; ChemDiv2_003456; AC1N8MZ4; Oprea1_836743; SCHEMBL846554; 4-propyl-N-(3-quinolyl)benzamide; ZINC188371; HMS1378N02; 4-propyl-N-quinolin-3-ylbenzamide; BDBM50376280; AKOS001583305; MCULE-1509884615; EU-0034321; SR-01000396314
DM4FLK6 DT Small molecular drug
DM4FLK6 PC 4298023
DM4FLK6 MW 290.4
DM4FLK6 FM C19H18N2O
DM4FLK6 IC InChI=1S/C19H18N2O/c1-2-5-14-8-10-15(11-9-14)19(22)21-17-12-16-6-3-4-7-18(16)20-13-17/h3-4,6-13H,2,5H2,1H3,(H,21,22)
DM4FLK6 CS CCCC1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM4FLK6 IK ACMQNRGXOSFSMZ-UHFFFAOYSA-N
DM4FLK6 IU 4-propyl-N-quinolin-3-ylbenzamide
DM4FLK6 DE Discovery agent
DMY8ZLM ID DMY8ZLM
DMY8ZLM DN 4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine
DMY8ZLM HS Investigative
DMY8ZLM SN CHEMBL186966; 4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine
DMY8ZLM DT Small molecular drug
DMY8ZLM PC 11403950
DMY8ZLM MW 304.4
DMY8ZLM FM C17H12N4S
DMY8ZLM IC InChI=1S/C17H12N4S/c18-17-21-15(13-7-3-4-10-19-13)16(22-17)14-9-8-11-5-1-2-6-12(11)20-14/h1-10H,(H2,18,21)
DMY8ZLM CS C1=CC=C2C(=C1)C=CC(=N2)C3=C(N=C(S3)N)C4=CC=CC=N4
DMY8ZLM IK XYMCAGVJYOESBU-UHFFFAOYSA-N
DMY8ZLM IU 4-pyridin-2-yl-5-quinolin-2-yl-1,3-thiazol-2-amine
DMY8ZLM DE Discovery agent
DM6RVB3 ID DM6RVB3
DM6RVB3 DN 4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine
DM6RVB3 HS Investigative
DM6RVB3 SN CHEMBL181640; SCHEMBL410002; 4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine; UPYLCJSMNYCTLZ-UHFFFAOYSA-N; BDBM50151348; 4-(pyridin-2-yl)-5-(quinolin-4-yl)thiazol-2-amine
DM6RVB3 DT Small molecular drug
DM6RVB3 PC 9796486
DM6RVB3 MW 304.4
DM6RVB3 FM C17H12N4S
DM6RVB3 IC InChI=1S/C17H12N4S/c18-17-21-15(14-7-3-4-9-19-14)16(22-17)12-8-10-20-13-6-2-1-5-11(12)13/h1-10H,(H2,18,21)
DM6RVB3 CS C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=CC=CC=N4
DM6RVB3 IK UPYLCJSMNYCTLZ-UHFFFAOYSA-N
DM6RVB3 IU 4-pyridin-2-yl-5-quinolin-4-yl-1,3-thiazol-2-amine
DM6RVB3 DE Discovery agent
DMFC8Q4 ID DMFC8Q4
DMFC8Q4 DN 4-Pyridin-2-yl-piperazine-1-carboxylic acid amide
DMFC8Q4 HS Investigative
DMFC8Q4 SN CHEMBL296963; SCHEMBL1270156; CTK7D3440; BDBM50224176; AKOS000158821; 4-(2-pyridyl)piperazine-1-carboxamide
DMFC8Q4 DT Small molecular drug
DMFC8Q4 PC 22418783
DMFC8Q4 MW 206.24
DMFC8Q4 FM C10H14N4O
DMFC8Q4 IC InChI=1S/C10H14N4O/c11-10(15)14-7-5-13(6-8-14)9-3-1-2-4-12-9/h1-4H,5-8H2,(H2,11,15)
DMFC8Q4 CS C1CN(CCN1C2=CC=CC=N2)C(=O)N
DMFC8Q4 IK XYIDWLYTWKIZQC-UHFFFAOYSA-N
DMFC8Q4 IU 4-pyridin-2-ylpiperazine-1-carboxamide
DMFC8Q4 DE Discovery agent
DM06AV8 ID DM06AV8
DM06AV8 DN 4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine
DM06AV8 HS Investigative
DM06AV8 SN CHEMBL359724; 4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine; BDBM50151364
DM06AV8 DT Small molecular drug
DM06AV8 PC 11231979
DM06AV8 MW 304.4
DM06AV8 FM C17H12N4S
DM06AV8 IC InChI=1S/C17H12N4S/c18-17-21-15(11-4-3-8-19-10-11)16(22-17)13-7-9-20-14-6-2-1-5-12(13)14/h1-10H,(H2,18,21)
DM06AV8 CS C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=CN=CC=C4
DM06AV8 IK SSOAVUCQSQRZGQ-UHFFFAOYSA-N
DM06AV8 IU 4-pyridin-3-yl-5-quinolin-4-yl-1,3-thiazol-2-amine
DM06AV8 DE Discovery agent
DMUGFS3 ID DMUGFS3
DMUGFS3 DN 4r-Fluoro-N6-Ethanimidoyl-L-Lysine
DMUGFS3 HS Investigative
DMUGFS3 SN 4R-FLUORO-N6-ETHANIMIDOYL-L-LYSINE; I58; AC1L9LS8; SCHEMBL4308483; DB01835; (4R)-N~6~-[(1Z)-ethanimidoyl]-4-fluoro-L-lysine; (2S,4R)-2-amino-6-ethanimidamido-4-fluorohexanoic acid; (2S,4R)-2-amino-6-(1-aminoethylideneamino)-4-fluorohexanoic acid
DMUGFS3 DT Small molecular drug
DMUGFS3 PC 448269
DMUGFS3 MW 205.23
DMUGFS3 FM C8H16FN3O2
DMUGFS3 IC InChI=1S/C8H16FN3O2/c1-5(10)12-3-2-6(9)4-7(11)8(13)14/h6-7H,2-4,11H2,1H3,(H2,10,12)(H,13,14)/t6-,7+/m1/s1
DMUGFS3 CS CC(=NCC[C@H](C[C@@H](C(=O)O)N)F)N
DMUGFS3 IK LTCJJIZTKXNFGK-RQJHMYQMSA-N
DMUGFS3 IU (2S,4R)-2-amino-6-(1-aminoethylideneamino)-4-fluorohexanoic acid
DMUGFS3 DE Discovery agent
DMQNT8D ID DMQNT8D
DMQNT8D DN 4S-4,5-Diamino-N-(4-phenoxyphenyl)pentanamide
DMQNT8D HS Investigative
DMQNT8D SN CHEMBL477275; BDBM24292; Modified amino acid analog, 12b
DMQNT8D DT Small molecular drug
DMQNT8D PC 24901637
DMQNT8D MW 299.37
DMQNT8D FM C17H21N3O2
DMQNT8D IC InChI=1S/C17H21N3O2/c18-12-13(19)6-11-17(21)20-14-7-9-16(10-8-14)22-15-4-2-1-3-5-15/h1-5,7-10,13H,6,11-12,18-19H2,(H,20,21)/t13-/m0/s1
DMQNT8D CS C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](CN)N
DMQNT8D IK YUSYHJFOQGXULG-ZDUSSCGKSA-N
DMQNT8D IU (4S)-4,5-diamino-N-(4-phenoxyphenyl)pentanamide
DMQNT8D DE Discovery agent
DMELGKY ID DMELGKY
DMELGKY DN 4-substituted 2,4-dioxobutanoic acids
DMELGKY HS Investigative
DMELGKY SN Guvacine; 1,2,5,6-tetrahydropyridine-3-carboxylic acid; 498-96-4; 1,2,5,6-Tetrahydro-3-pyridinecarboxylic acid; UNII-41538P325K; 1,2,5,6-Tetrahydronicotinic acid; CHEBI:5576; 1,2,3,6-tetrahydropyridine-5-carboxylic acid; 41538P325K; 1,2,5,6-Tetrahydro-pyridine-3-carboxylic acid; MLS000859975; SMR000326834; Spectrum_001426; Tocris-0234; SpecPlus_000808; Lopac-G-007; AC1Q5RCN; Spectrum2_001474; Spectrum4_001753; Spectrum3_001511; Spectrum5_000606; Biomol-NT_000253; C10149; AC1L1G5E; Lopac0_000571; BSPBio_003181; KBioSS_001906
DMELGKY DT Small molecular drug
DMELGKY PC 3532
DMELGKY MW 127.14
DMELGKY FM C6H9NO2
DMELGKY IC InChI=1S/C6H9NO2/c8-6(9)5-2-1-3-7-4-5/h2,7H,1,3-4H2,(H,8,9)
DMELGKY CS C1CNCC(=C1)C(=O)O
DMELGKY IK QTDZOWFRBNTPQR-UHFFFAOYSA-N
DMELGKY IU 1,2,3,6-tetrahydropyridine-5-carboxylic acid
DMELGKY CA CAS 498-96-4
DMELGKY CB CHEBI:5576
DMELGKY DE Discovery agent
DMWH2NT ID DMWH2NT
DMWH2NT DN 4-Sulfamoyloxy-benzoic acid butyl ester
DMWH2NT HS Investigative
DMWH2NT SN 4-Sulfamoyloxy-benzoic acid butyl ester; CHEMBL76374; BDBM50116810; 4-(Sulfamoyloxy)benzoic acid butyl ester
DMWH2NT DT Small molecular drug
DMWH2NT PC 10880277
DMWH2NT MW 273.31
DMWH2NT FM C11H15NO5S
DMWH2NT IC InChI=1S/C11H15NO5S/c1-2-3-8-16-11(13)9-4-6-10(7-5-9)17-18(12,14)15/h4-7H,2-3,8H2,1H3,(H2,12,14,15)
DMWH2NT CS CCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMWH2NT IK DTGVRFABWYOAMJ-UHFFFAOYSA-N
DMWH2NT IU butyl 4-sulfamoyloxybenzoate
DMWH2NT DE Discovery agent
DMDNRCU ID DMDNRCU
DMDNRCU DN 4-Sulfamoyloxy-benzoic acid cycloheptyl ester
DMDNRCU HS Investigative
DMDNRCU SN CHEMBL349091; 4-Sulfamoyloxy-benzoic acid cycloheptyl ester; BDBM50139113; 4-(Sulfamoyloxy)benzoic acid cycloheptyl ester
DMDNRCU DT Small molecular drug
DMDNRCU PC 10018465
DMDNRCU MW 313.37
DMDNRCU FM C14H19NO5S
DMDNRCU IC InChI=1S/C14H19NO5S/c15-21(17,18)20-13-9-7-11(8-10-13)14(16)19-12-5-3-1-2-4-6-12/h7-10,12H,1-6H2,(H2,15,17,18)
DMDNRCU CS C1CCCC(CC1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMDNRCU IK ZJGRMZILHPHGTJ-UHFFFAOYSA-N
DMDNRCU IU cycloheptyl 4-sulfamoyloxybenzoate
DMDNRCU DE Discovery agent
DMIX0UN ID DMIX0UN
DMIX0UN DN 4-Sulfamoyloxy-benzoic acid cyclohexyl ester
DMIX0UN HS Investigative
DMIX0UN SN CHEMBL443552; 4-Sulfamoyloxy-benzoic acid cyclohexyl ester; BDBM50139116; 4-(Sulfamoyloxy)benzoic acid cyclohexyl ester
DMIX0UN DT Small molecular drug
DMIX0UN PC 44371205
DMIX0UN MW 299.34
DMIX0UN FM C13H17NO5S
DMIX0UN IC InChI=1S/C13H17NO5S/c14-20(16,17)19-12-8-6-10(7-9-12)13(15)18-11-4-2-1-3-5-11/h6-9,11H,1-5H2,(H2,14,16,17)
DMIX0UN CS C1CCC(CC1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMIX0UN IK VMBLTTIYVBQGQH-UHFFFAOYSA-N
DMIX0UN IU cyclohexyl 4-sulfamoyloxybenzoate
DMIX0UN DE Discovery agent
DMG4LD9 ID DMG4LD9
DMG4LD9 DN 4-Sulfamoyloxy-benzoic acid cyclooctyl ester
DMG4LD9 HS Investigative
DMG4LD9 SN CHEMBL155465; 4-Sulfamoyloxy-benzoic acid cyclooctyl ester; BDBM50139114; 4-(Sulfamoyloxy)benzoic acid cyclooctyl ester
DMG4LD9 DT Small molecular drug
DMG4LD9 PC 10065009
DMG4LD9 MW 327.4
DMG4LD9 FM C15H21NO5S
DMG4LD9 IC InChI=1S/C15H21NO5S/c16-22(18,19)21-14-10-8-12(9-11-14)15(17)20-13-6-4-2-1-3-5-7-13/h8-11,13H,1-7H2,(H2,16,18,19)
DMG4LD9 CS C1CCCC(CCC1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMG4LD9 IK AGVIMIWKQHZOFR-UHFFFAOYSA-N
DMG4LD9 IU cyclooctyl 4-sulfamoyloxybenzoate
DMG4LD9 DE Discovery agent
DMF3C71 ID DMF3C71
DMF3C71 DN 4-Sulfamoyloxy-benzoic acid cyclopentyl ester
DMF3C71 HS Investigative
DMF3C71 SN CHEMBL347202; 4-Sulfamoyloxy-benzoic acid cyclopentyl ester; BDBM50139115; 4-(Sulfamoyloxy)benzoic acid cyclopentyl ester
DMF3C71 DT Small molecular drug
DMF3C71 PC 44370998
DMF3C71 MW 285.32
DMF3C71 FM C12H15NO5S
DMF3C71 IC InChI=1S/C12H15NO5S/c13-19(15,16)18-11-7-5-9(6-8-11)12(14)17-10-3-1-2-4-10/h5-8,10H,1-4H2,(H2,13,15,16)
DMF3C71 CS C1CCC(C1)OC(=O)C2=CC=C(C=C2)OS(=O)(=O)N
DMF3C71 IK UOISMBVIIRRGNN-UHFFFAOYSA-N
DMF3C71 IU cyclopentyl 4-sulfamoyloxybenzoate
DMF3C71 DE Discovery agent
DMTC25W ID DMTC25W
DMTC25W DN 4-Sulfamoyloxy-benzoic acid heptyl ester
DMTC25W HS Investigative
DMTC25W SN 4-Sulfamoyloxy-benzoic acid heptyl ester; CHEMBL420395; BDBM50116818; 4-(Sulfamoyloxy)benzoic acid heptyl ester
DMTC25W DT Small molecular drug
DMTC25W PC 9796948
DMTC25W MW 315.39
DMTC25W FM C14H21NO5S
DMTC25W IC InChI=1S/C14H21NO5S/c1-2-3-4-5-6-11-19-14(16)12-7-9-13(10-8-12)20-21(15,17)18/h7-10H,2-6,11H2,1H3,(H2,15,17,18)
DMTC25W CS CCCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMTC25W IK XTVXDGYXZNQKRA-UHFFFAOYSA-N
DMTC25W IU heptyl 4-sulfamoyloxybenzoate
DMTC25W DE Discovery agent
DMU784M ID DMU784M
DMU784M DN 4-Sulfamoyloxy-benzoic acid hexyl ester
DMU784M HS Investigative
DMU784M SN 4-Sulfamoyloxy-benzoic acid hexyl ester; CHEMBL78282; BDBM50116815; 4-(Sulfamoyloxy)benzoic acid hexyl ester
DMU784M DT Small molecular drug
DMU784M PC 9879424
DMU784M MW 301.36
DMU784M FM C13H19NO5S
DMU784M IC InChI=1S/C13H19NO5S/c1-2-3-4-5-10-18-13(15)11-6-8-12(9-7-11)19-20(14,16)17/h6-9H,2-5,10H2,1H3,(H2,14,16,17)
DMU784M CS CCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMU784M IK PJIPMHPXRQOHKO-UHFFFAOYSA-N
DMU784M IU hexyl 4-sulfamoyloxybenzoate
DMU784M DE Discovery agent
DM4Z7TU ID DM4Z7TU
DM4Z7TU DN 4-Sulfamoyloxy-benzoic acid nonyl ester
DM4Z7TU HS Investigative
DM4Z7TU SN 4-Sulfamoyloxy-benzoic acid nonyl ester; CHEMBL80330; BDBM50116813; 4-(Sulfamoyloxy)benzoic acid nonyl ester
DM4Z7TU DT Small molecular drug
DM4Z7TU PC 10914878
DM4Z7TU MW 343.4
DM4Z7TU FM C16H25NO5S
DM4Z7TU IC InChI=1S/C16H25NO5S/c1-2-3-4-5-6-7-8-13-21-16(18)14-9-11-15(12-10-14)22-23(17,19)20/h9-12H,2-8,13H2,1H3,(H2,17,19,20)
DM4Z7TU CS CCCCCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DM4Z7TU IK MIEAOZZHVJFVJY-UHFFFAOYSA-N
DM4Z7TU IU nonyl 4-sulfamoyloxybenzoate
DM4Z7TU DE Discovery agent
DMQMSW3 ID DMQMSW3
DMQMSW3 DN 4-Sulfamoyloxy-benzoic acid octyl ester
DMQMSW3 HS Investigative
DMQMSW3 SN 4-Sulfamoyloxy-benzoic acid octyl ester; CHEMBL421505; BDBM50116814; 4-(Sulfamoyloxy)benzoic acid octyl ester
DMQMSW3 DT Small molecular drug
DMQMSW3 PC 10958461
DMQMSW3 MW 329.4
DMQMSW3 FM C15H23NO5S
DMQMSW3 IC InChI=1S/C15H23NO5S/c1-2-3-4-5-6-7-12-20-15(17)13-8-10-14(11-9-13)21-22(16,18)19/h8-11H,2-7,12H2,1H3,(H2,16,18,19)
DMQMSW3 CS CCCCCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMQMSW3 IK YDCCVRPKBUQXHB-UHFFFAOYSA-N
DMQMSW3 IU octyl 4-sulfamoyloxybenzoate
DMQMSW3 DE Discovery agent
DMZIFW7 ID DMZIFW7
DMZIFW7 DN 4-Sulfamoyloxy-benzoic acid pentyl ester
DMZIFW7 HS Investigative
DMZIFW7 SN 4-Sulfamoyloxy-benzoic acid pentyl ester; CHEMBL306782; BDBM50116811; 4-(Sulfamoyloxy)benzoic acid pentyl ester
DMZIFW7 DT Small molecular drug
DMZIFW7 PC 11822292
DMZIFW7 MW 287.33
DMZIFW7 FM C12H17NO5S
DMZIFW7 IC InChI=1S/C12H17NO5S/c1-2-3-4-9-17-12(14)10-5-7-11(8-6-10)18-19(13,15)16/h5-8H,2-4,9H2,1H3,(H2,13,15,16)
DMZIFW7 CS CCCCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMZIFW7 IK ZFWKNIDIWKSQEP-UHFFFAOYSA-N
DMZIFW7 IU pentyl 4-sulfamoyloxybenzoate
DMZIFW7 DE Discovery agent
DMRILJC ID DMRILJC
DMRILJC DN 4-Sulfamoyloxy-benzoic acid propyl ester
DMRILJC HS Investigative
DMRILJC SN 4-Sulfamoyloxy-benzoic acid propyl ester; CHEMBL77121; BDBM50116817; 4-(Sulfamoyloxy)benzoic acid propyl ester
DMRILJC DT Small molecular drug
DMRILJC PC 10858185
DMRILJC MW 259.279
DMRILJC FM C10H13NO5S
DMRILJC IC InChI=1S/C10H13NO5S/c1-2-7-15-10(12)8-3-5-9(6-4-8)16-17(11,13)14/h3-6H,2,7H2,1H3,(H2,11,13,14)
DMRILJC CS CCCOC(=O)C1=CC=C(C=C1)OS(=O)(=O)N
DMRILJC IK LUBKCXRNDIXVCG-UHFFFAOYSA-N
DMRILJC IU propyl 4-sulfamoyloxybenzoate
DMRILJC DE Discovery agent
DM61CJK ID DM61CJK
DM61CJK DN 4-Sulfonamide-[1-(4-Aminobutane)]Benzamide
DM61CJK HS Investigative
DM61CJK SN 4-sulfonamide-[1-(4-aminobutane)]benzamide; N-(4-aminobutyl)-4-sulfamoylbenzamide; AC1L1C69; CHEMBL331282; DB03697
DM61CJK DT Small molecular drug
DM61CJK PC 1758
DM61CJK MW 271.34
DM61CJK FM C11H17N3O3S
DM61CJK IC InChI=1S/C11H17N3O3S/c12-7-1-2-8-14-11(15)9-3-5-10(6-4-9)18(13,16)17/h3-6H,1-2,7-8,12H2,(H,14,15)(H2,13,16,17)
DM61CJK CS C1=CC(=CC=C1C(=O)NCCCCN)S(=O)(=O)N
DM61CJK IK ZDYFRIZTYRFPJC-UHFFFAOYSA-N
DM61CJK IU N-(4-aminobutyl)-4-sulfamoylbenzamide
DM61CJK DE Discovery agent
DMGCYS1 ID DMGCYS1
DMGCYS1 DN 4-TERT-BUTYLBENZENESULFONIC ACID
DMGCYS1 HS Investigative
DMGCYS1 SN 4-TERT-BUTYLBENZENESULFONIC ACID; 1133-17-1; AC1L8AOG; SCHEMBL196750; DTXSID80314995; ZINC1565641; 4-tert-butylbenzene-1-sulfonic acid; NSC290811; AKOS022773375; NSC-290811; MCULE-2120234795; DB07440; AJ-27135; BBS; 4-tert-Butylbenzenesulfonic acid, AldrichCPR
DMGCYS1 DT Small molecular drug
DMGCYS1 PC 324690
DMGCYS1 MW 214.28
DMGCYS1 FM C10H14O3S
DMGCYS1 IC InChI=1S/C10H14O3S/c1-10(2,3)8-4-6-9(7-5-8)14(11,12)13/h4-7H,1-3H3,(H,11,12,13)
DMGCYS1 CS CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)O
DMGCYS1 IK LZQMCUIWYRQLOG-UHFFFAOYSA-N
DMGCYS1 IU 4-tert-butylbenzenesulfonic acid
DMGCYS1 CA CAS 1133-17-1
DMGCYS1 DE Discovery agent
DMDWRE5 ID DMDWRE5
DMDWRE5 DN 4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine
DMDWRE5 HS Investigative
DMDWRE5 SN CHEMBL206788; 4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine
DMDWRE5 DT Small molecular drug
DMDWRE5 PC 44411266
DMDWRE5 MW 274.4
DMDWRE5 FM C16H22N2S
DMDWRE5 IC InChI=1S/C16H22N2S/c1-11(2)12-8-6-7-9-13(12)17-15-18-14(10-19-15)16(3,4)5/h6-11H,1-5H3,(H,17,18)
DMDWRE5 CS CC(C)C1=CC=CC=C1NC2=NC(=CS2)C(C)(C)C
DMDWRE5 IK XGRAMFLJGHKCSV-UHFFFAOYSA-N
DMDWRE5 IU 4-tert-butyl-N-(2-propan-2-ylphenyl)-1,3-thiazol-2-amine
DMDWRE5 DE Discovery agent
DMLFZ6Q ID DMLFZ6Q
DMLFZ6Q DN 4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide
DMLFZ6Q HS Investigative
DMLFZ6Q SN 4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide; CHEMBL293635; 4-tert-butyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; BAS 03572060; AC1Q1LYP; AC1LGN92; Oprea1_621031; Oprea1_258896; MolPort-001-030-330; ZINC342768; BDBM50101785; STK401915; AKOS000569708; MCULE-2080665457; ST50017828; N-(4-Phenyl-2-thiazolyl)-4-tert-butylbenzamide; AG-690/09665053
DMLFZ6Q DT Small molecular drug
DMLFZ6Q PC 824266
DMLFZ6Q MW 336.5
DMLFZ6Q FM C20H20N2OS
DMLFZ6Q IC InChI=1S/C20H20N2OS/c1-20(2,3)16-11-9-15(10-12-16)18(23)22-19-21-17(13-24-19)14-7-5-4-6-8-14/h4-13H,1-3H3,(H,21,22,23)
DMLFZ6Q CS CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DMLFZ6Q IK JXOGYJOCFUSOPS-UHFFFAOYSA-N
DMLFZ6Q IU 4-tert-butyl-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMLFZ6Q DE Discovery agent
DM5U6ZW ID DM5U6ZW
DM5U6ZW DN 4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine
DM5U6ZW HS Investigative
DM5U6ZW SN CHEMBL206878; 4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine
DM5U6ZW DT Small molecular drug
DM5U6ZW PC 44411037
DM5U6ZW MW 266.34
DM5U6ZW FM C17H18N2O
DM5U6ZW IC InChI=1S/C17H18N2O/c1-17(2,3)15-11-20-16(19-15)18-14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H,18,19)
DM5U6ZW CS CC(C)(C)C1=COC(=N1)NC2=CC=CC3=CC=CC=C32
DM5U6ZW IK RDWFLGKWZJPVFQ-UHFFFAOYSA-N
DM5U6ZW IU 4-tert-butyl-N-naphthalen-1-yl-1,3-oxazol-2-amine
DM5U6ZW DE Discovery agent
DMBUZ75 ID DMBUZ75
DMBUZ75 DN 4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine
DMBUZ75 HS Investigative
DMBUZ75 SN CHEMBL379460; 4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine; SCHEMBL14433284; ZINC36159661
DMBUZ75 DT Small molecular drug
DMBUZ75 PC 9814340
DMBUZ75 MW 282.4
DMBUZ75 FM C17H18N2S
DMBUZ75 IC InChI=1S/C17H18N2S/c1-17(2,3)15-11-20-16(19-15)18-14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H,18,19)
DMBUZ75 CS CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMBUZ75 IK TXEFBOQHGSOELC-UHFFFAOYSA-N
DMBUZ75 IU 4-tert-butyl-N-naphthalen-1-yl-1,3-thiazol-2-amine
DMBUZ75 DE Discovery agent
DM1OBHQ ID DM1OBHQ
DM1OBHQ DN 4-tert-butyl-N-(quinolin-3-yl)benzamide
DM1OBHQ HS Investigative
DM1OBHQ SN CHEMBL258917; 331850-72-7; 4-tert-butyl-N-(quinolin-3-yl)benzamide; AC1LGMQ4; Oprea1_306931; Oprea1_506548; SCHEMBL846396; CTK1B8678; DTXSID30355358; MolPort-001-496-766; ZINC302143; BDBM50376277; AKOS000637295; MCULE-9209807944; 4-tert-butyl-N-quinolin-3-ylbenzamide; 4-tert-Butyl-N-quinolin-3-yl-benzamide; BAS 00631860; ST45006323; [4-(tert-butyl)phenyl]-N-(3-quinolyl)carboxamide; Benzamide, 4-(1,1-dimethylethyl)-N-3-quinolinyl-
DM1OBHQ DT Small molecular drug
DM1OBHQ PC 797382
DM1OBHQ MW 304.4
DM1OBHQ FM C20H20N2O
DM1OBHQ IC InChI=1S/C20H20N2O/c1-20(2,3)16-10-8-14(9-11-16)19(23)22-17-12-15-6-4-5-7-18(15)21-13-17/h4-13H,1-3H3,(H,22,23)
DM1OBHQ CS CC(C)(C)C1=CC=C(C=C1)C(=O)NC2=CC3=CC=CC=C3N=C2
DM1OBHQ IK MUZWQZALZQTMBA-UHFFFAOYSA-N
DM1OBHQ IU 4-tert-butyl-N-quinolin-3-ylbenzamide
DM1OBHQ CA CAS 331850-72-7
DM1OBHQ DE Discovery agent
DMUWTPX ID DMUWTPX
DMUWTPX DN 4-tert-butyl-N-hydroxybenzamide
DMUWTPX HS Investigative
DMUWTPX SN 4-tert-butyl-N-hydroxybenzamide; 62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279
DMUWTPX DT Small molecular drug
DMUWTPX PC 21397854
DMUWTPX MW 193.24
DMUWTPX FM C11H15NO2
DMUWTPX IC InChI=1S/C11H15NO2/c1-11(2,3)9-6-4-8(5-7-9)10(13)12-14/h4-7,14H,1-3H3,(H,12,13)
DMUWTPX CS CC(C)(C)C1=CC=C(C=C1)C(=O)NO
DMUWTPX IK HVTKRCPHQXJOFW-UHFFFAOYSA-N
DMUWTPX IU 4-tert-butyl-N-hydroxybenzamide
DMUWTPX CA CAS 62034-73-5
DMUWTPX DE Discovery agent
DM9K27Q ID DM9K27Q
DM9K27Q DN 4-tert-butyl-N-m-tolylthiazol-2-amine
DM9K27Q HS Investigative
DM9K27Q SN CHEMBL438248; 4-tert-butyl-N-m-tolylthiazol-2-amine; ZINC36159723
DM9K27Q DT Small molecular drug
DM9K27Q PC 44411325
DM9K27Q MW 246.37
DM9K27Q FM C14H18N2S
DM9K27Q IC InChI=1S/C14H18N2S/c1-10-6-5-7-11(8-10)15-13-16-12(9-17-13)14(2,3)4/h5-9H,1-4H3,(H,15,16)
DM9K27Q CS CC1=CC(=CC=C1)NC2=NC(=CS2)C(C)(C)C
DM9K27Q IK JCIZSRYCZWHMQK-UHFFFAOYSA-N
DM9K27Q IU 4-tert-butyl-N-(3-methylphenyl)-1,3-thiazol-2-amine
DM9K27Q DE Discovery agent
DMJQFD5 ID DMJQFD5
DMJQFD5 DN 4-tert-butyl-N-o-tolylthiazol-2-amine
DMJQFD5 HS Investigative
DMJQFD5 SN CHEMBL382244; 4-tert-butyl-N-o-tolylthiazol-2-amine; BDBM50183109
DMJQFD5 DT Small molecular drug
DMJQFD5 PC 44411322
DMJQFD5 MW 246.37
DMJQFD5 FM C14H18N2S
DMJQFD5 IC InChI=1S/C14H18N2S/c1-10-7-5-6-8-11(10)15-13-16-12(9-17-13)14(2,3)4/h5-9H,1-4H3,(H,15,16)
DMJQFD5 CS CC1=CC=CC=C1NC2=NC(=CS2)C(C)(C)C
DMJQFD5 IK LGKMKCIPKKOAPX-UHFFFAOYSA-N
DMJQFD5 IU 4-tert-butyl-N-(2-methylphenyl)-1,3-thiazol-2-amine
DMJQFD5 DE Discovery agent
DM5CPBK ID DM5CPBK
DM5CPBK DN 4-tert-butyl-N-phenylthiazol-2-amine
DM5CPBK HS Investigative
DM5CPBK SN CHEMBL206103; 4-tert-butyl-N-phenylthiazol-2-amine; SCHEMBL5486145; ZINC2161671; BDBM50183112; N-Phenyl-4-tert-butyl-2-thiazolamine
DM5CPBK DT Small molecular drug
DM5CPBK PC 9899450
DM5CPBK MW 232.35
DM5CPBK FM C13H16N2S
DM5CPBK IC InChI=1S/C13H16N2S/c1-13(2,3)11-9-16-12(15-11)14-10-7-5-4-6-8-10/h4-9H,1-3H3,(H,14,15)
DM5CPBK CS CC(C)(C)C1=CSC(=N1)NC2=CC=CC=C2
DM5CPBK IK OZPRKERRJSPXIW-UHFFFAOYSA-N
DM5CPBK IU 4-tert-butyl-N-phenyl-1,3-thiazol-2-amine
DM5CPBK DE Discovery agent
DMUGMVI ID DMUGMVI
DMUGMVI DN 4-Thiocyanato-benzenesulfonamide
DMUGMVI HS Investigative
DMUGMVI SN 4-Thiocyanato-benzenesulfonamide; CHEMBL363086; NSC166291; AC1L6PWF; (4-sulfamoylphenyl) thiocyanate; SCHEMBL16407107; ZINC1655602; BDBM50155502; NSC-166291
DMUGMVI DT Small molecular drug
DMUGMVI PC 296284
DMUGMVI MW 214.3
DMUGMVI FM C7H6N2O2S2
DMUGMVI IC InChI=1S/C7H6N2O2S2/c8-5-12-6-1-3-7(4-2-6)13(9,10)11/h1-4H,(H2,9,10,11)
DMUGMVI CS C1=CC(=CC=C1SC#N)S(=O)(=O)N
DMUGMVI IK JAOXYZVWRQDPGB-UHFFFAOYSA-N
DMUGMVI IU (4-sulfamoylphenyl) thiocyanate
DMUGMVI DE Discovery agent
DMA8SHN ID DMA8SHN
DMA8SHN DN 4-Thiomorpholin-4-yl-benzo[g]chromen-2-one
DMA8SHN HS Investigative
DMA8SHN SN CHEMBL179640; 4-Thiomorpholin-4-yl-benzo[g]chromen-2-one
DMA8SHN DT Small molecular drug
DMA8SHN PC 11358426
DMA8SHN MW 297.4
DMA8SHN FM C17H15NO2S
DMA8SHN IC InChI=1S/C17H15NO2S/c19-17-11-15(18-5-7-21-8-6-18)14-9-12-3-1-2-4-13(12)10-16(14)20-17/h1-4,9-11H,5-8H2
DMA8SHN CS C1CSCCN1C2=CC(=O)OC3=CC4=CC=CC=C4C=C23
DMA8SHN IK UYBNTAODFKOXIU-UHFFFAOYSA-N
DMA8SHN IU 4-thiomorpholin-4-ylbenzo[g]chromen-2-one
DMA8SHN DE Discovery agent
DM7YOXW ID DM7YOXW
DM7YOXW DN 4-thio-UTP
DM7YOXW HS Investigative
DM7YOXW SN 4-S-UTP; 4-thiouridine triphosphate
DM7YOXW DT Small molecular drug
DM7YOXW PC 3033941
DM7YOXW MW 500.21
DM7YOXW FM C9H15N2O14P3S
DM7YOXW IC InChI=1S/C9H15N2O14P3S/c12-6-4(3-22-27(18,19)25-28(20,21)24-26(15,16)17)23-8(7(6)13)11-2-1-5(29)10-9(11)14/h1-2,4,6-8,12-13H,3H2,(H,18,19)(H,20,21)(H,10,14,29)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DM7YOXW CS C1=CN(C(=O)NC1=S)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DM7YOXW IK GKVHYBAWZAYQDO-XVFCMESISA-N
DM7YOXW IU [[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM7YOXW CA CAS 31556-28-2
DM7YOXW DE Discovery agent
DMT81SD ID DMT81SD
DMT81SD DN 4'-trifluoromethyl-biphenyl-4-ylamine
DMT81SD HS Investigative
DMT81SD SN 57688-34-3; 4'-(trifluoromethyl)-[1,1'-biphenyl]-4-amine; 4'-trifluoromethylbiphenyl-4-ylamine; 4-[4-(trifluoromethyl)phenyl]aniline; 4'-trifluoromethyl-biphenyl-4-ylamine; [1,1'-biphenyl]-4-amine, 4'-(trifluoromethyl)-; CHEMBL242142; 4'-(trifluoromethyl)biphenyl-4-amine; 4'-(trifluoromethyl)[1,1'-biphenyl]-4-amine; [1,1'-Biphenyl]-4-amine,4'-(trifluoromethyl)-; ACMC-1AWVA; AC1MD2WS; SCHEMBL2655246; CTK5A7284; DTXSID50382227; PDKIAMYXBRKPBW-UHFFFAOYSA-N; MolPort-000-159-036; 4-amino-4'-trifluoromethyldiphenyl; ZINC2574122
DMT81SD DT Small molecular drug
DMT81SD PC 2782709
DMT81SD MW 237.22
DMT81SD FM C13H10F3N
DMT81SD IC InChI=1S/C13H10F3N/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(17)8-4-10/h1-8H,17H2
DMT81SD CS C1=CC(=CC=C1C2=CC=C(C=C2)N)C(F)(F)F
DMT81SD IK PDKIAMYXBRKPBW-UHFFFAOYSA-N
DMT81SD IU 4-[4-(trifluoromethyl)phenyl]aniline
DMT81SD CA CAS 57688-34-3
DMT81SD DE Discovery agent
DML4DSG ID DML4DSG
DML4DSG DN 5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline
DML4DSG HS Investigative
DML4DSG SN CHEMBL53068; dihydroquinoline 44; BDBM10025; ZINC13808186; 5-(1H-imidazol-1-ylmethyl)-7,8-dihydroquinoline; 5-[(Imidazol-1-yl)methyl]-7,8-dihydroquinoline
DML4DSG DT Small molecular drug
DML4DSG PC 10774864
DML4DSG MW 211.26
DML4DSG FM C13H13N3
DML4DSG IC InChI=1S/C13H13N3/c1-3-11(9-16-8-7-14-10-16)12-4-2-6-15-13(12)5-1/h2-4,6-8,10H,1,5,9H2
DML4DSG CS C1CC2=C(C=CC=N2)C(=C1)CN3C=CN=C3
DML4DSG IK DVAOHPCQHIOCSM-UHFFFAOYSA-N
DML4DSG IU 5-(imidazol-1-ylmethyl)-7,8-dihydroquinoline
DML4DSG DE Discovery agent
DMBSFLW ID DMBSFLW
DMBSFLW DN 5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile
DMBSFLW HS Investigative
DMBSFLW SN CHEMBL1098656; 5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile
DMBSFLW DT Small molecular drug
DMBSFLW PC 46861851
DMBSFLW MW 219.24
DMBSFLW FM C14H9N3
DMBSFLW IC InChI=1S/C14H9N3/c1-11-3-2-4-14(17-11)6-5-12-7-13(8-15)10-16-9-12/h2-4,7,9-10H,1H3
DMBSFLW CS CC1=NC(=CC=C1)C#CC2=CC(=CN=C2)C#N
DMBSFLW IK ZWOWJRDKGWIZDL-UHFFFAOYSA-N
DMBSFLW IU 5-[2-(6-methylpyridin-2-yl)ethynyl]pyridine-3-carbonitrile
DMBSFLW DE Discovery agent
DMH0QA7 ID DMH0QA7
DMH0QA7 DN 5-((E)-Styryl)-quinazoline-2,4-diamine
DMH0QA7 HS Investigative
DMH0QA7 SN CHEMBL164845; 5-((E)-Styryl)-quinazoline-2,4-diamine; AC1O6QWN; ZINC5974460; BDBM50036484
DMH0QA7 DT Small molecular drug
DMH0QA7 PC 6532431
DMH0QA7 MW 262.31
DMH0QA7 FM C16H14N4
DMH0QA7 IC InChI=1S/C16H14N4/c17-15-14-12(10-9-11-5-2-1-3-6-11)7-4-8-13(14)19-16(18)20-15/h1-10H,(H4,17,18,19,20)/b10-9+
DMH0QA7 CS C1=CC=C(C=C1)/C=C/C2=C3C(=CC=C2)N=C(N=C3N)N
DMH0QA7 IK YPIDSPOROIRHIL-MDZDMXLPSA-N
DMH0QA7 IU 5-[(E)-2-phenylethenyl]quinazoline-2,4-diamine
DMH0QA7 DE Discovery agent
DMT6D5V ID DMT6D5V
DMT6D5V DN 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine
DMT6D5V HS Investigative
DMT6D5V SN 123642-27-3; AC1O6FAJ; SCHEMBL13092296; 2-[[[(Z)-4-aminobut-2-enyl]-methylamino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DMT6D5V DT Small molecular drug
DMT6D5V PC 6474401
DMT6D5V MW 349.39
DMT6D5V FM C15H23N7O3
DMT6D5V IC InChI=1S/C15H23N7O3/c1-21(5-3-2-4-16)6-9-11(23)12(24)15(25-9)22-8-20-10-13(17)18-7-19-14(10)22/h2-3,7-9,11-12,15,23-24H,4-6,16H2,1H3,(H2,17,18,19)/b3-2-
DMT6D5V CS CN(C/C=C\\CN)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O
DMT6D5V IK YWJCZGDVJQLZET-IHWYPQMZSA-N
DMT6D5V IU 2-[[[(Z)-4-aminobut-2-enyl]-methylamino]methyl]-5-(6-aminopurin-9-yl)oxolane-3,4-diol
DMT6D5V DE Discovery agent
DMS31H9 ID DMS31H9
DMS31H9 DN 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol
DMS31H9 HS Investigative
DMS31H9 SN CHEMBL234207; 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol; SCHEMBL4888568; OYBDWAVFBKZYIO-UHFFFAOYSA-N; BDBM50213139; 5-(1,1-Dimethylheptyl)-2-pyridin-3-yl phenol
DMS31H9 DT Small molecular drug
DMS31H9 PC 11551123
DMS31H9 MW 297.4
DMS31H9 FM C20H27NO
DMS31H9 IC InChI=1S/C20H27NO/c1-4-5-6-7-12-20(2,3)17-10-11-18(19(22)14-17)16-9-8-13-21-15-16/h8-11,13-15,22H,4-7,12H2,1-3H3
DMS31H9 CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2=CN=CC=C2)O
DMS31H9 IK OYBDWAVFBKZYIO-UHFFFAOYSA-N
DMS31H9 IU 5-(2-methyloctan-2-yl)-2-pyridin-3-ylphenol
DMS31H9 DE Discovery agent
DMMSK9W ID DMMSK9W
DMMSK9W DN 5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine
DMMSK9W HS Investigative
DMMSK9W SN CHEMBL190295; 5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine; SCHEMBL11307517; (+/-)6-(2-Phenylethyl)nicotine
DMMSK9W DT Small molecular drug
DMMSK9W PC 11644688
DMMSK9W MW 266.4
DMMSK9W FM C18H22N2
DMMSK9W IC InChI=1S/C18H22N2/c1-20-13-5-8-18(20)16-10-12-17(19-14-16)11-9-15-6-3-2-4-7-15/h2-4,6-7,10,12,14,18H,5,8-9,11,13H2,1H3
DMMSK9W CS CN1CCCC1C2=CN=C(C=C2)CCC3=CC=CC=C3
DMMSK9W IK YJFYNYHEHYBROJ-UHFFFAOYSA-N
DMMSK9W IU 5-(1-methylpyrrolidin-2-yl)-2-(2-phenylethyl)pyridine
DMMSK9W DE Discovery agent
DMA2GIE ID DMA2GIE
DMA2GIE DN 5-(2-(1H-imidazol-1-yl)ethyl)quinoline
DMA2GIE HS Investigative
DMA2GIE SN CHEMBL54803; quinoline 33; BDBM10028; ZINC13808193; 5-[2-(Imidazol-1-yl)ethyl]quinoline; 5-[2-(1H-imidazol-1-yl)ethyl]quinoline
DMA2GIE DT Small molecular drug
DMA2GIE PC 10751574
DMA2GIE MW 223.27
DMA2GIE FM C14H13N3
DMA2GIE IC InChI=1S/C14H13N3/c1-3-12(6-9-17-10-8-15-11-17)13-4-2-7-16-14(13)5-1/h1-5,7-8,10-11H,6,9H2
DMA2GIE CS C1=CC(=C2C=CC=NC2=C1)CCN3C=CN=C3
DMA2GIE IK AVFNKJKCERQPJI-UHFFFAOYSA-N
DMA2GIE IU 5-(2-imidazol-1-ylethyl)quinoline
DMA2GIE DE Discovery agent
DMCFKGW ID DMCFKGW
DMCFKGW DN 5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine
DMCFKGW HS Investigative
DMCFKGW SN CHEMBL453979; 5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine
DMCFKGW DT Small molecular drug
DMCFKGW PC 44560633
DMCFKGW MW 208.26
DMCFKGW FM C14H12N2
DMCFKGW IC InChI=1S/C14H12N2/c1-11-3-4-12(2)14(7-11)6-5-13-8-15-10-16-9-13/h3-4,7-10H,1-2H3
DMCFKGW CS CC1=CC(=C(C=C1)C)C#CC2=CN=CN=C2
DMCFKGW IK XOIZHMAWDAZINA-UHFFFAOYSA-N
DMCFKGW IU 5-[2-(2,5-dimethylphenyl)ethynyl]pyrimidine
DMCFKGW DE Discovery agent
DM3XMKJ ID DM3XMKJ
DM3XMKJ DN 5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine
DM3XMKJ HS Investigative
DM3XMKJ SN CHEMBL488233; 5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine
DM3XMKJ DT Small molecular drug
DM3XMKJ PC 44560631
DM3XMKJ MW 216.19
DM3XMKJ FM C12H6F2N2
DM3XMKJ IC InChI=1S/C12H6F2N2/c13-11-3-9(4-12(14)5-11)1-2-10-6-15-8-16-7-10/h3-8H
DM3XMKJ CS C1=C(C=C(C=C1F)F)C#CC2=CN=CN=C2
DM3XMKJ IK AFBRTODAYUUWDJ-UHFFFAOYSA-N
DM3XMKJ IU 5-[2-(3,5-difluorophenyl)ethynyl]pyrimidine
DM3XMKJ DE Discovery agent
DM37KG6 ID DM37KG6
DM37KG6 DN 5-(2-(3-chlorophenyl)ethynyl)pyrimidine
DM37KG6 HS Investigative
DM37KG6 SN CHEMBL487870; 5-(2-(3-chlorophenyl)ethynyl)pyrimidine; SCHEMBL13732174
DM37KG6 DT Small molecular drug
DM37KG6 PC 24894086
DM37KG6 MW 214.65
DM37KG6 FM C12H7ClN2
DM37KG6 IC InChI=1S/C12H7ClN2/c13-12-3-1-2-10(6-12)4-5-11-7-14-9-15-8-11/h1-3,6-9H
DM37KG6 CS C1=CC(=CC(=C1)Cl)C#CC2=CN=CN=C2
DM37KG6 IK BYUKCJHVLPJKLQ-UHFFFAOYSA-N
DM37KG6 IU 5-[2-(3-chlorophenyl)ethynyl]pyrimidine
DM37KG6 DE Discovery agent
DMRS1Q5 ID DMRS1Q5
DMRS1Q5 DN 5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine
DMRS1Q5 HS Investigative
DMRS1Q5 SN CHEMBL488232; 5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine
DMRS1Q5 DT Small molecular drug
DMRS1Q5 PC 44560630
DMRS1Q5 MW 212.22
DMRS1Q5 FM C13H9FN2
DMRS1Q5 IC InChI=1S/C13H9FN2/c1-10-6-11(4-5-13(10)14)2-3-12-7-15-9-16-8-12/h4-9H,1H3
DMRS1Q5 CS CC1=C(C=CC(=C1)C#CC2=CN=CN=C2)F
DMRS1Q5 IK DCUICHQOGTUMNS-UHFFFAOYSA-N
DMRS1Q5 IU 5-[2-(4-fluoro-3-methylphenyl)ethynyl]pyrimidine
DMRS1Q5 DE Discovery agent
DMXAF7Y ID DMXAF7Y
DMXAF7Y DN 5-(2-(pyrrolidin-1-yl)ethyl)isothiazole
DMXAF7Y HS Investigative
DMXAF7Y SN CHEMBL272131
DMXAF7Y DT Small molecular drug
DMXAF7Y PC 44456451
DMXAF7Y MW 182.29
DMXAF7Y FM C9H14N2S
DMXAF7Y IC InChI=1S/C9H14N2S/c1-2-7-11(6-1)8-4-9-3-5-10-12-9/h3,5H,1-2,4,6-8H2
DMXAF7Y CS C1CCN(C1)CCC2=CC=NS2
DMXAF7Y IK GRXWPIZSBSTAQX-UHFFFAOYSA-N
DMXAF7Y IU 5-(2-pyrrolidin-1-ylethyl)-1,2-thiazole
DMXAF7Y DE Discovery agent
DM149IX ID DM149IX
DM149IX DN 5-(2-1H-indenyl)-1,3-benzodioxole
DM149IX HS Investigative
DM149IX SN CHEMBL229139; 5-(2-1H-indenyl)-1,3-benzodioxole; BDBM50217118
DM149IX DT Small molecular drug
DM149IX PC 44424411
DM149IX MW 236.26
DM149IX FM C16H12O2
DM149IX IC InChI=1S/C16H12O2/c1-2-4-12-8-14(7-11(12)3-1)13-5-6-15-16(9-13)18-10-17-15/h1-7,9H,8,10H2
DM149IX CS C1C2=CC=CC=C2C=C1C3=CC4=C(C=C3)OCO4
DM149IX IK JPKHJTXWUUOHEF-UHFFFAOYSA-N
DM149IX IU 5-(1H-inden-2-yl)-1,3-benzodioxole
DM149IX DE Discovery agent
DMJXI65 ID DMJXI65
DMJXI65 DN 5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide
DMJXI65 HS Investigative
DMJXI65 DE Discovery agent
DMQCYEK ID DMQCYEK
DMQCYEK DN 5-(2-fluorobenzyloxy)quinazoline-2,4-diamine
DMQCYEK HS Investigative
DMQCYEK SN CHEMBL251427; 5-(2-fluorobenzyloxy)quinazoline-2,4-diamine; SCHEMBL1154761
DMQCYEK DT Small molecular drug
DMQCYEK PC 24778025
DMQCYEK MW 284.29
DMQCYEK FM C15H13FN4O
DMQCYEK IC InChI=1S/C15H13FN4O/c16-10-5-2-1-4-9(10)8-21-12-7-3-6-11-13(12)14(17)20-15(18)19-11/h1-7H,8H2,(H4,17,18,19,20)
DMQCYEK CS C1=CC=C(C(=C1)COC2=CC=CC3=C2C(=NC(=N3)N)N)F
DMQCYEK IK SFJOSBAEWKPKPY-UHFFFAOYSA-N
DMQCYEK IU 5-[(2-fluorophenyl)methoxy]quinazoline-2,4-diamine
DMQCYEK DE Discovery agent
DMHBD1T ID DMHBD1T
DMHBD1T DN 5-(2-hydroxyethyl)nonane-1,9-diol
DMHBD1T HS Investigative
DMHBD1T SN 5-(2-Hydroxyethyl)nonane-1,9-Diol; DB07171
DMHBD1T DT Small molecular drug
DMHBD1T PC 25058136
DMHBD1T MW 204.31
DMHBD1T FM C11H24O3
DMHBD1T IC InChI=1S/C11H24O3/c12-8-3-1-5-11(7-10-14)6-2-4-9-13/h11-14H,1-10H2
DMHBD1T CS C(CCO)CC(CCCCO)CCO
DMHBD1T IK VICIXNZSEUYGFV-UHFFFAOYSA-N
DMHBD1T IU 5-(2-hydroxyethyl)nonane-1,9-diol
DMHBD1T DE Discovery agent
DMCP5U8 ID DMCP5U8
DMCP5U8 DN 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline
DMCP5U8 HS Investigative
DMCP5U8 SN CHEMBL293122; dihydroquinoline 31; BDBM10027; ZINC13808192; 5-[2-(Imidazol-1-yl)ethyl]-7,8-dihydroquinoline; 5-[2-(1H-imidazol-1-yl)ethyl]-7,8-dihydroquinoline
DMCP5U8 DT Small molecular drug
DMCP5U8 PC 10561174
DMCP5U8 MW 225.29
DMCP5U8 FM C14H15N3
DMCP5U8 IC InChI=1S/C14H15N3/c1-3-12(6-9-17-10-8-15-11-17)13-4-2-7-16-14(13)5-1/h2-4,7-8,10-11H,1,5-6,9H2
DMCP5U8 CS C1CC2=C(C=CC=N2)C(=C1)CCN3C=CN=C3
DMCP5U8 IK DJMSMHXCSIBVSA-UHFFFAOYSA-N
DMCP5U8 IU 5-(2-imidazol-1-ylethyl)-7,8-dihydroquinoline
DMCP5U8 DE Discovery agent
DMV3KBE ID DMV3KBE
DMV3KBE DN 5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline
DMV3KBE HS Investigative
DMV3KBE SN 1-(5-Isoquinolinylsulfonyl)-2-methylpiperazine; 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 84477-87-2; H-7; 5-(2-methylpiperazine-1-sulfonyl)isoquinoline; H 7; H7; Piperazine, 1-(5-isoquinolinylsulfonyl)-2-methyl-; BRN 5482740; MLS000069615; CHEMBL323556; CHEBI:43385; Isoquinoline,5-[(2-methyl-1-piperazinyl)sulfonyl]-,hydrochloride (1:2); 5-[(2-methylpiperazin-1-yl)sulfonyl]isoquinoline; SMR000058749; Isoquinoline-5-sulfonic 2-methyl-1-piperazide; 5-(2-methylpiperazin-1-yl)sulfonylisoquinoline; Piperazine, 1-(5-isoquino
DMV3KBE DT Small molecular drug
DMV3KBE PC 3542
DMV3KBE MW 291.37
DMV3KBE FM C14H17N3O2S
DMV3KBE IC InChI=1S/C14H17N3O2S/c1-11-9-16-7-8-17(11)20(18,19)14-4-2-3-12-10-15-6-5-13(12)14/h2-6,10-11,16H,7-9H2,1H3
DMV3KBE CS CC1CNCCN1S(=O)(=O)C2=CC=CC3=C2C=CN=C3
DMV3KBE IK BDVFVCGFMNCYPV-UHFFFAOYSA-N
DMV3KBE IU 5-(2-methylpiperazin-1-yl)sulfonylisoquinoline
DMV3KBE CA CAS 84477-87-2
DMV3KBE CB CHEBI:43385
DMV3KBE DE Discovery agent
DMIQJM4 ID DMIQJM4
DMIQJM4 DN 5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4 HS Investigative
DMIQJM4 SN CHEMBL1099113; 5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4 DT Small molecular drug
DMIQJM4 PC 46888045
DMIQJM4 MW 320.4
DMIQJM4 FM C23H16N2
DMIQJM4 IC InChI=1S/C23H16N2/c1-16-7-8-18-9-10-20(14-23(18)25-16)19-11-12-22(21(13-19)15-24)17-5-3-2-4-6-17/h2-14H,1H3
DMIQJM4 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(C=C3)C4=CC=CC=C4)C#N
DMIQJM4 IK AGKCPUQJKJZENU-UHFFFAOYSA-N
DMIQJM4 IU 5-(2-methylquinolin-7-yl)-2-phenylbenzonitrile
DMIQJM4 DE Discovery agent
DMO74HX ID DMO74HX
DMO74HX DN 5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile
DMO74HX HS Investigative
DMO74HX SN CHEMBL1096197; 5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile
DMO74HX DT Small molecular drug
DMO74HX PC 46888089
DMO74HX MW 321.4
DMO74HX FM C22H15N3
DMO74HX IC InChI=1S/C22H15N3/c1-15-7-8-16-9-10-18(12-21(16)25-15)20-11-19(13-23)22(24-14-20)17-5-3-2-4-6-17/h2-12,14H,1H3
DMO74HX CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=C(N=C3)C4=CC=CC=C4)C#N
DMO74HX IK NENPIXNGFVWRLL-UHFFFAOYSA-N
DMO74HX IU 5-(2-methylquinolin-7-yl)-2-phenylpyridine-3-carbonitrile
DMO74HX DE Discovery agent
DMMX69H ID DMMX69H
DMMX69H DN 5-(2-methylquinolin-7-yl)isophthalonitrile
DMMX69H HS Investigative
DMMX69H SN CHEMBL231788; 5-(2-methylquinolin-7-yl)isophthalonitrile; SCHEMBL4304888
DMMX69H DT Small molecular drug
DMMX69H PC 44432677
DMMX69H MW 269.3
DMMX69H FM C18H11N3
DMMX69H IC InChI=1S/C18H11N3/c1-12-2-3-15-4-5-16(9-18(15)21-12)17-7-13(10-19)6-14(8-17)11-20/h2-9H,1H3
DMMX69H CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC(=C3)C#N)C#N
DMMX69H IK KVBFHKKSOXHZCJ-UHFFFAOYSA-N
DMMX69H IU 5-(2-methylquinolin-7-yl)benzene-1,3-dicarbonitrile
DMMX69H DE Discovery agent
DM8LN2X ID DM8LN2X
DM8LN2X DN 5-(2-methylquinolin-7-yl)nicotinonitrile
DM8LN2X HS Investigative
DM8LN2X SN CHEMBL233418; 5-(2-methylquinolin-7-yl)nicotinonitrile
DM8LN2X DT Small molecular drug
DM8LN2X PC 44178396
DM8LN2X MW 245.28
DM8LN2X FM C16H11N3
DM8LN2X IC InChI=1S/C16H11N3/c1-11-2-3-13-4-5-14(7-16(13)19-11)15-6-12(8-17)9-18-10-15/h2-7,9-10H,1H3
DM8LN2X CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CN=CC(=C3)C#N
DM8LN2X IK AYJCNPHACWMDIG-UHFFFAOYSA-N
DM8LN2X IU 5-(2-methylquinolin-7-yl)pyridine-3-carbonitrile
DM8LN2X DE Discovery agent
DMO5WG8 ID DMO5WG8
DMO5WG8 DN 5-(2-m-tolylethynyl)pyrimidine
DMO5WG8 HS Investigative
DMO5WG8 SN 5-(M-Tolylethynyl)Pyrimidine; CHEMBL508497; 5-(2-m-tolylethynyl)pyrimidine
DMO5WG8 DT Small molecular drug
DMO5WG8 PC 24894087
DMO5WG8 MW 194.23
DMO5WG8 FM C13H10N2
DMO5WG8 IC InChI=1S/C13H10N2/c1-11-3-2-4-12(7-11)5-6-13-8-14-10-15-9-13/h2-4,7-10H,1H3
DMO5WG8 CS CC1=CC(=CC=C1)C#CC2=CN=CN=C2
DMO5WG8 IK WDWDORGIXVCIQC-UHFFFAOYSA-N
DMO5WG8 IU 5-[2-(3-methylphenyl)ethynyl]pyrimidine
DMO5WG8 DE Discovery agent
DMR7OHB ID DMR7OHB
DMR7OHB DN 5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile
DMR7OHB HS Investigative
DMR7OHB SN CHEMBL270909
DMR7OHB DT Small molecular drug
DMR7OHB PC 24824217
DMR7OHB MW 223.23
DMR7OHB FM C13H9N3O
DMR7OHB IC InChI=1S/C13H9N3O/c14-7-10-2-4-11(15-10)8-1-3-12-9(5-8)6-13(17)16-12/h1-5,15H,6H2,(H,16,17)
DMR7OHB CS C1C2=C(C=CC(=C2)C3=CC=C(N3)C#N)NC1=O
DMR7OHB IK TVDRXBFEEAXOTN-UHFFFAOYSA-N
DMR7OHB IU 5-(2-oxo-1,3-dihydroindol-5-yl)-1H-pyrrole-2-carbonitrile
DMR7OHB DE Discovery agent
DM07P5E ID DM07P5E
DM07P5E DN 5-(2-phenethylpiperazin-1-yl)-1H-indazole
DM07P5E HS Investigative
DM07P5E SN CHEMBL1170373; 5-(2-phenethylpiperazin-1-yl)-1H-indazole; SCHEMBL2944873
DM07P5E DT Small molecular drug
DM07P5E PC 49798218
DM07P5E MW 306.4
DM07P5E FM C19H22N4
DM07P5E IC InChI=1S/C19H22N4/c1-2-4-15(5-3-1)6-7-18-14-20-10-11-23(18)17-8-9-19-16(12-17)13-21-22-19/h1-5,8-9,12-13,18,20H,6-7,10-11,14H2,(H,21,22)
DM07P5E CS C1CN(C(CN1)CCC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4
DM07P5E IK OOXRIQOVBUMMQG-UHFFFAOYSA-N
DM07P5E IU 5-[2-(2-phenylethyl)piperazin-1-yl]-1H-indazole
DM07P5E DE Discovery agent
DMR35OM ID DMR35OM
DMR35OM DN 5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole
DMR35OM HS Investigative
DMR35OM SN CHEMBL513258; 5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole; SCHEMBL982062
DMR35OM DT Small molecular drug
DMR35OM PC 44230874
DMR35OM MW 294.4
DMR35OM FM C19H19FN2
DMR35OM IC InChI=1S/C19H19FN2/c20-17-4-1-14(2-5-17)12-19(8-10-21-13-19)16-3-6-18-15(11-16)7-9-22-18/h1-7,9,11,21-22H,8,10,12-13H2
DMR35OM CS C1CNCC1(CC2=CC=C(C=C2)F)C3=CC4=C(C=C3)NC=C4
DMR35OM IK RBNFIIOAQFISLC-UHFFFAOYSA-N
DMR35OM IU 5-[3-[(4-fluorophenyl)methyl]pyrrolidin-3-yl]-1H-indole
DMR35OM DE Discovery agent
DMRF0PS ID DMRF0PS
DMRF0PS DN 5-(3,4-dichlorophenyl)-1H-pyrazol-3-ol
DMRF0PS HS Investigative
DMRF0PS SN MLS000066902; SMR000078902; CHEMBL566068; 3-(3,4-Dichlorophenyl)-1H-pyrazol-5-ol; 5-(3,4-dichlorophenyl)-1,2-dihydropyrazol-3-one; AC1LCBRY; cid_598633; BDBM59701; MolPort-002-279-649; ANMVQJHGOQOZLG-UHFFFAOYSA-N; HMS2187N05; KUC104342N; KSC-10-40; 5-(3,4-dichlorophenyl)-3-pyrazolin-3-one; 3-(3,4-Dichlorophenyl)-1H-pyrazol-5-ol #; 2H-Pyrazol-3-ol, 5-(3,4-dichlorophenyl)-; SR-01000617714
DMRF0PS DT Small molecular drug
DMRF0PS PC 598633
DMRF0PS MW 229.06
DMRF0PS FM C9H6Cl2N2O
DMRF0PS IC InChI=1S/C9H6Cl2N2O/c10-6-2-1-5(3-7(6)11)8-4-9(14)13-12-8/h1-4H,(H2,12,13,14)
DMRF0PS CS C1=CC(=C(C=C1C2=CC(=O)NN2)Cl)Cl
DMRF0PS IK ANMVQJHGOQOZLG-UHFFFAOYSA-N
DMRF0PS IU 5-(3,4-dichlorophenyl)-1,2-dihydropyrazol-3-one
DMRF0PS DE Discovery agent
DMZK4AH ID DMZK4AH
DMZK4AH DN 5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix)
DMZK4AH HS Investigative
DMZK4AH SN CHEMBL487355; 5-(3-BENZYLPYRROLIDIN-3-YL)-1H-INDOLE (STRUCTURAL MIX); SCHEMBL982204; UZKWACFLBGIUSH-UHFFFAOYSA-N; BDBM50275438; 5-(3-benzylpyrrolidin-3-yl)-1H-indole; 5-(3-benzyl-pyrrolidin-3-yl)-1H-indole; (-)-5-(3-benzylpyrrolidin-3-yl)-1H-indole
DMZK4AH DT Small molecular drug
DMZK4AH PC 44230732
DMZK4AH MW 276.4
DMZK4AH FM C19H20N2
DMZK4AH IC InChI=1S/C19H20N2/c1-2-4-15(5-3-1)13-19(9-11-20-14-19)17-6-7-18-16(12-17)8-10-21-18/h1-8,10,12,20-21H,9,11,13-14H2
DMZK4AH CS C1CNCC1(CC2=CC=CC=C2)C3=CC4=C(C=C3)NC=C4
DMZK4AH IK UZKWACFLBGIUSH-UHFFFAOYSA-N
DMZK4AH IU 5-(3-benzylpyrrolidin-3-yl)-1H-indole
DMZK4AH DE Discovery agent
DM2ZUFO ID DM2ZUFO
DM2ZUFO DN 5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole
DM2ZUFO HS Investigative
DM2ZUFO SN CHEMBL459176; 5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole; SCHEMBL981431
DM2ZUFO DT Small molecular drug
DM2ZUFO PC 44230733
DM2ZUFO MW 290.4
DM2ZUFO FM C20H22N2
DM2ZUFO IC InChI=1S/C20H22N2/c1-22-12-9-17-13-18(7-8-19(17)22)20(10-11-21-15-20)14-16-5-3-2-4-6-16/h2-9,12-13,21H,10-11,14-15H2,1H3
DM2ZUFO CS CN1C=CC2=C1C=CC(=C2)C3(CCNC3)CC4=CC=CC=C4
DM2ZUFO IK OSXVIZKTSFAUPG-UHFFFAOYSA-N
DM2ZUFO IU 5-(3-benzylpyrrolidin-3-yl)-1-methylindole
DM2ZUFO DE Discovery agent
DMPKGJC ID DMPKGJC
DMPKGJC DN 5-(3-butylpyrrolidin-3-yl)-1H-indole
DMPKGJC HS Investigative
DMPKGJC SN CHEMBL463585; 5-(3-butylpyrrolidin-3-yl)-1H-indole; SCHEMBL983150
DMPKGJC DT Small molecular drug
DMPKGJC PC 25224941
DMPKGJC MW 242.36
DMPKGJC FM C16H22N2
DMPKGJC IC InChI=1S/C16H22N2/c1-2-3-7-16(8-10-17-12-16)14-4-5-15-13(11-14)6-9-18-15/h4-6,9,11,17-18H,2-3,7-8,10,12H2,1H3
DMPKGJC CS CCCCC1(CCNC1)C2=CC3=C(C=C2)NC=C3
DMPKGJC IK FIIZGBLPZZYXCS-UHFFFAOYSA-N
DMPKGJC IU 5-(3-butylpyrrolidin-3-yl)-1H-indole
DMPKGJC DE Discovery agent
DMCR9KX ID DMCR9KX
DMCR9KX DN 5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid
DMCR9KX HS Investigative
DMCR9KX SN CHEMBL394441; 595610-55-2; 1H-Pyrazole-3-carboxylic acid, 5-[(3-chlorophenyl)methyl]-; SCHEMBL569462; 5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid; CTK1D9284; DTXSID30472377; BDBM50216550; AKOS030620128; 5-meta-chlorobenzyl-3-carboxyl-pyrazole; 5-(3-Chlorobenzyl)-1H-pyrazole-3-carboxylic acid; 3-(3-chlorobenzyl)-1H-pyrazole-5-carboxylic acid
DMCR9KX DT Small molecular drug
DMCR9KX PC 11776293
DMCR9KX MW 236.65
DMCR9KX FM C11H9ClN2O2
DMCR9KX IC InChI=1S/C11H9ClN2O2/c12-8-3-1-2-7(4-8)5-9-6-10(11(15)16)14-13-9/h1-4,6H,5H2,(H,13,14)(H,15,16)
DMCR9KX CS C1=CC(=CC(=C1)Cl)CC2=CC(=NN2)C(=O)O
DMCR9KX IK UYMDSFKYOCEPFN-UHFFFAOYSA-N
DMCR9KX IU 5-[(3-chlorophenyl)methyl]-1H-pyrazole-3-carboxylic acid
DMCR9KX CA CAS 595610-55-2
DMCR9KX DE Discovery agent
DMABSOC ID DMABSOC
DMABSOC DN 5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine
DMABSOC HS Investigative
DMABSOC SN CHEMBL390802; 5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine; SCHEMBL4290682; 1,2,4-Triazine, 3-[2-(3-chlorophenyl)ethynyl]-5-methyl-; BDBM50215448; 945915-51-5
DMABSOC DT Small molecular drug
DMABSOC PC 16736031
DMABSOC MW 229.66
DMABSOC FM C12H8ClN3
DMABSOC IC InChI=1S/C12H8ClN3/c1-9-8-14-16-12(15-9)6-5-10-3-2-4-11(13)7-10/h2-4,7-8H,1H3
DMABSOC CS CC1=CN=NC(=N1)C#CC2=CC(=CC=C2)Cl
DMABSOC IK KPQLYWIRBOHKMO-UHFFFAOYSA-N
DMABSOC IU 3-[2-(3-chlorophenyl)ethynyl]-5-methyl-1,2,4-triazine
DMABSOC DE Discovery agent
DMPC9DV ID DMPC9DV
DMPC9DV DN 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMPC9DV HS Investigative
DMPC9DV SN CHEMBL574666; SCHEMBL5613445; BDBM50300481; 5-(3''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMPC9DV DT Small molecular drug
DMPC9DV PC 45483018
DMPC9DV MW 295.3
DMPC9DV FM C18H17NO3
DMPC9DV IC InChI=1S/C18H17NO3/c19-12-14-2-1-3-16(10-14)15-7-4-13(5-8-15)6-9-17(20)11-18(21)22/h1-5,7-8,10,17,20H,6,9,11H2,(H,21,22)
DMPC9DV CS C1=CC(=CC(=C1)C2=CC=C(C=C2)CCC(CC(=O)O)O)C#N
DMPC9DV IK WILNYVYWCSPWAP-UHFFFAOYSA-N
DMPC9DV IU 5-[4-(3-cyanophenyl)phenyl]-3-hydroxypentanoic acid
DMPC9DV DE Discovery agent
DM2H9ND ID DM2H9ND
DM2H9ND DN 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
DM2H9ND HS Investigative
DM2H9ND SN 3-(5-Mercapto-[1,3,4]oxadiazol-2-yl)-phenol; 3-(5-mercapto-1,3,4-oxadiazol-2-yl)phenol; 299465-12-6; 3-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenol; CHEMBL595356; 3-(5-Mercapto-1,3,4-Oxadiazol-2-Yl)-Phenol; AO-365/08835025; 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione; 5-[3-Hydroxyphenyl]-1,3,4-oxadiazole-2(3H)-thione; NSC524085; AC1LF1GV; Oprea1_836042; CTK8F4715; CTK8A0072; MolPort-000-932-334; ZX-AN016552; ZINC1605604; BB_SC-06098; CCG-15357; STK506749; FCH842308; BDBM50320729; BBL000571; AKOS000564154; FCH2245445; NSC-524085
DM2H9ND DT Small molecular drug
DM2H9ND PC 745318
DM2H9ND MW 194.21
DM2H9ND FM C8H6N2O2S
DM2H9ND IC InChI=1S/C8H6N2O2S/c11-6-3-1-2-5(4-6)7-9-10-8(13)12-7/h1-4,11H,(H,10,13)
DM2H9ND CS C1=CC(=CC(=C1)O)C2=NNC(=S)O2
DM2H9ND IK CNOGHDSTUCQSOV-UHFFFAOYSA-N
DM2H9ND IU 5-(3-hydroxyphenyl)-3H-1,3,4-oxadiazole-2-thione
DM2H9ND DE Discovery agent
DMPCFA6 ID DMPCFA6
DMPCFA6 DN 5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid
DMPCFA6 HS Investigative
DMPCFA6 SN CHEMBL129326; 5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid; ZINC13526614
DMPCFA6 DT Small molecular drug
DMPCFA6 PC 11746440
DMPCFA6 MW 230.26
DMPCFA6 FM C13H14N2O2
DMPCFA6 IC InChI=1S/C13H14N2O2/c16-13(17)12-9-11(14-15-12)8-4-7-10-5-2-1-3-6-10/h1-3,5-6,9H,4,7-8H2,(H,14,15)(H,16,17)
DMPCFA6 CS C1=CC=C(C=C1)CCCC2=CC(=NN2)C(=O)O
DMPCFA6 IK JDCXDGHZXKZHQL-UHFFFAOYSA-N
DMPCFA6 IU 5-(3-phenylpropyl)-1H-pyrazole-3-carboxylic acid
DMPCFA6 DE Discovery agent
DMZYE8W ID DMZYE8W
DMZYE8W DN 5-(4-((phenethylamino)methyl)phenoxy)picolinamide
DMZYE8W HS Investigative
DMZYE8W SN CHEMBL236376; 5-(4-((phenethylamino)methyl)phenoxy)picolinamide; SCHEMBL3771658
DMZYE8W DT Small molecular drug
DMZYE8W PC 44434951
DMZYE8W MW 347.4
DMZYE8W FM C21H21N3O2
DMZYE8W IC InChI=1S/C21H21N3O2/c22-21(25)20-11-10-19(15-24-20)26-18-8-6-17(7-9-18)14-23-13-12-16-4-2-1-3-5-16/h1-11,15,23H,12-14H2,(H2,22,25)
DMZYE8W CS C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=CN=C(C=C3)C(=O)N
DMZYE8W IK RDWUBDSRHFANBO-UHFFFAOYSA-N
DMZYE8W IU 5-[4-[(2-phenylethylamino)methyl]phenoxy]pyridine-2-carboxamide
DMZYE8W DE Discovery agent
DM6KSN9 ID DM6KSN9
DM6KSN9 DN 5-(4'-benzoylbiphenyl-4-yl)-2-furoic acid
DM6KSN9 HS Investigative
DM6KSN9 SN CHEMBL222717
DM6KSN9 DT Small molecular drug
DM6KSN9 PC 16202985
DM6KSN9 MW 368.4
DM6KSN9 FM C24H16O4
DM6KSN9 IC InChI=1S/C24H16O4/c25-23(19-4-2-1-3-5-19)20-12-8-17(9-13-20)16-6-10-18(11-7-16)21-14-15-22(28-21)24(26)27/h1-15H,(H,26,27)
DM6KSN9 CS C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)C4=CC=C(O4)C(=O)O
DM6KSN9 IK UKLDRYNCWUIPPD-UHFFFAOYSA-N
DM6KSN9 IU 5-[4-(4-benzoylphenyl)phenyl]furan-2-carboxylic acid
DM6KSN9 DE Discovery agent
DMT4856 ID DMT4856
DMT4856 DN 5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone
DMT4856 HS Investigative
DMT4856 SN 5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone; AC1LF4XJ; CTK7D4016; AKOS017263438; MCULE-1426418015
DMT4856 DT Small molecular drug
DMT4856 PC 6870109
DMT4856 MW 324.2
DMT4856 FM C12H10BrN3OS
DMT4856 IC InChI=1S/C12H10BrN3OS/c13-9-3-1-8(2-4-9)11-6-5-10(17-11)7-15-16-12(14)18/h1-7H,(H3,14,16,18)/b15-7+
DMT4856 CS C1=CC(=CC=C1C2=CC=C(O2)/C=N/NC(=S)N)Br
DMT4856 IK ZCUMFDMDQURMSL-VIZOYTHASA-N
DMT4856 IU [(E)-[5-(4-bromophenyl)furan-2-yl]methylideneamino]thiourea
DMT4856 DE Discovery agent
DMDCNZE ID DMDCNZE
DMDCNZE DN 5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid
DMDCNZE HS Investigative
DMDCNZE SN CHEMBL341520; 5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid; 1H-Pyrazole-3-carboxylic acid, 5-[(4-chlorophenyl)methyl]-; BDBM50132144
DMDCNZE DT Small molecular drug
DMDCNZE PC 10857469
DMDCNZE MW 236.65
DMDCNZE FM C11H9ClN2O2
DMDCNZE IC InChI=1S/C11H9ClN2O2/c12-8-3-1-7(2-4-8)5-9-6-10(11(15)16)14-13-9/h1-4,6H,5H2,(H,13,14)(H,15,16)
DMDCNZE CS C1=CC(=CC=C1CC2=CC(=NN2)C(=O)O)Cl
DMDCNZE IK YKKXGQMJMUSFFP-UHFFFAOYSA-N
DMDCNZE IU 5-[(4-chlorophenyl)methyl]-1H-pyrazole-3-carboxylic acid
DMDCNZE CA CAS 595610-52-9
DMDCNZE DE Discovery agent
DMJKAF0 ID DMJKAF0
DMJKAF0 DN 5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one
DMJKAF0 HS Investigative
DMJKAF0 SN CHEMBL294630; 5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one; BDBM50091709
DMJKAF0 DT Small molecular drug
DMJKAF0 PC 12012177
DMJKAF0 MW 223.7
DMJKAF0 FM C12H14ClNO
DMJKAF0 IC InChI=1S/C12H14ClNO/c1-14-8-10(4-7-12(14)15)9-2-5-11(13)6-3-9/h2-3,5-6,10H,4,7-8H2,1H3
DMJKAF0 CS CN1CC(CCC1=O)C2=CC=C(C=C2)Cl
DMJKAF0 IK QCCANQQHOCXGTL-UHFFFAOYSA-N
DMJKAF0 IU 5-(4-chlorophenyl)-1-methylpiperidin-2-one
DMJKAF0 DE Discovery agent
DMQB1UI ID DMQB1UI
DMQB1UI DN 5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione
DMQB1UI HS Investigative
DMQB1UI SN CHEMBL56517; 5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione; BDBM50091711
DMQB1UI DT Small molecular drug
DMQB1UI PC 12012178
DMQB1UI MW 239.76
DMQB1UI FM C12H14ClNS
DMQB1UI IC InChI=1S/C12H14ClNS/c1-14-8-10(4-7-12(14)15)9-2-5-11(13)6-3-9/h2-3,5-6,10H,4,7-8H2,1H3
DMQB1UI CS CN1CC(CCC1=S)C2=CC=C(C=C2)Cl
DMQB1UI IK FTCLELCCXKHRQL-UHFFFAOYSA-N
DMQB1UI IU 5-(4-chlorophenyl)-1-methylpiperidine-2-thione
DMQB1UI DE Discovery agent
DMSTG03 ID DMSTG03
DMSTG03 DN 5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole
DMSTG03 HS Investigative
DMSTG03 SN CHEMBL491089; 5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole
DMSTG03 DT Small molecular drug
DMSTG03 PC 44564457
DMSTG03 MW 301.8
DMSTG03 FM C16H12ClNOS
DMSTG03 IC InChI=1S/C16H12ClNOS/c1-19-14-8-4-11(5-9-14)15-10-18-20-16(15)12-2-6-13(17)7-3-12/h2-10H,1H3
DMSTG03 CS COC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)Cl
DMSTG03 IK XGOLGQNTCHMSDA-UHFFFAOYSA-N
DMSTG03 IU 5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1,2-thiazole
DMSTG03 DE Discovery agent
DMY0P86 ID DMY0P86
DMY0P86 DN 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole
DMY0P86 HS Investigative
DMY0P86 SN CHEMBL513405; 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole
DMY0P86 DT Small molecular drug
DMY0P86 PC 24884692
DMY0P86 MW 332.7
DMY0P86 FM C16H12ClNSe
DMY0P86 IC InChI=1S/C16H12ClNSe/c1-11-2-4-12(5-3-11)15-10-18-19-16(15)13-6-8-14(17)9-7-13/h2-10H,1H3
DMY0P86 CS CC1=CC=C(C=C1)C2=C([Se]N=C2)C3=CC=C(C=C3)Cl
DMY0P86 IK SIYWUUCHURNUOK-UHFFFAOYSA-N
DMY0P86 IU 5-(4-chlorophenyl)-4-(4-methylphenyl)-1,2-selenazole
DMY0P86 DE Discovery agent
DMFYEL8 ID DMFYEL8
DMFYEL8 DN 5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one
DMFYEL8 HS Investigative
DMFYEL8 SN CHEMBL475545; 5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one
DMFYEL8 DT Small molecular drug
DMFYEL8 PC 44564003
DMFYEL8 MW 318.8
DMFYEL8 FM C16H11ClOS2
DMFYEL8 IC InChI=1S/C16H11ClOS2/c1-10-2-4-11(5-3-10)14-15(19-20-16(14)18)12-6-8-13(17)9-7-12/h2-9H,1H3
DMFYEL8 CS CC1=CC=C(C=C1)C2=C(SSC2=O)C3=CC=C(C=C3)Cl
DMFYEL8 IK CUFDVUQUYHTZLD-UHFFFAOYSA-N
DMFYEL8 IU 5-(4-chlorophenyl)-4-(4-methylphenyl)dithiol-3-one
DMFYEL8 DE Discovery agent
DMA1N75 ID DMA1N75
DMA1N75 DN 5-(4-Chlorophenyl)-4-p-tolylisothiazole
DMA1N75 HS Investigative
DMA1N75 SN CHEMBL524133; 5-(4-Chlorophenyl)-4-p-tolylisothiazole
DMA1N75 DT Small molecular drug
DMA1N75 PC 44564454
DMA1N75 MW 285.8
DMA1N75 FM C16H12ClNS
DMA1N75 IC InChI=1S/C16H12ClNS/c1-11-2-4-12(5-3-11)15-10-18-19-16(15)13-6-8-14(17)9-7-13/h2-10H,1H3
DMA1N75 CS CC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)Cl
DMA1N75 IK LELNOQBBNOVPJP-UHFFFAOYSA-N
DMA1N75 IU 5-(4-chlorophenyl)-4-(4-methylphenyl)-1,2-thiazole
DMA1N75 DE Discovery agent
DMV7HA1 ID DMV7HA1
DMV7HA1 DN 5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide
DMV7HA1 HS Investigative
DMV7HA1 SN CHEMBL1269882; 5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide
DMV7HA1 DT Small molecular drug
DMV7HA1 PC 52945923
DMV7HA1 MW 336.8
DMV7HA1 FM C20H17ClN2O
DMV7HA1 IC InChI=1S/C20H17ClN2O/c1-14-4-2-3-5-16(14)13-23-20(24)18-10-17(11-22-12-18)15-6-8-19(21)9-7-15/h2-12H,13H2,1H3,(H,23,24)
DMV7HA1 CS CC1=CC=CC=C1CNC(=O)C2=CN=CC(=C2)C3=CC=C(C=C3)Cl
DMV7HA1 IK MLDMXXWILKZITA-UHFFFAOYSA-N
DMV7HA1 IU 5-(4-chlorophenyl)-N-[(2-methylphenyl)methyl]pyridine-3-carboxamide
DMV7HA1 DE Discovery agent
DM6CRVS ID DM6CRVS
DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide
DM6CRVS HS Investigative
DM6CRVS SN CHEMBL84288
DM6CRVS DT Small molecular drug
DM6CRVS PC 11528707
DM6CRVS MW 227.69
DM6CRVS FM C11H14ClNO2
DM6CRVS IC InChI=1S/C11H14ClNO2/c12-10-7-5-9(6-8-10)3-1-2-4-11(14)13-15/h5-8,15H,1-4H2,(H,13,14)
DM6CRVS CS C1=CC(=CC=C1CCCCC(=O)NO)Cl
DM6CRVS IK PRMXJXDYJXBBPT-UHFFFAOYSA-N
DM6CRVS IU 5-(4-chlorophenyl)-N-hydroxypentanamide
DM6CRVS DE Discovery agent
DMTDNX3 ID DMTDNX3
DMTDNX3 DN 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMTDNX3 HS Investigative
DMTDNX3 SN CHEMBL583588; SCHEMBL5613483; BDBM50300472; 5-(4''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
DMTDNX3 DT Small molecular drug
DMTDNX3 PC 44626352
DMTDNX3 MW 295.3
DMTDNX3 FM C18H17NO3
DMTDNX3 IC InChI=1S/C18H17NO3/c19-12-14-3-8-16(9-4-14)15-6-1-13(2-7-15)5-10-17(20)11-18(21)22/h1-4,6-9,17,20H,5,10-11H2,(H,21,22)
DMTDNX3 CS C1=CC(=CC=C1CCC(CC(=O)O)O)C2=CC=C(C=C2)C#N
DMTDNX3 IK YDAZWMGCTBJQEO-UHFFFAOYSA-N
DMTDNX3 IU 5-[4-(4-cyanophenyl)phenyl]-3-hydroxypentanoic acid
DMTDNX3 DE Discovery agent
DMISOLU ID DMISOLU
DMISOLU DN 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid
DMISOLU HS Investigative
DMISOLU SN CHEMBL216668; 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid
DMISOLU DT Small molecular drug
DMISOLU PC 44418518
DMISOLU MW 269.29
DMISOLU FM C16H15NO3
DMISOLU IC InChI=1S/C16H15NO3/c1-10-5-14(18)6-11(2)15(10)4-3-12-7-13(16(19)20)9-17-8-12/h3-9,18H,1-2H3,(H,19,20)/b4-3+
DMISOLU CS CC1=CC(=CC(=C1/C=C/C2=CC(=CN=C2)C(=O)O)C)O
DMISOLU IK QHRQJLLCYNFCCT-ONEGZZNKSA-N
DMISOLU IU 5-[(E)-2-(4-hydroxy-2,6-dimethylphenyl)ethenyl]pyridine-3-carboxylic acid
DMISOLU DE Discovery agent
DMB2GLE ID DMB2GLE
DMB2GLE DN 5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
DMB2GLE HS Investigative
DMB2GLE DT Small molecular drug
DMB2GLE PC 739395
DMB2GLE MW 194.21
DMB2GLE FM C8H6N2O2S
DMB2GLE IC InChI=1S/C8H6N2O2S/c11-6-3-1-5(2-4-6)7-9-10-8(13)12-7/h1-4,11H,(H,10,13)
DMB2GLE CS C1=CC(=CC=C1C2=NNC(=S)O2)O
DMB2GLE IK NGBOFOYNPCHKQQ-UHFFFAOYSA-N
DMB2GLE IU 5-(4-hydroxyphenyl)-3H-1,3,4-oxadiazole-2-thione
DMB2GLE CA CAS 69829-90-9
DMB2GLE DE Discovery agent
DM7KQXL ID DM7KQXL
DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione
DM7KQXL HS Investigative
DM7KQXL DT Small molecular drug
DM7KQXL PC 3082127
DM7KQXL MW 226.3
DM7KQXL FM C9H6OS3
DM7KQXL IC InChI=1S/C9H6OS3/c10-7-3-1-6(2-4-7)8-5-9(11)13-12-8/h1-5,10H
DM7KQXL CS C1=CC(=CC=C1C2=CC(=S)SS2)O
DM7KQXL IK IWBBKLMHAILHAR-UHFFFAOYSA-N
DM7KQXL IU 5-(4-hydroxyphenyl)dithiole-3-thione
DM7KQXL CA CAS 18274-81-2
DM7KQXL DE Discovery agent
DM3SQEY ID DM3SQEY
DM3SQEY DN 5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine
DM3SQEY HS Investigative
DM3SQEY SN 5-(4-METHOXYPHENOXY)-2,4-QUINAZOLINEDIAMINE; 5-(4-methoxyphenoxy)quinazoline-2,4-diamine; AC1L9KGI; SCHEMBL2128429
DM3SQEY DT Small molecular drug
DM3SQEY PC 447098
DM3SQEY MW 282.3
DM3SQEY FM C15H14N4O2
DM3SQEY IC InChI=1S/C15H14N4O2/c1-20-9-5-7-10(8-6-9)21-12-4-2-3-11-13(12)14(16)19-15(17)18-11/h2-8H,1H3,(H4,16,17,18,19)
DM3SQEY CS COC1=CC=C(C=C1)OC2=CC=CC3=C2C(=NC(=N3)N)N
DM3SQEY IK CPZJZAIZIMCJRC-UHFFFAOYSA-N
DM3SQEY IU 5-(4-methoxyphenoxy)quinazoline-2,4-diamine
DM3SQEY DE Discovery agent
DMCMNKA ID DMCMNKA
DMCMNKA DN 5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole
DMCMNKA HS Investigative
DMCMNKA SN benzimidazole 2; AC1NS6L8; CHEMBL81026; SCHEMBL7683792; BDBM5295; MolPort-028-745-333; ZINC13536068; 5-(4-methoxyphenyl)-1-phenylbenzimidazole; 1-Phenyl-5-(4-methoxyphenyl)-1H-benzimidazole
DMCMNKA DT Small molecular drug
DMCMNKA PC 5329338
DMCMNKA MW 300.4
DMCMNKA FM C20H16N2O
DMCMNKA IC InChI=1S/C20H16N2O/c1-23-18-10-7-15(8-11-18)16-9-12-20-19(13-16)21-14-22(20)17-5-3-2-4-6-17/h2-14H,1H3
DMCMNKA CS COC1=CC=C(C=C1)C2=CC3=C(C=C2)N(C=N3)C4=CC=CC=C4
DMCMNKA IK OPGUZRRLMQSMAQ-UHFFFAOYSA-N
DMCMNKA IU 5-(4-methoxyphenyl)-1-phenylbenzimidazole
DMCMNKA DE Discovery agent
DMEV8WS ID DMEV8WS
DMEV8WS DN 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole
DMEV8WS HS Investigative
DMEV8WS SN CHEMBL452730; 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole
DMEV8WS DT Small molecular drug
DMEV8WS PC 24884691
DMEV8WS MW 328.3
DMEV8WS FM C17H15NOSe
DMEV8WS IC InChI=1S/C17H15NOSe/c1-12-3-5-13(6-4-12)16-11-18-20-17(16)14-7-9-15(19-2)10-8-14/h3-11H,1-2H3
DMEV8WS CS CC1=CC=C(C=C1)C2=C([Se]N=C2)C3=CC=C(C=C3)OC
DMEV8WS IK ZTXIFGCFDLCGKN-UHFFFAOYSA-N
DMEV8WS IU 5-(4-methoxyphenyl)-4-(4-methylphenyl)-1,2-selenazole
DMEV8WS DE Discovery agent
DMJSTCK ID DMJSTCK
DMJSTCK DN 5-(4-Methoxyphenyl)-4-p-tolylisothiazole
DMJSTCK HS Investigative
DMJSTCK SN CHEMBL514950; 5-(4-Methoxyphenyl)-4-p-tolylisothiazole
DMJSTCK DT Small molecular drug
DMJSTCK PC 44564416
DMJSTCK MW 281.4
DMJSTCK FM C17H15NOS
DMJSTCK IC InChI=1S/C17H15NOS/c1-12-3-5-13(6-4-12)16-11-18-20-17(16)14-7-9-15(19-2)10-8-14/h3-11H,1-2H3
DMJSTCK CS CC1=CC=C(C=C1)C2=C(SN=C2)C3=CC=C(C=C3)OC
DMJSTCK IK KPYJYWIFJYUIBB-UHFFFAOYSA-N
DMJSTCK IU 5-(4-methoxyphenyl)-4-(4-methylphenyl)-1,2-thiazole
DMJSTCK DE Discovery agent
DMNSIF2 ID DMNSIF2
DMNSIF2 DN 5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole
DMNSIF2 HS Investigative
DMNSIF2 SN CHEMBL1276926; 5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole
DMNSIF2 DT Small molecular drug
DMNSIF2 PC 49836621
DMNSIF2 MW 370.5
DMNSIF2 FM C19H22N4O2S
DMNSIF2 IC InChI=1S/C19H22N4O2S/c1-14-3-6-16(7-4-14)26(24,25)19-17-13-15(5-8-18(17)20-21-19)23-11-9-22(2)10-12-23/h3-8,13H,9-12H2,1-2H3,(H,20,21)
DMNSIF2 CS CC1=CC=C(C=C1)S(=O)(=O)C2=C3C=C(C=CC3=NN2)N4CCN(CC4)C
DMNSIF2 IK DAXBNFVWZYVXTC-UHFFFAOYSA-N
DMNSIF2 IU 3-(4-methylphenyl)sulfonyl-5-(4-methylpiperazin-1-yl)-2H-indazole
DMNSIF2 DE Discovery agent
DM05OMF ID DM05OMF
DM05OMF DN 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione
DM05OMF HS Investigative
DM05OMF SN CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione
DM05OMF DT Small molecular drug
DM05OMF PC 53742316
DM05OMF MW 296.28
DM05OMF FM C16H12N2O4
DM05OMF IC InChI=1S/C16H12N2O4/c19-14-13(15(20)18-16(21)17-14)10-6-8-12(9-7-10)22-11-4-2-1-3-5-11/h1-9H,(H3,17,18,19,20,21)
DM05OMF CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=C(NC(=O)NC3=O)O
DM05OMF IK CVMFBMDAPZFQBR-UHFFFAOYSA-N
DM05OMF IU 6-hydroxy-5-(4-phenoxyphenyl)-1H-pyrimidine-2,4-dione
DM05OMF DE Discovery agent
DM3QFCV ID DM3QFCV
DM3QFCV DN 5-(4-Phenylbutoxy)psoralen
DM3QFCV HS Investigative
DM3QFCV SN 4-(4-Phenylbutoxy)furo[3,2-g]chromen-7-one; Psora-4; Psora 4; 724709-68-6; 4-(4-phenylbutoxy)furo[3,2-g]chromen-7-one; CHEMBL1256851; 4-(4-Phenylbutoxy)-7H-furo[3,2-g]chromen-7-one; 4-(4-Phenylbutoxy)-7H-furo[3,2-g][1]benzopyran-7-one; NCGC00015863-01; Lopac-P-9872; SCHEMBL2801777; GTPL9583; AC1O7G66; CTK8F0317; DTXSID10424970; MolPort-023-277-165; HMS3260K16; ZINC7997390; Psora-4, > Tox21_500137; BDBM50331458; AKOS024458119; LP00137; CCG-204232; NCGC00015863-02; NCGC00015863-03; NCGC00093627-02; NCGC00260822-01; NCGC00093627-01
DM3QFCV DT Small molecular drug
DM3QFCV PC 6603977
DM3QFCV MW 334.4
DM3QFCV FM C21H18O4
DM3QFCV IC InChI=1S/C21H18O4/c22-20-10-9-16-19(25-20)14-18-17(11-13-23-18)21(16)24-12-5-4-8-15-6-2-1-3-7-15/h1-3,6-7,9-11,13-14H,4-5,8,12H2
DM3QFCV CS C1=CC=C(C=C1)CCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
DM3QFCV IK JJAWGNIQEOFURP-UHFFFAOYSA-N
DM3QFCV IU 4-(4-phenylbutoxy)furo[3,2-g]chromen-7-one
DM3QFCV CA CAS 724709-68-6
DM3QFCV DE Discovery agent
DMZ7K5G ID DMZ7K5G
DMZ7K5G DN 5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G HS Investigative
DMZ7K5G SN CHEMBL382791; 5-(4-piperidyl)-4-propylisothiazol-3-ol
DMZ7K5G DT Small molecular drug
DMZ7K5G PC 11515063
DMZ7K5G MW 226.34
DMZ7K5G FM C11H18N2OS
DMZ7K5G IC InChI=1S/C11H18N2OS/c1-2-3-9-10(15-13-11(9)14)8-4-6-12-7-5-8/h8,12H,2-7H2,1H3,(H,13,14)
DMZ7K5G CS CCCC1=C(SNC1=O)C2CCNCC2
DMZ7K5G IK INIXNNKFVDXPBJ-UHFFFAOYSA-N
DMZ7K5G IU 5-piperidin-4-yl-4-propyl-1,2-thiazol-3-one
DMZ7K5G DE Discovery agent
DMVMBG0 ID DMVMBG0
DMVMBG0 DN 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one
DMVMBG0 HS Investigative
DMVMBG0 SN CHEMBL66981; SCHEMBL8176516; 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one; ZINC9633633; BDBM50039067
DMVMBG0 DT Small molecular drug
DMVMBG0 PC 11778521
DMVMBG0 MW 282.29
DMVMBG0 FM C16H14N2O3
DMVMBG0 IC InChI=1S/C16H14N2O3/c1-20-14-6-11-5-12(10-3-4-16(19)18-8-10)9-17-13(11)7-15(14)21-2/h3-9H,1-2H3,(H,18,19)
DMVMBG0 CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CNC(=O)C=C3
DMVMBG0 IK RWZAFECYIQQVPG-UHFFFAOYSA-N
DMVMBG0 IU 5-(6,7-dimethoxyquinolin-3-yl)-1H-pyridin-2-one
DMVMBG0 DE Discovery agent
DM0K7U5 ID DM0K7U5
DM0K7U5 DN 5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid
DM0K7U5 HS Investigative
DM0K7U5 SN compound 39 [PMID: 23581530]
DM0K7U5 DT Small molecular drug
DM0K7U5 PC 71655222
DM0K7U5 MW 349.8
DM0K7U5 FM C19H24ClNO3
DM0K7U5 IC InChI=1S/C19H24ClNO3/c1-2-3-4-5-7-16-12-14-10-11-15(20)13-17(14)21(16)18(22)8-6-9-19(23)24/h10-13H,2-9H2,1H3,(H,23,24)
DM0K7U5 CS CCCCCCC1=CC2=C(N1C(=O)CCCC(=O)O)C=C(C=C2)Cl
DM0K7U5 IK KNTPSPKZGNVRML-UHFFFAOYSA-N
DM0K7U5 IU 5-(6-chloro-2-hexylindol-1-yl)-5-oxopentanoic acid
DM0K7U5 DE Discovery agent
DMIB9AX ID DMIB9AX
DMIB9AX DN 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol
DMIB9AX HS Investigative
DMIB9AX SN CHEMBL246045; 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol; BDBM50197243
DMIB9AX DT Small molecular drug
DMIB9AX PC 25062609
DMIB9AX MW 268.26
DMIB9AX FM C16H12O4
DMIB9AX IC InChI=1S/C16H12O4/c17-13-4-3-9-5-10(1-2-11(9)6-13)12-7-14(18)16(20)15(19)8-12/h1-8,17-20H
DMIB9AX CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C(=C3)O)O)O
DMIB9AX IK PBTSXIZGBMXUHW-UHFFFAOYSA-N
DMIB9AX IU 5-(6-hydroxynaphthalen-2-yl)benzene-1,2,3-triol
DMIB9AX DE Discovery agent
DMJWIPS ID DMJWIPS
DMJWIPS DN 5-(6-hydroxy-2-naphthyl)pyridin-3-ol
DMJWIPS HS Investigative
DMJWIPS SN CHEMBL261427; SCHEMBL3002838; RTRRNSMMHNFJIV-UHFFFAOYSA-N; BDBM50373034
DMJWIPS DT Small molecular drug
DMJWIPS PC 24827431
DMJWIPS MW 237.25
DMJWIPS FM C15H11NO2
DMJWIPS IC InChI=1S/C15H11NO2/c17-14-4-3-10-5-11(1-2-12(10)6-14)13-7-15(18)9-16-8-13/h1-9,17-18H
DMJWIPS CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=CN=C3)O
DMJWIPS IK RTRRNSMMHNFJIV-UHFFFAOYSA-N
DMJWIPS IU 5-(6-hydroxynaphthalen-2-yl)pyridin-3-ol
DMJWIPS DE Discovery agent
DMJRBKO ID DMJRBKO
DMJRBKO DN 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DMJRBKO HS Investigative
DMJRBKO SN CHEMBL197892; 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol; SCHEMBL1741908; ZINC28527773; BDBM50186767; 5-(6-hydroxy-2-naphthyl)benzene-1,3-diol; 5-(6-Hydroxy-naphthalen-2-yl)-benzene-1,3-diol
DMJRBKO DT Small molecular drug
DMJRBKO PC 11514345
DMJRBKO MW 252.26
DMJRBKO FM C16H12O3
DMJRBKO IC InChI=1S/C16H12O3/c17-14-4-3-10-5-11(1-2-12(10)6-14)13-7-15(18)9-16(19)8-13/h1-9,17-19H
DMJRBKO CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=CC(=C3)O)O
DMJRBKO IK CKQUMNKKOYTAST-UHFFFAOYSA-N
DMJRBKO IU 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol
DMJRBKO DE Discovery agent
DMMPAWD ID DMMPAWD
DMMPAWD DN 5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol
DMMPAWD HS Investigative
DMMPAWD SN CHEMBL500636; 5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol; ZINC40425010
DMMPAWD DT Small molecular drug
DMMPAWD PC 25034344
DMMPAWD MW 251.28
DMMPAWD FM C16H13NO2
DMMPAWD IC InChI=1S/C16H13NO2/c1-19-16-5-4-11-6-12(2-3-13(11)8-16)14-7-15(18)10-17-9-14/h2-10,18H,1H3
DMMPAWD CS COC1=CC2=C(C=C1)C=C(C=C2)C3=CC(=CN=C3)O
DMMPAWD IK YXTBYYAJCILARD-UHFFFAOYSA-N
DMMPAWD IU 5-(6-methoxynaphthalen-2-yl)pyridin-3-ol
DMMPAWD DE Discovery agent
DMGIO3R ID DMGIO3R
DMGIO3R DN 5-(azepan-1-ylsulfonyl)indoline-2,3-dione
DMGIO3R HS Investigative
DMGIO3R SN 1H-Azepine, 1-[(2,3-dihydro-2,3-dioxo-1H-indol-5-yl)sulfonyl]hexahydro-; 220510-14-5; Isatin Sulfonamide 22; 5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione; CHEMBL302461; SCHEMBL6535562; CTK0I8877; BDBM10311; DTXSID20431675; 5-(azepane-1-sulfonyl)-2,3-dihydro-1H-indole-2,3-dione
DMGIO3R DT Small molecular drug
DMGIO3R PC 9839586
DMGIO3R MW 308.35
DMGIO3R FM C14H16N2O4S
DMGIO3R IC InChI=1S/C14H16N2O4S/c17-13-11-9-10(5-6-12(11)15-14(13)18)21(19,20)16-7-3-1-2-4-8-16/h5-6,9H,1-4,7-8H2,(H,15,17,18)
DMGIO3R CS C1CCCN(CC1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMGIO3R IK MLWAHVYFMDBXBL-UHFFFAOYSA-N
DMGIO3R IU 5-(azepan-1-ylsulfonyl)-1H-indole-2,3-dione
DMGIO3R CA CAS 220510-14-5
DMGIO3R DE Discovery agent
DMJIVLY ID DMJIVLY
DMJIVLY DN 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione
DMJIVLY HS Investigative
DMJIVLY SN 5-[1-(Azetidinyl)sulfonyl]isatin; Isatin Sulfonamide 19; 1H-Indole-2,3-dione, 5-(1-azetidinylsulfonyl)-; CHEMBL64789; SCHEMBL6535690; BDBM10308; 220510-08-7; 5-(Azetidine-1-ylsulfonyl)indoline-2,3-dione
DMJIVLY DT Small molecular drug
DMJIVLY PC 9903426
DMJIVLY MW 266.28
DMJIVLY FM C11H10N2O4S
DMJIVLY IC InChI=1S/C11H10N2O4S/c14-10-8-6-7(2-3-9(8)12-11(10)15)18(16,17)13-4-1-5-13/h2-3,6H,1,4-5H2,(H,12,14,15)
DMJIVLY CS C1CN(C1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMJIVLY IK VEHTUFDNCGHBFH-UHFFFAOYSA-N
DMJIVLY IU 5-(azetidin-1-ylsulfonyl)-1H-indole-2,3-dione
DMJIVLY DE Discovery agent
DMJAG7M ID DMJAG7M
DMJAG7M DN 5-(biphenyl-4-yl)-3-methoxypentanoic acid
DMJAG7M HS Investigative
DMJAG7M SN CHEMBL583771; 5-(biphenyl-4-yl)-3-methoxypentanoic acid
DMJAG7M DT Small molecular drug
DMJAG7M PC 45482998
DMJAG7M MW 284.3
DMJAG7M FM C18H20O3
DMJAG7M IC InChI=1S/C18H20O3/c1-21-17(13-18(19)20)12-9-14-7-10-16(11-8-14)15-5-3-2-4-6-15/h2-8,10-11,17H,9,12-13H2,1H3,(H,19,20)
DMJAG7M CS COC(CCC1=CC=C(C=C1)C2=CC=CC=C2)CC(=O)O
DMJAG7M IK KYPWLTXIHUQMGA-UHFFFAOYSA-N
DMJAG7M IU 3-methoxy-5-(4-phenylphenyl)pentanoic acid
DMJAG7M DE Discovery agent
DMQKU9H ID DMQKU9H
DMQKU9H DN 5-(biphenyl-4-yl)-3-oxopentanoic acid
DMQKU9H HS Investigative
DMQKU9H SN CHEMBL572979; 5-(biphenyl-4-yl)-3-oxopentanoic acid
DMQKU9H DT Small molecular drug
DMQKU9H PC 45483008
DMQKU9H MW 268.31
DMQKU9H FM C17H16O3
DMQKU9H IC InChI=1S/C17H16O3/c18-16(12-17(19)20)11-8-13-6-9-15(10-7-13)14-4-2-1-3-5-14/h1-7,9-10H,8,11-12H2,(H,19,20)
DMQKU9H CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCC(=O)CC(=O)O
DMQKU9H IK HDXADAWBGFXTBW-UHFFFAOYSA-N
DMQKU9H IU 3-oxo-5-(4-phenylphenyl)pentanoic acid
DMQKU9H DE Discovery agent
DMPQSZN ID DMPQSZN
DMPQSZN DN 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide
DMPQSZN HS Investigative
DMPQSZN SN CHEMBL541239; 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide; SCHEMBL7045815
DMPQSZN DT Small molecular drug
DMPQSZN PC 22915475
DMPQSZN MW 269.34
DMPQSZN FM C17H19NO2
DMPQSZN IC InChI=1S/C17H19NO2/c19-17(18-20)9-5-4-6-14-10-12-16(13-11-14)15-7-2-1-3-8-15/h1-3,7-8,10-13,20H,4-6,9H2,(H,18,19)
DMPQSZN CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCCCC(=O)NO
DMPQSZN IK QQLOLMJSVXGPGC-UHFFFAOYSA-N
DMPQSZN IU N-hydroxy-5-(4-phenylphenyl)pentanamide
DMPQSZN DE Discovery agent
DMPFX0S ID DMPFX0S
DMPFX0S DN 5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID
DMPFX0S HS Investigative
DMPFX0S SN 5-(dimethylamino)naphthalene-2-sulfonic acid; AC1NBV3O; 5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID; SCHEMBL18300795; DB07684; 5-dimethyl-aminonaphthalene-2-sulfonic acid
DMPFX0S DT Small molecular drug
DMPFX0S PC 4474224
DMPFX0S MW 251.3
DMPFX0S FM C12H13NO3S
DMPFX0S IC InChI=1S/C12H13NO3S/c1-13(2)12-5-3-4-9-8-10(17(14,15)16)6-7-11(9)12/h3-8H,1-2H3,(H,14,15,16)
DMPFX0S CS CN(C)C1=CC=CC2=C1C=CC(=C2)S(=O)(=O)O
DMPFX0S IK VENHBDIMAAXWKI-UHFFFAOYSA-N
DMPFX0S IU 5-(dimethylamino)naphthalene-2-sulfonic acid
DMPFX0S DE Discovery agent
DM1IGOD ID DM1IGOD
DM1IGOD DN 5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid
DM1IGOD HS Investigative
DM1IGOD SN CHEMBL496927
DM1IGOD DT Small molecular drug
DM1IGOD PC 44576817
DM1IGOD MW 349.34
DM1IGOD FM C15H19N5O5
DM1IGOD IC InChI=1S/C15H19N5O5/c16-13-10-14(18-6-17-13)20(7-19-10)15-12(24)11(23)8(25-15)4-2-1-3-5-9(21)22/h2,4,6-8,11-12,15,23-24H,1,3,5H2,(H,21,22)(H2,16,17,18)/b4-2+/t8-,11-,12-,15-/m1/s1
DM1IGOD CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)/C=C/CCCC(=O)O)O)O)N
DM1IGOD IK HAGCQDHTBHGTQC-VLCWARKCSA-N
DM1IGOD IU (E)-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]hex-5-enoic acid
DM1IGOD DE Discovery agent
DM45VRX ID DM45VRX
DM45VRX DN 5-(isopropylamino)quinolin-8-ol
DM45VRX HS Investigative
DM45VRX SN CHEMBL571661; 5-(isopropylamino)quinolin-8-ol; 8-Quinolinol, 5-[(1-methylethyl)amino]-; SCHEMBL12599076; BDBM50303920
DM45VRX DT Small molecular drug
DM45VRX PC 44466195
DM45VRX MW 202.25
DM45VRX FM C12H14N2O
DM45VRX IC InChI=1S/C12H14N2O/c1-8(2)14-10-5-6-11(15)12-9(10)4-3-7-13-12/h3-8,14-15H,1-2H3
DM45VRX CS CC(C)NC1=C2C=CC=NC2=C(C=C1)O
DM45VRX IK BRXAKDWFCHQCDT-UHFFFAOYSA-N
DM45VRX IU 5-(propan-2-ylamino)quinolin-8-ol
DM45VRX DE Discovery agent
DMYLIX9 ID DMYLIX9
DMYLIX9 DN 5-(methylthio)thiophene-2-carboxylic acid
DMYLIX9 HS Investigative
DMYLIX9 SN 20873-58-9; 5-methylsulfanylthiophene-2-carboxylic acid; 5-(methylthio)thiophene-2-carboxylic acid; 5-(methylsulfanyl)thiophene-2-carboxylic acid; CHEMBL450866; 2-thiophenecarboxylic acid, 5-(methylthio)-; 2-Thiophenecarboxylicacid, 5-(methylthio)-; 5-methylthiothiophene-2-carboxylic acid; ZERO/008316; AC1Q5UIM; Maybridge1_007717; ChemDiv2_000116; AC1Q4H1V; AC1LEM73; Cambridge id 5103856; SCHEMBL2723219; KS-00000KTP; HMS563G17; CTK1A1236; DTXSID70351935; FWFWUSLBIIIIEN-UHFFFAOYSA-N; MolPort-000-146-385; ZINC109304; HMS1369F06
DMYLIX9 DT Small molecular drug
DMYLIX9 PC 714372
DMYLIX9 MW 174.2
DMYLIX9 FM C6H6O2S2
DMYLIX9 IC InChI=1S/C6H6O2S2/c1-9-5-3-2-4(10-5)6(7)8/h2-3H,1H3,(H,7,8)
DMYLIX9 CS CSC1=CC=C(S1)C(=O)O
DMYLIX9 IK FWFWUSLBIIIIEN-UHFFFAOYSA-N
DMYLIX9 IU 5-methylsulfanylthiophene-2-carboxylic acid
DMYLIX9 CA CAS 20873-58-9
DMYLIX9 DE Discovery agent
DM3TPMO ID DM3TPMO
DM3TPMO DN 5'-(N-ethyl-N-isopropyl)amiloride
DM3TPMO HS Investigative
DM3TPMO SN EIPA; 5-(N-Ethyl-N-isopropyl)amiloride; 1154-25-2; Ethylisopropylamiloride; 5-(Ethylisopropyl)amiloride; Ethyl isopropyl amiloride; 5-(N-ethyl-N-isopropyl)-Amiloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]-2-pyrazinecarboxamide; N-Amidino-3-amino-5-ethylisopropylamino-6-chloropyrazine carboxamide; C11H18ClN7O; CHEMBL517986; 5-(N-Ethyl-N-isopropyl) Amiloride; 3-Amino-N-(aminoiminomethyl)-6-chloro-5-(ethyl(1-methylethyl)amino)pyrazinecarboxamide
DM3TPMO DT Small molecular drug
DM3TPMO PC 1795
DM3TPMO MW 299.76
DM3TPMO FM C11H18ClN7O
DM3TPMO IC InChI=1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)
DM3TPMO CS CCN(C1=NC(=C(N=C1Cl)C(=O)N=C(N)N)N)C(C)C
DM3TPMO IK QDERNBXNXJCIQK-UHFFFAOYSA-N
DM3TPMO IU 3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
DM3TPMO CA CAS 1154-25-2
DM3TPMO CB CHEBI:136538
DM3TPMO DE Discovery agent
DMG2VQB ID DMG2VQB
DMG2VQB DN 5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol
DMG2VQB HS Investigative
DMG2VQB DT Small molecular drug
DMG2VQB PC 135546485
DMG2VQB MW 255.4
DMG2VQB FM C10H13N3OS2
DMG2VQB IC InChI=1S/C10H13N3OS2/c1-2-3-4-5-15-10-12-8-7(9(14)13-10)16-6-11-8/h6H,2-5H2,1H3,(H,12,13,14)
DMG2VQB CS CCCCCSC1=NC2=C(C(=O)N1)SC=N2
DMG2VQB IK QONMYXCFINJDMT-UHFFFAOYSA-N
DMG2VQB IU 5-pentylsulfanyl-6H-[1,3]thiazolo[4,5-d]pyrimidin-7-one
DMG2VQB DE Discovery agent
DMP4RO3 ID DMP4RO3
DMP4RO3 DN 5-(phenylethynyl)pyrimidine
DMP4RO3 HS Investigative
DMP4RO3 SN 5-(phenylethynyl)pyrimidine; 71418-88-7; CHEMBL486244; 5-(2-phenylethynyl)pyrimidine; 5-phenylethynylpyrimidine; SCHEMBL4860070; DTXSID50399052; ZINC198515; AC1N4263; BDBM50243108; AKOS001674343; MCULE-6083144775; FCH1171193; AJ-17844; AX8280340; SR-01000501737; SR-01000501737-1
DMP4RO3 DT Small molecular drug
DMP4RO3 PC 4074142
DMP4RO3 MW 180.2
DMP4RO3 FM C12H8N2
DMP4RO3 IC InChI=1S/C12H8N2/c1-2-4-11(5-3-1)6-7-12-8-13-10-14-9-12/h1-5,8-10H
DMP4RO3 CS C1=CC=C(C=C1)C#CC2=CN=CN=C2
DMP4RO3 IK HSQDWKSXSIUOJC-UHFFFAOYSA-N
DMP4RO3 IU 5-(2-phenylethynyl)pyrimidine
DMP4RO3 CA CAS 71418-88-7
DMP4RO3 DE Discovery agent
DMT60AM ID DMT60AM
DMT60AM DN 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione
DMT60AM HS Investigative
DMT60AM SN 329905-79-5; 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione; 5-(piperidin-1-ylsulfonyl)-1H-indole-2,3-dione; 5-(Piperidine-1-sulfonyl)-1H-indole-2,3-dione; 5-[1-(Piperidinyl)sulfonyl]isatin; Isatin Sulfonamide 21; AC1N3S5Q; CHEMBL61320; BDBM10310; DTXSID40399501; MolPort-000-149-258; ZX-BK002316; ZINC2944779; MIX-0755; STK894352; BBL021638; 2990AJ; AKOS005144288; MCULE-6394963078; 5-(Piperidinosulfonyl)indoline-2,3-dione; AJ-44313; ACM329905795; AX8291419; H8238; 5-(piperidinosulfonyl)-1H-indole-2,3-dione
DMT60AM DT Small molecular drug
DMT60AM PC 4117383
DMT60AM MW 294.33
DMT60AM FM C13H14N2O4S
DMT60AM IC InChI=1S/C13H14N2O4S/c16-12-10-8-9(4-5-11(10)14-13(12)17)20(18,19)15-6-2-1-3-7-15/h4-5,8H,1-3,6-7H2,(H,14,16,17)
DMT60AM CS C1CCN(CC1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMT60AM IK YATIWPMEKYVTAO-UHFFFAOYSA-N
DMT60AM IU 5-piperidin-1-ylsulfonyl-1H-indole-2,3-dione
DMT60AM CA CAS 329905-79-5
DMT60AM CB CHEBI:149998
DMT60AM DE Discovery agent
DM4XGFW ID DM4XGFW
DM4XGFW DN 5-(piperidin-4-yl)isothiazol-3-ol
DM4XGFW HS Investigative
DM4XGFW SN CHEMBL109209; 5-(piperidin-4-yl)isothiazol-3-ol; Thio-4-PIOL; SCHEMBL2046840; 5-(4-Piperidyl)isothiazole-3-ol; 5-Piperidin-4-yl-isothiazol-3-ol; BDBM50032951; PDSP2_001589
DM4XGFW DT Small molecular drug
DM4XGFW PC 10035301
DM4XGFW MW 184.26
DM4XGFW FM C8H12N2OS
DM4XGFW IC InChI=1S/C8H12N2OS/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11)
DM4XGFW CS C1CNCCC1C2=CC(=O)NS2
DM4XGFW IK WUINUICOEAZPLK-UHFFFAOYSA-N
DM4XGFW IU 5-piperidin-4-yl-1,2-thiazol-3-one
DM4XGFW DE Discovery agent
DM6GO2I ID DM6GO2I
DM6GO2I DN 5-(piperidin-4-yl)isoxazol-3-ol
DM6GO2I HS Investigative
DM6GO2I SN 5-Piperidin-4-yl-isoxazol-3-ol
DM6GO2I DT Small molecular drug
DM6GO2I PC 125520
DM6GO2I MW 168.19
DM6GO2I FM C8H12N2O2
DM6GO2I IC InChI=1S/C8H12N2O2/c11-8-5-7(12-10-8)6-1-3-9-4-2-6/h5-6,9H,1-4H2,(H,10,11)
DM6GO2I CS C1CNCCC1C2=CC(=O)NO2
DM6GO2I IK YYOYGSTYWVHCJR-UHFFFAOYSA-N
DM6GO2I IU 5-piperidin-4-yl-1,2-oxazol-3-one
DM6GO2I CA CAS 132033-91-1
DM6GO2I CB CHEBI:34433
DM6GO2I DE Discovery agent
DM93MAX ID DM93MAX
DM93MAX DN 5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione
DM93MAX HS Investigative
DM93MAX SN 15264-63-8; 5-(4-Pyridyl)-1,3,4-oxadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thiol; 5-pyridin-4-yl-[1,3,4]oxadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione; CHEMBL571513; 5-pyridin-4-yl-1,3,4-oxadiazole-2-thiol; 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol; TXCXZVFDWQYTIC-UHFFFAOYSA-N; 1,3,4-Oxadiazole-2(3H)-thione,5-(4-pyridinyl)-; 1,3,4-Oxadiazole-2-thiol, 5-(4-pyridinyl)-; ZERO/005315; AC1LGNJA; ChemDiv2_000174; AC1Q7F3J; Oprea1_812023; Oprea1_290121; SCHEMBL987340; SCHEMBL17065364; CTK4C7526
DM93MAX DT Small molecular drug
DM93MAX PC 774383
DM93MAX MW 179.2
DM93MAX FM C7H5N3OS
DM93MAX IC InChI=1S/C7H5N3OS/c12-7-10-9-6(11-7)5-1-3-8-4-2-5/h1-4H,(H,10,12)
DM93MAX CS C1=CN=CC=C1C2=NNC(=S)O2
DM93MAX IK TXCXZVFDWQYTIC-UHFFFAOYSA-N
DM93MAX IU 5-pyridin-4-yl-3H-1,3,4-oxadiazole-2-thione
DM93MAX CA CAS 15264-63-8
DM93MAX DE Discovery agent
DMEL8XU ID DMEL8XU
DMEL8XU DN 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione
DMEL8XU HS Investigative
DMEL8XU SN 13581-25-4; 5-(pyridin-4-yl)-1,3,4-thiadiazole-2-thiol; CHEMBL596214; 5-(4-pyridyl)-1,3,4-thiadiazole-2-thiol; 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione; 5-pyridin-4-yl-1,3,4-thiadiazole-2-thiol; 5-mercapto-2-(pyridin-4-yl)-1,3,4-thiadiazole; 1,3,4-Thiadiazole-2(3H)-thione, 5-(4-pyridinyl)-; AC1NRXV6; 5-pyridin-4-yl-3H-1,3,4-thiadiazole-2-thione; SCHEMBL969939; CTK0F4035; DTXSID70415420; MolPort-002-738-405; BDBM50304604; ZINC13532584; STK328652; AKOS030229631; AKOS005174322; MCULE-1265725983; KB-243965; R9200; ST45106367
DMEL8XU DT Small molecular drug
DMEL8XU PC 5300214
DMEL8XU MW 195.3
DMEL8XU FM C7H5N3S2
DMEL8XU IC InChI=1S/C7H5N3S2/c11-7-10-9-6(12-7)5-1-3-8-4-2-5/h1-4H,(H,10,11)
DMEL8XU CS C1=CN=CC=C1C2=NNC(=S)S2
DMEL8XU IK BSPHQWQMWIUIPM-UHFFFAOYSA-N
DMEL8XU IU 5-pyridin-4-yl-3H-1,3,4-thiadiazole-2-thione
DMEL8XU CA CAS 13581-25-4
DMEL8XU DE Discovery agent
DMJBK7F ID DMJBK7F
DMJBK7F DN 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione
DMJBK7F HS Investigative
DMJBK7F SN 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione; 220510-17-8; 5-(Pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione; Isatin Sulfonamide 20; 5-pyrrolidinylsulfonylisatin; AC1N3S5K; 5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione; SCHEMBL2486952; CHEMBL305545; BDBM10309; DTXSID80399500; QKCWUYHXHMXOLG-UHFFFAOYSA-N; ZINC2944777; 5-[1-(pyrrolidinyl)sulfonyl]isatin; 2991AJ; AKOS024262065; AJ-44312; 5-(Pyrrolizinosulfonyl)indoline-2,3-dione; AX8291337; FT-0734877; 5-(Pyrrolidin-1-ylsulfonyl)-1H-indole-2,3-dione
DMJBK7F DT Small molecular drug
DMJBK7F PC 4117381
DMJBK7F MW 280.3
DMJBK7F FM C12H12N2O4S
DMJBK7F IC InChI=1S/C12H12N2O4S/c15-11-9-7-8(3-4-10(9)13-12(11)16)19(17,18)14-5-1-2-6-14/h3-4,7H,1-2,5-6H2,(H,13,15,16)
DMJBK7F CS C1CCN(C1)S(=O)(=O)C2=CC3=C(C=C2)NC(=O)C3=O
DMJBK7F IK QKCWUYHXHMXOLG-UHFFFAOYSA-N
DMJBK7F IU 5-pyrrolidin-1-ylsulfonyl-1H-indole-2,3-dione
DMJBK7F CA CAS 220510-17-8
DMJBK7F DE Discovery agent
DMK3TEV ID DMK3TEV
DMK3TEV DN 5-(trifluoromethoxy)-1H-indole-2,3-dione
DMK3TEV HS Investigative
DMK3TEV SN 5-(Trifluoromethoxy)isatin; 169037-23-4; 5-(TRIFLUOROMETHOXY)INDOLINE-2,3-DIONE; 5-(trifluoromethoxy)-1H-indole-2,3-dione; 5-trifluoromethoxyisatin; 5-Trifluoromethoxy-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5-(trifluoromethoxy)-; MFCD00192524; 5-(Trifluoromethoxy)-2,3-indolinedione; AK-33632; 5-(Trifluoromethoxy)isatin, 97%; AC1MBXBJ; 5-trifluoromethoxy isatin; buttpark 34\07-90; ACMC-209dz9; Isatin-based compound, 36; 5-(trifluoromethoxy)-isatin; KSC498C3D; SCHEMBL457929; CHEMBL116649; KS-00000IZD; BDBM22816
DMK3TEV DT Small molecular drug
DMK3TEV PC 2732752
DMK3TEV MW 231.13
DMK3TEV FM C9H4F3NO3
DMK3TEV IC InChI=1S/C9H4F3NO3/c10-9(11,12)16-4-1-2-6-5(3-4)7(14)8(15)13-6/h1-3H,(H,13,14,15)
DMK3TEV CS C1=CC2=C(C=C1OC(F)(F)F)C(=O)C(=O)N2
DMK3TEV IK XHAJMVPMNOBILF-UHFFFAOYSA-N
DMK3TEV IU 5-(trifluoromethoxy)-1H-indole-2,3-dione
DMK3TEV CA CAS 169037-23-4
DMK3TEV DE Discovery agent
DMM7N6K ID DMM7N6K
DMM7N6K DN 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine
DMM7N6K HS Investigative
DMM7N6K DT Small molecular drug
DMM7N6K PC 135468219
DMM7N6K MW 305.29
DMM7N6K FM C16H11N5O2
DMM7N6K IC InChI=1S/C16H11N5O2/c17-14-13-16(19-15(18-14)10-6-2-1-3-7-10)21(23)12-9-5-4-8-11(12)20(13)22/h1-9H,(H2,17,18,19)
DMM7N6K CS C1=CC=C(C=C1)C2=NC3=[N+](C4=CC=CC=C4[N+](=C3C(=N2)N)[O-])[O-]
DMM7N6K IK YWSUTRFYAQHJFZ-UHFFFAOYSA-N
DMM7N6K IU 5,10-dioxido-2-phenylbenzo[g]pteridine-5,10-diium-4-amine
DMM7N6K DE Discovery agent
DMAQDK9 ID DMAQDK9
DMAQDK9 DN 5,10-Methylene-6-Hydrofolic Acid
DMAQDK9 HS Investigative
DMAQDK9 DT Small molecular drug
DMAQDK9 PC 135403830
DMAQDK9 MW 455.4
DMAQDK9 FM C20H21N7O6
DMAQDK9 IC InChI=1S/C20H21N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,7,12-13H,5-6,8-9H2,(H,23,30)(H,28,29)(H,32,33)(H3,21,24,25,31)/t12-,13-/m1/s1
DMAQDK9 CS C1[C@H]2C=NC3=C(N2CN1C4=CC=C(C=C4)C(=O)N[C@H](CCC(=O)O)C(=O)O)C(=O)NC(=N3)N
DMAQDK9 IK BHJAPJNOACHPNI-CHWSQXEVSA-N
DMAQDK9 IU (2R)-2-[[4-[(6aS)-3-amino-1-oxo-2,6a,7,9-tetrahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid
DMAQDK9 DE Discovery agent
DMWSLTB ID DMWSLTB
DMWSLTB DN 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB HS Investigative
DMWSLTB SN 9-Hydroxyellipticine; 9-Hydroxyellipticin; 51131-85-2; 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol; Hydroxyellipticine; ELLIPTICINE, 9-HYDROXY-; UNII-9G4A3ET6XG; IGIG 929; Hydroxy-9 ellipticine [French]; EINECS 257-000-0; NSC 237070; NSC 210717; 9G4A3ET6XG; CHEMBL26559; CHEBI:88297; C17H14N2O; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazol-9-ol; 6H-Pyrido(4,3-b)carbazol-9-ol, 5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazol-9-ol, 5,11-dimethyl-; 9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; Hydroxy-9 ellipticine
DMWSLTB DT Small molecular drug
DMWSLTB PC 91643
DMWSLTB MW 262.3
DMWSLTB FM C17H14N2O
DMWSLTB IC InChI=1S/C17H14N2O/c1-9-14-8-18-6-5-12(14)10(2)17-16(9)13-7-11(20)3-4-15(13)19-17/h3-8,19-20H,1-2H3
DMWSLTB CS CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C
DMWSLTB IK QZTWUDDGLIDXSE-UHFFFAOYSA-N
DMWSLTB IU 5,11-dimethyl-6H-pyrido[4,3-b]carbazol-9-ol
DMWSLTB CA CAS 51131-85-2
DMWSLTB CB CHEBI:88297
DMWSLTB DE Discovery agent
DMJRXLD ID DMJRXLD
DMJRXLD DN 5,3'-Dipropyl-biphenyl-2,4'-diol
DMJRXLD HS Investigative
DMJRXLD SN CHEMBL330227; 35406-31-6; Magreth-2; SCHEMBL12319404; CTK1B6970; DTXSID90432573; 3',5-Dipropylbiphenyl-2,4'-diol; BDBM50157312; AKOS030533140; 5,3''-Dipropyl-biphenyl-2,4''-diol; 5,3''''-Dipropyl-biphenyl-2,4''''-diol; [1,1'-Biphenyl]-2,4'-diol, 3',5-dipropyl-
DMJRXLD DT Small molecular drug
DMJRXLD PC 9900113
DMJRXLD MW 270.4
DMJRXLD FM C18H22O2
DMJRXLD IC InChI=1S/C18H22O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h7-12,19-20H,3-6H2,1-2H3
DMJRXLD CS CCCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CCC
DMJRXLD IK PJBHWFHBOPMXAM-UHFFFAOYSA-N
DMJRXLD IU 2-(4-hydroxy-3-propylphenyl)-4-propylphenol
DMJRXLD CA CAS 35406-31-6
DMJRXLD DE Discovery agent
DMWL1UY ID DMWL1UY
DMWL1UY DN 5,5-diethyl-2-(phenethylamino)oxazol-4(5H)-one
DMWL1UY HS Investigative
DMWL1UY DT Small molecular drug
DMWL1UY PC 135950108
DMWL1UY MW 260.329
DMWL1UY FM C15H20N2O2
DMWL1UY IC InChI=1S/C15H20N2O2/c1-3-15(4-2)13(18)17-14(19-15)16-11-10-12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3,(H,16,17,18)
DMWL1UY CS CCC1(C(=O)NC(=NCCC2=CC=CC=C2)O1)CC
DMWL1UY IK ARZSETSNEBJNMA-UHFFFAOYSA-N
DMWL1UY IU 5,5-diethyl-2-(2-phenylethylimino)-1,3-oxazolidin-4-one
DMWL1UY DE Discovery agent
DM28LNV ID DM28LNV
DM28LNV DN 5,5-Diphenyl-2-iminohydantoin
DM28LNV HS Investigative
DM28LNV SN CHEMBL291784; 5,5-Diphenyl-2-iminohydantoin; SCHEMBL4237550; 2-amino-3-methyl-5,5-diphenyl-3,5-dihydro-imidazol-4-one; BDBM50300229; 26975-80-4; 2-Imino-3-methyl-5,5-diphenylimidazolidin-4-one; 2-Imino-3-methyl-5,5-diphenyl-imidazolidin-4-one; 1-methyl-4,4-diphenyl-4,5-dihydro-1H-imidazol-2-amine
DM28LNV DT Small molecular drug
DM28LNV PC 15054176
DM28LNV MW 265.31
DM28LNV FM C16H15N3O
DM28LNV IC InChI=1S/C16H15N3O/c1-19-14(20)16(18-15(19)17,12-8-4-2-5-9-12)13-10-6-3-7-11-13/h2-11H,1H3,(H2,17,18)
DM28LNV CS CN1C(=O)C(N=C1N)(C2=CC=CC=C2)C3=CC=CC=C3
DM28LNV IK RNWLAFWLSSMCLN-UHFFFAOYSA-N
DM28LNV IU 2-amino-3-methyl-5,5-diphenylimidazol-4-one
DM28LNV DE Discovery agent
DMPVBC2 ID DMPVBC2
DMPVBC2 DN 5,5'-methylenebis(1,3,4-oxadiazole-2(3H)-thione)
DMPVBC2 HS Investigative
DMPVBC2 SN CHEMBL608132; bis-(5-mercapto-1,3,4-oxadiazol-2-yl)-methane; BDBM50304603; 90748-72-4; Bis(1,3,4-oxadiazol-2-methyl)-5-thione
DMPVBC2 DT Small molecular drug
DMPVBC2 PC 14711339
DMPVBC2 MW 216.2
DMPVBC2 FM C5H4N4O2S2
DMPVBC2 IC InChI=1S/C5H4N4O2S2/c12-4-8-6-2(10-4)1-3-7-9-5(13)11-3/h1H2,(H,8,12)(H,9,13)
DMPVBC2 CS C(C1=NNC(=S)O1)C2=NNC(=S)O2
DMPVBC2 IK FIBRGBFKOVAXHJ-UHFFFAOYSA-N
DMPVBC2 IU 5-[(2-sulfanylidene-3H-1,3,4-oxadiazol-5-yl)methyl]-3H-1,3,4-oxadiazole-2-thione
DMPVBC2 DE Discovery agent
DMW13SO ID DMW13SO
DMW13SO DN 5,5'-methylenebis(1,3,4-thiadiazole-2(3H)-thione)
DMW13SO HS Investigative
DMW13SO SN CHEMBL595241; 70066-79-4; SCHEMBL737372; CTK2G3163; DTXSID80673150; BDBM50320717; Bis(1,3,4-thiadiazole-2-methyl)-5-thione; 5,5'-Methylenedi(1,3,4-thiadiazole-2(3H)-thione); 1,3,4-Thiadiazole-2(3H)-thione, 5,5'-methylenebis-
DMW13SO DT Small molecular drug
DMW13SO PC 46225958
DMW13SO MW 248.4
DMW13SO FM C5H4N4S4
DMW13SO IC InChI=1S/C5H4N4S4/c10-4-8-6-2(12-4)1-3-7-9-5(11)13-3/h1H2,(H,8,10)(H,9,11)
DMW13SO CS C(C1=NNC(=S)S1)C2=NNC(=S)S2
DMW13SO IK XUFJHTRVFXOZOI-UHFFFAOYSA-N
DMW13SO IU 5-[(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)methyl]-3H-1,3,4-thiadiazole-2-thione
DMW13SO CA CAS 70066-79-4
DMW13SO DE Discovery agent
DMZ693W ID DMZ693W
DMZ693W DN 5,5'-methylenebis(3,4-dibromobenzene-1,2-diol)
DMZ693W HS Investigative
DMZ693W SN CHEMBL253690; 65487-76-5; CTK1J6652; DTXSID90466393; BDBM50329688; 3,4-dibromo-5-[(2,3-dibromo-4,5-dihydroxy-phenyl)methyl]benzene-1,2-diol; 5,5'-Methylenebis(3,4-dibromopyrocatechol); 1,2-Benzenediol, 4,4'-methylenebis[5,6-dibromo-; 5,5''-methylenebis(3,4-dibromobenzene-1,2-diol); 2,2',3,3'-tetrabromo-4,4',5,5'-tetrahydroxy-diphenylmethane
DMZ693W DT Small molecular drug
DMZ693W PC 11455599
DMZ693W MW 547.8
DMZ693W FM C13H8Br4O4
DMZ693W IC InChI=1S/C13H8Br4O4/c14-8-4(2-6(18)12(20)10(8)16)1-5-3-7(19)13(21)11(17)9(5)15/h2-3,18-21H,1H2
DMZ693W CS C1=C(C(=C(C(=C1O)O)Br)Br)CC2=CC(=C(C(=C2Br)Br)O)O
DMZ693W IK WIAKRAUTQVUHHL-UHFFFAOYSA-N
DMZ693W IU 3,4-dibromo-5-[(2,3-dibromo-4,5-dihydroxyphenyl)methyl]benzene-1,2-diol
DMZ693W CA CAS 65487-76-5
DMZ693W DE Discovery agent
DMIQAO9 ID DMIQAO9
DMIQAO9 DN 5,6,7,8-tetrahydroanthracene-1,4-dione
DMIQAO9 HS Investigative
DMIQAO9 SN CHEMBL508233; 5,6,7,8-tetrahydroanthracene-1,4-dione; SCHEMBL11038167
DMIQAO9 DT Small molecular drug
DMIQAO9 PC 44582382
DMIQAO9 MW 212.24
DMIQAO9 FM C14H12O2
DMIQAO9 IC InChI=1S/C14H12O2/c15-13-5-6-14(16)12-8-10-4-2-1-3-9(10)7-11(12)13/h5-8H,1-4H2
DMIQAO9 CS C1CCC2=CC3=C(C=C2C1)C(=O)C=CC3=O
DMIQAO9 IK DWXLNXHEUIUNRF-UHFFFAOYSA-N
DMIQAO9 IU 5,6,7,8-tetrahydroanthracene-1,4-dione
DMIQAO9 DE Discovery agent
DMTL4S9 ID DMTL4S9
DMTL4S9 DN 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione
DMTL4S9 HS Investigative
DMTL4S9 SN 5,6,7-trichloro-1,4-dihydroquinoxaline-2,3-dione; CHEMBL43846; 172215-97-3; 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione; SCHEMBL8904175
DMTL4S9 DT Small molecular drug
DMTL4S9 PC 10849325
DMTL4S9 MW 265.5
DMTL4S9 FM C8H3Cl3N2O2
DMTL4S9 IC InChI=1S/C8H3Cl3N2O2/c9-2-1-3-6(5(11)4(2)10)13-8(15)7(14)12-3/h1H,(H,12,14)(H,13,15)
DMTL4S9 CS C1=C2C(=C(C(=C1Cl)Cl)Cl)NC(=O)C(=O)N2
DMTL4S9 IK MVCXAPXDPCEJBN-UHFFFAOYSA-N
DMTL4S9 IU 5,6,7-trichloro-1,4-dihydroquinoxaline-2,3-dione
DMTL4S9 DE Discovery agent
DM53CLY ID DM53CLY
DM53CLY DN 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline
DM53CLY HS Investigative
DM53CLY SN CHEMBL86717; 5,6,7-trimethoxy-3-pyridin-4-yl-quinoline; BDBM50039649
DM53CLY DT Small molecular drug
DM53CLY PC 9994707
DM53CLY MW 296.32
DM53CLY FM C17H16N2O3
DM53CLY IC InChI=1S/C17H16N2O3/c1-20-15-9-14-13(16(21-2)17(15)22-3)8-12(10-19-14)11-4-6-18-7-5-11/h4-10H,1-3H3
DM53CLY CS COC1=C(C(=C2C=C(C=NC2=C1)C3=CC=NC=C3)OC)OC
DM53CLY IK FQVDOOFEQQAHPX-UHFFFAOYSA-N
DM53CLY IU 5,6,7-trimethoxy-3-pyridin-4-ylquinoline
DM53CLY DE Discovery agent
DM6VPF4 ID DM6VPF4
DM6VPF4 DN 5,6,7-Trimethyl-2-p-tolyl-chromen-4-one
DM6VPF4 HS Investigative
DM6VPF4 SN CHEMBL168080; 5,6,7-Trimethyl-2-p-tolyl-chromen-4-one; 4',5,6,7-Tetramethylflavone
DM6VPF4 DT Small molecular drug
DM6VPF4 PC 44378768
DM6VPF4 MW 278.3
DM6VPF4 FM C19H18O2
DM6VPF4 IC InChI=1S/C19H18O2/c1-11-5-7-15(8-6-11)17-10-16(20)19-14(4)13(3)12(2)9-18(19)21-17/h5-10H,1-4H3
DM6VPF4 CS CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3C)C)C
DM6VPF4 IK CMMLREBGPOOVPU-UHFFFAOYSA-N
DM6VPF4 IU 5,6,7-trimethyl-2-(4-methylphenyl)chromen-4-one
DM6VPF4 DE Discovery agent
DMDCE1M ID DMDCE1M
DMDCE1M DN 5,6,8-trichloroquinoline-4-one-3-carboxylic acid
DMDCE1M HS Investigative
DMDCE1M SN 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; AC1LEUE0; Oprea1_066465; CHEMBL553336; 5,6,8-trichloro-4-oxo-1H-quinoline-3-carboxylic Acid; SCHEMBL19615682; MolPort-000-563-469; ZINC117346; STK970936
DMDCE1M DT Small molecular drug
DMDCE1M PC 718154
DMDCE1M MW 292.5
DMDCE1M FM C10H4Cl3NO3
DMDCE1M IC InChI=1S/C10H4Cl3NO3/c11-4-1-5(12)8-6(7(4)13)9(15)3(2-14-8)10(16)17/h1-2H,(H,14,15)(H,16,17)
DMDCE1M CS C1=C(C2=C(C(=C1Cl)Cl)C(=O)C(=CN2)C(=O)O)Cl
DMDCE1M IK DIMMLVONVUPWHB-UHFFFAOYSA-N
DMDCE1M IU 5,6,8-trichloro-4-oxo-1H-quinoline-3-carboxylic acid
DMDCE1M CA CAS 302553-01-1
DMDCE1M DE Discovery agent
DMNHT7Q ID DMNHT7Q
DMNHT7Q DN 5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one
DMNHT7Q HS Investigative
DMNHT7Q SN 5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1p; CHEMBL449065; BDBM29227; MolPort-028-745-486; ZINC40829644; 1,4-Dimethyl-5,6,8-trimethoxyquinolin-2(1H)-one
DMNHT7Q DT Small molecular drug
DMNHT7Q PC 15306617
DMNHT7Q MW 263.29
DMNHT7Q FM C14H17NO4
DMNHT7Q IC InChI=1S/C14H17NO4/c1-8-6-11(16)15(2)13-9(17-3)7-10(18-4)14(19-5)12(8)13/h6-7H,1-5H3
DMNHT7Q CS CC1=CC(=O)N(C2=C1C(=C(C=C2OC)OC)OC)C
DMNHT7Q IK PJUNWPXRLZUYPB-UHFFFAOYSA-N
DMNHT7Q IU 5,6,8-trimethoxy-1,4-dimethylquinolin-2-one
DMNHT7Q DE Discovery agent
DM97XZ1 ID DM97XZ1
DM97XZ1 DN 5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one
DM97XZ1 HS Investigative
DM97XZ1 SN 5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one; casimiroin analogue, 1o; CHEMBL493181; BDBM29226; MolPort-028-745-485; ZINC40957356; 4-Methyl-5,6,8-trimethoxyquinolin-2(1H)-one
DM97XZ1 DT Small molecular drug
DM97XZ1 PC 15306616
DM97XZ1 MW 249.26
DM97XZ1 FM C13H15NO4
DM97XZ1 IC InChI=1S/C13H15NO4/c1-7-5-10(15)14-12-8(16-2)6-9(17-3)13(18-4)11(7)12/h5-6H,1-4H3,(H,14,15)
DM97XZ1 CS CC1=CC(=O)NC2=C1C(=C(C=C2OC)OC)OC
DM97XZ1 IK YRUICGVVPDTGCH-UHFFFAOYSA-N
DM97XZ1 IU 5,6,8-trimethoxy-4-methyl-1H-quinolin-2-one
DM97XZ1 DE Discovery agent
DM6A4LM ID DM6A4LM
DM6A4LM DN 5,6-Bis-p-tolylamino-isoindole-1,3-dione
DM6A4LM HS Investigative
DM6A4LM SN CHEMBL7914; 5,6-Bis-p-tolylamino-isoindole-1,3-dione; SCHEMBL8834183; BDBM50040920
DM6A4LM DT Small molecular drug
DM6A4LM PC 10360970
DM6A4LM MW 357.4
DM6A4LM FM C22H19N3O2
DM6A4LM IC InChI=1S/C22H19N3O2/c1-13-3-7-15(8-4-13)23-19-11-17-18(22(27)25-21(17)26)12-20(19)24-16-9-5-14(2)6-10-16/h3-12,23-24H,1-2H3,(H,25,26,27)
DM6A4LM CS CC1=CC=C(C=C1)NC2=C(C=C3C(=C2)C(=O)NC3=O)NC4=CC=C(C=C4)C
DM6A4LM IK KSZXNFIEZNOXCC-UHFFFAOYSA-N
DM6A4LM IU 5,6-bis(4-methylanilino)isoindole-1,3-dione
DM6A4LM DE Discovery agent
DMDE7XJ ID DMDE7XJ
DMDE7XJ DN 5,6-Cyclic-Tetrahydropteridine
DMDE7XJ HS Investigative
DMDE7XJ DT Small molecular drug
DMDE7XJ PC 135509077
DMDE7XJ MW 223.19
DMDE7XJ FM C8H9N5O3
DMDE7XJ IC InChI=1S/C8H9N5O3/c9-7-11-5-4(6(14)12-7)13-3(1-10-5)2-16-8(13)15/h3H,1-2H2,(H4,9,10,11,12,14)/t3-/m1/s1
DMDE7XJ CS C1[C@@H]2COC(=O)N2C3=C(N1)N=C(NC3=O)N
DMDE7XJ IK XAZOBOCYEGBXHD-GSVOUGTGSA-N
DMDE7XJ IU (6aR)-3-amino-5,6,6a,7-tetrahydro-2H-[1,3]oxazolo[3,4-f]pteridine-1,9-dione
DMDE7XJ DE Discovery agent
DM3JB6S ID DM3JB6S
DM3JB6S DN 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
DM3JB6S HS Investigative
DM3JB6S SN 53-85-0; 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole; NSC 401575; Dichlororibofuranosylbenzimidazole; DRB; C12H12Cl2N2O4; 5,6-Dichlorobenzimidazole riboside; BRN 0039123; CHEMBL375530; UNII-8153319T3Q; 5,6-Dichloro-1-Beta-D-Ribofuranosyl-1h-Benzimidazole; 8153319T3Q; (2R,3R,4S,5R)-2-(5,6-Dichloro-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Benzimidazole, 5,6-dichloro-1-beta-D-ribofuranosyl-; 5,6-Dichloro-1-.beta.-D-ribofuranosylbenzimidazole
DM3JB6S DT Small molecular drug
DM3JB6S PC 5894
DM3JB6S MW 319.14
DM3JB6S FM C12H12Cl2N2O4
DM3JB6S IC InChI=1S/C12H12Cl2N2O4/c13-5-1-7-8(2-6(5)14)16(4-15-7)12-11(19)10(18)9(3-17)20-12/h1-2,4,9-12,17-19H,3H2/t9-,10-,11-,12-/m1/s1
DM3JB6S CS C1=C2C(=CC(=C1Cl)Cl)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DM3JB6S IK XHSQDZXAVJRBMX-DDHJBXDOSA-N
DM3JB6S IU (2R,3R,4S,5R)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM3JB6S CA CAS 53-85-0
DM3JB6S DE Discovery agent
DMN1S35 ID DMN1S35
DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine
DMN1S35 HS Investigative
DMN1S35 SN Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369
DMN1S35 DT Small molecular drug
DMN1S35 PC 9904281
DMN1S35 MW 216.06
DMN1S35 FM C8H7Cl2N3
DMN1S35 IC InChI=1S/C8H7Cl2N3/c9-5-1-2-6-4(7(5)10)3-12-8(11)13-6/h1-2H,3H2,(H3,11,12,13)
DMN1S35 CS C1C2=C(C=CC(=C2Cl)Cl)NC(=N1)N
DMN1S35 IK VBKOTIVQMCTTAQ-UHFFFAOYSA-N
DMN1S35 IU 5,6-dichloro-1,4-dihydroquinazolin-2-amine
DMN1S35 CA CAS 444904-63-6
DMN1S35 DE Discovery agent
DMR2OMU ID DMR2OMU
DMR2OMU DN 5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide
DMR2OMU HS Investigative
DMR2OMU SN 5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL589770; MolPort-005-210-928; ZINC21809540; BDBM50307191; AKOS005859120; 1039842-02-8; Z32410257
DMR2OMU DT Small molecular drug
DMR2OMU PC 29786172
DMR2OMU MW 304.17
DMR2OMU FM C12H15Cl2N3O2
DMR2OMU IC InChI=1S/C12H15Cl2N3O2/c13-10-7-9(8-16-11(10)14)12(18)15-1-2-17-3-5-19-6-4-17/h7-8H,1-6H2,(H,15,18)
DMR2OMU CS C1COCCN1CCNC(=O)C2=CC(=C(N=C2)Cl)Cl
DMR2OMU IK BNRXERZZOCTDMX-UHFFFAOYSA-N
DMR2OMU IU 5,6-dichloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMR2OMU DE Discovery agent
DMZL87A ID DMZL87A
DMZL87A DN 5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide
DMZL87A HS Investigative
DMZL87A SN CHEMBL597764; 5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide; BDBM50307204
DMZL87A DT Small molecular drug
DMZL87A PC 43236315
DMZL87A MW 318.2
DMZL87A FM C13H17Cl2N3O2
DMZL87A IC InChI=1S/C13H17Cl2N3O2/c14-11-8-10(9-17-12(11)15)13(19)16-2-1-3-18-4-6-20-7-5-18/h8-9H,1-7H2,(H,16,19)
DMZL87A CS C1COCCN1CCCNC(=O)C2=CC(=C(N=C2)Cl)Cl
DMZL87A IK TZOXTUGEEZYMTF-UHFFFAOYSA-N
DMZL87A IU 5,6-dichloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DMZL87A DE Discovery agent
DM94V8D ID DM94V8D
DM94V8D DN 5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one
DM94V8D HS Investigative
DM94V8D SN 5,6-dihydroxy-7-nitro-1-indanone; 383382-47-6; CHEMBL9039; SCHEMBL7432202; ULOQNEJBWLIGHK-UHFFFAOYSA-N; 5,6-Dihydroxy-7-nitro-indan-1-one
DM94V8D DT Small molecular drug
DM94V8D PC 9920742
DM94V8D MW 209.16
DM94V8D FM C9H7NO5
DM94V8D IC InChI=1S/C9H7NO5/c11-5-2-1-4-3-6(12)9(13)8(7(4)5)10(14)15/h3,12-13H,1-2H2
DM94V8D CS C1CC(=O)C2=C(C(=C(C=C21)O)O)[N+](=O)[O-]
DM94V8D IK ULOQNEJBWLIGHK-UHFFFAOYSA-N
DM94V8D IU 5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one
DM94V8D DE Discovery agent
DM07HYA ID DM07HYA
DM07HYA DN 5,6-dinitroacenaphthoquinone
DM07HYA HS Investigative
DM07HYA SN 5,6-dinitroacenaphthoquinone; 5,6-dinitroacenaphthylene-1,2-dione; AC1MQHVL; 5,6-dinitroacenaphthenequinone; CHEMBL235289; SCHEMBL2699746; BDBM22854; MolPort-003-895-771; 1,2-Dione-Based Compound, 11; AKOS024343013; MCULE-5132922926; 27471-02-9; 5,6-dinitro-1,2-dihydroacenaphthylenedione
DM07HYA DT Small molecular drug
DM07HYA PC 3477013
DM07HYA MW 272.17
DM07HYA FM C12H4N2O6
DM07HYA IC InChI=1S/C12H4N2O6/c15-11-5-1-3-7(13(17)18)10-8(14(19)20)4-2-6(9(5)10)12(11)16/h1-4H
DM07HYA CS C1=CC(=C2C(=CC=C3C2=C1C(=O)C3=O)[N+](=O)[O-])[N+](=O)[O-]
DM07HYA IK HKNXJYVCBQHLBT-UHFFFAOYSA-N
DM07HYA IU 5,6-dinitroacenaphthylene-1,2-dione
DM07HYA DE Discovery agent
DMXTYCU ID DMXTYCU
DMXTYCU DN 5,6-epoxyeicosatrienoic acid
DMXTYCU HS Investigative
DMXTYCU SN (+/-)5,6-EpETrE; (+/-)5,6-epoxy-8Z,11Z,14Z-eicosatrienoic acid
DMXTYCU DT Small molecular drug
DMXTYCU PC 5283202
DMXTYCU MW 320.5
DMXTYCU FM C20H32O3
DMXTYCU IC InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-19(23-18)16-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-
DMXTYCU CS CCCCC/C=C\\C/C=C\\C/C=C\\CC1C(O1)CCCC(=O)O
DMXTYCU IK VBQNSZQZRAGRIX-QNEBEIHSSA-N
DMXTYCU IU 4-[3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trienyl]oxiran-2-yl]butanoic acid
DMXTYCU CA CAS 81246-84-6
DMXTYCU CB CHEBI:34450
DMXTYCU DE Discovery agent
DMA50BQ ID DMA50BQ
DMA50BQ DN 5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione
DMA50BQ HS Investigative
DMA50BQ SN CHEMBL336017; 5,7-Dibromo-1,4-dihydro-2,3-quinoxalinedione; 153504-78-0; 5,7-dibromo-1,4-dihydroquinoxaline-2,3-dione; Oprea1_150165; SCHEMBL2638792; SCHEMBL8557193; KAMOVQVEAFPAHG-UHFFFAOYSA-N
DMA50BQ DT Small molecular drug
DMA50BQ PC 10591750
DMA50BQ MW 319.94
DMA50BQ FM C8H4Br2N2O2
DMA50BQ IC InChI=1S/C8H4Br2N2O2/c9-3-1-4(10)6-5(2-3)11-7(13)8(14)12-6/h1-2H,(H,11,13)(H,12,14)
DMA50BQ CS C1=C(C=C(C2=C1NC(=O)C(=O)N2)Br)Br
DMA50BQ IK KAMOVQVEAFPAHG-UHFFFAOYSA-N
DMA50BQ IU 5,7-dibromo-1,4-dihydroquinoxaline-2,3-dione
DMA50BQ DE Discovery agent
DMZLOVB ID DMZLOVB
DMZLOVB DN 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB HS Investigative
DMZLOVB SN 7-Bromoeudistomine D; 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol; 7-bromo-eudistomin D; CHEMBL272185; 101927-49-5; Bromo-eudistomin D; Bromoeudistomin D; AC1L2SZQ; 5,7-Dibromo-9H-prido(3,4-b)indol-6-ol; SCHEMBL7085913; DTXSID80144350; BDBM50207817; 9H-Prido(3,4-b)indol-6-ol, 5,7-dibromo-
DMZLOVB DT Small molecular drug
DMZLOVB PC 127993
DMZLOVB MW 341.99
DMZLOVB FM C11H6Br2N2O
DMZLOVB IC InChI=1S/C11H6Br2N2O/c12-6-3-7-9(10(13)11(6)16)5-1-2-14-4-8(5)15-7/h1-4,15-16H
DMZLOVB CS C1=CN=CC2=C1C3=C(C(=C(C=C3N2)Br)O)Br
DMZLOVB IK UNIUKKWPGRGSRQ-UHFFFAOYSA-N
DMZLOVB IU 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol
DMZLOVB CA CAS 101927-49-5
DMZLOVB DE Discovery agent
DMOJ5LM ID DMOJ5LM
DMOJ5LM DN 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione
DMOJ5LM HS Investigative
DMOJ5LM SN CHEMBL282003; 5,7-dichloroquinoxaline-2,3-diol; 5,7-Dichloro-quinoxaline-2,3-diol; BAS 01357242; 5,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 5,7-Dichloro-1,4-dihydro-2,3-quinoxalinedione; MLS000026787; AC1LCHFV; 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; Oprea1_426848; SCHEMBL7345532; SCHEMBL2639494; MolPort-002-737-915; DBSHFABBWSZJLZ-UHFFFAOYSA-N; HMS2397P18; ZINC12428297; STK782684; BDBM50008757; AKOS022421131; AKOS005619834; AKOS000543707; MCULE-5094494417; ST088493; ST042190; SMR000010423; 4029-54-3
DMOJ5LM DT Small molecular drug
DMOJ5LM PC 650260
DMOJ5LM MW 231.03
DMOJ5LM FM C8H4Cl2N2O2
DMOJ5LM IC InChI=1S/C8H4Cl2N2O2/c9-3-1-4(10)6-5(2-3)11-7(13)8(14)12-6/h1-2H,(H,11,13)(H,12,14)
DMOJ5LM CS C1=C(C=C(C2=C1NC(=O)C(=O)N2)Cl)Cl
DMOJ5LM IK DBSHFABBWSZJLZ-UHFFFAOYSA-N
DMOJ5LM IU 5,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
DMOJ5LM DE Discovery agent
DMFHDWG ID DMFHDWG
DMFHDWG DN 5,7-dichloro-1H-indole-2,3-dione
DMFHDWG HS Investigative
DMFHDWG SN 5,7-Dichloroisatin; 6374-92-1; 5,7-Dichloroindoline-2,3-dione; 5,7-Dichloro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5,7-dichloro-; NSC26045; 5,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; MLS002639083; AYGGQJHJRFZDFH-UHFFFAOYSA-N; 5,7-dichloro-1H-benzo[d]azolidine-2,3-dione; 5,7-dichlor-1h-indol-2,3-dion; EINECS 228-928-3; Indole-2,3-dione, 5,7-dichloro-; Isatin,7-dichloro-; PubChem22561; AC1Q3MQY; Isatin, 5,7-dichloro-; ACMC-1B7TC; NCIMech_000038; Isatin-based compound, 53; Cambridge id 5228213; AC1Q3I9X; CBDivE_012174
DMFHDWG DT Small molecular drug
DMFHDWG PC 80771
DMFHDWG MW 216.02
DMFHDWG FM C8H3Cl2NO2
DMFHDWG IC InChI=1S/C8H3Cl2NO2/c9-3-1-4-6(5(10)2-3)11-8(13)7(4)12/h1-2H,(H,11,12,13)
DMFHDWG CS C1=C(C=C(C2=C1C(=O)C(=O)N2)Cl)Cl
DMFHDWG IK AYGGQJHJRFZDFH-UHFFFAOYSA-N
DMFHDWG IU 5,7-dichloro-1H-indole-2,3-dione
DMFHDWG CA CAS 6374-92-1
DMFHDWG DE Discovery agent
DMUADN4 ID DMUADN4
DMUADN4 DN 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4 HS Investigative
DMUADN4 PC 23354226
DMUADN4 MW 247.03
DMUADN4 FM C8H4Cl2N2O3
DMUADN4 IC InChI=1S/C8H4Cl2N2O3/c9-3-1-4(10)6-5(2-3)11-8(14)12(15)7(6)13/h1-2,15H,(H,11,14)
DMUADN4 CS C1=C(C=C(C2=C1NC(=O)N(C2=O)O)Cl)Cl
DMUADN4 IK MVMRFDFKPNDLQJ-UHFFFAOYSA-N
DMUADN4 IU 5,7-dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMUADN4 DE Discovery agent
DMZJKIU ID DMZJKIU
DMZJKIU DN 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU HS Investigative
DMZJKIU SN CHEMBL104298
DMZJKIU DT Small molecular drug
DMZJKIU PC 54710618
DMZJKIU MW 306.1
DMZJKIU FM C15H9Cl2NO2
DMZJKIU IC InChI=1S/C15H9Cl2NO2/c16-9-6-10(17)13-11(7-9)18-15(20)12(14(13)19)8-4-2-1-3-5-8/h1-7H,(H2,18,19,20)
DMZJKIU CS C1=CC=C(C=C1)C2=C(C3=C(C=C(C=C3Cl)Cl)NC2=O)O
DMZJKIU IK ZIMBGBQTQUNKLP-UHFFFAOYSA-N
DMZJKIU IU 5,7-dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one
DMZJKIU DE Discovery agent
DMHKQ1L ID DMHKQ1L
DMHKQ1L DN 5,7-Dichlorokynurenic Acid
DMHKQ1L HS Investigative
DMHKQ1L SN Dcka
DMHKQ1L DT Small molecular drug
DMHKQ1L PC 1779
DMHKQ1L MW 258.05
DMHKQ1L FM C10H5Cl2NO3
DMHKQ1L IC InChI=1S/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)
DMHKQ1L CS C1=C(C=C(C2=C1NC(=CC2=O)C(=O)O)Cl)Cl
DMHKQ1L IK BGKFPRIGXAVYNX-UHFFFAOYSA-N
DMHKQ1L IU 5,7-dichloro-4-oxo-1H-quinoline-2-carboxylic acid
DMHKQ1L CA CAS 131123-76-7
DMHKQ1L CB CHEBI:107660
DMHKQ1L DE Discovery agent
DMA61I2 ID DMA61I2
DMA61I2 DN 5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one
DMA61I2 HS Investigative
DMA61I2 SN 3-arylquinazolinone, 1au; CHEMBL378572; BDBM19929
DMA61I2 DT Small molecular drug
DMA61I2 PC 11579722
DMA61I2 MW 254.24
DMA61I2 FM C14H10N2O3
DMA61I2 IC InChI=1S/C14H10N2O3/c17-10-6-11-13(12(18)7-10)14(19)16(8-15-11)9-4-2-1-3-5-9/h1-8,17-18H
DMA61I2 CS C1=CC=C(C=C1)N2C=NC3=C(C2=O)C(=CC(=C3)O)O
DMA61I2 IK LUBZIRZXRMLBKH-UHFFFAOYSA-N
DMA61I2 IU 5,7-dihydroxy-3-phenylquinazolin-4-one
DMA61I2 DE Discovery agent
DM724JF ID DM724JF
DM724JF DN 5,7-Dimethoxy-3-pyridin-4-yl-quinoline
DM724JF HS Investigative
DM724JF SN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline; 137206-97-4; 5,7-dimethoxy-3-(pyridin-4-yl)quinoline; CHEMBL68423; Quinoline,5,7-dimethoxy-3-(4-pyridinyl)-; 5,7-Dmpq; Bio1_000429; Tocris-1222; 5,7-Dimethoxy-3-pyridin-4-yl-quinoline; ACMC-20c86u; AC1L1F9B; AC1Q4YD3; SCHEMBL3652915; CTK4C0691; DTXSID90160107; Bio1_001407; Bio1_000918; ZINC2581408; BDBM50039655; AKOS030239521; 5,7-Dimethoxy-3-(4-pyridyl)quinoline; 5,7-dimethoxy-3-pyridin-4-ylquinoline; NCGC00025053-01; AJ-43025; KB-291722; DB-063190
DM724JF DT Small molecular drug
DM724JF PC 3139
DM724JF MW 266.29
DM724JF FM C16H14N2O2
DM724JF IC InChI=1S/C16H14N2O2/c1-19-13-8-15-14(16(9-13)20-2)7-12(10-18-15)11-3-5-17-6-4-11/h3-10H,1-2H3
DM724JF CS COC1=CC2=C(C=C(C=N2)C3=CC=NC=C3)C(=C1)OC
DM724JF IK HBXDLZBPKJEWHZ-UHFFFAOYSA-N
DM724JF IU 5,7-dimethoxy-3-pyridin-4-ylquinoline
DM724JF CA CAS 137206-97-4
DM724JF DE Discovery agent
DMJAQ41 ID DMJAQ41
DMJAQ41 DN 5,7-Dimethoxy-3-thiophen-3-yl-quinoline
DMJAQ41 HS Investigative
DMJAQ41 SN CHEMBL66071; 5,7-dimethoxy-3-thiophen-3-yl-quinoline; ZINC3834026
DMJAQ41 DT Small molecular drug
DMJAQ41 PC 10355832
DMJAQ41 MW 271.3
DMJAQ41 FM C15H13NO2S
DMJAQ41 IC InChI=1S/C15H13NO2S/c1-17-12-6-14-13(15(7-12)18-2)5-11(8-16-14)10-3-4-19-9-10/h3-9H,1-2H3
DMJAQ41 CS COC1=CC2=C(C=C(C=N2)C3=CSC=C3)C(=C1)OC
DMJAQ41 IK OOSYGDRIWJDGFV-UHFFFAOYSA-N
DMJAQ41 IU 5,7-dimethoxy-3-thiophen-3-ylquinoline
DMJAQ41 DE Discovery agent
DMU618S ID DMU618S
DMU618S DN 5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMU618S HS Investigative
DMU618S SN NSC676189; AC1NV5AO; SCHEMBL7921784; CHEMBL102019; ZINC6491121; NSC-676189; NCI60_026916; 5,7-dimethyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMU618S DT Small molecular drug
DMU618S PC 5468783
DMU618S MW 264.32
DMU618S FM C17H16N2O
DMU618S IC InChI=1S/C17H16N2O/c1-10-5-4-6-13(7-10)14-9-15(20)16-11(2)8-12(3)18-17(16)19-14/h4-9H,1-3H3,(H,18,19,20)
DMU618S CS CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=C(C=C3C)C
DMU618S IK RXJJJRMOQDHINF-UHFFFAOYSA-N
DMU618S IU 5,7-dimethyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMU618S DE Discovery agent
DM3P79O ID DM3P79O
DM3P79O DN 5,7-Dimethyl-3-thiophen-3-yl-quinoline
DM3P79O HS Investigative
DM3P79O SN CHEMBL304333; 5,7-dimethyl-3-thiophen-3-yl-quinoline; SCHEMBL8501282; ZINC3832218
DM3P79O DT Small molecular drug
DM3P79O PC 10060170
DM3P79O MW 239.3
DM3P79O FM C15H13NS
DM3P79O IC InChI=1S/C15H13NS/c1-10-5-11(2)14-7-13(8-16-15(14)6-10)12-3-4-17-9-12/h3-9H,1-2H3
DM3P79O CS CC1=CC(=C2C=C(C=NC2=C1)C3=CSC=C3)C
DM3P79O IK YXZQRTLGEGYVTJ-UHFFFAOYSA-N
DM3P79O IU 5,7-dimethyl-3-thiophen-3-ylquinoline
DM3P79O DE Discovery agent
DMG4UCX ID DMG4UCX
DMG4UCX DN 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione
DMG4UCX HS Investigative
DMG4UCX SN 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL323335; 136529-54-9; Biomol-NT_000208; SCHEMBL8123057; SCHEMBL8114607; SCHEMBL4706926; BPBio1_001268; BDBM50038162; NCGC00163270-01; 5,7-Dinitroquinoxaline-2,3(1H,4H)-dione
DMG4UCX DT Small molecular drug
DMG4UCX PC 16760018
DMG4UCX MW 252.14
DMG4UCX FM C8H4N4O6
DMG4UCX IC InChI=1S/C8H4N4O6/c13-7-8(14)10-6-4(9-7)1-3(11(15)16)2-5(6)12(17)18/h1-2H,(H,9,13)(H,10,14)
DMG4UCX CS C1=C(C=C(C2=C1NC(=O)C(=O)N2)[N+](=O)[O-])[N+](=O)[O-]
DMG4UCX IK YUVRBZPHIDJESL-UHFFFAOYSA-N
DMG4UCX IU 5,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
DMG4UCX DE Discovery agent
DM4TIXY ID DM4TIXY
DM4TIXY DN 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol
DM4TIXY HS Investigative
DM4TIXY SN CHEMBL374938; 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol; SCHEMBL14164225; BDBM50205282
DM4TIXY DT Small molecular drug
DM4TIXY PC 11150373
DM4TIXY MW 287.3
DM4TIXY FM C18H13N3O
DM4TIXY IC InChI=1S/C18H13N3O/c22-18-20-16-14(12-7-3-1-4-8-12)11-15(19-17(16)21-18)13-9-5-2-6-10-13/h1-11H,(H2,19,20,21,22)
DM4TIXY CS C1=CC=C(C=C1)C2=CC(=NC3=C2NC(=O)N3)C4=CC=CC=C4
DM4TIXY IK SHTZPAWLYJASHR-UHFFFAOYSA-N
DM4TIXY IU 5,7-diphenyl-1,3-dihydroimidazo[4,5-b]pyridin-2-one
DM4TIXY DE Discovery agent
DMKXIWQ ID DMKXIWQ
DMKXIWQ DN 5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol
DMKXIWQ HS Investigative
DMKXIWQ DT Small molecular drug
DMKXIWQ PC 135463744
DMKXIWQ MW 287.3
DMKXIWQ FM C18H13N3O
DMKXIWQ IC InChI=1S/C18H13N3O/c22-18-16-15(13-7-3-1-4-8-13)11-21(17(16)19-12-20-18)14-9-5-2-6-10-14/h1-12H,(H,19,20,22)
DMKXIWQ CS C1=CC=C(C=C1)C2=CN(C3=C2C(=O)NC=N3)C4=CC=CC=C4
DMKXIWQ IK YTLWLZPZXNOVGS-UHFFFAOYSA-N
DMKXIWQ IU 5,7-diphenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one
DMKXIWQ DE Discovery agent
DMOCEPA ID DMOCEPA
DMOCEPA DN 5,8-Dihydroxy-1,4-naphthoquinone
DMOCEPA HS Investigative
DMOCEPA SN Naphthazarin; 475-38-7; Naphthazarine; 5,8-dihydroxynaphthalene-1,4-dione; Naphthazarone; 5,8-Dihydroxynaphthoquinone; 5,8-Dihydroxy-1,4-naphthalenedione; NAPHTHAZALIN; 5,8-Dihydroxynaphthalene-1,4(4aH,8aH)-dione; 5,8-Dihydroxy-1,4-naphthosemiquinone; CCRIS 6670; Dihydroxynaphthoquinone; EINECS 207-495-4; NSC 26647; UNII-S9IX5I5C0K; S9IX5I5C0K; CHEMBL274056; CHEBI:28849; 1,4-NAPHTHOQUINONE, 5,8-DIHYDROXY-; NSC26647; 5,8-Dihydroxy-[1,4]naphthoquinone; NSC344555
DMOCEPA DT Small molecular drug
DMOCEPA PC 10141
DMOCEPA MW 190.15
DMOCEPA FM C10H6O4
DMOCEPA IC InChI=1S/C10H6O4/c11-5-1-2-6(12)10-8(14)4-3-7(13)9(5)10/h1-4,11-12H
DMOCEPA CS C1=CC(=C2C(=O)C=CC(=O)C2=C1O)O
DMOCEPA IK RQNVIKXOOKXAJQ-UHFFFAOYSA-N
DMOCEPA IU 5,8-dihydroxynaphthalene-1,4-dione
DMOCEPA CA CAS 475-38-7
DMOCEPA CB CHEBI:28849
DMOCEPA DE Malaria
DMJ1IRO ID DMJ1IRO
DMJ1IRO DN 5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMJ1IRO HS Investigative
DMJ1IRO SN 5,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one; 5,8-dimethoxy-1,4-dimethylquinolin-2-one; 131451-78-0; BAS 13027560; casimiroin analogue, 1l; AC1LT9OM; 5,8-Dimethoxy-1,4-dimethyl-1H-quinolin-2-one; CHEMBL490867; BDBM29223; MolPort-002-024-473; FTGZPMFPUDKJBX-UHFFFAOYSA-N; HMS3604K14; ZINC1423886; STK736911; AKOS000643970; DB08228; MCULE-6770591553; ST4106238; 5,8-dimethoxy-1,4-dimethylhydroquinolin-2-one; 5,8-dimethoxy-1,4-dimethyl-2(1H)-quinolinone; 1,4-Dimethyl-5,8-dimethoxyquinolin-2(1H)-one; 1H-Quinolin-2-one, 5,8-dimethoxy-1
DMJ1IRO DT Small molecular drug
DMJ1IRO PC 1504717
DMJ1IRO MW 233.26
DMJ1IRO FM C13H15NO3
DMJ1IRO IC InChI=1S/C13H15NO3/c1-8-7-11(15)14(2)13-10(17-4)6-5-9(16-3)12(8)13/h5-7H,1-4H3
DMJ1IRO CS CC1=CC(=O)N(C2=C(C=CC(=C12)OC)OC)C
DMJ1IRO IK FTGZPMFPUDKJBX-UHFFFAOYSA-N
DMJ1IRO IU 5,8-dimethoxy-1,4-dimethylquinolin-2-one
DMJ1IRO DE Discovery agent
DMEMBKW ID DMEMBKW
DMEMBKW DN 5,8-Dimethoxy-4-methylquinolin-2(1H)-one
DMEMBKW HS Investigative
DMEMBKW SN 5,8-Dimethoxy-4-methylquinolin-2(1H)-one; 23947-41-3; 2(1h)-quinolinone, 5,8-dimethoxy-4-methyl-; 5,8-dimethoxy-4-methyl-2-quinolinol; 5,8-dimethoxy-4-methylquinolin-2-ol; ST056710; 5,8-dimethoxy-4-methylhydroquinolin-2-one; 2(1H)-Quinolinone,5,8-dimethoxy-4-methyl-; MZX; NSC109761; casimiroin analogue, 1k; AC1L6LUU; AC1Q6I1R; TimTec1_003888; Oprea1_236890; Oprea1_728115; CHEMBL493174; BDBM29222; CTK4F2623; DTXSID30296530; MolPort-000-699-993; MolPort-002-514-269; BUHDAIGNGIXQJO-UHFFFAOYSA-N; HMS1545A16; ZINC8817671; ALBB-032301
DMEMBKW DT Small molecular drug
DMEMBKW PC 269167
DMEMBKW MW 219.24
DMEMBKW FM C12H13NO3
DMEMBKW IC InChI=1S/C12H13NO3/c1-7-6-10(14)13-12-9(16-3)5-4-8(15-2)11(7)12/h4-6H,1-3H3,(H,13,14)
DMEMBKW CS CC1=CC(=O)NC2=C(C=CC(=C12)OC)OC
DMEMBKW IK BUHDAIGNGIXQJO-UHFFFAOYSA-N
DMEMBKW IU 5,8-dimethoxy-4-methyl-1H-quinolin-2-one
DMEMBKW CA CAS 23947-41-3
DMEMBKW DE Discovery agent
DM1SO62 ID DM1SO62
DM1SO62 DN 5,8-hydroxy-naphthoquinone
DM1SO62 HS Investigative
DM1SO62 DE Discovery agent
DM3MSZN ID DM3MSZN
DM3MSZN DN 5,N-Dihydroxythalidomide
DM3MSZN HS Investigative
DM3MSZN SN 5,N-Dihydroxythalidomide; 5,1'-Dihydroxythalidomide; 5,1'-Dihydroxy thalidomide; 5,1'-Dihydroxy thalidomide, (+/-)-; CHEMBL479546; 1H-Isoindole-1,3(2H)-dione, 5-hydroxy-2-(1-hydroxy-2,6-dioxo-3-piperidinyl)-; 478785-12-5
DM3MSZN DT Small molecular drug
DM3MSZN PC 10356851
DM3MSZN MW 290.23
DM3MSZN FM C13H10N2O6
DM3MSZN IC InChI=1S/C13H10N2O6/c16-6-1-2-7-8(5-6)12(19)14(11(7)18)9-3-4-10(17)15(21)13(9)20/h1-2,5,9,16,21H,3-4H2
DM3MSZN CS C1CC(=O)N(C(=O)C1N2C(=O)C3=C(C2=O)C=C(C=C3)O)O
DM3MSZN IK RLBGOICZNMULCW-UHFFFAOYSA-N
DM3MSZN IU 5-hydroxy-2-(1-hydroxy-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
DM3MSZN CA CAS 478785-12-5
DM3MSZN DE Discovery agent
DM23PL4 ID DM23PL4
DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate
DM23PL4 HS Investigative
DM23PL4 SN CHEMBL283019; (r)-5-(1-aminoethyl)-3-isoxazolol
DM23PL4 DT Small molecular drug
DM23PL4 PC 44278344
DM23PL4 MW 128.13
DM23PL4 FM C5H8N2O2
DM23PL4 IC InChI=1S/C5H8N2O2/c1-3(6)4-2-5(8)7-9-4/h2-3H,6H2,1H3,(H,7,8)/t3-/m1/s1
DM23PL4 CS C[C@H](C1=CC(=O)NO1)N
DM23PL4 IK ICRYUJPBYIPXQF-GSVOUGTGSA-N
DM23PL4 IU 5-[(1R)-1-aminoethyl]-1,2-oxazol-3-one
DM23PL4 DE Discovery agent
DMYAPLT ID DMYAPLT
DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate
DMYAPLT HS Investigative
DMYAPLT SN CHEMBL285783; 5-[(S)-1-Aminoethyl]isoxazol-3-ol; AKOS022719281
DMYAPLT DT Small molecular drug
DMYAPLT PC 44279120
DMYAPLT MW 128.13
DMYAPLT FM C5H8N2O2
DMYAPLT IC InChI=1S/C5H8N2O2/c1-3(6)4-2-5(8)7-9-4/h2-3H,6H2,1H3,(H,7,8)/t3-/m0/s1
DMYAPLT CS C[C@@H](C1=CC(=O)NO1)N
DMYAPLT IK ICRYUJPBYIPXQF-VKHMYHEASA-N
DMYAPLT IU 5-[(1S)-1-aminoethyl]-1,2-oxazol-3-one
DMYAPLT DE Discovery agent
DMM9GCA ID DMM9GCA
DMM9GCA DN 5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine
DMM9GCA HS Investigative
DMM9GCA SN CHEMBL202042; 5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine; SCHEMBL4144583
DMM9GCA DT Small molecular drug
DMM9GCA PC 11600877
DMM9GCA MW 201.25
DMM9GCA FM C10H7N3S
DMM9GCA IC InChI=1S/C10H7N3S/c1-8-13-10(6-14-8)3-2-9-4-11-7-12-5-9/h4-7H,1H3
DMM9GCA CS CC1=NC(=CS1)C#CC2=CN=CN=C2
DMM9GCA IK ILVDLPMGOZQXLY-UHFFFAOYSA-N
DMM9GCA IU 2-methyl-4-(2-pyrimidin-5-ylethynyl)-1,3-thiazole
DMM9GCA DE Discovery agent
DMLFY2T ID DMLFY2T
DMLFY2T DN 5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole
DMLFY2T HS Investigative
DMLFY2T SN 5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole; 3fuj; DB06828; 5-[2-(pyrrol-1-yl)ethoxy]-1H-indole
DMLFY2T DT Small molecular drug
DMLFY2T PC 44129621
DMLFY2T MW 226.27
DMLFY2T FM C14H14N2O
DMLFY2T IC InChI=1S/C14H14N2O/c1-2-8-16(7-1)9-10-17-13-3-4-14-12(11-13)5-6-15-14/h1-8,11,15H,9-10H2
DMLFY2T CS C1=CN(C=C1)CCOC2=CC3=C(C=C2)NC=C3
DMLFY2T IK NSZDJRLPCLOQAM-UHFFFAOYSA-N
DMLFY2T IU 5-(2-pyrrol-1-ylethoxy)-1H-indole
DMLFY2T DE Discovery agent
DM1KO7U ID DM1KO7U
DM1KO7U DN 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol
DM1KO7U HS Investigative
DM1KO7U SN Dihydroresveratrol; 58436-28-5; 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol; 3,4',5-Trihydroxybibenzyl; CHEMBL111234; CHEBI:4582; 5-(4-hydroxyphenethyl)benzene-1,3-diol; Dihydroresveratol; 3ftu; Dihydro-Resveratrol; RE2; a, b-Dihydroresveratrol; AC1L4HRG; C10255; 5-[2-(4-hydroxyphenyl)ethyl]-1,3-Benzenediol; 3,5,4'-trihydroxybibenzyl; 3,4'',5-trihydroxybibenzyl; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethyl)-; SCHEMBL716856; AC1Q79W7; CTK5A8302; MolPort-035-706-156; ZINC899123; LMPK13090035; BDBM50085531; NSC723534; AKOS030555676
DM1KO7U DT Small molecular drug
DM1KO7U PC 185914
DM1KO7U MW 230.26
DM1KO7U FM C14H14O3
DM1KO7U IC InChI=1S/C14H14O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h3-9,15-17H,1-2H2
DM1KO7U CS C1=CC(=CC=C1CCC2=CC(=CC(=C2)O)O)O
DM1KO7U IK HITJFUSPLYBJPE-UHFFFAOYSA-N
DM1KO7U IU 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol
DM1KO7U CA CAS 58436-28-5
DM1KO7U CB CHEBI:4582
DM1KO7U DE Discovery agent
DMW8RLN ID DMW8RLN
DMW8RLN DN 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole
DMW8RLN HS Investigative
DMW8RLN SN CHEMBL1214737; 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole; ZINC58581744
DMW8RLN DT Small molecular drug
DMW8RLN PC 46901927
DMW8RLN MW 284.4
DMW8RLN FM C20H16N2
DMW8RLN IC InChI=1S/C20H16N2/c1-3-17(18-5-6-20-19(14-18)9-12-22-20)4-2-15(1)13-16-7-10-21-11-8-16/h1-12,14,22H,13H2
DMW8RLN CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC4=C(C=C3)NC=C4
DMW8RLN IK VVBPUVXDCLUNKF-UHFFFAOYSA-N
DMW8RLN IU 5-[4-(pyridin-4-ylmethyl)phenyl]-1H-indole
DMW8RLN DE Discovery agent
DMV7QU3 ID DMV7QU3
DMV7QU3 DN 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole
DMV7QU3 HS Investigative
DMV7QU3 SN Imidazolylmethyleneindane 9a; AC1O70GV; BDBM8883; SCHEMBL4231848; CHEMBL177293; 5-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole; 5-[(E)-(5-Bromo-2,3-dihydro-1H-inden-1-ylidene)methyl]-1H-imidazole
DMV7QU3 DT Small molecular drug
DMV7QU3 PC 6540042
DMV7QU3 MW 275.14
DMV7QU3 FM C13H11BrN2
DMV7QU3 IC InChI=1S/C13H11BrN2/c14-11-3-4-13-9(5-11)1-2-10(13)6-12-7-15-8-16-12/h3-8H,1-2H2,(H,15,16)/b10-6+
DMV7QU3 CS C1C/C(=C\\C2=CN=CN2)/C3=C1C=C(C=C3)Br
DMV7QU3 IK SNWLVVNOSVKKRA-UXBLZVDNSA-N
DMV7QU3 IU 5-[(E)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole
DMV7QU3 DE Discovery agent
DMZICL8 ID DMZICL8
DMZICL8 DN 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole
DMZICL8 HS Investigative
DMZICL8 SN AC1O70GX; SCHEMBL4231849; CHEMBL174579
DMZICL8 DT Small molecular drug
DMZICL8 PC 6540043
DMZICL8 MW 275.14
DMZICL8 FM C13H11BrN2
DMZICL8 IC InChI=1S/C13H11BrN2/c14-11-3-4-13-9(5-11)1-2-10(13)6-12-7-15-8-16-12/h3-8H,1-2H2,(H,15,16)/b10-6-
DMZICL8 CS C1C/C(=C/C2=CN=CN2)/C3=C1C=C(C=C3)Br
DMZICL8 IK SNWLVVNOSVKKRA-POHAHGRESA-N
DMZICL8 IU 5-[(Z)-(5-bromo-2,3-dihydroinden-1-ylidene)methyl]-1H-imidazole
DMZICL8 DE Discovery agent
DM2RIHT ID DM2RIHT
DM2RIHT DN 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine
DM2RIHT HS Investigative
DM2RIHT SN AC1O706P; CHEMBL195248; SCHEMBL4225537; SCHEMBL4225546; BDBM8631; (5-pyrimidylmethylene)indane 28a; ZINC13535842; 5-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DM2RIHT DT Small molecular drug
DM2RIHT PC 6539805
DM2RIHT MW 226.25
DM2RIHT FM C14H11FN2
DM2RIHT IC InChI=1S/C14H11FN2/c15-13-3-4-14-11(1-2-12(14)6-13)5-10-7-16-9-17-8-10/h3-9H,1-2H2/b11-5+
DM2RIHT CS C1C/C(=C\\C2=CN=CN=C2)/C3=C1C=C(C=C3)F
DM2RIHT IK LEJPKWXGQFBXRX-VZUCSPMQSA-N
DM2RIHT IU 5-[(E)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DM2RIHT DE Discovery agent
DMQGX2Z ID DMQGX2Z
DMQGX2Z DN 5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine
DMQGX2Z HS Investigative
DMQGX2Z SN (5-pyrimidylmethylene)indane 28b; SCHEMBL4225541; AC1O706V; CHEMBL364956; BDBM8634; 5-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DMQGX2Z DT Small molecular drug
DMQGX2Z PC 6539808
DMQGX2Z MW 226.25
DMQGX2Z FM C14H11FN2
DMQGX2Z IC InChI=1S/C14H11FN2/c15-13-3-4-14-11(1-2-12(14)6-13)5-10-7-16-9-17-8-10/h3-9H,1-2H2/b11-5-
DMQGX2Z CS C1C/C(=C/C2=CN=CN=C2)/C3=C1C=C(C=C3)F
DMQGX2Z IK LEJPKWXGQFBXRX-WZUFQYTHSA-N
DMQGX2Z IU 5-[(Z)-(5-fluoro-2,3-dihydroinden-1-ylidene)methyl]pyrimidine
DMQGX2Z DE Discovery agent
DM5FA74 ID DM5FA74
DM5FA74 DN 5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole
DM5FA74 HS Investigative
DM5FA74 SN (5-Thiazolemethylene)indane 27a; BDBM8632; CHEMBL192155; AC1O706R; 5-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole
DM5FA74 DT Small molecular drug
DM5FA74 PC 6539806
DM5FA74 MW 243.33
DM5FA74 FM C14H13NOS
DM5FA74 IC InChI=1S/C14H13NOS/c1-16-12-4-5-14-10(6-12)2-3-11(14)7-13-8-15-9-17-13/h4-9H,2-3H2,1H3/b11-7+
DM5FA74 CS COC1=CC2=C(C=C1)/C(=C/C3=CN=CS3)/CC2
DM5FA74 IK YBVSJXCRZPLUNH-YRNVUSSQSA-N
DM5FA74 IU 5-[(E)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole
DM5FA74 DE Discovery agent
DMPDN63 ID DMPDN63
DMPDN63 DN 5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole
DMPDN63 HS Investigative
DMPDN63 SN CHEMBL195354; BDBM8633; AC1O706T; (5-Thiazolemethylene)indane 27b; 5-{[(1Z)-5-methoxy-2,3-dihydro-1H-inden-1-ylidene]methyl}-1,3-thiazole
DMPDN63 DT Small molecular drug
DMPDN63 PC 6539807
DMPDN63 MW 243.33
DMPDN63 FM C14H13NOS
DMPDN63 IC InChI=1S/C14H13NOS/c1-16-12-4-5-14-10(6-12)2-3-11(14)7-13-8-15-9-17-13/h4-9H,2-3H2,1H3/b11-7-
DMPDN63 CS COC1=CC2=C(C=C1)/C(=C\\C3=CN=CS3)/CC2
DMPDN63 IK YBVSJXCRZPLUNH-XFFZJAGNSA-N
DMPDN63 IU 5-[(Z)-(5-methoxy-2,3-dihydroinden-1-ylidene)methyl]-1,3-thiazole
DMPDN63 DE Discovery agent
DMSZ3T6 ID DMSZ3T6
DMSZ3T6 DN 5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol
DMSZ3T6 HS Investigative
DMSZ3T6 SN Cardol triene; CHEMBL459603; 5-(8Z,11Z,14-Pentadecatrienyl)resorcinol; 79473-24-8; CHEBI:52680; 5-(pentadeca-8,11,14-trien-1-yl)resorcinol; 5-[(8Z,11Z)-pentadeca-8,11,14-trien-1-yl]benzene-1,3-diol; (8Z,11Z)-5-(pentadeca-8,11,14-trien-1-yl)resorcinol; 5-pentadecatrienyl resorcinol; 5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol; 5-((8Z,11Z)-pentadeca-8,11,14-trien-1-yl)benzene-1,3-diol; SCHEMBL2467234; MEGxp0_000811; ACon1_000596; DTXSID30872873; MolPort-001-740-965; 1,3-Benzenediol, 5-(8Z,11Z)-8,11,14-pentadecatrienyl-
DMSZ3T6 DT Small molecular drug
DMSZ3T6 PC 13259919
DMSZ3T6 MW 314.5
DMSZ3T6 FM C21H30O2
DMSZ3T6 IC InChI=1S/C21H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h2,4-5,7-8,16-18,22-23H,1,3,6,9-15H2/b5-4-,8-7-
DMSZ3T6 CS C=CC/C=C\\C/C=C\\CCCCCCCC1=CC(=CC(=C1)O)O
DMSZ3T6 IK OOXBEOHCOCMKAC-UTOQUPLUSA-N
DMSZ3T6 IU 5-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzene-1,3-diol
DMSZ3T6 CA CAS 79473-24-8
DMSZ3T6 CB CHEBI:52680
DMSZ3T6 DE Discovery agent
DM0EBWR ID DM0EBWR
DM0EBWR DN 5-{8(Z),11(Z)-pentadecadienyl}resorcinol
DM0EBWR HS Investigative
DM0EBWR SN 5-{8(Z),11(Z)-pentadecadienyl}resorcinol; CHEMBL459604; 5-(8,11-Pentadecadienyl)-1,3-benzenediol; 5-[(8Z,11Z)-pentadeca-8,11-dien-1-yl]benzene-1,3-diol; Cardoldiene; 5-((8Z,11Z)-pentadeca-8,11-dien-1-yl)benzene-1,3-diol; SCHEMBL9475761; DTXSID70872872; MolPort-005-944-663; 79473-25-9; ZINC31157863; LMPK15030021; BDBM50292428; AKOS030555484; MCULE-2398296746; RESORCINOL(15:2(8Z,11Z)); 5-(pentadeca-8,11-dienyl)benzene-1,3-diol; 5-((8Z,11Z)-pentadeca-8,11-dien-1-yl)resorcinol
DM0EBWR DT Small molecular drug
DM0EBWR PC 11702450
DM0EBWR MW 316.5
DM0EBWR FM C21H32O2
DM0EBWR IC InChI=1S/C21H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h4-5,7-8,16-18,22-23H,2-3,6,9-15H2,1H3/b5-4-,8-7-
DM0EBWR CS CCC/C=C\\C/C=C\\CCCCCCCC1=CC(=CC(=C1)O)O
DM0EBWR IK UFMJCOLGRWKUKO-UTOQUPLUSA-N
DM0EBWR IU 5-[(8Z,11Z)-pentadeca-8,11-dienyl]benzene-1,3-diol
DM0EBWR CA CAS 79473-25-9
DM0EBWR DE Discovery agent
DMNRWEV ID DMNRWEV
DMNRWEV DN 5-{8(Z),-pentadecenyl}resorcinol
DMNRWEV HS Investigative
DMNRWEV SN Bilobol; 5-[(8Z)-pentadec-8-en-1-yl]benzene-1,3-diol; 5-[(8Z)-pentadec-8-enyl]resorcinol; CHEBI:3104; CHEMBL461628; 5-(8Z-Pentadecenyl)resorcinol; 22910-86-7; 5-[(Z)-pentadec-8-enyl]benzene-1,3-diol; (Z)-5-(Pentadec-8-en-1-yl)benzene-1,3-diol; Trifurcatol A2; Cardol monoene; 5-{8(Z),-pentadecenyl}resorcinol; Bilobol C15:1; AC1NQZ6L; 21:1-.omega.7-Cardol; SCHEMBL164545; 5-(8'Z-heptadecenyl)resorcinol; DTXSID90872874; TUGAUFMQYWZJAB-FPLPWBNLSA-N; MolPort-005-945-917; ZINC8234356; 5-[8'(Z)-Pentadecenyl]Resorcinol
DMNRWEV DT Small molecular drug
DMNRWEV PC 5281852
DMNRWEV MW 318.5
DMNRWEV FM C21H34O2
DMNRWEV IC InChI=1S/C21H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h7-8,16-18,22-23H,2-6,9-15H2,1H3/b8-7-
DMNRWEV CS CCCCCC/C=C\\CCCCCCCC1=CC(=CC(=C1)O)O
DMNRWEV IK TUGAUFMQYWZJAB-FPLPWBNLSA-N
DMNRWEV IU 5-[(Z)-pentadec-8-enyl]benzene-1,3-diol
DMNRWEV CA CAS 22910-86-7
DMNRWEV CB CHEBI:3104
DMNRWEV DE Discovery agent
DMB7R95 ID DMB7R95
DMB7R95 DN 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide
DMB7R95 HS Investigative
DMB7R95 SN CHEMBL382537
DMB7R95 DT Small molecular drug
DMB7R95 PC 11717472
DMB7R95 MW 361.19
DMB7R95 FM C16H13BrN2O3
DMB7R95 IC InChI=1S/C16H13BrN2O3/c1-2-15(21)18-12-6-7-14(20)13(9-12)16(22)19-11-5-3-4-10(17)8-11/h2-9,20H,1H2,(H,18,21)(H,19,22)
DMB7R95 CS C=CC(=O)NC1=CC(=C(C=C1)O)C(=O)NC2=CC(=CC=C2)Br
DMB7R95 IK BVFCILADOWKWJB-UHFFFAOYSA-N
DMB7R95 IU N-(3-bromophenyl)-2-hydroxy-5-(prop-2-enoylamino)benzamide
DMB7R95 DE Discovery agent
DMHI7Y2 ID DMHI7Y2
DMHI7Y2 DN 5alpha-Androstan-3,17-Dione
DMHI7Y2 HS Investigative
DMHI7Y2 SN Androstanedione; 5alpha-Androstane-3,17-dione; 846-46-8; 5alpha-Androstan-3,17-dione; 5a-Androstanedione; 5-alpha-Androstane-3,17-dione; Dihydroandrostendione; 5alpha-Androstanedione; UNII-2KR72RNR8Z; Androstane-3,17-dione; 5.alpha.-Androstanedione; dihydroandrostenedione; 5a-Androstane-3,17-dione; 2KR72RNR8Z; A-androstane-3,17-dione; CHEMBL1230438; CHEBI:15994; 5.alpha.-Androsta-3,17-dione; RAJWOBJTTGJROA-WZNAKSSCSA-N; Androstane-3,17-dione, (5alpha)-; 5.alpha.-Androstane-3,17-dione; Androstane-3, (5.alpha.)-
DMHI7Y2 DT Small molecular drug
DMHI7Y2 PC 222865
DMHI7Y2 MW 288.4
DMHI7Y2 FM C19H28O2
DMHI7Y2 IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-16H,3-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1
DMHI7Y2 CS C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C
DMHI7Y2 IK RAJWOBJTTGJROA-WZNAKSSCSA-N
DMHI7Y2 IU (5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMHI7Y2 CA CAS 846-46-8
DMHI7Y2 CB CHEBI:15994
DMHI7Y2 DE Discovery agent
DMGA47N ID DMGA47N
DMGA47N DN 5-Amino-[1,3,4]thiadiazole-2-thiol
DMGA47N HS Investigative
DMGA47N SN 5-Amino-1,3,4-thiadiazole-2-thiol; 2349-67-9; 2-Amino-5-mercapto-1,3,4-thiadiazole; USAF PD-25; 1,3,4-Thiadiazole-2(3H)-thione, 5-amino-; NSC 21402; 5-Amino-1,3,4-thiadiazole-2(3H)-thione; 5-Amino-2-mercapto-1,3,4-thiadiazole; UNII-B1HEG7V21S; 2-AMINO-1,3,4-THIADIAZOLE-5-THIOL; 2-Thiol-5-amino-1,3,4-thiadiazole; NSC 209061; CCRIS 6893; 5-Amino-1,3,4-thiadiazoline-2-thione; 2-Mercapto-5-amino-1,3,4-thiadiazole; 1,3,4-Thiadiazole-2-thiol, 5-amino-; EINECS 219-078-4; B1HEG7V21S; 5-amino-3H-1,3,4-thiadiazole-2-thione
DMGA47N DT Small molecular drug
DMGA47N PC 2723847
DMGA47N MW 133.2
DMGA47N FM C2H3N3S2
DMGA47N IC InChI=1S/C2H3N3S2/c3-1-4-5-2(6)7-1/h(H2,3,4)(H,5,6)
DMGA47N CS C1(=NNC(=S)S1)N
DMGA47N IK GDGIVSREGUOIJZ-UHFFFAOYSA-N
DMGA47N IU 5-amino-3H-1,3,4-thiadiazole-2-thione
DMGA47N CA CAS 2349-67-9
DMGA47N DE Discovery agent
DMX37ZC ID DMX37ZC
DMX37ZC DN 5-amino-2-phenyl-oxazole-4-carboxylic acid amide
DMX37ZC HS Investigative
DMX37ZC SN CHEMBL207987; 5-amino-2-phenyloxazole-4-carboxylic acid amide; 99185-68-9; 5-amino-2-phenyl-oxazole-4-carboxylic acid amide
DMX37ZC DT Small molecular drug
DMX37ZC PC 11708263
DMX37ZC MW 203.2
DMX37ZC FM C10H9N3O2
DMX37ZC IC InChI=1S/C10H9N3O2/c11-8(14)7-9(12)15-10(13-7)6-4-2-1-3-5-6/h1-5H,12H2,(H2,11,14)
DMX37ZC CS C1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N
DMX37ZC IK UPWLRKVVLBSIPK-UHFFFAOYSA-N
DMX37ZC IU 5-amino-2-phenyl-1,3-oxazole-4-carboxamide
DMX37ZC DE Discovery agent
DM4SWJ7 ID DM4SWJ7
DM4SWJ7 DN 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide
DM4SWJ7 HS Investigative
DM4SWJ7 SN 5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide; CHEMBL382993; 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide; CTK6B8237; MolPort-000-894-518; SBB024037; BDBM50186628; STK351079; ZINC12394806; AKOS000313592; MCULE-2038651256
DM4SWJ7 DT Small molecular drug
DM4SWJ7 PC 11543063
DM4SWJ7 MW 217.22
DM4SWJ7 FM C11H11N3O2
DM4SWJ7 IC InChI=1S/C11H11N3O2/c1-6-2-4-7(5-3-6)11-14-8(9(12)15)10(13)16-11/h2-5H,13H2,1H3,(H2,12,15)
DM4SWJ7 CS CC1=CC=C(C=C1)C2=NC(=C(O2)N)C(=O)N
DM4SWJ7 IK RSMHDVYJLCPVNY-UHFFFAOYSA-N
DM4SWJ7 IU 5-amino-2-(4-methylphenyl)-1,3-oxazole-4-carboxamide
DM4SWJ7 DE Discovery agent
DMJKQ5I ID DMJKQ5I
DMJKQ5I DN 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole
DMJKQ5I HS Investigative
DMJKQ5I SN 3-(1-methyl-4-piperidyl)indole-5-ylamine; CHEMBL521235; 3-(1-methylpiperidin-4-yl)-1h-indol-5-amine; 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole; SCHEMBL427406; CTK6I2276; CKBJZDHVHHKARV-UHFFFAOYSA-N; BDBM50271135; AKOS024098950; 182564-38-1; 5-amino-3-(1-methylpiperidin-4-yl)-1H-indole; 3-(1-Methyl-4-piperidinyl)-5-amino-1H-indole
DMJKQ5I DT Small molecular drug
DMJKQ5I PC 11831220
DMJKQ5I MW 229.32
DMJKQ5I FM C14H19N3
DMJKQ5I IC InChI=1S/C14H19N3/c1-17-6-4-10(5-7-17)13-9-16-14-3-2-11(15)8-12(13)14/h2-3,8-10,16H,4-7,15H2,1H3
DMJKQ5I CS CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)N
DMJKQ5I IK CKBJZDHVHHKARV-UHFFFAOYSA-N
DMJKQ5I IU 3-(1-methylpiperidin-4-yl)-1H-indol-5-amine
DMJKQ5I DE Discovery agent
DMR853M ID DMR853M
DMR853M DN 5-amino-3,4-dihydroisoquinolin-1(2H)-one
DMR853M HS Investigative
DMR853M SN 5-amino-3,4-dihydroisoquinolin-1(2H)-one; 129075-53-2; CHEMBL594759; SCHEMBL7581623; RTPKPVYTPRJRBY-UHFFFAOYSA-N; ZINC45353622; BDBM50306284; AKOS023598631; AB53700; FCH1123505; KS-9128; CM10348; AJ-110485; 5-amino-3,4-dihydro-1(2H)-isoquinolinone; EN300-254419
DMR853M DT Small molecular drug
DMR853M PC 18369509
DMR853M MW 162.19
DMR853M FM C9H10N2O
DMR853M IC InChI=1S/C9H10N2O/c10-8-3-1-2-7-6(8)4-5-11-9(7)12/h1-3H,4-5,10H2,(H,11,12)
DMR853M CS C1CNC(=O)C2=C1C(=CC=C2)N
DMR853M IK RTPKPVYTPRJRBY-UHFFFAOYSA-N
DMR853M IU 5-amino-3,4-dihydro-2H-isoquinolin-1-one
DMR853M CA CAS 129075-53-2
DMR853M DE Discovery agent
DMBF42W ID DMBF42W
DMBF42W DN 5'-amino-5'-deoxy-alpha-D-thymidine
DMBF42W HS Investigative
DMBF42W SN CHEMBL428720; BDBM50223794; ZINC17000414
DMBF42W DT Small molecular drug
DMBF42W PC 27469877
DMBF42W MW 241.24
DMBF42W FM C10H15N3O4
DMBF42W IC InChI=1S/C10H15N3O4/c1-5-4-13(10(16)12-9(5)15)8-2-6(14)7(3-11)17-8/h4,6-8,14H,2-3,11H2,1H3,(H,12,15,16)/t6-,7+,8-/m0/s1
DMBF42W CS CC1=CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)CN)O
DMBF42W IK PYWLBQPICCQJFF-RNJXMRFFSA-N
DMBF42W IU 1-[(2S,4S,5R)-5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMBF42W DE Discovery agent
DMVPSXW ID DMVPSXW
DMVPSXW DN 5-aminoisoquinolin-1(2H)-one
DMVPSXW HS Investigative
DMVPSXW SN 5-aminoisoquinolin-1(2H)-one; 93117-08-9; 5-amino-2H-isoquinolin-1-one; 5-AMINOISOQUINOLIN-1-OL; 5-amino-1,2-dihydroisoquinolin-1-one; 5-AIQ; CHEMBL446240; 5-Amino-2H-isoquinoin-1-one; 5-AMINO-1(2H)-ISOQUINOLINONE; 5-aminoisoquinolinone; 4pnq; 32X; AC1Q6DVG; AC1L1CUR; 5-Amino-1-isoquinolinol; SCHEMBL215327; 5-Amino-1-hydroxyisoquinoline; BDBM27503; 5-amino-isoquinolin-1(2h)-one; 5-amino isoquinolin-1(2h)-one; CTK5H2122; DTXSID90274354; 1(2H)-Isoquinolinone,5-amino-; MolPort-008-423-043; MolPort-004-803-197
DMVPSXW DT Small molecular drug
DMVPSXW PC 2072
DMVPSXW MW 160.17
DMVPSXW FM C9H8N2O
DMVPSXW IC InChI=1S/C9H8N2O/c10-8-3-1-2-7-6(8)4-5-11-9(7)12/h1-5H,10H2,(H,11,12)
DMVPSXW CS C1=CC2=C(C=CNC2=O)C(=C1)N
DMVPSXW IK SVASVGVAQIVSEZ-UHFFFAOYSA-N
DMVPSXW IU 5-amino-2H-isoquinolin-1-one
DMVPSXW CA CAS 93117-08-9
DMVPSXW CB CHEBI:103965
DMVPSXW DE Discovery agent
DMWDUVC ID DMWDUVC
DMWDUVC DN 5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMWDUVC HS Investigative
DMWDUVC SN CHEMBL17643; 5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one; 2-Oxazolidinone, 5-(aminomethyl)-3-(1H-pyrrol-1-yl)-, (5R)-; BDBM50110724; 406934-17-6
DMWDUVC DT Small molecular drug
DMWDUVC PC 11008547
DMWDUVC MW 181.19
DMWDUVC FM C8H11N3O2
DMWDUVC IC InChI=1S/C8H11N3O2/c9-5-7-6-11(8(12)13-7)10-3-1-2-4-10/h1-4,7H,5-6,9H2/t7-/m0/s1
DMWDUVC CS C1[C@@H](OC(=O)N1N2C=CC=C2)CN
DMWDUVC IK OZSRSVNLPCHFKO-ZETCQYMHSA-N
DMWDUVC IU (5S)-5-(aminomethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DMWDUVC DE Discovery agent
DMZK8V5 ID DMZK8V5
DMZK8V5 DN 5-Aminomethyl-4,5-dihydro-isoxazol-3-ol
DMZK8V5 HS Investigative
DMZK8V5 SN Dihydromuscimol; 72241-46-4; CHEMBL40363; (RS)-4,5-Dihydromuscimol; 5-(aminomethyl)-1,2-oxazolidin-3-one; 3-isoxazolol, 5-(aminomethyl)-4,5-dihydro-; AC1L4Y9G; SCHEMBL2924224; AC1Q6H18; SCHEMBL12477033; CTK5D5767; 5-aminomethyl-isoxazolidin-3-one; ZHCZZTNIHDWRNS-UHFFFAOYSA-N; 5-(Aminomethyl)-3-isoxazolidinone; 3-Isoxazolidinone,5-(aminomethyl)-; BDBM50225363; 3-Isoxazolidinone, 5-(aminomethyl)-
DMZK8V5 DT Small molecular drug
DMZK8V5 PC 14601455
DMZK8V5 MW 116.12
DMZK8V5 FM C4H8N2O2
DMZK8V5 IC InChI=1S/C4H8N2O2/c5-2-3-1-4(7)6-8-3/h3H,1-2,5H2,(H,6,7)/t3-/m0/s1
DMZK8V5 CS C1[C@H](ONC1=O)CN
DMZK8V5 IK ZHCZZTNIHDWRNS-VKHMYHEASA-N
DMZK8V5 IU (5S)-5-(aminomethyl)-1,2-oxazolidin-3-one
DMZK8V5 DE Discovery agent
DMTP9DB ID DMTP9DB
DMTP9DB DN 5-Aminomethyl-naphthalen-2-ol
DMTP9DB HS Investigative
DMTP9DB SN 5-Aminomethyl-naphthalen-2-ol; 5-(aminomethyl)naphthalen-2-ol; CHEMBL131174; 170244-98-1; SCHEMBL15345565; CTK4D3537; DTXSID00658388; BDBM50061315; ZINC13766764; 1-(Aminomethyl)-6-hydroxynaphthalene; AKOS027292253; SC-29498; 1,2-Anthracenediol,10-(aminomethyl)-9,10-dihydro-
DMTP9DB DT Small molecular drug
DMTP9DB PC 44352201
DMTP9DB MW 173.21
DMTP9DB FM C11H11NO
DMTP9DB IC InChI=1S/C11H11NO/c12-7-9-3-1-2-8-6-10(13)4-5-11(8)9/h1-6,13H,7,12H2
DMTP9DB CS C1=CC2=C(C=CC(=C2)O)C(=C1)CN
DMTP9DB IK PFFJJFRURKJERG-UHFFFAOYSA-N
DMTP9DB IU 5-(aminomethyl)naphthalen-2-ol
DMTP9DB DE Discovery agent
DMYTUNE ID DMYTUNE
DMYTUNE DN 5-AMINO-NAPHTALENE-2-MONOSULFONATE
DMYTUNE HS Investigative
DMYTUNE SN 119-79-9; 5-Amino-2-naphthalenesulfonic acid; 5-aminonaphthalene-2-sulfonic acid; 1,6-Cleve's acid; 1-Aminonaphthalene-6-sulfonic acid; 2-Naphthalenesulfonic acid, 5-amino-; 1-NAPHTHYLAMINE-6-SULFONIC ACID; Kyselina cleve; 1-Amino-6-naphthalenesulfonic acid; 5-Aminonaphthalene-2-sulphonic acid; Cleve's acid-1,6; 5-Naphthylamine-2-sulfonic acid; 1-Amino-6-sulfonaphthalene; Cleve's beta-acid; Cleve's acid, mixed; Kyselina cleve [Czech]; Kyselina 1-naftylamin-6-sulfonova; 51548-48-2; NSC 31506; UNII-59G56TB11B; Cleve's .beta.-aci
DMYTUNE DT Small molecular drug
DMYTUNE PC 8408
DMYTUNE MW 223.25
DMYTUNE FM C10H9NO3S
DMYTUNE IC InChI=1S/C10H9NO3S/c11-10-3-1-2-7-6-8(15(12,13)14)4-5-9(7)10/h1-6H,11H2,(H,12,13,14)
DMYTUNE CS C1=CC2=C(C=CC(=C2)S(=O)(=O)O)C(=C1)N
DMYTUNE IK UWPJYQYRSWYIGZ-UHFFFAOYSA-N
DMYTUNE IU 5-aminonaphthalene-2-sulfonic acid
DMYTUNE CA CAS 119-79-9
DMYTUNE CB CHEBI:44188
DMYTUNE DE Discovery agent
DMIBHP5 ID DMIBHP5
DMIBHP5 DN 5-aminoquinolin-8-ol
DMIBHP5 HS Investigative
DMIBHP5 SN 5-aminoquinolin-8-ol; 13207-66-4; 5-Amino-8-hydroxyquinoline; 8-Quinolinol, 5-amino-; 5-Amino-8-quinolinol; 5-Amino-quinolin-8-ol; 5-azanylquinolin-8-ol; YDEUKNRKEYICTH-UHFFFAOYSA-N; AS-0308-225; 5-aminoquinoline-8-ol; AC1L9ASV; 5-Amino-8-quinolinol #; SCHEMBL688655; 5'-amino-8'-hydroxyquinoline; CHEMBL449298; AMOT0046; AC1Q523Z; cid_416002; BDBM32142; CTK0H3311; DTXSID20328975; MolPort-000-000-986; ZINC120515; ALBB-024871; 5-Amino-8-hydroxyquinoline HClsalt; ANW-61190; 5928AA; BBL028356; STK737829; SBB005680; AKOS000111586
DMIBHP5 DT Small molecular drug
DMIBHP5 PC 416002
DMIBHP5 MW 160.17
DMIBHP5 FM C9H8N2O
DMIBHP5 IC InChI=1S/C9H8N2O/c10-7-3-4-8(12)9-6(7)2-1-5-11-9/h1-5,12H,10H2
DMIBHP5 CS C1=CC2=C(C=CC(=C2N=C1)O)N
DMIBHP5 IK YDEUKNRKEYICTH-UHFFFAOYSA-N
DMIBHP5 IU 5-aminoquinolin-8-ol
DMIBHP5 CA CAS 13207-66-4
DMIBHP5 DE Discovery agent
DMURTHE ID DMURTHE
DMURTHE DN 5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine
DMURTHE HS Investigative
DMURTHE SN CHEMBL194401; 5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine
DMURTHE DT Small molecular drug
DMURTHE PC 44403591
DMURTHE MW 275.31
DMURTHE FM C16H13N5
DMURTHE IC InChI=1S/C16H13N5/c1-11-7-8-14-15(20-21-17)13(10-18-16(14)19-11)9-12-5-3-2-4-6-12/h2-8,10H,9H2,1H3
DMURTHE CS CC1=NC2=NC=C(C(=C2C=C1)N=[N+]=[N-])CC3=CC=CC=C3
DMURTHE IK GFTOIPQCHLKALF-UHFFFAOYSA-N
DMURTHE IU 5-azido-6-benzyl-2-methyl-1,8-naphthyridine
DMURTHE DE Discovery agent
DM0HO6C ID DM0HO6C
DM0HO6C DN 5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one
DM0HO6C HS Investigative
DM0HO6C SN CHEMBL18019; 5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one; BDBM50110717
DM0HO6C DT Small molecular drug
DM0HO6C PC 11074575
DM0HO6C MW 207.19
DM0HO6C FM C8H9N5O2
DM0HO6C IC InChI=1S/C8H9N5O2/c9-11-10-5-7-6-13(8(14)15-7)12-3-1-2-4-12/h1-4,7H,5-6H2/t7-/m1/s1
DM0HO6C CS C1[C@H](OC(=O)N1N2C=CC=C2)CN=[N+]=[N-]
DM0HO6C IK RJURJCGAHMMGOY-SSDOTTSWSA-N
DM0HO6C IU (5S)-5-(azidomethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DM0HO6C DE Discovery agent
DM65WZ7 ID DM65WZ7
DM65WZ7 DN 5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
DM65WZ7 HS Investigative
DM65WZ7 SN CHEMBL593832; 5-benzhydryl-1,3,4-oxadiazole-2-thiol; 93073-39-3; 5-(diphenylmethyl)-1,3,4-oxadiazole-2-thiol; AC1MJWI7; 5-benzhydryl-3H-1,3,4-oxadiazole-2-thione; 5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione; MolPort-001-902-005; ZINC17946026; STK803293; BDBM50320727; BBL012648; AKOS002344283; MCULE-6937439472; BAS 00805225; 5-Benzhydryl-[1,3,4]oxadiazole-2-thiol; SR-01000312098; 5-Diphenylmethyl-1,3,4-oxadiazole-2(3H)-thione
DM65WZ7 DT Small molecular drug
DM65WZ7 PC 3119329
DM65WZ7 MW 268.3
DM65WZ7 FM C15H12N2OS
DM65WZ7 IC InChI=1S/C15H12N2OS/c19-15-17-16-14(18-15)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13H,(H,17,19)
DM65WZ7 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NNC(=S)O3
DM65WZ7 IK YCCKTVQLIQQBMK-UHFFFAOYSA-N
DM65WZ7 IU 5-benzhydryl-3H-1,3,4-oxadiazole-2-thione
DM65WZ7 DE Discovery agent
DMBQ5HV ID DMBQ5HV
DMBQ5HV DN 5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione
DMBQ5HV HS Investigative
DMBQ5HV SN CHEMBL593062; 5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione; BDBM50320720
DMBQ5HV DT Small molecular drug
DMBQ5HV PC 46225813
DMBQ5HV MW 284.4
DMBQ5HV FM C15H12N2S2
DMBQ5HV IC InChI=1S/C15H12N2S2/c18-15-17-16-14(19-15)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13H,(H,17,18)
DMBQ5HV CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NNC(=S)S3
DMBQ5HV IK NYLCTMQHPFIJCL-UHFFFAOYSA-N
DMBQ5HV IU 5-benzhydryl-3H-1,3,4-thiadiazole-2-thione
DMBQ5HV DE Discovery agent
DM8QK2O ID DM8QK2O
DM8QK2O DN 5-benzyl-1,3,4-oxadiazole-2(3H)-thione
DM8QK2O HS Investigative
DM8QK2O SN 5-benzyl-1,3,4-oxadiazole-2-thiol; 23288-90-6; 5-Benzyl-[1,3,4]oxadiazole-2-thiol; CHEMBL1164364; 5-Benzyl-1,3,4-oxadiazol-2-yl hydrosulfide; 1,3,4-Oxadiazole-2(3H)-thione,5-(phenylmethyl)-; 2-benzyl-1,3,4-oxadiazole-5-thiol; AC1Q7GGP; 5-benzyl-1,3,4-oxadiazole-2(3H)-thione; ChemDiv2_001277; AC1M00UR; SCHEMBL7023603; SCHEMBL11835354; CTK4F1247; DTXSID60365768; MolPort-000-473-148; HMS1649K04; HMS1372M01; ZINC2379869; BDBM50320724; STK498480; CCG-21122; BBL007772; AKOS000100218; AKOS001054851; MCULE-7500395690
DM8QK2O DT Small molecular drug
DM8QK2O PC 1987817
DM8QK2O MW 192.24
DM8QK2O FM C9H8N2OS
DM8QK2O IC InChI=1S/C9H8N2OS/c13-9-11-10-8(12-9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,11,13)
DM8QK2O CS C1=CC=C(C=C1)CC2=NNC(=S)O2
DM8QK2O IK ARGIBMBTIISQNH-UHFFFAOYSA-N
DM8QK2O IU 5-benzyl-3H-1,3,4-oxadiazole-2-thione
DM8QK2O CA CAS 23288-90-6
DM8QK2O DE Discovery agent
DMJVGUZ ID DMJVGUZ
DMJVGUZ DN 5-Benzyl-1H-pyrazole-3-carboxylic acid
DMJVGUZ HS Investigative
DMJVGUZ SN 5-benzyl-1H-pyrazole-3-carboxylic Acid; 1H-Pyrazole-3-carboxylic acid, 5-(phenylmethyl)-; CHEMBL247317; 595610-51-8; 3-benzyl-1H-pyrazole-5-carboxylic acid; SCHEMBL12703568; MolPort-035-831-532; MolPort-022-664-582; ZINC13526594; BDBM50216537; AKOS026575568
DMJVGUZ DT Small molecular drug
DMJVGUZ PC 11041813
DMJVGUZ MW 202.21
DMJVGUZ FM C11H10N2O2
DMJVGUZ IC InChI=1S/C11H10N2O2/c14-11(15)10-7-9(12-13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H,12,13)(H,14,15)
DMJVGUZ CS C1=CC=C(C=C1)CC2=CC(=NN2)C(=O)O
DMJVGUZ IK YYEOXPLPYNYVRY-UHFFFAOYSA-N
DMJVGUZ IU 5-benzyl-1H-pyrazole-3-carboxylic acid
DMJVGUZ DE Discovery agent
DM5MJ3I ID DM5MJ3I
DM5MJ3I DN 5-benzyl-2-(2,4-dichlorophenoxy)phenol
DM5MJ3I HS Investigative
DM5MJ3I SN 5-benzyl-2-(2,4-dichlorophenoxy)phenol; Triclosan derivative, 20; CHEMBL405973; BDBM25419
DM5MJ3I DT Small molecular drug
DM5MJ3I PC 25023969
DM5MJ3I MW 345.2
DM5MJ3I FM C19H14Cl2O2
DM5MJ3I IC InChI=1S/C19H14Cl2O2/c20-15-7-9-18(16(21)12-15)23-19-8-6-14(11-17(19)22)10-13-4-2-1-3-5-13/h1-9,11-12,22H,10H2
DM5MJ3I CS C1=CC=C(C=C1)CC2=CC(=C(C=C2)OC3=C(C=C(C=C3)Cl)Cl)O
DM5MJ3I IK LUMKUDPYQGEIPU-UHFFFAOYSA-N
DM5MJ3I IU 5-benzyl-2-(2,4-dichlorophenoxy)phenol
DM5MJ3I DE Discovery agent
DMCKODQ ID DMCKODQ
DMCKODQ DN 5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione
DMCKODQ HS Investigative
DMCKODQ SN 5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione; 18493-82-8; Oprea1_007440; SCHEMBL2672214; CHEMBL394673; BDBM20060; LWRITIARHSTBLU-UHFFFAOYSA-N; 5-Substituted-6-chlorouracil, 5g; 5-benzyl-6-chloro-1H-pyrimidine-2,4-dione; SR-01000516321; SR-01000516321-1
DMCKODQ DT Small molecular drug
DMCKODQ PC 23648513
DMCKODQ MW 236.65
DMCKODQ FM C11H9ClN2O2
DMCKODQ IC InChI=1S/C11H9ClN2O2/c12-9-8(10(15)14-11(16)13-9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H2,13,14,15,16)
DMCKODQ CS C1=CC=C(C=C1)CC2=C(NC(=O)NC2=O)Cl
DMCKODQ IK LWRITIARHSTBLU-UHFFFAOYSA-N
DMCKODQ IU 5-benzyl-6-chloro-1H-pyrimidine-2,4-dione
DMCKODQ DE Discovery agent
DM8WB96 ID DM8WB96
DM8WB96 DN 5-Benzyloxy-benzo[b]thiophene-2-carboxamidine
DM8WB96 HS Investigative
DM8WB96 SN CHEMBL598385; 5-Benzyloxy-benzo[b]thiophene-2-carboxamidine; SCHEMBL13709665
DM8WB96 DT Small molecular drug
DM8WB96 PC 46233192
DM8WB96 MW 358.5
DM8WB96 FM C22H18N2OS
DM8WB96 IC InChI=1S/C22H18N2OS/c23-22(24)21-13-18-12-17(8-11-20(18)26-21)16-6-9-19(10-7-16)25-14-15-4-2-1-3-5-15/h1-13H,14H2,(H3,23,24)
DM8WB96 CS C1=CC=C(C=C1)COC2=CC=C(C=C2)C3=CC4=C(C=C3)SC(=C4)C(=N)N
DM8WB96 IK VZVHZNRYOZAOJD-UHFFFAOYSA-N
DM8WB96 IU 5-(4-phenylmethoxyphenyl)-1-benzothiophene-2-carboximidamide
DM8WB96 DE Discovery agent
DMOM35G ID DMOM35G
DMOM35G DN 5-Benzyloxytryptamine
DMOM35G HS Investigative
DMOM35G SN 5-Benzyloxytryptamine; 20776-45-8; 2-(5-Benzyloxy-1H-indol-3-yl)-ethylamine; 5-Benzyloxytriptamine; 2-[5-(benzyloxy)-1H-indol-3-yl]ethanamine; 3-(2-aminoethyl)-5-benzyloxyindole; 5-BT; CHEMBL1288652; 2-(5-(Benzyloxy)-1H-indol-3-yl)ethanamine; WKPDXBXNJWWWGQ-UHFFFAOYSA-N; 5-Benzyloxy-3-(2-ethylamino)indole hydrochloride; 1H-Indole-3-ethanamine,5-(phenylmethoxy)-; 1H-Indole-3-ethanamine, 5-(phenylmethoxy)-; B-2100; 2-[5-(benzyloxy)-1H-indol-3-yl]ethanamine hydrochloride; 2-[5-(phenylmethoxy)indol-3-yl]ethylamine; EINECS 244-
DMOM35G DT Small molecular drug
DMOM35G PC 89576
DMOM35G MW 266.34
DMOM35G FM C17H18N2O
DMOM35G IC InChI=1S/C17H18N2O/c18-9-8-14-11-19-17-7-6-15(10-16(14)17)20-12-13-4-2-1-3-5-13/h1-7,10-11,19H,8-9,12,18H2
DMOM35G CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)NC=C3CCN
DMOM35G IK WKPDXBXNJWWWGQ-UHFFFAOYSA-N
DMOM35G IU 2-(5-phenylmethoxy-1H-indol-3-yl)ethanamine
DMOM35G CA CAS 20776-45-8
DMOM35G DE Discovery agent
DMFAITE ID DMFAITE
DMFAITE DN 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione
DMFAITE HS Investigative
DMFAITE SN CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-
DMFAITE DT Small molecular drug
DMFAITE PC 2220392
DMFAITE MW 308.3
DMFAITE FM C18H16N2O3
DMFAITE IC InChI=1S/C18H16N2O3/c1-2-18(15(21)19-17(23)20-16(18)22)14-10-8-13(9-11-14)12-6-4-3-5-7-12/h3-11H,2H2,1H3,(H2,19,20,21,22,23)
DMFAITE CS CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMFAITE IK XWZIZWWEAJZAMO-UHFFFAOYSA-N
DMFAITE IU 5-ethyl-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
DMFAITE CA CAS 94209-48-0
DMFAITE DE Discovery agent
DMI2PXO ID DMI2PXO
DMI2PXO DN 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione
DMI2PXO HS Investigative
DMI2PXO SN CHEMBL175282; 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione; BDBM50099116
DMI2PXO DT Small molecular drug
DMI2PXO PC 44385624
DMI2PXO MW 364.4
DMI2PXO FM C22H24N2O3
DMI2PXO IC InChI=1S/C22H24N2O3/c1-2-3-4-8-15-22(19(25)23-21(27)24-20(22)26)18-13-11-17(12-14-18)16-9-6-5-7-10-16/h5-7,9-14H,2-4,8,15H2,1H3,(H2,23,24,25,26,27)
DMI2PXO CS CCCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMI2PXO IK KYTLMUVGULFASG-UHFFFAOYSA-N
DMI2PXO IU 5-hexyl-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
DMI2PXO DE Discovery agent
DMMG9PV ID DMMG9PV
DMMG9PV DN 5-Biphenyl-4-ylethynyl-pyrimidine
DMMG9PV HS Investigative
DMMG9PV SN CHEMBL447469; 5-Biphenyl-4-ylethynyl-pyrimidine
DMMG9PV DT Small molecular drug
DMMG9PV PC 44560632
DMMG9PV MW 256.3
DMMG9PV FM C18H12N2
DMMG9PV IC InChI=1S/C18H12N2/c1-2-4-17(5-3-1)18-10-8-15(9-11-18)6-7-16-12-19-14-20-13-16/h1-5,8-14H
DMMG9PV CS C1=CC=C(C=C1)C2=CC=C(C=C2)C#CC3=CN=CN=C3
DMMG9PV IK WSPLFBLWQURLSJ-UHFFFAOYSA-N
DMMG9PV IU 5-[2-(4-phenylphenyl)ethynyl]pyrimidine
DMMG9PV DE Discovery agent
DM6W0QI ID DM6W0QI
DM6W0QI DN 5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole
DM6W0QI HS Investigative
DM6W0QI SN CHEMBL255903
DM6W0QI DT Small molecular drug
DM6W0QI PC 44448616
DM6W0QI MW 292.4
DM6W0QI FM C18H20N4
DM6W0QI IC InChI=1S/C18H20N4/c1-14(2)13-22-18(19-20-21-22)12-15-8-10-17(11-9-15)16-6-4-3-5-7-16/h3-11,14H,12-13H2,1-2H3
DM6W0QI CS CC(C)CN1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
DM6W0QI IK GASXPOWMPRTYRR-UHFFFAOYSA-N
DM6W0QI IU 1-(2-methylpropyl)-5-[(4-phenylphenyl)methyl]tetrazole
DM6W0QI DE Discovery agent
DMCPIK5 ID DMCPIK5
DMCPIK5 DN 5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole
DMCPIK5 HS Investigative
DMCPIK5 SN CHEMBL255904
DMCPIK5 DT Small molecular drug
DMCPIK5 PC 44448617
DMCPIK5 MW 292.4
DMCPIK5 FM C18H20N4
DMCPIK5 IC InChI=1S/C18H20N4/c1-14(2)13-22-20-18(19-21-22)12-15-8-10-17(11-9-15)16-6-4-3-5-7-16/h3-11,14H,12-13H2,1-2H3
DMCPIK5 CS CC(C)CN1N=C(N=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
DMCPIK5 IK PPXBPBABGOMYLY-UHFFFAOYSA-N
DMCPIK5 IU 2-(2-methylpropyl)-5-[(4-phenylphenyl)methyl]tetrazole
DMCPIK5 DE Discovery agent
DM7BWG5 ID DM7BWG5
DM7BWG5 DN 5-BODMT
DM7BWG5 HS Investigative
DM7BWG5 SN 5-N-butyryloxy-N,N-dimethyltryptamine; compound 10 [PMID 21422162]
DM7BWG5 DT Small molecular drug
DM7BWG5 PC 91827360
DM7BWG5 MW 272.4
DM7BWG5 FM C17H24N2O
DM7BWG5 IC InChI=1S/C17H24N2O/c1-4-5-15(20)10-13-6-7-17-16(11-13)14(12-18-17)8-9-19(2)3/h6-7,11-12,18H,4-5,8-10H2,1-3H3
DM7BWG5 CS CCCC(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
DM7BWG5 IK OQDBJMBOPCUBGS-UHFFFAOYSA-N
DM7BWG5 IU 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]pentan-2-one
DM7BWG5 DE Discovery agent
DMPITR9 ID DMPITR9
DMPITR9 DN 5-boronothiophene-2-carboxylic acid
DMPITR9 HS Investigative
DMPITR9 SN 465515-31-5; 2-Carboxythiophene-5-boronic acid; 5-Carboxythiophene-2-boronic acid; 5-boronothiophene-2-carboxylic acid; 5-(dihydroxyboryl)thiophene-2-carboxylic acid; 5-(Dihydroxyboryl)-2-thiophenecarboxylic acid; C5H5BO4S; CHEMBL573906; 5-(dihydroxyboranyl)thiophene-2-carboxylic acid; AF-399/25053010; AK-26004; PubChem7851; AC1MCWDJ; ACMC-1AP1P; SCHEMBL363172; KS-00000JEI; CTK1D5505; 2-Carboxythiophene-5-boronicacid; DTXSID90381557; MolPort-000-144-982; OQGIKNPOYTVNNF-UHFFFAOYSA-N; 2-Carboxy-5-thiopheneboronic acid
DMPITR9 DT Small molecular drug
DMPITR9 PC 2779807
DMPITR9 MW 171.97
DMPITR9 FM C5H5BO4S
DMPITR9 IC InChI=1S/C5H5BO4S/c7-5(8)3-1-2-4(11-3)6(9)10/h1-2,9-10H,(H,7,8)
DMPITR9 CS B(C1=CC=C(S1)C(=O)O)(O)O
DMPITR9 IK OQGIKNPOYTVNNF-UHFFFAOYSA-N
DMPITR9 IU 5-boronothiophene-2-carboxylic acid
DMPITR9 CA CAS 465515-31-5
DMPITR9 DE Discovery agent
DM0HCG6 ID DM0HCG6
DM0HCG6 DN 5-bromo orotate
DM0HCG6 HS Investigative
DM0HCG6 DE Discovery agent
DM2QPHE ID DM2QPHE
DM2QPHE DN 5-bromo-1H-indazole
DM2QPHE HS Investigative
DM2QPHE SN 5-bromo-1H-indazole; 5-Bromoindazole; 53857-57-1; 5-Bromo-2H-indazole; 1h-indazole, 5-bromo-; 465529-55-9; CHEMBL16425; 5-Bromo-1H-indazole, 97%; 5-brom-1h-indazol; MLS000088501; 5-bromoazaindole; 5-bromo-indazole; 5- Bromoindazole; 5-bromo-azaindole; 5-bromo-1hindazole; AC1LFXVY; 4-Nitrotrityl chloride; PubChem15628; 5-bromo-1 h-indazole; ACMC-209lal; 5-bromanyl-1H-indazole; 2H-Indazole, 5-bromo-; SCHEMBL5562; AC1Q1H9U; KSC269G3N; cid_761929; AMBZ0279; CTK1G9336; DTXSID50354020; HID1020; STVHMYNPQCLUNJ-UHFFFAOYSA-N; MolPort-029-084-055
DM2QPHE DT Small molecular drug
DM2QPHE PC 761929
DM2QPHE MW 197.03
DM2QPHE FM C7H5BrN2
DM2QPHE IC InChI=1S/C7H5BrN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)
DM2QPHE CS C1=CC2=C(C=C1Br)C=NN2
DM2QPHE IK STVHMYNPQCLUNJ-UHFFFAOYSA-N
DM2QPHE IU 5-bromo-1H-indazole
DM2QPHE CA CAS 53857-57-1
DM2QPHE DE Discovery agent
DM4WVSB ID DM4WVSB
DM4WVSB DN 5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid
DM4WVSB HS Investigative
DM4WVSB SN 5-bromo-2-{[(4-chlorophenyl)sulfonyl]amino}benzoic acid; AC1LLKZK; BAS 00347593; sulfonamide compound, 1; CBDivE_004908; SCHEMBL5925257; CHEMBL212522; BDBM17595; MolPort-001-926-487; ZINC754636; HMS3604C20; STL325205; AKOS000541754; DB07309; MCULE-4831129771; 107143-69-1; ST50224787; EU-0033636; SR-01000389963; A193400; 5-bromo-2-(4-chlorobenzenesulfonamido)benzoic acid; SR-01000389963-1; 5-bromo-2-[(4-chlorobenzene)sulfonamido]benzoic acid; 5-bromo-2-[(4-chlorophenyl)sulfonylamino]benzoic acid
DM4WVSB DT Small molecular drug
DM4WVSB PC 1069140
DM4WVSB MW 390.64
DM4WVSB FM C13H9BrClNO4S
DM4WVSB IC InChI=1S/C13H9BrClNO4S/c14-8-1-6-12(11(7-8)13(17)18)16-21(19,20)10-4-2-9(15)3-5-10/h1-7,16H,(H,17,18)
DM4WVSB CS C1=CC(=CC=C1S(=O)(=O)NC2=C(C=C(C=C2)Br)C(=O)O)Cl
DM4WVSB IK JDVLYAYDIMUAAC-UHFFFAOYSA-N
DM4WVSB IU 5-bromo-2-[(4-chlorophenyl)sulfonylamino]benzoic acid
DM4WVSB DE Discovery agent
DM2YL0T ID DM2YL0T
DM2YL0T DN 5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol
DM2YL0T HS Investigative
DM2YL0T DT Small molecular drug
DM2YL0T PC 135421237
DM2YL0T MW 316.15
DM2YL0T FM C15H10BrNO2
DM2YL0T IC InChI=1S/C15H10BrNO2/c16-15-11-5-6-12(9-1-3-10(18)4-2-9)17-13(11)7-8-14(15)19/h1-8,18-19H
DM2YL0T CS C1=CC(=CC=C1C2=NC3=C(C=C2)C(=C(C=C3)O)Br)O
DM2YL0T IK BLXVDNNULRNBGB-UHFFFAOYSA-N
DM2YL0T IU 5-bromo-2-(4-hydroxyphenyl)quinolin-6-ol
DM2YL0T DE Discovery agent
DMMI4H3 ID DMMI4H3
DMMI4H3 DN 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMMI4H3 HS Investigative
DMMI4H3 SN CHEMBL6426; 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; BDBM50136501; AKOS023651923
DMMI4H3 DT Small molecular drug
DMMI4H3 PC 44264094
DMMI4H3 MW 251.12
DMMI4H3 FM C11H11BrN2
DMMI4H3 IC InChI=1S/C11H11BrN2/c12-8-2-1-3-9-11(8)7-4-5-13-6-10(7)14-9/h1-3,13-14H,4-6H2
DMMI4H3 CS C1CNCC2=C1C3=C(N2)C=CC=C3Br
DMMI4H3 IK AOMJWOGZKNQVBI-UHFFFAOYSA-N
DMMI4H3 IU 5-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMMI4H3 DE Discovery agent
DM2SEFR ID DM2SEFR
DM2SEFR DN 5-Bromo-4,9-dihydro-3H-beta-carboline
DM2SEFR HS Investigative
DM2SEFR SN CHEMBL267599; 5-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136504
DM2SEFR DT Small molecular drug
DM2SEFR PC 44264263
DM2SEFR MW 249.11
DM2SEFR FM C11H9BrN2
DM2SEFR IC InChI=1S/C11H9BrN2/c12-8-2-1-3-9-11(8)7-4-5-13-6-10(7)14-9/h1-3,6,14H,4-5H2
DM2SEFR CS C1CN=CC2=C1C3=C(N2)C=CC=C3Br
DM2SEFR IK FTDSATOEKTYHMK-UHFFFAOYSA-N
DM2SEFR IU 5-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DM2SEFR DE Discovery agent
DMRY0OL ID DMRY0OL
DMRY0OL DN 5-bromo-6-(cyclopropylamino)uracil hydrochloride
DMRY0OL HS Investigative
DMRY0OL SN CHEMBL537864
DMRY0OL DT Small molecular drug
DMRY0OL PC 45263353
DMRY0OL MW 282.52
DMRY0OL FM C7H9BrClN3O2
DMRY0OL IC InChI=1S/C7H8BrN3O2.ClH/c8-4-5(9-3-1-2-3)10-7(13)11-6(4)12;/h3H,1-2H2,(H3,9,10,11,12,13);1H
DMRY0OL CS C1CC1NC2=C(C(=O)NC(=O)N2)Br.Cl
DMRY0OL IK CUQFSKAHEOAMRH-UHFFFAOYSA-N
DMRY0OL IU 5-bromo-6-(cyclopropylamino)-1H-pyrimidine-2,4-dione;hydrochloride
DMRY0OL DE Discovery agent
DMZJE6M ID DMZJE6M
DMZJE6M DN 5-bromo-6-hydrazinouracil hydrochloride
DMZJE6M HS Investigative
DMZJE6M SN CHEMBL536284
DMZJE6M DT Small molecular drug
DMZJE6M PC 45263378
DMZJE6M MW 257.47
DMZJE6M FM C4H6BrClN4O2
DMZJE6M IC InChI=1S/C4H5BrN4O2.ClH/c5-1-2(9-6)7-4(11)8-3(1)10;/h6H2,(H3,7,8,9,10,11);1H
DMZJE6M CS C1(=C(NC(=O)NC1=O)NN)Br.Cl
DMZJE6M IK FSNHPVKPJNIXAD-UHFFFAOYSA-N
DMZJE6M IU 5-bromo-6-hydrazinyl-1H-pyrimidine-2,4-dione;hydrochloride
DMZJE6M DE Discovery agent
DM157OQ ID DM157OQ
DM157OQ DN 5-Bromo-6-methoxy-9H-beta-carboline
DM157OQ HS Investigative
DM157OQ SN 5-bromo-6-methoxy-beta-carboline; CHEMBL310975; 5-Bromo-6-methoxy-9H-beta-carboline; SCHEMBL6465779; BDBM50130233
DM157OQ DT Small molecular drug
DM157OQ PC 11414735
DM157OQ MW 277.12
DM157OQ FM C12H9BrN2O
DM157OQ IC InChI=1S/C12H9BrN2O/c1-16-10-3-2-8-11(12(10)13)7-4-5-14-6-9(7)15-8/h2-6,15H,1H3
DM157OQ CS COC1=C(C2=C(C=C1)NC3=C2C=CN=C3)Br
DM157OQ IK NXKWYFQQPHBFII-UHFFFAOYSA-N
DM157OQ IU 5-bromo-6-methoxy-9H-pyrido[3,4-b]indole
DM157OQ DE Discovery agent
DMTPRIW ID DMTPRIW
DMTPRIW DN 5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione
DMTPRIW HS Investigative
DMTPRIW SN CHEMBL353575; 5-bromo-6-(p-toluidino)uracil; 100763-66-4; 5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione
DMTPRIW DT Small molecular drug
DMTPRIW PC 44374273
DMTPRIW MW 296.12
DMTPRIW FM C11H10BrN3O2
DMTPRIW IC InChI=1S/C11H10BrN3O2/c1-6-2-4-7(5-3-6)13-9-8(12)10(16)15-11(17)14-9/h2-5H,1H3,(H3,13,14,15,16,17)
DMTPRIW CS CC1=CC=C(C=C1)NC2=C(C(=O)NC(=O)N2)Br
DMTPRIW IK XCZQWOVVHWQUMF-UHFFFAOYSA-N
DMTPRIW IU 5-bromo-6-(4-methylanilino)-1H-pyrimidine-2,4-dione
DMTPRIW DE Discovery agent
DM09Y72 ID DM09Y72
DM09Y72 DN 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one
DM09Y72 HS Investigative
DM09Y72 SN CHEMBL161530; 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one; BDBM50097371; 8-((1H-imidazol-1-yl)methyl)-5-bromo-4H-chromen-4-one
DM09Y72 DT Small molecular drug
DM09Y72 PC 10566470
DM09Y72 MW 305.13
DM09Y72 FM C13H9BrN2O2
DM09Y72 IC InChI=1S/C13H9BrN2O2/c14-10-2-1-9(7-16-5-4-15-8-16)13-12(10)11(17)3-6-18-13/h1-6,8H,7H2
DM09Y72 CS C1=CC(=C2C(=O)C=COC2=C1CN3C=CN=C3)Br
DM09Y72 IK QYFIAVSWVXIKAW-UHFFFAOYSA-N
DM09Y72 IU 5-bromo-8-(imidazol-1-ylmethyl)chromen-4-one
DM09Y72 DE Discovery agent
DMSVCJM ID DMSVCJM
DMSVCJM DN 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine
DMSVCJM HS Investigative
DMSVCJM SN CHEMBL123566; 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine; BDBM50002150; 143591-65-5; 5-Bromo-8-(1-piperazinyl)imidazo[1,2-a]pyrazine; Imidazo[1,2-a]pyrazine, 5-bromo-8-(1-piperazinyl)-
DMSVCJM DT Small molecular drug
DMSVCJM PC 10379016
DMSVCJM MW 282.14
DMSVCJM FM C10H12BrN5
DMSVCJM IC InChI=1S/C10H12BrN5/c11-8-7-14-9(10-13-3-6-16(8)10)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
DMSVCJM CS C1CN(CCN1)C2=NC=C(N3C2=NC=C3)Br
DMSVCJM IK SOIWQJOBNCOQPP-UHFFFAOYSA-N
DMSVCJM IU 5-bromo-8-piperazin-1-ylimidazo[1,2-a]pyrazine
DMSVCJM DE Discovery agent
DMH908V ID DMH908V
DMH908V DN 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine
DMH908V HS Investigative
DMH908V SN 5-Bromomethyl-4,5-dihydro-oxazol-2-ylamine; CHEMBL447832; 52886-60-9; 5-(bromomethyl)-4,5-dihydro-1,3-oxazol-2-amine; AC1MJII5; 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine; SCHEMBL11817450; MolPort-001-940-341; 5-(Bromomethyl)oxazolidine-2-imine; SBB010634; BDBM50138186; AKOS016344418; AKOS000301813; BAS 00615750; 5-(bromomethyl)-1,3-oxazoline-2-ylamine; BB 0261596
DMH908V DT Small molecular drug
DMH908V PC 3112983
DMH908V MW 179.02
DMH908V FM C4H7BrN2O
DMH908V IC InChI=1S/C4H7BrN2O/c5-1-3-2-7-4(6)8-3/h3H,1-2H2,(H2,6,7)
DMH908V CS C1C(OC(=N1)N)CBr
DMH908V IK DCJDVEKKUOXALB-UHFFFAOYSA-N
DMH908V IU 5-(bromomethyl)-4,5-dihydro-1,3-oxazol-2-amine
DMH908V DE Discovery agent
DM37T5L ID DM37T5L
DM37T5L DN 5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide
DM37T5L HS Investigative
DM37T5L SN 5-bromo-N-quinolin-8-ylthiophene-2-sulfonamide; 5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide; 620103-87-9; CHEMBL401504; AC1M3N93; SCHEMBL11995751; CTK5I7875; MolPort-000-693-109; ZINC2888883; ALBB-010070; STK506180; BDBM50372503; BBL018066; AKOS001440266; MCULE-3903306629; NCGC00161700-01; TR-061560; TR-039409; R9130; 2-Thiophenesulfonamide, 5-bromo-N-8-quinolinyl-
DM37T5L DT Small molecular drug
DM37T5L PC 2240993
DM37T5L MW 369.3
DM37T5L FM C13H9BrN2O2S2
DM37T5L IC InChI=1S/C13H9BrN2O2S2/c14-11-6-7-12(19-11)20(17,18)16-10-5-1-3-9-4-2-8-15-13(9)10/h1-8,16H
DM37T5L CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(S3)Br)N=CC=C2
DM37T5L IK BWZPDZRPJIBWAU-UHFFFAOYSA-N
DM37T5L IU 5-bromo-N-quinolin-8-ylthiophene-2-sulfonamide
DM37T5L DE Discovery agent
DMZ8X3H ID DMZ8X3H
DMZ8X3H DN 5-Bromothienyldeoxyuridine
DMZ8X3H HS Investigative
DMZ8X3H SN 5-BROMOTHIENYLDEOXYURIDINE; CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione
DMZ8X3H DT Small molecular drug
DMZ8X3H PC 446725
DMZ8X3H MW 389.22
DMZ8X3H FM C13H13BrN2O5S
DMZ8X3H IC InChI=1S/C13H13BrN2O5S/c14-10-2-1-9(22-10)6-4-16(13(20)15-12(6)19)11-3-7(18)8(5-17)21-11/h1-2,4,7-8,11,17-18H,3,5H2,(H,15,19,20)/t7-,8+,11+/m0/s1
DMZ8X3H CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C3=CC=C(S3)Br)CO)O
DMZ8X3H IK IGUZFFOBAZCVRK-VAOFZXAKSA-N
DMZ8X3H IU 5-(5-bromothiophen-2-yl)-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMZ8X3H DE Discovery agent
DMEVRH4 ID DMEVRH4
DMEVRH4 DN 5BrUTP
DMEVRH4 HS Investigative
DMEVRH4 SN 5-bromouridine triphosphate; bromouridine 5'-triphosphate; 5-bromo-UTP
DMEVRH4 DT Small molecular drug
DMEVRH4 PC 9872620
DMEVRH4 MW 563.04
DMEVRH4 FM C9H14BrN2O15P3
DMEVRH4 IC InChI=1S/C9H14BrN2O15P3/c10-3-1-12(9(16)11-7(3)15)8-6(14)5(13)4(25-8)2-24-29(20,21)27-30(22,23)26-28(17,18)19/h1,4-6,8,13-14H,2H2,(H,20,21)(H,22,23)(H,11,15,16)(H2,17,18,19)/t4-,5-,6-,8-/m1/s1
DMEVRH4 CS C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)Br
DMEVRH4 IK IWFHOSULCAJGRM-UAKXSSHOSA-N
DMEVRH4 IU [[(2R,3S,4R,5R)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMEVRH4 CA CAS 3398-50-3
DMEVRH4 CB CHEBI:88358
DMEVRH4 DE Discovery agent
DMXKQFM ID DMXKQFM
DMXKQFM DN 5-Butyl-1H-pyrazole-3-carboxylic acid
DMXKQFM HS Investigative
DMXKQFM SN 5-Butyl-1H-pyrazole-3-carboxylic acid; 92933-48-7; 5-Butyl-2H-pyrazole-3-carboxylic acid; 3-butyl-1H-pyrazole-5-carboxylic acid; CHEMBL428730; 890624-89-2; 3-butylpyrazole-5-carboxylic acid; 5-n-butyl-1H-pyrazole-3-carboxylic acid; BAS 13299640; AC1O5JK4; GTPL1591; SCHEMBL1527555; CTK8F6771; CTK6D6234; MolPort-027-640-734; ZJTXSGLJNBAMJS-UHFFFAOYSA-N; MolPort-002-026-457; ZX-AV000908; ZINC4386887; STL257894; BDBM50220842; BBL030719; 2213AF; SBB027985; AKOS024458395; 5-butyl-1H-pyrazol-3-carboxylic acid; AKOS000301963; CHM0075795
DMXKQFM DT Small molecular drug
DMXKQFM PC 6485181
DMXKQFM MW 168.19
DMXKQFM FM C8H12N2O2
DMXKQFM IC InChI=1S/C8H12N2O2/c1-2-3-4-6-5-7(8(11)12)10-9-6/h5H,2-4H2,1H3,(H,9,10)(H,11,12)
DMXKQFM CS CCCCC1=CC(=NN1)C(=O)O
DMXKQFM IK ZJTXSGLJNBAMJS-UHFFFAOYSA-N
DMXKQFM IU 5-butyl-1H-pyrazole-3-carboxylic acid
DMXKQFM CA CAS 92933-48-7
DMXKQFM DE Discovery agent
DMCNU6I ID DMCNU6I
DMCNU6I DN 5-butyl-2-(2,4-dichlorophenoxy)phenol
DMCNU6I HS Investigative
DMCNU6I SN 5-butyl-2-(2,4-dichlorophenoxy)phenol; Triclosan derivative, 10; CHEMBL405402
DMCNU6I DT Small molecular drug
DMCNU6I PC 25023960
DMCNU6I MW 311.2
DMCNU6I FM C16H16Cl2O2
DMCNU6I IC InChI=1S/C16H16Cl2O2/c1-2-3-4-11-5-7-16(14(19)9-11)20-15-8-6-12(17)10-13(15)18/h5-10,19H,2-4H2,1H3
DMCNU6I CS CCCCC1=CC(=C(C=C1)OC2=C(C=C(C=C2)Cl)Cl)O
DMCNU6I IK YJSDMDYNCMZAED-UHFFFAOYSA-N
DMCNU6I IU 5-butyl-2-(2,4-dichlorophenoxy)phenol
DMCNU6I DE Discovery agent
DMI7DSM ID DMI7DSM
DMI7DSM DN 5-butyl-2-(phenylsulfonamido)benzoic acid
DMI7DSM HS Investigative
DMI7DSM SN sulfonamide compound, 8; SCHEMBL3983649; CHEMBL425776; BDBM17602; 2-benzenesulfonamido-5-butylbenzoic acid
DMI7DSM DT Small molecular drug
DMI7DSM PC 10246233
DMI7DSM MW 333.4
DMI7DSM FM C17H19NO4S
DMI7DSM IC InChI=1S/C17H19NO4S/c1-2-3-7-13-10-11-16(15(12-13)17(19)20)18-23(21,22)14-8-5-4-6-9-14/h4-6,8-12,18H,2-3,7H2,1H3,(H,19,20)
DMI7DSM CS CCCCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DMI7DSM IK GUFYXBDBRAROGG-UHFFFAOYSA-N
DMI7DSM IU 2-(benzenesulfonamido)-5-butylbenzoic acid
DMI7DSM DE Discovery agent
DMFKMYV ID DMFKMYV
DMFKMYV DN 5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione
DMFKMYV HS Investigative
DMFKMYV SN 5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione; 18493-80-6; CHEMBL237996; BDBM20056; 5-Substituted-6-chlorouracil, 5c
DMFKMYV DT Small molecular drug
DMFKMYV PC 14956545
DMFKMYV MW 202.64
DMFKMYV FM C8H11ClN2O2
DMFKMYV IC InChI=1S/C8H11ClN2O2/c1-2-3-4-5-6(9)10-8(13)11-7(5)12/h2-4H2,1H3,(H2,10,11,12,13)
DMFKMYV CS CCCCC1=C(NC(=O)NC1=O)Cl
DMFKMYV IK CYNWJDGCUODOPW-UHFFFAOYSA-N
DMFKMYV IU 5-butyl-6-chloro-1H-pyrimidine-2,4-dione
DMFKMYV DE Discovery agent
DM2EPFZ ID DM2EPFZ
DM2EPFZ DN 5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine
DM2EPFZ HS Investigative
DM2EPFZ DT Small molecular drug
DM2EPFZ PC 135457998
DM2EPFZ MW 292.34
DM2EPFZ FM C16H16N6
DM2EPFZ IC InChI=1S/C16H16N6/c1-2-3-9-12-19-15-13(17-10-18-15)16-20-14(21-22(12)16)11-7-5-4-6-8-11/h4-8,10H,2-3,9H2,1H3,(H,17,18)
DM2EPFZ CS CCCCC1=NC2=C(C3=NC(=NN13)C4=CC=CC=C4)NC=N2
DM2EPFZ IK LTQQXOYFDPLYHI-UHFFFAOYSA-N
DM2EPFZ IU 5-butyl-8-phenyl-1H-[1,2,4]triazolo[5,1-f]purine
DM2EPFZ DE Discovery agent
DM0VGCX ID DM0VGCX
DM0VGCX DN 5-butyl-methyl immidazole carboxylate 30
DM0VGCX HS Investigative
DM0VGCX SN compound 30 [PMID: 22889560]
DM0VGCX DT Small molecular drug
DM0VGCX PC 73755250
DM0VGCX MW 348.4
DM0VGCX FM C22H24N2O2
DM0VGCX IC InChI=1S/C22H24N2O2/c1-3-4-8-19-14-23-21(22(25)26)24(19)15-17-10-12-18(13-11-17)20-9-6-5-7-16(20)2/h5-7,9-14H,3-4,8,15H2,1-2H3,(H,25,26)
DM0VGCX CS CCCCC1=CN=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C)C(=O)O
DM0VGCX IK ZCAMCVJTCSXPMT-UHFFFAOYSA-N
DM0VGCX IU 5-butyl-1-[[4-(2-methylphenyl)phenyl]methyl]imidazole-2-carboxylic acid
DM0VGCX DE Discovery agent
DM04WVH ID DM04WVH
DM04WVH DN 5-Carbazol-9-yl-pentanoic acid
DM04WVH HS Investigative
DM04WVH SN CHEMBL184795; 5-Carbazol-9-yl-pentanoic acid; SCHEMBL12951764; BDBM50152858
DM04WVH DT Small molecular drug
DM04WVH PC 28971834
DM04WVH MW 267.32
DM04WVH FM C17H17NO2
DM04WVH IC InChI=1S/C17H17NO2/c19-17(20)11-5-6-12-18-15-9-3-1-7-13(15)14-8-2-4-10-16(14)18/h1-4,7-10H,5-6,11-12H2,(H,19,20)
DM04WVH CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCCC(=O)O
DM04WVH IK YEPJVQJMLQBLOE-UHFFFAOYSA-N
DM04WVH IU 5-carbazol-9-ylpentanoic acid
DM04WVH DE Discovery agent
DMIH7W1 ID DMIH7W1
DMIH7W1 DN 5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione
DMIH7W1 HS Investigative
DMIH7W1 SN 5-chloro-1-(4-chlorobenzyl)-1H-indole-2,3-dione; CHEMBL333067; 87423-59-4; AC1M2SUT; Cambridge id 7142603; 5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione; SCHEMBL11186018; KS-00001SNW; MolPort-000-407-830; ZINC2813807; BDBM50133622; STK394570; BBL005671; AKOS001662460; MCULE-8294112694; 12F-374S; H3079; ST50867327; 5-chloro-1-[(4-chlorophenyl)methyl]indole-2,3-dione; 5-chloro-1-[(4-chlorophenyl)methyl]benzo[d]azoline-2,3-dione; 1-(4-Chlorobenzyl)-5-chloro-2,3-dihydro-1H-indole-2,3-dione
DMIH7W1 DT Small molecular drug
DMIH7W1 PC 2175573
DMIH7W1 MW 306.1
DMIH7W1 FM C15H9Cl2NO2
DMIH7W1 IC InChI=1S/C15H9Cl2NO2/c16-10-3-1-9(2-4-10)8-18-13-6-5-11(17)7-12(13)14(19)15(18)20/h1-7H,8H2
DMIH7W1 CS C1=CC(=CC=C1CN2C3=C(C=C(C=C3)Cl)C(=O)C2=O)Cl
DMIH7W1 IK NWUYWKYKVCEBTP-UHFFFAOYSA-N
DMIH7W1 IU 5-chloro-1-[(4-chlorophenyl)methyl]indole-2,3-dione
DMIH7W1 DE Discovery agent
DMTJNY0 ID DMTJNY0
DMTJNY0 DN 5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMTJNY0 HS Investigative
DMTJNY0 SN CHEMBL369661; 5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine; SCHEMBL12043414; ZINC27993222; BDBM50280623; AKOS011477647
DMTJNY0 DT Small molecular drug
DMTJNY0 PC 44381944
DMTJNY0 MW 232.71
DMTJNY0 FM C13H13ClN2
DMTJNY0 IC InChI=1S/C13H13ClN2/c14-10-6-3-5-9-12(15)8-4-1-2-7-11(8)16-13(9)10/h3,5-6H,1-2,4,7H2,(H2,15,16)
DMTJNY0 CS C1CCC2=C(C1)C(=C3C=CC=C(C3=N2)Cl)N
DMTJNY0 IK DREAHDLCWZKIJL-UHFFFAOYSA-N
DMTJNY0 IU 5-chloro-1,2,3,4-tetrahydroacridin-9-amine
DMTJNY0 DE Discovery agent
DMOCYDU ID DMOCYDU
DMOCYDU DN 5-chloro-1H-indazole
DMOCYDU HS Investigative
DMOCYDU SN 5-Chloro-1H-indazole; 698-26-0; 1H-Indazole, 5-chloro-; 5-Chloroindazole; 5-CHLORO INDAZOLE; EINECS 211-812-1; NSC 78434; BRN 0003260; CHEMBL246746; FVNCILPDWNBPLK-UHFFFAOYSA-N; AK-23822; 5-chloro-indazole; 2H-Indazole, 5-chloro-; NSC78434; 5-chloro-2H-indazole; AC1L2CF8; 5-23-06-00175 (Beilstein Handbook Reference); 5-CHLORO(1H)INDAZOLE; SCHEMBL3540025; SCHEMBL16523221; CTK2F6769; DTXSID70220091; MolPort-000-002-983; 5-Chloro-1H-indazole, AldrichCPR; ZX-CM006597; ZX-AT013670; ZINC4876880; BCP00023; ACT10091; FCH837623; BDBM50209242
DMOCYDU DT Small molecular drug
DMOCYDU PC 69681
DMOCYDU MW 152.58
DMOCYDU FM C7H5ClN2
DMOCYDU IC InChI=1S/C7H5ClN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)
DMOCYDU CS C1=CC2=C(C=C1Cl)C=NN2
DMOCYDU IK FVNCILPDWNBPLK-UHFFFAOYSA-N
DMOCYDU IU 5-chloro-1H-indazole
DMOCYDU CA CAS 698-26-0
DMOCYDU DE Discovery agent
DMQ350F ID DMQ350F
DMQ350F DN 5-chloro-1H-indole-2,3-dione
DMQ350F HS Investigative
DMQ350F SN 5-Chloroisatin; 17630-76-1; 5-chloroindoline-2,3-dione; 5-Chloro-1H-indole-2,3-dione; 5-chlorisatin; 1H-Indole-2,3-dione, 5-chloro-; 5-chloro-2,3-dihydro-1H-indole-2,3-dione; 5-CHLORO ISATIN; 5-chlor-2,3-dioxoindolin; NSC 135811; XHDJYQWGFIBCEP-UHFFFAOYSA-N; MFCD00014567; 5-chlor-1h-indol-2,3-dion; 2HQ; EINECS 241-614-0; NSC135811; PubChem13607; ACMC-209zyf; 5-Chloroisatin, 97%; AC1Q3MRO; AC1Q3KL6; Isatin-based compound, 33; AC1Q3KL5; AC1L3D5R; 5-chloro-2,3-dioxoindolin; 5-Chloroindolin-2,3-dione; 1H-Indole-2, 5-chloro-; KSC174O1F
DMQ350F DT Small molecular drug
DMQ350F PC 87203
DMQ350F MW 181.57
DMQ350F FM C8H4ClNO2
DMQ350F IC InChI=1S/C8H4ClNO2/c9-4-1-2-6-5(3-4)7(11)8(12)10-6/h1-3H,(H,10,11,12)
DMQ350F CS C1=CC2=C(C=C1Cl)C(=O)C(=O)N2
DMQ350F IK XHDJYQWGFIBCEP-UHFFFAOYSA-N
DMQ350F IU 5-chloro-1H-indole-2,3-dione
DMQ350F CA CAS 17630-76-1
DMQ350F CB CHEBI:149904
DMQ350F DE Discovery agent
DMDZ8NA ID DMDZ8NA
DMDZ8NA DN 5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol
DMDZ8NA HS Investigative
DMDZ8NA SN CHEMBL200379; 5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol; 656833-26-0; SCHEMBL10539354; CTK1J6007; DTXSID70611844; BDBM50174768; 2-(2-Chloro-4-hydroxyphenoxy)-5-chlorophenol; 3-chloro-4-(4-chloro-2-hydroxy-phenoxy)phenol; Phenol, 5-chloro-2-(2-chloro-4-hydroxyphenoxy)-
DMDZ8NA DT Small molecular drug
DMDZ8NA PC 21272512
DMDZ8NA MW 271.09
DMDZ8NA FM C12H8Cl2O3
DMDZ8NA IC InChI=1S/C12H8Cl2O3/c13-7-1-3-12(10(16)5-7)17-11-4-2-8(15)6-9(11)14/h1-6,15-16H
DMDZ8NA CS C1=CC(=C(C=C1O)Cl)OC2=C(C=C(C=C2)Cl)O
DMDZ8NA IK JVFMLMMBAJXPOQ-UHFFFAOYSA-N
DMDZ8NA IU 3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenol
DMDZ8NA CA CAS 656833-26-0
DMDZ8NA DE Discovery agent
DMAJ8BS ID DMAJ8BS
DMAJ8BS DN 5-chloro-2-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS HS Investigative
DMAJ8BS SN 5-CHLORO-2-(2-CHLORO-4-NITROPHENOXY)PHENOL; CHEMBL370595; TN2; AC1OA9SQ; Phenol, 5-chloro-2-(2-chloro-4-nitrophenoxy)-; BDBM50174770; 36859-73-1; 5-chloro-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS DT Small molecular drug
DMAJ8BS PC 6852143
DMAJ8BS MW 300.09
DMAJ8BS FM C12H7Cl2NO4
DMAJ8BS IC InChI=1S/C12H7Cl2NO4/c13-7-1-3-12(10(16)5-7)19-11-4-2-8(15(17)18)6-9(11)14/h1-6,16H
DMAJ8BS CS C1=CC(=C(C=C1[N+](=O)[O-])Cl)OC2=C(C=C(C=C2)Cl)O
DMAJ8BS IK DEDBMNCDHFNYKX-UHFFFAOYSA-N
DMAJ8BS IU 5-chloro-2-(2-chloro-4-nitrophenoxy)phenol
DMAJ8BS DE Discovery agent
DMH4SLZ ID DMH4SLZ
DMH4SLZ DN 5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ HS Investigative
DMH4SLZ SN CHEMBL1099112; 5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ DT Small molecular drug
DMH4SLZ PC 46888044
DMH4SLZ MW 278.7
DMH4SLZ FM C17H11ClN2
DMH4SLZ IC InChI=1S/C17H11ClN2/c1-11-2-3-12-4-5-13(9-17(12)20-11)16-7-6-15(18)8-14(16)10-19/h2-9H,1H3
DMH4SLZ CS CC1=NC2=C(C=C1)C=CC(=C2)C3=C(C=C(C=C3)Cl)C#N
DMH4SLZ IK BYFVDRQULSVRKZ-UHFFFAOYSA-N
DMH4SLZ IU 5-chloro-2-(2-methylquinolin-7-yl)benzonitrile
DMH4SLZ DE Discovery agent
DMCFIZN ID DMCFIZN
DMCFIZN DN 5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol
DMCFIZN HS Investigative
DMCFIZN DT Small molecular drug
DMCFIZN PC 135495079
DMCFIZN MW 261.66
DMCFIZN FM C13H8ClNO3
DMCFIZN IC InChI=1S/C13H8ClNO3/c14-9-5-10-12(6-11(9)17)18-13(15-10)7-1-3-8(16)4-2-7/h1-6,16-17H
DMCFIZN CS C1=CC(=CC=C1C2=NC3=CC(=C(C=C3O2)O)Cl)O
DMCFIZN IK BXCKDNMAGMSBHF-UHFFFAOYSA-N
DMCFIZN IU 5-chloro-2-(4-hydroxyphenyl)-1,3-benzoxazol-6-ol
DMCFIZN DE Discovery agent
DMXNPSB ID DMXNPSB
DMXNPSB DN 5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol
DMXNPSB HS Investigative
DMXNPSB DT Small molecular drug
DMXNPSB PC 135502634
DMXNPSB MW 271.7
DMXNPSB FM C15H10ClNO2
DMXNPSB IC InChI=1S/C15H10ClNO2/c16-15-11-5-6-12(9-1-3-10(18)4-2-9)17-13(11)7-8-14(15)19/h1-8,18-19H
DMXNPSB CS C1=CC(=CC=C1C2=NC3=C(C=C2)C(=C(C=C3)O)Cl)O
DMXNPSB IK FGSBNIBNUVNBIW-UHFFFAOYSA-N
DMXNPSB IU 5-chloro-2-(4-hydroxyphenyl)quinolin-6-ol
DMXNPSB DE Discovery agent
DM9QBAZ ID DM9QBAZ
DM9QBAZ DN 5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione
DM9QBAZ HS Investigative
DM9QBAZ SN CHEMBL397849
DM9QBAZ DT Small molecular drug
DM9QBAZ PC 44440475
DM9QBAZ MW 313.8
DM9QBAZ FM C18H16ClNO2
DM9QBAZ IC InChI=1S/C18H16ClNO2/c19-14-9-10-15-16(12-14)18(22)20(17(15)21)11-5-4-8-13-6-2-1-3-7-13/h1-3,6-7,9-10,12H,4-5,8,11H2
DM9QBAZ CS C1=CC=C(C=C1)CCCCN2C(=O)C3=C(C2=O)C=C(C=C3)Cl
DM9QBAZ IK QQYWRVQHDFXEFG-UHFFFAOYSA-N
DM9QBAZ IU 5-chloro-2-(4-phenylbutyl)isoindole-1,3-dione
DM9QBAZ DE Discovery agent
DMJBHR9 ID DMJBHR9
DMJBHR9 DN 5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMJBHR9 HS Investigative
DMJBHR9 SN 63053-15-6; 6-chloro-2-(pyridin-2-yl)-1H-1,3-benzodiazole; 1H-Benzimidazole, 6-chloro-2-(2-pyridinyl)-; CHEMBL166127; 5-chloro-2-pyridin-2-yl-3H-benzoimidazole; 5-chlor-2-(2-pyridinyl)-1h-benzimidazol; AC1L4JHX; AC1Q3S8V; 5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124391; CTK2F4016; MolPort-006-709-924; KS-00001PG4; BDBM50180732; ZINC13679488; AKOS008957084; AKOS005256857; NE28766; MCULE-2896710700; 6-chloro-2-pyridin-2-yl-1H-benzimidazole; 2-(2-Pyridyl)-5-chloro-1H-benzoimidazole
DMJBHR9 DT Small molecular drug
DMJBHR9 PC 186763
DMJBHR9 MW 229.66
DMJBHR9 FM C12H8ClN3
DMJBHR9 IC InChI=1S/C12H8ClN3/c13-8-4-5-9-11(7-8)16-12(15-9)10-3-1-2-6-14-10/h1-7H,(H,15,16)
DMJBHR9 CS C1=CC=NC(=C1)C2=NC3=C(N2)C=C(C=C3)Cl
DMJBHR9 IK AIASBFLKLNIZOK-UHFFFAOYSA-N
DMJBHR9 IU 6-chloro-2-pyridin-2-yl-1H-benzimidazole
DMJBHR9 CA CAS 63053-15-6
DMJBHR9 DE Discovery agent
DM6YBZR ID DM6YBZR
DM6YBZR DN 5-Chloro-2-methyl-3H-quinazolin-4-one
DM6YBZR HS Investigative
DM6YBZR DT Small molecular drug
DM6YBZR PC 135875707
DM6YBZR MW 194.62
DM6YBZR FM C9H7ClN2O
DM6YBZR IC InChI=1S/C9H7ClN2O/c1-5-11-7-4-2-3-6(10)8(7)9(13)12-5/h2-4H,1H3,(H,11,12,13)
DM6YBZR CS CC1=NC2=C(C(=CC=C2)Cl)C(=O)N1
DM6YBZR IK GKDIFKSYPXLUJS-UHFFFAOYSA-N
DM6YBZR IU 5-chloro-2-methyl-3H-quinazolin-4-one
DM6YBZR CA CAS 19407-56-8
DM6YBZR DE Discovery agent
DMKEFJ0 ID DMKEFJ0
DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine
DMKEFJ0 HS Investigative
DMKEFJ0 SN CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0
DMKEFJ0 DT Small molecular drug
DMKEFJ0 PC 13702393
DMKEFJ0 MW 181.62
DMKEFJ0 FM C8H8ClN3
DMKEFJ0 IC InChI=1S/C8H8ClN3/c9-6-2-1-3-7-5(6)4-11-8(10)12-7/h1-3H,4H2,(H3,10,11,12)
DMKEFJ0 CS C1C2=C(C=CC=C2Cl)NC(=N1)N
DMKEFJ0 IK UDUQYNVUNNDSEJ-UHFFFAOYSA-N
DMKEFJ0 IU 5-chloro-1,4-dihydroquinazolin-2-amine
DMKEFJ0 DE Discovery agent
DM207CQ ID DM207CQ
DM207CQ DN 5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole
DM207CQ HS Investigative
DM207CQ SN CHEMBL300907; 181116-12-1; 5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole; CTK0A6482; DTXSID30658199; BDBM50127987; ZINC13489982; AKOS030619591; 5-Chloro-3-ethyl-1-(4-fluorophenyl)-1H-indole; 1H-Indole, 5-chloro-3-ethyl-1-(4-fluorophenyl)-
DM207CQ DT Small molecular drug
DM207CQ PC 44297094
DM207CQ MW 273.73
DM207CQ FM C16H13ClFN
DM207CQ IC InChI=1S/C16H13ClFN/c1-2-11-10-19(14-6-4-13(18)5-7-14)16-8-3-12(17)9-15(11)16/h3-10H,2H2,1H3
DM207CQ CS CCC1=CN(C2=C1C=C(C=C2)Cl)C3=CC=C(C=C3)F
DM207CQ IK APVXBLPJSJGGAJ-UHFFFAOYSA-N
DM207CQ IU 5-chloro-3-ethyl-1-(4-fluorophenyl)indole
DM207CQ CA CAS 181116-12-1
DM207CQ DE Discovery agent
DMGDTNI ID DMGDTNI
DMGDTNI DN 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine
DMGDTNI HS Investigative
DMGDTNI SN CHEMBL270176; 918134-92-6; 2-Quinazolinamine, 5-chloro-4-ethyl-1,4-dihydro-; 5-Chloro-4-ethyl-1,4-dihydroquinazolin-2-amine; SCHEMBL3570857; CTK3H8593; DTXSID00659173
DMGDTNI DT Small molecular drug
DMGDTNI PC 44455973
DMGDTNI MW 209.67
DMGDTNI FM C10H12ClN3
DMGDTNI IC InChI=1S/C10H12ClN3/c1-2-7-9-6(11)4-3-5-8(9)14-10(12)13-7/h3-5,7H,2H2,1H3,(H3,12,13,14)
DMGDTNI CS CCC1C2=C(C=CC=C2Cl)NC(=N1)N
DMGDTNI IK MICIQKQOEFSTDP-UHFFFAOYSA-N
DMGDTNI IU 5-chloro-4-ethyl-1,4-dihydroquinazolin-2-amine
DMGDTNI CA CAS 918134-92-6
DMGDTNI DE Discovery agent
DM7FZU2 ID DM7FZU2
DM7FZU2 DN 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine
DM7FZU2 HS Investigative
DM7FZU2 SN CHEMBL270177; 918134-82-4; 2-Quinazolinamine, 5-chloro-1,4-dihydro-4-methyl-; 5-Chloro-4-methyl-1,4-dihydroquinazolin-2-amine; SCHEMBL1381915; CTK3H8599; DTXSID00581041; XFMPGBXLGWZMQP-UHFFFAOYSA-N; BDBM50371466
DM7FZU2 DT Small molecular drug
DM7FZU2 PC 16006492
DM7FZU2 MW 195.65
DM7FZU2 FM C9H10ClN3
DM7FZU2 IC InChI=1S/C9H10ClN3/c1-5-8-6(10)3-2-4-7(8)13-9(11)12-5/h2-5H,1H3,(H3,11,12,13)
DM7FZU2 CS CC1C2=C(C=CC=C2Cl)NC(=N1)N
DM7FZU2 IK XFMPGBXLGWZMQP-UHFFFAOYSA-N
DM7FZU2 IU 5-chloro-4-methyl-1,4-dihydroquinazolin-2-amine
DM7FZU2 CA CAS 918134-82-4
DM7FZU2 DE Discovery agent
DMRS82Q ID DMRS82Q
DMRS82Q DN 5-chloro-4-nitrothiophene-2-sulfonamide
DMRS82Q HS Investigative
DMRS82Q SN 5-chloro-4-nitrothiophene-2-sulfonamide; 61714-46-3; 2-Chloro-3-nitrothiophene-5-sulfonamide; CHEMBL1170927; 2-Thiophenesulfonamide,5-chloro-4-nitro-; 2-chloro-3-nitrothiophene-5-sulphonamide; C4H3ClN2O4S2; AC1MC43M; SCHEMBL1185703; AC1Q558E; CTK5B3617; DTXSID50370942; CKMLFNQCVNTKHN-UHFFFAOYSA-N; MolPort-000-153-347; ZINC4253283; 9258AB; SBB099627; BDBM50321449; AKOS016010801; MCULE-8003873982; 5-chloro-4-nitro-2-thiophenesulfonamide; AJ-49707; 5-chloro-4-nitro-thiophene-2-sulfonamide; DB-053977; KB-229486; FT-0640779
DMRS82Q DT Small molecular drug
DMRS82Q PC 2735782
DMRS82Q MW 242.7
DMRS82Q FM C4H3ClN2O4S2
DMRS82Q IC InChI=1S/C4H3ClN2O4S2/c5-4-2(7(8)9)1-3(12-4)13(6,10)11/h1H,(H2,6,10,11)
DMRS82Q CS C1=C(SC(=C1[N+](=O)[O-])Cl)S(=O)(=O)N
DMRS82Q IK CKMLFNQCVNTKHN-UHFFFAOYSA-N
DMRS82Q IU 5-chloro-4-nitrothiophene-2-sulfonamide
DMRS82Q CA CAS 61714-46-3
DMRS82Q DE Discovery agent
DMMT7WO ID DMMT7WO
DMMT7WO DN 5-chloro-6-hydrazinouracil hydrochloride
DMMT7WO HS Investigative
DMMT7WO SN CHEMBL558777
DMMT7WO DT Small molecular drug
DMMT7WO PC 45263377
DMMT7WO MW 213.02
DMMT7WO FM C4H6Cl2N4O2
DMMT7WO IC InChI=1S/C4H5ClN4O2.ClH/c5-1-2(9-6)7-4(11)8-3(1)10;/h6H2,(H3,7,8,9,10,11);1H
DMMT7WO CS C1(=C(NC(=O)NC1=O)NN)Cl.Cl
DMMT7WO IK CEUAYFMFBGNGQD-UHFFFAOYSA-N
DMMT7WO IU 5-chloro-6-hydrazinyl-1H-pyrimidine-2,4-dione;hydrochloride
DMMT7WO DE Discovery agent
DM2SKP7 ID DM2SKP7
DM2SKP7 DN 5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine
DM2SKP7 HS Investigative
DM2SKP7 SN CHEMBL1269621; 5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine; SCHEMBL12095512
DM2SKP7 DT Small molecular drug
DM2SKP7 PC 49843567
DM2SKP7 MW 272.73
DM2SKP7 FM C15H13ClN2O
DM2SKP7 IC InChI=1S/C15H13ClN2O/c1-2-10-3-6-12(7-4-10)17-15-18-13-9-11(16)5-8-14(13)19-15/h3-9H,2H2,1H3,(H,17,18)
DM2SKP7 CS CCC1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)Cl
DM2SKP7 IK CKVTZZTZMCGPHV-UHFFFAOYSA-N
DM2SKP7 IU 5-chloro-N-(4-ethylphenyl)-1,3-benzoxazol-2-amine
DM2SKP7 DE Discovery agent
DMZ5MDY ID DMZ5MDY
DMZ5MDY DN 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMZ5MDY HS Investigative
DMZ5MDY SN CHEMBL290395; 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide; SCHEMBL8527508; BYXYRVSXGVLRKM-UHFFFAOYSA-N; BDBM50321877; 5-Chloro-1-(3-pyridylcarbamoyl)indoline; N-(3-Pyridinyl)-5-chloro-2,3-dihydro-1H-indole-1-carboxamide; 5-Chloro-2,3-dihydro-indole-1-carboxylic acid pyridin-3-ylamide
DMZ5MDY DT Small molecular drug
DMZ5MDY PC 10826147
DMZ5MDY MW 273.72
DMZ5MDY FM C14H12ClN3O
DMZ5MDY IC InChI=1S/C14H12ClN3O/c15-11-3-4-13-10(8-11)5-7-18(13)14(19)17-12-2-1-6-16-9-12/h1-4,6,8-9H,5,7H2,(H,17,19)
DMZ5MDY CS C1CN(C2=C1C=C(C=C2)Cl)C(=O)NC3=CN=CC=C3
DMZ5MDY IK BYXYRVSXGVLRKM-UHFFFAOYSA-N
DMZ5MDY IU 5-chloro-N-pyridin-3-yl-2,3-dihydroindole-1-carboxamide
DMZ5MDY DE Discovery agent
DMMV931 ID DMMV931
DMMV931 DN 5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide
DMMV931 HS Investigative
DMMV931 SN CHEMBL257446; 620103-77-7; 5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide; AC1NGSHS; SCHEMBL13633877; CTK1I9417; DTXSID80406061; MolPort-003-263-222; ZINC6858682; BDBM50372504; AKOS001150619; MCULE-4753456414; NCGC00163030-02; NCGC00163030-01; 5-chloro-N-quinolin-8-ylthiophene-2-sulfonamide; 2-Thiophenesulfonamide, 5-chloro-N-8-quinolinyl-; CU-00000000281-1
DMMV931 DT Small molecular drug
DMMV931 PC 4729240
DMMV931 MW 324.8
DMMV931 FM C13H9ClN2O2S2
DMMV931 IC InChI=1S/C13H9ClN2O2S2/c14-11-6-7-12(19-11)20(17,18)16-10-5-1-3-9-4-2-8-15-13(9)10/h1-8,16H
DMMV931 CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=C(S3)Cl)N=CC=C2
DMMV931 IK SNSCETRSXPPXIM-UHFFFAOYSA-N
DMMV931 IU 5-chloro-N-quinolin-8-ylthiophene-2-sulfonamide
DMMV931 CA CAS 620103-77-7
DMMV931 DE Discovery agent
DMVQLFB ID DMVQLFB
DMVQLFB DN 5-Chloro-N-phenylbenzo[d]oxazol-2-amine
DMVQLFB HS Investigative
DMVQLFB SN CHEMBL1269620; 79558-94-4; 2-Benzoxazolamine, 5-chloro-N-phenyl-; 5-Chloro-N-phenylbenzo[d]oxazol-2-amine; AC1NKL9S; 5-chloro-N-phenyl-1,3-benzoxazol-2-amine; SCHEMBL3474865; CTK2G4049; DTXSID50406795; BDBM50329393; ZINC33559155; N-Phenyl-5-chlorobenzoxazole-2-amine; VU0404023-1; J3.559.656I
DMVQLFB DT Small molecular drug
DMVQLFB PC 4915226
DMVQLFB MW 244.67
DMVQLFB FM C13H9ClN2O
DMVQLFB IC InChI=1S/C13H9ClN2O/c14-9-6-7-12-11(8-9)16-13(17-12)15-10-4-2-1-3-5-10/h1-8H,(H,15,16)
DMVQLFB CS C1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)Cl
DMVQLFB IK YWNAVPSABPGECL-UHFFFAOYSA-N
DMVQLFB IU 5-chloro-N-phenyl-1,3-benzoxazol-2-amine
DMVQLFB CA CAS 79558-94-4
DMVQLFB DE Discovery agent
DMH397E ID DMH397E
DMH397E DN 5-Chlorosalicylic Acid
DMH397E HS Investigative
DMH397E SN 5-CHLOROSALICYLIC ACID; 5-Chloro-2-hydroxybenzoic acid; 321-14-2; Benzoic acid, 5-chloro-2-hydroxy-; 2-Hydroxy-5-chlorobenzoic acid; 5 CSA; Salicylic acid, 5-chloro-; 5-Chlorosalicyclic acid; 5-chloro salicylic acid; 5-Chloro-2-hydroxy-benzoic acid; UNII-J2YFG68VCZ; CCRIS 4485; EINECS 206-283-9; NSC 30111; J2YFG68VCZ; BRN 2046665; CHEMBL1375; AI3-22259; CHEBI:420128; NKBASRXWGAGQDP-UHFFFAOYSA-N; 5-chloro-salicylic acid; 5-chloro-salicyclic acid; ACMC-209hr2; Oprea1_451559; 5-chloro-2-hydroxy-benzoate; 4-10-00-00207 (Beilstein Handb
DMH397E DT Small molecular drug
DMH397E PC 9447
DMH397E MW 172.56
DMH397E FM C7H5ClO3
DMH397E IC InChI=1S/C7H5ClO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,(H,10,11)
DMH397E CS C1=CC(=C(C=C1Cl)C(=O)O)O
DMH397E IK NKBASRXWGAGQDP-UHFFFAOYSA-N
DMH397E IU 5-chloro-2-hydroxybenzoic acid
DMH397E CA CAS 321-14-2
DMH397E CB CHEBI:420128
DMH397E DE Discovery agent
DMWS3D6 ID DMWS3D6
DMWS3D6 DN 5-Chloryl-2,4,6-Quinazolinetriamine
DMWS3D6 HS Investigative
DMWS3D6 SN 2,4,6-Triamino-5-chloroquinazoline; 17511-20-5; CHEMBL6708; CLZ; AC1L47X8; SCHEMBL1611666; CTK4D5160; DTXSID70169931; MolPort-003-808-568; JZWXVYNQIJJTKF-UHFFFAOYSA-N; BDBM50404662; 5-chloroquinazoline-2,4,6-triamine; ZINC13282329; AKOS022649928; 2,4,6-Quinazolinetriamine,5-chloro-; 2,4,6-Quinazolinetriamine, 5-chloro-
DMWS3D6 DT Small molecular drug
DMWS3D6 PC 4627204
DMWS3D6 MW 241.63
DMWS3D6 FM C8H8ClN5O2
DMWS3D6 IC InChI=1S/C8H8ClN5O2/c10-3-1-2-4-5(6(3)9(15)16)7(11)14-8(12)13-4/h1-2H,10H2,(H4,11,12,13,14)
DMWS3D6 CS C1=CC2=C(C(=C1N)Cl(=O)=O)C(=NC(=N2)N)N
DMWS3D6 IK AOIWFGJNGXKHGL-UHFFFAOYSA-N
DMWS3D6 IU 5-chlorylquinazoline-2,4,6-triamine
DMWS3D6 DE Discovery agent
DM109IL ID DM109IL
DM109IL DN 5-Cl-5-deoxy-(+/-)-ENBA
DM109IL HS Investigative
DM109IL SN GTPL6560; 5-Cl-5-deoxy-(plusmn)-ENBA; ( )-5'-Chloro-5'-deoxy-ENBA; 2-[6-({bicyclo[2.2.1]heptan-2-yl}amino)-9H-purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
DM109IL DT Small molecular drug
DM109IL PC 15599147
DM109IL MW 379.8
DM109IL FM C17H22ClN5O3
DM109IL IC InChI=1S/C17H22ClN5O3/c18-5-11-13(24)14(25)17(26-11)23-7-21-12-15(19-6-20-16(12)23)22-10-4-8-1-2-9(10)3-8/h6-11,13-14,17,24-25H,1-5H2,(H,19,20,22)
DM109IL CS C1CC2CC1CC2NC3=C4C(=NC=N3)N(C=N4)C5C(C(C(O5)CCl)O)O
DM109IL IK PVJGDYDNVNCGBT-UHFFFAOYSA-N
DM109IL IU 2-[6-(2-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(chloromethyl)oxolane-3,4-diol
DM109IL CA CAS 103626-26-2
DM109IL DE Discovery agent
DM260KD ID DM260KD
DM260KD DN 5-CT
DM260KD HS Investigative
DM260KD SN 5-carboxamidotryptamine
DM260KD DT Small molecular drug
DM260KD PC 1809
DM260KD MW 203.24
DM260KD FM C11H13N3O
DM260KD IC InChI=1S/C11H13N3O/c12-4-3-8-6-14-10-2-1-7(11(13)15)5-9(8)10/h1-2,5-6,14H,3-4,12H2,(H2,13,15)
DM260KD CS C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN
DM260KD IK WKZLNEWVIAGNAW-UHFFFAOYSA-N
DM260KD IU 3-(2-aminoethyl)-1H-indole-5-carboxamide
DM260KD CA CAS 74885-09-9
DM260KD CB CHEBI:48292
DM260KD DE Discovery agent
DMMYENH ID DMMYENH
DMMYENH DN 5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
DMMYENH HS Investigative
DMMYENH SN 5-cyclohexyl-1,3,4-oxadiazole-2-thiol; 173589-87-2; 5-Cyclohexyl-[1,3,4]oxadiazole-2-thiol; CHEMBL456586; 5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione; 1,3,4-Oxadiazole-2(3H)-thione, 5-cyclohexyl-; BAS 09627004; AC1Q7GLG; AC1MWQ13; MLS000719170; SCHEMBL13401036; CTK0A7651; DTXSID20396654; MolPort-000-932-255; HMS1700P22; HMS2732D23; ZINC6675630; BDBM50320725; AKOS000669727; MCULE-5633296933; SMR000291438; KB-124591; 5-cyclohexyl-3H-1,3,4-oxadiazole-2-thione; EN300-10672; 5-Cyclohexyl-3H-[1,3,4]oxadiazole-2-thione; K-5320
DMMYENH DT Small molecular drug
DMMYENH PC 3803233
DMMYENH MW 184.26
DMMYENH FM C8H12N2OS
DMMYENH IC InChI=1S/C8H12N2OS/c12-8-10-9-7(11-8)6-4-2-1-3-5-6/h6H,1-5H2,(H,10,12)
DMMYENH CS C1CCC(CC1)C2=NNC(=S)O2
DMMYENH IK ONBUSMDUKULCRC-UHFFFAOYSA-N
DMMYENH IU 5-cyclohexyl-3H-1,3,4-oxadiazole-2-thione
DMMYENH CA CAS 173589-87-2
DMMYENH DE Discovery agent
DMRFH9U ID DMRFH9U
DMRFH9U DN 5'-deoxy-4'-hydroxy-5'-methylthio-DADMe-ImmH
DMRFH9U HS Investigative
DMRFH9U DT Small molecular drug
DMRFH9U PC 11722921
DMRFH9U DE Discovery agent
DMR28HG ID DMR28HG
DMR28HG DN 5'-Deoxy-5'-(Methylthio)-Tubercidin
DMR28HG HS Investigative
DMR28HG SN 5'-methylthiotubercidin; 5'-DEOXY-5'-(METHYLTHIO)-TUBERCIDIN; 2-(4-AMINO-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-METHYLSULFANYLMETHYL-TETRAHYDRO-FURAN-3,4-DIOL; MTH; 2qtg; 7-(5-S-methyl-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine; 7-(5-S-methyl-5-thio-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 61893-98-9; 1nc1; AC1Q7DT3; AC1L4MN1; 5'-(methylsulfanyl)tubercidin; CHEMBL551561; DB02933; 7-(5-s-methyl-5-thio-; A-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine,
DMR28HG DT Small molecular drug
DMR28HG PC 188350
DMR28HG MW 296.35
DMR28HG FM C12H16N4O3S
DMR28HG IC InChI=1S/C12H16N4O3S/c1-20-4-7-8(17)9(18)12(19-7)16-3-2-6-10(13)14-5-15-11(6)16/h2-3,5,7-9,12,17-18H,4H2,1H3,(H2,13,14,15)/t7-,8-,9-,12-/m1/s1
DMR28HG CS CSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC3=C(N=CN=C32)N)O)O
DMR28HG IK WBPLMFVTQMIPLW-MFYTUXHUSA-N
DMR28HG IU (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(methylsulfanylmethyl)oxolane-3,4-diol
DMR28HG CA CAS 61893-98-9
DMR28HG DE Discovery agent
DMOHSY0 ID DMOHSY0
DMOHSY0 DN 5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine
DMOHSY0 HS Investigative
DMOHSY0 SN 5'-deoxy-5'-(dimethylamino)-8-methyladenosine; SCHEMBL955366; 5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine; CHEMBL516214; AdoMet substrate analogue, 23a; BDBM28452; BDRUNDKEQQVJJG-QYVSTXNMSA-N; (2R,3R,4S,5R)-2-(6-amino-8-methyl-9H-purin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMOHSY0 DT Small molecular drug
DMOHSY0 PC 25231308
DMOHSY0 MW 308.34
DMOHSY0 FM C13H20N6O3
DMOHSY0 IC InChI=1S/C13H20N6O3/c1-6-17-8-11(14)15-5-16-12(8)19(6)13-10(21)9(20)7(22-13)4-18(2)3/h5,7,9-10,13,20-21H,4H2,1-3H3,(H2,14,15,16)/t7-,9-,10-,13-/m1/s1
DMOHSY0 CS CC1=NC2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CN(C)C)O)O)N
DMOHSY0 IK BDRUNDKEQQVJJG-QYVSTXNMSA-N
DMOHSY0 IU (2R,3R,4S,5R)-2-(6-amino-8-methylpurin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMOHSY0 DE Discovery agent
DMF7JPO ID DMF7JPO
DMF7JPO DN 5'-Deoxy-5'-(N,N-dimethylamino)adenosine
DMF7JPO HS Investigative
DMF7JPO SN 5'-Deoxy-5'-(Dimethylamino)adenosine; 5'-Deoxy-5'-(N,N-dimethylamino)adenosine; SCHEMBL952928; CHEMBL472733; AdoMet substrate analogue, 23b; BDBM28453; SLNWRDWGFHZRAQ-WOUKDFQISA-N; ZINC40914070; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMF7JPO DT Small molecular drug
DMF7JPO PC 25231309
DMF7JPO MW 294.31
DMF7JPO FM C12H18N6O3
DMF7JPO IC InChI=1S/C12H18N6O3/c1-17(2)3-6-8(19)9(20)12(21-6)18-5-16-7-10(13)14-4-15-11(7)18/h4-6,8-9,12,19-20H,3H2,1-2H3,(H2,13,14,15)/t6-,8-,9-,12-/m1/s1
DMF7JPO CS CN(C)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMF7JPO IK SLNWRDWGFHZRAQ-WOUKDFQISA-N
DMF7JPO IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[(dimethylamino)methyl]oxolane-3,4-diol
DMF7JPO DE Discovery agent
DM6HGUL ID DM6HGUL
DM6HGUL DN 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine
DM6HGUL HS Investigative
DM6HGUL SN MHZPA; 112621-42-8; 5'-Deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine; 5'-Deoxy-5'-(N-methyl-N-(3-hydrazinopropyl)amino)adenosine; 5'-Deoxy-5'-((3-hydrazinopropyl)methylamino)adenosine; Adenosine, 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]-; MHZ; Adenosine, 5'-deoxy-5'-((3-hydrazinopropyl)methylamino)-; AC1L3TYJ; SCHEMBL952217; Adenosine,5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]- (9CI); CTK4A7899; DTXSID50150125; AKOS030589592; 5'-[(3-Hydrazinopropyl)methylamino]-5'-deoxyadenosine
DM6HGUL DT Small molecular drug
DM6HGUL PC 122092
DM6HGUL MW 352.39
DM6HGUL FM C14H24N8O3
DM6HGUL IC InChI=1S/C14H24N8O3/c1-21(4-2-3-20-16)5-8-10(23)11(24)14(25-8)22-7-19-9-12(15)17-6-18-13(9)22/h6-8,10-11,14,20,23-24H,2-5,16H2,1H3,(H2,15,17,18)/t8-,10-,11-,14-/m1/s1
DM6HGUL CS CN(CCCNN)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM6HGUL IK MYNRDUPGBPOWQT-IDTAVKCVSA-N
DM6HGUL IU (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[3-hydrazinylpropyl(methyl)amino]methyl]oxolane-3,4-diol
DM6HGUL CA CAS 112621-42-8
DM6HGUL DE Discovery agent
DM1NAMK ID DM1NAMK
DM1NAMK DN 5'-Deoxy-5'-dimethylsulfonioadenosine chloride
DM1NAMK HS Investigative
DM1NAMK SN SCHEMBL952519
DM1NAMK DT Small molecular drug
DM1NAMK PC 25231315
DM1NAMK MW 347.82
DM1NAMK FM C12H18ClN5O3S
DM1NAMK IC InChI=1S/C12H18N5O3S.ClH/c1-21(2)3-6-8(18)9(19)12(20-6)17-5-16-7-10(13)14-4-15-11(7)17;/h4-6,8-9,12,18-19H,3H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1/t6-,8-,9-,12-;/m1./s1
DM1NAMK CS C[S+](C)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Cl-]
DM1NAMK IK UQRXECZPKCIHRJ-OUTCZKRVSA-M
DM1NAMK IU [(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-dimethylsulfanium;chloride
DM1NAMK DE Discovery agent
DMU4MCK ID DMU4MCK
DMU4MCK DN 5'-Deoxy-5'-phenyladenophostin A
DMU4MCK HS Investigative
DMU4MCK SN CHEMBL1161890; 3'-O-(3-O,4-O-Diphosphono-alpha-D-glucopyranosyl)-5'-phenyl-5'-deoxy-2'-adenylic acid
DMU4MCK DT Small molecular drug
DMU4MCK PC 44416175
DMU4MCK MW 723.4
DMU4MCK FM C22H24N5O17P3-6
DMU4MCK IC InChI=1S/C22H30N5O17P3/c23-19-13-20(25-8-24-19)27(9-26-13)21-18(44-47(36,37)38)15(11(39-21)6-10-4-2-1-3-5-10)41-22-14(29)17(43-46(33,34)35)16(12(7-28)40-22)42-45(30,31)32/h1-5,8-9,11-12,14-18,21-22,28-29H,6-7H2,(H2,23,24,25)(H2,30,31,32)(H2,33,34,35)(H2,36,37,38)/p-6/t11-,12-,14-,15-,16-,17-,18-,21-,22-/m1/s1
DMU4MCK CS C1=CC=C(C=C1)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)N)OP(=O)([O-])[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)OP(=O)([O-])[O-])OP(=O)([O-])[O-])O
DMU4MCK IK HQEPXXWNKLEIRE-NYCICKCISA-H
DMU4MCK IU [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-benzyl-4-[(2R,3R,4R,5R,6R)-3-hydroxy-6-(hydroxymethyl)-4,5-diphosphonatooxyoxan-2-yl]oxyoxolan-3-yl] phosphate
DMU4MCK DE Discovery agent
DM65XZJ ID DM65XZJ
DM65XZJ DN 5-deoxy-5-phosphono-D-arabinonate
DM65XZJ HS Investigative
DM65XZJ DT Small molecular drug
DM65XZJ PC 56603745
DM65XZJ MW 227.09
DM65XZJ FM C5H8O8P-3
DM65XZJ IC InChI=1S/C5H11O8P/c6-2(1-14(11,12)13)3(7)4(8)5(9)10/h2-4,6-8H,1H2,(H,9,10)(H2,11,12,13)/p-3
DM65XZJ CS C(C(C(C(C(=O)[O-])O)O)O)P(=O)([O-])[O-]
DM65XZJ IK XCBNBIPHASXSKG-UHFFFAOYSA-K
DM65XZJ IU 2,3,4-trihydroxy-5-phosphonatopentanoate
DM65XZJ DE Discovery agent
DM8IQX4 ID DM8IQX4
DM8IQX4 DN 5'-deoxy-5'-ureidoadenosine
DM8IQX4 HS Investigative
DM8IQX4 SN CHEMBL231952; 5''-deoxy-5''-ureidoadenosine
DM8IQX4 DT Small molecular drug
DM8IQX4 PC 23661679
DM8IQX4 MW 309.28
DM8IQX4 FM C11H15N7O4
DM8IQX4 IC InChI=1S/C11H15N7O4/c12-8-5-9(16-2-15-8)18(3-17-5)10-7(20)6(19)4(22-10)1-14-11(13)21/h2-4,6-7,10,19-20H,1H2,(H2,12,15,16)(H3,13,14,21)/t4-,6-,7-,10-/m1/s1
DM8IQX4 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CNC(=O)N)O)O)N
DM8IQX4 IK MRVWQDQRJFAPMW-KQYNXXCUSA-N
DM8IQX4 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylurea
DM8IQX4 DE Discovery agent
DM1Q0BF ID DM1Q0BF
DM1Q0BF DN 5-deoxyabyssinin II
DM1Q0BF HS Investigative
DM1Q0BF SN 5-deoxyabyssinin II; CHEMBL229670
DM1Q0BF DT Small molecular drug
DM1Q0BF PC 44424649
DM1Q0BF MW 354.4
DM1Q0BF FM C21H22O5
DM1Q0BF IC InChI=1S/C21H22O5/c1-12(2)4-5-13-8-14(9-20(25-3)21(13)24)18-11-17(23)16-7-6-15(22)10-19(16)26-18/h4,6-10,18,22,24H,5,11H2,1-3H3/t18-/m0/s1
DM1Q0BF CS CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)O)OC)O)C
DM1Q0BF IK GZTDFKLABHOHBU-SFHVURJKSA-N
DM1Q0BF IU (2S)-7-hydroxy-2-[4-hydroxy-3-methoxy-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DM1Q0BF DE Discovery agent
DMR48NG ID DMR48NG
DMR48NG DN 5'-deoxythymidine
DMR48NG HS Investigative
DMR48NG SN 5'-Deoxythymidine; 3458-14-8; Thymidine, 5'-deoxy-; 5'-Ddthd; 2',5'-Dideoxythymidine; 5'-Deoxythymidine, 98%; AC1L22MY; SCHEMBL2056693; CHEMBL465901; CTK1C3983; DTXSID70188127; MolPort-003-930-221; ZINC5765072; AKOS015892581; 5 inverted exclamation marka-Deoxythymidine; FT-0772769; C-44347; I03-1540; 5''-Deoxythymidine; AC1L22MY; SureCN2056693;; 2 inverted exclamation marka,5 inverted exclamation marka-Dideoxythymidine; 1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR48NG DT Small molecular drug
DMR48NG PC 65120
DMR48NG MW 226.23
DMR48NG FM C10H14N2O4
DMR48NG IC InChI=1S/C10H14N2O4/c1-5-4-12(10(15)11-9(5)14)8-3-7(13)6(2)16-8/h4,6-8,13H,3H2,1-2H3,(H,11,14,15)/t6-,7+,8-/m1/s1
DMR48NG CS C[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)O
DMR48NG IK UGUILUGCFSCUKR-GJMOJQLCSA-N
DMR48NG IU 1-[(2R,4S,5R)-4-hydroxy-5-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR48NG CA CAS 3458-14-8
DMR48NG DE Discovery agent
DM6TM1L ID DM6TM1L
DM6TM1L DN 5-desgalloylstachyurin
DM6TM1L HS Investigative
DM6TM1L SN 5-desgalloylstachyurin; CHEMBL488110
DM6TM1L DT Small molecular drug
DM6TM1L PC 10417809
DM6TM1L MW 784.5
DM6TM1L FM C34H24O22
DM6TM1L IC InChI=1S/C34H24O22/c35-8-1-5-12(21(42)18(8)39)13-6(2-9(36)19(40)22(13)43)32(50)54-28(11(38)4-53-31(5)49)30-29-26(47)17-16(34(52)55-29)15(24(45)27(48)25(17)46)14-7(33(51)56-30)3-10(37)20(41)23(14)44/h1-3,11,26,28-30,35-48H,4H2/t11-,26+,28-,29+,30+/m1/s1
DM6TM1L CS C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)[C@H]4[C@@H]5[C@H](C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)O)O
DM6TM1L IK CHBITXAMNKHJCR-VGYCLGPVSA-N
DM6TM1L IU (14R,15S,19S)-14-[(10R,11R)-3,4,5,11,17,18,19-heptahydroxy-8,14-dioxo-9,13-dioxatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]-2,3,4,7,8,9,19-heptahydroxy-13,16-dioxatetracyclo[13.3.1.05,18.06,11]nonadeca-1,3,5(18),6,8,10-hexaene-12,17-dione
DM6TM1L DE Discovery agent
DMX64E3 ID DMX64E3
DMX64E3 DN 5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine
DMX64E3 HS Investigative
DMX64E3 SN CHEMBL271300; SCHEMBL13990825; ZINC29131629
DMX64E3 DT Small molecular drug
DMX64E3 PC 44456496
DMX64E3 MW 204.31
DMX64E3 FM C13H20N2
DMX64E3 IC InChI=1S/C13H20N2/c1-2-12-5-6-13(14-11-12)7-10-15-8-3-4-9-15/h5-6,11H,2-4,7-10H2,1H3
DMX64E3 CS CCC1=CN=C(C=C1)CCN2CCCC2
DMX64E3 IK LTRFAPGENZNRNS-UHFFFAOYSA-N
DMX64E3 IU 5-ethyl-2-(2-pyrrolidin-1-ylethyl)pyridine
DMX64E3 DE Discovery agent
DM0E9O1 ID DM0E9O1
DM0E9O1 DN 5-ethyl-2-(phenylsulfonamido)benzoic acid
DM0E9O1 HS Investigative
DM0E9O1 SN Benzoic acid, 5-ethyl-2-[(phenylsulfonyl)amino]-; 677290-35-6; sulfonamide compound, 6; SCHEMBL3979169; CHEMBL377012; CTK1H6802; BDBM17600; DTXSID80439379; BUWBVEJQFXVJCT-UHFFFAOYSA-N; 2-benzenesulfonamido-5-ethylbenzoic acid; 5-ethyl-2-[(phenylsulfonyl)amino]benzoic acid
DM0E9O1 DT Small molecular drug
DM0E9O1 PC 10402833
DM0E9O1 MW 305.4
DM0E9O1 FM C15H15NO4S
DM0E9O1 IC InChI=1S/C15H15NO4S/c1-2-11-8-9-14(13(10-11)15(17)18)16-21(19,20)12-6-4-3-5-7-12/h3-10,16H,2H2,1H3,(H,17,18)
DM0E9O1 CS CCC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DM0E9O1 IK BUWBVEJQFXVJCT-UHFFFAOYSA-N
DM0E9O1 IU 2-(benzenesulfonamido)-5-ethylbenzoic acid
DM0E9O1 CA CAS 677290-35-6
DM0E9O1 DE Discovery agent
DMK57W2 ID DMK57W2
DMK57W2 DN 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMK57W2 HS Investigative
DMK57W2 SN CHEMBL49048; 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole; SCHEMBL8506288; PWLIYMBPGFVKOO-UHFFFAOYSA-N; BDBM50090520; 3-(2-Pyrrolizinoethyl)-5-ethyl-1H-indole; 5-ethyl-3-(2-pyrrolidinylethyl) -1H-indole
DMK57W2 DT Small molecular drug
DMK57W2 PC 15870567
DMK57W2 MW 242.36
DMK57W2 FM C16H22N2
DMK57W2 IC InChI=1S/C16H22N2/c1-2-13-5-6-16-15(11-13)14(12-17-16)7-10-18-8-3-4-9-18/h5-6,11-12,17H,2-4,7-10H2,1H3
DMK57W2 CS CCC1=CC2=C(C=C1)NC=C2CCN3CCCC3
DMK57W2 IK PWLIYMBPGFVKOO-UHFFFAOYSA-N
DMK57W2 IU 5-ethyl-3-(2-pyrrolidin-1-ylethyl)-1H-indole
DMK57W2 DE Discovery agent
DMRIGXA ID DMRIGXA
DMRIGXA DN 5-Ethyl-3,4-diphenyl-isoxazole
DMRIGXA HS Investigative
DMRIGXA SN CHEMBL361504; 5-Ethyl-3,4-diphenyl-isoxazole; 3,4-diphenyl-5-ethylisoxazole; SCHEMBL2279510; MXTWADCRLRQMDW-UHFFFAOYSA-N; ZINC13583259
DMRIGXA DT Small molecular drug
DMRIGXA PC 10377376
DMRIGXA MW 249.31
DMRIGXA FM C17H15NO
DMRIGXA IC InChI=1S/C17H15NO/c1-2-15-16(13-9-5-3-6-10-13)17(18-19-15)14-11-7-4-8-12-14/h3-12H,2H2,1H3
DMRIGXA CS CCC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=CC=C3
DMRIGXA IK MXTWADCRLRQMDW-UHFFFAOYSA-N
DMRIGXA IU 5-ethyl-3,4-diphenyl-1,2-oxazole
DMRIGXA DE Discovery agent
DMYD8GP ID DMYD8GP
DMYD8GP DN 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione
DMYD8GP HS Investigative
DMYD8GP SN CHEMBL41666; 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione; BDBM50227231; 68475-20-7
DMYD8GP DT Small molecular drug
DMYD8GP PC 12488718
DMYD8GP MW 219.24
DMYD8GP FM C12H13NO3
DMYD8GP IC InChI=1S/C12H13NO3/c1-3-12(9-7-5-4-6-8-9)10(14)13(2)11(15)16-12/h4-8H,3H2,1-2H3
DMYD8GP CS CCC1(C(=O)N(C(=O)O1)C)C2=CC=CC=C2
DMYD8GP IK BWNMMRKYEBCJHN-UHFFFAOYSA-N
DMYD8GP IU 5-ethyl-3-methyl-5-phenyl-1,3-oxazolidine-2,4-dione
DMYD8GP DE Discovery agent
DMS9TFC ID DMS9TFC
DMS9TFC DN 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine
DMS9TFC HS Investigative
DMS9TFC SN CHEMBL185585; 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine; SCHEMBL12617784; BDBM50150915
DMS9TFC DT Small molecular drug
DMS9TFC PC 17892465
DMS9TFC MW 126.2
DMS9TFC FM C7H14N2
DMS9TFC IC InChI=1S/C7H14N2/c1-3-6-4-5(2)7(8)9-6/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMS9TFC CS CCC1CC(C(=N1)N)C
DMS9TFC IK WPWKHPKZOKESJR-UHFFFAOYSA-N
DMS9TFC IU 2-ethyl-4-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMS9TFC DE Discovery agent
DMQWOIG ID DMQWOIG
DMQWOIG DN 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine
DMQWOIG HS Investigative
DMQWOIG SN CHEMBL185024; CHEMBL552935; 190909-71-8; SCHEMBL7624096; BDBM50066778; AKOS027401526; AKOS006376472; DA-08771; FT-0744003; 2-ethyl-3,4-dihydro-3-methyl-2H-Pyrrol-5-amine; 5-Ethyl-4-methyl-pyrrolidin-(2E)-ylideneamine
DMQWOIG DT Small molecular drug
DMQWOIG PC 10396852
DMQWOIG MW 126.2
DMQWOIG FM C7H14N2
DMQWOIG IC InChI=1S/C7H14N2/c1-3-6-5(2)4-7(8)9-6/h5-6H,3-4H2,1-2H3,(H2,8,9)
DMQWOIG CS CCC1C(CC(=N1)N)C
DMQWOIG IK APKCAWUHKKJFRX-UHFFFAOYSA-N
DMQWOIG IU 2-ethyl-3-methyl-3,4-dihydro-2H-pyrrol-5-amine
DMQWOIG DE Discovery agent
DMSA8X2 ID DMSA8X2
DMSA8X2 DN 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DMSA8X2 HS Investigative
DMSA8X2 SN CHEMBL360009; 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DMSA8X2 DT Small molecular drug
DMSA8X2 PC 19049087
DMSA8X2 MW 154.25
DMSA8X2 FM C9H18N2
DMSA8X2 IC InChI=1S/C9H18N2/c1-3-5-7-6-9(10)11-8(7)4-2/h7-8H,3-6H2,1-2H3,(H2,10,11)
DMSA8X2 CS CCCC1CC(=NC1CC)N
DMSA8X2 IK ZRHQCTSUMZLGON-UHFFFAOYSA-N
DMSA8X2 IU 2-ethyl-3-propyl-3,4-dihydro-2H-pyrrol-5-amine
DMSA8X2 DE Discovery agent
DM8Y4G5 ID DM8Y4G5
DM8Y4G5 DN 5-Ethyl-oxazolidin-(2Z)-ylideneamine
DM8Y4G5 HS Investigative
DM8Y4G5 SN CHEMBL108352; 5-Ethyl-oxazolidin-(2Z)-ylideneamine; 5-Ethyloxazolidine-2-imine; SCHEMBL8968728; BDBM50138193; AKOS013533140; AKOS006375671
DM8Y4G5 DT Small molecular drug
DM8Y4G5 PC 19096426
DM8Y4G5 MW 114.15
DM8Y4G5 FM C5H10N2O
DM8Y4G5 IC InChI=1S/C5H10N2O/c1-2-4-3-7-5(6)8-4/h4H,2-3H2,1H3,(H2,6,7)
DM8Y4G5 CS CCC1CN=C(O1)N
DM8Y4G5 IK MFMHWQFUMUNREN-UHFFFAOYSA-N
DM8Y4G5 IU 5-ethyl-4,5-dihydro-1,3-oxazol-2-amine
DM8Y4G5 DE Discovery agent
DMLSC10 ID DMLSC10
DMLSC10 DN 5-Fluoro orotate
DMLSC10 HS Investigative
DMLSC10 SN 5-Fluoroorotic acid; 703-95-7; 5-Fluoroorotate; 5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid; Fluoroorotic acid; Orotic acid, 5-fluoro-; 5-FOA; 5-Fluoro orotic acid; NSC 31712; ENT-26398; Ro 2-9945; 5-Fluorouracil-4-carboxylic acid; UNII-7IA9OUC93E; WR 152520; 5-Fluoroorotic acid (VAN); MLS000737636; EINECS 211-876-0; 4-Pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-; 7IA9OUC93E; AI3-26398; FOA; 5-Fluorouracil-6-carboxylic Acid; SEHFUALWMUWDKS-UHFFFAOYSA-N
DMLSC10 DT Small molecular drug
DMLSC10 PC 69711
DMLSC10 MW 174.09
DMLSC10 FM C5H3FN2O4
DMLSC10 IC InChI=1S/C5H3FN2O4/c6-1-2(4(10)11)7-5(12)8-3(1)9/h(H,10,11)(H2,7,8,9,12)
DMLSC10 CS C1(=C(NC(=O)NC1=O)C(=O)O)F
DMLSC10 IK SEHFUALWMUWDKS-UHFFFAOYSA-N
DMLSC10 IU 5-fluoro-2,4-dioxo-1H-pyrimidine-6-carboxylic acid
DMLSC10 CA CAS 703-95-7
DMLSC10 DE Discovery agent
DM9U1HV ID DM9U1HV
DM9U1HV DN 5-fluoro-1H-indole-2-carboxylic acid
DM9U1HV HS Investigative
DM9U1HV SN 5-Fluoroindole-2-carboxylic acid; 399-76-8; 5-Fluoro-1H-indole-2-carboxylic acid; 2-Carboxy-5-fluoroindole; 1H-Indole-2-carboxylic acid, 5-fluoro-; CHEMBL23507; MLS000080089; WTXBRZCVLDTWLP-UHFFFAOYSA-N; MFCD00005612; SMR000037735; 5-Fluoroindole-2-carboxylic acid, 98%; Spectrum_001495; EINECS 206-919-5; PubChem1683; SpecPlus_000678; Spectrum5_001733; Opera_ID_1340; Spectrum4_001182; Spectrum3_001043; Spectrum2_001469; ACMC-209j9k; AC1Q4NE3; Lopac-265128; cid_1820; AC1Q73TI; AC1L1CB9; AC1Q73TJ; Lopac0_000071; Oprea1_012690
DM9U1HV DT Small molecular drug
DM9U1HV PC 1820
DM9U1HV MW 179.15
DM9U1HV FM C9H6FNO2
DM9U1HV IC InChI=1S/C9H6FNO2/c10-6-1-2-7-5(3-6)4-8(11-7)9(12)13/h1-4,11H,(H,12,13)
DM9U1HV CS C1=CC2=C(C=C1F)C=C(N2)C(=O)O
DM9U1HV IK WTXBRZCVLDTWLP-UHFFFAOYSA-N
DM9U1HV IU 5-fluoro-1H-indole-2-carboxylic acid
DM9U1HV CA CAS 399-76-8
DM9U1HV CB CHEBI:111276
DM9U1HV DE Glioma; Melanoma
DMEA8WP ID DMEA8WP
DMEA8WP DN 5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMEA8WP HS Investigative
DMEA8WP SN 875468-81-8; CHEMBL199982; 5-FLUORO-2-(2-PYRIDYL)-1H-BENZIMIDAZOLE; 1H-Benzimidazole, 6-fluoro-2-(2-pyridinyl)-; 6-fluoro-2-(pyridin-2-yl)-1H-1,3-benzodiazole; 5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124265; DTXSID90470258; MolPort-009-677-335; MolPort-027-941-496; ZINC13679485; BDBM50180735; AKOS010206775; NE40467; PC450144; KB-87704; BC4242268; 5-fluoro-2-pyridin-2-yl-1H-benzoimidazole; TL80090069; US8748618, LD-1-31
DMEA8WP DT Small molecular drug
DMEA8WP PC 11665659
DMEA8WP MW 213.21
DMEA8WP FM C12H8FN3
DMEA8WP IC InChI=1S/C12H8FN3/c13-8-4-5-9-11(7-8)16-12(15-9)10-3-1-2-6-14-10/h1-7H,(H,15,16)
DMEA8WP CS C1=CC=NC(=C1)C2=NC3=C(N2)C=C(C=C3)F
DMEA8WP IK AUSVDSQFCRIAEX-UHFFFAOYSA-N
DMEA8WP IU 6-fluoro-2-pyridin-2-yl-1H-benzimidazole
DMEA8WP CA CAS 875468-81-8
DMEA8WP DE Discovery agent
DME1AGO ID DME1AGO
DME1AGO DN 5-Fluoro-2'-Deoxyuridine-5'-Monophosphate
DME1AGO HS Investigative
DME1AGO SN 5-fluorodeoxyuridine monophosphate; FLUORODEOXYURIDYLATE; 5-fluoro-2'-deoxyuridine-5'-monophosphate; F-dUMP; 134-46-3; FdUMP; CHEMBL886; CHEBI:2129; UNII-7CJ707H131; 7CJ707H131; 88410-68-8; 5-FLUORO-2-DEOXYURIDINE MONOPHOSPHATE (FDUMP); [(2R,3S,5R)-5-(5-fluoro-2,4-dioxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate; UFP; Poly(dF5U); Poly(5'-FU); Poly(5-fluoro-2'-deoxyuridylic acid); 5FdUMP; DB03761; 5'-Uridylic acid, 2'-deoxy-5-fluoro-; AC1L1RES; 5'-Uridylic acid,2'-deoxy-5-fluoro-, homopolymer
DME1AGO DT Small molecular drug
DME1AGO PC 8642
DME1AGO MW 326.17
DME1AGO FM C9H12FN2O8P
DME1AGO IC InChI=1S/C9H12FN2O8P/c10-4-2-12(9(15)11-8(4)14)7-1-5(13)6(20-7)3-19-21(16,17)18/h2,5-7,13H,1,3H2,(H,11,14,15)(H2,16,17,18)/t5-,6+,7+/m0/s1
DME1AGO CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)COP(=O)(O)O)O
DME1AGO IK HFEKDTCAMMOLQP-RRKCRQDMSA-N
DME1AGO IU [(2R,3S,5R)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DME1AGO CA CAS 134-46-3
DME1AGO CB CHEBI:2129
DME1AGO DE Discovery agent
DMOI7ME ID DMOI7ME
DMOI7ME DN 5-Fluoro-2-hydroxy-N-isopropyl-benzamide
DMOI7ME HS Investigative
DMOI7ME SN CHEMBL84730; 5-Fluoro-2-hydroxy-N-isopropyl-benzamide; BDBM50084016; AKOS018088189
DMOI7ME DT Small molecular drug
DMOI7ME PC 44321262
DMOI7ME MW 197.21
DMOI7ME FM C10H12FNO2
DMOI7ME IC InChI=1S/C10H12FNO2/c1-6(2)12-10(14)8-5-7(11)3-4-9(8)13/h3-6,13H,1-2H3,(H,12,14)
DMOI7ME CS CC(C)NC(=O)C1=C(C=CC(=C1)F)O
DMOI7ME IK OQHZTWFYOJLOMH-UHFFFAOYSA-N
DMOI7ME IU 5-fluoro-2-hydroxy-N-propan-2-ylbenzamide
DMOI7ME DE Discovery agent
DMUCLAV ID DMUCLAV
DMUCLAV DN 5-Fluoro-2-sulfanyl-phenylphosphonic acid
DMUCLAV HS Investigative
DMUCLAV SN CHEMBL1170425; 5-Fluoro-2-sulfanyl-phenylphosphonic acid
DMUCLAV DT Small molecular drug
DMUCLAV PC 49799138
DMUCLAV MW 208.15
DMUCLAV FM C6H6FO3PS
DMUCLAV IC InChI=1S/C6H6FO3PS/c7-4-1-2-6(12)5(3-4)11(8,9)10/h1-3,12H,(H2,8,9,10)
DMUCLAV CS C1=CC(=C(C=C1F)P(=O)(O)O)S
DMUCLAV IK RDAVYJKCJHOMSD-UHFFFAOYSA-N
DMUCLAV IU (5-fluoro-2-sulfanylphenyl)phosphonic acid
DMUCLAV DE Discovery agent
DM0OQTJ ID DM0OQTJ
DM0OQTJ DN 5-Fluoro-3-thiophen-3-yl-quinoline
DM0OQTJ HS Investigative
DM0OQTJ SN CHEMBL305056; 5-fluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501434; ZINC3834023
DM0OQTJ DT Small molecular drug
DM0OQTJ PC 10421346
DM0OQTJ MW 229.27
DM0OQTJ FM C13H8FNS
DM0OQTJ IC InChI=1S/C13H8FNS/c14-12-2-1-3-13-11(12)6-10(7-15-13)9-4-5-16-8-9/h1-8H
DM0OQTJ CS C1=CC2=C(C=C(C=N2)C3=CSC=C3)C(=C1)F
DM0OQTJ IK BEVNNTNJJJWQAK-UHFFFAOYSA-N
DM0OQTJ IU 5-fluoro-3-thiophen-3-ylquinoline
DM0OQTJ DE Discovery agent
DMEV0GO ID DMEV0GO
DMEV0GO DN 5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil
DMEV0GO HS Investigative
DMEV0GO SN CHEMBL1080896; 5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil
DMEV0GO DT Small molecular drug
DMEV0GO PC 44632008
DMEV0GO MW 225.18
DMEV0GO FM C8H8FN5O2
DMEV0GO IC InChI=1S/C8H8FN5O2/c9-5-4(12-8(16)13-6(5)15)3-14-2-1-11-7(14)10/h1-2H,3H2,(H2,10,11)(H2,12,13,15,16)
DMEV0GO CS C1=CN(C(=N1)N)CC2=C(C(=O)NC(=O)N2)F
DMEV0GO IK SFEMKOUUPCFITA-UHFFFAOYSA-N
DMEV0GO IU 6-[(2-aminoimidazol-1-yl)methyl]-5-fluoro-1H-pyrimidine-2,4-dione
DMEV0GO DE Discovery agent
DM6QHIA ID DM6QHIA
DM6QHIA DN 5-fluoro-6-amino-UMP
DM6QHIA HS Investigative
DM6QHIA SN 6-Amino-5-Fluorouridine 5'-(Dihydrogen Phosphate); FNU; uridine derivative, 42; SCHEMBL1363501; CHEMBL474165; BDBM27945; {[(2R,3S,4R,5R)-5-(6-amino-5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
DM6QHIA DT Small molecular drug
DM6QHIA PC 16666487
DM6QHIA MW 357.19
DM6QHIA FM C9H13FN3O9P
DM6QHIA IC InChI=1S/C9H13FN3O9P/c10-3-6(11)13(9(17)12-7(3)16)8-5(15)4(14)2(22-8)1-21-23(18,19)20/h2,4-5,8,14-15H,1,11H2,(H,12,16,17)(H2,18,19,20)/t2-,4-,5-,8-/m1/s1
DM6QHIA CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=C(C(=O)NC2=O)F)N)O)O)OP(=O)(O)O
DM6QHIA IK OLBMCLUPWOAIRA-UMMCILCDSA-N
DM6QHIA IU [(2R,3S,4R,5R)-5-(6-amino-5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM6QHIA DE Discovery agent
DMZLJRS ID DMZLJRS
DMZLJRS DN 5-fluoro-6-azido-UMP
DMZLJRS HS Investigative
DMZLJRS SN uridine derivative, 41; CHEMBL514166; SCHEMBL15189843; BDBM27944; {[(2R,3S,4R,5R)-5-(6-azido-5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
DMZLJRS DT Small molecular drug
DMZLJRS PC 16666489
DMZLJRS MW 383.18
DMZLJRS FM C9H11FN5O9P
DMZLJRS IC InChI=1S/C9H11FN5O9P/c10-3-6(13-14-11)15(9(19)12-7(3)18)8-5(17)4(16)2(24-8)1-23-25(20,21)22/h2,4-5,8,16-17H,1H2,(H,12,18,19)(H2,20,21,22)/t2-,4-,5-,8-/m1/s1
DMZLJRS CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=C(C(=O)NC2=O)F)N=[N+]=[N-])O)O)OP(=O)(O)O
DMZLJRS IK ARRBQQMKVQEOHQ-UMMCILCDSA-N
DMZLJRS IU [(2R,3S,4R,5R)-5-(6-azido-5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMZLJRS DE Discovery agent
DMTAZ71 ID DMTAZ71
DMTAZ71 DN 5-Fluoro-6-ethyluridine-5'-O-monophosphate
DMTAZ71 HS Investigative
DMTAZ71 SN uridine derivative, 43; CHEMBL473587; SCHEMBL3219344; BDBM27946; {[(2R,3S,4R,5R)-5-(6-ethyl-5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid
DMTAZ71 DT Small molecular drug
DMTAZ71 PC 25027092
DMTAZ71 MW 370.22
DMTAZ71 FM C11H16FN2O9P
DMTAZ71 IC InChI=1S/C11H16FN2O9P/c1-2-4-6(12)9(17)13-11(18)14(4)10-8(16)7(15)5(23-10)3-22-24(19,20)21/h5,7-8,10,15-16H,2-3H2,1H3,(H,13,17,18)(H2,19,20,21)/t5-,7-,8-,10-/m1/s1
DMTAZ71 CS CCC1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)F
DMTAZ71 IK JBBLQWFDKGRNST-VPCXQMTMSA-N
DMTAZ71 IU [(2R,3S,4R,5R)-5-(6-ethyl-5-fluoro-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMTAZ71 DE Discovery agent
DM3LMIS ID DM3LMIS
DM3LMIS DN 5-fluoro-6-iodo-UMP
DM3LMIS HS Investigative
DM3LMIS SN SCHEMBL1364021
DM3LMIS DT Small molecular drug
DM3LMIS PC 16124514
DM3LMIS MW 468.07
DM3LMIS FM C9H11FIN2O9P
DM3LMIS IC InChI=1S/C9H11FIN2O9P/c10-3-6(11)13(9(17)12-7(3)16)8-5(15)4(14)2(22-8)1-21-23(18,19)20/h2,4-5,8,14-15H,1H2,(H,12,16,17)(H2,18,19,20)/t2-,4-,5-,8-/m1/s1
DM3LMIS CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=C(C(=O)NC2=O)F)I)O)O)OP(=O)(O)O
DM3LMIS IK NJSVPTGGTXIMLP-UMMCILCDSA-N
DM3LMIS IU [(2R,3S,4R,5R)-5-(5-fluoro-6-iodo-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM3LMIS DE Discovery agent
DMDV48S ID DMDV48S
DMDV48S DN 5-Fluorolevulinic Acid
DMDV48S HS Investigative
DMDV48S SN 5-FLUOROLEVULINIC ACID; 5-Fluoro-4-oxopentanoic acid; 76385-49-4; 1gzg; LAF; 5-Fluoro-4-oxopentanoate; 5-Fluoro-4-ketopentanoic acid; Substrate analogue, 9; AC1L2YNX; AC1Q4OPQ; SCHEMBL1053778; Pentanoic acid,5-fluoro-4-oxo-; BDBM82192; CTK5E2869; DTXSID40227219; Pentanoic acid, 5-fluoro-4-oxo-
DMDV48S DT Small molecular drug
DMDV48S PC 131153
DMDV48S MW 134.11
DMDV48S FM C5H7FO3
DMDV48S IC InChI=1S/C5H7FO3/c6-3-4(7)1-2-5(8)9/h1-3H2,(H,8,9)
DMDV48S CS C(CC(=O)O)C(=O)CF
DMDV48S IK MBVLGMJBSFUHKW-UHFFFAOYSA-N
DMDV48S IU 5-fluoro-4-oxopentanoic acid
DMDV48S CA CAS 76385-49-4
DMDV48S DE Discovery agent
DM371WE ID DM371WE
DM371WE DN 5-Formyl-6-Hydrofolic Acid
DM371WE HS Investigative
DM371WE DT Small molecular drug
DM371WE PC 136122640
DM371WE MW 471.4
DM371WE FM C20H21N7O7
DM371WE IC InChI=1S/C20H21N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,8-9,12-13,22H,5-7H2,(H,24,31)(H,29,30)(H,33,34)(H3,21,25,26,32)/t12-,13-/m1/s1
DM371WE CS C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)O)C(=O)O)NC[C@@H]2C=NC3=C(N2C=O)C(=O)NC(=N3)N
DM371WE IK CJLRPFSRJZBYFE-CHWSQXEVSA-N
DM371WE IU (2R)-2-[[4-[[(6R)-2-amino-5-formyl-4-oxo-3,6-dihydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
DM371WE DE Discovery agent
DMIARG7 ID DMIARG7
DMIARG7 DN 5'-Guanosine-Diphosphate-Monothiophosphate
DMIARG7 HS Investigative
DMIARG7 DT Small molecular drug
DMIARG7 PC 135398675
DMIARG7 MW 539.25
DMIARG7 FM C10H16N5O13P3S
DMIARG7 IC InChI=1S/C10H16N5O13P3S/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(26-9)1-25-29(19,20)27-30(21,22)28-31(23,24)32/h2-3,5-6,9,16-17H,1H2,(H,19,20)(H,21,22)(H2,23,24,32)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DMIARG7 CS C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N=C(NC2=O)N
DMIARG7 IK XOFLBQFBSOEHOG-UUOKFMHZSA-N
DMIARG7 IU [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphinothioyl hydrogen phosphate
DMIARG7 CA CAS 37589-80-3
DMIARG7 CB CHEBI:43000
DMIARG7 DE Discovery agent
DM1SON5 ID DM1SON5
DM1SON5 DN 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DM1SON5 HS Investigative
DM1SON5 SN MLS000038106; SMR000040050; 5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide; 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; Oprea1_666568; CBDivE_011354; CHEMBL428064; cid_659101; AC1LD057; CHEMBL1589921; SCHEMBL11973195; BDBM36894; CHEBI:93609; MolPort-002-134-452; CYSOFAOLQAYKGU-UHFFFAOYSA-N; HMS2479M21; ZINC230033; DNDI1318477; STL328289; AKOS022139691; MCULE-7323909600; NCGC00070544-03; EU-0033328; SR-01000388300; 5H-quino[8,7-c][1,2]benzothiazine 6,6-dioxide; SR-01000388300-1
DM1SON5 DT Small molecular drug
DM1SON5 PC 659101
DM1SON5 MW 282.3
DM1SON5 FM C15H10N2O2S
DM1SON5 IC InChI=1S/C15H10N2O2S/c18-20(19)13-6-2-1-5-11(13)12-8-7-10-4-3-9-16-14(10)15(12)17-20/h1-9,17H
DM1SON5 CS C1=CC=C2C(=C1)C3=C(C4=C(C=CC=N4)C=C3)NS2(=O)=O
DM1SON5 IK CYSOFAOLQAYKGU-UHFFFAOYSA-N
DM1SON5 IU 5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DM1SON5 CB CHEBI:93609
DM1SON5 DE Discovery agent
DMKUT6A ID DMKUT6A
DMKUT6A DN 5-HEAT
DMKUT6A HS Investigative
DMKUT6A SN 5-hydroxyethoxy-N-acetyltryptamine
DMKUT6A DT Small molecular drug
DMKUT6A PC 10849065
DMKUT6A MW 262.3
DMKUT6A FM C14H18N2O3
DMKUT6A IC InChI=1S/C14H18N2O3/c1-10(18)15-5-4-11-9-16-14-3-2-12(8-13(11)14)19-7-6-17/h2-3,8-9,16-17H,4-7H2,1H3,(H,15,18)
DMKUT6A CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)OCCO
DMKUT6A IK CZPLTTWZQPLXMQ-UHFFFAOYSA-N
DMKUT6A IU N-[2-[5-(2-hydroxyethoxy)-1H-indol-3-yl]ethyl]acetamide
DMKUT6A CA CAS 214416-49-6
DMKUT6A DE Discovery agent
DMICKOU ID DMICKOU
DMICKOU DN 5-Heptyl-5-phenyl-imidazolidine-2,4-dione
DMICKOU HS Investigative
DMICKOU SN CHEMBL417155; SCHEMBL13946578
DMICKOU DT Small molecular drug
DMICKOU PC 10659949
DMICKOU MW 274.36
DMICKOU FM C16H22N2O2
DMICKOU IC InChI=1S/C16H22N2O2/c1-2-3-4-5-9-12-16(13-10-7-6-8-11-13)14(19)17-15(20)18-16/h6-8,10-11H,2-5,9,12H2,1H3,(H2,17,18,19,20)
DMICKOU CS CCCCCCCC1(C(=O)NC(=O)N1)C2=CC=CC=C2
DMICKOU IK UKJJKBMGJSMVEV-UHFFFAOYSA-N
DMICKOU IU 5-heptyl-5-phenylimidazolidine-2,4-dione
DMICKOU DE Discovery agent
DM49F6Z ID DM49F6Z
DM49F6Z DN 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione
DM49F6Z HS Investigative
DM49F6Z SN 5-HEPTYL-6-HYDROXY-1,3-BENZOTHIAZOLE-4,7-DIONE; AC1NRAPN; DB07636; 5-Heptyl-6-hydroxybenzothiazole-4,7-dione; 5-n-heptyl-6-hydroxy-4,7-dioxobenzothiazole
DM49F6Z DT Small molecular drug
DM49F6Z PC 5288033
DM49F6Z MW 279.36
DM49F6Z FM C14H17NO3S
DM49F6Z IC InChI=1S/C14H17NO3S/c1-2-3-4-5-6-7-9-11(16)10-14(19-8-15-10)13(18)12(9)17/h8,16H,2-7H2,1H3
DM49F6Z CS CCCCCCCC1=C(C2=C(C(=O)C1=O)SC=N2)O
DM49F6Z IK PJALLUJRPFUWAF-UHFFFAOYSA-N
DM49F6Z IU 5-heptyl-4-hydroxy-1,3-benzothiazole-6,7-dione
DM49F6Z CA CAS 611207-02-4
DM49F6Z DE Discovery agent
DMHGQRF ID DMHGQRF
DMHGQRF DN 5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF HS Investigative
DMHGQRF SN CHEMBL14331; 5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF DT Small molecular drug
DMHGQRF PC 14106263
DMHGQRF MW 277.5
DMHGQRF FM C19H35N
DMHGQRF IC InChI=1S/C19H35N/c1-3-5-7-9-10-11-13-15-19-17-16-18(20-19)14-12-8-6-4-2/h4,19H,2-3,5-17H2,1H3
DMHGQRF CS CCCCCCCCCC1CCC(=N1)CCCCC=C
DMHGQRF IK NNAFMHTUNBLVDA-UHFFFAOYSA-N
DMHGQRF IU 5-hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole
DMHGQRF DE Discovery agent
DM0OJZF ID DM0OJZF
DM0OJZF DN 5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF HS Investigative
DM0OJZF SN CHEMBL264415; 5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF DT Small molecular drug
DM0OJZF PC 44450122
DM0OJZF MW 315.4
DM0OJZF FM C18H21NO4
DM0OJZF IC InChI=1S/C18H21NO4/c1-2-3-4-5-8-14-11-12-18(16(20)13-14)23-17-10-7-6-9-15(17)19(21)22/h6-7,9-13,20H,2-5,8H2,1H3
DM0OJZF CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2[N+](=O)[O-])O
DM0OJZF IK ASCHWJRXPZBPHV-UHFFFAOYSA-N
DM0OJZF IU 5-hexyl-2-(2-nitrophenoxy)phenol
DM0OJZF DE Discovery agent
DM7EBQL ID DM7EBQL
DM7EBQL DN 5-hexyl-2-(3-nitrophenoxy)phenol
DM7EBQL HS Investigative
DM7EBQL SN CHEMBL264416
DM7EBQL DT Small molecular drug
DM7EBQL PC 44450123
DM7EBQL MW 315.4
DM7EBQL FM C18H21NO4
DM7EBQL IC InChI=1S/C18H21NO4/c1-2-3-4-5-7-14-10-11-18(17(20)12-14)23-16-9-6-8-15(13-16)19(21)22/h6,8-13,20H,2-5,7H2,1H3
DM7EBQL CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC(=C2)[N+](=O)[O-])O
DM7EBQL IK ZPFZCOJDEYCPSH-UHFFFAOYSA-N
DM7EBQL IU 5-hexyl-2-(3-nitrophenoxy)phenol
DM7EBQL DE Discovery agent
DMNBLPA ID DMNBLPA
DMNBLPA DN 5-hexyl-2-(4-nitrophenoxy)phenol
DMNBLPA HS Investigative
DMNBLPA SN 5-hexyl-2-(4-nitrophenoxy)phenol; CHEMBL264417; JA1
DMNBLPA DT Small molecular drug
DMNBLPA PC 44450124
DMNBLPA MW 315.4
DMNBLPA FM C18H21NO4
DMNBLPA IC InChI=1S/C18H21NO4/c1-2-3-4-5-6-14-7-12-18(17(20)13-14)23-16-10-8-15(9-11-16)19(21)22/h7-13,20H,2-6H2,1H3
DMNBLPA CS CCCCCCC1=CC(=C(C=C1)OC2=CC=C(C=C2)[N+](=O)[O-])O
DMNBLPA IK NNNQXCYHIVPZRH-UHFFFAOYSA-N
DMNBLPA IU 5-hexyl-2-(4-nitrophenoxy)phenol
DMNBLPA DE Discovery agent
DM9263J ID DM9263J
DM9263J DN 5-hexyl-2-(pyrazin-2-yloxy)phenol
DM9263J HS Investigative
DM9263J SN CHEMBL258932
DM9263J DT Small molecular drug
DM9263J PC 16063378
DM9263J MW 272.34
DM9263J FM C16H20N2O2
DM9263J IC InChI=1S/C16H20N2O2/c1-2-3-4-5-6-13-7-8-15(14(19)11-13)20-16-12-17-9-10-18-16/h7-12,19H,2-6H2,1H3
DM9263J CS CCCCCCC1=CC(=C(C=C1)OC2=NC=CN=C2)O
DM9263J IK DIBZNKWLKFDWAC-UHFFFAOYSA-N
DM9263J IU 5-hexyl-2-pyrazin-2-yloxyphenol
DM9263J DE Discovery agent
DMLIMOP ID DMLIMOP
DMLIMOP DN 5-hexyl-2-(pyridin-2-yloxy)phenol
DMLIMOP HS Investigative
DMLIMOP SN CHEMBL264679
DMLIMOP DT Small molecular drug
DMLIMOP PC 44450183
DMLIMOP MW 271.35
DMLIMOP FM C17H21NO2
DMLIMOP IC InChI=1S/C17H21NO2/c1-2-3-4-5-8-14-10-11-16(15(19)13-14)20-17-9-6-7-12-18-17/h6-7,9-13,19H,2-5,8H2,1H3
DMLIMOP CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=N2)O
DMLIMOP IK GGLAALKBNDMDTG-UHFFFAOYSA-N
DMLIMOP IU 5-hexyl-2-pyridin-2-yloxyphenol
DMLIMOP DE Discovery agent
DMHZT1S ID DMHZT1S
DMHZT1S DN 5-hexyl-2-(pyridin-3-yloxy)phenol
DMHZT1S HS Investigative
DMHZT1S SN CHEMBL405655
DMHZT1S DT Small molecular drug
DMHZT1S PC 44450159
DMHZT1S MW 271.35
DMHZT1S FM C17H21NO2
DMHZT1S IC InChI=1S/C17H21NO2/c1-2-3-4-5-7-14-9-10-17(16(19)12-14)20-15-8-6-11-18-13-15/h6,8-13,19H,2-5,7H2,1H3
DMHZT1S CS CCCCCCC1=CC(=C(C=C1)OC2=CN=CC=C2)O
DMHZT1S IK MMFBADBXBVJXTO-UHFFFAOYSA-N
DMHZT1S IU 5-hexyl-2-pyridin-3-yloxyphenol
DMHZT1S DE Discovery agent
DMP6U3L ID DMP6U3L
DMP6U3L DN 5-hexyl-2-(pyridin-4-yloxy)phenol
DMP6U3L HS Investigative
DMP6U3L SN CHEMBL259138
DMP6U3L DT Small molecular drug
DMP6U3L PC 44450160
DMP6U3L MW 271.35
DMP6U3L FM C17H21NO2
DMP6U3L IC InChI=1S/C17H21NO2/c1-2-3-4-5-6-14-7-8-17(16(19)13-14)20-15-9-11-18-12-10-15/h7-13,19H,2-6H2,1H3
DMP6U3L CS CCCCCCC1=CC(=C(C=C1)OC2=CC=NC=C2)O
DMP6U3L IK YVUSUCCKZBSLJS-UHFFFAOYSA-N
DMP6U3L IU 5-hexyl-2-pyridin-4-yloxyphenol
DMP6U3L DE Discovery agent
DMNYOV3 ID DMNYOV3
DMNYOV3 DN 5-hexyl-2-(pyrimidin-2-yloxy)phenol
DMNYOV3 HS Investigative
DMNYOV3 SN CHEMBL258931
DMNYOV3 DT Small molecular drug
DMNYOV3 PC 44450156
DMNYOV3 MW 272.34
DMNYOV3 FM C16H20N2O2
DMNYOV3 IC InChI=1S/C16H20N2O2/c1-2-3-4-5-7-13-8-9-15(14(19)12-13)20-16-17-10-6-11-18-16/h6,8-12,19H,2-5,7H2,1H3
DMNYOV3 CS CCCCCCC1=CC(=C(C=C1)OC2=NC=CC=N2)O
DMNYOV3 IK CWDKJRBSXCNZHS-UHFFFAOYSA-N
DMNYOV3 IU 5-hexyl-2-pyrimidin-2-yloxyphenol
DMNYOV3 DE Discovery agent
DMHNRXT ID DMHNRXT
DMHNRXT DN 5-hexyl-2-phenoxyphenol
DMHNRXT HS Investigative
DMHNRXT SN 5-hexyl-2-phenoxyphenol; 5-Hexyl-2-phenoxy-phenol; 6PP; AIDS227446; AC1NRXEM; 2-Phenoxy-5-hexylphenol; 5-hexyl-2-phenoxylphenol; SCHEMBL2878546; PT04; CHEMBL264682; BDBM16297; SXGQGHHNOWYMRT-UHFFFAOYSA-N
DMHNRXT DT Small molecular drug
DMHNRXT PC 5274977
DMHNRXT MW 270.4
DMHNRXT FM C18H22O2
DMHNRXT IC InChI=1S/C18H22O2/c1-2-3-4-6-9-15-12-13-18(17(19)14-15)20-16-10-7-5-8-11-16/h5,7-8,10-14,19H,2-4,6,9H2,1H3
DMHNRXT CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2)O
DMHNRXT IK SXGQGHHNOWYMRT-UHFFFAOYSA-N
DMHNRXT IU 5-hexyl-2-phenoxyphenol
DMHNRXT DE Discovery agent
DMCDUO1 ID DMCDUO1
DMCDUO1 DN 5-Hexyl-5-phenyl-imidazolidine-2,4-dione
DMCDUO1 HS Investigative
DMCDUO1 SN CHEMBL289499
DMCDUO1 DT Small molecular drug
DMCDUO1 PC 44285898
DMCDUO1 MW 260.329
DMCDUO1 FM C15H20N2O2
DMCDUO1 IC InChI=1S/C15H20N2O2/c1-2-3-4-8-11-15(12-9-6-5-7-10-12)13(18)16-14(19)17-15/h5-7,9-10H,2-4,8,11H2,1H3,(H2,16,17,18,19)
DMCDUO1 CS CCCCCCC1(C(=O)NC(=O)N1)C2=CC=CC=C2
DMCDUO1 IK QUCQUPBUCULYGF-UHFFFAOYSA-N
DMCDUO1 IU 5-hexyl-5-phenylimidazolidine-2,4-dione
DMCDUO1 DE Discovery agent
DM4S86L ID DM4S86L
DM4S86L DN 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione
DM4S86L HS Investigative
DM4S86L SN 5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512
DM4S86L DT Small molecular drug
DM4S86L PC 49292
DM4S86L MW 288.34
DM4S86L FM C16H20N2O3
DM4S86L IC InChI=1S/C16H20N2O3/c1-2-3-4-8-11-16(12-9-6-5-7-10-12)13(19)17-15(21)18-14(16)20/h5-7,9-10H,2-4,8,11H2,1H3,(H2,17,18,19,20,21)
DM4S86L CS CCCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DM4S86L IK LWBGXTORWSRDHX-UHFFFAOYSA-N
DM4S86L IU 5-hexyl-5-phenyl-1,3-diazinane-2,4,6-trione
DM4S86L CA CAS 67051-21-2
DM4S86L DE Discovery agent
DM98OEQ ID DM98OEQ
DM98OEQ DN 5-hydroxy-1H-indole-3-acetic acid
DM98OEQ HS Investigative
DM98OEQ SN 5-Hydroxyindole-3-acetic acid; 54-16-0; 5-HIAA; 2-(5-hydroxy-1H-indol-3-yl)acetic acid; 5-Hydroxyindoleacetic acid; 5-Hydroxyheteroauxin; (5-Hydroxy-1H-indol-3-yl)acetic acid; 5-Oxyindoleacetic acid; 5-Hydroxy-IAA; 5-Hydroxyindolacetic acid; 5-Hydroxy-3-indoleacetic acid; 5-Hydroxyindol-3-ylacetic acid; Hydroxyindoleacetic acid; 5-Hydroxy-1H-indole-3-acetic acid; 5-Hydroxyindolylacetic acid; 1H-Indole-3-acetic acid, 5-hydroxy-; 1321-73-9; Indole-3-acetic acid, 5-hydroxy-; 5-Hydroxyindoleacetate; UNII-YHC763JY1P; NSC 90432
DM98OEQ DT Small molecular drug
DM98OEQ PC 1826
DM98OEQ MW 191.18
DM98OEQ FM C10H9NO3
DM98OEQ IC InChI=1S/C10H9NO3/c12-7-1-2-9-8(4-7)6(5-11-9)3-10(13)14/h1-2,4-5,11-12H,3H2,(H,13,14)
DM98OEQ CS C1=CC2=C(C=C1O)C(=CN2)CC(=O)O
DM98OEQ IK DUUGKQCEGZLZNO-UHFFFAOYSA-N
DM98OEQ IU 2-(5-hydroxy-1H-indol-3-yl)acetic acid
DM98OEQ CA CAS 54-16-0
DM98OEQ CB CHEBI:27823
DM98OEQ DE Discovery agent
DM5RI4H ID DM5RI4H
DM5RI4H DN 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one
DM5RI4H HS Investigative
DM5RI4H SN CHEMBL1163554; 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one; BDBM50321257
DM5RI4H DT Small molecular drug
DM5RI4H PC 46871781
DM5RI4H MW 253.28
DM5RI4H FM C11H11NO4S
DM5RI4H IC InChI=1S/C11H11NO4S/c1-8-2-4-9(5-3-8)17(15,16)12-10(13)6-7-11(12)14/h2-7,10,13H,1H3
DM5RI4H CS CC1=CC=C(C=C1)S(=O)(=O)N2C(C=CC2=O)O
DM5RI4H IK LASNBXWNXQRYSO-UHFFFAOYSA-N
DM5RI4H IU 2-hydroxy-1-(4-methylphenyl)sulfonyl-2H-pyrrol-5-one
DM5RI4H DE Discovery agent
DM8KON3 ID DM8KON3
DM8KON3 DN 5-hydroxy-2-(4-aminophenyl)benzofuran
DM8KON3 HS Investigative
DM8KON3 SN CHEMBL380476; 5-hydroxy-2-(4-aminophenyl)benzofuran; CTK7D7241; ZINC13686340; BDBM50185949; 2-(4-Amino-phenyl)-benzofuran-5-ol
DM8KON3 DT Small molecular drug
DM8KON3 PC 11499570
DM8KON3 MW 225.24
DM8KON3 FM C14H11NO2
DM8KON3 IC InChI=1S/C14H11NO2/c15-11-3-1-9(2-4-11)14-8-10-7-12(16)5-6-13(10)17-14/h1-8,16H,15H2
DM8KON3 CS C1=CC(=CC=C1C2=CC3=C(O2)C=CC(=C3)O)N
DM8KON3 IK JDGXRZSZWVUFMN-UHFFFAOYSA-N
DM8KON3 IU 2-(4-aminophenyl)-1-benzofuran-5-ol
DM8KON3 CA CAS 888703-99-9
DM8KON3 DE Discovery agent
DMYL0ZF ID DMYL0ZF
DMYL0ZF DN 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran
DMYL0ZF HS Investigative
DMYL0ZF SN CHEMBL204414; 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran; CTK7J9733; ZINC13686356; BDBM50185950; AKOS015966036
DMYL0ZF DT Small molecular drug
DMYL0ZF PC 11543378
DMYL0ZF MW 253.29
DMYL0ZF FM C16H15NO2
DMYL0ZF IC InChI=1S/C16H15NO2/c1-17(2)13-5-3-11(4-6-13)16-10-12-9-14(18)7-8-15(12)19-16/h3-10,18H,1-2H3
DMYL0ZF CS CN(C)C1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)O
DMYL0ZF IK ZEWYMVJDOSXOEG-UHFFFAOYSA-N
DMYL0ZF IU 2-[4-(dimethylamino)phenyl]-1-benzofuran-5-ol
DMYL0ZF DE Discovery agent
DM4QC0R ID DM4QC0R
DM4QC0R DN 5-hydroxy-2-(4-methylaminophenyl)benzofuran
DM4QC0R HS Investigative
DM4QC0R SN CHEMBL204829; 2-(4-methylaminophenyl)benzofuran-5-ol; 5-hydroxy-2-(4-methylaminophenyl)benzofuran; CTK6I4824; BDBM50185948; ZINC13686348; AKOS015966035
DM4QC0R DT Small molecular drug
DM4QC0R PC 11550464
DM4QC0R MW 239.27
DM4QC0R FM C15H13NO2
DM4QC0R IC InChI=1S/C15H13NO2/c1-16-12-4-2-10(3-5-12)15-9-11-8-13(17)6-7-14(11)18-15/h2-9,16-17H,1H3
DM4QC0R CS CNC1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)O
DM4QC0R IK ZNESXKIPTICLME-UHFFFAOYSA-N
DM4QC0R IU 2-[4-(methylamino)phenyl]-1-benzofuran-5-ol
DM4QC0R DE Discovery agent
DMTO2L3 ID DMTO2L3
DMTO2L3 DN 5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one
DMTO2L3 HS Investigative
DMTO2L3 SN CHEMBL1269399; 5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one
DMTO2L3 DT Small molecular drug
DMTO2L3 PC 52945274
DMTO2L3 MW 228.31
DMTO2L3 FM C11H16O3S
DMTO2L3 IC InChI=1S/C11H16O3S/c1-2-3-4-5-15-8-9-6-10(12)11(13)7-14-9/h6-7,13H,2-5,8H2,1H3
DMTO2L3 CS CCCCCSCC1=CC(=O)C(=CO1)O
DMTO2L3 IK BSUYJCKSLPFPSA-UHFFFAOYSA-N
DMTO2L3 IU 5-hydroxy-2-(pentylsulfanylmethyl)pyran-4-one
DMTO2L3 DE Discovery agent
DM7M1RZ ID DM7M1RZ
DM7M1RZ DN 5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one
DM7M1RZ HS Investigative
DM7M1RZ SN CHEMBL1269350; 5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one
DM7M1RZ DT Small molecular drug
DM7M1RZ PC 23273746
DM7M1RZ MW 200.26
DM7M1RZ FM C9H12O3S
DM7M1RZ IC InChI=1S/C9H12O3S/c1-2-3-13-6-7-4-8(10)9(11)5-12-7/h4-5,11H,2-3,6H2,1H3
DM7M1RZ CS CCCSCC1=CC(=O)C(=CO1)O
DM7M1RZ IK DKYLUTJQQPXXLM-UHFFFAOYSA-N
DM7M1RZ IU 5-hydroxy-2-(propylsulfanylmethyl)pyran-4-one
DM7M1RZ DE Discovery agent
DMLZKNF ID DMLZKNF
DMLZKNF DN 5-hydroxy-2-phenylisoindoline-1,3-dione
DMLZKNF HS Investigative
DMLZKNF SN CHEMBL276030; 4-Hydroxy-N-phenylphthalimide; 3975-50-6; 5-hydroxy-2-phenylisoindoline-1,3-dione; 5-hydroxy-2-phenyl-isoindole-1,3-dione; SCHEMBL8615277; CTK1B3719; DTXSID80445430; HCUAWJNHCZEMJS-UHFFFAOYSA-N; ZINC26020837; BDBM50088673; 5-hydroxy-2-phenyl-1H-isoindole-1,3(2H)-dione; 1H-Isoindole-1,3(2H)-dione, 5-hydroxy-2-phenyl-
DMLZKNF DT Small molecular drug
DMLZKNF PC 10823890
DMLZKNF MW 239.23
DMLZKNF FM C14H9NO3
DMLZKNF IC InChI=1S/C14H9NO3/c16-10-6-7-11-12(8-10)14(18)15(13(11)17)9-4-2-1-3-5-9/h1-8,16H
DMLZKNF CS C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)C=C(C=C3)O
DMLZKNF IK HCUAWJNHCZEMJS-UHFFFAOYSA-N
DMLZKNF IU 5-hydroxy-2-phenylisoindole-1,3-dione
DMLZKNF CA CAS 3975-50-6
DMLZKNF DE Discovery agent
DMI0GMB ID DMI0GMB
DMI0GMB DN 5-hydroxyindole
DMI0GMB HS Investigative
DMI0GMB SN 5-Hydroxyindole; 1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ
DMI0GMB DT Small molecular drug
DMI0GMB PC 16054
DMI0GMB MW 133.15
DMI0GMB FM C8H7NO
DMI0GMB IC InChI=1S/C8H7NO/c10-7-1-2-8-6(5-7)3-4-9-8/h1-5,9-10H
DMI0GMB CS C1=CC2=C(C=CN2)C=C1O
DMI0GMB IK LMIQERWZRIFWNZ-UHFFFAOYSA-N
DMI0GMB IU 1H-indol-5-ol
DMI0GMB CA CAS 1953-54-4
DMI0GMB CB CHEBI:89649
DMI0GMB DE Discovery agent
DMDWZGJ ID DMDWZGJ
DMDWZGJ DN 5-hydroxy-L-tryptophan
DMDWZGJ HS Investigative
DMDWZGJ SN 5-hydroxytryptophan
DMDWZGJ DT Small molecular drug
DMDWZGJ PC 439280
DMDWZGJ MW 220.22
DMDWZGJ FM C11H12N2O3
DMDWZGJ IC InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1
DMDWZGJ CS C1=CC2=C(C=C1O)C(=CN2)C[C@@H](C(=O)O)N
DMDWZGJ IK LDCYZAJDBXYCGN-VIFPVBQESA-N
DMDWZGJ IU (2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid
DMDWZGJ CA CAS 4350-09-8
DMDWZGJ CB CHEBI:17780
DMDWZGJ DE Discovery agent
DMT9FQN ID DMT9FQN
DMT9FQN DN 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMT9FQN HS Investigative
DMT9FQN SN CHEMBL17653; 406934-09-6; 2-Oxazolidinone, 5-(hydroxymethyl)-3-(1H-pyrrol-1-yl)-, (5R)-; 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one; CTK1C9350; DTXSID00452964; BDBM50110714; BDBM50370193
DMT9FQN DT Small molecular drug
DMT9FQN PC 11095251
DMT9FQN MW 182.18
DMT9FQN FM C8H10N2O3
DMT9FQN IC InChI=1S/C8H10N2O3/c11-6-7-5-10(8(12)13-7)9-3-1-2-4-9/h1-4,7,11H,5-6H2/t7-/m0/s1
DMT9FQN CS C1[C@H](OC(=O)N1N2C=CC=C2)CO
DMT9FQN IK SITMGBVDSOSSTH-ZETCQYMHSA-N
DMT9FQN IU (5S)-5-(hydroxymethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DMT9FQN DE Discovery agent
DMN9FPV ID DMN9FPV
DMN9FPV DN 5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid
DMN9FPV HS Investigative
DMN9FPV SN CHEMBL395398; Boronic acid, B-(5-hydroxybenzo[b]thien-2-yl)-; 959636-67-0; 5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid; BDBM50225392
DMN9FPV DT Small molecular drug
DMN9FPV PC 44435712
DMN9FPV MW 194.02
DMN9FPV FM C8H7BO3S
DMN9FPV IC InChI=1S/C8H7BO3S/c10-6-1-2-7-5(3-6)4-8(13-7)9(11)12/h1-4,10-12H
DMN9FPV CS B(C1=CC2=C(S1)C=CC(=C2)O)(O)O
DMN9FPV IK VDCIKADVYWVDGT-UHFFFAOYSA-N
DMN9FPV IU (5-hydroxy-1-benzothiophen-2-yl)boronic acid
DMN9FPV CA CAS 959636-67-0
DMN9FPV DE Discovery agent
DMZHVRW ID DMZHVRW
DMZHVRW DN 5-Hydroxymethyl-Chonduritol
DMZHVRW HS Investigative
DMZHVRW SN Valienol; 5-HYDROXYMETHYL-CHONDURITOL; (1S,2S,3S,4R)-5-(hydroxymethyl)cyclohex-5-ene-1,2,3,4-tetrol; 111136-25-5; AC1NRBPE; CHEMBL1233349; DTXSID50415342
DMZHVRW DT Small molecular drug
DMZHVRW PC 5288564
DMZHVRW MW 176.17
DMZHVRW FM C7H12O5
DMZHVRW IC InChI=1S/C7H12O5/c8-2-3-1-4(9)6(11)7(12)5(3)10/h1,4-12H,2H2/t4-,5+,6-,7-/m0/s1
DMZHVRW CS C1=C([C@H]([C@@H]([C@H]([C@H]1O)O)O)O)CO
DMZHVRW IK PJPGMULJEYSZBS-VZFHVOOUSA-N
DMZHVRW IU (1S,2S,3S,4R)-5-(hydroxymethyl)cyclohex-5-ene-1,2,3,4-tetrol
DMZHVRW CA CAS 111136-25-5
DMZHVRW DE Discovery agent
DMWVCJ1 ID DMWVCJ1
DMWVCJ1 DN 5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate
DMWVCJ1 HS Investigative
DMWVCJ1 DT Small molecular drug
DMWVCJ1 PC 447206
DMWVCJ1 MW 338.21
DMWVCJ1 FM C10H15N2O9P
DMWVCJ1 IC InChI=1S/C10H15N2O9P/c13-3-5-2-12(10(16)11-9(5)15)8-1-6(14)7(21-8)4-20-22(17,18)19/h2,6-8,13-14H,1,3-4H2,(H,11,15,16)(H2,17,18,19)/t6-,7+,8+/m0/s1
DMWVCJ1 CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)CO)COP(=O)(O)O)O
DMWVCJ1 IK WEBVWKFGRVLCNS-XLPZGREQSA-N
DMWVCJ1 IU [(2R,3S,5R)-3-hydroxy-5-[5-(hydroxymethyl)-2,4-dioxopyrimidin-1-yl]oxolan-2-yl]methyl dihydrogen phosphate
DMWVCJ1 DE Discovery agent
DMMF57V ID DMMF57V
DMMF57V DN 5-hydroxynaphthalene-1-sulfonamide
DMMF57V HS Investigative
DMMF57V SN 5-hydroxynaphthalene-1-sulfonamide; 17286-26-9; 5-Hydroxynaphthalene-1-sulphonamide; NFVBVKHGDDDCEA-UHFFFAOYSA-N; 5-Hydroxy-1-naphthalenesulfonamide; 5-hydroxy-naphthalene-1-sulfonic acid amide; 2vth; EINECS 241-319-7; AC1L3CSX; AC1Q6ULI; SCHEMBL588923; CHEMBL457047; CTK4D4388; NFVBVKHGDDDCEA-UHFFFAOYSA-; BDBM24628; DTXSID50169414; ZINC2242749; 5-hydroxy-1-naphthalenesulphonamide; 1-Naphthalenesulfonamide,5-hydroxy-; 1-Naphthalenesulfonamide, 5-hydroxy-; 5-hydroxynaphthalene-1-sulfonamide, 7; AKOS030618521; DB08132; TX-017211
DMMF57V DT Small molecular drug
DMMF57V PC 87031
DMMF57V MW 223.25
DMMF57V FM C10H9NO3S
DMMF57V IC InChI=1S/C10H9NO3S/c11-15(13,14)10-6-2-3-7-8(10)4-1-5-9(7)12/h1-6,12H,(H2,11,13,14)
DMMF57V CS C1=CC2=C(C=CC=C2S(=O)(=O)N)C(=C1)O
DMMF57V IK NFVBVKHGDDDCEA-UHFFFAOYSA-N
DMMF57V IU 5-hydroxynaphthalene-1-sulfonamide
DMMF57V CA CAS 17286-26-9
DMMF57V DE Discovery agent
DMJQFZH ID DMJQFZH
DMJQFZH DN 5-hydroxy-pentanoate
DMJQFZH HS Investigative
DMJQFZH SN sodium 5-hydroxypentanoate; 37435-69-1; 5-Hydroxypentanoic Acid Sodium Salt; Pentanoic acid, 5-hydroxy-, monosodium salt; sodium 5-hydroxyvalerate; C5H9O3.Na; Sodium 5-Hydroxy-Pentanoate; SCHEMBL311152; 5-hydroxypentanoic acid sodium; CHEMBL170082; 5-HydroxypentanoicAcidSodiumSalt; MolPort-027-844-925; ZJDDLWNQIJLIQU-UHFFFAOYSA-M; 5-Hydroxyvaleric acid sodium salt; 6374AJ; AKOS022186958; KS-0000090D; SY019284; BC621003; AK146710; KB-269943; CS-0047732; K-8251; MFCD22192345 (95+%)
DMJQFZH DT Small molecular drug
DMJQFZH PC 23695195
DMJQFZH MW 140.11
DMJQFZH FM C5H9NaO3
DMJQFZH IC InChI=1S/C5H10O3.Na/c6-4-2-1-3-5(7)8;/h6H,1-4H2,(H,7,8);/q;+1/p-1
DMJQFZH CS C(CCO)CC(=O)[O-].[Na+]
DMJQFZH IK ZJDDLWNQIJLIQU-UHFFFAOYSA-M
DMJQFZH IU sodium;5-hydroxypentanoate
DMJQFZH DE Discovery agent
DMIXQG6 ID DMIXQG6
DMIXQG6 DN 5-hydroxyvaleric acid
DMIXQG6 HS Investigative
DMIXQG6 SN 5-HYDROXYPENTANOIC ACID; 5-Hydroxyvaleric acid; 13392-69-3; 5-Hydroxyvalerate; 5-hydroxy-pentanoic acid; delta-Hydroxypentanoic acid; Pentanoic acid, 5-hydroxy-; 5-hydroxy valeric acid; 5-Hydroxy-pentansaeure; omega-hydroxyvaleric acid; delta-hydroxyvaleric acid; 5-Hydroxy-valeriansaeure; 4-Oxy-butan-carbonsaeure; omega-hydroxypentanoic acid; Pentanoic acid,5-hydroxy-; 5-HYDROXYLAEVULINIC ACID; CHEBI:45564; delta-hydroxyvalerate; Omega-hydroxyvalerate; Omega-hydroxypentanoate; delta-Hydroxypentanoate
DMIXQG6 DT Small molecular drug
DMIXQG6 PC 25945
DMIXQG6 MW 118.13
DMIXQG6 FM C5H10O3
DMIXQG6 IC InChI=1S/C5H10O3/c6-4-2-1-3-5(7)8/h6H,1-4H2,(H,7,8)
DMIXQG6 CS C(CCO)CC(=O)O
DMIXQG6 IK PHOJOSOUIAQEDH-UHFFFAOYSA-N
DMIXQG6 IU 5-hydroxypentanoic acid
DMIXQG6 CA CAS 13392-69-3
DMIXQG6 CB CHEBI:45564
DMIXQG6 DE Discovery agent
DMVSBHU ID DMVSBHU
DMVSBHU DN 5-Imidazol-1-yl-5,6,7,8-tetrahydro-quinoline
DMVSBHU HS Investigative
DMVSBHU SN Quinoline, 5,6,7,8-tetrahydro-5-(1H-imidazol-1-yl)-; 273930-06-6; tetrahydroquinoline 40; CHEMBL52509; BDBM10023; 5-(Imidazol-1-yl)-5,6,7,8-tetrahydroquinoline; 5-(1H-imidazol-1-yl)-5,6,7,8-tetrahydroquinoline
DMVSBHU DT Small molecular drug
DMVSBHU PC 10703161
DMVSBHU MW 199.25
DMVSBHU FM C12H13N3
DMVSBHU IC InChI=1S/C12H13N3/c1-4-11-10(3-2-6-14-11)12(5-1)15-8-7-13-9-15/h2-3,6-9,12H,1,4-5H2
DMVSBHU CS C1CC(C2=C(C1)N=CC=C2)N3C=CN=C3
DMVSBHU IK QFNKKYLTOSVDJG-UHFFFAOYSA-N
DMVSBHU IU 5-imidazol-1-yl-5,6,7,8-tetrahydroquinoline
DMVSBHU DE Discovery agent
DMW8AOM ID DMW8AOM
DMW8AOM DN 5-Indan-(1E)-ylidenemethyl-1H-imidazole
DMW8AOM HS Investigative
DMW8AOM SN Imidazolylmethyleneindane 2a; AC1O70GB; SCHEMBL4235335; BDBM8873; CHEMBL177468; SCHEMBL13877092; 5-[(E)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole; 5-[(E)-2,3-Dihydro-1H-inden-1-ylidenemethyl]-1H-imidazole
DMW8AOM DT Small molecular drug
DMW8AOM PC 6540032
DMW8AOM MW 196.25
DMW8AOM FM C13H12N2
DMW8AOM IC InChI=1S/C13H12N2/c1-2-4-13-10(3-1)5-6-11(13)7-12-8-14-9-15-12/h1-4,7-9H,5-6H2,(H,14,15)/b11-7+
DMW8AOM CS C1C/C(=C\\C2=CN=CN2)/C3=CC=CC=C31
DMW8AOM IK FXLOWXDBTSZJFZ-YRNVUSSQSA-N
DMW8AOM IU 5-[(E)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole
DMW8AOM DE Discovery agent
DMKLY20 ID DMKLY20
DMKLY20 DN 5-Indan-(1Z)-ylidenemethyl-1H-imidazole
DMKLY20 HS Investigative
DMKLY20 SN AC1O70GD; SCHEMBL4236847; CHEMBL178036; SCHEMBL4235344
DMKLY20 DT Small molecular drug
DMKLY20 PC 6540033
DMKLY20 MW 196.25
DMKLY20 FM C13H12N2
DMKLY20 IC InChI=1S/C13H12N2/c1-2-4-13-10(3-1)5-6-11(13)7-12-8-14-9-15-12/h1-4,7-9H,5-6H2,(H,14,15)/b11-7-
DMKLY20 CS C1C/C(=C/C2=CN=CN2)/C3=CC=CC=C31
DMKLY20 IK FXLOWXDBTSZJFZ-XFFZJAGNSA-N
DMKLY20 IU 5-[(Z)-2,3-dihydroinden-1-ylidenemethyl]-1H-imidazole
DMKLY20 DE Discovery agent
DMDKFIO ID DMDKFIO
DMDKFIO DN 5-iodo orotate
DMDKFIO HS Investigative
DMDKFIO DE Discovery agent
DMVT2LW ID DMVT2LW
DMVT2LW DN 5-iodo,5'-deoxytubercidin
DMVT2LW HS Investigative
DMVT2LW SN CHEMBL66280; 7-(5-Deoxy-Beta-D-Ribofuranosyl)-5-Iodo-7h-Pyrrolo[2,3-D]pyrimidin-4-Amine; 5-iodo,5'-deoxytubercidin; 2i6a; 5-Iodo-5-deoxytubercidin; 5-Iodo-5'-deoxytubercidin; SCHEMBL6236636; BDBM14486; DB07173; 5I5; (2R,3R,4S,5R)-2-{4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl}-5-methyloxolane-3,4-diol; 5'-DEOXY-5-IODOTUBERCIDIN; (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(METHYL)TETRAHYDROFURAN-3,4-DIOL; (2R,3R,4S,5R)-2-{4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-5-methyloxolane-3,4-diol
DMVT2LW DT Small molecular drug
DMVT2LW PC 9842606
DMVT2LW MW 376.15
DMVT2LW FM C11H13IN4O3
DMVT2LW IC InChI=1S/C11H13IN4O3/c1-4-7(17)8(18)11(19-4)16-2-5(12)6-9(13)14-3-15-10(6)16/h2-4,7-8,11,17-18H,1H3,(H2,13,14,15)/t4-,7-,8-,11-/m1/s1
DMVT2LW CS C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C3=C(N=CN=C32)N)I)O)O
DMVT2LW IK NTXUAWGNGBSCRS-TZQXKBMNSA-N
DMVT2LW IU (2R,3R,4S,5R)-2-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-5-methyloxolane-3,4-diol
DMVT2LW DE Discovery agent
DM4NQY6 ID DM4NQY6
DM4NQY6 DN 5-iodo-1H-indazole
DM4NQY6 HS Investigative
DM4NQY6 SN 5-Iodo-1H-indazole; 55919-82-9; 5-IODOINDAZOLE; 5-IODO (1H)INDAZOLE; 5-iodanyl-1H-indazole; 1H-INDAZOLE, 5-IODO-; CHEMBL391348; AK-27902; 5-Iodo-1H-indazole, 95%; 5-Iodo(1H)indazole; 5-iodio-1H-indazole; PubChem20575; SCHEMBL264176; 5-IODO-(1H)-INDAZOLE; CTK5A4375; DTXSID00619590; CGCHCLICSHIAAM-UHFFFAOYSA-N; MolPort-000-004-505; BCP27249; CS-D1249; ZX-AT020681; KS-000003HB; OR2756; ANW-50835; ZINC14983580; CI-264; BDBM50209243; RW3195; AKOS007930518; QC-2142; CM10802; RP05949; PB10471; VI20054; TRA0057528; FCH1323980; AS-8203; CJ-14773
DM4NQY6 DT Small molecular drug
DM4NQY6 PC 21894739
DM4NQY6 MW 244.03
DM4NQY6 FM C7H5IN2
DM4NQY6 IC InChI=1S/C7H5IN2/c8-6-1-2-7-5(3-6)4-9-10-7/h1-4H,(H,9,10)
DM4NQY6 CS C1=CC2=C(C=C1I)C=NN2
DM4NQY6 IK CGCHCLICSHIAAM-UHFFFAOYSA-N
DM4NQY6 IU 5-iodo-1H-indazole
DM4NQY6 CA CAS 55919-82-9
DM4NQY6 DE Discovery agent
DMZACXG ID DMZACXG
DMZACXG DN 5-Iodo-2'-Deoxyuridine-5'-Monophosphate
DMZACXG HS Investigative
DMZACXG SN AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMZACXG DT Small molecular drug
DMZACXG PC 449489
DMZACXG MW 434.08
DMZACXG FM C9H12IN2O8P
DMZACXG IC InChI=1S/C9H12IN2O8P/c10-4-2-12(9(15)11-8(4)14)7-1-5(13)6(20-7)3-19-21(16,17)18/h2,5-7,13H,1,3H2,(H,11,14,15)(H2,16,17,18)/t5-,6+,7+/m0/s1
DMZACXG CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)COP(=O)(O)O)O
DMZACXG IK WXFYBFRZROJDLL-RRKCRQDMSA-N
DMZACXG IU [(2R,3S,5R)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMZACXG CA CAS 1763-02-6
DMZACXG DE Discovery agent
DMQINY5 ID DMQINY5
DMQINY5 DN 5'-iodoresiniferatoxin
DMQINY5 HS Investigative
DMQINY5 SN TZUJORCXGLGWDV-DZBJMWFRSA-N; Iodoresiniferatoxin; 5'-Iodoresiniferatoxin; CHEMBL595069; 535974-91-5; 5-Iodoesiniferatoxin; 5-Iodo-Resiniferatoxin; GTPL4109; ZINC95537470; BDBM50305278; LS-28832; I-RTX; IODORESINIFERATOXIN
DMQINY5 DT Small molecular drug
DMQINY5 PC 6324614
DMQINY5 MW 754.6
DMQINY5 FM C37H39IO9
DMQINY5 IC InChI=1S/C37H39IO9/c1-20(2)35-16-22(4)37-26(33(35)45-36(46-35,47-37)18-23-9-7-6-8-10-23)12-25(17-34(42)29(37)11-21(3)32(34)41)19-44-30(39)15-24-13-27(38)31(40)28(14-24)43-5/h6-14,22,26,29,33,40,42H,1,15-19H2,2-5H3/t22-,26+,29-,33-,34-,35-,36-,37-/m1/s1
DMQINY5 CS C[C@@H]1C[C@]2([C@H]3[C@H]4[C@]1([C@@H]5C=C(C(=O)[C@]5(CC(=C4)COC(=O)CC6=CC(=C(C(=C6)I)O)OC)O)C)O[C@](O3)(O2)CC7=CC=CC=C7)C(=C)C
DMQINY5 IK TZUJORCXGLGWDV-DZBJMWFRSA-N
DMQINY5 IU [(1R,2R,6R,10S,11R,13S,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-prop-1-en-2-yl-12,14,18-trioxapentacyclo[11.4.1.01,10.02,6.011,15]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-iodo-5-methoxyphenyl)acetate
DMQINY5 CA CAS 535974-91-5
DMQINY5 DE Discovery agent
DML5ZEJ ID DML5ZEJ
DML5ZEJ DN 5'-iodotubercidin
DML5ZEJ HS Investigative
DML5ZEJ SN 5-Iodotubercidin; 24386-93-4; 5-iodotubericidin; 7-Deaza-7-iodoadenosine; 7-iodo-7-deazaadenosine; 7-iodotubercidin; (2R,3R,4S,5R)-2-(4-AMINO-5-IODO-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL; CHEMBL99203; CHEBI:40167; 5-iodo-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; NSC 113939; 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,5-iodo-7-b-D-ribofuranosyl-; 7H-Pyrrolo(2,3-d)pyrimidin-4-amine, 5-iodo-7-beta-D-ribofuranosyl-
DML5ZEJ DT Small molecular drug
DML5ZEJ PC 101649230
DML5ZEJ MW 376.15
DML5ZEJ FM C11H13IN4O3
DML5ZEJ IC InChI=1S/C11H13IN4O3/c12-3-6-7(17)8(18)11(19-6)16-2-1-5-9(13)14-4-15-10(5)16/h1-2,4,6-8,11,17-18H,3H2,(H2,13,14,15)/t6-,7-,8-,11-/m1/s1
DML5ZEJ CS C1=CN(C2=NC=NC(=C21)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CI)O)O
DML5ZEJ IK RUOLUSLZJXGWAU-KCGFPETGSA-N
DML5ZEJ IU (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(iodomethyl)oxolane-3,4-diol
DML5ZEJ DE Discovery agent
DM4O6I5 ID DM4O6I5
DM4O6I5 DN 5-Iodouracil
DM4O6I5 HS Investigative
DM4O6I5 SN 5-Iodouracil; 696-07-1; 5-iodopyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-iodo-; 5-iodopyrimidine-2,4-diol; Uracil, 5-iodo-; 2,4-Dihydroxy-5-iodopyrimidine; 5-iodo-1H-pyrimidine-2,4-dione; 5-iodo uracil; UNII-H59BRK500M; NSC 57848; CHEBI:43636; EINECS 211-788-2; CHEMBL1173; AI3-50390; H59BRK500M; KSNXJLQDQOIRIP-UHFFFAOYSA-N; 5-iodo-1,2,3,4-tetrahydropyrimidine-2,4-dione; NSC57848; MFCD00006020; 5-Iodouracil, 99%; 5-iodo-1,3-dihydropyrimidine-2,4-dione; IUR; 5909-21-7; 5-Iodo-uracil; 5- Iodouracil; zlchem 530
DM4O6I5 DT Small molecular drug
DM4O6I5 PC 69672
DM4O6I5 MW 237.98
DM4O6I5 FM C4H3IN2O2
DM4O6I5 IC InChI=1S/C4H3IN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
DM4O6I5 CS C1=C(C(=O)NC(=O)N1)I
DM4O6I5 IK KSNXJLQDQOIRIP-UHFFFAOYSA-N
DM4O6I5 IU 5-iodo-1H-pyrimidine-2,4-dione
DM4O6I5 CA CAS 696-07-1
DM4O6I5 CB CHEBI:43636
DM4O6I5 DE Discovery agent
DME6BX5 ID DME6BX5
DME6BX5 DN 5-Isopropyl-1H-pyrazole-3-carboxylic acid
DME6BX5 HS Investigative
DME6BX5 SN 5-isopropyl-1H-pyrazole-3-carboxylic acid; 92933-47-6; 5-Isopropyl-2H-pyrazole-3-carboxylic acid; 3-isopropyl-1H-pyrazole-5-carboxylic acid; 5-ISOPROPYLPYRAZOLE-3-CARBOXYLIC ACID; 3-(propan-2-yl)-1H-pyrazole-5-carboxylic acid; CHEMBL238002; CHWXKAHFWLSLOQ-UHFFFAOYSA-N; 1H-Pyrazole-3-carboxylic acid, 5-(1-methylethyl)-; 890590-91-7; 5-isopropyl-1H-pyrazol-3-carboxylic acid; 5-(propan-2-yl)-1H-pyrazole-3-carboxylic acid; 3-(methylethyl)pyrazole-5-carboxylic acid; PubChem22754; BAS 15375081; ACMC-20cbo3; AC1Q5UGZ; AC1Q1OGL
DME6BX5 DT Small molecular drug
DME6BX5 PC 776421
DME6BX5 MW 154.17
DME6BX5 FM C7H10N2O2
DME6BX5 IC InChI=1S/C7H10N2O2/c1-4(2)5-3-6(7(10)11)9-8-5/h3-4H,1-2H3,(H,8,9)(H,10,11)
DME6BX5 CS CC(C)C1=CC(=NN1)C(=O)O
DME6BX5 IK CHWXKAHFWLSLOQ-UHFFFAOYSA-N
DME6BX5 IU 5-propan-2-yl-1H-pyrazole-3-carboxylic acid
DME6BX5 DE Discovery agent
DM2TNWO ID DM2TNWO
DM2TNWO DN 5-isopropyl-2-(phenylamino)thiazol-4(5H)-one
DM2TNWO HS Investigative
DM2TNWO DT Small molecular drug
DM2TNWO PC 90788829
DM2TNWO MW 234.32
DM2TNWO FM C12H14N2OS
DM2TNWO IC InChI=1S/C12H14N2OS/c1-8(2)10-11(15)14-12(16-10)13-9-6-4-3-5-7-9/h3-8,15H,1-2H3,(H,13,14)
DM2TNWO CS CC(C)C1=C(N=C(S1)NC2=CC=CC=C2)O
DM2TNWO IK RCZXLRFUEUEYCI-UHFFFAOYSA-N
DM2TNWO IU 2-anilino-5-propan-2-yl-1,3-thiazol-4-ol
DM2TNWO DE Discovery agent
DMXGRMB ID DMXGRMB
DMXGRMB DN 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole
DMXGRMB HS Investigative
DMXGRMB SN CHEMBL297660; 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole; SCHEMBL8507362; BDBM50090518; 3-(2-Pyrrolizinoethyl)-5-isopropyl-1H-indole
DMXGRMB DT Small molecular drug
DMXGRMB PC 10912152
DMXGRMB MW 256.399
DMXGRMB FM C17H24N2
DMXGRMB IC InChI=1S/C17H24N2/c1-13(2)14-5-6-17-16(11-14)15(12-18-17)7-10-19-8-3-4-9-19/h5-6,11-13,18H,3-4,7-10H2,1-2H3
DMXGRMB CS CC(C)C1=CC2=C(C=C1)NC=C2CCN3CCCC3
DMXGRMB IK BCHGFZYQLYUXBO-UHFFFAOYSA-N
DMXGRMB IU 5-propan-2-yl-3-(2-pyrrolidin-1-ylethyl)-1H-indole
DMXGRMB DE Discovery agent
DMXVPL1 ID DMXVPL1
DMXVPL1 DN 5-ketodihydromevinolin
DMXVPL1 HS Investigative
DMXVPL1 SN compound 69 [PMID: 3656359]
DMXVPL1 DT Small molecular drug
DMXVPL1 PC 44298287
DMXVPL1 MW 422.6
DMXVPL1 FM C24H38O6
DMXVPL1 IC InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,14-17,19-21,23,26H,5,8-13H2,1-4H3,(H,27,28)/t14-,15-,16-,17-,19+,20-,21-,23?/m0/s1
DMXVPL1 CS CC[C@H](C)C(=O)O[C@H]1C[C@H](C[C@H]2C1[C@H]([C@H](C=C2)C)CCC(=O)C[C@H](CC(=O)O)O)C
DMXVPL1 IK OOKAZRDERJMRCJ-KOUAFAAESA-N
DMXVPL1 IU (3R)-7-[(1S,2S,4aR,6S,8S)-2,6-dimethyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid
DMXVPL1 DE Discovery agent
DMFZN7J ID DMFZN7J
DMFZN7J DN 5-Me-IAA
DMFZN7J HS Investigative
DMFZN7J SN 5-methy-1H-imidazole-4-acetic acid
DMFZN7J DT Small molecular drug
DMFZN7J PC 22359367
DMFZN7J MW 140.14
DMFZN7J FM C6H8N2O2
DMFZN7J IC InChI=1S/C6H8N2O2/c1-4-5(2-6(9)10)8-3-7-4/h3H,2H2,1H3,(H,7,8)(H,9,10)
DMFZN7J CS CC1=C(N=CN1)CC(=O)O
DMFZN7J IK BINCHKHDIQXADS-UHFFFAOYSA-N
DMFZN7J IU 2-(5-methyl-1H-imidazol-4-yl)acetic acid
DMFZN7J DE Discovery agent
DMG0EL7 ID DMG0EL7
DMG0EL7 DN 5-MEO-DMT
DMG0EL7 HS Investigative
DMG0EL7 SN N,N-Dimethyl-5-methoxytryptamine; 5-Methoxy-N,N-dimethyltryptamine; 1019-45-0; Methoxybufotenin; O-Methylbufotenine; Methylbufotenine; MeODMT; 5-MeO-DMT; 5-Methoxydimethyltryptamine; Bufotenine, O-methyl-; 3-(2-Dimethylaminoethyl)-5-methoxyindole; 2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine; CT 4334; Methoxydimethyltryptamines; UNII-X0MKX3GWU9; 1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-; NSC 88624; 5-Methoxy-N,N-dimethyl-1H-indole-3-ethanamine; 5-OMe-DMT; INDOLE, 3-(2-(N,N-DIMETHYLAMINO)ETHYL)-5-METHOXY-
DMG0EL7 DT Small molecular drug
DMG0EL7 PC 1832
DMG0EL7 MW 218.29
DMG0EL7 FM C13H18N2O
DMG0EL7 IC InChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3
DMG0EL7 CS CN(C)CCC1=CNC2=C1C=C(C=C2)OC
DMG0EL7 IK ZSTKHSQDNIGFLM-UHFFFAOYSA-N
DMG0EL7 IU 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
DMG0EL7 CA CAS 1019-45-0
DMG0EL7 CB CHEBI:2086
DMG0EL7 DE Discovery agent
DM7YGJO ID DM7YGJO
DM7YGJO DN 5-Mercapto-pentanoic acid
DM7YGJO HS Investigative
DM7YGJO SN 5-sulfanylpentanoic Acid; 5-Mercaptopentanoic Acid; 30247-98-4; 5-Mercapto-pentanoic acid; Pentanoic acid, 5-mercapto-; CHEMBL294565; 5-mercaptovaleric acid; SCHEMBL204062; CTK1C0536; DTXSID90447945; GCIZMJUHGHGRNW-UHFFFAOYSA-N; MolPort-013-659-967; BDBM50127619; ZINC13519063; AKOS010615958
DM7YGJO DT Small molecular drug
DM7YGJO PC 10909614
DM7YGJO MW 134.2
DM7YGJO FM C5H10O2S
DM7YGJO IC InChI=1S/C5H10O2S/c6-5(7)3-1-2-4-8/h8H,1-4H2,(H,6,7)
DM7YGJO CS C(CCS)CC(=O)O
DM7YGJO IK GCIZMJUHGHGRNW-UHFFFAOYSA-N
DM7YGJO IU 5-sulfanylpentanoic acid
DM7YGJO CA CAS 30247-98-4
DM7YGJO DE Discovery agent
DMET3OJ ID DMET3OJ
DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide
DMET3OJ HS Investigative
DMET3OJ SN 5-Mercapto-pentanoic acid phenylamide; N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-
DMET3OJ DT Small molecular drug
DMET3OJ PC 11608171
DMET3OJ MW 209.31
DMET3OJ FM C11H15NOS
DMET3OJ IC InChI=1S/C11H15NOS/c13-11(8-4-5-9-14)12-10-6-2-1-3-7-10/h1-3,6-7,14H,4-5,8-9H2,(H,12,13)
DMET3OJ CS C1=CC=C(C=C1)NC(=O)CCCCS
DMET3OJ IK AGRMYYLOBIRRKQ-UHFFFAOYSA-N
DMET3OJ IU N-phenyl-5-sulfanylpentanamide
DMET3OJ DE Discovery agent
DMPEKWD ID DMPEKWD
DMPEKWD DN 5-Methoxy-1-phenyl-1H-benzoimidazole
DMPEKWD HS Investigative
DMPEKWD SN 1H-Benzimidazole, 5-methoxy-1-phenyl-; 38205-85-5; 1-Phenylbenzimidazole deriv. 64; AC1NS4LX; CHEMBL76202; BDBM3847; SCHEMBL8006768; 5-methoxy-1-phenylbenzimidazole; CTK1B5049; DTXSID40416161; 5-Methoxy-1-phenyl-1H-benzimidazole; AKOS023169650; 5-Substituted 1-Phenylbenzimidazole 6
DMPEKWD DT Small molecular drug
DMPEKWD PC 5328466
DMPEKWD MW 224.26
DMPEKWD FM C14H12N2O
DMPEKWD IC InChI=1S/C14H12N2O/c1-17-12-7-8-14-13(9-12)15-10-16(14)11-5-3-2-4-6-11/h2-10H,1H3
DMPEKWD CS COC1=CC2=C(C=C1)N(C=N2)C3=CC=CC=C3
DMPEKWD IK BMNCXCJXZKZJII-UHFFFAOYSA-N
DMPEKWD IU 5-methoxy-1-phenylbenzimidazole
DMPEKWD CA CAS 38205-85-5
DMPEKWD DE Discovery agent
DMX1LY3 ID DMX1LY3
DMX1LY3 DN 5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole
DMX1LY3 HS Investigative
DMX1LY3 SN CHEMBL403264
DMX1LY3 DT Small molecular drug
DMX1LY3 PC 44456023
DMX1LY3 MW 244.33
DMX1LY3 FM C15H20N2O
DMX1LY3 IC InChI=1S/C15H20N2O/c1-18-14-4-5-15-12(11-14)10-13(16-15)6-9-17-7-2-3-8-17/h4-5,10-11,16H,2-3,6-9H2,1H3
DMX1LY3 CS COC1=CC2=C(C=C1)NC(=C2)CCN3CCCC3
DMX1LY3 IK UXDACHZONACAIV-UHFFFAOYSA-N
DMX1LY3 IU 5-methoxy-2-(2-pyrrolidin-1-ylethyl)-1H-indole
DMX1LY3 DE Discovery agent
DMG2HSU ID DMG2HSU
DMG2HSU DN 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole
DMG2HSU HS Investigative
DMG2HSU SN CHEMBL565567; 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole
DMG2HSU DT Small molecular drug
DMG2HSU PC 45484514
DMG2HSU MW 301.4
DMG2HSU FM C16H15NO3S
DMG2HSU IC InChI=1S/C16H15NO3S/c1-20-13-5-8-15-12(9-13)10-16(17-15)11-3-6-14(7-4-11)21(2,18)19/h3-10,17H,1-2H3
DMG2HSU CS COC1=CC2=C(C=C1)NC(=C2)C3=CC=C(C=C3)S(=O)(=O)C
DMG2HSU IK RQIQNXKCKAJTPF-UHFFFAOYSA-N
DMG2HSU IU 5-methoxy-2-(4-methylsulfonylphenyl)-1H-indole
DMG2HSU DE Discovery agent
DMW7IXL ID DMW7IXL
DMW7IXL DN 5-methoxy-2-(4-aminophenyl)benzofuran
DMW7IXL HS Investigative
DMW7IXL SN CHEMBL205221; 5-methoxy-2-(4-aminophenyl)benzofuran; CTK7A8117; ZINC13686334; BDBM50185946; AKOS015965959; KB-238624; 4-(5-methoxybenzo[b]furan-2-yl)phenylamine
DMW7IXL DT Small molecular drug
DMW7IXL PC 11579589
DMW7IXL MW 239.27
DMW7IXL FM C15H13NO2
DMW7IXL IC InChI=1S/C15H13NO2/c1-17-13-6-7-14-11(8-13)9-15(18-14)10-2-4-12(16)5-3-10/h2-9H,16H2,1H3
DMW7IXL CS COC1=CC2=C(C=C1)OC(=C2)C3=CC=C(C=C3)N
DMW7IXL IK GICMHQJTKXNMGB-UHFFFAOYSA-N
DMW7IXL IU 4-(5-methoxy-1-benzofuran-2-yl)aniline
DMW7IXL DE Discovery agent
DM3NUMG ID DM3NUMG
DM3NUMG DN 5-methoxy-2-(4-dimethylaminophenyl)benzofuran
DM3NUMG HS Investigative
DM3NUMG SN CHEMBL383116; 5-methoxy-2-(4-dimethylaminophenyl)benzofuran; ZINC13686352; BDBM50185945; AKOS015965999; KB-289042
DM3NUMG DT Small molecular drug
DM3NUMG PC 11673398
DM3NUMG MW 267.32
DM3NUMG FM C17H17NO2
DM3NUMG IC InChI=1S/C17H17NO2/c1-18(2)14-6-4-12(5-7-14)17-11-13-10-15(19-3)8-9-16(13)20-17/h4-11H,1-3H3
DM3NUMG CS CN(C)C1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)OC
DM3NUMG IK KKKKLHNEZMGUPC-UHFFFAOYSA-N
DM3NUMG IU 4-(5-methoxy-1-benzofuran-2-yl)-N,N-dimethylaniline
DM3NUMG DE Discovery agent
DM5N1JX ID DM5N1JX
DM5N1JX DN 5-methoxy-2-(4-methylaminophenyl)benzofuran
DM5N1JX HS Investigative
DM5N1JX SN CHEMBL208212; 5-methoxy-2-(4-methylaminophenyl)benzofuran; BDBM50185947; ZINC13686344
DM5N1JX DT Small molecular drug
DM5N1JX PC 11708629
DM5N1JX MW 253.29
DM5N1JX FM C16H15NO2
DM5N1JX IC InChI=1S/C16H15NO2/c1-17-13-5-3-11(4-6-13)16-10-12-9-14(18-2)7-8-15(12)19-16/h3-10,17H,1-2H3
DM5N1JX CS CNC1=CC=C(C=C1)C2=CC3=C(O2)C=CC(=C3)OC
DM5N1JX IK UPVZXZTUTQNNFR-UHFFFAOYSA-N
DM5N1JX IU 4-(5-methoxy-1-benzofuran-2-yl)-N-methylaniline
DM5N1JX DE Discovery agent
DMNRSYA ID DMNRSYA
DMNRSYA DN 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMNRSYA HS Investigative
DMNRSYA SN 5-Methoxytryptoline; 30439-19-1; CHEMBL6586; 1H-Pyrido(3,4-b)indole, 2,3,4,9-tetrahydro-5-methoxy-; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-5-methoxy-; 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; SCHEMBL4525164; CTK4G5204; DTXSID10184522; VPZWHBCLJCKHGZ-UHFFFAOYSA-N; AC1Q5856; AC1L5390; BDBM50136499; AKOS023631742; 1,2,3,4-Tetrahydro-5-methoxy-beta-carboline; 5-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMNRSYA DT Small molecular drug
DMNRSYA PC 169160
DMNRSYA MW 202.25
DMNRSYA FM C12H14N2O
DMNRSYA IC InChI=1S/C12H14N2O/c1-15-11-4-2-3-9-12(11)8-5-6-13-7-10(8)14-9/h2-4,13-14H,5-7H2,1H3
DMNRSYA CS COC1=CC=CC2=C1C3=C(N2)CNCC3
DMNRSYA IK VPZWHBCLJCKHGZ-UHFFFAOYSA-N
DMNRSYA IU 5-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMNRSYA CA CAS 30439-19-1
DMNRSYA DE Discovery agent
DMW9D30 ID DMW9D30
DMW9D30 DN 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one
DMW9D30 HS Investigative
DMW9D30 SN CHEMBL505327; 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one
DMW9D30 DT Small molecular drug
DMW9D30 PC 44592117
DMW9D30 MW 296.3
DMW9D30 FM C18H16O4
DMW9D30 IC InChI=1S/C18H16O4/c1-20-15-7-4-3-6-12(15)10-13-11-14-16(21-2)8-5-9-17(14)22-18(13)19/h3-9,11H,10H2,1-2H3
DMW9D30 CS COC1=CC=CC=C1CC2=CC3=C(C=CC=C3OC)OC2=O
DMW9D30 IK PUMXCXWQMAPHFQ-UHFFFAOYSA-N
DMW9D30 IU 5-methoxy-3-[(2-methoxyphenyl)methyl]chromen-2-one
DMW9D30 DE Discovery agent
DMBOMZE ID DMBOMZE
DMBOMZE DN 5-Methoxy-4,9-dihydro-3H-beta-carboline
DMBOMZE HS Investigative
DMBOMZE SN CHEMBL6591; 5-Methoxy-4,9-dihydro-3H-beta-carboline; SCHEMBL19407272; BDBM50136491
DMBOMZE DT Small molecular drug
DMBOMZE PC 11424197
DMBOMZE MW 200.24
DMBOMZE FM C12H12N2O
DMBOMZE IC InChI=1S/C12H12N2O/c1-15-11-4-2-3-9-12(11)8-5-6-13-7-10(8)14-9/h2-4,7,14H,5-6H2,1H3
DMBOMZE CS COC1=CC=CC2=C1C3=C(N2)C=NCC3
DMBOMZE IK UXOCVYNVGBOVRY-UHFFFAOYSA-N
DMBOMZE IU 5-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DMBOMZE DE Discovery agent
DMCZSP3 ID DMCZSP3
DMCZSP3 DN 5-methoxycarbonylamino-N-acetyltryptamine
DMCZSP3 HS Investigative
DMCZSP3 SN 5-Methoxycarbonylamino-N-acetyltryptamine; GR 135531; 190277-13-5; 5-MCA-NAT; 5MCA-NAT; CHEMBL504585; methyl 3-(2-acetamidoethyl)-1H-indol-5-ylcarbamate; methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate; Methyl {3-[2-(Acetylamino)ethyl]-1h-Indol-5-Yl}carbamate; Methyl [3-[2-(acetylamino)ethyl]-1H-indol-5-yl]carbamate; Tocris-0896; AC1N7T0H; GTPL3393; SCHEMBL4655625; CTK6J2921; CHEBI:93457; DTXSID70401560; MPZVHKLZCUEJFO-UHFFFAOYSA-N; MolPort-003-848-587; HMS3266P16; ZINC2567732; BN0231; BDBM50260394; PDSP2_001790
DMCZSP3 DT Small molecular drug
DMCZSP3 PC 4284525
DMCZSP3 MW 275.3
DMCZSP3 FM C14H17N3O3
DMCZSP3 IC InChI=1S/C14H17N3O3/c1-9(18)15-6-5-10-8-16-13-4-3-11(7-12(10)13)17-14(19)20-2/h3-4,7-8,16H,5-6H2,1-2H3,(H,15,18)(H,17,19)
DMCZSP3 CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)NC(=O)OC
DMCZSP3 IK MPZVHKLZCUEJFO-UHFFFAOYSA-N
DMCZSP3 IU methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate
DMCZSP3 CA CAS 190277-13-5
DMCZSP3 CB CHEBI:93457
DMCZSP3 DE Discovery agent
DMQX3V9 ID DMQX3V9
DMQX3V9 DN 5-Methoxyflavone
DMQX3V9 HS Investigative
DMQX3V9 SN 5-Methoxyflavone; 42079-78-7; 5-methoxy-2-phenyl-4h-chromen-4-one; 5-methoxy-2-phenylchromen-4-one; 5-Methoxy-2-phenyl-4-benzopyrone; CHEMBL16685; 4H-1-Benzopyran-4-one, 5-methoxy-2-phenyl-; 5-Methoxy-2-phenyl-chromen-4-one; MFCD00016942; ST069360; EINECS 255-652-0; 5 - Methoxyflavone; ACMC-20am2h; AC1Q6AKD; AC1L3SE9; Oprea1_859852; Oprea1_842256; BIDD:ER0473; ghl.PD_Mitscher_leg0.1155; ZINC5954; MEGxp0_001704; SCHEMBL1629391; ACon1_000175; DTXSID40194917; XRQSPUXANRGDAV-UHFFFAOYSA-N; MolPort-001-742-472; KS-000014KU; BDBM50296862
DMQX3V9 DT Small molecular drug
DMQX3V9 PC 94525
DMQX3V9 MW 252.26
DMQX3V9 FM C16H12O3
DMQX3V9 IC InChI=1S/C16H12O3/c1-18-13-8-5-9-14-16(13)12(17)10-15(19-14)11-6-3-2-4-7-11/h2-10H,1H3
DMQX3V9 CS COC1=CC=CC2=C1C(=O)C=C(O2)C3=CC=CC=C3
DMQX3V9 IK XRQSPUXANRGDAV-UHFFFAOYSA-N
DMQX3V9 IU 5-methoxy-2-phenylchromen-4-one
DMQX3V9 CA CAS 42079-78-7
DMQX3V9 DE Discovery agent
DMUXTWC ID DMUXTWC
DMUXTWC DN 5-methoxy-luzindole
DMUXTWC HS Investigative
DMUXTWC SN 5-methoxyluzindole
DMUXTWC DT Small molecular drug
DMUXTWC PC 129776
DMUXTWC MW 322.4
DMUXTWC FM C20H22N2O2
DMUXTWC IC InChI=1S/C20H22N2O2/c1-14(23)21-11-10-17-18-13-16(24-2)8-9-19(18)22-20(17)12-15-6-4-3-5-7-15/h3-9,13,22H,10-12H2,1-2H3,(H,21,23)
DMUXTWC CS CC(=O)NCCC1=C(NC2=C1C=C(C=C2)OC)CC3=CC=CC=C3
DMUXTWC IK MUQOTEHRXIKHKR-UHFFFAOYSA-N
DMUXTWC IU N-[2-(2-benzyl-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMUXTWC CA CAS 122853-28-5
DMUXTWC DE Discovery agent
DMJ1HX2 ID DMJ1HX2
DMJ1HX2 DN 5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one
DMJ1HX2 HS Investigative
DMJ1HX2 SN CHEMBL18334; 5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one; BDBM50110719; 2-Oxazolidinone, 5-(methoxymethyl)-3-(1H-pyrrol-1-yl)-, (5R)-; 406934-10-9
DMJ1HX2 DT Small molecular drug
DMJ1HX2 PC 11019781
DMJ1HX2 MW 196.2
DMJ1HX2 FM C9H12N2O3
DMJ1HX2 IC InChI=1S/C9H12N2O3/c1-13-7-8-6-11(9(12)14-8)10-4-2-3-5-10/h2-5,8H,6-7H2,1H3/t8-/m0/s1
DMJ1HX2 CS COC[C@@H]1CN(C(=O)O1)N2C=CC=C2
DMJ1HX2 IK RWCYHUWSHCXNRR-QMMMGPOBSA-N
DMJ1HX2 IU (5S)-5-(methoxymethyl)-3-pyrrol-1-yl-1,3-oxazolidin-2-one
DMJ1HX2 DE Discovery agent
DM98EQX ID DM98EQX
DM98EQX DN 5-Methoxy-N-phenylbenzo[d]oxazol-2-amine
DM98EQX HS Investigative
DM98EQX SN CHEMBL1269705; 5-Methoxy-N-phenylbenzo[d]oxazol-2-amine
DM98EQX DT Small molecular drug
DM98EQX PC 16117802
DM98EQX MW 240.26
DM98EQX FM C14H12N2O2
DM98EQX IC InChI=1S/C14H12N2O2/c1-17-11-7-8-13-12(9-11)16-14(18-13)15-10-5-3-2-4-6-10/h2-9H,1H3,(H,15,16)
DM98EQX CS COC1=CC2=C(C=C1)OC(=N2)NC3=CC=CC=C3
DM98EQX IK PZJKFSCOZOTZRO-UHFFFAOYSA-N
DM98EQX IU 5-methoxy-N-phenyl-1,3-benzoxazol-2-amine
DM98EQX DE Discovery agent
DMARCKD ID DMARCKD
DMARCKD DN 5-METHOXYTRYPTAMINE
DMARCKD HS Investigative
DMARCKD SN 5-METHOXYTRYPTAMINE; 608-07-1; 2-(5-Methoxy-1H-indol-3-yl)ethanamine; Mexamine; Methoxytryptamine; 3-(2-Aminoethyl)-5-methoxyindole; Mexamine base; 5MOT; 5-Mot; 1H-Indole-3-ethanamine, 5-methoxy-; 2-(5-Methoxyindol-3-yl)ethylamine; Meksamin; Meksamin (free base); 5-MeOT; O-Methylserotonin; 2-(5-Methoxy-1H-Indol-3-Yl)Ethan-1-Amine; NSC 56422; 5-MT; UNII-3VMW6141KC; INDOLE, 3-(2-AMINOETHYL)-5-METHOXY-; 5-methoxy-1H-indole-3-ethanamine; EINECS 210-153-7; Lopac-M-6628; 5-Methoxytryptamine, 97%; BRN 0145587; CHEMBL8165; 3VMW6141KC
DMARCKD DT Small molecular drug
DMARCKD PC 1833
DMARCKD MW 190.24
DMARCKD FM C11H14N2O
DMARCKD IC InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3
DMARCKD CS COC1=CC2=C(C=C1)NC=C2CCN
DMARCKD IK JTEJPPKMYBDEMY-UHFFFAOYSA-N
DMARCKD IU 2-(5-methoxy-1H-indol-3-yl)ethanamine
DMARCKD CA CAS 608-07-1
DMARCKD CB CHEBI:2089
DMARCKD DE Discovery agent
DM0AIOW ID DM0AIOW
DM0AIOW DN 5-methyl nicotinic acid
DM0AIOW HS Investigative
DM0AIOW SN 5-Methylnicotinic acid; 3222-49-9; 5-methylpyridine-3-carboxylic acid; 5-Methyl-nicotinic acid; 5-methyl nicotinic acid; CHEMBL247132; DJDHHXDFKSLEQY-UHFFFAOYSA-N; MFCD00829036; 3-Pyridinecarboxylic acid, 5-methyl-; 5-METHYL-3-PYRIDINECARBOXYLIC ACID; 5-Methylnicotinic acid, 97%; 5-methyinicotinic acid; PubChem11961; ACMC-1AFVP; 5-methyl nicotinic aicd; EC 608-720-2; AC1L5U3L; Nicotinic acid, 5-methyl-; AC1Q5UC0; NCIOpen2_001043; 5-METHYLNICOTIC ACID; KSC222G7T; SCHEMBL185789; GTPL1592; Jsp005966; CTK1C2379; DTXSID60292444
DM0AIOW DT Small molecular drug
DM0AIOW PC 256208
DM0AIOW MW 137.14
DM0AIOW FM C7H7NO2
DM0AIOW IC InChI=1S/C7H7NO2/c1-5-2-6(7(9)10)4-8-3-5/h2-4H,1H3,(H,9,10)
DM0AIOW CS CC1=CC(=CN=C1)C(=O)O
DM0AIOW IK DJDHHXDFKSLEQY-UHFFFAOYSA-N
DM0AIOW IU 5-methylpyridine-3-carboxylic acid
DM0AIOW CA CAS 3222-49-9
DM0AIOW DE Discovery agent
DMYNFIP ID DMYNFIP
DMYNFIP DN 5-methyl orotate
DMYNFIP HS Investigative
DMYNFIP SN AC1LAAV1; SCHEMBL15531476; 4-[4-[[11-butyl-9-[(R)-cyclohexyl(hydroxy)methyl]-7,10-dioxo-3,8,11-triazaspiro[5.5]undecan-3-yl]methyl]phenoxy]benzoic acid
DMYNFIP DT Small molecular drug
DMYNFIP PC 464989
DMYNFIP MW 577.7
DMYNFIP FM C33H43N3O6
DMYNFIP IC InChI=1S/C33H43N3O6/c1-2-3-19-36-30(38)28(29(37)24-7-5-4-6-8-24)34-32(41)33(36)17-20-35(21-18-33)22-23-9-13-26(14-10-23)42-27-15-11-25(12-16-27)31(39)40/h9-16,24,28-29,37H,2-8,17-22H2,1H3,(H,34,41)(H,39,40)/t28?,29-/m1/s1
DMYNFIP CS CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O
DMYNFIP IK GWNOTCOIYUNTQP-YPJJGMIRSA-N
DMYNFIP IU 4-[4-[[1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]benzoic acid
DMYNFIP DE Discovery agent
DM0E1Y9 ID DM0E1Y9
DM0E1Y9 DN 5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM0E1Y9 HS Investigative
DM0E1Y9 SN CHEMBL319551; 2H-Imidazo[4,5-b]quinolin-2-one, 1,3-dihydro-5-methyl-; BDBM50229556
DM0E1Y9 DT Small molecular drug
DM0E1Y9 PC 15065143
DM0E1Y9 MW 199.21
DM0E1Y9 FM C11H9N3O
DM0E1Y9 IC InChI=1S/C11H9N3O/c1-6-3-2-4-7-5-8-10(13-9(6)7)14-11(15)12-8/h2-5H,1H3,(H2,12,13,14,15)
DM0E1Y9 CS CC1=C2C(=CC=C1)C=C3C(=N2)NC(=O)N3
DM0E1Y9 IK YZNZOJPHYDBVIZ-UHFFFAOYSA-N
DM0E1Y9 IU 5-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM0E1Y9 DE Discovery agent
DMC10HG ID DMC10HG
DMC10HG DN 5-methyl-2-(phenylsulfonamido)benzoic acid
DMC10HG HS Investigative
DMC10HG SN 5-Methyl-2-[(phenylsulfonyl)amino]benzoic acid; 5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID; 2-benzenesulfonamido-5-methylbenzoic acid; A41; 1yw7; sulfonamide compound, 4; AC1O0UU4; SCHEMBL2009251; CHEMBL378927; Anthranilic Acid Sulfonamide, 4; BDBM17477; MolPort-004-356-849; HMS3604F08; STK978137; ZINC14964411; AKOS000202786; MCULE-6409447208; DB07313; 138964-56-4; 2-(benzenesulfonamido)-5-methylbenzoic acid; A444148
DMC10HG DT Small molecular drug
DMC10HG PC 6102684
DMC10HG MW 291.32
DMC10HG FM C14H13NO4S
DMC10HG IC InChI=1S/C14H13NO4S/c1-10-7-8-13(12(9-10)14(16)17)15-20(18,19)11-5-3-2-4-6-11/h2-9,15H,1H3,(H,16,17)
DMC10HG CS CC1=CC(=C(C=C1)NS(=O)(=O)C2=CC=CC=C2)C(=O)O
DMC10HG IK HXQLTRSIZRSFTR-UHFFFAOYSA-N
DMC10HG IU 2-(benzenesulfonamido)-5-methylbenzoic acid
DMC10HG DE Discovery agent
DMAR4ZF ID DMAR4ZF
DMAR4ZF DN 5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole
DMAR4ZF HS Investigative
DMAR4ZF SN CHEMBL352049; 5-Methyl-2-pyridin-2-yl-1H-benzoimidazole; 7471-12-7; NSC403547; AC1L83HW; TimTec1_008296; 5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole; SCHEMBL124267; SCHEMBL12119033; DTXSID20323304; HMS1557J02; CCG-24525; BDBM50180733; ZINC12481420; AKOS002999038; AKOS000636609; NSC-403547; BAS 06347449; 6-methyl-2-pyridin-2-yl-1H-benzimidazole; 6-Methyl-2-(2-pyridyl)-1H-benzimidazole; KB-249126; US8748618, LD-2-11; 6-methyl-2-pyridin-2-yl-1h-benzo[d]imidazole
DMAR4ZF DT Small molecular drug
DMAR4ZF PC 345772
DMAR4ZF MW 209.25
DMAR4ZF FM C13H11N3
DMAR4ZF IC InChI=1S/C13H11N3/c1-9-5-6-10-12(8-9)16-13(15-10)11-4-2-3-7-14-11/h2-8H,1H3,(H,15,16)
DMAR4ZF CS CC1=CC2=C(C=C1)N=C(N2)C3=CC=CC=N3
DMAR4ZF IK HFYFOFMVURXVSD-UHFFFAOYSA-N
DMAR4ZF IU 6-methyl-2-pyridin-2-yl-1H-benzimidazole
DMAR4ZF CA CAS 7471-12-7
DMAR4ZF DE Discovery agent
DMH1IVN ID DMH1IVN
DMH1IVN DN 5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMH1IVN HS Investigative
DMH1IVN SN NSC676186; AC1L8OZL; CHEMBL317272; SCHEMBL7920133; CTK8D2147; ZINC5504116; NSC-676186; NCI60_026913; 5-methyl-2-(3-methylphenyl)-1,8-naphthyridin-4-ol; 5-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMH1IVN DT Small molecular drug
DMH1IVN PC 385182
DMH1IVN MW 250.29
DMH1IVN FM C16H14N2O
DMH1IVN IC InChI=1S/C16H14N2O/c1-10-4-3-5-12(8-10)13-9-14(19)15-11(2)6-7-17-16(15)18-13/h3-9H,1-2H3,(H,17,18,19)
DMH1IVN CS CC1=CC(=CC=C1)C2=CC(=O)C3=C(C=CN=C3N2)C
DMH1IVN IK ZLZNSSZWWMBAMD-UHFFFAOYSA-N
DMH1IVN IU 5-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMH1IVN DE Discovery agent
DMIE9BG ID DMIE9BG
DMIE9BG DN 5-Methyl-2-p-tolyl-thiazol-4-ol
DMIE9BG HS Investigative
DMIE9BG SN CHEMBL69094; 5-Methyl-2-p-tolyl-thiazol-4-ol; 4-Thiazolol, 5-methyl-2-(4-methylphenyl)-; SCHEMBL9629237; BDBM50012393; 131786-76-0
DMIE9BG DT Small molecular drug
DMIE9BG PC 15691812
DMIE9BG MW 205.28
DMIE9BG FM C11H11NOS
DMIE9BG IC InChI=1S/C11H11NOS/c1-7-3-5-9(6-4-7)11-12-10(13)8(2)14-11/h3-6,13H,1-2H3
DMIE9BG CS CC1=CC=C(C=C1)C2=NC(=C(S2)C)O
DMIE9BG IK CKXYNXQZWQQOOO-UHFFFAOYSA-N
DMIE9BG IU 5-methyl-2-(4-methylphenyl)-1,3-thiazol-4-ol
DMIE9BG DE Discovery agent
DM0G2N5 ID DM0G2N5
DM0G2N5 DN 5-Methyl-3,4-diphenyl-isoxazole
DM0G2N5 HS Investigative
DM0G2N5 SN 5-Methyl-3,4-diphenylisoxazole; 37928-17-9; 5-Methyl-3,4-diphenyl-isoxazole; 5-methyl-3,4-diphenyl-1,2-oxazole; CHEMBL365033; Isoxazole, 5-methyl-3,4-diphenyl-; AK110518; SCHEMBL2277199; 3,4-Diphenyl-5-methylisoxazole; DTXSID40433813; 3,4-diphenyl-5-methyl isoxazole; 5-methyl-3,4-diphenyl isoxazole; 3,4-diphenyl-5-methyl-isoxazole; ZXIRUKJWLADSJS-UHFFFAOYSA-N; MolPort-027-835-429; KS-00000PQ9; Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate); ZINC12352313; BDBM50153036; AKOS016008848; VO10067; DS-4629; LS40778
DM0G2N5 DT Small molecular drug
DM0G2N5 PC 9991673
DM0G2N5 MW 235.28
DM0G2N5 FM C16H13NO
DM0G2N5 IC InChI=1S/C16H13NO/c1-12-15(13-8-4-2-5-9-13)16(17-18-12)14-10-6-3-7-11-14/h2-11H,1H3
DM0G2N5 CS CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=CC=C3
DM0G2N5 IK ZXIRUKJWLADSJS-UHFFFAOYSA-N
DM0G2N5 IU 5-methyl-3,4-diphenyl-1,2-oxazole
DM0G2N5 CA CAS 37928-17-9
DM0G2N5 DE Discovery agent
DMF0IJ2 ID DMF0IJ2
DMF0IJ2 DN 5-methyl-3-phenylethynyl[1,2,4]triazine
DMF0IJ2 HS Investigative
DMF0IJ2 SN CHEMBL227199; 5-methyl-3-phenylethynyl[1,2,4]triazine; 1,2,4-Triazine, 5-methyl-3-(2-phenylethynyl)-; BDBM50215455; 945915-49-1
DMF0IJ2 DT Small molecular drug
DMF0IJ2 PC 16736030
DMF0IJ2 MW 195.22
DMF0IJ2 FM C12H9N3
DMF0IJ2 IC InChI=1S/C12H9N3/c1-10-9-13-15-12(14-10)8-7-11-5-3-2-4-6-11/h2-6,9H,1H3
DMF0IJ2 CS CC1=CN=NC(=N1)C#CC2=CC=CC=C2
DMF0IJ2 IK PXUGAXNBWJVVQY-UHFFFAOYSA-N
DMF0IJ2 IU 5-methyl-3-(2-phenylethynyl)-1,2,4-triazine
DMF0IJ2 CA CAS 945915-49-1
DMF0IJ2 DE Discovery agent
DM6DEOC ID DM6DEOC
DM6DEOC DN 5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine
DM6DEOC HS Investigative
DM6DEOC SN CHEMBL362366; 5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine; BDBM50150912
DM6DEOC DT Small molecular drug
DM6DEOC PC 19049152
DM6DEOC MW 140.23
DM6DEOC FM C8H16N2
DM6DEOC IC InChI=1S/C8H16N2/c1-3-4-7-5-8(9)10-6(7)2/h6-7H,3-5H2,1-2H3,(H2,9,10)
DM6DEOC CS CCCC1CC(=NC1C)N
DM6DEOC IK KBOKLILFNBAIHC-UHFFFAOYSA-N
DM6DEOC IU 2-methyl-3-propyl-3,4-dihydro-2H-pyrrol-5-amine
DM6DEOC DE Discovery agent
DMO37W4 ID DMO37W4
DMO37W4 DN 5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid
DMO37W4 HS Investigative
DMO37W4 SN compound 5aj [PMID: 17358052]
DMO37W4 DT Small molecular drug
DMO37W4 PC 11436345
DMO37W4 MW 238.26
DMO37W4 FM C11H10O4S
DMO37W4 IC InChI=1S/C11H10O4S/c1-6-3-7(5-16-6)11(2)9(12)4-8(15-11)10(13)14/h3-5H,1-2H3,(H,13,14)
DMO37W4 CS CC1=CC(=CS1)C2(C(=O)C=C(O2)C(=O)O)C
DMO37W4 IK NNWGOUJBCKZULC-UHFFFAOYSA-N
DMO37W4 IU 5-methyl-5-(5-methylthiophen-3-yl)-4-oxofuran-2-carboxylic acid
DMO37W4 DE Discovery agent
DMRMKXD ID DMRMKXD
DMRMKXD DN 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione
DMRMKXD HS Investigative
DMRMKXD SN Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMRMKXD DT Small molecular drug
DMRMKXD PC 66160
DMRMKXD MW 218.21
DMRMKXD FM C11H10N2O3
DMRMKXD IC InChI=1S/C11H10N2O3/c1-11(7-5-3-2-4-6-7)8(14)12-10(16)13-9(11)15/h2-6H,1H3,(H2,12,13,14,15,16)
DMRMKXD CS CC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
DMRMKXD IK LSAOZCAKUIANSQ-UHFFFAOYSA-N
DMRMKXD IU 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
DMRMKXD CA CAS 76-94-8
DMRMKXD CB CHEBI:134900
DMRMKXD DE Discovery agent
DMLJVB7 ID DMLJVB7
DMLJVB7 DN 5-methyl-benzo[b]thiophen-2-ylboronic acid
DMLJVB7 HS Investigative
DMLJVB7 SN 5-methylbenzo[b]thiophene-2-boronic acid; 136099-65-5; 5-METHYLBENZOTHIPHENE-2-BORONIC ACID; 5-methylbenzo[b]thiophen-2-ylboronic acid; CHEMBL238243; 5-METHYLBENZOTHIOPHENE-2-BORONIC ACID; (5-methyl-1-benzothiophen-2-yl)boronic acid; 5-methyl-1-benzothiophen-2-ylboronic acid; (5-methylbenzothiophen-2-yl)boronic Acid; AC1MDRK8; 5-methyl-benzo[b]thiophen-2-ylboronic acid; C9H9BO2S; SCHEMBL289762; CTK6C0387; DTXSID20383286; MolPort-000-145-050; DHNHZPQPQAINDI-UHFFFAOYSA-N; 2-Borono-5-methylbenzo[b]thiophene; 6437AA; SBB091358
DMLJVB7 DT Small molecular drug
DMLJVB7 PC 2794641
DMLJVB7 MW 192.05
DMLJVB7 FM C9H9BO2S
DMLJVB7 IC InChI=1S/C9H9BO2S/c1-6-2-3-8-7(4-6)5-9(13-8)10(11)12/h2-5,11-12H,1H3
DMLJVB7 CS B(C1=CC2=C(S1)C=CC(=C2)C)(O)O
DMLJVB7 IK DHNHZPQPQAINDI-UHFFFAOYSA-N
DMLJVB7 IU (5-methyl-1-benzothiophen-2-yl)boronic acid
DMLJVB7 CA CAS 136099-65-5
DMLJVB7 DE Discovery agent
DMRC8SO ID DMRC8SO
DMRC8SO DN 5-methyl-cyclosal-d4TMP
DMRC8SO HS Investigative
DMRC8SO SN CHEMBL223807; BDBM50206639; 5-methyl-cyclosal-d4TMP; 5-Methyl-1-[(2R,5S)-5-(6-methyl-2-oxo-4H-2lambda*5*-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione; 5-Me-CycloSal-d4TMP; AC1LABZ0; CHEMBL8458; BDBM50064051; 5-methyl-1-[(2R,5S)-5-[(6-methyl-2-oxo-4H-1,3,2; 5-Methyl-1-[5-(6-methyl-2-oxo-4H-2lambda*5*-benzo[1,3,2]dioxaphosphinin-2-yloxymethyl)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione
DMRC8SO DT Small molecular drug
DMRC8SO PC 465615
DMRC8SO MW 406.3
DMRC8SO FM C18H19N2O7P
DMRC8SO IC InChI=1S/C18H19N2O7P/c1-11-3-5-15-13(7-11)9-24-28(23,27-15)25-10-14-4-6-16(26-14)20-8-12(2)17(21)19-18(20)22/h3-8,14,16H,9-10H2,1-2H3,(H,19,21,22)/t14-,16+,28?/m0/s1
DMRC8SO CS CC1=CC2=C(C=C1)OP(=O)(OC2)OC[C@@H]3C=C[C@@H](O3)N4C=C(C(=O)NC4=O)C
DMRC8SO IK XCQZHNHBKUHUEJ-NIGMZYBYSA-N
DMRC8SO IU 5-methyl-1-[(2R,5S)-5-[(6-methyl-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DMRC8SO DE Discovery agent
DMIQ1X3 ID DMIQ1X3
DMIQ1X3 DN 5-methylenearisteromycin
DMIQ1X3 HS Investigative
DMIQ1X3 SN CHEMBL262063; 5-methylenearisteromycin; 5'-Methylenearisteromycin; BDBM50373100
DMIQ1X3 DT Small molecular drug
DMIQ1X3 PC 11737492
DMIQ1X3 MW 277.28
DMIQ1X3 FM C12H15N5O3
DMIQ1X3 IC InChI=1S/C12H15N5O3/c1-5-6(2-18)9(19)10(20)8(5)17-4-16-7-11(13)14-3-15-12(7)17/h3-4,6,8-10,18-20H,1-2H2,(H2,13,14,15)/t6-,8+,9+,10-/m0/s1
DMIQ1X3 CS C=C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO
DMIQ1X3 IK REGXGANNNMTWAW-ZQNVIIHSSA-N
DMIQ1X3 IU (1R,2S,3R,5R)-3-(6-aminopurin-9-yl)-5-(hydroxymethyl)-4-methylidenecyclopentane-1,2-diol
DMIQ1X3 DE Discovery agent
DMNJ0XZ ID DMNJ0XZ
DMNJ0XZ DN 5-Methyl-N-phenylbenzo[d]oxazol-2-amine
DMNJ0XZ HS Investigative
DMNJ0XZ SN CHEMBL1269622; 5-Methyl-N-phenylbenzo[d]oxazol-2-amine; SCHEMBL13436713; BDBM50329396; N-Phenyl-5-methylbenzoxazole-2-amine; (5-methyl-benzooxazol-2-yl)-phenyl-amine; 5-methyl-N-phenyl-1,3-benzoxazol-2-amine
DMNJ0XZ DT Small molecular drug
DMNJ0XZ PC 12751500
DMNJ0XZ MW 224.26
DMNJ0XZ FM C14H12N2O
DMNJ0XZ IC InChI=1S/C14H12N2O/c1-10-7-8-13-12(9-10)16-14(17-13)15-11-5-3-2-4-6-11/h2-9H,1H3,(H,15,16)
DMNJ0XZ CS CC1=CC2=C(C=C1)OC(=N2)NC3=CC=CC=C3
DMNJ0XZ IK SJERMAXXFIXBCQ-UHFFFAOYSA-N
DMNJ0XZ IU 5-methyl-N-phenyl-1,3-benzoxazol-2-amine
DMNJ0XZ DE Discovery agent
DMBQS31 ID DMBQS31
DMBQS31 DN 5-Methyl-oxazolidin-(2Z)-ylideneamine
DMBQS31 HS Investigative
DMBQS31 SN CHEMBL107413; 5-Methyl-oxazolidin-(2Z)-ylideneamine; 2-imino-5-methyloxazolidine; 5-Methyl-2-iminooxazolidine; SCHEMBL8968765; SCHEMBL6592796; BDBM50138201; AKOS006350070; AKOS013498557; 5-methyl-4,5-dihydro-oxazol-2-ylamine
DMBQS31 DT Small molecular drug
DMBQS31 PC 12495134
DMBQS31 MW 100.12
DMBQS31 FM C4H8N2O
DMBQS31 IC InChI=1S/C4H8N2O/c1-3-2-6-4(5)7-3/h3H,2H2,1H3,(H2,5,6)
DMBQS31 CS CC1CN=C(O1)N
DMBQS31 IK ZHFKVNRMZIOKGZ-UHFFFAOYSA-N
DMBQS31 IU 5-methyl-4,5-dihydro-1,3-oxazol-2-amine
DMBQS31 DE Discovery agent
DM4QB3G ID DM4QB3G
DM4QB3G DN 5-Methyl-pyrrolidin-(2Z)-ylideneamine
DM4QB3G HS Investigative
DM4QB3G SN CHEMBL182305; CHEMBL555587; 5-Methylpyrrolidine-2-imine; BDBM50066782; AKOS006365094; 5-Methyl-pyrrolidin-(2E)-ylideneamine
DM4QB3G DT Small molecular drug
DM4QB3G PC 12778906
DM4QB3G MW 98.15
DM4QB3G FM C5H10N2
DM4QB3G IC InChI=1S/C5H10N2/c1-4-2-3-5(6)7-4/h4H,2-3H2,1H3,(H2,6,7)
DM4QB3G CS CC1CCC(=N1)N
DM4QB3G IK DDQFWSHGBVMBEM-UHFFFAOYSA-N
DM4QB3G IU 2-methyl-3,4-dihydro-2H-pyrrol-5-amine
DM4QB3G DE Discovery agent
DMYERNM ID DMYERNM
DMYERNM DN 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMYERNM HS Investigative
DMYERNM SN CHEMBL201723; 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMYERNM DT Small molecular drug
DMYERNM PC 44407565
DMYERNM MW 250.25
DMYERNM FM C15H10N2O2
DMYERNM IC InChI=1S/C15H10N2O2/c1-7-6-9-12(15(19)17-14(9)18)11-8-4-2-3-5-10(8)16-13(7)11/h2-6,16H,1H3,(H,17,18,19)
DMYERNM CS CC1=CC2=C(C3=C1NC4=CC=CC=C43)C(=O)NC2=O
DMYERNM IK IMEDEXINTFAKNV-UHFFFAOYSA-N
DMYERNM IU 5-methyl-6H-pyrrolo[3,4-c]carbazole-1,3-dione
DMYERNM DE Discovery agent
DM3MVSD ID DM3MVSD
DM3MVSD DN 5-Methylsulfanyl-thiophene-2-carboxamidine
DM3MVSD HS Investigative
DM3MVSD SN CHEMBL28890; 5-Methylsulfanyl-thiophene-2-carboxamidine; 2-Thiophenecarboximidamide, 5-(methylthio)-; SCHEMBL5982145; AXSQTCBARFBKPH-UHFFFAOYSA-N; BDBM50099912; 5-methylthiothiophene-2-carboxamidine
DM3MVSD DT Small molecular drug
DM3MVSD PC 10313318
DM3MVSD MW 172.3
DM3MVSD FM C6H8N2S2
DM3MVSD IC InChI=1S/C6H8N2S2/c1-9-5-3-2-4(10-5)6(7)8/h2-3H,1H3,(H3,7,8)
DM3MVSD CS CSC1=CC=C(S1)C(=N)N
DM3MVSD IK AXSQTCBARFBKPH-UHFFFAOYSA-N
DM3MVSD IU 5-methylsulfanylthiophene-2-carboximidamide
DM3MVSD DE Discovery agent
DM3LY0Q ID DM3LY0Q
DM3LY0Q DN 5'-Methylthio-ImmH
DM3LY0Q HS Investigative
DM3LY0Q DT Small molecular drug
DM3LY0Q PC 135509131
DM3LY0Q MW 296.35
DM3LY0Q FM C12H16N4O3S
DM3LY0Q IC InChI=1S/C12H16N4O3S/c1-20-3-6-10(17)11(18)8(16-6)5-2-13-9-7(5)14-4-15-12(9)19/h2,4,6,8,10-11,13,16-18H,3H2,1H3,(H,14,15,19)/t6-,8+,10-,11+/m1/s1
DM3LY0Q CS CSC[C@@H]1[C@H]([C@H]([C@@H](N1)C2=CNC3=C2N=CNC3=O)O)O
DM3LY0Q IK CEGIKIXYDFDYDN-RXDXJJGDSA-N
DM3LY0Q IU 7-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(methylsulfanylmethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DM3LY0Q DE Discovery agent
DMK52UH ID DMK52UH
DMK52UH DN 5'-methylthio-immucillin-H
DMK52UH HS Investigative
DMK52UH PC 136002688
DMK52UH MW 282.32
DMK52UH FM C11H14N4O3S
DMK52UH IC InChI=1S/C11H14N4O3S/c1-19-11-9(17)8(16)6(15-11)5-2-4-7(14-5)10(18)13-3-12-4/h2-3,6,8-9,11,14-17H,1H3,(H,12,13,18)/t6-,8-,9-,11+/m0/s1
DMK52UH CS CS[C@@H]1[C@H]([C@H]([C@@H](N1)C2=CC3=C(N2)C(=O)NC=N3)O)O
DMK52UH IK ZXECYVBSYKBAAH-MRQALGCZSA-N
DMK52UH IU 6-[(2S,3S,4S,5R)-3,4-dihydroxy-5-methylsulfanylpyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMK52UH DE Discovery agent
DMCX9WN ID DMCX9WN
DMCX9WN DN 5-methylurapidil
DMCX9WN HS Investigative
DMCX9WN SN 5 methylurapidil; 5-methyl-urapidil
DMCX9WN DT Small molecular drug
DMCX9WN PC 5640
DMCX9WN MW 401.5
DMCX9WN FM C21H31N5O3
DMCX9WN IC InChI=1S/C21H31N5O3/c1-16-19(23(2)21(28)24(3)20(16)27)22-10-7-11-25-12-14-26(15-13-25)17-8-5-6-9-18(17)29-4/h5-6,8-9,22H,7,10-15H2,1-4H3
DMCX9WN CS CC1=C(N(C(=O)N(C1=O)C)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC
DMCX9WN IK HIHZDNKKIUQQSC-UHFFFAOYSA-N
DMCX9WN IU 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3,5-trimethylpyrimidine-2,4-dione
DMCX9WN CA CAS 34661-85-3
DMCX9WN DE Discovery agent
DMX0EAK ID DMX0EAK
DMX0EAK DN 5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine
DMX0EAK HS Investigative
DMX0EAK SN 5--MONOPHOSPHATE-9-BETA-D-RIBOFURANOSYL XANTHINE; AC1O43SS; DB02309; 5-MONOPHOSPHATE-9-BETA-D-RIBOFURANOSYL XANTHINE; [(2R,3S,4R,5R)-5-(2,6-dioxo-3,7-dihydropurin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMX0EAK DT Small molecular drug
DMX0EAK PC 6323540
DMX0EAK MW 365.21
DMX0EAK FM C10H14N4O9P+
DMX0EAK IC InChI=1S/C10H13N4O9P/c15-5-3(1-22-24(19,20)21)23-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17/h2-3,5-6,9,15-16H,1H2,(H4,12,13,17,18,19,20,21)/p+1/t3-,5-,6-,9-/m1/s1
DMX0EAK CS C1=[N+](C2=C(N1)C(=O)NC(=O)N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DMX0EAK IK XHDARDSMKMUDDI-UUOKFMHZSA-O
DMX0EAK IU [(2R,3S,4R,5R)-5-(2,6-dioxo-3,7-dihydropurin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMX0EAK DE Discovery agent
DMSRGTI ID DMSRGTI
DMSRGTI DN 5-MPEP
DMSRGTI HS Investigative
DMSRGTI SN 5-Methyl-2-(phenylethynyl)pyridine; 124300-38-5; 5MPEP; 5-MPEP; GTPL1419; SCHEMBL3955825; CTK8E1822; 2-(Phenylethynyl)-5-methylpyridine; ZINC65731259; 6379AJ; 5-methyl-2-(2-phenylethynyl)pyridine; AKOS022184010; SY015649; KB-73636; AX8280780; AJ-115560; TC-307922; MFCD18205120 (95%)
DMSRGTI DT Small molecular drug
DMSRGTI PC 14343211
DMSRGTI MW 193.24
DMSRGTI FM C14H11N
DMSRGTI IC InChI=1S/C14H11N/c1-12-7-9-14(15-11-12)10-8-13-5-3-2-4-6-13/h2-7,9,11H,1H3
DMSRGTI CS CC1=CN=C(C=C1)C#CC2=CC=CC=C2
DMSRGTI IK HESJPHOOGDBABM-UHFFFAOYSA-N
DMSRGTI IU 5-methyl-2-(2-phenylethynyl)pyridine
DMSRGTI DE Discovery agent
DMOSKJ8 ID DMOSKJ8
DMOSKJ8 DN 5-N-Allyl-Arginine
DMOSKJ8 HS Investigative
DMOSKJ8 SN 5-N-ALLYL-ARGININE; ARV; AC1NRA56; DB03892; N-[(1Z)-amino{[(4S)-4-amino-4-carboxybutyl]amino}methylidene]prop-2-en-1-aminium
DMOSKJ8 DT Small molecular drug
DMOSKJ8 PC 5287706
DMOSKJ8 MW 215.27
DMOSKJ8 FM C9H19N4O2+
DMOSKJ8 IC InChI=1S/C9H18N4O2/c1-2-5-12-9(11)13-6-3-4-7(10)8(14)15/h2,7H,1,3-6,10H2,(H,14,15)(H3,11,12,13)/p+1/t7-/m0/s1
DMOSKJ8 CS C=CCNC(=[NH+]CCC[C@@H](C(=O)O)N)N
DMOSKJ8 IK ZPQWZDPOLXVMOU-ZETCQYMHSA-O
DMOSKJ8 IU [(4S)-4-amino-4-carboxybutyl]-[amino-(prop-2-enylamino)methylidene]azanium
DMOSKJ8 DE Discovery agent
DMK0PAL ID DMK0PAL
DMK0PAL DN 5-Naphthalen-2-yl-1H-imidazole
DMK0PAL HS Investigative
DMK0PAL SN SCHEMBL2369049; BDBM8931; CHEMBL370822; 5-(2-Naphthyl)-1H-imidazole; 4-(2-Naphthyl)-1H-imidazole; BDBM220125; 5-(naphthalen-2-yl)-1h-imidazole; Imidazole-substituted naphthalene 27; ZINC13674488; US9271963, 27
DMK0PAL DT Small molecular drug
DMK0PAL PC 21772021
DMK0PAL MW 194.23
DMK0PAL FM C13H10N2
DMK0PAL IC InChI=1S/C13H10N2/c1-2-4-11-7-12(6-5-10(11)3-1)13-8-14-9-15-13/h1-9H,(H,14,15)
DMK0PAL CS C1=CC=C2C=C(C=CC2=C1)C3=CN=CN3
DMK0PAL IK CTUKWPHHWRYGEH-UHFFFAOYSA-N
DMK0PAL IU 5-naphthalen-2-yl-1H-imidazole
DMK0PAL DE Discovery agent
DMTH3BW ID DMTH3BW
DMTH3BW DN 5-Naphthalen-2-yl-oxazole
DMTH3BW HS Investigative
DMTH3BW SN 143659-20-5; 5-(naphthalen-2-yl)-1,3-oxazole; 5-(2-naphthalenyl)Oxazole; 5-(Naphthalen-2-yl)oxazole; Oxazole,5-(2-naphthalenyl)-; 5-(2-naphthyl)-1,3-oxazole; 5-(2-Naphthyl)oxazole; ACMC-1C0FI; 5-(2-naph-thyl-)oxazol; SCHEMBL4500585; BDBM8928; CHEMBL193653; 5-Naphth-2-yl-1,3-oxazole; CTK4C3747; DTXSID10460853; MolPort-001-758-948; UQGCSVOKHFBQIP-UHFFFAOYSA-N; oxazole-substituted naphthalene 29; KS-00001PB5; ZX-AT019030; ZINC13674492; AKOS005254941; MCULE-4854701546; OR12565; GL-1006; KB-269976; AX8104945; DB-057999
DMTH3BW DT Small molecular drug
DMTH3BW PC 11275595
DMTH3BW MW 195.22
DMTH3BW FM C13H9NO
DMTH3BW IC InChI=1S/C13H9NO/c1-2-4-11-7-12(6-5-10(11)3-1)13-8-14-9-15-13/h1-9H
DMTH3BW CS C1=CC=C2C=C(C=CC2=C1)C3=CN=CO3
DMTH3BW IK UQGCSVOKHFBQIP-UHFFFAOYSA-N
DMTH3BW IU 5-naphthalen-2-yl-1,3-oxazole
DMTH3BW CA CAS 143659-20-5
DMTH3BW DE Discovery agent
DMTS06Z ID DMTS06Z
DMTS06Z DN 5-Nitro-1H-indole-2,3-dione
DMTS06Z HS Investigative
DMTS06Z SN 5-Nitroisatin; 611-09-6; 5-Nitroindoline-2,3-dione; 5-Nitroindole-2,3-dione; 5-Nitro-1H-indole-2,3-dione; 1H-Indole-2,3-dione, 5-nitro-; N-Nitroisatin; Isatin, 5-nitro-; INDOLE-2,3-DIONE, 5-NITRO-; CCRIS 4031; UNII-J4J633881Z; 5-Nitroisatin, 97%; EINECS 210-252-5; NSC 525798; 2,3-Dihydro-5-nitroindole-2,3-dione; BRN 0180223; CHEMBL118305; UNMYHYODJHKLOC-UHFFFAOYSA-N; J4J633881Z; 5-nitro-2,3-dihydro-1H-indole-2,3-dione; 5-Nitro isatin; Isatin, 5-nitro- (6CI); 5-nitroisatine; Isatin analog 3; NSC525798; PubChem15514; Indole-2, 5-nitro
DMTS06Z DT Small molecular drug
DMTS06Z PC 4669250
DMTS06Z MW 192.13
DMTS06Z FM C8H4N2O4
DMTS06Z IC InChI=1S/C8H4N2O4/c11-7-5-3-4(10(13)14)1-2-6(5)9-8(7)12/h1-3H,(H,9,11,12)
DMTS06Z CS C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C(=O)N2
DMTS06Z IK UNMYHYODJHKLOC-UHFFFAOYSA-N
DMTS06Z IU 5-nitro-1H-indole-2,3-dione
DMTS06Z CA CAS 611-09-6
DMTS06Z CB CHEBI:149791
DMTS06Z DE Discovery agent
DM26MIC ID DM26MIC
DM26MIC DN 5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole
DM26MIC HS Investigative
DM26MIC SN CHEMBL175481; 5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole
DM26MIC DT Small molecular drug
DM26MIC PC 11325003
DM26MIC MW 331.3
DM26MIC FM C19H13N3O3
DM26MIC IC InChI=1S/C19H13N3O3/c23-22(24)14-8-11-17-18(12-14)21-19(20-17)13-6-9-16(10-7-13)25-15-4-2-1-3-5-15/h1-12H,(H,20,21)
DM26MIC CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-]
DM26MIC IK ZBWXPJPIZQAKGA-UHFFFAOYSA-N
DM26MIC IU 6-nitro-2-(4-phenoxyphenyl)-1H-benzimidazole
DM26MIC DE Discovery agent
DMH7SIX ID DMH7SIX
DMH7SIX DN 5-Nitroindazole
DMH7SIX HS Investigative
DMH7SIX SN 5-Nitro-1H-indazole; 5401-94-5; 1H-INDAZOLE, 5-NITRO-; UNII-235Y7P37ZD; CCRIS 4134; NSC 5032; EINECS 226-451-5; BRN 0007936; CHEMBL165372; WSGURAYTCUVDQL-UHFFFAOYSA-N; 235Y7P37ZD; MFCD00005693; 5NI; 2H-Indazole, 5-nitro-; 5-Nitroindazol; 5-nitro indazole; 5-nitro-indazole; 5-nitro-1H-indazol; 5-nitro-IH-indazole; 5-nitro-2H-indazole; PubChem15672; 4lm0; AC1L2IGS; ACMC-209lc9; DSSTox_RID_83391; DSSTox_CID_29272; 5-Nitroindazole, > DSSTox_GSID_49316; KSC490O7N; 5-Nitro-1H-indazole 99%; MLS000728712; 5-23-06-00180 (B
DMH7SIX DT Small molecular drug
DMH7SIX PC 21501
DMH7SIX MW 163.13
DMH7SIX FM C7H5N3O2
DMH7SIX IC InChI=1S/C7H5N3O2/c11-10(12)6-1-2-7-5(3-6)4-8-9-7/h1-4H,(H,8,9)
DMH7SIX CS C1=CC2=C(C=C1[N+](=O)[O-])C=NN2
DMH7SIX IK WSGURAYTCUVDQL-UHFFFAOYSA-N
DMH7SIX IU 5-nitro-1H-indazole
DMH7SIX CA CAS 5401-94-5
DMH7SIX DE Discovery agent
DM4K8N2 ID DM4K8N2
DM4K8N2 DN 5-nitroindirubin-3'-oxime
DM4K8N2 HS Investigative
DM4K8N2 DT Small molecular drug
DM4K8N2 PC 11450099
DM4K8N2 DE Discovery agent
DM2DWUQ ID DM2DWUQ
DM2DWUQ DN 5-Nonyl-5-phenyl-imidazolidine-2,4-dione
DM2DWUQ HS Investigative
DM2DWUQ SN CHEMBL39043
DM2DWUQ DT Small molecular drug
DM2DWUQ PC 10518486
DM2DWUQ MW 302.4
DM2DWUQ FM C18H26N2O2
DM2DWUQ IC InChI=1S/C18H26N2O2/c1-2-3-4-5-6-7-11-14-18(15-12-9-8-10-13-15)16(21)19-17(22)20-18/h8-10,12-13H,2-7,11,14H2,1H3,(H2,19,20,21,22)
DM2DWUQ CS CCCCCCCCCC1(C(=O)NC(=O)N1)C2=CC=CC=C2
DM2DWUQ IK YDNZJQWFOGASIE-UHFFFAOYSA-N
DM2DWUQ IU 5-nonyl-5-phenylimidazolidine-2,4-dione
DM2DWUQ DE Discovery agent
DM74JL8 ID DM74JL8
DM74JL8 DN 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole
DM74JL8 HS Investigative
DM74JL8 SN UHDBT; 6-Hydroxy-5-undecyl-4,7-benzothiazoledione; 43152-58-5; 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole; 4,7-Benzothiazoledione, 6-hydroxy-5-undecyl-; 6-HYDROXY-5-UNDECYL-1,3-BENZOTHIAZOLE-4,7-DIONE; 3-UNDECYL-2-HYDROXYDIOXOBENZOTHIAZOL; AC1MI2XQ; SCHEMBL6672079; CTK1D6913; DB04799; 4-hydroxy-5-undecyl-1,3-benzothiazole-6,7-dione; 3-UNDECYL-2-HYDROXYDIOXOBENZOTHIAZOL
DM74JL8 DT Small molecular drug
DM74JL8 PC 3016416
DM74JL8 MW 335.5
DM74JL8 FM C18H25NO3S
DM74JL8 IC InChI=1S/C18H25NO3S/c1-2-3-4-5-6-7-8-9-10-11-13-15(20)14-18(23-12-19-14)17(22)16(13)21/h12,20H,2-11H2,1H3
DM74JL8 CS CCCCCCCCCCCC1=C(C2=C(C(=O)C1=O)SC=N2)O
DM74JL8 IK VSIBLXWNANVQDH-UHFFFAOYSA-N
DM74JL8 IU 4-hydroxy-5-undecyl-1,3-benzothiazole-6,7-dione
DM74JL8 CA CAS 43152-58-5
DM74JL8 DE Discovery agent
DM20X8C ID DM20X8C
DM20X8C DN 5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine
DM20X8C HS Investigative
DM20X8C SN CHEMBL1163059; 1pfy; AC1L9LA4; SCHEMBL4308351; BDBM50222901; 5'-O-[N-(L-Methionyl)-sulfamoyl]adenosine; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl N-[(2S)-2-amino-4-methylsulfanylbutanoyl]sulfamate
DM20X8C DT Small molecular drug
DM20X8C PC 46936326
DM20X8C MW 479.5
DM20X8C FM C15H25N7O7S2
DM20X8C IC InChI=1S/C15H25N7O7S2/c1-30-3-2-7(16)14(25)21-31(26,27)28-4-8-10(23)11(24)15(29-8)22-6-20-9-12(17)18-5-19-13(9)22/h5-8,10-11,13,15,23-24H,2-4,16-17H2,1H3,(H,18,19)(H,21,25)/t7-,8+,10+,11-,13+,15-/m1/s1
DM20X8C CS CSCC[C@H](C(=O)NS(=O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N2C=NC3=C(NC=N[C@H]32)N)O)O)N
DM20X8C IK SQDXXTAOGLOMRP-JJWYTCDVSA-N
DM20X8C IU [(2S,3R,4R,5R)-5-[(4S)-6-amino-1,4-dihydropurin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl N-[(2R)-2-amino-4-methylsulfanylbutanoyl]sulfamate
DM20X8C DE Discovery agent
DMAXHEU ID DMAXHEU
DMAXHEU DN 5-octyl-2-phenoxyphenol
DMAXHEU HS Investigative
DMAXHEU SN 5-OCTYL-2-PHENOXYPHENOL; 5-Octyl-2-phenoxy-phenol; CHEMBL505886; 8PS; 8PP; AC1NRXEO; 2-Phenoxy-5-octylphenol; 5-octyl-2-phenoxy phenol; 5-heptyl-2-phenoxylphenol; SCHEMBL2873469; PT05; BDBM16298; JOWYBLIPWAMIHM-UHFFFAOYSA-N
DMAXHEU DT Small molecular drug
DMAXHEU PC 5274979
DMAXHEU MW 298.4
DMAXHEU FM C20H26O2
DMAXHEU IC InChI=1S/C20H26O2/c1-2-3-4-5-6-8-11-17-14-15-20(19(21)16-17)22-18-12-9-7-10-13-18/h7,9-10,12-16,21H,2-6,8,11H2,1H3
DMAXHEU CS CCCCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2)O
DMAXHEU IK JOWYBLIPWAMIHM-UHFFFAOYSA-N
DMAXHEU IU 5-octyl-2-phenoxyphenol
DMAXHEU DE Discovery agent
DMZT6JR ID DMZT6JR
DMZT6JR DN 5-OH-DPAT
DMZT6JR HS Investigative
DMZT6JR SN 5-OH-Dpat; CHEMBL273273; 68593-96-4; 6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; 6-dipropylaminotetralin-1-ol; 5-Hydroxy-2-N,N-dipropylaminotetralin; 5-Hydroxy-2-(di-n-propylamino)tetralin; (-)-5-hydroxy-2-(dipropylamino)tetralin; 6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol; GTPL128; SCHEMBL279021; AC1L58V4; 2-Dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene; 5-hydroxy-2-(dipropylamino)tetralin; BDBM50020221; 5-hydroxy-N,N-dipropyl-2-aminotetralin; L000957; 1-Naphthalenol,; 6-dipropylaminotetralin-1-ol
DMZT6JR DT Small molecular drug
DMZT6JR PC 172267
DMZT6JR MW 247.38
DMZT6JR FM C16H25NO
DMZT6JR IC InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-8-9-15-13(12-14)6-5-7-16(15)18/h5-7,14,18H,3-4,8-12H2,1-2H3
DMZT6JR CS CCCN(CCC)C1CCC2=C(C1)C=CC=C2O
DMZT6JR IK MDBWEQVKJDMEMK-UHFFFAOYSA-N
DMZT6JR IU 6-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
DMZT6JR CA CAS 68593-96-4
DMZT6JR DE Discovery agent
DME62OQ ID DME62OQ
DME62OQ DN 5-oxo-1-2-4-oxadiazol biphenyl
DME62OQ HS Investigative
DME62OQ SN compound 1c [PMID: 22410249]
DME62OQ DT Small molecular drug
DME62OQ PC 136218976
DME62OQ MW 423.5
DME62OQ FM C23H25N3O5
DME62OQ IC InChI=1S/C23H25N3O5/c1-3-7-19(22(28)29)26(20(27)4-2)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)21-24-23(30)31-25-21/h5-6,8-13,19H,3-4,7,14H2,1-2H3,(H,28,29)(H,24,25,30)/t19-/m0/s1
DME62OQ CS CCC[C@@H](C(=O)O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NOC(=O)N3)C(=O)CC
DME62OQ IK FXELTRKWYHPHAE-IBGZPJMESA-N
DME62OQ IU (2S)-2-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl-propanoylamino]pentanoic acid
DME62OQ DE Discovery agent
DMLABR9 ID DMLABR9
DMLABR9 DN 5-oxo-12-HETE
DMLABR9 HS Investigative
DMLABR9 SN 5-oxo-12S-hydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
DMLABR9 DT Small molecular drug
DMLABR9 PC 10568747
DMLABR9 MW 334.4
DMLABR9 FM C20H30O4
DMLABR9 IC InChI=1S/C20H30O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18,21H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7-,9-6-,14-10+,15-11+/t18-/m0/s1
DMLABR9 CS CCCCC/C=C\\C[C@@H](/C=C/C=C\\C=C\\C(=O)CCCC(=O)O)O
DMLABR9 IK MLZJFLKEKVDNAZ-XPKTZJOPSA-N
DMLABR9 IU (6E,8Z,10E,12S,14Z)-12-hydroxy-5-oxoicosa-6,8,10,14-tetraenoic acid
DMLABR9 CB CHEBI:137749
DMLABR9 DE Discovery agent
DM9ZC7B ID DM9ZC7B
DM9ZC7B DN 5-oxo-15-HETE
DM9ZC7B HS Investigative
DM9ZC7B SN 5-oxo-15-hydroxy-(6E,8Z,11Z,13E)-eicosatetraenoic acid
DM9ZC7B DT Small molecular drug
DM9ZC7B PC 6438757
DM9ZC7B MW 334.4
DM9ZC7B FM C20H30O4
DM9ZC7B IC InChI=1S/C20H30O4/c1-2-3-9-13-18(21)14-10-7-5-4-6-8-11-15-19(22)16-12-17-20(23)24/h5-8,10-11,14-15,18,21H,2-4,9,12-13,16-17H2,1H3,(H,23,24)/b7-5-,8-6-,14-10+,15-11+/t18-/m0/s1
DM9ZC7B CS CCCCC[C@@H](/C=C/C=C\\C/C=C\\C=C\\C(=O)CCCC(=O)O)O
DM9ZC7B IK RIUDRKHGFDAKPO-WWWYWCMOSA-N
DM9ZC7B IU (6E,8Z,11Z,13E,15S)-15-hydroxy-5-oxoicosa-6,8,11,13-tetraenoic acid
DM9ZC7B CA CAS 142828-12-4
DM9ZC7B CB CHEBI:137746
DM9ZC7B DE Discovery agent
DMQ94BX ID DMQ94BX
DMQ94BX DN 5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate
DMQ94BX HS Investigative
DMQ94BX SN CHEMBL1164744; 5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate
DMQ94BX DT Small molecular drug
DMQ94BX PC 46871782
DMQ94BX MW 295.31
DMQ94BX FM C13H13NO5S
DMQ94BX IC InChI=1S/C13H13NO5S/c1-9-3-5-11(6-4-9)20(17,18)14-12(16)7-8-13(14)19-10(2)15/h3-8,13H,1-2H3
DMQ94BX CS CC1=CC=C(C=C1)S(=O)(=O)N2C(C=CC2=O)OC(=O)C
DMQ94BX IK JVIFWMPUUHEQPE-UHFFFAOYSA-N
DMQ94BX IU [1-(4-methylphenyl)sulfonyl-5-oxo-2H-pyrrol-2-yl] acetate
DMQ94BX DE Discovery agent
DM493GU ID DM493GU
DM493GU DN 5-oxo-20-HETE
DM493GU HS Investigative
DM493GU SN 5-oxo-20-hydroxy-6E, 8Z,11Z, 14Z-eicosatetraenoic acid
DM493GU DT Small molecular drug
DM493GU PC 73755178
DM493GU MW 334.4
DM493GU FM C20H30O4
DM493GU IC InChI=1S/C20H30O4/c21-18-13-11-9-7-5-3-1-2-4-6-8-10-12-15-19(22)16-14-17-20(23)24/h2-5,8,10,12,15,21H,1,6-7,9,11,13-14,16-18H2,(H,23,24)/b4-2-,5-3-,10-8-,15-12+
DM493GU CS C(CC/C=C\\C/C=C\\C/C=C\\C=C\\C(=O)CCCC(=O)O)CCO
DM493GU IK DTSRZRUIWKDHMR-DHYYJNSCSA-N
DM493GU IU (6E,8Z,11Z,14Z)-20-hydroxy-5-oxoicosa-6,8,11,14-tetraenoic acid
DM493GU DE Discovery agent
DM6FSUW ID DM6FSUW
DM6FSUW DN 5-oxo-C20:3
DM6FSUW HS Investigative
DM6FSUW SN 5-oxo-6e,8z,11z-eicosatrienoic acid; 5-oxo-ETrE
DM6FSUW DT Small molecular drug
DM6FSUW PC 56947094
DM6FSUW MW 320.5
DM6FSUW FM C20H32O3
DM6FSUW IC InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h9-10,12-14,16H,2-8,11,15,17-18H2,1H3,(H,22,23)/b10-9-,13-12-,16-14-
DM6FSUW CS CCCCCCCC/C=C\\C/C=C\\C=C/C(=O)CCCC(=O)O
DM6FSUW IK ULMVEQWNDGUUBR-IEQFDQMRSA-N
DM6FSUW IU (6Z,8Z,11Z)-5-oxoicosa-6,8,11-trienoic acid
DM6FSUW DE Discovery agent
DM56TVA ID DM56TVA
DM56TVA DN 5-oxo-ODE
DM56TVA HS Investigative
DM56TVA SN 5-oxo-(6E,8Z)-octadecadienoic acid
DM56TVA DT Small molecular drug
DM56TVA PC 71751402
DM56TVA MW 294.4
DM56TVA FM C18H30O3
DM56TVA IC InChI=1S/C18H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19)15-13-16-18(20)21/h10-12,14H,2-9,13,15-16H2,1H3,(H,20,21)/b11-10-,14-12+
DM56TVA CS CCCCCCCCC/C=C\\C=C\\C(=O)CCCC(=O)O
DM56TVA IK YVWMHFYOIJMUMN-HSINTONASA-N
DM56TVA IU (6E,8Z)-5-oxooctadeca-6,8-dienoic acid
DM56TVA CA CAS 1021188-25-9
DM56TVA CB CHEBI:137754
DM56TVA DE Discovery agent
DMPLB3S ID DMPLB3S
DMPLB3S DN 5PAM523
DMPLB3S HS Investigative
DMPLB3S SN 5PAM523; SCHEMBL600403; GTPL6414; JOBPCEDWVKYVKZ-OCCSQVGLSA-N; 5-fluoro-2-{3-[(3S,6R)-1-[(4-fluorophenyl)carbonyl]-6-methylpiperidin-3-yl]-1,2,4-oxadiazol-5-yl}pyridine; 4-fluorophenyl((2r,5s)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl)methanone
DMPLB3S DT Small molecular drug
DMPLB3S PC 46946406
DMPLB3S MW 384.4
DMPLB3S FM C20H18F2N4O2
DMPLB3S IC InChI=1S/C20H18F2N4O2/c1-12-2-3-14(11-26(12)20(27)13-4-6-15(21)7-5-13)18-24-19(28-25-18)17-9-8-16(22)10-23-17/h4-10,12,14H,2-3,11H2,1H3/t12-,14+/m1/s1
DMPLB3S CS C[C@@H]1CC[C@@H](CN1C(=O)C2=CC=C(C=C2)F)C3=NOC(=N3)C4=NC=C(C=C4)F
DMPLB3S IK JOBPCEDWVKYVKZ-OCCSQVGLSA-N
DMPLB3S IU (4-fluorophenyl)-[(2R,5S)-5-[5-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-3-yl]-2-methylpiperidin-1-yl]methanone
DMPLB3S DE Discovery agent
DMKHFV4 ID DMKHFV4
DMKHFV4 DN 5-PENTYL-2-PHENOXYPHENOL
DMKHFV4 HS Investigative
DMKHFV4 SN 5-PENTYL-2-PHENOXYPHENOL; 5-Pentyl-2-phenoxy-phenol; 5PP; AC1NRXEL; 5-pentyl-2-phenoxylphenol; SCHEMBL2873530; PT03; CHEMBL1224745; BDBM16296; AIDS227445
DMKHFV4 DT Small molecular drug
DMKHFV4 PC 5274976
DMKHFV4 MW 256.339
DMKHFV4 FM C17H20O2
DMKHFV4 IC InChI=1S/C17H20O2/c1-2-3-5-8-14-11-12-17(16(18)13-14)19-15-9-6-4-7-10-15/h4,6-7,9-13,18H,2-3,5,8H2,1H3
DMKHFV4 CS CCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2)O
DMKHFV4 IK OJLYTHOKCYLPMA-UHFFFAOYSA-N
DMKHFV4 IU 5-pentyl-2-phenoxyphenol
DMKHFV4 DE Discovery agent
DMZKJF8 ID DMZKJF8
DMZKJF8 DN 5-Phenethyl-1H-pyrazole-3-carboxylic acid
DMZKJF8 HS Investigative
DMZKJF8 SN 5-phenethyl-1H-pyrazole-3-carboxylic Acid; 595610-56-3; CHEMBL129385; 3-(2-phenylethyl)-1H-pyrazole-5-carboxylic acid; 1H-Pyrazole-3-carboxylic acid, 5-(2-phenylethyl)-; SCHEMBL1149172; SCHEMBL17672395; CTK7I6521; DTXSID50474116; MolPort-022-664-580; MolPort-022-231-591; BDBM50132146; STL426411; ZINC13526610; BBL035265; AKOS016013666; AKOS022947847; AJ-64058; 3-phenethyl-1H-pyrazole-5-carboxylic acid; AX8249620; 5-(2-phenylethyl)-1h-pyrazole-3-carboxylic acid
DMZKJF8 DT Small molecular drug
DMZKJF8 PC 11830866
DMZKJF8 MW 216.24
DMZKJF8 FM C12H12N2O2
DMZKJF8 IC InChI=1S/C12H12N2O2/c15-12(16)11-8-10(13-14-11)7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H,13,14)(H,15,16)
DMZKJF8 CS C1=CC=C(C=C1)CCC2=CC(=NN2)C(=O)O
DMZKJF8 IK HHEBXMNODWRUEV-UHFFFAOYSA-N
DMZKJF8 IU 5-(2-phenylethyl)-1H-pyrazole-3-carboxylic acid
DMZKJF8 CA CAS 595610-56-3
DMZKJF8 DE Discovery agent
DMWI7XJ ID DMWI7XJ
DMWI7XJ DN 5-Phenethyl-quinazoline-2,4-diamine
DMWI7XJ HS Investigative
DMWI7XJ SN CHEMBL341703; 5-phenethylquinazoline-2,4-diamine; 5-Phenethyl-quinazoline-2,4-diamine; AC1LALFL; CTK7E0789; BDBM50036483; ZINC13740535; 5-(2-phenylethyl)quinazoline-2,4-diamine; 5-(2-phenylethyl)-2,4-quinazolinediamine; 2,4-Diamino-5-(2-phenylethyl)-quinazoline; (2-amino-5-phenethyl-quinazolin-4-yl)-amine; 2,4-Quinazolinediamine, 5-(2-phenylethyl)-
DMWI7XJ DT Small molecular drug
DMWI7XJ PC 490662
DMWI7XJ MW 264.32
DMWI7XJ FM C16H16N4
DMWI7XJ IC InChI=1S/C16H16N4/c17-15-14-12(10-9-11-5-2-1-3-6-11)7-4-8-13(14)19-16(18)20-15/h1-8H,9-10H2,(H4,17,18,19,20)
DMWI7XJ CS C1=CC=C(C=C1)CCC2=C3C(=CC=C2)N=C(N=C3N)N
DMWI7XJ IK UIHMRPRVKDDARV-UHFFFAOYSA-N
DMWI7XJ IU 5-(2-phenylethyl)quinazoline-2,4-diamine
DMWI7XJ DE Discovery agent
DMZ6TRV ID DMZ6TRV
DMZ6TRV DN 5-phenyl-1,3,4-oxadiazole-2(3H)-thione
DMZ6TRV HS Investigative
DMZ6TRV SN 3004-42-0; 5-Phenyl-1,3,4-oxadiazole-2-thiol; 5-Phenyl-1,3,4-oxadiazole-2(3H)-thione; 1,3,4-Oxadiazole-2(3H)-thione, 5-phenyl-; 2-Phenyl-1,3,4-oxadiazole-5-thiol; 1,3,4-oxadiazole-2-thiol, 5-phenyl-; EINECS 221-103-9; 5-Phenyl-[1,3,4]oxadiazole-2-thiol; 2-Fenil-5-mercapto-1,3,4-ossadiazolo; CHEMBL1164316; 1,3,4-OXADIAZOLE-5-THIOL, 2-PHENYL-; FOHWXVBZGSVUGO-UHFFFAOYSA-N; 2-Fenil-5-mercapto-1,3,4-ossadiazolo [Italian]; 5-phenyl-1,3,4-oxadiazole-2-thione; 2-Phenyl-1,3,4--oxadiazol-5-thiol
DMZ6TRV DT Small molecular drug
DMZ6TRV PC 735254
DMZ6TRV MW 178.21
DMZ6TRV FM C8H6N2OS
DMZ6TRV IC InChI=1S/C8H6N2OS/c12-8-10-9-7(11-8)6-4-2-1-3-5-6/h1-5H,(H,10,12)
DMZ6TRV CS C1=CC=C(C=C1)C2=NNC(=S)O2
DMZ6TRV IK FOHWXVBZGSVUGO-UHFFFAOYSA-N
DMZ6TRV IU 5-phenyl-3H-1,3,4-oxadiazole-2-thione
DMZ6TRV CA CAS 3004-42-0
DMZ6TRV DE Discovery agent
DMCKBQY ID DMCKBQY
DMCKBQY DN 5-phenyl-1,3,4-thiadiazole-2(3H)-thione
DMCKBQY HS Investigative
DMCKBQY SN 5-Phenyl-1,3,4-thiadiazole-2-thiol; 5585-19-3; 1,3,4-Thiadiazole-2-thiol, 5-phenyl-; L 1542; 2-Mercapto-5-fenil-1,3,4-tiadiazolo [Italian]; 5-Phenyl-1,3,4-thiadiazole-2(3H)-thione; CHEMBL596215; 2-mercapto-5-phenyl-1,3,4-thiadiazole; 2-Mercapto-5-fenil-1,3,4-tiadiazolo; AC1Q7GLK; AC1MHZ9V; SCHEMBL969040; DTXSID40204444; ZTLMHGOWADYAHM-UHFFFAOYSA-N; MolPort-000-932-663; ZINC13532595; MFCD01681863; BDBM50320718; 5-phenyl-1,3,4-thiadiazol-2-thiol; AKOS003056166; MCULE-7311616477; NE54511; LS-150315
DMCKBQY DT Small molecular drug
DMCKBQY PC 3035373
DMCKBQY MW 194.3
DMCKBQY FM C8H6N2S2
DMCKBQY IC InChI=1S/C8H6N2S2/c11-8-10-9-7(12-8)6-4-2-1-3-5-6/h1-5H,(H,10,11)
DMCKBQY CS C1=CC=C(C=C1)C2=NNC(=S)S2
DMCKBQY IK ZTLMHGOWADYAHM-UHFFFAOYSA-N
DMCKBQY IU 5-phenyl-3H-1,3,4-thiadiazole-2-thione
DMCKBQY CA CAS 5585-19-3
DMCKBQY DE Discovery agent
DMWF4HX ID DMWF4HX
DMWF4HX DN 5-phenyl-1H-1,2,3-triazole
DMWF4HX HS Investigative
DMWF4HX SN 1680-44-0; 5-phenyl-1H-1,2,3-triazole; 4-Phenyl-1H-1,2,3-triazole; 4-Phenyl-1H-[1,2,3]triazole; 4-Phenyl-1,2,3-triazole; 1H-1,2,3-Triazole, 4-phenyl-; 4-phenyl-2H-triazole; v-Triazole, 4-phenyl-; 4-phenyl-2H-[1,2,3]triazole; LUEYUHCBBXWTQT-UHFFFAOYSA-N; 4-phenyl-1h-1,2,3,-triazole; 5-Phenyl-1H-[1,2,3]triazole; 112614-96-7; phenyltriazole; 4-phenyltriazole; NSC83125; SCHEMBL9868; AC1L3A0F; 5-phenyl-1,2,3-triazole; SCHEMBL8221447; CHEMBL193664; 1,2,3-triazole analogue, 4; 1,2,3-Triazole, 4-phenyl-; ZINC27320; BDBM17448; CTK4D2851
DMWF4HX DT Small molecular drug
DMWF4HX PC 137153
DMWF4HX MW 145.16
DMWF4HX FM C8H7N3
DMWF4HX IC InChI=1S/C8H7N3/c1-2-4-7(5-3-1)8-6-9-11-10-8/h1-6H,(H,9,10,11)
DMWF4HX CS C1=CC=C(C=C1)C2=NNN=C2
DMWF4HX IK LUEYUHCBBXWTQT-UHFFFAOYSA-N
DMWF4HX IU 4-phenyl-2H-triazole
DMWF4HX CA CAS 1680-44-0
DMWF4HX DE Discovery agent
DMJBEIF ID DMJBEIF
DMJBEIF DN 5-phenyl-1H-indazol-3-amine
DMJBEIF HS Investigative
DMJBEIF SN 5-phenyl-1H-indazol-3-amine; CHEMBL500779; SCHEMBL3359889; 3e63; BDBM50254831; DB07161
DMJBEIF DT Small molecular drug
DMJBEIF PC 11492186
DMJBEIF MW 209.25
DMJBEIF FM C13H11N3
DMJBEIF IC InChI=1S/C13H11N3/c14-13-11-8-10(6-7-12(11)15-16-13)9-4-2-1-3-5-9/h1-8H,(H3,14,15,16)
DMJBEIF CS C1=CC=C(C=C1)C2=CC3=C(C=C2)NN=C3N
DMJBEIF IK ZCUSNQPYUNLATP-UHFFFAOYSA-N
DMJBEIF IU 5-phenyl-1H-indazol-3-amine
DMJBEIF DE Discovery agent
DMQHU0J ID DMQHU0J
DMQHU0J DN 5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole
DMQHU0J HS Investigative
DMQHU0J SN CHEMBL1257573; 5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole
DMQHU0J DT Small molecular drug
DMQHU0J PC 52946272
DMQHU0J MW 284.4
DMQHU0J FM C18H24N2O
DMQHU0J IC InChI=1S/C18H24N2O/c1-3-9-16(10-4-1)17-15-19-18(21-17)11-5-8-14-20-12-6-2-7-13-20/h1,3-4,9-10,15H,2,5-8,11-14H2
DMQHU0J CS C1CCN(CC1)CCCCC2=NC=C(O2)C3=CC=CC=C3
DMQHU0J IK XJINDZCEGQZNLD-UHFFFAOYSA-N
DMQHU0J IU 5-phenyl-2-(4-piperidin-1-ylbutyl)-1,3-oxazole
DMQHU0J DE Discovery agent
DMLK2VT ID DMLK2VT
DMLK2VT DN 5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one
DMLK2VT HS Investigative
DMLK2VT SN NSC675284; CHEMBL32718; 6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-one; 6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7(6h)-one; AC1L8OAU; 5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one; CTK8D2539; BDBM50041512; NSC-675284
DMLK2VT DT Small molecular drug
DMLK2VT PC 384831
DMLK2VT MW 291.4
DMLK2VT FM C18H13NOS
DMLK2VT IC InChI=1S/C18H13NOS/c20-17-15-10-6-12-19(15)14-9-4-5-11-16(14)21-18(17)13-7-2-1-3-8-13/h1-12,18H
DMLK2VT CS C1=CC=C(C=C1)C2C(=O)C3=CC=CN3C4=CC=CC=C4S2
DMLK2VT IK NZZPYZUATMBWAV-UHFFFAOYSA-N
DMLK2VT IU 6-phenylpyrrolo[2,1-d][1,5]benzothiazepin-7-one
DMLK2VT DE Discovery agent
DMUBCVL ID DMUBCVL
DMUBCVL DN 5-Phenyl-6-thia-10b-aza-benzo[e]azulene
DMUBCVL HS Investigative
DMUBCVL SN CHEMBL358133; 5-Phenyl-6-thia-10b-aza-benzo[e]azulene; ZINC13603874; BDBM50029752
DMUBCVL DT Small molecular drug
DMUBCVL PC 13057872
DMUBCVL MW 275.4
DMUBCVL FM C18H13NS
DMUBCVL IC InChI=1S/C18H13NS/c1-2-7-14(8-3-1)18-13-15-9-6-12-19(15)16-10-4-5-11-17(16)20-18/h1-13H
DMUBCVL CS C1=CC=C(C=C1)C2=CC3=CC=CN3C4=CC=CC=C4S2
DMUBCVL IK XBVRXEAOFZWJAH-UHFFFAOYSA-N
DMUBCVL IU 6-phenylpyrrolo[2,1-d][1,5]benzothiazepine
DMUBCVL DE Discovery agent
DMX6R0H ID DMX6R0H
DMX6R0H DN 5-phenylamino-4-cyano-3-hydroxy-isothiazole
DMX6R0H HS Investigative
DMX6R0H SN CHEMBL209793; 1137-65-1; 4-Isothiazolecarbonitrile, 2,3-dihydro-3-oxo-5-(phenylamino)-; AC1MBJGN; Maybridge4_002946; 5-phenylamino-4-cyano-3-hydroxy-isothiazole; 5-anilino-3-oxo-1,2-thiazole-4-carbonitrile; Oprea1_090337; MLS000850692; SCHEMBL3527060; CTK0G1139; DTXSID30369410; CHEBI:107126; MolPort-002-913-499; GHXPCAXQBVCFNU-UHFFFAOYSA-N; HMS2799B08; HMS1529F20; CCG-1976; ZINC15924361; BDBM50187849; AKOS022652528; AKOS030549246; MCULE-9694822584; NCGC00176381-01; SMR000456709; 5-anilino-3-oxo-isothiazole-4-carbonitrile
DMX6R0H DT Small molecular drug
DMX6R0H PC 2726555
DMX6R0H MW 217.25
DMX6R0H FM C10H7N3OS
DMX6R0H IC InChI=1S/C10H7N3OS/c11-6-8-9(14)13-15-10(8)12-7-4-2-1-3-5-7/h1-5,12H,(H,13,14)
DMX6R0H CS C1=CC=C(C=C1)NC2=C(C(=O)NS2)C#N
DMX6R0H IK GHXPCAXQBVCFNU-UHFFFAOYSA-N
DMX6R0H IU 5-anilino-3-oxo-1,2-thiazole-4-carbonitrile
DMX6R0H CA CAS 1137-65-1
DMX6R0H CB CHEBI:107126
DMX6R0H DE Discovery agent
DM3B6A8 ID DM3B6A8
DM3B6A8 DN 5-Phenyl-pentanoic acid benzyl-hydroxy-amide
DM3B6A8 HS Investigative
DM3B6A8 SN N-benzyl-N-hydroxy-5-phenylpentanamide; 158999-12-3; N-Benzyl-N-hydroxy-5-phenylpentamide; CHEMBL301253; N-Bhpp; AC1L4IPK; N-Hydroxy-N-(phenylmethyl)benzenepentanamide; 5-Phenyl-pentanoic acid benzyl-hydroxy-amide; SCHEMBL1271129; DTXSID60166550; ZINC5138973; BDBM50016680; KB-301817; Benzenepentanamide, N-hydroxy-N-(phenylmethyl)-
DM3B6A8 DT Small molecular drug
DM3B6A8 PC 157806
DM3B6A8 MW 283.4
DM3B6A8 FM C18H21NO2
DM3B6A8 IC InChI=1S/C18H21NO2/c20-18(19(21)15-17-12-5-2-6-13-17)14-8-7-11-16-9-3-1-4-10-16/h1-6,9-10,12-13,21H,7-8,11,14-15H2
DM3B6A8 CS C1=CC=C(C=C1)CCCCC(=O)N(CC2=CC=CC=C2)O
DM3B6A8 IK MXZUASJHVOWCLX-UHFFFAOYSA-N
DM3B6A8 IU N-benzyl-N-hydroxy-5-phenylpentanamide
DM3B6A8 CA CAS 158999-12-3
DM3B6A8 DE Discovery agent
DMMWYFR ID DMMWYFR
DMMWYFR DN 5-Phenylsulfanyl-2,4-Quinazolinediamine
DMMWYFR HS Investigative
DMMWYFR SN 5-Phenylsulfanyl-2,4-quinazolinediamine; 5-PHENYLSULFANYL-2,4-QUINAZOLINEDIAMINE; TCMDC-131943; 5-(phenylsulfanyl)quinazoline-2,4-diamine; 5-phenylsulfanylquinazoline-2,4-diamine; TQ3; AC1L9JD6; SCHEMBL2125192; CHEMBL100239; BDBM18045; GW997; ZINC5974663; 5-Phenylthioquinazoline-2,4-diamine; 2,4-Diamino-5-phenylthio-quinazoline; DB04163; 5-Phenylsulfanyl-quinazoline-2,4-diamine
DMMWYFR DT Small molecular drug
DMMWYFR PC 446244
DMMWYFR MW 268.34
DMMWYFR FM C14H12N4S
DMMWYFR IC InChI=1S/C14H12N4S/c15-13-12-10(17-14(16)18-13)7-4-8-11(12)19-9-5-2-1-3-6-9/h1-8H,(H4,15,16,17,18)
DMMWYFR CS C1=CC=C(C=C1)SC2=CC=CC3=C2C(=NC(=N3)N)N
DMMWYFR IK BUFDQCGCADQQQY-UHFFFAOYSA-N
DMMWYFR IU 5-phenylsulfanylquinazoline-2,4-diamine
DMMWYFR DE Discovery agent
DMQMZ0Y ID DMQMZ0Y
DMQMZ0Y DN 5'-phenylthio-ImmH
DMQMZ0Y HS Investigative
DMQMZ0Y DT Small molecular drug
DMQMZ0Y PC 135981935
DMQMZ0Y MW 358.4
DMQMZ0Y FM C17H18N4O3S
DMQMZ0Y IC InChI=1S/C17H18N4O3S/c22-15-11(7-25-9-4-2-1-3-5-9)21-13(16(15)23)10-6-18-14-12(10)19-8-20-17(14)24/h1-6,8,11,13,15-16,18,21-23H,7H2,(H,19,20,24)/t11-,13+,15-,16+/m1/s1
DMQMZ0Y CS C1=CC=C(C=C1)SC[C@@H]2[C@H]([C@H]([C@@H](N2)C3=CNC4=C3N=CNC4=O)O)O
DMQMZ0Y IK RILVLBFFRDXSEY-JMGFVUJMSA-N
DMQMZ0Y IU 7-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(phenylsulfanylmethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMQMZ0Y DE Discovery agent
DMGK05W ID DMGK05W
DMGK05W DN 5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate
DMGK05W HS Investigative
DMGK05W SN 5-PHOSPHORIBOSYL-1-(BETA-METHYLENE) PYROPHOSPHATE; AC1L9LOK; DB04294; 1-O-[(R)-hydroxy(phosphonomethyl)phosphoryl]-5-O-phosphono-alpha-D-ribofuranose; [[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]oxy-hydroxyphosphoryl]methylphosphonic acid
DMGK05W DT Small molecular drug
DMGK05W PC 448176
DMGK05W MW 388.1
DMGK05W FM C6H15O13P3
DMGK05W IC InChI=1S/C6H15O13P3/c7-4-3(1-17-22(14,15)16)18-6(5(4)8)19-21(12,13)2-20(9,10)11/h3-8H,1-2H2,(H,12,13)(H2,9,10,11)(H2,14,15,16)/t3-,4-,5-,6-/m1/s1
DMGK05W CS C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(CP(=O)(O)O)O)O)O)OP(=O)(O)O
DMGK05W IK JFMKBQDEISBIPL-KVTDHHQDSA-N
DMGK05W IU [[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]oxy-hydroxyphosphoryl]methylphosphonic acid
DMGK05W DE Discovery agent
DM6A902 ID DM6A902
DM6A902 DN 5-propenyl-2'-deoxyuridine triphosphate
DM6A902 HS Investigative
DM6A902 DE Discovery agent
DM762FY ID DM762FY
DM762FY DN 5-propenyl-arabinofuranosyluracil 5'-triphosphate
DM762FY HS Investigative
DM762FY DT Small molecular drug
DM762FY PC 56603747
DM762FY MW 524.2
DM762FY FM C12H19N2O15P3
DM762FY IC InChI=1S/C12H19N2O15P3/c1-2-3-6(27-31(22,23)29-32(24,25)28-30(19,20)21)10-8(16)9(17)11(26-10)14-5-4-7(15)13-12(14)18/h2-6,8-11,16-17H,1H3,(H,22,23)(H,24,25)(H,13,15,18)(H2,19,20,21)/b3-2+/t6?,8-,9-,10+,11?/m0/s1
DM762FY CS C/C=C/C([C@@H]1[C@H]([C@@H](C(O1)N2C=CC(=O)NC2=O)O)O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM762FY IK XLORWTLPILWCFG-GPJQKZQFSA-N
DM762FY IU [[(E)-1-[(2S,3S,4S)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]but-2-enoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate
DM762FY DE Discovery agent
DMSPVXM ID DMSPVXM
DMSPVXM DN 5-Propyl-1H-pyrazole-3-carboxylic acid
DMSPVXM HS Investigative
DMSPVXM SN 3-propyl-1H-pyrazole-5-carboxylic acid; 76424-47-0; 5-Propyl-1H-pyrazole-3-carboxylic acid; 5-Propyl-2H-pyrazole-3-carboxylic acid; CHEMBL237788; 3-n-propyl-1H-pyrazole-5-carboxylic acid; AC1LDWNQ; BAS 01543590; SCHEMBL1092; AC1Q2V2W; Oprea1_206890; ZINC39600; CTK6D4610; KS-00003OFY; CTK2H6772; DTXSID20350296; MolPort-001-965-385; QYPSYPPSHXDFLV-UHFFFAOYSA-N; MolPort-000-929-573; HMS1697E16; 3-propylpyrazole-5-carboxylic acid; BDBM50220850; BBL031087; STL244838; KM1764; 9410AE; AKOS000136076; AKOS000646963; MS-2036; MCULE-2411097064
DMSPVXM DT Small molecular drug
DMSPVXM PC 676464
DMSPVXM MW 154.17
DMSPVXM FM C7H10N2O2
DMSPVXM IC InChI=1S/C7H10N2O2/c1-2-3-5-4-6(7(10)11)9-8-5/h4H,2-3H2,1H3,(H,8,9)(H,10,11)
DMSPVXM CS CCCC1=CC(=NN1)C(=O)O
DMSPVXM IK QYPSYPPSHXDFLV-UHFFFAOYSA-N
DMSPVXM IU 5-propyl-1H-pyrazole-3-carboxylic acid
DMSPVXM CA CAS 76424-47-0
DMSPVXM DE Discovery agent
DM9IHV6 ID DM9IHV6
DM9IHV6 DN 5-propyl-2'-deoxyuridine
DM9IHV6 HS Investigative
DM9IHV6 SN 5-Propyl-2'-deoxyuridine; 27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione
DM9IHV6 DT Small molecular drug
DM9IHV6 PC 160155
DM9IHV6 MW 270.28
DM9IHV6 FM C12H18N2O5
DM9IHV6 IC InChI=1S/C12H18N2O5/c1-2-3-7-5-14(12(18)13-11(7)17)10-4-8(16)9(6-15)19-10/h5,8-10,15-16H,2-4,6H2,1H3,(H,13,17,18)/t8-,9+,10+/m0/s1
DM9IHV6 CS CCCC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
DM9IHV6 IK MBERTAKFBYOAHR-IVZWLZJFSA-N
DM9IHV6 IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione
DM9IHV6 CA CAS 27826-74-0
DM9IHV6 DE Discovery agent
DM2W0AD ID DM2W0AD
DM2W0AD DN 5-p-Tolyl-1H-[1,2,3]triazole
DM2W0AD HS Investigative
DM2W0AD SN 4-(p-Tolyl)-1H-1,2,3-triazole; 5301-96-2; 4-(p-Tolyl)-2H-1,2,3-triazole; 5-(4-methylphenyl)-1H-1,2,3-triazole; 1H-1,2,3-Triazole, 4-(4-methylphenyl)-; 4-(4-methylphenyl)-2H-triazole; 5-(p-Tolyl)-1H-1,2,3-triazole; 59066-81-8; v-Triazole, 4-p-tolyl-; AC1LC4W8; SCHEMBL20848; 1,2,3-triazole analogue, 3; CHEMBL193610; CTK1G1560; BDBM17447; DTXSID60344093; ZPCIKQLLQORQCV-UHFFFAOYSA-N; MolPort-023-332-536; 4-p-tolyl-1H-1,2,3-triazole; ZINC13671868; ANW-65599; AKOS015907809; FCH4165656; KS-0000101Z; SC-23256; AJ-64294; AK-90097
DM2W0AD DT Small molecular drug
DM2W0AD PC 594397
DM2W0AD MW 159.19
DM2W0AD FM C9H9N3
DM2W0AD IC InChI=1S/C9H9N3/c1-7-2-4-8(5-3-7)9-6-10-12-11-9/h2-6H,1H3,(H,10,11,12)
DM2W0AD CS CC1=CC=C(C=C1)C2=NNN=C2
DM2W0AD IK ZPCIKQLLQORQCV-UHFFFAOYSA-N
DM2W0AD IU 4-(4-methylphenyl)-2H-triazole
DM2W0AD CA CAS 29385-43-1
DM2W0AD DE Discovery agent
DMV4ICS ID DMV4ICS
DMV4ICS DN 5-p-Tolylsulfanyl-quinazoline-2,4-diamine
DMV4ICS HS Investigative
DMV4ICS SN 5-(4-Tolylthio)-2,4-diaminoquinazoline; 168910-32-5; 5-[(4-METHYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE; CHEMBL83547; 5-[(4-methylphenyl)sulfanyl]quinazoline-2,4-diamine; TQ4; Maybridge3_004364; AC1L9JD9; Oprea1_160965; SCHEMBL2126685; BDBM18046; CTK0E5148; DTXSID80332215; MolPort-002-910-071; HMS1443G08; GW578; ZINC172633; HMS3604M19; CCG-44692; AKOS027447345; MCULE-8600056307; DB04306; IDI1_015751; 5-(p-Tolylthio)quinazoline-2,4-diamine; RT-010103; 5-(p-tolylsulfanyl)quinazoline-2,4-diamine; FT-0675290
DMV4ICS DT Small molecular drug
DMV4ICS PC 446245
DMV4ICS MW 282.4
DMV4ICS FM C15H14N4S
DMV4ICS IC InChI=1S/C15H14N4S/c1-9-5-7-10(8-6-9)20-12-4-2-3-11-13(12)14(16)19-15(17)18-11/h2-8H,1H3,(H4,16,17,18,19)
DMV4ICS CS CC1=CC=C(C=C1)SC2=CC=CC3=C2C(=NC(=N3)N)N
DMV4ICS IK UOJFGEAPSYQDIP-UHFFFAOYSA-N
DMV4ICS IU 5-(4-methylphenyl)sulfanylquinazoline-2,4-diamine
DMV4ICS CA CAS 168910-32-5
DMV4ICS DE Discovery agent
DMLRM9Z ID DMLRM9Z
DMLRM9Z DN 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one
DMLRM9Z HS Investigative
DMLRM9Z SN CHEMBL459071; 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one; 5-(pyrid-3-yl)-2h-indolin-2-one; SCHEMBL748904; SCHEMBL6840746; LRXSVYIRRDZVNQ-UHFFFAOYSA-N; BDBM50273706; 220904-98-3
DMLRM9Z DT Small molecular drug
DMLRM9Z PC 12050204
DMLRM9Z MW 210.23
DMLRM9Z FM C13H10N2O
DMLRM9Z IC InChI=1S/C13H10N2O/c16-13-7-11-6-9(3-4-12(11)15-13)10-2-1-5-14-8-10/h1-6,8H,7H2,(H,15,16)
DMLRM9Z CS C1C2=C(C=CC(=C2)C3=CN=CC=C3)NC1=O
DMLRM9Z IK LRXSVYIRRDZVNQ-UHFFFAOYSA-N
DMLRM9Z IU 5-pyridin-3-yl-1,3-dihydroindol-2-one
DMLRM9Z DE Discovery agent
DMQYIBC ID DMQYIBC
DMQYIBC DN 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one
DMQYIBC HS Investigative
DMQYIBC SN 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one; CHEMBL448743; 5-(pyridin-3-yl)-2,3-dihydroinden-1-one; 5-Pyridin-3-yl-1-indanone; 5-(3-Pyridyl)-1-indanone; SCHEMBL6205709; CTK8E5276; QNSOPUXDEXJMIY-UHFFFAOYSA-N; BDBM50273704; ZINC40829496; 255895-87-5; TX-011073
DMQYIBC DT Small molecular drug
DMQYIBC PC 18407230
DMQYIBC MW 209.24
DMQYIBC FM C14H11NO
DMQYIBC IC InChI=1S/C14H11NO/c16-14-6-4-11-8-10(3-5-13(11)14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2
DMQYIBC CS C1CC(=O)C2=C1C=C(C=C2)C3=CN=CC=C3
DMQYIBC IK QNSOPUXDEXJMIY-UHFFFAOYSA-N
DMQYIBC IU 5-pyridin-3-yl-2,3-dihydroinden-1-one
DMQYIBC DE Discovery agent
DMZQPTU ID DMZQPTU
DMZQPTU DN 5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime
DMZQPTU HS Investigative
DMZQPTU SN SCHEMBL3649264; 2-Thiophenecarboxaldehyde, 5-(3-pyridinyl)-, oxime
DMZQPTU DT Small molecular drug
DMZQPTU PC 91196339
DMZQPTU MW 204.25
DMZQPTU FM C10H8N2OS
DMZQPTU IC InChI=1S/C10H8N2OS/c13-12-7-9-3-4-10(14-9)8-2-1-5-11-6-8/h1-6H,7H2
DMZQPTU CS C1=CC(=CN=C1)C2=CC=C(S2)CN=O
DMZQPTU IK JUZUBCBEFKWHQP-UHFFFAOYSA-N
DMZQPTU IU 3-[5-(nitrosomethyl)thiophen-2-yl]pyridine
DMZQPTU DE Discovery agent
DMNYQGS ID DMNYQGS
DMNYQGS DN 5''-Quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine
DMNYQGS HS Investigative
DMNYQGS SN CHEMBL362710; BDBM50151351; 5''-(quinolin-4-yl)-2,4''-bithiazol-2''-amine
DMNYQGS DT Small molecular drug
DMNYQGS PC 11197671
DMNYQGS MW 310.4
DMNYQGS FM C15H10N4S2
DMNYQGS IC InChI=1S/C15H10N4S2/c16-15-19-12(14-18-7-8-20-14)13(21-15)10-5-6-17-11-4-2-1-3-9(10)11/h1-8H,(H2,16,19)
DMNYQGS CS C1=CC=C2C(=C1)C(=CC=N2)C3=C(N=C(S3)N)C4=NC=CS4
DMNYQGS IK JHZIIPPDVRVCNU-UHFFFAOYSA-N
DMNYQGS IU 5-quinolin-4-yl-4-(1,3-thiazol-2-yl)-1,3-thiazol-2-amine
DMNYQGS DE Discovery agent
DMVX063 ID DMVX063
DMVX063 DN 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
DMVX063 HS Investigative
DMVX063 SN 5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione; AS-605240; 648450-29-7; AS605240; AS 605240; CHEMBL568150; (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione; (5E)-5-(QUINOXALIN-6-YLMETHYLENE)-1,3-THIAZOLIDINE-2,4-DIONE; 5-(6-QUINOXALINYLMETHYLENE)-2,4-THIAZOLIDINEDIONE; QYT; (Z)-5-(Quinoxalin-6-ylmethylene)thiazolidine-2,4-dione; PI 3-Kg inhibitor; 2a5u; AC1NRCY0; 5-(quinoxalin-6-ylmethylene)thiazolidine-2,4-dione; SCHEMBL668616; GTPL6023; AOB3848; MolPort-006-169-944; HMS3650I15
DMVX063 DT Small molecular drug
DMVX063 PC 5289247
DMVX063 MW 257.269
DMVX063 FM C12H7N3O2S
DMVX063 IC InChI=1S/C12H7N3O2S/c16-11-10(18-12(17)15-11)6-7-1-2-8-9(5-7)14-4-3-13-8/h1-6H,(H,15,16,17)/b10-6-
DMVX063 CS C1=CC2=NC=CN=C2C=C1/C=C\\3/C(=O)NC(=O)S3
DMVX063 IK SQWZFLMPDUSYGV-POHAHGRESA-N
DMVX063 IU (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
DMVX063 CB CHEBI:45302
DMVX063 DE Discovery agent
DM0PQH1 ID DM0PQH1
DM0PQH1 DN 5'-S-ethyl-5'-thioadenosine
DM0PQH1 HS Investigative
DM0PQH1 SN 5'-S-ethyl-5'-thioadenosine; S-adenosylethane; 5'-ethylthioadenosine; CHEBI:74046; SCHEMBL998091; CHEMBL195660; 5'-Deoxy-5'-(ethylthio)adenosine; DB07052; (2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[(ethylsulfanyl)methyl]oxolane-3,4-diol
DM0PQH1 DT Small molecular drug
DM0PQH1 PC 10041129
DM0PQH1 MW 311.36
DM0PQH1 FM C12H17N5O3S
DM0PQH1 IC InChI=1S/C12H17N5O3S/c1-2-21-3-6-8(18)9(19)12(20-6)17-5-16-7-10(13)14-4-15-11(7)17/h4-6,8-9,12,18-19H,2-3H2,1H3,(H2,13,14,15)/t6-,8-,9-,12-/m1/s1
DM0PQH1 CS CCSC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM0PQH1 IK HMXHURAGFHWODC-WOUKDFQISA-N
DM0PQH1 IU (2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-(ethylsulfanylmethyl)oxolane-3,4-diol
DM0PQH1 CB CHEBI:74046
DM0PQH1 DE Discovery agent
DM3Z6G4 ID DM3Z6G4
DM3Z6G4 DN 5S-HETE
DM3Z6G4 HS Investigative
DM3Z6G4 SN 5-Hydroxyeicosatetraenoic acid; 5(S)-HETE; 5-Hete; 5-Hydroxyeicosatetraenoate; 5-Hydroxy-6,8,11,14-eicosatetraenoic acid; UNII-467RNW8T91; 70608-72-9; CHEMBL164813; CHEBI:28209; 5(S)-hydroxyeicosatetraenoic acid; 467RNW8T91; 6,8,11,14-Eicosatetraenoic acid, 5-hydroxy-, (S-(E,Z,Z,Z))-; (5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid; 5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid; (6E,8Z,11Z,14Z)-(5S)-5-Hydroxyicosa-6,8,11,14-tetraenoic acid; 5-(S)-hydroxyeicosatetraenoic acid; AC1NQXIH; BSPBio_001443; 5-(S)-hydroxyeicosatetraenoic acid
DM3Z6G4 DT Small molecular drug
DM3Z6G4 PC 5280733
DM3Z6G4 MW 320.5
DM3Z6G4 FM C20H32O3
DM3Z6G4 IC InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16,19,21H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+/t19-/m1/s1
DM3Z6G4 CS CCCCC/C=C\\C/C=C\\C/C=C\\C=C\\[C@H](CCCC(=O)O)O
DM3Z6G4 IK KGIJOOYOSFUGPC-JGKLHWIESA-N
DM3Z6G4 IU (5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid
DM3Z6G4 CA CAS 330796-62-8
DM3Z6G4 CB CHEBI:28209
DM3Z6G4 DE Discovery agent
DME1304 ID DME1304
DME1304 DN 5S-HPETE
DME1304 HS Investigative
DME1304 SN 5-(S)-hydroperoxyeicosatetraenoic acid; 5S-HpETE
DME1304 DT Small molecular drug
DME1304 PC 5280778
DME1304 MW 336.5
DME1304 FM C20H32O4
DME1304 IC InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(24-23)17-15-18-20(21)22/h6-7,9-10,12-14,16,19,23H,2-5,8,11,15,17-18H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-14+/t19-/m1/s1
DME1304 CS CCCCC/C=C\\C/C=C\\C/C=C\\C=C\\[C@H](CCCC(=O)O)OO
DME1304 IK JNUUNUQHXIOFDA-JGKLHWIESA-N
DME1304 IU (5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoic acid
DME1304 CA CAS 71774-08-8
DME1304 CB CHEBI:15632
DME1304 DE Discovery agent
DMCG6EK ID DMCG6EK
DMCG6EK DN 5-tert-Butyl-2-(4-ethynyl-phenyl)-[1,3]dithiane
DMCG6EK HS Investigative
DMCG6EK SN 120076-03-1; 1,3-Dithiane, 5-(1,1-dimethylethyl)-2-(4-ethynylphenyl)-, trans-; ACMC-20mopv; CHEMBL90399; SCHEMBL8950548; CTK0F9221; DTXSID40625630; HKLYPSSDHPAOJM-UHFFFAOYSA-N; 2-(4-ethynylphenyl)-5-t-butyl-1,3-dithiane; 5-tert-Butyl-2-(4-ethynylphenyl)-1,3-dithiane
DMCG6EK DT Small molecular drug
DMCG6EK PC 22421021
DMCG6EK MW 276.5
DMCG6EK FM C16H20S2
DMCG6EK IC InChI=1S/C16H20S2/c1-5-12-6-8-13(9-7-12)15-17-10-14(11-18-15)16(2,3)4/h1,6-9,14-15H,10-11H2,2-4H3
DMCG6EK CS CC(C)(C)C1CSC(SC1)C2=CC=C(C=C2)C#C
DMCG6EK IK HKLYPSSDHPAOJM-UHFFFAOYSA-N
DMCG6EK IU 5-tert-butyl-2-(4-ethynylphenyl)-1,3-dithiane
DMCG6EK CA CAS 120076-03-1
DMCG6EK DE Discovery agent
DMQK32F ID DMQK32F
DMQK32F DN 5-tert-Butyl-2-(4-fluoro-phenyl)-[1,3]dithiane
DMQK32F HS Investigative
DMQK32F SN CHEMBL315953; ZINC584614859; ZINC584614855
DMQK32F DT Small molecular drug
DMQK32F PC 10015993
DMQK32F MW 270.4
DMQK32F FM C14H19FS2
DMQK32F IC InChI=1S/C14H19FS2/c1-14(2,3)11-8-16-13(17-9-11)10-4-6-12(15)7-5-10/h4-7,11,13H,8-9H2,1-3H3
DMQK32F CS CC(C)(C)C1CSC(SC1)C2=CC=C(C=C2)F
DMQK32F IK MFJQBAHBCVIQEE-UHFFFAOYSA-N
DMQK32F IU 5-tert-butyl-2-(4-fluorophenyl)-1,3-dithiane
DMQK32F DE Discovery agent
DMF4RGW ID DMF4RGW
DMF4RGW DN 5-thia-8,11,14,17-eicosatetraenoic acid
DMF4RGW HS Investigative
DMF4RGW SN CHEMBL460444; 5-thia-8,11,14,17-eicosatetraenoic acid; BDBM50242353; (8Z,11Z,14Z,17Z)-5-Thia-8,11,14,17-icosatetraenoic acid
DMF4RGW DT Small molecular drug
DMF4RGW PC 10019057
DMF4RGW MW 322.5
DMF4RGW FM C19H30O2S
DMF4RGW IC InChI=1S/C19H30O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-22-18-15-16-19(20)21/h3-4,6-7,9-10,12-13H,2,5,8,11,14-18H2,1H3,(H,20,21)/b4-3-,7-6-,10-9-,13-12-
DMF4RGW CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCSCCCC(=O)O
DMF4RGW IK JUGSAWFPXQSLMJ-LTKCOYKYSA-N
DMF4RGW IU 4-[(3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraenyl]sulfanylbutanoic acid
DMF4RGW DE Discovery agent
DMTB91D ID DMTB91D
DMTB91D DN 5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one
DMTB91D HS Investigative
DMTB91D SN CHEMBL498086; 24127-35-3; KCIOJLFKVQHRPU-UHFFFAOYSA-N; 5,6-dihydro-5-(p-tolylsulfonyl)-7h-dibenz[b,d]azepin-7-one; 5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one; AC1LCKZQ; TimTec1_004880; Oprea1_188679; SCHEMBL3034555; CTK8H7702; HMS1547N18; 7H-Dibenz[b,d]azepin-7-one, 5,6-dihydro-5-(p-tolylsulfonyl)-; BDBM50279063; KB-310270; 5-(4-methylphenyl)sulfonyl-6H-benzo[d][1]benzazepin-7-one; 5-(Toluene-4-sulfonyl)-5,6-dihydro-dibenzo[b,d]azepin-7-one; 5-[(4-Methylphenyl)sulfonyl]-5,6-dihydro-7H-dibenzo[b,d]azepin-7-one #
DMTB91D DT Small molecular drug
DMTB91D PC 602095
DMTB91D MW 363.4
DMTB91D FM C21H17NO3S
DMTB91D IC InChI=1S/C21H17NO3S/c1-15-10-12-16(13-11-15)26(24,25)22-14-21(23)19-8-3-2-6-17(19)18-7-4-5-9-20(18)22/h2-13H,14H2,1H3
DMTB91D CS CC1=CC=C(C=C1)S(=O)(=O)N2CC(=O)C3=CC=CC=C3C4=CC=CC=C42
DMTB91D IK KCIOJLFKVQHRPU-UHFFFAOYSA-N
DMTB91D IU 5-(4-methylphenyl)sulfonyl-6H-benzo[d][1]benzazepin-7-one
DMTB91D DE Discovery agent
DMOR04W ID DMOR04W
DMOR04W DN 6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione
DMOR04W HS Investigative
DMOR04W DE Discovery agent
DM5RX0K ID DM5RX0K
DM5RX0K DN 6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one
DM5RX0K HS Investigative
DM5RX0K SN benzoannulenone 1; AC1NS6NT; CHEMBL327029; BDBM5326; 6-(1H-benzimidazol-2-yl)benzo[7]annulen-7-one
DM5RX0K DT Small molecular drug
DM5RX0K PC 5329369
DM5RX0K MW 272.3
DM5RX0K FM C18H12N2O
DM5RX0K IC InChI=1S/C18H12N2O/c21-17-10-9-12-5-1-2-6-13(12)11-14(17)18-19-15-7-3-4-8-16(15)20-18/h1-11H,(H,19,20)
DM5RX0K CS C1=CC=C2C=C(C(=O)C=CC2=C1)C3=NC4=CC=CC=C4N3
DM5RX0K IK OZPIXWTVOIXFBH-UHFFFAOYSA-N
DM5RX0K IU 6-(1H-benzimidazol-2-yl)benzo[7]annulen-7-one
DM5RX0K DE Discovery agent
DM1TOFD ID DM1TOFD
DM1TOFD DN 6-(1H-Indole-2-sulfonyl)-2H-pyridazin-3-one
DM1TOFD HS Investigative
DM1TOFD SN indole, 20; CHEMBL72278; SCHEMBL4454291; BDBM16454; HXNAGYMCTAINEA-UHFFFAOYSA-N; Heterocyclic Sulfonylpyridazinone, 19a; 6-(indole-2-sulfonyl)-2H-pyridazin-3-one
DM1TOFD DT Small molecular drug
DM1TOFD PC 9856809
DM1TOFD MW 275.29
DM1TOFD FM C12H9N3O3S
DM1TOFD IC InChI=1S/C12H9N3O3S/c16-10-5-6-11(15-14-10)19(17,18)12-7-8-3-1-2-4-9(8)13-12/h1-7,13H,(H,14,16)
DM1TOFD CS C1=CC=C2C(=C1)C=C(N2)S(=O)(=O)C3=NNC(=O)C=C3
DM1TOFD IK HXNAGYMCTAINEA-UHFFFAOYSA-N
DM1TOFD IU 3-(1H-indol-2-ylsulfonyl)-1H-pyridazin-6-one
DM1TOFD DE Discovery agent
DMRU963 ID DMRU963
DMRU963 DN 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMRU963 HS Investigative
DMRU963 SN CHEMBL195289; 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3930290; VLJUOFGVEJAFFK-UHFFFAOYSA-N; ZINC13645040; BDBM50168359
DMRU963 DT Small molecular drug
DMRU963 PC 10308206
DMRU963 MW 272.24
DMRU963 FM C16H10F2O2
DMRU963 IC InChI=1S/C16H10F2O2/c17-14-8-16(20)15(18)7-13(14)11-2-1-10-6-12(19)4-3-9(10)5-11/h1-8,19-20H
DMRU963 CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C=C3F)O)F
DMRU963 IK VLJUOFGVEJAFFK-UHFFFAOYSA-N
DMRU963 IU 6-(2,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol
DMRU963 DE Discovery agent
DMFALTY ID DMFALTY
DMFALTY DN 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMFALTY HS Investigative
DMFALTY SN CHEMBL192621; 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3924515; AUZLISXBMGKYGA-UHFFFAOYSA-N; ZINC13645047; BDBM50168333
DMFALTY DT Small molecular drug
DMFALTY PC 10214708
DMFALTY MW 272.24
DMFALTY FM C16H10F2O2
DMFALTY IC InChI=1S/C16H10F2O2/c17-14-7-13(20)8-15(18)16(14)11-2-1-10-6-12(19)4-3-9(10)5-11/h1-8,19-20H
DMFALTY CS C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3F)O)F
DMFALTY IK AUZLISXBMGKYGA-UHFFFAOYSA-N
DMFALTY IU 6-(2,6-difluoro-4-hydroxyphenyl)naphthalen-2-ol
DMFALTY DE Discovery agent
DMA9LFR ID DMA9LFR
DMA9LFR DN 6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMA9LFR HS Investigative
DMA9LFR SN CHEMBL381869
DMA9LFR DT Small molecular drug
DMA9LFR PC 11552020
DMA9LFR MW 349.4
DMA9LFR FM C21H19NO4
DMA9LFR IC InChI=1S/C21H19NO4/c1-14(23)16-4-2-3-5-17(16)15-6-7-20-18(12-15)19(24)13-21(26-20)22-8-10-25-11-9-22/h2-7,12-13H,8-11H2,1H3
DMA9LFR CS CC(=O)C1=CC=CC=C1C2=CC3=C(C=C2)OC(=CC3=O)N4CCOCC4
DMA9LFR IK IMYDVWVTZRVBCX-UHFFFAOYSA-N
DMA9LFR IU 6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMA9LFR DE Discovery agent
DMO724D ID DMO724D
DMO724D DN 6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol
DMO724D HS Investigative
DMO724D SN CHEMBL57470; ZINC29557762; BDBM50025207
DMO724D DT Small molecular drug
DMO724D PC 44299852
DMO724D MW 245.27
DMO724D FM C14H15NO3
DMO724D IC InChI=1S/C14H15NO3/c15-8-7-10-3-6-12(17)14(18)13(10)9-1-4-11(16)5-2-9/h1-6,16-18H,7-8,15H2
DMO724D CS C1=CC(=CC=C1C2=C(C=CC(=C2O)O)CCN)O
DMO724D IK AHHHSPLFRASFOU-UHFFFAOYSA-N
DMO724D IU 4-(2-aminoethyl)-3-(4-hydroxyphenyl)benzene-1,2-diol
DMO724D DE Discovery agent
DMI8KOF ID DMI8KOF
DMI8KOF DN 6-(2-Amino-ethyl)-biphenyl-2,3-diol
DMI8KOF HS Investigative
DMI8KOF SN CHEMBL299511; 6-(2-Amino-ethyl)-biphenyl-2,3-diol; BDBM50025204
DMI8KOF DT Small molecular drug
DMI8KOF PC 13678304
DMI8KOF MW 229.27
DMI8KOF FM C14H15NO2
DMI8KOF IC InChI=1S/C14H15NO2/c15-9-8-11-6-7-12(16)14(17)13(11)10-4-2-1-3-5-10/h1-7,16-17H,8-9,15H2
DMI8KOF CS C1=CC=C(C=C1)C2=C(C=CC(=C2O)O)CCN
DMI8KOF IK DAKLNHHLHPIOPS-UHFFFAOYSA-N
DMI8KOF IU 4-(2-aminoethyl)-3-phenylbenzene-1,2-diol
DMI8KOF DE Discovery agent
DMXFRW9 ID DMXFRW9
DMXFRW9 DN 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine
DMXFRW9 HS Investigative
DMXFRW9 SN CHEMBL458612; 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine; SCHEMBL14241034; ZINC3818486; BDBM50274720; AKOS022180470; AJ-45722
DMXFRW9 DT Small molecular drug
DMXFRW9 PC 44224215
DMXFRW9 MW 257.31
DMXFRW9 FM C13H11N3OS
DMXFRW9 IC InChI=1S/C13H11N3OS/c14-10-3-1-2-4-11(10)17-8-5-6-9-12(7-8)18-16-13(9)15/h1-7H,14H2,(H2,15,16)
DMXFRW9 CS C1=CC=C(C(=C1)N)OC2=CC3=C(C=C2)C(=NS3)N
DMXFRW9 IK HQCTTYOADNAJJR-UHFFFAOYSA-N
DMXFRW9 IU 6-(2-aminophenoxy)-1,2-benzothiazol-3-amine
DMXFRW9 DE Discovery agent
DMUD2R9 ID DMUD2R9
DMUD2R9 DN 6-(2-benzylisoindolin-5-yloxy)nicotinamide
DMUD2R9 HS Investigative
DMUD2R9 SN CHEMBL238362; 6-(2-benzylisoindolin-5-yloxy)nicotinamide; SCHEMBL3690327; GGVSFVBTUMOASO-UHFFFAOYSA-N; BDBM50226248
DMUD2R9 DT Small molecular drug
DMUD2R9 PC 44434060
DMUD2R9 MW 345.4
DMUD2R9 FM C21H19N3O2
DMUD2R9 IC InChI=1S/C21H19N3O2/c22-21(25)16-7-9-20(23-11-16)26-19-8-6-17-13-24(14-18(17)10-19)12-15-4-2-1-3-5-15/h1-11H,12-14H2,(H2,22,25)
DMUD2R9 CS C1C2=C(CN1CC3=CC=CC=C3)C=C(C=C2)OC4=NC=C(C=C4)C(=O)N
DMUD2R9 IK GGVSFVBTUMOASO-UHFFFAOYSA-N
DMUD2R9 IU 6-[(2-benzyl-1,3-dihydroisoindol-5-yl)oxy]pyridine-3-carboxamide
DMUD2R9 DE Discovery agent
DM9LKXD ID DM9LKXD
DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide
DM9LKXD HS Investigative
DM9LKXD SN CHEMBL344920; 651767-99-6; 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-
DM9LKXD DT Small molecular drug
DM9LKXD PC 9927379
DM9LKXD MW 327.22
DM9LKXD FM C14H19BrN2O2
DM9LKXD IC InChI=1S/C14H19BrN2O2/c15-11-14(19)16-10-6-2-5-9-13(18)17-12-7-3-1-4-8-12/h1,3-4,7-8H,2,5-6,9-11H2,(H,16,19)(H,17,18)
DM9LKXD CS C1=CC=C(C=C1)NC(=O)CCCCCNC(=O)CBr
DM9LKXD IK HWYLREOMBVUGJQ-UHFFFAOYSA-N
DM9LKXD IU 6-[(2-bromoacetyl)amino]-N-phenylhexanamide
DM9LKXD CA CAS 651767-99-6
DM9LKXD DE Discovery agent
DMYDHLN ID DMYDHLN
DMYDHLN DN 6-(2-Bromo-benzenesulfonyl)-2H-pyridazin-3-one
DMYDHLN HS Investigative
DMYDHLN SN CHEMBL74579; SCHEMBL6206670; BDBM16445; 6-phenylsulfonylpyridazin-2H-3-one, 7; Phenyl-Substituted Sulfonylpyridazinone, 8a
DMYDHLN DT Small molecular drug
DMYDHLN PC 9901432
DMYDHLN MW 315.15
DMYDHLN FM C10H7BrN2O3S
DMYDHLN IC InChI=1S/C10H7BrN2O3S/c11-7-3-1-2-4-8(7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DMYDHLN CS C1=CC=C(C(=C1)S(=O)(=O)C2=NNC(=O)C=C2)Br
DMYDHLN IK MLFKNCYUUMLHTD-UHFFFAOYSA-N
DMYDHLN IU 3-(2-bromophenyl)sulfonyl-1H-pyridazin-6-one
DMYDHLN DE Discovery agent
DMTPAMS ID DMTPAMS
DMTPAMS DN 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DMTPAMS HS Investigative
DMTPAMS SN CHEMBL195311; 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3932692; FNSIACDWDZGUHN-UHFFFAOYSA-N; BDBM50168347; ZINC13645053
DMTPAMS DT Small molecular drug
DMTPAMS PC 10308197
DMTPAMS MW 270.71
DMTPAMS FM C16H11ClO2
DMTPAMS IC InChI=1S/C16H11ClO2/c17-16-9-14(19)5-6-15(16)12-2-1-11-8-13(18)4-3-10(11)7-12/h1-9,18-19H
DMTPAMS CS C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3)O)Cl
DMTPAMS IK FNSIACDWDZGUHN-UHFFFAOYSA-N
DMTPAMS IU 6-(2-chloro-4-hydroxyphenyl)naphthalen-2-ol
DMTPAMS DE Discovery agent
DM2Y9O4 ID DM2Y9O4
DM2Y9O4 DN 6-(2-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DM2Y9O4 HS Investigative
DM2Y9O4 SN CHEMBL72699; SCHEMBL6207180; BDBM16444; 6-phenylsulfonylpyridazin-2H-3-one, 6; Phenyl-Substituted Sulfonylpyridazinone, 8c
DM2Y9O4 DT Small molecular drug
DM2Y9O4 PC 9921581
DM2Y9O4 MW 270.69
DM2Y9O4 FM C10H7ClN2O3S
DM2Y9O4 IC InChI=1S/C10H7ClN2O3S/c11-7-3-1-2-4-8(7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DM2Y9O4 CS C1=CC=C(C(=C1)S(=O)(=O)C2=NNC(=O)C=C2)Cl
DM2Y9O4 IK FTLDTGWMVVXYAM-UHFFFAOYSA-N
DM2Y9O4 IU 3-(2-chlorophenyl)sulfonyl-1H-pyridazin-6-one
DM2Y9O4 DE Discovery agent
DM3VME7 ID DM3VME7
DM3VME7 DN 6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol
DM3VME7 HS Investigative
DM3VME7 SN CHEMBL60861; BDBM50025203
DM3VME7 DT Small molecular drug
DM3VME7 PC 13678327
DM3VME7 MW 329.4
DM3VME7 FM C20H27NO3
DM3VME7 IC InChI=1S/C20H27NO3/c1-3-12-21(13-4-2)14-11-16-7-10-18(23)20(24)19(16)15-5-8-17(22)9-6-15/h5-10,22-24H,3-4,11-14H2,1-2H3
DM3VME7 CS CCCN(CCC)CCC1=C(C(=C(C=C1)O)O)C2=CC=C(C=C2)O
DM3VME7 IK NTNWFRQRDDNMJY-UHFFFAOYSA-N
DM3VME7 IU 4-[2-(dipropylamino)ethyl]-3-(4-hydroxyphenyl)benzene-1,2-diol
DM3VME7 DE Discovery agent
DMNQWZO ID DMNQWZO
DMNQWZO DN 6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol
DMNQWZO HS Investigative
DMNQWZO SN CHEMBL300995; 6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol
DMNQWZO DT Small molecular drug
DMNQWZO PC 13678325
DMNQWZO MW 313.4
DMNQWZO FM C20H27NO2
DMNQWZO IC InChI=1S/C20H27NO2/c1-3-13-21(14-4-2)15-12-17-10-11-18(22)20(23)19(17)16-8-6-5-7-9-16/h5-11,22-23H,3-4,12-15H2,1-2H3
DMNQWZO CS CCCN(CCC)CCC1=C(C(=C(C=C1)O)O)C2=CC=CC=C2
DMNQWZO IK HDPTVXIDWCYRQU-UHFFFAOYSA-N
DMNQWZO IU 4-[2-(dipropylamino)ethyl]-3-phenylbenzene-1,2-diol
DMNQWZO DE Discovery agent
DM6Q3M7 ID DM6Q3M7
DM6Q3M7 DN 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DM6Q3M7 HS Investigative
DM6Q3M7 SN CHEMBL195878; 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3926652; MAFQDFZNSVYFEW-UHFFFAOYSA-N; ZINC13645034; BDBM50168350
DM6Q3M7 DT Small molecular drug
DM6Q3M7 PC 10125290
DM6Q3M7 MW 254.25
DM6Q3M7 FM C16H11FO2
DM6Q3M7 IC InChI=1S/C16H11FO2/c17-16-9-14(19)5-6-15(16)12-2-1-11-8-13(18)4-3-10(11)7-12/h1-9,18-19H
DM6Q3M7 CS C1=CC2=C(C=CC(=C2)O)C=C1C3=C(C=C(C=C3)O)F
DM6Q3M7 IK MAFQDFZNSVYFEW-UHFFFAOYSA-N
DM6Q3M7 IU 6-(2-fluoro-4-hydroxyphenyl)naphthalen-2-ol
DM6Q3M7 DE Discovery agent
DMQKR2W ID DMQKR2W
DMQKR2W DN 6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one
DMQKR2W HS Investigative
DMQKR2W SN 6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one; CHEMBL198119; SCHEMBL6205793; BDBM16600; AEDNYZQZIZUZTP-UHFFFAOYSA-N; Phenyl-Substituted Sulfonylpyridazinone, 8f
DMQKR2W DT Small molecular drug
DMQKR2W PC 9943009
DMQKR2W MW 254.24
DMQKR2W FM C10H7FN2O3S
DMQKR2W IC InChI=1S/C10H7FN2O3S/c11-7-3-1-2-4-8(7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DMQKR2W CS C1=CC=C(C(=C1)F)S(=O)(=O)C2=NNC(=O)C=C2
DMQKR2W IK AEDNYZQZIZUZTP-UHFFFAOYSA-N
DMQKR2W IU 3-(2-fluorophenyl)sulfonyl-1H-pyridazin-6-one
DMQKR2W DE Discovery agent
DME1JLM ID DME1JLM
DME1JLM DN 6-(2-Fluoropropyl)-4-methylpyridin-2-amine
DME1JLM HS Investigative
DME1JLM SN 6-(2-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL450726; 1146620-35-0; SCHEMBL13040574; BDBM50267272; 2-Pyridinamine, 6-(2-fluoropropyl)-4-methyl-
DME1JLM DT Small molecular drug
DME1JLM PC 42625451
DME1JLM MW 168.21
DME1JLM FM C9H13FN2
DME1JLM IC InChI=1S/C9H13FN2/c1-6-3-8(5-7(2)10)12-9(11)4-6/h3-4,7H,5H2,1-2H3,(H2,11,12)
DME1JLM CS CC1=CC(=NC(=C1)N)CC(C)F
DME1JLM IK MBHRCNFCHFHUKZ-UHFFFAOYSA-N
DME1JLM IU 6-(2-fluoropropyl)-4-methylpyridin-2-amine
DME1JLM CA CAS 1146620-35-0
DME1JLM DE Discovery agent
DMA2CPG ID DMA2CPG
DMA2CPG DN 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE
DMA2CPG HS Investigative
DMA2CPG SN 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE; GR157368; 1qhr; AC1O43NS; DB06861; (6R)-6-[(1R,2S)-2-hydroxycyclopentyl]-7-oxoheptanimidamide
DMA2CPG DT Small molecular drug
DMA2CPG PC 6323178
DMA2CPG MW 226.32
DMA2CPG FM C12H22N2O2
DMA2CPG IC InChI=1S/C12H22N2O2/c13-12(14)7-2-1-4-9(8-15)10-5-3-6-11(10)16/h8-11,16H,1-7H2,(H3,13,14)/t9-,10+,11-/m0/s1
DMA2CPG CS C1C[C@@H]([C@H](C1)O)[C@@H](CCCCC(=N)N)C=O
DMA2CPG IK FCDJKFJACUMSOZ-AXFHLTTASA-N
DMA2CPG IU (6R)-6-[(1R,2S)-2-hydroxycyclopentyl]-7-oxoheptanimidamide
DMA2CPG DE Discovery agent
DMM3798 ID DMM3798
DMM3798 DN 6-(2-Hydroxy-phenyl)-naphthalen-2-ol
DMM3798 HS Investigative
DMM3798 SN CHEMBL195058; 6-(2-hydroxyphenyl)-2-naphthol; 6-(2-Hydroxy-phenyl)-naphthalen-2-ol; 2-methyl-6-o-tolylnaphthalene; SCHEMBL3016027; SMFVAKMYNVSVKJ-UHFFFAOYSA-N; BDBM50168378
DMM3798 DT Small molecular drug
DMM3798 PC 11368353
DMM3798 MW 236.26
DMM3798 FM C16H12O2
DMM3798 IC InChI=1S/C16H12O2/c17-14-8-7-11-9-13(6-5-12(11)10-14)15-3-1-2-4-16(15)18/h1-10,17-18H
DMM3798 CS C1=CC=C(C(=C1)C2=CC3=C(C=C2)C=C(C=C3)O)O
DMM3798 IK SMFVAKMYNVSVKJ-UHFFFAOYSA-N
DMM3798 IU 6-(2-hydroxyphenyl)naphthalen-2-ol
DMM3798 DE Discovery agent
DMXZWOA ID DMXZWOA
DMXZWOA DN 6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one
DMXZWOA HS Investigative
DMXZWOA SN CHEMBL347379; 6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one; SCHEMBL10461779
DMXZWOA DT Small molecular drug
DMXZWOA PC 14373279
DMXZWOA MW 237.26
DMXZWOA FM C14H11N3O
DMXZWOA IC InChI=1S/C14H11N3O/c18-14-4-2-12-9-11(1-3-13(12)16-14)5-7-17-8-6-15-10-17/h1-10H,(H,16,18)/b7-5+
DMXZWOA CS C1=CC2=C(C=CC(=O)N2)C=C1/C=C/N3C=CN=C3
DMXZWOA IK ULTZJAJIZBBKSG-FNORWQNLSA-N
DMXZWOA IU 6-[(E)-2-imidazol-1-ylethenyl]-1H-quinolin-2-one
DMXZWOA DE Discovery agent
DM9P4LB ID DM9P4LB
DM9P4LB DN 6-(2-mercaptoacetamido)-N-phenylhexanamide
DM9P4LB HS Investigative
DM9P4LB SN CHEMBL178727; 6-(2-Mercaptoacetylamino)-N-Phenylhexanamide; 824970-14-1; 6-(2-mercaptoacetamido)-N-phenylhexanamide; 4cqf; SCHEMBL5998899; CTK3D8890; DTXSID50465903; ZINC13609328; BDBM50157884; AKOS030603047; N-phenyl-6-[(sulfanylacetyl)amino]hexanamide; N-Phenyl-6-[(mercaptoacetyl)amino]hexanamide; Hexanamide, 6-[(mercaptoacetyl)amino]-N-phenyl-; 6-(2-Mercapto-acetylamino)-hexanoic acid phenylamide
DM9P4LB DT Small molecular drug
DM9P4LB PC 11437457
DM9P4LB MW 280.39
DM9P4LB FM C14H20N2O2S
DM9P4LB IC InChI=1S/C14H20N2O2S/c17-13(16-12-7-3-1-4-8-12)9-5-2-6-10-15-14(18)11-19/h1,3-4,7-8,19H,2,5-6,9-11H2,(H,15,18)(H,16,17)
DM9P4LB CS C1=CC=C(C=C1)NC(=O)CCCCCNC(=O)CS
DM9P4LB IK ICMLRCZXRBTKLJ-UHFFFAOYSA-N
DM9P4LB IU N-phenyl-6-[(2-sulfanylacetyl)amino]hexanamide
DM9P4LB CA CAS 824970-14-1
DM9P4LB DE Discovery agent
DMQOJBN ID DMQOJBN
DMQOJBN DN 6-(2-phenethylisoindolin-5-yloxy)nicotinamide
DMQOJBN HS Investigative
DMQOJBN SN CHEMBL235154; 6-(2-phenethylisoindolin-5-yloxy)nicotinamide; SCHEMBL3696847
DMQOJBN DT Small molecular drug
DMQOJBN PC 44434061
DMQOJBN MW 359.4
DMQOJBN FM C22H21N3O2
DMQOJBN IC InChI=1S/C22H21N3O2/c23-22(26)17-7-9-21(24-13-17)27-20-8-6-18-14-25(15-19(18)12-20)11-10-16-4-2-1-3-5-16/h1-9,12-13H,10-11,14-15H2,(H2,23,26)
DMQOJBN CS C1C2=C(CN1CCC3=CC=CC=C3)C=C(C=C2)OC4=NC=C(C=C4)C(=O)N
DMQOJBN IK ACAQNMZIFFSQCU-UHFFFAOYSA-N
DMQOJBN IU 6-[[2-(2-phenylethyl)-1,3-dihydroisoindol-5-yl]oxy]pyridine-3-carboxamide
DMQOJBN DE Discovery agent
DMKXNP0 ID DMKXNP0
DMKXNP0 DN 6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine
DMKXNP0 HS Investigative
DMKXNP0 SN CHEMBL50379; 6-(2-phenylsulfanylethyl)pteridine-2,4-diamine; AC1L9YC2; 6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine; BDBM50127151; 2,4-Pteridinediamine, 6-[2-(phenylthio)ethyl]-
DMKXNP0 DT Small molecular drug
DMKXNP0 PC 504032
DMKXNP0 MW 298.37
DMKXNP0 FM C14H14N6S
DMKXNP0 IC InChI=1S/C14H14N6S/c15-12-11-13(20-14(16)19-12)17-8-9(18-11)6-7-21-10-4-2-1-3-5-10/h1-5,8H,6-7H2,(H4,15,16,17,19,20)
DMKXNP0 CS C1=CC=C(C=C1)SCCC2=CN=C3C(=N2)C(=NC(=N3)N)N
DMKXNP0 IK OVPXUMDQGFGLQK-UHFFFAOYSA-N
DMKXNP0 IU 6-(2-phenylsulfanylethyl)pteridine-2,4-diamine
DMKXNP0 DE Discovery agent
DMA8TWC ID DMA8TWC
DMA8TWC DN 6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol
DMA8TWC HS Investigative
DMA8TWC SN CHEMBL254326
DMA8TWC DT Small molecular drug
DMA8TWC PC 24936181
DMA8TWC MW 297.3
DMA8TWC FM C21H15NO
DMA8TWC IC InChI=1S/C21H15NO/c23-21-7-6-19-13-18(4-5-20(19)14-21)17-3-1-2-16(12-17)15-8-10-22-11-9-15/h1-14,23H
DMA8TWC CS C1=CC(=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)O)C4=CC=NC=C4
DMA8TWC IK JKPUOZDSUARXRX-UHFFFAOYSA-N
DMA8TWC IU 6-(3-pyridin-4-ylphenyl)naphthalen-2-ol
DMA8TWC DE Discovery agent
DMDYQE2 ID DMDYQE2
DMDYQE2 DN 6-(3-(trifluoromethyl)phenyl)picolinonitrile
DMDYQE2 HS Investigative
DMDYQE2 SN 6-(3-(trifluoromethyl)phenyl)picolinonitrile; CHEMBL1210691; 833457-45-7; SCHEMBL9954071; CTK3D2833; DTXSID80678807; BDBM50322920; 6-[3-(Trifluoromethyl)phenyl]pyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 6-[3-(trifluoromethyl)phenyl]-
DMDYQE2 DT Small molecular drug
DMDYQE2 PC 49863205
DMDYQE2 MW 248.2
DMDYQE2 FM C13H7F3N2
DMDYQE2 IC InChI=1S/C13H7F3N2/c14-13(15,16)10-4-1-3-9(7-10)12-6-2-5-11(8-17)18-12/h1-7H
DMDYQE2 CS C1=CC(=CC(=C1)C(F)(F)F)C2=CC=CC(=N2)C#N
DMDYQE2 IK FYQRYAIHFASLNM-UHFFFAOYSA-N
DMDYQE2 IU 6-[3-(trifluoromethyl)phenyl]pyridine-2-carbonitrile
DMDYQE2 CA CAS 833457-45-7
DMDYQE2 DE Discovery agent
DMZHFWX ID DMZHFWX
DMZHFWX DN 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX)
DMZHFWX HS Investigative
DMZHFWX SN CHEMBL1173087; 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX); BDBM50322696; rac-6-(3,4-dichlorophenyl)-5-methoxy-1-1-methoxybut-3-enyl)-3-azabicyclo[4.1.0]heptane
DMZHFWX DT Small molecular drug
DMZHFWX PC 49799108
DMZHFWX MW 326.3
DMZHFWX FM C17H21Cl2NO
DMZHFWX IC InChI=1S/C17H21Cl2NO/c1-3-4-15(21-2)17-10-16(17,7-8-20-11-17)12-5-6-13(18)14(19)9-12/h3,5-6,9,15,20H,1,4,7-8,10-11H2,2H3/t15?,16-,17+/m1/s1
DMZHFWX CS COC(CC=C)[C@@]12C[C@]1(CCNC2)C3=CC(=C(C=C3)Cl)Cl
DMZHFWX IK AOUKQWFJPNRGAH-FGJGXXMFSA-N
DMZHFWX IU (1S,6S)-6-(3,4-dichlorophenyl)-1-(1-methoxybut-3-enyl)-3-azabicyclo[4.1.0]heptane
DMZHFWX DE Discovery agent
DMKJOL6 ID DMKJOL6
DMKJOL6 DN 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMKJOL6 HS Investigative
DMKJOL6 SN CHEMBL191716; 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3934682; DZGRIHNLLUZLTL-UHFFFAOYSA-N; BDBM50168366; ZINC13645080
DMKJOL6 DT Small molecular drug
DMKJOL6 PC 10308207
DMKJOL6 MW 272.24
DMKJOL6 FM C16H10F2O2
DMKJOL6 IC InChI=1S/C16H10F2O2/c17-14-7-12(8-15(18)16(14)20)10-1-2-11-6-13(19)4-3-9(11)5-10/h1-8,19-20H
DMKJOL6 CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C(=C3)F)O)F
DMKJOL6 IK DZGRIHNLLUZLTL-UHFFFAOYSA-N
DMKJOL6 IU 6-(3,5-difluoro-4-hydroxyphenyl)naphthalen-2-ol
DMKJOL6 DE Discovery agent
DMIXT2L ID DMIXT2L
DMIXT2L DN 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol
DMIXT2L HS Investigative
DMIXT2L SN CHEMBL362997; 6-(3,5-Dimethoxy-phenyl)-naphthalen-2-ol; BDBM50186758
DMIXT2L DT Small molecular drug
DMIXT2L PC 11536458
DMIXT2L MW 280.3
DMIXT2L FM C18H16O3
DMIXT2L IC InChI=1S/C18H16O3/c1-20-17-9-15(10-18(11-17)21-2)13-3-4-14-8-16(19)6-5-12(14)7-13/h3-11,19H,1-2H3
DMIXT2L CS COC1=CC(=CC(=C1)C2=CC3=C(C=C2)C=C(C=C3)O)OC
DMIXT2L IK HYWKEQNSMAOKKU-UHFFFAOYSA-N
DMIXT2L IU 6-(3,5-dimethoxyphenyl)naphthalen-2-ol
DMIXT2L DE Discovery agent
DMJ92W0 ID DMJ92W0
DMJ92W0 DN 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine
DMJ92W0 HS Investigative
DMJ92W0 SN O6-Substituted Guanine Deriv. 33; BDBM5493; CHEMBL270977; AC1NS705; 2-Amino-6-(3 -aminobenzyl)oxypurine; 6-[(3-aminophenyl)methoxy]-9H-purin-2-amine
DMJ92W0 DT Small molecular drug
DMJ92W0 PC 5329517
DMJ92W0 MW 256.26
DMJ92W0 FM C12H12N6O
DMJ92W0 IC InChI=1S/C12H12N6O/c13-8-3-1-2-7(4-8)5-19-11-9-10(16-6-15-9)17-12(14)18-11/h1-4,6H,5,13H2,(H3,14,15,16,17,18)
DMJ92W0 CS C1=CC(=CC(=C1)N)COC2=NC(=NC3=C2NC=N3)N
DMJ92W0 IK QCEFDVCKQLVMCW-UHFFFAOYSA-N
DMJ92W0 IU 6-[(3-aminophenyl)methoxy]-7H-purin-2-amine
DMJ92W0 DE Discovery agent
DMYA4D2 ID DMYA4D2
DMYA4D2 DN 6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one
DMYA4D2 HS Investigative
DMYA4D2 SN CHEMBL250222; 6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one; SCHEMBL13659560
DMYA4D2 DT Small molecular drug
DMYA4D2 PC 44443516
DMYA4D2 MW 252.31
DMYA4D2 FM C16H16N2O
DMYA4D2 IC InChI=1S/C16H16N2O/c17-8-3-4-11-10-12-7-9-18-16(19)15(12)14-6-2-1-5-13(11)14/h1-2,5-7,9-10H,3-4,8,17H2,(H,18,19)
DMYA4D2 CS C1=CC=C2C(=C1)C(=CC3=C2C(=O)NC=C3)CCCN
DMYA4D2 IK LBNJYZFAUIDIPA-UHFFFAOYSA-N
DMYA4D2 IU 6-(3-aminopropyl)-2H-benzo[h]isoquinolin-1-one
DMYA4D2 DE Discovery agent
DMKFDQ7 ID DMKFDQ7
DMKFDQ7 DN 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline
DMKFDQ7 HS Investigative
DMKFDQ7 SN CHEMBL503444; 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline; SCHEMBL3471202
DMKFDQ7 DT Small molecular drug
DMKFDQ7 PC 25166858
DMKFDQ7 MW 210.27
DMKFDQ7 FM C14H14N2
DMKFDQ7 IC InChI=1S/C14H14N2/c1-2-10-6-11(3-4-13(10)16-5-1)14-7-12(14)8-15-9-14/h1-6,12,15H,7-9H2
DMKFDQ7 CS C1C2C1(CNC2)C3=CC4=C(C=C3)N=CC=C4
DMKFDQ7 IK RJVNCNHNNCNEMX-UHFFFAOYSA-N
DMKFDQ7 IU 6-(3-azabicyclo[3.1.0]hexan-1-yl)quinoline
DMKFDQ7 DE Discovery agent
DMQZTS3 ID DMQZTS3
DMQZTS3 DN 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide
DMQZTS3 HS Investigative
DMQZTS3 SN UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235
DMQZTS3 DT Small molecular drug
DMQZTS3 PC 11449246
DMQZTS3 MW 293.32
DMQZTS3 FM C14H19N3O4
DMQZTS3 IC InChI=1S/C14H19N3O4/c18-12(17-21)9-5-2-6-10-15-14(20)16-13(19)11-7-3-1-4-8-11/h1,3-4,7-8,21H,2,5-6,9-10H2,(H,17,18)(H2,15,16,19,20)
DMQZTS3 CS C1=CC=C(C=C1)C(=O)NC(=O)NCCCCCC(=O)NO
DMQZTS3 IK VQLQZMGNGMOMPU-UHFFFAOYSA-N
DMQZTS3 IU N-[[6-(hydroxyamino)-6-oxohexyl]carbamoyl]benzamide
DMQZTS3 CA CAS 851365-34-9
DMQZTS3 DE Discovery agent
DM89LF5 ID DM89LF5
DM89LF5 DN 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
DM89LF5 HS Investigative
DM89LF5 SN 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE; 6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine; 2qf6; HSP90 Inhibitor, 1; SCHEMBL10822557; BDBM81729; DB07319
DM89LF5 DT Small molecular drug
DM89LF5 PC 13373715
DM89LF5 MW 316.16
DM89LF5 FM C13H10BrN5
DM89LF5 IC InChI=1S/C13H10BrN5/c14-10-6-8-4-2-1-3-7(8)5-9(10)11-17-12(15)19-13(16)18-11/h1-6H,(H4,15,16,17,18,19)
DM89LF5 CS C1=CC=C2C=C(C(=CC2=C1)C3=NC(=NC(=N3)N)N)Br
DM89LF5 IK RXSSKAZHCZWJPP-UHFFFAOYSA-N
DM89LF5 IU 6-(3-bromonaphthalen-2-yl)-1,3,5-triazine-2,4-diamine
DM89LF5 DE Discovery agent
DMMFWYX ID DMMFWYX
DMMFWYX DN 6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione
DMMFWYX HS Investigative
DMMFWYX SN CHEMBL291461; 6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione; 72255-49-3; 2,4(1H,3H)-Pyrimidinedione, 6-[(3-bromophenyl)amino]-; 6-[(3-bromophenyl)amino]pyrimidine-2,4(1H,3H)-dione; AC1LFXXC; Oprea1_136416; Oprea1_839686; MLS000713738; CTK2H2676; DTXSID30355636; MolPort-001-933-580; ZINC322347; HMS3363I15; HMS2635L06; HMS1673K06; BDBM50028343; STK385018; AKOS000541603; MCULE-5935337788; SMR000273219; BAS 00450422; ST50002707; 6-(3-bromoanilino)-1H-pyrimidine-2,4-dione; AB00091424-01
DMMFWYX DT Small molecular drug
DMMFWYX PC 810824
DMMFWYX MW 282.09
DMMFWYX FM C10H8BrN3O2
DMMFWYX IC InChI=1S/C10H8BrN3O2/c11-6-2-1-3-7(4-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DMMFWYX CS C1=CC(=CC(=C1)Br)NC2=CC(=O)NC(=O)N2
DMMFWYX IK CFLHCISOVMSSHJ-UHFFFAOYSA-N
DMMFWYX IU 6-(3-bromoanilino)-1H-pyrimidine-2,4-dione
DMMFWYX CA CAS 72255-49-3
DMMFWYX DE Discovery agent
DM4YP3Q ID DM4YP3Q
DM4YP3Q DN 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol
DM4YP3Q HS Investigative
DM4YP3Q SN CHEMBL365999; 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL4012132; UVRXGDFVCKYIGU-UHFFFAOYSA-N; BDBM50168370; ZINC13645074
DM4YP3Q DT Small molecular drug
DM4YP3Q PC 10286087
DM4YP3Q MW 270.71
DM4YP3Q FM C16H11ClO2
DM4YP3Q IC InChI=1S/C16H11ClO2/c17-15-9-13(4-6-16(15)19)10-1-2-12-8-14(18)5-3-11(12)7-10/h1-9,18-19H
DM4YP3Q CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C=C3)O)Cl
DM4YP3Q IK UVRXGDFVCKYIGU-UHFFFAOYSA-N
DM4YP3Q IU 6-(3-chloro-4-hydroxyphenyl)naphthalen-2-ol
DM4YP3Q CA CAS 550997-74-5
DM4YP3Q DE Discovery agent
DMJO4I7 ID DMJO4I7
DMJO4I7 DN 6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DMJO4I7 HS Investigative
DMJO4I7 SN 6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one; SCHEMBL6206394; CHEMBL197924; BDBM16598; JORLLGPOJPMFRS-UHFFFAOYSA-N; Phenyl-Substituted Sulfonylpyridazinone, 8d
DMJO4I7 DT Small molecular drug
DMJO4I7 PC 9943365
DMJO4I7 MW 270.69
DMJO4I7 FM C10H7ClN2O3S
DMJO4I7 IC InChI=1S/C10H7ClN2O3S/c11-7-2-1-3-8(6-7)17(15,16)10-5-4-9(14)12-13-10/h1-6H,(H,12,14)
DMJO4I7 CS C1=CC(=CC(=C1)Cl)S(=O)(=O)C2=NNC(=O)C=C2
DMJO4I7 IK JORLLGPOJPMFRS-UHFFFAOYSA-N
DMJO4I7 IU 3-(3-chlorophenyl)sulfonyl-1H-pyridazin-6-one
DMJO4I7 DE Discovery agent
DMKUHN9 ID DMKUHN9
DMKUHN9 DN 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione
DMKUHN9 HS Investigative
DMKUHN9 SN CHEMBL51750; 72255-48-2; 2,4(1H,3H)-Pyrimidinedione, 6-[(3-ethylphenyl)amino]-; 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione; CTK2H2677; DTXSID90658211; BDBM50028320
DMKUHN9 DT Small molecular drug
DMKUHN9 PC 44297884
DMKUHN9 MW 231.25
DMKUHN9 FM C12H13N3O2
DMKUHN9 IC InChI=1S/C12H13N3O2/c1-2-8-4-3-5-9(6-8)13-10-7-11(16)15-12(17)14-10/h3-7H,2H2,1H3,(H3,13,14,15,16,17)
DMKUHN9 CS CCC1=CC(=CC=C1)NC2=CC(=O)NC(=O)N2
DMKUHN9 IK RFKOQVWQIOZRDE-UHFFFAOYSA-N
DMKUHN9 IU 6-(3-ethylanilino)-1H-pyrimidine-2,4-dione
DMKUHN9 CA CAS 72255-48-2
DMKUHN9 DE Discovery agent
DMAJEDG ID DMAJEDG
DMAJEDG DN 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol
DMAJEDG HS Investigative
DMAJEDG SN CHEMBL193727; 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3924993; QTDYCKGQBCKMGC-UHFFFAOYSA-N; ZINC13645068; BDBM50168372
DMAJEDG DT Small molecular drug
DMAJEDG PC 10236221
DMAJEDG MW 254.25
DMAJEDG FM C16H11FO2
DMAJEDG IC InChI=1S/C16H11FO2/c17-15-9-13(4-6-16(15)19)10-1-2-12-8-14(18)5-3-11(12)7-10/h1-9,18-19H
DMAJEDG CS C1=CC2=C(C=CC(=C2)O)C=C1C3=CC(=C(C=C3)O)F
DMAJEDG IK QTDYCKGQBCKMGC-UHFFFAOYSA-N
DMAJEDG IU 6-(3-fluoro-4-hydroxyphenyl)naphthalen-2-ol
DMAJEDG DE Discovery agent
DMTJPZU ID DMTJPZU
DMTJPZU DN 6-(3-Fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU HS Investigative
DMTJPZU SN 6-(3-Fluoropropyl)-4-methylpyridin-2-amine; CHEMBL443862; 1146620-54-3; SCHEMBL13040676
DMTJPZU DT Small molecular drug
DMTJPZU PC 42625617
DMTJPZU MW 168.21
DMTJPZU FM C9H13FN2
DMTJPZU IC InChI=1S/C9H13FN2/c1-7-5-8(3-2-4-10)12-9(11)6-7/h5-6H,2-4H2,1H3,(H2,11,12)
DMTJPZU CS CC1=CC(=NC(=C1)N)CCCF
DMTJPZU IK UWBOFUBWKXYIJF-UHFFFAOYSA-N
DMTJPZU IU 6-(3-fluoropropyl)-4-methylpyridin-2-amine
DMTJPZU DE Discovery agent
DMMZENV ID DMMZENV
DMMZENV DN 6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol
DMMZENV HS Investigative
DMMZENV SN CHEMBL469227; 6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol; SCHEMBL3008799
DMMZENV DT Small molecular drug
DMMZENV PC 24894072
DMMZENV MW 312.4
DMMZENV FM C22H16O2
DMMZENV IC InChI=1S/C22H16O2/c23-19-8-4-7-16(14-19)17-9-11-20-18(13-17)10-12-21(24)22(20)15-5-2-1-3-6-15/h1-14,23-24H
DMMZENV CS C1=CC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC(=CC=C4)O)O
DMMZENV IK ZYOIQICRHUXCRL-UHFFFAOYSA-N
DMMZENV IU 6-(3-hydroxyphenyl)-1-phenylnaphthalen-2-ol
DMMZENV DE Discovery agent
DM28DPY ID DM28DPY
DM28DPY DN 6-(3-hydroxyphenyl)-2-morpholino-4H-chromen-4-one
DM28DPY HS Investigative
DM28DPY SN CHEMBL427009
DM28DPY DT Small molecular drug
DM28DPY PC 11558836
DM28DPY MW 323.3
DM28DPY FM C19H17NO4
DM28DPY IC InChI=1S/C19H17NO4/c21-15-3-1-2-13(10-15)14-4-5-18-16(11-14)17(22)12-19(24-18)20-6-8-23-9-7-20/h1-5,10-12,21H,6-9H2
DM28DPY CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC(=CC=C4)O
DM28DPY IK PLPMLPUPRLWRRG-UHFFFAOYSA-N
DM28DPY IU 6-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM28DPY DE Discovery agent
DMMHRVO ID DMMHRVO
DMMHRVO DN 6-(3-Hydroxy-phenyl)-naphthalen-1-ol
DMMHRVO HS Investigative
DMMHRVO SN CHEMBL193010; 6-(3-hydroxyphenyl)-1-naphthol; 6-(3-Hydroxy-phenyl)-naphthalen-1-ol; SCHEMBL3010784; HXKYTCGOCJUQSE-UHFFFAOYSA-N; ZINC13644987
DMMHRVO DT Small molecular drug
DMMHRVO PC 11447703
DMMHRVO MW 236.26
DMMHRVO FM C16H12O2
DMMHRVO IC InChI=1S/C16H12O2/c17-14-5-1-3-11(10-14)12-7-8-15-13(9-12)4-2-6-16(15)18/h1-10,17-18H
DMMHRVO CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C(=CC=C3)O
DMMHRVO IK HXKYTCGOCJUQSE-UHFFFAOYSA-N
DMMHRVO IU 6-(3-hydroxyphenyl)naphthalen-1-ol
DMMHRVO DE Discovery agent
DMH8WA2 ID DMH8WA2
DMH8WA2 DN 6-(3-Hydroxy-phenyl)-naphthalen-2-ol
DMH8WA2 HS Investigative
DMH8WA2 SN 6-(3-hydroxyphenyl)-2-naphthol; 6-(3-hydroxyphenyl)naphthalen-2-ol
DMH8WA2 PC 10192730
DMH8WA2 MW 236.26
DMH8WA2 FM C16H12O2
DMH8WA2 IC InChI=1S/C16H12O2/c17-15-3-1-2-11(9-15)12-4-5-14-10-16(18)7-6-13(14)8-12/h1-10,17-18H
DMH8WA2 CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMH8WA2 IK VHWBXEUHUQDHDH-UHFFFAOYSA-N
DMH8WA2 IU 6-(3-hydroxyphenyl)naphthalen-2-ol
DMH8WA2 DE Discovery agent
DMISV5A ID DMISV5A
DMISV5A DN 6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione
DMISV5A HS Investigative
DMISV5A SN CHEMBL300465; 72255-50-6; 6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione; CTK2H2675; DTXSID50658212; BDBM50028331; 6-(3-Iodoanilino)pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-[(3-iodophenyl)amino]-
DMISV5A DT Small molecular drug
DMISV5A PC 44297894
DMISV5A MW 329.09
DMISV5A FM C10H8IN3O2
DMISV5A IC InChI=1S/C10H8IN3O2/c11-6-2-1-3-7(4-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DMISV5A CS C1=CC(=CC(=C1)I)NC2=CC(=O)NC(=O)N2
DMISV5A IK NUGFPABWAOETRO-UHFFFAOYSA-N
DMISV5A IU 6-(3-iodoanilino)-1H-pyrimidine-2,4-dione
DMISV5A CA CAS 72255-50-6
DMISV5A DE Discovery agent
DMSW3KN ID DMSW3KN
DMSW3KN DN 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine
DMSW3KN HS Investigative
DMSW3KN SN O6-Substituted Guanine Deriv. 32; CHEMBL405773; BDBM5492; AC1NS702; SCHEMBL12227591; O6-[3-(Methyl)Benzyl]Guanine; ZINC13475147; 2-Amino-6-(3 -methylbenzyl)oxypurine; 6-[(3-methylphenyl)methoxy]-9H-purin-2-amine
DMSW3KN DT Small molecular drug
DMSW3KN PC 5329516
DMSW3KN MW 255.28
DMSW3KN FM C13H13N5O
DMSW3KN IC InChI=1S/C13H13N5O/c1-8-3-2-4-9(5-8)6-19-12-10-11(16-7-15-10)17-13(14)18-12/h2-5,7H,6H2,1H3,(H3,14,15,16,17,18)
DMSW3KN CS CC1=CC(=CC=C1)COC2=NC(=NC3=C2NC=N3)N
DMSW3KN IK WSSNDTDMMVLPHS-UHFFFAOYSA-N
DMSW3KN IU 6-[(3-methylphenyl)methoxy]-7H-purin-2-amine
DMSW3KN DE Discovery agent
DM83VN6 ID DM83VN6
DM83VN6 DN 6-(3-Nitro-phenyl)-3H-benzothiazol-2-one
DM83VN6 HS Investigative
DM83VN6 SN CHEMBL315445; 6-(3-Nitro-phenyl)-3H-benzothiazol-2-one; SCHEMBL6541670; NGWRFPUBBONZGG-UHFFFAOYSA-N; BDBM50105566
DM83VN6 DT Small molecular drug
DM83VN6 PC 10221123
DM83VN6 MW 272.28
DM83VN6 FM C13H8N2O3S
DM83VN6 IC InChI=1S/C13H8N2O3S/c16-13-14-11-5-4-9(7-12(11)19-13)8-2-1-3-10(6-8)15(17)18/h1-7H,(H,14,16)
DM83VN6 CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC3=C(C=C2)NC(=O)S3
DM83VN6 IK NGWRFPUBBONZGG-UHFFFAOYSA-N
DM83VN6 IU 6-(3-nitrophenyl)-3H-1,3-benzothiazol-2-one
DM83VN6 DE Discovery agent
DMEM1BA ID DMEM1BA
DMEM1BA DN 6-(4-((benzylamino)methyl)phenoxy)nicotinamide
DMEM1BA HS Investigative
DMEM1BA SN CHEMBL238316; 6-(4-((benzylamino)methyl)phenoxy)nicotinamide; SCHEMBL3700197; LUBVSQAMVPXMBJ-UHFFFAOYSA-N; BDBM50219916
DMEM1BA DT Small molecular drug
DMEM1BA PC 44434949
DMEM1BA MW 333.4
DMEM1BA FM C20H19N3O2
DMEM1BA IC InChI=1S/C20H19N3O2/c21-20(24)17-8-11-19(23-14-17)25-18-9-6-16(7-10-18)13-22-12-15-4-2-1-3-5-15/h1-11,14,22H,12-13H2,(H2,21,24)
DMEM1BA CS C1=CC=C(C=C1)CNCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DMEM1BA IK LUBVSQAMVPXMBJ-UHFFFAOYSA-N
DMEM1BA IU 6-[4-[(benzylamino)methyl]phenoxy]pyridine-3-carboxamide
DMEM1BA DE Discovery agent
DM9VD4W ID DM9VD4W
DM9VD4W DN 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide
DM9VD4W HS Investigative
DM9VD4W SN CHEMBL238361; 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide; SCHEMBL3702187
DM9VD4W DT Small molecular drug
DM9VD4W PC 44434058
DM9VD4W MW 347.4
DM9VD4W FM C21H21N3O2
DM9VD4W IC InChI=1S/C21H21N3O2/c22-21(25)18-8-11-20(24-15-18)26-19-9-6-17(7-10-19)14-23-13-12-16-4-2-1-3-5-16/h1-11,15,23H,12-14H2,(H2,22,25)
DM9VD4W CS C1=CC=C(C=C1)CCNCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DM9VD4W IK XPIWSPZHJZLUGI-UHFFFAOYSA-N
DM9VD4W IU 6-[4-[(2-phenylethylamino)methyl]phenoxy]pyridine-3-carboxamide
DM9VD4W DE Discovery agent
DMDKOWP ID DMDKOWP
DMDKOWP DN 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide
DMDKOWP HS Investigative
DMDKOWP SN CHEMBL237066; 6-[4-(2-benzylamino-ethyl)-phenoxy]-nicotinamide; 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide; SCHEMBL3698270; FCDWJNPFPYAKET-UHFFFAOYSA-N; BDBM50219925
DMDKOWP DT Small molecular drug
DMDKOWP PC 44434057
DMDKOWP MW 347.4
DMDKOWP FM C21H21N3O2
DMDKOWP IC InChI=1S/C21H21N3O2/c22-21(25)18-8-11-20(24-15-18)26-19-9-6-16(7-10-19)12-13-23-14-17-4-2-1-3-5-17/h1-11,15,23H,12-14H2,(H2,22,25)
DMDKOWP CS C1=CC=C(C=C1)CNCCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DMDKOWP IK FCDWJNPFPYAKET-UHFFFAOYSA-N
DMDKOWP IU 6-[4-[2-(benzylamino)ethyl]phenoxy]pyridine-3-carboxamide
DMDKOWP DE Discovery agent
DMOSDM2 ID DMOSDM2
DMOSDM2 DN 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide
DMOSDM2 HS Investigative
DMOSDM2 SN CHEMBL235560; 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide; SCHEMBL3702023; JKDWSAGAQLISRL-UHFFFAOYSA-N; BDBM50219927
DMOSDM2 DT Small molecular drug
DMOSDM2 PC 44434931
DMOSDM2 MW 347.4
DMOSDM2 FM C21H21N3O2
DMOSDM2 IC InChI=1S/C21H21N3O2/c22-21(25)19-7-4-8-20(24-19)26-18-11-9-16(10-12-18)13-14-23-15-17-5-2-1-3-6-17/h1-12,23H,13-15H2,(H2,22,25)
DMOSDM2 CS C1=CC=C(C=C1)CNCCC2=CC=C(C=C2)OC3=CC=CC(=N3)C(=O)N
DMOSDM2 IK JKDWSAGAQLISRL-UHFFFAOYSA-N
DMOSDM2 IU 6-[4-[2-(benzylamino)ethyl]phenoxy]pyridine-2-carboxamide
DMOSDM2 DE Discovery agent
DMDTMB7 ID DMDTMB7
DMDTMB7 DN 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide
DMDTMB7 HS Investigative
DMDTMB7 SN CHEMBL236170; 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide; SCHEMBL3697663; FZBJOVYOONJNIG-UHFFFAOYSA-N; BDBM50219917
DMDTMB7 DT Small molecular drug
DMDTMB7 PC 44434946
DMDTMB7 MW 361.4
DMDTMB7 FM C22H23N3O2
DMDTMB7 IC InChI=1S/C22H23N3O2/c23-22(26)19-10-13-21(25-16-19)27-20-11-8-17(9-12-20)7-4-14-24-15-18-5-2-1-3-6-18/h1-3,5-6,8-13,16,24H,4,7,14-15H2,(H2,23,26)
DMDTMB7 CS C1=CC=C(C=C1)CNCCCC2=CC=C(C=C2)OC3=NC=C(C=C3)C(=O)N
DMDTMB7 IK FZBJOVYOONJNIG-UHFFFAOYSA-N
DMDTMB7 IU 6-[4-[3-(benzylamino)propyl]phenoxy]pyridine-3-carboxamide
DMDTMB7 DE Discovery agent
DM9K8DY ID DM9K8DY
DM9K8DY DN 6-(4-Bromo-benzenesulfonyl)-2H-pyridazin-3-one
DM9K8DY HS Investigative
DM9K8DY SN CHEMBL413566; BDBM16597; MolPort-035-757-148; HMS3437C04; ZINC11536222; AKOS024439117; AKOS001782802; MCULE-5808217949; Phenyl-Substituted Sulfonylpyridazinone, 8b; 6-[(4-bromophenyl)sulfonyl]-3(2H)-pyridazinone
DM9K8DY DT Small molecular drug
DM9K8DY PC 11674065
DM9K8DY MW 315.15
DM9K8DY FM C10H7BrN2O3S
DM9K8DY IC InChI=1S/C10H7BrN2O3S/c11-7-1-3-8(4-2-7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DM9K8DY CS C1=CC(=CC=C1S(=O)(=O)C2=NNC(=O)C=C2)Br
DM9K8DY IK MKFSHYSDCZFZEZ-UHFFFAOYSA-N
DM9K8DY IU 3-(4-bromophenyl)sulfonyl-1H-pyridazin-6-one
DM9K8DY DE Discovery agent
DMCYQDU ID DMCYQDU
DMCYQDU DN 6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione
DMCYQDU HS Investigative
DMCYQDU SN CHEMBL293964; 6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione; 21333-03-9; NSC212333; Cambridge id 5630405; AC1L7G1A; Oprea1_831727; Oprea1_666298; DTXSID70309572; 2,4(1H,3H)-Pyrimidinedione, 6-[(4-bromophenyl)amino]-; MolPort-001-898-229; ZINC245008; BDBM50028349; AKOS000541604; MCULE-6634356270; NSC-212333; BAS 00450423; 6-(4-bromoanilino)-1H-pyrimidine-2,4-dione
DMCYQDU DT Small molecular drug
DMCYQDU PC 309876
DMCYQDU MW 282.09
DMCYQDU FM C10H8BrN3O2
DMCYQDU IC InChI=1S/C10H8BrN3O2/c11-6-1-3-7(4-2-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DMCYQDU CS C1=CC(=CC=C1NC2=CC(=O)NC(=O)N2)Br
DMCYQDU IK KVJLEUZMCGNFGQ-UHFFFAOYSA-N
DMCYQDU IU 6-(4-bromoanilino)-1H-pyrimidine-2,4-dione
DMCYQDU CA CAS 21333-03-9
DMCYQDU DE Discovery agent
DMNAHVB ID DMNAHVB
DMNAHVB DN 6-(4-Chloro-benzenesulfonyl)-2H-pyridazin-3-one
DMNAHVB HS Investigative
DMNAHVB SN SCHEMBL6205548; CHEMBL425745; BDBM16599; MolPort-008-421-579; ZINC11536219; AKOS004915123; AKOS001782171; MCULE-3139216379; CCG-127350; 454181-53-4; Phenyl-Substituted Sulfonylpyridazinone, 8e; 6-[(4-chlorophenyl)sulfonyl]-3-pyridazinol; 6-[(4-chlorophenyl)sulfonyl]-3(2H)-pyridazinone; 3(2H)-Pyridazinone, 6-[(4-chlorophenyl)sulfonyl]-
DMNAHVB DT Small molecular drug
DMNAHVB PC 9878572
DMNAHVB MW 270.69
DMNAHVB FM C10H7ClN2O3S
DMNAHVB IC InChI=1S/C10H7ClN2O3S/c11-7-1-3-8(4-2-7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DMNAHVB CS C1=CC(=CC=C1S(=O)(=O)C2=NNC(=O)C=C2)Cl
DMNAHVB IK MLRLSUWJTAHEKD-UHFFFAOYSA-N
DMNAHVB IU 3-(4-chlorophenyl)sulfonyl-1H-pyridazin-6-one
DMNAHVB DE Discovery agent
DMSO2JW ID DMSO2JW
DMSO2JW DN 6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol
DMSO2JW HS Investigative
DMSO2JW SN CHEMBL225150; 6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol
DMSO2JW DT Small molecular drug
DMSO2JW PC 16203826
DMSO2JW MW 290.74
DMSO2JW FM C15H15ClN2O2
DMSO2JW IC InChI=1S/C15H15ClN2O2/c16-12-3-1-11(2-4-12)14-9-13(19)10-15(17-14)18-5-7-20-8-6-18/h1-4,9-10H,5-8H2,(H,17,19)
DMSO2JW CS C1COCCN1C2=CC(=O)C=C(N2)C3=CC=C(C=C3)Cl
DMSO2JW IK PETWHCAMQFMDRM-UHFFFAOYSA-N
DMSO2JW IU 2-(4-chlorophenyl)-6-morpholin-4-yl-1H-pyridin-4-one
DMSO2JW DE Discovery agent
DMMTG7L ID DMMTG7L
DMMTG7L DN 6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one
DMMTG7L HS Investigative
DMMTG7L SN CHEMBL222821; 6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one; SCHEMBL3537608
DMMTG7L DT Small molecular drug
DMMTG7L PC 21106425
DMMTG7L MW 291.73
DMMTG7L FM C15H14ClNO3
DMMTG7L IC InChI=1S/C15H14ClNO3/c16-12-3-1-11(2-4-12)14-9-13(10-15(18)20-14)17-5-7-19-8-6-17/h1-4,9-10H,5-8H2
DMMTG7L CS C1COCCN1C2=CC(=O)OC(=C2)C3=CC=C(C=C3)Cl
DMMTG7L IK QAPAFHWHAZOAOB-UHFFFAOYSA-N
DMMTG7L IU 6-(4-chlorophenyl)-4-morpholin-4-ylpyran-2-one
DMMTG7L DE Discovery agent
DM0C1FX ID DM0C1FX
DM0C1FX DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM0C1FX HS Investigative
DM0C1FX SN CHEMBL1082305; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); BDBM50320178
DM0C1FX DT Small molecular drug
DM0C1FX PC 46891274
DM0C1FX MW 461.8
DM0C1FX FM C23H19Cl3N2O2
DM0C1FX IC InChI=1S/C23H19Cl3N2O2/c1-23(2)11-18(21(27)29)17-10-16(12-3-5-13(24)6-4-12)20(28-22(17)30-23)15-8-7-14(25)9-19(15)26/h3-10,18H,11H2,1-2H3,(H2,27,29)
DM0C1FX CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)C(=O)N)C
DM0C1FX IK YYFWEVOTTPIJNN-UHFFFAOYSA-N
DM0C1FX IU 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridine-4-carboxamide
DM0C1FX DE Discovery agent
DM1N46J ID DM1N46J
DM1N46J DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM1N46J HS Investigative
DM1N46J SN CHEMBL1082650; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); BDBM50320181
DM1N46J DT Small molecular drug
DM1N46J PC 46891372
DM1N46J MW 518.9
DM1N46J FM C26H26Cl3N3O2
DM1N46J IC InChI=1S/C26H26Cl3N3O2/c1-14(33)30-25(34)21-13-26(2,3)32(4)24-20(21)12-19(15-5-7-16(27)8-6-15)23(31-24)18-10-9-17(28)11-22(18)29/h5-12,14,21,33H,13H2,1-4H3,(H,30,34)/t14-,21?/m1/s1
DM1N46J CS C[C@H](NC(=O)C1CC(N(C2=C1C=C(C(=N2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)C)(C)C)O
DM1N46J IK DIDXRIJBHXOGGD-CKAQCJTGSA-N
DM1N46J IU 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-[(1R)-1-hydroxyethyl]-1,2,2-trimethyl-3,4-dihydro-1,8-naphthyridine-4-carboxamide
DM1N46J DE Discovery agent
DM5H4KE ID DM5H4KE
DM5H4KE DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DM5H4KE HS Investigative
DM5H4KE SN CHEMBL1082321; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); SCHEMBL1404688; BDBM50320179
DM5H4KE DT Small molecular drug
DM5H4KE PC 24992763
DM5H4KE MW 533.9
DM5H4KE FM C27H27Cl3N2O3
DM5H4KE IC InChI=1S/C27H27Cl3N2O3/c1-26(2,14-33)32-24(34)21-13-27(3,4)35-25-20(21)12-19(15-5-7-16(28)8-6-15)23(31-25)18-10-9-17(29)11-22(18)30/h5-12,21,33H,13-14H2,1-4H3,(H,32,34)
DM5H4KE CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)C(=O)NC(C)(C)CO)C
DM5H4KE IK JUNWVTKDXNTEJW-UHFFFAOYSA-N
DM5H4KE IU 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-(1-hydroxy-2-methylpropan-2-yl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridine-4-carboxamide
DM5H4KE DE Discovery agent
DMEJ83H ID DMEJ83H
DMEJ83H DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX)
DMEJ83H HS Investigative
DMEJ83H SN CHEMBL1082330; 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX); BDBM50320180
DMEJ83H DT Small molecular drug
DMEJ83H PC 46891330
DMEJ83H MW 504.8
DMEJ83H FM C25H24Cl3N3O2
DMEJ83H IC InChI=1S/C25H24Cl3N3O2/c1-25(2)12-20(24(33)29-13-32)19-11-18(14-4-6-15(26)7-5-14)22(30-23(19)31(25)3)17-9-8-16(27)10-21(17)28/h4-11,20,32H,12-13H2,1-3H3,(H,29,33)
DMEJ83H CS CC1(CC(C2=C(N1C)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)C(=O)NCO)C
DMEJ83H IK URTQOVWDFKPXTI-UHFFFAOYSA-N
DMEJ83H IU 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-N-(hydroxymethyl)-1,2,2-trimethyl-3,4-dihydro-1,8-naphthyridine-4-carboxamide
DMEJ83H DE Ovarian cancer
DM5LUF4 ID DM5LUF4
DM5LUF4 DN 6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione
DM5LUF4 HS Investigative
DM5LUF4 SN CHEMBL51694; 6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione; STK374802; 21333-02-8; 6-[(4-chlorophenyl)amino]pyrimidine-2,4(1H,3H)-dione; NSC210499; AC1L7DC5; Oprea1_449957; Oprea1_000118; SCHEMBL5309531; 2,4(1H,3H)-Pyrimidinedione, 6-[(4-chlorophenyl)amino]-; DTXSID10308968; MolPort-002-117-140; ZINC169555; BDBM50028338; AKOS001620570; NSC-210499; MCULE-2076182094; BAS 00450419; ST50876537; 6-(4-chloroanilino)-1H-pyrimidine-2,4-dione; AB00091363-01; 6-(4-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione
DM5LUF4 DT Small molecular drug
DM5LUF4 PC 308646
DM5LUF4 MW 237.64
DM5LUF4 FM C10H8ClN3O2
DM5LUF4 IC InChI=1S/C10H8ClN3O2/c11-6-1-3-7(4-2-6)12-8-5-9(15)14-10(16)13-8/h1-5H,(H3,12,13,14,15,16)
DM5LUF4 CS C1=CC(=CC=C1NC2=CC(=O)NC(=O)N2)Cl
DM5LUF4 IK POKMZWROIKHVLE-UHFFFAOYSA-N
DM5LUF4 IU 6-(4-chloroanilino)-1H-pyrimidine-2,4-dione
DM5LUF4 CA CAS 21333-02-8
DM5LUF4 DE Discovery agent
DMOZFU5 ID DMOZFU5
DMOZFU5 DN 6-(4-chlorophenylamino)-N,N-diethylnicotinamide
DMOZFU5 HS Investigative
DMOZFU5 SN CHEMBL596589; 6-(4-chlorophenylamino)-N,N-diethylnicotinamide; BDBM50305021
DMOZFU5 DT Small molecular drug
DMOZFU5 PC 23725212
DMOZFU5 MW 303.78
DMOZFU5 FM C16H18ClN3O
DMOZFU5 IC InChI=1S/C16H18ClN3O/c1-3-20(4-2)16(21)12-5-10-15(18-11-12)19-14-8-6-13(17)7-9-14/h5-11H,3-4H2,1-2H3,(H,18,19)
DMOZFU5 CS CCN(CC)C(=O)C1=CN=C(C=C1)NC2=CC=C(C=C2)Cl
DMOZFU5 IK UEKPAIMMZMCKSL-UHFFFAOYSA-N
DMOZFU5 IU 6-(4-chloroanilino)-N,N-diethylpyridine-3-carboxamide
DMOZFU5 DE Discovery agent
DMYQB5R ID DMYQB5R
DMYQB5R DN 6-(4-Decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one
DMYQB5R HS Investigative
DMYQB5R SN CHEMBL513627
DMYQB5R DT Small molecular drug
DMYQB5R PC 25059557
DMYQB5R MW 386.5
DMYQB5R FM C22H33F3O2
DMYQB5R IC InChI=1S/C22H33F3O2/c1-2-3-4-5-6-7-8-11-18-27-20-16-14-19(15-17-20)12-9-10-13-21(26)22(23,24)25/h14-17H,2-13,18H2,1H3
DMYQB5R CS CCCCCCCCCCOC1=CC=C(C=C1)CCCCC(=O)C(F)(F)F
DMYQB5R IK LRMSMLKRXXVPRC-UHFFFAOYSA-N
DMYQB5R IU 6-(4-decoxyphenyl)-1,1,1-trifluorohexan-2-one
DMYQB5R DE Discovery agent
DM7WYNT ID DM7WYNT
DM7WYNT DN 6-(4-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one
DM7WYNT HS Investigative
DM7WYNT SN SCHEMBL6206599; CHEMBL425922; BDBM16601; 454181-47-6; Phenyl-Substituted Sulfonylpyridazinone, 8g; 3(2H)-Pyridazinone, 6-[(4-fluorophenyl)sulfonyl]-
DM7WYNT DT Small molecular drug
DM7WYNT PC 9856396
DM7WYNT MW 254.24
DM7WYNT FM C10H7FN2O3S
DM7WYNT IC InChI=1S/C10H7FN2O3S/c11-7-1-3-8(4-2-7)17(15,16)10-6-5-9(14)12-13-10/h1-6H,(H,12,14)
DM7WYNT CS C1=CC(=CC=C1F)S(=O)(=O)C2=NNC(=O)C=C2
DM7WYNT IK OVAVDZRNJWQJPL-UHFFFAOYSA-N
DM7WYNT IU 3-(4-fluorophenyl)sulfonyl-1H-pyridazin-6-one
DM7WYNT DE Discovery agent
DM3EDBO ID DM3EDBO
DM3EDBO DN 6-(4-Fluorobutyl)-4-methylpyridin-2-amine
DM3EDBO HS Investigative
DM3EDBO SN CHEMBL509542; 6-(4-Fluorobutyl)-4-methylpyridin-2-amine; 2-Pyridinamine, 6-(4-fluorobutyl)-4-methyl-; BDBM50267355
DM3EDBO DT Small molecular drug
DM3EDBO PC 42625618
DM3EDBO MW 182.24
DM3EDBO FM C10H15FN2
DM3EDBO IC InChI=1S/C10H15FN2/c1-8-6-9(4-2-3-5-11)13-10(12)7-8/h6-7H,2-5H2,1H3,(H2,12,13)
DM3EDBO CS CC1=CC(=NC(=C1)N)CCCCF
DM3EDBO IK OTKWRERYYAYGSY-UHFFFAOYSA-N
DM3EDBO IU 6-(4-fluorobutyl)-4-methylpyridin-2-amine
DM3EDBO DE Discovery agent
DM5JWEY ID DM5JWEY
DM5JWEY DN 6-(4-Fluoro-phenylsulfanyl)-9H-purine
DM5JWEY HS Investigative
DM5JWEY SN 6-(4-fluorophenylsulfanyl)-9H-purine; 736142-69-1; CHEMBL175603
DM5JWEY DT Small molecular drug
DM5JWEY PC 11265091
DM5JWEY MW 246.27
DM5JWEY FM C11H7FN4S
DM5JWEY IC InChI=1S/C11H7FN4S/c12-7-1-3-8(4-2-7)17-11-9-10(14-5-13-9)15-6-16-11/h1-6H,(H,13,14,15,16)
DM5JWEY CS C1=CC(=CC=C1F)SC2=NC=NC3=C2NC=N3
DM5JWEY IK MTSKQGGVBOTGLP-UHFFFAOYSA-N
DM5JWEY IU 6-(4-fluorophenyl)sulfanyl-7H-purine
DM5JWEY DE Discovery agent
DMKGTRF ID DMKGTRF
DMKGTRF DN 6-(4-fluorostyryl)-2-morpholino-4H-chromen-4-one
DMKGTRF HS Investigative
DMKGTRF SN CHEMBL426654
DMKGTRF DT Small molecular drug
DMKGTRF PC 11717289
DMKGTRF MW 351.4
DMKGTRF FM C21H18FNO3
DMKGTRF IC InChI=1S/C21H18FNO3/c22-17-6-3-15(4-7-17)1-2-16-5-8-20-18(13-16)19(24)14-21(26-20)23-9-11-25-12-10-23/h1-8,13-14H,9-12H2/b2-1+
DMKGTRF CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)/C=C/C4=CC=C(C=C4)F
DMKGTRF IK MGIIGLFUKQWDHF-OWOJBTEDSA-N
DMKGTRF IU 6-[(E)-2-(4-fluorophenyl)ethenyl]-2-morpholin-4-ylchromen-4-one
DMKGTRF DE Discovery agent
DMYM3EW ID DMYM3EW
DMYM3EW DN 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol
DMYM3EW HS Investigative
DMYM3EW SN CHEMBL427180; 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol; SCHEMBL3932725; TWSSGPRRAGPVKD-UHFFFAOYSA-N; BDBM50168373; ZINC13645059
DMYM3EW DT Small molecular drug
DMYM3EW PC 10125342
DMYM3EW MW 266.29
DMYM3EW FM C17H14O3
DMYM3EW IC InChI=1S/C17H14O3/c1-20-17-10-15(19)6-7-16(17)13-3-2-12-9-14(18)5-4-11(12)8-13/h2-10,18-19H,1H3
DMYM3EW CS COC1=C(C=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMYM3EW IK TWSSGPRRAGPVKD-UHFFFAOYSA-N
DMYM3EW IU 6-(4-hydroxy-2-methoxyphenyl)naphthalen-2-ol
DMYM3EW DE Discovery agent
DMYEIRH ID DMYEIRH
DMYEIRH DN 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol
DMYEIRH HS Investigative
DMYEIRH SN CHEMBL195389; 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol; SCHEMBL4077781; YIKDKHNOMWERET-UHFFFAOYSA-N; ZINC13645062; BDBM50168377
DMYEIRH DT Small molecular drug
DMYEIRH PC 10192794
DMYEIRH MW 250.29
DMYEIRH FM C17H14O2
DMYEIRH IC InChI=1S/C17H14O2/c1-11-8-15(18)6-7-17(11)14-3-2-13-10-16(19)5-4-12(13)9-14/h2-10,18-19H,1H3
DMYEIRH CS CC1=C(C=CC(=C1)O)C2=CC3=C(C=C2)C=C(C=C3)O
DMYEIRH IK YIKDKHNOMWERET-UHFFFAOYSA-N
DMYEIRH IU 6-(4-hydroxy-2-methylphenyl)naphthalen-2-ol
DMYEIRH DE Discovery agent
DMBG5Y8 ID DMBG5Y8
DMBG5Y8 DN 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol
DMBG5Y8 HS Investigative
DMBG5Y8 SN CHEMBL195786; 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol; SCHEMBL5980579; DSBWWPDVDPKMHN-UHFFFAOYSA-N; ZINC13645027; BDBM50168344
DMBG5Y8 DT Small molecular drug
DMBG5Y8 PC 11414445
DMBG5Y8 MW 266.29
DMBG5Y8 FM C17H14O3
DMBG5Y8 IC InChI=1S/C17H14O3/c1-20-17-15-8-4-12(10-13(15)5-9-16(17)19)11-2-6-14(18)7-3-11/h2-10,18-19H,1H3
DMBG5Y8 CS COC1=C(C=CC2=C1C=CC(=C2)C3=CC=C(C=C3)O)O
DMBG5Y8 IK DSBWWPDVDPKMHN-UHFFFAOYSA-N
DMBG5Y8 IU 6-(4-hydroxyphenyl)-1-methoxynaphthalen-2-ol
DMBG5Y8 DE Discovery agent
DMGLT0N ID DMGLT0N
DMGLT0N DN 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol
DMGLT0N HS Investigative
DMGLT0N SN CHEMBL372030; 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol; SCHEMBL3927148; FGIUXCLAHODWKV-UHFFFAOYSA-N; BDBM50168320; ZINC13645024
DMGLT0N DT Small molecular drug
DMGLT0N PC 10308075
DMGLT0N MW 250.29
DMGLT0N FM C17H14O2
DMGLT0N IC InChI=1S/C17H14O2/c1-11-16-8-4-13(10-14(16)5-9-17(11)19)12-2-6-15(18)7-3-12/h2-10,18-19H,1H3
DMGLT0N CS CC1=C(C=CC2=C1C=CC(=C2)C3=CC=C(C=C3)O)O
DMGLT0N IK FGIUXCLAHODWKV-UHFFFAOYSA-N
DMGLT0N IU 6-(4-hydroxyphenyl)-1-methylnaphthalen-2-ol
DMGLT0N DE Discovery agent
DMGC84U ID DMGC84U
DMGC84U DN 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol
DMGC84U HS Investigative
DMGC84U SN CHEMBL195788; 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol; SCHEMBL3935673; MYVOVZDBAWARDP-UHFFFAOYSA-N; ZINC13645031; BDBM50168340
DMGC84U DT Small molecular drug
DMGC84U PC 10308268
DMGC84U MW 281.26
DMGC84U FM C16H11NO4
DMGC84U IC InChI=1S/C16H11NO4/c18-13-5-1-10(2-6-13)11-3-7-14-12(9-11)4-8-15(19)16(14)17(20)21/h1-9,18-19H
DMGC84U CS C1=CC(=CC=C1C2=CC3=C(C=C2)C(=C(C=C3)O)[N+](=O)[O-])O
DMGC84U IK MYVOVZDBAWARDP-UHFFFAOYSA-N
DMGC84U IU 6-(4-hydroxyphenyl)-1-nitronaphthalen-2-ol
DMGC84U DE Discovery agent
DMI6UVN ID DMI6UVN
DMI6UVN DN 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol
DMI6UVN HS Investigative
DMI6UVN SN CHEMBL192102; 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol; SCHEMBL3927262; INNGVLJQICTRAF-UHFFFAOYSA-N; BDBM50168362
DMI6UVN DT Small molecular drug
DMI6UVN PC 10171886
DMI6UVN MW 312.4
DMI6UVN FM C22H16O2
DMI6UVN IC InChI=1S/C22H16O2/c23-19-10-6-15(7-11-19)17-8-12-20-18(14-17)9-13-21(24)22(20)16-4-2-1-3-5-16/h1-14,23-24H
DMI6UVN CS C1=CC=C(C=C1)C2=C(C=CC3=C2C=CC(=C3)C4=CC=C(C=C4)O)O
DMI6UVN IK INNGVLJQICTRAF-UHFFFAOYSA-N
DMI6UVN IU 6-(4-hydroxyphenyl)-1-phenylnaphthalen-2-ol
DMI6UVN DE Discovery agent
DMTYWCS ID DMTYWCS
DMTYWCS DN 6-(4-hydroxyphenyl)-2-morpholino-4H-chromen-4-one
DMTYWCS HS Investigative
DMTYWCS SN CHEMBL371103
DMTYWCS DT Small molecular drug
DMTYWCS PC 11623973
DMTYWCS MW 323.3
DMTYWCS FM C19H17NO4
DMTYWCS IC InChI=1S/C19H17NO4/c21-15-4-1-13(2-5-15)14-3-6-18-16(11-14)17(22)12-19(24-18)20-7-9-23-10-8-20/h1-6,11-12,21H,7-10H2
DMTYWCS CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=C(C=C4)O
DMTYWCS IK JERFBKBQDMCBEI-UHFFFAOYSA-N
DMTYWCS IU 6-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMTYWCS DE Discovery agent
DM2V9XI ID DM2V9XI
DM2V9XI DN 6-(4-Hydroxy-phenyl)-naphthalen-1-ol
DM2V9XI HS Investigative
DM2V9XI SN 6-(4-hydroxyphenyl)-1-naphthol
DM2V9XI PC 10308021
DM2V9XI MW 236.26
DM2V9XI FM C16H12O2
DM2V9XI IC InChI=1S/C16H12O2/c17-14-7-4-11(5-8-14)12-6-9-15-13(10-12)2-1-3-16(15)18/h1-10,17-18H
DM2V9XI CS C1=CC2=C(C=CC(=C2)C3=CC=C(C=C3)O)C(=C1)O
DM2V9XI IK MBESMLNJQCOTRU-UHFFFAOYSA-N
DM2V9XI IU 6-(4-hydroxyphenyl)naphthalen-1-ol
DM2V9XI DE Discovery agent
DM3L2OI ID DM3L2OI
DM3L2OI DN 6-(4-Hydroxy-phenyl)-naphthalen-2-ol
DM3L2OI HS Investigative
DM3L2OI SN CHEMBL191974; 6-(4-hydroxyphenyl)-2-naphthol; 6-(4-Hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL2699234; SKPPZWVFPOQPOT-UHFFFAOYSA-N; ZINC13644983
DM3L2OI DT Small molecular drug
DM3L2OI PC 11459006
DM3L2OI MW 236.26
DM3L2OI FM C16H12O2
DM3L2OI IC InChI=1S/C16H12O2/c17-15-6-3-11(4-7-15)12-1-2-14-10-16(18)8-5-13(14)9-12/h1-10,17-18H
DM3L2OI CS C1=CC(=CC=C1C2=CC3=C(C=C2)C=C(C=C3)O)O
DM3L2OI IK SKPPZWVFPOQPOT-UHFFFAOYSA-N
DM3L2OI IU 6-(4-hydroxyphenyl)naphthalen-2-ol
DM3L2OI DE Discovery agent
DM5LBCH ID DM5LBCH
DM5LBCH DN 6-(4-Methoxy-benzenesulfonyl)-2H-pyridazin-3-one
DM5LBCH HS Investigative
DM5LBCH SN CHEMBL74785; SCHEMBL6207869; BDBM16446; ZINC11536216; AKOS001782172; AKOS015830989; MCULE-9943571795; CCG-127351; 6-phenylsulfonylpyridazin-2H-3-one, 8; 454181-51-2; Phenyl-Substituted Sulfonylpyridazinone, 8h; 6-[(4-methoxyphenyl)sulfonyl]pyridazin-3(2H)-one; 3(2H)-Pyridazinone, 6-[(4-methoxyphenyl)sulfonyl]-
DM5LBCH DT Small molecular drug
DM5LBCH PC 9921499
DM5LBCH MW 266.28
DM5LBCH FM C11H10N2O4S
DM5LBCH IC InChI=1S/C11H10N2O4S/c1-17-8-2-4-9(5-3-8)18(15,16)11-7-6-10(14)12-13-11/h2-7H,1H3,(H,12,14)
DM5LBCH CS COC1=CC=C(C=C1)S(=O)(=O)C2=NNC(=O)C=C2
DM5LBCH IK KLWAIVHFGCYFDO-UHFFFAOYSA-N
DM5LBCH IU 3-(4-methoxyphenyl)sulfonyl-1H-pyridazin-6-one
DM5LBCH DE Discovery agent
DMUHCO8 ID DMUHCO8
DMUHCO8 DN 6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one
DMUHCO8 HS Investigative
DMUHCO8 SN CHEMBL221410; 6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one; SCHEMBL3538432
DMUHCO8 DT Small molecular drug
DMUHCO8 PC 21106426
DMUHCO8 MW 287.31
DMUHCO8 FM C16H17NO4
DMUHCO8 IC InChI=1S/C16H17NO4/c1-19-14-4-2-12(3-5-14)15-10-13(11-16(18)21-15)17-6-8-20-9-7-17/h2-5,10-11H,6-9H2,1H3
DMUHCO8 CS COC1=CC=C(C=C1)C2=CC(=CC(=O)O2)N3CCOCC3
DMUHCO8 IK PRPSUNXAZLZCBS-UHFFFAOYSA-N
DMUHCO8 IU 6-(4-methoxyphenyl)-4-morpholin-4-ylpyran-2-one
DMUHCO8 DE Discovery agent
DMWITYU ID DMWITYU
DMWITYU DN 6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine
DMWITYU HS Investigative
DMWITYU SN 6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine; CHEMBL594694; 1196993-60-8; SCHEMBL20093538; MolPort-039-193-873; BBL036459; STL490826; ZINC45352375; BDBM50304514
DMWITYU DT Small molecular drug
DMWITYU PC 46228161
DMWITYU MW 233.27
DMWITYU FM C10H15N7
DMWITYU IC InChI=1S/C10H15N7/c1-16-2-4-17(5-3-16)9-7-8(13-6-12-7)14-10(11)15-9/h6H,2-5H2,1H3,(H3,11,12,13,14,15)
DMWITYU CS CN1CCN(CC1)C2=NC(=NC3=C2NC=N3)N
DMWITYU IK HZZXEPZFOVOWIN-UHFFFAOYSA-N
DMWITYU IU 6-(4-methylpiperazin-1-yl)-7H-purin-2-amine
DMWITYU DE Discovery agent
DMA3FQP ID DMA3FQP
DMA3FQP DN 6-(4-methylpiperazin-1-yl)-9Hpurine
DMA3FQP HS Investigative
DMA3FQP SN 6-(4-methylpiperazin-1-yl)-9H-purine; 6-(4-methylpiperazin-1-yl)-7H-purine; CHEMBL594152; 99172-01-7; SDCCGMLS-0065440.P001; 6-(4-methylpiperazin-1-yl)-9Hpurine; AC1LFNRL; Oprea1_666011; MLS000419169; 6-(4-methylpiperazinyl)purine; SCHEMBL13718480; MolPort-000-847-583; MolPort-000-384-358; HMS2684L19; ZINC213869; HMS1650E09; CCG-26902; BBL036787; STK630143; BDBM50304512; NSC510935; AKOS001427557; AKOS005562847; NSC-510935; MCULE-5386395090; SMR000319851; ST45178781; AB00588487-02; SR-01000104630; SR-01000104630-1; Z57745256
DMA3FQP DT Small molecular drug
DMA3FQP PC 756701
DMA3FQP MW 218.26
DMA3FQP FM C10H14N6
DMA3FQP IC InChI=1S/C10H14N6/c1-15-2-4-16(5-3-15)10-8-9(12-6-11-8)13-7-14-10/h6-7H,2-5H2,1H3,(H,11,12,13,14)
DMA3FQP CS CN1CCN(CC1)C2=NC=NC3=C2NC=N3
DMA3FQP IK AXPCNBLIEMWMMG-UHFFFAOYSA-N
DMA3FQP IU 6-(4-methylpiperazin-1-yl)-7H-purine
DMA3FQP DE Discovery agent
DM1HAWR ID DM1HAWR
DM1HAWR DN 6-(4-Methyl-piperazin-1-yl)-phenanthridine
DM1HAWR HS Investigative
DM1HAWR SN CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; 6-(4-Methyl-piperazin-1-yl)-phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)-
DM1HAWR DT Small molecular drug
DM1HAWR PC 9993659
DM1HAWR MW 277.4
DM1HAWR FM C18H19N3
DM1HAWR IC InChI=1S/C18H19N3/c1-20-10-12-21(13-11-20)18-16-8-3-2-6-14(16)15-7-4-5-9-17(15)19-18/h2-9H,10-13H2,1H3
DM1HAWR CS CN1CCN(CC1)C2=NC3=CC=CC=C3C4=CC=CC=C42
DM1HAWR IK ZVJIBTNUNUXAIO-UHFFFAOYSA-N
DM1HAWR IU 6-(4-methylpiperazin-1-yl)phenanthridine
DM1HAWR CA CAS 23441-13-6
DM1HAWR DE Discovery agent
DMYAS2V ID DMYAS2V
DMYAS2V DN 6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine
DMYAS2V HS Investigative
DMYAS2V SN CHEMBL473662; 6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine; BAS 06575347; AC1LFG9R; 2,4-Pyrimidinediamine, 6-(4-methyl-1-piperazinyl)-; SCHEMBL2169898; MolPort-002-005-545; ZINC205303; BDBM50304501; CCG-24528; AKOS000670805; 4940-96-9; VU0047515-1
DMYAS2V DT Small molecular drug
DMYAS2V PC 753256
DMYAS2V MW 208.26
DMYAS2V FM C9H16N6
DMYAS2V IC InChI=1S/C9H16N6/c1-14-2-4-15(5-3-14)8-6-7(10)12-9(11)13-8/h6H,2-5H2,1H3,(H4,10,11,12,13)
DMYAS2V CS CN1CCN(CC1)C2=NC(=NC(=C2)N)N
DMYAS2V IK RBHNSRTVBDSNLG-UHFFFAOYSA-N
DMYAS2V IU 6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
DMYAS2V DE Discovery agent
DMTV753 ID DMTV753
DMTV753 DN 6-(4-Methylpyridin-3-yl)-2-naphthonitrile
DMTV753 HS Investigative
DMTV753 SN CHEMBL500665; 6-(4-Methylpyridin-3-yl)-2-naphthonitrile; BDBM50272247
DMTV753 DT Small molecular drug
DMTV753 PC 25034343
DMTV753 MW 244.29
DMTV753 FM C17H12N2
DMTV753 IC InChI=1S/C17H12N2/c1-12-6-7-19-11-17(12)16-5-4-14-8-13(10-18)2-3-15(14)9-16/h2-9,11H,1H3
DMTV753 CS CC1=C(C=NC=C1)C2=CC3=C(C=C2)C=C(C=C3)C#N
DMTV753 IK BVEDDOVOLJETRX-UHFFFAOYSA-N
DMTV753 IU 6-(4-methylpyridin-3-yl)naphthalene-2-carbonitrile
DMTV753 DE Discovery agent
DMPL5XV ID DMPL5XV
DMPL5XV DN 6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine
DMPL5XV HS Investigative
DMPL5XV SN CHEMBL362511; 6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine
DMPL5XV DT Small molecular drug
DMPL5XV PC 11165248
DMPL5XV MW 391.4
DMPL5XV FM C20H17N5O2S
DMPL5XV IC InChI=1S/C20H17N5O2S/c26-25(27)17-8-6-16(7-9-17)12-28-20-18-19(21-13-22-20)24(14-23-18)11-10-15-4-2-1-3-5-15/h1-9,13-14H,10-12H2
DMPL5XV CS C1=CC=C(C=C1)CCN2C=NC3=C2N=CN=C3SCC4=CC=C(C=C4)[N+](=O)[O-]
DMPL5XV IK RXUAVXPJZWEMTE-UHFFFAOYSA-N
DMPL5XV IU 6-[(4-nitrophenyl)methylsulfanyl]-9-(2-phenylethyl)purine
DMPL5XV DE Discovery agent
DMVMDJ3 ID DMVMDJ3
DMVMDJ3 DN 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide
DMVMDJ3 HS Investigative
DMVMDJ3 SN CHEMBL1290142; A1-02262; 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1
DMVMDJ3 DT Small molecular drug
DMVMDJ3 PC 46918725
DMVMDJ3 MW 296.4
DMVMDJ3 FM C18H20N2O2
DMVMDJ3 IC InChI=1S/C18H20N2O2/c21-18(19-22)12-2-1-7-13-20-16-10-5-3-8-14(16)15-9-4-6-11-17(15)20/h3-6,8-11,22H,1-2,7,12-13H2,(H,19,21)
DMVMDJ3 CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CCCCCC(=O)NO
DMVMDJ3 IK SOMDVJCUFVPZKM-UHFFFAOYSA-N
DMVMDJ3 IU 6-carbazol-9-yl-N-hydroxyhexanamide
DMVMDJ3 DE Discovery agent
DMYMJHF ID DMYMJHF
DMYMJHF DN 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol
DMYMJHF HS Investigative
DMYMJHF SN CHEMBL171118
DMYMJHF DT Small molecular drug
DMYMJHF PC 44382932
DMYMJHF MW 337.5
DMYMJHF FM C23H31NO
DMYMJHF IC InChI=1S/C23H31NO/c1-5-17-24(4)19(3)18-23(22(25)6-2,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h5,7-16,19,22,25H,1,6,17-18H2,2-4H3
DMYMJHF CS CCC(C(CC(C)N(C)CC=C)(C1=CC=CC=C1)C2=CC=CC=C2)O
DMYMJHF IK HXWBPTAZQDKQKI-UHFFFAOYSA-N
DMYMJHF IU 6-[methyl(prop-2-enyl)amino]-4,4-diphenylheptan-3-ol
DMYMJHF DE Discovery agent
DMJU9TG ID DMJU9TG
DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one
DMJU9TG HS Investigative
DMJU9TG SN CHEMBL567139; 6-aminomethylcoumarin; 927173-90-8; 6-(aminomethyl)-2H-chromen-2-one; 6-(Aminomethyl)coumarin; BDBM50303497
DMJU9TG DT Small molecular drug
DMJU9TG PC 45485270
DMJU9TG MW 175.18
DMJU9TG FM C10H9NO2
DMJU9TG IC InChI=1S/C10H9NO2/c11-6-7-1-3-9-8(5-7)2-4-10(12)13-9/h1-5H,6,11H2
DMJU9TG CS C1=CC2=C(C=CC(=O)O2)C=C1CN
DMJU9TG IK MXXNUQUOHJMQEU-UHFFFAOYSA-N
DMJU9TG IU 6-(aminomethyl)chromen-2-one
DMJU9TG DE Discovery agent
DM2GFI3 ID DM2GFI3
DM2GFI3 DN 6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-one
DM2GFI3 HS Investigative
DM2GFI3 SN CHEMBL241777; benzofuran, 22; SCHEMBL4448826; BDBM16456; Heterocyclic Sulfonylpyridazinone, 19h
DM2GFI3 DT Small molecular drug
DM2GFI3 PC 11807954
DM2GFI3 MW 276.27
DM2GFI3 FM C12H8N2O4S
DM2GFI3 IC InChI=1S/C12H8N2O4S/c15-10-5-6-11(14-13-10)19(16,17)12-7-8-3-1-2-4-9(8)18-12/h1-7H,(H,13,15)
DM2GFI3 CS C1=CC=C2C(=C1)C=C(O2)S(=O)(=O)C3=NNC(=O)C=C3
DM2GFI3 IK RBZSSTPBYFHRSR-UHFFFAOYSA-N
DM2GFI3 IU 3-(1-benzofuran-2-ylsulfonyl)-1H-pyridazin-6-one
DM2GFI3 DE Discovery agent
DMXLDHR ID DMXLDHR
DMXLDHR DN 6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one
DMXLDHR HS Investigative
DMXLDHR SN benzothiazole, 19; 6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one; CHEMBL73330; BDBM16453; Heterocyclic Sulfonylpyridazinone, 19z
DMXLDHR DT Small molecular drug
DMXLDHR PC 10902449
DMXLDHR MW 293.3
DMXLDHR FM C11H7N3O3S2
DMXLDHR IC InChI=1S/C11H7N3O3S2/c15-9-5-6-10(14-13-9)19(16,17)11-12-7-3-1-2-4-8(7)18-11/h1-6H,(H,13,15)
DMXLDHR CS C1=CC=C2C(=C1)N=C(S2)S(=O)(=O)C3=NNC(=O)C=C3
DMXLDHR IK AWYKKLWCTAPMDK-UHFFFAOYSA-N
DMXLDHR IU 3-(1,3-benzothiazol-2-ylsulfonyl)-1H-pyridazin-6-one
DMXLDHR DE Discovery agent
DM7BIJH ID DM7BIJH
DM7BIJH DN 6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile
DM7BIJH HS Investigative
DM7BIJH SN Compound 3{8,12}; 6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile; CHEMBL255079
DM7BIJH DT Small molecular drug
DM7BIJH PC 24777047
DM7BIJH MW 306.4
DM7BIJH FM C17H18N6
DM7BIJH IC InChI=1S/C17H18N6/c1-2-3-9-23-12-20-15-16(21-14(10-18)22-17(15)23)19-11-13-7-5-4-6-8-13/h4-8,12H,2-3,9,11H2,1H3,(H,19,21,22)
DM7BIJH CS CCCCN1C=NC2=C(N=C(N=C21)C#N)NCC3=CC=CC=C3
DM7BIJH IK OJVVVZACBFLFEJ-UHFFFAOYSA-N
DM7BIJH IU 6-(benzylamino)-9-butylpurine-2-carbonitrile
DM7BIJH DE Discovery agent
DM4KMDB ID DM4KMDB
DM4KMDB DN 6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one
DM4KMDB HS Investigative
DM4KMDB SN CHEMBL72752; SCHEMBL6207186; BDBM16448; 6-phenylsulfonylpyridazin-2H-3-one, 10; Phenyl-Substituted Sulfonylpyridazinone, 8j
DM4KMDB DT Small molecular drug
DM4KMDB PC 10267673
DM4KMDB MW 312.3
DM4KMDB FM C16H12N2O3S
DM4KMDB IC InChI=1S/C16H12N2O3S/c19-15-10-11-16(18-17-15)22(20,21)14-9-5-4-8-13(14)12-6-2-1-3-7-12/h1-11H,(H,17,19)
DM4KMDB CS C1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)C3=NNC(=O)C=C3
DM4KMDB IK PICCQCWBQAQOHS-UHFFFAOYSA-N
DM4KMDB IU 3-(2-phenylphenyl)sulfonyl-1H-pyridazin-6-one
DM4KMDB DE Discovery agent
DMAYWIN ID DMAYWIN
DMAYWIN DN 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine
DMAYWIN HS Investigative
DMAYWIN SN CHEMBL115498; O6-Substituted Guanine Deriv. 27; AC1NS6ZQ; 9H-Purin-2-amine, 6-(3-cyclohexen-1-ylmethoxy)-; SCHEMBL6267556; BDBM5487; 220035-95-0; 6-(cyclohex-3-en-1-ylmethoxy)-9H-purin-2-amine
DMAYWIN DT Small molecular drug
DMAYWIN PC 5329512
DMAYWIN MW 245.28
DMAYWIN FM C12H15N5O
DMAYWIN IC InChI=1S/C12H15N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-2,7-8H,3-6H2,(H3,13,14,15,16,17)
DMAYWIN CS C1CC(CC=C1)COC2=NC(=NC3=C2NC=N3)N
DMAYWIN IK RXNXVXFFAAPSTR-UHFFFAOYSA-N
DMAYWIN IU 6-(cyclohex-3-en-1-ylmethoxy)-7H-purin-2-amine
DMAYWIN DE Discovery agent
DMQPTL5 ID DMQPTL5
DMQPTL5 DN 6-(Dihydroxy-Isobutyl)-Thymine
DMQPTL5 HS Investigative
DMQPTL5 SN 6-(DIHYDROXY-ISOBUTYL)-THYMINE; DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione
DMQPTL5 DT Small molecular drug
DMQPTL5 PC 1855
DMQPTL5 MW 214.22
DMQPTL5 FM C9H14N2O4
DMQPTL5 IC InChI=1S/C9H14N2O4/c1-5-7(2-6(3-12)4-13)10-9(15)11-8(5)14/h6,12-13H,2-4H2,1H3,(H2,10,11,14,15)
DMQPTL5 CS CC1=C(NC(=O)NC1=O)CC(CO)CO
DMQPTL5 IK CLCPDSJUXHDRGX-UHFFFAOYSA-N
DMQPTL5 IU 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione
DMQPTL5 CB CHEBI:41485
DMQPTL5 DE Discovery agent
DMOYCBH ID DMOYCBH
DMOYCBH DN 6-(furan-2-yl)-9H-purin-2-amine
DMOYCBH HS Investigative
DMOYCBH SN CHEMBL404447; 6-(2-furanyl)-9h-purin-2-amine; 442682-77-1; 6-(furan-2-yl)-9H-purin-2-amine; SCHEMBL3272888; 6-(furanyl)-9h-purin-2-amine; JZSMPSCWNAYWOI-UHFFFAOYSA-N; 6-(2-furyl)1H-purine-2-amine; 6-(2-Furyl)-1H-purine-2-amine
DMOYCBH DT Small molecular drug
DMOYCBH PC 9834240
DMOYCBH MW 201.18
DMOYCBH FM C9H7N5O
DMOYCBH IC InChI=1S/C9H7N5O/c10-9-13-6(5-2-1-3-15-5)7-8(14-9)12-4-11-7/h1-4H,(H3,10,11,12,13,14)
DMOYCBH CS C1=COC(=C1)C2=C3C(=NC(=N2)N)N=CN3
DMOYCBH IK JZSMPSCWNAYWOI-UHFFFAOYSA-N
DMOYCBH IU 6-(furan-2-yl)-7H-purin-2-amine
DMOYCBH DE Discovery agent
DM5TOX2 ID DM5TOX2
DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one
DM5TOX2 HS Investigative
DM5TOX2 SN 6-(hydroxymethyl)-2H-chromen-2-one; CHEMBL571738; 2H-1-Benzopyran-2-one, 6-(hydroxymethyl)-; 6,7-hydroxy-4-methyl coumarin; SCHEMBL10350668; BDBM50303496; AKOS006293254
DM5TOX2 DT Small molecular drug
DM5TOX2 PC 20195365
DM5TOX2 MW 176.17
DM5TOX2 FM C10H8O3
DM5TOX2 IC InChI=1S/C10H8O3/c11-6-7-1-3-9-8(5-7)2-4-10(12)13-9/h1-5,11H,6H2
DM5TOX2 CS C1=CC2=C(C=CC(=O)O2)C=C1CO
DM5TOX2 IK BPTGMUVORRVIEP-UHFFFAOYSA-N
DM5TOX2 IU 6-(hydroxymethyl)chromen-2-one
DM5TOX2 DE Discovery agent
DMSH107 ID DMSH107
DMSH107 DN 6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione
DMSH107 HS Investigative
DMSH107 SN CHEMBL54950; 64054-69-9; 6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione; 6-[(5-Indanyl)amino]uracil; SCHEMBL3971654; CTK2A7431; DTXSID80591769; BDBM50022163; ZINC13798089; 6-[(3,4-trimethylene)anilino]uracil; 2,4(1H,3H)-Pyrimidinedione, 6-[(2,3-dihydro-1H-inden-5-yl)amino]-
DMSH107 DT Small molecular drug
DMSH107 PC 17960612
DMSH107 MW 243.26
DMSH107 FM C13H13N3O2
DMSH107 IC InChI=1S/C13H13N3O2/c17-12-7-11(15-13(18)16-12)14-10-5-4-8-2-1-3-9(8)6-10/h4-7H,1-3H2,(H3,14,15,16,17,18)
DMSH107 CS C1CC2=C(C1)C=C(C=C2)NC3=CC(=O)NC(=O)N3
DMSH107 IK CVUMGFDAIXWWCV-UHFFFAOYSA-N
DMSH107 IU 6-(2,3-dihydro-1H-inden-5-ylamino)-1H-pyrimidine-2,4-dione
DMSH107 CA CAS 64054-69-9
DMSH107 DE Discovery agent
DMM2TFX ID DMM2TFX
DMM2TFX DN 6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione
DMM2TFX HS Investigative
DMM2TFX SN CHEMBL124937; 6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione; 21333-09-5; NSC212338; AC1L7G1P; Oprea1_822744; Oprea1_362386; DTXSID70309577; ZINC322361; BDBM50028361; NSC-212338
DMM2TFX DT Small molecular drug
DMM2TFX PC 309881
DMM2TFX MW 253.26
DMM2TFX FM C14H11N3O2
DMM2TFX IC InChI=1S/C14H11N3O2/c18-13-8-12(16-14(19)17-13)15-11-6-5-9-3-1-2-4-10(9)7-11/h1-8H,(H3,15,16,17,18,19)
DMM2TFX CS C1=CC=C2C=C(C=CC2=C1)NC3=CC(=O)NC(=O)N3
DMM2TFX IK KADGSGKDRXSVOE-UHFFFAOYSA-N
DMM2TFX IU 6-(naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione
DMM2TFX CA CAS 21333-09-5
DMM2TFX DE Discovery agent
DMXSCQE ID DMXSCQE
DMXSCQE DN 6-(Naphthalene-1-sulfonyl)-2H-pyridazin-3-one
DMXSCQE HS Investigative
DMXSCQE SN CHEMBL194582; SCHEMBL6206673
DMXSCQE DT Small molecular drug
DMXSCQE PC 9943757
DMXSCQE MW 286.31
DMXSCQE FM C14H10N2O3S
DMXSCQE IC InChI=1S/C14H10N2O3S/c17-13-8-9-14(16-15-13)20(18,19)12-7-3-5-10-4-1-2-6-11(10)12/h1-9H,(H,15,17)
DMXSCQE CS C1=CC=C2C(=C1)C=CC=C2S(=O)(=O)C3=NNC(=O)C=C3
DMXSCQE IK HJXKXDILPXEWJY-UHFFFAOYSA-N
DMXSCQE IU 3-naphthalen-1-ylsulfonyl-1H-pyridazin-6-one
DMXSCQE DE Discovery agent
DMCIA63 ID DMCIA63
DMCIA63 DN 6-(Naphthalene-2-sulfonyl)-2H-pyridazin-3-one
DMCIA63 HS Investigative
DMCIA63 SN CHEMBL369911
DMCIA63 DT Small molecular drug
DMCIA63 PC 11673647
DMCIA63 MW 286.31
DMCIA63 FM C14H10N2O3S
DMCIA63 IC InChI=1S/C14H10N2O3S/c17-13-7-8-14(16-15-13)20(18,19)12-6-5-10-3-1-2-4-11(10)9-12/h1-9H,(H,15,17)
DMCIA63 CS C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)C3=NNC(=O)C=C3
DMCIA63 IK HXEYVOPGUKCHBE-UHFFFAOYSA-N
DMCIA63 IU 3-naphthalen-2-ylsulfonyl-1H-pyridazin-6-one
DMCIA63 DE Discovery agent
DMHM0RW ID DMHM0RW
DMHM0RW DN 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine
DMHM0RW HS Investigative
DMHM0RW SN 6-(N-PHENYLCARBAMYL)-2-NAPHTHALENECARBOXAMIDINE; CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide
DMHM0RW DT Small molecular drug
DMHM0RW PC 447732
DMHM0RW MW 289.3
DMHM0RW FM C18H15N3O
DMHM0RW IC InChI=1S/C18H15N3O/c19-17(20)14-8-6-13-11-15(9-7-12(13)10-14)18(22)21-16-4-2-1-3-5-16/h1-11H,(H3,19,20)(H,21,22)
DMHM0RW CS C1=CC=C(C=C1)NC(=O)C2=CC3=C(C=C2)C=C(C=C3)C(=N)N
DMHM0RW IK AECPTICWHONWNW-UHFFFAOYSA-N
DMHM0RW IU 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide
DMHM0RW DE Discovery agent
DM1LY0S ID DM1LY0S
DM1LY0S DN 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
DM1LY0S HS Investigative
DM1LY0S SN 6-(OXALYL-AMINO)-1H-INDOLE-5-CARBOXYLIC ACID; CHEMBL342478; 243967-44-4; 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-; 6-(carboxyformamido)-1H-indole-5-carboxylic acid; OAI; AC1L9GUL; SCHEMBL4318827; CTK0J4951; DTXSID50332166; 1c83; BDBM50118796; DB04001; N-(5-Carboxy-1H-indole-6-yl)oxamidic acid; 6-(oxaloamino)-1H-indole-5-carboxylic acid; 6-[(carboxycarbonyl)amino]-1H-indole-5-carboxylic acid
DM1LY0S DT Small molecular drug
DM1LY0S PC 444763
DM1LY0S MW 248.19
DM1LY0S FM C11H8N2O5
DM1LY0S IC InChI=1S/C11H8N2O5/c14-9(11(17)18)13-8-4-7-5(1-2-12-7)3-6(8)10(15)16/h1-4,12H,(H,13,14)(H,15,16)(H,17,18)
DM1LY0S CS C1=CNC2=CC(=C(C=C21)C(=O)O)NC(=O)C(=O)O
DM1LY0S IK AHWMERGBWWROMM-UHFFFAOYSA-N
DM1LY0S IU 6-(oxaloamino)-1H-indole-5-carboxylic acid
DM1LY0S CA CAS 243967-44-4
DM1LY0S DE Discovery agent
DMM9G0J ID DMM9G0J
DMM9G0J DN 6-(piperazin-1-yl)-3-tosyl-1H-indazole
DMM9G0J HS Investigative
DMM9G0J SN CHEMBL1277286; 6-(piperazin-1-yl)-3-tosyl-1H-indazole
DMM9G0J DT Small molecular drug
DMM9G0J PC 49836719
DMM9G0J MW 356.4
DMM9G0J FM C18H20N4O2S
DMM9G0J IC InChI=1S/C18H20N4O2S/c1-13-2-5-15(6-3-13)25(23,24)18-16-7-4-14(12-17(16)20-21-18)22-10-8-19-9-11-22/h2-7,12,19H,8-11H2,1H3,(H,20,21)
DMM9G0J CS CC1=CC=C(C=C1)S(=O)(=O)C2=C3C=CC(=CC3=NN2)N4CCNCC4
DMM9G0J IK HACUZCXCVMCHQD-UHFFFAOYSA-N
DMM9G0J IU 3-(4-methylphenyl)sulfonyl-6-piperazin-1-yl-2H-indazole
DMM9G0J CA CAS 744219-47-4
DMM9G0J DE Discovery agent
DMUNWJR ID DMUNWJR
DMUNWJR DN 6-(piperazin-1-yl)-9-propyl-9H-purine
DMUNWJR HS Investigative
DMUNWJR SN CHEMBL594489; 6-(piperazin-1-yl)-9-propyl-9H-purine
DMUNWJR DT Small molecular drug
DMUNWJR PC 46228441
DMUNWJR MW 246.31
DMUNWJR FM C12H18N6
DMUNWJR IC InChI=1S/C12H18N6/c1-2-5-18-9-16-10-11(14-8-15-12(10)18)17-6-3-13-4-7-17/h8-9,13H,2-7H2,1H3
DMUNWJR CS CCCN1C=NC2=C1N=CN=C2N3CCNCC3
DMUNWJR IK BWJIAIMMFVYUQA-UHFFFAOYSA-N
DMUNWJR IU 6-piperazin-1-yl-9-propylpurine
DMUNWJR DE Discovery agent
DMBQKGY ID DMBQKGY
DMBQKGY DN 6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY HS Investigative
DMBQKGY SN CHEMBL469552; 6-(piperidin-4-ylmethoxy)-2-naphthonitrile
DMBQKGY DT Small molecular drug
DMBQKGY PC 44592200
DMBQKGY MW 266.34
DMBQKGY FM C17H18N2O
DMBQKGY IC InChI=1S/C17H18N2O/c18-11-14-1-2-16-10-17(4-3-15(16)9-14)20-12-13-5-7-19-8-6-13/h1-4,9-10,13,19H,5-8,12H2
DMBQKGY CS C1CNCCC1COC2=CC3=C(C=C2)C=C(C=C3)C#N
DMBQKGY IK SHJHTXWKDLOBQS-UHFFFAOYSA-N
DMBQKGY IU 6-(piperidin-4-ylmethoxy)naphthalene-2-carbonitrile
DMBQKGY DE Discovery agent
DMC3SJI ID DMC3SJI
DMC3SJI DN 6-(pyridin-3-yl)-2-naphthonitrile
DMC3SJI HS Investigative
DMC3SJI SN CHEMBL196796; SCHEMBL4511285; BDBM8909; 6-pyridin-3-yl-2-naphthonitrile; Pyridine-substituted naphthalene 8; ZINC13674459
DMC3SJI DT Small molecular drug
DMC3SJI PC 11601068
DMC3SJI MW 230.26
DMC3SJI FM C16H10N2
DMC3SJI IC InChI=1S/C16H10N2/c17-10-12-3-4-14-9-15(6-5-13(14)8-12)16-2-1-7-18-11-16/h1-9,11H
DMC3SJI CS C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)C#N
DMC3SJI IK BRNSTMOAGOETDI-UHFFFAOYSA-N
DMC3SJI IU 6-pyridin-3-ylnaphthalene-2-carbonitrile
DMC3SJI DE Discovery agent
DMV3MF4 ID DMV3MF4
DMV3MF4 DN 6-(Toluene-4-sulfonyl)-2H-pyridazin-3-one
DMV3MF4 HS Investigative
DMV3MF4 SN CHEMBL72368; 6-tosylpyridazin-3(2H)-one; BDBM16447; ZINC11536215; AKOS015830955; AKOS001773373; MCULE-5757912617; CCG-126887; 6-phenylsulfonylpyridazin-2H-3-one, 9; 99985-09-8; Phenyl-Substituted Sulfonylpyridazinone, 8i; 3(2H)-Pyridazinone, 6-[(4-methylphenyl)sulfonyl]-; F6548-0368
DMV3MF4 DT Small molecular drug
DMV3MF4 PC 22424988
DMV3MF4 MW 250.28
DMV3MF4 FM C11H10N2O3S
DMV3MF4 IC InChI=1S/C11H10N2O3S/c1-8-2-4-9(5-3-8)17(15,16)11-7-6-10(14)12-13-11/h2-7H,1H3,(H,12,14)
DMV3MF4 CS CC1=CC=C(C=C1)S(=O)(=O)C2=NNC(=O)C=C2
DMV3MF4 IK SGMDNRFRSNYBCA-UHFFFAOYSA-N
DMV3MF4 IU 3-(4-methylphenyl)sulfonyl-1H-pyridazin-6-one
DMV3MF4 DE Discovery agent
DMSB8WQ ID DMSB8WQ
DMSB8WQ DN 6,11-dihydro-5H-benzo[a]carbazole
DMSB8WQ HS Investigative
DMSB8WQ SN 6,11-dihydro-5H-benzo[a]carbazole; 21064-49-3; 5H-Benzo[a]carbazole, 6,11-dihydro-; 1,2,7-trihydrobenzo[a]4aH-carbazole; ST076800; 5,11-Dihydro-6H-benzo[a]carbazole; 5,11-DIHYDRO-6H-BENZO(A)CARBAZOLE; NSC168810; AC1L6RUQ; Maybridge1_006237; AC1Q1H7M; CHEMBL239937; Aza-heterocyclic Derivative, 7; SCHEMBL12126575; HMS559D11; CTK0J8060; BDBM19186; DTXSID40305026; MolPort-000-737-601; ZX-AN022290; ALBB-023776; ZINC1023865; CCG-20433; STK874208; BBL028411; 5,6-Dihydro-11H-benzo[a]carbazole; AKOS000547063; MCULE-4710620349; NSC-168810; RH 00
DMSB8WQ DT Small molecular drug
DMSB8WQ PC 297591
DMSB8WQ MW 219.28
DMSB8WQ FM C16H13N
DMSB8WQ IC InChI=1S/C16H13N/c1-2-6-12-11(5-1)9-10-14-13-7-3-4-8-15(13)17-16(12)14/h1-8,17H,9-10H2
DMSB8WQ CS C1CC2=C(C3=CC=CC=C31)NC4=CC=CC=C24
DMSB8WQ IK UPUQYBJFFYMNQK-UHFFFAOYSA-N
DMSB8WQ IU 6,11-dihydro-5H-benzo[a]carbazole
DMSB8WQ CA CAS 21064-49-3
DMSB8WQ DE Discovery agent
DM0RB53 ID DM0RB53
DM0RB53 DN 6,11-dihydrothiochromeno[4,3-b]indol-8-ol
DM0RB53 HS Investigative
DM0RB53 SN CHEMBL210924; 6,11-dihydrothiochromeno[4,3-b]indol-8-ol; SCHEMBL1986592; BVGUKMAMOJMOFD-UHFFFAOYSA-N; BDBM50185203
DM0RB53 DT Small molecular drug
DM0RB53 PC 44411868
DM0RB53 MW 253.32
DM0RB53 FM C15H11NOS
DM0RB53 IC InChI=1S/C15H11NOS/c17-9-5-6-13-11(7-9)12-8-18-14-4-2-1-3-10(14)15(12)16-13/h1-7,16-17H,8H2
DM0RB53 CS C1C2=C(C3=CC=CC=C3S1)NC4=C2C=C(C=C4)O
DM0RB53 IK BVGUKMAMOJMOFD-UHFFFAOYSA-N
DM0RB53 IU 6,11-dihydrothiochromeno[4,3-b]indol-8-ol
DM0RB53 DE Discovery agent
DMMZTE3 ID DMMZTE3
DMMZTE3 DN 6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMMZTE3 HS Investigative
DMMZTE3 SN CHEMBL488639; 6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane
DMMZTE3 DT Small molecular drug
DMMZTE3 PC 44561134
DMMZTE3 MW 187.28
DMMZTE3 FM C13H17N
DMMZTE3 IC InChI=1S/C13H17N/c1-12(2)11-8-14-9-13(11,12)10-6-4-3-5-7-10/h3-7,11,14H,8-9H2,1-2H3
DMMZTE3 CS CC1(C2C1(CNC2)C3=CC=CC=C3)C
DMMZTE3 IK GCPODIFNAITRSC-UHFFFAOYSA-N
DMMZTE3 IU 6,6-dimethyl-1-phenyl-3-azabicyclo[3.1.0]hexane
DMMZTE3 DE Discovery agent
DMOIFAP ID DMOIFAP
DMOIFAP DN 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DMOIFAP HS Investigative
DMOIFAP SN 2-Oxaspiro[4.4]nonan-1-one, 6,6-dimethyl-; CHEMBL94885; 153579-89-6
DMOIFAP DT Small molecular drug
DMOIFAP PC 10352086
DMOIFAP MW 168.23
DMOIFAP FM C10H16O2
DMOIFAP IC InChI=1S/C10H16O2/c1-9(2)4-3-5-10(9)6-7-12-8(10)11/h3-7H2,1-2H3
DMOIFAP CS CC1(CCCC12CCOC2=O)C
DMOIFAP IK FHWLTPUPKBUBCF-UHFFFAOYSA-N
DMOIFAP IU 9,9-dimethyl-2-oxaspiro[4.4]nonan-1-one
DMOIFAP DE Discovery agent
DMNOI7B ID DMNOI7B
DMNOI7B DN 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene
DMNOI7B HS Investigative
DMNOI7B SN 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine; 58980-39-5; 2,3,4,5-tetrahydro-1,4-benzothiazepine; CHEMBL333343; 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene; 1,4-Benzothiazepine, 2,3,4,5-tetrahydro-; SCHEMBL2589907; CTK1D9777; DTXSID50483283; SUBDEKBXSIKCSA-UHFFFAOYSA-N; MolPort-022-153-088; BDBM50052886; 8761AB; ANW-63665; ZINC13757904; AKOS015856597; AJ-64367; AS-36127; KB-224927; TR-072578; AB0052636; ST24021452; FT-0733802; 2,3,4,5-tetrahydrobenzo[f]-1,4-thiazepine; X-3109; I14-16090
DMNOI7B DT Small molecular drug
DMNOI7B PC 12269106
DMNOI7B MW 165.26
DMNOI7B FM C9H11NS
DMNOI7B IC InChI=1S/C9H11NS/c1-2-4-9-8(3-1)7-10-5-6-11-9/h1-4,10H,5-7H2
DMNOI7B CS C1CSC2=CC=CC=C2CN1
DMNOI7B IK SUBDEKBXSIKCSA-UHFFFAOYSA-N
DMNOI7B IU 2,3,4,5-tetrahydro-1,4-benzothiazepine
DMNOI7B CA CAS 58980-39-5
DMNOI7B DE Discovery agent
DMAMD87 ID DMAMD87
DMAMD87 DN 6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one
DMAMD87 HS Investigative
DMAMD87 SN 6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1n; CHEMBL492382; BDBM29225
DMAMD87 DT Small molecular drug
DMAMD87 PC 42618033
DMAMD87 MW 263.29
DMAMD87 FM C14H17NO4
DMAMD87 IC InChI=1S/C14H17NO4/c1-8-6-11(16)15(2)12-9(8)7-10(17-3)13(18-4)14(12)19-5/h6-7H,1-5H3
DMAMD87 CS CC1=CC(=O)N(C2=C(C(=C(C=C12)OC)OC)OC)C
DMAMD87 IK QKOJIFYKROBOKN-UHFFFAOYSA-N
DMAMD87 IU 6,7,8-trimethoxy-1,4-dimethylquinolin-2-one
DMAMD87 DE Discovery agent
DMJX9NQ ID DMJX9NQ
DMJX9NQ DN 6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one
DMJX9NQ HS Investigative
DMJX9NQ SN 6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one; casimiroin analogue, 1m; CHEMBL454226; BDBM29224
DMJX9NQ DT Small molecular drug
DMJX9NQ PC 42618032
DMJX9NQ MW 249.26
DMJX9NQ FM C13H15NO4
DMJX9NQ IC InChI=1S/C13H15NO4/c1-7-5-10(15)14-11-8(7)6-9(16-2)12(17-3)13(11)18-4/h5-6H,1-4H3,(H,14,15)
DMJX9NQ CS CC1=CC(=O)NC2=C(C(=C(C=C12)OC)OC)OC
DMJX9NQ IK JAKHLWMOJRMVRW-UHFFFAOYSA-N
DMJX9NQ IU 6,7,8-trimethoxy-4-methyl-1H-quinolin-2-one
DMJX9NQ DE Discovery agent
DMDO083 ID DMDO083
DMDO083 DN 6,7-dibromoquinoline-5,8-dione
DMDO083 HS Investigative
DMDO083 SN 6,7-dibromoquinoline-5,8-dione; CHEMBL488961; 18633-05-1; 6,7-Dibrom-5,8-dihydrochinolin-5,8-dion; NSC82128; AC1L5TKN; SCHEMBL6866292; AC1Q6K93; 6,7-dibromo-5,8-quinolindion; CTK4D9216; DTXSID40292366; CPZKOUMVYNIHQE-UHFFFAOYSA-N; BDBM50264041; NSC-82128
DMDO083 DT Small molecular drug
DMDO083 PC 255964
DMDO083 MW 316.93
DMDO083 FM C9H3Br2NO2
DMDO083 IC InChI=1S/C9H3Br2NO2/c10-5-6(11)9(14)7-4(8(5)13)2-1-3-12-7/h1-3H
DMDO083 CS C1=CC2=C(C(=O)C(=C(C2=O)Br)Br)N=C1
DMDO083 IK CPZKOUMVYNIHQE-UHFFFAOYSA-N
DMDO083 IU 6,7-dibromoquinoline-5,8-dione
DMDO083 CA CAS 18633-05-1
DMDO083 DE Discovery agent
DMMX1QJ ID DMMX1QJ
DMMX1QJ DN 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione
DMMX1QJ HS Investigative
DMMX1QJ SN 25983-13-5; 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione; DCQX; 6,7-dichloroquinoxaline-2,3-diol; 6,7-DICHLORO-1,4-DIHYDRO-2,3-QUINOXALINEDIONE; 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione; 2,3-Dihydroxy-6,7-dichloroquinoxaline; 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione; CHEMBL284028; Spectrum_001661; ACMC-209gnv; SpecPlus_000650; Lopac-D-133; AC1L1CDC; Spectrum5_001426; Spectrum4_000630; Spectrum3_001668; Spectrum2_000537; Biomol-NT_000181; AC1Q3Q7M; Lopac0_000418; KBioSS_002141; KBioGR_001220; BSPBio_003455; Benzil-related co
DMMX1QJ DT Small molecular drug
DMMX1QJ PC 1845
DMMX1QJ MW 231.03
DMMX1QJ FM C8H4Cl2N2O2
DMMX1QJ IC InChI=1S/C8H4Cl2N2O2/c9-3-1-5-6(2-4(3)10)12-8(14)7(13)11-5/h1-2H,(H,11,13)(H,12,14)
DMMX1QJ CS C1=C2C(=CC(=C1Cl)Cl)NC(=O)C(=O)N2
DMMX1QJ IK AVBSIKMUAFYZAV-UHFFFAOYSA-N
DMMX1QJ IU 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
DMMX1QJ CA CAS 25983-13-5
DMMX1QJ CB CHEBI:113553
DMMX1QJ DE Discovery agent
DMZHDFM ID DMZHDFM
DMZHDFM DN 6,7-dichloro-1H-indole-2,3-dione
DMZHDFM HS Investigative
DMZHDFM SN 6,7-dichloro-1H-indole-2,3-dione; 18711-12-1; 6,7-Dichloroindoline-2,3-dione; 1H-Indole-2,3-dione,6,7-dichloro-; 6,7-dichloro-2,3-dihydro-1H-indole-2,3-dione; 6,7-dichlorisatin; 6,7-dichloroisatin; AC1Q3HQA; Isatin-based compound, 54; SCHEMBL1248801; CHEMBL222292; CTK4D9416; BDBM22834; DTXSID30588487; MolPort-004-304-808; XTXIILHWOQZVAQ-UHFFFAOYSA-N; STL381782; ZINC14979616; AKOS000139553; MCULE-1304306967; 1H-Indole-2,3-dione, 6,7-dichloro-; AJ-65537; KB-335070; FT-0620847; EN300-36024; Y-0718
DMZHDFM DT Small molecular drug
DMZHDFM PC 16786802
DMZHDFM MW 216.02
DMZHDFM FM C8H3Cl2NO2
DMZHDFM IC InChI=1S/C8H3Cl2NO2/c9-4-2-1-3-6(5(4)10)11-8(13)7(3)12/h1-2H,(H,11,12,13)
DMZHDFM CS C1=CC(=C(C2=C1C(=O)C(=O)N2)Cl)Cl
DMZHDFM IK XTXIILHWOQZVAQ-UHFFFAOYSA-N
DMZHDFM IU 6,7-dichloro-1H-indole-2,3-dione
DMZHDFM CA CAS 18711-12-1
DMZHDFM DE Discovery agent
DM592FB ID DM592FB
DM592FB DN 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB HS Investigative
DM592FB SN 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine; CHEMBL262862; 180160-89-8; SCHEMBL7885461; WMCWIMZEYWNBOQ-UHFFFAOYSA-N; BDBM50375903; L021806
DM592FB DT Small molecular drug
DM592FB PC 9813197
DM592FB MW 216.1
DM592FB FM C10H11Cl2N
DM592FB IC InChI=1S/C10H11Cl2N/c11-9-2-1-7-3-5-13-6-4-8(7)10(9)12/h1-2,13H,3-6H2
DM592FB CS C1CNCCC2=C1C=CC(=C2Cl)Cl
DM592FB IK WMCWIMZEYWNBOQ-UHFFFAOYSA-N
DM592FB IU 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine
DM592FB DE Discovery agent
DMNEJ8W ID DMNEJ8W
DMNEJ8W DN 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W HS Investigative
DMNEJ8W SN CHEMBL77569; 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W DT Small molecular drug
DMNEJ8W PC 44315523
DMNEJ8W MW 247.03
DMNEJ8W FM C8H4Cl2N2O3
DMNEJ8W IC InChI=1S/C8H4Cl2N2O3/c9-4-1-3-6(2-5(4)10)11-8(14)12(15)7(3)13/h1-2,15H,(H,11,14)
DMNEJ8W CS C1=C2C(=CC(=C1Cl)Cl)NC(=O)N(C2=O)O
DMNEJ8W IK URXMQPMLTVUBON-UHFFFAOYSA-N
DMNEJ8W IU 6,7-dichloro-3-hydroxy-1H-quinazoline-2,4-dione
DMNEJ8W DE Discovery agent
DMJNHSL ID DMJNHSL
DMJNHSL DN 6,7-Dichloro-3-thiophen-3-yl-quinoline
DMJNHSL HS Investigative
DMJNHSL SN CHEMBL66718; 6,7-dichloro-3-thiophen-3-yl-quinoline; SCHEMBL8503219; ZINC13737709
DMJNHSL DT Small molecular drug
DMJNHSL PC 10265642
DMJNHSL MW 280.2
DMJNHSL FM C13H7Cl2NS
DMJNHSL IC InChI=1S/C13H7Cl2NS/c14-11-4-9-3-10(8-1-2-17-7-8)6-16-13(9)5-12(11)15/h1-7H
DMJNHSL CS C1=CSC=C1C2=CN=C3C=C(C(=CC3=C2)Cl)Cl
DMJNHSL IK KNQSFKNTYMKKOR-UHFFFAOYSA-N
DMJNHSL IU 6,7-dichloro-3-thiophen-3-ylquinoline
DMJNHSL DE Discovery agent
DMI7FVJ ID DMI7FVJ
DMI7FVJ DN 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline
DMI7FVJ HS Investigative
DMI7FVJ SN CHEMBL399371; 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline
DMI7FVJ DT Small molecular drug
DMI7FVJ PC 44442182
DMI7FVJ MW 348.4
DMI7FVJ FM C22H24N2O2
DMI7FVJ IC InChI=1S/C22H24N2O2/c1-3-25-21-14-18-19(13-9-8-12-17-10-6-5-7-11-17)23-16-24-20(18)15-22(21)26-4-2/h5-7,9-11,13-16H,3-4,8,12H2,1-2H3/b13-9+
DMI7FVJ CS CCOC1=C(C=C2C(=C1)C(=NC=N2)/C=C/CCC3=CC=CC=C3)OCC
DMI7FVJ IK TYVCCOFEERYUGD-UKTHLTGXSA-N
DMI7FVJ IU 6,7-diethoxy-4-[(E)-4-phenylbut-1-enyl]quinazoline
DMI7FVJ DE Discovery agent
DMFVT8A ID DMFVT8A
DMFVT8A DN 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline
DMFVT8A HS Investigative
DMFVT8A SN CHEMBL251123; 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline
DMFVT8A DT Small molecular drug
DMFVT8A PC 44442183
DMFVT8A MW 362.5
DMFVT8A FM C23H26N2O2
DMFVT8A IC InChI=1S/C23H26N2O2/c1-3-26-22-15-19-20(24-17-25-21(19)16-23(22)27-4-2)14-10-6-9-13-18-11-7-5-8-12-18/h5,7-8,10-12,14-17H,3-4,6,9,13H2,1-2H3/b14-10+
DMFVT8A CS CCOC1=C(C=C2C(=C1)C(=NC=N2)/C=C/CCCC3=CC=CC=C3)OCC
DMFVT8A IK QLOYTAAAUVDJCT-GXDHUFHOSA-N
DMFVT8A IU 6,7-diethoxy-4-[(E)-5-phenylpent-1-enyl]quinazoline
DMFVT8A DE Discovery agent
DMVR4OW ID DMVR4OW
DMVR4OW DN 6,7-diethoxy-4-styrylquinazoline
DMVR4OW HS Investigative
DMVR4OW SN CHEMBL250925; 6,7-diethoxy-4-styrylquinazoline
DMVR4OW DT Small molecular drug
DMVR4OW PC 44442181
DMVR4OW MW 320.4
DMVR4OW FM C20H20N2O2
DMVR4OW IC InChI=1S/C20H20N2O2/c1-3-23-19-12-16-17(11-10-15-8-6-5-7-9-15)21-14-22-18(16)13-20(19)24-4-2/h5-14H,3-4H2,1-2H3/b11-10+
DMVR4OW CS CCOC1=C(C=C2C(=C1)C(=NC=N2)/C=C/C3=CC=CC=C3)OCC
DMVR4OW IK MVIQZBWZLCMZGF-ZHACJKMWSA-N
DMVR4OW IU 6,7-diethoxy-4-[(E)-2-phenylethenyl]quinazoline
DMVR4OW DE Discovery agent
DMUZYXQ ID DMUZYXQ
DMUZYXQ DN 6,7-Difluoro-3-thiophen-3-yl-quinoline
DMUZYXQ HS Investigative
DMUZYXQ SN CHEMBL68184; 6,7-difluoro-3-thiophen-3-yl-quinoline; SCHEMBL8501272; ZINC13737708
DMUZYXQ DT Small molecular drug
DMUZYXQ PC 10106010
DMUZYXQ MW 247.26
DMUZYXQ FM C13H7F2NS
DMUZYXQ IC InChI=1S/C13H7F2NS/c14-11-4-9-3-10(8-1-2-17-7-8)6-16-13(9)5-12(11)15/h1-7H
DMUZYXQ CS C1=CSC=C1C2=CN=C3C=C(C(=CC3=C2)F)F
DMUZYXQ IK RAEOQRGQVOSWAJ-UHFFFAOYSA-N
DMUZYXQ IU 6,7-difluoro-3-thiophen-3-ylquinoline
DMUZYXQ DE Discovery agent
DMF08UT ID DMF08UT
DMF08UT DN 6,7-Dihydroxy-2-phenyl-chromen-4-one
DMF08UT HS Investigative
DMF08UT SN 6,7-dihydroxyflavone; 38183-04-9; 6,7-dihydroxy-2-phenyl-4H-chromen-4-one; 6,7-Dihydroxy-2-phenyl-chromen-4-one; 6,7-dihydroxy flavone; 4H-1-Benzopyran-4-one, 6,7-dihydroxy-2-phenyl-; CHEMBL300814; 6,7-dihydroxy-2-phenylchromen-4-one; SR-05000002250; PubChem9843; 6,7 - Dihydroxyflavone; AC1NS43N; SPECTRUM1500718; SCHEMBL980197; DivK1c_000421; CTK4H9455; KBio1_000421; HMS501F03; DTXSID60191569; NINDS_000421; GSAOUZGPXSGVRS-UHFFFAOYSA-N; ZINC3871176; BDBM50077318; AKOS024283483; CCG-208431; MCULE-6698063887; IDI1_000421; ACM38183049
DMF08UT DT Small molecular drug
DMF08UT PC 5353357
DMF08UT MW 254.24
DMF08UT FM C15H10O4
DMF08UT IC InChI=1S/C15H10O4/c16-11-7-14(9-4-2-1-3-5-9)19-15-8-13(18)12(17)6-10(11)15/h1-8,17-18H
DMF08UT CS C1=CC=C(C=C1)C2=CC(=O)C3=CC(=C(C=C3O2)O)O
DMF08UT IK GSAOUZGPXSGVRS-UHFFFAOYSA-N
DMF08UT IU 6,7-dihydroxy-2-phenylchromen-4-one
DMF08UT CA CAS 38183-04-9
DMF08UT DE Discovery agent
DM9JLUS ID DM9JLUS
DM9JLUS DN 6,7-dihydroxy-8-nitro-1-tetralone
DM9JLUS HS Investigative
DM9JLUS SN 383382-48-7; 1(2h)-naphthalenone,3,4-dihydro-6,7-dihydroxy-8-nitro-; CHEMBL8752; SCHEMBL7428171; CTK8I5216; 1(2H)-Naphthalenone, 3,4-dihydro-6,7-dihydroxy-8-nitro-; ZINC25989269
DM9JLUS DT Small molecular drug
DM9JLUS PC 9877868
DM9JLUS MW 223.18
DM9JLUS FM C10H9NO5
DM9JLUS IC InChI=1S/C10H9NO5/c12-6-3-1-2-5-4-7(13)10(14)9(8(5)6)11(15)16/h4,13-14H,1-3H2
DM9JLUS CS C1CC2=CC(=C(C(=C2C(=O)C1)[N+](=O)[O-])O)O
DM9JLUS IK CXOQHHVPOJWTNP-UHFFFAOYSA-N
DM9JLUS IU 6,7-dihydroxy-8-nitro-3,4-dihydro-2H-naphthalen-1-one
DM9JLUS DE Discovery agent
DMSM0QV ID DMSM0QV
DMSM0QV DN 6,7-Dimethoxy-3-((E)-styryl)-quinoline
DMSM0QV HS Investigative
DMSM0QV SN CHEMBL70149; 6,7-Dimethoxy-3-((E)-styryl)-quinoline; ZINC3834019; BDBM50039041
DMSM0QV DT Small molecular drug
DMSM0QV PC 10017166
DMSM0QV MW 291.3
DMSM0QV FM C19H17NO2
DMSM0QV IC InChI=1S/C19H17NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h3-13H,1-2H3/b9-8+
DMSM0QV CS COC1=CC2=CC(=CN=C2C=C1OC)/C=C/C3=CC=CC=C3
DMSM0QV IK NQVBNOPSVRCGSI-CMDGGOBGSA-N
DMSM0QV IU 6,7-dimethoxy-3-[(E)-2-phenylethenyl]quinoline
DMSM0QV DE Discovery agent
DMPYGK9 ID DMPYGK9
DMPYGK9 DN 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline
DMPYGK9 HS Investigative
DMPYGK9 SN CHEMBL419248; 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline; ZINC13737710
DMPYGK9 DT Small molecular drug
DMPYGK9 PC 10085862
DMPYGK9 MW 295.3
DMPYGK9 FM C18H17NO3
DMPYGK9 IC InChI=1S/C18H17NO3/c1-20-16-7-5-4-6-14(16)13-8-12-9-17(21-2)18(22-3)10-15(12)19-11-13/h4-11H,1-3H3
DMPYGK9 CS COC1=CC=CC=C1C2=CN=C3C=C(C(=CC3=C2)OC)OC
DMPYGK9 IK ZGHJQSABDREYEE-UHFFFAOYSA-N
DMPYGK9 IU 6,7-dimethoxy-3-(2-methoxyphenyl)quinoline
DMPYGK9 DE Discovery agent
DMDENVF ID DMDENVF
DMDENVF DN 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline
DMDENVF HS Investigative
DMDENVF SN CHEMBL308466; 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline; ZINC13737704
DMDENVF DT Small molecular drug
DMDENVF PC 10447210
DMDENVF MW 295.3
DMDENVF FM C18H17NO3
DMDENVF IC InChI=1S/C18H17NO3/c1-20-15-6-4-5-12(8-15)14-7-13-9-17(21-2)18(22-3)10-16(13)19-11-14/h4-11H,1-3H3
DMDENVF CS COC1=CC=CC(=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC
DMDENVF IK RIQQTUOYRGIOFQ-UHFFFAOYSA-N
DMDENVF IU 6,7-dimethoxy-3-(3-methoxyphenyl)quinoline
DMDENVF DE Discovery agent
DM12DVT ID DM12DVT
DM12DVT DN 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline
DM12DVT HS Investigative
DM12DVT SN CHEMBL70130; 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline; SCHEMBL8501467; ZINC8074; BDBM50039071
DM12DVT DT Small molecular drug
DM12DVT PC 9882618
DM12DVT MW 295.3
DM12DVT FM C18H17NO3
DM12DVT IC InChI=1S/C18H17NO3/c1-20-15-6-4-12(5-7-15)14-8-13-9-17(21-2)18(22-3)10-16(13)19-11-14/h4-11H,1-3H3
DM12DVT CS COC1=CC=C(C=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC
DM12DVT IK UNALZVYBWFUPTL-UHFFFAOYSA-N
DM12DVT IU 6,7-dimethoxy-3-(4-methoxyphenyl)quinoline
DM12DVT DE Discovery agent
DMM7NHI ID DMM7NHI
DMM7NHI DN 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline
DMM7NHI HS Investigative
DMM7NHI SN CHEMBL69585; 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline; ZINC3834037
DMM7NHI DT Small molecular drug
DMM7NHI PC 11722903
DMM7NHI MW 310.3
DMM7NHI FM C17H14N2O4
DMM7NHI IC InChI=1S/C17H14N2O4/c1-22-16-8-12-7-13(10-18-15(12)9-17(16)23-2)11-3-5-14(6-4-11)19(20)21/h3-10H,1-2H3
DMM7NHI CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=C(C=C3)[N+](=O)[O-]
DMM7NHI IK FLEDIDSHIXDOQR-UHFFFAOYSA-N
DMM7NHI IU 6,7-dimethoxy-3-(4-nitrophenyl)quinoline
DMM7NHI DE Discovery agent
DMFRXDT ID DMFRXDT
DMFRXDT DN 6,7-Dimethoxy-3-phenylethynyl-quinoline
DMFRXDT HS Investigative
DMFRXDT SN CHEMBL67059; 6,7-Dimethoxy-3-phenylethynyl-quinoline; ZINC3834029
DMFRXDT DT Small molecular drug
DMFRXDT PC 10446889
DMFRXDT MW 289.3
DMFRXDT FM C19H15NO2
DMFRXDT IC InChI=1S/C19H15NO2/c1-21-18-11-16-10-15(9-8-14-6-4-3-5-7-14)13-20-17(16)12-19(18)22-2/h3-7,10-13H,1-2H3
DMFRXDT CS COC1=CC2=CC(=CN=C2C=C1OC)C#CC3=CC=CC=C3
DMFRXDT IK FIWNVHIDDOMDBP-UHFFFAOYSA-N
DMFRXDT IU 6,7-dimethoxy-3-(2-phenylethynyl)quinoline
DMFRXDT DE Discovery agent
DM516B4 ID DM516B4
DM516B4 DN 6,7-Dimethoxy-3-phenyl-quinoline
DM516B4 HS Investigative
DM516B4 SN CHEMBL66063; 6,7-dimethoxy-3-phenyl-quinoline; SCHEMBL8177777; ZINC3834036
DM516B4 DT Small molecular drug
DM516B4 PC 10422972
DM516B4 MW 265.31
DM516B4 FM C17H15NO2
DM516B4 IC InChI=1S/C17H15NO2/c1-19-16-9-13-8-14(12-6-4-3-5-7-12)11-18-15(13)10-17(16)20-2/h3-11H,1-2H3
DM516B4 CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=CC=C3
DM516B4 IK NZSMBYIPLGDVEM-UHFFFAOYSA-N
DM516B4 IU 6,7-dimethoxy-3-phenylquinoline
DM516B4 DE Discovery agent
DMM7IAK ID DMM7IAK
DMM7IAK DN 6,7-Dimethoxy-3-p-tolyl-quinoline
DMM7IAK HS Investigative
DMM7IAK SN CHEMBL67219; 6,7-Dimethoxy-3-p-tolyl-quinoline; ZINC13737715
DMM7IAK DT Small molecular drug
DMM7IAK PC 10401378
DMM7IAK MW 279.3
DMM7IAK FM C18H17NO2
DMM7IAK IC InChI=1S/C18H17NO2/c1-12-4-6-13(7-5-12)15-8-14-9-17(20-2)18(21-3)10-16(14)19-11-15/h4-11H,1-3H3
DMM7IAK CS CC1=CC=C(C=C1)C2=CN=C3C=C(C(=CC3=C2)OC)OC
DMM7IAK IK CMEIVVNDSVPQKC-UHFFFAOYSA-N
DMM7IAK IU 6,7-dimethoxy-3-(4-methylphenyl)quinoline
DMM7IAK DE Discovery agent
DMSG1AY ID DMSG1AY
DMSG1AY DN 6,7-Dimethoxy-3-pyridin-3-yl-quinoline
DMSG1AY HS Investigative
DMSG1AY SN CHEMBL304668; 6,7-dimethoxy-3-pyridin-3-yl-quinoline; SCHEMBL8170900; KYJQMVJJOORKLO-UHFFFAOYSA-N; ZINC3832247; BDBM50039050; 3-(6,7-dimethoxyquinolin-3-yl)pyridine; 6,7-dimethoxy-3-(3-pyridinyl)quinoline
DMSG1AY DT Small molecular drug
DMSG1AY PC 10445611
DMSG1AY MW 266.29
DMSG1AY FM C16H14N2O2
DMSG1AY IC InChI=1S/C16H14N2O2/c1-19-15-7-12-6-13(11-4-3-5-17-9-11)10-18-14(12)8-16(15)20-2/h3-10H,1-2H3
DMSG1AY CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CN=CC=C3
DMSG1AY IK KYJQMVJJOORKLO-UHFFFAOYSA-N
DMSG1AY IU 6,7-dimethoxy-3-pyridin-3-ylquinoline
DMSG1AY DE Discovery agent
DMW7K5P ID DMW7K5P
DMW7K5P DN 6,7-Dimethoxy-3-pyridin-4-yl-quinoline
DMW7K5P HS Investigative
DMW7K5P SN CHEMBL280069; 6,7-dimethoxy-3-pyridin-4-yl-quinoline; BDBM50039650
DMW7K5P DT Small molecular drug
DMW7K5P PC 10061448
DMW7K5P MW 266.29
DMW7K5P FM C16H14N2O2
DMW7K5P IC InChI=1S/C16H14N2O2/c1-19-15-8-12-7-13(11-3-5-17-6-4-11)10-18-14(12)9-16(15)20-2/h3-10H,1-2H3
DMW7K5P CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=NC=C3
DMW7K5P IK GDUOSVIOUNAARR-UHFFFAOYSA-N
DMW7K5P IU 6,7-dimethoxy-3-pyridin-4-ylquinoline
DMW7K5P DE Discovery agent
DM6WD8T ID DM6WD8T
DM6WD8T DN 6,7-Dimethoxy-3-thiophen-2-yl-quinoline
DM6WD8T HS Investigative
DM6WD8T SN CHEMBL304336; 6,7-dimethoxy-3-thiophen-2-yl-quinoline; SCHEMBL8501345; ZINC3834034
DM6WD8T DT Small molecular drug
DM6WD8T PC 10468421
DM6WD8T MW 271.3
DM6WD8T FM C15H13NO2S
DM6WD8T IC InChI=1S/C15H13NO2S/c1-17-13-7-10-6-11(15-4-3-5-19-15)9-16-12(10)8-14(13)18-2/h3-9H,1-2H3
DM6WD8T CS COC1=CC2=CC(=CN=C2C=C1OC)C3=CC=CS3
DM6WD8T IK DWCZKFGISHBMCE-UHFFFAOYSA-N
DM6WD8T IU 6,7-dimethoxy-3-thiophen-2-ylquinoline
DM6WD8T DE Discovery agent
DMU15YV ID DMU15YV
DMU15YV DN 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline
DMU15YV HS Investigative
DMU15YV SN CHEMBL415501; 6,7-Dimethoxy-4-(2-methoxyphenoxy)quinoline; 190726-38-6; 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline; SCHEMBL7487419; CTK0E1594; DTXSID50622690; ZTLZYKICAWTOKI-UHFFFAOYSA-N; BDBM50290848; Quinoline, 6,7-dimethoxy-4-(2-methoxyphenoxy)-
DMU15YV DT Small molecular drug
DMU15YV PC 22132763
DMU15YV MW 311.3
DMU15YV FM C18H17NO4
DMU15YV IC InChI=1S/C18H17NO4/c1-20-15-6-4-5-7-16(15)23-14-8-9-19-13-11-18(22-3)17(21-2)10-12(13)14/h4-11H,1-3H3
DMU15YV CS COC1=CC=CC=C1OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMU15YV IK ZTLZYKICAWTOKI-UHFFFAOYSA-N
DMU15YV IU 6,7-dimethoxy-4-(2-methoxyphenoxy)quinoline
DMU15YV CA CAS 190726-38-6
DMU15YV DE Discovery agent
DMQTHV7 ID DMQTHV7
DMQTHV7 DN 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline
DMQTHV7 HS Investigative
DMQTHV7 SN CHEMBL250315; 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline; SCHEMBL6180450; BDBM50222433
DMQTHV7 DT Small molecular drug
DMQTHV7 PC 18770812
DMQTHV7 MW 290.3
DMQTHV7 FM C18H14N2O2
DMQTHV7 IC InChI=1S/C18H14N2O2/c1-21-17-10-14-15(9-8-13-6-4-3-5-7-13)19-12-20-16(14)11-18(17)22-2/h3-7,10-12H,1-2H3
DMQTHV7 CS COC1=C(C=C2C(=C1)C(=NC=N2)C#CC3=CC=CC=C3)OC
DMQTHV7 IK ASHKAXPHUUQQTC-UHFFFAOYSA-N
DMQTHV7 IU 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline
DMQTHV7 DE Discovery agent
DMPS2GX ID DMPS2GX
DMPS2GX DN 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline
DMPS2GX HS Investigative
DMPS2GX SN CHEMBL98583; 6,7-Dimethoxy-4-(3-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline; SCHEMBL7481076; SORFICSDHDADIC-UHFFFAOYSA-N
DMPS2GX DT Small molecular drug
DMPS2GX PC 22132666
DMPS2GX MW 311.3
DMPS2GX FM C18H17NO4
DMPS2GX IC InChI=1S/C18H17NO4/c1-20-12-5-4-6-13(9-12)23-16-7-8-19-15-11-18(22-3)17(21-2)10-14(15)16/h4-11H,1-3H3
DMPS2GX CS COC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMPS2GX IK SORFICSDHDADIC-UHFFFAOYSA-N
DMPS2GX IU 6,7-dimethoxy-4-(3-methoxyphenoxy)quinoline
DMPS2GX DE Discovery agent
DM3YSNX ID DM3YSNX
DM3YSNX DN 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline
DM3YSNX HS Investigative
DM3YSNX SN CHEMBL99272; 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline; SCHEMBL7482913; OMYGYNKHKZLDSH-UHFFFAOYSA-N; BDBM50290844
DM3YSNX DT Small molecular drug
DM3YSNX PC 22132767
DM3YSNX MW 326.3
DM3YSNX FM C17H14N2O5
DM3YSNX IC InChI=1S/C17H14N2O5/c1-22-16-9-13-14(10-17(16)23-2)18-7-6-15(13)24-12-5-3-4-11(8-12)19(20)21/h3-10H,1-2H3
DM3YSNX CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC(=C3)[N+](=O)[O-]
DM3YSNX IK OMYGYNKHKZLDSH-UHFFFAOYSA-N
DM3YSNX IU 6,7-dimethoxy-4-(3-nitrophenoxy)quinoline
DM3YSNX DE Discovery agent
DMKO8QT ID DMKO8QT
DMKO8QT DN 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline
DMKO8QT HS Investigative
DMKO8QT SN CHEMBL250523; 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline; BDBM50222432
DMKO8QT DT Small molecular drug
DMKO8QT PC 44442168
DMKO8QT MW 320.3
DMKO8QT FM C19H16N2O3
DMKO8QT IC InChI=1S/C19H16N2O3/c1-22-18-11-15-16(20-13-21-17(15)12-19(18)23-2)9-6-10-24-14-7-4-3-5-8-14/h3-5,7-8,11-13H,10H2,1-2H3
DMKO8QT CS COC1=C(C=C2C(=C1)C(=NC=N2)C#CCOC3=CC=CC=C3)OC
DMKO8QT IK SKJFTWBCHDIBAC-UHFFFAOYSA-N
DMKO8QT IU 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline
DMKO8QT DE Discovery agent
DMX2VFP ID DMX2VFP
DMX2VFP DN 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline
DMX2VFP HS Investigative
DMX2VFP SN CHEMBL98584; 6,7-Dimethoxy-4-(4-methoxyphenoxy)quinoline; 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline; SCHEMBL7486400; GBYWCVLXEHHOFE-UHFFFAOYSA-N
DMX2VFP DT Small molecular drug
DMX2VFP PC 22132780
DMX2VFP MW 311.3
DMX2VFP FM C18H17NO4
DMX2VFP IC InChI=1S/C18H17NO4/c1-20-12-4-6-13(7-5-12)23-16-8-9-19-15-11-18(22-3)17(21-2)10-14(15)16/h4-11H,1-3H3
DMX2VFP CS COC1=CC=C(C=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMX2VFP IK GBYWCVLXEHHOFE-UHFFFAOYSA-N
DMX2VFP IU 6,7-dimethoxy-4-(4-methoxyphenoxy)quinoline
DMX2VFP DE Discovery agent
DMBI40Y ID DMBI40Y
DMBI40Y DN 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline
DMBI40Y HS Investigative
DMBI40Y SN CHEMBL250318; 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline; BDBM50222435
DMBI40Y DT Small molecular drug
DMBI40Y PC 44442165
DMBI40Y MW 318.4
DMBI40Y FM C20H18N2O2
DMBI40Y IC InChI=1S/C20H18N2O2/c1-23-19-12-16-17(21-14-22-18(16)13-20(19)24-2)11-7-6-10-15-8-4-3-5-9-15/h3-5,8-9,12-14H,6,10H2,1-2H3
DMBI40Y CS COC1=C(C=C2C(=C1)C(=NC=N2)C#CCCC3=CC=CC=C3)OC
DMBI40Y IK UJTHKWFURJCQDD-UHFFFAOYSA-N
DMBI40Y IU 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline
DMBI40Y DE Discovery agent
DMEMGPU ID DMEMGPU
DMEMGPU DN 6,7-Dimethoxy-4-m-tolyloxy-quinoline
DMEMGPU HS Investigative
DMEMGPU SN CHEMBL98839; 6,7-Dimethoxy-4-m-tolyloxy-quinoline; SCHEMBL19373176
DMEMGPU DT Small molecular drug
DMEMGPU PC 44331325
DMEMGPU MW 295.3
DMEMGPU FM C18H17NO3
DMEMGPU IC InChI=1S/C18H17NO3/c1-12-5-4-6-13(9-12)22-16-7-8-19-15-11-18(21-3)17(20-2)10-14(15)16/h4-11H,1-3H3
DMEMGPU CS CC1=CC(=CC=C1)OC2=C3C=C(C(=CC3=NC=C2)OC)OC
DMEMGPU IK DKQOYJJIXRSARC-UHFFFAOYSA-N
DMEMGPU IU 6,7-dimethoxy-4-(3-methylphenoxy)quinoline
DMEMGPU DE Discovery agent
DMBZP3I ID DMBZP3I
DMBZP3I DN 6,7-Dimethoxy-4-phenoxy-quinoline
DMBZP3I HS Investigative
DMBZP3I SN CHEMBL327534; 6,7-Dimethoxy-4-phenoxy-quinoline; SCHEMBL17117826
DMBZP3I DT Small molecular drug
DMBZP3I PC 13085778
DMBZP3I MW 281.3
DMBZP3I FM C17H15NO3
DMBZP3I IC InChI=1S/C17H15NO3/c1-19-16-10-13-14(11-17(16)20-2)18-9-8-15(13)21-12-6-4-3-5-7-12/h3-11H,1-2H3
DMBZP3I CS COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=CC=C3
DMBZP3I IK ZQNTXGWAYYJCOZ-UHFFFAOYSA-N
DMBZP3I IU 6,7-dimethoxy-4-phenoxyquinoline
DMBZP3I DE Discovery agent
DMP8LXB ID DMP8LXB
DMP8LXB DN 6,7-dimethoxy-N-m-tolylquinazolin-4-amine
DMP8LXB HS Investigative
DMP8LXB SN CHEMBL56802; 6,7-dimethoxy-N-m-tolylquinazolin-4-amine; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine
DMP8LXB DT Small molecular drug
DMP8LXB PC 2808977
DMP8LXB MW 295.34
DMP8LXB FM C17H17N3O2
DMP8LXB IC InChI=1S/C17H17N3O2/c1-11-5-4-6-12(7-11)20-17-13-8-15(21-2)16(22-3)9-14(13)18-10-19-17/h4-10H,1-3H3,(H,18,19,20)
DMP8LXB CS CC1=CC(=CC=C1)NC2=NC=NC3=CC(=C(C=C32)OC)OC
DMP8LXB IK RSVNNWQHWIOIOC-UHFFFAOYSA-N
DMP8LXB IU 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine
DMP8LXB DE Discovery agent
DM7U8ID ID DM7U8ID
DM7U8ID DN 6,7-Diphenyl-pteridine-2,4-diamine
DM7U8ID HS Investigative
DM7U8ID SN 6,7-diphenylpteridine-2,4-diamine; 18181-93-6; 2,4-DIAMINO-6,7-DIPHENYL-PTERIDINE; NSC10922; CHEMBL48296; 2,4-Diamino-6,7-diphenylpteridine; AC1Q4WHR; AC1L5CHW; diphenylpteridine-2,4-diamine; SCHEMBL3746280; diaminopteridine derivative, 24; CTK4D7985; BDBM25101; DTXSID80278987; DDZJPETYMUJLIW-UHFFFAOYSA-N; ZINC1712532; NSC-10922; 2,4-Pteridinediamine,6,7-diphenyl-; 6,7-Diphenyl-2,4-pteridinediamine #; 2,4-Pteridinediamine, 6,7-diphenyl-; ACM18181936; DB-081833
DM7U8ID DT Small molecular drug
DM7U8ID PC 223355
DM7U8ID MW 314.3
DM7U8ID FM C18H14N6
DM7U8ID IC InChI=1S/C18H14N6/c19-16-15-17(24-18(20)23-16)22-14(12-9-5-2-6-10-12)13(21-15)11-7-3-1-4-8-11/h1-10H,(H4,19,20,22,23,24)
DM7U8ID CS C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2C4=CC=CC=C4)N)N
DM7U8ID IK DDZJPETYMUJLIW-UHFFFAOYSA-N
DM7U8ID IU 6,7-diphenylpteridine-2,4-diamine
DM7U8ID CA CAS 18181-93-6
DM7U8ID DE Discovery agent
DMT09YC ID DMT09YC
DMT09YC DN 6,7'-oxybis(2-phenyl-4H-chromen-4-one)
DMT09YC HS Investigative
DMT09YC SN CHEMBL466800; BDBM50254285
DMT09YC DT Small molecular drug
DMT09YC PC 44569786
DMT09YC MW 458.5
DMT09YC FM C30H18O5
DMT09YC IC InChI=1S/C30H18O5/c31-25-17-29(20-9-5-2-6-10-20)35-30-16-22(11-13-23(25)30)33-21-12-14-27-24(15-21)26(32)18-28(34-27)19-7-3-1-4-8-19/h1-18H
DMT09YC CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)OC4=CC5=C(C=C4)C(=O)C=C(O5)C6=CC=CC=C6
DMT09YC IK IGRXBHDMCKHQQC-UHFFFAOYSA-N
DMT09YC IU 7-(4-oxo-2-phenylchromen-6-yl)oxy-2-phenylchromen-4-one
DMT09YC DE Discovery agent
DMUEFDM ID DMUEFDM
DMUEFDM DN 6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMUEFDM HS Investigative
DMUEFDM SN CHEMBL48643; Tacrine deriv. 2; 6,8-dichloro-1,2,3,4-tetrahydroacridin-9-amine; SCHEMBL15168338; BDBM10516; ZINC13492737; AKOS011484747
DMUEFDM DT Small molecular drug
DMUEFDM PC 10858442
DMUEFDM MW 267.15
DMUEFDM FM C13H12Cl2N2
DMUEFDM IC InChI=1S/C13H12Cl2N2/c14-7-5-9(15)12-11(6-7)17-10-4-2-1-3-8(10)13(12)16/h5-6H,1-4H2,(H2,16,17)
DMUEFDM CS C1CCC2=NC3=C(C(=CC(=C3)Cl)Cl)C(=C2C1)N
DMUEFDM IK ISUJWDYWYFLQFP-UHFFFAOYSA-N
DMUEFDM IU 6,8-dichloro-1,2,3,4-tetrahydroacridin-9-amine
DMUEFDM DE Discovery agent
DMAFP18 ID DMAFP18
DMAFP18 DN 6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMAFP18 HS Investigative
DMAFP18 SN 6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1j; CHEMBL493173; BDBM29221; MolPort-028-745-489; ZINC40955907; 1,4-Dimethyl-6,8-dimethoxyquinoline-2(1H)-one
DMAFP18 DT Small molecular drug
DMAFP18 PC 42618031
DMAFP18 MW 233.26
DMAFP18 FM C13H15NO3
DMAFP18 IC InChI=1S/C13H15NO3/c1-8-5-12(15)14(2)13-10(8)6-9(16-3)7-11(13)17-4/h5-7H,1-4H3
DMAFP18 CS CC1=CC(=O)N(C2=C1C=C(C=C2OC)OC)C
DMAFP18 IK BYYQQWLTZFBHIQ-UHFFFAOYSA-N
DMAFP18 IU 6,8-dimethoxy-1,4-dimethylquinolin-2-one
DMAFP18 DE Discovery agent
DMYKSTZ ID DMYKSTZ
DMYKSTZ DN 6,8-Dimethoxy-4-methylquinolin-2(1H)-one
DMYKSTZ HS Investigative
DMYKSTZ SN casimiroin analogue, 1i; 2(1H)-Quinolinone, 6,8-dimethoxy-4-methyl-; CHEMBL476126; BDBM29220; MolPort-028-745-488; ZINC40429907; 249737-05-1
DMYKSTZ DT Small molecular drug
DMYKSTZ PC 42618030
DMYKSTZ MW 219.24
DMYKSTZ FM C12H13NO3
DMYKSTZ IC InChI=1S/C12H13NO3/c1-7-4-11(14)13-12-9(7)5-8(15-2)6-10(12)16-3/h4-6H,1-3H3,(H,13,14)
DMYKSTZ CS CC1=CC(=O)NC2=C1C=C(C=C2OC)OC
DMYKSTZ IK TZVDVDRNKWYRNO-UHFFFAOYSA-N
DMYKSTZ IU 6,8-dimethoxy-4-methyl-1H-quinolin-2-one
DMYKSTZ DE Discovery agent
DME4193 ID DME4193
DME4193 DN 6,8-Dinitro-2-piperazin-1-yl-quinoline
DME4193 HS Investigative
DME4193 SN CHEMBL37739; 6,8-Dinitro-2-piperazin-1-yl-quinoline; 2-Piperazino-6,8-dinitroquinoline
DME4193 DT Small molecular drug
DME4193 PC 12044726
DME4193 MW 303.27
DME4193 FM C13H13N5O4
DME4193 IC InChI=1S/C13H13N5O4/c19-17(20)10-7-9-1-2-12(16-5-3-14-4-6-16)15-13(9)11(8-10)18(21)22/h1-2,7-8,14H,3-6H2
DME4193 CS C1CN(CCN1)C2=NC3=C(C=C(C=C3C=C2)[N+](=O)[O-])[N+](=O)[O-]
DME4193 IK LDLAXAIDSVRAEY-UHFFFAOYSA-N
DME4193 IU 6,8-dinitro-2-piperazin-1-ylquinoline
DME4193 DE Discovery agent
DM7FMWS ID DM7FMWS
DM7FMWS DN 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one
DM7FMWS HS Investigative
DM7FMWS DT Small molecular drug
DM7FMWS PC 44329120
DM7FMWS MW 168.23
DM7FMWS FM C10H16O2
DM7FMWS IC InChI=1S/C10H16O2/c1-7-3-4-8(2)10(7)5-6-12-9(10)11/h7-8H,3-6H2,1-2H3
DM7FMWS CS CC1CCC(C12CCOC2=O)C
DM7FMWS IK CQORSWAIFJDWPQ-UHFFFAOYSA-N
DM7FMWS IU 6,9-dimethyl-2-oxaspiro[4.4]nonan-1-one
DM7FMWS DE Discovery agent
DMDNG8F ID DMDNG8F
DMDNG8F DN 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine
DMDNG8F HS Investigative
DMDNG8F SN SCHEMBL6660879
DMDNG8F DT Small molecular drug
DMDNG8F PC 44387948
DMDNG8F MW 240.24
DMDNG8F FM C13H9FN4
DMDNG8F IC InChI=1S/C13H9FN4/c14-10-4-1-9(2-5-10)3-6-11-12-13(17-7-15-11)18-8-16-12/h1-8H,(H,15,16,17,18)/b6-3+
DMDNG8F CS C1=CC(=CC=C1/C=C/C2=C3C(=NC=N2)N=CN3)F
DMDNG8F IK QUTNZZOCHSVJRB-ZZXKWVIFSA-N
DMDNG8F IU 6-[(E)-2-(4-fluorophenyl)ethenyl]-7H-purine
DMDNG8F DE Discovery agent
DMNJPCD ID DMNJPCD
DMNJPCD DN 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
DMNJPCD HS Investigative
DMNJPCD SN 6IP
DMNJPCD DT Small molecular drug
DMNJPCD PC 11586735
DMNJPCD MW 237.3
DMNJPCD FM C15H15N3
DMNJPCD IC InChI=1S/C15H15N3/c16-15-3-1-2-13(18-15)7-5-11-4-6-12-8-9-17-14(12)10-11/h1-4,6,8-10,17H,5,7H2,(H2,16,18)
DMNJPCD CS C1=CC(=NC(=C1)N)CCC2=CC3=C(C=C2)C=CN3
DMNJPCD IK OSHSZKRWKLQZBV-UHFFFAOYSA-N
DMNJPCD IU 6-[2-(1H-indol-6-yl)ethyl]pyridin-2-amine
DMNJPCD DE Discovery agent
DM40LQ9 ID DM40LQ9
DM40LQ9 DN 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol
DM40LQ9 HS Investigative
DM40LQ9 SN CHEMBL1214739; 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol; SCHEMBL18770333
DM40LQ9 DT Small molecular drug
DM40LQ9 PC 46901929
DM40LQ9 MW 311.4
DM40LQ9 FM C22H17NO
DM40LQ9 IC InChI=1S/C22H17NO/c24-22-8-7-20-14-19(5-6-21(20)15-22)18-3-1-16(2-4-18)13-17-9-11-23-12-10-17/h1-12,14-15,24H,13H2
DM40LQ9 CS C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC4=C(C=C3)C=C(C=C4)O
DM40LQ9 IK OCQPVXWUPNNJIV-UHFFFAOYSA-N
DM40LQ9 IU 6-[4-(pyridin-4-ylmethyl)phenyl]naphthalen-2-ol
DM40LQ9 DE Discovery agent
DM1G7P9 ID DM1G7P9
DM1G7P9 DN 6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID
DM1G7P9 HS Investigative
DM1G7P9 SN 6-[(cyclohexylcarbamoyl)amino]hexanoic acid; 6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID; CHEMBL434374; 6-(3-cyclohexylureido)hexanoic acid; 4-(3-CYCLOHEXYLURIEDO)-HEXANOIC ACID; NC6; 479413-50-8; 1zd4; AC1O4WJZ; MolPort-004-305-491; HMS3604D15; ZINC13493677; BDBM50192966; AKOS000144586; DB08258; NE37451; MCULE-4614457618; 6-(cyclohexylcarbamoylamino)hexanoic acid; EN300-77810
DM1G7P9 DT Small molecular drug
DM1G7P9 PC 6420120
DM1G7P9 MW 256.339
DM1G7P9 FM C13H24N2O3
DM1G7P9 IC InChI=1S/C13H24N2O3/c16-12(17)9-5-2-6-10-14-13(18)15-11-7-3-1-4-8-11/h11H,1-10H2,(H,16,17)(H2,14,15,18)
DM1G7P9 CS C1CCC(CC1)NC(=O)NCCCCCC(=O)O
DM1G7P9 IK KFTVEPYSUSWBRD-UHFFFAOYSA-N
DM1G7P9 IU 6-(cyclohexylcarbamoylamino)hexanoic acid
DM1G7P9 DE Discovery agent
DM7D52Z ID DM7D52Z
DM7D52Z DN 677T
DM7D52Z HS Investigative
DM7D52Z TC Antisense
DM7D52Z DT Antisense drug
DM7D52Z DE Discovery agent
DMERKGH ID DMERKGH
DMERKGH DN 6-Acetyl-7-ethoxy-2H-chromen-2-one
DMERKGH HS Investigative
DMERKGH SN CHEMBL1288559; 6-Acetyl-7-ethoxy-2H-chromen-2-one
DMERKGH DT Small molecular drug
DMERKGH PC 52949265
DMERKGH MW 232.23
DMERKGH FM C13H12O4
DMERKGH IC InChI=1S/C13H12O4/c1-3-16-12-7-11-9(4-5-13(15)17-11)6-10(12)8(2)14/h4-7H,3H2,1-2H3
DMERKGH CS CCOC1=C(C=C2C=CC(=O)OC2=C1)C(=O)C
DMERKGH IK YPWNHEXIUIFWSP-UHFFFAOYSA-N
DMERKGH IU 6-acetyl-7-ethoxychromen-2-one
DMERKGH DE Discovery agent
DM1K0E2 ID DM1K0E2
DM1K0E2 DN 6-Acetyl-7-hydroxy-2H-chromen-2-one
DM1K0E2 HS Investigative
DM1K0E2 SN CHEMBL1288534; 6-Acetyl-7-hydroxy-2H-1-benzopyran-2-one; 6835-55-8; 6-Acetyl-7-hydroxy-2H-chromen-2-one; AC1NWHPN; 6-acetyl-7-hydroxycoumarin; 2H-1-Benzopyran-2-one, 6-acetyl-7-hydroxy-; SCHEMBL4640781; 6-acetyl-7-hydroxychromen-2-one; ZINC3848612; BDBM50332033
DM1K0E2 DT Small molecular drug
DM1K0E2 PC 5705744
DM1K0E2 MW 204.18
DM1K0E2 FM C11H8O4
DM1K0E2 IC InChI=1S/C11H8O4/c1-6(12)8-4-7-2-3-11(14)15-10(7)5-9(8)13/h2-5,13H,1H3
DM1K0E2 CS CC(=O)C1=C(C=C2C(=C1)C=CC(=O)O2)O
DM1K0E2 IK MYJIZBGGFRMXEM-UHFFFAOYSA-N
DM1K0E2 IU 6-acetyl-7-hydroxychromen-2-one
DM1K0E2 DE Discovery agent
DMXOB2K ID DMXOB2K
DMXOB2K DN 6-acetyl-7-methoxy-2H-chromen-2-one
DMXOB2K HS Investigative
DMXOB2K SN 6-acetyl-7-methoxychromen-2-one; CHEMBL1288558; 16850-94-5; 6-acetyl-7-methoxy-2H-chromen-2-one; AC1LGQHB; MolPort-002-843-897; ZINC384856
DMXOB2K DT Small molecular drug
DMXOB2K PC 850202
DMXOB2K MW 218.2
DMXOB2K FM C12H10O4
DMXOB2K IC InChI=1S/C12H10O4/c1-7(13)9-5-8-3-4-12(14)16-10(8)6-11(9)15-2/h3-6H,1-2H3
DMXOB2K CS CC(=O)C1=C(C=C2C(=C1)C=CC(=O)O2)OC
DMXOB2K IK QDWMZGNQFSIPKO-UHFFFAOYSA-N
DMXOB2K IU 6-acetyl-7-methoxychromen-2-one
DMXOB2K DE Discovery agent
DMCG8BJ ID DMCG8BJ
DMCG8BJ DN 6-acetyl-7-propoxy-2H-chromen-2-one
DMCG8BJ HS Investigative
DMCG8BJ SN CHEMBL1288560; 6-acetyl-7-propoxy-2H-chromen-2-one
DMCG8BJ DT Small molecular drug
DMCG8BJ PC 52940758
DMCG8BJ MW 246.26
DMCG8BJ FM C14H14O4
DMCG8BJ IC InChI=1S/C14H14O4/c1-3-6-17-13-8-12-10(4-5-14(16)18-12)7-11(13)9(2)15/h4-5,7-8H,3,6H2,1-2H3
DMCG8BJ CS CCCOC1=C(C=C2C=CC(=O)OC2=C1)C(=O)C
DMCG8BJ IK VIKCPCBUFQJHPC-UHFFFAOYSA-N
DMCG8BJ IU 6-acetyl-7-propoxychromen-2-one
DMCG8BJ DE Discovery agent
DMI2XUQ ID DMI2XUQ
DMI2XUQ DN 6-Allyloxy-9H-purin-2-ylamine
DMI2XUQ HS Investigative
DMI2XUQ SN CHEMBL325053; 50663-54-2; O6-Allylguanine; O6-Substituted Guanine Deriv. 15; 6-prop-2-enoxy-7H-purin-2-amine; NU 2028; AC1L45IB; SCHEMBL1263549; BDBM5475; 6-(prop-2-en-1-yloxy)-9H-purin-2-amine; 9H-Purin-2-amine, 6-(2-propen-1-yloxy)-
DMI2XUQ DT Small molecular drug
DMI2XUQ PC 179571
DMI2XUQ MW 191.19
DMI2XUQ FM C8H9N5O
DMI2XUQ IC InChI=1S/C8H9N5O/c1-2-3-14-7-5-6(11-4-10-5)12-8(9)13-7/h2,4H,1,3H2,(H3,9,10,11,12,13)
DMI2XUQ CS C=CCOC1=NC(=NC2=C1NC=N2)N
DMI2XUQ IK HJMGFQNIHIHSCQ-UHFFFAOYSA-N
DMI2XUQ IU 6-prop-2-enoxy-7H-purin-2-amine
DMI2XUQ CA CAS 50663-54-2
DMI2XUQ DE Discovery agent
DMMUE05 ID DMMUE05
DMMUE05 DN 6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid
DMMUE05 HS Investigative
DMMUE05 SN CHEMBL65910; 6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid; SCHEMBL7257200
DMMUE05 DT Small molecular drug
DMMUE05 PC 10035600
DMMUE05 MW 197.23
DMMUE05 FM C9H15N3O2
DMMUE05 IC InChI=1S/C9H15N3O2/c10-4-2-1-3-7(9(13)14)8-5-11-6-12-8/h5-7H,1-4,10H2,(H,11,12)(H,13,14)
DMMUE05 CS C1=C(NC=N1)C(CCCCN)C(=O)O
DMMUE05 IK ATNHCKIPIWIEGH-UHFFFAOYSA-N
DMMUE05 IU 6-amino-2-(1H-imidazol-5-yl)hexanoic acid
DMMUE05 DE Discovery agent
DMC5M76 ID DMC5M76
DMC5M76 DN 6-amino-4-trifluoromethylquinolin-2(1H)-one
DMC5M76 HS Investigative
DMC5M76 SN 6-amino-4-trifluoromethylquinolin-2(1H)-one; 328955-57-3; 6-amino-4-(trifluoromethyl)quinolin-2(1H)-one; 2(1H)-Quinolinone, 6-amino-4-(trifluoromethyl)-; SCHEMBL1770828; CHEMBL385509; SCHEMBL19680530; CTK8B4763; BDBM18526; DTXSID60582115; LMXZMEMPGRLDIG-UHFFFAOYSA-N; ANW-46096; ZINC12349446; AKOS015951346; AK-41783; AC-27434; SC-50493; AJ-61229; AB1009151; AB0024239; ST2406401; AX8208563; W5464; CS-0084832; FT-0688581; 6-Amino-4-trifluoromethyl-2(1H)-quinolinone; 6-Amino-4-(trifluoromethyl)-quinolin-2(1h)-one
DMC5M76 DT Small molecular drug
DMC5M76 PC 16090308
DMC5M76 MW 228.17
DMC5M76 FM C10H7F3N2O
DMC5M76 IC InChI=1S/C10H7F3N2O/c11-10(12,13)7-4-9(16)15-8-2-1-5(14)3-6(7)8/h1-4H,14H2,(H,15,16)
DMC5M76 CS C1=CC2=C(C=C1N)C(=CC(=O)N2)C(F)(F)F
DMC5M76 IK LMXZMEMPGRLDIG-UHFFFAOYSA-N
DMC5M76 IU 6-amino-4-(trifluoromethyl)-1H-quinolin-2-one
DMC5M76 CA CAS 328955-57-3
DMC5M76 DE Discovery agent
DM5SZHR ID DM5SZHR
DM5SZHR DN 6-amino-5-bromouracil
DM5SZHR HS Investigative
DM5SZHR SN 6312-73-8; 5-Bromo-6-aminouracil; 6-Amino-5-bromouracil; 6-Amino-5-bromopyrimidine-2,4(1H,3H)-dione; 6-Amino-5-bromo-1H-pyrimidine-2,4-dione; 6-amino-5-bromo-1,2,3,4-tetrahydropyrimidine-2,4-dione; CHEMBL64909; 6-amino-5-bromopyrimidine-2,4-diol; 6-amino-5-bromo-2,4(1H,3H)-pyrimidinedione; 6-amino-5-bromo-1,3-dihydropyrimidine-2,4-dione; NSC40394; EINECS 228-638-7; NSC 27652; NSC 40394; AC1Q24DM; AC1Q50HI; AC1L2ZP9; SCHEMBL2894070; CTK5B7686; KS-00001QBO; DTXSID60212460; MolPort-000-873-593; FSLBEEVCUZFKRL-UHFFFAOYSA-N
DM5SZHR DT Small molecular drug
DM5SZHR PC 80578
DM5SZHR MW 206
DM5SZHR FM C4H4BrN3O2
DM5SZHR IC InChI=1S/C4H4BrN3O2/c5-1-2(6)7-4(10)8-3(1)9/h(H4,6,7,8,9,10)
DM5SZHR CS C1(=C(NC(=O)NC1=O)N)Br
DM5SZHR IK FSLBEEVCUZFKRL-UHFFFAOYSA-N
DM5SZHR IU 6-amino-5-bromo-1H-pyrimidine-2,4-dione
DM5SZHR CA CAS 6312-73-8
DM5SZHR DE Discovery agent
DMFPCSJ ID DMFPCSJ
DMFPCSJ DN 6-amino-5-chlorouracil hydrochloride
DMFPCSJ HS Investigative
DMFPCSJ SN CHEMBL541900
DMFPCSJ DT Small molecular drug
DMFPCSJ PC 45265835
DMFPCSJ MW 198
DMFPCSJ FM C4H5Cl2N3O2
DMFPCSJ IC InChI=1S/C4H4ClN3O2.ClH/c5-1-2(6)7-4(10)8-3(1)9;/h(H4,6,7,8,9,10);1H
DMFPCSJ CS C1(=C(NC(=O)NC1=O)N)Cl.Cl
DMFPCSJ IK LZWPDUHEHWOBPF-UHFFFAOYSA-N
DMFPCSJ IU 6-amino-5-chloro-1H-pyrimidine-2,4-dione;hydrochloride
DMFPCSJ DE Discovery agent
DMU1CV4 ID DMU1CV4
DMU1CV4 DN 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one
DMU1CV4 HS Investigative
DMU1CV4 SN CHEMBL504356; 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one
DMU1CV4 DT Small molecular drug
DMU1CV4 PC 44563082
DMU1CV4 MW 231.2
DMU1CV4 FM C12H9NO4
DMU1CV4 IC InChI=1S/C12H9NO4/c1-15-11-9-6(2-3-16-9)4-7-5-8(13)12(14)17-10(7)11/h2-5H,13H2,1H3
DMU1CV4 CS COC1=C2C(=CC3=C1OC(=O)C(=C3)N)C=CO2
DMU1CV4 IK YFAQAXXPQHHTHA-UHFFFAOYSA-N
DMU1CV4 IU 6-amino-9-methoxyfuro[3,2-g]chromen-7-one
DMU1CV4 DE Discovery agent
DMWPELS ID DMWPELS
DMWPELS DN 6-Amino-benzothiazole-2-sulfonic acid amide
DMWPELS HS Investigative
DMWPELS SN 6-aminobenzo[d]thiazole-2-sulfonamide; 6-Amino-2-benzothiazolesulfonamide; 94641-11-9; MR69RTSOVN; UNII-MR69RTSOVN; CHEMBL35118; Aminozolamide; AC1L3QBY; 6-Amino-benzothiazole-2-sulfonic acid amide; SCHEMBL9459715; OFSGGVHHSMAUEI-UHFFFAOYSA-N; 6-aminobenzothiazole-2-sulfonamide; ZINC5162075; BDBM50079035; 2-Benzothiazolesulfonamide, 6-amino-; AKOS022656973; FCH1394039; 6-amino-1,3-benzothiazole-2-sulfonamide; AX8292464
DMWPELS DT Small molecular drug
DMWPELS PC 93505
DMWPELS MW 229.3
DMWPELS FM C7H7N3O2S2
DMWPELS IC InChI=1S/C7H7N3O2S2/c8-4-1-2-5-6(3-4)13-7(10-5)14(9,11)12/h1-3H,8H2,(H2,9,11,12)
DMWPELS CS C1=CC2=C(C=C1N)SC(=N2)S(=O)(=O)N
DMWPELS IK OFSGGVHHSMAUEI-UHFFFAOYSA-N
DMWPELS IU 6-amino-1,3-benzothiazole-2-sulfonamide
DMWPELS CA CAS 94641-11-9
DMWPELS DE Discovery agent
DMEHG2F ID DMEHG2F
DMEHG2F DN 6-amino-N-(2,4-dichlorobenzyl)nicotinamide
DMEHG2F HS Investigative
DMEHG2F SN CHEMBL567109; 6-amino-N-(2,4-dichlorobenzyl)nicotinamide
DMEHG2F DT Small molecular drug
DMEHG2F PC 45487830
DMEHG2F MW 296.15
DMEHG2F FM C13H11Cl2N3O
DMEHG2F IC InChI=1S/C13H11Cl2N3O/c14-10-3-1-8(11(15)5-10)6-18-13(19)9-2-4-12(16)17-7-9/h1-5,7H,6H2,(H2,16,17)(H,18,19)
DMEHG2F CS C1=CC(=C(C=C1Cl)Cl)CNC(=O)C2=CN=C(C=C2)N
DMEHG2F IK PWGDOYQXBPVPGB-UHFFFAOYSA-N
DMEHG2F IU 6-amino-N-[(2,4-dichlorophenyl)methyl]pyridine-3-carboxamide
DMEHG2F DE Discovery agent
DMYI5GU ID DMYI5GU
DMYI5GU DN 6-amino-N-(3,3-diphenylpropyl)nicotinamide
DMYI5GU HS Investigative
DMYI5GU SN CHEMBL568773; 6-amino-N-(3,3-diphenylpropyl)nicotinamide; SCHEMBL5947733
DMYI5GU DT Small molecular drug
DMYI5GU PC 11976309
DMYI5GU MW 331.4
DMYI5GU FM C21H21N3O
DMYI5GU IC InChI=1S/C21H21N3O/c22-20-12-11-18(15-24-20)21(25)23-14-13-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-12,15,19H,13-14H2,(H2,22,24)(H,23,25)
DMYI5GU CS C1=CC=C(C=C1)C(CCNC(=O)C2=CN=C(C=C2)N)C3=CC=CC=C3
DMYI5GU IK DZGHCDWBFODWBC-UHFFFAOYSA-N
DMYI5GU IU 6-amino-N-(3,3-diphenylpropyl)pyridine-3-carboxamide
DMYI5GU DE Discovery agent
DMUZOYN ID DMUZOYN
DMUZOYN DN 6-amino-uridine monophosphate
DMUZOYN HS Investigative
DMUZOYN DT Small molecular drug
DMUZOYN PC 11843563
DMUZOYN MW 339.2
DMUZOYN FM C9H14N3O9P
DMUZOYN IC InChI=1S/C9H14N3O9P/c10-4-1-5(13)11-9(16)12(4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h1,3,6-8,14-15H,2,10H2,(H,11,13,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1
DMUZOYN CS C1=C(N(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)N
DMUZOYN IK DUFXRFNPGXQQOI-YXZULKJRSA-N
DMUZOYN IU [(2R,3S,4R,5R)-5-(6-amino-2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMUZOYN DE Discovery agent
DM7WYCM ID DM7WYCM
DM7WYCM DN 6-aza-uridine monophosphate
DM7WYCM HS Investigative
DM7WYCM SN 6-Aza-ump; 6-Azauridine-5'-monophosphate; 6-aza uridine 5'-monophosphate; 1los; UP6; [(2R,3S,4R,5R)-5-(3,5-dioxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; aza UMP; 6-Azauridine-5'-phosphate; 6-Azauridine 5'M; NSC47549; 6-Azauridine 5'MP; 6-azauridine 5'-phosphate; AC1L45DF; 6-aza-uridine monophosphate; C6-Uridine Derivative, 18; 6-Azauridine-5-monophosphate; CHEMBL463480; SCHEMBL3214622; BDBM21340; 6-Azauridine 5'-phosphoric acid; ZINC12503861; AKOS027381721; DB03718; W-201761
DM7WYCM DT Small molecular drug
DM7WYCM PC 150959
DM7WYCM MW 325.17
DM7WYCM FM C8H12N3O9P
DM7WYCM IC InChI=1S/C8H12N3O9P/c12-4-1-9-11(8(15)10-4)7-6(14)5(13)3(20-7)2-19-21(16,17)18/h1,3,5-7,13-14H,2H2,(H,10,12,15)(H2,16,17,18)/t3-,5-,6-,7-/m1/s1
DM7WYCM CS C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DM7WYCM IK LRVZOSYMNMNQFR-SHUUEZRQSA-N
DM7WYCM IU [(2R,3S,4R,5R)-5-(3,5-dioxo-1,2,4-triazin-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM7WYCM CA CAS 2018-19-1
DM7WYCM CB CHEBI:46319
DM7WYCM DE Discovery agent
DM8BNWH ID DM8BNWH
DM8BNWH DN 6-Azido-8-(3-iodo-phenyl)-quinoline
DM8BNWH HS Investigative
DM8BNWH SN CHEMBL124575; 6-azido-8-(3-iodophenyl)quinoline; 6-Azido-8-(3-iodo-phenyl)-quinoline
DM8BNWH DT Small molecular drug
DM8BNWH PC 10547238
DM8BNWH MW 372.16
DM8BNWH FM C15H9IN4
DM8BNWH IC InChI=1S/C15H9IN4/c16-12-5-1-3-10(7-12)14-9-13(19-20-17)8-11-4-2-6-18-15(11)14/h1-9H
DM8BNWH CS C1=CC(=CC(=C1)I)C2=C3C(=CC(=C2)N=[N+]=[N-])C=CC=N3
DM8BNWH IK FZNQYXTXKRWFRF-UHFFFAOYSA-N
DM8BNWH IU 6-azido-8-(3-iodophenyl)quinoline
DM8BNWH DE Discovery agent
DM2I95Z ID DM2I95Z
DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z HS Investigative
DM2I95Z SN 6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4; 6-benzenesulfinylhexanoic acid hydroxamide
DM2I95Z DT Small molecular drug
DM2I95Z PC 11694528
DM2I95Z MW 255.34
DM2I95Z FM C12H17NO3S
DM2I95Z IC InChI=1S/C12H17NO3S/c14-12(13-15)9-5-2-6-10-17(16)11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DM2I95Z CS C1=CC=C(C=C1)S(=O)CCCCCC(=O)NO
DM2I95Z IK LIZWRHXVIWNMIS-UHFFFAOYSA-N
DM2I95Z IU 6-(benzenesulfinyl)-N-hydroxyhexanamide
DM2I95Z DE Discovery agent
DM81DTC ID DM81DTC
DM81DTC DN 6-Benzenesulfonyl-2H-pyridazin-3-one
DM81DTC HS Investigative
DM81DTC SN 6-(benzenesulfonyl)-2,3-dihydropyridazin-3-one; 141060-78-8; 3(2H)-Pyridazinone, 6-(phenylsulfonyl)-; AC1Q6GZS; CHEMBL74814; SCHEMBL7295107; BDBM16442; ZICCKDUVBPQRQT-UHFFFAOYSA-N; MolPort-007-599-834; ZINC11536236; AKOS001782098; MCULE-8830355611; NE56517; 6-phenylsulfonylpyridazin-2H-3-one, 1; 6-phenylsulfonyl-3-oxo-2,3-dihydropyridazine; EN300-72670
DM81DTC DT Small molecular drug
DM81DTC PC 11701437
DM81DTC MW 236.25
DM81DTC FM C10H8N2O3S
DM81DTC IC InChI=1S/C10H8N2O3S/c13-9-6-7-10(12-11-9)16(14,15)8-4-2-1-3-5-8/h1-7H,(H,11,13)
DM81DTC CS C1=CC=C(C=C1)S(=O)(=O)C2=NNC(=O)C=C2
DM81DTC IK ZICCKDUVBPQRQT-UHFFFAOYSA-N
DM81DTC IU 3-(benzenesulfonyl)-1H-pyridazin-6-one
DM81DTC DE Discovery agent
DMY9IK8 ID DMY9IK8
DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide
DMY9IK8 HS Investigative
DMY9IK8 SN 6-benzenesulfonylhexanoic acid hydroxamide; CHEMBL203207
DMY9IK8 DT Small molecular drug
DMY9IK8 PC 11572583
DMY9IK8 MW 271.33
DMY9IK8 FM C12H17NO4S
DMY9IK8 IC InChI=1S/C12H17NO4S/c14-12(13-15)9-5-2-6-10-18(16,17)11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DMY9IK8 CS C1=CC=C(C=C1)S(=O)(=O)CCCCCC(=O)NO
DMY9IK8 IK CUUZMQZWMSHEAR-UHFFFAOYSA-N
DMY9IK8 IU 6-(benzenesulfonyl)-N-hydroxyhexanamide
DMY9IK8 DE Discovery agent
DM0CZ1F ID DM0CZ1F
DM0CZ1F DN 6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one
DM0CZ1F HS Investigative
DM0CZ1F DT Small molecular drug
DM0CZ1F PC 467334
DM0CZ1F DE Discovery agent
DMZRQEF ID DMZRQEF
DMZRQEF DN 6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one
DMZRQEF HS Investigative
DMZRQEF DT Small molecular drug
DMZRQEF PC 467333
DMZRQEF DE Discovery agent
DMI5RNJ ID DMI5RNJ
DMI5RNJ DN 6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one
DMI5RNJ HS Investigative
DMI5RNJ DT Small molecular drug
DMI5RNJ PC 467331
DMI5RNJ DE Discovery agent
DM7ANE3 ID DM7ANE3
DM7ANE3 DN 6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one
DM7ANE3 HS Investigative
DM7ANE3 DT Small molecular drug
DM7ANE3 PC 467332
DM7ANE3 DE Discovery agent
DMICRFQ ID DMICRFQ
DMICRFQ DN 6-benzyl-3-ethoxycarbonyl-4-quinolone
DMICRFQ HS Investigative
DMICRFQ SN CHEMBL381059; 6-benzyl-3-ethoxycarbonyl-4-quinolone; SCHEMBL7728970; WQYYZNGOTUCWQX-UHFFFAOYSA-N; BDBM50185292; ZINC13685782; ethyl 6-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylate; ethyl 6-benzyl-1,4-dihydro-4-oxoquinoline-3-carboxylate; 6-Benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid EthylEster
DMICRFQ DT Small molecular drug
DMICRFQ PC 11529633
DMICRFQ MW 307.3
DMICRFQ FM C19H17NO3
DMICRFQ IC InChI=1S/C19H17NO3/c1-2-23-19(22)16-12-20-17-9-8-14(11-15(17)18(16)21)10-13-6-4-3-5-7-13/h3-9,11-12H,2,10H2,1H3,(H,20,21)
DMICRFQ CS CCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC3=CC=CC=C3
DMICRFQ IK WQYYZNGOTUCWQX-UHFFFAOYSA-N
DMICRFQ IU ethyl 6-benzyl-4-oxo-1H-quinoline-3-carboxylate
DMICRFQ DE Discovery agent
DMXMI5E ID DMXMI5E
DMXMI5E DN 6-benzyl-3-propoxycarbonyl-4-quinolone
DMXMI5E HS Investigative
DMXMI5E SN CHEMBL425590
DMXMI5E DT Small molecular drug
DMXMI5E PC 11594914
DMXMI5E MW 321.4
DMXMI5E FM C20H19NO3
DMXMI5E IC InChI=1S/C20H19NO3/c1-2-10-24-20(23)17-13-21-18-9-8-15(12-16(18)19(17)22)11-14-6-4-3-5-7-14/h3-9,12-13H,2,10-11H2,1H3,(H,21,22)
DMXMI5E CS CCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC3=CC=CC=C3
DMXMI5E IK JIOMLDXNFGNQFW-UHFFFAOYSA-N
DMXMI5E IU propyl 6-benzyl-4-oxo-1H-quinoline-3-carboxylate
DMXMI5E DE Discovery agent
DM7HNPJ ID DM7HNPJ
DM7HNPJ DN 6-benzyl-3-propylaminocarbonyl-4-quinolone
DM7HNPJ HS Investigative
DM7HNPJ SN CHEMBL380906
DM7HNPJ DT Small molecular drug
DM7HNPJ PC 44409492
DM7HNPJ MW 320.4
DM7HNPJ FM C20H20N2O2
DM7HNPJ IC InChI=1S/C20H20N2O2/c1-2-10-21-20(24)17-13-22-18-9-8-15(12-16(18)19(17)23)11-14-6-4-3-5-7-14/h3-9,12-13H,2,10-11H2,1H3,(H,21,24)(H,22,23)
DM7HNPJ CS CCCNC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC3=CC=CC=C3
DM7HNPJ IK RZALWHUVJLYKIZ-UHFFFAOYSA-N
DM7HNPJ IU 6-benzyl-4-oxo-N-propyl-1H-quinoline-3-carboxamide
DM7HNPJ DE Discovery agent
DM8FUZL ID DM8FUZL
DM8FUZL DN 6-Benzylamino-1H-pyrimidine-2,4-dione
DM8FUZL HS Investigative
DM8FUZL SN CHEMBL86482; 6-(Benzylamino)uracil; 6-(benzylamino)pyrimidine-2,4(1H,3H)-dione; 5759-80-8; 6-benzylaminouracil; NSC210509; 6-Benzylamino-1H-pyrimidine-2,4-dione; 6-(benzylamino)-1H-pyrimidine-2,4-dione; AC1L7DCT; ChemDiv2_000645; Oprea1_763542; Oprea1_040277; MLS001143323; SCHEMBL7563397; DTXSID80308975; MolPort-002-324-866; ZINC169533; HMS2799M09; HMS1370N07; STK385017; BDBM50022154; AKOS000627145; MCULE-8157405299; NSC-210509; CCG-107711; SMR000473158; ST50859108; EU-0040004; 6-(benzylamino)-2,4(1H,3H)-pyrimidinedione
DM8FUZL DT Small molecular drug
DM8FUZL PC 308654
DM8FUZL MW 217.22
DM8FUZL FM C11H11N3O2
DM8FUZL IC InChI=1S/C11H11N3O2/c15-10-6-9(13-11(16)14-10)12-7-8-4-2-1-3-5-8/h1-6H,7H2,(H3,12,13,14,15,16)
DM8FUZL CS C1=CC=C(C=C1)CNC2=CC(=O)NC(=O)N2
DM8FUZL IK NORSBFZJRBPBQZ-UHFFFAOYSA-N
DM8FUZL IU 6-(benzylamino)-1H-pyrimidine-2,4-dione
DM8FUZL CA CAS 5759-80-8
DM8FUZL DE Discovery agent
DMGJYWF ID DMGJYWF
DMGJYWF DN 6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione
DMGJYWF HS Investigative
DMGJYWF SN CHEMBL161517; 28484-80-2; 5-bromo-6-(benzylamino)uracil; NSC212354; AC1L7G2Y; 6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione; 6-(benzylamino)-5-bromo-1H-pyrimidine-2,4-dione; DTXSID60309581; BDBM50022146
DMGJYWF DT Small molecular drug
DMGJYWF PC 309896
DMGJYWF MW 296.12
DMGJYWF FM C11H10BrN3O2
DMGJYWF IC InChI=1S/C11H10BrN3O2/c12-8-9(14-11(17)15-10(8)16)13-6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,13,14,15,16,17)
DMGJYWF CS C1=CC=C(C=C1)CNC2=C(C(=O)NC(=O)N2)Br
DMGJYWF IK SLPLXDQXLWOWDS-UHFFFAOYSA-N
DMGJYWF IU 6-(benzylamino)-5-bromo-1H-pyrimidine-2,4-dione
DMGJYWF CA CAS 28484-80-2
DMGJYWF DE Discovery agent
DM8FTNC ID DM8FTNC
DM8FTNC DN 6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC HS Investigative
DM8FTNC SN 5-iodo-6-(benzylamino)uracil; CHEMBL161515; 100763-62-0; 6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC DT Small molecular drug
DM8FTNC PC 44374075
DM8FTNC MW 343.12
DM8FTNC FM C11H10IN3O2
DM8FTNC IC InChI=1S/C11H10IN3O2/c12-8-9(14-11(17)15-10(8)16)13-6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,13,14,15,16,17)
DM8FTNC CS C1=CC=C(C=C1)CNC2=C(C(=O)NC(=O)N2)I
DM8FTNC IK XDTXBEGCSPNEIV-UHFFFAOYSA-N
DM8FTNC IU 6-(benzylamino)-5-iodo-1H-pyrimidine-2,4-dione
DM8FTNC DE Discovery agent
DMK8XIO ID DMK8XIO
DMK8XIO DN 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine
DMK8XIO HS Investigative
DMK8XIO SN CHEMBL121479; 127116-64-7; 2,4-Pyrimidinediamine, 5-nitro-6-(phenylmethoxy)-; ACMC-20msby; 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine; SCHEMBL3309544; CTK0F6457; DTXSID40431990; VLVHHGNPHBVEIG-UHFFFAOYSA-N; BDBM50062813; AKOS030620964; 6-Benzyloxy-5-nitropyrimidine-2,4-diamine; 2,4-Diamino-6-benzyloxy-5-nitropyrimidine
DMK8XIO DT Small molecular drug
DMK8XIO PC 9860003
DMK8XIO MW 261.24
DMK8XIO FM C11H11N5O3
DMK8XIO IC InChI=1S/C11H11N5O3/c12-9-8(16(17)18)10(15-11(13)14-9)19-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,12,13,14,15)
DMK8XIO CS C1=CC=C(C=C1)COC2=NC(=NC(=C2[N+](=O)[O-])N)N
DMK8XIO IK VLVHHGNPHBVEIG-UHFFFAOYSA-N
DMK8XIO IU 5-nitro-6-phenylmethoxypyrimidine-2,4-diamine
DMK8XIO CA CAS 127116-64-7
DMK8XIO DE Discovery agent
DMUFSE2 ID DMUFSE2
DMUFSE2 DN 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine
DMUFSE2 HS Investigative
DMUFSE2 SN 101724-61-2; 2,4-Pyrimidinediamine, 5-nitroso-6-(phenylmethoxy)-; CHEMBL71484; 6-(benzyloxy)-5-nitrosopyrimidine-2,4-diamine; pyrimidine deriv. 1g; NU 6039; 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine; AC1L48AH; 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine; BDBM5573; SCHEMBL2054835; DTXSID50144145; MBQPVHNJEDDVCF-UHFFFAOYSA-N; ZINC6096446; AKOS028111161; 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine; 2,6-Diamino-4-benzyloxy-5-nitrosopyrimidine; 2,4-Diamino-5-nitroso-6-benzyloxypyrimidine
DMUFSE2 DT Small molecular drug
DMUFSE2 PC 181029
DMUFSE2 MW 245.24
DMUFSE2 FM C11H11N5O2
DMUFSE2 IC InChI=1S/C11H11N5O2/c12-9-8(16-17)10(15-11(13)14-9)18-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,12,13,14,15)
DMUFSE2 CS C1=CC=C(C=C1)COC2=NC(=NC(=C2N=O)N)N
DMUFSE2 IK MBQPVHNJEDDVCF-UHFFFAOYSA-N
DMUFSE2 IU 5-nitroso-6-phenylmethoxypyrimidine-2,4-diamine
DMUFSE2 CA CAS 101724-61-2
DMUFSE2 DE Discovery agent
DMFI7A8 ID DMFI7A8
DMFI7A8 DN 6-Benzyloxy-9H-purin-2-ylamine
DMFI7A8 HS Investigative
DMFI7A8 SN 6-O-Benzylguanine; 19916-73-5; 6-(Benzyloxy)-7H-purin-2-amine; 2-amino-6-benzyloxypurine; 6-(benzyloxy)-9H-purin-2-amine; 2-Amino-6-(benzyloxy)purine; O(6)-Bgua; 6-(Benzyloxy)guanine; 6-Benzyloxyguanine; 6-Benzyloxy guanine; 6-(Phenylmethoxy)-1H-purin-2-amine; 2-Amino-6-(phenylmethoxy)-9H-purine; O6-BG; UNII-01KC87F8FE; 1H-Purin-2-amine, 6-(phenylmethoxy)-; 6-BENZYLGUANINE; Purine, 2-amino-6-(benzyloxy)-; NSC 637037; CHEMBL407874; 01KC87F8FE; 6-benzyloxy-7H-purin-2-amine
DMFI7A8 DT Small molecular drug
DMFI7A8 PC 4578
DMFI7A8 MW 241.25
DMFI7A8 FM C12H11N5O
DMFI7A8 IC InChI=1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)
DMFI7A8 CS C1=CC=C(C=C1)COC2=NC(=NC3=C2NC=N3)N
DMFI7A8 IK KRWMERLEINMZFT-UHFFFAOYSA-N
DMFI7A8 IU 6-phenylmethoxy-7H-purin-2-amine
DMFI7A8 CA CAS 19916-73-5
DMFI7A8 DE Discovery agent
DMARP3M ID DMARP3M
DMARP3M DN 6-Benzyloxybenzo[b]thiophene-2-carboxamidine
DMARP3M HS Investigative
DMARP3M SN CHEMBL598170; 6-Benzyloxybenzo[b]thiophene-2-carboxamidine; SCHEMBL13709671
DMARP3M DT Small molecular drug
DMARP3M PC 46233193
DMARP3M MW 358.5
DMARP3M FM C22H18N2OS
DMARP3M IC InChI=1S/C22H18N2OS/c23-22(24)21-13-18-11-17(9-10-20(18)26-21)16-7-4-8-19(12-16)25-14-15-5-2-1-3-6-15/h1-13H,14H2,(H3,23,24)
DMARP3M CS C1=CC=C(C=C1)COC2=CC=CC(=C2)C3=CC4=C(C=C3)SC(=C4)C(=N)N
DMARP3M IK HCMFEDPYXOWDMW-UHFFFAOYSA-N
DMARP3M IU 5-(3-phenylmethoxyphenyl)-1-benzothiophene-2-carboximidamide
DMARP3M DE Discovery agent
DMI7FNZ ID DMI7FNZ
DMI7FNZ DN 6-Benzylsulfanyl-9H-purine
DMI7FNZ HS Investigative
DMI7FNZ SN Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-benzylsulfanyl-9H-purine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine
DMI7FNZ DT Small molecular drug
DMI7FNZ PC 93558
DMI7FNZ MW 242.3
DMI7FNZ FM C12H10N4S
DMI7FNZ IC InChI=1S/C12H10N4S/c1-2-4-9(5-3-1)6-17-12-10-11(14-7-13-10)15-8-16-12/h1-5,7-8H,6H2,(H,13,14,15,16)
DMI7FNZ CS C1=CC=C(C=C1)CSC2=NC=NC3=C2NC=N3
DMI7FNZ IK ULIQGBPQLPCTAJ-UHFFFAOYSA-N
DMI7FNZ IU 6-benzylsulfanyl-7H-purine
DMI7FNZ CA CAS 724-34-5
DMI7FNZ DE Discovery agent
DMNXGZP ID DMNXGZP
DMNXGZP DN 6-Benzylthioinosine
DMNXGZP HS Investigative
DMNXGZP SN 6-Benzylthioinosine; NSC26273; 6-Benzylthionebularine; MLS002702829; CHEMBL178704; 6-Benzylthiopurine ribonucleoside; 6165-03-3; NSC-26273; 6-(benzylsulfanyl)-9-pentofuranosyl-9h-purine; AC1L3TX3; AC1Q4YP0; cid_95263; ChEMBL_299712; SCHEMBL15427008; CTK5B3520; NSC 26273; BDBM50159129; SMR001566656; NCI60_002098; AI3-50272; Inosine,6-S-(phenylmethyl)-6-thio- (9CI); 9H-Purine, 6-(benzylthio)-9-.beta.-D-ribofuranosyl-; 9H-Purine, 6-(benzylthio)-9-beta-D-ribofuranosyl- (8CI); 9H-Purine, 6-((phenylmethyl)thio)-9-beta-D-ribofuranosyl-
DMNXGZP DT Small molecular drug
DMNXGZP PC 95263
DMNXGZP MW 374.4
DMNXGZP FM C17H18N4O4S
DMNXGZP IC InChI=1S/C17H18N4O4S/c22-6-11-13(23)14(24)17(25-11)21-9-20-12-15(21)18-8-19-16(12)26-7-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,22-24H,6-7H2
DMNXGZP CS C1=CC=C(C=C1)CSC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O
DMNXGZP IK OMJRXFOHHLLDFR-UHFFFAOYSA-N
DMNXGZP IU 2-(6-benzylsulfanylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMNXGZP CA CAS 6165-03-3
DMNXGZP DE Discovery agent
DMZ8PBE ID DMZ8PBE
DMZ8PBE DN 6beta-naltrexol HCl
DMZ8PBE HS Investigative
DMZ8PBE SN CHEMBL558140; UNII-765G11MG24; 765G11MG24; 55488-86-3; Naltrexone metabolite 6; A-Naltrexol (hydrochloride); 6beta-Naltrexol hydrochloride; HY-G0019; 6beta-Hydroxynaltrexone hydrochloride; Morphinan-3,6,14-triol, 17-(cyclopropylmethyl)-4,5-epoxy-, hydrochloride, (5alpha,6beta)-; Naltrexone metabolite 6AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Naltrexol (hydrochloride)
DMZ8PBE DT Small molecular drug
DMZ8PBE PC 45110000
DMZ8PBE MW 379.9
DMZ8PBE FM C20H26ClNO4
DMZ8PBE IC InChI=1S/C20H25NO4.ClH/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;/h3-4,11,14-15,18,22-24H,1-2,5-10H2;1H/t14-,15-,18+,19+,20-;/m1./s1
DMZ8PBE CS C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1O)OC5=C(C=C4)O)O.Cl
DMZ8PBE IK FSQFFCPJTDFOAN-CDHBEYIESA-N
DMZ8PBE IU (4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol;hydrochloride
DMZ8PBE CA CAS 55488-86-3
DMZ8PBE DE Discovery agent
DMZPY69 ID DMZPY69
DMZPY69 DN 6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one
DMZPY69 HS Investigative
DMZPY69 SN CHEMBL200678
DMZPY69 DT Small molecular drug
DMZPY69 PC 11603381
DMZPY69 MW 383.4
DMZPY69 FM C25H21NO3
DMZPY69 IC InChI=1S/C25H21NO3/c27-23-17-25(26-12-14-28-15-13-26)29-24-11-10-19(16-22(23)24)21-9-5-4-8-20(21)18-6-2-1-3-7-18/h1-11,16-17H,12-15H2
DMZPY69 CS C1COCCN1C2=CC(=O)C3=C(O2)C=CC(=C3)C4=CC=CC=C4C5=CC=CC=C5
DMZPY69 IK RYQNUEMYQYWYOR-UHFFFAOYSA-N
DMZPY69 IU 2-morpholin-4-yl-6-(2-phenylphenyl)chromen-4-one
DMZPY69 DE Discovery agent
DMU9WG0 ID DMU9WG0
DMU9WG0 DN 6-bromo-1H-indazole
DMU9WG0 HS Investigative
DMU9WG0 SN 6-bromo-1H-indazole; 79762-54-2; 6-Bromoindazole; 6-Bromo-2H-indazole; 1H-Indazole, 6-bromo-; CHEMBL247365; 1H-INDAZOLE,6-BROMO-; 1788080-23-8; 6-Bromo-1H-indazole, 97%; 6- Bromoindazole; PubChem7831; zlchem 1237; 6-broMo-1H indazole; 6-bromo-1-H-indazole; 6-bromanyl-1H-indazole; ACMC-209pi5; SCHEMBL5902; KSC376S4P; 6-Bromo-1H-indazole, 95%; AMBZ0200; AC1Q251Y; CTK2H6947; ZLE0012; DTXSID80591229; MolPort-029-084-056; WMKDUJVLNZANRN-UHFFFAOYSA-N; MolPort-000-001-819; ZINC8764137; KS-000002SJ; CS-D0757; BCP00386; ACN-S003161; ACT06505
DMU9WG0 DT Small molecular drug
DMU9WG0 PC 17842471
DMU9WG0 MW 197.03
DMU9WG0 FM C7H5BrN2
DMU9WG0 IC InChI=1S/C7H5BrN2/c8-6-2-1-5-4-9-10-7(5)3-6/h1-4H,(H,9,10)
DMU9WG0 CS C1=CC2=C(C=C1Br)NN=C2
DMU9WG0 IK WMKDUJVLNZANRN-UHFFFAOYSA-N
DMU9WG0 IU 6-bromo-1H-indazole
DMU9WG0 CA CAS 79762-54-2
DMU9WG0 DE Discovery agent
DMM9GOR ID DMM9GOR
DMM9GOR DN 6-bromo-1-methyl-3-(pyridin-4-yl)-1H-indole
DMM9GOR HS Investigative
DMM9GOR SN CHEMBL383060
DMM9GOR DT Small molecular drug
DMM9GOR PC 44410801
DMM9GOR MW 287.15
DMM9GOR FM C14H11BrN2
DMM9GOR IC InChI=1S/C14H11BrN2/c1-17-9-13(10-4-6-16-7-5-10)12-3-2-11(15)8-14(12)17/h2-9H,1H3
DMM9GOR CS CN1C=C(C2=C1C=C(C=C2)Br)C3=CC=NC=C3
DMM9GOR IK FSWMKLCDACNCRN-UHFFFAOYSA-N
DMM9GOR IU 6-bromo-1-methyl-3-pyridin-4-ylindole
DMM9GOR DE Discovery agent
DM7U58O ID DM7U58O
DM7U58O DN 6-Bromo-2-(2-nitro-phenyl)-chromen-4-one
DM7U58O HS Investigative
DM7U58O SN CHEMBL56906
DM7U58O DT Small molecular drug
DM7U58O PC 44298955
DM7U58O MW 346.13
DM7U58O FM C15H8BrNO4
DM7U58O IC InChI=1S/C15H8BrNO4/c16-9-5-6-14-11(7-9)13(18)8-15(21-14)10-3-1-2-4-12(10)17(19)20/h1-8H
DM7U58O CS C1=CC=C(C(=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)Br)[N+](=O)[O-]
DM7U58O IK GXUSNZYZTBJMIT-UHFFFAOYSA-N
DM7U58O IU 6-bromo-2-(2-nitrophenyl)chromen-4-one
DM7U58O DE Discovery agent
DMTJRF3 ID DMTJRF3
DMTJRF3 DN 6-Bromo-2-(3-bromo-phenyl)-chromen-4-one
DMTJRF3 HS Investigative
DMTJRF3 SN CHEMBL54878; 6,3'-Dibromoflavone; 3',6-Dibromoflavone; SCHEMBL6652108
DMTJRF3 DT Small molecular drug
DMTJRF3 PC 10045305
DMTJRF3 MW 380.03
DMTJRF3 FM C15H8Br2O2
DMTJRF3 IC InChI=1S/C15H8Br2O2/c16-10-3-1-2-9(6-10)15-8-13(18)12-7-11(17)4-5-14(12)19-15/h1-8H
DMTJRF3 CS C1=CC(=CC(=C1)Br)C2=CC(=O)C3=C(O2)C=CC(=C3)Br
DMTJRF3 IK UIPGLQFPZVUUQW-UHFFFAOYSA-N
DMTJRF3 IU 6-bromo-2-(3-bromophenyl)chromen-4-one
DMTJRF3 DE Discovery agent
DMP8ZVS ID DMP8ZVS
DMP8ZVS DN 6-Bromo-2-(3-nitro-phenyl)-chromen-4-one
DMP8ZVS HS Investigative
DMP8ZVS SN 6-bromo-2-(3-nitrophenyl)chromen-4-one; AC1MVVK1; 6-bromo-3'-nitroflavone; 3'-Nitro-6-bromoflavone; CHEMBL54341
DMP8ZVS DT Small molecular drug
DMP8ZVS PC 3714237
DMP8ZVS MW 346.13
DMP8ZVS FM C15H8BrNO4
DMP8ZVS IC InChI=1S/C15H8BrNO4/c16-10-4-5-14-12(7-10)13(18)8-15(21-14)9-2-1-3-11(6-9)17(19)20/h1-8H
DMP8ZVS CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)Br
DMP8ZVS IK IPHSQMSRIWZULE-UHFFFAOYSA-N
DMP8ZVS IU 6-bromo-2-(3-nitrophenyl)chromen-4-one
DMP8ZVS DE Discovery agent
DMCX3TM ID DMCX3TM
DMCX3TM DN 6-Bromo-2-(4-nitro-phenyl)-chromen-4-one
DMCX3TM HS Investigative
DMCX3TM SN CHEMBL55023; 6-bromo-4'-nitroflavone; SCHEMBL4990126; GMVMGIYPRPPNMB-UHFFFAOYSA-N; ZINC29544424
DMCX3TM DT Small molecular drug
DMCX3TM PC 11688794
DMCX3TM MW 346.13
DMCX3TM FM C15H8BrNO4
DMCX3TM IC InChI=1S/C15H8BrNO4/c16-10-3-6-14-12(7-10)13(18)8-15(21-14)9-1-4-11(5-2-9)17(19)20/h1-8H
DMCX3TM CS C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)Br)[N+](=O)[O-]
DMCX3TM IK GMVMGIYPRPPNMB-UHFFFAOYSA-N
DMCX3TM IU 6-bromo-2-(4-nitrophenyl)chromen-4-one
DMCX3TM DE Discovery agent
DMXQ8K1 ID DMXQ8K1
DMXQ8K1 DN 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMXQ8K1 HS Investigative
DMXQ8K1 SN 6-Bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 23046-69-7; CHEMBL6427; 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; 6-Bromo-1,2,3,4-tetrahydro-beta-carboline; AO-800/41069736; SCHEMBL1872944; CTK8H7143; MolPort-022-860-053; WUTVTUWSFMYRJK-UHFFFAOYSA-N; ZINC13587966; BDBM50136495; AKOS022471446; FCH1329538; AJ-64213; KB-205649
DMXQ8K1 DT Small molecular drug
DMXQ8K1 PC 14680201
DMXQ8K1 MW 251.12
DMXQ8K1 FM C11H11BrN2
DMXQ8K1 IC InChI=1S/C11H11BrN2/c12-7-1-2-10-9(5-7)8-3-4-13-6-11(8)14-10/h1-2,5,13-14H,3-4,6H2
DMXQ8K1 CS C1CNCC2=C1C3=C(N2)C=CC(=C3)Br
DMXQ8K1 IK WUTVTUWSFMYRJK-UHFFFAOYSA-N
DMXQ8K1 IU 6-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMXQ8K1 DE Discovery agent
DM39VT6 ID DM39VT6
DM39VT6 DN 6-bromo-2'-de-N-methylaplysinopsin
DM39VT6 HS Investigative
DM39VT6 DT Small molecular drug
DM39VT6 PC 10336056
DM39VT6 DE Discovery agent
DMMCNQI ID DMMCNQI
DMMCNQI DN 6-Bromo-2-phenyl-chromen-4-one
DMMCNQI HS Investigative
DMMCNQI SN 6-Bromoflavone; 1218-80-0; 6-bromo-2-phenyl-4H-chromen-4-one; 6-Bromo-2-phenyl-4H-1-benzopyran-4-one; 6-Bromo-2-phenyl-(4H)-4-benzopyranone; 6-bromo-2-phenylchromen-4-one; 6-Bromo-2-phenyl-chromen-4-one; ACMC-20alzx; AC1LAD8N; MLS002473413; CHEMBL52825; SCHEMBL4449962; ZINC58081; DTXSID00332792; HMS3343M11; HMS2224K05; 5956AH; MFCD00276169; AKOS015889624; MCULE-7797339727; ZB002311; ST059081; SMR001397504; KB-247810; TX-017285; 4H-1-Benzopyran-4-one, 6-bromo-2-phenyl-; K-1651; 6-Bromo-2-phenyl-(4H)-4-benzopyranone, 97%
DMMCNQI DT Small molecular drug
DMMCNQI PC 466276
DMMCNQI MW 301.13
DMMCNQI FM C15H9BrO2
DMMCNQI IC InChI=1S/C15H9BrO2/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9H
DMMCNQI CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)Br
DMMCNQI IK LPOZDKMXSPAATL-UHFFFAOYSA-N
DMMCNQI IU 6-bromo-2-phenylchromen-4-one
DMMCNQI CA CAS 1218-80-0
DMMCNQI DE Discovery agent
DMLT01H ID DMLT01H
DMLT01H DN 6-Bromo-2-piperazin-1-yl-quinoline
DMLT01H HS Investigative
DMLT01H SN 124782-95-2; 6-Bromo-2-piperazin-1-yl-quinoline; 6-bromo-2-(piperazin-1-yl)quinoline; 6-Bromoquipazine; 6-bromo-2-piperazin-1-ylquinoline; Quinoline, 6-bromo-2-(1-piperazinyl)-; CHEMBL39164; Quinoline,6-bromo-2-(1-piperazinyl)-; ACMC-20mr6z; AC1L2X2K; SCHEMBL5912936; CTK4B4077; DTXSID90154485; MKIHFWMBAKJYJL-UHFFFAOYSA-N; ZINC2527449; BDBM50090213; 6-bromo-2-(1-piperazinyl)quinoline; 3453AJ; AKOS022401899; AB19846; 6-bromanyl-2-piperazin-1-yl-quinoline; AJ-83658; DB-062320; AX8027344; FT-0713002; Z-6757; A805296
DMLT01H DT Small molecular drug
DMLT01H PC 130261
DMLT01H MW 292.17
DMLT01H FM C13H14BrN3
DMLT01H IC InChI=1S/C13H14BrN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2
DMLT01H CS C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)Br
DMLT01H IK MKIHFWMBAKJYJL-UHFFFAOYSA-N
DMLT01H IU 6-bromo-2-piperazin-1-ylquinoline
DMLT01H CA CAS 124782-95-2
DMLT01H DE Discovery agent
DMVWX62 ID DMVWX62
DMVWX62 DN 6-bromo-3-(pyridin-4-yl)-1H-indole
DMVWX62 HS Investigative
DMVWX62 SN CHEMBL206257; 6-bromo-3-(pyridin-4-yl)-1H-indole
DMVWX62 DT Small molecular drug
DMVWX62 PC 44410796
DMVWX62 MW 273.13
DMVWX62 FM C13H9BrN2
DMVWX62 IC InChI=1S/C13H9BrN2/c14-10-1-2-11-12(8-16-13(11)7-10)9-3-5-15-6-4-9/h1-8,16H
DMVWX62 CS C1=CC2=C(C=C1Br)NC=C2C3=CC=NC=C3
DMVWX62 IK KLYDZCDPTMADJL-UHFFFAOYSA-N
DMVWX62 IU 6-bromo-3-pyridin-4-yl-1H-indole
DMVWX62 DE Discovery agent
DM4HRIX ID DM4HRIX
DM4HRIX DN 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone
DM4HRIX HS Investigative
DM4HRIX SN CHEMBL206762; 88960-40-1; 3-Quinolinecarboxylic acid, 6-bromo-4-hydroxy-2-methyl-, ethyl ester; ACMC-20lfhk; CTK3A4318; DTXSID10469528
DM4HRIX DT Small molecular drug
DM4HRIX PC 11616547
DM4HRIX MW 310.14
DM4HRIX FM C13H12BrNO3
DM4HRIX IC InChI=1S/C13H12BrNO3/c1-3-18-13(17)11-7(2)15-10-5-4-8(14)6-9(10)12(11)16/h4-6H,3H2,1-2H3,(H,15,16)
DM4HRIX CS CCOC(=O)C1=C(NC2=C(C1=O)C=C(C=C2)Br)C
DM4HRIX IK OWQFPNVJMALXNK-UHFFFAOYSA-N
DM4HRIX IU ethyl 6-bromo-2-methyl-4-oxo-1H-quinoline-3-carboxylate
DM4HRIX CA CAS 88960-40-1
DM4HRIX DE Discovery agent
DM0MQHP ID DM0MQHP
DM0MQHP DN 6-bromo-3-ethoxycarbonyl-4-quinolone
DM0MQHP HS Investigative
DM0MQHP SN ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate; 122794-99-4; 79607-23-1; ethyl 6-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylate; 6-Bromo-4-hydroxyquinoline-3-carboxylic acid ethyl ester; Ethyl 6-bromo-4-hydroxy-3-quinolinecarboxylate; ethyl 6-bromo-4-oxo-1H-quinoline-3-carboxylate; 6-bromo-4-hydroxy-quinoline-3-carboxylic acid ethyl ester; CHEMBL205257; 3-QUINOLINECARBOXYLIC ACID, 6-BROMO-4-HYDROXY-, ETHYL ESTER; 6-BROMO-4-HYDROXY-3-QUINOLINECARBOXYLIC ACID ETHYL ESTER; 3-Quinolinecarboxylic acid, 6-bromo-1,4-dihydro-
DM0MQHP DT Small molecular drug
DM0MQHP PC 689824
DM0MQHP MW 296.12
DM0MQHP FM C12H10BrNO3
DM0MQHP IC InChI=1S/C12H10BrNO3/c1-2-17-12(16)9-6-14-10-4-3-7(13)5-8(10)11(9)15/h3-6H,2H2,1H3,(H,14,15)
DM0MQHP CS CCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)Br
DM0MQHP IK IVZIOBTVAJBBAS-UHFFFAOYSA-N
DM0MQHP IU ethyl 6-bromo-4-oxo-1H-quinoline-3-carboxylate
DM0MQHP CA CAS 122794-99-4
DM0MQHP DE Discovery agent
DM64KOZ ID DM64KOZ
DM64KOZ DN 6-Bromo-4,9-dihydro-3H-beta-carboline
DM64KOZ HS Investigative
DM64KOZ SN CHEMBL6626; 6-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136508; 6-Bromo-3,4-dihydro-beta-carboline
DM64KOZ DT Small molecular drug
DM64KOZ PC 42281505
DM64KOZ MW 249.11
DM64KOZ FM C11H9BrN2
DM64KOZ IC InChI=1S/C11H9BrN2/c12-7-1-2-10-9(5-7)8-3-4-13-6-11(8)14-10/h1-2,5-6,14H,3-4H2
DM64KOZ CS C1CN=CC2=C1C3=C(N2)C=CC(=C3)Br
DM64KOZ IK PAHAIWFYCZHWKN-UHFFFAOYSA-N
DM64KOZ IU 6-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DM64KOZ DE Discovery agent
DMFZ2PI ID DMFZ2PI
DMFZ2PI DN 6-bromo-5-methyl-1H-indole-2,3-dione
DMFZ2PI HS Investigative
DMFZ2PI SN 6-bromo-5-methyl-1H-indole-2,3-dione; 6-BROMO-5-METHYLISATIN; 306325-13-3; 6-bromo-5-methylindoline-2,3-dione; 6-bromo-5-methyl-2,3-dihydro-1H-indole-2,3-dione; 6-bromo-5-methyl-1H-benzo[d]azolidine-2,3-dione; AC1LW5IO; CBMicro_014209; Isatin-based compound, 58; SCHEMBL5526009; AC1Q2O90; CHEMBL221830; ARONIS016716; CTK7H5981; BDBM22838; BBC/891; MolPort-001-022-207; DQZFCBOXZKQQPM-UHFFFAOYSA-N; ALBB-012856; ZX-AN011645; ZINC2052963; SMSF0004612; STK042825; SBB071631; AKOS000484014; MCULE-6005372434; FCH1317267; CB09212; KS-000049B7
DMFZ2PI DT Small molecular drug
DMFZ2PI PC 1718647
DMFZ2PI MW 240.05
DMFZ2PI FM C9H6BrNO2
DMFZ2PI IC InChI=1S/C9H6BrNO2/c1-4-2-5-7(3-6(4)10)11-9(13)8(5)12/h2-3H,1H3,(H,11,12,13)
DMFZ2PI CS CC1=CC2=C(C=C1Br)NC(=O)C2=O
DMFZ2PI IK DQZFCBOXZKQQPM-UHFFFAOYSA-N
DMFZ2PI IU 6-bromo-5-methyl-1H-indole-2,3-dione
DMFZ2PI DE Discovery agent
DM8A1ZU ID DM8A1ZU
DM8A1ZU DN 6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione
DM8A1ZU HS Investigative
DM8A1ZU SN CHEMBL235666; BDBM20076; 6-Bromo-5-phenylpyrimidine-2,4(1H,3H)-dione, 23
DM8A1ZU DT Small molecular drug
DM8A1ZU PC 23648528
DM8A1ZU MW 267.08
DM8A1ZU FM C10H7BrN2O2
DM8A1ZU IC InChI=1S/C10H7BrN2O2/c11-8-7(6-4-2-1-3-5-6)9(14)13-10(15)12-8/h1-5H,(H2,12,13,14,15)
DM8A1ZU CS C1=CC=C(C=C1)C2=C(NC(=O)NC2=O)Br
DM8A1ZU IK XSEDFSJHHTXVPL-UHFFFAOYSA-N
DM8A1ZU IU 6-bromo-5-phenyl-1H-pyrimidine-2,4-dione
DM8A1ZU DE Discovery agent
DMZJ6M8 ID DMZJ6M8
DMZJ6M8 DN 6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine
DMZJ6M8 HS Investigative
DMZJ6M8 SN CHEMBL609595; 6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine; BDBM50304813
DMZJ6M8 DT Small molecular drug
DMZJ6M8 PC 46228424
DMZJ6M8 MW 282.14
DMZJ6M8 FM C10H12BrN5
DMZJ6M8 IC InChI=1S/C10H12BrN5/c11-8-7-16-6-3-13-9(16)10(14-8)15-4-1-12-2-5-15/h3,6-7,12H,1-2,4-5H2
DMZJ6M8 CS C1CN(CCN1)C2=NC(=CN3C2=NC=C3)Br
DMZJ6M8 IK XNILOZDQMHSDIZ-UHFFFAOYSA-N
DMZJ6M8 IU 6-bromo-8-piperazin-1-ylimidazo[1,2-a]pyrazine
DMZJ6M8 DE Discovery agent
DMQGB70 ID DMQGB70
DMQGB70 DN 6-bromoaplysinopsin
DMQGB70 HS Investigative
DMQGB70 DT Small molecular drug
DMQGB70 PC 135433933
DMQGB70 MW 333.18
DMQGB70 FM C14H13BrN4O
DMQGB70 IC InChI=1S/C14H13BrN4O/c1-18-12(13(20)19(2)14(18)16)5-8-7-17-11-6-9(15)3-4-10(8)11/h3-7,16,20H,1-2H3/b8-5+,16-14?
DMQGB70 CS CN1C(=C(N(C1=N)C)O)/C=C/2\\C=NC3=C2C=CC(=C3)Br
DMQGB70 IK RZEXTWCYINCKES-JENRKBSESA-N
DMQGB70 IU 5-[(Z)-(6-bromoindol-3-ylidene)methyl]-2-imino-1,3-dimethylimidazol-4-ol
DMQGB70 CA CAS 85079-45-4
DMQGB70 DE Discovery agent
DM12WYV ID DM12WYV
DM12WYV DN 6-bromoindirubin-3-oxime
DM12WYV HS Investigative
DM12WYV SN 6-bromoindirubin-3'-oxime (BIO)
DM12WYV DT Small molecular drug
DM12WYV PC 448949
DM12WYV MW 356.17
DM12WYV FM C16H10BrN3O2
DM12WYV IC InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18-19,21H
DM12WYV CS C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O
DM12WYV IK SAQUSDSPQYQNBG-UHFFFAOYSA-N
DM12WYV IU 6-bromo-3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
DM12WYV CA CAS 667463-62-9
DM12WYV CB CHEBI:86290
DM12WYV DE Discovery agent
DMP9O7G ID DMP9O7G
DMP9O7G DN 6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G HS Investigative
DMP9O7G SN CHEMBL1081536; 6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G DT Small molecular drug
DMP9O7G PC 46879644
DMP9O7G MW 379.05
DMP9O7G FM C14H9Br2N3
DMP9O7G IC InChI=1S/C14H9Br2N3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMP9O7G CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)Br
DMP9O7G IK GBBRIESLSQOJQX-UHFFFAOYSA-N
DMP9O7G IU 6-bromo-N-(3-bromophenyl)quinazolin-4-amine
DMP9O7G DE Discovery agent
DM0A3DB ID DM0A3DB
DM0A3DB DN 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
DM0A3DB HS Investigative
DM0A3DB SN 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine; CHEMBL1079374; AC1LEZQW; C14H9BrClN3; ChemDiv1_028574; Oprea1_590274; Neuro1_000364; MLS000572427; cid_720635; SCHEMBL4783154; HMS668C18; MolPort-000-660-268; ZINC122236; HMS2493B23; BDBM50311887; STK965864; AKOS002348868; MCULE-5418328745; SMR000194385; EU-0077259; ST50477345; 6-bromo-N-(3-chlorophenyl)-4-quinazolinamine; (6-bromoquinazolin-4-yl)(3-chlorophenyl)amine; SR-01000485096; SR-01000485096-1
DM0A3DB DT Small molecular drug
DM0A3DB PC 720635
DM0A3DB MW 334.6
DM0A3DB FM C14H9BrClN3
DM0A3DB IC InChI=1S/C14H9BrClN3/c15-9-4-5-13-12(6-9)14(18-8-17-13)19-11-3-1-2-10(16)7-11/h1-8H,(H,17,18,19)
DM0A3DB CS C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)Br
DM0A3DB IK LYKXFKUSOXETGV-UHFFFAOYSA-N
DM0A3DB IU 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
DM0A3DB DE Discovery agent
DM2IP5F ID DM2IP5F
DM2IP5F DN 6-bromo-N-(3-fluorophenyl)quinazolin-4-amine
DM2IP5F HS Investigative
DM2IP5F SN CHEMBL1079375; 6-bromo-N-(3-fluorophenyl)quinazolin-4-amine; ZINC32540960; BDBM50311885; AKOS002366762
DM2IP5F DT Small molecular drug
DM2IP5F PC 21002513
DM2IP5F MW 318.14
DM2IP5F FM C14H9BrFN3
DM2IP5F IC InChI=1S/C14H9BrFN3/c15-9-4-5-13-12(6-9)14(18-8-17-13)19-11-3-1-2-10(16)7-11/h1-8H,(H,17,18,19)
DM2IP5F CS C1=CC(=CC(=C1)F)NC2=NC=NC3=C2C=C(C=C3)Br
DM2IP5F IK ALKMBIXEONKULX-UHFFFAOYSA-N
DM2IP5F IU 6-bromo-N-(3-fluorophenyl)quinazolin-4-amine
DM2IP5F DE Discovery agent
DM2MJ9F ID DM2MJ9F
DM2MJ9F DN 6-bromo-N-m-tolylquinazolin-4-amine
DM2MJ9F HS Investigative
DM2MJ9F SN CHEMBL1081537; 6-bromo-N-m-tolylquinazolin-4-amine; AC1LEZQQ; Oprea1_147022; Neuro1_000540; MLS000684595; SCHEMBL4349199; MolPort-000-660-263; HMS3380E09; HMS2596L23; ZINC122234; BDBM50311883; AKOS002348862; MCULE-2560701920; SMR000268469; ST50477342; EU-0043981; 6-bromo-N-(3-methylphenyl)quinazolin-4-amine; 6-bromo-N-(3-methylphenyl)-4-quinazolinamine; (6-bromoquinazolin-4-yl)(3-methylphenyl)amine; SR-01000485095
DM2MJ9F DT Small molecular drug
DM2MJ9F PC 720633
DM2MJ9F MW 314.18
DM2MJ9F FM C15H12BrN3
DM2MJ9F IC InChI=1S/C15H12BrN3/c1-10-3-2-4-12(7-10)19-15-13-8-11(16)5-6-14(13)17-9-18-15/h2-9H,1H3,(H,17,18,19)
DM2MJ9F CS CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)Br
DM2MJ9F IK CGCSONSXFOSORP-UHFFFAOYSA-N
DM2MJ9F IU 6-bromo-N-(3-methylphenyl)quinazolin-4-amine
DM2MJ9F DE Discovery agent
DM46GLQ ID DM46GLQ
DM46GLQ DN 6-butyl-2,4-dipropylaminopyrimidine
DM46GLQ HS Investigative
DM46GLQ SN CHEMBL352024; 6-butyl-2,4-dipropylaminopyrimidine; BDBM50138883; ZINC13559144
DM46GLQ DT Small molecular drug
DM46GLQ PC 11276767
DM46GLQ MW 250.38
DM46GLQ FM C14H26N4
DM46GLQ IC InChI=1S/C14H26N4/c1-4-7-8-12-11-13(15-9-5-2)18-14(17-12)16-10-6-3/h11H,4-10H2,1-3H3,(H2,15,16,17,18)
DM46GLQ CS CCCCC1=CC(=NC(=N1)NCCC)NCCC
DM46GLQ IK UYWCDBMUBBSZOJ-UHFFFAOYSA-N
DM46GLQ IU 6-butyl-2-N,4-N-dipropylpyrimidine-2,4-diamine
DM46GLQ DE Discovery agent
DMWTMDH ID DMWTMDH
DMWTMDH DN 6-Carboxyfluorescein
DMWTMDH HS Investigative
DMWTMDH SN 3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]-6-carboxylic acid; 3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-6-carboxylic acid; 5(6)-carboxy fluorescein; 6-Carboxyfluorescein; 6-Carboxyfluorescein, 96%; 6-FAM; FLUOS; J-100061; Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-6-carboxylic acid, 3',6'-dihydroxy-3-oxo-; Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-6-carboxylic acid, 3',6'-dihydroxy-3-oxo-; carboxyfluorescein
DMWTMDH DT Small molecular drug
DMWTMDH PC 76806
DMWTMDH MW 376.32
DMWTMDH FM C21H12O7
DMWTMDH IC InChI=1S/C21H12O7/c22-11-2-5-14-17(8-11)27-18-9-12(23)3-6-15(18)21(14)16-7-10(19(24)25)1-4-13(16)20(26)28-21/h1-9,22-23H,(H,24,25)
DMWTMDH CS C1=CC2=C(C=C1C(=O)O)C3(C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O)OC2=O
DMWTMDH IK BZTDTCNHAFUJOG-UHFFFAOYSA-N
DMWTMDH IU 3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carboxylic acid
DMWTMDH CA CAS 3301-79-9
DMWTMDH CB ChEBI:39073
DM9MPDK ID DM9MPDK
DM9MPDK DN 6-Carboxymethyluracil
DM9MPDK HS Investigative
DM9MPDK SN 6-Carboxymethyluracil; 4628-39-1; URACIL-6-ACETIC ACID; Uracil-4-acetic acid; (2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic acid; 1,2,3,6-Tetrahydro-2,6-dioxo-4-pyrimidineacetic acid; 2-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetic acid; uracil-6-ylacetic acid; NSC13201; 4-Pyrimidineacetic acid, 1,2,3,6-tetrahydro-2,6-dioxo-; (2,6-Dioxo-1,2,3,6-tetrahydro-pyrimidin-4-yl)-acetic acid; CHEBI:46371; 2-(2,6-dihydroxypyrimidin-4-yl)acetic acid; 2-(2,4-dioxo-1H-pyrimidin-6-yl)acetic acid; 4-Pyrimidineaceticacid, 1,2,
DM9MPDK DT Small molecular drug
DM9MPDK PC 73271
DM9MPDK MW 170.12
DM9MPDK FM C6H6N2O4
DM9MPDK IC InChI=1S/C6H6N2O4/c9-4-1-3(2-5(10)11)7-6(12)8-4/h1H,2H2,(H,10,11)(H2,7,8,9,12)
DM9MPDK CS C1=C(NC(=O)NC1=O)CC(=O)O
DM9MPDK IK NQAUNZZEYKWTHM-UHFFFAOYSA-N
DM9MPDK IU 2-(2,4-dioxo-1H-pyrimidin-6-yl)acetic acid
DM9MPDK CA CAS 4628-39-1
DM9MPDK CB CHEBI:46371
DM9MPDK DE Discovery agent
DMW6320 ID DMW6320
DMW6320 DN 6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMW6320 HS Investigative
DMW6320 SN CHEMBL288445; 6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole; BDBM50108303; AKOS022692451
DMW6320 DT Small molecular drug
DMW6320 PC 44287208
DMW6320 MW 206.67
DMW6320 FM C11H11ClN2
DMW6320 IC InChI=1S/C11H11ClN2/c12-10-3-1-2-8-6-9-7-13-4-5-14(9)11(8)10/h1-3,6,13H,4-5,7H2
DMW6320 CS C1CN2C(=CC3=C2C(=CC=C3)Cl)CN1
DMW6320 IK AWEHDQNNOZXHOU-UHFFFAOYSA-N
DMW6320 IU 6-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMW6320 DE Discovery agent
DMURJ34 ID DMURJ34
DMURJ34 DN 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione
DMURJ34 HS Investigative
DMURJ34 SN 6-chloroquinoxaline-2,3-diol; 6639-79-8; 2,3-Dihydroxy-6-chloroquinoxaline; 6-Chloro-1,4-dihydroquinoxaline-2,3-dione; 6-Chloroquinoxaline-2,3(1H,4H)-dione; 6-Chloro-2,3-dihydroxyquinoxaline; 6-Chloro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; 169-14-2; 2,3-Quinoxalinedione, 6-chloro-1,4-dihydro-; CHEMBL21641; 6-CHLORO-2,3-DIOXO-1,2,3,4-TETRAHYDROQUINOXALINE; 6-chloro-1,4-dihydro-2,3-quinoxalinedione; Oprea1_205811; 2,3-Quinoxalinediol, 6-chloro-; EINECS 229-647-9; NSC 48940; PubChem15426; 2, 6-chloro-; AC1Q3ORE
DMURJ34 DT Small molecular drug
DMURJ34 PC 81143
DMURJ34 MW 196.59
DMURJ34 FM C8H5ClN2O2
DMURJ34 IC InChI=1S/C8H5ClN2O2/c9-4-1-2-5-6(3-4)11-8(13)7(12)10-5/h1-3H,(H,10,12)(H,11,13)
DMURJ34 CS C1=CC2=C(C=C1Cl)NC(=O)C(=O)N2
DMURJ34 IK RNOLFZACEWWIHP-UHFFFAOYSA-N
DMURJ34 IU 6-chloro-1,4-dihydroquinoxaline-2,3-dione
DMURJ34 CA CAS 6639-79-8
DMURJ34 DE Discovery agent
DMKCBIL ID DMKCBIL
DMKCBIL DN 6-chloro-1H-indazole
DMKCBIL HS Investigative
DMKCBIL SN 6-Chloro-1H-indazole; 698-25-9; 6-Chloroindazole; 1H-Indazole, 6-chloro-; 1H-INDAZOLE,6-CHLORO-; CHEMBL392184; VUZQHUVRBPILAX-UHFFFAOYSA-N; AK-27924; 6-chloroazaindole; 6-chloro-indazole; NSC92743; PubChem20592; AC1L9DR4; SCHEMBL3533806; SCHEMBL16523332; CTK2F6854; DTXSID70329119; MolPort-000-002-984; HMS1629J03; 6-Chloro-1H-indazole, AldrichCPR; ACT06345; ZINC4878475; BCP00929; EBD48419; NSC-92743; BDBM50209236; BBL101057; STL554851; ANW-50721; FCH835101; AKOS005256021; AKOS024124978; RP01765; CS-W005017; VI20061; FS-2891; QC-2958; PB34228
DMKCBIL DT Small molecular drug
DMKCBIL PC 417524
DMKCBIL MW 152.58
DMKCBIL FM C7H5ClN2
DMKCBIL IC InChI=1S/C7H5ClN2/c8-6-2-1-5-4-9-10-7(5)3-6/h1-4H,(H,9,10)
DMKCBIL CS C1=CC2=C(C=C1Cl)NN=C2
DMKCBIL IK VUZQHUVRBPILAX-UHFFFAOYSA-N
DMKCBIL IU 6-chloro-1H-indazole
DMKCBIL CA CAS 698-25-9
DMKCBIL DE Discovery agent
DMTWBOV ID DMTWBOV
DMTWBOV DN 6-Chloro-2-(3-nitro-phenyl)-chromen-4-one
DMTWBOV HS Investigative
DMTWBOV SN CHEMBL59263; 127767-40-2; 4H-1-Benzopyran-4-one, 6-chloro-2-(3-nitrophenyl)-; 6-chloro-2-(3-nitrophenyl)chromen-4-one; ACMC-20mskm; 3'-Nitro-6-chloroflavone; AC1NMK14; 6-chloro-3' -nitroflavone; CTK0C1861; DTXSID20407496; AKOS001600357; EU-0068162; SR-01000400460
DMTWBOV DT Small molecular drug
DMTWBOV PC 5011228
DMTWBOV MW 301.68
DMTWBOV FM C15H8ClNO4
DMTWBOV IC InChI=1S/C15H8ClNO4/c16-10-4-5-14-12(7-10)13(18)8-15(21-14)9-2-1-3-11(6-9)17(19)20/h1-8H
DMTWBOV CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)Cl
DMTWBOV IK DKCAUMRZSZVJCP-UHFFFAOYSA-N
DMTWBOV IU 6-chloro-2-(3-nitrophenyl)chromen-4-one
DMTWBOV CA CAS 127767-40-2
DMTWBOV DE Discovery agent
DMLMOC0 ID DMLMOC0
DMLMOC0 DN 6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMLMOC0 HS Investigative
DMLMOC0 DT Small molecular drug
DMLMOC0 PC 135546593
DMLMOC0 MW 261.66
DMLMOC0 FM C13H8ClNO3
DMLMOC0 IC InChI=1S/C13H8ClNO3/c14-9-5-12-10(6-11(9)17)15-13(18-12)7-1-3-8(16)4-2-7/h1-6,16-17H
DMLMOC0 CS C1=CC(=CC=C1C2=NC3=CC(=C(C=C3O2)Cl)O)O
DMLMOC0 IK FXPRHFKNZLXHRN-UHFFFAOYSA-N
DMLMOC0 IU 6-chloro-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMLMOC0 DE Discovery agent
DM5FZDI ID DM5FZDI
DM5FZDI DN 6-Chloro-2-phenyl-chromen-4-one
DM5FZDI HS Investigative
DM5FZDI SN 6-chloroflavone; 10420-73-2; 6-Chloro-2-phenyl-4H-chromen-4-one; 6-Chloro-2-phenyl-chromen-4-one; MLS002701775; CHEMBL293478; 6-chloro-2-phenylchromen-4-one; NSC63999; 4l2f; AC1L6LIW; Maybridge4_000538; AC1Q3RN7; NCIOpen2_003001; Oprea1_047009; SCHEMBL4649891; ZINC58093; DTXSID10289783; MolPort-002-893-915; IFNDLWHUYFSXBK-UHFFFAOYSA-N; HMS1522I10; KS-000017VJ; MRS-1131; NSC621450; BDBM50051364; NSC-63999; 5979AH; AKOS000603599; MCULE-8596095757; MB00919; CCG-233377; NSC-621450; IDI1_031120; NCGC00177472-01; SMR001565369; ZB002315
DM5FZDI DT Small molecular drug
DM5FZDI PC 248021
DM5FZDI MW 256.68
DM5FZDI FM C15H9ClO2
DM5FZDI IC InChI=1S/C15H9ClO2/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-9H
DM5FZDI CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)Cl
DM5FZDI IK IFNDLWHUYFSXBK-UHFFFAOYSA-N
DM5FZDI IU 6-chloro-2-phenylchromen-4-one
DM5FZDI CA CAS 10420-73-2
DM5FZDI DE Discovery agent
DMM41AQ ID DMM41AQ
DMM41AQ DN 6-Chloro-2-piperazin-1-yl-quinoline
DMM41AQ HS Investigative
DMM41AQ SN 6-chloro-2-piperazin-1-yl-quinoline; 78060-46-5; 6-Chloro-2-(piperazin-1-yl)quinoline; 6-chloro-2-piperazin-1-ylquinoline; 6-chloro-2-(1-piperazinyl)quinoline; CHEMBL290537; AC1Q3JZ5; 2-Piperazino-6-chloroquinoline; SCHEMBL4182196; CTK5E5334; DTXSID60437575; GSFXEINORRSYJW-UHFFFAOYSA-N; ZINC2527450; 3506AJ; BDBM50090216; AKOS022401900; AB19847; 6-chloranyl-2-piperazin-1-yl-quinoline; Quinoline,6-chloro-2-(1-piperazinyl)-; AJ-83656; AX8029614; KB-248323; DB-075405; FT-0719429; Z-5014
DMM41AQ DT Small molecular drug
DMM41AQ PC 10264015
DMM41AQ MW 247.72
DMM41AQ FM C13H14ClN3
DMM41AQ IC InChI=1S/C13H14ClN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2
DMM41AQ CS C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)Cl
DMM41AQ IK GSFXEINORRSYJW-UHFFFAOYSA-N
DMM41AQ IU 6-chloro-2-piperazin-1-ylquinoline
DMM41AQ CA CAS 78060-46-5
DMM41AQ DE Discovery agent
DMHJIN0 ID DMHJIN0
DMHJIN0 DN 6-Chloro-4-morpholin-4-yl-chromen-2-one
DMHJIN0 HS Investigative
DMHJIN0 SN CHEMBL179591; 6-chloro-4-morpholin-4-yl-chromen-2-one
DMHJIN0 DT Small molecular drug
DMHJIN0 PC 11459783
DMHJIN0 MW 265.69
DMHJIN0 FM C13H12ClNO3
DMHJIN0 IC InChI=1S/C13H12ClNO3/c14-9-1-2-12-10(7-9)11(8-13(16)18-12)15-3-5-17-6-4-15/h1-2,7-8H,3-6H2
DMHJIN0 CS C1COCCN1C2=CC(=O)OC3=C2C=C(C=C3)Cl
DMHJIN0 IK IKOYKMNERRYCAN-UHFFFAOYSA-N
DMHJIN0 IU 6-chloro-4-morpholin-4-ylchromen-2-one
DMHJIN0 DE Discovery agent
DMSZML2 ID DMSZML2
DMSZML2 DN 6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione
DMSZML2 HS Investigative
DMSZML2 SN 6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione; 1000680-81-8; CHEMBL397364; BDBM20069; 5-Substituted-6-chlorouracil, 10e
DMSZML2 DT Small molecular drug
DMSZML2 PC 23648522
DMSZML2 MW 228.66
DMSZML2 FM C8H5ClN2O2S
DMSZML2 IC InChI=1S/C8H5ClN2O2S/c9-6-5(4-2-1-3-14-4)7(12)11-8(13)10-6/h1-3H,(H2,10,11,12,13)
DMSZML2 CS C1=CSC(=C1)C2=C(NC(=O)NC2=O)Cl
DMSZML2 IK DPKZWAVQBQNTIP-UHFFFAOYSA-N
DMSZML2 IU 6-chloro-5-thiophen-2-yl-1H-pyrimidine-2,4-dione
DMSZML2 DE Discovery agent
DMASFR6 ID DMASFR6
DMASFR6 DN 6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione
DMASFR6 HS Investigative
DMASFR6 SN CHEMBL435558; BDBM20059; 5-Substituted-6-chlorouracil, 5f
DMASFR6 DT Small molecular drug
DMASFR6 PC 23648512
DMASFR6 MW 244.72
DMASFR6 FM C11H17ClN2O2
DMASFR6 IC InChI=1S/C11H17ClN2O2/c1-2-3-4-5-6-7-8-9(12)13-11(16)14-10(8)15/h2-7H2,1H3,(H2,13,14,15,16)
DMASFR6 CS CCCCCCCC1=C(NC(=O)NC1=O)Cl
DMASFR6 IK CIAJCIKDDKGJBP-UHFFFAOYSA-N
DMASFR6 IU 6-chloro-5-heptyl-1H-pyrimidine-2,4-dione
DMASFR6 DE Discovery agent
DMP4V8Y ID DMP4V8Y
DMP4V8Y DN 6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione
DMP4V8Y HS Investigative
DMP4V8Y SN CHEMBL234997; BDBM20058; 5-Substituted-6-chlorouracil, 5e
DMP4V8Y DT Small molecular drug
DMP4V8Y PC 23648511
DMP4V8Y MW 230.69
DMP4V8Y FM C10H15ClN2O2
DMP4V8Y IC InChI=1S/C10H15ClN2O2/c1-2-3-4-5-6-7-8(11)12-10(15)13-9(7)14/h2-6H2,1H3,(H2,12,13,14,15)
DMP4V8Y CS CCCCCCC1=C(NC(=O)NC1=O)Cl
DMP4V8Y IK KRFZZHACLHGMCH-UHFFFAOYSA-N
DMP4V8Y IU 6-chloro-5-hexyl-1H-pyrimidine-2,4-dione
DMP4V8Y DE Discovery agent
DMUJSP7 ID DMUJSP7
DMUJSP7 DN 6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione
DMUJSP7 HS Investigative
DMUJSP7 SN CHEMBL238183; BDBM20057; 5-Substituted-6-chlorouracil, 5d
DMUJSP7 DT Small molecular drug
DMUJSP7 PC 23648510
DMUJSP7 MW 216.66
DMUJSP7 FM C9H13ClN2O2
DMUJSP7 IC InChI=1S/C9H13ClN2O2/c1-2-3-4-5-6-7(10)11-9(14)12-8(6)13/h2-5H2,1H3,(H2,11,12,13,14)
DMUJSP7 CS CCCCCC1=C(NC(=O)NC1=O)Cl
DMUJSP7 IK XCFUGRSUKUUBGJ-UHFFFAOYSA-N
DMUJSP7 IU 6-chloro-5-pentyl-1H-pyrimidine-2,4-dione
DMUJSP7 DE Discovery agent
DM90JMN ID DM90JMN
DM90JMN DN 6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione
DM90JMN HS Investigative
DM90JMN SN 6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione; 1000680-77-2; CHEMBL235001; BDBM20065; 5-Substituted-6-chlorouracil, 10a
DM90JMN DT Small molecular drug
DM90JMN PC 23648518
DM90JMN MW 222.63
DM90JMN FM C10H7ClN2O2
DM90JMN IC InChI=1S/C10H7ClN2O2/c11-8-7(6-4-2-1-3-5-6)9(14)13-10(15)12-8/h1-5H,(H2,12,13,14,15)
DM90JMN CS C1=CC=C(C=C1)C2=C(NC(=O)NC2=O)Cl
DM90JMN IK ORRYLQRWCPCGJZ-UHFFFAOYSA-N
DM90JMN IU 6-chloro-5-phenyl-1H-pyrimidine-2,4-dione
DM90JMN DE Discovery agent
DMB24LJ ID DMB24LJ
DMB24LJ DN 6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione
DMB24LJ HS Investigative
DMB24LJ SN 6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione; 19030-76-3; 5-propyl-6-chloro-uracil; CHEMBL394425; BDBM20055; 5-Substituted-6-chlorouracil, 5b
DMB24LJ DT Small molecular drug
DMB24LJ PC 11095381
DMB24LJ MW 188.61
DMB24LJ FM C7H9ClN2O2
DMB24LJ IC InChI=1S/C7H9ClN2O2/c1-2-3-4-5(8)9-7(12)10-6(4)11/h2-3H2,1H3,(H2,9,10,11,12)
DMB24LJ CS CCCC1=C(NC(=O)NC1=O)Cl
DMB24LJ IK DTSULQDNDBSJQV-UHFFFAOYSA-N
DMB24LJ IU 6-chloro-5-propyl-1H-pyrimidine-2,4-dione
DMB24LJ CA CAS 19030-76-3
DMB24LJ DE Discovery agent
DM10A9S ID DM10A9S
DM10A9S DN 6-Chloro-N-(2-morpholinoethyl)nicotinamide
DM10A9S HS Investigative
DM10A9S SN 6-Chloro-N-(2-morpholinoethyl)nicotinamide; CHEMBL596768; 446269-58-5; 6-chloro-N-[2-(morpholin-4-yl)ethyl]pyridine-3-carboxamide; AC1LNWHD; Oprea1_139589; MLS001010907; CTK6H1374; cid_1228702; 6-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide; MolPort-000-431-678; HMS2765K07; ZINC19397174; BDBM50307188; AKOS000162940; MCULE-8413919053; SMR000352965; ST50046456; 6-chloro-N-(2-morpholin-4-ylethyl)nicotinamide; Z32410126; F1077-0095
DM10A9S DT Small molecular drug
DM10A9S PC 1228702
DM10A9S MW 269.73
DM10A9S FM C12H16ClN3O2
DM10A9S IC InChI=1S/C12H16ClN3O2/c13-11-2-1-10(9-15-11)12(17)14-3-4-16-5-7-18-8-6-16/h1-2,9H,3-8H2,(H,14,17)
DM10A9S CS C1COCCN1CCNC(=O)C2=CN=C(C=C2)Cl
DM10A9S IK DWSIBMFUHQAQMK-UHFFFAOYSA-N
DM10A9S IU 6-chloro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DM10A9S DE Discovery agent
DMPIFLA ID DMPIFLA
DMPIFLA DN 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine
DMPIFLA HS Investigative
DMPIFLA SN 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine; 4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397
DMPIFLA DT Small molecular drug
DMPIFLA PC 5328819
DMPIFLA MW 290.1
DMPIFLA FM C14H9Cl2N3
DMPIFLA IC InChI=1S/C14H9Cl2N3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMPIFLA CS C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)Cl
DMPIFLA IK QKCFZLIUAVWYRM-UHFFFAOYSA-N
DMPIFLA IU 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine
DMPIFLA DE Discovery agent
DM78I4P ID DM78I4P
DM78I4P DN 6-Chloro-N-(3-morpholinopropyl)nicotinamide
DM78I4P HS Investigative
DM78I4P SN CHEMBL610499; 6-Chloro-N-(3-morpholinopropyl)nicotinamide; BDBM50307201
DM78I4P DT Small molecular drug
DM78I4P PC 17144214
DM78I4P MW 283.75
DM78I4P FM C13H18ClN3O2
DM78I4P IC InChI=1S/C13H18ClN3O2/c14-12-3-2-11(10-16-12)13(18)15-4-1-5-17-6-8-19-9-7-17/h2-3,10H,1,4-9H2,(H,15,18)
DM78I4P CS C1COCCN1CCCNC(=O)C2=CN=C(C=C2)Cl
DM78I4P IK CNQVNEPLCSJWDF-UHFFFAOYSA-N
DM78I4P IU 6-chloro-N-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide
DM78I4P DE Discovery agent
DMUY9TF ID DMUY9TF
DMUY9TF DN 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide
DMUY9TF HS Investigative
DMUY9TF SN CHEMBL38911; 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide; SCHEMBL8526818; LOMPSBWQXLVHJX-UHFFFAOYSA-N; BDBM50321876; 6-Chloro-1-(3-pyridylcarbamoyl)indoline; N-(3-Pyridinyl)-6-chloro-2,3-dihydro-1H-indole-1-carboxamide; 6-Chloro-2,3-dihydro-indole-1-carboxylic acid pyridin-3-ylamide
DMUY9TF DT Small molecular drug
DMUY9TF PC 10730997
DMUY9TF MW 273.72
DMUY9TF FM C14H12ClN3O
DMUY9TF IC InChI=1S/C14H12ClN3O/c15-11-4-3-10-5-7-18(13(10)8-11)14(19)17-12-2-1-6-16-9-12/h1-4,6,8-9H,5,7H2,(H,17,19)
DMUY9TF CS C1CN(C2=C1C=CC(=C2)Cl)C(=O)NC3=CN=CC=C3
DMUY9TF IK LOMPSBWQXLVHJX-UHFFFAOYSA-N
DMUY9TF IU 6-chloro-N-pyridin-3-yl-2,3-dihydroindole-1-carboxamide
DMUY9TF DE Discovery agent
DMWB43U ID DMWB43U
DMWB43U DN 6-Chloropurine Riboside, 5'-Monophosphate
DMWB43U HS Investigative
DMWB43U SN 6-Cl-Purine Ribotide; CHEMBL1683023; 6-Chloropurine riboside 5'-phosphate; 6-Chloropurine riboside 5'-monophosphate; 6-Chloropurine ribotide; AC1L4ML7; AC1Q3SV8; 6-Chloroinosine monophosphate; SCHEMBL622623; 6-chloro-9-(5-o-phosphono-; A-d-ribofuranosyl)-9h-purine; ALOBOMYIOYNCBS-KQYNXXCUSA-N; ZINC13526959; BDBM50222697; A8843; 6-Chloropurine 9-beta-D-ribofuranosyl 5'-monophosphate; 6-Chloro-9-(5-O-phosphono-beta-D-ribofuranosyl)-9H-purine; [(2R,3S,4R,5R)-5-(6-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen pho
DMWB43U DT Small molecular drug
DMWB43U PC 17753915
DMWB43U MW 367.66
DMWB43U FM C10H13ClN4O7P+
DMWB43U IC InChI=1S/C10H12ClN4O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,18,19,20)/p+1/t4-,6-,7-,10-/m1/s1
DMWB43U CS C1=[N+](C2=C(N1)C(=NC=N2)Cl)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DMWB43U IK ALOBOMYIOYNCBS-KQYNXXCUSA-O
DMWB43U IU [(2R,3S,4R,5R)-5-(6-chloro-7H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMWB43U DE Discovery agent
DMV0C69 ID DMV0C69
DMV0C69 DN 6-chlorotacrine hydrochloride
DMV0C69 HS Investigative
DMV0C69 SN 6-chlorotacrine; 5778-84-7; 9-AMINO-6-CHLORO-1,2,3,4-TETRAHYDRO-ACRIDINE; Tacrine Analogue 4; 6-chlorotacrine.HCl; 6-Chlorotacrine HCl; 6-chloro-1,2,3,4-tetrahydroacridin-9-amine; SCHEMBL4271238; BDBM8987; ZINC5689; CHEMBL292314; GQZMDBQRGRRPMS-UHFFFAOYSA-N
DMV0C69 DT Small molecular drug
DMV0C69 PC 10399068
DMV0C69 MW 232.71
DMV0C69 FM C13H13ClN2
DMV0C69 IC InChI=1S/C13H13ClN2/c14-8-5-6-10-12(7-8)16-11-4-2-1-3-9(11)13(10)15/h5-7H,1-4H2,(H2,15,16)
DMV0C69 CS C1CCC2=NC3=C(C=CC(=C3)Cl)C(=C2C1)N
DMV0C69 IK GQZMDBQRGRRPMS-UHFFFAOYSA-N
DMV0C69 IU 6-chloro-1,2,3,4-tetrahydroacridin-9-amine
DMV0C69 DE Discovery agent
DMPULH3 ID DMPULH3
DMPULH3 DN 6-cinnamoylhernandine
DMPULH3 HS Investigative
DMPULH3 SN 6-cinnamoylhernandine; CHEMBL1097804
DMPULH3 DT Small molecular drug
DMPULH3 PC 46888587
DMPULH3 MW 521.6
DMPULH3 FM C29H31NO8
DMPULH3 IC InChI=1S/C29H31NO8/c1-30-22(31)16-27-14-21(37-23(32)13-10-17-8-6-5-7-9-17)26(35-3)29(36-4)28(27,30)15-20(38-29)18-11-12-19(34-2)25(33)24(18)27/h5-13,20-21,26,33H,14-16H2,1-4H3/b13-10+/t20-,21-,26-,27+,28-,29+/m0/s1
DMPULH3 CS CN1C(=O)C[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)OC(=O)/C=C/C6=CC=CC=C6)OC)OC
DMPULH3 IK KOKWRSAOHLOSAI-HXHZFJGXSA-N
DMPULH3 IU [(1R,8S,10S,11S,12S,13S)-3-hydroxy-4,11,12-trimethoxy-17-methyl-16-oxo-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-trien-13-yl] (E)-3-phenylprop-2-enoate
DMPULH3 DE Discovery agent
DMPXS9F ID DMPXS9F
DMPXS9F DN 6-cinnamoyl-N-methylstephasunoline
DMPXS9F HS Investigative
DMPXS9F SN CHEMBL1098354; 6-cinnamoyl-N-methylstephasunoline
DMPXS9F DT Small molecular drug
DMPXS9F PC 46888570
DMPXS9F MW 553.6
DMPXS9F FM C30H35NO9
DMPXS9F IC InChI=1S/C30H35NO9/c1-31-13-12-28-15-23(39-24(33)11-7-17-6-9-20(35-2)19(32)14-17)27(37-4)30(38-5)29(28,31)16-22(40-30)18-8-10-21(36-3)26(34)25(18)28/h6-11,14,22-23,27,32,34H,12-13,15-16H2,1-5H3/b11-7+/t22-,23-,27-,28-,29-,30+/m0/s1
DMPXS9F CS CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)OC(=O)/C=C/C6=CC(=C(C=C6)OC)O)OC)OC
DMPXS9F IK CDTWAPXUQYEAIP-YYRBTORNSA-N
DMPXS9F IU [(1S,8S,10S,11S,12S,13S)-3-hydroxy-4,11,12-trimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-trien-13-yl] (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoate
DMPXS9F DE Discovery agent
DMNTDFV ID DMNTDFV
DMNTDFV DN 6-Cl-IMP
DMNTDFV HS Investigative
DMNTDFV SN Hadacidin; N-FORMYL-N-HYDROXYGLYCINE; 689-13-4; Hadacidine; Asymmetrin; Hadacin; Nfhaa; N-Formyl hydroxyaminoacetic acid; UNII-BFO5P1010A; Glycine,N-formyl-N-hydroxy-; 2-(N-Hydroxyformamido)acetic acid; GLYCINE, N-FORMYL-N-HYDROXY-; NSC 72962; BRN 1927168; N-hydroxyformamidoacetic acid; CHEMBL331373; BFO5P1010A; CHEBI:43040; [formyl(hydroxy)amino]acetic acid; NSC 521778; N-formyl-N- hydroxyaminoacetic acid; hadicidine; SCHEMBL2115651; AC1L207A; DTXSID1043962; CTK5C8639; (Formyl-hydroxy-amino)-acetic acid; ZINC1482078
DMNTDFV DT Small molecular drug
DMNTDFV PC 12717
DMNTDFV MW 119.08
DMNTDFV FM C3H5NO4
DMNTDFV IC InChI=1S/C3H5NO4/c5-2-4(8)1-3(6)7/h2,8H,1H2,(H,6,7)
DMNTDFV CS C(C(=O)O)N(C=O)O
DMNTDFV IK URJHVPKUWOUENU-UHFFFAOYSA-N
DMNTDFV IU 2-[formyl(hydroxy)amino]acetic acid
DMNTDFV CA CAS 689-13-4
DMNTDFV CB CHEBI:43040
DMNTDFV DE Discovery agent
DMKNOLV ID DMKNOLV
DMKNOLV DN 6-Cl-MLT
DMKNOLV HS Investigative
DMKNOLV SN 6-Cl-melatonin; 6-chloromelatonin
DMKNOLV DT Small molecular drug
DMKNOLV PC 1858
DMKNOLV MW 266.72
DMKNOLV FM C13H15ClN2O2
DMKNOLV IC InChI=1S/C13H15ClN2O2/c1-8(17)15-4-3-9-7-16-12-6-11(14)13(18-2)5-10(9)12/h5-7,16H,3-4H2,1-2H3,(H,15,17)
DMKNOLV CS CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)Cl
DMKNOLV IK LUINDDOUWHRIPW-UHFFFAOYSA-N
DMKNOLV IU N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKNOLV CA CAS 63762-74-3
DMKNOLV CB CHEBI:109545
DMKNOLV DE Discovery agent
DMACTDZ ID DMACTDZ
DMACTDZ DN 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
DMACTDZ HS Investigative
DMACTDZ SN 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine; 444722-81-0; 1h1r; AC1L1IG7; CHEMBL341273; SCHEMBL6790651; BDBM5531; CTK1D2420; DTXSID10274437; O6-Cyclohexylmethylguanine deriv. 15; DB07203; 2-(3 -Chloroanilino)-6-cyclohexylmethoxypurine; N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine; N-(3-Chlorophenyl)-6-(cyclohexylmethoxy)-9H-purine-2-amine; 1H-Purin-2-amine, N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-
DMACTDZ DT Small molecular drug
DMACTDZ PC 4565
DMACTDZ MW 357.8
DMACTDZ FM C18H20ClN5O
DMACTDZ IC InChI=1S/C18H20ClN5O/c19-13-7-4-8-14(9-13)22-18-23-16-15(20-11-21-16)17(24-18)25-10-12-5-2-1-3-6-12/h4,7-9,11-12H,1-3,5-6,10H2,(H2,20,21,22,23,24)
DMACTDZ CS C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC(=CC=C4)Cl
DMACTDZ IK OUEGMEMDEAOAEG-UHFFFAOYSA-N
DMACTDZ IU N-(3-chlorophenyl)-6-(cyclohexylmethoxy)-7H-purin-2-amine
DMACTDZ CA CAS 444722-81-0
DMACTDZ DE Discovery agent
DM9IHYS ID DM9IHYS
DM9IHYS DN 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine
DM9IHYS HS Investigative
DM9IHYS SN 6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine; pyrimidine deriv. 16; AC1NS76Q; CHEMBL71036; BDBM5588; SCHEMBL6263731; IMNSQZHRHASLAR-UHFFFAOYSA-N
DM9IHYS DT Small molecular drug
DM9IHYS PC 5329597
DM9IHYS MW 237.3
DM9IHYS FM C11H19N5O
DM9IHYS IC InChI=1S/C11H19N5O/c12-8-9(13)15-11(14)16-10(8)17-6-7-4-2-1-3-5-7/h7H,1-6,12H2,(H4,13,14,15,16)
DM9IHYS CS C1CCC(CC1)COC2=NC(=NC(=C2N)N)N
DM9IHYS IK IMNSQZHRHASLAR-UHFFFAOYSA-N
DM9IHYS IU 6-(cyclohexylmethoxy)pyrimidine-2,4,5-triamine
DM9IHYS DE Discovery agent
DM6UP25 ID DM6UP25
DM6UP25 DN 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine
DM6UP25 HS Investigative
DM6UP25 SN 6-Cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine; CHEMBL340813; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}phenol; N20; NU-6086; 1oi9; AC1L9L2Q; BDBM5541; SCHEMBL6792176; O6-Cyclohexylmethylguanine deriv 25; DB08233; 6-Cyclohexylmethoxy-2-(4 -hydroxyanilino)purine
DM6UP25 DT Small molecular drug
DM6UP25 PC 447649
DM6UP25 MW 339.4
DM6UP25 FM C18H21N5O2
DM6UP25 IC InChI=1S/C18H21N5O2/c24-14-8-6-13(7-9-14)21-18-22-16-15(19-11-20-16)17(23-18)25-10-12-4-2-1-3-5-12/h6-9,11-12,24H,1-5,10H2,(H2,19,20,21,22,23)
DM6UP25 CS C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)O
DM6UP25 IK RFSDQDHHBKYQOD-UHFFFAOYSA-N
DM6UP25 IU 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]phenol
DM6UP25 DE Discovery agent
DM9HBY5 ID DM9HBY5
DM9HBY5 DN 6-Deoxy-Alpha-D-Glucose
DM9HBY5 HS Investigative
DM9HBY5 SN alpha-D-Quinovopyranose; 6-deoxy-alpha-D-glucopyranose; UNII-68BDH91OBS; 68BDH91OBS; Isorhodeose; Isorhamnose; D-Epifucose; D-Glucomethylose; D-Chinovose; 6-DEOXY-ALPHA-D-GLUCOSE; 551-63-3; alpha-D-quinovose; 3h-6-deoxyglucose; alpha-D-Quinovose pyranose; AC1L9B8Y; SCHEMBL79180; CHEBI:42606; alpha-D-Glucopyranose, 6-deoxy-; ZINC2042980; DB03773; C08352; (2S,3R,4S,5S,6R)-6-methyloxane-2,3,4,5-tetrol
DM9HBY5 DT Small molecular drug
DM9HBY5 PC 6713579
DM9HBY5 MW 164.16
DM9HBY5 FM C6H12O5
DM9HBY5 IC InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4+,5-,6-/m0/s1
DM9HBY5 CS C[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)O)O)O)O
DM9HBY5 IK SHZGCJCMOBCMKK-QYESYBIKSA-N
DM9HBY5 IU (2S,3S,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol
DM9HBY5 CA CAS 71116-61-5
DM9HBY5 DE Discovery agent
DMKPWN0 ID DMKPWN0
DMKPWN0 DN 6-deoxymanzamine X
DMKPWN0 HS Investigative
DMKPWN0 DT Small molecular drug
DMKPWN0 PC 44445400
DMKPWN0 MW 564.8
DMKPWN0 FM C36H44N4O2
DMKPWN0 IC InChI=1S/C36H44N4O2/c41-35-16-7-3-1-2-4-8-19-39-21-15-29(34(24-39)23-36-17-13-25(42-36)10-9-20-40(36)33(34)35)28(22-35)31-32-27(14-18-37-31)26-11-5-6-12-30(26)38-32/h1,3,5-6,11-12,14,18,22,25,29,33,38,41H,2,4,7-10,13,15-17,19-21,23-24H2/b3-1-/t25-,29?,33+,34-,35-,36+/m0/s1
DMKPWN0 CS C1CCN2CCC3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@]56N4CCC[C@H](O5)CC6)O)C7=NC=CC8=C7NC9=CC=CC=C89
DMKPWN0 IK CLKZPQNKNPCQGL-NZGBLPSWSA-N
DMKPWN0 IU (2R,4R,7S,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-28-oxa-11,22-diazahexacyclo[11.11.2.12,22.14,7.02,12.04,11]octacosa-16,25-dien-13-ol
DMKPWN0 DE Discovery agent
DMGZQNS ID DMGZQNS
DMGZQNS DN 6-desoxonaltrexone
DMGZQNS HS Investigative
DMGZQNS SN 6-desoxonaltrexone; CHEMBL511816; SCHEMBL3825815; XBPQMXFKKJADMC-WOUAJJJCSA-N; BDBM50278385; 3,14-Dihydroxy-17-cyclopropylmethyl-4,5alpha-epoxymorphinan
DMGZQNS DT Small molecular drug
DMGZQNS PC 13374610
DMGZQNS MW 327.4
DMGZQNS FM C20H25NO3
DMGZQNS IC InChI=1S/C20H25NO3/c22-14-6-5-13-10-15-20(23)7-1-2-16-19(20,17(13)18(14)24-16)8-9-21(15)11-12-3-4-12/h5-6,12,15-16,22-23H,1-4,7-11H2/t15-,16+,19-,20-/m1/s1
DMGZQNS CS C1C[C@H]2[C@@]34CCN([C@@H]([C@@]3(C1)O)CC5=C4C(=C(C=C5)O)O2)CC6CC6
DMGZQNS IK XBPQMXFKKJADMC-WOUAJJJCSA-N
DMGZQNS IU (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DMGZQNS DE Discovery agent
DML2AC1 ID DML2AC1
DML2AC1 DN 6-Dimethylamino-2-methyl-hex-4-ynal oxime
DML2AC1 HS Investigative
DML2AC1 DT Small molecular drug
DML2AC1 PC 91934661
DML2AC1 MW 168.24
DML2AC1 FM C9H16N2O
DML2AC1 IC InChI=1S/C9H16N2O/c1-9(8-10-12)6-4-5-7-11(2)3/h9H,6-8H2,1-3H3
DML2AC1 CS CC(CC#CCN(C)C)CN=O
DML2AC1 IK DMQFXDRNMHZPER-UHFFFAOYSA-N
DML2AC1 IU N,N,5-trimethyl-6-nitrosohex-2-yn-1-amine
DML2AC1 DE Discovery agent
DMBMRUI ID DMBMRUI
DMBMRUI DN 6-ethyl-2,4-diisobutylaminopyrimidine
DMBMRUI HS Investigative
DMBMRUI SN CHEMBL484451; 6-ethyl-2,4-diisobutylaminopyrimidine
DMBMRUI DT Small molecular drug
DMBMRUI PC 25133613
DMBMRUI MW 250.38
DMBMRUI FM C14H26N4
DMBMRUI IC InChI=1S/C14H26N4/c1-6-12-7-13(15-8-10(2)3)18-14(17-12)16-9-11(4)5/h7,10-11H,6,8-9H2,1-5H3,(H2,15,16,17,18)
DMBMRUI CS CCC1=CC(=NC(=N1)NCC(C)C)NCC(C)C
DMBMRUI IK MQGNVQNFJZWUAO-UHFFFAOYSA-N
DMBMRUI IU 6-ethyl-2-N,4-N-bis(2-methylpropyl)pyrimidine-2,4-diamine
DMBMRUI DE Discovery agent
DMUHOF4 ID DMUHOF4
DMUHOF4 DN 6-Ethyl-2-phenyl-chromen-4-one
DMUHOF4 HS Investigative
DMUHOF4 SN CHEMBL134732; 288401-00-3; 6-Ethylflavone; CTK4G2218; DTXSID80451374; ZINC2573995; AKOS030553658
DMUHOF4 DT Small molecular drug
DMUHOF4 PC 10999458
DMUHOF4 MW 250.29
DMUHOF4 FM C17H14O2
DMUHOF4 IC InChI=1S/C17H14O2/c1-2-12-8-9-16-14(10-12)15(18)11-17(19-16)13-6-4-3-5-7-13/h3-11H,2H2,1H3
DMUHOF4 CS CCC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMUHOF4 IK ILUYTTQELSQWNA-UHFFFAOYSA-N
DMUHOF4 IU 6-ethyl-2-phenylchromen-4-one
DMUHOF4 CA CAS 288401-00-3
DMUHOF4 DE Discovery agent
DMLEUP2 ID DMLEUP2
DMLEUP2 DN 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone
DMLEUP2 HS Investigative
DMLEUP2 SN CHEMBL383080
DMLEUP2 DT Small molecular drug
DMLEUP2 PC 11580305
DMLEUP2 MW 301.4
DMLEUP2 FM C18H23NO3
DMLEUP2 IC InChI=1S/C18H23NO3/c1-4-12(5-2)11-22-18(21)15-10-19-16-8-7-13(6-3)9-14(16)17(15)20/h7-10,12H,4-6,11H2,1-3H3,(H,19,20)
DMLEUP2 CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC(CC)CC
DMLEUP2 IK ANYBYQLGVQJDTI-UHFFFAOYSA-N
DMLEUP2 IU 2-ethylbutyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMLEUP2 DE Discovery agent
DMESU53 ID DMESU53
DMESU53 DN 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone
DMESU53 HS Investigative
DMESU53 SN CHEMBL377719
DMESU53 DT Small molecular drug
DMESU53 PC 11529369
DMESU53 MW 287.35
DMESU53 FM C17H21NO3
DMESU53 IC InChI=1S/C17H21NO3/c1-4-11(3)10-21-17(20)14-9-18-15-7-6-12(5-2)8-13(15)16(14)19/h6-9,11H,4-5,10H2,1-3H3,(H,18,19)
DMESU53 CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC(C)CC
DMESU53 IK CXKHROTTYJSKQI-UHFFFAOYSA-N
DMESU53 IU 2-methylbutyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMESU53 DE Discovery agent
DM1POEA ID DM1POEA
DM1POEA DN 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA HS Investigative
DM1POEA SN CHEMBL206071; 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone
DM1POEA DT Small molecular drug
DM1POEA PC 11587331
DM1POEA MW 287.35
DM1POEA FM C17H21NO3
DM1POEA IC InChI=1S/C17H21NO3/c1-4-12-5-6-15-13(9-12)16(19)14(10-18-15)17(20)21-8-7-11(2)3/h5-6,9-11H,4,7-8H2,1-3H3,(H,18,19)
DM1POEA CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCCC(C)C
DM1POEA IK YQYRRRVQWIMSFP-UHFFFAOYSA-N
DM1POEA IU 3-methylbutyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DM1POEA DE Discovery agent
DMG05V1 ID DMG05V1
DMG05V1 DN 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone
DMG05V1 HS Investigative
DMG05V1 SN CHEMBL205528
DMG05V1 DT Small molecular drug
DMG05V1 PC 11716193
DMG05V1 MW 287.35
DMG05V1 FM C17H21NO3
DMG05V1 IC InChI=1S/C17H21NO3/c1-4-11-7-8-15-13(9-11)16(19)14(10-18-15)17(20)21-12(5-2)6-3/h7-10,12H,4-6H2,1-3H3,(H,18,19)
DMG05V1 CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OC(CC)CC
DMG05V1 IK OLWFMJLLBYGGKS-UHFFFAOYSA-N
DMG05V1 IU pentan-3-yl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMG05V1 DE Discovery agent
DML9EU7 ID DML9EU7
DML9EU7 DN 6-ethyl-3-i-propoxycarbonyl-4-quinolone
DML9EU7 HS Investigative
DML9EU7 SN CHEMBL205724
DML9EU7 DT Small molecular drug
DML9EU7 PC 11586960
DML9EU7 MW 259.3
DML9EU7 FM C15H17NO3
DML9EU7 IC InChI=1S/C15H17NO3/c1-4-10-5-6-13-11(7-10)14(17)12(8-16-13)15(18)19-9(2)3/h5-9H,4H2,1-3H3,(H,16,17)
DML9EU7 CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OC(C)C
DML9EU7 IK XGNSUAGLUGPMKD-UHFFFAOYSA-N
DML9EU7 IU propan-2-yl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DML9EU7 DE Discovery agent
DMSGJM6 ID DMSGJM6
DMSGJM6 DN 6-ethyl-3-pentoxycarbonyl-4-quinolone
DMSGJM6 HS Investigative
DMSGJM6 SN CHEMBL205252
DMSGJM6 DT Small molecular drug
DMSGJM6 PC 11492986
DMSGJM6 MW 287.35
DMSGJM6 FM C17H21NO3
DMSGJM6 IC InChI=1S/C17H21NO3/c1-3-5-6-9-21-17(20)14-11-18-15-8-7-12(4-2)10-13(15)16(14)19/h7-8,10-11H,3-6,9H2,1-2H3,(H,18,19)
DMSGJM6 CS CCCCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMSGJM6 IK DEHHQRSKBIBSBX-UHFFFAOYSA-N
DMSGJM6 IU pentyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMSGJM6 DE Discovery agent
DMGVI08 ID DMGVI08
DMGVI08 DN 6-ethyl-3-propoxycarbonyl-4-quinolone
DMGVI08 HS Investigative
DMGVI08 SN CHEMBL206068
DMGVI08 DT Small molecular drug
DMGVI08 PC 11715856
DMGVI08 MW 259.3
DMGVI08 FM C15H17NO3
DMGVI08 IC InChI=1S/C15H17NO3/c1-3-7-19-15(18)12-9-16-13-6-5-10(4-2)8-11(13)14(12)17/h5-6,8-9H,3-4,7H2,1-2H3,(H,16,17)
DMGVI08 CS CCCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMGVI08 IK RSBPUSKIUBSGGR-UHFFFAOYSA-N
DMGVI08 IU propyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMGVI08 DE Discovery agent
DMC1F2E ID DMC1F2E
DMC1F2E DN 6-ethyl-3-propylaminocarbonyl-4-quinolone
DMC1F2E HS Investigative
DMC1F2E SN CHEMBL204566
DMC1F2E DT Small molecular drug
DMC1F2E PC 11521736
DMC1F2E MW 258.32
DMC1F2E FM C15H18N2O2
DMC1F2E IC InChI=1S/C15H18N2O2/c1-3-7-16-15(19)12-9-17-13-6-5-10(4-2)8-11(13)14(12)18/h5-6,8-9H,3-4,7H2,1-2H3,(H,16,19)(H,17,18)
DMC1F2E CS CCCNC(=O)C1=CNC2=C(C1=O)C=C(C=C2)CC
DMC1F2E IK YTLATZVRJZTHRQ-UHFFFAOYSA-N
DMC1F2E IU 6-ethyl-4-oxo-N-propyl-1H-quinoline-3-carboxamide
DMC1F2E DE Discovery agent
DMOGETD ID DMOGETD
DMOGETD DN 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DMOGETD HS Investigative
DMOGETD SN CHEMBL206547; 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol; SCHEMBL6828050
DMOGETD DT Small molecular drug
DMOGETD PC 10445833
DMOGETD MW 270.32
DMOGETD FM C17H18O3
DMOGETD IC InChI=1S/C17H18O3/c1-4-15-16-9(2)13(18)7-5-11(16)12-6-8-14(19)10(3)17(12)20-15/h5-8,15,18-19H,4H2,1-3H3
DMOGETD CS CCC1C2=C(C=CC(=C2C)O)C3=C(O1)C(=C(C=C3)O)C
DMOGETD IK IAFZPZLQCDKQGG-UHFFFAOYSA-N
DMOGETD IU 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol
DMOGETD DE Discovery agent
DM9OD7U ID DM9OD7U
DM9OD7U DN 6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE
DM9OD7U HS Investigative
DM9OD7U SN 6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE; 2,4-Diamino-5-phenyl-6-ethylpyrimidine; UNII-KMJ59LN22F; 2,4-Diamino-6-ethyl-5-phenylpyrimidine; TCMDC-124296; Pyrimidine, 2,4-diamino-6-ethyl-5-phenyl-; 27653-49-2; BRN 0190097; KMJ59LN22F; GNF-PF-26; CHEMBL22148; Diamino-5-phenyl-6-ethylpyrimidine, 2,4-; CP7; 2,4-Pyrimidinediamine, 6-ethyl-5-phenyl-; AC1L3PJ1; Oprea1_813184; SCHEMBL3498787; CTK8H9609; BDBM18788; DTXSID70182029; XREDUPOVEQDQQS-UHFFFAOYSA-N; MolPort-002-484-045; ZINC13282257; AKOS003622581; MCULE-8548953211; DB07577
DM9OD7U DT Small molecular drug
DM9OD7U PC 93114
DM9OD7U MW 214.27
DM9OD7U FM C12H14N4
DM9OD7U IC InChI=1S/C12H14N4/c1-2-9-10(8-6-4-3-5-7-8)11(13)16-12(14)15-9/h3-7H,2H2,1H3,(H4,13,14,15,16)
DM9OD7U CS CCC1=C(C(=NC(=N1)N)N)C2=CC=CC=C2
DM9OD7U IK XREDUPOVEQDQQS-UHFFFAOYSA-N
DM9OD7U IU 6-ethyl-5-phenylpyrimidine-2,4-diamine
DM9OD7U CA CAS 27653-49-2
DM9OD7U DE Discovery agent
DME4GBS ID DME4GBS
DME4GBS DN 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine
DME4GBS HS Investigative
DME4GBS DT Small molecular drug
DME4GBS PC 44420925
DME4GBS MW 424.5
DME4GBS FM C21H24N6O4
DME4GBS IC InChI=1S/C21H24N6O4/c1-2-14-16(28)17(29)20(31-14)27-10-24-15-18(22)25-21(26-19(15)27)30-8-7-11-9-23-13-6-4-3-5-12(11)13/h3-6,9-10,14,16-17,20,23,28-29H,2,7-8H2,1H3,(H2,22,25,26)/t14-,16-,17-,20-/m1/s1
DME4GBS CS CC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)OCCC4=CNC5=CC=CC=C54)N)O)O
DME4GBS IK USRXNKLXHDLOMQ-WVSUBDOOSA-N
DME4GBS IU (2R,3R,4S,5R)-2-[6-amino-2-[2-(1H-indol-3-yl)ethoxy]purin-9-yl]-5-ethyloxolane-3,4-diol
DME4GBS DE Discovery agent
DMPZIV0 ID DMPZIV0
DMPZIV0 DN 6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one
DMPZIV0 HS Investigative
DMPZIV0 SN CHEMBL55412; AKOS003616217
DMPZIV0 DT Small molecular drug
DMPZIV0 PC 21239768
DMPZIV0 MW 285.23
DMPZIV0 FM C15H8FNO4
DMPZIV0 IC InChI=1S/C15H8FNO4/c16-10-4-5-14-12(7-10)13(18)8-15(21-14)9-2-1-3-11(6-9)17(19)20/h1-8H
DMPZIV0 CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)F
DMPZIV0 IK QKZNNAUSAVZXNE-UHFFFAOYSA-N
DMPZIV0 IU 6-fluoro-2-(3-nitrophenyl)chromen-4-one
DMPZIV0 DE Discovery agent
DM2DTHV ID DM2DTHV
DM2DTHV DN 6-fluoro-2-methyl-9H-carbazole
DM2DTHV HS Investigative
DM2DTHV SN CHEMBL1172721; 6-fluoro-2-methyl-9H-carbazole
DM2DTHV DT Small molecular drug
DM2DTHV PC 44191658
DM2DTHV MW 199.22
DM2DTHV FM C13H10FN
DM2DTHV IC InChI=1S/C13H10FN/c1-8-2-4-10-11-7-9(14)3-5-12(11)15-13(10)6-8/h2-7,15H,1H3
DM2DTHV CS CC1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)F
DM2DTHV IK YMJCUFBPZUBEGB-UHFFFAOYSA-N
DM2DTHV IU 6-fluoro-2-methyl-9H-carbazole
DM2DTHV DE Discovery agent
DM4Q5TX ID DM4Q5TX
DM4Q5TX DN 6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione
DM4Q5TX HS Investigative
DM4Q5TX SN CHEMBL395907; BDBM20075; 6-Fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione, 21
DM4Q5TX DT Small molecular drug
DM4Q5TX PC 23648527
DM4Q5TX MW 206.17
DM4Q5TX FM C10H7FN2O2
DM4Q5TX IC InChI=1S/C10H7FN2O2/c11-8-7(6-4-2-1-3-5-6)9(14)13-10(15)12-8/h1-5H,(H2,12,13,14,15)
DM4Q5TX CS C1=CC=C(C=C1)C2=C(NC(=O)NC2=O)F
DM4Q5TX IK BMLADZLRZDTUAA-UHFFFAOYSA-N
DM4Q5TX IU 6-fluoro-5-phenyl-1H-pyrimidine-2,4-dione
DM4Q5TX DE Discovery agent
DMKFUO0 ID DMKFUO0
DMKFUO0 DN 6-Fluoromelatonin
DMKFUO0 HS Investigative
DMKFUO0 SN 6-Fluoromelatonin; 62106-00-7; CHEMBL333886; N-(2-(6-Fluoro-5-methoxy-1H-indol-3-yl)ethyl)acetamide; N-[2-(6-fluoro-5-methoxy-1H-indol-3-yl)ethyl]acetamide; ACETAMIDE, N-(2-(6-FLUORO-5-METHOXY-1H-INDOL-3-YL)ETHYL)-; AC1L2ASC; SCHEMBL1772618; SCHEMBL1772619; DTXSID10211165; BTTITVUHHXXLFM-UHFFFAOYSA-N; ZINC2032560; BDBM50330858; LS-9627; N-[2-(5-methoxy-6-fluoroindol-3-yl)ethyl]acetamide
DMKFUO0 DT Small molecular drug
DMKFUO0 PC 43922
DMKFUO0 MW 250.27
DMKFUO0 FM C13H15FN2O2
DMKFUO0 IC InChI=1S/C13H15FN2O2/c1-8(17)15-4-3-9-7-16-12-6-11(14)13(18-2)5-10(9)12/h5-7,16H,3-4H2,1-2H3,(H,15,17)
DMKFUO0 CS CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)F
DMKFUO0 IK BTTITVUHHXXLFM-UHFFFAOYSA-N
DMKFUO0 IU N-[2-(6-fluoro-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DMKFUO0 CA CAS 62106-00-7
DMKFUO0 DE Discovery agent
DMPZ92X ID DMPZ92X
DMPZ92X DN 6-fluoromevalonate 5-diphosphate
DMPZ92X HS Investigative
DMPZ92X SN GTPL3205; 6-fluoro-3-hydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}-3-methylhexanoic acid
DMPZ92X DT Small molecular drug
DMPZ92X PC 56947062
DMPZ92X MW 340.13
DMPZ92X FM C7H15FO10P2
DMPZ92X IC InChI=1S/C7H15FO10P2/c1-7(11,3-6(9)10)2-5(4-8)17-20(15,16)18-19(12,13)14/h5,11H,2-4H2,1H3,(H,9,10)(H,15,16)(H2,12,13,14)
DMPZ92X CS CC(CC(CF)OP(=O)(O)OP(=O)(O)O)(CC(=O)O)O
DMPZ92X IK YGLNCOGHKIHKSA-UHFFFAOYSA-N
DMPZ92X IU 6-fluoro-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxy-3-methylhexanoic acid
DMPZ92X DE Discovery agent
DMZ26LS ID DMZ26LS
DMZ26LS DN 6-fluoromevalonate pyrophosphate
DMZ26LS HS Investigative
DMZ26LS SN 6-FMevPP
DMZ26LS DT Small molecular drug
DMZ26LS PC 44306087
DMZ26LS MW 326.11
DMZ26LS FM C6H13FO10P2
DMZ26LS IC InChI=1S/C6H13FO10P2/c7-4-6(10,3-5(8)9)1-2-16-19(14,15)17-18(11,12)13/h10H,1-4H2,(H,8,9)(H,14,15)(H2,11,12,13)/t6-/m1/s1
DMZ26LS CS C(COP(=O)(O)OP(=O)(O)O)[C@@](CC(=O)O)(CF)O
DMZ26LS IK YIGLDWRZXXHIGZ-ZCFIWIBFSA-N
DMZ26LS IU (3R)-3-(fluoromethyl)-3-hydroxy-5-[hydroxy(phosphonooxy)phosphoryl]oxypentanoic acid
DMZ26LS DE Discovery agent
DMA1QH0 ID DMA1QH0
DMA1QH0 DN 6-Fluoro-N-(2-morpholinoethyl)nicotinamide
DMA1QH0 HS Investigative
DMA1QH0 SN 6-Fluoro-N-(2-morpholinoethyl)nicotinamide; CHEMBL611061; BDBM50307187; AKOS013288891
DMA1QH0 DT Small molecular drug
DMA1QH0 PC 46233363
DMA1QH0 MW 253.27
DMA1QH0 FM C12H16FN3O2
DMA1QH0 IC InChI=1S/C12H16FN3O2/c13-11-2-1-10(9-15-11)12(17)14-3-4-16-5-7-18-8-6-16/h1-2,9H,3-8H2,(H,14,17)
DMA1QH0 CS C1COCCN1CCNC(=O)C2=CN=C(C=C2)F
DMA1QH0 IK GHLPFUPTLVEUTA-UHFFFAOYSA-N
DMA1QH0 IU 6-fluoro-N-(2-morpholin-4-ylethyl)pyridine-3-carboxamide
DMA1QH0 DE Discovery agent
DMVADTP ID DMVADTP
DMVADTP DN 6-fluoro-N-m-tolylquinazolin-4-amine
DMVADTP HS Investigative
DMVADTP SN CHEMBL1079598; 6-fluoro-N-m-tolylquinazolin-4-amine; SCHEMBL8427296; BDBM50311857
DMVADTP DT Small molecular drug
DMVADTP PC 21847810
DMVADTP MW 253.27
DMVADTP FM C15H12FN3
DMVADTP IC InChI=1S/C15H12FN3/c1-10-3-2-4-12(7-10)19-15-13-8-11(16)5-6-14(13)17-9-18-15/h2-9H,1H3,(H,17,18,19)
DMVADTP CS CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)F
DMVADTP IK UBPLAEHESGUBAD-UHFFFAOYSA-N
DMVADTP IU 6-fluoro-N-(3-methylphenyl)quinazolin-4-amine
DMVADTP DE Discovery agent
DMF2RGY ID DMF2RGY
DMF2RGY DN 6-fluoro-noradrenaline
DMF2RGY HS Investigative
DMF2RGY SN 6-fluoronorepinephrine; 6-fluoro-NE
DMF2RGY DT Small molecular drug
DMF2RGY PC 1862
DMF2RGY MW 187.17
DMF2RGY FM C8H10FNO3
DMF2RGY IC InChI=1S/C8H10FNO3/c9-5-2-7(12)6(11)1-4(5)8(13)3-10/h1-2,8,11-13H,3,10H2
DMF2RGY CS C1=C(C(=CC(=C1O)O)F)C(CN)O
DMF2RGY IK SBUQBFTXTZSRMH-UHFFFAOYSA-N
DMF2RGY IU 4-(2-amino-1-hydroxyethyl)-5-fluorobenzene-1,2-diol
DMF2RGY CA CAS 86820-21-5
DMF2RGY CB CHEBI:125398
DMF2RGY DE Discovery agent
DMPWXI8 ID DMPWXI8
DMPWXI8 DN 6-fluoronorepinehprine
DMPWXI8 HS Investigative
DMPWXI8 SN 6-fluoronorepinehprine; CHEMBL295072; 2-Fluoronorepinephrine; fluoronorepinephrine; BDBM50087518
DMPWXI8 DT Small molecular drug
DMPWXI8 PC 10352428
DMPWXI8 MW 187.17
DMPWXI8 FM C8H10FNO3
DMPWXI8 IC InChI=1S/C8H10FNO3/c9-7-4(6(12)3-10)1-2-5(11)8(7)13/h1-2,6,11-13H,3,10H2/t6-/m0/s1
DMPWXI8 CS C1=CC(=C(C(=C1[C@H](CN)O)F)O)O
DMPWXI8 IK FOTRTWXNJQSQJS-LURJTMIESA-N
DMPWXI8 IU 4-[(1R)-2-amino-1-hydroxyethyl]-3-fluorobenzene-1,2-diol
DMPWXI8 DE Discovery agent
DMS325C ID DMS325C
DMS325C DN 6-fluoropyridin-3-ylboronic acid
DMS325C HS Investigative
DMS325C SN 351019-18-6; 2-Fluoropyridine-5-boronic acid; 2-Fluoro-5-pyridylboronic acid; (6-fluoropyridin-3-yl)boronic Acid; 6-fluoropyridine-3-boronic acid; 2-fluoro-5-pyridineboronic acid; 2-fluoropyridin-5-ylboronic acid; 6-fluoropyridin-3-ylboronic acid; 2-fluoropyridin-5-boronic acid; 6-Fluoro-3-pyridinylboronic acid; 6-Fluoro-3-pyridylboronic Acid; 6-fluoropyridin-3-yl-3-boronic acid; 6-FLUORO-3-PYRIDINEBORONIC ACID; (6-fluoropyridin-3-yl)boranediol; BORONIC ACID, (6-FLUORO-3-PYRIDINYL)-; (6-fluoro-3-pyridyl)boronic acid
DMS325C DT Small molecular drug
DMS325C PC 2783397
DMS325C MW 140.91
DMS325C FM C5H5BFNO2
DMS325C IC InChI=1S/C5H5BFNO2/c7-5-2-1-4(3-8-5)6(9)10/h1-3,9-10H
DMS325C CS B(C1=CN=C(C=C1)F)(O)O
DMS325C IK OJBYZWHAPXIJID-UHFFFAOYSA-N
DMS325C IU (6-fluoropyridin-3-yl)boronic acid
DMS325C CA CAS 351019-18-6
DMS325C DE Discovery agent
DM6YD3U ID DM6YD3U
DM6YD3U DN 6-fluorotryptophan
DM6YD3U HS Investigative
DM6YD3U SN 6-Fluoro-DL-tryptophan; 7730-20-3; 6-fluorotryptophan; 2-amino-3-(6-fluoro-1H-indol-3-yl)propanoic acid; DL-Tryptophan, 6-fluoro-; DL-6-Fluorotryptophane; (+-)-6-Fluorotryptophan; Tryptophan, 6-fluoro-, DL-; NSC 9364; 6-fluoro-D,L-tryptophan; EINECS 231-788-6; BRN 0482552; Tryptophan, 6-fluoro-; ST072163; 2-amino-3-(6-fluoroindol-3-yl)propanoic acid; 6-Fluoro-DL-tryptophan, 97%; D-Tryptophan, 6-fluoro-; 343-92-0; 6-Fluorotryptophan, DL-; ACMC-20mbi4; AC1Q5S5W; SCHEMBL248870; GTPL5126; CHEMBL472222; AC1L3T80; SCHEMBL18029199
DM6YD3U DT Small molecular drug
DM6YD3U PC 94937
DM6YD3U MW 222.22
DM6YD3U FM C11H11FN2O2
DM6YD3U IC InChI=1S/C11H11FN2O2/c12-7-1-2-8-6(3-9(13)11(15)16)5-14-10(8)4-7/h1-2,4-5,9,14H,3,13H2,(H,15,16)
DM6YD3U CS C1=CC2=C(C=C1F)NC=C2CC(C(=O)O)N
DM6YD3U IK YMEXGEAJNZRQEH-UHFFFAOYSA-N
DM6YD3U IU 2-amino-3-(6-fluoro-1H-indol-3-yl)propanoic acid
DM6YD3U CA CAS 7730-20-3
DM6YD3U DE Discovery agent
DMN84RM ID DMN84RM
DMN84RM DN 6-Formylindolo[3,2-b]carbazole
DMN84RM HS Investigative
DMN84RM SN Indolo[3,2-b]carbazole-6-carbaldehyde; 1555757-10-2; indolo[3,2-b]carbazole-12-carbaldehyde; SCHEMBL528518; ANW-57186; MFCD23140892; ZINC39957465; AKOS015837457; AKOS025396684; FT-0678209
DMN84RM DT Small molecular drug
DMN84RM PC 22245026
DMN84RM MW 282.3
DMN84RM FM C19H10N2O
DMN84RM IC InChI=1S/C19H10N2O/c22-10-14-18-12-6-2-4-8-16(12)20-17(18)9-13-11-5-1-3-7-15(11)21-19(13)14/h1-10H
DMN84RM CS C1=CC2=C3C=C4C(=C5C=CC=CC5=N4)C(=C3N=C2C=C1)C=O
DMN84RM IK OTWFDHQTFRXSAK-UHFFFAOYSA-N
DMN84RM IU indolo[3,2-b]carbazole-12-carbaldehyde
DMN84RM DE Dermatitis
DMOLIW4 ID DMOLIW4
DMOLIW4 DN 6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine
DMOLIW4 HS Investigative
DMOLIW4 SN CHEMBL194383; 6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine; SCHEMBL3272682
DMOLIW4 DT Small molecular drug
DMOLIW4 PC 44401799
DMOLIW4 MW 305.33
DMOLIW4 FM C17H15N5O
DMOLIW4 IC InChI=1S/C17H15N5O/c18-17-20-14(13-7-4-10-23-13)15-16(21-17)22(11-19-15)9-8-12-5-2-1-3-6-12/h1-7,10-11H,8-9H2,(H2,18,20,21)
DMOLIW4 CS C1=CC=C(C=C1)CCN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMOLIW4 IK LOCNLYLIABVQFH-UHFFFAOYSA-N
DMOLIW4 IU 6-(furan-2-yl)-9-(2-phenylethyl)purin-2-amine
DMOLIW4 DE Discovery agent
DMSJP6T ID DMSJP6T
DMSJP6T DN 6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine
DMSJP6T HS Investigative
DMSJP6T SN CHEMBL439336; 6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine
DMSJP6T DT Small molecular drug
DMSJP6T PC 44401937
DMSJP6T MW 277.28
DMSJP6T FM C15H11N5O
DMSJP6T IC InChI=1S/C15H11N5O/c16-15-18-12(11-7-4-8-21-11)13-14(19-15)20(9-17-13)10-5-2-1-3-6-10/h1-9H,(H2,16,18,19)
DMSJP6T CS C1=CC=C(C=C1)N2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMSJP6T IK VEZSQJIGMFDZRT-UHFFFAOYSA-N
DMSJP6T IU 6-(furan-2-yl)-9-phenylpurin-2-amine
DMSJP6T DE Discovery agent
DMM86PK ID DMM86PK
DMM86PK DN 6-guanidino-2-(3''-indolylethyloxy)adenosine
DMM86PK HS Investigative
DMM86PK DT Small molecular drug
DMM86PK PC 44420924
DMM86PK MW 438.4
DMM86PK FM C20H22N8O4
DMM86PK IC InChI=1S/C20H22N8O4/c21-16(22)15-13(29)14(30)19(32-15)28-8-25-12-17(23)26-20(27-18(12)28)31-6-5-9-7-24-11-4-2-1-3-10(9)11/h1-4,7-8,13-15,19,24,29-30H,5-6H2,(H3,21,22)(H2,23,26,27)/t13-,14+,15-,19+/m0/s1
DMM86PK CS C1=CC=C2C(=C1)C(=CN2)CCOC3=NC(=C4C(=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=N)N)O)O)N
DMM86PK IK AWBHOELFSQMGIY-QCUYGVNKSA-N
DMM86PK IU (2R,3S,4R,5R)-5-[6-amino-2-[2-(1H-indol-3-yl)ethoxy]purin-9-yl]-3,4-dihydroxyoxolane-2-carboximidamide
DMM86PK DE Discovery agent
DMF3W15 ID DMF3W15
DMF3W15 DN 6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one
DMF3W15 HS Investigative
DMF3W15 SN CHEMBL269138; 6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one; SCHEMBL10337594; BDBM50024653
DMF3W15 DT Small molecular drug
DMF3W15 PC 54678949
DMF3W15 MW 336.5
DMF3W15 FM C20H32O4
DMF3W15 IC InChI=1S/C20H32O4/c1-3-5-7-9-11-13-16-15-18(22)19(20(23)24-16)17(21)14-12-10-8-6-4-2/h15,22H,3-14H2,1-2H3
DMF3W15 CS CCCCCCCC1=CC(=C(C(=O)O1)C(=O)CCCCCCC)O
DMF3W15 IK UXMFHBGEDUHLJO-UHFFFAOYSA-N
DMF3W15 IU 6-heptyl-4-hydroxy-3-octanoylpyran-2-one
DMF3W15 DE Discovery agent
DMWLN2Y ID DMWLN2Y
DMWLN2Y DN 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium
DMWLN2Y HS Investigative
DMWLN2Y SN CHEMBL441868; 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium
DMWLN2Y DT Small molecular drug
DMWLN2Y PC 44419706
DMWLN2Y MW 227.28
DMWLN2Y FM C14H15N2O+
DMWLN2Y IC InChI=1S/C14H14N2O/c1-9-14-11(6-7-15(9)2)12-8-10(17)4-5-13(12)16(14)3/h4-8H,1-3H3/p+1
DMWLN2Y CS CC1=[N+](C=CC2=C1N(C3=C2C=C(C=C3)O)C)C
DMWLN2Y IK CHMZSXAIQRLCLX-UHFFFAOYSA-O
DMWLN2Y IU 1,2,9-trimethylpyrido[3,4-b]indol-2-ium-6-ol
DMWLN2Y DE Discovery agent
DM20DAG ID DM20DAG
DM20DAG DN 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DM20DAG HS Investigative
DM20DAG SN CHEMBL375862; 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DM20DAG DT Small molecular drug
DM20DAG PC 44419702
DM20DAG MW 213.25
DM20DAG FM C13H13N2O+
DM20DAG IC InChI=1S/C13H12N2O/c1-8-13-10(5-6-15(8)2)11-7-9(16)3-4-12(11)14-13/h3-7,16H,1-2H3/p+1
DM20DAG CS CC1=[N+](C=CC2=C1NC3=C2C=C(C=C3)O)C
DM20DAG IK ICPRLZDLIOARIN-UHFFFAOYSA-O
DM20DAG IU 1,2-dimethyl-9H-pyrido[3,4-b]indol-2-ium-6-ol
DM20DAG DE Discovery agent
DMPSOIF ID DMPSOIF
DMPSOIF DN 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE
DMPSOIF HS Investigative
DMPSOIF SN 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE; 6-Hydroxy-2-benzothiazolesulfonamide; CHEMBL6685; 6-Hydroxybenzothiazole-2-sulfonamide; ZEC; 1zfq; AC1OA9RN; SCHEMBL160105; BDBM10874; NOOBQTYVTDBXTL-UHFFFAOYSA-N; AKOS022657291; aromatic/heteroaromatic sulfonamide 19; DB08765
DMPSOIF DT Small molecular drug
DMPSOIF PC 6852129
DMPSOIF MW 230.3
DMPSOIF FM C7H6N2O3S2
DMPSOIF IC InChI=1S/C7H6N2O3S2/c8-14(11,12)7-9-5-2-1-4(10)3-6(5)13-7/h1-3,10H,(H2,8,11,12)
DMPSOIF CS C1=CC2=C(C=C1O)SC(=N2)S(=O)(=O)N
DMPSOIF IK NOOBQTYVTDBXTL-UHFFFAOYSA-N
DMPSOIF IU 6-hydroxy-1,3-benzothiazole-2-sulfonamide
DMPSOIF CA CAS 29927-14-8
DMPSOIF DE Discovery agent
DMUD1CG ID DMUD1CG
DMUD1CG DN 6-Hydroxy-1,6-Dihydro Purine Nucleoside
DMUD1CG HS Investigative
DMUD1CG SN 6-Hydroxy-1,6-Dihydro Purine Nucleoside; PRH; AC1NRCV9; DB03015; (6S)-6-hydroxy-9-beta-D-ribofuranosyl-6,9-dihydro-1H-purin-7-ium
DMUD1CG DT Small molecular drug
DMUD1CG PC 5289205
DMUD1CG MW 271.25
DMUD1CG FM C10H15N4O5+
DMUD1CG IC InChI=1S/C10H14N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,9-10,15-18H,1H2,(H,11,12)/p+1/t4-,6-,7-,9+,10-/m1/s1
DMUD1CG CS C1=N[C@H](C2=C(N1)[N+](=CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O
DMUD1CG IK WGRXVKRHIMUTPD-YOHZANMFSA-O
DMUD1CG IU (2R,3R,4S,5R)-2-[(6S)-6-hydroxy-6,7-dihydro-3H-purin-9-ium-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMUD1CG DE Discovery agent
DMU1CGD ID DMU1CGD
DMU1CGD DN 6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one
DMU1CGD HS Investigative
DMU1CGD SN CHEMBL56345; 6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one; BDBM50077322
DMU1CGD DT Small molecular drug
DMU1CGD PC 10539813
DMU1CGD MW 268.26
DMU1CGD FM C16H12O4
DMU1CGD IC InChI=1S/C16H12O4/c17-11-3-1-10(2-4-11)7-13-9-15(19)14-8-12(18)5-6-16(14)20-13/h1-6,8-9,17-18H,7H2
DMU1CGD CS C1=CC(=CC=C1CC2=CC(=O)C3=C(O2)C=CC(=C3)O)O
DMU1CGD IK LSIKXKVRDNWDKN-UHFFFAOYSA-N
DMU1CGD IU 6-hydroxy-2-[(4-hydroxyphenyl)methyl]chromen-4-one
DMU1CGD DE Discovery agent
DMNA2M6 ID DMNA2M6
DMNA2M6 DN 6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMNA2M6 HS Investigative
DMNA2M6 SN CHEMBL373651; 6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMNA2M6 DT Small molecular drug
DMNA2M6 PC 44419701
DMNA2M6 MW 213.25
DMNA2M6 FM C13H13N2O+
DMNA2M6 IC InChI=1S/C13H12N2O/c1-14-6-5-10-11-7-9(16)3-4-12(11)15(2)13(10)8-14/h3-8H,1-2H3/p+1
DMNA2M6 CS CN1C2=C(C=C(C=C2)O)C3=C1C=[N+](C=C3)C
DMNA2M6 IK OEJPDCAOADNKRJ-UHFFFAOYSA-O
DMNA2M6 IU 2,9-dimethylpyrido[3,4-b]indol-2-ium-6-ol
DMNA2M6 DE Discovery agent
DMAK35M ID DMAK35M
DMAK35M DN 6-hydroxy-2-methyl-9H-beta-carbolin-2-ium
DMAK35M HS Investigative
DMAK35M SN 6-hydroxy-2-methyl-9H-beta-carbolin-2-ium; CHEMBL220905; 2-methyl-beta-carbolinium-6-ol; CHEBI:59956; 2-methyl-9H-pyrido[3,4-b]indol-2-ium-6-ol
DMAK35M DT Small molecular drug
DMAK35M PC 44419700
DMAK35M MW 199.23
DMAK35M FM C12H11N2O+
DMAK35M IC InChI=1S/C12H10N2O/c1-14-5-4-9-10-6-8(15)2-3-11(10)13-12(9)7-14/h2-7,15H,1H3/p+1
DMAK35M CS C[N+]1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)O
DMAK35M IK FTXCPBMJKVPYRT-UHFFFAOYSA-O
DMAK35M IU 2-methyl-9H-pyrido[3,4-b]indol-2-ium-6-ol
DMAK35M CB CHEBI:59956
DMAK35M DE Discovery agent
DM4F5OG ID DM4F5OG
DM4F5OG DN 6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin
DM4F5OG HS Investigative
DM4F5OG SN CHEMBL199397; BDBM50176526
DM4F5OG DT Small molecular drug
DM4F5OG PC 11536337
DM4F5OG MW 270.24
DM4F5OG FM C15H10O5
DM4F5OG IC InChI=1S/C15H10O5/c16-10-1-2-14-9(5-10)6-13(15(19)20-14)8-3-11(17)7-12(18)4-8/h1-7,16-18H
DM4F5OG CS C1=CC2=C(C=C1O)C=C(C(=O)O2)C3=CC(=CC(=C3)O)O
DM4F5OG IK DKFCOAXLNVHDTF-UHFFFAOYSA-N
DM4F5OG IU 3-(3,5-dihydroxyphenyl)-6-hydroxychromen-2-one
DM4F5OG DE Discovery agent
DM0CVTI ID DM0CVTI
DM0CVTI DN 6-Hydroxy-5,7-dimethyl-beta-carboline
DM0CVTI HS Investigative
DM0CVTI SN CHEMBL458558; 6-Hydroxy-5,7-dimethyl-beta-carboline
DM0CVTI DT Small molecular drug
DM0CVTI PC 44567438
DM0CVTI MW 212.25
DM0CVTI FM C13H12N2O
DM0CVTI IC InChI=1S/C13H12N2O/c1-7-5-10-12(8(2)13(7)16)9-3-4-14-6-11(9)15-10/h3-6,15-16H,1-2H3
DM0CVTI CS CC1=CC2=C(C(=C1O)C)C3=C(N2)C=NC=C3
DM0CVTI IK RRUTVQQPPTZUTL-UHFFFAOYSA-N
DM0CVTI IU 5,7-dimethyl-9H-pyrido[3,4-b]indol-6-ol
DM0CVTI DE Discovery agent
DMNM1EZ ID DMNM1EZ
DMNM1EZ DN 6-Hydroxy-7,8-Dihydro Purine Nucleoside
DMNM1EZ HS Investigative
DMNM1EZ DT Small molecular drug
DMNM1EZ PC 136254582
DMNM1EZ MW 270.24
DMNM1EZ FM C10H14N4O5
DMNM1EZ IC InChI=1S/C10H14N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2,4,6-7,10,13,15-17H,1,3H2,(H,11,12,18)/t4-,6-,7+,10+/m0/s1
DMNM1EZ CS C1NC2=C(N1[C@H]3[C@@H]([C@H]([C@@H](O3)CO)O)O)N=CNC2=O
DMNM1EZ IK ZWTNXGIZBOQCAJ-FCIPNVEPSA-N
DMNM1EZ IU 9-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-1H-purin-6-one
DMNM1EZ DE Discovery agent
DMPQTNK ID DMPQTNK
DMPQTNK DN 6-hydroxy-7,9-octadecadiynoic acid
DMPQTNK HS Investigative
DMPQTNK SN 6-hydroxy-7,9-octadecadiynoic acid; CHEMBL448462; SCHEMBL3199736; 6-Hydroxyoctadeca-7,9-diynoic acid; LMFA01031024
DMPQTNK DT Small molecular drug
DMPQTNK PC 14309408
DMPQTNK MW 292.4
DMPQTNK FM C18H28O3
DMPQTNK IC InChI=1S/C18H28O3/c1-2-3-4-5-6-7-8-9-10-11-14-17(19)15-12-13-16-18(20)21/h17,19H,2-8,12-13,15-16H2,1H3,(H,20,21)
DMPQTNK CS CCCCCCCCC#CC#CC(CCCCC(=O)O)O
DMPQTNK IK APWVQFPFWVNZPF-UHFFFAOYSA-N
DMPQTNK IU 6-hydroxyoctadeca-7,9-diynoic acid
DMPQTNK DE Discovery agent
DMDRSNH ID DMDRSNH
DMDRSNH DN 6-hydroxybenzo[d][1,3]oxathiol-2-one
DMDRSNH HS Investigative
DMDRSNH SN Tioxolone; 4991-65-5; 6-Hydroxy-1,3-benzoxathiol-2-one; Thioxolone; 6-hydroxybenzo[d][1,3]oxathiol-2-one; Camyna; Tioxolon; Thioxalone; Tioxolonum; Tioxolona; 1,3-Benzoxathiol-2-one, 6-hydroxy-; Tioxolonum [INN-Latin]; UNII-S0FAJ1R9CD; Tioxolona [INN-Spanish]; 6-Hydro-2-oxo-1,3-benzoxathiole; C7H4O3S; 6-hydroxy-2H-1,3-benzoxathiol-2-one; EINECS 225-653-0; S0FAJ1R9CD; CHEMBL442687; CHEBI:568021; SLYPOVJCSQHITR-UHFFFAOYSA-N; NCGC00095003-01; Acnosan; 5-Hydroxy-1,3-benzothioxol-2-one; 6-hydroxybenzo[d]1,3-oxathiolen-2-one
DMDRSNH DT Small molecular drug
DMDRSNH PC 72139
DMDRSNH MW 168.17
DMDRSNH FM C7H4O3S
DMDRSNH IC InChI=1S/C7H4O3S/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3,8H
DMDRSNH CS C1=CC2=C(C=C1O)OC(=O)S2
DMDRSNH IK SLYPOVJCSQHITR-UHFFFAOYSA-N
DMDRSNH IU 6-hydroxy-1,3-benzoxathiol-2-one
DMDRSNH CA CAS 4991-65-5
DMDRSNH CB CHEBI:568021
DMDRSNH DE Discovery agent
DM2B4S5 ID DM2B4S5
DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide
DM2B4S5 HS Investigative
DM2B4S5 SN 6-hydroxybenzo[d]thiazole-2-sulfonamide
DM2B4S5 DE Discovery agent
DM7M58P ID DM7M58P
DM7M58P DN 6-hydroxydopa quinone
DM7M58P HS Investigative
DM7M58P SN Topa quinone; topaquinone; 6-hydroxydopa quinone; L-topaquinone; 6-Hydroxydopaquinone; 2,4,5-trihydroxyphenylalanine quinone; 135791-48-9; 64192-68-3; 3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)-l-alanine; 5-(2-CARBOXY-2-AMINOETHYL)-2-HYDROXY-1,4-BENZOQUINONE; (2S)-2-amino-3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)propanoic acid; o-Topaquinone; 6-Hydroxyphenylalanine-3,4-dione; L-topaquinone residue; 5-(2-CARBOXY-2-AMINOETHYL)-4-HYDROXY-1,2-BENZOQUINONE; AC1Q6BVC; AC1L3XGD; TPQ; 2',4',5'-topaquinone; SCHEMBL1781673
DM7M58P DT Small molecular drug
DM7M58P PC 123871
DM7M58P MW 211.17
DM7M58P FM C9H9NO5
DM7M58P IC InChI=1S/C9H9NO5/c10-5(9(14)15)1-4-2-7(12)8(13)3-6(4)11/h2-3,5,11H,1,10H2,(H,14,15)/t5-/m0/s1
DM7M58P CS C1=C(C(=CC(=O)C1=O)O)C[C@@H](C(=O)O)N
DM7M58P IK YWRFBISQAMHSIX-YFKPBYRVSA-N
DM7M58P IU (2S)-2-amino-3-(6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl)propanoic acid
DM7M58P CA CAS 64192-68-3
DM7M58P CB CHEBI:36076
DM7M58P DE Discovery agent
DM6FNVC ID DM6FNVC
DM6FNVC DN 6-Hydroxyflavanone
DM6FNVC HS Investigative
DM6FNVC SN 6-Hydroxyflavanone; 4250-77-5; 6-hydroxy-2-phenylchroman-4-one; 6-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; 6-Hydroxy-Flavanone; CHEMBL195033; 4H-1-Benzopyran-4-one, 2,3-dihydro-6-hydroxy-2-phenyl-; CHEBI:34471; XYHWPQUEOOBIOW-UHFFFAOYSA-N; 6-hydroxy-2-phenyl-chroman-4-one; MFCD00017485; 6-hydroxy-2-phenyl-2,3-dihydrochromen-4-one; Flavanone, 6-hydroxy-; (+/-)-6-Hydroxyflavanone; 6 - Hydroxyflavanone; ACMC-209jpu; AC1MC1GQ; Maybridge3_000570; 6-Hydroxyflavanone, 99%; bmse000985; C14221; Oprea1_761592; SCHEMBL126598
DM6FNVC DT Small molecular drug
DM6FNVC PC 2734580
DM6FNVC MW 240.25
DM6FNVC FM C15H12O3
DM6FNVC IC InChI=1S/C15H12O3/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-8,15-16H,9H2
DM6FNVC CS C1C(OC2=C(C1=O)C=C(C=C2)O)C3=CC=CC=C3
DM6FNVC IK XYHWPQUEOOBIOW-UHFFFAOYSA-N
DM6FNVC IU 6-hydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM6FNVC CA CAS 4250-77-5
DM6FNVC CB CHEBI:34471
DM6FNVC DE Discovery agent
DM89YV7 ID DM89YV7
DM89YV7 DN 6-hydroxymelatonin
DM89YV7 HS Investigative
DM89YV7 SN 6-OH-MLT; 6-OH-melatonin
DM89YV7 DT Small molecular drug
DM89YV7 PC 1864
DM89YV7 MW 248.28
DM89YV7 FM C13H16N2O3
DM89YV7 IC InChI=1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16)
DM89YV7 CS CC(=O)NCCC1=CNC2=CC(=C(C=C21)OC)O
DM89YV7 IK OMYMRCXOJJZYKE-UHFFFAOYSA-N
DM89YV7 IU N-[2-(6-hydroxy-5-methoxy-1H-indol-3-yl)ethyl]acetamide
DM89YV7 CA CAS 2208-41-5
DM89YV7 CB CHEBI:2198
DM89YV7 DE Discovery agent
DMYF60K ID DMYF60K
DMYF60K DN 6-Hydroxymethyl-7,8-Dihydropterin
DMYF60K HS Investigative
DMYF60K DT Small molecular drug
DMYF60K PC 135398568
DMYF60K MW 195.18
DMYF60K FM C7H9N5O2
DMYF60K IC InChI=1S/C7H9N5O2/c8-7-11-5-4(6(14)12-7)10-3(2-13)1-9-5/h13H,1-2H2,(H4,8,9,11,12,14)
DMYF60K CS C1C(=NC2=C(N1)N=C(NC2=O)N)CO
DMYF60K IK CQQNNQTXUGLUEV-UHFFFAOYSA-N
DMYF60K IU 2-amino-6-(hydroxymethyl)-7,8-dihydro-3H-pteridin-4-one
DMYF60K CA CAS 3672-03-5
DMYF60K CB CHEBI:17083
DMYF60K DE Discovery agent
DM7EWDN ID DM7EWDN
DM7EWDN DN 6-Hydroxymethylpterin
DM7EWDN HS Investigative
DM7EWDN DT Small molecular drug
DM7EWDN PC 135415975
DM7EWDN MW 193.16
DM7EWDN FM C7H7N5O2
DM7EWDN IC InChI=1S/C7H7N5O2/c8-7-11-5-4(6(14)12-7)10-3(2-13)1-9-5/h1,13H,2H2,(H3,8,9,11,12,14)
DM7EWDN CS C1=C(N=C2C(=O)NC(=NC2=N1)N)CO
DM7EWDN IK XGWIBNWDLMIPNF-UHFFFAOYSA-N
DM7EWDN IU 2-amino-6-(hydroxymethyl)-3H-pteridin-4-one
DM7EWDN CA CAS 712-29-8
DM7EWDN DE Discovery agent
DM6KVO0 ID DM6KVO0
DM6KVO0 DN 6-Hydroxy-N-(2-morpholinoethyl)nicotinamide
DM6KVO0 HS Investigative
DM6KVO0 SN 6-Hydroxy-N-(2-morpholinoethyl)nicotinamide; CHEMBL596971; BDBM50307189; AKOS008932018; AKOS027598195
DM6KVO0 DT Small molecular drug
DM6KVO0 PC 28826303
DM6KVO0 MW 251.28
DM6KVO0 FM C12H17N3O3
DM6KVO0 IC InChI=1S/C12H17N3O3/c16-11-2-1-10(9-14-11)12(17)13-3-4-15-5-7-18-8-6-15/h1-2,9H,3-8H2,(H,13,17)(H,14,16)
DM6KVO0 CS C1COCCN1CCNC(=O)C2=CNC(=O)C=C2
DM6KVO0 IK BNPSDTRXYVPPCU-UHFFFAOYSA-N
DM6KVO0 IU N-(2-morpholin-4-ylethyl)-6-oxo-1H-pyridine-3-carboxamide
DM6KVO0 DE Discovery agent
DMVRFU5 ID DMVRFU5
DMVRFU5 DN 6-Hydroxypropylthymine
DMVRFU5 HS Investigative
DMVRFU5 SN 6-hydroxypropylthymine; 6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139
DMVRFU5 DT Small molecular drug
DMVRFU5 PC 1865
DMVRFU5 MW 184.19
DMVRFU5 FM C8H12N2O3
DMVRFU5 IC InChI=1S/C8H12N2O3/c1-5-6(3-2-4-11)9-8(13)10-7(5)12/h11H,2-4H2,1H3,(H2,9,10,12,13)
DMVRFU5 CS CC1=C(NC(=O)NC1=O)CCCO
DMVRFU5 IK OIEJBPVNLZZLGQ-UHFFFAOYSA-N
DMVRFU5 IU 6-(3-hydroxypropyl)-5-methyl-1H-pyrimidine-2,4-dione
DMVRFU5 CB CHEBI:43299
DMVRFU5 DE Discovery agent
DMDMNQV ID DMDMNQV
DMDMNQV DN 6-Hydroxyuridine-5'-Phosphate
DMDMNQV HS Investigative
DMDMNQV SN 6-hydroxy-UMP; 6-HYDROXYURIDINE-5'-PHOSPHATE; 6-hydroxyuridine 5'-(dihydrogen phosphate); CHEMBL383923; 29741-00-2; Prfb acid; 1lor; 1dqx; 1eix; 6-hydroxyuridine 5'-phosphate; AC1Q69HY; AC1L4PT5; 5'-Uridylic acid,6-hydroxy-; SCHEMBL2130675; 5'-Uridylic acid, 6-hydroxy-; CTK4G3746; DTXSID50183892; Phosphoribofuranosylbarbituric acid; BDBM50199178; 6-Hydroxyuridine 5'-phosphoric acid; DB02890; 6-HYDROXYURIDINE-5''-PHOSPHATE; Barbituric acid ribonucleoside 5'-phosphate; 1-beta-D-ribofuranosyl(3H)pyrimidine-2,4,6-trione 5''-monophosp
DMDMNQV DT Small molecular drug
DMDMNQV PC 161647
DMDMNQV MW 340.18
DMDMNQV FM C9H13N2O10P
DMDMNQV IC InChI=1S/C9H13N2O10P/c12-4-1-5(13)11(9(16)10-4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h1,3,6-8,13-15H,2H2,(H,10,12,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1
DMDMNQV CS C1=C(N(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)O
DMDMNQV IK UDOBICLZEKUKCV-YXZULKJRSA-N
DMDMNQV IU [(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMDMNQV CA CAS 29741-00-2
DMDMNQV DE Discovery agent
DMQF8JG ID DMQF8JG
DMQF8JG DN 6-ile-ustiloxin
DMQF8JG HS Investigative
DMQF8JG DT Small molecular drug
DMQF8JG PC 56661181
DMQF8JG MW 508.6
DMQF8JG FM C24H36N4O8
DMQF8JG IC InChI=1S/C24H36N4O8/c1-6-12(3)17-21(33)28-20(23(35)26-11-16(30)31)24(4,7-2)36-15-10-13(8-9-14(15)29)19(32)18(25-5)22(34)27-17/h8-10,12,17-20,25,29,32H,6-7,11H2,1-5H3,(H,26,35)(H,27,34)(H,28,33)(H,30,31)/t12-,17+,18+,19-,20-,24-/m1/s1
DMQF8JG CS CC[C@@H](C)[C@H]1C(=O)N[C@@H]([C@@](OC2=C(C=CC(=C2)[C@H]([C@@H](C(=O)N1)NC)O)O)(C)CC)C(=O)NCC(=O)O
DMQF8JG IK HXTMSBIVCTYGAS-NBNOUWLYSA-N
DMQF8JG IU 2-[[(3R,4S,7S,10S,11R)-7-[(2R)-butan-2-yl]-3-ethyl-11,15-dihydroxy-3-methyl-10-(methylamino)-6,9-dioxo-2-oxa-5,8-diazabicyclo[10.3.1]hexadeca-1(15),12(16),13-triene-4-carbonyl]amino]acetic acid
DMQF8JG DE Discovery agent
DMRMSU5 ID DMRMSU5
DMRMSU5 DN 6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one
DMRMSU5 HS Investigative
DMRMSU5 SN CHEMBL17516; 119924-94-6; 3,4-dihydro-6-(1H-imidazol-1-yl)quinolin-2(1H)-one; 2(1H)-Quinolinone, 3,4-dihydro-6-(1H-imidazol-1-yl)-; ACMC-20momi; 6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one; SCHEMBL10463333; CTK0F9353; DTXSID20551867; BDMKPUAZENLRDY-UHFFFAOYSA-N; BDBM50000309; 6-(imidazol-1-yl)-3,4-dihydrocarbostyril
DMRMSU5 DT Small molecular drug
DMRMSU5 PC 13885278
DMRMSU5 MW 213.23
DMRMSU5 FM C12H11N3O
DMRMSU5 IC InChI=1S/C12H11N3O/c16-12-4-1-9-7-10(2-3-11(9)14-12)15-6-5-13-8-15/h2-3,5-8H,1,4H2,(H,14,16)
DMRMSU5 CS C1CC(=O)NC2=C1C=C(C=C2)N3C=CN=C3
DMRMSU5 IK BDMKPUAZENLRDY-UHFFFAOYSA-N
DMRMSU5 IU 6-imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one
DMRMSU5 CA CAS 119924-94-6
DMRMSU5 DE Discovery agent
DMQXL1Y ID DMQXL1Y
DMQXL1Y DN 6-Imidazol-1-yl-isoquinoline
DMQXL1Y HS Investigative
DMQXL1Y SN 6-(1H-imidazol-1-yl)isoquinoline
DMQXL1Y DT Small molecular drug
DMQXL1Y PC 10845522
DMQXL1Y MW 195.22
DMQXL1Y FM C12H9N3
DMQXL1Y IC InChI=1S/C12H9N3/c1-2-12(15-6-5-14-9-15)7-10-3-4-13-8-11(1)10/h1-9H
DMQXL1Y CS C1=CC2=C(C=CN=C2)C=C1N3C=CN=C3
DMQXL1Y IK YACWDKFXWATANA-UHFFFAOYSA-N
DMQXL1Y IU 6-imidazol-1-ylisoquinoline
DMQXL1Y DE Discovery agent
DMBQ3HV ID DMBQ3HV
DMBQ3HV DN 6-Imidazol-1-ylmethyl-8-phenyl-quinoline
DMBQ3HV HS Investigative
DMBQ3HV SN CHEMBL419416; 6-Imidazol-1-ylmethyl-8-phenyl-quinoline; BDBM50092624
DMBQ3HV DT Small molecular drug
DMBQ3HV PC 10565073
DMBQ3HV MW 285.3
DMBQ3HV FM C19H15N3
DMBQ3HV IC InChI=1S/C19H15N3/c1-2-5-16(6-3-1)18-12-15(13-22-10-9-20-14-22)11-17-7-4-8-21-19(17)18/h1-12,14H,13H2
DMBQ3HV CS C1=CC=C(C=C1)C2=C3C(=CC(=C2)CN4C=CN=C4)C=CC=N3
DMBQ3HV IK PBPLGORPOONLEQ-UHFFFAOYSA-N
DMBQ3HV IU 6-(imidazol-1-ylmethyl)-8-phenylquinoline
DMBQ3HV DE Discovery agent
DM31VLA ID DM31VLA
DM31VLA DN 6-Iodo-2-piperazin-1-yl-quinoline
DM31VLA HS Investigative
DM31VLA SN 6-Iodo-2-piperazin-1-yl-quinoline; 296759-25-6; 6-Iodo-2-(piperazin-1-yl)quinoline; CHEMBL38466; 2-Piperazino-6-iodoquinoline; SCHEMBL6364907; C13H14IN3; DTXSID00476408; ZINC2527444; 3556AJ; BDBM50090210; AKOS024260375; NE63975; AB19831; ACM296759256; AJ-83657; AX8289444; DB-068143
DM31VLA DT Small molecular drug
DM31VLA PC 12044728
DM31VLA MW 339.17
DM31VLA FM C13H14IN3
DM31VLA IC InChI=1S/C13H14IN3/c14-11-2-3-12-10(9-11)1-4-13(16-12)17-7-5-15-6-8-17/h1-4,9,15H,5-8H2
DM31VLA CS C1CN(CCN1)C2=NC3=C(C=C2)C=C(C=C3)I
DM31VLA IK BZVOKNDAJHHFPT-UHFFFAOYSA-N
DM31VLA IU 6-iodo-2-piperazin-1-ylquinoline
DM31VLA CA CAS 296759-25-6
DM31VLA DE Discovery agent
DMAL1UH ID DMAL1UH
DMAL1UH DN 6-iodo-4'-dimethyaminoflavone
DMAL1UH HS Investigative
DMAL1UH SN 871101-31-4; 2-(4-DIMETHYLAMINOPHENYL)-6-IODO-4-CHROMENONE; CHEMBL375934; 2-(4-dimethylaminophenyl)-6-iodo-chromen-4-one; 2-[4-(Dimethylamino)phenyl]-6-iodo-4H-1-benzopyran-4-one; SCHEMBL4985743; 6-iodo-4'-dimethylaminoflavone; 6-iodo-4''-dimethyaminoflavone; CTK8E3396; DTXSID30468831; MVKVWWKDDYBNOJ-UHFFFAOYSA-N; BDBM50176892; ZINC13675691; RT-007109
DMAL1UH DT Small molecular drug
DMAL1UH PC 11574659
DMAL1UH MW 391.2
DMAL1UH FM C17H14INO2
DMAL1UH IC InChI=1S/C17H14INO2/c1-19(2)13-6-3-11(4-7-13)17-10-15(20)14-9-12(18)5-8-16(14)21-17/h3-10H,1-2H3
DMAL1UH CS CN(C)C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)I
DMAL1UH IK MVKVWWKDDYBNOJ-UHFFFAOYSA-N
DMAL1UH IU 2-[4-(dimethylamino)phenyl]-6-iodochromen-4-one
DMAL1UH CA CAS 871101-31-4
DMAL1UH DE Discovery agent
DM5FZBI ID DM5FZBI
DM5FZBI DN 6-iodo-4'-hydroxyflavone
DM5FZBI HS Investigative
DM5FZBI SN CHEMBL388844; 6-iodo-4''-hydroxyflavone; SCHEMBL10144252
DM5FZBI DT Small molecular drug
DM5FZBI PC 11703303
DM5FZBI MW 364.13
DM5FZBI FM C15H9IO3
DM5FZBI IC InChI=1S/C15H9IO3/c16-10-3-6-14-12(7-10)13(18)8-15(19-14)9-1-4-11(17)5-2-9/h1-8,17H
DM5FZBI CS C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)I)O
DM5FZBI IK IFAJNNUYROKKPW-UHFFFAOYSA-N
DM5FZBI IU 2-(4-hydroxyphenyl)-6-iodochromen-4-one
DM5FZBI DE Discovery agent
DM6U9CY ID DM6U9CY
DM6U9CY DN 6-iodo-4'-methoxyflavone
DM6U9CY HS Investigative
DM6U9CY SN CHEMBL224064; 6-iodo-2-(4-methoxyphenyl)chromen-4-one; 1033-44-9; 4h-1-benzopyran-4-one,6-iodo-2-(4-methoxyphenyl)-; 6-iodo-4'-methoxyflavone; AC1LAD9Q; 6-iodo-4''-methoxyflavone; 4'-Methoxy-6-iodoflavanone; SCHEMBL4983190; BYDBCAPACOXVEH-UHFFFAOYSA-N; ZINC6484552; BDBM50176894
DM6U9CY DT Small molecular drug
DM6U9CY PC 466289
DM6U9CY MW 378.16
DM6U9CY FM C16H11IO3
DM6U9CY IC InChI=1S/C16H11IO3/c1-19-12-5-2-10(3-6-12)16-9-14(18)13-8-11(17)4-7-15(13)20-16/h2-9H,1H3
DM6U9CY CS COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)I
DM6U9CY IK BYDBCAPACOXVEH-UHFFFAOYSA-N
DM6U9CY IU 6-iodo-2-(4-methoxyphenyl)chromen-4-one
DM6U9CY DE Discovery agent
DM9GJAY ID DM9GJAY
DM9GJAY DN 6-iodo-4'-methylaminoflavone
DM9GJAY HS Investigative
DM9GJAY SN 6-iodo-4'-methylaminoflavone; 871101-30-3; CHEMBL224643; 6-iodo-2-(4-methylaminophenyl)-chromen-4-one; SCHEMBL4991516; 6-iodo-4''-methylaminoflavone; DTXSID20469771; QIZWRTNISFPGTO-UHFFFAOYSA-N; ZINC13675690; BDBM50176896; KB-248886
DM9GJAY DT Small molecular drug
DM9GJAY PC 11632242
DM9GJAY MW 377.18
DM9GJAY FM C16H12INO2
DM9GJAY IC InChI=1S/C16H12INO2/c1-18-12-5-2-10(3-6-12)16-9-14(19)13-8-11(17)4-7-15(13)20-16/h2-9,18H,1H3
DM9GJAY CS CNC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)I
DM9GJAY IK QIZWRTNISFPGTO-UHFFFAOYSA-N
DM9GJAY IU 6-iodo-2-[4-(methylamino)phenyl]chromen-4-one
DM9GJAY CA CAS 871101-30-3
DM9GJAY DE Discovery agent
DM0GSRL ID DM0GSRL
DM0GSRL DN 6'-Iodononivamide
DM0GSRL HS Investigative
DM0GSRL SN 859171-97-4; CHEMBL177809; Tocris-1975; NCGC00025334-01; AC1NP3A0; CTK8E7732; DTXSID70408796; MolPort-003-983-501; CHEBI:107654; HMS3268B17; ZINC8036052; MFCD09878233; BN0036; BDBM50170053; AKOS024456886; RT-010669; N-(4-hydroxy-2-iodo-5-methoxybenzyl)nonanamide; N-(2-Iodo-4-hydroxy-5-methoxybenzyl)nonanamide; 6-Iodonordihydrocapsaicin, > SR-01000597523; SR-01000597523-1; BRD-K49236613-001-01-5; Nonanoic acid 4-hydroxy-2-iodo-5-methoxy-benzylamide
DM0GSRL DT Small molecular drug
DM0GSRL PC 5149140
DM0GSRL MW 419.3
DM0GSRL FM C17H26INO3
DM0GSRL IC InChI=1S/C17H26INO3/c1-3-4-5-6-7-8-9-17(21)19-12-13-10-16(22-2)15(20)11-14(13)18/h10-11,20H,3-9,12H2,1-2H3,(H,19,21)
DM0GSRL CS CCCCCCCCC(=O)NCC1=CC(=C(C=C1I)O)OC
DM0GSRL IK AAORACFZMYMFCG-UHFFFAOYSA-N
DM0GSRL IU N-[(4-hydroxy-2-iodo-5-methoxyphenyl)methyl]nonanamide
DM0GSRL CA CAS 859171-97-4
DM0GSRL CB CHEBI:107654
DM0GSRL DE Discovery agent
DM1S9DB ID DM1S9DB
DM1S9DB DN 6-iodo-nordihydrocapsaicin
DM1S9DB HS Investigative
DM1S9DB SN GTPL4110
DM1S9DB DT Small molecular drug
DM1S9DB PC 24881008
DM1S9DB MW 419.3
DM1S9DB FM C17H26INO3
DM1S9DB IC InChI=1S/C17H26INO3/c1-12(2)7-5-4-6-8-17(21)19-11-13-9-16(22-3)15(20)10-14(13)18/h9-10,12,20H,4-8,11H2,1-3H3,(H,19,21)
DM1S9DB CS CC(C)CCCCCC(=O)NCC1=CC(=C(C=C1I)O)OC
DM1S9DB IK MGJQSBQUFTWMOG-UHFFFAOYSA-N
DM1S9DB IU N-[(4-hydroxy-2-iodo-5-methoxyphenyl)methyl]-7-methyloctanamide
DM1S9DB DE Discovery agent
DM2XB68 ID DM2XB68
DM2XB68 DN 6-isobutyl-4-methylpyridin-2-amine
DM2XB68 HS Investigative
DM2XB68 SN CHEMBL294609; 6-isobutyl-4-methylpyridin-2-amine; SCHEMBL7052362; VMTPVCVORKDABN-UHFFFAOYSA-N; BDBM50091801; 2-Amino-4-methyl-6-isobutylpyridine; 6-Isobutyl-4-methyl-pyridin-2-ylamine; 179555-28-3; 2-amino-4-methyl-6-(2-methylpropyl)pyridine; 2-Pyridinamine, 4-methyl-6-(2-methylpropyl)-
DM2XB68 DT Small molecular drug
DM2XB68 PC 10197851
DM2XB68 MW 164.25
DM2XB68 FM C10H16N2
DM2XB68 IC InChI=1S/C10H16N2/c1-7(2)4-9-5-8(3)6-10(11)12-9/h5-7H,4H2,1-3H3,(H2,11,12)
DM2XB68 CS CC1=CC(=NC(=C1)N)CC(C)C
DM2XB68 IK VMTPVCVORKDABN-UHFFFAOYSA-N
DM2XB68 IU 4-methyl-6-(2-methylpropyl)pyridin-2-amine
DM2XB68 DE Discovery agent
DMGXMZL ID DMGXMZL
DMGXMZL DN 6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMGXMZL HS Investigative
DMGXMZL SN CHEMBL222929; 6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMGXMZL DT Small molecular drug
DMGXMZL PC 16203712
DMGXMZL MW 239.34
DMGXMZL FM C12H17NO2S
DMGXMZL IC InChI=1S/C12H17NO2S/c1-9(2)11-7-10(14)8-12(16-11)13-3-5-15-6-4-13/h7-9H,3-6H2,1-2H3
DMGXMZL CS CC(C)C1=CC(=O)C=C(S1)N2CCOCC2
DMGXMZL IK AWDQFPIPWUUVQD-UHFFFAOYSA-N
DMGXMZL IU 2-morpholin-4-yl-6-propan-2-ylthiopyran-4-one
DMGXMZL DE Discovery agent
DMO2F8L ID DMO2F8L
DMO2F8L DN 6-Isopropyl-2-phenyl-chromen-4-one
DMO2F8L HS Investigative
DMO2F8L SN 288401-05-8; 6-ISO-PROPYLFLAVONE; 6-Isopropylflavone; CHEMBL133949; CTK4G2222; DTXSID70658395; ZINC2573996; AKOS030553653; 2-Phenyl-6-(propan-2-yl)-4H-1-benzopyran-4-one
DMO2F8L DT Small molecular drug
DMO2F8L PC 44355253
DMO2F8L MW 264.3
DMO2F8L FM C18H16O2
DMO2F8L IC InChI=1S/C18H16O2/c1-12(2)14-8-9-17-15(10-14)16(19)11-18(20-17)13-6-4-3-5-7-13/h3-12H,1-2H3
DMO2F8L CS CC(C)C1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMO2F8L IK APJYDAHXYGPDII-UHFFFAOYSA-N
DMO2F8L IU 2-phenyl-6-propan-2-ylchromen-4-one
DMO2F8L CA CAS 288401-05-8
DMO2F8L DE Discovery agent
DM2WUZP ID DM2WUZP
DM2WUZP DN 6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one
DM2WUZP HS Investigative
DM2WUZP SN CHEMBL456390; 6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one; SCHEMBL1120250; BDBM50273813
DM2WUZP DT Small molecular drug
DM2WUZP PC 25147692
DM2WUZP MW 274.3
DM2WUZP FM C18H14N2O
DM2WUZP IC InChI=1S/C18H14N2O/c21-18-8-6-13-9-12(5-7-17(13)20-18)16-11-19-10-14-3-1-2-4-15(14)16/h1-5,7,9-11H,6,8H2,(H,20,21)
DM2WUZP CS C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC4=CC=CC=C43
DM2WUZP IK TVVPAZUMRVMIFM-UHFFFAOYSA-N
DM2WUZP IU 6-isoquinolin-4-yl-3,4-dihydro-1H-quinolin-2-one
DM2WUZP DE Discovery agent
DMD2FW9 ID DMD2FW9
DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide
DMD2FW9 HS Investigative
DMD2FW9 SN 6-Mercapto-hexanoic acid phenylamide; CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600
DMD2FW9 DT Small molecular drug
DMD2FW9 PC 11436024
DMD2FW9 MW 223.34
DMD2FW9 FM C12H17NOS
DMD2FW9 IC InChI=1S/C12H17NOS/c14-12(9-5-2-6-10-15)13-11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DMD2FW9 CS C1=CC=C(C=C1)NC(=O)CCCCCS
DMD2FW9 IK IFUHTURYMZWNNJ-UHFFFAOYSA-N
DMD2FW9 IU N-phenyl-6-sulfanylhexanamide
DMD2FW9 DE Discovery agent
DMJUT70 ID DMJUT70
DMJUT70 DN 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DMJUT70 HS Investigative
DMJUT70 SN CHEMBL374729; 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium
DMJUT70 DT Small molecular drug
DMJUT70 PC 44419695
DMJUT70 MW 227.28
DMJUT70 FM C14H15N2O+
DMJUT70 IC InChI=1S/C14H14N2O/c1-9-14-11(6-7-16(9)2)12-8-10(17-3)4-5-13(12)15-14/h4-8H,1-3H3/p+1
DMJUT70 CS CC1=[N+](C=CC2=C1NC3=C2C=C(C=C3)OC)C
DMJUT70 IK GKOBEAWUMYEQIP-UHFFFAOYSA-O
DMJUT70 IU 6-methoxy-1,2-dimethyl-9H-pyrido[3,4-b]indol-2-ium
DMJUT70 DE Discovery agent
DMOHWPD ID DMOHWPD
DMOHWPD DN 6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole
DMOHWPD HS Investigative
DMOHWPD SN 6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole; CHEMBL375077; AC1L4QAL; SCHEMBL20159056; BDBM50194445; 22574-29-4
DMOHWPD DT Small molecular drug
DMOHWPD PC 211174
DMOHWPD MW 226.27
DMOHWPD FM C14H14N2O
DMOHWPD IC InChI=1S/C14H14N2O/c1-9-14-11(6-7-15-9)12-8-10(17-3)4-5-13(12)16(14)2/h4-8H,1-3H3
DMOHWPD CS CC1=NC=CC2=C1N(C3=C2C=C(C=C3)OC)C
DMOHWPD IK AJSYZGYPCGTQSU-UHFFFAOYSA-N
DMOHWPD IU 6-methoxy-1,9-dimethylpyrido[3,4-b]indole
DMOHWPD DE Discovery agent
DMZP3XJ ID DMZP3XJ
DMZP3XJ DN 6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZP3XJ HS Investigative
DMZP3XJ SN CHEMBL67196
DMZP3XJ DT Small molecular drug
DMZP3XJ PC 9797585
DMZP3XJ MW 330.4
DMZP3XJ FM C21H18N2O2
DMZP3XJ IC InChI=1S/C21H18N2O2/c1-24-18-11-12-19-20(14-18)23-21(22-19)13-15-7-9-17(10-8-15)25-16-5-3-2-4-6-16/h2-12,14H,13H2,1H3,(H,22,23)
DMZP3XJ CS COC1=CC2=C(C=C1)N=C(N2)CC3=CC=C(C=C3)OC4=CC=CC=C4
DMZP3XJ IK QXVTTYRBOJXPRC-UHFFFAOYSA-N
DMZP3XJ IU 6-methoxy-2-[(4-phenoxyphenyl)methyl]-1H-benzimidazole
DMZP3XJ DE Discovery agent
DMSA367 ID DMSA367
DMSA367 DN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMSA367 HS Investigative
DMSA367 SN 20315-68-8; 6-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 6-methoxytryptoline; 6-Methoxy-1,2,3,4-tetrahydro-beta-carboline; pinoline; 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole; 6-MeOthbc; 6-methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4b] indole; 6-Methoxytetrahydro-beta-carboline; 2,3,4,9-Tetrahydro-6-methoxy-1H-pyrido(3,4-b)indole; BRN 0172873; CHEMBL266084; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-6-methoxy-; QYMDEOQLJUUNOF-UHFFFAOYSA-N
DMSA367 DT Small molecular drug
DMSA367 PC 1868
DMSA367 MW 202.25
DMSA367 FM C12H14N2O
DMSA367 IC InChI=1S/C12H14N2O/c1-15-8-2-3-11-10(6-8)9-4-5-13-7-12(9)14-11/h2-3,6,13-14H,4-5,7H2,1H3
DMSA367 CS COC1=CC2=C(C=C1)NC3=C2CCNC3
DMSA367 IK QYMDEOQLJUUNOF-UHFFFAOYSA-N
DMSA367 IU 6-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMSA367 CA CAS 20315-68-8
DMSA367 DE Discovery agent
DMG3F7D ID DMG3F7D
DMG3F7D DN 6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMG3F7D HS Investigative
DMG3F7D SN CHEMBL385778; 6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium
DMG3F7D DT Small molecular drug
DMG3F7D PC 44419694
DMG3F7D MW 227.28
DMG3F7D FM C14H15N2O+
DMG3F7D IC InChI=1S/C14H15N2O/c1-15-7-6-11-12-8-10(17-3)4-5-13(12)16(2)14(11)9-15/h4-9H,1-3H3/q+1
DMG3F7D CS CN1C2=C(C=C(C=C2)OC)C3=C1C=[N+](C=C3)C
DMG3F7D IK DSZQQMUYRCNRKS-UHFFFAOYSA-N
DMG3F7D IU 6-methoxy-2,9-dimethylpyrido[3,4-b]indol-2-ium
DMG3F7D DE Discovery agent
DMHITF8 ID DMHITF8
DMHITF8 DN 6-methoxy-2-methyl-9H-beta-carbolin-2-ium
DMHITF8 HS Investigative
DMHITF8 SN CHEMBL376434; AC1NSY4Y; 6-methoxy-2-methyl-9H-beta-carbolin-2-ium; BDBM50194438
DMHITF8 DT Small molecular drug
DMHITF8 PC 5319470
DMHITF8 MW 213.25
DMHITF8 FM C13H13N2O+
DMHITF8 IC InChI=1S/C13H12N2O/c1-15-6-5-10-11-7-9(16-2)3-4-12(11)14-13(10)8-15/h3-8H,1-2H3/p+1
DMHITF8 CS C[N+]1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)OC
DMHITF8 IK UXIBWQLCPYHBSH-UHFFFAOYSA-O
DMHITF8 IU 6-methoxy-2-methyl-9H-pyrido[3,4-b]indol-2-ium
DMHITF8 DE Discovery agent
DM7WH82 ID DM7WH82
DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DM7WH82 HS Investigative
DM7WH82 SN 6-Methoxy-2-oxo-2H-chromene-3-carboxylic acid; 35924-44-8; 6-methoxy-2-oxochromene-3-carboxylic acid; CHEMBL568416; 6-methoxy-2-oxo-2H-1-benzopyran-3-carboxylic acid; MLS000061036; AC1LEG8M; CBMicro_000141; Oprea1_705276; Oprea1_357602; 6-methoxy-3-carboxy-coumarin; SCHEMBL978456; CTK1B0306; DTXSID90351856; XIQQAIQZABTSNZ-UHFFFAOYSA-N; MolPort-000-467-024; ZINC103684; HMS2443I11; HMS1607B10; SMSF0006060; ZX-AL001956; STL553633; SBB043625; BDBM50303489; AKOS000274154; CB01296; MCULE-7757033841; BAS 00518708; SMR000069802
DM7WH82 DT Small molecular drug
DM7WH82 PC 711717
DM7WH82 MW 220.18
DM7WH82 FM C11H8O5
DM7WH82 IC InChI=1S/C11H8O5/c1-15-7-2-3-9-6(4-7)5-8(10(12)13)11(14)16-9/h2-5H,1H3,(H,12,13)
DM7WH82 CS COC1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)O
DM7WH82 IK XIQQAIQZABTSNZ-UHFFFAOYSA-N
DM7WH82 IU 6-methoxy-2-oxochromene-3-carboxylic acid
DM7WH82 CA CAS 35924-44-8
DM7WH82 DE Discovery agent
DM52SDO ID DM52SDO
DM52SDO DN 6-Methoxy-3-pyridin-4-yl-quinoline
DM52SDO HS Investigative
DM52SDO SN CHEMBL90780; 6-methoxy-3-pyridin-4-yl-quinoline; 6-Methoxy-3-(4-pyridyl)quinoline
DM52SDO DT Small molecular drug
DM52SDO PC 10354094
DM52SDO MW 236.27
DM52SDO FM C15H12N2O
DM52SDO IC InChI=1S/C15H12N2O/c1-18-14-2-3-15-12(9-14)8-13(10-17-15)11-4-6-16-7-5-11/h2-10H,1H3
DM52SDO CS COC1=CC2=CC(=CN=C2C=C1)C3=CC=NC=C3
DM52SDO IK BGNDYXHAEMNSOM-UHFFFAOYSA-N
DM52SDO IU 6-methoxy-3-pyridin-4-ylquinoline
DM52SDO DE Discovery agent
DMOYL71 ID DMOYL71
DMOYL71 DN 6-Methoxy-3-thiophen-3-yl-quinoline
DMOYL71 HS Investigative
DMOYL71 SN CHEMBL303184; 6-methoxy-3-thiophen-3-yl-quinoline; ZINC3832230
DMOYL71 DT Small molecular drug
DMOYL71 PC 10083051
DMOYL71 MW 241.31
DMOYL71 FM C14H11NOS
DMOYL71 IC InChI=1S/C14H11NOS/c1-16-13-2-3-14-11(7-13)6-12(8-15-14)10-4-5-17-9-10/h2-9H,1H3
DMOYL71 CS COC1=CC2=CC(=CN=C2C=C1)C3=CSC=C3
DMOYL71 IK SQHKULNLQJHPDX-UHFFFAOYSA-N
DMOYL71 IU 6-methoxy-3-thiophen-3-ylquinoline
DMOYL71 DE Discovery agent
DM98FQO ID DM98FQO
DM98FQO DN 6-Methoxy-4,9-dihydro-3H-beta-carboline
DM98FQO HS Investigative
DM98FQO SN 6-Methoxy-4,9-dihydro-3H-beta-carboline; CHEMBL6717; SCHEMBL8369162; BDBM50136505; AKOS023554679; 3,4-Dihydro-6-methoxy-beta-carboline
DM98FQO DT Small molecular drug
DM98FQO PC 15160217
DM98FQO MW 200.24
DM98FQO FM C12H12N2O
DM98FQO IC InChI=1S/C12H12N2O/c1-15-8-2-3-11-10(6-8)9-4-5-13-7-12(9)14-11/h2-3,6-7,14H,4-5H2,1H3
DM98FQO CS COC1=CC2=C(C=C1)NC3=C2CCN=C3
DM98FQO IK BJODVFITWMPYMU-UHFFFAOYSA-N
DM98FQO IU 6-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DM98FQO DE Discovery agent
DMPB9MY ID DMPB9MY
DMPB9MY DN 6-Methoxy-4-morpholin-4-yl-chromen-2-one
DMPB9MY HS Investigative
DMPB9MY SN CHEMBL175510; NU-7031; 79105-88-7; 6-methoxy-4-morpholin-4-yl-chromen-2-one; 6-methoxy-4-morpholino-2H-chromen-2-one; SCHEMBL3666851; BDBM50159679
DMPB9MY DT Small molecular drug
DMPB9MY PC 11196279
DMPB9MY MW 261.269
DMPB9MY FM C14H15NO4
DMPB9MY IC InChI=1S/C14H15NO4/c1-17-10-2-3-13-11(8-10)12(9-14(16)19-13)15-4-6-18-7-5-15/h2-3,8-9H,4-7H2,1H3
DMPB9MY CS COC1=CC2=C(C=C1)OC(=O)C=C2N3CCOCC3
DMPB9MY IK UEDWCBYLFYRZFY-UHFFFAOYSA-N
DMPB9MY IU 6-methoxy-4-morpholin-4-ylchromen-2-one
DMPB9MY DE Discovery agent
DMHO7TZ ID DMHO7TZ
DMHO7TZ DN 6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole
DMHO7TZ HS Investigative
DMHO7TZ SN CHEMBL23590; 569352-88-1; 6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole; SCHEMBL5832036; CTK1F3437; DTXSID60623678; BDBM50126004; 2-Phenyl-5-(5-oxazolyl)-6-methoxy-1H-indole; 1H-Indole, 6-methoxy-5-(5-oxazolyl)-2-phenyl-
DMHO7TZ DT Small molecular drug
DMHO7TZ PC 22238483
DMHO7TZ MW 290.3
DMHO7TZ FM C18H14N2O2
DMHO7TZ IC InChI=1S/C18H14N2O2/c1-21-17-9-16-13(7-14(17)18-10-19-11-22-18)8-15(20-16)12-5-3-2-4-6-12/h2-11,20H,1H3
DMHO7TZ CS COC1=C(C=C2C=C(NC2=C1)C3=CC=CC=C3)C4=CN=CO4
DMHO7TZ IK BESGGLGAKGKEOC-UHFFFAOYSA-N
DMHO7TZ IU 5-(6-methoxy-2-phenyl-1H-indol-5-yl)-1,3-oxazole
DMHO7TZ CA CAS 569352-88-1
DMHO7TZ DE Discovery agent
DM5JB9D ID DM5JB9D
DM5JB9D DN 6-methoxykaempferol 3-O-beta-D-robinobioside
DM5JB9D HS Investigative
DM5JB9D SN 6-methoxykaempferol 3-O-beta-D-robinobioside; 90706-64-2; AC1NUSLN; CHEMBL445993; AKOS030567035; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one; 4H-1-Benzopyran-4-one, 3-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-galactopyranosyl)oxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-
DM5JB9D DT Small molecular drug
DM5JB9D PC 5491783
DM5JB9D MW 624.5
DM5JB9D FM C28H32O16
DM5JB9D IC InChI=1S/C28H32O16/c1-9-16(31)20(35)22(37)27(41-9)40-8-14-17(32)21(36)23(38)28(43-14)44-26-19(34)15-13(7-12(30)25(39-2)18(15)33)42-24(26)10-3-5-11(29)6-4-10/h3-7,9,14,16-17,20-23,27-33,35-38H,8H2,1-2H3/t9-,14+,16-,17-,20+,21-,22+,23+,27+,28-/m0/s1
DM5JB9D CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=C(C3=O)C(=C(C(=C4)O)OC)O)C5=CC=C(C=C5)O)O)O)O)O)O)O
DM5JB9D IK FPVLVSUOCXHCMR-GBNKVCQDSA-N
DM5JB9D IU 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
DM5JB9D CA CAS 90706-64-2
DM5JB9D DE Discovery agent
DMOIC64 ID DMOIC64
DMOIC64 DN 6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one
DMOIC64 HS Investigative
DMOIC64 SN 6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one; 6-Methyl[1,3]dioxolo[4,5-H]quinolin-8(9h)-One; 1137557-67-5; casimiroin analogue, 1a; CHEMBL482693; BDBM29212
DMOIC64 DT Small molecular drug
DMOIC64 PC 42618026
DMOIC64 MW 203.19
DMOIC64 FM C11H9NO3
DMOIC64 IC InChI=1S/C11H9NO3/c1-6-4-9(13)12-10-7(6)2-3-8-11(10)15-5-14-8/h2-4H,5H2,1H3,(H,12,13)
DMOIC64 CS CC1=CC(=O)NC2=C1C=CC3=C2OCO3
DMOIC64 IK XCKXJOHJSMHNFE-UHFFFAOYSA-N
DMOIC64 IU 6-methyl-9H-[1,3]dioxolo[4,5-h]quinolin-8-one
DMOIC64 DE Discovery agent
DMAQGZR ID DMAQGZR
DMAQGZR DN 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DMAQGZR HS Investigative
DMAQGZR SN CHEMBL49016; NSC676187; AC1L8OZO; 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one; SCHEMBL7921815; CTK8D2137; ZINC5504117; BDBM50059977; NSC-676187; NCI60_026914; 2-(3-Methylphenyl)-6-methyl-1,8-naphthyridin-4(1H)-one; 6-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMAQGZR DT Small molecular drug
DMAQGZR PC 385183
DMAQGZR MW 250.29
DMAQGZR FM C16H14N2O
DMAQGZR IC InChI=1S/C16H14N2O/c1-10-4-3-5-12(6-10)14-8-15(19)13-7-11(2)9-17-16(13)18-14/h3-9H,1-2H3,(H,17,18,19)
DMAQGZR CS CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=CC(=C3)C
DMAQGZR IK KDLJOBRGZSEPQS-UHFFFAOYSA-N
DMAQGZR IU 6-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DMAQGZR DE Discovery agent
DMNJRFP ID DMNJRFP
DMNJRFP DN 6-Methyl-2-oxa-spiro[4.4]nonan-1-one
DMNJRFP HS Investigative
DMNJRFP SN CHEMBL97469
DMNJRFP DT Small molecular drug
DMNJRFP PC 10511073
DMNJRFP MW 154.21
DMNJRFP FM C9H14O2
DMNJRFP IC InChI=1S/C9H14O2/c1-7-3-2-4-9(7)5-6-11-8(9)10/h7H,2-6H2,1H3
DMNJRFP CS CC1CCCC12CCOC2=O
DMNJRFP IK IDYXKZWAEUMDEE-UHFFFAOYSA-N
DMNJRFP IU 9-methyl-2-oxaspiro[4.4]nonan-1-one
DMNJRFP DE Discovery agent
DMZ6HQL ID DMZ6HQL
DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid
DMZ6HQL HS Investigative
DMZ6HQL SN 10242-13-4; 6-methyl-2-oxo-2H-chromene-3-carboxylic acid; 2H-1-BENZOPYRAN-3-CARBOXYLIC ACID, 6-METHYL-2-OXO-; BRN 0172386; 6-Methyl-2-oxo-2H-1-benzopyran-3-carboxylic acid; 6-methyl-2-oxochromene-3-carboxylic acid; CHEMBL577123; AC1L18EL; 5-18-08-00343 (Beilstein Handbook Reference); SCHEMBL2808135; CTK0H8591; DTXSID00145066; MolPort-007-984-853; FJICLQQBBFWGMZ-UHFFFAOYSA-N; HMS1622M11; ZINC2023765; SBB077427; BDBM50303488; AKOS002679479; MCULE-8314622881; LS-39185; VU0511228-1; 2-Oxo-6-methyl-2H-1-benzopyran-3-carboxylic acid
DMZ6HQL DT Small molecular drug
DMZ6HQL PC 25090
DMZ6HQL MW 204.18
DMZ6HQL FM C11H8O4
DMZ6HQL IC InChI=1S/C11H8O4/c1-6-2-3-9-7(4-6)5-8(10(12)13)11(14)15-9/h2-5H,1H3,(H,12,13)
DMZ6HQL CS CC1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)O
DMZ6HQL IK FJICLQQBBFWGMZ-UHFFFAOYSA-N
DMZ6HQL IU 6-methyl-2-oxochromene-3-carboxylic acid
DMZ6HQL CA CAS 10242-13-4
DMZ6HQL DE Discovery agent
DMAXBOU ID DMAXBOU
DMAXBOU DN 6-Methyl-2-phenyl-chromen-4-one
DMAXBOU HS Investigative
DMAXBOU SN 6-Methylflavone; 29976-75-8; 6-methyl-2-phenyl-4H-chromen-4-one; 6-methyl-2-phenylchromen-4-one; ST069348; 4H-1-Benzopyran-4-one,6-methyl-2-phenyl-; AC1Q6AKA; AC1LEN9R; Maybridge3_003437; Cambridge id 5479507; Oprea1_512723; BIDD:ER0442; SCHEMBL4648879; CHEMBL134291; ZINC58123; CTK4G4151; DTXSID40351008; MolPort-000-648-469; NOQJBXPAMJLUSS-UHFFFAOYSA-N; HMS1440M05; HY-N6630; KS-000017TV; SBB012439; 6019AH; AKOS002387497; MCULE-3565329436; CCG-250475; IDI1_014824; NCGC00142612-01; ZB002324; 6-Methylflavone solution, 20 mM in DMSO
DMAXBOU DT Small molecular drug
DMAXBOU PC 689013
DMAXBOU MW 236.26
DMAXBOU FM C16H12O2
DMAXBOU IC InChI=1S/C16H12O2/c1-11-7-8-15-13(9-11)14(17)10-16(18-15)12-5-3-2-4-6-12/h2-10H,1H3
DMAXBOU CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3
DMAXBOU IK NOQJBXPAMJLUSS-UHFFFAOYSA-N
DMAXBOU IU 6-methyl-2-phenylchromen-4-one
DMAXBOU CA CAS 29976-75-8
DMAXBOU DE Discovery agent
DM8KMEG ID DM8KMEG
DM8KMEG DN 6-Methyl-2-p-tolyl-chromen-4-one
DM8KMEG HS Investigative
DM8KMEG SN 88952-74-3; CHEMBL133226; 6-methyl-2-(4-methylphenyl)chromen-4-one; 6-methyl-2-(4-methylphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 6-methyl-2-(4-methylphenyl)-; 6-Methyl-2-p-tolyl-chromen-4-one; ACMC-20lfbb; AC1LFDMB; 4',6-Dimethylflavone; BAS 01121723; Oprea1_016511; Oprea1_052018; SCHEMBL10024074; CTK3A4544; DTXSID70354567; MolPort-000-450-864; ZINC265995; STK888587; AKOS000603226; MCULE-9170697941; NCGC00320777-01; 6-methyl-2-(p-tolyl)-4H-chromen-4-one; ST45177106; AB00086662-03; AB00086662-01
DM8KMEG DT Small molecular drug
DM8KMEG PC 776388
DM8KMEG MW 250.29
DM8KMEG FM C17H14O2
DM8KMEG IC InChI=1S/C17H14O2/c1-11-3-6-13(7-4-11)17-10-15(18)14-9-12(2)5-8-16(14)19-17/h3-10H,1-2H3
DM8KMEG CS CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)C
DM8KMEG IK RDMTVGAVRNFIEE-UHFFFAOYSA-N
DM8KMEG IU 6-methyl-2-(4-methylphenyl)chromen-4-one
DM8KMEG CA CAS 88952-74-3
DM8KMEG DE Discovery agent
DMFMK6Y ID DMFMK6Y
DMFMK6Y DN 6-Methyl-2-pyridin-3-yl-chromen-4-one
DMFMK6Y HS Investigative
DMFMK6Y SN CHEMBL337443
DMFMK6Y DT Small molecular drug
DMFMK6Y PC 10988288
DMFMK6Y MW 237.25
DMFMK6Y FM C15H11NO2
DMFMK6Y IC InChI=1S/C15H11NO2/c1-10-4-5-14-12(7-10)13(17)8-15(18-14)11-3-2-6-16-9-11/h2-9H,1H3
DMFMK6Y CS CC1=CC2=C(C=C1)OC(=CC2=O)C3=CN=CC=C3
DMFMK6Y IK KPZRGUDQIYLPKX-UHFFFAOYSA-N
DMFMK6Y IU 6-methyl-2-pyridin-3-ylchromen-4-one
DMFMK6Y DE Discovery agent
DMOVUP2 ID DMOVUP2
DMOVUP2 DN 6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin
DMOVUP2 HS Investigative
DMOVUP2 SN CHEMBL461382; 6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin
DMOVUP2 DT Small molecular drug
DMOVUP2 PC 44561935
DMOVUP2 MW 348.4
DMOVUP2 FM C21H20N2O3
DMOVUP2 IC InChI=1S/C21H20N2O3/c1-15-7-8-19-17(13-15)18(14-20(24)26-19)22-9-11-23(12-10-22)21(25)16-5-3-2-4-6-16/h2-8,13-14H,9-12H2,1H3
DMOVUP2 CS CC1=CC2=C(C=C1)OC(=O)C=C2N3CCN(CC3)C(=O)C4=CC=CC=C4
DMOVUP2 IK LSXVWZHPJRTGIV-UHFFFAOYSA-N
DMOVUP2 IU 4-(4-benzoylpiperazin-1-yl)-6-methylchromen-2-one
DMOVUP2 DE Discovery agent
DMN0SYW ID DMN0SYW
DMN0SYW DN 6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin
DMN0SYW HS Investigative
DMN0SYW SN CHEMBL509670; 6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin
DMN0SYW DT Small molecular drug
DMN0SYW PC 44561860
DMN0SYW MW 334.4
DMN0SYW FM C21H22N2O2
DMN0SYW IC InChI=1S/C21H22N2O2/c1-15-7-8-20-17(13-15)19(14-21(24)25-20)23-11-9-22(10-12-23)18-6-4-3-5-16(18)2/h3-8,13-14H,9-12H2,1-2H3
DMN0SYW CS CC1=CC2=C(C=C1)OC(=O)C=C2N3CCN(CC3)C4=CC=CC=C4C
DMN0SYW IK WISLSRMHRCKWLA-UHFFFAOYSA-N
DMN0SYW IU 6-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]chromen-2-one
DMN0SYW DE Discovery agent
DMU7E3O ID DMU7E3O
DMU7E3O DN 6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin
DMU7E3O HS Investigative
DMU7E3O SN CHEMBL461305; 6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin
DMU7E3O DT Small molecular drug
DMU7E3O PC 25141417
DMU7E3O MW 320.4
DMU7E3O FM C20H20N2O2
DMU7E3O IC InChI=1S/C20H20N2O2/c1-15-7-8-19-17(13-15)18(14-20(23)24-19)22-11-9-21(10-12-22)16-5-3-2-4-6-16/h2-8,13-14H,9-12H2,1H3
DMU7E3O CS CC1=CC2=C(C=C1)OC(=O)C=C2N3CCN(CC3)C4=CC=CC=C4
DMU7E3O IK FYWXEEJKGHDKBJ-UHFFFAOYSA-N
DMU7E3O IU 6-methyl-4-(4-phenylpiperazin-1-yl)chromen-2-one
DMU7E3O DE Discovery agent
DM1LW62 ID DM1LW62
DM1LW62 DN 6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine
DM1LW62 HS Investigative
DM1LW62 SN CHEMBL596328; 6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine
DM1LW62 DT Small molecular drug
DM1LW62 PC 46228435
DM1LW62 MW 218.26
DM1LW62 FM C11H14N4O
DM1LW62 IC InChI=1S/C11H14N4O/c1-8-6-9-10(13-7-14-11(9)16-8)15-4-2-12-3-5-15/h6-7,12H,2-5H2,1H3
DM1LW62 CS CC1=CC2=C(N=CN=C2O1)N3CCNCC3
DM1LW62 IK MNCCXFCOQHVIEX-UHFFFAOYSA-N
DM1LW62 IU 6-methyl-4-piperazin-1-ylfuro[2,3-d]pyrimidine
DM1LW62 DE Discovery agent
DMO7RPW ID DMO7RPW
DMO7RPW DN 6-Methyl-4-morpholin-4-yl-chromen-2-one
DMO7RPW HS Investigative
DMO7RPW SN CHEMBL361588; 6-methyl-4-morpholin-4-yl-chromen-2-one; 6-Methyl-4-morpholino-coumarin; MolPort-000-485-396; BDBM50159606; ZINC13608106; STK908587; AKOS002216573; MCULE-4100962736; NCGC00327351-01; 6-methyl-4-morpholin-4-ylchromen-2-one; ST096430; AB01322204-02
DMO7RPW DT Small molecular drug
DMO7RPW PC 11075707
DMO7RPW MW 245.27
DMO7RPW FM C14H15NO3
DMO7RPW IC InChI=1S/C14H15NO3/c1-10-2-3-13-11(8-10)12(9-14(16)18-13)15-4-6-17-7-5-15/h2-3,8-9H,4-7H2,1H3
DMO7RPW CS CC1=CC2=C(C=C1)OC(=O)C=C2N3CCOCC3
DMO7RPW IK XWKCKOOKHALUIU-UHFFFAOYSA-N
DMO7RPW IU 6-methyl-4-morpholin-4-ylchromen-2-one
DMO7RPW DE Discovery agent
DMSLT3I ID DMSLT3I
DMSLT3I DN 6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
DMSLT3I HS Investigative
DMSLT3I SN 2-amino-5,6-dihydro-6-methyl-4h-1,3-thiazine; 1121-91-1; 6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine; (+/-)-AMT hydrochloride; 4H-1,3-Thiazin-2-amine, 5,6-dihydro-6-methyl-; AC1L1BOF; Lopac0_000085; SCHEMBL523755; CHEMBL106322; CHEBI:91610; MolPort-009-018-788; BATVOUKHGLKDGQ-UHFFFAOYSA-N; FCH842002; AKOS006274541; CCG-204180; NCGC00024834-02; NCGC00015114-03; NCGC00015114-04; KB-19997; 5,6-dihydro-6-methyl-4h-1,3-thiazin-2-amine; C-41564
DMSLT3I DT Small molecular drug
DMSLT3I PC 1534
DMSLT3I MW 130.21
DMSLT3I FM C5H10N2S
DMSLT3I IC InChI=1S/C5H10N2S/c1-4-2-3-7-5(6)8-4/h4H,2-3H2,1H3,(H2,6,7)
DMSLT3I CS CC1CCN=C(S1)N
DMSLT3I IK BATVOUKHGLKDGQ-UHFFFAOYSA-N
DMSLT3I IU 6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
DMSLT3I CB CHEBI:91610
DMSLT3I DE Discovery agent
DMN6IDK ID DMN6IDK
DMN6IDK DN 6-Methylamino-5-Nitroisocytosine
DMN6IDK HS Investigative
DMN6IDK DT Small molecular drug
DMN6IDK PC 135509070
DMN6IDK MW 185.14
DMN6IDK FM C5H7N5O3
DMN6IDK IC InChI=1S/C5H7N5O3/c1-7-3-2(10(12)13)4(11)9-5(6)8-3/h1H3,(H4,6,7,8,9,11)
DMN6IDK CS CNC1=C(C(=O)NC(=N1)N)[N+](=O)[O-]
DMN6IDK IK NMCMUSAXKISTKW-UHFFFAOYSA-N
DMN6IDK IU 2-amino-4-(methylamino)-5-nitro-1H-pyrimidin-6-one
DMN6IDK DE Discovery agent
DMTG8D0 ID DMTG8D0
DMTG8D0 DN 6'-methylepibatidine
DMTG8D0 HS Investigative
DMTG8D0 SN CHEMBL235261; 6'-methylepibatidine; 6''-methylepibatidine; SCHEMBL6359134
DMTG8D0 DT Small molecular drug
DMTG8D0 PC 9816611
DMTG8D0 MW 222.71
DMTG8D0 FM C12H15ClN2
DMTG8D0 IC InChI=1S/C12H15ClN2/c1-7-9(3-5-12(13)14-7)10-6-8-2-4-11(10)15-8/h3,5,8,10-11,15H,2,4,6H2,1H3
DMTG8D0 CS CC1=C(C=CC(=N1)Cl)C2CC3CCC2N3
DMTG8D0 IK CEIOZCMVGWULLM-UHFFFAOYSA-N
DMTG8D0 IU 2-(6-chloro-2-methylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane
DMTG8D0 DE Discovery agent
DMTNZKU ID DMTNZKU
DMTNZKU DN 6-MORPHOLIN-4-YL-9H-PURINE
DMTNZKU HS Investigative
DMTNZKU SN 2846-96-0; 6-Morpholinopurine; 6-(morpholin-4-yl)-9H-purine; 6-Morpholin-4-Yl-9h-Purine; 4-(1H-Purin-6-yl)morpholine; 4-(9h-purin-6-yl)morpholine; 4-(7H-purin-6-yl)morpholine; SMR000017638; MLS000080575; 2wmu; EINECS 220-645-3; 4-purin-6-ylmorpholine; 6-morpholino-9H-purine; 6-Morpholino-1H-purine; AC1Q4X9J; AC1Q1I5S; Oprea1_261650; Oprea1_519977; MLS000104086; SCHEMBL336612; CHEMBL271138; AC1L2Q64; BDBM33210; CTK4G1553; 9H-Purine,6-(4-morpholinyl)-; DTXSID80182656; MEOMXKNIFWDDGZ-UHFFFAOYSA-N; MolPort-002-610-718; HMS2298A04
DMTNZKU DT Small molecular drug
DMTNZKU PC 76098
DMTNZKU MW 205.22
DMTNZKU FM C9H11N5O
DMTNZKU IC InChI=1S/C9H11N5O/c1-3-15-4-2-14(1)9-7-8(11-5-10-7)12-6-13-9/h5-6H,1-4H2,(H,10,11,12,13)
DMTNZKU CS C1COCCN1C2=NC=NC3=C2NC=N3
DMTNZKU IK MEOMXKNIFWDDGZ-UHFFFAOYSA-N
DMTNZKU IU 4-(7H-purin-6-yl)morpholine
DMTNZKU CA CAS 2846-96-0
DMTNZKU DE Discovery agent
DMHU78R ID DMHU78R
DMHU78R DN 6-m-Tolyl-pteridine-2,4,7-triamine
DMHU78R HS Investigative
DMHU78R SN 6-(3-methylphenyl)pteridine-2,4,7-triamine; 2853-70-5; UNII-Y75RNL3DWL; Y75RNL3DWL; CHEMBL48189; NSC19443; NSC 19443; 6-m-Tolyl-pteridine-2,4,7-triamine; NSC 639358; AC1Q4WBT; AC1L5FLS; CTK4G1672; DTXSID00182754; ZINC1566881; 6-meta-tolylpteridine-2,7-triamine; NSC639358; NSC-19443; BDBM50127144; 6-(m-tolyl)pteridine-2,4,7-triamine
DMHU78R DT Small molecular drug
DMHU78R PC 227595
DMHU78R MW 267.29
DMHU78R FM C13H13N7
DMHU78R IC InChI=1S/C13H13N7/c1-6-3-2-4-7(5-6)8-10(14)18-12-9(17-8)11(15)19-13(16)20-12/h2-5H,1H3,(H6,14,15,16,18,19,20)
DMHU78R CS CC1=CC(=CC=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
DMHU78R IK YCKFHKBIDNIARX-UHFFFAOYSA-N
DMHU78R IU 6-(3-methylphenyl)pteridine-2,4,7-triamine
DMHU78R CA CAS 2853-70-5
DMHU78R DE Discovery agent
DM84CTA ID DM84CTA
DM84CTA DN 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione
DM84CTA HS Investigative
DM84CTA SN 6-nitroquinoxaline-2,3-diol; 1,4-Dihydro-6-nitroquinoxaline-2,3-dione; 6-Nitro-1,4-dihydroquinoxaline-2,3-dione; 6-Nitro-2,3-dihydroxyquinoxaline; 6-Nitro-2,3-quinoxalinediol; 2,3-Dihydroxy-6-nitroquinoxaline; 6-nitro-1,2,3,4-tetrahydroquinoxaline-2,3-dione; RYMLSFWVYNAKAR-UHFFFAOYSA-N; 6-Nitroquinoxaline-2,3(1H,4H)-dione; AC1N1YFP; 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione; AC1Q1Y5W; Oprea1_565337; CHEMBL23044; ACMC-209g63; 6-nitro quinoxaline-2,3-dion; SCHEMBL1259529; SCHEMBL14385403; 6-Nitro-2,3-quinoxalinediol #
DM84CTA DT Small molecular drug
DM84CTA PC 4038142
DM84CTA MW 207.14
DM84CTA FM C8H5N3O4
DM84CTA IC InChI=1S/C8H5N3O4/c12-7-8(13)10-6-3-4(11(14)15)1-2-5(6)9-7/h1-3H,(H,9,12)(H,10,13)
DM84CTA CS C1=CC2=C(C=C1[N+](=O)[O-])NC(=O)C(=O)N2
DM84CTA IK RYMLSFWVYNAKAR-UHFFFAOYSA-N
DM84CTA IU 6-nitro-1,4-dihydroquinoxaline-2,3-dione
DM84CTA DE Discovery agent
DMRCTBA ID DMRCTBA
DMRCTBA DN 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one
DMRCTBA HS Investigative
DMRCTBA SN 6,3'-Dinitroflavone; 3',6-Dinitroflavone; 100914-36-1; 4H-1-Benzopyran-4-one,6-nitro-2-(3-nitrophenyl)-; 6-3'-Dinitroflavone; ACMC-20m3ym; AC1L2SI8; 6-Nitro-2-(3-nitrophenyl)-4H-1-benzopyran-4-one; SCHEMBL4607216; CHEMBL292868; CTK3J9355; DTXSID90143576; AKOS030553659
DMRCTBA DT Small molecular drug
DMRCTBA PC 127714
DMRCTBA MW 312.23
DMRCTBA FM C15H8N2O6
DMRCTBA IC InChI=1S/C15H8N2O6/c18-13-8-15(9-2-1-3-10(6-9)16(19)20)23-14-5-4-11(17(21)22)7-12(13)14/h1-8H
DMRCTBA CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-]
DMRCTBA IK CNVQMRWAJHEFGZ-UHFFFAOYSA-N
DMRCTBA IU 6-nitro-2-(3-nitrophenyl)chromen-4-one
DMRCTBA CA CAS 100914-36-1
DMRCTBA DE Discovery agent
DMM635K ID DMM635K
DMM635K DN 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one
DMM635K HS Investigative
DMM635K SN CHEMBL64704; 158555-11-4; 4',6-Dinitroflavone; 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one; SCHEMBL7538912; CTK0B0325; DTXSID60437292; BDBM50037398; AKOS030553425; 4H-1-Benzopyran-4-one, 6-nitro-2-(4-nitrophenyl)-
DMM635K DT Small molecular drug
DMM635K PC 10244983
DMM635K MW 312.23
DMM635K FM C15H8N2O6
DMM635K IC InChI=1S/C15H8N2O6/c18-13-8-15(9-1-3-10(4-2-9)16(19)20)23-14-6-5-11(17(21)22)7-12(13)14/h1-8H
DMM635K CS C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-])[N+](=O)[O-]
DMM635K IK FPLQIUAPEQSTCP-UHFFFAOYSA-N
DMM635K IU 6-nitro-2-(4-nitrophenyl)chromen-4-one
DMM635K CA CAS 158555-11-4
DMM635K DE Discovery agent
DMZTXDV ID DMZTXDV
DMZTXDV DN 6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole
DMZTXDV HS Investigative
DMZTXDV SN CHEMBL63146
DMZTXDV DT Small molecular drug
DMZTXDV PC 9950054
DMZTXDV MW 345.4
DMZTXDV FM C20H15N3O3
DMZTXDV IC InChI=1S/C20H15N3O3/c24-23(25)15-8-11-18-19(13-15)22-20(21-18)12-14-6-9-17(10-7-14)26-16-4-2-1-3-5-16/h1-11,13H,12H2,(H,21,22)
DMZTXDV CS C1=CC=C(C=C1)OC2=CC=C(C=C2)CC3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-]
DMZTXDV IK VRLHOPLBQZRORF-UHFFFAOYSA-N
DMZTXDV IU 6-nitro-2-[(4-phenoxyphenyl)methyl]-1H-benzimidazole
DMZTXDV DE Discovery agent
DMVLID9 ID DMVLID9
DMVLID9 DN 6-Nitro-2-phenyl-chromen-4-one
DMVLID9 HS Investigative
DMVLID9 SN 6-Nitroflavone; CHEMBL26742
DMVLID9 DT Small molecular drug
DMVLID9 PC 15731470
DMVLID9 MW 267.24
DMVLID9 FM C15H9NO4
DMVLID9 IC InChI=1S/C15H9NO4/c17-13-9-15(10-4-2-1-3-5-10)20-14-7-6-11(16(18)19)8-12(13)14/h1-9H
DMVLID9 CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)[N+](=O)[O-]
DMVLID9 IK ZDFHPVOEUNRYMP-UHFFFAOYSA-N
DMVLID9 IU 6-nitro-2-phenylchromen-4-one
DMVLID9 DE Discovery agent
DMAOUQI ID DMAOUQI
DMAOUQI DN 6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline
DMAOUQI HS Investigative
DMAOUQI SN CHEMBL166870; 6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline; SCHEMBL6365141; BFHGMHUBVIINKT-UHFFFAOYSA-N; BDBM50110583; 2-Piperazino-4-vinyl-6-nitroquinoline
DMAOUQI DT Small molecular drug
DMAOUQI PC 44379685
DMAOUQI MW 284.31
DMAOUQI FM C15H16N4O2
DMAOUQI IC InChI=1S/C15H16N4O2/c1-2-11-9-15(18-7-5-16-6-8-18)17-14-4-3-12(19(20)21)10-13(11)14/h2-4,9-10,16H,1,5-8H2
DMAOUQI CS C=CC1=CC(=NC2=C1C=C(C=C2)[N+](=O)[O-])N3CCNCC3
DMAOUQI IK BFHGMHUBVIINKT-UHFFFAOYSA-N
DMAOUQI IU 4-ethenyl-6-nitro-2-piperazin-1-ylquinoline
DMAOUQI DE Discovery agent
DMCEG6V ID DMCEG6V
DMCEG6V DN 6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline
DMCEG6V HS Investigative
DMCEG6V SN CHEMBL167487; 6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline; BDBM50110575
DMCEG6V DT Small molecular drug
DMCEG6V PC 44379683
DMCEG6V MW 334.4
DMCEG6V FM C19H18N4O2
DMCEG6V IC InChI=1S/C19H18N4O2/c24-23(25)15-6-7-18-17(12-15)16(14-4-2-1-3-5-14)13-19(21-18)22-10-8-20-9-11-22/h1-7,12-13,20H,8-11H2
DMCEG6V CS C1CN(CCN1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=C2)C4=CC=CC=C4
DMCEG6V IK VABDCPDEFUPFHF-UHFFFAOYSA-N
DMCEG6V IU 6-nitro-4-phenyl-2-piperazin-1-ylquinoline
DMCEG6V DE Discovery agent
DMYP7UG ID DMYP7UG
DMYP7UG DN 6-Nitro-benzothiazole-2-sulfonic acid amide
DMYP7UG HS Investigative
DMYP7UG SN CHEMBL186335; 6-nitro-2-benzothiazolesulfonamide; 6-Nitro-benzothiazole-2-sulfonic acid amide; SCHEMBL10347981; VDPWQQORTOWPSP-UHFFFAOYSA-N; 6-nitrobenzothiazole-2-sulfonamide; BDBM50155503
DMYP7UG DT Small molecular drug
DMYP7UG PC 13393427
DMYP7UG MW 259.3
DMYP7UG FM C7H5N3O4S2
DMYP7UG IC InChI=1S/C7H5N3O4S2/c8-16(13,14)7-9-5-2-1-4(10(11)12)3-6(5)15-7/h1-3H,(H2,8,13,14)
DMYP7UG CS C1=CC2=C(C=C1[N+](=O)[O-])SC(=N2)S(=O)(=O)N
DMYP7UG IK VDPWQQORTOWPSP-UHFFFAOYSA-N
DMYP7UG IU 6-nitro-1,3-benzothiazole-2-sulfonamide
DMYP7UG DE Discovery agent
DM2WZCX ID DM2WZCX
DM2WZCX DN 6-Nitroindazole
DM2WZCX HS Investigative
DM2WZCX SN 6-Nitro-1H-indazole; 6-Nitroindazole; 7597-18-4; 6-Nitro-2H-indazole; 6-Nitroisoindazole; 1H-INDAZOLE, 6-NITRO-; 65750-02-9; 2H-Indazole, 6-nitro-; CCRIS 3263; EINECS 231-500-9; NSC 35066; NSC 56816; BRN 0007812; CHEMBL54277; MLS000069593; ORZRMRUXSPNQQL-UHFFFAOYSA-N; SMR000059016; 6NI; 6-nitro-indazol; indazole,6-nitro; Tocris-0710; PubChem20594; Opera_ID_909; 2H-Indazole,6-nitro-; AC1Q1XVW; 6-Nitroindazole, 97%; ACMC-209p0z; AC1L2NB1; AC1Q1Y5L; MLS001148387; KSC379M3P; 5-23-06-00183 (Beilstein Handbook Reference); SCHEMBL271522
DM2WZCX DT Small molecular drug
DM2WZCX PC 24239
DM2WZCX MW 163.13
DM2WZCX FM C7H5N3O2
DM2WZCX IC InChI=1S/C7H5N3O2/c11-10(12)6-2-1-5-4-8-9-7(5)3-6/h1-4H,(H,8,9)
DM2WZCX CS C1=CC2=C(C=C1[N+](=O)[O-])NN=C2
DM2WZCX IK ORZRMRUXSPNQQL-UHFFFAOYSA-N
DM2WZCX IU 6-nitro-1H-indazole
DM2WZCX CA CAS 7597-18-4
DM2WZCX DE Discovery agent
DMXJFCQ ID DMXJFCQ
DMXJFCQ DN 6-n-octylaminouracil
DMXJFCQ HS Investigative
DMXJFCQ SN 6-n-octyl aminouracil
DMXJFCQ DT Small molecular drug
DMXJFCQ PC 10354234
DMXJFCQ MW 239.31
DMXJFCQ FM C12H21N3O2
DMXJFCQ IC InChI=1S/C12H21N3O2/c1-2-3-4-5-6-7-8-13-10-9-11(16)15-12(17)14-10/h9H,2-8H2,1H3,(H3,13,14,15,16,17)
DMXJFCQ CS CCCCCCCCNC1=CC(=O)NC(=O)N1
DMXJFCQ IK PFSWASUQURIOOR-UHFFFAOYSA-N
DMXJFCQ IU 6-(octylamino)-1H-pyrimidine-2,4-dione
DMXJFCQ DE Discovery agent
DMDPA2T ID DMDPA2T
DMDPA2T DN 6-N-propyl -4-trifluoromethylquinolin-2(1H)-one
DMDPA2T HS Investigative
DMDPA2T SN SCHEMBL1771502; CHEMBL405835; BDBM18527; ZINC14968235; 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-one, 4a; 4-(Trifluoromethyl)-6-(propylamino)quinoline-2(1H)-one
DMDPA2T DT Small molecular drug
DMDPA2T PC 9903530
DMDPA2T MW 270.25
DMDPA2T FM C13H13F3N2O
DMDPA2T IC InChI=1S/C13H13F3N2O/c1-2-5-17-8-3-4-11-9(6-8)10(13(14,15)16)7-12(19)18-11/h3-4,6-7,17H,2,5H2,1H3,(H,18,19)
DMDPA2T CS CCCNC1=CC2=C(C=C1)NC(=O)C=C2C(F)(F)F
DMDPA2T IK YGYHGNGCPLCHQH-UHFFFAOYSA-N
DMDPA2T IU 6-(propylamino)-4-(trifluoromethyl)-1H-quinolin-2-one
DMDPA2T DE Discovery agent
DMDIW08 ID DMDIW08
DMDIW08 DN 6-O-Cyclohexylmethyl Guanine
DMDIW08 HS Investigative
DMDIW08 SN 6-(Cyclohexylmethoxy)-9H-purin-2-amine; nu2058; 161058-83-9; 6-(cyclohexylmethoxy)-9H-purin-2-amine; 6-O-CYCLOHEXYLMETHYL GUANINE; 2-amino-6-[(cyclohexylmethyl)oxy]purine; NU 2058; 2-amino-6-cyclohexylmethoxypurine; NU-2058; O6-Cyclohexylmethylguanine; CHEMBL269881; 1e1v; 1h1p; O-Cyclohexylmethylguanine; AC1Q4XUD; 9H-Purin-2-amine, 6-(cyclohexylmethoxy)-; O6-Cyclohexylmethyl guanine; AC1L1IG4; MLS001074898; SCHEMBL3462331; BDBM5485; CTK8D6642; CTK0E6580; EX-A790; AOB6207; MolPort-033-437-778; MolPort-003-958-993; MolPort-044-561-861; HMS3372K06; HMS3262L18; HMS2233F06
DMDIW08 DT Small molecular drug
DMDIW08 PC 4564
DMDIW08 MW 247.3
DMDIW08 FM C12H17N5O
DMDIW08 IC InChI=1S/C12H17N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H3,13,14,15,16,17)
DMDIW08 CS C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)N
DMDIW08 IK MWGXGTJJAOZBNW-UHFFFAOYSA-N
DMDIW08 IU 6-(cyclohexylmethoxy)-7H-purin-2-amine
DMDIW08 DE Discovery agent
DM6YHBR ID DM6YHBR
DM6YHBR DN 6-O-Phosphoryl Inosine Monophosphate
DM6YHBR HS Investigative
DM6YHBR SN 6-o-phosphoryl inosine monophosphate; IMO; AC1L9GY0; SCHEMBL4321566; DB03510; 6-(phosphonooxy)-9-(5-O-phosphono-beta-D-ribofuranosyl)-9H-purine; [9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl] dihydrogen phosphate
DM6YHBR DT Small molecular drug
DM6YHBR PC 444818
DM6YHBR MW 428.19
DM6YHBR FM C10H14N4O11P2
DM6YHBR IC InChI=1S/C10H14N4O11P2/c15-6-4(1-23-26(17,18)19)24-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)25-27(20,21)22/h2-4,6-7,10,15-16H,1H2,(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DM6YHBR CS C1=NC2=C(C(=N1)OP(=O)(O)O)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DM6YHBR IK RXRZOKQPANIEDW-KQYNXXCUSA-N
DM6YHBR IU [9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl] dihydrogen phosphate
DM6YHBR DE Discovery agent
DM4TX9O ID DM4TX9O
DM4TX9O DN 6-o-tolylquinazolin-2-amine
DM4TX9O HS Investigative
DM4TX9O SN 6-o-tolylquinazolin-2-amine; CHEMBL215952; SCHEMBL5494575; RAWAQXBVMDKSIO-UHFFFAOYSA-N; ZINC35049815
DM4TX9O DT Small molecular drug
DM4TX9O PC 16086113
DM4TX9O MW 235.28
DM4TX9O FM C15H13N3
DM4TX9O IC InChI=1S/C15H13N3/c1-10-4-2-3-5-13(10)11-6-7-14-12(8-11)9-17-15(16)18-14/h2-9H,1H3,(H2,16,17,18)
DM4TX9O CS CC1=CC=CC=C1C2=CC3=CN=C(N=C3C=C2)N
DM4TX9O IK RAWAQXBVMDKSIO-UHFFFAOYSA-N
DM4TX9O IU 6-(2-methylphenyl)quinazolin-2-amine
DM4TX9O DE Discovery agent
DMPBE5H ID DMPBE5H
DMPBE5H DN 6-oxo-16-formyl-estrone
DMPBE5H HS Investigative
DMPBE5H SN CHEMBL202432
DMPBE5H DT Small molecular drug
DMPBE5H PC 44407480
DMPBE5H MW 312.4
DMPBE5H FM C19H20O4
DMPBE5H IC InChI=1S/C19H20O4/c1-19-5-4-13-12-3-2-11(21)7-15(12)17(22)8-14(13)16(19)6-10(9-20)18(19)23/h2-3,7,9,13-14,16,20-21H,4-6,8H2,1H3/b10-9-/t13?,14?,16?,19-/m0/s1
DMPBE5H CS C[C@]12CCC3C(C1C/C(=C/O)/C2=O)CC(=O)C4=C3C=CC(=C4)O
DMPBE5H IK ZRLTUTFRAVMGPJ-SSNSBQRSSA-N
DMPBE5H IU (13S,16Z)-3-hydroxy-16-(hydroxymethylidene)-13-methyl-8,9,11,12,14,15-hexahydro-7H-cyclopenta[a]phenanthrene-6,17-dione
DMPBE5H DE Discovery agent
DMKMYAJ ID DMKMYAJ
DMKMYAJ DN 6-oxo-estrone
DMKMYAJ HS Investigative
DMKMYAJ SN 6-Ketoestrone; 1476-34-2; 6-Oxoestrone; 6-Keto Estrone; CHEMBL1628005; 3-Hydroxyestra-1,3,5(10)-triene-6,17-dione; 6-oxo-estrone; Estra-1,3,5(10)-triene-6,17-dione, 3-hydroxy-; SCHEMBL1977286; DTXSID50514400; JOVYPIGRPWIXHQ-ONUSSAAZSA-N; MFCD00056399; BDBM50370698; ZINC13547985; 1,3,5(10)-Estratrien-3-ol-6,17-dione; C-44091; 3-Hydroxyestra-1,3,5(10)-triene-6,17-dione #
DMKMYAJ DT Small molecular drug
DMKMYAJ PC 12985714
DMKMYAJ MW 284.3
DMKMYAJ FM C18H20O3
DMKMYAJ IC InChI=1S/C18H20O3/c1-18-7-6-12-11-3-2-10(19)8-14(11)16(20)9-13(12)15(18)4-5-17(18)21/h2-3,8,12-13,15,19H,4-7,9H2,1H3/t12-,13-,15+,18+/m1/s1
DMKMYAJ CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=O)C4=C3C=CC(=C4)O
DMKMYAJ IK JOVYPIGRPWIXHQ-ONUSSAAZSA-N
DMKMYAJ IU (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-6,17-dione
DMKMYAJ CA CAS 1476-34-2
DMKMYAJ DE Discovery agent
DMVYIN2 ID DMVYIN2
DMVYIN2 DN 6-Phenoxy-hexane-1-thiol
DMVYIN2 HS Investigative
DMVYIN2 SN CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089
DMVYIN2 DT Small molecular drug
DMVYIN2 PC 11298778
DMVYIN2 MW 210.34
DMVYIN2 FM C12H18OS
DMVYIN2 IC InChI=1S/C12H18OS/c14-11-7-2-1-6-10-13-12-8-4-3-5-9-12/h3-5,8-9,14H,1-2,6-7,10-11H2
DMVYIN2 CS C1=CC=C(C=C1)OCCCCCCS
DMVYIN2 IK QUBILGABLBGKPV-UHFFFAOYSA-N
DMVYIN2 IU 6-phenoxyhexane-1-thiol
DMVYIN2 DE Discovery agent
DM3UBR5 ID DM3UBR5
DM3UBR5 DN 6-phenyl-3-(pyridin-4-yl)-1H-indole
DM3UBR5 HS Investigative
DM3UBR5 SN CHEMBL207621; 6-phenyl-3-(pyridin-4-yl)-1H-indole
DM3UBR5 DT Small molecular drug
DM3UBR5 PC 44410733
DM3UBR5 MW 270.3
DM3UBR5 FM C19H14N2
DM3UBR5 IC InChI=1S/C19H14N2/c1-2-4-14(5-3-1)16-6-7-17-18(13-21-19(17)12-16)15-8-10-20-11-9-15/h1-13,21H
DM3UBR5 CS C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=CN3)C4=CC=NC=C4
DM3UBR5 IK QPUYBWAAFGEKSG-UHFFFAOYSA-N
DM3UBR5 IU 6-phenyl-3-pyridin-4-yl-1H-indole
DM3UBR5 DE Discovery agent
DMG6PZT ID DMG6PZT
DMG6PZT DN 6-Phenylaminomethyl-quinazoline-2,4-diamine
DMG6PZT HS Investigative
DMG6PZT SN CHEMBL80746; 6-(anilinomethyl)quinazoline-2,4-diamine; 27133-39-7; AC1LAG5J; 6-Phenylaminomethyl-quinazoline-2,4-diamine; SCHEMBL4788363; CTK0I5781; DTXSID30333156; ZINC3814839; BDBM50101637; [(2,4-Diaminoquinazolin-6-yl)methyl]phenylamine; 2,4-Quinazolinediamine, 6-[(phenylamino)methyl]-
DMG6PZT DT Small molecular drug
DMG6PZT PC 487412
DMG6PZT MW 265.31
DMG6PZT FM C15H15N5
DMG6PZT IC InChI=1S/C15H15N5/c16-14-12-8-10(6-7-13(12)19-15(17)20-14)9-18-11-4-2-1-3-5-11/h1-8,18H,9H2,(H4,16,17,19,20)
DMG6PZT CS C1=CC=C(C=C1)NCC2=CC3=C(C=C2)N=C(N=C3N)N
DMG6PZT IK SQHNSLWKFCXHKZ-UHFFFAOYSA-N
DMG6PZT IU 6-(anilinomethyl)quinazoline-2,4-diamine
DMG6PZT CA CAS 27133-39-7
DMG6PZT DE Discovery agent
DMIKRP6 ID DMIKRP6
DMIKRP6 DN 6-phenylethynyl-nicotinic acid methyl ester
DMIKRP6 HS Investigative
DMIKRP6 SN 6-phenylethynyl-nicotinic acid methyl ester; CHEMBL400735; BDBM50231751; 6-(Phenylethynyl)pyridine-3-carboxylic acid methyl ester
DMIKRP6 DT Small molecular drug
DMIKRP6 PC 14343219
DMIKRP6 MW 237.25
DMIKRP6 FM C15H11NO2
DMIKRP6 IC InChI=1S/C15H11NO2/c1-18-15(17)13-8-10-14(16-11-13)9-7-12-5-3-2-4-6-12/h2-6,8,10-11H,1H3
DMIKRP6 CS COC(=O)C1=CN=C(C=C1)C#CC2=CC=CC=C2
DMIKRP6 IK DRFBUAIOGNADQC-UHFFFAOYSA-N
DMIKRP6 IU methyl 6-(2-phenylethynyl)pyridine-3-carboxylate
DMIKRP6 DE Discovery agent
DMLJN8Z ID DMLJN8Z
DMLJN8Z DN 6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester
DMLJN8Z HS Investigative
DMLJN8Z SN CHEMBL486493; 6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester
DMLJN8Z DT Small molecular drug
DMLJN8Z PC 24881806
DMLJN8Z MW 373.5
DMLJN8Z FM C25H27NO2
DMLJN8Z IC InChI=1S/C25H27NO2/c27-25(26-19-10-2-1-5-12-21-13-6-3-7-14-21)28-24-18-11-17-23(20-24)22-15-8-4-9-16-22/h3-4,6-9,11,13-18,20H,1-2,5,10,12,19H2,(H,26,27)
DMLJN8Z CS C1=CC=C(C=C1)CCCCCCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMLJN8Z IK MGXPWHVQDGCMAC-UHFFFAOYSA-N
DMLJN8Z IU (3-phenylphenyl) N-(6-phenylhexyl)carbamate
DMLJN8Z DE Discovery agent
DMPA534 ID DMPA534
DMPA534 DN 6-Phenylmethanesulfonyl-2H-pyridazin-3-one
DMPA534 HS Investigative
DMPA534 SN 6-Phenylmethanesulfonyl-2H-pyridazin-3-one; 92016-73-4; CHEMBL199028; BDBM16611; Benzyl-Substituted Sulfonylpyridazinone, 15
DMPA534 DT Small molecular drug
DMPA534 PC 23647383
DMPA534 MW 250.28
DMPA534 FM C11H10N2O3S
DMPA534 IC InChI=1S/C11H10N2O3S/c14-10-6-7-11(13-12-10)17(15,16)8-9-4-2-1-3-5-9/h1-7H,8H2,(H,12,14)
DMPA534 CS C1=CC=C(C=C1)CS(=O)(=O)C2=NNC(=O)C=C2
DMPA534 IK QUZYPEPCSQAPEU-UHFFFAOYSA-N
DMPA534 IU 3-benzylsulfonyl-1H-pyridazin-6-one
DMPA534 DE Discovery agent
DMEYOF7 ID DMEYOF7
DMEYOF7 DN 6-Phenyl-naphthalen-2-ol
DMEYOF7 HS Investigative
DMEYOF7 SN 6-phenyl-2-naphthol; 6-Phenylnaphthalene-2-ol; CHEMBL191714; 6-Phenyl-naphthalen-2-ol; SCHEMBL3019399; PZOXFBPKKGTQDZ-UHFFFAOYSA-N; ZINC13644999
DMEYOF7 DT Small molecular drug
DMEYOF7 PC 10125182
DMEYOF7 MW 220.26
DMEYOF7 FM C16H12O
DMEYOF7 IC InChI=1S/C16H12O/c17-16-9-8-14-10-13(6-7-15(14)11-16)12-4-2-1-3-5-12/h1-11,17H
DMEYOF7 CS C1=CC=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)O
DMEYOF7 IK PZOXFBPKKGTQDZ-UHFFFAOYSA-N
DMEYOF7 IU 6-phenylnaphthalen-2-ol
DMEYOF7 DE Discovery agent
DMXTV1B ID DMXTV1B
DMXTV1B DN 6-phenylpyridazin-3-yl thiophene-2-carboxylate
DMXTV1B HS Investigative
DMXTV1B SN CHEMBL1253380; AC1O4BXS; 6-phenylpyridazin-3-yl thiophene-2-carboxylate; MolPort-002-097-410; HMS1597J02; ZINC1059557; BDBM50326574; MCULE-6134548476; (6-phenylpyridazin-3-yl) thiophene-2-carboxylate
DMXTV1B DT Small molecular drug
DMXTV1B PC 6403448
DMXTV1B MW 282.3
DMXTV1B FM C15H10N2O2S
DMXTV1B IC InChI=1S/C15H10N2O2S/c18-15(13-7-4-10-20-13)19-14-9-8-12(16-17-14)11-5-2-1-3-6-11/h1-10H
DMXTV1B CS C1=CC=C(C=C1)C2=NN=C(C=C2)OC(=O)C3=CC=CS3
DMXTV1B IK WIJDBDCYFCOSHK-UHFFFAOYSA-N
DMXTV1B IU (6-phenylpyridazin-3-yl) thiophene-2-carboxylate
DMXTV1B DE Discovery agent
DMZ76NQ ID DMZ76NQ
DMZ76NQ DN 6-Phenylsulfanyl-9H-purine
DMZ76NQ HS Investigative
DMZ76NQ SN Purine, 6-(phenylthio)-; 6-(Phenylthio)purine; 1H-Purine, 6-(phenylthio)-; 5450-35-1; NSC 15746; UNII-3KH11DU8DY; 6-phenylsulfanyl-7H-purine; BRN 0013668; 3KH11DU8DY; AI3-52068; AC1Q4XUH; AC1L3TI0; 4-26-00-01985 (Beilstein Handbook Reference); 9H-Purine,6-(phenylthio)-; SCHEMBL796397; 6-(phenylsulfanyl)-7H-purine; CHEMBL175600; 9H-Purine, 6-(phenylthio)-; CTK5A1336; DTXSID20202908; NSC15746; ZINC13608565; NSC-15746; AKOS030562402
DMZ76NQ DT Small molecular drug
DMZ76NQ PC 95065
DMZ76NQ MW 228.28
DMZ76NQ FM C11H8N4S
DMZ76NQ IC InChI=1S/C11H8N4S/c1-2-4-8(5-3-1)16-11-9-10(13-6-12-9)14-7-15-11/h1-7H,(H,12,13,14,15)
DMZ76NQ CS C1=CC=C(C=C1)SC2=NC=NC3=C2NC=N3
DMZ76NQ IK CTDPZFBZKUUAED-UHFFFAOYSA-N
DMZ76NQ IU 6-phenylsulfanyl-7H-purine
DMZ76NQ CA CAS 5450-35-1
DMZ76NQ DE Discovery agent
DM3OLM6 ID DM3OLM6
DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide
DM3OLM6 HS Investigative
DM3OLM6 SN Hexanamide, N-hydroxy-6-(phenylthio)-; 6-phenylsulfanylhexanoic acid hydroxamide; CHEMBL203028; SCHEMBL7317658
DM3OLM6 DT Small molecular drug
DM3OLM6 PC 11637291
DM3OLM6 MW 239.34
DM3OLM6 FM C12H17NO2S
DM3OLM6 IC InChI=1S/C12H17NO2S/c14-12(13-15)9-5-2-6-10-16-11-7-3-1-4-8-11/h1,3-4,7-8,15H,2,5-6,9-10H2,(H,13,14)
DM3OLM6 CS C1=CC=C(C=C1)SCCCCCC(=O)NO
DM3OLM6 IK RFQHGQGHSXXDPZ-UHFFFAOYSA-N
DM3OLM6 IU N-hydroxy-6-phenylsulfanylhexanamide
DM3OLM6 DE Discovery agent
DM6GWRB ID DM6GWRB
DM6GWRB DN 6-Phenylsulfanylmethyl-pteridine-2,4-diamine
DM6GWRB HS Investigative
DM6GWRB SN NSC232965; 57963-58-3; UNII-D5VU87D2MN; D5VU87D2MN; 2,4-Diamino-6-phenylthiomethyl-pteridine; CHEMBL279243; 6-(phenylsulfanylmethyl)pteridine-2,4-diamine; 2,4-Pteridinediamine, 6-((phenylthio)methyl)-; 2,4-Pteridinediamine, 6-[(phenylthio)methyl]-; NSC 232965; AC1L7PXP; 6-Phenylsulfanylmethyl-pteridine-2,4-diamine; ZINC5088; SCHEMBL11630631; DTXSID30206699; BDBM50049602; NSC-232965; 6-(Phenylthiomethyl)pteridine-2,4-diamine
DM6GWRB DT Small molecular drug
DM6GWRB PC 314604
DM6GWRB MW 284.34
DM6GWRB FM C13H12N6S
DM6GWRB IC InChI=1S/C13H12N6S/c14-11-10-12(19-13(15)18-11)16-6-8(17-10)7-20-9-4-2-1-3-5-9/h1-6H,7H2,(H4,14,15,16,18,19)
DM6GWRB CS C1=CC=C(C=C1)SCC2=CN=C3C(=N2)C(=NC(=N3)N)N
DM6GWRB IK ZJOATKLQTCGUSP-UHFFFAOYSA-N
DM6GWRB IU 6-(phenylsulfanylmethyl)pteridine-2,4-diamine
DM6GWRB CA CAS 57963-58-3
DM6GWRB DE Discovery agent
DME230I ID DME230I
DME230I DN 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine
DME230I HS Investigative
DME230I SN 6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamine; CHEMBL311108; CTK7E1320; ZINC13588156; BDBM50137196; AKOS015965750; 6-phenylthieno[3,2-d]pyrimidin-4-ylamine
DME230I DT Small molecular drug
DME230I PC 11499583
DME230I MW 227.29
DME230I FM C12H9N3S
DME230I IC InChI=1S/C12H9N3S/c13-12-11-9(14-7-15-12)6-10(16-11)8-4-2-1-3-5-8/h1-7H,(H2,13,14,15)
DME230I CS C1=CC=C(C=C1)C2=CC3=C(S2)C(=NC=N3)N
DME230I IK WQVHTLKGGYMXIO-UHFFFAOYSA-N
DME230I IU 6-phenylthieno[3,2-d]pyrimidin-4-amine
DME230I DE Discovery agent
DMB1QCY ID DMB1QCY
DMB1QCY DN 6-Phosphogluconic Acid
DMB1QCY HS Investigative
DMB1QCY SN 6-phosphogluconic acid; 6-Phosphogluconate; 921-62-0; 6-phospho-D-gluconic acid; 6-phospho-D-gluconate; 6-O-phosphono-D-gluconic acid; Gluconic acid-6-phosphate; (2R,3S,4R,5R)-2,3,4,5-Tetrahydroxy-6-(phosphonooxy)hexanoic acid; UNII-W31WK7B8U0; D-Gluconic acid 6-(dihydrogen phosphate); CHEBI:48928; W31WK7B8U0; CHEMBL1230513; BIRSGZKFKXLSJQ-SQOUGZDYSA-N; 1pgp; 6PG; 6-phosphogluconic acid barium salt; C6H13O10P; 6-p-gluconate; EINECS 213-069-9; D-Gluconic acid, 6-(dihydrogen phosphate); bmse000198; AC1Q6RV2; AC1L3M6P; SCHEMBL50297
DMB1QCY DT Small molecular drug
DMB1QCY PC 91493
DMB1QCY MW 276.14
DMB1QCY FM C6H13O10P
DMB1QCY IC InChI=1S/C6H13O10P/c7-2(1-16-17(13,14)15)3(8)4(9)5(10)6(11)12/h2-5,7-10H,1H2,(H,11,12)(H2,13,14,15)/t2-,3-,4+,5-/m1/s1
DMB1QCY CS C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)OP(=O)(O)O
DMB1QCY IK BIRSGZKFKXLSJQ-SQOUGZDYSA-N
DMB1QCY IU (2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-phosphonooxyhexanoic acid
DMB1QCY CA CAS 921-62-0
DMB1QCY CB CHEBI:48928
DMB1QCY DE Discovery agent
DMIAQUC ID DMIAQUC
DMIAQUC DN 6-p-Tolylamino-1H-pyrimidine-2,4-dione
DMIAQUC HS Investigative
DMIAQUC SN CHEMBL57397; 6-p-Tolylamino-1H-pyrimidine-2,4-dione; 6948-11-4; 6-[(4-methylphenyl)amino]pyrimidine-2,4(1h,3h)-dione; NSC55724; AC1Q6LTF; CBMicro_020485; Oprea1_316803; Oprea1_212741; SCHEMBL5298937; AC1L6E57; CTK5D0097; 2,4(1H,3H)-Pyrimidinedione, 6-[(4-methylphenyl)amino]-; MolPort-003-722-204; ZINC227430; CCG-8301; NSC-55724; BDBM50022161; AKOS001620102; MCULE-6764538026; BIM-0020481.P001; EU-0034750; SR-01000400155; SR-01000400155-1
DMIAQUC DT Small molecular drug
DMIAQUC PC 244640
DMIAQUC MW 217.22
DMIAQUC FM C11H11N3O2
DMIAQUC IC InChI=1S/C11H11N3O2/c1-7-2-4-8(5-3-7)12-9-6-10(15)14-11(16)13-9/h2-6H,1H3,(H3,12,13,14,15,16)
DMIAQUC CS CC1=CC=C(C=C1)NC2=CC(=O)NC(=O)N2
DMIAQUC IK QKHUPPJBNXWLJB-UHFFFAOYSA-N
DMIAQUC IU 6-(4-methylanilino)-1H-pyrimidine-2,4-dione
DMIAQUC CA CAS 6948-11-4
DMIAQUC DE Discovery agent
DM86XG5 ID DM86XG5
DM86XG5 DN 6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5 HS Investigative
DM86XG5 SN CHEMBL461458; 6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5 DT Small molecular drug
DM86XG5 PC 25180104
DM86XG5 MW 225.28
DM86XG5 FM C15H15NO
DM86XG5 IC InChI=1S/C15H15NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-4,7-8,10,15,17H,5-6,9H2
DM86XG5 CS C1CC2=C(CC1O)C=CC(=C2)C3=CN=CC=C3
DM86XG5 IK ROYVUWJYYRTBSK-UHFFFAOYSA-N
DM86XG5 IU 6-pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol
DM86XG5 DE Discovery agent
DMG5ABT ID DMG5ABT
DMG5ABT DN 6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one
DMG5ABT HS Investigative
DMG5ABT SN 6-Pyridin-3-yl-3,4-dihydroquinolin-2(1H)-on
DMG5ABT PC 13728862
DMG5ABT MW 224.26
DMG5ABT FM C14H12N2O
DMG5ABT IC InChI=1S/C14H12N2O/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)
DMG5ABT CS C1CC(=O)NC2=C1C=C(C=C2)C3=CN=CC=C3
DMG5ABT IK MPGBYGNPFRLHAO-UHFFFAOYSA-N
DMG5ABT IU 6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one
DMG5ABT CA CAS 99471-41-7
DMG5ABT DE Discovery agent
DMIM5DL ID DMIM5DL
DMIM5DL DN 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one
DMIM5DL HS Investigative
DMIM5DL SN CHEMBL462093; 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one; 2(1H)-Naphthalenone,3,4-dihydro-6-(3-pyridinyl)-; BDBM50273703
DMIM5DL DT Small molecular drug
DMIM5DL PC 25180108
DMIM5DL MW 223.27
DMIM5DL FM C15H13NO
DMIM5DL IC InChI=1S/C15H13NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-4,7-8,10H,5-6,9H2
DMIM5DL CS C1CC2=C(CC1=O)C=CC(=C2)C3=CN=CC=C3
DMIM5DL IK XMIVJNDWTQQRAQ-UHFFFAOYSA-N
DMIM5DL IU 6-pyridin-3-yl-3,4-dihydro-1H-naphthalen-2-one
DMIM5DL DE Discovery agent
DMHAS2B ID DMHAS2B
DMHAS2B DN 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione
DMHAS2B HS Investigative
DMHAS2B SN CHEMBL511329; 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione; SCHEMBL1119425; BBIRVEDVKRWBOZ-UHFFFAOYSA-N; BDBM50273815; ZINC40380214; 6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione
DMHAS2B DT Small molecular drug
DMHAS2B PC 25180300
DMHAS2B MW 240.33
DMHAS2B FM C14H12N2S
DMHAS2B IC InChI=1S/C14H12N2S/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)
DMHAS2B CS C1CC(=S)NC2=C1C=C(C=C2)C3=CN=CC=C3
DMHAS2B IK BBIRVEDVKRWBOZ-UHFFFAOYSA-N
DMHAS2B IU 6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione
DMHAS2B DE Discovery agent
DMGWNDB ID DMGWNDB
DMGWNDB DN 6-Pyridin-3-yl-naphthalen-2-ol
DMGWNDB HS Investigative
DMGWNDB SN 6-pyridin-3-ylnaphthalen-2-ol; CHEMBL195571; SCHEMBL3008490; BDBM8906; Pyridine-substituted naphthalene 3; 6-(pyridin-3-yl)naphthalen-2-ol
DMGWNDB DT Small molecular drug
DMGWNDB PC 11514074
DMGWNDB MW 221.25
DMGWNDB FM C15H11NO
DMGWNDB IC InChI=1S/C15H11NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-10,17H
DMGWNDB CS C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)O
DMGWNDB IK MDXMZUQFVFTPDO-UHFFFAOYSA-N
DMGWNDB IU 6-pyridin-3-ylnaphthalen-2-ol
DMGWNDB DE Discovery agent
DMIA7ND ID DMIA7ND
DMIA7ND DN 6s-5,6,7,8-Tetrahydrobiopterin
DMIA7ND HS Investigative
DMIA7ND DT Small molecular drug
DMIA7ND PC 135509079
DMIA7ND MW 241.25
DMIA7ND FM C9H15N5O3
DMIA7ND IC InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4-,6-/m1/s1
DMIA7ND CS C[C@H]([C@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DMIA7ND IK FNKQXYHWGSIFBK-ZMIZWQJLSA-N
DMIA7ND IU (6R)-2-amino-6-[(1S,2R)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DMIA7ND DE Discovery agent
DMDO13Y ID DMDO13Y
DMDO13Y DN 6-Styryl-naphthalene-2-carboxamidine
DMDO13Y HS Investigative
DMDO13Y SN CHEMBL185345; 6-Styryl-naphthalene-2-carboxamidine; ZINC28365935
DMDO13Y DT Small molecular drug
DMDO13Y PC 21707121
DMDO13Y MW 272.3
DMDO13Y FM C19H16N2
DMDO13Y IC InChI=1S/C19H16N2/c20-19(21)18-11-10-16-12-15(8-9-17(16)13-18)7-6-14-4-2-1-3-5-14/h1-13H,(H3,20,21)/b7-6+
DMDO13Y CS C1=CC=C(C=C1)/C=C/C2=CC3=C(C=C2)C=C(C=C3)C(=N)N
DMDO13Y IK YRAFBVUQILDIDH-VOTSOKGWSA-N
DMDO13Y IU 6-[(E)-2-phenylethenyl]naphthalene-2-carboximidamide
DMDO13Y DE Discovery agent
DMQAG1B ID DMQAG1B
DMQAG1B DN 6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMQAG1B HS Investigative
DMQAG1B SN CHEMBL224827; 6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one
DMQAG1B DT Small molecular drug
DMQAG1B PC 16204165
DMQAG1B MW 253.36
DMQAG1B FM C13H19NO2S
DMQAG1B IC InChI=1S/C13H19NO2S/c1-13(2,3)11-8-10(15)9-12(17-11)14-4-6-16-7-5-14/h8-9H,4-7H2,1-3H3
DMQAG1B CS CC(C)(C)C1=CC(=O)C=C(S1)N2CCOCC2
DMQAG1B IK HCEFXOMYHGQVRM-UHFFFAOYSA-N
DMQAG1B IU 2-tert-butyl-6-morpholin-4-ylthiopyran-4-one
DMQAG1B DE Discovery agent
DM9EA3C ID DM9EA3C
DM9EA3C DN 6-tert-butyl-m-cresol
DM9EA3C HS Investigative
DM9EA3C SN 6-tert-Butyl-m-cresol; 2-tert-Butyl-5-methylphenol; 88-60-8; 6-tert-Butyl-3-methylphenol; 2-(tert-butyl)-5-methylphenol; m-Cresol, 6-tert-butyl-; Phenol, 2-(1,1-dimethylethyl)-5-methyl-; 5-Methyl-2-tert-butylphenol; 3-Methyl-6-tert-butylphenol; UNII-UXV32MJ2CA; 2-tert-butyl-5-methyl-phenol; 6-t-butyl-m-cresol; HSDB 5260; EINECS 201-842-3; NSC 48467; UXV32MJ2CA; 2-t-Butyl-5-methylphenol; BRN 1908225; Benzene, 1-tert-butyl-2-hydroxy-4-methyl-; 2-(1,1-DIMETHYLETHYL)-5-METHYLPHENOL; Phenol, 2-tert-butyl-5-methyl-
DM9EA3C DT Small molecular drug
DM9EA3C PC 6937
DM9EA3C MW 164.24
DM9EA3C FM C11H16O
DM9EA3C IC InChI=1S/C11H16O/c1-8-5-6-9(10(12)7-8)11(2,3)4/h5-7,12H,1-4H3
DM9EA3C CS CC1=CC(=C(C=C1)C(C)(C)C)O
DM9EA3C IK XOUQAVYLRNOXDO-UHFFFAOYSA-N
DM9EA3C IU 2-tert-butyl-5-methylphenol
DM9EA3C CA CAS 88-60-8
DM9EA3C DE Discovery agent
DMVGC7H ID DMVGC7H
DMVGC7H DN 6-Thia-10b-aza-benzo[e]azulen-4-one
DMVGC7H HS Investigative
DMVGC7H SN 80008-53-3; NSC363827; Pyrrolo(2,1-d)(1,5)benzothiazepin-7(6H)-one; pyrrolo[2,1-d][1,5]benzothiazepin-7-one; CHEMBL286138; Pyrrolo[2,1-d][1,5]benzothiazepin-7(6H)-one; NSC 363827; 6-Thia-10b-aza-benzo[e]azulen-4-one; AC1L7OX1; CTK3F0749; DTXSID30230010; ZINC1585392; BDBM50041484
DMVGC7H DT Small molecular drug
DMVGC7H PC 338956
DMVGC7H MW 215.27
DMVGC7H FM C12H9NOS
DMVGC7H IC InChI=1S/C12H9NOS/c14-11-8-15-12-6-2-1-4-10(12)13-7-3-5-9(11)13/h1-7H,8H2
DMVGC7H CS C1C(=O)C2=CC=CN2C3=CC=CC=C3S1
DMVGC7H IK WRMQVQBFXFIZIY-UHFFFAOYSA-N
DMVGC7H IU pyrrolo[2,1-d][1,5]benzothiazepin-7-one
DMVGC7H CA CAS 80008-53-3
DMVGC7H DE Discovery agent
DMC013U ID DMC013U
DMC013U DN 6-Thiophen-2-yl-imidazo[2,1-b]thiazole
DMC013U HS Investigative
DMC013U SN 6-(thiophen-2-yl)imidazo[2,1-b][1,3]thiazole; AC1Q7FWK; AC1N51XV; CHEMBL12113; IFLab2_000013; IFLab1_003798; MolPort-000-476-548; HMS1422M14; ZINC406855; STL115074; CCG-22586; AKOS002232733; MCULE-2716534216; 6-(2-Thienyl)imidazo[2,1-b]thiazole; IDI1_019039; IDI1_009905; imidazo[2,1-b]thiazole,6-(2-thienyl)-; KB-305118; EU-0080970; ST50113084; 6-(2-thienyl)imidazo[2,1-b]1,3-thiazoline; 6-thiophen-2-ylimidazo[2,1-b][1,3]thiazole; SR-01000506671
DMC013U DT Small molecular drug
DMC013U PC 4164759
DMC013U MW 206.3
DMC013U FM C9H6N2S2
DMC013U IC InChI=1S/C9H6N2S2/c1-2-8(12-4-1)7-6-11-3-5-13-9(11)10-7/h1-6H
DMC013U CS C1=CSC(=C1)C2=CN3C=CSC3=N2
DMC013U IK YKINBJCTANWRJC-UHFFFAOYSA-N
DMC013U IU 6-thiophen-2-ylimidazo[2,1-b][1,3]thiazole
DMC013U DE Discovery agent
DM90VJ6 ID DM90VJ6
DM90VJ6 DN 6-Thiophen-3-yl-imidazo[2,1-b]thiazole
DM90VJ6 HS Investigative
DM90VJ6 SN 6-Thiophen-3-yl-imidazo[2,1-b]thiazole; 163851-59-0; CHEMBL273842; AKOS005145119
DM90VJ6 DT Small molecular drug
DM90VJ6 PC 10352957
DM90VJ6 MW 206.3
DM90VJ6 FM C9H6N2S2
DM90VJ6 IC InChI=1S/C9H6N2S2/c1-3-12-6-7(1)8-5-11-2-4-13-9(11)10-8/h1-6H
DM90VJ6 CS C1=CSC=C1C2=CN3C=CSC3=N2
DM90VJ6 IK QNYBFCDYFVERKH-UHFFFAOYSA-N
DM90VJ6 IU 6-thiophen-3-ylimidazo[2,1-b][1,3]thiazole
DM90VJ6 DE Discovery agent
DMVL218 ID DMVL218
DMVL218 DN 6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
DMVL218 HS Investigative
DMVL218 SN CHEMBL479349; 6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole
DMVL218 DT Small molecular drug
DMVL218 PC 44567986
DMVL218 MW 340.4
DMVL218 FM C19H20N2O2S
DMVL218 IC InChI=1S/C19H20N2O2S/c1-14-6-8-15(9-7-14)24(22,23)21-18-5-3-2-4-16(18)17-10-12-20-13-11-19(17)21/h2-9,20H,10-13H2,1H3
DMVL218 CS CC1=CC=C(C=C1)S(=O)(=O)N2C3=C(CCNCC3)C4=CC=CC=C42
DMVL218 IK LXDIYGJJOWTGAR-UHFFFAOYSA-N
DMVL218 IU 6-(4-methylphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-azepino[4,5-b]indole
DMVL218 DE Discovery agent
DM2UTEA ID DM2UTEA
DM2UTEA DN 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
DM2UTEA HS Investigative
DM2UTEA SN CHEMBL224649; Coumarin deriv. 27; BDBM9478; ZINC13586720
DM2UTEA DT Small molecular drug
DM2UTEA PC 11401873
DM2UTEA MW 226.23
DM2UTEA FM C13H10N2O2
DM2UTEA IC InChI=1S/C13H10N2O2/c16-13-4-3-11-2-1-10(7-12(11)17-13)8-15-6-5-14-9-15/h1-7,9H,8H2
DM2UTEA CS C1=CC(=CC2=C1C=CC(=O)O2)CN3C=CN=C3
DM2UTEA IK HXFIMHPPOABVMO-UHFFFAOYSA-N
DM2UTEA IU 7-(imidazol-1-ylmethyl)chromen-2-one
DM2UTEA DE Discovery agent
DMOS4ZQ ID DMOS4ZQ
DMOS4ZQ DN 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one
DMOS4ZQ HS Investigative
DMOS4ZQ SN CHEMBL158984; 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one; ZINC13861991; BDBM50097369; 7-Imidazol-1-ylmethyl-chromen-4-one
DMOS4ZQ DT Small molecular drug
DMOS4ZQ PC 10585323
DMOS4ZQ MW 226.23
DMOS4ZQ FM C13H10N2O2
DMOS4ZQ IC InChI=1S/C13H10N2O2/c16-12-3-6-17-13-7-10(1-2-11(12)13)8-15-5-4-14-9-15/h1-7,9H,8H2
DMOS4ZQ CS C1=CC2=C(C=C1CN3C=CN=C3)OC=CC2=O
DMOS4ZQ IK KLOFOSXNENLIKT-UHFFFAOYSA-N
DMOS4ZQ IU 7-(imidazol-1-ylmethyl)chromen-4-one
DMOS4ZQ DE Discovery agent
DM9ID4T ID DM9ID4T
DM9ID4T DN 7-((1H-imidazol-1-yl)methyl)isoquinoline
DM9ID4T HS Investigative
DM9ID4T SN CHEMBL298720; isoquinoline 56; BDBM10041; ZINC13808228; 7-[(Imidazol-1-yl)methyl]isoquinoline; 7-(1H-imidazol-1-ylmethyl)isoquinoline
DM9ID4T DT Small molecular drug
DM9ID4T PC 10750911
DM9ID4T MW 209.25
DM9ID4T FM C13H11N3
DM9ID4T IC InChI=1S/C13H11N3/c1-2-12-3-4-14-8-13(12)7-11(1)9-16-6-5-15-10-16/h1-8,10H,9H2
DM9ID4T CS C1=CC(=CC2=C1C=CN=C2)CN3C=CN=C3
DM9ID4T IK SIZZGSWTNCSETD-UHFFFAOYSA-N
DM9ID4T IU 7-(imidazol-1-ylmethyl)isoquinoline
DM9ID4T DE Discovery agent
DMRPFNU ID DMRPFNU
DMRPFNU DN 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
DMRPFNU HS Investigative
DMRPFNU SN CHEMBL505550; 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol
DMRPFNU DT Small molecular drug
DMRPFNU PC 44586828
DMRPFNU MW 276.3
DMRPFNU FM C18H16N2O
DMRPFNU IC InChI=1S/C18H16N2O/c1-12(20-7-6-19-11-20)13-2-4-17-14(8-13)9-15-10-16(21)3-5-18(15)17/h2-8,10-12,21H,9H2,1H3
DMRPFNU CS CC(C1=CC2=C(C=C1)C3=C(C2)C=C(C=C3)O)N4C=CN=C4
DMRPFNU IK LVWQDZJSHTWZHR-UHFFFAOYSA-N
DMRPFNU IU 7-(1-imidazol-1-ylethyl)-9H-fluoren-2-ol
DMRPFNU DE Discovery agent
DMOZV9W ID DMOZV9W
DMOZV9W DN 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide
DMOZV9W HS Investigative
DMOZV9W SN CHEMBL426516; 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide
DMOZV9W DT Small molecular drug
DMOZV9W PC 44418145
DMOZV9W MW 276.33
DMOZV9W FM C15H20N2O3
DMOZV9W IC InChI=1S/C15H20N2O3/c18-15(17-19)5-3-1-2-4-10-20-13-6-7-14-12(11-13)8-9-16-14/h6-9,11,16,19H,1-5,10H2,(H,17,18)
DMOZV9W CS C1=CC2=C(C=CN2)C=C1OCCCCCCC(=O)NO
DMOZV9W IK YJOHRQFBXILUHS-UHFFFAOYSA-N
DMOZV9W IU N-hydroxy-7-(1H-indol-5-yloxy)heptanamide
DMOZV9W DE Discovery agent
DM4HUO1 ID DM4HUO1
DM4HUO1 DN 7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one
DM4HUO1 HS Investigative
DM4HUO1 SN Coumarin deriv. 29; CHEMBL390152; BDBM9480
DM4HUO1 DT Small molecular drug
DM4HUO1 PC 11230598
DM4HUO1 MW 256.26
DM4HUO1 FM C14H12N2O3
DM4HUO1 IC InChI=1S/C14H12N2O3/c17-14-4-2-11-1-3-12(9-13(11)19-14)18-8-7-16-6-5-15-10-16/h1-6,9-10H,7-8H2
DM4HUO1 CS C1=CC(=CC2=C1C=CC(=O)O2)OCCN3C=CN=C3
DM4HUO1 IK JUOCDQIZOPYANC-UHFFFAOYSA-N
DM4HUO1 IU 7-(2-imidazol-1-ylethoxy)chromen-2-one
DM4HUO1 DE Discovery agent
DMPV674 ID DMPV674
DMPV674 DN 7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one
DMPV674 HS Investigative
DMPV674 SN CHEMBL17357; 108773-04-2; 7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one; SCHEMBL4740762; 2(3H)-BENZOTHIAZOLONE,7-(2-AMINOETHYL)-4-HYDROXY-; ZINC26894070; BDBM50020679; AKOS027394867; KB-293910; 7-(2-Aminoethyl)-1,3-benzothiazole-2,4-diol; 2(3H)-Benzothiazolone, 7-(2-aminoethyl)-4-hydroxy-
DMPV674 DT Small molecular drug
DMPV674 PC 10856744
DMPV674 MW 210.26
DMPV674 FM C9H10N2O2S
DMPV674 IC InChI=1S/C9H10N2O2S/c10-4-3-5-1-2-6(12)7-8(5)14-9(13)11-7/h1-2,12H,3-4,10H2,(H,11,13)
DMPV674 CS C1=CC(=C2C(=C1CCN)SC(=O)N2)O
DMPV674 IK YPLJLRNXOFWVTL-UHFFFAOYSA-N
DMPV674 IU 7-(2-aminoethyl)-4-hydroxy-3H-1,3-benzothiazol-2-one
DMPV674 DE Discovery agent
DMWXGLE ID DMWXGLE
DMWXGLE DN 7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one
DMWXGLE HS Investigative
DMWXGLE SN CHEMBL418548; 7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one; SCHEMBL10986865
DMWXGLE DT Small molecular drug
DMWXGLE PC 13814264
DMWXGLE MW 278.4
DMWXGLE FM C15H22N2OS
DMWXGLE IC InChI=1S/C15H22N2OS/c1-3-9-17(10-4-2)11-8-12-6-5-7-13-14(12)19-15(18)16-13/h5-7H,3-4,8-11H2,1-2H3,(H,16,18)
DMWXGLE CS CCCN(CCC)CCC1=C2C(=CC=C1)NC(=O)S2
DMWXGLE IK ZAHKGALZXMOXJH-UHFFFAOYSA-N
DMWXGLE IU 7-[2-(dipropylamino)ethyl]-3H-1,3-benzothiazol-2-one
DMWXGLE DE Discovery agent
DMBIY98 ID DMBIY98
DMBIY98 DN 7-(2-Hydroxyethyl)-3-O-rhamnosylicariin
DMBIY98 HS Investigative
DMBIY98 SN CHEMBL504656; 7-(2-Hydroxyethyl)-3-O-rhamnosylicariin
DMBIY98 DT Small molecular drug
DMBIY98 PC 44587253
DMBIY98 MW 558.6
DMBIY98 FM C29H34O11
DMBIY98 IC InChI=1S/C29H34O11/c1-14(2)5-10-18-20(37-12-11-30)13-19(31)21-23(33)28(40-29-25(35)24(34)22(32)15(3)38-29)26(39-27(18)21)16-6-8-17(36-4)9-7-16/h5-9,13,15,22,24-25,29-32,34-35H,10-12H2,1-4H3/t15-,22-,24+,25+,29+/m1/s1
DMBIY98 CS C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OCCO)O)C4=CC=C(C=C4)OC)O)O)O
DMBIY98 IK MMEHTVTVEQHORK-NXPCAARESA-N
DMBIY98 IU 5-hydroxy-7-(2-hydroxyethoxy)-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMBIY98 DE Discovery agent
DMO8DYW ID DMO8DYW
DMO8DYW DN 7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW HS Investigative
DMO8DYW SN CHEMBL231991; 7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW DT Small molecular drug
DMO8DYW PC 44432672
DMO8DYW MW 249.31
DMO8DYW FM C17H15NO
DMO8DYW IC InChI=1S/C17H15NO/c1-12-7-8-13-9-10-14(11-16(13)18-12)15-5-3-4-6-17(15)19-2/h3-11H,1-2H3
DMO8DYW CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC=C3OC
DMO8DYW IK JLXDREZJLZGNTK-UHFFFAOYSA-N
DMO8DYW IU 7-(2-methoxyphenyl)-2-methylquinoline
DMO8DYW DE Discovery agent
DMK28IS ID DMK28IS
DMK28IS DN 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine
DMK28IS HS Investigative
DMK28IS SN CHEMBL315194; 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine; SCHEMBL6980573; BDBM50104649
DMK28IS DT Small molecular drug
DMK28IS PC 10375155
DMK28IS MW 185.22
DMK28IS FM C8H15N3O2
DMK28IS IC InChI=1S/C8H15N3O2/c9-8-4-2-1-3-7(10-8)5-6-11(12)13/h7H,1-6H2,(H2,9,10)
DMK28IS CS C1CCC(=NC(C1)CC[N+](=O)[O-])N
DMK28IS IK ILALABPIKINZAM-UHFFFAOYSA-N
DMK28IS IU 2-(2-nitroethyl)-3,4,5,6-tetrahydro-2H-azepin-7-amine
DMK28IS DE Discovery agent
DMYNLOI ID DMYNLOI
DMYNLOI DN 7-(3-(methoxymethyl)phenyl)-2-methylquinoline
DMYNLOI HS Investigative
DMYNLOI SN CHEMBL231985; 7-(3-(methoxymethyl)phenyl)-2-methylquinoline
DMYNLOI DT Small molecular drug
DMYNLOI PC 44432664
DMYNLOI MW 263.3
DMYNLOI FM C18H17NO
DMYNLOI IC InChI=1S/C18H17NO/c1-13-6-7-15-8-9-17(11-18(15)19-13)16-5-3-4-14(10-16)12-20-2/h3-11H,12H2,1-2H3
DMYNLOI CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=CC(=C3)COC
DMYNLOI IK JADKCVGREWVUKV-UHFFFAOYSA-N
DMYNLOI IU 7-[3-(methoxymethyl)phenyl]-2-methylquinoline
DMYNLOI DE Discovery agent
DM9BS5L ID DM9BS5L
DM9BS5L DN 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L HS Investigative
DM9BS5L SN CHEMBL392209; 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L DT Small molecular drug
DM9BS5L PC 44438240
DM9BS5L MW 268.26
DM9BS5L FM C16H12O4
DM9BS5L IC InChI=1S/C16H12O4/c17-12-4-11(5-13(18)7-12)9-1-2-10-3-14(19)8-16(20)15(10)6-9/h1-8,17-20H
DM9BS5L CS C1=CC(=CC2=C(C=C(C=C21)O)O)C3=CC(=CC(=C3)O)O
DM9BS5L IK VMEOGCASIHYHCW-UHFFFAOYSA-N
DM9BS5L IU 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol
DM9BS5L DE Discovery agent
DM2RFOB ID DM2RFOB
DM2RFOB DN 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine
DM2RFOB HS Investigative
DM2RFOB SN CHEMBL236262; 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine; MLS002402797; HMS3344J20; HMS2201J14; BDBM50224927
DM2RFOB DT Small molecular drug
DM2RFOB PC 44142284
DM2RFOB MW 266.29
DM2RFOB FM C16H14N2O2
DM2RFOB IC InChI=1S/C16H14N2O2/c1-19-13-6-12(7-14(8-13)20-2)16-9-15-11(10-18-16)4-3-5-17-15/h3-10H,1-2H3
DM2RFOB CS COC1=CC(=CC(=C1)C2=NC=C3C=CC=NC3=C2)OC
DM2RFOB IK HVIBISIIVPOREN-UHFFFAOYSA-N
DM2RFOB IU 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine
DM2RFOB DE Discovery agent
DMNQW2B ID DMNQW2B
DMNQW2B DN 7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline
DMNQW2B HS Investigative
DMNQW2B SN CHEMBL591242; 7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline
DMNQW2B DT Small molecular drug
DMNQW2B PC 46229111
DMNQW2B MW 508.7
DMNQW2B FM C26H44N4O6
DMNQW2B IC InChI=1S/C26H44N4O6/c1-4-5-6-7-8-9-10-11-12-14-33-16-18-35-20-21-36-19-17-34-15-13-30-22-27-24-23(30)25(31)29(3)26(32)28(24)2/h4,22H,1,5-21H2,2-3H3
DMNQW2B CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOCCOCCOCCOCCCCCCCCCC=C
DMNQW2B IK VWEZUVSKUQSAQQ-UHFFFAOYSA-N
DMNQW2B IU 1,3-dimethyl-7-[2-[2-[2-(2-undec-10-enoxyethoxy)ethoxy]ethoxy]ethyl]purine-2,6-dione
DMNQW2B DE Discovery agent
DMCFV0X ID DMCFV0X
DMCFV0X DN 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide
DMCFV0X HS Investigative
DMCFV0X SN CHEMBL1083440; 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide; SCHEMBL4922807
DMCFV0X DT Small molecular drug
DMCFV0X PC 11426781
DMCFV0X MW 307.34
DMCFV0X FM C15H21N3O4
DMCFV0X IC InChI=1S/C15H21N3O4/c19-13(18-22)10-6-1-2-7-11-16-15(21)17-14(20)12-8-4-3-5-9-12/h3-5,8-9,22H,1-2,6-7,10-11H2,(H,18,19)(H2,16,17,20,21)
DMCFV0X CS C1=CC=C(C=C1)C(=O)NC(=O)NCCCCCCC(=O)NO
DMCFV0X IK XEBCJLKRZJZBNT-UHFFFAOYSA-N
DMCFV0X IU N-[[7-(hydroxyamino)-7-oxoheptyl]carbamoyl]benzamide
DMCFV0X DE Discovery agent
DM762G3 ID DM762G3
DM762G3 DN 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin
DM762G3 HS Investigative
DM762G3 SN 7-[(3-Chlorobenzyl)oxy]-2-Oxo-2h-Chromene-4-Carbaldehyde; C17; CHEMBL239508; BDBM19189; DB07512; 7-(3-Chlorobenzyloxy)-4-carboxaldehyde-coumarin, 3; 7-[(3-chlorophenyl)methoxy]-2-oxochromene-4-carbaldehyde
DM762G3 DT Small molecular drug
DM762G3 PC 16750123
DM762G3 MW 314.7
DM762G3 FM C17H11ClO4
DM762G3 IC InChI=1S/C17H11ClO4/c18-13-3-1-2-11(6-13)10-21-14-4-5-15-12(9-19)7-17(20)22-16(15)8-14/h1-9H,10H2
DM762G3 CS C1=CC(=CC(=C1)Cl)COC2=CC3=C(C=C2)C(=CC(=O)O3)C=O
DM762G3 IK ZOCADHRNWNJARU-UHFFFAOYSA-N
DM762G3 IU 7-[(3-chlorophenyl)methoxy]-2-oxochromene-4-carbaldehyde
DM762G3 DE Discovery agent
DM0Q56N ID DM0Q56N
DM0Q56N DN 7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N HS Investigative
DM0Q56N SN CHEMBL231987; 7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N DT Small molecular drug
DM0Q56N PC 44432666
DM0Q56N MW 253.72
DM0Q56N FM C16H12ClN
DM0Q56N IC InChI=1S/C16H12ClN/c1-11-5-6-12-7-8-14(10-16(12)18-11)13-3-2-4-15(17)9-13/h2-10H,1H3
DM0Q56N CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)Cl
DM0Q56N IK HNAVWOSKROEPOM-UHFFFAOYSA-N
DM0Q56N IU 7-(3-chlorophenyl)-2-methylquinoline
DM0Q56N DE Discovery agent
DME2VD7 ID DME2VD7
DME2VD7 DN 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7 HS Investigative
DME2VD7 SN CHEMBL238389; 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7 DT Small molecular drug
DME2VD7 PC 44434723
DME2VD7 MW 238.26
DME2VD7 FM C15H11FN2
DME2VD7 IC InChI=1S/C15H11FN2/c1-10-5-12(7-13(16)6-10)15-8-14-11(9-18-15)3-2-4-17-14/h2-9H,1H3
DME2VD7 CS CC1=CC(=CC(=C1)F)C2=NC=C3C=CC=NC3=C2
DME2VD7 IK ZJIGDEYNCCHRKX-UHFFFAOYSA-N
DME2VD7 IU 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine
DME2VD7 DE Discovery agent
DMDXOBH ID DMDXOBH
DMDXOBH DN 7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH HS Investigative
DMDXOBH SN CHEMBL231764; 7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH DT Small molecular drug
DMDXOBH PC 44432661
DMDXOBH MW 237.27
DMDXOBH FM C16H12FN
DMDXOBH IC InChI=1S/C16H12FN/c1-11-5-6-12-7-8-14(10-16(12)18-11)13-3-2-4-15(17)9-13/h2-10H,1H3
DMDXOBH CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)F
DMDXOBH IK BBNRSYMDJKFBOU-UHFFFAOYSA-N
DMDXOBH IU 7-(3-fluorophenyl)-2-methylquinoline
DMDXOBH DE Discovery agent
DM2I91C ID DM2I91C
DM2I91C DN 7-(3-Hydroxy-phenyl)-naphthalen-2-ol
DM2I91C HS Investigative
DM2I91C SN 7-(3-hydroxyphenyl)-2-naphthol
DM2I91C PC 10171410
DM2I91C MW 236.26
DM2I91C FM C16H12O2
DM2I91C IC InChI=1S/C16H12O2/c17-15-3-1-2-12(9-15)13-5-4-11-6-7-16(18)10-14(11)8-13/h1-10,17-18H
DM2I91C CS C1=CC(=CC(=C1)O)C2=CC3=C(C=C2)C=CC(=C3)O
DM2I91C IK VEQWNMMVQWDERW-UHFFFAOYSA-N
DM2I91C IU 7-(3-hydroxyphenyl)naphthalen-2-ol
DM2I91C DE Discovery agent
DMEC9YK ID DMEC9YK
DMEC9YK DN 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK HS Investigative
DMEC9YK SN CHEMBL238139; 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK DT Small molecular drug
DMEC9YK PC 44434751
DMEC9YK MW 250.29
DMEC9YK FM C16H14N2O
DMEC9YK IC InChI=1S/C16H14N2O/c1-11-6-7-13-10-17-15(9-16(13)18-11)12-4-3-5-14(8-12)19-2/h3-10H,1-2H3
DMEC9YK CS CC1=NC2=CC(=NC=C2C=C1)C3=CC(=CC=C3)OC
DMEC9YK IK FNFGNQRSMXJCIJ-UHFFFAOYSA-N
DMEC9YK IU 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine
DMEC9YK DE Discovery agent
DMW6LCH ID DMW6LCH
DMW6LCH DN 7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH HS Investigative
DMW6LCH SN CHEMBL394876; 7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH DT Small molecular drug
DMW6LCH PC 44432660
DMW6LCH MW 249.31
DMW6LCH FM C17H15NO
DMW6LCH IC InChI=1S/C17H15NO/c1-12-6-7-13-8-9-15(11-17(13)18-12)14-4-3-5-16(10-14)19-2/h3-11H,1-2H3
DMW6LCH CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC(=CC=C3)OC
DMW6LCH IK JQAHRDJGLFSZFY-UHFFFAOYSA-N
DMW6LCH IU 7-(3-methoxyphenyl)-2-methylquinoline
DMW6LCH DE Discovery agent
DM2TNCK ID DM2TNCK
DM2TNCK DN 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide
DM2TNCK HS Investigative
DM2TNCK SN CHEMBL265479; 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide
DM2TNCK DT Small molecular drug
DM2TNCK PC 44418155
DM2TNCK MW 280.36
DM2TNCK FM C15H24N2O3
DM2TNCK IC InChI=1S/C15H24N2O3/c1-17(2)13-8-10-14(11-9-13)20-12-6-4-3-5-7-15(18)16-19/h8-11,19H,3-7,12H2,1-2H3,(H,16,18)
DM2TNCK CS CN(C)C1=CC=C(C=C1)OCCCCCCC(=O)NO
DM2TNCK IK UVUVYSYWSTVIBF-UHFFFAOYSA-N
DM2TNCK IU 7-[4-(dimethylamino)phenoxy]-N-hydroxyheptanamide
DM2TNCK DE Discovery agent
DMHXMY5 ID DMHXMY5
DMHXMY5 DN 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5 HS Investigative
DMHXMY5 SN CHEMBL245235; 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5 DT Small molecular drug
DMHXMY5 PC 44427383
DMHXMY5 MW 281.31
DMHXMY5 FM C16H15N3O2
DMHXMY5 IC InChI=1S/C16H15N3O2/c1-10-4-5-11-6-7-12(8-13(11)17-10)16-18-14(20-2)9-15(19-16)21-3/h4-9H,1-3H3
DMHXMY5 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=NC(=CC(=N3)OC)OC
DMHXMY5 IK BWVPGOLPFZULHO-UHFFFAOYSA-N
DMHXMY5 IU 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline
DMHXMY5 DE Discovery agent
DMQFBTW ID DMQFBTW
DMQFBTW DN 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW HS Investigative
DMQFBTW SN CHEMBL245236; 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW DT Small molecular drug
DMQFBTW PC 44427384
DMQFBTW MW 249.31
DMQFBTW FM C16H15N3
DMQFBTW IC InChI=1S/C16H15N3/c1-10-4-5-13-6-7-14(9-15(13)17-10)16-18-11(2)8-12(3)19-16/h4-9H,1-3H3
DMQFBTW CS CC1=NC2=C(C=C1)C=CC(=C2)C3=NC(=CC(=N3)C)C
DMQFBTW IK QOOQRVAAEYZPDS-UHFFFAOYSA-N
DMQFBTW IU 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline
DMQFBTW DE Discovery agent
DMM9IXB ID DMM9IXB
DMM9IXB DN 7-(4-Hydroxy-phenyl)-naphthalen-2-ol
DMM9IXB HS Investigative
DMM9IXB SN CHEMBL191715; 7-(4-Hydroxyphenyl)-2-naphthol; 7-(4-Hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3932603; NSCZTZNRMFWAIY-UHFFFAOYSA-N; ZINC13645002; BDBM50168330
DMM9IXB DT Small molecular drug
DMM9IXB PC 10171409
DMM9IXB MW 236.26
DMM9IXB FM C16H12O2
DMM9IXB IC InChI=1S/C16H12O2/c17-15-6-3-11(4-7-15)13-2-1-12-5-8-16(18)10-14(12)9-13/h1-10,17-18H
DMM9IXB CS C1=CC(=CC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O
DMM9IXB IK NSCZTZNRMFWAIY-UHFFFAOYSA-N
DMM9IXB IU 7-(4-hydroxyphenyl)naphthalen-2-ol
DMM9IXB DE Discovery agent
DMBT1KS ID DMBT1KS
DMBT1KS DN 7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS HS Investigative
DMBT1KS SN CHEMBL396134; 7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS DT Small molecular drug
DMBT1KS PC 44432673
DMBT1KS MW 249.31
DMBT1KS FM C17H15NO
DMBT1KS IC InChI=1S/C17H15NO/c1-12-3-4-14-5-6-15(11-17(14)18-12)13-7-9-16(19-2)10-8-13/h3-11H,1-2H3
DMBT1KS CS CC1=NC2=C(C=C1)C=CC(=C2)C3=CC=C(C=C3)OC
DMBT1KS IK NCNHXSMXZZAGHM-UHFFFAOYSA-N
DMBT1KS IU 7-(4-methoxyphenyl)-2-methylquinoline
DMBT1KS DE Discovery agent
DMLIYUJ ID DMLIYUJ
DMLIYUJ DN 7-(4-methoxyphenyl)pteridine-2,4-diol
DMLIYUJ HS Investigative
DMLIYUJ SN CHEMBL511249; AC1NTQMH; 7-(4-methoxyphenyl)pteridine-2,4-diol; 7-(4-methoxyphenyl)-2,4-pteridinediol; 7-(4-methoxyphenyl)-1H-pteridine-2,4-dione; SCHEMBL13401704; MolPort-002-799-584; ZINC6493631; BDBM50262040; MCULE-1306601038
DMLIYUJ DT Small molecular drug
DMLIYUJ PC 5409710
DMLIYUJ MW 270.24
DMLIYUJ FM C13H10N4O3
DMLIYUJ IC InChI=1S/C13H10N4O3/c1-20-8-4-2-7(3-5-8)9-6-14-10-11(15-9)16-13(19)17-12(10)18/h2-6H,1H3,(H2,15,16,17,18,19)
DMLIYUJ CS COC1=CC=C(C=C1)C2=CN=C3C(=N2)NC(=O)NC3=O
DMLIYUJ IK LQVUFGDEIPMWPT-UHFFFAOYSA-N
DMLIYUJ IU 7-(4-methoxyphenyl)-1H-pteridine-2,4-dione
DMLIYUJ DE Discovery agent
DMSRKF0 ID DMSRKF0
DMSRKF0 DN 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0 HS Investigative
DMSRKF0 SN CHEMBL395327; 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0 DT Small molecular drug
DMSRKF0 PC 44427382
DMSRKF0 MW 251.28
DMSRKF0 FM C15H13N3O
DMSRKF0 IC InChI=1S/C15H13N3O/c1-10-3-4-11-5-6-12(9-13(11)17-10)15-16-8-7-14(18-15)19-2/h3-9H,1-2H3
DMSRKF0 CS CC1=NC2=C(C=C1)C=CC(=C2)C3=NC=CC(=N3)OC
DMSRKF0 IK RMLLQYDXXOIJNH-UHFFFAOYSA-N
DMSRKF0 IU 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline
DMSRKF0 DE Discovery agent
DMTKFPW ID DMTKFPW
DMTKFPW DN 7-(benzyloxy)-2H-chromen-2-one
DMTKFPW HS Investigative
DMTKFPW SN 7-(benzyloxy)-2H-chromen-2-one; 7-BENZYLOXYCOUMARIN; CHEMBL145781; 31005-04-6; 7-phenylmethoxychromen-2-one; AC1LIRVN; AC1Q6HKT; 7-benzyloxychromen-2-one; ChemDiv3_006648; Oprea1_123644; MLS001198544; CM16; SCHEMBL3901170; BEN294; 7-(phenylmethoxy)chromen-2-one; CTK1C0068; DTXSID30358687; QDLFCBKKECTJSK-UHFFFAOYSA-N; MolPort-001-573-426; ZINC493069; HMS2864P20; HMS1491O04; CCG-25276; STK373844; BDBM50378564; AKOS001064953; MCULE-8905496403; IDI1_024558; SMR000558913; ST50429120; 2H-1-Benzopyran-2-one, 7-(phenylmethoxy)
DMTKFPW DT Small molecular drug
DMTKFPW PC 910172
DMTKFPW MW 252.26
DMTKFPW FM C16H12O3
DMTKFPW IC InChI=1S/C16H12O3/c17-16-9-7-13-6-8-14(10-15(13)19-16)18-11-12-4-2-1-3-5-12/h1-10H,11H2
DMTKFPW CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)C=CC(=O)O3
DMTKFPW IK QDLFCBKKECTJSK-UHFFFAOYSA-N
DMTKFPW IU 7-phenylmethoxychromen-2-one
DMTKFPW CA CAS 31005-04-6
DMTKFPW DE Discovery agent
DMLCGSY ID DMLCGSY
DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one
DMLCGSY HS Investigative
DMLCGSY SN CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone
DMLCGSY DT Small molecular drug
DMLCGSY PC 44350718
DMLCGSY MW 349.4
DMLCGSY FM C22H23NO3
DMLCGSY IC InChI=1S/C22H23NO3/c24-21(22-23-14-16-26-22)13-6-1-2-7-15-25-20-12-8-11-19(17-20)18-9-4-3-5-10-18/h3-5,8-12,14,16-17H,1-2,6-7,13,15H2
DMLCGSY CS C1=CC=C(C=C1)C2=CC(=CC=C2)OCCCCCCC(=O)C3=NC=CO3
DMLCGSY IK HWZHDGRMABBYOV-UHFFFAOYSA-N
DMLCGSY IU 1-(1,3-oxazol-2-yl)-7-(3-phenylphenoxy)heptan-1-one
DMLCGSY DE Discovery agent
DM28GZ7 ID DM28GZ7
DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one
DM28GZ7 HS Investigative
DM28GZ7 SN CHEMBL326529; SCHEMBL7365237; BDBM50217957
DM28GZ7 DT Small molecular drug
DM28GZ7 PC 44342825
DM28GZ7 MW 336.3
DM28GZ7 FM C19H19F3O2
DM28GZ7 IC InChI=1S/C19H19F3O2/c20-19(21,22)18(23)9-5-2-6-14-24-17-12-10-16(11-13-17)15-7-3-1-4-8-15/h1,3-4,7-8,10-13H,2,5-6,9,14H2
DM28GZ7 CS C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCC(=O)C(F)(F)F
DM28GZ7 IK JQEVPQYABGWLCL-UHFFFAOYSA-N
DM28GZ7 IU 1,1,1-trifluoro-7-(4-phenylphenoxy)heptan-2-one
DM28GZ7 DE Discovery agent
DMY027P ID DMY027P
DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one
DMY027P HS Investigative
DMY027P SN CHEMBL126355; BDBM50222394
DMY027P DT Small molecular drug
DMY027P PC 44350626
DMY027P MW 349.4
DMY027P FM C22H23NO3
DMY027P IC InChI=1S/C22H23NO3/c24-21(22-23-15-17-26-22)10-6-1-2-7-16-25-20-13-11-19(12-14-20)18-8-4-3-5-9-18/h3-5,8-9,11-15,17H,1-2,6-7,10,16H2
DMY027P CS C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)C3=NC=CO3
DMY027P IK ASDDHZUEOBVPNO-UHFFFAOYSA-N
DMY027P IU 1-(1,3-oxazol-2-yl)-7-(4-phenylphenoxy)heptan-1-one
DMY027P DE Discovery agent
DMO4YLA ID DMO4YLA
DMO4YLA DN 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide
DMO4YLA HS Investigative
DMO4YLA SN CHEMBL114184; SCHEMBL3383144
DMO4YLA DT Small molecular drug
DMO4YLA PC 22915465
DMO4YLA MW 313.4
DMO4YLA FM C19H23NO3
DMO4YLA IC InChI=1S/C19H23NO3/c21-19(20-22)10-6-1-2-7-15-23-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14,22H,1-2,6-7,10,15H2,(H,20,21)
DMO4YLA CS C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)NO
DMO4YLA IK KASXKFPWIZYBSG-UHFFFAOYSA-N
DMO4YLA IU N-hydroxy-7-(4-phenylphenoxy)heptanamide
DMO4YLA DE Discovery agent
DMU74R8 ID DMU74R8
DMU74R8 DN 7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine
DMU74R8 HS Investigative
DMU74R8 SN CHEMBL385112; 1,2,4-Benzotriazin-3-amine,7-(2-naphthalenyl)-; 7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine; BDBM50193895
DMU74R8 DT Small molecular drug
DMU74R8 PC 44419363
DMU74R8 MW 272.3
DMU74R8 FM C17H12N4
DMU74R8 IC InChI=1S/C17H12N4/c18-17-19-15-8-7-14(10-16(15)20-21-17)13-6-5-11-3-1-2-4-12(11)9-13/h1-10H,(H2,18,19,21)
DMU74R8 CS C1=CC=C2C=C(C=CC2=C1)C3=CC4=C(C=C3)N=C(N=N4)N
DMU74R8 IK XEBDWUZHTXSJGH-UHFFFAOYSA-N
DMU74R8 IU 7-naphthalen-2-yl-1,2,4-benzotriazin-3-amine
DMU74R8 DE Discovery agent
DM4VQN8 ID DM4VQN8
DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one
DM4VQN8 HS Investigative
DM4VQN8 SN CHEMBL127328
DM4VQN8 DT Small molecular drug
DM4VQN8 PC 44350703
DM4VQN8 MW 323.4
DM4VQN8 FM C20H21NO3
DM4VQN8 IC InChI=1S/C20H21NO3/c22-19(20-21-12-14-24-20)9-3-1-2-6-13-23-18-11-10-16-7-4-5-8-17(16)15-18/h4-5,7-8,10-12,14-15H,1-3,6,9,13H2
DM4VQN8 CS C1=CC=C2C=C(C=CC2=C1)OCCCCCCC(=O)C3=NC=CO3
DM4VQN8 IK BKNPQEYYRAPRRP-UHFFFAOYSA-N
DM4VQN8 IU 7-naphthalen-2-yloxy-1-(1,3-oxazol-2-yl)heptan-1-one
DM4VQN8 DE Discovery agent
DM6I5K1 ID DM6I5K1
DM6I5K1 DN 7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1 HS Investigative
DM6I5K1 SN CHEMBL444985; 7-(piperidin-4-ylmethoxy)-2-naphthonitrile
DM6I5K1 DT Small molecular drug
DM6I5K1 PC 44592241
DM6I5K1 MW 266.34
DM6I5K1 FM C17H18N2O
DM6I5K1 IC InChI=1S/C17H18N2O/c18-11-14-1-2-15-3-4-17(10-16(15)9-14)20-12-13-5-7-19-8-6-13/h1-4,9-10,13,19H,5-8,12H2
DM6I5K1 CS C1CNCCC1COC2=CC3=C(C=CC(=C3)C#N)C=C2
DM6I5K1 IK ZINGRQZUIVEPKX-UHFFFAOYSA-N
DM6I5K1 IU 7-(piperidin-4-ylmethoxy)naphthalene-2-carbonitrile
DM6I5K1 DE Discovery agent
DM46VT2 ID DM46VT2
DM46VT2 DN 7-(trifluoromethyl)-1H-indole-2,3-dione
DM46VT2 HS Investigative
DM46VT2 SN 391-12-8; 7-Trifluoromethylisatin; 7-(Trifluoromethyl)isatin; 7-(Trifluoromethyl)indoline-2,3-dione; 7-(Trifluoromethyl)-1H-indole-2,3-dione; 7-trifluoromethyl-1h-indole-2,3-dione; 7-(trifluoromethyl)-2,3-dihydro-1h-indole-2,3-dione; MXLDJTXXAYVWDF-UHFFFAOYSA-N; 1H-INDOLE-2,3-DIONE, 7-(TRIFLUOROMETHYL)-; 7-(trifluoromethyl)-1~{H}-indole-2,3-dione; 7-Trifluoroisatin; PubChem9557; AC1LCPWB; ACMC-1CLGD; 7-trifluoromethyl-isatin; Isatin-based compound, 45; AC1Q4IR6; KSC493C7F; SCHEMBL594546; CHEMBL376435; Jsp006801; CTK3J3172
DM46VT2 DT Small molecular drug
DM46VT2 PC 604575
DM46VT2 MW 215.13
DM46VT2 FM C9H4F3NO2
DM46VT2 IC InChI=1S/C9H4F3NO2/c10-9(11,12)5-3-1-2-4-6(5)13-8(15)7(4)14/h1-3H,(H,13,14,15)
DM46VT2 CS C1=CC2=C(C(=C1)C(F)(F)F)NC(=O)C2=O
DM46VT2 IK MXLDJTXXAYVWDF-UHFFFAOYSA-N
DM46VT2 IU 7-(trifluoromethyl)-1H-indole-2,3-dione
DM46VT2 CA CAS 391-12-8
DM46VT2 DE Discovery agent
DM3FXRC ID DM3FXRC
DM3FXRC DN 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene
DM3FXRC HS Investigative
DM3FXRC SN CHEMBL301605; 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene; 7,12-dihydropyrido[3,2-b:5,4-b']diindole; NCI60_006891; AC1L7HBP; AC1Q4YR3; CTK5J6980; ZINC12941871
DM3FXRC DT Small molecular drug
DM3FXRC PC 360772
DM3FXRC MW 257.29
DM3FXRC FM C17H11N3
DM3FXRC IC InChI=1S/C17H11N3/c1-3-7-12-10(5-1)15-14(19-12)9-18-16-11-6-2-4-8-13(11)20-17(15)16/h1-9,19-20H
DM3FXRC CS C1=CC=C2C(=C1)C3=C4C(=NC=C3N2)C5=CC=CC=C5N4
DM3FXRC IK UFTKNTUWDMJOIX-UHFFFAOYSA-N
DM3FXRC IU 9,12,20-triazapentacyclo[11.7.0.02,10.03,8.014,19]icosa-1(13),2(10),3,5,7,11,14,16,18-nonaene
DM3FXRC DE Discovery agent
DMTZ943 ID DMTZ943
DMTZ943 DN 7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene
DMTZ943 HS Investigative
DMTZ943 SN 5,12-Dihydroindolo[3,2-a]carbazole; 111296-91-4; 5,12-dihydroindolo[3,2-c]carbazole; Indolo[3,2-]arbazole, 5,12-ihydro-; Indolo[3,2-a]carbazole, 5,12-dihydro-; 5H,12H-Indolo[3,2-a]carbazole; AC1NFSZ0; SCHEMBL224017; CHEMBL53230; DTXSID80405771; QQWXDAWSMPLECU-UHFFFAOYSA-N; MolPort-027-835-190; ZINC13490703; 2059AA; AKOS016009131; 5,12-dihydro-indolo[3,2-a]carbazole; Indolo[3,2-a]carbazole,5,12-dihydro-; SC-48298; AJ-63955; AX8227529
DMTZ943 DT Small molecular drug
DMTZ943 PC 4713445
DMTZ943 MW 256.3
DMTZ943 FM C18H12N2
DMTZ943 IC InChI=1S/C18H12N2/c1-3-7-14-11(5-1)12-9-10-16-17(18(12)20-14)13-6-2-4-8-15(13)19-16/h1-10,19-20H
DMTZ943 CS C1=CC=C2C(=C1)C3=C(N2)C4=C(C=C3)NC5=CC=CC=C54
DMTZ943 IK QQWXDAWSMPLECU-UHFFFAOYSA-N
DMTZ943 IU 5,12-dihydroindolo[3,2-c]carbazole
DMTZ943 CA CAS 111296-91-4
DMTZ943 DE Discovery agent
DM5JV8G ID DM5JV8G
DM5JV8G DN 7,3',4'-trihydroxyisoflavone
DM5JV8G HS Investigative
DM5JV8G SN 3',4',7-Trihydroxyisoflavone; 3'-Hydroxydaidzein; 485-63-2; 3-(3,4-Dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one; 7,3',4'-Trihydroxyisoflavone; UNII-T08Y239E7Y; CHEMBL13486; CHEBI:50399; 3',4',7-trihydroxy isoflavone; DDKGKOOLFLYZDL-UHFFFAOYSA-N; 3'',4'',7-trihydroxyisoflavone; T08Y239E7Y; 3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one; 3-(3,4-dihydroxyphenyl)-7-hydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3,4-dihydroxyphenyl)-7-hydroxy-; 47X; Orita-13; 3l5r; AC1NR4TZ; SCHEMBL73012; BIDD:ER0118; GTPL9985
DM5JV8G DT Small molecular drug
DM5JV8G PC 5284648
DM5JV8G MW 270.24
DM5JV8G FM C15H10O5
DM5JV8G IC InChI=1S/C15H10O5/c16-9-2-3-10-14(6-9)20-7-11(15(10)19)8-1-4-12(17)13(18)5-8/h1-7,16-18H
DM5JV8G CS C1=CC(=C(C=C1C2=COC3=C(C2=O)C=CC(=C3)O)O)O
DM5JV8G IK DDKGKOOLFLYZDL-UHFFFAOYSA-N
DM5JV8G IU 3-(3,4-dihydroxyphenyl)-7-hydroxychromen-4-one
DM5JV8G CA CAS 485-63-2
DM5JV8G CB CHEBI:50399
DM5JV8G DE Discovery agent
DMXQ1K0 ID DMXQ1K0
DMXQ1K0 DN 7,4'-Dihydroxyflavone
DMXQ1K0 HS Investigative
DMXQ1K0 SN 7,4'-Dihydroxyflavone; 4',7-Dihydroxyflavone; 2196-14-7; 7-Hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-2-(4-hydroxyphenyl)-; FLAVONE, 4',7-DIHYDROXY-; UNII-53ZZF57X0U; CHEMBL294878; 53ZZF57X0U; 7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one; CHEBI:29503; LCAWNFIFMLXZPQ-UHFFFAOYSA-N; BRN 0224356; PubChem9844; AC1NQZG5; 7, 4'-Dihydroxyflavone; Spectrum4_001280; 7,4''-Dihydroxyflavone; 7,4' - Dihydroxyflavone; C12123; 7,4'-dihydroxyflavone; KBioGR_001900; SPECTRUM1500721; SCHEMBL157723
DMXQ1K0 DT Small molecular drug
DMXQ1K0 PC 5282073
DMXQ1K0 MW 254.24
DMXQ1K0 FM C15H10O4
DMXQ1K0 IC InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-8,16-17H
DMXQ1K0 CS C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C=C3)O)O
DMXQ1K0 IK LCAWNFIFMLXZPQ-UHFFFAOYSA-N
DMXQ1K0 IU 7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMXQ1K0 CA CAS 2196-14-7
DMXQ1K0 CB CHEBI:29503
DMXQ1K0 DE Discovery agent
DMOBEL9 ID DMOBEL9
DMOBEL9 DN 7,8,3',4'-tetrahydroxyflavone
DMOBEL9 HS Investigative
DMOBEL9 SN 7,8,3',4'-tetrahydroxyflavone; 3440-24-2; 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4H-chromen-4-one; 3',4',7,8-Tetrahydroxyflavone; CHEMBL222541; ARYCMKPCDNHQCL-UHFFFAOYSA-N; ST059620; 2-(3,4-dihydroxyphenyl)-7,8-dihydroxychromen-4-one; AC1LEMTC; AC1Q6AJ1; SCHEMBL35318; CTK4H2335; ZINC57844; DTXSID20350973; 2-(3,4-dihydroxyphenyl)-7,8-dihydroxy-4h-chromen-4-on; CHEBI:125596; 7,8,3'',4''-tetrahydroxyflavone; BDBM50157547; AKOS024283046; ACM3440242; MCULE-5496936655; ZB002260; DB-048618; FT-0614178; C-57754
DMOBEL9 DT Small molecular drug
DMOBEL9 PC 688798
DMOBEL9 MW 286.24
DMOBEL9 FM C15H10O6
DMOBEL9 IC InChI=1S/C15H10O6/c16-9-3-1-7(5-12(9)19)13-6-11(18)8-2-4-10(17)14(20)15(8)21-13/h1-6,16-17,19-20H
DMOBEL9 CS C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C(=C(C=C3)O)O)O)O
DMOBEL9 IK ARYCMKPCDNHQCL-UHFFFAOYSA-N
DMOBEL9 IU 2-(3,4-dihydroxyphenyl)-7,8-dihydroxychromen-4-one
DMOBEL9 CA CAS 3440-24-2
DMOBEL9 CB CHEBI:125596
DMOBEL9 DE Discovery agent
DM80GFL ID DM80GFL
DM80GFL DN 7,8,4'-trihydroxyisoflavone
DM80GFL HS Investigative
DM80GFL SN 7,8,4'-Trihydroxyisoflavone; 8-Hydroxydaidzein; 75187-63-2; 4',7,8-Trihydroxyisoflavone; 7,8-Dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7,8-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one; 7,8-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; NSC678112; CHEMBL242739; NSC 678112; 4H-1-Benzopyran-4-one, 7,8-dihydroxy-3-(4-hydroxyphenyl)-; 7,4'-Trihydroxyisoflavone; AC1NV1M1; SCHEMBL571127; 7,8,4''-trihydroxyisoflavone; 4'',7,8-trihydroxyisoflavone; CTK5E1244; DTXSID20226169; MolPort-000-165-583; BMZFZTMWBCFKSS-UHFFFAOYSA-N
DM80GFL DT Small molecular drug
DM80GFL PC 5466139
DM80GFL MW 270.24
DM80GFL FM C15H10O5
DM80GFL IC InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-15-10(13(11)18)5-6-12(17)14(15)19/h1-7,16-17,19H
DM80GFL CS C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3O)O)O
DM80GFL IK BMZFZTMWBCFKSS-UHFFFAOYSA-N
DM80GFL IU 7,8-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
DM80GFL CA CAS 75187-63-2
DM80GFL DE Discovery agent
DMIMLUO ID DMIMLUO
DMIMLUO DN 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine
DMIMLUO HS Investigative
DMIMLUO SN CHEMBL261490; BDBM50375901
DMIMLUO DT Small molecular drug
DMIMLUO PC 44451373
DMIMLUO MW 187.24
DMIMLUO FM C12H13NO
DMIMLUO IC InChI=1S/C12H13NO/c1-2-10-5-8-14-12(10)11-4-7-13-6-3-9(1)11/h1-2,5,8,13H,3-4,6-7H2
DMIMLUO CS C1CNCCC2=C1C=CC3=C2OC=C3
DMIMLUO IK QDAAIWYKQLAISZ-UHFFFAOYSA-N
DMIMLUO IU 7,8,9,10-tetrahydro-6H-furo[3,2-i][3]benzazepine
DMIMLUO DE Discovery agent
DMVZA27 ID DMVZA27
DMVZA27 DN 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine
DMVZA27 HS Investigative
DMVZA27 SN CHEMBL261489
DMVZA27 DT Small molecular drug
DMVZA27 PC 44451369
DMVZA27 MW 187.24
DMVZA27 FM C12H13NO
DMVZA27 IC InChI=1S/C12H13NO/c1-2-12-11(5-8-14-12)10-4-7-13-6-3-9(1)10/h1-2,5,8,13H,3-4,6-7H2
DMVZA27 CS C1CNCCC2=C1C=CC3=C2C=CO3
DMVZA27 IK BGHAWUGGSCZWBN-UHFFFAOYSA-N
DMVZA27 IU 7,8,9,10-tetrahydro-6H-furo[2,3-i][3]benzazepine
DMVZA27 DE Discovery agent
DMKNQW4 ID DMKNQW4
DMKNQW4 DN 7,8-dichloroquinoline-4-one-3-carboxylic acid
DMKNQW4 HS Investigative
DMKNQW4 SN 300675-28-9; 7,8-DICHLORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID; 144061-33-6; 7,8-dichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 7,8-dichloro-4-oxo-1H-quinoline-3-carboxylic Acid; CHEMBL218566; 7,8-Dichloro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid; J-650168; 7,8-dichloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; AC1LEVOV; Oprea1_635608; Oprea1_583373; SCHEMBL9654331; SCHEMBL17502115; CTK7I6370; CHEBI:94582; DTXSID00351180; MolPort-000-680-344; MolPort-000-651-074; ZINC3945161; STK539875; MFCD01909987
DMKNQW4 DT Small molecular drug
DMKNQW4 PC 693139
DMKNQW4 MW 258.05
DMKNQW4 FM C10H5Cl2NO3
DMKNQW4 IC InChI=1S/C10H5Cl2NO3/c11-6-2-1-4-8(7(6)12)13-3-5(9(4)14)10(15)16/h1-3H,(H,13,14)(H,15,16)
DMKNQW4 CS C1=CC(=C(C2=C1C(=O)C(=CN2)C(=O)O)Cl)Cl
DMKNQW4 IK HVXHDYSWCHQWBD-UHFFFAOYSA-N
DMKNQW4 IU 7,8-dichloro-4-oxo-1H-quinoline-3-carboxylic acid
DMKNQW4 CA CAS 144061-33-6
DMKNQW4 CB CHEBI:94582
DMKNQW4 DE Discovery agent
DMQU4XM ID DMQU4XM
DMQU4XM DN 7,8-dihydrobiopterin
DMQU4XM HS Investigative
DMQU4XM SN Quinonoid dihydrobiopterin; q-BH2; L-erythro-q-dihydrobiopterin; dihydrobiopterin; L-erythro-7,8-Dihydrobiopterin; L-erythro-dihydrobiopterin; 7,8-Dihydro-L-biopterin; 6779-87-9; 2-amino-6-((1r,2s)-1,2-dihydroxypropyl)-7,8-dihydro-4(1h)-pteridinone; 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydropteridin-4(3H)-one; 2toh; 4(1H)-pteridinone, 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydro-; 4(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-7,8-dihydro-, [S-(R*,S*)]-; 4(1H)-Pteridinone; 7,8-Dihydro-L-Biopterin
DMQU4XM DT Small molecular drug
DMQU4XM PC 135398687
DMQU4XM MW 239.23
DMQU4XM FM C9H13N5O3
DMQU4XM IC InChI=1S/C9H13N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,6,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,6-/m0/s1
DMQU4XM CS C[C@@H]([C@@H](C1=NC2=C(NC1)N=C(NC2=O)N)O)O
DMQU4XM IK FEMXZDUTFRTWPE-DZSWIPIPSA-N
DMQU4XM IU 2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-7,8-dihydro-3H-pteridin-4-one
DMQU4XM CA CAS 6779-87-9
DMQU4XM CB CHEBI:43029
DMQU4XM DE Discovery agent
DM5TXY1 ID DM5TXY1
DM5TXY1 DN 7,8-Dihydroneopterin
DM5TXY1 HS Investigative
DM5TXY1 DT Small molecular drug
DM5TXY1 PC 135398602
DM5TXY1 MW 255.23
DM5TXY1 FM C9H13N5O4
DM5TXY1 IC InChI=1S/C9H13N5O4/c10-9-13-7-5(8(18)14-9)12-3(1-11-7)6(17)4(16)2-15/h4,6,15-17H,1-2H2,(H4,10,11,13,14,18)/t4-,6+/m1/s1
DM5TXY1 CS C1C(=NC2=C(N1)N=C(NC2=O)N)[C@@H]([C@@H](CO)O)O
DM5TXY1 IK YQIFAMYNGGOTFB-XINAWCOVSA-N
DM5TXY1 IU 2-amino-6-[(1S,2R)-1,2,3-trihydroxypropyl]-7,8-dihydro-3H-pteridin-4-one
DM5TXY1 CA CAS 1218-98-0
DM5TXY1 CB CHEBI:17001
DM5TXY1 DE Discovery agent
DMUB5E8 ID DMUB5E8
DMUB5E8 DN 7,8-dihydroxy-4-phenyl-2H-chromen-2-one
DMUB5E8 HS Investigative
DMUB5E8 SN 7,8-dihydroxy-4-phenyl-2H-chromen-2-one; 842-01-3; 7,8-Dihydroxy-4-phenylcoumarin; 7,8-dihydroxy-4-phenylchromen-2-one; 2zvj; AC1NTWI0; AC1Q78GB; Oprea1_803491; IFLab1_001650; SCHEMBL1181304; CHEMBL1233867; 4-phenyl-7,8-dihydroxycoumarin; CTK5F1973; 4-phenyl-7,8-dihydroxycoumarine; DTXSID10419942; MolPort-000-852-912; JRVIIPJSVKTPBK-UHFFFAOYSA-N; ZINC406883; HMS1416K22; DNDI1417012; ALBB-015578; BBL029555; 0375AF; STL372126; AKOS005175244; MCULE-8639896630; DB08049; 7,8-dihydroxy-4-phenyl-chromen-2-one; 7,8-DIHYDROXY-4-PHENYL COUMARIN
DMUB5E8 DT Small molecular drug
DMUB5E8 PC 5413034
DMUB5E8 MW 254.24
DMUB5E8 FM C15H10O4
DMUB5E8 IC InChI=1S/C15H10O4/c16-12-7-6-10-11(9-4-2-1-3-5-9)8-13(17)19-15(10)14(12)18/h1-8,16,18H
DMUB5E8 CS C1=CC=C(C=C1)C2=CC(=O)OC3=C2C=CC(=C3O)O
DMUB5E8 IK JRVIIPJSVKTPBK-UHFFFAOYSA-N
DMUB5E8 IU 7,8-dihydroxy-4-phenylchromen-2-one
DMUB5E8 CA CAS 842-01-3
DMUB5E8 DE Discovery agent
DMPF6MD ID DMPF6MD
DMPF6MD DN 7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one
DMPF6MD HS Investigative
DMPF6MD SN 7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one; casimiroin analogue, 1h; CHEMBL453233
DMPF6MD DT Small molecular drug
DMPF6MD PC 42618029
DMPF6MD MW 233.26
DMPF6MD FM C13H15NO3
DMPF6MD IC InChI=1S/C13H15NO3/c1-8-7-11(15)14(2)12-9(8)5-6-10(16-3)13(12)17-4/h5-7H,1-4H3
DMPF6MD CS CC1=CC(=O)N(C2=C1C=CC(=C2OC)OC)C
DMPF6MD IK DHJBSOKLGMWDBA-UHFFFAOYSA-N
DMPF6MD IU 7,8-dimethoxy-1,4-dimethylquinolin-2-one
DMPF6MD DE Discovery agent
DMO8GEI ID DMO8GEI
DMO8GEI DN 7,9-octadecadiynoic acid
DMO8GEI HS Investigative
DMO8GEI SN 7,9-Octadecadiynoic acid; CHEMBL485858; 33128-25-5; LMFA01030532; AC1NSN9N; octadeca-7,9-diynoic acid; CTK1B8718; DTXSID00415579
DMO8GEI DT Small molecular drug
DMO8GEI PC 5312662
DMO8GEI MW 276.4
DMO8GEI FM C18H28O2
DMO8GEI IC InChI=1S/C18H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-8,13-17H2,1H3,(H,19,20)
DMO8GEI CS CCCCCCCCC#CC#CCCCCCC(=O)O
DMO8GEI IK LDZUDUYCHODRLO-UHFFFAOYSA-N
DMO8GEI IU octadeca-7,9-diynoic acid
DMO8GEI CA CAS 33128-25-5
DMO8GEI DE Discovery agent
DMPEXTB ID DMPEXTB
DMPEXTB DN 7,9-tetradecadiynoic acid
DMPEXTB HS Investigative
DMPEXTB SN 7,9-tetradecadiynoic acid; CHEMBL501307; 7,9-Tetradecadiyneoic acid; Tetradecan-7,9-diynoic acid; LMFA01031094; BDBM50292399
DMPEXTB DT Small molecular drug
DMPEXTB PC 14309406
DMPEXTB MW 220.31
DMPEXTB FM C14H20O2
DMPEXTB IC InChI=1S/C14H20O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-4,9-13H2,1H3,(H,15,16)
DMPEXTB CS CCCCC#CC#CCCCCCC(=O)O
DMPEXTB IK UDDQRZKIDJCZJF-UHFFFAOYSA-N
DMPEXTB IU tetradeca-7,9-diynoic acid
DMPEXTB DE Discovery agent
DMNGLM1 ID DMNGLM1
DMNGLM1 DN 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one
DMNGLM1 HS Investigative
DMNGLM1 SN CHEMBL157925; 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one; 4H-1-Benzopyran-4-one, 7-(4H-1,2,4-triazol-4-ylmethyl)-; BDBM50097361; 331684-17-4
DMNGLM1 DT Small molecular drug
DMNGLM1 PC 10823163
DMNGLM1 MW 227.22
DMNGLM1 FM C12H9N3O2
DMNGLM1 IC InChI=1S/C12H9N3O2/c16-11-3-4-17-12-5-9(1-2-10(11)12)6-15-7-13-14-8-15/h1-5,7-8H,6H2
DMNGLM1 CS C1=CC2=C(C=C1CN3C=NN=C3)OC=CC2=O
DMNGLM1 IK QNCWBRMMGXVBEU-UHFFFAOYSA-N
DMNGLM1 IU 7-(1,2,4-triazol-4-ylmethyl)chromen-4-one
DMNGLM1 DE Discovery agent
DMQCDT1 ID DMQCDT1
DMQCDT1 DN 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin
DMQCDT1 HS Investigative
DMQCDT1 SN 307550-03-4; CHEMBL488073; 4-METHYL-3-(2-OXOPROPOXY)-7,8,9,10-TETRAHYDRO-6H-BENZO[C]CHROMEN-6-ONE; CHEMBRDG-BB 6148717; AC1LDV7A; CBMicro_031517; 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin; ZINC83523; CTK4G5861; DTXSID00351504; MolPort-000-688-897; ZX-CM016547; STL303255; BDBM50246265; AKOS002377920; MCULE-4345433569; AJ-10643; ACM307550034; BIM-0031568.P001; W-8890; SR-01000229174; SR-01000229174-1; 4-methyl-3-(2-oxopropoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one; 6H-Dibenzo[b,d]pyran-6-one, 7,8,9,10-tetrahydro-4-methyl-3-
DMQCDT1 DT Small molecular drug
DMQCDT1 PC 701943
DMQCDT1 MW 286.32
DMQCDT1 FM C17H18O4
DMQCDT1 IC InChI=1S/C17H18O4/c1-10(18)9-20-15-8-7-13-12-5-3-4-6-14(12)17(19)21-16(13)11(15)2/h7-8H,3-6,9H2,1-2H3
DMQCDT1 CS CC1=C(C=CC2=C1OC(=O)C3=C2CCCC3)OCC(=O)C
DMQCDT1 IK FPBPSCOEWNGWAT-UHFFFAOYSA-N
DMQCDT1 IU 4-methyl-3-(2-oxopropoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one
DMQCDT1 CA CAS 307550-03-4
DMQCDT1 DE Discovery agent
DMQMTSX ID DMQMTSX
DMQMTSX DN 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin
DMQMTSX HS Investigative
DMQMTSX SN 307548-94-3; CHEMBL488076; 6-methyl-7-(2-oxopropoxy)-2,3-dihydrocyclopenta[c]chromen-4(1H)-one; 6-METHYL-7-(2-OXOPROPOXY)-2,3-DIHYDROCYCLOPENTA(C)CHROMEN-4(1H)-ONE; CHEMBRDG-BB 6159766; AC1MY6ZC; CBMicro_001748; 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin; CTK4G5858; DTXSID20397328; MolPort-000-688-742; ZX-CM016564; SMSF0015818; ZINC4387711; STK829219; BDBM50246264; AKOS001021363; CB03533; MCULE-6433360521; ACM307548943; AJ-51032; BIM-0001876.P001; W-8723; SR-01000229477; SR-01000229477-1
DMQMTSX DT Small molecular drug
DMQMTSX PC 3852139
DMQMTSX MW 272.29
DMQMTSX FM C16H16O4
DMQMTSX IC InChI=1S/C16H16O4/c1-9(17)8-19-14-7-6-12-11-4-3-5-13(11)16(18)20-15(12)10(14)2/h6-7H,3-5,8H2,1-2H3
DMQMTSX CS CC1=C(C=CC2=C1OC(=O)C3=C2CCC3)OCC(=O)C
DMQMTSX IK JLYIBZRYQJEBHZ-UHFFFAOYSA-N
DMQMTSX IU 6-methyl-7-(2-oxopropoxy)-2,3-dihydro-1H-cyclopenta[c]chromen-4-one
DMQMTSX CA CAS 307548-94-3
DMQMTSX DE Discovery agent
DMYSNQO ID DMYSNQO
DMYSNQO DN 7-acetonyloxy-3-acetylamino-8-methoxycoumarin
DMYSNQO HS Investigative
DMYSNQO SN CHEMBL201250; 7-acetonyloxy-3-acetylamino-8-methoxycoumarin; CTK6J4706; BDBM50181853; AKOS015965518; N-[8-Methoxy-2-oxo-7-(2-oxo-propoxy; N-(8-methoxy-2-oxo-7-(2-oxopropoxy)-2H-chromen-3-yl)acetamide
DMYSNQO DT Small molecular drug
DMYSNQO PC 11623661
DMYSNQO MW 305.28
DMYSNQO FM C15H15NO6
DMYSNQO IC InChI=1S/C15H15NO6/c1-8(17)7-21-12-5-4-10-6-11(16-9(2)18)15(19)22-13(10)14(12)20-3/h4-6H,7H2,1-3H3,(H,16,18)
DMYSNQO CS CC(=O)COC1=C(C2=C(C=C1)C=C(C(=O)O2)NC(=O)C)OC
DMYSNQO IK BPSQKFACFYVPBO-UHFFFAOYSA-N
DMYSNQO IU N-[8-methoxy-2-oxo-7-(2-oxopropoxy)chromen-3-yl]acetamide
DMYSNQO DE Discovery agent
DMPRBO1 ID DMPRBO1
DMPRBO1 DN 7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione
DMPRBO1 HS Investigative
DMPRBO1 SN 7-Allyltheophylline; Theophylline, 7-allyl-; 61444-26-6; UNII-NC789Z71XR; BRN 0226015; CHEMBL24289; NC789Z71XR; 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-7-(2-propenyl)-; 7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione; 7-allyl-1,3-dimethylxanthine; 7-Allyl-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 1,3-dimethyl-7-(prop-2-en-1-yl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione; NSC521015; AC1L2QUV; ChemDiv2_003783; 1,3-dimethyl-7-prop-2-enylpurine-2,6-dione; Cambridge id 6249500; AC1Q3ZA3; SCHEMBL316279
DMPRBO1 DT Small molecular drug
DMPRBO1 PC 101446
DMPRBO1 MW 220.23
DMPRBO1 FM C10H12N4O2
DMPRBO1 IC InChI=1S/C10H12N4O2/c1-4-5-14-6-11-8-7(14)9(15)13(3)10(16)12(8)2/h4,6H,1,5H2,2-3H3
DMPRBO1 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC=C
DMPRBO1 IK ZGIBYCLLIMGXEZ-UHFFFAOYSA-N
DMPRBO1 IU 1,3-dimethyl-7-prop-2-enylpurine-2,6-dione
DMPRBO1 CA CAS 61444-26-6
DMPRBO1 DE Discovery agent
DMHJ6TU ID DMHJ6TU
DMHJ6TU DN 7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
DMHJ6TU HS Investigative
DMHJ6TU SN CHEMBL284860; 7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione; BDBM50025571
DMHJ6TU DT Small molecular drug
DMHJ6TU PC 44274626
DMHJ6TU MW 276.33
DMHJ6TU FM C14H20N4O2
DMHJ6TU IC InChI=1S/C14H20N4O2/c1-4-7-16-10-15-12-11(16)13(19)18(9-6-3)14(20)17(12)8-5-2/h4,10H,1,5-9H2,2-3H3
DMHJ6TU CS CCCN1C2=C(C(=O)N(C1=O)CCC)N(C=N2)CC=C
DMHJ6TU IK NRUARHUVQRNQPB-UHFFFAOYSA-N
DMHJ6TU IU 7-prop-2-enyl-1,3-dipropylpurine-2,6-dione
DMHJ6TU DE Discovery agent
DMSRQ1L ID DMSRQ1L
DMSRQ1L DN 7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMSRQ1L HS Investigative
DMSRQ1L DT Small molecular drug
DMSRQ1L PC 135458122
DMSRQ1L MW 267.28
DMSRQ1L FM C16H13NO3
DMSRQ1L IC InChI=1S/C16H13NO3/c1-2-3-11-8-13(19)9-14-15(11)20-16(17-14)10-4-6-12(18)7-5-10/h2,4-9,18-19H,1,3H2
DMSRQ1L CS C=CCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMSRQ1L IK XQORYXRHJJULMI-UHFFFAOYSA-N
DMSRQ1L IU 2-(4-hydroxyphenyl)-7-prop-2-enyl-1,3-benzoxazol-5-ol
DMSRQ1L DE Discovery agent
DM2N8TW ID DM2N8TW
DM2N8TW DN 7alpha,25-dihydroxycholesterol
DM2N8TW HS Investigative
DM2N8TW SN 7alpha-25-OHC
DM2N8TW DT Small molecular drug
DM2N8TW PC 11954197
DM2N8TW MW 418.7
DM2N8TW FM C27H46O3
DM2N8TW IC InChI=1S/C27H46O3/c1-17(7-6-12-25(2,3)30)20-8-9-21-24-22(11-14-27(20,21)5)26(4)13-10-19(28)15-18(26)16-23(24)29/h16-17,19-24,28-30H,6-15H2,1-5H3/t17-,19+,20-,21+,22+,23-,24+,26+,27-/m1/s1
DM2N8TW CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DM2N8TW IK BQMSKLCEWBSPPY-IKVTXIKFSA-N
DM2N8TW IU (3S,7S,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DM2N8TW CA CAS 64907-22-8
DM2N8TW CB CHEBI:37623
DM2N8TW DE Discovery agent
DM52UOM ID DM52UOM
DM52UOM DN 7alpha,27-dihydroxycholesterol
DM52UOM HS Investigative
DM52UOM SN 7alpha, 27-OHC
DM52UOM DT Small molecular drug
DM52UOM PC 440985
DM52UOM MW 418.7
DM52UOM FM C27H46O3
DM52UOM IC InChI=1S/C27H46O3/c1-17(16-28)6-5-7-18(2)21-8-9-22-25-23(11-13-27(21,22)4)26(3)12-10-20(29)14-19(26)15-24(25)30/h15,17-18,20-25,28-30H,5-14,16H2,1-4H3/t17?,18-,20+,21-,22+,23+,24-,25+,26+,27-/m1/s1
DM52UOM CS C[C@H](CCCC(C)CO)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DM52UOM IK RXMHNAKZMGJANZ-DTTSCKGMSA-N
DM52UOM IU (3S,7S,8S,9S,10R,13R,14S,17R)-17-[(2R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DM52UOM CA CAS 4725-24-0
DM52UOM CB CHEBI:18431
DM52UOM DE Discovery agent
DMD6UC9 ID DMD6UC9
DMD6UC9 DN 7alpha-Cl-ginkgolide B
DMD6UC9 HS Investigative
DMD6UC9 SN 7alpha-Cl-ginkgolide B; 7alpha-Cl-GB
DMD6UC9 DT Small molecular drug
DMD6UC9 PC 73755014
DMD6UC9 MW 458.8
DMD6UC9 FM C20H23ClO10
DMD6UC9 IC InChI=1S/C20H23ClO10/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,22-23,27H,1-4H3/t5?,6?,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMD6UC9 CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C(C5Cl)C(C)(C)C)O
DMD6UC9 IK GXEIWFYPUUOBJY-UUSFTXJGSA-N
DMD6UC9 IU (1S,6R,13S,17R)-8-tert-butyl-9-chloro-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMD6UC9 DE Discovery agent
DMRQ24A ID DMRQ24A
DMRQ24A DN 7alpha-F-ginkgolide B
DMRQ24A HS Investigative
DMRQ24A SN 7alpha-F-ginkgolide B; 7alpha-F-GB
DMRQ24A DT Small molecular drug
DMRQ24A PC 73755015
DMRQ24A MW 442.4
DMRQ24A FM C20H23FO10
DMRQ24A IC InChI=1S/C20H23FO10/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,22-23,27H,1-4H3/t5?,6?,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMRQ24A CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C(C5F)C(C)(C)C)O
DMRQ24A IK NKHCTSYWTBHOAK-UUSFTXJGSA-N
DMRQ24A IU (1S,6R,13S,17R)-8-tert-butyl-9-fluoro-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMRQ24A DE Discovery agent
DMH6LD0 ID DMH6LD0
DMH6LD0 DN 7alpha-hydroxycholesterol
DMH6LD0 HS Investigative
DMH6LD0 SN 7-alpha-OHC
DMH6LD0 DT Small molecular drug
DMH6LD0 PC 107722
DMH6LD0 MW 402.7
DMH6LD0 FM C27H46O2
DMH6LD0 IC InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24-,25+,26+,27-/m1/s1
DMH6LD0 CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMH6LD0 IK OYXZMSRRJOYLLO-RVOWOUOISA-N
DMH6LD0 IU (3S,7S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMH6LD0 CA CAS 566-26-7
DMH6LD0 CB CHEBI:17500
DMH6LD0 DE Discovery agent
DMGNWBV ID DMGNWBV
DMGNWBV DN 7alpha-N3-ginkgolide B
DMGNWBV HS Investigative
DMGNWBV SN 7alpha-N3-ginkgolide B; 7alpha-N3-GB
DMGNWBV DT Small molecular drug
DMGNWBV PC 73755016
DMGNWBV MW 465.4
DMGNWBV FM C20H23N3O10
DMGNWBV IC InChI=1S/C20H23N3O10/c1-5-12(26)30-11-8(24)18-10-6(22-23-21)7(16(2,3)4)17(18)9(25)13(27)32-15(17)33-20(18,14(28)31-10)19(5,11)29/h5-11,15,24-25,29H,1-4H3/t5?,6-,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMGNWBV CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5N=[N+]=[N-])C(C)(C)C)O
DMGNWBV IK GLXZEIIDXFBXMR-AQPRMESZSA-N
DMGNWBV IU (1S,6R,9S,13S,17R)-9-azido-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMGNWBV DE Discovery agent
DMZUYX1 ID DMZUYX1
DMZUYX1 DN 7alpha-NH2-ginkgolide B
DMZUYX1 HS Investigative
DMZUYX1 SN 7alpha-NH2-ginkgolide B; 7alpha-NH2-GB
DMZUYX1 DT Small molecular drug
DMZUYX1 PC 73755017
DMZUYX1 MW 439.4
DMZUYX1 FM C20H25NO10
DMZUYX1 IC InChI=1S/C20H25NO10/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,22-23,27H,21H2,1-4H3/t5?,6-,7?,8?,9-,10?,11-,15?,17?,18?,19+,20-/m0/s1
DMZUYX1 CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5N)C(C)(C)C)O
DMZUYX1 IK OONDPNQTNMFTRA-AQPRMESZSA-N
DMZUYX1 IU (1S,6R,9S,13S,17R)-9-amino-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMZUYX1 DE Discovery agent
DMWAB7F ID DMWAB7F
DMWAB7F DN 7alpha-NHEt-ginkgolide B
DMWAB7F HS Investigative
DMWAB7F SN 7alpha-NHEt-ginkgolide B; 7alpha-NHEt-GB
DMWAB7F DT Small molecular drug
DMWAB7F PC 73755018
DMWAB7F MW 467.5
DMWAB7F FM C22H29NO10
DMWAB7F IC InChI=1S/C22H29NO10/c1-6-23-8-9(18(3,4)5)19-11(25)15(27)32-17(19)33-22-16(28)31-12(8)20(19,22)10(24)13-21(22,29)7(2)14(26)30-13/h7-13,17,23-25,29H,6H2,1-5H3/t7?,8-,9?,10?,11-,12?,13-,17?,19?,20?,21+,22-/m0/s1
DMWAB7F CS CCN[C@H]1C(C23[C@H](C(=O)OC2O[C@]45C3(C1OC4=O)C([C@H]6[C@@]5(C(C(=O)O6)C)O)O)O)C(C)(C)C
DMWAB7F IK UIERCQIWSNGSNJ-YUTHRBKVSA-N
DMWAB7F IU (1S,6R,9S,13S,17R)-8-tert-butyl-9-(ethylamino)-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMWAB7F DE Discovery agent
DMSPLYF ID DMSPLYF
DMSPLYF DN 7alpha-NHMe-ginkgolide B
DMSPLYF HS Investigative
DMSPLYF SN 7alpha-NHMe-ginkgolide B; 7alpha-NHMe-GB
DMSPLYF DT Small molecular drug
DMSPLYF PC 73755019
DMSPLYF MW 453.4
DMSPLYF FM C21H27NO10
DMSPLYF IC InChI=1S/C21H27NO10/c1-6-13(25)29-12-9(23)19-11-7(22-5)8(17(2,3)4)18(19)10(24)14(26)31-16(18)32-21(19,15(27)30-11)20(6,12)28/h6-12,16,22-24,28H,1-5H3/t6?,7-,8?,9?,10-,11?,12-,16?,18?,19?,20+,21-/m0/s1
DMSPLYF CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5NC)C(C)(C)C)O
DMSPLYF IK IFVRBXXBLQUPAA-WOBCBQRJSA-N
DMSPLYF IU (1S,6R,9S,13S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-9-(methylamino)-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMSPLYF DE Discovery agent
DMN1U56 ID DMN1U56
DMN1U56 DN 7alpha-OAc-ginkgolide B
DMN1U56 HS Investigative
DMN1U56 SN 7alpha-OAc-ginkgolide B; 7alpha-OAc-GB
DMN1U56 DT Small molecular drug
DMN1U56 PC 73755020
DMN1U56 MW 482.4
DMN1U56 FM C22H26O12
DMN1U56 IC InChI=1S/C22H26O12/c1-6-14(26)31-13-10(24)20-12-8(30-7(2)23)9(18(3,4)5)19(20)11(25)15(27)33-17(19)34-22(20,16(28)32-12)21(6,13)29/h6,8-13,17,24-25,29H,1-5H3/t6?,8?,9?,10?,11-,12?,13-,17?,19?,20?,21+,22-/m0/s1
DMN1U56 CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C(C5OC(=O)C)C(C)(C)C)O
DMN1U56 IK PTVXMWRAVPFHBG-OIYCRRHPSA-N
DMN1U56 IU [(1S,6R,13S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] acetate
DMN1U56 DE Discovery agent
DMGAPCD ID DMGAPCD
DMGAPCD DN 7alpha-OCOCH2Ph-ginkgolide B
DMGAPCD HS Investigative
DMGAPCD SN 7alpha-OCOCH2Ph-ginkgolide B; 7alpha-OCOCH2Ph-GB
DMGAPCD DT Small molecular drug
DMGAPCD PC 73755021
DMGAPCD MW 558.5
DMGAPCD FM C28H30O12
DMGAPCD IC InChI=1S/C28H30O12/c1-11-20(32)37-19-16(30)26-18-14(36-13(29)10-12-8-6-5-7-9-12)15(24(2,3)4)25(26)17(31)21(33)39-23(25)40-28(26,22(34)38-18)27(11,19)35/h5-9,11,14-19,23,30-31,35H,10H2,1-4H3/t11?,14-,15?,16?,17-,18?,19-,23?,25?,26?,27+,28-/m0/s1
DMGAPCD CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@@H]5OC(=O)CC7=CC=CC=C7)C(C)(C)C)O
DMGAPCD IK IYWGNBBAQNQGIC-MAVMKJRYSA-N
DMGAPCD IU [(1S,6R,9S,13S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-5,15,18-trioxo-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecan-9-yl] 2-phenylacetate
DMGAPCD DE Discovery agent
DMDUB63 ID DMDUB63
DMDUB63 DN 7-amino-4-hydroxy-2-naphthalenesulfonic acid
DMDUB63 HS Investigative
DMDUB63 SN 87-02-5; J acid; 7-AMINO-4-HYDROXY-2-NAPHTHALENESULFONIC ACID; 7-amino-4-hydroxynaphthalene-2-sulfonic acid; Isogamma acid; I acid; 2-Naphthalenesulfonic acid, 7-amino-4-hydroxy-; Kyselina I; 2-Amino-5-naphthol-7-sulfonic Acid; Kyselina I [Czech]; Aminonaphthol sulfonic acid J; 6-Amino-1-naphthol-3-sulfonic acid; CCRIS 8989; EINECS 201-718-9; NSC 31510; Kyselina 2-amino-5-naftol-7-sulfonova; BRN 2217192; UNII-9A1IU1C93L; MLS002638012; CHEMBL220259; 9A1IU1C93L; CHEBI:87316; 7-Amino-4-hydroxynaphthalene-2-sulphonic acid; Kyselina 6
DMDUB63 DT Small molecular drug
DMDUB63 PC 6868
DMDUB63 MW 239.25
DMDUB63 FM C10H9NO4S
DMDUB63 IC InChI=1S/C10H9NO4S/c11-7-1-2-9-6(3-7)4-8(5-10(9)12)16(13,14)15/h1-5,12H,11H2,(H,13,14,15)
DMDUB63 CS C1=CC2=C(C=C(C=C2C=C1N)S(=O)(=O)O)O
DMDUB63 IK KYARBIJYVGJZLB-UHFFFAOYSA-N
DMDUB63 IU 7-amino-4-hydroxynaphthalene-2-sulfonic acid
DMDUB63 CA CAS 87-02-5
DMDUB63 CB CHEBI:87316
DMDUB63 DE Discovery agent
DMC8O3Z ID DMC8O3Z
DMC8O3Z DN 7-AMINO-4-METHYL-CHROMEN-2-ONE
DMC8O3Z HS Investigative
DMC8O3Z SN 7-Amino-4-methylcoumarin; 26093-31-2; Coumarin 120; 7-Amino-4-methyl-2H-chromen-2-one; 4-Methyl-7-aminocoumarin; 2H-1-Benzopyran-2-one, 7-amino-4-methyl-; Coumarin, 7-amino-4-methyl-; 7-AMINO-4-METHYL-CHROMEN-2-ONE; UNII-OCY3JCT44X; CCRIS 4961; 7-amino-4-methylchromen-2-one; EINECS 247-454-8; NSC 45796; OCY3JCT44X; 7-amino-4-methyl-coumarin; MLS000057660; AMC; CHEBI:51771; GLNDAGDHSLMOKX-UHFFFAOYSA-N; NSC45796; MFCD00006868; GEO-02697; SMR000067752; AK-34405; 7-amino-4-methyl-2H-1-Benzopyran-2-one; A-6591; A1-00199; J-100007
DMC8O3Z DT Small molecular drug
DMC8O3Z PC 92249
DMC8O3Z MW 175.18
DMC8O3Z FM C10H9NO2
DMC8O3Z IC InChI=1S/C10H9NO2/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5H,11H2,1H3
DMC8O3Z CS CC1=CC(=O)OC2=C1C=CC(=C2)N
DMC8O3Z IK GLNDAGDHSLMOKX-UHFFFAOYSA-N
DMC8O3Z IU 7-amino-4-methylchromen-2-one
DMC8O3Z CA CAS 26093-31-2
DMC8O3Z CB CHEBI:51771
DMC8O3Z DE Discovery agent
DMZDP5S ID DMZDP5S
DMZDP5S DN 7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one
DMZDP5S HS Investigative
DMZDP5S SN CHEMBL198944; 7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one; SCHEMBL3534476
DMZDP5S DT Small molecular drug
DMZDP5S PC 11508573
DMZDP5S MW 351.4
DMZDP5S FM C20H17NO5
DMZDP5S IC InChI=1S/C20H17NO5/c22-17-13-19(21-8-10-24-11-9-21)26-18-12-15(6-7-16(17)18)25-20(23)14-4-2-1-3-5-14/h1-7,12-13H,8-11H2
DMZDP5S CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OC(=O)C4=CC=CC=C4
DMZDP5S IK GIEJDWWZPMOULL-UHFFFAOYSA-N
DMZDP5S IU (2-morpholin-4-yl-4-oxochromen-7-yl) benzoate
DMZDP5S DE Discovery agent
DMCJED6 ID DMCJED6
DMCJED6 DN 7-benzylidenenaltrexone
DMCJED6 HS Investigative
DMCJED6 SN Bntx-7; CHEMBL101519; Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-, (5alpha)-; C27H27NO4; 7-BNTX; 129468-28-6; (Z)-7-Benzylidenenaltrexone; GTPL1634; SCHEMBL15354616; CHEBI:125500; BDBM50450986; LS-172729
DMCJED6 DT Small molecular drug
DMCJED6 PC 5310988
DMCJED6 MW 429.5
DMCJED6 FM C27H27NO4
DMCJED6 IC InChI=1S/C27H27NO4/c29-20-9-8-18-13-21-27(31)14-19(12-16-4-2-1-3-5-16)23(30)25-26(27,22(18)24(20)32-25)10-11-28(21)15-17-6-7-17/h1-5,8-9,12,17,21,25,29,31H,6-7,10-11,13-15H2/b19-12+/t21-,25+,26+,27-/m1/s1
DMCJED6 CS C1CC1CN2CC[C@]34[C@@H]5C(=O)/C(=C/C6=CC=CC=C6)/C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O
DMCJED6 IK WXOUFNFMPVMGFZ-BDQAUFNLSA-N
DMCJED6 IU (4R,4aS,6E,7aR,12bS)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMCJED6 CB CHEBI:138855
DMCJED6 DE Discovery agent
DMMXAEN ID DMMXAEN
DMMXAEN DN 7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one
DMMXAEN HS Investigative
DMMXAEN SN CHEMBL95298; 7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one; SCHEMBL3536307; BDBM50178028; 7-Benzyloxy-2-morpholin-4-yl-chromen-4-one
DMMXAEN DT Small molecular drug
DMMXAEN PC 11522900
DMMXAEN MW 337.4
DMMXAEN FM C20H19NO4
DMMXAEN IC InChI=1S/C20H19NO4/c22-18-13-20(21-8-10-23-11-9-21)25-19-12-16(6-7-17(18)19)24-14-15-4-2-1-3-5-15/h1-7,12-13H,8-11,14H2
DMMXAEN CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OCC4=CC=CC=C4
DMMXAEN IK KUCJYOZKCJHLND-UHFFFAOYSA-N
DMMXAEN IU 2-morpholin-4-yl-7-phenylmethoxychromen-4-one
DMMXAEN DE Discovery agent
DMYKXWE ID DMYKXWE
DMYKXWE DN 7beta, 25-dihydroxycholesterol
DMYKXWE HS Investigative
DMYKXWE SN CHEMBL3311219; (3S,7R,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol; 7beta,25-dihydroxycholesterol; 7beta, 25-dihydroxycholesterol; AC1LAQHU; GTPL4355; SCHEMBL2485860; 7.beta.,25-Dihydroxycholesterol; BDBM50045543; (3.beta.,7.beta.)-7,25-Dihydroxycholest-5-en-3-ol
DMYKXWE DT Small molecular drug
DMYKXWE PC 473142
DMYKXWE MW 418.7
DMYKXWE FM C27H46O3
DMYKXWE IC InChI=1S/C27H46O3/c1-17(7-6-12-25(2,3)30)20-8-9-21-24-22(11-14-27(20,21)5)26(4)13-10-19(28)15-18(26)16-23(24)29/h16-17,19-24,28-30H,6-15H2,1-5H3/t17-,19+,20-,21+,22+,23+,24+,26+,27-/m1/s1
DMYKXWE CS C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMYKXWE IK BQMSKLCEWBSPPY-CGSQRZAOSA-N
DMYKXWE IU (3S,7R,8S,9S,10R,13R,14S,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMYKXWE DE Discovery agent
DMSDINR ID DMSDINR
DMSDINR DN 7beta, 27-dihydroxycholesterol
DMSDINR HS Investigative
DMSDINR SN 7beta,26-dihydroxycholesterol
DMSDINR DT Small molecular drug
DMSDINR PC 52931518
DMSDINR MW 418.7
DMSDINR FM C27H46O3
DMSDINR IC InChI=1S/C27H46O3/c1-17(16-28)6-5-7-18(2)21-8-9-22-25-23(11-13-27(21,22)4)26(3)12-10-20(29)14-19(26)15-24(25)30/h15,17-18,20-25,28-30H,5-14,16H2,1-4H3/t17-,18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1
DMSDINR CS C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C)CO
DMSDINR IK RXMHNAKZMGJANZ-BMOLSTJGSA-N
DMSDINR IU (3S,7R,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMSDINR DE Discovery agent
DMPHJZU ID DMPHJZU
DMPHJZU DN 7beta-hydroxycholesterol
DMPHJZU HS Investigative
DMPHJZU SN 7-beta-OHC
DMPHJZU DT Small molecular drug
DMPHJZU PC 473141
DMPHJZU MW 402.7
DMPHJZU FM C27H46O2
DMPHJZU IC InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24+,25+,26+,27-/m1/s1
DMPHJZU CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMPHJZU IK OYXZMSRRJOYLLO-KGZHIOMZSA-N
DMPHJZU IU (3S,7R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMPHJZU CA CAS 566-27-8
DMPHJZU CB CHEBI:42989
DMPHJZU DE Discovery agent
DMV54MT ID DMV54MT
DMV54MT DN 7-Biphenyl-4-yl-heptanoic acid hydroxyamide
DMV54MT HS Investigative
DMV54MT SN CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid
DMV54MT DT Small molecular drug
DMV54MT PC 44349481
DMV54MT MW 297.4
DMV54MT FM C19H23NO2
DMV54MT IC InChI=1S/C19H23NO2/c21-19(20-22)11-7-2-1-4-8-16-12-14-18(15-13-16)17-9-5-3-6-10-17/h3,5-6,9-10,12-15,22H,1-2,4,7-8,11H2,(H,20,21)
DMV54MT CS C1=CC=C(C=C1)C2=CC=C(C=C2)CCCCCCC(=O)NO
DMV54MT IK UDSUAIGMNDAMBQ-UHFFFAOYSA-N
DMV54MT IU N-hydroxy-7-(4-phenylphenyl)heptanamide
DMV54MT DE Discovery agent
DMYBNCO ID DMYBNCO
DMYBNCO DN 7-bromo-1H-indazole
DMYBNCO HS Investigative
DMYBNCO SN 7-bromo-1H-indazole; 53857-58-2; 7-Bromoindazole; 7-Bromo-2H-indazole; 845751-59-9; 1H-Indazole, 7-bromo-; 1H-INDAZOLE,7-BROMO-; CHEMBL439566; AK-26850; PubChem14406; 2H-Indazole, 7-bromo-; ACMC-1B1ZL; BROMOINDAZOLE(7-); T56 BMNJ IE; KSC268A6L; 7-Bromo-1H-indazole, 97%; SCHEMBL1855857; CTK1G8065; MolPort-027-946-828; MolPort-006-717-407; KMHHWCPTROQUFM-UHFFFAOYSA-N; ZX-AT005164; BCP00108; STL555654; 2999AC; FCH835100; ANW-31868; ZINC14007945; MFCD07371564; BBL101857; SBB092096; BDBM50209239; AKOS016013628; AKOS005072291; RTC-062730; RP04094
DMYBNCO DT Small molecular drug
DMYBNCO PC 20323899
DMYBNCO MW 197.03
DMYBNCO FM C7H5BrN2
DMYBNCO IC InChI=1S/C7H5BrN2/c8-6-3-1-2-5-4-9-10-7(5)6/h1-4H,(H,9,10)
DMYBNCO CS C1=CC2=C(C(=C1)Br)NN=C2
DMYBNCO IK KMHHWCPTROQUFM-UHFFFAOYSA-N
DMYBNCO IU 7-bromo-1H-indazole
DMYBNCO CA CAS 53857-58-2
DMYBNCO DE Discovery agent
DMA8DXG ID DMA8DXG
DMA8DXG DN 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DMA8DXG HS Investigative
DMA8DXG SN CHEMBL183782; 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol; SCHEMBL3927964; UBYHIUUMRHTEFF-UHFFFAOYSA-N
DMA8DXG DT Small molecular drug
DMA8DXG PC 10286352
DMA8DXG MW 305.12
DMA8DXG FM C14H9BrO3
DMA8DXG IC InChI=1S/C14H9BrO3/c15-12-7-11(17)5-9-6-13(18-14(9)12)8-1-3-10(16)4-2-8/h1-7,16-17H
DMA8DXG CS C1=CC(=CC=C1C2=CC3=CC(=CC(=C3O2)Br)O)O
DMA8DXG IK UBYHIUUMRHTEFF-UHFFFAOYSA-N
DMA8DXG IU 7-bromo-2-(4-hydroxyphenyl)-1-benzofuran-5-ol
DMA8DXG DE Discovery agent
DMVTH0Q ID DMVTH0Q
DMVTH0Q DN 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMVTH0Q HS Investigative
DMVTH0Q SN 7-Bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 108061-47-8; CHEMBL441891; 7-Bromo-1,2,3,4-tetrahydro-beta-carboline; 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; CS-WAA0033; SCHEMBL3476066; CTK8C1152; DTXSID00434588; XAHAQVIJZAMMLO-UHFFFAOYSA-N; ZINC13587967; BDBM50136507; 1620AA; ANW-65970; AKOS016005623; CB-3796; FCH1610363; CS-15602; AJ-64214; TC-154715; KB-249517; AX8236304
DMVTH0Q DT Small molecular drug
DMVTH0Q PC 10037784
DMVTH0Q MW 251.12
DMVTH0Q FM C11H11BrN2
DMVTH0Q IC InChI=1S/C11H11BrN2/c12-7-1-2-8-9-3-4-13-6-11(9)14-10(8)5-7/h1-2,5,13-14H,3-4,6H2
DMVTH0Q CS C1CNCC2=C1C3=C(N2)C=C(C=C3)Br
DMVTH0Q IK XAHAQVIJZAMMLO-UHFFFAOYSA-N
DMVTH0Q IU 7-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMVTH0Q CA CAS 108061-47-8
DMVTH0Q DE Discovery agent
DMG8ZJA ID DMG8ZJA
DMG8ZJA DN 7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol
DMG8ZJA HS Investigative
DMG8ZJA SN CHEMBL97687; 7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol; BDBM50090700; ZINC13579521; 7-bromo-2-phenyl-1,8-naphthyridin-4-ol
DMG8ZJA DT Small molecular drug
DMG8ZJA PC 10402581
DMG8ZJA MW 301.14
DMG8ZJA FM C14H9BrN2O
DMG8ZJA IC InChI=1S/C14H9BrN2O/c15-13-7-6-10-12(18)8-11(16-14(10)17-13)9-4-2-1-3-5-9/h1-8H,(H,16,17,18)
DMG8ZJA CS C1=CC=C(C=C1)C2=CC(=O)C3=C(N2)N=C(C=C3)Br
DMG8ZJA IK ZVIMMGQTBAKKGA-UHFFFAOYSA-N
DMG8ZJA IU 7-bromo-2-phenyl-1H-1,8-naphthyridin-4-one
DMG8ZJA DE Discovery agent
DMCWYT7 ID DMCWYT7
DMCWYT7 DN 7-Bromo-4,9-dihydro-3H-beta-carboline
DMCWYT7 HS Investigative
DMCWYT7 SN CHEMBL428999; 7-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136497
DMCWYT7 DT Small molecular drug
DMCWYT7 PC 44264453
DMCWYT7 MW 249.11
DMCWYT7 FM C11H9BrN2
DMCWYT7 IC InChI=1S/C11H9BrN2/c12-7-1-2-8-9-3-4-13-6-11(9)14-10(8)5-7/h1-2,5-6,14H,3-4H2
DMCWYT7 CS C1CN=CC2=C1C3=C(N2)C=C(C=C3)Br
DMCWYT7 IK NTZLLWPDAQVIOA-UHFFFAOYSA-N
DMCWYT7 IU 7-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DMCWYT7 DE Discovery agent
DMX85IF ID DMX85IF
DMX85IF DN 7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol
DMX85IF HS Investigative
DMX85IF DT Small molecular drug
DMX85IF PC 135520118
DMX85IF MW 344.16
DMX85IF FM C16H10BrNO3
DMX85IF IC InChI=1S/C16H10BrNO3/c17-15-11-5-8(19)2-4-13(11)18-16-10-3-1-9(20)6-14(10)21-7-12(15)16/h1-6,19-20H,7H2
DMX85IF CS C1C2=C(C3=C(C=CC(=C3)O)N=C2C4=C(O1)C=C(C=C4)O)Br
DMX85IF IK UHDQHUPIXKORDL-UHFFFAOYSA-N
DMX85IF IU 7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol
DMX85IF DE Discovery agent
DM3G8I7 ID DM3G8I7
DM3G8I7 DN 7-bromoindirubin-3-acetoxime
DM3G8I7 HS Investigative
DM3G8I7 DT Small molecular drug
DM3G8I7 PC 136104465
DM3G8I7 MW 398.2
DM3G8I7 FM C18H12BrN3O3
DM3G8I7 IC InChI=1S/C18H12BrN3O3/c1-9(23)25-22-16-10-5-2-3-8-13(10)20-17(16)14-11-6-4-7-12(19)15(11)21-18(14)24/h2-8,21,24H,1H3/b22-16-
DM3G8I7 CS CC(=O)O/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC=C4Br)O
DM3G8I7 IK CHULSJBNZJIYCG-JWGURIENSA-N
DM3G8I7 IU [(Z)-[2-(7-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DM3G8I7 DE Discovery agent
DM07QD3 ID DM07QD3
DM07QD3 DN 7-bromoindirubin-3-oxime
DM07QD3 HS Investigative
DM07QD3 DT Small molecular drug
DM07QD3 PC 91936028
DM07QD3 MW 356.17
DM07QD3 FM C16H10BrN3O2
DM07QD3 IC InChI=1S/C16H10BrN3O2/c17-10-6-3-5-9-12(16(21)19-13(9)10)15-14(20-22)8-4-1-2-7-11(8)18-15/h1-7,12,18H,(H,19,21)
DM07QD3 CS C1=CC=C2C(=C1)C(=C(N2)C3C4=C(C(=CC=C4)Br)NC3=O)N=O
DM07QD3 IK GMRAFJUVKHMGPN-UHFFFAOYSA-N
DM07QD3 IU 7-bromo-3-(3-nitroso-1H-indol-2-yl)-1,3-dihydroindol-2-one
DM07QD3 DE Discovery agent
DML8PH7 ID DML8PH7
DML8PH7 DN 7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7 HS Investigative
DML8PH7 SN CHEMBL1080277; 7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7 DT Small molecular drug
DML8PH7 PC 46879685
DML8PH7 MW 378.06
DML8PH7 FM C15H10Br2N2
DML8PH7 IC InChI=1S/C15H10Br2N2/c16-11-2-1-3-13(8-11)19-15-14-9-12(17)5-4-10(14)6-7-18-15/h1-9H,(H,18,19)
DML8PH7 CS C1=CC(=CC(=C1)Br)NC2=NC=CC3=C2C=C(C=C3)Br
DML8PH7 IK FGMDNVCIUONADU-UHFFFAOYSA-N
DML8PH7 IU 7-bromo-N-(3-bromophenyl)isoquinolin-1-amine
DML8PH7 DE Discovery agent
DM78C5A ID DM78C5A
DM78C5A DN 7-butoxy-2H-chromen-2-one
DM78C5A HS Investigative
DM78C5A SN 7-butoxy-2H-chromen-2-one; 7-BUTOXYCOUMARIN; 7-butoxychromen-2-one; 2H-1-Benzopyran-2-one, 7-butoxy-; CHEMBL571514; 71783-00-1; CBMicro_045472; AC1L4FS0; SCHEMBL6686295; DTXSID40221994; MolPort-002-085-798; ZINC2950199; STK371317; BDBM50303502; AKOS001064182; MCULE-1530014848; BIM-0045671.P001; ST50462808; SR-01000227430
DM78C5A DT Small molecular drug
DM78C5A PC 156219
DM78C5A MW 218.25
DM78C5A FM C13H14O3
DM78C5A IC InChI=1S/C13H14O3/c1-2-3-8-15-11-6-4-10-5-7-13(14)16-12(10)9-11/h4-7,9H,2-3,8H2,1H3
DM78C5A CS CCCCOC1=CC2=C(C=C1)C=CC(=O)O2
DM78C5A IK BDOGTORASJEUBW-UHFFFAOYSA-N
DM78C5A IU 7-butoxychromen-2-one
DM78C5A CA CAS 71783-00-1
DM78C5A DE Discovery agent
DMQ8BIX ID DMQ8BIX
DMQ8BIX DN 7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMQ8BIX HS Investigative
DMQ8BIX DT Small molecular drug
DMQ8BIX PC 135499774
DMQ8BIX MW 283.32
DMQ8BIX FM C17H17NO3
DMQ8BIX IC InChI=1S/C17H17NO3/c1-2-3-4-12-9-14(20)10-15-16(12)21-17(18-15)11-5-7-13(19)8-6-11/h5-10,19-20H,2-4H2,1H3
DMQ8BIX CS CCCCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMQ8BIX IK MEBUPUARJUIPAP-UHFFFAOYSA-N
DMQ8BIX IU 7-butyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMQ8BIX DE Discovery agent
DMVTK0A ID DMVTK0A
DMVTK0A DN 7-Butyl-azepan-(2Z)-ylideneamine
DMVTK0A HS Investigative
DMVTK0A SN CHEMBL89288; CHEMBL543514; SCHEMBL7628313; BDBM50064011; 2-Imino-7-butylhexahydro-1H-azepine; 7-Butyl-azepan-(2Z)-ylideneamine
DMVTK0A DT Small molecular drug
DMVTK0A PC 10104379
DMVTK0A MW 168.28
DMVTK0A FM C10H20N2
DMVTK0A IC InChI=1S/C10H20N2/c1-2-3-6-9-7-4-5-8-10(11)12-9/h9H,2-8H2,1H3,(H2,11,12)
DMVTK0A CS CCCCC1CCCCC(=N1)N
DMVTK0A IK LXZWIIJORJEBKG-UHFFFAOYSA-N
DMVTK0A IU 2-butyl-3,4,5,6-tetrahydro-2H-azepin-7-amine
DMVTK0A DE Discovery agent
DM1SEXA ID DM1SEXA
DM1SEXA DN 7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DM1SEXA HS Investigative
DM1SEXA SN 7-chloro-1,2,3,4-tetrahydroacridin-9-amine; BRN 0394541; ACRIDINE, 1,2,3,4-TETRAHYDRO-9-AMINO-7-CHLORO-; 6115-67-9; 9-Amino-7-chloro-1,2,3,4-tetrahydroacridine; Tacrine Analogue 3; AC1L2KHB; CHEMBL62084; BDBM8986; DTXSID20210043; ZINC2034186; AKOS011482955; LS-14463
DM1SEXA DT Small molecular drug
DM1SEXA PC 22493
DM1SEXA MW 232.71
DM1SEXA FM C13H13ClN2
DM1SEXA IC InChI=1S/C13H13ClN2/c14-8-5-6-12-10(7-8)13(15)9-3-1-2-4-11(9)16-12/h5-7H,1-4H2,(H2,15,16)
DM1SEXA CS C1CCC2=NC3=C(C=C(C=C3)Cl)C(=C2C1)N
DM1SEXA IK PUKKYURTEBJMKJ-UHFFFAOYSA-N
DM1SEXA IU 7-chloro-1,2,3,4-tetrahydroacridin-9-amine
DM1SEXA CA CAS 6115-67-9
DM1SEXA DE Discovery agent
DMP5JF8 ID DMP5JF8
DMP5JF8 DN 7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMP5JF8 HS Investigative
DMP5JF8 SN 7-chloro-1H,2H,3H,4H-pyrazino[1,2-a]indole; CHEMBL290779; 287384-61-6; 7-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole; 7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole; SCHEMBL5619809; PSLRQWHMXFDQNK-UHFFFAOYSA-N; MolPort-022-445-854; BDBM50108315; ZINC13586841; AKOS022692453; NE33360
DMP5JF8 DT Small molecular drug
DMP5JF8 PC 21868720
DMP5JF8 MW 206.67
DMP5JF8 FM C11H11ClN2
DMP5JF8 IC InChI=1S/C11H11ClN2/c12-9-2-1-8-5-10-7-13-3-4-14(10)11(8)6-9/h1-2,5-6,13H,3-4,7H2
DMP5JF8 CS C1CN2C(=CC3=C2C=C(C=C3)Cl)CN1
DMP5JF8 IK PSLRQWHMXFDQNK-UHFFFAOYSA-N
DMP5JF8 IU 7-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMP5JF8 DE Discovery agent
DMWUS5Q ID DMWUS5Q
DMWUS5Q DN 7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMWUS5Q HS Investigative
DMWUS5Q SN CHEMBL98851; 7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL10758208; 2H-Imidazo[4,5-b]quinolin-2-one, 7-chloro-1,3-dihydro-; BDBM50007221
DMWUS5Q DT Small molecular drug
DMWUS5Q PC 13936972
DMWUS5Q MW 219.63
DMWUS5Q FM C10H6ClN3O
DMWUS5Q IC InChI=1S/C10H6ClN3O/c11-6-1-2-7-5(3-6)4-8-9(12-7)14-10(15)13-8/h1-4H,(H2,12,13,14,15)
DMWUS5Q CS C1=CC2=NC3=C(C=C2C=C1Cl)NC(=O)N3
DMWUS5Q IK OSBMKBWTTUTUMA-UHFFFAOYSA-N
DMWUS5Q IU 7-chloro-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMWUS5Q DE Discovery agent
DMPJWIB ID DMPJWIB
DMPJWIB DN 7-chloro-1,3-dihydroxyacridone
DMPJWIB HS Investigative
DMPJWIB DE Discovery agent
DMX8DZM ID DMX8DZM
DMX8DZM DN 7-chloro-1H-indazole
DMX8DZM HS Investigative
DMX8DZM SN 7-chloro-1H-indazole; 37435-12-4; 7-Chloroindazole; 1H-Indazole, 7-chloro-; CHEMBL247367; AK-24465; 7-chlor-1H-indazol; ACMC-1AG86; SCHEMBL104360; SCHEMBL19152469; CTK1C1806; DTXSID80455690; WIYOYUQVNPTVQG-UHFFFAOYSA-N; MolPort-001-767-757; 7-Chloro-1H-indazole, AldrichCPR; ZX-AT002536; BCP27378; BDBM50209244; ZINC12336533; STL554161; SBB054730; MFCD07368214; ANW-28635; OR3680; FCH921470; BBL100367; AKOS024124979; AKOS005072025; VI20076; RP01758; MCULE-5657266195; CB-0833; PB17411; ACM37435124; KB-46237; SC-27673; QC-11238; BL000561; AN-17144
DMX8DZM DT Small molecular drug
DMX8DZM PC 11116249
DMX8DZM MW 152.58
DMX8DZM FM C7H5ClN2
DMX8DZM IC InChI=1S/C7H5ClN2/c8-6-3-1-2-5-4-9-10-7(5)6/h1-4H,(H,9,10)
DMX8DZM CS C1=CC2=C(C(=C1)Cl)NN=C2
DMX8DZM IK WIYOYUQVNPTVQG-UHFFFAOYSA-N
DMX8DZM IU 7-chloro-1H-indazole
DMX8DZM CA CAS 37435-12-4
DMX8DZM DE Discovery agent
DMCZLKA ID DMCZLKA
DMCZLKA DN 7-chloro-1H-indole-2,3-dione
DMCZLKA HS Investigative
DMCZLKA SN 7-Chloroisatin; 7477-63-6; 7-chloro-1H-indole-2,3-dione; 7-chloroindoline-2,3-dione; 7-chloro-2,3-dihydro-1H-indole-2,3-dione; 7-chloro-2,3-indolinedione; MLS003171490; 1H-INDOLE-2,3-DIONE, 7-CHLORO-; 1H-Indole-2,3-dione,7-chloro-; MFCD00022796; 7-chloro-1H-benzo[d]azolidine-2,3-dione; 7-chlorisatin; 7-chloro isatin; NSC400868; PubChem15537; 7-Chloroisatin, 97%; AC1Q3HYB; AC1L7ZVK; AC1Q3KGY; ACMC-209zr4; 7-Chloroindole-2,3-dione; Isatin-based compound, 43; KSC640I8T; 7-chloro-indoline-2,3-dione; SCHEMBL1247382; CHEMBL222190
DMCZLKA DT Small molecular drug
DMCZLKA PC 344135
DMCZLKA MW 181.57
DMCZLKA FM C8H4ClNO2
DMCZLKA IC InChI=1S/C8H4ClNO2/c9-5-3-1-2-4-6(5)10-8(12)7(4)11/h1-3H,(H,10,11,12)
DMCZLKA CS C1=CC2=C(C(=C1)Cl)NC(=O)C2=O
DMCZLKA IK MPLXQMMMGDYXIT-UHFFFAOYSA-N
DMCZLKA IU 7-chloro-1H-indole-2,3-dione
DMCZLKA CA CAS 7477-63-6
DMCZLKA DE Discovery agent
DM38HKE ID DM38HKE
DM38HKE DN 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol
DM38HKE HS Investigative
DM38HKE SN CHEMBL184448; 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol; SCHEMBL3922992
DM38HKE DT Small molecular drug
DM38HKE PC 10236250
DM38HKE MW 260.67
DM38HKE FM C14H9ClO3
DM38HKE IC InChI=1S/C14H9ClO3/c15-12-7-11(17)5-9-6-13(18-14(9)12)8-1-3-10(16)4-2-8/h1-7,16-17H
DM38HKE CS C1=CC(=CC=C1C2=CC3=CC(=CC(=C3O2)Cl)O)O
DM38HKE IK OCILFYQUCSGLEE-UHFFFAOYSA-N
DM38HKE IU 7-chloro-2-(4-hydroxyphenyl)-1-benzofuran-5-ol
DM38HKE DE Discovery agent
DM9TZH4 ID DM9TZH4
DM9TZH4 DN 7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol
DM9TZH4 HS Investigative
DM9TZH4 SN 7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine; CHEMBL97760; 286411-09-4; NCGC00015250-01; Lopac-C-5982; 7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol; AC1O0Y6J; Lopac0_000305; SCHEMBL378998; CTK8F7271; CTK8E5517; HMS3260N12; ZINC8582290; Tox21_500305; BDBM50090697; AKOS028113015; TRA0054236; LP00305; CCG-204400; NCGC00093754-02; NCGC00015250-03; NCGC00260990-01; NCGC00093754-01; NCGC00015250-05; NCGC00015250-02; NCGC00015250-04; 7-chloro-2-phenyl-1,8-naphthyridin-4-ol; TX-017366; KB-270267; 2-Phenyl-7-chloro-1,8-naphthyridine-4-ol
DM9TZH4 DT Small molecular drug
DM9TZH4 PC 6105572
DM9TZH4 MW 256.68
DM9TZH4 FM C14H9ClN2O
DM9TZH4 IC InChI=1S/C14H9ClN2O/c15-13-7-6-10-12(18)8-11(16-14(10)17-13)9-4-2-1-3-5-9/h1-8H,(H,16,17,18)
DM9TZH4 CS C1=CC=C(C=C1)C2=CC(=O)C3=C(N2)N=C(C=C3)Cl
DM9TZH4 IK JSCUNIPKMPNPFX-UHFFFAOYSA-N
DM9TZH4 IU 7-chloro-2-phenyl-1H-1,8-naphthyridin-4-one
DM9TZH4 DE Discovery agent
DM3OMLU ID DM3OMLU
DM3OMLU DN 7-chloro-3-hydroxyquinazoline-2,4-dione
DM3OMLU HS Investigative
DM3OMLU SN CHEMBL80594; 3-hydroxy-7-chloro-1H-quinazoline-2,4-dione; 705977-20-4; 7-chloro-3-hydroxyquinazoline-2,4-dione; BDBM50144806
DM3OMLU DT Small molecular drug
DM3OMLU PC 44315786
DM3OMLU MW 212.59
DM3OMLU FM C8H5ClN2O3
DM3OMLU IC InChI=1S/C8H5ClN2O3/c9-4-1-2-5-6(3-4)10-8(13)11(14)7(5)12/h1-3,14H,(H,10,13)
DM3OMLU CS C1=CC2=C(C=C1Cl)NC(=O)N(C2=O)O
DM3OMLU IK CRTPJJNXJPKDEZ-UHFFFAOYSA-N
DM3OMLU IU 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione
DM3OMLU DE Discovery agent
DM53A1R ID DM53A1R
DM53A1R DN 7-Chloro-3-pyridin-4-yl-quinoline
DM53A1R HS Investigative
DM53A1R SN CHEMBL86664; 7-chloro-3-pyridin-4-yl-quinoline; 7-Chloro-3-(4-pyridyl)quinoline
DM53A1R DT Small molecular drug
DM53A1R PC 10354294
DM53A1R MW 240.69
DM53A1R FM C14H9ClN2
DM53A1R IC InChI=1S/C14H9ClN2/c15-13-2-1-11-7-12(9-17-14(11)8-13)10-3-5-16-6-4-10/h1-9H
DM53A1R CS C1=CC(=CC2=NC=C(C=C21)C3=CC=NC=C3)Cl
DM53A1R IK WMECTFBVYBAOOF-UHFFFAOYSA-N
DM53A1R IU 7-chloro-3-pyridin-4-ylquinoline
DM53A1R DE Discovery agent
DMRNZYQ ID DMRNZYQ
DMRNZYQ DN 7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol
DMRNZYQ HS Investigative
DMRNZYQ DT Small molecular drug
DMRNZYQ PC 135466468
DMRNZYQ MW 299.71
DMRNZYQ FM C16H10ClNO3
DMRNZYQ IC InChI=1S/C16H10ClNO3/c17-15-11-5-8(19)2-4-13(11)18-16-10-3-1-9(20)6-14(10)21-7-12(15)16/h1-6,19-20H,7H2
DMRNZYQ CS C1C2=C(C3=C(C=CC(=C3)O)N=C2C4=C(O1)C=C(C=C4)O)Cl
DMRNZYQ IK RYBHKLZSHRZGQK-UHFFFAOYSA-N
DMRNZYQ IU 7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol
DMRNZYQ DE Discovery agent
DM28NAB ID DM28NAB
DM28NAB DN 7-chloroindirubin-3-oxime
DM28NAB HS Investigative
DM28NAB DT Small molecular drug
DM28NAB PC 11845976
DM28NAB DE Discovery agent
DM2MIJY ID DM2MIJY
DM2MIJY DN 7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one
DM2MIJY HS Investigative
DM2MIJY SN SCHEMBL1700973
DM2MIJY DT Small molecular drug
DM2MIJY PC 46914767
DM2MIJY MW 322.4
DM2MIJY FM C20H18O4
DM2MIJY IC InChI=1S/C20H18O4/c21-14-7-5-13(6-8-14)18-12-23-19-11-16(9-10-17(19)20(18)22)24-15-3-1-2-4-15/h5-12,15,21H,1-4H2
DM2MIJY CS C1CCC(C1)OC2=CC3=C(C=C2)C(=O)C(=CO3)C4=CC=C(C=C4)O
DM2MIJY IK RFDBJXQLCPTPCX-UHFFFAOYSA-N
DM2MIJY IU 7-cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one
DM2MIJY DE Discovery agent
DMANYSO ID DMANYSO
DMANYSO DN 7-Diazonium-naphthalene-1-sulfonic acid anion
DMANYSO HS Investigative
DMANYSO SN CHEMBL71830
DMANYSO DT Small molecular drug
DMANYSO PC 13948289
DMANYSO MW 234.23
DMANYSO FM C10H6N2O3S
DMANYSO IC InChI=1S/C10H6N2O3S/c11-12-8-5-4-7-2-1-3-10(9(7)6-8)16(13,14)15/h1-6H
DMANYSO CS C1=CC2=C(C=C(C=C2)[N+]#N)C(=C1)S(=O)(=O)[O-]
DMANYSO IK ABQHTWPSSABLIQ-UHFFFAOYSA-N
DMANYSO IU 7-diazonionaphthalene-1-sulfonate
DMANYSO DE Discovery agent
DMNEAU0 ID DMNEAU0
DMNEAU0 DN 7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol
DMNEAU0 HS Investigative
DMNEAU0 SN CHEMBL102429; 7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol; ZINC13579545; BDBM50147858
DMNEAU0 DT Small molecular drug
DMNEAU0 PC 10378184
DMNEAU0 MW 265.31
DMNEAU0 FM C16H15N3O
DMNEAU0 IC InChI=1S/C16H15N3O/c1-19(2)15-9-8-12-14(20)10-13(17-16(12)18-15)11-6-4-3-5-7-11/h3-10H,1-2H3,(H,17,18,20)
DMNEAU0 CS CN(C)C1=NC2=C(C=C1)C(=O)C=C(N2)C3=CC=CC=C3
DMNEAU0 IK BEMRWFAUJDRLIY-UHFFFAOYSA-N
DMNEAU0 IU 7-(dimethylamino)-2-phenyl-1H-1,8-naphthyridin-4-one
DMNEAU0 DE Discovery agent
DMDY2PQ ID DMDY2PQ
DMDY2PQ DN 7-Dimethylamino-3-methyl-hept-5-yn-2-one
DMDY2PQ HS Investigative
DMDY2PQ SN CHEMBL165985
DMDY2PQ DT Small molecular drug
DMDY2PQ PC 15685978
DMDY2PQ MW 167.25
DMDY2PQ FM C10H17NO
DMDY2PQ IC InChI=1S/C10H17NO/c1-9(10(2)12)7-5-6-8-11(3)4/h9H,7-8H2,1-4H3
DMDY2PQ CS CC(CC#CCN(C)C)C(=O)C
DMDY2PQ IK PDSSGGXKHZHTIQ-UHFFFAOYSA-N
DMDY2PQ IU 7-(dimethylamino)-3-methylhept-5-yn-2-one
DMDY2PQ DE Discovery agent
DMH782V ID DMH782V
DMH782V DN 7-Dimethylamino-hept-5-yn-2-one
DMH782V HS Investigative
DMH782V SN CHEMBL166736; 7-(dimethylamino)hept-5-yn-2-one; 7-Dimethylamino-hept-5-yn-2-one; AC1L2EXE; AC1Q5H3K
DMH782V DT Small molecular drug
DMH782V PC 19816
DMH782V MW 153.22
DMH782V FM C9H15NO
DMH782V IC InChI=1S/C9H15NO/c1-9(11)7-5-4-6-8-10(2)3/h5,7-8H2,1-3H3
DMH782V CS CC(=O)CCC#CCN(C)C
DMH782V IK UYTLBASHEWACKP-UHFFFAOYSA-N
DMH782V IU 7-(dimethylamino)hept-5-yn-2-one
DMH782V DE Discovery agent
DMRAZDW ID DMRAZDW
DMRAZDW DN 7-epi-ginkgolide C
DMRAZDW HS Investigative
DMRAZDW SN 7-epi-GC
DMRAZDW DT Small molecular drug
DMRAZDW PC 58761009
DMRAZDW MW 440.4
DMRAZDW FM C20H24O11
DMRAZDW IC InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5?,6-,7?,8?,9+,10?,11+,15?,17?,18?,19-,20+/m1/s1
DMRAZDW CS CC1C(=O)O[C@@H]2[C@]1([C@]34C(=O)OC5C3(C2O)C6([C@H](C(=O)OC6O4)O)C([C@H]5O)C(C)(C)C)O
DMRAZDW IK AMOGMTLMADGEOQ-RNOCTPMTSA-N
DMRAZDW IU (1S,6R,9R,13S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMRAZDW DE Discovery agent
DMI16MD ID DMI16MD
DMI16MD DN 7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMI16MD HS Investigative
DMI16MD SN CHEMBL98812; SCHEMBL10760128; 2H-Imidazo[4,5-b]quinolin-2-one, 7-ethoxy-1,3-dihydro-; BDBM50229572
DMI16MD DT Small molecular drug
DMI16MD PC 13936989
DMI16MD MW 229.23
DMI16MD FM C12H11N3O2
DMI16MD IC InChI=1S/C12H11N3O2/c1-2-17-8-3-4-9-7(5-8)6-10-11(13-9)15-12(16)14-10/h3-6H,2H2,1H3,(H2,13,14,15,16)
DMI16MD CS CCOC1=CC2=CC3=C(NC(=O)N3)N=C2C=C1
DMI16MD IK SBMFEGWRZYIWGG-UHFFFAOYSA-N
DMI16MD IU 7-ethoxy-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMI16MD DE Discovery agent
DMYJBPI ID DMYJBPI
DMYJBPI DN 7-ethoxy-8-propionyl-2H-chromen-2-one
DMYJBPI HS Investigative
DMYJBPI SN CHEMBL1288622; 7-ethoxy-8-propionyl-2H-chromen-2-one
DMYJBPI DT Small molecular drug
DMYJBPI PC 52949288
DMYJBPI MW 246.26
DMYJBPI FM C14H14O4
DMYJBPI IC InChI=1S/C14H14O4/c1-3-10(15)13-11(17-4-2)7-5-9-6-8-12(16)18-14(9)13/h5-8H,3-4H2,1-2H3
DMYJBPI CS CCC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OCC
DMYJBPI IK LJTVZULEIDSNAK-UHFFFAOYSA-N
DMYJBPI IU 7-ethoxy-8-propanoylchromen-2-one
DMYJBPI DE Discovery agent
DMUMN4B ID DMUMN4B
DMUMN4B DN 7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DMUMN4B HS Investigative
DMUMN4B DT Small molecular drug
DMUMN4B PC 135442585
DMUMN4B MW 255.27
DMUMN4B FM C15H13NO3
DMUMN4B IC InChI=1S/C15H13NO3/c1-2-9-7-12(18)8-13-14(9)19-15(16-13)10-3-5-11(17)6-4-10/h3-8,17-18H,2H2,1H3
DMUMN4B CS CCC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DMUMN4B IK PRIKKCCDYUBJIV-UHFFFAOYSA-N
DMUMN4B IU 7-ethyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DMUMN4B DE Discovery agent
DMSFODU ID DMSFODU
DMSFODU DN 7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMSFODU HS Investigative
DMSFODU DT Small molecular drug
DMSFODU PC 135466462
DMSFODU MW 293.3
DMSFODU FM C18H15NO3
DMSFODU IC InChI=1S/C18H15NO3/c1-2-12-14-7-10(20)4-6-16(14)19-18-13-5-3-11(21)8-17(13)22-9-15(12)18/h3-8,20-21H,2,9H2,1H3
DMSFODU CS CCC1=C2COC3=C(C2=NC4=C1C=C(C=C4)O)C=CC(=C3)O
DMSFODU IK OGDCTCUVBBYZTK-UHFFFAOYSA-N
DMSFODU IU 7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMSFODU DE Discovery agent
DMXM2G7 ID DMXM2G7
DMXM2G7 DN 7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMXM2G7 HS Investigative
DMXM2G7 SN CHEMBL196920; 7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMXM2G7 DT Small molecular drug
DMXM2G7 PC 11529823
DMXM2G7 MW 319.4
DMXM2G7 FM C17H21NO5
DMXM2G7 IC InChI=1S/C17H21NO5/c1-2-20-9-10-22-13-3-4-14-15(19)12-17(23-16(14)11-13)18-5-7-21-8-6-18/h3-4,11-12H,2,5-10H2,1H3
DMXM2G7 CS CCOCCOC1=CC2=C(C=C1)C(=O)C=C(O2)N3CCOCC3
DMXM2G7 IK ICGVDPFEKFHPNV-UHFFFAOYSA-N
DMXM2G7 IU 7-(2-ethoxyethoxy)-2-morpholin-4-ylchromen-4-one
DMXM2G7 DE Discovery agent
DM92EG5 ID DM92EG5
DM92EG5 DN 7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol
DM92EG5 HS Investigative
DM92EG5 DT Small molecular drug
DM92EG5 PC 135409723
DM92EG5 MW 251.24
DM92EG5 FM C15H9NO3
DM92EG5 IC InChI=1S/C15H9NO3/c1-2-9-7-12(18)8-13-14(9)19-15(16-13)10-3-5-11(17)6-4-10/h1,3-8,17-18H
DM92EG5 CS C#CC1=C2C(=CC(=C1)O)N=C(O2)C3=CC=C(C=C3)O
DM92EG5 IK UASSHNIRIMIZTA-UHFFFAOYSA-N
DM92EG5 IU 7-ethynyl-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol
DM92EG5 DE Discovery agent
DMJWCAH ID DMJWCAH
DMJWCAH DN 7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMJWCAH HS Investigative
DMJWCAH DT Small molecular drug
DMJWCAH PC 135453199
DMJWCAH MW 289.3
DMJWCAH FM C18H11NO3
DMJWCAH IC InChI=1S/C18H11NO3/c1-2-12-14-7-10(20)4-6-16(14)19-18-13-5-3-11(21)8-17(13)22-9-15(12)18/h1,3-8,20-21H,9H2
DMJWCAH CS C#CC1=C2COC3=C(C2=NC4=C1C=C(C=C4)O)C=CC(=C3)O
DMJWCAH IK NFDYBNVVFHAKIV-UHFFFAOYSA-N
DMJWCAH IU 7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DMJWCAH DE Discovery agent
DMNRCDI ID DMNRCDI
DMNRCDI DN 7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DMNRCDI HS Investigative
DMNRCDI SN CHEMBL323071; 7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL10757077; 2H-Imidazo[4,5-b]quinolin-2-one, 7-fluoro-1,3-dihydro-; BDBM50007234
DMNRCDI DT Small molecular drug
DMNRCDI PC 13936969
DMNRCDI MW 203.17
DMNRCDI FM C10H6FN3O
DMNRCDI IC InChI=1S/C10H6FN3O/c11-6-1-2-7-5(3-6)4-8-9(12-7)14-10(15)13-8/h1-4H,(H2,12,13,14,15)
DMNRCDI CS C1=CC2=NC3=C(C=C2C=C1F)NC(=O)N3
DMNRCDI IK XTXHKKBSLRGOJD-UHFFFAOYSA-N
DMNRCDI IU 7-fluoro-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DMNRCDI DE Discovery agent
DM4HJZI ID DM4HJZI
DM4HJZI DN 7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione
DM4HJZI HS Investigative
DM4HJZI SN CHEMBL599545; 7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione
DM4HJZI DT Small molecular drug
DM4HJZI PC 46231935
DM4HJZI MW 274.29
DM4HJZI FM C15H8F2OS
DM4HJZI IC InChI=1S/C15H8F2OS/c16-10-3-1-9(2-4-10)13-8-15(19)12-6-5-11(17)7-14(12)18-13/h1-8H
DM4HJZI CS C1=CC(=CC=C1C2=CC(=S)C3=C(O2)C=C(C=C3)F)F
DM4HJZI IK JDKXGUUVCBWLSB-UHFFFAOYSA-N
DM4HJZI IU 7-fluoro-2-(4-fluorophenyl)chromene-4-thione
DM4HJZI DE Discovery agent
DMUPXBJ ID DMUPXBJ
DMUPXBJ DN 7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one
DMUPXBJ HS Investigative
DMUPXBJ SN 7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one; CHEMBL599149; 7-fluoro-2-(4-methoxyphenyl)chromen-4-one; AC1LAD85; 4'-Methoxy-7-fluoroflavanone; BDBM50310186; MB10522
DMUPXBJ DT Small molecular drug
DMUPXBJ PC 466270
DMUPXBJ MW 270.25
DMUPXBJ FM C16H11FO3
DMUPXBJ IC InChI=1S/C16H11FO3/c1-19-12-5-2-10(3-6-12)15-9-14(18)13-7-4-11(17)8-16(13)20-15/h2-9H,1H3
DMUPXBJ CS COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)F
DMUPXBJ IK STGBQHUMAHPOBT-UHFFFAOYSA-N
DMUPXBJ IU 7-fluoro-2-(4-methoxyphenyl)chromen-4-one
DMUPXBJ DE Discovery agent
DMFOU8G ID DMFOU8G
DMFOU8G DN 7-fluoro-2-p-tolyl-4H-chromen-4-one
DMFOU8G HS Investigative
DMFOU8G SN CHEMBL599148; 7-fluoro-2-p-tolyl-4H-chromen-4-one
DMFOU8G DT Small molecular drug
DMFOU8G PC 46231795
DMFOU8G MW 254.25
DMFOU8G FM C16H11FO2
DMFOU8G IC InChI=1S/C16H11FO2/c1-10-2-4-11(5-3-10)15-9-14(18)13-7-6-12(17)8-16(13)19-15/h2-9H,1H3
DMFOU8G CS CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)F
DMFOU8G IK NGYCVQPULTXSDL-UHFFFAOYSA-N
DMFOU8G IU 7-fluoro-2-(4-methylphenyl)chromen-4-one
DMFOU8G DE Discovery agent
DMJFXKA ID DMJFXKA
DMJFXKA DN 7-fluoro-2-p-tolyl-4H-chromene-4-thione
DMJFXKA HS Investigative
DMJFXKA SN CHEMBL599547; 7-fluoro-2-p-tolyl-4H-chromene-4-thione
DMJFXKA DT Small molecular drug
DMJFXKA PC 46231936
DMJFXKA MW 270.3
DMJFXKA FM C16H11FOS
DMJFXKA IC InChI=1S/C16H11FOS/c1-10-2-4-11(5-3-10)14-9-16(19)13-7-6-12(17)8-15(13)18-14/h2-9H,1H3
DMJFXKA CS CC1=CC=C(C=C1)C2=CC(=S)C3=C(O2)C=C(C=C3)F
DMJFXKA IK SJJJFWHFSTWMGP-UHFFFAOYSA-N
DMJFXKA IU 7-fluoro-2-(4-methylphenyl)chromene-4-thione
DMJFXKA DE Discovery agent
DM0QI8V ID DM0QI8V
DM0QI8V DN 7-Fluoro-3-thiophen-3-yl-quinoline
DM0QI8V HS Investigative
DM0QI8V SN CHEMBL307093; 7-fluoro-3-thiophen-3-yl-quinoline; ZINC3834021
DM0QI8V DT Small molecular drug
DM0QI8V PC 10398928
DM0QI8V MW 229.27
DM0QI8V FM C13H8FNS
DM0QI8V IC InChI=1S/C13H8FNS/c14-12-2-1-9-5-11(7-15-13(9)6-12)10-3-4-16-8-10/h1-8H
DM0QI8V CS C1=CC(=CC2=NC=C(C=C21)C3=CSC=C3)F
DM0QI8V IK OQYVAKAMHRACJL-UHFFFAOYSA-N
DM0QI8V IU 7-fluoro-3-thiophen-3-ylquinoline
DM0QI8V DE Discovery agent
DMQ2ZTJ ID DMQ2ZTJ
DMQ2ZTJ DN 7-fluorochromone-2-carboxamide
DMQ2ZTJ HS Investigative
DMQ2ZTJ SN CHEMBL214021; 7-fluorochromone-2-carboxamide; GTPL1303; SCHEMBL2669492; BDBM50197139; LS-193885; N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide; N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxochromene-2-carboxamide
DMQ2ZTJ DT Small molecular drug
DMQ2ZTJ PC 11539096
DMQ2ZTJ MW 424.4
DMQ2ZTJ FM C23H21FN2O5
DMQ2ZTJ IC InChI=1S/C23H21FN2O5/c24-15-2-3-17-18(27)11-22(31-20(17)10-15)23(28)25-16-5-7-26(8-6-16)12-14-1-4-19-21(9-14)30-13-29-19/h1-4,9-11,16H,5-8,12-13H2,(H,25,28)
DMQ2ZTJ CS C1CN(CCC1NC(=O)C2=CC(=O)C3=C(O2)C=C(C=C3)F)CC4=CC5=C(C=C4)OCO5
DMQ2ZTJ IK FVFURMJFTAJXRH-UHFFFAOYSA-N
DMQ2ZTJ IU N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxochromene-2-carboxamide
DMQ2ZTJ DE Discovery agent
DM70I3V ID DM70I3V
DM70I3V DN 7-fluoroindirubin-3-acetoxime
DM70I3V HS Investigative
DM70I3V DT Small molecular drug
DM70I3V PC 136104466
DM70I3V MW 337.3
DM70I3V FM C18H12FN3O3
DM70I3V IC InChI=1S/C18H12FN3O3/c1-9(23)25-22-16-10-5-2-3-8-13(10)20-17(16)14-11-6-4-7-12(19)15(11)21-18(14)24/h2-8,21,24H,1H3/b22-16-
DM70I3V CS CC(=O)O/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC=C4F)O
DM70I3V IK NFIUKUJUBYCMTC-JWGURIENSA-N
DM70I3V IU [(Z)-[2-(7-fluoro-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DM70I3V DE Discovery agent
DMQD34N ID DMQD34N
DMQD34N DN 7-fluoroindirubin-3-oxime
DMQD34N HS Investigative
DMQD34N DT Small molecular drug
DMQD34N PC 11845975
DMQD34N DE Discovery agent
DMEGSZD ID DMEGSZD
DMEGSZD DN 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine
DMEGSZD HS Investigative
DMEGSZD DT Small molecular drug
DMEGSZD PC 334409
DMEGSZD MW 199.21
DMEGSZD FM C10H9N5
DMEGSZD IC InChI=1S/C10H9N5/c11-9-8-5-3-4-13-6(5)1-2-7(8)14-10(12)15-9/h1-4H,11H2,(H3,12,14,15)
DMEGSZD CS C1=C2C(=C(N=C(N2)N)N)C3=CC=NC3=C1
DMEGSZD IK TYJMBWNFQVCGFT-UHFFFAOYSA-N
DMEGSZD IU 4H-pyrrolo[3,2-f]quinazoline-1,3-diamine
DMEGSZD CA CAS 65795-37-1
DMEGSZD DE Discovery agent
DMKSJE3 ID DMKSJE3
DMKSJE3 DN 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3 HS Investigative
DMKSJE3 SN CHEMBL377622; 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3 DT Small molecular drug
DMKSJE3 PC 44412953
DMKSJE3 MW 200.23
DMKSJE3 FM C13H12O2
DMKSJE3 IC InChI=1S/C13H12O2/c14-10-3-4-12-9(6-10)5-8-1-2-11(15)7-13(8)12/h3-4,6-8,14H,1-2,5H2
DMKSJE3 CS C1CC(=O)C=C2C1CC3=C2C=CC(=C3)O
DMKSJE3 IK TVWXDDLDMKKZJT-UHFFFAOYSA-N
DMKSJE3 IU 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one
DMKSJE3 DE Discovery agent
DMXBUNV ID DMXBUNV
DMXBUNV DN 7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one
DMXBUNV HS Investigative
DMXBUNV SN CHEMBL255110; 62252-06-6; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(3-hydroxyphenyl)-; AC1LDLCQ; CTK2C3909; DTXSID60347362; MXNJBOFUFMJXOB-UHFFFAOYSA-N; BDBM50374256; AKOS030552838; 7-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one; 2,3-Dihydro-7-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-Hydroxy-2-(3-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one #
DMXBUNV DT Small molecular drug
DMXBUNV PC 620596
DMXBUNV MW 256.25
DMXBUNV FM C15H12O4
DMXBUNV IC InChI=1S/C15H12O4/c16-10-3-1-2-9(6-10)14-8-13(18)12-5-4-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2
DMXBUNV CS C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC(=CC=C3)O
DMXBUNV IK MXNJBOFUFMJXOB-UHFFFAOYSA-N
DMXBUNV IU 7-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMXBUNV CA CAS 62252-06-6
DMXBUNV DE Discovery agent
DMCB2IM ID DMCB2IM
DMCB2IM DN 7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one
DMCB2IM HS Investigative
DMCB2IM SN CHEMBL56650; 7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one; ZINC13797581; BDBM50077320; 2-(4-Hydroxybenzyl)-7-hydroxychromone
DMCB2IM DT Small molecular drug
DMCB2IM PC 10084377
DMCB2IM MW 268.26
DMCB2IM FM C16H12O4
DMCB2IM IC InChI=1S/C16H12O4/c17-11-3-1-10(2-4-11)7-13-9-15(19)14-6-5-12(18)8-16(14)20-13/h1-6,8-9,17-18H,7H2
DMCB2IM CS C1=CC(=CC=C1CC2=CC(=O)C3=C(O2)C=C(C=C3)O)O
DMCB2IM IK ZUDKQDRWUFGUDQ-UHFFFAOYSA-N
DMCB2IM IU 7-hydroxy-2-[(4-hydroxyphenyl)methyl]chromen-4-one
DMCB2IM DE Discovery agent
DM2BV6P ID DM2BV6P
DM2BV6P DN 7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one
DM2BV6P HS Investigative
DM2BV6P SN CHEMBL56447; 7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one; ZINC13797575; BDBM50077321
DM2BV6P DT Small molecular drug
DM2BV6P PC 10708015
DM2BV6P MW 282.29
DM2BV6P FM C17H14O4
DM2BV6P IC InChI=1S/C17H14O4/c1-20-13-5-2-11(3-6-13)8-14-10-16(19)15-7-4-12(18)9-17(15)21-14/h2-7,9-10,18H,8H2,1H3
DM2BV6P CS COC1=CC=C(C=C1)CC2=CC(=O)C3=C(O2)C=C(C=C3)O
DM2BV6P IK SKFOCRVUNCGDHR-UHFFFAOYSA-N
DM2BV6P IU 7-hydroxy-2-[(4-methoxyphenyl)methyl]chromen-4-one
DM2BV6P DE Discovery agent
DMIKSTL ID DMIKSTL
DMIKSTL DN 7-hydroxy-2-(morpholin-4-yl)chromen-4-one
DMIKSTL HS Investigative
DMIKSTL SN CHEMBL197536; 7-hydroxy-2-(morpholin-4-yl)chromen-4-one; SCHEMBL3533604; ULTRFFGNTUDFJW-UHFFFAOYSA-N; BDBM50178123
DMIKSTL DT Small molecular drug
DMIKSTL PC 11715743
DMIKSTL MW 247.25
DMIKSTL FM C13H13NO4
DMIKSTL IC InChI=1S/C13H13NO4/c15-9-1-2-10-11(16)8-13(18-12(10)7-9)14-3-5-17-6-4-14/h1-2,7-8,15H,3-6H2
DMIKSTL CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)O
DMIKSTL IK ULTRFFGNTUDFJW-UHFFFAOYSA-N
DMIKSTL IU 7-hydroxy-2-morpholin-4-ylchromen-4-one
DMIKSTL DE Discovery agent
DM4UW65 ID DM4UW65
DM4UW65 DN 7-hydroxy-2-phenylchroman-4-one
DM4UW65 HS Investigative
DM4UW65 SN 7-Hydroxyflavanone; 6515-36-2; 7-Hydroxy-2-phenylchroman-4-one; 7-Hydroxyflavanone, 98%; CHEMBL97542; CHEBI:34483; SWAJPHCXKPCPQZ-UHFFFAOYSA-N; 7-hydroxy-2-phenyl-2,3-dihydro-4H-chromen-4-one; MFCD00017487; 2,3-dihydro-7-hydroxy-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-phenyl-; 7-hydroxy-2-phenyl-4-chromanone; 2545-13-3; 7-hydroxy-flavanone; AC1L1CGO; AC1Q6KJV; ACMC-1B5B3; Oprea1_401356; MLS001181922; SCHEMBL130266; DTXSID0022430; CTK4F5779; MolPort-002-903-717; HMS2865F07; HMS1664L06
DM4UW65 DT Small molecular drug
DM4UW65 PC 1890
DM4UW65 MW 240.25
DM4UW65 FM C15H12O3
DM4UW65 IC InChI=1S/C15H12O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14,16H,9H2
DM4UW65 CS C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC=CC=C3
DM4UW65 IK SWAJPHCXKPCPQZ-UHFFFAOYSA-N
DM4UW65 IU 7-hydroxy-2-phenyl-2,3-dihydrochromen-4-one
DM4UW65 CA CAS 6515-36-2
DM4UW65 CB CHEBI:34483
DM4UW65 DE Discovery agent
DMS2NZA ID DMS2NZA
DMS2NZA DN 7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile
DMS2NZA HS Investigative
DMS2NZA SN 7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile; SCHEMBL3020111; CHEMBL467183; UXJULIKCAFGFJL-UHFFFAOYSA-N
DMS2NZA DT Small molecular drug
DMS2NZA PC 24950551
DMS2NZA MW 261.269
DMS2NZA FM C17H11NO2
DMS2NZA IC InChI=1S/C17H11NO2/c18-10-14-7-13(11-2-1-3-15(19)8-11)6-12-4-5-16(20)9-17(12)14/h1-9,19-20H
DMS2NZA CS C1=CC(=CC(=C1)O)C2=CC(=C3C=C(C=CC3=C2)O)C#N
DMS2NZA IK UXJULIKCAFGFJL-UHFFFAOYSA-N
DMS2NZA IU 7-hydroxy-3-(3-hydroxyphenyl)naphthalene-1-carbonitrile
DMS2NZA DE Discovery agent
DM46J2H ID DM46J2H
DM46J2H DN 7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one
DM46J2H HS Investigative
DM46J2H SN 3-arylquinazolinone, 1as; CHEMBL203370; SCHEMBL1795123; BDBM19927; AKOS002674620
DM46J2H DT Small molecular drug
DM46J2H PC 11579721
DM46J2H MW 254.24
DM46J2H FM C14H10N2O3
DM46J2H IC InChI=1S/C14H10N2O3/c17-10-3-1-9(2-4-10)16-8-15-13-7-11(18)5-6-12(13)14(16)19/h1-8,17-18H
DM46J2H CS C1=CC(=CC=C1N2C=NC3=C(C2=O)C=CC(=C3)O)O
DM46J2H IK NECCEJFVHJYYDA-UHFFFAOYSA-N
DM46J2H IU 7-hydroxy-3-(4-hydroxyphenyl)quinazolin-4-one
DM46J2H DE Discovery agent
DM2ZE8U ID DM2ZE8U
DM2ZE8U DN 7-hydroxy-3-phenyl-2H-chromen-2-one
DM2ZE8U HS Investigative
DM2ZE8U SN 7-hydroxy-3-phenyl-2H-chromen-2-one; 6468-96-8; 3-Phenylumbelliferone; 7-Hydroxy-3-phenylcoumarin; 7-hydroxy-3-phenylchromen-2-one; 3-phenyl-7-hydroxycoumarin; CHEMBL153505; 7-Hydroxy-3-phenyl-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one,7-hydroxy-3-phenyl-; 7-Hydroxy-3-phenyl-chromen-2-one; EN300-36438; AE-641/01995035; AC1NU2DD; MLS001167019; SCHEMBL591688; AC1Q797K; ZINC58069; CTK5C1589; cid_5393176; DTXSID60419831; MolPort-000-870-829; RIPZCQZTVDNJHQ-UHFFFAOYSA-N; HMS2955O07; BB_NC-01950; SBB042221; STL033560; MFCD00037574
DM2ZE8U DT Small molecular drug
DM2ZE8U PC 5393176
DM2ZE8U MW 238.24
DM2ZE8U FM C15H10O3
DM2ZE8U IC InChI=1S/C15H10O3/c16-12-7-6-11-8-13(10-4-2-1-3-5-10)15(17)18-14(11)9-12/h1-9,16H
DM2ZE8U CS C1=CC=C(C=C1)C2=CC3=C(C=C(C=C3)O)OC2=O
DM2ZE8U IK RIPZCQZTVDNJHQ-UHFFFAOYSA-N
DM2ZE8U IU 7-hydroxy-3-phenylchromen-2-one
DM2ZE8U CA CAS 6468-96-8
DM2ZE8U DE Discovery agent
DM3T612 ID DM3T612
DM3T612 DN 7-Hydroxy-4-phenylcoumarin
DM3T612 HS Investigative
DM3T612 SN 7-Hydroxy-4-phenylcoumarin; 2555-30-8; 7-hydroxy-4-phenyl-2H-chromen-2-one; 7-hydroxy-4-phenylchromen-2-one; NSC78474; 4-Phenyl-7-hydroxycoumarin; UNII-L0487H6Q0H; CHEMBL325841; L0487H6Q0H; 7-Hydroxy-4-phenyl-chromen-2-one; 7-oxidanyl-4-phenyl-chromen-2-one; NSC-78474; 2H-1-Benzopyran-2-one,7-hydroxy-4-phenyl-; 2H-1-Benzopyran-2-one, 7-hydroxy-4-phenyl-; 4-Phenylumbelliferone; PubChem8691; Coumarin derivative, 3c; AC1NSAV1; 7-Hydroxy4-phenylcoumarin; Oprea1_774373; 7-hydroxy-4-phenyl coumarin; MLS001143868; SCHEMBL2987658
DM3T612 DT Small molecular drug
DM3T612 PC 5357479
DM3T612 MW 238.24
DM3T612 FM C15H10O3
DM3T612 IC InChI=1S/C15H10O3/c16-11-6-7-12-13(10-4-2-1-3-5-10)9-15(17)18-14(12)8-11/h1-9,16H
DM3T612 CS C1=CC=C(C=C1)C2=CC(=O)OC3=C2C=CC(=C3)O
DM3T612 IK IVJMJRRORVMRJJ-UHFFFAOYSA-N
DM3T612 IU 7-hydroxy-4-phenylchromen-2-one
DM3T612 CA CAS 2555-30-8
DM3T612 DE Discovery agent
DM49RWY ID DM49RWY
DM49RWY DN 7-Hydroxy-6-nitro-2-phenyl-chromen-4-one
DM49RWY HS Investigative
DM49RWY SN CHEMBL56730; 7-hydroxy-6-nitro-2-phenyl-chromen-4-one; 6-Nitro-7-hydroxyflavone
DM49RWY DT Small molecular drug
DM49RWY PC 10755384
DM49RWY MW 283.23
DM49RWY FM C15H9NO5
DM49RWY IC InChI=1S/C15H9NO5/c17-12-7-14(9-4-2-1-3-5-9)21-15-8-13(18)11(16(19)20)6-10(12)15/h1-8,18H
DM49RWY CS C1=CC=C(C=C1)C2=CC(=O)C3=CC(=C(C=C3O2)O)[N+](=O)[O-]
DM49RWY IK KJSLXXZBGFZOAH-UHFFFAOYSA-N
DM49RWY IU 7-hydroxy-6-nitro-2-phenylchromen-4-one
DM49RWY DE Discovery agent
DMQ3RVK ID DMQ3RVK
DMQ3RVK DN 7-hydroxy-6-propionyl-2H-chromen-2-one
DMQ3RVK HS Investigative
DMQ3RVK SN 7-hydroxy-6-propanoylcoumarin; CHEMBL1288535; 144582-52-5; 7-hydroxy-6-propionyl-2H-chromen-2-one
DMQ3RVK DT Small molecular drug
DMQ3RVK PC 52949920
DMQ3RVK MW 218.2
DMQ3RVK FM C12H10O4
DMQ3RVK IC InChI=1S/C12H10O4/c1-2-9(13)8-5-7-3-4-12(15)16-11(7)6-10(8)14/h3-6,14H,2H2,1H3
DMQ3RVK CS CCC(=O)C1=C(C=C2C(=C1)C=CC(=O)O2)O
DMQ3RVK IK GJOCMGDMAGUOKE-UHFFFAOYSA-N
DMQ3RVK IU 7-hydroxy-6-propanoylchromen-2-one
DMQ3RVK DE Discovery agent
DMFKSMW ID DMFKSMW
DMFKSMW DN 7-hydroxy-8-propionyl-2H-chromen-2-one
DMFKSMW HS Investigative
DMFKSMW SN 7-hydroxy-8-propionyl-coumarin; CHEMBL1288557; 67752-18-5; 7-hydroxy-8-propionyl-2H-chromen-2-one; 7-hydroxy-8-propionylcoumarin
DMFKSMW DT Small molecular drug
DMFKSMW PC 52943164
DMFKSMW MW 218.2
DMFKSMW FM C12H10O4
DMFKSMW IC InChI=1S/C12H10O4/c1-2-8(13)11-9(14)5-3-7-4-6-10(15)16-12(7)11/h3-6,14H,2H2,1H3
DMFKSMW CS CCC(=O)C1=C(C=CC2=C1OC(=O)C=C2)O
DMFKSMW IK DVLIOVBNBOBBGS-UHFFFAOYSA-N
DMFKSMW IU 7-hydroxy-8-propanoylchromen-2-one
DMFKSMW DE Discovery agent
DMZXMB7 ID DMZXMB7
DMZXMB7 DN 7-hydroxycholesterol
DMZXMB7 HS Investigative
DMZXMB7 SN 7-hydroxy-cholesterol; 7-OHC; SCHEMBL281943; GTPL3432; KB-200035
DMZXMB7 DT Small molecular drug
DMZXMB7 PC 15571093
DMZXMB7 MW 402.7
DMZXMB7 FM C27H46O2
DMZXMB7 IC InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24?,25+,26+,27-/m1/s1
DMZXMB7 CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C(C=C4[C@@]3(CC[C@@H](C4)O)C)O)C
DMZXMB7 IK OYXZMSRRJOYLLO-UOQFGJKXSA-N
DMZXMB7 IU (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
DMZXMB7 DE Discovery agent
DMV0PT8 ID DMV0PT8
DMV0PT8 DN 7-hydroxycostunolide
DMV0PT8 HS Investigative
DMV0PT8 SN 7-hydroxycostunolide; NSC711176; AC1NV7KU; CHEMBL206443; CHEMBL1976955; NSC-711176; Cyclodeca[b]furan-2(3H)-one,4,5,8,9,11a-hexahydro-3a-hydroxy- 6,10-dimethyl-3-methylene-, stereoisomer
DMV0PT8 DT Small molecular drug
DMV0PT8 PC 5471440
DMV0PT8 MW 248.32
DMV0PT8 FM C15H20O3
DMV0PT8 IC InChI=1S/C15H20O3/c1-10-5-4-6-11(2)9-13-15(17,8-7-10)12(3)14(16)18-13/h5,9,13,17H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,15-/m1/s1
DMV0PT8 CS C/C/1=C\\CC/C(=C/[C@@H]2[C@@](CC1)(C(=C)C(=O)O2)O)/C
DMV0PT8 IK AZKRCCHLNBJNOK-HZAIZTQPSA-N
DMV0PT8 IU (3aR,6E,10E,11aR)-3a-hydroxy-6,10-dimethyl-3-methylidene-5,8,9,11a-tetrahydro-4H-cyclodeca[b]furan-2-one
DMV0PT8 DE Discovery agent
DMTMNO7 ID DMTMNO7
DMTMNO7 DN 7-hydroxycoumarin
DMTMNO7 HS Investigative
DMTMNO7 SN Umbelliferone; 93-35-6; 7-Hydroxy-2H-chromen-2-one; Skimmetin; Hydrangin; 7-hydroxycoumarine; 7-Oxycoumarin; Umbelliferon; Skimmetine; Hydrangine; 2H-1-Benzopyran-2-one, 7-hydroxy-; 7-Hydroxy-2H-1-benzopyran-2-one; Coumarin, 7-hydroxy-; beta-Umbelliferone; 7-hydroxychromen-2-one; 7 HC; UNII-60Z60NTL4G; 7-hydroxy-coumarin; NSC 19790; CCRIS 3591; NSC19790; EINECS 202-240-3; 7H-1-Benzopyran-7-one, 2-hydroxy-; BRN 0127683; CHEMBL51628; AI3-38054; 7-hydroxy-1-benzopyran-2-one; 7-HC; 60Z60NTL4G; CHEBI:27510; UMBELLIFERONE
DMTMNO7 DT Small molecular drug
DMTMNO7 PC 5281426
DMTMNO7 MW 162.14
DMTMNO7 FM C9H6O3
DMTMNO7 IC InChI=1S/C9H6O3/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5,10H
DMTMNO7 CS C1=CC(=CC2=C1C=CC(=O)O2)O
DMTMNO7 IK ORHBXUUXSCNDEV-UHFFFAOYSA-N
DMTMNO7 IU 7-hydroxychromen-2-one
DMTMNO7 CA CAS 93-35-6
DMTMNO7 CB CHEBI:27510
DMTMNO7 DE Discovery agent
DMV39XT ID DMV39XT
DMV39XT DN 7-Hydroxy-Pyrazolo[4,3-D]Pyrimidine
DMV39XT HS Investigative
DMV39XT DT Small molecular drug
DMV39XT PC 135460353
DMV39XT MW 136.11
DMV39XT FM C5H4N4O
DMV39XT IC InChI=1S/C5H4N4O/c10-5-4-3(1-8-9-4)6-2-7-5/h1-2H,(H,8,9)(H,6,7,10)
DMV39XT CS C1=NNC2=C1N=CNC2=O
DMV39XT IK JFZSDNLQDTYVEE-UHFFFAOYSA-N
DMV39XT IU 1,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
DMV39XT CA CAS 13877-55-9
DMV39XT DE Discovery agent
DM6K5NF ID DM6K5NF
DM6K5NF DN 7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one
DM6K5NF HS Investigative
DM6K5NF DT Small molecular drug
DM6K5NF PC 14177141
DM6K5NF DE Discovery agent
DMNFI02 ID DMNFI02
DMNFI02 DN 7-iodoindirubin-3-oxime
DMNFI02 HS Investigative
DMNFI02 DT Small molecular drug
DMNFI02 PC 11846149
DMNFI02 DE Discovery agent
DMVSF0O ID DMVSF0O
DMVSF0O DN 7-Isopropyl-7H-adenine
DMVSF0O HS Investigative
DMVSF0O SN 7-Isopropyl-7H-adenine; CHEMBL448396; 55146-09-3; SCHEMBL756635
DMVSF0O DT Small molecular drug
DMVSF0O PC 23562742
DMVSF0O MW 177.21
DMVSF0O FM C8H11N5
DMVSF0O IC InChI=1S/C8H11N5/c1-5(2)13-4-12-8-6(13)7(9)10-3-11-8/h3-5H,1-2H3,(H2,9,10,11)
DMVSF0O CS CC(C)N1C=NC2=NC=NC(=C21)N
DMVSF0O IK WAPXYHTXSGPYEX-UHFFFAOYSA-N
DMVSF0O IU 7-propan-2-ylpurin-6-amine
DMVSF0O DE Discovery agent
DMPYTHV ID DMPYTHV
DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide
DMPYTHV HS Investigative
DMPYTHV SN CHEMBL178779
DMPYTHV DT Small molecular drug
DMPYTHV PC 11346934
DMPYTHV MW 294.4
DMPYTHV FM C14H18N2OS2
DMPYTHV IC InChI=1S/C14H18N2OS2/c17-13(9-3-1-2-6-10-18)16-14-15-11-7-4-5-8-12(11)19-14/h4-5,7-8,18H,1-3,6,9-10H2,(H,15,16,17)
DMPYTHV CS C1=CC=C2C(=C1)N=C(S2)NC(=O)CCCCCCS
DMPYTHV IK QMWKKGIVGMUWJC-UHFFFAOYSA-N
DMPYTHV IU N-(1,3-benzothiazol-2-yl)-7-sulfanylheptanamide
DMPYTHV DE Discovery agent
DMEQKPO ID DMEQKPO
DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide
DMEQKPO HS Investigative
DMEQKPO SN CHEMBL320323
DMEQKPO DT Small molecular drug
DMEQKPO PC 11449823
DMEQKPO MW 313.5
DMEQKPO FM C19H23NOS
DMEQKPO IC InChI=1S/C19H23NOS/c21-19(13-6-1-2-7-14-22)20-18-12-8-11-17(15-18)16-9-4-3-5-10-16/h3-5,8-12,15,22H,1-2,6-7,13-14H2,(H,20,21)
DMEQKPO CS C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CCCCCCS
DMEQKPO IK VJSUVWGNKFMQET-UHFFFAOYSA-N
DMEQKPO IU N-(3-phenylphenyl)-7-sulfanylheptanamide
DMEQKPO DE Discovery agent
DMJMOUK ID DMJMOUK
DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide
DMJMOUK HS Investigative
DMJMOUK SN CHEMBL112311
DMJMOUK DT Small molecular drug
DMJMOUK PC 11220728
DMJMOUK MW 313.5
DMJMOUK FM C19H23NOS
DMJMOUK IC InChI=1S/C19H23NOS/c21-19(10-6-1-2-7-15-22)20-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14,22H,1-2,6-7,10,15H2,(H,20,21)
DMJMOUK CS C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)CCCCCCS
DMJMOUK IK QTXIBRBGYJCFEU-UHFFFAOYSA-N
DMJMOUK IU N-(4-phenylphenyl)-7-sulfanylheptanamide
DMJMOUK DE Discovery agent
DM4912P ID DM4912P
DM4912P DN 7-Mercapto-heptanoic acid phenylamide
DM4912P HS Investigative
DM4912P SN 7-Mercapto-heptanoic acid phenylamide; Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692
DM4912P DT Small molecular drug
DM4912P PC 11379392
DM4912P MW 237.36
DM4912P FM C13H19NOS
DM4912P IC InChI=1S/C13H19NOS/c15-13(10-6-1-2-7-11-16)14-12-8-4-3-5-9-12/h3-5,8-9,16H,1-2,6-7,10-11H2,(H,14,15)
DM4912P CS C1=CC=C(C=C1)NC(=O)CCCCCCS
DM4912P IK CFKBMXXDXYFDET-UHFFFAOYSA-N
DM4912P IU N-phenyl-7-sulfanylheptanamide
DM4912P DE Discovery agent
DMQ9PLA ID DMQ9PLA
DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide
DMQ9PLA HS Investigative
DMQ9PLA SN CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
DMQ9PLA DT Small molecular drug
DMQ9PLA PC 11345433
DMQ9PLA MW 238.35
DMQ9PLA FM C12H18N2OS
DMQ9PLA IC InChI=1S/C12H18N2OS/c15-12(7-3-1-2-4-9-16)14-11-6-5-8-13-10-11/h5-6,8,10,16H,1-4,7,9H2,(H,14,15)
DMQ9PLA CS C1=CC(=CN=C1)NC(=O)CCCCCCS
DMQ9PLA IK SHPVLBRAGPXPLH-UHFFFAOYSA-N
DMQ9PLA IU N-pyridin-3-yl-7-sulfanylheptanamide
DMQ9PLA DE Discovery agent
DMTAGJ1 ID DMTAGJ1
DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide
DMTAGJ1 HS Investigative
DMTAGJ1 SN CHEMBL112234
DMTAGJ1 DT Small molecular drug
DMTAGJ1 PC 10379373
DMTAGJ1 MW 288.4
DMTAGJ1 FM C16H20N2OS
DMTAGJ1 IC InChI=1S/C16H20N2OS/c19-16(9-3-1-2-6-10-20)18-14-11-13-7-4-5-8-15(13)17-12-14/h4-5,7-8,11-12,20H,1-3,6,9-10H2,(H,18,19)
DMTAGJ1 CS C1=CC=C2C(=C1)C=C(C=N2)NC(=O)CCCCCCS
DMTAGJ1 IK XAFIWTHVBLRJFM-UHFFFAOYSA-N
DMTAGJ1 IU N-quinolin-3-yl-7-sulfanylheptanamide
DMTAGJ1 DE Discovery agent
DM03XYF ID DM03XYF
DM03XYF DN 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide
DM03XYF HS Investigative
DM03XYF SN CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
DM03XYF DT Small molecular drug
DM03XYF PC 11427204
DM03XYF MW 320.5
DM03XYF FM C16H20N2OS2
DM03XYF IC InChI=1S/C16H20N2OS2/c19-15(10-6-1-2-7-11-20)18-16-17-14(12-21-16)13-8-4-3-5-9-13/h3-5,8-9,12,20H,1-2,6-7,10-11H2,(H,17,18,19)
DM03XYF CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)CCCCCCS
DM03XYF IK LUXAHBUKMVESIS-UHFFFAOYSA-N
DM03XYF IU N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
DM03XYF DE Discovery agent
DMTFBCU ID DMTFBCU
DMTFBCU DN 7-Methoxy-1H-indazole
DMTFBCU HS Investigative
DMTFBCU SN 7-methoxy-1H-indazole; 133841-05-1; 1H-Indazole, 7-methoxy-; CHEMBL15921; ACMC-20aa2r; 7-METHOXYINDAZOLE; SCHEMBL5483794; SCHEMBL18003573; CTK0H0012; KS-00000DHI; DTXSID90439880; QCBANHQTMCETBI-UHFFFAOYSA-N; MolPort-009-199-308; BDBM50099399; ANW-63985; ZINC26894532; AKOS024124789; AKOS006290288; TRA0059918; AS-8550; RP01575; PB32675; RTC-062053; AN-6943; KB-46446; AC-29510; SY032798; SC-54780; AK-58155; AJ-82859; 1429222-35-4; TC-062053; DB-062996; Y7436; ST24045679; FT-0767863; 4CH-023995; CS-0043993; AM20020408; MFCD08752584 (97%); Q-2252
DMTFBCU DT Small molecular drug
DMTFBCU PC 10441839
DMTFBCU MW 148.16
DMTFBCU FM C8H8N2O
DMTFBCU IC InChI=1S/C8H8N2O/c1-11-7-4-2-3-6-5-9-10-8(6)7/h2-5H,1H3,(H,9,10)
DMTFBCU CS COC1=CC=CC2=C1NN=C2
DMTFBCU IK QCBANHQTMCETBI-UHFFFAOYSA-N
DMTFBCU IU 7-methoxy-1H-indazole
DMTFBCU CA CAS 133841-05-1
DMTFBCU DE Discovery agent
DM3MXI5 ID DM3MXI5
DM3MXI5 DN 7-methoxy-1-naphthylpiperazine
DM3MXI5 HS Investigative
DM3MXI5 SN 7-methoxy-1-naphthylpiperazine; GTPL6; SCHEMBL9478699; oxiran-2-ylmethyl N-[2-(dimethyl-trimethylsilylsilyl)ethyl]carbamate
DM3MXI5 DT Small molecular drug
DM3MXI5 PC 14533720
DM3MXI5 MW 275.49
DM3MXI5 FM C11H25NO3Si2
DM3MXI5 IC InChI=1S/C11H25NO3Si2/c1-16(2,3)17(4,5)7-6-12-11(13)15-9-10-8-14-10/h10H,6-9H2,1-5H3,(H,12,13)
DM3MXI5 CS C[Si](C)(C)[Si](C)(C)CCNC(=O)OCC1CO1
DM3MXI5 IK RMYUPIFLALKWOD-UHFFFAOYSA-N
DM3MXI5 IU oxiran-2-ylmethyl N-[2-[dimethyl(trimethylsilyl)silyl]ethyl]carbamate
DM3MXI5 DE Discovery agent
DMQ1BE8 ID DMQ1BE8
DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMQ1BE8 HS Investigative
DMQ1BE8 SN CHEMBL6310; 7-Methoxy-1,2,3,4-tetrahydro-beta-carboline; AC1LCCZT; 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; 7-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole; SCIRNASYBOGBOO-UHFFFAOYSA-N; BDBM50132097; ZINC13587968; AKOS004119616; 91566-22-2; 7-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; Methyl 2,3,4,9-tetrahydro-1H-beta-carbolin-7-yl ether #
DMQ1BE8 DT Small molecular drug
DMQ1BE8 PC 599482
DMQ1BE8 MW 202.25
DMQ1BE8 FM C12H14N2O
DMQ1BE8 IC InChI=1S/C12H14N2O/c1-15-8-2-3-9-10-4-5-13-7-12(10)14-11(9)6-8/h2-3,6,13-14H,4-5,7H2,1H3
DMQ1BE8 CS COC1=CC2=C(C=C1)C3=C(N2)CNCC3
DMQ1BE8 IK SCIRNASYBOGBOO-UHFFFAOYSA-N
DMQ1BE8 IU 7-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMQ1BE8 DE Discovery agent
DMR713M ID DMR713M
DMR713M DN 7-Methoxy-2-morpholin-4-yl-chromen-4-one
DMR713M HS Investigative
DMR713M SN CHEMBL175459; 130735-66-9; 4H-1-Benzopyran-4-one, 7-methoxy-2-(4-morpholinyl)-; 7-methoxy-2-morpholin-4-yl-chromen-4-one; ACMC-20mts5; 4H-1-Benzopyran-4-one,7-methoxy-2-(4-morpholinyl)-; SCHEMBL3536694; CTK0C1164; DTXSID00466243; BDBM50159634
DMR713M DT Small molecular drug
DMR713M PC 11448366
DMR713M MW 261.269
DMR713M FM C14H15NO4
DMR713M IC InChI=1S/C14H15NO4/c1-17-10-2-3-11-12(16)9-14(19-13(11)8-10)15-4-6-18-7-5-15/h2-3,8-9H,4-7H2,1H3
DMR713M CS COC1=CC2=C(C=C1)C(=O)C=C(O2)N3CCOCC3
DMR713M IK TVHCBKPEOVWUEQ-UHFFFAOYSA-N
DMR713M IU 7-methoxy-2-morpholin-4-ylchromen-4-one
DMR713M CA CAS 130735-66-9
DMR713M DE Discovery agent
DMJITU0 ID DMJITU0
DMJITU0 DN 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
DMJITU0 HS Investigative
DMJITU0 SN CHEMBL12567; 7-Methoxy-2-oxo-2H-chromene-4-carboxylic acid; 2H-1-Benzopyran-4-carboxylic acid, 7-methoxy-2-oxo-; BDBM50022188; 74802-00-9; 2-Oxo-7-methoxy-2H-1-benzopyran-4-carboxylic acid
DMJITU0 DT Small molecular drug
DMJITU0 PC 44268050
DMJITU0 MW 220.18
DMJITU0 FM C11H8O5
DMJITU0 IC InChI=1S/C11H8O5/c1-15-6-2-3-7-8(11(13)14)5-10(12)16-9(7)4-6/h2-5H,1H3,(H,13,14)
DMJITU0 CS COC1=CC2=C(C=C1)C(=CC(=O)O2)C(=O)O
DMJITU0 IK IHHLDCASADSHEG-UHFFFAOYSA-N
DMJITU0 IU 7-methoxy-2-oxochromene-4-carboxylic acid
DMJITU0 DE Discovery agent
DME5WZQ ID DME5WZQ
DME5WZQ DN 7-methoxy-2-p-tolyl-4H-chromen-4-one
DME5WZQ HS Investigative
DME5WZQ SN CHEMBL17052; 7-methoxy-2-(4-methylphenyl)chromen-4-one; 7-methoxy-2-(4-methylphenyl)-4H-chromen-4-one; 108980-49-0; 7-methoxy-2-p-tolyl-4H-chromen-4-one; AC1LIGD7; MolPort-000-450-862; ZINC522064; STK893155; BDBM50310185; 7-Methoxy-2-p-tolyl-chromen-4-one; AKOS002182021; MCULE-3043616847; NCGC00318207-01; 7-methoxy-2-(p-tolyl)-4H-chromen-4-one; ST50070846; VU0510077-1; AB01311569-01; 2-(4-Methylphenyl)-7-methoxy-4H-1-benzopyran-4-one
DME5WZQ DT Small molecular drug
DME5WZQ PC 930709
DME5WZQ MW 266.29
DME5WZQ FM C17H14O3
DME5WZQ IC InChI=1S/C17H14O3/c1-11-3-5-12(6-4-11)16-10-15(18)14-8-7-13(19-2)9-17(14)20-16/h3-10H,1-2H3
DME5WZQ CS CC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3)OC
DME5WZQ IK OBNQAKAHHNLJHT-UHFFFAOYSA-N
DME5WZQ IU 7-methoxy-2-(4-methylphenyl)chromen-4-one
DME5WZQ DE Discovery agent
DM4WMGK ID DM4WMGK
DM4WMGK DN 7-methoxy-2-p-tolyl-4H-chromene-4-thione
DM4WMGK HS Investigative
DM4WMGK SN CHEMBL597716; 7-methoxy-2-p-tolyl-4H-chromene-4-thione
DM4WMGK DT Small molecular drug
DM4WMGK PC 46232008
DM4WMGK MW 282.4
DM4WMGK FM C17H14O2S
DM4WMGK IC InChI=1S/C17H14O2S/c1-11-3-5-12(6-4-11)15-10-17(20)14-8-7-13(18-2)9-16(14)19-15/h3-10H,1-2H3
DM4WMGK CS CC1=CC=C(C=C1)C2=CC(=S)C3=C(O2)C=C(C=C3)OC
DM4WMGK IK HJUOMZBCQPCXHZ-UHFFFAOYSA-N
DM4WMGK IU 7-methoxy-2-(4-methylphenyl)chromene-4-thione
DM4WMGK DE Discovery agent
DMUZIDT ID DMUZIDT
DMUZIDT DN 7-Methoxy-3-pyridin-4-yl-quinoline
DMUZIDT HS Investigative
DMUZIDT SN CHEMBL329622; 7-methoxy-3-pyridin-4-yl-quinoline; 7-Methoxy-3-(4-pyridyl)quinoline
DMUZIDT DT Small molecular drug
DMUZIDT PC 11776270
DMUZIDT MW 236.27
DMUZIDT FM C15H12N2O
DMUZIDT IC InChI=1S/C15H12N2O/c1-18-14-3-2-12-8-13(10-17-15(12)9-14)11-4-6-16-7-5-11/h2-10H,1H3
DMUZIDT CS COC1=CC2=NC=C(C=C2C=C1)C3=CC=NC=C3
DMUZIDT IK NGPCGERQDPJHQQ-UHFFFAOYSA-N
DMUZIDT IU 7-methoxy-3-pyridin-4-ylquinoline
DMUZIDT DE Discovery agent
DM9QKLC ID DM9QKLC
DM9QKLC DN 7-Methoxy-3-thiophen-3-yl-quinoline
DM9QKLC HS Investigative
DM9QKLC SN CHEMBL68185; 7-methoxy-3-thiophen-3-yl-quinoline; SCHEMBL8500071; ZINC8076
DM9QKLC DT Small molecular drug
DM9QKLC PC 10331922
DM9QKLC MW 241.31
DM9QKLC FM C14H11NOS
DM9QKLC IC InChI=1S/C14H11NOS/c1-16-13-3-2-10-6-12(8-15-14(10)7-13)11-4-5-17-9-11/h2-9H,1H3
DM9QKLC CS COC1=CC2=NC=C(C=C2C=C1)C3=CSC=C3
DM9QKLC IK AOLUUEDZXBVWED-UHFFFAOYSA-N
DM9QKLC IU 7-methoxy-3-thiophen-3-ylquinoline
DM9QKLC DE Discovery agent
DMNFIZD ID DMNFIZD
DMNFIZD DN 7-Methoxy-4-morpholin-4-yl-chromen-2-one
DMNFIZD HS Investigative
DMNFIZD SN CHEMBL177241; 7-methoxy-4-morpholin-4-yl-chromen-2-one; BDBM50159670
DMNFIZD DT Small molecular drug
DMNFIZD PC 11357448
DMNFIZD MW 261.269
DMNFIZD FM C14H15NO4
DMNFIZD IC InChI=1S/C14H15NO4/c1-17-10-2-3-11-12(15-4-6-18-7-5-15)9-14(16)19-13(11)8-10/h2-3,8-9H,4-7H2,1H3
DMNFIZD CS COC1=CC2=C(C=C1)C(=CC(=O)O2)N3CCOCC3
DMNFIZD IK DRJQJIYPCHBMLO-UHFFFAOYSA-N
DMNFIZD IU 7-methoxy-4-morpholin-4-ylchromen-2-one
DMNFIZD DE Discovery agent
DMH0UVE ID DMH0UVE
DMH0UVE DN 7-methoxy-8-propionyl-2H-chromen-2-one
DMH0UVE HS Investigative
DMH0UVE SN CHEMBL1288621; 7-methoxy-8-propionyl-2H-chromen-2-one
DMH0UVE DT Small molecular drug
DMH0UVE PC 52950111
DMH0UVE MW 232.23
DMH0UVE FM C13H12O4
DMH0UVE IC InChI=1S/C13H12O4/c1-3-9(14)12-10(16-2)6-4-8-5-7-11(15)17-13(8)12/h4-7H,3H2,1-2H3
DMH0UVE CS CCC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OC
DMH0UVE IK XQJPTVQKFUWDCL-UHFFFAOYSA-N
DMH0UVE IU 7-methoxy-8-propanoylchromen-2-one
DMH0UVE DE Discovery agent
DMHKMU1 ID DMHKMU1
DMHKMU1 DN 7-Methoxy-9H-beta-carboline
DMHKMU1 HS Investigative
DMHKMU1 SN NORHARMINE; 7-Methoxy-9H-pyrido[3,4-b]indole; 6253-19-6; CHEMBL6470; SCHEMBL4823690; CTK5B5241; DTXSID30431161
DMHKMU1 DT Small molecular drug
DMHKMU1 PC 9815570
DMHKMU1 MW 198.22
DMHKMU1 FM C12H10N2O
DMHKMU1 IC InChI=1S/C12H10N2O/c1-15-8-2-3-9-10-4-5-13-7-12(10)14-11(9)6-8/h2-7,14H,1H3
DMHKMU1 CS COC1=CC2=C(C=C1)C3=C(N2)C=NC=C3
DMHKMU1 IK LMDPJJFWLNRVEH-UHFFFAOYSA-N
DMHKMU1 IU 7-methoxy-9H-pyrido[3,4-b]indole
DMHKMU1 CA CAS 6253-19-6
DMHKMU1 DE Discovery agent
DMUCJA6 ID DMUCJA6
DMUCJA6 DN 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine
DMUCJA6 HS Investigative
DMUCJA6 SN CHEMBL365202; 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine; SCHEMBL7682273; BDBM50155792
DMUCJA6 DT Small molecular drug
DMUCJA6 PC 15552206
DMUCJA6 MW 144.24
DMUCJA6 FM C6H12N2S
DMUCJA6 IC InChI=1S/C6H12N2S/c1-5-4-6(7)8-2-3-9-5/h5H,2-4H2,1H3,(H2,7,8)
DMUCJA6 CS CC1CC(=NCCS1)N
DMUCJA6 IK JXQWNOBSLLRHKM-UHFFFAOYSA-N
DMUCJA6 IU 7-methyl-2,3,6,7-tetrahydro-1,4-thiazepin-5-amine
DMUCJA6 DE Discovery agent
DM5EQJU ID DM5EQJU
DM5EQJU DN 7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM5EQJU HS Investigative
DM5EQJU SN CHEMBL98738; 7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one; SCHEMBL10758549
DM5EQJU DT Small molecular drug
DM5EQJU PC 13936971
DM5EQJU MW 199.21
DM5EQJU FM C11H9N3O
DM5EQJU IC InChI=1S/C11H9N3O/c1-6-2-3-8-7(4-6)5-9-10(12-8)14-11(15)13-9/h2-5H,1H3,(H2,12,13,14,15)
DM5EQJU CS CC1=CC2=CC3=C(NC(=O)N3)N=C2C=C1
DM5EQJU IK BSAKVJKPJIQKNP-UHFFFAOYSA-N
DM5EQJU IU 7-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM5EQJU DE Discovery agent
DM7LGDC ID DM7LGDC
DM7LGDC DN 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
DM7LGDC HS Investigative
DM7LGDC SN CHEMBL45620; NSC676188; AC1NV5AM; 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one; SCHEMBL7920165; ZINC6491122; BDBM50059974; NSC-676188; NCI60_026915; 2-(3-Methylphenyl)-7-methyl-1,8-naphthyridin-4(1H)-one
DM7LGDC DT Small molecular drug
DM7LGDC PC 5468782
DM7LGDC MW 250.29
DM7LGDC FM C16H14N2O
DM7LGDC IC InChI=1S/C16H14N2O/c1-10-4-3-5-12(8-10)14-9-15(19)13-7-6-11(2)17-16(13)18-14/h3-9H,1-2H3,(H,17,18,19)
DM7LGDC CS CC1=CC(=CC=C1)C2=CC(=O)C3=C(N2)N=C(C=C3)C
DM7LGDC IK WHANICGPAJMUTA-UHFFFAOYSA-N
DM7LGDC IU 7-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
DM7LGDC DE Discovery agent
DMCV891 ID DMCV891
DMCV891 DN 7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine
DMCV891 HS Investigative
DMCV891 SN CHEMBL238552; 7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine
DMCV891 DT Small molecular drug
DMCV891 PC 44435026
DMCV891 MW 235.28
DMCV891 FM C15H13N3
DMCV891 IC InChI=1S/C15H13N3/c1-10-4-3-5-12(8-10)14-16-9-13-7-6-11(2)17-15(13)18-14/h3-9H,1-2H3
DMCV891 CS CC1=CC(=CC=C1)C2=NC=C3C=CC(=NC3=N2)C
DMCV891 IK AHSIQPYQWYRYSS-UHFFFAOYSA-N
DMCV891 IU 7-methyl-2-(3-methylphenyl)pyrido[2,3-d]pyrimidine
DMCV891 DE Discovery agent
DMJ4G27 ID DMJ4G27
DMJ4G27 DN 7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27 HS Investigative
DMJ4G27 SN CHEMBL394304; 7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27 DT Small molecular drug
DMJ4G27 PC 44435020
DMJ4G27 MW 221.26
DMJ4G27 FM C14H11N3
DMJ4G27 IC InChI=1S/C14H11N3/c1-10-7-8-12-9-15-13(17-14(12)16-10)11-5-3-2-4-6-11/h2-9H,1H3
DMJ4G27 CS CC1=NC2=NC(=NC=C2C=C1)C3=CC=CC=C3
DMJ4G27 IK KWVJWWRUSUZAGY-UHFFFAOYSA-N
DMJ4G27 IU 7-methyl-2-phenylpyrido[2,3-d]pyrimidine
DMJ4G27 DE Discovery agent
DMGB9IE ID DMGB9IE
DMGB9IE DN 7-Methyl-2-propyl-[1,8]naphthyridin-4-ol
DMGB9IE HS Investigative
DMGB9IE SN CHEMBL103150; 7-Methyl-2-propyl-[1,8]naphthyridin-4-ol; 1,8-Naphthyridin-4-ol, 7-methyl-2-propyl-; BDBM50147877; 718624-73-8
DMGB9IE DT Small molecular drug
DMGB9IE PC 13155595
DMGB9IE MW 202.25
DMGB9IE FM C12H14N2O
DMGB9IE IC InChI=1S/C12H14N2O/c1-3-4-9-7-11(15)10-6-5-8(2)13-12(10)14-9/h5-7H,3-4H2,1-2H3,(H,13,14,15)
DMGB9IE CS CCCC1=CC(=O)C2=C(N1)N=C(C=C2)C
DMGB9IE IK JAFFZYFREVCDTP-UHFFFAOYSA-N
DMGB9IE IU 7-methyl-2-propyl-1H-1,8-naphthyridin-4-one
DMGB9IE DE Discovery agent
DMB9YA8 ID DMB9YA8
DMB9YA8 DN 7-methyl-2-p-tolyl-4H-chromene-4-thione
DMB9YA8 HS Investigative
DMB9YA8 SN CHEMBL592642; 7-methyl-2-p-tolyl-4H-chromene-4-thione
DMB9YA8 DT Small molecular drug
DMB9YA8 PC 46232005
DMB9YA8 MW 266.4
DMB9YA8 FM C17H14OS
DMB9YA8 IC InChI=1S/C17H14OS/c1-11-3-6-13(7-4-11)15-10-17(19)14-8-5-12(2)9-16(14)18-15/h3-10H,1-2H3
DMB9YA8 CS CC1=CC=C(C=C1)C2=CC(=S)C3=C(O2)C=C(C=C3)C
DMB9YA8 IK LDIMKSQQZFWQLA-UHFFFAOYSA-N
DMB9YA8 IU 7-methyl-2-(4-methylphenyl)chromene-4-thione
DMB9YA8 DE Discovery agent
DMZKO14 ID DMZKO14
DMZKO14 DN 7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine
DMZKO14 HS Investigative
DMZKO14 SN TCMDC-139863; 7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine; CHEMBL174414; 7-methylpyrrolo[3,2-f]quinazoline-1,3-diamine; AC1LAG62; SCHEMBL11612134; 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine, 7-methyl-; WSISEVQVCUARDZ-UHFFFAOYSA-N; BDBM50049900; 65796-02-3
DMZKO14 DT Small molecular drug
DMZKO14 PC 467889
DMZKO14 MW 213.24
DMZKO14 FM C11H11N5
DMZKO14 IC InChI=1S/C11H11N5/c1-16-5-4-6-8(16)3-2-7-9(6)10(12)15-11(13)14-7/h2-5H,1H3,(H4,12,13,14,15)
DMZKO14 CS CN1C=CC2=C1C=CC3=C2C(=NC(=N3)N)N
DMZKO14 IK WSISEVQVCUARDZ-UHFFFAOYSA-N
DMZKO14 IU 7-methylpyrrolo[3,2-f]quinazoline-1,3-diamine
DMZKO14 DE Discovery agent
DMMENDC ID DMMENDC
DMMENDC DN 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX)
DMMENDC HS Investigative
DMMENDC SN CHEMBL107172; SCHEMBL7850311; TAK-622; BDBM50030589; N-Methyl-N-[3,5-bis(trifluoromethyl)benzyl]-7-methyl-8-oxo-5-(4-methylphenyl)-1,7-naphthyridine-6-carboxamide
DMMENDC DT Small molecular drug
DMMENDC PC 9871754
DMMENDC MW 533.5
DMMENDC FM C27H21F6N3O2
DMMENDC IC InChI=1S/C27H21F6N3O2/c1-15-6-8-17(9-7-15)21-20-5-4-10-34-22(20)24(37)36(3)23(21)25(38)35(2)14-16-11-18(26(28,29)30)13-19(12-16)27(31,32)33/h4-13H,14H2,1-3H3
DMMENDC CS CC1=CC=C(C=C1)C2=C(N(C(=O)C3=C2C=CC=N3)C)C(=O)N(C)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMMENDC IK GIAQQXUCTFYCHO-UHFFFAOYSA-N
DMMENDC IU N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
DMMENDC DE Discovery agent
DMO0RGL ID DMO0RGL
DMO0RGL DN 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)
DMO0RGL HS Investigative
DMO0RGL SN CHEMBL135572; 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX); BDBM50067521; 5-(4-Methylphenyl)-7,N-dimethyl-N-[(R)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl]-8-oxo-7,8-dihydro-1,7-naphthyridine-6-carboxamide; 7-Methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (S)-[(R)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide
DMO0RGL DT Small molecular drug
DMO0RGL PC 10650263
DMO0RGL MW 547.5
DMO0RGL FM C28H23F6N3O2
DMO0RGL IC InChI=1S/C28H23F6N3O2/c1-15-7-9-17(10-8-15)22-21-6-5-11-35-23(21)25(38)37(4)24(22)26(39)36(3)16(2)18-12-19(27(29,30)31)14-20(13-18)28(32,33)34/h5-14,16H,1-4H3/t16-/m1/s1
DMO0RGL CS CC1=CC=C(C=C1)C2=C(N(C(=O)C3=C2C=CC=N3)C)C(=O)N(C)[C@H](C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMO0RGL IK TTZWDLZPHOQUAU-MRXNPFEDSA-N
DMO0RGL IU N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
DMO0RGL DE Discovery agent
DMOAJ0E ID DMOAJ0E
DMOAJ0E DN 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX)
DMOAJ0E HS Investigative
DMOAJ0E SN CHEMBL336589; 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX); BDBM50067516; 7-Methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (S)-[(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide; 7-Methyl-8-oxo-5-p-tolyl-7,8-dihydro-[1,7]naphthyridine-6-carboxylic acid (R)-[(S)-1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide
DMOAJ0E DT Small molecular drug
DMOAJ0E PC 10053205
DMOAJ0E MW 547.5
DMOAJ0E FM C28H23F6N3O2
DMOAJ0E IC InChI=1S/C28H23F6N3O2/c1-15-7-9-17(10-8-15)22-21-6-5-11-35-23(21)25(38)37(4)24(22)26(39)36(3)16(2)18-12-19(27(29,30)31)14-20(13-18)28(32,33)34/h5-14,16H,1-4H3/t16-/m0/s1
DMOAJ0E CS CC1=CC=C(C=C1)C2=C(N(C(=O)C3=C2C=CC=N3)C)C(=O)N(C)[C@@H](C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMOAJ0E IK TTZWDLZPHOQUAU-INIZCTEOSA-N
DMOAJ0E IU N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-N,7-dimethyl-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide
DMOAJ0E DE Discovery agent
DME39U2 ID DME39U2
DME39U2 DN 7-Methyl-Gpppa
DME39U2 HS Investigative
DME39U2 DT Small molecular drug
DME39U2 PC 135415790
DME39U2 MW 787.4
DME39U2 FM C21H30N10O17P3+
DME39U2 IC InChI=1S/C21H29N10O17P3/c1-29-6-31(17-10(29)18(36)28-21(23)27-17)20-14(35)12(33)8(46-20)3-44-50(39,40)48-51(41,42)47-49(37,38)43-2-7-11(32)13(34)19(45-7)30-5-26-9-15(22)24-4-25-16(9)30/h4-8,11-14,19-20,32-35H,2-3H2,1H3,(H7-,22,23,24,25,27,28,36,37,38,39,40,41,42)/p+1/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
DME39U2 CS CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O
DME39U2 IK QQOHNVHGNZYSBP-XPWFQUROSA-O
DME39U2 IU [[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DME39U2 DE Discovery agent
DMCGNUO ID DMCGNUO
DMCGNUO DN 7-Methyl-Guanosine-5'-Triphosphate
DMCGNUO HS Investigative
DMCGNUO DT Small molecular drug
DMCGNUO PC 135419182
DMCGNUO MW 538.22
DMCGNUO FM C11H19N5O14P3+
DMCGNUO IC InChI=1S/C11H18N5O14P3/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(28-10)2-27-32(23,24)30-33(25,26)29-31(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H6-,12,13,14,19,20,21,22,23,24,25,26)/p+1/t4-,6-,7-,10-/m1/s1
DMCGNUO CS CN1C=[N+](C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMCGNUO IK DKVRNHPCAOHRSI-KQYNXXCUSA-O
DMCGNUO IU [[(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMCGNUO CB CHEBI:50226
DMCGNUO DE Discovery agent
DMBDFP2 ID DMBDFP2
DMBDFP2 DN 7-m-tolyl-1,6-naphthyridine
DMBDFP2 HS Investigative
DMBDFP2 SN CHEMBL238388; 7-m-tolyl-1,6-naphthyridine
DMBDFP2 DT Small molecular drug
DMBDFP2 PC 44434721
DMBDFP2 MW 220.27
DMBDFP2 FM C15H12N2
DMBDFP2 IC InChI=1S/C15H12N2/c1-11-4-2-5-12(8-11)14-9-15-13(10-17-14)6-3-7-16-15/h2-10H,1H3
DMBDFP2 CS CC1=CC(=CC=C1)C2=NC=C3C=CC=NC3=C2
DMBDFP2 IK QFKQBMHTZFGQHK-UHFFFAOYSA-N
DMBDFP2 IU 7-(3-methylphenyl)-1,6-naphthyridine
DMBDFP2 DE Discovery agent
DMX3UV1 ID DMX3UV1
DMX3UV1 DN 7-Nitro-1,2,3,4-tetrahydro-isoquinoline
DMX3UV1 HS Investigative
DMX3UV1 SN 7-Nitro-1,2,3,4-tetrahydroisoquinoline; 42923-79-5; 7-Nitro-1,2,3,4-tetrahydro-isoquinoline; 1,2,3,4-Tetrahydro-7-nitroisoquinoline; CHEMBL281289; YPRWYZSUBZXORL-UHFFFAOYSA-N; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-7-NITRO-; N90100; 7-nitrotetrahydroisoquinoline; SCHEMBL324460; 7-Nitro-tetrahydroisoquinoline; AC1O502M; SCHEMBL10066165; CTK4I6796; DTXSID30423728; MolPort-003-886-230; BCP09681; KS-00000DK2; ACT10738; CS-D0150; ANW-50594; ZINC13686846; BDBM50072991; AKOS005259136; QC-5046; AB21318; RP03102; MCULE-4384372233; AC-9598
DMX3UV1 DT Small molecular drug
DMX3UV1 PC 6424833
DMX3UV1 MW 178.19
DMX3UV1 FM C9H10N2O2
DMX3UV1 IC InChI=1S/C9H10N2O2/c12-11(13)9-2-1-7-3-4-10-6-8(7)5-9/h1-2,5,10H,3-4,6H2
DMX3UV1 CS C1CNCC2=C1C=CC(=C2)[N+](=O)[O-]
DMX3UV1 IK YPRWYZSUBZXORL-UHFFFAOYSA-N
DMX3UV1 IU 7-nitro-1,2,3,4-tetrahydroisoquinoline
DMX3UV1 CA CAS 42923-79-5
DMX3UV1 DE Discovery agent
DMW4XKQ ID DMW4XKQ
DMW4XKQ DN 7-nitro-1H-indazole
DMW4XKQ HS Investigative
DMW4XKQ SN 7-Nitroindazole; 7-nitroindazole; 7-Nitro-1H-indazole; 2942-42-9; 1H-Indazole, 7-nitro-; 7-nitro-indazole; 7-NI; UNII-UX0N37CMVH; CCRIS 3309; EINECS 220-934-4; NSC 72843; UX0N37CMVH; BRN 0006809; MLS000028452; CHEMBL247378; PQCAUHUKTBHUSA-UHFFFAOYSA-N; MFCD00022789; SMR000058266; 7NI; 2h-indazole,7-nitro-; SR-01000075512; 7- Nitroindazole; 7-Nitroisoindazole; Tocris-0602; PubChem14009; AC1L1CGU; Spectrum3_001980; Spectrum2_001715; Opera_ID_1690; Lopac-N-7778; ACMC-209h8w; AC1Q1Y3U; 7-Nitroindazole, > NCIOpen2_000477; Lopac0_000839; BSPBio_003580
DMW4XKQ DT Small molecular drug
DMW4XKQ PC 1893
DMW4XKQ MW 163.13
DMW4XKQ FM C7H5N3O2
DMW4XKQ IC InChI=1S/C7H5N3O2/c11-10(12)6-3-1-2-5-4-8-9-7(5)6/h1-4H,(H,8,9)
DMW4XKQ CS C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2
DMW4XKQ IK PQCAUHUKTBHUSA-UHFFFAOYSA-N
DMW4XKQ IU 7-nitro-1H-indazole
DMW4XKQ CA CAS 2942-42-9
DMW4XKQ DE Discovery agent
DMGLWOM ID DMGLWOM
DMGLWOM DN 7-Nitroindazole-2-Carboxamidine
DMGLWOM HS Investigative
DMGLWOM SN 7-nitroindazole-2-carboxamidine; 7-nitro-2h-indazole-2-carboximidamide; 7I2; AC1L1CGX; SCHEMBL4315825; CTK5I3867; 7-nitroindazole-2-carboximidamide; 7-Nitro-2H-indazole-2-carboxamidine
DMGLWOM DT Small molecular drug
DMGLWOM PC 1894
DMGLWOM MW 205.17
DMGLWOM FM C8H7N5O2
DMGLWOM IC InChI=1S/C8H7N5O2/c9-8(10)12-4-5-2-1-3-6(13(14)15)7(5)11-12/h1-4H,(H3,9,10)
DMGLWOM CS C1=CC2=CN(N=C2C(=C1)[N+](=O)[O-])C(=N)N
DMGLWOM IK GFYAZUABYOOPCN-UHFFFAOYSA-N
DMGLWOM IU 7-nitroindazole-2-carboximidamide
DMGLWOM DE Discovery agent
DM2403T ID DM2403T
DM2403T DN 7n-Methyl-8-Hydroguanosine-5'-Diphosphate
DM2403T HS Investigative
DM2403T DT Small molecular drug
DM2403T PC 135509116
DM2403T MW 459.24
DM2403T FM C11H19N5O11P2
DM2403T IC InChI=1S/C11H19N5O11P2/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(26-10)2-25-29(23,24)27-28(20,21)22/h4,6-7,10,17-18H,2-3H2,1H3,(H,23,24)(H2,20,21,22)(H3,12,13,14,19)/t4-,6-,7-,10-/m1/s1
DM2403T CS CN1CN(C2=C1C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O
DM2403T IK QQODJOAVWUWVHJ-KQYNXXCUSA-N
DM2403T IU [(2R,3S,4R,5R)-5-(2-amino-7-methyl-6-oxo-1,8-dihydropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM2403T CA CAS 104809-16-7
DM2403T CB CHEBI:43977
DM2403T DE Discovery agent
DM8IY3D ID DM8IY3D
DM8IY3D DN 7-O-b-D-Glucopyranosyl-a-homonojirimycin
DM8IY3D HS Investigative
DM8IY3D SN CHEMBL478209; NSC630254; 104343-33-1; MDL-25637; 7-O-b-D-Glucopyranosyl-a-homonojirimycin; AC1L9X0M; SCHEMBL305712; BDBM50263042; 2,6-Dideoxy-2,6-imino-7-O-.beta.-D-glucopyranosyl-D-glycero-L-gulo-heptitol hydrochloride hydrate; (2R,3R,4S,5S,6R)-2-(hydroxymethyl)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]piperidine-3,4,5-triol; .beta.-D-glucopyranoside, [(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-piperidinyl]methyl
DM8IY3D DT Small molecular drug
DM8IY3D PC 457676
DM8IY3D MW 355.34
DM8IY3D FM C13H25NO10
DM8IY3D IC InChI=1S/C13H25NO10/c15-1-4-7(17)10(20)8(18)5(14-4)3-23-13-12(22)11(21)9(19)6(2-16)24-13/h4-22H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11+,12-,13-/m1/s1
DM8IY3D CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](N1)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O
DM8IY3D IK VCIPQQCYKMORDY-KBYFLBCBSA-N
DM8IY3D IU (2R,3R,4S,5S,6R)-2-(hydroxymethyl)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]piperidine-3,4,5-triol
DM8IY3D CA CAS 104343-33-1
DM8IY3D DE Discovery agent
DMJZR0A ID DMJZR0A
DMJZR0A DN 7-Oxo-7H-dibenzo[de,g]quinoline
DMJZR0A HS Investigative
DMJZR0A SN CHEMBL559502; 38750-39-9; 7-Oxo-7H-dibenzo[de,g]quinoline; NSC296570; AC1L6XTV; CTK1C6162; DTXSID80315725; 7H-Dibenzo[de,g]quinolin-7-one; 7H-Dibenzo[de,g]quinoline-7-one; BDBM50293443
DMJZR0A DT Small molecular drug
DMJZR0A PC 326183
DMJZR0A MW 231.25
DMJZR0A FM C16H9NO
DMJZR0A IC InChI=1S/C16H9NO/c18-16-13-6-2-1-5-11(13)12-7-3-4-10-8-9-17-15(16)14(10)12/h1-9H
DMJZR0A CS C1=CC=C2C(=C1)C3=CC=CC4=C3C(=NC=C4)C2=O
DMJZR0A IK GHWKWAMIXPOYPG-UHFFFAOYSA-N
DMJZR0A IU 10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17),14-octaen-8-one
DMJZR0A CA CAS 38750-39-9
DMJZR0A DE Discovery agent
DM8Q267 ID DM8Q267
DM8Q267 DN 7-phenethoxy-2H-chromen-2-one
DM8Q267 HS Investigative
DM8Q267 SN CHEMBL567544; 7-phenethoxy-2H-chromen-2-one
DM8Q267 DT Small molecular drug
DM8Q267 PC 45485279
DM8Q267 MW 250.29
DM8Q267 FM C17H14O2
DM8Q267 IC InChI=1S/C17H14O2/c18-17-11-10-15-9-8-14(12-16(15)19-17)7-6-13-4-2-1-3-5-13/h1-5,8-12H,6-7H2
DM8Q267 CS C1=CC=C(C=C1)CCC2=CC3=C(C=C2)C=CC(=O)O3
DM8Q267 IK FQWWPSNGCTYUHH-UHFFFAOYSA-N
DM8Q267 IU 7-(2-phenylethyl)chromen-2-one
DM8Q267 DE Discovery agent
DM1FL5G ID DM1FL5G
DM1FL5G DN 7-Phenoxy-heptanoic acid hydroxyamide
DM1FL5G HS Investigative
DM1FL5G SN 7-Phenoxy-heptanoic acid hydroxyamide; CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid
DM1FL5G DT Small molecular drug
DM1FL5G PC 25798548
DM1FL5G MW 237.29
DM1FL5G FM C13H19NO3
DM1FL5G IC InChI=1S/C13H19NO3/c15-13(14-16)10-6-1-2-7-11-17-12-8-4-3-5-9-12/h3-5,8-9,16H,1-2,6-7,10-11H2,(H,14,15)
DM1FL5G CS C1=CC=C(C=C1)OCCCCCCC(=O)NO
DM1FL5G IK IHTQKNINBYXIDN-UHFFFAOYSA-N
DM1FL5G IU N-hydroxy-7-phenoxyheptanamide
DM1FL5G DE Discovery agent
DMQMRGD ID DMQMRGD
DMQMRGD DN 7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one
DMQMRGD HS Investigative
DMQMRGD SN CHEMBL477371; SCHEMBL2162232; 7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one
DMQMRGD DT Small molecular drug
DMQMRGD PC 24951315
DMQMRGD MW 274.4
DMQMRGD FM C15H18N2OS
DMQMRGD IC InChI=1S/C15H18N2OS/c18-14(15-17-16-12-19-15)11-7-2-1-4-8-13-9-5-3-6-10-13/h3,5-6,9-10,12H,1-2,4,7-8,11H2
DMQMRGD CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CS2
DMQMRGD IK QUVXRHLPGVMXRU-UHFFFAOYSA-N
DMQMRGD IU 7-phenyl-1-(1,3,4-thiadiazol-2-yl)heptan-1-one
DMQMRGD DE Discovery agent
DMEABGI ID DMEABGI
DMEABGI DN 7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one
DMEABGI HS Investigative
DMEABGI SN CHEMBL456450; 7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one; SCHEMBL2161929; ZINC40380109; BDBM50274982
DMEABGI DT Small molecular drug
DMEABGI PC 24950683
DMEABGI MW 258.32
DMEABGI FM C14H18N4O
DMEABGI IC InChI=1S/C14H18N4O/c19-13(14-15-17-18-16-14)11-7-2-1-4-8-12-9-5-3-6-10-12/h3,5-6,9-10H,1-2,4,7-8,11H2,(H,15,16,17,18)
DMEABGI CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NNN=N2
DMEABGI IK JVOYAZCLPXVADL-UHFFFAOYSA-N
DMEABGI IU 7-phenyl-1-(2H-tetrazol-5-yl)heptan-1-one
DMEABGI DE Discovery agent
DM62PAU ID DM62PAU
DM62PAU DN 7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one
DM62PAU HS Investigative
DM62PAU SN CHEMBL460316; 7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one; SCHEMBL2162579
DM62PAU DT Small molecular drug
DM62PAU PC 44554614
DM62PAU MW 333.4
DM62PAU FM C22H23NO2
DM62PAU IC InChI=1S/C22H23NO2/c24-21(16-10-2-1-5-11-18-12-6-3-7-13-18)22-23-20(17-25-22)19-14-8-4-9-15-19/h3-4,6-9,12-15,17H,1-2,5,10-11,16H2
DM62PAU CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC(=CO2)C3=CC=CC=C3
DM62PAU IK XOLGPHAVLXMSGU-UHFFFAOYSA-N
DM62PAU IU 7-phenyl-1-(4-phenyl-1,3-oxazol-2-yl)heptan-1-one
DM62PAU DE Discovery agent
DM9SGBW ID DM9SGBW
DM9SGBW DN 7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one
DM9SGBW HS Investigative
DM9SGBW SN CHEMBL173992; 7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one; 7-phenyl-1-(5-phenyl-1,3-oxazol-2-yl)heptan-1-one; BDBM50163187
DM9SGBW DT Small molecular drug
DM9SGBW PC 11279040
DM9SGBW MW 333.4
DM9SGBW FM C22H23NO2
DM9SGBW IC InChI=1S/C22H23NO2/c24-20(16-10-2-1-5-11-18-12-6-3-7-13-18)22-23-17-21(25-22)19-14-8-4-9-15-19/h3-4,6-9,12-15,17H,1-2,5,10-11,16H2
DM9SGBW CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=C(O2)C3=CC=CC=C3
DM9SGBW IK GEHXWVPLQWJJQM-UHFFFAOYSA-N
DM9SGBW IU 7-phenyl-1-(5-phenyl-1,3-oxazol-2-yl)heptan-1-one
DM9SGBW DE Discovery agent
DMG1PNX ID DMG1PNX
DMG1PNX DN 7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one
DMG1PNX HS Investigative
DMG1PNX SN CHEMBL455556; 7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one; SCHEMBL2161875; BDBM50262479
DMG1PNX DT Small molecular drug
DMG1PNX PC 24951319
DMG1PNX MW 268.35
DMG1PNX FM C17H20N2O
DMG1PNX IC InChI=1S/C17H20N2O/c20-17(16-12-8-14-18-19-16)13-7-2-1-4-9-15-10-5-3-6-11-15/h3,5-6,8,10-12,14H,1-2,4,7,9,13H2
DMG1PNX CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NN=CC=C2
DMG1PNX IK DXGZKZUTNHLJNE-UHFFFAOYSA-N
DMG1PNX IU 7-phenyl-1-pyridazin-3-ylheptan-1-one
DMG1PNX DE Discovery agent
DMLHI5T ID DMLHI5T
DMLHI5T DN 7-Phenyl-1-(thiazol-2-yl)-heptan-1-one
DMLHI5T HS Investigative
DMLHI5T SN CHEMBL468221; 7-Phenyl-1-(thiazol-2-yl)-heptan-1-one; SCHEMBL2161939
DMLHI5T DT Small molecular drug
DMLHI5T PC 24951160
DMLHI5T MW 273.4
DMLHI5T FM C16H19NOS
DMLHI5T IC InChI=1S/C16H19NOS/c18-15(16-17-12-13-19-16)11-7-2-1-4-8-14-9-5-3-6-10-14/h3,5-6,9-10,12-13H,1-2,4,7-8,11H2
DMLHI5T CS C1=CC=C(C=C1)CCCCCCC(=O)C2=NC=CS2
DMLHI5T IK BBVVJTRLCDWSMU-UHFFFAOYSA-N
DMLHI5T IU 7-phenyl-1-(1,3-thiazol-2-yl)heptan-1-one
DMLHI5T DE Discovery agent
DMEDOFB ID DMEDOFB
DMEDOFB DN 7-phenylethoxy-2-morpholin-4-yl-chromen-4-one
DMEDOFB HS Investigative
DMEDOFB SN CHEMBL199127; 7-phenylethoxy-2-morpholin-4-yl-chromen-4-one
DMEDOFB DT Small molecular drug
DMEDOFB PC 11624481
DMEDOFB MW 351.4
DMEDOFB FM C21H21NO4
DMEDOFB IC InChI=1S/C21H21NO4/c23-19-15-21(22-9-12-24-13-10-22)26-20-14-17(6-7-18(19)20)25-11-8-16-4-2-1-3-5-16/h1-7,14-15H,8-13H2
DMEDOFB CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OCCC4=CC=CC=C4
DMEDOFB IK KIOBMXIHRJGBLA-UHFFFAOYSA-N
DMEDOFB IU 2-morpholin-4-yl-7-(2-phenylethoxy)chromen-4-one
DMEDOFB DE Discovery agent
DM1WJFR ID DM1WJFR
DM1WJFR DN 7-Phenyl-naphthalen-2-ol
DM1WJFR HS Investigative
DM1WJFR SN 7-Phenyl-naphthalen-2-ol; CHEMBL194718; 7-Phenyl-2-naphthol; 7-Phenylnaphthalene-2-ol; SCHEMBL5981104; MLFRZWHPLMDWES-UHFFFAOYSA-N; BDBM50168338
DM1WJFR DT Small molecular drug
DM1WJFR PC 11458674
DM1WJFR MW 220.26
DM1WJFR FM C16H12O
DM1WJFR IC InChI=1S/C16H12O/c17-16-9-8-13-6-7-14(10-15(13)11-16)12-4-2-1-3-5-12/h1-11,17H
DM1WJFR CS C1=CC=C(C=C1)C2=CC3=C(C=C2)C=CC(=C3)O
DM1WJFR IK MLFRZWHPLMDWES-UHFFFAOYSA-N
DM1WJFR IU 7-phenylnaphthalen-2-ol
DM1WJFR DE Discovery agent
DMSBJ4M ID DMSBJ4M
DMSBJ4M DN 7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one
DMSBJ4M HS Investigative
DMSBJ4M SN CHEMBL372804; 7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one; SCHEMBL9535095
DMSBJ4M DT Small molecular drug
DMSBJ4M PC 11566823
DMSBJ4M MW 367.4
DMSBJ4M FM C21H21NO5
DMSBJ4M IC InChI=1S/C21H21NO5/c23-19-15-21(22-8-10-24-11-9-22)27-20-14-17(6-7-18(19)20)26-13-12-25-16-4-2-1-3-5-16/h1-7,14-15H,8-13H2
DMSBJ4M CS C1COCCN1C2=CC(=O)C3=C(O2)C=C(C=C3)OCCOC4=CC=CC=C4
DMSBJ4M IK WZUWDKBMBHSVAZ-UHFFFAOYSA-N
DMSBJ4M IU 2-morpholin-4-yl-7-(2-phenoxyethoxy)chromen-4-one
DMSBJ4M DE Discovery agent
DM19I62 ID DM19I62
DM19I62 DN 7-Phloroethol
DM19I62 HS Investigative
DM19I62 SN 7-Phloroeckol; 7-Phloroethol; UNII-97GCC12YF0; CHEMBL456228; 97GCC12YF0; CHEBI:65790; 4-(3,5-dihydroxyphenoxy)-8-(2,4,6-trihydroxyphenoxy)oxanthrene-1,3,6-triol; 1-(3',5'-Dihydroxyphenoxy)-7-(2'',4'',6''-trihydroxyphenoxy)-2,4,9-trihydroxydibenzo-1,4-dioxin; 7-Phloroglucinoleckol; SCHEMBL10271928; BDBM50276826; 4-(3,5-Dihydroxyphenoxy)-8-(2,4,6-trihydroxyphenoxy)dibenzo(b,E)(1,4)dioxin-1,3,6-triol; [(2,4,9-Trihydroxydibenzo-p-dioxin-1,7-diyl)dioxydibenzene]-2',3,4',5,6'-pentol; Dibenzo(b,E)(1,4)dioxin-1,3,6-triol, 4-(3,
DM19I62 DT Small molecular drug
DM19I62 PC 10480940
DM19I62 MW 496.4
DM19I62 FM C24H16O12
DM19I62 IC InChI=1S/C24H16O12/c25-9-1-10(26)3-12(2-9)34-22-17(31)8-18(32)23-24(22)36-21-16(30)6-13(7-19(21)35-23)33-20-14(28)4-11(27)5-15(20)29/h1-8,25-32H
DM19I62 CS C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)OC5=C(C=C(C=C5O)O)O)O)O)O)O
DM19I62 IK JLEVVQRBEATTCM-UHFFFAOYSA-N
DM19I62 IU 4-(3,5-dihydroxyphenoxy)-8-(2,4,6-trihydroxyphenoxy)dibenzo-p-dioxin-1,3,6-triol
DM19I62 CA CAS 662165-35-7
DM19I62 CB CHEBI:65790
DM19I62 DE Discovery agent
DMO8WB2 ID DMO8WB2
DMO8WB2 DN 7-propoxy-2-(morpholin-4-yl)-chromen-4-one
DMO8WB2 HS Investigative
DMO8WB2 SN CHEMBL426099; 7-propoxy-2-(morpholin-4-yl)-chromen-4-one; SCHEMBL3537201
DMO8WB2 DT Small molecular drug
DMO8WB2 PC 11630658
DMO8WB2 MW 289.33
DMO8WB2 FM C16H19NO4
DMO8WB2 IC InChI=1S/C16H19NO4/c1-2-7-20-12-3-4-13-14(18)11-16(21-15(13)10-12)17-5-8-19-9-6-17/h3-4,10-11H,2,5-9H2,1H3
DMO8WB2 CS CCCOC1=CC2=C(C=C1)C(=O)C=C(O2)N3CCOCC3
DMO8WB2 IK RXAXOVGTCLFYCQ-UHFFFAOYSA-N
DMO8WB2 IU 2-morpholin-4-yl-7-propoxychromen-4-one
DMO8WB2 DE Discovery agent
DMD5CB6 ID DMD5CB6
DMD5CB6 DN 7-propoxy-2H-chromen-2-one
DMD5CB6 HS Investigative
DMD5CB6 SN 7-Propoxy-chromen-2-one; 7-propoxy-2H-chromen-2-one; 6093-73-8; 7-PROPOXYCOUMARIN; 2H-1-Benzopyran-2-one, 7-propoxy-; CHEMBL568516; 7-Propoxy-2H-1-benzopyran-2-one; AC1LUIIJ; 7-propoxychromen-2-one; CBMicro_001394; SCHEMBL6690398; CTK6E6140; DTXSID90209762; MolPort-000-158-388; ZINC1893420; SMSF0015515; BDBM50303501; STK829267; AKOS001042495; MCULE-7191883680; CB03116; RP26084; KB-46577; CJ-30724; BIM-0001595.P001; DB-072872; FT-0687986
DMD5CB6 DT Small molecular drug
DMD5CB6 PC 1631814
DMD5CB6 MW 204.22
DMD5CB6 FM C12H12O3
DMD5CB6 IC InChI=1S/C12H12O3/c1-2-7-14-10-5-3-9-4-6-12(13)15-11(9)8-10/h3-6,8H,2,7H2,1H3
DMD5CB6 CS CCCOC1=CC2=C(C=C1)C=CC(=O)O2
DMD5CB6 IK FCCCOTWGEKNZMI-UHFFFAOYSA-N
DMD5CB6 IU 7-propoxychromen-2-one
DMD5CB6 CA CAS 6093-73-8
DMD5CB6 DE Discovery agent
DM4I0B1 ID DM4I0B1
DM4I0B1 DN 7-Propyl-7H-adenine
DM4I0B1 HS Investigative
DM4I0B1 SN CHEMBL449108; 7-Propyl-7H-adenine; 7H-Purin-6-amine, 7-propyl-; BDBM50256892
DM4I0B1 DT Small molecular drug
DM4I0B1 PC 44572291
DM4I0B1 MW 177.21
DM4I0B1 FM C8H11N5
DM4I0B1 IC InChI=1S/C8H11N5/c1-2-3-13-5-12-8-6(13)7(9)10-4-11-8/h4-5H,2-3H2,1H3,(H2,9,10,11)
DM4I0B1 CS CCCN1C=NC2=NC=NC(=C21)N
DM4I0B1 IK RKILQGBFRKICCA-UHFFFAOYSA-N
DM4I0B1 IU 7-propylpurin-6-amine
DM4I0B1 DE Discovery agent
DMW8XME ID DMW8XME
DMW8XME DN 7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one
DMW8XME HS Investigative
DMW8XME SN CHEMBL509971; 7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one; SCHEMBL1119417
DMW8XME DT Small molecular drug
DMW8XME PC 25180103
DMW8XME MW 242.3
DMW8XME FM C13H10N2OS
DMW8XME IC InChI=1S/C13H10N2OS/c16-13-8-17-12-6-9(3-4-11(12)15-13)10-2-1-5-14-7-10/h1-7H,8H2,(H,15,16)
DMW8XME CS C1C(=O)NC2=C(S1)C=C(C=C2)C3=CN=CC=C3
DMW8XME IK QVFBOIKMDDLOQP-UHFFFAOYSA-N
DMW8XME IU 7-pyridin-3-yl-4H-1,4-benzothiazin-3-one
DMW8XME DE Discovery agent
DMQJ26K ID DMQJ26K
DMQJ26K DN 7-Pyrrolidin-1-yl-hept-5-yn-2-one
DMQJ26K HS Investigative
DMQJ26K SN CHEMBL167419; 7-pyrrolidin-1-ylhept-5-yn-2-one; AC1Q5CHA; AC1L2EX8; BDBM50212578
DMQJ26K DT Small molecular drug
DMQJ26K PC 19814
DMQJ26K MW 179.26
DMQJ26K FM C11H17NO
DMQJ26K IC InChI=1S/C11H17NO/c1-11(13)7-3-2-4-8-12-9-5-6-10-12/h3,5-10H2,1H3
DMQJ26K CS CC(=O)CCC#CCN1CCCC1
DMQJ26K IK DBUFGNBWZXFABF-UHFFFAOYSA-N
DMQJ26K IU 7-pyrrolidin-1-ylhept-5-yn-2-one
DMQJ26K DE Discovery agent
DMSU06X ID DMSU06X
DMSU06X DN 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30)
DMSU06X HS Investigative
DMSU06X SN Hemicholinium; 16478-59-4; 2,2'-(Biphenyl)-4,4'-diylbis(2-hydroxy-4,4-dimethylmorpholinium); 2,2'-(4,4'-Biphenylene)bis(2-hydroxy-4,4-dimethylmorpholinium); 2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol; Morpholinium, 2,2'-(4,4'-biphenylene)bis(2-hydroxy-4,4-dimethyl-; Prestwick3_000393; Prestwick0_000393; Prestwick1_000393; Prestwick2_000393; AC1L1G9B; Lopac0_000578; BSPBio_000605; SPBio_002526; CHEMBL268697; BPBio1_000667; GTPL4494; SCHEMBL12638596; 8-amino-5'-deoxy-5'-chloroguanosine
DMSU06X DT Small molecular drug
DMSU06X PC 3585
DMSU06X MW 414.5
DMSU06X FM C24H34N2O4+2
DMSU06X IC InChI=1S/C24H34N2O4/c1-25(2)13-15-29-23(27,17-25)21-9-5-19(6-10-21)20-7-11-22(12-8-20)24(28)18-26(3,4)14-16-30-24/h5-12,27-28H,13-18H2,1-4H3/q+2
DMSU06X CS C[N+]1(CCOC(C1)(C2=CC=C(C=C2)C3=CC=C(C=C3)C4(C[N+](CCO4)(C)C)O)O)C
DMSU06X IK JIWUESGGKYLPPG-UHFFFAOYSA-N
DMSU06X IU 2-[4-[4-(2-hydroxy-4,4-dimethylmorpholin-4-ium-2-yl)phenyl]phenyl]-4,4-dimethylmorpholin-4-ium-2-ol
DMSU06X CA CAS 16478-59-4
DMSU06X CB CHEBI:94343
DMSU06X DE Discovery agent
DMD7Q1R ID DMD7Q1R
DMD7Q1R DN 7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R HS Investigative
DMD7Q1R SN CHEMBL1171078; 7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R DT Small molecular drug
DMD7Q1R PC 46855215
DMD7Q1R MW 267.32
DMD7Q1R FM C17H17NO2
DMD7Q1R IC InChI=1S/C17H17NO2/c1-17(2,3)11-5-6-12-13-8-10(16(19)20)4-7-14(13)18-15(12)9-11/h4-9,18H,1-3H3,(H,19,20)
DMD7Q1R CS CC(C)(C)C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(=O)O
DMD7Q1R IK DIDFDNKTXWWCAJ-UHFFFAOYSA-N
DMD7Q1R IU 7-tert-butyl-9H-carbazole-3-carboxylic acid
DMD7Q1R DE Discovery agent
DMMU5SO ID DMMU5SO
DMMU5SO DN 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline
DMMU5SO HS Investigative
DMMU5SO SN CHEMBL69378; 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline; ZINC3832255
DMMU5SO DT Small molecular drug
DMMU5SO PC 10083695
DMMU5SO MW 255.29
DMMU5SO FM C14H9NO2S
DMMU5SO IC InChI=1S/C14H9NO2S/c1-2-18-7-9(1)11-3-10-4-13-14(17-8-16-13)5-12(10)15-6-11/h1-7H,8H2
DMMU5SO CS C1OC2=CC3=CC(=CN=C3C=C2O1)C4=CSC=C4
DMMU5SO IK YSBLLMHIZDPXPM-UHFFFAOYSA-N
DMMU5SO IU 7-thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline
DMMU5SO DE Discovery agent
DMOQMA0 ID DMOQMA0
DMOQMA0 DN 7-trans-OH-PIPAT
DMOQMA0 HS Investigative
DMOQMA0 SN 8-OH-PIPAT
DMOQMA0 DT Small molecular drug
DMOQMA0 PC 6604758
DMOQMA0 MW 371.26
DMOQMA0 FM C16H22INO
DMOQMA0 IC InChI=1S/C16H22INO/c1-2-10-18(11-4-9-17)14-8-7-13-5-3-6-16(19)15(13)12-14/h3-6,9,14,19H,2,7-8,10-12H2,1H3/b9-4-/t14-/m1/s1
DMOQMA0 CS CCCN(C/C=C\\I)[C@@H]1CCC2=C(C1)C(=CC=C2)O
DMOQMA0 IK QBXHUZJZYDSLRH-RXTQTKKPSA-N
DMOQMA0 IU (7R)-7-[[(Z)-3-iodoprop-2-enyl]-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMOQMA0 DE Discovery agent
DM14OHR ID DM14OHR
DM14OHR DN 7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DM14OHR HS Investigative
DM14OHR DT Small molecular drug
DM14OHR PC 135438472
DM14OHR MW 291.3
DM14OHR FM C18H13NO3
DM14OHR IC InChI=1S/C18H13NO3/c1-2-12-14-7-10(20)4-6-16(14)19-18-13-5-3-11(21)8-17(13)22-9-15(12)18/h2-8,20-21H,1,9H2
DM14OHR CS C=CC1=C2COC3=C(C2=NC4=C1C=C(C=C4)O)C=CC(=C3)O
DM14OHR IK SDQIIVSWOGDEKO-UHFFFAOYSA-N
DM14OHR IU 7-ethenyl-6H-chromeno[4,3-b]quinoline-3,9-diol
DM14OHR DE Discovery agent
DMUE15B ID DMUE15B
DMUE15B DN 8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine
DMUE15B HS Investigative
DMUE15B SN CHEMBL185095; 8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine; SCHEMBL5883706
DMUE15B DT Small molecular drug
DMUE15B PC 10466406
DMUE15B MW 230.31
DMUE15B FM C14H18N2O
DMUE15B IC InChI=1S/C14H18N2O/c1-9(2)10(3)17-12-6-4-5-11-7-8-13(15)16-14(11)12/h4-10H,1-3H3,(H2,15,16)
DMUE15B CS CC(C)C(C)OC1=CC=CC2=C1N=C(C=C2)N
DMUE15B IK UQTSQIVXJFEZMJ-UHFFFAOYSA-N
DMUE15B IU 8-(3-methylbutan-2-yloxy)quinolin-2-amine
DMUE15B DE Discovery agent
DMGS7CE ID DMGS7CE
DMGS7CE DN 8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine
DMGS7CE HS Investigative
DMGS7CE SN CHEMBL183159; 8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884151; ZDVPLVAZUCNXKZ-UHFFFAOYSA-N; BDBM50152425
DMGS7CE DT Small molecular drug
DMGS7CE PC 10083869
DMGS7CE MW 258.36
DMGS7CE FM C16H22N2O
DMGS7CE IC InChI=1S/C16H22N2O/c1-11(10-16(2,3)4)19-13-7-5-6-12-8-9-14(17)18-15(12)13/h5-9,11H,10H2,1-4H3,(H2,17,18)
DMGS7CE CS CC(CC(C)(C)C)OC1=CC=CC2=C1N=C(C=C2)N
DMGS7CE IK ZDVPLVAZUCNXKZ-UHFFFAOYSA-N
DMGS7CE IU 8-(4,4-dimethylpentan-2-yloxy)quinolin-2-amine
DMGS7CE DE Discovery agent
DMYERNW ID DMYERNW
DMYERNW DN 8-(1-Ethyl-propoxy)-quinolin-2-ylamine
DMYERNW HS Investigative
DMYERNW SN CHEMBL185096; 8-(1-Ethyl-propoxy)-quinolin-2-ylamine; SCHEMBL5884073
DMYERNW DT Small molecular drug
DMYERNW PC 10353807
DMYERNW MW 230.31
DMYERNW FM C14H18N2O
DMYERNW IC InChI=1S/C14H18N2O/c1-3-11(4-2)17-12-7-5-6-10-8-9-13(15)16-14(10)12/h5-9,11H,3-4H2,1-2H3,(H2,15,16)
DMYERNW CS CCC(CC)OC1=CC=CC2=C1N=C(C=C2)N
DMYERNW IK ZYSOQSQXCCTFTO-UHFFFAOYSA-N
DMYERNW IU 8-pentan-3-yloxyquinolin-2-amine
DMYERNW DE Discovery agent
DMMBH9N ID DMMBH9N
DMMBH9N DN 8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N HS Investigative
DMMBH9N SN CHEMBL200567; 8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N DT Small molecular drug
DMMBH9N PC 11501108
DMMBH9N MW 346.4
DMMBH9N FM C21H18N2O3
DMMBH9N IC InChI=1S/C21H18N2O3/c24-19-13-20(23-8-10-25-11-9-23)26-21-16(2-1-3-17(19)21)14-4-5-18-15(12-14)6-7-22-18/h1-7,12-13,22H,8-11H2
DMMBH9N CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC5=C(C=C4)NC=C5
DMMBH9N IK LXMAOXUZAUDVCG-UHFFFAOYSA-N
DMMBH9N IU 8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one
DMMBH9N DE Discovery agent
DM7VT3P ID DM7VT3P
DM7VT3P DN 8-(1-Methyl-butoxy)-quinolin-2-ylamine
DM7VT3P HS Investigative
DM7VT3P SN CHEMBL187702; 8-(1-Methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884359
DM7VT3P DT Small molecular drug
DM7VT3P PC 11776033
DM7VT3P MW 230.31
DM7VT3P FM C14H18N2O
DM7VT3P IC InChI=1S/C14H18N2O/c1-3-5-10(2)17-12-7-4-6-11-8-9-13(15)16-14(11)12/h4,6-10H,3,5H2,1-2H3,(H2,15,16)
DM7VT3P CS CCCC(C)OC1=CC=CC2=C1N=C(C=C2)N
DM7VT3P IK KMEFXXMANWGJCR-UHFFFAOYSA-N
DM7VT3P IU 8-pentan-2-yloxyquinolin-2-amine
DM7VT3P DE Discovery agent
DMV5FZO ID DMV5FZO
DMV5FZO DN 8-(2,2-dimethylpropyl)naringenin
DMV5FZO HS Investigative
DMV5FZO SN 8-(2,2-dimethylpropyl)naringenin
DMV5FZO DT Small molecular drug
DMV5FZO PC 16066665
DMV5FZO MW 342.4
DMV5FZO FM C20H22O5
DMV5FZO IC InChI=1S/C20H22O5/c1-20(2,3)10-13-14(22)8-15(23)18-16(24)9-17(25-19(13)18)11-4-6-12(21)7-5-11/h4-8,17,21-23H,9-10H2,1-3H3/t17-/m0/s1
DMV5FZO CS CC(C)(C)CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMV5FZO IK SBFJMGDUIWYKMQ-KRWDZBQOSA-N
DMV5FZO IU (2S)-8-(2,2-dimethylpropyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMV5FZO DE Discovery agent
DM3QV95 ID DM3QV95
DM3QV95 DN 8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine
DM3QV95 HS Investigative
DM3QV95 SN 8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL105759; AC1LAR8U; CTK7A1388; BDBM50059922; 2,6-Diamino-8-(2',3',4'-trimethoxyphenyl)purine; 8-(2,3,4-Trimethoxy-phenyl)-9H-purine-2,6-diamine; 8-(2,3,4-trimethoxyphenyl)-7H-purine-2,6-diamine
DM3QV95 DT Small molecular drug
DM3QV95 PC 473567
DM3QV95 MW 316.32
DM3QV95 FM C14H16N6O3
DM3QV95 IC InChI=1S/C14H16N6O3/c1-21-7-5-4-6(9(22-2)10(7)23-3)12-17-8-11(15)18-14(16)20-13(8)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DM3QV95 CS COC1=C(C(=C(C=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC)OC
DM3QV95 IK PMHAERKHAISVTI-UHFFFAOYSA-N
DM3QV95 IU 8-(2,3,4-trimethoxyphenyl)-7H-purine-2,6-diamine
DM3QV95 DE Discovery agent
DM4KP5M ID DM4KP5M
DM4KP5M DN 8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine
DM4KP5M HS Investigative
DM4KP5M SN 8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine; 1H-Purine-2,6-diamine, 8-(3,4,5-trimethoxyphenyl)-; CHEMBL105523; 194613-10-0; 8-(2,4,5-trimethoxyphenyl)-3h-purine-2,6-diamine; 2,6-Diamino-8-(2',4',5'-trimethoxyphenyl)purine; AC1Q4FDE; AC1LAR90; CTK4E1570; DTXSID40173101; BDBM50059923; AKOS030559902; 8-(2,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DM4KP5M DT Small molecular drug
DM4KP5M PC 473569
DM4KP5M MW 316.32
DM4KP5M FM C14H16N6O3
DM4KP5M IC InChI=1S/C14H16N6O3/c1-21-7-5-9(23-3)8(22-2)4-6(7)12-17-10-11(15)18-14(16)20-13(10)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DM4KP5M CS COC1=CC(=C(C=C1C2=NC3=NC(=NC(=C3N2)N)N)OC)OC
DM4KP5M IK RPTOJQVHIPKIRX-UHFFFAOYSA-N
DM4KP5M IU 8-(2,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DM4KP5M CA CAS 194613-10-0
DM4KP5M DE Discovery agent
DM5TSJF ID DM5TSJF
DM5TSJF DN 8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine
DM5TSJF HS Investigative
DM5TSJF SN 8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL103474; AC1LAR8X; CTK6J8980; BDBM50059931; 2,6-Diamino-8-(2',4',6'-trimethoxyphenyl)purine; 8-(2,4,6-trimethoxyphenyl)-7H-purine-2,6-diamine; 8-(2,4,6-trimethoxyphenyl)-3h-purine-2,6-diamine
DM5TSJF DT Small molecular drug
DM5TSJF PC 473568
DM5TSJF MW 316.32
DM5TSJF FM C14H16N6O3
DM5TSJF IC InChI=1S/C14H16N6O3/c1-21-6-4-7(22-2)9(8(5-6)23-3)12-17-10-11(15)18-14(16)20-13(10)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DM5TSJF CS COC1=CC(=C(C(=C1)OC)C2=NC3=NC(=NC(=C3N2)N)N)OC
DM5TSJF IK DGDMBWNOPVGWKG-UHFFFAOYSA-N
DM5TSJF IU 8-(2,4,6-trimethoxyphenyl)-7H-purine-2,6-diamine
DM5TSJF DE Discovery agent
DMJPYIZ ID DMJPYIZ
DMJPYIZ DN 8-(2,4-dimethoxyphenyl)-9H-purine-2,6-diamine
DMJPYIZ HS Investigative
DMJPYIZ SN 8-(2,4-Dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL421594; AC1L9X4S; SCHEMBL2947301; BDBM50059921; 8-(2,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMJPYIZ DT Small molecular drug
DMJPYIZ PC 457736
DMJPYIZ MW 286.29
DMJPYIZ FM C13H14N6O2
DMJPYIZ IC InChI=1S/C13H14N6O2/c1-20-6-3-4-7(8(5-6)21-2)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DMJPYIZ CS COC1=CC(=C(C=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC
DMJPYIZ IK GCFWRZGRJQMBPE-UHFFFAOYSA-N
DMJPYIZ IU 8-(2,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMJPYIZ DE Discovery agent
DM0MIGU ID DM0MIGU
DM0MIGU DN 8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine
DM0MIGU HS Investigative
DM0MIGU SN 8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL106070; AC1LAR93; CTK7A0688; BDBM50059939; 2,6-Diamino-8-(2',5'-dimethoxyphenyl)purine; 8-(2,5-dimethoxyphenyl)-3h-purine-2,6-diamine; 8-(2,5-dimethoxyphenyl)-7H-purine-2,6-diamine
DM0MIGU DT Small molecular drug
DM0MIGU PC 473570
DM0MIGU MW 286.29
DM0MIGU FM C13H14N6O2
DM0MIGU IC InChI=1S/C13H14N6O2/c1-20-6-3-4-8(21-2)7(5-6)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DM0MIGU CS COC1=CC(=C(C=C1)OC)C2=NC3=NC(=NC(=C3N2)N)N
DM0MIGU IK FFAMOOJMNMXIFW-UHFFFAOYSA-N
DM0MIGU IU 8-(2,5-dimethoxyphenyl)-7H-purine-2,6-diamine
DM0MIGU DE Discovery agent
DMECWL1 ID DMECWL1
DMECWL1 DN 8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine
DMECWL1 HS Investigative
DMECWL1 SN CHEMBL318601; 8-(2,6-dichlorophenyl)-9H-purine-2,6-diamine; 8-(2,6-dichlorophenyl)-7H-purine-2,6-diamine; AC1LAR9F; 8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine; CTK7E1079; BDBM50059926
DMECWL1 DT Small molecular drug
DMECWL1 PC 473574
DMECWL1 MW 295.12
DMECWL1 FM C11H8Cl2N6
DMECWL1 IC InChI=1S/C11H8Cl2N6/c12-4-2-1-3-5(13)6(4)9-16-7-8(14)17-11(15)19-10(7)18-9/h1-3H,(H5,14,15,16,17,18,19)
DMECWL1 CS C1=CC(=C(C(=C1)Cl)C2=NC3=NC(=NC(=C3N2)N)N)Cl
DMECWL1 IK ZBIYAIOEBKNMQY-UHFFFAOYSA-N
DMECWL1 IU 8-(2,6-dichlorophenyl)-7H-purine-2,6-diamine
DMECWL1 DE Discovery agent
DM8SRM0 ID DM8SRM0
DM8SRM0 DN 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0 HS Investigative
DM8SRM0 SN CHEMBL197284; 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0 DT Small molecular drug
DM8SRM0 PC 11609954
DM8SRM0 MW 349.4
DM8SRM0 FM C21H19NO4
DM8SRM0 IC InChI=1S/C21H19NO4/c1-14(23)15-5-2-3-6-16(15)17-7-4-8-18-19(24)13-20(26-21(17)18)22-9-11-25-12-10-22/h2-8,13H,9-12H2,1H3
DM8SRM0 CS CC(=O)C1=CC=CC=C1C2=CC=CC3=C2OC(=CC3=O)N4CCOCC4
DM8SRM0 IK GMTPLPJMRGXINX-UHFFFAOYSA-N
DM8SRM0 IU 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DM8SRM0 DE Discovery agent
DMJKL3Z ID DMJKL3Z
DMJKL3Z DN 8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine
DMJKL3Z HS Investigative
DMJKL3Z SN CHEMBL186949; 8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine; SCHEMBL5884150
DMJKL3Z DT Small molecular drug
DMJKL3Z PC 22254580
DMJKL3Z MW 228.29
DMJKL3Z FM C14H16N2O
DMJKL3Z IC InChI=1S/C14H16N2O/c15-13-7-6-11-2-1-3-12(14(11)16-13)17-9-8-10-4-5-10/h1-3,6-7,10H,4-5,8-9H2,(H2,15,16)
DMJKL3Z CS C1CC1CCOC2=CC=CC3=C2N=C(C=C3)N
DMJKL3Z IK YLXQVSWEPLSGKN-UHFFFAOYSA-N
DMJKL3Z IU 8-(2-cyclopropylethoxy)quinolin-2-amine
DMJKL3Z DE Discovery agent
DMOB8XT ID DMOB8XT
DMOB8XT DN 8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine
DMOB8XT HS Investigative
DMOB8XT SN CHEMBL184001; 8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine; SCHEMBL5884055
DMOB8XT DT Small molecular drug
DMOB8XT PC 10399674
DMOB8XT MW 246.3
DMOB8XT FM C14H18N2O2
DMOB8XT IC InChI=1S/C14H18N2O2/c1-3-17-9-10(2)18-12-6-4-5-11-7-8-13(15)16-14(11)12/h4-8,10H,3,9H2,1-2H3,(H2,15,16)
DMOB8XT CS CCOCC(C)OC1=CC=CC2=C1N=C(C=C2)N
DMOB8XT IK NPQHPGOWIVAOJW-UHFFFAOYSA-N
DMOB8XT IU 8-(1-ethoxypropan-2-yloxy)quinolin-2-amine
DMOB8XT DE Discovery agent
DMSKTVW ID DMSKTVW
DMSKTVW DN 8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine
DMSKTVW HS Investigative
DMSKTVW SN CHEMBL365459; 8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884532
DMSKTVW DT Small molecular drug
DMSKTVW PC 10377822
DMSKTVW MW 258.36
DMSKTVW FM C16H22N2O
DMSKTVW IC InChI=1S/C16H22N2O/c1-4-12(5-2)11(3)19-14-8-6-7-13-9-10-15(17)18-16(13)14/h6-12H,4-5H2,1-3H3,(H2,17,18)
DMSKTVW CS CCC(CC)C(C)OC1=CC=CC2=C1N=C(C=C2)N
DMSKTVW IK UMDWRYRCTHHCNV-UHFFFAOYSA-N
DMSKTVW IU 8-(3-ethylpentan-2-yloxy)quinolin-2-amine
DMSKTVW DE Discovery agent
DMA5K04 ID DMA5K04
DMA5K04 DN 8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine
DMA5K04 HS Investigative
DMA5K04 SN CHEMBL363011; 8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine; SCHEMBL5884451
DMA5K04 DT Small molecular drug
DMA5K04 PC 10466478
DMA5K04 MW 232.28
DMA5K04 FM C13H16N2O2
DMA5K04 IC InChI=1S/C13H16N2O2/c1-9(8-16-2)17-11-5-3-4-10-6-7-12(14)15-13(10)11/h3-7,9H,8H2,1-2H3,(H2,14,15)
DMA5K04 CS CC(COC)OC1=CC=CC2=C1N=C(C=C2)N
DMA5K04 IK HFVYCRXMQPWHFZ-UHFFFAOYSA-N
DMA5K04 IU 8-(1-methoxypropan-2-yloxy)quinolin-2-amine
DMA5K04 DE Discovery agent
DMVBRMF ID DMVBRMF
DMVBRMF DN 8-(2-Methyl-butoxy)-quinolin-2-ylamine
DMVBRMF HS Investigative
DMVBRMF SN CHEMBL362720; 8-(2-Methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884531
DMVBRMF DT Small molecular drug
DMVBRMF PC 10466405
DMVBRMF MW 230.31
DMVBRMF FM C14H18N2O
DMVBRMF IC InChI=1S/C14H18N2O/c1-3-10(2)9-17-12-6-4-5-11-7-8-13(15)16-14(11)12/h4-8,10H,3,9H2,1-2H3,(H2,15,16)
DMVBRMF CS CCC(C)COC1=CC=CC2=C1N=C(C=C2)N
DMVBRMF IK YLIRVLXATQGNTR-UHFFFAOYSA-N
DMVBRMF IU 8-(2-methylbutoxy)quinolin-2-amine
DMVBRMF DE Discovery agent
DMUIFJY ID DMUIFJY
DMUIFJY DN 8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMUIFJY HS Investigative
DMUIFJY SN CHEMBL362713; 8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine; SCHEMBL5884370
DMUIFJY DT Small molecular drug
DMUIFJY PC 22254604
DMUIFJY MW 256.339
DMUIFJY FM C16H20N2O
DMUIFJY IC InChI=1S/C16H20N2O/c1-11-5-2-3-7-13(11)19-14-8-4-6-12-9-10-15(17)18-16(12)14/h4,6,8-11,13H,2-3,5,7H2,1H3,(H2,17,18)
DMUIFJY CS CC1CCCCC1OC2=CC=CC3=C2N=C(C=C3)N
DMUIFJY IK MXXMNBSDHISKHW-UHFFFAOYSA-N
DMUIFJY IU 8-(2-methylcyclohexyl)oxyquinolin-2-amine
DMUIFJY DE Discovery agent
DMQUZSJ ID DMQUZSJ
DMQUZSJ DN 8-(2-methylpropyl)naringenin
DMQUZSJ HS Investigative
DMQUZSJ SN 8-(2-methylpropyl)naringenin
DMQUZSJ DT Small molecular drug
DMQUZSJ PC 44418729
DMQUZSJ MW 328.4
DMQUZSJ FM C19H20O5
DMQUZSJ IC InChI=1S/C19H20O5/c1-10(2)7-13-14(21)8-15(22)18-16(23)9-17(24-19(13)18)11-3-5-12(20)6-4-11/h3-6,8,10,17,20-22H,7,9H2,1-2H3/t17-/m0/s1
DMQUZSJ CS CC(C)CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMQUZSJ IK ZYVQEHNABDHJGN-KRWDZBQOSA-N
DMQUZSJ IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(2-methylpropyl)-2,3-dihydrochromen-4-one
DMQUZSJ DE Discovery agent
DMRUP0A ID DMRUP0A
DMRUP0A DN 8-(3,3,3-trifluoropropoxy)quinolin-2-amine
DMRUP0A HS Investigative
DMRUP0A SN CHEMBL187165; 8-(3,3,3-trifluoropropoxy)quinolin-2-amine; SCHEMBL5884488
DMRUP0A DT Small molecular drug
DMRUP0A PC 22254540
DMRUP0A MW 256.22
DMRUP0A FM C12H11F3N2O
DMRUP0A IC InChI=1S/C12H11F3N2O/c13-12(14,15)6-7-18-9-3-1-2-8-4-5-10(16)17-11(8)9/h1-5H,6-7H2,(H2,16,17)
DMRUP0A CS C1=CC2=C(C(=C1)OCCC(F)(F)F)N=C(C=C2)N
DMRUP0A IK ZGZSZXFSLMTFBX-UHFFFAOYSA-N
DMRUP0A IU 8-(3,3,3-trifluoropropoxy)quinolin-2-amine
DMRUP0A DE Discovery agent
DM72EM9 ID DM72EM9
DM72EM9 DN 8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine
DM72EM9 HS Investigative
DM72EM9 SN CHEMBL364104; 8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884452
DM72EM9 DT Small molecular drug
DM72EM9 PC 10421933
DM72EM9 MW 244.33
DM72EM9 FM C15H20N2O
DM72EM9 IC InChI=1S/C15H20N2O/c1-15(2,3)9-10-18-12-6-4-5-11-7-8-13(16)17-14(11)12/h4-8H,9-10H2,1-3H3,(H2,16,17)
DM72EM9 CS CC(C)(C)CCOC1=CC=CC2=C1N=C(C=C2)N
DM72EM9 IK GUJKDUVYIJMAPL-UHFFFAOYSA-N
DM72EM9 IU 8-(3,3-dimethylbutoxy)quinolin-2-amine
DM72EM9 DE Discovery agent
DMV63G1 ID DMV63G1
DMV63G1 DN 8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine
DMV63G1 HS Investigative
DMV63G1 SN 8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL431257; AC1LAR8R; CTK6J4531; BDBM50059933; 2,6-Diamino-8-(3',4',5'-trimethoxyphenyl)purine; 8-(3,4,5-trimethoxyphenyl)-3h-purine-2,6-diamine; 8-(3,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DMV63G1 DT Small molecular drug
DMV63G1 PC 473566
DMV63G1 MW 316.32
DMV63G1 FM C14H16N6O3
DMV63G1 IC InChI=1S/C14H16N6O3/c1-21-7-4-6(5-8(22-2)10(7)23-3)12-17-9-11(15)18-14(16)20-13(9)19-12/h4-5H,1-3H3,(H5,15,16,17,18,19,20)
DMV63G1 CS COC1=CC(=CC(=C1OC)OC)C2=NC3=NC(=NC(=C3N2)N)N
DMV63G1 IK QPWGTISXOSFSHJ-UHFFFAOYSA-N
DMV63G1 IU 8-(3,4,5-trimethoxyphenyl)-7H-purine-2,6-diamine
DMV63G1 DE Discovery agent
DMZU0YF ID DMZU0YF
DMZU0YF DN 8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine
DMZU0YF HS Investigative
DMZU0YF SN 8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine; CHEMBL312688; 8-(3,4-dichlorophenyl)-7H-purine-2,6-diamine; AC1LAR9C; CTK7E1080; BDBM50059929; 2,6-Diamino-8-(3',4'-dichlorophenyl)purine
DMZU0YF DT Small molecular drug
DMZU0YF PC 473573
DMZU0YF MW 295.12
DMZU0YF FM C11H8Cl2N6
DMZU0YF IC InChI=1S/C11H8Cl2N6/c12-5-2-1-4(3-6(5)13)9-16-7-8(14)17-11(15)19-10(7)18-9/h1-3H,(H5,14,15,16,17,18,19)
DMZU0YF CS C1=CC(=C(C=C1C2=NC3=NC(=NC(=C3N2)N)N)Cl)Cl
DMZU0YF IK GZDRYQKQDXYCQK-UHFFFAOYSA-N
DMZU0YF IU 8-(3,4-dichlorophenyl)-7H-purine-2,6-diamine
DMZU0YF DE Discovery agent
DMYZC3I ID DMYZC3I
DMYZC3I DN 8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine
DMYZC3I HS Investigative
DMYZC3I SN 8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL102518; AC1LAR99; CTK7A7284; BDBM50059936; 2,6-Diamino-8-(3',4'-dimethoxyphenyl)purine; 8-(3,4-dimethoxyphenyl)-3h-purine-2,6-diamine; 8-(3,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMYZC3I DT Small molecular drug
DMYZC3I PC 473572
DMYZC3I MW 286.29
DMYZC3I FM C13H14N6O2
DMYZC3I IC InChI=1S/C13H14N6O2/c1-20-7-4-3-6(5-8(7)21-2)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DMYZC3I CS COC1=C(C=C(C=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC
DMYZC3I IK LXQDFGKWPJDZOK-UHFFFAOYSA-N
DMYZC3I IU 8-(3,4-dimethoxyphenyl)-7H-purine-2,6-diamine
DMYZC3I DE Discovery agent
DM920XR ID DM920XR
DM920XR DN 8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine
DM920XR HS Investigative
DM920XR SN 8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine; CHEMBL105323; AC1LAR96; CTK6J9242; BDBM50059940; 2,6-Diamino-8-(3',5'-dimethoxyphenyl)purine; 8-(3,5-dimethoxyphenyl)-7H-purine-2,6-diamine; 8-(3,5-dimethoxyphenyl)-3h-purine-2,6-diamine
DM920XR DT Small molecular drug
DM920XR PC 473571
DM920XR MW 286.29
DM920XR FM C13H14N6O2
DM920XR IC InChI=1S/C13H14N6O2/c1-20-7-3-6(4-8(5-7)21-2)11-16-9-10(14)17-13(15)19-12(9)18-11/h3-5H,1-2H3,(H5,14,15,16,17,18,19)
DM920XR CS COC1=CC(=CC(=C1)C2=NC3=NC(=NC(=C3N2)N)N)OC
DM920XR IK CFTYJGDHKCKXBN-UHFFFAOYSA-N
DM920XR IU 8-(3,5-dimethoxyphenyl)-7H-purine-2,6-diamine
DM920XR DE Discovery agent
DM9J2LT ID DM9J2LT
DM9J2LT DN 8-(3-Azido-phenyl)-6-iodo-quinoline
DM9J2LT HS Investigative
DM9J2LT SN CHEMBL127994; 8-(3-Azido-phenyl)-6-iodo-quinoline; 6-Iodo-8-(3-azidophenyl)quinoline
DM9J2LT DT Small molecular drug
DM9J2LT PC 10642995
DM9J2LT MW 372.16
DM9J2LT FM C15H9IN4
DM9J2LT IC InChI=1S/C15H9IN4/c16-12-7-11-4-2-6-18-15(11)14(9-12)10-3-1-5-13(8-10)19-20-17/h1-9H
DM9J2LT CS C1=CC(=CC(=C1)N=[N+]=[N-])C2=C3C(=CC(=C2)I)C=CC=N3
DM9J2LT IK PBIQIEZSLAPKDM-UHFFFAOYSA-N
DM9J2LT IU 8-(3-azidophenyl)-6-iodoquinoline
DM9J2LT DE Discovery agent
DMON7RZ ID DMON7RZ
DMON7RZ DN 8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline
DMON7RZ HS Investigative
DMON7RZ SN CHEMBL339083; 8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline; BDBM50092630
DMON7RZ DT Small molecular drug
DMON7RZ PC 10404815
DMON7RZ MW 337.4
DMON7RZ FM C21H15N5
DMON7RZ IC InChI=1S/C21H15N5/c22-26-25-19-5-1-3-17(14-19)20-13-16(11-15-6-9-23-10-7-15)12-18-4-2-8-24-21(18)20/h1-10,12-14H,11H2
DMON7RZ CS C1=CC(=CC(=C1)N=[N+]=[N-])C2=C3C(=CC(=C2)CC4=CC=NC=C4)C=CC=N3
DMON7RZ IK SJSUBWZFLWXJFL-UHFFFAOYSA-N
DMON7RZ IU 8-(3-azidophenyl)-6-(pyridin-4-ylmethyl)quinoline
DMON7RZ DE Discovery agent
DMW2NJR ID DMW2NJR
DMW2NJR DN 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide
DMW2NJR HS Investigative
DMW2NJR SN CHEMBL1083441; 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N
DMW2NJR DT Small molecular drug
DMW2NJR PC 11381650
DMW2NJR MW 321.37
DMW2NJR FM C16H23N3O4
DMW2NJR IC InChI=1S/C16H23N3O4/c20-14(19-23)11-7-2-1-3-8-12-17-16(22)18-15(21)13-9-5-4-6-10-13/h4-6,9-10,23H,1-3,7-8,11-12H2,(H,19,20)(H2,17,18,21,22)
DMW2NJR CS C1=CC=C(C=C1)C(=O)NC(=O)NCCCCCCCC(=O)NO
DMW2NJR IK WUKFQTZVXXYEAB-UHFFFAOYSA-N
DMW2NJR IU N-[[8-(hydroxyamino)-8-oxooctyl]carbamoyl]benzamide
DMW2NJR DE Discovery agent
DM2RA4N ID DM2RA4N
DM2RA4N DN 8-(3-Bromobenzyloxy)caffeine
DM2RA4N HS Investigative
DM2RA4N SN 8-(3-Bromobenzyloxy)caffeine; CHEMBL602464
DM2RA4N DT Small molecular drug
DM2RA4N PC 46232852
DM2RA4N MW 379.21
DM2RA4N FM C15H15BrN4O3
DM2RA4N IC InChI=1S/C15H15BrN4O3/c1-18-11-12(19(2)15(22)20(3)13(11)21)17-14(18)23-8-9-5-4-6-10(16)7-9/h4-7H,8H2,1-3H3
DM2RA4N CS CN1C2=C(N=C1OCC3=CC(=CC=C3)Br)N(C(=O)N(C2=O)C)C
DM2RA4N IK UMXJQISLIGIYPW-UHFFFAOYSA-N
DM2RA4N IU 8-[(3-bromophenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DM2RA4N DE Discovery agent
DM7HMNP ID DM7HMNP
DM7HMNP DN 8-(3-Chlorobenzyloxy)caffeine
DM7HMNP HS Investigative
DM7HMNP SN 8-(3-Chlorobenzyloxy)caffeine; CHEMBL602260
DM7HMNP DT Small molecular drug
DM7HMNP PC 46232851
DM7HMNP MW 334.76
DM7HMNP FM C15H15ClN4O3
DM7HMNP IC InChI=1S/C15H15ClN4O3/c1-18-11-12(19(2)15(22)20(3)13(11)21)17-14(18)23-8-9-5-4-6-10(16)7-9/h4-7H,8H2,1-3H3
DM7HMNP CS CN1C2=C(N=C1OCC3=CC(=CC=C3)Cl)N(C(=O)N(C2=O)C)C
DM7HMNP IK XCVMGVIPMZLFEU-UHFFFAOYSA-N
DM7HMNP IU 8-[(3-chlorophenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DM7HMNP DE Discovery agent
DME85GS ID DME85GS
DME85GS DN 8-(3-Fluorobenzyloxy)caffeine
DME85GS HS Investigative
DME85GS SN 8-(3-Fluorobenzyloxy)caffeine; CHEMBL602465
DME85GS DT Small molecular drug
DME85GS PC 46232853
DME85GS MW 318.3
DME85GS FM C15H15FN4O3
DME85GS IC InChI=1S/C15H15FN4O3/c1-18-11-12(19(2)15(22)20(3)13(11)21)17-14(18)23-8-9-5-4-6-10(16)7-9/h4-7H,8H2,1-3H3
DME85GS CS CN1C2=C(N=C1OCC3=CC(=CC=C3)F)N(C(=O)N(C2=O)C)C
DME85GS IK YAQZRUHNOYDFHZ-UHFFFAOYSA-N
DME85GS IU 8-[(3-fluorophenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DME85GS DE Discovery agent
DMLQPVH ID DMLQPVH
DMLQPVH DN 8-(3-Fluoro-phenyl)-9-methyl-9H-purin-6-ylamine
DMLQPVH HS Investigative
DMLQPVH SN CHEMBL48682
DMLQPVH DT Small molecular drug
DMLQPVH PC 10633978
DMLQPVH MW 243.24
DMLQPVH FM C12H10FN5
DMLQPVH IC InChI=1S/C12H10FN5/c1-18-11(7-3-2-4-8(13)5-7)17-9-10(14)15-6-16-12(9)18/h2-6H,1H3,(H2,14,15,16)
DMLQPVH CS CN1C(=NC2=C(N=CN=C21)N)C3=CC(=CC=C3)F
DMLQPVH IK JXJYLIUAIVDUNX-UHFFFAOYSA-N
DMLQPVH IU 8-(3-fluorophenyl)-9-methylpurin-6-amine
DMLQPVH DE Discovery agent
DM15LVG ID DM15LVG
DM15LVG DN 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM15LVG HS Investigative
DM15LVG SN CHEMBL200685; 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one; SCHEMBL5258643; WPUKKEMHTVGTFK-UHFFFAOYSA-N; BDBM50178081
DM15LVG DT Small molecular drug
DM15LVG PC 11609490
DM15LVG MW 323.3
DM15LVG FM C19H17NO4
DM15LVG IC InChI=1S/C19H17NO4/c21-14-4-1-3-13(11-14)15-5-2-6-16-17(22)12-18(24-19(15)16)20-7-9-23-10-8-20/h1-6,11-12,21H,7-10H2
DM15LVG CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC(=CC=C4)O
DM15LVG IK WPUKKEMHTVGTFK-UHFFFAOYSA-N
DM15LVG IU 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DM15LVG DE Discovery agent
DM3WEQA ID DM3WEQA
DM3WEQA DN 8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine
DM3WEQA HS Investigative
DM3WEQA SN CHEMBL361288; 8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884407
DM3WEQA DT Small molecular drug
DM3WEQA PC 10377914
DM3WEQA MW 260.329
DM3WEQA FM C15H20N2O2
DM3WEQA IC InChI=1S/C15H20N2O2/c1-15(2,18-3)9-10-19-12-6-4-5-11-7-8-13(16)17-14(11)12/h4-8H,9-10H2,1-3H3,(H2,16,17)
DM3WEQA CS CC(C)(CCOC1=CC=CC2=C1N=C(C=C2)N)OC
DM3WEQA IK LPHQANHABFNXJD-UHFFFAOYSA-N
DM3WEQA IU 8-(3-methoxy-3-methylbutoxy)quinolin-2-amine
DM3WEQA DE Discovery agent
DMLY46X ID DMLY46X
DMLY46X DN 8-(3-Methoxybenzyloxy)caffeine
DMLY46X HS Investigative
DMLY46X SN 8-(3-Methoxybenzyloxy)caffeine; CHEMBL602880; AC1LCY7O; Oprea1_481626; MLS000038017; MolPort-002-545-851; ZINC497710; HMS2326N19; BDBM50306702; AKOS030507253; MCULE-4574508539; NCGC00020867-02; NCGC00020867-01; SMR000039153; 8-[(3-methoxyphenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione; 8-((3-methoxybenzyl)oxy)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione
DMLY46X DT Small molecular drug
DMLY46X PC 658198
DMLY46X MW 330.34
DMLY46X FM C16H18N4O4
DMLY46X IC InChI=1S/C16H18N4O4/c1-18-12-13(19(2)16(22)20(3)14(12)21)17-15(18)24-9-10-6-5-7-11(8-10)23-4/h5-8H,9H2,1-4H3
DMLY46X CS CN1C2=C(N=C1OCC3=CC(=CC=C3)OC)N(C(=O)N(C2=O)C)C
DMLY46X IK SDEMBXFOALFRQD-UHFFFAOYSA-N
DMLY46X IU 8-[(3-methoxyphenyl)methoxy]-1,3,7-trimethylpurine-2,6-dione
DMLY46X DE Discovery agent
DMB9645 ID DMB9645
DMB9645 DN 8-(3-Methylbenzyloxy)caffeine
DMB9645 HS Investigative
DMB9645 SN 8-(3-Methylbenzyloxy)caffeine; CHEMBL589765
DMB9645 DT Small molecular drug
DMB9645 PC 46232855
DMB9645 MW 314.34
DMB9645 FM C16H18N4O3
DMB9645 IC InChI=1S/C16H18N4O3/c1-10-6-5-7-11(8-10)9-23-15-17-13-12(18(15)2)14(21)20(4)16(22)19(13)3/h5-8H,9H2,1-4H3
DMB9645 CS CC1=CC(=CC=C1)COC2=NC3=C(N2C)C(=O)N(C(=O)N3C)C
DMB9645 IK AFSVTGXZVYXITM-UHFFFAOYSA-N
DMB9645 IU 1,3,7-trimethyl-8-[(3-methylphenyl)methoxy]purine-2,6-dione
DMB9645 DE Discovery agent
DMNYPCQ ID DMNYPCQ
DMNYPCQ DN 8-(3-Methyl-butoxy)-quinolin-2-ylamine
DMNYPCQ HS Investigative
DMNYPCQ SN CHEMBL184476; 8-(3-Methyl-butoxy)-quinolin-2-ylamine; SCHEMBL5884316
DMNYPCQ DT Small molecular drug
DMNYPCQ PC 10443853
DMNYPCQ MW 230.31
DMNYPCQ FM C14H18N2O
DMNYPCQ IC InChI=1S/C14H18N2O/c1-10(2)8-9-17-12-5-3-4-11-6-7-13(15)16-14(11)12/h3-7,10H,8-9H2,1-2H3,(H2,15,16)
DMNYPCQ CS CC(C)CCOC1=CC=CC2=C1N=C(C=C2)N
DMNYPCQ IK RGLJKEQVQXDAIT-UHFFFAOYSA-N
DMNYPCQ IU 8-(3-methylbutoxy)quinolin-2-amine
DMNYPCQ DE Discovery agent
DM2VAJE ID DM2VAJE
DM2VAJE DN 8-(3-methylbutyl)naringenin
DM2VAJE HS Investigative
DM2VAJE SN 8-(3-methylbutyl)naringenin
DM2VAJE DT Small molecular drug
DM2VAJE PC 44418728
DM2VAJE MW 342.4
DM2VAJE FM C20H22O5
DM2VAJE IC InChI=1S/C20H22O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h4-7,9,11,18,21-23H,3,8,10H2,1-2H3/t18-/m0/s1
DM2VAJE CS CC(C)CCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DM2VAJE IK UKBYGNGSGOXLFO-SFHVURJKSA-N
DM2VAJE IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbutyl)-2,3-dihydrochromen-4-one
DM2VAJE DE Discovery agent
DMPMJHV ID DMPMJHV
DMPMJHV DN 8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMPMJHV HS Investigative
DMPMJHV SN CHEMBL183932; 8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine; SCHEMBL5883847
DMPMJHV DT Small molecular drug
DMPMJHV PC 10038053
DMPMJHV MW 256.339
DMPMJHV FM C16H20N2O
DMPMJHV IC InChI=1S/C16H20N2O/c1-11-4-2-6-13(10-11)19-14-7-3-5-12-8-9-15(17)18-16(12)14/h3,5,7-9,11,13H,2,4,6,10H2,1H3,(H2,17,18)
DMPMJHV CS CC1CCCC(C1)OC2=CC=CC3=C2N=C(C=C3)N
DMPMJHV IK AZGLOGDXDJFQFK-UHFFFAOYSA-N
DMPMJHV IU 8-(3-methylcyclohexyl)oxyquinolin-2-amine
DMPMJHV DE Discovery agent
DM8N314 ID DM8N314
DM8N314 DN 8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine
DM8N314 HS Investigative
DM8N314 SN CHEMBL183739; 8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine; SCHEMBL5883724
DM8N314 DT Small molecular drug
DM8N314 PC 10083101
DM8N314 MW 242.32
DM8N314 FM C15H18N2O
DM8N314 IC InChI=1S/C15H18N2O/c1-10-5-7-12(9-10)18-13-4-2-3-11-6-8-14(16)17-15(11)13/h2-4,6,8,10,12H,5,7,9H2,1H3,(H2,16,17)
DM8N314 CS CC1CCC(C1)OC2=CC=CC3=C2N=C(C=C3)N
DM8N314 IK XSBYTVRYECCAPQ-UHFFFAOYSA-N
DM8N314 IU 8-(3-methylcyclopentyl)oxyquinolin-2-amine
DM8N314 DE Discovery agent
DMP6Z3R ID DMP6Z3R
DMP6Z3R DN 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine
DMP6Z3R HS Investigative
DMP6Z3R SN CHEMBL161465; 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine; 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine; SCHEMBL7015917; SRVUGPYWYLBZNI-UHFFFAOYSA-N; ZINC13805266
DMP6Z3R DT Small molecular drug
DMP6Z3R PC 10711281
DMP6Z3R MW 327.3
DMP6Z3R FM C20H13N3O2
DMP6Z3R IC InChI=1S/C20H13N3O2/c24-23(25)17-10-4-8-15(12-17)20-19-16(9-5-11-21-19)13-18(22-20)14-6-2-1-3-7-14/h1-13H
DMP6Z3R CS C1=CC=C(C=C1)C2=NC(=C3C(=C2)C=CC=N3)C4=CC(=CC=C4)[N+](=O)[O-]
DMP6Z3R IK SRVUGPYWYLBZNI-UHFFFAOYSA-N
DMP6Z3R IU 8-(3-nitrophenyl)-6-phenyl-1,7-naphthyridine
DMP6Z3R DE Discovery agent
DM0N68L ID DM0N68L
DM0N68L DN 8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline
DM0N68L HS Investigative
DM0N68L SN 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline; 159925-31-2; RS-14203; CHEMBL127944; 8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline; 8-(3-nitrophenyl)-6-(4-pyridinylmethyl)Quinoline; ZINC6165; SCHEMBL3698956; DTXSID20431317; XRSKAWJXBDACRF-UHFFFAOYSA-N; 3g58; 3g45; BDBM50092632; AKOS022171718; 4CA-1115; KB-74213; DA-09714; AJ-08271; AX8257760; FT-0733089
DM0N68L DT Small molecular drug
DM0N68L PC 9819356
DM0N68L MW 341.4
DM0N68L FM C21H15N3O2
DM0N68L IC InChI=1S/C21H15N3O2/c25-24(26)19-5-1-3-17(14-19)20-13-16(11-15-6-9-22-10-7-15)12-18-4-2-8-23-21(18)20/h1-10,12-14H,11H2
DM0N68L CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=C3C(=CC(=C2)CC4=CC=NC=C4)C=CC=N3
DM0N68L IK XRSKAWJXBDACRF-UHFFFAOYSA-N
DM0N68L IU 8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline
DM0N68L CA CAS 159925-31-2
DM0N68L DE Discovery agent
DMAK0P3 ID DMAK0P3
DMAK0P3 DN 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3 HS Investigative
DMAK0P3 SN CHEMBL197218; 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3 DT Small molecular drug
DMAK0P3 PC 11710022
DMAK0P3 MW 349.4
DMAK0P3 FM C21H19NO4
DMAK0P3 IC InChI=1S/C21H19NO4/c1-14(23)15-5-7-16(8-6-15)17-3-2-4-18-19(24)13-20(26-21(17)18)22-9-11-25-12-10-22/h2-8,13H,9-12H2,1H3
DMAK0P3 CS CC(=O)C1=CC=C(C=C1)C2=CC=CC3=C2OC(=CC3=O)N4CCOCC4
DMAK0P3 IK OEHLKVQEMZKDOJ-UHFFFAOYSA-N
DMAK0P3 IU 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one
DMAK0P3 DE Discovery agent
DMVOCWY ID DMVOCWY
DMVOCWY DN 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide
DMVOCWY HS Investigative
DMVOCWY SN CHEMBL319070; 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide
DMVOCWY DT Small molecular drug
DMVOCWY PC 11120992
DMVOCWY MW 328.2
DMVOCWY FM C14H18BrNO3
DMVOCWY IC InChI=1S/C14H18BrNO3/c15-12-9-7-11(8-10-12)13(17)5-3-1-2-4-6-14(18)16-19/h7-10,19H,1-6H2,(H,16,18)
DMVOCWY CS C1=CC(=CC=C1C(=O)CCCCCCC(=O)NO)Br
DMVOCWY IK RFYYZRFJBNAHCG-UHFFFAOYSA-N
DMVOCWY IU 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide
DMVOCWY DE Discovery agent
DM4186A ID DM4186A
DM4186A DN 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A HS Investigative
DM4186A SN CHEMBL200733; 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A DT Small molecular drug
DM4186A PC 11515664
DM4186A MW 341.8
DM4186A FM C19H16ClNO3
DM4186A IC InChI=1S/C19H16ClNO3/c20-14-6-4-13(5-7-14)15-2-1-3-16-17(22)12-18(24-19(15)16)21-8-10-23-11-9-21/h1-7,12H,8-11H2
DM4186A CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=C(C=C4)Cl
DM4186A IK HYBIQRLHJUFHFC-UHFFFAOYSA-N
DM4186A IU 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one
DM4186A DE Discovery agent
DMLANGY ID DMLANGY
DMLANGY DN 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY HS Investigative
DMLANGY SN CHEMBL200517; 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY DT Small molecular drug
DMLANGY PC 11652716
DMLANGY MW 323.3
DMLANGY FM C19H17NO4
DMLANGY IC InChI=1S/C19H17NO4/c21-14-6-4-13(5-7-14)15-2-1-3-16-17(22)12-18(24-19(15)16)20-8-10-23-11-9-20/h1-7,12,21H,8-11H2
DMLANGY CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=C(C=C4)O
DMLANGY IK WSNZUFRPSRSILZ-UHFFFAOYSA-N
DMLANGY IU 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
DMLANGY DE Discovery agent
DMPVQN3 ID DMPVQN3
DMPVQN3 DN 8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine
DMPVQN3 HS Investigative
DMPVQN3 SN CHEMBL184573; 8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine; SCHEMBL5884069
DMPVQN3 DT Small molecular drug
DMPVQN3 PC 10244148
DMPVQN3 MW 256.339
DMPVQN3 FM C16H20N2O
DMPVQN3 IC InChI=1S/C16H20N2O/c1-11-5-8-13(9-6-11)19-14-4-2-3-12-7-10-15(17)18-16(12)14/h2-4,7,10-11,13H,5-6,8-9H2,1H3,(H2,17,18)
DMPVQN3 CS CC1CCC(CC1)OC2=CC=CC3=C2N=C(C=C3)N
DMPVQN3 IK OQURIDUAVDCPLT-UHFFFAOYSA-N
DMPVQN3 IU 8-(4-methylcyclohexyl)oxyquinolin-2-amine
DMPVQN3 DE Discovery agent
DMH3SDO ID DMH3SDO
DMH3SDO DN 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one
DMH3SDO HS Investigative
DMH3SDO SN CHEMBL116023; SCHEMBL7368359; BDBM50218558
DMH3SDO DT Small molecular drug
DMH3SDO PC 44343094
DMH3SDO MW 350.4
DMH3SDO FM C20H21F3O2
DMH3SDO IC InChI=1S/C20H21F3O2/c21-20(22,23)19(24)13-6-1-2-7-14-25-18-12-8-11-17(15-18)16-9-4-3-5-10-16/h3-5,8-12,15H,1-2,6-7,13-14H2
DMH3SDO CS C1=CC=C(C=C1)C2=CC(=CC=C2)OCCCCCCC(=O)C(F)(F)F
DMH3SDO IK OFSLRFDWUPANFG-UHFFFAOYSA-N
DMH3SDO IU 1,1,1-trifluoro-8-(3-phenylphenoxy)octan-2-one
DMH3SDO DE Discovery agent
DMD6VSY ID DMD6VSY
DMD6VSY DN 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide
DMD6VSY HS Investigative
DMD6VSY SN CHEMBL95313; 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide
DMD6VSY DT Small molecular drug
DMD6VSY PC 10314237
DMD6VSY MW 325.4
DMD6VSY FM C20H23NO3
DMD6VSY IC InChI=1S/C20H23NO3/c22-19(10-6-1-2-7-11-20(23)21-24)18-14-12-17(13-15-18)16-8-4-3-5-9-16/h3-5,8-9,12-15,24H,1-2,6-7,10-11H2,(H,21,23)
DMD6VSY CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)CCCCCCC(=O)NO
DMD6VSY IK LZZJBJLIOVNVKE-UHFFFAOYSA-N
DMD6VSY IU N-hydroxy-8-oxo-8-(4-phenylphenyl)octanamide
DMD6VSY DE Discovery agent
DM23XGW ID DM23XGW
DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one
DM23XGW HS Investigative
DM23XGW SN CHEMBL112148; SCHEMBL7364383; BDBM50218532
DM23XGW DT Small molecular drug
DM23XGW PC 44341053
DM23XGW MW 350.4
DM23XGW FM C20H21F3O2
DM23XGW IC InChI=1S/C20H21F3O2/c21-20(22,23)19(24)10-6-1-2-7-15-25-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14H,1-2,6-7,10,15H2
DM23XGW CS C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)C(F)(F)F
DM23XGW IK LRVOZKXSFOOZRP-UHFFFAOYSA-N
DM23XGW IU 1,1,1-trifluoro-8-(4-phenylphenoxy)octan-2-one
DM23XGW DE Discovery agent
DMDIGPW ID DMDIGPW
DMDIGPW DN 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid
DMDIGPW HS Investigative
DMDIGPW SN CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-
DMDIGPW DT Small molecular drug
DMDIGPW PC 44341224
DMDIGPW MW 326.4
DMDIGPW FM C20H22O4
DMDIGPW IC InChI=1S/C20H22O4/c21-19(20(22)23)10-6-1-2-7-15-24-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14H,1-2,6-7,10,15H2,(H,22,23)
DMDIGPW CS C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCC(=O)C(=O)O
DMDIGPW IK VREZMJDAPPMITK-UHFFFAOYSA-N
DMDIGPW IU 2-oxo-8-(4-phenylphenoxy)octanoic acid
DMDIGPW CA CAS 436150-72-0
DMDIGPW DE Discovery agent
DMT1NW2 ID DMT1NW2
DMT1NW2 DN 8(S)-amino-2(R)-methyl-7-oxononanoic acid
DMT1NW2 HS Investigative
DMT1NW2 SN 8(S)-Amino-2(R)-methyl-7-oxononanoic acid; CHEMBL465576; Nonanoic acid, 8-amino-2-methyl-7-oxo-, (S-(R*,S*))-; 181886-81-7; SCHEMBL4098289; AC1L42P6; DTXSID90171213; BDBM50292361; (2R,8S)-8-amino-2-methyl-7-oxononanoic acid; (2R,8S)-2-Methyl-7-oxo-8-aminononanoic acid
DMT1NW2 DT Small molecular drug
DMT1NW2 PC 177363
DMT1NW2 MW 201.26
DMT1NW2 FM C10H19NO3
DMT1NW2 IC InChI=1S/C10H19NO3/c1-7(10(13)14)5-3-4-6-9(12)8(2)11/h7-8H,3-6,11H2,1-2H3,(H,13,14)/t7-,8+/m1/s1
DMT1NW2 CS C[C@H](CCCCC(=O)[C@H](C)N)C(=O)O
DMT1NW2 IK YBWPFLPQZXWNNM-SFYZADRCSA-N
DMT1NW2 IU (2R,8S)-8-amino-2-methyl-7-oxononanoic acid
DMT1NW2 CA CAS 181886-81-7
DMT1NW2 DE Discovery agent
DMT3IOB ID DMT3IOB
DMT3IOB DN 8-[(3-Trifluoromethyl)benzyloxy]caffeine
DMT3IOB HS Investigative
DMT3IOB SN 8-[(3-Trifluoromethyl)benzyloxy]caffeine; CHEMBL602466
DMT3IOB DT Small molecular drug
DMT3IOB PC 46232854
DMT3IOB MW 368.31
DMT3IOB FM C16H15F3N4O3
DMT3IOB IC InChI=1S/C16H15F3N4O3/c1-21-11-12(22(2)15(25)23(3)13(11)24)20-14(21)26-8-9-5-4-6-10(7-9)16(17,18)19/h4-7H,8H2,1-3H3
DMT3IOB CS CN1C2=C(N=C1OCC3=CC(=CC=C3)C(F)(F)F)N(C(=O)N(C2=O)C)C
DMT3IOB IK MJKQEGLZEOPZNY-UHFFFAOYSA-N
DMT3IOB IU 1,3,7-trimethyl-8-[[3-(trifluoromethyl)phenyl]methoxy]purine-2,6-dione
DMT3IOB DE Discovery agent
DM4R2EX ID DM4R2EX
DM4R2EX DN 8-acetyl-7-(benzyloxy)-2H-chromen-2-one
DM4R2EX HS Investigative
DM4R2EX SN CHEMBL1290111; 65535-49-1; 8-acetyl-7-(benzyloxy)-2H-chromen-2-one; SCHEMBL7518570; CTK1J6469; DTXSID60555920; BDBM50332028; 8-Acetyl-7-(benzyloxy)-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 8-acetyl-7-(phenylmethoxy)-
DM4R2EX DT Small molecular drug
DM4R2EX PC 14101447
DM4R2EX MW 294.3
DM4R2EX FM C18H14O4
DM4R2EX IC InChI=1S/C18H14O4/c1-12(19)17-15(21-11-13-5-3-2-4-6-13)9-7-14-8-10-16(20)22-18(14)17/h2-10H,11H2,1H3
DM4R2EX CS CC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OCC3=CC=CC=C3
DM4R2EX IK QMLSJCDSHGYBMT-UHFFFAOYSA-N
DM4R2EX IU 8-acetyl-7-phenylmethoxychromen-2-one
DM4R2EX CA CAS 65535-49-1
DM4R2EX DE Discovery agent
DMCTWBL ID DMCTWBL
DMCTWBL DN 8-acetyl-7-butoxy-2H-chromen-2-one
DMCTWBL HS Investigative
DMCTWBL SN CHEMBL1288620; 8-acetyl-7-butoxy-2H-chromen-2-one
DMCTWBL DT Small molecular drug
DMCTWBL PC 52943193
DMCTWBL MW 260.279
DMCTWBL FM C15H16O4
DMCTWBL IC InChI=1S/C15H16O4/c1-3-4-9-18-12-7-5-11-6-8-13(17)19-15(11)14(12)10(2)16/h5-8H,3-4,9H2,1-2H3
DMCTWBL CS CCCCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)C
DMCTWBL IK ULYJCIVHEFSJIF-UHFFFAOYSA-N
DMCTWBL IU 8-acetyl-7-butoxychromen-2-one
DMCTWBL DE Discovery agent
DMDV8UT ID DMDV8UT
DMDV8UT DN 8-acetyl-7-ethoxy-2H-chromen-2-one
DMDV8UT HS Investigative
DMDV8UT SN CHEMBL1288595; 8-acetyl-7-ethoxy-2H-chromen-2-one
DMDV8UT DT Small molecular drug
DMDV8UT PC 50925425
DMDV8UT MW 232.23
DMDV8UT FM C13H12O4
DMDV8UT IC InChI=1S/C13H12O4/c1-3-16-10-6-4-9-5-7-11(15)17-13(9)12(10)8(2)14/h4-7H,3H2,1-2H3
DMDV8UT CS CCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)C
DMDV8UT IK KWMPAFCHEJYQEQ-UHFFFAOYSA-N
DMDV8UT IU 8-acetyl-7-ethoxychromen-2-one
DMDV8UT DE Discovery agent
DMAMJW2 ID DMAMJW2
DMAMJW2 DN 8-Acetyl-7-hydroxy-2H-chromen-2-one
DMAMJW2 HS Investigative
DMAMJW2 SN 8-Acetyl-7-hydroxycoumarin; 6748-68-1; 8-acetyl-7-hydroxy-2H-chromen-2-one; 7-hydroxy-8-acetylcoumarin; CHEMBL446518; AN-829/13872055; AC1NTTTW; SCHEMBL4639845; CTK5C6237; 8-acetyl-7-hydroxychromen-2-one; DTXSID40419935; MolPort-003-821-703; 8-acetyl-7-hydroxy-2-oxochromene; ZINC366861; 8-acetyl-7-hydroxy-chromen-2-one; 8-Acetyl-7-hydroxycoumarin, 97%; BDBM50332038; MFCD00270162; 8 - Acetyl - 7 - hydroxycoumarin; AKOS022647720; OR345001; KB-200256; ST50309088; Z3067; 2H-1-Benzopyran-2-one, 8-acetyl-7-hydroxy-
DMAMJW2 DT Small molecular drug
DMAMJW2 PC 5411574
DMAMJW2 MW 204.18
DMAMJW2 FM C11H8O4
DMAMJW2 IC InChI=1S/C11H8O4/c1-6(12)10-8(13)4-2-7-3-5-9(14)15-11(7)10/h2-5,13H,1H3
DMAMJW2 CS CC(=O)C1=C(C=CC2=C1OC(=O)C=C2)O
DMAMJW2 IK XWYMACPLPPQCHC-UHFFFAOYSA-N
DMAMJW2 IU 8-acetyl-7-hydroxychromen-2-one
DMAMJW2 CA CAS 6748-68-1
DMAMJW2 DE Discovery agent
DMZSJRC ID DMZSJRC
DMZSJRC DN 8-acetyl-7-methoxy-2H-chromen-2-one
DMZSJRC HS Investigative
DMZSJRC SN 8-Acetyl-7-methoxycoumarin; 8-acetyl-7-methoxy-2H-chromen-2-one; 89019-07-8; CHEMBL1288594; 8-Acetyl-7-methoxy-chromen-2-one; 2H-1-Benzopyran-2-one,8-acetyl-7-methoxy-; acetyl methoxycoumarin; ACMC-20lgfq; acetyl-7-methoxycoumarin, 8-; SCHEMBL16283617; CTK5G2445; DTXSID20556130; 8-acetyl-7-methoxy-2-oxochromene; 8-acetyl-7-methoxycoumarin ,98%; ZINC2562448; MFCD00270164; 8 - Acetyl - 7 - methoxycoumarin; BDBM50332024; 7-methoxy-8-coumarinul methyl ketone; AKOS016009510; RP27113; ST085908; AJ-40748; DB-078289; KB-200257; AX8111029
DMZSJRC DT Small molecular drug
DMZSJRC PC 14116752
DMZSJRC MW 218.2
DMZSJRC FM C12H10O4
DMZSJRC IC InChI=1S/C12H10O4/c1-7(13)11-9(15-2)5-3-8-4-6-10(14)16-12(8)11/h3-6H,1-2H3
DMZSJRC CS CC(=O)C1=C(C=CC2=C1OC(=O)C=C2)OC
DMZSJRC IK OTYBDEHZHXKGBO-UHFFFAOYSA-N
DMZSJRC IU 8-acetyl-7-methoxychromen-2-one
DMZSJRC CA CAS 89019-07-8
DMZSJRC DE Discovery agent
DMGRK3V ID DMGRK3V
DMGRK3V DN 8-acetyl-7-propoxy-2H-chromen-2-one
DMGRK3V HS Investigative
DMGRK3V SN CHEMBL1288596; 8-acetyl-7-propoxy-2H-chromen-2-one
DMGRK3V DT Small molecular drug
DMGRK3V PC 52946829
DMGRK3V MW 246.26
DMGRK3V FM C14H14O4
DMGRK3V IC InChI=1S/C14H14O4/c1-3-8-17-11-6-4-10-5-7-12(16)18-14(10)13(11)9(2)15/h4-7H,3,8H2,1-2H3
DMGRK3V CS CCCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)C
DMGRK3V IK XDGJEUMPGBUXDY-UHFFFAOYSA-N
DMGRK3V IU 8-acetyl-7-propoxychromen-2-one
DMGRK3V DE Discovery agent
DM7K2DN ID DM7K2DN
DM7K2DN DN 8alpha,19-dihydroxylabd-13 E-en-15-oic acid
DM7K2DN HS Investigative
DM7K2DN SN CHEBI:65789; (2E)-5-[(1R,2R,4aR,5R,8aS)-2-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyldecahydronaphthalen-1-yl]-3-methylpent-2-enoic acid; CHEMBL507405; 8alpha-19-dihydroxylabd-13E-ene-15-oic acid; 8alpha,19-dihydroxylabd-13E-ene-15-oic acid; (13E)-8,18-Dihydroxylabda-13-ene-15-oic acid
DM7K2DN DT Small molecular drug
DM7K2DN PC 24899923
DM7K2DN MW 338.5
DM7K2DN FM C20H34O4
DM7K2DN IC InChI=1S/C20H34O4/c1-14(12-17(22)23)6-7-16-19(3)10-5-9-18(2,13-21)15(19)8-11-20(16,4)24/h12,15-16,21,24H,5-11,13H2,1-4H3,(H,22,23)/b14-12+/t15-,16+,18-,19-,20+/m0/s1
DM7K2DN CS C/C(=C\\C(=O)O)/CC[C@@H]1[C@]2(CCC[C@@]([C@@H]2CC[C@@]1(C)O)(C)CO)C
DM7K2DN IK IYSBWLRXTOIYFZ-KBLZDMJYSA-N
DM7K2DN IU (E)-5-[(1R,2R,4aR,5R,8aS)-2-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoic acid
DM7K2DN CB CHEBI:65789
DM7K2DN DE Discovery agent
DM84D9W ID DM84D9W
DM84D9W DN 8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione
DM84D9W HS Investigative
DM84D9W SN 8-Aminotheophylline; 8-Aminoteofiliny; Theophylline, 8-amino-; 19410-53-8; 8-Aminoteofiliny [Polish]; 8-AMINO-1,3-DIMETHYL-3,7-DIHYDROPURINE-2,6-DIONE; 1H-Purine-2,6-dione, 8-amino-3,7-dihydro-1,3-dimethyl-; 8-Amino-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; 8-amino-1,3-dimethyl-7H-purine-2,6-dione; 8-amino-1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione; 8-amino-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; 8-Aminotheophyline; 1rs2; AC1L3TFO; AC1Q6LC1; Oprea1_659892; Oprea1_298061; Oprea1_442990; CHEMBL298737
DM84D9W DT Small molecular drug
DM84D9W PC 95034
DM84D9W MW 195.18
DM84D9W FM C7H9N5O2
DM84D9W IC InChI=1S/C7H9N5O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H3,8,9,10)
DM84D9W CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)N
DM84D9W IK ZZESAIGPDOBLKZ-UHFFFAOYSA-N
DM84D9W IU 8-amino-1,3-dimethyl-7H-purine-2,6-dione
DM84D9W CA CAS 19410-53-8
DM84D9W DE Discovery agent
DMTRBDP ID DMTRBDP
DMTRBDP DN 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMTRBDP HS Investigative
DMTRBDP SN SCHEMBL4662780; CHEMBL363363; BDBM27514; LQEYAIKMIJUZNT-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2a; ZINC13652898; 5,6-Dihydro-5-oxo-8-amino-indeno[1,2-c]isoquinoline
DMTRBDP DT Small molecular drug
DMTRBDP PC 11736764
DMTRBDP MW 248.28
DMTRBDP FM C16H12N2O
DMTRBDP IC InChI=1S/C16H12N2O/c17-10-6-5-9-7-14-11-3-1-2-4-12(11)16(19)18-15(14)13(9)8-10/h1-6,8H,7,17H2,(H,18,19)
DMTRBDP CS C1C2=C(C=C(C=C2)N)C3=C1C4=CC=CC=C4C(=O)N3
DMTRBDP IK LQEYAIKMIJUZNT-UHFFFAOYSA-N
DMTRBDP IU 8-amino-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMTRBDP DE Discovery agent
DMSNG7M ID DMSNG7M
DMSNG7M DN 8-amino-9-benzylguanine
DMSNG7M HS Investigative
DMSNG7M SN 8-Amino-9-benzylguanine; 100890-94-6; NSC650999; CHEMBL8230; NSC-650999; 6H-Purin-6-one,2,8-diamino-1,9-dihydro-9-(phenylmethyl)-; 8-Amino-9-benzyl-guanine; 8-ABG; 2,8-diamino-9-benzyl-3H-purin-6-one; ACMC-20m3xx; AC1L2SFN; SCHEMBL6359274; CTK3J9334; ZINC16958226; BDBM50005799; AKOS030559033; NCI60_017833; 2-amino-9-benzyl-8-imino-7H-purin-6-ol; 2-Amino-9-benzyl-8-imino-8,9-dihydro-7H-purin-6-ol; 6H-Purin-6-one,
DMSNG7M DT Small molecular drug
DMSNG7M PC 135408972
DMSNG7M MW 256.26
DMSNG7M FM C12H12N6O
DMSNG7M IC InChI=1S/C12H12N6O/c13-11-16-9-8(10(19)17-11)15-12(14)18(9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H2,14,15)(H3,13,16,17,19)
DMSNG7M CS C1=CC=C(C=C1)CN2C3=C(C(=O)NC(=N3)N)N=C2N
DMSNG7M IK DPDYTYOWSIRPMB-UHFFFAOYSA-N
DMSNG7M IU 2,8-diamino-9-benzyl-1H-purin-6-one
DMSNG7M CA CAS 100890-94-6
DMYXJG7 ID DMYXJG7
DMYXJG7 DN 8-AMINOGUANINE
DMYXJG7 HS Investigative
DMYXJG7 DT Small molecular drug
DMYXJG7 PC 135421887
DMYXJG7 MW 166.14
DMYXJG7 FM C5H6N6O
DMYXJG7 IC InChI=1S/C5H6N6O/c6-4-8-1-2(9-4)10-5(7)11-3(1)12/h(H6,6,7,8,9,10,11,12)
DMYXJG7 CS C12=C(N=C(N1)N)N=C(NC2=O)N
DMYXJG7 IK WYDKPTZGVLTYPG-UHFFFAOYSA-N
DMYXJG7 IU 2,8-diamino-1,7-dihydropurin-6-one
DMYXJG7 CA CAS 28128-41-8
DMYXJG7 DE Discovery agent
DM0JEA6 ID DM0JEA6
DM0JEA6 DN 8-aminoguanosine
DM0JEA6 HS Investigative
DM0JEA6 DT Small molecular drug
DM0JEA6 PC 135518164
DM0JEA6 MW 298.26
DM0JEA6 FM C10H14N6O5
DM0JEA6 IC InChI=1S/C10H14N6O5/c11-9-14-6-3(7(20)15-9)13-10(12)16(6)8-5(19)4(18)2(1-17)21-8/h2,4-5,8,17-19H,1H2,(H2,12,13)(H3,11,14,15,20)/t2-,4-,5-,8-/m1/s1
DM0JEA6 CS C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)NC(=N3)N)N=C2N)O)O)O
DM0JEA6 IK FNXPTCITVCRFRK-UMMCILCDSA-N
DM0JEA6 IU 2,8-diamino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DM0JEA6 CA CAS 3868-32-4
DM0JEA6 DE Discovery agent
DMN8QAF ID DMN8QAF
DMN8QAF DN 8-aminoquinolines
DMN8QAF HS Investigative
DMN8QAF SN Hexamethonium; hexamethonium; Hexonium; Benzohexamethonium; Hexamethonum; Bistrium; Hexanium; 60-26-4; UNII-3C9PSP36Z2; Esametonio [Italian]; CHEMBL100622; CHEBI:5700; 3C9PSP36Z2; N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium; NCGC00163239-01; Hexane-1,6-bis(trimethylammonium); 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-; DSSTox_RID_80651; DSSTox_CID_25053; DSSTox_GSID_45053; BRN 1760389; Esametonio; CHEMBL332524; CAS-60-26-4; Hexamethonium [INN]; Ammonium, hexamethylenebis(trimethyl-; trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
DMN8QAF DT Small molecular drug
DMN8QAF PC 3604
DMN8QAF MW 202.38
DMN8QAF FM C12H30N2+2
DMN8QAF IC InChI=1S/C12H30N2/c1-13(2,3)11-9-7-8-10-12-14(4,5)6/h7-12H2,1-6H3/q+2
DMN8QAF CS C[N+](C)(C)CCCCCC[N+](C)(C)C
DMN8QAF IK VZJFGSRCJCXDSG-UHFFFAOYSA-N
DMN8QAF IU trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
DMN8QAF CA CAS 60-26-4
DMN8QAF CB CHEBI:5700
DMN8QAF DE Discovery agent
DMYBPGA ID DMYBPGA
DMYBPGA DN 8-aza-11-deoxyprostaglandin E1
DMYBPGA HS Investigative
DMYBPGA SN CHEMBL42027; 8-aza-11-deoxyprostaglandin E1; BDBM50142481; 7-[(R)-2-((E)-(S)-3-Hydroxy-oct-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid
DMYBPGA DT Small molecular drug
DMYBPGA PC 44289922
DMYBPGA MW 339.5
DMYBPGA FM C19H33NO4
DMYBPGA IC InChI=1S/C19H33NO4/c1-2-3-6-9-17(21)13-11-16-12-14-18(22)20(16)15-8-5-4-7-10-19(23)24/h11,13,16-17,21H,2-10,12,14-15H2,1H3,(H,23,24)/b13-11+/t16-,17-/m0/s1
DMYBPGA CS CCCCC[C@@H](/C=C/[C@H]1CCC(=O)N1CCCCCCC(=O)O)O
DMYBPGA IK XOPMUDZOEKPBQZ-NSNJOPQOSA-N
DMYBPGA IU 7-[(2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid
DMYBPGA DE Discovery agent
DMQMSZR ID DMQMSZR
DMQMSZR DN 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide
DMQMSZR HS Investigative
DMQMSZR SN CHEMBL1257578; CHEMBL1223815; SCHEMBL15031381; BDBM50325848; BDBM50327244; AZ-MTAB, > ZINC101363709
DMQMSZR DT Small molecular drug
DMQMSZR PC 49765077
DMQMSZR MW 356.5
DMQMSZR FM C20H24N2O2S
DMQMSZR IC InChI=1S/C20H24N2O2S/c1-13-5-8-19(25-13)12-22-15-6-7-16(22)11-18(10-15)24-17-4-2-3-14(9-17)20(21)23/h2-5,8-9,15-16,18H,6-7,10-12H2,1H3,(H2,21,23)/t15-,16+,18?
DMQMSZR CS CC1=CC=C(S1)CN2[C@@H]3CC[C@H]2CC(C3)OC4=CC=CC(=C4)C(=O)N
DMQMSZR IK RLHOWHVHHMGIKE-BYICEURKSA-N
DMQMSZR IU 3-[[(1S,5R)-8-[(5-methylthiophen-2-yl)methyl]-8-azabicyclo[3.2.1]octan-3-yl]oxy]benzamide
DMQMSZR DE Discovery agent
DMBVFKR ID DMBVFKR
DMBVFKR DN 8-aza-DADMe-ImmH
DMBVFKR HS Investigative
DMBVFKR DT Small molecular drug
DMBVFKR PC 56603748
DMBVFKR DE Discovery agent
DM7VP90 ID DM7VP90
DM7VP90 DN 8-Azaguanine
DM7VP90 HS Investigative
DM7VP90 DT Small molecular drug
DM7VP90 PC 135403646
DM7VP90 MW 152.11
DM7VP90 FM C4H4N6O
DM7VP90 IC InChI=1S/C4H4N6O/c5-4-6-2-1(3(11)7-4)8-10-9-2/h(H4,5,6,7,8,9,10,11)
DM7VP90 CS C12=NNN=C1N=C(NC2=O)N
DM7VP90 IK LPXQRXLUHJKZIE-UHFFFAOYSA-N
DM7VP90 IU 5-amino-2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one
DM7VP90 CA CAS 134-58-7
DM7VP90 CB CHEBI:63486
DM7VP90 DE Discovery agent
DMT8QAP ID DMT8QAP
DMT8QAP DN 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
DMT8QAP HS Investigative
DMT8QAP SN 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-; CHEMBL326564; PU6; 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-9H-purin-6-amine; 1uy9; Purine-Based Inhibitor 4; AC1L9MK7; BDBM15377; DB08436; 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(2H-1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine; 8-(1,3-Benzodioxole-5-ylmethyl)-9-butyl-9H-purine-6-amine
DMT8QAP DT Small molecular drug
DMT8QAP PC 448968
DMT8QAP MW 325.4
DMT8QAP FM C17H19N5O2
DMT8QAP IC InChI=1S/C17H19N5O2/c1-2-3-6-22-14(21-15-16(18)19-9-20-17(15)22)8-11-4-5-12-13(7-11)24-10-23-12/h4-5,7,9H,2-3,6,8,10H2,1H3,(H2,18,19,20)
DMT8QAP CS CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC4=C(C=C3)OCO4
DMT8QAP IK JCDXXNIRWRRGBX-UHFFFAOYSA-N
DMT8QAP IU 8-(1,3-benzodioxol-5-ylmethyl)-9-butylpurin-6-amine
DMT8QAP DE Discovery agent
DM32OQB ID DM32OQB
DM32OQB DN 8-benzyl-9H-purine-2,6-diamine
DM32OQB HS Investigative
DM32OQB SN 8-Benzyl-9H-purine-2,6-diamine; CHEMBL102303; 9H-Purine-2,6-diamine, 8-(phenylmethyl)-; AC1L9X4P; SCHEMBL3923325; 8-benzyl-7H-purine-2,6-diamine; BDBM50059941
DM32OQB DT Small molecular drug
DM32OQB PC 457735
DM32OQB MW 240.26
DM32OQB FM C12H12N6
DM32OQB IC InChI=1S/C12H12N6/c13-10-9-11(18-12(14)17-10)16-8(15-9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H5,13,14,15,16,17,18)
DM32OQB CS C1=CC=C(C=C1)CC2=NC3=NC(=NC(=C3N2)N)N
DM32OQB IK AFWYNOWVYKOMGZ-UHFFFAOYSA-N
DM32OQB IU 8-benzyl-7H-purine-2,6-diamine
DM32OQB DE Discovery agent
DMKHF87 ID DMKHF87
DMKHF87 DN 8-benzylnaringenin
DMKHF87 HS Investigative
DMKHF87 SN 8-benzylnaringenin
DMKHF87 DT Small molecular drug
DMKHF87 PC 44418733
DMKHF87 MW 362.4
DMKHF87 FM C22H18O5
DMKHF87 IC InChI=1S/C22H18O5/c23-15-8-6-14(7-9-15)20-12-19(26)21-18(25)11-17(24)16(22(21)27-20)10-13-4-2-1-3-5-13/h1-9,11,20,23-25H,10,12H2/t20-/m0/s1
DMKHF87 CS C1[C@H](OC2=C(C(=CC(=C2C1=O)O)O)CC3=CC=CC=C3)C4=CC=C(C=C4)O
DMKHF87 IK JCMOCGVRZVEPSS-FQEVSTJZSA-N
DMKHF87 IU (2S)-8-benzyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMKHF87 DE Discovery agent
DMJQ8AP ID DMJQ8AP
DMJQ8AP DN 8-Benzyloxycaffeine
DMJQ8AP HS Investigative
DMJQ8AP SN 8-Benzyloxycaffeine; CHEMBL602259; 8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1h-purine-2,6-dione; 5422-51-5; NSC11301; AC1L5CNO; ChemDiv2_004644; AC1Q6NU8; MLS000115142; cid_223566; SCHEMBL15648367; CTK5A0068; DTXSID60279114; HMS1382D02; HMS2252G09; NSC-11301; BDBM50306696; ZINC37868689; AKOS001694622; CCG-117368; IDI1_003359; SMR000092353
DMJQ8AP DT Small molecular drug
DMJQ8AP PC 223566
DMJQ8AP MW 300.31
DMJQ8AP FM C15H16N4O3
DMJQ8AP IC InChI=1S/C15H16N4O3/c1-17-11-12(18(2)15(21)19(3)13(11)20)16-14(17)22-9-10-7-5-4-6-8-10/h4-8H,9H2,1-3H3
DMJQ8AP CS CN1C2=C(N=C1OCC3=CC=CC=C3)N(C(=O)N(C2=O)C)C
DMJQ8AP IK LSJWXGMOPMJCHP-UHFFFAOYSA-N
DMJQ8AP IU 1,3,7-trimethyl-8-phenylmethoxypurine-2,6-dione
DMJQ8AP CA CAS 5422-51-5
DMJQ8AP DE Discovery agent
DMMCAZG ID DMMCAZG
DMMCAZG DN 8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one
DMMCAZG HS Investigative
DMMCAZG SN CHEMBL425391; 8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one
DMMCAZG DT Small molecular drug
DMMCAZG PC 11552705
DMMCAZG MW 383.4
DMMCAZG FM C25H21NO3
DMMCAZG IC InChI=1S/C25H21NO3/c27-23-17-24(26-13-15-28-16-14-26)29-25-21(11-6-12-22(23)25)20-10-5-4-9-19(20)18-7-2-1-3-8-18/h1-12,17H,13-16H2
DMMCAZG CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4C5=CC=CC=C5
DMMCAZG IK VKLCRMQPVMPSKE-UHFFFAOYSA-N
DMMCAZG IU 2-morpholin-4-yl-8-(2-phenylphenyl)chromen-4-one
DMMCAZG DE Discovery agent
DMVPIYG ID DMVPIYG
DMVPIYG DN 8-Br-adenine
DMVPIYG HS Investigative
DMVPIYG SN 8-Bromoadenine; 8-bromo-7H-purin-6-amine; 6974-78-3; 8-Bromo-9H-purin-6-amine; 8-Br-adenine; 8-Bromo-1H-adenine; 6-Amino-8-bromopurine; 8-bromopurine-6-ylamine; EINECS 230-225-1; NSC 21697; CHEMBL65747; 8-Bromo-9H-purin-6-ylamine; FVXHPCVBOXMRJP-UHFFFAOYSA-N; W-203555; 1H-Purin-6-amine, 8-bromo-; 8-bromo-1h-purin-6-amine; 8-bromadenin; 8-Bromo adenine; SCHEMBL8565; AC1L31DI; Oprea1_043695; 8-Bromo-9H-purine-6-amine; 9H-Purin-6-amine,2-bromo-; 9H-Purin-6-amine,8-bromo-; 8-Bromo-9H-purin-6-amine #; CTK4G0895; DTXSID70220036
DMVPIYG DT Small molecular drug
DMVPIYG PC 81457
DMVPIYG MW 214.02
DMVPIYG FM C5H4BrN5
DMVPIYG IC InChI=1S/C5H4BrN5/c6-5-10-2-3(7)8-1-9-4(2)11-5/h1H,(H3,7,8,9,10,11)
DMVPIYG CS C1=NC(=C2C(=N1)N=C(N2)Br)N
DMVPIYG IK FVXHPCVBOXMRJP-UHFFFAOYSA-N
DMVPIYG IU 8-bromo-7H-purin-6-amine
DMVPIYG CA CAS 6974-78-3
DMVPIYG DE Discovery agent
DMALRU4 ID DMALRU4
DMALRU4 DN 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline
DMALRU4 HS Investigative
DMALRU4 SN 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline; CHEMBL6857; BDBM50136494; AKOS022804102
DMALRU4 DT Small molecular drug
DMALRU4 PC 10467319
DMALRU4 MW 251.12
DMALRU4 FM C11H11BrN2
DMALRU4 IC InChI=1S/C11H11BrN2/c12-9-3-1-2-8-7-4-5-13-6-10(7)14-11(8)9/h1-3,13-14H,4-6H2
DMALRU4 CS C1CNCC2=C1C3=C(N2)C(=CC=C3)Br
DMALRU4 IK QDAJATJOFYZEDN-UHFFFAOYSA-N
DMALRU4 IU 8-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMALRU4 DE Discovery agent
DMPVU7H ID DMPVU7H
DMPVU7H DN 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMPVU7H HS Investigative
DMPVU7H SN SCHEMBL9007836; CHEMBL143380
DMPVU7H DT Small molecular drug
DMPVU7H PC 10400801
DMPVU7H MW 268.06
DMPVU7H FM C10H6BrNO3
DMPVU7H IC InChI=1S/C10H6BrNO3/c11-5-1-2-6-7(3-5)12-10(15)9(14)4-8(6)13/h1-4,13H,(H,12,14,15)
DMPVU7H CS C1=CC2=C(C=C1Br)NC(=O)C(=O)C=C2O
DMPVU7H IK VCORQELOMRIIBS-UHFFFAOYSA-N
DMPVU7H IU 8-bromo-5-hydroxy-1H-1-benzazepine-2,3-dione
DMPVU7H DE Discovery agent
DM4V5RU ID DM4V5RU
DM4V5RU DN 8-Bromo-4,9-dihydro-3H-beta-carboline
DM4V5RU HS Investigative
DM4V5RU SN CHEMBL6746; 8-Bromo-4,9-dihydro-3H-beta-carboline; BDBM50136503
DM4V5RU DT Small molecular drug
DM4V5RU PC 44264251
DM4V5RU MW 249.11
DM4V5RU FM C11H9BrN2
DM4V5RU IC InChI=1S/C11H9BrN2/c12-9-3-1-2-8-7-4-5-13-6-10(7)14-11(8)9/h1-3,6,14H,4-5H2
DM4V5RU CS C1CN=CC2=C1C3=C(N2)C(=CC=C3)Br
DM4V5RU IK BHLUQLWTEJKCOP-UHFFFAOYSA-N
DM4V5RU IU 8-bromo-4,9-dihydro-3H-pyrido[3,4-b]indole
DM4V5RU DE Discovery agent
DM51FL9 ID DM51FL9
DM51FL9 DN 8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin
DM51FL9 HS Investigative
DM51FL9 SN CHEMBL1221980; SCHEMBL17857193; BDBM50324964
DM51FL9 DT Small molecular drug
DM51FL9 PC 46933990
DM51FL9 MW 345.2
DM51FL9 FM C17H13BrO3
DM51FL9 IC InChI=1S/C17H13BrO3/c1-10-7-12-9-14(11-3-5-13(20-2)6-4-11)17(19)21-16(12)15(18)8-10/h3-9H,1-2H3
DM51FL9 CS CC1=CC2=C(C(=C1)Br)OC(=O)C(=C2)C3=CC=C(C=C3)OC
DM51FL9 IK QMFYGKBIXCRXNB-UHFFFAOYSA-N
DM51FL9 IU 8-bromo-3-(4-methoxyphenyl)-6-methylchromen-2-one
DM51FL9 DE Discovery agent
DMD1LM8 ID DMD1LM8
DMD1LM8 DN 8-Bromo-6-methyl-3-phenylcoumarin
DMD1LM8 HS Investigative
DMD1LM8 SN CHEMBL1221930; 8-Bromo-6-methyl-3-phenylcoumarin; SCHEMBL17857186; 8-bromo-3-phenyl-6-methylcumarin
DMD1LM8 DT Small molecular drug
DMD1LM8 PC 46933989
DMD1LM8 MW 315.16
DMD1LM8 FM C16H11BrO2
DMD1LM8 IC InChI=1S/C16H11BrO2/c1-10-7-12-9-13(11-5-3-2-4-6-11)16(18)19-15(12)14(17)8-10/h2-9H,1H3
DMD1LM8 CS CC1=CC2=C(C(=C1)Br)OC(=O)C(=C2)C3=CC=CC=C3
DMD1LM8 IK TYLXEMSZGAPZTD-UHFFFAOYSA-N
DMD1LM8 IU 8-bromo-6-methyl-3-phenylchromen-2-one
DMD1LM8 DE Discovery agent
DMKU06T ID DMKU06T
DMKU06T DN 8-Bromo-6-styryl-naphthalene-2-carboxamidine
DMKU06T HS Investigative
DMKU06T SN CHEMBL360703; 8-Bromo-6-styryl-naphthalene-2-carboxamidine; BDBM50157086
DMKU06T DT Small molecular drug
DMKU06T PC 44392405
DMKU06T MW 351.2
DMKU06T FM C19H15BrN2
DMKU06T IC InChI=1S/C19H15BrN2/c20-18-11-14(7-6-13-4-2-1-3-5-13)10-15-8-9-16(19(21)22)12-17(15)18/h1-12H,(H3,21,22)/b7-6+
DMKU06T CS C1=CC=C(C=C1)/C=C/C2=CC(=C3C=C(C=CC3=C2)C(=N)N)Br
DMKU06T IK QHYGSRQJBXWIGI-VOTSOKGWSA-N
DMKU06T IU 8-bromo-6-[(E)-2-phenylethenyl]naphthalene-2-carboximidamide
DMKU06T DE Discovery agent
DMMQ79W ID DMMQ79W
DMMQ79W DN 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine
DMMQ79W HS Investigative
DMMQ79W SN CHEMBL505633; 3-(6-amino-8-bromopurin-9-yl)propane-1,2-diol; 3-(6-Amino-8-bromo-purin-9-yl)-propane-1,2-diol; AC1MCMJY; 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine; C8H10BrN5O2; Oprea1_182885; Oprea1_060925; MolPort-000-712-951; 3-(6-AMINO-8-BROMO-9H-PURIN-9-YL)PROPANE-1,2-DIOL; STL558390; CCG-18677; BDBM50257096; AKOS001644314; MCULE-9507586118; BAS 00110783; 69369-04-6; ST50975882
DMMQ79W DT Small molecular drug
DMMQ79W PC 2773172
DMMQ79W MW 288.1
DMMQ79W FM C8H10BrN5O2
DMMQ79W IC InChI=1S/C8H10BrN5O2/c9-8-13-5-6(10)11-3-12-7(5)14(8)1-4(16)2-15/h3-4,15-16H,1-2H2,(H2,10,11,12)
DMMQ79W CS C1=NC(=C2C(=N1)N(C(=N2)Br)CC(CO)O)N
DMMQ79W IK XXTHNUCUAMMCPB-UHFFFAOYSA-N
DMMQ79W IU 3-(6-amino-8-bromopurin-9-yl)propane-1,2-diol
DMMQ79W DE Discovery agent
DM5DCPF ID DM5DCPF
DM5DCPF DN 8-Bromo-9-(2-butyl)-9H-adenine
DM5DCPF HS Investigative
DM5DCPF SN CHEMBL505089; 202136-43-4; (8-bromo-9-butyl-9H-purin-6-yl)amine; 8-Bromo-9-(2-butyl)-9H-adenine; 8-bromo-9-butyladenine; SCHEMBL1965296; CTK4E3576; DTXSID80469393; FKNNQOCJLMQVAV-UHFFFAOYSA-N; BDBM50256953; AKOS015965383; 9H-Purin-6-amine,8-bromo-9-butyl-
DM5DCPF DT Small molecular drug
DM5DCPF PC 11608719
DM5DCPF MW 270.13
DM5DCPF FM C9H12BrN5
DM5DCPF IC InChI=1S/C9H12BrN5/c1-2-3-4-15-8-6(14-9(15)10)7(11)12-5-13-8/h5H,2-4H2,1H3,(H2,11,12,13)
DM5DCPF CS CCCCN1C2=NC=NC(=C2N=C1Br)N
DM5DCPF IK FKNNQOCJLMQVAV-UHFFFAOYSA-N
DM5DCPF IU 8-bromo-9-butylpurin-6-amine
DM5DCPF CA CAS 202136-43-4
DM5DCPF DE Discovery agent
DMKW2PE ID DMKW2PE
DMKW2PE DN 8-Bromo-9-(2-hydroxypropyl)-9H-adenine
DMKW2PE HS Investigative
DMKW2PE SN 8-Bromo-9-(2-hydroxypropyl)-9H-adenine; CHEMBL475617; 98411-78-0
DMKW2PE DT Small molecular drug
DMKW2PE PC 44572473
DMKW2PE MW 272.1
DMKW2PE FM C8H10BrN5O
DMKW2PE IC InChI=1S/C8H10BrN5O/c1-4(15)2-14-7-5(13-8(14)9)6(10)11-3-12-7/h3-4,15H,2H2,1H3,(H2,10,11,12)
DMKW2PE CS CC(CN1C2=NC=NC(=C2N=C1Br)N)O
DMKW2PE IK MMKXSEBGGSBLDX-UHFFFAOYSA-N
DMKW2PE IU 1-(6-amino-8-bromopurin-9-yl)propan-2-ol
DMKW2PE DE Discovery agent
DMA258T ID DMA258T
DMA258T DN 8-Bromo-9-(3-hydroxypropyl)-9H-adenine
DMA258T HS Investigative
DMA258T SN 8-Bromo-9-(3-hydroxypropyl)-9H-adenine; CHEMBL475455; 98411-75-7
DMA258T DT Small molecular drug
DMA258T PC 44572471
DMA258T MW 272.1
DMA258T FM C8H10BrN5O
DMA258T IC InChI=1S/C8H10BrN5O/c9-8-13-5-6(10)11-4-12-7(5)14(8)2-1-3-15/h4,15H,1-3H2,(H2,10,11,12)
DMA258T CS C1=NC(=C2C(=N1)N(C(=N2)Br)CCCO)N
DMA258T IK MUZYIFHIQGFDMZ-UHFFFAOYSA-N
DMA258T IU 3-(6-amino-8-bromopurin-9-yl)propan-1-ol
DMA258T DE Discovery agent
DMXNF3V ID DMXNF3V
DMXNF3V DN 8-Bromo-9-(but-3-enyl)-9H-adenine
DMXNF3V HS Investigative
DMXNF3V SN CHEMBL508561; 8-Bromo-9-(but-3-enyl)-9H-adenine
DMXNF3V DT Small molecular drug
DMXNF3V PC 44572357
DMXNF3V MW 268.11
DMXNF3V FM C9H10BrN5
DMXNF3V IC InChI=1S/C9H10BrN5/c1-2-3-4-15-8-6(14-9(15)10)7(11)12-5-13-8/h2,5H,1,3-4H2,(H2,11,12,13)
DMXNF3V CS C=CCCN1C2=NC=NC(=C2N=C1Br)N
DMXNF3V IK PZPGDJLTSOBNOR-UHFFFAOYSA-N
DMXNF3V IU 8-bromo-9-but-3-enylpurin-6-amine
DMXNF3V DE Discovery agent
DMSQPFM ID DMSQPFM
DMSQPFM DN 8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM HS Investigative
DMSQPFM SN CHEMBL509367; 8-Bromo-9-(sec-butyl)-9H-adenine
DMSQPFM DT Small molecular drug
DMSQPFM PC 44572295
DMSQPFM MW 270.13
DMSQPFM FM C9H12BrN5
DMSQPFM IC InChI=1S/C9H12BrN5/c1-3-5(2)15-8-6(14-9(15)10)7(11)12-4-13-8/h4-5H,3H2,1-2H3,(H2,11,12,13)
DMSQPFM CS CCC(C)N1C2=NC=NC(=C2N=C1Br)N
DMSQPFM IK HDNHXVSBLXMYPH-UHFFFAOYSA-N
DMSQPFM IU 8-bromo-9-butan-2-ylpurin-6-amine
DMSQPFM DE Discovery agent
DMUTV76 ID DMUTV76
DMUTV76 DN 8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76 HS Investigative
DMUTV76 SN CHEMBL515419; 8-Bromo-9-cyclobutyl-9H-adenine
DMUTV76 DT Small molecular drug
DMUTV76 PC 44572409
DMUTV76 MW 268.11
DMUTV76 FM C9H10BrN5
DMUTV76 IC InChI=1S/C9H10BrN5/c10-9-14-6-7(11)12-4-13-8(6)15(9)5-2-1-3-5/h4-5H,1-3H2,(H2,11,12,13)
DMUTV76 CS C1CC(C1)N2C3=NC=NC(=C3N=C2Br)N
DMUTV76 IK ODVHXPRTEZXIFW-UHFFFAOYSA-N
DMUTV76 IU 8-bromo-9-cyclobutylpurin-6-amine
DMUTV76 DE Discovery agent
DMLVCON ID DMLVCON
DMLVCON DN 8-Bromo-9-cyclohexyl-9H-adenine
DMLVCON HS Investigative
DMLVCON SN 8-Bromo-9-cyclohexyl-9H-adenine; CHEMBL516238; BDBM50256952
DMLVCON DT Small molecular drug
DMLVCON PC 44572356
DMLVCON MW 296.17
DMLVCON FM C11H14BrN5
DMLVCON IC InChI=1S/C11H14BrN5/c12-11-16-8-9(13)14-6-15-10(8)17(11)7-4-2-1-3-5-7/h6-7H,1-5H2,(H2,13,14,15)
DMLVCON CS C1CCC(CC1)N2C3=NC=NC(=C3N=C2Br)N
DMLVCON IK IVKXIMVGTFMPDF-UHFFFAOYSA-N
DMLVCON IU 8-bromo-9-cyclohexylpurin-6-amine
DMLVCON DE Discovery agent
DMCK0O1 ID DMCK0O1
DMCK0O1 DN 8-Bromo-9-cyclopentyl-9H-adenine
DMCK0O1 HS Investigative
DMCK0O1 SN CHEMBL449924; 8-Bromo-9-cyclopentyl-9H-adenine; SCHEMBL5732373
DMCK0O1 DT Small molecular drug
DMCK0O1 PC 12016633
DMCK0O1 MW 282.14
DMCK0O1 FM C10H12BrN5
DMCK0O1 IC InChI=1S/C10H12BrN5/c11-10-15-7-8(12)13-5-14-9(7)16(10)6-3-1-2-4-6/h5-6H,1-4H2,(H2,12,13,14)
DMCK0O1 CS C1CCC(C1)N2C3=NC=NC(=C3N=C2Br)N
DMCK0O1 IK UIZPGNXMMMDTHD-UHFFFAOYSA-N
DMCK0O1 IU 8-bromo-9-cyclopentylpurin-6-amine
DMCK0O1 DE Discovery agent
DM4YAD6 ID DM4YAD6
DM4YAD6 DN 8-Bromo-9-ethyl-9H-adenine
DM4YAD6 HS Investigative
DM4YAD6 SN 8-bromo-9-ethyladenine; CHEMBL468633; 21031-79-8; 8-Bromo-9-ethyl-9H-adenine; AC1NRVH3; SCHEMBL1755068; ANR-82; 8-bromo-9-ethylpurin-6-amine
DM4YAD6 DT Small molecular drug
DM4YAD6 PC 5248753
DM4YAD6 MW 242.08
DM4YAD6 FM C7H8BrN5
DM4YAD6 IC InChI=1S/C7H8BrN5/c1-2-13-6-4(12-7(13)8)5(9)10-3-11-6/h3H,2H2,1H3,(H2,9,10,11)
DM4YAD6 CS CCN1C2=NC=NC(=C2N=C1Br)N
DM4YAD6 IK GACDSQLJMZANKT-UHFFFAOYSA-N
DM4YAD6 IU 8-bromo-9-ethylpurin-6-amine
DM4YAD6 DE Discovery agent
DMZF3UN ID DMZF3UN
DMZF3UN DN 8-bromo-9-isobutyl-9H-purin-6-amine
DMZF3UN HS Investigative
DMZF3UN SN CHEMBL474207; 8-bromo-9-isobutyl-9H-purin-6-amine; 8-Bromo-9-isobutyl-9H-adenine
DMZF3UN DT Small molecular drug
DMZF3UN PC 44572355
DMZF3UN MW 270.13
DMZF3UN FM C9H12BrN5
DMZF3UN IC InChI=1S/C9H12BrN5/c1-5(2)3-15-8-6(14-9(15)10)7(11)12-4-13-8/h4-5H,3H2,1-2H3,(H2,11,12,13)
DMZF3UN CS CC(C)CN1C2=NC=NC(=C2N=C1Br)N
DMZF3UN IK RLPKQFORPDRBQT-UHFFFAOYSA-N
DMZF3UN IU 8-bromo-9-(2-methylpropyl)purin-6-amine
DMZF3UN DE Discovery agent
DMIN9HC ID DMIN9HC
DMIN9HC DN 8-Bromo-9-isopropyl-9H-adenine
DMIN9HC HS Investigative
DMIN9HC SN CHEMBL446264; 8-Bromo-9-isopropyl-9H-adenine; BDBM50256895
DMIN9HC DT Small molecular drug
DMIN9HC PC 44572292
DMIN9HC MW 256.1
DMIN9HC FM C8H10BrN5
DMIN9HC IC InChI=1S/C8H10BrN5/c1-4(2)14-7-5(13-8(14)9)6(10)11-3-12-7/h3-4H,1-2H3,(H2,10,11,12)
DMIN9HC CS CC(C)N1C2=NC=NC(=C2N=C1Br)N
DMIN9HC IK AFKIJCJUVRTHPD-UHFFFAOYSA-N
DMIN9HC IU 8-bromo-9-propan-2-ylpurin-6-amine
DMIN9HC DE Discovery agent
DM1DS3B ID DM1DS3B
DM1DS3B DN 8-Bromo-9-methyl-9H-adenine
DM1DS3B HS Investigative
DM1DS3B SN 8-Bromo-9-methyl-9H-adenine; 8-bromo-9-methyladenine; CHEMBL510288; 56489-40-8; AC1LGJ6D; Oprea1_555380; SCHEMBL8832637; 8-bromo-9-methylpurin-6-amine; CTK1E1875; DTXSID90356366; ICJDGKILGBQWGF-UHFFFAOYSA-N; BDBM50256842; AKOS022687396; 6-Amino-8-bromo-9-methyl-9H-purine; 9H-Purin-6-amine, 8-bromo-9-methyl-
DM1DS3B DT Small molecular drug
DM1DS3B PC 822296
DM1DS3B MW 228.05
DM1DS3B FM C6H6BrN5
DM1DS3B IC InChI=1S/C6H6BrN5/c1-12-5-3(11-6(12)7)4(8)9-2-10-5/h2H,1H3,(H2,8,9,10)
DM1DS3B CS CN1C2=NC=NC(=C2N=C1Br)N
DM1DS3B IK ICJDGKILGBQWGF-UHFFFAOYSA-N
DM1DS3B IU 8-bromo-9-methylpurin-6-amine
DM1DS3B CA CAS 56489-40-8
DM1DS3B DE Discovery agent
DMB7EWZ ID DMB7EWZ
DMB7EWZ DN 8-Bromo-9-phenylethyl-9H-adenine
DMB7EWZ HS Investigative
DMB7EWZ SN CHEMBL503376; 8-Bromo-9-phenylethyl-9H-adenine; SCHEMBL5364361
DMB7EWZ DT Small molecular drug
DMB7EWZ PC 12016636
DMB7EWZ MW 318.17
DMB7EWZ FM C13H12BrN5
DMB7EWZ IC InChI=1S/C13H12BrN5/c14-13-18-10-11(15)16-8-17-12(10)19(13)7-6-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H2,15,16,17)
DMB7EWZ CS C1=CC=C(C=C1)CCN2C3=NC=NC(=C3N=C2Br)N
DMB7EWZ IK LQIMXMMBTNEKMZ-UHFFFAOYSA-N
DMB7EWZ IU 8-bromo-9-(2-phenylethyl)purin-6-amine
DMB7EWZ DE Discovery agent
DMRIPU5 ID DMRIPU5
DMRIPU5 DN 8-Bromo-9-propyl-9H-adenine
DMRIPU5 HS Investigative
DMRIPU5 SN CHEMBL506450; 8-bromo-9-propyl-9H-purin-6-ylamine; 908355-66-8; 8-Bromo-9-propyl-9H-adenine; BDBM50256893; 8-Bromo-9-propyl-9H-purine-6-amine
DMRIPU5 DT Small molecular drug
DMRIPU5 PC 11849871
DMRIPU5 MW 256.1
DMRIPU5 FM C8H10BrN5
DMRIPU5 IC InChI=1S/C8H10BrN5/c1-2-3-14-7-5(13-8(14)9)6(10)11-4-12-7/h4H,2-3H2,1H3,(H2,10,11,12)
DMRIPU5 CS CCCN1C2=NC=NC(=C2N=C1Br)N
DMRIPU5 IK ATNWURROUOXVHM-UHFFFAOYSA-N
DMRIPU5 IU 8-bromo-9-propylpurin-6-amine
DMRIPU5 DE Discovery agent
DM4CV1E ID DM4CV1E
DM4CV1E DN 8-Bromo-Adenosine-5'-Monophosphate
DM4CV1E HS Investigative
DM4CV1E SN 8-Bromoadenosine 5'-monophosphate; 8-BROMO-ADENOSINE-5'-MONOPHOSPHATE; 8-Bromoadenosine 5'-(dihydrogen phosphate); 23567-96-6; 8-Br-AMP; CHEMBL1230617; 8-Bromo-Adenosine Mono Phosphate; 50828-34-7; Poly 8-bromoadenylic acid; 8BR; Poly(8-bra); Poly(8-bromoriboadenylic acid); 8-Bromo-AMP; Adenosine, 8-bromo-, 5'-(dihydrogen phosphate); AC1L518I; SCHEMBL4315602; AC1Q270V; CTK4J3218; 23567-96-6 (monomer); DNPIJKNXFSPNNY-UUOKFMHZSA-N; 8-bromoadenosine-5'-monophosphate; 50828-34-7 (Parent); ZINC13527361; MFCD00056945; BDBM50222467
DM4CV1E DT Small molecular drug
DM4CV1E PC 168120
DM4CV1E MW 426.12
DM4CV1E FM C10H13BrN5O7P
DM4CV1E IC InChI=1S/C10H13BrN5O7P/c11-10-15-4-7(12)13-2-14-8(4)16(10)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,13,14)(H2,19,20,21)/t3-,5-,6-,9-/m1/s1
DM4CV1E CS C1=NC(=C2C(=N1)N(C(=N2)Br)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N
DM4CV1E IK DNPIJKNXFSPNNY-UUOKFMHZSA-N
DM4CV1E IU [(2R,3S,4R,5R)-5-(6-amino-8-bromopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM4CV1E CA CAS 23567-96-6
DM4CV1E DE Discovery agent
DM5RFCN ID DM5RFCN
DM5RFCN DN 8-Butoxy-quinolin-2-ylamine
DM5RFCN HS Investigative
DM5RFCN SN CHEMBL186659; 8-Butoxy-quinolin-2-ylamine; SCHEMBL5884456
DM5RFCN DT Small molecular drug
DM5RFCN PC 10443307
DM5RFCN MW 216.28
DM5RFCN FM C13H16N2O
DM5RFCN IC InChI=1S/C13H16N2O/c1-2-3-9-16-11-6-4-5-10-7-8-12(14)15-13(10)11/h4-8H,2-3,9H2,1H3,(H2,14,15)
DM5RFCN CS CCCCOC1=CC=CC2=C1N=C(C=C2)N
DM5RFCN IK RANHBKGFWNIVKN-UHFFFAOYSA-N
DM5RFCN IU 8-butoxyquinolin-2-amine
DM5RFCN DE Discovery agent
DMD18V5 ID DMD18V5
DMD18V5 DN 8-carboxamidocyclazocine
DMD18V5 HS Investigative
DMD18V5 SN 8-carboxamidocyclazocine; CHEMBL58646; 8-CAC; SCHEMBL12014004; (6S,11R)-3-Cyclopropylmethyl-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine-8-carboxylic acid amide; PDSP1_000954; PDSP2_000939
DMD18V5 DT Small molecular drug
DMD18V5 PC 10086063
DMD18V5 MW 298.4
DMD18V5 FM C19H26N2O
DMD18V5 IC InChI=1S/C19H26N2O/c1-12-17-10-14-5-6-15(18(20)22)9-16(14)19(12,2)7-8-21(17)11-13-3-4-13/h5-6,9,12-13,17H,3-4,7-8,10-11H2,1-2H3,(H2,20,22)/t12-,17?,19-/m0/s1
DMD18V5 CS C[C@H]1C2CC3=C([C@]1(CCN2CC4CC4)C)C=C(C=C3)C(=O)N
DMD18V5 IK FAVQVALXVLMHLE-BKBNBNODSA-N
DMD18V5 IU (1S,13R)-10-(cyclopropylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-triene-4-carboxamide
DMD18V5 DE Discovery agent
DMS7DA3 ID DMS7DA3
DMS7DA3 DN 8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine
DMS7DA3 HS Investigative
DMS7DA3 SN CHEMBL134057; 8-chloro-1,2,3,4-tetrahydroacridin-9-amine; 122994-74-5; 8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine; SCHEMBL9584574; MolPort-039-242-295; ZINC27416388; BDBM50279984; AKOS033887449; 9-Amino-8-chloro-1,2,3,4-tetrahydro-acridinium
DMS7DA3 DT Small molecular drug
DMS7DA3 PC 19770285
DMS7DA3 MW 232.71
DMS7DA3 FM C13H13ClN2
DMS7DA3 IC InChI=1S/C13H13ClN2/c14-9-5-3-7-11-12(9)13(15)8-4-1-2-6-10(8)16-11/h3,5,7H,1-2,4,6H2,(H2,15,16)
DMS7DA3 CS C1CCC2=NC3=C(C(=CC=C3)Cl)C(=C2C1)N
DMS7DA3 IK KVGMGGLTJLJDFE-UHFFFAOYSA-N
DMS7DA3 IU 8-chloro-1,2,3,4-tetrahydroacridin-9-amine
DMS7DA3 DE Discovery agent
DMFW6Q0 ID DMFW6Q0
DMFW6Q0 DN 8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole
DMFW6Q0 HS Investigative
DMFW6Q0 SN CHEMBL443258; 8-chloro-1H,2H,3H,4H-pyrazino[1,2-a]indole; 126718-22-7; 8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole; SCHEMBL5917499; MolPort-022-445-855; BDBM50108304; ZINC13586842; AKOS022692454; MCULE-6563903231; NE39901; 8-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMFW6Q0 DT Small molecular drug
DMFW6Q0 PC 14595512
DMFW6Q0 MW 206.67
DMFW6Q0 FM C11H11ClN2
DMFW6Q0 IC InChI=1S/C11H11ClN2/c12-9-1-2-11-8(5-9)6-10-7-13-3-4-14(10)11/h1-2,5-6,13H,3-4,7H2
DMFW6Q0 CS C1CN2C(=CC3=C2C=CC(=C3)Cl)CN1
DMFW6Q0 IK QKGDOWUCRMVFPY-UHFFFAOYSA-N
DMFW6Q0 IU 8-chloro-1,2,3,4-tetrahydropyrazino[1,2-a]indole
DMFW6Q0 DE Discovery agent
DM5IGOL ID DM5IGOL
DM5IGOL DN 8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM5IGOL HS Investigative
DM5IGOL SN CHEMBL98373; SCHEMBL10757832; 2H-Imidazo[4,5-b]quinolin-2-one, 8-chloro-1,3-dihydro-; BDBM50229559
DM5IGOL DT Small molecular drug
DM5IGOL PC 15065155
DM5IGOL MW 219.63
DM5IGOL FM C10H6ClN3O
DM5IGOL IC InChI=1S/C10H6ClN3O/c11-6-2-1-3-7-5(6)4-8-9(12-7)14-10(15)13-8/h1-4H,(H2,12,13,14,15)
DM5IGOL CS C1=CC2=NC3=C(C=C2C(=C1)Cl)NC(=O)N3
DM5IGOL IK VZXBGYRONYENIL-UHFFFAOYSA-N
DM5IGOL IU 8-chloro-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM5IGOL DE Discovery agent
DM61VJO ID DM61VJO
DM61VJO DN 8-chloro-3,4-dihydroquinazolin-2-amine
DM61VJO HS Investigative
DM61VJO SN CHEMBL272752
DM61VJO DT Small molecular drug
DM61VJO PC 44456244
DM61VJO MW 181.62
DM61VJO FM C8H8ClN3
DM61VJO IC InChI=1S/C8H8ClN3/c9-6-3-1-2-5-4-11-8(10)12-7(5)6/h1-3H,4H2,(H3,10,11,12)
DM61VJO CS C1C2=C(C(=CC=C2)Cl)NC(=N1)N
DM61VJO IK AWSSYPVAGZEEAA-UHFFFAOYSA-N
DM61VJO IU 8-chloro-1,4-dihydroquinazolin-2-amine
DM61VJO DE Discovery agent
DM842L6 ID DM842L6
DM842L6 DN 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DM842L6 HS Investigative
DM842L6 SN CHEMBL93798; 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione; 1H-1-Benzazepine-2,5-dione, 8-chloro-3-hydroxy-; SCHEMBL7350621; PUWRZSGQAPPNEC-UHFFFAOYSA-N; BDBM50054631; 144066-23-9; 3-Hydroxy-8-chloro-1H-1-benzazepine-2,5-dione; 8-chloro-3-hydroxy-2,5-dihydro-1h-benzazepine-2,5-dione
DM842L6 DT Small molecular drug
DM842L6 PC 9815930
DM842L6 MW 223.61
DM842L6 FM C10H6ClNO3
DM842L6 IC InChI=1S/C10H6ClNO3/c11-5-1-2-6-7(3-5)12-10(15)9(14)4-8(6)13/h1-4,13H,(H,12,14,15)
DM842L6 CS C1=CC2=C(C=C1Cl)NC(=O)C(=O)C=C2O
DM842L6 IK CPGVEVDFZYFBBP-UHFFFAOYSA-N
DM842L6 IU 8-chloro-5-hydroxy-1H-1-benzazepine-2,3-dione
DM842L6 DE Discovery agent
DMB76ZN ID DMB76ZN
DMB76ZN DN 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMB76ZN HS Investigative
DMB76ZN SN CHEMBL363367; 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3923941; IVJIWGTXXHDRCU-UHFFFAOYSA-N; BDBM50168384; ZINC13645099
DMB76ZN DT Small molecular drug
DMB76ZN PC 10214699
DMB76ZN MW 270.71
DMB76ZN FM C16H11ClO2
DMB76ZN IC InChI=1S/C16H11ClO2/c17-16-8-12(10-1-4-13(18)5-2-10)7-11-3-6-14(19)9-15(11)16/h1-9,18-19H
DMB76ZN CS C1=CC(=CC=C1C2=CC(=C3C=C(C=CC3=C2)O)Cl)O
DMB76ZN IK IVJIWGTXXHDRCU-UHFFFAOYSA-N
DMB76ZN IU 8-chloro-6-(4-hydroxyphenyl)naphthalen-2-ol
DMB76ZN DE Discovery agent
DMFNUHQ ID DMFNUHQ
DMFNUHQ DN 8-chloro-quinoline-3-carbonitrile
DMFNUHQ HS Investigative
DMFNUHQ SN CHEMBL436817; Cyanoquinoline, 11; SCHEMBL6071997; BDBM21898; CHEBI:94979; BRD-K00088062-001-01-3; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1H-imidazole-5-ylmethyl)amino]-8-chloro-3-quinolinecarbonitrile
DMFNUHQ DT Small molecular drug
DMFNUHQ PC 17759555
DMFNUHQ MW 427.3
DMFNUHQ FM C20H13Cl2FN6
DMFNUHQ IC InChI=1S/C20H13Cl2FN6/c21-16-4-12(1-2-18(16)23)29-19-11(6-24)7-27-20-15(19)3-13(5-17(20)22)26-9-14-8-25-10-28-14/h1-5,7-8,10,26H,9H2,(H,25,28)(H,27,29)
DMFNUHQ CS C1=CC(=C(C=C1NC2=C3C=C(C=C(C3=NC=C2C#N)Cl)NCC4=CN=CN4)Cl)F
DMFNUHQ IK ONXROKMQGCSOMG-UHFFFAOYSA-N
DMFNUHQ IU 8-chloro-4-(3-chloro-4-fluoroanilino)-6-(1H-imidazol-5-ylmethylamino)quinoline-3-carbonitrile
DMFNUHQ CB CHEBI:94979
DMFNUHQ DE Discovery agent
DM4VTM2 ID DM4VTM2
DM4VTM2 DN 8-Cyclobutylmethoxy-quinolin-2-ylamine
DM4VTM2 HS Investigative
DM4VTM2 SN CHEMBL184980; 8-Cyclobutylmethoxy-quinolin-2-ylamine; SCHEMBL5883878
DM4VTM2 DT Small molecular drug
DM4VTM2 PC 22254575
DM4VTM2 MW 228.29
DM4VTM2 FM C14H16N2O
DM4VTM2 IC InChI=1S/C14H16N2O/c15-13-8-7-11-5-2-6-12(14(11)16-13)17-9-10-3-1-4-10/h2,5-8,10H,1,3-4,9H2,(H2,15,16)
DM4VTM2 CS C1CC(C1)COC2=CC=CC3=C2N=C(C=C3)N
DM4VTM2 IK LOSCSSHHWRUJGD-UHFFFAOYSA-N
DM4VTM2 IU 8-(cyclobutylmethoxy)quinolin-2-amine
DM4VTM2 DE Discovery agent
DMEBYRW ID DMEBYRW
DMEBYRW DN 8-Cycloheptyloxy-quinolin-2-ylamine
DMEBYRW HS Investigative
DMEBYRW SN CHEMBL184394; 8-Cycloheptyloxy-quinolin-2-ylamine; SCHEMBL5884483
DMEBYRW DT Small molecular drug
DMEBYRW PC 10332650
DMEBYRW MW 256.339
DMEBYRW FM C16H20N2O
DMEBYRW IC InChI=1S/C16H20N2O/c17-15-11-10-12-6-5-9-14(16(12)18-15)19-13-7-3-1-2-4-8-13/h5-6,9-11,13H,1-4,7-8H2,(H2,17,18)
DMEBYRW CS C1CCCC(CC1)OC2=CC=CC3=C2N=C(C=C3)N
DMEBYRW IK MGAFXFCQBHUFIL-UHFFFAOYSA-N
DMEBYRW IU 8-cycloheptyloxyquinolin-2-amine
DMEBYRW DE Discovery agent
DM79VQM ID DM79VQM
DM79VQM DN 8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine
DM79VQM HS Investigative
DM79VQM SN CHEMBL381112; 8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine
DM79VQM DT Small molecular drug
DM79VQM PC 11610347
DM79VQM MW 368.5
DM79VQM FM C24H24N4
DM79VQM IC InChI=1S/C24H24N4/c1-16-12-14-17(15-13-16)20-21-24(27-22(25-20)18-8-4-2-5-9-18)28-23(26-21)19-10-6-3-7-11-19/h2,4-5,8-9,12-15,19H,3,6-7,10-11H2,1H3,(H,25,26,27,28)
DM79VQM CS CC1=CC=C(C=C1)C2=C3C(=NC(=N2)C4=CC=CC=C4)N=C(N3)C5CCCCC5
DM79VQM IK JOTMQRFWDYAWIE-UHFFFAOYSA-N
DM79VQM IU 8-cyclohexyl-6-(4-methylphenyl)-2-phenyl-7H-purine
DM79VQM DE Discovery agent
DMKT0YQ ID DMKT0YQ
DMKT0YQ DN 8-Cyclohexyloxy-quinolin-2-ylamine
DMKT0YQ HS Investigative
DMKT0YQ SN CHEMBL185235; 8-Cyclohexyloxy-quinolin-2-ylamine; SCHEMBL5883787
DMKT0YQ DT Small molecular drug
DMKT0YQ PC 10399494
DMKT0YQ MW 242.32
DMKT0YQ FM C15H18N2O
DMKT0YQ IC InChI=1S/C15H18N2O/c16-14-10-9-11-5-4-8-13(15(11)17-14)18-12-6-2-1-3-7-12/h4-5,8-10,12H,1-3,6-7H2,(H2,16,17)
DMKT0YQ CS C1CCC(CC1)OC2=CC=CC3=C2N=C(C=C3)N
DMKT0YQ IK MPHNEJNPZMBSBN-UHFFFAOYSA-N
DMKT0YQ IU 8-cyclohexyloxyquinolin-2-amine
DMKT0YQ DE Discovery agent
DM16KZS ID DM16KZS
DM16KZS DN 8-Cyclopentylmethoxy-quinolin-2-ylamine
DM16KZS HS Investigative
DM16KZS SN CHEMBL186770; 8-Cyclopentylmethoxy-quinolin-2-ylamine; SCHEMBL5883835
DM16KZS DT Small molecular drug
DM16KZS PC 22254582
DM16KZS MW 242.32
DM16KZS FM C15H18N2O
DM16KZS IC InChI=1S/C15H18N2O/c16-14-9-8-12-6-3-7-13(15(12)17-14)18-10-11-4-1-2-5-11/h3,6-9,11H,1-2,4-5,10H2,(H2,16,17)
DM16KZS CS C1CCC(C1)COC2=CC=CC3=C2N=C(C=C3)N
DM16KZS IK KGRRNRLJYPHJMT-UHFFFAOYSA-N
DM16KZS IU 8-(cyclopentylmethoxy)quinolin-2-amine
DM16KZS DE Discovery agent
DMMITAJ ID DMMITAJ
DMMITAJ DN 8-cyclopentyltheophylline
DMMITAJ HS Investigative
DMMITAJ SN 8-Cyclopentyl-1,3-dimethylxanthine; 8-cyclopentyltheophylline; 35873-49-5; 8-Cyclopentyl theophylline; UNII-U7PWT4CPL5; U7PWT4CPL5; 8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione; NSC 101806; BRN 1133199; Xanthine, 8-cyclopentyl-1,3-dimethyl-; Theophylline, 8-cyclopentyl-; CHEMBL106265; 8-Cyclopentyl-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione; 1,3-dimethyl-8-cyclopentylxanthine; Spectrum_000351; Lopac-C-102; AC1Q6LAU; AC1L1CIO; Spectrum4_000760; Spectrum2_001734; Spectrum5_001769; Spectrum3_000658; NCIOpen2_006919; Lopac0_000391
DMMITAJ DT Small molecular drug
DMMITAJ PC 1917
DMMITAJ MW 248.28
DMMITAJ FM C12H16N4O2
DMMITAJ IC InChI=1S/C12H16N4O2/c1-15-10-8(11(17)16(2)12(15)18)13-9(14-10)7-5-3-4-6-7/h7H,3-6H2,1-2H3,(H,13,14)
DMMITAJ CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3CCCC3
DMMITAJ IK SCVHFRLUNIOSGI-UHFFFAOYSA-N
DMMITAJ IU 8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione
DMMITAJ CA CAS 35873-49-5
DMMITAJ CB CHEBI:109538
DMMITAJ DE Discovery agent
DMEOP4J ID DMEOP4J
DMEOP4J DN 8-DEOXYGARTANIN
DMEOP4J HS Investigative
DMEOP4J SN 8-Desoxygartanin; 8-DEOXYGARTANIN; 33390-41-9; CHEMBL488606; 1,3,5-trihydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,5-trihydroxy-2,4-bis(3-methylbut-2-en-1-yl)-9h-xanthen-9-one; 9H-Xanthen-9-one, 1,3,5-trihydroxy-2,4-bis(3-methyl-2-butenyl)-; Deoxygartinin; Desoxygartanin,8-; NSC692944; AC1L944B; SCHEMBL17056909; CTK8C7216; MolPort-039-052-631; ZINC5849312; BDBM50311742; AKOS028108663; NSC-692944; FT-0686569; 390D419; 1,3,5-Trihydroxy-2,4-bis(3-methyl-2-butenyl)-9H-xanthen-9-one
DMEOP4J DT Small molecular drug
DMEOP4J PC 392450
DMEOP4J MW 380.4
DMEOP4J FM C23H24O5
DMEOP4J IC InChI=1S/C23H24O5/c1-12(2)8-10-14-19(25)16(11-9-13(3)4)23-18(20(14)26)21(27)15-6-5-7-17(24)22(15)28-23/h5-9,24-26H,10-11H2,1-4H3
DMEOP4J CS CC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=C(O2)C(=CC=C3)O)CC=C(C)C)O)C
DMEOP4J IK GVQOVMKBYJKZSY-UHFFFAOYSA-N
DMEOP4J IU 1,3,5-trihydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one
DMEOP4J CA CAS 33390-41-9
DMEOP4J DE Discovery agent
DM7YW3B ID DM7YW3B
DM7YW3B DN 8-deoxy-neodysiherbaine
DM7YW3B HS Investigative
DM7YW3B SN 8-deoxy-neoDH
DM7YW3B DT Small molecular drug
DM7YW3B PC 73755079
DM7YW3B MW 274.25
DM7YW3B FM C11H16NO7-
DM7YW3B IC InChI=1S/C11H17NO7/c12-6(9(14)15)2-11(10(16)17)3-8-7(19-11)1-5(13)4-18-8/h5-8,13H,1-4,12H2,(H,14,15)(H,16,17)/p-1/t5-,6-,7?,8?,11+/m0/s1
DM7YW3B CS C1[C@@H](COC2C1O[C@@](C2)(C[C@@H](C(=O)[O-])[NH3+])C(=O)[O-])O
DM7YW3B IK JVLNPAVKDNEYGY-SCTSMQQKSA-M
DM7YW3B IU (2R,6S)-2-[(2S)-2-azaniumyl-2-carboxylatoethyl]-6-hydroxy-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylate
DM7YW3B DE Discovery agent
DMQJA4F ID DMQJA4F
DMQJA4F DN 8-Diazonium-naphthalene-1-sulfonic acid anion
DMQJA4F HS Investigative
DMQJA4F SN CHEMBL304774
DMQJA4F DT Small molecular drug
DMQJA4F PC 13948288
DMQJA4F MW 234.23
DMQJA4F FM C10H6N2O3S
DMQJA4F IC InChI=1S/C10H6N2O3S/c11-12-8-5-1-3-7-4-2-6-9(10(7)8)16(13,14)15/h1-6H
DMQJA4F CS C1=CC2=C(C(=C1)[N+]#N)C(=CC=C2)S(=O)(=O)[O-]
DMQJA4F IK FBINSYHNLCGKLZ-UHFFFAOYSA-N
DMQJA4F IU 8-diazonionaphthalene-1-sulfonate
DMQJA4F DE Discovery agent
DMUR97N ID DMUR97N
DMUR97N DN 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one
DMUR97N HS Investigative
DMUR97N SN CHEMBL186048; 503468-92-6; 8-(dibenzo[b,d]furan-4-yl)-2-morpholino-4H-chromen-4-one; 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one; 8-dibenzofuran-4-yl-2-morpholin-4-yl-chromen-4-one; SCHEMBL13346347; CTK1G6916; DTXSID50470335; BDBM50156503; AKOS030553517; 4H-1-Benzopyran-4-one, 8-(4-dibenzofuranyl)-2-(4-morpholinyl)-
DMUR97N DT Small molecular drug
DMUR97N PC 11668417
DMUR97N MW 397.4
DMUR97N FM C25H19NO4
DMUR97N IC InChI=1S/C25H19NO4/c27-21-15-23(26-11-13-28-14-12-26)30-25-19(8-4-9-20(21)25)18-7-3-6-17-16-5-1-2-10-22(16)29-24(17)18/h1-10,15H,11-14H2
DMUR97N CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4OC6=CC=CC=C56
DMUR97N IK LEWYWLXLBNVBFP-UHFFFAOYSA-N
DMUR97N IU 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one
DMUR97N CA CAS 503468-92-6
DMUR97N DE Discovery agent
DMY8W0K ID DMY8W0K
DMY8W0K DN 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMY8W0K HS Investigative
DMY8W0K SN 1H-1-Benzazepine-2,5-dione, 8-ethyl-3-hydroxy-; SCHEMBL9389409; CHEMBL143292; 183663-81-2
DMY8W0K DT Small molecular drug
DMY8W0K PC 10680274
DMY8W0K MW 217.22
DMY8W0K FM C12H11NO3
DMY8W0K IC InChI=1S/C12H11NO3/c1-2-7-3-4-8-9(5-7)13-12(16)11(15)6-10(8)14/h3-6,14H,2H2,1H3,(H,13,15,16)
DMY8W0K CS CCC1=CC2=C(C=C1)C(=CC(=O)C(=O)N2)O
DMY8W0K IK FPLGJFSMGRDPES-UHFFFAOYSA-N
DMY8W0K IU 8-ethyl-5-hydroxy-1H-1-benzazepine-2,3-dione
DMY8W0K DE Discovery agent
DMBZSAO ID DMBZSAO
DMBZSAO DN 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione
DMBZSAO HS Investigative
DMBZSAO SN 1H-1-Benzazepine-2,5-dione, 8-fluoro-3-hydroxy-; SCHEMBL9007832; CHEMBL142890; 144066-26-2
DMBZSAO DT Small molecular drug
DMBZSAO PC 15029643
DMBZSAO MW 207.16
DMBZSAO FM C10H6FNO3
DMBZSAO IC InChI=1S/C10H6FNO3/c11-5-1-2-6-7(3-5)12-10(15)9(14)4-8(6)13/h1-4,13H,(H,12,14,15)
DMBZSAO CS C1=CC2=C(C=C1F)NC(=O)C(=O)C=C2O
DMBZSAO IK ZAZQJJXYILGMQL-UHFFFAOYSA-N
DMBZSAO IU 8-fluoro-5-hydroxy-1H-1-benzazepine-2,3-dione
DMBZSAO DE Discovery agent
DMGJ3L6 ID DMGJ3L6
DMGJ3L6 DN 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol
DMGJ3L6 HS Investigative
DMGJ3L6 SN CHEMBL192386; 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol; SCHEMBL3924505; KBQSRNQTSRTYGN-UHFFFAOYSA-N; ZINC13645086; BDBM50168353
DMGJ3L6 DT Small molecular drug
DMGJ3L6 PC 10308090
DMGJ3L6 MW 254.25
DMGJ3L6 FM C16H11FO2
DMGJ3L6 IC InChI=1S/C16H11FO2/c17-16-8-12(10-1-4-13(18)5-2-10)7-11-3-6-14(19)9-15(11)16/h1-9,18-19H
DMGJ3L6 CS C1=CC(=CC=C1C2=CC(=C3C=C(C=CC3=C2)O)F)O
DMGJ3L6 IK KBQSRNQTSRTYGN-UHFFFAOYSA-N
DMGJ3L6 IU 8-fluoro-6-(4-hydroxyphenyl)naphthalen-2-ol
DMGJ3L6 DE Discovery agent
DMKPMFJ ID DMKPMFJ
DMKPMFJ DN 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMKPMFJ HS Investigative
DMKPMFJ SN CHEMBL370045; BDBM27512; indeno[1,2-c]isoquinolinone, 1d; ZINC13652896; 8-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
DMKPMFJ DT Small molecular drug
DMKPMFJ PC 25190931
DMKPMFJ MW 251.25
DMKPMFJ FM C16H10FNO
DMKPMFJ IC InChI=1S/C16H10FNO/c17-10-6-5-9-7-14-11-3-1-2-4-12(11)16(19)18-15(14)13(9)8-10/h1-6,8H,7H2,(H,18,19)
DMKPMFJ CS C1C2=C(C=C(C=C2)F)C3=C1C4=CC=CC=C4C(=O)N3
DMKPMFJ IK JDHAGQFOPJNKLS-UHFFFAOYSA-N
DMKPMFJ IU 8-fluoro-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMKPMFJ DE Discovery agent
DMPY9OI ID DMPY9OI
DMPY9OI DN 8-furan-2-yl-2-morpholin-4-ylchromen-4-one
DMPY9OI HS Investigative
DMPY9OI SN CHEMBL369990; 8-furan-2-yl-2-morpholin-4-ylchromen-4-one
DMPY9OI DT Small molecular drug
DMPY9OI PC 11637964
DMPY9OI MW 297.3
DMPY9OI FM C17H15NO4
DMPY9OI IC InChI=1S/C17H15NO4/c19-14-11-16(18-6-9-20-10-7-18)22-17-12(14)3-1-4-13(17)15-5-2-8-21-15/h1-5,8,11H,6-7,9-10H2
DMPY9OI CS C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CO4
DMPY9OI IK KEXLPFOPRBRYIA-UHFFFAOYSA-N
DMPY9OI IU 8-(furan-2-yl)-2-morpholin-4-ylchromen-4-one
DMPY9OI DE Discovery agent
DMFNCG8 ID DMFNCG8
DMFNCG8 DN 8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine
DMFNCG8 HS Investigative
DMFNCG8 SN CHEMBL360195; 8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine
DMFNCG8 DT Small molecular drug
DMFNCG8 PC 44392430
DMFNCG8 MW 338.4
DMFNCG8 FM C23H18N2O
DMFNCG8 IC InChI=1S/C23H18N2O/c24-23(25)19-9-8-18-12-17(7-6-16-4-2-1-3-5-16)13-21(22(18)14-19)20-10-11-26-15-20/h1-15H,(H3,24,25)/b7-6+
DMFNCG8 CS C1=CC=C(C=C1)/C=C/C2=CC(=C3C=C(C=CC3=C2)C(=N)N)C4=COC=C4
DMFNCG8 IK VWKDMGIRFQHGHQ-VOTSOKGWSA-N
DMFNCG8 IU 8-(furan-3-yl)-6-[(E)-2-phenylethenyl]naphthalene-2-carboximidamide
DMFNCG8 DE Discovery agent
DM7PJN9 ID DM7PJN9
DM7PJN9 DN 8-Hexyloxy-quinolin-2-ylamine
DM7PJN9 HS Investigative
DM7PJN9 SN CHEMBL187295; 8-Hexyloxy-quinolin-2-ylamine; SCHEMBL5884086
DM7PJN9 DT Small molecular drug
DM7PJN9 PC 10421932
DM7PJN9 MW 244.33
DM7PJN9 FM C15H20N2O
DM7PJN9 IC InChI=1S/C15H20N2O/c1-2-3-4-5-11-18-13-8-6-7-12-9-10-14(16)17-15(12)13/h6-10H,2-5,11H2,1H3,(H2,16,17)
DM7PJN9 CS CCCCCCOC1=CC=CC2=C1N=C(C=C2)N
DM7PJN9 IK SBZZEIZRHJBKKE-UHFFFAOYSA-N
DM7PJN9 IU 8-hexoxyquinolin-2-amine
DM7PJN9 DE Discovery agent
DMNE52B ID DMNE52B
DMNE52B DN 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DMNE52B HS Investigative
DMNE52B DT Small molecular drug
DMNE52B PC 135492389
DMNE52B MW 283.24
DMNE52B FM C14H9N3O4
DMNE52B IC InChI=1S/C14H9N3O4/c18-11-3-1-2-10-12(11)15-13(16-14(10)19)8-4-6-9(7-5-8)17(20)21/h1-7,18H,(H,15,16,19)
DMNE52B CS C1=CC2=C(C(=C1)O)N=C(NC2=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMNE52B IK FKPMZNSEGYFIDN-UHFFFAOYSA-N
DMNE52B IU 8-hydroxy-2-(4-nitrophenyl)-3H-quinazolin-4-one
DMNE52B CA CAS 172462-88-3
DMNE52B DE Discovery agent
DMKD2Q4 ID DMKD2Q4
DMKD2Q4 DN 8-Hydroxy-2-phenyl-3H-quinazolin-4-one
DMKD2Q4 HS Investigative
DMKD2Q4 DT Small molecular drug
DMKD2Q4 PC 135528341
DMKD2Q4 MW 238.24
DMKD2Q4 FM C14H10N2O2
DMKD2Q4 IC InChI=1S/C14H10N2O2/c17-11-8-4-7-10-12(11)15-13(16-14(10)18)9-5-2-1-3-6-9/h1-8,17H,(H,15,16,18)
DMKD2Q4 CS C1=CC=C(C=C1)C2=NC3=C(C=CC=C3O)C(=O)N2
DMKD2Q4 IK JRDFYUFZPYBDNH-UHFFFAOYSA-N
DMKD2Q4 IU 8-hydroxy-2-phenyl-3H-quinazolin-4-one
DMKD2Q4 DE Discovery agent
DMG4W2C ID DMG4W2C
DMG4W2C DN 8-Hydroxy-5,7,9-trimethyl-delta-carboline
DMG4W2C HS Investigative
DMG4W2C SN CHEMBL458947; 8-Hydroxy-5,7,9-trimethyl-delta-carboline
DMG4W2C DT Small molecular drug
DMG4W2C PC 44567454
DMG4W2C MW 226.27
DMG4W2C FM C14H14N2O
DMG4W2C IC InChI=1S/C14H14N2O/c1-8-7-11-12(9(2)14(8)17)13-10(16(11)3)5-4-6-15-13/h4-7,17H,1-3H3
DMG4W2C CS CC1=CC2=C(C(=C1O)C)C3=C(N2C)C=CC=N3
DMG4W2C IK HGIQNBUVVTWBSJ-UHFFFAOYSA-N
DMG4W2C IU 5,7,9-trimethylpyrido[3,2-b]indol-8-ol
DMG4W2C DE Discovery agent
DMFL46R ID DMFL46R
DMFL46R DN 8-Hydroxy-7,9-dimethyl-delta-carboline
DMFL46R HS Investigative
DMFL46R SN CHEMBL458465; 8-Hydroxy-7,9-dimethyl-delta-carboline
DMFL46R DT Small molecular drug
DMFL46R PC 25113696
DMFL46R MW 212.25
DMFL46R FM C13H12N2O
DMFL46R IC InChI=1S/C13H12N2O/c1-7-6-10-11(8(2)13(7)16)12-9(15-10)4-3-5-14-12/h3-6,15-16H,1-2H3
DMFL46R CS CC1=CC2=C(C(=C1O)C)C3=C(N2)C=CC=N3
DMFL46R IK ISLNUDFCPIKSRK-UHFFFAOYSA-N
DMFL46R IU 7,9-dimethyl-5H-pyrido[3,2-b]indol-8-ol
DMFL46R DE Discovery agent
DMT9BPN ID DMT9BPN
DMT9BPN DN 8-hydroxyguanine
DMT9BPN HS Investigative
DMT9BPN DT Small molecular drug
DMT9BPN PC 135420630
DMT9BPN MW 167.13
DMT9BPN FM C5H5N5O2
DMT9BPN IC InChI=1S/C5H5N5O2/c6-4-8-2-1(3(11)10-4)7-5(12)9-2/h(H5,6,7,8,9,10,11,12)
DMT9BPN CS C12=C(NC(=O)N1)N=C(NC2=O)N
DMT9BPN IK CLGFIVUFZRGQRP-UHFFFAOYSA-N
DMT9BPN IU 2-amino-7,9-dihydro-1H-purine-6,8-dione
DMT9BPN CA CAS 5614-64-2
DMT9BPN CB CHEBI:52617
DMT9BPN DE Discovery agent
DMA26L4 ID DMA26L4
DMA26L4 DN 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one
DMA26L4 HS Investigative
DMA26L4 SN CHEMBL351167; 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one; BDBM50097362; 8-((1H-imidazol-1-yl)methyl)-5-nitro-4H-chromen-4-one
DMA26L4 DT Small molecular drug
DMA26L4 PC 10659706
DMA26L4 MW 271.23
DMA26L4 FM C13H9N3O4
DMA26L4 IC InChI=1S/C13H9N3O4/c17-11-3-6-20-13-9(7-15-5-4-14-8-15)1-2-10(12(11)13)16(18)19/h1-6,8H,7H2
DMA26L4 CS C1=CC(=C2C(=O)C=COC2=C1CN3C=CN=C3)[N+](=O)[O-]
DMA26L4 IK YKATXTHPSQAGQZ-UHFFFAOYSA-N
DMA26L4 IU 8-(imidazol-1-ylmethyl)-5-nitrochromen-4-one
DMA26L4 DE Discovery agent
DM3K1EO ID DM3K1EO
DM3K1EO DN 8-Iodo-Guanine
DM3K1EO HS Investigative
DM3K1EO DT Small molecular drug
DM3K1EO PC 135431972
DM3K1EO MW 277.02
DM3K1EO FM C5H4IN5O
DM3K1EO IC InChI=1S/C5H4IN5O/c6-4-8-1-2(9-4)10-5(7)11-3(1)12/h(H4,7,8,9,10,11,12)
DM3K1EO CS C12=C(N=C(NC1=O)N)N=C(N2)I
DM3K1EO IK SXGFECRAKVVEJT-UHFFFAOYSA-N
DM3K1EO IU 2-amino-8-iodo-1,7-dihydropurin-6-one
DM3K1EO DE Discovery agent
DMBIAGJ ID DMBIAGJ
DMBIAGJ DN 8-Isopropoxy-quinolin-2-ylamine
DMBIAGJ HS Investigative
DMBIAGJ SN CHEMBL365254; 8-Isopropoxy-quinolin-2-ylamine; 2-Quinolinamine, 8-(1-methylethoxy)-; SCHEMBL5884565; BDBM50152417
DMBIAGJ DT Small molecular drug
DMBIAGJ PC 10198125
DMBIAGJ MW 202.25
DMBIAGJ FM C12H14N2O
DMBIAGJ IC InChI=1S/C12H14N2O/c1-8(2)15-10-5-3-4-9-6-7-11(13)14-12(9)10/h3-8H,1-2H3,(H2,13,14)
DMBIAGJ CS CC(C)OC1=CC=CC2=C1N=C(C=C2)N
DMBIAGJ IK IJQWZUBUZMKYCW-UHFFFAOYSA-N
DMBIAGJ IU 8-propan-2-yloxyquinolin-2-amine
DMBIAGJ DE Discovery agent
DMD3FWU ID DMD3FWU
DMD3FWU DN 8-Mercapto-octanoic acid phenylamide
DMD3FWU HS Investigative
DMD3FWU SN 8-Mercapto-octanoic acid phenylamide; 8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343
DMD3FWU DT Small molecular drug
DMD3FWU PC 11149404
DMD3FWU MW 251.39
DMD3FWU FM C14H21NOS
DMD3FWU IC InChI=1S/C14H21NOS/c16-14(11-7-2-1-3-8-12-17)15-13-9-5-4-6-10-13/h4-6,9-10,17H,1-3,7-8,11-12H2,(H,15,16)
DMD3FWU CS C1=CC=C(C=C1)NC(=O)CCCCCCCS
DMD3FWU IK VTVJPXWTXILBGK-UHFFFAOYSA-N
DMD3FWU IU N-phenyl-8-sulfanyloctanamide
DMD3FWU DE Discovery agent
DMY50UR ID DMY50UR
DMY50UR DN 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline
DMY50UR HS Investigative
DMY50UR SN CHEMBL338311; 8-methoxy-1,2,3,4-tetrahydrobenzo[h]isoquinoline; 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline; BDBM50061314; ZINC13766766
DMY50UR DT Small molecular drug
DMY50UR PC 44352179
DMY50UR MW 213.27
DMY50UR FM C14H15NO
DMY50UR IC InChI=1S/C14H15NO/c1-16-12-4-5-13-11(8-12)3-2-10-6-7-15-9-14(10)13/h2-5,8,15H,6-7,9H2,1H3
DMY50UR CS COC1=CC2=C(C=C1)C3=C(CCNC3)C=C2
DMY50UR IK LTVUTAZPBISUIF-UHFFFAOYSA-N
DMY50UR IU 8-methoxy-1,2,3,4-tetrahydrobenzo[h]isoquinoline
DMY50UR DE Discovery agent
DMFOM10 ID DMFOM10
DMFOM10 DN 8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine
DMFOM10 HS Investigative
DMFOM10 SN 8-Methoxy-2-aminotetralin; 3880-77-1; 8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine; CHEMBL26688; ACMC-20msdp; ACMC-20mscg; 2-amino-8-methoxytetralin; 8-methoxytetralin-2-amine; 8-methoxy-2-amino-tetralin; 2-Naphthalenamine,1,2,3,4-tetrahydro-8-methoxy-, (2R)-; 2-Naphthalenamine,1,2,3,4-tetrahydro-8-methoxy-, (2S)-; SCHEMBL266921; CTK4I0515; 2-NAPHTHALENAMINE, 1,2,3,4-TETRAHYDRO-8-METHOXY-; RVKOHSCTEHZRRT-UHFFFAOYSA-N; MFCD00906373; BDBM50016733; AKOS022393176; FCH1122360
DMFOM10 DT Small molecular drug
DMFOM10 PC 10197933
DMFOM10 MW 177.24
DMFOM10 FM C11H15NO
DMFOM10 IC InChI=1S/C11H15NO/c1-13-11-4-2-3-8-5-6-9(12)7-10(8)11/h2-4,9H,5-7,12H2,1H3
DMFOM10 CS COC1=CC=CC2=C1CC(CC2)N
DMFOM10 IK RVKOHSCTEHZRRT-UHFFFAOYSA-N
DMFOM10 IU 8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine
DMFOM10 CA CAS 3880-77-1
DMFOM10 DE Discovery agent
DM0Y52J ID DM0Y52J
DM0Y52J DN 8-Methoxy-1,4-dimethylquinolin-2(1H)-one
DM0Y52J HS Investigative
DM0Y52J SN 8-Methoxy-1,4-dimethylquinolin-2(1H)-one; 8-methoxy-1,4-dimethyl-1h-quinolin-2-one; 63791-96-8; casimiroin analogue, 1f; AC1NT5XU; CHEMBL506858; SCHEMBL17509827; BDBM29217; NCNFIHNRVBJRPR-UHFFFAOYSA-N; MolPort-028-745-487; ZINC33835729; 8-methoxy-1,4-dimethylquinolin-2-one; 1,4-Dimethyl-8-methoxyquinoline-2(1H)-one
DM0Y52J DT Small molecular drug
DM0Y52J PC 5324988
DM0Y52J MW 203.24
DM0Y52J FM C12H13NO2
DM0Y52J IC InChI=1S/C12H13NO2/c1-8-7-11(14)13(2)12-9(8)5-4-6-10(12)15-3/h4-7H,1-3H3
DM0Y52J CS CC1=CC(=O)N(C2=C1C=CC=C2OC)C
DM0Y52J IK NCNFIHNRVBJRPR-UHFFFAOYSA-N
DM0Y52J IU 8-methoxy-1,4-dimethylquinolin-2-one
DM0Y52J DE Discovery agent
DMQIFZC ID DMQIFZC
DMQIFZC DN 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline
DMQIFZC HS Investigative
DMQIFZC SN CHEMBL80775; 8-Methoxy-N-methylquipazine; 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline; BDBM50025469
DMQIFZC DT Small molecular drug
DMQIFZC PC 44316216
DMQIFZC MW 257.329
DMQIFZC FM C15H19N3O
DMQIFZC IC InChI=1S/C15H19N3O/c1-17-8-10-18(11-9-17)14-7-6-12-4-3-5-13(19-2)15(12)16-14/h3-7H,8-11H2,1-2H3
DMQIFZC CS CN1CCN(CC1)C2=NC3=C(C=CC=C3OC)C=C2
DMQIFZC IK XPBCUYLZAWCBJJ-UHFFFAOYSA-N
DMQIFZC IU 8-methoxy-2-(4-methylpiperazin-1-yl)quinoline
DMQIFZC DE Discovery agent
DMSN0ZE ID DMSN0ZE
DMSN0ZE DN 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DMSN0ZE HS Investigative
DMSN0ZE DT Small molecular drug
DMSN0ZE PC 135417274
DMSN0ZE MW 297.26
DMSN0ZE FM C15H11N3O4
DMSN0ZE IC InChI=1S/C15H11N3O4/c1-22-12-4-2-3-11-13(12)16-14(17-15(11)19)9-5-7-10(8-6-9)18(20)21/h2-8H,1H3,(H,16,17,19)
DMSN0ZE CS COC1=CC=CC2=C1N=C(NC2=O)C3=CC=C(C=C3)[N+](=O)[O-]
DMSN0ZE IK PGAMJHQYVDYIQX-UHFFFAOYSA-N
DMSN0ZE IU 8-methoxy-2-(4-nitrophenyl)-3H-quinazolin-4-one
DMSN0ZE DE Discovery agent
DMHE7J5 ID DMHE7J5
DMHE7J5 DN 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline
DMHE7J5 HS Investigative
DMHE7J5 SN CHEMBL269571; 8-Methoxy-1,2,3,4-tetrahydro-beta-carboline; 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline; BDBM50136502; AKOS022647299; 122835-07-8
DMHE7J5 DT Small molecular drug
DMHE7J5 PC 14355088
DMHE7J5 MW 202.25
DMHE7J5 FM C12H14N2O
DMHE7J5 IC InChI=1S/C12H14N2O/c1-15-11-4-2-3-9-8-5-6-13-7-10(8)14-12(9)11/h2-4,13-14H,5-7H2,1H3
DMHE7J5 CS COC1=CC=CC2=C1NC3=C2CCNC3
DMHE7J5 IK KKTKOWJABJYACN-UHFFFAOYSA-N
DMHE7J5 IU 8-methoxy-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMHE7J5 DE Discovery agent
DMOPN4K ID DMOPN4K
DMOPN4K DN 8-Methoxy-2-methyl-3H-quinazolin-4-one
DMOPN4K HS Investigative
DMOPN4K DT Small molecular drug
DMOPN4K PC 135411146
DMOPN4K MW 190.2
DMOPN4K FM C10H10N2O2
DMOPN4K IC InChI=1S/C10H10N2O2/c1-6-11-9-7(10(13)12-6)4-3-5-8(9)14-2/h3-5H,1-2H3,(H,11,12,13)
DMOPN4K CS CC1=NC2=C(C=CC=C2OC)C(=O)N1
DMOPN4K IK ZWCBMSNYXIFTCM-UHFFFAOYSA-N
DMOPN4K IU 8-methoxy-2-methyl-3H-quinazolin-4-one
DMOPN4K CA CAS 90915-45-0
DMOPN4K DE Discovery agent
DMYE1X2 ID DMYE1X2
DMYE1X2 DN 8-Methoxy-2-morpholin-4-yl-chromen-4-one
DMYE1X2 HS Investigative
DMYE1X2 SN CHEMBL97024; 8-methoxy-2-morpholin-4-yl-chromen-4-one; SCHEMBL3542889; BDBM50159658
DMYE1X2 DT Small molecular drug
DMYE1X2 PC 11482391
DMYE1X2 MW 261.269
DMYE1X2 FM C14H15NO4
DMYE1X2 IC InChI=1S/C14H15NO4/c1-17-12-4-2-3-10-11(16)9-13(19-14(10)12)15-5-7-18-8-6-15/h2-4,9H,5-8H2,1H3
DMYE1X2 CS COC1=CC=CC2=C1OC(=CC2=O)N3CCOCC3
DMYE1X2 IK USIRKXHEGVTPLO-UHFFFAOYSA-N
DMYE1X2 IU 8-methoxy-2-morpholin-4-ylchromen-4-one
DMYE1X2 DE Discovery agent
DMHCWY8 ID DMHCWY8
DMHCWY8 DN 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
DMHCWY8 HS Investigative
DMHCWY8 SN 8-Methoxy-2-oxo-2H-chromene-3-carboxylic acid; 2555-20-6; 8-methoxy-2-oxochromene-3-carboxylic acid; 8-methoxycoumarin-3-carboxylic acid; CHEMBL568348; SFAPWVZFUHJZIC-UHFFFAOYSA-N; 2H-1-Benzopyran-3-carboxylic acid, 8-methoxy-2-oxo-; NSC34647; AC1L5SHQ; AC1Q5T4B; 3-Carboxy-8-methoxycoumarin; Oprea1_510137; Oprea1_497732; 8-methoxy-3-carboxy-coumarin; SCHEMBL980310; methoxyoxochromenecarboxylicacid; SCHEMBL3659230; ZINC84532; KS-00001VYM; CTK4F6014; DTXSID30283980; MolPort-000-145-720; ALBB-000306; NSC-34647; STK411116; BBL013903
DMHCWY8 DT Small molecular drug
DMHCWY8 PC 234562
DMHCWY8 MW 220.18
DMHCWY8 FM C11H8O5
DMHCWY8 IC InChI=1S/C11H8O5/c1-15-8-4-2-3-6-5-7(10(12)13)11(14)16-9(6)8/h2-5H,1H3,(H,12,13)
DMHCWY8 CS COC1=CC=CC2=C1OC(=O)C(=C2)C(=O)O
DMHCWY8 IK SFAPWVZFUHJZIC-UHFFFAOYSA-N
DMHCWY8 IU 8-methoxy-2-oxochromene-3-carboxylic acid
DMHCWY8 CA CAS 2555-20-6
DMHCWY8 DE Discovery agent
DM56EW7 ID DM56EW7
DM56EW7 DN 8-Methoxy-2-phenyl-3H-quinazolin-4-one
DM56EW7 HS Investigative
DM56EW7 DT Small molecular drug
DM56EW7 PC 135439437
DM56EW7 MW 252.27
DM56EW7 FM C15H12N2O2
DM56EW7 IC InChI=1S/C15H12N2O2/c1-19-12-9-5-8-11-13(12)16-14(17-15(11)18)10-6-3-2-4-7-10/h2-9H,1H3,(H,16,17,18)
DM56EW7 CS COC1=CC=CC2=C1N=C(NC2=O)C3=CC=CC=C3
DM56EW7 IK XMLHWESTKAFTNA-UHFFFAOYSA-N
DM56EW7 IU 8-methoxy-2-phenyl-3H-quinazolin-4-one
DM56EW7 CA CAS 172462-89-4
DM56EW7 DE Discovery agent
DMNWC29 ID DMNWC29
DMNWC29 DN 8-Methoxy-2-piperazin-1-yl-quinoline
DMNWC29 HS Investigative
DMNWC29 SN 8-Methoxy-2-piperazin-1-yl-quinoline; CHEMBL80691; Quinoline, 8-methoxy-2-(1-piperazinyl)-; 104090-79-1; 8-Methoxyquipazine; ACMC-20m6vj; SCHEMBL6767019; CTK0G6599; DTXSID30627183; CUULVNAZRYFNIT-UHFFFAOYSA-N; ZINC26467647; BDBM50025465; AKOS022401904
DMNWC29 DT Small molecular drug
DMNWC29 PC 22636319
DMNWC29 MW 243.3
DMNWC29 FM C14H17N3O
DMNWC29 IC InChI=1S/C14H17N3O/c1-18-12-4-2-3-11-5-6-13(16-14(11)12)17-9-7-15-8-10-17/h2-6,15H,7-10H2,1H3
DMNWC29 CS COC1=CC=CC2=C1N=C(C=C2)N3CCNCC3
DMNWC29 IK CUULVNAZRYFNIT-UHFFFAOYSA-N
DMNWC29 IU 8-methoxy-2-piperazin-1-ylquinoline
DMNWC29 CA CAS 104090-79-1
DMNWC29 DE Discovery agent
DM8MBSN ID DM8MBSN
DM8MBSN DN 8-Methoxy-4,9-dihydro-3H-beta-carboline
DM8MBSN HS Investigative
DM8MBSN SN CHEMBL269367; 8-Methoxy-4,9-dihydro-3H-beta-carboline; BDBM50136509; 8-Methoxy-3,4-dihydro-beta-carboline
DM8MBSN DT Small molecular drug
DM8MBSN PC 14355089
DM8MBSN MW 200.24
DM8MBSN FM C12H12N2O
DM8MBSN IC InChI=1S/C12H12N2O/c1-15-11-4-2-3-9-8-5-6-13-7-10(8)14-12(9)11/h2-4,7,14H,5-6H2,1H3
DM8MBSN CS COC1=CC=CC2=C1NC3=C2CCN=C3
DM8MBSN IK LIUNAKJFUYIJFE-UHFFFAOYSA-N
DM8MBSN IU 8-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DM8MBSN DE Discovery agent
DMK6U2V ID DMK6U2V
DMK6U2V DN 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine
DMK6U2V HS Investigative
DMK6U2V SN CHEMBL408152; SCHEMBL1382388; SCKPQZMXGISHHF-UHFFFAOYSA-N; BDBM50371445; 918136-34-2; 8-Methoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamine; 2-Quinazolinamine, 1,4-dihydro-8-methoxy-4-methyl-
DMK6U2V DT Small molecular drug
DMK6U2V PC 16006606
DMK6U2V MW 191.23
DMK6U2V FM C10H13N3O
DMK6U2V IC InChI=1S/C10H13N3O/c1-6-7-4-3-5-8(14-2)9(7)13-10(11)12-6/h3-6H,1-2H3,(H3,11,12,13)
DMK6U2V CS CC1C2=C(C(=CC=C2)OC)NC(=N1)N
DMK6U2V IK SCKPQZMXGISHHF-UHFFFAOYSA-N
DMK6U2V IU 8-methoxy-4-methyl-1,4-dihydroquinazolin-2-amine
DMK6U2V DE Discovery agent
DMHLKAE ID DMHLKAE
DMHLKAE DN 8-Methoxy-4-morpholin-4-yl-chromen-2-one
DMHLKAE HS Investigative
DMHLKAE SN CHEMBL176325; 8-methoxy-4-morpholin-4-yl-chromen-2-one
DMHLKAE DT Small molecular drug
DMHLKAE PC 11346012
DMHLKAE MW 261.269
DMHLKAE FM C14H15NO4
DMHLKAE IC InChI=1S/C14H15NO4/c1-17-12-4-2-3-10-11(9-13(16)19-14(10)12)15-5-7-18-8-6-15/h2-4,9H,5-8H2,1H3
DMHLKAE CS COC1=CC=CC2=C1OC(=O)C=C2N3CCOCC3
DMHLKAE IK QMOLGKOGXTXVPG-UHFFFAOYSA-N
DMHLKAE IU 8-methoxy-4-morpholin-4-ylchromen-2-one
DMHLKAE DE Discovery agent
DMHZ5SB ID DMHZ5SB
DMHZ5SB DN 8-Methoxy-quinolin-2-ylamine
DMHZ5SB HS Investigative
DMHZ5SB SN 2-Quinolinamine, 8-methoxy-; 8-Methoxyquinolin-2-amine; 104090-86-0; CHEMBL77072; 8-Methoxy-quinolin-2-ylamine; ACMC-20m6vk; SCHEMBL1655715; CTK0G6598; DTXSID90624077; MolPort-020-915-686; PMXFKGCLUAFLMH-UHFFFAOYSA-N; 2-AMINO-8-METHOXYQUINOLINE; ZINC26399714; BDBM50025466; AKOS013465271
DMHZ5SB DT Small molecular drug
DMHZ5SB PC 22266820
DMHZ5SB MW 174.2
DMHZ5SB FM C10H10N2O
DMHZ5SB IC InChI=1S/C10H10N2O/c1-13-8-4-2-3-7-5-6-9(11)12-10(7)8/h2-6H,1H3,(H2,11,12)
DMHZ5SB CS COC1=CC=CC2=C1N=C(C=C2)N
DMHZ5SB IK PMXFKGCLUAFLMH-UHFFFAOYSA-N
DMHZ5SB IU 8-methoxyquinolin-2-amine
DMHZ5SB CA CAS 104090-86-0
DMHZ5SB DE Discovery agent
DM92XPO ID DM92XPO
DM92XPO DN 8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one
DM92XPO HS Investigative
DM92XPO SN CHEMBL97922; SCHEMBL10757167
DM92XPO DT Small molecular drug
DM92XPO PC 15065156
DM92XPO MW 199.21
DM92XPO FM C11H9N3O
DM92XPO IC InChI=1S/C11H9N3O/c1-6-3-2-4-8-7(6)5-9-10(12-8)14-11(15)13-9/h2-5H,1H3,(H2,12,13,14,15)
DM92XPO CS CC1=C2C=C3C(=NC2=CC=C1)NC(=O)N3
DM92XPO IK NFWDGDAZJTYAHA-UHFFFAOYSA-N
DM92XPO IU 8-methyl-1,3-dihydroimidazo[4,5-b]quinolin-2-one
DM92XPO DE Discovery agent
DM7FSZM ID DM7FSZM
DM7FSZM DN 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one
DM7FSZM HS Investigative
DM7FSZM DT Small molecular drug
DM7FSZM PC 135457978
DM7FSZM MW 281.27
DM7FSZM FM C15H11N3O3
DM7FSZM IC InChI=1S/C15H11N3O3/c1-9-3-2-4-12-13(9)16-14(17-15(12)19)10-5-7-11(8-6-10)18(20)21/h2-8H,1H3,(H,16,17,19)
DM7FSZM CS CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=C(C=C3)[N+](=O)[O-]
DM7FSZM IK NSQTWPGTGYHDIM-UHFFFAOYSA-N
DM7FSZM IU 8-methyl-2-(4-nitrophenyl)-3H-quinazolin-4-one
DM7FSZM DE Discovery agent
DMLQ90D ID DMLQ90D
DMLQ90D DN 8-Methyl-2-morpholin-4-yl-chromen-4-one
DMLQ90D HS Investigative
DMLQ90D SN CHEMBL179635; 8-methyl-2-morpholin-4-yl-chromen-4-one; SCHEMBL3539026; BDBM50159667
DMLQ90D DT Small molecular drug
DMLQ90D PC 10083230
DMLQ90D MW 245.27
DMLQ90D FM C14H15NO3
DMLQ90D IC InChI=1S/C14H15NO3/c1-10-3-2-4-11-12(16)9-13(18-14(10)11)15-5-7-17-8-6-15/h2-4,9H,5-8H2,1H3
DMLQ90D CS CC1=C2C(=CC=C1)C(=O)C=C(O2)N3CCOCC3
DMLQ90D IK OHUSJSSDFKPFTJ-UHFFFAOYSA-N
DMLQ90D IU 8-methyl-2-morpholin-4-ylchromen-4-one
DMLQ90D DE Discovery agent
DMWZ27A ID DMWZ27A
DMWZ27A DN 8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one
DMWZ27A HS Investigative
DMWZ27A SN CHEMBL203942
DMWZ27A DT Small molecular drug
DMWZ27A PC 23586753
DMWZ27A MW 337.4
DMWZ27A FM C20H19NO4
DMWZ27A IC InChI=1S/C20H19NO4/c1-14-18(24-15-5-3-2-4-6-15)8-7-16-17(22)13-19(25-20(14)16)21-9-11-23-12-10-21/h2-8,13H,9-12H2,1H3
DMWZ27A CS CC1=C(C=CC2=C1OC(=CC2=O)N3CCOCC3)OC4=CC=CC=C4
DMWZ27A IK OOXOMHKMWGSWSD-UHFFFAOYSA-N
DMWZ27A IU 8-methyl-2-morpholin-4-yl-7-phenoxychromen-4-one
DMWZ27A DE Discovery agent
DMUI1YZ ID DMUI1YZ
DMUI1YZ DN 8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one
DMUI1YZ HS Investigative
DMUI1YZ SN CHEMBL95782
DMUI1YZ DT Small molecular drug
DMUI1YZ PC 21460270
DMUI1YZ MW 321.4
DMUI1YZ FM C20H19NO3
DMUI1YZ IC InChI=1S/C20H19NO3/c1-14-16(15-5-3-2-4-6-15)7-8-17-18(22)13-19(24-20(14)17)21-9-11-23-12-10-21/h2-8,13H,9-12H2,1H3
DMUI1YZ CS CC1=C(C=CC2=C1OC(=CC2=O)N3CCOCC3)C4=CC=CC=C4
DMUI1YZ IK ZMYPEBFYGCAKQT-UHFFFAOYSA-N
DMUI1YZ IU 8-methyl-2-morpholin-4-yl-7-phenylchromen-4-one
DMUI1YZ DE Discovery agent
DMEM6Q0 ID DMEM6Q0
DMEM6Q0 DN 8-Methyl-2-phenyl-3H-quinazolin-4-one
DMEM6Q0 HS Investigative
DMEM6Q0 DT Small molecular drug
DMEM6Q0 PC 135531482
DMEM6Q0 MW 236.27
DMEM6Q0 FM C15H12N2O
DMEM6Q0 IC InChI=1S/C15H12N2O/c1-10-6-5-9-12-13(10)16-14(17-15(12)18)11-7-3-2-4-8-11/h2-9H,1H3,(H,16,17,18)
DMEM6Q0 CS CC1=C2C(=CC=C1)C(=O)NC(=N2)C3=CC=CC=C3
DMEM6Q0 IK WLZJEOODSSBWMB-UHFFFAOYSA-N
DMEM6Q0 IU 8-methyl-2-phenyl-3H-quinazolin-4-one
DMEM6Q0 DE Discovery agent
DMOM4VS ID DMOM4VS
DMOM4VS DN 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane
DMOM4VS HS Investigative
DMOM4VS SN CHEMBL82027; 130342-81-3; ACMC-20mtlb; 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane; SCHEMBL12959169; 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester; 8-Azabicyclo[3.2.1]octane-2-carboxylicacid, 8-methyl-3-(4-methylphenyl)-, methyl ester, (1R,2S,3S,5S)-
DMOM4VS DT Small molecular drug
DMOM4VS PC 9881979
DMOM4VS MW 273.37
DMOM4VS FM C17H23NO2
DMOM4VS IC InChI=1S/C17H23NO2/c1-11-4-6-12(7-5-11)14-10-13-8-9-15(18(13)2)16(14)17(19)20-3/h4-7,13-16H,8-10H2,1-3H3
DMOM4VS CS CC1=CC=C(C=C1)C2CC3CCC(C2C(=O)OC)N3C
DMOM4VS IK MMKZDDDDODERSJ-UHFFFAOYSA-N
DMOM4VS IU methyl 8-methyl-3-(4-methylphenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
DMOM4VS DE Discovery agent
DMA28OL ID DMA28OL
DMA28OL DN 8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one
DMA28OL HS Investigative
DMA28OL SN CHEMBL388936; 8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one
DMA28OL DT Small molecular drug
DMA28OL PC 44425819
DMA28OL MW 222.24
DMA28OL FM C14H10N2O
DMA28OL IC InChI=1S/C14H10N2O/c1-7-5-9-8-3-2-4-11-13(8)10(14(17)16-11)6-12(9)15-7/h2-6,15H,1H3,(H,16,17)
DMA28OL CS CC1=CC2=C(N1)C=C3C4=C2C=CC=C4NC3=O
DMA28OL IK ACTSTIBGWRUXHI-UHFFFAOYSA-N
DMA28OL IU 4-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),2(6),3,7,11,13-hexaen-9-one
DMA28OL DE Discovery agent
DMVAOIG ID DMVAOIG
DMVAOIG DN 8-Methyl-4-morpholin-4-yl-chromen-2-one
DMVAOIG HS Investigative
DMVAOIG SN CHEMBL369452; 8-methyl-4-morpholin-4-yl-chromen-2-one
DMVAOIG DT Small molecular drug
DMVAOIG PC 10857738
DMVAOIG MW 245.27
DMVAOIG FM C14H15NO3
DMVAOIG IC InChI=1S/C14H15NO3/c1-10-3-2-4-11-12(9-13(16)18-14(10)11)15-5-7-17-8-6-15/h2-4,9H,5-8H2,1H3
DMVAOIG CS CC1=C2C(=CC=C1)C(=CC(=O)O2)N3CCOCC3
DMVAOIG IK HXUJEFDGGXBUQX-UHFFFAOYSA-N
DMVAOIG IU 8-methyl-4-morpholin-4-ylchromen-2-one
DMVAOIG DE Discovery agent
DMK63P2 ID DMK63P2
DMK63P2 DN 8-methylnaringenin
DMK63P2 HS Investigative
DMK63P2 SN 8-methylnaringenin; CHEMBL426154; MolPort-039-339-073; ZINC14814929; 5,7,4'-Trihydroxy-8-methylflavanone
DMK63P2 DT Small molecular drug
DMK63P2 PC 44418717
DMK63P2 MW 286.28
DMK63P2 FM C16H14O5
DMK63P2 IC InChI=1S/C16H14O5/c1-8-11(18)6-12(19)15-13(20)7-14(21-16(8)15)9-2-4-10(17)5-3-9/h2-6,14,17-19H,7H2,1H3/t14-/m0/s1
DMK63P2 CS CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMK63P2 IK GMVYLXBMPRDZDR-AWEZNQCLSA-N
DMK63P2 IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-methyl-2,3-dihydrochromen-4-one
DMK63P2 DE Discovery agent
DMWMVI3 ID DMWMVI3
DMWMVI3 DN 8-n-heptylnaringenin
DMWMVI3 HS Investigative
DMWMVI3 SN 8-n-heptylnaringenin
DMWMVI3 DT Small molecular drug
DMWMVI3 PC 44418724
DMWMVI3 MW 370.4
DMWMVI3 FM C22H26O5
DMWMVI3 IC InChI=1S/C22H26O5/c1-2-3-4-5-6-7-16-17(24)12-18(25)21-19(26)13-20(27-22(16)21)14-8-10-15(23)11-9-14/h8-12,20,23-25H,2-7,13H2,1H3/t20-/m0/s1
DMWMVI3 CS CCCCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMWMVI3 IK JDJYVQUSVHXJHY-FQEVSTJZSA-N
DMWMVI3 IU (2S)-8-heptyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMWMVI3 DE Discovery agent
DM5L40C ID DM5L40C
DM5L40C DN 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DM5L40C HS Investigative
DM5L40C SN SCHEMBL4661629; CHEMBL370673; BDBM27510; SWBDUXDIPMGDNO-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 1b; ZINC13652894; 5,6-dihydro-5-oxo-8-nitro-indeno[1,2-c]isoquinoline; 8-Nitro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
DM5L40C DT Small molecular drug
DM5L40C PC 25190929
DM5L40C MW 278.26
DM5L40C FM C16H10N2O3
DM5L40C IC InChI=1S/C16H10N2O3/c19-16-12-4-2-1-3-11(12)14-7-9-5-6-10(18(20)21)8-13(9)15(14)17-16/h1-6,8H,7H2,(H,17,19)
DM5L40C CS C1C2=C(C=C(C=C2)[N+](=O)[O-])C3=C1C4=CC=CC=C4C(=O)N3
DM5L40C IK SWBDUXDIPMGDNO-UHFFFAOYSA-N
DM5L40C IU 8-nitro-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DM5L40C DE Discovery agent
DMC2JLQ ID DMC2JLQ
DMC2JLQ DN 8-n-nonylnaringenin
DMC2JLQ HS Investigative
DMC2JLQ SN 8-n-nonylnaringenin
DMC2JLQ DT Small molecular drug
DMC2JLQ PC 44418725
DMC2JLQ MW 398.5
DMC2JLQ FM C24H30O5
DMC2JLQ IC InChI=1S/C24H30O5/c1-2-3-4-5-6-7-8-9-18-19(26)14-20(27)23-21(28)15-22(29-24(18)23)16-10-12-17(25)13-11-16/h10-14,22,25-27H,2-9,15H2,1H3/t22-/m0/s1
DMC2JLQ CS CCCCCCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMC2JLQ IK PGTXFXPDRFSQPT-QFIPXVFZSA-N
DMC2JLQ IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-nonyl-2,3-dihydrochromen-4-one
DMC2JLQ DE Discovery agent
DMRDOP0 ID DMRDOP0
DMRDOP0 DN 8-n-pentylnaringenin
DMRDOP0 HS Investigative
DMRDOP0 SN 8-n-pentylnaringenin
DMRDOP0 DT Small molecular drug
DMRDOP0 PC 44418723
DMRDOP0 MW 342.4
DMRDOP0 FM C20H22O5
DMRDOP0 IC InChI=1S/C20H22O5/c1-2-3-4-5-14-15(22)10-16(23)19-17(24)11-18(25-20(14)19)12-6-8-13(21)9-7-12/h6-10,18,21-23H,2-5,11H2,1H3/t18-/m0/s1
DMRDOP0 CS CCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMRDOP0 IK NKWHELZNPRCJAS-SFHVURJKSA-N
DMRDOP0 IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-pentyl-2,3-dihydrochromen-4-one
DMRDOP0 DE Discovery agent
DMDOW5S ID DMDOW5S
DMDOW5S DN 8-n-propylnaringenin
DMDOW5S HS Investigative
DMDOW5S SN 8-n-propylnaringenin
DMDOW5S DT Small molecular drug
DMDOW5S PC 44418722
DMDOW5S MW 314.3
DMDOW5S FM C18H18O5
DMDOW5S IC InChI=1S/C18H18O5/c1-2-3-12-13(20)8-14(21)17-15(22)9-16(23-18(12)17)10-4-6-11(19)7-5-10/h4-8,16,19-21H,2-3,9H2,1H3/t16-/m0/s1
DMDOW5S CS CCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMDOW5S IK PFCDDRUHZAMKHP-INIZCTEOSA-N
DMDOW5S IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-propyl-2,3-dihydrochromen-4-one
DMDOW5S DE Discovery agent
DMXURM8 ID DMXURM8
DMXURM8 DN 8-n-undecylnaringenin
DMXURM8 HS Investigative
DMXURM8 SN 8-n-undecylnaringenin
DMXURM8 DT Small molecular drug
DMXURM8 PC 44418726
DMXURM8 MW 426.5
DMXURM8 FM C26H34O5
DMXURM8 IC InChI=1S/C26H34O5/c1-2-3-4-5-6-7-8-9-10-11-20-21(28)16-22(29)25-23(30)17-24(31-26(20)25)18-12-14-19(27)15-13-18/h12-16,24,27-29H,2-11,17H2,1H3/t24-/m0/s1
DMXURM8 CS CCCCCCCCCCCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O
DMXURM8 IK MQGTUCCMXKRAMD-DEOSSOPVSA-N
DMXURM8 IU (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-undecyl-2,3-dihydrochromen-4-one
DMXURM8 DE Discovery agent
DMDRPLA ID DMDRPLA
DMDRPLA DN 8-O-(4-bromobenzenesulfonyl)manzamine F
DMDRPLA HS Investigative
DMDRPLA SN CHEMBL414128; 8-O-(4-bromobenzenesulfonyl)manzamine F
DMDRPLA DT Small molecular drug
DMDRPLA PC 23643732
DMDRPLA MW 799.8
DMDRPLA FM C42H47BrN4O5S
DMDRPLA IC InChI=1S/C42H47BrN4O5S/c43-28-12-16-31(17-13-28)53(50,51)52-36-11-7-10-32-33-18-21-44-38(39(33)45-37(32)36)34-26-42(49)20-5-3-1-2-4-6-22-46-24-19-35(34)41(27-46)25-29-14-15-30(48)9-8-23-47(29)40(41)42/h1,3,7,10-13,16-18,21,26,29,35,40,45,49H,2,4-6,8-9,14-15,19-20,22-25,27H2/b3-1-/t29-,35?,40+,41-,42-/m0/s1
DMDRPLA CS C1CCN2CCC3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]5N4CCCC(=O)CC5)O)C6=NC=CC7=C6NC8=C7C=CC=C8OS(=O)(=O)C9=CC=C(C=C9)Br
DMDRPLA IK WYQZODVBTOVVOF-WXPZYUJUSA-N
DMDRPLA IU [1-[(2R,4S,12R,13S,16Z)-13-hydroxy-7-oxo-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-16,25-dien-25-yl]-9H-pyrido[3,4-b]indol-8-yl] 4-bromobenzenesulfonate
DMDRPLA DE Discovery agent
DM48JMC ID DM48JMC
DM48JMC DN 8-O-(4-chlorobenzenesulfonyl)manzamine F
DM48JMC HS Investigative
DM48JMC SN CHEMBL400717; 8-O-(4-chlorobenzenesulfonyl)manzamine F
DM48JMC DT Small molecular drug
DM48JMC PC 23643731
DM48JMC MW 755.4
DM48JMC FM C42H47ClN4O5S
DM48JMC IC InChI=1S/C42H47ClN4O5S/c43-28-12-16-31(17-13-28)53(50,51)52-36-11-7-10-32-33-18-21-44-38(39(33)45-37(32)36)34-26-42(49)20-5-3-1-2-4-6-22-46-24-19-35(34)41(27-46)25-29-14-15-30(48)9-8-23-47(29)40(41)42/h1,3,7,10-13,16-18,21,26,29,35,40,45,49H,2,4-6,8-9,14-15,19-20,22-25,27H2/b3-1-/t29-,35?,40+,41-,42-/m0/s1
DM48JMC CS C1CCN2CCC3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]5N4CCCC(=O)CC5)O)C6=NC=CC7=C6NC8=C7C=CC=C8OS(=O)(=O)C9=CC=C(C=C9)Cl
DM48JMC IK MSUMHGMGRZWLMN-WXPZYUJUSA-N
DM48JMC IU [1-[(2R,4S,12R,13S,16Z)-13-hydroxy-7-oxo-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-16,25-dien-25-yl]-9H-pyrido[3,4-b]indol-8-yl] 4-chlorobenzenesulfonate
DM48JMC DE Discovery agent
DM249GI ID DM249GI
DM249GI DN 8-O-(4-toluenesulfonyl)manzamine A
DM249GI HS Investigative
DM249GI SN CHEMBL403561
DM249GI DT Small molecular drug
DM249GI PC 101437199
DM249GI MW 718.9
DM249GI FM C43H50N4O4S
DM249GI IC InChI=1S/C43H50N4O4S/c1-30-16-18-32(19-17-30)52(49,50)51-37-15-12-14-33-34-20-23-44-39(40(34)45-38(33)37)35-28-43(48)22-9-5-2-3-6-10-24-46-26-21-36(35)42(29-46)27-31-13-8-4-7-11-25-47(31)41(42)43/h2,5,8,12-20,23,28,31,36,41,45,48H,3-4,6-7,9-11,21-22,24-27,29H2,1H3/b5-2-,13-8-/t31-,36-,41+,42-,43-/m0/s1
DM249GI CS CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=CC3=C2NC4=C3C=CN=C4C5=C[C@]6(CC/C=C\\CCCCN7CC[C@@H]5[C@]8(C7)[C@H]6N9CCCC/C=C\\[C@H]9C8)O
DM249GI IK YYODILDWWWVNHZ-PPDYSKKASA-N
DM249GI IU [1-[(1R,2R,4R,5Z,12R,13S,16Z)-13-hydroxy-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-25-yl]-9H-pyrido[3,4-b]indol-8-yl] 4-methylbenzenesulfonate
DM249GI DE Discovery agent
DM4Z15M ID DM4Z15M
DM4Z15M DN 8-Octyl-benzolactam-V9
DM4Z15M HS Investigative
DM4Z15M SN CHEMBL206866; 8-Octyl-benzolactam-V9; 8-Octylbenzolactam-V9
DM4Z15M DT Small molecular drug
DM4Z15M PC 11574614
DM4Z15M MW 388.6
DM4Z15M FM C24H40N2O2
DM4Z15M IC InChI=1S/C24H40N2O2/c1-5-6-7-8-9-10-12-19-13-11-14-22-21(19)16-15-20(17-27)25-24(28)23(18(2)3)26(22)4/h11,13-14,18,20,23,27H,5-10,12,15-17H2,1-4H3,(H,25,28)/t20-,23-/m0/s1
DM4Z15M CS CCCCCCCCC1=C2CC[C@H](NC(=O)[C@@H](N(C2=CC=C1)C)C(C)C)CO
DM4Z15M IK IDVIOLNZWSXZGL-REWPJTCUSA-N
DM4Z15M IU (2S,5S)-5-(hydroxymethyl)-1-methyl-8-octyl-2-propan-2-yl-4,5,6,7-tetrahydro-2H-1,4-benzodiazonin-3-one
DM4Z15M DE Discovery agent
DM4QYEF ID DM4QYEF
DM4QYEF DN 8-OH-MANZAMINE A
DM4QYEF HS Investigative
DM4QYEF SN 8-Hydroxymanzamine A; 154466-37-2; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(8-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol; 8-OH-MANZAMINE A; (+)8-Hydroxymanzamine A; CHEBI:66669
DM4QYEF DT Small molecular drug
DM4QYEF PC 5270765
DM4QYEF MW 564.8
DM4QYEF FM C36H44N4O2
DM4QYEF IC InChI=1S/C36H44N4O2/c41-30-14-11-13-26-27-15-18-37-32(33(27)38-31(26)30)28-23-36(42)17-8-4-1-2-5-9-19-39-21-16-29(28)35(24-39)22-25-12-7-3-6-10-20-40(25)34(35)36/h1,4,7,11-15,18,23,25,29,34,38,41-42H,2-3,5-6,8-10,16-17,19-22,24H2/b4-1-,12-7-/t25-,29-,34+,35-,36-/m0/s1
DM4QYEF CS C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)O)C6=NC=CC7=C6NC8=C7C=CC=C8O
DM4QYEF IK AMSNINGPDSUBHZ-WAUQNXBMSA-N
DM4QYEF IU (1R,2R,4R,5Z,12R,13S,16Z)-25-(8-hydroxy-9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DM4QYEF CA CAS 154466-37-2
DM4QYEF CB CHEBI:66669
DM4QYEF DE Discovery agent
DMXDQ25 ID DMXDQ25
DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid
DMXDQ25 HS Investigative
DMXDQ25 SN 8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837
DMXDQ25 DT Small molecular drug
DMXDQ25 PC 298878
DMXDQ25 MW 234.29
DMXDQ25 FM C14H18O3
DMXDQ25 IC InChI=1S/C14H18O3/c15-13(12-8-4-3-5-9-12)10-6-1-2-7-11-14(16)17/h3-5,8-9H,1-2,6-7,10-11H2,(H,16,17)
DMXDQ25 CS C1=CC=C(C=C1)C(=O)CCCCCCC(=O)O
DMXDQ25 IK UMCSRRHQLAVYRS-UHFFFAOYSA-N
DMXDQ25 IU 8-oxo-8-phenyloctanoic acid
DMXDQ25 CA CAS 24314-23-6
DMXDQ25 DE Discovery agent
DMWM1UL ID DMWM1UL
DMWM1UL DN 8-Oxo-8-phenyl-octanoic acid hydroxyamide
DMWM1UL HS Investigative
DMWM1UL SN CHEMBL95959; 8-Oxo-8-phenyl-octanoic acid hydroxyamide; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
DMWM1UL DT Small molecular drug
DMWM1UL PC 11075845
DMWM1UL MW 249.3
DMWM1UL FM C14H19NO3
DMWM1UL IC InChI=1S/C14H19NO3/c16-13(12-8-4-3-5-9-12)10-6-1-2-7-11-14(17)15-18/h3-5,8-9,18H,1-2,6-7,10-11H2,(H,15,17)
DMWM1UL CS C1=CC=C(C=C1)C(=O)CCCCCCC(=O)NO
DMWM1UL IK DPHGSTLAQCKOFV-UHFFFAOYSA-N
DMWM1UL IU N-hydroxy-8-oxo-8-phenyloctanamide
DMWM1UL DE Discovery agent
DME8S0R ID DME8S0R
DME8S0R DN 8-Pentyloxy-quinolin-2-ylamine
DME8S0R HS Investigative
DME8S0R SN CHEMBL186481; 8-Pentyloxy-quinolin-2-ylamine; SCHEMBL5883752
DME8S0R DT Small molecular drug
DME8S0R PC 10353806
DME8S0R MW 230.31
DME8S0R FM C14H18N2O
DME8S0R IC InChI=1S/C14H18N2O/c1-2-3-4-10-17-12-7-5-6-11-8-9-13(15)16-14(11)12/h5-9H,2-4,10H2,1H3,(H2,15,16)
DME8S0R CS CCCCCOC1=CC=CC2=C1N=C(C=C2)N
DME8S0R IK CTMPUINXCIZFAU-UHFFFAOYSA-N
DME8S0R IU 8-pentoxyquinolin-2-amine
DME8S0R DE Discovery agent
DMFGUCY ID DMFGUCY
DMFGUCY DN 8-PHENYL THEOPHYLLINE
DMFGUCY HS Investigative
DMFGUCY SN 8-Phenyltheophylline; 1,3-Dimethyl-8-phenylxanthine; 961-45-5; Theophylline, 8-phenyl-; UNII-E6M543P3BL; NSC 14127; CHEMBL62350; E6M543P3BL; MFCD00005582; 1,3-dimethyl-8-phenyl-3,7-dihydro-1H-purine-2,6-dione; 1,3-dimethyl-8-phenyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione, 2,3,6,7-tetrahydro-1,3-dimethyl-8-phenyl-; AC1L1CIX; Lopac-P-2278; Oprea1_390706; Lopac0_000917; MLS000069624; SCHEMBL516432; 8-PT; 8-Phenyl-1,3-dimethylxanthine; 1,3-dimethyl-8-phenyl-1H-purine-2,6(3H,7H)-dione; BDBM82015; DTXSID90242119; MolPort-002-605-303
DMFGUCY DT Small molecular drug
DMFGUCY PC 1922
DMFGUCY MW 256.26
DMFGUCY FM C13H12N4O2
DMFGUCY IC InChI=1S/C13H12N4O2/c1-16-11-9(12(18)17(2)13(16)19)14-10(15-11)8-6-4-3-5-7-8/h3-7H,1-2H3,(H,14,15)
DMFGUCY CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3=CC=CC=C3
DMFGUCY IK PJFMAVHETLRJHJ-UHFFFAOYSA-N
DMFGUCY IU 1,3-dimethyl-8-phenyl-7H-purine-2,6-dione
DMFGUCY CA CAS 961-45-5
DMFGUCY DE Discovery agent
DMHQGOC ID DMHQGOC
DMHQGOC DN 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC HS Investigative
DMHQGOC SN CHEMBL274855; propyl-8-phenyl xanthine; 1-Propyl-8-phenylxanthine; 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione
DMHQGOC DT Small molecular drug
DMHQGOC PC 15627855
DMHQGOC MW 270.29
DMHQGOC FM C14H14N4O2
DMHQGOC IC InChI=1S/C14H14N4O2/c1-2-8-18-13(19)10-12(17-14(18)20)16-11(15-10)9-6-4-3-5-7-9/h3-7H,2,8H2,1H3,(H,15,16)(H,17,20)
DMHQGOC CS CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=CC=C3
DMHQGOC IK LNATVXLECNOWHK-UHFFFAOYSA-N
DMHQGOC IU 8-phenyl-1-propyl-3,7-dihydropurine-2,6-dione
DMHQGOC DE Discovery agent
DM29L4D ID DM29L4D
DM29L4D DN 8-Phenyl-2-piperidin-1-yl-chromen-4-one
DM29L4D HS Investigative
DM29L4D SN CHEMBL176064; 8-Phenyl-2-piperidin-1-yl-chromen-4-one; SCHEMBL259239
DM29L4D DT Small molecular drug
DM29L4D PC 11185819
DM29L4D MW 305.4
DM29L4D FM C20H19NO2
DM29L4D IC InChI=1S/C20H19NO2/c22-18-14-19(21-12-5-2-6-13-21)23-20-16(10-7-11-17(18)20)15-8-3-1-4-9-15/h1,3-4,7-11,14H,2,5-6,12-13H2
DM29L4D CS C1CCN(CC1)C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DM29L4D IK OSJZAQVQDRSBPT-UHFFFAOYSA-N
DM29L4D IU 8-phenyl-2-piperidin-1-ylchromen-4-one
DM29L4D CA CAS 154447-39-9
DM29L4D DE Discovery agent
DMJMWOE ID DMJMWOE
DMJMWOE DN 8-Phenyl-2-thiomorpholin-4-yl-chromen-4-one
DMJMWOE HS Investigative
DMJMWOE SN CHEMBL175944; 8-phenyl-2-thiomorpholin-4-yl-chromen-4-one
DMJMWOE DT Small molecular drug
DMJMWOE PC 11324758
DMJMWOE MW 323.4
DMJMWOE FM C19H17NO2S
DMJMWOE IC InChI=1S/C19H17NO2S/c21-17-13-18(20-9-11-23-12-10-20)22-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
DMJMWOE CS C1CSCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DMJMWOE IK BJZCLUNKKGYDPF-UHFFFAOYSA-N
DMJMWOE IU 8-phenyl-2-thiomorpholin-4-ylchromen-4-one
DMJMWOE CA CAS 154447-37-7
DMJMWOE DE Discovery agent
DMJB1NI ID DMJB1NI
DMJB1NI DN 8-Phenyl-3,7-dihydro-purine-2,6-dione
DMJB1NI HS Investigative
DMJB1NI SN 8-Phenylxanthine; 2879-14-3; UNII-0S2BVG6C31; CHEMBL285191; 0S2BVG6C31; 1H-Purine-2,6-dione, 3,9-dihydro-8-phenyl-; 1H-Purine-2,6-dione, 3,7-dihydro-8-phenyl-; Xanthine, 8-phenyl-; 8-Phenyl-3,7-dihydro-purine-2,6-dione; SCHEMBL378879; CTK0J1822; DTXSID50485464; BDBM50042214; ZINC13472986; 8-Phenyl-1H-purine-2,6(3H,7H)-dione
DMJB1NI DT Small molecular drug
DMJB1NI PC 12295530
DMJB1NI MW 228.21
DMJB1NI FM C11H8N4O2
DMJB1NI IC InChI=1S/C11H8N4O2/c16-10-7-9(14-11(17)15-10)13-8(12-7)6-4-2-1-3-5-6/h1-5H,(H3,12,13,14,15,16,17)
DMJB1NI CS C1=CC=C(C=C1)C2=NC3=C(N2)C(=O)NC(=O)N3
DMJB1NI IK ACCCXSZCOGNLFL-UHFFFAOYSA-N
DMJB1NI IU 8-phenyl-3,7-dihydropurine-2,6-dione
DMJB1NI CA CAS 2879-14-3
DMJB1NI DE Discovery agent
DM516NE ID DM516NE
DM516NE DN 8-Phenyl-octanoic acid hydroxyamide
DM516NE HS Investigative
DM516NE SN 8-Phenyl-octanoic acid hydroxyamide; CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174
DM516NE DT Small molecular drug
DM516NE PC 14098189
DM516NE MW 235.32
DM516NE FM C14H21NO2
DM516NE IC InChI=1S/C14H21NO2/c16-14(15-17)12-8-3-1-2-5-9-13-10-6-4-7-11-13/h4,6-7,10-11,17H,1-3,5,8-9,12H2,(H,15,16)
DM516NE CS C1=CC=C(C=C1)CCCCCCCC(=O)NO
DM516NE IK JUCDFXVDGUXPMJ-UHFFFAOYSA-N
DM516NE IU N-hydroxy-8-phenyloctanamide
DM516NE DE Discovery agent
DM4TWRJ ID DM4TWRJ
DM4TWRJ DN 8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester
DM4TWRJ HS Investigative
DM4TWRJ SN CHEMBL486701; 8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester
DM4TWRJ DT Small molecular drug
DM4TWRJ PC 24881808
DM4TWRJ MW 401.5
DM4TWRJ FM C27H31NO2
DM4TWRJ IC InChI=1S/C27H31NO2/c29-27(30-26-20-13-19-25(22-26)24-17-10-6-11-18-24)28-21-12-4-2-1-3-7-14-23-15-8-5-9-16-23/h5-6,8-11,13,15-20,22H,1-4,7,12,14,21H2,(H,28,29)
DM4TWRJ CS C1=CC=C(C=C1)CCCCCCCCNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM4TWRJ IK IKKKZTIUGOILBU-UHFFFAOYSA-N
DM4TWRJ IU (3-phenylphenyl) N-(8-phenyloctyl)carbamate
DM4TWRJ DE Discovery agent
DM958EN ID DM958EN
DM958EN DN 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine
DM958EN HS Investigative
DM958EN SN 76537-53-6; 8-(1-Piperazinyl)imidazo(1,2-a)pyrazine; 8-(1-piperazinyl)imidazo[1,2-a]pyrazine; CHEMBL331036; 8-piperazin-1-ylimidazo[1,2-a]pyrazine; 8-Pdpr; Imidazo(1,2-a)pyrazine, 8-(1-piperazinyl)-; Imidazo[1,2-a]pyrazine, 8-(1-piperazinyl)-; 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine; AC1L2YVL; 8-(piperazin-1-yl)imidazo[1,2-a]pyrazine; AC1Q4X6M; SCHEMBL5496661; AC1Q1I52; CTK5E3085; DTXSID50227346; ZINC5117657; BDBM50002151; AKOS024075563; FT-0756627; Imidazo[1,2-a]pyrazine,8-(1-piperazinyl)-; A839966
DM958EN DT Small molecular drug
DM958EN PC 131268
DM958EN MW 203.24
DM958EN FM C10H13N5
DM958EN IC InChI=1S/C10H13N5/c1-5-14(6-2-11-1)9-10-13-4-8-15(10)7-3-12-9/h3-4,7-8,11H,1-2,5-6H2
DM958EN CS C1CN(CCN1)C2=NC=CN3C2=NC=C3
DM958EN IK NSHLOJVJEGEMSF-UHFFFAOYSA-N
DM958EN IU 8-piperazin-1-ylimidazo[1,2-a]pyrazine
DM958EN CA CAS 76537-53-6
DM958EN DE Discovery agent
DM2VC0E ID DM2VC0E
DM2VC0E DN 8-prenylapigenin
DM2VC0E HS Investigative
DM2VC0E SN Licoflavone C; 8-Prenylapigenin; 72357-31-4; UNII-0DQ85982ZY; 4',5,7-Trihydroxy-8-prenylflavone; CHEMBL371562; 0DQ85982ZY; SCHEMBL1231403; MEGxp0_002023; ACon1_001079; ZINC21406; MolPort-001-742-698; 4,5,7-trihydroxy-8-prenylflavone; LMPK12110422; BDBM50240972; 5,7,4'-Trihydroxy-8-prenylflavone; AKOS027326549; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-; NCGC00169697-01; BRD-K74687851-001-01-8
DM2VC0E DT Small molecular drug
DM2VC0E PC 10246505
DM2VC0E MW 338.4
DM2VC0E FM C20H18O5
DM2VC0E IC InChI=1S/C20H18O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h3-7,9-10,21-23H,8H2,1-2H3
DM2VC0E CS CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C=C(O2)C3=CC=C(C=C3)O)C
DM2VC0E IK MEHHCBRCXIDGKZ-UHFFFAOYSA-N
DM2VC0E IU 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
DM2VC0E CA CAS 72357-31-4
DM2VC0E DE Discovery agent
DMZC1SV ID DMZC1SV
DMZC1SV DN 8-prenylquercetin
DMZC1SV HS Investigative
DMZC1SV SN 8-prenylquercetin; CHEMBL193059; 8-prenyl-quercetin; SCHEMBL2686819; BDBM50240974
DMZC1SV DT Small molecular drug
DMZC1SV PC 9799499
DMZC1SV MW 370.4
DMZC1SV FM C20H18O7
DMZC1SV IC InChI=1S/C20H18O7/c1-9(2)3-5-11-13(22)8-15(24)16-17(25)18(26)19(27-20(11)16)10-4-6-12(21)14(23)7-10/h3-4,6-8,21-24,26H,5H2,1-2H3
DMZC1SV CS CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC(=C(C=C3)O)O)O)C
DMZC1SV IK ZHTTWVRMGWQEOH-UHFFFAOYSA-N
DMZC1SV IU 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-8-(3-methylbut-2-enyl)chromen-4-one
DMZC1SV CA CAS 143724-75-8
DMZC1SV DE Discovery agent
DMKWYJX ID DMKWYJX
DMKWYJX DN 8-Propionyl-7-propoxy-2H-chromen-2-one
DMKWYJX HS Investigative
DMKWYJX SN CHEMBL1288623; 8-Propionyl-7-propoxy-2H-chromen-2-one
DMKWYJX DT Small molecular drug
DMKWYJX PC 52946831
DMKWYJX MW 260.279
DMKWYJX FM C15H16O4
DMKWYJX IC InChI=1S/C15H16O4/c1-3-9-18-12-7-5-10-6-8-13(17)19-15(10)14(12)11(16)4-2/h5-8H,3-4,9H2,1-2H3
DMKWYJX CS CCCOC1=C(C2=C(C=C1)C=CC(=O)O2)C(=O)CC
DMKWYJX IK CVYSNMWNCSOWAN-UHFFFAOYSA-N
DMKWYJX IU 8-propanoyl-7-propoxychromen-2-one
DMKWYJX DE Discovery agent
DM0TVL5 ID DM0TVL5
DM0TVL5 DN 8-Propoxy-quinolin-2-ylamine
DM0TVL5 HS Investigative
DM0TVL5 SN CHEMBL427153; 8-Propoxy-quinolin-2-ylamine; SCHEMBL5884205; BDBM50152441
DM0TVL5 DT Small molecular drug
DM0TVL5 PC 10420382
DM0TVL5 MW 202.25
DM0TVL5 FM C12H14N2O
DM0TVL5 IC InChI=1S/C12H14N2O/c1-2-8-15-10-5-3-4-9-6-7-11(13)14-12(9)10/h3-7H,2,8H2,1H3,(H2,13,14)
DM0TVL5 CS CCCOC1=CC=CC2=C1N=C(C=C2)N
DM0TVL5 IK SZBXIIUHFFFWME-UHFFFAOYSA-N
DM0TVL5 IU 8-propoxyquinolin-2-amine
DM0TVL5 DE Discovery agent
DMT6YUF ID DMT6YUF
DMT6YUF DN 8-propyl-2,6-diphenyl-9H-purine
DMT6YUF HS Investigative
DMT6YUF SN CHEMBL424869; 8-propyl-2,6-diphenyl-9H-purine
DMT6YUF DT Small molecular drug
DMT6YUF PC 11565892
DMT6YUF MW 314.4
DMT6YUF FM C20H18N4
DMT6YUF IC InChI=1S/C20H18N4/c1-2-9-16-21-18-17(14-10-5-3-6-11-14)23-19(24-20(18)22-16)15-12-7-4-8-13-15/h3-8,10-13H,2,9H2,1H3,(H,21,22,23,24)
DMT6YUF CS CCCC1=NC2=NC(=NC(=C2N1)C3=CC=CC=C3)C4=CC=CC=C4
DMT6YUF IK LIJDFWULFIYULY-UHFFFAOYSA-N
DMT6YUF IU 2,6-diphenyl-8-propyl-7H-purine
DMT6YUF DE Discovery agent
DM1I25F ID DM1I25F
DM1I25F DN 8-Pyridin-4-yl-9H-purine-2,6-diamine
DM1I25F HS Investigative
DM1I25F SN CHEMBL317618; 8-Pyridin-4-yl-9H-purine-2,6-diamine; 9H-Purine-2,6-diamine, 8-(4-pyridinyl)-; AC1L9X4Y; BDBM50059928; 2,6-Diamino-8-(4'-pyridinyl)purine; 8-pyridin-4-yl-7H-purine-2,6-diamine; 8-(4-pyridyl)-9H-purine-2,6-diamine; 194613-23-5
DM1I25F DT Small molecular drug
DM1I25F PC 457739
DM1I25F MW 227.23
DM1I25F FM C10H9N7
DM1I25F IC InChI=1S/C10H9N7/c11-7-6-9(17-10(12)15-7)16-8(14-6)5-1-3-13-4-2-5/h1-4H,(H5,11,12,14,15,16,17)
DM1I25F CS C1=CN=CC=C1C2=NC3=NC(=NC(=C3N2)N)N
DM1I25F IK FRFATUHEQSVWHE-UHFFFAOYSA-N
DM1I25F IU 8-pyridin-4-yl-7H-purine-2,6-diamine
DM1I25F DE Discovery agent
DML9HDA ID DML9HDA
DML9HDA DN 8R-hydroxylobel-9-ene
DML9HDA HS Investigative
DML9HDA SN CHEMBL425617; 8R-hydroxylobel-9-ene; SCHEMBL13845050
DML9HDA DT Small molecular drug
DML9HDA PC 12018178
DML9HDA MW 321.5
DML9HDA FM C22H27NO
DML9HDA IC InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22+/m0/s1
DML9HDA CS CN1[C@H](CCC[C@H]1/C=C/C2=CC=CC=C2)C[C@H](C3=CC=CC=C3)O
DML9HDA IK IKYXUFYHDWVXST-OWHMEISOSA-N
DML9HDA IU (1R)-2-[(2R,6S)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DML9HDA DE Discovery agent
DMJ82TO ID DMJ82TO
DMJ82TO DN 8R-hydroxylobelane
DMJ82TO HS Investigative
DMJ82TO SN 8R-hydroxylobelane; CHEMBL125511; SCHEMBL14178948; BDBM50080821; (R)-1-Phenyl-2-(1-methyl-6beta-phenethyl-2beta-piperidinyl)ethanol
DMJ82TO DT Small molecular drug
DMJ82TO PC 10782198
DMJ82TO MW 323.5
DMJ82TO FM C22H29NO
DMJ82TO IC InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22+/m0/s1
DMJ82TO CS CN1[C@@H](CCC[C@@H]1C[C@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMJ82TO IK MUSFCRGEWKAWEE-BHDDXSALSA-N
DMJ82TO IU (1R)-2-[(2R,6S)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DMJ82TO DE Discovery agent
DMLK4WO ID DMLK4WO
DMLK4WO DN 8R-Lisuride
DMLK4WO HS Investigative
DMLK4WO SN BKRGVLQUQGGVSM-RDTXWAMCSA-N; S-(-)-Lisuride; 8R-lisuride; NCGC00163158-01; Biomol-NT_000024; Lopac0_000781; BPBio1_001092; CHEMBL1528238; CHEBI:93550; BDBM22867; CCG-204866; L-122; EU-0100781; SR-01000075971; SR-01000075971-1; BRD-K88871508-001-01-9; 1,1-diethyl-3-(9,10-didehydro-6-methyl-8beta-ergolinyl)urea; N'-(9,10-Didehydro-6-methylergoline-8beta-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8beta)-6-methyl-9,10-didehydroergolin-8-yl]urea; S(-)-N'-[(8a)-9,10-Didehydro-6-methylergolin-8-yl]-N,N-diethyl-urea
DMLK4WO DT Small molecular drug
DMLK4WO PC 11957615
DMLK4WO MW 338.4
DMLK4WO FM C20H26N4O
DMLK4WO IC InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18-/m1/s1
DMLK4WO CS CCN(CC)C(=O)N[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
DMLK4WO IK BKRGVLQUQGGVSM-RDTXWAMCSA-N
DMLK4WO IU 3-[(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
DMLK4WO CA CAS 140387-89-9
DMLK4WO CB CHEBI:93550
DMLK4WO DE Discovery agent
DMFPWJL ID DMFPWJL
DMFPWJL DN 8-sec-Butoxy-quinolin-2-ylamine
DMFPWJL HS Investigative
DMFPWJL SN CHEMBL186818; 8-sec-Butoxy-quinolin-2-ylamine; SCHEMBL5883697
DMFPWJL DT Small molecular drug
DMFPWJL PC 10262766
DMFPWJL MW 216.28
DMFPWJL FM C13H16N2O
DMFPWJL IC InChI=1S/C13H16N2O/c1-3-9(2)16-11-6-4-5-10-7-8-12(14)15-13(10)11/h4-9H,3H2,1-2H3,(H2,14,15)
DMFPWJL CS CCC(C)OC1=CC=CC2=C1N=C(C=C2)N
DMFPWJL IK RDHSHZSWPBWALB-UHFFFAOYSA-N
DMFPWJL IU 8-butan-2-yloxyquinolin-2-amine
DMFPWJL DE Discovery agent
DMT9SAC ID DMT9SAC
DMT9SAC DN 8S-HETE
DMT9SAC HS Investigative
DMT9SAC SN 8-hydroxyeicosatetraenoic acid
DMT9SAC DT Small molecular drug
DMT9SAC PC 5283154
DMT9SAC MW 320.5
DMT9SAC FM C20H32O3
DMT9SAC IC InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-13-16-19(21)17-14-11-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,14-11-,16-13+/t19-/m1/s1
DMT9SAC CS CCCCC/C=C\\C/C=C\\C=C\\[C@H](C/C=C\\CCCC(=O)O)O
DMT9SAC IK NLUNAYAEIJYXRB-VYOQERLCSA-N
DMT9SAC IU (5Z,8S,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoic acid
DMT9SAC CA CAS 98462-03-4
DMT9SAC CB CHEBI:34486
DMT9SAC DE Discovery agent
DMRL3BK ID DMRL3BK
DMRL3BK DN 8S-hydroxylobel-9-ene
DMRL3BK HS Investigative
DMRL3BK SN CHEMBL213613; 8S-hydroxylobel-9-ene; SCHEMBL14178965
DMRL3BK DT Small molecular drug
DMRL3BK PC 12018177
DMRL3BK MW 321.5
DMRL3BK FM C22H27NO
DMRL3BK IC InChI=1S/C22H27NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,15-16,20-22,24H,8,13-14,17H2,1H3/b16-15+/t20-,21+,22-/m0/s1
DMRL3BK CS CN1[C@H](CCC[C@H]1/C=C/C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
DMRL3BK IK IKYXUFYHDWVXST-HTNBDEJSSA-N
DMRL3BK IU (1S)-2-[(2R,6S)-1-methyl-6-[(E)-2-phenylethenyl]piperidin-2-yl]-1-phenylethanol
DMRL3BK DE Discovery agent
DMLONTS ID DMLONTS
DMLONTS DN 8S-hydroxylobelane
DMLONTS HS Investigative
DMLONTS SN 8S-hydroxylobelane; CHEMBL377539; SCHEMBL14178958
DMLONTS DT Small molecular drug
DMLONTS PC 44416452
DMLONTS MW 323.5
DMLONTS FM C22H29NO
DMLONTS IC InChI=1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22-/m0/s1
DMLONTS CS CN1[C@@H](CCC[C@@H]1C[C@@H](C2=CC=CC=C2)O)CCC3=CC=CC=C3
DMLONTS IK MUSFCRGEWKAWEE-BDTNDASRSA-N
DMLONTS IU (1S)-2-[(2R,6S)-1-methyl-6-(2-phenylethyl)piperidin-2-yl]-1-phenylethanol
DMLONTS DE Discovery agent
DMOHB3Z ID DMOHB3Z
DMOHB3Z DN 8-sulfophenyl theophylline
DMOHB3Z HS Investigative
DMOHB3Z SN 8-(p-Sulfophenyl)theophylline; 8-(4-Sulfophenyl)theophylline; 80206-91-3; 8-SPT; 4-(1,3-dimethyl-2,6-dioxo-2,3,6,9-tetrahydro-1H-purin-8-yl)benzenesulfonic acid; CHEMBL8488; Psp-theophylline; 8-Sulphophenyltheophylline; Lopac-A-013; AC1Q6X0T; AC1L1CI3; Lopac0_000135; 8-(P-Sulfophenyl)Thiophylline; SCHEMBL1320226; 8-(p-Sulfophenyl)-theophylline; CTK6I1750; BDBM82023; CTK3E8290; DTXSID90230152; LXJSJIXZOAMHTG-UHFFFAOYSA-N; MolPort-006-068-692; HMS3260K12; ALBB-009371; ZX-AN008233; ZINC5322904; NSC_1908; Tox21_500135; PDSP1_000449
DMOHB3Z DT Small molecular drug
DMOHB3Z PC 1908
DMOHB3Z MW 336.33
DMOHB3Z FM C13H12N4O5S
DMOHB3Z IC InChI=1S/C13H12N4O5S/c1-16-11-9(12(18)17(2)13(16)19)14-10(15-11)7-3-5-8(6-4-7)23(20,21)22/h3-6H,1-2H3,(H,14,15)(H,20,21,22)
DMOHB3Z CS CN1C2=C(C(=O)N(C1=O)C)NC(=N2)C3=CC=C(C=C3)S(=O)(=O)O
DMOHB3Z IK LXJSJIXZOAMHTG-UHFFFAOYSA-N
DMOHB3Z IU 4-(1,3-dimethyl-2,6-dioxo-7H-purin-8-yl)benzenesulfonic acid
DMOHB3Z CA CAS 80206-91-3
DMOHB3Z DE Discovery agent
DM4Y9U3 ID DM4Y9U3
DM4Y9U3 DN 9-(2-aminoethyl)-9,10-dihydroanthracene
DM4Y9U3 HS Investigative
DM4Y9U3 SN CHEMBL160893; 9-(2-aminoethyl)-9,10-dihydroanthracene; BDBM35923; 9,10-dihydroanthracene(DHA), 2a
DM4Y9U3 DT Small molecular drug
DM4Y9U3 PC 44373221
DM4Y9U3 MW 223.31
DM4Y9U3 FM C16H17N
DM4Y9U3 IC InChI=1S/C16H17N/c17-10-9-16-14-7-3-1-5-12(14)11-13-6-2-4-8-15(13)16/h1-8,16H,9-11,17H2
DM4Y9U3 CS C1C2=CC=CC=C2C(C3=CC=CC=C31)CCN
DM4Y9U3 IK OWPHKTVZEZNCMB-UHFFFAOYSA-N
DM4Y9U3 IU 2-(9,10-dihydroanthracen-9-yl)ethanamine
DM4Y9U3 DE Discovery agent
DMND39P ID DMND39P
DMND39P DN 9-(2-aminopropyl)-9,10-dihydroanthracene
DMND39P HS Investigative
DMND39P SN CHEMBL158780; 9-(2-aminopropyl)-9,10-dihydroanthracene; BDBM35926; 9,10-dihydroanthracene(DHA), 3a; 9-(3-Aminopropyl)-9,10-dihydroanthracene
DMND39P DT Small molecular drug
DMND39P PC 10354158
DMND39P MW 237.34
DMND39P FM C17H19N
DMND39P IC InChI=1S/C17H19N/c18-11-5-10-17-15-8-3-1-6-13(15)12-14-7-2-4-9-16(14)17/h1-4,6-9,17H,5,10-12,18H2
DMND39P CS C1C2=CC=CC=C2C(C3=CC=CC=C31)CCCN
DMND39P IK AUTKMGMMFJXIDV-UHFFFAOYSA-N
DMND39P IU 3-(9,10-dihydroanthracen-9-yl)propan-1-amine
DMND39P DE Discovery agent
DMYUMHG ID DMYUMHG
DMYUMHG DN 9-(2-Hydroxyethyl)-9H-adenine
DMYUMHG HS Investigative
DMYUMHG SN 2-(6-aminopurin-9-yl)ethanol; 707-99-3; 9-(2-Hydroxyethyl)adenine; 9h-purine-9-ethanol, 6-amino-; 9-(2-hydroxyethyl) adenine; CHEMBL95897; 6-Amino-9H-purin-9-ethanol; VAQOTZQDXZDBJK-UHFFFAOYSA-N; 6-Amino-9-(2-hydroxyethyl)purine; 2-(6-Amino-9H-purin-9-yl)ethanol; 9-(2-Hydroxyethyl)-9H-adenine; NSC51467; N9 -hydroxyethyladenine; AC1Q4VHV; 9-(2hydroxyethyl)adenine; ACMC-209og5; TimTec1_003634; 9-(2'-hydroxyethyl)adenine; 9-(2-Hydroxyethyl)adenine.; SCHEMBL984944; 6-Amino-9h-purine-9-ethanol; AC1L69W8; ZINC36416; KS-00000VZR
DMYUMHG DT Small molecular drug
DMYUMHG PC 242652
DMYUMHG MW 179.18
DMYUMHG FM C7H9N5O
DMYUMHG IC InChI=1S/C7H9N5O/c8-6-5-7(10-3-9-6)12(1-2-13)4-11-5/h3-4,13H,1-2H2,(H2,8,9,10)
DMYUMHG CS C1=NC(=C2C(=N1)N(C=N2)CCO)N
DMYUMHG IK VAQOTZQDXZDBJK-UHFFFAOYSA-N
DMYUMHG IU 2-(6-aminopurin-9-yl)ethanol
DMYUMHG CA CAS 707-99-3
DMYUMHG DE Discovery agent
DM2UQ0R ID DM2UQ0R
DM2UQ0R DN 9-(2-Hydroxypropyl)-9H-adenine
DM2UQ0R HS Investigative
DM2UQ0R SN 9-(2-Hydroxypropyl)adenine; 1-(6-aminopurin-9-yl)propan-2-ol; CHEMBL504495; MJZYTEBKXLVLMY-UHFFFAOYSA-N; 9-(2-Hydroxypropyl)-9H-adenine; AC1L1CKL; 9H-Purine-9-ethanol, 6-amino-.alpha.-methyl-; SCHEMBL904363; CTK6A8458; 9-(2-Hydroxy-1-propyl)adenine; BCP14341; BDBM50257055; 3-(6-Amino-9-purinyl)-2-propanol; AKOS010941288; TRA0093894; AN-7936; 1-(6-Amino-purin-9-yl)-propan-2-ol; SY022843; A3032; 4CH-024207; 4CH-018216; 1-(6-Amino-9H-purin-9-yl)-2-propanol #; MFCD07369451 (97+%)
DM2UQ0R DT Small molecular drug
DM2UQ0R PC 1942
DM2UQ0R MW 193.21
DM2UQ0R FM C8H11N5O
DM2UQ0R IC InChI=1S/C8H11N5O/c1-5(14)2-13-4-12-6-7(9)10-3-11-8(6)13/h3-5,14H,2H2,1H3,(H2,9,10,11)
DM2UQ0R CS CC(CN1C=NC2=C(N=CN=C21)N)O
DM2UQ0R IK MJZYTEBKXLVLMY-UHFFFAOYSA-N
DM2UQ0R IU 1-(6-aminopurin-9-yl)propan-2-ol
DM2UQ0R DE Discovery agent
DMDYZCH ID DMDYZCH
DMDYZCH DN 9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMDYZCH HS Investigative
DMDYZCH SN CHEMBL260788; SCHEMBL3268186; XBESCJVITPKCJA-UHFFFAOYSA-N; BDBM50377513
DMDYZCH DT Small molecular drug
DMDYZCH PC 9836155
DMDYZCH MW 306.32
DMDYZCH FM C16H14N6O
DMDYZCH IC InChI=1S/C16H14N6O/c17-11-4-1-3-10(7-11)8-22-9-19-14-13(12-5-2-6-23-12)20-16(18)21-15(14)22/h1-7,9H,8,17H2,(H2,18,20,21)
DMDYZCH CS C1=CC(=CC(=C1)N)CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMDYZCH IK XBESCJVITPKCJA-UHFFFAOYSA-N
DMDYZCH IU 9-[(3-aminophenyl)methyl]-6-(furan-2-yl)purin-2-amine
DMDYZCH DE Discovery agent
DM51MRV ID DM51MRV
DM51MRV DN 9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one
DM51MRV HS Investigative
DM51MRV SN CHEMBL382645; 119802-72-1; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-(3-aminopropoxy)-; ACMC-20moke; 9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one; SCHEMBL17373028; CTK0F9398; DTXSID90470955
DM51MRV DT Small molecular drug
DM51MRV PC 11708692
DM51MRV MW 259.26
DM51MRV FM C14H13NO4
DM51MRV IC InChI=1S/C14H13NO4/c15-5-1-6-17-14-12-10(4-7-18-12)8-9-2-3-11(16)19-13(9)14/h2-4,7-8H,1,5-6,15H2
DM51MRV CS C1=CC(=O)OC2=C(C3=C(C=CO3)C=C21)OCCCN
DM51MRV IK ZTTJBZXILLQBLD-UHFFFAOYSA-N
DM51MRV IU 9-(3-aminopropoxy)furo[3,2-g]chromen-7-one
DM51MRV CA CAS 119802-72-1
DM51MRV DE Discovery agent
DM80MTI ID DM80MTI
DM80MTI DN 9-(3-Hydroxypropyl)-9H-adenine
DM80MTI HS Investigative
DM80MTI SN 711-64-8; 9H-Purine-9-propanol, 6-amino-; CHEMBL445974; 9-(3-Hydroxypropyl)-9H-adenine; 3-(6-Amino-9H-purin-9-yl)propan-1-ol; 9-(3-Hydroxypropyl)adenine; Oprea1_108729; 9-(3'-hydroxypropyl)adenine; SCHEMBL1635576; CTK2H3970; DTXSID10500041; MolPort-014-160-140; ZINC5391161; BDBM50257052; 3-(6-aminopurin-9-yl)propan-1-ol; AKOS010941287; 3-(6-Amino-9H-purine-9-yl)-1-propanol
DM80MTI DT Small molecular drug
DM80MTI PC 12486289
DM80MTI MW 193.21
DM80MTI FM C8H11N5O
DM80MTI IC InChI=1S/C8H11N5O/c9-7-6-8(11-4-10-7)13(5-12-6)2-1-3-14/h4-5,14H,1-3H2,(H2,9,10,11)
DM80MTI CS C1=NC(=C2C(=N1)N(C=N2)CCCO)N
DM80MTI IK BLZBVHFRNUTFCH-UHFFFAOYSA-N
DM80MTI IU 3-(6-aminopurin-9-yl)propan-1-ol
DM80MTI CA CAS 711-64-8
DM80MTI DE Discovery agent
DMOP5AJ ID DMOP5AJ
DMOP5AJ DN 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
DMOP5AJ HS Investigative
DMOP5AJ SN 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE; I40; N-[(3-iodophenyl)methyl]-1,2,3,4-tetrahydroacridin-9-amine; 1qon; AC1L9LOA; SCHEMBL3361969; DB07940
DMOP5AJ DT Small molecular drug
DMOP5AJ PC 448167
DMOP5AJ MW 414.3
DMOP5AJ FM C20H19IN2
DMOP5AJ IC InChI=1S/C20H19IN2/c21-15-7-5-6-14(12-15)13-22-20-16-8-1-3-10-18(16)23-19-11-4-2-9-17(19)20/h1,3,5-8,10,12H,2,4,9,11,13H2,(H,22,23)
DMOP5AJ CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCC4=CC(=CC=C4)I
DMOP5AJ IK ZUCWQTWGZGIYPV-UHFFFAOYSA-N
DMOP5AJ IU N-[(3-iodophenyl)methyl]-1,2,3,4-tetrahydroacridin-9-amine
DMOP5AJ DE Discovery agent
DM4X18V ID DM4X18V
DM4X18V DN 9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DM4X18V HS Investigative
DM4X18V SN CHEMBL260790; SCHEMBL3268445; LYSMIARHRJVSBZ-UHFFFAOYSA-N; BDBM50377515
DM4X18V DT Small molecular drug
DM4X18V PC 44449695
DM4X18V MW 336.3
DM4X18V FM C16H12N6O3
DM4X18V IC InChI=1S/C16H12N6O3/c17-16-19-13(12-5-2-6-25-12)14-15(20-16)21(9-18-14)8-10-3-1-4-11(7-10)22(23)24/h1-7,9H,8H2,(H2,17,19,20)
DM4X18V CS C1=CC(=CC(=C1)[N+](=O)[O-])CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DM4X18V IK LYSMIARHRJVSBZ-UHFFFAOYSA-N
DM4X18V IU 6-(furan-2-yl)-9-[(3-nitrophenyl)methyl]purin-2-amine
DM4X18V DE Discovery agent
DMUIRS1 ID DMUIRS1
DMUIRS1 DN 9-(3-n-Pentylureido)non-4(Z)-enoic acid
DMUIRS1 HS Investigative
DMUIRS1 SN CHEMBL551899; 9-(3-n-Pentylureido)non-4(Z)-enoic acid
DMUIRS1 DT Small molecular drug
DMUIRS1 PC 44235414
DMUIRS1 MW 284.39
DMUIRS1 FM C15H28N2O3
DMUIRS1 IC InChI=1S/C15H28N2O3/c1-2-3-9-12-16-15(20)17-13-10-7-5-4-6-8-11-14(18)19/h4,6H,2-3,5,7-13H2,1H3,(H,18,19)(H2,16,17,20)/b6-4-
DMUIRS1 CS CCCCCNC(=O)NCCCC/C=C\\CCC(=O)O
DMUIRS1 IK ABERTDKHAIMZFF-XQRVVYSFSA-N
DMUIRS1 IU (Z)-9-(pentylcarbamoylamino)non-4-enoic acid
DMUIRS1 DE Discovery agent
DMJYMFE ID DMJYMFE
DMJYMFE DN 9-(3-n-Pentylureido)non-4-ynoic acid
DMJYMFE HS Investigative
DMJYMFE SN CHEMBL551900; 9-(3-n-Pentylureido)non-4-ynoic acid
DMJYMFE DT Small molecular drug
DMJYMFE PC 44235634
DMJYMFE MW 282.38
DMJYMFE FM C15H26N2O3
DMJYMFE IC InChI=1S/C15H26N2O3/c1-2-3-9-12-16-15(20)17-13-10-7-5-4-6-8-11-14(18)19/h2-3,5,7-13H2,1H3,(H,18,19)(H2,16,17,20)
DMJYMFE CS CCCCCNC(=O)NCCCCC#CCCC(=O)O
DMJYMFE IK RYPHFFFUDQDRHY-UHFFFAOYSA-N
DMJYMFE IU 9-(pentylcarbamoylamino)non-4-ynoic acid
DMJYMFE DE Discovery agent
DMW2NY9 ID DMW2NY9
DMW2NY9 DN 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine
DMW2NY9 HS Investigative
DMW2NY9 SN CHEMBL176245
DMW2NY9 DT Small molecular drug
DMW2NY9 PC 11175093
DMW2NY9 MW 336.4
DMW2NY9 FM C18H13FN4S
DMW2NY9 IC InChI=1S/C18H13FN4S/c19-14-8-6-13(7-9-14)10-23-12-22-16-17(23)20-11-21-18(16)24-15-4-2-1-3-5-15/h1-9,11-12H,10H2
DMW2NY9 CS C1=CC=C(C=C1)SC2=NC=NC3=C2N=CN3CC4=CC=C(C=C4)F
DMW2NY9 IK IHJWHIRJWNFCOO-UHFFFAOYSA-N
DMW2NY9 IU 9-[(4-fluorophenyl)methyl]-6-phenylsulfanylpurine
DMW2NY9 DE Discovery agent
DMLKJD9 ID DMLKJD9
DMLKJD9 DN 9-(4-Hydroxybutyl)-N2-Phenylguanine
DMLKJD9 HS Investigative
DMLKJD9 SN 9-(4-HYDROXYBUTYL)-N2-PHENYLGUANINE; HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one
DMLKJD9 DT Small molecular drug
DMLKJD9 PC 135415618
DMLKJD9 MW 299.33
DMLKJD9 FM C15H17N5O2
DMLKJD9 IC InChI=1S/C15H17N5O2/c21-9-5-4-8-20-10-16-12-13(20)18-15(19-14(12)22)17-11-6-2-1-3-7-11/h1-3,6-7,10,21H,4-5,8-9H2,(H2,17,18,19,22)
DMLKJD9 CS C1=CC=C(C=C1)NC2=NC3=C(C(=O)N2)N=CN3CCCCO
DMLKJD9 IK JHBXNPBKSPYOFT-UHFFFAOYSA-N
DMLKJD9 IU 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one
DMLKJD9 CA CAS 161363-19-5
DMLKJD9 DE Discovery agent
DMOL01E ID DMOL01E
DMOL01E DN 9-(4-Hydroxyphenyl)-2,7-Phenanthroline
DMOL01E HS Investigative
DMOL01E DT Small molecular drug
DMOL01E PC 447874
DMOL01E MW 272.3
DMOL01E FM C18H12N2O
DMOL01E IC InChI=1S/C18H12N2O/c21-15-4-1-12(2-5-15)14-9-16-17-11-19-8-7-13(17)3-6-18(16)20-10-14/h1-11,21H
DMOL01E CS C1=CC2=C(C=C(C=N2)C3=CC=C(C=C3)O)C4=C1C=CN=C4
DMOL01E IK IUSSGTWHFMSCOY-UHFFFAOYSA-N
DMOL01E IU 4-(2,7-phenanthrolin-9-yl)phenol
DMOL01E CB CHEBI:40444
DMOL01E DE Discovery agent
DMURKL9 ID DMURKL9
DMURKL9 DN 9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
DMURKL9 HS Investigative
DMURKL9 SN CHEMBL410445; SCHEMBL3269368
DMURKL9 DT Small molecular drug
DMURKL9 PC 44449696
DMURKL9 MW 336.3
DMURKL9 FM C16H12N6O3
DMURKL9 IC InChI=1S/C16H12N6O3/c17-16-19-13(12-2-1-7-25-12)14-15(20-16)21(9-18-14)8-10-3-5-11(6-4-10)22(23)24/h1-7,9H,8H2,(H2,17,19,20)
DMURKL9 CS C1=COC(=C1)C2=C3C(=NC(=N2)N)N(C=N3)CC4=CC=C(C=C4)[N+](=O)[O-]
DMURKL9 IK QAQYSXUIQQIGHU-UHFFFAOYSA-N
DMURKL9 IU 6-(furan-2-yl)-9-[(4-nitrophenyl)methyl]purin-2-amine
DMURKL9 DE Discovery agent
DMGFQLE ID DMGFQLE
DMGFQLE DN 9-(5,5-Difluoro-5-Phosphonopentyl)Guanine
DMGFQLE HS Investigative
DMGFQLE SN 9-(5,5-DIFLUORO-5-PHOSPHONOPENTYL)GUANINE; CHEMBL236708; HA1; 5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-1,1-difluoropentylphosphonate; AC1L9MLH; SCHEMBL2230046; 1v48; BDBM50214705; DB04260; 9-(5'',5''-difluoro-5''-phosphonopentyl)guanine; 5-(2-amino-6-oxo-1H-purin-9-yl)-1,1-difluoropentylphosphonic acid; [5-(2-amino-6-oxo-3H-purin-9-yl)-1,1-difluoropentyl]phosphonic acid; [5-(2-Amino-6-oxo-1,6-dihydro-purin-9-yl)-1,1-difluoro-pentyl]-phosphonic acid; 9-(5',5'-difluoro-5'-phosphonopentyl)guanine
DMGFQLE DT Small molecular drug
DMGFQLE PC 135460987
DMGFQLE MW 337.22
DMGFQLE FM C10H14F2N5O4P
DMGFQLE IC InChI=1S/C10H14F2N5O4P/c11-10(12,22(19,20)21)3-1-2-4-17-5-14-6-7(17)15-9(13)16-8(6)18/h5H,1-4H2,(H2,19,20,21)(H3,13,15,16,18)
DMGFQLE CS C1=NC2=C(N1CCCCC(F)(F)P(=O)(O)O)N=C(NC2=O)N
DMGFQLE IK JANQQPWTLXUSCD-UHFFFAOYSA-N
DMGFQLE IU [5-(2-amino-6-oxo-1H-purin-9-yl)-1,1-difluoropentyl]phosphonic acid
DMGFQLE DE Discovery agent
DM6QDNH ID DM6QDNH
DM6QDNH DN 9-(Aminomethyl)-9,10-dihydroanthracene
DM6QDNH HS Investigative
DM6QDNH SN C-(9,10-Dihydro-anthracen-9-yl)-methylamine
DM6QDNH DT Small molecular drug
DM6QDNH PC 10398175
DM6QDNH MW 209.29
DM6QDNH FM C15H15N
DM6QDNH IC InChI=1S/C15H15N/c16-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)15/h1-8,15H,9-10,16H2
DM6QDNH CS C1C2=CC=CC=C2C(C3=CC=CC=C31)CN
DM6QDNH IK GEICAQNIOJFRQN-UHFFFAOYSA-N
DM6QDNH IU 9,10-dihydroanthracen-9-ylmethanamine
DM6QDNH CA CAS 22136-76-1
DM6QDNH DE Discovery agent
DMIY3D6 ID DMIY3D6
DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one
DMIY3D6 HS Investigative
DMIY3D6 SN SCHEMBL7373122; CHEMBL116578
DMIY3D6 DT Small molecular drug
DMIY3D6 PC 44342872
DMIY3D6 MW 364.4
DMIY3D6 FM C21H23F3O2
DMIY3D6 IC InChI=1S/C21H23F3O2/c22-21(23,24)20(25)11-7-2-1-3-8-16-26-19-14-12-18(13-15-19)17-9-5-4-6-10-17/h4-6,9-10,12-15H,1-3,7-8,11,16H2
DMIY3D6 CS C1=CC=C(C=C1)C2=CC=C(C=C2)OCCCCCCCC(=O)C(F)(F)F
DMIY3D6 IK SJSZPXVUCDJGAB-UHFFFAOYSA-N
DMIY3D6 IU 1,1,1-trifluoro-9-(4-phenylphenoxy)nonan-2-one
DMIY3D6 DE Discovery agent
DMA2RCD ID DMA2RCD
DMA2RCD DN 9-(N-benzylaminomethyl)-9,10-dihydroanthracene
DMA2RCD HS Investigative
DMA2RCD SN CHEMBL349543; 9-(N-benzylaminomethyl)-9,10-dihydroanthracene; BDBM50097644; 9-(Benzylaminomethyl)-9,10-dihydroanthracene
DMA2RCD DT Small molecular drug
DMA2RCD PC 44373281
DMA2RCD MW 299.4
DMA2RCD FM C22H21N
DMA2RCD IC InChI=1S/C22H21N/c1-2-8-17(9-3-1)15-23-16-22-20-12-6-4-10-18(20)14-19-11-5-7-13-21(19)22/h1-13,22-23H,14-16H2
DMA2RCD CS C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCC4=CC=CC=C4
DMA2RCD IK PJLWLZAKVLPHRL-UHFFFAOYSA-N
DMA2RCD IU N-benzyl-1-(9,10-dihydroanthracen-9-yl)methanamine
DMA2RCD DE Discovery agent
DMFKVPA ID DMFKVPA
DMFKVPA DN 9-(sec-Butyl)-9H-adenine
DMFKVPA HS Investigative
DMFKVPA SN CHEMBL466044; 9-(sec-Butyl)-9H-adenine; SCHEMBL240049
DMFKVPA DT Small molecular drug
DMFKVPA PC 44572293
DMFKVPA MW 191.23
DMFKVPA FM C9H13N5
DMFKVPA IC InChI=1S/C9H13N5/c1-3-6(2)14-5-13-7-8(10)11-4-12-9(7)14/h4-6H,3H2,1-2H3,(H2,10,11,12)
DMFKVPA CS CCC(C)N1C=NC2=C(N=CN=C21)N
DMFKVPA IK WUUGZXPFGNZPJO-UHFFFAOYSA-N
DMFKVPA IU 9-butan-2-ylpurin-6-amine
DMFKVPA DE Discovery agent
DMVBCID ID DMVBCID
DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide
DMVBCID HS Investigative
DMVBCID SN 9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553
DMVBCID DT Small molecular drug
DMVBCID PC 9882812
DMVBCID MW 301.3
DMVBCID FM C15H18F3NO2
DMVBCID IC InChI=1S/C15H18F3NO2/c16-15(17,18)13(20)10-6-1-2-7-11-14(21)19-12-8-4-3-5-9-12/h3-5,8-9H,1-2,6-7,10-11H2,(H,19,21)
DMVBCID CS C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)C(F)(F)F
DMVBCID IK KRCXZGYVOZSCSF-UHFFFAOYSA-N
DMVBCID IU 9,9,9-trifluoro-8-oxo-N-phenylnonanamide
DMVBCID DE Discovery agent
DMOGD42 ID DMOGD42
DMOGD42 DN 9-[2-(1-Phosphonobutan-2-yloxy)ethyl]guanine
DMOGD42 HS Investigative
DMOGD42 DT Small molecular drug
DMOGD42 PC 135867624
DMOGD42 MW 331.27
DMOGD42 FM C11H18N5O5P
DMOGD42 IC InChI=1S/C11H18N5O5P/c1-2-7(5-22(18,19)20)21-4-3-16-6-13-8-9(16)14-11(12)15-10(8)17/h6-7H,2-5H2,1H3,(H2,18,19,20)(H3,12,14,15,17)
DMOGD42 CS CCC(CP(=O)(O)O)OCCN1C=NC2=C1N=C(NC2=O)N
DMOGD42 IK RGMQGNHVNYSQHV-UHFFFAOYSA-N
DMOGD42 IU 2-[2-(2-amino-6-oxo-1H-purin-9-yl)ethoxy]butylphosphonic acid
DMOGD42 DE Discovery agent
DMKHXT9 ID DMKHXT9
DMKHXT9 DN 9-[2-(1-Phosphonobutan-2-yloxy)ethyl]hypoxanthine
DMKHXT9 HS Investigative
DMKHXT9 DT Small molecular drug
DMKHXT9 PC 135867626
DMKHXT9 MW 316.25
DMKHXT9 FM C11H17N4O5P
DMKHXT9 IC InChI=1S/C11H17N4O5P/c1-2-8(5-21(17,18)19)20-4-3-15-7-14-9-10(15)12-6-13-11(9)16/h6-8H,2-5H2,1H3,(H,12,13,16)(H2,17,18,19)
DMKHXT9 CS CCC(CP(=O)(O)O)OCCN1C=NC2=C1N=CNC2=O
DMKHXT9 IK WLWRLYCRISPQDH-UHFFFAOYSA-N
DMKHXT9 IU 2-[2-(6-oxo-1H-purin-9-yl)ethoxy]butylphosphonic acid
DMKHXT9 DE Discovery agent
DMCXN6R ID DMCXN6R
DMCXN6R DN 9-[2-(1-Phosphonopropan-2-yloxy)ethyl]guanine
DMCXN6R HS Investigative
DMCXN6R DT Small molecular drug
DMCXN6R PC 135867622
DMCXN6R MW 317.24
DMCXN6R FM C10H16N5O5P
DMCXN6R IC InChI=1S/C10H16N5O5P/c1-6(4-21(17,18)19)20-3-2-15-5-12-7-8(15)13-10(11)14-9(7)16/h5-6H,2-4H2,1H3,(H2,17,18,19)(H3,11,13,14,16)
DMCXN6R CS CC(CP(=O)(O)O)OCCN1C=NC2=C1N=C(NC2=O)N
DMCXN6R IK XUOAETDFEFTPTL-UHFFFAOYSA-N
DMCXN6R IU 2-[2-(2-amino-6-oxo-1H-purin-9-yl)ethoxy]propylphosphonic acid
DMCXN6R DE Discovery agent
DMFR3SD ID DMFR3SD
DMFR3SD DN 9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline
DMFR3SD HS Investigative
DMFR3SD SN CHEMBL1098470; 9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline; SCHEMBL17502362
DMFR3SD DT Small molecular drug
DMFR3SD PC 46223112
DMFR3SD MW 404.5
DMFR3SD FM C27H24N4
DMFR3SD IC InChI=1S/C27H24N4/c1(6-16-30-24-10-4-2-8-20(24)22-12-14-28-18-26(22)30)7-17-31-25-11-5-3-9-21(25)23-13-15-29-19-27(23)31/h2-5,8-15,18-19H,1,6-7,16-17H2
DMFR3SD CS C1=CC=C2C(=C1)C3=C(N2CCCCCN4C5=CC=CC=C5C6=C4C=NC=C6)C=NC=C3
DMFR3SD IK MRZCXQWEBCLSNO-UHFFFAOYSA-N
DMFR3SD IU 9-(5-pyrido[3,4-b]indol-9-ylpentyl)pyrido[3,4-b]indole
DMFR3SD DE Discovery agent
DM6M5A4 ID DM6M5A4
DM6M5A4 DN 9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline
DM6M5A4 HS Investigative
DM6M5A4 SN CHEMBL1098471; 9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline; BDBM50317203
DM6M5A4 DT Small molecular drug
DM6M5A4 PC 46223113
DM6M5A4 MW 460.6
DM6M5A4 FM C31H32N4
DM6M5A4 IC InChI=1S/C31H32N4/c1(2-4-10-20-34-28-14-8-6-12-24(28)26-16-18-32-22-30(26)34)3-5-11-21-35-29-15-9-7-13-25(29)27-17-19-33-23-31(27)35/h6-9,12-19,22-23H,1-5,10-11,20-21H2
DM6M5A4 CS C1=CC=C2C(=C1)C3=C(N2CCCCCCCCCN4C5=CC=CC=C5C6=C4C=NC=C6)C=NC=C3
DM6M5A4 IK JJAATQLWMKLMJU-UHFFFAOYSA-N
DM6M5A4 IU 9-(9-pyrido[3,4-b]indol-9-ylnonyl)pyrido[3,4-b]indole
DM6M5A4 DE Discovery agent
DMJ1VAE ID DMJ1VAE
DMJ1VAE DN 98mTc-CIM-ANT
DMJ1VAE HS Investigative
DMJ1VAE SN 99mTC-chelator SSTR2 antagonist (radiolabeled, neuroendocrine tumor imaging), Molecular Insight
DMJ1VAE CP Molecular Insight Pharmaceuticals Inc
DMJ1VAE DE Neuroendocrine cancer
DMAGTL1 ID DMAGTL1
DMAGTL1 DN 99mTc-EC-0652
DMAGTL1 HS Investigative
DMAGTL1 SN EC-0652; PSMA-targeted imaging agent (prostate cancer), Endocyte; Prostate-specific membrane antigen targeted imaging agent (prostate cancer), Endocyte
DMAGTL1 CP Endocyte Inc
DMAGTL1 DE Prostate cancer
DMQOFX2 ID DMQOFX2
DMQOFX2 DN 99mTc-MIP-1340
DMQOFX2 HS Investigative
DMQOFX2 SN MIP-1340; MIP-1340-[99mTc]; Technetium-99m-MIP-1340
DMQOFX2 CP Molecular Insight Pharmaceuticals Inc
DMQOFX2 DE Prostate cancer
DMYPD5L ID DMYPD5L
DMYPD5L DN 99mTc-MIP-1407
DMYPD5L HS Investigative
DMYPD5L SN MIP-1407; MIP-1407-[99mTc]; Somatostatin receptor modulator imaging agent (neuroendocrine cancer), Molecular Insight; Technetium-99m-MIP-1407
DMYPD5L CP Molecular Insight Pharmaceuticals Inc
DMYPD5L DE Neuroendocrine cancer
DM8VZIY ID DM8VZIY
DM8VZIY DN 9-Allyl-8-bromo-9H-adenine
DM8VZIY HS Investigative
DM8VZIY SN CHEMBL506888; 9-Allyl-8-bromo-9H-adenine; 8-Brom-9-allyladenin
DM8VZIY DT Small molecular drug
DM8VZIY PC 44572408
DM8VZIY MW 254.09
DM8VZIY FM C8H8BrN5
DM8VZIY IC InChI=1S/C8H8BrN5/c1-2-3-14-7-5(13-8(14)9)6(10)11-4-12-7/h2,4H,1,3H2,(H2,10,11,12)
DM8VZIY CS C=CCN1C2=NC=NC(=C2N=C1Br)N
DM8VZIY IK RSFSQISQTSQYRO-UHFFFAOYSA-N
DM8VZIY IU 8-bromo-9-prop-2-enylpurin-6-amine
DM8VZIY DE Discovery agent
DMO9R6T ID DMO9R6T
DMO9R6T DN 9alpha-acetoxy-miller-1(10)Z-enolide
DMO9R6T HS Investigative
DMO9R6T SN CHEMBL433971
DMO9R6T DT Small molecular drug
DMO9R6T PC 44398369
DMO9R6T MW 404.4
DMO9R6T FM C21H24O8
DMO9R6T IC InChI=1S/C21H24O8/c1-10(2)20(25)29-19-15-12(4)21(26)28-18(15)16(24)11(3)7-6-8-14(9-22)17(19)27-13(5)23/h8-9,15-19,24H,1,3-4,6-7H2,2,5H3/b14-8-/t15-,16-,17-,18-,19-/m0/s1
DMO9R6T CS CC(=C)C(=O)O[C@H]1[C@@H]2[C@@H]([C@H](C(=C)CC/C=C(\\[C@@H]1OC(=O)C)/C=O)O)OC(=O)C2=C
DMO9R6T IK QCTYKEDNIPKZDW-QHWUSFJTSA-N
DMO9R6T IU [(3aS,4S,5S,6E,11S,11aS)-5-acetyloxy-6-formyl-11-hydroxy-3,10-dimethylidene-2-oxo-4,5,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DMO9R6T DE Discovery agent
DMNHZFG ID DMNHZFG
DMNHZFG DN 9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol
DMNHZFG HS Investigative
DMNHZFG SN CHEMBL354601; 1,7-Dihydroxytacrine; 9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol; SCHEMBL10846147
DMNHZFG DT Small molecular drug
DMNHZFG PC 15043995
DMNHZFG MW 230.26
DMNHZFG FM C13H14N2O2
DMNHZFG IC InChI=1S/C13H14N2O2/c14-13-8-6-7(16)4-5-9(8)15-10-2-1-3-11(17)12(10)13/h4-6,11,16-17H,1-3H2,(H2,14,15)
DMNHZFG CS C1CC(C2=C(C3=C(C=CC(=C3)O)N=C2C1)N)O
DMNHZFG IK RIGISKTXVJDQAZ-UHFFFAOYSA-N
DMNHZFG IU 9-amino-1,2,3,4-tetrahydroacridine-1,7-diol
DMNHZFG DE Discovery agent
DMUL6QR ID DMUL6QR
DMUL6QR DN 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMUL6QR HS Investigative
DMUL6QR SN 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one; CHEMBL194155; SCHEMBL4078284; BDBM27515; BIBLEFNXUYTZIB-UHFFFAOYSA-N; indeno[1,2-c]isoquinolinone, 2b; ZINC13652899; 5,6-Dihydro-5-oxo-9-amino-indeno[1,2-c]isoquinoline
DMUL6QR DT Small molecular drug
DMUL6QR PC 11288114
DMUL6QR MW 248.28
DMUL6QR FM C16H12N2O
DMUL6QR IC InChI=1S/C16H12N2O/c17-10-5-6-11-9(7-10)8-14-12-3-1-2-4-13(12)16(19)18-15(11)14/h1-7H,8,17H2,(H,18,19)
DMUL6QR CS C1C2=C(C=CC(=C2)N)C3=C1C4=CC=CC=C4C(=O)N3
DMUL6QR IK BIBLEFNXUYTZIB-UHFFFAOYSA-N
DMUL6QR IU 9-amino-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMUL6QR DE Discovery agent
DMNMVCZ ID DMNMVCZ
DMNMVCZ DN 9-amino-7H-dibenzo[de,h]quinolin-7-one
DMNMVCZ HS Investigative
DMNMVCZ SN CHEMBL246681; 9-amino-7H-dibenzo[de,h]quinolin-7-one; 9-Amino-1-azabenzanthrone; SCHEMBL18573118; BDBM50211247; 9-amino-1-aza-benzo[de]anthracen-7-one
DMNMVCZ DT Small molecular drug
DMNMVCZ PC 44440937
DMNMVCZ MW 246.26
DMNMVCZ FM C16H10N2O
DMNMVCZ IC InChI=1S/C16H10N2O/c17-10-4-5-11-13(8-10)16(19)12-3-1-2-9-6-7-18-15(11)14(9)12/h1-8H,17H2
DMNMVCZ CS C1=CC2=C3C(=C1)C(=O)C4=C(C3=NC=C2)C=CC(=C4)N
DMNMVCZ IK SWTAISDIUOZWOE-UHFFFAOYSA-N
DMNMVCZ IU 5-amino-16-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17),14-octaen-8-one
DMNMVCZ DE Discovery agent
DM9123M ID DM9123M
DM9123M DN 9-Aminomethyl-9H-fluorene-2,5,6-triol
DM9123M HS Investigative
DM9123M SN 9-(Aminomethyl)-9H-fluorene-2,5,6-triol; CHEMBL57672; 103692-55-3; 9H-Fluorene-2,5,6-triol,9-(aminomethyl)-; 2,5,6-Tfma; 9-Aminomethyl-9H-fluorene-2,5,6-triol; AC1L3YRM; ACMC-1C8EO; 2,5,6-Trihydroxy-9H-fluorene-9-methanamine; CTK4A2322; BDBM50025202; 9H-Fluorene-2,5,6-triol, 9-(aminomethyl)-
DM9123M DT Small molecular drug
DM9123M PC 124618
DM9123M MW 243.26
DM9123M FM C14H13NO3
DM9123M IC InChI=1S/C14H13NO3/c15-6-11-9-3-4-12(17)14(18)13(9)8-2-1-7(16)5-10(8)11/h1-5,11,16-18H,6,15H2
DM9123M CS C1=CC2=C(C=C1O)C(C3=C2C(=C(C=C3)O)O)CN
DM9123M IK KQVZVMZWAHAQGC-UHFFFAOYSA-N
DM9123M IU 9-(aminomethyl)-9H-fluorene-2,5,6-triol
DM9123M CA CAS 103692-55-3
DM9123M DE Discovery agent
DMNG6O7 ID DMNG6O7
DMNG6O7 DN 9-Aminomethyl-9H-fluorene-3,4-diol
DMNG6O7 HS Investigative
DMNG6O7 SN 103692-53-1; CHEMBL55693; 9H-Fluorene-3,4-diol,9-(aminomethyl)-; 3,4-Dfma; F 103243; 9-(aminomethyl)-9H-fluorene-3,4-diol; Skf 103243; F-103243; ACMC-20m6ix; 3,4-Dihydroxy-9H-fluorene-9-methanamine; AC1L2TS9; CTK4A2321; BDBM50025201; 9H-Fluorene-3,4-diol, 9-(aminomethyl)-
DMNG6O7 DT Small molecular drug
DMNG6O7 PC 128434
DMNG6O7 MW 227.26
DMNG6O7 FM C14H13NO2
DMNG6O7 IC InChI=1S/C14H13NO2/c15-7-11-8-3-1-2-4-9(8)13-10(11)5-6-12(16)14(13)17/h1-6,11,16-17H,7,15H2
DMNG6O7 CS C1=CC=C2C(=C1)C(C3=C2C(=C(C=C3)O)O)CN
DMNG6O7 IK YLOTUMWDVNOPBU-UHFFFAOYSA-N
DMNG6O7 IU 9-(aminomethyl)-9H-fluorene-3,4-diol
DMNG6O7 CA CAS 103692-53-1
DMNG6O7 DE Discovery agent
DMGCVT2 ID DMGCVT2
DMGCVT2 DN 9-anthroic acid
DMGCVT2 HS Investigative
DMGCVT2 SN anthracene-10-carboxylic acid; 9-AC
DMGCVT2 DT Small molecular drug
DMGCVT2 PC 2201
DMGCVT2 MW 222.24
DMGCVT2 FM C15H10O2
DMGCVT2 IC InChI=1S/C15H10O2/c16-15(17)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-9H,(H,16,17)
DMGCVT2 CS C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)O
DMGCVT2 IK XGWFJBFNAQHLEF-UHFFFAOYSA-N
DMGCVT2 IU anthracene-9-carboxylic acid
DMGCVT2 CA CAS 723-62-6
DMGCVT2 CB CHEBI:34507
DMGCVT2 DE Discovery agent
DM8Q0D9 ID DM8Q0D9
DM8Q0D9 DN 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine
DM8Q0D9 HS Investigative
DM8Q0D9 SN SCHEMBL6659707
DM8Q0D9 DT Small molecular drug
DM8Q0D9 PC 11336624
DM8Q0D9 MW 336.4
DM8Q0D9 FM C18H13FN4S
DM8Q0D9 IC InChI=1S/C18H13FN4S/c19-14-6-8-15(9-7-14)24-18-16-17(20-11-21-18)23(12-22-16)10-13-4-2-1-3-5-13/h1-9,11-12H,10H2
DM8Q0D9 CS C1=CC=C(C=C1)CN2C=NC3=C2N=CN=C3SC4=CC=C(C=C4)F
DM8Q0D9 IK MYVLGUBXADPZJM-UHFFFAOYSA-N
DM8Q0D9 IU 9-benzyl-6-(4-fluorophenyl)sulfanylpurine
DM8Q0D9 DE Discovery agent
DM4JG60 ID DM4JG60
DM4JG60 DN 9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine
DM4JG60 HS Investigative
DM4JG60 SN CHEMBL594468; 9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine
DM4JG60 DT Small molecular drug
DM4JG60 PC 46228160
DM4JG60 MW 308.4
DM4JG60 FM C17H20N6
DM4JG60 IC InChI=1S/C17H20N6/c1-21-7-9-22(10-8-21)16-15-17(19-12-18-16)23(13-20-15)11-14-5-3-2-4-6-14/h2-6,12-13H,7-11H2,1H3
DM4JG60 CS CN1CCN(CC1)C2=NC=NC3=C2N=CN3CC4=CC=CC=C4
DM4JG60 IK JSSGUCJSJQMEEQ-UHFFFAOYSA-N
DM4JG60 IU 9-benzyl-6-(4-methylpiperazin-1-yl)purine
DM4JG60 DE Discovery agent
DMNY5P1 ID DMNY5P1
DMNY5P1 DN 9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine
DMNY5P1 HS Investigative
DMNY5P1 SN CHEMBL362047; 9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine; SCHEMBL2965769
DMNY5P1 DT Small molecular drug
DMNY5P1 PC 10237315
DMNY5P1 MW 377.4
DMNY5P1 FM C19H15N5O2S
DMNY5P1 IC InChI=1S/C19H15N5O2S/c25-24(26)16-8-6-15(7-9-16)11-27-19-17-18(20-12-21-19)23(13-22-17)10-14-4-2-1-3-5-14/h1-9,12-13H,10-11H2
DMNY5P1 CS C1=CC=C(C=C1)CN2C=NC3=C2N=CN=C3SCC4=CC=C(C=C4)[N+](=O)[O-]
DMNY5P1 IK VKPWNJKIHUERPQ-UHFFFAOYSA-N
DMNY5P1 IU 9-benzyl-6-[(4-nitrophenyl)methylsulfanyl]purine
DMNY5P1 DE Discovery agent
DMUMOE2 ID DMUMOE2
DMUMOE2 DN 9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile
DMUMOE2 HS Investigative
DMUMOE2 SN Compound 3{8,17}; 9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile; CHEMBL400454
DMUMOE2 DT Small molecular drug
DMUMOE2 PC 24778186
DMUMOE2 MW 340.4
DMUMOE2 FM C20H16N6
DMUMOE2 IC InChI=1S/C20H16N6/c21-11-17-24-19(22-12-15-7-3-1-4-8-15)18-20(25-17)26(14-23-18)13-16-9-5-2-6-10-16/h1-10,14H,12-13H2,(H,22,24,25)
DMUMOE2 CS C1=CC=C(C=C1)CNC2=C3C(=NC(=N2)C#N)N(C=N3)CC4=CC=CC=C4
DMUMOE2 IK VVLPZPSTQWLQHU-UHFFFAOYSA-N
DMUMOE2 IU 9-benzyl-6-(benzylamino)purine-2-carbonitrile
DMUMOE2 DE Discovery agent
DMO6CB7 ID DMO6CB7
DMO6CB7 DN 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine
DMO6CB7 HS Investigative
DMO6CB7 SN CHEMBL196436; 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine; SCHEMBL3268454; 2-amino-6-furyl-9-benzyl purine; BDBM50165066
DMO6CB7 DT Small molecular drug
DMO6CB7 PC 44401938
DMO6CB7 MW 291.31
DMO6CB7 FM C16H13N5O
DMO6CB7 IC InChI=1S/C16H13N5O/c17-16-19-13(12-7-4-8-22-12)14-15(20-16)21(10-18-14)9-11-5-2-1-3-6-11/h1-8,10H,9H2,(H2,17,19,20)
DMO6CB7 CS C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
DMO6CB7 IK FZKKCBUDFSOYPA-UHFFFAOYSA-N
DMO6CB7 IU 9-benzyl-6-(furan-2-yl)purin-2-amine
DMO6CB7 DE Discovery agent
DMNCL5G ID DMNCL5G
DMNCL5G DN 9-Benzyl-6-phenylsulfanyl-9H-purine
DMNCL5G HS Investigative
DMNCL5G SN SCHEMBL6662063
DMNCL5G DT Small molecular drug
DMNCL5G PC 11347708
DMNCL5G MW 318.4
DMNCL5G FM C18H14N4S
DMNCL5G IC InChI=1S/C18H14N4S/c1-3-7-14(8-4-1)11-22-13-21-16-17(22)19-12-20-18(16)23-15-9-5-2-6-10-15/h1-10,12-13H,11H2
DMNCL5G CS C1=CC=C(C=C1)CN2C=NC3=C2N=CN=C3SC4=CC=CC=C4
DMNCL5G IK ADCGNZUTMCMTDC-UHFFFAOYSA-N
DMNCL5G IU 9-benzyl-6-phenylsulfanylpurine
DMNCL5G DE Discovery agent
DMMWGVI ID DMMWGVI
DMMWGVI DN 9-Benzyl-8-bromo-9H-adenine
DMMWGVI HS Investigative
DMMWGVI SN 9-benzyl-8-bromoadenine; CHEMBL151071; 9-benzyl-8-bromo-9H-purin-6-amine; 56046-34-5; 9-Benzyl-8-bromo-9H-adenine; 8-bromo-9-benzyladenine; N9-benzyl-8-bromoadenine; 8-Bromo-N9-benzyladenine; SCHEMBL4341941; OUPAEJUFVKPEHM-UHFFFAOYSA-N; BDBM50240851; 6-Amino-8-bromo-9-benzyl-9H-purine; 9-Benzyl-8-bromo-9H-purin-6-ylamine; 9-benzyl-8-bromo-9H-purin-6-yl amine
DMMWGVI DT Small molecular drug
DMMWGVI PC 9904551
DMMWGVI MW 304.15
DMMWGVI FM C12H10BrN5
DMMWGVI IC InChI=1S/C12H10BrN5/c13-12-17-9-10(14)15-7-16-11(9)18(12)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,14,15,16)
DMMWGVI CS C1=CC=C(C=C1)CN2C3=NC=NC(=C3N=C2Br)N
DMMWGVI IK OUPAEJUFVKPEHM-UHFFFAOYSA-N
DMMWGVI IU 9-benzyl-8-bromopurin-6-amine
DMMWGVI DE Discovery agent
DMONCUL ID DMONCUL
DMONCUL DN 9-BENZYL-9H-ADENINE
DMONCUL HS Investigative
DMONCUL SN 9-Benzyladenine; 4261-14-7; 9-benzyl-9H-purin-6-amine; N9-Benzyladenine; 9-Benzylaminopurine; ADENINE, 9-BENZYL-; 9-Bap; 9-Benzyl-6-aminopurine; N(sup 9)-Benzyladenine; 9-BENZYL-9H-ADENINE; 9-Benzyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-(phenylmethyl)-; CCRIS 6908; SQ 21611; 9-benzylpurin-6-amine; NSC 35649; 9-(Phenylmethyl)-9H-purin-6-amine; CHEMBL266094; 9H-Purin-6-amine,9-(phenylmethyl)-; AC1L2FWA; MLS000660735; SCHEMBL104932; 9-Benzyl-9H-purine-6-amine; CTK4I6467; DTXSID70195371; MRHCSNNEUHXNIC-UHFFFAOYSA-N; HMS2676M21
DMONCUL DT Small molecular drug
DMONCUL PC 20262
DMONCUL MW 225.25
DMONCUL FM C12H11N5
DMONCUL IC InChI=1S/C12H11N5/c13-11-10-12(15-7-14-11)17(8-16-10)6-9-4-2-1-3-5-9/h1-5,7-8H,6H2,(H2,13,14,15)
DMONCUL CS C1=CC=C(C=C1)CN2C=NC3=C(N=CN=C32)N
DMONCUL IK MRHCSNNEUHXNIC-UHFFFAOYSA-N
DMONCUL IU 9-benzylpurin-6-amine
DMONCUL CA CAS 4261-14-7
DMONCUL DE Discovery agent
DMQEO7F ID DMQEO7F
DMQEO7F DN 9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMQEO7F HS Investigative
DMQEO7F SN 9-Bromoellipticine; Ellipticine, 9-bromo-; 9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; 18073-34-2; NSC 98927; BRN 0543507; CHEMBL194474; NSC98927; 9-Bromo-5,11-dimethyl-6H-pyrido(4,3-b)carbazole; 6H-Pyrido(4,3-b)carbazole, 9-bromo-5,11-dimethyl-; AC1L3XSF; 5-23-09-00418 (Beilstein Handbook Reference); DTXSID80171005; ZINC13284221; NSC-98927; BDBM50174409; ACM18073342; 6H-Pyrido[4, 9-bromo-5,11-dimethyl-
DMQEO7F DT Small molecular drug
DMQEO7F PC 97080
DMQEO7F MW 325.2
DMQEO7F FM C17H13BrN2
DMQEO7F IC InChI=1S/C17H13BrN2/c1-9-14-8-19-6-5-12(14)10(2)17-16(9)13-7-11(18)3-4-15(13)20-17/h3-8,20H,1-2H3
DMQEO7F CS CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)Br)C
DMQEO7F IK OSDDZVXUCKZOQA-UHFFFAOYSA-N
DMQEO7F IU 9-bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMQEO7F CA CAS 18073-34-2
DMQEO7F DE Discovery agent
DMSWQY7 ID DMSWQY7
DMSWQY7 DN 9-But-3-enyl-9H-adenine
DMSWQY7 HS Investigative
DMSWQY7 SN CHEMBL510907; 9-But-3-enyl-9H-adenine; BDBM50256954
DMSWQY7 DT Small molecular drug
DMSWQY7 PC 13789211
DMSWQY7 MW 189.22
DMSWQY7 FM C9H11N5
DMSWQY7 IC InChI=1S/C9H11N5/c1-2-3-4-14-6-13-7-8(10)11-5-12-9(7)14/h2,5-6H,1,3-4H2,(H2,10,11,12)
DMSWQY7 CS C=CCCN1C=NC2=C(N=CN=C21)N
DMSWQY7 IK LMZZJSTVOIDJFV-UHFFFAOYSA-N
DMSWQY7 IU 9-but-3-enylpurin-6-amine
DMSWQY7 DE Discovery agent
DMXU90T ID DMXU90T
DMXU90T DN 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
DMXU90T HS Investigative
DMXU90T SN 9-BUTYL-8-(3-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL109612; AC1NRCWL; 1uy8; Purine-Based Inhibitor 3; SCHEMBL1966787; BDBM15376; BWLWUGBHOXIUBP-UHFFFAOYSA-N; DB03809; 8-(3-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine; 9-Butyl-8-(3-methoxy-benzyl)-9H-purin-6-ylamine
DMXU90T DT Small molecular drug
DMXU90T PC 5289228
DMXU90T MW 311.4
DMXU90T FM C17H21N5O
DMXU90T IC InChI=1S/C17H21N5O/c1-3-4-8-22-14(10-12-6-5-7-13(9-12)23-2)21-15-16(18)19-11-20-17(15)22/h5-7,9,11H,3-4,8,10H2,1-2H3,(H2,18,19,20)
DMXU90T CS CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC(=CC=C3)OC
DMXU90T IK BWLWUGBHOXIUBP-UHFFFAOYSA-N
DMXU90T IU 9-butyl-8-[(3-methoxyphenyl)methyl]purin-6-amine
DMXU90T DE Discovery agent
DMKHPAE ID DMKHPAE
DMKHPAE DN 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
DMKHPAE HS Investigative
DMKHPAE SN 9-BUTYL-8-(4-METHOXYBENZYL)-9H-PURIN-6-AMINE; CHEMBL112834; 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine; 376629-53-7; PU4; AC1NRCWI; 1uy7; Purine-Based Inhibitor 2; SCHEMBL4320278; CTK1A9432; BDBM15375; DTXSID80415355; AKOS030562187; DB03899; 8-(4-Methoxybenzyl)-9-butyl-9H-purine-6-amine; 9-butyl-8-[(4-methoxyphenyl)methyl]-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl-8-[(4-methoxyphenyl)methyl]-
DMKHPAE DT Small molecular drug
DMKHPAE PC 5289227
DMKHPAE MW 311.4
DMKHPAE FM C17H21N5O
DMKHPAE IC InChI=1S/C17H21N5O/c1-3-4-9-22-14(10-12-5-7-13(23-2)8-6-12)21-15-16(18)19-11-20-17(15)22/h5-8,11H,3-4,9-10H2,1-2H3,(H2,18,19,20)
DMKHPAE CS CCCCN1C(=NC2=C(N=CN=C21)N)CC3=CC=C(C=C3)OC
DMKHPAE IK NVYATAJRTRFKSW-UHFFFAOYSA-N
DMKHPAE IU 9-butyl-8-[(4-methoxyphenyl)methyl]purin-6-amine
DMKHPAE CA CAS 376629-53-7
DMKHPAE DE Discovery agent
DMZQLBD ID DMZQLBD
DMZQLBD DN 9-Butyl-9H-adenine
DMZQLBD HS Investigative
DMZQLBD SN 2715-70-0; 9-butyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-butyl-; 9-Butyl-9H-purin-6-amine; 9H-Purin-6-amine, 9-butyl- (9CI); CHEMBL449628; 9-Butyl-9H-adenine; 9-butylpurin-6-amine; 9-butyladenine; NSC19094; NSC 19094; Adenine, 9-butyl-; AC1L2PTM; AC1Q4VHO; 9H-Purin-6-amine,9-butyl-; SCHEMBL1074972; CTK4F9171; DTXSID10181617; MolPort-011-342-029; BKXMJMZKKNIYRD-UHFFFAOYSA-N; ZINC1562338; NSC-19094; BDBM50256951; AKOS012922662; MCULE-9977877843; 9-Butyl-9H-purin-6-amine, AldrichCPR
DMZQLBD DT Small molecular drug
DMZQLBD PC 75929
DMZQLBD MW 191.23
DMZQLBD FM C9H13N5
DMZQLBD IC InChI=1S/C9H13N5/c1-2-3-4-14-6-13-7-8(10)11-5-12-9(7)14/h5-6H,2-4H2,1H3,(H2,10,11,12)
DMZQLBD CS CCCCN1C=NC2=C(N=CN=C21)N
DMZQLBD IK BKXMJMZKKNIYRD-UHFFFAOYSA-N
DMZQLBD IU 9-butylpurin-6-amine
DMZQLBD CA CAS 2715-70-0
DMZQLBD DE Discovery agent
DMK5DUA ID DMK5DUA
DMK5DUA DN 9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMK5DUA HS Investigative
DMK5DUA SN CHEMBL429599; 9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; SCHEMBL11973725; JVPPTVNJBXFSPQ-UHFFFAOYSA-N; BDBM50372498; NCGC00163054-01; CU-00000000357-1; 2-(8-Amino*-7-quinolinyl)-4-chlorobenzenesulfonic acid sultam
DMK5DUA DT Small molecular drug
DMK5DUA PC 16759933
DMK5DUA MW 316.8
DMK5DUA FM C15H9ClN2O2S
DMK5DUA IC InChI=1S/C15H9ClN2O2S/c16-10-4-6-13-12(8-10)11-5-3-9-2-1-7-17-14(9)15(11)18-21(13,19)20/h1-8,18H
DMK5DUA CS C1=CC2=C(C3=C(C=C2)C4=C(C=CC(=C4)Cl)S(=O)(=O)N3)N=C1
DMK5DUA IK JVPPTVNJBXFSPQ-UHFFFAOYSA-N
DMK5DUA IU 9-chloro-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DMK5DUA DE Discovery agent
DM6EFN2 ID DM6EFN2
DM6EFN2 DN 9-chlorobenzo[h]isoquinolin-1(2H)-one
DM6EFN2 HS Investigative
DM6EFN2 SN 9-chlorobenzo[h]isoquinolin-1(2H)-one; CHEMBL248988; 919290-40-7; SCHEMBL4296798; CTK3H3900; DTXSID50475406; XSQDWQSZUGGKPF-UHFFFAOYSA-N; ZINC28955758; BDBM50223471; Benz[h]isoquinolin-1(2H)-one, 9-chloro-
DM6EFN2 DT Small molecular drug
DM6EFN2 PC 11993732
DM6EFN2 MW 229.66
DM6EFN2 FM C13H8ClNO
DM6EFN2 IC InChI=1S/C13H8ClNO/c14-10-4-3-8-1-2-9-5-6-15-13(16)12(9)11(8)7-10/h1-7H,(H,15,16)
DM6EFN2 CS C1=CC2=C(C3=C1C=CC(=C3)Cl)C(=O)NC=C2
DM6EFN2 IK XSQDWQSZUGGKPF-UHFFFAOYSA-N
DM6EFN2 IU 9-chloro-2H-benzo[h]isoquinolin-1-one
DM6EFN2 CA CAS 919290-40-7
DM6EFN2 DE Discovery agent
DM04QWX ID DM04QWX
DM04QWX DN 9-Cyclobutyl-9H-adenine
DM04QWX HS Investigative
DM04QWX SN 9-Cyclobutyladenine; 9-Cyclobutyl-9H-adenine; 9-cBuA; 9H-Purin-6-amine, 9-cyclobutyl-; 132406-73-6; 9-cyclobutylpurin-6-amine; CHEMBL455493; AC1L9QF6; 9-Cyclobutyl-9H-purin-6-amine; CTK4B7898; DTXSID80157526; BDBM50257000
DM04QWX DT Small molecular drug
DM04QWX PC 452612
DM04QWX MW 189.22
DM04QWX FM C9H11N5
DM04QWX IC InChI=1S/C9H11N5/c10-8-7-9(12-4-11-8)14(5-13-7)6-2-1-3-6/h4-6H,1-3H2,(H2,10,11,12)
DM04QWX CS C1CC(C1)N2C=NC3=C(N=CN=C32)N
DM04QWX IK JGFAEEKLMAWINF-UHFFFAOYSA-N
DM04QWX IU 9-cyclobutylpurin-6-amine
DM04QWX CA CAS 132406-73-6
DM04QWX DE Discovery agent
DMP8VM2 ID DMP8VM2
DMP8VM2 DN 9-Cycloheptyl-9H-adenine
DMP8VM2 HS Investigative
DMP8VM2 SN 9-cycloheptylpurin-6-amine; 9-cycloheptyl-9h-purin-6-amine; CHEMBL62835; 6961-60-0; 9-Cycloheptyl-9H-adenine; NSC62733; AC1L6KRZ; AC1Q4VH9; CTK5D0614; DTXSID20289678; 6-Amino-9-cycloheptyl-9H-purine; 9-Cycloheptyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-cycloheptyl-; BDBM50013702; NSC-62733
DMP8VM2 DT Small molecular drug
DMP8VM2 PC 247678
DMP8VM2 MW 231.3
DMP8VM2 FM C12H17N5
DMP8VM2 IC InChI=1S/C12H17N5/c13-11-10-12(15-7-14-11)17(8-16-10)9-5-3-1-2-4-6-9/h7-9H,1-6H2,(H2,13,14,15)
DMP8VM2 CS C1CCCC(CC1)N2C=NC3=C(N=CN=C32)N
DMP8VM2 IK FHZRSYFMJLJWBS-UHFFFAOYSA-N
DMP8VM2 IU 9-cycloheptylpurin-6-amine
DMP8VM2 CA CAS 6961-60-0
DMP8VM2 DE Discovery agent
DMSGU2L ID DMSGU2L
DMSGU2L DN 9-Cyclopentyl-9H-adenine
DMSGU2L HS Investigative
DMSGU2L SN 9-Cyclopentyl-9H-purin-6-ylamine
DMSGU2L DT Small molecular drug
DMSGU2L PC 12852
DMSGU2L MW 203.24
DMSGU2L FM C10H13N5
DMSGU2L IC InChI=1S/C10H13N5/c11-9-8-10(13-5-12-9)15(6-14-8)7-3-1-2-4-7/h5-7H,1-4H2,(H2,11,12,13)
DMSGU2L CS C1CCC(C1)N2C=NC3=C(N=CN=C32)N
DMSGU2L IK KTJWHJNBTXITCB-UHFFFAOYSA-N
DMSGU2L IU 9-cyclopentylpurin-6-amine
DMSGU2L CA CAS 715-91-3
DMSGU2L DE Discovery agent
DMAFCZL ID DMAFCZL
DMAFCZL DN 9-Cyclopropyl-9H-adenine
DMAFCZL HS Investigative
DMAFCZL SN CHEMBL469409; 9-Cyclopropyl-9H-adenine; 9-cyclopropylpurin-6-amine; AC1L987W
DMAFCZL DT Small molecular drug
DMAFCZL PC 414708
DMAFCZL MW 175.19
DMAFCZL FM C8H9N5
DMAFCZL IC InChI=1S/C8H9N5/c9-7-6-8(11-3-10-7)13(4-12-6)5-1-2-5/h3-5H,1-2H2,(H2,9,10,11)
DMAFCZL CS C1CC1N2C=NC3=C(N=CN=C32)N
DMAFCZL IK QKMZACGKMJHVSI-UHFFFAOYSA-N
DMAFCZL IU 9-cyclopropylpurin-6-amine
DMAFCZL DE Discovery agent
DM68IPZ ID DM68IPZ
DM68IPZ DN 9-Deazaguanine
DM68IPZ HS Investigative
DM68IPZ DT Small molecular drug
DM68IPZ PC 135461003
DM68IPZ MW 150.14
DM68IPZ FM C6H6N4O
DM68IPZ IC InChI=1S/C6H6N4O/c7-6-9-3-1-2-8-4(3)5(11)10-6/h1-2,8H,(H3,7,9,10,11)
DM68IPZ CS C1=CNC2=C1N=C(NC2=O)N
DM68IPZ IK FFYPRJYSJODFFD-UHFFFAOYSA-N
DM68IPZ IU 2-amino-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DM68IPZ CA CAS 65996-58-9
DM68IPZ DE Discovery agent
DM3G6LY ID DM3G6LY
DM3G6LY DN 9-Deazahypoxanthine
DM3G6LY HS Investigative
DM3G6LY DT Small molecular drug
DM3G6LY PC 135488881
DM3G6LY MW 135.12
DM3G6LY FM C6H5N3O
DM3G6LY IC InChI=1S/C6H5N3O/c10-6-5-4(1-2-7-5)8-3-9-6/h1-3,7H,(H,8,9,10)
DM3G6LY CS C1=CNC2=C1N=CNC2=O
DM3G6LY IK UWMXUDUWVFWJPX-UHFFFAOYSA-N
DM3G6LY IU 3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DM3G6LY DE Discovery agent
DME7ONQ ID DME7ONQ
DME7ONQ DN 9-Deazainosine
DME7ONQ HS Investigative
DME7ONQ DT Small molecular drug
DME7ONQ PC 135483765
DME7ONQ MW 267.24
DME7ONQ FM C11H13N3O5
DME7ONQ IC InChI=1S/C11H13N3O5/c15-2-5-8(16)9(17)10(19-5)4-1-12-7-6(4)13-3-14-11(7)18/h1,3,5,8-10,12,15-17H,2H2,(H,13,14,18)/t5-,8-,9-,10+/m1/s1
DME7ONQ CS C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DME7ONQ IK WKDMPDYUJKSXBW-KBHCAIDQSA-N
DME7ONQ IU 7-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DME7ONQ CA CAS 89458-19-5
DME7ONQ DE Discovery agent
DM9BCDT ID DM9BCDT
DM9BCDT DN 9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
DM9BCDT HS Investigative
DM9BCDT DT Small molecular drug
DM9BCDT PC 135464487
DM9BCDT MW 373.25
DM9BCDT FM C13H16N3O8P
DM9BCDT IC InChI=1S/C13H16N3O8P/c17-2-6-11-12(24-7(23-11)3-25(19,20)21)10(22-6)5-1-14-9-8(5)15-4-16-13(9)18/h1,4,6-7,10-12,14,17H,2-3H2,(H,15,16,18)(H2,19,20,21)/t6-,7-,10+,11-,12+/m1/s1
DM9BCDT CS C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@H]4[C@@H]([C@H](O3)CO)O[C@H](O4)CP(=O)(O)O
DM9BCDT IK ZOEDLCUBOBTIHG-USQSKNHBSA-N
DM9BCDT IU [(2S,3aS,4S,6R,6aR)-6-(hydroxymethyl)-4-(4-oxo-3,5-dihydropyrrolo[3,2-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]methylphosphonic acid
DM9BCDT DE Discovery agent
DM70MPJ ID DM70MPJ
DM70MPJ DN 9-Ethyl-2-methyl-beta-carboline-2-ium iodide
DM70MPJ HS Investigative
DM70MPJ SN CHEMBL1097826
DM70MPJ DT Small molecular drug
DM70MPJ PC 46223109
DM70MPJ MW 211.28
DM70MPJ FM C14H15N2+
DM70MPJ IC InChI=1S/C14H15N2/c1-3-16-13-7-5-4-6-11(13)12-8-9-15(2)10-14(12)16/h4-10H,3H2,1-2H3/q+1
DM70MPJ CS CCN1C2=CC=CC=C2C3=C1C=[N+](C=C3)C
DM70MPJ IK UYPDJRFFVNWZQV-UHFFFAOYSA-N
DM70MPJ IU 9-ethyl-2-methylpyrido[3,4-b]indol-2-ium
DM70MPJ DE Discovery agent
DMRVS2D ID DMRVS2D
DMRVS2D DN 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine
DMRVS2D HS Investigative
DMRVS2D SN CHEMBL61259; 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine; 8-phenylethynyl-9-ethyladenine; BDBM50102169
DMRVS2D DT Small molecular drug
DMRVS2D PC 44300688
DMRVS2D MW 263.3
DMRVS2D FM C15H13N5
DMRVS2D IC InChI=1S/C15H13N5/c1-2-20-12(9-8-11-6-4-3-5-7-11)19-13-14(16)17-10-18-15(13)20/h3-7,10H,2H2,1H3,(H2,16,17,18)
DMRVS2D CS CCN1C(=NC2=C(N=CN=C21)N)C#CC3=CC=CC=C3
DMRVS2D IK AXENMZHFYBPHQF-UHFFFAOYSA-N
DMRVS2D IU 9-ethyl-8-(2-phenylethynyl)purin-6-amine
DMRVS2D DE Discovery agent
DMWV8YX ID DMWV8YX
DMWV8YX DN 9-Ethyl-9H-adenine
DMWV8YX HS Investigative
DMWV8YX SN 9-ethyl-9h-purin-6-amine; 2715-68-6; 9-Ethyladenine; 9H-Purin-6-amine,9-ethyl; N9-Ethyladenine; 9-ethylpurin-6-amine; 9H-Purin-6-amine, 9-ethyl-; 9-ethyl adenine; 9-Ethyl-9H-purin-6-ylamine; 9H-Purin-6-amine,9-ethyl-; CHEMBL304009; Adenine, 9-ethyl-; 9-Ethyl-9H-adenine; N9 -ethyladenine; NSC 14580; 6-Amino-9-ethylpurine; AC1Q4VHH; ACMC-1CJP6; (9-ethylpurin-6-yl)amine; Adenine, 9-ethyl- (8CI); AC1L189M; SCHEMBL1924594; CTK4F9170; DTXSID50181616; MUIPLRMGAXZWSQ-UHFFFAOYSA-N; MolPort-004-964-357; ZINC402896; NSC14580; KS-000000ID
DMWV8YX DT Small molecular drug
DMWV8YX PC 7
DMWV8YX MW 163.18
DMWV8YX FM C7H9N5
DMWV8YX IC InChI=1S/C7H9N5/c1-2-12-4-11-5-6(8)9-3-10-7(5)12/h3-4H,2H2,1H3,(H2,8,9,10)
DMWV8YX CS CCN1C=NC2=C(N=CN=C21)N
DMWV8YX IK MUIPLRMGAXZWSQ-UHFFFAOYSA-N
DMWV8YX IU 9-ethylpurin-6-amine
DMWV8YX CA CAS 2715-68-6
DMWV8YX DE Discovery agent
DMHKUO9 ID DMHKUO9
DMHKUO9 DN 9-Ethyl-beta-carboline
DMHKUO9 HS Investigative
DMHKUO9 SN 9-Ethyl-beta-carboline; CHEMBL1097825; SCHEMBL2220005; BMGUCVPPDGYFRV-UHFFFAOYSA-N
DMHKUO9 DT Small molecular drug
DMHKUO9 PC 14221745
DMHKUO9 MW 196.25
DMHKUO9 FM C13H12N2
DMHKUO9 IC InChI=1S/C13H12N2/c1-2-15-12-6-4-3-5-10(12)11-7-8-14-9-13(11)15/h3-9H,2H2,1H3
DMHKUO9 CS CCN1C2=CC=CC=C2C3=C1C=NC=C3
DMHKUO9 IK BMGUCVPPDGYFRV-UHFFFAOYSA-N
DMHKUO9 IU 9-ethylpyrido[3,4-b]indole
DMHKUO9 DE Discovery agent
DMLK0TX ID DMLK0TX
DMLK0TX DN 9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMLK0TX HS Investigative
DMLK0TX SN CHEMBL270799; 9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; SCHEMBL11972977; KNMYXLXOQAHLHK-UHFFFAOYSA-N; BDBM50372499; NCGC00163040-01
DMLK0TX DT Small molecular drug
DMLK0TX PC 16759921
DMLK0TX MW 300.31
DMLK0TX FM C15H9FN2O2S
DMLK0TX IC InChI=1S/C15H9FN2O2S/c16-10-4-6-13-12(8-10)11-5-3-9-2-1-7-17-14(9)15(11)18-21(13,19)20/h1-8,18H
DMLK0TX CS C1=CC2=C(C3=C(C=C2)C4=C(C=CC(=C4)F)S(=O)(=O)N3)N=C1
DMLK0TX IK KNMYXLXOQAHLHK-UHFFFAOYSA-N
DMLK0TX IU 9-fluoro-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DMLK0TX DE Discovery agent
DMGAE9Z ID DMGAE9Z
DMGAE9Z DN 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one
DMGAE9Z HS Investigative
DMGAE9Z SN CHEMBL190895; BDBM27513; indeno[1,2-c]isoquinolinone, 1e; 9-Fluoro-5,6-dihydro-11H-indeno[1,2-c]isoquinoline-5-one
DMGAE9Z DT Small molecular drug
DMGAE9Z PC 25190932
DMGAE9Z MW 251.25
DMGAE9Z FM C16H10FNO
DMGAE9Z IC InChI=1S/C16H10FNO/c17-10-5-6-11-9(7-10)8-14-12-3-1-2-4-13(12)16(19)18-15(11)14/h1-7H,8H2,(H,18,19)
DMGAE9Z CS C1C2=C(C=CC(=C2)F)C3=C1C4=CC=CC=C4C(=O)N3
DMGAE9Z IK YZRNXEMHDKXRRA-UHFFFAOYSA-N
DMGAE9Z IU 9-fluoro-6,11-dihydroindeno[1,2-c]isoquinolin-5-one
DMGAE9Z DE Discovery agent
DMBWAMR ID DMBWAMR
DMBWAMR DN 9H-beta-Carbolin-3-ol
DMBWAMR HS Investigative
DMBWAMR SN 3-hydroxy-beta-carboline; 91985-78-3; 3H-Pyrido[3,4-b]indol-3-one, 2,9-dihydro-; beta-Carbolin-3-ol; ACMC-20lva1; CHEMBL443140; CHEMBL299662; SCHEMBL10644440; CTK3H2577; 9H-pyrido[3,4-b]indol-3-ol; DTXSID90556566; UDTDJSXOXQLKGM-UHFFFAOYSA-N; AKOS006373463
DMBWAMR DT Small molecular drug
DMBWAMR PC 14146438
DMBWAMR MW 184.19
DMBWAMR FM C11H8N2O
DMBWAMR IC InChI=1S/C11H8N2O/c14-11-5-8-7-3-1-2-4-9(7)13-10(8)6-12-11/h1-6,13H,(H,12,14)
DMBWAMR CS C1=CC=C2C(=C1)C3=CC(=O)NC=C3N2
DMBWAMR IK UDTDJSXOXQLKGM-UHFFFAOYSA-N
DMBWAMR IU 2,9-dihydropyrido[3,4-b]indol-3-one
DMBWAMR CA CAS 91985-78-3
DMBWAMR DE Discovery agent
DMBLEI7 ID DMBLEI7
DMBLEI7 DN 9H-beta-Carbolin-6-ylamine
DMBLEI7 HS Investigative
DMBLEI7 SN 9H-pyrido[3,4-b]indol-6-amine; 6-amino-beta-carboline; 6453-27-6; NSC248004; AC1L7VIB; CHEMBL164120; SCHEMBL10642567; PPCJCNSRVOYTKC-UHFFFAOYSA-N; AKOS022912596
DMBLEI7 DT Small molecular drug
DMBLEI7 PC 317218
DMBLEI7 MW 183.21
DMBLEI7 FM C11H9N3
DMBLEI7 IC InChI=1S/C11H9N3/c12-7-1-2-10-9(5-7)8-3-4-13-6-11(8)14-10/h1-6,14H,12H2
DMBLEI7 CS C1=CC2=C(C=C1N)C3=C(N2)C=NC=C3
DMBLEI7 IK PPCJCNSRVOYTKC-UHFFFAOYSA-N
DMBLEI7 IU 9H-pyrido[3,4-b]indol-6-amine
DMBLEI7 DE Discovery agent
DMK459I ID DMK459I
DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester
DMK459I HS Investigative
DMK459I SN Ethyl beta-carboline-3-carboxylate; beta-CCE; 74214-62-3; Ethyl 9H-pyrido[3,4-b]indole-3-carboxylate; beta-Carboline-3-carboxylic acid ethyl ester; UNII-HYW8K5N21Y; Ethyl 9H-pyrido(3,4-b)indole-3-carboxylate; HYW8K5N21Y; Ro 15-2538; CHEMBL11709; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, ethyl ester; MLS000069492; CHEMBL454606; KOVRZNUMIKACTB-UHFFFAOYSA-N; SMR000059107; 9H-Pyrido[3,4-b]indole-3-carboxylic acid, ethyl ester; b-cce; Ethylbeta-carboline-3-carboxylate; Beta CCE
DMK459I DT Small molecular drug
DMK459I PC 105078
DMK459I MW 240.26
DMK459I FM C14H12N2O2
DMK459I IC InChI=1S/C14H12N2O2/c1-2-18-14(17)12-7-10-9-5-3-4-6-11(9)16-13(10)8-15-12/h3-8,16H,2H2,1H3
DMK459I CS CCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMK459I IK KOVRZNUMIKACTB-UHFFFAOYSA-N
DMK459I IU ethyl 9H-pyrido[3,4-b]indole-3-carboxylate
DMK459I CA CAS 74214-62-3
DMK459I CB CHEBI:92850
DMK459I DE Discovery agent
DMMUH98 ID DMMUH98
DMMUH98 DN 9H-beta-Carboline-3-carboxylic acid propyl ester
DMMUH98 HS Investigative
DMMUH98 SN beta-Ccp; 76808-18-9; beta-Carboline-3-carboxylic acid propyl ester; propyl beta-carboline-3-carboxylate; Pbc-3-C; propyl 9H-pyrido[3,4-b]indole-3-carboxylate; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, propyl ester; C15H14N2O2; Beta CCP; Biomol-NT_000275; AC1Q2Y9C; AC1L3X2D; AC1Q66NN; .beta.-Carboline-3-carboxylic acid propyl ester; SCHEMBL2348263; 9H-B-CARBOLINE-3-CARBOXYLIC ACID PROPYL ESTER; CHEMBL274847; BPBio1_001101; CTK5E3459; CHEBI:93491; BDBM84992; DTXSID30227627; WGRVAGIQTHEEQW-UHFFFAOYSA-N; ZINC2391117; PDSP2_001744
DMMUH98 DT Small molecular drug
DMMUH98 PC 123662
DMMUH98 MW 254.28
DMMUH98 FM C15H14N2O2
DMMUH98 IC InChI=1S/C15H14N2O2/c1-2-7-19-15(18)13-8-11-10-5-3-4-6-12(10)17-14(11)9-16-13/h3-6,8-9,17H,2,7H2,1H3
DMMUH98 CS CCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMMUH98 IK WGRVAGIQTHEEQW-UHFFFAOYSA-N
DMMUH98 IU propyl 9H-pyrido[3,4-b]indole-3-carboxylate
DMMUH98 CA CAS 76808-18-9
DMMUH98 CB CHEBI:93491
DMMUH98 DE Discovery agent
DM6WHIA ID DM6WHIA
DM6WHIA DN 9H-carbazole-2-carbaldehyde
DM6WHIA HS Investigative
DM6WHIA SN 9H-CARBAZOLE-2-CARBALDEHYDE; 9H-Carbazole-2-carboxaldehyde; 99585-18-9; CHEMBL1172395; SCHEMBL7963280; CTK3I5755; DTXSID90479100; LCENSQOWDHIKAN-UHFFFAOYSA-N; ZINC22003786; BDBM50322588; AKOS006329833; DB-080615; AB0108318
DM6WHIA DT Small molecular drug
DM6WHIA PC 12169810
DM6WHIA MW 195.22
DM6WHIA FM C13H9NO
DM6WHIA IC InChI=1S/C13H9NO/c15-8-9-5-6-11-10-3-1-2-4-12(10)14-13(11)7-9/h1-8,14H
DM6WHIA CS C1=CC=C2C(=C1)C3=C(N2)C=C(C=C3)C=O
DM6WHIA IK LCENSQOWDHIKAN-UHFFFAOYSA-N
DM6WHIA IU 9H-carbazole-2-carbaldehyde
DM6WHIA CA CAS 99585-18-9
DM6WHIA DE Discovery agent
DM0HNU3 ID DM0HNU3
DM0HNU3 DN 9H-carbazole-3-carbaldehyde
DM0HNU3 HS Investigative
DM0HNU3 SN 9H-Carbazole-3-carbaldehyde; 9H-Carbazole-3-carboxaldehyde; 3-Formylcarbazole; 51761-07-0; CHEMBL1172392; 3-Formyl-9H-carbazole; AC1L9YEB; 2-Formylcarbazole (obsol.); SCHEMBL2775335; CTK1G4153; DTXSID70333418; WRBOHOGDAJPJOQ-UHFFFAOYSA-N; ZINC3641069; BDBM50322592; STL367222; BBL026891; AKOS000113618; AB51127
DM0HNU3 DT Small molecular drug
DM0HNU3 PC 504067
DM0HNU3 MW 195.22
DM0HNU3 FM C13H9NO
DM0HNU3 IC InChI=1S/C13H9NO/c15-8-9-5-6-13-11(7-9)10-3-1-2-4-12(10)14-13/h1-8,14H
DM0HNU3 CS C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)C=O
DM0HNU3 IK WRBOHOGDAJPJOQ-UHFFFAOYSA-N
DM0HNU3 IU 9H-carbazole-3-carbaldehyde
DM0HNU3 CA CAS 51761-07-0
DM0HNU3 DE Discovery agent
DMF1XLZ ID DMF1XLZ
DMF1XLZ DN 9H-purine derivative
DMF1XLZ HS Investigative
DMF1XLZ DE Discovery agent
DMOX21P ID DMOX21P
DMOX21P DN 9-hydrazino-1,2,3,4-tetrahydroacridine
DMOX21P HS Investigative
DMOX21P SN 9-hydrazino-1,2,3,4-tetrahydroacridine; CHEMBL219388; ZINC40576784; AKOS011534842
DMOX21P DT Small molecular drug
DMOX21P PC 12383029
DMOX21P MW 213.28
DMOX21P FM C13H15N3
DMOX21P IC InChI=1S/C13H15N3/c14-16-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8,14H2,(H,15,16)
DMOX21P CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NN
DMOX21P IK DUEMTPVZWKGXAY-UHFFFAOYSA-N
DMOX21P IU 1,2,3,4-tetrahydroacridin-9-ylhydrazine
DMOX21P DE Discovery agent
DMH72MU ID DMH72MU
DMH72MU DN 9-Hydroxy-7,8-benzoflavone
DMH72MU HS Investigative
DMH72MU SN CHEMBL1097042; 9-Hydroxy-7,8-benzoflavone
DMH72MU DT Small molecular drug
DMH72MU PC 46887421
DMH72MU MW 288.3
DMH72MU FM C19H12O3
DMH72MU IC InChI=1S/C19H12O3/c20-15-8-4-7-13-9-10-14-16(21)11-17(22-19(14)18(13)15)12-5-2-1-3-6-12/h1-11,20H
DMH72MU CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=C(C=CC=C4O)C=C3
DMH72MU IK UQEKEVFKEDHKOB-UHFFFAOYSA-N
DMH72MU IU 10-hydroxy-2-phenylbenzo[h]chromen-4-one
DMH72MU DE Discovery agent
DM0FWNJ ID DM0FWNJ
DM0FWNJ DN 9-hydroxyoctadecadienoic acid
DM0FWNJ HS Investigative
DM0FWNJ SN (9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoic acid; 9(S)-HODE; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid; alpha-dimorphecolic acid; 9S-HODE; (9S)-Hydroxyoctadecadienoic acid; UNII-42KE04U9BM; 9S-hydroxy-10E,12Z-octadecadienoic acid; 42KE04U9BM; CHEBI:34496; (9S)-Hydroxyoctadecadinoiec acid; 73543-67-6; (10E,12Z)-(9S)-9-Hydroxyoctadeca-10,12-dienoic acid; (9s,10e,12z)-9-hydroxy-10,12-octadecadienoic acid; (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoate; 9(S)-hydroxyoctadecadienoic acid; Alpha-dimorphecolic; AC1NSNNN; (9S)-Hydroxyoctadecadienoate; (+)-alpha-Dimorphecolic; 9(S)-HODE
DM0FWNJ DT Small molecular drug
DM0FWNJ PC 5312830
DM0FWNJ MW 296.4
DM0FWNJ FM C18H32O3
DM0FWNJ IC InChI=1S/C18H32O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h6,8,11,14,17,19H,2-5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b8-6-,14-11+/t17-/m1/s1
DM0FWNJ CS CCCCC/C=C\\C=C\\[C@H](CCCCCCCC(=O)O)O
DM0FWNJ IK NPDSHTNEKLQQIJ-UINYOVNOSA-N
DM0FWNJ IU (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
DM0FWNJ CA CAS 73543-67-6
DM0FWNJ CB CHEBI:34496
DM0FWNJ DE Discovery agent
DMB9FCK ID DMB9FCK
DMB9FCK DN 9-Hydroxypropyladenine, R-Isomer
DMB9FCK HS Investigative
DMB9FCK SN 14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; 9-HYDROXYPROPYLADENINE, R-ISOMER; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-
DMB9FCK DT Small molecular drug
DMB9FCK PC 445211
DMB9FCK MW 193.21
DMB9FCK FM C8H11N5O
DMB9FCK IC InChI=1S/C8H11N5O/c1-5(14)2-13-4-12-6-7(9)10-3-11-8(6)13/h3-5,14H,2H2,1H3,(H2,9,10,11)/t5-/m1/s1
DMB9FCK CS C[C@H](CN1C=NC2=C(N=CN=C21)N)O
DMB9FCK IK MJZYTEBKXLVLMY-RXMQYKEDSA-N
DMB9FCK IU (2R)-1-(6-aminopurin-9-yl)propan-2-ol
DMB9FCK CA CAS 14047-28-0
DMB9FCK DE Discovery agent
DM8QJUH ID DM8QJUH
DM8QJUH DN 9-Hydroxypropyladenine, S-Isomer
DM8QJUH HS Investigative
DM8QJUH SN (S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; 9-hydroxypropyladenine, s-isomer; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731
DM8QJUH DT Small molecular drug
DM8QJUH PC 445210
DM8QJUH MW 193.21
DM8QJUH FM C8H11N5O
DM8QJUH IC InChI=1S/C8H11N5O/c1-5(14)2-13-4-12-6-7(9)10-3-11-8(6)13/h3-5,14H,2H2,1H3,(H2,9,10,11)/t5-/m0/s1
DM8QJUH CS C[C@@H](CN1C=NC2=C(N=CN=C21)N)O
DM8QJUH IK MJZYTEBKXLVLMY-YFKPBYRVSA-N
DM8QJUH IU (2S)-1-(6-aminopurin-9-yl)propan-2-ol
DM8QJUH CA CAS 14047-27-9
DM8QJUH DE Discovery agent
DMGCX7E ID DMGCX7E
DMGCX7E DN 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
DMGCX7E HS Investigative
DMGCX7E SN CHEMBL209907; 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione; SCHEMBL5829446; IJHAYZZOYYQESB-UHFFFAOYSA-N; BDBM50192426
DMGCX7E DT Small molecular drug
DMGCX7E PC 11844342
DMGCX7E MW 252.22
DMGCX7E FM C14H8N2O3
DMGCX7E IC InChI=1S/C14H8N2O3/c17-6-1-3-9-8(5-6)11-10(15-9)4-2-7-12(11)14(19)16-13(7)18/h1-5,15,17H,(H,16,18,19)
DMGCX7E CS C1=CC2=C(C=C1O)C3=C(N2)C=CC4=C3C(=O)NC4=O
DMGCX7E IK IJHAYZZOYYQESB-UHFFFAOYSA-N
DMGCX7E IU 9-hydroxy-6H-pyrrolo[3,4-c]carbazole-1,3-dione
DMGCX7E DE Discovery agent
DMBQLAI ID DMBQLAI
DMBQLAI DN 9-Isopropyl-9H-adenine
DMBQLAI HS Investigative
DMBQLAI SN CHEMBL67199; 9-isopropyl-9H-purin-6-amine; 31601-35-1; 9-Isopropyl-9H-adenine; 9-propan-2-ylpurin-6-amine; SCHEMBL754007; AC1L987T; 6-Amino-9-isopropyl-9H-purine; 9-Isopropyl-9H-purin-6-ylamine; BDBM50013685; AKOS022639673; 9H-Purin-6-amine, 9-(1-methylethyl)-
DMBQLAI DT Small molecular drug
DMBQLAI PC 414707
DMBQLAI MW 177.21
DMBQLAI FM C8H11N5
DMBQLAI IC InChI=1S/C8H11N5/c1-5(2)13-4-12-6-7(9)10-3-11-8(6)13/h3-5H,1-2H3,(H2,9,10,11)
DMBQLAI CS CC(C)N1C=NC2=C(N=CN=C21)N
DMBQLAI IK BCMZIPWCRGOWEV-UHFFFAOYSA-N
DMBQLAI IU 9-propan-2-ylpurin-6-amine
DMBQLAI DE Discovery agent
DMW905K ID DMW905K
DMW905K DN 9-mercapto-8-oxo-N-phenylnonanamide
DMW905K HS Investigative
DMW905K SN CHEMBL402451
DMW905K DT Small molecular drug
DMW905K PC 11964503
DMW905K MW 279.4
DMW905K FM C15H21NO2S
DMW905K IC InChI=1S/C15H21NO2S/c17-14(12-19)10-6-1-2-7-11-15(18)16-13-8-4-3-5-9-13/h3-5,8-9,19H,1-2,6-7,10-12H2,(H,16,18)
DMW905K CS C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)CS
DMW905K IK UJRMRSNAFIQQLD-UHFFFAOYSA-N
DMW905K IU 8-oxo-N-phenyl-9-sulfanylnonanamide
DMW905K DE Discovery agent
DMM2GQC ID DMM2GQC
DMM2GQC DN 9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid
DMM2GQC HS Investigative
DMM2GQC SN CHEMBL333720; 9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid; SCHEMBL7391643
DMM2GQC DT Small molecular drug
DMM2GQC PC 19930853
DMM2GQC MW 245.34
DMM2GQC FM C11H19NO3S
DMM2GQC IC InChI=1S/C11H19NO3S/c13-10-8(7-16)5-3-1-2-4-6-9(12-10)11(14)15/h8-9,16H,1-7H2,(H,12,13)(H,14,15)
DMM2GQC CS C1CCCC(NC(=O)C(CC1)CS)C(=O)O
DMM2GQC IK MWNHNWDDMZYRSH-UHFFFAOYSA-N
DMM2GQC IU 10-oxo-9-(sulfanylmethyl)azecane-2-carboxylic acid
DMM2GQC DE Discovery agent
DM1YK42 ID DM1YK42
DM1YK42 DN 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine
DM1YK42 HS Investigative
DM1YK42 SN CHEMBL64303; 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine; SCHEMBL8406908
DM1YK42 DT Small molecular drug
DM1YK42 PC 10775682
DM1YK42 MW 227.3
DM1YK42 FM C15H17NO
DM1YK42 IC InChI=1S/C15H17NO/c1-17-15-13-5-3-2-4-10(13)8-11-6-7-12(16)9-14(11)15/h2-5,8,12H,6-7,9,16H2,1H3
DM1YK42 CS COC1=C2CC(CCC2=CC3=CC=CC=C31)N
DM1YK42 IK XZOPIEFNQZTGHL-UHFFFAOYSA-N
DM1YK42 IU 9-methoxy-1,2,3,4-tetrahydroanthracen-2-amine
DM1YK42 CA CAS 179041-74-8
DM1YK42 DE Discovery agent
DMDW267 ID DMDW267
DMDW267 DN 9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMDW267 HS Investigative
DMDW267 SN 9-Methoxyellipticine; Methoxyelliptione; Methoxyellipticine; 9-Methoxyellipticin; 9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole; 10371-86-5; ICI 180 base; Ellipticine, 9-methoxy-; AT 181; ICIG 772; NSC69187; NSC 69187; B 656501 K003; 9-Methoxy-Ellipticine; UNII-U0924292N9; EINECS 233-812-0; BRN 0279742; 9-Methoxy-5,11-dimethyl-6H-pyrido(4,3-b)carbazole; CHEMBL19954; MLS000736760; C18H16N2O; BKRMCDAOAQWNTG-UHFFFAOYSA-N; NSC-69187; 6H-Pyrido[4,3-b]carbazole, 9-methoxy-5,11-dimethyl-; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-9-me
DMDW267 DT Small molecular drug
DMDW267 PC 72512
DMDW267 MW 276.3
DMDW267 FM C18H16N2O
DMDW267 IC InChI=1S/C18H16N2O/c1-10-15-9-19-7-6-13(15)11(2)18-17(10)14-8-12(21-3)4-5-16(14)20-18/h4-9,20H,1-3H3
DMDW267 CS CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)OC)C
DMDW267 IK BKRMCDAOAQWNTG-UHFFFAOYSA-N
DMDW267 IU 9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMDW267 CA CAS 10371-86-5
DMDW267 DE Discovery agent
DMKLTD5 ID DMKLTD5
DMKLTD5 DN 9-methyl-2-(trifluoromethyl)-9H-carbazole
DMKLTD5 HS Investigative
DMKLTD5 SN CHEMBL1173162; 9-methyl-2-(trifluoromethyl)-9H-carbazole; ZINC53295380
DMKLTD5 DT Small molecular drug
DMKLTD5 PC 49799223
DMKLTD5 MW 249.23
DMKLTD5 FM C14H10F3N
DMKLTD5 IC InChI=1S/C14H10F3N/c1-18-12-5-3-2-4-10(12)11-7-6-9(8-13(11)18)14(15,16)17/h2-8H,1H3
DMKLTD5 CS CN1C2=CC=CC=C2C3=C1C=C(C=C3)C(F)(F)F
DMKLTD5 IK XEEUWRNTJAAJOP-UHFFFAOYSA-N
DMKLTD5 IU 9-methyl-2-(trifluoromethyl)carbazole
DMKLTD5 DE Discovery agent
DMF7QS5 ID DMF7QS5
DMF7QS5 DN 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline
DMF7QS5 HS Investigative
DMF7QS5 SN 16502-02-6; 9-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-9-methyl-; 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline; SCHEMBL967629; CHEMBL263883; STMNLEHELVDDKF-UHFFFAOYSA-N; AKOS022703460; AS-53673; 9-Methyl-1,2,3,4-tetrahydro-beta-carboline
DMF7QS5 DT Small molecular drug
DMF7QS5 PC 10997754
DMF7QS5 MW 186.25
DMF7QS5 FM C12H14N2
DMF7QS5 IC InChI=1S/C12H14N2/c1-14-11-5-3-2-4-9(11)10-6-7-13-8-12(10)14/h2-5,13H,6-8H2,1H3
DMF7QS5 CS CN1C2=C(CCNC2)C3=CC=CC=C31
DMF7QS5 IK STMNLEHELVDDKF-UHFFFAOYSA-N
DMF7QS5 IU 9-methyl-1,2,3,4-tetrahydropyrido[3,4-b]indole
DMF7QS5 DE Discovery agent
DMKD0ZP ID DMKD0ZP
DMKD0ZP DN 9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
DMKD0ZP HS Investigative
DMKD0ZP SN CHEMBL271669; 9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide; SCHEMBL11973219; CHEBI:94994; KYPLTYNYSYVGGA-UHFFFAOYSA-N; BDBM50372501; NCGC00163045-01; CU-00000000359-1
DMKD0ZP DT Small molecular drug
DMKD0ZP PC 16759925
DMKD0ZP MW 296.3
DMKD0ZP FM C16H12N2O2S
DMKD0ZP IC InChI=1S/C16H12N2O2S/c1-10-4-7-14-13(9-10)12-6-5-11-3-2-8-17-15(11)16(12)18-21(14,19)20/h2-9,18H,1H3
DMKD0ZP CS CC1=CC2=C(C=C1)S(=O)(=O)NC3=C2C=CC4=C3N=CC=C4
DMKD0ZP IK KYPLTYNYSYVGGA-UHFFFAOYSA-N
DMKD0ZP IU 9-methyl-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
DMKD0ZP CB CHEBI:94994
DMKD0ZP DE Discovery agent
DMO4CSP ID DMO4CSP
DMO4CSP DN 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine
DMO4CSP HS Investigative
DMO4CSP SN CHEMBL194728; SCHEMBL4462539; 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine; BDBM50176057; 496955-70-5; 9H-Purin-6-amine, 9-methyl-8-(2H-1,2,3-triazol-2-yl)-
DMO4CSP DT Small molecular drug
DMO4CSP PC 9877796
DMO4CSP MW 216.2
DMO4CSP FM C8H8N8
DMO4CSP IC InChI=1S/C8H8N8/c1-15-7-5(6(9)10-4-11-7)14-8(15)16-12-2-3-13-16/h2-4H,1H3,(H2,9,10,11)
DMO4CSP CS CN1C2=NC=NC(=C2N=C1N3N=CC=N3)N
DMO4CSP IK ZTJZVOMEMRNYKF-UHFFFAOYSA-N
DMO4CSP IU 9-methyl-8-(triazol-2-yl)purin-6-amine
DMO4CSP DE Discovery agent
DM6DOVL ID DM6DOVL
DM6DOVL DN 9-Methyl-9H-adenine
DM6DOVL HS Investigative
DM6DOVL SN 9-Methyl-9H-purin-6-ylamine
DM6DOVL DT Small molecular drug
DM6DOVL PC 69689
DM6DOVL MW 149.15
DM6DOVL FM C6H7N5
DM6DOVL IC InChI=1S/C6H7N5/c1-11-3-10-4-5(7)8-2-9-6(4)11/h2-3H,1H3,(H2,7,8,9)
DM6DOVL CS CN1C=NC2=C(N=CN=C21)N
DM6DOVL IK WRXCXOUDSPTXNX-UHFFFAOYSA-N
DM6DOVL IU 9-methylpurin-6-amine
DM6DOVL CA CAS 700-00-5
DM6DOVL CB CHEBI:40526
DM6DOVL DE Discovery agent
DM54FRI ID DM54FRI
DM54FRI DN 9-Methylguanine
DM54FRI HS Investigative
DM54FRI DT Small molecular drug
DM54FRI PC 135403591
DM54FRI MW 165.15
DM54FRI FM C6H7N5O
DM54FRI IC InChI=1S/C6H7N5O/c1-11-2-8-3-4(11)9-6(7)10-5(3)12/h2H,1H3,(H3,7,9,10,12)
DM54FRI CS CN1C=NC2=C1N=C(NC2=O)N
DM54FRI IK UUWJNBOCAPUTBK-UHFFFAOYSA-N
DM54FRI IU 2-amino-9-methyl-1H-purin-6-one
DM54FRI CA CAS 5502-78-3
DM54FRI DE Discovery agent
DMPXLEU ID DMPXLEU
DMPXLEU DN 9-N-ETHYL-8-ETHOXY-MANZAMINE A
DMPXLEU HS Investigative
DMPXLEU SN 9-N-ethyl-8-ethoxy-manzamine A; CHEMBL403562
DMPXLEU DT Small molecular drug
DMPXLEU PC 23643537
DMPXLEU MW 620.9
DMPXLEU FM C40H52N4O2
DMPXLEU IC InChI=1S/C40H52N4O2/c1-3-43-36-30(17-15-18-34(36)46-4-2)31-19-22-41-35(37(31)43)32-27-40(45)21-12-8-5-6-9-13-23-42-25-20-33(32)39(28-42)26-29-16-11-7-10-14-24-44(29)38(39)40/h5,8,11,15-19,22,27,29,33,38,45H,3-4,6-7,9-10,12-14,20-21,23-26,28H2,1-2H3/b8-5-,16-11-/t29-,33?,38+,39-,40-/m0/s1
DMPXLEU CS CCN1C2=C(C=CC=C2OCC)C3=C1C(=NC=C3)C4=C[C@]5(CC/C=C\\CCCCN6CCC4[C@]7(C6)[C@H]5N8CCCC/C=C\\[C@H]8C7)O
DMPXLEU IK ZOZMQOQRAXCUJA-OGIDAHSQSA-N
DMPXLEU IU (2R,4R,5Z,12R,13S,16Z)-25-(8-ethoxy-9-ethylpyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DMPXLEU DE Discovery agent
DM8LUYM ID DM8LUYM
DM8LUYM DN 9-Nitropaullone
DM8LUYM HS Investigative
DM8LUYM SN Alsterpaullone; alsterpaullone; 237430-03-4; NSC 705701; NSC-705701; CHEMBL50894; MLS002702475; 9-Nitro-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one; 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one; 9-Nitro-7,12-dihydroindolo-[3,2-d][1]benzazepin-6(5)-one; 9-NITRO-5,12-DIHYDRO-7H-BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONE; Paullone Analog 1; AC1NMCUD; Kinome_3754; 1q3w; Alsterpaullone derivative, 2; Lopac0_000057; CBiol_001723; GTPL5925; BDBM7262; SCHEMBL2170104; CTK8F0374; ZINC23894; BDBM84528; DTXSID50407444
DM8LUYM DT Small molecular drug
DM8LUYM PC 5005498
DM8LUYM MW 293.28
DM8LUYM FM C16H11N3O3
DM8LUYM IC InChI=1S/C16H11N3O3/c20-15-8-12-11-7-9(19(21)22)5-6-14(11)18-16(12)10-3-1-2-4-13(10)17-15/h1-7,18H,8H2,(H,17,20)
DM8LUYM CS C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)[N+](=O)[O-]
DM8LUYM IK OLUKILHGKRVDCT-UHFFFAOYSA-N
DM8LUYM IU 9-nitro-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-6-one
DM8LUYM CA CAS 237430-03-4
DM8LUYM CB CHEBI:138488
DM8LUYM DE Discovery agent
DM1YUBX ID DM1YUBX
DM1YUBX DN 9-N-METHYL-8-METHOXY-MANZAMINE A
DM1YUBX HS Investigative
DM1YUBX SN 9-N-methyl-8-methoxy-manzamine A
DM1YUBX DT Small molecular drug
DM1YUBX PC 23643639
DM1YUBX MW 592.8
DM1YUBX FM C38H48N4O2
DM1YUBX IC InChI=1S/C38H48N4O2/c1-40-34-28(15-13-16-32(34)44-2)29-17-20-39-33(35(29)40)30-25-38(43)19-10-6-3-4-7-11-21-41-23-18-31(30)37(26-41)24-27-14-9-5-8-12-22-42(27)36(37)38/h3,6,9,13-17,20,25,27,31,36,43H,4-5,7-8,10-12,18-19,21-24,26H2,1-2H3/b6-3-,14-9-/t27-,31?,36+,37-,38-/m0/s1
DM1YUBX CS CN1C2=C(C=CC=C2OC)C3=C1C(=NC=C3)C4=C[C@]5(CC/C=C\\CCCCN6CCC4[C@]7(C6)[C@H]5N8CCCC/C=C\\[C@H]8C7)O
DM1YUBX IK LANFUCOONSVQMQ-MCMDJTBWSA-N
DM1YUBX IU (2R,4R,5Z,12R,13S,16Z)-25-(8-methoxy-9-methylpyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DM1YUBX DE Discovery agent
DMGMD1K ID DMGMD1K
DMGMD1K DN 9-N-Phenylmethylamino-Tacrine
DMGMD1K HS Investigative
DMGMD1K SN 9-N-PHENYLMETHYLAMINO-TACRINE; N-benzyl-1,2,3,4-tetrahydroacridin-9-amine; 9-(3-phenylmethylamino)-1,2,3,4-tetrahydroacridine; AC1L1CJU; SCHEMBL3366446; CHEMBL215344; BDBM199182; DB03672; 9-benzylamino-1,2,3,4-tetrahydroacridine; N-Benzyl-1,2,3,4-tetrahydroacridine-9-amine; N-benzyl-1,2,3,4-tetrahydroacridin-9-amine (8a); 9-Acridinamine, 1,2,3,4-tetrahydro-N-(phenylmethyl)-
DMGMD1K DT Small molecular drug
DMGMD1K PC 1933
DMGMD1K MW 288.4
DMGMD1K FM C20H20N2
DMGMD1K IC InChI=1S/C20H20N2/c1-2-8-15(9-3-1)14-21-20-16-10-4-6-12-18(16)22-19-13-7-5-11-17(19)20/h1-4,6,8-10,12H,5,7,11,13-14H2,(H,21,22)
DMGMD1K CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCC4=CC=CC=C4
DMGMD1K IK JYJAEHAURXXPSD-UHFFFAOYSA-N
DMGMD1K IU N-benzyl-1,2,3,4-tetrahydroacridin-9-amine
DMGMD1K DE Discovery agent
DMYXEJ8 ID DMYXEJ8
DMYXEJ8 DN 9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide
DMYXEJ8 HS Investigative
DMYXEJ8 SN CHEMBL602662
DMYXEJ8 DT Small molecular drug
DMYXEJ8 PC 46232033
DMYXEJ8 MW 442.5
DMYXEJ8 FM C27H24NO5+
DMYXEJ8 IC InChI=1S/C27H24NO5/c1-29-24-8-7-18-13-23-21-15-26-25(32-17-33-26)14-19(21)9-10-28(23)16-22(18)27(24)31-12-11-30-20-5-3-2-4-6-20/h2-8,13-16H,9-12,17H2,1H3/q+1
DMYXEJ8 CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCOC6=CC=CC=C6
DMYXEJ8 IK BTWWJBNJLCMOGS-UHFFFAOYSA-N
DMYXEJ8 IU 17-methoxy-16-(2-phenoxyethoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMYXEJ8 DE Discovery agent
DM081G2 ID DM081G2
DM081G2 DN 9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide
DM081G2 HS Investigative
DM081G2 SN CHEMBL605344
DM081G2 DT Small molecular drug
DM081G2 PC 46232101
DM081G2 MW 498.6
DM081G2 FM C31H32NO5+
DM081G2 IC InChI=1S/C31H32NO5/c1-33-28-12-11-22-17-27-25-19-30-29(36-21-37-30)18-23(25)13-14-32(27)20-26(22)31(28)35-16-8-3-2-7-15-34-24-9-5-4-6-10-24/h4-6,9-12,17-20H,2-3,7-8,13-16,21H2,1H3/q+1
DM081G2 CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCCCOC6=CC=CC=C6
DM081G2 IK LXNXNTQFJHYTEN-UHFFFAOYSA-N
DM081G2 IU 17-methoxy-16-(6-phenoxyhexoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM081G2 DE Discovery agent
DMHRV2A ID DMHRV2A
DMHRV2A DN 9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide
DMHRV2A HS Investigative
DMHRV2A SN CHEMBL1163829
DMHRV2A DT Small molecular drug
DMHRV2A PC 46906661
DMHRV2A MW 471.5
DMHRV2A FM C28H27N2O5+
DMHRV2A IC InChI=1S/C28H27N2O5/c1-31-24-8-7-19-14-23-21-16-26-25(34-18-35-26)15-20(21)9-11-30(23)17-22(19)28(24)33-13-5-4-12-32-27-6-2-3-10-29-27/h2-3,6-8,10,14-17H,4-5,9,11-13,18H2,1H3/q+1
DMHRV2A CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=CC=N6
DMHRV2A IK MZPIENUCQFUDBE-UHFFFAOYSA-N
DMHRV2A IU 17-methoxy-16-(4-pyridin-2-yloxybutoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMHRV2A DE Discovery agent
DM4JG9S ID DM4JG9S
DM4JG9S DN 9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide
DM4JG9S HS Investigative
DM4JG9S SN CHEMBL1163985
DM4JG9S DT Small molecular drug
DM4JG9S PC 46906615
DM4JG9S MW 549.4
DM4JG9S FM C29H27BrNO5+
DM4JG9S IC InChI=1S/C29H27BrNO5/c1-32-26-9-4-19-14-25-23-16-28-27(35-18-36-28)15-20(23)10-11-31(25)17-24(19)29(26)34-13-3-2-12-33-22-7-5-21(30)6-8-22/h4-9,14-17H,2-3,10-13,18H2,1H3/q+1
DM4JG9S CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=C(C=C6)Br
DM4JG9S IK XSYYQOISAKERBC-UHFFFAOYSA-N
DM4JG9S IU 16-[4-(4-bromophenoxy)butoxy]-17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM4JG9S DE Discovery agent
DMWVSPH ID DMWVSPH
DMWVSPH DN 9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide
DMWVSPH HS Investigative
DMWVSPH SN CHEMBL1165676
DMWVSPH DT Small molecular drug
DMWVSPH PC 46906659
DMWVSPH MW 515.5
DMWVSPH FM C29H27N2O7+
DMWVSPH IC InChI=1S/C29H27N2O7/c1-34-26-9-4-19-14-25-23-16-28-27(37-18-38-28)15-20(23)10-11-30(25)17-24(19)29(26)36-13-3-2-12-35-22-7-5-21(6-8-22)31(32)33/h4-9,14-17H,2-3,10-13,18H2,1H3/q+1
DMWVSPH CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=C(C=C6)[N+](=O)[O-]
DMWVSPH IK APBFBLUUWLQIQX-UHFFFAOYSA-N
DMWVSPH IU 17-methoxy-16-[4-(4-nitrophenoxy)butoxy]-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMWVSPH DE Discovery agent
DMKPUWX ID DMKPUWX
DMKPUWX DN 9-O-[3-(Phenylamino)propyl]-berberine bromide
DMKPUWX HS Investigative
DMKPUWX SN CHEMBL1164163
DMKPUWX DT Small molecular drug
DMKPUWX PC 46906703
DMKPUWX MW 455.5
DMKPUWX FM C28H27N2O4+
DMKPUWX IC InChI=1S/C28H27N2O4/c1-31-25-9-8-19-14-24-22-16-27-26(33-18-34-27)15-20(22)10-12-30(24)17-23(19)28(25)32-13-5-11-29-21-6-3-2-4-7-21/h2-4,6-9,14-17,29H,5,10-13,18H2,1H3/q+1
DMKPUWX CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCNC6=CC=CC=C6
DMKPUWX IK BRNHZXILANUSDI-UHFFFAOYSA-N
DMKPUWX IU N-[3-[(17-methoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-16-yl)oxy]propyl]aniline
DMKPUWX DE Discovery agent
DM0FNUX ID DM0FNUX
DM0FNUX DN 9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide
DM0FNUX HS Investigative
DM0FNUX SN CHEMBL602663
DM0FNUX DT Small molecular drug
DM0FNUX PC 46232035
DM0FNUX MW 456.5
DM0FNUX FM C28H26NO5+
DM0FNUX IC InChI=1S/C28H26NO5/c1-30-25-9-8-19-14-24-22-16-27-26(33-18-34-27)15-20(22)10-11-29(24)17-23(19)28(25)32-13-5-12-31-21-6-3-2-4-7-21/h2-4,6-9,14-17H,5,10-13,18H2,1H3/q+1
DM0FNUX CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCOC6=CC=CC=C6
DM0FNUX IK GGIRCXOFADOIHD-UHFFFAOYSA-N
DM0FNUX IU 17-methoxy-16-(3-phenoxypropoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM0FNUX DE Discovery agent
DM58XF6 ID DM58XF6
DM58XF6 DN 9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide
DM58XF6 HS Investigative
DM58XF6 SN CHEMBL602861
DM58XF6 DT Small molecular drug
DM58XF6 PC 46232037
DM58XF6 MW 470.5
DM58XF6 FM C29H28NO5+
DM58XF6 IC InChI=1S/C29H28NO5/c1-31-26-10-9-20-15-25-23-17-28-27(34-19-35-28)16-21(23)11-12-30(25)18-24(20)29(26)33-14-6-5-13-32-22-7-3-2-4-8-22/h2-4,7-10,15-18H,5-6,11-14,19H2,1H3/q+1
DM58XF6 CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCOC6=CC=CC=C6
DM58XF6 IK BKMOSBYJXKOCTP-UHFFFAOYSA-N
DM58XF6 IU 17-methoxy-16-(4-phenoxybutoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DM58XF6 DE Discovery agent
DMPZTG9 ID DMPZTG9
DMPZTG9 DN 9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide
DMPZTG9 HS Investigative
DMPZTG9 SN CHEMBL598528
DMPZTG9 DT Small molecular drug
DMPZTG9 PC 46232099
DMPZTG9 MW 484.6
DMPZTG9 FM C30H30NO5+
DMPZTG9 IC InChI=1S/C30H30NO5/c1-32-27-11-10-21-16-26-24-18-29-28(35-20-36-29)17-22(24)12-13-31(26)19-25(21)30(27)34-15-7-3-6-14-33-23-8-4-2-5-9-23/h2,4-5,8-11,16-19H,3,6-7,12-15,20H2,1H3/q+1
DMPZTG9 CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OCCCCCOC6=CC=CC=C6
DMPZTG9 IK DIJNAHNGFYBCMU-UHFFFAOYSA-N
DMPZTG9 IU 17-methoxy-16-(5-phenoxypentoxy)-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
DMPZTG9 DE Discovery agent
DM1DYU4 ID DM1DYU4
DM1DYU4 DN 9-octadecynoic acid
DM1DYU4 HS Investigative
DM1DYU4 SN Stearolic acid; 9-Octadecynoic acid; Octadec-9-ynoic acid; 506-24-1; 9-Stearolic acid; Delta(9)-octadecynoic acid; CHEMBL482804; CHEBI:28801; RGTIBVZDHOMOKC-UHFFFAOYSA-N; Stearolsaeure; Octadec-9-insaeure; EINECS 208-030-8; Octadeca-9-ynoic acid; 9-ODYA; 9-ODA; SCHEMBL196385; AC1L296J; MEGxp0_001740; AC1Q5W60; CTK1H2272; ACon1_002039; DTXSID90198647; MolPort-001-742-497; ZINC8221125; SBB069546; BDBM50292401; MFCD00014386; LMFA01030455; AKOS025117038; NCGC00179891-01; AN-45417; 9a-18:1; FT-0621682; C08459; 506S241; C-51779
DM1DYU4 DT Small molecular drug
DM1DYU4 PC 68167
DM1DYU4 MW 280.4
DM1DYU4 FM C18H32O2
DM1DYU4 IC InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-8,11-17H2,1H3,(H,19,20)
DM1DYU4 CS CCCCCCCCC#CCCCCCCCC(=O)O
DM1DYU4 IK RGTIBVZDHOMOKC-UHFFFAOYSA-N
DM1DYU4 IU octadec-9-ynoic acid
DM1DYU4 CA CAS 506-24-1
DM1DYU4 CB CHEBI:28801
DM1DYU4 DE Discovery agent
DMGORXQ ID DMGORXQ
DMGORXQ DN 9-OH-risperidone
DMGORXQ HS Investigative
DMGORXQ SN 9-hydroxy-risperidone
DMGORXQ DT Small molecular drug
DMGORXQ PC 475100
DMGORXQ MW 426.5
DMGORXQ FM C23H27FN4O3
DMGORXQ IC InChI=1S/C23H27FN4O3/c1-14-18(23(30)28-13-17(29)3-5-21(28)25-14)8-11-27-9-6-15(7-10-27)22-19-4-2-16(24)12-20(19)31-26-22/h2,4,12,15,17,29H,3,5-11,13H2,1H3
DMGORXQ CS CC1=C(C(=O)N2CC(CCC2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
DMGORXQ IK ABWPQNZPAOAQSG-UHFFFAOYSA-N
DMGORXQ IU 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-7-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
DMGORXQ CA CAS 147663-04-5
DMGORXQ DE Discovery agent
DMJFBQ1 ID DMJFBQ1
DMJFBQ1 DN 9-phenanthrol
DMJFBQ1 HS Investigative
DMJFBQ1 SN Phenanthren-9-ol; 9-PHENANTHROL; 9-Hydroxyphenanthrene; 9-Phenanthrenol; 484-17-3; UNII-9FYU45OV9H; NSC 50554; CCRIS 1840; EINECS 207-602-4; BRN 2047057; 9FYU45OV9H; CHEBI:28820; DZKIUEHLEXLYKM-UHFFFAOYSA-N; AC1Q7B0Z; AC1L1UR8; DSSTox_RID_82439; DSSTox_CID_27592; ACMC-1AD67; DSSTox_GSID_47592; 4-06-00-04937 (Beilstein Handbook Reference); SCHEMBL508755; 9-Phenanthrol, technical grade; GTPL4114; CHEMBL2407182; DTXSID9047592; CTK1D6170; DZKIUEHLEXLYKM-UHFFFAOYSA-; MolPort-001-787-230; ZINC967824; KS-000018CG; NSC50554; AC1Q7986
DMJFBQ1 DT Small molecular drug
DMJFBQ1 PC 10229
DMJFBQ1 MW 194.23
DMJFBQ1 FM C14H10O
DMJFBQ1 IC InChI=1S/C14H10O/c15-14-9-10-5-1-2-6-11(10)12-7-3-4-8-13(12)14/h1-9,15H
DMJFBQ1 CS C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)O
DMJFBQ1 IK DZKIUEHLEXLYKM-UHFFFAOYSA-N
DMJFBQ1 IU phenanthren-9-ol
DMJFBQ1 CA CAS 484-17-3
DMJFBQ1 CB CHEBI:28820
DMJFBQ1 DE Discovery agent
DMRCM7Q ID DMRCM7Q
DMRCM7Q DN 9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q HS Investigative
DMRCM7Q SN CHEMBL279297; 9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q DT Small molecular drug
DMRCM7Q PC 15830914
DMRCM7Q MW 245.3
DMRCM7Q FM C18H15N
DMRCM7Q IC InChI=1S/C18H15N/c1-2-6-13(7-3-1)18-16-9-5-4-8-14(16)15-10-11-19-12-17(15)18/h1-10,19H,11-12H2
DMRCM7Q CS C1C=C2C(=C(C3=CC=CC=C23)C4=CC=CC=C4)CN1
DMRCM7Q IK KIUIXTNMEMKNGK-UHFFFAOYSA-N
DMRCM7Q IU 9-phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine
DMRCM7Q DE Discovery agent
DM73O2A ID DM73O2A
DM73O2A DN 9-Phenyl-9H-purin-6-ylamine
DM73O2A HS Investigative
DM73O2A SN 9-phenylpurin-6-amine; CHEMBL62756; 20145-09-9; 9-phenyladenine; 9-Phenyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-phenyl-; NSC516599; AC1L6X8K; 6-Amino-9-phenyl-9H-purine; SCHEMBL5146335; CTK1A5420; DTXSID30325733; ZINC1604448; BDBM50009689; AKOS030561953
DM73O2A DT Small molecular drug
DM73O2A PC 350901
DM73O2A MW 211.22
DM73O2A FM C11H9N5
DM73O2A IC InChI=1S/C11H9N5/c12-10-9-11(14-6-13-10)16(7-15-9)8-4-2-1-3-5-8/h1-7H,(H2,12,13,14)
DM73O2A CS C1=CC=C(C=C1)N2C=NC3=C(N=CN=C32)N
DM73O2A IK QOZYZBRNUYGQNF-UHFFFAOYSA-N
DM73O2A IU 9-phenylpurin-6-amine
DM73O2A CA CAS 20145-09-9
DM73O2A DE Discovery agent
DMO17J0 ID DMO17J0
DMO17J0 DN 9-Phenylethyl-9H-adenine
DMO17J0 HS Investigative
DMO17J0 SN 9-Phenethyladenine; CHEMBL445696; 7051-86-7; 9-Phenylethyl-9H-adenine; NSC211638; AC1L7EWL; Maybridge3_003004; 9-phenethylpurin-6-amine; 9-(2-phenylethyl)adenine; MLS001181918; SCHEMBL1230786; 6-Amino-9-phenethyl-9H-purine; DTXSID10309298; MolPort-002-902-800; ZINC158322; HMS1439I12; HMS2852H03; BDBM50257097; CCG-51741; AKOS012923591; NSC-211638; MCULE-7488166280; IDI1_014391; SMR000567667
DMO17J0 DT Small molecular drug
DMO17J0 PC 309375
DMO17J0 MW 239.28
DMO17J0 FM C13H13N5
DMO17J0 IC InChI=1S/C13H13N5/c14-12-11-13(16-8-15-12)18(9-17-11)7-6-10-4-2-1-3-5-10/h1-5,8-9H,6-7H2,(H2,14,15,16)
DMO17J0 CS C1=CC=C(C=C1)CCN2C=NC3=C(N=CN=C32)N
DMO17J0 IK MALQBKDZBRRFOM-UHFFFAOYSA-N
DMO17J0 IU 9-(2-phenylethyl)purin-6-amine
DMO17J0 CA CAS 7051-86-7
DMO17J0 DE Discovery agent
DMQTEPY ID DMQTEPY
DMQTEPY DN 9-Propyl-9H-adenine
DMQTEPY HS Investigative
DMQTEPY SN 9-propyl-9h-purin-6-amine; CHEMBL475023; 707-98-2; 9-propyl-9H-purin-6-ylamine; 9-Propyl-9H-adenine; 9-propylpurin-6-amine; 9-propyladenine; NSC61961; AC1Q4VHN; AC1L6K9K; SCHEMBL233405; 9-Propyl-9H-purine-6-amine; CTK5D3013; DTXSID10289561; BDBM50256891; NSC-61961
DMQTEPY DT Small molecular drug
DMQTEPY PC 247436
DMQTEPY MW 177.21
DMQTEPY FM C8H11N5
DMQTEPY IC InChI=1S/C8H11N5/c1-2-3-13-5-12-6-7(9)10-4-11-8(6)13/h4-5H,2-3H2,1H3,(H2,9,10,11)
DMQTEPY CS CCCN1C=NC2=C(N=CN=C21)N
DMQTEPY IK QTULKOMMYIUZQD-UHFFFAOYSA-N
DMQTEPY IU 9-propylpurin-6-amine
DMQTEPY CA CAS 707-98-2
DMQTEPY DE Discovery agent
DM1H3FJ ID DM1H3FJ
DM1H3FJ DN A 137491
DM1H3FJ HS Investigative
DM1H3FJ SN ABT 491
DM1H3FJ DT Small molecular drug
DM1H3FJ PC 154086
DM1H3FJ MW 516
DM1H3FJ FM C28H23ClFN5O2
DM1H3FJ IC InChI=1S/C28H22FN5O2.ClH/c1-5-18-7-6-8-25-26(18)21(16-34(25)28(36)32(3)4)27(35)19-9-10-20(22(29)13-19)15-33-17(2)31-23-14-30-12-11-24(23)33;/h1,6-14,16H,15H2,2-4H3;1H
DM1H3FJ CS CC1=NC2=C(N1CC3=C(C=C(C=C3)C(=O)C4=CN(C5=CC=CC(=C54)C#C)C(=O)N(C)C)F)C=CN=C2.Cl
DM1H3FJ IK AWRGBOKANQBIBM-UHFFFAOYSA-N
DM1H3FJ IU 4-ethynyl-3-[3-fluoro-4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzoyl]-N,N-dimethylindole-1-carboxamide;hydrochloride
DM1H3FJ CA CAS 189689-94-9
DM1H3FJ DE Discovery agent
DMHSPRE ID DMHSPRE
DMHSPRE DN A-058
DMHSPRE HS Investigative
DMHSPRE SN A-095; A-166; A-167; A-168; A-169; A-448; A-510; A-521; A-524; A-526; A-629; A-640; A-644; A-850; A-874; A-972; HCV NS5b polymerase inhibitors, Arrow Therapeutics
DMHSPRE CP Arrow Therapeutics Ltd
DMHSPRE DE Hepatitis C virus infection
DM1DWRN ID DM1DWRN
DM1DWRN DN A-119637
DM1DWRN HS Investigative
DM1DWRN SN A-119637; CHEMBL268758; A119637; GTPL490; SCHEMBL7837611; BDBM50099322; A 119637; 3-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-5-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione; 3-[2-[4-(2-Methoxyphenyl)piperazino]ethyl]-5-phenyl-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-2,4-dione
DM1DWRN DT Small molecular drug
DM1DWRN PC 9890547
DM1DWRN MW 462.6
DM1DWRN FM C25H26N4O3S
DM1DWRN IC InChI=1S/C25H26N4O3S/c1-32-21-10-6-5-9-20(21)28-14-11-27(12-15-28)13-16-29-24(30)22-19(18-7-3-2-4-8-18)17-33-23(22)26-25(29)31/h2-10,17H,11-16H2,1H3,(H,26,31)
DM1DWRN CS COC1=CC=CC=C1N2CCN(CC2)CCN3C(=O)C4=C(NC3=O)SC=C4C5=CC=CC=C5
DM1DWRN IK HLVQBOYEHQRWHG-UHFFFAOYSA-N
DM1DWRN IU 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione
DM1DWRN DE Discovery agent
DMZ51UJ ID DMZ51UJ
DMZ51UJ DN A-123189
DMZ51UJ HS Investigative
DMZ51UJ SN A-123189; CHEMBL13856; GTPL491; SCHEMBL7834335; BDBM50099325; A123189; A 123189; 3-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-5-m-tolyl-1H-thieno[2,3-d]pyrimidine-2,4-dione; 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5-(3-methylphenyl)-1H-thieno[3,2-e]pyrimidine-2,4-dione
DMZ51UJ DT Small molecular drug
DMZ51UJ PC 9891167
DMZ51UJ MW 476.6
DMZ51UJ FM C26H28N4O3S
DMZ51UJ IC InChI=1S/C26H28N4O3S/c1-18-6-5-7-19(16-18)20-17-34-24-23(20)25(31)30(26(32)27-24)15-12-28-10-13-29(14-11-28)21-8-3-4-9-22(21)33-2/h3-9,16-17H,10-15H2,1-2H3,(H,27,32)
DMZ51UJ CS CC1=CC(=CC=C1)C2=CSC3=C2C(=O)N(C(=O)N3)CCN4CCN(CC4)C5=CC=CC=C5OC
DMZ51UJ IK PANBMHHKBRMYAL-UHFFFAOYSA-N
DMZ51UJ IU 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5-(3-methylphenyl)-1H-thieno[2,3-d]pyrimidine-2,4-dione
DMZ51UJ DE Discovery agent
DMV03NS ID DMV03NS
DMV03NS DN A-192558
DMV03NS HS Investigative
DMV03NS SN A-192558; UNII-SQ95TK2P11; CHEMBL19309; SQ95TK2P11; 4-Amino-1-(ethyl-isopropyl-carbamoyl)-5-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidine-3-carboxylic acid; BDBM50098745; 341969-96-8; 3-Pyrrolidinecarboxylic acid, 4-amino-1-((ethyl(1-methylethyl)amino)carbonyl)-5-(((2,2,2-trifluoroacetyl)amino)methyl)-, (3R,4R,5S)-; 1-[(Ethylisopropylamino)carbonyl]-2beta-[(trifluoroacetylamino)methyl]-3alpha-aminopyrrolidine-4alpha-carboxylic acid; 3-Pyrrolidinecarboxylic acid, 4-amino-1-((ethyl(1-methylethyl)amino)carbonyl)-5
DMV03NS DT Small molecular drug
DMV03NS PC 9885589
DMV03NS MW 368.35
DMV03NS FM C14H23F3N4O4
DMV03NS IC InChI=1S/C14H23F3N4O4/c1-4-20(7(2)3)13(25)21-6-8(11(22)23)10(18)9(21)5-19-12(24)14(15,16)17/h7-10H,4-6,18H2,1-3H3,(H,19,24)(H,22,23)/t8-,9+,10-/m1/s1
DMV03NS CS CCN(C(C)C)C(=O)N1C[C@H]([C@H]([C@@H]1CNC(=O)C(F)(F)F)N)C(=O)O
DMV03NS IK KRSIVMHLZOHCGR-KXUCPTDWSA-N
DMV03NS IU (3R,4R,5S)-4-amino-1-[ethyl(propan-2-yl)carbamoyl]-5-[[(2,2,2-trifluoroacetyl)amino]methyl]pyrrolidine-3-carboxylic acid
DMV03NS CA CAS 341969-96-8
DMV03NS DE Discovery agent
DMV8AH6 ID DMV8AH6
DMV8AH6 DN A192621
DMV8AH6 HS Investigative
DMV8AH6 SN A-192621; A 192621
DMV8AH6 DT Small molecular drug
DMV8AH6 PC 5310991
DMV8AH6 MW 558.7
DMV8AH6 FM C33H38N2O6
DMV8AH6 IC InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1
DMV8AH6 CS CCCOC1=CC=C(C=C1)[C@H]2[C@@H]([C@H](CN2CC(=O)NC3=C(C=CC=C3CC)CC)C4=CC5=C(C=C4)OCO5)C(=O)O
DMV8AH6 IK LQEHCKYYIXQEBM-FUKIBTTHSA-N
DMV8AH6 IU (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(2,6-diethylanilino)-2-oxoethyl]-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid
DMV8AH6 CA CAS 195529-54-5
DMV8AH6 DE Discovery agent
DM5VQ8E ID DM5VQ8E
DM5VQ8E DN A-224940
DM5VQ8E HS Investigative
DM5VQ8E SN CHEMBL364377; A-224940; 635755-66-7; SCHEMBL5884420; CTK2A8845; DTXSID90623944; BDBM50152424; 8-(cyclohexylmethoxy)quinolin-2-amine; 8-Cyclohexylmethoxy-quinolin-2-ylamine; 2-Quinolinamine, 8-(cyclohexylmethoxy)-
DM5VQ8E DT Small molecular drug
DM5VQ8E PC 22254551
DM5VQ8E MW 256.339
DM5VQ8E FM C16H20N2O
DM5VQ8E IC InChI=1S/C16H20N2O/c17-15-10-9-13-7-4-8-14(16(13)18-15)19-11-12-5-2-1-3-6-12/h4,7-10,12H,1-3,5-6,11H2,(H2,17,18)
DM5VQ8E CS C1CCC(CC1)COC2=CC=CC3=C2N=C(C=C3)N
DM5VQ8E IK OTJOSBTUERTNPP-UHFFFAOYSA-N
DM5VQ8E IU 8-(cyclohexylmethoxy)quinolin-2-amine
DM5VQ8E CA CAS 635755-66-7
DM5VQ8E DE Discovery agent
DM98VFW ID DM98VFW
DM98VFW DN A-286982
DM98VFW HS Investigative
DM98VFW SN A-286982; 280749-17-9; UNII-5I8WFS075A; A 286982; CHEMBL19677; 5I8WFS075A; C24H27N3O4S; (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one; SCHEMBL5829786; GTPL6592; SCHEMBL12063498; AOB1772; SYN5060; MolPort-023-277-110; ZINC602716; BDBM50092956; AKOS024458044; API0010263; Piperazine, 1-acetyl-4-((2E)-3-(4-((2-(1-methylethyl)phenyl)thio)-3-nitrophenyl)-1-oxo-2-propenyl)-; (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one; AS-16426
DM98VFW DT Small molecular drug
DM98VFW PC 9846729
DM98VFW MW 453.6
DM98VFW FM C24H27N3O4S
DM98VFW IC InChI=1S/C24H27N3O4S/c1-17(2)20-6-4-5-7-22(20)32-23-10-8-19(16-21(23)27(30)31)9-11-24(29)26-14-12-25(13-15-26)18(3)28/h4-11,16-17H,12-15H2,1-3H3/b11-9+
DM98VFW CS CC(C)C1=CC=CC=C1SC2=C(C=C(C=C2)/C=C/C(=O)N3CCN(CC3)C(=O)C)[N+](=O)[O-]
DM98VFW IK HTGGAYLWTDOFDK-PKNBQFBNSA-N
DM98VFW IU (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one
DM98VFW CA CAS 280749-17-9
DM98VFW DE Discovery agent
DMK4OD7 ID DMK4OD7
DMK4OD7 DN A2P5P
DMK4OD7 HS Investigative
DMK4OD7 SN 2,5-ADP; adenosine 2',5'-bisphosphate; adenosine-2'-5'-diphosphate
DMK4OD7 DT Small molecular drug
DMK4OD7 PC 440141
DMK4OD7 MW 427.2
DMK4OD7 FM C10H15N5O10P2
DMK4OD7 IC InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(25-27(20,21)22)6(16)4(24-10)1-23-26(17,18)19/h2-4,6-7,10,16H,1H2,(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DMK4OD7 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)OP(=O)(O)O)N
DMK4OD7 IK AEOBEOJCBAYXBA-KQYNXXCUSA-N
DMK4OD7 IU [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
DMK4OD7 CA CAS 3805-37-6
DMK4OD7 DE Discovery agent
DMPI0YX ID DMPI0YX
DMPI0YX DN A-304121
DMPI0YX HS Investigative
DMPI0YX SN A304121; A 304121
DMPI0YX DT Small molecular drug
DMPI0YX PC 9906860
DMPI0YX MW 359.5
DMPI0YX FM C20H29N3O3
DMPI0YX IC InChI=1S/C20H29N3O3/c1-15(21)20(25)23-12-10-22(11-13-23)9-2-14-26-18-7-5-17(6-8-18)19(24)16-3-4-16/h5-8,15-16H,2-4,9-14,21H2,1H3/t15-/m1/s1
DMPI0YX CS C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
DMPI0YX IK KPXVCGPCRXEDLT-OAHLLOKOSA-N
DMPI0YX IU (2R)-2-amino-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]propan-1-one
DMPI0YX CA CAS 360551-71-9
DMPI0YX DE Discovery agent
DML4P6O ID DML4P6O
DML4P6O DN A-313326
DML4P6O HS Investigative
DML4P6O SN CHEMBL41748; A-313326; SCHEMBL7083765; BDBM13389; A313326; 4-[alpha-(1-Methyl-1H-imidazole-5-yl)-3-(1-naphthyl)-4-cyanobenzyloxymethyl]benzonitrile
DML4P6O DT Small molecular drug
DML4P6O PC 23646371
DML4P6O MW 454.5
DML4P6O FM C30H22N4O
DML4P6O IC InChI=1S/C30H22N4O/c1-34-20-33-18-29(34)30(35-19-22-11-9-21(16-31)10-12-22)24-13-14-25(17-32)28(15-24)27-8-4-6-23-5-2-3-7-26(23)27/h2-15,18,20,30H,19H2,1H3
DML4P6O CS CN1C=NC=C1C(C2=CC(=C(C=C2)C#N)C3=CC=CC4=CC=CC=C43)OCC5=CC=C(C=C5)C#N
DML4P6O IK ZBRVJLSHNVWEKS-UHFFFAOYSA-N
DML4P6O IU 4-[(4-cyanophenyl)methoxy-(3-methylimidazol-4-yl)methyl]-2-naphthalen-1-ylbenzonitrile
DML4P6O DE Discovery agent
DMV8MKP ID DMV8MKP
DMV8MKP DN A-315456
DMV8MKP HS Investigative
DMV8MKP SN CHEMBL362863; N-[3-(cyclohexylidene(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide; NCGC00015076-01; AC1O7FZN; Lopac-A-6351; Lopac0_000059; MLS002153477; CTK8F7477; HMS3370M22; HMS3260K19; HMS2235H14; ZINC9229227; Tox21_500059; BDBM50160163; LP00059; CCG-204154; NCGC00093573-02; NCGC00015076-03; NCGC00093573-01; NCGC00015076-02; NCGC00260744-01; NCGC00015076-04; SMR001230830; EU-0100059; A-315456, > A 6351; SR-01000076218; SR-01000076218-1
DMV8MKP DT Small molecular drug
DMV8MKP PC 6603710
DMV8MKP MW 345.5
DMV8MKP FM C18H23N3O2S
DMV8MKP IC InChI=1S/C18H23N3O2S/c1-2-24(22,23)21-16-10-6-9-15(11-16)18(17-12-19-13-20-17)14-7-4-3-5-8-14/h6,9-13,21H,2-5,7-8H2,1H3,(H,19,20)
DMV8MKP CS CCS(=O)(=O)NC1=CC=CC(=C1)C(=C2CCCCC2)C3=CN=CN3
DMV8MKP IK MTZVJHSZYMWIAG-UHFFFAOYSA-N
DMV8MKP IU N-[3-[cyclohexylidene(1H-imidazol-5-yl)methyl]phenyl]ethanesulfonamide
DMV8MKP DE Discovery agent
DMSQLZF ID DMSQLZF
DMSQLZF DN A-315675
DMSQLZF HS Investigative
DMSQLZF SN UNII-H8E590FKGW; A-315675; H8E590FKGW; CHEMBL473062; A 315675; 335679-69-1; 5-((2S,1R)-1-(Acetylamino)-2-methoxy-2-methylpentyl)(4S,2R)-4-(prop-1-enyl)pyrrolidine-2-carboxylic acid; D-Proline, 5-((1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl)-4-(1Z)-1-propenyl-, (4S,5R)-; D-Proline, 5-[(1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl]-4-(1Z)-1-propenyl-, (4S,5R)-; 5-[(2S,1R)-1-(Acetylamino)-2-methoxy-2-methylpentyl](4S,2R)-4-(prop-1-enyl)pyrrolidine-2-carboxylic acid; AC1O52P7; SCHEMBL6696713; BDBM50371257
DMSQLZF DT Small molecular drug
DMSQLZF PC 6451053
DMSQLZF MW 326.4
DMSQLZF FM C17H30N2O4
DMSQLZF IC InChI=1S/C17H30N2O4/c1-6-8-12-10-13(16(21)22)19-14(12)15(18-11(3)20)17(4,23-5)9-7-2/h6,8,12-15,19H,7,9-10H2,1-5H3,(H,18,20)(H,21,22)/b8-6-/t12-,13-,14-,15-,17+/m1/s1
DMSQLZF CS CCC[C@@](C)([C@@H]([C@H]1[C@@H](C[C@@H](N1)C(=O)O)/C=C\\C)NC(=O)C)OC
DMSQLZF IK UUVKABIGWGMYCE-FLMGFEAJSA-N
DMSQLZF IU (2R,4S,5R)-5-[(1R,2S)-1-acetamido-2-methoxy-2-methylpentyl]-4-[(Z)-prop-1-enyl]pyrrolidine-2-carboxylic acid
DMSQLZF CA CAS 335679-69-1
DMSQLZF DE Discovery agent
DMGWO9J ID DMGWO9J
DMGWO9J DN A-317567
DMGWO9J HS Investigative
DMGWO9J SN A317567; A 317567
DMGWO9J DT Small molecular drug
DMGWO9J PC 10200844
DMGWO9J MW 397.6
DMGWO9J FM C27H31N3
DMGWO9J IC InChI=1S/C27H31N3/c1-16(2)26-25-14-21(7-4-17(25)10-11-30(26)3)24-15-23(24)20-8-5-19-13-22(27(28)29)9-6-18(19)12-20/h4-9,12-14,16,23-24,26H,10-11,15H2,1-3H3,(H3,28,29)
DMGWO9J CS CC(C)C1C2=C(CCN1C)C=CC(=C2)C3CC3C4=CC5=C(C=C4)C=C(C=C5)C(=N)N
DMGWO9J IK FEPIUXBUJVISNN-UHFFFAOYSA-N
DMGWO9J IU 6-[2-(2-methyl-1-propan-2-yl-3,4-dihydro-1H-isoquinolin-7-yl)cyclopropyl]naphthalene-2-carboximidamide
DMGWO9J DE Discovery agent
DM124K5 ID DM124K5
DM124K5 DN A-317920
DM124K5 HS Investigative
DM124K5 SN UNII-5P909HKP24; A 317920; A-317920; CHEMBL361355; 360551-59-3; 5P909HKP24; A317920; SCHEMBL7244823; GTPL1216; DTXSID00189622; BDBM50158601; N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide; Furan-2-carboxylic acid ((R)-2-{4-[3-(4-cyclopropanecarbonyl-phenoxy)-propyl]-piperazin-1-yl}-1-methyl-2-oxo-ethyl)-amide; N-(2-(4-(3-(4-(Cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide; 2-Furancarboxamide, N-((1R)-2-(4-(3-(4- (cyclopro
DM124K5 CP Abbott
DM124K5 DT Small molecular drug
DM124K5 PC 10389213
DM124K5 MW 453.5
DM124K5 FM C25H31N3O5
DM124K5 IC InChI=1S/C25H31N3O5/c1-18(26-24(30)22-4-2-16-33-22)25(31)28-14-12-27(13-15-28)11-3-17-32-21-9-7-20(8-10-21)23(29)19-5-6-19/h2,4,7-10,16,18-19H,3,5-6,11-15,17H2,1H3,(H,26,30)/t18-/m1/s1
DM124K5 CS C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(=O)C4=CC=CO4
DM124K5 IK RTRADBQSZJIRMT-GOSISDBHSA-N
DM124K5 IU N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide
DM124K5 CA CAS 360551-59-3
DM124K5 DE Attention deficit hyperactivity disorder
DMPU3QR ID DMPU3QR
DMPU3QR DN A-331440
DMPU3QR HS Investigative
DMPU3QR SN A-331440; UNII-45WZM2FLYQ; 392338-13-5; A 331440; 45WZM2FLYQ; CHEMBL319000; GTPL4023; SCHEMBL5216650; ZINC22452295; BDBM50240709; 4-[4-[3-[(3R)-3-dimethylaminopyrrolidin-1-yl]propoxy]phenyl]benzonitrile; 4'-(3-((3R)-3-(Dimethylamino)pyrrolidinyl)propoxy)(1,1'-biphenyl)-4-carbonitrile; (1,1'-Biphenyl)-4-carbonitrile, 4'-(3-((3R)-3-(dimethylamino)-1-pyrrolidinyl)propoxy)-; KB-74351; A331440; 4''-[3-((R)-3-Dimethylamino-pyrrolidin-1-yl)-propoxy]-biphenyl-4-carbonitrile
DMPU3QR CP Abbott
DMPU3QR DT Small molecular drug
DMPU3QR PC 9884746
DMPU3QR MW 349.5
DMPU3QR FM C22H27N3O
DMPU3QR IC InChI=1S/C22H27N3O/c1-24(2)21-12-14-25(17-21)13-3-15-26-22-10-8-20(9-11-22)19-6-4-18(16-23)5-7-19/h4-11,21H,3,12-15,17H2,1-2H3/t21-/m1/s1
DMPU3QR CS CN(C)[C@@H]1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
DMPU3QR IK FXIPXWLVYIHFEP-OAQYLSRUSA-N
DMPU3QR IU 4-[4-[3-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]benzonitrile
DMPU3QR CA CAS 392338-13-5
DMPU3QR DE Obesity
DMFNR3Y ID DMFNR3Y
DMFNR3Y DN A35566-A
DMFNR3Y HS Investigative
DMFNR3Y SN A35566-B
DMFNR3Y CP Sankyo Co Ltd
DMFNR3Y DE Solid tumour/cancer
DMZHDWN ID DMZHDWN
DMZHDWN DN A-357300
DMZHDWN HS Investigative
DMZHDWN DT Small molecular drug
DMZHDWN PC 448285
DMZHDWN MW 359.9
DMZHDWN FM C15H22ClN3O3S
DMZHDWN IC InChI=1S/C15H22ClN3O3S/c1-9(2)23-7-6-12(17)13(20)15(22)19-18-14(21)10-4-3-5-11(16)8-10/h3-5,8-9,12-13,20H,6-7,17H2,1-2H3,(H,18,21)(H,19,22)/t12-,13+/m1/s1
DMZHDWN CS CC(C)SCC[C@H]([C@@H](C(=O)NNC(=O)C1=CC(=CC=C1)Cl)O)N
DMZHDWN IK BYBVYIPUGPZRSX-OLZOCXBDSA-N
DMZHDWN IU N'-[(2S,3R)-3-amino-2-hydroxy-5-propan-2-ylsulfanylpentanoyl]-3-chlorobenzohydrazide
DMZHDWN DE Discovery agent
DMI4TVB ID DMI4TVB
DMI4TVB DN A-381393
DMI4TVB HS Investigative
DMI4TVB SN CHEMBL127257; A-381393; GTPL8441; BDBM50150141; A 381393; A-381,393; 2-[[4-(3,4-dimethylphenyl)piperazin-1-yl]methyl]-1H-benzimidazole; 2-[4-(3,4-dimethylphenyl)piperazin-1-ylmethyl]-1h-benzimidazole
DMI4TVB DT Small molecular drug
DMI4TVB PC 11301655
DMI4TVB MW 320.4
DMI4TVB FM C20H24N4
DMI4TVB IC InChI=1S/C20H24N4/c1-15-7-8-17(13-16(15)2)24-11-9-23(10-12-24)14-20-21-18-5-3-4-6-19(18)22-20/h3-8,13H,9-12,14H2,1-2H3,(H,21,22)
DMI4TVB CS CC1=C(C=C(C=C1)N2CCN(CC2)CC3=NC4=CC=CC=C4N3)C
DMI4TVB IK SAQMCVDGOIRQTC-UHFFFAOYSA-N
DMI4TVB IU 2-[[4-(3,4-dimethylphenyl)piperazin-1-yl]methyl]-1H-benzimidazole
DMI4TVB DE Discovery agent
DMSTZ14 ID DMSTZ14
DMSTZ14 DN A-395
DMSTZ14 HS Investigative
DMSTZ14 SN CHEMBL4104741; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine; GTPL9525; SCHEMBL19549392; BDBM223987; BDBM50241662; A-395 hydrochloride, >=98% (HPLC); HY-101512; CS-0021615; J3.609.234C; A-395 (5); A392089148-72-9; (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]pyrrolidin-3-amine; 2089148-71-8; rac-(3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine (4); rel-(3R,4S)-1-(7-Fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)pyrrolidin-3-amine
DMSTZ14 DT Small molecular drug
DMSTZ14 PC 123132213
DMSTZ14 MW 486.6
DMSTZ14 FM C26H35FN4O2S
DMSTZ14 IC InChI=1S/C26H35FN4O2S/c1-28(2)25-18-30(24-12-9-20-5-4-6-23(27)26(20)24)17-22(25)19-7-10-21(11-8-19)29-13-15-31(16-14-29)34(3,32)33/h4-8,10-11,22,24-25H,9,12-18H2,1-3H3/t22-,24?,25+/m1/s1
DMSTZ14 CS CN(C)[C@H]1CN(C[C@@H]1C2=CC=C(C=C2)N3CCN(CC3)S(=O)(=O)C)C4CCC5=C4C(=CC=C5)F
DMSTZ14 IK REVJNSVNICWODC-KIDMSAQOSA-N
DMSTZ14 IU (3R,4S)-1-(7-fluoro-2,3-dihydro-1H-inden-1-yl)-N,N-dimethyl-4-[4-(4-methylsulfonylpiperazin-1-yl)phenyl]pyrrolidin-3-amine
DMSTZ14 DE Discovery agent
DMKY9G5 ID DMKY9G5
DMKY9G5 DN A412997
DMKY9G5 HS Investigative
DMKY9G5 SN A-412,997; A-412997
DMKY9G5 DT Small molecular drug
DMKY9G5 PC 10425450
DMKY9G5 MW 309.4
DMKY9G5 FM C19H23N3O
DMKY9G5 IC InChI=1S/C19H23N3O/c1-15-5-4-6-17(13-15)21-19(23)14-22-11-8-16(9-12-22)18-7-2-3-10-20-18/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,21,23)
DMKY9G5 CS CC1=CC(=CC=C1)NC(=O)CN2CCC(CC2)C3=CC=CC=N3
DMKY9G5 IK JFCDMGGMCUKHST-UHFFFAOYSA-N
DMKY9G5 IU N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide
DMKY9G5 CA CAS 630116-49-3
DMKY9G5 DE Discovery agent
DM7HSCI ID DM7HSCI
DM7HSCI DN A-420983
DM7HSCI HS Investigative
DM7HSCI SN CHEMBL314627; A-420983; N-(4-{4-Amino-1-[4-(4-Methylpiperazin-1-Yl)-Trans-Cyclohexyl]-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; SCHEMBL6221049; SCHEMBL5803074; SCHEMBL19999345; SCHEMBL14106773; SCHEMBL16752208; STVKLDUINKMZFE-RQNOJGIXSA-N; STVKLDUINKMZFE-PSWAGMNNSA-N; BDBM50145571; L1G; N-(4-(4-amino-1-((trans)-4-(4-methylpiperazin-1-yl)cyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide
DM7HSCI DT Small molecular drug
DM7HSCI PC 9549183
DM7HSCI MW 593.7
DM7HSCI FM C33H39N9O2
DM7HSCI IC InChI=1S/C33H39N9O2/c1-39-14-16-41(17-15-39)23-9-11-24(12-10-23)42-32-29(31(34)35-20-36-32)30(38-42)22-8-13-25(28(19-22)44-3)37-33(43)27-18-21-6-4-5-7-26(21)40(27)2/h4-8,13,18-20,23-24H,9-12,14-17H2,1-3H3,(H,37,43)(H2,34,35,36)
DM7HSCI CS CN1CCN(CC1)C2CCC(CC2)N3C4=NC=NC(=C4C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)N
DM7HSCI IK STVKLDUINKMZFE-UHFFFAOYSA-N
DM7HSCI IU N-[4-[4-amino-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide
DM7HSCI DE Discovery agent
DMM5XD6 ID DMM5XD6
DMM5XD6 DN A-425444
DMM5XD6 HS Investigative
DMM5XD6 SN CHEMBL219179; A-425444; SCHEMBL4809015; CBDXXUZXRDBOGH-UHFFFAOYSA-N; BDBM50200029; LS-193223; 6-[4-(1H-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-ol; 6-[4-(1H-Benzoimidazole-2-ylmethyl)piperazino]-3-pyridinol
DMM5XD6 DT Small molecular drug
DMM5XD6 PC 9861462
DMM5XD6 MW 309.4
DMM5XD6 FM C17H19N5O
DMM5XD6 IC InChI=1S/C17H19N5O/c23-13-5-6-17(18-11-13)22-9-7-21(8-10-22)12-16-19-14-3-1-2-4-15(14)20-16/h1-6,11,23H,7-10,12H2,(H,19,20)
DMM5XD6 CS C1CN(CCN1CC2=NC3=CC=CC=C3N2)C4=NC=C(C=C4)O
DMM5XD6 IK CBDXXUZXRDBOGH-UHFFFAOYSA-N
DMM5XD6 IU 6-[4-(1H-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-ol
DMM5XD6 DE Discovery agent
DMQHKIA ID DMQHKIA
DMQHKIA DN A-432411
DMQHKIA HS Investigative
DMQHKIA SN 43A; (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; 2ayp; indolinone analog 13; A-432411; CHEMBL202930; SCHEMBL6674605; BDBM14649; DB07078; 29690-EP2311842A2; 29690-EP2289868A1; 29690-EP2289894A2; (3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one; (3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one
DMQHKIA DT Small molecular drug
DMQHKIA PC 10125830
DMQHKIA MW 332.4
DMQHKIA FM C20H16N2O3
DMQHKIA IC InChI=1S/C20H16N2O3/c1-25-19-10-13(5-7-18(19)23)12-4-6-15-16(11-14-3-2-8-21-14)20(24)22-17(15)9-12/h2-11,21,23H,1H3,(H,22,24)/b16-11-
DMQHKIA CS COC1=C(C=CC(=C1)C2=CC3=C(C=C2)/C(=C/C4=CC=CN4)/C(=O)N3)O
DMQHKIA IK AYSXURJZVXBSRV-WJDWOHSUSA-N
DMQHKIA IU (3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DMQHKIA DE Discovery agent
DMUBM8X ID DMUBM8X
DMUBM8X DN A438079
DMUBM8X HS Investigative
DMUBM8X SN A-438079; A 438079
DMUBM8X DT Small molecular drug
DMUBM8X PC 11673921
DMUBM8X MW 306.15
DMUBM8X FM C13H9Cl2N5
DMUBM8X IC InChI=1S/C13H9Cl2N5/c14-11-5-1-4-10(12(11)15)13-17-18-19-20(13)8-9-3-2-6-16-7-9/h1-7H,8H2
DMUBM8X CS C1=CC(=C(C(=C1)Cl)Cl)C2=NN=NN2CC3=CN=CC=C3
DMUBM8X IK MMPAULQSJLVKHP-UHFFFAOYSA-N
DMUBM8X IU 3-[[5-(2,3-dichlorophenyl)tetrazol-1-yl]methyl]pyridine
DMUBM8X DE Discovery agent
DMLMU63 ID DMLMU63
DMLMU63 DN A-443654
DMLMU63 HS Investigative
DMLMU63 SN A-4436554
DMLMU63 DT Small molecular drug
DMLMU63 PC 10172943
DMLMU63 MW 397.5
DMLMU63 FM C24H23N5O
DMLMU63 IC InChI=1S/C24H23N5O/c1-15-22-10-16(6-7-24(22)29-28-15)17-9-20(13-26-11-17)30-14-19(25)8-18-12-27-23-5-3-2-4-21(18)23/h2-7,9-13,19,27H,8,14,25H2,1H3,(H,28,29)/t19-/m0/s1
DMLMU63 CS CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CNC5=CC=CC=C54)N
DMLMU63 IK YWTBGJGMTBHQTM-IBGZPJMESA-N
DMLMU63 IU (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine
DMLMU63 CA CAS 552325-16-3
DMLMU63 CB CHEBI:91351
DMLMU63 DE Discovery agent
DMN320E ID DMN320E
DMN320E DN A-558693
DMN320E HS Investigative
DMN320E SN A-705239; A-705253; Calpain inhibitors (neurological disorders); Calpain inhibitors, Knoll; Calpain inhibitors (neurological disorders), Abbott
DMN320E CP Knoll GmbH
DMN320E DE Neurological disorder
DM7R8DJ ID DM7R8DJ
DM7R8DJ DN A-582941
DM7R8DJ HS Investigative
DM7R8DJ SN A582941; A 582941
DM7R8DJ DT Small molecular drug
DM7R8DJ PC 11173546
DM7R8DJ MW 280.37
DM7R8DJ FM C17H20N4
DM7R8DJ IC InChI=1S/C17H20N4/c1-20-9-14-11-21(12-15(14)10-20)17-8-7-16(18-19-17)13-5-3-2-4-6-13/h2-8,14-15H,9-12H2,1H3
DM7R8DJ CS CN1CC2CN(CC2C1)C3=NN=C(C=C3)C4=CC=CC=C4
DM7R8DJ IK GTMRUYCIJSNXGB-UHFFFAOYSA-N
DM7R8DJ IU 2-methyl-5-(6-phenylpyridazin-3-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole
DM7R8DJ DE Discovery agent
DM7W2ME ID DM7W2ME
DM7W2ME DN A61603
DM7W2ME HS Investigative
DM7W2ME SN A-61603; A 61603
DM7W2ME DT Small molecular drug
DM7W2ME PC 4038180
DM7W2ME MW 309.39
DM7W2ME FM C14H19N3O3S
DM7W2ME IC InChI=1S/C14H19N3O3S/c1-21(19,20)17-13-10-3-2-4-11(14-15-7-8-16-14)9(10)5-6-12(13)18/h5-6,11,17-18H,2-4,7-8H2,1H3,(H,15,16)
DM7W2ME CS CS(=O)(=O)NC1=C(C=CC2=C1CCCC2C3=NCCN3)O
DM7W2ME IK OQFCXJDXHCDLHX-UHFFFAOYSA-N
DM7W2ME IU N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide
DM7W2ME CB CHEBI:103854
DM7W2ME DE Discovery agent
DM9SXDI ID DM9SXDI
DM9SXDI DN A-620223
DM9SXDI HS Investigative
DM9SXDI SN A-866111; A-966492; ABT-472; ABT-999; PARP inhibitor, Abbott; PARP inhibitors, Abbott; Poly (ADP)ribose polymer inhibitor, Abbott; Poly (ADP)ribose inhibitors (cancer), Abbott
DM9SXDI CP Abbott Laboratories
DM9SXDI DT Small molecular drug
DM9SXDI PC 9925908
DM9SXDI MW 286.37
DM9SXDI FM C16H22N4O
DM9SXDI IC InChI=1S/C16H22N4O/c1-2-8-20-9-6-11(7-10-20)16-18-13-5-3-4-12(15(17)21)14(13)19-16/h3-5,11H,2,6-10H2,1H3,(H2,17,21)(H,18,19)
DM9SXDI CS CCCN1CCC(CC1)C2=NC3=C(C=CC=C3N2)C(=O)N
DM9SXDI IK KXSIHXHEHABEJX-UHFFFAOYSA-N
DM9SXDI IU 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide
DM9SXDI CA CAS 272769-49-0
DM9SXDI DE Solid tumour/cancer
DMJ6IMZ ID DMJ6IMZ
DMJ6IMZ DN A-62824
DMJ6IMZ HS Investigative
DMJ6IMZ SN A-62824; CHEMBL202864; SCHEMBL607791; BDBM50178926; 111279-87-9
DMJ6IMZ DT Small molecular drug
DMJ6IMZ PC 10406223
DMJ6IMZ MW 360.4
DMJ6IMZ FM C17H17FN4O2S
DMJ6IMZ IC InChI=1S/C17H17FN4O2S/c18-11-7-10-12(8-13(11)21-5-3-19-4-6-21)22(9-1-2-9)17-14(15(10)23)16(24)20-25-17/h7-9,19H,1-6H2,(H,20,24)
DMJ6IMZ CS C1CC1N2C3=CC(=C(C=C3C(=O)C4=C2SNC4=O)F)N5CCNCC5
DMJ6IMZ IK BEZDZMQEVWAVTH-UHFFFAOYSA-N
DMJ6IMZ IU 9-cyclopropyl-6-fluoro-7-piperazin-1-yl-[1,2]thiazolo[5,4-b]quinoline-3,4-dione
DMJ6IMZ DE Discovery agent
DM5JSXI ID DM5JSXI
DM5JSXI DN A-641359
DM5JSXI HS Investigative
DM5JSXI SN CHEMBL381203; A-641359; N-(4-{4-Amino-1-[1-(Tetrahydro-2h-Pyran-4-Yl)piperidin-4-Yl]-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; N-(4-(4-amino-1-(1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide; SCHEMBL4822105; BDBM50175207
DM5JSXI DT Small molecular drug
DM5JSXI PC 9549185
DM5JSXI MW 580.7
DM5JSXI FM C32H36N8O3
DM5JSXI IC InChI=1S/C32H36N8O3/c1-38-25-6-4-3-5-20(25)17-26(38)32(41)36-24-8-7-21(18-27(24)42-2)29-28-30(33)34-19-35-31(28)40(37-29)23-9-13-39(14-10-23)22-11-15-43-16-12-22/h3-8,17-19,22-23H,9-16H2,1-2H3,(H,36,41)(H2,33,34,35)
DM5JSXI CS CN1C2=CC=CC=C2C=C1C(=O)NC3=C(C=C(C=C3)C4=NN(C5=NC=NC(=C45)N)C6CCN(CC6)C7CCOCC7)OC
DM5JSXI IK CMFPSTWYLODPNE-UHFFFAOYSA-N
DM5JSXI IU N-[4-[4-amino-1-[1-(oxan-4-yl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide
DM5JSXI DE Discovery agent
DMJ83LK ID DMJ83LK
DMJ83LK DN A-674563
DMJ83LK HS Investigative
DMJ83LK SN A 674563; A674563
DMJ83LK DT Small molecular drug
DMJ83LK PC 11314340
DMJ83LK MW 358.4
DMJ83LK FM C22H22N4O
DMJ83LK IC InChI=1S/C22H22N4O/c1-15-21-11-17(7-8-22(21)26-25-15)18-10-20(13-24-12-18)27-14-19(23)9-16-5-3-2-4-6-16/h2-8,10-13,19H,9,14,23H2,1H3,(H,25,26)/t19-/m0/s1
DMJ83LK CS CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OC[C@H](CC4=CC=CC=C4)N
DMJ83LK IK BPNUQXPIQBZCMR-IBGZPJMESA-N
DMJ83LK IU (2S)-1-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxy-3-phenylpropan-2-amine
DMJ83LK CA CAS 552325-73-2
DMJ83LK DE Discovery agent
DMT6A7G ID DMT6A7G
DMT6A7G DN A-690344
DMT6A7G HS Investigative
DMT6A7G SN CHEMBL201115; A-690344; BDBM50177356
DMT6A7G DT Small molecular drug
DMT6A7G PC 9806160
DMT6A7G MW 468.5
DMT6A7G FM C22H31F3N6O2
DMT6A7G IC InChI=1S/C22H31F3N6O2/c1-15-14-31(20(33)28-18(15)32)8-6-5-7-29-9-11-30(12-10-29)17-13-16(22(23,24)25)26-19(27-17)21(2,3)4/h13-14H,5-12H2,1-4H3,(H,28,32,33)
DMT6A7G CS CC1=CN(C(=O)NC1=O)CCCCN2CCN(CC2)C3=NC(=NC(=C3)C(F)(F)F)C(C)(C)C
DMT6A7G IK LRAYIUHUAWSEDX-UHFFFAOYSA-N
DMT6A7G IU 1-[4-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-5-methylpyrimidine-2,4-dione
DMT6A7G DE Schizophrenia
DMXOPFU ID DMXOPFU
DMXOPFU DN A-706149
DMXOPFU HS Investigative
DMXOPFU SN CHEMBL201232; A-706149; SCHEMBL3290844; FKHBHNWGBJHKGW-UHFFFAOYSA-N; BDBM50176440; 1-(4-(4-(2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione
DMXOPFU DT Small molecular drug
DMXOPFU PC 11237664
DMXOPFU MW 517.6
DMXOPFU FM C27H34F3N5O2
DMXOPFU IC InChI=1S/C27H34F3N5O2/c1-26(2,3)25-31-22(27(28,29)30)18-23(32-25)34-16-14-33(15-17-34)12-6-7-13-35-20-9-5-4-8-19(20)21(36)10-11-24(35)37/h4-5,8-9,18H,6-7,10-17H2,1-3H3
DMXOPFU CS CC(C)(C)C1=NC(=CC(=N1)N2CCN(CC2)CCCCN3C(=O)CCC(=O)C4=CC=CC=C43)C(F)(F)F
DMXOPFU IK FKHBHNWGBJHKGW-UHFFFAOYSA-N
DMXOPFU IU 1-[4-[4-[2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-3,4-dihydro-1-benzazepine-2,5-dione
DMXOPFU DE Discovery agent
DMI7J1L ID DMI7J1L
DMI7J1L DN A-740003
DMI7J1L HS Investigative
DMI7J1L SN A-740003; 861393-28-4; A 740003; n-(1-(((cyanoamino)(5-quinolinylimino)methyl)amino)-2,2-dimethylpropyl)-3,4-dimethoxybenzeneacetamide; (E)-N-(1-((cyanamido(quinolin-5-ylamino)methylene)amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide; CHEMBL255787; SCHEMBL3357263; MolPort-044-567-676; EX-A1789; AKOS022184697; RL05324; CS-0297; Benzeneacetamide, N-(1-(((cyanoamino)(5-quinolinylamino)methylene)amino)-2,2-dimethylpropyl)-3,4-dimethoxy-; HY-50697; Benzeneacetamide, N-(1-(((cyanoamino)(5-quinolinylimino)methyl)ami
DMI7J1L DT Small molecular drug
DMI7J1L PC 23232014
DMI7J1L MW 474.6
DMI7J1L FM C26H30N6O3
DMI7J1L IC InChI=1S/C26H30N6O3/c1-26(2,3)24(31-23(33)15-17-11-12-21(34-4)22(14-17)35-5)32-25(29-16-27)30-20-10-6-9-19-18(20)8-7-13-28-19/h6-14,24H,15H2,1-5H3,(H,31,33)(H2,29,30,32)
DMI7J1L CS CC(C)(C)C(NC(=O)CC1=CC(=C(C=C1)OC)OC)/N=C(/NC#N)\\NC2=CC=CC3=C2C=CC=N3
DMI7J1L IK PUHSRMSFDASMAE-UHFFFAOYSA-N
DMI7J1L IU N-[1-[(E)-[(cyanoamino)-(quinolin-5-ylamino)methylidene]amino]-2,2-dimethylpropyl]-2-(3,4-dimethoxyphenyl)acetamide
DMI7J1L CA CAS 861393-28-4
DMI7J1L DE Discovery agent
DMT9N1I ID DMT9N1I
DMT9N1I DN A-76341
DMT9N1I HS Investigative
DMT9N1I CP Sankyo Co Ltd
DMT9N1I DE Diabetic complication
DMP78JY ID DMP78JY
DMP78JY DN A-770041
DMP78JY HS Investigative
DMP78JY SN A-770041; 869748-10-7; UNII-U9855G2ZPR; U9855G2ZPR; CHEMBL197603; KIN001-111; N-(4-{1-[4-(4-Acetylpiperazin-1-Yl)-Trans-Cyclohexyl]-4-Amino-1h-Pyrazolo[3,4-D]pyrimidin-3-Yl}-2-Methoxyphenyl)-1-Methyl-1h-Indole-2-Carboxamide; A 770041; Kinome_3267; 2c0o; MLS006010241; CHEMBL1970879; SCHEMBL15705796; CHEBI:91457; MolPort-039-139-535; C34H39N9O3; 3413AH; ZINC14210723; BDBM50175196; ABP001109; AKOS030526954; ZINC253387967; CS-0057; NCGC00386613-01; NCGC00346955-01; SMR004701317; HY-11011; L2G; 1H-Indole-2-carboxamide, N-(4-(1-(trans-4-(4-
DMP78JY DT Small molecular drug
DMP78JY PC 9549184
DMP78JY MW 621.7
DMP78JY FM C34H39N9O3
DMP78JY IC InChI=1S/C34H39N9O3/c1-21(44)41-14-16-42(17-15-41)24-9-11-25(12-10-24)43-33-30(32(35)36-20-37-33)31(39-43)23-8-13-26(29(19-23)46-3)38-34(45)28-18-22-6-4-5-7-27(22)40(28)2/h4-8,13,18-20,24-25H,9-12,14-17H2,1-3H3,(H,38,45)(H2,35,36,37)
DMP78JY CS CC(=O)N1CCN(CC1)C2CCC(CC2)N3C4=NC=NC(=C4C(=N3)C5=CC(=C(C=C5)NC(=O)C6=CC7=CC=CC=C7N6C)OC)N
DMP78JY IK ZMNWFTYYYCSSTF-UHFFFAOYSA-N
DMP78JY IU N-[4-[1-[4-(4-acetylpiperazin-1-yl)cyclohexyl]-4-aminopyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-1-methylindole-2-carboxamide
DMP78JY CA CAS 869748-10-7
DMP78JY CB CHEBI:91457
DMP78JY DE Discovery agent
DMG6ZHO ID DMG6ZHO
DMG6ZHO DN A778317
DMG6ZHO HS Investigative
DMG6ZHO SN A-778317; A 778317
DMG6ZHO DT Small molecular drug
DMG6ZHO PC 17757384
DMG6ZHO MW 359.5
DMG6ZHO FM C23H25N3O
DMG6ZHO IC InChI=1S/C23H25N3O/c1-23(2,3)17-8-9-18-15(13-17)7-10-21(18)26-22(27)25-20-6-4-5-16-14-24-12-11-19(16)20/h4-6,8-9,11-14,21H,7,10H2,1-3H3,(H2,25,26,27)/t21-/m1/s1
DMG6ZHO CS CC(C)(C)C1=CC2=C(C=C1)[C@@H](CC2)NC(=O)NC3=CC=CC4=C3C=CN=C4
DMG6ZHO IK VPSCJCQPUGKRNC-OAQYLSRUSA-N
DMG6ZHO IU 1-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-3-isoquinolin-5-ylurea
DMG6ZHO DE Discovery agent
DM6BRTF ID DM6BRTF
DM6BRTF DN A-794278
DM6BRTF HS Investigative
DM6BRTF SN compound 1ac [PMID: 16279797]; A 794278; A794278
DM6BRTF DT Small molecular drug
DM6BRTF PC 11537456
DM6BRTF MW 342.5
DM6BRTF FM C18H22N4OS
DM6BRTF IC InChI=1S/C18H22N4OS/c1-21(2)13-9-10-19-17-14(13)15-16(24-17)18(23)22(11-20-15)12-7-5-3-4-6-8-12/h9-12H,3-8H2,1-2H3
DM6BRTF CS CN(C)C1=C2C3=C(C(=O)N(C=N3)C4CCCCCC4)SC2=NC=C1
DM6BRTF IK WOADNNTWYZOWNV-UHFFFAOYSA-N
DM6BRTF IU 5-cycloheptyl-13-(dimethylamino)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DM6BRTF DE Discovery agent
DMU965M ID DMU965M
DMU965M DN A-794282
DMU965M HS Investigative
DMU965M SN compound 1n [PMID: 16279797]; A 794282; A794282
DMU965M DT Small molecular drug
DMU965M PC 11530404
DMU965M MW 350.4
DMU965M FM C19H18N4OS
DMU965M IC InChI=1S/C19H18N4OS/c1-4-12-5-7-13(8-6-12)23-11-21-16-15-14(22(2)3)9-10-20-18(15)25-17(16)19(23)24/h5-11H,4H2,1-3H3
DMU965M CS CCC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=NC=CC(=C34)N(C)C
DMU965M IK VCUKKMIXURRDKL-UHFFFAOYSA-N
DMU965M IU 13-(dimethylamino)-5-(4-ethylphenyl)-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
DMU965M CA CAS 869802-44-8
DMU965M DE Discovery agent
DM2W4IQ ID DM2W4IQ
DM2W4IQ DN A-795614
DM2W4IQ HS Investigative
DM2W4IQ SN CHEMBL520995; A-795614; SCHEMBL1862020; BDBM50264581; (R)-1-(1H-indazol-4-yl)-3-(5-(piperidin-1-yl)-2,3-dihydro-1H-inden-1-yl)urea
DM2W4IQ DT Small molecular drug
DM2W4IQ PC 11451659
DM2W4IQ MW 375.5
DM2W4IQ FM C22H25N5O
DM2W4IQ IC InChI=1S/C22H25N5O/c28-22(24-19-5-4-6-21-18(19)14-23-26-21)25-20-10-7-15-13-16(8-9-17(15)20)27-11-2-1-3-12-27/h4-6,8-9,13-14,20H,1-3,7,10-12H2,(H,23,26)(H2,24,25,28)/t20-/m1/s1
DM2W4IQ CS C1CCN(CC1)C2=CC3=C(C=C2)[C@@H](CC3)NC(=O)NC4=CC=CC5=C4C=NN5
DM2W4IQ IK SVYGRCSOIPQXGO-HXUWFJFHSA-N
DM2W4IQ IU 1-(1H-indazol-4-yl)-3-[(1R)-5-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl]urea
DM2W4IQ DE Discovery agent
DMHFPRJ ID DMHFPRJ
DMHFPRJ DN A-796260
DMHFPRJ HS Investigative
DMHFPRJ SN 895155-26-7; (1-(2-morpholinoethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; A-796260; UNII-5N69DXA53Z; CHEMBL262865; 5N69DXA53Z; A 796260; A-796,260; ZCFHOMLAFTWDFM-UHFFFAOYSA-N; A796260; Morpholino-ethyl analogue, 32; SCHEMBL2076954; CTK8B4187; BDBM21311; MolPort-023-278-969; ZINC14975818; ANW-44204; AKOS015999103; (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; KB-74376; AJ-65531; AS-19178; AX8228482; TC-132949; ST24020055; X5014; J3.566.431I
DMHFPRJ DT Small molecular drug
DMHFPRJ PC 11584525
DMHFPRJ MW 354.5
DMHFPRJ FM C22H30N2O2
DMHFPRJ IC InChI=1S/C22H30N2O2/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23/h5-8,15,20H,9-14H2,1-4H3
DMHFPRJ CS CC1(C(C1(C)C)C(=O)C2=CN(C3=CC=CC=C32)CCN4CCOCC4)C
DMHFPRJ IK ZCFHOMLAFTWDFM-UHFFFAOYSA-N
DMHFPRJ IU [1-(2-morpholin-4-ylethyl)indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
DMHFPRJ CA CAS 895155-26-7
DMHFPRJ DE Pain
DML20N9 ID DML20N9
DML20N9 DN A-80040
DML20N9 HS Investigative
DML20N9 SN CHEMBL378186; A-80040; SCHEMBL16705052; BDBM50189633
DML20N9 DT Small molecular drug
DML20N9 PC 11675600
DML20N9 MW 395.4
DML20N9 FM C20H17N3O4S
DML20N9 IC InChI=1S/C20H17N3O4S/c1-14(23(25)19(21)24)7-12-18-13-22-20(28-18)27-17-10-8-16(9-11-17)26-15-5-3-2-4-6-15/h2-6,8-11,13-14,25H,1H3,(H2,21,24)
DML20N9 CS CC(C#CC1=CN=C(S1)OC2=CC=C(C=C2)OC3=CC=CC=C3)N(C(=O)N)O
DML20N9 IK MCMUCDFOFIZPSA-UHFFFAOYSA-N
DML20N9 IU 1-hydroxy-1-[4-[2-(4-phenoxyphenoxy)-1,3-thiazol-5-yl]but-3-yn-2-yl]urea
DML20N9 DE Discovery agent
DMWGRL8 ID DMWGRL8
DMWGRL8 DN A-803467
DMWGRL8 HS Investigative
DMWGRL8 SN A-803467; 944261-79-4; A 803467; UNII-339LBH1395; A803467; 5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide; 5-(4-CHLOROPHENYL)-N-(3,5-DIMETHOXYPHENYL)-2-FURANCARBOXAMIDE; CHEMBL250699; 339LBH1395; 5-4(-Chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide; MLS006011118; GTPL5734; SCHEMBL9275137; CTK5H6562; EX-A083; DTXSID90241480; AOB2888; MolPort-006-069-060; HMS3656L08; BCP04519; 2-Furancarboxamide, 5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)-; BN0738; ABP001000; ZINC14982453; MFCD10574689; BDBM50212239; s2785
DMWGRL8 TC Analgesics
DMWGRL8 DT Small molecular drug
DMWGRL8 PC 16038374
DMWGRL8 MW 357.8
DMWGRL8 FM C19H16ClNO4
DMWGRL8 IC InChI=1S/C19H16ClNO4/c1-23-15-9-14(10-16(11-15)24-2)21-19(22)18-8-7-17(25-18)12-3-5-13(20)6-4-12/h3-11H,1-2H3,(H,21,22)
DMWGRL8 CS COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl)OC
DMWGRL8 IK VHKBTPQDHDSBSP-UHFFFAOYSA-N
DMWGRL8 IU 5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide
DMWGRL8 CA CAS 944261-79-4
DMWGRL8 DE Pain
DMLC7HE ID DMLC7HE
DMLC7HE DN A804598
DMLC7HE HS Investigative
DMLC7HE SN A-804598; A 804598
DMLC7HE DT Small molecular drug
DMLC7HE PC 53325874
DMLC7HE MW 315.4
DMLC7HE FM C19H17N5
DMLC7HE IC InChI=1S/C19H17N5/c1-14(15-7-3-2-4-8-15)23-19(22-13-20)24-18-11-5-10-17-16(18)9-6-12-21-17/h2-12,14H,1H3,(H2,22,23,24)/t14-/m0/s1
DMLC7HE CS C[C@@H](C1=CC=CC=C1)N=C(NC#N)NC2=CC=CC3=C2C=CC=N3
DMLC7HE IK PQYCRDPLPKGSME-AWEZNQCLSA-N
DMLC7HE IU 1-cyano-2-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine
DMQ5AJW ID DMQ5AJW
DMQ5AJW DN A-82186
DMQ5AJW HS Investigative
DMQ5AJW SN IDDB7311
DMQ5AJW CP Abbott Laboratories
DMQ5AJW DE Hypertension
DMPXKOE ID DMPXKOE
DMPXKOE DN A839977
DMPXKOE HS Investigative
DMPXKOE SN A-839977; A 839977
DMPXKOE DT Small molecular drug
DMPXKOE PC 53325875
DMPXKOE MW 413.3
DMPXKOE FM C19H14Cl2N6O
DMPXKOE IC InChI=1S/C19H14Cl2N6O/c20-14-7-5-8-15(18(14)21)27-19(24-25-26-27)23-12-13-6-1-2-9-16(13)28-17-10-3-4-11-22-17/h1-11H,12H2,(H,23,24,26)
DMPXKOE CS C1=CC=C(C(=C1)CNC2=NN=NN2C3=C(C(=CC=C3)Cl)Cl)OC4=CC=CC=N4
DMPXKOE IK GMVNBKZQJFRFAR-UHFFFAOYSA-N
DMPXKOE IU 1-(2,3-dichlorophenyl)-N-[(2-pyridin-2-yloxyphenyl)methyl]tetrazol-5-amine
DMPXKOE DE Discovery agent
DM5TDEW ID DM5TDEW
DM5TDEW DN A-846714
DM5TDEW HS Investigative
DM5TDEW SN JMC516547 Compound 2; A-846714; 2-Aminopyrimidine analog., 4; SCHEMBL2166660; CHEMBL494678; BDBM26229
DM5TDEW DT Small molecular drug
DM5TDEW PC 25130235
DM5TDEW MW 294.35
DM5TDEW FM C16H18N6
DM5TDEW IC InChI=1S/C16H18N6/c1-21-6-8-22(9-7-21)15-10-14(19-16(18)20-15)13-4-2-12(11-17)3-5-13/h2-5,10H,6-9H2,1H3,(H2,18,19,20)
DM5TDEW CS CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=C(C=C3)C#N)N
DM5TDEW IK QFKQUMBUFVKQBH-UHFFFAOYSA-N
DM5TDEW IU 4-[2-amino-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]benzonitrile
DM5TDEW DE Discovery agent
DMJBPR3 ID DMJBPR3
DMJBPR3 DN A-849531
DMJBPR3 HS Investigative
DMJBPR3 CP Abbott Laboratories
DMJBPR3 DE Metabolic disorder
DMJCPSD ID DMJCPSD
DMJCPSD DN A-850002
DMJCPSD HS Investigative
DMJCPSD SN compound 28b [PMID: 16279797]; A 850002; A850002
DMJCPSD DT Small molecular drug
DMJCPSD PC 11515548
DMJCPSD MW 336.4
DMJCPSD FM C18H16N4OS
DMJCPSD IC InChI=1S/C18H16N4OS/c1-11-4-6-12(7-5-11)22-10-20-16-15-13(21(2)3)8-19-9-14(15)24-17(16)18(22)23/h4-10H,1-3H3
DMJCPSD CS CC1=CC=C(C=C1)N2C=NC3=C(C2=O)SC4=C3C(=CN=C4)N(C)C
DMJCPSD IK LPWKFUVWWQYLOD-UHFFFAOYSA-N
DMJCPSD IU 13-(dimethylamino)-5-(4-methylphenyl)-8-thia-3,5,11-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one
DMJCPSD DE Discovery agent
DM96F8U ID DM96F8U
DM96F8U DN A-867744
DM96F8U HS Investigative
DM96F8U SN A867744; A 867744
DM96F8U DT Small molecular drug
DM96F8U PC 23642319
DM96F8U MW 402.9
DM96F8U FM C20H19ClN2O3S
DM96F8U IC InChI=1S/C20H19ClN2O3S/c1-3-20(24)18-12-19(14-4-6-15(21)7-5-14)23(13(18)2)16-8-10-17(11-9-16)27(22,25)26/h4-12H,3H2,1-2H3,(H2,22,25,26)
DM96F8U CS CCC(=O)C1=C(N(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)S(=O)(=O)N)C
DM96F8U IK ABACVOXFUHDKNZ-UHFFFAOYSA-N
DM96F8U IU 4-[5-(4-chlorophenyl)-2-methyl-3-propanoylpyrrol-1-yl]benzenesulfonamide
DM96F8U CA CAS 1000279-69-5
DM96F8U DE Discovery agent
DM8IWUE ID DM8IWUE
DM8IWUE DN A-887755
DM8IWUE HS Investigative
DM8IWUE CP Abbott Laboratories
DM8IWUE DE Alzheimer disease
DMBF1OY ID DMBF1OY
DMBF1OY DN A-935142
DMBF1OY HS Investigative
DMBF1OY SN A935142; A 935142
DMBF1OY DT Small molecular drug
DMBF1OY PC 25125452
DMBF1OY MW 352.4
DMBF1OY FM C18H19F3N2O2
DMBF1OY IC InChI=1S/C18H19F3N2O2/c19-18(20,21)16-10-15(22-23-16)14-7-5-13(6-8-14)12-3-1-11(2-4-12)9-17(24)25/h5-8,10-12H,1-4,9H2,(H,22,23)(H,24,25)
DMBF1OY CS C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NNC(=C3)C(F)(F)F
DMBF1OY IK YPHFQSYEKIEMNC-UHFFFAOYSA-N
DMBF1OY IU 2-[4-[4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]cyclohexyl]acetic acid
DMBF1OY DE Discovery agent
DMROD7Q ID DMROD7Q
DMROD7Q DN A-943931
DMROD7Q HS Investigative
DMROD7Q SN UNII-Q598HK01AO; A-943931; Q598HK01AO; 1027330-97-7; SCHEMBL602812; CHEMBL502347; BDBM26396; MolPort-035-936-414; SDTRYHWIXVHTLM-GFCCVEGCSA-N; ZINC40977166; NCGC00370827-02; 5H-Benzo(6,7)cyclohepta(1,2-d)pyrimidin-2-amine, 4-((3R)-3-amino-1-pyrrolidinyl)-6,7-dihydro-; 2,4-diamino-5,6-disubstituted pyrimidine, 10; 6-[(3R)-3-aminopyrrolidin-1-yl]-3,5-diazatricyclo[9.4.0.0^{2,7}]pentadeca-1(15),2(7),3,5,11,13-hexaen-4-amine
DMROD7Q DT Small molecular drug
DMROD7Q PC 25068753
DMROD7Q MW 295.4
DMROD7Q FM C17H21N5
DMROD7Q IC InChI=1S/C17H21N5/c18-12-8-9-22(10-12)16-14-7-3-5-11-4-1-2-6-13(11)15(14)20-17(19)21-16/h1-2,4,6,12H,3,5,7-10,18H2,(H2,19,20,21)/t12-/m1/s1
DMROD7Q CS C1CC2=CC=CC=C2C3=C(C1)C(=NC(=N3)N)N4CC[C@H](C4)N
DMROD7Q IK SDTRYHWIXVHTLM-GFCCVEGCSA-N
DMROD7Q IU 6-[(3R)-3-aminopyrrolidin-1-yl]-3,5-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaen-4-amine
DMROD7Q CA CAS 1027330-97-7
DMROD7Q DE Discovery agent
DMOY7TF ID DMOY7TF
DMOY7TF DN A-967079
DMOY7TF HS Investigative
DMOY7TF SN TRPA1 receptor antagonist (pain), Abbott
DMOY7TF CP Abbott Laboratories
DMOY7TF DT Small molecular drug
DMOY7TF PC 60150207
DMOY7TF MW 207.24
DMOY7TF FM C12H14FNO
DMOY7TF IC InChI=1S/C12H14FNO/c1-3-12(14-15)9(2)8-10-4-6-11(13)7-5-10/h4-8,15H,3H2,1-2H3/b9-8+,14-12-
DMOY7TF CS CC/C(=N/O)/C(=C/C1=CC=C(C=C1)F)/C
DMOY7TF IK HKROEBDHHKMNBZ-BYKJOZEVSA-N
DMOY7TF IU (NZ)-N-[(E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-ylidene]hydroxylamine
DMOY7TF DE Pain
DMU34BK ID DMU34BK
DMU34BK DN A-987306
DMU34BK HS Investigative
DMU34BK SN SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS*,11aS*)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR*,11aR*)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine
DMU34BK DT Small molecular drug
DMU34BK PC 44538833
DMU34BK MW 327.4
DMU34BK FM C18H25N5O
DMU34BK IC InChI=1S/C18H25N5O/c19-18-21-16-12(17(22-18)23-9-7-20-8-10-23)5-6-14-15(16)11-3-1-2-4-13(11)24-14/h11,13,20H,1-10H2,(H2,19,21,22)/t11-,13+/m0/s1
DMU34BK CS C1CC[C@@H]2[C@H](C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N
DMU34BK IK DJKJVWJQAVGLHJ-WCQYABFASA-N
DMU34BK IU (7aR,11aR)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro-[1]benzofuro[2,3-h]quinazolin-2-amine
DMU34BK CA CAS 1082954-71-9
DMU34BK DE Discovery agent
DME4ULA ID DME4ULA
DME4ULA DN A-993610
DME4ULA HS Investigative
DME4ULA CP Abbott
DME4ULA TC Analgesics
DME4ULA PC 25224408
DME4ULA MW 395.8
DME4ULA FM C19H17ClF3N3O
DME4ULA IC InChI=1S/C19H17ClF3N3O/c1-12-11-26(17-16(20)3-2-9-24-17)10-8-15(12)18(27)25-14-6-4-13(5-7-14)19(21,22)23/h2-9,12H,10-11H2,1H3,(H,25,27)/t12-/m1/s1
DME4ULA CS C[C@@H]1CN(CC=C1C(=O)NC2=CC=C(C=C2)C(F)(F)F)C3=C(C=CC=N3)Cl
DME4ULA IK IYXRQYVHUISAIP-GFCCVEGCSA-N
DME4ULA IU (3S)-1-(3-chloropyridin-2-yl)-3-methyl-N-[4-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-4-carboxamide
DME4ULA DE Pain
DMW73A8 ID DMW73A8
DMW73A8 DN AA-123
DMW73A8 HS Investigative
DMW73A8 SN BMP agonist (prostate cancer), Thrasos Therapeutics
DMW73A8 CP Thrasos Therapeutics Inc
DMW73A8 DE Prostate cancer
DM2BMAZ ID DM2BMAZ
DM2BMAZ DN AA-166
DM2BMAZ HS Investigative
DM2BMAZ SN BMP agonist (cartilage repair), Thrasos Therapeutics
DM2BMAZ CP Thrasos Therapeutics Inc
DM2BMAZ DE Articular cartilage disorder
DMCN4ZD ID DMCN4ZD
DMCN4ZD DN AA-184
DMCN4ZD HS Investigative
DMCN4ZD SN BMP agonist (acute kidney injury), Thrasos Therapeutics
DMCN4ZD CP Thrasos Therapeutics Inc
DMCN4ZD DE Kidney injury
DMBGTX9 ID DMBGTX9
DMBGTX9 DN AA-204
DMBGTX9 HS Investigative
DMBGTX9 SN BMP agonist (chronic kidney disease), Thrasos Therapeutics
DMBGTX9 CP Thrasos Therapeutics Inc
DMBGTX9 DE Kidney disease
DMI59T7 ID DMI59T7
DMI59T7 DN AA-29504
DMI59T7 HS Investigative
DMI59T7 SN Retigabine analogs (depression), Lundbeck
DMI59T7 CP Lundbeck Research USA Inc
DMI59T7 DE Major depressive disorder
DMNO51B ID DMNO51B
DMNO51B DN AAE-M-PBP-amine
DMNO51B HS Investigative
DMNO51B SN acetylaminoethyl-methyl-phenylbutoxyphenyl-amine
DMNO51B DT Small molecular drug
DMNO51B PC 24763223
DMNO51B MW 340.5
DMNO51B FM C21H28N2O2
DMNO51B IC InChI=1S/C21H28N2O2/c1-18(24)22-14-15-23(2)20-12-8-13-21(17-20)25-16-7-6-11-19-9-4-3-5-10-19/h3-5,8-10,12-13,17H,6-7,11,14-16H2,1-2H3,(H,22,24)
DMNO51B CS CC(=O)NCCN(C)C1=CC(=CC=C1)OCCCCC2=CC=CC=C2
DMNO51B IK VJIVACBGAAEDPS-UHFFFAOYSA-N
DMNO51B IU N-[2-[N-methyl-3-(4-phenylbutoxy)anilino]ethyl]acetamide
DMNO51B DE Discovery agent
DM35RFH ID DM35RFH
DM35RFH DN AAL-993
DM35RFH HS Investigative
DM35RFH SN AAL-993; 269390-77-4; CHEMBL153843; 2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl] benzamide; 2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide; 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide; 2-[(4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide; 2-[(pyridin-4-ylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide; 2-((pyridin-4-ylmethyl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide; BLAFVGLBBOPRLP-UHFFFAOYSA-N; AC1O4QQI; anthranyl amide derivative C
DM35RFH DT Small molecular drug
DM35RFH PC 6398883
DM35RFH MW 371.4
DM35RFH FM C20H16F3N3O
DM35RFH IC InChI=1S/C20H16F3N3O/c21-20(22,23)15-4-3-5-16(12-15)26-19(27)17-6-1-2-7-18(17)25-13-14-8-10-24-11-9-14/h1-12,25H,13H2,(H,26,27)
DM35RFH CS C1=CC=C(C(=C1)C(=O)NC2=CC=CC(=C2)C(F)(F)F)NCC3=CC=NC=C3
DM35RFH IK BLAFVGLBBOPRLP-UHFFFAOYSA-N
DM35RFH IU 2-(pyridin-4-ylmethylamino)-N-[3-(trifluoromethyl)phenyl]benzamide
DM35RFH DE Discovery agent
DMDBWT6 ID DMDBWT6
DMDBWT6 DN Abbott 14c
DMDBWT6 HS Investigative
DMDBWT6 SN 2,4-diaminopyrimidine-based antagonist, 14c
DMDBWT6 DT Small molecular drug
DMDBWT6 PC 11441554
DMDBWT6 MW 420.5
DMDBWT6 FM C23H28N6O2
DMDBWT6 IC InChI=1S/C23H28N6O2/c1-23(2,3)29-22(30)26-17-11-9-16(10-12-17)19-18(27-21(25)28-20(19)24)14-31-13-15-7-5-4-6-8-15/h4-12H,13-14H2,1-3H3,(H2,26,29,30)(H4,24,25,27,28)
DMDBWT6 CS CC(C)(C)NC(=O)NC1=CC=C(C=C1)C2=C(N=C(N=C2N)N)COCC3=CC=CC=C3
DMDBWT6 IK MLBYOWASRACYDH-UHFFFAOYSA-N
DMDBWT6 IU 1-tert-butyl-3-[4-[2,4-diamino-6-(phenylmethoxymethyl)pyrimidin-5-yl]phenyl]urea
DMDBWT6 DE Discovery agent
DMHRPAM ID DMHRPAM
DMHRPAM DN ABBV-744
DMHRPAM HS Investigative
DMHRPAM SN ABBV744; UNII-9MX546E2SF; 9MX546E2SF; HWV; ABBV 744; SCHEMBL19463409
DMHRPAM TC Antiviral Agents
DMHRPAM DT Small molecular drug
DMHRPAM PC 132010322
DMHRPAM MW 491.6
DMHRPAM FM C28H30FN3O4
DMHRPAM IC InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)
DMHRPAM CS CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C
DMHRPAM IK OEDSFMUSNZDJFD-UHFFFAOYSA-N
DMHRPAM IU N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
DMHRPAM CA CAS 2138861-99-9
DMHRPAM DE Coronavirus Disease 2019 (COVID-19)
DMA01OF ID DMA01OF
DMA01OF DN ABC-4
DMA01OF HS Investigative
DMA01OF SN FGFR4 targeted antibody (solid tumors), XOMA; Fibroblast growth factor receptor 4 targeted antibody (solid tumors), Xoma
DMA01OF CP XOMA Ltd
DMA01OF DT Antibody
DMA01OF DE Solid tumour/cancer
DM2AIE9 ID DM2AIE9
DM2AIE9 DN ABC-7
DM2AIE9 HS Investigative
DM2AIE9 SN RON tyrosine kinase targeted antibody (solid tumor), XOMA; Recepteur d'origine nantais tyrosine kinase targeted antibody (solid tumor), XOMA
DM2AIE9 CP XOMA Ltd
DM2AIE9 DT Antibody
DM2AIE9 DE Solid tumour/cancer
DMW1Y2G ID DMW1Y2G
DMW1Y2G DN Abietic acid
DMW1Y2G HS Investigative
DMW1Y2G SN ABIETIC ACID; 514-10-3; Sylvic acid; Abietate; l-Abietic acid; Rosin Acid; 7,13-Abietadien-18-oic acid; Kyselina abietova; Kyselina abietova [Czech]; UNII-V3DHX33184; CCRIS 3183; Abieta-7,13-dien-18-oic acid; Abietic acid, technical; 13-Isopropylpodocarpa-7,13-dien-15-oic acid; EINECS 208-178-3; NSC 25149; Abietinic acid; AI3-17273; CHEBI:28987; V3DHX33184; NSC25149; (-)-Abietic acid; MFCD03423567; Abietic acid, 85%; NCGC00166273-01; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-,
DMW1Y2G DT Small molecular drug
DMW1Y2G PC 10569
DMW1Y2G MW 302.5
DMW1Y2G FM C20H30O2
DMW1Y2G IC InChI=1S/C20H30O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h7,12-13,16-17H,5-6,8-11H2,1-4H3,(H,21,22)/t16-,17+,19+,20+/m0/s1
DMW1Y2G CS CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)O)C
DMW1Y2G IK RSWGJHLUYNHPMX-ONCXSQPRSA-N
DMW1Y2G IU (1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid
DMW1Y2G CA CAS 514-10-3
DMW1Y2G CB CHEBI:28987
DMW1Y2G DE Discovery agent
DM0LUOM ID DM0LUOM
DM0LUOM DN ABIO 09-01
DM0LUOM HS Investigative
DM0LUOM SN Antidepressants, Abiogen; BTG-1675A
DM0LUOM CP BTG plc
DM0LUOM DE Anxiety disorder
DMRC3A5 ID DMRC3A5
DMRC3A5 DN ABL127
DMRC3A5 HS Investigative
DMRC3A5 SN ABL-127; ABL 127
DMRC3A5 DT Small molecular drug
DMRC3A5 PC 24856225
DMRC3A5 MW 332.4
DMRC3A5 FM C17H20N2O5
DMRC3A5 IC InChI=1S/C17H20N2O5/c1-23-15(21)18-14(20)17(13-10-6-7-11-13,19(18)16(22)24-2)12-8-4-3-5-9-12/h3-5,8-9,13H,6-7,10-11H2,1-2H3/t17-/m0/s1
DMRC3A5 CS COC(=O)N1C(=O)[C@@](N1C(=O)OC)(C2CCCC2)C3=CC=CC=C3
DMRC3A5 IK ZRHWCAFAIHTQKD-KRWDZBQOSA-N
DMRC3A5 IU dimethyl (3R)-3-cyclopentyl-4-oxo-3-phenyldiazetidine-1,2-dicarboxylate
DMRC3A5 DE Discovery agent
DMKN10X ID DMKN10X
DMKN10X DN Abloid
DMKN10X HS Investigative
DMKN10X SN Amyloid protein deposition inhibitor (Alzheimer's disease), Virionics
DMKN10X CP Virionics Corp
DMKN10X DE Alzheimer disease
DMQPHFU ID DMQPHFU
DMQPHFU DN AB-MECA
DMQPHFU HS Investigative
DMQPHFU SN AB-MECA; 152918-26-8; (2S,3S,4R,5R)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide; AB-MECA, solid; AC1NSJSB; [3H]AB-MECA; GTPL416; SCHEMBL16585151; CTK8E8476; BDBM21242; DTXSID70415501; LDYMCRRFCMRFKB-MOROJQBDSA-N; MolPort-003-940-100; ZINC4475069; AKOS030526575; CS-5220; NCGC00162075-03; NCGC00162075-02; NCGC00162075-01; HY-19365; RT-011146; N6-(4-Aminobenzyl)-N-methylcarboxamidoadenosine; J-008959; 5'-Methylamino-N-(4-aminobenzyl)-5'-oxo-5'-deoxyadenosine
DMQPHFU DT Small molecular drug
DMQPHFU PC 5310992
DMQPHFU MW 399.4
DMQPHFU FM C18H21N7O4
DMQPHFU IC InChI=1S/C18H21N7O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-2-4-10(19)5-3-9/h2-5,7-8,12-14,18,26-27H,6,19H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
DMQPHFU CS CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)N)O)O
DMQPHFU IK LDYMCRRFCMRFKB-MOROJQBDSA-N
DMQPHFU IU (2S,3S,4R,5R)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
DMQPHFU CA CAS 152918-26-8
DMQPHFU DE Discovery agent
DME8G7F ID DME8G7F
DME8G7F DN AB-NECA
DME8G7F HS Investigative
DME8G7F SN aminobenzyl-5'-N-ethylcarboxamidoadenosine
DME8G7F DT Small molecular drug
DME8G7F PC 57340157
DME8G7F MW 457.4
DME8G7F FM C20H23N7O6
DME8G7F IC InChI=1S/C20H23N7O6/c1-2-21-17(31)18(32)26-20-24-15(23-10-6-4-3-5-7-10)12-16(25-20)27(9-22-12)19-14(30)13(29)11(8-28)33-19/h3-7,9,11,13-14,19,28-30H,2,8H2,1H3,(H,21,31)(H2,23,24,25,26,32)/t11-,13-,14-,19-/m1/s1
DME8G7F CS CCNC(=O)C(=O)NC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NC4=CC=CC=C4
DME8G7F IK ZLZSAUQLHYWSOL-HLFSEMCJSA-N
DME8G7F IU N'-[6-anilino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-ethyloxamide
DME8G7F DE Discovery agent
DMV6DAO ID DMV6DAO
DMV6DAO DN abnormal cannabidiol
DMV6DAO HS Investigative
DMV6DAO SN Abn-CBD; CAY10429
DMV6DAO DT Small molecular drug
DMV6DAO PC 89949
DMV6DAO MW 314.5
DMV6DAO FM C21H30O2
DMV6DAO IC InChI=1S/C21H30O2/c1-5-6-7-8-16-12-17(22)13-20(23)21(16)19-11-15(4)9-10-18(19)14(2)3/h11-13,18-19,22-23H,2,5-10H2,1,3-4H3/t18-,19+/m0/s1
DMV6DAO CS CCCCCC1=C(C(=CC(=C1)O)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C
DMV6DAO IK YWEZXUNAYVCODW-RBUKOAKNSA-N
DMV6DAO IU 4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
DMV6DAO CA CAS 22972-55-0
DMV6DAO DE Discovery agent
DMJ6MUE ID DMJ6MUE
DMJ6MUE DN ABT-116
DMJ6MUE HS Investigative
DMJ6MUE SN A-1165442
DMJ6MUE CP Abbott Laboratories
DMJ6MUE PC 46890602
DMJ6MUE MW 432.5
DMJ6MUE FM C23H27F3N4O
DMJ6MUE IC InChI=1S/C23H27F3N4O/c1-22(2,3)11-10-15-12-17(23(24,25)26)9-8-16(15)13-27-21(31)29-19-6-5-7-20-18(19)14-28-30(20)4/h5-9,12,14H,10-11,13H2,1-4H3,(H2,27,29,31)
DMJ6MUE CS CC(C)(C)CCC1=C(C=CC(=C1)C(F)(F)F)CNC(=O)NC2=C3C=NN(C3=CC=C2)C
DMJ6MUE IK SMJCAASNPAKOIB-UHFFFAOYSA-N
DMJ6MUE IU 1-[[2-(3,3-dimethylbutyl)-4-(trifluoromethyl)phenyl]methyl]-3-(1-methylindazol-4-yl)urea
DMJ6MUE CA CAS 1008529-42-7
DMJ6MUE DE Pain
DMZ3YTO ID DMZ3YTO
DMZ3YTO DN ABT-341
DMZ3YTO HS Investigative
DMZ3YTO SN CHEMBL437341
DMZ3YTO DT Small molecular drug
DMZ3YTO PC 11974440
DMZ3YTO MW 445.4
DMZ3YTO FM C19H17F6N5O
DMZ3YTO IC InChI=1S/C19H17F6N5O/c20-12-7-14(22)13(21)6-11(12)10-2-1-9(5-15(10)26)17(31)29-3-4-30-16(8-29)27-28-18(30)19(23,24)25/h1,6-7,10,15H,2-5,8,26H2/t10-,15+/m1/s1
DMZ3YTO CS C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C3=CC[C@@H]([C@H](C3)N)C4=CC(=C(C=C4F)F)F
DMZ3YTO IK NVVSPGQEXMJZIR-BMIGLBTASA-N
DMZ3YTO IU [(4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohexen-1-yl]-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
DMZ3YTO CA CAS 913623-69-5
DMZ3YTO DE Discovery agent
DM6J57N ID DM6J57N
DM6J57N DN ABT-670
DM6J57N HS Investigative
DM6J57N SN ABT-670; UNII-4L6071XH2J; CHEMBL219182; 630119-43-6; 4L6071XH2J; GTPL8439; ABT670; SCHEMBL4010523; CTK2B0090; DTXSID30212235; ABT 670; ZINC35075418; BDBM50200050; compound 6b [PMID 17149874]; CS-6805; 3-methyl-n-(1-oxy-3',4',5',6'-tetrahydro-2'h-(2,4'-bipyridine)-1'-ylmethyl)benzamide; HY-19483; 3-methyl-N-[[4-(1-oxidopyridin-1-ium-2-yl)piperidin-1-yl]methyl]benzamide; Benzamide, 3-methyl-N-[[4-(1-oxido-2-pyridinyl)-1-piperidinyl]methyl]-
DM6J57N DT Small molecular drug
DM6J57N PC 16094676
DM6J57N MW 325.4
DM6J57N FM C19H23N3O2
DM6J57N IC InChI=1S/C19H23N3O2/c1-15-5-4-6-17(13-15)19(23)20-14-21-11-8-16(9-12-21)18-7-2-3-10-22(18)24/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,20,23)
DM6J57N CS CC1=CC(=CC=C1)C(=O)NCN2CCC(CC2)C3=CC=CC=[N+]3[O-]
DM6J57N IK PUMMPCXNEPHBNN-UHFFFAOYSA-N
DM6J57N IU 3-methyl-N-[[4-(1-oxidopyridin-1-ium-2-yl)piperidin-1-yl]methyl]benzamide
DM6J57N CA CAS 630119-43-6
DM6J57N DE Discovery agent
DM79DSN ID DM79DSN
DM79DSN DN ABTAA
DM79DSN HS Investigative
DM79DSN DT Antibody
DM79DSN DE Sepsis
DMC02FP ID DMC02FP
DMC02FP DN Abyssinin I
DMC02FP HS Investigative
DMC02FP SN CHEMBL389736
DMC02FP DT Small molecular drug
DMC02FP PC 10761522
DMC02FP MW 368.4
DMC02FP FM C21H20O6
DMC02FP IC InChI=1S/C21H20O6/c1-21(2)5-4-11-6-12(7-18(25-3)20(11)27-21)16-10-15(24)19-14(23)8-13(22)9-17(19)26-16/h4-9,16,22-23H,10H2,1-3H3/t16-/m0/s1
DMC02FP CS CC1(C=CC2=C(O1)C(=CC(=C2)[C@@H]3CC(=O)C4=C(C=C(C=C4O3)O)O)OC)C
DMC02FP IK SDUMAACMVUGGAC-INIZCTEOSA-N
DMC02FP IU (2S)-5,7-dihydroxy-2-(8-methoxy-2,2-dimethylchromen-6-yl)-2,3-dihydrochromen-4-one
DMC02FP DE Discovery agent
DMR7IGZ ID DMR7IGZ
DMR7IGZ DN Abyssinin II
DMR7IGZ HS Investigative
DMR7IGZ SN 5'-Prenylhomoeriodictyol; abyssinin II; CHEMBL388722; 671781-82-1; Abyssinoflavanone II; AC1L9CV8; SCHEMBL4743888; DTXSID10331832; ZINC4098362; LMPK12140439; BDBM50212397; C09831
DMR7IGZ DT Small molecular drug
DMR7IGZ PC 442457
DMR7IGZ MW 370.4
DMR7IGZ FM C21H22O6
DMR7IGZ IC InChI=1S/C21H22O6/c1-11(2)4-5-12-6-13(7-19(26-3)21(12)25)17-10-16(24)20-15(23)8-14(22)9-18(20)27-17/h4,6-9,17,22-23,25H,5,10H2,1-3H3/t17-/m0/s1
DMR7IGZ CS CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)OC)O)C
DMR7IGZ IK UQFQODVSORPELA-KRWDZBQOSA-N
DMR7IGZ IU (2S)-5,7-dihydroxy-2-[4-hydroxy-3-methoxy-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMR7IGZ CA CAS 671781-82-1
DMR7IGZ DE Discovery agent
DMEYQF9 ID DMEYQF9
DMEYQF9 DN Abyssinoflavanone VI
DMEYQF9 HS Investigative
DMEYQF9 SN CHEMBL389650
DMEYQF9 DT Small molecular drug
DMEYQF9 PC 10551087
DMEYQF9 MW 440.5
DMEYQF9 FM C25H28O7
DMEYQF9 IC InChI=1S/C25H28O7/c1-24(2)6-5-12-7-14(15-10-20(29)25(3,4)32-23(15)22(12)31-24)18-11-17(28)21-16(27)8-13(26)9-19(21)30-18/h7-9,18,20,26-27,29H,5-6,10-11H2,1-4H3
DMEYQF9 CS CC1(CCC2=CC(=C3CC(C(OC3=C2O1)(C)C)O)C4CC(=O)C5=C(C=C(C=C5O4)O)O)C
DMEYQF9 IK ZAGCAZVMJBNNSU-UHFFFAOYSA-N
DMEYQF9 IU 5,7-dihydroxy-2-(3-hydroxy-2,2,9,9-tetramethyl-3,4,7,8-tetrahydropyrano[3,2-h]chromen-5-yl)-2,3-dihydrochromen-4-one
DMEYQF9 DE Discovery agent
DMTVQSL ID DMTVQSL
DMTVQSL DN Abyssinoflavanone VII
DMTVQSL HS Investigative
DMTVQSL SN abyssinoflavanone VII; CHEMBL229220
DMTVQSL DT Small molecular drug
DMTVQSL PC 16737250
DMTVQSL MW 424.5
DMTVQSL FM C25H28O6
DMTVQSL IC InChI=1S/C25H28O6/c1-13(2)5-6-15-7-16(8-17(25(15)30)9-19(27)14(3)4)22-12-21(29)24-20(28)10-18(26)11-23(24)31-22/h5,7-8,10-11,19,22,26-28,30H,3,6,9,12H2,1-2,4H3/t19?,22-/m0/s1
DMTVQSL CS CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)CC(C(=C)C)O)O)C
DMTVQSL IK FZUJHUDJFJCWMT-BPARTEKVSA-N
DMTVQSL IU (2S)-5,7-dihydroxy-2-[4-hydroxy-3-(2-hydroxy-3-methylbut-3-enyl)-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMTVQSL DE Discovery agent
DMH3CK2 ID DMH3CK2
DMH3CK2 DN ABYSSINONE V
DMH3CK2 HS Investigative
DMH3CK2 SN 5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one; NSC618154; NSC 618154; AC1L2QBU; CHEMBL454332; CTK5E4111; NSC-618154; 5,7,4'-trihydroxy-3',5'-diprenylflavanone; 4H-1-Benzopyran-4-one,3-Dihydro-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl]-, (S)-; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methyl-2-buten-1-yl)phenyl]-,(2S)-; 4H-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-, (S)-
DMH3CK2 DT Small molecular drug
DMH3CK2 PC 442153
DMH3CK2 MW 408.5
DMH3CK2 FM C25H28O5
DMH3CK2 IC InChI=1S/C25H28O5/c1-14(2)5-7-16-9-18(10-17(25(16)29)8-6-15(3)4)22-13-21(28)24-20(27)11-19(26)12-23(24)30-22/h5-6,9-12,22,26-27,29H,7-8,13H2,1-4H3/t22-/m0/s1
DMH3CK2 CS CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)C
DMH3CK2 IK LQHKFMYWTKORCE-QFIPXVFZSA-N
DMH3CK2 IU (2S)-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMH3CK2 CA CAS 77263-11-7
DMH3CK2 CB CHEBI:2368
DMH3CK2 DE Discovery agent
DM9YAVX ID DM9YAVX
DM9YAVX DN Abyssinone-IV
DM9YAVX HS Investigative
DM9YAVX SN CHEMBL470454; Abyssinone IV; abyssinone-IV; AC1OK505; ZINC4716488; BDBM50241806
DM9YAVX DT Small molecular drug
DM9YAVX PC 7330513
DM9YAVX MW 392.5
DM9YAVX FM C25H28O4
DM9YAVX IC InChI=1S/C25H28O4/c1-15(2)5-7-17-11-19(12-18(25(17)28)8-6-16(3)4)23-14-22(27)21-10-9-20(26)13-24(21)29-23/h5-6,9-13,23,26,28H,7-8,14H2,1-4H3/t23-/m0/s1
DM9YAVX CS CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)[C@@H]2CC(=O)C3=C(O2)C=C(C=C3)O)C
DM9YAVX IK JBQLRZGPTDOWQA-QHCPKHFHSA-N
DM9YAVX IU (2S)-7-hydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DM9YAVX DE Discovery agent
DMZUY93 ID DMZUY93
DMZUY93 DN Abyssinone-VI-4-O-methyl ether
DMZUY93 HS Investigative
DMZUY93 SN CHEMBL470865; abyssinone-VI-4-O-methyl ether; Abyssinone VI 4-O-methyl ether
DMZUY93 DT Small molecular drug
DMZUY93 PC 11995582
DMZUY93 MW 406.5
DMZUY93 FM C26H30O4
DMZUY93 IC InChI=1S/C26H30O4/c1-17(2)6-9-20-14-19(15-21(26(20)30-5)10-7-18(3)4)8-13-24(28)23-12-11-22(27)16-25(23)29/h6-8,11-16,27,29H,9-10H2,1-5H3/b13-8+
DMZUY93 CS CC(=CCC1=CC(=CC(=C1OC)CC=C(C)C)/C=C/C(=O)C2=C(C=C(C=C2)O)O)C
DMZUY93 IK AHQPCANDOCWXDN-MDWZMJQESA-N
DMZUY93 IU (E)-1-(2,4-dihydroxyphenyl)-3-[4-methoxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-en-1-one
DMZUY93 DE Discovery agent
DMZ0RP5 ID DMZ0RP5
DMZ0RP5 DN AC-(D)PHE-PRO-BOROHOMOLYS-OH
DMZ0RP5 HS Investigative
DMZ0RP5 SN AC-(D)PHE-PRO-BOROHOMOLYS-OH; AC1NRARZ; DB07659; N-acetyl-D-phenylalanyl-N-[(1R)-6-amino-1-(dihydroxyboranyl)hexyl]-L-prolinamide; (1R)-6-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}hexylboronic acid; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-6-aminohexyl]boronic acid
DMZ0RP5 DT Small molecular drug
DMZ0RP5 PC 5288066
DMZ0RP5 MW 446.4
DMZ0RP5 FM C22H35BN4O5
DMZ0RP5 IC InChI=1S/C22H35BN4O5/c1-16(28)25-18(15-17-9-4-2-5-10-17)22(30)27-14-8-11-19(27)21(29)26-20(23(31)32)12-6-3-7-13-24/h2,4-5,9-10,18-20,31-32H,3,6-8,11-15,24H2,1H3,(H,25,28)(H,26,29)/t18-,19+,20+/m1/s1
DMZ0RP5 CS B([C@H](CCCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMZ0RP5 IK AILSWIBFGYYZTK-AABGKKOBSA-N
DMZ0RP5 IU [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-6-aminohexyl]boronic acid
DMZ0RP5 DE Discovery agent
DMPHV7K ID DMPHV7K
DMPHV7K DN AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH
DMPHV7K HS Investigative
DMPHV7K SN AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH; AC1NRAS2; DB07660; N-acetyl-D-phenylalanyl-N-[(1R)-4-amino-1-(dihydroxyboranyl)butyl]-L-prolinamide; (1R)-4-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}butylboronic acid; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-aminobutyl]boronic acid
DMPHV7K DT Small molecular drug
DMPHV7K PC 5288067
DMPHV7K MW 418.3
DMPHV7K FM C20H31BN4O5
DMPHV7K IC InChI=1S/C20H31BN4O5/c1-14(26)23-16(13-15-7-3-2-4-8-15)20(28)25-12-6-9-17(25)19(27)24-18(21(29)30)10-5-11-22/h2-4,7-8,16-18,29-30H,5-6,9-13,22H2,1H3,(H,23,26)(H,24,27)/t16-,17+,18+/m1/s1
DMPHV7K CS B([C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DMPHV7K IK YKWKWNKWBGQECF-SQNIBIBYSA-N
DMPHV7K IU [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-aminobutyl]boronic acid
DMPHV7K DE Discovery agent
DM2YWRL ID DM2YWRL
DM2YWRL DN AC-(D)PHE-PRO-BOROLYS-OH
DM2YWRL HS Investigative
DM2YWRL SN AC-(D)PHE-PRO-BOROLYS-OH; CHEMBL100109; AC1NRART; BDBM50288414; DB07658; N-acetyl-D-phenylalanyl-N-[(1R)-5-amino-1-(dihydroxyboranyl)pentyl]-L-prolinamide; 1-(2-Acetylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid (5-amino-1-dihydroxyboranyl-pentyl)-amide; [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-aminopentyl]boronic acid; (1R)-5-amino-1-{[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}pentylboronic acid
DM2YWRL DT Small molecular drug
DM2YWRL PC 5288064
DM2YWRL MW 432.3
DM2YWRL FM C21H33BN4O5
DM2YWRL IC InChI=1S/C21H33BN4O5/c1-15(27)24-17(14-16-8-3-2-4-9-16)21(29)26-13-7-10-18(26)20(28)25-19(22(30)31)11-5-6-12-23/h2-4,8-9,17-19,30-31H,5-7,10-14,23H2,1H3,(H,24,27)(H,25,28)/t17-,18+,19+/m1/s1
DM2YWRL CS B([C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CC2=CC=CC=C2)NC(=O)C)(O)O
DM2YWRL IK UCQIHCRMWNRFNP-QYZOEREBSA-N
DM2YWRL IU [(1R)-1-[[(2S)-1-[(2R)-2-acetamido-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-aminopentyl]boronic acid
DM2YWRL DE Discovery agent
DMRLOGP ID DMRLOGP
DMRLOGP DN Ac-[CEHdFRWC]-NH2
DMRLOGP HS Investigative
DMRLOGP SN CHEMBL385556; Ac-[CEHdFRWC]-NH2
DMRLOGP PC 44400398
DMRLOGP MW 1019.2
DMRLOGP FM C45H58N14O10S2
DMRLOGP IC InChI=1S/C45H58N14O10S2/c1-24(60)53-36-22-71-70-21-35(38(46)63)59-42(67)33(17-26-19-51-29-11-6-5-10-28(26)29)57-39(64)30(12-7-15-50-45(47)48)54-41(66)32(16-25-8-3-2-4-9-25)56-43(68)34(18-27-20-49-23-52-27)58-40(65)31(55-44(36)69)13-14-37(61)62/h2-6,8-11,19-20,23,30-36,51H,7,12-18,21-22H2,1H3,(H2,46,63)(H,49,52)(H,53,60)(H,54,66)(H,55,69)(H,56,68)(H,57,64)(H,58,65)(H,59,67)(H,61,62)(H4,47,48,50)/t30-,31+,32-,33+,34-,35+,36+/m0/s1
DMRLOGP CS CC(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)CCC(=O)O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DMRLOGP IK DCRRHKOGXQUJTJ-VCFUPWAGSA-N
DMRLOGP IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-acetamido-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMRLOGP DE Discovery agent
DM9IN4T ID DM9IN4T
DM9IN4T DN Ac-[CFWKFC]-NH2
DM9IN4T HS Investigative
DM9IN4T SN CHEMBL1163471; Ac-[CFWKFC]-NH2
DM9IN4T DT Small molecular drug
DM9IN4T PC 11125778
DM9IN4T MW 872.1
DM9IN4T FM C43H53N9O7S2
DM9IN4T IC InChI=1S/C43H53N9O7S2/c1-26(53)47-37-25-61-60-24-36(38(45)54)52-41(57)34(21-28-14-6-3-7-15-28)49-39(55)32(18-10-11-19-44)48-42(58)35(22-29-23-46-31-17-9-8-16-30(29)31)51-40(56)33(50-43(37)59)20-27-12-4-2-5-13-27/h2-9,12-17,23,32-37,46H,10-11,18-22,24-25,44H2,1H3,(H2,45,54)(H,47,53)(H,48,58)(H,49,55)(H,50,59)(H,51,56)(H,52,57)/t32-,33-,34-,35-,36-,37-/m0/s1
DM9IN4T CS CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=CC=C5)C(=O)N
DM9IN4T IK PRZDRTMXFMEFAP-DUGSHLAESA-N
DM9IN4T IU (4R,7S,10S,13S,16S,19R)-19-acetamido-10-(4-aminobutyl)-7,16-dibenzyl-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM9IN4T DE Discovery agent
DMW24UH ID DMW24UH
DMW24UH DN Ac-[CFWkYC]-NH2
DMW24UH HS Investigative
DMW24UH SN CHEMBL1163477; Ac-[CFWKYC]-NH2
DMW24UH DT Small molecular drug
DMW24UH PC 11007453
DMW24UH MW 888.1
DMW24UH FM C43H53N9O8S2
DMW24UH IC InChI=1S/C43H53N9O8S2/c1-25(53)47-37-24-62-61-23-36(38(45)55)52-41(58)34(20-27-14-16-29(54)17-15-27)49-39(56)32(13-7-8-18-44)48-42(59)35(21-28-22-46-31-12-6-5-11-30(28)31)51-40(57)33(50-43(37)60)19-26-9-3-2-4-10-26/h2-6,9-12,14-17,22,32-37,46,54H,7-8,13,18-21,23-24,44H2,1H3,(H2,45,55)(H,47,53)(H,48,59)(H,49,56)(H,50,60)(H,51,57)(H,52,58)/t32-,33-,34+,35-,36-,37-/m0/s1
DMW24UH CS CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=C(C=C5)O)C(=O)N
DMW24UH IK UHSPHALTSYXFRP-PCRAMSICSA-N
DMW24UH IU (4R,7R,10S,13S,16S,19R)-19-acetamido-10-(4-aminobutyl)-16-benzyl-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMW24UH DE Discovery agent
DMFKV97 ID DMFKV97
DMFKV97 DN AC1LG8KT
DMFKV97 HS Investigative
DMFKV97 SN BAS 01816608; TCS JNK 5a
DMFKV97 DT Small molecular drug
DMFKV97 PC 766949
DMFKV97 MW 332.4
DMFKV97 FM C20H16N2OS
DMFKV97 IC InChI=1S/C20H16N2OS/c21-12-17-15-9-3-4-11-18(15)24-20(17)22-19(23)16-10-5-7-13-6-1-2-8-14(13)16/h1-2,5-8,10H,3-4,9,11H2,(H,22,23)
DMFKV97 CS C1CCC2=C(C1)C(=C(S2)NC(=O)C3=CC=CC4=CC=CC=C43)C#N
DMFKV97 IK WQGDQGAFSDMBLA-UHFFFAOYSA-N
DMFKV97 IU N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)naphthalene-1-carboxamide
DMFKV97 CA CAS 312917-14-9
DMFKV97 CB CHEBI:91453
DMFKV97 DE Discovery agent
DMSKE1I ID DMSKE1I
DMSKE1I DN AC261066
DMSKE1I HS Investigative
DMSKE1I SN AC 261066; AC-261066
DMSKE1I DT Small molecular drug
DMSKE1I PC 11530459
DMSKE1I MW 353.4
DMSKE1I FM C17H20FNO4S
DMSKE1I IC InChI=1S/C17H20FNO4S/c1-3-4-7-22-8-9-23-15-11(2)24-16(19-15)12-5-6-13(17(20)21)14(18)10-12/h5-6,10H,3-4,7-9H2,1-2H3,(H,20,21)
DMSKE1I CS CCCCOCCOC1=C(SC(=N1)C2=CC(=C(C=C2)C(=O)O)F)C
DMSKE1I IK HSAOETBFVAWNRP-UHFFFAOYSA-N
DMSKE1I IU 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid
DMSKE1I CA CAS 870773-76-5
DMSKE1I DE Discovery agent
DM4G60V ID DM4G60V
DM4G60V DN AC265347
DM4G60V HS Investigative
DM4G60V SN AC-265347; AC 265347
DM4G60V DT Small molecular drug
DM4G60V PC 52943938
DM4G60V MW 283.4
DM4G60V FM C17H17NOS
DM4G60V IC InChI=1S/C17H17NOS/c1-11-8-9-13(12(2)10-11)17(3,19)16-18-14-6-4-5-7-15(14)20-16/h4-10,19H,1-3H3
DM4G60V CS CC1=CC(=C(C=C1)C(C)(C2=NC3=CC=CC=C3S2)O)C
DM4G60V IK IGSZVEPQZANNAB-UHFFFAOYSA-N
DM4G60V IU 1-(1,3-benzothiazol-2-yl)-1-(2,4-dimethylphenyl)ethanol
DM4G60V DE Discovery agent
DMNUE4H ID DMNUE4H
DMNUE4H DN AC-3174
DMNUE4H HS Investigative
DMNUE4H SN GLP-1 agonist (type 2 diabetes), Amylin Pharmaceuticals; Glucagon-like peptide-1 receptor agonist (type 2diabetes/non-alcoholic steatohepatitis), Amylin Pharmaceuticals; (Leu14)exendin-4
DMNUE4H CP Amylin Pharmaceuticals Inc
DMNUE4H DT Small molecular drug
DMNUE4H PC 817098
DMNUE4H MW 192.44
DMNUE4H FM C5H3BrClN
DMNUE4H IC InChI=1S/C5H3BrClN/c6-5-2-1-4(7)3-8-5/h1-3H
DMNUE4H CS C1=CC(=NC=C1Cl)Br
DMNUE4H IK BZUUVQCSPHPUQA-UHFFFAOYSA-N
DMNUE4H IU 2-bromo-5-chloropyridine
DMNUE4H CA CAS 40473-01-6
DMNUE4H DE Non-alcoholic steatohepatitis
DM4JNY9 ID DM4JNY9
DM4JNY9 DN AC55649
DM4JNY9 HS Investigative
DM4JNY9 SN AC 55649; AC-55649
DM4JNY9 DT Small molecular drug
DM4JNY9 PC 1714884
DM4JNY9 MW 310.4
DM4JNY9 FM C21H26O2
DM4JNY9 IC InChI=1S/C21H26O2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)19-13-15-20(16-14-19)21(22)23/h9-16H,2-8H2,1H3,(H,22,23)
DM4JNY9 CS CCCCCCCCC1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)O
DM4JNY9 IK HXBKPYIEQLLNBK-UHFFFAOYSA-N
DM4JNY9 IU 4-(4-octylphenyl)benzoic acid
DM4JNY9 CA CAS 59662-49-6
DM4JNY9 CB CHEBI:95048
DM4JNY9 DE Discovery agent
DMXS72J ID DMXS72J
DMXS72J DN AC-710
DMXS72J HS Investigative
DMXS72J SN CSF1R inhibitor (cancer), Ambit Biosciences; CSF1R inhibitor (cancer/autoimmune/inflammatory disease), Ambit Biosciences
DMXS72J CP Ambit Biosciences Corp
DMXS72J DT Small molecular drug
DMXS72J PC 54760053
DMXS72J MW 562.7
DMXS72J FM C31H42N6O4
DMXS72J IC InChI=1S/C31H42N6O4/c1-9-37-30(5,6)17-23(18-31(37,7)8)40-22-14-15-24(32-19-22)27(38)33-20-10-12-21(13-11-20)34-28(39)35-26-16-25(41-36-26)29(2,3)4/h10-16,19,23H,9,17-18H2,1-8H3,(H,33,38)(H2,34,35,36,39)
DMXS72J CS CCN1C(CC(CC1(C)C)OC2=CN=C(C=C2)C(=O)NC3=CC=C(C=C3)NC(=O)NC4=NOC(=C4)C(C)(C)C)(C)C
DMXS72J IK JVCWPUFNLFSKFS-UHFFFAOYSA-N
DMXS72J IU N-[4-[(5-tert-butyl-1,2-oxazol-3-yl)carbamoylamino]phenyl]-5-(1-ethyl-2,2,6,6-tetramethylpiperidin-4-yl)oxypyridine-2-carboxamide
DMXS72J DE Autoimmune diabetes
DM367MF ID DM367MF
DM367MF DN AC-7954
DM367MF HS Investigative
DM367MF SN AC7954; AC 7954
DM367MF DT Small molecular drug
DM367MF PC 9797568
DM367MF MW 329.8
DM367MF FM C19H20ClNO2
DM367MF IC InChI=1S/C19H20ClNO2/c1-21(2)12-11-19(15-7-9-16(20)10-8-15)13-14-5-3-4-6-17(14)18(22)23-19/h3-10H,11-13H2,1-2H3
DM367MF CS CN(C)CCC1(CC2=CC=CC=C2C(=O)O1)C3=CC=C(C=C3)Cl
DM367MF IK HIVBATDUVFEJFZ-UHFFFAOYSA-N
DM367MF IU 3-(4-chlorophenyl)-3-[2-(dimethylamino)ethyl]-4H-isochromen-1-one
DM367MF CB CHEBI:103978
DM367MF DE Discovery agent
DM09BJ4 ID DM09BJ4
DM09BJ4 DN AC-8632
DM09BJ4 HS Investigative
DM09BJ4 SN 5-(Tetradecyloxy)-2-furoic acid; TOFA; 54857-86-2; 5-(Tetradecyloxy)-2-furancarboxylic acid; 5-Tetradecyloxy-2-furonic acid; Rmi 14514; UNII-BI12FRY055; 2-Furancarboxylic acid, 5-(tetradecyloxy)-; MDL 14514; RMI-14514; BRN 0539681; 5-(tetradecyloxy)furan-2-carboxylic acid; BI12FRY055; CHEBI:77936; C19H32O4; 2-Furancarboxylic acid,5-(tetradecyloxy)-; AC1Q5UHU; AC1L3GNQ; 5-(tetradecyloxy)furoic acid; SCHEMBL543676; 5-tetradecyloxy-2-furoic acid; GTPL5280; CHEMBL1562779; TOFA, RMI 14514; CTK5A2675; DTXSID60203338; Acetyl-coenzyme A carboxylase inhibitor (Parkinson's disease), Accera; Acetyl-coenzyme A carboxylase inhibitor (Parkinson's disease), Neuera
DM09BJ4 CP Accera Inc
DM09BJ4 DT Small molecular drug
DM09BJ4 PC 115175
DM09BJ4 MW 324.5
DM09BJ4 FM C19H32O4
DM09BJ4 IC InChI=1S/C19H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22-18-15-14-17(23-18)19(20)21/h14-15H,2-13,16H2,1H3,(H,20,21)
DM09BJ4 CS CCCCCCCCCCCCCCOC1=CC=C(O1)C(=O)O
DM09BJ4 IK CZRCFAOMWRAFIC-UHFFFAOYSA-N
DM09BJ4 IU 5-tetradecoxyfuran-2-carboxylic acid
DM09BJ4 CA CAS 54857-86-2
DM09BJ4 CB CHEBI:77936
DM09BJ4 DE Parkinson disease
DMACYPW ID DMACYPW
DMACYPW DN ACAA
DMACYPW HS Investigative
DMACYPW SN ACA
DMACYPW DT Small molecular drug
DMACYPW PC 5353376
DMACYPW MW 337.4
DMACYPW FM C21H23NO3
DMACYPW IC InChI=1S/C21H23NO3/c1-2-3-4-7-16-10-12-17(13-11-16)14-15-20(23)22-19-9-6-5-8-18(19)21(24)25/h5-6,8-15H,2-4,7H2,1H3,(H,22,23)(H,24,25)/b15-14+
DMACYPW CS CCCCCC1=CC=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O
DMACYPW IK GAMRBCZMOOMBSQ-CCEZHUSRSA-N
DMACYPW IU 2-[[(E)-3-(4-pentylphenyl)prop-2-enoyl]amino]benzoic acid
DMACYPW CA CAS 99196-74-4
DMACYPW CB CHEBI:114200
DMACYPW DE Discovery agent
DMQOB0X ID DMQOB0X
DMQOB0X DN Acacetin
DMQOB0X HS Investigative
DMQOB0X SN acacetin; 480-44-4; Linarigenin; 5,7-Dihydroxy-4'-methoxyflavone; Acacetine; 4'-Methoxyapigenin; Buddleoflavonol; Linarisenin; Akatsetin; 5,7-Dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; Apigenin 4'-methyl ether; 5,7-Dioxy-4'-methoxyflavone; Apisenin 4'-methyl ether; Apigenin 4'-dimethyl ether; UNII-KWI7J0A2CC; NSC 76061; Flavone, 5,7-dihydroxy-4'-methoxy-; 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one; ACAETIN; 4'-Methoxy-5,7-dihydroxyflavone; NSC76061; EINECS 207-552-3; KWI7J0A2CC
DMQOB0X DT Small molecular drug
DMQOB0X PC 5280442
DMQOB0X MW 284.26
DMQOB0X FM C16H12O5
DMQOB0X IC InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)14-8-13(19)16-12(18)6-10(17)7-15(16)21-14/h2-8,17-18H,1H3
DMQOB0X CS COC1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O
DMQOB0X IK DANYIYRPLHHOCZ-UHFFFAOYSA-N
DMQOB0X IU 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one
DMQOB0X CA CAS 480-44-4
DMQOB0X CB CHEBI:15335
DMQOB0X DE Discovery agent
DMJ3C20 ID DMJ3C20
DMJ3C20 DN Ac-Ala-Pro-Val-(2-benzoxazole)
DMJ3C20 HS Investigative
DMJ3C20 SN CHEMBL438709
DMJ3C20 DT Small molecular drug
DMJ3C20 PC 44454029
DMJ3C20 MW 428.5
DMJ3C20 FM C22H28N4O5
DMJ3C20 IC InChI=1S/C22H28N4O5/c1-12(2)18(19(28)21-24-15-8-5-6-10-17(15)31-21)25-20(29)16-9-7-11-26(16)22(30)13(3)23-14(4)27/h5-6,8,10,12-13,16,18H,7,9,11H2,1-4H3,(H,23,27)(H,25,29)/t13-,16-,18-/m0/s1
DMJ3C20 CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)C2=NC3=CC=CC=C3O2)NC(=O)C
DMJ3C20 IK BITOROACNLSRME-OWQGQXMQSA-N
DMJ3C20 IU (2S)-1-[(2S)-2-acetamidopropanoyl]-N-[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMJ3C20 DE Discovery agent
DMZDFRI ID DMZDFRI
DMZDFRI DN Acanthus ilicifolius Linn
DMZDFRI HS Investigative
DMZDFRI SN AC1L1B2B; CBiol_001885; KBioGR_000483; KBioSS_000483; BSPBio_001143; (-)-Huperzine A-d5 (Major); CHEMBL3184073; KBio3_000886; CTK8E6796; KBio2_003051; BDBM10441; KBio2_005619; KBio2_000483; KBio3_000885; Bio2_000402; Bio1_001149; Bio1_000660; HMS1990I05; Bio2_000882; Bio1_000171; AKOS032962044; AN-1052; KS-0000000G; IDI1_002157; NCGC00163246-01; FT-0642946; N1881; Acarviostatin III03; Acarviostatin IV03
DMZDFRI DT Small molecular drug
DMZDFRI PC 1253
DMZDFRI MW 242.32
DMZDFRI FM C15H18N2O
DMZDFRI IC InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)
DMZDFRI CS CC=C1C2CC3=C(C1(CC(=C2)C)N)C=CC(=O)N3
DMZDFRI IK ZRJBHWIHUMBLCN-UHFFFAOYSA-N
DMZDFRI IU 1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.02,7]trideca-2(7),3,10-trien-5-one
DMZDFRI CA CAS 102518-79-6
DMZDFRI DE Discovery agent
DMS9COH ID DMS9COH
DMS9COH DN Acarbose Derived Hexasaccharide
DMS9COH HS Investigative
DMS9COH DT Small molecular drug
DMS9COH PC 46936851
DMS9COH MW 969.9
DMS9COH FM C37H63NO28
DMS9COH IC InChI=1S/C37H63NO28/c1-8-15(19(46)26(53)35(59-8)65-31-12(5-41)62-34(28(55)23(31)50)58-7-14-18(45)20(47)25(52)33(57)60-14)38-10-2-9(3-39)30(22(49)16(10)43)64-37-29(56)24(51)32(13(6-42)63-37)66-36-27(54)21(48)17(44)11(4-40)61-36/h2,8,10-57H,3-7H2,1H3/t8-,10+,11+,12+,13-,14+,15-,16-,17+,18+,19+,20-,21-,22+,23-,24-,25+,26-,27+,28-,29-,30-,31-,32-,33+,34-,35+,36-,37+/m1/s1
DMS9COH CS C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@@H](O[C@H]([C@@H]([C@H]2O)O)OC[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)O)O)O)O)CO)O)O)N[C@H]4C=C([C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O[C@@H]6[C@H]([C@@H]([C@H]([C@@H](O6)CO)O)O)O)O)O)CO
DMS9COH IK MBNITLCAVXHYER-AGOKNQOUSA-N
DMS9COH IU (2S,3S,4R,5R,6S)-6-[[(2R,3R,4R,5S,6S)-5-[(2S,3R,4S,5S,6R)-5-[[(1S,4R,5S,6R)-4-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,6-dihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]-3,4-dihydroxy-6-methyloxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
DMS9COH DE Discovery agent
DMYHADT ID DMYHADT
DMYHADT DN Ac-Asp-Arg-Leu-Asp-Ser-OH
DMYHADT HS Investigative
DMYHADT SN CHEMBL238484; Ac-Asp-Arg-Leu-Asp-Ser-OH; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420
DMYHADT DT Small molecular drug
DMYHADT PC 11764797
DMYHADT MW 646.6
DMYHADT FM C25H42N8O12
DMYHADT IC InChI=1S/C25H42N8O12/c1-11(2)7-14(21(41)32-16(9-19(38)39)23(43)33-17(10-34)24(44)45)31-20(40)13(5-4-6-28-25(26)27)30-22(42)15(8-18(36)37)29-12(3)35/h11,13-17,34H,4-10H2,1-3H3,(H,29,35)(H,30,42)(H,31,40)(H,32,41)(H,33,43)(H,36,37)(H,38,39)(H,44,45)(H4,26,27,28)/t13-,14-,15-,16-,17-/m0/s1
DMYHADT CS CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMYHADT IK MBZXDXZGPJKBRJ-WOYTXXSLSA-N
DMYHADT IU (3S)-3-acetamido-4-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMYHADT DE Discovery agent
DMT74F5 ID DMT74F5
DMT74F5 DN AcAsp-D-Gla-Leu-Ile-Cha-Cys
DMT74F5 HS Investigative
DMT74F5 SN CHEMBL179084; AcAsp-D-Gla-Leu-Ile-Cha-Cys; AC1NX3UI; BDBM50158804; (4S)-4-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-[[(2S)-1-[[(2S,3R)-1-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMT74F5 DT Small molecular drug
DMT74F5 PC 5742851
DMT74F5 MW 786.9
DMT74F5 FM C35H58N6O12S
DMT74F5 IC InChI=1S/C35H58N6O12S/c1-6-19(4)29(34(51)39-24(15-21-10-8-7-9-11-21)31(48)40-26(17-54)35(52)53)41-33(50)23(14-18(2)3)38-30(47)22(12-13-27(43)44)37-32(49)25(16-28(45)46)36-20(5)42/h18-19,21-26,29,54H,6-17H2,1-5H3,(H,36,42)(H,37,49)(H,38,47)(H,39,51)(H,40,48)(H,41,50)(H,43,44)(H,45,46)(H,52,53)/t19-,22+,23+,24+,25+,26+,29+/m1/s1
DMT74F5 CS CC[C@@H](C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMT74F5 IK CSWPZICAVWHBCE-ZZOXDLJQSA-N
DMT74F5 IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMT74F5 DE Discovery agent
DMDC71B ID DMDC71B
DMDC71B DN AcAsp-D-Glu-Leu-Glu-Cha-Cys
DMDC71B HS Investigative
DMDC71B SN AcAsp-D-Glu-Leu-Glu-Cha-Cys; CHEMBL60967; AC1LAOO4; BDBM50096410; AcAsp-D-Glu-Leu-Glu-.beta.-Cyclohexylalanine-Cys; Ac-L-Asp-D-Glu-L-Leu-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDC71B DT Small molecular drug
DMDC71B PC 492320
DMDC71B MW 802.9
DMDC71B FM C34H54N6O14S
DMDC71B IC InChI=1S/C34H54N6O14S/c1-17(2)13-22(38-29(48)20(9-11-26(42)43)37-33(52)24(15-28(46)47)35-18(3)41)31(50)36-21(10-12-27(44)45)30(49)39-23(14-19-7-5-4-6-8-19)32(51)40-25(16-55)34(53)54/h17,19-25,55H,4-16H2,1-3H3,(H,35,41)(H,36,50)(H,37,52)(H,38,48)(H,39,49)(H,40,51)(H,42,43)(H,44,45)(H,46,47)(H,53,54)/t20-,21+,22+,23+,24+,25+/m1/s1
DMDC71B CS CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMDC71B IK SYHFABLPDKKGNQ-RFXJPFPRSA-N
DMDC71B IU (4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDC71B DE Discovery agent
DMXQATR ID DMXQATR
DMXQATR DN AcAsp-Gla-Leu-Ile-Cha-Cys
DMXQATR HS Investigative
DMXQATR DT Small molecular drug
DMXQATR PC 44305052
DMXQATR MW 830.9
DMXQATR FM C36H58N6O14S
DMXQATR IC InChI=1S/C36H58N6O14S/c1-6-18(4)28(33(51)39-23(13-20-10-8-7-9-11-20)30(48)40-25(16-57)36(55)56)41-31(49)22(12-17(2)3)38-34(52)29(21(35(53)54)14-26(44)45)42-32(50)24(15-27(46)47)37-19(5)43/h17-18,20-25,28-29,57H,6-16H2,1-5H3,(H,37,43)(H,38,52)(H,39,51)(H,40,48)(H,41,49)(H,42,50)(H,44,45)(H,46,47)(H,53,54)(H,55,56)/t18?,21?,22-,23-,24-,25-,28-,29+/m0/s1
DMXQATR CS CCC(C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMXQATR IK SBWANKMZZMQXKQ-JHOOERKCSA-N
DMXQATR IU 2-[(1R)-1-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]butanedioic acid
DMXQATR DE Discovery agent
DMHZ5W3 ID DMHZ5W3
DMHZ5W3 DN AcAsp-Glu-Cha-Val-Prb-Cpg
DMHZ5W3 HS Investigative
DMHZ5W3 SN CHEMBL360983; AcAsp-Glu-Cha-Val-Prb-Cpg
DMHZ5W3 DT Small molecular drug
DMHZ5W3 PC 44388180
DMHZ5W3 MW 842.9
DMHZ5W3 FM C41H58N6O13
DMHZ5W3 IC InChI=1S/C41H58N6O13/c1-23(2)34(39(57)47-21-27(60-22-26-12-8-5-9-13-26)19-31(47)38(56)46-41(16-17-41)40(58)59)45-37(55)29(18-25-10-6-4-7-11-25)44-35(53)28(14-15-32(49)50)43-36(54)30(20-33(51)52)42-24(3)48/h5,8-9,12-13,23,25,27-31,34H,4,6-7,10-11,14-22H2,1-3H3,(H,42,48)(H,43,54)(H,44,53)(H,45,55)(H,46,56)(H,49,50)(H,51,52)(H,58,59)/t27-,28-,29-,30-,31-,34-/m0/s1
DMHZ5W3 CS CC(C)[C@@H](C(=O)N1C[C@H](C[C@H]1C(=O)NC2(CC2)C(=O)O)OCC3=CC=CC=C3)NC(=O)[C@H](CC4CCCCC4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMHZ5W3 IK DDYNDQYNGBVAAZ-HWKKFYSMSA-N
DMHZ5W3 IU 1-[[(2S,4S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-cyclohexylpropanoyl]amino]-3-methylbutanoyl]-4-phenylmethoxypyrrolidine-2-carbonyl]amino]cyclopropane-1-carboxylic acid
DMHZ5W3 DE Discovery agent
DMDH5EJ ID DMDH5EJ
DMDH5EJ DN AcAsp-Glu-Cha-Val-Prb-Cys
DMDH5EJ HS Investigative
DMDH5EJ SN AcAsp-Glu-Cha-Val-Prb-Cys; CHEMBL179963
DMDH5EJ DT Small molecular drug
DMDH5EJ PC 44388179
DMDH5EJ MW 863
DMDH5EJ FM C40H58N6O13S
DMDH5EJ IC InChI=1S/C40H58N6O13S/c1-22(2)34(39(56)46-19-26(59-20-25-12-8-5-9-13-25)17-31(46)38(55)44-30(21-60)40(57)58)45-37(54)28(16-24-10-6-4-7-11-24)43-35(52)27(14-15-32(48)49)42-36(53)29(18-33(50)51)41-23(3)47/h5,8-9,12-13,22,24,26-31,34,60H,4,6-7,10-11,14-21H2,1-3H3,(H,41,47)(H,42,53)(H,43,52)(H,44,55)(H,45,54)(H,48,49)(H,50,51)(H,57,58)/t26-,27+,28+,29+,30?,31+,34+/m1/s1
DMDH5EJ CS CC(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)NC(CS)C(=O)O)OCC2=CC=CC=C2)NC(=O)[C@H](CC3CCCCC3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMDH5EJ IK UINXWQSPCZCPNY-MKVQYLHRSA-N
DMDH5EJ IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S,4R)-2-[(1-carboxy-2-sulfanylethyl)carbamoyl]-4-phenylmethoxypyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDH5EJ DE Discovery agent
DMEB8UA ID DMEB8UA
DMEB8UA DN AcAsp-Glu-Dif-Glu-Cha-Cys
DMEB8UA HS Investigative
DMEB8UA SN CHEMBL417559; Ac-Asp-Glu-Dif-Glu-Cha-Cys-OH; AcAsp-Glu-Dif-Glu-Cha-Cys; (4S)-4-[[(2S)-2-acetamido-4-hydroxy-4-oxo-butanoyl]amino]-5-[[(1S)-1-benzhydryl-2-[[(1S)-1-[[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-2-hydroxy-2-oxo-1-(sulfanylmethyl)ethyl]amino]-2-oxo-ethyl]carbamoyl]-4-hydroxy-4-oxo-butyl]amino]-2-oxo-ethyl]amino]-5-oxo-pentanoic acid; AC1LA689; BDBM50084685; Ac-Asp-Glu-3,3-Diphenylalanine-GLu-beta-Cyclohexylalanine-Cys-OH; Ac-L-Asp-L-Glu-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH
DMEB8UA DT Small molecular drug
DMEB8UA PC 482211
DMEB8UA MW 913
DMEB8UA FM C43H56N6O14S
DMEB8UA IC InChI=1S/C43H56N6O14S/c1-24(50)44-31(22-35(55)56)41(60)45-29(18-20-34(53)54)39(58)49-37(36(26-13-7-3-8-14-26)27-15-9-4-10-16-27)42(61)46-28(17-19-33(51)52)38(57)47-30(21-25-11-5-2-6-12-25)40(59)48-32(23-64)43(62)63/h3-4,7-10,13-16,25,28-32,36-37,64H,2,5-6,11-12,17-23H2,1H3,(H,44,50)(H,45,60)(H,46,61)(H,47,57)(H,48,59)(H,49,58)(H,51,52)(H,53,54)(H,55,56)(H,62,63)/t28-,29-,30-,31-,32-,37-/m0/s1
DMEB8UA CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DMEB8UA IK UJAUCRPOZPWCGV-XJJOYFJPSA-N
DMEB8UA IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMEB8UA DE Discovery agent
DMPQ8Z9 ID DMPQ8Z9
DMPQ8Z9 DN AcAsp-Glu-Dif-Glu-Cha-Fab
DMPQ8Z9 HS Investigative
DMPQ8Z9 SN CHEMBL349186; AcAsp-Glu-Dif-Glu-Cha-Fab; AC1L9WIG; BDBM50110121; Ac-L-Asp-L-Glu-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-[(3S)-2-oxo-3-(2,2-difluoroethyl)-betaAla-]-OH; 3-[2-(2-{2-[2-(2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-3,3-diphenyl-propionylamino}-4-carboxy-butyrylamino)-3-cyclohexyl-propionylamino]-5,5-difluoro-2-oxo-pentanoic acid
DMPQ8Z9 DT Small molecular drug
DMPQ8Z9 PC 457393
DMPQ8Z9 MW 959
DMPQ8Z9 FM C45H56F2N6O15
DMPQ8Z9 IC InChI=1S/C45H56F2N6O15/c1-24(54)48-32(23-36(59)60)43(65)49-29(18-20-35(57)58)41(63)53-38(37(26-13-7-3-8-14-26)27-15-9-4-10-16-27)44(66)50-28(17-19-34(55)56)40(62)52-31(21-25-11-5-2-6-12-25)42(64)51-30(22-33(46)47)39(61)45(67)68/h3-4,7-10,13-16,25,28-33,37-38H,2,5-6,11-12,17-23H2,1H3,(H,48,54)(H,49,65)(H,50,66)(H,51,64)(H,52,62)(H,53,63)(H,55,56)(H,57,58)(H,59,60)(H,67,68)/t28-,29-,30-,31-,32-,38-/m0/s1
DMPQ8Z9 CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O
DMPQ8Z9 IK FIGPTAABOPCRSH-BHTNCQBCSA-N
DMPQ8Z9 IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3,3-diphenylpropanoyl]amino]-4-carboxybutanoyl]amino]-3-cyclohexylpropanoyl]amino]-5,5-difluoro-2-oxopentanoic acid
DMPQ8Z9 DE Discovery agent
DM6IP17 ID DM6IP17
DM6IP17 DN AcAsp-Glu-Dif-Ile-Cha-Cys
DM6IP17 HS Investigative
DM6IP17 SN CHEMBL61390; AcAsp-Glu-Dif-Ile-Cha-Cys
DM6IP17 DT Small molecular drug
DM6IP17 PC 44305085
DM6IP17 MW 897
DM6IP17 FM C44H60N6O12S
DM6IP17 IC InChI=1S/C44H60N6O12S/c1-4-25(2)37(42(59)47-31(22-27-14-8-5-9-15-27)40(57)48-33(24-63)44(61)62)49-43(60)38(36(28-16-10-6-11-17-28)29-18-12-7-13-19-29)50-39(56)30(20-21-34(52)53)46-41(58)32(23-35(54)55)45-26(3)51/h6-7,10-13,16-19,25,27,30-33,36-38,63H,4-5,8-9,14-15,20-24H2,1-3H3,(H,45,51)(H,46,58)(H,47,59)(H,48,57)(H,49,60)(H,50,56)(H,52,53)(H,54,55)(H,61,62)/t25-,30+,31+,32+,33-,37-,38+/m1/s1
DM6IP17 CS CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](CS)C(=O)O)NC(=O)[C@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DM6IP17 IK ZZXPMGNPISOZPV-IFWKXTFSSA-N
DM6IP17 IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2R,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM6IP17 DE Discovery agent
DM3W68X ID DM3W68X
DM3W68X DN AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2
DM3W68X HS Investigative
DM3W68X SN N-{[(3R)-2-(N-Acetyl-L-alpha-aspartyl-L-alpha-glutamyl-3,3-diphenyl-L-alanyl-L-alloisoleucyl-3-cyclohexyl-L-alanyl-L-cysteinyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl}-L-norleucyl-L-seryl-L-tyrosinamide
DM3W68X PC 16133705
DM3W68X MW 1418.7
DM3W68X FM C72H95N11O17S
DM3W68X IC InChI=1S/C72H95N11O17S/c1-5-7-27-50(64(92)79-55(39-84)68(96)77-52(63(73)91)34-44-28-30-49(86)31-29-44)76-69(97)57-36-47-25-17-18-26-48(47)38-83(57)72(100)56(40-101)80-66(94)53(35-43-19-11-8-12-20-43)78-70(98)61(41(3)6-2)81-71(99)62(60(45-21-13-9-14-22-45)46-23-15-10-16-24-46)82-65(93)51(32-33-58(87)88)75-67(95)54(37-59(89)90)74-42(4)85/h9-10,13-18,21-26,28-31,41,43,50-57,60-62,84,86,101H,5-8,11-12,19-20,27,32-40H2,1-4H3,(H2,73,91)(H,74,85)(H,75,95)(H,76,97)(H,77,96)(H,78,98)(H,79,92)(H,80,94)(H,81,99)(H,82,93)(H,87,88)(H,89,90)/t41?,50-,51-,52-,53-,54-,55-,56-,57+,61-,62-/m0/s1
DM3W68X CS CCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H]2CC3=CC=CC=C3CN2C(=O)[C@H](CS)NC(=O)[C@H](CC4CCCCC4)NC(=O)[C@H](C(C)CC)NC(=O)[C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DM3W68X IK NAFMHFOWWVFCTM-BPJKRSAYSA-N
DM3W68X IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(3R)-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM3W68X DE Discovery agent
DMCIJ6Q ID DMCIJ6Q
DMCIJ6Q DN AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2
DMCIJ6Q HS Investigative
DMCIJ6Q PC 44388155
DMCIJ6Q MW 1360.6
DMCIJ6Q FM C67H97N11O17S
DMCIJ6Q IC InChI=1S/C67H97N11O17S/c1-6-38(4)56(76-66(94)57(54(42-24-15-9-16-25-42)43-26-17-10-18-27-43)77-59(87)44(29-30-51(80)81)70-62(90)47(34-52(82)83)69-39(5)79)65(93)73-46(33-41-22-13-8-14-23-41)61(89)74-49(36-96)67(95)78-31-19-28-50(78)64(92)72-45(32-40-20-11-7-12-21-40)60(88)71-48(35-53(84)85)63(91)75-55(37(2)3)58(68)86/h9-10,15-18,24-27,37-38,40-41,44-50,54-57,96H,6-8,11-14,19-23,28-36H2,1-5H3,(H2,68,86)(H,69,79)(H,70,90)(H,71,88)(H,72,92)(H,73,93)(H,74,89)(H,75,91)(H,76,94)(H,77,87)(H,80,81)(H,82,83)(H,84,85)/t38?,44-,45?,46-,47-,48-,49-,50+,55-,56-,57-/m0/s1
DMCIJ6Q CS CCC(C)[C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)NC(CC3CCCCC3)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](C(C4=CC=CC=C4)C5=CC=CC=C5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMCIJ6Q IK HHWSXWBIJCFKKB-VQTAYXAZSA-N
DMCIJ6Q IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(2R)-2-[[1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMCIJ6Q DE Discovery agent
DMA7ZSY ID DMA7ZSY
DMA7ZSY DN AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2
DMA7ZSY HS Investigative
DMA7ZSY PC 44388154
DMA7ZSY MW 1320.6
DMA7ZSY FM C64H93N11O17S
DMA7ZSY IC InChI=1S/C64H93N11O17S/c1-7-9-26-41(56(84)69-45(33-50(81)82)60(88)72-52(35(3)4)55(65)83)68-61(89)47-27-19-30-75(47)64(92)46(34-93)71-58(86)43(31-38-20-13-10-14-21-38)70-62(90)53(36(5)8-2)73-63(91)54(51(39-22-15-11-16-23-39)40-24-17-12-18-25-40)74-57(85)42(28-29-48(77)78)67-59(87)44(32-49(79)80)66-37(6)76/h11-12,15-18,22-25,35-36,38,41-47,51-54,93H,7-10,13-14,19-21,26-34H2,1-6H3,(H2,65,83)(H,66,76)(H,67,87)(H,68,89)(H,69,84)(H,70,90)(H,71,86)(H,72,88)(H,73,91)(H,74,85)(H,77,78)(H,79,80)(H,81,82)/t36?,41?,42-,43-,44-,45-,46-,47+,52-,53-,54-/m0/s1
DMA7ZSY CS CCCCC(C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](C(C)CC)NC(=O)[C@H](C(C3=CC=CC=C3)C4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMA7ZSY IK BZVYIEQNRWILPS-CPLDFCFASA-N
DMA7ZSY IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(2R)-2-[[1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMA7ZSY DE Discovery agent
DM6PZ45 ID DM6PZ45
DM6PZ45 DN AcAsp-Glu-Dif-Lys-Cha-Cys
DM6PZ45 HS Investigative
DM6PZ45 SN CHEMBL294440; AcAsp-Glu-Dif-Lys-Cha-Cys; AC1LAAJ1; BDBM50096413; AcAsp-Glu-Dif(3,3-diphenylalanine)-Lys-Cha-(beta-cyclohexylalanine)-Cys; Ac-L-Asp-L-Glu-3,3-Diphenyl-L-Ala-L-Lys-3-cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM6PZ45 DT Small molecular drug
DM6PZ45 PC 484572
DM6PZ45 MW 912.1
DM6PZ45 FM C44H61N7O12S
DM6PZ45 IC InChI=1S/C44H61N7O12S/c1-26(52)46-33(24-36(55)56)42(60)47-31(20-21-35(53)54)40(58)51-38(37(28-15-7-3-8-16-28)29-17-9-4-10-18-29)43(61)48-30(19-11-12-22-45)39(57)49-32(23-27-13-5-2-6-14-27)41(59)50-34(25-64)44(62)63/h3-4,7-10,15-18,27,30-34,37-38,64H,2,5-6,11-14,19-25,45H2,1H3,(H,46,52)(H,47,60)(H,48,61)(H,49,57)(H,50,59)(H,51,58)(H,53,54)(H,55,56)(H,62,63)/t30-,31-,32-,33-,34-,38-/m0/s1
DM6PZ45 CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DM6PZ45 IK MMHRSDHCRGNWNY-PHPRXEDMSA-N
DM6PZ45 IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM6PZ45 DE Discovery agent
DMKDZH4 ID DMKDZH4
DMKDZH4 DN AcAsp-Glu-Leu-Glu-Cha-Cys
DMKDZH4 HS Investigative
DMKDZH4 SN AcAsp-Glu-Leu-Glu-Cha-Cys; CHEMBL305570; AC1LAON7; Ac-Asp-Glu-Leu-Glu-Cha-Cys-OH; BDBM50096404; AcAsp-Glu-Leu-Glu-.beta.-Cyclohexylalanine-Cys; Ac-Asp-Glu-Leu-Glu-beta-Cyclohexylalanine-Cys-OH; Ac-L-Asp-Glu-L-Leu-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDZH4 DT Small molecular drug
DMKDZH4 PC 492309
DMKDZH4 MW 802.9
DMKDZH4 FM C34H54N6O14S
DMKDZH4 IC InChI=1S/C34H54N6O14S/c1-17(2)13-22(38-29(48)20(9-11-26(42)43)37-33(52)24(15-28(46)47)35-18(3)41)31(50)36-21(10-12-27(44)45)30(49)39-23(14-19-7-5-4-6-8-19)32(51)40-25(16-55)34(53)54/h17,19-25,55H,4-16H2,1-3H3,(H,35,41)(H,36,50)(H,37,52)(H,38,48)(H,39,49)(H,40,51)(H,42,43)(H,44,45)(H,46,47)(H,53,54)/t20-,21-,22-,23-,24-,25-/m0/s1
DMKDZH4 CS CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMKDZH4 IK SYHFABLPDKKGNQ-OOPVGHQCSA-N
DMKDZH4 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDZH4 DE Discovery agent
DMOMI91 ID DMOMI91
DMOMI91 DN AcAsp-Glu-Met-Glu-Cha-Cys
DMOMI91 HS Investigative
DMOMI91 SN CHEMBL64867; AcAsp-Glu-Met-Glu-Cha-Cys; AC1LAAJ4; BDBM50096409; AcAsp-Glu-Met-Glu-Nal(2-naphthylalanine)-Cys; Ac-L-Asp-L-Glu-L-Met-L-Glu-3-(2-Naphthyl)-L-Ala-L-Cys-OH; (R)-2-[(S)-2-((S)-2-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-carboxy-propanoylamino)-4-carboxy-butanoylamino]-4-methylsulfanyl-butanoylamino}-4-carboxy-butanoylamino)-3-naphthalen-2-yl-propanoylamino]-3-mercapto-propionic acid
DMOMI91 DT Small molecular drug
DMOMI91 PC 484573
DMOMI91 MW 864.9
DMOMI91 FM C37H48N6O14S2
DMOMI91 IC InChI=1S/C37H48N6O14S2/c1-19(44)38-27(17-31(49)50)36(55)40-23(9-11-29(45)46)32(51)41-25(13-14-59-2)34(53)39-24(10-12-30(47)48)33(52)42-26(35(54)43-28(18-58)37(56)57)16-20-7-8-21-5-3-4-6-22(21)15-20/h3-8,15,23-28,58H,9-14,16-18H2,1-2H3,(H,38,44)(H,39,53)(H,40,55)(H,41,51)(H,42,52)(H,43,54)(H,45,46)(H,47,48)(H,49,50)(H,56,57)/t23-,24-,25-,26-,27-,28-/m0/s1
DMOMI91 CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](CS)C(=O)O
DMOMI91 IK FCGQLGIFPLXKQV-QUQVWLGBSA-N
DMOMI91 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMOMI91 DE Discovery agent
DMIVFZE ID DMIVFZE
DMIVFZE DN AcAsp-Glu-Met-Glu-Glu-Cys
DMIVFZE HS Investigative
DMIVFZE SN CHEMBL62717; AcAsp-Glu-Met-Glu-Glu-Cys; AC1LA8TV; Ac-Asp-Glu-Met-Glu-Glu-Cys-OH; BDBM50084634; 4-(2-Acetylamino-3-carboxy-propionylamino)-4-(1-{3-carboxy-1-[3-carboxy-1-(1-carboxy-2-mercapto-ethylcarbamoyl)-propylcarbamoyl]-propylcarbamoyl}-3-methylsulfanyl-propylcarbamoyl)-butyric acid(NS4A-NS4B)
DMIVFZE DT Small molecular drug
DMIVFZE PC 483675
DMIVFZE MW 796.8
DMIVFZE FM C29H44N6O16S2
DMIVFZE IC InChI=1S/C29H44N6O16S2/c1-13(36)30-18(11-23(43)44)28(49)33-15(4-7-21(39)40)25(46)34-17(9-10-53-2)27(48)32-14(3-6-20(37)38)24(45)31-16(5-8-22(41)42)26(47)35-19(12-52)29(50)51/h14-19,52H,3-12H2,1-2H3,(H,30,36)(H,31,45)(H,32,48)(H,33,49)(H,34,46)(H,35,47)(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,50,51)/t14-,15-,16-,17-,18-,19-/m0/s1
DMIVFZE CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O
DMIVFZE IK VGFHUYLCQHZNFZ-DYKIIFRCSA-N
DMIVFZE IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-4-carboxy-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMIVFZE DE Discovery agent
DMBGHX7 ID DMBGHX7
DMBGHX7 DN AcAsp-Glu-Met-Glu-Nal-Cyse
DMBGHX7 HS Investigative
DMBGHX7 SN CHEMBL64618; Ac-Asp-Glu-Met-Glu-Cha-Cys-OH; AcAsp-Glu-Met-Glu-Nal-Cyse; AC1LAAIY; BDBM50096405; AcAsp-Glu-Met-GLu-Cha(beta-cyclohexylalanine)-Cys; Ac-Asp-Glu-Met-Glu-beta-Cyclohexylalanine-Cys-OH; Ac-L-Asp-L-Glu-L-Met-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-hydroxy-4-oxobutanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMBGHX7 DT Small molecular drug
DMBGHX7 PC 484571
DMBGHX7 MW 820.9
DMBGHX7 FM C33H52N6O14S2
DMBGHX7 IC InChI=1S/C33H52N6O14S2/c1-17(40)34-23(15-27(45)46)32(51)36-19(8-10-25(41)42)28(47)37-21(12-13-55-2)30(49)35-20(9-11-26(43)44)29(48)38-22(14-18-6-4-3-5-7-18)31(50)39-24(16-54)33(52)53/h18-24,54H,3-16H2,1-2H3,(H,34,40)(H,35,49)(H,36,51)(H,37,47)(H,38,48)(H,39,50)(H,41,42)(H,43,44)(H,45,46)(H,52,53)/t19-,20-,21-,22-,23-,24-/m0/s1
DMBGHX7 CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O
DMBGHX7 IK QFFHVIGQVJVQSD-BTNSXGMBSA-N
DMBGHX7 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMBGHX7 DE Discovery agent
DM4KQUS ID DM4KQUS
DM4KQUS DN Ac-Asp-Glu-Val-Asp-CHO
DM4KQUS HS Investigative
DM4KQUS SN ICE INHIBITOR; AC1L1HX4; SCHEMBL13194679; AL010; AKOS015916330; AN-30897; N-Acetyl-Asp-Glu-Val-Asp-al, > =95%, powder; I14-51535; 4-[(2-acetamido-4-hydroxy-4-oxobutanoyl)amino]-5-[[1-[(4-hydroxy-1,4-dioxobutan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid; 4-(3-carboxy-2-acetamidopropanamido)-4-({1-[(1-carboxy-3-oxopropan-2-yl)carbamoyl]-2-methylpropyl}carbamoyl)butanoic acid
DM4KQUS DT Small molecular drug
DM4KQUS PC 4330
DM4KQUS MW 502.5
DM4KQUS FM C20H30N4O11
DM4KQUS IC InChI=1S/C20H30N4O11/c1-9(2)17(20(35)22-11(8-25)6-15(29)30)24-18(33)12(4-5-14(27)28)23-19(34)13(7-16(31)32)21-10(3)26/h8-9,11-13,17H,4-7H2,1-3H3,(H,21,26)(H,22,35)(H,23,34)(H,24,33)(H,27,28)(H,29,30)(H,31,32)
DM4KQUS CS CC(C)C(C(=O)NC(CC(=O)O)C=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C
DM4KQUS IK UMBVAPCONCILTL-UHFFFAOYSA-N
DM4KQUS IU 4-[(2-acetamido-3-carboxypropanoyl)amino]-5-[[1-[(1-carboxy-3-oxopropan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM4KQUS DE Discovery agent
DM1KDJV ID DM1KDJV
DM1KDJV DN Ac-bhg-F-N-Y-Y-W
DM1KDJV HS Investigative
DM1KDJV SN CHEMBL385405; Ac-bhg-F-N-Y-Y-W
DM1KDJV PC 44371670
DM1KDJV MW 1083.2
DM1KDJV FM C61H62N8O11
DM1KDJV IC InChI=1S/C61H62N8O11/c1-35(70)64-55(54-45-16-7-5-13-39(45)23-24-40-14-6-8-17-46(40)54)60(78)68-50(29-36-11-3-2-4-12-36)57(75)67-51(33-53(62)73)59(77)66-48(30-37-19-25-42(71)26-20-37)56(74)65-49(31-38-21-27-43(72)28-22-38)58(76)69-52(61(79)80)32-41-34-63-47-18-10-9-15-44(41)47/h2-22,25-28,34,48-52,54-55,63,71-72H,23-24,29-33H2,1H3,(H2,62,73)(H,64,70)(H,65,74)(H,66,77)(H,67,75)(H,68,78)(H,69,76)(H,79,80)/t48-,49-,50-,51-,52-,55-/m0/s1
DM1KDJV CS CC(=O)N[C@@H](C1C2=CC=CC=C2CCC3=CC=CC=C13)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)O
DM1KDJV IK DTNUUCGDOGDUBL-NHTZSVLLSA-N
DM1KDJV IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-3-phenylpropanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DM1KDJV DE Discovery agent
DMSE29N ID DMSE29N
DMSE29N DN Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSE29N HS Investigative
DMSE29N SN CHEMBL380685; Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSE29N DT Small molecular drug
DMSE29N PC 44409592
DMSE29N MW 879.9
DMSE29N FM C41H50N7O11PS
DMSE29N IC InChI=1S/C41H50N7O11PS/c1-23(59-60(56,57)58)36(47-39(53)32(44-24(2)49)21-28-22-61-34-13-6-5-11-29(28)34)41(55)48-18-8-7-12-33(48)40(54)46-31(38(52)45-30(37(43)51)16-17-35(42)50)20-25-14-15-26-9-3-4-10-27(26)19-25/h3-6,9-11,13-15,19,22-23,30-33,36H,7-8,12,16-18,20-21H2,1-2H3,(H2,42,50)(H2,43,51)(H,44,49)(H,45,52)(H,46,54)(H,47,53)(H2,56,57,58)/t23-,30+,31+,32+,33-,36+/m1/s1
DMSE29N CS C[C@H]([C@@H](C(=O)N1CCCC[C@@H]1C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC4=CSC5=CC=CC=C54)NC(=O)C)OP(=O)(O)O
DMSE29N IK WPZGCIDLTHYADD-YIVWXNOFSA-N
DMSE29N IU [(2R,3S)-3-[[(2S)-2-acetamido-3-(1-benzothiophen-3-yl)propanoyl]amino]-4-[(2R)-2-[[(2S)-1-[[(2S)-1,5-diamino-1,5-dioxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutan-2-yl] dihydrogen phosphate
DMSE29N DE Discovery agent
DMH0SQC ID DMH0SQC
DMH0SQC DN Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr
DMH0SQC HS Investigative
DMH0SQC DE Discovery agent
DMG19LW ID DMG19LW
DMG19LW DN Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr
DMG19LW HS Investigative
DMG19LW DT Small molecular drug
DMG19LW PC 44412036
DMG19LW MW 952
DMG19LW FM C44H57N9O13S
DMG19LW IC InChI=1S/C44H57N9O13S/c1-4-25(2)38(51-42(59)37(24-67)46-26(3)54)43(60)49-35(22-28-10-16-31(17-11-28)53(65)66)40(57)47-33(7-5-6-20-45)39(56)48-34(21-27-8-14-30(15-9-27)52(63)64)41(58)50-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,55,67H,4-7,20-24,45H2,1-3H3,(H,46,54)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMG19LW CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMG19LW IK BQZNGWRLXCQNSI-LBNFHWTGSA-N
DMG19LW IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMG19LW DE Discovery agent
DMORPDV ID DMORPDV
DMORPDV DN Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2)
DMORPDV HS Investigative
DMORPDV DT Small molecular drug
DMORPDV PC 44412129
DMORPDV MW 952
DMORPDV FM C44H57N9O13S
DMORPDV IC InChI=1S/C44H57N9O13S/c1-4-25(2)38(51-42(59)37(24-67)46-26(3)54)43(60)49-35(21-27-8-14-30(15-9-27)52(63)64)40(57)47-33(7-5-6-20-45)39(56)48-34(22-29-12-18-32(55)19-13-29)41(58)50-36(44(61)62)23-28-10-16-31(17-11-28)53(65)66/h8-19,25,33-38,55,67H,4-7,20-24,45H2,1-3H3,(H,46,54)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMORPDV CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMORPDV IK YSCBRLXTMTYHMK-LBNFHWTGSA-N
DMORPDV IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-nitrophenyl)propanoic acid
DMORPDV DE Discovery agent
DMK7YIG ID DMK7YIG
DMK7YIG DN Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr
DMK7YIG HS Investigative
DMK7YIG DT Small molecular drug
DMK7YIG PC 44412137
DMK7YIG MW 923
DMK7YIG FM C44H58N8O12S
DMK7YIG IC InChI=1S/C44H58N8O12S/c1-4-25(2)38(51-42(59)37(24-65)46-26(3)53)43(60)49-35(21-27-8-14-30(15-9-27)52(63)64)40(57)47-33(7-5-6-20-45)39(56)48-34(22-28-10-16-31(54)17-11-28)41(58)50-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,54-55,65H,4-7,20-24,45H2,1-3H3,(H,46,53)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMK7YIG CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)[N+](=O)[O-])C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMK7YIG IK IFJPPNMSIWSRDX-LBNFHWTGSA-N
DMK7YIG IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMK7YIG DE Discovery agent
DMUWI2F ID DMUWI2F
DMUWI2F DN Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr
DMUWI2F HS Investigative
DMUWI2F DT Small molecular drug
DMUWI2F PC 44412001
DMUWI2F MW 912.5
DMUWI2F FM C44H58ClN7O10S
DMUWI2F IC InChI=1S/C44H58ClN7O10S/c1-4-25(2)38(52-42(59)37(24-63)47-26(3)53)43(60)50-35(22-28-10-16-31(54)17-11-28)40(57)48-33(7-5-6-20-46)39(56)49-34(21-27-8-14-30(45)15-9-27)41(58)51-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,54-55,63H,4-7,20-24,46H2,1-3H3,(H,47,53)(H,48,57)(H,49,56)(H,50,60)(H,51,58)(H,52,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMUWI2F CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)Cl)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMUWI2F IK MJPZCPCJFBXRAJ-LBNFHWTGSA-N
DMUWI2F IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMUWI2F DE Discovery agent
DMNW7GR ID DMNW7GR
DMNW7GR DN Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr
DMNW7GR HS Investigative
DMNW7GR DT Small molecular drug
DMNW7GR PC 44412118
DMNW7GR MW 903.1
DMNW7GR FM C45H58N8O10S
DMNW7GR IC InChI=1S/C45H58N8O10S/c1-4-26(2)39(53-43(60)38(25-64)48-27(3)54)44(61)51-36(22-29-12-16-32(55)17-13-29)41(58)49-34(7-5-6-20-46)40(57)50-35(21-28-8-10-31(24-47)11-9-28)42(59)52-37(45(62)63)23-30-14-18-33(56)19-15-30/h8-19,26,34-39,55-56,64H,4-7,20-23,25,46H2,1-3H3,(H,48,54)(H,49,58)(H,50,57)(H,51,61)(H,52,59)(H,53,60)(H,62,63)/t26?,34-,35-,36-,37-,38-,39-/m0/s1
DMNW7GR CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)C#N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMNW7GR IK HMZZZPUDXBITDY-QCGUVPLXSA-N
DMNW7GR IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-cyanophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMNW7GR DE Discovery agent
DMO4MYI ID DMO4MYI
DMO4MYI DN Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr
DMO4MYI HS Investigative
DMO4MYI PC 44412037
DMO4MYI MW 1003.9
DMO4MYI FM C44H58IN7O10S
DMO4MYI IC InChI=1S/C44H58IN7O10S/c1-4-25(2)38(52-42(59)37(24-63)47-26(3)53)43(60)50-35(22-28-10-16-31(54)17-11-28)40(57)48-33(7-5-6-20-46)39(56)49-34(21-27-8-14-30(45)15-9-27)41(58)51-36(44(61)62)23-29-12-18-32(55)19-13-29/h8-19,25,33-38,54-55,63H,4-7,20-24,46H2,1-3H3,(H,47,53)(H,48,57)(H,49,56)(H,50,60)(H,51,58)(H,52,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DMO4MYI CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)I)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMO4MYI IK SFPMFCZXYBGJAR-LBNFHWTGSA-N
DMO4MYI IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-iodophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DMO4MYI DE Discovery agent
DME4FZD ID DME4FZD
DME4FZD DN Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr
DME4FZD HS Investigative
DME4FZD DT Small molecular drug
DME4FZD PC 44412139
DME4FZD MW 919.1
DME4FZD FM C44H58N10O10S
DME4FZD IC InChI=1S/C44H58N10O10S/c1-4-25(2)38(52-42(61)37(24-65)47-26(3)55)43(62)50-35(22-28-10-16-31(56)17-11-28)40(59)48-33(7-5-6-20-45)39(58)49-34(21-27-8-14-30(15-9-27)53-54-46)41(60)51-36(44(63)64)23-29-12-18-32(57)19-13-29/h8-19,25,33-38,56-57,65H,4-7,20-24,45H2,1-3H3,(H,47,55)(H,48,59)(H,49,58)(H,50,62)(H,51,60)(H,52,61)(H,63,64)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DME4FZD CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)N=[N+]=[N-])C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DME4FZD IK YGJYKNHKRWZTIL-LBNFHWTGSA-N
DME4FZD IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-azidophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DME4FZD DE Discovery agent
DM856JM ID DM856JM
DM856JM DN Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2)
DM856JM HS Investigative
DM856JM DT Small molecular drug
DM856JM PC 44412138
DM856JM MW 952
DM856JM FM C44H57N9O13S
DM856JM IC InChI=1S/C44H57N9O13S/c1-4-25(2)38(51-42(59)37(24-67)46-26(3)54)43(60)49-35(22-29-12-18-32(55)19-13-29)40(57)47-33(7-5-6-20-45)39(56)48-34(21-27-8-14-30(15-9-27)52(63)64)41(58)50-36(44(61)62)23-28-10-16-31(17-11-28)53(65)66/h8-19,25,33-38,55,67H,4-7,20-24,45H2,1-3H3,(H,46,54)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DM856JM CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)N[C@@H](CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DM856JM IK YTKNXUJJRVGMTM-LBNFHWTGSA-N
DM856JM IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-3-(4-nitrophenyl)propanoic acid
DM856JM DE Discovery agent
DMU2PT1 ID DMU2PT1
DMU2PT1 DN Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe
DMU2PT1 HS Investigative
DMU2PT1 PC 44412130
DMU2PT1 MW 1070.2
DMU2PT1 FM C53H67N9O13S
DMU2PT1 IC InChI=1S/C53H67N9O13S/c1-4-31(2)46(61-51(70)45(30-76)55-32(3)63)52(71)59-43(28-36-17-23-39(65)24-18-36)48(67)56-40(12-8-9-25-54)47(66)57-41(26-34-13-19-37(20-14-34)62(74)75)49(68)58-42(27-35-15-21-38(64)22-16-35)50(69)60-44(53(72)73)29-33-10-6-5-7-11-33/h5-7,10-11,13-24,31,40-46,64-65,76H,4,8-9,12,25-30,54H2,1-3H3,(H,55,63)(H,56,67)(H,57,66)(H,58,68)(H,59,71)(H,60,69)(H,61,70)(H,72,73)/t31?,40-,41-,42-,43-,44-,45-,46-/m0/s1
DMU2PT1 CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)[N+](=O)[O-])C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DMU2PT1 IK NYGFMHJKDBNTFT-GLNKEJAVSA-N
DMU2PT1 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-nitrophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoic acid
DMU2PT1 DE Discovery agent
DM4MP69 ID DM4MP69
DM4MP69 DN Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2)
DM4MP69 HS Investigative
DM4MP69 DT Small molecular drug
DM4MP69 PC 44412128
DM4MP69 MW 923
DM4MP69 FM C44H58N8O12S
DM4MP69 IC InChI=1S/C44H58N8O12S/c1-4-25(2)38(51-42(59)37(24-65)46-26(3)53)43(60)49-35(22-29-12-18-32(55)19-13-29)40(57)47-33(7-5-6-20-45)39(56)48-34(21-28-10-16-31(54)17-11-28)41(58)50-36(44(61)62)23-27-8-14-30(15-9-27)52(63)64/h8-19,25,33-38,54-55,65H,4-7,20-24,45H2,1-3H3,(H,46,53)(H,47,57)(H,48,56)(H,49,60)(H,50,58)(H,51,59)(H,61,62)/t25?,33-,34-,35-,36-,37-,38-/m0/s1
DM4MP69 CS CCC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)O)NC(=O)[C@H](CS)NC(=O)C
DM4MP69 IK FNBOPWDKOOFHTM-LBNFHWTGSA-N
DM4MP69 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-sulfanylpropanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-nitrophenyl)propanoic acid
DM4MP69 DE Discovery agent
DMW02H7 ID DMW02H7
DMW02H7 DN Ac-DEVD-CHO
DMW02H7 HS Investigative
DMW02H7 SN 169332-60-9; Caspase-3 Inhibitor I; N-acetyl-asp-glu-val-asp-al; acetyl-aspartyl-glutamyl-valyl-aspartal; Ac-Asp-Glu-Val-Asp-Aldehyde; AC-ASP-GLU-VAL-ASP-H; CHEMBL417149; CHEBI:59385; 184179-08-6; (4S,7S,10S,13S)-7-(2-carboxyethyl)-4-(carboxymethyl)-13-formyl-10-isopropyl-2,5,8,11-tetraoxo-3,6,9,12-tetraazapentadecan-15-oic acid; acetyl-Asp-Glu-Val-Asp-aldehyde; acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp aldehyde; N-acetyl-Asp-Glu-Val-Asp-aldehyde
DMW02H7 DT Small molecular drug
DMW02H7 PC 644345
DMW02H7 MW 502.5
DMW02H7 FM C20H30N4O11
DMW02H7 IC InChI=1S/C20H30N4O11/c1-9(2)17(20(35)22-11(8-25)6-15(29)30)24-18(33)12(4-5-14(27)28)23-19(34)13(7-16(31)32)21-10(3)26/h8-9,11-13,17H,4-7H2,1-3H3,(H,21,26)(H,22,35)(H,23,34)(H,24,33)(H,27,28)(H,29,30)(H,31,32)/t11-,12-,13-,17-/m0/s1
DMW02H7 CS CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)C
DMW02H7 IK UMBVAPCONCILTL-MRHIQRDNSA-N
DMW02H7 IU (4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMW02H7 CB CHEBI:59385
DMW02H7 DE Discovery agent
DMKDEWH ID DMKDEWH
DMKDEWH DN AcDif-Glu-Cha-Cys
DMKDEWH HS Investigative
DMKDEWH SN CHEMBL62433; AcDif-Glu-Cha-Cys; AC1LAAI7; Ac-Dif-Glu-Cha-Cys-OH; BDBM50096401; Ac-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH; AcDif(3,3-diphenylalanine)-Glu-Cha(beta-cyclohexylalanine)-Cys; (4S)-4-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDEWH DT Small molecular drug
DMKDEWH PC 484562
DMKDEWH MW 668.8
DMKDEWH FM C34H44N4O8S
DMKDEWH IC InChI=1S/C34H44N4O8S/c1-21(39)35-30(29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)33(44)36-25(17-18-28(40)41)31(42)37-26(19-22-11-5-2-6-12-22)32(43)38-27(20-47)34(45)46/h3-4,7-10,13-16,22,25-27,29-30,47H,2,5-6,11-12,17-20H2,1H3,(H,35,39)(H,36,44)(H,37,42)(H,38,43)(H,40,41)(H,45,46)/t25-,26-,27-,30-/m0/s1
DMKDEWH CS CC(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DMKDEWH IK CJVPMARHOWZLLI-YRUYCOJQSA-N
DMKDEWH IU (4S)-4-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMKDEWH DE Discovery agent
DM1DWCP ID DM1DWCP
DM1DWCP DN AcDif-Ile-Cha-Cys
DM1DWCP HS Investigative
DM1DWCP SN CHEMBL293631; AcDif-Ile-Cha-Cys
DM1DWCP DT Small molecular drug
DM1DWCP PC 44305023
DM1DWCP MW 652.8
DM1DWCP FM C35H48N4O6S
DM1DWCP IC InChI=1S/C35H48N4O6S/c1-4-22(2)30(33(42)37-27(20-24-14-8-5-9-15-24)32(41)38-28(21-46)35(44)45)39-34(43)31(36-23(3)40)29(25-16-10-6-11-17-25)26-18-12-7-13-19-26/h6-7,10-13,16-19,22,24,27-31,46H,4-5,8-9,14-15,20-21H2,1-3H3,(H,36,40)(H,37,42)(H,38,41)(H,39,43)(H,44,45)/t22-,27+,28-,30-,31+/m1/s1
DM1DWCP CS CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](CS)C(=O)O)NC(=O)[C@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)C
DM1DWCP IK IIYOAVWUFJFCOP-SHQUAMPASA-N
DM1DWCP IU (2S)-2-[[(2S)-2-[[(2R,3R)-2-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-3-methylpentanoyl]amino]-3-cyclohexylpropanoyl]amino]-3-sulfanylpropanoic acid
DM1DWCP DE Discovery agent
DMPMH7Z ID DMPMH7Z
DMPMH7Z DN ACDPP
DMPMH7Z HS Investigative
DMPMH7Z SN 3-amino-6-chloro-5-(dimethylamino)-N-(pyridin-3-yl)pyrazine-2-carboxamide; GTPL3388; CHEMBL1616372; CHEBI:104024; ZINC7992851; BRD-K68633617-003-01-1
DMPMH7Z DT Small molecular drug
DMPMH7Z PC 16759169
DMPMH7Z MW 292.72
DMPMH7Z FM C12H13ClN6O
DMPMH7Z IC InChI=1S/C12H13ClN6O/c1-19(2)11-9(13)17-8(10(14)18-11)12(20)16-7-4-3-5-15-6-7/h3-6H,1-2H3,(H2,14,18)(H,16,20)
DMPMH7Z CS CN(C)C1=NC(=C(N=C1Cl)C(=O)NC2=CN=CC=C2)N
DMPMH7Z IK RNGRUHWJJPTYNR-UHFFFAOYSA-N
DMPMH7Z IU 3-amino-6-chloro-5-(dimethylamino)-N-pyridin-3-ylpyrazine-2-carboxamide
DMPMH7Z CB CHEBI:104024
DMPMH7Z DE Discovery agent
DMVDH4I ID DMVDH4I
DMVDH4I DN Ac-D-pro-L-Phe-D-trp-L-Phe-NH2
DMVDH4I HS Investigative
DMVDH4I SN CHEMBL450818; Ac-D-pro-L-Phe-D-trp-L-Phe-NH2
DMVDH4I DT Small molecular drug
DMVDH4I PC 44583427
DMVDH4I MW 636.7
DMVDH4I FM C36H40N6O5
DMVDH4I IC InChI=1S/C36H40N6O5/c1-23(43)42-18-10-17-32(42)36(47)41-30(20-25-13-6-3-7-14-25)34(45)40-31(21-26-22-38-28-16-9-8-15-27(26)28)35(46)39-29(33(37)44)19-24-11-4-2-5-12-24/h2-9,11-16,22,29-32,38H,10,17-21H2,1H3,(H2,37,44)(H,39,46)(H,40,45)(H,41,47)/t29-,30-,31+,32+/m0/s1
DMVDH4I CS CC(=O)N1CCC[C@@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N
DMVDH4I IK WEBVKDVBAOYUMD-GASGPIRDSA-N
DMVDH4I IU (2R)-1-acetyl-N-[(2S)-1-[[(2R)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMVDH4I DE Discovery agent
DM7XY41 ID DM7XY41
DM7XY41 DN Ac-dR[CEHdFRWC]-NH2
DM7XY41 HS Investigative
DM7XY41 SN CHEMBL267900; Ac-dR[CEHdFRWC]-NH2
DM7XY41 PC 44400402
DM7XY41 MW 1175.4
DM7XY41 FM C51H70N18O11S2
DM7XY41 IC InChI=1S/C51H70N18O11S2/c1-27(70)62-33(13-7-17-58-50(53)54)43(74)69-40-25-82-81-24-39(42(52)73)68-47(78)37(20-29-22-60-32-12-6-5-11-31(29)32)66-44(75)34(14-8-18-59-51(55)56)63-46(77)36(19-28-9-3-2-4-10-28)65-48(79)38(21-30-23-57-26-61-30)67-45(76)35(64-49(40)80)15-16-41(71)72/h2-6,9-12,22-23,26,33-40,60H,7-8,13-21,24-25H2,1H3,(H2,52,73)(H,57,61)(H,62,70)(H,63,77)(H,64,80)(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,74)(H,71,72)(H4,53,54,58)(H4,55,56,59)/t33-,34+,35-,36+,37-,38+,39-,40-/m0/s1
DM7XY41 CS CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCC(=O)O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DM7XY41 IK UNXFCHHFXJFRRB-ABRXVHCYSA-N
DM7XY41 IU 3-[(4R,7S,10R,13R,16R,19S,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DM7XY41 DE Discovery agent
DM9MDBO ID DM9MDBO
DM9MDBO DN AcDRGDS
DM9MDBO HS Investigative
DM9MDBO SN CHEMBL241297; AcDRGDS; Acetyl-Asp-Arg-Gly-Asp-Ser-OH
DM9MDBO DT Small molecular drug
DM9MDBO PC 10415998
DM9MDBO MW 590.5
DM9MDBO FM C21H34N8O12
DM9MDBO IC InChI=1S/C21H34N8O12/c1-9(31)26-11(5-15(33)34)18(38)28-10(3-2-4-24-21(22)23)17(37)25-7-14(32)27-12(6-16(35)36)19(39)29-13(8-30)20(40)41/h10-13,30H,2-8H2,1H3,(H,25,37)(H,26,31)(H,27,32)(H,28,38)(H,29,39)(H,33,34)(H,35,36)(H,40,41)(H4,22,23,24)/t10-,11-,12-,13-/m0/s1
DM9MDBO CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O
DM9MDBO IK SSQXWSYTLDJJAP-CYDGBPFRSA-N
DM9MDBO IU (3S)-3-acetamido-4-[[(2S)-1-[[2-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DM9MDBO DE Discovery agent
DMOJGF3 ID DMOJGF3
DMOJGF3 DN ACE-435
DMOJGF3 HS Investigative
DMOJGF3 SN RAP-435; TGF beta protein superfamily signaling inhibitor (cancer cachexia/metabolic disease/age-related muscle loss), Acceleron
DMOJGF3 CP Acceleron Pharma Inc
DMOJGF3 DE Cachexia
DMWX3HT ID DMWX3HT
DMWX3HT DN ACEA
DMWX3HT HS Investigative
DMWX3HT SN Arachidonyl-2-chloroethylamide; arachidonyl-2-chloroethylamide; Arachidonyl-2'-chloroethylamide; CHEMBL151167; (5Z,8Z,11Z,14Z)-N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide; C22H36ClNO; Arachidonoyl-2-chloroethylamide; AC1NSJTE; GTPL738; SCHEMBL1517676; MolPort-003-940-362; HMS3649N11; MFCD02683581; BN0049; BDBM50072769; ZINC13675373; 1595AH; AKOS024456526; Arachidonyl-2'-chloroethylamide hydrate; NCGC00162406-01; LS-63778; ACM273734079; SR-01000946682; L000112; SR-01000946682-1; N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide
DMWX3HT DT Small molecular drug
DMWX3HT PC 5311006
DMWX3HT MW 366
DMWX3HT FM C22H36ClNO
DMWX3HT IC InChI=1S/C22H36ClNO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)24-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,24,25)/b7-6-,10-9-,13-12-,16-15-
DMWX3HT CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCCl
DMWX3HT IK SCJNCDSAIRBRIA-DOFZRALJSA-N
DMWX3HT IU (5Z,8Z,11Z,14Z)-N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMWX3HT CA CAS 220556-69-4
DMWX3HT DE Discovery agent
DMVTSM8 ID DMVTSM8
DMVTSM8 DN Acefylline
DMVTSM8 HS Investigative
DMVTSM8 SN Carboxymethyltheophylline; Theophyllin-7-ylacetic acid; Theophylline-7-acetic acid; Theophyllineacetic acid; (1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid; 1,3-Dimethylxanthine-7-acetic acid; 2-(1,3-Dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)acetic acid; 652-37-9; 7-(Carboxymethyl)theophylline; 7-Theophyllineacetic acid; 7-Theophyllinessigsaeure; 7-Theophyllinylacetic acid; 7-Theophyllinylessigsaeure; Acefylline; Acephylline; BRN 0279221; EINECS 211-490-2; MFCD00022832; NSC 52996; UNII-M494UE2YEP
DMVTSM8 PC 69550
DMVTSM8 MW 238.2
DMVTSM8 FM C9H10N4O4
DMVTSM8 IC HCYFGRCYSCXKNQ-UHFFFAOYSA-N
DMVTSM8 CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O
DMVTSM8 IK 1S/C9H10N4O4/c1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15/h4H,3H2,1-2H3,(H,14,15)
DMVTSM8 IU 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid
DMVTSM8 CA CAS 652-37-9
DMVTSM8 CB CHEBI:94615
DMVTSM8 DE Discovery agent
DMU9O7K ID DMU9O7K
DMU9O7K DN Acenanthrene-9,10-dione
DMU9O7K HS Investigative
DMU9O7K SN 1,2-Aceanthrylenedione; Aceanthrenequinone; 6373-11-1; 1,2-Aceanthrenedione; aceanthrylene-1,2-dione; acenanthrene-9,10-dione; Aceanthrenchinon; NSC245130; AC1L7ULB; Aceanthrenequinone, 96%; ACMC-20ap73; SCHEMBL579274; CHEMBL235503; CTK2F3554; BDBM22859; DTXSID90311753; YAIBDWAANBTYIA-UHFFFAOYSA-N; MolPort-002-800-851; 1,2-Dione-Based Compound, 16; 1,2-dihydroaceanthrylene-1,2-dione; MFCD00035767; AKOS015902885; NSC-245130; MCULE-7113625880; VZ20381; CJ-29850; CC-02809; KB-64253; TC-172326; DB-054531; ST50825822; AE-641/00376058; 373A111
DMU9O7K DT Small molecular drug
DMU9O7K PC 316765
DMU9O7K MW 232.23
DMU9O7K FM C16H8O2
DMU9O7K IC InChI=1S/C16H8O2/c17-15-12-7-3-5-10-8-9-4-1-2-6-11(9)14(13(10)12)16(15)18/h1-8H
DMU9O7K CS C1=CC=C2C(=C1)C=C3C=CC=C4C3=C2C(=O)C4=O
DMU9O7K IK YAIBDWAANBTYIA-UHFFFAOYSA-N
DMU9O7K IU aceanthrylene-1,2-dione
DMU9O7K CA CAS 6373-11-1
DMU9O7K DE Discovery agent
DMT3QYZ ID DMT3QYZ
DMT3QYZ DN Acenaphthenol
DMT3QYZ HS Investigative
DMT3QYZ SN GEO-00001; MXUCIEHYJYRTLT-UHFFFAOYSA-; MXUCIEHYJYRTLT-UHFFFAOYSA-N; SCHEMBL345448; W-200056; 1,2-Dihydro-1-acenaphthylenol; 1,2-dihydroacenaphthylen-1-ol; 1-ACENAPHTHENOL; 1-Acenaphthalenol; 1-Acenaphthenol, 99%; 1-Acenaphthylenol, 1,2-dihydro-; 1-Acenaphthylenol,1,2-dihydro-; 1-Acenaphthylenol,2-dihydro-; 1-Hydroxyacenaphthene; 28807-94-5; 7-Acenaphthenol; AC1L2L0C; AC1Q7A0H; ACMC-1B4IN; Acenaphthen-1-ol; Acenaphthene-1-ol; 1-Acenaphthenol; Acenaphthenol-1; Acenaphthylenol, 1,2-dihydro-; DTXSID20951449; HMS1666F13
DMT3QYZ PC 22750
DMT3QYZ MW 170.21
DMT3QYZ FM C12H10O
DMT3QYZ IC MXUCIEHYJYRTLT-UHFFFAOYSA-N
DMT3QYZ CS C1C(C2=CC=CC3=C2C1=CC=C3)O
DMT3QYZ IK 1S/C12H10O/c13-11-7-9-5-1-3-8-4-2-6-10(11)12(8)9/h1-6,11,13H,7H2
DMT3QYZ IU 1,2-dihydroacenaphthylen-1-ol
DMT3QYZ CA CAS 6306-07-6
DMT3QYZ DE Discovery agent
DMU3DMH ID DMU3DMH
DMU3DMH DN ACENAPHTHOQUINONE
DMU3DMH HS Investigative
DMU3DMH SN Acenaphthenequinone; 82-86-0; Acenaphthoquinone; acenaphthylene-1,2-dione; 1,2-ACENAPHTHYLENEDIONE; Acenaphthenedione; 1,2-Acenaphthenequinone; 1,2-Acenaphthenedione; Acenaphthaquinone; Acenaphthylene-1,2-quinone; Acenaphthylenequinone; acenaphthodione; 1,2-Diketoacenaphthene; acenaphthene-1,2-dione; diketoacenaphthene; acenaphthylenedione; UNII-3950D6UEIQ; acenaphthene quinone; CCRIS 5318; CHEBI:15342; HSDB 2660; NSC 7656; EINECS 201-441-3; 1,2-dihydroacenaphthylene-1,2-dione; BRN 0879172; 3950D6UEIQ; AFPRJLBZLPBTPZ-UHFFFAOYSA-N
DMU3DMH DT Small molecular drug
DMU3DMH PC 6724
DMU3DMH MW 182.17
DMU3DMH FM C12H6O2
DMU3DMH IC InChI=1S/C12H6O2/c13-11-8-5-1-3-7-4-2-6-9(10(7)8)12(11)14/h1-6H
DMU3DMH CS C1=CC2=C3C(=C1)C(=O)C(=O)C3=CC=C2
DMU3DMH IK AFPRJLBZLPBTPZ-UHFFFAOYSA-N
DMU3DMH IU acenaphthylene-1,2-dione
DMU3DMH CA CAS 82-86-0
DMU3DMH CB CHEBI:15342
DMU3DMH DE Discovery agent
DM4BWMO ID DM4BWMO
DM4BWMO DN Acerogenin A
DM4BWMO HS Investigative
DM4BWMO SN acerogenin A; CHEMBL516665; SCHEMBL10048511
DM4BWMO DT Small molecular drug
DM4BWMO PC 12000158
DM4BWMO MW 298.4
DM4BWMO FM C19H22O3
DM4BWMO IC InChI=1S/C19H22O3/c20-16-4-2-1-3-15-8-12-18(21)19(13-15)22-17-10-6-14(5-9-16)7-11-17/h6-8,10-13,16,20-21H,1-5,9H2/t16-/m1/s1
DM4BWMO CS C1CCC2=CC(=C(C=C2)O)OC3=CC=C(CC[C@@H](C1)O)C=C3
DM4BWMO IK JHRMYLCWJWLUQL-MRXNPFEDSA-N
DM4BWMO IU (12R)-2-oxatricyclo[13.2.2.13,7]icosa-1(17),3,5,7(20),15,18-hexaene-4,12-diol
DM4BWMO CA CAS 60503-28-8
DM4BWMO DE Discovery agent
DMVQ30P ID DMVQ30P
DMVQ30P DN Acerogenin B
DMVQ30P HS Investigative
DMVQ30P SN acerogenin B
DMVQ30P DT Small molecular drug
DMVQ30P PC 10913542
DMVQ30P MW 298.4
DMVQ30P FM C19H22O3
DMVQ30P IC InChI=1S/C19H22O3/c20-16-4-2-1-3-14-6-10-17(11-7-14)22-19-13-15(5-9-16)8-12-18(19)21/h6-8,10-13,16,20-21H,1-5,9H2/t16-/m0/s1
DMVQ30P CS C1CCC2=CC=C(C=C2)OC3=C(C=CC(=C3)CC[C@H](C1)O)O
DMVQ30P IK BDTAPCJUUZRFKY-INIZCTEOSA-N
DMVQ30P IU (10S)-2-oxatricyclo[13.2.2.13,7]icosa-1(17),3,5,7(20),15,18-hexaene-4,10-diol
DMVQ30P DE Discovery agent
DMNETSX ID DMNETSX
DMNETSX DN Acerogenin C
DMNETSX HS Investigative
DMNETSX SN acerogenin C; SCHEMBL4112475
DMNETSX DT Small molecular drug
DMNETSX PC 10040223
DMNETSX MW 296.4
DMNETSX FM C19H20O3
DMNETSX IC InChI=1S/C19H20O3/c20-16-4-2-1-3-15-8-12-18(21)19(13-15)22-17-10-6-14(5-9-16)7-11-17/h6-8,10-13,21H,1-5,9H2
DMNETSX CS C1CCC2=CC(=C(C=C2)O)OC3=CC=C(CCC(=O)C1)C=C3
DMNETSX IK DMCJCKWHLCLVNV-UHFFFAOYSA-N
DMNETSX IU 4-hydroxy-2-oxatricyclo[13.2.2.13,7]icosa-1(17),3,5,7(20),15,18-hexaen-12-one
DMNETSX DE Discovery agent
DMB2463 ID DMB2463
DMB2463 DN ACET
DMB2463 HS Investigative
DMB2463 SN CHEMBL373429; 3-({3-[(2s)-2-Amino-2-Carboxyethyl]-5-Methyl-2,6-Dioxo-3,6-Dihydropyrimidin-1(2h)-Yl}methyl)-5-Phenylthiophene-2-Carboxylic Acid; (S)-1-(2-amino-2-carboxyethyl)-3-(2-carboxy-5-phenylthiophene-3-yl-methyl)-5-methylpyrimidine-2,4-dione; GTPL4123; MolPort-023-276-559; ZINC35324127; BDBM50207591; AKOS024457262; NCGC00378702-01; UBE; 3-({3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl}methyl)-5-phenylthiophene-2-carboxylic acid
DMB2463 DT Small molecular drug
DMB2463 PC 16125102
DMB2463 MW 429.4
DMB2463 FM C20H19N3O6S
DMB2463 IC InChI=1S/C20H19N3O6S/c1-11-8-22(10-14(21)18(25)26)20(29)23(17(11)24)9-13-7-15(30-16(13)19(27)28)12-5-3-2-4-6-12/h2-8,14H,9-10,21H2,1H3,(H,25,26)(H,27,28)/t14-/m0/s1
DMB2463 CS CC1=CN(C(=O)N(C1=O)CC2=C(SC(=C2)C3=CC=CC=C3)C(=O)O)C[C@@H](C(=O)O)N
DMB2463 IK LCZDCKMQSBGXAH-AWEZNQCLSA-N
DMB2463 IU 3-[[3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxopyrimidin-1-yl]methyl]-5-phenylthiophene-2-carboxylic acid
DMB2463 DE Discovery agent
DMJFKG4 ID DMJFKG4
DMJFKG4 DN Acetaldehyde
DMJFKG4 HS Investigative
DMJFKG4 SN acetic aldehyde; ethanal; ethyl aldehyde; NSC 7594
DMJFKG4 DT Small molecular drug
DMJFKG4 PC 177
DMJFKG4 MW 44.05
DMJFKG4 FM C2H4O
DMJFKG4 IC InChI=1S/C2H4O/c1-2-3/h2H,1H3
DMJFKG4 CS CC=O
DMJFKG4 IK IKHGUXGNUITLKF-UHFFFAOYSA-N
DMJFKG4 IU acetaldehyde
DMJFKG4 CA CAS 75-07-0
DMJFKG4 CB CHEBI:15343
DMJFKG4 DE Discovery agent
DMD08RH ID DMD08RH
DMD08RH DN Acetate Ion
DMD08RH HS Investigative
DMD08RH SN acetate; Acetate Ion; Acetic acid, ion(1-); Acetate ions; 71-50-1; monoacetate; MeCO2 anion; UNII-569DQM74SC; ethanoate; Acetat; 569DQM74SC; Shotgun; Ethanoat; CHEMBL1354; racemic acetate; Azetat; acetyl hydroxide; Acetic acid ion; Acetic cid glacial; TCLP extraction fluid 2; AC1Q1J9D; AC1Q1J2O; CH3-COO(-); AC1L18N9; DTXSID1037694; CTK5D4394; CHEBI:30089; MolPort-006-169-563; QTBSBXVTEAMEQO-UHFFFAOYSA-M; STL282721; CMC_13391; BDBM50159793; AKOS022101130; AN-25008; AN-23801; LS-189936; 1395-EP2380874A2; 1395-EP2380661A2; 1395-EP2316837A1
DMD08RH DT Small molecular drug
DMD08RH PC 175
DMD08RH MW 59.04
DMD08RH FM C2H3O2-
DMD08RH IC InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)/p-1
DMD08RH CS CC(=O)[O-]
DMD08RH IK QTBSBXVTEAMEQO-UHFFFAOYSA-M
DMD08RH IU acetate
DMD08RH CA CAS 71-50-1
DMD08RH CB CHEBI:30089
DMD08RH DE Discovery agent
DMBP5L4 ID DMBP5L4
DMBP5L4 DN Acetic acid 2,6-diisopropyl-phenyl ester
DMBP5L4 HS Investigative
DMBP5L4 SN 2,6-Diisopropylphenyl acetate; UVYYQAXNOURFPH-UHFFFAOYSA-N; [2,6-di(propan-2-yl)phenyl] acetate; Acetic acid 2,6-diisopropyl-phenyl ester; AC1LC89D; CHEMBL56587; SCHEMBL1927023; UVYYQAXNOURFPH-UHFFFAOYSA-; ZINC13779584; InChI=1/C14H20O2/c1-9(2)12-7-6-8-13(10(3)4)14(12)16-11(5)15/h6-10H,1-5H3
DMBP5L4 DT Small molecular drug
DMBP5L4 PC 596091
DMBP5L4 MW 220.31
DMBP5L4 FM C14H20O2
DMBP5L4 IC InChI=1S/C14H20O2/c1-9(2)12-7-6-8-13(10(3)4)14(12)16-11(5)15/h6-10H,1-5H3
DMBP5L4 CS CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C
DMBP5L4 IK UVYYQAXNOURFPH-UHFFFAOYSA-N
DMBP5L4 IU [2,6-di(propan-2-yl)phenyl] acetate
DMBP5L4 DE Discovery agent
DM97DJL ID DM97DJL
DM97DJL DN Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester
DM97DJL HS Investigative
DM97DJL SN aphs; 209125-28-0; 2-(2-Heptynylthio)phenol Acetate; (2-hept-2-ynylsulfanylphenyl) acetate; CHEMBL345018; o-(Acetophenyl)hept-2-ynyl sulphide; Phenol, 2-(2-heptynylthio)-, acetate; Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester; AC1L1D69; SCHEMBL3842943; DTXSID40175069; ZINC1903162; BDBM50068160; o-(Acetoxyphenyl)hept-2-ynyl sulphide; RT-011298; FT-0669138
DM97DJL DT Small molecular drug
DM97DJL PC 2211
DM97DJL MW 262.4
DM97DJL FM C15H18O2S
DM97DJL IC InChI=1S/C15H18O2S/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-5,12H2,1-2H3
DM97DJL CS CCCCC#CCSC1=CC=CC=C1OC(=O)C
DM97DJL IK GXMBHQRROXQUJS-UHFFFAOYSA-N
DM97DJL IU (2-hept-2-ynylsulfanylphenyl) acetate
DM97DJL CA CAS 209125-28-0
DM97DJL DE Discovery agent
DMD89A1 ID DMD89A1
DMD89A1 DN Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester
DMD89A1 HS Investigative
DMD89A1 SN CHEMBL145412; Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester; ZINC13782091; BDBM50068194; Acetic acid 2-(3-heptynylthio)phenyl ester
DMD89A1 DT Small molecular drug
DMD89A1 PC 9965111
DMD89A1 MW 262.4
DMD89A1 FM C15H18O2S
DMD89A1 IC InChI=1S/C15H18O2S/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-4,9,12H2,1-2H3
DMD89A1 CS CCCC#CCCSC1=CC=CC=C1OC(=O)C
DMD89A1 IK DWPABKWGLDPTEB-UHFFFAOYSA-N
DMD89A1 IU (2-hept-3-ynylsulfanylphenyl) acetate
DMD89A1 DE Discovery agent
DM50BTA ID DM50BTA
DM50BTA DN Acetic acid 2-heptylselanyl-phenyl ester
DM50BTA HS Investigative
DM50BTA SN Acetic acid 2-heptylselanyl-phenyl ester; CHEMBL342799; BDBM50068185; Acetic acid 2-(heptylseleno)phenyl ester
DM50BTA DT Small molecular drug
DM50BTA PC 9944615
DM50BTA MW 313.3
DM50BTA FM C15H22O2Se
DM50BTA IC InChI=1S/C15H22O2Se/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-6,9,12H2,1-2H3
DM50BTA CS CCCCCCC[Se]C1=CC=CC=C1OC(=O)C
DM50BTA IK FDXGTFIBPBOUCY-UHFFFAOYSA-N
DM50BTA IU (2-heptylselanylphenyl) acetate
DM50BTA DE Discovery agent
DMLPRIG ID DMLPRIG
DMLPRIG DN Acetic acid 2-heptylsulfanyl-phenyl ester
DMLPRIG HS Investigative
DMLPRIG SN Acetic acid 2-heptylsulfanyl-phenyl ester; CHEMBL143339; SCHEMBL6535129; BDBM50068166
DMLPRIG DT Small molecular drug
DMLPRIG PC 9965195
DMLPRIG MW 266.4
DMLPRIG FM C15H22O2S
DMLPRIG IC InChI=1S/C15H22O2S/c1-3-4-5-6-9-12-18-15-11-8-7-10-14(15)17-13(2)16/h7-8,10-11H,3-6,9,12H2,1-2H3
DMLPRIG CS CCCCCCCSC1=CC=CC=C1OC(=O)C
DMLPRIG IK FBOXARNCZRHBOP-UHFFFAOYSA-N
DMLPRIG IU (2-heptylsulfanylphenyl) acetate
DMLPRIG DE Discovery agent
DMFQE1C ID DMFQE1C
DMFQE1C DN Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester
DMFQE1C HS Investigative
DMFQE1C SN CHEMBL144920; Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester; ZINC13782090; BDBM50068198; Acetic acid 2-(2-hexynylthio)phenyl ester
DMFQE1C DT Small molecular drug
DMFQE1C PC 9813643
DMFQE1C MW 248.34
DMFQE1C FM C14H16O2S
DMFQE1C IC InChI=1S/C14H16O2S/c1-3-4-5-8-11-17-14-10-7-6-9-13(14)16-12(2)15/h6-7,9-10H,3-4,11H2,1-2H3
DMFQE1C CS CCCC#CCSC1=CC=CC=C1OC(=O)C
DMFQE1C IK MMWWBFVDWFUERO-UHFFFAOYSA-N
DMFQE1C IU (2-hex-2-ynylsulfanylphenyl) acetate
DMFQE1C DE Discovery agent
DMAKNUH ID DMAKNUH
DMAKNUH DN Acetic acid 2-hexylsulfanyl-phenyl ester
DMAKNUH HS Investigative
DMAKNUH SN Acetic acid 2-hexylsulfanyl-phenyl ester; CHEMBL144218; ZINC13782080
DMAKNUH DT Small molecular drug
DMAKNUH PC 10220627
DMAKNUH MW 252.37
DMAKNUH FM C14H20O2S
DMAKNUH IC InChI=1S/C14H20O2S/c1-3-4-5-8-11-17-14-10-7-6-9-13(14)16-12(2)15/h6-7,9-10H,3-5,8,11H2,1-2H3
DMAKNUH CS CCCCCCSC1=CC=CC=C1OC(=O)C
DMAKNUH IK IIONGZARVQOSAZ-UHFFFAOYSA-N
DMAKNUH IU (2-hexylsulfanylphenyl) acetate
DMAKNUH DE Discovery agent
DMFKRIH ID DMFKRIH
DMFKRIH DN Acetic acid 2-pentylsulfanyl-phenyl ester
DMFKRIH HS Investigative
DMFKRIH SN Acetic acid 2-pentylsulfanyl-phenyl ester; CHEMBL144806; SCHEMBL13659627; BDBM50068195
DMFKRIH DT Small molecular drug
DMFKRIH PC 9837624
DMFKRIH MW 238.35
DMFKRIH FM C13H18O2S
DMFKRIH IC InChI=1S/C13H18O2S/c1-3-4-7-10-16-13-9-6-5-8-12(13)15-11(2)14/h5-6,8-9H,3-4,7,10H2,1-2H3
DMFKRIH CS CCCCCSC1=CC=CC=C1OC(=O)C
DMFKRIH IK QCBPAZOETZPVCH-UHFFFAOYSA-N
DMFKRIH IU (2-pentylsulfanylphenyl) acetate
DMFKRIH DE Discovery agent
DMUYKIE ID DMUYKIE
DMUYKIE DN Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester
DMUYKIE HS Investigative
DMUYKIE SN CHEMBL413975; Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester; SCHEMBL9629413; BDBM50012407; Acetic acid 2-phenyl-5-propyl-4-thiazolyl ester
DMUYKIE DT Small molecular drug
DMUYKIE PC 15691791
DMUYKIE MW 261.339
DMUYKIE FM C14H15NO2S
DMUYKIE IC InChI=1S/C14H15NO2S/c1-3-7-12-13(17-10(2)16)15-14(18-12)11-8-5-4-6-9-11/h4-6,8-9H,3,7H2,1-2H3
DMUYKIE CS CCCC1=C(N=C(S1)C2=CC=CC=C2)OC(=O)C
DMUYKIE IK PNDOMGBHENBUGB-UHFFFAOYSA-N
DMUYKIE IU (2-phenyl-5-propyl-1,3-thiazol-4-yl) acetate
DMUYKIE DE Discovery agent
DM95QEA ID DM95QEA
DM95QEA DN Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester
DM95QEA HS Investigative
DM95QEA SN CHEMBL303221; Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester; SCHEMBL9630562; BDBM50012410; Acetic acid 5-butyl-2-phenyl-4-thiazolyl ester
DM95QEA DT Small molecular drug
DM95QEA PC 15691792
DM95QEA MW 275.4
DM95QEA FM C15H17NO2S
DM95QEA IC InChI=1S/C15H17NO2S/c1-3-4-10-13-14(18-11(2)17)16-15(19-13)12-8-6-5-7-9-12/h5-9H,3-4,10H2,1-2H3
DM95QEA CS CCCCC1=C(N=C(S1)C2=CC=CC=C2)OC(=O)C
DM95QEA IK NEOJOUJFNJKBMX-UHFFFAOYSA-N
DM95QEA IU (5-butyl-2-phenyl-1,3-thiazol-4-yl) acetate
DM95QEA DE Discovery agent
DMVEH40 ID DMVEH40
DMVEH40 DN Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DMVEH40 HS Investigative
DMVEH40 SN CHEMBL64000; Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester; BDBM50064609
DMVEH40 DT Small molecular drug
DMVEH40 PC 9815331
DMVEH40 MW 169.22
DMVEH40 FM C9H15NO2
DMVEH40 IC InChI=1S/C9H15NO2/c1-6(11)12-9-5-7-3-2-4-8(9)10-7/h7-10H,2-5H2,1H3
DMVEH40 CS CC(=O)OC1CC2CCCC1N2
DMVEH40 IK HHXDJDWQQPSWHW-UHFFFAOYSA-N
DMVEH40 IU 8-azabicyclo[3.2.1]octan-6-yl acetate
DMVEH40 DE Discovery agent
DMLTNHY ID DMLTNHY
DMLTNHY DN Acetic Acid Salicyloyl-Amino-Ester
DMLTNHY HS Investigative
DMLTNHY SN O-Acetylsalicylhydroxamic Acid; ACETIC ACID SALICYLOYL-AMINO-ESTER; 199854-00-7; C9H9NO4; O-Acetyl Salicylhydroxamic Acid; N-(Acetyloxy)-2-hydroxybenzamide; SCL; N-Acetoxysalicylamide; AC1L9HR3; SCHEMBL4318044; CTK0A0021; PCFWLDHLJWUGSU-UHFFFAOYSA-N; MolPort-003-844-411; [(2-hydroxybenzoyl)amino] acetate; ZINC2046853; FCH850362; 1962AH; Benzamide, N-(acetyloxy)-2-hydroxy-; AKOS006293238; DB03667; AB22745; ACM199854007; (2-HYDROXYPHENYL)FORMAMIDO ACETATE; RT-014810; FT-0661357; 1846-EP2298783A1
DMLTNHY DT Small molecular drug
DMLTNHY PC 445302
DMLTNHY MW 195.17
DMLTNHY FM C9H9NO4
DMLTNHY IC InChI=1S/C9H9NO4/c1-6(11)14-10-9(13)7-4-2-3-5-8(7)12/h2-5,12H,1H3,(H,10,13)
DMLTNHY CS CC(=O)ONC(=O)C1=CC=CC=C1O
DMLTNHY IK PCFWLDHLJWUGSU-UHFFFAOYSA-N
DMLTNHY IU [(2-hydroxybenzoyl)amino] acetate
DMLTNHY DE Discovery agent
DM3HYU8 ID DM3HYU8
DM3HYU8 DN Acetoacetyl-Coenzyme A
DM3HYU8 HS Investigative
DM3HYU8 SN acetoacetyl-CoA; Acetoacetyl coenzyme A; acetoacetyl-coenzyme a; 3-acetoacetyl-CoA; Acetoacetyl coa; S-Acetoacetyl-CoA; S-Acetoacetylcoenzyme A; 1420-36-6; S-Acetoacetyl-coenzym A; S-acetoacetyl-coenzyme A; OJFDKHTZOUZBOS-CITAKDKDSA-N; acetoacetyl-S-CoA; S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-oxobutanethioate; s-acetoacetyl coenzyme a; bofuranosyl]-; 1dub
DM3HYU8 DT Small molecular drug
DM3HYU8 PC 92153
DM3HYU8 MW 851.6
DM3HYU8 FM C25H40N7O18P3S
DM3HYU8 IC InChI=1S/C25H40N7O18P3S/c1-13(33)8-16(35)54-7-6-27-15(34)4-5-28-23(38)20(37)25(2,3)10-47-53(44,45)50-52(42,43)46-9-14-19(49-51(39,40)41)18(36)24(48-14)32-12-31-17-21(26)29-11-30-22(17)32/h11-12,14,18-20,24,36-37H,4-10H2,1-3H3,(H,27,34)(H,28,38)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t14-,18-,19-,20+,24-/m1/s1
DM3HYU8 CS CC(=O)CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DM3HYU8 IK OJFDKHTZOUZBOS-CITAKDKDSA-N
DM3HYU8 IU S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-oxobutanethioate
DM3HYU8 CA CAS 1420-36-6
DM3HYU8 CB CHEBI:15345
DM3HYU8 DE Discovery agent
DMH65Q8 ID DMH65Q8
DMH65Q8 DN Acetyl Coa
DMH65Q8 HS Investigative
DMH65Q8 SN acetyl coenzyme A; S-acetyl coenzyme A; acetylCoA; acetyl-CoA
DMH65Q8 DT Small molecular drug
DMH65Q8 PC 444493
DMH65Q8 MW 809.6
DMH65Q8 FM C23H38N7O17P3S
DMH65Q8 IC InChI=1S/C23H38N7O17P3S/c1-12(31)51-7-6-25-14(32)4-5-26-21(35)18(34)23(2,3)9-44-50(41,42)47-49(39,40)43-8-13-17(46-48(36,37)38)16(33)22(45-13)30-11-29-15-19(24)27-10-28-20(15)30/h10-11,13,16-18,22,33-34H,4-9H2,1-3H3,(H,25,32)(H,26,35)(H,39,40)(H,41,42)(H2,24,27,28)(H2,36,37,38)/t13-,16-,17-,18+,22-/m1/s1
DMH65Q8 CS CC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DMH65Q8 IK ZSLZBFCDCINBPY-ZSJPKINUSA-N
DMH65Q8 IU S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate
DMH65Q8 CA CAS 72-89-9
DMH65Q8 CB CHEBI:15351
DMH65Q8 DE Discovery agent
DMUH4N7 ID DMUH4N7
DMUH4N7 DN Acetyl ethylene
DMUH4N7 HS Investigative
DMUH4N7 SN Acetone, methylene-; 3-Buten-2-one; Butenone; Ketone, methyl vinyl; METHYL VINYL KETONE; Methyl ethenyl ketone; Methyl-vinyl-cetone; Methyl-vinyl-cetone [French]; Methylene acetone; Methylvinyl ketone; Methylvinylketon; Methylvinylketon [German]; Methylvinylketone; Vinyl methyl ketone; but-1-en-3-one; but-3-en-2-one; delta(sup 3)-2-Butenone; gamma-Oxo-alpha-butylene; methylvinylcetone; 1-Buten-3-one; 2-Butenone; 3-Butene-2-one; 3-Butenone-2; 3-oxo-1-butene; 78-94-4; CCRIS 3423; HSDB 716; NSC 4853; UNII-AR7642I1MP
DMUH4N7 PC 6570
DMUH4N7 MW 70.09
DMUH4N7 FM C4H6O
DMUH4N7 IC FUSUHKVFWTUUBE-UHFFFAOYSA-N
DMUH4N7 CS CC(=O)C=C
DMUH4N7 IK 1S/C4H6O/c1-3-4(2)5/h3H,1H2,2H3
DMUH4N7 IU but-3-en-2-one
DMUH4N7 CA CAS 78-94-4
DMUH4N7 CB CHEBI:48058
DMUH4N7 DE Discovery agent
DMFZJRN ID DMFZJRN
DMFZJRN DN Acetyl-Ala-Ala-Pro-Ala-trifluromethane
DMFZJRN HS Investigative
DMFZJRN SN CHEMBL130128; Acetyl-Ala-Ala-Pro-Ala-trifluromethane; BDBM50014742
DMFZJRN DT Small molecular drug
DMFZJRN PC 44353386
DMFZJRN MW 422.4
DMFZJRN FM C17H25F3N4O5
DMFZJRN IC InChI=1S/C17H25F3N4O5/c1-8(13(26)17(18,19)20)22-15(28)12-6-5-7-24(12)16(29)10(3)23-14(27)9(2)21-11(4)25/h8-10,12H,5-7H2,1-4H3,(H,21,25)(H,22,28)(H,23,27)/t8-,9-,10-,12-/m0/s1
DMFZJRN CS C[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C
DMFZJRN IK WGJCUKQNQHAXLF-GMOBBJLQSA-N
DMFZJRN IU (2S)-1-[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]propanoyl]-N-[(2S)-4,4,4-trifluoro-3-oxobutan-2-yl]pyrrolidine-2-carboxamide
DMFZJRN DE Discovery agent
DM1VE6S ID DM1VE6S
DM1VE6S DN Acetyl-Ile-Glu-Thr-Asp-aldehyde
DM1VE6S HS Investigative
DM1VE6S SN Ac-IETD-CHO; 191338-86-0; CHEMBL478695; Ac-Ile-Glu-Thr-Asp-CHO; SCHEMBL20257131; N-acetyl-Ile-Glu-Thr-Asp-aldehyde; ZINC14947181; BDBM50340547; Acetyl-isoleucyl-glutamyl-threonyl-aspartal; 338A860; N-Acetyl-Ile-Glu-Thr-Asp-al, ~99% (TLC), powder; (4S)-4-{[(1S,2R)-1-{[(2S)-1-carboxy-3-oxopropan-2-yl]carbamoyl}-2-hydroxypropyl]carbamoyl}-4-[(2S,3S)-2-acetamido-3-methylpentanamido]butanoic acid
DM1VE6S DT Small molecular drug
DM1VE6S PC 11466200
DM1VE6S MW 502.5
DM1VE6S FM C21H34N4O10
DM1VE6S IC InChI=1S/C21H34N4O10/c1-5-10(2)17(22-12(4)28)20(34)24-14(6-7-15(29)30)19(33)25-18(11(3)27)21(35)23-13(9-26)8-16(31)32/h9-11,13-14,17-18,27H,5-8H2,1-4H3,(H,22,28)(H,23,35)(H,24,34)(H,25,33)(H,29,30)(H,31,32)/t10-,11+,13-,14-,17-,18-/m0/s1
DM1VE6S CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)C
DM1VE6S IK AXTKTZHLZLOIIO-PBEPODTISA-N
DM1VE6S IU (4S)-4-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-5-[[(2S,3R)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM1VE6S DE Discovery agent
DM74HGJ ID DM74HGJ
DM74HGJ DN Acetyl-L-carnitine
DM74HGJ HS Investigative
DM74HGJ SN UNII-521T0J13MA; acetyl-d-carnitine; 521T0J13MA; (3S)-3-acetoxy-4-(trimethylammonio)butyrate; 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, inner salt, (2S)-; 4398-79-2; O-acetylcarnitine; CAR(2:0); Acylcarnitine C2:0; O-acetyl-D-carnitine; AC1L2BM0; Acetylcarnitine, (R)-Isomer; SCHEMBL677128; C9H18NO4; GTPL4520; CHEBI:86045; DTXSID90196007; 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, acetate, L-
DM74HGJ DT Small molecular drug
DM74HGJ PC 7045767
DM74HGJ MW 203.24
DM74HGJ FM C9H17NO4
DM74HGJ IC InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1
DM74HGJ CS CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C
DM74HGJ IK RDHQFKQIGNGIED-MRVPVSSYSA-N
DM74HGJ IU (3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate
DM74HGJ CA CAS 3040-38-8
DM74HGJ CB CHEBI:57589
DM74HGJ DE Discovery agent
DMGTPFY ID DMGTPFY
DMGTPFY DN acetyl-podocarpic dimer
DMGTPFY HS Investigative
DMGTPFY SN acetyl podocarpic acid anhydride
DMGTPFY DT Small molecular drug
DMGTPFY PC 9830426
DMGTPFY MW 614.8
DMGTPFY FM C38H46O7
DMGTPFY IC InChI=1S/C38H46O7/c1-23(39)43-27-13-9-25-11-15-31-35(3,29(25)21-27)17-7-19-37(31,5)33(41)45-34(42)38(6)20-8-18-36(4)30-22-28(44-24(2)40)14-10-26(30)12-16-32(36)38/h9-10,13-14,21-22,31-32H,7-8,11-12,15-20H2,1-6H3/t31-,32-,35-,36-,37+,38+/m1/s1
DMGTPFY CS CC(=O)OC1=CC2=C(CC[C@@H]3[C@@]2(CCC[C@]3(C)C(=O)OC(=O)[C@]4(CCC[C@]5([C@H]4CCC6=C5C=C(C=C6)OC(=O)C)C)C)C)C=C1
DMGTPFY IK OUJQRQRBNRGQTC-SPGSYPTKSA-N
DMGTPFY IU [(1S,4aS,10aR)-6-acetyloxy-1,4a-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carbonyl] (1S,4aS,10aR)-6-acetyloxy-1,4a-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
DMGTPFY DE Discovery agent
DMN5Z0F ID DMN5Z0F
DMN5Z0F DN Acetyl-Pro-Ala-Pro-Ala-trifluoro methane
DMN5Z0F HS Investigative
DMN5Z0F SN CHEMBL130718; Acetyl-Pro-Ala-Pro-Ala-trifluoro methane; BDBM50014740
DMN5Z0F DT Small molecular drug
DMN5Z0F PC 44353385
DMN5Z0F MW 448.4
DMN5Z0F FM C19H27F3N4O5
DMN5Z0F IC InChI=1S/C19H27F3N4O5/c1-10(15(28)19(20,21)22)23-17(30)14-7-5-9-26(14)18(31)11(2)24-16(29)13-6-4-8-25(13)12(3)27/h10-11,13-14H,4-9H2,1-3H3,(H,23,30)(H,24,29)/t10-,11-,13-,14-/m0/s1
DMN5Z0F CS C[C@@H](C(=O)C(F)(F)F)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)C
DMN5Z0F IK DLOFUPNOARUTLN-IMIFBBOLSA-N
DMN5Z0F IU (2S)-1-acetyl-N-[(2S)-1-oxo-1-[(2S)-2-[[(2S)-4,4,4-trifluoro-3-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]propan-2-yl]pyrrolidine-2-carboxamide
DMN5Z0F DE Discovery agent
DMG8P24 ID DMG8P24
DMG8P24 DN ACETYLSULFANILAMIDE
DMG8P24 HS Investigative
DMG8P24 SN 4-Acetamidobenzenesulfonamide; 121-61-9; N-(4-Sulfamoylphenyl)acetamide; Acetylsulfanilamide; Neotherapol; p-Sulfamylacetanilide; N4-ACETYLSULFANILAMIDE; Erytrin; N4-Acetsulfanilamide; 4-Acetylaminobenzenesulfonamide; 4'-Sulfamylacetanilide; 4'-Sulfamoylacetanilide; Sulfanilamide-N4-acetate; p-Sulfamoylacetanilide; p-Acetamidobenzenesulfonamide; N'-Acetylsulphanilamide; 4'-Sulphamoylacetanilide; N-(4-Sulphamoylphenyl)acetamide; Benzenesulfonamide, p-acetamido-; p-(Acetylamino)benzenesulfonamide; Acetanilide, 4'-sulfamoyl-
DMG8P24 DT Small molecular drug
DMG8P24 PC 8482
DMG8P24 MW 214.24
DMG8P24 FM C8H10N2O3S
DMG8P24 IC InChI=1S/C8H10N2O3S/c1-6(11)10-7-2-4-8(5-3-7)14(9,12)13/h2-5H,1H3,(H,10,11)(H2,9,12,13)
DMG8P24 CS CC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMG8P24 IK PKOFBDHYTMYVGJ-UHFFFAOYSA-N
DMG8P24 IU N-(4-sulfamoylphenyl)acetamide
DMG8P24 CA CAS 121-61-9
DMG8P24 DE Discovery agent
DM3XHIY ID DM3XHIY
DM3XHIY DN Ac-FWKY-NH2
DM3XHIY HS Investigative
DM3XHIY SN CHEMBL1165795
DM3XHIY DT Small molecular drug
DM3XHIY PC 10985299
DM3XHIY MW 683.8
DM3XHIY FM C37H45N7O6
DM3XHIY IC InChI=1S/C37H45N7O6/c1-23(45)41-32(20-24-9-3-2-4-10-24)36(49)44-33(21-26-22-40-29-12-6-5-11-28(26)29)37(50)42-30(13-7-8-18-38)35(48)43-31(34(39)47)19-25-14-16-27(46)17-15-25/h2-6,9-12,14-17,22,30-33,40,46H,7-8,13,18-21,38H2,1H3,(H2,39,47)(H,41,45)(H,42,50)(H,43,48)(H,44,49)/t30-,31-,32-,33-/m0/s1
DM3XHIY CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N
DM3XHIY IK YBFQDCKGFBIRPS-YRCZKMHPSA-N
DM3XHIY IU (2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide
DM3XHIY DE Discovery agent
DMAI43O ID DMAI43O
DMAI43O DN AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2
DMAI43O HS Investigative
DMAI43O SN CHEMBL386885; AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2
DMAI43O PC 44388164
DMAI43O MW 1254.5
DMAI43O FM C59H87N11O17S
DMAI43O IC InChI=1S/C59H87N11O17S/c1-9-10-15-38(51(79)66-43(28-71)55(83)64-41(50(60)78)25-34-16-18-37(73)19-17-34)63-56(84)45-26-35-13-11-12-14-36(35)27-70(45)59(87)44(29-88)67-54(82)42(24-30(2)3)65-57(85)48(31(4)5)69-58(86)49(32(6)7)68-53(81)40(21-23-47(76)77)62-52(80)39(61-33(8)72)20-22-46(74)75/h11-14,16-19,30-32,38-45,48-49,71,73,88H,9-10,15,20-29H2,1-8H3,(H2,60,78)(H,61,72)(H,62,80)(H,63,84)(H,64,83)(H,65,85)(H,66,79)(H,67,82)(H,68,81)(H,69,86)(H,74,75)(H,76,77)/t38-,39-,40-,41-,42-,43-,44-,45+,48-,49-/m0/s1
DMAI43O CS CCCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H]2CC3=CC=CC=C3CN2C(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)C
DMAI43O IK HGLKSJLIZCXTFK-SEAKOTFTSA-N
DMAI43O IU (4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[(3R)-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-3,4-dihydro-1H-isoquinolin-2-yl]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMAI43O DE Discovery agent
DM6T09B ID DM6T09B
DM6T09B DN Ac-Glu-Cha-Cys
DM6T09B HS Investigative
DM6T09B SN CHEMBL303340; Ac-Glu-Cha-Cys; AcGlu-Cha-Cys; AC1NRQFL; AcGlu-.beta.-Cyclohexylalanine-Cys; BDBM50096406; Ac-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (4S)-4-acetamido-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid; (4S)-4-acetamido-5-[[(1S)-1-(cyclohexylmethyl)-2-[[(1R)-2-hydroxy-2-oxo-1-(sulfanylmethyl)ethyl]amino]-2-oxo-ethyl]amino]-5-oxo-pentanoic acid
DM6T09B DT Small molecular drug
DM6T09B PC 5271014
DM6T09B MW 445.5
DM6T09B FM C19H31N3O7S
DM6T09B IC InChI=1S/C19H31N3O7S/c1-11(23)20-13(7-8-16(24)25)17(26)21-14(9-12-5-3-2-4-6-12)18(27)22-15(10-30)19(28)29/h12-15,30H,2-10H2,1H3,(H,20,23)(H,21,26)(H,22,27)(H,24,25)(H,28,29)/t13-,14-,15-/m0/s1
DM6T09B CS CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O
DM6T09B IK JOZDKRPORTUAIW-KKUMJFAQSA-N
DM6T09B IU (4S)-4-acetamido-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DM6T09B DE Discovery agent
DM0BV9I ID DM0BV9I
DM0BV9I DN AcGlu-Dif-Glu-Cha-Cys
DM0BV9I HS Investigative
DM0BV9I SN CHEMBL431559; AcGlu-Dif-Glu-Cha-Cys; AC1LAAI4; Ac-Glu-Dif-Glu-Cha-Cys-OH; BDBM50096407; Ac-L-Glu-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH; AcGlu-Dif(3,3-diphenylalanine)-Glu-Cha(beta-cychohexylalanine)-Cys; (4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-hydroxy-1,5-dioxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM0BV9I DT Small molecular drug
DM0BV9I PC 484561
DM0BV9I MW 797.9
DM0BV9I FM C39H51N5O11S
DM0BV9I IC InChI=1S/C39H51N5O11S/c1-23(45)40-27(17-19-31(46)47)36(51)44-34(33(25-13-7-3-8-14-25)26-15-9-4-10-16-26)38(53)41-28(18-20-32(48)49)35(50)42-29(21-24-11-5-2-6-12-24)37(52)43-30(22-56)39(54)55/h3-4,7-10,13-16,24,27-30,33-34,56H,2,5-6,11-12,17-22H2,1H3,(H,40,45)(H,41,53)(H,42,50)(H,43,52)(H,44,51)(H,46,47)(H,48,49)(H,54,55)/t27-,28-,29-,30-,34-/m0/s1
DM0BV9I CS CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C1=CC=CC=C1)C2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3CCCCC3)C(=O)N[C@@H](CS)C(=O)O
DM0BV9I IK JVFCWJBRHCCRTF-ULYIESCMSA-N
DM0BV9I IU (4S)-4-acetamido-5-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DM0BV9I DE Discovery agent
DMK6HGI ID DMK6HGI
DMK6HGI DN AcGlu-Dif-Ile-Cha-Cys
DMK6HGI HS Investigative
DMK6HGI SN CHEMBL304005; AcGlu-Dif-Ile-Cha-Cys
DMK6HGI DT Small molecular drug
DMK6HGI PC 44304858
DMK6HGI MW 782
DMK6HGI FM C40H55N5O9S
DMK6HGI IC InChI=1S/C40H55N5O9S/c1-4-24(2)34(38(51)42-30(22-26-14-8-5-9-15-26)37(50)43-31(23-55)40(53)54)44-39(52)35(45-36(49)29(41-25(3)46)20-21-32(47)48)33(27-16-10-6-11-17-27)28-18-12-7-13-19-28/h6-7,10-13,16-19,24,26,29-31,33-35,55H,4-5,8-9,14-15,20-23H2,1-3H3,(H,41,46)(H,42,51)(H,43,50)(H,44,52)(H,45,49)(H,47,48)(H,53,54)/t24-,29+,30+,31-,34-,35+/m1/s1
DMK6HGI CS CC[C@@H](C)[C@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](CS)C(=O)O)NC(=O)[C@H](C(C2=CC=CC=C2)C3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)C
DMK6HGI IK WLXMMKXNDCWWHB-KGIQSIOISA-N
DMK6HGI IU (4S)-4-acetamido-5-[[(2S)-1-[[(2R,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-5-oxopentanoic acid
DMK6HGI DE Discovery agent
DMMNQE3 ID DMMNQE3
DMMNQE3 DN ACH-702
DMMNQE3 HS Investigative
DMMNQE3 SN ACH-702; UNII-35QF8GE1L1; 35QF8GE1L1; CHEMBL1256993; ACH702; ACH 702; SCHEMBL728226; BDBM50330327; Isothiazolo(5,4-b)quinoline-3,4(2H,9H)-dione, 7-((3R)-3-(1-amino-1-methylethyl)-1-pyrrolidinyl)-9-cyclopropyl-6-fluoro-8-methoxy-; 922491-46-1; (R)-7-[3-(1-amino-1-methyl-ethyl)-pyrrolidin-1-yl]-9-cyclopropyl-6-fluoro-8-methoxy-9H isothiazolo[5,4-b]quinoline-3,4-dione; (r)-7-(3-(2-aminopropan-2-yl)pyrrolidin-1-yl)-9-cyclopropyl-6-fluoro-8-methoxyisothiazolo[5,4-b]quinoline-3,4(2h,9h)-dione
DMMNQE3 DT Small molecular drug
DMMNQE3 PC 16048804
DMMNQE3 MW 432.5
DMMNQE3 FM C21H25FN4O3S
DMMNQE3 IC InChI=1S/C21H25FN4O3S/c1-21(2,23)10-6-7-25(9-10)16-13(22)8-12-15(18(16)29-3)26(11-4-5-11)20-14(17(12)27)19(28)24-30-20/h8,10-11H,4-7,9,23H2,1-3H3,(H,24,28)/t10-/m1/s1
DMMNQE3 CS CC(C)([C@@H]1CCN(C1)C2=C(C=C3C(=C2OC)N(C4=C(C3=O)C(=O)NS4)C5CC5)F)N
DMMNQE3 IK CECJUHKZSOSOJJ-SNVBAGLBSA-N
DMMNQE3 IU 7-[(3R)-3-(2-aminopropan-2-yl)pyrrolidin-1-yl]-9-cyclopropyl-6-fluoro-8-methoxy-[1,2]thiazolo[5,4-b]quinoline-3,4-dione
DMMNQE3 CA CAS 922491-46-1
DMMNQE3 DE Bacterial infection
DMUEBRN ID DMUEBRN
DMUEBRN DN Ac-His-DNal(2)-Arg-Trp-NH2
DMUEBRN HS Investigative
DMUEBRN SN CHEMBL454736; Ac-His-DNal(2)-Arg-Trp-NH2
DMUEBRN DT Small molecular drug
DMUEBRN PC 44568851
DMUEBRN MW 735.8
DMUEBRN FM C38H45N11O5
DMUEBRN IC InChI=1S/C38H45N11O5/c1-22(50)46-33(18-27-20-42-21-45-27)37(54)49-32(16-23-12-13-24-7-2-3-8-25(24)15-23)36(53)47-30(11-6-14-43-38(40)41)35(52)48-31(34(39)51)17-26-19-44-29-10-5-4-9-28(26)29/h2-5,7-10,12-13,15,19-21,30-33,44H,6,11,14,16-18H2,1H3,(H2,39,51)(H,42,45)(H,46,50)(H,47,53)(H,48,52)(H,49,54)(H4,40,41,43)/t30-,31-,32-,33+/m0/s1
DMUEBRN CS CC(=O)N[C@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N
DMUEBRN IK OHBCPCNJWIQQPW-ZWDYZTTJSA-N
DMUEBRN IU (2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMUEBRN DE Discovery agent
DMR31Z9 ID DMR31Z9
DMR31Z9 DN Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2
DMR31Z9 HS Investigative
DMR31Z9 SN CHEMBL501394; Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2
DMR31Z9 DT Small molecular drug
DMR31Z9 PC 25108218
DMR31Z9 MW 754.7
DMR31Z9 FM C34H41Cl2N11O5
DMR31Z9 IC InChI=1S/C34H41Cl2N11O5/c1-18(48)44-29(14-21-16-40-17-43-21)33(52)47-28(12-19-8-9-23(35)24(36)11-19)32(51)45-26(7-4-10-41-34(38)39)31(50)46-27(30(37)49)13-20-15-42-25-6-3-2-5-22(20)25/h2-3,5-6,8-9,11,15-17,26-29,42H,4,7,10,12-14H2,1H3,(H2,37,49)(H,40,43)(H,44,48)(H,45,51)(H,46,50)(H,47,52)(H4,38,39,41)/t26-,27-,28+,29-/m0/s1
DMR31Z9 CS CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC(=C(C=C2)Cl)Cl)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMR31Z9 IK ULVZZVUTBBXNBL-FKWFRFQNSA-N
DMR31Z9 IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(3,4-dichlorophenyl)propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMR31Z9 DE Discovery agent
DMXU5ZP ID DMXU5ZP
DMXU5ZP DN Ac-His-DPhe(pBr)-Arg-Trp-NH2
DMXU5ZP HS Investigative
DMXU5ZP SN CHEMBL502093; Ac-His-DPhe(pBr)-Arg-Trp-NH2
DMXU5ZP DT Small molecular drug
DMXU5ZP PC 25108216
DMXU5ZP MW 764.7
DMXU5ZP FM C34H42BrN11O5
DMXU5ZP IC InChI=1S/C34H42BrN11O5/c1-19(47)43-29(15-23-17-39-18-42-23)33(51)46-28(13-20-8-10-22(35)11-9-20)32(50)44-26(7-4-12-40-34(37)38)31(49)45-27(30(36)48)14-21-16-41-25-6-3-2-5-24(21)25/h2-3,5-6,8-11,16-18,26-29,41H,4,7,12-15H2,1H3,(H2,36,48)(H,39,42)(H,43,47)(H,44,50)(H,45,49)(H,46,51)(H4,37,38,40)/t26-,27-,28+,29-/m0/s1
DMXU5ZP CS CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=C(C=C2)Br)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMXU5ZP IK UDLFTFKLQRVSSE-FKWFRFQNSA-N
DMXU5ZP IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-bromophenyl)propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMXU5ZP DE Discovery agent
DMTA6I5 ID DMTA6I5
DMTA6I5 DN Ac-His-DPhe(pCF3)-Arg-Trp-NH2
DMTA6I5 HS Investigative
DMTA6I5 SN CHEMBL501679; Ac-His-DPhe(pCF3)-Arg-Trp-NH2
DMTA6I5 DT Small molecular drug
DMTA6I5 PC 25108217
DMTA6I5 MW 753.8
DMTA6I5 FM C35H42F3N11O5
DMTA6I5 IC InChI=1S/C35H42F3N11O5/c1-19(50)46-29(15-23-17-42-18-45-23)33(54)49-28(13-20-8-10-22(11-9-20)35(36,37)38)32(53)47-26(7-4-12-43-34(40)41)31(52)48-27(30(39)51)14-21-16-44-25-6-3-2-5-24(21)25/h2-3,5-6,8-11,16-18,26-29,44H,4,7,12-15H2,1H3,(H2,39,51)(H,42,45)(H,46,50)(H,47,53)(H,48,52)(H,49,54)(H4,40,41,43)/t26-,27-,28+,29-/m0/s1
DMTA6I5 CS CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=C(C=C2)C(F)(F)F)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMTA6I5 IK OBZQTNACJLTWOC-FKWFRFQNSA-N
DMTA6I5 IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-[4-(trifluoromethyl)phenyl]propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMTA6I5 DE Discovery agent
DM3GSPX ID DM3GSPX
DM3GSPX DN Ac-His-DPhe(pI)-Arg-Trp-NH2
DM3GSPX HS Investigative
DM3GSPX SN CHEMBL322610; Ac-His-DPhe(pI)-Arg-Trp-NH2; BDBM50115373; JRH-322-18; 2-[2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-(4-iodo-phenyl)-propionylamino]-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide
DM3GSPX DT Small molecular drug
DM3GSPX PC 9875763
DM3GSPX MW 811.7
DM3GSPX FM C34H42IN11O5
DM3GSPX IC InChI=1S/C34H42IN11O5/c1-19(47)43-29(15-23-17-39-18-42-23)33(51)46-28(13-20-8-10-22(35)11-9-20)32(50)44-26(7-4-12-40-34(37)38)31(49)45-27(30(36)48)14-21-16-41-25-6-3-2-5-24(21)25/h2-3,5-6,8-11,16-18,26-29,41H,4,7,12-15H2,1H3,(H2,36,48)(H,39,42)(H,43,47)(H,44,50)(H,45,49)(H,46,51)(H4,37,38,40)/t26-,27-,28+,29-/m0/s1
DM3GSPX CS CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=C(C=C2)I)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DM3GSPX IK OBADRSUMIBIHEX-FKWFRFQNSA-N
DM3GSPX IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-iodophenyl)propanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DM3GSPX DE Discovery agent
DMAQR29 ID DMAQR29
DMAQR29 DN Ac-His-D-Phe-Arg-2-Nal-NHCH3
DMAQR29 HS Investigative
DMAQR29 SN CHEMBL211699; Ac-His-D-Phe-Arg-2-Nal-NHCH3; BDBM50189018; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide
DMAQR29 DT Small molecular drug
DMAQR29 PC 44413876
DMAQR29 MW 710.8
DMAQR29 FM C37H46N10O5
DMAQR29 IC InChI=1S/C37H46N10O5/c1-23(48)44-32(20-28-21-41-22-43-28)36(52)47-31(18-24-9-4-3-5-10-24)35(51)45-29(13-8-16-42-37(38)39)34(50)46-30(33(49)40-2)19-25-14-15-26-11-6-7-12-27(26)17-25/h3-7,9-12,14-15,17,21-22,29-32H,8,13,16,18-20H2,1-2H3,(H,40,49)(H,41,43)(H,44,48)(H,45,51)(H,46,50)(H,47,52)(H4,38,39,42)/t29-,30-,31+,32-/m0/s1
DMAQR29 CS CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NC
DMAQR29 IK KXPKJVIQPPHENQ-IHZBLBIESA-N
DMAQR29 IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)-N-[(2S)-1-(methylamino)-3-naphthalen-2-yl-1-oxopropan-2-yl]pentanamide
DMAQR29 DE Discovery agent
DMMP0D8 ID DMMP0D8
DMMP0D8 DN Ac-His-DPhe-Arg-Trp-NH2
DMMP0D8 HS Investigative
DMMP0D8 SN Ac-His-Phe-Arg-Trp-NH2; CHEMBL50056; Ac-His-Phe-Arg-Trp-NH(2); L-Tryptophanamide, N-acetyl-L-histidyl-L-phenylalanyl-L-arginyl-; Ac-His-D-Phe-Arg-D-Trp-NH2; CTK0D4815; 2-{2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide; 110392-38-6; BDBM50034910; (S)-2-{(S)-2-[(S)-2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid [(S)-1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide
DMMP0D8 DT Small molecular drug
DMMP0D8 PC 11093672
DMMP0D8 MW 685.8
DMMP0D8 FM C34H43N11O5
DMMP0D8 IC InChI=1S/C34H43N11O5/c1-20(46)42-29(16-23-18-38-19-41-23)33(50)45-28(14-21-8-3-2-4-9-21)32(49)43-26(12-7-13-39-34(36)37)31(48)44-27(30(35)47)15-22-17-40-25-11-6-5-10-24(22)25/h2-6,8-11,17-19,26-29,40H,7,12-16H2,1H3,(H2,35,47)(H,38,41)(H,42,46)(H,43,49)(H,44,48)(H,45,50)(H4,36,37,39)/t26-,27-,28+,29-/m0/s1
DMMP0D8 CS CC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N
DMMP0D8 IK DFCJPPDAOZROBS-FKWFRFQNSA-N
DMMP0D8 IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-5-(diaminomethylideneamino)pentanamide
DMMP0D8 DE Discovery agent
DMCA4QR ID DMCA4QR
DMCA4QR DN Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2
DMCA4QR HS Investigative
DMCA4QR SN CHEMBL438290; Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2
DMCA4QR PC 44306522
DMCA4QR MW 1005.2
DMCA4QR FM C47H68N14O9S
DMCA4QR IC InChI=1S/C47H68N14O9S/c1-24(2)15-35(44(67)57-34(40(48)63)13-14-71-8)59-46(69)38(18-31-21-50-23-53-31)58-41(64)26(5)55-47(70)39(25(3)4)61-42(65)27(6)54-43(66)36(16-29-19-51-33-12-10-9-11-32(29)33)60-45(68)37(56-28(7)62)17-30-20-49-22-52-30/h9-12,19-27,34-39,51H,13-18H2,1-8H3,(H2,48,63)(H,49,52)(H,50,53)(H,54,66)(H,55,70)(H,56,62)(H,57,67)(H,58,64)(H,59,69)(H,60,68)(H,61,65)/t26-,27-,34-,35-,36-,37-,38-,39-/m0/s1
DMCA4QR CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C
DMCA4QR IK FLMAIOAFTCGWGR-YDDHTLEASA-N
DMCA4QR IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
DMCA4QR DE Discovery agent
DMUINVT ID DMUINVT
DMUINVT DN Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2
DMUINVT HS Investigative
DMUINVT SN CHEMBL263873; Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2
DMUINVT PC 44306563
DMUINVT MW 1005.2
DMUINVT FM C47H68N14O9S
DMUINVT IC InChI=1S/C47H68N14O9S/c1-24(2)15-35(44(67)57-34(40(48)63)13-14-71-8)59-46(69)38(18-31-21-50-23-53-31)58-41(64)26(5)55-47(70)39(25(3)4)61-42(65)27(6)54-43(66)36(16-29-19-51-33-12-10-9-11-32(29)33)60-45(68)37(56-28(7)62)17-30-20-49-22-52-30/h9-12,19-27,34-39,51H,13-18H2,1-8H3,(H2,48,63)(H,49,52)(H,50,53)(H,54,66)(H,55,70)(H,56,62)(H,57,67)(H,58,64)(H,59,69)(H,60,68)(H,61,65)/t26-,27+,34+,35+,36+,37+,38+,39+/m1/s1
DMUINVT CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C
DMUINVT IK FLMAIOAFTCGWGR-UGUXQERMSA-N
DMUINVT IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
DMUINVT DE Discovery agent
DMUGO9M ID DMUGO9M
DMUGO9M DN Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
DMUGO9M HS Investigative
DMUGO9M SN CHEMBL274874; Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2; Acetyl-GRP(20-27); BDBM50012306; ZINC169366208
DMUGO9M DT Small molecular drug
DMUGO9M PC 13049019
DMUGO9M MW 991.2
DMUGO9M FM C46H66N14O9S
DMUGO9M IC InChI=1S/C46H66N14O9S/c1-24(2)14-34(43(66)57-33(40(47)63)12-13-70-7)58-45(68)37(17-30-20-49-23-53-30)56-38(62)21-51-46(69)39(25(3)4)60-41(64)26(5)54-42(65)35(15-28-18-50-32-11-9-8-10-31(28)32)59-44(67)36(55-27(6)61)16-29-19-48-22-52-29/h8-11,18-20,22-26,33-37,39,50H,12-17,21H2,1-7H3,(H2,47,63)(H,48,52)(H,49,53)(H,51,69)(H,54,65)(H,55,61)(H,56,62)(H,57,66)(H,58,68)(H,59,67)(H,60,64)/t26-,33-,34-,35-,36-,37-,39-/m0/s1
DMUGO9M CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C
DMUGO9M IK PESSCGOLEUORDO-IFIOYJEKSA-N
DMUGO9M IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide
DMUGO9M DE Discovery agent
DMZO5Y7 ID DMZO5Y7
DMZO5Y7 DN ACHP
DMZO5Y7 HS Investigative
DMZO5Y7 DT Small molecular drug
DMZO5Y7 PC 135465539
DMZO5Y7 MW 364.4
DMZO5Y7 FM C21H24N4O2
DMZO5Y7 IC InChI=1S/C21H24N4O2/c22-11-16-15(14-6-8-24-9-7-14)10-17(25-21(16)23)20-18(26)2-1-3-19(20)27-12-13-4-5-13/h1-3,10,13-14,24,26H,4-9,12H2,(H2,23,25)
DMZO5Y7 CS C1CC1COC2=CC=CC(=C2C3=NC(=C(C(=C3)C4CCNCC4)C#N)N)O
DMZO5Y7 IK DYVFBWXIOCLHPP-UHFFFAOYSA-N
DMZO5Y7 IU 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-ylpyridine-3-carbonitrile
DMZO5Y7 CB CHEBI:91445
DMZO5Y7 DE Multiple myeloma
DMU7SBD ID DMU7SBD
DMU7SBD DN Ac-hPhe-Leu-Ala-LeuVSMe
DMU7SBD HS Investigative
DMU7SBD SN CHEMBL207579; Ac-hPhe-Leu-Ala-LeuVSMe
DMU7SBD DT Small molecular drug
DMU7SBD PC 11556056
DMU7SBD MW 578.8
DMU7SBD FM C29H46N4O6S
DMU7SBD IC InChI=1S/C29H46N4O6S/c1-19(2)17-24(15-16-40(7,38)39)32-27(35)21(5)30-29(37)26(18-20(3)4)33-28(36)25(31-22(6)34)14-13-23-11-9-8-10-12-23/h8-12,15-16,19-21,24-26H,13-14,17-18H2,1-7H3,(H,30,37)(H,31,34)(H,32,35)(H,33,36)/b16-15+/t21-,24+,25-,26-/m0/s1
DMU7SBD CS C[C@@H](C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)C
DMU7SBD IK WUQZWLVEKPBGGU-WXIXLNPNSA-N
DMU7SBD IU (2S)-2-[[(2S)-2-acetamido-4-phenylbutanoyl]amino]-4-methyl-N-[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]pentanamide
DMU7SBD DE Discovery agent
DMH2SU4 ID DMH2SU4
DMH2SU4 DN Ac-hPhe-Leu-Gly-LeuVSMe
DMH2SU4 HS Investigative
DMH2SU4 SN CHEMBL209243; Ac-hPhe-Leu-Gly-LeuVSMe
DMH2SU4 DT Small molecular drug
DMH2SU4 PC 11713852
DMH2SU4 MW 564.7
DMH2SU4 FM C28H44N4O6S
DMH2SU4 IC InChI=1S/C28H44N4O6S/c1-19(2)16-23(14-15-39(6,37)38)31-26(34)18-29-27(35)25(17-20(3)4)32-28(36)24(30-21(5)33)13-12-22-10-8-7-9-11-22/h7-11,14-15,19-20,23-25H,12-13,16-18H2,1-6H3,(H,29,35)(H,30,33)(H,31,34)(H,32,36)/b15-14+/t23-,24+,25+/m1/s1
DMH2SU4 CS CC(C)C[C@@H](/C=C/S(=O)(=O)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)C
DMH2SU4 IK NYFDCVWCYDTELB-GNEZGTDISA-N
DMH2SU4 IU (2S)-2-[[(2S)-2-acetamido-4-phenylbutanoyl]amino]-4-methyl-N-[2-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-2-oxoethyl]pentanamide
DMH2SU4 DE Discovery agent
DMMDJPC ID DMMDJPC
DMMDJPC DN Ac-hPhe-Leu-Phe-LeuVSMe
DMMDJPC HS Investigative
DMMDJPC SN CHEMBL379669; Ac-hPhe-Leu-Phe-LeuVSMe; BDBM50186702
DMMDJPC DT Small molecular drug
DMMDJPC PC 11693148
DMMDJPC MW 654.9
DMMDJPC FM C35H50N4O6S
DMMDJPC IC InChI=1S/C35H50N4O6S/c1-24(2)21-29(19-20-46(6,44)45)37-34(42)32(23-28-15-11-8-12-16-28)39-35(43)31(22-25(3)4)38-33(41)30(36-26(5)40)18-17-27-13-9-7-10-14-27/h7-16,19-20,24-25,29-32H,17-18,21-23H2,1-6H3,(H,36,40)(H,37,42)(H,38,41)(H,39,43)/b20-19+/t29-,30+,31+,32+/m1/s1
DMMDJPC CS CC(C)C[C@@H](/C=C/S(=O)(=O)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC2=CC=CC=C2)NC(=O)C
DMMDJPC IK UIUWSHIRBDIYGM-QLEUBDALSA-N
DMMDJPC IU (2S)-2-[[(2S)-2-acetamido-4-phenylbutanoyl]amino]-4-methyl-N-[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanamide
DMMDJPC DE Discovery agent
DMV58GQ ID DMV58GQ
DMV58GQ DN Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC
DMV58GQ HS Investigative
DMV58GQ PC 91936071
DMV58GQ MW 3916
DMV58GQ FM C174H280N52O49S
DMV58GQ IC InChI=1S/C174H280N52O49S/c1-17-90(10)137(168(271)209-109(40-25-30-68-179)146(249)205-113(56-60-129(180)235)151(254)202-106(37-22-27-65-176)144(247)203-111(42-32-70-192-173(186)187)149(252)214-120(76-99-46-52-103(233)53-47-99)159(262)221-128(84-276)171(274)275)224-165(268)127(83-228)219-153(256)115(58-62-131(182)237)207-157(260)118(73-87(4)5)212-158(261)119(75-98-44-50-102(232)51-45-98)213-148(251)108(39-24-29-67-178)201-143(246)105(36-21-26-64-175)199-141(244)92(12)195-140(243)91(11)197-166(269)135(88(6)7)223-154(257)116(59-63-132(183)238)206-145(248)107(38-23-28-66-177)200-147(250)110(41-31-69-191-172(184)185)204-156(259)117(72-86(2)3)211-150(253)112(43-33-71-193-174(188)189)210-169(272)138(94(14)229)225-162(265)121(77-100-48-54-104(234)55-49-100)215-152(255)114(57-61-130(181)236)208-161(264)125(80-134(241)242)218-170(273)139(95(15)230)226-163(266)122(74-97-34-19-18-20-35-97)217-167(270)136(89(8)9)222-142(245)93(13)196-155(258)124(79-133(239)240)216-164(267)126(82-227)220-160(263)123(198-96(16)231)78-101-81-190-85-194-101/h18-20,34-35,44-55,81,85-95,105-128,135-139,227-230,232-234,276H,17,21-33,36-43,56-80,82-84,175-179H2,1-16H3,(H2,180,235)(H2,181,236)(H2,182,237)(H2,183,238)(H,190,194)(H,195,243)(H,196,258)(H,197,269)(H,198,231)(H,199,244)(H,200,250)(H,201,246)(H,202,254)(H,203,247)(H,204,259)(H,205,249)(H,206,248)(H,207,260)(H,208,264)(H,209,271)(H,210,272)(H,211,253)(H,212,261)(H,213,251)(H,214,252)(H,215,255)(H,216,267)(H,217,270)(H,218,273)(H,219,256)(H,220,263)(H,221,262)(H,222,245)(H,223,257)(H,224,268)(H,225,265)(H,226,266)(H,239,240)(H,241,242)(H,274,275)(H4,184,185,191)(H4,186,187,192)(H4,188,189,193)/t90-,91-,92-,93-,94+,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,135-,136-,137-,138-,139-/m0/s1
DMV58GQ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CN=CN5)NC(=O)C
DMV58GQ IK IBAUXWGAMLDSHW-KCQDCZGMSA-N
DMV58GQ IU (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMV58GQ DE Discovery agent
DMJVRPD ID DMJVRPD
DMJVRPD DN Ac-I[CV(1Nal)QDWGAHRC]T
DMJVRPD HS Investigative
DMJVRPD PC 91933231
DMJVRPD MW 1625.8
DMJVRPD FM C73H100N20O19S2
DMJVRPD IC InChI=1S/C73H100N20O19S2/c1-8-36(4)59(83-39(7)95)71(110)91-54-33-114-113-32-53(69(108)93-60(38(6)94)72(111)112)90-63(102)47(21-14-24-78-73(75)76)84-66(105)51(27-43-30-77-34-81-43)86-61(100)37(5)82-56(97)31-80-62(101)49(26-42-29-79-46-20-12-11-19-45(42)46)87-67(106)52(28-57(98)99)88-64(103)48(22-23-55(74)96)85-65(104)50(89-70(109)58(35(2)3)92-68(54)107)25-41-17-13-16-40-15-9-10-18-44(40)41/h9-13,15-20,29-30,34-38,47-54,58-60,79,94H,8,14,21-28,31-33H2,1-7H3,(H2,74,96)(H,77,81)(H,80,101)(H,82,97)(H,83,95)(H,84,105)(H,85,104)(H,86,100)(H,87,106)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,75,76,78)/t36-,37-,38+,47-,48-,49-,50-,51+,52+,53-,54-,58-,59-,60-/m0/s1
DMJVRPD CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=CC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMJVRPD IK ACANXZYPSQGZJT-UZUHPOSNSA-N
DMJVRPD IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-28-(naphthalen-1-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMJVRPD DE Discovery agent
DM14DEL ID DM14DEL
DM14DEL DN Ac-I[CV(2Igl)QDWGAHRC]T
DM14DEL HS Investigative
DM14DEL PC 91933237
DM14DEL MW 1601.8
DM14DEL FM C71H100N20O19S2
DM14DEL IC InChI=1S/C71H100N20O19S2/c1-8-34(4)56(81-37(7)93)68(107)88-51-31-112-111-30-50(66(105)90-57(36(6)92)70(109)110)87-61(100)45(18-13-23-76-71(73)74)82-63(102)48(25-40-28-75-32-79-40)84-59(98)35(5)80-53(95)29-78-60(99)47(24-39-27-77-44-17-12-11-16-42(39)44)85-64(103)49(26-54(96)97)86-62(101)46(21-22-52(72)94)83-69(108)58(43-20-19-38-14-9-10-15-41(38)43)91-67(106)55(33(2)3)89-65(51)104/h9-12,14-17,27-28,32-36,43,45-51,55-58,77,92H,8,13,18-26,29-31H2,1-7H3,(H2,72,94)(H,75,79)(H,78,99)(H,80,95)(H,81,93)(H,82,102)(H,83,108)(H,84,98)(H,85,103)(H,86,101)(H,87,100)(H,88,107)(H,89,104)(H,90,105)(H,91,106)(H,96,97)(H,109,110)(H4,73,74,76)/t34-,35-,36+,43?,45-,46-,47-,48+,49+,50-,51-,55-,56-,57-,58-/m0/s1
DM14DEL CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)C2CCC3=CC=CC=C23)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM14DEL IK HDGDWRFDJRCNRO-FUQOBRPNSA-N
DM14DEL IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-28-(2,3-dihydro-1H-inden-1-yl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DM14DEL DE Discovery agent
DMQISG6 ID DMQISG6
DMQISG6 DN Ac-I[CV(2Igl)QDWGAHRC]T-NH2
DMQISG6 HS Investigative
DMQISG6 PC 91933239
DMQISG6 MW 1600.8
DMQISG6 FM C71H101N21O18S2
DMQISG6 IC InChI=1S/C71H101N21O18S2/c1-8-34(4)56(82-37(7)94)69(109)89-51-31-112-111-30-50(67(107)91-57(36(6)93)59(73)99)88-62(102)45(18-13-23-77-71(74)75)83-64(104)48(25-40-28-76-32-80-40)85-60(100)35(5)81-53(96)29-79-61(101)47(24-39-27-78-44-17-12-11-16-42(39)44)86-65(105)49(26-54(97)98)87-63(103)46(21-22-52(72)95)84-70(110)58(43-20-19-38-14-9-10-15-41(38)43)92-68(108)55(33(2)3)90-66(51)106/h9-12,14-17,27-28,32-36,43,45-51,55-58,78,93H,8,13,18-26,29-31H2,1-7H3,(H2,72,95)(H2,73,99)(H,76,80)(H,79,101)(H,81,96)(H,82,94)(H,83,104)(H,84,110)(H,85,100)(H,86,105)(H,87,103)(H,88,102)(H,89,109)(H,90,106)(H,91,107)(H,92,108)(H,97,98)(H4,74,75,77)/t34-,35-,36+,43?,45-,46-,47-,48+,49+,50-,51-,55-,56-,57-,58-/m0/s1
DMQISG6 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)C2CCC3=CC=CC=C23)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMQISG6 IK YYPFHDDBPCSRKO-FUQOBRPNSA-N
DMQISG6 IU 2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-28-(2,3-dihydro-1H-inden-1-yl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMQISG6 DE Discovery agent
DM20PEO ID DM20PEO
DM20PEO DN Ac-I[CV(2Nal)QDWGAHRC]T
DM20PEO HS Investigative
DM20PEO PC 91933249
DM20PEO MW 1625.8
DM20PEO FM C73H100N20O19S2
DM20PEO IC InChI=1S/C73H100N20O19S2/c1-8-36(4)59(83-39(7)95)71(110)91-54-33-114-113-32-53(69(108)93-60(38(6)94)72(111)112)90-63(102)47(18-13-23-78-73(75)76)84-66(105)51(27-44-30-77-34-81-44)86-61(100)37(5)82-56(97)31-80-62(101)50(26-43-29-79-46-17-12-11-16-45(43)46)87-67(106)52(28-57(98)99)88-64(103)48(21-22-55(74)96)85-65(104)49(89-70(109)58(35(2)3)92-68(54)107)25-40-19-20-41-14-9-10-15-42(41)24-40/h9-12,14-17,19-20,24,29-30,34-38,47-54,58-60,79,94H,8,13,18,21-23,25-28,31-33H2,1-7H3,(H2,74,96)(H,77,81)(H,80,101)(H,82,97)(H,83,95)(H,84,105)(H,85,104)(H,86,100)(H,87,106)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,75,76,78)/t36-,37-,38+,47-,48-,49-,50-,51+,52+,53-,54-,58-,59-,60-/m0/s1
DM20PEO CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC3=CC=CC=C3C=C2)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM20PEO IK UCWQZBKPQJMNPR-UZUHPOSNSA-N
DM20PEO IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-28-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DM20PEO DE Discovery agent
DMX2IRY ID DMX2IRY
DMX2IRY DN Ac-I[CV(2Nal)QDWGAHRC]T-NH2
DMX2IRY HS Investigative
DMX2IRY PC 91933228
DMX2IRY MW 1624.8
DMX2IRY FM C73H101N21O18S2
DMX2IRY IC InChI=1S/C73H101N21O18S2/c1-8-36(4)59(84-39(7)96)72(112)92-54-33-114-113-32-53(70(110)94-60(38(6)95)61(75)101)91-64(104)47(18-13-23-79-73(76)77)85-67(107)51(27-44-30-78-34-82-44)87-62(102)37(5)83-56(98)31-81-63(103)50(26-43-29-80-46-17-12-11-16-45(43)46)88-68(108)52(28-57(99)100)89-65(105)48(21-22-55(74)97)86-66(106)49(90-71(111)58(35(2)3)93-69(54)109)25-40-19-20-41-14-9-10-15-42(41)24-40/h9-12,14-17,19-20,24,29-30,34-38,47-54,58-60,80,95H,8,13,18,21-23,25-28,31-33H2,1-7H3,(H2,74,97)(H2,75,101)(H,78,82)(H,81,103)(H,83,98)(H,84,96)(H,85,107)(H,86,106)(H,87,102)(H,88,108)(H,89,105)(H,90,111)(H,91,104)(H,92,112)(H,93,109)(H,94,110)(H,99,100)(H4,76,77,79)/t36-,37-,38+,47-,48-,49-,50-,51+,52+,53-,54-,58-,59-,60-/m0/s1
DMX2IRY CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC3=CC=CC=C3C=C2)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMX2IRY IK BFGQANAKHJAOQY-UZUHPOSNSA-N
DMX2IRY IU 2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-28-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMX2IRY DE Discovery agent
DMDFKU3 ID DMDFKU3
DMDFKU3 DN Ac-I[CV(Bpa)QDWGAHRC]T
DMDFKU3 HS Investigative
DMDFKU3 PC 91933244
DMDFKU3 MW 1679.9
DMDFKU3 FM C76H102N20O20S2
DMDFKU3 IC InChI=1S/C76H102N20O20S2/c1-8-38(4)61(86-41(7)98)74(114)94-56-35-118-117-34-55(72(112)96-62(40(6)97)75(115)116)93-66(106)49(19-14-26-81-76(78)79)87-69(109)53(29-46-32-80-36-84-46)89-64(104)39(5)85-58(100)33-83-65(105)52(28-45-31-82-48-18-13-12-17-47(45)48)90-70(110)54(30-59(101)102)91-67(107)50(24-25-57(77)99)88-68(108)51(92-73(113)60(37(2)3)95-71(56)111)27-42-20-22-44(23-21-42)63(103)43-15-10-9-11-16-43/h9-13,15-18,20-23,31-32,36-40,49-56,60-62,82,97H,8,14,19,24-30,33-35H2,1-7H3,(H2,77,99)(H,80,84)(H,83,105)(H,85,100)(H,86,98)(H,87,109)(H,88,108)(H,89,104)(H,90,110)(H,91,107)(H,92,113)(H,93,106)(H,94,114)(H,95,111)(H,96,112)(H,101,102)(H,115,116)(H4,78,79,81)/t38-,39-,40+,49-,50-,51-,52-,53+,54?,55-,56-,60-,61-,62-/m0/s1
DMDFKU3 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMDFKU3 IK PWSUDTBGJHZYGB-MPCJNSQXSA-N
DMDFKU3 IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-28-[(4-benzoylphenyl)methyl]-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMDFKU3 DE Discovery agent
DMZG46O ID DMZG46O
DMZG46O DN Ac-I[CV(Bpa)QDWGAHRC]T-NH2
DMZG46O HS Investigative
DMZG46O PC 91933235
DMZG46O MW 1678.9
DMZG46O FM C76H103N21O19S2
DMZG46O IC InChI=1S/C76H103N21O19S2/c1-8-38(4)61(87-41(7)99)75(116)95-56-35-118-117-34-55(73(114)97-62(40(6)98)64(78)105)94-67(108)49(19-14-26-82-76(79)80)88-70(111)53(29-46-32-81-36-85-46)90-65(106)39(5)86-58(101)33-84-66(107)52(28-45-31-83-48-18-13-12-17-47(45)48)91-71(112)54(30-59(102)103)92-68(109)50(24-25-57(77)100)89-69(110)51(93-74(115)60(37(2)3)96-72(56)113)27-42-20-22-44(23-21-42)63(104)43-15-10-9-11-16-43/h9-13,15-18,20-23,31-32,36-40,49-56,60-62,83,98H,8,14,19,24-30,33-35H2,1-7H3,(H2,77,100)(H2,78,105)(H,81,85)(H,84,107)(H,86,101)(H,87,99)(H,88,111)(H,89,110)(H,90,106)(H,91,112)(H,92,109)(H,93,115)(H,94,108)(H,95,116)(H,96,113)(H,97,114)(H,102,103)(H4,79,80,82)/t38-,39-,40+,49-,50-,51-,52-,53+,54+,55-,56-,60-,61-,62-/m0/s1
DMZG46O CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMZG46O IK WGQRWXBFHFOWBH-SORWEXASSA-N
DMZG46O IU 2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-28-[(4-benzoylphenyl)methyl]-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMZG46O DE Discovery agent
DM5NMVP ID DM5NMVP
DM5NMVP DN Ac-I[CV(Bta)QDWGAHRC]T
DM5NMVP HS Investigative
DM5NMVP PC 91933248
DM5NMVP MW 1631.9
DM5NMVP FM C71H98N20O19S3
DM5NMVP IC InChI=1S/C71H98N20O19S3/c1-9-34(4)56(81-37(7)93)66(106)87-50-31-113-112-30-49(65(105)90-57(36(6)92)68(108)109)86-60(100)44(18-14-22-76-70(73)74)82-62(102)47(24-39-27-75-32-79-39)83-58(98)35(5)80-53(95)28-78-59(99)46(23-38-26-77-43-17-12-10-15-40(38)43)84-63(103)48(25-54(96)97)85-61(101)45(20-21-52(72)94)88-69(110)71(8,42-29-111-51-19-13-11-16-41(42)51)91-67(107)55(33(2)3)89-64(50)104/h10-13,15-17,19,26-27,29,32-36,44-50,55-57,77,92H,9,14,18,20-25,28,30-31H2,1-8H3,(H2,72,94)(H,75,79)(H,78,99)(H,80,95)(H,81,93)(H,82,102)(H,83,98)(H,84,103)(H,85,101)(H,86,100)(H,87,106)(H,88,110)(H,89,104)(H,90,105)(H,91,107)(H,96,97)(H,108,109)(H4,73,74,76)/t34-,35-,36+,44-,45-,46-,47+,48+,49-,50-,55-,56-,57-,71-/m0/s1
DM5NMVP CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@@H](NC1=O)C(C)C)(C)C2=CSC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM5NMVP IK JSPKWLRQUPIDRS-NWJDZPOUSA-N
DM5NMVP IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-28-(1-benzothiophen-3-yl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,28-dimethyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DM5NMVP DE Discovery agent
DMFLA5T ID DMFLA5T
DMFLA5T DN Ac-I[CV(Bta)QDWGAHRC]T-NH2
DMFLA5T HS Investigative
DMFLA5T PC 91933234
DMFLA5T MW 1630.9
DMFLA5T FM C71H99N21O18S3
DMFLA5T IC InChI=1S/C71H99N21O18S3/c1-9-34(4)56(82-37(7)94)67(108)88-50-31-113-112-30-49(66(107)91-57(36(6)93)58(73)99)87-61(102)44(18-14-22-77-70(74)75)83-63(104)47(24-39-27-76-32-80-39)84-59(100)35(5)81-53(96)28-79-60(101)46(23-38-26-78-43-17-12-10-15-40(38)43)85-64(105)48(25-54(97)98)86-62(103)45(20-21-52(72)95)89-69(110)71(8,42-29-111-51-19-13-11-16-41(42)51)92-68(109)55(33(2)3)90-65(50)106/h10-13,15-17,19,26-27,29,32-36,44-50,55-57,78,93H,9,14,18,20-25,28,30-31H2,1-8H3,(H2,72,95)(H2,73,99)(H,76,80)(H,79,101)(H,81,96)(H,82,94)(H,83,104)(H,84,100)(H,85,105)(H,86,103)(H,87,102)(H,88,108)(H,89,110)(H,90,106)(H,91,107)(H,92,109)(H,97,98)(H4,74,75,77)/t34-,35-,36+,44-,45-,46-,47+,48+,49-,50-,55-,56-,57-,71-/m0/s1
DMFLA5T CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@](NC(=O)[C@@H](NC1=O)C(C)C)(C)C2=CSC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMFLA5T IK OCTUQYZUSWCCJV-NWJDZPOUSA-N
DMFLA5T IU 2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-28-(1-benzothiophen-3-yl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,28-dimethyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMFLA5T DE Discovery agent
DMO9VWH ID DMO9VWH
DMO9VWH DN Ac-I[CV(Dht)QDWGAHRC]T
DMO9VWH HS Investigative
DMO9VWH PC 91933240
DMO9VWH MW 1614.8
DMO9VWH FM C71H99N21O19S2
DMO9VWH IC InChI=1S/C71H99N21O19S2/c1-8-34(4)57(82-37(7)94)69(109)90-52-31-113-112-30-51(67(107)92-58(36(6)93)70(110)111)89-61(101)45(18-13-21-76-71(73)74)83-64(104)49(24-40-28-75-32-80-40)85-59(99)35(5)81-54(96)29-79-60(100)47(22-38-26-77-43-16-11-9-14-41(38)43)86-65(105)50(25-55(97)98)87-62(102)46(19-20-53(72)95)84-63(103)48(88-68(108)56(33(2)3)91-66(52)106)23-39-27-78-44-17-12-10-15-42(39)44/h9-12,14-17,26-28,32-36,45-52,56-58,77-78,93H,8,13,18-25,29-31H2,1-7H3,(H2,72,95)(H,75,80)(H,79,100)(H,81,96)(H,82,94)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,97,98)(H,110,111)(H4,73,74,76)/t34-,35-,36+,45-,46-,47-,48-,49+,50+,51-,52-,56-,57-,58-/m0/s1
DMO9VWH CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMO9VWH IK XVHYFABBPDIZAN-YEKOCRBCSA-N
DMO9VWH IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMO9VWH DE Discovery agent
DMY18ET ID DMY18ET
DMY18ET DN Ac-I[CV(Yphs)QDWGAHRC]I-NH2
DMY18ET HS Investigative
DMY18ET PC 91933247
DMY18ET MW 1682.8
DMY18ET FM C71H104N21O21PS2
DMY18ET IC InChI=1S/C71H104N21O21PS2/c1-9-35(5)57(59(73)98)92-68(107)51-31-115-116-32-52(90-70(109)58(36(6)10-2)82-38(8)93)67(106)91-56(34(3)4)69(108)88-47(24-39-17-19-42(20-18-39)113-114(110,111)112)64(103)84-46(21-22-53(72)94)63(102)87-50(27-55(96)97)66(105)86-48(25-40-28-78-44-15-12-11-14-43(40)44)61(100)79-30-54(95)81-37(7)60(99)85-49(26-41-29-76-33-80-41)65(104)83-45(62(101)89-51)16-13-23-77-71(74)75/h11-12,14-15,17-20,28-29,33-37,45-52,56-58,78H,9-10,13,16,21-27,30-32H2,1-8H3,(H2,72,94)(H2,73,98)(H,76,80)(H,79,100)(H,81,95)(H,82,93)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,96,97)(H4,74,75,77)(H2,110,111,112)/t35-,36-,37-,45-,46-,47-,48-,49+,50+,51-,52-,56-,57-,58-/m0/s1
DMY18ET CS CC[C@H](C)[C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC2=CN=CN2)C)CC3=CNC4=CC=CC=C43)CC(=O)O)CCC(=O)N)CC5=CC=C(C=C5)OP(=O)(O)O)C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)C
DMY18ET IK GQCVZDSVWSDPKX-FWGFZLTPSA-N
DMY18ET IU 2-[(4R,7S,10R,13S,19S,22R,25S,28S,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-28-[(4-phosphonooxyphenyl)methyl]-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMY18ET DE Discovery agent
DMFOTYQ ID DMFOTYQ
DMFOTYQ DN Ac-I[CVFQDWGHHRC]T-NH2
DMFOTYQ HS Investigative
DMFOTYQ PC 91933233
DMFOTYQ MW 1640.9
DMFOTYQ FM C72H101N23O18S2
DMFOTYQ IC InChI=1S/C72H101N23O18S2/c1-7-36(4)58(84-38(6)97)71(113)93-53-32-115-114-31-52(69(111)95-59(37(5)96)60(74)102)92-62(104)45(18-13-21-79-72(75)76)86-66(108)50(25-42-29-78-34-83-42)89-65(107)49(24-41-28-77-33-82-41)85-55(99)30-81-61(103)48(23-40-27-80-44-17-12-11-16-43(40)44)88-67(109)51(26-56(100)101)90-63(105)46(19-20-54(73)98)87-64(106)47(22-39-14-9-8-10-15-39)91-70(112)57(35(2)3)94-68(53)110/h8-12,14-17,27-29,33-37,45-53,57-59,80,96H,7,13,18-26,30-32H2,1-6H3,(H2,73,98)(H2,74,102)(H,77,82)(H,78,83)(H,81,103)(H,84,97)(H,85,99)(H,86,108)(H,87,106)(H,88,109)(H,89,107)(H,90,105)(H,91,112)(H,92,104)(H,93,113)(H,94,110)(H,95,111)(H,100,101)(H4,75,76,79)/t36-,37+,45-,46-,47+,48-,49-,50+,51+,52-,53-,57-,58-,59-/m0/s1
DMFOTYQ CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=CC=C2)CCC(=O)N)CC(=O)O)CC3=CNC4=CC=CC=C43)CC5=CN=CN5)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMFOTYQ IK RBQLSOPILCDKPP-IJVDDTIBSA-N
DMFOTYQ IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-28-benzyl-7-(3-carbamimidamidopropyl)-10,13-bis(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMFOTYQ DE Discovery agent
DMLU3PZ ID DMLU3PZ
DMLU3PZ DN Ac-I[CVHQDWGHHRC]T-NH2
DMLU3PZ HS Investigative
DMLU3PZ PC 91933241
DMLU3PZ MW 1630.8
DMLU3PZ FM C69H99N25O18S2
DMLU3PZ IC InChI=1S/C69H99N25O18S2/c1-7-33(4)55(83-35(6)96)68(112)92-50-28-114-113-27-49(66(110)94-56(34(5)95)57(71)101)91-59(103)42(13-10-16-77-69(72)73)85-62(106)46(19-38-24-75-30-81-38)88-61(105)45(18-37-23-74-29-80-37)84-52(98)26-79-58(102)44(17-36-22-78-41-12-9-8-11-40(36)41)87-64(108)48(21-53(99)100)89-60(104)43(14-15-51(70)97)86-63(107)47(20-39-25-76-31-82-39)90-67(111)54(32(2)3)93-65(50)109/h8-9,11-12,22-25,29-34,42-50,54-56,78,95H,7,10,13-21,26-28H2,1-6H3,(H2,70,97)(H2,71,101)(H,74,80)(H,75,81)(H,76,82)(H,79,102)(H,83,96)(H,84,98)(H,85,106)(H,86,107)(H,87,108)(H,88,105)(H,89,104)(H,90,111)(H,91,103)(H,92,112)(H,93,109)(H,94,110)(H,99,100)(H4,72,73,77)/t33-,34+,42-,43-,44-,45-,46+,47+,48+,49-,50-,54-,55-,56-/m0/s1
DMLU3PZ CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CN=CN2)CCC(=O)N)CC(=O)O)CC3=CNC4=CC=CC=C43)CC5=CN=CN5)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMLU3PZ IK BOKLLRIGSLYOHT-OYMOBXHASA-N
DMLU3PZ IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10,13,28-tris(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMLU3PZ DE Discovery agent
DMDPSBQ ID DMDPSBQ
DMDPSBQ DN Ac-I[CVSQDWGHHRC]T-NH2
DMDPSBQ HS Investigative
DMDPSBQ PC 91933246
DMDPSBQ MW 1580.8
DMDPSBQ FM C66H97N23O19S2
DMDPSBQ IC InChI=1S/C66H97N23O19S2/c1-7-31(4)52(78-33(6)92)65(108)87-47-27-110-109-26-46(63(106)89-53(32(5)91)54(68)97)86-56(99)39(13-10-16-73-66(69)70)80-59(102)43(19-36-23-72-29-77-36)83-58(101)42(18-35-22-71-28-76-35)79-49(94)24-75-55(98)41(17-34-21-74-38-12-9-8-11-37(34)38)82-60(103)44(20-50(95)96)84-57(100)40(14-15-48(67)93)81-61(104)45(25-90)85-64(107)51(30(2)3)88-62(47)105/h8-9,11-12,21-23,28-32,39-47,51-53,74,90-91H,7,10,13-20,24-27H2,1-6H3,(H2,67,93)(H2,68,97)(H,71,76)(H,72,77)(H,75,98)(H,78,92)(H,79,94)(H,80,102)(H,81,104)(H,82,103)(H,83,101)(H,84,100)(H,85,107)(H,86,99)(H,87,108)(H,88,105)(H,89,106)(H,95,96)(H4,69,70,73)/t31-,32+,39-,40-,41-,42-,43+,44+,45+,46-,47-,51-,52-,53-/m0/s1
DMDPSBQ CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CO)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)CC4=CN=CN4)CC5=CN=CN5)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMDPSBQ IK HZUYXHSRYLPHAY-PSEHRYLKSA-N
DMDPSBQ IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-28-(hydroxymethyl)-10,13-bis(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMDPSBQ DE Discovery agent
DMNVMB5 ID DMNVMB5
DMNVMB5 DN Ac-I[CVTQDWGHHRC]T-NH2
DMNVMB5 HS Investigative
DMNVMB5 PC 91933229
DMNVMB5 MW 1594.8
DMNVMB5 FM C67H99N23O19S2
DMNVMB5 IC InChI=1S/C67H99N23O19S2/c1-8-31(4)52(79-34(7)93)65(108)87-47-27-111-110-26-46(63(106)89-53(32(5)91)55(69)98)86-57(100)40(14-11-17-74-67(70)71)81-60(103)44(20-37-24-73-29-78-37)84-59(102)43(19-36-23-72-28-77-36)80-49(95)25-76-56(99)42(18-35-22-75-39-13-10-9-12-38(35)39)83-61(104)45(21-50(96)97)85-58(101)41(15-16-48(68)94)82-66(109)54(33(6)92)90-64(107)51(30(2)3)88-62(47)105/h9-10,12-13,22-24,28-33,40-47,51-54,75,91-92H,8,11,14-21,25-27H2,1-7H3,(H2,68,94)(H2,69,98)(H,72,77)(H,73,78)(H,76,99)(H,79,93)(H,80,95)(H,81,103)(H,82,109)(H,83,104)(H,84,102)(H,85,101)(H,86,100)(H,87,108)(H,88,105)(H,89,106)(H,90,107)(H,96,97)(H4,70,71,74)/t31-,32+,33+,40-,41-,42-,43-,44+,45+,46-,47-,51-,52-,53-,54+/m0/s1
DMNVMB5 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)[C@@H](C)O)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)CC4=CN=CN4)CC5=CN=CN5)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMNVMB5 IK VOXWWAJOYBYONB-RTTZVKIOSA-N
DMNVMB5 IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-28-[(1R)-1-hydroxyethyl]-10,13-bis(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMNVMB5 DE Discovery agent
DMRSKIY ID DMRSKIY
DMRSKIY DN Ac-I[CVVQDWGAHRC]T-NH2
DMRSKIY HS Investigative
DMRSKIY SN CHEMBL269043; Ac-I[CVVQDWGAHRC]T-NH2
DMRSKIY PC 44388602
DMRSKIY MW 1526.7
DMRSKIY FM C65H99N21O18S2
DMRSKIY IC InChI=1S/C65H99N21O18S2/c1-10-31(6)51(76-34(9)88)64(104)83-45-27-106-105-26-44(61(101)86-52(33(8)87)53(67)93)82-56(96)39(16-13-19-71-65(68)69)77-58(98)42(21-36-24-70-28-74-36)79-54(94)32(7)75-47(90)25-73-55(95)41(20-35-23-72-38-15-12-11-14-37(35)38)80-59(99)43(22-48(91)92)81-57(97)40(17-18-46(66)89)78-62(102)49(29(2)3)85-63(103)50(30(4)5)84-60(45)100/h11-12,14-15,23-24,28-33,39-45,49-52,72,87H,10,13,16-22,25-27H2,1-9H3,(H2,66,89)(H2,67,93)(H,70,74)(H,73,95)(H,75,90)(H,76,88)(H,77,98)(H,78,102)(H,79,94)(H,80,99)(H,81,97)(H,82,96)(H,83,104)(H,84,100)(H,85,103)(H,86,101)(H,91,92)(H4,68,69,71)/t31-,32-,33+,39-,40-,41-,42+,43+,44-,45-,49+,50-,51-,52-/m0/s1
DMRSKIY CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)C(C)C)CCC(=O)N)CC(=O)O)CC2=CNC3=CC=CC=C32)C)CC4=CN=CN4)CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMRSKIY IK OSAZHXWZENYRCV-WKOWKQLHSA-N
DMRSKIY IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-28,31-di(propan-2-yl)-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMRSKIY DE Discovery agent
DMUW3T4 ID DMUW3T4
DMUW3T4 DN Ac-I[CVWQDWG(Abu)HRC]T-NH2
DMUW3T4 HS Investigative
DMUW3T4 PC 91933232
DMUW3T4 MW 1628.8
DMUW3T4 FM C72H101N21O19S2
DMUW3T4 IC InChI=1S/C72H101N21O19S2/c1-8-35(5)58(82-37(7)95)70(110)91-53-32-114-113-31-52(68(108)93-59(36(6)94)71(111)112)90-62(102)46(19-14-22-77-72(74)75)84-65(105)50(25-40-29-76-33-81-40)87-61(101)43(9-2)83-55(97)30-80-60(100)48(23-38-27-78-44-17-12-10-15-41(38)44)86-66(106)51(26-56(98)99)88-63(103)47(20-21-54(73)96)85-64(104)49(89-69(109)57(34(3)4)92-67(53)107)24-39-28-79-45-18-13-11-16-42(39)45/h10-13,15-18,27-29,33-36,43,46-53,57-59,78-79,94H,8-9,14,19-26,30-32H2,1-7H3,(H2,73,96)(H,76,81)(H,80,100)(H,82,95)(H,83,97)(H,84,105)(H,85,104)(H,86,106)(H,87,101)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,74,75,77)/t35-,36+,43?,46+,47-,48-,49+,50-,51+,52+,53-,57-,58-,59-/m0/s1
DMUW3T4 CS CCC1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CC2=CNC3=CC=CC=C32)CC(=O)O)CCC(=O)N)CC4=CNC5=CC=CC=C54)C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)CCCNC(=N)N)CC6=CN=CN6
DMUW3T4 IK IRAHVUBILQLJJK-POSIHDSISA-N
DMUW3T4 IU (2S,3R)-2-[[(4S,7R,10S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-13-ethyl-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMUW3T4 DE Discovery agent
DML5ZSJ ID DML5ZSJ
DML5ZSJ DN Ac-I[CVWQDWGAHRC]dT
DML5ZSJ HS Investigative
DML5ZSJ PC 91933250
DML5ZSJ MW 1614.8
DML5ZSJ FM C71H99N21O19S2
DML5ZSJ IC InChI=1S/C71H99N21O19S2/c1-8-34(4)57(82-37(7)94)69(109)90-52-31-113-112-30-51(67(107)92-58(36(6)93)70(110)111)89-61(101)45(18-13-21-76-71(73)74)83-64(104)49(24-40-28-75-32-80-40)85-59(99)35(5)81-54(96)29-79-60(100)47(22-38-26-77-43-16-11-9-14-41(38)43)86-65(105)50(25-55(97)98)87-62(102)46(19-20-53(72)95)84-63(103)48(88-68(108)56(33(2)3)91-66(52)106)23-39-27-78-44-17-12-10-15-42(39)44/h9-12,14-17,26-28,32-36,45-52,56-58,77-78,93H,8,13,18-25,29-31H2,1-7H3,(H2,72,95)(H,75,80)(H,79,100)(H,81,96)(H,82,94)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,97,98)(H,110,111)(H4,73,74,76)/t34-,35-,36-,45-,46-,47-,48+,49+,50+,51-,52-,56-,57-,58-/m0/s1
DML5ZSJ CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@H](C)O)C(=O)O)NC(=O)C
DML5ZSJ IK XVHYFABBPDIZAN-AHNXIUSDSA-N
DML5ZSJ IU (2S,3S)-2-[[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DML5ZSJ DE Discovery agent
DMV3PC7 ID DMV3PC7
DMV3PC7 DN Ac-I[CVWQDWGAHRC]T
DMV3PC7 HS Investigative
DMV3PC7 PC 91933222
DMV3PC7 MW 1614.8
DMV3PC7 FM C71H99N21O19S2
DMV3PC7 IC InChI=1S/C71H99N21O19S2/c1-8-34(4)57(82-37(7)94)69(109)90-52-31-113-112-30-51(67(107)92-58(36(6)93)70(110)111)89-61(101)45(18-13-21-76-71(73)74)83-64(104)49(24-40-28-75-32-80-40)85-59(99)35(5)81-54(96)29-79-60(100)47(22-38-26-77-43-16-11-9-14-41(38)43)86-65(105)50(25-55(97)98)87-62(102)46(19-20-53(72)95)84-63(103)48(88-68(108)56(33(2)3)91-66(52)106)23-39-27-78-44-17-12-10-15-42(39)44/h9-12,14-17,26-28,32-36,45-52,56-58,77-78,93H,8,13,18-25,29-31H2,1-7H3,(H2,72,95)(H,75,80)(H,79,100)(H,81,96)(H,82,94)(H,83,104)(H,84,103)(H,85,99)(H,86,105)(H,87,102)(H,88,108)(H,89,101)(H,90,109)(H,91,106)(H,92,107)(H,97,98)(H,110,111)(H4,73,74,76)/t34-,35-,36+,45-,46-,47-,48+,49+,50+,51-,52-,56-,57-,58-/m0/s1
DMV3PC7 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)C)CC6=CN=CN6)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMV3PC7 IK XVHYFABBPDIZAN-DRXBSEAFSA-N
DMV3PC7 IU (2S,3R)-2-[[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-22-(carboxymethyl)-10-(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carbonyl]amino]-3-hydroxybutanoic acid
DMV3PC7 DE Discovery agent
DMBA1LS ID DMBA1LS
DMBA1LS DN Ac-I[CVWQDWGHHRC]T-NH2
DMBA1LS HS Investigative
DMBA1LS PC 91933238
DMBA1LS MW 1679.9
DMBA1LS FM C74H102N24O18S2
DMBA1LS IC InChI=1S/C74H102N24O18S2/c1-7-36(4)60(87-38(6)100)73(116)96-55-32-118-117-31-54(71(114)98-61(37(5)99)62(76)105)95-64(107)47(17-12-20-81-74(77)78)89-68(111)52(24-42-29-80-34-86-42)92-67(110)51(23-41-28-79-33-85-41)88-57(102)30-84-63(106)49(21-39-26-82-45-15-10-8-13-43(39)45)91-69(112)53(25-58(103)104)93-65(108)48(18-19-56(75)101)90-66(109)50(94-72(115)59(35(2)3)97-70(55)113)22-40-27-83-46-16-11-9-14-44(40)46/h8-11,13-16,26-29,33-37,47-55,59-61,82-83,99H,7,12,17-25,30-32H2,1-6H3,(H2,75,101)(H2,76,105)(H,79,85)(H,80,86)(H,84,106)(H,87,100)(H,88,102)(H,89,111)(H,90,109)(H,91,112)(H,92,110)(H,93,108)(H,94,115)(H,95,107)(H,96,116)(H,97,113)(H,98,114)(H,103,104)(H4,77,78,81)/t36-,37+,47-,48-,49-,50+,51-,52+,53+,54-,55-,59-,60-,61-/m0/s1
DMBA1LS CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)CC6=CN=CN6)CC7=CN=CN7)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMBA1LS IK WCPUCPVVFQIWRA-BEXWAHHISA-N
DMBA1LS IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10,13-bis(1H-imidazol-5-ylmethyl)-19,28-bis(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMBA1LS DE Discovery agent
DMDIUK6 ID DMDIUK6
DMDIUK6 DN Ac-I[CVWQDWGWHRC]T-NH2
DMDIUK6 HS Investigative
DMDIUK6 PC 91933242
DMDIUK6 MW 1729
DMDIUK6 FM C79H105N23O18S2
DMDIUK6 IC InChI=1S/C79H105N23O18S2/c1-7-39(4)65(91-41(6)104)78(120)100-60-36-122-121-35-59(76(118)102-66(40(5)103)67(81)109)99-69(111)52(21-14-24-85-79(82)83)93-73(115)57(28-45-33-84-37-90-45)96-71(113)55(26-43-31-87-50-19-12-9-16-47(43)50)92-62(106)34-89-68(110)54(25-42-30-86-49-18-11-8-15-46(42)49)95-74(116)58(29-63(107)108)97-70(112)53(22-23-61(80)105)94-72(114)56(98-77(119)64(38(2)3)101-75(60)117)27-44-32-88-51-20-13-10-17-48(44)51/h8-13,15-20,30-33,37-40,52-60,64-66,86-88,103H,7,14,21-29,34-36H2,1-6H3,(H2,80,105)(H2,81,109)(H,84,90)(H,89,110)(H,91,104)(H,92,106)(H,93,115)(H,94,114)(H,95,116)(H,96,113)(H,97,112)(H,98,119)(H,99,111)(H,100,120)(H,101,117)(H,102,118)(H,107,108)(H4,82,83,85)/t39-,40+,52-,53-,54-,55-,56+,57+,58+,59-,60-,64-,65-,66-/m0/s1
DMDIUK6 CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CNC3=CC=CC=C32)CCC(=O)N)CC(=O)O)CC4=CNC5=CC=CC=C54)CC6=CNC7=CC=CC=C76)CC8=CN=CN8)CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DMDIUK6 IK FLYCCQRIADFTOH-RHIYSSTNSA-N
DMDIUK6 IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-13,19,28-tris(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DMDIUK6 DE Discovery agent
DM3Q5SU ID DM3Q5SU
DM3Q5SU DN Ac-I[CVYQDWGAHRC]T-NH2
DM3Q5SU HS Investigative
DM3Q5SU PC 44388582
DM3Q5SU MW 1590.8
DM3Q5SU FM C69H99N21O19S2
DM3Q5SU IC InChI=1S/C69H99N21O19S2/c1-8-33(4)55(80-36(7)92)68(109)88-50-30-111-110-29-49(66(107)90-56(35(6)91)57(71)98)87-60(101)43(14-11-21-75-69(72)73)81-63(104)47(24-39-27-74-31-78-39)83-58(99)34(5)79-52(95)28-77-59(100)46(23-38-26-76-42-13-10-9-12-41(38)42)84-64(105)48(25-53(96)97)85-61(102)44(19-20-51(70)94)82-62(103)45(22-37-15-17-40(93)18-16-37)86-67(108)54(32(2)3)89-65(50)106/h9-10,12-13,15-18,26-27,31-35,43-50,54-56,76,91,93H,8,11,14,19-25,28-30H2,1-7H3,(H2,70,94)(H2,71,98)(H,74,78)(H,77,100)(H,79,95)(H,80,92)(H,81,104)(H,82,103)(H,83,99)(H,84,105)(H,85,102)(H,86,108)(H,87,101)(H,88,109)(H,89,106)(H,90,107)(H,96,97)(H4,72,73,75)/t33-,34-,35+,43-,44-,45+,46-,47+,48+,49-,50-,54-,55-,56-/m0/s1
DM3Q5SU CS CC[C@H](C)[C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C(C)C)CC2=CC=C(C=C2)O)CCC(=O)N)CC(=O)O)CC3=CNC4=CC=CC=C43)C)CC5=CNC=N5)CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)C
DM3Q5SU IK PQVLDHFPSLWLQN-VEMXNSRSSA-N
DM3Q5SU IU 2-[(4R,7S,10R,13S,19S,22R,25S,28R,31S,34R)-34-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-4-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-28-[(4-hydroxyphenyl)methyl]-10-(1H-imidazol-4-ylmethyl)-19-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid
DM3Q5SU DE Discovery agent
DMPLNTM ID DMPLNTM
DMPLNTM DN ACI-636
DMPLNTM HS Investigative
DMPLNTM SN Morphomers; ACI-140; Beta amyloid beta sheet formation inhibitor (CNS diseases), AC Immune; Beta-amyloid oligomer inhibitors (Alzheimer's disease), AC Immune
DMPLNTM CP AC Immune SA
DMPLNTM DE Alzheimer disease
DM351NL ID DM351NL
DM351NL DN Ac-ICV(1MeW)QDWGAHRCT-NH2
DM351NL HS Investigative
DM351NL PC 77280229
DM351NL MW 1648.8
DM351NL FM C72H102FN21O19S2
DM351NL IC InChI=1S/C72H102FN21O19S2/c1-9-34(4)58(83-37(7)96)70(111)91-52(31-115)67(108)92-57(33(2)3)69(110)89-48(22-39-29-94(8)53-15-11-10-13-42(39)53)64(105)85-46(18-19-54(74)97)63(104)88-50(25-56(99)100)66(107)87-47(21-38-26-79-44-17-16-40(73)23-43(38)44)61(102)80-28-55(98)82-35(5)60(101)86-49(24-41-27-77-32-81-41)65(106)84-45(14-12-20-78-72(75)76)62(103)90-51(30-114)68(109)93-59(36(6)95)71(112)113/h10-11,13,15-17,23,26-27,29,32-36,45-52,57-59,79,95,114-115H,9,12,14,18-22,24-25,28,30-31H2,1-8H3,(H2,74,97)(H,77,81)(H,80,102)(H,82,98)(H,83,96)(H,84,106)(H,85,105)(H,86,101)(H,87,107)(H,88,104)(H,89,110)(H,90,103)(H,91,111)(H,92,108)(H,93,109)(H,99,100)(H,112,113)(H4,75,76,78)/t34-,35-,36+,45-,46-,47-,48-,49-,50-,51-,52-,57-,58-,59-/m0/s1
DM351NL CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CNC4=C3C=C(C=C4)F)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CN=CN5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DM351NL IK ZTPZPGGQKAOPSL-ULRAUGTQSA-N
DM351NL IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1-methylindol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DM351NL DE Discovery agent
DMQLPGA ID DMQLPGA
DMQLPGA DN Ac-ICV(5fW)QDWGAHRCT-NH2
DMQLPGA HS Investigative
DMQLPGA PC 44413817
DMQLPGA MW 1606.8
DMQLPGA FM C70H100FN21O18S2
DMQLPGA IC InChI=1S/C70H100FN21O18S2/c1-8-33(4)57(69(109)110-7)92-66(106)51(30-112)90-68(108)56(32(2)3)91-64(104)47(21-37-26-79-43-16-15-38(71)22-41(37)43)86-60(100)45(17-18-52(72)94)85-63(103)49(24-54(96)97)88-62(102)46(20-36-25-78-42-13-10-9-12-40(36)42)83-53(95)28-80-58(98)34(5)82-61(101)48(23-39-27-76-31-81-39)87-59(99)44(14-11-19-77-70(74)75)84-65(105)50(29-111)89-67(107)55(73)35(6)93/h9-10,12-13,15-16,22,25-27,31-35,44-51,55-57,78-79,93,111-112H,8,11,14,17-21,23-24,28-30,73H2,1-7H3,(H2,72,94)(H,76,81)(H,80,98)(H,82,101)(H,83,95)(H,84,105)(H,85,103)(H,86,100)(H,87,99)(H,88,102)(H,89,107)(H,90,108)(H,91,104)(H,92,106)(H,96,97)(H4,74,75,77)/t33?,34-,35+,44-,45-,46-,47-,48-,49-,50-,51-,55-,56-,57-/m0/s1
DMQLPGA CS CCC(C)[C@@H](C(=O)OC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=C1C=C(C=C2)F)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)N
DMQLPGA IK LNBPPCFNDRANJB-IIMWSTDNSA-N
DMQLPGA IU (3S)-4-[[(2S)-5-amino-1-[[(2S)-3-(5-fluoro-1H-indol-3-yl)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-methoxy-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoic acid
DMQLPGA DE Discovery agent
DM52T90 ID DM52T90
DM52T90 DN Ac-ICV(5MeW)QDWGAHRCT-NH2
DM52T90 HS Investigative
DM52T90 PC 44413713
DM52T90 MW 1602.8
DM52T90 FM C71H103N21O18S2
DM52T90 IC InChI=1S/C71H103N21O18S2/c1-9-35(5)58(70(109)110-8)92-67(106)52(31-112)90-69(108)57(33(2)3)91-65(104)48(23-39-27-79-44-17-16-34(4)21-42(39)44)86-61(100)46(18-19-53(72)94)85-64(103)50(25-55(96)97)88-63(102)47(22-38-26-78-43-14-11-10-13-41(38)43)83-54(95)29-80-59(98)36(6)82-62(101)49(24-40-28-76-32-81-40)87-60(99)45(15-12-20-77-71(74)75)84-66(105)51(30-111)89-68(107)56(73)37(7)93/h10-11,13-14,16-17,21,26-28,32-33,35-37,45-52,56-58,78-79,93,111-112H,9,12,15,18-20,22-25,29-31,73H2,1-8H3,(H2,72,94)(H,76,81)(H,80,98)(H,82,101)(H,83,95)(H,84,105)(H,85,103)(H,86,100)(H,87,99)(H,88,102)(H,89,107)(H,90,108)(H,91,104)(H,92,106)(H,96,97)(H4,74,75,77)/t35?,36-,37+,45-,46-,47-,48-,49-,50-,51-,52-,56-,57-,58-/m0/s1
DM52T90 CS CCC(C)[C@@H](C(=O)OC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=C1C=C(C=C2)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)N
DM52T90 IK BZCORVKMPCMYEF-LXVAIGNUSA-N
DM52T90 IU (3S)-3-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-methoxy-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(5-methyl-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DM52T90 DE Discovery agent
DMPK9LG ID DMPK9LG
DMPK9LG DN Ac-ICVWQD(5fW)GAHRCT-NH2
DMPK9LG HS Investigative
DMPK9LG PC 77280228
DMPK9LG MW 1634.8
DMPK9LG FM C71H100FN21O19S2
DMPK9LG IC InChI=1S/C71H100FN21O19S2/c1-8-33(4)57(83-36(7)95)69(110)91-52(30-114)66(107)92-56(32(2)3)68(109)89-48(20-37-25-78-43-13-10-9-12-41(37)43)63(104)85-46(17-18-53(73)96)62(103)88-50(24-55(98)99)65(106)87-47(21-38-26-79-44-16-15-39(72)22-42(38)44)60(101)80-28-54(97)82-34(5)59(100)86-49(23-40-27-76-31-81-40)64(105)84-45(14-11-19-77-71(74)75)61(102)90-51(29-113)67(108)93-58(35(6)94)70(111)112/h9-10,12-13,15-16,22,25-27,31-35,45-52,56-58,78-79,94,113-114H,8,11,14,17-21,23-24,28-30H2,1-7H3,(H2,73,96)(H,76,81)(H,80,101)(H,82,97)(H,83,95)(H,84,105)(H,85,104)(H,86,100)(H,87,106)(H,88,103)(H,89,109)(H,90,102)(H,91,110)(H,92,107)(H,93,108)(H,98,99)(H,111,112)(H4,74,75,77)/t33-,34-,35+,45-,46-,47-,48-,49-,50-,51-,52-,56-,57-,58-/m0/s1
DMPK9LG CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CNC4=C3C=C(C=C4)F)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CN=CN5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)C
DMPK9LG IK KSDNMEGNCSHTNC-MZUDAGKNSA-N
DMPK9LG IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-acetamido-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(5-fluoro-1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMPK9LG DE Discovery agent
DMPSI26 ID DMPSI26
DMPSI26 DN Ac-ICVWQDWGAHRCT-NH2
DMPSI26 HS Investigative
DMPSI26 PC 44413816
DMPSI26 MW 1588.8
DMPSI26 FM C70H101N21O18S2
DMPSI26 IC InChI=1S/C70H101N21O18S2/c1-8-34(4)57(69(108)109-7)91-66(105)51(31-111)89-68(107)56(33(2)3)90-64(103)47(23-38-27-78-43-17-12-10-15-41(38)43)85-60(99)45(19-20-52(71)93)84-63(102)49(25-54(95)96)87-62(101)46(22-37-26-77-42-16-11-9-14-40(37)42)82-53(94)29-79-58(97)35(5)81-61(100)48(24-39-28-75-32-80-39)86-59(98)44(18-13-21-76-70(73)74)83-65(104)50(30-110)88-67(106)55(72)36(6)92/h9-12,14-17,26-28,32-36,44-51,55-57,77-78,92,110-111H,8,13,18-25,29-31,72H2,1-7H3,(H2,71,93)(H,75,80)(H,79,97)(H,81,100)(H,82,94)(H,83,104)(H,84,102)(H,85,99)(H,86,98)(H,87,101)(H,88,106)(H,89,107)(H,90,103)(H,91,105)(H,95,96)(H4,73,74,76)/t34?,35-,36+,44-,45-,46-,47-,48-,49-,50-,51-,55-,56-,57-/m0/s1
DMPSI26 CS CCC(C)[C@@H](C(=O)OC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)N
DMPSI26 IK UQCBIVMMKZHRCG-CREZQNEJSA-N
DMPSI26 IU (3S)-3-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-[[(2S)-5-amino-1-[[(2S)-3-(1H-indol-3-yl)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-methoxy-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
DMPSI26 DE Discovery agent
DMCU6XV ID DMCU6XV
DMCU6XV DN Acid blue 25
DMCU6XV HS Investigative
DMCU6XV SN Acid Blue 25; 6408-78-2; C.I. ACID BLUE 25; UNII-S2E15W6FSN; S2E15W6FSN; W-110136; CHEMBL256057; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-, sodium salt (1:1); EINECS 229-068-1; EC 229-068-1; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-, monosodium salt; C20H13N2NaO5S; SCHEMBL790822; DTXSID2044711; CTK8F7553; Sodium 1-amino-9,10-dioxo-4-phenylaminoanthracene-2-sulphonate; MFCD00001214; Acid Blue 25, Dye content 45 %; AKOS015894441; AN-19165; Q394; I04-8965; sodium 1
DMCU6XV DT Small molecular drug
DMCU6XV PC 23675622
DMCU6XV MW 416.4
DMCU6XV FM C20H13N2NaO5S
DMCU6XV IC InChI=1S/C20H14N2O5S.Na/c21-18-15(28(25,26)27)10-14(22-11-6-2-1-3-7-11)16-17(18)20(24)13-9-5-4-8-12(13)19(16)23;/h1-10,22H,21H2,(H,25,26,27);/q;+1/p-1
DMCU6XV CS C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+]
DMCU6XV IK LIKZXCROQGHXTI-UHFFFAOYSA-M
DMCU6XV IU sodium;1-amino-4-anilino-9,10-dioxoanthracene-2-sulfonate
DMCU6XV CA CAS 6408-78-2
DMCU6XV DE Discovery agent
DMTOEJX ID DMTOEJX
DMTOEJX DN Acid-activated omeprazole
DMTOEJX HS Investigative
DMTOEJX SN Hydroxyfasudil; HYDROXYFASUDIL; 105628-72-6; Hydroxy-Fasudil; 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine; HA 1100; HA-1100; 1-[(1,2-DIHYDRO-1-OXO-5-ISOQUINOLINYL)SULFONYL]HEXAHYDRO-1H-1,4-DIAZEPINE; CHEMBL1233300; Hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-1H-1,4-diazepine; 5-(1,4-diazepane-1-sulfonyl)-1,2-dihydroisoquinolin-1-one; HYDROXYFASUDIL;5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one; 1H-1,4-Diazepine, hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-; HFS; 2etk; 2erz; AC1MI8J4; SCHEMBL123699
DMTOEJX DT Small molecular drug
DMTOEJX PC 3064778
DMTOEJX MW 307.37
DMTOEJX FM C14H17N3O3S
DMTOEJX IC InChI=1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18)
DMTOEJX CS C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O
DMTOEJX IK ZAVGJDAFCZAWSZ-UHFFFAOYSA-N
DMTOEJX IU 5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one
DMTOEJX CA CAS 105628-72-6
DMTOEJX DE Discovery agent
DMKVU8P ID DMKVU8P
DMKVU8P DN Ac-L-Phe-D-trp-L-Phe-D-pro-NH2
DMKVU8P HS Investigative
DMKVU8P SN CHEMBL442612; Ac-L-Phe-D-trp-L-Phe-D-pro-NH2
DMKVU8P DT Small molecular drug
DMKVU8P PC 44583428
DMKVU8P MW 636.7
DMKVU8P FM C36H40N6O5
DMKVU8P IC InChI=1S/C36H40N6O5/c1-23(43)39-29(19-24-11-4-2-5-12-24)34(45)40-30(21-26-22-38-28-16-9-8-15-27(26)28)35(46)41-31(20-25-13-6-3-7-14-25)36(47)42-18-10-17-32(42)33(37)44/h2-9,11-16,22,29-32,38H,10,17-21H2,1H3,(H2,37,44)(H,39,43)(H,40,45)(H,41,46)/t29-,30+,31-,32+/m0/s1
DMKVU8P CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N5CCC[C@@H]5C(=O)N
DMKVU8P IK FCKYLHYBJRMIPQ-MLMSKLGMSA-N
DMKVU8P IU (2R)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMKVU8P DE Discovery agent
DMIAYTP ID DMIAYTP
DMIAYTP DN Ac-Lys-[Leu(8)]-des-Arg(9)-BK
DMIAYTP HS Investigative
DMIAYTP SN 4-(5-AMINO-4-OXO-4H-PYRAZOL-3-YL)-2-BROMO-4,5,6,7-TETRAHYDRO-3AH-PYRROLO[2,3-C]AZEPIN-8-ONE; AC1L1GFH; CTK5I6002; 4-(2-amino-4-oxo-4h-imidazol-5-yl)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8(3ah)-one; 4-(2-amino-5-oxoimidazol-4-yl)-2-bromo-4,5,6,7-tetrahydro-3aH-pyrrolo[2,3-c]azepin-8-one; (3aR,4S)-4-(2-amino-4-oxo-4H-imidazol-5-yl)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8(3aH)-one
DMIAYTP DT Small molecular drug
DMIAYTP PC 3660
DMIAYTP MW 324.13
DMIAYTP FM C11H10BrN5O2
DMIAYTP IC InChI=1S/C11H10BrN5O2/c12-6-3-5-4(7-10(19)17-11(13)16-7)1-2-14-9(18)8(5)15-6/h3-5H,1-2H2,(H,14,18)(H2,13,17,19)
DMIAYTP CS C1CNC(=O)C2=NC(=CC2C1C3=NC(=NC3=O)N)Br
DMIAYTP IK QPCBNXNDVYOBIP-UHFFFAOYSA-N
DMIAYTP IU 4-(2-amino-5-oxoimidazol-4-yl)-2-bromo-4,5,6,7-tetrahydro-3aH-pyrrolo[2,3-c]azepin-8-one
DMIAYTP DE Discovery agent
DMRQ70X ID DMRQ70X
DMRQ70X DN ACMC-1AKLT
DMRQ70X HS Investigative
DMRQ70X SN Maybridge1_006885; PubChem8688; SCHEMBL307508; ZINC57916; 2H-1-Benzopyran-2-one, 7-hydroxy-4-(trifluoromethyl)-; 4-(Trifluoromethyl)umbelliferone; 4-(trifluoromethyl)umbeilliferone; 575-03-1; 7,4-Hfc; 7-Hydroxy-4-(trifluoromethyl)-2H-chromen-2-one; 7-Hydroxy-4-(trifluoromethyl)coumarin; 7-Hydroxy-4-trifluoromethyl-chromen-2-one; 7-Hydroxy-4-trifluoromethylcoumarin; 7-hydroxy-4-(trifluoromethyl)chromen-2-one; AC1NT9P6; AC1Q795W; CCKWMCUOHJAVOL-UHFFFAOYSA-N; CHEMBL104679; CTK5A6979; HMS561A21; MFCD00037578; TFMU
DMRQ70X PC 5375667
DMRQ70X MW 230.14
DMRQ70X FM C10H5F3O3
DMRQ70X IC CCKWMCUOHJAVOL-UHFFFAOYSA-N
DMRQ70X CS C1=CC2=C(C=C1O)OC(=O)C=C2C(F)(F)F
DMRQ70X IK 1S/C10H5F3O3/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4,14H
DMRQ70X IU 7-hydroxy-4-(trifluoromethyl)chromen-2-one
DMRQ70X CA CAS 575-03-1
DMRQ70X DE Discovery agent
DMQCSFB ID DMQCSFB
DMQCSFB DN ACMC-209cv7
DMQCSFB HS Investigative
DMQCSFB SN Ketone, phenyl 4-pyridyl; Methanone, phenyl-4-pyridinyl-; Phenyl 4-pyridyl ketone; Phenyl(4-pyridinyl)methanone; Pyridine, 4-benzoyl-; SKFLCXNDKRUHTA-UHFFFAOYSA-N; WLN: T6NJ DVR; gamma-Benzoylpyridine; phenyl 4-pyridinyl ketone; phenyl(pyridin-4-yl)methanone; .gamma.-Benzoylpyridine; 14548-46-0; 4-Benzoylpyridine; 4-Benzoylpyridine, 98%; 4-Pyridyl phenyl ketone; ChemDiv2_000073; 4-benzoyl pyridine; 524YQ3O21T; AC1L1BRW; AC1Q5CWK; BRN 0003864; Ba 33215; EINECS 238-586-7; NSC 9488; UNII-524YQ3O21T
DMQCSFB PC 26731
DMQCSFB MW 183.21
DMQCSFB FM C12H9NO
DMQCSFB IC SKFLCXNDKRUHTA-UHFFFAOYSA-N
DMQCSFB CS C1=CC=C(C=C1)C(=O)C2=CC=NC=C2
DMQCSFB IK 1S/C12H9NO/c14-12(10-4-2-1-3-5-10)11-6-8-13-9-7-11/h1-9H
DMQCSFB IU phenyl(pyridin-4-yl)methanone
DMQCSFB CA CAS 14548-46-0
DMQCSFB DE Discovery agent
DM3E4QR ID DM3E4QR
DM3E4QR DN ACN-1052
DM3E4QR HS Investigative
DM3E4QR SN Adenosine A3 antagonists (ophthalmic, glaucoma), Acorn
DM3E4QR CP Acorn Biomedical Inc
DM3E4QR DE Glaucoma/ocular hypertension
DMLYGPW ID DMLYGPW
DMLYGPW DN Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2
DMLYGPW HS Investigative
DMLYGPW SN CHEMBL194552; BDBM50268798
DMLYGPW PC 16724004
DMLYGPW MW 1015.2
DMLYGPW FM C53H66N12O9
DMLYGPW IC InChI=1S/C53H66N12O9/c1-3-4-15-40(59-31(2)66)48(69)62-43-27-46(67)56-21-10-9-17-39(47(54)68)60-49(70)41(25-35-28-57-38-16-8-7-14-37(35)38)63-52(73)45-18-11-22-65(45)53(74)44(24-32-19-20-33-12-5-6-13-34(33)23-32)64-50(71)42(61-51(43)72)26-36-29-55-30-58-36/h5-8,12-14,16,19-20,23,28-30,39-45,57H,3-4,9-11,15,17-18,21-22,24-27H2,1-2H3,(H2,54,68)(H,55,58)(H,56,67)(H,59,66)(H,60,70)(H,61,72)(H,62,69)(H,63,73)(H,64,71)/t39-,40-,41-,42-,43-,44+,45-/m0/s1
DMLYGPW CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)[C@@H](NC1=O)CC3=CN=CN3)CC4=CC5=CC=CC=C5C=C4)CC6=CNC7=CC=CC=C76)C(=O)N)NC(=O)C
DMLYGPW IK NUEQNUVEEKTGQM-GTBIJRGCSA-N
DMLYGPW IU (3R,6S,9S,17S,20S,23S)-9-[[(2S)-2-acetamidohexanoyl]amino]-6-(1H-imidazol-5-ylmethyl)-20-(1H-indol-3-ylmethyl)-3-(naphthalen-2-ylmethyl)-2,5,8,11,19,22-hexaoxo-1,4,7,12,18,21-hexazabicyclo[21.3.0]hexacosane-17-carboxamide
DMLYGPW DE Discovery agent
DMOVI7Y ID DMOVI7Y
DMOVI7Y DN Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2
DMOVI7Y HS Investigative
DMOVI7Y PC 44366173
DMOVI7Y MW 1074.2
DMOVI7Y FM C54H71N15O9
DMOVI7Y IC InChI=1S/C54H71N15O9/c1-3-4-15-40(63-31(2)70)48(73)69-45-27-46(71)59-21-10-9-17-39(47(55)72)64-51(76)43(25-35-28-61-38-16-8-7-14-37(35)38)67-49(74)41(18-11-22-60-54(56)57)65-50(75)42(24-32-19-20-33-12-5-6-13-34(33)23-32)66-52(77)44(68-53(45)78)26-36-29-58-30-62-36/h5-8,12-14,16,19-20,23,28-30,39-45,61H,3-4,9-11,15,17-18,21-22,24-27H2,1-2H3,(H2,55,72)(H,58,62)(H,59,71)(H,63,70)(H,64,76)(H,65,75)(H,66,77)(H,67,74)(H,68,78)(H,69,73)(H4,56,57,60)/t39-,40+,41+,42-,43-,44?,45+/m0/s1
DMOVI7Y CS CCCC[C@H](C(=O)N[C@@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC4=CC=CC=C4C=C3)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N)NC(=O)C
DMOVI7Y IK GGYWLZFXFKFWKL-ZCMLEEDBSA-N
DMOVI7Y IU (3S,6R,9S,15R,23S)-15-[[(2R)-2-acetamidohexanoyl]amino]-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-9-(naphthalen-2-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
DMOVI7Y DE Discovery agent
DMG418C ID DMG418C
DMG418C DN AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2
DMG418C HS Investigative
DMG418C SN CHEMBL501642; AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2
DMG418C DT Small molecular drug
DMG418C PC 44158031
DMG418C MW 965.1
DMG418C FM C49H64N12O9
DMG418C IC InChI=1S/C49H64N12O9/c1-3-4-16-36(55-29(2)62)44(65)58-39-25-42(63)52-20-11-10-18-35(43(50)64)56-45(66)37(23-31-26-53-34-17-9-8-15-33(31)34)59-48(69)41-19-12-21-61(41)49(70)40(22-30-13-6-5-7-14-30)60-46(67)38(57-47(39)68)24-32-27-51-28-54-32/h5-9,13-15,17,26-28,35-41,53H,3-4,10-12,16,18-25H2,1-2H3,(H2,50,64)(H,51,54)(H,52,63)(H,55,62)(H,56,66)(H,57,68)(H,58,65)(H,59,69)(H,60,67)/t35-,36-,37-,38-,39-,40+,41-/m0/s1
DMG418C CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)[C@@H](NC1=O)CC3=CN=CN3)CC4=CC=CC=C4)CC5=CNC6=CC=CC=C65)C(=O)N)NC(=O)C
DMG418C IK ZHWWUNQUSCAJKE-CQPWUTEUSA-N
DMG418C IU (3R,6S,9S,17S,20S,23S)-9-[[(2S)-2-acetamidohexanoyl]amino]-3-benzyl-6-(1H-imidazol-5-ylmethyl)-20-(1H-indol-3-ylmethyl)-2,5,8,11,19,22-hexaoxo-1,4,7,12,18,21-hexazabicyclo[21.3.0]hexacosane-17-carboxamide
DMG418C DE Discovery agent
DMZBOQW ID DMZBOQW
DMZBOQW DN AcNPY(25-36)
DMZBOQW HS Investigative
DMZBOQW PC 91936053
DMZBOQW MW 1698.9
DMZBOQW FM C76H119N27O18
DMZBOQW IC InChI=1S/C76H119N27O18/c1-6-40(4)61-73(121)97-52(68(116)93-49(14-10-30-89-75(82)83)64(112)96-51(24-26-58(77)107)67(115)94-50(15-11-31-90-76(84)85)65(113)98-53(62(79)110)33-42-16-20-45(105)21-17-42)25-27-60(109)87-28-8-7-12-48(66(114)102-57(36-59(78)108)71(119)99-54(32-39(2)3)72(120)103-61)95-69(117)55(34-43-18-22-46(106)23-19-43)100-70(118)56(35-44-37-86-38-91-44)101-63(111)47(92-41(5)104)13-9-29-88-74(80)81/h16-23,37-40,47-57,61,105-106H,6-15,24-36H2,1-5H3,(H2,77,107)(H2,78,108)(H2,79,110)(H,86,91)(H,87,109)(H,92,104)(H,93,116)(H,94,115)(H,95,117)(H,96,112)(H,97,121)(H,98,113)(H,99,119)(H,100,118)(H,101,111)(H,102,114)(H,103,120)(H4,80,81,88)(H4,82,83,89)(H4,84,85,90)/t40-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,61+/m1/s1
DMZBOQW CS CC[C@@H](C)[C@H]1C(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(C)C)CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N
DMZBOQW IK RDOFKMDVEDQFIJ-WQSAXVMWSA-N
DMZBOQW IU (2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,20S)-20-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-(2-amino-2-oxoethyl)-8-[(2R)-butan-2-yl]-5-(2-methylpropyl)-3,6,9,14,21-pentaoxo-1,4,7,10,15-pentazacyclohenicosane-11-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMZBOQW DE Discovery agent
DMQ0YW7 ID DMQ0YW7
DMQ0YW7 DN Acocantherin
DMQ0YW7 HS Investigative
DMQ0YW7 SN Ouabain; Ouabagenin L-Rhamnoside; Ouabagenin L-rhamnoside; Acocantherin; Acocantherine; Acolongifloroside K; Astrobain; G-Strophanthin; G-Strophanthin (JAN); G-Strophicor; Gratibain; Gratus strophanthin; Kombetin; O 3125; OBN; Ouabagenin-L-rhamnosid; Ouabagenin-L-rhamnosid [German]; Ouabain (anhydrous); Ouabain anhydrous; Ouabain octahydrate; Ouabain, Octahydrate; Ouabaine; Oubain; Purostrophan; Quabain; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
DMQ0YW7 TC Antiviral Agents
DMQ0YW7 DT Small molecular drug
DMQ0YW7 PC 439501
DMQ0YW7 MW 584.7
DMQ0YW7 FM C29H44O12
DMQ0YW7 IC InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
DMQ0YW7 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
DMQ0YW7 IK LPMXVESGRSUGHW-HBYQJFLCSA-N
DMQ0YW7 IU 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DMQ0YW7 CA CAS 630-60-4
DMQ0YW7 CB CHEBI:472805
DMQ0YW7 DE Atrial fibrillation; Heart failure; Middle East Respiratory Syndrome (MERS)
DMJ5U8C ID DMJ5U8C
DMJ5U8C DN Aconitate Ion
DMJ5U8C HS Investigative
DMJ5U8C SN Aconitate Ion; (E)-prop-1-ene-1,2,3-tricarboxylate; (1E)-prop-1-ene-1,2,3-tricarboxylate; trans-aconitate(3-); AC1NRDE4
DMJ5U8C DT Small molecular drug
DMJ5U8C PC 5459816
DMJ5U8C MW 171.08
DMJ5U8C FM C6H3O6-3
DMJ5U8C IC InChI=1S/C6H6O6/c7-4(8)1-3(6(11)12)2-5(9)10/h1H,2H2,(H,7,8)(H,9,10)(H,11,12)/p-3/b3-1-
DMJ5U8C CS C(/C(=C/C(=O)[O-])/C(=O)[O-])C(=O)[O-]
DMJ5U8C IK GTZCVFVGUGFEME-IWQZZHSRSA-K
DMJ5U8C IU (Z)-prop-1-ene-1,2,3-tricarboxylate
DMJ5U8C CB CHEBI:16383
DMJ5U8C DE Discovery agent
DMFOZ60 ID DMFOZ60
DMFOZ60 DN aconitine
DMFOZ60 HS Investigative
DMFOZ60 SN aconitine; 302-27-2; CHEBI:2430; Acetylbenzoylaconine; NSC56464; 20-ethyl-3alpha,13,15alpha-trihydroxy-1alpha,6alpha,16beta-trimethoxy-4-(methoxymethyl)aconitane-8,14alpha-diyl 8-acetate 14-benzoate; 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate; NCGC00163146-01; CAS-302-27-2; DSSTox_RID_81535; DSSTox_CID_26319; SCHEMBL73323; DSSTox_GSID_46319; GTPL2617; DTXSID4046319; CHEMBL1979562; MolPort-002-527-310; Tox21_112015; NSC-56464; AKOS032428256
DMFOZ60 DT Small molecular drug
DMFOZ60 PC 245005
DMFOZ60 MW 645.7
DMFOZ60 FM C34H47NO11
DMFOZ60 IC InChI=1S/C34H47NO11/c1-7-35-15-31(16-41-3)20(37)13-21(42-4)33-19-14-32(40)28(45-30(39)18-11-9-8-10-12-18)22(19)34(46-17(2)36,27(38)29(32)44-6)23(26(33)35)24(43-5)25(31)33/h8-12,19-29,37-38,40H,7,13-16H2,1-6H3/t19-,20-,21+,22-,23+,24+,25-,26?,27+,28-,29+,31+,32-,33+,34-/m1/s1
DMFOZ60 CS CCN1C[C@@]2([C@@H](C[C@@H]([C@@]34[C@@H]2[C@H]([C@@H](C31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC
DMFOZ60 IK XFSBVAOIAHNAPC-XTHSEXKGSA-N
DMFOZ60 IU [(1S,2R,3R,4R,5R,6S,7S,8R,9R,13R,14R,16S,17S,18R)-8-acetyloxy-11-ethyl-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate
DMFOZ60 CA CAS 302-27-2
DMFOZ60 CB CHEBI:2430
DMFOZ60 DE Discovery agent
DMBVHLT ID DMBVHLT
DMBVHLT DN ACP-106
DMBVHLT HS Investigative
DMBVHLT SN 5-HT2A inverse agonists (CNS disorders/sleep disorders), ACADIA
DMBVHLT CP ACADIA Pharmaceuticals Inc
DMBVHLT DE Central nervous system disease
DMAZLWR ID DMAZLWR
DMAZLWR DN ACPC
DMAZLWR HS Investigative
DMAZLWR SN 1-Aminocyclopropanecarboxylic acid
DMAZLWR DE Neurological disorder
DM6ONY7 ID DM6ONY7
DM6ONY7 DN Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2
DM6ONY7 HS Investigative
DM6ONY7 SN CHEMBL436759; Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2
DM6ONY7 DT Small molecular drug
DM6ONY7 PC 44409555
DM6ONY7 MW 823.8
DM6ONY7 FM C39H50N7O11P
DM6ONY7 IC InChI=1S/C39H50N7O11P/c1-23(57-58(54,55)56)34(45-37(51)30(42-24(2)47)21-25-10-4-3-5-11-25)39(53)46-19-9-8-14-32(46)38(52)44-31(36(50)43-29(35(41)49)17-18-33(40)48)22-26-15-16-27-12-6-7-13-28(27)20-26/h3-7,10-13,15-16,20,23,29-32,34H,8-9,14,17-19,21-22H2,1-2H3,(H2,40,48)(H2,41,49)(H,42,47)(H,43,50)(H,44,52)(H,45,51)(H2,54,55,56)/t23-,29-,30-,31-,32+,34+/m0/s1
DM6ONY7 CS C[C@@H]([C@H](C(=O)N1CCCC[C@@H]1C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)C)OP(=O)(O)O
DM6ONY7 IK KZSGJDBAWAUUMC-DHQPFQMDSA-N
DM6ONY7 IU [(2S,3R)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[(2R)-2-[[(2S)-1-[[(2S)-1,5-diamino-1,5-dioxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutan-2-yl] dihydrogen phosphate
DM6ONY7 DE Discovery agent
DMDXBQA ID DMDXBQA
DMDXBQA DN Ac-Phe-Phe-NH2
DMDXBQA HS Investigative
DMDXBQA SN CHEMBL464178; Ac-Phe-Phe-NH2; Ac-(Phe)2-CONH2; BDBM50308387; N-acetyl-l-phenylalanyl-l-phenylalanine amide
DMDXBQA DT Small molecular drug
DMDXBQA PC 11100291
DMDXBQA MW 353.4
DMDXBQA FM C20H23N3O3
DMDXBQA IC InChI=1S/C20H23N3O3/c1-14(24)22-18(13-16-10-6-3-7-11-16)20(26)23-17(19(21)25)12-15-8-4-2-5-9-15/h2-11,17-18H,12-13H2,1H3,(H2,21,25)(H,22,24)(H,23,26)/t17-,18-/m0/s1
DMDXBQA CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N
DMDXBQA IK MRIDWVSVNKEVEJ-ROUUACIJSA-N
DMDXBQA IU (2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-3-phenylpropanamide
DMDXBQA DE Discovery agent
DMSWTPX ID DMSWTPX
DMSWTPX DN Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSWTPX HS Investigative
DMSWTPX SN CHEMBL383244; Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2
DMSWTPX DT Small molecular drug
DMSWTPX PC 44409591
DMSWTPX MW 823.8
DMSWTPX FM C39H50N7O11P
DMSWTPX IC InChI=1S/C39H50N7O11P/c1-23(57-58(54,55)56)34(45-37(51)30(42-24(2)47)21-25-10-4-3-5-11-25)39(53)46-19-9-8-14-32(46)38(52)44-31(36(50)43-29(35(41)49)17-18-33(40)48)22-26-15-16-27-12-6-7-13-28(27)20-26/h3-7,10-13,15-16,20,23,29-32,34H,8-9,14,17-19,21-22H2,1-2H3,(H2,40,48)(H2,41,49)(H,42,47)(H,43,50)(H,44,52)(H,45,51)(H2,54,55,56)/t23-,29-,30-,31-,32+,34-/m0/s1
DMSWTPX CS C[C@@H]([C@@H](C(=O)N1CCCC[C@@H]1C(=O)N[C@@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)C)OP(=O)(O)O
DMSWTPX IK KZSGJDBAWAUUMC-UHZLREMTSA-N
DMSWTPX IU [(2S,3S)-3-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-[(2R)-2-[[(2S)-1-[[(2S)-1,5-diamino-1,5-dioxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutan-2-yl] dihydrogen phosphate
DMSWTPX DE Discovery agent
DM264XN ID DM264XN
DM264XN DN ACPT-I
DM264XN HS Investigative
DM264XN SN 1-aminocyclopentane-1,3,4-tricarboxylic acid
DM264XN DT Small molecular drug
DM264XN PC 6604820
DM264XN MW 217.18
DM264XN FM C8H11NO6
DM264XN IC InChI=1S/C8H11NO6/c9-8(7(14)15)1-3(5(10)11)4(2-8)6(12)13/h3-4H,1-2,9H2,(H,10,11)(H,12,13)(H,14,15)/t3-,4+,8?
DM264XN CS C1[C@H]([C@H](CC1(C(=O)O)N)C(=O)O)C(=O)O
DM264XN IK FERIKTBTNCSGJS-OBLUMXEWSA-N
DM264XN IU (1R,2S)-4-aminocyclopentane-1,2,4-tricarboxylic acid
DM264XN DE Discovery agent
DMDEFPS ID DMDEFPS
DMDEFPS DN AcPYY(22-36)
DMDEFPS HS Investigative
DMDEFPS PC 44342691
DMDEFPS MW 1931.2
DMDEFPS FM C86H139N29O22
DMDEFPS IC InChI=1S/C86H139N29O22/c1-41(2)31-58(109-81(135)64(39-116)113-70(124)45(9)101-47(11)118)75(129)103-54(16-13-29-98-85(92)93)73(127)111-62(36-50-38-96-40-100-50)78(132)110-61(35-49-20-24-52(120)25-21-49)77(131)107-59(32-42(3)4)76(130)112-63(37-66(88)122)79(133)108-60(33-43(5)6)80(134)114-67(44(7)8)82(136)115-68(46(10)117)83(137)105-55(17-14-30-99-86(94)95)71(125)104-56(26-27-65(87)121)74(128)102-53(15-12-28-97-84(90)91)72(126)106-57(69(89)123)34-48-18-22-51(119)23-19-48/h18-25,38,40-46,53-64,67-68,116-117,119-120H,12-17,26-37,39H2,1-11H3,(H2,87,121)(H2,88,122)(H2,89,123)(H,96,100)(H,101,118)(H,102,128)(H,103,129)(H,104,125)(H,105,137)(H,106,126)(H,107,131)(H,108,133)(H,109,135)(H,110,132)(H,111,127)(H,112,130)(H,113,124)(H,114,134)(H,115,136)(H4,90,91,97)(H4,92,93,98)(H4,94,95,99)/t45-,46+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,67-,68-/m0/s1
DMDEFPS CS C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)C)O
DMDEFPS IK NDQIPMDOGHILHE-UXUJTPOBSA-N
DMDEFPS IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamidopropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMDEFPS DE Discovery agent
DMRSU2K ID DMRSU2K
DMRSU2K DN AcPYY(25-36)
DMRSU2K HS Investigative
DMRSU2K PC 91936052
DMRSU2K MW 1659.9
DMRSU2K FM C74H118N26O18
DMRSU2K IC InChI=1S/C74H118N26O18/c1-36(2)28-51(94-66(113)53(31-42-17-21-45(104)22-18-42)96-67(114)54(32-43-34-84-35-88-43)97-61(108)46(89-40(8)102)12-9-25-85-72(78)79)65(112)98-55(33-57(76)106)68(115)95-52(29-37(3)4)69(116)99-58(38(5)6)70(117)100-59(39(7)101)71(118)92-48(14-11-27-87-74(82)83)62(109)91-49(23-24-56(75)105)64(111)90-47(13-10-26-86-73(80)81)63(110)93-50(60(77)107)30-41-15-19-44(103)20-16-41/h15-22,34-39,46-55,58-59,101,103-104H,9-14,23-33H2,1-8H3,(H2,75,105)(H2,76,106)(H2,77,107)(H,84,88)(H,89,102)(H,90,111)(H,91,109)(H,92,118)(H,93,110)(H,94,113)(H,95,115)(H,96,114)(H,97,108)(H,98,112)(H,99,116)(H,100,117)(H4,78,79,85)(H4,80,81,86)(H4,82,83,87)/t39-,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,58+,59+/m1/s1
DMRSU2K CS C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)O
DMRSU2K IK AQWCJJKYINAYIM-QIRMFHLNSA-N
DMRSU2K IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMRSU2K DE Discovery agent
DM7RELC ID DM7RELC
DM7RELC DN AcPYY(26-36)
DM7RELC HS Investigative
DM7RELC SN CHEMBL397527
DM7RELC PC 44439563
DM7RELC MW 1503.7
DM7RELC FM C68H106N22O17
DM7RELC IC InChI=1S/C68H106N22O17/c1-33(2)25-47(85-61(102)49(28-39-15-19-42(94)20-16-39)87-62(103)50(80-37(8)92)29-40-31-76-32-79-40)60(101)88-51(30-53(70)96)63(104)86-48(26-34(3)4)64(105)89-54(35(5)6)65(106)90-55(36(7)91)66(107)83-44(12-10-24-78-68(74)75)57(98)82-45(21-22-52(69)95)59(100)81-43(11-9-23-77-67(72)73)58(99)84-46(56(71)97)27-38-13-17-41(93)18-14-38/h13-20,31-36,43-51,54-55,91,93-94H,9-12,21-30H2,1-8H3,(H2,69,95)(H2,70,96)(H2,71,97)(H,76,79)(H,80,92)(H,81,100)(H,82,98)(H,83,107)(H,84,99)(H,85,102)(H,86,104)(H,87,103)(H,88,101)(H,89,105)(H,90,106)(H4,72,73,77)(H4,74,75,78)/t36-,43+,44+,45+,46+,47+,48+,49+,50+,51+,54+,55+/m1/s1
DM7RELC CS C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)C)O
DM7RELC IK JFWAFYNFTBNEPH-XATDXXKLSA-N
DM7RELC IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DM7RELC DE Discovery agent
DMBFUD0 ID DMBFUD0
DMBFUD0 DN Ac-R[CEHdFRWC]-NH2
DMBFUD0 HS Investigative
DMBFUD0 SN CHEMBL408257; Ac-R[CEHdFRWC]-NH2
DMBFUD0 PC 44400401
DMBFUD0 MW 1175.4
DMBFUD0 FM C51H70N18O11S2
DMBFUD0 IC InChI=1S/C51H70N18O11S2/c1-27(70)62-33(13-7-17-58-50(53)54)43(74)69-40-25-82-81-24-39(42(52)73)68-47(78)37(20-29-22-60-32-12-6-5-11-31(29)32)66-44(75)34(14-8-18-59-51(55)56)63-46(77)36(19-28-9-3-2-4-10-28)65-48(79)38(21-30-23-57-26-61-30)67-45(76)35(64-49(40)80)15-16-41(71)72/h2-6,9-12,22-23,26,33-40,60H,7-8,13-21,24-25H2,1H3,(H2,52,73)(H,57,61)(H,62,70)(H,63,77)(H,64,80)(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,74)(H,71,72)(H4,53,54,58)(H4,55,56,59)/t33-,34-,35+,36-,37+,38-,39+,40+/m1/s1
DMBFUD0 CS CC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCC(=O)O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DMBFUD0 IK UNXFCHHFXJFRRB-VYZFECEFSA-N
DMBFUD0 IU 3-[(4R,7S,10R,13R,16R,19S,22R)-22-[[(2R)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMBFUD0 DE Discovery agent
DMYZJ5B ID DMYZJ5B
DMYZJ5B DN Acriflavinium chloride
DMYZJ5B HS Investigative
DMYZJ5B SN Acriflavine (component of); Acriflavon; Burnol; Chromoflavine; Flavine; Flavosan; Gonacrine; Gonocrin; Neutroflavine; Panflavin; Trypaflavin; Xanthacridine; ACRIFLAVINIUM HYDROCHLORIDE; 10-methylacridine-3,6-diamine, chloride; 1TW3Q60E36; 3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE; 3,6-diamino-10-methylacridin-10-ium chloride; 86-40-8; Acridinium, 3,6-diamino-10-methyl-, chloride; Acridinium, 3,6-diamino-10-methyl-, chloride (1:1); Avlon; C.I. 46000; CCRIS 2116; CHEBI:383703; EINECS 201-668-8; NSC 2755; NSC2755; UNII-1TW3Q60E36
DMYZJ5B PC 6842
DMYZJ5B MW 259.73
DMYZJ5B FM C14H14ClN3
DMYZJ5B IC KKAJSJJFBSOMGS-UHFFFAOYSA-N
DMYZJ5B CS C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.[Cl-]
DMYZJ5B IK 1S/C14H13N3.ClH/c1-17-13-7-11(15)4-2-9(13)6-10-3-5-12(16)8-14(10)17;/h2-8H,1H3,(H3,15,16);1H
DMYZJ5B IU 10-methylacridin-10-ium-3,6-diamine;chloride
DMYZJ5B CA CAS 86-40-8
DMYZJ5B CB CHEBI:383703
DMYZJ5B DE Trypanosomiasis
DMAMCSR ID DMAMCSR
DMAMCSR DN acrolein
DMAMCSR HS Investigative
DMAMCSR SN ACROLEIN; Acrylaldehyde; 2-Propenal; Propenal; 107-02-8; Acrylic aldehyde; Allyl aldehyde; prop-2-enal; Ethylene aldehyde; Acraldehyde; Aqualin; Magnacide H; 2-Propen-1-one; Aqualine; Slimicide; Crolean; Acquinite; Magnacide; Prop-2-en-1-al; Acrylaldehyd; Akroleina; Akrolein; Acroleine; Acroleina; Papite; Biocide; Aldeide acrilica; Aldehyde acrylique; Acraldehydeacroleina; polyacrolein; Propenaldehyde; trans-Acrolein; NSC 8819; Akrolein [Czech]; Propenal [Czech]; Rcra waste number P003; Magnacide H and B; Akroleina [Polish]; Acroleina [Italian]
DMAMCSR DT Small molecular drug
DMAMCSR PC 7847
DMAMCSR MW 56.06
DMAMCSR FM C3H4O
DMAMCSR IC InChI=1S/C3H4O/c1-2-3-4/h2-3H,1H2
DMAMCSR CS C=CC=O
DMAMCSR IK HGINCPLSRVDWNT-UHFFFAOYSA-N
DMAMCSR IU prop-2-enal
DMAMCSR CA CAS 107-02-8
DMAMCSR CB CHEBI:15368
DMAMCSR DE Discovery agent
DM512OP ID DM512OP
DM512OP DN Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG
DM512OP HS Investigative
DM512OP SN CHEMBL414736; Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG
DM512OP PC 44416159
DM512OP MW 2138.4
DM512OP FM C100H144N28O25
DM512OP IC InChI=1S/C100H144N28O25/c1-5-56(2)85(127-93(148)72(21-14-42-110-100(106)107)121-94(149)74(46-61-25-33-65(132)34-26-61)125-95(150)75(47-62-27-35-66(133)36-28-62)124-92(147)71(118-58(4)130)20-13-41-109-99(104)105)97(152)122-70(19-9-11-39-101)89(144)114-51-81(137)112-50-80(136)113-53-83(139)119-69(86(103)141)18-10-12-40-108-79(135)49-111-82(138)52-115-91(146)77(55-129)126-96(151)78-22-15-43-128(78)98(153)76(48-63-29-37-67(134)38-30-63)120-84(140)54-116-90(145)73(45-59-16-7-6-8-17-59)123-87(142)57(3)117-88(143)68(102)44-60-23-31-64(131)32-24-60/h6-8,16-17,23-38,56-57,68-78,85,129,131-134H,5,9-15,18-22,39-55,101-102H2,1-4H3,(H2,103,141)(H,108,135)(H,111,138)(H,112,137)(H,113,136)(H,114,144)(H,115,146)(H,116,145)(H,117,143)(H,118,130)(H,119,139)(H,120,140)(H,121,149)(H,122,152)(H,123,142)(H,124,147)(H,125,150)(H,126,151)(H,127,148)(H4,104,105,109)(H4,106,107,110)/t56-,57-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,85-/m0/s1
DM512OP CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DM512OP IK JSLWGMSGFRFMOR-GCASCPCBSA-N
DM512OP IU (2S)-N-[(2S)-1-[[2-[[2-[[(5S)-5-[[2-[[2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-aminohexanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-6-amino-6-oxohexyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM512OP DE Discovery agent
DMAHQIV ID DMAHQIV
DMAHQIV DN Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG
DMAHQIV HS Investigative
DMAHQIV SN CHEMBL441930; Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG
DMAHQIV PC 44416445
DMAHQIV MW 1848.1
DMAHQIV FM C85H130N28O19
DMAHQIV IC InChI=1S/C85H130N28O19/c1-3-49(2)72(113-79(129)62(20-13-38-100-85(94)95)108-80(130)65(43-53-25-31-56(116)32-26-53)112-81(131)64(42-52-23-29-55(115)30-24-52)110-74(124)57(87)16-11-36-98-83(90)91)82(132)109-60(18-7-9-34-86)76(126)105-47-70(121)103-46-69(120)104-48-71(122)106-59(73(89)123)17-8-10-35-96-67(118)44-102-68(119)45-101-66(117)33-39-97-77(127)63(41-50-14-5-4-6-15-50)111-78(128)61(19-12-37-99-84(92)93)107-75(125)58(88)40-51-21-27-54(114)28-22-51/h4-6,14-15,21-32,49,57-65,72,114-116H,3,7-13,16-20,33-48,86-88H2,1-2H3,(H2,89,123)(H,96,118)(H,97,127)(H,101,117)(H,102,119)(H,103,121)(H,104,120)(H,105,126)(H,106,122)(H,107,125)(H,108,130)(H,109,132)(H,110,124)(H,111,128)(H,112,131)(H,113,129)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t49-,57-,58-,59-,60-,61+,62-,63-,64-,65-,72-/m0/s1
DMAHQIV CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)CCNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCN=C(N)N)N
DMAHQIV IK FJZYPQNKFGDFEG-NWGZXSTASA-N
DMAHQIV IU (2S)-6-amino-N-[2-[[2-[[2-[[(2S)-1-amino-6-[[2-[[2-[3-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]propanoylamino]acetyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-2-oxoethyl]-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMAHQIV DE Discovery agent
DM2ND3U ID DM2ND3U
DM2ND3U DN Ac-RYYRIK-K-(NH2)-YAFGYPS
DM2ND3U HS Investigative
DM2ND3U SN CHEMBL404792; Ac-RYYRIK-K-(NH2)-YAFGYPS
DM2ND3U PC 44416158
DM2ND3U MW 1853.1
DM2ND3U FM C90H129N23O20
DM2ND3U IC InChI=1S/C90H129N23O20/c1-5-51(2)75(112-83(128)67(21-14-42-100-90(96)97)106-84(129)69(46-56-25-33-60(117)34-26-56)110-85(130)70(47-57-27-35-61(118)36-28-57)109-81(126)65(103-53(4)115)20-13-41-99-89(94)95)87(132)107-66(19-9-11-39-91)82(127)105-64(76(93)121)18-10-12-40-98-80(125)72(50-114)111-86(131)73-22-15-43-113(73)88(133)71(48-58-29-37-62(119)38-30-58)104-74(120)49-101-79(124)68(45-54-16-7-6-8-17-54)108-77(122)52(3)102-78(123)63(92)44-55-23-31-59(116)32-24-55/h6-8,16-17,23-38,51-52,63-73,75,114,116-119H,5,9-15,18-22,39-50,91-92H2,1-4H3,(H2,93,121)(H,98,125)(H,101,124)(H,102,123)(H,103,115)(H,104,120)(H,105,127)(H,106,129)(H,107,132)(H,108,122)(H,109,126)(H,110,130)(H,111,131)(H,112,128)(H4,94,95,99)(H4,96,97,100)/t51-,52-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,75-/m0/s1
DM2ND3U CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DM2ND3U IK DHDRBUQCZPZXNW-IJPMLFLGSA-N
DM2ND3U IU (2S)-N-[(2S)-1-[[(5S)-5-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-amino-6-oxohexyl]amino]-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM2ND3U DE Discovery agent
DMNA3F4 ID DMNA3F4
DMNA3F4 DN Ac-RYYRIK-K-(NH2)-YRFB
DMNA3F4 HS Investigative
DMNA3F4 SN CHEMBL412939; Ac-RYYRIK-K-(NH2)-YRFB
DMNA3F4 PC 44416444
DMNA3F4 MW 1604.9
DMNA3F4 FM C77H117N23O15
DMNA3F4 IC InChI=1S/C77H117N23O15/c1-4-45(2)64(100-71(112)59(21-14-39-91-77(85)86)95-72(113)61(43-49-24-30-52(103)31-25-49)99-73(114)62(44-50-26-32-53(104)33-27-50)98-68(109)56(92-46(3)101)19-12-37-89-75(81)82)74(115)96-57(18-8-10-35-78)69(110)93-55(65(80)106)17-9-11-36-87-63(105)34-40-88-67(108)60(42-47-15-6-5-7-16-47)97-70(111)58(20-13-38-90-76(83)84)94-66(107)54(79)41-48-22-28-51(102)29-23-48/h5-7,15-16,22-33,45,54-62,64,102-104H,4,8-14,17-21,34-44,78-79H2,1-3H3,(H2,80,106)(H,87,105)(H,88,108)(H,92,101)(H,93,110)(H,94,107)(H,95,113)(H,96,115)(H,97,111)(H,98,109)(H,99,114)(H,100,112)(H4,81,82,89)(H4,83,84,90)(H4,85,86,91)/t45-,54-,55-,56-,57-,58+,59-,60-,61-,62-,64-/m0/s1
DMNA3F4 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCNC(=O)CCNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMNA3F4 IK XLFHOYFYEWSAKV-OKFGKCNJSA-N
DMNA3F4 IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-amino-N-[(2S)-1-amino-6-[3-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]propanoylamino]-1-oxohexan-2-yl]hexanamide
DMNA3F4 DE Discovery agent
DMI87UE ID DMI87UE
DMI87UE DN Ac-RYYRIK-NH2
DMI87UE HS Investigative
DMI87UE SN Ac-RYYRIK-NH2; 200959-48-4; CHEMBL437723; Ac-Arg-Tyr-Tyr-Arg-Ile-Lys-NH(2); acetyl-Arg-Tyr-Tyr-Arg-Ile-Lys-NH(2); Ac-RYYRIK-NH; BDBM85192; BDBM50190305; ZINC169289387; AKOS024456481; CA-1321; CAS_200959-48-4
DMI87UE DT Small molecular drug
DMI87UE PC 9963005
DMI87UE MW 939.1
DMI87UE FM C44H70N14O9
DMI87UE IC InChI=1S/C44H70N14O9/c1-4-25(2)36(42(67)54-31(37(46)62)9-5-6-20-45)58-39(64)33(11-8-22-52-44(49)50)55-40(65)34(23-27-12-16-29(60)17-13-27)57-41(66)35(24-28-14-18-30(61)19-15-28)56-38(63)32(53-26(3)59)10-7-21-51-43(47)48/h12-19,25,31-36,60-61H,4-11,20-24,45H2,1-3H3,(H2,46,62)(H,53,59)(H,54,67)(H,55,65)(H,56,63)(H,57,66)(H,58,64)(H4,47,48,51)(H4,49,50,52)/t25-,31-,32-,33-,34-,35-,36-/m0/s1
DMI87UE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C
DMI87UE IK WBBBVZGQADABSU-RERZDIOCSA-N
DMI87UE IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-6-aminohexanamide
DMI87UE DE Discovery agent
DM8XBR1 ID DM8XBR1
DM8XBR1 DN Ac-SFWKYS-NH2
DM8XBR1 HS Investigative
DM8XBR1 SN CHEMBL1163474
DM8XBR1 DT Small molecular drug
DM8XBR1 PC 10974939
DM8XBR1 MW 858
DM8XBR1 FM C43H55N9O10
DM8XBR1 IC InChI=1S/C43H55N9O10/c1-25(55)47-37(24-54)43(62)50-33(19-26-9-3-2-4-10-26)40(59)51-35(21-28-22-46-31-12-6-5-11-30(28)31)42(61)48-32(13-7-8-18-44)39(58)49-34(20-27-14-16-29(56)17-15-27)41(60)52-36(23-53)38(45)57/h2-6,9-12,14-17,22,32-37,46,53-54,56H,7-8,13,18-21,23-24,44H2,1H3,(H2,45,57)(H,47,55)(H,48,61)(H,49,58)(H,50,62)(H,51,59)(H,52,60)/t32-,33-,34-,35-,36-,37-/m0/s1
DM8XBR1 CS CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CO)C(=O)N
DM8XBR1 IK QNAVIRFMKUQHRS-DUGSHLAESA-N
DM8XBR1 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-N-[(2S)-1-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide
DM8XBR1 DE Discovery agent
DMPHSU8 ID DMPHSU8
DMPHSU8 DN ACTB-1003
DMPHSU8 HS Investigative
DMPHSU8 SN Multi-mode kinase inhibitor (oral, cancer), ACT Biotech; Multi-mode kinase inhibitor (oral, cancer), Bayer
DMPHSU8 CP Bayer AG
DMPHSU8 PC 23653175
DMPHSU8 MW 591.5
DMPHSU8 FM C27H26F5N7O3
DMPHSU8 IC InChI=1S/C27H26F5N7O3/c1-41-13-17-22(12-38-6-8-42-9-7-38)39-24(25(33)34-14-35-39)23(17)15-2-5-20(19(29)10-15)36-26(40)37-21-11-16(27(30,31)32)3-4-18(21)28/h2-5,10-11,14H,6-9,12-13H2,1H3,(H2,33,34,35)(H2,36,37,40)
DMPHSU8 CS COCC1=C(N2C(=C1C3=CC(=C(C=C3)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F)F)C(=NC=N2)N)CN5CCOCC5
DMPHSU8 IK GZPJCJKUZPUFAL-UHFFFAOYSA-N
DMPHSU8 IU 1-[4-[4-amino-6-(methoxymethyl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
DMPHSU8 CA CAS 939805-30-8
DMPHSU8 DE Solid tumour/cancer
DMXIDS9 ID DMXIDS9
DMXIDS9 DN ACTINOPLANIC ACID A
DMXIDS9 HS Investigative
DMXIDS9 SN CHEMBL100684; ACTINOPLANIC ACID A; SCHEMBL8909241; BDBM50059873; 3-Carboxy-pentanedioic acid mono-{(E)-10-[(14E,18Z)-4-carboxy-19-(6-carboxy-4-ethyl-3-oxo-heptyl)-12-hydroxy-11,13,15,17-tetramethyl-2,6-dioxo-1,7dioxa-cycloicosa-14,18-dien-8-yl]-1,4-dimethyl-dec-5-enyl} ester
DMXIDS9 DT Small molecular drug
DMXIDS9 PC 10102380
DMXIDS9 MW 949.2
DMXIDS9 FM C51H80O16
DMXIDS9 IC InChI=1S/C51H80O16/c1-9-39(25-36(7)49(59)60)43(52)21-19-38-24-33(4)22-32(3)23-35(6)48(58)34(5)17-20-42(67-47(57)29-41(51(63)64)27-45(55)65-30-38)15-13-11-10-12-14-31(2)16-18-37(8)66-46(56)28-40(50(61)62)26-44(53)54/h12,14,23-24,31,33-37,39-42,48,58H,9-11,13,15-22,25-30H2,1-8H3,(H,53,54)(H,59,60)(H,61,62)(H,63,64)/b14-12+,32-23+,38-24-
DMXIDS9 CS CCC(CC(C)C(=O)O)C(=O)CC/C/1=C/C(C/C(=C/C(C(C(CCC(OC(=O)CC(CC(=O)OC1)C(=O)O)CCCC/C=C/C(C)CCC(C)OC(=O)CC(CC(=O)O)C(=O)O)C)O)C)/C)C
DMXIDS9 IK ZJCPEIGQYKMZFE-PXQKRTIOSA-N
DMXIDS9 IU 2-[2-[(E)-11-[(14E,18Z)-4-carboxy-19-(6-carboxy-4-ethyl-3-oxoheptyl)-12-hydroxy-11,13,15,17-tetramethyl-2,6-dioxo-1,7-dioxacycloicosa-14,18-dien-8-yl]-5-methylundec-6-en-2-yl]oxy-2-oxoethyl]butanedioic acid
DMXIDS9 DE Discovery agent
DMIH5CD ID DMIH5CD
DMIH5CD DN Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3
DMIH5CD HS Investigative
DMIH5CD SN CHEMBL202699; Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3; BDBM50179459; (S)-2-{(R)-2-[(S)-2-acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoic acid ((S)-1-methylcarbamoyl-2-naphthalen-2-yl-ethyl)-amide
DMIH5CD DT Small molecular drug
DMIH5CD PC 44409240
DMIH5CD MW 736.9
DMIH5CD FM C40H48N8O6
DMIH5CD IC InChI=1S/C40H48N8O6/c1-25(49)45-34(23-27-15-18-31(50)19-16-27)38(53)48-35(22-26-9-4-3-5-10-26)39(54)46-32(13-8-20-44-40(41)42)37(52)47-33(36(51)43-2)24-28-14-17-29-11-6-7-12-30(29)21-28/h3-7,9-12,14-19,21,32-35,50H,8,13,20,22-24H2,1-2H3,(H,43,51)(H,45,49)(H,46,54)(H,47,52)(H,48,53)(H4,41,42,44)/t32-,33-,34-,35+/m0/s1
DMIH5CD CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NC
DMIH5CD IK QVTMGASDQFBYLJ-AYXCPNKJSA-N
DMIH5CD IU (2S)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)-N-[(2S)-1-(methylamino)-3-naphthalen-2-yl-1-oxopropan-2-yl]pentanamide
DMIH5CD DE Discovery agent
DM7ZWRN ID DM7ZWRN
DM7ZWRN DN ACU-0101979
DM7ZWRN HS Investigative
DM7ZWRN SN HuC091; ACU-5A5; ADDL formation inhibitors, Acumen/Merck; Anti-ADDL antibodies (Alzheimers disease); Anti-ADDL antibodies (Alzheimers disease), Acumen/Merck & Co; Anti-ADDL vaccines (Alzheimers disease), Acumen/Merck & Co
DM7ZWRN CP Acumen Pharmaceuticals Inc
DM7ZWRN DT Vaccine
DM7ZWRN DE Alzheimer disease
DMR2MUG ID DMR2MUG
DMR2MUG DN ACULEACIN A
DMR2MUG HS Investigative
DMR2MUG SN Aculeacin A; 58814-86-1; AC1Q6G0M; AC1L3U84; YKPHLXGEPNYRPY-UHFFFAOYSA-N; LS-14909; n-{23-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis(1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}hexadecanamide; Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N(sup 2)-(1-oxohexadecyl)-L-ornithine)-
DMR2MUG PC 14315169
DMR2MUG MW 1036.2
DMR2MUG FM C50H81N7O16
DMR2MUG IC InChI=1S/C50H81N7O16/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-36(63)51-33-24-35(62)46(69)55-48(71)40-41(64)27(2)25-57(40)50(73)38(29(4)59)53-47(70)39(43(66)42(65)30-19-21-31(60)22-20-30)54-45(68)34-23-32(61)26-56(34)49(72)37(28(3)58)52-44(33)67/h19-22,27-29,32-35,37-43,46,58-62,64-66,69H,5-18,23-26H2,1-4H3,(H,51,63)(H,52,67)(H,53,70)(H,54,68)(H,55,71)/t27-,28+,29+,32+,33-,34-,35+,37-,38-,39-,40-,41-,42-,43-,46+/m0/s1
DMR2MUG CS CCCCCCCCCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H]([C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](C)O)C)O)O)O
DMR2MUG IK YKPHLXGEPNYRPY-ZIUFDZNVSA-N
DMR2MUG IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]hexadecanamide
DMR2MUG DE Discovery agent
DMMQKCV ID DMMQKCV
DMMQKCV DN Acurea
DMMQKCV HS Investigative
DMMQKCV SN tetrahydrohyperforin; AC1L1GFN; SCHEMBL8168239; CTK5J8870; KGSZHKRKHXOAMG-UHFFFAOYSA-N; Bicyclo[3.3.1]non-3-ene-2,9-dione,4-hydroxy-6-methyl-1,3,7-tris(3-methyl-2-buten-1-yl)-5-(2-methyl-1-oxopropyl)-6-(4-methyl-3-penten-1-yl)-,(1R,5S,6R,7S)-; VA11063; 2-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-2-ene-4,9-dione
DMMQKCV DT Small molecular drug
DMMQKCV PC 3662
DMMQKCV MW 536.8
DMMQKCV FM C35H52O4
DMMQKCV IC InChI=1S/C35H52O4/c1-22(2)13-12-19-33(11)27(16-14-23(3)4)21-34(20-18-25(7)8)30(37)28(17-15-24(5)6)31(38)35(33,32(34)39)29(36)26(9)10/h13-15,18,26-27,37H,12,16-17,19-21H2,1-11H3
DMMQKCV CS CC(C)C(=O)C12C(=O)C(=C(C(C1=O)(CC(C2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C
DMMQKCV IK KGSZHKRKHXOAMG-UHFFFAOYSA-N
DMMQKCV IU 4-hydroxy-8-methyl-3,5,7-tris(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-1-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione
DMMQKCV CA CAS 11079-53-1
DMMQKCV DE Discovery agent
DMWOYCZ ID DMWOYCZ
DMWOYCZ DN Ac-VEID-CHO
DMWOYCZ HS Investigative
DMWOYCZ SN Ac-VEID-CHO; CHEMBL478081; Ac-Val-Glu-Ile-Asp-CHO; acetyl-Val-Ile-Asp-aldehyde; GTPL8566; SCHEMBL20257260; acetyl-Val-Glu-Ile-Asp-aldehyde; N-acetyl-Val-Glu-Ile-Asp-aldehyde; ZINC14947179; BDBM50340548; 319494-39-8; N-Acetyl-Val-Glu-Ile-Asp-al, ~99% (HPLC), powder; (4S)-4-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMWOYCZ DT Small molecular drug
DMWOYCZ PC 15487887
DMWOYCZ MW 500.5
DMWOYCZ FM C22H36N4O9
DMWOYCZ IC InChI=1S/C22H36N4O9/c1-6-12(4)19(22(35)24-14(10-27)9-17(31)32)26-20(33)15(7-8-16(29)30)25-21(34)18(11(2)3)23-13(5)28/h10-12,14-15,18-19H,6-9H2,1-5H3,(H,23,28)(H,24,35)(H,25,34)(H,26,33)(H,29,30)(H,31,32)/t12-,14-,15-,18-,19-/m0/s1
DMWOYCZ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)C
DMWOYCZ IK KYUFGGNCJRWMDN-GOYXDOSHSA-N
DMWOYCZ IU (4S)-4-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMWOYCZ DE Discovery agent
DML7Z1H ID DML7Z1H
DML7Z1H DN ACVR2B
DML7Z1H HS Investigative
DML7Z1H SN ACVR2B program (muscle atrophy); ACVR2B program (muscle atrophy), Rigel Pharmaceuticals; Activin type IIB receptorantagonist, (small molecule therapeutic, muscle atrophy), Rigel Pharmaceuticals
DML7Z1H CP Rigel Pharmaceuticals Inc
DML7Z1H DE Muscle wasting disease
DMO0W9V ID DMO0W9V
DMO0W9V DN Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2
DMO0W9V HS Investigative
DMO0W9V PC 91935699
DMO0W9V MW 3197.6
DMO0W9V FM C146H230N42O39
DMO0W9V IC InChI=1S/C146H230N42O39/c1-71(2)53-92(166-108(197)66-159-120(203)79(17)163-126(209)93(54-72(3)4)171-124(207)89(44-33-49-156-145(151)152)167-130(213)97(59-87-63-155-70-162-87)177-143(226)118(82(20)192)186-140(223)113(75(9)10)165-83(21)193)128(211)172-94(55-73(5)6)129(212)180-102(69-190)135(218)168-90(45-34-50-157-146(153)154)125(208)179-101(68-189)122(205)160-64-107(196)158-65-109(198)181-114(76(11)12)141(224)183-115(77(13)14)139(222)169-88(43-31-32-48-147)123(206)174-98(60-105(148)194)132(215)175-99(61-106(149)195)131(214)173-96(58-86-41-29-24-30-42-86)133(216)184-116(78(15)16)144(227)188-52-36-47-104(188)137(220)185-117(81(19)191)142(225)178-100(62-111(200)201)134(217)182-112(74(7)8)138(221)161-67-110(199)187-51-35-46-103(187)136(219)176-95(57-85-39-27-23-28-40-85)127(210)164-80(18)121(204)170-91(119(150)202)56-84-37-25-22-26-38-84/h22-30,37-42,63,70-82,88-104,112-118,189-192H,31-36,43-62,64-69,147H2,1-21H3,(H2,148,194)(H2,149,195)(H2,150,202)(H,155,162)(H,158,196)(H,159,203)(H,160,205)(H,161,221)(H,163,209)(H,164,210)(H,165,193)(H,166,197)(H,167,213)(H,168,218)(H,169,222)(H,170,204)(H,171,207)(H,172,211)(H,173,214)(H,174,206)(H,175,215)(H,176,219)(H,177,226)(H,178,225)(H,179,208)(H,180,212)(H,181,198)(H,182,217)(H,183,224)(H,184,216)(H,185,220)(H,186,223)(H,200,201)(H4,151,152,156)(H4,153,154,157)/t79-,80-,81+,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,112-,113-,114-,115-,116-,117-,118-/m0/s1
DMO0W9V CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)C)O
DMO0W9V IK OYUUVTJIINDYIH-ZCHJXOKKSA-N
DMO0W9V IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMO0W9V DE Discovery agent
DMWJ2M5 ID DMWJ2M5
DMWJ2M5 DN Ac-VTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMWJ2M5 HS Investigative
DMWJ2M5 PC 91935700
DMWJ2M5 MW 3239.7
DMWJ2M5 FM C148H236N44O38
DMWJ2M5 IC InChI=1S/C148H236N44O38/c1-73(2)56-95(170-109(200)68-163-121(206)81(17)167-128(213)96(57-74(3)4)176-126(211)91(45-33-51-159-146(152)153)172-132(217)100(62-89-65-158-72-166-89)181-144(229)119(84(20)196)190-141(226)114(77(9)10)169-85(21)197)130(215)177-97(58-75(5)6)131(216)184-104(71-194)136(221)173-92(46-34-52-160-147(154)155)127(212)183-103(70-193)123(208)164-66-108(199)162-67-110(201)185-115(78(11)12)142(227)187-116(79(13)14)140(225)174-93(47-35-53-161-148(156)157)124(209)171-90(44-31-32-50-149)125(210)179-101(63-107(150)198)133(218)178-99(61-88-42-29-24-30-43-88)134(219)188-117(80(15)16)145(230)192-55-37-49-106(192)138(223)189-118(83(19)195)143(228)182-102(64-112(203)204)135(220)186-113(76(7)8)139(224)165-69-111(202)191-54-36-48-105(191)137(222)180-98(60-87-40-27-23-28-41-87)129(214)168-82(18)122(207)175-94(120(151)205)59-86-38-25-22-26-39-86/h22-30,38-43,65,72-84,90-106,113-119,193-196H,31-37,44-64,66-71,149H2,1-21H3,(H2,150,198)(H2,151,205)(H,158,166)(H,162,199)(H,163,206)(H,164,208)(H,165,224)(H,167,213)(H,168,214)(H,169,197)(H,170,200)(H,171,209)(H,172,217)(H,173,221)(H,174,225)(H,175,207)(H,176,211)(H,177,215)(H,178,218)(H,179,210)(H,180,222)(H,181,229)(H,182,228)(H,183,212)(H,184,216)(H,185,201)(H,186,220)(H,187,227)(H,188,219)(H,189,223)(H,190,226)(H,203,204)(H4,152,153,159)(H4,154,155,160)(H4,156,157,161)/t81-,82-,83+,84+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-,118-,119-/m0/s1
DMWJ2M5 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)C)O
DMWJ2M5 IK KPPNHHWOHREFKE-POKONUJPSA-N
DMWJ2M5 IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMWJ2M5 DE Discovery agent
DMP89K4 ID DMP89K4
DMP89K4 DN Ac-w-F-F-N-Y-Y-W
DMP89K4 HS Investigative
DMP89K4 SN CHEMBL405677; Ac-W-F-F-N-Y-Y-W
DMP89K4 PC 44371613
DMP89K4 MW 1124.2
DMP89K4 FM C63H65N9O11
DMP89K4 IC InChI=1S/C63H65N9O11/c1-37(73)50(32-42-35-65-48-18-10-8-16-46(42)48)67-51(28-38-12-4-2-5-13-38)58(77)68-52(29-39-14-6-3-7-15-39)60(79)71-55(34-57(64)76)62(81)70-53(30-40-20-24-44(74)25-21-40)59(78)69-54(31-41-22-26-45(75)27-23-41)61(80)72-56(63(82)83)33-43-36-66-49-19-11-9-17-47(43)49/h2-27,35-36,50-56,65-67,74-75H,28-34H2,1H3,(H2,64,76)(H,68,77)(H,69,78)(H,70,81)(H,71,79)(H,72,80)(H,82,83)/t50-,51+,52+,53+,54+,55+,56+/m1/s1
DMP89K4 CS CC(=O)[C@@H](CC1=CNC2=CC=CC=C21)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)O
DMP89K4 IK JNMRBSLUOYEORH-GMXKVRHKSA-N
DMP89K4 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-1-(1H-indol-3-yl)-3-oxobutan-2-yl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMP89K4 DE Discovery agent
DM7J9O6 ID DM7J9O6
DM7J9O6 DN Ac-WKY-NH2
DM7J9O6 HS Investigative
DM7J9O6 SN CHEMBL1164996
DM7J9O6 DT Small molecular drug
DM7J9O6 PC 11006017
DM7J9O6 MW 536.6
DM7J9O6 FM C28H36N6O5
DM7J9O6 IC InChI=1S/C28H36N6O5/c1-17(35)32-25(15-19-16-31-22-7-3-2-6-21(19)22)28(39)33-23(8-4-5-13-29)27(38)34-24(26(30)37)14-18-9-11-20(36)12-10-18/h2-3,6-7,9-12,16,23-25,31,36H,4-5,8,13-15,29H2,1H3,(H2,30,37)(H,32,35)(H,33,39)(H,34,38)/t23-,24-,25-/m0/s1
DM7J9O6 CS CC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N
DM7J9O6 IK NIAKXWGYSYBRJH-SDHOMARFSA-N
DM7J9O6 IU (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide
DM7J9O6 DE Discovery agent
DM9W21L ID DM9W21L
DM9W21L DN Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2
DM9W21L HS Investigative
DM9W21L PC 91935709
DM9W21L MW 3546.1
DM9W21L FM C166H254N48O39
DM9W21L IC InChI=1S/C166H254N48O39/c1-86(2)69-112-148(238)192-104(51-31-35-63-178-125(220)60-58-110(146(236)202-117(75-100-79-176-85-187-100)150(240)194-108(144(234)199-112)54-38-66-181-166(174)175)197-159(249)133(90(9)10)209-153(243)116(189-95(17)217)74-99-78-182-102-48-28-27-47-101(99)102)140(230)185-82-127(222)190-109-57-59-124(219)177-62-34-30-50-103(191-142(232)107(53-37-65-180-165(172)173)195-155(245)120(84-215)206-149(239)113(70-87(3)4)200-145(109)235)139(229)184-80-126(221)183-81-128(223)207-132(89(7)8)161(251)210-134(91(11)12)160(250)196-106(52-32-36-64-179-164(170)171)141(231)193-105(49-29-33-61-167)143(233)203-118(76-123(168)218)151(241)201-115(73-98-45-25-20-26-46-98)152(242)211-135(92(13)14)163(253)214-68-40-56-122(214)157(247)212-136(94(16)216)162(252)205-119(77-130(225)226)154(244)208-131(88(5)6)158(248)186-83-129(224)213-67-39-55-121(213)156(246)204-114(72-97-43-23-19-24-44-97)147(237)188-93(15)138(228)198-111(137(169)227)71-96-41-21-18-22-42-96/h18-28,41-48,78-79,85-94,103-122,131-136,182,215-216H,29-40,49-77,80-84,167H2,1-17H3,(H2,168,218)(H2,169,227)(H,176,187)(H,177,219)(H,178,220)(H,183,221)(H,184,229)(H,185,230)(H,186,248)(H,188,237)(H,189,217)(H,190,222)(H,191,232)(H,192,238)(H,193,231)(H,194,240)(H,195,245)(H,196,250)(H,197,249)(H,198,228)(H,199,234)(H,200,235)(H,201,241)(H,202,236)(H,203,233)(H,204,246)(H,205,252)(H,206,239)(H,207,223)(H,208,244)(H,209,243)(H,210,251)(H,211,242)(H,212,247)(H,225,226)(H4,170,171,179)(H4,172,173,180)(H4,174,175,181)/t93-,94+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,131-,132-,133-,134-,135-,136-/m0/s1
DM9W21L CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H]6CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N6)CCCN=C(N)N)CO)CC(C)C)NC(=O)CNC(=O)[C@@H]7CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N7)CC(C)C)CCCN=C(N)N)CC8=CN=CN8)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC9=CNC1=CC=CC=C19)NC(=O)C)O
DM9W21L IK WKTOEIRIAWMLPL-KFCCYEGLSA-N
DM9W21L IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S,5S,8S,11S,20S)-20-[[2-[[(2S,5S,8S,11S,20S)-20-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-5-[3-(diaminomethylideneamino)propyl]-2-(1H-imidazol-5-ylmethyl)-8-(2-methylpropyl)-3,6,9,17,21-pentaoxo-1,4,7,10,16-pentazacyclohenicosane-11-carbonyl]amino]acetyl]amino]-8-[3-(diaminomethylideneamino)propyl]-5-(hydroxymethyl)-2-(2-methylpropyl)-3,6,9,17,21-pentaoxo-1,4,7,10,16-pentazacyclohenicosane-11-carbonyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM9W21L DE Discovery agent
DMJU4AM ID DMJU4AM
DMJU4AM DN Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2
DMJU4AM HS Investigative
DMJU4AM PC 91935704
DMJU4AM MW 3427.9
DMJU4AM FM C159H244N44O41
DMJU4AM IC InChI=1S/C159H244N44O41/c1-79(2)60-104(180-119(211)74-173-131(217)87(17)177-138(224)105(61-80(3)4)186-136(222)100(50-36-56-169-158(165)243)182-142(228)110(67-96-71-167-78-176-96)191-155(241)129(90(20)207)201-153(239)126(85(13)14)197-145(231)109(179-91(21)208)66-95-70-171-98-47-32-31-46-97(95)98)140(226)187-106(62-81(5)6)141(227)194-114(77-205)147(233)183-101(51-37-57-170-159(166)244)137(223)193-113(76-204)133(219)174-72-118(210)172-73-120(212)195-124(83(9)10)152(238)198-125(84(11)12)151(237)184-102(49-35-55-168-157(163)164)134(220)181-99(48-33-34-54-160)135(221)189-111(68-117(161)209)143(229)188-108(65-94-44-29-24-30-45-94)144(230)199-127(86(15)16)156(242)203-59-39-53-116(203)149(235)200-128(89(19)206)154(240)192-112(69-122(214)215)146(232)196-123(82(7)8)150(236)175-75-121(213)202-58-38-52-115(202)148(234)190-107(64-93-42-27-23-28-43-93)139(225)178-88(18)132(218)185-103(130(162)216)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,171,204-207H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,209)(H2,162,216)(H,167,176)(H,172,210)(H,173,217)(H,174,219)(H,175,236)(H,177,224)(H,178,225)(H,179,208)(H,180,211)(H,181,220)(H,182,228)(H,183,233)(H,184,237)(H,185,218)(H,186,222)(H,187,226)(H,188,229)(H,189,221)(H,190,234)(H,191,241)(H,192,240)(H,193,223)(H,194,227)(H,195,212)(H,196,232)(H,197,231)(H,198,238)(H,199,230)(H,200,235)(H,201,239)(H,214,215)(H4,163,164,168)(H3,165,169,243)(H3,166,170,244)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMJU4AM CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMJU4AM IK VDLYRUOYUCCKKR-BQWGFPJXSA-N
DMJU4AM IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMJU4AM DE Discovery agent
DMR1N53 ID DMR1N53
DMR1N53 DN Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMR1N53 HS Investigative
DMR1N53 PC 91935702
DMR1N53 MW 3426.9
DMR1N53 FM C159H245N45O40
DMR1N53 IC InChI=1S/C159H245N45O40/c1-79(2)60-104(181-119(212)74-174-131(218)87(17)178-138(225)105(61-80(3)4)187-136(223)100(51-37-57-171-159(167)244)183-142(229)110(67-96-71-168-78-177-96)192-155(242)129(90(20)208)202-153(240)126(85(13)14)198-145(232)109(180-91(21)209)66-95-70-172-98-47-32-31-46-97(95)98)140(227)188-106(62-81(5)6)141(228)195-114(77-206)147(234)184-101(49-35-55-169-157(163)164)137(224)194-113(76-205)133(220)175-72-118(211)173-73-120(213)196-124(83(9)10)152(239)199-125(84(11)12)151(238)185-102(50-36-56-170-158(165)166)134(221)182-99(48-33-34-54-160)135(222)190-111(68-117(161)210)143(230)189-108(65-94-44-29-24-30-45-94)144(231)200-127(86(15)16)156(243)204-59-39-53-116(204)149(236)201-128(89(19)207)154(241)193-112(69-122(215)216)146(233)197-123(82(7)8)150(237)176-75-121(214)203-58-38-52-115(203)148(235)191-107(64-93-42-27-23-28-43-93)139(226)179-88(18)132(219)186-103(130(162)217)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,172,205-208H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,210)(H2,162,217)(H,168,177)(H,173,211)(H,174,218)(H,175,220)(H,176,237)(H,178,225)(H,179,226)(H,180,209)(H,181,212)(H,182,221)(H,183,229)(H,184,234)(H,185,238)(H,186,219)(H,187,223)(H,188,227)(H,189,230)(H,190,222)(H,191,235)(H,192,242)(H,193,241)(H,194,224)(H,195,228)(H,196,213)(H,197,233)(H,198,232)(H,199,239)(H,200,231)(H,201,236)(H,202,240)(H,215,216)(H4,163,164,169)(H4,165,166,170)(H3,167,171,244)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMR1N53 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMR1N53 IK CSCIPTVNDXPCSL-BQWGFPJXSA-N
DMR1N53 IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMR1N53 DE Discovery agent
DM19NMF ID DM19NMF
DM19NMF DN Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2
DM19NMF HS Investigative
DM19NMF PC 91935706
DM19NMF MW 3454
DM19NMF FM C161H250N46O39
DM19NMF IC InChI=1S/C161H250N46O39/c1-81(2)62-106(184-121(215)76-177-133(221)89(17)181-140(228)107(63-82(3)4)190-137(225)102(51-34-37-57-172-159(165)166)186-144(232)112(69-98-73-171-80-180-98)195-157(245)131(92(20)211)205-155(243)128(87(13)14)201-147(235)111(183-93(21)212)68-97-72-175-100-49-32-31-48-99(97)100)142(230)191-108(64-83(5)6)143(231)198-116(79-209)149(237)187-103(52-35-38-58-173-160(167)168)139(227)197-115(78-208)135(223)178-74-120(214)176-75-122(216)199-126(85(9)10)154(242)202-127(86(11)12)153(241)188-104(53-39-59-174-161(169)170)136(224)185-101(50-33-36-56-162)138(226)193-113(70-119(163)213)145(233)192-110(67-96-46-29-24-30-47-96)146(234)203-129(88(15)16)158(246)207-61-41-55-118(207)151(239)204-130(91(19)210)156(244)196-114(71-124(218)219)148(236)200-125(84(7)8)152(240)179-77-123(217)206-60-40-54-117(206)150(238)194-109(66-95-44-27-23-28-45-95)141(229)182-90(18)134(222)189-105(132(164)220)65-94-42-25-22-26-43-94/h22-32,42-49,72-73,80-92,101-118,125-131,175,208-211H,33-41,50-71,74-79,162H2,1-21H3,(H2,163,213)(H2,164,220)(H,171,180)(H,176,214)(H,177,221)(H,178,223)(H,179,240)(H,181,228)(H,182,229)(H,183,212)(H,184,215)(H,185,224)(H,186,232)(H,187,237)(H,188,241)(H,189,222)(H,190,225)(H,191,230)(H,192,233)(H,193,226)(H,194,238)(H,195,245)(H,196,244)(H,197,227)(H,198,231)(H,199,216)(H,200,236)(H,201,235)(H,202,242)(H,203,234)(H,204,239)(H,205,243)(H,218,219)(H4,165,166,172)(H4,167,168,173)(H4,169,170,174)/t89-,90-,91+,92+,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,125-,126-,127-,128-,129-,130-,131-/m0/s1
DM19NMF CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DM19NMF IK DJNZEIOMSBZSIW-DTFUFJKDSA-N
DM19NMF IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-6-(diaminomethylideneamino)hexanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM19NMF DE Discovery agent
DM3BUP6 ID DM3BUP6
DM3BUP6 DN Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2
DM3BUP6 HS Investigative
DM3BUP6 PC 91935705
DM3BUP6 MW 3369.8
DM3BUP6 FM C157H238N42O41
DM3BUP6 IC InChI=1S/C157H238N42O41/c1-77(2)58-102(176-119(209)72-169-131(215)85(17)173-138(222)103(59-78(3)4)182-136(220)99(50-52-115(159)205)178-142(226)108(65-94-69-165-76-172-94)187-155(239)129(88(20)203)197-153(237)126(83(13)14)193-145(229)107(175-89(21)204)64-93-68-167-96-45-32-31-44-95(93)96)140(224)183-104(60-79(5)6)141(225)190-112(75-201)147(231)179-100(51-53-116(160)206)137(221)189-111(74-200)133(217)170-70-118(208)168-71-120(210)191-124(81(9)10)152(236)194-125(82(11)12)151(235)180-98(47-35-55-166-157(163)164)134(218)177-97(46-33-34-54-158)135(219)185-109(66-117(161)207)143(227)184-106(63-92-42-29-24-30-43-92)144(228)195-127(84(15)16)156(240)199-57-37-49-114(199)149(233)196-128(87(19)202)154(238)188-110(67-122(212)213)146(230)192-123(80(7)8)150(234)171-73-121(211)198-56-36-48-113(198)148(232)186-105(62-91-40-27-23-28-41-91)139(223)174-86(18)132(216)181-101(130(162)214)61-90-38-25-22-26-39-90/h22-32,38-45,68-69,76-88,97-114,123-129,167,200-203H,33-37,46-67,70-75,158H2,1-21H3,(H2,159,205)(H2,160,206)(H2,161,207)(H2,162,214)(H,165,172)(H,168,208)(H,169,215)(H,170,217)(H,171,234)(H,173,222)(H,174,223)(H,175,204)(H,176,209)(H,177,218)(H,178,226)(H,179,231)(H,180,235)(H,181,216)(H,182,220)(H,183,224)(H,184,227)(H,185,219)(H,186,232)(H,187,239)(H,188,238)(H,189,221)(H,190,225)(H,191,210)(H,192,230)(H,193,229)(H,194,236)(H,195,228)(H,196,233)(H,197,237)(H,212,213)(H4,163,164,166)/t85-,86-,87+,88+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DM3BUP6 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DM3BUP6 IK NNTUVPALHRZTKJ-BHNOSDEFSA-N
DM3BUP6 IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM3BUP6 DE Discovery agent
DMKO982 ID DMKO982
DMKO982 DN Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2
DMKO982 HS Investigative
DMKO982 PC 91935703
DMKO982 MW 3426.9
DMKO982 FM C159H245N45O40
DMKO982 IC InChI=1S/C159H245N45O40/c1-79(2)60-104(181-119(212)74-174-131(218)87(17)178-138(225)105(61-80(3)4)187-136(223)100(49-35-55-169-157(163)164)183-142(229)110(67-96-71-168-78-177-96)192-155(242)129(90(20)208)202-153(240)126(85(13)14)198-145(232)109(180-91(21)209)66-95-70-172-98-47-32-31-46-97(95)98)140(227)188-106(62-81(5)6)141(228)195-114(77-206)147(234)184-101(51-37-57-171-159(167)244)137(224)194-113(76-205)133(220)175-72-118(211)173-73-120(213)196-124(83(9)10)152(239)199-125(84(11)12)151(238)185-102(50-36-56-170-158(165)166)134(221)182-99(48-33-34-54-160)135(222)190-111(68-117(161)210)143(230)189-108(65-94-44-29-24-30-45-94)144(231)200-127(86(15)16)156(243)204-59-39-53-116(204)149(236)201-128(89(19)207)154(241)193-112(69-122(215)216)146(233)197-123(82(7)8)150(237)176-75-121(214)203-58-38-52-115(203)148(235)191-107(64-93-42-27-23-28-43-93)139(226)179-88(18)132(219)186-103(130(162)217)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,172,205-208H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,210)(H2,162,217)(H,168,177)(H,173,211)(H,174,218)(H,175,220)(H,176,237)(H,178,225)(H,179,226)(H,180,209)(H,181,212)(H,182,221)(H,183,229)(H,184,234)(H,185,238)(H,186,219)(H,187,223)(H,188,227)(H,189,230)(H,190,222)(H,191,235)(H,192,242)(H,193,241)(H,194,224)(H,195,228)(H,196,213)(H,197,233)(H,198,232)(H,199,239)(H,200,231)(H,201,236)(H,202,240)(H,215,216)(H4,163,164,169)(H4,165,166,170)(H3,167,171,244)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMKO982 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMKO982 IK APWOLIUOOPBJRZ-BQWGFPJXSA-N
DMKO982 IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMKO982 DE Discovery agent
DMSMVK4 ID DMSMVK4
DMSMVK4 DN Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2
DMSMVK4 HS Investigative
DMSMVK4 PC 91935701
DMSMVK4 MW 3425.9
DMSMVK4 FM C159H246N46O39
DMSMVK4 IC InChI=1S/C159H246N46O39/c1-79(2)60-104(182-119(213)74-175-131(219)87(17)179-138(226)105(61-80(3)4)188-136(224)100(49-35-55-170-157(163)164)184-142(230)110(67-96-71-169-78-178-96)193-155(243)129(90(20)209)203-153(241)126(85(13)14)199-145(233)109(181-91(21)210)66-95-70-173-98-47-32-31-46-97(95)98)140(228)189-106(62-81(5)6)141(229)196-114(77-207)147(235)185-101(50-36-56-171-158(165)166)137(225)195-113(76-206)133(221)176-72-118(212)174-73-120(214)197-124(83(9)10)152(240)200-125(84(11)12)151(239)186-102(51-37-57-172-159(167)168)134(222)183-99(48-33-34-54-160)135(223)191-111(68-117(161)211)143(231)190-108(65-94-44-29-24-30-45-94)144(232)201-127(86(15)16)156(244)205-59-39-53-116(205)149(237)202-128(89(19)208)154(242)194-112(69-122(216)217)146(234)198-123(82(7)8)150(238)177-75-121(215)204-58-38-52-115(204)148(236)192-107(64-93-42-27-23-28-43-93)139(227)180-88(18)132(220)187-103(130(162)218)63-92-40-25-22-26-41-92/h22-32,40-47,70-71,78-90,99-116,123-129,173,206-209H,33-39,48-69,72-77,160H2,1-21H3,(H2,161,211)(H2,162,218)(H,169,178)(H,174,212)(H,175,219)(H,176,221)(H,177,238)(H,179,226)(H,180,227)(H,181,210)(H,182,213)(H,183,222)(H,184,230)(H,185,235)(H,186,239)(H,187,220)(H,188,224)(H,189,228)(H,190,231)(H,191,223)(H,192,236)(H,193,243)(H,194,242)(H,195,225)(H,196,229)(H,197,214)(H,198,234)(H,199,233)(H,200,240)(H,201,232)(H,202,237)(H,203,241)(H,216,217)(H4,163,164,170)(H4,165,166,171)(H4,167,168,172)/t87-,88-,89+,90+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,123-,124-,125-,126-,127-,128-,129-/m0/s1
DMSMVK4 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC6=CN=CN6)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)C)O
DMSMVK4 IK LVJLXLXVWDOXCC-BQWGFPJXSA-N
DMSMVK4 IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMSMVK4 DE Discovery agent
DMAVPXL ID DMAVPXL
DMAVPXL DN Ac-YCit[CEHdFRWC]-NH2
DMAVPXL HS Investigative
DMAVPXL SN CHEMBL412494; Ac-YCit[CEHdFRWC]-NH2
DMAVPXL PC 44400399
DMAVPXL MW 1339.5
DMAVPXL FM C60H78N18O14S2
DMAVPXL IC InChI=1S/C60H78N18O14S2/c1-32(79)70-43(24-34-15-17-37(80)18-16-34)54(87)71-41(14-8-22-67-60(64)92)52(85)78-48-30-94-93-29-47(50(61)83)77-56(89)45(25-35-27-68-39-12-6-5-11-38(35)39)75-51(84)40(13-7-21-66-59(62)63)72-55(88)44(23-33-9-3-2-4-10-33)74-57(90)46(26-36-28-65-31-69-36)76-53(86)42(73-58(48)91)19-20-49(81)82/h2-6,9-12,15-18,27-28,31,40-48,68,80H,7-8,13-14,19-26,29-30H2,1H3,(H2,61,83)(H,65,69)(H,70,79)(H,71,87)(H,72,88)(H,73,91)(H,74,90)(H,75,84)(H,76,86)(H,77,89)(H,78,85)(H,81,82)(H4,62,63,66)(H3,64,67,92)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DMAVPXL CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=O)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMAVPXL IK OODHJMPCOPKKSM-XVRHLUALSA-N
DMAVPXL IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMAVPXL DE Discovery agent
DMC0TU5 ID DMC0TU5
DMC0TU5 DN Ac-YGGFL-NH2
DMC0TU5 HS Investigative
DMC0TU5 SN CHEMBL500212; Ac-YGGFL-NH2
DMC0TU5 DT Small molecular drug
DMC0TU5 PC 15747210
DMC0TU5 MW 596.7
DMC0TU5 FM C30H40N6O7
DMC0TU5 IC InChI=1S/C30H40N6O7/c1-18(2)13-23(28(31)41)36-30(43)25(14-20-7-5-4-6-8-20)35-27(40)17-32-26(39)16-33-29(42)24(34-19(3)37)15-21-9-11-22(38)12-10-21/h4-12,18,23-25,38H,13-17H2,1-3H3,(H2,31,41)(H,32,39)(H,33,42)(H,34,37)(H,35,40)(H,36,43)/t23-,24-,25-/m0/s1
DMC0TU5 CS CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C
DMC0TU5 IK GFXHMPKMESGSMX-SDHOMARFSA-N
DMC0TU5 IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanamide
DMC0TU5 DE Discovery agent
DM5SJX8 ID DM5SJX8
DM5SJX8 DN Ac-YK[CEHdFRWC]-NH2
DM5SJX8 HS Investigative
DM5SJX8 SN CHEMBL412495; Ac-YK[CEHdFRWC]-NH2
DM5SJX8 PC 44400400
DM5SJX8 MW 1310.5
DM5SJX8 FM C60H79N17O13S2
DM5SJX8 IC InChI=1S/C60H79N17O13S2/c1-33(78)69-44(25-35-16-18-38(79)19-17-35)55(86)70-41(14-7-8-22-61)53(84)77-49-31-92-91-30-48(51(62)82)76-57(88)46(26-36-28-67-40-13-6-5-12-39(36)40)74-52(83)42(15-9-23-66-60(63)64)71-56(87)45(24-34-10-3-2-4-11-34)73-58(89)47(27-37-29-65-32-68-37)75-54(85)43(72-59(49)90)20-21-50(80)81/h2-6,10-13,16-19,28-29,32,41-49,67,79H,7-9,14-15,20-27,30-31,61H2,1H3,(H2,62,82)(H,65,68)(H,69,78)(H,70,86)(H,71,87)(H,72,90)(H,73,89)(H,74,83)(H,75,85)(H,76,88)(H,77,84)(H,80,81)(H4,63,64,66)/t41-,42-,43+,44-,45-,46+,47-,48+,49+/m0/s1
DM5SJX8 CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DM5SJX8 IK ASUAOIWGQADQOH-PYPSSTHSSA-N
DM5SJX8 IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-6-aminohexanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DM5SJX8 DE Discovery agent
DMIZ5VO ID DMIZ5VO
DMIZ5VO DN Acylated Ceftazidime
DMIZ5VO HS Investigative
DMIZ5VO SN ACYLATED CEFTAZIDIME; DB03530; (2R)-2-[(1R)-1-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-2-oxoethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMIZ5VO DT Small molecular drug
DMIZ5VO PC 9600404
DMIZ5VO MW 469.5
DMIZ5VO FM C17H19N5O7S2
DMIZ5VO IC InChI=1S/C17H19N5O7S2/c1-7-5-30-13(21-10(7)14(25)26)8(4-23)19-12(24)11(9-6-31-16(18)20-9)22-29-17(2,3)15(27)28/h4,6,8,13H,1,5H2,2-3H3,(H2,18,20)(H,19,24)(H,25,26)(H,27,28)/b22-11-/t8-,13-/m1/s1
DMIZ5VO CS CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H](C=O)[C@@H]2N=C(C(=C)CS2)C(=O)O
DMIZ5VO IK VEHPZKIFULQYFS-BZXVCXBKSA-N
DMIZ5VO IU (2R)-2-[(1R)-1-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-oxoethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
DMIZ5VO DE Discovery agent
DM4CYKE ID DM4CYKE
DM4CYKE DN Acylureido penicillin mezlocillin
DM4CYKE HS Investigative
DM4CYKE DE Discovery agent
DMJK8QZ ID DMJK8QZ
DMJK8QZ DN Ac-YR[CE(1-Me-H)dFRWC]-NH2
DMJK8QZ HS Investigative
DMJK8QZ SN CHEMBL264132; Ac-YR[CE(1-Me-H)dFRWC]-NH2
DMJK8QZ PC 44400322
DMJK8QZ MW 1352.6
DMJK8QZ FM C61H81N19O13S2
DMJK8QZ IC InChI=1S/C61H81N19O13S2/c1-33(81)71-44(25-35-16-18-38(82)19-17-35)55(89)72-42(15-9-23-69-61(65)66)53(87)79-49-31-95-94-30-48(51(62)85)78-57(91)46(26-36-28-70-40-13-7-6-12-39(36)40)76-52(86)41(14-8-22-68-60(63)64)73-56(90)45(24-34-10-4-3-5-11-34)75-58(92)47(27-37-29-67-32-80(37)2)77-54(88)43(74-59(49)93)20-21-50(83)84/h3-7,10-13,16-19,28-29,32,41-49,70,82H,8-9,14-15,20-27,30-31H2,1-2H3,(H2,62,85)(H,71,81)(H,72,89)(H,73,90)(H,74,93)(H,75,92)(H,76,86)(H,77,88)(H,78,91)(H,79,87)(H,83,84)(H4,63,64,68)(H4,65,66,69)/t41-,42-,43+,44-,45-,46+,47-,48+,49+/m0/s1
DMJK8QZ CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3C)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMJK8QZ IK JCRBBWBYSVHLIT-PYPSSTHSSA-N
DMJK8QZ IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-7-(1H-indol-3-ylmethyl)-16-[(3-methylimidazol-4-yl)methyl]-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMJK8QZ DE Discovery agent
DMVQ4KG ID DMVQ4KG
DMVQ4KG DN Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2
DMVQ4KG HS Investigative
DMVQ4KG PC 91936743
DMVQ4KG MW 1388.6
DMVQ4KG FM C64H81N19O13S2
DMVQ4KG IC InChI=1S/C64H81N19O13S2/c1-34(84)75-47(25-35-15-18-41(85)19-16-35)58(92)76-45(13-7-23-72-64(68)69)56(90)83-52-32-98-97-31-51(54(65)88)82-60(94)49(27-39-29-73-43-11-5-4-10-42(39)43)80-55(89)44(12-6-22-71-63(66)67)77-59(93)48(26-36-14-17-37-8-2-3-9-38(37)24-36)79-61(95)50(28-40-30-70-33-74-40)81-57(91)46(78-62(52)96)20-21-53(86)87/h2-5,8-11,14-19,24,29-30,33,44-52,73,85H,6-7,12-13,20-23,25-28,31-32H2,1H3,(H2,65,88)(H,70,74)(H,75,84)(H,76,92)(H,77,93)(H,78,96)(H,79,95)(H,80,89)(H,81,91)(H,82,94)(H,83,90)(H,86,87)(H4,66,67,71)(H4,68,69,72)/t44-,45-,46+,47-,48-,49+,50-,51+,52+/m0/s1
DMVQ4KG CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC5=CC=CC=C5C=C4)CCCNC(=N)N)CC6=CNC7=CC=CC=C76)C(=O)N
DMVQ4KG IK LZYYGZAXFMYSBE-UHFDWKIASA-N
DMVQ4KG IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-10-(3-carbamimidamidopropyl)-4-carbamoyl-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-13-(naphthalen-2-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMVQ4KG DE Discovery agent
DM25JXM ID DM25JXM
DM25JXM DN Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM HS Investigative
DM25JXM SN CHEMBL415661; Ac-YR[CEH(pCl-dF)RWC]-NH2
DM25JXM PC 44400320
DM25JXM MW 1373
DM25JXM FM C60H78ClN19O13S2
DM25JXM IC InChI=1S/C60H78ClN19O13S2/c1-31(81)72-43(22-33-12-16-37(82)17-13-33)54(89)73-41(9-5-21-69-60(65)66)52(87)80-48-29-95-94-28-47(50(62)85)79-56(91)45(24-34-26-70-39-7-3-2-6-38(34)39)77-51(86)40(8-4-20-68-59(63)64)74-55(90)44(23-32-10-14-35(61)15-11-32)76-57(92)46(25-36-27-67-30-71-36)78-53(88)42(75-58(48)93)18-19-49(83)84/h2-3,6-7,10-17,26-27,30,40-48,70,82H,4-5,8-9,18-25,28-29H2,1H3,(H2,62,85)(H,67,71)(H,72,81)(H,73,89)(H,74,90)(H,75,93)(H,76,92)(H,77,86)(H,78,88)(H,79,91)(H,80,87)(H,83,84)(H4,63,64,68)(H4,65,66,69)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DM25JXM CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=C(C=C4)Cl)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DM25JXM IK KIFNALNSUOJQPJ-XVRHLUALSA-N
DM25JXM IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-carbamoyl-13-[(4-chlorophenyl)methyl]-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DM25JXM DE Discovery agent
DMXCF9T ID DMXCF9T
DMXCF9T DN Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T HS Investigative
DMXCF9T SN CHEMBL407809; Ac-YR[CEH(pF-dF)RWC]-NH2
DMXCF9T PC 44400321
DMXCF9T MW 1356.5
DMXCF9T FM C60H78FN19O13S2
DMXCF9T IC InChI=1S/C60H78FN19O13S2/c1-31(81)72-43(22-33-12-16-37(82)17-13-33)54(89)73-41(9-5-21-69-60(65)66)52(87)80-48-29-95-94-28-47(50(62)85)79-56(91)45(24-34-26-70-39-7-3-2-6-38(34)39)77-51(86)40(8-4-20-68-59(63)64)74-55(90)44(23-32-10-14-35(61)15-11-32)76-57(92)46(25-36-27-67-30-71-36)78-53(88)42(75-58(48)93)18-19-49(83)84/h2-3,6-7,10-17,26-27,30,40-48,70,82H,4-5,8-9,18-25,28-29H2,1H3,(H2,62,85)(H,67,71)(H,72,81)(H,73,89)(H,74,90)(H,75,93)(H,76,92)(H,77,86)(H,78,88)(H,79,91)(H,80,87)(H,83,84)(H4,63,64,68)(H4,65,66,69)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DMXCF9T CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=C(C=C4)F)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMXCF9T IK CHBTZNAADZTZLP-XVRHLUALSA-N
DMXCF9T IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-13-[(4-fluorophenyl)methyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMXCF9T DE Discovery agent
DMBMY73 ID DMBMY73
DMBMY73 DN Ac-YR[CEHdFRWC]-NH2
DMBMY73 HS Investigative
DMBMY73 SN CHEMBL264352; Ac-YR[CEHdFRWC]-NH2
DMBMY73 PC 44400370
DMBMY73 MW 1338.5
DMBMY73 FM C60H79N19O13S2
DMBMY73 IC InChI=1S/C60H79N19O13S2/c1-32(80)71-43(24-34-15-17-37(81)18-16-34)54(88)72-41(14-8-22-68-60(64)65)52(86)79-48-30-94-93-29-47(50(61)84)78-56(90)45(25-35-27-69-39-12-6-5-11-38(35)39)76-51(85)40(13-7-21-67-59(62)63)73-55(89)44(23-33-9-3-2-4-10-33)75-57(91)46(26-36-28-66-31-70-36)77-53(87)42(74-58(48)92)19-20-49(82)83/h2-6,9-12,15-18,27-28,31,40-48,69,81H,7-8,13-14,19-26,29-30H2,1H3,(H2,61,84)(H,66,70)(H,71,80)(H,72,88)(H,73,89)(H,74,92)(H,75,91)(H,76,85)(H,77,87)(H,78,90)(H,79,86)(H,82,83)(H4,62,63,67)(H4,64,65,68)/t40-,41-,42+,43-,44-,45+,46-,47+,48+/m0/s1
DMBMY73 CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMBMY73 IK FEKXKTLLBDRSQH-XVRHLUALSA-N
DMBMY73 IU 3-[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMBMY73 DE Discovery agent
DMDO468 ID DMDO468
DMDO468 DN Ac-YR[CEHdFRWC]SPPKD-NH2
DMDO468 HS Investigative
DMDO468 SN CHEMBL2373515; Ac-YR[CEHdFRWC]SPPKD-NH2; CHEMBL437086
DMDO468 PC 44400369
DMDO468 MW 1863.1
DMDO468 FM C83H115N25O21S2
DMDO468 IC InChI=1S/C83H115N25O21S2/c1-44(110)95-57(34-46-22-24-49(111)25-23-46)73(121)96-54(19-10-30-92-83(88)89)71(119)105-62-41-130-131-42-63(78(126)104-61(40-109)80(128)108-32-12-21-65(108)81(129)107-31-11-20-64(107)79(127)99-52(17-7-8-28-84)69(117)100-56(68(85)116)37-67(114)115)106-75(123)59(35-47-38-93-51-16-6-5-15-50(47)51)102-70(118)53(18-9-29-91-82(86)87)97-74(122)58(33-45-13-3-2-4-14-45)101-76(124)60(36-48-39-90-43-94-48)103-72(120)55(98-77(62)125)26-27-66(112)113/h2-6,13-16,22-25,38-39,43,52-65,93,109,111H,7-12,17-21,26-37,40-42,84H2,1H3,(H2,85,116)(H,90,94)(H,95,110)(H,96,121)(H,97,122)(H,98,125)(H,99,127)(H,100,117)(H,101,124)(H,102,118)(H,103,120)(H,104,126)(H,105,119)(H,106,123)(H,112,113)(H,114,115)(H4,86,87,91)(H4,88,89,92)/t52-,53-,54-,55+,56-,57-,58-,59+,60-,61-,62+,63+,64-,65-/m0/s1
DMDO468 CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CNC=N3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CO)C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N
DMDO468 IK PPKIGEMCDOLKEY-AURDXFKRSA-N
DMDO468 IU (3S)-3-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(4S,7R,10S,13S,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-19-(2-carboxyethyl)-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-4-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoic acid
DMDO468 DE Discovery agent
DMH0EAI ID DMH0EAI
DMH0EAI DN Ac-YR[CEHFRWC]-NH2
DMH0EAI HS Investigative
DMH0EAI SN CHEMBL410672; Ac-YR[CEHFRWC]-NH2
DMH0EAI PC 44400371
DMH0EAI MW 1338.5
DMH0EAI FM C60H79N19O13S2
DMH0EAI IC InChI=1S/C60H79N19O13S2/c1-32(80)71-43(24-34-15-17-37(81)18-16-34)54(88)72-41(14-8-22-68-60(64)65)52(86)79-48-30-94-93-29-47(50(61)84)78-56(90)45(25-35-27-69-39-12-6-5-11-38(35)39)76-51(85)40(13-7-21-67-59(62)63)73-55(89)44(23-33-9-3-2-4-10-33)75-57(91)46(26-36-28-66-31-70-36)77-53(87)42(74-58(48)92)19-20-49(82)83/h2-6,9-12,15-18,27-28,31,40-48,69,81H,7-8,13-14,19-26,29-30H2,1H3,(H2,61,84)(H,66,70)(H,71,80)(H,72,88)(H,73,89)(H,74,92)(H,75,91)(H,76,85)(H,77,87)(H,78,90)(H,79,86)(H,82,83)(H4,62,63,67)(H4,64,65,68)/t40-,41-,42+,43-,44+,45+,46-,47+,48+/m0/s1
DMH0EAI CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]2CSSC[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC2=O)CCC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)C(=O)N
DMH0EAI IK FEKXKTLLBDRSQH-JUYCQENKSA-N
DMH0EAI IU 3-[(4S,7R,10S,13R,16S,19R,22S)-22-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-4-carbamoyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricos-19-yl]propanoic acid
DMH0EAI DE Discovery agent
DMWJ8UR ID DMWJ8UR
DMWJ8UR DN Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR HS Investigative
DMWJ8UR SN CHEMBL427666; Ac-YRC(Me)*EHdFRWC(Me)NH2
DMWJ8UR PC 25078242
DMWJ8UR MW 1368.6
DMWJ8UR FM C62H85N19O13S2
DMWJ8UR IC InChI=1S/C62H85N19O13S2/c1-34(82)73-45(26-36-17-19-39(83)20-18-36)56(90)74-43(16-10-24-70-62(66)67)54(88)81-50(32-96-3)60(94)76-44(21-22-51(84)85)55(89)79-48(28-38-30-68-33-72-38)59(93)77-46(25-35-11-5-4-6-12-35)57(91)75-42(15-9-23-69-61(64)65)53(87)78-47(58(92)80-49(31-95-2)52(63)86)27-37-29-71-41-14-8-7-13-40(37)41/h4-8,11-14,17-20,29-30,33,42-50,71,83H,9-10,15-16,21-28,31-32H2,1-3H3,(H2,63,86)(H,68,72)(H,73,82)(H,74,90)(H,75,91)(H,76,94)(H,77,93)(H,78,87)(H,79,89)(H,80,92)(H,81,88)(H,84,85)(H4,64,65,69)(H4,66,67,70)/t42-,43-,44-,45-,46+,47-,48-,49-,50-/m0/s1
DMWJ8UR CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CSC)C(=O)N
DMWJ8UR IK PWVUYOZSIWYFJW-MYBKRMQRSA-N
DMWJ8UR IU (4S)-4-[[(2R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylsulfanylpropanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-3-methylsulfanyl-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMWJ8UR DE Discovery agent
DMN2UKC ID DMN2UKC
DMN2UKC DN Ac-YRMEHdFRWG-NH2
DMN2UKC HS Investigative
DMN2UKC SN CHEMBL266879; Ac-YRMEHdFRWG-NH2
DMN2UKC PC 25078192
DMN2UKC MW 1322.5
DMN2UKC FM C61H83N19O13S
DMN2UKC IC InChI=1S/C61H83N19O13S/c1-34(81)73-46(27-36-16-18-39(82)19-17-36)57(91)74-42(14-8-23-68-60(63)64)53(87)77-45(22-25-94-2)56(90)76-44(20-21-51(84)85)55(89)80-49(29-38-31-67-33-72-38)59(93)78-47(26-35-10-4-3-5-11-35)58(92)75-43(15-9-24-69-61(65)66)54(88)79-48(52(86)71-32-50(62)83)28-37-30-70-41-13-7-6-12-40(37)41/h3-7,10-13,16-19,30-31,33,42-49,70,82H,8-9,14-15,20-29,32H2,1-2H3,(H2,62,83)(H,67,72)(H,71,86)(H,73,81)(H,74,91)(H,75,92)(H,76,90)(H,77,87)(H,78,93)(H,79,88)(H,80,89)(H,84,85)(H4,63,64,68)(H4,65,66,69)/t42-,43-,44-,45-,46-,47+,48-,49-/m0/s1
DMN2UKC CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)NCC(=O)N
DMN2UKC IK ZSONGANRJTVTCP-FHYJZJLOSA-N
DMN2UKC IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMN2UKC DE Discovery agent
DMDH5B3 ID DMDH5B3
DMDH5B3 DN Ac-YRMEHdFRWGSPPKD-NH2
DMDH5B3 HS Investigative
DMDH5B3 PC 91936747
DMDH5B3 MW 1847.1
DMDH5B3 FM C84H119N25O21S
DMDH5B3 IC InChI=1S/C84H119N25O21S/c1-46(111)97-60(37-48-23-25-51(112)26-24-48)77(125)99-55(19-10-31-92-83(87)88)72(120)102-58(29-35-131-2)76(124)101-57(27-28-68(114)115)75(123)107-63(39-50-42-91-45-96-50)79(127)105-61(36-47-14-4-3-5-15-47)78(126)100-56(20-11-32-93-84(89)90)74(122)106-62(38-49-41-94-53-17-7-6-16-52(49)53)71(119)95-43-67(113)98-64(44-110)81(129)109-34-13-22-66(109)82(130)108-33-12-21-65(108)80(128)103-54(18-8-9-30-85)73(121)104-59(70(86)118)40-69(116)117/h3-7,14-17,23-26,41-42,45,54-66,94,110,112H,8-13,18-22,27-40,43-44,85H2,1-2H3,(H2,86,118)(H,91,96)(H,95,119)(H,97,111)(H,98,113)(H,99,125)(H,100,126)(H,101,124)(H,102,120)(H,103,128)(H,104,121)(H,105,127)(H,106,122)(H,107,123)(H,114,115)(H,116,117)(H4,87,88,92)(H4,89,90,93)/t54-,55-,56-,57-,58-,59-,60-,61+,62-,63-,64-,65-,66-/m0/s1
DMDH5B3 CS CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)NCC(=O)N[C@@H](CO)C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N
DMDH5B3 IK XDLJELQQEILLFZ-URRWLXDFSA-N
DMDH5B3 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMDH5B3 DE Discovery agent
DM23QND ID DM23QND
DM23QND DN AD-0802
DM23QND HS Investigative
DM23QND SN Humanized monoclonal antibody vaccine (Alzheimers disease), Bioarctic
DM23QND CP Bioarctic Neuroscience AB
DM23QND DT Vaccine
DM23QND DE Alzheimer disease
DMYLA29 ID DMYLA29
DMYLA29 DN AD10-1025
DMYLA29 HS Investigative
DMYLA29 SN AD10-369; AD10-371; AD10-797; AD10-798; Partial PPAR gamma agonist (oral, type 2 diabetes); Partial PPAR gamma agonist (oral, type 2 diabetes), Adamed SP; Phenyl propionic acid derivative 3 (oral, type 2 diabetes), Adamed SP; PPAR modulators (oral, hypercholesterolemia/NIDDM), Adamed
DMYLA29 CP Adamed Sp zoo
DMYLA29 DE Hypercholesterolaemia
DMJMCDP ID DMJMCDP
DMJMCDP DN AD-412
DMJMCDP HS Investigative
DMJMCDP SN JAK3 inhibitor (autoimmune disease/transplant rejection), INSERM
DMJMCDP CP INSERM
DMJMCDP DE Autoimmune diabetes
DM5WV13 ID DM5WV13
DM5WV13 DN AD-5061
DM5WV13 HS Investigative
DM5WV13 SN AD-7057; AD7057; AD 7057; AD5061; AD 5061
DM5WV13 DT Small molecular drug
DM5WV13 PC 9953271
DM5WV13 MW 408.5
DM5WV13 FM C22H20N2O4S
DM5WV13 IC InChI=1S/C22H20N2O4S/c1-14-18(23-21(28-14)16-5-3-2-4-6-16)11-12-27-17-9-7-15(8-10-17)13-19-20(25)24-22(26)29-19/h2-10,19H,11-13H2,1H3,(H,24,25,26)
DM5WV13 CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DM5WV13 IK GUTCYOKMCPFRGH-UHFFFAOYSA-N
DM5WV13 IU 5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DM5WV13 DE Discovery agent
DMV48L3 ID DMV48L3
DMV48L3 DN AD5-10
DMV48L3 HS Investigative
DMV48L3 SN Zaptuzumab; Death receptor 5 (DR5) human murine antibody (cancer), Chinese Academy of Medical Science
DMV48L3 CP Chinese Academy of Medical Science
DMV48L3 DT Antibody
DMV48L3 DE Solid tumour/cancer
DMQW612 ID DMQW612
DMQW612 DN Ad5f35-LMPd1-2-transduced autologous dendritic cells
DMQW612 HS Investigative
DMQW612 SN AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI
DMQW612 CP National Cancer Institute
DMQW612 DT Vaccine
DMQW612 DE Nasopharyngeal carcinoma
DMKDRVZ ID DMKDRVZ
DMKDRVZ DN Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester
DMKDRVZ HS Investigative
DMKDRVZ SN CHEMBL485883; Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester
DMKDRVZ DT Small molecular drug
DMKDRVZ PC 24881677
DMKDRVZ MW 347.4
DMKDRVZ FM C23H25NO2
DMKDRVZ IC InChI=1S/C23H25NO2/c25-22(24-23-13-16-9-17(14-23)11-18(10-16)15-23)26-21-8-4-7-20(12-21)19-5-2-1-3-6-19/h1-8,12,16-18H,9-11,13-15H2,(H,24,25)
DMKDRVZ CS C1C2CC3CC1CC(C2)(C3)NC(=O)OC4=CC=CC(=C4)C5=CC=CC=C5
DMKDRVZ IK STNJKWWAIGCDRW-UHFFFAOYSA-N
DMKDRVZ IU (3-phenylphenyl) N-(1-adamantyl)carbamate
DMKDRVZ DE Discovery agent
DM4S279 ID DM4S279
DM4S279 DN Adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone
DM4S279 HS Investigative
DM4S279 SN CHEMBL396928; AC1N8RTC; 1-adamantyl-(4-ethylpiperazin-1-yl)methanone; Oprea1_784934; adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone; MolPort-005-510-679; BDBM50207776
DM4S279 DT Small molecular drug
DM4S279 PC 4348598
DM4S279 MW 276.4
DM4S279 FM C17H28N2O
DM4S279 IC InChI=1S/C17H28N2O/c1-2-18-3-5-19(6-4-18)16(20)17-10-13-7-14(11-17)9-15(8-13)12-17/h13-15H,2-12H2,1H3
DM4S279 CS CCN1CCN(CC1)C(=O)C23CC4CC(C2)CC(C4)C3
DM4S279 IK XOWWNQSYPPTVEH-UHFFFAOYSA-N
DM4S279 IU 1-adamantyl-(4-ethylpiperazin-1-yl)methanone
DM4S279 DE Discovery agent
DM5K0EI ID DM5K0EI
DM5K0EI DN Adamantan-1-yl-piperazin-1-yl-methanone
DM5K0EI HS Investigative
DM5K0EI SN 1-(1-adamantylcarbonyl)piperazine; 29869-08-7; adamantanyl piperazinyl ketone; CHEMBL391335; piperazin-1-yl(tricyclo[3.3.1.1~3,7~]dec-1-yl)methanone; adamantan-1-yl-piperazin-1-yl-methanone; AC1Q5KAX; SCHEMBL1150471; CTK4G3954; DTXSID70589438; XAFSAELWLMDLKL-UHFFFAOYSA-N; MolPort-006-345-515; 1-(1-adamantanecarbonyl)piperazine; ALBB-024506; ZINC12343593; STL412114; BDBM50207783; SBB071957; BBL037233; AKOS009097513; MCULE-3925280273; ST072044; EN300-25317; AB00983558-01; piperazine, 1-(tricyclo[3.3.1.1~3,7~]dec-1-ylcarbonyl)-
DM5K0EI DT Small molecular drug
DM5K0EI PC 17233943
DM5K0EI MW 248.36
DM5K0EI FM C15H24N2O
DM5K0EI IC InChI=1S/C15H24N2O/c18-14(17-3-1-16-2-4-17)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13,16H,1-10H2
DM5K0EI CS C1CN(CCN1)C(=O)C23CC4CC(C2)CC(C4)C3
DM5K0EI IK XAFSAELWLMDLKL-UHFFFAOYSA-N
DM5K0EI IU 1-adamantyl(piperazin-1-yl)methanone
DM5K0EI CA CAS 29869-08-7
DM5K0EI DE Discovery agent
DMTUL9J ID DMTUL9J
DMTUL9J DN Adamantan-1-yl-piperidin-1-yl-methanone
DMTUL9J HS Investigative
DMTUL9J SN Adamantan-1-yl-piperidin-1-yl-methanone; adamantanyl piperidyl ketone; CHEMBL245590; 1-adamantyl(piperidino)methanone; 22508-49-2; (3r,5r,7r)-adamantan-1-yl(piperidin-1-yl)methanone; 1-adamantyl(piperidin-1-yl)methanone; SMR000117086; AC1LBKY9; Maybridge1_008125; Oprea1_633750; Oprea1_290126; MLS000526612; Piperidino(1-adamantyl) ketone; SCHEMBL3457055; SCHEMBL19841773; CTK7F5375; HMS564J07; BURUIZXRHQWZQI-UHFFFAOYSA-N; MolPort-001-930-823; 1-(1-Adamantylcarbonyl)piperidine; HMS2178P18; ZINC4031797
DMTUL9J DT Small molecular drug
DMTUL9J PC 584509
DMTUL9J MW 247.38
DMTUL9J FM C16H25NO
DMTUL9J IC InChI=1S/C16H25NO/c18-15(17-4-2-1-3-5-17)16-9-12-6-13(10-16)8-14(7-12)11-16/h12-14H,1-11H2
DMTUL9J CS C1CCN(CC1)C(=O)C23CC4CC(C2)CC(C4)C3
DMTUL9J IK BURUIZXRHQWZQI-UHFFFAOYSA-N
DMTUL9J IU 1-adamantyl(piperidin-1-yl)methanone
DMTUL9J DE Discovery agent
DMAEN9Y ID DMAEN9Y
DMAEN9Y DN Adamantan-1-yl-pyrrolidin-1-yl-methanone
DMAEN9Y HS Investigative
DMAEN9Y SN Adamantan-1-yl-pyrrolidin-1-yl-methanone; CHEMBL392866; 1-adamantyl(1-pyrrolidinyl)methanone; 22508-51-6; (3r,5r,7r)-adamantan-1-yl(pyrrolidin-1-yl)methanone; 1-adamantyl(pyrrolidin-1-yl)methanone; AC1MCDV9; CBMicro_007397; Cambridge id 5142982; Oprea1_111627; Oprea1_295021; MLS000526196; adamantanyl pyrrolidinyl ketone; SCHEMBL3456185; MolPort-001-930-821; HMS2477C05; HMS1608M03; ZINC4031845; SMSF0003738; STK091400; BDBM50207788; 1-(adamantane-1-carbonyl)pyrrolidine; AKOS000612243; CCG-246226; CB09819; MCULE-7009966643
DMAEN9Y DT Small molecular drug
DMAEN9Y PC 2741656
DMAEN9Y MW 233.35
DMAEN9Y FM C15H23NO
DMAEN9Y IC InChI=1S/C15H23NO/c17-14(16-3-1-2-4-16)15-8-11-5-12(9-15)7-13(6-11)10-15/h11-13H,1-10H2
DMAEN9Y CS C1CCN(C1)C(=O)C23CC4CC(C2)CC(C4)C3
DMAEN9Y IK RVXVNLMWQYKNHL-UHFFFAOYSA-N
DMAEN9Y IU 1-adamantyl(pyrrolidin-1-yl)methanone
DMAEN9Y CA CAS 22508-51-6
DMAEN9Y DE Discovery agent
DMBRAV5 ID DMBRAV5
DMBRAV5 DN Adamantan-2-yl-piperidin-1-yl-methanone
DMBRAV5 HS Investigative
DMBRAV5 SN CHEMBL245393; adamantan-2-yl-piperidin-1-yl-methanone; MolPort-027-725-528; BDBM50207799; AKOS017280695
DMBRAV5 DT Small molecular drug
DMBRAV5 PC 9450114
DMBRAV5 MW 247.38
DMBRAV5 FM C16H25NO
DMBRAV5 IC InChI=1S/C16H25NO/c18-16(17-4-2-1-3-5-17)15-13-7-11-6-12(9-13)10-14(15)8-11/h11-15H,1-10H2
DMBRAV5 CS C1CCN(CC1)C(=O)C2C3CC4CC(C3)CC2C4
DMBRAV5 IK AHSGKCRVZWMWDM-UHFFFAOYSA-N
DMBRAV5 IU 2-adamantyl(piperidin-1-yl)methanone
DMBRAV5 DE Discovery agent
DM1MAVU ID DM1MAVU
DM1MAVU DN Ada-RYYRIK-NH2
DM1MAVU HS Investigative
DM1MAVU SN CHEMBL256687
DM1MAVU PC 44456141
DM1MAVU MW 1043.3
DM1MAVU FM C53H82N14O8
DM1MAVU IC InChI=1S/C53H82N14O8/c1-3-31(2)43(49(74)62-38(44(55)69)13-7-8-20-54)67-46(71)39(14-9-21-60-51(56)57)63-47(72)42(27-33-16-18-37(68)19-17-33)65-48(73)41(26-32-11-5-4-6-12-32)64-45(70)40(15-10-22-61-52(58)59)66-50(75)53-28-34-23-35(29-53)25-36(24-34)30-53/h4-6,11-12,16-19,31,34-36,38-43,68H,3,7-10,13-15,20-30,54H2,1-2H3,(H2,55,69)(H,62,74)(H,63,72)(H,64,70)(H,65,73)(H,66,75)(H,67,71)(H4,56,57,60)(H4,58,59,61)/t31-,34?,35?,36?,38-,39-,40-,41-,42-,43-,53?/m0/s1
DM1MAVU CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C34CC5CC(C3)CC(C5)C4
DM1MAVU IK CHQPBFJDZBBZJD-OGHQQVQQSA-N
DM1MAVU IU N-[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S,3S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]adamantane-1-carboxamide
DM1MAVU DE Discovery agent
DMJQM7H ID DMJQM7H
DMJQM7H DN ADC-1012
DMJQM7H HS Investigative
DMJQM7H SN IL-23 antagonist (protein recombinant, cancer/inflammation), Alligator Bioscience
DMJQM7H CP Alligator Bioscience AB
DMJQM7H DE Solid tumour/cancer
DMV761D ID DMV761D
DMV761D DN ADC-5510
DMV761D HS Investigative
DMV761D SN ADC-02265510; ADL-5510; Centrally acting mu opoid receptor antagonists, Adolor
DMV761D CP Adolor Corp
DMV761D DE Movement disorder
DM19KY6 ID DM19KY6
DM19KY6 DN ADC-7828
DM19KY6 HS Investigative
DM19KY6 SN Neutrophil elastase inhibitors (inhaled, CF/COPD); Neutrophil elastase inhibitor (inhaled, cystic fibrosis/chronic obstructive pulmonary disease), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Argenta; Neutrophil elastase inhibitors (inhaled, CF/COPD), Pulmagen
DM19KY6 CP Argenta Discovery Ltd
DM19KY6 DE Chronic obstructive pulmonary disease
DMY6PMJ ID DMY6PMJ
DMY6PMJ DN ADC-9971
DMY6PMJ HS Investigative
DMY6PMJ SN ADS-9971; CRTh2 antagonist (oral, COPD/allergic asthma/allergic rhinitis), Argenta Discovery; Prostaglandin D2 receptor antagonist (oral, allergic asthma/allergic rhinitis/COPD), Argenta Discovery
DMY6PMJ CP Argenta Discovery Ltd
DMY6PMJ DE Allergic rhinitis
DMZYJHV ID DMZYJHV
DMZYJHV DN AdcAhxArg4Lys(biotin)-PEG-OMe
DMZYJHV HS Investigative
DMZYJHV SN CHEMBL413173
DMZYJHV PC 44387501
DMZYJHV MW 1474.7
DMZYJHV FM C61H107N27O14S
DMZYJHV IC InChI=1S/C61H107N27O14S/c1-100-29-30-101-28-27-73-50(93)34(13-6-8-21-71-41(89)19-5-4-18-40-43-39(31-103-40)86-61(99)87-43)82-52(95)36(15-10-24-75-58(65)66)84-54(97)38(17-12-26-77-60(69)70)85-53(96)37(16-11-25-76-59(67)68)83-51(94)35(14-9-23-74-57(63)64)81-42(90)20-3-2-7-22-72-55(98)47-45(91)46(92)56(102-47)88-33-80-44-48(62)78-32-79-49(44)88/h32-40,43,45-47,56,91-92H,2-31H2,1H3,(H,71,89)(H,72,98)(H,73,93)(H,81,90)(H,82,95)(H,83,94)(H,84,97)(H,85,96)(H2,62,78,79)(H4,63,64,74)(H4,65,66,75)(H4,67,68,76)(H4,69,70,77)(H2,86,87,99)/t34?,35-,36-,37-,38-,39-,40-,43-,45-,46+,47-,56+/m0/s1
DMZYJHV CS COCCOCCNC(=O)C(CCCCNC(=O)CCCC[C@H]1[C@@H]2[C@H](CS1)NC(=O)N2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CCCCCNC(=O)[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O
DMZYJHV IK HKRIJYTUBFTJDB-GQHJETKOSA-N
DMZYJHV IU (2S,3S,4R,5R)-N-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[6-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-[2-(2-methoxyethoxy)ethylamino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMZYJHV DE Discovery agent
DMQ2C8X ID DMQ2C8X
DMQ2C8X DN AdcAhxArg4Lys-PEGOMe
DMQ2C8X HS Investigative
DMQ2C8X SN CHEMBL426336
DMQ2C8X PC 44387499
DMQ2C8X MW 1248.4
DMQ2C8X FM C51H93N25O12
DMQ2C8X IC InChI=1S/C51H93N25O12/c1-86-25-26-87-24-23-63-41(80)29(11-4-5-17-52)72-43(82)31(13-8-20-65-49(56)57)74-45(84)33(15-10-22-67-51(60)61)75-44(83)32(14-9-21-66-50(58)59)73-42(81)30(12-7-19-64-48(54)55)71-34(77)16-3-2-6-18-62-46(85)38-36(78)37(79)47(88-38)76-28-70-35-39(53)68-27-69-40(35)76/h27-33,36-38,47,78-79H,2-26,52H2,1H3,(H,62,85)(H,63,80)(H,71,77)(H,72,82)(H,73,81)(H,74,84)(H,75,83)(H2,53,68,69)(H4,54,55,64)(H4,56,57,65)(H4,58,59,66)(H4,60,61,67)/t29?,30-,31-,32-,33-,36-,37+,38-,47+/m0/s1
DMQ2C8X CS COCCOCCNC(=O)C(CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CCCCCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DMQ2C8X IK JBQKHDQXRCCDGW-NZDGIOGASA-N
DMQ2C8X IU (2S,3S,4R,5R)-N-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[6-amino-1-[2-(2-methoxyethoxy)ethylamino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMQ2C8X DE Discovery agent
DMSYMRJ ID DMSYMRJ
DMSYMRJ DN AdcAhxArg4NH(CH2)6NH2
DMSYMRJ HS Investigative
DMSYMRJ SN CHEMBL263964
DMSYMRJ PC 44387500
DMSYMRJ MW 1117.3
DMSYMRJ FM C46H84N24O9
DMSYMRJ IC InChI=1S/C46H84N24O9/c47-17-5-1-2-6-18-57-37(74)26(12-8-20-59-43(49)50)67-39(76)28(14-10-22-61-45(53)54)69-40(77)29(15-11-23-62-46(55)56)68-38(75)27(13-9-21-60-44(51)52)66-30(71)16-4-3-7-19-58-41(78)34-32(72)33(73)42(79-34)70-25-65-31-35(48)63-24-64-36(31)70/h24-29,32-34,42,72-73H,1-23,47H2,(H,57,74)(H,58,78)(H,66,71)(H,67,76)(H,68,75)(H,69,77)(H2,48,63,64)(H4,49,50,59)(H4,51,52,60)(H4,53,54,61)(H4,55,56,62)/t26-,27-,28-,29-,32-,33+,34-,42+/m0/s1
DMSYMRJ CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCCCCCN)O)O)N
DMSYMRJ IK AKYVNHGFJFUSDY-HYKQOWLKSA-N
DMSYMRJ IU (2S,3S,4R,5R)-N-[6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-(6-aminohexylamino)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DMSYMRJ DE Discovery agent
DM7J3K0 ID DM7J3K0
DM7J3K0 DN AdcAhxArg6
DM7J3K0 HS Investigative
DM7J3K0 SN CHEMBL438544
DM7J3K0 PC 10441484
DM7J3K0 MW 1331.5
DM7J3K0 FM C52H94N30O12
DM7J3K0 IC InChI=1S/C52H94N30O12/c53-37-33-38(74-24-73-37)82(25-75-33)45-35(85)34(84)36(94-45)44(91)66-17-3-1-2-16-32(83)76-26(10-4-18-67-47(54)55)39(86)77-27(11-5-19-68-48(56)57)40(87)78-28(12-6-20-69-49(58)59)41(88)79-29(13-7-21-70-50(60)61)42(89)80-30(14-8-22-71-51(62)63)43(90)81-31(46(92)93)15-9-23-72-52(64)65/h24-31,34-36,45,84-85H,1-23H2,(H,66,91)(H,76,83)(H,77,86)(H,78,87)(H,79,88)(H,80,89)(H,81,90)(H,92,93)(H2,53,73,74)(H4,54,55,67)(H4,56,57,68)(H4,58,59,69)(H4,60,61,70)(H4,62,63,71)(H4,64,65,72)/t26-,27-,28-,29-,30-,31-,34-,35+,36-,45+/m0/s1
DM7J3K0 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)O)O)N
DM7J3K0 IK QLSCMEHEXBNFGR-HDLKDVBUSA-N
DM7J3K0 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[6-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]hexanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM7J3K0 DE Discovery agent
DMV39AW ID DMV39AW
DMV39AW DN ADENOPHOSTIN A
DMV39AW HS Investigative
DMV39AW SN adenophostin a; 149091-92-9; Adenophostin; CHEMBL204385; AC1L3X4M; CHEBI:34524; 2'-Adenylic acid, 3'-O-(3,4-di-O-phosphono-alpha-D-glucopyranosyl)-; C16H26N5O18P3; GTPL4124; DTXSID10164167; BDBM50184325; LS-173343; C13727; 2-[5-(6-amino-9H-9-purinyl)-2-hydroxymethyl-4-oxyphosphate-(2R,3R,4R,5R)-tetrahydro-3-furanyloxy]-6-hydroxymethyl-4,5-dioxyphosphate-(2R,3R,4S,5R,6R)-tetrahydro-2H-3-pyranol
DMV39AW DT Small molecular drug
DMV39AW PC 123695
DMV39AW MW 669.3
DMV39AW FM C16H26N5O18P3
DMV39AW IC InChI=1S/C16H26N5O18P3/c17-13-7-14(19-3-18-13)21(4-20-7)15-12(39-42(31,32)33)9(5(1-22)34-15)36-16-8(24)11(38-41(28,29)30)10(6(2-23)35-16)37-40(25,26)27/h3-6,8-12,15-16,22-24H,1-2H2,(H2,17,18,19)(H2,25,26,27)(H2,28,29,30)(H2,31,32,33)/t5-,6-,8-,9-,10-,11-,12-,15-,16-/m1/s1
DMV39AW CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)OP(=O)(O)O)OP(=O)(O)O)O)OP(=O)(O)O)N
DMV39AW IK RENVITLQVBEFDT-MZQFDOALSA-N
DMV39AW IU [(2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-4-[(2R,3R,4R,5R,6R)-3-hydroxy-6-(hydroxymethyl)-4,5-diphosphonooxyoxan-2-yl]oxy-5-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate
DMV39AW CA CAS 149091-92-9
DMV39AW CB CHEBI:34524
DMV39AW DE Discovery agent
DMFUHKP ID DMFUHKP
DMFUHKP DN adenosine diphosphate
DMFUHKP HS Investigative
DMFUHKP SN Adenosine diphosphate; 58-64-0; ADP; Adenosine 5'-(trihydrogen diphosphate); adenosine pyrophosphate; adenosine 5'-pyrophosphate; ADP (nucleotide); adenosine-diphosphate; 5'-Adenylphosphoric acid; 5'-Adp; Adenosindiphosphorsaeure; Adenosine 5'-pyrophosphoric acid; Adenosine-5'-diphosphat; Adenosine 5'-diphosphoric acid; Adenosine diphosphoric acid; Ado-5'-P-P; UNII-61D2G4IYVH; H3adp; BRN 0067722; CHEBI:16761; EINECS 200-392-5; 61D2G4IYVH; CHEMBL14830
DMFUHKP DT Small molecular drug
DMFUHKP PC 6022
DMFUHKP MW 427.2
DMFUHKP FM C10H15N5O10P2
DMFUHKP IC InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMFUHKP CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N
DMFUHKP IK XTWYTFMLZFPYCI-KQYNXXCUSA-N
DMFUHKP IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMFUHKP CA CAS 58-64-0
DMFUHKP CB CHEBI:16761
DMJZPSX ID DMJZPSX
DMJZPSX DN Adenosine Monotungstate
DMJZPSX HS Investigative
DMJZPSX SN ADENOSINE MONOTUNGSTATE
DMJZPSX DT Small molecular drug
DMJZPSX PC 46936368
DMJZPSX MW 501.1
DMJZPSX FM C10H15N5O7W
DMJZPSX IC InChI=1S/C10H13N5O4.2H2O.O.W/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10;;;;/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13);2*1H2;;/q;;;;+2/p-2/t4-,6-,7+,10+;;;;/m0..../s1
DMJZPSX CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@H]([C@@H](O3)CO)O)O)N.O[W](=O)O
DMJZPSX IK YGGXZRZCGFLZPM-LRDMJOKZSA-L
DMJZPSX IU (2R,3R,4R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;dihydroxy(oxo)tungsten
DMJZPSX DE Discovery agent
DMSOVFD ID DMSOVFD
DMSOVFD DN adenosine-3'-5'-bisphosphate
DMSOVFD HS Investigative
DMSOVFD SN adenosine 3',5'-diphosphate; adenosine 3',5'-bisphosphate
DMSOVFD DT Small molecular drug
DMSOVFD PC 159296
DMSOVFD MW 427.2
DMSOVFD FM C10H15N5O10P2
DMSOVFD IC InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(16)7(25-27(20,21)22)4(24-10)1-23-26(17,18)19/h2-4,6-7,10,16H,1H2,(H2,11,12,13)(H2,17,18,19)(H2,20,21,22)/t4-,6-,7-,10-/m1/s1
DMSOVFD CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)OP(=O)(O)O)O)N
DMSOVFD IK WHTCPDAXWFLDIH-KQYNXXCUSA-N
DMSOVFD IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
DMSOVFD CA CAS 1053-73-2
DMSOVFD CB CHEBI:17985
DMSOVFD DE Discovery agent
DM96LBV ID DM96LBV
DM96LBV DN Adenosine-5-Diphosphoribose
DM96LBV HS Investigative
DM96LBV SN Adenosine-5-Diphosphoribose; [(2r,3s,4r,5r)-5-(6-Aminopurin-9-Yl)-3,4-Dihydroxy-Oxolan-2-Yl]methyl [hydroxy-[[(2r,3s,4r,5s)-3,4,5-Trihydroxyoxolan-2-Yl]methoxy]phosphoryl] Hydrogen Phosphate; 2bfq; AR6; AC1L9KEO; ZINC14880207; DB02059; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl [(2R,3S,4R,5S)-3,4,5-trihydroxytetrahydrof
DM96LBV DT Small molecular drug
DM96LBV PC 447048
DM96LBV MW 559.32
DM96LBV FM C15H23N5O14P2
DM96LBV IC InChI=1S/C15H23N5O14P2/c16-12-7-13(18-3-17-12)20(4-19-7)14-10(23)8(21)5(32-14)1-30-35(26,27)34-36(28,29)31-2-6-9(22)11(24)15(25)33-6/h3-6,8-11,14-15,21-25H,1-2H2,(H,26,27)(H,28,29)(H2,16,17,18)/t5-,6-,8-,9-,10-,11-,14-,15+/m1/s1
DM96LBV CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@H](O4)O)O)O)O)O)N
DM96LBV IK SRNWOUGRCWSEMX-ZQSHOCFMSA-N
DM96LBV IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM96LBV DE Discovery agent
DMJDO2F ID DMJDO2F
DMJDO2F DN Adenosine-5'-O-(2-thiodiphosphate)
DMJDO2F HS Investigative
DMJDO2F SN Adpbetas; adenosine 5'-O-(2-thiodiphosphate); beta-Thio-ADP; Adenosine-5'-O-(2-thiodiphosphate); CHEMBL335206; 35094-45-2; ADP-beta-S; 73536-95-5; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate; ADP beta S; 5'-Adps; 5'-Adenosine diphosphate beta-S; ADP-gamma-S; AT4; EINECS 277-530-6; AC1NSJSN; (32S)Adenosine 5'-O-(2-thiodiphosphate)
DMJDO2F DT Small molecular drug
DMJDO2F PC 5310996
DMJDO2F MW 443.27
DMJDO2F FM C10H15N5O9P2S
DMJDO2F IC InChI=1S/C10H15N5O9P2S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(23-10)1-22-25(18,19)24-26(20,21)27/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H2,20,21,27)/t4-,6-,7-,10-/m1/s1
DMJDO2F CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=S)(O)O)O)O)N
DMJDO2F IK HCIKUKNAJRJFOW-KQYNXXCUSA-N
DMJDO2F IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydroxyphosphinothioyl hydrogen phosphate
DMJDO2F CA CAS 35094-45-2
DMJDO2F DE Discovery agent
DMKY7T8 ID DMKY7T8
DMKY7T8 DN Adenosine-5'-Rp-Alpha-Thio-Triphosphate
DMKY7T8 HS Investigative
DMKY7T8 SN ADENOSINE-5'-RP-ALPHA-THIO-TRIPHOSPHATE; ATP-alpha-S; AC1OAHXZ; SCHEMBL307389; CHEMBL3774733; adenosine 5'-O-(1-thiotriphosphate); DB02355; T99; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
DMKY7T8 DT Small molecular drug
DMKY7T8 PC 6858181
DMKY7T8 MW 523.25
DMKY7T8 FM C10H16N5O12P3S
DMKY7T8 IC InChI=1S/C10H16N5O12P3S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-30(23,31)27-29(21,22)26-28(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,31)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-,30?/m1/s1
DMKY7T8 CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=S)(O)OP(=O)(O)OP(=O)(O)O)O)O)N
DMKY7T8 IK ROYJKVPBJVNHCQ-VWJVIAGJSA-N
DMKY7T8 IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
DMKY7T8 DE Discovery agent
DM0YQ2I ID DM0YQ2I
DM0YQ2I DN Adenylylsulfate
DM0YQ2I HS Investigative
DM0YQ2I SN ADENOSINE-5'-PHOSPHOSULFATE; Adenosine 5'-phosphosulfate; Adenosine 5'-sulfatophosphate; Adenosine sulfatophosphate; Adenylyl sulfate; Adenylylsulfate; Phosphosulphate; adenosine 5'-sulphatophosphate; adenosine phosphosulfate; adenylyl-sulfate; adenylyl-sulphate; phosphosulfate; sulfatophosphate; 485-84-7; 5'-Adenylic acid, monoanhydride with sulfuric acid; 5'-Adenylyl sulfate; AMPS; BRN 0067726; CHEBI:17709; [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]sulfonic acid
DM0YQ2I PC 10238
DM0YQ2I MW 427.29
DM0YQ2I FM C10H14N5O10PS
DM0YQ2I IC IRLPACMLTUPBCL-KQYNXXCUSA-N
DM0YQ2I CS C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)OS(=O)(=O)O)O)O)N
DM0YQ2I IK 1S/C10H14N5O10PS/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-26(18,19)25-27(20,21)22/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H,20,21,22)/t4-,6-,7-,10-/m1/s1
DM0YQ2I IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl sulfo hydrogen phosphate
DM0YQ2I CA CAS 485-84-7
DM0YQ2I CB CHEBI:17709
DM0YQ2I DE Discovery agent
DM2XI09 ID DM2XI09
DM2XI09 DN Adipate
DM2XI09 HS Investigative
DM2XI09 SN adipic acid; hexanedioic acid; 124-04-9; Adipinic acid; 1,4-Butanedicarboxylic acid; Adilactetten; Acifloctin; Acinetten; 1,6-Hexanedioic acid; Molten adipic acid; Kyselina adipova; Adipinsaure [German]; Acide adipique [French]; Kyselina adipova [Czech]; Hexanedioate; Adipinsaeure; FEMA Number 2011; Adi-pure; UNII-76A0JE0FKJ; NSC 7622; CCRIS 812; Adipic acid [NF]; FEMA No. 2011; HSDB 188; Adipic acid, 99%; Hexan-1,6-dicarboxylate; EINECS 204-673-3; BRN 1209788; 76A0JE0FKJ; AI3-03700; 1,6-HEXANE-DIOIC ACID; CHEBI:30832; NSC7622
DM2XI09 DT Small molecular drug
DM2XI09 PC 200164
DM2XI09 MW 144.12
DM2XI09 FM C6H8O4-2
DM2XI09 IC InChI=1S/C6H10O4/c7-5(8)3-1-2-4-6(9)10/h1-4H2,(H,7,8)(H,9,10)/p-2
DM2XI09 CS C(CCC(=O)[O-])CC(=O)[O-]
DM2XI09 IK WNLRTRBMVRJNCN-UHFFFAOYSA-L
DM2XI09 IU hexanedioate
DM2XI09 CA CAS 764-65-8
DM2XI09 CB CHEBI:17128
DM2XI09 DE Discovery agent
DMW5HO0 ID DMW5HO0
DMW5HO0 DN AdoC(Ahx)Arg6
DMW5HO0 HS Investigative
DMW5HO0 SN CHEMBL610874
DMW5HO0 PC 46877390
DMW5HO0 MW 1331.5
DMW5HO0 FM C52H94N30O12
DMW5HO0 IC InChI=1S/C52H94N30O12/c53-37-33-38(74-24-73-37)82(25-75-33)45-35(85)34(84)36(94-45)44(91)66-17-3-1-2-16-32(83)76-26(10-4-18-67-47(54)55)39(86)77-27(11-5-19-68-48(56)57)40(87)78-28(12-6-20-69-49(58)59)41(88)79-29(13-7-21-70-50(60)61)42(89)80-30(14-8-22-71-51(62)63)43(90)81-31(46(92)93)15-9-23-72-52(64)65/h24-31,34-36,45,84-85H,1-23H2,(H,66,91)(H,76,83)(H,77,86)(H,78,87)(H,79,88)(H,80,89)(H,81,90)(H,92,93)(H2,53,73,74)(H4,54,55,67)(H4,56,57,68)(H4,58,59,69)(H4,60,61,70)(H4,62,63,71)(H4,64,65,72)/t26-,27-,28-,29-,30-,31-,34+,35-,36+,45?/m1/s1
DMW5HO0 CS C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMW5HO0 IK QLSCMEHEXBNFGR-FBEAYKSBSA-N
DMW5HO0 IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[6-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]hexanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMW5HO0 DE Discovery agent
DMRSCO2 ID DMRSCO2
DMRSCO2 DN AdoC(Aoc)Arg6
DMRSCO2 HS Investigative
DMRSCO2 SN CHEMBL610876
DMRSCO2 PC 46877392
DMRSCO2 MW 1359.6
DMRSCO2 FM C54H98N30O12
DMRSCO2 IC InChI=1S/C54H98N30O12/c55-39-35-40(76-26-75-39)84(27-77-35)47-37(87)36(86)38(96-47)46(93)68-19-5-3-1-2-4-18-34(85)78-28(12-6-20-69-49(56)57)41(88)79-29(13-7-21-70-50(58)59)42(89)80-30(14-8-22-71-51(60)61)43(90)81-31(15-9-23-72-52(62)63)44(91)82-32(16-10-24-73-53(64)65)45(92)83-33(48(94)95)17-11-25-74-54(66)67/h26-33,36-38,47,86-87H,1-25H2,(H,68,93)(H,78,85)(H,79,88)(H,80,89)(H,81,90)(H,82,91)(H,83,92)(H,94,95)(H2,55,75,76)(H4,56,57,69)(H4,58,59,70)(H4,60,61,71)(H4,62,63,72)(H4,64,65,73)(H4,66,67,74)/t28-,29-,30-,31-,32-,33-,36+,37-,38+,47?/m1/s1
DMRSCO2 CS C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMRSCO2 IK HBUMOBPTTFUJHS-FIYJFMLKSA-N
DMRSCO2 IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[8-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]octanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMRSCO2 DE Discovery agent
DMDLHAB ID DMDLHAB
DMDLHAB DN AdoC(Aun)Arg6
DMDLHAB HS Investigative
DMDLHAB SN CHEMBL611121
DMDLHAB PC 46877396
DMDLHAB MW 1401.6
DMDLHAB FM C57H104N30O12
DMDLHAB IC InChI=1S/C57H104N30O12/c58-42-38-43(79-29-78-42)87(30-80-38)50-40(90)39(89)41(99-50)49(96)71-22-8-6-4-2-1-3-5-7-21-37(88)81-31(15-9-23-72-52(59)60)44(91)82-32(16-10-24-73-53(61)62)45(92)83-33(17-11-25-74-54(63)64)46(93)84-34(18-12-26-75-55(65)66)47(94)85-35(19-13-27-76-56(67)68)48(95)86-36(51(97)98)20-14-28-77-57(69)70/h29-36,39-41,50,89-90H,1-28H2,(H,71,96)(H,81,88)(H,82,91)(H,83,92)(H,84,93)(H,85,94)(H,86,95)(H,97,98)(H2,58,78,79)(H4,59,60,72)(H4,61,62,73)(H4,63,64,74)(H4,65,66,75)(H4,67,68,76)(H4,69,70,77)/t31-,32-,33-,34-,35-,36-,39+,40-,41+,50?/m1/s1
DMDLHAB CS C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMDLHAB IK VPJLJWJUVPAMHK-MOSAXMBESA-N
DMDLHAB IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[11-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]undecanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMDLHAB DE Discovery agent
DMPUAFC ID DMPUAFC
DMPUAFC DN AdoC(beta-Ala)2AlaArg6
DMPUAFC HS Investigative
DMPUAFC SN CHEMBL610875
DMPUAFC PC 46877391
DMPUAFC MW 1431.6
DMPUAFC FM C55H98N32O14
DMPUAFC IC InChI=1S/C55H98N32O14/c1-26(80-34(89)15-22-69-33(88)14-23-70-47(98)38-36(90)37(91)48(101-38)87-25-79-35-39(56)77-24-78-40(35)87)41(92)81-27(8-2-16-71-50(57)58)42(93)82-28(9-3-17-72-51(59)60)43(94)83-29(10-4-18-73-52(61)62)44(95)84-30(11-5-19-74-53(63)64)45(96)85-31(12-6-20-75-54(65)66)46(97)86-32(49(99)100)13-7-21-76-55(67)68/h24-32,36-38,48,90-91H,2-23H2,1H3,(H,69,88)(H,70,98)(H,80,89)(H,81,92)(H,82,93)(H,83,94)(H,84,95)(H,85,96)(H,86,97)(H,99,100)(H2,56,77,78)(H4,57,58,71)(H4,59,60,72)(H4,61,62,73)(H4,63,64,74)(H4,65,66,75)(H4,67,68,76)/t26-,27-,28-,29-,30-,31-,32-,36+,37-,38+,48?/m1/s1
DMPUAFC CS C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)CCNC(=O)CCNC(=O)[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O
DMPUAFC IK QDXYEHKCQQMPGT-LSDLINHMSA-N
DMPUAFC IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[3-[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]propanoylamino]propanoylamino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMPUAFC DE Discovery agent
DMO8D4V ID DMO8D4V
DMO8D4V DN AdoC(beta-Ala)Arg6
DMO8D4V HS Investigative
DMO8D4V SN CHEMBL611122
DMO8D4V PC 46877397
DMO8D4V MW 1289.4
DMO8D4V FM C49H88N30O12
DMO8D4V IC InChI=1S/C49H88N30O12/c50-34-30-35(71-21-70-34)79(22-72-30)42-32(82)31(81)33(91-42)41(88)63-20-13-29(80)73-23(7-1-14-64-44(51)52)36(83)74-24(8-2-15-65-45(53)54)37(84)75-25(9-3-16-66-46(55)56)38(85)76-26(10-4-17-67-47(57)58)39(86)77-27(11-5-18-68-48(59)60)40(87)78-28(43(89)90)12-6-19-69-49(61)62/h21-28,31-33,42,81-82H,1-20H2,(H,63,88)(H,73,80)(H,74,83)(H,75,84)(H,76,85)(H,77,86)(H,78,87)(H,89,90)(H2,50,70,71)(H4,51,52,64)(H4,53,54,65)(H4,55,56,66)(H4,57,58,67)(H4,59,60,68)(H4,61,62,69)/t23-,24-,25-,26-,27-,28-,31+,32-,33+,42?/m1/s1
DMO8D4V CS C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMO8D4V IK SKHJPFQNPQEHHQ-VOMWTDLXSA-N
DMO8D4V IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]propanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMO8D4V DE Discovery agent
DM65B7Y ID DM65B7Y
DM65B7Y DN AdoC(betaAsp)2AlaArg6
DM65B7Y HS Investigative
DM65B7Y SN CHEMBL611127
DM65B7Y PC 46877402
DM65B7Y MW 1519.6
DM65B7Y FM C57H98N32O18
DM65B7Y IC InChI=1S/C57H98N32O18/c1-24(82-41(94)26(50(103)104)21-77-40(93)25(49(101)102)20-78-47(100)36-34(90)35(91)48(107-36)89-23-81-33-37(58)79-22-80-38(33)89)39(92)83-27(8-2-14-71-52(59)60)42(95)84-28(9-3-15-72-53(61)62)43(96)85-29(10-4-16-73-54(63)64)44(97)86-30(11-5-17-74-55(65)66)45(98)87-31(12-6-18-75-56(67)68)46(99)88-32(51(105)106)13-7-19-76-57(69)70/h22-32,34-36,48,90-91H,2-21H2,1H3,(H,77,93)(H,78,100)(H,82,94)(H,83,92)(H,84,95)(H,85,96)(H,86,97)(H,87,98)(H,88,99)(H,101,102)(H,103,104)(H,105,106)(H2,58,79,80)(H4,59,60,71)(H4,61,62,72)(H4,63,64,73)(H4,65,66,74)(H4,67,68,75)(H4,69,70,76)/t24-,25?,26?,27-,28-,29-,30-,31-,32-,34+,35-,36+,48?/m1/s1
DM65B7Y CS C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)C(CNC(=O)C(CNC(=O)[C@@H]1[C@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C(=O)O)C(=O)O
DM65B7Y IK RAUBYAYMEJMYTN-VDLZJJBUSA-N
DM65B7Y IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[3-[[3-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]-2-carboxypropanoyl]amino]-2-carboxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM65B7Y DE Discovery agent
DM2TWSZ ID DM2TWSZ
DM2TWSZ DN AdoC(Dpr)2AlaArg6
DM2TWSZ HS Investigative
DM2TWSZ SN CHEMBL611120
DM2TWSZ PC 46877395
DM2TWSZ MW 1440.6
DM2TWSZ FM C58H101N31O13
DM2TWSZ IC InChI=1S/C58H101N31O13/c1-28(87-24-9-17-36(87)50(99)88-25-8-16-35(88)38(90)41-39(91)40(92)51(102-41)89-27-80-37-42(59)78-26-79-43(37)89)44(93)81-29(10-2-18-72-53(60)61)45(94)82-30(11-3-19-73-54(62)63)46(95)83-31(12-4-20-74-55(64)65)47(96)84-32(13-5-21-75-56(66)67)48(97)85-33(14-6-22-76-57(68)69)49(98)86-34(52(100)101)15-7-23-77-58(70)71/h26-36,39-41,51,91-92H,2-25H2,1H3,(H,81,93)(H,82,94)(H,83,95)(H,84,96)(H,85,97)(H,86,98)(H,100,101)(H2,59,78,79)(H4,60,61,72)(H4,62,63,73)(H4,64,65,74)(H4,66,67,75)(H4,68,69,76)(H4,70,71,77)/t28-,29-,30-,31-,32-,33-,34-,35-,36+,39+,40-,41-,51?/m1/s1
DM2TWSZ CS C[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)N1CCC[C@H]1C(=O)N2CCC[C@@H]2C(=O)[C@@H]3[C@H]([C@H](C(O3)N4C=NC5=C(N=CN=C54)N)O)O
DM2TWSZ IK MKVGDINXVXQIHD-OALVHANWSA-N
DM2TWSZ IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[(2S)-2-[(2R)-2-[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DM2TWSZ DE Discovery agent
DMMWNPT ID DMMWNPT
DMMWNPT DN AdoC(GABA)Arg6
DMMWNPT HS Investigative
DMMWNPT SN CHEMBL611125
DMMWNPT PC 46877400
DMMWNPT MW 1303.4
DMMWNPT FM C50H90N30O12
DMMWNPT IC InChI=1S/C50H90N30O12/c51-35-31-36(72-22-71-35)80(23-73-31)43-33(83)32(82)34(92-43)42(89)64-15-7-14-30(81)74-24(8-1-16-65-45(52)53)37(84)75-25(9-2-17-66-46(54)55)38(85)76-26(10-3-18-67-47(56)57)39(86)77-27(11-4-19-68-48(58)59)40(87)78-28(12-5-20-69-49(60)61)41(88)79-29(44(90)91)13-6-21-70-50(62)63/h22-29,32-34,43,82-83H,1-21H2,(H,64,89)(H,74,81)(H,75,84)(H,76,85)(H,77,86)(H,78,87)(H,79,88)(H,90,91)(H2,51,71,72)(H4,52,53,65)(H4,54,55,66)(H4,56,57,67)(H4,58,59,68)(H4,60,61,69)(H4,62,63,70)/t24-,25-,26-,27-,28-,29-,32+,33-,34+,43?/m1/s1
DMMWNPT CS C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMMWNPT IK RAWZLEKTUTUGLH-PYGBFABJSA-N
DMMWNPT IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[4-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]butanoylamino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMMWNPT DE Discovery agent
DMVQJP0 ID DMVQJP0
DMVQJP0 DN AdoCGlyArg6
DMVQJP0 HS Investigative
DMVQJP0 SN CHEMBL611123
DMVQJP0 PC 46877398
DMVQJP0 MW 1275.4
DMVQJP0 FM C48H86N30O12
DMVQJP0 IC InChI=1S/C48H86N30O12/c49-33-29-34(70-20-69-33)78(21-71-29)41-31(81)30(80)32(90-41)40(87)68-19-28(79)72-22(7-1-13-62-43(50)51)35(82)73-23(8-2-14-63-44(52)53)36(83)74-24(9-3-15-64-45(54)55)37(84)75-25(10-4-16-65-46(56)57)38(85)76-26(11-5-17-66-47(58)59)39(86)77-27(42(88)89)12-6-18-67-48(60)61/h20-27,30-32,41,80-81H,1-19H2,(H,68,87)(H,72,79)(H,73,82)(H,74,83)(H,75,84)(H,76,85)(H,77,86)(H,88,89)(H2,49,69,70)(H4,50,51,62)(H4,52,53,63)(H4,54,55,64)(H4,56,57,65)(H4,58,59,66)(H4,60,61,67)/t22-,23-,24-,25-,26-,27-,30+,31-,32+,41?/m1/s1
DMVQJP0 CS C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)O)O)N
DMVQJP0 IK RQOKDGUOYJQMIS-CUDNWQCBSA-N
DMVQJP0 IU (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[2-[[(2S,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMVQJP0 DE Discovery agent
DMPOU86 ID DMPOU86
DMPOU86 DN ADOCIAQUINONE B
DMPOU86 HS Investigative
DMPOU86 SN Adociaquinone B
DMPOU86 DT Small molecular drug
DMPOU86 PC 11201041
DMPOU86 MW 423.4
DMPOU86 FM C22H17NO6S
DMPOU86 IC InChI=1S/C22H17NO6S/c1-22-4-2-3-10-9-29-20(15(10)22)18(25)13-7-11-12(8-14(13)22)19(26)21-16(17(11)24)23-5-6-30(21,27)28/h7-9,23H,2-6H2,1H3/t22-/m0/s1
DMPOU86 CS C[C@@]12CCCC3=COC(=C31)C(=O)C4=C2C=C5C(=C4)C(=O)C6=C(C5=O)S(=O)(=O)CCN6
DMPOU86 IK KJMXEMKLXNMFIG-QFIPXVFZSA-N
DMPOU86 IU (1S)-1-methyl-7,7-dioxo-18-oxa-7lambda6-thia-10-azahexacyclo[15.6.1.02,15.04,13.06,11.020,24]tetracosa-2(15),3,6(11),13,17(24),19-hexaene-5,12,16-trione
DMPOU86 DE Discovery agent
DM6MRSC ID DM6MRSC
DM6MRSC DN Adociasulfate-2
DM6MRSC HS Investigative
DM6MRSC SN adociasulfate-2; CHEMBL426141; Adociasulfate 2
DM6MRSC DT Small molecular drug
DM6MRSC PC 10010225
DM6MRSC MW 738.9
DM6MRSC FM C36H52Na2O9S2
DM6MRSC IC InChI=1S/C36H54O9S2.2Na/c1-31(2)15-8-16-36(7)25(31)11-18-34(5)27-12-17-33(4)26(32(27,3)20-14-29(34)43-36)13-19-35(6)28(33)21-22-23(44-46(37,38)39)9-10-24(30(22)35)45-47(40,41)42;;/h9-10,25-29H,8,11-21H2,1-7H3,(H,37,38,39)(H,40,41,42);;/q;2*+1/p-2/t25-,26+,27+,28-,29-,32+,33+,34-,35-,36-;;/m0../s1
DM6MRSC CS C[C@]12CC[C@H]3[C@]([C@@H]1CC[C@@]4([C@@H]2CC[C@]5([C@H]4CC6=C(C=CC(=C65)OS(=O)(=O)[O-])OS(=O)(=O)[O-])C)C)(CC[C@@H]7[C@@](O3)(CCCC7(C)C)C)C.[Na+].[Na+]
DM6MRSC IK LLFWGACFIWPWDA-TZYHAVDYSA-L
DM6MRSC IU disodium;[(1R,2S,5S,13S,14R,17R,18S,21S,26S,28S)-1,5,14,18,22,22,26-heptamethyl-7-sulfonatooxy-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-10-yl] sulfate
DM6MRSC DE Discovery agent
DM9IBHU ID DM9IBHU
DM9IBHU DN Ado-P-Ch2-P-Ps-Ado
DM9IBHU HS Investigative
DM9IBHU SN ADO-P-CH2-P-PS-ADO; p1-p2-methylene-p3-thio-diadenosine triphosphate; IB2; AC1OAHZQ; DB04389; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-hydroxyphosphoryl]methyl]phosphinic acid; Adenosine 5'-[[alpha,beta-methylene]diphosphoric acid beta-[5'-adenosyloxy(mercapto)phosphinyl]] ester
DM9IBHU DT Small molecular drug
DM9IBHU PC 6858209
DM9IBHU MW 770.5
DM9IBHU FM C21H29N10O14P3S
DM9IBHU IC InChI=1S/C21H29N10O14P3S/c22-16-10-18(26-3-24-16)30(5-28-10)20-14(34)12(32)8(43-20)1-41-46(36,37)7-47(38,39)45-48(40,49)42-2-9-13(33)15(35)21(44-9)31-6-29-11-17(23)25-4-27-19(11)31/h3-6,8-9,12-15,20-21,32-35H,1-2,7H2,(H,36,37)(H,38,39)(H,40,49)(H2,22,24,26)(H2,23,25,27)/t8-,9-,12-,13-,14-,15-,20-,21-,48?/m1/s1
DM9IBHU CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)OP(=S)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O)N
DM9IBHU IK UJCWOSLCGXVJOD-VEBDTVEDSA-N
DM9IBHU IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-hydroxyphosphoryl]methyl]phosphinic acid
DM9IBHU DE Discovery agent
DMQ1F7J ID DMQ1F7J
DMQ1F7J DN ADP ribose
DMQ1F7J HS Investigative
DMQ1F7J SN ADP Ribose; ADPR (nucleotide); Adenosine diphosphoribose; Ribose adenosinediphosphate; Adenosine pyrophosphate-ribose; [32P]-ADP-ribose; AC1L1J3O; GTPL2444; Adenosine 5'-diphosphate, D-ribose ester; Adenosine 5'-diphosphate, D-ribose ester (6CI); Adenosine 5'-pyrophosphate, 5'-5-ester with D-ribofuranose (7CI); Ribofuranose, 5-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), D-; Adenosine 5'-(trihydrogen pyrophosphate), 5'-5-ester with D-ribofuranose; Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribo
DMQ1F7J DT Small molecular drug
DMQ1F7J PC 30243
DMQ1F7J MW 559.32
DMQ1F7J FM C15H23N5O14P2
DMQ1F7J IC InChI=1S/C15H23N5O14P2/c16-13-9-14(18-4-17-13)20(5-19-9)15-12(26)11(25)8(33-15)3-32-36(29,30)34-35(27,28)31-2-7(23)10(24)6(22)1-21/h1,4-8,10-12,15,22-26H,2-3H2,(H,27,28)(H,29,30)(H2,16,17,18)/t6-,7+,8+,10-,11+,12+,15+/m0/s1
DMQ1F7J CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OC[C@H]([C@H]([C@H](C=O)O)O)O)O)O)N
DMQ1F7J IK PWJFNRJRHXWEPT-AOOZFPJJSA-N
DMQ1F7J IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4R)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate
DMQ1F7J CA CAS 20762-30-5
DMQ1F7J DE Discovery agent
DMVWM75 ID DMVWM75
DMVWM75 DN Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2
DMVWM75 HS Investigative
DMVWM75 PC 73345612
DMVWM75 MW 1696
DMVWM75 FM C80H118N28O14
DMVWM75 IC InChI=1S/C80H118N28O14/c1-3-13-55(69(115)101-59(21-11-35-95-79(89)90)73(119)105-61(65(83)111)37-43-23-27-47(109)28-24-43)99-71(117)57(19-9-33-93-77(85)86)103-75(121)63(39-45-41-97-53-17-7-5-15-49(45)53)107-67(113)51(81)31-32-52(82)68(114)108-64(40-46-42-98-54-18-8-6-16-50(46)54)76(122)104-58(20-10-34-94-78(87)88)72(118)100-56(14-4-2)70(116)102-60(22-12-36-96-80(91)92)74(120)106-62(66(84)112)38-44-25-29-48(110)30-26-44/h5-8,15-18,23-30,41-42,51-52,55-64,97-98,109-110H,3-4,9-14,19-22,31-40,81-82H2,1-2H3,(H2,83,111)(H2,84,112)(H,99,117)(H,100,118)(H,101,115)(H,102,116)(H,103,121)(H,104,122)(H,105,119)(H,106,120)(H,107,113)(H,108,114)(H4,85,86,93)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t51-,52-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1
DMVWM75 CS CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC[C@@H](C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N)N)N
DMVWM75 IK TWBRLXCGQXCXSU-HCHGDIHTSA-N
DMVWM75 IU (2S,5S)-2,5-diamino-N,N'-bis[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]hexanediamide
DMVWM75 DE Discovery agent
DMQBCPK ID DMQBCPK
DMQBCPK DN ADR58
DMQBCPK HS Investigative
DMQBCPK DT Aptamer
DMQBCPK DE Rheumatoid arthritis
DMP8NSU ID DMP8NSU
DMP8NSU DN ADRENOGLOMERULOTROPIN
DMP8NSU HS Investigative
DMP8NSU SN Adrenoglomerulotropin; MMTC; 1210-56-6; BRN 0747865; 1-Methyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline; CHEMBL221811; RDUORFDQRFHYBF-UHFFFAOYSA-N; 6-Methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline; 9H-Pyrido(3,4-b)indole, 1,2,3,4-tetrahydro-6-methoxy-1-methyl-; 6-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1H-Pyrido[3,4-b]indole, 2,3,4,9-tetrahydro-6-methoxy-1-methyl-; 1-Methyl-6-methoxy-1,2,3,4-tetrahydro-2-carboline; 1H-Pyrido(3,4-b)indole, 2,3,4,9-tetrahydro-6-methoxy-1-methyl-; Mmthc
DMP8NSU DT Small molecular drug
DMP8NSU PC 71028
DMP8NSU MW 216.28
DMP8NSU FM C13H16N2O
DMP8NSU IC InChI=1S/C13H16N2O/c1-8-13-10(5-6-14-8)11-7-9(16-2)3-4-12(11)15-13/h3-4,7-8,14-15H,5-6H2,1-2H3
DMP8NSU CS CC1C2=C(CCN1)C3=C(N2)C=CC(=C3)OC
DMP8NSU IK RDUORFDQRFHYBF-UHFFFAOYSA-N
DMP8NSU IU 6-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
DMP8NSU CA CAS 1210-56-6
DMP8NSU DE Discovery agent
DMP7IS0 ID DMP7IS0
DMP7IS0 DN ADS-0101
DMP7IS0 HS Investigative
DMP7IS0 SN ADS-0102; DOM-0101; DOM-0102; Domain antibody therapy (inhalant formulation, COPD/respiratory disease); Domain antibody therapy (inhalant formulation, COPD/respiratory disease), Domantis; DAbs (inhalant formulation, COPD/respiratory disorders), Domantis/Argenta
DMP7IS0 CP Domantis Ltd
DMP7IS0 DT Antibody
DMP7IS0 DE Chronic obstructive pulmonary disease
DM7U4OT ID DM7U4OT
DM7U4OT DN ADS-100380
DM7U4OT HS Investigative
DM7U4OT SN ADS-100380; CHEMBL216885; SCHEMBL5904027; BDBM50198221
DM7U4OT DT Small molecular drug
DM7U4OT PC 44418141
DM7U4OT MW 291.25
DM7U4OT FM C10H8F3N3O2S
DM7U4OT IC InChI=1S/C10H8F3N3O2S/c1-16-5(4-8(14-16)10(11,12)13)6-2-3-7(19-6)9(17)15-18/h2-4,18H,1H3,(H,15,17)
DM7U4OT CS CN1C(=CC(=N1)C(F)(F)F)C2=CC=C(S2)C(=O)NO
DM7U4OT IK CBAUPWKIZUBNOQ-UHFFFAOYSA-N
DM7U4OT IU N-hydroxy-5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-carboxamide
DM7U4OT DE Discovery agent
DMEU6MH ID DMEU6MH
DMEU6MH DN ADS-102550
DMEU6MH HS Investigative
DMEU6MH SN ADS-102550; CHEMBL217716; SCHEMBL5903759; BDBM50198218
DMEU6MH DT Small molecular drug
DMEU6MH PC 10452725
DMEU6MH MW 386.4
DMEU6MH FM C18H18N4O4S
DMEU6MH IC InChI=1S/C18H18N4O4S/c23-18(21-24)17-4-3-16(27-17)13-5-7-22(20-13)8-6-19-10-12-1-2-14-15(9-12)26-11-25-14/h1-5,7,9,19,24H,6,8,10-11H2,(H,21,23)
DMEU6MH CS C1OC2=C(O1)C=C(C=C2)CNCCN3C=CC(=N3)C4=CC=C(S4)C(=O)NO
DMEU6MH IK CCCCPSHFLXQUBH-UHFFFAOYSA-N
DMEU6MH IU 5-[1-[2-(1,3-benzodioxol-5-ylmethylamino)ethyl]pyrazol-3-yl]-N-hydroxythiophene-2-carboxamide
DMEU6MH DE Discovery agent
DMXD0C3 ID DMXD0C3
DMXD0C3 DN ADS-102891
DMXD0C3 HS Investigative
DMXD0C3 SN ADS-102891; CHEMBL424728; SCHEMBL6508765; BDBM50200792
DMXD0C3 DT Small molecular drug
DMXD0C3 PC 11189610
DMXD0C3 MW 430.4
DMXD0C3 FM C22H21F3N4O2
DMXD0C3 IC InChI=1S/C22H21F3N4O2/c1-14-18-12-16(6-9-19(18)28-21(26-14)29-10-2-3-11-29)27-20(30)13-31-17-7-4-15(5-8-17)22(23,24)25/h4-9,12H,2-3,10-11,13H2,1H3,(H,27,30)
DMXD0C3 CS CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)C(F)(F)F
DMXD0C3 IK UPUPELYLRJEQHO-UHFFFAOYSA-N
DMXD0C3 IU N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide
DMXD0C3 DE Discovery agent
DMMYUB9 ID DMMYUB9
DMMYUB9 DN ADS-103168
DMMYUB9 HS Investigative
DMMYUB9 SN ADS-103168; CHEMBL424739; SCHEMBL6532244; BDBM50200783
DMMYUB9 DT Small molecular drug
DMMYUB9 PC 11153928
DMMYUB9 MW 404.4
DMMYUB9 FM C20H19F3N4O2
DMMYUB9 IC InChI=1S/C20H19F3N4O2/c21-20(22,23)13-3-6-15(7-4-13)29-12-18(28)24-14-5-8-16-17(11-14)26-19(25-16)27-9-1-2-10-27/h3-8,11H,1-2,9-10,12H2,(H,24,28)(H,25,26)
DMMYUB9 CS C1CCN(C1)C2=NC3=C(N2)C=C(C=C3)NC(=O)COC4=CC=C(C=C4)C(F)(F)F
DMMYUB9 IK UWZAIHJEZDRIJB-UHFFFAOYSA-N
DMMYUB9 IU N-(2-pyrrolidin-1-yl-3H-benzimidazol-5-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide
DMMYUB9 DE Discovery agent
DMUMF0B ID DMUMF0B
DMUMF0B DN ADS-103214
DMUMF0B HS Investigative
DMUMF0B SN ADS-103214; CHEMBL216430; SCHEMBL3831809; BDBM50200793
DMUMF0B DT Small molecular drug
DMUMF0B PC 11281523
DMUMF0B MW 418.4
DMUMF0B FM C21H21F3N4O2
DMUMF0B IC InChI=1S/C21H21F3N4O2/c1-27-18-12-15(6-9-17(18)26-20(27)28-10-2-3-11-28)25-19(29)13-30-16-7-4-14(5-8-16)21(22,23)24/h4-9,12H,2-3,10-11,13H2,1H3,(H,25,29)
DMUMF0B CS CN1C2=C(C=CC(=C2)NC(=O)COC3=CC=C(C=C3)C(F)(F)F)N=C1N4CCCC4
DMUMF0B IK BHTNQFXUFJJYNG-UHFFFAOYSA-N
DMUMF0B IU N-(3-methyl-2-pyrrolidin-1-ylbenzimidazol-5-yl)-2-[4-(trifluoromethyl)phenoxy]acetamide
DMUMF0B DE Discovery agent
DMH9A4S ID DMH9A4S
DMH9A4S DN ADS-103253
DMH9A4S HS Investigative
DMH9A4S SN ADS-103253; CHEMBL216228; SCHEMBL6507329; BDBM50200788
DMH9A4S DT Small molecular drug
DMH9A4S PC 11452268
DMH9A4S MW 396.9
DMH9A4S FM C21H21ClN4O2
DMH9A4S IC InChI=1S/C21H21ClN4O2/c1-14-18-12-16(24-20(27)13-28-17-7-4-15(22)5-8-17)6-9-19(18)25-21(23-14)26-10-2-3-11-26/h4-9,12H,2-3,10-11,13H2,1H3,(H,24,27)
DMH9A4S CS CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)Cl
DMH9A4S IK MXDQNCXNQJMIEH-UHFFFAOYSA-N
DMH9A4S IU 2-(4-chlorophenoxy)-N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)acetamide
DMH9A4S DE Discovery agent
DMLIOV2 ID DMLIOV2
DMLIOV2 DN ADS-103254
DMLIOV2 HS Investigative
DMLIOV2 SN ADS-103254; CHEMBL217712; SCHEMBL6509918; BDBM50200785
DMLIOV2 DT Small molecular drug
DMLIOV2 PC 11155432
DMLIOV2 MW 461.5
DMLIOV2 FM C23H26F3N5O2
DMLIOV2 IC InChI=1S/C23H26F3N5O2/c1-15-19-13-17(7-10-20(19)29-22(27-15)31(4)12-11-30(2)3)28-21(32)14-33-18-8-5-16(6-9-18)23(24,25)26/h5-10,13H,11-12,14H2,1-4H3,(H,28,32)
DMLIOV2 CS CC1=C2C=C(C=CC2=NC(=N1)N(C)CCN(C)C)NC(=O)COC3=CC=C(C=C3)C(F)(F)F
DMLIOV2 IK ZALRLWFCZSVMRA-UHFFFAOYSA-N
DMLIOV2 IU N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methylquinazolin-6-yl]-2-[4-(trifluoromethyl)phenoxy]acetamide
DMLIOV2 DE Discovery agent
DMBN6IE ID DMBN6IE
DMBN6IE DN ADS-103274
DMBN6IE HS Investigative
DMBN6IE SN ADS-103274; CHEMBL276393; BDBM50241099
DMBN6IE DT Small molecular drug
DMBN6IE PC 16665072
DMBN6IE MW 449.5
DMBN6IE FM C22H26F3N5O2
DMBN6IE IC InChI=1S/C22H26F3N5O2/c1-28(2)11-12-29(3)21-27-18-10-7-16(13-19(18)30(21)4)26-20(31)14-32-17-8-5-15(6-9-17)22(23,24)25/h5-10,13H,11-12,14H2,1-4H3,(H,26,31)
DMBN6IE CS CN1C2=C(C=CC(=C2)NC(=O)COC3=CC=C(C=C3)C(F)(F)F)N=C1N(C)CCN(C)C
DMBN6IE IK KMPCTCXLXOJTGD-UHFFFAOYSA-N
DMBN6IE IU N-[2-[2-(dimethylamino)ethyl-methylamino]-3-methylbenzimidazol-5-yl]-2-[4-(trifluoromethyl)phenoxy]acetamide
DMBN6IE DE Discovery agent
DM0C4QD ID DM0C4QD
DM0C4QD DN ADS-103293
DM0C4QD HS Investigative
DM0C4QD SN ADS-103293; CHEMBL217626; SCHEMBL6507646; BDBM50200786
DM0C4QD DT Small molecular drug
DM0C4QD PC 11440885
DM0C4QD MW 396.9
DM0C4QD FM C21H21ClN4O2
DM0C4QD IC InChI=1S/C21H21ClN4O2/c1-14-16-12-15(24-20(27)13-28-19-7-3-2-6-17(19)22)8-9-18(16)25-21(23-14)26-10-4-5-11-26/h2-3,6-9,12H,4-5,10-11,13H2,1H3,(H,24,27)
DM0C4QD CS CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=CC=C4Cl
DM0C4QD IK XIYWAMFWFFFEQL-UHFFFAOYSA-N
DM0C4QD IU 2-(2-chlorophenoxy)-N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)acetamide
DM0C4QD DE Discovery agent
DMM2Q9L ID DMM2Q9L
DMM2Q9L DN ADS-103294
DMM2Q9L HS Investigative
DMM2Q9L SN ADS-103294; CHEMBL214678; SCHEMBL6533940; BDBM50200791
DMM2Q9L DT Small molecular drug
DMM2Q9L PC 11188955
DMM2Q9L MW 406.4
DMM2Q9L FM C20H21F3N4O2
DMM2Q9L IC InChI=1S/C20H21F3N4O2/c1-12(2)24-19-26-16-9-6-14(10-17(16)27(19)3)25-18(28)11-29-15-7-4-13(5-8-15)20(21,22)23/h4-10,12H,11H2,1-3H3,(H,24,26)(H,25,28)
DMM2Q9L CS CC(C)NC1=NC2=C(N1C)C=C(C=C2)NC(=O)COC3=CC=C(C=C3)C(F)(F)F
DMM2Q9L IK YFLYQHULFMRTHA-UHFFFAOYSA-N
DMM2Q9L IU N-[3-methyl-2-(propan-2-ylamino)benzimidazol-5-yl]-2-[4-(trifluoromethyl)phenoxy]acetamide
DMM2Q9L DE Discovery agent
DMKCOYE ID DMKCOYE
DMKCOYE DN ADS-103316
DMKCOYE HS Investigative
DMKCOYE SN ADS-103316; CHEMBL216754; SCHEMBL6507269; BDBM50200790
DMKCOYE DT Small molecular drug
DMKCOYE PC 11440762
DMKCOYE MW 392.5
DMKCOYE FM C22H24N4O3
DMKCOYE IC InChI=1S/C22H24N4O3/c1-15-19-13-16(5-10-20(19)25-22(23-15)26-11-3-4-12-26)24-21(27)14-29-18-8-6-17(28-2)7-9-18/h5-10,13H,3-4,11-12,14H2,1-2H3,(H,24,27)
DMKCOYE CS CC1=C2C=C(C=CC2=NC(=N1)N3CCCC3)NC(=O)COC4=CC=C(C=C4)OC
DMKCOYE IK YXNSFDJSYOVION-UHFFFAOYSA-N
DMKCOYE IU 2-(4-methoxyphenoxy)-N-(4-methyl-2-pyrrolidin-1-ylquinazolin-6-yl)acetamide
DMKCOYE DE Discovery agent
DMA74PO ID DMA74PO
DMA74PO DN ADX-63365
DMA74PO HS Investigative
DMA74PO SN MGluR5 PAM; ADX-4; ADX-47273; ADX-50938; MGluR5 positive modulators, Addex; ADX-4 program, Addex
DMA74PO CP Addex Pharmaceuticals SA
DMA74PO DT Small molecular drug
DMA74PO PC 11383075
DMA74PO MW 369.4
DMA74PO FM C20H17F2N3O2
DMA74PO IC InChI=1S/C20H17F2N3O2/c21-16-7-3-13(4-8-16)18-23-19(27-24-18)15-2-1-11-25(12-15)20(26)14-5-9-17(22)10-6-14/h3-10,15H,1-2,11-12H2/t15-/m0/s1
DMA74PO CS C1C[C@@H](CN(C1)C(=O)C2=CC=C(C=C2)F)C3=NC(=NO3)C4=CC=C(C=C4)F
DMA74PO IK VXQCCZHCFBHTTD-HNNXBMFYSA-N
DMA74PO IU (4-fluorophenyl)-[(3S)-3-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone
DMA74PO CA CAS 851881-60-2
DMA74PO DE Central nervous system disease
DM3WAG6 ID DM3WAG6
DM3WAG6 DN ADX71743
DM3WAG6 HS Investigative
DM3WAG6 SN ADX 71743; ADX-71743
DM3WAG6 DT Small molecular drug
DM3WAG6 PC 53391766
DM3WAG6 MW 269.34
DM3WAG6 FM C17H19NO2
DM3WAG6 IC InChI=1S/C17H19NO2/c1-4-16-18-17-14(19)8-12(9-15(17)20-16)13-6-5-10(2)7-11(13)3/h5-7,12H,4,8-9H2,1-3H3
DM3WAG6 CS CCC1=NC2=C(O1)CC(CC2=O)C3=C(C=C(C=C3)C)C
DM3WAG6 IK CPKZCQHJDFSOJT-UHFFFAOYSA-N
DM3WAG6 IU 6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydro-5H-1,3-benzoxazol-4-one
DM3WAG6 DE Discovery agent
DM70H6P ID DM70H6P
DM70H6P DN ADX-88178
DM70H6P HS Investigative
DM70H6P SN MGluR4 positive modulators, Addex/Merck; MGluR4 PAM modulators (oral, Parkinson's disease/anxiety); MGluR4 PAM modulators (oral, Parkinson's disease/anxiety), Addex/Merck & Co
DM70H6P CP Addex Pharmaceuticals SA
DM70H6P DT Small molecular drug
DM70H6P PC 46836872
DM70H6P MW 272.33
DM70H6P FM C12H12N6S
DM70H6P IC InChI=1S/C12H12N6S/c1-7-3-4-13-11(16-7)18-12-17-10(8(2)19-12)9-5-14-15-6-9/h3-6H,1-2H3,(H,14,15)(H,13,16,17,18)
DM70H6P CS CC1=NC(=NC=C1)NC2=NC(=C(S2)C)C3=CNN=C3
DM70H6P IK MIQNXKWDQRNHAU-UHFFFAOYSA-N
DM70H6P IU 5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-amine
DM70H6P DE Anxiety disorder
DMANEH2 ID DMANEH2
DMANEH2 DN AE-9C90CB
DMANEH2 HS Investigative
DMANEH2 SN Muscarinic M3 antagonists (urinary incontinence); RBx-7643; RBx-8444; RBx-9611; Muscarinic M3 antagonists (urinary incontinence), Daiichi Sankyo; Muscarinic M3 antagonists (urinary incontinence), Ranbaxy
DMANEH2 CP Ranbaxy Laboratories Ltd
DMANEH2 DE Overactive bladder
DMZ8SV3 ID DMZ8SV3
DMZ8SV3 DN AEKKDEGPYRMEHFRWGSPPKD
DMZ8SV3 HS Investigative
DMZ8SV3 PC 16135998
DMZ8SV3 MW 2660.9
DMZ8SV3 FM C118H174N34O35S
DMZ8SV3 IC InChI=1S/C118H174N34O35S/c1-63(122)97(167)135-77(36-39-93(159)160)105(175)137-71(23-8-11-42-119)100(170)136-72(24-9-12-43-120)102(172)147-84(55-95(163)164)111(181)140-76(35-38-92(157)158)98(168)132-60-91(156)150-47-16-28-87(150)112(182)148-81(52-65-31-33-68(154)34-32-65)109(179)138-74(26-14-45-128-117(123)124)101(171)142-79(41-50-188-2)107(177)141-78(37-40-94(161)162)106(176)146-83(54-67-58-127-62-133-67)110(180)144-80(51-64-19-4-3-5-20-64)108(178)139-75(27-15-46-129-118(125)126)103(173)145-82(53-66-57-130-70-22-7-6-21-69(66)70)99(169)131-59-90(155)134-86(61-153)114(184)152-49-18-30-89(152)115(185)151-48-17-29-88(151)113(183)143-73(25-10-13-44-121)104(174)149-85(116(186)187)56-96(165)166/h3-7,19-22,31-34,57-58,62-63,71-89,130,153-154H,8-18,23-30,35-56,59-61,119-122H2,1-2H3,(H,127,133)(H,131,169)(H,132,168)(H,134,155)(H,135,167)(H,136,170)(H,137,175)(H,138,179)(H,139,178)(H,140,181)(H,141,177)(H,142,171)(H,143,183)(H,144,180)(H,145,173)(H,146,176)(H,147,172)(H,148,182)(H,149,174)(H,157,158)(H,159,160)(H,161,162)(H,163,164)(H,165,166)(H,186,187)(H4,123,124,128)(H4,125,126,129)/t63-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-/m0/s1
DMZ8SV3 CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)NCC(=O)N[C@@H](CO)C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N
DMZ8SV3 IK XLLJFSCSXTYVTN-UPWOUFKKSA-N
DMZ8SV3 IU (2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]butanedioic acid
DMZ8SV3 CA CAS 9034-42-8
DMZ8SV3 DE Discovery agent
DME0I6U ID DME0I6U
DME0I6U DN Aerophobin-1
DME0I6U HS Investigative
DME0I6U SN aerophobin-1; CHEMBL479515
DME0I6U DT Small molecular drug
DME0I6U PC 14484008
DME0I6U MW 476.12
DME0I6U FM C15H16Br2N4O4
DME0I6U IC InChI=1S/C15H16Br2N4O4/c1-24-12-9(16)4-15(13(22)11(12)17)5-10(21-25-15)14(23)19-3-2-8-6-18-7-20-8/h4,6-7,13,22H,2-3,5H2,1H3,(H,18,20)(H,19,23)
DME0I6U CS COC1=C(C(C2(CC(=NO2)C(=O)NCCC3=CN=CN3)C=C1Br)O)Br
DME0I6U IK MDUQIEXQKMPARD-UHFFFAOYSA-N
DME0I6U IU 7,9-dibromo-6-hydroxy-N-[2-(1H-imidazol-5-yl)ethyl]-8-methoxy-1-oxa-2-azaspiro[4.5]deca-2,7,9-triene-3-carboxamide
DME0I6U DE Discovery agent
DMULWOG ID DMULWOG
DMULWOG DN AEZS-115
DMULWOG HS Investigative
DMULWOG SN D-85108; LHRH antagonist, Solvay; LHRH antagonist, Zentaris; ZEN-019; LHRH antagonists, Solvay/AEterna Zentaris
DMULWOG CP AEterna Zentaris Inc
DMULWOG DE Solid tumour/cancer
DMM52FD ID DMM52FD
DMM52FD DN AEZS-126
DMM52FD HS Investigative
DMM52FD SN AEZS-129; AEZS-132; D-106669; D-87503; Dual PI3K/ERK kinase inhibitors, AEterna Zentaris
DMM52FD CP AEterna Zentaris Inc
DMM52FD PC 25151705
DMM52FD MW 414.5
DMM52FD FM C19H22N6O3S
DMM52FD IC InChI=1S/C19H22N6O3S/c1-5-20-19(29)25-15-7-6-12-18(23-15)24-16(10-21-12)22-11-8-13(26-2)17(28-4)14(9-11)27-3/h6-10H,5H2,1-4H3,(H3,20,22,23,24,25,29)
DMM52FD CS CCNC(=S)NC1=NC2=NC(=CN=C2C=C1)NC3=CC(=C(C(=C3)OC)OC)OC
DMM52FD IK YJGOOHUUMIONLF-UHFFFAOYSA-N
DMM52FD IU 1-ethyl-3-[3-(3,4,5-trimethoxyanilino)pyrido[2,3-b]pyrazin-6-yl]thiourea
DMM52FD DE Solid tumour/cancer
DMN9RE5 ID DMN9RE5
DMN9RE5 DN AEZS-131
DMN9RE5 HS Investigative
DMN9RE5 SN ERK inhibitor (cancer), AEterna
DMN9RE5 CP AEterna Zentaris Inc
DMN9RE5 DE Solid tumour/cancer
DMOYADT ID DMOYADT
DMOYADT DN AF150(S)
DMOYADT HS Investigative
DMOYADT SN AF150(S); SCHEMBL1328277; AF-150S; VGGGBQVTSUMURJ-UHFFFAOYSA-N; AF 150(S); AF-150(S); L007073; 1-methylpiperidine-4-spiro-(2'-methylthiazoline); 2,8-dimethyl-1-thia-3,8-diaza-spiro[4.5]dec-2-ene; 1-Thia-3,8-diazaspiro(4.5)dec-2-ene, 2,8-dimethyl-
DMOYADT DT Small molecular drug
DMOYADT PC 10176415
DMOYADT MW 184.3
DMOYADT FM C9H16N2S
DMOYADT IC InChI=1S/C9H16N2S/c1-8-10-7-9(12-8)3-5-11(2)6-4-9/h3-7H2,1-2H3
DMOYADT CS CC1=NCC2(S1)CCN(CC2)C
DMOYADT IK VGGGBQVTSUMURJ-UHFFFAOYSA-N
DMOYADT IU 2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-2-ene
DMOYADT CA CAS 138300-72-8
DMOYADT DE Discovery agent
DM6B9CK ID DM6B9CK
DM6B9CK DN AF-3473
DM6B9CK HS Investigative
DM6B9CK SN 5-HT4 antagonist (neuropathic pain), Angelini Pharmaceuticals
DM6B9CK CP Angelini Pharmaceuticals SpA
DM6B9CK DE Neuropathic pain
DMXQ3MO ID DMXQ3MO
DMXQ3MO DN AF353
DMXQ3MO HS Investigative
DMXQ3MO SN AF-353; AF 353
DMXQ3MO DT Small molecular drug
DMXQ3MO PC 15953802
DMXQ3MO MW 400.21
DMXQ3MO FM C14H17IN4O2
DMXQ3MO IC InChI=1S/C14H17IN4O2/c1-7(2)8-4-11(20-3)9(15)5-10(8)21-12-6-18-14(17)19-13(12)16/h4-7H,1-3H3,(H4,16,17,18,19)
DMXQ3MO CS CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)I)OC
DMXQ3MO IK AATPYXMXFBBKFO-UHFFFAOYSA-N
DMXQ3MO IU 5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidine-2,4-diamine
DMXQ3MO CA CAS 865305-30-2
DMXQ3MO DE Discovery agent
DM65TUP ID DM65TUP
DM65TUP DN AFC-5128
DM65TUP HS Investigative
DM65TUP SN AFC-5261; P2X7 purinoreceptor antagonists (neuropathic pain/ multiple sclerosis); P2X7 purinoreceptor antagonist (inflammatory disease/neurodegenerative disorder), Affectis; P2X7 purinoreceptor antagonists (neuropathic pain/ multiple sclerosis), Affectis
DM65TUP CP Affectis Pharmaceuticals AG
DM65TUP DE Autoimmune diabetes
DME9Y8Q ID DME9Y8Q
DME9Y8Q DN AFD(R)
DME9Y8Q HS Investigative
DME9Y8Q SN AFD(R); GTPL2937; CHEMBL382739; SCHEMBL12084862; Phosphoric acid (R)-2-methyl-2-amino-4-(4-heptyloxyphenyl)butyl ester; [(2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate
DME9Y8Q DT Small molecular drug
DME9Y8Q PC 10904818
DME9Y8Q MW 373.4
DME9Y8Q FM C18H32NO5P
DME9Y8Q IC InChI=1S/C18H32NO5P/c1-3-4-5-6-7-14-23-17-10-8-16(9-11-17)12-13-18(2,19)15-24-25(20,21)22/h8-11H,3-7,12-15,19H2,1-2H3,(H2,20,21,22)/t18-/m1/s1
DME9Y8Q CS CCCCCCCOC1=CC=C(C=C1)CC[C@](C)(COP(=O)(O)O)N
DME9Y8Q IK NMRLBSIYIBOLLJ-GOSISDBHSA-N
DME9Y8Q IU [(2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate
DME9Y8Q DE Discovery agent
DMNY8H7 ID DMNY8H7
DMNY8H7 DN AF-DX-384
DMNY8H7 HS Investigative
DMNY8H7 SN MZDYABXXPZNUCT-UHFFFAOYSA-N; AF-DX 384; AFDX384; 118290-27-0; CHEMBL279453; N-(2-(2-((Dipropylamino)methyl)piperidin-1-yl)ethyl)-6-oxo-5H-benzo[e]pyrido[3,2-b][1,4]diazepine-11(6H)-carboxamide; N-[2-[2-[(Dipropylamino)methyl]-1-piperidinyl]ethyl]-5,6-dihydro-6-oxo-11H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide; AFDX-384; N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide; [3H]AF-DX 384; [3H]AF DX-384; AC1L3ONW; GTPL368; 118290-26-9; SCHEMBL9824222; AF-DX-384
DMNY8H7 DT Small molecular drug
DMNY8H7 PC 119357
DMNY8H7 MW 478.6
DMNY8H7 FM C27H38N6O2
DMNY8H7 IC InChI=1S/C27H38N6O2/c1-3-16-31(17-4-2)20-21-10-7-8-18-32(21)19-15-29-27(35)33-24-13-6-5-11-22(24)26(34)30-23-12-9-14-28-25(23)33/h5-6,9,11-14,21H,3-4,7-8,10,15-20H2,1-2H3,(H,29,35)(H,30,34)
DMNY8H7 CS CCCN(CCC)CC1CCCCN1CCNC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
DMNY8H7 IK MZDYABXXPZNUCT-UHFFFAOYSA-N
DMNY8H7 IU N-[2-[2-[(dipropylamino)methyl]piperidin-1-yl]ethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepine-11-carboxamide
DMNY8H7 CB CHEBI:110176
DMNY8H7 DE Discovery agent
DM6D3NQ ID DM6D3NQ
DM6D3NQ DN Affinitak + Cisplatin
DM6D3NQ HS Investigative
DM6D3NQ TC Antisense
DM6D3NQ DT Combination drug (Antisense drug)
DM6D3NQ PC 71587700; 84093
DM6D3NQ DE Non-small-cell lung cancer
DMU98ES ID DMU98ES
DMU98ES DN Affinitak + Gemcitabine
DMU98ES HS Investigative
DMU98ES TC Antisense
DMU98ES DT Combination drug (Antisense drug)
DMU98ES PC 71587700; 60750
DMU98ES DE Non-small-cell lung cancer
DM2R5F9 ID DM2R5F9
DM2R5F9 DN AFLATREME
DM2R5F9 HS Investigative
DM2R5F9 SN Aflatrem; UNII-ZEL123Y65D; 70553-75-2; ZEL123Y65D; CHEMBL327558; AFLATREME; C20555; 4H-3,15a-Epoxy-1-benzoxepino(6',7':6,7)indeno(1,2-b)indol-4-one, 9-(1,1-dimethyl-2-propenyl)-2,3,5b,6,7,7a,8,13,13b,13c,14,15-dodecahydro-5b-hydroxy-2,2,13b,13c-tetramethyl-, (3R-(3alpha,5balpha,7abeta,13balpha,13cbeta,15aalpha))-; 4H-3,15a-Epoxy-1-benzoxepino(6',7':6,7)indeno(1,2-b)indol-4-one, 9-(1,1-dimethyl-2-propenyl)-2,3,5b,6,7,7a,8,13,13b,13c,14,15-dodecahydro-5b-hydroxy-2,2,13b,13c-tetramethyl-, (3R,5bS,7aS,13bS,13cR,15aS)-
DM2R5F9 DT Small molecular drug
DM2R5F9 PC 21118293
DM2R5F9 MW 501.7
DM2R5F9 FM C32H39NO4
DM2R5F9 IC InChI=1S/C32H39NO4/c1-8-27(2,3)20-10-9-11-21-24(20)19-16-18-12-13-31(35)23-17-22(34)26-28(4,5)37-32(23,36-26)15-14-29(31,6)30(18,7)25(19)33-21/h8-11,17-18,26,33,35H,1,12-16H2,2-7H3/t18-,26-,29+,30+,31+,32-/m0/s1
DM2R5F9 CS C[C@]12CC[C@]34C(=CC(=O)[C@H](O3)C(O4)(C)C)[C@@]1(CC[C@@H]5[C@@]2(C6=C(C5)C7=C(C=CC=C7N6)C(C)(C)C=C)C)O
DM2R5F9 IK YVDJBQQJIDPRKP-SLUQHKSNSA-N
DM2R5F9 IU (1S,4R,5S,16S,19S,23R)-19-hydroxy-4,5,24,24-tetramethyl-12-(2-methylbut-3-en-2-yl)-25,26-dioxa-7-azaheptacyclo[21.2.1.01,20.04,19.05,16.06,14.08,13]hexacosa-6(14),8,10,12,20-pentaen-22-one
DM2R5F9 CA CAS 70553-75-2
DM2R5F9 DE Discovery agent
DM8U1IW ID DM8U1IW
DM8U1IW DN AFM-21
DM8U1IW HS Investigative
DM8U1IW SN Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed
DM8U1IW CP Affimed Therapeutics AG
DM8U1IW DT Antibody
DM8U1IW DE Solid tumour/cancer
DM4WVMU ID DM4WVMU
DM4WVMU DN AFP-07
DM4WVMU HS Investigative
DM4WVMU SN AFP07; AFP 07
DM4WVMU DT Small molecular drug
DM4WVMU PC 5311226
DM4WVMU MW 388.4
DM4WVMU FM C20H30F2O5
DM4WVMU IC InChI=1S/C20H30F2O5/c1-2-3-4-7-13(23)10-11-14-15(24)12-16-19(14)20(21,22)17(27-16)8-5-6-9-18(25)26/h8,10-11,13-16,19,23-24H,2-7,9,12H2,1H3,(H,25,26)/b11-10+,17-8-/t13-,14-,15+,16-,19+/m0/s1
DM4WVMU CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C(/C(=C/CCCC(=O)O)/O2)(F)F)O)O
DM4WVMU IK ILUYAOVLMOPQAI-BFOOZVJSSA-N
DM4WVMU IU (5Z)-5-[(3aR,4R,5R,6aS)-3,3-difluoro-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-2-ylidene]pentanoic acid
DM4WVMU DE Discovery agent
DMF0SPB ID DMF0SPB
DMF0SPB DN AG 1024
DMF0SPB HS Investigative
DMF0SPB SN tyrphostin AG 1024; AG-1024; AG1024
DMF0SPB DT Small molecular drug
DMF0SPB PC 2044
DMF0SPB MW 305.17
DMF0SPB FM C14H13BrN2O
DMF0SPB IC InChI=1S/C14H13BrN2O/c1-14(2,3)11-5-9(4-10(7-16)8-17)6-12(15)13(11)18/h4-6,18H,1-3H3
DMF0SPB CS CC(C)(C)C1=C(C(=CC(=C1)C=C(C#N)C#N)Br)O
DMF0SPB IK ABBADGFSRBWENF-UHFFFAOYSA-N
DMF0SPB IU 2-[(3-bromo-5-tert-butyl-4-hydroxyphenyl)methylidene]propanedinitrile
DMF0SPB CA CAS 65678-07-1
DMF0SPB CB CHEBI:93757
DMF0SPB DE Discovery agent
DMDYS0L ID DMDYS0L
DMDYS0L DN AG 112
DMDYS0L HS Investigative
DMDYS0L SN tyrphostin A48; tyrphostin AG 112; AG-112; AG112
DMDYS0L DT Small molecular drug
DMDYS0L PC 5328804
DMDYS0L MW 236.23
DMDYS0L FM C13H8N4O
DMDYS0L IC InChI=1S/C13H8N4O/c14-6-10(13(17)11(7-15)8-16)5-9-1-3-12(18)4-2-9/h1-5,18H,17H2/b10-5+
DMDYS0L CS C1=CC(=CC=C1/C=C(\\C#N)/C(=C(C#N)C#N)N)O
DMDYS0L IK DXVJRTIPBNBLLB-BJMVGYQFSA-N
DMDYS0L IU (3Z)-2-amino-4-(4-hydroxyphenyl)buta-1,3-diene-1,1,3-tricarbonitrile
DMDYS0L CA CAS 122520-87-0
DMDYS0L CB CHEBI:93930
DMDYS0L DE Discovery agent
DMSOUI0 ID DMSOUI0
DMSOUI0 DN AG 9
DMSOUI0 HS Investigative
DMSOUI0 SN tyrphostin 1; tyrphostin A1; AG9; AG-9
DMSOUI0 DT Small molecular drug
DMSOUI0 PC 2063
DMSOUI0 MW 184.19
DMSOUI0 FM C11H8N2O
DMSOUI0 IC InChI=1S/C11H8N2O/c1-14-11-4-2-9(3-5-11)6-10(7-12)8-13/h2-6H,1H3
DMSOUI0 CS COC1=CC=C(C=C1)C=C(C#N)C#N
DMSOUI0 IK UOHFCPXBKJPCAD-UHFFFAOYSA-N
DMSOUI0 IU 2-[(4-methoxyphenyl)methylidene]propanedinitrile
DMSOUI0 CA CAS 2826-26-8
DMSOUI0 CB CHEBI:92740
DMSOUI0 DE Discovery agent
DMHFYNE ID DMHFYNE
DMHFYNE DN AG-014376
DMHFYNE HS Investigative
DMHFYNE SN AG-014376; CHEMBL361489; SCHEMBL7159231; BDBM50154730; 6-(4-Dimethylaminomethyl-phenyl)-3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-one
DMHFYNE DT Small molecular drug
DMHFYNE PC 9797108
DMHFYNE MW 319.4
DMHFYNE FM C20H21N3O
DMHFYNE IC InChI=1S/C20H21N3O/c1-22(2)13-14-6-8-15(9-7-14)18-12-16-4-3-5-17-19(16)23(18)11-10-21-20(17)24/h3-9,12H,10-11,13H2,1-2H3,(H,21,24)
DMHFYNE CS CN(C)CC1=CC=C(C=C1)C2=CC3=C4N2CCNC(=O)C4=CC=C3
DMHFYNE IK PISBNXWDAGANOP-UHFFFAOYSA-N
DMHFYNE IU 2-[4-[(dimethylamino)methyl]phenyl]-1,10-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7-tetraen-9-one
DMHFYNE DE Discovery agent
DMW7H28 ID DMW7H28
DMW7H28 DN AG-09/1
DMW7H28 HS Investigative
DMW7H28 SN AG-09/1 [benzimidazole derivative]; ST024252
DMW7H28 DT Small molecular drug
DMW7H28 PC 3901842
DMW7H28 MW 358.4
DMW7H28 FM C16H14N4O4S
DMW7H28 IC InChI=1S/C16H14N4O4S/c1-24-12-6-7-13-14(8-12)19-16(18-13)25-9-15(21)17-10-2-4-11(5-3-10)20(22)23/h2-8H,9H2,1H3,(H,17,21)(H,18,19)
DMW7H28 CS COC1=CC2=C(C=C1)N=C(N2)SCC(=O)NC3=CC=C(C=C3)[N+](=O)[O-]
DMW7H28 IK LYQDSNOFTIZWAX-UHFFFAOYSA-N
DMW7H28 IU 2-[(6-methoxy-1H-benzimidazol-2-yl)sulfanyl]-N-(4-nitrophenyl)acetamide
DMW7H28 CA CAS 356776-32-4
DMW7H28 DE Discovery agent
DMZINUY ID DMZINUY
DMZINUY DN AG-11/03
DMZINUY HS Investigative
DMZINUY SN AG-11/03 [benzimidazole derivative]; STK220090
DMZINUY DT Small molecular drug
DMZINUY PC 7342912
DMZINUY MW 359.5
DMZINUY FM C17H17N3O2S2
DMZINUY IC InChI=1S/C17H17N3O2S2/c1-22-12-5-8-14-15(9-12)20-17(19-14)24-10-16(21)18-11-3-6-13(23-2)7-4-11/h3-9H,10H2,1-2H3,(H,18,21)(H,19,20)
DMZINUY CS COC1=CC2=C(C=C1)N=C(N2)SCC(=O)NC3=CC=C(C=C3)SC
DMZINUY IK FKTAXVGJKVSANI-UHFFFAOYSA-N
DMZINUY IU 2-[(6-methoxy-1H-benzimidazol-2-yl)sulfanyl]-N-(4-methylsulfanylphenyl)acetamide
DMZINUY DE Discovery agent
DMVR9G0 ID DMVR9G0
DMVR9G0 DN AG-14
DMVR9G0 HS Investigative
DMVR9G0 SN AG14; AG 14
DMVR9G0 DT Small molecular drug
DMVR9G0 PC 5503194
DMVR9G0 MW 404.4
DMVR9G0 FM C23H20N2O5
DMVR9G0 IC InChI=1S/C23H20N2O5/c1-27-21-11-17(7-9-19(21)28-14-16-5-3-2-4-6-16)13-24-25-23(26)18-8-10-20-22(12-18)30-15-29-20/h2-13H,14-15H2,1H3,(H,25,26)/b24-13-
DMVR9G0 CS COC1=C(C=CC(=C1)/C=N\\NC(=O)C2=CC3=C(C=C2)OCO3)OCC4=CC=CC=C4
DMVR9G0 IK ULOKADSYVZOTTL-CFRMEGHHSA-N
DMVR9G0 IU N-[(Z)-(3-methoxy-4-phenylmethoxyphenyl)methylideneamino]-1,3-benzodioxole-5-carboxamide
DMVR9G0 DE Discovery agent
DMT3ML6 ID DMT3ML6
DMT3ML6 DN AG-213
DMT3ML6 HS Investigative
DMT3ML6 DT Small molecular drug
DMT3ML6 PC 667601
DMT3ML6 MW 220.25
DMT3ML6 FM C10H8N2O2S
DMT3ML6 IC InChI=1S/C10H8N2O2S/c11-5-7(10(12)15)3-6-1-2-8(13)9(14)4-6/h1-4,13-14H,(H2,12,15)/b7-3+
DMT3ML6 CS C1=CC(=C(C=C1/C=C(\\C#N)/C(=S)N)O)O
DMT3ML6 IK ZGHQGWOETPXKLY-XVNBXDOJSA-N
DMT3ML6 IU (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enethioamide
DMT3ML6 CA CAS 122520-86-9
DMT3ML6 CB CHEBI:93703
DMT3ML6 DE Discovery agent
DMMFQR2 ID DMMFQR2
DMMFQR2 DN AG-26
DMMFQR2 HS Investigative
DMMFQR2 SN AG26; AG 26
DMMFQR2 DT Small molecular drug
DMMFQR2 PC 727787
DMMFQR2 MW 304.77
DMMFQR2 FM C16H17ClN2O2
DMMFQR2 IC InChI=1S/C16H17ClN2O2/c1-21-15-8-2-12(3-9-15)10-11-18-16(20)19-14-6-4-13(17)5-7-14/h2-9H,10-11H2,1H3,(H2,18,19,20)
DMMFQR2 CS COC1=CC=C(C=C1)CCNC(=O)NC2=CC=C(C=C2)Cl
DMMFQR2 IK OVFMMJNKICPJJH-UHFFFAOYSA-N
DMMFQR2 IU 1-(4-chlorophenyl)-3-[2-(4-methoxyphenyl)ethyl]urea
DMMFQR2 DE Discovery agent
DM9KIS8 ID DM9KIS8
DM9KIS8 DN AG-538
DM9KIS8 HS Investigative
DM9KIS8 SN Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3& -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02
DM9KIS8 DT Small molecular drug
DM9KIS8 PC 5328760
DM9KIS8 MW 297.26
DM9KIS8 FM C16H11NO5
DM9KIS8 IC InChI=1S/C16H11NO5/c17-8-11(5-9-1-3-12(18)14(20)6-9)16(22)10-2-4-13(19)15(21)7-10/h1-7,18-21H/b11-5+
DM9KIS8 CS C1=CC(=C(C=C1/C=C(\\C#N)/C(=O)C2=CC(=C(C=C2)O)O)O)O
DM9KIS8 IK CANOJKGQDCJDOX-VZUCSPMQSA-N
DM9KIS8 IU (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile
DM9KIS8 CB CHEBI:92138
DM9KIS8 DE Discovery agent
DMAUJOM ID DMAUJOM
DMAUJOM DN agatoxin 489
DMAUJOM HS Investigative
DMAUJOM SN AG 489
DMAUJOM DT Small molecular drug
DMAUJOM PC 131007
DMAUJOM MW 489.7
DMAUJOM FM C26H47N7O2
DMAUJOM IC InChI=1S/C26H47N7O2/c27-11-5-14-28-12-3-4-13-29-15-6-16-30-17-7-19-33(35)20-8-18-31-26(34)21-23-22-32-25-10-2-1-9-24(23)25/h1-2,9-10,22,28-30,32,35H,3-8,11-21,27H2,(H,31,34)
DMAUJOM CS C1=CC=C2C(=C1)C(=CN2)CC(=O)NCCCN(CCCNCCCNCCCCNCCCN)O
DMAUJOM IK LIURIBSBVUMOJS-UHFFFAOYSA-N
DMAUJOM IU N-[3-[3-[3-[4-(3-aminopropylamino)butylamino]propylamino]propyl-hydroxyamino]propyl]-2-(1H-indol-3-yl)acetamide
DMAUJOM CA CAS 128549-96-2
DMAUJOM DE Discovery agent
DM83951 ID DM83951
DM83951 DN AG-E-85378
DM83951 HS Investigative
DM83951 SN N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide; 269390-69-4; VEGFR Tyrosine Kinase Inhibitor II; VEGF Receptor Tyrosine Kinase Inhibitor II; CHEMBL101683; 3hng; AG-E-85378; ZINC8732; SCHEMBL3005186; GTPL6056; N-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide; CTK4F8762; DTXSID60430900; MolPort-044-561-457; HMS3229O07; IN1017; BDBM50132151; AKOS030580576; DB07288; CCG-206804; NCGC00387770-01; ACM269390694; RT-016223; KB-299355; J-016613; N-(4-Chlorophenyl)-2-(4-pyridinylmethylamino)benzamide
DM83951 DT Small molecular drug
DM83951 PC 9797919
DM83951 MW 337.8
DM83951 FM C19H16ClN3O
DM83951 IC InChI=1S/C19H16ClN3O/c20-15-5-7-16(8-6-15)23-19(24)17-3-1-2-4-18(17)22-13-14-9-11-21-12-10-14/h1-12,22H,13H2,(H,23,24)
DM83951 CS C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)Cl)NCC3=CC=NC=C3
DM83951 IK GGPZCOONYBPZEW-UHFFFAOYSA-N
DM83951 IU N-(4-chlorophenyl)-2-(pyridin-4-ylmethylamino)benzamide
DM83951 CA CAS 269390-69-4
DM83951 DE Discovery agent
DMOJ3CW ID DMOJ3CW
DMOJ3CW DN AGELADINE A
DMOJ3CW HS Investigative
DMOJ3CW SN AGELADINE A; CHEMBL230806; CHEBI:65373; 4-(4,5-dibromo-1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-amine; Ageladine A, TFA; SCHEMBL12563004; BDBM50215926
DMOJ3CW DT Small molecular drug
DMOJ3CW PC 10089677
DMOJ3CW MW 357
DMOJ3CW FM C10H7Br2N5
DMOJ3CW IC InChI=1S/C10H7Br2N5/c11-4-3-6(15-9(4)12)7-8-5(1-2-14-7)16-10(13)17-8/h1-3,15H,(H3,13,16,17)
DMOJ3CW CS C1=CN=C(C2=C1NC(=N2)N)C3=CC(=C(N3)Br)Br
DMOJ3CW IK QAKGJAQGTQLMFN-UHFFFAOYSA-N
DMOJ3CW IU 4-(4,5-dibromo-1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-amine
DMOJ3CW CB CHEBI:65373
DMOJ3CW DE Discovery agent
DM26AMU ID DM26AMU
DM26AMU DN AGK2
DM26AMU HS Investigative
DM26AMU SN AGK-2; AGK 2
DM26AMU DT Small molecular drug
DM26AMU PC 2130404
DM26AMU MW 434.3
DM26AMU FM C23H13Cl2N3O2
DM26AMU IC InChI=1S/C23H13Cl2N3O2/c24-15-6-8-19(25)18(12-15)22-9-7-16(30-22)11-14(13-26)23(29)28-21-5-1-4-20-17(21)3-2-10-27-20/h1-12H,(H,28,29)/b14-11+
DM26AMU CS C1=CC2=C(C=CC=N2)C(=C1)NC(=O)/C(=C/C3=CC=C(O3)C4=C(C=CC(=C4)Cl)Cl)/C#N
DM26AMU IK SVENPFFEMUOOGK-SDNWHVSQSA-N
DM26AMU IU (E)-2-cyano-3-[5-(2,5-dichlorophenyl)furan-2-yl]-N-quinolin-5-ylprop-2-enamide
DM26AMU CA CAS 304896-28-4
DM26AMU CB CHEBI:94578
DM26AMU DE Discovery agent
DMM9A5N ID DMM9A5N
DMM9A5N DN AGL 2043
DMM9A5N HS Investigative
DMM9A5N SN AGL-2043; HMS3229A05; AGL2043
DMM9A5N DT Small molecular drug
DMM9A5N PC 9817165
DMM9A5N MW 280.3
DMM9A5N FM C15H12N4S
DMM9A5N IC InChI=1S/C15H12N4S/c1-9-17-12-6-11-10(7-14(12)19(9)2)16-8-13(18-11)15-4-3-5-20-15/h3-8H,1-2H3
DMM9A5N CS CC1=NC2=C(N1C)C=C3C(=C2)N=C(C=N3)C4=CC=CS4
DMM9A5N IK ZGDACLBJJXLKJY-UHFFFAOYSA-N
DMM9A5N IU 1,2-dimethyl-6-thiophen-2-ylimidazo[4,5-g]quinoxaline
DMM9A5N CA CAS 226717-28-8
DMM9A5N DE Discovery agent
DMSBZ29 ID DMSBZ29
DMSBZ29 DN Agmatine
DMSBZ29 HS Investigative
DMSBZ29 SN agmatine; 1-(4-Aminobutyl)guanidine; (4-Aminobutyl)guanidine; Argmatine; 306-60-5; 1-Amino-4-guanidobutane; N-4-Aminobutylguanidine; guanidine, (4-aminobutyl)-; N-(4-aminobutyl)guanidine; (4-Aminobutyl) guanidine; 1,4-Butanediamine, N-(aminoiminomethyl)-; 2-(4-aminobutyl)guanidine; UNII-70J407ZL5Q; EINECS 206-187-7; NSC 56332; 4-Guanidino-1-butanamine; CHEMBL58343; CHEBI:17431; QYPPJABKJHAVHS-UHFFFAOYSA-N; 70J407ZL5Q; agmatinium; Guanidine, (4-aminobutyl)- (8CI)(9CI); AGMATINE SULFATE ENDOGENOUS AGONIST AT; AG2
DMSBZ29 DT Small molecular drug
DMSBZ29 PC 199
DMSBZ29 MW 130.19
DMSBZ29 FM C5H14N4
DMSBZ29 IC InChI=1S/C5H14N4/c6-3-1-2-4-9-5(7)8/h1-4,6H2,(H4,7,8,9)
DMSBZ29 CS C(CCN=C(N)N)CN
DMSBZ29 IK QYPPJABKJHAVHS-UHFFFAOYSA-N
DMSBZ29 IU 2-(4-aminobutyl)guanidine
DMSBZ29 CA CAS 306-60-5
DMSBZ29 CB CHEBI:17431
DMSBZ29 DE Discovery agent
DMTPV4Y ID DMTPV4Y
DMTPV4Y DN AGN 191976
DMTPV4Y HS Investigative
DMTPV4Y SN AGN-191976; AGN191976
DMTPV4Y DT Small molecular drug
DMTPV4Y PC 73755173
DMTPV4Y MW 382.5
DMTPV4Y FM C21H34O6
DMTPV4Y IC InChI=1S/C21H34O6/c1-2-3-6-9-15(22)12-13-17-16(10-7-4-5-8-11-20(23)24)18-14-19(17)27-21(25)26-18/h4,7,15-19,22H,2-3,5-6,8-14H2,1H3,(H,23,24)/b7-4-/t15-,16+,17+,18-,19+/m0/s1
DMTPV4Y CS CCCCC[C@@H](CC[C@H]1[C@H]2C[C@@H]([C@@H]1C/C=C\\CCCC(=O)O)OC(=O)O2)O
DMTPV4Y IK CVQLYMOSZQTFDP-NFUXFLSFSA-N
DMTPV4Y IU (Z)-7-[(1R,5S,6R,7R)-7-[(3S)-3-hydroxyoctyl]-3-oxo-2,4-dioxabicyclo[3.2.1]octan-6-yl]hept-5-enoic acid
DMTPV4Y DE Discovery agent
DM53R94 ID DM53R94
DM53R94 DN AGN-190383
DM53R94 HS Investigative
DM53R94 SN 120755-15-9
DM53R94 DT Small molecular drug
DM53R94 PC 149069
DM53R94 MW 340.5
DM53R94 FM C19H32O5
DM53R94 IC InChI=1S/C19H32O5/c1-3-4-5-6-7-8-9-10-11-12-13-17(23-15(2)20)16-14-18(21)24-19(16)22/h14,17,19,22H,3-13H2,1-2H3
DM53R94 CS CCCCCCCCCCCCC(C1=CC(=O)OC1O)OC(=O)C
DM53R94 IK QDXHMXIOLIYZHD-UHFFFAOYSA-N
DM53R94 IU 1-(2-hydroxy-5-oxo-2H-furan-3-yl)tridecyl acetate
DM53R94 CA CAS 120755-15-9
DM53R94 DE Discovery agent
DMIKDAR ID DMIKDAR
DMIKDAR DN AGN-190744
DMIKDAR HS Investigative
DMIKDAR SN 130162-96-8
DMIKDAR DE Discovery agent
DMISJXB ID DMISJXB
DMISJXB DN AGN192093
DMISJXB HS Investigative
DMISJXB SN AGN-192093; AGN 192093
DMISJXB DT Small molecular drug
DMISJXB PC 11968293
DMISJXB MW 366.5
DMISJXB FM C21H34O5
DMISJXB IC InChI=1S/C21H34O5/c1-2-3-7-10-16(23)12-13-18-17(11-8-5-4-6-9-14-22)19-15-20(18)26-21(24)25-19/h5,8,12-13,16-20,22-23H,2-4,6-7,9-11,14-15H2,1H3/b8-5-,13-12+/t16-,17+,18+,19-,20-/m0/s1
DMISJXB CS CCCCC[C@@H](/C=C/[C@H]1[C@@H]2C[C@@H]([C@@H]1C/C=C\\CCCCO)OC(=O)O2)O
DMISJXB IK PTIUXNGGNGQHQK-KTEVXADTSA-N
DMISJXB IU (1S,5S,6R,7R)-6-[(Z)-7-hydroxyhept-2-enyl]-7-[(E,3S)-3-hydroxyoct-1-enyl]-2,4-dioxabicyclo[3.2.1]octan-3-one
DMISJXB DE Discovery agent
DM946RA ID DM946RA
DM946RA DN AGN-192172
DM946RA HS Investigative
DM946RA SN AGN-192172; CHEMBL49284; BDBM50052881
DM946RA DT Small molecular drug
DM946RA PC 9816048
DM946RA MW 231.3
DM946RA FM C12H17N5
DM946RA IC InChI=1S/C12H17N5/c1-8-9(17-12-15-6-7-16-12)2-3-10-11(8)14-5-4-13-10/h2-3,13-14H,4-7H2,1H3,(H2,15,16,17)
DM946RA CS CC1=C(C=CC2=C1NCCN2)NC3=NCCN3
DM946RA IK PGOVKWAJCVAZNG-UHFFFAOYSA-N
DM946RA IU N-(4,5-dihydro-1H-imidazol-2-yl)-5-methyl-1,2,3,4-tetrahydroquinoxalin-6-amine
DM946RA DE Discovery agent
DMC0YOE ID DMC0YOE
DMC0YOE DN AGN193109
DMC0YOE HS Investigative
DMC0YOE SN AGN 193109; AGN-93109
DMC0YOE DT Small molecular drug
DMC0YOE PC 177238
DMC0YOE MW 392.5
DMC0YOE FM C28H24O2
DMC0YOE IC InChI=1S/C28H24O2/c1-19-4-11-22(12-5-19)24-16-17-28(2,3)26-15-10-21(18-25(24)26)7-6-20-8-13-23(14-9-20)27(29)30/h4-5,8-16,18H,17H2,1-3H3,(H,29,30)
DMC0YOE CS CC1=CC=C(C=C1)C2=CCC(C3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C
DMC0YOE IK NCEQLLNVRRTCKJ-UHFFFAOYSA-N
DMC0YOE IU 4-[2-[5,5-dimethyl-8-(4-methylphenyl)-6H-naphthalen-2-yl]ethynyl]benzoic acid
DMC0YOE CA CAS 171746-21-7
DMC0YOE DE Discovery agent
DMEB93D ID DMEB93D
DMEB93D DN AGN193836
DMEB93D HS Investigative
DMEB93D SN AGN-193836; AGN 193836
DMEB93D DT Small molecular drug
DMEB93D PC 23001780
DMEB93D MW 482.3
DMEB93D FM C22H22BrF2NO4
DMEB93D IC InChI=1S/C22H22BrF2NO4/c1-21(2)5-6-22(3,4)16-11(21)9-14(18(27)17(16)23)26-19(28)10-7-12(24)15(20(29)30)13(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)
DMEB93D CS CC1(CCC(C2=C(C(=C(C=C21)NC(=O)C3=CC(=C(C(=C3)F)C(=O)O)F)O)Br)(C)C)C
DMEB93D IK FADQHUSDAKOWFT-UHFFFAOYSA-N
DMEB93D IU 4-[(4-bromo-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]-2,6-difluorobenzoic acid
DMEB93D DE Discovery agent
DM5ECDM ID DM5ECDM
DM5ECDM DN AGN-34
DM5ECDM HS Investigative
DM5ECDM SN AGN-34; CHEMBL190635; SCHEMBL1984049; 7-[2-(Hexyloxy)-3,5-diisopropylphenyl]-3-methyl-2,4,6-octatrienoic acid
DM5ECDM DT Small molecular drug
DM5ECDM PC 9887925
DM5ECDM MW 412.6
DM5ECDM FM C27H40O3
DM5ECDM IC InChI=1S/C27H40O3/c1-8-9-10-11-15-30-27-24(20(4)5)17-23(19(2)3)18-25(27)22(7)14-12-13-21(6)16-26(28)29/h12-14,16-20H,8-11,15H2,1-7H3,(H,28,29)/b13-12+,21-16+,22-14-
DM5ECDM CS CCCCCCOC1=C(C=C(C=C1/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C)C(C)C)C(C)C
DM5ECDM IK VTUYATVOWGSQFU-AQIGWABESA-N
DM5ECDM IU (2E,4E,6Z)-7-[2-hexoxy-3,5-di(propan-2-yl)phenyl]-3-methylocta-2,4,6-trienoic acid
DM5ECDM DE Discovery agent
DMT9FJZ ID DMT9FJZ
DMT9FJZ DN AGROCLAVINE
DMT9FJZ HS Investigative
DMT9FJZ SN Agroclavine; 8,9-Didehydro-6,8-dimethylergoline; 548-42-5; UNII-A8SW57GO7T; (-)-agroclavine; CCRIS 2099; Ergoline, 8,9-didehydro-6,8-dimethyl-; EINECS 208-947-3; (5R,10R)-agroclavine; NSC 93132; 6,8-Dimethyl-8,9-didehydroergoline; AGROCLAVIN; BRN 0024966; A8SW57GO7T; CHEMBL449081; CHEBI:2519; Indolo(4,3-fg)quinoline, 4,6,6a,7,8,10a-hexahydro-7,9-dimethyl-; NSC93132; (6aR,10aR)-7,9-dimethyl-4,6,6a,7,8,10a-hexahydroindolo[4,3-fg]quinoline; agroclavine-1; Lopac-A-206; AC1L2JXJ; Biomol-NT_000066; Lopac0_000128; MLS001216424; cid_73484
DMT9FJZ DT Small molecular drug
DMT9FJZ PC 73484
DMT9FJZ MW 238.33
DMT9FJZ FM C16H18N2
DMT9FJZ IC InChI=1S/C16H18N2/c1-10-6-13-12-4-3-5-14-16(12)11(8-17-14)7-15(13)18(2)9-10/h3-6,8,13,15,17H,7,9H2,1-2H3/t13-,15-/m1/s1
DMT9FJZ CS CC1=C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
DMT9FJZ IK XJOOMMHNYOJWCZ-UKRRQHHQSA-N
DMT9FJZ IU (6aR,10aR)-7,9-dimethyl-6,6a,8,10a-tetrahydro-4H-indolo[4,3-fg]quinoline
DMT9FJZ CA CAS 548-42-5
DMT9FJZ CB CHEBI:2519
DMT9FJZ DE Discovery agent
DMP9QW0 ID DMP9QW0
DMP9QW0 DN AGT-2000
DMP9QW0 HS Investigative
DMP9QW0 SN Gene therapy (intravenous, brain cancer), ArmaGen
DMP9QW0 CP ArmaGen Technologies Inc
DMP9QW0 DE Brain cancer
DMMO9YR ID DMMO9YR
DMMO9YR DN AGTAD[CFWKYC]V
DMMO9YR HS Investigative
DMMO9YR SN CHEMBL1163463; AGTAD[CFWKYC]V; 9047-55-6; Urotensin II mouse; BDBM50320454
DMMO9YR PC 16150418
DMMO9YR MW 1361.5
DMMO9YR FM C62H84N14O17S2
DMMO9YR IC InChI=1S/C62H84N14O17S2/c1-31(2)50(62(92)93)76-60(90)47-30-95-94-29-46(73-58(88)45(26-49(80)81)69-53(83)33(4)67-61(91)51(34(5)77)75-48(79)28-66-52(82)32(3)64)59(89)71-42(23-35-13-7-6-8-14-35)55(85)72-44(25-37-27-65-40-16-10-9-15-39(37)40)57(87)68-41(17-11-12-22-63)54(84)70-43(56(86)74-47)24-36-18-20-38(78)21-19-36/h6-10,13-16,18-21,27,31-34,41-47,50-51,65,77-78H,11-12,17,22-26,28-30,63-64H2,1-5H3,(H,66,82)(H,67,91)(H,68,87)(H,69,83)(H,70,84)(H,71,89)(H,72,85)(H,73,88)(H,74,86)(H,75,79)(H,76,90)(H,80,81)(H,92,93)/t32-,33-,34+,41-,42-,43-,44-,45-,46-,47-,50-,51-/m0/s1
DMMO9YR CS C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC=CC=C2)CC3=CNC4=CC=CC=C43)CCCCN)CC5=CC=C(C=C5)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)CNC(=O)[C@H](C)N)O
DMMO9YR IK YNQKMDDGZLLKHF-SYGGZGJOSA-N
DMMO9YR IU (2S)-2-[[(4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-16-benzyl-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoic acid
DMMO9YR DE Discovery agent
DMF7ZYQ ID DMF7ZYQ
DMF7ZYQ DN AH 11110
DMF7ZYQ HS Investigative
DMF7ZYQ SN AH11110; AH-11110
DMF7ZYQ DT Small molecular drug
DMF7ZYQ PC 9907616
DMF7ZYQ MW 374.9
DMF7ZYQ FM C21H27ClN2O2
DMF7ZYQ IC InChI=1S/C21H26N2O2.ClH/c22-21(23-13-7-2-8-14-23)15-18(24)16-25-20-12-6-5-11-19(20)17-9-3-1-4-10-17;/h1,3-6,9-12,18,22,24H,2,7-8,13-16H2;1H
DMF7ZYQ CS C1CCN(CC1)C(=N)CC(COC2=CC=CC=C2C3=CC=CC=C3)O.Cl
DMF7ZYQ IK WWHGFIXWBLHHQB-UHFFFAOYSA-N
DMF7ZYQ IU 4-imino-1-(2-phenylphenoxy)-4-piperidin-1-ylbutan-2-ol;hydrochloride
DMF7ZYQ CA CAS 179388-65-9
DMF7ZYQ DE Discovery agent
DM2VEHG ID DM2VEHG
DM2VEHG DN AH13205
DM2VEHG HS Investigative
DM2VEHG SN AH 13205; AH-13205
DM2VEHG DT Small molecular drug
DM2VEHG PC 5310998
DM2VEHG MW 388.5
DM2VEHG FM C24H36O4
DM2VEHG IC InChI=1S/C24H36O4/c1-2-3-6-10-22(25)19-14-12-18(13-15-19)20-16-17-23(26)21(20)9-7-4-5-8-11-24(27)28/h12-15,20-22,25H,2-11,16-17H2,1H3,(H,27,28)
DM2VEHG CS CCCCCC(C1=CC=C(C=C1)C2CCC(=O)C2CCCCCCC(=O)O)O
DM2VEHG IK XMQKDOCUWFCMEJ-UHFFFAOYSA-N
DM2VEHG IU 7-[2-[4-(1-hydroxyhexyl)phenyl]-5-oxocyclopentyl]heptanoic acid
DM2VEHG DE Discovery agent
DM4S1Y6 ID DM4S1Y6
DM4S1Y6 DN AH23848
DM4S1Y6 HS Investigative
DM4S1Y6 SN (-)AH23848; (-)-AH23848; AH 23848; AH-23848
DM4S1Y6 DT Small molecular drug
DM4S1Y6 PC 5310999
DM4S1Y6 MW 477.6
DM4S1Y6 FM C29H35NO5
DM4S1Y6 IC InChI=1S/C29H35NO5/c31-26-20-27(35-21-22-12-14-24(15-13-22)23-8-4-3-5-9-23)25(10-6-1-2-7-11-28(32)33)29(26)30-16-18-34-19-17-30/h1-5,8-9,12-15,25,27,29H,6-7,10-11,16-21H2,(H,32,33)/b2-1-/t25-,27-,29+/m0/s1
DM4S1Y6 CS C1COCCN1[C@@H]2[C@H]([C@H](CC2=O)OCC3=CC=C(C=C3)C4=CC=CC=C4)CC/C=C\\CCC(=O)O
DM4S1Y6 IK IOFUFYLETVNNRF-OSAZKUMMSA-N
DM4S1Y6 IU (Z)-7-[(1R,2R,5S)-2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid
DM4S1Y6 CB CHEBI:90389
DM4S1Y6 DE Discovery agent
DMKN3R9 ID DMKN3R9
DMKN3R9 DN AH6809
DMKN3R9 HS Investigative
DMKN3R9 SN AH 6809; AH-6809
DMKN3R9 DT Small molecular drug
DMKN3R9 PC 119461
DMKN3R9 MW 298.29
DMKN3R9 FM C17H14O5
DMKN3R9 IC InChI=1S/C17H14O5/c1-9(2)21-11-4-5-12-15(8-11)22-14-6-3-10(17(19)20)7-13(14)16(12)18/h3-9H,1-2H3,(H,19,20)
DMKN3R9 CS CC(C)OC1=CC2=C(C=C1)C(=O)C3=C(O2)C=CC(=C3)C(=O)O
DMKN3R9 IK AQFFXPQJLZFABJ-UHFFFAOYSA-N
DMKN3R9 IU 9-oxo-6-propan-2-yloxyxanthene-2-carboxylic acid
DMKN3R9 CA CAS 33458-93-4
DMKN3R9 CB CHEBI:95289
DMKN3R9 DE Discovery agent
DMVZLIB ID DMVZLIB
DMVZLIB DN AHL
DMVZLIB HS Investigative
DMVZLIB SN AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
DMVZLIB CP Quark Pharmaceuticals Inc
DMVZLIB DT siRNA drug
DMVZLIB DE Hearing disorder
DM8G6O4 ID DM8G6O4
DM8G6O4 DN AHPN
DM8G6O4 HS Investigative
DM8G6O4 SN Ro 47-2077; 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid; CD437; CD 437
DM8G6O4 DT Small molecular drug
DM8G6O4 PC 135411
DM8G6O4 MW 398.5
DM8G6O4 FM C27H26O3
DM8G6O4 IC InChI=1S/C27H26O3/c28-25-6-5-22(20-1-2-21-11-23(26(29)30)4-3-19(21)10-20)12-24(25)27-13-16-7-17(14-27)9-18(8-16)15-27/h1-6,10-12,16-18,28H,7-9,13-15H2,(H,29,30)
DM8G6O4 CS C1C2CC3CC1CC(C2)(C3)C4=C(C=CC(=C4)C5=CC6=C(C=C5)C=C(C=C6)C(=O)O)O
DM8G6O4 IK LDGIHZJOIQSHPB-UHFFFAOYSA-N
DM8G6O4 IU 6-[3-(1-adamantyl)-4-hydroxyphenyl]naphthalene-2-carboxylic acid
DM8G6O4 CA CAS 125316-60-1
DM8G6O4 CB CHEBI:88334
DM8G6O4 DE Discovery agent
DM3LCDK ID DM3LCDK
DM3LCDK DN AIDA
DM3LCDK HS Investigative
DM3LCDK SN UPF 523; UPF523; GNF-Pf-1401
DM3LCDK DT Small molecular drug
DM3LCDK PC 2071
DM3LCDK MW 221.21
DM3LCDK FM C11H11NO4
DM3LCDK IC InChI=1S/C11H11NO4/c12-11(10(15)16)4-3-6-5-7(9(13)14)1-2-8(6)11/h1-2,5H,3-4,12H2,(H,13,14)(H,15,16)
DM3LCDK CS C1CC(C2=C1C=C(C=C2)C(=O)O)(C(=O)O)N
DM3LCDK IK LSTPKMWNRWCNLS-UHFFFAOYSA-N
DM3LCDK IU 1-amino-2,3-dihydroindene-1,5-dicarboxylic acid
DM3LCDK CA CAS 168560-79-0
DM3LCDK DE Discovery agent
DMUQ6XH ID DMUQ6XH
DMUQ6XH DN AIKO-151
DMUQ6XH HS Investigative
DMUQ6XH SN Mu-opioid antagonist (oral, opiate dependence), Aiko Biotechnology
DMUQ6XH CP Aiko Biotechnology Inc
DMUQ6XH DE Opioid dependence
DML5Y1Q ID DML5Y1Q
DML5Y1Q DN AIKO-152
DML5Y1Q HS Investigative
DML5Y1Q SN AIKO-150 + opioid analgesic (pain/opiate dependence), Aiko Biotechnology
DML5Y1Q CP Aiko Biotechnology Inc
DML5Y1Q DE Opioid dependence
DMHMVOI ID DMHMVOI
DMHMVOI DN Ajinomoto 1
DMHMVOI HS Investigative
DMHMVOI TC Analgesics
DMHMVOI DE Pain
DMZE45V ID DMZE45V
DMZE45V DN Ajinomoto 2
DMZE45V HS Investigative
DMZE45V TC Analgesics
DMZE45V DE Pain
DMG12AE ID DMG12AE
DMG12AE DN Ajinomoto 3
DMG12AE HS Investigative
DMG12AE TC Analgesics
DMG12AE DE Pain
DMWKPJH ID DMWKPJH
DMWKPJH DN AK198
DMWKPJH HS Investigative
DMWKPJH SN {2-[(4-Amino-2-Fluorobenzyl)carbamoyl]-5-Chlorophenoxy}acetic Acid; AK198; GTPL8637; 2-[2-[(4-amino-2-fluorophenyl)methylcarbamoyl]-5-chlorophenoxy]acetic acid
DMWKPJH DT Small molecular drug
DMWKPJH PC 91820714
DMWKPJH MW 352.74
DMWKPJH FM C16H14ClFN2O4
DMWKPJH IC InChI=1S/C16H14ClFN2O4/c17-10-2-4-12(14(5-10)24-8-15(21)22)16(23)20-7-9-1-3-11(19)6-13(9)18/h1-6H,7-8,19H2,(H,20,23)(H,21,22)
DMWKPJH CS C1=CC(=C(C=C1N)F)CNC(=O)C2=C(C=C(C=C2)Cl)OCC(=O)O
DMWKPJH IK GFJYPJDGRCZNDI-UHFFFAOYSA-N
DMWKPJH IU 2-[2-[(4-amino-2-fluorophenyl)methylcarbamoyl]-5-chlorophenoxy]acetic acid
DMWKPJH DE Discovery agent
DMQ90PJ ID DMQ90PJ
DMQ90PJ DN AK-41099
DMQ90PJ HS Investigative
DMQ90PJ SN Trans-3-hydroxy-l-proline; DL-trans-Hydroxyproline; L-Proline, 3-hydroxy-, (3S)-; SCHEMBL114870; trans-3-Hydroxyproline; trans-3-hydroxy-(L)-proline; trans-3-hydroxy-L-proline; trans-3-hydroxy-l -proline; trans-L-3-Hydroxyproline; (+)-cis-(2R,3S)-3-hydroxyproline; (2S,3S)-(-)-3-Hydroxy-L-proline; (2S,3S)-3-Hydroxypyrrolidine-2-carboxylic acid; (2S,3S)-3-hydroxyproline; (3S)-3-hydroxy-L-proline; 4298-06-0; 8ZWY97A2NG; AC1L99JX; AK-41099; CHEBI:16889; CHEMBL1233466; UNII-8ZWY97A2NG; trans-3-Hydroxypyrrolidine-2-carboxylic acid
DMQ90PJ PC 440575
DMQ90PJ MW 131.13
DMQ90PJ FM C5H9NO3
DMQ90PJ IC BJBUEDPLEOHJGE-IMJSIDKUSA-N
DMQ90PJ CS C1CNC(C1O)C(=O)O
DMQ90PJ IK 1S/C5H9NO3/c7-3-1-2-6-4(3)5(8)9/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4-/m0/s1
DMQ90PJ IU (2S,3S)-3-hydroxypyrrolidine-2-carboxylic acid
DMQ90PJ CA CAS 4298-08-2
DMQ90PJ CB CHEBI:16889
DMQ90PJ DE Discovery agent
DMANYU5 ID DMANYU5
DMANYU5 DN AKN-028
DMANYU5 HS Investigative
DMANYU5 SN Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska
DMANYU5 CP Swedish Orphan Biovitrum AB
DMANYU5 DT Small molecular drug
DMANYU5 PC 44177328
DMANYU5 MW 302.33
DMANYU5 FM C17H14N6
DMANYU5 IC InChI=1S/C17H14N6/c18-16-17(22-13-1-2-14-12(9-13)5-8-20-14)23-15(10-21-16)11-3-6-19-7-4-11/h1-10,20H,(H2,18,21)(H,22,23)
DMANYU5 CS C1=CC2=C(C=CN2)C=C1NC3=NC(=CN=C3N)C4=CC=NC=C4
DMANYU5 IK JLRIJKVMMZEKDF-UHFFFAOYSA-N
DMANYU5 IU 3-N-(1H-indol-5-yl)-5-pyridin-4-ylpyrazine-2,3-diamine
DMANYU5 CA CAS 1175017-90-9
DMANYU5 DE Acute myeloid leukaemia
DM4E6H1 ID DM4E6H1
DM4E6H1 DN AKNADILACTAM
DM4E6H1 HS Investigative
DM4E6H1 SN aknadilactam; CHEMBL1097185
DM4E6H1 DT Small molecular drug
DM4E6H1 PC 15764659
DM4E6H1 MW 373.4
DM4E6H1 FM C20H23NO6
DM4E6H1 IC InChI=1S/C20H23NO6/c1-21-14(23)10-19-9-12(22)17(26-3)18(27-4)20(19,21)8-7-11-5-6-13(25-2)16(24)15(11)19/h5-6,24H,7-10H2,1-4H3/t19-,20-/m1/s1
DM4E6H1 CS CN1C(=O)C[C@@]23[C@@]1(CCC4=C2C(=C(C=C4)OC)O)C(=C(C(=O)C3)OC)OC
DM4E6H1 IK CLWJGNIITFMBQR-WOJBJXKFSA-N
DM4E6H1 IU (1R,10S)-3-hydroxy-4,11,12-trimethoxy-17-methyl-17-azatetracyclo[8.4.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraene-13,16-dione
DM4E6H1 DE Discovery agent
DMDVIT1 ID DMDVIT1
DMDVIT1 DN Akt inhibitor VIII
DMDVIT1 HS Investigative
DMDVIT1 SN isozyme-selective, Akti-1/2
DMDVIT1 DT Small molecular drug
DMDVIT1 PC 135398501
DMDVIT1 MW 551.6
DMDVIT1 FM C34H29N7O
DMDVIT1 IC InChI=1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25,38H,14-17,20H2,(H,39,42)
DMDVIT1 CS C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8
DMDVIT1 IK IWCQHVUQEFDRIW-UHFFFAOYSA-N
DMDVIT1 IU 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
DMDVIT1 CA CAS 612847-09-3
DMDVIT1 CB CHEBI:91346
DMDVIT1 DE Discovery agent
DMJW4I5 ID DMJW4I5
DMJW4I5 DN AKUAMMIGINE
DMJW4I5 HS Investigative
DMJW4I5 SN akuammigine; 642-17-1; UNII-1E21YYE0UM; 1E21YYE0UM; CHEMBL122404; C21H24N2O3; AC1LOQX5; SCHEMBL563799; MolPort-039-052-713; CHEBI:141878; ZINC53174616; PDSP1_001665; BDBM50030622; 9078AF; AKOS032948886; Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, methyl ester, (3beta,19alpha,20alpha)-; 4H-Indolo(2,3-a)pyrano(3,4-g)quinolizine-1-carboxylic acid, 4a,5,7,8,13,13b,14,14a-octahydro-4-methyl-, methyl ester, (4S,4aS,13bR,14aS)-; methyl (3beta,19alpha,20alpha)-19-methyl-16,17-didehydro-18-oxayohimban-16-carboxylate
DMJW4I5 DT Small molecular drug
DMJW4I5 PC 1268096
DMJW4I5 MW 352.4
DMJW4I5 FM C21H24N2O3
DMJW4I5 IC InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16-,19+/m0/s1
DMJW4I5 CS C[C@H]1[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45
DMJW4I5 IK GRTOGORTSDXSFK-BMYCAMMWSA-N
DMJW4I5 IU methyl (1R,15S,16S,20S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
DMJW4I5 CA CAS 642-17-1
DMJW4I5 CB CHEBI:141878
DMJW4I5 DE Discovery agent
DM8DYWN ID DM8DYWN
DM8DYWN DN AKUAMMINE
DM8DYWN HS Investigative
DM8DYWN DT Small molecular drug
DM8DYWN PC 13491909
DM8DYWN MW 382.5
DM8DYWN FM C22H26N2O4
DM8DYWN IC InChI=1S/C22H26N2O4/c1-4-13-11-24-8-7-21-16-9-14(25)5-6-17(16)23(2)22(21)18(24)10-15(13)20(21,12-28-22)19(26)27-3/h4-6,9,15,18,25H,7-8,10-12H2,1-3H3/b13-4-/t15-,18-,20-,21-,22+/m0/s1
DM8DYWN CS C/C=C\\1/CN2CC[C@@]34C5=C(C=CC(=C5)O)N([C@@]36[C@@H]2C[C@@H]1[C@@]4(CO6)C(=O)OC)C
DM8DYWN IK YILKZADAWNUTTB-QLWRWLBVSA-N
DM8DYWN IU methyl (1S,9S,14E,15S,16R,19S)-14-ethylidene-6-hydroxy-2-methyl-18-oxa-2,12-diazahexacyclo[13.3.2.01,9.03,8.09,16.012,19]icosa-3(8),4,6-triene-16-carboxylate
DM8DYWN CA CAS 3512-87-6
DM8DYWN DE Discovery agent
DM0JE4N ID DM0JE4N
DM0JE4N DN AL12180
DM0JE4N HS Investigative
DM0JE4N SN 5,6-dihydro-4,5-didehydro-11-deoxy-11-oxa-16-(3-chlorophenoxy)-omega-tetranor-PGF2alpha; AL-12180
DM0JE4N DT Small molecular drug
DM0JE4N PC 59107184
DM0JE4N MW 410.9
DM0JE4N FM C21H27ClO6
DM0JE4N IC InChI=1S/C21H27ClO6/c22-15-6-5-7-17(12-15)27-13-16(23)10-11-20-18(19(24)14-28-20)8-3-1-2-4-9-21(25)26/h1-2,5-7,10-12,16,18-20,23-24H,3-4,8-9,13-14H2,(H,25,26)/b2-1-,11-10+/t16-,18+,19+,20-/m1/s1
DM0JE4N CS C1[C@@H]([C@@H]([C@H](O1)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)CC/C=C\\CCC(=O)O)O
DM0JE4N IK GLYAVTUPQOQHAD-MOBTWWNESA-N
DM0JE4N IU (Z)-7-[(2R,3S,4R)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-4-hydroxyoxolan-3-yl]hept-4-enoic acid
DM0JE4N CA CAS 748816-43-5
DM0JE4N DE Discovery agent
DM7XHDC ID DM7XHDC
DM7XHDC DN AL-209
DM7XHDC HS Investigative
DM7XHDC SN SAL; ADNF-9
DM7XHDC CP Allon Therapeutics Inc
DM7XHDC DE Central nervous system disease
DM69X2Z ID DM69X2Z
DM69X2Z DN AL-309
DM69X2Z HS Investigative
DM69X2Z SN D-SAL
DM69X2Z CP Allon Therapeutics Inc
DM69X2Z DE Central nervous system disease
DMRJ2GK ID DMRJ2GK
DMRJ2GK DN AL-37350A
DMRJ2GK HS Investigative
DMRJ2GK SN AL37350A; AL 37350A
DMRJ2GK DT Small molecular drug
DMRJ2GK PC 10331436
DMRJ2GK MW 230.31
DMRJ2GK FM C14H18N2O
DMRJ2GK IC InChI=1S/C14H18N2O/c1-9(15)7-10-8-16-12-4-5-13-11(14(10)12)3-2-6-17-13/h4-5,8-9,16H,2-3,6-7,15H2,1H3/t9-/m0/s1
DMRJ2GK CS C[C@@H](CC1=CNC2=C1C3=C(C=C2)OCCC3)N
DMRJ2GK IK VVHJUSGIUWQPIT-VIFPVBQESA-N
DMRJ2GK IU (2S)-1-(3,7,8,9-tetrahydropyrano[3,2-e]indol-1-yl)propan-2-amine
DMRJ2GK CA CAS 362603-40-5
DMRJ2GK DE Discovery agent
DM7K360 ID DM7K360
DM7K360 DN AL-408
DM7K360 HS Investigative
DM7K360 SN AL-108 analog (neurodegenerative diseases), Allon
DM7K360 CP Allon Therapeutics Inc
DM7K360 DE Central nervous system disease
DMLEDHR ID DMLEDHR
DMLEDHR DN AL-43
DMLEDHR HS Investigative
DMLEDHR SN AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene
DMLEDHR DT Small molecular drug
DMLEDHR PC 9906282
DMLEDHR MW 347.4
DMLEDHR FM C23H25NO2
DMLEDHR IC InChI=1S/C23H25NO2/c1-6-8-18-22-15(21-17(25-5)9-7-10-19(21)26-18)11-12-16-20(22)14(2)13-23(3,4)24-16/h6-7,9-13,18,24H,1,8H2,2-5H3
DMLEDHR CS CC1=CC(NC2=C1C3=C(C=C2)C4=C(C=CC=C4OC)OC3CC=C)(C)C
DMLEDHR IK CZSDJYXNNJQXBB-UHFFFAOYSA-N
DMLEDHR IU 10-methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline
DMLEDHR DE Discovery agent
DMHG54F ID DMHG54F
DMHG54F DN AL4623
DMHG54F HS Investigative
DMHG54F SN AL4623; UNII-1M7AKN51DU; 1M7AKN51DU; (r)-4-ethylamino-3,4-dihydro-2-(2-methoylethyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 1bnq; AC1N9ZNF; AL-4623A free base; SCHEMBL7508613; BDBM11934; AL-4623; DB03877; 138890-59-2; (4R)-4-(ethylamino)-2-(2-methoxyethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno(3,2-E)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(2-methoxyethyl)-, 1,1-dioxide, (4R)-
DMHG54F DT Small molecular drug
DMHG54F PC 4369102
DMHG54F MW 369.5
DMHG54F FM C11H19N3O5S3
DMHG54F IC InChI=1S/C11H19N3O5S3/c1-3-13-9-7-14(4-5-19-2)22(17,18)11-8(9)6-10(20-11)21(12,15)16/h6,9,13H,3-5,7H2,1-2H3,(H2,12,15,16)/t9-/m0/s1
DMHG54F CS CCN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCOC
DMHG54F IK XACIEZJJSXJZMD-VIFPVBQESA-N
DMHG54F IU (4R)-4-(ethylamino)-2-(2-methoxyethyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMHG54F CA CAS 138890-59-2
DMHG54F DE Discovery agent
DM1QJIV ID DM1QJIV
DM1QJIV DN AL5300
DM1QJIV HS Investigative
DM1QJIV SN AC1L1BUF; SCHEMBL5080690; BDBM11932; CTK8A0654; 4-hydroxy-2-(thiophen-2-ylmethyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 4-hydroxy-1,1-dioxo-2-(thiophen-2-ylmethyl)-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
DM1QJIV DT Small molecular drug
DM1QJIV PC 4369103
DM1QJIV MW 380.5
DM1QJIV FM C11H12N2O5S4
DM1QJIV IC InChI=1S/C11H12N2O5S4/c12-21(15,16)10-4-8-9(14)6-13(5-7-2-1-3-19-7)22(17,18)11(8)20-10/h1-4,9,14H,5-6H2,(H2,12,15,16)/t9-/m0/s1
DM1QJIV CS C1[C@@H](C2=C(SC(=C2)S(=O)(=O)N)S(=O)(=O)N1CC3=CC=CS3)O
DM1QJIV IK HHPUQNGRNUOYCD-VIFPVBQESA-N
DM1QJIV IU (4R)-4-hydroxy-1,1-dioxo-2-(thiophen-2-ylmethyl)-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DM1QJIV DE Discovery agent
DMSD2U1 ID DMSD2U1
DMSD2U1 DN AL5424
DMSD2U1 HS Investigative
DMSD2U1 SN 3,4-dihydro-4-hydroxy-2-(4-methoxyphenyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; AC1L1BUI; SCHEMBL678716; CTK7A4444; BDBM11933; 4-hydroxy-2-(4-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMSD2U1 DT Small molecular drug
DMSD2U1 PC 444612
DMSD2U1 MW 390.5
DMSD2U1 FM C13H14N2O6S3
DMSD2U1 IC InChI=1S/C13H14N2O6S3/c1-21-9-4-2-8(3-5-9)15-7-11(16)10-6-12(23(14,17)18)22-13(10)24(15,19)20/h2-6,11,16H,7H2,1H3,(H2,14,17,18)/t11-/m0/s1
DMSD2U1 CS COC1=CC=C(C=C1)N2C[C@@H](C3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N)O
DMSD2U1 IK ZWTSOJQGEWPWGO-NSHDSACASA-N
DMSD2U1 IU (4R)-4-hydroxy-2-(4-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMSD2U1 DE Discovery agent
DM624WO ID DM624WO
DM624WO DN AL5927
DM624WO HS Investigative
DM624WO SN AL5927; n-[(4-methoxyphenyl)methyl]2,5-thiophenedesulfonamide; 2-N-[(4-methoxyphenyl)methyl]thiophene-2,5-disulfonamide; N-(4-methoxybenzyl)thiophene-2,5-disulfonamide; AL9; 1bn4; AC1L1HW5; SCHEMBL680127; BDBM11930; 2,5-Thiophenedisulfonamide, N2-[(4-methoxyphenyl)methyl]-; DB03526
DM624WO DT Small molecular drug
DM624WO PC 4316
DM624WO MW 362.5
DM624WO FM C12H14N2O5S3
DM624WO IC InChI=1S/C12H14N2O5S3/c1-19-10-4-2-9(3-5-10)8-14-22(17,18)12-7-6-11(20-12)21(13,15)16/h2-7,14H,8H2,1H3,(H2,13,15,16)
DM624WO CS COC1=CC=C(C=C1)CNS(=O)(=O)C2=CC=C(S2)S(=O)(=O)N
DM624WO IK LRRAIRJIZOLGPR-UHFFFAOYSA-N
DM624WO IU 2-N-[(4-methoxyphenyl)methyl]thiophene-2,5-disulfonamide
DM624WO DE Discovery agent
DMPHTX0 ID DMPHTX0
DMPHTX0 DN AL-59640
DMPHTX0 HS Investigative
DMPHTX0 CP Alcon Inc
DMPHTX0 DE Xerophthalmia
DM1JIVR ID DM1JIVR
DM1JIVR DN AL6528
DM1JIVR HS Investigative
DM1JIVR SN AL6528; 2-(3-methoxyphenyl)-2h-thieno-[3,2-e]-1,2-thiazine-6-sulfinamide-1,1-dioxide; 2-(3-methoxyphenyl)-2h-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 1bn3; AC1L1BMR; CTK7A9592; BDBM11938; DB04371; 2-(3-methoxyphenyl)-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide; 2-(3-methoxyphenyl)-1,1-dioxo-2H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide; 2-(3-Methoxyphenyl)-6-sulfamoyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
DM1JIVR DT Small molecular drug
DM1JIVR PC 1514
DM1JIVR MW 372.4
DM1JIVR FM C13H12N2O5S3
DM1JIVR IC InChI=1S/C13H12N2O5S3/c1-20-11-4-2-3-10(8-11)15-6-5-9-7-12(22(14,16)17)21-13(9)23(15,18)19/h2-8H,1H3,(H2,14,16,17)
DM1JIVR CS COC1=CC=CC(=C1)N2C=CC3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N
DM1JIVR IK FBBLOSCXOZYUSS-UHFFFAOYSA-N
DM1JIVR IU 2-(3-methoxyphenyl)-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide
DM1JIVR DE Discovery agent
DM3JNRC ID DM3JNRC
DM3JNRC DN AL-6802
DM3JNRC HS Investigative
DM3JNRC SN EGFR modulators (cancer), Advenchen/Simcere
DM3JNRC CP Advenchen Laboratories LLC
DM3JNRC DE Solid tumour/cancer
DMTXPJI ID DMTXPJI
DMTXPJI DN Al7089a
DMTXPJI HS Investigative
DMTXPJI SN AL7089A; 220402-83-5; (r)-3,4-dihydro-2-(3-methoxyphenyl)-4-methylamino-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; AL8; 1bnm; AC1MHYPX; SCHEMBL679736; BDBM11936; DTXSID20388458; AL7089; AL 7089; DB02220; (4R)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide; (4R)-2-(3-methoxyphenyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide, 3,4-dihydro-2-(3-methoxyphenyl)-4-(m
DMTXPJI DT Small molecular drug
DMTXPJI PC 3013848
DMTXPJI MW 403.5
DMTXPJI FM C14H17N3O5S3
DMTXPJI IC InChI=1S/C14H17N3O5S3/c1-16-12-8-17(9-4-3-5-10(6-9)22-2)25(20,21)14-11(12)7-13(23-14)24(15,18)19/h3-7,12,16H,8H2,1-2H3,(H2,15,18,19)/t12-/m0/s1
DMTXPJI CS CN[C@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C3=CC(=CC=C3)OC
DMTXPJI IK RMOXCYSVWCHXII-LBPRGKRZSA-N
DMTXPJI IU (4R)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMTXPJI CA CAS 220402-83-5
DMTXPJI DE Discovery agent
DMRI08C ID DMRI08C
DMRI08C DN AL7099A
DMRI08C HS Investigative
DMRI08C SN AL7099A; (s)-3,4-dihydro-2-(3-methoxyphenyl)-4-methylamino-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 1bnv; AC1N9ZNC; SCHEMBL678443; BDBM11937; AL7099; DB03221; (4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; (4S)-2-(3-methoxyphenyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; (4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-2H,3H,4H-1$l^{6},7,2-thieno[3,2-e][1,2]thiazine-6-sulfonamide
DMRI08C DT Small molecular drug
DMRI08C PC 4369101
DMRI08C MW 403.5
DMRI08C FM C14H17N3O5S3
DMRI08C IC InChI=1S/C14H17N3O5S3/c1-16-12-8-17(9-4-3-5-10(6-9)22-2)25(20,21)14-11(12)7-13(23-14)24(15,18)19/h3-7,12,16H,8H2,1-2H3,(H2,15,18,19)/t12-/m1/s1
DMRI08C CS CN[C@@H]1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C3=CC(=CC=C3)OC
DMRI08C IK RMOXCYSVWCHXII-GFCCVEGCSA-N
DMRI08C IU (4S)-2-(3-methoxyphenyl)-4-(methylamino)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMRI08C DE Discovery agent
DMG2D4S ID DMG2D4S
DMG2D4S DN AL7182
DMG2D4S HS Investigative
DMG2D4S SN AL7182; 3,,4-dihydro-2-(3-methoxyphenyl)-2h-thieno-[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide; 1bnn; AC1L1BTX; SCHEMBL678649; CHEMBL331858; BDBM11935; DB02602; AL-7182; 2-(3-Methoxyphenyl)-6-sulfamoyl-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide; 2-(3-methoxyphenyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide; 2-(3-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide; 2-(3-methoxyphenyl)-1,1-dioxo-3H,4H-1$l^{6},7,2-thieno[3,2-e][1$l^{6},2]thiazine-6-sulfonamide
DMG2D4S DT Small molecular drug
DMG2D4S PC 1604
DMG2D4S MW 374.5
DMG2D4S FM C13H14N2O5S3
DMG2D4S IC InChI=1S/C13H14N2O5S3/c1-20-11-4-2-3-10(8-11)15-6-5-9-7-12(22(14,16)17)21-13(9)23(15,18)19/h2-4,7-8H,5-6H2,1H3,(H2,14,16,17)
DMG2D4S CS COC1=CC=CC(=C1)N2CCC3=C(S2(=O)=O)SC(=C3)S(=O)(=O)N
DMG2D4S IK ICIXQGGQPKFQRL-UHFFFAOYSA-N
DMG2D4S IU 2-(3-methoxyphenyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
DMG2D4S DE Discovery agent
DMRWLQM ID DMRWLQM
DMRWLQM DN AL-8810
DMRWLQM HS Investigative
DMRWLQM SN AL8810; AL 8810
DMRWLQM DT Small molecular drug
DMRWLQM PC 5311238
DMRWLQM MW 402.5
DMRWLQM FM C24H31FO4
DMRWLQM IC InChI=1S/C24H31FO4/c25-21-15-23(27)20(9-3-1-2-4-10-24(28)29)19(21)11-12-22(26)18-13-16-7-5-6-8-17(16)14-18/h1,3,5-8,11-12,18-23,26-27H,2,4,9-10,13-15H2,(H,28,29)/b3-1-,12-11+/t19-,20-,21+,22+,23+/m1/s1
DMRWLQM CS C1[C@@H]([C@@H]([C@H]([C@H]1F)/C=C/[C@@H](C2CC3=CC=CC=C3C2)O)C/C=C\\CCCC(=O)O)O
DMRWLQM IK WTYSXBKKVNOOIX-JTGCGUAKSA-N
DMRWLQM IU (Z)-7-[(1R,2R,3S,5S)-2-[(E,3R)-3-(2,3-dihydro-1H-inden-2-yl)-3-hydroxyprop-1-enyl]-3-fluoro-5-hydroxycyclopentyl]hept-5-enoic acid
DMRWLQM CA CAS 246246-19-5
DMRWLQM DE Discovery agent
DMRWUQ5 ID DMRWUQ5
DMRWUQ5 DN Ala(1-naph)-Pro-CN
DMRWUQ5 HS Investigative
DMRWUQ5 SN Ala(1-naph)-Pro-CN; GTPL8607
DMRWUQ5 DT Small molecular drug
DMRWUQ5 PC 74765859
DMRWUQ5 MW 293.4
DMRWUQ5 FM C18H19N3O
DMRWUQ5 IC InChI=1S/C18H19N3O/c19-12-15-8-4-10-21(15)18(22)17(20)11-14-7-3-6-13-5-1-2-9-16(13)14/h1-3,5-7,9,15,17H,4,8,10-11,20H2/t15-,17-/m0/s1
DMRWUQ5 CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC3=CC=CC=C32)N)C#N
DMRWUQ5 IK ZVRWNKCHASBEDZ-RDJZCZTQSA-N
DMRWUQ5 IU (2S)-1-[(2S)-2-amino-3-naphthalen-1-ylpropanoyl]pyrrolidine-2-carbonitrile
DMRWUQ5 DE Discovery agent
DMZH4NQ ID DMZH4NQ
DMZH4NQ DN Ala11-SRIF-14-amide
DMZH4NQ HS Investigative
DMZH4NQ PC 44400605
DMZH4NQ MW 1560.8
DMZH4NQ FM C70H101N19O18S2
DMZH4NQ IC InChI=1S/C70H101N19O18S2/c1-36(73)59(96)77-32-55(94)79-53-35-109-108-34-52(58(75)95)87-67(104)51(33-90)86-70(107)57(39(4)92)88-60(97)37(2)78-69(106)56(38(3)91)89-62(99)46(24-14-16-26-72)80-65(102)49(29-42-31-76-44-22-12-11-21-43(42)44)84-64(101)48(28-41-19-9-6-10-20-41)82-63(100)47(27-40-17-7-5-8-18-40)83-66(103)50(30-54(74)93)85-61(98)45(81-68(53)105)23-13-15-25-71/h5-12,17-22,31,36-39,45-53,56-57,76,90-92H,13-16,23-30,32-35,71-73H2,1-4H3,(H2,74,93)(H2,75,95)(H,77,96)(H,78,106)(H,79,94)(H,80,102)(H,81,105)(H,82,100)(H,83,103)(H,84,101)(H,85,98)(H,86,107)(H,87,104)(H,88,97)(H,89,99)/t36-,37-,38?,39?,45-,46+,47-,48+,49-,50+,51-,52-,53-,56+,57+/m0/s1
DMZH4NQ CS C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)C(C)O)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)N)CO)C(C)O
DMZH4NQ IK DWTUVBZITHQYDR-CFWAKGAOSA-N
DMZH4NQ IU (4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-25,28-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-13-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxamide
DMZH4NQ DE Discovery agent
DM9RQ7E ID DM9RQ7E
DM9RQ7E DN Ala6-SRIF-14-amide
DM9RQ7E HS Investigative
DM9RQ7E PC 44400675
DM9RQ7E MW 1560.8
DM9RQ7E FM C70H101N19O18S2
DM9RQ7E IC InChI=1S/C70H101N19O18S2/c1-36(73)59(96)77-32-55(94)79-53-35-109-108-34-52(58(75)95)87-67(104)51(33-90)86-70(107)57(39(4)92)89-66(103)48(28-41-19-9-6-10-20-41)85-69(106)56(38(3)91)88-62(99)46(24-14-16-26-72)80-65(102)49(29-42-31-76-44-22-12-11-21-43(42)44)83-64(101)47(27-40-17-7-5-8-18-40)82-60(97)37(2)78-63(100)50(30-54(74)93)84-61(98)45(81-68(53)105)23-13-15-25-71/h5-12,17-22,31,36-39,45-53,56-57,76,90-92H,13-16,23-30,32-35,71-73H2,1-4H3,(H2,74,93)(H2,75,95)(H,77,96)(H,78,100)(H,79,94)(H,80,102)(H,81,105)(H,82,97)(H,83,101)(H,84,98)(H,85,106)(H,86,107)(H,87,104)(H,88,99)(H,89,103)/t36-,37-,38?,39?,45-,46+,47+,48-,49-,50+,51-,52-,53-,56+,57+/m0/s1
DM9RQ7E CS C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)N)CO)C(C)O)CC2=CC=CC=C2)C(C)O)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5
DM9RQ7E IK XOOYWFHODVEJSJ-XEOGGQMXSA-N
DM9RQ7E IU (4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-28-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxamide
DM9RQ7E DE Discovery agent
DMWF8GN ID DMWF8GN
DMWF8GN DN Ala7-SRIF-14-amide
DMWF8GN HS Investigative
DMWF8GN PC 44400676
DMWF8GN MW 1560.8
DMWF8GN FM C70H101N19O18S2
DMWF8GN IC InChI=1S/C70H101N19O18S2/c1-36(73)59(96)77-32-55(94)79-53-35-109-108-34-52(58(75)95)87-67(104)51(33-90)86-70(107)57(39(4)92)89-66(103)48(28-41-19-9-6-10-20-41)85-69(106)56(38(3)91)88-62(99)46(24-14-16-26-72)80-64(101)49(29-42-31-76-44-22-12-11-21-43(42)44)82-60(97)37(2)78-63(100)47(27-40-17-7-5-8-18-40)83-65(102)50(30-54(74)93)84-61(98)45(81-68(53)105)23-13-15-25-71/h5-12,17-22,31,36-39,45-53,56-57,76,90-92H,13-16,23-30,32-35,71-73H2,1-4H3,(H2,74,93)(H2,75,95)(H,77,96)(H,78,100)(H,79,94)(H,80,101)(H,81,105)(H,82,97)(H,83,102)(H,84,98)(H,85,106)(H,86,107)(H,87,104)(H,88,99)(H,89,103)/t36-,37+,38?,39?,45-,46+,47-,48-,49-,50+,51-,52-,53-,56+,57+/m0/s1
DMWF8GN CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)N)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)N)CO)C(C)O)CC3=CC=CC=C3)C(C)O)CCCCN)CC4=CNC5=CC=CC=C54
DMWF8GN IK IMPCJRRYNLCKNP-IORPGQRLSA-N
DMWF8GN IU (4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,28-dibenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-25-methyl-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxamide
DMWF8GN DE Discovery agent
DMTWB54 ID DMTWB54
DMTWB54 DN Ala-Pro-Glu
DMTWB54 HS Investigative
DMTWB54 SN Ala-Pro-Glu; 71190-92-6; CHEMBL381831; CTK2G2707; DTXSID10658778; L-Alanyl-L-prolyl-L-glutamic acid; L-Glutamic acid, L-alanyl-L-prolyl-
DMTWB54 DT Small molecular drug
DMTWB54 PC 44408970
DMTWB54 MW 315.32
DMTWB54 FM C13H21N3O6
DMTWB54 IC InChI=1S/C13H21N3O6/c1-7(14)12(20)16-6-2-3-9(16)11(19)15-8(13(21)22)4-5-10(17)18/h7-9H,2-6,14H2,1H3,(H,15,19)(H,17,18)(H,21,22)/t7-,8-,9-/m0/s1
DMTWB54 CS C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
DMTWB54 IK IORKCNUBHNIMKY-CIUDSAMLSA-N
DMTWB54 IU (2S)-2-[[(2S)-1-[(2S)-2-aminopropanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMTWB54 CA CAS 71190-92-6
DMTWB54 CB CHEBI:158455
DMTWB54 DE Discovery agent
DMO1ZC2 ID DMO1ZC2
DMO1ZC2 DN ALBAFURAN A
DMO1ZC2 HS Investigative
DMO1ZC2 SN Albafuran A; CHEMBL564896; CHEBI:2543; 84323-14-8; 4-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol; Albafuran; AC1NQYBF; C08732; BDBM50303002; 1,3-Benzenediol, 4-((2E)-3,7-dimethyl-2,6-octadienyl)-5-(6-hydroxy-2-benzofuranyl)-; 4-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol; 4-(3,7-Dimethyl-2,6-octadienyl)-5-(6-hydroxy-2-benzofuranyl)-1,3-benzenediol, 9CI; 4-(3,7-dimethylocta-2,6-dien-1-yl)-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol
DMO1ZC2 DT Small molecular drug
DMO1ZC2 PC 5281297
DMO1ZC2 MW 378.5
DMO1ZC2 FM C24H26O4
DMO1ZC2 IC InChI=1S/C24H26O4/c1-15(2)5-4-6-16(3)7-10-20-21(12-19(26)13-22(20)27)24-11-17-8-9-18(25)14-23(17)28-24/h5,7-9,11-14,25-27H,4,6,10H2,1-3H3/b16-7+
DMO1ZC2 CS CC(=CCC/C(=C/CC1=C(C=C(C=C1O)O)C2=CC3=C(O2)C=C(C=C3)O)/C)C
DMO1ZC2 IK KGOOVUKZICPAIZ-FRKPEAEDSA-N
DMO1ZC2 IU 4-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(6-hydroxy-1-benzofuran-2-yl)benzene-1,3-diol
DMO1ZC2 CA CAS 84323-14-8
DMO1ZC2 CB CHEBI:2543
DMO1ZC2 DE Discovery agent
DMHIW2L ID DMHIW2L
DMHIW2L DN ALBANOL A
DMHIW2L HS Investigative
DMHIW2L SN Mulberrofuran G; Albanol A; 87085-00-5; NSC649229; iso-mulbel-rochromene; NSC 649229; AC1L51ZD; SCHEMBL4926236; AKOS032948258; 3aH-Benzo[3,4][2]benzopyrano[1,8-bc][1]-benzopyran-4,11-diol, 8a-(2,4-dihydroxphenyl)-1,8a,13b,13c-tetrahydro-6-(6-hydroxy-2-benzofuranyl)-2-methyl-, (3a,S,8aS,13bS,13cR)-
DMHIW2L DT Small molecular drug
DMHIW2L PC 9959532
DMHIW2L MW 562.6
DMHIW2L FM C34H26O8
DMHIW2L IC InChI=1S/C34H26O8/c1-16-8-23-22-6-4-21(37)15-30(22)41-34(25-7-5-19(35)13-26(25)38)33(23)24(9-16)32-27(39)10-18(12-31(32)42-34)28-11-17-2-3-20(36)14-29(17)40-28/h2-7,9-15,23-24,33,35-39H,8H2,1H3/t23-,24-,33-,34+/m0/s1
DMHIW2L CS CC1=C[C@@H]2[C@@H]3[C@@H](C1)C4=C(C=C(C=C4)O)O[C@@]3(OC5=CC(=CC(=C25)O)C6=CC7=C(O6)C=C(C=C7)O)C8=C(C=C(C=C8)O)O
DMHIW2L IK MJJWBJFYYRAYKU-OPKNDJPNSA-N
DMHIW2L IU (1S,9R,13R,21S)-1-(2,4-dihydroxyphenyl)-17-(6-hydroxy-1-benzofuran-2-yl)-11-methyl-2,20-dioxapentacyclo[11.7.1.03,8.09,21.014,19]henicosa-3(8),4,6,11,14,16,18-heptaene-5,15-diol
DMHIW2L CB CHEBI:2544
DMHIW2L DE Discovery agent
DMQXO5G ID DMQXO5G
DMQXO5G DN ALD-805
DMQXO5G HS Investigative
DMQXO5G CP Alder Biopharmaceuticals Inc
DMQXO5G DT Antibody
DMQXO5G DE Solid tumour/cancer
DMWBKH1 ID DMWBKH1
DMWBKH1 DN ALD-806
DMWBKH1 HS Investigative
DMWBKH1 SN Anti-HGF mAb (cancer), Alder Biopharmaceuticals
DMWBKH1 CP Alder Biopharmaceuticals Inc
DMWBKH1 DT Antibody
DMWBKH1 DE Solid tumour/cancer
DMAYGK9 ID DMAYGK9
DMAYGK9 DN ALD-901
DMAYGK9 HS Investigative
DMAYGK9 SN ALD-916; Pain pathway antagonist mAb, Alder Biopharmaceuticals; Anti-NGF monoclonal antibody (pain), Alder Biopharmaceuticals
DMAYGK9 CP Alder Biopharmaceuticals Inc
DMAYGK9 DT Antibody
DMAYGK9 DE Pain
DMS80DF ID DMS80DF
DMS80DF DN ALDISIN
DMS80DF HS Investigative
DMS80DF SN 72908-87-3; Aldisin; Aldisine; 6,7-dihydropyrrolo[2,3-c]azepine-4,8(1H,5H)-dione; 6,7-Dihydro-1H,5H-pyrrolo[2,3-c]azepine-4,8-dione; CHEMBL357047; AK134979; Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione, 6,7-dihydro-; Pyrrolo(2,3-c)azepine-4,8(1H,5H)-dione, 6,7-dihydro-; AC1MJ57G; SCHEMBL7844916; 6,7-dihydro-Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione; CTK5D7039; KS-00000FCK; DTXSID40223211; Pyrrolo[2,3-c]azepine-4,8(1H,5H)-dione,6,7-dihydro-; AAPGLCCSVSGLFH-UHFFFAOYSA-N; MolPort-000-003-213; ZINC13310235; BDBM50108777; FCH858612
DMS80DF DT Small molecular drug
DMS80DF PC 3085877
DMS80DF MW 164.16
DMS80DF FM C8H8N2O2
DMS80DF IC InChI=1S/C8H8N2O2/c11-6-2-4-10-8(12)7-5(6)1-3-9-7/h1,3,9H,2,4H2,(H,10,12)
DMS80DF CS C1CNC(=O)C2=C(C1=O)C=CN2
DMS80DF IK AAPGLCCSVSGLFH-UHFFFAOYSA-N
DMS80DF IU 1,5,6,7-tetrahydropyrrolo[2,3-c]azepine-4,8-dione
DMS80DF CA CAS 72908-87-3
DMS80DF DE Discovery agent
DM83CDK ID DM83CDK
DM83CDK DN Alexa-488-telenzepine
DM83CDK HS Investigative
DM83CDK SN Alexa-488-telenzepine
DM83CDK DT Small molecular drug
DM83CDK PC 91827379
DM83CDK MW 1026.2
DM83CDK FM C49H51N7O12S3-6
DM83CDK IC InChI=1S/C49H57N7O12S3/c1-29-42-35(28-69-29)48(59)53-38-12-8-9-13-39(38)56(42)40(57)27-55-24-22-54(23-25-55)21-11-7-5-3-2-4-6-10-20-52-47(58)30-14-15-31(34(26-30)49(60)61)41-32-16-18-36(50)45(70(62,63)64)43(32)68-44-33(41)17-19-37(51)46(44)71(65,66)67/h8-9,12-19,26,28,50,62-67H,2-7,10-11,20-25,27,51H2,1H3,(H,52,58)(H,53,59)(H,60,61)/p-6
DM83CDK CS CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)CCCCCCCCCCNC(=O)C5=CC(=C(C=C5)C6=C7C=CC(=N)C(=C7OC8=C6C=CC(=C8S([O-])([O-])[O-])N)S([O-])([O-])[O-])C(=O)O
DM83CDK IK SRLBGILQMKQWSJ-UHFFFAOYSA-H
DM83CDK IU 2-[3-amino-6-imino-4,5-bis(trioxido-lambda4-sulfanyl)xanthen-9-yl]-5-[10-[4-[2-(1-methyl-4-oxo-5H-thieno[3,4-b][1,5]benzodiazepin-10-yl)-2-oxoethyl]piperazin-1-yl]decylcarbamoyl]benzoic acid
DM83CDK DE Discovery agent
DM53KRA ID DM53KRA
DM53KRA DN ALF-421
DM53KRA HS Investigative
DM53KRA SN CORM-A1; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation); Carbon monoxide-releasing molecules (inflammatory diseases), Alfama; Macromolecular carrier-linked CORMs (inflammation), Alfama; Macromolecular carrier-linked carbon monoxide releasing molecules (inflammation), Alfama
DM53KRA CP Alfama
DM53KRA DE Acute liver failure
DMI4OTW ID DMI4OTW
DMI4OTW DN ALFAXALONE
DMI4OTW HS Investigative
DMI4OTW SN Alphaxalone; Alfaxalone; 23930-19-0; 5alpha-Pregnan-3alpha-ol-11,20-dione; GR 2/234; Alfaxalonum [INN-Latin]; Alfaxalona [INN-Spanish]; 3alpha-Hydroxy-5alpha-pregnane-11,20-dione; UNII-BD07M97B2A; BRN 3217240; MLS001076262; MLS000069684; 3alpha-Hydroxy-5alpha-pregnan-11,20-dion; BD07M97B2A; CHEMBL190279; CHEBI:34531; 3-alpha-Hydroxy-5-alpha-pregnane-11,20-dione; (3-alpha,5-alpha)-3-Hydroxypregnane-11,20-dione; alfaxolone; 3-Hydroxypregnane-11,20-dione; NCGC00023100-03; SMR000058494; (3a,5a)-3-Hydroxypregnane-11,20-dione
DMI4OTW DT Small molecular drug
DMI4OTW PC 104845
DMI4OTW MW 332.5
DMI4OTW FM C21H32O3
DMI4OTW IC InChI=1S/C21H32O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h13-17,19,23H,4-11H2,1-3H3/t13-,14+,15-,16+,17-,19+,20-,21+/m0/s1
DMI4OTW CS CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
DMI4OTW IK DUHUCHOQIDJXAT-OLVMNOGESA-N
DMI4OTW IU (3R,5S,8S,9S,10S,13S,14S,17S)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
DMI4OTW CA CAS 23930-19-0
DMI4OTW CB CHEBI:34531
DMI4OTW DE Discovery agent
DMWMIRL ID DMWMIRL
DMWMIRL DN Alisporivir
DMWMIRL HS Investigative
DMWMIRL SN DEB-025; Debio-025; HCV infection therapy, Debiopharm/Novartis; HIV infection therapy, Debiopharm
DMWMIRL CP Novartis pharmaceuticals
DMWMIRL TC Antiviral Agents
DMWMIRL DT Protein/peptide drug
DMWMIRL PC 11513676
DMWMIRL MW 1216.6
DMWMIRL FM C63H113N11O12
DMWMIRL IC InChI=1S/C63H113N11O12/c1-26-29-30-40(16)52(75)51-56(79)66-44(27-2)59(82)68(20)43(19)58(81)74(28-3)49(38(12)13)55(78)67-48(37(10)11)62(85)69(21)45(31-34(4)5)54(77)64-41(17)53(76)65-42(18)57(80)70(22)46(32-35(6)7)60(83)71(23)47(33-36(8)9)61(84)72(24)50(39(14)15)63(86)73(51)25/h26,29,34-52,75H,27-28,30-33H2,1-25H3,(H,64,77)(H,65,76)(H,66,79)(H,67,78)/b29-26+/t40-,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-/m1/s1
DMWMIRL CS CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C
DMWMIRL IK OLROWHGDTNFZBH-XEMWPYQTSA-N
DMWMIRL IU (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMWMIRL CA CAS 254435-95-5
DMWMIRL DE Duchenne muscular dystrophy; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM3DERI ID DM3DERI
DM3DERI DN alkyl glycerol phosphate 18:1
DM3DERI HS Investigative
DM3DERI SN AGP 18.1
DM3DERI DT Small molecular drug
DM3DERI PC 10717228
DM3DERI MW 424.6
DM3DERI FM C21H45O6P
DM3DERI IC InChI=1S/C21H45O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26-19-21(22)20-27-28(23,24)25/h21-22H,2-20H2,1H3,(H2,23,24,25)/t21-/m0/s1
DM3DERI CS CCCCCCCCCCCCCCCCCCOC[C@@H](COP(=O)(O)O)O
DM3DERI IK HUUYDUFSUADEJQ-NRFANRHFSA-N
DM3DERI IU [(2S)-2-hydroxy-3-octadecoxypropyl] dihydrogen phosphate
DM3DERI DE Discovery agent
DMM19AO ID DMM19AO
DMM19AO DN alkyl OMPT
DMM19AO HS Investigative
DMM19AO SN alkyl OMPT; GTPL2913; CHEMBL3621962; [(2S)-2-methoxy-3-[(9Z)-octadec-9-en-1-yloxy]propoxy](sulfanylidene)phosphonous acid
DMM19AO DT Small molecular drug
DMM19AO PC 56947064
DMM19AO MW 452.6
DMM19AO FM C22H45O5PS
DMM19AO IC InChI=1S/C22H45O5PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26-20-22(25-2)21-27-28(23,24)29/h10-11,22H,3-9,12-21H2,1-2H3,(H2,23,24,29)/b11-10-/t22-/m0/s1
DMM19AO CS CCCCCCCC/C=C\\CCCCCCCCOC[C@@H](COP(=S)(O)O)OC
DMM19AO IK FEHMGBUAJYEJMW-YRBAHSOBSA-N
DMM19AO IU dihydroxy-[(2S)-2-methoxy-3-[(Z)-octadec-9-enoxy]propoxy]-sulfanylidene-lambda5-phosphane
DMM19AO DE Discovery agent
DMQH481 ID DMQH481
DMQH481 DN alkylbenzene sulfonate
DMQH481 HS Investigative
DMQH481 SN 4-dodecan-6-ylbenzenesulfonic Acid; Alkylbenzene sulfonate; AC1Q6WLV; AC1L28EL; 6-(p-sulfophenyl) dodecane; SCHEMBL6128184; GTPL2362; DTXSID30860093; 4-(dodecan-6-yl)benzenesulfonic acid; 4-(1-Hexylhexyl)benzenesulfonic acid; 4-(Dodecan-6-yl)benzene-1-sulfonic acid
DMQH481 DT Small molecular drug
DMQH481 PC 16652
DMQH481 MW 326.5
DMQH481 FM C18H30O3S
DMQH481 IC InChI=1S/C18H30O3S/c1-3-5-7-9-11-16(10-8-6-4-2)17-12-14-18(15-13-17)22(19,20)21/h12-16H,3-11H2,1-2H3,(H,19,20,21)
DMQH481 CS CCCCCCC(CCCCC)C1=CC=C(C=C1)S(=O)(=O)O
DMQH481 IK GHNRTXCRBJQVGN-UHFFFAOYSA-N
DMQH481 IU 4-dodecan-6-ylbenzenesulfonic acid
DMQH481 CA CAS 23003-92-1
DMQH481 DE Discovery agent
DMSOJ6H ID DMSOJ6H
DMSOJ6H DN ALLICIN
DMSOJ6H HS Investigative
DMSOJ6H SN Allicin; 539-86-6; Diallyl thiosulfinate; Diallyldisulfid-S-oxid; Thio-2-propene-1-sulfinic acid S-allyl ester; S-Allyl acrylo-1-sulphinothioate; Allylthiosulphinic acid allyl ester; DADSO; S-allyl prop-2-ene-1-sulfinothioate; diallyl disulfide-oxide; S-allyl 2-propene-1-sulfinothioate; C6H10OS2; CCRIS 9053; EINECS 208-727-7; 2-Propene-1-sulfinothioic acid, S-2-propenyl ester; BRN 1752823; 3-prop-2-enylsulfinylsulfanylprop-1-ene; CHEMBL359965; CHEBI:28411; 3-allylsulfinylsulfanylprop-1-ene; 2-Propene-1-sulfinic acid, thio-, S-
DMSOJ6H DT Small molecular drug
DMSOJ6H PC 65036
DMSOJ6H MW 162.3
DMSOJ6H FM C6H10OS2
DMSOJ6H IC InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2
DMSOJ6H CS C=CCSS(=O)CC=C
DMSOJ6H IK JDLKFOPOAOFWQN-UHFFFAOYSA-N
DMSOJ6H IU 3-prop-2-enylsulfinylsulfanylprop-1-ene
DMSOJ6H CA CAS 539-86-6
DMSOJ6H CB CHEBI:28411
DMSOJ6H DE Discovery agent
DM05AYE ID DM05AYE
DM05AYE DN alloswitch-1
DM05AYE HS Investigative
DM05AYE SN trans-alloswitch-1
DM05AYE DT Small molecular drug
DM05AYE PC 76853680
DM05AYE MW 366.8
DM05AYE FM C19H15ClN4O2
DM05AYE IC InChI=1S/C19H15ClN4O2/c1-26-17-12-13(23-24-18-8-4-5-11-21-18)9-10-16(17)22-19(25)14-6-2-3-7-15(14)20/h2-12H,1H3,(H,22,25)
DM05AYE CS COC1=C(C=CC(=C1)N=NC2=CC=CC=N2)NC(=O)C3=CC=CC=C3Cl
DM05AYE IK JJRNGNCTPCWXGM-UHFFFAOYSA-N
DM05AYE IU 2-chloro-N-[2-methoxy-4-(pyridin-2-yldiazenyl)phenyl]benzamide
DM05AYE DE Discovery agent
DM7U2BE ID DM7U2BE
DM7U2BE DN Alloxazine
DM7U2BE HS Investigative
DM7U2BE SN Alloxazine; Isoalloxazine; 490-59-5; Alloxazin; benzo[g]pteridine-2,4(1H,3H)-dione; 1H-Benzo[g]pteridine-2,4-dione; Benzo(g)pteridine-2,4(1H,3H)-dione; UNII-880W3VF9YW; benzo[g]pteridine-2,4(3H,10H)-dione; CHEMBL68500; 880W3VF9YW; CHEBI:37325; HAUGRYOERYOXHX-UHFFFAOYSA-N; Benzo[g]pteridine-2,4[1H,3H]-dione; 1H,2H,3H,4H-benzo[g]pteridine-2,4-dione; Benzo[g]pteridine-2,3H)-dione; WLN: T C666 BN DMVMV INJ; 1,3-dihydrobenzo[g]pteridine-2,4-dione; SR-01000075199; Alloxazine, 96%; EINECS 207-714-3; NSC 203056; AC1NSYUA; Lopac-A-242
DM7U2BE DT Small molecular drug
DM7U2BE PC 5372720
DM7U2BE MW 214.18
DM7U2BE FM C10H6N4O2
DM7U2BE IC InChI=1S/C10H6N4O2/c15-9-7-8(13-10(16)14-9)12-6-4-2-1-3-5(6)11-7/h1-4H,(H2,12,13,14,15,16)
DM7U2BE CS C1=CC=C2C(=C1)N=C3C(=N2)NC(=O)NC3=O
DM7U2BE IK HAUGRYOERYOXHX-UHFFFAOYSA-N
DM7U2BE IU 1H-benzo[g]pteridine-2,4-dione
DM7U2BE CA CAS 490-59-5
DM7U2BE CB CHEBI:37325
DM7U2BE DE Discovery agent
DMM2R1N ID DMM2R1N
DMM2R1N DN all-trans-4-oxo-retinoic acid
DMM2R1N HS Investigative
DMM2R1N SN 4-oxoretinoic acid; Ro 12-4824
DMM2R1N DT Small molecular drug
DMM2R1N PC 6437063
DMM2R1N MW 314.4
DMM2R1N FM C20H26O3
DMM2R1N IC InChI=1S/C20H26O3/c1-14(7-6-8-15(2)13-19(22)23)9-10-17-16(3)18(21)11-12-20(17,4)5/h6-10,13H,11-12H2,1-5H3,(H,22,23)/b8-6+,10-9+,14-7+,15-13+
DMM2R1N CS CC1=C(C(CCC1=O)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
DMM2R1N IK GGCUJPCCTQNTJF-FRCNGJHJSA-N
DMM2R1N IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
DMM2R1N CA CAS 38030-57-8
DMM2R1N CB CHEBI:80656
DMM2R1N DE Discovery agent
DM6CEVB ID DM6CEVB
DM6CEVB DN All-trans-retinal
DM6CEVB HS Investigative
DM6CEVB DT Small molecular drug
DM6CEVB PC 638015
DM6CEVB MW 284.4
DM6CEVB FM C20H28O
DM6CEVB IC InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
DM6CEVB CS CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=O)/C)/C
DM6CEVB IK NCYCYZXNIZJOKI-OVSJKPMPSA-N
DM6CEVB IU (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenal
DM6CEVB CA CAS 116-31-4
DM6CEVB CB CHEBI:17898
DM6CEVB DE Discovery agent
DM8R5AS ID DM8R5AS
DM8R5AS DN Allyl 4-(2-oxohexadecanamido)butanoate
DM8R5AS HS Investigative
DM8R5AS SN CHEMBL520227
DM8R5AS DT Small molecular drug
DM8R5AS PC 44563072
DM8R5AS MW 395.6
DM8R5AS FM C23H41NO4
DM8R5AS IC InChI=1S/C23H41NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-17-21(25)23(27)24-19-16-18-22(26)28-20-4-2/h4H,2-3,5-20H2,1H3,(H,24,27)
DM8R5AS CS CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)OCC=C
DM8R5AS IK NCGQJUXYFOTZRW-UHFFFAOYSA-N
DM8R5AS IU prop-2-enyl 4-(2-oxohexadecanoylamino)butanoate
DM8R5AS DE Discovery agent
DMYNKLR ID DMYNKLR
DMYNKLR DN Allyl 4-(aminosulfonyl)benzoate
DMYNKLR HS Investigative
DMYNKLR SN CHEMBL381455; 103204-31-5; Benzoic acid, 4-(aminosulfonyl)-, 2-propenyl ester; allyl 4-(aminosulfonyl)benzoate; ACMC-20m632; SCHEMBL6705334; CTK0G7183; DTXSID90468211; VWKMDRWBZTWKNM-UHFFFAOYSA-N; BDBM50175049; 4-Sulfamoyl-benzoic acid allyl ester
DMYNKLR DT Small molecular drug
DMYNKLR PC 11536043
DMYNKLR MW 241.27
DMYNKLR FM C10H11NO4S
DMYNKLR IC InChI=1S/C10H11NO4S/c1-2-7-15-10(12)8-3-5-9(6-4-8)16(11,13)14/h2-6H,1,7H2,(H2,11,13,14)
DMYNKLR CS C=CCOC(=O)C1=CC=C(C=C1)S(=O)(=O)N
DMYNKLR IK VWKMDRWBZTWKNM-UHFFFAOYSA-N
DMYNKLR IU prop-2-enyl 4-sulfamoylbenzoate
DMYNKLR CA CAS 103204-31-5
DMYNKLR DE Discovery agent
DMNFGRV ID DMNFGRV
DMNFGRV DN Allylamines
DMNFGRV HS Investigative
DMNFGRV DE Discovery agent
DMJWZB3 ID DMJWZB3
DMJWZB3 DN Allylcarbamic Acid Biphenyl-3-yl Ester
DMJWZB3 HS Investigative
DMJWZB3 SN Allylcarbamic Acid Biphenyl-3-yl Ester; CHEMBL451174; SCHEMBL4563341
DMJWZB3 DT Small molecular drug
DMJWZB3 PC 24881608
DMJWZB3 MW 253.29
DMJWZB3 FM C16H15NO2
DMJWZB3 IC InChI=1S/C16H15NO2/c1-2-11-17-16(18)19-15-10-6-9-14(12-15)13-7-4-3-5-8-13/h2-10,12H,1,11H2,(H,17,18)
DMJWZB3 CS C=CCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMJWZB3 IK IVZVLOUIEAWCIN-UHFFFAOYSA-N
DMJWZB3 IU (3-phenylphenyl) N-prop-2-enylcarbamate
DMJWZB3 DE Discovery agent
DM1VHCL ID DM1VHCL
DM1VHCL DN Allyl-trimethyl-ammonium
DM1VHCL HS Investigative
DM1VHCL DT Small molecular drug
DM1VHCL PC 10425
DM1VHCL MW 100.18
DM1VHCL FM C6H14N+
DM1VHCL IC InChI=1S/C6H14N/c1-5-6-7(2,3)4/h5H,1,6H2,2-4H3/q+1
DM1VHCL CS C[N+](C)(C)CC=C
DM1VHCL IK KGVWWFCEYXERAE-UHFFFAOYSA-N
DM1VHCL IU trimethyl(prop-2-enyl)azanium
DM1VHCL DE Discovery agent
DMY1OG7 ID DMY1OG7
DMY1OG7 DN ALM-301
DMY1OG7 HS Investigative
DMY1OG7 SN Akt inhibitors (cancer), Almac
DMY1OG7 CP Almac Discovery Ltd
DMY1OG7 DE Solid tumour/cancer
DMPTY8S ID DMPTY8S
DMPTY8S DN Aloe-emodin
DMPTY8S HS Investigative
DMPTY8S SN Aloe-emodin; Aloe emodin; 481-72-1; Aloeemodin; Aloe-emodine; Rhabarberone; EMODINE; 3-Hydroxymethylchrysazin; 1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione; 3-Hydroxymethylchrysazine; 1,8-Dihydroxy-3-hydroxymethylanthraquinone; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone; NSC 38628; 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione; UNII-C8IYT9CR7C; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)-; CCRIS 3526; EINECS 207-571-7; C8IYT9CR7C; 3-(Hydroxymethyl)chrysazin; BRN 2059062; CHEMBL40275; CHEBI:2607
DMPTY8S DT Small molecular drug
DMPTY8S PC 10207
DMPTY8S MW 270.24
DMPTY8S FM C15H10O5
DMPTY8S IC InChI=1S/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-5,16-18H,6H2
DMPTY8S CS C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)CO
DMPTY8S IK YDQWDHRMZQUTBA-UHFFFAOYSA-N
DMPTY8S IU 1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione
DMPTY8S CA CAS 481-72-1
DMPTY8S CB CHEBI:2607
DMPTY8S DE Discovery agent
DM7HGX8 ID DM7HGX8
DM7HGX8 DN aloisine
DM7HGX8 HS Investigative
DM7HGX8 SN IN1538; RP106
DM7HGX8 DT Small molecular drug
DM7HGX8 PC 3641059
DM7HGX8 MW 281.35
DM7HGX8 FM C17H19N3O
DM7HGX8 IC InChI=1S/C17H19N3O/c1-3-4-5-14-15(12-6-8-13(21-2)9-7-12)20-17-16(14)18-10-11-19-17/h6-11H,3-5H2,1-2H3,(H,19,20)
DM7HGX8 CS CCCCC1=C(NC2=NC=CN=C12)C3=CC=C(C=C3)OC
DM7HGX8 IK WVMANZPBOBRWCB-UHFFFAOYSA-N
DM7HGX8 IU 7-butyl-6-(4-methoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine
DM7HGX8 CA CAS 496864-15-4
DM7HGX8 CB CHEBI:92890
DM7HGX8 DE Discovery agent
DM5U1LN ID DM5U1LN
DM5U1LN DN aloisine A
DM5U1LN HS Investigative
DM5U1LN SN ALOISINE A; 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol; 496864-16-5; RP107; 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE; CHEMBL75680; 7-n-Butyl-6-(4-hydroxyphenyl)[5H]pyrrolo[2,3-b]pyrazine; RP-107; ALH; 4-{7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenol; 1ung; SCHEMBL80147; BDBM7377; GTPL5924; AC1NS169; 4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol; CHEBI:93641; CTK8D4068; DTXSID30416115; HMS3229A14; RM-39; BCP26893; ZINC2540737; ACT06534; IN1539; HSCI1_000219; MFCD04973541; AKOS005145972; CCG-206814; DB07364; RTC-063070; AJ-39131
DM5U1LN DT Small molecular drug
DM5U1LN PC 448912
DM5U1LN MW 267.33
DM5U1LN FM C16H17N3O
DM5U1LN IC InChI=1S/C16H17N3O/c1-2-3-4-13-14(11-5-7-12(20)8-6-11)19-16-15(13)17-9-10-18-16/h5-10,20H,2-4H2,1H3,(H,18,19)
DM5U1LN CS CCCCC1=C(NC2=NC=CN=C12)C3=CC=C(C=C3)O
DM5U1LN IK PRIGRJPRGZCFAS-UHFFFAOYSA-N
DM5U1LN IU 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol
DM5U1LN CA CAS 496864-16-5
DM5U1LN CB CHEBI:93641
DM5U1LN DE Discovery agent
DMHRME4 ID DMHRME4
DMHRME4 DN Alpha,beta-methylene-dATP
DMHRME4 HS Investigative
DMHRME4 SN CHEMBL1162297; 2'-Deoxy-5'-O-[(S)-Hydroxy{[(S)-Hydroxy(Phosphonooxy)phosphoryl]methyl}phosphoryl]adenosine; alpha,beta-methylene-dATP; F2A
DMHRME4 DT Small molecular drug
DMHRME4 PC 15667210
DMHRME4 MW 489.21
DMHRME4 FM C11H18N5O11P3
DMHRME4 IC InChI=1S/C11H18N5O11P3/c12-10-9-11(14-3-13-10)16(4-15-9)8-1-6(17)7(26-8)2-25-28(18,19)5-29(20,21)27-30(22,23)24/h3-4,6-8,17H,1-2,5H2,(H,18,19)(H,20,21)(H2,12,13,14)(H2,22,23,24)/t6-,7+,8+/m0/s1
DMHRME4 CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMHRME4 IK XETARULVTCYJAN-XLPZGREQSA-N
DMHRME4 IU [(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMHRME4 DE Discovery agent
DMJI8TX ID DMJI8TX
DMJI8TX DN Alpha,beta-methylene-dCTP
DMJI8TX HS Investigative
DMJI8TX SN 2'-Deoxy-5'-O-[(S)-Hydroxy{[(S)-Hydroxy(Phosphonooxy)phosphoryl]methyl}phosphoryl]cytidine; alpha,beta-methylene-dCTP; XC5
DMJI8TX DT Small molecular drug
DMJI8TX PC 25128802
DMJI8TX MW 465.18
DMJI8TX FM C10H18N3O12P3
DMJI8TX IC InChI=1S/C10H18N3O12P3/c11-8-1-2-13(10(15)12-8)9-3-6(14)7(24-9)4-23-26(16,17)5-27(18,19)25-28(20,21)22/h1-2,6-7,9,14H,3-5H2,(H,16,17)(H,18,19)(H2,11,12,15)(H2,20,21,22)/t6-,7+,9+/m0/s1
DMJI8TX CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMJI8TX IK YSCOIIOUWFAHFY-LKEWCRSYSA-N
DMJI8TX IU [(2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMJI8TX DE Discovery agent
DMPZS80 ID DMPZS80
DMPZS80 DN Alpha,beta-methylene-dGTP
DMPZS80 HS Investigative
DMPZS80 DT Small molecular drug
DMPZS80 PC 135566546
DMPZS80 MW 505.21
DMPZS80 FM C11H18N5O12P3
DMPZS80 IC InChI=1S/C11H18N5O12P3/c12-11-14-9-8(10(18)15-11)13-3-16(9)7-1-5(17)6(27-7)2-26-29(19,20)4-30(21,22)28-31(23,24)25/h3,5-7,17H,1-2,4H2,(H,19,20)(H,21,22)(H2,23,24,25)(H3,12,14,15,18)/t5-,6+,7+/m0/s1
DMPZS80 CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMPZS80 IK JTBKCZGNQPBEJY-RRKCRQDMSA-N
DMPZS80 IU [(2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[[hydroxy(phosphonooxy)phosphoryl]methyl]phosphinic acid
DMPZS80 DE Discovery agent
DMPAHJF ID DMPAHJF
DMPAHJF DN Alpha,beta-methylene-dTTP
DMPAHJF HS Investigative
DMPAHJF SN alpha,beta-CH2-DTTP; alpha,beta-methylene-dTTP; alpha,beta-Methylenedeoxythymidine 5'-triphosphate; CHEMBL1162299; 24716-71-0; Thymidine, 5'-O-(1,3,5,5-tetrahydroxy-4-oxa-1,3,5-triphosphapent-1-yl)-, P,P',P''-trioxide
DMPAHJF DT Small molecular drug
DMPAHJF PC 15667207
DMPAHJF MW 480.2
DMPAHJF FM C11H19N2O13P3
DMPAHJF IC InChI=1S/C11H19N2O13P3/c1-6-3-13(11(16)12-10(6)15)9-2-7(14)8(25-9)4-24-27(17,18)5-28(19,20)26-29(21,22)23/h3,7-9,14H,2,4-5H2,1H3,(H,17,18)(H,19,20)(H,12,15,16)(H2,21,22,23)/t7-,8+,9+/m0/s1
DMPAHJF CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(CP(=O)(O)OP(=O)(O)O)O)O
DMPAHJF IK AFUOLHFRDGMFSB-DJLDLDEBSA-N
DMPAHJF IU [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]methyl-phosphonooxyphosphinic acid
DMPAHJF CA CAS 24716-71-0
DMPAHJF DE Discovery agent
DMLGMTQ ID DMLGMTQ
DMLGMTQ DN alpha.beta-methylene-2-thio-UDP
DMLGMTQ HS Investigative
DMLGMTQ SN alpha,beta-methylene-UDP
DMLGMTQ DT Small molecular drug
DMLGMTQ PC 73755188
DMLGMTQ MW 414.31
DMLGMTQ FM C12H20N2O8P2S
DMLGMTQ IC InChI=1S/C12H20N2O8P2S/c1-7-8(2)11(14-4-3-10(15)13-12(14)25)22-9(7)5-21-24(19,20)6-23(16,17)18/h3-4,7-9,11H,5-6H2,1-2H3,(H,19,20)(H,13,15,25)(H2,16,17,18)/t7-,8+,9+,11+/m0/s1
DMLGMTQ CS C[C@H]1[C@H]([C@@H](O[C@@H]1COP(=O)(CP(=O)(O)O)O)N2C=CC(=O)NC2=S)C
DMLGMTQ IK HGGLEWIKYOGGHB-YSSBGUOXSA-N
DMLGMTQ IU [[(2S,3S,4R,5R)-3,4-dimethyl-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMLGMTQ DE Discovery agent
DM257WX ID DM257WX
DM257WX DN alpha3IA
DM257WX HS Investigative
DM257WX SN CHEMBL413325; alpha3IA; GTPL4094; BDBM50112236; 3-(4-Methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-[2,4'']bipyridinyl-5-carboxylic acid methyl ester; methyl 5-(4-methoxyphenyl)-1-methyl-2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridine-3-carboxylate
DM257WX DT Small molecular drug
DM257WX PC 11824289
DM257WX MW 350.4
DM257WX FM C20H18N2O4
DM257WX IC InChI=1S/C20H18N2O4/c1-22-18(14-8-10-21-11-9-14)16(12-17(19(22)23)20(24)26-3)13-4-6-15(25-2)7-5-13/h4-12H,1-3H3
DM257WX CS CN1C(=C(C=C(C1=O)C(=O)OC)C2=CC=C(C=C2)OC)C3=CC=NC=C3
DM257WX IK LENMNEQXCQXJHV-UHFFFAOYSA-N
DM257WX IU methyl 5-(4-methoxyphenyl)-1-methyl-2-oxo-6-pyridin-4-ylpyridine-3-carboxylate
DM257WX DE Discovery agent
DMTU5QR ID DMTU5QR
DMTU5QR DN alpha5IA
DMTU5QR HS Investigative
DMTU5QR SN 215874-86-5; 3-(5-Methylisoxazol-3-yl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy][1,2,4]triazolo[3,4-a]phthalazine; alpha5IA; UNII-1M7NI1A92L; 1M7NI1A92L; CHEMBL306422; L-822179; alpha-5IA; 3-(5-METHYLISOXAZOL-3-YL)-6-[(1-METHYL-1H-1,2,3-TRIAZOL-4-YL)METHOXY][1,2,4]TRIAZOLO[3,4-A]PHTHALAZI; 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine; a5ia; alpha 5IA; 1,2,4-Triazolo[3,4-a]phthalazine, 3-(5-methyl-3-isoxazolyl)-6-[(1-methyl-1H-1,2,3-triazol-4-yl)methoxy]-
DMTU5QR DT Small molecular drug
DMTU5QR PC 6918451
DMTU5QR MW 362.3
DMTU5QR FM C17H14N8O2
DMTU5QR IC InChI=1S/C17H14N8O2/c1-10-7-14(22-27-10)16-20-19-15-12-5-3-4-6-13(12)17(21-25(15)16)26-9-11-8-24(2)23-18-11/h3-8H,9H2,1-2H3
DMTU5QR CS CC1=CC(=NO1)C2=NN=C3N2N=C(C4=CC=CC=C43)OCC5=CN(N=N5)C
DMTU5QR IK NZMJFRXKGUCYNP-UHFFFAOYSA-N
DMTU5QR IU 5-methyl-3-[6-[(1-methyltriazol-4-yl)methoxy]-[1,2,4]triazolo[3,4-a]phthalazin-3-yl]-1,2-oxazole
DMTU5QR CA CAS 215874-86-5
DMTU5QR DE Discovery agent
DMND5EU ID DMND5EU
DMND5EU DN Alpha-7-Deoxyhomonojirimycin
DMND5EU HS Investigative
DMND5EU SN CHEMBL503021; 7-Deoxyhomonojirimycin; alpha-1-C-Methyl-DNJ; SCHEMBL2438896; BDBM18359
DMND5EU DT Small molecular drug
DMND5EU PC 10921056
DMND5EU MW 177.2
DMND5EU FM C7H15NO4
DMND5EU IC InChI=1S/C7H15NO4/c1-3-5(10)7(12)6(11)4(2-9)8-3/h3-12H,2H2,1H3/t3-,4-,5+,6-,7-/m1/s1
DMND5EU CS C[C@@H]1[C@@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O
DMND5EU IK ZEWFPWKROPWRKE-XUUWZHRGSA-N
DMND5EU IU (2R,3R,4R,5S,6R)-2-(hydroxymethyl)-6-methylpiperidine-3,4,5-triol
DMND5EU DE Discovery agent
DMHV14R ID DMHV14R
DMHV14R DN Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen
DMHV14R HS Investigative
DMHV14R SN 156715-37-6
DMHV14R DT Small molecular drug
DMHV14R PC 23724922
DMHV14R MW 462.5
DMHV14R FM C25H31N2NaO5
DMHV14R IC InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20+,21+,23-;/m0./s1
DMHV14R CS CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+]
DMHV14R IK WOHSQDNIXPEQAE-SLWCZEQYSA-M
DMHV14R IU sodium;3-[2-[[(1R,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
DMHV14R DE Discovery agent
DM4IXUQ ID DM4IXUQ
DM4IXUQ DN Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen
DM4IXUQ HS Investigative
DM4IXUQ DE Discovery agent
DMW1LF0 ID DMW1LF0
DMW1LF0 DN Alpha-Aminobutyric Acid
DMW1LF0 HS Investigative
DMW1LF0 SN 1492-24-6; L-2-Aminobutyric acid; h-abu-oh; (S)-2-Aminobutanoic acid; (2S)-2-aminobutanoic acid; (S)-(+)-2-Aminobutyric Acid; L-alpha-Aminobutyric acid; L-(+)-2-aminobutyric acid; (S)-2-Aminobutyric acid; (-)-2-Aminobutyric acid; (S)-2-Amino-butyric acid; L-Butyrine; L-alpha-Amino-n-butyric acid; h-2-abu-oh; L-alpha-Aminobutyrate; Butanoic acid, 2-amino-, (2S)-; (S)-2-Aminobutanoate; 2S-amino-butanoic acid; UNII-0QAJ5KN9IM; S-Butyrine; ALPHA-AMINOBUTYRIC ACID; (2S)-2-Aminobutyric acid; L-2-Aminobuttersaeure; l(+)-2-aminobutyric a
DMW1LF0 DT Small molecular drug
DMW1LF0 PC 6657
DMW1LF0 MW 103.12
DMW1LF0 FM C4H9NO2
DMW1LF0 IC InChI=1S/C4H9NO2/c1-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)
DMW1LF0 CS CCC(C(=O)O)N
DMW1LF0 IK QWCKQJZIFLGMSD-UHFFFAOYSA-N
DMW1LF0 IU 2-aminobutanoic acid
DMW1LF0 CA CAS 2835-81-6
DMW1LF0 CB CHEBI:35621
DMW1LF0 DE Discovery agent
DM9GXFJ ID DM9GXFJ
DM9GXFJ DN Alpha-Aminoisobutyric Acid
DM9GXFJ HS Investigative
DM9GXFJ SN 2-Aminoisobutyric acid; 62-57-7; 2-Methylalanine; 2-Amino-2-methylpropanoic acid; H-Aib-OH; Alanine, 2-methyl-; ALPHA-AMINOISOBUTYRIC ACID; 2-Amino-2-methylpropionic acid; alpha-Methylalanine; alpha-Aminoisobutanoic acid; a-Aminoisobutyric acid; 2-amino isobutyric acid; NSC 16590; alpha,alpha-Dimethylglycine; AIB; Propionic acid, 2-amino-2-methyl-; 2-amino-isobutyric acid; 2-amino-2-methyl-propanoic acid; UNII-1E7ZW41IQU; a-Aminoisobutyrate; 2-Amino-2-methylpropanoate; .alpha.-Aminoisobutanoic acid; 2,2-dimethylglycine
DM9GXFJ DT Small molecular drug
DM9GXFJ PC 6119
DM9GXFJ MW 103.12
DM9GXFJ FM C4H9NO2
DM9GXFJ IC InChI=1S/C4H9NO2/c1-4(2,5)3(6)7/h5H2,1-2H3,(H,6,7)
DM9GXFJ CS CC(C)(C(=O)O)N
DM9GXFJ IK FUOOLUPWFVMBKG-UHFFFAOYSA-N
DM9GXFJ IU 2-amino-2-methylpropanoic acid
DM9GXFJ CA CAS 62-57-7
DM9GXFJ CB CHEBI:27971
DM9GXFJ DE Discovery agent
DMRGFEM ID DMRGFEM
DMRGFEM DN alphabeta-methyleneADP
DMRGFEM HS Investigative
DMRGFEM SN Phosphomethylphosphonic acid adenosyl ester; Adenosine 5'-methylenediphosphate; phosphomethylphosphonic acid adenosyl ester; 3768-14-7; alpha,beta-methylene ADP; MethADP; AMP-CP; UNII-0T2A5439OE; Adenosine, 5'-(trihydrogen methylenebis(phosphonate)); EINECS 223-194-0; NSC 614641; ALPHA,BETA-METHYLENEADENOSINE 5'-DIPHOSPHATE; Adenosine 5'-(hydrogen (phosphonomethyl)phosphonate); CHEBI:40730; 0T2A5439OE; ALPHA,BETA-METHYLENEADENOSINE-5'-DIPHOSPHATE; AMPCP; 5'-O-[hydroxy(phosphonomethyl)phosphoryl]adenosine; Adenosine 5'-(alpha,beta-methylene)diphosphoric acid; alpha,beta-methyleneadenosine 5'-diphosphate (alphabetameADP); [alphabetaCH2]ADP; Phosphomethylphosphonic Acid Adenosyl Ester
DMRGFEM DT Small molecular drug
DMRGFEM PC 92199
DMRGFEM MW 425.23
DMRGFEM FM C11H17N5O9P2
DMRGFEM IC InChI=1S/C11H17N5O9P2/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(25-11)1-24-27(22,23)4-26(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1
DMRGFEM CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)N
DMRGFEM IK OLCWZBFDIYXLAA-IOSLPCCCSA-N
DMRGFEM IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMRGFEM CA CAS 3768-14-7
DMRGFEM CB CHEBI:40730
DMRGFEM DE Discovery agent
DM96EJ1 ID DM96EJ1
DM96EJ1 DN alpha-conotoxin AuIB
DM96EJ1 HS Investigative
DM96EJ1 SN GTPL3973
DM96EJ1 DT Small molecular drug
DM96EJ1 PC 73755065
DM96EJ1 MW 1572.8
DM96EJ1 FM C65H89N17O21S4
DM96EJ1 IC InChI=1S/C65H89N17O21S4/c1-31-53(91)79-51(32(2)84)62(100)74-39(23-48(67)86)64(102)80-18-6-11-45(80)60(98)72-37(24-50(88)89)55(93)76-41(52(68)90)27-104-106-29-43-59(97)75-40(26-83)56(94)73-38(22-34-14-16-35(85)17-15-34)63(101)82-20-8-13-47(82)65(103)81-19-7-12-46(81)61(99)78-44(30-107-105-28-42(57(95)77-43)70-49(87)25-66)58(96)71-36(54(92)69-31)21-33-9-4-3-5-10-33/h3-5,9-10,14-17,31-32,36-47,51,83-85H,6-8,11-13,18-30,66H2,1-2H3,(H2,67,86)(H2,68,90)(H,69,92)(H,70,87)(H,71,96)(H,72,98)(H,73,94)(H,74,100)(H,75,97)(H,76,93)(H,77,95)(H,78,99)(H,79,91)(H,88,89)/t31-,32+,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,51-/m0/s1
DM96EJ1 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)NC(=O)CN)C(=O)N[C@H](C(=O)N1)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)CO)C(=O)N)CC(=O)O)CC(=O)N)[C@@H](C)O
DM96EJ1 IK SVNSCQIKKAACJG-SBLJLSJOSA-N
DM96EJ1 IU 2-[(1R,6R,9S,12S,18S,21S,24S,27S,30R,33S,39S,45S,48S,53R)-53-[(2-aminoacetyl)amino]-18-(2-amino-2-oxoethyl)-27-benzyl-6-carbamoyl-21-[(1R)-1-hydroxyethyl]-48-(hydroxymethyl)-45-[(4-hydroxyphenyl)methyl]-24-methyl-8,11,17,20,23,26,29,32,38,44,47,50,52-tridecaoxo-3,4,55,56-tetrathia-7,10,16,19,22,25,28,31,37,43,46,49,51-tridecazapentacyclo[28.20.7.012,16.033,37.039,43]heptapentacontan-9-yl]acetic acid
DM96EJ1 DE Discovery agent
DMHO634 ID DMHO634
DMHO634 DN alpha-conotoxin GI
DMHO634 HS Investigative
DMHO634 DT Small molecular drug
DMHO634 PC 25084484
DMHO634 MW 1437.6
DMHO634 FM C55H80N20O18S4
DMHO634 IC InChI=1S/C55H80N20O18S4/c1-25-44(83)72-36-21-95-97-22-37(73-45(84)29(56)9-10-42(80)81)52(91)74-38(51(90)69-33(16-40(57)78)54(93)75-12-4-8-39(75)53(92)65-25)23-96-94-20-35(43(58)82)71-50(89)34(19-76)70-48(87)31(14-26-5-2-6-28(77)13-26)67-49(88)32(15-27-17-61-24-64-27)68-47(86)30(7-3-11-62-55(59)60)66-41(79)18-63-46(36)85/h2,5-6,13,17,24-25,29-39,76-77H,3-4,7-12,14-16,18-23,56H2,1H3,(H2,57,78)(H2,58,82)(H,61,64)(H,63,85)(H,65,92)(H,66,79)(H,67,88)(H,68,86)(H,69,90)(H,70,87)(H,71,89)(H,72,83)(H,73,84)(H,74,91)(H,80,81)(H4,59,60,62)/t25-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-/m0/s1
DMHO634 CS C[C@H]1C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC2=O)CCCN=C(N)N)CC3=CN=CN3)CC4=CC(=CC=C4)O)CO)C(=O)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)NC(=O)[C@H](CCC(=O)O)N
DMHO634 IK CSUQNJQRLCOOSR-NAKBKFBQSA-N
DMHO634 IU (4S)-4-amino-5-[[(1R,7S,10S,13S,16S,19R,24R,27S,33S,36S,43R)-27-(2-amino-2-oxoethyl)-19-carbamoyl-7-[3-(diaminomethylideneamino)propyl]-16-(hydroxymethyl)-13-[(3-hydroxyphenyl)methyl]-10-(1H-imidazol-5-ylmethyl)-36-methyl-2,5,8,11,14,17,25,28,34,37,44-undecaoxo-21,22,40,41-tetrathia-3,6,9,12,15,18,26,29,35,38,45-undecazatricyclo[22.14.7.029,33]pentatetracontan-43-yl]amino]-5-oxopentanoic acid
DMHO634 CA CAS 76862-65-2
DMHO634 DE Discovery agent
DM1QOY0 ID DM1QOY0
DM1QOY0 DN alpha-conotoxin PnIA
DM1QOY0 HS Investigative
DM1QOY0 SN GTPL3982
DM1QOY0 DT Small molecular drug
DM1QOY0 PC 73755066
DM1QOY0 MW 1622.8
DM1QOY0 FM C65H95N19O22S4
DM1QOY0 IC InChI=1S/C65H95N19O22S4/c1-29(2)18-37-63(104)84-17-7-10-46(84)65(106)83-16-6-9-45(83)62(103)81-42-27-110-108-26-41(72-49(89)23-66)59(100)80-43(60(101)78-39(24-85)57(98)76-37)28-109-107-25-40(51(69)92)79-54(95)34(19-32-11-13-33(86)14-12-32)74-56(97)36(22-50(90)91)75-61(102)44-8-5-15-82(44)64(105)38(21-48(68)88)77-55(96)35(20-47(67)87)73-53(94)31(4)70-52(93)30(3)71-58(42)99/h11-14,29-31,34-46,85-86H,5-10,15-28,66H2,1-4H3,(H2,67,87)(H2,68,88)(H2,69,92)(H,70,93)(H,71,99)(H,72,89)(H,73,94)(H,74,97)(H,75,102)(H,76,98)(H,77,96)(H,78,101)(H,79,95)(H,80,100)(H,81,103)(H,90,91)/t30-,31-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-/m0/s1
DM1QOY0 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)NC(=O)CN)C(=O)N[C@H](C(=O)N1)C)CC(C)C)CO)C(=O)N)CC6=CC=C(C=C6)O)CC(=O)O)CC(=O)N)CC(=O)N
DM1QOY0 IK VUVGEYBNLLGGBG-MVPSLEAZSA-N
DM1QOY0 IU 2-[(1R,6R,9S,12S,15S,21S,24S,27S,30S,33R,36S,42S,48S,51S,56R)-56-[(2-aminoacetyl)amino]-21,24-bis(2-amino-2-oxoethyl)-6-carbamoyl-51-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-27,30-dimethyl-48-(2-methylpropyl)-8,11,14,20,23,26,29,32,35,41,47,50,53,55-tetradecaoxo-3,4,58,59-tetrathia-7,10,13,19,22,25,28,31,34,40,46,49,52,54-tetradecazapentacyclo[31.20.7.015,19.036,40.042,46]hexacontan-12-yl]acetic acid
DM1QOY0 DE Discovery agent
DM6VH7A ID DM6VH7A
DM6VH7A DN Alpha-D-Fucose
DM6VH7A HS Investigative
DM6VH7A SN Alpha-D-Fucose; alpha-D-fucopyranose; alpha-D-Fucp; 6-deoxy-alpha-D-galactopyranose; alpha-D-Fuc; UNII-K15K52FOK4; CHEBI:42564; K15K52FOK4; (2S,3R,4S,5R,6R)-6-methyloxane-2,3,4,5-tetrol; 6-Deoxy-D-galactose; Fucopyranose, alpha-D-; 6-Deoxy-alpha-D-galactose; fucoside; 1abf; 7abp; alpha-D-Galactopyranose, 6-deoxy-; 6-dideoxy galactose; AC1L9FWD; Epitope ID:115015; SCHEMBL1399668; CHEMBL609880; ZINC1532815; AKOS006272406; RP22690; DB03485; 6189-71-5; CJ-24263; F-8000; A823144; 111719-EP2371811A2; 111719-EP2275420A1; 111719-EP2298757A2
DM6VH7A DT Small molecular drug
DM6VH7A PC 444200
DM6VH7A MW 164.16
DM6VH7A FM C6H12O5
DM6VH7A IC InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6+/m1/s1
DM6VH7A CS C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O)O)O)O
DM6VH7A IK SHZGCJCMOBCMKK-PHYPRBDBSA-N
DM6VH7A IU (2S,3R,4S,5R,6R)-6-methyloxane-2,3,4,5-tetrol
DM6VH7A CA CAS 6189-71-5
DM6VH7A CB CHEBI:42564
DM6VH7A DE Discovery agent
DMD2TPA ID DMD2TPA
DMD2TPA DN Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide
DMD2TPA HS Investigative
DMD2TPA SN ALPHA-D-GLUCOPYRANOSYL-2-CARBOXYLIC ACID AMIDE; CHEMBL135302; GLG; AC1L9IMU; SCHEMBL5961308; 3,4,5-Trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-carboxylic acid amide; (alpha-D-Glucopyranosyl)formamide; BDBM50306562; DB02720; (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-carboxamide; (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide; (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide (non-preferred name)
DMD2TPA DT Small molecular drug
DMD2TPA PC 445825
DMD2TPA MW 207.18
DMD2TPA FM C7H13NO6
DMD2TPA IC InChI=1S/C7H13NO6/c8-7(13)6-5(12)4(11)3(10)2(1-9)14-6/h2-6,9-12H,1H2,(H2,8,13)/t2-,3-,4+,5-,6+/m1/s1
DMD2TPA CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)C(=O)N)O)O)O)O
DMD2TPA IK UKWLGCFJAVEFPE-DVKNGEFBSA-N
DMD2TPA IU (2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-carboxamide
DMD2TPA CA CAS 58825-13-1
DMD2TPA DE Discovery agent
DM1X3VQ ID DM1X3VQ
DM1X3VQ DN Alpha-D-glucose
DM1X3VQ HS Investigative
DM1X3VQ SN D-gluco-hexose; D-gluose; Glucopyranose, alpha-D-; a-D-Glucopyranose; alpha-D-Glucopyranose; alpha-Dextrose; alpha-glucose; glucoses; (2S,3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; (2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; (2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; .alpha.-D-Glucose; 492-62-6; 5J5I9EB41E; CHEBI:17925; CHEMBL423707; UNII-5J5I9EB41E; alpha-D(+)-Glucose, 99+%, anhydrous; alpha-D-Glc; alpha-D-glucose
DM1X3VQ PC 79025
DM1X3VQ MW 180.16
DM1X3VQ FM C6H12O6
DM1X3VQ IC WQZGKKKJIJFFOK-DVKNGEFBSA-N
DM1X3VQ CS C(C1C(C(C(C(O1)O)O)O)O)O
DM1X3VQ IK 1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6+/m1/s1
DM1X3VQ IU (2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM1X3VQ CA CAS 492-62-6
DM1X3VQ CB CHEBI:17925
DM1X3VQ DE Discovery agent
DMU36HT ID DMU36HT
DMU36HT DN Alpha-D-Glucose-1-Phosphate
DMU36HT HS Investigative
DMU36HT SN beta-D-Glucose 1-phosphate; 1-O-phosphono-beta-D-glucopyranose; 1-phospho-beta-D-glucopyranose; CHEBI:16218; beta-glucose-1-phosphate; UNII-X9QC3WD5G5; X9QC3WD5G5; beta-D-glucopyranose 1-(dihydrogen phosphate); 1-o-phosphono-; A-d-glucopyranose; Dol-P-glc; XGP; Glucosylphosphodolichol; Dolichylglucose phosphate; Epitope ID:145000; AC1L3U9A; AC1Q6S5M; NCIStruc2_000464; NCIStruc1_000461; SCHEMBL361623; CHEMBL67622; beta-d-glucopyranosyl phosphate; dolichol-D-glucosylmonophosphate; .alpha.-D-Glucose, 1-phosphate; ZINC3953999
DMU36HT DT Small molecular drug
DMU36HT PC 65533
DMU36HT MW 260.14
DMU36HT FM C6H13O9P
DMU36HT IC InChI=1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6-/m1/s1
DMU36HT CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OP(=O)(O)O)O)O)O)O
DMU36HT IK HXXFSFRBOHSIMQ-VFUOTHLCSA-N
DMU36HT IU [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DMU36HT CA CAS 59-56-3
DMU36HT CB CHEBI:29042
DMU36HT DE Discovery agent
DMR0EVN ID DMR0EVN
DMR0EVN DN Alpha-D-Glucose-6-Phosphate
DMR0EVN HS Investigative
DMR0EVN SN 6-O-phosphono-alpha-D-glucopyranose; UNII-03JQ7I74CO; 03JQ7I74CO; CHEBI:17665; alpha-D-Glucopyranose, 6-(dihydrogen phosphate); alpha-D-glucopyranose 6-(dihydrogen phosphate); 15209-11-7; alpha-D-glucopyranose 6-phosphate; G6P; 1gpy; Epitope ID:144999; SCHEMBL6598; AC1L971Q; NBSCHQHZLSJFNQ-DVKNGEFBSA-N; CHEBI:136602; ZINC3875375; DB02007; C00668; WURCS=2.0/1,1,0/[a2122h-1a_1-5_6*OPO/3O/3=O]/1/
DMR0EVN DT Small molecular drug
DMR0EVN PC 439284
DMR0EVN MW 260.14
DMR0EVN FM C6H13O9P
DMR0EVN IC InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6+/m1/s1
DMR0EVN CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)O)O)OP(=O)(O)O
DMR0EVN IK NBSCHQHZLSJFNQ-DVKNGEFBSA-N
DMR0EVN IU [(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DMR0EVN CA CAS 15209-11-7
DMR0EVN CB CHEBI:17665
DMR0EVN DE Discovery agent
DM6ZTOW ID DM6ZTOW
DM6ZTOW DN Alpha-dihydroaldosterone
DM6ZTOW HS Investigative
DM6ZTOW SN 5-Dihydroaldosterone; 5alpha-Dihydroaldosterone; 5Alpha-dihydroaldosterone; 6005-92-1; AC1MI1I2; 18,21-Dihydroxy-11,18-epoxypregnane-3,20-dione; DTXSID00975481
DM6ZTOW PC 3036614
DM6ZTOW MW 362.5
DM6ZTOW FM C21H30O5
DM6ZTOW IC WCYSTKTYJRHHAV-RXKCSFKASA-N
DM6ZTOW CS CC12CCC(=O)CC1CCC3C2C4CC5(C3CCC5C(=O)CO)C(O4)O
DM6ZTOW IK 1S/C21H30O5/c1-20-7-6-12(23)8-11(20)2-3-13-14-4-5-15(16(24)10-22)21(14)9-17(18(13)20)26-19(21)25/h11,13-15,17-19,22,25H,2-10H2,1H3/t11-,13+,14+,15-,17-,18-,19?,20+,21?/m1/s1
DM6ZTOW IU (2S,5S,6S,9R,14S,15S,16R)-18-hydroxy-2-(2-hydroxyacetyl)-14-methyl-17-oxapentacyclo[14.2.1.01,5.06,15.09,14]nonadecan-11-one
DM6ZTOW CA CAS 6005-92-1
DM6ZTOW DE Discovery agent
DMF5DLW ID DMF5DLW
DMF5DLW DN Alpha-D-Mannose
DMF5DLW HS Investigative
DMF5DLW SN alpha-D-Mannose; alpha-D-Mannopyranose; alpha-Mannose; alpha-D-Man; UNII-W3F28J9G0W; CHEBI:28729; 7296-15-3; W3F28J9G0W; 3h-mannose; Manalpha1,; 1rdl; 1rin; 29696-75-1; Epitope ID:130701; AC1Q59RC; AC1L4HD7; SCHEMBL76882; CHEMBL365590; WQZGKKKJIJFFOK-PQMKYFCFSA-N; ZINC3860903; FT-0773891; C00936; WURCS=2.0/1,1,0/[a1122h-1a_1-5]/1/
DMF5DLW DT Small molecular drug
DMF5DLW PC 185698
DMF5DLW MW 180.16
DMF5DLW FM C6H12O6
DMF5DLW IC InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6+/m1/s1
DMF5DLW CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O)O)O
DMF5DLW IK WQZGKKKJIJFFOK-PQMKYFCFSA-N
DMF5DLW IU (2S,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMF5DLW CA CAS 7296-15-3
DMF5DLW CB CHEBI:28729
DMF5DLW DE Discovery agent
DM3NCM1 ID DM3NCM1
DM3NCM1 DN Alpha-D-Mannose-6-Phosphate
DM3NCM1 HS Investigative
DM3NCM1 SN alpha-D-mannose-6-phosphate; 6-H2PO3Manalpha; alpha-D-mannose 6-phosphate; (6P)Manalpha; Man6P; (6P)Mana; 6-O-phosphono-alpha-D-mannopyranose; UNII-C77UQ006XD; C77UQ006XD; CHEBI:43896; Mannose 6-phosphate; M6P; 1syo; 1m6p; 1sz0; AC1L9KGE; SCHEMBL742653; CHEMBL402001; NBSCHQHZLSJFNQ-PQMKYFCFSA-N; ZINC4096188; DB02900; alpha-D-Mannopyranose, 6-(dihydrogen phosphate); WURCS=2.0/1,1,0/[a1122h-1a_1-5_6*OPO/3O/3=O]/1/; [(2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DM3NCM1 DT Small molecular drug
DM3NCM1 PC 447096
DM3NCM1 MW 260.14
DM3NCM1 FM C6H13O9P
DM3NCM1 IC InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6+/m1/s1
DM3NCM1 CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O)O)O)O)OP(=O)(O)O
DM3NCM1 IK NBSCHQHZLSJFNQ-PQMKYFCFSA-N
DM3NCM1 IU [(2R,3S,4S,5S,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl dihydrogen phosphate
DM3NCM1 CA CAS 40436-60-0
DM3NCM1 CB CHEBI:43896
DM3NCM1 DE Discovery agent
DMULXO3 ID DMULXO3
DMULXO3 DN alpha-Emtbl
DMULXO3 HS Investigative
DMULXO3 SN alpha-Emtbl; 3-ethyl-3-methylthiolan-2-one; 103620-92-4; alpha-Ethyl-alpha-methyl-thiobutyrolactone; AC1L2TRI; CHEBI:35058; C13720; 2(3H)-Thiophenone, 3-ethyldihydro-3-methyl-; CHEMBL34197; GTPL2363
DMULXO3 DT Small molecular drug
DMULXO3 PC 128423
DMULXO3 MW 144.24
DMULXO3 FM C7H12OS
DMULXO3 IC InChI=1S/C7H12OS/c1-3-7(2)4-5-9-6(7)8/h3-5H2,1-2H3
DMULXO3 CS CCC1(CCSC1=O)C
DMULXO3 IK PSYRIJIIQVMBLR-UHFFFAOYSA-N
DMULXO3 IU 3-ethyl-3-methylthiolan-2-one
DMULXO3 CA CAS 103620-92-4
DMULXO3 CB CHEBI:35058
DMULXO3 DE Discovery agent
DMMPOEK ID DMMPOEK
DMMPOEK DN alpha-ergocryptine
DMMPOEK HS Investigative
DMMPOEK SN Ergocryptine; alpha-Ergocryptine; Ergocryptine-alpha; 511-09-1; UNII-6WFB60157B; alpha-Ergokryptine; NSC 169479; CHEMBL1403281; CHEBI:10276; YDOTUXAWKBPQJW-NSLWYYNWSA-N; 12'-Hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione; 6WFB60157B; EINECS 208-121-2; 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)ergotaman-3',6',18-trione; 12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman; BRN 0078810; 12'-Hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotaman-3',6',18-trione
DMMPOEK DT Small molecular drug
DMMPOEK PC 134551
DMMPOEK MW 575.7
DMMPOEK FM C32H41N5O5
DMMPOEK IC InChI=1S/C32H41N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,13,15,17-18,20,24-26,33,41H,7,10-12,14,16H2,1-5H3,(H,34,38)/t20-,24-,25+,26+,31-,32+/m1/s1
DMMPOEK CS CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
DMMPOEK IK YDOTUXAWKBPQJW-NSLWYYNWSA-N
DMMPOEK IU (6aR,9R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMMPOEK CA CAS 511-09-1
DMMPOEK CB CHEBI:10276
DMMPOEK DE Discovery agent
DMYSCQU ID DMYSCQU
DMYSCQU DN Alpha-eudesmol
DMYSCQU HS Investigative
DMYSCQU SN .alpha.-Eudesmol; 2-Naphthalenemethanol, 1,2,3,4,4a,5,6,8a-octahydro-.alpha.,.alpha.,4a,8-tetramethyl-, [2R-(2.alpha.,4a.alpha.,8a.beta.)]-; AC1NSVC3; SCHEMBL17962962; FCSRUSQUAVXUKK-ILWWEHDPSA-N; 2-(4a,8-Dimethyl-1,2,3,4,4a,5,6,8a-octahydro-2-naphthalenyl)-2-propanol #
DMYSCQU DT Small molecular drug
DMYSCQU PC 92762
DMYSCQU MW 222.37
DMYSCQU FM C15H26O
DMYSCQU IC InChI=1S/C15H26O/c1-11-6-5-8-15(4)9-7-12(10-13(11)15)14(2,3)16/h6,12-13,16H,5,7-10H2,1-4H3/t12-,13+,15-/m1/s1
DMYSCQU CS CC1=CCC[C@]2([C@H]1C[C@@H](CC2)C(C)(C)O)C
DMYSCQU IK FCSRUSQUAVXUKK-VNHYZAJKSA-N
DMYSCQU IU 2-[(2R,4aR,8aR)-4a,8-dimethyl-2,3,4,5,6,8a-hexahydro-1H-naphthalen-2-yl]propan-2-ol
DMYSCQU CA CAS 473-16-5
DMYSCQU CB CHEBI:10278
DMYSCQU DE Discovery agent
DM4GLZU ID DM4GLZU
DM4GLZU DN alpha-fluoromethylenephosphonate
DM4GLZU HS Investigative
DM4GLZU SN alpha-fluoromethylenephosphonate; GTPL2915; CHEMBL190717; [(3S)-1-fluoro-3-methoxy-4-[(9E)-octadec-9-enoyloxy]butyl]phosphonic acid
DM4GLZU DT Small molecular drug
DM4GLZU PC 44400349
DM4GLZU MW 466.6
DM4GLZU FM C23H44FO6P
DM4GLZU IC InChI=1S/C23H44FO6P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23(25)30-20-21(29-2)19-22(24)31(26,27)28/h10-11,21-22H,3-9,12-20H2,1-2H3,(H2,26,27,28)/b11-10+/t21-,22?/m0/s1
DM4GLZU CS CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H](CC(F)P(=O)(O)O)OC
DM4GLZU IK KGVHPTQYUKZZPY-VXECIVMWSA-N
DM4GLZU IU [(3S)-1-fluoro-3-methoxy-4-[(E)-octadec-9-enoyl]oxybutyl]phosphonic acid
DM4GLZU DE Discovery agent
DMT17H0 ID DMT17H0
DMT17H0 DN Alpha-Homonojirimycin
DMT17H0 HS Investigative
DMT17H0 SN alpha-Homonojirimycin; Homonojirimycin; 119557-99-2; a-Homonojirimycin; alpha-Homoallonojirimycin; (2r,3r,5s,6r)-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol; CHEMBL501355; CHEMBL2111688; Hnj cpd; .alpha.-Homonojirimycin; 2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol; AC1Q59RO; AC1L4LY0; 3,4,5-Piperidinetriol,2,6-bis(hydroxymethyl)-, (2R,3R,5S,6R)-; SCHEMBL2265531; SCHEMBL1469250; SCHEMBL2265529; BDBM18366; CTK4B1372; CLVUFWXGNIFGNC-OVHBTUCOSA-N; CLVUFWXGNIFGNC-QTSLKERKSA-N; alpha-homonojirimycin (alpha-HNJ); BDBM50259956
DMT17H0 DT Small molecular drug
DMT17H0 PC 159496
DMT17H0 MW 193.2
DMT17H0 FM C7H15NO5
DMT17H0 IC InChI=1S/C7H15NO5/c9-1-3-5(11)7(13)6(12)4(2-10)8-3/h3-13H,1-2H2/t3-,4-,5-,6+,7?/m1/s1
DMT17H0 CS C([C@@H]1[C@H](C([C@H]([C@H](N1)CO)O)O)O)O
DMT17H0 IK CLVUFWXGNIFGNC-QTSLKERKSA-N
DMT17H0 IU (2R,3S,5R,6R)-2,6-bis(hydroxymethyl)piperidine-3,4,5-triol
DMT17H0 CA CAS 119557-99-2
DMT17H0 DE Discovery agent
DMIH38V ID DMIH38V
DMIH38V DN ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID
DMIH38V HS Investigative
DMIH38V SN alpha-hydroxyfarnesylphosphonic acid; HFPA; MONZTFSZTWQCKH-IJFRVEDASA-N; 140633-12-1; 148796-53-6; alpha-Hydroxyfarnesylphosphonic aicd; alpha-hydroxy Farnesyl Phosphonic Acid; AC1NS45W; C15H27O4P; MolPort-003-941-743; HMS3649I13; 1609AH; .alpha.-hydroxy Farnesyl Phosphonic Acid; RT-011376; C-28812; SR-01000946574; J-008515; SR-01000946574-1; L-704272; 1-Hydroxy-3,7,11-trimethyl-2E,6E,10-dodecatriene-1-phosphonic acid; [1-Hydroxy-(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]phosphonic acid
DMIH38V DT Small molecular drug
DMIH38V PC 5353399
DMIH38V MW 302.35
DMIH38V FM C15H27O4P
DMIH38V IC InChI=1S/C15H27O4P/c1-12(2)7-5-8-13(3)9-6-10-14(4)11-15(16)20(17,18)19/h7,9,11,15-16H,5-6,8,10H2,1-4H3,(H2,17,18,19)/b13-9+,14-11+
DMIH38V CS CC(=CCC/C(=C/CC/C(=C/C(O)P(=O)(O)O)/C)/C)C
DMIH38V IK MONZTFSZTWQCKH-IJFRVEDASA-N
DMIH38V IU [(2E,6E)-1-hydroxy-3,7,11-trimethyldodeca-2,6,10-trienyl]phosphonic acid
DMIH38V CA CAS 148796-53-6
DMIH38V DE Discovery agent
DMAQBKX ID DMAQBKX
DMAQBKX DN Alpha-Hydroxy-Midazolam
DMAQBKX HS Investigative
DMAQBKX SN 1'-hydroxymidazolam; 1-Hydroxymidazolam; alpha-Hydroxymidazolam; 1-Hydroxymethylmidazolam; 59468-90-5; UNII-E5142BN92Z; ALPHA-HYDROXY-MIDAZOLAM; CHEMBL1188; QHSMEGADRFZVNE-UHFFFAOYSA-N; E5142BN92Z; C18H13ClFN3O; 1-OH-Mdz; 8-Chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepine-1-methanol; [8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methanol; 8-Chloro-6-(2-fluorophenyl)-4H-imidazo(1,5-a)(1,4)benzodiazepine-1-methanol; 1'-Hydroxy Midazolam; AC1L32ZB; SCHEMBL7310758; DTXSID50208175
DMAQBKX DT Small molecular drug
DMAQBKX PC 107917
DMAQBKX MW 341.8
DMAQBKX FM C18H13ClFN3O
DMAQBKX IC InChI=1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2
DMAQBKX CS C1C2=CN=C(N2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4F)CO
DMAQBKX IK QHSMEGADRFZVNE-UHFFFAOYSA-N
DMAQBKX IU [8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,5-a][1,4]benzodiazepin-1-yl]methanol
DMAQBKX CA CAS 59468-90-5
DMAQBKX CB CHEBI:145330
DMAQBKX DE Discovery agent
DM5LFYN ID DM5LFYN
DM5LFYN DN Alpha-ketoglutaric acid
DM5LFYN HS Investigative
DM5LFYN SN 2-ketoglutarate; 2-oxoglutarate; alpha-ketoglutarate; 2-ketoglutaric acid; oxoglutarate
DM5LFYN DT Small molecular drug
DM5LFYN PC 51
DM5LFYN MW 146.1
DM5LFYN FM C5H6O5
DM5LFYN IC InChI=1S/C5H6O5/c6-3(5(9)10)1-2-4(7)8/h1-2H2,(H,7,8)(H,9,10)
DM5LFYN CS C(CC(=O)O)C(=O)C(=O)O
DM5LFYN IK KPGXRSRHYNQIFN-UHFFFAOYSA-N
DM5LFYN IU 2-oxopentanedioic acid
DM5LFYN CA CAS 328-50-7
DM5LFYN CB CHEBI:30915
DM5LFYN DE Discovery agent
DMBZTS5 ID DMBZTS5
DMBZTS5 DN Alpha-ketoisovalerate
DMBZTS5 HS Investigative
DMBZTS5 SN 3-Methyl-2-oxobutanoic acid; 759-05-7; 3-methyl-2-oxo-butanoic acid; alpha-Ketoisovalerate; alpha-Ketoisovaleric acid; 2-Ketoisovaleric acid; alpha-ketovaline; 2-oxoisovalerate; 3-Methyl-2-oxobutyric acid; Butanoic acid, 3-methyl-2-oxo-; 2-Oxoisovaleric acid; 2-ketovaline; 3-methyl-2-oxobutanoate; 2-keto-3-methylbutyric acid; 2-oxo-3-methylbutanoate; 2-oxoisopentanoate; alpha-oxoisovalerate; Dimethylpyruvic acid; a-ketoisovaleric acid; KETOVALINE; Isopropylglyoxylic acid; alpha-keto-isovaleric acid; 2-Oxo-3-methylbutanoic acid
DMBZTS5 DT Small molecular drug
DMBZTS5 PC 49
DMBZTS5 MW 116.11
DMBZTS5 FM C5H8O3
DMBZTS5 IC InChI=1S/C5H8O3/c1-3(2)4(6)5(7)8/h3H,1-2H3,(H,7,8)
DMBZTS5 CS CC(C)C(=O)C(=O)O
DMBZTS5 IK QHKABHOOEWYVLI-UHFFFAOYSA-N
DMBZTS5 IU 3-methyl-2-oxobutanoic acid
DMBZTS5 CA CAS 759-05-7
DMBZTS5 CB CHEBI:16530
DMBZTS5 DE Discovery agent
DM2I564 ID DM2I564
DM2I564 DN Alpha-l-arabinose
DM2I564 HS Investigative
DM2I564 SN Arabinopyranose, alpha-L-; Arabinose l-form; SCHEMBL112371; SRBFZHDQGSBBOR-QMKXCQHVSA-N; UO2PIV2K4C; ZINC1532575; alpha-L-Arabinose; alpha-L-arabinopyranose; 6abp; 7296-55-1; C02604; CHEBI:46987; CHEMBL505348; CTK5D7165; UNII-UO2PIV2K4C
DM2I564 PC 439731
DM2I564 MW 150.13
DM2I564 FM C5H10O5
DM2I564 IC SRBFZHDQGSBBOR-QMKXCQHVSA-N
DM2I564 CS C1C(C(C(C(O1)O)O)O)O
DM2I564 IK 1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3-,4+,5+/m0/s1
DM2I564 IU (2R,3R,4S,5S)-oxane-2,3,4,5-tetrol
DM2I564 CA CAS 7296-55-1
DM2I564 CB CHEBI:46987
DM2I564 DE Discovery agent
DMY64HE ID DMY64HE
DMY64HE DN Alpha-linolenic acid
DMY64HE HS Investigative
DMY64HE SN Linolenic acid; linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; alpha-Linolenate; 9-cis,12-cis,15-cis-Octadecatrienoic acid; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; Linolenic acid (8CI); 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (9,12,15)-linolenic acid; alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; CCRIS 656; UNII-0RBV727H71; (9Z,12Z,15Z)-Octadecatrienoic acid; linolenate; alpha-LA; C18:3; LINOLENIC ACID
DMY64HE DT Small molecular drug
DMY64HE PC 5280934
DMY64HE MW 278.4
DMY64HE FM C18H30O2
DMY64HE IC InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-
DMY64HE CS CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O
DMY64HE IK DTOSIQBPPRVQHS-PDBXOOCHSA-N
DMY64HE IU (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid
DMY64HE CA CAS 463-40-1
DMY64HE CB CHEBI:27432
DMY64HE DE Discovery agent
DMCAYXF ID DMCAYXF
DMCAYXF DN alpha-methyl-5-HT
DMCAYXF HS Investigative
DMCAYXF SN alpha-Me-5-HT; alpha-methylserotonin
DMCAYXF DT Small molecular drug
DMCAYXF PC 2107
DMCAYXF MW 190.24
DMCAYXF FM C11H14N2O
DMCAYXF IC InChI=1S/C11H14N2O/c1-7(12)4-8-6-13-11-3-2-9(14)5-10(8)11/h2-3,5-7,13-14H,4,12H2,1H3
DMCAYXF CS CC(CC1=CNC2=C1C=C(C=C2)O)N
DMCAYXF IK LYPCGXKCQDYTFV-UHFFFAOYSA-N
DMCAYXF IU 3-(2-aminopropyl)-1H-indol-5-ol
DMCAYXF CA CAS 304-52-9
DMCAYXF CB CHEBI:48295
DMCAYXF DE Discovery agent
DM7DBTZ ID DM7DBTZ
DM7DBTZ DN Alpha-methylalanyl-L-proline butylamide
DM7DBTZ HS Investigative
DM7DBTZ SN CHEMBL388062; alpha-methylalanyl-L-proline butylamide
DM7DBTZ DT Small molecular drug
DM7DBTZ PC 11658913
DM7DBTZ MW 255.36
DM7DBTZ FM C13H25N3O2
DM7DBTZ IC InChI=1S/C13H25N3O2/c1-4-5-8-15-11(17)10-7-6-9-16(10)12(18)13(2,3)14/h10H,4-9,14H2,1-3H3,(H,15,17)/t10-/m0/s1
DM7DBTZ CS CCCCNC(=O)[C@@H]1CCCN1C(=O)C(C)(C)N
DM7DBTZ IK XPMXVLRTYROPLL-JTQLQIEISA-N
DM7DBTZ IU (2S)-1-(2-amino-2-methylpropanoyl)-N-butylpyrrolidine-2-carboxamide
DM7DBTZ DE Discovery agent
DM892JF ID DM892JF
DM892JF DN Alpha-methyl-alpha-phenylsuccinimide (MPS)
DM892JF HS Investigative
DM892JF SN 2-Methyl-2-phenylsuccinimide; 1497-17-2; 3-methyl-3-phenylpyrrolidine-2,5-dione; alpha-Methyl-alpha-phenylsuccinimide; N-Desmethylmethsuximide; Normesuximide; 2,5-Pyrrolidinedione, 3-methyl-3-phenyl-; a-methyl-a-phenylsuccinimide; N-Demethylmethsuximide; UDESUGJZUFALAM-UHFFFAOYSA-N; 3-Methyl-3-phenyl-2,5-pyrrolidinedione; .alpha.-Methyl-.alpha.-phenylsuccinimide; Normethsuximide; N-Normethsuximide; Desmethylmethsuximide; EINECS 216-091-7; Mesuximide, M(nor-); AC1Q6LV6; AC1L3NJ7; SCHEMBL1568276; UDESUGJZUFALAM-UHFFFAOYSA-
DM892JF DT Small molecular drug
DM892JF PC 92154
DM892JF MW 189.21
DM892JF FM C11H11NO2
DM892JF IC InChI=1S/C11H11NO2/c1-11(7-9(13)12-10(11)14)8-5-3-2-4-6-8/h2-6H,7H2,1H3,(H,12,13,14)
DM892JF CS CC1(CC(=O)NC1=O)C2=CC=CC=C2
DM892JF IK UDESUGJZUFALAM-UHFFFAOYSA-N
DM892JF IU 3-methyl-3-phenylpyrrolidine-2,5-dione
DM892JF CA CAS 1497-17-2
DM892JF DE Discovery agent
DM0C4GP ID DM0C4GP
DM0C4GP DN Alpha-methylcubebin
DM0C4GP HS Investigative
DM0C4GP SN alpha-methylcubebin; CHEMBL520915
DM0C4GP DT Small molecular drug
DM0C4GP PC 44575384
DM0C4GP MW 370.4
DM0C4GP FM C21H22O6
DM0C4GP IC InChI=1S/C21H22O6/c1-22-21-16(7-14-3-5-18-20(9-14)27-12-25-18)15(10-23-21)6-13-2-4-17-19(8-13)26-11-24-17/h2-5,8-9,15-16,21H,6-7,10-12H2,1H3/t15-,16+,21+/m0/s1
DM0C4GP CS CO[C@H]1[C@@H]([C@H](CO1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DM0C4GP IK UUUXPUGZNDRYSV-GCKMJXCFSA-N
DM0C4GP IU 5-[[(2R,3R,4R)-4-(1,3-benzodioxol-5-ylmethyl)-2-methoxyoxolan-3-yl]methyl]-1,3-benzodioxole
DM0C4GP DE Discovery agent
DM3YGWL ID DM3YGWL
DM3YGWL DN Alpha-Methylisocitric Acid
DM3YGWL HS Investigative
DM3YGWL SN alpha-methylisocitric acid; methylisocitrate; 71183-66-9; (2S,3R)-3-hydroxybutane-1,2,3-tricarboxylic acid; Methylisocitric acid; (2S,3R)-3-Hydroxybutane-1,2,3-tricarboxylate; AC1NUSCP; SCHEMBL1533821; CHEBI:15607; ZINC902108; LMFA01050444; AKOS030526883; DB04072; HY-16581; C04593; 3-carboxy-2,3-dideoxy-4-C-methyl-L-threo-pentaric acid; UNII-8518EC1Z2E component HHKPKXCSHMJWCF-WVBDSBKLSA-N; UNII-ZC5YS92LCE component HHKPKXCSHMJWCF-WVBDSBKLSA-N
DM3YGWL DT Small molecular drug
DM3YGWL PC 5459784
DM3YGWL MW 206.15
DM3YGWL FM C7H10O7
DM3YGWL IC InChI=1S/C7H10O7/c1-7(14,6(12)13)3(5(10)11)2-4(8)9/h3,14H,2H2,1H3,(H,8,9)(H,10,11)(H,12,13)/t3-,7-/m1/s1
DM3YGWL CS C[C@@]([C@H](CC(=O)O)C(=O)O)(C(=O)O)O
DM3YGWL IK HHKPKXCSHMJWCF-WVBDSBKLSA-N
DM3YGWL IU (2S,3R)-3-hydroxybutane-1,2,3-tricarboxylic acid
DM3YGWL CA CAS 71183-66-9
DM3YGWL CB CHEBI:15607
DM3YGWL DE Discovery agent
DMAUH96 ID DMAUH96
DMAUH96 DN alpha-methylphenylalanine
DMAUH96 HS Investigative
DMAUH96 SN alpha-Methyl-DL-phenylalanine; 1132-26-9; 2-amino-2-methyl-3-phenylpropanoic acid; 2-Amino-2-methyl-3-phenylpropionic acid; alpha-Methylphenylalanine; H--Me-DL-Phe-OH; HYOWVAAEQCNGLE-UHFFFAOYSA-N; alpha-Methyl-DL-phenylalanine, 98%; MFCD00010512; Phenylalanine, alpha-methyl-; 2-amino-2-methyl-3-phenyl-propanoic acid; 2-Methylphenylalanine #; D,L-Phe(alphaMe)-OH; a-methyl-dl-phenylalanine; alpha-me-dl-phenylalanine; Methylphenylalanine, alpha; H-DL-(ME)PHE-OH; dl-alpha-methylphenylalanine; ACMC-1AH59
DMAUH96 DT Small molecular drug
DMAUH96 PC 108055
DMAUH96 MW 179.22
DMAUH96 FM C10H13NO2
DMAUH96 IC InChI=1S/C10H13NO2/c1-10(11,9(12)13)7-8-5-3-2-4-6-8/h2-6H,7,11H2,1H3,(H,12,13)
DMAUH96 CS CC(CC1=CC=CC=C1)(C(=O)O)N
DMAUH96 IK HYOWVAAEQCNGLE-UHFFFAOYSA-N
DMAUH96 IU 2-amino-2-methyl-3-phenylpropanoic acid
DMAUH96 CA CAS 1132-26-9
DMAUH96 DE Discovery agent
DMCIH1X ID DMCIH1X
DMCIH1X DN alpha-methylserine-O-phosphate
DMCIH1X HS Investigative
DMCIH1X SN alpha-MSOP
DMCIH1X DT Small molecular drug
DMCIH1X PC 3964633
DMCIH1X MW 199.1
DMCIH1X FM C4H10NO6P
DMCIH1X IC InChI=1S/C4H10NO6P/c1-4(5,3(6)7)2-11-12(8,9)10/h2,5H2,1H3,(H,6,7)(H2,8,9,10)
DMCIH1X CS CC(COP(=O)(O)O)(C(=O)O)N
DMCIH1X IK GSFCOAGADOGIGE-UHFFFAOYSA-N
DMCIH1X IU 2-amino-2-methyl-3-phosphonooxypropanoic acid
DMCIH1X CA CAS 66515-29-5
DMCIH1X DE Discovery agent
DML7SU3 ID DML7SU3
DML7SU3 DN Alpha-monofluoromethyl-3,4-dehydroornithine
DML7SU3 HS Investigative
DML7SU3 DE Discovery agent
DMJTGZV ID DMJTGZV
DMJTGZV DN Alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester
DMJTGZV HS Investigative
DMJTGZV SN Mdl-72430; 2-(Fluoromethyl)dehydroornithine ethyl ester; AC1O5Q9S; SCHEMBL10981099; 97501-15-0; ethyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate; 3-Pentenoic acid, 2,5-diamino-2-(fluoromethyl)-, ethyl ester
DMJTGZV DT Small molecular drug
DMJTGZV PC 6438751
DMJTGZV MW 190.22
DMJTGZV FM C8H15FN2O2
DMJTGZV IC InChI=1S/C8H15FN2O2/c1-2-13-7(12)8(11,6-9)4-3-5-10/h3-4H,2,5-6,10-11H2,1H3/b4-3+
DMJTGZV CS CCOC(=O)C(CF)(/C=C/CN)N
DMJTGZV IK RQVGWIPBGFYUQU-ONEGZZNKSA-N
DMJTGZV IU ethyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate
DMJTGZV CA CAS 97501-15-0
DMJTGZV DE Discovery agent
DMGI9SM ID DMGI9SM
DMGI9SM DN Alpha-monofluoromethyl-3,4-dehydroornithine methyl ester
DMGI9SM HS Investigative
DMGI9SM SN MFMOme; Methyl, 2-fluoromethyl-2,5-diamino-3-pentenoate; Mdl-72403; methyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate; 2-(Fluoromethyl)dehydroornithine methyl ester; 107742-04-1; AC1O5Q3S; SCHEMBL6361254; 2,5-Diamino-2-(fluoromethyl)-3-pentenoic acid methyl ester; 96681-91-3; .alpha.-monofluoromethyldehydroornithine methyl ester; 3-Pentenoic acid, 2,5-diamino-2-(fluoromethyl)-, methyl ester
DMGI9SM DT Small molecular drug
DMGI9SM PC 6438668
DMGI9SM MW 176.19
DMGI9SM FM C7H13FN2O2
DMGI9SM IC InChI=1S/C7H13FN2O2/c1-12-6(11)7(10,5-8)3-2-4-9/h2-3H,4-5,9-10H2,1H3/b3-2+
DMGI9SM CS COC(=O)C(CF)(/C=C/CN)N
DMGI9SM IK KIQXCFBLXGRXPY-NSCUHMNNSA-N
DMGI9SM IU methyl (E)-2,5-diamino-2-(fluoromethyl)pent-3-enoate
DMGI9SM CA CAS 96681-91-3
DMGI9SM DE Discovery agent
DMELOIQ ID DMELOIQ
DMELOIQ DN Alpha-naphthoflavone
DMELOIQ HS Investigative
DMELOIQ SN 7,8-Benzoflavone; alpha-Naphthoflavone; 604-59-1; 2-Phenyl-4H-benzo[h]chromen-4-one; alpha-Naphthylflavone; 2-phenylbenzo[h]chromen-4-one; Benzo(h)flavone; 7,8-BF; 4H-Naphtho[1,2-b]pyran-4-one, 2-phenyl-; .alpha.-Naphthoflavone; 2-Phenyl-benzo[h]chromen-4-one; 2-Phenyl-4H-naphtho(1,2-b)pyran-4-one; CCRIS 3607; 2-Phenylbenzo(h)chromen-4-one; EINECS 210-071-1; UNII-FML65D8PY5; NSC 407011; BRN 0210862; FML65D8PY5; benzo[h]flavone; MLS003171601; CHEMBL283196; CHEBI:76995; VFMMPHCGEFXGIP-UHFFFAOYSA-N; 4H-NAPHTHO(1,2-b)PYRAN-4-ONE, 2-PH
DMELOIQ DT Small molecular drug
DMELOIQ PC 11790
DMELOIQ MW 272.3
DMELOIQ FM C19H12O2
DMELOIQ IC InChI=1S/C19H12O2/c20-17-12-18(14-7-2-1-3-8-14)21-19-15-9-5-4-6-13(15)10-11-16(17)19/h1-12H
DMELOIQ CS C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DMELOIQ IK VFMMPHCGEFXGIP-UHFFFAOYSA-N
DMELOIQ IU 2-phenylbenzo[h]chromen-4-one
DMELOIQ CA CAS 604-59-1
DMELOIQ CB CHEBI:76995
DMELOIQ DE Discovery agent
DM0KXN4 ID DM0KXN4
DM0KXN4 DN Alpha-oxoadipic acid
DM0KXN4 HS Investigative
DM0KXN4 SN alpha-ketoadipic acid; 2-ketoadipate; 2-oxoadipate
DM0KXN4 DT Small molecular drug
DM0KXN4 PC 71
DM0KXN4 MW 160.12
DM0KXN4 FM C6H8O5
DM0KXN4 IC InChI=1S/C6H8O5/c7-4(6(10)11)2-1-3-5(8)9/h1-3H2,(H,8,9)(H,10,11)
DM0KXN4 CS C(CC(=O)C(=O)O)CC(=O)O
DM0KXN4 IK FGSBNBBHOZHUBO-UHFFFAOYSA-N
DM0KXN4 IU 2-oxohexanedioic acid
DM0KXN4 CA CAS 3184-35-8
DM0KXN4 CB CHEBI:15753
DM0KXN4 DE Discovery agent
DMT6KI7 ID DMT6KI7
DMT6KI7 DN Alpha-Phosphoribosylpyrophosphoric Acid
DMT6KI7 HS Investigative
DMT6KI7 SN PRPP; PHOSPHORIBOSYL PYROPHOSPHATE; 5-Phospho-alpha-D-ribose 1-diphosphate; 5-Phosphoribosyl diphosphate; PRib-PP; 7540-64-9; phosphoribosylpyrophosphate; 5-Phosphoribosyl 1-pyrophosphate; Ribofuranose, 5-phosphate 1-pyrophosphate; PQGCEDQWHSBAJP-TXICZTDVSA-N; 5-Phosphorylribose 1-pyrophosphate; alpha-D-Ribofuranose 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate); 13270-65-0; 5-PHOSPHORYLRIBOSE-1-PYROPHOSPHATE; 5-phosphoribosyl-1-pyrophosphate
DMT6KI7 DT Small molecular drug
DMT6KI7 PC 7339
DMT6KI7 MW 390.07
DMT6KI7 FM C5H13O14P3
DMT6KI7 IC InChI=1S/C5H13O14P3/c6-3-2(1-16-20(8,9)10)17-5(4(3)7)18-22(14,15)19-21(11,12)13/h2-7H,1H2,(H,14,15)(H2,8,9,10)(H2,11,12,13)/t2-,3-,4-,5-/m1/s1
DMT6KI7 CS C([C@@H]1[C@H]([C@H]([C@H](O1)OP(=O)(O)OP(=O)(O)O)O)O)OP(=O)(O)O
DMT6KI7 IK PQGCEDQWHSBAJP-TXICZTDVSA-N
DMT6KI7 IU [(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl] phosphono hydrogen phosphate
DMT6KI7 CA CAS 7540-64-9
DMT6KI7 CB CHEBI:17111
DMT6KI7 DE Discovery agent
DMQKMX3 ID DMQKMX3
DMQKMX3 DN alpha-propyldopacetamide
DMQKMX3 HS Investigative
DMQKMX3 SN alpha-Propyldopacetamide; 2-(3,4-Dihydroxyphenyl)pentanamide; 154-62-1; a-propyldopacetamide; Dihydroxyphenylvaleramide; EINECS 205-830-9; Benzeneacetamide,3,4-dihydroxy-a-propyl-,(aR)-; Benzeneacetamide,3,4-dihydroxy-a-propyl-,(aS)-; .alpha.-Propyldopacetamide; ACMC-20mn67; ACMC-20mn66; AC1Q5IT3; AC1L2R8E; GTPL5095; CTK8G6411; GDXQWRJYXZXWMT-UHFFFAOYSA-N; MolPort-003-894-618; KUC106729N; 2-(3,4-Dihydroxyphenyl)valeramide; AKOS024285098; a-propyl-3,4-dihydroxyphenyl-acetamide; MCULE-1302132273
DMQKMX3 DT Small molecular drug
DMQKMX3 PC 101635
DMQKMX3 MW 209.24
DMQKMX3 FM C11H15NO3
DMQKMX3 IC InChI=1S/C11H15NO3/c1-2-3-8(11(12)15)7-4-5-9(13)10(14)6-7/h4-6,8,13-14H,2-3H2,1H3,(H2,12,15)
DMQKMX3 CS CCCC(C1=CC(=C(C=C1)O)O)C(=O)N
DMQKMX3 IK GDXQWRJYXZXWMT-UHFFFAOYSA-N
DMQKMX3 IU 2-(3,4-dihydroxyphenyl)pentanamide
DMQKMX3 CA CAS 154-62-1
DMQKMX3 DE Discovery agent
DMWL172 ID DMWL172
DMWL172 DN Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid
DMWL172 HS Investigative
DMWL172 SN alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid
DMWL172 DT Small molecular drug
DMWL172 PC 46855771
DMWL172 MW 273.07
DMWL172 FM C7H7Cl2O3PS
DMWL172 IC InChI=1S/C7H7Cl2O3PS/c8-4-1-2-5(6(9)3-4)7(14)13(10,11)12/h1-3,7,14H,(H2,10,11,12)
DMWL172 CS C1=CC(=C(C=C1Cl)Cl)C(P(=O)(O)O)S
DMWL172 IK WJVBVZOYOCLGPI-UHFFFAOYSA-N
DMWL172 IU [(2,4-dichlorophenyl)-sulfanylmethyl]phosphonic acid
DMWL172 DE Discovery agent
DM42M6I ID DM42M6I
DM42M6I DN Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid
DM42M6I HS Investigative
DM42M6I DT Small molecular drug
DM42M6I PC 46855772
DM42M6I MW 234.21
DM42M6I FM C8H11O4PS
DM42M6I IC InChI=1S/C8H11O4PS/c1-12-7-5-3-2-4-6(7)8(14)13(9,10)11/h2-5,8,14H,1H3,(H2,9,10,11)
DM42M6I CS COC1=CC=CC=C1C(P(=O)(O)O)S
DM42M6I IK QXHIPTMANGQMPP-UHFFFAOYSA-N
DM42M6I IU [(2-methoxyphenyl)-sulfanylmethyl]phosphonic acid
DM42M6I DE Discovery agent
DMRIWDV ID DMRIWDV
DMRIWDV DN Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid
DMRIWDV HS Investigative
DMRIWDV DT Small molecular drug
DMRIWDV PC 46855773
DMRIWDV MW 283.08
DMRIWDV FM C7H8BrO3PS
DMRIWDV IC InChI=1S/C7H8BrO3PS/c8-6-3-1-5(2-4-6)7(13)12(9,10)11/h1-4,7,13H,(H2,9,10,11)
DMRIWDV CS C1=CC(=CC=C1C(P(=O)(O)O)S)Br
DMRIWDV IK UIINFAMEMQXUIX-UHFFFAOYSA-N
DMRIWDV IU [(4-bromophenyl)-sulfanylmethyl]phosphonic acid
DMRIWDV DE Discovery agent
DMP6GXU ID DMP6GXU
DMP6GXU DN Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid
DMP6GXU HS Investigative
DMP6GXU DT Small molecular drug
DMP6GXU PC 46855774
DMP6GXU MW 238.63
DMP6GXU FM C7H8ClO3PS
DMP6GXU IC InChI=1S/C7H8ClO3PS/c8-6-3-1-5(2-4-6)7(13)12(9,10)11/h1-4,7,13H,(H2,9,10,11)
DMP6GXU CS C1=CC(=CC=C1C(P(=O)(O)O)S)Cl
DMP6GXU IK AVCBLMMQVNLVBY-UHFFFAOYSA-N
DMP6GXU IU [(4-chlorophenyl)-sulfanylmethyl]phosphonic acid
DMP6GXU DE Discovery agent
DMP9V42 ID DMP9V42
DMP9V42 DN Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid
DMP9V42 HS Investigative
DMP9V42 DT Small molecular drug
DMP9V42 PC 46855775
DMP9V42 MW 222.18
DMP9V42 FM C7H8FO3PS
DMP9V42 IC InChI=1S/C7H8FO3PS/c8-6-3-1-5(2-4-6)7(13)12(9,10)11/h1-4,7,13H,(H2,9,10,11)
DMP9V42 CS C1=CC(=CC=C1C(P(=O)(O)O)S)F
DMP9V42 IK SWPCIELITKHGKY-UHFFFAOYSA-N
DMP9V42 IU [(4-fluorophenyl)-sulfanylmethyl]phosphonic acid
DMP9V42 DE Discovery agent
DMWB07I ID DMWB07I
DMWB07I DN Alpha-Sulfanylbenzylphosphonic acid
DMWB07I HS Investigative
DMWB07I DT Small molecular drug
DMWB07I PC 46855909
DMWB07I MW 204.19
DMWB07I FM C7H9O3PS
DMWB07I IC InChI=1S/C7H9O3PS/c8-11(9,10)7(12)6-4-2-1-3-5-6/h1-5,7,12H,(H2,8,9,10)
DMWB07I CS C1=CC=C(C=C1)C(P(=O)(O)O)S
DMWB07I IK FSPBPXVXCWHRHO-UHFFFAOYSA-N
DMWB07I IU [phenyl(sulfanyl)methyl]phosphonic acid
DMWB07I DE Discovery agent
DM19NAI ID DM19NAI
DM19NAI DN Alpha-Sulfanylpropylphosphonic acid
DM19NAI HS Investigative
DM19NAI SN SCHEMBL2530501
DM19NAI DT Small molecular drug
DM19NAI PC 46855908
DM19NAI MW 156.14
DM19NAI FM C3H9O3PS
DM19NAI IC InChI=1S/C3H9O3PS/c1-2-3(8)7(4,5)6/h3,8H,2H2,1H3,(H2,4,5,6)
DM19NAI CS CCC(P(=O)(O)O)S
DM19NAI IK PMCCSSODVYHTNA-UHFFFAOYSA-N
DM19NAI IU 1-sulfanylpropylphosphonic acid
DM19NAI DE Discovery agent
DMDI2KH ID DMDI2KH
DMDI2KH DN alsterpaullone 2-cyanoethyl
DMDI2KH HS Investigative
DMDI2KH SN alsterpaullone derivative7
DMDI2KH DT Small molecular drug
DMDI2KH PC 16760286
DMDI2KH MW 346.3
DMDI2KH FM C19H14N4O3
DMDI2KH IC InChI=1S/C19H14N4O3/c20-7-1-2-11-3-5-17-15(8-11)19-14(10-18(24)21-17)13-9-12(23(25)26)4-6-16(13)22-19/h3-6,8-9,22H,1-2,10H2,(H,21,24)
DMDI2KH CS C1C2=C(C3=C(C=CC(=C3)CCC#N)NC1=O)NC4=C2C=C(C=C4)[N+](=O)[O-]
DMDI2KH IK UBLFSMURWWWWMH-UHFFFAOYSA-N
DMDI2KH IU 3-(9-nitro-6-oxo-7,12-dihydro-5H-indolo[3,2-d][1]benzazepin-2-yl)propanenitrile
DMDI2KH DE Discovery agent
DM2FLDJ ID DM2FLDJ
DM2FLDJ DN Alstiphyllanine D
DM2FLDJ HS Investigative
DM2FLDJ SN Alstiphyllanine D; CHEMBL540945
DM2FLDJ DT Small molecular drug
DM2FLDJ PC 45269680
DM2FLDJ MW 606.7
DM2FLDJ FM C33H38N2O9
DM2FLDJ IC InChI=1S/C33H38N2O9/c1-8-18-16-35-26-14-21(18)31(30(37)42-7,17-43-29(36)19-11-24(39-4)28(41-6)25(12-19)40-5)32-15-27(35)44-33(26,32)34(2)23-10-9-20(38-3)13-22(23)32/h8-13,21,26-27H,14-17H2,1-7H3/b18-8-/t21-,26-,27-,31-,32-,33-/m0/s1
DM2FLDJ CS C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(N(C6=C4C=C(C=C6)OC)C)O[C@H]2C5)(COC(=O)C7=CC(=C(C(=C7)OC)OC)OC)C(=O)OC
DM2FLDJ IK JIGZBLWURVFVNC-MPYFAWNJSA-N
DM2FLDJ IU methyl (1R,9S,11S,14E,15S,17S,19R)-14-ethylidene-6-methoxy-2-methyl-19-[(3,4,5-trimethoxybenzoyl)oxymethyl]-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3(8),4,6-triene-19-carboxylate
DM2FLDJ DE Discovery agent
DMTNQ5E ID DMTNQ5E
DMTNQ5E DN Alstiphyllanine E
DMTNQ5E HS Investigative
DMTNQ5E SN Alstiphyllanine E; CHEMBL592477
DMTNQ5E DT Small molecular drug
DMTNQ5E PC 46229071
DMTNQ5E MW 532.6
DMTNQ5E FM C30H32N2O7
DMTNQ5E IC InChI=1S/C30H32N2O7/c1-5-17-15-32-24-13-20(17)28(27(34)37-4,16-38-26(33)18-10-11-22(35-2)23(12-18)36-3)29-14-25(32)39-30(24,29)31-21-9-7-6-8-19(21)29/h5-12,20,24-25,31H,13-16H2,1-4H3/b17-5-/t20-,24-,25-,28-,29-,30-/m0/s1
DMTNQ5E CS C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(NC6=CC=CC=C64)O[C@H]2C5)(COC(=O)C7=CC(=C(C=C7)OC)OC)C(=O)OC
DMTNQ5E IK NPAPHJSGCRCHBM-UMLFCLJTSA-N
DMTNQ5E IU methyl (1R,9S,11S,14E,15S,17S,19R)-19-[(3,4-dimethoxybenzoyl)oxymethyl]-14-ethylidene-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3,5,7-triene-19-carboxylate
DMTNQ5E DE Discovery agent
DMKRAEW ID DMKRAEW
DMKRAEW DN Alstiphyllanine F
DMKRAEW HS Investigative
DMKRAEW SN Alstiphyllanine F; CHEMBL592521
DMKRAEW DT Small molecular drug
DMKRAEW PC 46229072
DMKRAEW MW 592.6
DMKRAEW FM C32H36N2O9
DMKRAEW IC InChI=1S/C32H36N2O9/c1-7-17-15-34-25-13-20(17)30(29(36)41-6,16-42-28(35)18-10-23(38-3)27(40-5)24(11-18)39-4)31-14-26(34)43-32(25,31)33-22-9-8-19(37-2)12-21(22)31/h7-12,20,25-26,33H,13-16H2,1-6H3/b17-7-/t20-,25-,26-,30-,31-,32-/m0/s1
DMKRAEW CS C/C=C\\1/CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(NC6=C4C=C(C=C6)OC)O[C@H]2C5)(COC(=O)C7=CC(=C(C(=C7)OC)OC)OC)C(=O)OC
DMKRAEW IK JIBNKPQBEIZZCU-DYWXBFQLSA-N
DMKRAEW IU methyl (1R,9S,11S,14E,15S,17S,19R)-14-ethylidene-6-methoxy-19-[(3,4,5-trimethoxybenzoyl)oxymethyl]-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3(8),4,6-triene-19-carboxylate
DMKRAEW DE Discovery agent
DMBGAWI ID DMBGAWI
DMBGAWI DN ALTANSERIN
DMBGAWI HS Investigative
DMBGAWI SN ALTANSERIN TARTRATE; UNII-9P204CHE8J; 79449-96-0; Altanserin tartrate [USAN]; 9P204CHE8J; Altanserin tartrate (USAN); 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one; EINECS 279-159-5; AC1Q59OU; AC1MHW43; SCHEMBL124036; DTXSID20229675; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2-thio-2,4(1H,3H)-quinazolinedione L-(+)-tartrate (1:1); D02836; R-53,200; 4(1H)-Quinazolinone, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-2,3-dihydro-2-thioxo-, (R-(R*,R
DMBGAWI DT Small molecular drug
DMBGAWI PC 3033677
DMBGAWI MW 411.5
DMBGAWI FM C22H22FN3O2S
DMBGAWI IC InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
DMBGAWI CS C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=S
DMBGAWI IK SMYALUSCZJXWHG-UHFFFAOYSA-N
DMBGAWI IU 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
DMBGAWI CA CAS 76330-71-7
DMBGAWI CB CHEBI:2613
DMBGAWI DE Discovery agent
DMYCS0B ID DMYCS0B
DMYCS0B DN ALTENUSIN
DMYCS0B HS Investigative
DMYCS0B SN AC1L4N6W; AC1Q68NU; SCHEMBL16971034; 4',5'-dihydroxy-5-methoxy-2'-methylbiphenyl-2-carboperoxoic acid; ACM31186126; J-018273; 2-(4,5-dihydroxy-2-methylphenyl)-4-methoxybenzenecarboperoxoic acid
DMYCS0B DT Small molecular drug
DMYCS0B PC 6918469
DMYCS0B MW 290.27
DMYCS0B FM C15H14O6
DMYCS0B IC InChI=1S/C15H14O6/c1-7-3-11(16)12(17)6-9(7)10-4-8(21-2)5-13(18)14(10)15(19)20/h3-6,16-18H,1-2H3,(H,19,20)
DMYCS0B CS CC1=CC(=C(C=C1C2=C(C(=CC(=C2)OC)O)C(=O)O)O)O
DMYCS0B IK ADPBTBPPIIKLEH-UHFFFAOYSA-N
DMYCS0B IU 2-(4,5-dihydroxy-2-methylphenyl)-6-hydroxy-4-methoxybenzoic acid
DMYCS0B CA CAS 31186-12-6
DMYCS0B CB CHEBI:141340
DMYCS0B DE Discovery agent
DMDLN9S ID DMDLN9S
DMDLN9S DN ALTU-236
DMDLN9S HS Investigative
DMDLN9S CP Altus Pharmaceuticals Inc
DMDLN9S DE Genetic disease
DMP26K9 ID DMP26K9
DMP26K9 DN Alx 1393
DMP26K9 HS Investigative
DMP26K9 SN O-[2-benzyloxyphenyl-3-flurophenyl]methyl-L-serine; ALX-1393; ALX1393
DMP26K9 DT Small molecular drug
DMP26K9 PC 16078939
DMP26K9 MW 395.4
DMP26K9 FM C23H22FNO4
DMP26K9 IC InChI=1S/C23H22FNO4/c24-18-10-6-9-17(13-18)22(29-15-20(25)23(26)27)19-11-4-5-12-21(19)28-14-16-7-2-1-3-8-16/h1-13,20,22H,14-15,25H2,(H,26,27)/t20-,22?/m0/s1
DMP26K9 CS C1=CC=C(C=C1)COC2=CC=CC=C2C(C3=CC(=CC=C3)F)OC[C@@H](C(=O)O)N
DMP26K9 IK ADUSZEGHFWRTQS-AIBWNMTMSA-N
DMP26K9 IU (2S)-2-amino-3-[(3-fluorophenyl)-(2-phenylmethoxyphenyl)methoxy]propanoic acid
DMP26K9 DE Discovery agent
DMFVGXW ID DMFVGXW
DMFVGXW DN AM-1241
DMFVGXW HS Investigative
DMFVGXW SN 444912-48-5; AM1241; AM-1241; (2-iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone; ZUHIXXCLLBMBDW-UHFFFAOYSA-N; AM 1241; GTPL3316; SCHEMBL2030690; CHEMBL408430; CTK8B9184; BDBM21283; MolPort-009-019-655; HMS3651A13; HMS3650F09; MFCD11045986; (R,S)-AM1241; (1-(Methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole); ANW-62168; s1544; AKOS016004972; SB19545; CCG-208738; NCGC00165726-04; NCGC00165726-01; HY-18640; TC-150913; LS-192021; KB-206133; AX8233934; SW219858-1; CS-0011638; ST24033932; Z-3231
DMFVGXW DT Small molecular drug
DMFVGXW PC 10141893
DMFVGXW MW 503.3
DMFVGXW FM C22H22IN3O3
DMFVGXW IC InChI=1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3
DMFVGXW CS CN1CCCCC1CN2C=C(C3=CC=CC=C32)C(=O)C4=C(C=CC(=C4)[N+](=O)[O-])I
DMFVGXW IK ZUHIXXCLLBMBDW-UHFFFAOYSA-N
DMFVGXW IU (2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone
DMFVGXW CA CAS 444912-48-5
DMFVGXW DE Discovery agent
DMGCOQF ID DMGCOQF
DMGCOQF DN AM-156
DMGCOQF HS Investigative
DMGCOQF SN AM-206; AM-432; CRTH2 receptor antagonists (oral, allergic rhinitis); CRTH2 receptor antagonists (oral, allergic rhinitis), Amira Pharmaceuticals; CRTH2 antagonists (COPD/asthma/allergic rhinitis), Amira; DP2 antagonists (COPD/asthma/allergic rhinitis), Amira; Prostaglandin D2 (PGD2) antagonists (COPD/asthma/allergic rhinitis), Amira
DMGCOQF CP Amira Pharmaceuticals Inc
DMGCOQF DT Small molecular drug
DMGCOQF PC 46702966
DMGCOQF MW 457.4
DMGCOQF FM C23H23F3NNaO4
DMGCOQF IC InChI=1S/C23H24F3NO4.Na/c1-3-27(22(30)15-5-6-15)13-16-12-17(23(24,25)26)7-8-18(16)19-10-14(11-21(28)29)4-9-20(19)31-2;/h4,7-10,12,15H,3,5-6,11,13H2,1-2H3,(H,28,29);/q;+1/p-1
DMGCOQF CS CCN(CC1=C(C=CC(=C1)C(F)(F)F)C2=C(C=CC(=C2)CC(=O)[O-])OC)C(=O)C3CC3.[Na+]
DMGCOQF IK WFUYBZRTYBYLFG-UHFFFAOYSA-M
DMGCOQF IU sodium;2-[3-[2-[[cyclopropanecarbonyl(ethyl)amino]methyl]-4-(trifluoromethyl)phenyl]-4-methoxyphenyl]acetate
DMGCOQF CA CAS 1224977-85-8
DMGCOQF DE Allergic rhinitis
DMO7QUP ID DMO7QUP
DMO7QUP DN AM-1710
DMO7QUP HS Investigative
DMO7QUP SN AM-1710; UNII-R0GPP0WDF9; R0GPP0WDF9; CHEMBL266712; 3-(1,1-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo(b,d)pyran-6-one; 3-(1,1-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-dibenzo[b,d]pyran-6-one; SCHEMBL3297145; GTPL10202; ZAIKPEWFCSQNQB-UHFFFAOYSA-N; BDBM50228073; AM1710; analog 4b [PMID: 18038967]; 1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one; 3-(1',1'-dimethylheptyl)-1-hydroxy-9-methoxy-6h-benzo[c]chromene-6-one; 6H-Dibenzo(b,d)pyran-6-one, 3-(1,1-dimethylheptyl)-1-hydroxy-9-methoxy-
DMO7QUP DT Small molecular drug
DMO7QUP PC 11268660
DMO7QUP MW 368.5
DMO7QUP FM C23H28O4
DMO7QUP IC InChI=1S/C23H28O4/c1-5-6-7-8-11-23(2,3)15-12-19(24)21-18-14-16(26-4)9-10-17(18)22(25)27-20(21)13-15/h9-10,12-14,24H,5-8,11H2,1-4H3
DMO7QUP CS CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(=O)C3=C2C=C(C=C3)OC)O
DMO7QUP IK ZAIKPEWFCSQNQB-UHFFFAOYSA-N
DMO7QUP IU 1-hydroxy-9-methoxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one
DMO7QUP CA CAS 335371-36-3
DMO7QUP DE Discovery agent
DMW9ERM ID DMW9ERM
DMW9ERM DN AM-1714
DMW9ERM HS Investigative
DMW9ERM SN AM-1714; UNII-E3OY6PCU04; E3OY6PCU04; CHEMBL429797; BWKBVEVEQOCSCF-UHFFFAOYSA-N; 335371-37-4; SCHEMBL3298491; BDBM50228072; 6H-Dibenzo(b,d)pyran-6-one, 3-(1,1-dimethylheptyl)-1,9-dihydroxy-; 3-(1,1-Dimethylheptyl)-1,9-dihydroxy-6H-dibenzo[b,d]pyran-6-one; 1,9-dihydroxy-3-(2-methyloctan-2-yl)-6H-benzo[c]chromen-6-one
DMW9ERM DT Small molecular drug
DMW9ERM PC 9950486
DMW9ERM MW 354.4
DMW9ERM FM C22H26O4
DMW9ERM IC InChI=1S/C22H26O4/c1-4-5-6-7-10-22(2,3)14-11-18(24)20-17-13-15(23)8-9-16(17)21(25)26-19(20)12-14/h8-9,11-13,23-24H,4-7,10H2,1-3H3
DMW9ERM CS CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(=O)C3=C2C=C(C=C3)O)O
DMW9ERM IK BWKBVEVEQOCSCF-UHFFFAOYSA-N
DMW9ERM IU 1,9-dihydroxy-3-(2-methyloctan-2-yl)benzo[c]chromen-6-one
DMW9ERM CA CAS 335371-37-4
DMW9ERM DE Discovery agent
DMKJQZ4 ID DMKJQZ4
DMKJQZ4 DN AM-1715
DMKJQZ4 HS Investigative
DMKJQZ4 SN AM-1715; CHEMBL235585; BDBM50228074
DMKJQZ4 DT Small molecular drug
DMKJQZ4 PC 24748863
DMKJQZ4 MW 382.5
DMKJQZ4 FM C25H34O3
DMKJQZ4 IC InChI=1S/C25H34O3/c1-7-8-9-10-13-24(2,3)17-14-21(26)23-19-16-18(27-6)11-12-20(19)25(4,5)28-22(23)15-17/h11-12,14-16,26H,7-10,13H2,1-6H3
DMKJQZ4 CS CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)OC)(C)C)O
DMKJQZ4 IK ZNHVPFVYQXICIO-UHFFFAOYSA-N
DMKJQZ4 IU 9-methoxy-6,6-dimethyl-3-(2-methyloctan-2-yl)benzo[c]chromen-1-ol
DMKJQZ4 DE Discovery agent
DMTAWHL ID DMTAWHL
DMTAWHL DN AM251
DMTAWHL HS Investigative
DMTAWHL SN AM251; 183232-66-8; AM-251; AM 251; UNII-3I4FA44MAI; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 3I4FA44MAI; CHEMBL285932; CHEBI:90724; MFCD01861181; CPD000466284; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
DMTAWHL DT Small molecular drug
DMTAWHL PC 2125
DMTAWHL MW 555.2
DMTAWHL FM C22H21Cl2IN4O
DMTAWHL IC InChI=1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
DMTAWHL CS CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
DMTAWHL IK BUZAJRPLUGXRAB-UHFFFAOYSA-N
DMTAWHL IU 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
DMTAWHL CA CAS 183232-66-8
DMTAWHL CB CHEBI:90724
DMTAWHL DE Discovery agent
DMOKN27 ID DMOKN27
DMOKN27 DN AM-281
DMOKN27 HS Investigative
DMOKN27 SN AM 281; 202463-68-1; AM281; AM-281; UNII-SBP4A4DYH2; SBP4A4DYH2; 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide; CHEMBL476833; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholino-1H-pyrazole-3-carboxamide; Tocris-1115; AC1N7ICF; GTPL741; SCHEMBL1517458; CTK8E9266; CHEBI:93039; AJFFBPZYXRNAIC-UHFFFAOYSA-N; MolPort-003-940-033; HMS3267K18; EX-A1546; ZINC2575699; BCP07951; BN0064
DMOKN27 DT Small molecular drug
DMOKN27 PC 4302962
DMOKN27 MW 557.2
DMOKN27 FM C21H19Cl2IN4O2
DMOKN27 IC InChI=1S/C21H19Cl2IN4O2/c1-13-19(21(29)26-27-8-10-30-11-9-27)25-28(18-7-4-15(22)12-17(18)23)20(13)14-2-5-16(24)6-3-14/h2-7,12H,8-11H2,1H3,(H,26,29)
DMOKN27 CS CC1=C(N(N=C1C(=O)NN2CCOCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)I
DMOKN27 IK AJFFBPZYXRNAIC-UHFFFAOYSA-N
DMOKN27 IU 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholin-4-ylpyrazole-3-carboxamide
DMOKN27 CA CAS 202463-68-1
DMOKN27 CB CHEBI:93039
DMOKN27 DE Discovery agent
DMZ46GI ID DMZ46GI
DMZ46GI DN AM-2S
DMZ46GI HS Investigative
DMZ46GI SN AM-2S; CHEMBL470194; SCHEMBL13208678; BDBM50278743
DMZ46GI DT Small molecular drug
DMZ46GI PC 54726664
DMZ46GI MW 351.4
DMZ46GI FM C20H17NO3S
DMZ46GI IC InChI=1S/C20H17NO3S/c1-13-11-17(25)18(22)19(24-13)20(23)21-12-14-7-9-16(10-8-14)15-5-3-2-4-6-15/h2-11,22H,12H2,1H3,(H,21,23)
DMZ46GI CS CC1=CC(=S)C(=C(O1)C(=O)NCC2=CC=C(C=C2)C3=CC=CC=C3)O
DMZ46GI IK ZOMMNLRHGAAUNM-UHFFFAOYSA-N
DMZ46GI IU 3-hydroxy-6-methyl-N-[(4-phenylphenyl)methyl]-4-sulfanylidenepyran-2-carboxamide
DMZ46GI DE Discovery agent
DMZVLJH ID DMZVLJH
DMZVLJH DN AM-3701
DMZVLJH HS Investigative
DMZVLJH SN Cathepsin K inhibitors (oral, osteoporosis/bone metastasis), Amura
DMZVLJH CP Amura Therapeutics Ltd
DMZVLJH DE Bone metastases
DM2AOF8 ID DM2AOF8
DM2AOF8 DN AM-3840
DM2AOF8 HS Investigative
DM2AOF8 SN Cathepsin S inihibitors (oral, autoimmune disease/pain), Amura
DM2AOF8 CP Amura Therapeutics Ltd
DM2AOF8 DE Autoimmune diabetes
DMBK9PS ID DMBK9PS
DMBK9PS DN AM-404
DMBK9PS HS Investigative
DMBK9PS SN AM 404; AM-404; 183718-77-6; am404; UNII-XVJ94H0U21; 198022-70-7; CHEMBL39878; XVJ94H0U21; CPD000449274; (5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide; N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide; SMR000449274; SR-01000597390; N-(4-Hydroxyphenyl)-arachidonylamide; N-(4-Hydroxyphenyl)arachidonylamide; N-(4-Hydroxyphenyl)arachidonoyl amide; NCGC00025010-01; Tocris-1116; AC1O7GXA; 5,8,11,14-Eicosatetraenamide, N-(4-hydroxyphenyl)-, (all-Z)-; N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide
DMBK9PS DT Small molecular drug
DMBK9PS PC 6604822
DMBK9PS MW 395.6
DMBK9PS FM C26H37NO2
DMBK9PS IC InChI=1S/C26H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-26(29)27-24-20-22-25(28)23-21-24/h6-7,9-10,12-13,15-16,20-23,28H,2-5,8,11,14,17-19H2,1H3,(H,27,29)/b7-6-,10-9-,13-12-,16-15-
DMBK9PS CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NC1=CC=C(C=C1)O
DMBK9PS IK IJBZOOZRAXHERC-DOFZRALJSA-N
DMBK9PS IU (5Z,8Z,11Z,14Z)-N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide
DMBK9PS CA CAS 183718-77-6
DMBK9PS DE Discovery agent
DMU3Y4J ID DMU3Y4J
DMU3Y4J DN AM-411
DMU3Y4J HS Investigative
DMU3Y4J SN AM-411; CHEMBL434351; BDBM50169951; (6aR,10aR)-3-Adamantan-1-yl-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol
DMU3Y4J DT Small molecular drug
DMU3Y4J PC 9799945
DMU3Y4J MW 378.5
DMU3Y4J FM C26H34O2
DMU3Y4J IC InChI=1S/C26H34O2/c1-15-4-5-21-20(6-15)24-22(27)10-19(11-23(24)28-25(21,2)3)26-12-16-7-17(13-26)9-18(8-16)14-26/h4,10-11,16-18,20-21,27H,5-9,12-14H2,1-3H3/t16?,17?,18?,20-,21-,26?/m1/s1
DMU3Y4J CS CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)C45CC6CC(C4)CC(C6)C5)O
DMU3Y4J IK RPBMPWGKZFLMFN-OKFSJJLXSA-N
DMU3Y4J IU (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMU3Y4J CA CAS 212835-02-4
DMU3Y4J DE Discovery agent
DMETXA8 ID DMETXA8
DMETXA8 DN AM-4768
DMETXA8 HS Investigative
DMETXA8 SN AM-4768; CHEMBL238359; BDBM50228075
DMETXA8 DT Small molecular drug
DMETXA8 PC 24748864
DMETXA8 MW 368.5
DMETXA8 FM C24H32O3
DMETXA8 IC InChI=1S/C24H32O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h10-11,13-15,25-26H,6-9,12H2,1-5H3
DMETXA8 CS CCCCCCC(C)(C)C1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)O)(C)C)O
DMETXA8 IK UNSSGNVPLKLAPB-UHFFFAOYSA-N
DMETXA8 IU 6,6-dimethyl-3-(2-methyloctan-2-yl)benzo[c]chromene-1,9-diol
DMETXA8 DE Discovery agent
DM7R605 ID DM7R605
DM7R605 DN AM-630
DM7R605 HS Investigative
DM7R605 SN 164178-33-0; AM630; AM-630; iodopravadoline; (6-iodo-2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)(4-methoxyphenyl)methanone; AM 630; UNII-U1LNJ6NBKA; U1LNJ6NBKA; CHEMBL181633; [6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone; 6-iodopravadoline; 1-(2-(Morpholin-4-yl)ethyl)-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole; 1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole; Tocris-1120; AC1N7ICI; Iodopravadoline(AM-630); Iodopravadoline (AM630); GTPL750; MLS006010265
DM7R605 DT Small molecular drug
DM7R605 PC 4302963
DM7R605 MW 504.4
DM7R605 FM C23H25IN2O3
DM7R605 IC InChI=1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3
DM7R605 CS CC1=C(C2=C(N1CCN3CCOCC3)C=C(C=C2)I)C(=O)C4=CC=C(C=C4)OC
DM7R605 IK JHOTYHDSLIUKCJ-UHFFFAOYSA-N
DM7R605 IU [6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone
DM7R605 CA CAS 164178-33-0
DM7R605 CB CHEBI:93112
DM7R605 DE Discovery agent
DMYVQFN ID DMYVQFN
DMYVQFN DN AM7
DMYVQFN HS Investigative
DMYVQFN SN pyrimidone, 22; AM 7; AM-7
DMYVQFN DT Small molecular drug
DMYVQFN PC 11650194
DMYVQFN MW 610.7
DMYVQFN FM C35H35FN4O5
DMYVQFN IC InChI=1S/C35H35FN4O5/c1-39-34(19-24-7-4-3-5-8-24)38-23-27(35(39)41)25-9-10-31(28(36)20-25)45-30-11-12-37-29-22-33(32(42-2)21-26(29)30)44-16-6-13-40-14-17-43-18-15-40/h3-5,7-12,20-23H,6,13-19H2,1-2H3
DMYVQFN CS CN1C(=NC=C(C1=O)C2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OCCCN5CCOCC5)OC)F)CC6=CC=CC=C6
DMYVQFN IK PEGWVOKOYYAQEV-UHFFFAOYSA-N
DMYVQFN IU 2-benzyl-5-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-3-methylpyrimidin-4-one
DMYVQFN DE Discovery agent
DM5JZUB ID DM5JZUB
DM5JZUB DN AMA
DM5JZUB HS Investigative
DM5JZUB SN S-(5'-deoxy-5'-adenosyl)-methylthioethyl-hydroxylamine
DM5JZUB DT Small molecular drug
DM5JZUB PC 10428412
DM5JZUB MW 357.41
DM5JZUB FM C13H21N6O4S+
DM5JZUB IC InChI=1S/C13H21N6O4S/c1-24(3-2-18-22)4-7-9(20)10(21)13(23-7)19-6-17-8-11(14)15-5-16-12(8)19/h5-7,9-10,13,18,20-22H,2-4H2,1H3,(H2,14,15,16)/q+1/t7-,9-,10-,13-,24?/m1/s1
DM5JZUB CS C[S+](CCNO)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O
DM5JZUB IK VJHFTTWXKUEKQP-VCZNENMGSA-N
DM5JZUB IU [(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-[2-(hydroxyamino)ethyl]-methylsulfanium
DM5JZUB DE Discovery agent
DMW9TRD ID DMW9TRD
DMW9TRD DN AMA-237
DMW9TRD HS Investigative
DMW9TRD SN AMA-63; ROCK inhibitors (COPD); ROCK inhibitors (COPD), Amakem
DMW9TRD CP Amakem NV
DMW9TRD DE Chronic obstructive pulmonary disease
DMIZQOG ID DMIZQOG
DMIZQOG DN AMA37
DMIZQOG HS Investigative
DMIZQOG SN arylmorpholine analog 37
DMIZQOG DT Small molecular drug
DMIZQOG PC 16760391
DMIZQOG MW 283.32
DMIZQOG FM C17H17NO3
DMIZQOG IC InChI=1S/C17H17NO3/c19-16-12-14(18-8-10-21-11-9-18)6-7-15(16)17(20)13-4-2-1-3-5-13/h1-7,12,19H,8-11H2
DMIZQOG CS C1COCCN1C2=CC(=C(C=C2)C(=O)C3=CC=CC=C3)O
DMIZQOG IK FALILNHGILFDLC-UHFFFAOYSA-N
DMIZQOG IU (2-hydroxy-4-morpholin-4-ylphenyl)-phenylmethanone
DMIZQOG CA CAS 404009-46-7
DMIZQOG CB CHEBI:92885
DMIZQOG DE Discovery agent
DM59IT4 ID DM59IT4
DM59IT4 DN Amanitin
DM59IT4 HS Investigative
DM59IT4 SN alpha-amanitin
DM59IT4 DT Small molecular drug
DM59IT4 PC 2100
DM59IT4 MW 919
DM59IT4 FM C39H54N10O14S
DM59IT4 IC InChI=1S/C39H54N10O14S/c1-4-16(2)31-36(60)42-11-29(55)43-25-15-64(63)38-21(20-6-5-18(51)7-22(20)46-38)9-23(33(57)41-12-30(56)47-31)44-37(61)32(17(3)27(53)14-50)48-35(59)26-8-19(52)13-49(26)39(62)24(10-28(40)54)45-34(25)58/h5-7,16-17,19,23-27,31-32,46,50-53H,4,8-15H2,1-3H3,(H2,40,54)(H,41,57)(H,42,60)(H,43,55)(H,44,61)(H,45,58)(H,47,56)(H,48,59)
DM59IT4 CS CCC(C)C1C(=O)NCC(=O)NC2CS(=O)C3=C(CC(C(=O)NCC(=O)N1)NC(=O)C(NC(=O)C4CC(CN4C(=O)C(NC2=O)CC(=O)N)O)C(C)C(CO)O)C5=C(N3)C=C(C=C5)O
DM59IT4 IK CIORWBWIBBPXCG-UHFFFAOYSA-N
DM59IT4 IU 2-[34-butan-2-yl-13-(3,4-dihydroxybutan-2-yl)-8,22-dihydroxy-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide
DM59IT4 CA CAS 23109-05-9
DM59IT4 DE Discovery agent
DML9W2V ID DML9W2V
DML9W2V DN Amarylline
DML9W2V HS Investigative
DML9W2V SN Lycorine; BSPBio_0; CHEBI:6601; CHEMBL400092; EINECS 207-503-6; GNF-PF-4974; Galanthidine; (-)-Lycorine; 2188-68-3; 3,2.beta.-diol; I9Q105R5BU; KBioGR_000022; KBioSS_000022; Licorine; Likorin; Lycorine hydrochloride; NSC 401360; NSC401360; NSC683873; Narcissine; UNII-I9Q105R5BU
DML9W2V TC Antiviral Agents
DML9W2V DT Small molecular drug
DML9W2V PC 72378
DML9W2V MW 287.31
DML9W2V FM C16H17NO4
DML9W2V IC InChI=1S/C16H17NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h3-5,11,14-16,18-19H,1-2,6-7H2/t11-,14-,15+,16+/m0/s1
DML9W2V CS C1CN2CC3=CC4=C(C=C3[C@H]5[C@H]2C1=C[C@@H]([C@H]5O)O)OCO4
DML9W2V IK XGVJWXAYKUHDOO-DANNLKNASA-N
DML9W2V IU (1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol
DML9W2V CA CAS 476-28-8
DML9W2V CB CHEBI:6601
DML9W2V DE Middle East Respiratory Syndrome (MERS)
DMAVC9T ID DMAVC9T
DMAVC9T DN AMBAZONE
DMAVC9T HS Investigative
DMAVC9T SN Ambazone < Rec INNM; P-Benzoquinone amidinohydrazone thiosemicarbazone monohydrate; 1,4-Benzoquinoneguanylhydrazone thiosemicarbazone monohydrate
DMAVC9T DT Small molecular drug
DMAVC9T PC 1549158
DMAVC9T MW 237.29
DMAVC9T FM C8H11N7S
DMAVC9T IC InChI=1S/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4,12H,(H2,11,16)(H4,9,10,14)
DMAVC9T CS C1=CC(=CC=C1NN=C(N)N)N=NC(=S)N
DMAVC9T IK ANZIOUQAFBXNHU-UHFFFAOYSA-N
DMAVC9T IU [4-[2-(diaminomethylidene)hydrazinyl]phenyl]iminothiourea
DMAVC9T CA CAS 539-21-9
DMAVC9T CB CHEBI:134962
DMAVC9T DE Solid tumour/cancer
DM75UK8 ID DM75UK8
DM75UK8 DN AMD3101
DM75UK8 HS Investigative
DM75UK8 DT Small molecular drug
DM75UK8 PC 23644377
DM75UK8 DE Discovery agent
DMLRNV2 ID DMLRNV2
DMLRNV2 DN AMENTOFLAVONE
DMLRNV2 HS Investigative
DMLRNV2 SN Amentoflavone; 1617-53-4; 3',8''-Biapigenin; Didemethyl-ginkgetin; Amenthoflavone; UNII-9I1VC79L77; MLS000574827; CHEBI:2631; 9I1VC79L77; SMR000156235; Q-100192; 8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
DMLRNV2 DT Small molecular drug
DMLRNV2 PC 5281600
DMLRNV2 MW 538.5
DMLRNV2 FM C30H18O10
DMLRNV2 IC InChI=1S/C30H18O10/c31-15-4-1-13(2-5-15)24-12-23(38)29-21(36)10-20(35)27(30(29)40-24)17-7-14(3-6-18(17)33)25-11-22(37)28-19(34)8-16(32)9-26(28)39-25/h1-12,31-36H
DMLRNV2 CS C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O
DMLRNV2 IK YUSWMAULDXZHPY-UHFFFAOYSA-N
DMLRNV2 IU 8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMLRNV2 CA CAS 1617-53-4
DMLRNV2 CB CHEBI:2631
DMLRNV2 DE Discovery agent
DMDRSFE ID DMDRSFE
DMDRSFE DN Ametantrone
DMDRSFE HS Investigative
DMDRSFE SN Ametantrone; 64862-96-0; Ametantrone [INN]; NSC-196473; NSC 196473; Ametantronum [INN-Latin]; Ametantrona [INN-Spanish]; UNII-PNT6041ST1; BRN 2791800; PNT6041ST1; C22H28N4O4; 1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone; 1,4-Bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 9,10-Anthracenedione,1,4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-; 1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione; 1,4-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione; Ametantronum
DMDRSFE DT Small molecular drug
DMDRSFE PC 2134
DMDRSFE MW 412.5
DMDRSFE FM C22H28N4O4
DMDRSFE IC InChI=1S/C22H28N4O4/c27-13-11-23-7-9-25-17-5-6-18(26-10-8-24-12-14-28)20-19(17)21(29)15-3-1-2-4-16(15)22(20)30/h1-6,23-28H,7-14H2
DMDRSFE CS C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCCNCCO)NCCNCCO
DMDRSFE IK FFGSXKJJVBXWCY-UHFFFAOYSA-N
DMDRSFE IU 1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
DMDRSFE CA CAS 64862-96-0
DMDRSFE DE Discovery agent
DM589XV ID DM589XV
DM589XV DN AMG 9810
DM589XV HS Investigative
DM589XV SN AMG-9810; AMG9810
DM589XV DT Small molecular drug
DM589XV PC 680502
DM589XV MW 337.4
DM589XV FM C21H23NO3
DM589XV IC InChI=1S/C21H23NO3/c1-21(2,3)16-7-4-15(5-8-16)6-11-20(23)22-17-9-10-18-19(14-17)25-13-12-24-18/h4-11,14H,12-13H2,1-3H3,(H,22,23)/b11-6+
DM589XV CS CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC3=C(C=C2)OCCO3
DM589XV IK GZTFUVZVLYUPRG-IZZDOVSWSA-N
DM589XV IU (E)-3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)prop-2-enamide
DM589XV CA CAS 545395-94-6
DM589XV CB CHEBI:92757
DM589XV DE Discovery agent
DMUONK5 ID DMUONK5
DMUONK5 DN amg-1
DMUONK5 HS Investigative
DMUONK5 SN CHEMBL3342402; N-(1,3-benzodioxol-5-yl)-2-{[5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl}acetamide; BAS 06591295; AC1LLIU7; GTPL8227; SCHEMBL20313457; MolPort-000-220-791; ZINC801901; STL305655; BDBM50030791; AKOS000657540; MCULE-5294683561; ST50049773; Z56882059; N-(2H-1,3-benzodioxol-5-yl)-2-{[5-(4-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3]thiazol-3-yl]sulfanyl}acetamide; 496023-55-3; N-(2H-benzo[3,4-d]1,3-dioxolen-5-yl)-2-[5-(4-methylphenyl)(1,3-thiazolino[3,2- d]1,2,4-triazol-3-ylthio)]acetamide
DMUONK5 DT Small molecular drug
DMUONK5 PC 1085108
DMUONK5 MW 424.5
DMUONK5 FM C20H16N4O3S2
DMUONK5 IC InChI=1S/C20H16N4O3S2/c1-12-2-4-13(5-3-12)15-9-28-19-22-23-20(24(15)19)29-10-18(25)21-14-6-7-16-17(8-14)27-11-26-16/h2-9H,10-11H2,1H3,(H,21,25)
DMUONK5 CS CC1=CC=C(C=C1)C2=CSC3=NN=C(N23)SCC(=O)NC4=CC5=C(C=C4)OCO5
DMUONK5 IK XYXNYQAJSYUYNZ-UHFFFAOYSA-N
DMUONK5 IU N-(1,3-benzodioxol-5-yl)-2-[[5-(4-methylphenyl)-[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl]acetamide
DMUONK5 DE Discovery agent
DM9H7AZ ID DM9H7AZ
DM9H7AZ DN AMG-126737
DM9H7AZ HS Investigative
DM9H7AZ DT Small molecular drug
DM9H7AZ PC 10462207
DM9H7AZ MW 678.8
DM9H7AZ FM C33H38N6O6S2
DM9H7AZ IC InChI=1S/C33H38N6O6S2/c34-32(35)26-6-4-8-30(20-26)46(40,41)38-22-24-10-14-28(15-11-24)44-18-2-1-3-19-45-29-16-12-25(13-17-29)23-39-47(42,43)31-9-5-7-27(21-31)33(36)37/h4-17,20-21,38-39H,1-3,18-19,22-23H2,(H3,34,35)(H3,36,37)
DM9H7AZ CS C1=CC(=CC(=C1)S(=O)(=O)NCC2=CC=C(C=C2)OCCCCCOC3=CC=C(C=C3)CNS(=O)(=O)C4=CC=CC(=C4)C(=N)N)C(=N)N
DM9H7AZ IK CTLMBCYIAXNYOG-UHFFFAOYSA-N
DM9H7AZ IU 3-[[4-[5-[4-[[(3-carbamimidoylphenyl)sulfonylamino]methyl]phenoxy]pentoxy]phenyl]methylsulfamoyl]benzenecarboximidamide
DM9H7AZ CA CAS 224054-76-6
DM9H7AZ DE Discovery agent
DMU6WR9 ID DMU6WR9
DMU6WR9 DN AMG-247
DMU6WR9 HS Investigative
DMU6WR9 SN AMG-369; Multiple sclerosis therapeutics, Amgen; S1P1 receptor antagonists (multiple sclerosis/inflammation); S1P1 receptor antagonists (multiple sclerosis/inflammation), Amgen
DMU6WR9 CP Amgen Inc
DMU6WR9 DE Inflammation
DMRD83Q ID DMRD83Q
DMRD83Q DN AMG-2504
DMRD83Q HS Investigative
DMRD83Q SN AMG-2504; CHEMBL1086587; 4-nitro-N-{2,2,2-trichloro-1-[(4-chlorophenyl)sulfanyl]ethyl}benzamide; 4-nitro-n-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide; AC1MD3F6; SCHEMBL19743227; MolPort-002-133-093; STK822395; BDBM50318457; AKOS016332516; AKOS003622338; MCULE-9954660789; AE-848/32004034; 4-nitro-N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide
DMRD83Q DT Small molecular drug
DMRD83Q PC 2830271
DMRD83Q MW 440.1
DMRD83Q FM C15H10Cl4N2O3S
DMRD83Q IC InChI=1S/C15H10Cl4N2O3S/c16-10-3-7-12(8-4-10)25-14(15(17,18)19)20-13(22)9-1-5-11(6-2-9)21(23)24/h1-8,14H,(H,20,22)
DMRD83Q CS C1=CC(=CC=C1C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl)[N+](=O)[O-]
DMRD83Q IK DNTIPHKVCXUYRM-UHFFFAOYSA-N
DMRD83Q IU 4-nitro-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMRD83Q DE Discovery agent
DME04BH ID DME04BH
DME04BH DN AMG-429
DME04BH HS Investigative
DME04BH SN KDR inhibitors (anticancer), Amgen; VEGFR-2 inhibitors (anticancer); VEGFR-2 inhibitors (anticancer), Amgen
DME04BH CP Amgen Inc
DME04BH DE Solid tumour/cancer
DMNEVXT ID DMNEVXT
DMNEVXT DN AMG-5445
DMNEVXT HS Investigative
DMNEVXT SN AMG-5445; CHEMBL1086586; 4-Methoxy-N-[2,2,2-trichloro-1-(4-chloro-phenylsulfanyl)-ethyl]-benzamide; BAS 00092441; AC1MD3F3; CBDivE_009656; SCHEMBL15159500; MolPort-001-914-251; BDBM50318456; AKOS016361849; AKOS000521797; MCULE-5981280288; ST50216415; 4-methoxy-N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide; 4-methoxy-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide; 4-methoxy-n-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide
DMNEVXT DT Small molecular drug
DMNEVXT PC 2830270
DMNEVXT MW 425.2
DMNEVXT FM C16H13Cl4NO2S
DMNEVXT IC InChI=1S/C16H13Cl4NO2S/c1-23-12-6-2-10(3-7-12)14(22)21-15(16(18,19)20)24-13-8-4-11(17)5-9-13/h2-9,15H,1H3,(H,21,22)
DMNEVXT CS COC1=CC=C(C=C1)C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl
DMNEVXT IK MRIRDTYIRGDISF-UHFFFAOYSA-N
DMNEVXT IU 4-methoxy-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMNEVXT DE Discovery agent
DMI39YX ID DMI39YX
DMI39YX DN AMG-628
DMI39YX HS Investigative
DMI39YX SN AMG-628; UNII-G8JW58493W; G8JW58493W; N-{4-[(6-{4-[(1R)-1-(4-fluorophenyl)ethyl]piperazin-1-yl}pyrimidin-4-yl)oxy]-1,3-benzothiazol-2-yl}acetamide; 862269-93-0; AMG 628; AMG628; AMG-628, (R)-; SCHEMBL3841997; GTPL4130; CHEMBL226574; BDBM20581; QUHZTEMPQQZPNB-MRXNPFEDSA-N; MolPort-029-996-161; KS-00003MQ7; Piperazinylpyrimidine analogue, 16p; ZINC14974185; AKOS022193590; MB-0047; Acetamide, N-(4-((6-(4-((1R)-1-(4-fluorophenyl)ethyl)-1-piperazinyl)-4-pyrimidinyl)oxy)-2-benzothiazolyl)-; UNII-28J966TN3X component QUHZTEMPQQZPNB-M
DMI39YX DT Small molecular drug
DMI39YX PC 11352366
DMI39YX MW 492.6
DMI39YX FM C25H25FN6O2S
DMI39YX IC InChI=1S/C25H25FN6O2S/c1-16(18-6-8-19(26)9-7-18)31-10-12-32(13-11-31)22-14-23(28-15-27-22)34-20-4-3-5-21-24(20)30-25(35-21)29-17(2)33/h3-9,14-16H,10-13H2,1-2H3,(H,29,30,33)/t16-/m1/s1
DMI39YX CS C[C@H](C1=CC=C(C=C1)F)N2CCN(CC2)C3=CC(=NC=N3)OC4=C5C(=CC=C4)SC(=N5)NC(=O)C
DMI39YX IK QUHZTEMPQQZPNB-MRXNPFEDSA-N
DMI39YX IU N-[4-[6-[4-[(1R)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide
DMI39YX CA CAS 862269-93-0
DMI39YX DE Pain
DMEVNZI ID DMEVNZI
DMEVNZI DN AMG-7160
DMEVNZI HS Investigative
DMEVNZI SN AMG-7160; CHEMBL1086588; 4-Bromo-N-[2,2,2-trichloro-1-(4-chloro-phenylsulfanyl)-ethyl]-benzamide; 4-bromo-N-{2,2,2-trichloro-1-[(4-chlorophenyl)sulfanyl]ethyl}benzamide; 4-bromo-n-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide; BAS 00084574; AC1MJD0X; SCHEMBL19743234; MolPort-001-818-003; BDBM50318458; AKOS016369423; AKOS000619708; MCULE-2387805859; ST082345; AG-690/32533021; 4-bromo-N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide; 4-bromo-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMEVNZI DT Small molecular drug
DMEVNZI PC 3089985
DMEVNZI MW 474
DMEVNZI FM C15H10BrCl4NOS
DMEVNZI IC InChI=1S/C15H10BrCl4NOS/c16-10-3-1-9(2-4-10)13(22)21-14(15(18,19)20)23-12-7-5-11(17)6-8-12/h1-8,14H,(H,21,22)
DMEVNZI CS C1=CC(=CC=C1C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl)Br
DMEVNZI IK APLQHKFABMHWHP-UHFFFAOYSA-N
DMEVNZI IU 4-bromo-N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DMEVNZI DE Discovery agent
DMJ6L9U ID DMJ6L9U
DMJ6L9U DN AMG7703
DMJ6L9U HS Investigative
DMJ6L9U SN AMG 7703; AMG-7703
DMJ6L9U DT Small molecular drug
DMJ6L9U PC 854189
DMJ6L9U MW 294.8
DMJ6L9U FM C14H15ClN2OS
DMJ6L9U IC InChI=1S/C14H15ClN2OS/c1-9(2)12(10-3-5-11(15)6-4-10)13(18)17-14-16-7-8-19-14/h3-9,12H,1-2H3,(H,16,17,18)/t12-/m0/s1
DMJ6L9U CS CC(C)[C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=NC=CS2
DMJ6L9U IK AZYDQCGCBQYFSE-LBPRGKRZSA-N
DMJ6L9U IU (2S)-2-(4-chlorophenyl)-3-methyl-N-(1,3-thiazol-2-yl)butanamide
DMJ6L9U DE Discovery agent
DMNHM1B ID DMNHM1B
DMNHM1B DN AMG-837
DMNHM1B HS Investigative
DMNHM1B SN AMG 837; AMG837
DMNHM1B DT Small molecular drug
DMNHM1B PC 46854655
DMNHM1B MW 438.4
DMNHM1B FM C26H21F3O3
DMNHM1B IC InChI=1S/C26H21F3O3/c1-2-4-21(16-25(30)31)20-9-13-24(14-10-20)32-17-18-5-3-6-22(15-18)19-7-11-23(12-8-19)26(27,28)29/h3,5-15,21H,16-17H2,1H3,(H,30,31)/t21-/m0/s1
DMNHM1B CS CC#C[C@@H](CC(=O)O)C1=CC=C(C=C1)OCC2=CC(=CC=C2)C3=CC=C(C=C3)C(F)(F)F
DMNHM1B IK ZOPNBMMVVZRSGH-NRFANRHFSA-N
DMNHM1B IU (3S)-3-[4-[[3-[4-(trifluoromethyl)phenyl]phenyl]methoxy]phenyl]hex-4-ynoic acid
DMNHM1B CA CAS 865231-46-5
DMNHM1B DE Discovery agent
DMU8M0I ID DMU8M0I
DMU8M0I DN AMG-8563
DMU8M0I HS Investigative
DMU8M0I SN SCHEMBL15446081
DMU8M0I CP Amgen
DMU8M0I TC Analgesics
DMU8M0I DT Small molecular drug
DMU8M0I PC 24863103
DMU8M0I MW 430.5
DMU8M0I FM C24H25F3N2O2
DMU8M0I IC InChI=1S/C24H25F3N2O2/c25-24(26,27)18-9-7-16(22(14-18)29-11-2-1-3-12-29)8-10-23(31)28-21-6-4-5-17-13-19(30)15-20(17)21/h4-10,14,19,30H,1-3,11-13,15H2,(H,28,31)/b10-8+/t19-/m0/s1
DMU8M0I CS C1CCN(CC1)C2=C(C=CC(=C2)C(F)(F)F)/C=C/C(=O)NC3=CC=CC4=C3C[C@H](C4)O
DMU8M0I IK HAZYXDWNLMGLIS-RQMBKDMJSA-N
DMU8M0I IU (E)-N-[(2S)-2-hydroxy-2,3-dihydro-1H-inden-4-yl]-3-[2-piperidin-1-yl-4-(trifluoromethyl)phenyl]prop-2-enamide
DMU8M0I DE Pain
DMKP8L9 ID DMKP8L9
DMKP8L9 DN AMG-889436
DMKP8L9 HS Investigative
DMKP8L9 SN Metabotropic glutamate receptor 4 agonist (Parkinson's disease), Amgen; Metabotropic glutamate receptor 4 positive allosteric modulator (Parkinson's disease), Amgen
DMKP8L9 CP Amgen Inc
DMKP8L9 DE Parkinson disease
DM1J46S ID DM1J46S
DM1J46S DN AMG-9090
DM1J46S HS Investigative
DM1J46S SN AMG-9090; 118215-82-0; CHEMBL1086371; N-{2,2,2-trichloro-1-[(4-chlorophenyl)sulfanyl]ethyl}benzamide; N-(2,2,2-trichloro-1-((4-chlorophenyl)sulfanyl)ethyl)benzamide; AC1MLXZ1; SCHEMBL15159501; MolPort-002-804-203; BDBM50318455; AKOS001602233; MCULE-4762847116; NCGC00322013-01; BC600809; A-300; ST50981355; AB01317363-02; AF-962/31929042; N-(2,2,2-trichloro-1-(4-chlorophenylthio)ethyl)benzamide; N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide; N-{2,2,2-trichloro-1-[(4-chlorophenyl)thio]ethyl}benzamide
DM1J46S DT Small molecular drug
DM1J46S PC 3277297
DM1J46S MW 395.1
DM1J46S FM C15H11Cl4NOS
DM1J46S IC InChI=1S/C15H11Cl4NOS/c16-11-6-8-12(9-7-11)22-14(15(17,18)19)20-13(21)10-4-2-1-3-5-10/h1-9,14H,(H,20,21)
DM1J46S CS C1=CC=C(C=C1)C(=O)NC(C(Cl)(Cl)Cl)SC2=CC=C(C=C2)Cl
DM1J46S IK NOXDIPWNQOTUAB-UHFFFAOYSA-N
DM1J46S IU N-[2,2,2-trichloro-1-(4-chlorophenyl)sulfanylethyl]benzamide
DM1J46S DE Discovery agent
DMSQ49N ID DMSQ49N
DMSQ49N DN AMG-JAK2-01
DMSQ49N HS Investigative
DMSQ49N SN JAK2 inhibitor (myeloproliferative disorder), Amgen
DMSQ49N CP Amgen Inc
DMSQ49N DE Myeloproliferative syndrome
DM4MXOB ID DM4MXOB
DM4MXOB DN AMI-1
DM4MXOB HS Investigative
DM4MXOB SN AMI1; AMI 1
DM4MXOB DT Small molecular drug
DM4MXOB PC 88489
DM4MXOB MW 548.5
DM4MXOB FM C21H14N2Na2O9S2
DM4MXOB IC InChI=1S/C21H16N2O9S2.2Na/c24-19-9-15(33(27,28)29)7-11-5-13(1-3-17(11)19)22-21(26)23-14-2-4-18-12(6-14)8-16(10-20(18)25)34(30,31)32;;/h1-10,24-25H,(H2,22,23,26)(H,27,28,29)(H,30,31,32);;/q;2*+1/p-2
DM4MXOB CS C1=CC2=C(C=C(C=C2C=C1NC(=O)NC3=CC4=CC(=CC(=C4C=C3)O)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+]
DM4MXOB IK MOUNHKKCIGVIDI-UHFFFAOYSA-L
DM4MXOB IU disodium;4-hydroxy-7-[(5-hydroxy-7-sulfonatonaphthalen-2-yl)carbamoylamino]naphthalene-2-sulfonate
DM4MXOB CA CAS 20324-87-2
DM4MXOB DE Discovery agent
DMST5VW ID DMST5VW
DMST5VW DN amidephrine
DMST5VW HS Investigative
DMST5VW SN amidephrine; Amidefrine; Amidefrine mesilate; UNII-U56LDN9FFT; 37571-84-9; UNII-NI24N176MY; U56LDN9FFT; NI24N176MY; 3354-67-4; Amidephrine, (+)-; N-(3-(1-Hydroxy-2-(methylamino)-ethyl)phenyl)methanesulfonamide; Amidephrine, (-)-; Amidefrine [INN:BAN]; Amidefrin; AC1L24YQ; GTPL514; SCHEMBL122479; CHEMBL146408; ZHOWHMXTJFZXRB-UHFFFAOYSA-N; CHEBI:134994; N-[3-[1-hydroxy-2-(methylamino)ethyl]phenyl]methanesulfonamide; BDBM50225291; Methanesulfonamide, N-(3-(1-hydroxy-2-(methylamino)ethyl)phenyl)-, (-)-; Methanesulfonamide, N-(3-(1-hy
DMST5VW DT Small molecular drug
DMST5VW PC 15010
DMST5VW MW 244.31
DMST5VW FM C10H16N2O3S
DMST5VW IC InChI=1S/C10H16N2O3S/c1-11-7-10(13)8-4-3-5-9(6-8)12-16(2,14)15/h3-6,10-13H,7H2,1-2H3
DMST5VW CS CNCC(C1=CC(=CC=C1)NS(=O)(=O)C)O
DMST5VW IK ZHOWHMXTJFZXRB-UHFFFAOYSA-N
DMST5VW IU N-[3-[1-hydroxy-2-(methylamino)ethyl]phenyl]methanesulfonamide
DMST5VW CA CAS 37571-84-9
DMST5VW CB CHEBI:134994
DMST5VW DE Discovery agent
DMJ0BEG ID DMJ0BEG
DMJ0BEG DN AMIFLAMINE
DMJ0BEG HS Investigative
DMJ0BEG SN Amiflamine; UNII-NE25WV9C8S; 77518-07-1; NE25WV9C8S; 4-[(2S)-2-aminopropyl]-N,N,3-trimethylaniline; Amiflaminum; Amiflamina; Amiflamine [INN]; Amiflaminum [Latin]; Amiflamina [Spanish]; Astra FLA 336; (+)-FLA 336; AC1Q4TOK; AC1L2FRS; AC1Q29JB; ZINC915; SCHEMBL198456; CHEMBL3989773; DTXSID00228222; AKOS006272872; (+)-4-(dimethylamino)-; A,2-dimethylphenethylamine; (+)-4-(Dimethylamino)-alpha-2-dimethylphenethylamine; Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-, (S); Benzeneethanamine, 4-(dimethylamino)-alpha,2-dimethyl-,
DMJ0BEG DT Small molecular drug
DMJ0BEG PC 71221
DMJ0BEG MW 192.3
DMJ0BEG FM C12H20N2
DMJ0BEG IC InChI=1S/C12H20N2/c1-9-7-12(14(3)4)6-5-11(9)8-10(2)13/h5-7,10H,8,13H2,1-4H3/t10-/m0/s1
DMJ0BEG CS CC1=C(C=CC(=C1)N(C)C)C[C@H](C)N
DMJ0BEG IK HFQMYSHATTXRTC-JTQLQIEISA-N
DMJ0BEG IU 4-[(2S)-2-aminopropyl]-N,N,3-trimethylaniline
DMJ0BEG CA CAS 77518-07-1
DMJ0BEG DE Discovery agent
DMNGW2M ID DMNGW2M
DMNGW2M DN Aminobenzoic acid
DMNGW2M HS Investigative
DMNGW2M SN AMINOBENZOIC ACID; Anti-chromotrichia factor; Anticanitic vitamin; Bacterial vitamin H1; Benzoic acid, 4-amino-; Benzoic acid, p-amino-; Chromotrichia factor; Hachemina; Pabacyd; Pabafilm; Pabamine; Papacidum; Paraminol; Paranate; Potaba; RVPaba Lipstick; Romavit; Rvpaba; Sunbrella; Super Shade by Coppertone; Trichochromogenic factor; Vitamin BX; Vitamin H'; p-Carboxyaniline; p-Carboxyphenylamine; p-aminobenzoic acid; para-aminobenzoic acid; 1-Amino-4-carboxybenzene; 150-13-0; 4-Carboxyaniline; 4-aminobenzoic acid; Amben; PABA
DMNGW2M PC 978
DMNGW2M MW 137.14
DMNGW2M FM C7H7NO2
DMNGW2M IC ALYNCZNDIQEVRV-UHFFFAOYSA-N
DMNGW2M CS C1=CC(=CC=C1C(=O)O)N
DMNGW2M IK 1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)
DMNGW2M IU 4-aminobenzoic acid
DMNGW2M CA CAS 150-13-0
DMNGW2M CB CHEBI:30753
DMNGW2M DE Penile fibromatosis
DMWYS0Z ID DMWYS0Z
DMWYS0Z DN Aminobenzolamide derivative
DMWYS0Z HS Investigative
DMWYS0Z SN CHEMBL435094; Aminobenzolamide derivative
DMWYS0Z DT Small molecular drug
DMWYS0Z PC 44395692
DMWYS0Z MW 955.2
DMWYS0Z FM C28H38N14O8S8
DMWYS0Z IC InChI=1S/C28H38N14O8S8/c29-55(43,44)27-37-35-25(53-27)39-57(47,48)21-7-3-19(4-8-21)33-23(51)31-11-1-13-41-15-17-42(18-16-41)14-2-12-32-24(52)34-20-5-9-22(10-6-20)58(49,50)40-26-36-38-28(54-26)56(30,45)46/h3-10H,1-2,11-18H2,(H,35,39)(H,36,40)(H2,29,43,44)(H2,30,45,46)(H2,31,33,51)(H2,32,34,52)
DMWYS0Z CS C1CN(CCN1CCCNC(=S)NC2=CC=C(C=C2)S(=O)(=O)NC3=NN=C(S3)S(=O)(=O)N)CCCNC(=S)NC4=CC=C(C=C4)S(=O)(=O)NC5=NN=C(S5)S(=O)(=O)N
DMWYS0Z IK OCNLOXNOURUUDD-UHFFFAOYSA-N
DMWYS0Z IU 1-[4-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl]-3-[3-[4-[3-[[4-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl]carbamothioylamino]propyl]piperazin-1-yl]propyl]thiourea
DMWYS0Z DE Discovery agent
DMCILV7 ID DMCILV7
DMCILV7 DN aminobenzovesamicol
DMCILV7 HS Investigative
DMCILV7 SN compound 11 [PMID: :7702637]; M-iodobenzyltrozamicol
DMCILV7 DT Small molecular drug
DMCILV7 PC 10390222
DMCILV7 MW 476.4
DMCILV7 FM C23H29IN2O
DMCILV7 IC InChI=1S/C23H29IN2O/c24-21-8-4-5-18(15-21)16-25-12-11-23(27)22(17-25)26-13-9-20(10-14-26)19-6-2-1-3-7-19/h1-8,15,20,22-23,27H,9-14,16-17H2/t22-,23-/m1/s1
DMCILV7 CS C1CN(C[C@H]([C@@H]1O)N2CCC(CC2)C3=CC=CC=C3)CC4=CC(=CC=C4)I
DMCILV7 IK UBVKSFDICLMPLH-DHIUTWEWSA-N
DMCILV7 IU (3R,4R)-1-[(3-iodophenyl)methyl]-3-(4-phenylpiperidin-1-yl)piperidin-4-ol
DMCILV7 DE Discovery agent
DMT13EW ID DMT13EW
DMT13EW DN AMINOBENZTROPINE
DMT13EW HS Investigative
DMT13EW SN Aminobenztropine; CHEMBL330957; 88097-86-3; 3-(2'-Aminobenzhydryloxy)tropane; ABHT; Aminobenztropine, solid; Spectrum_000273; SpecPlus_000797; Spectrum5_001758; Spectrum4_001211; Spectrum3_000745; AC1L1D0L; AC1Q57ZN; Lopac0_000126; KBioGR_001642; BSPBio_002330; KBioSS_000753; MLS000859976; SPECTRUM2300334; DivK1c_006893; SCHEMBL1231000; 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy-phenylmethyl]aniline; KBio3_001550; KBio2_003321; KBio1_001837; KBio2_005889; KBio2_000753; CTK5F9344; CHEBI:125384; HMS3260I14; HMS3374M03; HMS2232P19
DMT13EW DT Small molecular drug
DMT13EW PC 2143
DMT13EW MW 322.4
DMT13EW FM C21H26N2O
DMT13EW IC InChI=1S/C21H26N2O/c1-23-16-11-12-17(23)14-18(13-16)24-21(15-7-3-2-4-8-15)19-9-5-6-10-20(19)22/h2-10,16-18,21H,11-14,22H2,1H3
DMT13EW CS CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4N
DMT13EW IK KZFDKINRISJFCO-UHFFFAOYSA-N
DMT13EW IU 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy-phenylmethyl]aniline
DMT13EW CA CAS 88097-86-3
DMT13EW CB CHEBI:125384
DMT13EW DE Discovery agent
DMCLVOZ ID DMCLVOZ
DMCLVOZ DN Aminocarbonyl dihydrogen phosphate
DMCLVOZ HS Investigative
DMCLVOZ SN carbamoylphosphate; CARBAMYL PHOSPHATE; Carbamoyl phosphate; phosphono carbamate; 590-55-6; aminocarbonyl dihydrogen phosphate; monocarbamoyl phosphate; PHOSPHORIC ACID MONO(FORMAMIDE)ESTER; carbamoyl dihydrogen phosphate; CHEMBL369105; carbamic phosphoric monoanhydride; CHEBI:17672; carbamoyl-P; carbamyl-phosphate; carbamoyl-phosphate; carbamoyl phosphoric acid; AC1L18VP; SCHEMBL50374; Carbamic acid, monoanhydride with phosphoric acid; (carbamoyloxy)phosphonic acid; AC1Q68Q7; ZINC8383183; BDBM50162819; AKOS006341689; carbamic aci
DMCLVOZ DT Small molecular drug
DMCLVOZ PC 278
DMCLVOZ MW 141.02
DMCLVOZ FM CH4NO5P
DMCLVOZ IC InChI=1S/CH4NO5P/c2-1(3)7-8(4,5)6/h(H2,2,3)(H2,4,5,6)
DMCLVOZ CS C(=O)(N)OP(=O)(O)O
DMCLVOZ IK FFQKYPRQEYGKAF-UHFFFAOYSA-N
DMCLVOZ IU phosphono carbamate
DMCLVOZ CA CAS 590-55-6
DMCLVOZ CB CHEBI:17672
DMCLVOZ DE Discovery agent
DM79E2K ID DM79E2K
DM79E2K DN Aminodeoxykanamycin
DM79E2K HS Investigative
DM79E2K SN Aminodeoxykanamycin; bekanamycin; Kanamycin B; nebramycin factor 5; Bekanamycine; Bekanamycinum; Becanamicina; Bekanamycinum [INN-Latin]; Bekanamycine [INN-French]; Becanamicina [INN-Spanish]; EINECS 225-170-5; BRN 0061646; Aminodeoxykanamycin sulfate; 4696-76-8; Antibiotic derived from Streptomyces kanamyceticus; AC1L2FQA; AC1Q57UP; Antibiotic derived from Streptomyces kanamyceticus. Kanamycin B; (1r,2s,4r,6s)-4,6-diamino-3-[(3-amino-3-deoxy-; A-d-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-
DM79E2K DT Small molecular drug
DM79E2K PC 439318
DM79E2K MW 483.5
DM79E2K FM C18H37N5O10
DM79E2K IC InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
DM79E2K CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N
DM79E2K IK SKKLOUVUUNMCJE-FQSMHNGLSA-N
DM79E2K IU (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol
DM79E2K CA CAS 4696-76-8
DM79E2K CB CHEBI:28098
DM79E2K DE Discovery agent
DM7Y6AL ID DM7Y6AL
DM7Y6AL DN AMINOFENTANYL
DM7Y6AL HS Investigative
DM7Y6AL SN CHEMBL385168; AMINOFENTANYL; BDBM50191054
DM7Y6AL DT Small molecular drug
DM7Y6AL PC 44416393
DM7Y6AL MW 351.5
DM7Y6AL FM C22H29N3O
DM7Y6AL IC InChI=1S/C22H29N3O/c23-15-11-22(26)25(20-9-5-2-6-10-20)21-13-17-24(18-14-21)16-12-19-7-3-1-4-8-19/h1-10,21H,11-18,23H2
DM7Y6AL CS C1CN(CCC1N(C2=CC=CC=C2)C(=O)CCN)CCC3=CC=CC=C3
DM7Y6AL IK WBHIZNRNVFOZMJ-UHFFFAOYSA-N
DM7Y6AL IU 3-amino-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
DM7Y6AL DE Discovery agent
DMUN54G ID DMUN54G
DMUN54G DN Aminohippuric acid
DMUN54G HS Investigative
DMUN54G SN 4-Aminohippuric acid; aminohippuric acid; 61-78-9; P-AMINOHIPPURIC ACID; Paha; Glycine, N-(4-aminobenzoyl)-; N-(4-Aminobenzoyl)glycine; para-Aminohippuric acid; Nefrotest; 2-(4-aminobenzamido)acetic acid; N-(p-Aminobenzoyl)glycine; p-Aminohippurate; Aminohippurate; PAH (amino acid); 4-Amino hippuric acid; N-(para-aminobenzoyl)glycine; Hippuric acid, p-amino-; N-(p-Aminobenzoyl)aminoacetic acid; para-Aminohippurate; paraaminohippuric acid; PAH; UNII-Y79XT83BJ9; NSC 13064; HSDB 2139; 4-Aminobenzoyl Glycine; EINECS 200-518-9
DMUN54G DT Small molecular drug
DMUN54G PC 2148
DMUN54G MW 194.19
DMUN54G FM C9H10N2O3
DMUN54G IC InChI=1S/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)
DMUN54G CS C1=CC(=CC=C1C(=O)NCC(=O)O)N
DMUN54G IK HSMNQINEKMPTIC-UHFFFAOYSA-N
DMUN54G IU 2-[(4-aminobenzoyl)amino]acetic acid
DMUN54G CA CAS 61-78-9
DMUN54G CB CHEBI:104011
DMUN54G DE Discovery agent
DMNX9FC ID DMNX9FC
DMNX9FC DN Aminomethylcyclohexane
DMNX9FC HS Investigative
DMNX9FC SN Cyclohexanemethylamine; Cyclohexylmethanamine; 3218-02-8; Aminomethylcyclohexane; (Aminomethyl)cyclohexane; Cyclohexanemethanamine; 1-Cyclohexylmethanamine; Hexahydrobenzylamine; 1-cyclohexylmethylamine; 4-aminomethylcyclohexane; C-Cyclohexyl-methylamine; CHEMBL1049; DECARBOXYLATED DERIVATIVE; AVKNGPAMCBSNSO-UHFFFAOYSA-N; EINECS 221-741-8; NSC 172991; BRN 0635751; 1tng; Cyclohexanemethyamine; cyclohexylmethyl amine; cyclohexanemethylamirie; CyclohexYl-Methanamine; cyclohexanemethyl amine; cyclohexane methylamine
DMNX9FC DT Small molecular drug
DMNX9FC PC 76688
DMNX9FC MW 113.2
DMNX9FC FM C7H15N
DMNX9FC IC InChI=1S/C7H15N/c8-6-7-4-2-1-3-5-7/h7H,1-6,8H2
DMNX9FC CS C1CCC(CC1)CN
DMNX9FC IK AVKNGPAMCBSNSO-UHFFFAOYSA-N
DMNX9FC IU cyclohexylmethanamine
DMNX9FC CA CAS 3218-02-8
DMNX9FC DE Discovery agent
DMHNDTW ID DMHNDTW
DMHNDTW DN aminooxyacetic acid
DMHNDTW HS Investigative
DMHNDTW SN Aminooxyacetic acid; (aminooxy)acetic acid; 2-(Aminooxy)acetic acid; AOAA; carboxymethoxylamine; 645-88-5; Carboxymethoxyamine; ACETIC ACID, (AMINOOXY)-; Aminooxyacetate; Aminooxy-acetic acid; (Carboxymethoxy)amine; (o-Carboxymethyl)hydroxylamine; aminoxyacetic acid; UNII-14I68GI3OQ; BRN 0878238; C2H5NO3; 14I68GI3OQ; U 7524; NQRKYASMKDDGHT-UHFFFAOYSA-N; u-7524; AOA; Aminooxyacetic acid hemihydrochloride; Carboxymethoxylamine hemihydrochloride; aminoxy-acetic acid; amino-oxyacetic acid; AOA hemihydrochloride; 2-aminooxyacetic acid; AOAA
DMHNDTW DT Small molecular drug
DMHNDTW PC 286
DMHNDTW MW 91.07
DMHNDTW FM C2H5NO3
DMHNDTW IC InChI=1S/C2H5NO3/c3-6-1-2(4)5/h1,3H2,(H,4,5)
DMHNDTW CS C(C(=O)O)ON
DMHNDTW IK NQRKYASMKDDGHT-UHFFFAOYSA-N
DMHNDTW IU 2-aminooxyacetic acid
DMHNDTW CA CAS 645-88-5
DMHNDTW CB CHEBI:40823
DMHNDTW DE Discovery agent
DMEMCQ9 ID DMEMCQ9
DMEMCQ9 DN Aminophenol
DMEMCQ9 HS Investigative
DMEMCQ9 SN Benzofur GG; Fouramine OP; Nako Yellow 3GA; Nako Yellow ga; O-AMINOPHENOL; ORTHO AMINO PHENOL; Paradone Olive Green B; Pelagol 3GA; Pelagol Grey GG; 2-Aminophenol; BASF ursol 3GA; Phenol, 2-amino-; Phenol, o-amino-; Questiomycin B; Zoba 3GA; o-Hydroxyaniline; o-Hydroxyphenylamine; ortho-aminophenol; 1-Amino-2-hydroxybenzene; 1-Hydroxy-2-aminobenzene; 2-Amino-1-hydroxybenzene; 2-Aminobenzenol; 2-Hydroxyanaline; 2-Hydroxyaniline; 2-amino-phenol; 95-55-6; C.I. 76520; C.I. Oxidation Base 17; CI Oxidation Base 17; NSC 1534
DMEMCQ9 PC 5801
DMEMCQ9 MW 109.13
DMEMCQ9 FM C6H7NO
DMEMCQ9 IC CDAWCLOXVUBKRW-UHFFFAOYSA-N
DMEMCQ9 CS C1=CC=C(C(=C1)N)O
DMEMCQ9 IK 1S/C6H7NO/c7-5-3-1-2-4-6(5)8/h1-4,8H,7H2
DMEMCQ9 IU 2-aminophenol
DMEMCQ9 CA CAS 95-55-6
DMEMCQ9 CB CHEBI:18112
DMEMCQ9 DE Discovery agent
DMT5HOA ID DMT5HOA
DMT5HOA DN amino-propylphosphinic acid
DMT5HOA HS Investigative
DMT5HOA SN Diadenosine diphosphate; AC1L4MLM; [({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5S)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy})phosphinic acid; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DMT5HOA DT Small molecular drug
DMT5HOA PC 188326
DMT5HOA MW 676.4
DMT5HOA FM C20H26N10O13P2
DMT5HOA IC InChI=1S/C20H26N10O13P2/c21-15-9-17(25-3-23-15)29(5-27-9)19-12(33)11(32)8(41-19)2-39-44(35,36)43-45(37,38)42-14-7(1-31)40-20(13(14)34)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20+/m1/s1
DMT5HOA CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O[C@@H]4[C@H](O[C@@H]([C@@H]4O)N5C=NC6=C(N=CN=C65)N)CO)O)O)N
DMT5HOA IK FHISWBUCBBVWGG-SNESVTBZSA-N
DMT5HOA IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5S)-5-(6-aminopurin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate
DMT5HOA CA CAS 14938-28-4
DMT5HOA DE Discovery agent
DMKLC3O ID DMKLC3O
DMKLC3O DN aminopurvalanol A
DMKLC3O HS Investigative
DMKLC3O SN NG-97
DMKLC3O DT Small molecular drug
DMKLC3O PC 6604931
DMKLC3O MW 403.9
DMKLC3O FM C19H26ClN7O
DMKLC3O IC InChI=1S/C19H26ClN7O/c1-10(2)15(8-28)24-19-25-17(23-14-6-12(20)5-13(21)7-14)16-18(26-19)27(9-22-16)11(3)4/h5-7,9-11,15,28H,8,21H2,1-4H3,(H2,23,24,25,26)/t15-/m0/s1
DMKLC3O CS CC(C)[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=CC(=C3)N)Cl
DMKLC3O IK RAMROQQYRRQPDL-HNNXBMFYSA-N
DMKLC3O IU (2R)-2-[[6-(3-amino-5-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
DMKLC3O CB CHEBI:38937
DM94KQP ID DM94KQP
DM94KQP DN Aminopyridine deriv. 2
DM94KQP HS Investigative
DM94KQP SN JNK Inhibitor VIII; TCS JNK 6o; 894804-07-0; aminopyridine deriv. 2; N-(4-Amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide; Kinome_3020; SCHEMBL157014; GTPL5998; CHEMBL210618; BDBM15908; Aminopyridine-Based Inhibitor 6o; CTK8E8164; DTXSID20469650; MolPort-023-276-703; HMS3229K06; IN1283; ZINC14959960; AKOS024457488; CCG-206859; NCGC00387087-01; RT-013406; B7321
DM94KQP DT Small molecular drug
DM94KQP PC 11624601
DM94KQP MW 356.4
DM94KQP FM C18H20N4O4
DM94KQP IC InChI=1S/C18H20N4O4/c1-4-26-18-13(10-19)14(20)9-16(22-18)21-17(23)8-11-7-12(24-2)5-6-15(11)25-3/h5-7,9H,4,8H2,1-3H3,(H3,20,21,22,23)
DM94KQP CS CCOC1=C(C(=CC(=N1)NC(=O)CC2=C(C=CC(=C2)OC)OC)N)C#N
DM94KQP IK KQMPRSZTUSSXND-UHFFFAOYSA-N
DM94KQP IU N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide
DM94KQP CA CAS 894804-07-0
DM94KQP DE Discovery agent
DMGEVBH ID DMGEVBH
DMGEVBH DN Aminothiazoline
DMGEVBH HS Investigative
DMGEVBH SN 2-AMINOTHIAZOLE; aminothiazole; 96-50-4; thiazol-2-amine; 2-Thiazolamine; 1,3-Thiazol-2-amine; 2-Thiazolylamine; Abadole; Basedol; Abadol; 2-Thiazylamine; 4-Thiazolin-2-onimine; 2-Amino-1,3-thiazole; Aminothiazol; Aminotiazol; Aminothiazolum; Thiazole, 2-amino-; 2-Aminothiazol; 2-amino thiazole; USAF EK-P-5501; Aminothiazole [INN]; Aminotiazolo [DCIT]; Thiazolamine; RP 2921; Aminothiazol [INN-French]; Aminotiazol [INN-Spanish]; NSC 1900; Aminothiazolum [INN-Latin]; Thiazol-2-ylamine; UNII-5K8WKN668K; CCRIS 1279; 2-Aminothiazole, 97%
DMGEVBH DT Small molecular drug
DMGEVBH PC 2155
DMGEVBH MW 100.14
DMGEVBH FM C3H4N2S
DMGEVBH IC InChI=1S/C3H4N2S/c4-3-5-1-2-6-3/h1-2H,(H2,4,5)
DMGEVBH CS C1=CSC(=N1)N
DMGEVBH IK RAIPHJJURHTUIC-UHFFFAOYSA-N
DMGEVBH IU 1,3-thiazol-2-amine
DMGEVBH CA CAS 96-50-4
DMGEVBH CB CHEBI:40782
DMGEVBH DE Discovery agent
DMXDUCP ID DMXDUCP
DMXDUCP DN AMN082
DMXDUCP HS Investigative
DMXDUCP SN AMN-082; AMN 082
DMXDUCP DT Small molecular drug
DMXDUCP PC 11698390
DMXDUCP MW 465.5
DMXDUCP FM C28H30Cl2N2
DMXDUCP IC InChI=1S/C28H28N2.2ClH/c1-5-13-23(14-6-1)27(24-15-7-2-8-16-24)29-21-22-30-28(25-17-9-3-10-18-25)26-19-11-4-12-20-26;;/h1-20,27-30H,21-22H2;2*1H
DMXDUCP CS C1=CC=C(C=C1)C(C2=CC=CC=C2)NCCNC(C3=CC=CC=C3)C4=CC=CC=C4.Cl.Cl
DMXDUCP IK YRQCDCNQANSUPB-UHFFFAOYSA-N
DMXDUCP IU N,N'-dibenzhydrylethane-1,2-diamine;dihydrochloride
DMXDUCP DE Discovery agent
DMC15DM ID DMC15DM
DMC15DM DN Amooranin
DMC15DM HS Investigative
DMC15DM SN MCH-100XC2; Caspase-8 stimulator/apoptosis stimulator/cell cycle inhibitor (cancer), Dharma Biomedical; P-glycoprotein modulator (small molecule therapeutic/natural product, cancer/autoimmune diseases/inflammatory diseases), Dharma BioMedical
DMC15DM CP Dharma Biomedical
DMC15DM PC 11503749
DMC15DM MW 470.7
DMC15DM FM C30H46O4
DMC15DM IC InChI=1S/C30H46O4/c1-25(2)13-15-29(24(33)34)16-14-27(5)19(20(29)17-25)7-8-22-28(27,6)11-9-21-26(3,4)23(32)10-12-30(21,22)18-31/h7,20-22,31H,8-18H2,1-6H3,(H,33,34)/t20-,21-,22-,27+,28+,29-,30+/m0/s1
DMC15DM CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(CCC(=O)C3(C)C)CO
DMC15DM IK SEOWASFHYNYGBU-RHXAIUOTSA-N
DMC15DM IU (4aS,6aS,6aS,6bR,8aR,12aS,14bS)-12a-(hydroxymethyl)-2,2,6a,6b,9,9-hexamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
DMC15DM DE Autoimmune diabetes
DM64X25 ID DM64X25
DM64X25 DN AMPE4L
DM64X25 HS Investigative
DM64X25 SN Exendin4-Fc-Leptin; GLP1-Fc-Leptin; Exendin4-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
DM64X25 CP AmProtein Corp
DM64X25 DE Diabetic complication
DMVHOQE ID DMVHOQE
DMVHOQE DN AMPPL
DMVHOQE HS Investigative
DMVHOQE SN PYY-Fc-Leptin; PYY-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
DMVHOQE CP AmProtein Corp
DMVHOQE DE Diabetic complication
DMTOK1D ID DMTOK1D
DMTOK1D DN AMP-PNP
DMTOK1D HS Investigative
DMTOK1D SN Phosphoaminophosphonic acid-adenylate ester; gamma-Imino-ATP; ADENYLYL IMIDODIPHOSPHATE; AMPPNP; Adenyl imidodiphosphate; phosphoaminophosphonic acid-adenylate ester; 25612-73-1; adenyl-5'-yl imidodiphosphate; CHEBI:47785; App(NH)p; O(5')-(1,2-dihydroxy-2-phosphonoaminodiphosphoryl)adenosine; 5'-O-(hydroxy{[hydroxy(phosphonoamino)phosphoryl]oxy}phosphoryl)adenosine; [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid; p(NH)Ppf; beta,gamma-Imido-ATP; beta,gamma-Imidoadenosine; Phosphoaminophosphonic Acid-Adenylate Ester
DMTOK1D DT Small molecular drug
DMTOK1D PC 33113
DMTOK1D MW 506.2
DMTOK1D FM C10H17N6O12P3
DMTOK1D IC InChI=1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7-,10-/m1/s1
DMTOK1D CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(NP(=O)(O)O)O)O)O)N
DMTOK1D IK PVKSNHVPLWYQGJ-KQYNXXCUSA-N
DMTOK1D IU [[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]amino]phosphonic acid
DMTOK1D CA CAS 25612-73-1
DMTOK1D CB CHEBI:47785
DMTOK1D DE Discovery agent
DMXRIUT ID DMXRIUT
DMXRIUT DN AMPSL
DMXRIUT HS Investigative
DMXRIUT SN Symlin-Fc-Leptin; Symlin-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
DMXRIUT CP AmProtein Corp
DMXRIUT DE Diabetic complication
DM7WTKJ ID DM7WTKJ
DM7WTKJ DN AMR-SIX-1
DM7WTKJ HS Investigative
DM7WTKJ SN 5-HT 6 modulators (obesity), Albany Molecular Research
DM7WTKJ CP Albany Molecular Research Inc
DM7WTKJ DE Obesity
DMO7EBX ID DMO7EBX
DMO7EBX DN AMSH
DMO7EBX HS Investigative
DMO7EBX DE Female sexual arousal dysfunction
DM4OCAH ID DM4OCAH
DM4OCAH DN AMTB
DM4OCAH HS Investigative
DM4OCAH SN AMTB; CHEMBL1289953; GTPL4132; SCHEMBL10039870; ZINC35076019; BDBM50331290; N-(3-aminopropyl)-2-(3-methylbenzyloxy)-N-(thiophen-2-ylmethyl)benzamide; N-(3-aminopropyl)-2-{[(3-methylphenyl)methyl]oxy}-N-(2-thienylmethyl)benzamide
DM4OCAH DT Small molecular drug
DM4OCAH PC 16095384
DM4OCAH MW 394.5
DM4OCAH FM C23H26N2O2S
DM4OCAH IC InChI=1S/C23H26N2O2S/c1-18-7-4-8-19(15-18)17-27-22-11-3-2-10-21(22)23(26)25(13-6-12-24)16-20-9-5-14-28-20/h2-5,7-11,14-15H,6,12-13,16-17,24H2,1H3
DM4OCAH CS CC1=CC(=CC=C1)COC2=CC=CC=C2C(=O)N(CCCN)CC3=CC=CS3
DM4OCAH IK LCQJRANJHOEQFG-UHFFFAOYSA-N
DM4OCAH IU N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(thiophen-2-ylmethyl)benzamide
DM4OCAH DE Discovery agent
DMBAX3P ID DMBAX3P
DMBAX3P DN amthamine
DMBAX3P HS Investigative
DMBAX3P SN Amthamine; 142437-67-0; 2-Amino-5-(2-aminoethyl)-4-methylthiazole; 5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine; Tocris-0668; 5-(2-aminoethyl)-4-methylthiazol-2-amine; AC1L2QR3; SCHEMBL400272; ZINC5099; GTPL4025; CHEMBL293762; BDBM22881; CTK8E9579; CHEBI:92694; DTXSID80162039; AKOS006271424; RL01758; NCGC00024719-01; NCGC00024719-02; 5-Thiazoleethanamine, 2-amino-4-methyl-; KB-47389; RT-011284; FT-0694778; 2-AMINO-4-METHYLTHIAZOLE-5-ETHANAMINE; L000107; J-007652
DMBAX3P DT Small molecular drug
DMBAX3P PC 126688
DMBAX3P MW 157.24
DMBAX3P FM C6H11N3S
DMBAX3P IC InChI=1S/C6H11N3S/c1-4-5(2-3-7)10-6(8)9-4/h2-3,7H2,1H3,(H2,8,9)
DMBAX3P CS CC1=C(SC(=N1)N)CCN
DMBAX3P IK LHVRFUVVRXGZPV-UHFFFAOYSA-N
DMBAX3P IU 5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine
DMBAX3P CA CAS 142437-67-0
DMBAX3P CB CHEBI:92694
DMBAX3P DE Discovery agent
DMGHXQE ID DMGHXQE
DMGHXQE DN AMX-256
DMGHXQE HS Investigative
DMGHXQE SN GLP-2 (XTEN formulation, Crohns disease), Amunix; GLP-2 (XTEN formulation, Crohns disease/short bowel syndrome), Amunix
DMGHXQE CP Amunix Inc
DMGHXQE DE Short bowel syndrome
DMPSRZ0 ID DMPSRZ0
DMPSRZ0 DN AMXT-1501
DMPSRZ0 HS Investigative
DMPSRZ0 SN Difluoromethylornithine + polyamine transport inhibitors (head and neck cancer), Aminex Therapeutics; Polyamine transport inhibitors + polyamine biosynthesis inhibitor (head and neck cancer), Aminex Therapeutics/MediQuest Therapeutics; MQT-1426 + DFMO (head and neck cancer), Aminex Therapeutics/MediQuest Therapeutics; Polyamine-based therapy (head and neck-squamous cell carcinoma), Aminex Therapeutics/MediQuest Therapeutics
DMPSRZ0 CP MediQuest Therapeutics Inc
DMPSRZ0 DE Head and neck cancer
DM7SHQ1 ID DM7SHQ1
DM7SHQ1 DN Amythiamicin
DM7SHQ1 HS Investigative
DM7SHQ1 DE Discovery agent
DMRS0LA ID DMRS0LA
DMRS0LA DN AN-207
DMRS0LA HS Investigative
DMRS0LA SN D-26232; Doxorubicin-analog-[D-Lys(6)]LHRH conjugate, Tulane University/Zentaris
DMRS0LA CP Tulane University
DMRS0LA PC 16134408
DMRS0LA MW 1945.1
DMRS0LA FM C95H121N19O26
DMRS0LA IC InChI=1S/C95H121N19O26/c1-48(2)35-61(87(129)107-60(19-13-31-101-94(97)98)93(135)114-34-14-20-66(114)92(134)103-44-71(96)118)108-85(127)58(106-88(130)62(36-50-24-26-53(116)27-25-50)109-91(133)65(45-115)112-89(131)63(37-51-42-102-57-17-6-5-15-54(51)57)110-90(132)64(38-52-43-99-47-104-52)111-86(128)59-28-29-73(120)105-59)18-7-8-30-100-72(119)22-12-23-74(121)138-46-70(117)95(136)40-56-77(69(41-95)140-75-39-67(80(122)49(3)139-75)113-32-9-10-33-113)84(126)79-78(82(56)124)81(123)55-16-11-21-68(137-4)76(55)83(79)125/h5-6,9,11,15-17,21,24-27,32,42-43,47-49,58-67,69,75,80,102,115-116,122,124,126,136H,7-8,10,12-14,18-20,22-23,28-31,33-41,44-46H2,1-4H3,(H2,96,118)(H,99,104)(H,100,119)(H,103,134)(H,105,120)(H,106,130)(H,107,129)(H,108,127)(H,109,133)(H,110,132)(H,111,128)(H,112,131)(H4,97,98,101)/t49-,58+,59-,60-,61-,62-,63-,64-,65-,66-,67-,69-,75-,80+,95-/m0/s1
DMRS0LA CS C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N6CCC[C@H]6C(=O)NCC(=O)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)O)N1CCC=C1)O
DMRS0LA IK OIUSKDFJNIKIQX-OACKXKLTSA-N
DMRS0LA IU [2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate
DMRS0LA DE Solid tumour/cancer
DMIY134 ID DMIY134
DMIY134 DN ANA-04
DMIY134 HS Investigative
DMIY134 SN ANA-506; ANA-506); ANB-004; Human monoclonal antibody (inflammatory disease/autoimmune disease), AnaptysBio; Multi-specific antibody (autoimmune disease/inflammatory disease), AnaptysBio/VLST Corp
DMIY134 CP AnaptysBio Inc
DMIY134 DT Antibody
DMIY134 DE Autoimmune diabetes
DM3DPSO ID DM3DPSO
DM3DPSO DN ANA-5
DM3DPSO HS Investigative
DM3DPSO CP Alzhyme Pty Ltd
DM3DPSO DE Alzheimer disease
DMAS5BI ID DMAS5BI
DMAS5BI DN anacardic acid
DMAS5BI HS Investigative
DMAS5BI SN Anacardic acid C15:3; CHEMBL464925; (8E,11E,14E)-Anacardic acid; NSC638512; 2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid; 18654-18-7; 2-hydroxy-6-[(8E,11E)-pentadeca-8,11,14-trienyl]benzoic acid; 2-hydroxy-6-[(8E,11E)-pentadeca-8,11,14-trien-1-yl]benzoic acid; 6-(8(Z),11(Z),14-Pentadecatrienyl)salicylic acid; 8,11,14-Anacardic acid; Anacardic acid IV; AC1NTUKB; 6-(8,11,14-Pentadecatrienyl)salicylic acid; Salicylic acid, 6-(8,11,14-pentadecatrienyl)-; SCHEMBL154720; GTPL6999; Benzoic acid, 2-hydroxy-6-(8,11,14-pentade
DMAS5BI DT Small molecular drug
DMAS5BI PC 167551
DMAS5BI MW 348.5
DMAS5BI FM C22H36O3
DMAS5BI IC InChI=1S/C22H36O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20(23)21(19)22(24)25/h15,17-18,23H,2-14,16H2,1H3,(H,24,25)
DMAS5BI CS CCCCCCCCCCCCCCCC1=C(C(=CC=C1)O)C(=O)O
DMAS5BI IK ADFWQBGTDJIESE-UHFFFAOYSA-N
DMAS5BI IU 2-hydroxy-6-pentadecylbenzoic acid
DMAS5BI CA CAS 16611-84-0
DMAS5BI CB CHEBI:2696
DMAS5BI DE Discovery agent
DMMKGT4 ID DMMKGT4
DMMKGT4 DN analog 3 (Vlattas et al., 1996)
DMMKGT4 HS Investigative
DMMKGT4 SN GTPL7994; CHEMBL1160330; analog 3 [Vlattas et al., 1996]; 2-[2-[hydroxy(phosphonooxy)phosphoryl]oxyethyl-methylamino]acetic acid
DMMKGT4 DT Small molecular drug
DMMKGT4 PC 44306132
DMMKGT4 MW 293.11
DMMKGT4 FM C5H13NO9P2
DMMKGT4 IC InChI=1S/C5H13NO9P2/c1-6(4-5(7)8)2-3-14-17(12,13)15-16(9,10)11/h2-4H2,1H3,(H,7,8)(H,12,13)(H2,9,10,11)
DMMKGT4 CS CN(CCOP(=O)(O)OP(=O)(O)O)CC(=O)O
DMMKGT4 IK YERUUUBBRAPJND-UHFFFAOYSA-N
DMMKGT4 IU 2-[2-[hydroxy(phosphonooxy)phosphoryl]oxyethyl-methylamino]acetic acid
DMMKGT4 DE Discovery agent
DMYW5JX ID DMYW5JX
DMYW5JX DN ANALOG OF DYNORPHIN A
DMYW5JX HS Investigative
DMYW5JX SN Dynorphin A (1-13); 72957-38-1; Analog of Dynorphin A; UNII-VFC23V742Z; Porcine dynorphin A(1-13); dynorphin (1-13); VFC23V742Z; CHEMBL405618; Dinorphin A (1-13); Dynorphin 1-13; dynorphin A(1-13); BDBM50241435; dynorphin A 1-13; 1-13-Dynorphin A (swine); Dynorphin A1-13; YGGFLRRIRPKLK; YGGFLRRXRPKLK; Dynorphin-(1-13); DYNORPHIN(1-13)-OH; BDBM224024; BDBM214798; L-Lysine, L-tyrosylglycylglycyl-L-phenylalanyl-L-leucyl-L-arginyl-L-arginyl-L-isoleucyl-L-arginyl-L-prolyl-L-lysyl-L-leucyl-; NCGC00163681-02; NCGC00163681-01; 957H381
DMYW5JX PC 25075996
DMYW5JX MW 1604
DMYW5JX FM C75H126N24O15
DMYW5JX IC InChI=1S/C75H126N24O15/c1-7-45(6)61(70(111)94-53(25-17-35-87-75(83)84)71(112)99-36-18-26-58(99)69(110)93-50(21-11-13-31-76)64(105)96-56(38-44(4)5)67(108)95-54(72(113)114)22-12-14-32-77)98-65(106)52(24-16-34-86-74(81)82)91-63(104)51(23-15-33-85-73(79)80)92-66(107)55(37-43(2)3)97-68(109)57(40-46-19-9-8-10-20-46)90-60(102)42-88-59(101)41-89-62(103)49(78)39-47-27-29-48(100)30-28-47/h8-10,19-20,27-30,43-45,49-58,61,100H,7,11-18,21-26,31-42,76-78H2,1-6H3,(H,88,101)(H,89,103)(H,90,102)(H,91,104)(H,92,107)(H,93,110)(H,94,111)(H,95,108)(H,96,105)(H,97,109)(H,98,106)(H,113,114)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t45-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-/m0/s1
DMYW5JX CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMYW5JX IK OVVIBUHLQIYUEU-IWIISZHXSA-N
DMYW5JX IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]hexanoic acid
DMYW5JX CA CAS 72957-38-1
DMYW5JX DE Discovery agent
DM5JN3P ID DM5JN3P
DM5JN3P DN ANALOGUE A
DM5JN3P HS Investigative
DM5JN3P SN ANALOGUE A; CHEMBL410852
DM5JN3P DT Small molecular drug
DM5JN3P PC 44450788
DM5JN3P MW 460.3
DM5JN3P FM C23H23Cl2N3O3
DM5JN3P IC InChI=1S/C23H23Cl2N3O3/c24-16-5-6-19-15(11-16)13-20(26-19)22(30)27-21(12-14-3-1-2-4-18(14)25)23(31)28-9-7-17(29)8-10-28/h1-6,11,13,17,21,26,29H,7-10,12H2,(H,27,30)/t21-/m0/s1
DM5JN3P CS C1CN(CCC1O)C(=O)[C@H](CC2=CC=CC=C2Cl)NC(=O)C3=CC4=C(N3)C=CC(=C4)Cl
DM5JN3P IK HJMXVPPJJMSWFO-NRFANRHFSA-N
DM5JN3P IU 5-chloro-N-[(2S)-3-(2-chlorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide
DM5JN3P DE Discovery agent
DMCKH3P ID DMCKH3P
DMCKH3P DN Anandamide
DMCKH3P HS Investigative
DMCKH3P SN Anandamide; Arachidonylethanolamide; Arachidonoyl ethanolamide; N-Arachidonoylethanolamine; Anandamide (20.4, n-6); N-Arachidonoyl-2-hydroxyethylamide; 94421-68-8; AEA; N-arachidonoyl ethanolamine; N-(2-Hydroxyethyl)anachidonamide; 5,8,11,14-Eicosatetraenoylethanolamide; arachidonoylethanolamide; (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide; Arachidonoyl-EA; UNII-UR5G69TJKH; Arachidonic acid N-(hydroxyethyl)amide; Anandamide(20:4, n-6); Anandamide (20:4, n-6)
DMCKH3P DT Small molecular drug
DMCKH3P PC 5281969
DMCKH3P MW 347.5
DMCKH3P FM C22H37NO2
DMCKH3P IC InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-
DMCKH3P CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCO
DMCKH3P IK LGEQQWMQCRIYKG-DOFZRALJSA-N
DMCKH3P IU (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
DMCKH3P CA CAS 94421-68-8
DMCKH3P CB CHEBI:2700
DMCKH3P DE Discovery agent
DMX4P5A ID DMX4P5A
DMX4P5A DN andarine
DMX4P5A HS Investigative
DMX4P5A SN GTX007; GTX-007
DMX4P5A DT Small molecular drug
DMX4P5A PC 9824562
DMX4P5A MW 441.4
DMX4P5A FM C19H18F3N3O6
DMX4P5A IC InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1
DMX4P5A CS CC(=O)NC1=CC=C(C=C1)OC[C@@](C)(C(=O)NC2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)O
DMX4P5A IK YVXVTLGIDOACBJ-SFHVURJKSA-N
DMX4P5A IU (2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
DMX4P5A CA CAS 401900-40-1
DMX4P5A CB CHEBI:94760
DMX4P5A DE Discovery agent
DMHL0ID ID DMHL0ID
DMHL0ID DN Andromustine
DMHL0ID HS Investigative
DMHL0ID SN GTx-200; SARM (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), GTx; Selective androgen receptor modulator (hormone refractory prostate cancer), Merck & Co
DMHL0ID CP GTx Inc
DMHL0ID DE Prostate cancer
DMPXF5I ID DMPXF5I
DMPXF5I DN androstanol
DMPXF5I HS Investigative
DMPXF5I SN 5alpha-androstan-3alpha-ol
DMPXF5I DT Small molecular drug
DMPXF5I PC 92877
DMPXF5I MW 276.5
DMPXF5I FM C19H32O
DMPXF5I IC InChI=1S/C19H32O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h13-17,20H,3-12H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
DMPXF5I CS C[C@@]12CCC[C@H]1[C@@H]3CC[C@H]4C[C@H](CC[C@@]4([C@H]3CC2)C)O
DMPXF5I IK DJTOLSNIKJIDFF-LOVVWNRFSA-N
DMPXF5I IU (3S,5S,8S,9S,10S,13S,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMPXF5I CA CAS 1224-92-6
DMPXF5I DE Discovery agent
DMPL0BA ID DMPL0BA
DMPL0BA DN ANDROSTENEDONE
DMPL0BA HS Investigative
DMPL0BA SN androsta-1,4-diene-3,17-dione; Boldione; 1,4-Androstadiene-3,17-dione; 897-06-3; Androstadienedione; 1-Dehydroandrostenedione; NSC 49080; UNII-2166Q8568W; EINECS 212-977-2; ANDROSTA-1,4-DIEN-3,17-DIONE; CHEBI:40799; LUJVUUWNAPIQQI-QAGGRKNESA-N; Androstra-1,4-diene-3,17-dione; 2166Q8568W; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione; (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; ANB
DMPL0BA DT Small molecular drug
DMPL0BA PC 13472
DMPL0BA MW 284.4
DMPL0BA FM C19H24O2
DMPL0BA IC InChI=1S/C19H24O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
DMPL0BA CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)C=C[C@]34C
DMPL0BA IK LUJVUUWNAPIQQI-QAGGRKNESA-N
DMPL0BA IU (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-dione
DMPL0BA CA CAS 897-06-3
DMPL0BA CB CHEBI:40799
DMPL0BA DE Discovery agent
DM7RXQ6 ID DM7RXQ6
DM7RXQ6 DN androstenol
DM7RXQ6 HS Investigative
DM7RXQ6 SN 5alpha-Androst-16-en-3alpha-ol; Androstenol; 1153-51-1; Androst-16-en-3alpha-ol; 16,17-ANDROSTENE-3-OL; Androst-16-en-3-ol; 3alpha-Hydroxyandrost-16-ene; alpha-androstenol; UNII-48K9VAM062; (3alpha,5alpha)-Androst-16-en-3-ol; Androst-16-en-3-ol, (3alpha,5alpha)-; CHEMBL142348; CHEBI:40933; KRVXMNNRSSQZJP-PHFHYRSDSA-N; 48K9VAM062; Androst-16-en-3-ol, (3a,5a)-; androst-16-en-3-ol; 16,17-Androstene-3-Ol
DM7RXQ6 DT Small molecular drug
DM7RXQ6 PC 101989
DM7RXQ6 MW 274.4
DM7RXQ6 FM C19H30O
DM7RXQ6 IC InChI=1S/C19H30O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,13-17,20H,4-8,10-12H2,1-2H3/t13-,14+,15-,16-,17-,18-,19-/m0/s1
DM7RXQ6 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CC[C@@H]4[C@@]3(CC[C@H](C4)O)C
DM7RXQ6 IK KRVXMNNRSSQZJP-PHFHYRSDSA-N
DM7RXQ6 IU (3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM7RXQ6 CA CAS 1153-51-1
DM7RXQ6 CB CHEBI:40933
DM7RXQ6 DE Discovery agent
DMK1IMC ID DMK1IMC
DMK1IMC DN ANG-2004
DMK1IMC HS Investigative
DMK1IMC SN ANG-Leptin; EPiC-peptide conjugated leptin (obesity), AngioChem
DMK1IMC CP AngioChem Inc
DMK1IMC DE Obesity
DMDLVH5 ID DMDLVH5
DMDLVH5 DN ANG-2684
DMDLVH5 HS Investigative
DMDLVH5 SN ANG-3038; PARP-1 inhibitors (acute pancreatitis/stroke); PARP-1 inhibitors (acute pancreatitis/stroke), Angion Biomedica
DMDLVH5 CP Angion Biomedica Corp
DMDLVH5 DE Cerebrovascular ischaemia
DMQ2TNL ID DMQ2TNL
DMQ2TNL DN ANG-2864
DMQ2TNL HS Investigative
DMQ2TNL SN PARP inhibitor (ischemia/cancer), Angion Biomedica
DMQ2TNL CP Angion Biomedica Corp
DMQ2TNL DE Solid tumour/cancer
DMVI93X ID DMVI93X
DMVI93X DN ANG-3407
DMVI93X HS Investigative
DMVI93X SN CYP17 inhibitor (prostate tumor), Angion
DMVI93X CP Angion Biomedica Corp
DMVI93X DE Prostate cancer
DM3KZ7P ID DM3KZ7P
DM3KZ7P DN Angiostatin/paclitaxel/carboplatin
DM3KZ7P HS Investigative
DM3KZ7P CP EntreMed
DM3KZ7P DE Lung cancer
DMYK0Z9 ID DMYK0Z9
DMYK0Z9 DN angiotensin III
DMYK0Z9 HS Investigative
DMYK0Z9 SN ang III
DMYK0Z9 DT Small molecular drug
DMYK0Z9 PC 3082042
DMYK0Z9 MW 931.1
DMYK0Z9 FM C46H66N12O9
DMYK0Z9 IC InChI=1S/C46H66N12O9/c1-5-27(4)38(57-40(61)33(21-29-15-17-31(59)18-16-29)53-42(63)37(26(2)3)56-39(60)32(47)13-9-19-51-46(48)49)43(64)54-34(23-30-24-50-25-52-30)44(65)58-20-10-14-36(58)41(62)55-35(45(66)67)22-28-11-7-6-8-12-28/h6-8,11-12,15-18,24-27,32-38,59H,5,9-10,13-14,19-23,47H2,1-4H3,(H,50,52)(H,53,63)(H,54,64)(H,55,62)(H,56,60)(H,57,61)(H,66,67)(H4,48,49,51)/t27-,32-,33-,34-,35-,36-,37-,38-/m0/s1
DMYK0Z9 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)N
DMYK0Z9 IK QMMRCKSBBNJCMR-KMZPNFOHSA-N
DMYK0Z9 IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMYK0Z9 CA CAS 13602-53-4
DMYK0Z9 CB CHEBI:89666
DMYK0Z9 DE Discovery agent
DMR9OD1 ID DMR9OD1
DMR9OD1 DN Angiotensin IV
DMR9OD1 HS Investigative
DMR9OD1 SN Nle-angiv; Human angiotensin IV; Ile3-angiotensin IV; Huamn angiotensin (3-8); Ang IV; VAL-TYR-ILE-HIS-PRO-PHE; Angiotensin II (3-8), human; 1-De-asp-2-de-arg-5-ile-angiotensin II; (Ile5)-angiotensin II (3-8); Human angiotensin hexapeptide (3-8); (3-8)-5-Isoleucine-angiotensin II; (Des(Asp1,Arg2)-Ile5)angiotensin II; (Isoleucine5)-angiotensin II hexapeptide; CHEMBL261120; 12676-15-2; 5-Isoleucine-angiotensin II 3-8-hexapeptide; 23025-68-5; ANGIOTENSIN I/II (3-8); Angiotensin II (3-8); MLS000069773
DMR9OD1 DT Small molecular drug
DMR9OD1 PC 123814
DMR9OD1 MW 774.9
DMR9OD1 FM C40H54N8O8
DMR9OD1 IC InChI=1S/C40H54N8O8/c1-5-24(4)34(47-35(50)29(44-37(52)33(41)23(2)3)18-26-13-15-28(49)16-14-26)38(53)45-30(20-27-21-42-22-43-27)39(54)48-17-9-12-32(48)36(51)46-31(40(55)56)19-25-10-7-6-8-11-25/h6-8,10-11,13-16,21-24,29-34,49H,5,9,12,17-20,41H2,1-4H3,(H,42,43)(H,44,52)(H,45,53)(H,46,51)(H,47,50)(H,55,56)/t24-,29-,30-,31-,32-,33-,34-/m0/s1
DMR9OD1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)N
DMR9OD1 IK QSBGWDDCOJYQGY-KOQODJNWSA-N
DMR9OD1 IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMR9OD1 CA CAS 23025-68-5
DMR9OD1 CB CHEBI:80127
DMR9OD1 DE Discovery agent
DMGRWA3 ID DMGRWA3
DMGRWA3 DN ANHYDRORYANIDINE
DMGRWA3 HS Investigative
DMGRWA3 SN anhydroryanidine; CHEMBL283783; BDBM50044991; 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(2R,7S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate(Dehydroryanodine); 2,6,9,11,13,14-hexahydroxy-11-isopropyl-7,10-dimethyl-3-methylene-(1R,7S,9S,12R)-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadec-12-yl 1H-2-pyrrolecarboxylate
DMGRWA3 DT Small molecular drug
DMGRWA3 PC 44275813
DMGRWA3 MW 491.5
DMGRWA3 FM C25H33NO9
DMGRWA3 IC InChI=1S/C25H33NO9/c1-12(2)22(31)17(34-16(28)14-7-6-10-26-14)23(32)18(4)11-21(30)19(22,5)25(23,33)24(35-21)15(27)13(3)8-9-20(18,24)29/h6-7,10,12,15,17,26-27,29-33H,3,8-9,11H2,1-2,4-5H3/t15-,17-,18+,19?,20?,21?,22?,23?,24?,25?/m1/s1
DMGRWA3 CS CC(C)C1([C@H](C2([C@]3(CC4(C1(C2(C5(C3(CCC(=C)[C@H]5O)O)O4)O)C)O)C)O)OC(=O)C6=CC=CN6)O
DMGRWA3 IK BPFNBBLVUYSFRK-MKKQGFNNSA-N
DMGRWA3 IU [(2R,7S,12R)-2,6,9,11,13,14-hexahydroxy-7,10-dimethyl-3-methylidene-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMGRWA3 DE Discovery agent
DMJX1G9 ID DMJX1G9
DMJX1G9 DN ANIBAMINE
DMJX1G9 HS Investigative
DMJX1G9 SN anibamine TFA
DMJX1G9 DT Small molecular drug
DMJX1G9 PC 6479877
DMJX1G9 MW 424.7
DMJX1G9 FM C30H50N+
DMJX1G9 IC InChI=1S/C30H50N/c1-5-7-9-11-13-15-17-19-22-28-26(3)29(30-24-21-25-31(30)27(28)4)23-20-18-16-14-12-10-8-6-2/h19-20,22-23H,5-18,21,24-25H2,1-4H3/q+1/b22-19-,23-20-
DMJX1G9 CS CCCCCCCC/C=C\\C1=C(C(=C2CCC[N+]2=C1C)/C=C\\CCCCCCCC)C
DMJX1G9 IK LOTZSYKJMYSNJV-IKJQKJQYSA-N
DMJX1G9 IU 6,8-bis[(Z)-dec-1-enyl]-5,7-dimethyl-2,3-dihydro-1H-indolizin-4-ium
DMJX1G9 DE Discovery agent
DMJCWXK ID DMJCWXK
DMJCWXK DN Anidulafungin
DMJCWXK HS Investigative
DMJCWXK SN Ecalta; Eraxis; Anidulafungin [USAN:INN]; Ecalta (TN); Eraxis (TN); LY-303366; V-Echinocandin; VER-002
DMJCWXK CP Pfizer Pharmaceuticals
DMJCWXK TC Antiviral Agents
DMJCWXK DT Small molecular drug
DMJCWXK PC 166548
DMJCWXK MW 1140.2
DMJCWXK FM C58H73N7O17
DMJCWXK IC InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1
DMJCWXK CS CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O
DMJCWXK IK JHVAMHSQVVQIOT-MFAJLEFUSA-N
DMJCWXK IU N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
DMJCWXK CA CAS 166663-25-8
DMJCWXK CB CHEBI:55346
DMJCWXK DE Convulsion; Coronavirus Disease 2019 (COVID-19)
DMLCAR9 ID DMLCAR9
DMLCAR9 DN Aniline
DMLCAR9 HS Investigative
DMLCAR9 SN ANILINE; Aminobenzene; Aminophen; Anilin; Anilin [Czech]; Anilina; Anilina [Italian, Polish]; Aniline (and salts); Aniline and homologs; Aniline and homologues; Aniline oil; Aniline reagent; Anyvim; Arylamine; Benzenamine; Benzene, amino; Benzeneamine; Benzidam; Blue Oil; Cyanol; Krystallin; Kyanol; Phenylamine; RCRA waste no. U012; Rcra waste number U012; UN 1547; 62-53-3; C.I. 76000; C.I. Oxidation Base 1; CCRIS 44; CI Oxidation Base 1; Caswell No. 051C; HSDB 43; Huile D'aniline; Huile d'aniline [French]; NCI-C03736; UNII-SIR7XX2F1K
DMLCAR9 PC 6115
DMLCAR9 MW 93.13
DMLCAR9 FM C6H7N
DMLCAR9 IC PAYRUJLWNCNPSJ-UHFFFAOYSA-N
DMLCAR9 CS C1=CC=C(C=C1)N
DMLCAR9 IK 1S/C6H7N/c7-6-4-2-1-3-5-6/h1-5H,7H2
DMLCAR9 IU aniline
DMLCAR9 CA CAS 62-53-3
DMLCAR9 CB CHEBI:17296
DMLCAR9 DE Discovery agent
DMHA9S3 ID DMHA9S3
DMHA9S3 DN ANISOCOUMARIN H
DMHA9S3 HS Investigative
DMHA9S3 SN ANISOCOUMARIN H; 123237-86-5; 5'-hydroxyauraptene; MLS000863598; MEGxp0_000088; CHEMBL408980; ACon1_000064; MolPort-001-740-267; HMS2270P13; BDBM50375220; MCULE-1296401261; NCGC00168829-01; SMR000440765; BRD-A19484421-001-01-1
DMHA9S3 DT Small molecular drug
DMHA9S3 PC 14376449
DMHA9S3 MW 314.4
DMHA9S3 FM C19H22O4
DMHA9S3 IC InChI=1S/C19H22O4/c1-13(2)10-16(20)11-14(3)8-9-22-17-6-4-15-5-7-19(21)23-18(15)12-17/h4-8,10,12,16,20H,9,11H2,1-3H3/b14-8+
DMHA9S3 CS CC(=CC(C/C(=C/COC1=CC2=C(C=C1)C=CC(=O)O2)/C)O)C
DMHA9S3 IK VNADFOGBKXRWGC-RIYZIHGNSA-N
DMHA9S3 IU 7-[(2E)-5-hydroxy-3,7-dimethylocta-2,6-dienoxy]chromen-2-one
DMHA9S3 DE Discovery agent
DMZKC7S ID DMZKC7S
DMZKC7S DN Ankinara
DMZKC7S HS Investigative
DMZKC7S DE Rheumatoid arthritis; Psoriasis vulgaris; Inflammatory bowel disease
DM0RUQ8 ID DM0RUQ8
DM0RUQ8 DN ANNULIN A
DM0RUQ8 HS Investigative
DM0RUQ8 SN annulin A; CHEMBL465019; SCHEMBL10013625
DM0RUQ8 DT Small molecular drug
DM0RUQ8 PC 16059787
DM0RUQ8 MW 360.4
DM0RUQ8 FM C19H20O7
DM0RUQ8 IC InChI=1S/C19H20O7/c1-6-9-8(2)7-10-11(14(9)20)16(22)13-12(15(10)21)18(3,4)26-19(13,24)17(23)25-5/h7,20,24H,6H2,1-5H3
DM0RUQ8 CS CCC1=C(C2=C(C=C1C)C(=O)C3=C(C2=O)C(OC3(C)C)(C(=O)OC)O)O
DM0RUQ8 IK YRVWWGFREKZPIN-UHFFFAOYSA-N
DM0RUQ8 IU methyl 6-ethyl-3,5-dihydroxy-1,1,7-trimethyl-4,9-dioxobenzo[f][2]benzofuran-3-carboxylate
DM0RUQ8 DE Discovery agent
DMDQXJ2 ID DMDQXJ2
DMDQXJ2 DN ANNULIN B
DMDQXJ2 HS Investigative
DMDQXJ2 SN SCHEMBL10013624
DMDQXJ2 DT Small molecular drug
DMDQXJ2 PC 44559102
DMDQXJ2 MW 388.4
DMDQXJ2 FM C21H24O7
DMDQXJ2 IC InChI=1S/C21H24O7/c1-7-10-9(2)8-11-12(14(10)22)16(24)17-13(15(11)23)20(3,4)18(25)21(5,28-17)19(26)27-6/h8,13,17,22H,7H2,1-6H3
DMDQXJ2 CS CCC1=C(C2=C(C=C1C)C(=O)C3C(C2=O)OC(C(=O)C3(C)C)(C)C(=O)OC)O
DMDQXJ2 IK OHWPXNCKGWEEQM-UHFFFAOYSA-N
DMDQXJ2 IU methyl 8-ethyl-9-hydroxy-2,4,4,7-tetramethyl-3,5,10-trioxo-4a,10a-dihydrobenzo[g]chromene-2-carboxylate
DMDQXJ2 DE Discovery agent
DMTYQDO ID DMTYQDO
DMTYQDO DN ANNULIN C
DMTYQDO HS Investigative
DMTYQDO SN annulin C; CHEMBL518688; SCHEMBL10013628; BDBM50241707; methyl 7-ethyl-8-hydroxy-1-methoxy-3,3,6-trimethyl-4,9-dioxo-1,3,4,9-tetrahydronaphtho[2,3-c]furan-1-carboxylate
DMTYQDO DT Small molecular drug
DMTYQDO PC 16091658
DMTYQDO MW 374.4
DMTYQDO FM C20H22O7
DMTYQDO IC InChI=1S/C20H22O7/c1-7-10-9(2)8-11-12(15(10)21)17(23)14-13(16(11)22)19(3,4)27-20(14,26-6)18(24)25-5/h8,21H,7H2,1-6H3
DMTYQDO CS CCC1=C(C2=C(C=C1C)C(=O)C3=C(C2=O)C(OC3(C)C)(C(=O)OC)OC)O
DMTYQDO IK DSYKJFFQHNSURC-UHFFFAOYSA-N
DMTYQDO IU methyl 6-ethyl-5-hydroxy-3-methoxy-1,1,7-trimethyl-4,9-dioxobenzo[f][2]benzofuran-3-carboxylate
DMTYQDO DE Discovery agent
DM6DYZ0 ID DM6DYZ0
DM6DYZ0 DN ANOLOBINE
DM6DYZ0 HS Investigative
DM6DYZ0 SN Anolobine; Anolobin; Annolobine; AC1Q6ZQY; 641-17-8; (R)-6,7,7a,8-Tetrahydro-5H-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinolin-10-ol; CHEBI:2742; CHEMBL257746; Analobine; AC1L4VB7; CTK5C0739; DTXSID60214303; BDBM50202287; 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinolin-10-ol, 6,7,7a,8-tetrahydro-, (R)-; C09338; 5H-Benzo[g]-1,3-benzodioxolo[6,5,4-de]quinolin-10-ol,6,7,7a,8-tetrahydro-, (7aR)-
DM6DYZ0 DT Small molecular drug
DM6DYZ0 PC 164710
DM6DYZ0 MW 281.3
DM6DYZ0 FM C17H15NO3
DM6DYZ0 IC InChI=1S/C17H15NO3/c19-11-1-2-12-10(5-11)6-13-15-9(3-4-18-13)7-14-17(16(12)15)21-8-20-14/h1-2,5,7,13,18-19H,3-4,6,8H2/t13-/m1/s1
DM6DYZ0 CS C1CN[C@@H]2CC3=C(C=CC(=C3)O)C4=C2C1=CC5=C4OCO5
DM6DYZ0 IK LTSPCGWFQLHECP-CYBMUJFWSA-N
DM6DYZ0 IU (12R)-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14(19),15,17-hexaen-16-ol
DM6DYZ0 CA CAS 641-17-8
DM6DYZ0 CB CHEBI:2742
DM6DYZ0 DE Discovery agent
DMM5PEV ID DMM5PEV
DMM5PEV DN ANONAINE
DMM5PEV HS Investigative
DMM5PEV SN Anonaine; (-)-Anonaine; Anonain; (-)-Annonaine; 1862-41-5; CHEBI:76; (7ar)-6,7,7a,8-tetrahydro-5h-[1,3]benzodioxolo[6,5,4-de]benzo[g]quinoline; CHEMBL401798; AC1L4NWO; AC1Q6ZR1; SCHEMBL15800856; CTK4D9192; DTXSID00171865; BDBM50202322; C09339; A15375; 5H-Benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline,6,7,7a,8-tetrahydro-, (7aR)-; (R)-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-de]quinoline; 5H-Benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-, (R)-
DMM5PEV DT Small molecular drug
DMM5PEV PC 160597
DMM5PEV MW 265.31
DMM5PEV FM C17H15NO2
DMM5PEV IC InChI=1S/C17H15NO2/c1-2-4-12-10(3-1)7-13-15-11(5-6-18-13)8-14-17(16(12)15)20-9-19-14/h1-4,8,13,18H,5-7,9H2/t13-/m1/s1
DMM5PEV CS C1CN[C@@H]2CC3=CC=CC=C3C4=C2C1=CC5=C4OCO5
DMM5PEV IK VZTUKBKUWSHDFM-CYBMUJFWSA-N
DMM5PEV IU (12R)-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14,16,18-hexaene
DMM5PEV CA CAS 1862-41-5
DMM5PEV CB CHEBI:76
DMM5PEV DE Discovery agent
DMGDZ6Q ID DMGDZ6Q
DMGDZ6Q DN Antanal 1
DMGDZ6Q HS Investigative
DMGDZ6Q SN antanal 1; CHEMBL507442
DMGDZ6Q DT Small molecular drug
DMGDZ6Q PC 44568843
DMGDZ6Q MW 688.8
DMGDZ6Q FM C40H44N6O5
DMGDZ6Q IC InChI=1S/C40H44N6O5/c1-23-16-29(47)17-24(2)31(23)21-32(41)40(51)46-15-7-12-36(46)39(50)45-35(20-28-22-43-33-11-6-5-10-30(28)33)38(49)44-34(37(42)48)19-25-13-14-26-8-3-4-9-27(26)18-25/h3-6,8-11,13-14,16-18,22,32,34-36,43,47H,7,12,15,19-21,41H2,1-2H3,(H2,42,48)(H,44,49)(H,45,50)/t32-,34+,35-,36+/m0/s1
DMGDZ6Q CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC6=CC=CC=C6C=C5)C(=O)N)N)C)O
DMGDZ6Q IK RVBUBWGVXJZPJO-GIFUDOJISA-N
DMGDZ6Q IU (2R)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGDZ6Q DE Discovery agent
DMZSUHY ID DMZSUHY
DMZSUHY DN Antanal 2
DMZSUHY HS Investigative
DMZSUHY SN antanal 2; CHEMBL454035
DMZSUHY DT Small molecular drug
DMZSUHY PC 44568844
DMZSUHY MW 649.8
DMZSUHY FM C38H43N5O5
DMZSUHY IC InChI=1S/C38H43N5O5/c1-23-17-29(44)18-24(2)30(23)22-31(39)38(48)43-16-8-13-34(43)37(47)42-33(20-25-9-4-3-5-10-25)36(46)41-32(35(40)45)21-26-14-15-27-11-6-7-12-28(27)19-26/h3-7,9-12,14-15,17-19,31-34,44H,8,13,16,20-22,39H2,1-2H3,(H2,40,45)(H,41,46)(H,42,47)/t31-,32+,33-,34+/m0/s1
DMZSUHY CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N)N)C)O
DMZSUHY IK XQWLHPWPDQSALN-GJZXTFMBSA-N
DMZSUHY IU (2R)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMZSUHY DE Discovery agent
DMA7LUR ID DMA7LUR
DMA7LUR DN ANTAQ
DMA7LUR HS Investigative
DMA7LUR DT Small molecular drug
DMA7LUR PC 44381715
DMA7LUR MW 338.4
DMA7LUR FM C22H14N2O2
DMA7LUR IC InChI=1S/C22H14N2O2/c25-21-18-11-5-6-12-19(18)23-22(26)24(21)20-16-9-3-1-7-14(16)13-15-8-2-4-10-17(15)20/h1-13H,(H,23,26)
DMA7LUR CS C1=CC=C2C(=C1)C=C3C=CC=CC3=C2N4C(=O)C5=CC=CC=C5NC4=O
DMA7LUR IK SISSLRJYACXIQF-UHFFFAOYSA-N
DMA7LUR IU 3-anthracen-9-yl-1H-quinazoline-2,4-dione
DMA7LUR DE Discovery agent
DM7TOGW ID DM7TOGW
DM7TOGW DN antarelix
DM7TOGW HS Investigative
DM7TOGW SN EP 24332; D-23234
DM7TOGW DT Small molecular drug
DM7TOGW PC 16132443
DM7TOGW MW 1459.1
DM7TOGW FM C74H100ClN15O14
DM7TOGW IC InChI=1S/C74H100ClN15O14/c1-43(2)35-57(66(96)84-56(19-10-11-32-79-44(3)4)73(103)90-34-14-20-63(90)72(102)81-45(5)64(76)94)85-65(95)55(18-9-12-33-80-74(77)104)83-68(98)59(38-48-24-29-54(93)30-25-48)88-71(101)62(42-91)89-70(100)61(40-50-15-13-31-78-41-50)87-69(99)60(37-47-22-27-53(75)28-23-47)86-67(97)58(82-46(6)92)39-49-21-26-51-16-7-8-17-52(51)36-49/h7-8,13,15-17,21-31,36,41,43-45,55-63,79,91,93H,9-12,14,18-20,32-35,37-40,42H2,1-6H3,(H2,76,94)(H,81,102)(H,82,92)(H,83,98)(H,84,96)(H,85,95)(H,86,97)(H,87,99)(H,88,101)(H,89,100)(H3,77,80,104)/t45?,55-,56+,57+,58-,59+,60+,61-,62+,63-/m1/s1
DM7TOGW CS CC(C)C[C@@H](C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)NC(C)C(=O)N)NC(=O)[C@@H](CCCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM7TOGW IK NOENHWMKHNSHGX-FAZSUBJTSA-N
DM7TOGW IU (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(carbamoylamino)hexanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-(1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide
DM7TOGW CA CAS 151272-78-5
DM7TOGW DE Discovery agent
DMRQVW9 ID DMRQVW9
DMRQVW9 DN Anthoptilide C
DMRQVW9 HS Investigative
DMRQVW9 SN Anthoptilide C; CHEMBL496433
DMRQVW9 DT Small molecular drug
DMRQVW9 PC 21775681
DMRQVW9 MW 444.5
DMRQVW9 FM C25H32O7
DMRQVW9 IC InChI=1S/C25H32O7/c1-7-22(28)32-21-9-8-13(2)10-20-17(15(4)24(29)31-20)12-18-14(3)11-19(27)23(25(18,21)6)30-16(5)26/h10-11,18,20-21,23H,7-9,12H2,1-6H3/b13-10-/t18-,20-,21+,23-,25-/m0/s1
DMRQVW9 CS CCC(=O)O[C@@H]1CC/C(=C\\[C@H]2C(=C(C(=O)O2)C)C[C@@H]3[C@@]1([C@H](C(=O)C=C3C)OC(=O)C)C)/C
DMRQVW9 IK SOZYLLOAOCBQFQ-GUNDZKFLSA-N
DMRQVW9 IU [(1S,7S,8Z,12R,13S,14R)-14-acetyloxy-4,9,13,17-tetramethyl-5,15-dioxo-6-oxatricyclo[11.4.0.03,7]heptadeca-3,8,16-trien-12-yl] propanoate
DMRQVW9 DE Discovery agent
DMGEMQX ID DMGEMQX
DMGEMQX DN Anthracen-10-yl(10H-phenothiazin-10-yl)methanone
DMGEMQX HS Investigative
DMGEMQX SN CHEMBL392577; anthracen-10-yl(10H-phenothiazin-10-yl)methanone; BDBM50219206; 10-(9-Anthrylcarbonyl)Phenothiazine; Anthracen-9-yl (10H-phenothiazine-10yl) methanone, 5
DMGEMQX DT Small molecular drug
DMGEMQX PC 44435223
DMGEMQX MW 403.5
DMGEMQX FM C27H17NOS
DMGEMQX IC InChI=1S/C27H17NOS/c29-27(26-20-11-3-1-9-18(20)17-19-10-2-4-12-21(19)26)28-22-13-5-7-15-24(22)30-25-16-8-6-14-23(25)28/h1-17H
DMGEMQX CS C1=CC=C2C(=C1)C=C3C=CC=CC3=C2C(=O)N4C5=CC=CC=C5SC6=CC=CC=C64
DMGEMQX IK GEDDVJWUHICGPI-UHFFFAOYSA-N
DMGEMQX IU anthracen-9-yl(phenothiazin-10-yl)methanone
DMGEMQX DE Discovery agent
DMRC3OU ID DMRC3OU
DMRC3OU DN Anthracene-2-carboxylic acid hydroxyamide
DMRC3OU HS Investigative
DMRC3OU SN Anthracene-2-carboxylic acid hydroxyamide; CHEMBL175319; SCHEMBL10362855; Anthracene-2-carbohydroximic acid; BDBM50015189
DMRC3OU DT Small molecular drug
DMRC3OU PC 20227315
DMRC3OU MW 237.25
DMRC3OU FM C15H11NO2
DMRC3OU IC InChI=1S/C15H11NO2/c17-15(16-18)13-6-5-12-7-10-3-1-2-4-11(10)8-14(12)9-13/h1-9,18H,(H,16,17)
DMRC3OU CS C1=CC=C2C=C3C=C(C=CC3=CC2=C1)C(=O)NO
DMRC3OU IK YGGCUZPPJKJWPE-UHFFFAOYSA-N
DMRC3OU IU N-hydroxyanthracene-2-carboxamide
DMRC3OU DE Discovery agent
DMN1YFU ID DMN1YFU
DMN1YFU DN Anthraflavic acid
DMN1YFU HS Investigative
DMN1YFU SN APAJFZPFBHMFQR-UHFFFAOYSA-N; Anthraflavic acid; Anthraflavin; Anthrafravic acid; Anthraquinone, 2,6-dihydroxy-; W83883330W; 2,6-DIHYDROXY-ANTHRAQUINONE; 2,6-Dihydroxyanthra-9,10-quinone; 2,6-Dihydroxyanthraquinone; 2,6-dihydroxy-9,10-anthracenedione; 2,6-dihydroxy-9,10-anthraquinone; 2,6-dihydroxyanthracene-9,10-dione; 84-60-6; 9,10-Anthracenedione, 2,6-dihydroxy-; AK-86236; Az-F; BRN 2054127; CCRIS 5593; CHEBI:34250; CHEMBL298398; EINECS 201-544-3; MFCD00001228; NSC-33531; UNII-W83883330W
DMN1YFU PC 6776
DMN1YFU MW 240.21
DMN1YFU FM C14H8O4
DMN1YFU IC APAJFZPFBHMFQR-UHFFFAOYSA-N
DMN1YFU CS C1=CC2=C(C=C1O)C(=O)C3=C(C2=O)C=C(C=C3)O
DMN1YFU IK 1S/C14H8O4/c15-7-1-3-9-11(5-7)14(18)10-4-2-8(16)6-12(10)13(9)17/h1-6,15-16H
DMN1YFU IU 2,6-dihydroxyanthracene-9,10-dione
DMN1YFU CA CAS 84-60-6
DMN1YFU CB CHEBI:34250
DMN1YFU DE Discovery agent
DMNEGHJ ID DMNEGHJ
DMNEGHJ DN Anthramycin
DMNEGHJ HS Investigative
DMNEGHJ SN Antramycin; ANTHRAMYCIN; Anthramycin [USAN]; C16H17N3O4; Anthramycin (USAN); Antramycinum [INN-Latin]; Antramycine [INN-French]; Antramicina [INN-Spanish]; Antramycin (INN); Ro 5-9000; 4803-27-4; Antibiotic PBA; (E)-5,10,11,11a-Tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1H-pyrrolo(2,1-c)(1,4)-benzodiazepine-2-acrylamide; AC1NSJTB; AC1Q5IYM; SCHEMBL4513; CHEMBL39373; 1H-Pyrrolo(2,1-c)(1,4)benzodiazepine-2-acrylamide, 5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-, (E)-; 2-Propenamide, 3-(5,10,11,11a-tetrahydro-9,11-dihyd
DMNEGHJ PC 5311005
DMNEGHJ MW 315.32
DMNEGHJ FM C16H17N3O4
DMNEGHJ IC InChI=1S/C16H17N3O4/c1-8-2-4-10-13(14(8)21)18-15(22)11-6-9(3-5-12(17)20)7-19(11)16(10)23/h2-5,7,11,15,18,21-22H,6H2,1H3,(H2,17,20)/b5-3+
DMNEGHJ CS CC1=C(C2=C(C=C1)C(=O)N3C=C(CC3C(N2)O)/C=C/C(=O)N)O
DMNEGHJ IK VGQOVCHZGQWAOI-HWKANZROSA-N
DMNEGHJ IU (E)-3-(4,6-dihydroxy-3-methyl-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl)prop-2-enamide
DMNEGHJ DE Discovery agent
DM29I0Y ID DM29I0Y
DM29I0Y DN ANTHRAQUINONE
DM29I0Y HS Investigative
DM29I0Y SN 84-65-1; 9,10-Anthraquinone; anthracene-9,10-dione; 9,10-Anthracenedione; Anthradione; Hoelite; 9,10-Dioxoanthracene; Corbit; Morkit; 9,10-Anthrachinon; Anthra-9,10-quinone; Anthrapel; 9,10-quinone; Anthrachinon; Caswell No. 052A; Anthraquinone [BSI:ISO]; UNII-030MS0JBDO; NSC 7957; Bis-alkylamino anthraquinone; 9,10-Anthrachinon [Czech]; CCRIS 649; 9,10-Anthracendion; Anthracene, 9,10-dihydro-9,10-dioxo-; CHEBI:40448; HSDB 2074; EINECS 201-549-0; Anthracene-9,10-quinone; EPA Pesticide Chemical Code 122701
DM29I0Y DT Small molecular drug
DM29I0Y PC 6780
DM29I0Y MW 208.21
DM29I0Y FM C14H8O2
DM29I0Y IC InChI=1S/C14H8O2/c15-13-9-5-1-2-6-10(9)14(16)12-8-4-3-7-11(12)13/h1-8H
DM29I0Y CS C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O
DM29I0Y IK RZVHIXYEVGDQDX-UHFFFAOYSA-N
DM29I0Y IU anthracene-9,10-dione
DM29I0Y CA CAS 84-65-1
DM29I0Y CB CHEBI:40448
DM29I0Y DE Discovery agent
DMWZ093 ID DMWZ093
DMWZ093 DN ANTHRONE
DMWZ093 HS Investigative
DMWZ093 SN ANTHRONE; 90-44-8; 9(10H)-Anthracenone; Carbothrone; Anthranone; 9-Oxoanthracene; 9,10-Dihydro-9-oxoanthracene; 10H-anthracen-9-one; anthracen-9(10H)-one; Az-O; Anthracene, 9,10-dihydro-9-oxo-; UNII-FP0FJ7K744; CCRIS 3175; CHEBI:33835; HSDB 2158; NSC 1965; EINECS 201-994-0; AI3-11256; FP0FJ7K744; CHEMBL124440; 9-10-dihydro-9-oxoanthracene; 9,10-Dihydro-9-ketoanthracene; RJGDLRCDCYRQOQ-UHFFFAOYSA-N; MFCD00001187; Anthrone, ACS reagent; Anthrone, 95%, pure; 10-hydroanthracen-9-one; A-8100; 9-anthrone; Anthrone, 96%; AC1L1NTG
DMWZ093 DT Small molecular drug
DMWZ093 PC 7018
DMWZ093 MW 194.23
DMWZ093 FM C14H10O
DMWZ093 IC InChI=1S/C14H10O/c15-14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-8H,9H2
DMWZ093 CS C1C2=CC=CC=C2C(=O)C3=CC=CC=C31
DMWZ093 IK RJGDLRCDCYRQOQ-UHFFFAOYSA-N
DMWZ093 IU 10H-anthracen-9-one
DMWZ093 CA CAS 90-44-8
DMWZ093 CB CHEBI:33835
DMWZ093 DE Discovery agent
DM3IOR0 ID DM3IOR0
DM3IOR0 DN anti-BrP-LPA
DM3IOR0 HS Investigative
DM3IOR0 SN CHEMBL3621356; anti-BrP-LPA; GTPL6987; BDBM50187696; [(1S,3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid; Hexadecanoic acid (2S,4S)-2-hydroxy-4-bromo-4-(dihydroxyphosphinyl)butyl ester
DM3IOR0 DT Small molecular drug
DM3IOR0 PC 24771260
DM3IOR0 MW 487.4
DM3IOR0 FM C20H40BrO6P
DM3IOR0 IC InChI=1S/C20H40BrO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26/h18-19,22H,2-17H2,1H3,(H2,24,25,26)/t18-,19+/m0/s1
DM3IOR0 CS CCCCCCCCCCCCCCCC(=O)OC[C@H](C[C@@H](P(=O)(O)O)Br)O
DM3IOR0 IK HLVKVWDSLLFMSX-RBUKOAKNSA-N
DM3IOR0 IU [(1S,3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid
DM3IOR0 DE Discovery agent
DMQJ3ZL ID DMQJ3ZL
DMQJ3ZL DN Anticalin
DMQJ3ZL HS Investigative
DMQJ3ZL SN Anticalin (Alzheimer's disease)
DMQJ3ZL CP Pieris AG
DMQJ3ZL DE Alzheimer disease
DMEHRKA ID DMEHRKA
DMEHRKA DN Anti-CD20 engineered toxin bodies
DMEHRKA HS Investigative
DMEHRKA SN Anti-CD20 engineered toxin bodies (lymphoma); Anti-CD20 ETBs (lymphoma), Molecular Templates; Anti-CD20 engineered toxin bodies (lymphoma), Molecular Templates
DMEHRKA CP Molecular Templates Inc
DMEHRKA DE Lymphoma
DMCYOPR ID DMCYOPR
DMCYOPR DN Anti-CD-20 mab
DMCYOPR HS Investigative
DMCYOPR SN Anti-CD-20 mAb (undisclosed indication); Anti-CD-20 mAb (undisclosed indication), PharmAbcine; CD-20 inhibitor (mAb, undisclosed indication), PharmAbcine
DMCYOPR CP PharmAbcine
DMCYOPR DT Monoclonal antibody
DMCYOPR DE Discovery agent
DM8QIB2 ID DM8QIB2
DM8QIB2 DN Anti-CD22/CD19 mab-toxin conjugate
DM8QIB2 HS Investigative
DM8QIB2 CP Abiogen Pharma
DM8QIB2 DT Monoclonal antibody
DM8QIB2 DE Acute lymphoblastic leukaemia
DM5BH7J ID DM5BH7J
DM5BH7J DN Anti-CD28
DM5BH7J HS Investigative
DM5BH7J SN Anti-CD28 (immune disease); Anti-CD28 antibody (immune disorder), BMS; Anti-CD28 (immune disease), Bristol-Myers Squibb
DM5BH7J CP Bristol-Myers Squibb Co
DM5BH7J DT Antibody
DM5BH7J DE Immune System disease
DMGZM6V ID DMGZM6V
DMGZM6V DN Anti-CD40-XTEN
DMGZM6V HS Investigative
DMGZM6V SN CD40 ligand receptor antagonist (XTEN, rheumatoid arthritis/transplant rejection), Amunix
DMGZM6V CP Amunix Inc
DMGZM6V DE Rheumatoid arthritis
DM2X1SG ID DM2X1SG
DM2X1SG DN Anti-cMET mab
DM2X1SG HS Investigative
DM2X1SG SN Anti-cMET mAb (undisclosed indication); Anti-cMET mAb (undisclosed indication), PharmAbcine; CMET inhibitor (mAb, undisclosed indication), PharmAbcine
DM2X1SG CP PharmAbcine
DM2X1SG DT Monoclonal antibody
DM2X1SG DE Discovery agent
DMG7PC0 ID DMG7PC0
DMG7PC0 DN Anti-D
DMG7PC0 HS Investigative
DMG7PC0 SN (2-Amino-D-glucose Hydrochloride); glu-cosamine hydrochloride; 3h-glucosamine hydrochloride; SCHEMBL21212; SPECTRUM1500316; MolPort-003-666-196; Pharmakon1600-01500316; HMS1920B13; NSC757051; CCG-39600
DMG7PC0 DT Small molecular drug
DMG7PC0 PC 9859210
DMG7PC0 MW 215.63
DMG7PC0 FM C6H14ClNO5
DMG7PC0 IC InChI=1S/C6H13NO5.ClH/c7-3-5(10)4(9)2(1-8)12-6(3)11;/h2-6,8-11H,1,7H2;1H/t2-,3-,4-,5-,6-;/m1./s1
DMG7PC0 CS C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)O.Cl
DMG7PC0 IK QKPLRMLTKYXDST-OCOFDJSDSA-N
DMG7PC0 IU (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride
DMG7PC0 CA CAS 66-84-2
DMG7PC0 DE Idiopathic thrombocytopenic purpura
DMWLMV2 ID DMWLMV2
DMWLMV2 DN Anti-EGFR humanized mabs
DMWLMV2 HS Investigative
DMWLMV2 SN Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor
DMWLMV2 CP Xencor Inc
DMWLMV2 DT Antibody
DMWLMV2 DE Solid tumour/cancer
DMW85FP ID DMW85FP
DMW85FP DN Anti-EGFR mab
DMW85FP HS Investigative
DMW85FP CP GTC Biotherapeutics Inc
DMW85FP DT Antibody
DMW85FP DE Discovery agent
DMXWHDC ID DMXWHDC
DMXWHDC DN Anti-Fas mabs
DMXWHDC HS Investigative
DMXWHDC SN Anti-Fas mAbs (misfolded proteins, cancer); Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Apexigen; Anticancer monoclonal antibodies (misfolded Fas receptor-targeting), Amorfix/Epitomics; Anti-Fas mAbs (misfolded proteins, cancer), Amorfix/Apexigen
DMXWHDC CP Amorfix Life Sciences Ltd
DMXWHDC DT Antibody
DMXWHDC DE Solid tumour/cancer
DMP5VZQ ID DMP5VZQ
DMP5VZQ DN Anti-FGFR1 mab program
DMP5VZQ HS Investigative
DMP5VZQ SN Anti-FGFR1 mAb program (cancer); Anti-FGFR1 mAb program (cancer), AVEO Pharmaceuticals; Anti-fibroblast growth factor receptor-1 monoclonal antibody program (cancer), AVEO Pharmaceuticals
DMP5VZQ CP Cardiovascular biotherapeutics
DMP5VZQ DT Antibody
DMP5VZQ DE Solid tumour/cancer
DMMQ3WX ID DMMQ3WX
DMMQ3WX DN Anti-FGFR2 humanized mab
DMMQ3WX HS Investigative
DMMQ3WX SN HuGAL-FR21; HuGAL-FR22; Anti-FGFR2 humanized mAb (cancer); Anti-FGFR2 humanized mAb (cancer), Galaxy
DMMQ3WX CP Galaxy Biotech LLC
DMMQ3WX DT Antibody
DMMQ3WX DE Solid tumour/cancer
DM4HKC8 ID DM4HKC8
DM4HKC8 DN Anti-GnRH Spiegelmer
DM4HKC8 HS Investigative
DM4HKC8 DE Discovery agent
DMVF2YH ID DMVF2YH
DMVF2YH DN Antileukoprotease (ALP)
DMVF2YH HS Investigative
DMVF2YH DE Discovery agent
DMO41UZ ID DMO41UZ
DMO41UZ DN Anti-miR-191 modified oligonucleotide
DMO41UZ HS Investigative
DMO41UZ DT Antisense drug
DMO41UZ DE Hepatocellular carcinoma
DM2EMCW ID DM2EMCW
DM2EMCW DN Antimycin A
DM2EMCW HS Investigative
DM2EMCW SN Antimycin A; Antipiricullin; Fintrol; Virosin; Antimycin A1b; antimycin A1; Caswell No. 052B; Antimycin-A; CCRIS 924; HSDB 6417; UNII-75G3NMU1TS; EPA Pesticide Chemical Code 006314; 75G3NMU1TS; CHEMBL211501; CHEBI:22584; 1397-94-0; (2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl 3-methylbutanoate; 642-15-9; 116095-18-2; [(2r,3s,6s,7r,8r)-3-[(3-Formamido-2-Oxidanyl-Phenyl)carbonylamino]-8-Hexyl-2,6-Dimethyl-4,9-Bis(Oxidanylidene)-1,5-Dioxonan-7-Yl] 3-Methylbutanoate
DM2EMCW DT Small molecular drug
DM2EMCW PC 14957
DM2EMCW MW 548.6
DM2EMCW FM C28H40N2O9
DM2EMCW IC InChI=1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1
DM2EMCW CS CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C
DM2EMCW IK UIFFUZWRFRDZJC-SBOOETFBSA-N
DM2EMCW IU [(2R,3S,6S,7R,8R)-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate
DM2EMCW CA CAS 1397-94-0
DM2EMCW CB CHEBI:22584
DM2EMCW DE Discovery agent
DMUESP8 ID DMUESP8
DMUESP8 DN ANTIOQUINE
DMUESP8 HS Investigative
DMUESP8 SN CHEMBL452904; Antioquine (S,R); SCHEMBL6044740
DMUESP8 DT Small molecular drug
DMUESP8 PC 10393931
DMUESP8 MW 608.7
DMUESP8 FM C37H40N2O6
DMUESP8 IC InChI=1S/C37H40N2O6/c1-38-12-10-23-18-32(43-4)33-20-25(23)28(38)16-21-6-8-30(40)26(14-21)27-15-22(7-9-31(27)42-3)17-29-35-24(11-13-39(29)2)19-34(44-5)36(41)37(35)45-33/h6-9,14-15,18-20,28-29,40-41H,10-13,16-17H2,1-5H3/t28-,29+/m1/s1
DMUESP8 CS CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC(=C(C=C4)O)C5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC
DMUESP8 IK MNNXIEANPHEHSB-WDYNHAJCSA-N
DMUESP8 IU (1R,14S)-9,20,25-trimethoxy-15,30-dimethyl-23-oxa-15,30-diazaheptacyclo[22.6.2.13,7.18,12.114,18.027,31.022,33]pentatriaconta-3(35),4,6,8,10,12(34),18,20,22(33),24,26,31-dodecaene-6,21-diol
DMUESP8 CA CAS 93767-27-2
DMUESP8 DE Discovery agent
DM9THZE ID DM9THZE
DM9THZE DN Antiproliferative Agent A771726
DM9THZE HS Investigative
DM9THZE SN AC1L1BPO; 2-cyano-3-hydroxy-n-(4-trifluoromethyl-phenyl)-butyramide
DM9THZE DT Small molecular drug
DM9THZE PC 17753809
DM9THZE MW 272.22
DM9THZE FM C12H11F3N2O2
DM9THZE IC InChI=1S/C12H11F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,7,10,18H,1H3,(H,17,19)/t7-,10-/m1/s1
DM9THZE CS C[C@H]([C@@H](C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
DM9THZE IK YODXEQNROKSLLQ-GMSGAONNSA-N
DM9THZE IU (2R,3R)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]butanamide
DM9THZE DE Discovery agent
DMO21T7 ID DMO21T7
DMO21T7 DN Anti-PSA mabs
DMO21T7 HS Investigative
DMO21T7 SN Anti-PSA IgG1; Anti-PSA IgG3; Anti-PSA mAbs (prostate cancer); Anti-PSA mAbs (prostate cancer), University of California/AIT; Anti-PSA monoclonal antibodies (prostate cancer), University of California/Advanced Immune Therapeutics
DMO21T7 CP Advanced Immune Therapeutics Inc
DMO21T7 DT Antibody
DMO21T7 DE Prostate cancer
DMXACM2 ID DMXACM2
DMXACM2 DN Anti-RON receptor mabs
DMXACM2 HS Investigative
DMXACM2 SN AV-368 series; Hu-07F01; Hu-29B06; Anti-RON receptor mAbs (cancer); Anti-RON receptor mAbs (cancer), AVEO Pharmaceuticals; Anti-RON receptor mAbs (cancer), Centocor Ortho Biotech
DMXACM2 CP AVEO Pharmaceuticals Inc
DMXACM2 DT Antibody
DMXACM2 DE Solid tumour/cancer
DMN76A4 ID DMN76A4
DMN76A4 DN Anti-TLR3 mabs
DMN76A4 HS Investigative
DMN76A4 SN Anti-TLR3 mAbs (autoimmune and inflammatory disorders)
DMN76A4 CP Innate Pharma SA
DMN76A4 DT Monoclonal antibody
DMN76A4 DE Autoimmune diabetes
DMYKTF6 ID DMYKTF6
DMYKTF6 DN Anti-TNF human mabs
DMYKTF6 HS Investigative
DMYKTF6 SN Anti-TNF human mAbs (autoimmune disease); Anti-TNF human mAbs (autoimmune disease), Xencor; Anti-TNF human monoclonal antibodies (autoimmune disease), Xencor
DMYKTF6 CP Xencor Inc
DMYKTF6 DT Antibody
DMYKTF6 DE Autoimmune diabetes
DMAJ6TC ID DMAJ6TC
DMAJ6TC DN Anti-VEGFR 3 mab
DMAJ6TC HS Investigative
DMAJ6TC SN Anti-VEGFR 3 mAb (undisclosed indication); Anti-VEGFR 3 mAb (undisclosed indication), PharmAbcine; Vascular endothelial growth factor receptor 3 inhibitor (mAb, undisclosed indication), PharmAbcine
DMAJ6TC CP PharmAbcine
DMAJ6TC DT Monoclonal antibody
DMAJ6TC DE Discovery agent
DML1PV3 ID DML1PV3
DML1PV3 DN Aom-0763
DML1PV3 HS Investigative
DML1PV3 SN Aim-0763; Xanthine oxidase inhibitor (oral/tablet, gout), Hangzhou Adamerck Pharmlabs
DML1PV3 CP Hangzhou Adamerck Pharmlabs Inc
DML1PV3 DE Gout
DMT4I2W ID DMT4I2W
DMT4I2W DN Aom-0890
DMT4I2W HS Investigative
DMT4I2W SN Aom-0891; PDE5 inhibitors (oral/tablet, erectile dysfunction); PDE5 inhibitors (oral/tablet, erectile dysfunction), Hangzhou Adamerck
DMT4I2W CP Hangzhou Adamerck Pharmlabs Inc
DMT4I2W DE Erectile dysfunction
DMHR3ZG ID DMHR3ZG
DMHR3ZG DN AP-101
DMHR3ZG HS Investigative
DMHR3ZG CP Aprogen Inc
DMHR3ZG DE Ischemia
DMRZMKT ID DMRZMKT
DMRZMKT DN AP-1189
DMRZMKT HS Investigative
DMRZMKT SN AP-1089; Melanocortin receptor-1 modulator (oral, inflammation), Action Pharma
DMRZMKT CP Action Pharma A/S
DMRZMKT DE Atopic dermatitis
DMCNG74 ID DMCNG74
DMCNG74 DN AP-21967
DMCNG74 HS Investigative
DMCNG74 SN CHEMBL525042; AP-21967; SCHEMBL18176922; C-16-(S)-7-methylindolerapamycin
DMCNG74 PC 44576241
DMCNG74 MW 1017.3
DMCNG74 FM C59H88N2O12
DMCNG74 IC InChI=1S/C59H88N2O12/c1-34-17-12-11-13-18-35(2)45(46-33-60-52-36(3)19-16-20-44(46)52)31-43-24-22-41(8)59(69,73-43)56(66)57(67)61-26-15-14-21-47(61)58(68)72-50(38(5)29-42-23-25-48(62)51(30-42)70-9)32-49(63)37(4)28-40(7)54(65)55(71-10)53(64)39(6)27-34/h11-13,16-20,28,33-34,37-39,41-43,45,47-51,53-55,60,62-65,69H,14-15,21-27,29-32H2,1-10H3/b13-11+,17-12+,35-18+,40-28+/t34-,37-,38-,39-,41-,42+,43+,45+,47+,48-,49+,50+,51-,53+,54-,55+,59-/m1/s1
DMCNG74 CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H]([C@@H]([C@@H]([C@@H](/C(=C/[C@H]([C@H](C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)O)C)/C)O)OC)O)C)C)/C)C5=CNC6=C(C=CC=C56)C
DMCNG74 IK PSLNMAUXUJLNBW-OUPLBGLBSA-N
DMCNG74 IU (1R,9S,12S,14S,15R,16E,18R,19S,20S,21R,23S,24E,26E,28E,30S,32S,35R)-1,14,18,20-tetrahydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-30-(7-methyl-1H-indol-3-yl)-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10-trione
DMCNG74 DE Discovery agent
DMQWIEL ID DMQWIEL
DMQWIEL DN AP-2238
DMQWIEL HS Investigative
DMQWIEL SN AP-2238; UNII-545225E0BC; CHEMBL75121; 545225E0BC; 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone; AP2238; 553681-56-4; BDBM10949; 2H-1-Benzopyran-2-one, 6,7-dimethoxy-3-(4-((methyl(phenylmethyl)amino)methyl)phenyl)-
DMQWIEL DT Small molecular drug
DMQWIEL PC 9844749
DMQWIEL MW 415.5
DMQWIEL FM C26H25NO4
DMQWIEL IC InChI=1S/C26H25NO4/c1-27(16-18-7-5-4-6-8-18)17-19-9-11-20(12-10-19)22-13-21-14-24(29-2)25(30-3)15-23(21)31-26(22)28/h4-15H,16-17H2,1-3H3
DMQWIEL CS CN(CC1=CC=CC=C1)CC2=CC=C(C=C2)C3=CC4=CC(=C(C=C4OC3=O)OC)OC
DMQWIEL IK KXMCSAUVAHKCOR-UHFFFAOYSA-N
DMQWIEL IU 3-[4-[[benzyl(methyl)amino]methyl]phenyl]-6,7-dimethoxychromen-2-one
DMQWIEL CA CAS 553681-56-4
DMQWIEL DE Discovery agent
DMRYL9X ID DMRYL9X
DMRYL9X DN AP-2243
DMRYL9X HS Investigative
DMRYL9X SN AP-2243; CHEMBL244416; BDBM50218528; 3-{4-[(benzylethylamino)methyl]phenyl}-6,7-dimethoxychromen-2-one
DMRYL9X DT Small molecular drug
DMRYL9X PC 23643351
DMRYL9X MW 429.5
DMRYL9X FM C27H27NO4
DMRYL9X IC InChI=1S/C27H27NO4/c1-4-28(17-19-8-6-5-7-9-19)18-20-10-12-21(13-11-20)23-14-22-15-25(30-2)26(31-3)16-24(22)32-27(23)29/h5-16H,4,17-18H2,1-3H3
DMRYL9X CS CCN(CC1=CC=CC=C1)CC2=CC=C(C=C2)C3=CC4=CC(=C(C=C4OC3=O)OC)OC
DMRYL9X IK PNZIOQNBQOTGPK-UHFFFAOYSA-N
DMRYL9X IU 3-[4-[[benzyl(ethyl)amino]methyl]phenyl]-6,7-dimethoxychromen-2-one
DMRYL9X DE Discovery agent
DMVT6Y3 ID DMVT6Y3
DMVT6Y3 DN AP-24163
DMVT6Y3 HS Investigative
DMVT6Y3 SN AP-24163; CHEMBL539433; 926922-16-9; 3-{(E)-2-[6-(Cyclopropylamino)-9h-Purin-9-Yl]ethenyl}-4-Methyl-N-[3-(4-Methyl-1h-Imidazol-1-Yl)-5-(Trifluoromethyl)phenyl]benzamide; Benzamide,3-[(1E)-2-[6-(cyclopropylamino)-9H-purin-9-yl]ethenyl]-4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-; 3kfa; SCHEMBL4129401; SCHEMBL4129397; ZINC42919869; BDBM50294011; AP24163; KB-74929; 3-(2-(6-(cyclopropylamino)-9H-purin-9-yl)vinyl)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide
DMVT6Y3 DT Small molecular drug
DMVT6Y3 PC 44517649
DMVT6Y3 MW 558.6
DMVT6Y3 FM C29H25F3N8O
DMVT6Y3 IC InChI=1S/C29H25F3N8O/c1-17-3-4-20(9-19(17)7-8-39-16-36-25-26(37-22-5-6-22)33-14-34-27(25)39)28(41)38-23-10-21(29(30,31)32)11-24(12-23)40-13-18(2)35-15-40/h3-4,7-16,22H,5-6H2,1-2H3,(H,38,41)(H,33,34,37)/b8-7+
DMVT6Y3 CS CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)/C=C/N4C=NC5=C(N=CN=C54)NC6CC6
DMVT6Y3 IK XQBYDVRVYRYLCH-BQYQJAHWSA-N
DMVT6Y3 IU 3-[(E)-2-[6-(cyclopropylamino)purin-9-yl]ethenyl]-4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]benzamide
DMVT6Y3 DE Discovery agent
DMGTEXD ID DMGTEXD
DMGTEXD DN AP-24226
DMGTEXD HS Investigative
DMGTEXD SN AP-24226; UNII-53D46B0TIH; AP24226; 926922-22-7; 53D46B0TIH; CHEMBL556874; SCHEMBL4135035; SCHEMBL4135027; ZINC43058954; BDBM50294010; KB-74711; Benzamide, 3-((1E)-2-(6-(cyclopropylamino)-9H-purin-9-yl)ethenyl)-4-methyl-N-(4-(trifluoromethyl)-2-pyridinyl)-; 3-(2-(6-(cyclopropylamino)-9H-purin-9-yl)vinyl)-4-methyl-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide
DMGTEXD DT Small molecular drug
DMGTEXD PC 25210550
DMGTEXD MW 479.5
DMGTEXD FM C24H20F3N7O
DMGTEXD IC InChI=1S/C24H20F3N7O/c1-14-2-3-16(23(35)33-19-11-17(6-8-28-19)24(25,26)27)10-15(14)7-9-34-13-31-20-21(32-18-4-5-18)29-12-30-22(20)34/h2-3,6-13,18H,4-5H2,1H3,(H,28,33,35)(H,29,30,32)/b9-7+
DMGTEXD CS CC1=C(C=C(C=C1)C(=O)NC2=NC=CC(=C2)C(F)(F)F)/C=C/N3C=NC4=C(N=CN=C43)NC5CC5
DMGTEXD IK PPHMKXKASWTCSZ-VQHVLOKHSA-N
DMGTEXD IU 3-[(E)-2-[6-(cyclopropylamino)purin-9-yl]ethenyl]-4-methyl-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide
DMGTEXD CA CAS 926922-22-7
DMGTEXD DE Discovery agent
DMBU942 ID DMBU942
DMBU942 DN AP-7
DMBU942 HS Investigative
DMBU942 SN 2-Amino-7-phosphonoheptanoic acid; DL-AP7; 78966-69-5; DL-2-Amino-7-phosphonoheptanoic acid; NSC672105; 85797-13-3; BRN 3544152; CHEMBL274440; Heptanoic acid, 2-amino-7-phosphono-, (+-)-; 2-Amino-7-phosphono-heptanoic acid; Heptanoic acid, 2-amino-7-phosphono-; (+/-)-2-Amino-7-phosphonoheptanoic acid; C7H16NO5P; AP-7 compound; L(+)-2-Amino-7-phosphonoheptanoic acid; AP-7 (drug); AC1L1F7W; Lopac0_000008; SCHEMBL154303; CTK7D4156; ( inverted question mark)-AP-7; MYDMWESTDPJANS-UHFFFAOYSA-N; MolPort-002-514-441
DMBU942 DT Small molecular drug
DMBU942 PC 3122
DMBU942 MW 225.18
DMBU942 FM C7H16NO5P
DMBU942 IC InChI=1S/C7H16NO5P/c8-6(7(9)10)4-2-1-3-5-14(11,12)13/h6H,1-5,8H2,(H,9,10)(H2,11,12,13)
DMBU942 CS C(CCC(C(=O)O)N)CCP(=O)(O)O
DMBU942 IK MYDMWESTDPJANS-UHFFFAOYSA-N
DMBU942 IU 2-amino-7-phosphonoheptanoic acid
DMBU942 CA CAS 85797-13-3
DMBU942 DE Discovery agent
DMILA4P ID DMILA4P
DMILA4P DN AP811
DMILA4P HS Investigative
DMILA4P SN AP-811; AP 811
DMILA4P DT Small molecular drug
DMILA4P PC 73755108
DMILA4P MW 914.1
DMILA4P FM C47H67N11O8
DMILA4P IC InChI=1S/C47H67N11O8/c1-6-28(3)27-53-43(63)36(14-11-23-52-47(49)50)56-45(65)38(26-40(60)61)57-46(66)41(29(4)7-2)58-44(64)37(15-10-22-51-30(5)48)55-39(59)24-31-16-20-35(21-17-31)54-42(62)34-19-18-32-12-8-9-13-33(32)25-34/h8-9,12-13,16-21,25,28-29,36-38,41H,6-7,10-11,14-15,22-24,26-27H2,1-5H3,(H2,48,51)(H,53,63)(H,54,62)(H,55,59)(H,56,65)(H,57,66)(H,58,64)(H,60,61)(H4,49,50,52)/t28-,29-,36-,37-,38-,41-/m0/s1
DMILA4P CS CC[C@H](C)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCN=C(C)N)NC(=O)CC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3C=C2
DMILA4P IK SSSOLDGLOKWDSV-VLDRZRDYSA-N
DMILA4P IU (3S)-3-[[(2S,3S)-2-[[(2S)-5-(1-aminoethylideneamino)-2-[[2-[4-(naphthalene-2-carbonylamino)phenyl]acetyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-2-methylbutyl]amino]-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMILA4P DE Discovery agent
DMVG3K1 ID DMVG3K1
DMVG3K1 DN APA
DMVG3K1 HS Investigative
DMVG3K1 SN 1-Aminooxy-3-aminopropane; 3-aminooxy-1-aminopropane; O-(3-aminopropyl)hydroxylamine; 98532-00-4; CHEMBL281021; 1-Propanamine, 3-(aminooxy)-; 3-Aminooxy-1-propanamine; XAP; 3-Aminooxypropylamine; 3-(aminooxy)propan-1-amine; GTPL5139; AC1L22F5; CTK3I7322; DTXSID20243634; BDBM50005719; AKOS006348478; (APA)O-(3-Amino-propyl)-hydroxylamine; O-(3-Aminopropyl)hydroxylamine,; 1-aminooxy-3-aminopropane
DMVG3K1 DT Small molecular drug
DMVG3K1 PC 65020
DMVG3K1 MW 90.12
DMVG3K1 FM C3H10N2O
DMVG3K1 IC InChI=1S/C3H10N2O/c4-2-1-3-6-5/h1-5H2
DMVG3K1 CS C(CN)CON
DMVG3K1 IK VSZFWDPIWSPZON-UHFFFAOYSA-N
DMVG3K1 IU O-(3-aminopropyl)hydroxylamine
DMVG3K1 CA CAS 98532-00-4
DMVG3K1 DE Discovery agent
DMYNBK5 ID DMYNBK5
DMYNBK5 DN Apamin
DMYNBK5 HS Investigative
DMYNBK5 SN 08APA001_SMARTOX; GTPL2311; 08APA001; Apamin, synthetic, > Apamin, from bee venom, >
DMYNBK5 DT Small molecular drug
DMYNBK5 PC 16218850
DMYNBK5 MW 2027.4
DMYNBK5 FM C79H131N31O24S4
DMYNBK5 IC InChI=1S/C79H131N31O24S4/c1-35(2)26-49-70(127)107-51-31-136-135-30-41(81)63(120)105-50(28-57(84)114)71(128)108-53(73(130)99-42(12-7-8-22-80)64(121)96-38(5)77(134)110-25-11-15-54(110)75(132)102-47(18-21-58(115)116)69(126)109-59(39(6)111)76(133)95-37(4)62(119)104-49)33-138-137-32-52(106-66(123)44(14-10-24-92-79(88)89)98-65(122)43(13-9-23-91-78(86)87)97-61(118)36(3)94-72(51)129)74(131)101-45(16-19-55(82)112)67(124)100-46(17-20-56(83)113)68(125)103-48(60(85)117)27-40-29-90-34-93-40/h29,34-39,41-54,59,111H,7-28,30-33,80-81H2,1-6H3,(H2,82,112)(H2,83,113)(H2,84,114)(H2,85,117)(H,90,93)(H,94,129)(H,95,133)(H,96,121)(H,97,118)(H,98,122)(H,99,130)(H,100,124)(H,101,131)(H,102,132)(H,103,125)(H,104,119)(H,105,120)(H,106,123)(H,107,127)(H,108,128)(H,109,126)(H,115,116)(H4,86,87,91)(H4,88,89,92)/t36-,37-,38-,39+,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,59-/m0/s1
DMYNBK5 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)N)C(=O)N1)CC(C)C)C)[C@@H](C)O)CCC(=O)O)C)CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N)CCCNC(=N)N)CCCNC(=N)N
DMYNBK5 IK YVIIHEKJCKCXOB-STYWVVQQSA-N
DMYNBK5 IU 3-[(1R,4S,7S,13S,16S,19S,22S,25S,28R,31S,34S,37S,40R,47S,50R)-50-amino-40-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-amino-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]-4-(4-aminobutyl)-47-(2-amino-2-oxoethyl)-34,37-bis(3-carbamimidamidopropyl)-19-[(1R)-1-hydroxyethyl]-7,22,31-trimethyl-25-(2-methylpropyl)-2,5,8,14,17,20,23,26,29,32,35,38,46,49-tetradecaoxo-42,43,52,53-tetrathia-3,6,9,15,18,21,24,27,30,33,36,39,45,48-tetradecazatricyclo[26.16.10.09,13]tetrapentacontan-16-yl]propanoic acid
DMYNBK5 DE Discovery agent
DMNIEHV ID DMNIEHV
DMNIEHV DN APC-300
DMNIEHV HS Investigative
DMNIEHV SN CPC-300
DMNIEHV CP Colby Pharmaceuticals
DMNIEHV DE Prostate cancer
DMT9Z5A ID DMT9Z5A
DMT9Z5A DN AP-Cav
DMT9Z5A HS Investigative
DMT9Z5A SN AP-Cav
DMT9Z5A DT Small molecular drug
DMT9Z5A PC 24779772
DMT9Z5A MW 607.2
DMT9Z5A FM C33H51ClN2O6
DMT9Z5A IC InChI=1S/C20H30NO3.C13H21NO3.ClH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;4-6,12,14-17H,7-8H2,1-3H3;1H/q+1;;/p-1/t16-,17+,18?,19?,21?;12-;/m.0./s1
DMT9Z5A CS CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)[O-])CO)O.Cl
DMT9Z5A IK ABSQYTODNZGQMD-ORLLXICISA-M
DMT9Z5A IU 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolate;[(1R,5S)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;hydrochloride
DMT9Z5A DE Discovery agent
DMNQ9M1 ID DMNQ9M1
DMNQ9M1 DN APCK-110
DMNQ9M1 HS Investigative
DMNQ9M1 SN APcK-110MD; C-Kit inhibitors (cancer); C-Kit inhibitors (cancer), MD Anderson
DMNQ9M1 CP MD Anderson Cancer Center
DMNQ9M1 DE Solid tumour/cancer
DM2CKUZ ID DM2CKUZ
DM2CKUZ DN apelin-13
DM2CKUZ HS Investigative
DM2CKUZ SN [Pyr1]-Apelin-13
DM2CKUZ DT Small molecular drug
DM2CKUZ PC 25078060
DM2CKUZ MW 1550.8
DM2CKUZ FM C69H111N23O16S
DM2CKUZ IC InChI=1S/C69H111N23O16S/c1-39(2)32-47(86-58(98)44(17-9-26-78-68(73)74)83-63(103)52-20-12-29-91(52)65(105)45(18-10-27-79-69(75)76)84-56(96)42(71)22-23-54(72)94)59(99)89-50(37-93)61(101)87-48(34-41-35-77-38-81-41)60(100)82-43(16-7-8-25-70)57(97)80-36-55(95)90-28-11-19-51(90)62(102)85-46(24-31-109-3)66(106)92-30-13-21-53(92)64(104)88-49(67(107)108)33-40-14-5-4-6-15-40/h4-6,14-15,35,38-39,42-53,93H,7-13,16-34,36-37,70-71H2,1-3H3,(H2,72,94)(H,77,81)(H,80,97)(H,82,100)(H,83,103)(H,84,96)(H,85,102)(H,86,98)(H,87,101)(H,88,104)(H,89,99)(H,107,108)(H4,73,74,78)(H4,75,76,79)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
DM2CKUZ CS CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N
DM2CKUZ IK XXCCRHIAIBQDPX-PEWBXTNBSA-N
DM2CKUZ IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DM2CKUZ CB CHEBI:80131
DM2CKUZ DE Discovery agent
DM0JW2V ID DM0JW2V
DM0JW2V DN APETX2
DM0JW2V HS Investigative
DM0JW2V TC Analgesics
DM0JW2V PC 90488973
DM0JW2V MW 4561
DM0JW2V FM C196H280N54O61S6
DM0JW2V IC InChI=1S/C196H280N54O61S6/c1-12-94(4)152-186(303)230-125(71-107-48-56-112(263)57-49-107)169(286)229-126(72-108-77-209-114-34-20-19-33-113(108)114)170(287)228-122(67-103-31-17-14-18-32-103)167(284)227-123(69-105-44-52-110(261)53-45-105)165(282)223-118(38-25-61-208-196(204)205)190(307)248-62-26-40-141(248)183(300)235-133(86-254)177(294)241-139-92-317-316-91-138(181(298)247-157(101(11)259)192(309)250-64-28-39-140(250)182(299)215-95(5)158(275)232-129(193(310)311)75-151(273)274)239-180(297)137-90-315-313-88-135(236-159(276)96(6)216-187(304)154(98(8)256)242-144(265)76-198)179(296)234-132(85-253)176(293)237-134(163(280)213-79-146(267)218-127(73-143(199)264)171(288)233-131(84-252)175(292)221-115(35-21-22-58-197)160(277)211-81-148(269)243-152)87-312-314-89-136(178(295)222-117(37-24-60-207-195(202)203)164(281)225-124(70-106-46-54-111(262)55-47-106)168(285)226-121(66-102-29-15-13-16-30-102)166(283)224-119(65-93(2)3)162(279)212-82-149(270)244-155(99(9)257)188(305)240-137)238-174(291)130(83-251)219-147(268)80-214-185(302)153(97(7)255)245-173(290)120(68-104-42-50-109(260)51-43-104)217-145(266)78-210-161(278)116(36-23-59-206-194(200)201)220-172(289)128(74-150(271)272)231-189(306)156(100(10)258)246-184(301)142-41-27-63-249(142)191(139)308/h13-20,29-34,42-57,77,93-101,115-142,152-157,209,251-263H,12,21-28,35-41,58-76,78-92,197-198H2,1-11H3,(H2,199,264)(H,210,278)(H,211,277)(H,212,279)(H,213,280)(H,214,302)(H,215,299)(H,216,304)(H,217,266)(H,218,267)(H,219,268)(H,220,289)(H,221,292)(H,222,295)(H,223,282)(H,224,283)(H,225,281)(H,226,285)(H,227,284)(H,228,287)(H,229,286)(H,230,303)(H,231,306)(H,232,275)(H,233,288)(H,234,296)(H,235,300)(H,236,276)(H,237,293)(H,238,291)(H,239,297)(H,240,305)(H,241,294)(H,242,265)(H,243,269)(H,244,270)(H,245,290)(H,246,301)(H,247,298)(H,271,272)(H,273,274)(H,310,311)(H4,200,201,206)(H4,202,203,207)(H4,204,205,208)
DM0JW2V CS CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC3CSSCC(NC(=O)C4CSSCC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N4)C(C)O)CC(C)C)CC5=CC=CC=C5)CC6=CC=C(C=C6)O)CCCNC(=N)N)NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C7CCCN7C3=O)C(C)O)CC(=O)O)CCCNC(=N)N)CC8=CC=C(C=C8)O)C(C)O)CO)C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N1)CCCCN)CO)CC(=O)N)CO)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)CN)C(=O)NC(C(C)O)C(=O)N9CCCC9C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)O)CO)CCCNC(=N)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CC1=CC=C(C=C1)O
DM0JW2V IK HEHYILNFEUDIQC-UHFFFAOYSA-N
DM0JW2V IU 2-[2-[[1-[2-[[52-[2-[[2-[(2-aminoacetyl)amino]-3-hydroxybutanoyl]amino]propanoylamino]-34-(4-aminobutyl)-40-(2-amino-2-oxoethyl)-19,69-dibenzyl-28-butan-2-yl-13,75,96-tris(3-carbamimidamidopropyl)-99-(carboxymethyl)-2a,60,87-tris(1-hydroxyethyl)-4,37,49,81-tetrakis(hydroxymethyl)-16,25,72,90-tetrakis[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-66-(2-methylpropyl)-1a,3,4a,6,10a,12,15,17a,18,21,24,27,30,33,36,39,42,45,48,51,59,62,65,68,71,74,77,80,83,86,89,92,95,98-tetratriacontaoxo-12a,13a,19a,20a,54,55-hexathia-a,2,3a,5,9a,11,14,16a,17,20,23,26,29,32,35,38,41,44,47,50,58,61,64,67,70,73,76,79,82,85,88,91,94,97-tetratriacontazapentacyclo[55.53.7.446,78.07,11.0105,109]henicosahectane-15a-carbonyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]propanoylamino]butanedioic acid
DM0JW2V DE Pain
DMR93WE ID DMR93WE
DMR93WE DN APG-103
DMR93WE HS Investigative
DMR93WE SN CD95 receptor inhibitor (inflammatory disease), Apogenix
DMR93WE CP Apogenix GmbH
DMR93WE DE Inflammation
DM0BVJN ID DM0BVJN
DM0BVJN DN APG-201
DM0BVJN HS Investigative
DM0BVJN SN Protein-based apoptosis sensitizer (cancer), Apogenix
DM0BVJN CP Apogenix Biotechnology AG
DM0BVJN DE Solid tumour/cancer
DMBSDTR ID DMBSDTR
DMBSDTR DN APG-2305
DMBSDTR HS Investigative
DMBSDTR SN APG-2303; APG-2307; APG-2309; IL-23 receptor inhibitor (oral, autoimmune disease), Allostera
DMBSDTR CP Allostera Pharma Inc
DMBSDTR DE Autoimmune diabetes
DMYGKW7 ID DMYGKW7
DMYGKW7 DN APH-0911
DMYGKW7 HS Investigative
DMYGKW7 SN Docetaxel prodrug (oral nanoparticle formulation), Aphios; Paclitaxel prodrug (oral formulation), Aphios; Docetaxel prodrug (water-soluble), Aphios; Paclitaxel prodrug (water-soluble), Aphios; 10alpha-GAG-docetaxel
DMYGKW7 CP Aphios Corp
DMYGKW7 DE Solid tumour/cancer
DM83WVF ID DM83WVF
DM83WVF DN Apicidin
DM83WVF HS Investigative
DM83WVF SN CHEMBL430060; OSI-2040; (3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone; Acipidin; AC1OCFAM; Apicidin _120249; SCHEMBL147997; ChEMBL_275631; GTPL7495; DTXSID40274182; MolPort-005-944-562; BDBM50238632; ZINC17654900; AKOS030622920; MCULE-8969470747; NCGC00165733-01
DM83WVF DT Small molecular drug
DM83WVF PC 6918328
DM83WVF MW 623.8
DM83WVF FM C34H49N5O6
DM83WVF IC InChI=1S/C34H49N5O6/c1-5-22(3)30-34(44)38-19-13-12-18-29(38)33(43)35-26(16-9-7-8-14-24(40)6-2)31(41)36-27(32(42)37-30)20-23-21-39(45-4)28-17-11-10-15-25(23)28/h10-11,15,17,21-22,26-27,29-30H,5-9,12-14,16,18-20H2,1-4H3,(H,35,43)(H,36,41)(H,37,42)/t22-,26-,27-,29+,30-/m0/s1
DM83WVF CS CC[C@H](C)[C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC
DM83WVF IK JWOGUUIOCYMBPV-GMFLJSBRSA-N
DM83WVF IU (3S,6S,9S,12R)-3-[(2S)-butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone
DM83WVF DE Solid tumour/cancer
DMI3491 ID DMI3491
DMI3491 DN Apigenin
DMI3491 HS Investigative
DMI3491 SN apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Chamomile; Versulin; Spigenin; Apigenol; 4',5,7-Trihydroxyflavone; Apigenine; C.I. Natural Yellow 1; 5,7,4'-Trihydroxyflavone; Pelargidenon 1449; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; UCCF 031; NSC 83244; UNII-7V515PI7F6; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 3789; CHEBI:18388; CHEMBL28; EINECS 208-292-3; 4H-1-Benzopyran-4-one, 5,7-di
DMI3491 DT Small molecular drug
DMI3491 PC 5280443
DMI3491 MW 270.24
DMI3491 FM C15H10O5
DMI3491 IC InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H
DMI3491 CS C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DMI3491 IK KZNIFHPLKGYRTM-UHFFFAOYSA-N
DMI3491 IU 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMI3491 CA CAS 520-36-5
DMI3491 CB CHEBI:18388
DMI3491 DE Discovery agent
DMIQOXH ID DMIQOXH
DMIQOXH DN Apigenin-7-O-beta-D-glucuronide
DMIQOXH HS Investigative
DMIQOXH SN 29741-09-1; Apigenin-7-glucuronide; Apigenin 7-O-b-glucuronide; Apigenin 7-glucuronide; apigenin-7-o-glucuronide; UNII-2CQ5KB3CH0; 2CQ5KB3CH0; CHEMBL254213; Scutellarin A; Apigenin 7-O-glucuronide; Apigenin 7-beta-glucuronide; apigenin-7-O-beta-D-glucuronide; Apigenin 7-O-beta-D-glucuronide; Apigenin-7-O-beta-D-glucuronoside; Apigenin 7-O-beta-D-glucuronopyranoside; AC1NSY61; MEGxp0_000795; SCHEMBL2400851; ACon1_001025; DTXSID10183893; MolPort-001-740-947; apigenin-7-O-betaD-glucuronic acid; HY-N1454; Apigenin 7-O-.beta.-D-glucur
DMIQOXH DT Small molecular drug
DMIQOXH PC 5319484
DMIQOXH MW 446.4
DMIQOXH FM C21H18O11
DMIQOXH IC InChI=1S/C21H18O11/c22-9-3-1-8(2-4-9)13-7-12(24)15-11(23)5-10(6-14(15)31-13)30-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21-23,25-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1
DMIQOXH CS C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O
DMIQOXH IK JBFOLLJCGUCDQP-ZFORQUDYSA-N
DMIQOXH IU (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid
DMIQOXH CA CAS 29741-09-1
DMIQOXH DE Discovery agent
DMP7J0I ID DMP7J0I
DMP7J0I DN Apigenin-7-O-beta-D-glucuronide methyl ester
DMP7J0I HS Investigative
DMP7J0I SN 53538-13-9; (2S,3S,4S,5R,6S)-Methyl 3,4,5-trihydroxy-6-((5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylate; CHEMBL464868; Apigenin 7-O-methylglucuronide; apigenin-7-O-beta-D-glucuronide methyl ester; MolPort-035-684-098; Apigenin 7-(6-O-methylglucuronide); ZINC40874044; BDBM50251270; AKOS024258585; AJ-103820; ST24034139
DMP7J0I DT Small molecular drug
DMP7J0I PC 13844658
DMP7J0I MW 460.4
DMP7J0I FM C22H20O11
DMP7J0I IC InChI=1S/C22H20O11/c1-30-21(29)20-18(27)17(26)19(28)22(33-20)31-11-6-12(24)16-13(25)8-14(32-15(16)7-11)9-2-4-10(23)5-3-9/h2-8,17-20,22-24,26-28H,1H3/t17-,18-,19+,20-,22+/m0/s1
DMP7J0I CS COC(=O)[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=CC(=C3C(=C2)OC(=CC3=O)C4=CC=C(C=C4)O)O)O)O)O
DMP7J0I IK XXKIWCKZQFBXIR-SXFAUFNYSA-N
DMP7J0I IU methyl (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylate
DMP7J0I DE Discovery agent
DM6NM8V ID DM6NM8V
DM6NM8V DN APLYSAMINE
DM6NM8V HS Investigative
DM6NM8V SN Aplysamine-1; APLYSAMINE; NSC625525; CHEMBL380697; 3-(2,6-Dibromo-4-(2-(dimethylamino)ethyl)phenoxy)-N,N-dimethyl-1-propanamine; AC1L7JVE; AC1Q25RU; BDBM50177729; NSC-625525; 3-[2,6-dibromo-4-(2-dimethylaminoethyl)phenoxy]-N,N-dimethyl-propan-1-amine; 3-(2,6-dibromo-4-(2-(dimethylamino)ethyl)phenoxy)-N,N-dimethylpropan-1-amine; N-(3-(2,6-Dibromo-4-(2-(dimethylamino)ethyl)phenoxy)propyl)-N,N-dimethylamine; 3-[2,6-dibromo-4-(2-dimethylaminoethyl)phenoxy]-N,N-dimethylpropan-1-amine
DM6NM8V DT Small molecular drug
DM6NM8V PC 362025
DM6NM8V MW 408.17
DM6NM8V FM C15H24Br2N2O
DM6NM8V IC InChI=1S/C15H24Br2N2O/c1-18(2)7-5-9-20-15-13(16)10-12(11-14(15)17)6-8-19(3)4/h10-11H,5-9H2,1-4H3
DM6NM8V CS CN(C)CCCOC1=C(C=C(C=C1Br)CCN(C)C)Br
DM6NM8V IK LWENJEAGCYZOBC-UHFFFAOYSA-N
DM6NM8V IU 3-[2,6-dibromo-4-[2-(dimethylamino)ethyl]phenoxy]-N,N-dimethylpropan-1-amine
DM6NM8V DE Discovery agent
DMUPL3J ID DMUPL3J
DMUPL3J DN Aplysinopsin
DMUPL3J HS Investigative
DMUPL3J DT Small molecular drug
DMUPL3J PC 135476741
DMUPL3J MW 254.29
DMUPL3J FM C14H14N4O
DMUPL3J IC InChI=1S/C14H14N4O/c1-17-12(13(19)18(2)14(17)15)7-9-8-16-11-6-4-3-5-10(9)11/h3-8,15,19H,1-2H3/b9-7+,15-14?
DMUPL3J CS CN1C(=C(N(C1=N)C)O)/C=C/2\\C=NC3=CC=CC=C32
DMUPL3J IK CYKDGQFRORUDQP-YHUDWFPJSA-N
DMUPL3J IU 2-imino-5-[(Z)-indol-3-ylidenemethyl]-1,3-dimethylimidazol-4-ol
DMUPL3J CA CAS 63153-56-0
DMUPL3J DE Discovery agent
DMW45GK ID DMW45GK
DMW45GK DN APNEA
DMW45GK HS Investigative
DMW45GK SN 89705-21-5; CHEMBL1256714; N-[2-(4-Aminophenyl)ethyl]-adenosine; SMR000326823; MLS000859964; MLS002153195; SCHEMBL1230660; DTXSID40433272; XTPOZVLRZZIEBW-SCFUHWHPSA-N; HMS2233B08; ZINC8660412; BDBM50453442; AKOS030526973; CS-4923; Adenosine, N6-2-(4-aminophenyl)ethyl; HY-18687; LS-15099; N6-2-(4-Aminophenyl)ethyladenosine, >
DMW45GK DT Small molecular drug
DMW45GK PC 9952135
DMW45GK MW 386.4
DMW45GK FM C18H22N6O4
DMW45GK IC InChI=1S/C18H22N6O4/c19-11-3-1-10(2-4-11)5-6-20-16-13-17(22-8-21-16)24(9-23-13)18-15(27)14(26)12(7-25)28-18/h1-4,8-9,12,14-15,18,25-27H,5-7,19H2,(H,20,21,22)/t12-,14-,15-,18-/m1/s1
DMW45GK CS C1=CC(=CC=C1CCNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DMW45GK IK XTPOZVLRZZIEBW-SCFUHWHPSA-N
DMW45GK IU (2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMW45GK CA CAS 89705-21-5
DMW45GK DE Discovery agent
DM7OPCH ID DM7OPCH
DM7OPCH DN Apogossypol
DM7OPCH HS Investigative
DM7OPCH SN BI-79D10; BI-97C1; CNDO-103; CNDO-133
DM7OPCH CP Sanford-Burnham Medical Research Institute
DM7OPCH DT Small molecular drug
DM7OPCH PC 454878
DM7OPCH MW 462.5
DM7OPCH FM C28H30O6
DM7OPCH IC InChI=1S/C28H30O6/c1-11(2)21-15-7-13(5)23(25(31)17(15)9-19(29)27(21)33)24-14(6)8-16-18(26(24)32)10-20(30)28(34)22(16)12(3)4/h7-12,29-34H,1-6H3
DM7OPCH CS CC1=CC2=C(C(=C(C=C2C(=C1C3=C(C4=CC(=C(C(=C4C=C3C)C(C)C)O)O)O)O)O)O)C(C)C
DM7OPCH IK PBJKWGWHZVXBGU-UHFFFAOYSA-N
DM7OPCH IU 3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol
DM7OPCH CA CAS 475-56-9
DM7OPCH DE Solid tumour/cancer
DMPH7EO ID DMPH7EO
DMPH7EO DN Apomorphine SL
DMPH7EO HS Investigative
DMPH7EO SN Apomorphine HCl; Apomorphine chloride; (R)-(-)-Apomorphine hydrochloride; Apomorphinium chloride; Apomorphin hydrochlorid; 314-19-2; pomorphini hydrochloridum; Apomorphinum hydrochloricum; N-Methylnorapomorphine hydrochloride; UNII-9K13MD7A0D; (-)-Apomorphinium hydrochloride; Apomorphine hydrochloride anhydrous; EINECS 206-243-0; NSC 11442; 9K13MD7A0D; 6a-beta-Aporphine-10,11-diol, hydrochloride; 6abeta-Noraporphine-10,11-diol, 6-methyl-, hyd
DMPH7EO DT Small molecular drug
DMPH7EO PC 9410
DMPH7EO MW 303.8
DMPH7EO FM C17H18ClNO2
DMPH7EO IC InChI=1S/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H/t13-;/m1./s1
DMPH7EO CS CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.Cl
DMPH7EO IK SKYZYDSNJIOXRL-BTQNPOSSSA-N
DMPH7EO IU (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;hydrochloride
DMPH7EO CA CAS 314-19-2
DMPH7EO DE Discovery agent
DM0VBUL ID DM0VBUL
DM0VBUL DN Aprophen
DM0VBUL HS Investigative
DM0VBUL SN Aprofene; Aprophen; Aprofen; Aprophenum; Aprofene [INN]; 3563-01-7; 2-Diethylaminoethyl 2,2-diphenylpropionate; Aprofenum [INN-Latin]; Aprofeno [INN-Spanish]; UNII-PL791XXJ7B; PL791XXJ7B; CHEMBL26505; 2-(Diethylamino)ethyl 2,2-diphenylpropanoate; 2,2-Diphenylpropionic acid 2-diethylaminoethyl ester; BRN 2509326; NCGC00160676-01; Propionic acid, 2,2-diphenyl-, 2-(diethylamino)ethyl ester; DSSTox_CID_26294; DSSTox_RID_81519; DSSTox_GSID_46294; alpha,alpha-Diphenylpropionic acid beta-diethylaminoethyl ester
DM0VBUL DT Small molecular drug
DM0VBUL PC 71128
DM0VBUL MW 325.4
DM0VBUL FM C21H27NO2
DM0VBUL IC InChI=1S/C21H27NO2/c1-4-22(5-2)16-17-24-20(23)21(3,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15H,4-5,16-17H2,1-3H3
DM0VBUL CS CCN(CC)CCOC(=O)C(C)(C1=CC=CC=C1)C2=CC=CC=C2
DM0VBUL IK DIDYGLSKVUKRRP-UHFFFAOYSA-N
DM0VBUL IU 2-(diethylamino)ethyl 2,2-diphenylpropanoate
DM0VBUL CA CAS 3563-01-7
DM0VBUL DE Discovery agent
DM8DOBG ID DM8DOBG
DM8DOBG DN APS-3010
DM8DOBG HS Investigative
DM8DOBG SN Hepatic growth factor inhibitor (cancer), Atlas Pharmaceuticals
DM8DOBG CP Atlas Pharmaceuticals Inc
DM8DOBG DE Solid tumour/cancer
DMF1264 ID DMF1264
DMF1264 DN Aptiganel HCl
DMF1264 HS Investigative
DMF1264 SN Cerestat; CNS-1102; Aptiganel HCl; APTIGANEL HYDROCHLORIDE; UNII-40PWH14OXW; Cns 1102; 137160-11-3; 40PWH14OXW; NCGC00093759-01; DSSTox_CID_25762; DSSTox_RID_81104; DSSTox_GSID_45762; CHEMBL554054; N-(1-Naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine hcl; SMR000326976; CAS-137160-11-3; AC1Q3CFJ; MLS001056791; MLS000862213; SCHEMBL871689; AC1L1U12; DTXSID9045762; MolPort-003-940-636; CKAKVKWRMCAYJD-UHFFFAOYSA-N; Tox21_500312; Tox21_111220; Tox21_111220_1; AKOS025293480; CCG-221616; LP00312; NCGC00015236-04; NCGC00260997-01; CNS-1102, >9
DMF1264 DT Small molecular drug
DMF1264 PC 60839
DMF1264 MW 339.9
DMF1264 FM C20H22ClN3
DMF1264 IC InChI=1S/C20H21N3.ClH/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19;/h4-14H,3H2,1-2H3,(H2,21,22);1H
DMF1264 CS CCC1=CC(=CC=C1)N(C)C(=NC2=CC=CC3=CC=CC=C32)N.Cl
DMF1264 IK CKAKVKWRMCAYJD-UHFFFAOYSA-N
DMF1264 IU 1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine;hydrochloride
DMF1264 CA CAS 137160-11-3
DMF1264 DE Ischemic stroke
DMCOMLS ID DMCOMLS
DMCOMLS DN APY29
DMCOMLS HS Investigative
DMCOMLS SN 1216665-49-4; APY 29; APY-29; N~2~-1h-Benzimidazol-5-Yl-N~4~-(3-Cyclopropyl-1h-Pyrazol-5-Yl)pyrimidine-2,4-Diamine; N2-1H-Benzimidazol-6-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine; N2-(1H-benzo[d]imidazol-6-yl)-N4-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; (E)-N-(6-((5-cyclopropyl-1H-pyrazol-3-yl)imino)-1,6-dihydropyrimidin-2-yl)-1H-benzo[d]imidazol-6-amine; APY 29;APY-29; CHEMBL1231018; SCHEMBL12045464; SCHEMBL20438003; SCHEMBL21067744; EX-A305; BCP09071; MFCD28023582; s6623; ZINC40163635; AKOS024458384; DB07382; 2-N-(3H-benzimidazol-5-yl)-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine; NCGC00379217-02; NCGC00379217-03; AK547105; BS-14553; DA-47145; HY-17537; QC-11386; AB0098417; FT-0700119; J3.589.967G; Q27096602; 2,4-Pyrimidinediamine, N2-1H-benzimidazol-6-yl-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-
DMCOMLS DT Small molecular drug
DMCOMLS PC 42627755
DMCOMLS MW 332.4
DMCOMLS FM C17H16N8
DMCOMLS IC InChI=1S/C17H16N8/c1-2-10(1)13-8-16(25-24-13)22-15-5-6-18-17(23-15)21-11-3-4-12-14(7-11)20-9-19-12/h3-10H,1-2H2,(H,19,20)(H3,18,21,22,23,24,25)
DMCOMLS CS C1CC1C2=CC(=NN2)NC3=NC(=NC=C3)NC4=CC5=C(C=C4)N=CN5
DMCOMLS IK WJNBSTLIALIIEW-UHFFFAOYSA-N
DMCOMLS IU 2-N-(3H-benzimidazol-5-yl)-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
DMCOMLS DE Solid tumour/cancer
DMK2XB7 ID DMK2XB7
DMK2XB7 DN AR-00341677
DMK2XB7 HS Investigative
DMK2XB7 SN GDC-0879; Anticancer program, Array/Genentech; B-Raf kinase inhibitors (cancer), Array/Genentech
DMK2XB7 CP Array BioPharma Inc
DMK2XB7 DT Small molecular drug
DMK2XB7 PC 25093303
DMK2XB7 MW 334.4
DMK2XB7 FM C19H18N4O2
DMK2XB7 IC InChI=1S/C19H18N4O2/c24-10-9-23-12-17(19(21-23)13-5-7-20-8-6-13)15-1-3-16-14(11-15)2-4-18(16)22-25/h1,3,5-8,11-12,24-25H,2,4,9-10H2/b22-18-
DMK2XB7 CS C1C/C(=N/O)/C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO
DMK2XB7 IK DEZZLWQELQORIU-PYCFMQQDSA-N
DMK2XB7 IU 2-[4-[(1Z)-1-hydroxyimino-2,3-dihydroinden-5-yl]-3-pyridin-4-ylpyrazol-1-yl]ethanol
DMK2XB7 CA CAS 905281-76-7
DMK2XB7 CB CHEBI:91434
DMK2XB7 DE Solid tumour/cancer
DMUSYKG ID DMUSYKG
DMUSYKG DN AR-129330
DMUSYKG HS Investigative
DMUSYKG SN CHEMBL193438; CHEMBL537846; SCHEMBL3938380; SCHEMBL3941081; SCHEMBL3938377; CHEMBL1188966; NWUCPBLQECHRFK-QAQDUYKDSA-N; BDBM50170189; BDBM50166555; trans-4-bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide; 4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide
DMUSYKG DT Small molecular drug
DMUSYKG PC 9895867
DMUSYKG MW 653
DMUSYKG FM C25H30BrClF3N5O3S
DMUSYKG IC InChI=1S/C25H29BrF3N5O3S.ClH/c1-34(2)23-19-5-3-4-6-20(19)32-24(33-23)30-14-16-7-9-17(10-8-16)15-31-38(35,36)22-12-11-18(26)13-21(22)37-25(27,28)29;/h3-6,11-13,16-17,31H,7-10,14-15H2,1-2H3,(H,30,32,33);1H
DMUSYKG CS CN(C)C1=NC(=NC2=CC=CC=C21)NCC3CCC(CC3)CNS(=O)(=O)C4=C(C=C(C=C4)Br)OC(F)(F)F.Cl
DMUSYKG IK SMEDDEAAKQVMQD-UHFFFAOYSA-N
DMUSYKG IU 4-bromo-N-[[4-[[[4-(dimethylamino)quinazolin-2-yl]amino]methyl]cyclohexyl]methyl]-2-(trifluoromethoxy)benzenesulfonamide;hydrochloride
DMUSYKG DE Discovery agent
DMN8W46 ID DMN8W46
DMN8W46 DN AR231453
DMN8W46 HS Investigative
DMN8W46 SN AR-231,453; AR 231453; AR-231453
DMN8W46 DT Small molecular drug
DMN8W46 PC 24939268
DMN8W46 MW 505.5
DMN8W46 FM C21H24FN7O5S
DMN8W46 IC InChI=1S/C21H24FN7O5S/c1-12(2)18-26-21(34-27-18)13-6-8-28(9-7-13)20-17(29(30)31)19(23-11-24-20)25-16-5-4-14(10-15(16)22)35(3,32)33/h4-5,10-13H,6-9H2,1-3H3,(H,23,24,25)
DMN8W46 CS CC(C)C1=NOC(=N1)C2CCN(CC2)C3=NC=NC(=C3[N+](=O)[O-])NC4=C(C=C(C=C4)S(=O)(=O)C)F
DMN8W46 IK DGBKNTVAKIFYNU-UHFFFAOYSA-N
DMN8W46 IU N-(2-fluoro-4-methylsulfonylphenyl)-5-nitro-6-[4-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]pyrimidin-4-amine
DMN8W46 CA CAS 733750-99-7
DMN8W46 DE Discovery agent
DMTN10D ID DMTN10D
DMTN10D DN AR234960
DMTN10D HS Investigative
DMTN10D SN AR 234960; AR-234960
DMTN10D DT Small molecular drug
DMTN10D PC 89560738
DMTN10D MW 555.6
DMTN10D FM C27H30FN5O5S
DMTN10D IC InChI=1S/C27H30FN5O5S/c1-38-25-16-23(33(34)35)8-9-26(25)39(36,37)32-18-21(24(19-32)20-5-4-6-22(28)15-20)17-30-11-13-31(14-12-30)27-7-2-3-10-29-27/h2-10,15-16,21,24H,11-14,17-19H2,1H3
DMTN10D CS COC1=C(C=CC(=C1)[N+](=O)[O-])S(=O)(=O)N2CC(C(C2)C3=CC(=CC=C3)F)CN4CCN(CC4)C5=CC=CC=N5
DMTN10D IK TUSCHIFEASZBBF-UHFFFAOYSA-N
DMTN10D IU 1-[[4-(3-fluorophenyl)-1-(2-methoxy-4-nitrophenyl)sulfonylpyrrolidin-3-yl]methyl]-4-pyridin-2-ylpiperazine
DMTN10D DE Discovery agent
DM68QY0 ID DM68QY0
DM68QY0 DN AR244555
DM68QY0 HS Investigative
DM68QY0 SN AR 244555; AR-244555
DM68QY0 DT Small molecular drug
DM68QY0 PC 59004159
DM68QY0 MW 416.9
DM68QY0 FM C23H23ClF2N2O
DM68QY0 IC InChI=1S/C23H23ClF2N2O/c1-2-3-11-27-12-9-23(10-13-27)15-28(20-8-7-16(24)14-17(20)23)22(29)21-18(25)5-4-6-19(21)26/h2,4-8,14H,1,3,9-13,15H2
DM68QY0 CS C=CCCN1CCC2(CC1)CN(C3=C2C=C(C=C3)Cl)C(=O)C4=C(C=CC=C4F)F
DM68QY0 IK QKPSTNGNDWHYCH-UHFFFAOYSA-N
DM68QY0 IU (1'-but-3-enyl-5-chlorospiro[2H-indole-3,4'-piperidine]-1-yl)-(2,6-difluorophenyl)methanone
DM68QY0 DE Discovery agent
DMNJ632 ID DMNJ632
DMNJ632 DN AR-534
DMNJ632 HS Investigative
DMNJ632 SN CHEMBL2177159
DMNJ632 DT Small molecular drug
DMNJ632 PC 56603751
DMNJ632 MW 428.5
DMNJ632 FM C19H20N6O4S
DMNJ632 IC InChI=1S/C19H20N6O4S/c1-29-10-9-23-30(27,28)15-6-4-13(5-7-15)16-12-22-18(20)17(25-16)19(26)24-14-3-2-8-21-11-14/h2-8,11-12,23H,9-10H2,1H3,(H2,20,22)(H,24,26)
DMNJ632 CS COCCNS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CN=CC=C3)N
DMNJ632 IK OMGQIHJJEYTELG-UHFFFAOYSA-N
DMNJ632 IU 3-amino-6-[4-(2-methoxyethylsulfamoyl)phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide
DMNJ632 DE Discovery agent
DM34P90 ID DM34P90
DM34P90 DN AR-7947
DM34P90 HS Investigative
DM34P90 CP Array BioPharma Inc
DM34P90 DE Non-insulin dependent diabetes
DMAM619 ID DMAM619
DMAM619 DN Arabinose-5-Phosphate
DMAM619 HS Investigative
DMAM619 SN D-arabinose 5-phosphate; arabinose 5-phosphate; 13137-52-5; 5-O-phosphono-D-arabinose; D-A-5-P; D-arabinose, 5-(dihydrogen phosphate); CHEBI:16241; aldehydo-D-arabinose 5-phosphate; arabinose-5P; arabinose-5-P; 1uj6; AC1L4MLG; (2,3,4-trihydroxy-5-oxopentyl) dihydrogen phosphate; AC1Q6RV6; SCHEMBL939515; D-Arabinose 5-phosphoric acid; CHEMBL1162524; ZINC3606137; D-arabinose 5-(dihydrogen phosphate); AKOS027382411; C01112; (2,3,4-trihydroxy-5-oxo-pentyl) dihydrogen phosphate
DMAM619 DT Small molecular drug
DMAM619 PC 5287584
DMAM619 MW 232.13
DMAM619 FM C5H13O8P
DMAM619 IC InChI=1S/C5H13O8P/c6-1-3(7)5(9)4(8)2-13-14(10,11)12/h3-9H,1-2H2,(H2,10,11,12)/t3-,4-,5+/m1/s1
DMAM619 CS C([C@H]([C@@H]([C@@H](COP(=O)(O)O)O)O)O)O
DMAM619 IK VJDOAZKNBQCAGE-WDCZJNDASA-N
DMAM619 IU [(2R,3S,4R)-2,3,4,5-tetrahydroxypentyl] dihydrogen phosphate
DMAM619 DE Discovery agent
DMUOQZD ID DMUOQZD
DMUOQZD DN Arachidonic acid
DMUOQZD HS Investigative
DMUOQZD SN arachidonic acid; 506-32-1; arachidonate; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; Immunocytophyte; (all-Z)-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; UNII-27YG812J1I; all-cis-5,8,11,14-eicosatetraenoic acid; Arachidonic Acid, 99%; CHEMBL15594; CHEBI:15843; YZXBAPSDXZZRGB-DOFZRALJSA-N; 27YG812J1I; cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic Acid
DMUOQZD DT Small molecular drug
DMUOQZD PC 444899
DMUOQZD MW 304.5
DMUOQZD FM C20H32O2
DMUOQZD IC InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-
DMUOQZD CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O
DMUOQZD IK YZXBAPSDXZZRGB-DOFZRALJSA-N
DMUOQZD IU (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid
DMUOQZD CA CAS 506-32-1
DMUOQZD CB CHEBI:15843
DMUOQZD DE Discovery agent
DMHL48F ID DMHL48F
DMHL48F DN ARACHIDONYL TRIFLUOROMETHYLKETONE
DMHL48F HS Investigative
DMHL48F SN Arachidonyl trifluoromethyl ketone; Aacocf3; arachidonyl trifluoromethyl ketone; Arachidonyltrifluoromethane; 149301-79-1; Arachidonic acid trifluoromethyl ketone; Arachidonyltrifluoromethyl Ketone; ATFMK; UNII-00XIW1CR0F; C21H31F3O; (6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one; 00XIW1CR0F; CHEBI:2341; CHEMBL281211; 1,1,1-Trifluoro-6Z,9Z,12Z,15Z-heneicosatetraen-2-one; 6,9,12,15-Heneicosatetraen-2-one, 1,1,1-trifluoro-, (6Z,9Z,12Z,15Z)-; 6,9,12,15-Heneicosatetraen-2-one, 1,1,1-trifluoro-, (all-Z)-; Arachidonyl trifluoromethylketone; Arachidonyltrifluoromethyl ketone
DMHL48F DT Small molecular drug
DMHL48F PC 5280436
DMHL48F MW 356.5
DMHL48F FM C21H31F3O
DMHL48F IC InChI=1S/C21H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(25)21(22,23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMHL48F CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)C(F)(F)F
DMHL48F IK PLWROONZUDKYKG-DOFZRALJSA-N
DMHL48F IU (6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
DMHL48F CA CAS 149301-79-1
DMHL48F CB CHEBI:2341
DMHL48F DE Discovery agent
DMZM5KE ID DMZM5KE
DMZM5KE DN arachidonylcyclopropylamide
DMZM5KE HS Investigative
DMZM5KE SN arachidonyl cyclopropylamide
DMZM5KE DT Small molecular drug
DMZM5KE PC 5311007
DMZM5KE MW 343.5
DMZM5KE FM C23H37NO
DMZM5KE IC InChI=1S/C23H37NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(25)24-22-20-21-22/h6-7,9-10,12-13,15-16,22H,2-5,8,11,14,17-21H2,1H3,(H,24,25)/b7-6-,10-9-,13-12-,16-15-
DMZM5KE CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NC1CC1
DMZM5KE IK GLGAUBPACOBAMV-DOFZRALJSA-N
DMZM5KE IU (5Z,8Z,11Z,14Z)-N-cyclopropylicosa-5,8,11,14-tetraenamide
DMZM5KE CA CAS 229021-64-1
DMZM5KE DE Discovery agent
DMSM1PV ID DMSM1PV
DMSM1PV DN ARC-069
DMSM1PV HS Investigative
DMSM1PV SN Gamma secretase inhibitors (Alzheimer's disease), Archer Pharmaceuticals
DMSM1PV CP Archer Pharmaceuticals
DMSM1PV DE Alzheimer disease
DMWVULN ID DMWVULN
DMWVULN DN AR-C102222
DMWVULN HS Investigative
DMWVULN SN AR-C102222; CHEMBL447183; 5-(4-Amino-5,8-difluorospiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile; 1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE; SCHEMBL7806912; ZINC1489460; BDBM50124535; DB07405; NCGC00371031-01; 5-[(4'-amino-5',8'-difluoro-1H,1'H-spiro[piperidine-4,2'-quinazolin]-1-yl)carbonyl]pyridine-2-carbonitrile; 5-(4-Amino-5,8-difluorospiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile, 3
DMWVULN DT Small molecular drug
DMWVULN PC 9886249
DMWVULN MW 382.4
DMWVULN FM C19H16F2N6O
DMWVULN IC InChI=1S/C19H16F2N6O/c20-13-3-4-14(21)16-15(13)17(23)26-19(25-16)5-7-27(8-6-19)18(28)11-1-2-12(9-22)24-10-11/h1-4,10,25H,5-8H2,(H2,23,26)
DMWVULN CS C1CN(CCC12NC3=C(C=CC(=C3C(=N2)N)F)F)C(=O)C4=CN=C(C=C4)C#N
DMWVULN IK GIZYIOOBBUHOBS-UHFFFAOYSA-N
DMWVULN IU 5-(4-amino-5,8-difluorospiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile
DMWVULN DE Discovery agent
DM0KDTG ID DM0KDTG
DM0KDTG DN ARC-1028
DM0KDTG HS Investigative
DM0KDTG SN ARC-1028; CHEMBL525385; BDBM27227; ARC-1028, 22
DM0KDTG PC 25190769
DM0KDTG MW 1571.8
DM0KDTG FM C64H118N34O13
DM0KDTG IC InChI=1S/C64H118N34O13/c65-24-6-5-15-36(91-42(99)22-4-2-8-26-81-57(110)47-45(101)46(102)58(111-47)98-34-90-44-48(66)88-33-89-50(44)98)51(104)80-25-7-1-3-23-43(100)92-37(17-10-28-83-60(70)71)52(105)94-39(19-12-30-85-62(74)75)54(107)96-41(21-14-32-87-64(78)79)56(109)97-40(20-13-31-86-63(76)77)55(108)95-38(18-11-29-84-61(72)73)53(106)93-35(49(67)103)16-9-27-82-59(68)69/h33-41,45-47,58,101-102H,1-32,65H2,(H2,67,103)(H,80,104)(H,81,110)(H,91,99)(H,92,100)(H,93,106)(H,94,105)(H,95,108)(H,96,107)(H,97,109)(H2,66,88,89)(H4,68,69,82)(H4,70,71,83)(H4,72,73,84)(H4,74,75,85)(H4,76,77,86)(H4,78,79,87)/t35-,36-,37-,38-,39-,40-,41-,45+,46-,47+,58-/m1/s1
DM0KDTG CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C(=O)NCCCCCC(=O)N[C@H](CCCCN)C(=O)NCCCCCC(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N)O)O)N
DM0KDTG IK FBAPHDWTBAGCKW-LJDCWIOTSA-N
DM0KDTG IU (2S,3S,4R,5R)-N-[6-[[(2R)-6-amino-1-[[6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-6-oxohexyl]amino]-1-oxohexan-2-yl]amino]-6-oxohexyl]-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carboxamide
DM0KDTG DE Discovery agent
DMQCPXL ID DMQCPXL
DMQCPXL DN AR-C118925XX
DMQCPXL HS Investigative
DMQCPXL SN AR-C118925
DMQCPXL DT Small molecular drug
DMQCPXL PC 54210200
DMQCPXL MW 537.6
DMQCPXL FM C28H23N7O3S
DMQCPXL IC InChI=1S/C28H23N7O3S/c1-15-3-8-20-17(11-15)5-6-18-12-16(2)4-9-21(18)24(20)22-14-35(28(37)30-26(22)39)13-19-7-10-23(38-19)25(36)29-27-31-33-34-32-27/h3-12,14,24H,13H2,1-2H3,(H,30,37,39)(H2,29,31,32,33,34,36)
DMQCPXL CS CC1=CC2=C(C=C1)C(C3=C(C=C2)C=C(C=C3)C)C4=CN(C(=O)NC4=S)CC5=CC=C(O5)C(=O)NC6=NNN=N6
DMQCPXL IK PVKNPGQAFNALOI-UHFFFAOYSA-N
DMQCPXL IU 5-[[5-(6,13-dimethyl-2-tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaenyl)-2-oxo-4-sulfanylidenepyrimidin-1-yl]methyl]-N-(2H-tetrazol-5-yl)furan-2-carboxamide
DMQCPXL DE Discovery agent
DMP1EWV ID DMP1EWV
DMP1EWV DN AR-C126313
DMP1EWV HS Investigative
DMP1EWV SN compound 71a [PMID: 15078212]; compound 52 [PMID: 18600475]
DMP1EWV DT Small molecular drug
DMP1EWV PC 22003577
DMP1EWV MW 373.9
DMP1EWV FM C17H12ClN3OS2
DMP1EWV IC InChI=1S/C17H12ClN3OS2/c1-21-7-12(16(23)20-17(21)22)14-11-4-3-10(18)6-9(11)2-5-13-15(14)19-8-24-13/h2-8,14H,1H3,(H,20,22,23)
DMP1EWV CS CN1C=C(C(=S)NC1=O)C2C3=C(C=CC4=C2N=CS4)C=C(C=C3)Cl
DMP1EWV IK ZDHQVQVNOIWLNX-UHFFFAOYSA-N
DMP1EWV IU 5-(12-chloro-6-thia-4-azatricyclo[8.4.0.03,7]tetradeca-1(10),3(7),4,8,11,13-hexaen-2-yl)-1-methyl-4-sulfanylidenepyrimidin-2-one
DMP1EWV DE Discovery agent
DM71WQT ID DM71WQT
DM71WQT DN AR-C133057XX
DM71WQT HS Investigative
DM71WQT SN CHEMBL114500; 4-({4-[(4-Methoxypyridin-2-Yl)amino]piperidin-1-Yl}carbonyl)benzonitrile; 4-[4-[(4-Methoxypyridin-2-yl)amino]piperidine-1-carbonyl]benzonitrile; 4-{4-[(4-methoxypyridin-2-yl)amino]piperidine-1-carbonyl}benzonitrile; AR-C133057XX; SCHEMBL7824352; CHEBI:95013; BDBM50148167; DB07002; BRD-K40892394-001-01-9; 4-(4-(4-methoxypyridin-2-ylamino)piperidine-1-carbonyl)benzonitrile; 4-[4-(4-Methoxy-pyridin-2-ylamino)-piperidine-1-carbonyl]-benzonitrile
DM71WQT DT Small molecular drug
DM71WQT PC 9797857
DM71WQT MW 336.4
DM71WQT FM C19H20N4O2
DM71WQT IC InChI=1S/C19H20N4O2/c1-25-17-6-9-21-18(12-17)22-16-7-10-23(11-8-16)19(24)15-4-2-14(13-20)3-5-15/h2-6,9,12,16H,7-8,10-11H2,1H3,(H,21,22)
DM71WQT CS COC1=CC(=NC=C1)NC2CCN(CC2)C(=O)C3=CC=C(C=C3)C#N
DM71WQT IK SZUVGMCKKLJAFX-UHFFFAOYSA-N
DM71WQT IU 4-[4-[(4-methoxypyridin-2-yl)amino]piperidine-1-carbonyl]benzonitrile
DM71WQT CA CAS 268730-08-1
DM71WQT CB CHEBI:95013
DM71WQT DE Discovery agent
DMAZV5D ID DMAZV5D
DMAZV5D DN ARC-200
DMAZV5D HS Investigative
DMAZV5D CP Archer Biosciences Inc
DMAZV5D DE Solid tumour/cancer
DMU3A57 ID DMU3A57
DMU3A57 DN AR-C70484XX
DMU3A57 HS Investigative
DMU3A57 SN CHEMBL30108; AR-C70484XX; SCHEMBL3688521; BDBM50110846; 4-[3-[4-(Decyloxy)phenoxy]acetonyloxy]benzoic acid; 4-[3-(4-Decyloxy-phenoxy)-2-oxo-propoxy]-benzoic acid; 4-(3-(4-(decyloxy)phenoxy)-2-oxopropoxy)benzoic acid; 4-[3-(4-Decyloxy-phenoxy)-2-oxo-propoxy]-benzoic acid(AR-C70484XX)
DMU3A57 DT Small molecular drug
DMU3A57 PC 9846199
DMU3A57 MW 442.5
DMU3A57 FM C26H34O6
DMU3A57 IC InChI=1S/C26H34O6/c1-2-3-4-5-6-7-8-9-18-30-23-14-16-25(17-15-23)32-20-22(27)19-31-24-12-10-21(11-13-24)26(28)29/h10-17H,2-9,18-20H2,1H3,(H,28,29)
DMU3A57 CS CCCCCCCCCCOC1=CC=C(C=C1)OCC(=O)COC2=CC=C(C=C2)C(=O)O
DMU3A57 IK BBWMRBSEGFTSQC-UHFFFAOYSA-N
DMU3A57 IU 4-[3-(4-decoxyphenoxy)-2-oxopropoxy]benzoic acid
DMU3A57 DE Discovery agent
DMXOYK0 ID DMXOYK0
DMXOYK0 DN Arcaine
DMXOYK0 HS Investigative
DMXOYK0 SN arcaine; Tetramethylenediguanide; 1,4-Diguanidinobutane; N,N'''-1,4-Butanediylbisguanidine; Arcain; 544-05-8; 1-(4-guanidinobutyl)guanidine; CHEMBL102740; CHEBI:16652; 1,1'-(butane-1,4-diyl)diguanidine; Guanidine, N,N'''-1,4-butanediylbis-; A-8340; 1-(4-carbamimidamidobutyl)guanidine; 58585-47-0; 2,2'-butane-1,4-diyldiguanidine; Tocris-0389; Spectrum_001819; Prestwick2_000876; Spectrum5_001638; Prestwick1_000876; Prestwick0_000876; Spectrum3_001100; Spectrum2_000601; Prestwick3_000876; Spectrum4_001929; Lopac-A-0384
DMXOYK0 DT Small molecular drug
DMXOYK0 PC 2227
DMXOYK0 MW 172.23
DMXOYK0 FM C6H16N6
DMXOYK0 IC InChI=1S/C6H16N6/c7-5(8)11-3-1-2-4-12-6(9)10/h1-4H2,(H4,7,8,11)(H4,9,10,12)
DMXOYK0 CS C(CCN=C(N)N)CN=C(N)N
DMXOYK0 IK HGMDNMBBCKDWTQ-UHFFFAOYSA-N
DMXOYK0 IU 2-[4-(diaminomethylideneamino)butyl]guanidine
DMXOYK0 CA CAS 544-05-8
DMXOYK0 CB CHEBI:16652
DMXOYK0 DE Discovery agent
DM03E28 ID DM03E28
DM03E28 DN ARD-412
DM03E28 HS Investigative
DM03E28 SN Oral delta opioid agonists (premature ejaculation); Oral delta opioid agonists (premature ejaculation), Enhance
DM03E28 CP Ardent Pharmaceuticals Inc
DM03E28 DE Premature ejaculation
DMSA6IY ID DMSA6IY
DMSA6IY DN arecaidine propargyl ester
DMSA6IY HS Investigative
DMSA6IY SN Arecaidine propargyl ester; 35516-99-5; NCGC00015006-01; Lopac-A-140; AC1L1D7L; AC1Q62JO; Lopac0_000136; GTPL295; CHEMBL128365; SCHEMBL13184690; CTK1B6885; CHEBI:92418; DTXSID30274358; SPHRJZBOFYIKMC-UHFFFAOYSA-N; prop-2-ynyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate; 2-Propynyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate; ZINC25720839; AKOS030566155; CCG-204231; NCGC00015006-03; NCGC00162072-01; NCGC00015006-04; NCGC00162072-02; NCGC00015006-02; L000114; BRD-K23922020-075-01-1; prop-2-ynyl 1-methyl-5,6-dihydro-2H-pyridin
DMSA6IY DT Small molecular drug
DMSA6IY PC 2229
DMSA6IY MW 179.22
DMSA6IY FM C10H13NO2
DMSA6IY IC InChI=1S/C10H13NO2/c1-3-7-13-10(12)9-5-4-6-11(2)8-9/h1,5H,4,6-8H2,2H3
DMSA6IY CS CN1CCC=C(C1)C(=O)OCC#C
DMSA6IY IK SPHRJZBOFYIKMC-UHFFFAOYSA-N
DMSA6IY IU prop-2-ynyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate
DMSA6IY CA CAS 35516-99-5
DMSA6IY CB CHEBI:92418
DMSA6IY DE Discovery agent
DM8KN0Q ID DM8KN0Q
DM8KN0Q DN ARGENINE VASOPRESSIN
DM8KN0Q HS Investigative
DM8KN0Q SN 8-arginine vasopressin; Arginine-vasopressin (AVP); AVP (Arginine-vasopressin ); CHEMBL264048; BDBM50291330; cyclo[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Arg-Gly-NH2; 1-[19-Amino-13-benzyl-10-(2-carbamoyl-ethyl)-7-carbamoylmethyl-16-(4-hydroxy-benzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carbonyl]-pyrrolidine-2-carboxylic acid [1-(carbamoylmethyl-carbamoyl)-4-guanidino-butyl]-amide
DM8KN0Q PC 44285245
DM8KN0Q MW 1084.2
DM8KN0Q FM C46H65N15O12S2
DM8KN0Q IC InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28+,29-,30-,31+,32+,33+,34-/m1/s1
DM8KN0Q CS C1C[C@@H](N(C1)C(=O)[C@@H]2CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DM8KN0Q IK KBZOIRJILGZLEJ-BOXDWKHASA-N
DM8KN0Q IU (2R)-1-[(4R,7S,10R,13S,16R,19S)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM8KN0Q DE Discovery agent
DMQ1DWU ID DMQ1DWU
DMQ1DWU DN Argiotoxin-636
DMQ1DWU HS Investigative
DMQ1DWU SN argiotoxin 636; Argiotoxin-636; Argiopine; Argiopin; CHEMBL1098240; CHEBI:34541; 105029-41-2; 108687-79-2; Butanediamide, N1-(16,21-diamino-21-imino-15-oxo-6,10,14,20-tetraazaheneicos-1-yl)-2-(((2,4-dihydroxyphenyl)acetyl)amino)-, (S-(R*,R*))-; AR 636; AC1L3UBP; GTPL4138; SCHEMBL17014644; BDBM50316373; (S-(R*,R*))-N1-(16,21-Diamino-21-imino-15-oxo-6,10,14,20-tetraazaheneicos-1-yl)-2-(((2,4-dihydroxyphenyl)acetyl)amino)butanediamide; C13927
DMQ1DWU DT Small molecular drug
DMQ1DWU PC 122294
DMQ1DWU MW 636.8
DMQ1DWU FM C29H52N10O6
DMQ1DWU IC InChI=1S/C29H52N10O6/c30-22(7-4-15-38-29(32)33)27(44)36-16-6-13-35-12-5-11-34-10-2-1-3-14-37-28(45)23(19-25(31)42)39-26(43)17-20-8-9-21(40)18-24(20)41/h8-9,18,22-23,34-35,40-41H,1-7,10-17,19,30H2,(H2,31,42)(H,36,44)(H,37,45)(H,39,43)(H4,32,33,38)/t22-,23-/m0/s1
DMQ1DWU CS C1=CC(=C(C=C1O)O)CC(=O)N[C@@H](CC(=O)N)C(=O)NCCCCCNCCCNCCCNC(=O)[C@H](CCCN=C(N)N)N
DMQ1DWU IK FTNICLJXPYLDAH-GOTSBHOMSA-N
DMQ1DWU IU (2S)-N-[5-[3-[3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propylamino]propylamino]pentyl]-2-[[2-(2,4-dihydroxyphenyl)acetyl]amino]butanediamide
DMQ1DWU CA CAS 105029-41-2
DMQ1DWU CB CHEBI:34541
DMQ1DWU DE Discovery agent
DM6PA1S ID DM6PA1S
DM6PA1S DN Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2
DM6PA1S HS Investigative
DM6PA1S SN CHEMBL396426; Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2
DM6PA1S PC 44434485
DM6PA1S MW 1290.6
DM6PA1S FM C61H95N17O12S
DM6PA1S IC InChI=1S/C61H95N17O12S/c1-36(2)32-44(55(85)72-41(51(65)81)26-31-91-4)71-50(80)35-69-53(83)45(33-38-16-7-5-8-17-38)75-56(86)46(34-39-18-9-6-10-19-39)76-54(84)42(24-25-49(64)79)73-52(82)37(3)70-57(87)47-22-15-30-78(47)60(90)43(21-11-12-27-62)74-58(88)48-23-14-29-77(48)59(89)40(63)20-13-28-68-61(66)67/h5-10,16-19,36-37,40-48H,11-15,20-35,62-63H2,1-4H3,(H2,64,79)(H2,65,81)(H,69,83)(H,70,87)(H,71,80)(H,72,85)(H,73,82)(H,74,88)(H,75,86)(H,76,84)(H4,66,67,68)/t37-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
DM6PA1S CS C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DM6PA1S IK VWZGDJIFNOBMMB-DYIQZKFVSA-N
DM6PA1S IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanediamide
DM6PA1S DE Discovery agent
DMYM91S ID DMYM91S
DMYM91S DN Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMYM91S HS Investigative
DMYM91S SN CHEMBL413827; Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMYM91S PC 44434487
DMYM91S MW 1249.5
DMYM91S FM C59H92N16O12S
DMYM91S IC InChI=1S/C59H92N16O12S/c1-35(2)30-42(52(81)69-40(49(62)78)24-29-88-4)68-48(77)33-66-51(80)43(31-37-16-7-5-8-17-37)71-53(82)44(32-38-18-9-6-10-19-38)72-54(83)45(34-76)73-50(79)36(3)67-55(84)46-22-15-28-75(46)58(87)41(21-11-12-25-60)70-56(85)47-23-14-27-74(47)57(86)39(61)20-13-26-65-59(63)64/h5-10,16-19,35-36,39-47,76H,11-15,20-34,60-61H2,1-4H3,(H2,62,78)(H,66,80)(H,67,84)(H,68,77)(H,69,81)(H,70,85)(H,71,82)(H,72,83)(H,73,79)(H4,63,64,65)/t36-,39-,40-,41-,42-,43-,44-,45-,46-,47-/m0/s1
DMYM91S CS C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMYM91S IK HMZBUUAKDIVOFX-KWWDQKRUSA-N
DMYM91S IU (2S)-N-[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxamide
DMYM91S DE Discovery agent
DMA318X ID DMA318X
DMA318X DN Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMA318X HS Investigative
DMA318X SN CHEMBL394671; Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2
DMA318X PC 44434486
DMA318X MW 1306.6
DMA318X FM C61H95N17O13S
DMA318X IC InChI=1S/C61H95N17O13S/c1-36(2)31-43(54(85)71-40(51(65)82)25-30-92-3)70-50(81)34-69-52(83)44(32-37-15-6-4-7-16-37)74-55(86)45(33-38-17-8-5-9-18-38)75-56(87)46(35-79)76-53(84)41(23-24-49(64)80)72-57(88)48-22-14-29-78(48)60(91)42(20-10-11-26-62)73-58(89)47-21-13-28-77(47)59(90)39(63)19-12-27-68-61(66)67/h4-9,15-18,36,39-48,79H,10-14,19-35,62-63H2,1-3H3,(H2,64,80)(H2,65,82)(H,69,83)(H,70,81)(H,71,85)(H,72,88)(H,73,89)(H,74,86)(H,75,87)(H,76,84)(H4,66,67,68)/t39-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
DMA318X CS CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMA318X IK MXTQBPBXNQHASJ-BHEJXMHWSA-N
DMA318X IU (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]pentanediamide
DMA318X DE Discovery agent
DM8NETP ID DM8NETP
DM8NETP DN ARH-1029
DM8NETP HS Investigative
DM8NETP SN AR-HP; Dual-acting H. pylori therapeutic (peptic ulcer disease), CJ Corp; Dual-acting H. pylori therapeutic, (peptic ulcer disease), Taiho Pharmaceutical
DM8NETP CP ARigen Pharmaceuticals Inc
DM8NETP DE Helicobacter infection
DM2PRHX ID DM2PRHX
DM2PRHX DN AR-HO29953XX
DM2PRHX HS Investigative
DM2PRHX SN CHEMBL117520; AR-HO29953XX; AR-H-029953XX; BDBM50149274; 2-[4-(3,4-Dichloro-phenylcarbamoyl)-benzylamino]-4-nitro-benzoic acid
DM2PRHX DT Small molecular drug
DM2PRHX PC 10479348
DM2PRHX MW 460.3
DM2PRHX FM C21H15Cl2N3O5
DM2PRHX IC InChI=1S/C21H15Cl2N3O5/c22-17-8-5-14(9-18(17)23)25-20(27)13-3-1-12(2-4-13)11-24-19-10-15(26(30)31)6-7-16(19)21(28)29/h1-10,24H,11H2,(H,25,27)(H,28,29)
DM2PRHX CS C1=CC(=CC=C1CNC2=C(C=CC(=C2)[N+](=O)[O-])C(=O)O)C(=O)NC3=CC(=C(C=C3)Cl)Cl
DM2PRHX IK HMZYRLHWICHTKH-UHFFFAOYSA-N
DM2PRHX IU 2-[[4-[(3,4-dichlorophenyl)carbamoyl]phenyl]methylamino]-4-nitrobenzoic acid
DM2PRHX DE Discovery agent
DMIMD0T ID DMIMD0T
DMIMD0T DN ARI-3099
DMIMD0T HS Investigative
DMIMD0T SN compound 6 [PMID: 23594271]; compound 226 [PMID: 24997602]; Py(D)AlaboroPro
DMIMD0T DT Small molecular drug
DMIMD0T PC 71655266
DMIMD0T MW 291.11
DMIMD0T FM C13H18BN3O4
DMIMD0T IC InChI=1S/C13H18BN3O4/c1-9(16-12(18)10-4-6-15-7-5-10)13(19)17-8-2-3-11(17)14(20)21/h4-7,9,11,20-21H,2-3,8H2,1H3,(H,16,18)/t9-,11+/m1/s1
DMIMD0T CS B([C@@H]1CCCN1C(=O)[C@@H](C)NC(=O)C2=CC=NC=C2)(O)O
DMIMD0T IK DRBWRJPFNOBNIO-KOLCDFICSA-N
DMIMD0T IU [(2R)-1-[(2R)-2-(pyridine-4-carbonylamino)propanoyl]pyrrolidin-2-yl]boronic acid
DMIMD0T DE Discovery agent
DMEO82V ID DMEO82V
DMEO82V DN ARI-3531
DMEO82V HS Investigative
DMEO82V SN compound 22 [PMID: 23594271]
DMEO82V DT Small molecular drug
DMEO82V PC 91827371
DMEO82V MW 319.17
DMEO82V FM C15H22BN3O4
DMEO82V IC InChI=1S/C15H22BN3O4/c1-10(2)13(18-14(20)11-5-7-17-8-6-11)15(21)19-9-3-4-12(19)16(22)23/h5-8,10,12-13,22-23H,3-4,9H2,1-2H3,(H,18,20)/t12-,13-/m1/s1
DMEO82V CS B([C@H]1CCCN1C(=O)[C@@H](C(C)C)NC(=O)C2=CC=NC=C2)(O)O
DMEO82V IK MXZNUGFCDVAXLG-CHWSQXEVSA-N
DMEO82V IU [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid
DMEO82V DE Discovery agent
DMNPEM4 ID DMNPEM4
DMNPEM4 DN ARL66096
DMNPEM4 HS Investigative
DMNPEM4 SN 2-propylthio-betagamma-difluoromethylene ATP; FPL66096; ARL 66096
DMNPEM4 DT Small molecular drug
DMNPEM4 PC 5311009
DMNPEM4 MW 615.3
DMNPEM4 FM C14H22F2N5O12P3S
DMNPEM4 IC InChI=1S/C14H22F2N5O12P3S/c1-2-3-37-13-19-10(17)7-11(20-13)21(5-18-7)12-9(23)8(22)6(32-12)4-31-36(29,30)33-35(27,28)14(15,16)34(24,25)26/h5-6,8-9,12,22-23H,2-4H2,1H3,(H,27,28)(H,29,30)(H2,17,19,20)(H2,24,25,26)/t6-,8-,9-,12-/m1/s1
DMNPEM4 CS CCCSC1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(F)(F)P(=O)(O)O)O)O)O)N
DMNPEM4 IK ZQXUQOHLHUWLSA-WOUKDFQISA-N
DMNPEM4 IU [[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-difluoromethyl]phosphonic acid
DMNPEM4 DE Discovery agent
DM24MKI ID DM24MKI
DM24MKI DN AR-mTOR-26
DM24MKI HS Investigative
DM24MKI SN AR-mTOR-1; MTORC1/2 inhibitors (cancer); MTORC1/2 inhibitors (cancer), Array BioPharma
DM24MKI CP Array BioPharma Inc
DM24MKI DE Solid tumour/cancer
DMBE0H8 ID DMBE0H8
DMBE0H8 DN ARN-2966
DMBE0H8 HS Investigative
DMBE0H8 SN ARN-4261; Abeta aggregation inhibitors (Alzheimer's disease); Abeta aggregation inhibitors (Alzheimer's disease), New York University/Aria Neurosciences
DMBE0H8 CP New York University
DMBE0H8 DT Small molecular drug
DMBE0H8 PC 14936865
DMBE0H8 MW 200.24
DMBE0H8 FM C12H12N2O
DMBE0H8 IC InChI=1S/C12H12N2O/c15-12-7-2-1-6-11(12)14-9-10-5-3-4-8-13-10/h1-8,14-15H,9H2
DMBE0H8 CS C1=CC=C(C(=C1)NCC2=CC=CC=N2)O
DMBE0H8 IK GXJRVWZNMZGWAQ-UHFFFAOYSA-N
DMBE0H8 IU 2-(pyridin-2-ylmethylamino)phenol
DMBE0H8 DE Alzheimer disease
DMMCFEX ID DMMCFEX
DMMCFEX DN ARN34
DMMCFEX HS Investigative
DMMCFEX DE Discovery agent
DMNAJQY ID DMNAJQY
DMNAJQY DN ARO 087
DMNAJQY HS Investigative
DMNAJQY CP Aroule
DMNAJQY DE Solid tumour/cancer
DM6KQXF ID DM6KQXF
DM6KQXF DN ARP100
DM6KQXF HS Investigative
DM6KQXF SN ARP 100; ARP-100
DM6KQXF DT Small molecular drug
DM6KQXF PC 10044321
DM6KQXF MW 364.4
DM6KQXF FM C17H20N2O5S
DM6KQXF IC InChI=1S/C17H20N2O5S/c1-13(2)24-19(12-17(20)18-21)25(22,23)16-10-8-15(9-11-16)14-6-4-3-5-7-14/h3-11,13,21H,12H2,1-2H3,(H,18,20)
DM6KQXF CS CC(C)ON(CC(=O)NO)S(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DM6KQXF IK PHGLPDURIUEELR-UHFFFAOYSA-N
DM6KQXF IU N-hydroxy-2-[(4-phenylphenyl)sulfonyl-propan-2-yloxyamino]acetamide
DM6KQXF CA CAS 704888-90-4
DM6KQXF DE Discovery agent
DMU70YP ID DMU70YP
DMU70YP DN ARPFAQK-FAM
DMU70YP HS Investigative
DMU70YP SN CHEMBL441156
DMU70YP PC 44460581
DMU70YP MW 1272.3
DMU70YP FM C62H73N13O17
DMU70YP IC InChI=1S/C62H73N13O17/c1-32(63)53(81)71-42(16-9-27-68-62(65)66)59(87)74-28-10-17-45(74)57(85)73-44(29-34-11-4-3-5-12-34)56(84)69-33(2)54(82)70-41(22-23-48(64)78)55(83)72-43(60(88)89)15-6-7-26-67-58(86)52-39(13-8-14-40(52)61(90)92-75-49(79)24-25-50(75)80)51-37-20-18-35(76)30-46(37)91-47-31-36(77)19-21-38(47)51/h3-5,8,11-14,18-21,30-33,41-45,76H,6-7,9-10,15-17,22-29,63H2,1-2H3,(H2,64,78)(H,67,86)(H,69,84)(H,70,82)(H,71,81)(H,72,83)(H,73,85)(H,88,89)(H4,65,66,68)/t32-,33-,41-,42-,43-,44-,45-/m0/s1
DMU70YP CS C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCNC(=O)C3=C(C=CC=C3C(=O)ON4C(=O)CCC4=O)C5=C6C=CC(=O)C=C6OC7=C5C=CC(=C7)O)C(=O)O)N
DMU70YP IK IVWCINIISIMQBR-IPQUOSPJSA-N
DMU70YP IU (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-6-[[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-6-(3-hydroxy-6-oxoxanthen-9-yl)benzoyl]amino]hexanoic acid
DMU70YP DE Discovery agent
DMB9PDA ID DMB9PDA
DMB9PDA DN arpromidine
DMB9PDA HS Investigative
DMB9PDA SN Arpromidine; 106669-71-0; Arpromidinum; Arpromidina; Arpromidine [INN]; Arpromidinum [INN-Latin]; Arpromidina [INN-Spanish]; AC1Q4NMJ; SCHEMBL138015; CHEMBL293802; SCHEMBL9710060; GTPL1221; BDBM86171; AC1L2472; PDSP2_001296; PDSP1_001312; NSC_65895; CAS_65895; L000115; Guanidine, N-(3-(4-fluorophenyl)-3-(2-pyridinyl)propyl)-N'-(3-(1H-imidazol-4-yl)propyl)-; 1-[3-(4-fluorophenyl)-3-(2-pyridyl)propyl]-n2-[3-(1h-imidazol-4-yl)propyl]guanidine; (+-)-1-(3-(p-Fluorophenyl)-3-(2-pyridyl)propyl)-3-(3-imidazol-4-ylpropyl)guanidine
DMB9PDA DT Small molecular drug
DMB9PDA PC 65895
DMB9PDA MW 380.5
DMB9PDA FM C21H25FN6
DMB9PDA IC InChI=1S/C21H25FN6/c22-17-8-6-16(7-9-17)19(20-5-1-2-11-25-20)10-13-27-21(23)26-12-3-4-18-14-24-15-28-18/h1-2,5-9,11,14-15,19H,3-4,10,12-13H2,(H,24,28)(H3,23,26,27)
DMB9PDA CS C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)F
DMB9PDA IK KZZIVOLMJPSDEP-UHFFFAOYSA-N
DMB9PDA IU 1-[3-(4-fluorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1H-imidazol-5-yl)propyl]guanidine
DMB9PDA CA CAS 106669-71-0
DMB9PDA DE Discovery agent
DMIRTF5 ID DMIRTF5
DMIRTF5 DN ARRY-575
DMIRTF5 HS Investigative
DMIRTF5 CP Array BioPharma Inc
DMIRTF5 DE Solid tumour/cancer
DMBCO4Q ID DMBCO4Q
DMBCO4Q DN Arsenite
DMBCO4Q HS Investigative
DMBCO4Q SN Arsenenous acid; 13768-07-5; Arsenite (ion); AC1L2NJ5
DMBCO4Q DT Small molecular drug
DMBCO4Q PC 24577
DMBCO4Q MW 107.928
DMBCO4Q FM AsHO2
DMBCO4Q IC InChI=1S/AsHO2/c2-1-3/h(H,2,3)
DMBCO4Q CS O[As]=O
DMBCO4Q IK XHTRYVMKFMUJLU-UHFFFAOYSA-N
DMBCO4Q IU arsenous acid
DMBCO4Q CA CAS 13768-07-5
DMBCO4Q DE Discovery agent
DMEVT4I ID DMEVT4I
DMEVT4I DN ART-144
DMEVT4I HS Investigative
DMEVT4I SN Anti-inflammatory agent (intra-articular/injectable, sustained release, osteoarthritis), Artyx pharmaceuticals
DMEVT4I CP ARTYX Pharmaceuticals Inc
DMEVT4I DE Osteoarthritis
DM8SP4X ID DM8SP4X
DM8SP4X DN Arteminolide
DM8SP4X HS Investigative
DM8SP4X DT Small molecular drug
DM8SP4X PC 10627242
DM8SP4X MW 590.7
DM8SP4X FM C35H42O8
DM8SP4X IC InChI=1S/C35H42O8/c1-16(2)12-23(37)41-22-14-18(4)24-21(36)13-17(3)25(24)28-26(22)35(31(39)43-28)15-34-11-10-32(35,6)29(34)27-20(8-9-33(34,7)40)19(5)30(38)42-27/h10-11,13,16,20,22,25-29,40H,5,8-9,12,14-15H2,1-4,6-7H3/t20-,22-,25-,26+,27-,28+,29-,32+,33+,34-,35+/m0/s1
DM8SP4X CS CC1=C2[C@@H]([C@@H]3[C@@H]([C@H](C1)OC(=O)CC(C)C)[C@]4(C[C@@]56C=C[C@@]4([C@@H]5[C@@H]7[C@@H](CC[C@@]6(C)O)C(=C)C(=O)O7)C)C(=O)O3)C(=CC2=O)C
DM8SP4X IK RAKYLPJLLBOHHN-CFTUDFFSSA-N
DM8SP4X IU [(1'R,2'R,3S,3aR,4S,5'S,9'S,9aS,9bR,10'S,11'R)-2'-hydroxy-2',6,9,11'-tetramethyl-6'-methylidene-2,7,7'-trioxospiro[4,5,9a,9b-tetrahydro-3aH-azuleno[4,5-b]furan-3,15'-8-oxatetracyclo[9.2.2.01,10.05,9]pentadec-12-ene]-4-yl] 3-methylbutanoate
DM8SP4X DE Discovery agent
DMWCDM8 ID DMWCDM8
DMWCDM8 DN artepillin C
DMWCDM8 HS Investigative
DMWCDM8 SN Artepillin C; artepillin; 72944-19-5; (E)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid; CCRIS 8746; AC1NV86P; SCHEMBL1229229; CHEMBL456309; GTPL6302; NSC718732; 3-(4-Hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-2-propenoic acid; BDBM50362836; NSC-718732; 3,5-Bis(3-methyl-2-butenyl)-4-hydroxybenzenepropenoic acid; 2-Propenoic acid, 3-(4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-, (E)-
DMWCDM8 DT Small molecular drug
DMWCDM8 PC 5472440
DMWCDM8 MW 300.4
DMWCDM8 FM C19H24O3
DMWCDM8 IC InChI=1S/C19H24O3/c1-13(2)5-8-16-11-15(7-10-18(20)21)12-17(19(16)22)9-6-14(3)4/h5-7,10-12,22H,8-9H2,1-4H3,(H,20,21)/b10-7+
DMWCDM8 CS CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)/C=C/C(=O)O)C
DMWCDM8 IK KABCFARPAMSXCC-JXMROGBWSA-N
DMWCDM8 IU (E)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid
DMWCDM8 CA CAS 72944-19-5
DMWCDM8 DE Discovery agent
DMB9AR7 ID DMB9AR7
DMB9AR7 DN ARTOBILOXANTHONE
DMB9AR7 HS Investigative
DMB9AR7 SN artobiloxanthone; CHEMBL1099162
DMB9AR7 DT Small molecular drug
DMB9AR7 PC 46887866
DMB9AR7 MW 434.4
DMB9AR7 FM C25H22O7
DMB9AR7 IC InChI=1S/C25H22O7/c1-10(2)12-7-13-21(29)20-15(27)9-17-11(5-6-25(3,4)32-17)23(20)31-24(13)19-14(26)8-16(28)22(30)18(12)19/h5-6,8-9,12,26-28,30H,1,7H2,2-4H3/t12-/m1/s1
DMB9AR7 CS CC(=C)[C@H]1CC2=C(C3=C1C(=C(C=C3O)O)O)OC4=C(C2=O)C(=CC5=C4C=CC(O5)(C)C)O
DMB9AR7 IK ZIYAGIMFLYOZDS-GFCCVEGCSA-N
DMB9AR7 IU (16R)-11,18,19,21-tetrahydroxy-7,7-dimethyl-16-prop-1-en-2-yl-2,8-dioxapentacyclo[12.8.0.03,12.04,9.017,22]docosa-1(14),3(12),4(9),5,10,17(22),18,20-octaen-13-one
DMB9AR7 CA CAS 121748-25-2
DMB9AR7 DE Discovery agent
DMHUXRP ID DMHUXRP
DMHUXRP DN ARTORIGIDIN A
DMHUXRP HS Investigative
DMHUXRP SN Artorigidin A; CHEMBL1094756
DMHUXRP DT Small molecular drug
DMHUXRP PC 46834285
DMHUXRP MW 504.6
DMHUXRP FM C30H32O7
DMHUXRP IC InChI=1S/C30H32O7/c1-13(2)7-9-16-25(33)17(10-8-14(3)4)29-24(26(16)34)27(35)19-11-18(15(5)6)22-23(30(19)37-29)20(31)12-21(32)28(22)36/h7-8,12,18,31-34,36H,5,9-11H2,1-4,6H3/t18-/m1/s1
DMHUXRP CS CC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=C(O2)C4=C([C@H](C3)C(=C)C)C(=C(C=C4O)O)O)CC=C(C)C)O)C
DMHUXRP IK LAAYVNVIRVOBNR-GOSISDBHSA-N
DMHUXRP IU (5R)-1,3,4,8,10-pentahydroxy-9,11-bis(3-methylbut-2-enyl)-5-prop-1-en-2-yl-5,6-dihydrobenzo[c]xanthen-7-one
DMHUXRP DE Discovery agent
DMO5LUF ID DMO5LUF
DMO5LUF DN arvanil
DMO5LUF HS Investigative
DMO5LUF SN N-vanillylarachidonamide
DMO5LUF DT Small molecular drug
DMO5LUF PC 6449767
DMO5LUF MW 439.6
DMO5LUF FM C28H41NO3
DMO5LUF IC InChI=1S/C28H41NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-28(31)29-24-25-21-22-26(30)27(23-25)32-2/h7-8,10-11,13-14,16-17,21-23,30H,3-6,9,12,15,18-20,24H2,1-2H3,(H,29,31)/b8-7-,11-10-,14-13-,17-16-
DMO5LUF CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCC1=CC(=C(C=C1)O)OC
DMO5LUF IK QVLMCRFQGHWOPM-ZKWNWVNESA-N
DMO5LUF IU (5Z,8Z,11Z,14Z)-N-[(4-hydroxy-3-methoxyphenyl)methyl]icosa-5,8,11,14-tetraenamide
DMO5LUF CA CAS 128007-31-8
DMO5LUF DE Discovery agent
DM15KLR ID DM15KLR
DM15KLR DN ARX-AHD
DM15KLR HS Investigative
DM15KLR SN Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx
DM15KLR CP Ambrx Inc
DM15KLR DT Antibody
DM15KLR DE Breast cancer
DMWHUKZ ID DMWHUKZ
DMWHUKZ DN AR-XYZ
DMWHUKZ HS Investigative
DMWHUKZ SN CB2 agonists (pain/inflammation); CB2 agonists (pain/inflammation), Arena Pharmaceuticals
DMWHUKZ CP Arena Pharmaceuticals Inc
DMWHUKZ DE Inflammation
DMAWJPE ID DMAWJPE
DMAWJPE DN AS04
DMAWJPE HS Investigative
DMAWJPE CP GlaxoSmithKline plc
DMAWJPE DE Discovery agent
DMXZ8S9 ID DMXZ8S9
DMXZ8S9 DN AS100
DMXZ8S9 HS Investigative
DMXZ8S9 SN AS 100; AS-100
DMXZ8S9 DT Small molecular drug
DMXZ8S9 PC 135489238
DMXZ8S9 MW 534.4
DMXZ8S9 FM C23H25Cl2N7O4
DMXZ8S9 IC InChI=1S/C23H25Cl2N7O4/c1-4-8-31-21-19(22(34)32(9-5-2)23(31)35)27-20(28-21)16-11-18(29-30(16)3)36-12-17(33)26-13-6-7-14(24)15(25)10-13/h6-7,10-11H,4-5,8-9,12H2,1-3H3,(H,26,33)(H,27,28)
DMXZ8S9 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC(=C(C=C4)Cl)Cl
DMXZ8S9 IK OESRCCUPNGDTIR-UHFFFAOYSA-N
DMXZ8S9 IU N-(3,4-dichlorophenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetamide
DMXZ8S9 DE Discovery agent
DM170G5 ID DM170G5
DM170G5 DN AS1269574
DM170G5 HS Investigative
DM170G5 SN AS 1269574; AS-1269574
DM170G5 DT Small molecular drug
DM170G5 PC 5332859
DM170G5 MW 308.17
DM170G5 FM C13H14BrN3O
DM170G5 IC InChI=1S/C13H14BrN3O/c1-9-8-12(15-6-7-18)17-13(16-9)10-2-4-11(14)5-3-10/h2-5,8,18H,6-7H2,1H3,(H,15,16,17)
DM170G5 CS CC1=CC(=NC(=N1)C2=CC=C(C=C2)Br)NCCO
DM170G5 IK DUKPGOOUJNUIOI-UHFFFAOYSA-N
DM170G5 IU 2-[[2-(4-bromophenyl)-6-methylpyrimidin-4-yl]amino]ethanol
DM170G5 CA CAS 330981-72-1
DM170G5 DE Discovery agent
DMPX5SJ ID DMPX5SJ
DMPX5SJ DN AS-1397
DMPX5SJ HS Investigative
DMPX5SJ SN AS-1397; 10-(2-(Diethylamino)propionyl)phenothiazine; Methyldifazine; 10-(alpha-Diethylaminopropionyl)-phenothiazine hydrochloride; AC1L1BEE; AC1Q5K0B; Lopac0_000351; SCHEMBL1320997; CHEMBL376514; NIOSH/SO4600000; BDBM13551; CTK5B9958; 2-(diethylamino)-1-(10H-phenothiazin-10-yl)propan-1-one; CCG-204446; LS-105449; 10-(a-diethyl-aminopropionyl)-phenothiazine; SO46000000; Phenothiazine, 10-(2-(diethylamino)propionyl)-; 2-(diethylamino)-1-phenothiazin-10-ylpropan-1-one
DMPX5SJ DT Small molecular drug
DMPX5SJ PC 1403
DMPX5SJ MW 326.5
DMPX5SJ FM C19H22N2OS
DMPX5SJ IC InChI=1S/C19H22N2OS/c1-4-20(5-2)14(3)19(22)21-15-10-6-8-12-17(15)23-18-13-9-7-11-16(18)21/h6-14H,4-5H2,1-3H3
DMPX5SJ CS CCN(CC)C(C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMPX5SJ IK QCEWCMMSOWEHFC-UHFFFAOYSA-N
DMPX5SJ IU 2-(diethylamino)-1-phenothiazin-10-ylpropan-1-one
DMPX5SJ DE Discovery agent
DM7A8PX ID DM7A8PX
DM7A8PX DN AS-1522489-00
DM7A8PX HS Investigative
DM7A8PX SN GlyT-1 inhibitors (schizophrenia, dementia); GlyT-1 inhibitors (schizophrenia, dementia), Astellas
DM7A8PX CP Astellas Pharma Inc
DM7A8PX DE Dementia
DMP0A17 ID DMP0A17
DMP0A17 DN AS16
DMP0A17 HS Investigative
DMP0A17 SN AS 16; AS-16
DMP0A17 DT Small molecular drug
DMP0A17 PC 135529391
DMP0A17 MW 555.6
DMP0A17 FM C30H33N7O4
DMP0A17 IC InChI=1S/C30H33N7O4/c1-4-15-36-28-26(29(39)37(16-5-2)30(36)40)32-27(33-28)23-18-24(34-35(23)3)31-25(38)17-20-11-13-22(14-12-20)41-19-21-9-7-6-8-10-21/h6-14,18H,4-5,15-17,19H2,1-3H3,(H,32,33)(H,31,34,38)
DMP0A17 CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)NC(=O)CC4=CC=C(C=C4)OCC5=CC=CC=C5
DMP0A17 IK YJWWRRYUAYGZCB-UHFFFAOYSA-N
DMP0A17 IU N-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]-2-(4-phenylmethoxyphenyl)acetamide
DMP0A17 DE Discovery agent
DM6MWDH ID DM6MWDH
DM6MWDH DN AS-1708727
DM6MWDH HS Investigative
DM6MWDH CP Astellas Pharma Inc
DM6MWDH DE Hypertriglyceridemia
DMS86PI ID DMS86PI
DMS86PI DN AS-1892802
DMS86PI HS Investigative
DMS86PI SN ROCK inhibitor (osteoarthritis pain), Astellas; Rho kinase inhibitor (osteoarthritis pain), Astellas
DMS86PI CP Astellas Pharma Inc
DMS86PI PC 46911016
DMS86PI MW 333.4
DMS86PI FM C20H19N3O2
DMS86PI IC InChI=1S/C20H19N3O2/c24-14-19(17-4-2-1-3-5-17)23-20(25)22-18-8-6-15(7-9-18)16-10-12-21-13-11-16/h1-13,19,24H,14H2,(H2,22,23,25)/t19-/m1/s1
DMS86PI CS C1=CC=C(C=C1)[C@@H](CO)NC(=O)NC2=CC=C(C=C2)C3=CC=NC=C3
DMS86PI IK WDTFYYZHMRBVHK-LJQANCHMSA-N
DMS86PI IU 1-[(1S)-2-hydroxy-1-phenylethyl]-3-(4-pyridin-4-ylphenyl)urea
DMS86PI DE Pain
DMASE5O ID DMASE5O
DMASE5O DN AS-19
DMASE5O HS Investigative
DMASE5O SN AS 19; AS19
DMASE5O DT Small molecular drug
DMASE5O PC 23642275
DMASE5O MW 283.4
DMASE5O FM C18H25N3
DMASE5O IC InChI=1S/C18H25N3/c1-12-18(13(2)21(5)19-12)17-8-6-7-14-11-15(20(3)4)9-10-16(14)17/h6-8,15H,9-11H2,1-5H3/t15-/m0/s1
DMASE5O CS CC1=C(C(=NN1C)C)C2=CC=CC3=C2CC[C@@H](C3)N(C)C
DMASE5O IK BTTOYOKCLDAHHO-HNNXBMFYSA-N
DMASE5O IU (2S)-N,N-dimethyl-5-(1,3,5-trimethylpyrazol-4-yl)-1,2,3,4-tetrahydronaphthalen-2-amine
DMASE5O CA CAS 1000578-26-6
DMASE5O DE Discovery agent
DM0MAIW ID DM0MAIW
DM0MAIW DN AS-1907417
DM0MAIW HS Investigative
DM0MAIW SN AS-1535907; AS-1669058; AS-179009; GPR119 agonists (type 2 diabetes), Astellas Pharma
DM0MAIW CP Astellas Pharma Inc
DM0MAIW DT Small molecular drug
DM0MAIW PC 11567371
DM0MAIW MW 393.5
DM0MAIW FM C19H27N3O4S
DM0MAIW IC InChI=1S/C19H27N3O4S/c23-17(24)6-1-3-13-7-9-22(10-8-13)19-15-11-27(25,26)12-16(15)20-18(21-19)14-4-2-5-14/h13-14H,1-12H2,(H,23,24)
DM0MAIW CS C1CC(C1)C2=NC3=C(CS(=O)(=O)C3)C(=N2)N4CCC(CC4)CCCC(=O)O
DM0MAIW IK NFFANIJTECFGGM-UHFFFAOYSA-N
DM0MAIW IU 4-[1-(2-cyclobutyl-6,6-dioxo-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl)piperidin-4-yl]butanoic acid
DM0MAIW DE Non-insulin dependent diabetes
DMQ95EB ID DMQ95EB
DMQ95EB DN AS-601245
DMQ95EB HS Investigative
DMQ95EB SN JNK Inhibitor V; SAPK Inhibitor V; 1,3-Benzothiazol-2-yl-(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile; GTPL5997; SCHEMBL12242792; MolPort-044-724-552; HMS3229I20; CCG-206858; RT-013405; J-019673
DMQ95EB DT Small molecular drug
DMQ95EB PC 10109823
DMQ95EB MW 372.4
DMQ95EB FM C20H16N6S
DMQ95EB IC InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,15H,7,10H2,(H,23,24,26)
DMQ95EB CS C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4
DMQ95EB IK RCYPVQCPYKNSTG-UHFFFAOYSA-N
DMQ95EB IU 2-(1,3-benzothiazol-2-yl)-2-[2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile
DMQ95EB CA CAS 345987-15-7
DMQ95EB CB CHEBI:91345
DMQ95EB DE Discovery agent
DMANU3W ID DMANU3W
DMANU3W DN AS-602704
DMANU3W HS Investigative
DMANU3W SN 339990-02-2; AIPs (Alzheimers), Axonyx/Serono; Ac-LPFFD-NH2; amyloid-inhibiting peptides, Serono/Axonyx; beta-amyloid inhibitors, Serono/Axonyx; beta-sheet breaker peptides (Alzheimers), Serono/Axonyx
DMANU3W DE Discovery agent
DM9IUSM ID DM9IUSM
DM9IUSM DN AS-604850
DM9IUSM HS Investigative
DM9IUSM SN AS 604850; PI 3-Kgamma inhibitor II
DM9IUSM DT Small molecular drug
DM9IUSM PC 5287855
DM9IUSM MW 285.23
DM9IUSM FM C11H5F2NO4S
DM9IUSM IC InChI=1S/C11H5F2NO4S/c12-11(13)17-6-2-1-5(3-7(6)18-11)4-8-9(15)14-10(16)19-8/h1-4H,(H,14,15,16)/b8-4-
DM9IUSM CS C1=CC2=C(C=C1/C=C\\3/C(=O)NC(=O)S3)OC(O2)(F)F
DM9IUSM IK SRLVNYDXMUGOFI-YWEYNIOJSA-N
DM9IUSM IU (5Z)-5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylidene]-1,3-thiazolidine-2,4-dione
DM9IUSM CB CHEBI:94690
DM9IUSM DE Discovery agent
DM9V5GS ID DM9V5GS
DM9V5GS DN AS604872
DM9V5GS HS Investigative
DM9V5GS SN AS 604872; AS-604872
DM9V5GS DT Small molecular drug
DM9V5GS PC 10152528
DM9V5GS MW 515.6
DM9V5GS FM C28H25N3O3S2
DM9V5GS IC InChI=1S/C28H25N3O3S2/c32-27(30-26(23-11-5-2-6-12-23)25-13-7-8-18-29-25)28-31(19-20-35-28)36(33,34)24-16-14-22(15-17-24)21-9-3-1-4-10-21/h1-18,26,28H,19-20H2,(H,30,32)/t26-,28+/m1/s1
DM9V5GS CS C1CS[C@H](N1S(=O)(=O)C2=CC=C(C=C2)C3=CC=CC=C3)C(=O)N[C@H](C4=CC=CC=C4)C5=CC=CC=N5
DM9V5GS IK LSSZZFZFFKZTCL-IAPPQJPRSA-N
DM9V5GS IU (2S)-3-(4-phenylphenyl)sulfonyl-N-[(R)-phenyl(pyridin-2-yl)methyl]-1,3-thiazolidine-2-carboxamide
DM9V5GS DE Discovery agent
DM9CIJP ID DM9CIJP
DM9CIJP DN AS70
DM9CIJP HS Investigative
DM9CIJP SN AS-70; AS 70
DM9CIJP DT Small molecular drug
DM9CIJP PC 135443367
DM9CIJP MW 534.6
DM9CIJP FM C27H34N8O4
DM9CIJP IC InChI=1S/C27H34N8O4/c1-4-11-34-25-23(26(37)35(12-5-2)27(34)38)28-24(29-25)20-17-21(30-31(20)3)39-18-22(36)33-15-13-32(14-16-33)19-9-7-6-8-10-19/h6-10,17H,4-5,11-16,18H2,1-3H3,(H,28,29)
DM9CIJP CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)N4CCN(CC4)C5=CC=CC=C5
DM9CIJP IK BVHLYIIHYJFKSI-UHFFFAOYSA-N
DM9CIJP IU 8-[2-methyl-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethoxy]pyrazol-3-yl]-1,3-dipropyl-7H-purine-2,6-dione
DM9CIJP DE Discovery agent
DMZPHKG ID DMZPHKG
DMZPHKG DN AS74
DMZPHKG HS Investigative
DMZPHKG SN AS 74; AS-74
DMZPHKG DT Small molecular drug
DMZPHKG PC 135465785
DMZPHKG MW 496.5
DMZPHKG FM C23H24N6O7
DMZPHKG IC InChI=1S/C23H24N6O7/c1-3-7-28-21-19(22(31)29(8-4-2)23(28)32)25-20(26-21)16-10-18(27-36-16)33-11-17(30)24-13-5-6-14-15(9-13)35-12-34-14/h5-6,9-10H,3-4,7-8,11-12H2,1-2H3,(H,24,30)(H,25,26)
DMZPHKG CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NO3)OCC(=O)NC4=CC5=C(C=C4)OCO5
DMZPHKG IK ZPOGAROKPIBRMR-UHFFFAOYSA-N
DMZPHKG IU N-(1,3-benzodioxol-5-yl)-2-[[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1,2-oxazol-3-yl]oxy]acetamide
DMZPHKG DE Discovery agent
DM7WJ6F ID DM7WJ6F
DM7WJ6F DN AS94
DM7WJ6F HS Investigative
DM7WJ6F SN AS 94; AS-94
DM7WJ6F DT Small molecular drug
DM7WJ6F PC 135529386
DM7WJ6F MW 537.6
DM7WJ6F FM C26H31N7O6
DM7WJ6F IC InChI=1S/C26H31N7O6/c1-5-12-32-23-21(24(35)33(13-6-2)26(32)37)28-22(29-23)18-14-20(30-31(18)4)39-15-19(34)27-17-10-8-16(9-11-17)25(36)38-7-3/h8-11,14H,5-7,12-13,15H2,1-4H3,(H,27,34)(H,28,29)
DM7WJ6F CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC=C(C=C4)C(=O)OCC
DM7WJ6F IK BVABUBJIQWDRNZ-UHFFFAOYSA-N
DM7WJ6F IU ethyl 4-[[2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetyl]amino]benzoate
DM7WJ6F DE Discovery agent
DMN3E9Q ID DMN3E9Q
DMN3E9Q DN AS95
DMN3E9Q HS Investigative
DMN3E9Q SN AS 95; AS-95
DMN3E9Q DT Small molecular drug
DMN3E9Q PC 135443359
DMN3E9Q MW 509.5
DMN3E9Q FM C24H27N7O6
DMN3E9Q IC InChI=1S/C24H27N7O6/c1-4-10-30-21-19(22(33)31(11-5-2)24(30)36)26-20(27-21)16-12-18(28-29(16)3)37-13-17(32)25-15-8-6-14(7-9-15)23(34)35/h6-9,12H,4-5,10-11,13H2,1-3H3,(H,25,32)(H,26,27)(H,34,35)
DMN3E9Q CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC=C(C=C4)C(=O)O
DMN3E9Q IK JTHIYDNBNYRAEL-UHFFFAOYSA-N
DMN3E9Q IU 4-[[2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetyl]amino]benzoic acid
DMN3E9Q DE Discovery agent
DML6I8J ID DML6I8J
DML6I8J DN AS96
DML6I8J HS Investigative
DML6I8J SN AS 96; AS-96
DML6I8J DT Small molecular drug
DML6I8J PC 135416058
DML6I8J MW 530.6
DML6I8J FM C27H30N8O4
DML6I8J IC InChI=1S/C27H30N8O4/c1-4-11-34-25-23(26(37)35(12-5-2)27(34)38)28-24(29-25)20-17-21(30-31(20)3)39-18-22(36)33-15-13-32(14-16-33)19-9-7-6-8-10-19/h4-10,17H,1-2,11-16,18H2,3H3,(H,28,29)
DML6I8J CS CN1C(=CC(=N1)OCC(=O)N2CCN(CC2)C3=CC=CC=C3)C4=NC5=C(N4)C(=O)N(C(=O)N5CC=C)CC=C
DML6I8J IK HCIZQLZOFGBZIE-UHFFFAOYSA-N
DML6I8J IU 8-[2-methyl-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethoxy]pyrazol-3-yl]-1,3-bis(prop-2-enyl)-7H-purine-2,6-dione
DML6I8J DE Discovery agent
DMR01O4 ID DMR01O4
DMR01O4 DN AS-9705
DMR01O4 HS Investigative
DMR01O4 CP Dainippon Pharmaceuticals
DMR01O4 DT Small molecular drug
DMR01O4 PC 2779822
DMR01O4 MW 249.3
DMR01O4 FM C14H19NO3
DMR01O4 IC InChI=1S/C14H19NO3/c1-5-18-14(17)13-9(3)15(11-6-7-11)8(2)12(13)10(4)16/h11H,5-7H2,1-4H3
DMR01O4 CS CCOC(=O)C1=C(N(C(=C1C(=O)C)C)C2CC2)C
DMR01O4 IK KUMRNXGGFLRUIV-UHFFFAOYSA-N
DMR01O4 IU ethyl 4-acetyl-1-cyclopropyl-2,5-dimethylpyrrole-3-carboxylate
DMR01O4 CA CAS 423768-51-8
DMR01O4 DE Gastric motility disorder; Vomiting
DMZ7FJN ID DMZ7FJN
DMZ7FJN DN AS99
DMZ7FJN HS Investigative
DMZ7FJN SN AS 99; AS-99
DMZ7FJN DT Small molecular drug
DMZ7FJN PC 135522368
DMZ7FJN MW 493.6
DMZ7FJN FM C25H31N7O4
DMZ7FJN IC InChI=1S/C25H31N7O4/c1-6-10-31-23-21(24(34)32(11-7-2)25(31)35)27-22(28-23)18-13-20(29-30(18)5)36-14-19(33)26-17-9-8-15(3)16(4)12-17/h8-9,12-13H,6-7,10-11,14H2,1-5H3,(H,26,33)(H,27,28)
DMZ7FJN CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC(=C(C=C4)C)C
DMZ7FJN IK FCMUQGWJTIVYIU-UHFFFAOYSA-N
DMZ7FJN IU N-(3,4-dimethylphenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetamide
DMZ7FJN DE Discovery agent
DM3WVPJ ID DM3WVPJ
DM3WVPJ DN Asacolitin
DM3WVPJ HS Investigative
DM3WVPJ SN Apriso; Asacol; Asacol HD; 5-Aminosalicylic acid; Benzoic acid, 5-amino-2-hydroxy-; Canasa; Claversal; Fisalamine; Lialda; Lixacol; Mesalamine [USAN]; Mesalazina; Mesalazina [Spanish]; Mesalazine; Mesalazinum; Mesalazinum [Latin]; Mesasal; Pentasa; Rowasa; Salofalk; m-Aminosalicylic acid; mesalamine; p-Aminosalicylsaeure; p-Aminosalicylsaeure [German]; sfRowasa; 2-Hydroxy-5-aminobenzoic acid; 5-ASA; 5-Amino Salicylic Acid; 5-Amino-2-hydroxybenzoic acid; 5-amino-2-hydroxy-benzoic acid; 89-57-6
DM3WVPJ PC 4075
DM3WVPJ MW 153.14
DM3WVPJ FM C7H7NO3
DM3WVPJ IC KBOPZPXVLCULAV-UHFFFAOYSA-N
DM3WVPJ CS C1=CC(=C(C=C1N)C(=O)O)O
DM3WVPJ IK 1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
DM3WVPJ IU 5-amino-2-hydroxybenzoic acid
DM3WVPJ CA CAS 89-57-6
DM3WVPJ CB CHEBI:6775
DM3WVPJ DE Inflammatory bowel disease
DM5WR0L ID DM5WR0L
DM5WR0L DN ASC-201
DM5WR0L HS Investigative
DM5WR0L SN Dipeptidyl peptidase-4 inhibitor (bone marrow transplantation), America Stem Cell
DM5WR0L CP America Stem Cell Inc
DM5WR0L DE Bone marrow transplantation
DMYJ87C ID DMYJ87C
DMYJ87C DN ASC-JMX2
DMYJ87C HS Investigative
DMYJ87C SN ASCJ-M12; ASCJ-M5; Q-103; Q-49; Androgen antagonist (prostate tumor/benign prostatic hyperplasia), AndroScience; ARD enhancers (oral, prostate tumor/benign prostatic hyperplasia), AndroScience
DMYJ87C CP AndroScience Corp
DMYJ87C DE Prostate hyperplasia
DMT5LJN ID DMT5LJN
DMT5LJN DN ASC-JMZ1
DMT5LJN HS Investigative
DMT5LJN CP AndroScience Corp
DMT5LJN DE Bladder cancer
DMT8Y65 ID DMT8Y65
DMT8Y65 DN ASIATIC ACID
DMT8Y65 HS Investigative
DMT8Y65 SN Asiatic acid; 464-92-6; Dammarolic acid; UNII-9PA5A687X5; NSC 166063; CHEBI:2873; CHEMBL404313; JXSVIVRDWWRQRT-UYDOISQJSA-N; 9PA5A687X5; Asiantic acid; (1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid; Asiatic-acid; MFCD00238541; HSDB 7662; NSC-166063; 2,3,23-trihydroxyurs-12-en-28-oic acid; A)-2,3,23-trihydroxyurs-12-en-28-oic acid; Asiatic acid, 97%; AC1Q5QHS; AC1L3O2W
DMT8Y65 DT Small molecular drug
DMT8Y65 PC 119034
DMT8Y65 MW 488.7
DMT8Y65 FM C30H48O5
DMT8Y65 IC InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1
DMT8Y65 CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DMT8Y65 IK JXSVIVRDWWRQRT-UYDOISQJSA-N
DMT8Y65 IU (1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DMT8Y65 CA CAS 464-92-6
DMT8Y65 CB CHEBI:2873
DMT8Y65 DE Discovery agent
DMTBZUC ID DMTBZUC
DMTBZUC DN ASKENDOSIDE B
DMTBZUC HS Investigative
DMTBZUC SN askendoside B; CHEMBL411981
DMTBZUC DT Small molecular drug
DMTBZUC PC 44406305
DMTBZUC MW 929.1
DMTBZUC FM C47H76O18
DMTBZUC IC InChI=1S/C47H76O18/c1-21(48)61-34-25(52)19-60-40(35(34)64-39-33(56)31(54)24(51)18-59-39)63-28-10-12-47-20-46(47)14-13-43(6)36(45(8)11-9-29(65-45)42(4,5)57)22(49)16-44(43,7)27(46)15-26(37(47)41(28,2)3)62-38-32(55)30(53)23(50)17-58-38/h22-40,49-57H,9-20H2,1-8H3/t22-,23+,24-,25+,26-,27-,28-,29+,30-,31-,32+,33+,34-,35+,36-,37-,38-,39-,40-,43+,44-,45+,46-,47+/m0/s1
DMTBZUC CS CC(=O)O[C@H]1[C@@H](CO[C@H]([C@@H]1O[C@H]2[C@@H]([C@H]([C@H](CO2)O)O)O)O[C@H]3CC[C@]45C[C@]46CC[C@@]7([C@H]([C@H](C[C@]7([C@@H]6C[C@@H]([C@H]5C3(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)C)O)[C@]9(CC[C@@H](O9)C(C)(C)O)C)C)O
DMTBZUC IK BTTRQTJYXLOSMR-WEWBRACISA-N
DMTBZUC IU [(2S,3R,4S,5R)-5-hydroxy-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-3-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-4-yl] acetate
DMTBZUC DE Discovery agent
DM2DPYQ ID DM2DPYQ
DM2DPYQ DN ASKH95
DM2DPYQ HS Investigative
DM2DPYQ DE Discovery agent
DMEO3Y4 ID DMEO3Y4
DMEO3Y4 DN ASN02563583
DMEO3Y4 HS Investigative
DMEO3Y4 SN ASN 02563583; ASN-02563583
DMEO3Y4 DT Small molecular drug
DMEO3Y4 PC 3167869
DMEO3Y4 MW 460.5
DMEO3Y4 FM C25H24N4O3S
DMEO3Y4 IC InChI=1S/C25H24N4O3S/c1-17(24(30)26-18-9-5-4-6-10-18)33-25-28-27-23(21-11-7-8-12-22(21)32-3)29(25)19-13-15-20(31-2)16-14-19/h4-17H,1-3H3,(H,26,30)
DMEO3Y4 CS CC(C(=O)NC1=CC=CC=C1)SC2=NN=C(N2C3=CC=C(C=C3)OC)C4=CC=CC=C4OC
DMEO3Y4 IK KGGHSILNBGUJEN-UHFFFAOYSA-N
DMEO3Y4 IU 2-[[5-(2-methoxyphenyl)-4-(4-methoxyphenyl)-1,2,4-triazol-3-yl]sulfanyl]-N-phenylpropanamide
DMEO3Y4 DE Discovery agent
DMC82XN ID DMC82XN
DMC82XN DN ASN04421891
DMC82XN HS Investigative
DMC82XN SN ASN 04421891; ASN-04421891
DMC82XN DT Small molecular drug
DMC82XN PC 3187704
DMC82XN MW 524.6
DMC82XN FM C30H32N6O3
DMC82XN IC InChI=1S/C30H32N6O3/c1-38-18-17-36-29(32-33-34-36)28(26-20-24-19-25(39-2)13-14-27(24)31-30(26)37)35(21-23-11-7-4-8-12-23)16-15-22-9-5-3-6-10-22/h3-14,19-20,28H,15-18,21H2,1-2H3,(H,31,37)
DMC82XN CS COCCN1C(=NN=N1)C(C2=CC3=C(C=CC(=C3)OC)NC2=O)N(CCC4=CC=CC=C4)CC5=CC=CC=C5
DMC82XN IK JKKKHIBCTKIWFJ-UHFFFAOYSA-N
DMC82XN IU 3-[[benzyl(2-phenylethyl)amino]-[1-(2-methoxyethyl)tetrazol-5-yl]methyl]-6-methoxy-1H-quinolin-2-one
DMC82XN DE Discovery agent
DMKR69T ID DMKR69T
DMKR69T DN ASN04450772
DMKR69T HS Investigative
DMKR69T SN ASN 04450772; ASN-04450772
DMKR69T DT Small molecular drug
DMKR69T PC 3188786
DMKR69T MW 535.6
DMKR69T FM C26H25N5O6S
DMKR69T IC InChI=1S/C26H25N5O6S/c1-36-18-10-4-15(5-11-18)13-29-25(34)22(16-6-8-17(32)9-7-16)31(14-19-3-2-12-37-19)26(35)23-20(27)21(24(28)33)30-38-23/h2-12,22,32H,13-14,27H2,1H3,(H2,28,33)(H,29,34)
DMKR69T CS COC1=CC=C(C=C1)CNC(=O)C(C2=CC=C(C=C2)O)N(CC3=CC=CO3)C(=O)C4=C(C(=NS4)C(=O)N)N
DMKR69T IK TVONKIFIPYRNRD-UHFFFAOYSA-N
DMKR69T IU 4-amino-5-N-(furan-2-ylmethyl)-5-N-[1-(4-hydroxyphenyl)-2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-1,2-thiazole-3,5-dicarboxamide
DMKR69T DE Discovery agent
DMQ0VZ8 ID DMQ0VZ8
DMQ0VZ8 DN ASN04885796
DMQ0VZ8 HS Investigative
DMQ0VZ8 SN ASN 04885796; ASN-04885796
DMQ0VZ8 DT Small molecular drug
DMQ0VZ8 PC 3191600
DMQ0VZ8 MW 517.6
DMQ0VZ8 FM C28H28FN5O4
DMQ0VZ8 IC InChI=1S/C28H28FN5O4/c1-37-22-14-12-21(13-15-22)34(26(35)18-33-25-7-3-2-6-24(25)31-32-33)27(19-8-10-20(29)11-9-19)28(36)30-17-23-5-4-16-38-23/h2-3,6-15,23,27H,4-5,16-18H2,1H3,(H,30,36)
DMQ0VZ8 CS COC1=CC=C(C=C1)N(C(C2=CC=C(C=C2)F)C(=O)NCC3CCCO3)C(=O)CN4C5=CC=CC=C5N=N4
DMQ0VZ8 IK HIWKGPKZDUQDKF-UHFFFAOYSA-N
DMQ0VZ8 IU 2-(N-[2-(benzotriazol-1-yl)acetyl]-4-methoxyanilino)-2-(4-fluorophenyl)-N-(oxolan-2-ylmethyl)acetamide
DMQ0VZ8 DE Discovery agent
DMA20JP ID DMA20JP
DMA20JP DN ASN06917370
DMA20JP HS Investigative
DMA20JP SN ASN 06917370; ASN-06917370
DMA20JP DT Small molecular drug
DMA20JP PC 135439060
DMA20JP MW 531.9
DMA20JP FM C24H21ClF3N7O2
DMA20JP IC InChI=1S/C24H21ClF3N7O2/c25-18-4-2-1-3-15(18)13-35-21-19(32-33-35)22(36)31-20(30-21)14-9-11-34(12-10-14)23(37)29-17-7-5-16(6-8-17)24(26,27)28/h1-8,14H,9-13H2,(H,29,37)(H,30,31,36)
DMA20JP CS C1CN(CCC1C2=NC3=C(C(=O)N2)N=NN3CC4=CC=CC=C4Cl)C(=O)NC5=CC=C(C=C5)C(F)(F)F
DMA20JP IK SKWHAHNDWJREJG-UHFFFAOYSA-N
DMA20JP IU 4-[3-[(2-chlorophenyl)methyl]-7-oxo-6H-triazolo[4,5-d]pyrimidin-5-yl]-N-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide
DMA20JP DE Discovery agent
DMFNZOI ID DMFNZOI
DMFNZOI DN ASN-11124542
DMFNZOI HS Investigative
DMFNZOI SN AC1O5VPR; ASN 11124542
DMFNZOI DT Small molecular drug
DMFNZOI PC 6490494
DMFNZOI MW 268.3
DMFNZOI FM C13H8N4OS
DMFNZOI IC InChI=1S/C13H8N4OS/c18-13-8(3-7-4-14-5-15-7)11-9(17-13)1-2-10-12(11)19-6-16-10/h1-6H,(H,14,15)(H,17,18)/b8-3-
DMFNZOI CS C1=CC2=C(C\\3=C1NC(=O)/C3=C\\C4=CN=CN4)SC=N2
DMFNZOI IK VFBGXTUGODTSPK-BAQGIRSFSA-N
DMFNZOI IU (8Z)-8-(1H-imidazol-5-ylmethylidene)-6H-pyrrolo[2,3-g][1,3]benzothiazol-7-one
DMFNZOI DE Discovery agent
DM8XT1Y ID DM8XT1Y
DM8XT1Y DN ASOBAMAST
DM8XT1Y HS Investigative
DM8XT1Y SN Asobamast < Rec INN; Z-1819; N-[4-(3-Methylisoxazol-5-yl)thiazol-2-yl]oxamic acid 2-ethoxyethyl ester
DM8XT1Y DT Small molecular drug
DM8XT1Y PC 72033
DM8XT1Y MW 325.34
DM8XT1Y FM C13H15N3O5S
DM8XT1Y IC InChI=1S/C13H15N3O5S/c1-3-19-4-5-20-12(18)11(17)15-13-14-9(7-22-13)10-6-8(2)16-21-10/h6-7H,3-5H2,1-2H3,(H,14,15,17)
DM8XT1Y CS CCOCCOC(=O)C(=O)NC1=NC(=CS1)C2=CC(=NO2)C
DM8XT1Y IK IKYTUOHXXXPNOG-UHFFFAOYSA-N
DM8XT1Y IU 2-ethoxyethyl 2-[[4-(3-methyl-1,2-oxazol-5-yl)-1,3-thiazol-2-yl]amino]-2-oxoacetate
DM8XT1Y CA CAS 104777-03-9
DM8XT1Y DE Asthma
DM3XCM1 ID DM3XCM1
DM3XCM1 DN ASP-2002
DM3XCM1 HS Investigative
DM3XCM1 SN Integrin antagonist (ulcerative colitis), Asphelia
DM3XCM1 CP Asphelia Pharmaceuticals Inc
DM3XCM1 DE Ulcerative colitis
DMZ9GQR ID DMZ9GQR
DMZ9GQR DN ASP-3258
DMZ9GQR HS Investigative
DMZ9GQR SN PDE 4 inhibitor (airway inflammation), Astellas; Phosphodiesterase 4 inhibitor (airway inflammation), Astellas
DMZ9GQR CP Astellas Pharma Inc
DMZ9GQR PC 10156040
DMZ9GQR MW 370.8
DMZ9GQR FM C20H19ClN2O3
DMZ9GQR IC InChI=1S/C20H19ClN2O3/c1-3-23-19-15(8-7-12(2)22-19)18(13-5-4-6-14(21)11-13)16(20(23)26)9-10-17(24)25/h4-8,11H,3,9-10H2,1-2H3,(H,24,25)
DMZ9GQR CS CCN1C2=C(C=CC(=N2)C)C(=C(C1=O)CCC(=O)O)C3=CC(=CC=C3)Cl
DMZ9GQR IK XYFVLSWIYKWKTC-UHFFFAOYSA-N
DMZ9GQR IU 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,8-naphthyridin-3-yl]propanoic acid
DMZ9GQR DE Respiratory tract inflammation
DMFWTOP ID DMFWTOP
DMFWTOP DN ASP-8370
DMFWTOP HS Investigative
DMFWTOP SN AS-1725195; AS-1928370; TRPV1 antagonists (neuropathic pain); TRPV1 antagonists (neuropathic pain), Astellas
DMFWTOP CP Astellas Pharma Inc
DMFWTOP DE Neuropathic pain
DMGB90V ID DMGB90V
DMGB90V DN Aspartate Semialdehyde
DMGB90V HS Investigative
DMGB90V SN Aspartate semialdehyde; (2S)-2-ammonio-4-oxobutanoate; L-Aspartate 4-semialdehyde; aspartate semi-aldehyde; L-aspartate beta-semialdehyde; 15106-57-7; AC1NRA59; L-2-ammonio-4-oxobutanoate; HOSWPDPVFBCLSY-VKHMYHEASA-N; CHEBI:537519; (2S)-2-azaniumyl-4-oxobutanoate; L-aspartic acid 4-semialdehyde betaine; (2S)-2-azaniumyl-4-oxidanylidene-butanoate
DMGB90V DT Small molecular drug
DMGB90V PC 5287708
DMGB90V MW 117.1
DMGB90V FM C4H7NO3
DMGB90V IC InChI=1S/C4H7NO3/c5-3(1-2-6)4(7)8/h2-3H,1,5H2,(H,7,8)/t3-/m0/s1
DMGB90V CS C(C=O)[C@@H](C(=O)[O-])[NH3+]
DMGB90V IK HOSWPDPVFBCLSY-VKHMYHEASA-N
DMGB90V IU (2S)-2-azaniumyl-4-oxobutanoate
DMGB90V CA CAS 2338-03-6
DMGB90V CB CHEBI:537519
DMGB90V DE Discovery agent
DMK7EYA ID DMK7EYA
DMK7EYA DN Aspartic acid
DMK7EYA HS Investigative
DMK7EYA SN (2S)-2-aminobutanedioic acid; (2S)-Aspartic acid; (S)-2-Aminosuccinic acid; (S)-Aminobutanedioic acid; (S)-Aspartic acid; Acidum asparticum; Aminosuccinic acid; Asparagic acid; Asparaginic acid; Asparaginsaeure [German]; Aspartate, L-; Aspartic acid, L-; Aspatofort; Butanedioic acid, amino-, (S); H-Asp-OH; L-(+)-Aspartic acid; L-2-Aminobutanedioic acid; L-Aminosuccinic acid; L-Asp; L-Asparagic acid; L-Asparaginic acid; L-Asparaginsaeure; L-Asparaginsyra; L-Aspartinsaeure; L-aspartate; L-aspartic acid; aspartate; aspartic acid
DMK7EYA DT Small molecular drug
DMK7EYA PC 5960
DMK7EYA MW 133.103
DMK7EYA FM C4H7NO4
DMK7EYA IC InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1
DMK7EYA CS C(C(C(=O)O)N)C(=O)O
DMK7EYA IK CKLJMWTZIZZHCS-REOHCLBHSA-N
DMK7EYA IU (2S)-2-aminobutanedioic acid
DMK7EYA CA CAS 56-84-8
DMK7EYA CB ChEBI:17053
DMJEZ62 ID DMJEZ62
DMJEZ62 DN Asp-BrPmp-Leu
DMJEZ62 HS Investigative
DMJEZ62 SN Asp-BrPmp-Leu; CHEMBL1289231; BDBM50331945
DMJEZ62 DT Small molecular drug
DMJEZ62 PC 52949968
DMJEZ62 MW 566.3
DMJEZ62 FM C20H29BrN3O9P
DMJEZ62 IC InChI=1S/C20H29BrN3O9P/c1-10(2)7-15(20(29)30)24-19(28)14(23-18(27)13(22)9-16(25)26)8-11-3-5-12(6-4-11)17(21)34(31,32)33/h3-6,10,13-15,17H,7-9,22H2,1-2H3,(H,23,27)(H,24,28)(H,25,26)(H,29,30)(H2,31,32,33)/t13-,14-,15-,17?/m0/s1
DMJEZ62 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)C(P(=O)(O)O)Br)NC(=O)[C@H](CC(=O)O)N
DMJEZ62 IK VZSILTSENHCLNI-CKSGOKGCSA-N
DMJEZ62 IU (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-[4-[bromo(phosphono)methyl]phenyl]propanoyl]amino]-4-methylpentanoic acid
DMJEZ62 DE Discovery agent
DMEW37R ID DMEW37R
DMEW37R DN Asp-D-Glu-Leu-Glu-Cha-Cys
DMEW37R HS Investigative
DMEW37R SN CHEMBL303541; Asp-D-Glu-Leu-Glu-Cha-Cys; AC1LAAJ7; BDBM50096402; Asp-D-Glu-Leu-Glu-Cha(beta-cyclohexylanine)-Cys; L-Asp-D-Glu-L-Leu-L-Glu-3-Cyclohexyl-L-Ala-L-Cys-OH; (R)-2-[(S)-2-((S)-2-{(S)-2-[(R)-2-((S)-2-Amino-3-carboxy-propanoylamino)-4-carboxy-butanoylamino]-4-methyl-pentanoylamino}-4-carboxy-butanoylamino)-3-cyclohexyl-propanoylamino]-3-mercapto-propionic acid
DMEW37R DT Small molecular drug
DMEW37R PC 484574
DMEW37R MW 760.9
DMEW37R FM C32H52N6O13S
DMEW37R IC InChI=1S/C32H52N6O13S/c1-16(2)12-21(36-28(46)19(8-10-24(39)40)34-27(45)18(33)14-26(43)44)30(48)35-20(9-11-25(41)42)29(47)37-22(13-17-6-4-3-5-7-17)31(49)38-23(15-52)32(50)51/h16-23,52H,3-15,33H2,1-2H3,(H,34,45)(H,35,48)(H,36,46)(H,37,47)(H,38,49)(H,39,40)(H,41,42)(H,43,44)(H,50,51)/t18-,19+,20-,21-,22-,23-/m0/s1
DMEW37R CS CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N
DMEW37R IK ZFRKNLVWQDBGEY-ZKPZVSKHSA-N
DMEW37R IU (4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMEW37R DE Discovery agent
DMAY2N3 ID DMAY2N3
DMAY2N3 DN Asperlicin
DMAY2N3 HS Investigative
DMAY2N3 SN asperlicin; UNII-U0MJE9LRXV; 93413-04-8; U0MJE9LRXV; CHEMBL283117; (S-(2alpha,9beta,9(R*),9alpha,beta))-6,7-Dihydro-7-((2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo(1,2-a)indol-9-yl)methyl)quinazolino(3,2-a)(1,4)benzodiazepine-5,13-dione; Quinazolino(3,2-a)(1,4)benzodiazepine-5,13-dione, 6,7-dihydro-7-((2,3,9,9a-tetrahydro-9-hydroxy-2-(2-methylpropyl)-3-oxo-1H-imidazo(1,2-a)indol-9-yl)methyl)-, (2S-(2alpha,9beta,9(R*),9abeta))-; C31H29N5O4; AC1MHZCP; SCHEMBL1004269; BDBM50019777; LS-178211
DMAY2N3 DT Small molecular drug
DMAY2N3 PC 3035433
DMAY2N3 MW 535.6
DMAY2N3 FM C31H29N5O4
DMAY2N3 IC InChI=1S/C31H29N5O4/c1-17(2)15-22-29(39)36-25-14-8-5-11-20(25)31(40,30(36)34-22)16-23-26-32-21-12-6-3-9-18(21)28(38)35(26)24-13-7-4-10-19(24)27(37)33-23/h3-14,17,22-23,30,34,40H,15-16H2,1-2H3,(H,33,37)/t22-,23-,30-,31-/m0/s1
DMAY2N3 CS CC(C)C[C@H]1C(=O)N2[C@H](N1)[C@@](C3=CC=CC=C32)(C[C@H]4C5=NC6=CC=CC=C6C(=O)N5C7=CC=CC=C7C(=O)N4)O
DMAY2N3 IK MGMRIOLWEROPJY-FPACPZPDSA-N
DMAY2N3 IU (7S)-7-[[(2S,3aS,4S)-4-hydroxy-2-(2-methylpropyl)-1-oxo-3,3a-dihydro-2H-imidazo[1,2-a]indol-4-yl]methyl]-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione
DMAY2N3 CA CAS 93413-04-8
DMAY2N3 DE Gastrointestinal disease
DMLBSNP ID DMLBSNP
DMLBSNP DN aspirin triggered lipoxin A4
DMLBSNP HS Investigative
DMLBSNP SN aspirin-triggered lipoxin A4; ATL; aspirin triggered 15-epi lipoxin A4
DMLBSNP DT Small molecular drug
DMLBSNP PC 9841438
DMLBSNP MW 352.5
DMLBSNP FM C20H32O5
DMLBSNP IC InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18-,19+/m1/s1
DMLBSNP CS CCCCC[C@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)O)O
DMLBSNP IK IXAQOQZEOGMIQS-JEWNPAEBSA-N
DMLBSNP IU (5S,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
DMLBSNP CB CHEBI:72789
DMLBSNP DE Discovery agent
DMOP941 ID DMOP941
DMOP941 DN aspirin-triggered resolvin D1
DMOP941 HS Investigative
DMOP941 SN AT-Resolvin D1; AT-RvD1
DMOP941 DT Small molecular drug
DMOP941 PC 16126783
DMOP941 MW 376.5
DMOP941 FM C22H32O5
DMOP941 IC InChI=1S/C22H32O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-12,15-16,19-21,23-25H,2,13-14,17-18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,12-8-,15-10+,16-11+/t19-,20-,21+/m1/s1
DMOP941 CS CC/C=C\\C[C@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](C/C=C\\CCC(=O)O)O)O)O
DMOP941 IK OIWTWACQMDFHJG-BJEBZIPWSA-N
DMOP941 IU (4Z,7S,8R,9E,11E,13Z,15E,17R,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
DMOP941 CA CAS 528583-91-7
DMOP941 CB CHEBI:138179
DMOP941 DE Discovery agent
DMKAHYQ ID DMKAHYQ
DMKAHYQ DN Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe
DMKAHYQ HS Investigative
DMKAHYQ SN Asp-Tyr(SO3Na)-Met-Gly-Trp-Met-Asp-Phe-NH2
DMKAHYQ DE Discovery agent
DME76KU ID DME76KU
DME76KU DN AST-487
DME76KU HS Investigative
DME76KU SN AST 487; NVP-AST 487; NVP-AST487
DME76KU DT Small molecular drug
DME76KU PC 11409972
DME76KU MW 529.6
DME76KU FM C26H30F3N7O2
DME76KU IC InChI=1S/C26H30F3N7O2/c1-3-35-10-12-36(13-11-35)16-18-4-5-20(14-22(18)26(27,28)29)34-25(37)33-19-6-8-21(9-7-19)38-24-15-23(30-2)31-17-32-24/h4-9,14-15,17H,3,10-13,16H2,1-2H3,(H,30,31,32)(H2,33,34,37)
DME76KU CS CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)NC3=CC=C(C=C3)OC4=NC=NC(=C4)NC)C(F)(F)F
DME76KU IK ODPGGGTTYSGTGO-UHFFFAOYSA-N
DME76KU IU 1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea
DME76KU CA CAS 630124-46-8
DME76KU DE Discovery agent
DMJAPFH ID DMJAPFH
DMJAPFH DN Asterric acid
DMJAPFH HS Investigative
DMJAPFH SN 577-64-0; MLS000863583; CHEMBL469424; SMR000440714; 2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid; AC1MIV9I; Asterric acid_120092; MEGxm0_000244; ZINC7778; SCHEMBL6046569; XOKVHFNTYHPEHN-UHFFFAOYSA-; cid_3080568; ACon1_001529; ACon0_000930; CTK8F7847; BDBM50711; DTXSID60206405; MolPort-001-739-484; HMS2270H17; MFCD00216131; MCULE-7550426133; NCGC00180411-01; Asterric acid, > L007432; BRD-K20637966-001-01-0
DMJAPFH DT Small molecular drug
DMJAPFH PC 3080568
DMJAPFH MW 348.3
DMJAPFH FM C17H16O8
DMJAPFH IC InChI=1S/C17H16O8/c1-8-4-11(19)14(16(20)21)12(5-8)25-15-10(17(22)24-3)6-9(18)7-13(15)23-2/h4-7,18-19H,1-3H3,(H,20,21)
DMJAPFH CS CC1=CC(=C(C(=C1)OC2=C(C=C(C=C2OC)O)C(=O)OC)C(=O)O)O
DMJAPFH IK XOKVHFNTYHPEHN-UHFFFAOYSA-N
DMJAPFH IU 2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid
DMJAPFH CA CAS 577-64-0
DMJAPFH DE Discovery agent
DMZHWPG ID DMZHWPG
DMZHWPG DN ASTRAGALIN
DMZHWPG HS Investigative
DMZHWPG SN Astragalin; 480-10-4; Astragaline; kaempferol-3-glucoside; Kaempferol 3-O-glucoside; Kaempferol 3-glucoside; Kaempferol-3-O-glucoside; asragalin; Kaempferol-3-beta-monoglucoside; Kaempferol-3-D-glucoside; Kaempferol-3-beta-glucopyranoside; UNII-APM8UQ3Z9O; 3,4',5,7-Tetrahydroxyflavone-3-glucoside; Kaempferol 3-O-beta-D-glucopyranoside; 3-Glucosylkaempferol; Kaempferol 3-O-beta-D-glucoside; APM8UQ3Z9O; 4H-1-Benzopyran-4-one, 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; CHEMBL233930; CHEBI:30200
DMZHWPG DT Small molecular drug
DMZHWPG PC 5282102
DMZHWPG MW 448.4
DMZHWPG FM C21H20O11
DMZHWPG IC InChI=1S/C21H20O11/c22-7-13-15(26)17(28)18(29)21(31-13)32-20-16(27)14-11(25)5-10(24)6-12(14)30-19(20)8-1-3-9(23)4-2-8/h1-6,13,15,17-18,21-26,28-29H,7H2/t13-,15-,17+,18-,21+/m1/s1
DMZHWPG CS C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
DMZHWPG IK JPUKWEQWGBDDQB-QSOFNFLRSA-N
DMZHWPG IU 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMZHWPG CA CAS 480-10-4
DMZHWPG CB CHEBI:30200
DMZHWPG DE Discovery agent
DMSFLTK ID DMSFLTK
DMSFLTK DN astressin
DMSFLTK HS Investigative
DMSFLTK SN Astressin; 170809-51-5; GTPL925; CHEBI:76649; MFCD00798715; AKOS024456701; fHLLREVLE-Nle-ARAEQLAQ-cyclo-(EAHK)NRKL-Nle-EII-NH2; [D-Phe(12), Nle(21,38), Glu(30), Lys(33)]-CRF (12-41); [D-Phe12, Nle21,38, Glu30, Lys33]-Corticotropin Releasing Factor fragment 12-41; D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo-(Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2; [D-Phe(12), Nle(21,38), Glu(30), Lys(33)]-corticotropin releasing factor fragment 12-41
DMSFLTK DT Small molecular drug
DMSFLTK PC 16133798
DMSFLTK MW 3563.2
DMSFLTK FM C161H269N49O42
DMSFLTK IC InChI=1S/C161H269N49O42/c1-23-27-41-96(189-145(239)107(52-59-123(217)218)199-152(246)114(71-84(13)14)207-157(251)126(85(15)16)208-147(241)108(53-60-124(219)220)197-140(234)102(47-38-66-179-161(172)173)193-151(245)112(69-82(9)10)204-153(247)113(70-83(11)12)205-155(249)116(74-94-77-175-79-181-94)201-134(228)95(163)72-92-39-30-29-31-40-92)135(229)182-88(19)130(224)186-100(45-36-64-177-159(168)169)136(230)183-89(20)131(225)188-106(51-58-122(215)216)144(238)195-104(49-56-119(165)212)146(240)202-110(67-80(5)6)149(243)185-90(21)132(226)187-103(48-55-118(164)211)143(237)196-105-50-57-121(214)176-63-35-33-44-99(192-154(248)115(73-93-76-174-78-180-93)200-133(227)91(22)184-137(105)231)142(236)206-117(75-120(166)213)156(250)194-101(46-37-65-178-160(170)171)139(233)190-98(43-32-34-62-162)141(235)203-111(68-81(7)8)150(244)191-97(42-28-24-2)138(232)198-109(54-61-125(221)222)148(242)210-128(87(18)26-4)158(252)209-127(129(167)223)86(17)25-3/h29-31,39-40,76-91,95-117,126-128H,23-28,32-38,41-75,162-163H2,1-22H3,(H2,164,211)(H2,165,212)(H2,166,213)(H2,167,223)(H,174,180)(H,175,181)(H,176,214)(H,182,229)(H,183,230)(H,184,231)(H,185,243)(H,186,224)(H,187,226)(H,188,225)(H,189,239)(H,190,233)(H,191,244)(H,192,248)(H,193,245)(H,194,250)(H,195,238)(H,196,237)(H,197,234)(H,198,232)(H,199,246)(H,200,227)(H,201,228)(H,202,240)(H,203,235)(H,204,247)(H,205,249)(H,206,236)(H,207,251)(H,208,241)(H,209,252)(H,210,242)(H,215,216)(H,217,218)(H,219,220)(H,221,222)(H4,168,169,177)(H4,170,171,178)(H4,172,173,179)/t86-,87-,88-,89-,90-,91-,95+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,126-,127-,128-/m0/s1
DMSFLTK CS CCCC[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C)CC2=CNC=N2)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@@H](CC4=CC=CC=C4)N
DMSFLTK IK HPYIIXJJVYSMCV-MGDXKYBTSA-N
DMSFLTK IU (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(3S,6S,9S,18S)-18-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]-3-(1H-imidazol-4-ylmethyl)-6-methyl-2,5,8,12-tetraoxo-1,4,7,13-tetrazacyclooctadec-9-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMSFLTK CB CHEBI:76649
DMSFLTK DE Discovery agent
DMODLPS ID DMODLPS
DMODLPS DN AT-008
DMODLPS HS Investigative
DMODLPS CP Affitech A/S
DMODLPS DE Autoimmune diabetes
DMCO2S4 ID DMCO2S4
DMCO2S4 DN AT-009
DMCO2S4 HS Investigative
DMCO2S4 CP Affitech A/S
DMCO2S4 DE Solid tumour/cancer
DMJNQ5G ID DMJNQ5G
DMJNQ5G DN ATC0065
DMJNQ5G HS Investigative
DMJNQ5G SN ATC-0065; ATC 0065
DMJNQ5G DT Small molecular drug
DMJNQ5G PC 11238212
DMJNQ5G MW 552.4
DMJNQ5G FM C25H29BrF3N5O
DMJNQ5G IC InChI=1S/C25H29BrF3N5O/c1-34(2)23-20-5-3-4-6-21(20)32-24(33-23)31-19-11-9-18(10-12-19)30-14-13-16-7-8-17(26)15-22(16)35-25(27,28)29/h3-8,15,18-19,30H,9-14H2,1-2H3,(H,31,32,33)
DMJNQ5G CS CN(C)C1=NC(=NC2=CC=CC=C21)NC3CCC(CC3)NCCC4=C(C=C(C=C4)Br)OC(F)(F)F
DMJNQ5G IK FWKVXHBRMCTKHZ-UHFFFAOYSA-N
DMJNQ5G IU 2-N-[4-[2-[4-bromo-2-(trifluoromethoxy)phenyl]ethylamino]cyclohexyl]-4-N,4-N-dimethylquinazoline-2,4-diamine
DMJNQ5G CA CAS 509145-82-8
DMJNQ5G DE Discovery agent
DMIA2F1 ID DMIA2F1
DMIA2F1 DN ATC-120
DMIA2F1 HS Investigative
DMIA2F1 SN CHEMBL412885; ATC-120; thiourea analogue, 14; SCHEMBL5947715; BDBM20317; ZINC14973328; BDBM50142759; N-(4-tert-butylbenzyl)-N''-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea; (R)-N-(4-(1-(3-(4-tert-butylbenzyl)thioureido)ethyl)phenyl)methanesulfonamide; N-(4-{(R)-1-[3-(4-tert-Butyl-benzyl)-thioureido]-ethyl}-phenyl)-methanesulfonamide
DMIA2F1 DT Small molecular drug
DMIA2F1 PC 10093552
DMIA2F1 MW 419.6
DMIA2F1 FM C21H29N3O2S2
DMIA2F1 IC InChI=1S/C21H29N3O2S2/c1-15(17-8-12-19(13-9-17)24-28(5,25)26)23-20(27)22-14-16-6-10-18(11-7-16)21(2,3)4/h6-13,15,24H,14H2,1-5H3,(H2,22,23,27)/t15-/m1/s1
DMIA2F1 CS C[C@H](C1=CC=C(C=C1)NS(=O)(=O)C)NC(=S)NCC2=CC=C(C=C2)C(C)(C)C
DMIA2F1 IK MRGDOZGZFFCDRJ-OAHLLOKOSA-N
DMIA2F1 IU 1-[(4-tert-butylphenyl)methyl]-3-[(1R)-1-[4-(methanesulfonamido)phenyl]ethyl]thiourea
DMIA2F1 DE Discovery agent
DMPJRHX ID DMPJRHX
DMPJRHX DN ATF-HI-8
DMPJRHX HS Investigative
DMPJRHX SN urokinase/urinary trypsin inhibitor chimera, Nissin/Hamamatsu University
DMPJRHX DE Discovery agent
DMSNBMQ ID DMSNBMQ
DMSNBMQ DN ATH-90879
DMSNBMQ HS Investigative
DMSNBMQ SN Histamine H3 antagonists (cognitive disorders/obesity); Histamine H3 antagonists (cognitive disorders/obesity), Athersys
DMSNBMQ CP Athersys Inc
DMSNBMQ DE Obesity
DMN5VDB ID DMN5VDB
DMN5VDB DN ATI-1150
DMN5VDB HS Investigative
DMN5VDB SN SN-38 (Protein Stabilized Nanoparticle, cancer), Azaya; SN-38 (injectable liposomal, Protein Stabilized Nanoparticle), Azaya
DMN5VDB CP Azaya Therapeutics
DMN5VDB DE Solid tumour/cancer
DMLDWHP ID DMLDWHP
DMLDWHP DN ATI-2341
DMLDWHP HS Investigative
DMLDWHP SN ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent
DMLDWHP CP Anchor Therapeutics Inc
DMLDWHP PC 121513892
DMLDWHP MW 2256.8
DMLDWHP FM C104H178N26O25S2
DMLDWHP IC InChI=1S/C104H178N26O25S2/c1-9-10-11-12-13-14-15-16-17-18-19-20-21-35-84(136)116-75(46-53-156-7)88(140)115-60-85(137)117-78(57-65-36-40-67(133)41-37-65)97(149)123-74(44-45-83(108)135)94(146)119-69(30-22-25-48-105)89(141)118-70(31-23-26-49-106)90(142)125-77(55-62(2)3)96(148)121-73(34-29-52-114-104(111)112)93(145)129-82(61-131)100(152)124-76(47-54-157-8)95(147)130-87(64(6)132)101(153)127-80(59-86(138)139)99(151)120-71(32-24-27-50-107)91(143)126-79(58-66-38-42-68(134)43-39-66)98(150)122-72(33-28-51-113-103(109)110)92(144)128-81(102(154)155)56-63(4)5/h36-43,62-64,69-82,87,131-134H,9-35,44-61,105-107H2,1-8H3,(H2,108,135)(H,115,140)(H,116,136)(H,117,137)(H,118,141)(H,119,146)(H,120,151)(H,121,148)(H,122,150)(H,123,149)(H,124,152)(H,125,142)(H,126,143)(H,127,153)(H,128,144)(H,129,145)(H,130,147)(H,138,139)(H,154,155)(H4,109,110,113)(H4,111,112,114)/t64-,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,87+/m1/s1
DMLDWHP CS CCCCCCCCCCCCCCCC(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)O
DMLDWHP IK YMLOFEANRZSEGQ-QNHYGVTPSA-N
DMLDWHP IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-(hexadecanoylamino)-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoic acid
DMLDWHP DE Bone marrow transplantation
DMAZ0EQ ID DMAZ0EQ
DMAZ0EQ DN ATL-801
DMAZ0EQ HS Investigative
DMAZ0EQ SN BWA-1433; Adenosine A2b receptor antagonists (coronary artery occlusion), Pennsylvania State University;Adenosine A2b receptor antagonists (diabetes), Pennsylvania State University
DMAZ0EQ CP Pennsylvania State University
DMAZ0EQ DT Small molecular drug
DMAZ0EQ PC 24780665
DMAZ0EQ MW 459.5
DMAZ0EQ FM C24H25N7O3
DMAZ0EQ IC InChI=1S/C24H25N7O3/c1-3-12-30-21-19(23(33)31(24(30)34)17-8-9-17)27-20(28-21)15-7-10-18(26-14-15)29(4-2)22(32)16-6-5-11-25-13-16/h5-7,10-11,13-14,17H,3-4,8-9,12H2,1-2H3,(H,27,28)
DMAZ0EQ CS CCCN1C2=C(C(=O)N(C1=O)C3CC3)NC(=N2)C4=CN=C(C=C4)N(CC)C(=O)C5=CN=CC=C5
DMAZ0EQ IK WULKGVCEOREGQF-UHFFFAOYSA-N
DMAZ0EQ IU N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7H-purin-8-yl)pyridin-2-yl]-N-ethylpyridine-3-carboxamide
DMAZ0EQ CA CAS 1000005-71-9
DMAZ0EQ DE Non-insulin dependent diabetes
DMYMCQA ID DMYMCQA
DMYMCQA DN ATL802
DMYMCQA HS Investigative
DMYMCQA SN ATL802; SCHEMBL1243258; GTPL5616
DMYMCQA DT Small molecular drug
DMYMCQA PC 24780383
DMYMCQA MW 513.5
DMYMCQA FM C24H22F3N7O3
DMYMCQA IC InChI=1S/C24H22F3N7O3/c1-3-10-33-20-18(22(36)34(23(33)37)15-6-7-15)30-19(31-20)13-5-9-17(29-11-13)32(2)21(35)14-4-8-16(28-12-14)24(25,26)27/h4-5,8-9,11-12,15H,3,6-7,10H2,1-2H3,(H,30,31)
DMYMCQA CS CCCN1C2=C(C(=O)N(C1=O)C3CC3)NC(=N2)C4=CN=C(C=C4)N(C)C(=O)C5=CN=C(C=C5)C(F)(F)F
DMYMCQA IK IKIXRBGOWUFFBN-UHFFFAOYSA-N
DMYMCQA IU N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7H-purin-8-yl)pyridin-2-yl]-N-methyl-6-(trifluoromethyl)pyridine-3-carboxamide
DMYMCQA DE Discovery agent
DM6V9SC ID DM6V9SC
DM6V9SC DN ATL-844
DM6V9SC HS Investigative
DM6V9SC SN N-(4-Cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; MRS 1754; 264622-58-4; MRS-1754; MRS1754; CHEMBL273807; N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide; N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide; [3H]MRS1754; [3H]-MRS1754; NCGC00015689-01; Lopac-M-6316; Lopac0_000729; GTPL453; GTPL449; MLS002153324; SCHEMBL1222380; AC1O7G54; CTK8E7916; CHEBI:93269; AOB5542; DTXSID80424967; MolPort-023-276-567; HMS3373J21; HMS3268F13; HMS2230A06; ZINC4475274; BDBM50086170; AKOS027427086; AKOS024457276; EX-3306; ATL-618; ATL-GW-22; ATL-GW-8; A2B adenosine receptor antagonists, Adenosine/Ortho-McNeil; A2B adenosine receptor antagonists (oral, asthma/diabetes), Adenosine Therapeutics; A2B adenosine receptor antagonists (oral, asthma/diabetes), Clinical Data
DM6V9SC CP University of Virginia
DM6V9SC DT Small molecular drug
DM6V9SC PC 6603931
DM6V9SC MW 486.5
DM6V9SC FM C26H26N6O4
DM6V9SC IC InChI=1S/C26H26N6O4/c1-3-13-31-24-22(25(34)32(14-4-2)26(31)35)29-23(30-24)18-7-11-20(12-8-18)36-16-21(33)28-19-9-5-17(15-27)6-10-19/h5-12H,3-4,13-14,16H2,1-2H3,(H,28,33)(H,29,30)
DM6V9SC CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NC4=CC=C(C=C4)C#N
DM6V9SC IK AJBBEYXFRYFVNM-UHFFFAOYSA-N
DM6V9SC IU N-(4-cyanophenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
DM6V9SC CA CAS 264622-58-4
DM6V9SC CB CHEBI:93269
DM6V9SC DE Asthma
DMA632U ID DMA632U
DMA632U DN ATLa2
DMA632U HS Investigative
DMA632U SN ATL analog [15-epi-16-(para-fluoro)-phenoxy-LXA4]
DMA632U DT Small molecular drug
DMA632U PC 73755048
DMA632U MW 404.5
DMA632U FM C23H29FO5
DMA632U IC InChI=1S/C23H29FO5/c1-18(17-29-20-15-13-19(24)14-16-20)9-6-4-2-3-5-7-10-21(25)22(26)11-8-12-23(27)28/h2-7,9-10,13-16,18,21-22,25-26H,8,11-12,17H2,1H3,(H,27,28)/b4-2-,5-3+,9-6+,10-7+/t18-,21+,22-/m0/s1
DMA632U CS C[C@H](COC1=CC=C(C=C1)F)/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)O
DMA632U IK SGFIFYSIHRWSCE-LLXPRBAESA-N
DMA632U IU (5S,6R,7E,9E,11Z,13E,15S)-16-(4-fluorophenoxy)-5,6-dihydroxy-15-methylhexadeca-7,9,11,13-tetraenoic acid
DMA632U DE Discovery agent
DMR2M7L ID DMR2M7L
DMR2M7L DN ATN-658
DMR2M7L HS Investigative
DMR2M7L SN ATN-291; ATN-292; HuATN-658; UPA mAbs, Attenuon; MAb (urokinase plasminogen activator system), Attenuon/Kyowa Hakko Kirin
DMR2M7L CP Attenuon LLC
DMR2M7L DE Solid tumour/cancer
DM2DAFS ID DM2DAFS
DM2DAFS DN ATPA
DM2DAFS HS Investigative
DM2DAFS SN ATPA; AC1Q6BQV; AC1L1D9I; 3-(5-tert-butyl-3-hydroxy-1,2-oxazol-4-yl)alanine; GTPL4140; HMS3260K20; Tox21_500139; LP00139; CCG-204234; NCGC00093629-02; NCGC00093629-01; NCGC00015027-03; NCGC00015027-02; NCGC00260824-01; NCGC00015027-04; EU-0100139; 2-azaniumyl-3-(5-tert-butyl-3-oxo-1,2-oxazol-4-yl)propanoate
DM2DAFS DT Small molecular drug
DM2DAFS PC 2253
DM2DAFS MW 228.24
DM2DAFS FM C10H16N2O4
DM2DAFS IC InChI=1S/C10H16N2O4/c1-10(2,3)7-5(8(13)12-16-7)4-6(11)9(14)15/h6H,4,11H2,1-3H3,(H,12,13)(H,14,15)
DM2DAFS CS CC(C)(C)C1=C(C(=O)NO1)CC(C(=O)O)N
DM2DAFS IK PIXJURSCCVBKRF-UHFFFAOYSA-N
DM2DAFS IU 2-amino-3-(5-tert-butyl-3-oxo-1,2-oxazol-4-yl)propanoic acid
DM2DAFS CA CAS 140158-50-5
DM2DAFS CB CHEBI:91806
DM2DAFS DE Discovery agent
DMXHQIN ID DMXHQIN
DMXHQIN DN ATPgammaS
DMXHQIN HS Investigative
DMXHQIN SN adenosine 5'-(3-thio)triphosphate
DMXHQIN DT Small molecular drug
DMXHQIN PC 44123300
DMXHQIN MW 519.22
DMXHQIN FM C10H12N5O12P3S-4
DMXHQIN IC InChI=1S/C10H16N5O12P3S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(25-10)1-24-28(18,19)26-29(20,21)27-30(22,23)31/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H,20,21)(H2,11,12,13)(H2,22,23,31)/p-4/t4-,6-,7-,10-/m1/s1
DMXHQIN CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])OP(=S)([O-])[O-])O)O)N
DMXHQIN IK NLTUCYMLOPLUHL-KQYNXXCUSA-J
DMXHQIN IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] dioxidophosphinothioyl phosphate
DMXHQIN DE Discovery agent
DMXLS78 ID DMXLS78
DMXLS78 DN ATPO
DMXLS78 HS Investigative
DMXLS78 SN ATPO; 252930-37-3; (R,S)-2-Amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid; 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid; ATPO, solid; AC1NECDZ; Lopac0_000092; SCHEMBL4318475; CHEMBL265301; GTPL4141; DTXSID70404915; MolPort-003-940-289; HMS3261F20; HMS3260C06; Tox21_500589; Tox21_500092; MFCD03452828; LP00092; LP00589; CCG-204187; NCGC00261274-01; NCGC00260777-01; NCGC00015093-05; NCGC00015093-02; NCGC00093594-01; NCGC00015093-04; NCGC00093594-02; NCGC00015093-03; EU-0100092; A 7845
DMXLS78 DT Small molecular drug
DMXLS78 PC 4615193
DMXLS78 MW 322.25
DMXLS78 FM C11H19N2O7P
DMXLS78 IC InChI=1S/C11H19N2O7P/c1-11(2,3)8-6(4-7(12)10(14)15)9(13-20-8)19-5-21(16,17)18/h7H,4-5,12H2,1-3H3,(H,14,15)(H2,16,17,18)
DMXLS78 CS CC(C)(C)C1=C(C(=NO1)OCP(=O)(O)O)CC(C(=O)O)N
DMXLS78 IK AGSOOCUNMTYPSE-UHFFFAOYSA-N
DMXLS78 IU 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid
DMXLS78 CA CAS 252930-37-3
DMXLS78 DE Discovery agent
DML2MAI ID DML2MAI
DML2MAI DN ATRIPLICIOLIDTIGLATE
DML2MAI HS Investigative
DML2MAI SN atripliciolidtiglate; Atripliciolide tiglate
DML2MAI DT Small molecular drug
DML2MAI PC 14314512
DML2MAI MW 358.4
DML2MAI FM C20H22O6
DML2MAI IC InChI=1S/C20H22O6/c1-6-10(2)18(22)25-15-9-20(5)16(21)8-13(26-20)11(3)7-14-17(15)12(4)19(23)24-14/h6-8,14-15,17H,4,9H2,1-3,5H3/b10-6+,11-7-/t14-,15-,17+,20-/m1/s1
DML2MAI CS C/C=C(\\C)/C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/C)C
DML2MAI IK QATUWZPYBIHFFR-GAZZCERVSA-N
DML2MAI IU [(2Z,4R,8R,9R,11R)-2,11-dimethyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (E)-2-methylbut-2-enoate
DML2MAI DE Discovery agent
DML3R5Z ID DML3R5Z
DML3R5Z DN Atropisomer 1
DML3R5Z HS Investigative
DML3R5Z SN CHEMBL584052; atropisomer 1; Atropisomer 2; SCHEMBL2601123; BDBM50300196
DML3R5Z DT Small molecular drug
DML3R5Z PC 44605611
DML3R5Z MW 341.4
DML3R5Z FM C21H15N3O2
DML3R5Z IC InChI=1S/C21H15N3O2/c25-13-7-5-12(6-8-13)18-16-11-23-20-19(16)15(9-10-22-20)14-3-1-2-4-17(14)24-21(18)26/h1-11,18,25H,(H,22,23)(H,24,26)
DML3R5Z CS C1=CC=C2C(=C1)C3=C4C(=CNC4=NC=C3)C(C(=O)N2)C5=CC=C(C=C5)O
DML3R5Z IK LGIBDQRYOFBMTC-UHFFFAOYSA-N
DML3R5Z IU 10-(4-hydroxyphenyl)-8,13,15-triazatetracyclo[9.6.1.02,7.014,18]octadeca-1(18),2,4,6,11,14,16-heptaen-9-one
DML3R5Z DE Discovery agent
DMHEK4U ID DMHEK4U
DMHEK4U DN ATS-907
DMHEK4U HS Investigative
DMHEK4U SN AK-138 series; ATS-907M1; Rho kinase inhibitor (ophthalmic liquid, glaucoma/ocular hypertension), Altheos
DMHEK4U CP Asahi Kasei Pharma Corp
DMHEK4U DE Glaucoma/ocular hypertension
DMKVDAN ID DMKVDAN
DMKVDAN DN Augustic acid
DMKVDAN HS Investigative
DMKVDAN SN augustic acid; CHEMBL482673; 2-hydroxyoleanolic acid; SCHEMBL829270; BDBM50299747; ZINC14980269; 26707-60-8; 2beta,3beta-Dihydroxyolean-12-en-28-oic Acid
DMKVDAN DT Small molecular drug
DMKVDAN PC 15560128
DMKVDAN MW 472.7
DMKVDAN FM C30H48O4
DMKVDAN IC InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20-,21-,22+,23-,27-,28+,29+,30-/m0/s1
DMKVDAN CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@@H]([C@@H](C3(C)C)O)O)C
DMKVDAN IK MDZKJHQSJHYOHJ-KRGADYIYSA-N
DMKVDAN IU (4aS,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMKVDAN CA CAS 26707-60-8
DMKVDAN DE Discovery agent
DMZNUDT ID DMZNUDT
DMZNUDT DN Aurachin
DMZNUDT HS Investigative
DMZNUDT SN Aurachin E; aurachin
DMZNUDT PC 13746957
DMZNUDT MW 404.5
DMZNUDT FM C26H32N2O2
DMZNUDT IC CQZZUPSXBXLXRM-CFBAGHHKSA-N
DMZNUDT CS CC1=C(C(=O)C2=C3N1C(=O)NC3=CC=C2)CC=C(C)CCC=C(C)CCC=C(C)C
DMZNUDT IK 1S/C26H32N2O2/c1-17(2)9-6-10-18(3)11-7-12-19(4)15-16-21-20(5)28-24-22(25(21)29)13-8-14-23(24)27-26(28)30/h8-9,11,13-15H,6-7,10,12,16H2,1-5H3,(H,27,30)/b18-11+,19-15+
DMZNUDT IU 11-methyl-10-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-1,3-diazatricyclo[6.3.1.04,12]dodeca-4,6,8(12),10-tetraene-2,9-dione
DMZNUDT CA CAS 113366-10-2
DMZNUDT DE Malaria
DMDKH8N ID DMDKH8N
DMDKH8N DN AURASPERONE A
DMDKH8N HS Investigative
DMDKH8N SN Aurasperone A; Aurasperone; UNII-B9PTQ8Z021; B9PTQ8Z021; 15085-74-2; (7,10'-Bi-4H-naphtho(2,3-b)pyran)-4,4'-dione, 5,5'-dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-; AC1MJ24O; CHEMBL450763; DTXSID30164629; CHEBI:133760; 5-HYDROXY-10-{5-HYDROXY-6,8-DIMETHOXY-2-METHYL-4-OXO-4H-BENZO[G]CHROMEN-7-YL}-6,8-DIMETHOXY-2-METHYL-4H-BENZO[G]CHROMEN-4-ONE; 5,5'-Dihydroxy-6,6',8,8'-tetramethoxy-2,2'-dimethyl-7,10'-bi-4H-naphtho[2,3-b]pyran-4,4'-dione, 9CI
DMDKH8N DT Small molecular drug
DMDKH8N PC 3084216
DMDKH8N MW 570.5
DMDKH8N FM C32H26O10
DMDKH8N IC InChI=1S/C32H26O10/c1-13-7-18(33)26-22(41-13)10-15-9-20(38-4)28(31(40-6)23(15)29(26)35)25-17-11-16(37-3)12-21(39-5)24(17)30(36)27-19(34)8-14(2)42-32(25)27/h7-12,35-36H,1-6H3
DMDKH8N CS CC1=CC(=O)C2=C(O1)C=C3C=C(C(=C(C3=C2O)OC)C4=C5C(=C(C6=C4C=C(C=C6OC)OC)O)C(=O)C=C(O5)C)OC
DMDKH8N IK QAHRSPAZSGMZMT-UHFFFAOYSA-N
DMDKH8N IU 5-hydroxy-7-(5-hydroxy-6,8-dimethoxy-2-methyl-4-oxobenzo[g]chromen-10-yl)-6,8-dimethoxy-2-methylbenzo[g]chromen-4-one
DMDKH8N CA CAS 15085-74-2
DMDKH8N CB CHEBI:133760
DMDKH8N DE Discovery agent
DMOIQ4K ID DMOIQ4K
DMOIQ4K DN Auryntricarboxylic acid (ATA)
DMOIQ4K HS Investigative
DMOIQ4K SN 244218-51-7; UNII-7I21WLZ2FP; TCMDC-125882; JTC-801 HCl; 7I21WLZ2FP; N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide hydrochloride; N-(4-Amino-2-methyl-6-quinolinyl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride; C26H26ClN3O2; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride; N-(4-amino-2-methylquinolin-6-yl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride; AC1NSKGE; MLS006011235; SCHEMBL2240337; CHEMBL531742; CTK8E7568; DTXSID10415525
DMOIQ4K DT Small molecular drug
DMOIQ4K DE Discovery agent
DMFS4RD ID DMFS4RD
DMFS4RD DN Autoantibody LKM-3
DMFS4RD HS Investigative
DMFS4RD DE Discovery agent
DMVGIO5 ID DMVGIO5
DMVGIO5 DN AUY954
DMVGIO5 HS Investigative
DMVGIO5 SN AUY 954
DMVGIO5 DT Small molecular drug
DMVGIO5 PC 11259583
DMVGIO5 MW 455.5
DMVGIO5 FM C25H20F3NO2S
DMVGIO5 IC InChI=1S/C25H20F3NO2S/c26-25(27,28)21-13-18(7-8-20(21)17-4-2-1-3-5-17)23-14-19-12-16(6-9-22(19)32-23)15-29-11-10-24(30)31/h1-9,12-14,29H,10-11,15H2,(H,30,31)
DMVGIO5 CS C1=CC=C(C=C1)C2=C(C=C(C=C2)C3=CC4=C(S3)C=CC(=C4)CNCCC(=O)O)C(F)(F)F
DMVGIO5 IK SKYYWSWIUKISCX-UHFFFAOYSA-N
DMVGIO5 IU 3-[[2-[4-phenyl-3-(trifluoromethyl)phenyl]-1-benzothiophen-5-yl]methylamino]propanoic acid
DMVGIO5 DE Discovery agent
DMF1VS9 ID DMF1VS9
DMF1VS9 DN AV-370
DMF1VS9 HS Investigative
DMF1VS9 SN Anti-FGF3 receptor antibody (cancer), AVEO Pharmaceuticals
DMF1VS9 CP AVEO Pharmaceuticals Inc
DMF1VS9 DT Antibody
DMF1VS9 DE Solid tumour/cancer
DM9R3WT ID DM9R3WT
DM9R3WT DN AVE 0991
DM9R3WT HS Investigative
DM9R3WT SN AVE 0991; 304462-19-9; AVE-0991; AVE0991; UNII-68JR6NCI7I; 68JR6NCI7I; GTPL5579; SCHEMBL15045765; KS-00000LDU; DTXSID50184526; C29H32N4O5S2; MolPort-019-995-543; BCP11067; ZINC3927311; 3460AH; FD5038; AKOS027338221; CS-1752; HY-15778; AK340230; 4CA-0212; 2-Thiophenesulfonamide, N-((ethylamino)carbonyl)-3-(4-((5-formyl-4-methoxy-2-phenyl-1H-imidazol-1-yl)methyl)phenyl)-5-(2-methylpropyl)-; AB0087841; B1007; A820377
DM9R3WT DT Small molecular drug
DM9R3WT PC 9851724
DM9R3WT MW 580.7
DM9R3WT FM C29H32N4O5S2
DM9R3WT IC InChI=1S/C29H32N4O5S2/c1-5-30-29(35)32-40(36,37)28-24(16-23(39-28)15-19(2)3)21-13-11-20(12-14-21)17-33-25(18-34)27(38-4)31-26(33)22-9-7-6-8-10-22/h6-14,16,18-19H,5,15,17H2,1-4H3,(H2,30,32,35)
DM9R3WT CS CCNC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C(=C(N=C3C4=CC=CC=C4)OC)C=O
DM9R3WT IK QTOZBSNPDCWHPV-UHFFFAOYSA-N
DM9R3WT IU 1-ethyl-3-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea
DM9R3WT CA CAS 304462-19-9
DM9R3WT DE Discovery agent
DMC0PY5 ID DMC0PY5
DMC0PY5 DN AVE-1876
DMC0PY5 HS Investigative
DMC0PY5 SN AVE-1876A; GABA-B antagonists (depression/anxiety), sanofi-aventis
DMC0PY5 DE Discovery agent
DMDTONZ ID DMDTONZ
DMDTONZ DN AVP-13546
DMDTONZ HS Investigative
DMDTONZ DE Autoimmune disease
DMBNDYK ID DMBNDYK
DMBNDYK DN AVP-13748
DMBNDYK HS Investigative
DMBNDYK DE Autoimmune disease
DMNQ9R4 ID DMNQ9R4
DMNQ9R4 DN AVPIAQKSEK-FAM
DMNQ9R4 HS Investigative
DMNQ9R4 SN CHEMBL404788; AVPIAQKSEK-FAM
DMNQ9R4 PC 44460469
DMNQ9R4 MW 1525.6
DMNQ9R4 FM C72H96N14O23
DMNQ9R4 IC InChI=1S/C72H96N14O23/c1-7-36(4)60(84-67(101)50-18-13-31-85(50)70(104)59(35(2)3)83-61(95)37(5)74)69(103)77-38(6)62(96)78-46(23-25-53(75)90)64(98)79-45(16-8-10-29-73)63(97)82-49(34-87)66(100)80-47(24-28-56(93)94)65(99)81-48(71(105)106)17-9-11-30-76-68(102)58-43(14-12-15-44(58)72(107)109-86-54(91)26-27-55(86)92)57-41-21-19-39(88)32-51(41)108-52-33-40(89)20-22-42(52)57/h12,14-15,19-22,32-33,35-38,45-50,59-60,87-88H,7-11,13,16-18,23-31,34,73-74H2,1-6H3,(H2,75,90)(H,76,102)(H,77,103)(H,78,96)(H,79,98)(H,80,100)(H,81,99)(H,82,97)(H,83,95)(H,84,101)(H,93,94)(H,105,106)/t36-,37-,38-,45-,46-,47-,48-,49-,50-,59-,60-/m0/s1
DMNQ9R4 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCNC(=O)C1=C(C=CC=C1C(=O)ON2C(=O)CCC2=O)C3=C4C=CC(=O)C=C4OC5=C3C=CC(=C5)O)C(=O)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
DMNQ9R4 IK UIHIJARXXMWKOD-UVBGQCGDSA-N
DMNQ9R4 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-6-[[2-(2,5-dioxopyrrolidin-1-yl)oxycarbonyl-6-(3-hydroxy-6-oxoxanthen-9-yl)benzoyl]amino]hexanoic acid
DMNQ9R4 DE Discovery agent
DMK9BMQ ID DMK9BMQ
DMK9BMQ DN AVVYPWT
DMK9BMQ HS Investigative
DMK9BMQ SN CHEMBL238310; AVVYPWT
DMK9BMQ DT Small molecular drug
DMK9BMQ PC 25054398
DMK9BMQ MW 835
DMK9BMQ FM C42H58N8O10
DMK9BMQ IC InChI=1S/C42H58N8O10/c1-21(2)33(48-40(57)34(22(3)4)47-36(53)23(5)43)39(56)46-31(18-25-13-15-27(52)16-14-25)41(58)50-17-9-12-32(50)38(55)45-30(37(54)49-35(24(6)51)42(59)60)19-26-20-44-29-11-8-7-10-28(26)29/h7-8,10-11,13-16,20-24,30-35,44,51-52H,9,12,17-19,43H2,1-6H3,(H,45,55)(H,46,56)(H,47,53)(H,48,57)(H,49,54)(H,59,60)/t23-,24+,30-,31-,32-,33-,34-,35-/m0/s1
DMK9BMQ CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N)O
DMK9BMQ IK JZZWLFSCHMSJQR-XXWLAZNXSA-N
DMK9BMQ IU (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DMK9BMQ DE Discovery agent
DMG6LJ8 ID DMG6LJ8
DMG6LJ8 DN AW-00430
DMG6LJ8 HS Investigative
DMG6LJ8 SN MLS000849730; SMR000455748; N-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide; N2-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide; Bio1C2; AW-00430; AC1Q2OSF; AC1MDU2J; Oprea1_610998; CHEMBL212314; cid_2795741; BDBM58217; MolPort-001-805-761; HMS2792P22; ZINC1023475; MCULE-6709059808; N-(4-bromo-2-chlorophenyl)-5-(2-methyl-4-thiazolyl)-2-thiophenesulfonamide; N-(4-bromo-2-chloro-phenyl)-5-(2-methylthiazol-4-yl)thiophene-2-sulfonamide
DMG6LJ8 DT Small molecular drug
DMG6LJ8 PC 2795741
DMG6LJ8 MW 449.8
DMG6LJ8 FM C14H10BrClN2O2S3
DMG6LJ8 IC InChI=1S/C14H10BrClN2O2S3/c1-8-17-12(7-21-8)13-4-5-14(22-13)23(19,20)18-11-3-2-9(15)6-10(11)16/h2-7,18H,1H3
DMG6LJ8 CS CC1=NC(=CS1)C2=CC=C(S2)S(=O)(=O)NC3=C(C=C(C=C3)Br)Cl
DMG6LJ8 IK AMNKYHFERGWVCB-UHFFFAOYSA-N
DMG6LJ8 IU N-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide
DMG6LJ8 DE Discovery agent
DMIWMJP ID DMIWMJP
DMIWMJP DN AwFwLL-NH2
DMIWMJP HS Investigative
DMIWMJP SN CHEMBL509976; AwFwLL-NH2
DMIWMJP DT Small molecular drug
DMIWMJP PC 44576252
DMIWMJP MW 834
DMIWMJP FM C46H59N9O6
DMIWMJP IC InChI=1S/C46H59N9O6/c1-26(2)19-36(41(48)56)51-43(58)37(20-27(3)4)53-46(61)40(23-31-25-50-35-18-12-10-16-33(31)35)55-44(59)38(21-29-13-7-6-8-14-29)54-45(60)39(52-42(57)28(5)47)22-30-24-49-34-17-11-9-15-32(30)34/h6-18,24-28,36-40,49-50H,19-23,47H2,1-5H3,(H2,48,56)(H,51,58)(H,52,57)(H,53,61)(H,54,60)(H,55,59)/t28-,36-,37-,38-,39+,40+/m0/s1
DMIWMJP CS C[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)N
DMIWMJP IK SHJLXMWODYAZLK-JKHVPLMQSA-N
DMIWMJP IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-aminopropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanamide
DMIWMJP DE Discovery agent
DMDWCY7 ID DMDWCY7
DMDWCY7 DN AX-006
DMDWCY7 HS Investigative
DMDWCY7 SN AX-006
DMDWCY7 DT Small molecular drug
DMDWCY7 PC 45482341
DMDWCY7 MW 369.5
DMDWCY7 FM C21H39NO4
DMDWCY7 IC InChI=1S/C21H39NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-20(25)21(26)22-17-14-15-19(24)18-23/h23H,2-18H2,1H3,(H,22,26)
DMDWCY7 CS CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)CO
DMDWCY7 IK JVJFDPHNZMYFII-UHFFFAOYSA-N
DMDWCY7 IU N-(5-hydroxy-4-oxopentyl)-2-oxohexadecanamide
DMDWCY7 DE Discovery agent
DMIDXSN ID DMIDXSN
DMIDXSN DN AX-048
DMIDXSN HS Investigative
DMIDXSN SN CHEMBL573332
DMIDXSN DT Small molecular drug
DMIDXSN PC 15950454
DMIDXSN MW 383.6
DMIDXSN FM C22H41NO4
DMIDXSN IC InChI=1S/C22H41NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-17-20(24)22(26)23-19-16-18-21(25)27-4-2/h3-19H2,1-2H3,(H,23,26)
DMIDXSN CS CCCCCCCCCCCCCCC(=O)C(=O)NCCCC(=O)OCC
DMIDXSN IK FMFKQXKYWWJNJS-UHFFFAOYSA-N
DMIDXSN IU ethyl 4-(2-oxohexadecanoylamino)butanoate
DMIDXSN CA CAS 873079-69-7
DMIDXSN DE Discovery agent
DMKCT0M ID DMKCT0M
DMKCT0M DN AX-9657
DMKCT0M HS Investigative
DMKCT0M SN Neutrophil elastase inhibitors (lung disease); HNE inhibitors (lung disease), Kyorin; Neutrophil elastase inhibitors (lung disease), Kyorin
DMKCT0M CP Kyorin Pharmaceutical Co Ltd
DMKCT0M DT Small molecular drug
DMKCT0M PC 25205741
DMKCT0M MW 394.5
DMKCT0M FM C22H26N4O3
DMKCT0M IC InChI=1S/C22H26N4O3/c1-5-14-11-16(28-4)12-18-19(14)22(27)29-21(24-18)17-7-6-9-23-20(17)26-10-8-15(13-26)25(2)3/h6-7,9,11-12,15H,5,8,10,13H2,1-4H3/t15-/m0/s1
DMKCT0M CS CCC1=C2C(=CC(=C1)OC)N=C(OC2=O)C3=C(N=CC=C3)N4CC[C@@H](C4)N(C)C
DMKCT0M IK RCPIMTCZGQJSGZ-HNNXBMFYSA-N
DMKCT0M IU 2-[2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl]-5-ethyl-7-methoxy-3,1-benzoxazin-4-one
DMKCT0M CA CAS 1015439-77-6
DMKCT0M DE Pulmonary disease
DMT5P8O ID DMT5P8O
DMT5P8O DN Axogenesis Factor-1
DMT5P8O HS Investigative
DMT5P8O SN Oncomodulin; CNS nerve growth factors, Alseres; CNS nerve growth factors, Boston Life Sciences; AF-1, Alseres; AF-1, Boston Life Sciences; Axogenesis Factor-1, Alseres; Axogenesis Factor-1, Boston Life Sciences
DMT5P8O CP Children's Hospital Boston
DMT5P8O DE Cerebrovascular ischaemia
DMNO6PL ID DMNO6PL
DMNO6PL DN AZ10417808
DMNO6PL HS Investigative
DMNO6PL SN AZ-10417808; AZ 10417808
DMNO6PL DT Small molecular drug
DMNO6PL PC 135665263
DMNO6PL MW 434.2
DMNO6PL FM C18H13Cl2N5O4
DMNO6PL IC InChI=1S/C18H13Cl2N5O4/c1-2-5-21-16(26)11-7-10(25(28)29)8-12-15(11)23-18(24-17(12)27)22-9-3-4-13(19)14(20)6-9/h2-4,6-8H,1,5H2,(H,21,26)(H2,22,23,24,27)
DMNO6PL CS C=CCNC(=O)C1=CC(=CC2=C1N=C(NC2=O)NC3=CC(=C(C=C3)Cl)Cl)[N+](=O)[O-]
DMNO6PL IK VUBILPOZTRGZJK-UHFFFAOYSA-N
DMNO6PL IU 2-(3,4-dichloroanilino)-6-nitro-4-oxo-N-prop-2-enyl-3H-quinazoline-8-carboxamide
DMNO6PL CA CAS 331645-84-2
DMNO6PL CB CHEBI:92637
DMNO6PL DE Discovery agent
DMDRXCP ID DMDRXCP
DMDRXCP DN AZ11645373
DMDRXCP HS Investigative
DMDRXCP SN AZ 11645373; AZ-11645373
DMDRXCP DT Small molecular drug
DMDRXCP PC 9804433
DMDRXCP MW 463.5
DMDRXCP FM C24H21N3O5S
DMDRXCP IC InChI=1S/C24H21N3O5S/c28-23-16-33-24(29)26(23)21(7-4-17-10-12-25-13-11-17)15-32-22-8-5-18(6-9-22)19-2-1-3-20(14-19)27(30)31/h1-3,5-6,8-14,21H,4,7,15-16H2
DMDRXCP CS C1C(=O)N(C(=O)S1)C(CCC2=CC=NC=C2)COC3=CC=C(C=C3)C4=CC(=CC=C4)[N+](=O)[O-]
DMDRXCP IK VQEHBLGYANQWEA-UHFFFAOYSA-N
DMDRXCP IU 3-[1-[4-(3-nitrophenyl)phenoxy]-4-pyridin-4-ylbutan-2-yl]-1,3-thiazolidine-2,4-dione
DMDRXCP CA CAS 227088-94-0
DMDRXCP DE Discovery agent
DMRUA0Y ID DMRUA0Y
DMRUA0Y DN AZ-11657312
DMRUA0Y HS Investigative
DMRUA0Y SN P2X7 purinoceptor antagonists (inflammation); P2X7 purinoceptor antagonists (inflammation), AstraZeneca
DMRUA0Y CP AstraZeneca plc
DMRUA0Y DE Inflammation
DMVX8LO ID DMVX8LO
DMVX8LO DN AZ11657312 (salt free)
DMVX8LO HS Investigative
DMVX8LO SN AZ11657312 (salt free); SCHEMBL5079735; GTPL7722; CHEMBL550637
DMVX8LO DT Small molecular drug
DMVX8LO PC 11193842
DMVX8LO MW 437.6
DMVX8LO FM C26H35N3O3
DMVX8LO IC InChI=1S/C26H35N3O3/c1-16-2-3-20(25(31)29-14-21-12-27-13-22(15-29)32-21)7-23(16)28-24(30)11-26-8-17-4-18(9-26)6-19(5-17)10-26/h2-3,7,17-19,21-22,27H,4-6,8-15H2,1H3,(H,28,30)
DMVX8LO CS CC1=C(C=C(C=C1)C(=O)N2CC3CNCC(C2)O3)NC(=O)CC45CC6CC(C4)CC(C6)C5
DMVX8LO IK XYNNEMHCLNODBL-UHFFFAOYSA-N
DMVX8LO IU 2-(1-adamantyl)-N-[2-methyl-5-(9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carbonyl)phenyl]acetamide
DMVX8LO DE Discovery agent
DM1IN35 ID DM1IN35
DM1IN35 DN AZ12216052
DM1IN35 HS Investigative
DM1IN35 SN AZ 12216052; AZ-12216052
DM1IN35 DT Small molecular drug
DM1IN35 PC 73755190
DM1IN35 MW 392.4
DM1IN35 FM C19H22BrNOS
DM1IN35 IC InChI=1S/C19H22BrNOS/c1-3-14(2)16-6-10-18(11-7-16)21-19(22)13-23-12-15-4-8-17(20)9-5-15/h4-11,14H,3,12-13H2,1-2H3,(H,21,22)
DM1IN35 CS CCC(C)C1=CC=C(C=C1)NC(=O)CSCC2=CC=C(C=C2)Br
DM1IN35 IK QKUYZJOTWYRWNF-UHFFFAOYSA-N
DM1IN35 IU 2-[(4-bromophenyl)methylsulfanyl]-N-(4-butan-2-ylphenyl)acetamide
DM1IN35 DE Discovery agent
DMQ5H2V ID DMQ5H2V
DMQ5H2V DN AZ12260493
DMQ5H2V HS Investigative
DMQ5H2V SN AZ 12260493; AZ-12260493
DMQ5H2V DT Small molecular drug
DMQ5H2V PC 11655079
DMQ5H2V MW 439.6
DMQ5H2V FM C24H29N3O3S
DMQ5H2V IC InChI=1S/C24H29N3O3S/c1-24(2,3)27-23(28)21(22(31(27,29)30)18-10-6-4-7-11-18)25-19-12-14-20(15-13-19)26-16-8-5-9-17-26/h4,6-7,10-15,25H,5,8-9,16-17H2,1-3H3
DMQ5H2V CS CC(C)(C)N1C(=O)C(=C(S1(=O)=O)C2=CC=CC=C2)NC3=CC=C(C=C3)N4CCCCC4
DMQ5H2V IK IVANYIPLGFVBGR-UHFFFAOYSA-N
DMQ5H2V IU 2-tert-butyl-1,1-dioxo-5-phenyl-4-(4-piperidin-1-ylanilino)-1,2-thiazol-3-one
DMQ5H2V DE Discovery agent
DMYDWH1 ID DMYDWH1
DMYDWH1 DN AZ13483342
DMYDWH1 HS Investigative
DMYDWH1 SN AZ 13483342; AZ-13483342
DMYDWH1 DT Small molecular drug
DMYDWH1 PC 9927967
DMYDWH1 MW 341.5
DMYDWH1 FM C19H23N3OS
DMYDWH1 IC InChI=1S/C19H23N3OS/c1-14-10-19(22-18-5-4-16(23-2)11-17(14)18)21-8-3-7-20-12-15-6-9-24-13-15/h4-6,9-11,13,20H,3,7-8,12H2,1-2H3,(H,21,22)
DMYDWH1 CS CC1=CC(=NC2=C1C=C(C=C2)OC)NCCCNCC3=CSC=C3
DMYDWH1 IK ZDKZIFSAJUTJSK-UHFFFAOYSA-N
DMYDWH1 IU N'-(6-methoxy-4-methylquinolin-2-yl)-N-(thiophen-3-ylmethyl)propane-1,3-diamine
DMYDWH1 DE Discovery agent
DMNQ3HV ID DMNQ3HV
DMNQ3HV DN AZ20
DMNQ3HV HS Investigative
DMNQ3HV SN AZ-20; AZ 20; compound 6 [PMID: 46244454]
DMNQ3HV DT Small molecular drug
DMNQ3HV PC 46244454
DMNQ3HV MW 412.5
DMNQ3HV FM C21H24N4O3S
DMNQ3HV IC InChI=1S/C21H24N4O3S/c1-14-13-28-11-10-25(14)19-12-18(21(7-8-21)29(2,26)27)23-20(24-19)16-4-3-5-17-15(16)6-9-22-17/h3-6,9,12,14,22H,7-8,10-11,13H2,1-2H3/t14-/m1/s1
DMNQ3HV CS C[C@@H]1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=O)(=O)C)C4=C5C=CNC5=CC=C4
DMNQ3HV IK SCGCBAAYLFTIJU-CQSZACIVSA-N
DMNQ3HV IU (3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)pyrimidin-4-yl]-3-methylmorpholine
DMNQ3HV CB CHEBI:124915
DMNQ3HV DE Discovery agent
DMVMW9S ID DMVMW9S
DMVMW9S DN AZ3971
DMVMW9S HS Investigative
DMVMW9S SN AZ 3971; AZ-3971
DMVMW9S DT Small molecular drug
DMVMW9S PC 49858172
DMVMW9S MW 422.5
DMVMW9S FM C25H22N6O
DMVMW9S IC InChI=1S/C25H22N6O/c1-15-9-20(10-16(2)22(15)32-3)25(23-21(24(26)31-25)29-7-8-30-23)19-6-4-5-17(11-19)18-12-27-14-28-13-18/h4-14H,1-3H3,(H2,26,31)/t25-/m0/s1
DMVMW9S CS CC1=CC(=CC(=C1OC)C)[C@]2(C3=NC=CN=C3C(=N2)N)C4=CC=CC(=C4)C5=CN=CN=C5
DMVMW9S IK BICGYFRWDDPYEI-VWLOTQADSA-N
DMVMW9S IU (5S)-5-(4-methoxy-3,5-dimethylphenyl)-5-(3-pyrimidin-5-ylphenyl)pyrrolo[3,4-b]pyrazin-7-amine
DMVMW9S DE Discovery agent
DMATC5P ID DMATC5P
DMATC5P DN AZ4800
DMATC5P HS Investigative
DMATC5P SN AZ 4800; AZ-4800
DMATC5P DT Small molecular drug
DMATC5P PC 50996844
DMATC5P MW 435.5
DMATC5P FM C24H29N5O3
DMATC5P IC InChI=1S/C24H29N5O3/c1-16-12-29(15-25-16)22-8-7-17(11-23(22)30-2)26-24-27-20-9-10-31-13-19(20)21(28-24)14-32-18-5-3-4-6-18/h7-8,11-12,15,18H,3-6,9-10,13-14H2,1-2H3,(H,26,27,28)
DMATC5P CS CC1=CN(C=N1)C2=C(C=C(C=C2)NC3=NC4=C(COCC4)C(=N3)COC5CCCC5)OC
DMATC5P IK RMRFSIAFQBYBSN-UHFFFAOYSA-N
DMATC5P IU 4-(cyclopentyloxymethyl)-N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amine
DMATC5P DE Discovery agent
DM1XE4F ID DM1XE4F
DM1XE4F DN AZ-599
DM1XE4F HS Investigative
DM1XE4F SN CB1 agonist (pain), AstraZeneca
DM1XE4F CP AstraZeneca plc
DM1XE4F DE Pain
DMEWQHP ID DMEWQHP
DMEWQHP DN AZ-628
DMEWQHP HS Investigative
DMEWQHP SN Mutant B-Raf Kinase inhibitors, AstraZeneca; Mutant B-Raf (V600E) kinase inhibitors (cancer), AstraZeneca
DMEWQHP CP AstraZeneca plc
DMEWQHP DT Small molecular drug
DMEWQHP PC 11676786
DMEWQHP MW 451.5
DMEWQHP FM C27H25N5O2
DMEWQHP IC InChI=1S/C27H25N5O2/c1-17-8-9-21(31-25(33)18-6-5-7-19(12-18)27(2,3)15-28)14-24(17)30-20-10-11-23-22(13-20)26(34)32(4)16-29-23/h5-14,16,30H,1-4H3,(H,31,33)
DMEWQHP CS CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)C(C)(C)C#N)NC3=CC4=C(C=C3)N=CN(C4=O)C
DMEWQHP IK ZGBGPEDJXCYQPH-UHFFFAOYSA-N
DMEWQHP IU 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxoquinazolin-6-yl)amino]phenyl]benzamide
DMEWQHP CA CAS 878739-06-1
DMEWQHP CB CHEBI:91354
DMEWQHP DE Solid tumour/cancer
DM95Y82 ID DM95Y82
DM95Y82 DN AZ960
DM95Y82 HS Investigative
DM95Y82 SN AZ 960; AZ-960
DM95Y82 DT Small molecular drug
DM95Y82 PC 25099184
DM95Y82 MW 354.4
DM95Y82 FM C18H16F2N6
DM95Y82 IC InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)/t11-/m0/s1
DM95Y82 CS CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F
DM95Y82 IK SUNXHXDJOIXABJ-NSHDSACASA-N
DM95Y82 IU 5-fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile
DM95Y82 CA CAS 905586-69-8
DM95Y82 DE Discovery agent
DMOSI4U ID DMOSI4U
DMOSI4U DN Aza-C-nucleosides
DMOSI4U HS Investigative
DMOSI4U DT Small molecular drug
DMOSI4U PC 1336
DMOSI4U DE Discovery agent
DM61H07 ID DM61H07
DM61H07 DN AZAKENPAULLONE
DM61H07 HS Investigative
DM61H07 SN 1-Azakenpaullone; 676596-65-9; azakenpaullone; 9-bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one; C15H10BrN3O; Kinome_3492; 1-AKP; SCHEMBL378920; GTPL8018; CHEMBL336961; BDBM7497; DTXSID8042686; NOCAS_42686; CTK8F0375; MolPort-003-844-675; CHEBI:131490; HMS3653A17; HMS3229B07; BCP21061; ZINC13588927; s7193; 2138AH; 1-Azakenpaullone, > AKOS030240424; SB19270; TRA0006688; NCGC00386322-01; RT-006179; FT-0662368; SW220021-1; KS-00001866
DM61H07 DT Small molecular drug
DM61H07 PC 6538897
DM61H07 MW 328.16
DM61H07 FM C15H10BrN3O
DM61H07 IC InChI=1S/C15H10BrN3O/c16-8-3-4-11-9(6-8)10-7-13(20)18-12-2-1-5-17-15(12)14(10)19-11/h1-6,19H,7H2,(H,18,20)
DM61H07 CS C1C2=C(C3=C(C=CC=N3)NC1=O)NC4=C2C=C(C=C4)Br
DM61H07 IK NTSBZVCEIVPKBJ-UHFFFAOYSA-N
DM61H07 IU 14-bromo-3,8,18-triazatetracyclo[9.7.0.02,7.012,17]octadeca-1(11),2(7),3,5,12(17),13,15-heptaen-9-one
DM61H07 CB CHEBI:131490
DM61H07 DE Discovery agent
DMN861Q ID DMN861Q
DMN861Q DN AZALINE B
DMN861Q HS Investigative
DMN861Q PC 44422930
DMN861Q MW 1613.3
DMN861Q FM C80H102ClN23O12
DMN861Q IC InChI=1S/C80H102ClN23O12/c1-44(2)35-59(68(108)91-58(16-9-10-33-86-45(3)4)76(116)104-34-12-17-66(104)75(115)87-46(5)67(82)107)92-70(110)62(38-49-21-28-56(29-22-49)89-79-98-77(83)100-102-79)94-72(112)63(39-50-23-30-57(31-24-50)90-80-99-78(84)101-103-80)96-74(114)65(43-105)97-73(113)64(41-52-13-11-32-85-42-52)95-71(111)61(37-48-19-26-55(81)27-20-48)93-69(109)60(88-47(6)106)40-51-18-25-53-14-7-8-15-54(53)36-51/h7-8,11,13-15,18-32,36,42,44-46,58-66,86,105H,9-10,12,16-17,33-35,37-41,43H2,1-6H3,(H2,82,107)(H,87,115)(H,88,106)(H,91,108)(H,92,110)(H,93,109)(H,94,112)(H,95,111)(H,96,114)(H,97,113)(H4,83,89,98,100,102)(H4,84,90,99,101,103)/t46-,58-,59-,60-,61-,62+,63-,64+,65-,66-/m0/s1
DMN861Q CS C[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC3=NC(=NN3)N)NC(=O)[C@H](CC4=CC=C(C=C4)NC5=NC(=NN5)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC6=CN=CC=C6)NC(=O)[C@H](CC7=CC=C(C=C7)Cl)NC(=O)[C@H](CC8=CC9=CC=CC=C9C=C8)NC(=O)C
DMN861Q IK VLGKQBGBPIVGBX-SIHJNPAHSA-N
DMN861Q IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]phenyl]propanoyl]amino]-3-[4-[(3-amino-1H-1,2,4-triazol-5-yl)amino]phenyl]propanoyl]amino]-4-methylpentanoyl]amino]-6-(propan-2-ylamino)hexanoyl]-N-[(2S)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMN861Q DE Discovery agent
DM3BXUJ ID DM3BXUJ
DM3BXUJ DN Azapeptide
DM3BXUJ HS Investigative
DM3BXUJ DE Discovery agent
DMKI2GJ ID DMKI2GJ
DMKI2GJ DN Azaperone
DMKI2GJ HS Investigative
DMKI2GJ SN Azaperone; 1649-18-9; Azaperon; Stresnil; Fluoperidol; Suicalm; Eucalmyl; Azeperone; Sedaperone vet; Azaperona; Azaperonum; R-1929; NSC 170976; Azaperonum [INN-Latin]; Azaperona [INN-Spanish]; 1-Butanone, 1-(4-fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-; UNII-19BV78AK7W; 1-(3-(4-Fluorobenzoyl)propyl)-4-(2-pyridyl)piperazine; CCRIS 1586; C19H22FN3O; 1-(4-Fluorophenyl)-4-[4-(2-pyridinyl)-1-piperazinyl]-1-butanone; 4'-Fluoro-4-(4-(2-pyridyl)-1-piperazinyl)butyrophenone; EINECS 216-715-8; R 1929; BRN 0565491; MLS003106751
DMKI2GJ DT Small molecular drug
DMKI2GJ PC 15443
DMKI2GJ MW 327.4
DMKI2GJ FM C19H22FN3O
DMKI2GJ IC InChI=1S/C19H22FN3O/c20-17-8-6-16(7-9-17)18(24)4-3-11-22-12-14-23(15-13-22)19-5-1-2-10-21-19/h1-2,5-10H,3-4,11-15H2
DMKI2GJ CS C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=CC=N3
DMKI2GJ IK XTKDAFGWCDAMPY-UHFFFAOYSA-N
DMKI2GJ IU 1-(4-fluorophenyl)-4-(4-pyridin-2-ylpiperazin-1-yl)butan-1-one
DMKI2GJ CA CAS 1649-18-9
DMKI2GJ CB CHEBI:88301
DMKI2GJ DE Discovery agent
DML70NC ID DML70NC
DML70NC DN aza-THIP
DML70NC HS Investigative
DML70NC SN 654666-65-6; 1,2,4,5,6,7-Hexahydro-3H-pyrazolo[3,4-c]pyridin-3-one; 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-ol; 3H-Pyrazolo[3,4-c]pyridin-3-one, 1,2,4,5,6,7-hexahydro-; 1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-3-ol; 4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-ol; aza-THIP; THIP, Aza-; 4,5,6,7-tetrahydropyrazolo[5,4-c]pyridin-3-ol; SCHEMBL2946381; GTPL4143; SCHEMBL16057201; CTK1J6712; BDBM86256; DTXSID20717441; UPMMUUFLHUEUKP-UHFFFAOYSA-N; MolPort-022-468-866; ZINC13859300; AKOS022182337; AKOS022718659; AKOS006351664
DML70NC DT Small molecular drug
DML70NC PC 55285412
DML70NC MW 139.16
DML70NC FM C6H9N3O
DML70NC IC InChI=1S/C6H9N3O/c10-6-4-1-2-7-3-5(4)8-9-6/h7H,1-3H2,(H2,8,9,10)
DML70NC CS C1CNCC2=C1C(=O)NN2
DML70NC IK UPMMUUFLHUEUKP-UHFFFAOYSA-N
DML70NC IU 1,2,4,5,6,7-hexahydropyrazolo[3,4-c]pyridin-3-one
DML70NC CA CAS 654666-65-6
DML70NC DE Discovery agent
DM0PVD9 ID DM0PVD9
DM0PVD9 DN AZD1332
DM0PVD9 HS Investigative
DM0PVD9 SN AZD 1332; AZD-1332
DM0PVD9 DT Small molecular drug
DM0PVD9 PC 49831044
DM0PVD9 MW 391.8
DM0PVD9 FM C17H19ClFN7O
DM0PVD9 IC InChI=1S/C17H19ClFN7O/c1-9(2)27-15-6-14(25-26-15)23-16-12(18)8-21-17(24-16)22-10(3)13-5-4-11(19)7-20-13/h4-10H,1-3H3,(H3,21,22,23,24,25,26)
DM0PVD9 CS CC(C)OC1=NNC(=C1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=C3)F
DM0PVD9 IK LBVKEEFIPBQIMD-UHFFFAOYSA-N
DM0PVD9 IU 5-chloro-2-N-[1-(5-fluoropyridin-2-yl)ethyl]-4-N-(3-propan-2-yloxy-1H-pyrazol-5-yl)pyrimidine-2,4-diamine
DM0PVD9 DE Discovery agent
DMAX9C3 ID DMAX9C3
DMAX9C3 DN AZD3463
DMAX9C3 HS Investigative
DMAX9C3 SN AZD-3463; CS-1382; HY-15609; KB-154896
DMAX9C3 DT Small molecular drug
DMAX9C3 PC 56599293
DMAX9C3 MW 448.9
DMAX9C3 FM C24H25ClN6O
DMAX9C3 IC InChI=1S/C24H25ClN6O/c1-32-22-12-16(31-10-8-15(26)9-11-31)6-7-21(22)29-24-28-14-19(25)23(30-24)18-13-27-20-5-3-2-4-17(18)20/h2-7,12-15,27H,8-11,26H2,1H3,(H,28,29,30)
DMAX9C3 CS COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl
DMAX9C3 IK GCYIGMXOIWJGBU-UHFFFAOYSA-N
DMAX9C3 IU N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine
DMAX9C3 CA CAS 1356962-20-3
DMAX9C3 DE Discovery agent
DMPIHN6 ID DMPIHN6
DMPIHN6 DN AZD5582
DMPIHN6 HS Investigative
DMPIHN6 SN AZD 5582; AZD-5582
DMPIHN6 DT Small molecular drug
DMPIHN6 PC 49847690
DMPIHN6 MW 1015.3
DMPIHN6 FM C58H78N8O8
DMPIHN6 IC InChI=1S/C58H78N8O8/c1-37(59-3)53(67)61-49(39-21-9-7-10-22-39)57(71)65-31-19-29-45(65)55(69)63-51-43-27-15-13-25-41(43)35-47(51)73-33-17-5-6-18-34-74-48-36-42-26-14-16-28-44(42)52(48)64-56(70)46-30-20-32-66(46)58(72)50(40-23-11-8-12-24-40)62-54(68)38(2)60-4/h13-16,25-28,37-40,45-52,59-60H,7-12,19-24,29-36H2,1-4H3,(H,61,67)(H,62,68)(H,63,69)(H,64,70)/t37-,38-,45-,46-,47+,48+,49-,50-,51-,52-/m0/s1
DMPIHN6 CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)OCC#CC#CCO[C@@H]5CC6=CC=CC=C6[C@@H]5NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC
DMPIHN6 IK WLMCRYCCYXHPQF-ZVMUOSSASA-N
DMPIHN6 IU (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(1S,2R)-2-[6-[[(1S,2R)-1-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]oxy]hexa-2,4-diynoxy]-2,3-dihydro-1H-inden-1-yl]pyrrolidine-2-carboxamide
DMPIHN6 DE Discovery agent
DMD4YO9 ID DMD4YO9
DMD4YO9 DN AZD-6319
DMD4YO9 HS Investigative
DMD4YO9 SN Alpha 7 neuronal nicotinic receptor agonist (Alzheimer's disease), AstraZeneca
DMD4YO9 CP AstraZeneca plc
DMD4YO9 DE Alzheimer disease
DMLJPDW ID DMLJPDW
DMLJPDW DN AZD-7507
DMLJPDW HS Investigative
DMLJPDW SN CSF-1R inhibitors (cancer); CSF-1R inhibitors (cancer), AstraZeneca; Colony stimulating factor-1 receptor inhibitors (cancer), AstraZeneca
DMLJPDW CP AstraZeneca plc
DMLJPDW DE Solid tumour/cancer
DM34W56 ID DM34W56
DM34W56 DN AZD-7806
DM34W56 HS Investigative
DM34W56 SN AZD 7806; AZD7806
DM34W56 DT Small molecular drug
DM34W56 PC 9939892
DM34W56 MW 695.9
DM34W56 FM C36H45N3O7S2
DM34W56 IC InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
DM34W56 CS CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)N[C@H](C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC
DM34W56 IK XFLQIRAKKLNXRQ-UUWRZZSWSA-N
DM34W56 IU 2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid
DM34W56 CA CAS 439087-18-0
DM34W56 DE Discovery agent
DM0HTXO ID DM0HTXO
DM0HTXO DN AZD8542
DM0HTXO HS Investigative
DM0HTXO SN AZD 8542; AZD-8542
DM0HTXO DT Small molecular drug
DM0HTXO PC 53344810
DM0HTXO MW 412.5
DM0HTXO FM C25H24N4O2
DM0HTXO IC InChI=1S/C25H24N4O2/c1-17-12-18(2)23(13-22(17)24-14-29(3)16-27-24)28-25(30)19-7-9-21(10-8-19)31-15-20-6-4-5-11-26-20/h4-14,16H,15H2,1-3H3,(H,28,30)
DM0HTXO CS CC1=CC(=C(C=C1C2=CN(C=N2)C)NC(=O)C3=CC=C(C=C3)OCC4=CC=CC=N4)C
DM0HTXO IK SMQVBAGSZVHCJP-UHFFFAOYSA-N
DM0HTXO IU N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(pyridin-2-ylmethoxy)benzamide
DM0HTXO DE Discovery agent
DMKSQY1 ID DMKSQY1
DMKSQY1 DN Azelaic bishydroxamic acid
DMKSQY1 HS Investigative
DMKSQY1 SN Azelaic bishydroxamic acid; 18992-11-5; Azelaic bis(hydroxamic acid); Nonanedihydroximic acid; N,N'-dihydroxynonanediamide; Azelaic bis hydroxamic acid; AC1L22XV; SCHEMBL4741072; CHEMBL495390; Nonanediamide, N,N'-dihydroxy-; DTXSID30172421; ZINC5178518; NSC611775
DMKSQY1 DT Small molecular drug
DMKSQY1 PC 65268
DMKSQY1 MW 218.25
DMKSQY1 FM C9H18N2O4
DMKSQY1 IC InChI=1S/C9H18N2O4/c12-8(10-14)6-4-2-1-3-5-7-9(13)11-15/h14-15H,1-7H2,(H,10,12)(H,11,13)
DMKSQY1 CS C(CCCC(=O)NO)CCCC(=O)NO
DMKSQY1 IK VBJZDMOTYJEHEP-UHFFFAOYSA-N
DMKSQY1 IU N,N'-dihydroxynonanediamide
DMKSQY1 CA CAS 18992-11-5
DMKSQY1 DE Discovery agent
DMZHV39 ID DMZHV39
DMZHV39 DN Azepan-(2Z)-ylideneamine
DMZHV39 HS Investigative
DMZHV39 SN Azepan-(2Z)-ylideneamine; 3,4,5,6-tetrahydro-2H-azepin-7-amine; CHEMBL315857; 2214-67-7; iminohomopiperidine; 2-Iminohexahydro-1H-azepine; SCHEMBL1575752; MolPort-007-996-393; GTLJSJNKRLFVSJ-UHFFFAOYSA-N; STL163828; ZINC13746433; BBL012958; BDBM50049257; AKOS002684184; AKOS006375172; MCULE-7781415779
DMZHV39 DT Small molecular drug
DMZHV39 PC 9793728
DMZHV39 MW 112.17
DMZHV39 FM C6H12N2
DMZHV39 IC InChI=1S/C6H12N2/c7-6-4-2-1-3-5-8-6/h1-5H2,(H2,7,8)
DMZHV39 CS C1CCC(=NCC1)N
DMZHV39 IK GTLJSJNKRLFVSJ-UHFFFAOYSA-N
DMZHV39 IU 3,4,5,6-tetrahydro-2H-azepin-7-amine
DMZHV39 DE Discovery agent
DM5XZYB ID DM5XZYB
DM5XZYB DN Azide
DM5XZYB HS Investigative
DM5XZYB DT Small molecular drug
DM5XZYB PC 33558
DM5XZYB MW 42.021
DM5XZYB FM N3-
DM5XZYB IC InChI=1S/N3/c1-3-2/q-1
DM5XZYB CS [N-]=[N+]=[N-]
DM5XZYB IK IVRMZWNICZWHMI-UHFFFAOYSA-N
DM5XZYB IU azide
DM5XZYB CA CAS 14343-69-2
DM5XZYB CB CHEBI:40910
DM5XZYB DE Discovery agent
DMD0LCA ID DMD0LCA
DMD0LCA DN Azidopine
DMD0LCA HS Investigative
DMD0LCA SN Azidopine; 90523-31-2; AC1LCUW1; NSC617999; CHEBI:2952; CHEMBL1993397; NSC-617999; O5-[2-[(4-azidobenzoyl)amino]ethyl] O3-ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate; GTPL6980; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-(trifluoromethyl)phenyl)-, 2-((4-azidobenzoyl)amino)ethyl ethyl ester; NCI60_005410; C11282; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-2-[(4-azidobenzoyl)amino]ethyl ethyl ester (9CI)
DMD0LCA DT Small molecular drug
DMD0LCA PC 656406
DMD0LCA MW 557.5
DMD0LCA FM C27H26F3N5O5
DMD0LCA IC InChI=1S/C27H26F3N5O5/c1-4-39-25(37)21-15(2)33-16(3)22(23(21)19-7-5-6-8-20(19)27(28,29)30)26(38)40-14-13-32-24(36)17-9-11-18(12-10-17)34-35-31/h5-12,23,33H,4,13-14H2,1-3H3,(H,32,36)
DMD0LCA CS CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C(F)(F)F)C(=O)OCCNC(=O)C3=CC=C(C=C3)N=[N+]=[N-])C)C
DMD0LCA IK SWMHKFTXBOJETC-UHFFFAOYSA-N
DMD0LCA IU 5-O-[2-[(4-azidobenzoyl)amino]ethyl] 3-O-ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMD0LCA CA CAS 90523-31-2
DMD0LCA CB CHEBI:2952
DMD0LCA DE Discovery agent
DM8ZQG3 ID DM8ZQG3
DM8ZQG3 DN Azithromycinarylalkylhydroxamic Acid
DM8ZQG3 HS Investigative
DM8ZQG3 SN Azithromycinarylalkylhydroxamic Acid; CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8
DM8ZQG3 PC 25151109
DM8ZQG3 MW 1011.3
DM8ZQG3 FM C52H90N4O15
DM8ZQG3 IC InChI=1S/C52H90N4O15/c1-14-39-52(10,64)45(60)34(6)55(11)28-30(2)26-50(8,63)47(32(4)44(33(5)48(62)69-39)70-42-27-51(9,66-13)46(61)35(7)68-42)71-49-43(59)38(25-31(3)67-49)56(12)29-36-21-23-37(24-22-36)53-40(57)19-17-15-16-18-20-41(58)54-65/h21-24,30-35,38-39,42-47,49,59-61,63-65H,14-20,25-29H2,1-13H3,(H,53,57)(H,54,58)/t30-,31-,32+,33-,34-,35+,38+,39-,42+,43-,44+,45-,46+,47-,49+,50-,51-,52-/m1/s1
DM8ZQG3 CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)NC(=O)CCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DM8ZQG3 IK FRRIWMVHMJBTRB-CSAKRERUSA-N
DM8ZQG3 IU N-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]-N'-hydroxyoctanediamide
DM8ZQG3 DE Discovery agent
DMDQ2VN ID DMDQ2VN
DMDQ2VN DN Azithromycin-N-benzyltriazolyldecahydroxamic Acid
DMDQ2VN HS Investigative
DMDQ2VN SN Azithromycin-N-benzyltriazolyldecahydroxamic Acid; CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h
DMDQ2VN PC 25190759
DMDQ2VN MW 1077.4
DMDQ2VN FM C56H96N6O14
DMDQ2VN IC InChI=1S/C56H96N6O14/c1-14-44-56(10,69)49(65)38(6)60(11)31-34(2)29-54(8,68)51(36(4)48(37(5)52(67)74-44)75-46-30-55(9,71-13)50(66)39(7)73-46)76-53-47(64)43(28-35(3)72-53)61(12)32-40-23-25-41(26-24-40)42-33-62(59-57-42)27-21-19-17-15-16-18-20-22-45(63)58-70/h23-26,33-39,43-44,46-51,53,64-66,68-70H,14-22,27-32H2,1-13H3,(H,58,63)/t34-,35-,36+,37-,38-,39+,43+,44-,46+,47-,48+,49-,50+,51-,53+,54-,55-,56-/m1/s1
DMDQ2VN CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMDQ2VN IK PVDBHHHRLSRBII-GJUNKSMQSA-N
DMDQ2VN IU 10-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxydecanamide
DMDQ2VN DE Discovery agent
DM7KD5Y ID DM7KD5Y
DM7KD5Y DN Azithromycin-N-benzyltriazolylhexahydroxamic Acid
DM7KD5Y HS Investigative
DM7KD5Y SN Azithromycin-N-benzyltriazolylhexahydroxamic Acid; CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a
DM7KD5Y PC 25152062
DM7KD5Y MW 1021.3
DM7KD5Y FM C52H88N6O14
DM7KD5Y IC InChI=1S/C52H88N6O14/c1-14-40-52(10,65)45(61)34(6)56(11)27-30(2)25-50(8,64)47(32(4)44(33(5)48(63)70-40)71-42-26-51(9,67-13)46(62)35(7)69-42)72-49-43(60)39(24-31(3)68-49)57(12)28-36-19-21-37(22-20-36)38-29-58(55-53-38)23-17-15-16-18-41(59)54-66/h19-22,29-35,39-40,42-47,49,60-62,64-66H,14-18,23-28H2,1-13H3,(H,54,59)/t30-,31-,32+,33-,34-,35+,39+,40-,42+,43-,44+,45-,46+,47-,49+,50-,51-,52-/m1/s1
DM7KD5Y CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DM7KD5Y IK BCHUJJCIGPEYFV-RAYHFQHHSA-N
DM7KD5Y IU 6-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxyhexanamide
DM7KD5Y DE Discovery agent
DMW0HXO ID DMW0HXO
DMW0HXO DN Azithromycin-N-benzyltriazolylnonahydroxamic Acid
DMW0HXO HS Investigative
DMW0HXO SN Azithromycin-N-benzyltriazolylnonahydroxamic Acid; CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g
DMW0HXO PC 25190758
DMW0HXO MW 1063.4
DMW0HXO FM C55H94N6O14
DMW0HXO IC InChI=1S/C55H94N6O14/c1-14-43-55(10,68)48(64)37(6)59(11)30-33(2)28-53(8,67)50(35(4)47(36(5)51(66)73-43)74-45-29-54(9,70-13)49(65)38(7)72-45)75-52-46(63)42(27-34(3)71-52)60(12)31-39-22-24-40(25-23-39)41-32-61(58-56-41)26-20-18-16-15-17-19-21-44(62)57-69/h22-25,32-38,42-43,45-50,52,63-65,67-69H,14-21,26-31H2,1-13H3,(H,57,62)/t33-,34-,35+,36-,37-,38+,42+,43-,45+,46-,47+,48-,49+,50-,52+,53-,54-,55-/m1/s1
DMW0HXO CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMW0HXO IK ZZONRCLYCNUZKQ-IEOJUODTSA-N
DMW0HXO IU 9-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxynonanamide
DMW0HXO DE Discovery agent
DMAJ4LI ID DMAJ4LI
DMAJ4LI DN Azithromycin-N-benzyltriazolyloctahydroxamic Acid
DMAJ4LI HS Investigative
DMAJ4LI SN Azithromycin-N-benzyltriazolyloctahydroxamic Acid; SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e
DMAJ4LI PC 25151675
DMAJ4LI MW 1049.3
DMAJ4LI FM C54H92N6O14
DMAJ4LI IC InChI=1S/C54H92N6O14/c1-14-42-54(10,67)47(63)36(6)58(11)29-32(2)27-52(8,66)49(34(4)46(35(5)50(65)72-42)73-44-28-53(9,69-13)48(64)37(7)71-44)74-51-45(62)41(26-33(3)70-51)59(12)30-38-21-23-39(24-22-38)40-31-60(57-55-40)25-19-17-15-16-18-20-43(61)56-68/h21-24,31-37,41-42,44-49,51,62-64,66-68H,14-20,25-30H2,1-13H3,(H,56,61)/t32-,33-,34+,35-,36-,37+,41+,42-,44+,45-,46+,47-,48+,49-,51+,52-,53-,54-/m1/s1
DMAJ4LI CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)CC4=CC=C(C=C4)C5=CN(N=N5)CCCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMAJ4LI IK YOTANXLDCGWPPQ-QASXAQIXSA-N
DMAJ4LI IU 8-[4-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]triazol-1-yl]-N-hydroxyoctanamide
DMAJ4LI DE Discovery agent
DMQ13PZ ID DMQ13PZ
DMQ13PZ DN Azocan-(2Z)-ylideneamine
DMQ13PZ HS Investigative
DMQ13PZ SN Azocan-(2Z)-ylideneamine; CHEMBL329431; 2-Iminooctahydroazocine; SCHEMBL3928259; BDBM50049249
DMQ13PZ DT Small molecular drug
DMQ13PZ PC 10749191
DMQ13PZ MW 126.2
DMQ13PZ FM C7H14N2
DMQ13PZ IC InChI=1S/C7H14N2/c8-7-5-3-1-2-4-6-9-7/h1-6H2,(H2,8,9)
DMQ13PZ CS C1CCCN=C(CC1)N
DMQ13PZ IK AZNNPSMXKKWOPY-UHFFFAOYSA-N
DMQ13PZ IU 2,3,4,5,6,7-hexahydroazocin-8-amine
DMQ13PZ DE Discovery agent
DMTQSNK ID DMTQSNK
DMTQSNK DN Azonan-(2Z)-ylideneamine
DMTQSNK HS Investigative
DMTQSNK SN Azonan-(2Z)-ylideneamine; CHEMBL158641; SCHEMBL8466372; SCHEMBL2661739; BDBM50049256; AKOS006356817
DMTQSNK DT Small molecular drug
DMTQSNK PC 10606829
DMTQSNK MW 140.23
DMTQSNK FM C8H16N2
DMTQSNK IC InChI=1S/C8H16N2/c9-8-6-4-2-1-3-5-7-10-8/h1-7H2,(H2,9,10)
DMTQSNK CS C1CCCC(=NCCC1)N
DMTQSNK IK NHHGJWDDKUEZBV-UHFFFAOYSA-N
DMTQSNK IU 3,4,5,6,7,8-hexahydro-2H-azonin-9-amine
DMTQSNK DE Discovery agent
DMD4LGN ID DMD4LGN
DMD4LGN DN AZ-TAK1
DMD4LGN HS Investigative
DMD4LGN SN TAK1 inhibitor (mantle cell lymphoma), AstraZeneca; TGF-beta-activated kinase 1 inhibitor (mantle cell lymphoma), AstraZeneca
DMD4LGN CP AstraZeneca plc
DMD4LGN DE Mantle cell lymphoma
DMXOGE8 ID DMXOGE8
DMXOGE8 DN AZUMAMIDE B
DMXOGE8 HS Investigative
DMXOGE8 SN AZUMAMIDE B; CHEMBL402727
DMXOGE8 DT Small molecular drug
DMXOGE8 PC 16095112
DMXOGE8 MW 529.6
DMXOGE8 FM C27H39N5O6
DMXOGE8 IC InChI=1S/C27H39N5O6/c1-15(2)23-27(38)29-17(4)25(36)31-21(14-18-10-12-19(33)13-11-18)26(37)30-20(16(3)24(35)32-23)8-6-5-7-9-22(28)34/h5-6,10-13,15-17,20-21,23,33H,7-9,14H2,1-4H3,(H2,28,34)(H,29,38)(H,30,37)(H,31,36)(H,32,35)/b6-5-/t16-,17+,20+,21+,23+/m0/s1
DMXOGE8 CS C[C@H]1[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)C(C)C)C)CC2=CC=C(C=C2)O)C/C=C\\CCC(=O)N
DMXOGE8 IK RFGAANHNJBCQAS-LFUPQXEOSA-N
DMXOGE8 IU (Z)-6-[(2R,5R,8R,11R,12S)-8-[(4-hydroxyphenyl)methyl]-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enamide
DMXOGE8 DE Discovery agent
DMEBA61 ID DMEBA61
DMEBA61 DN AZUMAMIDE C
DMEBA61 HS Investigative
DMEBA61 SN AZUMAMIDE C; CHEMBL257972
DMEBA61 DT Small molecular drug
DMEBA61 PC 16095114
DMEBA61 MW 530.6
DMEBA61 FM C27H38N4O7
DMEBA61 IC InChI=1S/C27H38N4O7/c1-15(2)23-27(38)28-17(4)25(36)30-21(14-18-10-12-19(32)13-11-18)26(37)29-20(16(3)24(35)31-23)8-6-5-7-9-22(33)34/h5-6,10-13,15-17,20-21,23,32H,7-9,14H2,1-4H3,(H,28,38)(H,29,37)(H,30,36)(H,31,35)(H,33,34)/b6-5-/t16-,17+,20+,21+,23+/m0/s1
DMEBA61 CS C[C@H]1[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)C(C)C)C)CC2=CC=C(C=C2)O)C/C=C\\CCC(=O)O
DMEBA61 IK QKNOLJBQLJGNKI-LFUPQXEOSA-N
DMEBA61 IU (Z)-6-[(2R,5R,8R,11R,12S)-8-[(4-hydroxyphenyl)methyl]-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enoic acid
DMEBA61 DE Discovery agent
DMAX06G ID DMAX06G
DMAX06G DN AZUMAMIDE E
DMAX06G HS Investigative
DMAX06G SN azumamide E; CHEMBL402363
DMAX06G DT Small molecular drug
DMAX06G PC 16095101
DMAX06G MW 514.6
DMAX06G FM C27H38N4O6
DMAX06G IC InChI=1S/C27H38N4O6/c1-16(2)23-27(37)28-18(4)25(35)30-21(15-19-11-7-5-8-12-19)26(36)29-20(17(3)24(34)31-23)13-9-6-10-14-22(32)33/h5-9,11-12,16-18,20-21,23H,10,13-15H2,1-4H3,(H,28,37)(H,29,36)(H,30,35)(H,31,34)(H,32,33)/b9-6-/t17-,18+,20+,21+,23+/m0/s1
DMAX06G CS C[C@H]1[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)C(C)C)C)CC2=CC=CC=C2)C/C=C\\CCC(=O)O
DMAX06G IK DMXROUYLQHFRCS-GIORXHJXSA-N
DMAX06G IU (Z)-6-[(2R,5R,8R,11R,12S)-8-benzyl-5,12-dimethyl-3,6,9,13-tetraoxo-2-propan-2-yl-1,4,7,10-tetrazacyclotridec-11-yl]hex-4-enoic acid
DMAX06G DE Discovery agent
DMN2XTQ ID DMN2XTQ
DMN2XTQ DN B173
DMN2XTQ HS Investigative
DMN2XTQ SN BRL 54443 maleate; BRL 54443 maleate salt; 1197333-54-2; EU-0100207; 3-(1-Methylpiperidin-4-yl)-1H-indol-5-ol maleate; SCHEMBL4799792; CHEMBL1256797; MolPort-003-940-420; BRL 54443 maleate salt, solid; HMS3260J15; Tox21_500207; BN0117; LP00207; CCG-221511; NCGC00093680-01; NCGC00260892-01; B-173; SR-01000075573-1; J-004192; 3-(1-Methylpiperidin-4-yl)-1H-indol-5-ol maleate salt
DMN2XTQ DT Small molecular drug
DMN2XTQ PC 11957480
DMN2XTQ MW 346.4
DMN2XTQ FM C18H22N2O5
DMN2XTQ IC InChI=1S/C14H18N2O.C4H4O4/c1-16-6-4-10(5-7-16)13-9-15-14-3-2-11(17)8-12(13)14;5-3(6)1-2-4(7)8/h2-3,8-10,15,17H,4-7H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
DMN2XTQ CS CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)O.C(=C\\C(=O)O)\\C(=O)O
DMN2XTQ IK INGCLXPSKXSYND-BTJKTKAUSA-N
DMN2XTQ IU (Z)-but-2-enedioic acid;3-(1-methylpiperidin-4-yl)-1H-indol-5-ol
DMN2XTQ DE Discovery agent
DMEGX8H ID DMEGX8H
DMEGX8H DN B-2-Octylglucoside
DMEGX8H HS Investigative
DMEGX8H SN B-2-OCTYLGLUCOSIDE; BGL; AC1L9I1F; SCHEMBL61561; 2-O-octyl-beta-D-glucopyranose; DB03152; (2R,3R,4S,5S,6R)-6-(hydroxymethyl)-3-octoxyoxane-2,4,5-triol
DMEGX8H DT Small molecular drug
DMEGX8H PC 445463
DMEGX8H MW 292.37
DMEGX8H FM C14H28O6
DMEGX8H IC InChI=1S/C14H28O6/c1-2-3-4-5-6-7-8-19-13-12(17)11(16)10(9-15)20-14(13)18/h10-18H,2-9H2,1H3/t10-,11-,12+,13-,14-/m1/s1
DMEGX8H CS CCCCCCCCO[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O
DMEGX8H IK BVHPDIWLWHHJPD-RKQHYHRCSA-N
DMEGX8H IU (2R,3R,4S,5S,6R)-6-(hydroxymethyl)-3-octoxyoxane-2,4,5-triol
DMEGX8H DE Discovery agent
DMV3H0C ID DMV3H0C
DMV3H0C DN B3C
DMV3H0C HS Investigative
DMV3H0C SN compound 23 [PMID: 18752942]
DMV3H0C DT Small molecular drug
DMV3H0C PC 24892831
DMV3H0C MW 777.9
DMV3H0C FM C44H51N5O8
DMV3H0C IC InChI=1S/C44H51N5O8/c1-30-19-21-33(22-20-30)28-55-34-26-37(40(50)48-39(18-10-11-25-45)44(53,54)42-46-35-16-8-9-17-38(35)57-42)49(27-34)41(51)36(24-23-31-12-4-2-5-13-31)47-43(52)56-29-32-14-6-3-7-15-32/h2-9,12-17,19-22,34,36-37,39,53-54H,10-11,18,23-29,45H2,1H3,(H,47,52)(H,48,50)/t34-,36-,37+,39+/m1/s1
DMV3H0C CS CC1=CC=C(C=C1)CO[C@@H]2C[C@H](N(C2)C(=O)[C@@H](CCC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(C5=NC6=CC=CC=C6O5)(O)O
DMV3H0C IK KGNDCEVUMONOKF-UGPLYTSKSA-N
DMV3H0C IU benzyl N-[(2R)-1-[(2S,4R)-2-[[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate
DMV3H0C DE Discovery agent
DMIUD0L ID DMIUD0L
DMIUD0L DN B-623
DMIUD0L HS Investigative
DMIUD0L SN 149732-37-6
DMIUD0L PC 9820186
DMIUD0L MW 322.4
DMIUD0L FM C18H14N2O2S
DMIUD0L IC InChI=1S/C18H14N2O2S/c19-18(20)17-9-13-12(2-1-3-16(13)23-17)6-4-11-5-7-14-15(8-11)22-10-21-14/h1-9H,10H2,(H3,19,20)/b6-4+
DMIUD0L CS C1OC2=C(O1)C=C(C=C2)/C=C/C3=C4C=C(SC4=CC=C3)C(=N)N
DMIUD0L IK BGFUKOBHJOFLNH-GQCTYLIASA-N
DMIUD0L IU 4-[(E)-2-(1,3-benzodioxol-5-yl)ethenyl]-1-benzothiophene-2-carboximidamide
DMIUD0L DE Discovery agent
DMCK5DG ID DMCK5DG
DMCK5DG DN BADGE
DMCK5DG HS Investigative
DMCK5DG SN SCHEMBL7915436; GTPL2708; 2,2-Bis[4-(oxiranyloxy)phenyl]propane
DMCK5DG DT Small molecular drug
DMCK5DG PC 2286
DMCK5DG MW 340.4
DMCK5DG FM C21H24O4
DMCK5DG IC InChI=1S/C21H24O4/c1-21(2,15-3-7-17(8-4-15)22-11-19-13-24-19)16-5-9-18(10-6-16)23-12-20-14-25-20/h3-10,19-20H,11-14H2,1-2H3
DMCK5DG CS CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4
DMCK5DG IK LCFVJGUPQDGYKZ-UHFFFAOYSA-N
DMCK5DG IU 2-[[4-[2-[4-(oxiran-2-ylmethoxy)phenyl]propan-2-yl]phenoxy]methyl]oxirane
DMCK5DG CA CAS 1675-54-3
DMCK5DG CB CHEBI:34578
DMCK5DG DE Discovery agent
DMUNK59 ID DMUNK59
DMUNK59 DN Bafilomycin A1
DMUNK59 HS Investigative
DMUNK59 SN bafilomycin A1; 88899-55-2; MFCD06795130; CHEMBL290814; CHEBI:22689; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-{(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyltetrahydro-2H-pyran-2-yl]-3-hydroxypentan-2-yl}-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one; Bafilomycin; NSC381866; Bafilomycin A1/; Hygrolidin, 21-O-de(3-carboxy-1-oxo-2-propenyl)-2-demethyl-2-methoxy-24-methyl-; Bafilomycin A1 from Streptomyces griseus; BSPBio_001470; MEGxm0_000385; SCHEMBL13775181; ACon0_000813; HMS3402J12; Bafilomycin A1 Ready Made Solution; ABP000610; BDBM50064186; AKOS030213158; ZINC169647947; DB06733; MCULE-2359469972; NCGC00163426-02; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one; Q4841341; (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyl-tetrahydropyran-2-yl]-2-hydroxy-1-methyl-butyl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
DMUNK59 DT Small molecular drug
DMUNK59 PC 6436223
DMUNK59 MW 622.8
DMUNK59 FM C35H58O9
DMUNK59 IC InChI=1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23+,24-,25-,26-,27+,28-,30-,31+,32+,33+,35+/m0/s1
DMUNK59 CS C[C@H]1C/C(=C/C=C/[C@@H]([C@H](OC(=O)/C(=C/C(=C/[C@H]([C@H]1O)C)/C)/OC)[C@@H](C)[C@H]([C@H](C)[C@]2(C[C@H]([C@@H]([C@H](O2)C(C)C)C)O)O)O)OC)/C
DMUNK59 IK XDHNQDDQEHDUTM-JQWOJBOSSA-N
DMUNK59 IU (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-[(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one
DMUNK59 CA CAS 88899-55-2
DMUNK59 CB CHEBI:22689
DMUNK59 DE B-cell acute lymphoblastic leukaemia
DMSWQED ID DMSWQED
DMSWQED DN bag-1
DMSWQED HS Investigative
DMSWQED SN AK120413
DMSWQED DT Small molecular drug
DMSWQED PC 25025860
DMSWQED MW 333.5
DMSWQED FM C22H27N3
DMSWQED IC InChI=1S/C22H27N3/c1-4-22(2,3)15-19-16-24-21(25-19)13-10-17-8-11-18(12-9-17)20-7-5-6-14-23-20/h5-9,11-12,14,16H,4,10,13,15H2,1-3H3,(H,24,25)
DMSWQED CS CCC(C)(C)CC1=CN=C(N1)CCC2=CC=C(C=C2)C3=CC=CC=N3
DMSWQED IK WVAKRQOMAINQPU-UHFFFAOYSA-N
DMSWQED IU 2-[4-[2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl]phenyl]pyridine
DMSWQED CA CAS 1021937-07-4
DMSWQED DE Discovery agent
DMWC34B ID DMWC34B
DMWC34B DN BAG956
DMWC34B HS Investigative
DMWC34B SN NVP-BAG956; 853910-02-8; BAG 956; NVP-BAG956(BAG 956); BAG-956; UNII-4UFC2K6E50; 4UFC2K6E50; 2-Methyl-2-(4-(2-methyl-8-((pyridin-3-yl)ethynyl)imidazo(4,5-C)quinolin-1-yl)phenyl)propionitrile; 2-methyl-2-(4-(2-methyl-8-(pyridin-3-ylethynyl)-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile; BAG956; 2-Methyl-2-{4-[2-methyl-8-(pyridin-3-ylethynyl)-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile; 2-Methyl-2-[4-[2-methyl-8-[(pyridin-3-yl)ethynyl]imidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile; NVP-BAG-956
DMWC34B TC Anticancer Agents
DMWC34B DT Small molecular drug
DMWC34B PC 24882589
DMWC34B MW 427.5
DMWC34B FM C28H21N5
DMWC34B IC InChI=1S/C28H21N5/c1-19-32-26-17-31-25-13-8-20(6-7-21-5-4-14-30-16-21)15-24(25)27(26)33(19)23-11-9-22(10-12-23)28(2,3)18-29/h4-5,8-17H,1-3H3
DMWC34B CS CC1=NC2=CN=C3C=CC(=CC3=C2N1C4=CC=C(C=C4)C(C)(C)C#N)C#CC5=CN=CC=C5
DMWC34B IK GVPAGJWVBUZHNQ-UHFFFAOYSA-N
DMWC34B IU 2-methyl-2-[4-[2-methyl-8-(2-pyridin-3-ylethynyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
DMWC34B CA CAS 853910-02-8
DMWC34B DE Haematological malignancy
DMX6KTO ID DMX6KTO
DMX6KTO DN BAN-2203
DMX6KTO HS Investigative
DMX6KTO SN Beta amyloid modulator (Alzheimer's disease), BioArctic
DMX6KTO CP Bioarctic Neuroscience AB
DMX6KTO DE Alzheimer disease
DM4OT8M ID DM4OT8M
DM4OT8M DN bantag-1
DM4OT8M HS Investigative
DM4OT8M SN bantag-1; GTPL6176
DM4OT8M DT Small molecular drug
DM4OT8M PC 73755180
DM4OT8M MW 895.2
DM4OT8M FM C49H82N8O7+2
DM4OT8M IC InChI=1S/C49H80N8O7/c1-33(2)23-40(45(60)51-29-36-21-16-22-37(24-36)31-57(7,8)9)53-44(59)28-43(58)39(25-34-17-12-10-13-18-34)54-46(61)42(27-38-30-50-32-52-38)56(6)47(62)41(26-35-19-14-11-15-20-35)55-48(63)64-49(3,4)5/h11,14,19,21,24,30,32-34,39-43,46,54,58,61H,10,12-13,15-18,20,22-23,25-29,31H2,1-9H3,(H3-,50,51,52,53,55,59,60,63)/p+2/t39-,40-,41-,42-,43-,46?/m0/s1
DM4OT8M CS CC(C)C[C@@H](C(=O)NCC1=CCCC(=C1)C[N+](C)(C)C)NC(=O)C[C@@H]([C@H](CC2CCCCC2)NC([C@H](CC3=C[NH+]=CN3)N(C)C(=O)[C@H](CC4=CC=CCC4)NC(=O)OC(C)(C)C)O)O
DM4OT8M IK DAWSYEXBFLQUER-SLMIJXFKSA-P
DM4OT8M IU [3-[[[(2S)-2-[[(3S,4S)-4-[[(2S)-2-[[(2S)-3-cyclohexa-1,3-dien-1-yl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]-methylamino]-1-hydroxy-3-(1H-imidazol-3-ium-5-yl)propyl]amino]-5-cyclohexyl-3-hydroxypentanoyl]amino]-4-methylpentanoyl]amino]methyl]cyclohexa-1,3-dien-1-yl]methyl-trimethylazanium
DM4OT8M DE Discovery agent
DM9JXIZ ID DM9JXIZ
DM9JXIZ DN banyu (I)
DM9JXIZ HS Investigative
DM9JXIZ SN 2-(6-Amino-benzothiazol-2-ylsulfanyl)-N-[1-(3,4-dichloro-benzyl)-piperidin-4-yl]-acetamide; CHEMBL20921; Banyu Compound 1b; [3H]banyu (I); GTPL795; GTPL796; SCHEMBL5489840; BDBM50099482; N-[1-(3,4-Dichlorobenzyl)-4-piperidinyl](6-amino-2-benzothiazolylthio)acetamide; 2-[(6-amino-1,3-benzothiazol-2-yl)sulfanyl]-N-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]acetamid; 290363-23-4; Banyu Compound 1b
DM9JXIZ DT Small molecular drug
DM9JXIZ PC 9913085
DM9JXIZ MW 481.5
DM9JXIZ FM C21H22Cl2N4OS2
DM9JXIZ IC InChI=1S/C21H22Cl2N4OS2/c22-16-3-1-13(9-17(16)23)11-27-7-5-15(6-8-27)25-20(28)12-29-21-26-18-4-2-14(24)10-19(18)30-21/h1-4,9-10,15H,5-8,11-12,24H2,(H,25,28)
DM9JXIZ CS C1CN(CCC1NC(=O)CSC2=NC3=C(S2)C=C(C=C3)N)CC4=CC(=C(C=C4)Cl)Cl
DM9JXIZ IK QOHFBKIKGAINLL-UHFFFAOYSA-N
DM9JXIZ IU 2-[(6-amino-1,3-benzothiazol-2-yl)sulfanyl]-N-[1-[(3,4-dichlorophenyl)methyl]piperidin-4-yl]acetamide
DM9JXIZ DE Discovery agent
DMD26XN ID DMD26XN
DMD26XN DN Banyu Compound-24
DMD26XN HS Investigative
DMD26XN SN C-24
DMD26XN DT Small molecular drug
DMD26XN PC 10296561
DMD26XN MW 433.6
DMD26XN FM C27H35N3O2
DMD26XN IC InChI=1S/C27H35N3O2/c31-26(25-12-6-17-30(25)20-22-8-2-1-3-9-22)28-15-7-16-29-18-13-27(14-19-29)24-11-5-4-10-23(24)21-32-27/h1-5,8-11,25H,6-7,12-21H2,(H,28,31)/t25-/m1/s1
DMD26XN CS C1C[C@@H](N(C1)CC2=CC=CC=C2)C(=O)NCCCN3CCC4(CC3)C5=CC=CC=C5CO4
DMD26XN IK MAKMQGKJURAJEN-RUZDIDTESA-N
DMD26XN IU (2R)-1-benzyl-N-(3-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylpropyl)pyrrolidine-2-carboxamide
DMD26XN DE Discovery agent
DM2I19P ID DM2I19P
DM2I19P DN Barbituric acid derivative
DM2I19P HS Investigative
DM2I19P SN Barbituric acid derivative; UNII-R1JI58032B; R1JI58032B; AC1MHEP3; DB01496; 2-thioxo-5-[[5-[2-(trifluoromethyl)phenyl]-2-furyl]methyl]hexahydropyrimidine-4,6-dione; 2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methyl]-1,3-diazinane-4,6-dione; 959343-20-5; 4,6(1H,5H)-Pyrimidinedione, dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-
DM2I19P DT Small molecular drug
DM2I19P PC 3003157
DM2I19P MW 368.3
DM2I19P FM C16H11F3N2O3S
DM2I19P IC InChI=1S/C16H11F3N2O3S/c17-16(18,19)11-4-2-1-3-9(11)12-6-5-8(24-12)7-10-13(22)20-15(25)21-14(10)23/h1-6,10H,7H2,(H2,20,21,22,23,25)
DM2I19P CS C1=CC=C(C(=C1)C2=CC=C(O2)CC3C(=O)NC(=S)NC3=O)C(F)(F)F
DM2I19P IK DNZPLHRZXUJATK-UHFFFAOYSA-N
DM2I19P IU 2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methyl]-1,3-diazinane-4,6-dione
DM2I19P CA CAS 959343-20-5
DM2I19P DE Discovery agent
DMU3D2O ID DMU3D2O
DMU3D2O DN BARETTIN
DMU3D2O HS Investigative
DMU3D2O SN (-)-Barettine; GBB 1-Z; 104311-70-8; AC1O5Z3U; 606933-69-1
DMU3D2O DT Small molecular drug
DMU3D2O PC 11177588
DMU3D2O MW 419.3
DMU3D2O FM C17H19BrN6O2
DMU3D2O IC InChI=1S/C17H19BrN6O2/c18-10-3-4-11-9(8-22-13(11)7-10)6-14-16(26)23-12(15(25)24-14)2-1-5-21-17(19)20/h3-4,6-8,12,22H,1-2,5H2,(H,23,26)(H,24,25)(H4,19,20,21)/b14-6-/t12-/m0/s1
DMU3D2O CS C1=CC2=C(C=C1Br)NC=C2/C=C\\3/C(=O)N[C@H](C(=O)N3)CCCN=C(N)N
DMU3D2O IK YYFNNPXWRXQUPR-JVXNRYDGSA-N
DMU3D2O IU 2-[3-[(2S,5Z)-5-[(6-bromo-1H-indol-3-yl)methylidene]-3,6-dioxopiperazin-2-yl]propyl]guanidine
DMU3D2O CA CAS 104311-70-8
DMU3D2O DE Discovery agent
DMZPKGS ID DMZPKGS
DMZPKGS DN BAS-00387275
DMZPKGS HS Investigative
DMZPKGS SN BAS-00387275; CHEMBL379308; (4Z)-4-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-1-(4-iodophenyl)pyrazolidine-3,5-dione; AC1M44RA; MolPort-001-928-844; ZINC37858290; STL508972; STL430984; BDBM50187579; AKOS000437993; BAS 00387275; 4-((6-bromobenzo[d][1,3]dioxol-5-yl)methylene)-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMZPKGS DT Small molecular drug
DMZPKGS PC 2250919
DMZPKGS MW 513.1
DMZPKGS FM C17H10BrIN2O4
DMZPKGS IC InChI=1S/C17H10BrIN2O4/c18-13-7-15-14(24-8-25-15)6-9(13)5-12-16(22)20-21(17(12)23)11-3-1-10(19)2-4-11/h1-7H,8H2,(H,20,22)/b12-5-
DMZPKGS CS C1OC2=C(O1)C=C(C(=C2)/C=C\\3/C(=O)NN(C3=O)C4=CC=C(C=C4)I)Br
DMZPKGS IK WMFFHUYJLJSDEU-XGICHPGQSA-N
DMZPKGS IU (4Z)-4-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMZPKGS DE Discovery agent
DM4OSFD ID DM4OSFD
DM4OSFD DN BAS-00387328
DM4OSFD HS Investigative
DM4OSFD SN CHEMBL210766; BAS-00387328; SCHEMBL5737024; BDBM50187569
DM4OSFD DT Small molecular drug
DM4OSFD PC 10301426
DM4OSFD MW 516.07
DM4OSFD FM C16H10I2N2O2
DM4OSFD IC InChI=1S/C16H10I2N2O2/c17-11-3-1-10(2-4-11)9-14-15(21)19-20(16(14)22)13-7-5-12(18)6-8-13/h1-9H,(H,19,21)/b14-9-
DM4OSFD CS C1=CC(=CC=C1/C=C\\2/C(=O)NN(C2=O)C3=CC=C(C=C3)I)I
DM4OSFD IK HOZMXIPMJIGFMB-ZROIWOOFSA-N
DM4OSFD IU (4Z)-1-(4-iodophenyl)-4-[(4-iodophenyl)methylidene]pyrazolidine-3,5-dione
DM4OSFD DE Discovery agent
DMUF28Q ID DMUF28Q
DMUF28Q DN BAS-00387347
DMUF28Q HS Investigative
DMUF28Q SN BAS-00387347; CHEMBL209617; AC1LKSRL; 4-benzylidene-1-(4-iodophenyl)pyrazolidine-3,5-dione; SCHEMBL5735322; ZINC726017; BDBM50187575; AKOS000438122; AG-690/10031054; 4-benzylidene-1-(4-iodophenyl)-3,5-pyrazolidinedione
DMUF28Q DT Small molecular drug
DMUF28Q PC 1049055
DMUF28Q MW 390.17
DMUF28Q FM C16H11IN2O2
DMUF28Q IC InChI=1S/C16H11IN2O2/c17-12-6-8-13(9-7-12)19-16(21)14(15(20)18-19)10-11-4-2-1-3-5-11/h1-10H,(H,18,20)/b14-10-
DMUF28Q CS C1=CC=C(C=C1)/C=C\\2/C(=O)NN(C2=O)C3=CC=C(C=C3)I
DMUF28Q IK KAGAMCCGZCDKMX-UVTDQMKNSA-N
DMUF28Q IU (4Z)-4-benzylidene-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMUF28Q DE Discovery agent
DM6R4X8 ID DM6R4X8
DM6R4X8 DN BAS-00672722
DM6R4X8 HS Investigative
DM6R4X8 SN BAS-00672722; CHEMBL207360; AC1LKX7K; BDBM50187572; 4-(3-(benzyloxy)benzylidene)-1-(3,4-dichlorophenyl)pyrazolidine-3,5-dione
DM6R4X8 DT Small molecular drug
DM6R4X8 PC 1075248
DM6R4X8 MW 439.3
DM6R4X8 FM C23H16Cl2N2O3
DM6R4X8 IC InChI=1S/C23H16Cl2N2O3/c24-20-10-9-17(13-21(20)25)27-23(29)19(22(28)26-27)12-16-7-4-8-18(11-16)30-14-15-5-2-1-3-6-15/h1-13H,14H2,(H,26,28)/b19-12-
DM6R4X8 CS C1=CC=C(C=C1)COC2=CC=CC(=C2)/C=C\\3/C(=O)NN(C3=O)C4=CC(=C(C=C4)Cl)Cl
DM6R4X8 IK OSJPWEILZQFNPI-UNOMPAQXSA-N
DM6R4X8 IU (4Z)-1-(3,4-dichlorophenyl)-4-[(3-phenylmethoxyphenyl)methylidene]pyrazolidine-3,5-dione
DM6R4X8 DE Discovery agent
DMNB7CW ID DMNB7CW
DMNB7CW DN BAS-01047341
DMNB7CW HS Investigative
DMNB7CW SN BAS-01047341; CHEMBL208828; AC1LLNNX; MolPort-001-953-454; BDBM50187577; CCG-12153; ZINC13633981; AKOS000446912; BAS 01047341; BIM-0025124.P001; 4-(4-(diethylamino)-2-hydroxybenzylidene)-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMNB7CW DT Small molecular drug
DMNB7CW PC 1113004
DMNB7CW MW 477.3
DMNB7CW FM C20H20IN3O3
DMNB7CW IC InChI=1S/C20H20IN3O3/c1-3-23(4-2)16-8-5-13(18(25)12-16)11-17-19(26)22-24(20(17)27)15-9-6-14(21)7-10-15/h5-12,25H,3-4H2,1-2H3,(H,22,26)/b17-11-
DMNB7CW CS CCN(CC)C1=CC(=C(C=C1)/C=C\\2/C(=O)NN(C2=O)C3=CC=C(C=C3)I)O
DMNB7CW IK QOVNZWROVBIKQY-BOPFTXTBSA-N
DMNB7CW IU (4Z)-4-[[4-(diethylamino)-2-hydroxyphenyl]methylidene]-1-(4-iodophenyl)pyrazolidine-3,5-dione
DMNB7CW DE Discovery agent
DMC0FLB ID DMC0FLB
DMC0FLB DN BAS-01047655
DMC0FLB HS Investigative
DMC0FLB SN BAS-01047655; CHEMBL380706; AC1LKNKS; MolPort-001-663-455; MolPort-019-782-693; ZINC12376560; STK392633; BDBM50187570; AKOS000548089; MCULE-2522435117; ST033733; BAS 01047655; AK-968/37005047; A2180/0091610; 4-[2-(benzyloxy)benzylidene]-1-phenyl-3,5-pyrazolidinedione; 4-(2-Benzyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione; 4-(2-(benzyloxy)benzylidene)-1-phenylpyrazolidine-3,5-dione; (4Z)-4-[2-(benzyloxy)benzylidene]-1-phenylpyrazolidine-3,5-dione
DMC0FLB DT Small molecular drug
DMC0FLB PC 1021453
DMC0FLB MW 370.4
DMC0FLB FM C23H18N2O3
DMC0FLB IC InChI=1S/C23H18N2O3/c26-22-20(23(27)25(24-22)19-12-5-2-6-13-19)15-18-11-7-8-14-21(18)28-16-17-9-3-1-4-10-17/h1-15H,16H2,(H,24,26)/b20-15-
DMC0FLB CS C1=CC=C(C=C1)COC2=CC=CC=C2/C=C\\3/C(=O)NN(C3=O)C4=CC=CC=C4
DMC0FLB IK NDWMSBYUWXNXGT-HKWRFOASSA-N
DMC0FLB IU (4Z)-1-phenyl-4-[(2-phenylmethoxyphenyl)methylidene]pyrazolidine-3,5-dione
DMC0FLB DE Discovery agent
DMZBIC3 ID DMZBIC3
DMZBIC3 DN BAS-01373578
DMZBIC3 HS Investigative
DMZBIC3 SN BAS-01373578; CHEMBL206575; (4Z)-4-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; (4Z)-4-{[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene}-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione; AC1LWF8S; MolPort-030-043-249; MolPort-001-963-180; ZINC4471294; STL387426; STL383260; BDBM50187574; AKOS025249675; AKOS000447221; BAS 01373578; 4-((5-(3-chloro-4-methylphenyl)furan-2-yl)methylene)-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione
DMZBIC3 DT Small molecular drug
DMZBIC3 PC 1728080
DMZBIC3 MW 406.9
DMZBIC3 FM C23H19ClN2O3
DMZBIC3 IC InChI=1S/C23H19ClN2O3/c1-13-5-7-17(10-15(13)3)26-23(28)19(22(27)25-26)12-18-8-9-21(29-18)16-6-4-14(2)20(24)11-16/h4-12H,1-3H3,(H,25,27)/b19-12-
DMZBIC3 CS CC1=C(C=C(C=C1)N2C(=O)/C(=C\\C3=CC=C(O3)C4=CC(=C(C=C4)C)Cl)/C(=O)N2)C
DMZBIC3 IK GCEFTTIUEIKKPW-UNOMPAQXSA-N
DMZBIC3 IU (4Z)-4-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-1-(3,4-dimethylphenyl)pyrazolidine-3,5-dione
DMZBIC3 DE Discovery agent
DMZGLHJ ID DMZGLHJ
DMZGLHJ DN BAS-0338868
DMZGLHJ HS Investigative
DMZGLHJ SN BAS-0338868; CHEMBL378903; N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; N-(5-Phenethyl-[1,3,4]thiadiazol-2-yl)-benzamide; AC1LGHJD; BAS 00338868; Oprea1_674367; Oprea1_387539; MLS001208166; cid_821478; MolPort-001-925-654; ZINC338374; HMS2838C05; BDBM50187578; AKOS000542350; MCULE-7705926672; SMR000513539
DMZGLHJ DT Small molecular drug
DMZGLHJ PC 821478
DMZGLHJ MW 309.4
DMZGLHJ FM C17H15N3OS
DMZGLHJ IC InChI=1S/C17H15N3OS/c21-16(14-9-5-2-6-10-14)18-17-20-19-15(22-17)12-11-13-7-3-1-4-8-13/h1-10H,11-12H2,(H,18,20,21)
DMZGLHJ CS C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=CC=CC=C3
DMZGLHJ IK LZMYTXMTFJGQJA-UHFFFAOYSA-N
DMZGLHJ IU N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMZGLHJ DE Discovery agent
DMZK0SC ID DMZK0SC
DMZK0SC DN BAS-0338872
DMZK0SC HS Investigative
DMZK0SC SN BAS-0338872; CHEMBL207986; 2-iodo-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; BAS 00338872; AC1LM5IX; Oprea1_394225; Oprea1_118842; ZINC820816; BDBM50187565; AKOS000542403; MCULE-8600906341; ST50224059; 2-Iodo-N-(5-phenethyl-[1,3,4]thiadiazol-2-yl)-benzamide
DMZK0SC DT Small molecular drug
DMZK0SC PC 1097674
DMZK0SC MW 435.3
DMZK0SC FM C17H14IN3OS
DMZK0SC IC InChI=1S/C17H14IN3OS/c18-14-9-5-4-8-13(14)16(22)19-17-21-20-15(23-17)11-10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,21,22)
DMZK0SC CS C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=CC=CC=C3I
DMZK0SC IK SLBMNZPBYUAWPO-UHFFFAOYSA-N
DMZK0SC IU 2-iodo-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMZK0SC DE Discovery agent
DMBS8N9 ID DMBS8N9
DMBS8N9 DN BAS-0338876
DMBS8N9 HS Investigative
DMBS8N9 SN BAS-0338876; CHEMBL206046; BDBM50187566
DMBS8N9 DT Small molecular drug
DMBS8N9 PC 44412060
DMBS8N9 MW 435.3
DMBS8N9 FM C17H14IN3OS
DMBS8N9 IC InChI=1S/C17H14IN3OS/c18-14-9-7-13(8-10-14)16(22)19-17-21-20-15(23-17)11-6-12-4-2-1-3-5-12/h1-5,7-10H,6,11H2,(H,19,21,22)
DMBS8N9 CS C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=CC=C(C=C3)I
DMBS8N9 IK ISVOIGTWCBLSQY-UHFFFAOYSA-N
DMBS8N9 IU 4-iodo-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMBS8N9 DE Discovery agent
DMFMBZ9 ID DMFMBZ9
DMFMBZ9 DN BAS-09534324
DMFMBZ9 HS Investigative
DMFMBZ9 SN BAS 09534324; BAS-09534324; CHEMBL376993; AC1LM0SZ; MolPort-002-015-109; ZINC815475; BDBM50187571; STK175770; AKOS000654857; MCULE-5021008908; 2-methoxy-4-methylsulfanyl-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; 2-methoxy-4-(methylthio)-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; 2-methoxy-4-(methylsulfanyl)-N~1~-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; 2-Methoxy-4-methylsulfanyl-N-(5-phenethyl-[1,3,4]thiadiazol-2-yl)-benzamide; 2-methoxy-4-(methylthio)-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMFMBZ9 DT Small molecular drug
DMFMBZ9 PC 1094114
DMFMBZ9 MW 385.5
DMFMBZ9 FM C19H19N3O2S2
DMFMBZ9 IC InChI=1S/C19H19N3O2S2/c1-24-16-12-14(25-2)9-10-15(16)18(23)20-19-22-21-17(26-19)11-8-13-6-4-3-5-7-13/h3-7,9-10,12H,8,11H2,1-2H3,(H,20,22,23)
DMFMBZ9 CS COC1=C(C=CC(=C1)SC)C(=O)NC2=NN=C(S2)CCC3=CC=CC=C3
DMFMBZ9 IK JYHRBJVBNRDAJX-UHFFFAOYSA-N
DMFMBZ9 IU 2-methoxy-4-methylsulfanyl-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMFMBZ9 DE Discovery agent
DMTH1JQ ID DMTH1JQ
DMTH1JQ DN BAS-450225
DMTH1JQ HS Investigative
DMTH1JQ SN BAS-450225; CHEMBL210036; 2,4-dichloro-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)benzamide; AC1LL38T; Oprea1_759762; Oprea1_195875
DMTH1JQ DT Small molecular drug
DMTH1JQ PC 1103113
DMTH1JQ MW 378.3
DMTH1JQ FM C17H13Cl2N3OS
DMTH1JQ IC InChI=1S/C17H13Cl2N3OS/c18-12-7-8-13(14(19)10-12)16(23)20-17-22-21-15(24-17)9-6-11-4-2-1-3-5-11/h1-5,7-8,10H,6,9H2,(H,20,22,23)
DMTH1JQ CS C1=CC=C(C=C1)CCC2=NN=C(S2)NC(=O)C3=C(C=C(C=C3)Cl)Cl
DMTH1JQ IK BVZCHEPRCHHCRQ-UHFFFAOYSA-N
DMTH1JQ IU 2,4-dichloro-N-[5-(2-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide
DMTH1JQ DE Discovery agent
DMFNAKU ID DMFNAKU
DMFNAKU DN BAS-4844343
DMFNAKU HS Investigative
DMFNAKU SN BAS-4844343; CHEMBL207672; N-[5-(1H-indol-3-ylmethyl)-1,3,4-thiadiazol-2-yl]-4-methoxybenzamide; AC1LK4AS; Oprea1_740559; MolPort-000-746-934; MolPort-001-911-292; ZINC17747698; STK758751; STK846597; BDBM50187576; AKOS005626974; AKOS000597970; MCULE-8653633709; BAS 04844343; SR-01000521375; SR-01000521375-1; A1870/0078659; N-[5-(1H-Indol-3-ylmethyl)-[1,3,4]thiadiazol-2-yl]-4-methoxy-benzamide; N~1~-[5-(1H-indol-3-ylmethyl)-1,3,4-thiadiazol-2-yl]-4-methoxybenzamide
DMFNAKU DT Small molecular drug
DMFNAKU PC 1036901
DMFNAKU MW 364.4
DMFNAKU FM C19H16N4O2S
DMFNAKU IC InChI=1S/C19H16N4O2S/c1-25-14-8-6-12(7-9-14)18(24)21-19-23-22-17(26-19)10-13-11-20-16-5-3-2-4-15(13)16/h2-9,11,20H,10H2,1H3,(H,21,23,24)
DMFNAKU CS COC1=CC=C(C=C1)C(=O)NC2=NN=C(S2)CC3=CNC4=CC=CC=C43
DMFNAKU IK AXHAJBIEOINPDH-UHFFFAOYSA-N
DMFNAKU IU N-[5-(1H-indol-3-ylmethyl)-1,3,4-thiadiazol-2-yl]-4-methoxybenzamide
DMFNAKU DE Discovery agent
DMTQX1G ID DMTQX1G
DMTQX1G DN Batimistat
DMTQX1G HS Investigative
DMTQX1G DE Discovery agent
DMYH9SU ID DMYH9SU
DMYH9SU DN Batrachotoxin
DMYH9SU HS Investigative
DMYH9SU SN BATRACHOTOXIN; UNII-TSG6XHX09R; TSG6XHX09R; Batrachotoxinin A, 20-(2,4-dimethyl-1H-pyrrole-3-carboxylate); Betrachotoxinin A, 20-alpha-(2,4-dimethyl-1H-pyrrole-3-carboxylate); 23509-16-2; GTPL2619; LS-24727; Betrachotoxinin A, 20-alpha-(2,4-dimethyl-1H-pyrrole-3-carboxylate) (9CI)
DMYH9SU DT Small molecular drug
DMYH9SU PC 6324647
DMYH9SU MW 538.7
DMYH9SU FM C31H42N2O6
DMYH9SU IC InChI=1S/C31H42N2O6/c1-18-16-32-19(2)25(18)26(35)38-20(3)22-8-9-30-23-7-6-21-14-29(36)11-10-27(21,4)31(23,39-29)24(34)15-28(22,30)17-33(5)12-13-37-30/h7-8,16,20-21,24,32,34,36H,6,9-15,17H2,1-5H3/t20-,21+,24+,27-,28-,29+,30-,31-/m0/s1
DMYH9SU CS CC1=CNC(=C1C(=O)O[C@@H](C)C2=CC[C@@]34[C@@]2(C[C@H]([C@@]56C3=CC[C@H]7[C@@]5(CC[C@](C7)(O6)O)C)O)CN(CCO4)C)C
DMYH9SU IK ISNYUQWBWALXEY-OMIQOYQYSA-N
DMYH9SU IU [(1S)-1-[(1R,5R,6S,9R,11S,12R,14R)-9,12-dihydroxy-6,16-dimethyl-10,19-dioxa-16-azahexacyclo[12.5.3.15,9.01,14.02,11.06,11]tricosa-2,21-dien-22-yl]ethyl] 2,4-dimethyl-1H-pyrrole-3-carboxylate
DMYH9SU CA CAS 23509-16-2
DMYH9SU DE Discovery agent
DMVP74I ID DMVP74I
DMVP74I DN BAY 367620
DMVP74I HS Investigative
DMVP74I SN BAY 36-7620; BAY36-7620; BAY-367620
DMVP74I DT Small molecular drug
DMVP74I PC 9903757
DMVP74I MW 278.3
DMVP74I FM C19H18O2
DMVP74I IC InChI=1S/C19H18O2/c1-13-8-17-12-21-18(20)19(17,10-13)11-14-6-7-15-4-2-3-5-16(15)9-14/h2-7,9,17H,1,8,10-12H2/t17-,19+/m1/s1
DMVP74I CS C=C1C[C@@H]2COC(=O)[C@@]2(C1)CC3=CC4=CC=CC=C4C=C3
DMVP74I IK CVIRWLJKDBYYOG-MJGOQNOKSA-N
DMVP74I IU (3aS,6aS)-5-methylidene-3a-(naphthalen-2-ylmethyl)-1,4,6,6a-tetrahydrocyclopenta[c]furan-3-one
DMVP74I CA CAS 232605-26-4
DMVP74I DE Discovery agent
DM743XB ID DM743XB
DM743XB DN BAY 50-7952
DM743XB HS Investigative
DM743XB SN CHEMBL157769; BAY-507952
DM743XB DT Small molecular drug
DM743XB PC 9895647
DM743XB MW 639.5
DM743XB FM C24H23BrN4O8S2
DM743XB IC InChI=1S/C24H23BrN4O8S2/c1-34-19-9-18(30)15(20(21(19)25)23(31)35-2)10-38-11-17(22-28-37-8-7-36-22)27-24-26-16(12-39-24)13-3-5-14(6-4-13)29(32)33/h3-6,9,12,17,30H,7-8,10-11H2,1-2H3,(H,26,27)/t17-/m0/s1
DM743XB CS COC1=C(C(=C(C(=C1)O)CSC[C@@H](C2=NOCCO2)NC3=NC(=CS3)C4=CC=C(C=C4)[N+](=O)[O-])C(=O)OC)Br
DM743XB IK MRGBDARDZKENAD-KRWDZBQOSA-N
DM743XB IU methyl 2-bromo-6-[[(2R)-2-(5,6-dihydro-1,4,2-dioxazin-3-yl)-2-[[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino]ethyl]sulfanylmethyl]-5-hydroxy-3-methoxybenzoate
DM743XB DE Discovery agent
DMRWSGO ID DMRWSGO
DMRWSGO DN Bay K 8644
DMRWSGO HS Investigative
DMRWSGO SN 71145-03-4; methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate; MLS000028858; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, methyl ester; C16H15F3N2O4; R(+)-BAY K 8644; SMR000058424; Methyl 2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylate
DMRWSGO DT Small molecular drug
DMRWSGO PC 2303
DMRWSGO MW 356.3
DMRWSGO FM C16H15F3N2O4
DMRWSGO IC InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13,20H,1-3H3
DMRWSGO CS CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)OC
DMRWSGO IK ZFLWDHHVRRZMEI-UHFFFAOYSA-N
DMRWSGO IU methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
DMRWSGO CA CAS 71145-03-4
DMRWSGO CB CHEBI:34555
DMRWSGO DE Discovery agent
DMQNOFA ID DMQNOFA
DMQNOFA DN BAY11-7082
DMQNOFA HS Investigative
DMQNOFA SN bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; BAY11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile
DMQNOFA CP Biomol
DMQNOFA DT Small molecular drug
DMQNOFA PC 5353431
DMQNOFA MW 207.25
DMQNOFA FM C10H9NO2S
DMQNOFA IC InChI=1S/C10H9NO2S/c1-9-3-5-10(6-4-9)14(12,13)8-2-7-11/h2-6,8H,1H3/b8-2+
DMQNOFA CS CC1=CC=C(C=C1)S(=O)(=O)/C=C/C#N
DMQNOFA IK DOEWDSDBFRHVAP-KRXBUXKQSA-N
DMQNOFA IU (E)-3-(4-methylphenyl)sulfonylprop-2-enenitrile
DMQNOFA CA CAS 19542-67-7
DMQNOFA CB CHEBI:85928
DMQNOFA DE Multiple myeloma
DM0M59T ID DM0M59T
DM0M59T DN BAY412272
DM0M59T HS Investigative
DM0M59T SN BAY 41-2272; BAY-412272
DM0M59T DT Small molecular drug
DM0M59T PC 9798973
DM0M59T MW 360.4
DM0M59T FM C20H17FN6
DM0M59T IC InChI=1S/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25)
DM0M59T CS C1CC1C2=CN=C(N=C2N)C3=NN(C4=C3C=CC=N4)CC5=CC=CC=C5F
DM0M59T IK ATOAHNRJAXSBOR-UHFFFAOYSA-N
DM0M59T IU 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-amine
DM0M59T CA CAS 256376-24-6
DM0M59T CB CHEBI:142435
DM0M59T DE Discovery agent
DMQZ7JD ID DMQZ7JD
DMQZ7JD DN BAY-60-7550
DMQZ7JD HS Investigative
DMQZ7JD DT Small molecular drug
DMQZ7JD PC 135564787
DMQZ7JD MW 476.6
DMQZ7JD FM C27H32N4O4
DMQZ7JD IC InChI=1S/C27H32N4O4/c1-17-25-27(33)29-24(16-20-13-14-22(34-3)23(15-20)35-4)30-31(25)26(28-17)21(18(2)32)12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,18,21,32H,8,11-12,16H2,1-4H3,(H,29,30,33)/t18-,21+/m1/s1
DMQZ7JD CS CC1=C2C(=O)NC(=NN2C(=N1)[C@@H](CCCC3=CC=CC=C3)[C@@H](C)O)CC4=CC(=C(C=C4)OC)OC
DMQZ7JD IK MYTWFJKBZGMYCS-NQIIRXRSSA-N
DMQZ7JD IU 2-[(3,4-dimethoxyphenyl)methyl]-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
DMQZ7JD CA CAS 439083-90-6
DMQZ7JD DE Discovery agent
DM5CPJ2 ID DM5CPJ2
DM5CPJ2 DN BAY-73-1449
DM5CPJ2 HS Investigative
DM5CPJ2 SN BAY-73-1449; SCHEMBL5906729; GTPL5851; (2S)-3-phenyl-2-[[6-[4-(phenylmethoxy)phenyl]pyrimidin-4-yl]amino]propanoic acid
DM5CPJ2 DT Small molecular drug
DM5CPJ2 PC 11743147
DM5CPJ2 MW 425.5
DM5CPJ2 FM C26H23N3O3
DM5CPJ2 IC InChI=1S/C26H23N3O3/c30-26(31)24(15-19-7-3-1-4-8-19)29-25-16-23(27-18-28-25)21-11-13-22(14-12-21)32-17-20-9-5-2-6-10-20/h1-14,16,18,24H,15,17H2,(H,30,31)(H,27,28,29)/t24-/m0/s1
DM5CPJ2 CS C1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=NC=NC(=C2)C3=CC=C(C=C3)OCC4=CC=CC=C4
DM5CPJ2 IK RRYFPNITZGCUPZ-DEOSSOPVSA-N
DM5CPJ2 IU (2S)-3-phenyl-2-[[6-(4-phenylmethoxyphenyl)pyrimidin-4-yl]amino]propanoic acid
DM5CPJ2 DE Discovery agent
DMW625B ID DMW625B
DMW625B DN BAY-85-3474
DMW625B HS Investigative
DMW625B SN Met inhibitor (cancer), Bayer Schering
DMW625B CP Bayer Schering Pharma AG
DMW625B DE Solid tumour/cancer
DMKFTZA ID DMKFTZA
DMKFTZA DN BayCysLT2
DMKFTZA HS Investigative
DMKFTZA SN CysLT2cpd
DMKFTZA DT Small molecular drug
DMKFTZA PC 53394034
DMKFTZA MW 589.7
DMKFTZA FM C34H39NO8
DMKFTZA IC InChI=1S/C34H39NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h1-3,11-18,23,25,27H,4-10,19-22H2,(H,35,36)(H,37,38)(H,39,40)
DMKFTZA CS C1CC(CC(C1)NC(=O)C2=C(C=CC(=C2)C(=O)O)OCCCC3=CC=C(C=C3)OCCCCOC4=CC=CC=C4)C(=O)O
DMKFTZA IK GKPAULTWHHPIHX-UHFFFAOYSA-N
DMKFTZA IU 3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-phenoxybutoxy)phenyl]propoxy]benzoic acid
DMKFTZA CA CAS 712313-33-2
DMKFTZA DE Discovery agent
DMXQ14V ID DMXQ14V
DMXQ14V DN BAYu9773
DMXQ14V HS Investigative
DMXQ14V SN BAY u9773
DMXQ14V DT Small molecular drug
DMXQ14V PC 5311015
DMXQ14V MW 472.6
DMXQ14V FM C27H36O5S
DMXQ14V IC InChI=1S/C27H36O5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(28)15-14-17-26(29)30)33-23-20-18-22(19-21-23)27(31)32/h6-7,9-13,16,18-21,24-25,28H,2-5,8,14-15,17H2,1H3,(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t24-,25+/m0/s1
DMXQ14V CS CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC1=CC=C(C=C1)C(=O)O
DMXQ14V IK PKJINWOACFYDQN-RBVMPENBSA-N
DMXQ14V IU 4-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylbenzoic acid
DMXQ14V DE Discovery agent
DMKDZLG ID DMKDZLG
DMKDZLG DN BAZ2-ICR
DMKDZLG HS Investigative
DMKDZLG SN inhibitor 13 [PMID: 25719566]
DMKDZLG DT Small molecular drug
DMKDZLG PC 91654625
DMKDZLG MW 357.4
DMKDZLG FM C20H19N7
DMKDZLG IC InChI=1S/C20H19N7/c1-25-12-16(10-23-25)7-8-27-14-22-19(18-11-24-26(2)13-18)20(27)17-5-3-15(9-21)4-6-17/h3-6,10-14H,7-8H2,1-2H3
DMKDZLG CS CN1C=C(C=N1)CCN2C=NC(=C2C3=CC=C(C=C3)C#N)C4=CN(N=C4)C
DMKDZLG IK RRZVGDGTWNQAPW-UHFFFAOYSA-N
DMKDZLG IU 4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile
DMKDZLG DE Discovery agent
DM5SDV9 ID DM5SDV9
DM5SDV9 DN Bb-3497
DM5SDV9 HS Investigative
DM5SDV9 SN BB-3497; CHEMBL431210; BB 3497; 235784-88-0; 2-[(FORMYL-HYDROXY-AMINO)-METHYL]-HEXANOIC ACID (1-DIMETHYLCARBAMOYL-2,2-DIMETHYL-PROPYL)-AMIDE; (2r)-n-[(2s)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-{[formyl(hydroxy)amino]methyl}hexanamide; BB1; 1g27; (2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide; AC1L4M3L; AC1Q5HZ8; SCHEMBL13754309; DTXSID80178216; BDBM50104501; BB3497; DB04368; (R)-2-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid ((S)-1-dimethylcarbamoyl-2,2-
DM5SDV9 DT Small molecular drug
DM5SDV9 PC 159596
DM5SDV9 MW 329.43
DM5SDV9 FM C16H31N3O4
DM5SDV9 IC InChI=1S/C16H31N3O4/c1-7-8-9-12(10-19(23)11-20)14(21)17-13(16(2,3)4)15(22)18(5)6/h11-13,23H,7-10H2,1-6H3,(H,17,21)/t12-,13-/m1/s1
DM5SDV9 CS CCCC[C@H](CN(C=O)O)C(=O)N[C@H](C(=O)N(C)C)C(C)(C)C
DM5SDV9 IK AVDLWYHBABSSHC-CHWSQXEVSA-N
DM5SDV9 IU (2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
DM5SDV9 CA CAS 235784-88-0
DM5SDV9 DE Discovery agent
DMFBN9O ID DMFBN9O
DMFBN9O DN BB-78484
DMFBN9O HS Investigative
DMFBN9O SN SCHEMBL5482389
DMFBN9O DT Small molecular drug
DMFBN9O PC 9846531
DMFBN9O MW 449.3
DMFBN9O FM C19H17BrN2O4S
DMFBN9O IC InChI=1S/C19H17BrN2O4S/c20-16-7-9-17(10-8-16)27(25,26)22-18(19(23)21-24)12-13-5-6-14-3-1-2-4-15(14)11-13/h1-11,18,22,24H,12H2,(H,21,23)/t18-/m1/s1
DMFBN9O CS C1=CC=C2C=C(C=CC2=C1)C[C@H](C(=O)NO)NS(=O)(=O)C3=CC=C(C=C3)Br
DMFBN9O IK WJFADFOFCRGJHM-GOSISDBHSA-N
DMFBN9O IU (2R)-2-[(4-bromophenyl)sulfonylamino]-N-hydroxy-3-naphthalen-2-ylpropanamide
DMFBN9O DE Discovery agent
DMJKA3F ID DMJKA3F
DMJKA3F DN BB-78485
DMJKA3F HS Investigative
DMJKA3F SN (2r)-N-Hydroxy-3-Naphthalen-2-Yl-2-[(Naphthalen-2-Ylsulfonyl)amino]propanamide; 2ves; BB-78485; SCHEMBL5485583; CHEMBL261713; DB07861; (2R)-N-hydroxy-3-(naphthalen-2-yl)-2-(naphthalene-2-sulfonamido)propanamide; (2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide (non-preferred name)
DMJKA3F DT Small molecular drug
DMJKA3F PC 9823454
DMJKA3F MW 420.5
DMJKA3F FM C23H20N2O4S
DMJKA3F IC InChI=1S/C23H20N2O4S/c26-23(24-27)22(14-16-9-10-17-5-1-3-7-19(17)13-16)25-30(28,29)21-12-11-18-6-2-4-8-20(18)15-21/h1-13,15,22,25,27H,14H2,(H,24,26)/t22-/m1/s1
DMJKA3F CS C1=CC=C2C=C(C=CC2=C1)C[C@H](C(=O)NO)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3
DMJKA3F IK MMOUXLMPQFMDRD-JOCHJYFZSA-N
DMJKA3F IU (2R)-N-hydroxy-3-naphthalen-2-yl-2-(naphthalen-2-ylsulfonylamino)propanamide
DMJKA3F DE Discovery agent
DMZPL63 ID DMZPL63
DMZPL63 DN BB-823
DMZPL63 HS Investigative
DMZPL63 SN 139133-28-1
DMZPL63 DT Small molecular drug
DMZPL63 PC 9954410
DMZPL63 MW 430.6
DMZPL63 FM C22H30N4O3S
DMZPL63 IC InChI=1S/C22H30N4O3S/c1-5-29-15-19(12-16(2)3)25-30(27,28)20-8-6-18(7-9-20)14-26-17(4)24-21-13-23-11-10-22(21)26/h6-11,13,16,19,25H,5,12,14-15H2,1-4H3/t19-/m0/s1
DMZPL63 CS CCOC[C@H](CC(C)C)NS(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C
DMZPL63 IK BCRDOIMCNBBVGM-IBGZPJMESA-N
DMZPL63 IU N-[(2S)-1-ethoxy-4-methylpentan-2-yl]-4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzenesulfonamide
DMZPL63 DE Discovery agent
DMMUIQ6 ID DMMUIQ6
DMMUIQ6 DN BBI-11008
DMMUIQ6 HS Investigative
DMMUIQ6 SN DOR agonists (oral, chronic inflammatory pain), Biousian Biosystems; Delta opioid receptor agonists (oral, chronic inflammatory pain), Biousian Biosystems
DMMUIQ6 CP Biousian Biosystems Inc
DMMUIQ6 DE Pain
DM85AJ4 ID DM85AJ4
DM85AJ4 DN BB-PTH 1-84
DM85AJ4 HS Investigative
DM85AJ4 SN Aursos BB; BB-PTH 1-34; Black bear parathyroid hormone (osteoporosis), Aursos
DM85AJ4 CP Michigan Technological University
DM85AJ4 DE Osteoporosis
DMMJ4I5 ID DMMJ4I5
DMMJ4I5 DN Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir
DMMJ4I5 HS Investigative
DMMJ4I5 SN CHEMBL414125; Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir
DMMJ4I5 PC 44405684
DMMJ4I5 MW 3188.5
DMMJ4I5 FM C142H215N31O50S
DMMJ4I5 IC InChI=1S/C142H215N31O50S/c1-14-75(9)64-96(165-129(209)95(63-74(7)8)163-119(199)82(27-19-21-57-143)153-121(201)84(39-48-104(144)176)154-120(200)83(41-50-108(180)181)151-106(178)70-150-136(216)102-29-20-22-59-172(102)138(218)91(28-23-58-148-141(146)147)171-224(222,223)81-37-33-79(34-38-81)142(11,12)13)130(210)169-101(71-174)135(215)159-86(43-52-110(184)185)123(203)155-88(45-54-112(188)189)126(206)168-100(68-116(196)197)134(214)162-93(61-72(3)4)118(198)149-69-107(179)152-99(67-115(194)195)133(213)167-97(65-77-25-17-16-18-26-77)131(211)158-85(42-51-109(182)183)122(202)157-90(47-56-114(192)193)127(207)170-117(76(10)15-2)139(219)173-60-24-30-103(173)137(217)160-89(46-55-113(190)191)124(204)156-87(44-53-111(186)187)125(205)166-98(66-78-31-35-80(175)36-32-78)132(212)164-94(62-73(5)6)128(208)161-92(140(220)221)40-49-105(145)177/h16-18,25-26,31-38,72-76,82-103,117,171,174-175H,14-15,19-24,27-30,39-71,143H2,1-13H3,(H2,144,176)(H2,145,177)(H,149,198)(H,150,216)(H,151,178)(H,152,179)(H,153,201)(H,154,200)(H,155,203)(H,156,204)(H,157,202)(H,158,211)(H,159,215)(H,160,217)(H,161,208)(H,162,214)(H,163,199)(H,164,212)(H,165,209)(H,166,205)(H,167,213)(H,168,206)(H,169,210)(H,170,207)(H,180,181)(H,182,183)(H,184,185)(H,186,187)(H,188,189)(H,190,191)(H,192,193)(H,194,195)(H,196,197)(H,220,221)(H4,146,147,148)/t75-,76-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102+,103-,117-/m0/s1
DMMJ4I5 CS CC[C@H](C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H]4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMMJ4I5 IK GEUGFPVPSWNWIJ-JOTHITJKSA-N
DMMJ4I5 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,4S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylhexanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMMJ4I5 DE Discovery agent
DM8TH4B ID DM8TH4B
DM8TH4B DN Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir
DM8TH4B HS Investigative
DM8TH4B PC 91936664
DM8TH4B MW 2997.1
DM8TH4B FM C132H191N30O46PS
DM8TH4B IC InChI=1S/C132H191N30O46PS/c1-10-71(6)109(129(200)162-56-20-27-98(162)124(195)149-84(44-50-105(175)176)113(184)145-83(43-49-104(173)174)114(185)152-91(59-73-28-34-77(165)35-29-73)120(191)151-88(57-69(2)3)117(188)150-87(130(201)202)40-46-99(134)166)158-116(187)85(45-51-106(177)178)146-112(183)82(42-48-103(171)172)148-118(189)89(58-72-21-12-11-13-22-72)154-122(193)93(62-107(179)180)142-100(167)64-139-110(181)94(66-163)156-126(197)108(70(4)5)157-115(186)80(23-14-16-52-133)144-111(182)81(41-47-102(169)170)147-119(190)90(60-74-30-36-78(37-31-74)208-209(203,204)205)153-121(192)92(61-76-63-137-68-141-76)155-125(196)97-26-19-55-161(97)128(199)95(67-164)143-101(168)65-140-123(194)96-25-15-17-54-160(96)127(198)86(24-18-53-138-131(135)136)159-210(206,207)79-38-32-75(33-39-79)132(7,8)9/h11-13,21-22,28-39,63,68-71,80-98,108-109,159,163-165H,10,14-20,23-27,40-62,64-67,133H2,1-9H3,(H2,134,166)(H,137,141)(H,139,181)(H,140,194)(H,142,167)(H,143,168)(H,144,182)(H,145,184)(H,146,183)(H,147,190)(H,148,189)(H,149,195)(H,150,188)(H,151,191)(H,152,185)(H,153,192)(H,154,193)(H,155,196)(H,156,197)(H,157,186)(H,158,187)(H,169,170)(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H,201,202)(H4,135,136,138)(H2,203,204,205)/t71-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96+,97-,98-,108-,109-/m0/s1
DM8TH4B CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)OP(=O)(O)O)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]7CCCCN7C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C8=CC=C(C=C8)C(C)(C)C
DM8TH4B IK RUWSMOQBPSRIJB-OZHMLDCXSA-N
DM8TH4B IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM8TH4B DE Discovery agent
DMQVRHG ID DMQVRHG
DMQVRHG DN Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir
DMQVRHG HS Investigative
DMQVRHG PC 91936665
DMQVRHG MW 2917.2
DMQVRHG FM C132H190N30O43S
DMQVRHG IC InChI=1S/C132H190N30O43S/c1-10-71(6)109(129(201)162-56-20-27-98(162)124(196)149-84(44-50-105(176)177)113(185)145-83(43-49-104(174)175)114(186)152-91(60-74-30-36-78(166)37-31-74)120(192)151-88(57-69(2)3)117(189)150-87(130(202)203)40-46-99(134)167)158-116(188)85(45-51-106(178)179)146-112(184)82(42-48-103(172)173)148-118(190)89(58-72-21-12-11-13-22-72)154-122(194)93(62-107(180)181)142-100(168)64-139-110(182)94(66-163)156-126(198)108(70(4)5)157-115(187)80(23-14-16-52-133)144-111(183)81(41-47-102(170)171)147-119(191)90(59-73-28-34-77(165)35-29-73)153-121(193)92(61-76-63-137-68-141-76)155-125(197)97-26-19-55-161(97)128(200)95(67-164)143-101(169)65-140-123(195)96-25-15-17-54-160(96)127(199)86(24-18-53-138-131(135)136)159-206(204,205)79-38-32-75(33-39-79)132(7,8)9/h11-13,21-22,28-39,63,68-71,80-98,108-109,159,163-166H,10,14-20,23-27,40-62,64-67,133H2,1-9H3,(H2,134,167)(H,137,141)(H,139,182)(H,140,195)(H,142,168)(H,143,169)(H,144,183)(H,145,185)(H,146,184)(H,147,191)(H,148,190)(H,149,196)(H,150,189)(H,151,192)(H,152,186)(H,153,193)(H,154,194)(H,155,197)(H,156,198)(H,157,187)(H,158,188)(H,170,171)(H,172,173)(H,174,175)(H,176,177)(H,178,179)(H,180,181)(H,202,203)(H4,135,136,138)/t71-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96+,97-,98-,108-,109-/m0/s1
DMQVRHG CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]7CCCCN7C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C8=CC=C(C=C8)C(C)(C)C
DMQVRHG IK GRDGGKZCNFVXJO-OZHMLDCXSA-N
DMQVRHG IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMQVRHG DE Discovery agent
DMXECFJ ID DMXECFJ
DMXECFJ DN Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir
DMXECFJ HS Investigative
DMXECFJ SN Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir; CHEMBL438400
DMXECFJ PC 44405788
DMXECFJ MW 3661.7
DMXECFJ FM C148H222N42O65S
DMXECFJ IC InChI=1S/C148H222N42O65S/c1-8-72(4)121(145(251)190-41-15-20-101(190)143(249)182-80(32-37-118(222)223)135(241)179-79(31-36-117(220)221)136(242)185-86(44-74-21-25-76(203)26-22-74)140(246)184-84(42-71(2)3)138(244)183-83(146(252)253)29-34-102(149)204)187-137(243)81(33-38-119(224)225)180-134(240)78(30-35-116(218)219)181-139(245)85(43-73-16-10-9-11-17-73)186-141(247)87(45-120(226)227)166-103(205)46-153-122(228)88(59-191)167-104(206)47-154-123(229)89(60-192)168-105(207)48-155-124(230)90(61-193)169-106(208)49-156-125(231)91(62-194)170-107(209)50-157-126(232)92(63-195)171-108(210)51-158-127(233)93(64-196)172-109(211)52-159-128(234)94(65-197)173-110(212)53-160-129(235)95(66-198)174-111(213)54-161-130(236)96(67-199)175-112(214)55-162-131(237)97(68-200)176-113(215)56-163-132(238)98(69-201)177-114(216)57-164-133(239)99(70-202)178-115(217)58-165-142(248)100-19-12-13-40-189(100)144(250)82(18-14-39-152-147(150)151)188-256(254,255)77-27-23-75(24-28-77)148(5,6)7/h9-11,16-17,21-28,71-72,78-101,121,188,191-203H,8,12-15,18-20,29-70H2,1-7H3,(H2,149,204)(H,153,228)(H,154,229)(H,155,230)(H,156,231)(H,157,232)(H,158,233)(H,159,234)(H,160,235)(H,161,236)(H,162,237)(H,163,238)(H,164,239)(H,165,248)(H,166,205)(H,167,206)(H,168,207)(H,169,208)(H,170,209)(H,171,210)(H,172,211)(H,173,212)(H,174,213)(H,175,214)(H,176,215)(H,177,216)(H,178,217)(H,179,241)(H,180,240)(H,181,245)(H,182,249)(H,183,244)(H,184,246)(H,185,242)(H,186,247)(H,187,243)(H,218,219)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,252,253)(H4,150,151,152)/t72-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100?,101-,121-/m0/s1
DMXECFJ CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMXECFJ IK CZTBIQRSYJGOBZ-NBINKJFGSA-N
DMXECFJ IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMXECFJ DE Discovery agent
DM5N6YE ID DM5N6YE
DM5N6YE DN Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir
DM5N6YE HS Investigative
DM5N6YE SN Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir; CHEMBL415370
DM5N6YE PC 44405789
DM5N6YE MW 3949.9
DM5N6YE FM C158H238N46O71S
DM5N6YE IC InChI=1S/C158H238N46O71S/c1-8-76(4)129(155(271)204-41-15-20-107(204)153(269)196-84(32-37-126(240)241)145(261)193-83(31-36-125(238)239)146(262)199-90(44-78-21-25-80(219)26-22-78)150(266)198-88(42-75(2)3)148(264)197-87(156(272)273)29-34-108(159)220)201-147(263)85(33-38-127(242)243)194-144(260)82(30-35-124(236)237)195-149(265)89(43-77-16-10-9-11-17-77)200-151(267)91(45-128(244)245)178-109(221)46-163-130(246)92(61-205)179-110(222)47-164-131(247)93(62-206)180-111(223)48-165-132(248)94(63-207)181-112(224)49-166-133(249)95(64-208)182-113(225)50-167-134(250)96(65-209)183-114(226)51-168-135(251)97(66-210)184-115(227)52-169-136(252)98(67-211)185-116(228)53-170-137(253)99(68-212)186-117(229)54-171-138(254)100(69-213)187-118(230)55-172-139(255)101(70-214)188-119(231)56-173-140(256)102(71-215)189-120(232)57-174-141(257)103(72-216)190-121(233)58-175-142(258)104(73-217)191-122(234)59-176-143(259)105(74-218)192-123(235)60-177-152(268)106-19-12-13-40-203(106)154(270)86(18-14-39-162-157(160)161)202-276(274,275)81-27-23-79(24-28-81)158(5,6)7/h9-11,16-17,21-28,75-76,82-107,129,202,205-219H,8,12-15,18-20,29-74H2,1-7H3,(H2,159,220)(H,163,246)(H,164,247)(H,165,248)(H,166,249)(H,167,250)(H,168,251)(H,169,252)(H,170,253)(H,171,254)(H,172,255)(H,173,256)(H,174,257)(H,175,258)(H,176,259)(H,177,268)(H,178,221)(H,179,222)(H,180,223)(H,181,224)(H,182,225)(H,183,226)(H,184,227)(H,185,228)(H,186,229)(H,187,230)(H,188,231)(H,189,232)(H,190,233)(H,191,234)(H,192,235)(H,193,261)(H,194,260)(H,195,265)(H,196,269)(H,197,264)(H,198,266)(H,199,262)(H,200,267)(H,201,263)(H,236,237)(H,238,239)(H,240,241)(H,242,243)(H,244,245)(H,272,273)(H4,160,161,162)/t76-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106?,107-,129-/m0/s1
DM5N6YE CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DM5N6YE IK UZMGIFBITDOUBH-GDGQYZPBSA-N
DM5N6YE IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DM5N6YE DE Discovery agent
DMTU0HR ID DMTU0HR
DMTU0HR DN Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir
DMTU0HR HS Investigative
DMTU0HR SN CHEMBL439881; Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir
DMTU0HR PC 44405859
DMTU0HR MW 2220.4
DMTU0HR FM C98H142N22O35S
DMTU0HR IC InChI=1S/C98H142N22O35S/c1-8-52(4)81(95(151)120-41-15-20-71(120)93(149)112-60(32-37-78(132)133)85(141)109-59(31-36-77(130)131)86(142)115-66(44-54-21-25-56(123)26-22-54)90(146)114-64(42-51(2)3)88(144)113-63(96(152)153)29-34-72(99)124)117-87(143)61(33-38-79(134)135)110-84(140)58(30-35-76(128)129)111-89(145)65(43-53-16-10-9-11-17-53)116-91(147)67(45-80(136)137)106-73(125)46-103-82(138)68(49-121)107-74(126)47-104-83(139)69(50-122)108-75(127)48-105-92(148)70-19-12-13-40-119(70)94(150)62(18-14-39-102-97(100)101)118-156(154,155)57-27-23-55(24-28-57)98(5,6)7/h9-11,16-17,21-28,51-52,58-71,81,118,121-123H,8,12-15,18-20,29-50H2,1-7H3,(H2,99,124)(H,103,138)(H,104,139)(H,105,148)(H,106,125)(H,107,126)(H,108,127)(H,109,141)(H,110,140)(H,111,145)(H,112,149)(H,113,144)(H,114,146)(H,115,142)(H,116,147)(H,117,143)(H,128,129)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,152,153)(H4,100,101,102)/t52-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70+,71-,81-/m0/s1
DMTU0HR CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMTU0HR IK UHXXZAFTLUMNIB-KZKSJJABSA-N
DMTU0HR IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMTU0HR DE Discovery agent
DMEL2GK ID DMEL2GK
DMEL2GK DN Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir
DMEL2GK HS Investigative
DMEL2GK SN CHEMBL414341; Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir
DMEL2GK PC 44405865
DMEL2GK MW 2508.6
DMEL2GK FM C108H158N26O41S
DMEL2GK IC InChI=1S/C108H158N26O41S/c1-8-56(4)89(105(171)134-41-15-20-77(134)103(169)126-64(32-37-86(150)151)95(161)123-63(31-36-85(148)149)96(162)129-70(44-58-21-25-60(139)26-22-58)100(166)128-68(42-55(2)3)98(164)127-67(106(172)173)29-34-78(109)140)131-97(163)65(33-38-87(152)153)124-94(160)62(30-35-84(146)147)125-99(165)69(43-57-16-10-9-11-17-57)130-101(167)71(45-88(154)155)118-79(141)46-113-90(156)72(51-135)119-80(142)47-114-91(157)73(52-136)120-81(143)48-115-92(158)74(53-137)121-82(144)49-116-93(159)75(54-138)122-83(145)50-117-102(168)76-19-12-13-40-133(76)104(170)66(18-14-39-112-107(110)111)132-176(174,175)61-27-23-59(24-28-61)108(5,6)7/h9-11,16-17,21-28,55-56,62-77,89,132,135-139H,8,12-15,18-20,29-54H2,1-7H3,(H2,109,140)(H,113,156)(H,114,157)(H,115,158)(H,116,159)(H,117,168)(H,118,141)(H,119,142)(H,120,143)(H,121,144)(H,122,145)(H,123,161)(H,124,160)(H,125,165)(H,126,169)(H,127,164)(H,128,166)(H,129,162)(H,130,167)(H,131,163)(H,146,147)(H,148,149)(H,150,151)(H,152,153)(H,154,155)(H,172,173)(H4,110,111,112)/t56-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76+,77-,89-/m0/s1
DMEL2GK CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMEL2GK IK QVAVWYLBNALTPM-TVNHPFTQSA-N
DMEL2GK IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2R)-1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMEL2GK DE Discovery agent
DMCN48J ID DMCN48J
DMCN48J DN Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir
DMCN48J HS Investigative
DMCN48J SN Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir; CHEMBL265596
DMCN48J PC 44405866
DMCN48J MW 2796.9
DMCN48J FM C118H174N30O47S
DMCN48J IC InChI=1S/C118H174N30O47S/c1-8-60(4)97(115(191)148-41-15-20-83(148)113(189)140-68(32-37-94(168)169)105(181)137-67(31-36-93(166)167)106(182)143-74(44-62-21-25-64(155)26-22-62)110(186)142-72(42-59(2)3)108(184)141-71(116(192)193)29-34-84(119)156)145-107(183)69(33-38-95(170)171)138-104(180)66(30-35-92(164)165)139-109(185)73(43-61-16-10-9-11-17-61)144-111(187)75(45-96(172)173)130-85(157)46-123-98(174)76(53-149)131-86(158)47-124-99(175)77(54-150)132-87(159)48-125-100(176)78(55-151)133-88(160)49-126-101(177)79(56-152)134-89(161)50-127-102(178)80(57-153)135-90(162)51-128-103(179)81(58-154)136-91(163)52-129-112(188)82-19-12-13-40-147(82)114(190)70(18-14-39-122-117(120)121)146-196(194,195)65-27-23-63(24-28-65)118(5,6)7/h9-11,16-17,21-28,59-60,66-83,97,146,149-155H,8,12-15,18-20,29-58H2,1-7H3,(H2,119,156)(H,123,174)(H,124,175)(H,125,176)(H,126,177)(H,127,178)(H,128,179)(H,129,188)(H,130,157)(H,131,158)(H,132,159)(H,133,160)(H,134,161)(H,135,162)(H,136,163)(H,137,181)(H,138,180)(H,139,185)(H,140,189)(H,141,184)(H,142,186)(H,143,182)(H,144,187)(H,145,183)(H,164,165)(H,166,167)(H,168,169)(H,170,171)(H,172,173)(H,192,193)(H4,120,121,122)/t60-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82?,83-,97-/m0/s1
DMCN48J CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMCN48J IK PUATYUGHSGBOAZ-BSPCXEMDSA-N
DMCN48J IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMCN48J DE Discovery agent
DMLK5I0 ID DMLK5I0
DMLK5I0 DN Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir
DMLK5I0 HS Investigative
DMLK5I0 SN Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir; CHEMBL427951
DMLK5I0 PC 44405786
DMLK5I0 MW 3085.1
DMLK5I0 FM C128H190N34O53S
DMLK5I0 IC InChI=1S/C128H190N34O53S/c1-8-64(4)105(125(211)162-41-15-20-89(162)123(209)154-72(32-37-102(186)187)115(201)151-71(31-36-101(184)185)116(202)157-78(44-66-21-25-68(171)26-22-66)120(206)156-76(42-63(2)3)118(204)155-75(126(212)213)29-34-90(129)172)159-117(203)73(33-38-103(188)189)152-114(200)70(30-35-100(182)183)153-119(205)77(43-65-16-10-9-11-17-65)158-121(207)79(45-104(190)191)142-91(173)46-133-106(192)80(55-163)143-92(174)47-134-107(193)81(56-164)144-93(175)48-135-108(194)82(57-165)145-94(176)49-136-109(195)83(58-166)146-95(177)50-137-110(196)84(59-167)147-96(178)51-138-111(197)85(60-168)148-97(179)52-139-112(198)86(61-169)149-98(180)53-140-113(199)87(62-170)150-99(181)54-141-122(208)88-19-12-13-40-161(88)124(210)74(18-14-39-132-127(130)131)160-216(214,215)69-27-23-67(24-28-69)128(5,6)7/h9-11,16-17,21-28,63-64,70-89,105,160,163-171H,8,12-15,18-20,29-62H2,1-7H3,(H2,129,172)(H,133,192)(H,134,193)(H,135,194)(H,136,195)(H,137,196)(H,138,197)(H,139,198)(H,140,199)(H,141,208)(H,142,173)(H,143,174)(H,144,175)(H,145,176)(H,146,177)(H,147,178)(H,148,179)(H,149,180)(H,150,181)(H,151,201)(H,152,200)(H,153,205)(H,154,209)(H,155,204)(H,156,206)(H,157,202)(H,158,207)(H,159,203)(H,182,183)(H,184,185)(H,186,187)(H,188,189)(H,190,191)(H,212,213)(H4,130,131,132)/t64-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88?,89-,105-/m0/s1
DMLK5I0 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMLK5I0 IK WEYFLOFTQVOIIG-JSWHDTCYSA-N
DMLK5I0 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMLK5I0 DE Discovery agent
DMLZ5R6 ID DMLZ5R6
DMLZ5R6 DN Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir
DMLZ5R6 HS Investigative
DMLZ5R6 SN Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir; CHEMBL441004
DMLZ5R6 PC 44405787
DMLZ5R6 MW 3373.4
DMLZ5R6 FM C138H206N38O59S
DMLZ5R6 IC InChI=1S/C138H206N38O59S/c1-8-68(4)113(135(231)176-41-15-20-95(176)133(229)168-76(32-37-110(204)205)125(221)165-75(31-36-109(202)203)126(222)171-82(44-70-21-25-72(187)26-22-70)130(226)170-80(42-67(2)3)128(224)169-79(136(232)233)29-34-96(139)188)173-127(223)77(33-38-111(206)207)166-124(220)74(30-35-108(200)201)167-129(225)81(43-69-16-10-9-11-17-69)172-131(227)83(45-112(208)209)154-97(189)46-143-114(210)84(57-177)155-98(190)47-144-115(211)85(58-178)156-99(191)48-145-116(212)86(59-179)157-100(192)49-146-117(213)87(60-180)158-101(193)50-147-118(214)88(61-181)159-102(194)51-148-119(215)89(62-182)160-103(195)52-149-120(216)90(63-183)161-104(196)53-150-121(217)91(64-184)162-105(197)54-151-122(218)92(65-185)163-106(198)55-152-123(219)93(66-186)164-107(199)56-153-132(228)94-19-12-13-40-175(94)134(230)78(18-14-39-142-137(140)141)174-236(234,235)73-27-23-71(24-28-73)138(5,6)7/h9-11,16-17,21-28,67-68,74-95,113,174,177-187H,8,12-15,18-20,29-66H2,1-7H3,(H2,139,188)(H,143,210)(H,144,211)(H,145,212)(H,146,213)(H,147,214)(H,148,215)(H,149,216)(H,150,217)(H,151,218)(H,152,219)(H,153,228)(H,154,189)(H,155,190)(H,156,191)(H,157,192)(H,158,193)(H,159,194)(H,160,195)(H,161,196)(H,162,197)(H,163,198)(H,164,199)(H,165,221)(H,166,220)(H,167,225)(H,168,229)(H,169,224)(H,170,226)(H,171,222)(H,172,227)(H,173,223)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,232,233)(H4,140,141,142)/t68-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94?,95-,113-/m0/s1
DMLZ5R6 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)C4CCCCN4C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C
DMLZ5R6 IK UFWRMLMUWLGVGM-PIMIKREUSA-N
DMLZ5R6 IU (2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[1-[(2S)-2-[(4-tert-butylphenyl)sulfonylamino]-5-(diaminomethylideneamino)pentanoyl]piperidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoic acid
DMLZ5R6 DE Discovery agent
DMT0X6Q ID DMT0X6Q
DMT0X6Q DN BBT-007
DMT0X6Q HS Investigative
DMT0X6Q SN Long-acting GM-CSF (PEGylated, neutropenia), Bolder BioTechnology
DMT0X6Q CP Bolder BioTechnology Inc
DMT0X6Q DE Neutropenia
DM2YTXL ID DM2YTXL
DM2YTXL DN BBT-009
DM2YTXL HS Investigative
DM2YTXL SN BBT-004; Long-acting erythropoietin (PEGylated, anemia), Bolder BioTechnology Inc
DM2YTXL CP Bolder BioTechnology Inc
DM2YTXL DE Anemia
DMLIT84 ID DMLIT84
DMLIT84 DN BBT-021
DMLIT84 HS Investigative
DMLIT84 SN BBT-003; Erythropoietin IgG-Fc fusion proteins (anemia), Bolder BioTechnology Inc
DMLIT84 CP Bolder BioTechnology Inc
DMLIT84 DE Anemia
DMQNA7V ID DMQNA7V
DMQNA7V DN BC11-38
DMQNA7V HS Investigative
DMQNA7V SN 686770-80-9; BC11-38; BC 11-38; C15H16N2OS2; AC1M0MXE; GTPL6559; CHEMBL3928332; SCHEMBL16200740; BDBM86642; AOB1847; SYN5070; MolPort-003-028-365; HMS1650C11; ZINC2459456; CCG-26916; AKOS024458190; MCULE-6438827024; AS-16436; KB-270820; B7673; EU-0088935; SR-01000093012; SR-01000093012-1; F0579-0060; 3-phenyl-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one; 3-phenyl-2-(propylthio)-6,7-dihydrothieno[3,2-d]pyrimidin-4(3H)-one; 6,7-Dihydro-3-phenyl-2-(propylthio)thieno[3,2-d]pyrimidin-4(3H)one
DMQNA7V DT Small molecular drug
DMQNA7V PC 2052828
DMQNA7V MW 304.4
DMQNA7V FM C15H16N2OS2
DMQNA7V IC InChI=1S/C15H16N2OS2/c1-2-9-20-15-16-12-8-10-19-13(12)14(18)17(15)11-6-4-3-5-7-11/h3-7H,2,8-10H2,1H3
DMQNA7V CS CCCSC1=NC2=C(C(=O)N1C3=CC=CC=C3)SCC2
DMQNA7V IK YHNDCCKFNWDQGW-UHFFFAOYSA-N
DMQNA7V IU 3-phenyl-2-propylsulfanyl-6,7-dihydrothieno[3,2-d]pyrimidin-4-one
DMQNA7V DE Discovery agent
DMQWOZ5 ID DMQWOZ5
DMQWOZ5 DN BC-264
DMQWOZ5 HS Investigative
DMQWOZ5 SN BC264; BC 264
DMQWOZ5 DT Small molecular drug
DMQWOZ5 PC 5311016
DMQWOZ5 MW 1106.2
DMQWOZ5 FM C53H71N9O15S
DMQWOZ5 IC InChI=1S/C53H71N9O15S/c1-7-9-20-42(62(6)51(71)41(56-45(64)30-43(54)63)28-34-31-55-37-19-15-14-18-36(34)37)50(70)58-40(29-46(65)66)47(67)57-38(26-32-16-12-11-13-17-32)48(68)60-44(21-10-8-2)61-49(69)39(59-52(72)76-53(3,4)5)27-33-22-24-35(25-23-33)77-78(73,74)75/h11-19,22-25,31,38-42,44,55H,7-10,20-21,26-30H2,1-6H3,(H2,54,63)(H,56,64)(H,57,67)(H,58,70)(H,59,72)(H,60,68)(H,61,69)(H,65,66)(H,73,74,75)/t38-,39-,40-,41-,42-,44-/m0/s1
DMQWOZ5 CS CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CCCC)NC(=O)[C@H](CC2=CC=C(C=C2)OS(=O)(=O)O)NC(=O)OC(C)(C)C)N(C)C(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CC(=O)N
DMQWOZ5 IK LEXXPLMUWFLNAN-OZUMUDGSSA-N
DMQWOZ5 IU (3S)-3-[[(2S)-2-[[(2S)-2-[(3-amino-3-oxopropanoyl)amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]hexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]pentyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMQWOZ5 DE Discovery agent
DM047DQ ID DM047DQ
DM047DQ DN BCEAB
DM047DQ HS Investigative
DM047DQ SN CHEBI:6426; Ac-Leu-Leu-Arg-H; Ac-Leu-Leu-Argininal; Acetyl-L-leucyl-L-leucylargininal; N-Acetyl-L-leucyl-L-leucyl-L-argininal; 55123-66-5; UNII-J97339NR3V; J97339NR3V; 103476-89-7; Acetyl-Leu-Leu-Arg-al; Leupeptin hemisulfate; L-Leucinamide, N-acetyl-L-leucyl-N-(4-((aminoiminomethyl)amino)-1-formylbutyl)-; N-acetyl-L-leucyl-N-[(1S)-4-{[amino(imino)methyl]amino}-1-formylbutyl]-L-leucinamide
DM047DQ DT Small molecular drug
DM047DQ PC 101210881
DM047DQ MW 578.7
DM047DQ FM C35H34N2O6
DM047DQ IC InChI=1S/C35H34N2O6/c1-4-42-30-8-6-5-7-27(30)21-29-32(38)37(33(29)43-28-19-17-26(18-20-28)34(39)40)35(41)36-31(24-13-9-22(2)10-14-24)25-15-11-23(3)12-16-25/h5-20,29,31,33H,4,21H2,1-3H3,(H,36,41)(H,39,40)/t29-,33+/m1/s1
DM047DQ CS CCOC1=CC=CC=C1C[C@H]2[C@@H](N(C2=O)C(=O)NC(C3=CC=C(C=C3)C)C4=CC=C(C=C4)C)OC5=CC=C(C=C5)C(=O)O
DM047DQ IK IGIOAZWNIRIBNB-CPBHLAHYSA-N
DM047DQ IU 4-[(2S,3S)-1-[bis(4-methylphenyl)methylcarbamoyl]-3-[(2-ethoxyphenyl)methyl]-4-oxoazetidin-2-yl]oxybenzoic acid
DM047DQ DE Discovery agent
DMPG1LJ ID DMPG1LJ
DMPG1LJ DN Bcecf-Am
DMPG1LJ HS Investigative
DMPG1LJ SN 117464-70-7; 2',7'-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester; 2',7'-bis(2-Carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester Mixed isomers; AKOS015916474; BCECF-AM solution; BCECF-AM solution (5 mM in DMSO), 1 mg in 0.25 ml DMSO; BCECF-acetoxymethyl; FT-0622598; I14-51975; J-100048; MFCD00036969; SCHEMBL15570087; Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-2',7'-dipropanoic acid; ZINC169730836
DMPG1LJ PC 53229972
DMPG1LJ MW 880.761
DMPG1LJ FM C42H40O21
DMPG1LJ IC InChI=1S/C42H40O21/c1-22(43)52-17-57-34-15-36-32(13-27(34)7-10-38(48)59-19-54-24(3)45)42(31-9-6-29(12-30(31)41(51)63-42)40(50)61-21-56-26(5)47)33-14-28(8-11-39(49)60-20-55-25(4)46)35(16-37(33)62-36)58-18-53-23(2)44/h6,9,12-16H,7-8,10-11,17-21H2,1-5H3
DMPG1LJ CS CC(=O)OCOC1=C(C=C2C(=C1)OC3=CC(=C(C=C3C24C5=C(C=C(C=C5)C(=O)OCOC(=O)C)C(=O)O4)CCC(=O)OCOC(=O)C)OCOC(=O)C)CCC(=O)OCOC(=O)C
DMPG1LJ IK NTECHUXHORNEGZ-UHFFFAOYSA-N
DMPG1LJ IU acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate
DMPG1LJ CA CAS 117464-70-7
DM9IN0U ID DM9IN0U
DM9IN0U DN BCH
DM9IN0U HS Investigative
DM9IN0U SN 20448-79-7; 2-Amino-2-norbornanecarboxylic acid; 2-Aminobicyclo[2.2.1]heptane-2-carboxylic acid; 2-Aminonorbornane-2-carboxylic acid; MPUVBVXDFRDIPT-UHFFFAOYSA-N; Bicyclo[2.2.1]heptane-2-carboxylicacid, 2-amino-; b-BCH; 2-Amino-2-carboxy-bicyclo-2,2,1-heptane; AC1L3GVN; AC1Q5TB7; 2-Aminobicyclo(2,2,1)heptane-2-carboxylic acid; SCHEMBL202772; GTPL4700; CHEMBL2074957; CTK1A1593; MolPort-003-928-121; 2-amino-2-norbornane carboxylic acid; AKOS016044739; AKOS002666381; VZ23542; MCULE-9216762478; Norbornane-2-carboxylic acid, 2-amino
DM9IN0U DT Small molecular drug
DM9IN0U PC 115288
DM9IN0U MW 155.19
DM9IN0U FM C8H13NO2
DM9IN0U IC InChI=1S/C8H13NO2/c9-8(7(10)11)4-5-1-2-6(8)3-5/h5-6H,1-4,9H2,(H,10,11)
DM9IN0U CS C1CC2CC1CC2(C(=O)O)N
DM9IN0U IK MPUVBVXDFRDIPT-UHFFFAOYSA-N
DM9IN0U IU 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid
DM9IN0U CA CAS 20448-79-7
DM9IN0U CB CHEBI:167508
DM9IN0U DE Discovery agent
DMT5AGJ ID DMT5AGJ
DMT5AGJ DN BCTC
DMT5AGJ HS Investigative
DMT5AGJ SN 393514-24-4; N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide; CHEMBL441472; 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide, BCTC; SCHEMBL1269620; GTPL2460; KS-00001DIH; CTK8F0011; DTXSID90432997; MolPort-003-983-482; BCP19629; BCTC, > BDBM50133817; ZINC27109670; MFCD08690556; BN0674; AKOS024457842; TRA0012037; MCULE-6176078265; CS-5476; NCGC00370959-01; HY-19960; DA-42544; RT-011429; B-110; FT-0696667; B7520; AZ0001-0587
DMT5AGJ CP Purdue Pharma
DMT5AGJ TC Analgesics
DMT5AGJ DT Small molecular drug
DMT5AGJ PC 9929425
DMT5AGJ MW 372.9
DMT5AGJ FM C20H25ClN4O
DMT5AGJ IC InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
DMT5AGJ CS CC(C)(C)C1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C(C=CC=N3)Cl
DMT5AGJ IK ROGUAPYLUCHQGK-UHFFFAOYSA-N
DMT5AGJ IU N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
DMT5AGJ CA CAS 393514-24-4
DMT5AGJ DE Pain
DMVOS2C ID DMVOS2C
DMVOS2C DN BCX-1827
DMVOS2C HS Investigative
DMVOS2C SN BCX-1827; (-)-(1R,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-[[amino(imino)methyl]amino]cyclopentanecarboxylic acid; (-)-(1R,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}cyclopentanecarboxylic Acid; AC1LAL6X; Cyclopentane Derivative 50; BDBM5023; CHEMBL136111; SCHEMBL14834652; CTK6C6205; (1R,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-cyclopentanecarboxylic acid; (1R,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMVOS2C DT Small molecular drug
DMVOS2C PC 490519
DMVOS2C MW 312.41
DMVOS2C FM C15H28N4O3
DMVOS2C IC InChI=1S/C15H28N4O3/c1-4-9(5-2)13(18-8(3)20)11-6-10(14(21)22)7-12(11)19-15(16)17/h9-13H,4-7H2,1-3H3,(H,18,20)(H,21,22)(H4,16,17,19)/t10-,11-,12-,13+/m1/s1
DMVOS2C CS CCC(CC)[C@@H]([C@@H]1C[C@H](C[C@H]1N=C(N)N)C(=O)O)NC(=O)C
DMVOS2C IK FOCBRFMNUQOMCY-LPWJVIDDSA-N
DMVOS2C IU (1R,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMVOS2C DE Discovery agent
DM6JB32 ID DM6JB32
DM6JB32 DN BCX-1898
DM6JB32 HS Investigative
DM6JB32 SN BCX-1898
DM6JB32 DT Small molecular drug
DM6JB32 PC 89337704
DM6JB32 MW 356.5
DM6JB32 FM C17H32N4O4
DM6JB32 IC InChI=1S/C17H32N4O4/c1-4-6-10(7-5-2)14(20-9(3)22)13-12(21-17(18)19)8-11(15(13)23)16(24)25/h10-15,23H,4-8H2,1-3H3,(H,20,22)(H,24,25)(H4,18,19,21)/t11-,12+,13+,14-,15+/m0/s1
DM6JB32 CS CCCC(CCC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C
DM6JB32 IK IIZTWIZWLKRAMW-VYDRJRHOSA-N
DM6JB32 IU (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-propylpentyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DM6JB32 DE Discovery agent
DM8G4HS ID DM8G4HS
DM8G4HS DN BCX-1923
DM8G4HS HS Investigative
DM8G4HS PC 500459
DM8G4HS MW 340.5
DM8G4HS FM C17H32N4O3
DM8G4HS IC InChI=1S/C17H32N4O3/c1-4-6-11(7-5-2)15(20-10(3)22)13-8-12(16(23)24)9-14(13)21-17(18)19/h11-15H,4-9H2,1-3H3,(H,20,22)(H,23,24)(H4,18,19,21)
DM8G4HS CS CCCC(CCC)C(C1CC(CC1N=C(N)N)C(=O)O)NC(=O)C
DM8G4HS IK VUROMZOEXLKRSQ-UHFFFAOYSA-N
DM8G4HS IU 3-(1-acetamido-2-propylpentyl)-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DM8G4HS DE Discovery agent
DMFIDA0 ID DMFIDA0
DMFIDA0 DN BD-1047
DMFIDA0 HS Investigative
DMFIDA0 SN BD1047; BD 1047
DMFIDA0 DT Small molecular drug
DMFIDA0 PC 188914
DMFIDA0 MW 275.21
DMFIDA0 FM C13H20Cl2N2
DMFIDA0 IC InChI=1S/C13H20Cl2N2/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11/h4-5,10H,6-9H2,1-3H3
DMFIDA0 CS CN(C)CCN(C)CCC1=CC(=C(C=C1)Cl)Cl
DMFIDA0 IK MGVRNMUKTZOQOW-UHFFFAOYSA-N
DMFIDA0 IU N'-[2-(3,4-dichlorophenyl)ethyl]-N,N,N'-trimethylethane-1,2-diamine
DMFIDA0 CA CAS 138356-20-4
DMFIDA0 CB CHEBI:92648
DMFIDA0 DE Discovery agent
DMT0S7M ID DMT0S7M
DMT0S7M DN BD-NP
DMT0S7M HS Investigative
DMT0S7M SN ASBNP2.1
DMT0S7M CP Mayo Foundation
DMT0S7M DE Hypertension
DMZX57Y ID DMZX57Y
DMZX57Y DN befetupitant
DMZX57Y HS Investigative
DMZX57Y SN Ro 67-5930; Ro-675930
DMZX57Y DT Small molecular drug
DMZX57Y PC 6450815
DMZX57Y MW 565.5
DMZX57Y FM C29H29F6N3O2
DMZX57Y IC InChI=1S/C29H29F6N3O2/c1-18-7-5-6-8-22(18)23-16-25(38-9-11-40-12-10-38)36-17-24(23)37(4)26(39)27(2,3)19-13-20(28(30,31)32)15-21(14-19)29(33,34)35/h5-8,13-17H,9-12H2,1-4H3
DMZX57Y CS CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCOCC4
DMZX57Y IK ZGNPLCMMVKCTHM-UHFFFAOYSA-N
DMZX57Y IU 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-morpholin-4-ylpyridin-3-yl]propanamide
DMZX57Y CA CAS 290296-68-3
DMZX57Y DE Discovery agent
DMV15JC ID DMV15JC
DMV15JC DN Befunolol
DMV15JC HS Investigative
DMV15JC SN Befunolol; Befunolol (INN); Befunolol HCl; Befunolol [INN]; Befunololum; Befunololum [INN-Latin]; 1-(7-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)ethanone; 1-(7-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)ethanone hydrochloride; 2-Acetyl-7-(2-hyroxy-3-isopropylaminopropoxy)benzofuran; 39552-01-7; 7-(2-Hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl ketone; AC1L1DE0; BRN 3620832; C16H21NO4; KETONE, 7-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)-2-BENZOFURANYL METHYL; SCHEMBL78720
DMV15JC PC 2309
DMV15JC MW 291.34
DMV15JC FM C16H21NO4
DMV15JC IC ZPQPDBIHYCBNIG-UHFFFAOYSA-N
DMV15JC CS CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O
DMV15JC IK 1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3
DMV15JC IU 1-[7-[2-hydroxy-3-(propan-2-ylamino)propoxy]-1-benzofuran-2-yl]ethanone
DMV15JC CA CAS 39552-01-7
DMV15JC CB CHEBI:135212
DMV15JC DE Glaucoma
DM0WOS6 ID DM0WOS6
DM0WOS6 DN BELFOSDIL
DM0WOS6 HS Investigative
DM0WOS6 SN 103486-79-9; 2-(2-Phenoxyethyl)-1,3-propylenediphosphonic acid tetrabutyl ester; BMY-21891; Belfosdil < Rec INN; SR-7037
DM0WOS6 DT Small molecular drug
DM0WOS6 PC 72122
DM0WOS6 MW 548.6
DM0WOS6 FM C27H50O7P2
DM0WOS6 IC InChI=1S/C27H50O7P2/c1-5-9-19-31-35(28,32-20-10-6-2)24-26(18-23-30-27-16-14-13-15-17-27)25-36(29,33-21-11-7-3)34-22-12-8-4/h13-17,26H,5-12,18-25H2,1-4H3
DM0WOS6 CS CCCCOP(=O)(CC(CCOC1=CC=CC=C1)CP(=O)(OCCCC)OCCCC)OCCCC
DM0WOS6 IK QTBMDDQRDDABNC-UHFFFAOYSA-N
DM0WOS6 IU [4-dibutoxyphosphoryl-3-(dibutoxyphosphorylmethyl)butoxy]benzene
DM0WOS6 CA CAS 103486-79-9
DM0WOS6 DE Discovery agent
DM7H3VY ID DM7H3VY
DM7H3VY DN Bencyclane
DM7H3VY HS Investigative
DM7H3VY SN BENCYCLANE; Benciclano; Benciclano [INN-Spanish]; Bencyclan; Bencyclane (INN); Bencyclane [INN]; Bencyclanum; Bencyclanum [INN-Latin]; Benzcyclan; benzcyclane; 1-Propanamine, N,N-dimethyl-3-((1-(phenylmethyl)cycloheptyl)oxy)-; 1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)cycloheptyl]oxy]-; 2179-37-5; 3-((1-Benzylcycloheptyl)oxy)-N,N-dimethylpropylamin; 6I97Z6S135; AC1L1DE9; AC1Q58XJ; C19H31NO; CHEMBL2110767; DSSTox_CID_2646; DSSTox_GSID_22646; DSSTox_RID_97536; DTXSID0022646; EINECS 218-547-0; SCHEMBL64881; UNII-6I97Z6S135
DM7H3VY PC 2312
DM7H3VY MW 289.5
DM7H3VY FM C19H31NO
DM7H3VY IC FYJJXENSONZJRG-UHFFFAOYSA-N
DM7H3VY CS CC(C)NCC(COC1=CC=CC2=C1OC(=C2)C(=O)C)O
DM7H3VY IK 1S/C19H31NO/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3
DM7H3VY IU 3-(1-benzylcycloheptyl)oxy-N,N-dimethylpropan-1-amine
DM7H3VY CA CAS 2179-37-5
DM7H3VY CB CHEBI:135205
DM7H3VY DE Cerebral vasospasm
DMFPSOQ ID DMFPSOQ
DMFPSOQ DN Benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime
DMFPSOQ HS Investigative
DMFPSOQ SN CHEMBL597431; benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime
DMFPSOQ DT Small molecular drug
DMFPSOQ PC 20872793
DMFPSOQ MW 396.5
DMFPSOQ FM C24H32N2O3
DMFPSOQ IC InChI=1S/C24H32N2O3/c1-2-3-4-5-6-7-8-12-19-28-23-17-15-22(16-18-23)26-24(27)29-25-20-21-13-10-9-11-14-21/h9-11,13-18,20H,2-8,12,19H2,1H3,(H,26,27)/b25-20+
DMFPSOQ CS CCCCCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMFPSOQ IK LFWYEOAFEYYRNZ-LKUDQCMESA-N
DMFPSOQ IU [(E)-benzylideneamino] N-(4-decoxyphenyl)carbamate
DMFPSOQ DE Discovery agent
DMU7INH ID DMU7INH
DMU7INH DN Benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime
DMU7INH HS Investigative
DMU7INH SN CHEMBL597228; benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime
DMU7INH DT Small molecular drug
DMU7INH PC 20872796
DMU7INH MW 354.4
DMU7INH FM C21H26N2O3
DMU7INH IC InChI=1S/C21H26N2O3/c1-2-3-4-5-9-16-25-20-14-12-19(13-15-20)23-21(24)26-22-17-18-10-7-6-8-11-18/h6-8,10-15,17H,2-5,9,16H2,1H3,(H,23,24)/b22-17+
DMU7INH CS CCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMU7INH IK QGTJCMKYCHZBTK-OQKWZONESA-N
DMU7INH IU [(E)-benzylideneamino] N-(4-heptoxyphenyl)carbamate
DMU7INH DE Discovery agent
DMOK0U8 ID DMOK0U8
DMOK0U8 DN Benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime
DMOK0U8 HS Investigative
DMOK0U8 SN CHEMBL598245; benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime
DMOK0U8 DT Small molecular drug
DMOK0U8 PC 20872797
DMOK0U8 MW 340.4
DMOK0U8 FM C20H24N2O3
DMOK0U8 IC InChI=1S/C20H24N2O3/c1-2-3-4-8-15-24-19-13-11-18(12-14-19)22-20(23)25-21-16-17-9-6-5-7-10-17/h5-7,9-14,16H,2-4,8,15H2,1H3,(H,22,23)/b21-16+
DMOK0U8 CS CCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMOK0U8 IK HNESYIHKTKWBMV-LTGZKZEYSA-N
DMOK0U8 IU [(E)-benzylideneamino] N-(4-hexoxyphenyl)carbamate
DMOK0U8 DE Discovery agent
DMIV3S8 ID DMIV3S8
DMIV3S8 DN Benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime
DMIV3S8 HS Investigative
DMIV3S8 SN CHEMBL597430; benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime
DMIV3S8 DT Small molecular drug
DMIV3S8 PC 20872799
DMIV3S8 MW 382.5
DMIV3S8 FM C23H30N2O3
DMIV3S8 IC InChI=1S/C23H30N2O3/c1-2-3-4-5-6-7-11-18-27-22-16-14-21(15-17-22)25-23(26)28-24-19-20-12-9-8-10-13-20/h8-10,12-17,19H,2-7,11,18H2,1H3,(H,25,26)/b24-19+
DMIV3S8 CS CCCCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMIV3S8 IK GOOXRXVIMOMQCL-LYBHJNIJSA-N
DMIV3S8 IU [(E)-benzylideneamino] N-(4-nonoxyphenyl)carbamate
DMIV3S8 DE Discovery agent
DMBW7PX ID DMBW7PX
DMBW7PX DN Benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime
DMBW7PX HS Investigative
DMBW7PX SN CHEMBL597229; benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime
DMBW7PX DT Small molecular drug
DMBW7PX PC 20872800
DMBW7PX MW 368.5
DMBW7PX FM C22H28N2O3
DMBW7PX IC InChI=1S/C22H28N2O3/c1-2-3-4-5-6-10-17-26-21-15-13-20(14-16-21)24-22(25)27-23-18-19-11-8-7-9-12-19/h7-9,11-16,18H,2-6,10,17H2,1H3,(H,24,25)/b23-18+
DMBW7PX CS CCCCCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMBW7PX IK BALHAPBNIAUXLM-PTGBLXJZSA-N
DMBW7PX IU [(E)-benzylideneamino] N-(4-octoxyphenyl)carbamate
DMBW7PX DE Discovery agent
DMWEXOY ID DMWEXOY
DMWEXOY DN Benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime
DMWEXOY HS Investigative
DMWEXOY SN CHEMBL598244; benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime
DMWEXOY DT Small molecular drug
DMWEXOY PC 20872801
DMWEXOY MW 326.4
DMWEXOY FM C19H22N2O3
DMWEXOY IC InChI=1S/C19H22N2O3/c1-2-3-7-14-23-18-12-10-17(11-13-18)21-19(22)24-20-15-16-8-5-4-6-9-16/h4-6,8-13,15H,2-3,7,14H2,1H3,(H,21,22)/b20-15+
DMWEXOY CS CCCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMWEXOY IK RMGKIVHTNJBERM-HMMYKYKNSA-N
DMWEXOY IU [(E)-benzylideneamino] N-(4-pentoxyphenyl)carbamate
DMWEXOY DE Discovery agent
DMHUQWN ID DMHUQWN
DMHUQWN DN Benzaldehyde O-4-butoxyphenylcarbamoyl oxime
DMHUQWN HS Investigative
DMHUQWN SN CHEMBL598243; benzaldehyde O-4-butoxyphenylcarbamoyl oxime
DMHUQWN DT Small molecular drug
DMHUQWN PC 20872791
DMHUQWN MW 312.4
DMHUQWN FM C18H20N2O3
DMHUQWN IC InChI=1S/C18H20N2O3/c1-2-3-13-22-17-11-9-16(10-12-17)20-18(21)23-19-14-15-7-5-4-6-8-15/h4-12,14H,2-3,13H2,1H3,(H,20,21)/b19-14+
DMHUQWN CS CCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMHUQWN IK BRPRTDQSLVFYMR-XMHGGMMESA-N
DMHUQWN IU [(E)-benzylideneamino] N-(4-butoxyphenyl)carbamate
DMHUQWN DE Discovery agent
DMD98YP ID DMD98YP
DMD98YP DN Benzaldehyde O-4-ethoxyphenylcarbamoyl oxime
DMD98YP HS Investigative
DMD98YP SN CHEMBL599470; benzaldehyde O-4-ethoxyphenylcarbamoyl oxime
DMD98YP DT Small molecular drug
DMD98YP PC 20872795
DMD98YP MW 284.31
DMD98YP FM C16H16N2O3
DMD98YP IC InChI=1S/C16H16N2O3/c1-2-20-15-10-8-14(9-11-15)18-16(19)21-17-12-13-6-4-3-5-7-13/h3-12H,2H2,1H3,(H,18,19)/b17-12+
DMD98YP CS CCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMD98YP IK QJZVEQAWKFWLAR-SFQUDFHCSA-N
DMD98YP IU [(E)-benzylideneamino] N-(4-ethoxyphenyl)carbamate
DMD98YP DE Discovery agent
DMLHKQS ID DMLHKQS
DMLHKQS DN Benzaldehyde O-4-methoxyphenylcarbamoyl oxime
DMLHKQS HS Investigative
DMLHKQS SN CHEMBL599469; benzaldehyde O-4-methoxyphenylcarbamoyl oxime; AC1NSB21; MLS001207590; MolPort-001-926-439; BDBM50309693; AKOS000588577; BAS 00346640; SMR000513623; ST50224746; AB00076721-01; [(E)-benzylideneamino] N-(4-methoxyphenyl)carbamate
DMLHKQS DT Small molecular drug
DMLHKQS PC 5331416
DMLHKQS MW 270.28
DMLHKQS FM C15H14N2O3
DMLHKQS IC InChI=1S/C15H14N2O3/c1-19-14-9-7-13(8-10-14)17-15(18)20-16-11-12-5-3-2-4-6-12/h2-11H,1H3,(H,17,18)/b16-11+
DMLHKQS CS COC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMLHKQS IK TZKNCCSAQUKSHR-LFIBNONCSA-N
DMLHKQS IU [(E)-benzylideneamino] N-(4-methoxyphenyl)carbamate
DMLHKQS DE Discovery agent
DMARBF9 ID DMARBF9
DMARBF9 DN Benzaldehyde O-4-propoxyphenylcarbamoyl oxime
DMARBF9 HS Investigative
DMARBF9 SN CHEMBL592635; benzaldehyde O-4-propoxyphenylcarbamoyl oxime
DMARBF9 DT Small molecular drug
DMARBF9 PC 20872805
DMARBF9 MW 298.34
DMARBF9 FM C17H18N2O3
DMARBF9 IC InChI=1S/C17H18N2O3/c1-2-12-21-16-10-8-15(9-11-16)19-17(20)22-18-13-14-6-4-3-5-7-14/h3-11,13H,2,12H2,1H3,(H,19,20)/b18-13+
DMARBF9 CS CCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CC=CC=C2
DMARBF9 IK AIEVCSUZILYYSA-QGOAFFKASA-N
DMARBF9 IU [(E)-benzylideneamino] N-(4-propoxyphenyl)carbamate
DMARBF9 DE Discovery agent
DMB7DFT ID DMB7DFT
DMB7DFT DN Benzaldehyde O-benzoyloxime
DMB7DFT HS Investigative
DMB7DFT SN benzaldehyde O-benzoyloxime; CHEMBL178391; SCHEMBL3222745; SCHEMBL3222751; (Z)-Benzaldehyde O-benzoyloxime
DMB7DFT DT Small molecular drug
DMB7DFT PC 11206881
DMB7DFT MW 225.24
DMB7DFT FM C14H11NO2
DMB7DFT IC InChI=1S/C14H11NO2/c16-14(13-9-5-2-6-10-13)17-15-11-12-7-3-1-4-8-12/h1-11H/b15-11+
DMB7DFT CS C1=CC=C(C=C1)/C=N/OC(=O)C2=CC=CC=C2
DMB7DFT IK OILVJUHCCAKJGC-RVDMUPIBSA-N
DMB7DFT IU [(E)-benzylideneamino] benzoate
DMB7DFT DE Discovery agent
DM37GWL ID DM37GWL
DM37GWL DN Benzamidine
DM37GWL HS Investigative
DM37GWL SN benzamidine; Benzimidamide; Benzenecarboximidamide; 618-39-3; Phenylamidine; UNII-KUE3ZY3J1F; NSC 243704; CCRIS 2952; Benzamidine (Protonated); EINECS 210-546-3; KUE3ZY3J1F; CHEMBL20936; CHEBI:41033; PXXJHWLDUBFPOL-UHFFFAOYSA-N; BDN; 1oss; 2ast; 1bra; Benzenecarboxamidine; 1v2m; 1v2j; 1h4w; 1ce5; 1c5o; 2j9n; 1f5k; 1c5p; 1v2v; 1v2s; 1v2l; 1c5z; 1v2u; AC1L1DFX; Lopac-B-6506; ACMC-1B9LG; SCHEMBL9207; Lopac0_000203; MLS001066369; GTPL7566; AC1Q1U98; DTXSID8045012; 1670-14-0 (hydrochloride); ZINC36634; CTK2F5055; 1w80; 1j16; 1j15; MolPort-000-001-395
DM37GWL DT Small molecular drug
DM37GWL PC 2332
DM37GWL MW 120.15
DM37GWL FM C7H8N2
DM37GWL IC InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)
DM37GWL CS C1=CC=C(C=C1)C(=N)N
DM37GWL IK PXXJHWLDUBFPOL-UHFFFAOYSA-N
DM37GWL IU benzenecarboximidamide
DM37GWL CA CAS 618-39-3
DM37GWL CB CHEBI:41033
DM37GWL DE Discovery agent
DM57SVW ID DM57SVW
DM57SVW DN Benzamil
DM57SVW HS Investigative
DM57SVW SN Benzamil; 2898-76-2; UNII-04659UUJ94; N-(N-Benzylamidino)-3,5-diamino-6-chloropyrazine carboxamide; GNF-Pf-192; CHEMBL212579; CHEBI:34558; 04659UUJ94; 3,5-Diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)pyrazinecarboxamide; 3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide; Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)-; Spectrum3_001823; Prestwick1_000657; Prestwick3_000657; Prestwick2_000657; Prestwick0_000657; Lopac-B-2417; AC1L33CQ; Lopac0_000211; KBioGR_000300
DM57SVW DT Small molecular drug
DM57SVW PC 108107
DM57SVW MW 319.75
DM57SVW FM C13H14ClN7O
DM57SVW IC InChI=1S/C13H14ClN7O/c14-9-11(16)20-10(15)8(19-9)12(22)21-13(17)18-6-7-4-2-1-3-5-7/h1-5H,6H2,(H4,15,16,20)(H3,17,18,21,22)
DM57SVW CS C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N
DM57SVW IK KXDROGADUISDGY-UHFFFAOYSA-N
DM57SVW IU 3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide
DM57SVW CA CAS 2898-76-2
DM57SVW CB CHEBI:34558
DM57SVW DE Discovery agent
DMK5QYW ID DMK5QYW
DMK5QYW DN BENZENEMETHANETHIOL
DMK5QYW HS Investigative
DMK5QYW SN BENZYL MERCAPTAN; Benzenemethanethiol; Phenylmethanethiol; 100-53-8; Benzylthiol; Thiobenzyl alcohol; alpha-Toluenethiol; Benzyl hydrosulfide; (Mercaptomethyl)benzene; alpha-Mercaptotoluene; Benzylhydrosulfide; alpha-Toluolthiol; Phenylmethyl mercaptan; Benzylmercaptan; Toluene-alpha-thiol; benzyl thiol; Methanethiol, phenyl-; alpha-Tolyl mercaptan; phenyl-methanethiol; USAF ex-1509; .alpha.-Toluenethiol; Toluene, alpha-mercapto-; UNII-OS34A21OBZ; NSC 41897; benzyl-MERCAPTAN; .alpha.-Toluolthiol; FEMA No. 2147; CCRIS 9
DMK5QYW DT Small molecular drug
DMK5QYW PC 7509
DMK5QYW MW 124.21
DMK5QYW FM C7H8S
DMK5QYW IC InChI=1S/C7H8S/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
DMK5QYW CS C1=CC=C(C=C1)CS
DMK5QYW IK UENWRTRMUIOCKN-UHFFFAOYSA-N
DMK5QYW IU phenylmethanethiol
DMK5QYW CA CAS 100-53-8
DMK5QYW CB CHEBI:137674
DMK5QYW DE Discovery agent
DM3I8A1 ID DM3I8A1
DM3I8A1 DN BENZENESULFONAMIDE
DM3I8A1 HS Investigative
DM3I8A1 SN 1998/10/2; Benzenesulphonamide; Benzosulfonamide; Benzolsulfonamide; phenyl sulfonamide; phenylsulfonamide; C6H7NO2S; M and B 7973; NSC 5341; EINECS 202-637-1; BRN 1100566; CHEMBL27601; AI3-04492; KHBQMWCZKVMBLN-UHFFFAOYSA-N; MFCD00007930; Benzenesulfonamide, 98+%; benzolsulfonamid; benzensulfonamide; phenylsulphonamide; 4jsa; 4jsz; 2wej; benzene sulphonamide; 1-benzenesulfonamide; Benzenesulfonyl amine; WLN: ZSWR; AC1Q6VDE; AC1L1OLV; benzenesulfonic acid amide; SCHEMBL729; EC 202
DM3I8A1 DT Small molecular drug
DM3I8A1 PC 7370
DM3I8A1 MW 157.19
DM3I8A1 FM C6H7NO2S
DM3I8A1 IC InChI=1S/C6H7NO2S/c7-10(8,9)6-4-2-1-3-5-6/h1-5H,(H2,7,8,9)
DM3I8A1 CS C1=CC=C(C=C1)S(=O)(=O)N
DM3I8A1 IK KHBQMWCZKVMBLN-UHFFFAOYSA-N
DM3I8A1 IU benzenesulfonamide
DM3I8A1 CA CAS 98-10-2
DM3I8A1 DE Discovery agent
DMMBYGE ID DMMBYGE
DMMBYGE DN Benzenesulfonyl
DMMBYGE HS Investigative
DMMBYGE SN benzenesulfinate; 16722-50-2; BENZENESULFONYL; phenylsulfinate; phenyl sulfinate; Phenylsulfinsaure; (Phenylsulfonyl)radical; AC1MYJCD; Benzenethiol S,S-dioxide; C6H5O2S; SCHEMBL13707414; CHEBI:38100; MolPort-019-857-533; JEHKKBHWRAXMCH-UHFFFAOYSA-M; STL483233; HTS027703; ZINC150345494; AKOS015890258; AB00990983-01
DMMBYGE DT Small molecular drug
DMMBYGE PC 3857574
DMMBYGE MW 141.17
DMMBYGE FM C6H5O2S-
DMMBYGE IC InChI=1S/C6H6O2S/c7-9(8)6-4-2-1-3-5-6/h1-5H,(H,7,8)/p-1
DMMBYGE CS C1=CC=C(C=C1)S(=O)[O-]
DMMBYGE IK JEHKKBHWRAXMCH-UHFFFAOYSA-M
DMMBYGE IU benzenesulfinate
DMMBYGE CB CHEBI:38100
DMMBYGE DE Discovery agent
DM5Y2M8 ID DM5Y2M8
DM5Y2M8 DN BENZIL
DM5Y2M8 HS Investigative
DM5Y2M8 SN BENZIL; 134-81-6; Diphenylethanedione; Dibenzoyl; Diphenylglyoxal; 1,2-Diphenylethane-1,2-dione; Bibenzoyl; Ethanedione, diphenyl-; 1,2-Diphenylethanedione; diphenylethane-1,2-dione; Glyoxal, diphenyl-; Diphenyldiketon; 1,2-ethanedione, 1,2-diphenyl-; Diphenyl-alpha,beta-diketone; NSC 220315; CCRIS 6179; UNII-S85X61172J; EINECS 205-157-0; WY-20910; AI3-00898; CHEMBL189886; CHEBI:51507; 1,2-diphenyl-ethane-1,2-dione; Diphenyl-.alpha.,.beta.-diketone; WURBFLDFSFBTLW-UHFFFAOYSA-N; C14H10O2; MFCD00003080; S85X61172J; 1,2-dione; Benzil, 99+
DM5Y2M8 DT Small molecular drug
DM5Y2M8 PC 8651
DM5Y2M8 MW 210.23
DM5Y2M8 FM C14H10O2
DM5Y2M8 IC InChI=1S/C14H10O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10H
DM5Y2M8 CS C1=CC=C(C=C1)C(=O)C(=O)C2=CC=CC=C2
DM5Y2M8 IK WURBFLDFSFBTLW-UHFFFAOYSA-N
DM5Y2M8 IU 1,2-diphenylethane-1,2-dione
DM5Y2M8 CA CAS 134-81-6
DM5Y2M8 CB CHEBI:51507
DM5Y2M8 DE Discovery agent
DM75U9X ID DM75U9X
DM75U9X DN Benzimidazole 5-carboxamide
DM75U9X HS Investigative
DM75U9X SN 116568-17-3; 1H-Benzo[d]imidazole-6-carboxamide; 1H-benzimidazole-5-carboxamide; 1H-Benzoimidazole-5-carboxylic acid amide; 1H-Benzimidazole-6-carboxamide; 1H-Benzo[d]imidazole-5-carboxamide; 1H-1,3-benzodiazole-5-carboxamide; benzimidazole-5-carboxamide; FNLQDVXHDNFXIY-UHFFFAOYSA-N; ACMC-20mmnb; benzoimidazole-5-carboxamide; SCHEMBL476587; 1H-Benzoimidazole-5-carboxamide; CTK8E3251; CTK0H3052; DTXSID30572624; MolPort-000-353-183; BCP27970; 2711AA; ZINC27986912; STL200279; AKOS002314950; AKOS022171450; FS-2220; MCULE-9328613043
DM75U9X DT Small molecular drug
DM75U9X PC 15421642
DM75U9X MW 161.16
DM75U9X FM C8H7N3O
DM75U9X IC InChI=1S/C8H7N3O/c9-8(12)5-1-2-6-7(3-5)11-4-10-6/h1-4H,(H2,9,12)(H,10,11)
DM75U9X CS C1=CC2=C(C=C1C(=O)N)NC=N2
DM75U9X IK FNLQDVXHDNFXIY-UHFFFAOYSA-N
DM75U9X IU 3H-benzimidazole-5-carboxamide
DM75U9X CA CAS 116568-17-3
DM75U9X DE Hepatovirus infection
DM067NL ID DM067NL
DM067NL DN Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine
DM067NL HS Investigative
DM067NL SN CHEMBL66732; Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine; SCHEMBL5137740; MolPort-007-049-029; ZINC12360740; BDBM50038983; AKOS002366252; MCULE-7168990543
DM067NL DT Small molecular drug
DM067NL PC 10356247
DM067NL MW 279.29
DM067NL FM C16H13N3O2
DM067NL IC InChI=1S/C16H13N3O2/c1-2-4-13-12(3-1)16(19-9-18-13)17-8-11-5-6-14-15(7-11)21-10-20-14/h1-7,9H,8,10H2,(H,17,18,19)
DM067NL CS C1OC2=C(O1)C=C(C=C2)CNC3=NC=NC4=CC=CC=C43
DM067NL IK MLVNLAHRZDXSAM-UHFFFAOYSA-N
DM067NL IU N-(1,3-benzodioxol-5-ylmethyl)quinazolin-4-amine
DM067NL DE Discovery agent
DMJQSLW ID DMJQSLW
DMJQSLW DN Benzo[b]thiophen-2-ylboronic acid
DMJQSLW HS Investigative
DMJQSLW SN Benzo[B]thiophene-2-boronic acid; 98437-23-1; benzo[b]thiophen-2-ylboronic acid; 2-benzothienylboronic acid; BENZO[B]THIOPHENE-2-BORONIC ACID; 1-Benzothiophen-2-ylboronic acid; 1-benzothien-2-ylboronic acid; benzo(b)thiophene-2-boronic acid; Benzothiophene-2-boronic acid; Thianaphthene-2-boronic acid; Benzo[b]thiophene-2-ylboronic Acid; C8H7BO2S; 2-benzothiopheneboronic acid; CHEMBL34964; Benzothiophen-2-ylboronic acid; benzo[b]thiophen-2-boronic acid; 1-Benzothiophen-2-Yl-Boranediol; Boronic acid, benzo[b]thien-2-yl-; (1-benzothiophen-2-yl)boronic acid; Benzo[B]Thiophene-2-Boronic Acid
DMJQSLW DT Small molecular drug
DMJQSLW PC 2359
DMJQSLW MW 178.02
DMJQSLW FM C8H7BO2S
DMJQSLW IC InChI=1S/C8H7BO2S/c10-9(11)8-5-6-3-1-2-4-7(6)12-8/h1-5,10-11H
DMJQSLW CS B(C1=CC2=CC=CC=C2S1)(O)O
DMJQSLW IK YNCYPMUJDDXIRH-UHFFFAOYSA-N
DMJQSLW IU 1-benzothiophen-2-ylboronic acid
DMJQSLW CA CAS 98437-23-1
DMJQSLW DE Discovery agent
DMZR02J ID DMZR02J
DMZR02J DN Benzo[c][1,2]oxaborol-1(3H)-ol
DMZR02J HS Investigative
DMZR02J SN 5735-41-1; 1-Hydroxy-2,1-benzoxaborolane; benzo[c][1,2]oxaborol-1(3H)-ol; 2,1-benzoxaborol-1(3h)-ol; monoester; 1,3-dihydro-1-hydroxy-2,1-benzoxaborole; 1,3-DIHYDRO-2,1-BENZOXABOROL-1-OL; 2,1-Benzoxaborole, 1,3-dihydro-1-hydroxy-; CHEBI:78238; 1-hydroxy-3H-2,1-benzoxaborole; 2-(Hydroxymethyl)phenylboronic Acid Cyclic Monoester; 2-(HYDROXYMETHYL)PHENYLBORONIC ACID, DEHYDRATE; KSC-6-288; NSC719278; PubChem5079; 2,1-benzoxaborol-1-ol; 2-Oxa-1-boraindan-1-ol; AMTB152; C7H7BO2; 3H-2,1-benzoxaborol-1-ol; 1-hydroxy-2,1-benzoxaborole
DMZR02J DT Small molecular drug
DMZR02J PC 403788
DMZR02J MW 133.94
DMZR02J FM C7H7BO2
DMZR02J IC InChI=1S/C7H7BO2/c9-8-7-4-2-1-3-6(7)5-10-8/h1-4,9H,5H2
DMZR02J CS B1(C2=CC=CC=C2CO1)O
DMZR02J IK XOQABDOICLHPIS-UHFFFAOYSA-N
DMZR02J IU 1-hydroxy-3H-2,1-benzoxaborole
DMZR02J CA CAS 5735-41-1
DMZR02J CB CHEBI:78238
DMZR02J DE Discovery agent
DMMYGB9 ID DMMYGB9
DMMYGB9 DN Benzo[c][1,5]naphthyridin-6(5H)-one
DMMYGB9 HS Investigative
DMMYGB9 SN benzo[c][1,5]naphthyridin-6(5H)-one; CHEMBL320031; Benzo[c]-1,5-naphthyridin-6(5H)-one; SCHEMBL12750384; BDBM50130585; 5H-Benzo[c][1,5]naphthyridin-6-one; Benzo[c][1,5]naphthyridine-6(5H)-one
DMMYGB9 DT Small molecular drug
DMMYGB9 PC 10535869
DMMYGB9 MW 196.2
DMMYGB9 FM C12H8N2O
DMMYGB9 IC InChI=1S/C12H8N2O/c15-12-9-5-2-1-4-8(9)11-10(14-12)6-3-7-13-11/h1-7H,(H,14,15)
DMMYGB9 CS C1=CC=C2C(=C1)C3=C(C=CC=N3)NC2=O
DMMYGB9 IK NGHUYPCHBUPCNK-UHFFFAOYSA-N
DMMYGB9 IU 5H-benzo[c][1,5]naphthyridin-6-one
DMMYGB9 DE Discovery agent
DMISHTB ID DMISHTB
DMISHTB DN Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine
DMISHTB HS Investigative
DMISHTB SN CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine
DMISHTB DT Small molecular drug
DMISHTB PC 5328245
DMISHTB MW 350.2
DMISHTB FM C18H12BrN3
DMISHTB IC InChI=1S/C18H12BrN3/c19-14-6-3-7-15(10-14)22-18-16-8-12-4-1-2-5-13(12)9-17(16)20-11-21-18/h1-11H,(H,20,21,22)
DMISHTB CS C1=CC=C2C=C3C(=CC2=C1)C(=NC=N3)NC4=CC(=CC=C4)Br
DMISHTB IK BUVKJPOCMOXSSQ-UHFFFAOYSA-N
DMISHTB IU N-(3-bromophenyl)benzo[g]quinazolin-4-amine
DMISHTB DE Discovery agent
DM9H34M ID DM9H34M
DM9H34M DN Benzodiazepine
DM9H34M HS Investigative
DM9H34M SN Benzodiazepine (Aversion, anxiety)
DM9H34M CP Acura Pharmaceuticals Inc
DM9H34M DT Small molecular drug
DM9H34M PC 134664
DM9H34M MW 144.17
DM9H34M FM C9H8N2
DM9H34M IC InChI=1S/C9H8N2/c1-2-6-9-8(4-1)5-3-7-10-11-9/h1-7,11H
DM9H34M CS C1=CC=C2C(=C1)C=CC=NN2
DM9H34M IK SVUOLADPCWQTTE-UHFFFAOYSA-N
DM9H34M IU 1H-1,2-benzodiazepine
DM9H34M CA CAS 12794-10-4
DM9H34M DE Anxiety disorder
DMF1ZE6 ID DMF1ZE6
DMF1ZE6 DN Benzofuran-2-yl(indolin-1-yl)methanone
DMF1ZE6 HS Investigative
DMF1ZE6 SN CHEMBL496155; benzofuran-2-yl(indolin-1-yl)methanone; AC1LFLO9; Oprea1_781741; SCHEMBL2757847; MolPort-002-146-725; ZINC272979; BDBM50265522; ZINC 00272979; AKOS001474069; MCULE-1146733513; SR-01000206937; 1-benzofuran-2-yl(2,3-dihydroindol-1-yl)methanone
DMF1ZE6 DT Small molecular drug
DMF1ZE6 PC 780029
DMF1ZE6 MW 263.29
DMF1ZE6 FM C17H13NO2
DMF1ZE6 IC InChI=1S/C17H13NO2/c19-17(16-11-13-6-2-4-8-15(13)20-16)18-10-9-12-5-1-3-7-14(12)18/h1-8,11H,9-10H2
DMF1ZE6 CS C1CN(C2=CC=CC=C21)C(=O)C3=CC4=CC=CC=C4O3
DMF1ZE6 IK NWLAYUVGWMPNSG-UHFFFAOYSA-N
DMF1ZE6 IU 1-benzofuran-2-yl(2,3-dihydroindol-1-yl)methanone
DMF1ZE6 DE Discovery agent
DMQ7I06 ID DMQ7I06
DMQ7I06 DN Benzofuran-2-ylboronic acid
DMQ7I06 HS Investigative
DMQ7I06 SN Benzofuran-2-boronic acid; 98437-24-2; Benzo[b]furan-2-boronic acid; Benzofuran-2-ylboronic acid; 1-benzofuran-2-ylboronic acid; 2-Benzofuranboronic acid; 2-BENZOFURANYLBORONIC ACID; Benzo(b)furan-2-boronic acid; (1-benzofuran-2-yl)boronic acid; 2,3-Benzo[b]furan-2-boronic acid; Boronic acid, 2-benzofuranyl-; CHEMBL143399; MFCD00236019; Benzo[b]furan-2-boronic acid, 97%; Benzofuran-2-boronicacid; benzofurylboronic acid; PubChem1724; bezofuran boronic acid; PubChem1754; Benzofuran boronic acid; 2-Boronobenzo[b]furan
DMQ7I06 DT Small molecular drug
DMQ7I06 PC 2776266
DMQ7I06 MW 161.95
DMQ7I06 FM C8H7BO3
DMQ7I06 IC InChI=1S/C8H7BO3/c10-9(11)8-5-6-3-1-2-4-7(6)12-8/h1-5,10-11H
DMQ7I06 CS B(C1=CC2=CC=CC=C2O1)(O)O
DMQ7I06 IK PKRRNTJIHGOMRC-UHFFFAOYSA-N
DMQ7I06 IU 1-benzofuran-2-ylboronic acid
DMQ7I06 CA CAS 98437-24-2
DMQ7I06 DE Discovery agent
DMNVG1M ID DMNVG1M
DMNVG1M DN Benzofuran-3-yl-(indol-3-yl)maleimides
DMNVG1M HS Investigative
DMNVG1M DT Small molecular drug
DMNVG1M PC 9831814
DMNVG1M MW 731.9
DMNVG1M FM C38H41N3O8S2
DMNVG1M IC InChI=1S/C22H23NO5S2.C16H18N2O3/c1-15(14-30(28)22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h2-11,15,18-19H,12-14H2,1H3,(H,25,26);5-6,8,14-15,20H,3-4,7H2,1-2H3/t15-,18-,19-,30?;14-,15+/m01/s1
DMNVG1M CS C[C@@H](CS(=O)C(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)O)SC3=CC=CC=C3.CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C
DMNVG1M IK CPIFLUAOCGEKJE-QTQBKYSQSA-N
DMNVG1M IU (2S,4S)-1-[(2R)-3-benzoylsulfinyl-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid;(3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydrochromene-6-carbonitrile
DMNVG1M DE Discovery agent
DMAQK0G ID DMAQK0G
DMAQK0G DN Benzoic acid 2,6-diisopropyl-phenyl ester
DMAQK0G HS Investigative
DMAQK0G SN Benzoic acid 2,6-diisopropyl-phenyl ester; CHEMBL55916; SCHEMBL8380667; ZINC13779585; Benzoic acid 2,6-diisopropylphenyl ester
DMAQK0G DT Small molecular drug
DMAQK0G PC 10779272
DMAQK0G MW 282.4
DMAQK0G FM C19H22O2
DMAQK0G IC InChI=1S/C19H22O2/c1-13(2)16-11-8-12-17(14(3)4)18(16)21-19(20)15-9-6-5-7-10-15/h5-14H,1-4H3
DMAQK0G CS CC(C)C1=C(C(=CC=C1)C(C)C)OC(=O)C2=CC=CC=C2
DMAQK0G IK FWWZVJVOMUKVKV-UHFFFAOYSA-N
DMAQK0G IU [2,6-di(propan-2-yl)phenyl] benzoate
DMAQK0G CA CAS 2005-09-6
DMAQK0G DE Discovery agent
DM6T8YM ID DM6T8YM
DM6T8YM DN Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM HS Investigative
DM6T8YM SN CHEMBL84113; Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester
DM6T8YM DT Small molecular drug
DM6T8YM PC 10105296
DM6T8YM MW 231.29
DM6T8YM FM C14H17NO2
DM6T8YM IC InChI=1S/C14H17NO2/c16-14(10-5-2-1-3-6-10)17-13-9-11-7-4-8-12(13)15-11/h1-3,5-6,11-13,15H,4,7-9H2
DM6T8YM CS C1CC2CC(C(C1)N2)OC(=O)C3=CC=CC=C3
DM6T8YM IK AKLGENRCHBXEKW-UHFFFAOYSA-N
DM6T8YM IU 8-azabicyclo[3.2.1]octan-6-yl benzoate
DM6T8YM DE Discovery agent
DM50QMB ID DM50QMB
DM50QMB DN Benzoin
DM50QMB HS Investigative
DM50QMB SN BENZOIN; 119-53-9; 2-Hydroxy-1,2-diphenylethanone; 2-Hydroxy-2-phenylacetophenone; Benzoylphenylcarbinol; Benzoin tincture; Ethanone, 2-hydroxy-1,2-diphenyl-; Bitter almond oil camphor; Phenylbenzoyl carbinol; 2-hydroxy-1,2-diphenylethan-1-one; (+-)-Benzoin; DL-BENZOIN; alpha-Hydroxybenzyl phenyl ketone; 579-44-2; alpha-Hydroxy-alpha-phenylacetophenone; Benzoin resin; Phenyl-alpha-hydroxybenzyl ketone; NCI-C50011; Acetophenone, 2-hydroxy-2-phenyl-; Benzoin gum; Bitter-almond-oil camphor; Benzoin Siam; Benzoin extract (resinoid)
DM50QMB DT Small molecular drug
DM50QMB PC 8400
DM50QMB MW 212.24
DM50QMB FM C14H12O2
DM50QMB IC InChI=1S/C14H12O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13,15H
DM50QMB CS C1=CC=C(C=C1)C(C(=O)C2=CC=CC=C2)O
DM50QMB IK ISAOCJYIOMOJEB-UHFFFAOYSA-N
DM50QMB IU 2-hydroxy-1,2-diphenylethanone
DM50QMB CA CAS 119-53-9
DM50QMB CB CHEBI:17682
DM50QMB DE Discovery agent
DME5QPX ID DME5QPX
DME5QPX DN BENZOLAMIDE
DME5QPX HS Investigative
DME5QPX SN BENZOLAMIDE; 3368-13-6; UNII-FC5AAH89R5; CL 11366; FC5AAH89R5; 2-benzenesulfonamido-1,3,4-thiadiazole-5-sulfonamide; CHEMBL73962; 1,3,4-Thiadiazole-2-sulfonamide, 5-[(phenylsulfonyl)amino]-; W 1803; 5-(phenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide; 2-(Phenylsulfonylamino)-1,3,4-thiadiazole-5-sulfonamide; 5-[(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide; 1,3,4-Thiadiazole-2-sulfonamide, 5-((phenylsulfonyl)amino)-; 5-benzenesulfonamido-1,3,4-thiadiazol-2-sulfonamide; 3dbu; D8W; Benzolamide (BZA); 3d8w; AC1L2CTC
DME5QPX DT Small molecular drug
DME5QPX PC 18794
DME5QPX MW 320.4
DME5QPX FM C8H8N4O4S3
DME5QPX IC InChI=1S/C8H8N4O4S3/c9-18(13,14)8-11-10-7(17-8)12-19(15,16)6-4-2-1-3-5-6/h1-5H,(H,10,12)(H2,9,13,14)
DME5QPX CS C1=CC=C(C=C1)S(=O)(=O)NC2=NN=C(S2)S(=O)(=O)N
DME5QPX IK PWDGTQXZLNDOKS-UHFFFAOYSA-N
DME5QPX IU 5-(benzenesulfonamido)-1,3,4-thiadiazole-2-sulfonamide
DME5QPX CA CAS 3368-13-6
DME5QPX DE Discovery agent
DMRE96F ID DMRE96F
DMRE96F DN Benzomate
DMRE96F HS Investigative
DMRE96F SN Benzoxamate; Acarmate; Artaban; Citrazon; Azomate; Benzoximate [BSI:ISO]; UNII-32TAI9ZK5N; 32TAI9ZK5N; NA-53M; NA-53; EINECS 249-439-1; BRN 2783319; BENZOHYDROXAMIC ACID, O-BENZOYL-3-CHLORO-2,6-DIMETHOXY-N-ETHYL-; Benzoic acid, anhydride with 3-chloro-N-ethoxy-2,6-dimethoxybenzimidic acid; AC1L1RMU; 67011-39-6; SCHEMBL9806359; HOERQTQCTISLFR-UHFFFAOYSA-N; LS-35432; C19021; N-(Benzoyloxy)-3-chloro-N-ethyl-2,6-dimethoxybenzamide; Benzoic acid anhydride with 3-chloro-N-ethoxy-2,6-dimethoxybenzenecarboximidic acid (9CI); Benzoic aci
DMRE96F DT Small molecular drug
DMRE96F PC 6035168
DMRE96F MW 363.8
DMRE96F FM C18H18ClNO5
DMRE96F IC InChI=1S/C18H18ClNO5/c1-4-24-20-17(25-18(21)12-8-6-5-7-9-12)15-14(22-2)11-10-13(19)16(15)23-3/h5-11H,4H2,1-3H3/b20-17-
DMRE96F CS CCO/N=C(/C1=C(C=CC(=C1OC)Cl)OC)\\OC(=O)C2=CC=CC=C2
DMRE96F IK BZMIHNKNQJJVRO-JZJYNLBNSA-N
DMRE96F IU [(Z)-C-(3-chloro-2,6-dimethoxyphenyl)-N-ethoxycarbonimidoyl] benzoate
DMRE96F CA CAS 29104-30-1
DMRE96F DE Discovery agent
DMMKBFN ID DMMKBFN
DMMKBFN DN benzoquinazolinone 12
DMMKBFN HS Investigative
DMMKBFN SN benzoquinazolinone 12; SCHEMBL2404136; GTPL8549; 3-[(1S,2S)-2-hydroxycyclohexyl]-6-{[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]methyl}-3H,4H-benzo[h]quinazolin-4-one
DMMKBFN DT Small molecular drug
DMMKBFN PC 46196414
DMMKBFN MW 465.5
DMMKBFN FM C28H27N5O2
DMMKBFN IC InChI=1S/C28H27N5O2/c1-32-16-20(15-31-32)24-11-10-18(14-29-24)12-19-13-23-27(22-7-3-2-6-21(19)22)30-17-33(28(23)35)25-8-4-5-9-26(25)34/h2-3,6-7,10-11,13-17,25-26,34H,4-5,8-9,12H2,1H3/t25-,26-/m0/s1
DMMKBFN CS CN1C=C(C=N1)C2=NC=C(C=C2)CC3=CC4=C(C5=CC=CC=C53)N=CN(C4=O)[C@H]6CCCC[C@@H]6O
DMMKBFN IK SXJQBWJPNSOKQV-UIOOFZCWSA-N
DMMKBFN IU 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[[6-(1-methylpyrazol-4-yl)pyridin-3-yl]methyl]benzo[h]quinazolin-4-one
DMMKBFN DE Discovery agent
DMNBA0G ID DMNBA0G
DMNBA0G DN Benzoquinone
DMNBA0G HS Investigative
DMNBA0G SN p-benzoquinone; Benzoquinone; 1,4-BENZOQUINONE; Quinone; 106-51-4; p-Quinone; Chinone; 2,5-Cyclohexadiene-1,4-dione; para-Benzoquinone; cyclohexa-2,5-diene-1,4-dione; Cyclohexadienedione; para-Quinone; 1,4-Benzoquine; Steara pbq; 1,4-Dioxybenzene; p-Chinon; 1,4-Cyclohexadienedione; Benzo-chinon; Benzo-1,4-quinone; 1,4-Diossibenzene; Chinon; 1,4-Dioxy-benzol; 1,4-Cyclohexadiene dioxide; Semiquinone anion; semiquinone radicals; RCRA waste number U197; p-Chinon [German]; NCI-C55845; Caswell No. 719C; Benzo-chinon [German]; USAF P-220
DMNBA0G DT Small molecular drug
DMNBA0G PC 4650
DMNBA0G MW 108.09
DMNBA0G FM C6H4O2
DMNBA0G IC InChI=1S/C6H4O2/c7-5-1-2-6(8)4-3-5/h1-4H
DMNBA0G CS C1=CC(=O)C=CC1=O
DMNBA0G IK AZQWKYJCGOJGHM-UHFFFAOYSA-N
DMNBA0G IU cyclohexa-2,5-diene-1,4-dione
DMNBA0G CA CAS 106-51-4
DMNBA0G CB CHEBI:16509
DMNBA0G DE Discovery agent
DM4OKXI ID DM4OKXI
DM4OKXI DN Benzotetronic acid
DM4OKXI HS Investigative
DM4OKXI SN Coumarin, 4-hydroxy-; X954ZLL2RD; 1076-38-6; 2-Hydroxychromone; 2-hydroxychromen-4-one; 2H-1-BENZOPYRAN-2-ONE, 4-HYDROXY-; 4-Coumarinol; 4-Hydroxycoumarin; 4-HYDROXY-1-BENZOPYRAN-2-ONE; 4-Hydroxy-2H-1-benzopyran-2-one; 4-Hydroxy-2H-chromen-2-one; 4-Hydroxy-chromen-2-one; 4-Hydroxycoumarin, 98%; 4-Hydroxycoumarine; 4-hydroxy-2-chromenone; 4-hydroxy-coumarin; 4-hydroxychromen-2-one; 4H-1-Benzopyran-4-one, 2-hydroxy-; AI3-52393; BRN 0129768; CHEMBL301141; EINECS 214-060-2; MFCD00006856; NSC 11889; UNII-X954ZLL2RD
DM4OKXI PC 54682930
DM4OKXI MW 162.14
DM4OKXI FM C9H6O3
DM4OKXI IC VXIXUWQIVKSKSA-UHFFFAOYSA-N
DM4OKXI CS C1=CC=C2C(=C1)C(=CC(=O)O2)O
DM4OKXI IK 1S/C9H6O3/c10-7-5-9(11)12-8-4-2-1-3-6(7)8/h1-5,10H
DM4OKXI IU 4-hydroxychromen-2-one
DM4OKXI CA CAS 1076-38-6
DM4OKXI CB CHEBI:40070
DM4OKXI DE Discovery agent
DMV7MPL ID DMV7MPL
DMV7MPL DN BENZOTHIAZOLE
DMV7MPL HS Investigative
DMV7MPL SN BENZOTHIAZOLE; 95-16-9; BENZO[D]THIAZOLE; 1,3-Benzothiazole; Benzosulfonazole; 1-Thia-3-azaindene; Vangard BT; benzothiazol; USAF EK-4812; benzthiazole; CHEBI:45993; FEMA Number 3256; UNII-G5BW2593EP; O-2857; FEMA No. 3256; CCRIS 7893; HSDB 2796; NSC 8040; EINECS 202-396-2; BRN 0109468; AI3-05742; G5BW2593EP; IOJUPLGTWVMSFF-UHFFFAOYSA-N; MFCD00005775; Benzothiazole, 97%; DSSTox_CID_4586; DSSTox_RID_77458; DSSTox_GSID_24586; CAS-95-16-9; BOT; Benzothiazole, 96%; 1,3-Benzothiazole #; ACMC-209rv5; Epitope ID:138946; EC 202-396-2; SCHEMBL8430
DMV7MPL DT Small molecular drug
DMV7MPL PC 7222
DMV7MPL MW 135.19
DMV7MPL FM C7H5NS
DMV7MPL IC InChI=1S/C7H5NS/c1-2-4-7-6(3-1)8-5-9-7/h1-5H
DMV7MPL CS C1=CC=C2C(=C1)N=CS2
DMV7MPL IK IOJUPLGTWVMSFF-UHFFFAOYSA-N
DMV7MPL IU 1,3-benzothiazole
DMV7MPL CA CAS 95-16-9
DMV7MPL CB CHEBI:45993
DMV7MPL DE Discovery agent
DMROP5Q ID DMROP5Q
DMROP5Q DN Benzothiazole-2-sulfonic acid amide
DMROP5Q HS Investigative
DMROP5Q SN 2-Benzothiazolesulfonamide; 433-17-0; Benzo[d]thiazole-2-sulfonamide; 1,3-benzothiazole-2-sulfonamide; BENZOTHIAZOLE-2-SULFONAMIDE; Benzothiazole-2-sulfonic acid amide; CHEMBL168552; CHEBI:34262; 2-BTS; 6-Hydrogen-2-benzothiazolesulfonamide; AC1Q1HM9; AC1L28OQ; SCHEMBL81178; AC1Q55G4; CTK1D5756; DTXSID30195812; MolPort-006-728-089; SDYMYAFSQACTQP-UHFFFAOYSA-N; 3s73; ZINC1847418; ANW-70718; 5987AB; BDBM50160671; AKOS010998801; MCULE-9059575102; EN001332; AM100818; TC-159463; KB-142553; EN300-60766; C14181
DMROP5Q DT Small molecular drug
DMROP5Q PC 67944
DMROP5Q MW 214.3
DMROP5Q FM C7H6N2O2S2
DMROP5Q IC InChI=1S/C7H6N2O2S2/c8-13(10,11)7-9-5-3-1-2-4-6(5)12-7/h1-4H,(H2,8,10,11)
DMROP5Q CS C1=CC=C2C(=C1)N=C(S2)S(=O)(=O)N
DMROP5Q IK SDYMYAFSQACTQP-UHFFFAOYSA-N
DMROP5Q IU 1,3-benzothiazole-2-sulfonamide
DMROP5Q CA CAS 433-17-0
DMROP5Q CB CHEBI:34262
DMROP5Q DE Discovery agent
DMC7TNF ID DMC7TNF
DMC7TNF DN Benzoyl-Arginine-Alanine-Methyl Ketone
DMC7TNF HS Investigative
DMC7TNF SN AC1NRDMD; benzyl N-[(2S)-5-(diaminomethylamino)-1-oxo-1-(3-oxobutan-2-ylamino)pentan-2-yl]carbamate; molecular hydrogen
DMC7TNF DT Small molecular drug
DMC7TNF PC 6398520
DMC7TNF MW 379.5
DMC7TNF FM C18H29N5O4
DMC7TNF IC InChI=1S/C18H29N5O4/c1-12(13(2)24)22-16(25)15(9-6-10-21-17(19)20)23-18(26)27-11-14-7-4-3-5-8-14/h3-5,7-8,12,15,17,21H,6,9-11,19-20H2,1-2H3,(H,22,25)(H,23,26)/t12-,15-/m0/s1
DMC7TNF CS C[C@@H](C(=O)C)NC(=O)[C@H](CCCNC(N)N)NC(=O)OCC1=CC=CC=C1
DMC7TNF IK SLLMMFWUJVANSC-WFASDCNBSA-N
DMC7TNF IU benzyl N-[(2S)-5-(diaminomethylamino)-1-oxo-1-[[(2S)-3-oxobutan-2-yl]amino]pentan-2-yl]carbamate
DMC7TNF CA CAS 1033745-37-7
DMC7TNF DE Discovery agent
DMY5O1U ID DMY5O1U
DMY5O1U DN BENZOYLENUREA
DMY5O1U HS Investigative
DMY5O1U SN Benzoyleneurea; 86-96-4; quinazoline-2,4(1H,3H)-dione; 2,4(1H,3H)-Quinazolinedione; 2,4-Dihydroxyquinazoline; Quinazolinedione; Benzouracil; Quinazoline-2,4-diol; Quinazoline-2,4-dione; 1H-Quinazoline-2,4-dione; Urea, benzoylene-; 1,2,3,4-Tetrahydroquinazoline-2,4-dione; 2-Keto-4-quinazolinone; 2,4-Dioxotetrahydroquinazoline; NSC 2108; (1H,3H)Quinazoline dione-2,4; (1H,3H)-Quinazoline-2,4-dione; EINECS 201-712-6; (1H,3H)Quinazoline dione-2,4 [French]; AI3-28016; CHEMBL421646; 1H,3H-quinazoline-2,4-dione; UNII-18K00A531C
DMY5O1U DT Small molecular drug
DMY5O1U PC 64048
DMY5O1U MW 162.15
DMY5O1U FM C8H6N2O2
DMY5O1U IC InChI=1S/C8H6N2O2/c11-7-5-3-1-2-4-6(5)9-8(12)10-7/h1-4H,(H2,9,10,11,12)
DMY5O1U CS C1=CC=C2C(=C1)C(=O)NC(=O)N2
DMY5O1U IK SDQJTWBNWQABLE-UHFFFAOYSA-N
DMY5O1U IU 1H-quinazoline-2,4-dione
DMY5O1U CA CAS 86-96-4
DMY5O1U DE Discovery agent
DMIRD8S ID DMIRD8S
DMIRD8S DN BENZOYL-TYROSINE-ALANINE-METHYL KETONE
DMIRD8S HS Investigative
DMIRD8S SN benzoyl-tyrosine-alanine-methyl ketone
DMIRD8S DT Small molecular drug
DMIRD8S PC 46937178
DMIRD8S MW 384.4
DMIRD8S FM C21H24N2O5
DMIRD8S IC InChI=1S/C21H24N2O5/c1-14(15(2)24)22-20(26)19(12-16-8-10-18(25)11-9-16)23-21(27)28-13-17-6-4-3-5-7-17/h3-11,14,19,25H,12-13H2,1-2H3,(H,22,26)(H,23,27)/t14-,19-/m0/s1
DMIRD8S CS C[C@@H](C(=O)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)OCC2=CC=CC=C2
DMIRD8S IK CLDDOKCDXBMMKZ-LIRRHRJNSA-N
DMIRD8S IU benzyl N-[(2S)-3-(4-hydroxyphenyl)-1-oxo-1-[[(2S)-3-oxobutan-2-yl]amino]propan-2-yl]carbamate
DMIRD8S DE Discovery agent
DMT3JYE ID DMT3JYE
DMT3JYE DN Benzyl 2-hydroxyiminoolean-12-en-28-oate
DMT3JYE HS Investigative
DMT3JYE SN 2-(Hydroxyimino)oleana-12-ene-28-oic acid benzyl ester
DMT3JYE DT Small molecular drug
DMT3JYE PC 91937013
DMT3JYE MW 559.8
DMT3JYE FM C37H53NO3
DMT3JYE IC InChI=1S/C37H53NO3/c1-32(2)17-19-37(31(39)41-24-25-11-9-8-10-12-25)20-18-35(6)27(28(37)23-32)13-14-30-34(5)22-26(38-40)21-33(3,4)29(34)15-16-36(30,35)7/h8-13,26,28-30H,14-24H2,1-7H3/t26?,28-,29-,30+,34-,35+,36+,37-/m0/s1
DMT3JYE CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OCC6=CC=CC=C6)C)(CC(CC3(C)C)N=O)C
DMT3JYE IK UQAJJIWPUXUAMF-NUBQHGELSA-N
DMT3JYE IU benzyl (4aS,6aR,6aS,6bR,8aS,12aS,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-11-nitroso-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMT3JYE DE Discovery agent
DMOKVAT ID DMOKVAT
DMOKVAT DN Benzyl 4-aminobutyl(3-aminopropyl)carbamate
DMOKVAT HS Investigative
DMOKVAT SN Benzyl 4-aminobutyl(3-aminopropyl)carbamate; CHEMBL418644; NSC685957; benzyl N-(4-aminobutyl)-N-(3-aminopropyl)carbamate; AC1L8YAY; SCHEMBL7535687; CTK8D1272; ZINC1650370; BDBM50184788; NSC-685957; NCI60_030939; benzyl(4-aminobutyl)(3-aminopropyl)carbamate; 3-Aminopropyl(4-aminobutyl)carbamic acid benzyl ester; (4-Amino-butyl)-(3-amino-propyl)-carbamic acid benzyl ester
DMOKVAT DT Small molecular drug
DMOKVAT PC 389610
DMOKVAT MW 279.38
DMOKVAT FM C15H25N3O2
DMOKVAT IC InChI=1S/C15H25N3O2/c16-9-4-5-11-18(12-6-10-17)15(19)20-13-14-7-2-1-3-8-14/h1-3,7-8H,4-6,9-13,16-17H2
DMOKVAT CS C1=CC=C(C=C1)COC(=O)N(CCCCN)CCCN
DMOKVAT IK ADDDUQKJZAGBIG-UHFFFAOYSA-N
DMOKVAT IU benzyl N-(4-aminobutyl)-N-(3-aminopropyl)carbamate
DMOKVAT DE Discovery agent
DM857X2 ID DM857X2
DM857X2 DN benzyl bromide
DM857X2 HS Investigative
DM857X2 SN BENZYL BROMIDE; 100-39-0; (Bromomethyl)benzene; alpha-Bromotoluene; Bromophenylmethane; Benzene, (bromomethyl)-; Benzene, bromomethyl-; Phenylmethyl bromide; 1-Bromotoluene; benzylbromide; Cyclite; bromomethylbenzene; A-BROMOTOLUENE; Toluene, alpha-bromo-; BnBr; NSC 8041; UNII-XR75BS721D; HSDB 369; .alpha.-Bromotoluene; .omega.-Bromotoluene; CCRIS 5980; EINECS 249-248-3; EINECS 202-847-3; UN1737; Toluene, .alpha.-bromo-; ALPHA-BROMOPHENYLMETHANE; AI3-15300; XR75BS721D; CHEMBL1085946; CHEBI:59858; AGEZXYOZHKGVCM-UHFFFAOYSA-N
DM857X2 DT Small molecular drug
DM857X2 PC 7498
DM857X2 MW 171.03
DM857X2 FM C7H7Br
DM857X2 IC InChI=1S/C7H7Br/c8-6-7-4-2-1-3-5-7/h1-5H,6H2
DM857X2 CS C1=CC=C(C=C1)CBr
DM857X2 IK AGEZXYOZHKGVCM-UHFFFAOYSA-N
DM857X2 IU bromomethylbenzene
DM857X2 CA CAS 100-39-0
DM857X2 CB CHEBI:59858
DM857X2 DE Discovery agent
DMX8W4G ID DMX8W4G
DMX8W4G DN Benzyl derivative of M6G
DMX8W4G HS Investigative
DMX8W4G SN CHEMBL366917; Benzyl derivative of M6G
DMX8W4G DT Small molecular drug
DMX8W4G PC 44390359
DMX8W4G MW 865.1
DMX8W4G FM C54H60N2O8
DMX8W4G IC InChI=1S/C54H60N2O8/c1-56-28-27-54-43(46(56)29-41-23-24-42(57)30-44(41)54)25-26-45(53(54)59-2)55-49(58)31-47-50(61-33-38-17-9-4-10-18-38)52(63-35-40-21-13-6-14-22-40)51(62-34-39-19-11-5-12-20-39)48(64-47)36-60-32-37-15-7-3-8-16-37/h3-26,30,43,45-48,50-53,57H,27-29,31-36H2,1-2H3,(H,55,58)/t43-,45+,46+,47?,48?,50?,51?,52?,53?,54-/m0/s1
DMX8W4G CS CN1CC[C@]23[C@H]([C@H]1CC4=C2C=C(C=C4)O)C=C[C@H](C3OC)NC(=O)CC5C(C(C(C(O5)COCC6=CC=CC=C6)OCC7=CC=CC=C7)OCC8=CC=CC=C8)OCC9=CC=CC=C9
DMX8W4G IK AKEFSYMTVVZMKO-GZNILVGYSA-N
DMX8W4G IU N-[(1S,9R,10R,13R)-4-hydroxy-14-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-yl]-2-[3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]acetamide
DMX8W4G DE Discovery agent
DM6I5MU ID DM6I5MU
DM6I5MU DN Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine
DM6I5MU HS Investigative
DM6I5MU SN CHEMBL118944; Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine; SCHEMBL7280806; FNTPEBIGZTYDQK-UHFFFAOYSA-N; BDBM50033290; 4-Phenylmethylamino-2-(1-Imidazolyl)Quinazoline
DM6I5MU DT Small molecular drug
DM6I5MU PC 10266864
DM6I5MU MW 301.3
DM6I5MU FM C18H15N5
DM6I5MU IC InChI=1S/C18H15N5/c1-2-6-14(7-3-1)12-20-17-15-8-4-5-9-16(15)21-18(22-17)23-11-10-19-13-23/h1-11,13H,12H2,(H,20,21,22)
DM6I5MU CS C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)N4C=CN=C4
DM6I5MU IK FNTPEBIGZTYDQK-UHFFFAOYSA-N
DM6I5MU IU N-benzyl-2-imidazol-1-ylquinazolin-4-amine
DM6I5MU DE Discovery agent
DM3X50C ID DM3X50C
DM3X50C DN Benzyl-(2-phenyl-quinazolin-4-yl)-amine
DM3X50C HS Investigative
DM3X50C SN Benzyl-(2-phenyl-quinazolin-4-yl)-amine; N-Benzyl-2-phenyl-4-quinazolinamine; CHEMBL72650; N-benzyl-2-phenylquinazolin-4-amine; AC1LFMYC; BAS 01023367; Oprea1_781281; Oprea1_710967; MLS001210388; SCHEMBL1083763; MolPort-001-952-692; HMS2816J14; KUC104420N; ZINC274067; STL227888; BDBM50033296; KSC-1-145; benzyl(2-phenylquinazolin-4-yl)amine; AKOS000533392; MCULE-1161339740; SMR000515839
DM3X50C DT Small molecular drug
DM3X50C PC 780643
DM3X50C MW 311.4
DM3X50C FM C21H17N3
DM3X50C IC InChI=1S/C21H17N3/c1-3-9-16(10-4-1)15-22-21-18-13-7-8-14-19(18)23-20(24-21)17-11-5-2-6-12-17/h1-14H,15H2,(H,22,23,24)
DM3X50C CS C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4
DM3X50C IK WXCHSHPXEPXKFN-UHFFFAOYSA-N
DM3X50C IU N-benzyl-2-phenylquinazolin-4-amine
DM3X50C DE Discovery agent
DMYDGCI ID DMYDGCI
DMYDGCI DN Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine
DMYDGCI HS Investigative
DMYDGCI SN CHEMBL119841; AC1LDIC6; Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine; Oprea1_641196; MLS001163907; cid_667555; ZINC5903; SCHEMBL7286130; MolPort-002-565-372; HMS2878H17; PCOP-956263; BDBM50033284; STK536221; NCGC00012858; AKOS001104531; MCULE-1376892352; NCGC00012858-02; SMR000539306; benzyl(2-(3-pyridyl)quinazolin-4-yl)amine; N-benzyl-2-pyridin-3-ylquinazolin-4-amine; N-Benzyl-2-(3-pyridinyl)quinazolin-4-amine; ST50015136; N-benzyl-2-(pyridin-3-yl)quinazolin-4-amine
DMYDGCI DT Small molecular drug
DMYDGCI PC 667555
DMYDGCI MW 312.4
DMYDGCI FM C20H16N4
DMYDGCI IC InChI=1S/C20H16N4/c1-2-7-15(8-3-1)13-22-20-17-10-4-5-11-18(17)23-19(24-20)16-9-6-12-21-14-16/h1-12,14H,13H2,(H,22,23,24)
DMYDGCI CS C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CN=CC=C4
DMYDGCI IK AELMNLIYFALJIR-UHFFFAOYSA-N
DMYDGCI IU N-benzyl-2-pyridin-3-ylquinazolin-4-amine
DMYDGCI DE Discovery agent
DMESVWC ID DMESVWC
DMESVWC DN Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine
DMESVWC HS Investigative
DMESVWC SN CHEMBL118462; AC1LJDWH; N-benzyl-2-pyridin-4-ylquinazolin-4-amine; Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine; SCHEMBL7277479; MolPort-000-723-072; ZINC509842; BDBM50033302; AKOS030512862
DMESVWC DT Small molecular drug
DMESVWC PC 921562
DMESVWC MW 312.4
DMESVWC FM C20H16N4
DMESVWC IC InChI=1S/C20H16N4/c1-2-6-15(7-3-1)14-22-20-17-8-4-5-9-18(17)23-19(24-20)16-10-12-21-13-11-16/h1-13H,14H2,(H,22,23,24)
DMESVWC CS C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CC=NC=C4
DMESVWC IK NZWWYUMFUATSTK-UHFFFAOYSA-N
DMESVWC IU N-benzyl-2-pyridin-4-ylquinazolin-4-amine
DMESVWC DE Discovery agent
DMH318X ID DMH318X
DMH318X DN Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine
DMH318X HS Investigative
DMH318X SN CHEMBL117108; Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine; MLS000334673; SCHEMBL7287132; AC1MA981; HMS3383C08; HMS2596E12; BDBM50033291; MCULE-3637836664; NCGC00184968-01; SMR000249431
DMH318X DT Small molecular drug
DMH318X PC 2573787
DMH318X MW 317.4
DMH318X FM C19H15N3S
DMH318X IC InChI=1S/C19H15N3S/c1-2-7-14(8-3-1)13-20-18-15-9-4-5-10-16(15)21-19(22-18)17-11-6-12-23-17/h1-12H,13H2,(H,20,21,22)
DMH318X CS C1=CC=C(C=C1)CNC2=NC(=NC3=CC=CC=C32)C4=CC=CS4
DMH318X IK XITKIGBKTNSGCP-UHFFFAOYSA-N
DMH318X IU N-benzyl-2-thiophen-2-ylquinazolin-4-amine
DMH318X DE Discovery agent
DMFTIMS ID DMFTIMS
DMFTIMS DN Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine
DMFTIMS HS Investigative
DMFTIMS SN CHEMBL65850; Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine; ZINC3834030
DMFTIMS DT Small molecular drug
DMFTIMS PC 10424517
DMFTIMS MW 294.3
DMFTIMS FM C18H18N2O2
DMFTIMS IC InChI=1S/C18H18N2O2/c1-21-17-9-14-8-15(12-20-16(14)10-18(17)22-2)19-11-13-6-4-3-5-7-13/h3-10,12,19H,11H2,1-2H3
DMFTIMS CS COC1=CC2=CC(=CN=C2C=C1OC)NCC3=CC=CC=C3
DMFTIMS IK JDKRDQWKIJSKHE-UHFFFAOYSA-N
DMFTIMS IU N-benzyl-6,7-dimethoxyquinolin-3-amine
DMFTIMS DE Discovery agent
DMW167A ID DMW167A
DMW167A DN Benzyl-(9H-beta-carbolin-6-yl)-amine
DMW167A HS Investigative
DMW167A SN N-benzyl-9H-pyrido[3,4-b]indol-6-amine; NSC629813; AC1Q4YVW; AC1L7O8V; CHEMBL54968; ZINC13223121; Benzyl-(9H-; A-carbolin-6-yl)-amine; NCI60_009694; N-Benzyl-9H-beta-carbolin-6-amine hydrochloride
DMW167A DT Small molecular drug
DMW167A PC 364142
DMW167A MW 273.3
DMW167A FM C18H15N3
DMW167A IC InChI=1S/C18H15N3/c1-2-4-13(5-3-1)11-20-14-6-7-17-16(10-14)15-8-9-19-12-18(15)21-17/h1-10,12,20-21H,11H2
DMW167A CS C1=CC=C(C=C1)CNC2=CC3=C(C=C2)NC4=C3C=CN=C4
DMW167A IK QLFFRGDGVGTTAT-UHFFFAOYSA-N
DMW167A IU N-benzyl-9H-pyrido[3,4-b]indol-6-amine
DMW167A DE Discovery agent
DMNE1M3 ID DMNE1M3
DMNE1M3 DN Benzyl-(9-isopropyl-9H-purin-6-yl)-amine
DMNE1M3 HS Investigative
DMNE1M3 SN CHEMBL85015; 111853-20-4; 9H-Purin-6-amine, 9-(1-methylethyl)-N-(phenylmethyl)-; purine deriv. 9; ACMC-20mewm; SCHEMBL754120; BDBM10641; CTK0D3360; DTXSID10444118; 6-(benzylamino)-9-isopropylpurine; ZINC13538226; AKOS030562149; 6-(Benzylamino)-9-isopropyl-9H-purine; N-benzyl-9-isopropyl-9H-purin-6-amine
DMNE1M3 DT Small molecular drug
DMNE1M3 PC 10730551
DMNE1M3 MW 267.33
DMNE1M3 FM C15H17N5
DMNE1M3 IC InChI=1S/C15H17N5/c1-11(2)20-10-19-13-14(17-9-18-15(13)20)16-8-12-6-4-3-5-7-12/h3-7,9-11H,8H2,1-2H3,(H,16,17,18)
DMNE1M3 CS CC(C)N1C=NC2=C(N=CN=C21)NCC3=CC=CC=C3
DMNE1M3 IK JBLZWJCKPDQCNX-UHFFFAOYSA-N
DMNE1M3 IU N-benzyl-9-propan-2-ylpurin-6-amine
DMNE1M3 CA CAS 111853-20-4
DMNE1M3 DE Discovery agent
DMTC4G0 ID DMTC4G0
DMTC4G0 DN Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine
DMTC4G0 HS Investigative
DMTC4G0 SN CHEMBL87137; Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine; SCHEMBL8612003; BDBM50081109
DMTC4G0 DT Small molecular drug
DMTC4G0 PC 9816808
DMTC4G0 MW 267.33
DMTC4G0 FM C16H17N3O
DMTC4G0 IC InChI=1S/C16H17N3O/c1-2-5-13(6-3-1)11-17-9-10-20-16-8-4-7-15-14(16)12-18-19-15/h1-8,12,17H,9-11H2,(H,18,19)
DMTC4G0 CS C1=CC=C(C=C1)CNCCOC2=CC=CC3=C2C=NN3
DMTC4G0 IK WYGBVOBBNUHWLX-UHFFFAOYSA-N
DMTC4G0 IU N-benzyl-2-(1H-indazol-4-yloxy)ethanamine
DMTC4G0 DE Discovery agent
DMV6DY7 ID DMV6DY7
DMV6DY7 DN Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine
DMV6DY7 HS Investigative
DMV6DY7 SN CHEMBL64283; Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine; SCHEMBL7206828; ZINC1903142; BDBM50077576
DMV6DY7 DT Small molecular drug
DMV6DY7 PC 9838216
DMV6DY7 MW 266.34
DMV6DY7 FM C17H18N2O
DMV6DY7 IC InChI=1S/C17H18N2O/c1-2-5-14(6-3-1)13-18-11-12-20-17-8-4-7-16-15(17)9-10-19-16/h1-10,18-19H,11-13H2
DMV6DY7 CS C1=CC=C(C=C1)CNCCOC2=CC=CC3=C2C=CN3
DMV6DY7 IK ZEHDEZWEFBOGNZ-UHFFFAOYSA-N
DMV6DY7 IU N-benzyl-2-(1H-indol-4-yloxy)ethanamine
DMV6DY7 DE Discovery agent
DMRM6ES ID DMRM6ES
DMRM6ES DN Benzylamine
DMRM6ES HS Investigative
DMRM6ES SN Aminotoluene; BENZYLAMINE; Benzenemethanamine; Monobenzylamine; Moringine; N-Benzylamine; Phenylmethylamine; Sumine 2005; Sumine 2006; TOLUENE,ALPHA-AMINO; benzyl amine; benzyl-amine; omega-Aminotoluene; phenylmethanamine; (Aminomethyl)benzene; (Phenylmethyl)amine; .alpha.-Aminotoluene; .omega.-Aminotoluene; 1-phenylmethanamine; 100-46-9; 1utj; 1utn; 2bza; A1O31ROR09; AI3-15299; BRN 0741984; CHEBI:40538; CHEMBL522; EINECS 202-854-1; HSDB 2795; MFCD00008106; NSC 8046; UNII-A1O31ROR09; a-Aminotoluene; alpha-Aminotoluene
DMRM6ES PC 7504
DMRM6ES MW 107.15
DMRM6ES FM C7H9N
DMRM6ES IC WGQKYBSKWIADBV-UHFFFAOYSA-N
DMRM6ES CS C1=CC=C(C=C1)CN
DMRM6ES IK 1S/C7H9N/c8-6-7-4-2-1-3-5-7/h1-5H,6,8H2
DMRM6ES IU phenylmethanamine
DMRM6ES CA CAS 100-46-9
DMRM6ES CB CHEBI:40538
DMRM6ES DE Functional nausea/vomiting
DMFB4M5 ID DMFB4M5
DMFB4M5 DN Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine
DMFB4M5 HS Investigative
DMFB4M5 SN CHEMBL490794; N-benzyl-N-[(4-phenylphenyl)methyl]imidazol-1-amine; Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine; AC1LA79Y; BDBM50263717; 1H-Imidazol-1-amine, N-([1,1'-biphenyl]-4-ylmethyl)-N-(phenylmethyl)-
DMFB4M5 DT Small molecular drug
DMFB4M5 PC 508445
DMFB4M5 MW 339.4
DMFB4M5 FM C23H21N3
DMFB4M5 IC InChI=1S/C23H21N3/c1-3-7-20(8-4-1)17-26(25-16-15-24-19-25)18-21-11-13-23(14-12-21)22-9-5-2-6-10-22/h1-16,19H,17-18H2
DMFB4M5 CS C1=CC=C(C=C1)CN(CC2=CC=C(C=C2)C3=CC=CC=C3)N4C=CN=C4
DMFB4M5 IK PHOWNTQCWGWFEX-UHFFFAOYSA-N
DMFB4M5 IU N-benzyl-N-[(4-phenylphenyl)methyl]imidazol-1-amine
DMFB4M5 DE Discovery agent
DM7M9O2 ID DM7M9O2
DM7M9O2 DN Benzylcarbamic Acid Biphenyl-3-yl Ester
DM7M9O2 HS Investigative
DM7M9O2 SN CHEMBL485689; Benzylcarbamic Acid Biphenyl-3-yl Ester
DM7M9O2 DT Small molecular drug
DM7M9O2 PC 24881737
DM7M9O2 MW 303.4
DM7M9O2 FM C20H17NO2
DM7M9O2 IC InChI=1S/C20H17NO2/c22-20(21-15-16-8-3-1-4-9-16)23-19-13-7-12-18(14-19)17-10-5-2-6-11-17/h1-14H,15H2,(H,21,22)
DM7M9O2 CS C1=CC=C(C=C1)CNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM7M9O2 IK OSVRGOZPWLNARR-UHFFFAOYSA-N
DM7M9O2 IU (3-phenylphenyl) N-benzylcarbamate
DM7M9O2 DE Discovery agent
DMTCYHM ID DMTCYHM
DMTCYHM DN Benzylcysteine
DMTCYHM HS Investigative
DMTCYHM SN S-Benzyl-L-cysteine; 3054/1/1; H-Cys(Bzl)-OH; Poly-S-benzylcysteine; (R)-S-Benzylcysteine; (R)-2-amino-3-(benzylthio)propanoic acid; (S)-Benzyl-L-Cys; cysteine, s-(phenylmethyl)-; CHEMBL63130; UNII-9VRE13M548; GHBAYRBVXCRIHT-VIFPVBQESA-N; 9VRE13M548; MFCD00002613; NSC 523123; 25988-62-9; (2R)-2-amino-3-benzylsulfanyl-propanoic acid; B-1025; J-300089; D-S-butylcysteine; BCS; (2R)-2-amino-3-(phenylmethylthio)propanoic acid
DMTCYHM DT Small molecular drug
DMTCYHM PC 193613
DMTCYHM MW 211.28
DMTCYHM FM C10H13NO2S
DMTCYHM IC InChI=1S/C10H13NO2S/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1
DMTCYHM CS C1=CC=C(C=C1)CSC[C@@H](C(=O)O)N
DMTCYHM IK GHBAYRBVXCRIHT-VIFPVBQESA-N
DMTCYHM IU (2R)-2-amino-3-benzylsulfanylpropanoic acid
DMTCYHM CA CAS 3054-01-1
DMTCYHM DE Discovery agent
DMNRHSO ID DMNRHSO
DMNRHSO DN BENZYLIMIDAZOLE
DMNRHSO HS Investigative
DMNRHSO SN 1-Benzylimidazole; 1-Benzyl-1H-imidazole; 4238-71-5; N-Benzylimidazole; Imidazole, 1-benzyl-; BENZYLIMIDAZOLE; 1H-Imidazole, 1-(phenylmethyl)-; 1-BENZYL IMIDAZOLE; CCRIS 5821; EINECS 224-200-4; 1-Benzylimidazole, 99%; NSC 217337; NSC 126828; CHEMBL14192; AI3-52572; MLS000069473; KKKDZZRICRFGSD-UHFFFAOYSA-N; MFCD00005296; SMR000059044; 1BN; 1-benzylimdazole; 2afx; 1-benzyl-imidazole; 3pb9; 1-Benzylimidazole (BI); Maybridge3_003880; Opera_ID_1637; SCHEMBL414; ACMC-209jp9; AC1Q28WR; AC1L2U3N; AC1Q4X5Z; AC1Q28WS; KSC492M7H; MLS001424205
DMNRHSO DT Small molecular drug
DMNRHSO PC 77918
DMNRHSO MW 158.2
DMNRHSO FM C10H10N2
DMNRHSO IC InChI=1S/C10H10N2/c1-2-4-10(5-3-1)8-12-7-6-11-9-12/h1-7,9H,8H2
DMNRHSO CS C1=CC=C(C=C1)CN2C=CN=C2
DMNRHSO IK KKKDZZRICRFGSD-UHFFFAOYSA-N
DMNRHSO IU 1-benzylimidazole
DMNRHSO CA CAS 4238-71-5
DMNRHSO DE Discovery agent
DMQAEOL ID DMQAEOL
DMQAEOL DN Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine
DMQAEOL HS Investigative
DMQAEOL SN CHEMBL171809; Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine
DMQAEOL DT Small molecular drug
DMQAEOL PC 44384137
DMQAEOL MW 212.29
DMQAEOL FM C14H16N2
DMQAEOL IC InChI=1S/C14H16N2/c1-12(14-9-6-10-15-14)16(2)11-13-7-4-3-5-8-13/h3-10,15H,1,11H2,2H3
DMQAEOL CS CN(CC1=CC=CC=C1)C(=C)C2=CC=CN2
DMQAEOL IK UBPBOEOYYZRWQS-UHFFFAOYSA-N
DMQAEOL IU N-benzyl-N-methyl-1-(1H-pyrrol-2-yl)ethenamine
DMQAEOL DE Discovery agent
DMLJMOD ID DMLJMOD
DMLJMOD DN Benzyloxycarbonyl-glycylryanodine
DMLJMOD HS Investigative
DMLJMOD SN Benzyloxycarbonyl-glycylryanodine; CHEMBL28383
DMLJMOD DT Small molecular drug
DMLJMOD PC 44275860
DMLJMOD MW 684.7
DMLJMOD FM C35H44N2O12
DMLJMOD IC InChI=1S/C35H44N2O12/c1-19(2)32(43)26(48-25(39)22-12-9-15-36-22)33(44)28(4)18-31(42)29(32,5)35(33,45)34(49-31)24(20(3)13-14-30(28,34)41)47-23(38)16-37-27(40)46-17-21-10-7-6-8-11-21/h6-12,15,19-20,24,26,36,41-45H,13-14,16-18H2,1-5H3,(H,37,40)/t20?,24-,26-,28+,29?,30?,31?,32?,33?,34?,35?/m1/s1
DMLJMOD CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CNC(=O)OCC6=CC=CC=C6)O4)O)O)OC(=O)C7=CC=CN7)(C(C)C)O)C)O)C)O
DMLJMOD IK ZJAWJJNLZWLOIL-JIVHGXQSSA-N
DMLJMOD IU [(2R,7S,12R)-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-2-[2-(phenylmethoxycarbonylamino)acetyl]oxy-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMLJMOD DE Discovery agent
DM26SR7 ID DM26SR7
DM26SR7 DN Benzyloxyresorufin
DM26SR7 HS Investigative
DM26SR7 SN Benzyloxyresorfin; 7-Benzyloxyresorufin; J-100240; MCULE-6922850124; O7-Benzylresorufin; Resorufin benzyl ether; SCHEMBL563335; STK299141; ZINC4534147; 3H-Phenoxazin-3-one, 7-(phenylmethoxy)-; 7-(Phenylmethoxy)-3H-phenoxazin-3-one; 7-(benzyloxy)-3H-phenoxazin-3-one; 7-Benzoxyresorufin; 7-Benzyloxy-3H-phenoxazin-3-one; 87687-02-3; AKOS005429005; CTK8D9518; DTXSID90236553; FT-0642066; MFCD00171613; Resorufin benzyl ether CYP450 substrate; Resorufin benzyl ether, CYP450 substrate
DM26SR7 PC 114982
DM26SR7 MW 303.3
DM26SR7 FM C19H13NO3
DM26SR7 IC XNZRYTITWLGTJS-UHFFFAOYSA-N
DM26SR7 CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)N=C4C=CC(=O)C=C4O3
DM26SR7 IK 1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2
DM26SR7 IU 7-phenylmethoxyphenoxazin-3-one
DM26SR7 CA CAS 87687-02-3
DM26SR7 DE Discovery agent
DMRW5J4 ID DMRW5J4
DMRW5J4 DN Benzyl-quinazolin-4-yl-amine
DMRW5J4 HS Investigative
DMRW5J4 SN N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; Benzyl-quinazolin-4-yl-amine; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine
DMRW5J4 DT Small molecular drug
DMRW5J4 PC 6603129
DMRW5J4 MW 271.74
DMRW5J4 FM C15H14ClN3
DMRW5J4 IC InChI=1S/C15H13N3.ClH/c1-2-6-12(7-3-1)10-16-15-13-8-4-5-9-14(13)17-11-18-15;/h1-9,11H,10H2,(H,16,17,18);1H
DMRW5J4 CS C1=CC=C(C=C1)CNC2=NC=NC3=CC=CC=C32.Cl
DMRW5J4 IK DIKWZEPKULLMFX-UHFFFAOYSA-N
DMRW5J4 IU N-benzylquinazolin-4-amine;hydrochloride
DMRW5J4 DE Discovery agent
DMHIGDM ID DMHIGDM
DMHIGDM DN Benzylserine
DMHIGDM HS Investigative
DMHIGDM SN O-benzyl-L-serine
DMHIGDM DT Small molecular drug
DMHIGDM PC 78457
DMHIGDM MW 195.21
DMHIGDM FM C10H13NO3
DMHIGDM IC InChI=1S/C10H13NO3/c11-9(10(12)13)7-14-6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1
DMHIGDM CS C1=CC=C(C=C1)COC[C@@H](C(=O)O)N
DMHIGDM IK IDGQXGPQOGUGIX-VIFPVBQESA-N
DMHIGDM IU (2S)-2-amino-3-phenylmethoxypropanoic acid
DMHIGDM CA CAS 4726-96-9
DMHIGDM DE Discovery agent
DM7XK28 ID DM7XK28
DM7XK28 DN Benzylsulfinic Acid
DM7XK28 HS Investigative
DM7XK28 SN phenylmethanesulfinic acid; 4403-73-0; Benzenemethanesulfinic acid; Benzylfulfinic acid; AC1MNXPH; SCHEMBL50116; SCHEMBL14899852; MolPort-006-168-965; ZINC12503424
DM7XK28 DT Small molecular drug
DM7XK28 PC 3311411
DM7XK28 MW 156.2
DM7XK28 FM C7H8O2S
DM7XK28 IC InChI=1S/C7H8O2S/c8-10(9)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,8,9)
DM7XK28 CS C1=CC=C(C=C1)CS(=O)O
DM7XK28 IK NVSONFIVLCXXDH-UHFFFAOYSA-N
DM7XK28 IU phenylmethanesulfinic acid
DM7XK28 DE Discovery agent
DMDITNB ID DMDITNB
DMDITNB DN BERGAPTOL
DMDITNB HS Investigative
DMDITNB SN Bergaptol; 486-60-2; 5-Hydroxypsoralen; 4-Hydroxy-7H-furo[3,2-g]chromen-7-one; 5-Hydroxyfuranocoumarin; Psoralin, 5-hydroxy-; UNII-KTC8ANI30F; 4-Hydroxybergapten; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-hydroxy-; NSC341958; KTC8ANI30F; 4-oxidanylfuro[3,2-g]chromen-7-one; NSC 341958; 5-Hydroxy-6,7-furanocoumarin; CHEMBL242711; CHEBI:17377; GIJHDGJRTUSBJR-UHFFFAOYSA-N; 4-hydroxyfuro[3,2-g]chromen-7-one; AK158894; Bergaptols; 5-Hydroxy-Psoralen; 5-Hydroxyfurocoumarin; AC1NQWYH; 5-HYDROXY-PSORALIN; 7H-Furo[3, 4-hydroxy-; BSPBio_002390
DMDITNB DT Small molecular drug
DMDITNB PC 5280371
DMDITNB MW 202.16
DMDITNB FM C11H6O4
DMDITNB IC InChI=1S/C11H6O4/c12-10-2-1-6-9(15-10)5-8-7(11(6)13)3-4-14-8/h1-5,13H
DMDITNB CS C1=CC(=O)OC2=CC3=C(C=CO3)C(=C21)O
DMDITNB IK GIJHDGJRTUSBJR-UHFFFAOYSA-N
DMDITNB IU 4-hydroxyfuro[3,2-g]chromen-7-one
DMDITNB CA CAS 486-60-2
DMDITNB CB CHEBI:17377
DMDITNB DE Discovery agent
DMP21ZO ID DMP21ZO
DMP21ZO DN Beta-(2-Naphthyl)-Alanine
DMP21ZO HS Investigative
DMP21ZO SN 58438-03-2; 3-(2-Naphthyl)-L-alanine; H-2-Nal-OH; (S)-2-Amino-3-(naphthalen-2-yl)propanoic acid; l-2-naphthylalanine; BETA-(2-NAPHTHYL)-ALANINE; UNII-W425Q6KV9R; L-3-(2-Naphthyl)-alanine; (2S)-2-amino-3-(2-naphthyl)propanoic acid; (s)-2-amino-3-naphthalen-2-yl-propionic acid; W425Q6KV9R; NAL; (2S)-2-amino-3-naphthalen-2-ylpropanoic acid; (2S)-2-amino-3-(naphthalen-2-yl)propanoic acid; 3-(2-Naphthyl)-L-alanine, 98%; 3-(2-Naphthyl)alanine; beta-2-naphthyl-l-alanine; L-beta-(2-Naphthyl)alanine; L-3-(2-NAPHTHYL)ALANINE
DMP21ZO DT Small molecular drug
DMP21ZO PC 185915
DMP21ZO MW 215.25
DMP21ZO FM C13H13NO2
DMP21ZO IC InChI=1S/C13H13NO2/c14-12(13(15)16)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7,12H,8,14H2,(H,15,16)/t12-/m0/s1
DMP21ZO CS C1=CC=C2C=C(C=CC2=C1)C[C@@H](C(=O)O)N
DMP21ZO IK JPZXHKDZASGCLU-LBPRGKRZSA-N
DMP21ZO IU (2S)-2-amino-3-naphthalen-2-ylpropanoic acid
DMP21ZO CA CAS 58438-03-2
DMP21ZO DE Discovery agent
DM6FHQD ID DM6FHQD
DM6FHQD DN Beta,beta-dimethylmelatonin
DM6FHQD HS Investigative
DM6FHQD SN CHEMBL206472; beta,beta-dimethylmelatonin; BDBM50188423
DM6FHQD DT Small molecular drug
DM6FHQD PC 11536239
DM6FHQD MW 260.329
DM6FHQD FM C15H20N2O2
DM6FHQD IC InChI=1S/C15H20N2O2/c1-10(18)17-9-15(2,3)13-8-16-14-6-5-11(19-4)7-12(13)14/h5-8,16H,9H2,1-4H3,(H,17,18)
DM6FHQD CS CC(=O)NCC(C)(C)C1=CNC2=C1C=C(C=C2)OC
DM6FHQD IK OMYMGFDKAPBSGB-UHFFFAOYSA-N
DM6FHQD IU N-[2-(5-methoxy-1H-indol-3-yl)-2-methylpropyl]acetamide
DM6FHQD DE Discovery agent
DM6GTBC ID DM6GTBC
DM6GTBC DN Beta-1-C-butenyl-1-deoxygalactonojirimycin
DM6GTBC HS Investigative
DM6GTBC SN CHEMBL1163562; beta-1-C-butenyl-1-deoxygalactonojirimycin
DM6GTBC DT Small molecular drug
DM6GTBC PC 46906931
DM6GTBC MW 215.29
DM6GTBC FM C11H21NO3
DM6GTBC IC InChI=1S/C11H21NO3/c1-3-4-5-8-7(2)10(14)11(15)9(6-13)12-8/h3,7-15H,1,4-6H2,2H3/t7-,8-,9+,10+,11-/m0/s1
DM6GTBC CS C[C@H]1[C@@H](N[C@@H]([C@@H]([C@@H]1O)O)CO)CCC=C
DM6GTBC IK DJRPURFURDDUBK-DAWVFNFOSA-N
DM6GTBC IU (2R,3S,4R,5S,6S)-6-but-3-enyl-2-(hydroxymethyl)-5-methylpiperidine-3,4-diol
DM6GTBC DE Discovery agent
DMMKDEZ ID DMMKDEZ
DMMKDEZ DN Beta-1-C-Butyl-1-deoxygalactonojirimycin
DMMKDEZ HS Investigative
DMMKDEZ SN CHEMBL1163255; beta-1-C-Butyl-1-deoxygalactonojirimycin
DMMKDEZ DT Small molecular drug
DMMKDEZ PC 46906930
DMMKDEZ MW 217.31
DMMKDEZ FM C11H23NO3
DMMKDEZ IC InChI=1S/C11H23NO3/c1-3-4-5-8-7(2)10(14)11(15)9(6-13)12-8/h7-15H,3-6H2,1-2H3/t7-,8-,9+,10+,11-/m0/s1
DMMKDEZ CS CCCC[C@H]1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)C
DMMKDEZ IK CAVTXTZKYKUABF-DAWVFNFOSA-N
DMMKDEZ IU (2R,3S,4R,5S,6S)-6-butyl-2-(hydroxymethyl)-5-methylpiperidine-3,4-diol
DMMKDEZ DE Discovery agent
DMBAN5P ID DMBAN5P
DMBAN5P DN beta3-tetrapeptide
DMBAN5P HS Investigative
DMBAN5P SN beta3-tetrapeptide
DMBAN5P DT Small molecular drug
DMBAN5P PC 73755026
DMBAN5P MW 662.8
DMBAN5P FM C35H46N6O7
DMBAN5P IC InChI=1S/C35H46N6O7/c1-21-30(19-34(46)48-21)40-32(44)17-25(9-5-6-13-36)39-35(47)31(16-24-20-37-29-12-4-3-11-28(24)29)41-33(45)18-26(38-22(2)42)14-23-8-7-10-27(43)15-23/h3-4,7-8,10-12,15,20-21,25-26,30-31,37,43H,5-6,9,13-14,16-19,36H2,1-2H3,(H,38,42)(H,39,47)(H,40,44)(H,41,45)/t21-,25+,26+,30-,31?/m1/s1
DMBAN5P CS C[C@@H]1[C@@H](CC(=O)O1)NC(=O)C[C@H](CCCCN)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C[C@H](CC4=CC(=CC=C4)O)NC(=O)C
DMBAN5P IK GQYXVIIYXPRQJK-JZYDGZRSSA-N
DMBAN5P IU (3S)-3-[[2-[[(3S)-3-acetamido-4-(3-hydroxyphenyl)butanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-7-amino-N-[(2R,3R)-2-methyl-5-oxooxolan-3-yl]heptanamide
DMBAN5P DE Discovery agent
DMC64EI ID DMC64EI
DMC64EI DN Beta-alanine
DMC64EI HS Investigative
DMC64EI SN beta-alanine; 107-95-9; 3-Aminopropanoic acid; 3-Aminopropionic acid; Beta Alanine; Abufene; H-beta-Ala-OH; beta-Aminopropionic acid; 2-Carboxyethylamine; .beta.-Alanine; Propanoic acid, 3-amino-; Alanine, beta-; 3-Aminopropionsaeure; beta-Ala; beta-Aminopropionsaeure; 3-Aminopropanoate; omega-Aminopropionic acid; B-ALANINE; FEMA No. 3252; 3-amino-propionic acid; beta-Alaine; AI3-18470; .beta.-Aminopropionic acid; NSC 7603; UNII-11P2JDE17B; beta-Alanine, 99%; EINECS 203-536-5; MFCD00008200; 11P2JDE17B; CHEMBL297569; CHEBI:16958; NSC7603
DMC64EI DT Small molecular drug
DMC64EI PC 239
DMC64EI MW 89.09
DMC64EI FM C3H7NO2
DMC64EI IC InChI=1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)
DMC64EI CS C(CN)C(=O)O
DMC64EI IK UCMIRNVEIXFBKS-UHFFFAOYSA-N
DMC64EI IU 3-aminopropanoic acid
DMC64EI CA CAS 107-95-9
DMC64EI CB CHEBI:16958
DMC64EI DE Discovery agent
DMN7DJ5 ID DMN7DJ5
DMN7DJ5 DN BetaARKct
DMN7DJ5 HS Investigative
DMN7DJ5 DE Discovery agent
DM9LT60 ID DM9LT60
DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester
DM9LT60 HS Investigative
DM9LT60 DT Small molecular drug
DM9LT60 PC 124514
DM9LT60 MW 268.31
DM9LT60 FM C16H16N2O2
DM9LT60 IC InChI=1S/C16H16N2O2/c1-16(2,3)20-15(19)13-8-11-10-6-4-5-7-12(10)18-14(11)9-17-13/h4-9,18H,1-3H3
DM9LT60 CS CC(C)(C)OC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DM9LT60 IK FVFFDKKTXYVCCW-UHFFFAOYSA-N
DM9LT60 IU tert-butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM9LT60 CA CAS 93835-05-3
DM1MFTZ ID DM1MFTZ
DM1MFTZ DN BETA-CCM
DM1MFTZ HS Investigative
DM1MFTZ SN beta-CCM; Methyl beta-carboline-3-carboxylate; beta-Carboline-3-carboxylic acid methyl ester; 69954-48-9; 3-Carbomethoxy-beta-carboline; UNII-I2A008F6YL; methyl 9H-pyrido[3,4-b]indole-3-carboxylate; CHEMBL453066; CHEMBL268191; I2A008F6YL; Methyl 9H-Pyrido(3,4-b)indole-3-carboxylate; methyl 9H-beta-carboline-3-carboxylate; 9H-beta-Carboline-3-carboxylic acid methyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, methyl ester; C13H10N2O2; Beta CCM; Lopac-E-002; Biomol-NT_000273; AC1L32LA; Lopac0_000523; SCHEMBL1066725
DM1MFTZ DT Small molecular drug
DM1MFTZ PC 107704
DM1MFTZ MW 226.23
DM1MFTZ FM C13H10N2O2
DM1MFTZ IC InChI=1S/C13H10N2O2/c1-17-13(16)11-6-9-8-4-2-3-5-10(8)15-12(9)7-14-11/h2-7,15H,1H3
DM1MFTZ CS COC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DM1MFTZ IK UKHFPVCOXBJPIN-UHFFFAOYSA-N
DM1MFTZ IU methyl 9H-pyrido[3,4-b]indole-3-carboxylate
DM1MFTZ CA CAS 69954-48-9
DM1MFTZ CB CHEBI:92505
DM1MFTZ DE Discovery agent
DMZ2BR9 ID DMZ2BR9
DMZ2BR9 DN Beta-D-Glucopyranose Spirohydantoin
DMZ2BR9 HS Investigative
DMZ2BR9 SN BETA-D-GLUCOPYRANOSE SPIROHYDANTOIN; CHEMBL510975; GLS; (5S,7R,8S,9S,10R)-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione; 1a8i; AC1L9FVJ; BDBM50263768; 1beta,1-(Iminocarbonyliminocarbonyl)-1-deoxy-D-glucopyranose; (5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione
DMZ2BR9 DT Small molecular drug
DMZ2BR9 PC 444185
DMZ2BR9 MW 248.19
DMZ2BR9 FM C8H12N2O7
DMZ2BR9 IC InChI=1S/C8H12N2O7/c11-1-2-3(12)4(13)5(14)8(17-2)6(15)9-7(16)10-8/h2-5,11-14H,1H2,(H2,9,10,15,16)/t2-,3-,4+,5-,8+/m1/s1
DMZ2BR9 CS C([C@@H]1[C@H]([C@@H]([C@H]([C@]2(O1)C(=O)NC(=O)N2)O)O)O)O
DMZ2BR9 IK QRXBDPYWCAAAAI-WWHASAIZSA-N
DMZ2BR9 IU (5S,7R,8S,9S,10R)-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione
DMZ2BR9 DE Discovery agent
DM5IHYP ID DM5IHYP
DM5IHYP DN Beta-D-Glucose
DM5IHYP HS Investigative
DM5IHYP SN beta-D-glucose; beta-D-glucopyranose; 492-61-5; glucoside; b-D-Glucopyranose; beta-glucose; beta-Dextrose; b-Glucose; b-d-glucose; UNII-J4R00M814D; 28905-12-6; .beta.-D-Glucopyranose; 9001-37-0; (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; CHEMBL1614854; CHEBI:15903; WQZGKKKJIJFFOK-VFUOTHLCSA-N; J4R00M814D; Curdlan; (2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; .beta.-D-Glucose; BGC; ZYMOSAN; Glucose, (beta-D)-Isomer; Callose; b-Dextrose; beta-D-Glucopyranose, anhydrous
DM5IHYP DT Small molecular drug
DM5IHYP PC 64689
DM5IHYP MW 180.16
DM5IHYP FM C6H12O6
DM5IHYP IC InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6-/m1/s1
DM5IHYP CS C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)O)O)O)O
DM5IHYP IK WQZGKKKJIJFFOK-VFUOTHLCSA-N
DM5IHYP IU (2R,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DM5IHYP CA CAS 492-61-5
DM5IHYP CB CHEBI:15903
DM5IHYP DE Discovery agent
DMNE4C6 ID DMNE4C6
DMNE4C6 DN beta-D-hydroxybutyric acid
DMNE4C6 HS Investigative
DMNE4C6 SN 3-hydroxybutyrate; (R)-3-hydroxybutanoate
DMNE4C6 DT Small molecular drug
DMNE4C6 PC 92135
DMNE4C6 MW 104.1
DMNE4C6 FM C4H8O3
DMNE4C6 IC InChI=1S/C4H8O3/c1-3(5)2-4(6)7/h3,5H,2H2,1H3,(H,6,7)/t3-/m1/s1
DMNE4C6 CS C[C@H](CC(=O)O)O
DMNE4C6 IK WHBMMWSBFZVSSR-GSVOUGTGSA-N
DMNE4C6 IU (3R)-3-hydroxybutanoic acid
DMNE4C6 CA CAS 625-72-9
DMNE4C6 CB CHEBI:17066
DMNE4C6 DE Discovery agent
DMHIG9K ID DMHIG9K
DMHIG9K DN Beta-D-Mannose
DMHIG9K HS Investigative
DMHIG9K SN beta-D-Mannopyranose; beta-D-Mannose; beta-Mannose; 7322-31-8; UNII-CUO87O37MT; (2R,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; CUO87O37MT; CHEBI:28563; beta-1,4-Mannan; Epitope ID:137485; (1-> 2)-beta-D-mannan; 4)-beta-D-mannan; AC1L97TQ; SCHEMBL396651; 2)-beta-D-mannopyranan; CHEBI:80962; CHEBI:59573; CHEBI:27857; [2)-beta-D-Manp-(1-> WQZGKKKJIJFFOK-RWOPYEJCSA-N; ZINC3830679; GUP; NE16895; C02209; WURCS=2.0/1,1,0/[a1122h-1b_1-5]/1/; (2RS,3S,4S,5S,6R)-6-(Hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol
DMHIG9K DT Small molecular drug
DMHIG9K PC 439680
DMHIG9K MW 180.16
DMHIG9K FM C6H12O6
DMHIG9K IC InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6-/m1/s1
DMHIG9K CS C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)O)O)O)O
DMHIG9K IK WQZGKKKJIJFFOK-RWOPYEJCSA-N
DMHIG9K IU (2R,3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMHIG9K CA CAS 7322-31-8
DMHIG9K CB CHEBI:28563
DMHIG9K DE Discovery agent
DM7XC6B ID DM7XC6B
DM7XC6B DN Beta-endorphin
DM7XC6B HS Investigative
DM7XC6B SN UNII-3S51P4W3XQ; 3S51P4W3XQ; 61214-51-5; LPH (61-91); beta-Endorphin, human; SCHEMBL6238339; CHEMBL1866903; EINECS 262-330-3; beta-Endorphin human, > NCGC00163196-01; NCGC00163196-02; 27-L-Tyrosine-31-L-glutamic acid-beta-endorphin (sheep); beta-Endorphin (sheep), 27-L-tyrosine-31-L-glutamic acid-
DM7XC6B DT Small molecular drug
DM7XC6B PC 16132316
DM7XC6B MW 3465
DM7XC6B FM C158H251N39O46S
DM7XC6B IC InChI=1S/C158H251N39O46S/c1-17-84(9)126(153(237)182-102(44-29-34-65-163)137(221)186-112(74-118(166)206)142(226)171-86(11)131(215)183-110(73-94-48-52-96(204)53-49-94)146(230)177-99(41-26-31-62-160)135(219)175-98(40-25-30-61-159)134(218)170-78-122(210)173-106(158(242)243)56-59-124(213)214)193-154(238)127(85(10)18-2)192-132(216)87(12)172-143(227)113(75-119(167)207)185-136(220)100(42-27-32-63-161)178-147(231)111(72-92-38-23-20-24-39-92)184-144(228)107(68-81(3)4)188-155(239)129(89(14)201)195-152(236)125(83(7)8)191-148(232)108(69-82(5)6)187-151(235)116-45-35-66-197(116)157(241)130(90(15)202)196-140(224)103(54-57-117(165)205)179-149(233)114(79-198)189-138(222)101(43-28-33-64-162)176-139(223)104(55-58-123(211)212)180-150(234)115(80-199)190-156(240)128(88(13)200)194-141(225)105(60-67-244-16)181-145(229)109(71-91-36-21-19-22-37-91)174-121(209)77-168-120(208)76-169-133(217)97(164)70-93-46-50-95(203)51-47-93/h19-24,36-39,46-53,81-90,97-116,125-130,198-204H,17-18,25-35,40-45,54-80,159-164H2,1-16H3,(H2,165,205)(H2,166,206)(H2,167,207)(H,168,208)(H,169,217)(H,170,218)(H,171,226)(H,172,227)(H,173,210)(H,174,209)(H,175,219)(H,176,223)(H,177,230)(H,178,231)(H,179,233)(H,180,234)(H,181,229)(H,182,237)(H,183,215)(H,184,228)(H,185,220)(H,186,221)(H,187,235)(H,188,239)(H,189,222)(H,190,240)(H,191,232)(H,192,216)(H,193,238)(H,194,225)(H,195,236)(H,196,224)(H,211,212)(H,213,214)(H,242,243)/t84-,85-,86-,87-,88+,89+,90+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,125-,126-,127-,128-,129-,130-/m0/s1
DM7XC6B CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)CNC(=O)[C@H](CC5=CC=C(C=C5)O)N
DM7XC6B IK JMHFFDIMOUKDCZ-NTXHZHDSSA-N
DM7XC6B IU (2S)-2-[[2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]hexanoyl]amino]acetyl]amino]pentanedioic acid
DM7XC6B CA CAS 60617-12-1
DM7XC6B DE Discovery agent
DMU3YXR ID DMU3YXR
DMU3YXR DN beta-ergocriptine
DMU3YXR HS Investigative
DMU3YXR SN beta-Ergocryptine; beta-Ergokryptine; EINECS 243-728-6; beta-ergocriptine; 5'alpha(S)-sec-Butyl-12'-hydroxy-2'-isopropylergotaman-3',6',18-trione; AC1L4P6P; GTPL988; YYWXOXLDOMRDHW-SGVWFJRMSA-N; PDSP2_001492; AKOS027307800; LS-64294
DMU3YXR DT Small molecular drug
DMU3YXR PC 161309
DMU3YXR MW 575.7
DMU3YXR FM C32H41N5O5
DMU3YXR IC InChI=1S/C32H41N5O5/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20/h7,9-10,13,15,17-18,20,24-25,27,33,41H,6,8,11-12,14,16H2,1-5H3,(H,34,38)/t18-,20+,24+,25-,27+,31+,32-/m0/s1
DMU3YXR CS CC[C@H](C)[C@@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
DMU3YXR IK YYWXOXLDOMRDHW-SGVWFJRMSA-N
DMU3YXR IU (6aR,9R)-N-[(1S,2S,4R,7R)-7-[(2S)-butan-2-yl]-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMU3YXR DE Discovery agent
DM25QXM ID DM25QXM
DM25QXM DN Beta-fructose phosphate
DM25QXM HS Investigative
DM25QXM SN Beta-D-Fructose 6-phosphate; SCHEMBL8056; ZINC4096690; 1mto; 6-O-phosphono-beta-D-fructofuranose; AC1L99OC; C05345; CHEBI:16084; CHEMBL604196; DTXSID90889361; F6P; WURCS=2.0/1,1,0/[ha122h-2b_2-5_6*OPO/3O/3=O]/1/; beta-D-Fructofuranose 6-phosphoric acid; beta-D-fructofuranose 6-(dihydrogen phosphate); {[(2R,3S,4S,5R)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methoxy}phosphonic acid
DM25QXM PC 440641
DM25QXM MW 260.14
DM25QXM FM C6H13O9P
DM25QXM IC BGWGXPAPYGQALX-ARQDHWQXSA-N
DM25QXM CS C(C1C(C(C(O1)(CO)O)O)O)OP(=O)(O)O
DM25QXM IK 1S/C6H13O9P/c7-2-6(10)5(9)4(8)3(15-6)1-14-16(11,12)13/h3-5,7-10H,1-2H2,(H2,11,12,13)/t3-,4-,5+,6-/m1/s1
DM25QXM IU [(2R,3S,4S,5R)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
DM25QXM CB CHEBI:16084
DM25QXM DE Discovery agent
DMJORFK ID DMJORFK
DMJORFK DN Beta-funaltrexamine
DMJORFK HS Investigative
DMJORFK SN beta-Funaltrexamine; beta-Fna; Naltrexone fumarate methyl ester; 72782-05-9; CHEMBL473136; CHEBI:81527; 2-Butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (E)-; Beta Funaltrexamine; Beta-Funeltrexamine; SCHEMBL1240811; GTPL1631; ZINC3995756; PDSP2_001549; PDSP2_000394; BDBM50247803; NCGC00163180-01; LS-47116; C18127; methyl 3-[4-cyclopropylmethyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ylcarbamoyl]-
DMJORFK DT Small molecular drug
DMJORFK PC 5311018
DMJORFK MW 454.5
DMJORFK FM C25H30N2O6
DMJORFK IC InChI=1S/C25H30N2O6/c1-32-20(30)7-6-19(29)26-16-8-9-25(31)18-12-15-4-5-17(28)22-21(15)24(25,23(16)33-22)10-11-27(18)13-14-2-3-14/h4-7,14,16,18,23,28,31H,2-3,8-13H2,1H3,(H,26,29)/b7-6+/t16-,18-,23+,24+,25-/m1/s1
DMJORFK CS COC(=O)/C=C/C(=O)N[C@@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O
DMJORFK IK PQKHESYTSKMWFP-WZJCLRDWSA-N
DMJORFK IU methyl (E)-4-[[(4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl]amino]-4-oxobut-2-enoate
DMJORFK CA CAS 72782-05-9
DMJORFK CB CHEBI:81527
DMJORFK DE Discovery agent
DMO8LPZ ID DMO8LPZ
DMO8LPZ DN Beta-Hydroxy Aspartic Acid
DMO8LPZ HS Investigative
DMO8LPZ SN 71653-06-0; 2-Amino-3-hydroxysuccinic Acid; Malic acid, 3-amino-; 2-amino-3-hydroxybutanedioic acid; d,l-threo-3-HYDROXYASPARTIC ACID; NSC618260; 1860-87-3; CHEBI:83981; 2-amino-3-hydroxy-butanedioic acid; 3-Hydroxy-DL-aspartic acid; Aspartic acid, 3-hydroxy-; D,L-Threo-b-hydroxyaspartic acid; DL-threo-3-Hydroxyaspartic acid; 3-aminomalic acid; EINECS 275-771-1
DMO8LPZ DT Small molecular drug
DMO8LPZ PC 5425
DMO8LPZ MW 149.1
DMO8LPZ FM C4H7NO5
DMO8LPZ IC InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)
DMO8LPZ CS C(C(C(=O)O)O)(C(=O)O)N
DMO8LPZ IK YYLQUHNPNCGKJQ-UHFFFAOYSA-N
DMO8LPZ IU 2-amino-3-hydroxybutanedioic acid
DMO8LPZ CA CAS 71653-06-0
DMO8LPZ CB CHEBI:83981
DMO8LPZ DE Discovery agent
DMGP9MN ID DMGP9MN
DMGP9MN DN BETA-HYDROXYETHYL THEOPHYLLINE
DMGP9MN HS Investigative
DMGP9MN SN Etofylline
DMGP9MN DT Small molecular drug
DMGP9MN PC 1892
DMGP9MN MW 224.22
DMGP9MN FM C9H12N4O3
DMGP9MN IC InChI=1S/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3
DMGP9MN CS CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCO
DMGP9MN IK NWPRCRWQMGIBOT-UHFFFAOYSA-N
DMGP9MN IU 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione
DMGP9MN CA CAS 519-37-9
DMGP9MN CB CHEBI:94764
DMGP9MN DE Discovery agent
DM6QV8A ID DM6QV8A
DM6QV8A DN Beta-ionone
DM6QV8A HS Investigative
DM6QV8A SN BETA-IONONE; beta-Cyclocitrylideneacetone; beta-E-Ionone; trans-beta-Ionone; (3E)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)but-3-en-2-one; (E)-4-(2,6,6-Trimethylcyclohex-1-en-1-yl)but-3-en-2-one; (E)-beta-Ionone; .beta.-Ionone; 14901-07-6; 3-Buten-2-one, 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (3E)-; 4-(2,6,6-Trimethyl-1-cyclohexen-1-yl)-3-buten-2-one; 4-(2,6,6-Trimethyl-1-cyclohexenyl)-3-buten-2-one; 4-(2,6,6-Trimethylcyclohex-1-en-1-yl)but-3-en-2-one; 79-77-6; NSC 402758; UNII-A7NRR1HLH6
DM6QV8A PC 638014
DM6QV8A MW 192.3
DM6QV8A FM C13H20O
DM6QV8A IC PSQYTAPXSHCGMF-BQYQJAHWSA-N
DM6QV8A CS CC1=C(C(CCC1)(C)C)C=CC(=O)C
DM6QV8A IK 1S/C13H20O/c1-10-6-5-9-13(3,4)12(10)8-7-11(2)14/h7-8H,5-6,9H2,1-4H3/b8-7+
DM6QV8A IU (E)-4-(2,6,6-trimethylcyclohexen-1-yl)but-3-en-2-one
DM6QV8A CA CAS 79-77-6
DM6QV8A CB CHEBI:32325
DM6QV8A DE Breast cancer
DM3BOQA ID DM3BOQA
DM3BOQA DN Beta-L-fucose
DM3BOQA HS Investigative
DM3BOQA SN BETA-L-FUCOSE; beta-L-fucopyranose; 6-deoxy-beta-L-galactopyranose; beta-L-Fuc; 6-DEOXY-BETA-L-GALACTOSE; UNII-3MLV1G4S4M; 3MLV1G4S4M; 13224-93-6; (2S,3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol; FUL; MFB; 1rdj; 1ofz; AC1L9H0R; SCHEMBL1259620; CHEBI:42589; beta-L-Galactopyranose, 6-deoxy-; ZINC1532813; AKOS024286278; DB03283; CJ-24261; ST092737; AJ-26816; C20836; A817260; WURCS=2.0/1,1,0/[a1221m-1b_1-5]/1/
DM3BOQA DT Small molecular drug
DM3BOQA PC 444863
DM3BOQA MW 164.16
DM3BOQA FM C6H12O5
DM3BOQA IC InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6-/m0/s1
DM3BOQA CS C[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)O)O)O)O
DM3BOQA IK SHZGCJCMOBCMKK-KGJVWPDLSA-N
DM3BOQA IU (2S,3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol
DM3BOQA CA CAS 13224-93-6
DM3BOQA CB CHEBI:42589
DM3BOQA DE Discovery agent
DMA9CSG ID DMA9CSG
DMA9CSG DN Beta-methoxyamphetamine
DMA9CSG HS Investigative
DMA9CSG SN 4-Methoxyamphetamine; p-Methoxyamphetamine; para-methoxyamphetamine; 1-(4-methoxyphenyl)propan-2-amine; 64-13-1; 1-p-Methoxyphenyl-2-propylamine; 1-p-Methoxyphenyl-2-aminopropane; paramethoxyamphetamine; beta-methoxyamphetamine; 1-(4-Methoxybenzyl)ethylamine; 2-Amino-1-(4'-methoxyphenyl)propane; p-Methoxy-alpha-methylphenethylamine; (+-)-p-Methoxyamphetamine; DEA No 7411; NSC 32757; 50505-80-1; 23239-32-9; DL-p-Methoxy-alpha-methylphenethylamine; (+-)-p-Methoxy-alpha-methylphenethylamine; Para-Methoxyamphetamine
DMA9CSG DT Small molecular drug
DMA9CSG PC 31721
DMA9CSG MW 165.23
DMA9CSG FM C10H15NO
DMA9CSG IC InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3
DMA9CSG CS CC(CC1=CC=C(C=C1)OC)N
DMA9CSG IK NEGYEDYHPHMHGK-UHFFFAOYSA-N
DMA9CSG IU 1-(4-methoxyphenyl)propan-2-amine
DMA9CSG CA CAS 64-13-1
DMA9CSG DE Discovery agent
DMKH32S ID DMKH32S
DMKH32S DN Beta-methylmelatonin
DMKH32S HS Investigative
DMKH32S SN beta-methylmelatonin; CHEMBL210147; SCHEMBL7055939
DMKH32S DT Small molecular drug
DMKH32S PC 11630146
DMKH32S MW 246.3
DMKH32S FM C14H18N2O2
DMKH32S IC InChI=1S/C14H18N2O2/c1-9(7-15-10(2)17)13-8-16-14-5-4-11(18-3)6-12(13)14/h4-6,8-9,16H,7H2,1-3H3,(H,15,17)
DMKH32S CS CC(CNC(=O)C)C1=CNC2=C1C=C(C=C2)OC
DMKH32S IK CKJPQNIMWAHOBV-UHFFFAOYSA-N
DMKH32S IU N-[2-(5-methoxy-1H-indol-3-yl)propyl]acetamide
DMKH32S DE Discovery agent
DMZ8Y67 ID DMZ8Y67
DMZ8Y67 DN Beta-naphthylboronic acid
DMZ8Y67 HS Investigative
DMZ8Y67 SN 2-Naphthaleneboronic acid; 32316-92-0; Naphthalen-2-ylboronic Acid; 2-Naphthylboronic acid; Naphthalene-2-boronic acid; 2-naphthalene boronic acid; 2-naphthaleneylboronic acid; Naphthalenyl-2-boronic acid; 2-Naphtahaleneboronic acid; beta-naphthylboronic acid; Naphthalen-2-boronic acid; Naphthalen-2-Yl-Boranediol; 2-NAPHTHYLBORONIC CAID; Boronic acid, 2-naphthalenyl-; (naphthalen-2-yl)boronic acid; CHEMBL141079; MFCD00236051; NAPHTHALEN-2-YL-2-BORONIC ACID; 2-Naphthaleneboronic acid, 97+%; Naphthalene-2-boronicacid
DMZ8Y67 DT Small molecular drug
DMZ8Y67 PC 2734375
DMZ8Y67 MW 171.99
DMZ8Y67 FM C10H9BO2
DMZ8Y67 IC InChI=1S/C10H9BO2/c12-11(13)10-6-5-8-3-1-2-4-9(8)7-10/h1-7,12-13H
DMZ8Y67 CS B(C1=CC2=CC=CC=C2C=C1)(O)O
DMZ8Y67 IK KPTRDYONBVUWPD-UHFFFAOYSA-N
DMZ8Y67 IU naphthalen-2-ylboronic acid
DMZ8Y67 CA CAS 32316-92-0
DMZ8Y67 DE Discovery agent
DMQXMKB ID DMQXMKB
DMQXMKB DN Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide
DMQXMKB HS Investigative
DMQXMKB SN beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide; proline scaffold, 26; CHEMBL490730; BDBM29377; DB07083; (2S)-1-[(2R)-2-amino-3,3-diphenylpropanoyl]-N-propylpyrrolidine-2-carboxamide
DMQXMKB DT Small molecular drug
DMQXMKB PC 25271577
DMQXMKB MW 379.5
DMQXMKB FM C23H29N3O2
DMQXMKB IC InChI=1S/C23H29N3O2/c1-2-15-25-22(27)19-14-9-16-26(19)23(28)21(24)20(17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19-21H,2,9,14-16,24H2,1H3,(H,25,27)/t19-,21+/m0/s1
DMQXMKB CS CCCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](C(C2=CC=CC=C2)C3=CC=CC=C3)N
DMQXMKB IK HZKKJPDVZGOOPU-PZJWPPBQSA-N
DMQXMKB IU (2S)-1-[(2R)-2-amino-3,3-diphenylpropanoyl]-N-propylpyrrolidine-2-carboxamide
DMQXMKB DE Discovery agent
DM4MZQW ID DM4MZQW
DM4MZQW DN BETP
DM4MZQW HS Investigative
DM4MZQW SN 1371569-69-5; (4-(3-Benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine; GTPL7585; SCHEMBL20657432; MolPort-035-765-832; BETP, > BCP19312; AKOS024458341; NCGC00379201-03; KB-271527; HY-103546; CS-0028074; 4-(3-Benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP); 2-ethylsulfinyl-4-(3-phenylmethoxyphenyl)-6-(trifluoromethyl)pyrimidine; 2-(Ethylsulfinyl)-4-[3-(phenylmethoxy)phenyl]-6-(trifluoromethyl)pyrimidine
DM4MZQW DT Small molecular drug
DM4MZQW PC 49868481
DM4MZQW MW 406.4
DM4MZQW FM C20H17F3N2O2S
DM4MZQW IC InChI=1S/C20H17F3N2O2S/c1-2-28(26)19-24-17(12-18(25-19)20(21,22)23)15-9-6-10-16(11-15)27-13-14-7-4-3-5-8-14/h3-12H,2,13H2,1H3
DM4MZQW CS CCS(=O)C1=NC(=CC(=N1)C(F)(F)F)C2=CC(=CC=C2)OCC3=CC=CC=C3
DM4MZQW IK NTDFYGSSDDMNHI-UHFFFAOYSA-N
DM4MZQW IU 2-ethylsulfinyl-4-(3-phenylmethoxyphenyl)-6-(trifluoromethyl)pyrimidine
DM4MZQW DE Discovery agent
DMGQRON ID DMGQRON
DMGQRON DN BETULIN
DMGQRON HS Investigative
DMGQRON SN Betulin; 473-98-3; Betulinol; Betuline; Trochol; Lup-20(29)-ene-3b,28-diol; Betulol; Lup-20(29)-ene-3beta,28-diol; UNII-6W70HN7X7O; NSC 4644; C30H50O2; EINECS 207-475-5; Lup-20(30)-ene-3beta,28-diol; AI3-62999; CHEBI:3086; 6W70HN7X7O; Lup-20(29)-ene-3,28-diol, (3beta)-; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(Hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; Betulinic alcohol; lup-20(29)-ene-3 beta,28-diol
DMGQRON DT Small molecular drug
DMGQRON PC 72326
DMGQRON MW 442.7
DMGQRON FM C30H50O2
DMGQRON IC InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21+,22-,23+,24-,25+,27-,28+,29+,30+/m0/s1
DMGQRON CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)CO
DMGQRON IK FVWJYYTZTCVBKE-ROUWMTJPSA-N
DMGQRON IU (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol
DMGQRON CA CAS 473-98-3
DMGQRON CB CHEBI:3086
DMGQRON DE Discovery agent
DMOQEZK ID DMOQEZK
DMOQEZK DN BF/PC-18
DMOQEZK HS Investigative
DMOQEZK SN PC18-BF; Cathepsin S inhibitor (inflammation), Biofrontera
DMOQEZK CP Biofrontera Bioscience GmbH
DMOQEZK DE Inflammation
DMCWB1V ID DMCWB1V
DMCWB1V DN BF/PC-21
DMCWB1V HS Investigative
DMCWB1V SN Cathepsin X inhibitors (inflammation), Biofrontera
DMCWB1V CP Biofrontera Bioscience GmbH
DMCWB1V DE Inflammation
DM4XMZW ID DM4XMZW
DM4XMZW DN BH4
DM4XMZW HS Investigative
DM4XMZW DT Small molecular drug
DM4XMZW PC 135398654
DM4XMZW MW 241.25
DM4XMZW FM C9H15N5O3
DM4XMZW IC InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1
DM4XMZW CS C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O
DM4XMZW IK FNKQXYHWGSIFBK-RPDRRWSUSA-N
DM4XMZW IU (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-3H-pteridin-4-one
DM4XMZW CA CAS 62989-33-7
DM4XMZW CB CHEBI:59560
DM4XMZW DE Discovery agent
DMP21ST ID DMP21ST
DMP21ST DN BHF-177
DMP21ST HS Investigative
DMP21ST SN Allosteric GABA B receptor modulators, Novartis; CGP-13501; CGP-7930; CPG-37656; GS-39783
DMP21ST CP Novartis AG
DMP21ST DT Small molecular drug
DMP21ST PC 56940925
DMP21ST MW 347.4
DMP21ST FM C19H20F3N3
DMP21ST IC InChI=1S/C19H20F3N3/c1-11-23-10-16(13-4-6-15(7-5-13)19(20,21)22)18(24-11)25-17-9-12-2-3-14(17)8-12/h4-7,10,12,14,17H,2-3,8-9H2,1H3,(H,23,24,25)/t12-,14+,17+/m0/s1
DMP21ST CS CC1=NC=C(C(=N1)N[C@@H]2C[C@H]3CC[C@@H]2C3)C4=CC=C(C=C4)C(F)(F)F
DMP21ST IK ADHZHPOKTRHZGT-DXCKQFNASA-N
DMP21ST IU N-[(1R,2R,4S)-2-bicyclo[2.2.1]heptanyl]-2-methyl-5-[4-(trifluoromethyl)phenyl]pyrimidin-4-amine
DMP21ST CA CAS 917896-43-6
DMP21ST DE Anxiety disorder
DMVH4LK ID DMVH4LK
DMVH4LK DN Bhg-F-N-Y-Y-W
DMVH4LK HS Investigative
DMVH4LK SN CHEMBL414917; bhg-F-N-Y-Y-W
DMVH4LK PC 44371614
DMVH4LK MW 1041.2
DMVH4LK FM C59H60N8O10
DMVH4LK IC InChI=1S/C59H60N8O10/c60-51(70)32-49(65-55(72)48(28-34-10-2-1-3-11-34)66-58(75)53(61)52-43-15-6-4-12-37(43)22-23-38-13-5-7-16-44(38)52)57(74)64-46(29-35-18-24-40(68)25-19-35)54(71)63-47(30-36-20-26-41(69)27-21-36)56(73)67-50(59(76)77)31-39-33-62-45-17-9-8-14-42(39)45/h1-21,24-27,33,46-50,52-53,62,68-69H,22-23,28-32,61H2,(H2,60,70)(H,63,71)(H,64,74)(H,65,72)(H,66,75)(H,67,73)(H,76,77)/t46-,47-,48-,49-,50-,53-/m0/s1
DMVH4LK CS C1CC2=CC=CC=C2C(C3=CC=CC=C31)[C@@H](C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)O)N
DMVH4LK IK ODHKJPGCAWIPPT-ZQJLCUDRSA-N
DMVH4LK IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)acetyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMVH4LK DE Discovery agent
DMZRS7A ID DMZRS7A
DMZRS7A DN BHT-3034
DMZRS7A HS Investigative
DMZRS7A SN RBHT-3034; Immunomodulator (myasthenia gravis), Bayhill
DMZRS7A CP Bayhill Therapeutics Inc
DMZRS7A DE Myasthenia gravis
DMI3ANC ID DMI3ANC
DMI3ANC DN BI 7273
DMI3ANC HS Investigative
DMI3ANC SN BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221
DMI3ANC DT Small molecular drug
DMI3ANC PC 118796358
DMI3ANC MW 353.4
DMI3ANC FM C20H23N3O3
DMI3ANC IC InChI=1S/C20H23N3O3/c1-22(2)11-17-18(25-4)8-13(9-19(17)26-5)16-12-23(3)20(24)15-10-21-7-6-14(15)16/h6-10,12H,11H2,1-5H3
DMI3ANC CS CN1C=C(C2=C(C1=O)C=NC=C2)C3=CC(=C(C(=C3)OC)CN(C)C)OC
DMI3ANC IK RBUYFHLQNPJMQM-UHFFFAOYSA-N
DMI3ANC IU 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one
DMI3ANC DE Acute myeloid leukaemia
DMN052T ID DMN052T
DMN052T DN BI-32169
DMN052T HS Investigative
DMN052T SN BI-32169; CHEMBL526383
DMN052T PC 44584360
DMN052T MW 2037.3
DMN052T FM C95H125N23O24S2
DMN052T IC InChI=1S/C95H125N23O24S2/c1-7-48(4)78-93(139)117-30-14-24-69(117)87(133)102-43-75(123)104-61(34-52-39-98-58-22-12-9-19-55(52)58)84(130)107-63(36-73(96)121)85(131)114-79(50(6)120)94(140)118-31-17-27-72(118)89(135)110-62(35-53-40-99-59-23-13-10-20-56(53)59)83(129)103-49(5)80(126)112-68(95(141)142)46-144-143-45-67-92(138)116-29-16-26-71(116)90(136)111-66(44-119)86(132)108-64(37-74(122)113-78)82(128)101-41-76(124)105-65(32-47(2)3)91(137)115-28-15-25-70(115)88(134)109-60(81(127)100-42-77(125)106-67)33-51-38-97-57-21-11-8-18-54(51)57/h8-13,18-23,38-40,47-50,60-72,78-79,97-99,119-120H,7,14-17,24-37,41-46H2,1-6H3,(H2,96,121)(H,100,127)(H,101,128)(H,102,133)(H,103,129)(H,104,123)(H,105,124)(H,106,125)(H,107,130)(H,108,132)(H,109,134)(H,110,135)(H,111,136)(H,112,126)(H,113,122)(H,114,131)(H,141,142)/t48-,49-,50+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,78-,79-/m0/s1
DMN052T CS CC[C@H](C)[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@H](C(=O)N[C@@H](CC(=O)N1)C(=O)NCC(=O)N[C@H](C(=O)N6CCC[C@H]6C(=O)N[C@H](C(=O)NCC(=O)N4)CC7=CNC8=CC=CC=C87)CC(C)C)CO)C(=O)O)C)CC9=CNC1=CC=CC=C19)[C@@H](C)O)CC(=O)N)CC1=CNC2=CC=CC=C21
DMN052T IK VXOKYTDMQDFAQT-VJFZWUEESA-N
DMN052T IU (1S,5S,11S,17S,20S,23S,29S,32S,35S,38R,43R,49S,52S,58S,66S,69S)-20-(2-amino-2-oxoethyl)-5-[(2S)-butan-2-yl]-23-[(1R)-1-hydroxyethyl]-66-(hydroxymethyl)-17,32,49-tris(1H-indol-3-ylmethyl)-35-methyl-58-(2-methylpropyl)-3,6,12,15,18,21,24,30,33,36,45,48,51,57,60,63,65,68,74-nonadecaoxo-40,41-dithia-4,7,13,16,19,22,25,31,34,37,44,47,50,56,59,62,64,67,73-nonadecazahexacyclo[41.20.11.07,11.025,29.052,56.069,73]tetraheptacontane-38-carboxylic acid
DMN052T DE Discovery agent
DMRXK5G ID DMRXK5G
DMRXK5G DN BI6015
DMRXK5G HS Investigative
DMRXK5G SN BI 6015; BI-6015
DMRXK5G DT Small molecular drug
DMRXK5G PC 3269393
DMRXK5G MW 331.3
DMRXK5G FM C15H13N3O4S
DMRXK5G IC InChI=1S/C15H13N3O4S/c1-10-7-8-12(18(19)20)9-15(10)23(21,22)17-11(2)16-13-5-3-4-6-14(13)17/h3-9H,1-2H3
DMRXK5G CS CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N2C(=NC3=CC=CC=C32)C
DMRXK5G IK ILVCPQPMRPHZSG-UHFFFAOYSA-N
DMRXK5G IU 2-methyl-1-(2-methyl-5-nitrophenyl)sulfonylbenzimidazole
DMRXK5G DE Discovery agent
DM4RZ9A ID DM4RZ9A
DM4RZ9A DN BIA
DM4RZ9A HS Investigative
DM4RZ9A SN UNII-X6H65DT067; X6H65DT067; 1-(3,4,DIHYDROXY-5-NITROPHENYL)-3-{4-[3-(TRIFLUOROMETHYL) PHENYL] PIPERAZIN-1-YL}PROPAN-1-ONE; BIA-3-335; BIA-3-335 free base; 1-(3,4-dihydroxy-5-nitrophenyl)-3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propan-1-one; 1-(3,4-dihydroxy-5-nitrophenyl)-3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propan-1-one; 1h1d; AC1N9ZVE; CHEMBL387347; DB03336; 747401-28-1; 1-Propanone, 1-(3,4-dihydroxy-5-nitrophenyl)-3-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)-
DM4RZ9A DT Small molecular drug
DM4RZ9A PC 4369285
DM4RZ9A MW 439.4
DM4RZ9A FM C20H20F3N3O5
DM4RZ9A IC InChI=1S/C20H20F3N3O5/c21-20(22,23)14-2-1-3-15(12-14)25-8-6-24(7-9-25)5-4-17(27)13-10-16(26(30)31)19(29)18(28)11-13/h1-3,10-12,28-29H,4-9H2
DM4RZ9A CS C1CN(CCN1CCC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-])C3=CC=CC(=C3)C(F)(F)F
DM4RZ9A IK KVIVJQWOYSWCCZ-UHFFFAOYSA-N
DM4RZ9A IU 1-(3,4-dihydroxy-5-nitrophenyl)-3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propan-1-one
DM4RZ9A CA CAS 747401-28-1
DM4RZ9A DE Non-insulin dependent diabetes
DMUWO6D ID DMUWO6D
DMUWO6D DN BIBF100
DMUWO6D HS Investigative
DMUWO6D CP Boehringer Ingelheim
DMUWO6D DE Multiple myeloma
DMDTLSP ID DMDTLSP
DMDTLSP DN BIBF-1202
DMDTLSP HS Investigative
DMDTLSP SN BIBF 1202
DMDTLSP DT Small molecular drug
DMDTLSP PC 135461425
DMDTLSP MW 525.6
DMDTLSP FM C30H31N5O4
DMDTLSP IC InChI=1S/C30H31N5O4/c1-33-14-16-35(17-15-33)19-26(36)34(2)23-11-9-22(10-12-23)31-28(20-6-4-3-5-7-20)27-24-13-8-21(30(38)39)18-25(24)32-29(27)37/h3-13,18,32,37H,14-17,19H2,1-2H3,(H,38,39)
DMDTLSP CS CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)O)O
DMDTLSP IK SDJMWYVJAVLZEG-UHFFFAOYSA-N
DMDTLSP IU 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylic acid
DMDTLSP DE Discovery agent
DML7HFP ID DML7HFP
DML7HFP DN BIBO3304
DML7HFP HS Investigative
DML7HFP SN UNII-QKC82E736Q; BIBO3304; QKC82E736Q; CHEMBL1774204; 191868-14-1; BIBO-3304; BIBO 3304 TRIFLUOROACETATE; BIBO-3304 free base; AC1NSJUH; 191868-13-0; GTPL1528; SCHEMBL6899864; CTK8E9767; ZINC3952359; BDBM50343731; AKOS024457083; Benzeneacetamide, N-(1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-, (R)-; Benzeneacetamide, N-((1R)-1-((((4-(((aminocarbonyl)amino)methyl)phenyl)methyl)amino)carbonyl)-4-((aminoiminomethyl)amino)butyl)-alpha-phenyl-; RT-011503
DML7HFP DT Small molecular drug
DML7HFP PC 5311022
DML7HFP MW 529.6
DML7HFP FM C29H35N7O3
DML7HFP IC InChI=1S/C29H35N7O3/c30-28(31)33-17-7-12-24(26(37)34-18-20-13-15-21(16-14-20)19-35-29(32)39)36-27(38)25(22-8-3-1-4-9-22)23-10-5-2-6-11-23/h1-6,8-11,13-16,24-25H,7,12,17-19H2,(H,34,37)(H,36,38)(H4,30,31,33)(H3,32,35,39)/t24-/m1/s1
DML7HFP CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)CNC(=O)N
DML7HFP IK TVMJSGGZULFVCZ-XMMPIXPASA-N
DML7HFP IU (2R)-N-[[4-[(carbamoylamino)methyl]phenyl]methyl]-5-(diaminomethylideneamino)-2-[(2,2-diphenylacetyl)amino]pentanamide
DML7HFP CA CAS 191868-13-0
DML7HFP DE Discovery agent
DMFS2V9 ID DMFS2V9
DMFS2V9 DN BIC1
DMFS2V9 HS Investigative
DMFS2V9 SN CHEMBL1738777; 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methyl-1,3-dihydro-2H-benzimidazole-2-thione; 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methylbenzimidazole-2-thione; BIC1; AC1LDQIR; TimTec1_003670; Oprea1_027553; 433249-32-2; GTPL7510; SCHEMBL8248939; ZINC34355; MolPort-000-901-027; HMS1544G18; BDBM50365462; STK767484; AKOS003573654; MCULE-4889087096; 1-[2-(1h-benzimidazol-2-ylthio)ethyl]-1,3-dihydro-3-methyl-2h-benzimidazole-2-thione; ST049583; KB-258991; SR-01000537551; SR-01000537551-1; BRD-K75297647-001-01-4
DMFS2V9 DT Small molecular drug
DMFS2V9 PC 672548
DMFS2V9 MW 340.5
DMFS2V9 FM C17H16N4S2
DMFS2V9 IC InChI=1S/C17H16N4S2/c1-20-14-8-4-5-9-15(14)21(17(20)22)10-11-23-16-18-12-6-2-3-7-13(12)19-16/h2-9H,10-11H2,1H3,(H,18,19)
DMFS2V9 CS CN1C2=CC=CC=C2N(C1=S)CCSC3=NC4=CC=CC=C4N3
DMFS2V9 IK KDPSGIFCBZTBEZ-UHFFFAOYSA-N
DMFS2V9 IU 1-[2-(1H-benzimidazol-2-ylsulfanyl)ethyl]-3-methylbenzimidazole-2-thione
DMFS2V9 DE Discovery agent
DMT5E36 ID DMT5E36
DMT5E36 DN Bicarbonate
DMT5E36 HS Investigative
DMT5E36 SN bicarbonate; Hydrogen carbonate; Bicarbonate ion; Carbonate, hydrogen; Hydrogencarbonate; Bicarbonate ions; 71-52-3; UNII-HN1ZRA3Q20; HCO3-; HN1ZRA3Q20; Bicarbonate anion; Hydrocarbonate(1-); Monohydrogen carbonate; Hydrogen carbonate ion; Hydrogen carbonate anion; Carbonate (HCO31-); Bicarbonates; Carbonate ion (HCO31-); Carboxyolate; Acid carbonate; hydrogen-carbonate; HYDROXYFORMATE; hydrogencarbonate(1-); HCO3; Carbonic acid, ion(1-); hydrogentrioxocarbonate(IV); hydrogentrioxocarbonate(1-); AC1L19ZH
DMT5E36 DT Small molecular drug
DMT5E36 PC 769
DMT5E36 MW 61.017
DMT5E36 FM CHO3-
DMT5E36 IC InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4)/p-1
DMT5E36 CS C(=O)(O)[O-]
DMT5E36 IK BVKZGUZCCUSVTD-UHFFFAOYSA-M
DMT5E36 IU hydrogen carbonate
DMT5E36 CA CAS 71-52-3
DMT5E36 CB CHEBI:17544
DMT5E36 DE Discovery agent
DMTRDPI ID DMTRDPI
DMTRDPI DN Bicine
DMTRDPI HS Investigative
DMTRDPI SN Bicine; 150-25-4; N,N-Bis(2-hydroxyethyl)glycine; Diethylolglycine; Dihydroxyethylglycine; 2-(bis(2-hydroxyethyl)amino)acetic acid; Diethanol glycine; N,N-Di(2-hydroxyethyl)glycine; Bicene; N,N-Dihydroxyethylglycine; N,N-Dihydroxyethyl glycine; Fe-3-Specific; DHEG; Glycine, N,N-bis(2-hydroxyethyl)-; Bis(2-Hydroxyethyl)glycine; N,N-(2-Hydroxyethyl)glycine; 2-[bis(2-hydroxyethyl)amino]acetic acid; N,N-Bis(2-hydroxyethyl)aminoacetic acid; N,N-Bis(beta-hydroxyethyl)glycine; NSC 7342; GLYCINE, N,N-DIHYDROXYETHYL-; UNII-1J484QFI1O
DMTRDPI DT Small molecular drug
DMTRDPI PC 8761
DMTRDPI MW 163.17
DMTRDPI FM C6H13NO4
DMTRDPI IC InChI=1S/C6H13NO4/c8-3-1-7(2-4-9)5-6(10)11/h8-9H,1-5H2,(H,10,11)
DMTRDPI CS C(CO)N(CCO)CC(=O)O
DMTRDPI IK FSVCELGFZIQNCK-UHFFFAOYSA-N
DMTRDPI IU 2-[bis(2-hydroxyethyl)amino]acetic acid
DMTRDPI CA CAS 150-25-4
DMTRDPI CB CHEBI:40957
DMTRDPI DE Discovery agent
DMA6VQW ID DMA6VQW
DMA6VQW DN Bicuculline
DMA6VQW HS Investigative
DMA6VQW SN (+)-Bicuculline; bicuculline; d-Bicuculline; 485-49-4; Bicculine; Bicucullin; Bicuculline (+); UNII-Y37615DVKC; NSC 32192; C20H17NO6; EINECS 207-619-7; BRN 0098786; CHEMBL417990; CHEBI:3092; Y37615DVKC; (6R)-6-[(5S)-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]furo[3,4-e][1,3]benzodioxol-8(6H)-one; NSC32192; Furo(3,4-e)-1,3-benzodioxol-8(6H)-one, 6-(5,6,7,8-tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (R-(R*,S*))-
DMA6VQW DT Small molecular drug
DMA6VQW PC 10237
DMA6VQW MW 367.4
DMA6VQW FM C20H17NO6
DMA6VQW IC InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1
DMA6VQW CS CN1CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3
DMA6VQW IK IYGYMKDQCDOMRE-ZWKOTPCHSA-N
DMA6VQW IU (6R)-6-[(5S)-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6H-furo[3,4-g][1,3]benzodioxol-8-one
DMA6VQW CA CAS 485-49-4
DMA6VQW CB CHEBI:3092
DMA6VQW DE Discovery agent
DM4MUXT ID DM4MUXT
DM4MUXT DN BIFENOX
DM4MUXT HS Investigative
DM4MUXT SN BIFENOX; 42576-02-3; Methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate; Modown; Caswell No. 561AA; MC-4379; 5-(2,4-Dichlorophenoxy)-2-nitrobenzoic acid methyl ester; UNII-KSB85XT26Y; Bifenox [ANSI:BSI:ISO]; CCRIS 7158; Benzoic acid, 5-(2,4-dichlorophenoxy)-2-nitro-, methyl ester; HSDB 6567; EINECS 255-894-7; EPA Pesticide Chemical Code 104301; BRN 2170169; KSB85XT26Y; CHEMBL449928; CHEBI:6613; SUSRORUBZHMPCO-UHFFFAOYSA-N; W-110976; Modown 4 flowable; MODOWN(R); AC1L21BG; DSSTox_RID_79477; DSSTox_CID_20320; DSSTox_GSID_40320
DM4MUXT DT Small molecular drug
DM4MUXT PC 39230
DM4MUXT MW 342.1
DM4MUXT FM C14H9Cl2NO5
DM4MUXT IC InChI=1S/C14H9Cl2NO5/c1-21-14(18)10-7-9(3-4-12(10)17(19)20)22-13-5-2-8(15)6-11(13)16/h2-7H,1H3
DM4MUXT CS COC(=O)C1=C(C=CC(=C1)OC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-]
DM4MUXT IK SUSRORUBZHMPCO-UHFFFAOYSA-N
DM4MUXT IU methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate
DM4MUXT CA CAS 42576-02-3
DM4MUXT CB CHEBI:6613
DM4MUXT DE Discovery agent
DML4DQ3 ID DML4DQ3
DML4DQ3 DN BIIB-513
DML4DQ3 HS Investigative
DML4DQ3 SN NHE-1 inhibitors (myocardial infarction/reperfusion injury); NHE-1 inhibitors (myocardial infarction/reperfusion injury), Boehringer Ingelheim
DML4DQ3 CP Boehringer Ingelheim Corp
DML4DQ3 DT Small molecular drug
DML4DQ3 PC 6918374
DML4DQ3 MW 515.6
DML4DQ3 FM C19H25N5O8S2
DML4DQ3 IC InChI=1S/C18H21N5O5S.CH4O3S/c1-29(26,27)15-11-12(16(24)21-18(19)20)4-5-13(15)22-6-8-23(9-7-22)17(25)14-3-2-10-28-14;1-5(2,3)4/h2-5,10-11H,6-9H2,1H3,(H4,19,20,21,24);1H3,(H,2,3,4)
DML4DQ3 CS CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)N2CCN(CC2)C(=O)C3=CC=CO3.CS(=O)(=O)O
DML4DQ3 IK CIZHNWRBNREPCL-UHFFFAOYSA-N
DML4DQ3 IU N-(diaminomethylidene)-4-[4-(furan-2-carbonyl)piperazin-1-yl]-3-methylsulfonylbenzamide;methanesulfonic acid
DML4DQ3 CA CAS 265986-98-9
DML4DQ3 DE Myocardial infarction
DMR2SEB ID DMR2SEB
DMR2SEB DN BIIE0246
DMR2SEB HS Investigative
DMR2SEB SN BIIE 0246; BIIE-0246
DMR2SEB DT Small molecular drug
DMR2SEB PC 5311024
DMR2SEB MW 896
DMR2SEB FM C49H57N11O6
DMR2SEB IC InChI=1S/C49H57N11O6/c50-46(51)53-25-13-22-40(45(64)52-26-27-58-47(65)59(34-14-3-1-4-15-34)60(48(58)66)35-16-5-2-6-17-35)54-41(61)32-49(23-11-12-24-49)33-42(62)56-28-30-57(31-29-56)43-36-18-7-8-19-37(36)44(63)55-39-21-10-9-20-38(39)43/h1-10,14-21,40,43H,11-13,22-33H2,(H,52,64)(H,54,61)(H,55,63)(H4,50,51,53)
DMR2SEB CS C1CCC(C1)(CC(=O)NC(CCCN=C(N)N)C(=O)NCCN2C(=O)N(N(C2=O)C3=CC=CC=C3)C4=CC=CC=C4)CC(=O)N5CCN(CC5)C6C7=CC=CC=C7C(=O)NC8=CC=CC=C68
DMR2SEB IK RSJAXPUYVJKAAA-UHFFFAOYSA-N
DMR2SEB IU 5-(diaminomethylideneamino)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-2-[[2-[1-[2-oxo-2-[4-(6-oxo-5,11-dihydrobenzo[c][1]benzazepin-11-yl)piperazin-1-yl]ethyl]cyclopentyl]acetyl]amino]pentanamide
DMR2SEB CA CAS 246146-55-4
DMR2SEB DE Discovery agent
DMU09E4 ID DMU09E4
DMU09E4 DN BIIL 260
DMU09E4 HS Investigative
DMU09E4 SN BIIL-260; BIIL260
DMU09E4 DT Small molecular drug
DMU09E4 PC 9956189
DMU09E4 MW 466.6
DMU09E4 FM C30H30N2O3
DMU09E4 IC InChI=1S/C30H30N2O3/c1-30(2,24-8-12-26(33)13-9-24)25-10-16-28(17-11-25)35-20-22-5-3-4-21(18-22)19-34-27-14-6-23(7-15-27)29(31)32/h3-18,33H,19-20H2,1-2H3,(H3,31,32)
DMU09E4 CS CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCC3=CC=CC(=C3)COC4=CC=C(C=C4)C(=N)N
DMU09E4 IK MBLJFKQACMILLC-UHFFFAOYSA-N
DMU09E4 IU 4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidamide
DMU09E4 CA CAS 204974-93-6
DMU09E4 DE Discovery agent
DMIY2HW ID DMIY2HW
DMIY2HW DN Bile acid
DMIY2HW HS Investigative
DMIY2HW SN SCHEMBL18394606; CHEMBL1258080; BDBM21679; 23(S)-methyl-BA derivative, 7c; (2S,4R)-4-[(1S,2S,5R,7S,8R,9R,10S,11S,14R,15R)-8-ethyl-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2-methylpentanoic acid
DMIY2HW DT Small molecular drug
DMIY2HW PC 439520
DMIY2HW MW 408.6
DMIY2HW FM C24H40O5
DMIY2HW IC InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13?,14-,15+,16?,17?,18?,19+,20-,22?,23?,24?/m0/s1
DMIY2HW CS CC(CCC(=O)O)C1CCC2C1([C@H](CC3C2[C@@H](C[C@H]4C3(CC[C@H](C4)O)C)O)O)C
DMIY2HW IK BHQCQFFYRZLCQQ-UMZBRFQRSA-N
DMIY2HW IU 4-[(3R,5S,7R,12S)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMIY2HW CB CHEBI:22868
DMIY2HW DE Discovery agent
DMI0V4O ID DMI0V4O
DMI0V4O DN Bilirubin
DMI0V4O HS Investigative
DMI0V4O SN bilirubin; 635-65-4; Hematoidin; Hemetoidin; Principal bile pigment; UNII-RFM9X3LJ49; Bilirubin IXalpha; Bilirubin IX-alpha; EINECS 211-239-7; NSC 26685; BRN 0074376; RFM9X3LJ49; AI3-23078; 21H-Biline-8,12-dipropanoic acid, 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-; CHEBI:16990; BPYKTIZUTYGOLE-IFADSCNNSA-N; PHEOPHYTIN; MFCD00005499; Bilirubin, 99%; Biline-8,12-dipropionic acid, 1,10,19,22,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-
DMI0V4O DT Small molecular drug
DMI0V4O PC 5280352
DMI0V4O MW 584.7
DMI0V4O FM C33H36N4O6
DMI0V4O IC InChI=1S/C33H36N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-14,34-35H,1-2,9-12,15H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b26-13-,27-14-
DMI0V4O CS CC1=C(NC(=C1CCC(=O)O)CC2=C(C(=C(N2)/C=C\\3/C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)/C=C\\4/C(=C(C(=O)N4)C=C)C
DMI0V4O IK BPYKTIZUTYGOLE-IFADSCNNSA-N
DMI0V4O IU 3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
DMI0V4O CA CAS 635-65-4
DMI0V4O CB CHEBI:16990
DMI0V4O DE Discovery agent
DMCA0WJ ID DMCA0WJ
DMCA0WJ DN Biliverdine Ix Alpha
DMCA0WJ HS Investigative
DMCA0WJ SN biliverdine; UNII-O9MIA842K9; NSC 62793; O9MIA842K9; CHEBI:17033; Biliverdin IX; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbilin-1(19)(21H,24H)-dione; Biliverdine dihydrochloride; QBUVFDKTZJNUPP-BBROENKCSA-N; Protobiliverdin IX; EINECS 204-042-2
DMCA0WJ DT Small molecular drug
DMCA0WJ PC 5280353
DMCA0WJ MW 582.6
DMCA0WJ FM C33H34N4O6
DMCA0WJ IC InChI=1S/C33H34N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-15,34-35H,1-2,9-12H2,3-6H3,(H,37,42)(H,38,39)(H,40,41)/b24-13-,27-14-,28-15-
DMCA0WJ CS CC\\1=C(/C(=C/C2=C(C(=C(N2)/C=C\\3/C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)/N/C1=C\\C4=NC(=O)C(=C4C)C=C)CCC(=O)O
DMCA0WJ IK RCNSAJSGRJSBKK-NSQVQWHSSA-N
DMCA0WJ IU 3-[(2Z,5Z)-2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methylidene]-5-[(4-ethenyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid
DMCA0WJ CA CAS 114-25-0
DMCA0WJ CB CHEBI:17033
DM09Z35 ID DM09Z35
DM09Z35 DN bilobalide
DM09Z35 HS Investigative
DM09Z35 SN Bilobalide; 33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS*,5aalpha,8beta,8aS*,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448
DM09Z35 DT Small molecular drug
DM09Z35 PC 73581
DM09Z35 MW 326.3
DM09Z35 FM C15H18O8
DM09Z35 IC InChI=1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3/t6-,8-,11-,13-,14+,15+/m0/s1
DM09Z35 CS CC(C)(C)[C@@]1(C[C@H]2[C@@]3([C@]14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O
DM09Z35 IK MOLPUWBMSBJXER-YDGSQGCISA-N
DM09Z35 IU (1S,4R,7R,8S,9R,11S)-9-tert-butyl-7,9-dihydroxy-3,5,12-trioxatetracyclo[6.6.0.01,11.04,8]tetradecane-2,6,13-trione
DM09Z35 CA CAS 33570-04-6
DM09Z35 CB CHEBI:3103
DM09Z35 DE Discovery agent
DMPR14J ID DMPR14J
DMPR14J DN Bimetopyrole
DMPR14J HS Investigative
DMPR14J TC Analgesics
DMPR14J DE Pain
DM0HPWY ID DM0HPWY
DM0HPWY DN biochanin A
DM0HPWY HS Investigative
DM0HPWY SN Biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether; 4'-methylgenistein; BIOCHANIN
DM0HPWY DT Small molecular drug
DM0HPWY PC 5280373
DM0HPWY MW 284.26
DM0HPWY FM C16H12O5
DM0HPWY IC InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3
DM0HPWY CS COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O
DM0HPWY IK WUADCCWRTIWANL-UHFFFAOYSA-N
DM0HPWY IU 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one
DM0HPWY CA CAS 491-80-5
DM0HPWY CB CHEBI:17574
DM0HPWY DE Discovery agent
DMLNQ2F ID DMLNQ2F
DMLNQ2F DN Biopterin
DMLNQ2F HS Investigative
DMLNQ2F DT Small molecular drug
DMLNQ2F PC 135449517
DMLNQ2F MW 237.22
DMLNQ2F FM C9H11N5O3
DMLNQ2F IC InChI=1S/C9H11N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h2-3,6,15-16H,1H3,(H3,10,11,13,14,17)/t3-,6-/m1/s1
DMLNQ2F CS C[C@H]([C@H](C1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O
DMLNQ2F IK LHQIJBMDNUYRAM-AWFVSMACSA-N
DMLNQ2F IU 2-amino-6-[(1S,2R)-1,2-dihydroxypropyl]-3H-pteridin-4-one
DMLNQ2F CA CAS 36183-24-1
DMLNQ2F CB CHEBI:41183
DMLNQ2F DE Discovery agent
DMKMCE1 ID DMKMCE1
DMKMCE1 DN Biotin
DMKMCE1 HS Investigative
DMKMCE1 SN Biodermatin; Bioepiderm; Bios II; Biotin Forte; Factor S; Lutavit H2; Meribin; Rovimix H2
DMKMCE1 DT Small molecular drug
DMKMCE1 PC 171548
DMKMCE1 MW 244.31
DMKMCE1 FM C10H16N2O3S
DMKMCE1 IC InChI=1S/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1
DMKMCE1 CS C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2
DMKMCE1 IK YBJHBAHKTGYVGT-ZKWXMUAHSA-N
DMKMCE1 IU 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid
DMKMCE1 CA CAS 58-85-5
DMKMCE1 CB CHEBI:15956
DMKMCE1 DE Discovery agent
DMVOJ0X ID DMVOJ0X
DMVOJ0X DN BioVant
DMVOJ0X HS Investigative
DMVOJ0X SN CAP vaccine adjuvant, BioSante; Calcium phosphate nanoparticles, BioSante; Nanoparticle adjuvant technology, BioSante
DMVOJ0X CP University of California
DMVOJ0X DT Vaccine
DMVOJ0X DE Vaccination
DM4D7V6 ID DM4D7V6
DM4D7V6 DN Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine
DM4D7V6 HS Investigative
DM4D7V6 SN CHEMBL478836; Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine; BDBM50262725
DM4D7V6 DT Small molecular drug
DM4D7V6 PC 44578367
DM4D7V6 MW 252.35
DM4D7V6 FM C17H20N2
DM4D7V6 IC InChI=1S/C17H20N2/c1-2-6-14(7-3-1)17-9-5-4-8-15(17)12-19-16-10-11-18-13-16/h1-9,16,18-19H,10-13H2/t16-/m0/s1
DM4D7V6 CS C1CNC[C@H]1NCC2=CC=CC=C2C3=CC=CC=C3
DM4D7V6 IK DGKNIGATLZIOSX-INIZCTEOSA-N
DM4D7V6 IU (3S)-N-[(2-phenylphenyl)methyl]pyrrolidin-3-amine
DM4D7V6 DE Discovery agent
DMROG71 ID DMROG71
DMROG71 DN Biphenyl-3-carboxylic acid hydroxyamide
DMROG71 HS Investigative
DMROG71 SN CHEMBL154517; Biphenyl-3-carboxylic acid hydroxyamide; 3-biphenyl hydroxamic acid; 3-Phenylbenzohydroximic acid; SCHEMBL10363097; SEPGPMDDTZHYJV-UHFFFAOYSA-N; ZINC27646665
DMROG71 DT Small molecular drug
DMROG71 PC 44369352
DMROG71 MW 213.23
DMROG71 FM C13H11NO2
DMROG71 IC InChI=1S/C13H11NO2/c15-13(14-16)12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,16H,(H,14,15)
DMROG71 CS C1=CC=C(C=C1)C2=CC(=CC=C2)C(=O)NO
DMROG71 IK SEPGPMDDTZHYJV-UHFFFAOYSA-N
DMROG71 IU N-hydroxy-3-phenylbenzamide
DMROG71 DE Discovery agent
DMIAUB1 ID DMIAUB1
DMIAUB1 DN Biphenyl-3-ylboronic acid
DMIAUB1 HS Investigative
DMIAUB1 SN 3-Biphenylboronic acid; 5122-95-2; Biphenyl-3-boronic acid; [1,1'-Biphenyl]-3-ylboronic acid; biphenyl-3-ylboronic acid; (3-phenylphenyl)boronic Acid; 3-biphenyl boronic acid; (3-phenylphenyl)boranediol; 3-PHENYLBENZENEBORONIC ACID; (1,1'-biphenyl-3-yl)boronic acid; [1,1'-Diphenyl]-3-ylboronic acid; MFCD01318102; Boronic acid, [1,1'-biphenyl]-3-yl-; AK-35405; Biphenyl-3-boronicacid; PubChem6404; Phenylboronic Acid, 5; Biphenyl-3-bronic acid; 3-biphenyl-boronic acid; ACMC-1AKSL; AC1MC0UE; Biphenyl-3-ylbronic acid
DMIAUB1 DT Small molecular drug
DMIAUB1 PC 2734315
DMIAUB1 MW 198.03
DMIAUB1 FM C12H11BO2
DMIAUB1 IC InChI=1S/C12H11BO2/c14-13(15)12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,14-15H
DMIAUB1 CS B(C1=CC(=CC=C1)C2=CC=CC=C2)(O)O
DMIAUB1 IK GOXICVKOZJFRMB-UHFFFAOYSA-N
DMIAUB1 IU (3-phenylphenyl)boronic acid
DMIAUB1 CA CAS 5122-95-2
DMIAUB1 DE Discovery agent
DMYCKGH ID DMYCKGH
DMYCKGH DN Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester
DMYCKGH HS Investigative
DMYCKGH SN CHEMBL451443; Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester; URB602, 3j
DMYCKGH DT Small molecular drug
DMYCKGH PC 44585895
DMYCKGH MW 365.4
DMYCKGH FM C25H19NO2
DMYCKGH IC InChI=1S/C25H19NO2/c27-25(26-23-15-7-13-21(17-23)19-9-3-1-4-10-19)28-24-16-8-14-22(18-24)20-11-5-2-6-12-20/h1-18H,(H,26,27)
DMYCKGH CS C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)OC3=CC=CC(=C3)C4=CC=CC=C4
DMYCKGH IK GJGNAZXEUGJLTC-UHFFFAOYSA-N
DMYCKGH IU (3-phenylphenyl) N-(3-phenylphenyl)carbamate
DMYCKGH DE Discovery agent
DM10AUP ID DM10AUP
DM10AUP DN Biphenyl-3-ylcarbamic acid cyclohexyl ester
DM10AUP HS Investigative
DM10AUP SN 565460-15-3; URB602; cyclohexyl biphenyl-3-ylcarbamate; Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate; URB-602; UNII-B8371SFA9K; CHEMBL77767; Monoacylglycerol Lipase Inhibitor, URB602; biphenyl-3-ylcarbamic acid cyclohexyl ester; B8371SFA9K; URB 602; N-Biphenyl-3-ylcarbamic acid, cyclohexyl ester; N-[1,1'-Biphenyl]-3-yl-carbamic Acid Cyclohexyl Ester; SCHEMBL4274165; Cyclohexylbiphenyl-3-ylcarbamate; CTK8C4433; DTXSID90450611; HHVUFQYJOSFTEH-UHFFFAOYSA-N; MolPort-003-850-812; EX-A1228; BCP19101; BDBM50128581; ANW-71925; ZINC13520725
DM10AUP DT Small molecular drug
DM10AUP PC 10979337
DM10AUP MW 295.4
DM10AUP FM C19H21NO2
DM10AUP IC InChI=1S/C19H21NO2/c21-19(22-18-12-5-2-6-13-18)20-17-11-7-10-16(14-17)15-8-3-1-4-9-15/h1,3-4,7-11,14,18H,2,5-6,12-13H2,(H,20,21)
DM10AUP CS C1CCC(CC1)OC(=O)NC2=CC=CC(=C2)C3=CC=CC=C3
DM10AUP IK HHVUFQYJOSFTEH-UHFFFAOYSA-N
DM10AUP IU cyclohexyl N-(3-phenylphenyl)carbamate
DM10AUP CA CAS 565460-15-3
DM10AUP DE Discovery agent
DMK5VYG ID DMK5VYG
DMK5VYG DN Biphenyl-4-carboxylic acid hydroxyamide
DMK5VYG HS Investigative
DMK5VYG SN Biphenylhydroxamic acid; UNII-R3GRG20IPQ; R3GRG20IPQ; CHEMBL154585; 106359-54-0; Biphenyl-4-carboxylic acid hydroxyamide; 4-biphenyl hydroxamic acid; (1,1'-Biphenyl)-4-carboxamide, N-hydroxy-; 4-Phenylbenzohydroximic acid; SCHEMBL2143958; DTXSID00147585; JWLKPHOMARIZAB-UHFFFAOYSA-N; BDBM50015086
DMK5VYG DT Small molecular drug
DMK5VYG PC 44369716
DMK5VYG MW 213.23
DMK5VYG FM C13H11NO2
DMK5VYG IC InChI=1S/C13H11NO2/c15-13(14-16)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,16H,(H,14,15)
DMK5VYG CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NO
DMK5VYG IK JWLKPHOMARIZAB-UHFFFAOYSA-N
DMK5VYG IU N-hydroxy-4-phenylbenzamide
DMK5VYG CA CAS 106359-54-0
DMK5VYG DE Discovery agent
DM5DPHO ID DM5DPHO
DM5DPHO DN BIPHENYL-4-YL-ACETALDEHYDE
DM5DPHO HS Investigative
DM5DPHO SN 2-([1,1'-biphenyl]-4-yl)acetaldehyde; 61502-90-7; 2-(4-phenylphenyl)acetaldehyde; 4-biphenylacetaldehyde; 2-{[1,1'-biphenyl]-4-yl}acetaldehyde; AC1MRDQD; (biphenyl-4-yl)ethanone; SCHEMBL850634; 2-(biphenyl-4-yl)acetaldehyde; CTK2D8632; DTXSID30392980; OIDMZCMVYZLDLI-UHFFFAOYSA-N; MolPort-020-915-677; [1,1'-Biphenyl]-4-acetaldehyde; ZINC2581188; AKOS006278290; AS-49992; BP4
DM5DPHO DT Small molecular drug
DM5DPHO PC 3491292
DM5DPHO MW 196.24
DM5DPHO FM C14H12O
DM5DPHO IC InChI=1S/C14H12O/c15-11-10-12-6-8-14(9-7-12)13-4-2-1-3-5-13/h1-9,11H,10H2
DM5DPHO CS C1=CC=C(C=C1)C2=CC=C(C=C2)CC=O
DM5DPHO IK OIDMZCMVYZLDLI-UHFFFAOYSA-N
DM5DPHO IU 2-(4-phenylphenyl)acetaldehyde
DM5DPHO CA CAS 61502-90-7
DM5DPHO DE Discovery agent
DMIHMP5 ID DMIHMP5
DMIHMP5 DN Biphenyl-4-ylboronic acid
DMIHMP5 HS Investigative
DMIHMP5 SN Biphenylboronic acid
DMIHMP5 DT Small molecular drug
DMIHMP5 PC 151253
DMIHMP5 MW 198.03
DMIHMP5 FM C12H11BO2
DMIHMP5 IC InChI=1S/C12H11BO2/c14-13(15)12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,14-15H
DMIHMP5 CS B(C1=CC=C(C=C1)C2=CC=CC=C2)(O)O
DMIHMP5 IK XPEIJWZLPWNNOK-UHFFFAOYSA-N
DMIHMP5 IU (4-phenylphenyl)boronic acid
DMIHMP5 CA CAS 5122-94-1
DMIHMP5 DE Discovery agent
DM2MYKC ID DM2MYKC
DM2MYKC DN biphenylindanone A
DM2MYKC HS Investigative
DM2MYKC SN LS-193,571
DM2MYKC DT Small molecular drug
DM2MYKC PC 9868580
DM2MYKC MW 454.6
DM2MYKC FM C30H30O4
DM2MYKC IC InChI=1S/C30H30O4/c1-18-19(2)28-25(15-26(29(28)31)22-7-3-4-8-22)16-27(18)34-17-20-6-5-9-24(14-20)21-10-12-23(13-11-21)30(32)33/h5-6,9-14,16,22,26H,3-4,7-8,15,17H2,1-2H3,(H,32,33)
DM2MYKC CS CC1=C(C=C2CC(C(=O)C2=C1C)C3CCCC3)OCC4=CC(=CC=C4)C5=CC=C(C=C5)C(=O)O
DM2MYKC IK KMKBEESNZAPKMP-UHFFFAOYSA-N
DM2MYKC IU 4-[3-[(2-cyclopentyl-6,7-dimethyl-1-oxo-2,3-dihydroinden-5-yl)oxymethyl]phenyl]benzoic acid
DM2MYKC CA CAS 866823-73-6
DM2MYKC DE Discovery agent
DM4FSXK ID DM4FSXK
DM4FSXK DN Bip-tyr(3bzl)-thr-pro-lys-thr
DM4FSXK HS Investigative
DM4FSXK SN CHEMBL385983; bip-tyr(3bzl)-thr-pro-lys-thr
DM4FSXK PC 44413638
DM4FSXK MW 1009.2
DM4FSXK FM C53H68N8O12
DM4FSXK IC InChI=1S/C53H68N8O12/c1-30(62)45(51(69)61-24-8-12-43(61)50(68)57-41(11-6-7-23-54)48(66)60-46(31(2)63)53(72)73)59-49(67)42(29-35-17-22-44(64)38(26-35)25-32-9-4-3-5-10-32)58-47(65)39(55)27-33-13-18-36(19-14-33)37-20-15-34(16-21-37)28-40(56)52(70)71/h3-5,9-10,13-22,26,30-31,39-43,45-46,62-64H,6-8,11-12,23-25,27-29,54-56H2,1-2H3,(H,57,68)(H,58,65)(H,59,67)(H,60,66)(H,70,71)(H,72,73)/t30-,31-,39+,40+,41+,42+,43+,45+,46+/m1/s1
DM4FSXK CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC(=C(C=C2)O)CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DM4FSXK IK VGTTXQUWJIRLOZ-PMDNFMOISA-N
DM4FSXK IU (2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-3-[4-[4-[(2S)-2-amino-2-carboxyethyl]phenyl]phenyl]propanoyl]amino]-3-(3-benzyl-4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-hydroxybutanoic acid
DM4FSXK DE Discovery agent
DM0VKA2 ID DM0VKA2
DM0VKA2 DN Bip-tyr-ala-pro-lys-thr(obzl)-gly
DM0VKA2 HS Investigative
DM0VKA2 SN CHEMBL277108; bip-tyr-ala-pro-lys-thr(obzl)-gly
DM0VKA2 PC 44413593
DM0VKA2 MW 1036.2
DM0VKA2 FM C54H69N9O12
DM0VKA2 IC InChI=1S/C54H69N9O12/c1-32(53(72)63-26-8-12-45(63)51(70)60-43(11-6-7-25-55)49(68)62-47(52(71)58-30-46(65)66)33(2)75-31-37-9-4-3-5-10-37)59-50(69)44(29-36-17-23-40(64)24-18-36)61-48(67)41(56)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(57)54(73)74/h3-5,9-10,13-24,32-33,41-45,47,64H,6-8,11-12,25-31,55-57H2,1-2H3,(H,58,71)(H,59,69)(H,60,70)(H,61,67)(H,62,68)(H,65,66)(H,73,74)/t32-,33+,41-,42-,43-,44-,45-,47-/m0/s1
DM0VKA2 CS C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N)OCC5=CC=CC=C5
DM0VKA2 IK WWXCYGORDIEWIZ-YAXCISKESA-N
DM0VKA2 IU (2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DM0VKA2 DE Discovery agent
DMUWE81 ID DMUWE81
DMUWE81 DN Bip-tyr-thr-ala-pro-phe
DMUWE81 HS Investigative
DMUWE81 SN bip-tyr-thr-ala-pro-phe; CHEMBL439332
DMUWE81 DT Small molecular drug
DMUWE81 PC 44413270
DMUWE81 MW 836.9
DMUWE81 FM C45H52N6O10
DMUWE81 IC InChI=1S/C45H52N6O10/c1-26(52)39(43(57)51-21-5-8-38(51)42(56)49-37(45(60)61)25-27-6-3-2-4-7-27)50-41(55)36(24-30-13-19-33(53)20-14-30)48-40(54)34(46)22-28-9-15-31(16-10-28)32-17-11-29(12-18-32)23-35(47)44(58)59/h2-4,6-7,9-20,26,34-39,52-53H,5,8,21-25,46-47H2,1H3,(H,48,54)(H,49,56)(H,50,55)(H,58,59)(H,60,61)/t26-,34+,35+,36+,37+,38?,39+/m1/s1
DMUWE81 CS C[C@H]([C@@H](C(=O)N1CCCC1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DMUWE81 IK WOXOMROGQFUOGC-DWIRJLQSSA-N
DMUWE81 IU (2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S,3R)-1-[2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DMUWE81 DE Discovery agent
DMN38JC ID DMN38JC
DMN38JC DN Bip-tyr-thr-pro-ala-thr(obzl)-gly
DMN38JC HS Investigative
DMN38JC SN bip-tyr-thr-pro-ala-thr(obzl)-gly; CHEMBL219358
DMN38JC PC 44413374
DMN38JC MW 1066.2
DMN38JC FM C55H71N9O13
DMN38JC IC InChI=1S/C55H71N9O13/c1-32(65)47(54(74)64-26-8-12-45(64)52(72)60-43(11-6-7-25-56)50(70)63-48(53(73)59-30-46(67)68)33(2)77-31-37-9-4-3-5-10-37)62-51(71)44(29-36-17-23-40(66)24-18-36)61-49(69)41(57)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(58)55(75)76/h3-5,9-10,13-24,32-33,41-45,47-48,65-66H,6-8,11-12,25-31,56-58H2,1-2H3,(H,59,73)(H,60,72)(H,61,69)(H,62,71)(H,63,70)(H,67,68)(H,75,76)/t32-,33?,41+,42+,43+,44+,45+,47+,48+/m1/s1
DMN38JC CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DMN38JC IK WVGBZWZFWUOODF-AWANZDLNSA-N
DMN38JC IU (2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DMN38JC DE Discovery agent
DM7EKH3 ID DM7EKH3
DM7EKH3 DN Bip-tyr-thr-pro-lys-thr
DM7EKH3 HS Investigative
DM7EKH3 SN CHEMBL379496; bip-tyr-thr-pro-lys-thr
DM7EKH3 DT Small molecular drug
DM7EKH3 PC 44413628
DM7EKH3 MW 919
DM7EKH3 FM C46H62N8O12
DM7EKH3 IC InChI=1S/C46H62N8O12/c1-25(55)38(44(62)54-21-5-7-37(54)43(61)50-35(6-3-4-20-47)41(59)53-39(26(2)56)46(65)66)52-42(60)36(24-29-12-18-32(57)19-13-29)51-40(58)33(48)22-27-8-14-30(15-9-27)31-16-10-28(11-17-31)23-34(49)45(63)64/h8-19,25-26,33-39,55-57H,3-7,20-24,47-49H2,1-2H3,(H,50,61)(H,51,58)(H,52,60)(H,53,59)(H,63,64)(H,65,66)/t25-,26-,33+,34+,35+,36+,37+,38+,39+/m1/s1
DM7EKH3 CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)C4=CC=C(C=C4)C[C@@H](C(=O)O)N)N)O
DM7EKH3 IK IBJQKBDBQJHDOQ-KOXSSGOCSA-N
DM7EKH3 IU (2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-3-[4-[4-[(2S)-2-amino-2-carboxyethyl]phenyl]phenyl]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-hydroxybutanoic acid
DM7EKH3 DE Discovery agent
DMAPX9G ID DMAPX9G
DMAPX9G DN Bip-tyr-thr-pro-lys-thr(obzl)-gly
DMAPX9G HS Investigative
DMAPX9G SN CHEMBL428483; bip-tyr-thr-pro-lys-thr(obzl)-gly
DMAPX9G PC 44413501
DMAPX9G MW 1066.2
DMAPX9G FM C55H71N9O13
DMAPX9G IC InChI=1S/C55H71N9O13/c1-32(65)47(54(74)64-26-8-12-45(64)52(72)60-43(11-6-7-25-56)50(70)63-48(53(73)59-30-46(67)68)33(2)77-31-37-9-4-3-5-10-37)62-51(71)44(29-36-17-23-40(66)24-18-36)61-49(69)41(57)27-34-13-19-38(20-14-34)39-21-15-35(16-22-39)28-42(58)55(75)76/h3-5,9-10,13-24,32-33,41-45,47-48,65-66H,6-8,11-12,25-31,56-58H2,1-2H3,(H,59,73)(H,60,72)(H,61,69)(H,62,71)(H,63,70)(H,67,68)(H,75,76)/t32-,33-,41+,42+,43+,44+,45+,47+,48+/m1/s1
DMAPX9G CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DMAPX9G IK WVGBZWZFWUOODF-QHLFIVFVSA-N
DMAPX9G IU (2S)-2-amino-3-[4-[4-[(2S)-2-amino-3-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S)-6-amino-1-[[(2S,3R)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]phenyl]propanoic acid
DMAPX9G DE Discovery agent
DM4CZ5B ID DM4CZ5B
DM4CZ5B DN Bip-tyr-thr-pro-thr(obzl)-gly
DM4CZ5B HS Investigative
DM4CZ5B SN CHEMBL374492; bip-tyr-thr-pro-thr(obzl)-gly
DM4CZ5B DT Small molecular drug
DM4CZ5B PC 44413375
DM4CZ5B MW 952.1
DM4CZ5B FM C50H61N7O12
DM4CZ5B IC InChI=1S/C50H61N7O12/c1-28(34-17-19-36(20-18-34)35-15-11-31(12-16-35)24-38(51)50(67)68)42(52)47(64)54-39(25-32-13-21-37(59)22-14-32)45(62)55-43(29(2)58)49(66)57-23-7-10-40(57)46(63)56-44(48(65)53-26-41(60)61)30(3)69-27-33-8-5-4-6-9-33/h4-6,8-9,11-22,28-30,38-40,42-44,58-59H,7,10,23-27,51-52H2,1-3H3,(H,53,65)(H,54,64)(H,55,62)(H,56,63)(H,60,61)(H,67,68)/t28?,29-,30-,38+,39+,40+,42+,43+,44+/m1/s1
DM4CZ5B CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)OCC2=CC=CC=C2)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C4=CC=C(C=C4)C5=CC=C(C=C5)C[C@@H](C(=O)O)N)N)O
DM4CZ5B IK MGKWXTIOHURCAH-LZDYDXGASA-N
DM4CZ5B IU (2S)-2-amino-3-[4-[4-[(3S)-3-amino-4-[[(2S)-1-[[(2S,3R)-1-[(2S)-2-[[(2S,3R)-1-(carboxymethylamino)-1-oxo-3-phenylmethoxybutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutan-2-yl]phenyl]phenyl]propanoic acid
DM4CZ5B DE Discovery agent
DM0WKNI ID DM0WKNI
DM0WKNI DN Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI HS Investigative
DM0WKNI SN CHEMBL372823; bis-((-)-N-propargylmorphinan-3-yl) sebacoylate
DM0WKNI DT Small molecular drug
DM0WKNI PC 44406704
DM0WKNI MW 729
DM0WKNI FM C48H60N2O4
DM0WKNI IC InChI=1S/C48H60N2O4/c1-3-27-49-29-25-47-23-13-11-15-39(47)43(49)31-35-19-21-37(33-41(35)47)53-45(51)17-9-7-5-6-8-10-18-46(52)54-38-22-20-36-32-44-40-16-12-14-24-48(40,42(36)34-38)26-30-50(44)28-4-2/h1-2,19-22,33-34,39-40,43-44H,5-18,23-32H2/t39?,40?,43-,44-,47-,48-/m1/s1
DM0WKNI CS C#CCN1CC[C@]23CCCCC2[C@H]1CC4=C3C=C(C=C4)OC(=O)CCCCCCCCC(=O)OC5=CC6=C(C[C@@H]7C8[C@@]6(CCCC8)CCN7CC#C)C=C5
DM0WKNI IK CMJNSGDVJLNRPB-TXEWOLIYSA-N
DM0WKNI IU bis[(1R,9R)-17-prop-2-ynyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] decanedioate
DM0WKNI DE Discovery agent
DMWAS4Q ID DMWAS4Q
DMWAS4Q DN BIS(12)-HUPERZINE B
DMWAS4Q HS Investigative
DMWAS4Q SN Bis(12)-Huperzine B; Bis-huperzine B 5c; bis(12)-HupB; CHEMBL175975; BDBM10943
DMWAS4Q DT Small molecular drug
DMWAS4Q PC 23645104
DMWAS4Q MW 737
DMWAS4Q FM C44H60N6O4
DMWAS4Q IC InChI=1S/C44H60N6O4/c1-29-21-31-23-37-35(13-15-39(51)45-37)43(25-29)33(31)11-9-19-49(43)41(53)27-47(3)17-7-5-6-8-18-48(4)28-42(54)50-20-10-12-34-32-22-30(2)26-44(34,50)36-14-16-40(52)46-38(36)24-32/h13-16,21-22,31-34H,5-12,17-20,23-28H2,1-4H3,(H,45,51)(H,46,52)/t31?,32?,33-,34-,43-,44-/m1/s1
DMWAS4Q CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CN(C)CCCCCCN(C)CC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMWAS4Q IK OSYUHORWAUGEMC-ZTZPCQEHSA-N
DMWAS4Q IU (1R,10R)-16-methyl-14-[2-[methyl-[6-[methyl-[2-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-2-oxoethyl]amino]hexyl]amino]acetyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMWAS4Q DE Discovery agent
DM58YDV ID DM58YDV
DM58YDV DN Bis(14)-Huperzine B
DM58YDV HS Investigative
DM58YDV DE Discovery agent
DMYQM3B ID DMYQM3B
DMYQM3B DN BIS(16)-HUPERZINE B
DMYQM3B HS Investigative
DMYQM3B SN Bis(16)-Huperzine B; Bis-huperzine B 5f; bis(16)-HupB; CHEMBL434898; BDBM10946
DMYQM3B DT Small molecular drug
DMYQM3B PC 23645107
DMYQM3B MW 793.1
DMYQM3B FM C48H68N6O4
DMYQM3B IC InChI=1S/C48H68N6O4/c1-33-27-35-29-41-39(15-17-43(55)49-41)47(31-33)37(35)13-11-23-53(47)45(57)19-25-51(3)21-9-7-5-6-8-10-22-52(4)26-20-46(58)54-24-12-14-38-36-28-34(2)32-48(38,54)40-16-18-44(56)50-42(40)30-36/h15-18,27-28,35-38H,5-14,19-26,29-32H2,1-4H3,(H,49,55)(H,50,56)/t35?,36?,37-,38-,47-,48-/m1/s1
DMYQM3B CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CCN(C)CCCCCCCCN(C)CCC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMYQM3B IK XCDQISLHKSKFLH-AZGNAIHRSA-N
DMYQM3B IU (1R,10R)-16-methyl-14-[3-[methyl-[8-[methyl-[3-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-3-oxopropyl]amino]octyl]amino]propanoyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMYQM3B DE Discovery agent
DM3W1T4 ID DM3W1T4
DM3W1T4 DN BIS(18)-HUPERZINE B
DM3W1T4 HS Investigative
DM3W1T4 SN Bis(18)-Huperzine B; Bis-huperzine B 5g; bis(18)-HupB; CHEMBL176132; BDBM10947
DM3W1T4 DT Small molecular drug
DM3W1T4 PC 23645108
DM3W1T4 MW 821.1
DM3W1T4 FM C50H72N6O4
DM3W1T4 IC InChI=1S/C50H72N6O4/c1-35-29-37-31-43-41(17-19-45(57)51-43)49(33-35)39(37)15-13-25-55(49)47(59)21-27-53(3)23-11-9-7-5-6-8-10-12-24-54(4)28-22-48(60)56-26-14-16-40-38-30-36(2)34-50(40,56)42-18-20-46(58)52-44(42)32-38/h17-20,29-30,37-40H,5-16,21-28,31-34H2,1-4H3,(H,51,57)(H,52,58)/t37?,38?,39-,40-,49-,50-/m1/s1
DM3W1T4 CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CCN(C)CCCCCCCCCCN(C)CCC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DM3W1T4 IK AATUHPZQANSFHE-NKUZXIPXSA-N
DM3W1T4 IU (1R,10R)-16-methyl-14-[3-[methyl-[10-[methyl-[3-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-3-oxopropyl]amino]decyl]amino]propanoyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DM3W1T4 DE Discovery agent
DMQ7KR1 ID DMQ7KR1
DMQ7KR1 DN Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether
DMQ7KR1 HS Investigative
DMQ7KR1 SN CHEMBL1269935; Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether; SCHEMBL15511613; BDBM50329693
DMQ7KR1 DT Small molecular drug
DMQ7KR1 PC 52944683
DMQ7KR1 MW 549.79
DMQ7KR1 FM C12H6Br4O5
DMQ7KR1 IC InChI=1S/C12H6Br4O5/c13-7-5(1-3(17)11(19)9(7)15)21-6-2-4(18)12(20)10(16)8(6)14/h1-2,17-20H
DMQ7KR1 CS C1=C(C(=C(C(=C1OC2=C(C(=C(C(=C2)O)O)Br)Br)Br)Br)O)O
DMQ7KR1 IK USVLQGJGFKJBRW-UHFFFAOYSA-N
DMQ7KR1 IU 3,4-dibromo-5-(2,3-dibromo-4,5-dihydroxyphenoxy)benzene-1,2-diol
DMQ7KR1 DE Discovery agent
DMEW49T ID DMEW49T
DMEW49T DN Bis(2,4-dinitrophenyl)sulfane
DMEW49T HS Investigative
DMEW49T SN Sulfide, bis(2,4-dinitrophenyl); 2,4-dinitrophenyl sulfide; CHEMBL204688; NSC633009; 2253-67-0; Benzene, 1,1'-thiobis(2,4-dinitro-; BRN 2067338; AI3-16371; 1-[(2,4-Dinitrophenyl)sulfanyl]-2,4-dinitrobenzene; Benzene, 1,1'-thiobis[2,4-dinitro-; 1-(2,4-dinitrophenyl)sulfanyl-2,4-dinitro-benzene; bis(2,4-dinitrophenyl)sulfane; NSC44806; AC1L3VGX; 1-[(2,4-dinitrophenyl)thio]-2,4-dinitrobenzene; SCHEMBL1032814; CTK5I2738; DTXSID00177044; MolPort-001-016-796; DMIUPZAMXYQKBR-UHFFFAOYSA-N; ZINC1846448; ZX-AT024794; NSC-44806
DMEW49T DT Small molecular drug
DMEW49T PC 95960
DMEW49T MW 366.27
DMEW49T FM C12H6N4O8S
DMEW49T IC InChI=1S/C12H6N4O8S/c17-13(18)7-1-3-11(9(5-7)15(21)22)25-12-4-2-8(14(19)20)6-10(12)16(23)24/h1-6H
DMEW49T CS C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])SC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]
DMEW49T IK DMIUPZAMXYQKBR-UHFFFAOYSA-N
DMEW49T IU 1-(2,4-dinitrophenyl)sulfanyl-2,4-dinitrobenzene
DMEW49T CA CAS 2253-67-0
DMEW49T DE Discovery agent
DMHQKCJ ID DMHQKCJ
DMHQKCJ DN BIS(20)-HUPERZINE B
DMHQKCJ HS Investigative
DMHQKCJ SN Bis(20)-Huperzine B; Bis-huperzine B 5h; bis(20)-HupB; CHEMBL368897; BDBM10948
DMHQKCJ DT Small molecular drug
DMHQKCJ PC 23645348
DMHQKCJ MW 849.2
DMHQKCJ FM C52H76N6O4
DMHQKCJ IC InChI=1S/C52H76N6O4/c1-37-31-39-33-45-43(19-21-47(59)53-45)51(35-37)41(39)17-15-27-57(51)49(61)23-29-55(3)25-13-11-9-7-5-6-8-10-12-14-26-56(4)30-24-50(62)58-28-16-18-42-40-32-38(2)36-52(42,58)44-20-22-48(60)54-46(44)34-40/h19-22,31-32,39-42H,5-18,23-30,33-36H2,1-4H3,(H,53,59)(H,54,60)/t39?,40?,41-,42-,51-,52-/m1/s1
DMHQKCJ CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CCN(C)CCCCCCCCCCCCN(C)CCC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMHQKCJ IK TUYZMCKAYFZSRO-JDUDQBENSA-N
DMHQKCJ IU (1R,10R)-16-methyl-14-[3-[methyl-[12-[methyl-[3-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-3-oxopropyl]amino]dodecyl]amino]propanoyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMHQKCJ DE Discovery agent
DMKANOH ID DMKANOH
DMKANOH DN Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]
DMKANOH HS Investigative
DMKANOH SN Loxiglumide; LOXIGLUMIDE; 107097-80-3; Loxiglumide [INN]; Loxiglumidum [Latin]; Loxiglumida [Spanish]; CR 1505; CR-1505; CHEMBL206025; (+-)-4-(3,4-Dichlorobenzamido)-N-(3-methoxypropyl)-N-pentylglutaramic acid; 4-(3,4-dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; (+-)-4-((3,4-Dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxopentanoic acid; D,L-4-(3,4-Dichlorobenzoylamino)-5-(N-3-methoxypropylpentylamino)-5-oxo-pentanoic acid; Loxiglumidum; Loxiglumida; Pentanoic
DMKANOH DT Small molecular drug
DMKANOH PC 60182
DMKANOH MW 461.4
DMKANOH FM C21H30Cl2N2O5
DMKANOH IC InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)
DMKANOH CS CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
DMKANOH IK QNQZBKQEIFTHFZ-UHFFFAOYSA-N
DMKANOH IU 4-[(3,4-dichlorobenzoyl)amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid
DMKANOH CA CAS 107097-80-3
DMKANOH CB CHEBI:31785
DMKANOH DE Discovery agent
DMUN50H ID DMUN50H
DMUN50H DN Bis(3-bromo-4,5-dihydroxyphenyl)methanone
DMUN50H HS Investigative
DMUN50H SN CHEMBL1269421; Bis(3-bromo-4,5-dihydroxyphenyl)methanone; SCHEMBL15511901; BDBM50329695
DMUN50H DT Small molecular drug
DMUN50H PC 52948935
DMUN50H MW 404.01
DMUN50H FM C13H8Br2O5
DMUN50H IC InChI=1S/C13H8Br2O5/c14-7-1-5(3-9(16)12(7)19)11(18)6-2-8(15)13(20)10(17)4-6/h1-4,16-17,19-20H
DMUN50H CS C1=C(C=C(C(=C1O)O)Br)C(=O)C2=CC(=C(C(=C2)Br)O)O
DMUN50H IK QWGGKBRLOGNRAY-UHFFFAOYSA-N
DMUN50H IU bis(3-bromo-4,5-dihydroxyphenyl)methanone
DMUN50H DE Discovery agent
DM784AU ID DM784AU
DM784AU DN Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone
DM784AU HS Investigative
DM784AU DT Small molecular drug
DM784AU PC 136002679
DM784AU MW 429.1
DM784AU FM C14H11Br2N3OS
DM784AU IC InChI=1S/C14H11Br2N3OS/c15-10-3-1-2-8(6-10)13(18-19-14(17)21)9-4-5-12(20)11(16)7-9/h1-7,20H,(H3,17,19,21)/b18-13-
DM784AU CS C1=CC(=CC(=C1)Br)/C(=N/NC(=S)N)/C2=CC(=C(C=C2)O)Br
DM784AU IK UIMSYLGHIQKPJZ-AQTBWJFISA-N
DM784AU IU [(Z)-[(3-bromo-4-hydroxyphenyl)-(3-bromophenyl)methylidene]amino]thiourea
DM784AU DE Discovery agent
DMASNGX ID DMASNGX
DMASNGX DN Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone
DMASNGX HS Investigative
DMASNGX SN CHEMBL1271493; Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone
DMASNGX DT Small molecular drug
DMASNGX PC 52942034
DMASNGX MW 429.1
DMASNGX FM C14H11Br2N3OS
DMASNGX IC InChI=1S/C14H11Br2N3OS/c15-10-3-1-2-8(4-10)13(18-19-14(17)21)9-5-11(16)7-12(20)6-9/h1-7,20H,(H3,17,19,21)/b18-13-
DMASNGX CS C1=CC(=CC(=C1)Br)/C(=N/NC(=S)N)/C2=CC(=CC(=C2)Br)O
DMASNGX IK PWIIBRZZZZNLFE-AQTBWJFISA-N
DMASNGX IU [(Z)-[(3-bromo-5-hydroxyphenyl)-(3-bromophenyl)methylidene]amino]thiourea
DMASNGX DE Discovery agent
DMMJ635 ID DMMJ635
DMMJ635 DN Bis(3-Fluorophenyl)-ketone]thiosemicarbazone
DMMJ635 HS Investigative
DMMJ635 SN CHEMBL602732; Bis(3-Fluorophenyl)-ketone]thiosemicarbazone
DMMJ635 DT Small molecular drug
DMMJ635 PC 46232386
DMMJ635 MW 291.32
DMMJ635 FM C14H11F2N3S
DMMJ635 IC InChI=1S/C14H11F2N3S/c15-11-5-1-3-9(7-11)13(18-19-14(17)20)10-4-2-6-12(16)8-10/h1-8H,(H3,17,19,20)
DMMJ635 CS C1=CC(=CC(=C1)F)C(=NNC(=S)N)C2=CC(=CC=C2)F
DMMJ635 IK OBIMSARJMGBMKZ-UHFFFAOYSA-N
DMMJ635 IU [bis(3-fluorophenyl)methylideneamino]thiourea
DMMJ635 DE Discovery agent
DMO6HWJ ID DMO6HWJ
DMO6HWJ DN Bis(4-fluorophenyl)-2-fluorophenylacetamide
DMO6HWJ HS Investigative
DMO6HWJ SN CHEMBL272039; bis(4-fluorophenyl)-2-fluorophenylacetamide; SCHEMBL1443968; VDPKWHHLYDETTO-UHFFFAOYSA-N
DMO6HWJ DT Small molecular drug
DMO6HWJ PC 9798060
DMO6HWJ MW 341.3
DMO6HWJ FM C20H14F3NO
DMO6HWJ IC InChI=1S/C20H14F3NO/c21-15-9-5-13(6-10-15)20(19(24)25,14-7-11-16(22)12-8-14)17-3-1-2-4-18(17)23/h1-12H,(H2,24,25)
DMO6HWJ CS C1=CC=C(C(=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N)F
DMO6HWJ IK VDPKWHHLYDETTO-UHFFFAOYSA-N
DMO6HWJ IU 2-(2-fluorophenyl)-2,2-bis(4-fluorophenyl)acetamide
DMO6HWJ DE Discovery agent
DM36VKH ID DM36VKH
DM36VKH DN Bis(5-acetoxybenzo[b]furan-2-yl)methanone
DM36VKH HS Investigative
DM36VKH SN CHEMBL226182; bis(5-acetoxybenzo[b]furan-2-yl)methanone
DM36VKH DT Small molecular drug
DM36VKH PC 13471348
DM36VKH MW 378.3
DM36VKH FM C21H14O7
DM36VKH IC InChI=1S/C21H14O7/c1-11(22)25-15-3-5-17-13(7-15)9-19(27-17)21(24)20-10-14-8-16(26-12(2)23)4-6-18(14)28-20/h3-10H,1-2H3
DM36VKH CS CC(=O)OC1=CC2=C(C=C1)OC(=C2)C(=O)C3=CC4=C(O3)C=CC(=C4)OC(=O)C
DM36VKH IK UACDZFCKAGJOFV-UHFFFAOYSA-N
DM36VKH IU [2-(5-acetyloxy-1-benzofuran-2-carbonyl)-1-benzofuran-5-yl] acetate
DM36VKH DE Discovery agent
DMHRGTY ID DMHRGTY
DMHRGTY DN Bis(5-aminobenzo[b]furan-2-yl)methanone
DMHRGTY HS Investigative
DMHRGTY SN CHEMBL376787; bis(5-aminobenzo[b]furan-2-yl)methanone
DMHRGTY DT Small molecular drug
DMHRGTY PC 11098310
DMHRGTY MW 292.29
DMHRGTY FM C17H12N2O3
DMHRGTY IC InChI=1S/C17H12N2O3/c18-11-1-3-13-9(5-11)7-15(21-13)17(20)16-8-10-6-12(19)2-4-14(10)22-16/h1-8H,18-19H2
DMHRGTY CS C1=CC2=C(C=C1N)C=C(O2)C(=O)C3=CC4=C(O3)C=CC(=C4)N
DMHRGTY IK UMBJVNBINWLZLH-UHFFFAOYSA-N
DMHRGTY IU bis(5-amino-1-benzofuran-2-yl)methanone
DMHRGTY DE Discovery agent
DMTSEXB ID DMTSEXB
DMTSEXB DN Bis-(5-hydroxy-1H-indol-2-yl)-methanone
DMTSEXB HS Investigative
DMTSEXB SN Flt-3 Inhibitor II; 896138-40-2; CHEMBL377193; Bis-(5-hydroxy-1H-indol-2-yl)methanone; Bis(5-hydroxy-1H-indol-2-yl)methanone; SCHEMBL2230377; GTPL5971; CTK8F1061; DTXSID40469293; HMS3229E09; IN1480; BDBM50187351; AKOS028113701; CCG-206752; RT-012728; Flt-3 inhibitor II
DMTSEXB DT Small molecular drug
DMTSEXB PC 11601743
DMTSEXB MW 292.29
DMTSEXB FM C17H12N2O3
DMTSEXB IC InChI=1S/C17H12N2O3/c20-11-1-3-13-9(5-11)7-15(18-13)17(22)16-8-10-6-12(21)2-4-14(10)19-16/h1-8,18-21H
DMTSEXB CS C1=CC2=C(C=C1O)C=C(N2)C(=O)C3=CC4=C(N3)C=CC(=C4)O
DMTSEXB IK NIMIWWQLOGNYHD-UHFFFAOYSA-N
DMTSEXB IU bis(5-hydroxy-1H-indol-2-yl)methanone
DMTSEXB CA CAS 896138-40-2
DMTSEXB DE Discovery agent
DMGRKDP ID DMGRKDP
DMGRKDP DN Bis(5-hydroxybenzo[b]furan-2-yl)methanone
DMGRKDP HS Investigative
DMGRKDP SN CHEMBL225826; bis(5-hydroxybenzo[b]furan-2-yl)methanone
DMGRKDP DT Small molecular drug
DMGRKDP PC 13454380
DMGRKDP MW 294.26
DMGRKDP FM C17H10O5
DMGRKDP IC InChI=1S/C17H10O5/c18-11-1-3-13-9(5-11)7-15(21-13)17(20)16-8-10-6-12(19)2-4-14(10)22-16/h1-8,18-19H
DMGRKDP CS C1=CC2=C(C=C1O)C=C(O2)C(=O)C3=CC4=C(O3)C=CC(=C4)O
DMGRKDP IK TYHFGEDRLCAJMH-UHFFFAOYSA-N
DMGRKDP IU bis(5-hydroxy-1-benzofuran-2-yl)methanone
DMGRKDP DE Discovery agent
DM9XC6A ID DM9XC6A
DM9XC6A DN Bis(5-methoxybenzo[b]furan-2-yl)methanone
DM9XC6A HS Investigative
DM9XC6A SN CHEMBL225772; bis(5-methoxybenzo[b]furan-2-yl)methanone
DM9XC6A DT Small molecular drug
DM9XC6A PC 13454368
DM9XC6A MW 322.3
DM9XC6A FM C19H14O5
DM9XC6A IC InChI=1S/C19H14O5/c1-21-13-3-5-15-11(7-13)9-17(23-15)19(20)18-10-12-8-14(22-2)4-6-16(12)24-18/h3-10H,1-2H3
DM9XC6A CS COC1=CC2=C(C=C1)OC(=C2)C(=O)C3=CC4=C(O3)C=CC(=C4)OC
DM9XC6A IK HEAUVWMQZFRPLK-UHFFFAOYSA-N
DM9XC6A IU bis(5-methoxy-1-benzofuran-2-yl)methanone
DM9XC6A DE Discovery agent
DMQ98H5 ID DMQ98H5
DMQ98H5 DN Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine
DMQ98H5 HS Investigative
DMQ98H5 SN CHEMBL178711; Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine; SCHEMBL3615338
DMQ98H5 DT Small molecular drug
DMQ98H5 PC 11210706
DMQ98H5 MW 363.5
DMQ98H5 FM C20H17N3S2
DMQ98H5 IC InChI=1S/C20H17N3S2/c1-3-15(11-21-9-1)19-7-5-17(24-19)13-23-14-18-6-8-20(25-18)16-4-2-10-22-12-16/h1-12,23H,13-14H2
DMQ98H5 CS C1=CC(=CN=C1)C2=CC=C(S2)CNCC3=CC=C(S3)C4=CN=CC=C4
DMQ98H5 IK CKCZUAVVHJHNJY-UHFFFAOYSA-N
DMQ98H5 IU 1-(5-pyridin-3-ylthiophen-2-yl)-N-[(5-pyridin-3-ylthiophen-2-yl)methyl]methanamine
DMQ98H5 DE Discovery agent
DMRGNSQ ID DMRGNSQ
DMRGNSQ DN Bis(6-hydroxybenzo[b]furan-2-yl)methanone
DMRGNSQ HS Investigative
DMRGNSQ SN CHEMBL225827; bis(6-hydroxybenzo[b]furan-2-yl)methanone
DMRGNSQ DT Small molecular drug
DMRGNSQ PC 13393486
DMRGNSQ MW 294.26
DMRGNSQ FM C17H10O5
DMRGNSQ IC InChI=1S/C17H10O5/c18-11-3-1-9-5-15(21-13(9)7-11)17(20)16-6-10-2-4-12(19)8-14(10)22-16/h1-8,18-19H
DMRGNSQ CS C1=CC2=C(C=C1O)OC(=C2)C(=O)C3=CC4=C(O3)C=C(C=C4)O
DMRGNSQ IK RMZPEAFTFQMIEY-UHFFFAOYSA-N
DMRGNSQ IU bis(6-hydroxy-1-benzofuran-2-yl)methanone
DMRGNSQ DE Discovery agent
DMER5GT ID DMER5GT
DMER5GT DN BIS(8)-HUPERZINE B
DMER5GT HS Investigative
DMER5GT SN Bis(8)-Huperzine B; Bis-huperzine B 5a; bis(8)-Hup B; CHEMBL360092; BDBM10941
DMER5GT DT Small molecular drug
DMER5GT PC 23645102
DMER5GT MW 680.9
DMER5GT FM C40H52N6O4
DMER5GT IC InChI=1S/C40H52N6O4/c1-25-17-27-19-33-31(9-11-35(47)41-33)39(21-25)29(27)7-5-13-45(39)37(49)23-43(3)15-16-44(4)24-38(50)46-14-6-8-30-28-18-26(2)22-40(30,46)32-10-12-36(48)42-34(32)20-28/h9-12,17-18,27-30H,5-8,13-16,19-24H2,1-4H3,(H,41,47)(H,42,48)/t27?,28?,29-,30-,39-,40-/m1/s1
DMER5GT CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CN(C)CCN(C)CC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DMER5GT IK CTEOPWRYKGOSFE-KUNPEOQISA-N
DMER5GT IU (1R,10R)-16-methyl-14-[2-[methyl-[2-[methyl-[2-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-2-oxoethyl]amino]ethyl]amino]acetyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMER5GT DE Discovery agent
DM5WFQM ID DM5WFQM
DM5WFQM DN BIS(9)-HUPERZINE B
DM5WFQM HS Investigative
DM5WFQM SN Bis(9)-Huperzine B; Bis-huperzine B 5b; bis(9)-Hup B; CHEMBL367977; BDBM10942
DM5WFQM DT Small molecular drug
DM5WFQM PC 23645103
DM5WFQM MW 694.9
DM5WFQM FM C41H54N6O4
DM5WFQM IC InChI=1S/C41H54N6O4/c1-26-18-28-20-34-32(10-12-36(48)42-34)40(22-26)30(28)8-5-16-46(40)38(50)24-44(3)14-7-15-45(4)25-39(51)47-17-6-9-31-29-19-27(2)23-41(31,47)33-11-13-37(49)43-35(33)21-29/h10-13,18-19,28-31H,5-9,14-17,20-25H2,1-4H3,(H,42,48)(H,43,49)/t28?,29?,30-,31-,40-,41-/m1/s1
DM5WFQM CS CC1=CC2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2CCCN4C(=O)CN(C)CCCN(C)CC(=O)N5CCC[C@H]6[C@@]57CC(=CC6CC8=C7C=CC(=O)N8)C
DM5WFQM IK KTFGBMXGPUIYSS-LMMAWDAISA-N
DM5WFQM IU (1R,10R)-16-methyl-14-[2-[methyl-[3-[methyl-[2-[(1R,10R)-16-methyl-5-oxo-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-14-yl]-2-oxoethyl]amino]propyl]amino]acetyl]-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DM5WFQM DE Discovery agent
DMK2ZG4 ID DMK2ZG4
DMK2ZG4 DN Bis(benzo[b]furan-2-yl)methanone
DMK2ZG4 HS Investigative
DMK2ZG4 SN CHEMBL226417; bis(benzo[b]furan-2-yl)methanone; bis-benzofuranyl ketone; AC1PLNEG; SCHEMBL244107; bis(1-benzofuran-2-yl)methanone; MolPort-000-640-603; ZINC8048290; BDBM50202218; AKOS002385499; MCULE-1633046929; 2-(1-benzofuran-2-carbonyl)-1-benzofuran; Z232333564
DMK2ZG4 DT Small molecular drug
DMK2ZG4 PC 9179241
DMK2ZG4 MW 262.26
DMK2ZG4 FM C17H10O3
DMK2ZG4 IC InChI=1S/C17H10O3/c18-17(15-9-11-5-1-3-7-13(11)19-15)16-10-12-6-2-4-8-14(12)20-16/h1-10H
DMK2ZG4 CS C1=CC=C2C(=C1)C=C(O2)C(=O)C3=CC4=CC=CC=C4O3
DMK2ZG4 IK ZLYFWIZGRHGKMM-UHFFFAOYSA-N
DMK2ZG4 IU bis(1-benzofuran-2-yl)methanone
DMK2ZG4 DE Discovery agent
DMYSQ2B ID DMYSQ2B
DMYSQ2B DN Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether
DMYSQ2B HS Investigative
DMYSQ2B SN CHEMBL444149; Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether
DMYSQ2B DT Small molecular drug
DMYSQ2B PC 44567598
DMYSQ2B MW 636.7
DMYSQ2B FM C38H40N2O7
DMYSQ2B IC InChI=1S/C38H40N2O7/c1-39-9-7-23-15-25(19-27-33(23)29(39)17-21-3-5-31(41)37(43)35(21)27)46-13-11-45-12-14-47-26-16-24-8-10-40(2)30-18-22-4-6-32(42)38(44)36(22)28(20-26)34(24)30/h3-6,15-16,19-20,29-30,41-44H,7-14,17-18H2,1-2H3/t29-,30-/m1/s1
DMYSQ2B CS CN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OCCOCCOC5=CC6=C7[C@@H](CC8=C(C7=C5)C(=C(C=C8)O)O)N(CC6)C)C(=C(C=C4)O)O
DMYSQ2B IK GJLNFWNMAQBYPC-LOYHVIPDSA-N
DMYSQ2B IU (6aR)-2-[2-[2-[[(6aR)-10,11-dihydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-2-yl]oxy]ethoxy]ethoxy]-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMYSQ2B DE Discovery agent
DMVNC1R ID DMVNC1R
DMVNC1R DN Bis-7-tacrine
DMVNC1R HS Investigative
DMVNC1R SN Bis(7)-tacrine
DMVNC1R DT Small molecular drug
DMVNC1R PC 9549196
DMVNC1R MW 492.7
DMVNC1R FM C33H40N4
DMVNC1R IC InChI=1S/C33H40N4/c1(2-12-22-34-32-24-14-4-8-18-28(24)36-29-19-9-5-15-25(29)32)3-13-23-35-33-26-16-6-10-20-30(26)37-31-21-11-7-17-27(31)33/h4,6,8,10,14,16,18,20H,1-3,5,7,9,11-13,15,17,19,21-23H2,(H,34,36)(H,35,37)
DMVNC1R CS C1CCC2=NC3=CC=CC=C3C(=C2C1)NCCCCCCCNC4=C5CCCCC5=NC6=CC=CC=C64
DMVNC1R IK ITZOKHKOFJOBFS-UHFFFAOYSA-N
DMVNC1R IU N,N'-bis(1,2,3,4-tetrahydroacridin-9-yl)heptane-1,7-diamine
DMVNC1R CA CAS 181865-13-4
DMVNC1R CB CHEBI:138435
DMVNC1R DE Discovery agent
DMRSKGC ID DMRSKGC
DMRSKGC DN bisandrographolide
DMRSKGC HS Investigative
DMRSKGC SN bisandrographolide; Bisandrographolide A; Bisandrographolide C; 160498-00-0; 160498-02-2; C40H56O8; GTPL2502; MolPort-039-338-289; 9116AF; 9115AF; AKOS032948243
DMRSKGC DT Small molecular drug
DMRSKGC PC 12000062
DMRSKGC MW 664.9
DMRSKGC FM C40H56O8
DMRSKGC IC InChI=1S/C40H56O8/c1-23-7-11-31-37(3,16-13-33(43)39(31,5)21-41)28(23)10-9-25-19-30(48-35(25)45)27(26-15-18-47-36(26)46)20-29-24(2)8-12-32-38(29,4)17-14-34(44)40(32,6)22-42/h9-10,15,19,27-34,41-44H,1-2,7-8,11-14,16-18,20-22H2,3-6H3/b10-9+/t27?,28-,29-,30?,31+,32+,33-,34-,37+,38+,39+,40+/m1/s1
DMRSKGC CS C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2CC(C3C=C(C(=O)O3)/C=C/[C@@H]4C(=C)CC[C@H]5[C@]4(CC[C@H]([C@@]5(C)CO)O)C)C6=CCOC6=O)(C)CO)O
DMRSKGC IK WQHWOZANSOUSAY-LZBAHHAZSA-N
DMRSKGC IU 4-[(E)-2-[(1R,4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethenyl]-2-[2-[(1R,4aS,5R,6R,8aR)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-1-(5-oxo-2H-furan-4-yl)ethyl]-2H-furan-5-one
DMRSKGC DE Discovery agent
DMF4AHD ID DMF4AHD
DMF4AHD DN Bis-cyclosal-d4TMP
DMF4AHD HS Investigative
DMF4AHD SN bis-cyclosal-d4TMP; CHEMBL376095; 5-methyl-1-[(2R,5S)-5-[[8-[2-[[(2S,5R)-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]-2-oxo-4H-1,3,2$l^{5}-benzodioxaphosphinin-8-yl]-2-oxo-4H-1,3,2$l^{5}-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione; 2,4(1H,3H)-Pyrimidinedione, 1,1'-[(2,2'-dioxido[8,8'-bi-4H-1,3,2-benzodioxaphosphorin]-2,2'-diyl)bis[oxymethylene[(2R,5S)-2,5-dihydro-5,2-furandiyl]]]bis[5-methyl-
DMF4AHD DT Small molecular drug
DMF4AHD PC 16115140
DMF4AHD MW 782.6
DMF4AHD FM C34H32N4O14P2
DMF4AHD IC InChI=1S/C34H32N4O14P2/c1-19-13-37(33(41)35-31(19)39)27-11-9-23(49-27)17-47-53(43)45-15-21-5-3-7-25(29(21)51-53)26-8-4-6-22-16-46-54(44,52-30(22)26)48-18-24-10-12-28(50-24)38-14-20(2)32(40)36-34(38)42/h3-14,23-24,27-28H,15-18H2,1-2H3,(H,35,39,41)(H,36,40,42)/t23-,24-,27+,28+,53?,54?/m0/s1
DMF4AHD CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=C(O3)C(=CC=C4)C5=CC=CC6=C5OP(=O)(OC6)OC[C@@H]7C=C[C@@H](O7)N8C=C(C(=O)NC8=O)C
DMF4AHD IK KHOMSKKMHVGQFN-QIKIAYFISA-N
DMF4AHD IU 5-methyl-1-[(2R,5S)-5-[[8-[2-[[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methoxy]-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-8-yl]-2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl]oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DMF4AHD DE Discovery agent
DMVRXH3 ID DMVRXH3
DMVRXH3 DN Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
DMVRXH3 HS Investigative
DMVRXH3 SN BISHYDROXY[2H-1-BENZOPYRAN-2-ONE,1,2-BENZOPYRONE]; DB04392
DMVRXH3 DT Small molecular drug
DMVRXH3 PC 17753965
DMVRXH3 MW 336.3
DMVRXH3 FM C19H12O6
DMVRXH3 IC InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,12-13H,9H2/t12-,13+
DMVRXH3 CS C1=CC=C2C(=C1)C(=O)[C@H](C(=O)O2)C[C@H]3C(=O)C4=CC=CC=C4OC3=O
DMVRXH3 IK HIZKPJUTKKJDGA-BETUJISGSA-N
DMVRXH3 IU (3S)-3-[[(3R)-2,4-dioxochromen-3-yl]methyl]chromene-2,4-dione
DMVRXH3 DE Discovery agent
DM0MK6D ID DM0MK6D
DM0MK6D DN BIS-IMIDE A
DM0MK6D HS Investigative
DM0MK6D SN CHEMBL388648; BIS-IMIDE A; SCHEMBL5879127; BDBM50220067; 9H-Carbazole-1,2:3,4-bisdicarbimide
DM0MK6D DT Small molecular drug
DM0MK6D PC 10086414
DM0MK6D MW 305.24
DM0MK6D FM C16H7N3O4
DM0MK6D IC InChI=1S/C16H7N3O4/c20-13-8-7-5-3-1-2-4-6(5)17-12(7)11-10(9(8)14(21)18-13)15(22)19-16(11)23/h1-4,17H,(H,18,20,21)(H,19,22,23)
DM0MK6D CS C1=CC=C2C(=C1)C3=C4C(=C5C(=C3N2)C(=O)NC5=O)C(=O)NC4=O
DM0MK6D IK IZHSJTMCSHXFHX-UHFFFAOYSA-N
DM0MK6D IU 4,9,19-triazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1,6,11,13,15,17-hexaene-3,5,8,10-tetrone
DM0MK6D DE Discovery agent
DMOQJZC ID DMOQJZC
DMOQJZC DN Bisindolylmaleimide-I
DMOQJZC HS Investigative
DMOQJZC SN Bisindolylmaleimide i; bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; Go 6850; GF-109203X; RBT205 INHIBITOR; Go-6850; UNII-L79H6N0V6C; 6850; Bisindolylmaleimide I (GF 109203X); CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; L79H6N0V6C; QMGUOJYZJKLOLH-UHFFFAOYSA-N; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; GF-109203; Go6850
DMOQJZC DT Small molecular drug
DMOQJZC PC 2396
DMOQJZC MW 412.5
DMOQJZC FM C25H24N4O2
DMOQJZC IC InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)
DMOQJZC CS CN(C)CCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54
DMOQJZC IK QMGUOJYZJKLOLH-UHFFFAOYSA-N
DMOQJZC IU 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione
DMOQJZC CA CAS 133052-90-1
DMOQJZC DE Discovery agent
DM0K6QH ID DM0K6QH
DM0K6QH DN Bis-Napthyl Beta-Ketophosphonic Acid
DM0K6QH HS Investigative
DM0K6QH SN BIS-NAPTHYL BETA-KETOPHOSPHONIC ACID; [(1R)-1-naphthalen-1-yl-2-naphthalen-2-yl-2-oxoethyl]phosphonic acid; (2-NAPHTHALEN-2-YL-1-NAPHTHALEN-1-YL-2-OXO-ETHYL)-PHOSPHONIC ACID; KTP; 1kyn; AC1L9K5C; DB02360; (1R)-1-(naphthalen-1-yl)-2-(naphthalen-2-yl)-2-oxoethylphosphonic acid
DM0K6QH DT Small molecular drug
DM0K6QH PC 446833
DM0K6QH MW 376.3
DM0K6QH FM C22H17O4P
DM0K6QH IC InChI=1S/C22H17O4P/c23-21(18-13-12-15-6-1-2-8-17(15)14-18)22(27(24,25)26)20-11-5-9-16-7-3-4-10-19(16)20/h1-14,22H,(H2,24,25,26)/t22-/m1/s1
DM0K6QH CS C1=CC=C2C=C(C=CC2=C1)C(=O)[C@@H](C3=CC=CC4=CC=CC=C43)P(=O)(O)O
DM0K6QH IK OFHMUASCSJJNNA-JOCHJYFZSA-N
DM0K6QH IU [(1R)-1-naphthalen-1-yl-2-naphthalen-2-yl-2-oxoethyl]phosphonic acid
DM0K6QH DE Discovery agent
DM2ZLD7 ID DM2ZLD7
DM2ZLD7 DN Bisphenol A
DM2ZLD7 HS Investigative
DM2ZLD7 SN BPA
DM2ZLD7 DT Small molecular drug
DM2ZLD7 PC 6623
DM2ZLD7 MW 228.29
DM2ZLD7 FM C15H16O2
DM2ZLD7 IC InChI=1S/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H3
DM2ZLD7 CS CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O
DM2ZLD7 IK IISBACLAFKSPIT-UHFFFAOYSA-N
DM2ZLD7 IU 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol
DM2ZLD7 CA CAS 80-05-7
DM2ZLD7 CB CHEBI:33216
DM2ZLD7 DE Discovery agent
DMFHY04 ID DMFHY04
DMFHY04 DN BIX 02188
DMFHY04 HS Investigative
DMFHY04 SN BIX02188; BIX-02188
DMFHY04 DT Small molecular drug
DMFHY04 PC 135398492
DMFHY04 MW 412.5
DMFHY04 FM C25H24N4O2
DMFHY04 IC InChI=1S/C25H24N4O2/c1-29(2)15-16-7-6-10-19(13-16)27-23(17-8-4-3-5-9-17)22-20-12-11-18(24(26)30)14-21(20)28-25(22)31/h3-14,28,31H,15H2,1-2H3,(H2,26,30)
DMFHY04 CS CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O
DMFHY04 IK WGPXKFOFEXJMBD-UHFFFAOYSA-N
DMFHY04 IU 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide
DMFHY04 CA CAS 1094614-84-2
DMFHY04 DE Discovery agent
DMNAX1Q ID DMNAX1Q
DMNAX1Q DN BIX 02565
DMNAX1Q HS Investigative
DMNAX1Q SN BIX02565; BIX-02565
DMNAX1Q DT Small molecular drug
DMNAX1Q PC 53246941
DMNAX1Q MW 458.6
DMNAX1Q FM C26H30N6O2
DMNAX1Q IC InChI=1S/C26H30N6O2/c1-17-11-12-27-25(34)23-15-18-9-10-19(16-22(18)32(17)23)24(33)29-26-28-20-7-4-5-8-21(20)31(26)14-6-13-30(2)3/h4-5,7-10,15-17H,6,11-14H2,1-3H3,(H,27,34)(H,28,29,33)/t17-/m1/s1
DMNAX1Q CS C[C@@H]1CCNC(=O)C2=CC3=C(N12)C=C(C=C3)C(=O)NC4=NC5=CC=CC=C5N4CCCN(C)C
DMNAX1Q IK ZHMXXVNQAFCXKK-QGZVFWFLSA-N
DMNAX1Q IU (5R)-N-[1-[3-(dimethylamino)propyl]benzimidazol-2-yl]-5-methyl-1-oxo-2,3,4,5-tetrahydro-[1,4]diazepino[1,2-a]indole-8-carboxamide
DMNAX1Q DE Discovery agent
DMGULNZ ID DMGULNZ
DMGULNZ DN BL-5040
DMGULNZ HS Investigative
DMGULNZ SN Leptin antagonist (anorexia), BioLineRx; Leptin antagonist (cachexia), BioLineRx; Leptin antagonist (inflammatory bowel disease), BioLineRx
DMGULNZ CP Hebrew University of Jerusalem
DMGULNZ DE Cachexia
DMQLJMC ID DMQLJMC
DMQLJMC DN BL-6020
DMQLJMC HS Investigative
DMQLJMC SN SNT-207707; SNT-207858; SNT-209858; MC4-R antagonists (anorexia), Santhera; MC4-R antagonists (cachexia), Santhera; Melanocortin 4 receptor antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera; MC4-R antagonists (cachexia/anorexia), Santhera/ BioLineRx
DMQLJMC CP MyoContract Pharmaceutical Research Ltd
DMQLJMC DE Cachexia
DMBRZ4P ID DMBRZ4P
DMBRZ4P DN BLV-0703
DMBRZ4P HS Investigative
DMBRZ4P SN BLV-200703; KTP-NH2; TAU-targeting compound (CNS disorders), Bioalvo
DMBRZ4P CP Bioalvo SA
DMBRZ4P DE Central nervous system disease
DMGB9PN ID DMGB9PN
DMGB9PN DN BLV-0801
DMGB9PN HS Investigative
DMGB9PN SN SBLK-200801; IDO inhibitor (CNS disorders), Bioalvo; Indoleamine dioxygenase inhibitor (CNS disorders), Bioalvo
DMGB9PN CP Bioalvo SA
DMGB9PN DE Solid tumour/cancer
DM728RW ID DM728RW
DM728RW DN BLX-301
DM728RW HS Investigative
DM728RW SN Glyco-optimized rituximab; Anti-CD20 antibody (LEX, non-Hodgkin lymphoma); Anti-CD20 antibody (non-Hodgkin lymphoma), EPIcyte; Anti-CD20 antibody (LEX, non-Hodgkin lymphoma), Biolex
DM728RW CP EPIcyte Pharmaceutical Inc
DM728RW DT Antibody
DM728RW DE Non-hodgkin lymphoma
DMDNPML ID DMDNPML
DMDNPML DN BM-162115
DMDNPML HS Investigative
DMDNPML SN 115077-66-2; 1,6-Dioxadispiro[4.1.5.1]trideca-8,11-diene-2,10-dione; 1,6-Dioxadispiro(4.1.5.1)trideca-8,11-diene-2,10-dione; BM 162115; ACMC-20ml0u; BM-162115; BM 16.2115; SCHEMBL8797307; AC1L526V; CTK0I0331
DMDNPML CP Boehringer Mannheim GmbH
DMDNPML DT Small molecular drug
DMDNPML PC 196711
DMDNPML MW 206.19
DMDNPML FM C11H10O4
DMDNPML IC InChI=1S/C11H10O4/c12-8-1-4-10(5-2-8)7-11(15-10)6-3-9(13)14-11/h1-2,4-5H,3,6-7H2
DMDNPML CS C1CC2(CC3(O2)C=CC(=O)C=C3)OC1=O
DMDNPML IK CAZSBBDSSNQJGI-UHFFFAOYSA-N
DMDNPML IU 4,13-dioxadispiro[4.1.57.15]trideca-8,11-diene-3,10-dione
DMDNPML CA CAS 115077-66-2
DMDNPML DE Inflammation
DMD2H7L ID DMD2H7L
DMD2H7L DN BM-573
DMD2H7L HS Investigative
DMD2H7L SN BM-573; UNII-8E9L957C3G; CHEMBL210602; 8E9L957C3G; AC1NSM3C; SCHEMBL3393325; BM 573; BDBM50188619; NSC732094; NSC-732094; 284464-83-1; Benzenesulfonamide, N-(((1,1-dimethylethyl)amino)carbonyl)-2-((4-methylphenyl)amino)-5-nitro-; LS-191119; 1-(2-(p-toluidino)-5-nitrophenylsulfonyl)-3-tert-butylurea; 1-tert-butyl-3-[2-(4-methylanilino)-5-nitrophenyl]sulfonylurea; N-tert-butyl-N''-[2-(4-methylphenylamino)-5-nitrobenzenesulfonyl]urea; N-tertbutyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfo nyl]urea
DMD2H7L DT Small molecular drug
DMD2H7L PC 5312142
DMD2H7L MW 406.5
DMD2H7L FM C18H22N4O5S
DMD2H7L IC InChI=1S/C18H22N4O5S/c1-12-5-7-13(8-6-12)19-15-10-9-14(22(24)25)11-16(15)28(26,27)21-17(23)20-18(2,3)4/h5-11,19H,1-4H3,(H2,20,21,23)
DMD2H7L CS CC1=CC=C(C=C1)NC2=C(C=C(C=C2)[N+](=O)[O-])S(=O)(=O)NC(=O)NC(C)(C)C
DMD2H7L IK SILRUCMXYIKULW-UHFFFAOYSA-N
DMD2H7L IU 1-tert-butyl-3-[2-(4-methylanilino)-5-nitrophenyl]sulfonylurea
DMD2H7L CA CAS 284464-83-1
DMD2H7L DE Discovery agent
DM8AEQX ID DM8AEQX
DM8AEQX DN Bmab-200
DM8AEQX HS Investigative
DM8AEQX SN Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon
DM8AEQX CP Biocon Ltd
DM8AEQX DT Antibody
DM8AEQX DE Solid tumour/cancer
DMER2WS ID DMER2WS
DMER2WS DN BML3-C01
DMER2WS HS Investigative
DMER2WS SN Adrenic acid; TWSWSIQAPQLDBP-DOFZRALJSA-N; (7Z,10Z,13Z,16Z)-Docosa-7,10,13,16-tetraenoic acid; 28874-58-0; 7,10,13,16-Docosatetraenoate; 7,10,13,16-Docosatetraenoic acid; 7,10,13,16-Docosatetraenoic acid, (all-Z)-; 7,10,13,16-docosatetraenoic acid, (7Z,10Z,13Z,16Z)-; 7Z,10Z,13Z,16Z-Docosatetraenoic acid; AC1NUZMR; Cis-7,10,13,16-docosatetraenoic acid; BSPBio_001499; CHEBI:53487; CHEMBL1491103; HMS1791K21; HMS1989K21; SCHEMBL19452; all-cis-7,10,13,16-Docosatetraenoic acid; all-cis-docosa-7,10,13,16-tetraenoic acid; cis-7,10,13,16-Docosatetraenoic acid
DMER2WS PC 5497181
DMER2WS MW 332.5
DMER2WS FM C22H36O2
DMER2WS IC TWSWSIQAPQLDBP-DOFZRALJSA-N
DMER2WS CS CCCCCC=CCC=CCC=CCC=CCCCCCC(=O)O
DMER2WS IK 1S/C22H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,23,24)/b7-6-,10-9-,13-12-,16-15-
DMER2WS IU (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoic acid
DMER2WS CA CAS 28874-58-0
DMER2WS CB CHEBI:53487
DMER2WS DE Discovery agent
DMYWEO6 ID DMYWEO6
DMYWEO6 DN BMN-103
DMYWEO6 HS Investigative
DMYWEO6 SN Alpha-glucosidase (Pompe disease), BioMarin
DMYWEO6 CP BioMarin Pharmaceutical Inc
DMYWEO6 DE Pompe disease
DM0VMZ4 ID DM0VMZ4
DM0VMZ4 DN BMN-168
DM0VMZ4 HS Investigative
DM0VMZ4 SN Sapropterin prodrug, BioMarin; 6R-BH4 prodrug, BioMarin
DM0VMZ4 CP BioMarin Pharmaceutical Inc
DM0VMZ4 DE Phenylketonuria
DMR82WI ID DMR82WI
DMR82WI DN BMS compound 4c
DMR82WI HS Investigative
DMR82WI DT Small molecular drug
DMR82WI PC 71655433
DMR82WI MW 470.5
DMR82WI FM C24H21F3N4OS
DMR82WI IC InChI=1S/C24H21F3N4OS/c1-23(2,3)17-7-4-5-9-19(17)32-20-18(8-6-14-28-20)29-22-31-30-21(33-22)15-10-12-16(13-11-15)24(25,26)27/h4-14H,1-3H3,(H,29,31)
DMR82WI CS CC(C)(C)C1=CC=CC=C1OC2=C(C=CC=N2)NC3=NN=C(S3)C4=CC=C(C=C4)C(F)(F)F
DMR82WI IK ROIKEXLVELZTIZ-UHFFFAOYSA-N
DMR82WI IU N-[2-(2-tert-butylphenoxy)pyridin-3-yl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-amine
DMR82WI DE Discovery agent
DMJM8OQ ID DMJM8OQ
DMJM8OQ DN BMS pyrazole inhibitor 7f
DMJM8OQ HS Investigative
DMJM8OQ SN CHEMBL468927; BMS pyrazole inhibitor 7f; ASIS-P021; GTPL7030; SCHEMBL14565559; ZINC40891759; BDBM50258790; (2S)-2-amino-N-[(3-{5-[5-(1,3-benzothiazol-7-yl)-1,3,4-oxadiazol-2-yl]-3-(trifluoromethyl)-1H-pyrazol-1-yl}phenyl)methyl]propanamide; (S)-2-amino-N-(3-(5-(5-(benzo[d]thiazol-7-yl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide
DMJM8OQ DT Small molecular drug
DMJM8OQ PC 44219611
DMJM8OQ MW 513.5
DMJM8OQ FM C23H18F3N7O2S
DMJM8OQ IC InChI=1S/C23H18F3N7O2S/c1-12(27)20(34)28-10-13-4-2-5-14(8-13)33-17(9-18(32-33)23(24,25)26)22-31-30-21(35-22)15-6-3-7-16-19(15)36-11-29-16/h2-9,11-12H,10,27H2,1H3,(H,28,34)/t12-/m0/s1
DMJM8OQ CS C[C@@H](C(=O)NCC1=CC(=CC=C1)N2C(=CC(=N2)C(F)(F)F)C3=NN=C(O3)C4=C5C(=CC=C4)N=CS5)N
DMJM8OQ IK KODBDIFHMBDFOH-LBPRGKRZSA-N
DMJM8OQ IU (2S)-2-amino-N-[[3-[5-[5-(1,3-benzothiazol-7-yl)-1,3,4-oxadiazol-2-yl]-3-(trifluoromethyl)pyrazol-1-yl]phenyl]methyl]propanamide
DMJM8OQ DE Discovery agent
DM4D6ZB ID DM4D6ZB
DM4D6ZB DN BMS-1
DM4D6ZB HS Investigative
DM4D6ZB SN 474429-87-3; Carbamic acid,N-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]-,2-fluorophenyl ester; SCHEMBL1709522; CHEMBL232782; bisarylimidazole derivative, 17; BDBM26758; ZINC1912275; KB-75932; 2-fluorophenyl N-[6-(2-methyl-4,5-diphenyl-1H-imidazol-1-yl)hexyl]carbamate
DM4D6ZB DT Small molecular drug
DM4D6ZB PC 91663303
DM4D6ZB MW 475.6
DM4D6ZB FM C29H33NO5
DM4D6ZB IC InChI=1S/C29H33NO5/c1-20-22(12-9-13-24(20)21-10-5-4-6-11-21)19-35-23-16-27(33-2)25(28(17-23)34-3)18-30-15-8-7-14-26(30)29(31)32/h4-6,9-13,16-17,26H,7-8,14-15,18-19H2,1-3H3,(H,31,32)/t26-/m0/s1
DM4D6ZB CS CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC(=C(C(=C3)OC)CN4CCCC[C@H]4C(=O)O)OC
DM4D6ZB IK ZBOYJODMIAUJHH-SANMLTNESA-N
DM4D6ZB IU (2S)-1-[[2,6-dimethoxy-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid
DM4D6ZB DE Discovery agent
DMGE82R ID DMGE82R
DMGE82R DN BMS184394
DMGE82R HS Investigative
DMGE82R SN CHEMBL82089; AC1NBJP6; SCHEMBL6372648; BDBM31885; 6-[hydroxy-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic Acid
DMGE82R DT Small molecular drug
DMGE82R PC 445575
DMGE82R MW 388.5
DMGE82R FM C26H28O3
DMGE82R IC InChI=1S/C26H28O3/c1-25(2)11-12-26(3,4)22-15-19(9-10-21(22)25)23(27)18-7-5-17-14-20(24(28)29)8-6-16(17)13-18/h5-10,13-15,23,27H,11-12H2,1-4H3,(H,28,29)/t23-/m0/s1
DMGE82R CS CC1(CCC(C2=C1C=CC(=C2)[C@H](C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)O)(C)C)C
DMGE82R IK AYAJZQYENGWICE-QHCPKHFHSA-N
DMGE82R IU 6-[(S)-hydroxy-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)methyl]naphthalene-2-carboxylic acid
DMGE82R DE Discovery agent
DMJ218E ID DMJ218E
DMJ218E DN BMS-187308
DMJ218E HS Investigative
DMJ218E SN 153624-15-8
DMJ218E DT Small molecular drug
DMJ218E PC 9908909
DMJ218E MW 399.5
DMJ218E FM C21H25N3O3S
DMJ218E IC InChI=1S/C21H25N3O3S/c1-13(2)11-16-9-10-17(19(22)12-16)18-7-5-6-8-20(18)28(25,26)24-21-14(3)15(4)23-27-21/h5-10,12-13,24H,11,22H2,1-4H3
DMJ218E CS CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC=C2C3=C(C=C(C=C3)CC(C)C)N
DMJ218E IK OZDIAVKCLFSBME-UHFFFAOYSA-N
DMJ218E IU 2-[2-amino-4-(2-methylpropyl)phenyl]-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide
DMJ218E CA CAS 153624-15-8
DMJ218E DE Discovery agent
DM7GUDC ID DM7GUDC
DM7GUDC DN BMS-189323
DM7GUDC HS Investigative
DM7GUDC SN SCHEMBL8353870; 2,6-Dimethyl-4-[3-[3-[3-[4-(2-methoxyphenyl)piperazino]propyl]ureido]phenyl]-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester
DM7GUDC DT Small molecular drug
DM7GUDC PC 11548842
DM7GUDC MW 591.7
DM7GUDC FM C32H41N5O6
DM7GUDC IC InChI=1S/C32H41N5O6/c1-21-27(30(38)42-4)29(28(22(2)34-21)31(39)43-5)23-10-8-11-24(20-23)35-32(40)33-14-9-15-36-16-18-37(19-17-36)25-12-6-7-13-26(25)41-3/h6-8,10-13,20,29,34H,9,14-19H2,1-5H3,(H2,33,35,40)
DM7GUDC CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=O)NCCCN3CCN(CC3)C4=CC=CC=C4OC)C(=O)OC
DM7GUDC IK HSUYTMPXLKOBTD-UHFFFAOYSA-N
DM7GUDC IU dimethyl 4-[3-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylcarbamoylamino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM7GUDC DE Discovery agent
DM1ZBU3 ID DM1ZBU3
DM1ZBU3 DN BMS-193885
DM1ZBU3 HS Investigative
DM1ZBU3 SN BMS-193885; UNII-819SRG2Y6N; 819SRG2Y6N; 186185-03-5; 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid; HMS3263K13; Tox21_501016; ZINC27088632; CCG-222320; NCGC00261701-01; NCGC00485144-01; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(3-((((3-(4-(3-methoxyphenyl)-1-piperidinyl)propyl)amino)carbonyl)amino)phenyl)-2,6-dimethyl-, dimethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(3-((((3-(4-(3-methoxyphen
DM1ZBU3 DT Small molecular drug
DM1ZBU3 PC 9960164
DM1ZBU3 MW 590.7
DM1ZBU3 FM C33H42N4O6
DM1ZBU3 IC InChI=1S/C33H42N4O6/c1-21-28(31(38)42-4)30(29(22(2)35-21)32(39)43-5)25-10-6-11-26(19-25)36-33(40)34-15-8-16-37-17-13-23(14-18-37)24-9-7-12-27(20-24)41-3/h6-7,9-12,19-20,23,30,35H,8,13-18H2,1-5H3,(H2,34,36,40)
DM1ZBU3 CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=O)NCCCN3CCC(CC3)C4=CC(=CC=C4)OC)C(=O)OC
DM1ZBU3 IK WMYSXJSJXZFODY-UHFFFAOYSA-N
DM1ZBU3 IU dimethyl 4-[3-[3-[4-(3-methoxyphenyl)piperidin-1-yl]propylcarbamoylamino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM1ZBU3 CA CAS 186185-03-5
DM1ZBU3 DE Discovery agent
DM5SNMQ ID DM5SNMQ
DM5SNMQ DN BMS-245782
DM5SNMQ HS Investigative
DM5SNMQ DT Small molecular drug
DM5SNMQ PC 11505425
DM5SNMQ MW 615.7
DM5SNMQ FM C33H41N7O5
DM5SNMQ IC InChI=1S/C33H41N7O5/c1-22-28(31(41)44-4)30(29(23(2)37-22)32(42)45-5)24-9-6-10-25(19-24)38-33(36-21-34)35-13-8-14-39-15-17-40(18-16-39)26-11-7-12-27(20-26)43-3/h6-7,9-12,19-20,30,37H,8,13-18H2,1-5H3,(H2,35,36,38)
DM5SNMQ CS CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC(=CC=C2)NC(=NCCCN3CCN(CC3)C4=CC(=CC=C4)OC)NC#N)C(=O)OC
DM5SNMQ IK HDRYBCLMRKGHSG-UHFFFAOYSA-N
DM5SNMQ IU dimethyl 4-[3-[[N-cyano-N'-[3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]carbamimidoyl]amino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DM5SNMQ DE Discovery agent
DMETNA3 ID DMETNA3
DMETNA3 DN BMS-262084
DMETNA3 HS Investigative
DMETNA3 SN BMS-262084; UNII-I0IR71971G; CHEMBL71037; I0IR71971G; 253174-92-4; (-)-BMS-262084; BDBM50120368; BDBM50220841; SB18716; 2-Azetidinecarboxylic acid, 3-(3-((aminoiminomethyl)amino)propyl)-1-((4-(((1,1-dimethylethyl)amino)carbonyl)-1-piperazinyl)carbonyl)-4-oxo-, (2S,3R)-; (R)-1-(4-tert-Butylcarbamoyl-piperazine-1-carbonyl)-3-(3-guanidino-propyl)-4-oxo-azetidine-2-carboxylic acid; (3S,4R)-1-(4-tert-Butylcarbamoyl-piperazine-1-carbonyl)-3-(3-guanidino-propyl)-4-oxo-azetidine-2-carboxylic acid
DMETNA3 DT Small molecular drug
DMETNA3 PC 9802488
DMETNA3 MW 425.5
DMETNA3 FM C18H31N7O5
DMETNA3 IC InChI=1S/C18H31N7O5/c1-18(2,3)22-16(29)23-7-9-24(10-8-23)17(30)25-12(14(27)28)11(13(25)26)5-4-6-21-15(19)20/h11-12H,4-10H2,1-3H3,(H,22,29)(H,27,28)(H4,19,20,21)/t11-,12+/m1/s1
DMETNA3 CS CC(C)(C)NC(=O)N1CCN(CC1)C(=O)N2[C@@H]([C@H](C2=O)CCCN=C(N)N)C(=O)O
DMETNA3 IK MFTQITSPGQORDA-NEPJUHHUSA-N
DMETNA3 IU (2S,3R)-1-[4-(tert-butylcarbamoyl)piperazine-1-carbonyl]-3-[3-(diaminomethylideneamino)propyl]-4-oxoazetidine-2-carboxylic acid
DMETNA3 CA CAS 253174-92-4
DMETNA3 DE Discovery agent
DM6LPIG ID DM6LPIG
DM6LPIG DN BMS-265246
DM6LPIG HS Investigative
DM6LPIG SN BMS 265246; BMS265246
DM6LPIG DT Small molecular drug
DM6LPIG PC 135402864
DM6LPIG MW 345.3
DM6LPIG FM C18H17F2N3O2
DM6LPIG IC InChI=1S/C18H17F2N3O2/c1-3-4-5-25-17-11(8-21-18-12(17)9-22-23-18)16(24)15-13(19)6-10(2)7-14(15)20/h6-9H,3-5H2,1-2H3,(H,21,22,23)
DM6LPIG CS CCCCOC1=C(C=NC2=NNC=C12)C(=O)C3=C(C=C(C=C3F)C)F
DM6LPIG IK SCFMWQIQBVZOQR-UHFFFAOYSA-N
DM6LPIG IU (4-butoxy-2H-pyrazolo[3,4-b]pyridin-5-yl)-(2,6-difluoro-4-methylphenyl)methanone
DM6LPIG CA CAS 582315-72-8
DM6LPIG DE Discovery agent
DMZLE0U ID DMZLE0U
DMZLE0U DN BMS-269223
DMZLE0U HS Investigative
DMZLE0U SN CHEMBL551991; cyanoguanidine, 3; BMS-269223
DMZLE0U DT Small molecular drug
DMZLE0U PC 44249821
DMZLE0U MW 436.5
DMZLE0U FM C23H28N6O3
DMZLE0U IC InChI=1S/C23H28N6O3/c1-16-12-17-13-18(7-8-20(17)32-16)26-23(25-15-24)27-19-6-2-3-11-29(22(19)31)14-21(30)28-9-4-5-10-28/h7-8,12-13,19H,2-6,9-11,14H2,1H3,(H2,25,26,27)/t19-/m0/s1
DMZLE0U CS CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC#N
DMZLE0U IK BQUXAJWDRCSKFN-IBGZPJMESA-N
DMZLE0U IU 1-cyano-3-(2-methyl-1-benzofuran-5-yl)-2-[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]guanidine
DMZLE0U DE Discovery agent
DM82SJP ID DM82SJP
DM82SJP DN BMS270394
DM82SJP HS Investigative
DM82SJP SN BMS 961; BMS-270394; BMS 270394
DM82SJP DT Small molecular drug
DM82SJP PC 445455
DM82SJP MW 399.5
DM82SJP FM C23H26FNO4
DM82SJP IC InChI=1S/C23H26FNO4/c1-22(2)9-10-23(3,4)16-11-13(5-7-15(16)22)19(26)20(27)25-18-8-6-14(21(28)29)12-17(18)24/h5-8,11-12,19,26H,9-10H2,1-4H3,(H,25,27)(H,28,29)/t19-/m1/s1
DM82SJP CS CC1(CCC(C2=C1C=CC(=C2)[C@H](C(=O)NC3=C(C=C(C=C3)C(=O)O)F)O)(C)C)C
DM82SJP IK AANFHDFOMFRLLR-LJQANCHMSA-N
DM82SJP IU 3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid
DM82SJP DE Discovery agent
DMOLCFQ ID DMOLCFQ
DMOLCFQ DN BMS-279700
DMOLCFQ HS Investigative
DMOLCFQ SN BMS-279700; UNII-8FX9DP2Y1W; 8FX9DP2Y1W; CHEMBL189338; 240814-54-4; SCHEMBL4036209; BDBM50151366; Imidazo(1,5-a)pyrido(3,2-E)pyrazin-6-amine, N-(2-chloro-6-methylphenyl)-2-((3S)-3-methyl-1-piperazinyl)-
DMOLCFQ DT Small molecular drug
DMOLCFQ PC 9844320
DMOLCFQ MW 407.9
DMOLCFQ FM C21H22ClN7
DMOLCFQ IC InChI=1S/C21H22ClN7/c1-13-4-3-5-15(22)19(13)27-20-17-10-23-12-29(17)21-16(25-20)6-7-18(26-21)28-9-8-24-14(2)11-28/h3-7,10,12,14,24H,8-9,11H2,1-2H3,(H,25,27)/t14-/m0/s1
DMOLCFQ CS C[C@H]1CN(CCN1)C2=NC3=C(C=C2)N=C(C4=CN=CN43)NC5=C(C=CC=C5Cl)C
DMOLCFQ IK PUNYTBZWCMNSRO-AWEZNQCLSA-N
DMOLCFQ IU N-(2-chloro-6-methylphenyl)-12-[(3S)-3-methylpiperazin-1-yl]-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),3,5,7,10,12-hexaen-7-amine
DMOLCFQ CA CAS 240814-54-4
DMOLCFQ DE Discovery agent
DM21CYI ID DM21CYI
DM21CYI DN BMS-316810
DM21CYI HS Investigative
DM21CYI SN BMS-316810; CHEMBL360330; SCHEMBL12961958; BDBM50164025; Pyridine-2-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-thiophen-3-ylmethyl-amide
DM21CYI DT Small molecular drug
DM21CYI PC 9806149
DM21CYI MW 504.6
DM21CYI FM C25H24N6O2S2
DM21CYI IC InChI=1S/C25H24N6O2S2/c1-29-18-27-13-23(29)16-30-15-22(11-21-10-19(12-26)5-6-24(21)30)31(14-20-7-9-34-17-20)35(32,33)25-4-2-3-8-28-25/h2-10,13,17-18,22H,11,14-16H2,1H3
DM21CYI CS CN1C=NC=C1CN2CC(CC3=C2C=CC(=C3)C#N)N(CC4=CSC=C4)S(=O)(=O)C5=CC=CC=N5
DM21CYI IK FPEPZFNRGIPRRN-UHFFFAOYSA-N
DM21CYI IU N-[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-N-(thiophen-3-ylmethyl)pyridine-2-sulfonamide
DM21CYI DE Discovery agent
DM9WRUG ID DM9WRUG
DM9WRUG DN BMS-344577
DM9WRUG HS Investigative
DM9WRUG SN BMS-344577; UNII-U259PQB19A; U259PQB19A; CHEMBL570867; 288079-93-6; BDBM35316; BDBM50328724; 2,5-Pyridinedicarboxamide, N5-((((3S)-hexahydro-2-oxo-1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-1H-azepin-3-yl)imino)((2-methyl-5-benzofuranyl)amino)methyl)-N2,N2-dimethyl-; 2,5-Pyridinedicarboxamide, N5-((((3S)-hexahydro-2-oxo-1-(2-oxo-2-(1-pyrrolidinyl)ethyl)-1H-azepin-3-yl)amino)((2-methyl-5-benzofuranyl)amino)methylene)-N2,N2-dimethyl-
DM9WRUG DT Small molecular drug
DM9WRUG PC 44473100
DM9WRUG MW 587.7
DM9WRUG FM C31H37N7O5
DM9WRUG IC InChI=1S/C31H37N7O5/c1-20-16-22-17-23(10-12-26(22)43-20)33-31(35-28(40)21-9-11-24(32-18-21)29(41)36(2)3)34-25-8-4-5-15-38(30(25)42)19-27(39)37-13-6-7-14-37/h9-12,16-18,25H,4-8,13-15,19H2,1-3H3,(H2,33,34,35,40)/t25-/m0/s1
DM9WRUG CS CC1=CC2=C(O1)C=CC(=C2)NC(=N[C@H]3CCCCN(C3=O)CC(=O)N4CCCC4)NC(=O)C5=CN=C(C=C5)C(=O)N(C)C
DM9WRUG IK YLSKCQOVDOZHTQ-VWLOTQADSA-N
DM9WRUG IU 2-N,2-N-dimethyl-5-N-[N-(2-methyl-1-benzofuran-5-yl)-N'-[(3S)-2-oxo-1-(2-oxo-2-pyrrolidin-1-ylethyl)azepan-3-yl]carbamimidoyl]pyridine-2,5-dicarboxamide
DM9WRUG CA CAS 288079-93-6
DM9WRUG DE Discovery agent
DM7D519 ID DM7D519
DM7D519 DN BMS-345541
DM7D519 HS Investigative
DM7D519 SN 445430-58-0; BMS345541; BMS-345541 free base; BMS-345541 (free base); UNII-26SU0NEF5F; N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine; 26SU0NEF5F; IKK Inhibitor III, BMS-345541; C14H17N5; 4-(2& -Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline; BMS-345541(free base); IKK Inhibitor III; Kinome_3215; SCHEMBL118886; GTPL5669; CHEMBL249697; CTK8E9618; KS-00001CRN; CHEBI:91340; BDBM25919; DTXSID60196216; PSPFQEBFYXJZEV-UHFFFAOYSA-N; MolPort-035-395-836; HMS3653F06; HMS2043P05
DM7D519 DT Small molecular drug
DM7D519 PC 9926054
DM7D519 MW 291.78
DM7D519 FM C14H18ClN5
DM7D519 IC InChI=1S/C14H17N5.ClH/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15;/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18);1H
DM7D519 CS CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN.Cl
DM7D519 IK MIDKPVLYXNLFGZ-UHFFFAOYSA-N
DM7D519 IU N'-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine;hydrochloride
DM7D519 CA CAS 445430-59-1
DM7D519 DE Arthritis
DM1ZDFG ID DM1ZDFG
DM1ZDFG DN BMS-404683
DM1ZDFG HS Investigative
DM1ZDFG SN BMS-404683
DM1ZDFG DT Small molecular drug
DM1ZDFG PC 11409845
DM1ZDFG MW 521.6
DM1ZDFG FM C26H31N7O3S
DM1ZDFG IC InChI=1S/C26H31N7O3S/c1-26(2,3)30-24(34)17-33(37(35,36)25-7-5-6-10-29-25)21-12-20-11-19(13-27)8-9-23(20)32(15-21)16-22-14-28-18-31(22)4/h5-11,14,18,21H,12,15-17H2,1-4H3,(H,30,34)
DM1ZDFG CS CC(C)(C)NC(=O)CN(C1CC2=C(C=CC(=C2)C#N)N(C1)CC3=CN=CN3C)S(=O)(=O)C4=CC=CC=N4
DM1ZDFG IK BRCRPMJRHQPZEZ-UHFFFAOYSA-N
DM1ZDFG IU N-tert-butyl-2-[[6-cyano-1-[(3-methylimidazol-4-yl)methyl]-3,4-dihydro-2H-quinolin-3-yl]-pyridin-2-ylsulfonylamino]acetamide
DM1ZDFG DE Discovery agent
DMTPNI4 ID DMTPNI4
DMTPNI4 DN BMS-480404
DMTPNI4 HS Investigative
DMTPNI4 SN UNII-T78485CEYD; BMS-480404; T78485CEYD; CHEMBL378857; 533889-36-0; BDBM50192462; Benzeneacetic acid, 2,3-bis((2-chlorophenyl)methoxy)-alpha-hydroxy-, (alphaS)-; (S)-2-(2,3-bis(2-chlorobenzyloxy)phenyl)-2-hydroxyacetic acid
DMTPNI4 DT Small molecular drug
DMTPNI4 PC 16046219
DMTPNI4 MW 433.3
DMTPNI4 FM C22H18Cl2O5
DMTPNI4 IC InChI=1S/C22H18Cl2O5/c23-17-9-3-1-6-14(17)12-28-19-11-5-8-16(20(25)22(26)27)21(19)29-13-15-7-2-4-10-18(15)24/h1-11,20,25H,12-13H2,(H,26,27)/t20-/m0/s1
DMTPNI4 CS C1=CC=C(C(=C1)COC2=CC=CC(=C2OCC3=CC=CC=C3Cl)[C@@H](C(=O)O)O)Cl
DMTPNI4 IK NCWQPARYSYJFNI-FQEVSTJZSA-N
DMTPNI4 IU (2S)-2-[2,3-bis[(2-chlorophenyl)methoxy]phenyl]-2-hydroxyacetic acid
DMTPNI4 CA CAS 533889-36-0
DMTPNI4 DE Discovery agent
DM6Y1QF ID DM6Y1QF
DM6Y1QF DN BMS-488516
DM6Y1QF HS Investigative
DM6Y1QF CP Bristol-Myers Squibb
DM6Y1QF PC 11527400
DM6Y1QF MW 621.9
DM6Y1QF FM C33H43N5O3S2
DM6Y1QF IC InChI=1S/C33H43N5O3S2/c1-21-16-26(17-28(22(21)2)31(41)38-14-12-37(13-15-38)24(4)39)20-42-29-19-35-32(43-29)36-30(40)27-10-8-25(9-11-27)18-34-23(3)33(5,6)7/h8-11,16-17,19,23,34H,12-15,18,20H2,1-7H3,(H,35,36,40)
DM6Y1QF CS CC1=CC(=CC(=C1C)C(=O)N2CCN(CC2)C(=O)C)CSC3=CN=C(S3)NC(=O)C4=CC=C(C=C4)CNC(C)C(C)(C)C
DM6Y1QF IK DQPJVNQWPBLBAB-UHFFFAOYSA-N
DM6Y1QF IU N-[5-[[3-(4-acetylpiperazine-1-carbonyl)-4,5-dimethylphenyl]methylsulfanyl]-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
DM6Y1QF DE Inflammation
DMGH1LX ID DMGH1LX
DMGH1LX DN BMS-509744
DMGH1LX HS Investigative
DMGH1LX SN BMS-509744; 439575-02-7; BMS 509744; CHEMBL209148; N-(5-((5-(4-Acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl)thio)thiazol-2-yl)-4-(((3,3-dimethylbutan-2-yl)amino)methyl)benzamide; N-[5-[5-(4-acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl]sulfanyl-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide; GTPL9994; SCHEMBL14460651; KS-00001CVA; CHEBI:91404; MolPort-039-101-283; C32H41N5O4S2; BMS509744; BDBM50186460; 3499AH; compound 3 [PMID:16682193]; AKOS025142036; NCGC00229512-02; NCGC00229512-01
DMGH1LX CP Bristol-Myers Squibb
DMGH1LX DT Small molecular drug
DMGH1LX PC 11467730
DMGH1LX MW 623.8
DMGH1LX FM C32H41N5O4S2
DMGH1LX IC InChI=1S/C32H41N5O4S2/c1-20-16-26(41-7)25(30(40)37-14-12-36(13-15-37)22(3)38)17-27(20)42-28-19-34-31(43-28)35-29(39)24-10-8-23(9-11-24)18-33-21(2)32(4,5)6/h8-11,16-17,19,21,33H,12-15,18H2,1-7H3,(H,34,35,39)
DMGH1LX CS CC1=CC(=C(C=C1SC2=CN=C(S2)NC(=O)C3=CC=C(C=C3)CNC(C)C(C)(C)C)C(=O)N4CCN(CC4)C(=O)C)OC
DMGH1LX IK ZHXNIYGJAOPMSO-UHFFFAOYSA-N
DMGH1LX IU N-[5-[5-(4-acetylpiperazine-1-carbonyl)-4-methoxy-2-methylphenyl]sulfanyl-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide
DMGH1LX CA CAS 439575-02-7
DMGH1LX CB CHEBI:91404
DMGH1LX DE Inflammation
DMAY9TM ID DMAY9TM
DMAY9TM DN BMS-520
DMAY9TM HS Investigative
DMAY9TM SN S1P1 agonists (immunology); S1P1 agonists (immunology), Bristol-Myers Squibb
DMAY9TM CP Bristol-Myers Squibb Co
DMAY9TM DE Immune System disease
DMXJB4N ID DMXJB4N
DMXJB4N DN BMS-536924
DMXJB4N HS Investigative
DMXJB4N DT Small molecular drug
DMXJB4N PC 135440466
DMXJB4N MW 480
DMXJB4N FM C25H26ClN5O3
DMXJB4N IC InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1
DMXJB4N CS CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5
DMXJB4N IK ZWVZORIKUNOTCS-OAQYLSRUSA-N
DMXJB4N IU 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one
DMXJB4N CA CAS 468740-43-4
DMXJB4N CB CHEBI:91454
DMXJB4N DE Discovery agent
DM3WBKN ID DM3WBKN
DM3WBKN DN BMS-561388
DM3WBKN HS Investigative
DM3WBKN SN UNII-NQ8L686GDJ; NQ8L686GDJ; BMS-561388 besylate; SCHEMBL5104174; CHEMBL474287; BMS-561388 monobenzenesulfonate; 383368-51-2; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, N,N-bis(2-methoxyethyl)-8-(4-methoxy-2-methylphenyl)-2,7-dimethyl-, monobenzenesulfonate; Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, N,N-bis(2-methoxyethyl)-8-(4-methoxy-2-methylphenyl)-2,7-dimethyl-, benzenesulfonate (1:1)
DM3WBKN DT Small molecular drug
DM3WBKN PC 11249907
DM3WBKN MW 557.7
DM3WBKN FM C27H35N5O6S
DM3WBKN IC InChI=1S/C21H29N5O3.C6H6O3S/c1-14-13-17(29-6)7-8-18(14)19-15(2)24-26-20(19)22-16(3)23-21(26)25(9-11-27-4)10-12-28-5;7-10(8,9)6-4-2-1-3-5-6/h7-8,13H,9-12H2,1-6H3;1-5H,(H,7,8,9)
DM3WBKN CS CC1=C(C=CC(=C1)OC)C2=C3N=C(N=C(N3N=C2C)N(CCOC)CCOC)C.C1=CC=C(C=C1)S(=O)(=O)O
DM3WBKN IK ZQUBMILBXQLTDU-UHFFFAOYSA-N
DM3WBKN IU benzenesulfonic acid;N,N-bis(2-methoxyethyl)-8-(4-methoxy-2-methylphenyl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DM3WBKN CA CAS 383368-51-2
DM3WBKN DE Anxiety disorder
DMILMHZ ID DMILMHZ
DMILMHZ DN BMS-564929
DMILMHZ HS Investigative
DMILMHZ SN BMS-564929; 627530-84-1; UNII-9BLW27W4X7; BMS 564929; 9BLW27W4X7; C14H12ClN3O3; 2-Chloro-4-[(7r,7as)-7-Hydroxy-1,3-Dioxotetrahydro-1h-Pyrrolo[1,2-C]imidazol-2(3h)-Yl]-3-Methylbenzonitrile; 2-Chloro-3-methyl-4-[(7R,7AS)-tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]benzonitrile; KEJORAMIZFOODM-PWSUYJOCSA-N; 2nw4; SCHEMBL2967577; DTXSID50432357; ZINC3938678; 3500AH; AKOS027288930; CS-1381; DB07286; BMS-564,929; NCGC00378909-01; HY-12111; 8NH; KB-75607; BMS 564929;BMS564929; W-5594; S900006120
DMILMHZ DT Small molecular drug
DMILMHZ PC 9882972
DMILMHZ MW 305.71
DMILMHZ FM C14H12ClN3O3
DMILMHZ IC InChI=1S/C14H12ClN3O3/c1-7-9(3-2-8(6-16)11(7)15)18-13(20)12-10(19)4-5-17(12)14(18)21/h2-3,10,12,19H,4-5H2,1H3/t10-,12+/m1/s1
DMILMHZ CS CC1=C(C=CC(=C1Cl)C#N)N2C(=O)[C@@H]3[C@@H](CCN3C2=O)O
DMILMHZ IK KEJORAMIZFOODM-PWSUYJOCSA-N
DMILMHZ IU 4-[(7R,7aS)-7-hydroxy-1,3-dioxo-5,6,7,7a-tetrahydropyrrolo[1,2-c]imidazol-2-yl]-2-chloro-3-methylbenzonitrile
DMILMHZ CA CAS 627530-84-1
DMILMHZ DE Discovery agent
DMZWNO9 ID DMZWNO9
DMZWNO9 DN BMS614
DMZWNO9 HS Investigative
DMZWNO9 SN BMS 614; BMS-614
DMZWNO9 DT Small molecular drug
DMZWNO9 PC 445091
DMZWNO9 MW 448.5
DMZWNO9 FM C29H24N2O3
DMZWNO9 IC InChI=1S/C29H24N2O3/c1-29(2)14-13-23(21-15-19-5-3-4-6-26(19)30-17-21)24-16-20(9-12-25(24)29)27(32)31-22-10-7-18(8-11-22)28(33)34/h3-13,15-17H,14H2,1-2H3,(H,31,32)(H,33,34)
DMZWNO9 CS CC1(CC=C(C2=C1C=CC(=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)C4=CC5=CC=CC=C5N=C4)C
DMZWNO9 IK WGLMBRZXZDAQHP-UHFFFAOYSA-N
DMZWNO9 IU 4-[(5,5-dimethyl-8-quinolin-3-yl-6H-naphthalene-2-carbonyl)amino]benzoic acid
DMZWNO9 CA CAS 182135-66-6
DMZWNO9 CB CHEBI:132571
DMZWNO9 DE Discovery agent
DMRT7G3 ID DMRT7G3
DMRT7G3 DN BMS641
DMRT7G3 HS Investigative
DMRT7G3 SN BMS-641; BMS 641
DMRT7G3 DT Small molecular drug
DMRT7G3 PC 22737393
DMRT7G3 MW 414.9
DMRT7G3 FM C27H23ClO2
DMRT7G3 IC InChI=1S/C27H23ClO2/c1-27(2)15-14-22(19-6-4-3-5-7-19)23-16-18(9-13-24(23)27)8-10-20-11-12-21(26(29)30)17-25(20)28/h3-14,16-17H,15H2,1-2H3,(H,29,30)/b10-8+
DMRT7G3 CS CC1(CC=C(C2=C1C=CC(=C2)/C=C/C3=C(C=C(C=C3)C(=O)O)Cl)C4=CC=CC=C4)C
DMRT7G3 IK FRTYVAKGTFXRNY-CSKARUKUSA-N
DMRT7G3 IU 3-chloro-4-[(E)-2-(5,5-dimethyl-8-phenyl-6H-naphthalen-2-yl)ethenyl]benzoic acid
DMRT7G3 DE Discovery agent
DMBTMO9 ID DMBTMO9
DMBTMO9 DN BMS-645737
DMBTMO9 HS Investigative
DMBTMO9 SN 651744-16-0; BMS-645737; BMS645737; 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; UNII-86H6HFH34L; 86H6HFH34L; CHEMBL261592; 6-(5-methyl-1,3,4-oxadiazol-2-yl)-n-{2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl}-5-(propan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; 5-Isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo-[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine; C20H20N8O
DMBTMO9 DT Small molecular drug
DMBTMO9 PC 22273644
DMBTMO9 MW 388.4
DMBTMO9 FM C20H20N8O
DMBTMO9 IC InChI=1S/C20H20N8O/c1-10(2)16-15(20-27-26-12(4)29-20)8-28-17(16)19(22-9-23-28)25-14-6-13-5-11(3)24-18(13)21-7-14/h5-10H,1-4H3,(H,21,24)(H,22,23,25)
DMBTMO9 CS CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)C)C(C)C
DMBTMO9 IK OOQXPATWSOGSAV-UHFFFAOYSA-N
DMBTMO9 IU 6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine
DMBTMO9 CA CAS 651744-16-0
DMBTMO9 DE Discovery agent
DMYAPG5 ID DMYAPG5
DMYAPG5 DN BMS-687453
DMYAPG5 HS Investigative
DMYAPG5 SN BMS-687453; 1000998-59-3; UNII-39TL5L7XDX; BMS 687453; 39TL5L7XDX; 2-{[(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}phenyl)methyl](methoxycarbonyl)amino}acetic acid; SCHEMBL2742714; CHEMBL1089501; BDBM28800; EX-A592; BCP14808; ZINC44460341; AKOS030526188; CS-5523; DA-48472; HY-10678; FT-0749275; J-690001; 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid; 7HA; N-(3-{[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyl)-N-(methoxycarbonyl)glycine
DMYAPG5 DT Small molecular drug
DMYAPG5 PC 16725047
DMYAPG5 MW 444.9
DMYAPG5 FM C22H21ClN2O6
DMYAPG5 IC InChI=1S/C22H21ClN2O6/c1-14-19(24-21(31-14)16-6-8-17(23)9-7-16)13-30-18-5-3-4-15(10-18)11-25(12-20(26)27)22(28)29-2/h3-10H,11-13H2,1-2H3,(H,26,27)
DMYAPG5 CS CC1=C(N=C(O1)C2=CC=C(C=C2)Cl)COC3=CC=CC(=C3)CN(CC(=O)O)C(=O)OC
DMYAPG5 IK UJIBXDMNCMEJAY-UHFFFAOYSA-N
DMYAPG5 IU 2-[[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]methyl-methoxycarbonylamino]acetic acid
DMYAPG5 CA CAS 1000998-59-3
DMYAPG5 DE Discovery agent
DM8PA3U ID DM8PA3U
DM8PA3U DN BMS-694153
DM8PA3U HS Investigative
DM8PA3U SN BMS-694153; UNII-69MB5VHL5J; 69MB5VHL5J; CHEMBL450668; (R)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide; BMS 694153; 1050381-35-5; BDBM50268484; 1-Piperidinecarboxamide, N-((1R)-2-(1,4'-bipiperidin)-1'-yl-1-((7-methyl-1H-indazol-5-yl)methyl)-2-oxoethyl)-4-(8-fluoro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-
DM8PA3U DT Small molecular drug
DM8PA3U PC 44593666
DM8PA3U MW 644.8
DM8PA3U FM C35H45FN8O3
DM8PA3U IC InChI=1S/C35H45FN8O3/c1-23-18-24(19-26-21-37-40-31(23)26)20-30(33(45)42-14-8-27(9-15-42)41-12-3-2-4-13-41)38-34(46)43-16-10-28(11-17-43)44-22-25-6-5-7-29(36)32(25)39-35(44)47/h5-7,18-19,21,27-28,30H,2-4,8-17,20,22H2,1H3,(H,37,40)(H,38,46)(H,39,47)/t30-/m1/s1
DM8PA3U CS CC1=CC(=CC2=C1NN=C2)C[C@H](C(=O)N3CCC(CC3)N4CCCCC4)NC(=O)N5CCC(CC5)N6CC7=C(C(=CC=C7)F)NC6=O
DM8PA3U IK HBOINTMVWRSZQS-SSEXGKCCSA-N
DM8PA3U IU 4-(8-fluoro-2-oxo-1,4-dihydroquinazolin-3-yl)-N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-piperidin-1-ylpiperidin-1-yl)propan-2-yl]piperidine-1-carboxamide
DM8PA3U CA CAS 1050381-35-5
DM8PA3U DE Migraine
DMFODQV ID DMFODQV
DMFODQV DN BMS-739562
DMFODQV HS Investigative
DMFODQV SN Pyrrolo triazine-based aurora kinase inhibitors (cancer); Pyrrolo triazine-based aurora kinase inhibitors (cancer), Bristol-Myers Squibb
DMFODQV CP Bristol-Myers Squibb Co
DMFODQV DE Solid tumour/cancer
DMQ24TI ID DMQ24TI
DMQ24TI DN BMS-740808
DMQ24TI HS Investigative
DMQ24TI SN BMS-740808; 280118-23-2; BMS 740808; UNII-LDD74E663F; BMS740808; LDD74E663F; 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-{[(3R)-3-HYDROXYPYRROLIDIN-1-YL]METHYL}BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE; 2fzz; 1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]phenyl]phenyl]-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one; 5QC; AC1OCAC6; SCHEMBL8360280; CHEMBL378093; BDBM12693; DTXSID40182293; C31H27F3N6O3; BCPP000326; BCP23400; ZINC14210470
DMQ24TI DT Small molecular drug
DMQ24TI PC 6914623
DMQ24TI MW 588.6
DMQ24TI FM C31H27F3N6O3
DMQ24TI IC InChI=1S/C31H27F3N6O3/c32-31(33,34)28-24-12-14-39(30(42)27(24)40(36-28)21-9-10-26-25(15-21)29(35)37-43-26)20-7-5-18(6-8-20)23-4-2-1-3-19(23)16-38-13-11-22(41)17-38/h1-10,15,22,41H,11-14,16-17H2,(H2,35,37)/t22-/m1/s1
DMQ24TI CS C1CN(C[C@@H]1O)CC2=CC=CC=C2C3=CC=C(C=C3)N4CCC5=C(C4=O)N(N=C5C(F)(F)F)C6=CC7=C(C=C6)ON=C7N
DMQ24TI IK DFRIQJHMGZBFOM-JOCHJYFZSA-N
DMQ24TI IU 1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]phenyl]phenyl]-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one
DMQ24TI CA CAS 280118-23-2
DMQ24TI DE Discovery agent
DMSX1NF ID DMSX1NF
DMSX1NF DN BMS753
DMSX1NF HS Investigative
DMSX1NF SN BMS-753; BMS 753
DMSX1NF DT Small molecular drug
DMSX1NF PC 9884820
DMSX1NF MW 351.4
DMSX1NF FM C21H21NO4
DMSX1NF IC InChI=1S/C21H21NO4/c1-20(2)15-10-7-13(11-16(15)21(3,4)19(20)26)17(23)22-14-8-5-12(6-9-14)18(24)25/h5-11H,1-4H3,(H,22,23)(H,24,25)
DMSX1NF CS CC1(C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)C(=O)O)C(C1=O)(C)C)C
DMSX1NF IK KFBPBWUZXBYJDG-UHFFFAOYSA-N
DMSX1NF IU 4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid
DMSX1NF DE Discovery agent
DM1HBF5 ID DM1HBF5
DM1HBF5 DN BMS-812204
DM1HBF5 HS Investigative
DM1HBF5 SN CB1 antagonists (obesity), BMS; CB1 antagonists (obesity), Bristol-Myers Squibb
DM1HBF5 CP Bristol-Myers Squibb Co
DM1HBF5 DE Obesity
DMI796T ID DMI796T
DMI796T DN BMS-A
DMI796T HS Investigative
DMI796T SN CCR2 antagonists (inflammatory/metabolic diseases); CCR2 antagonists (inflammatory/metabolic diseases), Bristol-Myers Squibb
DMI796T CP Bristol-Myers Squibb Co
DMI796T DT Small molecular drug
DMI796T PC 10474339
DMI796T MW 370.71
DMI796T FM C16H10ClF3N2O3
DMI796T IC InChI=1S/C16H10ClF3N2O3/c17-12-5-6-13(23)10(7-12)8-22-15(24)25-14(21-22)9-1-3-11(4-2-9)16(18,19)20/h1-7,23H,8H2
DMI796T CS C1=CC(=CC=C1C2=NN(C(=O)O2)CC3=C(C=CC(=C3)Cl)O)C(F)(F)F
DMI796T IK QKOWACXSXTXRKA-UHFFFAOYSA-N
DMI796T IU 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-one
DMI796T CA CAS 202821-81-6
DMI796T CB CHEBI:93672
DMI796T DE Inflammation
DMT02B8 ID DMT02B8
DMT02B8 DN BMY 45778
DMT02B8 HS Investigative
DMT02B8 SN BMY45778; BMY-45778
DMT02B8 DT Small molecular drug
DMT02B8 PC 127861
DMT02B8 MW 438.4
DMT02B8 FM C26H18N2O5
DMT02B8 IC InChI=1S/C26H18N2O5/c29-21(30)15-31-20-13-7-12-19(14-20)24-23(27-16-32-24)26-28-22(17-8-3-1-4-9-17)25(33-26)18-10-5-2-6-11-18/h1-14,16H,15H2,(H,29,30)
DMT02B8 CS C1=CC=C(C=C1)C2=C(OC(=N2)C3=C(OC=N3)C4=CC(=CC=C4)OCC(=O)O)C5=CC=CC=C5
DMT02B8 IK DSRSEEYZGWTODH-UHFFFAOYSA-N
DMT02B8 IU 2-[3-[4-(4,5-diphenyl-1,3-oxazol-2-yl)-1,3-oxazol-5-yl]phenoxy]acetic acid
DMT02B8 CA CAS 152575-66-1
DMT02B8 CB CHEBI:51544
DMT02B8 DE Discovery agent
DMAMYWL ID DMAMYWL
DMAMYWL DN BMY-27709
DMAMYWL HS Investigative
DMAMYWL SN BMY-27709; AC1L2RSV; AC1Q3LRY; 99390-76-8; CHEMBL68649; Brl 20627; SCHEMBL15532024; 4-amino-5-chloro-2-hydroxy-n-[(2s,6r,9ar)-6-methyloctahydro-2h-quinolizin-2-yl]benzamide; 4-Amino-5-chloro-2-hydroxy-N-(octahydro-6-methyl-2H-quinolizin-2yl)benzamide; N-[(2S,6R,9aR)-6-methyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-4-amino-5-chloro-2-hydroxy-benzamide; Benzamide, 4-amino-N-[(2S,6R,9aR)-octahydro-6-methyl-2H-quinolizin-2-yl]-5-chloro-2-hydroxy-
DMAMYWL DT Small molecular drug
DMAMYWL PC 127317
DMAMYWL MW 337.8
DMAMYWL FM C17H24ClN3O2
DMAMYWL IC InChI=1S/C17H24ClN3O2/c1-10-3-2-4-12-7-11(5-6-21(10)12)20-17(23)13-8-14(18)15(19)9-16(13)22/h8-12,22H,2-7,19H2,1H3,(H,20,23)/t10-,11+,12-/m1/s1
DMAMYWL CS C[C@@H]1CCC[C@H]2N1CC[C@@H](C2)NC(=O)C3=CC(=C(C=C3O)N)Cl
DMAMYWL IK SQQXDSFKORQHET-GRYCIOLGSA-N
DMAMYWL IU N-[(2S,6R,9aR)-6-methyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-4-amino-5-chloro-2-hydroxybenzamide
DMAMYWL CA CAS 99390-76-8
DMAMYWL DE Discovery agent
DM1CNU5 ID DM1CNU5
DM1CNU5 DN BN-81,644
DM1CNU5 HS Investigative
DM1CNU5 SN BN 81,644; BN81,644; BN-81644; BN81644; BN 81644
DM1CNU5 DT Small molecular drug
DM1CNU5 PC 9802572
DM1CNU5 MW 426.6
DM1CNU5 FM C28H34N4
DM1CNU5 IC InChI=1S/C28H34N4/c1-3-5-16-28(17-6-4-2)26-22(21-14-10-11-15-23(21)30-26)18-24(32-28)27-29-19-25(31-27)20-12-8-7-9-13-20/h7-15,19,24,30,32H,3-6,16-18H2,1-2H3,(H,29,31)/t24-/m1/s1
DM1CNU5 CS CCCCC1(C2=C(C[C@@H](N1)C3=NC=C(N3)C4=CC=CC=C4)C5=CC=CC=C5N2)CCCC
DM1CNU5 IK FOBFICSYUINKAA-XMMPIXPASA-N
DM1CNU5 IU (3R)-1,1-dibutyl-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole
DM1CNU5 DE Discovery agent
DM7RPQ4 ID DM7RPQ4
DM7RPQ4 DN BN-81,674
DM7RPQ4 HS Investigative
DM7RPQ4 SN BN 81,674; BN81,674; BN-81674; BN81674; BN 81674
DM7RPQ4 DT Small molecular drug
DM7RPQ4 PC 5311378
DM7RPQ4 MW 454.6
DM7RPQ4 FM C30H38N4
DM7RPQ4 IC InChI=1S/C30H38N4/c1-3-5-12-18-30(19-13-6-4-2)28-24(23-16-10-11-17-25(23)32-28)20-26(34-30)29-31-21-27(33-29)22-14-8-7-9-15-22/h7-11,14-17,21,26,32,34H,3-6,12-13,18-20H2,1-2H3,(H,31,33)/t26-/m1/s1
DM7RPQ4 CS CCCCCC1(C2=C(C[C@@H](N1)C3=NC=C(N3)C4=CC=CC=C4)C5=CC=CC=C5N2)CCCCC
DM7RPQ4 IK DGSMSHNIDMODOQ-AREMUKBSSA-N
DM7RPQ4 IU (3R)-1,1-dipentyl-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole
DM7RPQ4 CA CAS 252278-73-2
DM7RPQ4 DE Discovery agent
DMXY574 ID DMXY574
DMXY574 DN BN-82002
DMXY574 HS Investigative
DMXY574 DE Solid tumour/cancer
DMZME4N ID DMZME4N
DMZME4N DN BN-82685
DMZME4N HS Investigative
DMZME4N SN UNII-YLE5P531SS; BN-82685; YLE5P531SS; IRC-083065; SCHEMBL1917819; 4,7-Benzothiazoledione, 5-((2-(dimethylamino)ethyl)amino)-2-methyl-; 5-((2-(Dimethylamino)ethyl)amino)-2-methyl-1,3-benzothiazole-4,7-dione; 477603-18-2
DMZME4N DT Small molecular drug
DMZME4N PC 10286059
DMZME4N MW 265.33
DMZME4N FM C12H15N3O2S
DMZME4N IC InChI=1S/C12H15N3O2S/c1-7-14-10-11(17)8(13-4-5-15(2)3)6-9(16)12(10)18-7/h6,13H,4-5H2,1-3H3
DMZME4N CS CC1=NC2=C(S1)C(=O)C=C(C2=O)NCCN(C)C
DMZME4N IK MTUYOFGUEXWKLC-UHFFFAOYSA-N
DMZME4N IU 5-[2-(dimethylamino)ethylamino]-2-methyl-1,3-benzothiazole-4,7-dione
DMZME4N CA CAS 477603-18-2
DMZME4N DE Discovery agent
DMJI1EA ID DMJI1EA
DMJI1EA DN BND-001
DMJI1EA HS Investigative
DMJI1EA SN NiK-001; NiK-10001; NiK-10034; NiK-18862; Nik-21273; ORL-1 antagonists (CNS disorders); ORL-1 antagonists (CNS disorders), Brane; Opioid receptor like-1 antagonists (CNS disorders), NiKem Research
DMJI1EA CP NiKem Research Srl
DMJI1EA DE Central nervous system disease
DM48VJR ID DM48VJR
DM48VJR DN B-Nonylglucoside
DM48VJR HS Investigative
DM48VJR SN 69984-73-2; B-Nonylglucoside; Nonyl beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(nonyloxy)tetrahydro-2H-pyran-3,4,5-triol; Nonyl b-D-glucopyranoside; n-nonyl -d-glucopyranoside; NONYL-beta-D-GLUCOPYRANOSIDE; n-Nonyl -D-glucoside-(1,5);NGP; b-D-Glucopyranoside, nonyl; N-NONYL-BETA-D-GLUCOPYRANOSIDE; BNG; beta-D-Glucopyranoside, nonyl; 4gby; 4gbz; Nonyl -D-glucopyranoside; Nonyl -D-glucopyranoside; AC1L4EB7; SCHEMBL136394; Nonyl-I(2)-D-glucopyranoside; CHEMBL490225; MolPort-002-893-587; C15H30O6; GC1498
DM48VJR DT Small molecular drug
DM48VJR PC 155448
DM48VJR MW 306.39
DM48VJR FM C15H30O6
DM48VJR IC InChI=1S/C15H30O6/c1-2-3-4-5-6-7-8-9-20-15-14(19)13(18)12(17)11(10-16)21-15/h11-19H,2-10H2,1H3/t11-,12-,13+,14-,15-/m1/s1
DM48VJR CS CCCCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DM48VJR IK QFAPUKLCALRPLH-UXXRCYHCSA-N
DM48VJR IU (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol
DM48VJR CA CAS 69984-73-2
DM48VJR DE Discovery agent
DMJY1KR ID DMJY1KR
DMJY1KR DN BNP-FIX
DMJY1KR HS Investigative
DMJY1KR SN Gene therapy (BNP, hemophilia B); Biological Nano Particles-Factor IX (hemophilia B), Asklepios; Gene therapy (BNP, hemophilia B), Asklepios; Gene therapy (hemophilia B), Asklepios/Bayer
DMJY1KR CP Asklepios Biopharmaceutical Inc
DMJY1KR DE Factor IX deficiency
DMIOHMZ ID DMIOHMZ
DMIOHMZ DN BNV-222
DMIOHMZ HS Investigative
DMIOHMZ CP Bionevia Pharmaceuticals Inc
DMIOHMZ DE Diabetic neuropathy
DMCUJH5 ID DMCUJH5
DMCUJH5 DN Bo(15)PZ
DMCUJH5 HS Investigative
DMCUJH5 SN CHEMBL198982; Bo(15)PZ
DMCUJH5 DT Small molecular drug
DMCUJH5 PC 44405301
DMCUJH5 MW 849.8
DMCUJH5 FM C44H50BF2N9O4S
DMCUJH5 IC InChI=1S/C44H50BF2N9O4S/c46-45(47)55-32(15-16-33(55)30-34-17-19-38(56(34)45)39-13-9-29-61-39)18-20-41(58)49-21-5-1-2-14-40(57)48-22-6-7-24-52-25-27-53(28-26-52)31-42(59)54-37-12-4-3-10-35(37)44(60)51-36-11-8-23-50-43(36)54/h3-4,8-13,15-17,19,23,29-30H,1-2,5-7,14,18,20-22,24-28,31H2,(H,48,57)(H,49,58)(H,51,60)
DMCUJH5 CS [B-]1(N2C(=CC=C2CCC(=O)NCCCCCC(=O)NCCCCN3CCN(CC3)CC(=O)N4C5=CC=CC=C5C(=O)NC6=C4N=CC=C6)C=C7[N+]1=C(C=C7)C8=CC=CS8)(F)F
DMCUJH5 IK AZMSBCBXXBLHQP-UHFFFAOYSA-N
DMCUJH5 IU 6-[3-(2,2-difluoro-12-thiophen-2-yl-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-4-yl)propanoylamino]-N-[4-[4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazin-1-yl]butyl]hexanamide
DMCUJH5 DE Discovery agent
DMDX8M3 ID DMDX8M3
DMDX8M3 DN Boc-Agly-Val-Agly-OEt
DMDX8M3 HS Investigative
DMDX8M3 SN Boc-Agly-Val-Agly-OEt; CHEMBL135413
DMDX8M3 DT Small molecular drug
DMDX8M3 PC 44355107
DMDX8M3 MW 416.5
DMDX8M3 FM C19H36N4O6
DMDX8M3 IC InChI=1S/C19H36N4O6/c1-9-28-18(27)23-22-16(25)14(12(4)5)21-15(24)13(10-11(2)3)20-17(26)29-19(6,7)8/h11-14H,9-10H2,1-8H3,(H,20,26)(H,21,24)(H,22,25)(H,23,27)
DMDX8M3 CS CCOC(=O)NNC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)OC(C)(C)C
DMDX8M3 IK CCIRNXXUWFWJAR-UHFFFAOYSA-N
DMDX8M3 IU tert-butyl N-[1-[[1-(2-ethoxycarbonylhydrazinyl)-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate
DMDX8M3 DE Discovery agent
DMPJR98 ID DMPJR98
DMPJR98 DN Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2
DMPJR98 HS Investigative
DMPJR98 SN CHEMBL1159915
DMPJR98 PC 44278569
DMPJR98 MW 1193.3
DMPJR98 FM C55H72N10O18S
DMPJR98 IC InChI=1S/C55H72N10O18S/c1-6-8-18-37(47(71)62-42(28-44(66)67)51(75)60-39(46(56)70)25-31-15-11-10-12-16-31)58-50(74)41(27-33-30-57-36-20-14-13-17-35(33)36)63-53(77)65-48(72)38(19-9-7-2)59-49(73)40(26-32-21-23-34(24-22-32)83-84(79,80)81)61-52(76)43(29-45(68)69)64-54(78)82-55(3,4)5/h10-17,20-24,30,37-43,57H,6-9,18-19,25-29H2,1-5H3,(H2,56,70)(H,58,74)(H,59,73)(H,60,75)(H,61,76)(H,62,71)(H,64,78)(H,66,67)(H,68,69)(H,79,80,81)(H2,63,65,72,77)/t37-,38-,39-,40-,41-,42-,43-/m0/s1
DMPJR98 CS CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)NC(=O)[C@H](CCCC)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)OC(C)(C)C
DMPJR98 IK LWZREZWAQQSATC-NKUVHBIJSA-N
DMPJR98 IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]carbamoylamino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DMPJR98 DE Discovery agent
DMRQVME ID DMRQVME
DMRQVME DN Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2
DMRQVME HS Investigative
DMRQVME SN CHEMBL273880; Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2
DMRQVME PC 44272056
DMRQVME MW 1194.4
DMRQVME FM C61H83N11O14
DMRQVME IC InChI=1S/C61H83N11O14/c1-6-8-20-42-53(78)65-44(23-15-16-30-63-50(74)29-28-45(72-60(85)86-61(3,4)5)56(81)69-47(57(82)66-42)32-37-24-26-39(73)27-25-37)55(80)70-48(33-38-35-64-41-22-14-13-19-40(38)41)58(83)67-43(21-9-7-2)54(79)71-49(34-51(75)76)59(84)68-46(52(62)77)31-36-17-11-10-12-18-36/h10-14,17-19,22,24-27,35,42-49,64,73H,6-9,15-16,20-21,23,28-34H2,1-5H3,(H2,62,77)(H,63,74)(H,65,78)(H,66,82)(H,67,83)(H,68,84)(H,69,81)(H,70,80)(H,71,79)(H,72,85)(H,75,76)/t42-,43-,44-,45+,46-,47+,48-,49-/m0/s1
DMRQVME CS CCCC[C@H]1C(=O)N[C@@H](CCCCNC(=O)CC[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N
DMRQVME IK RJGYFDISIBJKFO-UZLGZYMTSA-N
DMRQVME IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-[[(2R,5S,8S,17R)-5-butyl-2-[(4-hydroxyphenyl)methyl]-17-[(2-methylpropan-2-yl)oxycarbonylamino]-3,6,14,18-tetraoxo-1,4,7,13-tetrazacyclooctadecane-8-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DMRQVME DE Discovery agent
DMBCPKF ID DMBCPKF
DMBCPKF DN Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMBCPKF HS Investigative
DMBCPKF SN CHEMBL440259; Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMBCPKF PC 44272077
DMBCPKF MW 1292.5
DMBCPKF FM C61H85N11O18S
DMBCPKF IC InChI=1S/C61H85N11O18S/c1-6-8-20-42(66-57(82)47(32-37-24-26-39(27-25-37)90-91(86,87)88)69-56(81)45(28-29-50(73)74)72-60(85)89-61(3,4)5)53(78)65-44(23-15-16-30-62)55(80)70-48(33-38-35-64-41-22-14-13-19-40(38)41)58(83)67-43(21-9-7-2)54(79)71-49(34-51(75)76)59(84)68-46(52(63)77)31-36-17-11-10-12-18-36/h10-14,17-19,22,24-27,35,42-49,64H,6-9,15-16,20-21,23,28-34,62H2,1-5H3,(H2,63,77)(H,65,78)(H,66,82)(H,67,83)(H,68,84)(H,69,81)(H,70,80)(H,71,79)(H,72,85)(H,73,74)(H,75,76)(H,86,87,88)/t42-,43-,44-,45+,46-,47-,48-,49-/m0/s1
DMBCPKF CS CCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)OC(C)(C)C
DMBCPKF IK NLVKBXFAISROGJ-LMZFJFGWSA-N
DMBCPKF IU (4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
DMBCPKF DE Discovery agent
DM1IXOG ID DM1IXOG
DM1IXOG DN Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2
DM1IXOG HS Investigative
DM1IXOG SN CHEMBL216831; Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2
DM1IXOG PC 44272095
DM1IXOG MW 1277.4
DM1IXOG FM C61H84N10O18S
DM1IXOG IC InChI=1S/C61H84N10O18S/c1-7-10-21-42(65-57(81)47(32-37-25-27-39(28-26-37)89-90(85,86)87)68-56(80)45(29-30-50(72)73)71-60(84)88-61(4,5)6)53(77)64-43(22-11-8-2)54(78)69-48(33-38-35-63-41-24-17-16-20-40(38)41)58(82)66-44(23-12-9-3)55(79)70-49(34-51(74)75)59(83)67-46(52(62)76)31-36-18-14-13-15-19-36/h13-20,24-28,35,42-49,63H,7-12,21-23,29-34H2,1-6H3,(H2,62,76)(H,64,77)(H,65,81)(H,66,82)(H,67,83)(H,68,80)(H,69,78)(H,70,79)(H,71,84)(H,72,73)(H,74,75)(H,85,86,87)/t42-,43-,44-,45+,46-,47-,48-,49-/m0/s1
DM1IXOG CS CCCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CCCC)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)OC(C)(C)C
DM1IXOG IK JFEDUJOXWDESON-LMZFJFGWSA-N
DM1IXOG IU (4R)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
DM1IXOG DE Discovery agent
DMFWJC2 ID DMFWJC2
DMFWJC2 DN Boceprevir
DMFWJC2 HS Investigative
DMFWJC2 SN Victrelis; EBP 520; Sch 503034
DMFWJC2 TC Antiviral Agents
DMFWJC2 DT Small molecular drug
DMFWJC2 PC 10324367
DMFWJC2 MW 519.7
DMFWJC2 FM C27H45N5O5
DMFWJC2 IC InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
DMFWJC2 CS CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
DMFWJC2 IK LHHCSNFAOIFYRV-DOVBMPENSA-N
DMFWJC2 IU (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DMFWJC2 CA CAS 394730-60-0
DMFWJC2 CB CHEBI:68621
DMFWJC2 DE Coronavirus Disease 2019 (COVID-19)
DMN3EU9 ID DMN3EU9
DMN3EU9 DN Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMN3EU9 HS Investigative
DMN3EU9 SN CHEMBL386304; Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2
DMN3EU9 PC 44272078
DMN3EU9 MW 1292.5
DMN3EU9 FM C61H85N11O18S
DMN3EU9 IC InChI=1S/C61H85N11O18S/c1-6-8-20-42(66-57(82)47(32-37-24-26-39(27-25-37)90-91(86,87)88)69-56(81)45(28-29-50(73)74)72-60(85)89-61(3,4)5)53(78)65-44(23-15-16-30-62)55(80)70-48(33-38-35-64-41-22-14-13-19-40(38)41)58(83)67-43(21-9-7-2)54(79)71-49(34-51(75)76)59(84)68-46(52(63)77)31-36-17-11-10-12-18-36/h10-14,17-19,22,24-27,35,42-49,64H,6-9,15-16,20-21,23,28-34,62H2,1-5H3,(H2,63,77)(H,65,78)(H,66,82)(H,67,83)(H,68,84)(H,69,81)(H,70,80)(H,71,79)(H,72,85)(H,73,74)(H,75,76)(H,86,87,88)/t42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
DMN3EU9 CS CCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)OC(C)(C)C
DMN3EU9 IK NLVKBXFAISROGJ-XJIZABAQSA-N
DMN3EU9 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
DMN3EU9 DE Discovery agent
DMG35MJ ID DMG35MJ
DMG35MJ DN Boc-Ile-Leu-L-(difluoro)aminobutyric aid
DMG35MJ HS Investigative
DMG35MJ SN Boc-Ile-Leu-L-(difluoro)aminobutyric aid; CHEMBL175479
DMG35MJ DT Small molecular drug
DMG35MJ PC 44388200
DMG35MJ MW 493.5
DMG35MJ FM C22H37F2N3O7
DMG35MJ IC InChI=1S/C22H37F2N3O7/c1-8-12(4)16(27-21(33)34-22(5,6)7)19(30)26-14(9-11(2)3)18(29)25-13(10-15(23)24)17(28)20(31)32/h11-16H,8-10H2,1-7H3,(H,25,29)(H,26,30)(H,27,33)(H,31,32)/t12?,13?,14-,16-/m0/s1
DMG35MJ CS CCC(C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NC(CC(F)F)C(=O)C(=O)O)NC(=O)OC(C)(C)C
DMG35MJ IK JOMMVUMCDVMUOS-UJJWPFCGSA-N
DMG35MJ IU 5,5-difluoro-3-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoyl]amino]-2-oxopentanoic acid
DMG35MJ DE Discovery agent
DMMO75G ID DMMO75G
DMMO75G DN B-Octylglucoside
DMMO75G HS Investigative
DMMO75G SN 29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL
DMMO75G DT Small molecular drug
DMMO75G PC 62852
DMMO75G MW 292.37
DMMO75G FM C14H28O6
DMMO75G IC InChI=1S/C14H28O6/c1-2-3-4-5-6-7-8-19-14-13(18)12(17)11(16)10(9-15)20-14/h10-18H,2-9H2,1H3/t10-,11-,12+,13-,14-/m1/s1
DMMO75G CS CCCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMMO75G IK HEGSGKPQLMEBJL-RKQHYHRCSA-N
DMMO75G IU (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol
DMMO75G CA CAS 29836-26-8
DMMO75G CB CHEBI:41128
DMMO75G DE Discovery agent
DMAYWTI ID DMAYWTI
DMAYWTI DN Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2
DMAYWTI HS Investigative
DMAYWTI SN CHEMBL384035; Cholecystokinin (27-33), tert-butyloxycarbonyl-nle(28,31)-; Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2; 98640-66-5; Boc-28,31-nle-cck-7; BDNL; Boc-tyr(SO3H)nle-gly-trp-nle-asp-phenh2; t-Boc(nle(28,31))-cck (27-33); AC1MJ67S; DTXSID90243747; tert-Butyloxycarbonyl-28,31-nle-cholecystokinin (27-33); Cholecystokinin (27-33), tert-butyloxycarbonylnorleucyl(28,31)-; BDBM50016425; tert-Butoxycarbonyltyrosyl(sulfo)-norleucyl-glycyl-tryptophyl-norleucyl-aspartyl-phenylalaninamide
DMAYWTI PC 3086453
DMAYWTI MW 1092.2
DMAYWTI FM C52H69N9O15S
DMAYWTI IC InChI=1S/C52H69N9O15S/c1-6-8-18-37(57-48(68)40(61-51(71)75-52(3,4)5)26-32-21-23-34(24-22-32)76-77(72,73)74)46(66)55-30-43(62)56-41(27-33-29-54-36-20-14-13-17-35(33)36)49(69)58-38(19-9-7-2)47(67)60-42(28-44(63)64)50(70)59-39(45(53)65)25-31-15-11-10-12-16-31/h10-17,20-24,29,37-42,54H,6-9,18-19,25-28,30H2,1-5H3,(H2,53,65)(H,55,66)(H,56,62)(H,57,68)(H,58,69)(H,59,70)(H,60,67)(H,61,71)(H,63,64)(H,72,73,74)/t37-,38-,39-,40-,41-,42-/m0/s1
DMAYWTI CS CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)OC(C)(C)C
DMAYWTI IK CSXIDZJPJYRGSK-UJKKYYSESA-N
DMAYWTI IU (3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DMAYWTI CA CAS 98640-66-5
DMAYWTI DE Discovery agent
DMY7CN3 ID DMY7CN3
DMY7CN3 DN BODIPY-pirenzepine
DMY7CN3 HS Investigative
DMY7CN3 SN BoPz
DMY7CN3 DT Small molecular drug
DMY7CN3 PC 101244456
DMY7CN3 MW 764.7
DMY7CN3 FM C40H43BF2N8O3S
DMY7CN3 IC InChI=1S/C40H43BF2N8O3S/c42-41(43)51-30(14-15-31(51)27-29-13-17-33(46-29)36-12-8-26-55-36)16-18-37(52)44-19-5-1-2-6-21-48-22-24-49(25-23-48)28-38(53)50-35-11-4-3-9-32(35)40(54)47-34-10-7-20-45-39(34)50/h3-4,7-15,17,20,26-27H,1-2,5-6,16,18-19,21-25,28H2,(H,44,52)(H,47,54)/b29-27+
DMY7CN3 CS B(N1C(=CC=C1/C=C/2\\C=CC(=N2)C3=CC=CS3)CCC(=O)NCCCCCCN4CCN(CC4)CC(=O)N5C6=CC=CC=C6C(=O)NC7=C5N=CC=C7)(F)F
DMY7CN3 IK QGXCAYBSIKPOHP-ORIPQNMZSA-N
DMY7CN3 IU 3-[1-difluoroboranyl-5-[(E)-(5-thiophen-2-ylpyrrol-2-ylidene)methyl]pyrrol-2-yl]-N-[6-[4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazin-1-yl]hexyl]propanamide
DMY7CN3 DE Discovery agent
DMLCMA3 ID DMLCMA3
DMLCMA3 DN BOHEMINE
DMLCMA3 HS Investigative
DMLCMA3 SN bohemine; 189232-42-6; 3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol; 3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007; 2-(3-Hydroxypropylamino)-6-benzylamino-9-isopropylpurine; [6-Benzylamino-2-(3-hydroxypropylamino)-9-isopropylpurine; 2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopropylpurine; 3-{[6-(benzylamino)-9-isopropyl-9H-purin-2-yl]amino}propan-1-ol; purine deriv. 1; AC1L1DN2; SCHEMBL1443403; GTPL5938; BDBM10633; CTK8A4395; DTXSID00274365; EX-A931
DMLCMA3 DT Small molecular drug
DMLCMA3 PC 2422
DMLCMA3 MW 340.4
DMLCMA3 FM C18H24N6O
DMLCMA3 IC InChI=1S/C18H24N6O/c1-13(2)24-12-21-15-16(20-11-14-7-4-3-5-8-14)22-18(23-17(15)24)19-9-6-10-25/h3-5,7-8,12-13,25H,6,9-11H2,1-2H3,(H2,19,20,22,23)
DMLCMA3 CS CC(C)N1C=NC2=C(N=C(N=C21)NCCCO)NCC3=CC=CC=C3
DMLCMA3 IK OPQGFIAVPSXOBO-UHFFFAOYSA-N
DMLCMA3 IU 3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]propan-1-ol
DMLCMA3 CA CAS 189232-42-6
DMLCMA3 CB CHEBI:86007
DMLCMA3 DE Discovery agent
DM0EKO5 ID DM0EKO5
DM0EKO5 DN Boldenone
DM0EKO5 HS Investigative
DM0EKO5 SN Boldenone; Dehydrotestosterone; 846-48-0; 1,2-Dehydrotestosterone; 1-Dehydrotestosterone; 1,2-Didehydrotestosterone; 17beta-Boldenone; delta1-Testosterone; Boldenonum; Boldenona; 17beta-Hydroxyandrosta-1,4-dien-3-one; 1,4-Androstadien-17beta-ol-3-one; Boldenonum [INN-Latin]; Boldenona [INN-Spanish]; Boldenone [INN:BAN]; UNII-5H7I2IP58X; 17beta-Hydroxyandrosta-1,4-diene-3-one; 17-beta-Hydroxyandrosta-1,4-dien-3-one; EINECS 212-686-0; NSC 79102; 17-beta-Hydroxy-17-alpha-1,4-androstadien-3-one; 5H7I2IP58X; CHEBI:34584
DM0EKO5 DT Small molecular drug
DM0EKO5 PC 13308
DM0EKO5 MW 286.4
DM0EKO5 FM C19H26O2
DM0EKO5 IC InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
DM0EKO5 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)C=C[C@]34C
DM0EKO5 IK RSIHSRDYCUFFLA-DYKIIFRCSA-N
DM0EKO5 IU (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DM0EKO5 CA CAS 846-48-0
DM0EKO5 CB CHEBI:34584
DM0EKO5 DE Discovery agent
DMMVB5P ID DMMVB5P
DMMVB5P DN BOLDINE
DMMVB5P HS Investigative
DMMVB5P SN Boldine; 476-70-0; Uniboldina; Boldin; (S)-Boldine; Boldine chloroform; (+)-Boldine; NSC 65689; UNII-8I91GE2769; (S)-(+)-Boldine; EINECS 207-509-9; BRN 0094036; 1,10-Dimethoxy-2,9-dihydroxyaporphine; CHEMBL388342; CHEBI:3148; 1,10-Dimethoxy-6a-alpha-aporphine-2,9-diol; LZJRNLRASBVRRX-ZDUSSCGKSA-N; 8I91GE2769; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (S)-; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)-
DMMVB5P DT Small molecular drug
DMMVB5P PC 10154
DMMVB5P MW 327.4
DMMVB5P FM C19H21NO4
DMMVB5P IC InChI=1S/C19H21NO4/c1-20-5-4-10-7-15(22)19(24-3)18-12-9-16(23-2)14(21)8-11(12)6-13(20)17(10)18/h7-9,13,21-22H,4-6H2,1-3H3/t13-/m0/s1
DMMVB5P CS CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)O)OC)O
DMMVB5P IK LZJRNLRASBVRRX-ZDUSSCGKSA-N
DMMVB5P IU (6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
DMMVB5P CA CAS 476-70-0
DMMVB5P CB CHEBI:3148
DMMVB5P DE Discovery agent
DMVB6UG ID DMVB6UG
DMVB6UG DN BOLINAQUINONE
DMVB6UG HS Investigative
DMVB6UG SN bolinaquinone; SCHEMBL1231059
DMVB6UG DT Small molecular drug
DMVB6UG PC 10066979
DMVB6UG MW 358.5
DMVB6UG FM C22H30O4
DMVB6UG IC InChI=1S/C22H30O4/c1-13-7-6-8-16-14(2)21(3,9-10-22(13,16)4)12-15-19(24)17(23)11-18(26-5)20(15)25/h7,11,14,16,24H,6,8-10,12H2,1-5H3/t14-,16+,21-,22-/m1/s1
DMVB6UG CS C[C@@H]1[C@@H]2CCC=C([C@]2(CC[C@]1(C)CC3=C(C(=O)C=C(C3=O)OC)O)C)C
DMVB6UG IK PYUXUMSQSVWNDS-NSAJDELNSA-N
DMVB6UG IU 3-[[(1R,2R,4aS,8aS)-1,2,4a,5-tetramethyl-1,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
DMVB6UG DE Discovery agent
DMAW40Y ID DMAW40Y
DMAW40Y DN BOMA
DMAW40Y HS Investigative
DMAW40Y SN BOMA; SCHEMBL660569; GTPL1421; LWSOZPNJUFEDJU-UHFFFAOYSA-N; [4-(1,3-benzoxazol-2-yl)-2-methoxyphenyl]acetonitrile
DMAW40Y DT Small molecular drug
DMAW40Y PC 10192854
DMAW40Y MW 264.28
DMAW40Y FM C16H12N2O2
DMAW40Y IC InChI=1S/C16H12N2O2/c1-19-15-10-12(7-6-11(15)8-9-17)16-18-13-4-2-3-5-14(13)20-16/h2-7,10H,8H2,1H3
DMAW40Y CS COC1=C(C=CC(=C1)C2=NC3=CC=CC=C3O2)CC#N
DMAW40Y IK LWSOZPNJUFEDJU-UHFFFAOYSA-N
DMAW40Y IU 2-[4-(1,3-benzoxazol-2-yl)-2-methoxyphenyl]acetonitrile
DMAW40Y DE Discovery agent
DMDFQ0Y ID DMDFQ0Y
DMDFQ0Y DN bombesin
DMDFQ0Y HS Investigative
DMDFQ0Y SN GTPL616; AKOS024456418; FT-0688038
DMDFQ0Y DT Small molecular drug
DMDFQ0Y PC 16133800
DMDFQ0Y MW 1619.9
DMDFQ0Y FM C71H110N24O18S
DMDFQ0Y IC InChI=1S/C71H110N24O18S/c1-34(2)24-47(92-62(105)43(14-11-22-79-71(76)77)89-64(107)45(15-18-52(72)96)90-63(106)44-17-20-55(99)85-44)61(104)81-31-56(100)87-51(28-54(74)98)69(112)91-46(16-19-53(73)97)65(108)94-49(26-38-29-80-41-13-10-9-12-40(38)41)66(109)84-37(7)60(103)95-58(36(5)6)70(113)82-32-57(101)86-50(27-39-30-78-33-83-39)68(111)93-48(25-35(3)4)67(110)88-42(59(75)102)21-23-114-8/h9-10,12-13,29-30,33-37,42-51,58,80H,11,14-28,31-32H2,1-8H3,(H2,72,96)(H2,73,97)(H2,74,98)(H2,75,102)(H,78,83)(H,81,104)(H,82,113)(H,84,109)(H,85,99)(H,86,101)(H,87,100)(H,88,110)(H,89,107)(H,90,106)(H,91,112)(H,92,105)(H,93,111)(H,94,108)(H,95,103)(H4,76,77,79)/t37-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,58-/m0/s1
DMDFQ0Y CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCC(=O)N4
DMDFQ0Y IK QXZBMSIDSOZZHK-DOPDSADYSA-N
DMDFQ0Y IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanediamide
DMDFQ0Y CA CAS 31362-50-2
DMDFQ0Y DE Discovery agent
DMI75A3 ID DMI75A3
DMI75A3 DN BOMPPA
DMI75A3 HS Investigative
DMI75A3 SN benzyloxy-methoxyphenyl-propylamide; compound 10 [PMID: 23228808]
DMI75A3 DT Small molecular drug
DMI75A3 PC 71508234
DMI75A3 MW 341.4
DMI75A3 FM C21H27NO3
DMI75A3 IC InChI=1S/C21H27NO3/c1-4-21(23)22-12-6-8-17-15-20(25-3)11-10-18(17)13-16-7-5-9-19(14-16)24-2/h5,7,9-11,14-15H,4,6,8,12-13H2,1-3H3,(H,22,23)
DMI75A3 CS CCC(=O)NCCCC1=C(C=CC(=C1)OC)CC2=CC(=CC=C2)OC
DMI75A3 IK GJRIGACGWLYZAO-UHFFFAOYSA-N
DMI75A3 IU N-[3-[5-methoxy-2-[(3-methoxyphenyl)methyl]phenyl]propyl]propanamide
DMI75A3 DE Discovery agent
DMWALXQ ID DMWALXQ
DMWALXQ DN bongkrek acid
DMWALXQ HS Investigative
DMWALXQ SN bongkrekic acid; flavotoxin A
DMWALXQ DT Small molecular drug
DMWALXQ PC 6433556
DMWALXQ MW 486.6
DMWALXQ FM C28H38O7
DMWALXQ IC InChI=1S/C28H38O7/c1-21(15-18-24(19-26(29)30)20-27(31)32)13-11-9-7-5-6-8-10-12-14-25(35-4)22(2)16-17-23(3)28(33)34/h6,8-12,15-19,21,25H,5,7,13-14,20H2,1-4H3,(H,29,30)(H,31,32)(H,33,34)/b8-6+,11-9+,12-10-,18-15+,22-16-,23-17+,24-19+/t21-,25+/m0/s1
DMWALXQ CS C[C@@H](C/C=C/CC/C=C/C=C\\C[C@H](/C(=C\\C=C(/C)\\C(=O)O)/C)OC)/C=C/C(=C\\C(=O)O)/CC(=O)O
DMWALXQ IK SHCXABJSXUACKU-WUTQZGRKSA-N
DMWALXQ IU (2E,4Z,6R,8Z,10E,14E,17S,18E,20Z)-20-(carboxymethyl)-6-methoxy-2,5,17-trimethyldocosa-2,4,8,10,14,18,20-heptaenedioic acid
DMWALXQ CA CAS 11076-19-0
DMWALXQ CB CHEBI:77742
DMWALXQ DE Discovery agent
DMWBV1P ID DMWBV1P
DMWBV1P DN borneol
DMWBV1P HS Investigative
DMWBV1P SN isoborneol; (+)-borneol
DMWBV1P DT Small molecular drug
DMWBV1P PC 64685
DMWBV1P MW 154.25
DMWBV1P FM C10H18O
DMWBV1P IC InChI=1S/C10H18O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7-8,11H,4-6H2,1-3H3
DMWBV1P CS CC1(C2CCC1(C(C2)O)C)C
DMWBV1P IK DTGKSKDOIYIVQL-UHFFFAOYSA-N
DMWBV1P IU 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol
DMWBV1P CA CAS 507-70-0
DMWBV1P CB CHEBI:28093
DMWBV1P DE Discovery agent
DMR70ZO ID DMR70ZO
DMR70ZO DN Bornyl (3,4,5-trihydroxy)-cinnamate
DMR70ZO HS Investigative
DMR70ZO SN CHEMBL408621; bornyl (3,4,5-trihydroxy)-cinnamate
DMR70ZO DT Small molecular drug
DMR70ZO PC 24882417
DMR70ZO MW 332.4
DMR70ZO FM C19H24O5
DMR70ZO IC InChI=1S/C19H24O5/c1-18(2)12-6-7-19(18,3)15(10-12)24-16(22)5-4-11-8-13(20)17(23)14(21)9-11/h4-5,8-9,12,15,20-21,23H,6-7,10H2,1-3H3/b5-4+/t12?,15?,19-/m1/s1
DMR70ZO CS C[C@]12CCC(C1(C)C)CC2OC(=O)/C=C/C3=CC(=C(C(=C3)O)O)O
DMR70ZO IK IMMWANKYSKQCQN-UOAQAXRFSA-N
DMR70ZO IU [(1S)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl] (E)-3-(3,4,5-trihydroxyphenyl)prop-2-enoate
DMR70ZO DE Discovery agent
DMBSQTR ID DMBSQTR
DMBSQTR DN Borrelidin
DMBSQTR HS Investigative
DMBSQTR SN Borrelidin; 7184-60-3; 2-(7-Cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxooxacyclooctadeca-4,6-dien-2-yl)cyclopentanecarboxylic acid; Quinquangulin K 182; Quinquangulin K 031; AC1O53K5; Cyclopentanecarboxylic acid, 2-(7-cyano-8, 16-dihydroxy-9,11,13,15-tetramethyl-18-oxooxacyclooctadeca-4, 6-dien-2-yl)-; 2-[(4Z,6Z)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid
DMBSQTR DT Small molecular drug
DMBSQTR PC 6436801
DMBSQTR MW 489.6
DMBSQTR FM C28H43NO6
DMBSQTR IC InChI=1S/C28H43NO6/c1-17-12-18(2)14-20(4)27(32)21(16-29)8-5-6-11-25(22-9-7-10-23(22)28(33)34)35-26(31)15-24(30)19(3)13-17/h5-6,8,17-20,22-25,27,30,32H,7,9-15H2,1-4H3,(H,33,34)/b6-5+,21-8-/t17-,18+,19-,20-,22+,23+,24-,25-,27+/m0/s1
DMBSQTR CS C[C@H]1C[C@H](C[C@@H]([C@H](/C(=C\\C=C\\C[C@H](OC(=O)C[C@@H]([C@H](C1)C)O)[C@@H]2CCC[C@H]2C(=O)O)/C#N)O)C)C
DMBSQTR IK OJCKRNPLOZHAOU-UGKRXNSESA-N
DMBSQTR IU (1R,2R)-2-[(2S,4E,6Z,8R,9S,11R,13S,15S,16S)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid
DMBSQTR CA CAS 7184-60-3
DMBSQTR DE Discovery agent
DMRELJ0 ID DMRELJ0
DMRELJ0 DN Bovinic acid
DMRELJ0 HS Investigative
DMRELJ0 SN Trans-11 conjugated linoleic acid; Conjugated linoleic acid; Ricinenic acid; Rumenic acid; (9Z,11E)-9,11-octadecadienoic acid; (9Z,11E)-Octadecadienoic acid; (9Z,11E)-octadeca-9,11-dienoic acid; 2540-56-9; 46JZW3MR59; 9(Z),11(E)-octadecadienoic acid; 9,11-Octadecadienoic acid, (9Z,11E)-; 9-cis,11-trans-Octadecadienoic acid solution; 9-cis,11-trans-octadecadienoic acid; 9Z, 11E-Linoleic acid; 9Z,11E-octadecadienoic acid; UNII-46JZW3MR59; c9t11CLA; cis-9, trans-11-octadecadienoic acid; cis-9,trans-11 conjugated linoleic acid
DMRELJ0 PC 5280644
DMRELJ0 MW 280.4
DMRELJ0 FM C18H32O2
DMRELJ0 IC JBYXPOFIGCOSSB-GOJKSUSPSA-N
DMRELJ0 CS CCCCCCC=CC=CCCCCCCCC(=O)O
DMRELJ0 IK 1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h7-10H,2-6,11-17H2,1H3,(H,19,20)/b8-7+,10-9-
DMRELJ0 IU (9Z,11E)-octadeca-9,11-dienoic acid
DMRELJ0 CA CAS 2540-56-9
DMRELJ0 CB CHEBI:32798
DMRELJ0 DE Discovery agent
DMGEYFB ID DMGEYFB
DMGEYFB DN BP-100-1.02
DMGEYFB HS Investigative
DMGEYFB SN Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path
DMGEYFB CP Bio-Path Holdings Inc
DMGEYFB DT Antisense drug
DMGEYFB DE Lymphoma
DMUOS3G ID DMUOS3G
DMUOS3G DN BPH-252
DMUOS3G HS Investigative
DMUOS3G SN BPH 252; BPH252
DMUOS3G DT Small molecular drug
DMUOS3G PC 5276503
DMUOS3G MW 318.24
DMUOS3G FM C10H24O7P2
DMUOS3G IC InChI=1S/C10H24O7P2/c1-2-3-4-5-6-7-8-9-10(11,18(12,13)14)19(15,16)17/h11H,2-9H2,1H3,(H2,12,13,14)(H2,15,16,17)
DMUOS3G CS CCCCCCCCCC(O)(P(=O)(O)O)P(=O)(O)O
DMUOS3G IK NSCPCMXKWUFFNL-UHFFFAOYSA-N
DMUOS3G IU (1-hydroxy-1-phosphonodecyl)phosphonic acid
DMUOS3G DE Discovery agent
DM0NQLI ID DM0NQLI
DM0NQLI DN BPH-608
DM0NQLI HS Investigative
DM0NQLI SN BPH608; BPH 608
DM0NQLI DT Small molecular drug
DM0NQLI PC 16086422
DM0NQLI MW 434.3
DM0NQLI FM C20H20O7P2
DM0NQLI IC InChI=1S/C20H20O7P2/c21-20(28(22,23)24,29(25,26)27)14-15-6-4-9-17(12-15)19-11-5-10-18(13-19)16-7-2-1-3-8-16/h1-13,21H,14H2,(H2,22,23,24)(H2,25,26,27)
DM0NQLI CS C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC=CC(=C3)CC(O)(P(=O)(O)O)P(=O)(O)O
DM0NQLI IK YXQQNSYZOQHKHD-UHFFFAOYSA-N
DM0NQLI IU [1-hydroxy-2-[3-(3-phenylphenyl)phenyl]-1-phosphonoethyl]phosphonic acid
DM0NQLI DE Discovery agent
DM0TJ6R ID DM0TJ6R
DM0TJ6R DN BPH-628
DM0TJ6R HS Investigative
DM0TJ6R SN BPH 628; B28; BPH628
DM0TJ6R DT Small molecular drug
DM0TJ6R PC 16122554
DM0TJ6R MW 434.3
DM0TJ6R FM C20H20O7P2
DM0TJ6R IC InChI=1S/C20H20O7P2/c21-20(28(22,23)24,29(25,26)27)14-15-5-4-8-19(13-15)18-11-9-17(10-12-18)16-6-2-1-3-7-16/h1-13,21H,14H2,(H2,22,23,24)(H2,25,26,27)
DM0TJ6R CS C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=CC(=C3)CC(O)(P(=O)(O)O)P(=O)(O)O
DM0TJ6R IK MPBUFKZCEBTBSK-UHFFFAOYSA-N
DM0TJ6R IU [1-hydroxy-2-[3-(4-phenylphenyl)phenyl]-1-phosphonoethyl]phosphonic acid
DM0TJ6R DE Discovery agent
DM49BFM ID DM49BFM
DM49BFM DN BPH-629
DM49BFM HS Investigative
DM49BFM SN BPH 629; BPH629
DM49BFM DT Small molecular drug
DM49BFM PC 16122553
DM49BFM MW 448.3
DM49BFM FM C20H18O8P2
DM49BFM IC InChI=1S/C20H18O8P2/c21-20(29(22,23)24,30(25,26)27)12-13-5-3-6-14(11-13)15-8-4-9-17-16-7-1-2-10-18(16)28-19(15)17/h1-11,21H,12H2,(H2,22,23,24)(H2,25,26,27)
DM49BFM CS C1=CC=C2C(=C1)C3=C(O2)C(=CC=C3)C4=CC=CC(=C4)CC(O)(P(=O)(O)O)P(=O)(O)O
DM49BFM IK BYVXAUZOTGITQZ-UHFFFAOYSA-N
DM49BFM IU [2-(3-dibenzofuran-4-ylphenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
DM49BFM DE Discovery agent
DMX4WI7 ID DMX4WI7
DMX4WI7 DN BPH-652
DMX4WI7 HS Investigative
DMX4WI7 SN FX24B-04652; Dehydrosqualene synthase inhibitor (MRSA), AuricX
DMX4WI7 CP AuricX Pharmaceuticals Inc
DMX4WI7 DT Small molecular drug
DMX4WI7 PC 16730264
DMX4WI7 MW 500.6
DMX4WI7 FM C16H16K3O7PS
DMX4WI7 IC InChI=1S/C16H19O7PS.3K/c17-24(18,19)16(25(20,21)22)11-5-7-13-6-4-10-15(12-13)23-14-8-2-1-3-9-14;;;/h1-4,6,8-10,12,16H,5,7,11H2,(H2,17,18,19)(H,20,21,22);;;/q;3*+1/p-3
DMX4WI7 CS C1=CC=C(C=C1)OC2=CC=CC(=C2)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-].[K+].[K+].[K+]
DMX4WI7 IK DRADVLDMPYYQDB-UHFFFAOYSA-K
DMX4WI7 IU tripotassium;4-(3-phenoxyphenyl)-1-phosphonatobutane-1-sulfonate
DMX4WI7 DE Hypercholesterolaemia
DM3IPYV ID DM3IPYV
DM3IPYV DN BPH-675
DM3IPYV HS Investigative
DM3IPYV SN BPH675; BPH 675
DM3IPYV DT Small molecular drug
DM3IPYV PC 16122555
DM3IPYV MW 563.5
DM3IPYV FM C24H23NO9P2S
DM3IPYV IC InChI=1S/C24H23NO9P2S/c26-24(35(27,28)29,36(30,31)32)16-17-5-3-8-19(13-17)20-9-4-10-22(14-20)25-37(33,34)23-12-11-18-6-1-2-7-21(18)15-23/h1-15,25-26H,16H2,(H2,27,28,29)(H2,30,31,32)
DM3IPYV CS C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)NC3=CC=CC(=C3)C4=CC=CC(=C4)CC(O)(P(=O)(O)O)P(=O)(O)O
DM3IPYV IK MZVWVRVNMXTDAK-UHFFFAOYSA-N
DM3IPYV IU [1-hydroxy-2-[3-[3-(naphthalen-2-ylsulfonylamino)phenyl]phenyl]-1-phosphonoethyl]phosphonic acid
DM3IPYV DE Discovery agent
DMPKAEW ID DMPKAEW
DMPKAEW DN BPH-676
DMPKAEW HS Investigative
DMPKAEW SN BPH676; BPH 676
DMPKAEW DT Small molecular drug
DMPKAEW PC 16122556
DMPKAEW MW 450.3
DMPKAEW FM C20H20O8P2
DMPKAEW IC InChI=1S/C20H20O8P2/c21-20(29(22,23)24,30(25,26)27)14-28-19-11-5-10-18(13-19)17-9-4-8-16(12-17)15-6-2-1-3-7-15/h1-13,21H,14H2,(H2,22,23,24)(H2,25,26,27)
DMPKAEW CS C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC(=CC=C3)OCC(O)(P(=O)(O)O)P(=O)(O)O
DMPKAEW IK NWIARQRYIRVYCM-UHFFFAOYSA-N
DMPKAEW IU [1-hydroxy-2-[3-(3-phenylphenyl)phenoxy]-1-phosphonoethyl]phosphonic acid
DMPKAEW DE Discovery agent
DMTHW3F ID DMTHW3F
DMTHW3F DN BPH-715
DMTHW3F HS Investigative
DMTHW3F SN BPH 715; BPH715
DMTHW3F DT Small molecular drug
DMTHW3F PC 25014899
DMTHW3F MW 423.4
DMTHW3F FM C17H31NO7P2
DMTHW3F IC InChI=1S/C17H31NO7P2/c1-2-3-4-5-6-7-8-9-13-25-16-11-10-12-18(14-16)15-17(26(19,20)21)27(22,23)24/h10-12,14,17H,2-9,13,15H2,1H3,(H3-,19,20,21,22,23,24)
DMTHW3F CS CCCCCCCCCCOC1=C[N+](=CC=C1)CC(P(=O)(O)O)P(=O)(O)[O-]
DMTHW3F IK QYJHUOZDBUEKQC-UHFFFAOYSA-N
DMTHW3F IU [2-(3-decoxypyridin-1-ium-1-yl)-1-phosphonoethyl]-hydroxyphosphinate
DMTHW3F CA CAS 1059677-23-4
DMTHW3F DE Discovery agent
DMD0XEO ID DMD0XEO
DMD0XEO DN BPH-742
DMD0XEO HS Investigative
DMD0XEO SN bisphosphonate, 9; BPH742; BPH 742
DMD0XEO DT Small molecular drug
DMD0XEO PC 25023860
DMD0XEO MW 418.38
DMD0XEO FM C16H37O6P3
DMD0XEO IC InChI=1S/C16H37O6P3/c1-4-5-6-7-8-9-10-11-12-13-14-23(2,3)15-16(24(17,18)19)25(20,21)22/h16H,4-15H2,1-3H3,(H3-,17,18,19,20,21,22)
DMD0XEO CS CCCCCCCCCCCC[P+](C)(C)CC(P(=O)(O)O)P(=O)(O)[O-]
DMD0XEO IK QCMHKGWUOSRYCF-UHFFFAOYSA-N
DMD0XEO IU [2-[dodecyl(dimethyl)phosphaniumyl]-1-phosphonoethyl]-hydroxyphosphinate
DMD0XEO DE Discovery agent
DM15L2J ID DM15L2J
DM15L2J DN BPH-830
DM15L2J HS Investigative
DM15L2J SN BPH830; BPH 830
DM15L2J DT Small molecular drug
DM15L2J PC 44182294
DM15L2J MW 349.32
DM15L2J FM C17H20NO5P
DM15L2J IC InChI=1S/C17H20NO5P/c19-17(13-24(20,21)22)18-11-5-7-14-6-4-10-16(12-14)23-15-8-2-1-3-9-15/h1-4,6,8-10,12H,5,7,11,13H2,(H,18,19)(H2,20,21,22)
DM15L2J CS C1=CC=C(C=C1)OC2=CC=CC(=C2)CCCNC(=O)CP(=O)(O)O
DM15L2J IK GNETVUVZFYJATO-UHFFFAOYSA-N
DM15L2J IU [2-oxo-2-[3-(3-phenoxyphenyl)propylamino]ethyl]phosphonic acid
DM15L2J DE Discovery agent
DMGQXTR ID DMGQXTR
DMGQXTR DN BPI-704001
DMGQXTR HS Investigative
DMGQXTR SN BPI-705001; BPI-715001; PARP-1 inhibitors (cancer); PARP-1 inhibitors (cancer), Beta Pharma
DMGQXTR CP Beta Pharma Inc
DMGQXTR DE Solid tumour/cancer
DMOSG0Q ID DMOSG0Q
DMOSG0Q DN BPI-711001
DMOSG0Q HS Investigative
DMOSG0Q SN BPI-712001; DPP-4 inhibitors (oral, diabetes); DPP-4 inhibitors (oral, diabetes), Beta Pharma
DMOSG0Q CP Beta Pharma Inc
DMOSG0Q DE Hypoglycemia
DMNHEUT ID DMNHEUT
DMNHEUT DN BPIQ-I
DMNHEUT HS Investigative
DMNHEUT SN bpiq-i; 174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1
DMNHEUT DT Small molecular drug
DMNHEUT PC 2427
DMNHEUT MW 354.2
DMNHEUT FM C16H12BrN5
DMNHEUT IC InChI=1S/C16H12BrN5/c1-22-9-20-14-6-12-13(7-15(14)22)18-8-19-16(12)21-11-4-2-3-10(17)5-11/h2-9H,1H3,(H,18,19,21)
DMNHEUT CS CN1C=NC2=C1C=C3C(=C2)C(=NC=N3)NC4=CC(=CC=C4)Br
DMNHEUT IK YAMAGACQNDAKFB-UHFFFAOYSA-N
DMNHEUT IU N-(3-bromophenyl)-3-methylimidazo[4,5-g]quinazolin-8-amine
DMNHEUT CA CAS 174709-30-9
DMNHEUT DE Discovery agent
DM5OHIY ID DM5OHIY
DM5OHIY DN BPKDi
DM5OHIY HS Investigative
DM5OHIY PC 46901383
DM5OHIY MW 380.5
DM5OHIY FM C21H28N6O
DM5OHIY IC InChI=1S/C21H28N6O/c22-21(28)16-12-18(26-20(14-16)27-10-8-23-9-11-27)15-6-7-24-19(13-15)25-17-4-2-1-3-5-17/h6-7,12-14,17,23H,1-5,8-11H2,(H2,22,28)(H,24,25)
DM5OHIY CS C1CCC(CC1)NC2=NC=CC(=C2)C3=NC(=CC(=C3)C(=O)N)N4CCNCC4
DM5OHIY IK XNWDRALEEPGBHB-UHFFFAOYSA-N
DM5OHIY IU 2-[2-(cyclohexylamino)pyridin-4-yl]-6-piperazin-1-ylpyridine-4-carboxamide
DM5OHIY DE Solid tumour/cancer
DMKX6LY ID DMKX6LY
DMKX6LY DN BPL-001
DMKX6LY HS Investigative
DMKX6LY SN HMG CoA reductase inhibitors (cardiovascular disease), Bradford Pharma; HMG CoA reductase inhibitors (cardiovascular disease), Redx Pharma; BPL-001 series (cardiovascular disease), Bradford Pharma; BPL-001 series (cardiovascular disease), Redx Pharma
DMKX6LY CP Bradford Pharma Ltd
DMKX6LY DE Cardiovascular disease
DMJPN8Z ID DMJPN8Z
DMJPN8Z DN BPR1K-0224
DMJPN8Z HS Investigative
DMJPN8Z SN Aurora kinase inhibitors (cancer); BPR1K-0025; BPR1K-0432; BPR1K-0648; BPR1K-0724; Aurora kinase inhibitors (cancer), National Health Research Institutes
DMJPN8Z CP National Health Research Institutes
DMJPN8Z DE Solid tumour/cancer
DMQBRSM ID DMQBRSM
DMQBRSM DN BQ 3020
DMQBRSM HS Investigative
DMQBRSM SN BQ3020; BQ-3020
DMQBRSM DT Small molecular drug
DMQBRSM PC 16133801
DMQBRSM MW 1992.3
DMQBRSM FM C95H138N20O25S
DMQBRSM IC InChI=1S/C95H138N20O25S/c1-15-52(10)79(94(138)114-78(51(8)9)93(137)112-73(95(139)140)41-58-45-98-62-26-20-19-25-61(58)62)115-91(135)72(44-76(122)123)110-87(131)67(38-49(4)5)107-89(133)70(42-59-46-97-47-99-59)106-80(124)53(11)101-85(129)68(39-56-23-17-16-18-24-56)108-88(132)69(40-57-28-30-60(117)31-29-57)111-92(136)77(50(6)7)113-81(125)54(12)100-82(126)64(32-33-74(118)119)104-83(127)63(27-21-22-35-96)103-90(134)71(43-75(120)121)109-84(128)65(34-36-141-14)105-86(130)66(37-48(2)3)102-55(13)116/h16-20,23-26,28-31,45-54,63-73,77-79,98,117H,15,21-22,27,32-44,96H2,1-14H3,(H,97,99)(H,100,126)(H,101,129)(H,102,116)(H,103,134)(H,104,127)(H,105,130)(H,106,124)(H,107,133)(H,108,132)(H,109,128)(H,110,131)(H,111,136)(H,112,137)(H,113,125)(H,114,138)(H,115,135)(H,118,119)(H,120,121)(H,122,123)(H,139,140)/t52-,53-,54-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,77-,78-,79-/m0/s1
DMQBRSM CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)C
DMQBRSM IK KBQLINQFUQUHIY-SGOWJZKMSA-N
DMQBRSM IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S,3S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMQBRSM DE Discovery agent
DMSGIXK ID DMSGIXK
DMSGIXK DN BQCA
DMSGIXK HS Investigative
DMSGIXK SN TBPB; Benzyl quinolone carboxylic acid; M1 muscarinic acetylcholine receptor agonist (Alzherimer's disease); M1mAChRs (neurological disorder), Merck & Co; M1 muscarinic acetylcholine receptor agonist (Alzherimer's disease), Merck & Co
DMSGIXK CP Merck & Co Inc
DMSGIXK DT Small molecular drug
DMSGIXK PC 1476756
DMSGIXK MW 309.3
DMSGIXK FM C18H15NO4
DMSGIXK IC InChI=1S/C18H15NO4/c1-23-13-8-6-12(7-9-13)10-19-11-15(18(21)22)17(20)14-4-2-3-5-16(14)19/h2-9,11H,10H2,1H3,(H,21,22)
DMSGIXK CS COC1=CC=C(C=C1)CN2C=C(C(=O)C3=CC=CC=C32)C(=O)O
DMSGIXK IK BZBBTGCKPRSPGF-UHFFFAOYSA-N
DMSGIXK IU 1-[(4-methoxyphenyl)methyl]-4-oxoquinoline-3-carboxylic acid
DMSGIXK CA CAS 338747-41-4
DMSGIXK DE Neurological disorder
DMBTC23 ID DMBTC23
DMBTC23 DN Br-5MPEPy
DMBTC23 HS Investigative
DMBTC23 SN Br-5MPEPy; SCHEMBL3963310; GTPL6397; CHEMBL475270
DMBTC23 DT Small molecular drug
DMBTC23 PC 16067787
DMBTC23 MW 273.13
DMBTC23 FM C13H9BrN2
DMBTC23 IC InChI=1S/C13H9BrN2/c1-10-2-4-13(16-7-10)5-3-11-6-12(14)9-15-8-11/h2,4,6-9H,1H3
DMBTC23 CS CC1=CN=C(C=C1)C#CC2=CC(=CN=C2)Br
DMBTC23 IK IHHBVGZPZBDKRA-UHFFFAOYSA-N
DMBTC23 IU 2-[2-(5-bromopyridin-3-yl)ethynyl]-5-methylpyridine
DMBTC23 CA CAS 872428-51-8
DMBTC23 DE Discovery agent
DM0DWSR ID DM0DWSR
DM0DWSR DN bradyzide
DM0DWSR HS Investigative
DM0DWSR SN Bradyzide; CHEMBL308468; AC1NSM1I; GTPL680; SCHEMBL8488232; LS-137389; 263011-13-8; (2S)-N-[2-(2-dimethylaminoethyl-methylamino)ethyl]-1-[4-[2-[di(phenyl)methylcarbamothioyl]hydrazinyl]-3-nitrophenyl]sulfonylpyrrolidine-2-carboxamide
DM0DWSR DT Small molecular drug
DM0DWSR PC 5312119
DM0DWSR MW 682.9
DM0DWSR FM C32H42N8O5S2
DM0DWSR IC InChI=1S/C32H42N8O5S2/c1-37(2)21-22-38(3)20-18-33-31(41)28-15-10-19-39(28)47(44,45)26-16-17-27(29(23-26)40(42)43)35-36-32(46)34-30(24-11-6-4-7-12-24)25-13-8-5-9-14-25/h4-9,11-14,16-17,23,28,30,35H,10,15,18-22H2,1-3H3,(H,33,41)(H2,34,36,46)/t28-/m0/s1
DM0DWSR CS CN(C)CCN(C)CCNC(=O)[C@@H]1CCCN1S(=O)(=O)C2=CC(=C(C=C2)NNC(=S)NC(C3=CC=CC=C3)C4=CC=CC=C4)[N+](=O)[O-]
DM0DWSR IK ZIBIVIRBYMBEHZ-NDEPHWFRSA-N
DM0DWSR IU (2S)-1-[4-[2-(benzhydrylcarbamothioyl)hydrazinyl]-3-nitrophenyl]sulfonyl-N-[2-[2-(dimethylamino)ethyl-methylamino]ethyl]pyrrolidine-2-carboxamide
DM0DWSR DE Discovery agent
DMIZ9ON ID DMIZ9ON
DMIZ9ON DN BRD1240
DMIZ9ON HS Investigative
DMIZ9ON SN BRD-1240; 3-(1,3-benzodioxol-5-yl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea; CHEMBL2355724; CHEBI:96315; BRD-K63431240-001-01-4; BRD-K63431240-001-02-2; Q27168409
DMIZ9ON CP Harvard University
DMIZ9ON DT Small molecular drug
DMIZ9ON PC 54618771
DMIZ9ON MW 592.7
DMIZ9ON FM C30H32N4O7S
DMIZ9ON IC InChI=1S/C30H32N4O7S/c1-20-16-34(21(2)18-35)42(37,38)29-9-6-23(5-4-22-10-12-31-13-11-22)14-27(29)41-28(20)17-33(3)30(36)32-24-7-8-25-26(15-24)40-19-39-25/h6-15,20-21,28,35H,16-19H2,1-3H3,(H,32,36)/t20-,21-,28+/m0/s1
DMIZ9ON CS C[C@H]1CN(S(=O)(=O)C2=C(C=C(C=C2)C#CC3=CC=NC=C3)O[C@@H]1CN(C)C(=O)NC4=CC5=C(C=C4)OCO5)[C@@H](C)CO
DMIZ9ON IK OYKBHWDUAQJSNT-YHGPEZAFSA-N
DMIZ9ON IU 3-(1,3-benzodioxol-5-yl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
DMIZ9ON CB CHEBI:96315
DMIZ9ON DE Solid tumour/cancer
DMFAVB5 ID DMFAVB5
DMFAVB5 DN BRD9539
DMFAVB5 HS Investigative
DMFAVB5 SN BRD-9539; BRD 9539
DMFAVB5 DT Small molecular drug
DMFAVB5 PC 73755260
DMFAVB5 MW 399.4
DMFAVB5 FM C24H21N3O3
DMFAVB5 IC InChI=1S/C24H21N3O3/c28-22(18-11-5-2-6-12-18)26-24-25-20-16-19(23(29)30)13-14-21(20)27(24)15-7-10-17-8-3-1-4-9-17/h1-6,8-9,11-14,16H,7,10,15H2,(H,29,30)(H,25,26,28)
DMFAVB5 CS C1=CC=C(C=C1)CCCN2C3=C(C=C(C=C3)C(=O)O)N=C2NC(=O)C4=CC=CC=C4
DMFAVB5 IK WPXMEOBILYVKBC-UHFFFAOYSA-N
DMFAVB5 IU 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylic acid
DMFAVB5 CA CAS 1374601-41-8
DMFAVB5 DE Discovery agent
DM21ZBU ID DM21ZBU
DM21ZBU DN Breceptin
DM21ZBU HS Investigative
DM21ZBU SN B-10206; B-10396; B-10410; B-10458; B-199; B-201 acetate; B-202; B-9340; B-9430; B-9698; B-9870; CU-202; CU-201, Apoplogic
DM21ZBU CP University of Colorado System
DM21ZBU DE Solid tumour/cancer
DM3EIBU ID DM3EIBU
DM3EIBU DN BREMAZOCINE
DM3EIBU HS Investigative
DM3EIBU SN Bremazocine; (-)-Bremazocine; Bremazocine, (-)-; 75684-07-0; 2-(1-Hydroxy-cyclopropylmethyl)-5-ethyl-9,9-dimethyl-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-, (2R)-; SureCN157210; AC1Q2C6X; SCHEMBL157210; CHEBI:3171; GTPL1603; ZINC3870315; PDSP2_001570; PDSP1_001586; C11791; UNII-ISF76M2DBE component ZDXGFIXMPOUDFF-XLIONFOSSA-N
DM3EIBU DT Small molecular drug
DM3EIBU PC 443406
DM3EIBU MW 315.4
DM3EIBU FM C20H29NO2
DM3EIBU IC InChI=1S/C20H29NO2/c1-4-20-9-10-21(13-19(23)7-8-19)17(18(20,2)3)11-14-5-6-15(22)12-16(14)20/h5-6,12,17,22-23H,4,7-11,13H2,1-3H3/t17-,20+/m1/s1
DM3EIBU CS CC[C@@]12CCN([C@@H](C1(C)C)CC3=C2C=C(C=C3)O)CC4(CC4)O
DM3EIBU IK ZDXGFIXMPOUDFF-XLIONFOSSA-N
DM3EIBU IU (1S,9R)-1-ethyl-10-[(1-hydroxycyclopropyl)methyl]-13,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DM3EIBU CA CAS 75684-07-0
DM3EIBU CB CHEBI:3171
DM3EIBU DE Discovery agent
DM2JPX7 ID DM2JPX7
DM2JPX7 DN BRIFENTANIL
DM2JPX7 HS Investigative
DM2JPX7 SN Brifentanil < Rec INN; A-3331 (monohydrochloride); Rac-cis-1-[2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-3-methyl-4-[N-(2-fluorophenyl)methoxyacetamido]piperidine; Rac-cis-N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide
DM2JPX7 DT Small molecular drug
DM2JPX7 PC 60672
DM2JPX7 MW 420.5
DM2JPX7 FM C20H29FN6O3
DM2JPX7 IC InChI=1S/C20H29FN6O3/c1-4-25-20(29)26(23-22-25)12-11-24-10-9-17(15(2)13-24)27(19(28)14-30-3)18-8-6-5-7-16(18)21/h5-8,15,17H,4,9-14H2,1-3H3/t15-,17+/m1/s1
DM2JPX7 CS CCN1C(=O)N(N=N1)CCN2CC[C@@H]([C@@H](C2)C)N(C3=CC=CC=C3F)C(=O)COC
DM2JPX7 IK KKMGCTVJCQYQPV-WBVHZDCISA-N
DM2JPX7 IU N-[(3R,4S)-1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-3-methylpiperidin-4-yl]-N-(2-fluorophenyl)-2-methoxyacetamide
DM2JPX7 CA CAS 101345-71-5
DM2JPX7 DE Pain
DMTM7W0 ID DMTM7W0
DMTM7W0 DN BRL 43694A
DMTM7W0 HS Investigative
DMTM7W0 SN Granisetron HCl; Granisetron hydrochloride; 107007-99-8; Kytril; Granisetron (Hydrochloride); Kytril Injection; BRL 43694A; 1-Methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide hydrochloride; 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide hydrochloride; 1044956-47-9; BRL-43694A; Granisetron hydrochloride [USAN]; endo-1-Methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide hydrochloride
DMTM7W0 DT Small molecular drug
DMTM7W0 PC 65264
DMTM7W0 MW 348.9
DMTM7W0 FM C18H25ClN4O
DMTM7W0 IC InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H
DMTM7W0 CS CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C.Cl
DMTM7W0 IK QYZRTBKYBJRGJB-UHFFFAOYSA-N
DMTM7W0 IU 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;hydrochloride
DMTM7W0 CA CAS 107007-99-8
DMTM7W0 DE Discovery agent
DM3WPO4 ID DM3WPO4
DM3WPO4 DN BRL 44408
DM3WPO4 HS Investigative
DM3WPO4 SN Brl-44408; BRL 44408; 118343-19-4; BRL44408; 2-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2,3-dihydro-1-methyl-1H-isoindole; 1H-Isoindole, 2-((4,5-dihydro-1H-imidazol-2-yl)methyl)-2,3-dihydro-1-methyl-; Brl 48553; C13H17N3; 2-(4,5-dihydro-1H-imidazol-2-ylmethyl)-1-methyl-1,3-dihydroisoindole; Brl 48962; 2-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole; BRL-48553; BRL-48962; AC1L3TIM; GTPL525; SCHEMBL7596949; CHEMBL216097; CTK8E7463; BDBM82520; PDSP2_001727; PDSP1_001744; NSC_121850; CAS_121850
DM3WPO4 DT Small molecular drug
DM3WPO4 PC 121850
DM3WPO4 MW 215.29
DM3WPO4 FM C13H17N3
DM3WPO4 IC InChI=1S/C13H17N3/c1-10-12-5-3-2-4-11(12)8-16(10)9-13-14-6-7-15-13/h2-5,10H,6-9H2,1H3,(H,14,15)
DM3WPO4 CS CC1C2=CC=CC=C2CN1CC3=NCCN3
DM3WPO4 IK SGOFAUSEYBZKDQ-UHFFFAOYSA-N
DM3WPO4 IU 2-(4,5-dihydro-1H-imidazol-2-ylmethyl)-1-methyl-1,3-dihydroisoindole
DM3WPO4 CA CAS 118343-19-4
DM3WPO4 DE Discovery agent
DM16GUV ID DM16GUV
DM16GUV DN BRL 52537 hydrochloride
DM16GUV HS Investigative
DM16GUV SN 2-(3,4-Dichlorophenyl)-1-(2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethanone hydrochloride; 130497-33-5; 112282-24-3; BRL 52537; AK-57392; (+/-)-1-(3,4-Dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine hydrochloride; 2-(3,4-DICHLOROPHENYL)-1-(2-(PYRROLIDIN-1-YLMETHYL)PIPERIDIN-1-YL)ETHANONE HCL; SR-01000076141; EU-0101141; BRL-52537 hydrochloride; Brl 52537 HCl; MLS002153457; SCHEMBL8435659; CHEMBL1256835; KS-00000FTT; CTK8C4721; DTXSID00462129; MolPort-003-940-484; BCP21081; EBD29079
DM16GUV DT Small molecular drug
DM16GUV PC 11315337
DM16GUV MW 391.8
DM16GUV FM C18H25Cl3N2O
DM16GUV IC InChI=1S/C18H24Cl2N2O.ClH/c19-16-7-6-14(11-17(16)20)12-18(23)22-10-2-1-5-15(22)13-21-8-3-4-9-21;/h6-7,11,15H,1-5,8-10,12-13H2;1H
DM16GUV CS C1CCN(C(C1)CN2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.Cl
DM16GUV IK NGVLSOWJSUUYDE-UHFFFAOYSA-N
DM16GUV IU 2-(3,4-dichlorophenyl)-1-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]ethanone;hydrochloride
DM16GUV CA CAS 130497-33-5
DM16GUV DE Discovery agent
DM6XO72 ID DM6XO72
DM6XO72 DN BRL 52974
DM6XO72 HS Investigative
DM6XO72 SN 145544-79-2; Ethanone,2-(3,4-dichlorophenyl)-1-[3,4,6,7-tetrahydro-4-(1-pyrrolidinylmethyl)-5H-imidazo[4,5-c]pyridin-5-yl]-; Brl-52974; Brl 52974; ACMC-20n4kx; SCHEMBL7641688; CTK4C4597; CJLJXCDVYJKDTR-UHFFFAOYSA-N; AKOS030599156; 5-((3,4-Dichlorophenyl)acetyl)-4-(1-pyrrolidinylmethyl)-4,5,6,7-tetrahydro-1H-imidazo(4,5-c)pyridine; 1H-Imidazo(4,5-c)pyridine, 5-((3,4-dichlorophenyl)acetyl)-4,5,6,7-tetrahydro-4-(1-pyrrolidinylmethyl)-
DM6XO72 DT Small molecular drug
DM6XO72 PC 10000638
DM6XO72 MW 393.3
DM6XO72 FM C19H22Cl2N4O
DM6XO72 IC InChI=1S/C19H22Cl2N4O/c20-14-4-3-13(9-15(14)21)10-18(26)25-8-5-16-19(23-12-22-16)17(25)11-24-6-1-2-7-24/h3-4,9,12,17H,1-2,5-8,10-11H2,(H,22,23)
DM6XO72 CS C1CCN(C1)CC2C3=C(CCN2C(=O)CC4=CC(=C(C=C4)Cl)Cl)NC=N3
DM6XO72 IK CJLJXCDVYJKDTR-UHFFFAOYSA-N
DM6XO72 IU 2-(3,4-dichlorophenyl)-1-[4-(pyrrolidin-1-ylmethyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone
DM6XO72 CA CAS 145544-79-2
DM6XO72 DE Discovery agent
DMM61Y2 ID DMM61Y2
DMM61Y2 DN BRL-15572
DMM61Y2 HS Investigative
DMM61Y2 SN BRL15572; BRL-15,572; BRL 15572
DMM61Y2 DT Small molecular drug
DMM61Y2 PC 3654103
DMM61Y2 MW 406.9
DMM61Y2 FM C25H27ClN2O
DMM61Y2 IC InChI=1S/C25H27ClN2O/c26-22-12-7-13-23(18-22)28-16-14-27(15-17-28)19-24(29)25(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-13,18,24-25,29H,14-17,19H2
DMM61Y2 CS C1CN(CCN1CC(C(C2=CC=CC=C2)C3=CC=CC=C3)O)C4=CC(=CC=C4)Cl
DMM61Y2 IK QJHCTHPYUOXOGM-UHFFFAOYSA-N
DMM61Y2 IU 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol
DMM61Y2 CA CAS 734517-40-9
DMM61Y2 CB CHEBI:64060
DMM61Y2 DE Discovery agent
DMSB4EW ID DMSB4EW
DMSB4EW DN BRL-24682
DMSB4EW HS Investigative
DMSB4EW SN Brl-24682; Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-
DMSB4EW DT Small molecular drug
DMSB4EW PC 9797313
DMSB4EW MW 323.82
DMSB4EW FM C16H22ClN3O2
DMSB4EW IC InChI=1S/C16H22ClN3O2/c1-20-10-3-4-11(20)6-9(5-10)19-16(21)12-7-13(17)14(18)8-15(12)22-2/h7-11H,3-6,18H2,1-2H3,(H,19,21)
DMSB4EW CS CN1C2CCC1CC(C2)NC(=O)C3=CC(=C(C=C3OC)N)Cl
DMSB4EW IK HTMNINCXKXABOI-UHFFFAOYSA-N
DMSB4EW IU 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide
DMSB4EW CA CAS 76272-78-1
DMSB4EW DE Discovery agent
DMD0YL1 ID DMD0YL1
DMD0YL1 DN BRL-25594
DMD0YL1 HS Investigative
DMD0YL1 PC 10069545
DMD0YL1 MW 399.9
DMD0YL1 FM C22H26ClN3O2
DMD0YL1 IC InChI=1S/C22H26ClN3O2/c1-28-21-12-20(24)19(23)11-18(21)22(27)25-15-9-16-7-8-17(10-15)26(16)13-14-5-3-2-4-6-14/h2-6,11-12,15-17H,7-10,13,24H2,1H3,(H,25,27)
DMD0YL1 CS COC1=CC(=C(C=C1C(=O)NC2CC3CCC(C2)N3CC4=CC=CC=C4)Cl)N
DMD0YL1 IK BQHYHGXYIOWFJL-UHFFFAOYSA-N
DMD0YL1 IU 4-amino-N-(8-benzyl-8-azabicyclo[3.2.1]octan-3-yl)-5-chloro-2-methoxybenzamide
DMD0YL1 DE Discovery agent
DMQ4MFY ID DMQ4MFY
DMQ4MFY DN BRL-26175
DMQ4MFY HS Investigative
DMQ4MFY SN BRL-26175; CHEMBL122533; BDBM50042732
DMQ4MFY DT Small molecular drug
DMQ4MFY PC 44348012
DMQ4MFY MW 413.9
DMQ4MFY FM C23H28ClN3O2
DMQ4MFY IC InChI=1S/C23H28ClN3O2/c1-29-22-13-21(25)20(24)12-19(22)23(28)26-16-10-17-8-5-9-18(11-16)27(17)14-15-6-3-2-4-7-15/h2-4,6-7,12-13,16-18H,5,8-11,14,25H2,1H3,(H,26,28)
DMQ4MFY CS COC1=CC(=C(C=C1C(=O)NC2CC3CCCC(C2)N3CC4=CC=CC=C4)Cl)N
DMQ4MFY IK BUPWFKLTAPZHIE-UHFFFAOYSA-N
DMQ4MFY IU 4-amino-N-(9-benzyl-9-azabicyclo[3.3.1]nonan-3-yl)-5-chloro-2-methoxybenzamide
DMQ4MFY DE Discovery agent
DMRI49D ID DMRI49D
DMRI49D DN BRL-36378
DMRI49D HS Investigative
DMRI49D SN N-[4-(2,3-Dihydrobenzofuran-2-yl)-1-(ethoxycarbonyl)butyl]-L-alanyl-L-proline
DMRI49D DT Small molecular drug
DMRI49D PC 134835
DMRI49D MW 432.5
DMRI49D FM C23H32N2O6
DMRI49D IC InChI=1S/C23H32N2O6/c1-3-30-23(29)18(10-6-9-17-14-16-8-4-5-12-20(16)31-17)24-15(2)21(26)25-13-7-11-19(25)22(27)28/h4-5,8,12,15,17-19,24H,3,6-7,9-11,13-14H2,1-2H3,(H,27,28)/t15-,17?,18?,19-/m0/s1
DMRI49D CS CCOC(=O)C(CCCC1CC2=CC=CC=C2O1)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)O
DMRI49D IK HTBXOXWJOIKINE-RXQRSOPUSA-N
DMRI49D IU (2S)-1-[(2S)-2-[[5-(2,3-dihydro-1-benzofuran-2-yl)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
DMRI49D CA CAS 84768-09-2
DMRI49D DE Discovery agent
DMT4NM5 ID DMT4NM5
DMT4NM5 DN BRL-48482
DMT4NM5 HS Investigative
DMT4NM5 SN BRL-48482; SCHEMBL1850299; ZYKPNHFCNSVFNF-UHFFFAOYSA-N; 5-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(benzoxazol-2-yl-methylamino)ethoxy] benzyl]thiazolidine-2,4-dione
DMT4NM5 DT Small molecular drug
DMT4NM5 PC 9822139
DMT4NM5 MW 397.4
DMT4NM5 FM C20H19N3O4S
DMT4NM5 IC InChI=1S/C20H19N3O4S/c1-23(19-21-15-4-2-3-5-16(15)27-19)10-11-26-14-8-6-13(7-9-14)12-17-18(24)22-20(25)28-17/h2-9,17H,10-12H2,1H3,(H,22,24,25)
DMT4NM5 CS CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=NC4=CC=CC=C4O3
DMT4NM5 IK ZYKPNHFCNSVFNF-UHFFFAOYSA-N
DMT4NM5 IU 5-[[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMT4NM5 DE Discovery agent
DMV2XUM ID DMV2XUM
DMV2XUM DN BRL50481
DMV2XUM HS Investigative
DMV2XUM SN BRL-50481; BRL 50481
DMV2XUM DT Small molecular drug
DMV2XUM PC 2921148
DMV2XUM MW 244.27
DMV2XUM FM C9H12N2O4S
DMV2XUM IC InChI=1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3
DMV2XUM CS CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)C
DMV2XUM IK IFIUFCJFLGCQPH-UHFFFAOYSA-N
DMV2XUM IU N,N,2-trimethyl-5-nitrobenzenesulfonamide
DMV2XUM CA CAS 433695-36-4
DMV2XUM CB CHEBI:93472
DMV2XUM DE Discovery agent
DM3TWBU ID DM3TWBU
DM3TWBU DN BRL54443
DM3TWBU HS Investigative
DM3TWBU SN 57477-39-1; BRL 54443; BRL-54443; 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol; BRL54443; UNII-Q2DH1CHI0Y; Q2DH1CHI0Y; 1H-Indol-5-ol, 3-(1-methyl-4-piperidinyl)-; 5-Hydroxy-3-(1-methylpiperidin-4-yl)-1H-indole; 3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-OL; AK163730; NCGC00015134-01; Tocris-1129; Lopac-B-173; AC1L1DOE; Biomol-NT_000107; Lopac0_000207; ZINC7339; BPBio1_001401; SCHEMBL3546728; GTPL3927; CHEMBL1371156; CTK6I2277; CHEBI:92321; KS-00000SOT; QCR-209; DTXSID40206089; WKNFADCGOAHBPG-UHFFFAOYSA-N; MolPort-021-804-935; BCPP000316
DM3TWBU DT Small molecular drug
DM3TWBU PC 2438
DM3TWBU MW 230.31
DM3TWBU FM C14H18N2O
DM3TWBU IC InChI=1S/C14H18N2O/c1-16-6-4-10(5-7-16)13-9-15-14-3-2-11(17)8-12(13)14/h2-3,8-10,15,17H,4-7H2,1H3
DM3TWBU CS CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)O
DM3TWBU IK WKNFADCGOAHBPG-UHFFFAOYSA-N
DM3TWBU IU 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol
DM3TWBU CA CAS 57477-39-1
DM3TWBU CB CHEBI:92321
DM3TWBU DE Discovery agent
DM2J1FA ID DM2J1FA
DM2J1FA DN BRL-54504AX
DM2J1FA HS Investigative
DM2J1FA SN CHEMBL87114; BRL-54504AX
DM2J1FA DT Small molecular drug
DM2J1FA PC 9903796
DM2J1FA MW 279.34
DM2J1FA FM C17H17N3O
DM2J1FA IC InChI=1S/C17H17N3O/c1-9-7-8-11-14(16(9)21)15(18)13-10-5-3-4-6-12(10)20(2)17(13)19-11/h3-6,9H,7-8H2,1-2H3,(H2,18,19)
DM2J1FA CS CC1CCC2=C(C1=O)C(=C3C4=CC=CC=C4N(C3=N2)C)N
DM2J1FA IK NWCDOCLEZPSZBM-UHFFFAOYSA-N
DM2J1FA IU 11-amino-2,6-dimethyl-3,4-dihydro-2H-indolo[2,3-b]quinolin-1-one
DM2J1FA DE Discovery agent
DMEMZ6Q ID DMEMZ6Q
DMEMZ6Q DN BRL-55473
DMEMZ6Q HS Investigative
DMEMZ6Q SN CHEMBL336590; SCHEMBL3133982; SCHEMBL3133975; SCHEMBL12390534; BRL-57269A; BDBM50212570
DMEMZ6Q DT Small molecular drug
DMEMZ6Q PC 9816018
DMEMZ6Q MW 193.25
DMEMZ6Q FM C10H15N3O
DMEMZ6Q IC InChI=1S/C10H15N3O/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13/h8-9H,2-5,7H2,1H3/b12-10+
DMEMZ6Q CS CO/N=C(\\C#N)/C1CN2CCC1CC2
DMEMZ6Q IK IQWCBYSUUOFOMF-ZRDIBKRKSA-N
DMEMZ6Q IU (3Z)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl cyanide
DMEMZ6Q DE Discovery agent
DMZMWVX ID DMZMWVX
DMZMWVX DN BRN-0471734
DMZMWVX HS Investigative
DMZMWVX SN Benzaldehyde-4-carboxylic acid; Benzoic acid, 4-formyl-; GOUHYARYYWKXHS-UHFFFAOYSA-N; PubChem8075; Terephthalaldehydic acid; Terephthaldehydic acid; UES4QRK36E; p-Carboxybenzaldehyde; p-Formylbenzoic acid; 4-Carboxybenzaladehyde; 4-Carboxybenzaldehyde; 4-Carboxybenzaldehyde, 96%; 4-FORMYLBENZOIC ACID; 4-Formyl-benzoic acid; 4-FormylbenzoicAcid; 4-carboxybenzaldehyd; 4-formyl benzoic acid; 4carboxybenzaldehyde; 4formyl-benzoic acid; 619-66-9; EINECS 210-607-4; HSDB 5719; MFCD00006951; NSC 15797; UNII-UES4QRK36E
DMZMWVX PC 12088
DMZMWVX MW 150.13
DMZMWVX FM C8H6O3
DMZMWVX IC GOUHYARYYWKXHS-UHFFFAOYSA-N
DMZMWVX CS C1=CC(=CC=C1C=O)C(=O)O
DMZMWVX IK 1S/C8H6O3/c9-5-6-1-3-7(4-2-6)8(10)11/h1-5H,(H,10,11)
DMZMWVX IU 4-formylbenzoic acid
DMZMWVX CA CAS 619-66-9
DMZMWVX DE Discovery agent
DMOTU4P ID DMOTU4P
DMOTU4P DN BRN-1980310
DMOTU4P HS Investigative
DMOTU4P SN Benzo(a)pyrene, 9-hydroxy-; 9-Hydroxybenzo(a)Pyrene; Benzo[def]chrysen-9-ol; LS-40103; SCHEMBL3348130; ZINC4655178; benzo[a]pyren-9-ol; 17573-21-6; 9-Hydroxy Benzopyrene; 9-Hydroxy benzo[a]pyrene; 9-Hydroxybenzo[a]pyrene; 9-hydroxybenzo(a)pyrene, 3H-labeled; AC1L1FO7; ACM17573216; AKOS027321432; BIDD:ER0395; BRN 1980310; CCRIS 1073; CHEBI:34512; BENZO(a)PYREN-9-OL; CHEMBL351406; CTK0H8447; DTXSID20170012; FT-0669411
DMOTU4P PC 28598
DMOTU4P MW 268.3
DMOTU4P FM C20H12O
DMOTU4P IC OBBBXCAFTKLFGZ-UHFFFAOYSA-N
DMOTU4P CS C1=CC2=C3C(=C1)C=CC4=C5C=C(C=CC5=CC(=C43)C=C2)O
DMOTU4P IK 1S/C20H12O/c21-16-8-6-14-10-15-5-4-12-2-1-3-13-7-9-17(18(14)11-16)20(15)19(12)13/h1-11,21H
DMOTU4P IU benzo[a]pyren-9-ol
DMOTU4P CA CAS 17573-21-6
DMOTU4P CB CHEBI:34512
DMOTU4P DE Discovery agent
DMC9Q4D ID DMC9Q4D
DMC9Q4D DN BRN-1999480
DMC9Q4D HS Investigative
DMC9Q4D SN 4-Hydroxyestrone; SCHEMBL223170; (8R,9S,13S,14S)-3,4-Dihydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; 1,3,5(10)-Estratriene-3,4-diol-17-one; 3,4-Dihydroxyestra-1,3,5(10)-trien-17-one; 3,4-dihydroxy-1,3,5(10)-estratrien-17-one; 3,4-dihydroxy-estra-1,3,5(10)-trien-17-one; 3131-23-5; 3MN57C55S2; 4-Hydroxy Estrone; 4-Hydroxy-Estrone; BIDD:ER0089; BRN 1999480; CCRIS 9275; CHEBI:87602; ESTRA-1,3,5(10)-TRIEN-17-ONE, 3,4-DIHYDROXY-; UNII-3MN57C55S2; estra-1,3,5(10)-triene-3,4-diol-17-one
DMC9Q4D PC 9971251
DMC9Q4D MW 286.4
DMC9Q4D FM C18H22O3
DMC9Q4D IC XQZVQQZZOVBNLU-QDTBLXIISA-N
DMC9Q4D CS CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4O)O
DMC9Q4D IK 1S/C18H22O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,19,21H,2-3,5,7-9H2,1H3/t11-,12-,14+,18+/m1/s1
DMC9Q4D IU (8R,9S,13S,14S)-3,4-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DMC9Q4D CA CAS 3131-23-5
DMC9Q4D CB CHEBI:87602
DMC9Q4D DE Discovery agent
DM87VP6 ID DM87VP6
DM87VP6 DN BRN-2330710
DM87VP6 HS Investigative
DM87VP6 SN Pyren-2-ylmethanol; 2-(Hydroxymethyl)pyrene; 2-Hydroxymethylpyrene; 2-Pyrenemethanol; SCHEMBL9609744; 24471-48-5; 4-06-00-05008 (Beilstein Handbook Reference); AC1L3U62; CCRIS 7295; CTK1A3560; DTXSID90179234
DM87VP6 PC 146932
DM87VP6 MW 232.28
DM87VP6 FM C17H12O
DM87VP6 IC XIKICBSLAFJTDZ-UHFFFAOYSA-N
DM87VP6 CS C1=CC2=C3C(=C1)C=CC4=C3C(=CC(=C4)CO)C=C2
DM87VP6 IK 1S/C17H12O/c18-10-11-8-14-6-4-12-2-1-3-13-5-7-15(9-11)17(14)16(12)13/h1-9,18H,10H2
DM87VP6 IU pyren-2-ylmethanol
DM87VP6 CA CAS 24471-48-5
DM87VP6 DE Discovery agent
DM4KXT0 ID DM4KXT0
DM4KXT0 DN BRN-3548355
DM4KXT0 HS Investigative
DM4KXT0 SN NNK (carcinogen); 1-Butanone, 4-(methylnitrosoamino)-1-(3-pyridinyl)-; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE; 4-(Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 4-(N-Nitroso-N-methylamino)-1-(3-pyridyl)-1-butanone; 4-Methylnitrosoamino-1-(3-pyridinyl)-1-butanone; 4-[methyl(nitroso)amino]-1-(pyridin-3-yl)butan-1-one; 64091-91-4; 7S395EDO61; CCRIS 1150; CHEBI:32692; MFCD00274580; N-Methyl-N-nitroso-4-oxo-4-(3-pyridyl)butyl amine; NNK; UNII-7S395EDO61
DM4KXT0 PC 47289
DM4KXT0 MW 207.23
DM4KXT0 FM C10H13N3O2
DM4KXT0 IC FLAQQSHRLBFIEZ-UHFFFAOYSA-N
DM4KXT0 CS CN(CCCC(=O)C1=CN=CC=C1)N=O
DM4KXT0 IK 1S/C10H13N3O2/c1-13(12-15)7-3-5-10(14)9-4-2-6-11-8-9/h2,4,6,8H,3,5,7H2,1H3
DM4KXT0 IU N-methyl-N-(4-oxo-4-pyridin-3-ylbutyl)nitrous amide
DM4KXT0 CA CAS 64091-50-5
DM4KXT0 CB CHEBI:32692
DM4KXT0 DE Discovery agent
DM9UF02 ID DM9UF02
DM9UF02 DN Brocresine
DM9UF02 HS Investigative
DM9UF02 SN Brocresine; Brocresin; 555-65-7; 3-(Aminooxymethyl)-6-bromphenol; Brocresinum [INN-Latin]; Brocresina [INN-Spanish]; NSD 1055; Brocresine [USAN:INN:BAN]; UNII-11F6O06WN0; CL 54998; NSD-1055; alpha-(Aminooxy)-6-bromo-m-cresol; C7H8BrNO2; 5-((Aminooxy)methyl)-2-bromophenol; O-)4-Brom-3-hydroxybenzyl)hydroxylamin; BRN 1945736; Phenol, 5-((aminooxy)methyl)-2-bromo-; 4-Bromo-3-hydroxybenzyloxyamine; QNWOSJAGFSUDFE-UHFFFAOYSA-N; 11F6O06WN0; 5-[(Aminooxy)methyl]-2-bromophenol; m-CRESOL, alpha-(AMINOOXY)-6-BROMO-; Brocresina
DM9UF02 DT Small molecular drug
DM9UF02 PC 11151
DM9UF02 MW 218.05
DM9UF02 FM C7H8BrNO2
DM9UF02 IC InChI=1S/C7H8BrNO2/c8-6-2-1-5(4-11-9)3-7(6)10/h1-3,10H,4,9H2
DM9UF02 CS C1=CC(=C(C=C1CON)O)Br
DM9UF02 IK QNWOSJAGFSUDFE-UHFFFAOYSA-N
DM9UF02 IU 5-(aminooxymethyl)-2-bromophenol
DM9UF02 CA CAS 555-65-7
DM9UF02 DE Discovery agent
DM7OF6N ID DM7OF6N
DM7OF6N DN Brodimoprim-4,6-Dicarboxylate
DM7OF6N HS Investigative
DM7OF6N SN brodimoprim-4,6-dicarboxylate; (2S)-2-[3-[2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy]propyl]pentanedioate; (2S)-2-(3-{2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy}propyl)pentanedioate; AC1NRA8B
DM7OF6N DT Small molecular drug
DM7OF6N PC 5287754
DM7OF6N MW 496.3
DM7OF6N FM C20H24BrN4O6-
DM7OF6N IC InChI=1S/C20H25BrN4O6/c1-30-14-8-11(7-13-10-24-20(23)25-18(13)22)9-15(17(14)21)31-6-2-3-12(19(28)29)4-5-16(26)27/h8-10,12H,2-7H2,1H3,(H,26,27)(H,28,29)(H4,22,23,24,25)/p-1/t12-/m0/s1
DM7OF6N CS COC1=C(C(=CC(=C1)CC2=C[NH+]=C(N=C2N)N)OCCC[C@@H](CCC(=O)[O-])C(=O)[O-])Br
DM7OF6N IK SZAVCZNFKJSWRN-LBPRGKRZSA-M
DM7OF6N IU (2S)-2-[3-[2-bromo-5-[(2,4-diaminopyrimidin-1-ium-5-yl)methyl]-3-methoxyphenoxy]propyl]pentanedioate
DM7OF6N DE Discovery agent
DMC4PF0 ID DMC4PF0
DMC4PF0 DN Brolamfetamine
DMC4PF0 HS Investigative
DMC4PF0 SN Brolamfetamine; 2,5-Dimethoxy-4-bromoamphetamine; 4-Bromo-2,5-dimethoxyamphetamine; DOB-4; 4-Bromo-2,5-dimethoxyphenylisopropylamine; 4-Bromo-DMA; 32156-26-6; 2,5-Dimethoxy-(4-bromo)phenylisopropylamine; 64638-07-9; 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine; 1-(2,5-Dimethoxyphenyl-4-bromo)-2-aminopropane; 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane; 4-Bromo-2,5-dimethoxy-alpha-methylbenzeneethanamine; CHEMBL6607; DOB; DEA No. 7391; Benzeneethanamine, 4-bromo-2,5-dimethoxy-alpha-methyl-; Brolamfetaminum
DMC4PF0 DT Small molecular drug
DMC4PF0 PC 62065
DMC4PF0 MW 274.15
DMC4PF0 FM C11H16BrNO2
DMC4PF0 IC InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
DMC4PF0 CS CC(CC1=CC(=C(C=C1OC)Br)OC)N
DMC4PF0 IK FXMWUTGUCAKGQL-UHFFFAOYSA-N
DMC4PF0 IU 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
DMC4PF0 CA CAS 64638-07-9
DMC4PF0 DE Discovery agent
DMMC4BY ID DMMC4BY
DMMC4BY DN Brominide tartrate
DMMC4BY HS Investigative
DMMC4BY SN BRIMONIDINE TARTRATE; 70359-46-5; Brimonidine tartarate; Alphagan; Brimonidine D-tartrate; UNII-4S9CL2DY2H; Brimonidinne tartrate; C11H10BrN5.C4H6O6; Brimonidine L-Tartrate; Brimonidine (tartrate); Brimonidine D-tartarate; 79570-19-7; 4S9CL2DY2H; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate; UK-14304-18; Qoliana; brimonidine Purite; Brimonidine tartrate [USAN]
DMMC4BY DT Small molecular drug
DMMC4BY PC 54405
DMMC4BY MW 442.22
DMMC4BY FM C15H16BrN5O6
DMMC4BY IC InChI=1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
DMMC4BY CS C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMMC4BY IK QZHBYNSSDLTCRG-LREBCSMRSA-N
DMMC4BY IU 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;(2R,3R)-2,3-dihydroxybutanedioic acid
DMMC4BY CA CAS 70359-46-5
DMMC4BY DE Discovery agent
DMTBO7F ID DMTBO7F
DMTBO7F DN bromoacetone
DMTBO7F HS Investigative
DMTBO7F SN martonite; monobromoacetone; acetonyl bromide
DMTBO7F DT Small molecular drug
DMTBO7F PC 11715
DMTBO7F MW 136.98
DMTBO7F FM C3H5BrO
DMTBO7F IC InChI=1S/C3H5BrO/c1-3(5)2-4/h2H2,1H3
DMTBO7F CS CC(=O)CBr
DMTBO7F IK VQFAIAKCILWQPZ-UHFFFAOYSA-N
DMTBO7F IU 1-bromopropan-2-one
DMTBO7F CA CAS 598-31-2
DMTBO7F CB CHEBI:51845
DMTBO7F DE Discovery agent
DMXTVZ8 ID DMXTVZ8
DMXTVZ8 DN bromocresol green
DMXTVZ8 HS Investigative
DMXTVZ8 SN Bromocresol green; 76-60-8; BROMCRESOL GREEN; bromo cresol green; 3,3-Bis(3,5-dibromo-4-hydroxy-2-methylphenyl)-3H-benzo[c][1,2]oxathiole 1,1-dioxide; Tetrabromo-m-cresolphthalein sulfone; 3',3'',5',5''-Tetrabromo-m-cresolsulfonephthalein; Bromocresol blue; NSC 7817; UNII-8YGN0Y942M; EINECS 200-972-8; BRN 0372527; CHEMBL145704; 8YGN0Y942M; Bromocresol Green, ACS reagent; NSC7817; FRPHFZCDPYBUAU-UHFFFAOYSA-N; MFCD00005874; o-Toluenesulfonic acid, alpha-hydroxy-, gamma-sultone; BROMOCRESOL GREEN, ACS; Phenol, 4,4'-(3H-2,1-benzox
DMXTVZ8 DT Small molecular drug
DMXTVZ8 PC 6451
DMXTVZ8 MW 698
DMXTVZ8 FM C21H14Br4O5S
DMXTVZ8 IC InChI=1S/C21H14Br4O5S/c1-9-12(7-14(22)19(26)17(9)24)21(13-8-15(23)20(27)18(25)10(13)2)11-5-3-4-6-16(11)31(28,29)30-21/h3-8,26-27H,1-2H3
DMXTVZ8 CS CC1=C(C(=C(C=C1C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4C)Br)O)Br)Br)O)Br
DMXTVZ8 IK FRPHFZCDPYBUAU-UHFFFAOYSA-N
DMXTVZ8 IU 2,6-dibromo-4-[3-(3,5-dibromo-4-hydroxy-2-methylphenyl)-1,1-dioxo-2,1lambda6-benzoxathiol-3-yl]-3-methylphenol
DMXTVZ8 CA CAS 76-60-8
DMXTVZ8 DE Discovery agent
DMX2U7G ID DMX2U7G
DMX2U7G DN bromo-deaza-SAH
DMX2U7G HS Investigative
DMX2U7G SN CHEMBL2349526; bromo-deaza-SAH; (2s)-2-Amino-4-({[(2s,3s,4r,5r)-5-(4-Amino-5-Bromo-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl)-3,4-Dihydroxytetrahydrofuran-2-Yl]methyl}sulfanyl)butanoic Acid (Non-Preferred Name); GTPL7018; BDBM50431676; (S)-2-Amino-4-[[(2S)-3beta,4beta-dihydroxy-5alpha-(4-amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidine-7-yl)tetrahydrofuran-2alpha-yl]methylthio]butanoic acid; (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DMX2U7G DT Small molecular drug
DMX2U7G PC 53339032
DMX2U7G MW 462.3
DMX2U7G FM C15H20BrN5O5S
DMX2U7G IC InChI=1S/C15H20BrN5O5S/c16-6-3-21(13-9(6)12(18)19-5-20-13)14-11(23)10(22)8(26-14)4-27-2-1-7(17)15(24)25/h3,5,7-8,10-11,14,22-23H,1-2,4,17H2,(H,24,25)(H2,18,19,20)/t7-,8+,10+,11+,14+/m0/s1
DMX2U7G CS C1=C(C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CSCC[C@@H](C(=O)O)N)O)O)N)Br
DMX2U7G IK DIULHULFPSIBAK-TWBCTODHSA-N
DMX2U7G IU (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid
DMX2U7G DE Discovery agent
DM0D7LA ID DM0D7LA
DM0D7LA DN BROMODEOXYURIDINE
DM0D7LA HS Investigative
DM0D7LA SN 5-BROMO-2'-DEOXYURIDINE; 59-14-3; Broxuridine; Bromodeoxyuridine; 5-Bromodeoxyuridine; BRDU; 5-BrdU; BUDR; 5-Bromouracil deoxyriboside; Bromouracil deoxyriboside; 5-Bromodesoxyuridine; 5-Bdu; Broxuridinum; Broxuridina; 5-Bromouracil-2-deoxyriboside; 5-Bromo-2-deoxyuridine; bromodeoxyuridine (brdu); Broxuridinum [INN-Latin]; Uridine, 5-bromo-2'-deoxy-; Broxuridina [INN-Spanish]; C9H11BrN2O5; NSC-38297; Bromoouridine; Radibud; CCRIS 818; Brudr; UNII-G34N38R2N1; HSDB 7477; CHEBI:472552; EINECS 200-415-9; 5-Budr; 5-bromo-2'-deoxy uridine
DM0D7LA DT Small molecular drug
DM0D7LA PC 6035
DM0D7LA MW 307.1
DM0D7LA FM C9H11BrN2O5
DM0D7LA IC InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DM0D7LA CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Br)CO)O
DM0D7LA IK WOVKYSAHUYNSMH-RRKCRQDMSA-N
DM0D7LA IU 5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DM0D7LA CA CAS 59-14-3
DM0D7LA CB CHEBI:472552
DM0D7LA DE Discovery agent
DMKQ0CA ID DMKQ0CA
DMKQ0CA DN bromoenol lactone
DMKQ0CA HS Investigative
DMKQ0CA SN Bromoenol lactone; HELSS; 88070-98-8; 6-Btnpo; BTNP; C16H13BrO2; CHEMBL6206; BEL; 6-(Bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; Haloenol lactone suicide substrate; BYUCSFWXCMTYOI-ZRDIBKRKSA-N; (E)-6-(Bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-Pyran-2-one; (E)-6-(Bromomethylene)-3-(1-naphthalenyl)tetrahydro-2H-pyran-2-one; bromoenolactone; E-6-(Bromoethylene)tetrahydro-3-(1-naphthyl)-2H-pyran-2-one; 2H-Pyran-2-one, 6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-, (E)-; SR-01000075707; bromoenolactone
DMKQ0CA DT Small molecular drug
DMKQ0CA PC 5940264
DMKQ0CA MW 317.18
DMKQ0CA FM C16H13BrO2
DMKQ0CA IC InChI=1S/C16H13BrO2/c17-10-12-8-9-15(16(18)19-12)14-7-3-5-11-4-1-2-6-13(11)14/h1-7,10,15H,8-9H2/b12-10+
DMKQ0CA CS C1C/C(=C\\Br)/OC(=O)C1C2=CC=CC3=CC=CC=C32
DMKQ0CA IK BYUCSFWXCMTYOI-ZRDIBKRKSA-N
DMKQ0CA IU (6E)-6-(bromomethylidene)-3-naphthalen-1-yloxan-2-one
DMKQ0CA CA CAS 88070-98-8
DMKQ0CA DE Discovery agent
DMKFTW8 ID DMKFTW8
DMKFTW8 DN Bromo-WR99210
DMKFTW8 HS Investigative
DMKFTW8 SN BROMO-WR99210; 1-[3-(4-BROMO-PHENOXY)-PROPOXY]-6,6-DIMETHYL-1.6-DIHYDRO-[1,3,5]TRIAZINE-2,4-DIAMINE; WRB; 1-[3-(4-bromophenoxy)propoxy]-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine; AC1L1DNN; SCHEMBL8934292; CHEMBL126726; CTK7D5371; DB04007
DMKFTW8 DT Small molecular drug
DMKFTW8 PC 2429
DMKFTW8 MW 370.24
DMKFTW8 FM C14H20BrN5O2
DMKFTW8 IC InChI=1S/C14H20BrN5O2/c1-14(2)19-12(16)18-13(17)20(14)22-9-3-8-21-11-6-4-10(15)5-7-11/h4-7H,3,8-9H2,1-2H3,(H4,16,17,18,19)
DMKFTW8 CS CC1(N=C(N=C(N1OCCCOC2=CC=C(C=C2)Br)N)N)C
DMKFTW8 IK MPXYCOHVHSXSDC-UHFFFAOYSA-N
DMKFTW8 IU 1-[3-(4-bromophenoxy)propoxy]-6,6-dimethyl-1,3,5-triazine-2,4-diamine
DMKFTW8 DE Discovery agent
DM9W2ZV ID DM9W2ZV
DM9W2ZV DN Bromsulphthalein
DM9W2ZV HS Investigative
DM9W2ZV SN sulfobromophthalein; BSP
DM9W2ZV DT Small molecular drug
DM9W2ZV PC 6282
DM9W2ZV MW 838
DM9W2ZV FM C20H8Br4Na2O10S2
DM9W2ZV IC InChI=1S/C20H10Br4O10S2.2Na/c21-15-13-14(16(22)18(24)17(15)23)20(34-19(13)27,7-1-3-9(25)11(5-7)35(28,29)30)8-2-4-10(26)12(6-8)36(31,32)33;;/h1-6,25-26H,(H,28,29,30)(H,31,32,33);;/q;2*+1/p-2
DM9W2ZV CS C1=CC(=C(C=C1C2(C3=C(C(=C(C(=C3Br)Br)Br)Br)C(=O)O2)C4=CC(=C(C=C4)O)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+]
DM9W2ZV IK GHAFORRTMVIXHS-UHFFFAOYSA-L
DM9W2ZV IU disodium;2-hydroxy-5-[4,5,6,7-tetrabromo-1-(4-hydroxy-3-sulfonatophenyl)-3-oxo-2-benzofuran-1-yl]benzenesulfonate
DM9W2ZV CA CAS 71-67-0
DM9W2ZV CB CHEBI:63827
DMB9SEI ID DMB9SEI
DMB9SEI DN Broussoflavonol F
DMB9SEI HS Investigative
DMB9SEI SN Broussoflavonol F; CHEMBL464007; 162558-94-3; Biooussoflavonol F; SCHEMBL6822778; MolPort-039-338-587; ZINC14727564; LMPK12111986
DMB9SEI DT Small molecular drug
DMB9SEI PC 9866908
DMB9SEI MW 422.5
DMB9SEI FM C25H26O6
DMB9SEI IC InChI=1S/C25H26O6/c1-13(2)5-7-15-11-16(8-10-18(15)26)24-23(30)22(29)21-20(28)12-19(27)17(25(21)31-24)9-6-14(3)4/h5-6,8,10-12,26-28,30H,7,9H2,1-4H3
DMB9SEI CS CC(=CCC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C(=C3O2)CC=C(C)C)O)O)O)O)C
DMB9SEI IK KNMMNUQOUANAJS-UHFFFAOYSA-N
DMB9SEI IU 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-8-(3-methylbut-2-enyl)chromen-4-one
DMB9SEI DE Discovery agent
DMXFN6H ID DMXFN6H
DMXFN6H DN BROUSSONIN A
DMXFN6H HS Investigative
DMXFN6H SN Broussonin A; 73731-87-0; CHEMBL465879; Biooussonin A; AC1NST4K; 2-[3-(4-hydroxyphenyl)propyl]-5-methoxyphenol; SCHEMBL774802; MSNVBURPCQDLEP-UHFFFAOYSA-N; MolPort-019-937-120; BDBM50251012; ZINC13341109; MCULE-7164788732
DMXFN6H DT Small molecular drug
DMXFN6H PC 5315502
DMXFN6H MW 258.31
DMXFN6H FM C16H18O3
DMXFN6H IC InChI=1S/C16H18O3/c1-19-15-10-7-13(16(18)11-15)4-2-3-12-5-8-14(17)9-6-12/h5-11,17-18H,2-4H2,1H3
DMXFN6H CS COC1=CC(=C(C=C1)CCCC2=CC=C(C=C2)O)O
DMXFN6H IK MSNVBURPCQDLEP-UHFFFAOYSA-N
DMXFN6H IU 2-[3-(4-hydroxyphenyl)propyl]-5-methoxyphenol
DMXFN6H CA CAS 73731-87-0
DMXFN6H DE Discovery agent
DMKM9F0 ID DMKM9F0
DMKM9F0 DN Broussonin C
DMKM9F0 HS Investigative
DMKM9F0 SN Broussonin C; 76045-49-3; CHEBI:3186; CHEMBL468906; AC1L9CJQ; MolPort-039-052-705; ZINC898642; BDBM50254430; 9122AF; 1,3-Benzenediol,4-[3-[4-hydroxy-3-(3- methyl-2-butenyl)phenyl]propyl]-
DMKM9F0 DT Small molecular drug
DMKM9F0 PC 442289
DMKM9F0 MW 312.4
DMKM9F0 FM C20H24O3
DMKM9F0 IC InChI=1S/C20H24O3/c1-14(2)6-8-17-12-15(7-11-19(17)22)4-3-5-16-9-10-18(21)13-20(16)23/h6-7,9-13,21-23H,3-5,8H2,1-2H3
DMKM9F0 CS CC(=CCC1=C(C=CC(=C1)CCCC2=C(C=C(C=C2)O)O)O)C
DMKM9F0 IK CMOZGCJOTGLPKO-UHFFFAOYSA-N
DMKM9F0 IU 4-[3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]propyl]benzene-1,3-diol
DMKM9F0 CA CAS 76045-49-3
DMKM9F0 CB CHEBI:3186
DMKM9F0 DE Discovery agent
DMPGEO1 ID DMPGEO1
DMPGEO1 DN BrP-LPA
DMPGEO1 HS Investigative
DMPGEO1 SN alpha-bromomethylene phosphonate
DMPGEO1 DT Small molecular drug
DMPGEO1 PC 16725999
DMPGEO1 MW 487.4
DMPGEO1 FM C20H40BrO6P
DMPGEO1 IC InChI=1S/C20H40BrO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(23)27-17-18(22)16-19(21)28(24,25)26/h18-19,22H,2-17H2,1H3,(H2,24,25,26)/t18-,19?/m0/s1
DMPGEO1 CS CCCCCCCCCCCCCCCC(=O)OC[C@H](CC(P(=O)(O)O)Br)O
DMPGEO1 IK HLVKVWDSLLFMSX-OYKVQYDMSA-N
DMPGEO1 IU [(3S)-1-bromo-4-hexadecanoyloxy-3-hydroxybutyl]phosphonic acid
DMPGEO1 DE Discovery agent
DM50RUD ID DM50RUD
DM50RUD DN brucine
DM50RUD HS Investigative
DM50RUD SN 10,11-dimethoxy strychnine
DM50RUD DT Small molecular drug
DM50RUD PC 442021
DM50RUD MW 394.5
DM50RUD FM C23H26N2O4
DM50RUD IC InChI=1S/C23H26N2O4/c1-27-16-8-14-15(9-17(16)28-2)25-20(26)10-18-21-13-7-19-23(14,22(21)25)4-5-24(19)11-12(13)3-6-29-18/h3,8-9,13,18-19,21-22H,4-7,10-11H2,1-2H3/t13-,18-,19-,21-,22-,23+/m0/s1
DM50RUD CS COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)OC
DM50RUD IK RRKTZKIUPZVBMF-IBTVXLQLSA-N
DM50RUD IU (4aR,5aS,8aR,13aS,15aS,15bR)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one
DM50RUD CA CAS 357-57-3
DM50RUD CB CHEBI:3193
DM50RUD DE Discovery agent
DMKZM1L ID DMKZM1L
DMKZM1L DN Brutieridin
DMKZM1L HS Investigative
DMKZM1L SN Melitidin; Bergamot juice flavonoids (hypercholesterolemia), Biopharm technologies; Brutieridin/melitidin (hypercholesterolemia), Biopharm technologies
DMKZM1L CP Biopharm Technology Corp
DMKZM1L PC 101485561
DMKZM1L MW 738.7
DMKZM1L FM C34H42O18
DMKZM1L IC InChI=1S/C34H42O18/c1-13-26(41)28(43)30(45)33(49-13)52-32-29(44)27(42)22(12-48-24(40)11-34(2,46)10-23(38)39)51-31(32)15-7-17(36)25-18(37)9-20(50-21(25)8-15)14-4-5-19(47-3)16(35)6-14/h4-8,13,20,22,26-33,35-36,41-46H,9-12H2,1-3H3,(H,38,39)/t13-,20?,22+,26-,27+,28+,29-,30+,31-,32+,33-,34?/m0/s1
DMKZM1L CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2C3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)COC(=O)CC(C)(CC(=O)O)O)O)O)O)O)O
DMKZM1L IK YZURXYIFQZWQHI-RODJDRFJSA-N
DMKZM1L IU 5-[[(2R,3S,4S,5R,6S)-3,4-dihydroxy-6-[5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-7-yl]-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]methoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid
DMKZM1L DE Hypercholesterolaemia
DM1VF6H ID DM1VF6H
DM1VF6H DN BS 7581
DM1VF6H HS Investigative
DM1VF6H SN BS 7581; CHEMBL444541; CHEMBL1790046
DM1VF6H DT Small molecular drug
DM1VF6H PC 56661208
DM1VF6H MW 353.5
DM1VF6H FM C26H27N
DM1VF6H IC InChI=1S/C26H27N/c1-18(16-19-8-3-2-4-9-19)27-25-17-24-22-12-6-5-10-20(22)14-15-21-11-7-13-23(25)26(21)24/h2-13,18,24-25,27H,14-17H2,1H3
DM1VF6H CS CC(CC1=CC=CC=C1)NC2CC3C4=CC=CC=C4CCC5=C3C2=CC=C5
DM1VF6H IK DNSDIYWJKBRJKP-UHFFFAOYSA-N
DM1VF6H IU N-(1-phenylpropan-2-yl)tetracyclo[8.6.1.02,7.014,17]heptadeca-2,4,6,10(17),11,13-hexaen-15-amine
DM1VF6H DE Discovery agent
DMDYNBT ID DMDYNBT
DMDYNBT DN BS 7840
DMDYNBT HS Investigative
DMDYNBT SN BS 7840; CHEMBL380748
DMDYNBT DT Small molecular drug
DMDYNBT PC 11964445
DMDYNBT MW 331.4
DMDYNBT FM C23H25NO
DMDYNBT IC InChI=1S/C23H25NO/c1-24(2)16-15-23(25)21-10-6-4-8-18(21)12-14-19-13-11-17-7-3-5-9-20(17)22(19)23/h3-11,13,25H,12,14-16H2,1-2H3
DMDYNBT CS CN(C)CCC1(C2=CC=CC=C2CCC3=C1C4=CC=CC=C4C=C3)O
DMDYNBT IK IUXDSDVOBHKNSE-UHFFFAOYSA-N
DMDYNBT IU 2-[2-(dimethylamino)ethyl]tetracyclo[9.8.0.03,8.014,19]nonadeca-1(11),3,5,7,12,14,16,18-octaen-2-ol
DMDYNBT DE Discovery agent
DMQ2FDA ID DMQ2FDA
DMQ2FDA DN BS 9106
DMQ2FDA HS Investigative
DMQ2FDA SN BS 9106; CHEMBL206647; CHEMBL1790047
DMQ2FDA DT Small molecular drug
DMQ2FDA PC 56678302
DMQ2FDA MW 345.5
DMQ2FDA FM C23H23NS
DMQ2FDA IC InChI=1S/C23H23NS/c1-2-8-18(9-3-1)14-16-24-17-15-19-20-10-4-6-12-22(20)25-23-13-7-5-11-21(19)23/h1-13,19,24H,14-17H2
DMQ2FDA CS C1=CC=C(C=C1)CCNCCC2C3=CC=CC=C3SC4=CC=CC=C24
DMQ2FDA IK BTFWDABQNDILAN-UHFFFAOYSA-N
DMQ2FDA IU N-(2-phenylethyl)-2-(9H-thioxanthen-9-yl)ethanamine
DMQ2FDA DE Discovery agent
DMLXFHD ID DMLXFHD
DMLXFHD DN BS-194
DMLXFHD HS Investigative
DMLXFHD SN CDK inhibitors (cancer), Imperial College London/Emory University
DMLXFHD CP Imperial College London
DMLXFHD DT Small molecular drug
DMLXFHD PC 25125014
DMLXFHD MW 385.5
DMLXFHD FM C20H27N5O3
DMLXFHD IC InChI=1S/C20H27N5O3/c1-13(2)15-10-22-25-19(21-9-14-6-4-3-5-7-14)8-18(24-20(15)25)23-16(11-26)17(28)12-27/h3-8,10,13,16-17,21,26-28H,9,11-12H2,1-2H3,(H,23,24)/t16-,17+/m0/s1
DMLXFHD CS CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)N[C@@H](CO)[C@@H](CO)O
DMLXFHD IK KRIWIRSMQRQYJG-DLBZAZTESA-N
DMLXFHD IU (2S,3S)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol
DMLXFHD CA CAS 1092443-55-4
DMLXFHD DE Solid tumour/cancer
DMJIKHQ ID DMJIKHQ
DMJIKHQ DN BsAb cG7-MICA
DMJIKHQ HS Investigative
DMNM63G ID DMNM63G
DMNM63G DN BTP2
DMNM63G HS Investigative
DMNM63G SN YM-58483
DMNM63G DT Small molecular drug
DMNM63G PC 2455
DMNM63G MW 421.3
DMNM63G FM C15H9F6N5OS
DMNM63G IC InChI=1S/C15H9F6N5OS/c1-7-12(28-25-23-7)13(27)22-8-2-4-9(5-3-8)26-11(15(19,20)21)6-10(24-26)14(16,17)18/h2-6H,1H3,(H,22,27)
DMNM63G CS CC1=C(SN=N1)C(=O)NC2=CC=C(C=C2)N3C(=CC(=N3)C(F)(F)F)C(F)(F)F
DMNM63G IK XPRZIORDEVHURQ-UHFFFAOYSA-N
DMNM63G IU N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-4-methylthiadiazole-5-carboxamide
DMNM63G CA CAS 223499-30-7
DMNM63G DE Discovery agent
DMGFY4X ID DMGFY4X
DMGFY4X DN BUDDLEDIN A
DMGFY4X HS Investigative
DMGFY4X SN BUDDLEDIN A; CHEBI:3206; CHEMBL485981; AC1NQYK4; 62346-20-7; CHEBI:542717; BDBM50241571; C09623; [(1S,5E,8R,9R)-6,10,10-trimethyl-2-methylidene-7-oxo-8-bicyclo[7.2.0]undec-5-enyl] acetate; [(1S,5E,8R,9R)-6,10,10-trimethyl-2-methylene-7-oxo-8-bicyclo[7.2.0]undec-5-enyl] acetate; (1R,2R,4E,9S)-4,11,11-trimethyl-8-methylidene-3-oxobicyclo[7.2.0]undec-4-en-2-yl acetate
DMGFY4X DT Small molecular drug
DMGFY4X PC 5281514
DMGFY4X MW 276.4
DMGFY4X FM C17H24O3
DMGFY4X IC InChI=1S/C17H24O3/c1-10-7-6-8-11(2)15(19)16(20-12(3)18)14-13(10)9-17(14,4)5/h8,13-14,16H,1,6-7,9H2,2-5H3/b11-8+/t13-,14+,16-/m1/s1
DMGFY4X CS C/C/1=C\\CCC(=C)[C@H]2CC([C@@H]2[C@H](C1=O)OC(=O)C)(C)C
DMGFY4X IK SXWKLEULMBLXJM-PCRFWOPQSA-N
DMGFY4X IU [(1R,2R,4E,9S)-4,11,11-trimethyl-8-methylidene-3-oxo-2-bicyclo[7.2.0]undec-4-enyl] acetate
DMGFY4X CA CAS 62346-20-7
DMGFY4X CB CHEBI:3206
DMGFY4X DE Discovery agent
DMQVL2U ID DMQVL2U
DMQVL2U DN BUDLEIN A
DMQVL2U HS Investigative
DMQVL2U SN Budlein A tiglate; CHEMBL189707; BDBM50433422; (E)-2-Methyl-2-butenoic acid [(3aR,4R,6R,10Z,11aR)-2,3,3a,4,5,6,7,11a-octahydro-10-hydroxymethyl-6-methyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca[b]furan]-4-yl ester
DMQVL2U DT Small molecular drug
DMQVL2U PC 5281430
DMQVL2U MW 374.4
DMQVL2U FM C20H22O7
DMQVL2U IC InChI=1S/C20H22O7/c1-5-10(2)18(23)26-15-8-20(4)16(22)7-13(27-20)12(9-21)6-14-17(15)11(3)19(24)25-14/h5-7,14-15,17,21H,3,8-9H2,1-2,4H3/b10-5-,12-6-/t14-,15-,17+,20-/m1/s1
DMQVL2U CS C/C=C(/C)\\C(=O)O[C@@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/CO)C
DMQVL2U IK BMVJFNLJSZHNNS-ZXRHVTAXSA-N
DMQVL2U IU [(2Z,4R,8R,9R,11R)-2-(hydroxymethyl)-11-methyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (Z)-2-methylbut-2-enoate
DMQVL2U CA CAS 59481-48-0
DMQVL2U CB CHEBI:3208
DMQVL2U DE Discovery agent
DM1D47I ID DM1D47I
DM1D47I DN BU-E 47
DM1D47I HS Investigative
DM1D47I SN CHEMBL304239; GTPL1219; SCHEMBL9710041; BU-E-47; BDBM50406050; PDSP1_001313; PDSP2_001297
DM1D47I DT Small molecular drug
DM1D47I PC 14660352
DM1D47I MW 396.9
DM1D47I FM C21H25ClN6
DM1D47I IC InChI=1S/C21H25ClN6/c22-17-8-6-16(7-9-17)19(20-5-1-2-11-25-20)10-13-27-21(23)26-12-3-4-18-14-24-15-28-18/h1-2,5-9,11,14-15,19H,3-4,10,12-13H2,(H,24,28)(H3,23,26,27)
DM1D47I CS C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)Cl
DM1D47I IK ZOROCGHIPADEFK-UHFFFAOYSA-N
DM1D47I IU 1-[3-(4-chlorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1H-imidazol-5-yl)propyl]guanidine
DM1D47I DE Discovery agent
DMD1SY9 ID DMD1SY9
DMD1SY9 DN bufotenine
DMD1SY9 HS Investigative
DMD1SY9 SN DM5-HT; dimethylserotonin; N,N-dimethyl-5-HT; N,N-dimethylserotonin; 5-OH-DMT
DMD1SY9 DT Small molecular drug
DMD1SY9 PC 10257
DMD1SY9 MW 204.27
DMD1SY9 FM C12H16N2O
DMD1SY9 IC InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
DMD1SY9 CS CN(C)CCC1=CNC2=C1C=C(C=C2)O
DMD1SY9 IK VTTONGPRPXSUTJ-UHFFFAOYSA-N
DMD1SY9 IU 3-[2-(dimethylamino)ethyl]-1H-indol-5-ol
DMD1SY9 CA CAS 487-93-4
DMD1SY9 CB CHEBI:3210
DMD1SY9 DE Discovery agent
DM61F5W ID DM61F5W
DM61F5W DN BUFROLIN
DM61F5W HS Investigative
DM61F5W SN Bufrolin; 54867-56-0; UNII-46C1PX266N; ICI-74917; CHEMBL150764; 46C1PX266N; Bufrolinum; Bufroline; Bufrolino; Bufrolin [INN:BAN]; Bufrolinum [INN-Latin]; Bufroline [INN-French]; Bufrolino [INN-Spanish]; AC1Q5RDE; AC1L2HFD; SCHEMBL2109492; CTK1H2392; DTXSID60203353; ZINC4215124; 6-butyl-4,10-dihydroxy-1,7-phenanthroline-2,8-dicarboxylic acid; BDBM50020876; 6-Butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenanthroline-2,8-dicarbonsaeure; 6-butyl-4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid
DM61F5W DT Small molecular drug
DM61F5W PC 72103
DM61F5W MW 356.3
DM61F5W FM C18H16N2O6
DM61F5W IC InChI=1S/C18H16N2O6/c1-2-3-4-8-5-9-12(21)6-10(17(23)24)20-16(9)14-13(22)7-11(18(25)26)19-15(8)14/h5-7H,2-4H2,1H3,(H,19,22)(H,20,21)(H,23,24)(H,25,26)
DM61F5W CS CCCCC1=CC2=C(C3=C1NC(=CC3=O)C(=O)O)NC(=CC2=O)C(=O)O
DM61F5W IK BQVIONBNDNFCCP-UHFFFAOYSA-N
DM61F5W IU 6-butyl-4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid
DM61F5W CA CAS 54867-56-0
DM61F5W DE Discovery agent
DMWQ3RH ID DMWQ3RH
DMWQ3RH DN bufrudin
DMWQ3RH HS Investigative
DMWQ3RH SN 137879-02-8; bufrudin
DMWQ3RH DE Discovery agent
DMJSC07 ID DMJSC07
DMJSC07 DN Bufuralol
DMJSC07 HS Investigative
DMJSC07 SN Bufuralol; Bufuralol [BAN:INN]; Bufuralol [INN:BAN]; Bufuralolum; Bufuralolum [INN-Latin]; Ro 3-4787; dl-Bufuralol; (RS)-alpha-(tert-Butylamino)methyl)-7-ethyl-12-benzofuranmethanol; 1-(7-Ethylbenzofuran-2-yl)-2-tert-butylamino-1-hydroxyethane; 2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol; 2-(tert-butylamino)-1-(7-ethylbenzofuran-2-yl)ethanol; 54340-62-4; AC1L2GPJ; AC1Q777C; CHEBI:34593; CHEMBL296035; EINECS 259-112-5; GTPL9834; SCHEMBL78552; alpha-((tert-Butylamino)methyl)-7-ethyl-2-benzofuranmethanol
DMJSC07 PC 71733
DMJSC07 MW 261.36
DMJSC07 FM C16H23NO2
DMJSC07 IC SSEBTPPFLLCUMN-UHFFFAOYSA-N
DMJSC07 CS CCC1=CC=CC2=C1OC(=C2)C(CNC(C)(C)C)O
DMJSC07 IK 1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3
DMJSC07 IU 2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol
DMJSC07 CA CAS 54340-62-4
DMJSC07 CB CHEBI:34593
DMJSC07 DE Cardiac arrhythmia
DMUT9IQ ID DMUT9IQ
DMUT9IQ DN Bupranolol
DMUT9IQ HS Investigative
DMUT9IQ SN BUPRANOLOL; Betadrenol; Bupranol; Bupranolol [INN:DCF]; Bupranololum; Bupranololum [INN-Latin]; HQIRNZOQPUAHHV-UHFFFAOYSA-N; KL 255; KL-255 [AS HYDROCHLORIDE]; Ophtorenin; SK&F 16805-A; 1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol; 14556-46-8; 2-Propanol, 1-(2-chloro-5-methylphenoxy)-3-((1,1-dimethylethyl)amino)-; 2-Propanol, 1-(tert-butylamino)-3-(6-chloro-m-tolyloxy)-; 3-(tert-Butylamino)-1-(6-chloro-m-tolyloxy)-2-propanol; B 1312; BRN 2272923; C14H22ClNO2
DMUT9IQ PC 2475
DMUT9IQ MW 271.78
DMUT9IQ FM C14H22ClNO2
DMUT9IQ IC HQIRNZOQPUAHHV-UHFFFAOYSA-N
DMUT9IQ CS CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O
DMUT9IQ IK 1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3
DMUT9IQ IU 1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
DMUT9IQ CA CAS 14556-46-8
DMUT9IQ CB CHEBI:135123
DMUT9IQ DE Ventricular tachyarrhythmia
DMZ2VYG ID DMZ2VYG
DMZ2VYG DN burimamide
DMZ2VYG HS Investigative
DMZ2VYG SN 1-[4-(1H-indazol-4-yl)butyl]-3-methylthiourea; AC1NSKDK; GTPL1229
DMZ2VYG DT Small molecular drug
DMZ2VYG PC 3032915
DMZ2VYG MW 212.32
DMZ2VYG FM C9H16N4S
DMZ2VYG IC InChI=1S/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14)
DMZ2VYG CS CNC(=S)NCCCCC1=CN=CN1
DMZ2VYG IK HXRBAVXGYZUSED-UHFFFAOYSA-N
DMZ2VYG IU 1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
DMZ2VYG CA CAS 34970-69-9
DMZ2VYG CB CHEBI:3221
DMZ2VYG DE Discovery agent
DMBO0WI ID DMBO0WI
DMBO0WI DN Burnamine-17-O-3',4',5'-trimethoxybenzoate
DMBO0WI HS Investigative
DMBO0WI SN CHEMBL592589; BDBM50308526
DMBO0WI DT Small molecular drug
DMBO0WI PC 15837283
DMBO0WI MW 562.6
DMBO0WI FM C31H34N2O8
DMBO0WI IC InChI=1S/C31H34N2O8/c1-6-17-15-33-24-13-20(17)29(28(35)39-5,16-40-27(34)18-11-22(36-2)26(38-4)23(12-18)37-3)30-14-25(33)41-31(24,30)32-21-10-8-7-9-19(21)30/h6-12,20,24-25,32H,13-16H2,1-5H3/b17-6+/t20-,24-,25-,29-,30-,31-/m0/s1
DMBO0WI CS C/C=C/1\\CN2[C@H]3C[C@@H]1[C@@]([C@@]45[C@@]3(NC6=CC=CC=C64)O[C@H]2C5)(COC(=O)C7=CC(=C(C(=C7)OC)OC)OC)C(=O)OC
DMBO0WI IK CLCDMQIWPVOTMQ-RKJOYVLNSA-N
DMBO0WI IU methyl (1R,9S,11S,14Z,15S,17S,19R)-14-ethylidene-19-[(3,4,5-trimethoxybenzoyl)oxymethyl]-18-oxa-2,12-diazahexacyclo[9.6.1.19,15.01,9.03,8.012,17]nonadeca-3,5,7-triene-19-carboxylate
DMBO0WI DE Discovery agent
DMJP0QT ID DMJP0QT
DMJP0QT DN BURTTINONE
DMJP0QT HS Investigative
DMJP0QT SN burttinone; CHEMBL515837; 5,7-Dihydroxy-4'-methoxy-3'-prenyl-5'-[(3-methyl-2-butenyl)phenyl]flavanone; LMPK12140350
DMJP0QT DT Small molecular drug
DMJP0QT PC 42607959
DMJP0QT MW 438.5
DMJP0QT FM C26H30O6
DMJP0QT IC InChI=1S/C26H30O6/c1-15(2)6-7-16-10-18(11-17(25(16)31-5)8-9-26(3,4)30)22-14-21(29)24-20(28)12-19(27)13-23(24)32-22/h6,8-13,22,27-28,30H,7,14H2,1-5H3/b9-8+/t22-/m0/s1
DMJP0QT CS CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)/C=C/C(C)(C)O)OC)C
DMJP0QT IK BOBWTYODGOYWRC-UVIRAJKCSA-N
DMJP0QT IU (2S)-5,7-dihydroxy-2-[3-[(E)-3-hydroxy-3-methylbut-1-enyl]-4-methoxy-5-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
DMJP0QT DE Discovery agent
DMDC7MT ID DMDC7MT
DMDC7MT DN Bu-RYYRIK-NH2
DMDC7MT HS Investigative
DMDC7MT SN CHEMBL428076
DMDC7MT DT Small molecular drug
DMDC7MT PC 44456185
DMDC7MT MW 951.2
DMDC7MT FM C46H74N14O8
DMDC7MT IC InChI=1S/C46H74N14O8/c1-4-13-37(62)55-33(17-11-24-53-45(49)50)40(64)58-35(26-29-14-7-6-8-15-29)43(67)59-36(27-30-19-21-31(61)22-20-30)42(66)57-34(18-12-25-54-46(51)52)41(65)60-38(28(3)5-2)44(68)56-32(39(48)63)16-9-10-23-47/h6-8,14-15,19-22,28,32-36,38,61H,4-5,9-13,16-18,23-27,47H2,1-3H3,(H2,48,63)(H,55,62)(H,56,68)(H,57,66)(H,58,64)(H,59,67)(H,60,65)(H4,49,50,53)(H4,51,52,54)/t28-,32-,33-,34-,35-,36-,38-/m0/s1
DMDC7MT CS CCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DMDC7MT IK DPJOADTYQPSSOH-LWFLANIVSA-N
DMDC7MT IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(butanoylamino)-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMDC7MT DE Discovery agent
DMMHGIN ID DMMHGIN
DMMHGIN DN But-3-enyl-trimethyl-ammonium bromide
DMMHGIN HS Investigative
DMMHGIN DE Discovery agent
DMTAJP7 ID DMTAJP7
DMTAJP7 DN Butanoic acid
DMTAJP7 HS Investigative
DMTAJP7 SN butyric acid; butanoic acid; n-Butyric acid; 107-92-6; n-Butanoic acid; propylformic acid; ethylacetic acid; 1-propanecarboxylic acid; Butanic acid; butyrate; 1-Butyric acid; Buttersaeure; butanoate; Kyselina maselna; Butyric acid (natural); Propanecarboxylic acid; Buttersaeure [German]; 1-butanoic acid; FEMA Number 2221; Kyselina maselna [Czech]; FEMA No. 2221; CCRIS 6552; HSDB 940; butoic acid; Ethyacetic Acid; 2-butanoate; NSC 8415; UNII-40UIR9Q29H; UN2820; AI3-15306; EINECS 203-532-3; BRN 0906770; CH3-[CH2]2-COOH; 40UIR9Q29H
DMTAJP7 DT Small molecular drug
DMTAJP7 PC 264
DMTAJP7 MW 88.11
DMTAJP7 FM C4H8O2
DMTAJP7 IC InChI=1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)
DMTAJP7 CS CCCC(=O)O
DMTAJP7 IK FERIUCNNQQJTOY-UHFFFAOYSA-N
DMTAJP7 IU butanoic acid
DMTAJP7 CA CAS 107-92-6
DMTAJP7 CB CHEBI:30772
DMTAJP7 DE Discovery agent
DM5MZHP ID DM5MZHP
DM5MZHP DN butaprost (free acid form)
DM5MZHP HS Investigative
DM5MZHP SN butaprost acid
DM5MZHP DT Small molecular drug
DM5MZHP PC 25886893
DM5MZHP MW 394.5
DM5MZHP FM C23H38O5
DM5MZHP IC InChI=1S/C23H38O5/c1-2-13-23(14-8-15-23)21(26)11-7-10-18-17(19(24)16-20(18)25)9-5-3-4-6-12-22(27)28/h7,10,17-18,20-21,25-26H,2-6,8-9,11-16H2,1H3,(H,27,28)/b10-7+/t17-,18-,20-,21+/m1/s1
DM5MZHP CS CCCC1(CCC1)[C@H](C/C=C/[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O)O
DM5MZHP IK PAYNQYXOKJDXAV-ZHIWTBQHSA-N
DM5MZHP IU 7-[(1R,2R,3R)-3-hydroxy-2-[(E,4S)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoic acid
DM5MZHP DE Discovery agent
DM8E54P ID DM8E54P
DM8E54P DN BUTEIN
DM8E54P HS Investigative
DM8E54P SN butein; 487-52-5; 2',3,4,4'-Tetrahydroxychalcone; 3,4,2',4'-Tetrahydroxychalcone; 2',4',3,4-Tetrahydroxychalcone; UNII-4WVS5M0LGF; EINECS 207-659-5; 4WVS5M0LGF; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; CHEMBL128000; CHEBI:3237; (2E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one; ,3,4-Tetrahydroxychalcone; Chalcone, 2',3,4,4'-tetrahydroxy- (7CI,8CI); Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihy
DM8E54P DT Small molecular drug
DM8E54P PC 5281222
DM8E54P MW 272.25
DM8E54P FM C15H12O5
DM8E54P IC InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H/b5-1+
DM8E54P CS C1=CC(=C(C=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)O
DM8E54P IK AYMYWHCQALZEGT-ORCRQEGFSA-N
DM8E54P IU (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
DM8E54P CA CAS 487-52-5
DM8E54P CB CHEBI:3237
DM8E54P DE Discovery agent
DMJ46CB ID DMJ46CB
DMJ46CB DN Buthionine sulfoximine
DMJ46CB HS Investigative
DMJ46CB SN AC1MS6SH
DMJ46CB DT Small molecular drug
DMJ46CB PC 21157
DMJ46CB MW 222.31
DMJ46CB FM C8H18N2O3S
DMJ46CB IC InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)
DMJ46CB CS CCCCS(=N)(=O)CCC(C(=O)O)N
DMJ46CB IK KJQFBVYMGADDTQ-UHFFFAOYSA-N
DMJ46CB IU 2-amino-4-(butylsulfonimidoyl)butanoic acid
DMJ46CB CA CAS 5072-26-4
DMJ46CB CB CHEBI:28714
DMJ46CB DE Malaria; Solid tumour/cancer
DMR6GJK ID DMR6GJK
DMR6GJK DN Butirosin B
DMR6GJK HS Investigative
DMR6GJK SN Ambuyrosin A; AC1Q5OCU; AC1L1DSB; SCHEMBL19944113; C21H41N5O12; D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1-4)-O-(beta-D-xylofuranosyl-(1-5))-N(sup 1)-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-; Butirosin A from Bacillus vitellinus; LS-16557; 4-amino-n-{5-amino-4-[(2,6-diamino-2,6-dideoxyhexopyranosyl)oxy]-2-hydroxy-3-(pentofuranosyloxy)cyclohexyl}-2-hydroxybutanamide; LS-147025
DMR6GJK DT Small molecular drug
DMR6GJK PC 12302172
DMR6GJK MW 555.6
DMR6GJK FM C21H41N5O12
DMR6GJK IC InChI=1S/C21H41N5O12/c22-2-1-8(28)19(34)26-7-3-6(24)17(37-20-11(25)15(32)13(30)9(4-23)35-20)18(12(7)29)38-21-16(33)14(31)10(5-27)36-21/h6-18,20-21,27-33H,1-5,22-25H2,(H,26,34)/t6-,7+,8-,9+,10+,11+,12-,13+,14+,15+,16+,17+,18+,20+,21-/m0/s1
DMR6GJK CS C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O)O[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N
DMR6GJK IK XEQLFNPSYWZPOW-HBYCGHPUSA-N
DMR6GJK IU (2S)-4-amino-N-[(1R,2S,3R,4R,5S)-5-amino-4-[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide
DMR6GJK CA CAS 34291-03-7
DMR6GJK CB CHEBI:65110
DMR6GJK DE Discovery agent
DM82KPQ ID DM82KPQ
DM82KPQ DN BUTORPHAN
DM82KPQ HS Investigative
DM82KPQ SN CHEMBL301160; butorphan; MCL-101; SCHEMBL11805323; ZINC3982790; 3-Hydroxy-N-cyclobutylmethylmorphinan; BDBM50135808; 3-hydroxy-n-cyclobutylmethyl morphinan
DM82KPQ DT Small molecular drug
DM82KPQ PC 9804450
DM82KPQ MW 311.5
DM82KPQ FM C21H29NO
DM82KPQ IC InChI=1S/C21H29NO/c23-17-8-7-16-12-20-18-6-1-2-9-21(18,19(16)13-17)10-11-22(20)14-15-4-3-5-15/h7-8,13,15,18,20,23H,1-6,9-12,14H2/t18-,20+,21+/m0/s1
DM82KPQ CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC5CCC5
DM82KPQ IK YSTAPDGDOHWKQR-CEWLAPEOSA-N
DM82KPQ IU (1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DM82KPQ DE Discovery agent
DM7XN2J ID DM7XN2J
DM7XN2J DN Butoxamine
DM7XN2J HS Investigative
DM7XN2J SN AC1LELZ5; ZINC57209
DM7XN2J DT Small molecular drug
DM7XN2J PC 134495
DM7XN2J MW 267.36
DM7XN2J FM C15H25NO3
DM7XN2J IC InChI=1S/C15H25NO3/c1-10(16-15(2,3)4)14(17)12-9-11(18-5)7-8-13(12)19-6/h7-10,14,16-17H,1-6H3/t10-,14-/m0/s1
DM7XN2J CS C[C@@H]([C@@H](C1=C(C=CC(=C1)OC)OC)O)NC(C)(C)C
DM7XN2J IK TWUSDDMONZULSC-HZMBPMFUSA-N
DM7XN2J IU (1R,2S)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol
DM7XN2J CA CAS 2922-20-5
DM7XN2J DE Discovery agent
DMGHEQV ID DMGHEQV
DMGHEQV DN Butyl 10H-phenothiazine-10-carboxylate
DMGHEQV HS Investigative
DMGHEQV SN CHEMBL481142; butyl 10H-phenothiazine-10-carboxylate
DMGHEQV DT Small molecular drug
DMGHEQV PC 24905534
DMGHEQV MW 299.4
DMGHEQV FM C17H17NO2S
DMGHEQV IC InChI=1S/C17H17NO2S/c1-2-3-12-20-17(19)18-13-8-4-6-10-15(13)21-16-11-7-5-9-14(16)18/h4-11H,2-3,12H2,1H3
DMGHEQV CS CCCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMGHEQV IK YNOVMVUUQJTZIS-UHFFFAOYSA-N
DMGHEQV IU butyl phenothiazine-10-carboxylate
DMGHEQV DE Discovery agent
DM1CX9Y ID DM1CX9Y
DM1CX9Y DN Butyl-indol-1-yl-pyridin-4-yl-amine
DM1CX9Y HS Investigative
DM1CX9Y SN CHEMBL155109; Butyl-indol-1-yl-pyridin-4-yl-amine; SCHEMBL7616007; BDBM50048576
DM1CX9Y DT Small molecular drug
DM1CX9Y PC 10801657
DM1CX9Y MW 265.35
DM1CX9Y FM C17H19N3
DM1CX9Y IC InChI=1S/C17H19N3/c1-2-3-13-19(16-8-11-18-12-9-16)20-14-10-15-6-4-5-7-17(15)20/h4-12,14H,2-3,13H2,1H3
DM1CX9Y CS CCCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DM1CX9Y IK OSRPQIAWURAKDF-UHFFFAOYSA-N
DM1CX9Y IU N-butyl-N-pyridin-4-ylindol-1-amine
DM1CX9Y DE Discovery agent
DMJUTWG ID DMJUTWG
DMJUTWG DN Butyl-methyl-prop-2-ynyl-amine hydrochloride
DMJUTWG HS Investigative
DMJUTWG DE Discovery agent
DMF5D1N ID DMF5D1N
DMF5D1N DN Butylphosphonate
DMF5D1N HS Investigative
DMF5D1N SN Dibutyl phosphite; Dibutyl phosphonate; Phosphonic acid, dibutyl ester; Dibutoxyphosphine oxide; Mobil DBHP; Dibutyl hydrogen phosphonate; Di-n-butyl hydrogen phosphite; Dibutylfosfit; Phosphorous acid, dibutyl ester; Butyl phosphonate ((BuO)2HPO); Butyl alcohol, hydrogen phosphite; di-n-Butylphosphite; Dibutylfosfit [Czech]; NSC 2668; Dibutyl phosphite (VAN); Phosphonic Acid Dibutyl Ester; UNII-R149712Z1F; HSDB 2597; Dibutyl hydrogen phosphite (VAN); EINECS 217-316-1; R149712Z1F; Phosphorous acid, dibutyl ester (VAN); BRN 10997
DMF5D1N DT Small molecular drug
DMF5D1N PC 76839
DMF5D1N MW 138.1
DMF5D1N FM C4H11O3P
DMF5D1N IC InChI=1S/C4H11O3P/c1-2-3-4-8(5,6)7/h2-4H2,1H3,(H2,5,6,7)
DMF5D1N CS CCCCP(=O)(O)O
DMF5D1N IK UOKRBSXOBUKDGE-UHFFFAOYSA-N
DMF5D1N IU butylphosphonic acid
DMF5D1N CA CAS 3321-64-0
DMF5D1N CB CHEBI:41384
DMF5D1N DE Discovery agent
DM9X2FV ID DM9X2FV
DM9X2FV DN Butyrfentanyl
DM9X2FV HS Investigative
DM9X2FV SN Butyr-fentanyl; Butyrfentanyl; Butyrfentanyl (Butyrylfentanyl); Butyryl fentanyl; Methyl-3-fentanyl; QQOMYEQLWQJRKK-UHFFFAOYSA-N; TRA0094848; ZINC32266443; 07V1H7R6ZN; 1169-70-6; AC1LDM56; AKOS025243418; AS-48590; Butanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-; CS-D0505; CTK0G0348; DB09173; DEA No. 9822; DTXSID30347410; MFCD22054430; N-(1-Phenethylpiperidin-4-yl)-N-phenylbutyramide; N-PHENYL-N-[1-(2-PHENYLETHYL)PIPERIDIN-4-YL]BUTANAMIDE; N-Phenyl-N-(1-phenethyl-4-piperidinyl)butanamide; SCHEMBL18623773; UNII-07V1H7R6ZN
DM9X2FV PC 621174
DM9X2FV MW 350.5
DM9X2FV FM C23H30N2O
DM9X2FV IC QQOMYEQLWQJRKK-UHFFFAOYSA-N
DM9X2FV CS CCCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
DM9X2FV IK 1S/C23H30N2O/c1-2-9-23(26)25(21-12-7-4-8-13-21)22-15-18-24(19-16-22)17-14-20-10-5-3-6-11-20/h3-8,10-13,22H,2,9,14-19H2,1H3
DM9X2FV IU N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide
DM9X2FV CA CAS 1169-70-6
DM9X2FV DE Anaesthesia
DMOBYVL ID DMOBYVL
DMOBYVL DN Butyrylthiocholine
DMOBYVL HS Investigative
DMOBYVL SN BUTYRYLTHIOCHOLINE; 4555-00-4; CHEMBL139908; CHEBI:41055; 2-(BUTYRYLSULFANYL)-N,N,N-TRIMETHYLETHANAMINIUM; CHEMBL148530; (Propylcarbonylthioethyl)trimethylammonium iodide; butanoylthiocholine; s-butyrylthiocholine; S-butanoylthiocholine; 2ha7; AC1L2GSR; SCHEMBL570209; Ethanaminium, N,N,N-trimethyl-2-((1-oxobutyl)thio)-; BDBM8978; CTK4I8879; AWBGQVBMGBZGLS-UHFFFAOYSA-; DTXSID00196553; ZINC1592591; MCULE-2436087085; DB04250; 2-butanoylsulfanylethyl(trimethyl)azanium; AN-22197; AJ-27734; CJ-25507
DMOBYVL DT Small molecular drug
DMOBYVL PC 20689
DMOBYVL MW 190.33
DMOBYVL FM C9H20NOS+
DMOBYVL IC InChI=1S/C9H20NOS/c1-5-6-9(11)12-8-7-10(2,3)4/h5-8H2,1-4H3/q+1
DMOBYVL CS CCCC(=O)SCC[N+](C)(C)C
DMOBYVL IK AWBGQVBMGBZGLS-UHFFFAOYSA-N
DMOBYVL IU 2-butanoylsulfanylethyl(trimethyl)azanium
DMOBYVL CA CAS 4555-00-4
DMOBYVL CB CHEBI:41055
DMOBYVL DE Discovery agent
DMDTV7A ID DMDTV7A
DMDTV7A DN BV-6
DMDTV7A HS Investigative
DMDTV7A SN BV6
DMDTV7A DT Small molecular drug
DMDTV7A PC 23657864
DMDTV7A MW 1205.6
DMDTV7A FM C70H96N10O8
DMDTV7A IC InChI=1S/C70H96N10O8/c1-47(71-3)63(81)75-59(53-37-21-11-22-38-53)69(87)79-45-27-41-55(79)65(83)77-61(57(49-29-13-7-14-30-49)50-31-15-8-16-32-50)67(85)73-43-25-5-6-26-44-74-68(86)62(58(51-33-17-9-18-34-51)52-35-19-10-20-36-52)78-66(84)56-42-28-46-80(56)70(88)60(54-39-23-12-24-40-54)76-64(82)48(2)72-4/h7-10,13-20,29-36,47-48,53-62,71-72H,5-6,11-12,21-28,37-46H2,1-4H3,(H,73,85)(H,74,86)(H,75,81)(H,76,82)(H,77,83)(H,78,84)/t47-,48-,55-,56-,59-,60-,61-,62-/m0/s1
DMDTV7A CS C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)NCCCCCCNC(=O)[C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC(=O)[C@@H]7CCCN7C(=O)[C@H](C8CCCCC8)NC(=O)[C@H](C)NC)NC
DMDTV7A IK DPXJXGNXKOVBJV-YLOPQIBLSA-N
DMDTV7A IU (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(2S)-1-[6-[[(2S)-2-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3,3-diphenylpropanoyl]amino]hexylamino]-1-oxo-3,3-diphenylpropan-2-yl]pyrrolidine-2-carboxamide
DMDTV7A CB CHEBI:47924
DMDTV7A DE Discovery agent
DM10UHA ID DM10UHA
DM10UHA DN BVB-808
DM10UHA HS Investigative
DM10UHA SN JAK2 tyrosine kinase inhibitors (cancer), Novartis; NVP-BSK-805
DM10UHA CP Novartis AG
DM10UHA PC 90480481
DM10UHA MW 533.6
DM10UHA FM C29H33F2N7O
DM10UHA IC InChI=1S/C29H33F2N7O/c1-19-16-37(17-20(2)33-19)23-5-3-22(4-6-23)34-29-32-15-21-7-8-38(28(21)35-29)24-13-26(30)25(27(31)14-24)18-36-9-11-39-12-10-36/h3-8,13-15,19-20,33H,9-12,16-18H2,1-2H3,(H,32,34,35)/t19-,20+
DM10UHA CS C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)NC3=NC=C4C=CN(C4=N3)C5=CC(=C(C(=C5)F)CN6CCOCC6)F
DM10UHA IK VIIPVCPPCBLRRL-BGYRXZFFSA-N
DM10UHA IU 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]phenyl]pyrrolo[2,3-d]pyrimidin-2-amine
DM10UHA CA CAS 1414587-22-6
DM10UHA DE Solid tumour/cancer
DMI1H3Y ID DMI1H3Y
DMI1H3Y DN BVDU-MP
DMI1H3Y HS Investigative
DMI1H3Y SN SCHEMBL4287705
DMI1H3Y DT Small molecular drug
DMI1H3Y PC 46936977
DMI1H3Y MW 413.11
DMI1H3Y FM C11H14BrN2O8P
DMI1H3Y IC InChI=1S/C11H14BrN2O8P/c12-2-1-6-4-14(11(17)13-10(6)16)9-3-7(15)8(22-9)5-21-23(18,19)20/h1-2,4,7-9,15H,3,5H2,(H,13,16,17)(H2,18,19,20)/b2-1+/t7-,8+,9-/m1/s1
DMI1H3Y CS C1[C@H]([C@@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)COP(=O)(O)O)O
DMI1H3Y IK LKWCVKAHHUJPQO-UDGIAEMFSA-N
DMI1H3Y IU [(2S,3R,5R)-5-[5-[(E)-2-bromoethenyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMI1H3Y DE Discovery agent
DM8N7BA ID DM8N7BA
DM8N7BA DN BVT 933
DM8N7BA HS Investigative
DM8N7BA DE Obesity
DMULZOP ID DMULZOP
DMULZOP DN BVT173187
DMULZOP HS Investigative
DMULZOP SN BVT 173187
DMULZOP DT Small molecular drug
DMULZOP PC 73755160
DMULZOP MW 330.6
DMULZOP FM C14H10Cl3NO2
DMULZOP IC InChI=1S/C14H10Cl3NO2/c1-7-2-3-10(16)12(4-7)18-14(20)9-5-8(15)6-11(17)13(9)19/h2-6,19H,1H3,(H,18,20)
DMULZOP CS CC1=CC(=C(C=C1)Cl)NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O
DMULZOP IK UCOQCHLODZCXRH-UHFFFAOYSA-N
DMULZOP IU 3,5-dichloro-N-(2-chloro-5-methylphenyl)-2-hydroxybenzamide
DMULZOP DE Discovery agent
DMAVDNU ID DMAVDNU
DMAVDNU DN BVX-20-CD20
DMAVDNU HS Investigative
DMAVDNU SN BVX-20; Anti-CD20 mAb (NHL), Biocon; Anti-CD20 monoclonal antibody (non-Hodgkin's lymphoma), Biocon
DMAVDNU CP Vaccinex Inc
DMAVDNU DT Antibody
DMAVDNU DE Non-hodgkin lymphoma
DMA0FO5 ID DMA0FO5
DMA0FO5 DN BW 245C
DMA0FO5 HS Investigative
DMA0FO5 SN BW245C; BW-245C
DMA0FO5 DT Small molecular drug
DMA0FO5 PC 119304
DMA0FO5 MW 368.5
DMA0FO5 FM C19H32N2O5
DMA0FO5 IC InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)
DMA0FO5 CS C1CCC(CC1)C(CCN2C(C(=O)NC2=O)CCCCCCC(=O)O)O
DMA0FO5 IK ZIDQIOZJEJFMOH-UHFFFAOYSA-N
DMA0FO5 IU 7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid
DMA0FO5 CA CAS 75693-75-3
DMA0FO5 CB CHEBI:131502
DMA0FO5 DE Discovery agent
DMNSLGC ID DMNSLGC
DMNSLGC DN BW A360C
DMNSLGC HS Investigative
DMNSLGC SN 139290-69-0; MDL 100151; C22H28FNO3; HXTGXYRHXAGCFP-UHFFFAOYSA-N; AC1Q4NRW; AC1L1U2G; SCHEMBL340674; CHEMBL257283; SCHEMBL13701277; 4-Piperidinemethanol, alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (+)-; MolPort-039-331-873; MDL100105; BDBM50232153; PDSP2_001480; PDSP1_001496; AKOS027338720; MDL 100105; AN-5556; LS-115604
DMNSLGC DT Small molecular drug
DMNSLGC PC 60858
DMNSLGC MW 373.5
DMNSLGC FM C22H28FNO3
DMNSLGC IC InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3
DMNSLGC CS COC1=CC=CC(=C1OC)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O
DMNSLGC IK HXTGXYRHXAGCFP-UHFFFAOYSA-N
DMNSLGC IU (2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol
DMNSLGC CA CAS 139290-69-0
DMNSLGC DE Discovery agent
DMHQP84 ID DMHQP84
DMHQP84 DN BW B218C
DMHQP84 HS Investigative
DMHQP84 SN BW B218C; BW-B218C; ZLIVOFMPDUIULQ-VAWYXSNFSA-N; 134470-36-3; AC1O5RJN; SCHEMBL6008832; N-(1-Methyl-3-(3-phenoxyphenyl)prop-2-enyl)acetohydroxamic acid; N-hydroxy-N-[(E)-4-(3-phenoxyphenyl)but-3-en-2-yl]acetamide; Acetamide, N-hydroxy-N-(1-methyl-3-(3-phenoxyphenyl)-2-propenyl)-; (+)-(E)-N-[1-methyl-3-(3-phenoxyphenyl)prop-2-enyl]acetohydroxamic acid; N-[(E)-3-(3-Phenoxyphenyl)-1-methyl-2-propenyl]acetohydroxamic acid
DMHQP84 DT Small molecular drug
DMHQP84 PC 6439376
DMHQP84 MW 297.3
DMHQP84 FM C18H19NO3
DMHQP84 IC InChI=1S/C18H19NO3/c1-14(19(21)15(2)20)11-12-16-7-6-10-18(13-16)22-17-8-4-3-5-9-17/h3-14,21H,1-2H3/b12-11+
DMHQP84 CS CC(/C=C/C1=CC(=CC=C1)OC2=CC=CC=C2)N(C(=O)C)O
DMHQP84 IK ZLIVOFMPDUIULQ-VAWYXSNFSA-N
DMHQP84 IU N-hydroxy-N-[(E)-4-(3-phenoxyphenyl)but-3-en-2-yl]acetamide
DMHQP84 CA CAS 134470-36-3
DMHQP84 DE Discovery agent
DMFKXMT ID DMFKXMT
DMFKXMT DN BW-202W92
DMFKXMT HS Investigative
DMFKXMT SN BW-202W92; SCHEMBL136398; CHEMBL448556; QEDNOUAODRFJQN-UHFFFAOYSA-N; BW202W92; 2.4-Diamino-5-(2,3,5-trichlorophenyl)-6-fluoromethylpyrimidine; 2,4-diamino-5-(2,3,5-trichlorophenyl)-6-fluoromethylpyrimidine
DMFKXMT DT Small molecular drug
DMFKXMT PC 9883607
DMFKXMT MW 321.6
DMFKXMT FM C11H8Cl3FN4
DMFKXMT IC InChI=1S/C11H8Cl3FN4/c12-4-1-5(9(14)6(13)2-4)8-7(3-15)18-11(17)19-10(8)16/h1-2H,3H2,(H4,16,17,18,19)
DMFKXMT CS C1=C(C=C(C(=C1C2=C(N=C(N=C2N)N)CF)Cl)Cl)Cl
DMFKXMT IK QEDNOUAODRFJQN-UHFFFAOYSA-N
DMFKXMT IU 6-(fluoromethyl)-5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine
DMFKXMT DE Discovery agent
DMQ3AC0 ID DMQ3AC0
DMQ3AC0 DN BW284C51
DMQ3AC0 HS Investigative
DMQ3AC0 SN 4-(5-{4-[Dimethyl(prop-2-enyl)ammonio]phenyl}-3-oxopentyl)-N,N-dimethyl-N-prop-2-enylbenzenaminium; BW284c51; CHEMBL140020; BW-28C51; EBW; 4-(5-{4-[DIMETHYL(PROP-2-ENYL)AMMONIO]PHENYL}-3-OXOPENTYL)-N,N-DIMETHYL-N-PROP-2-ENYLBENZENAMINIUM; CHEMBL464538; SCHEMBL7449688; GTPL6600; AC1L1B98; BDBM10624; ZAEXMNKDGJNLTA-UHFFFAOYSA-N; ZINC3814201; NCGC00247016-01; 1,5-Bis[4-(allyldimethylaminio)phenyl]pentane-3-one; 1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one dibromide; 4,4'-(3-oxopentane-1,5-diyl)bis(N,N-dimethyl-N-prop-2-en-1-ylanilinium)
DMQ3AC0 DT Small molecular drug
DMQ3AC0 PC 1338
DMQ3AC0 MW 406.6
DMQ3AC0 FM C27H38N2O+2
DMQ3AC0 IC InChI=1S/C27H38N2O/c1-7-21-28(3,4)25-15-9-23(10-16-25)13-19-27(30)20-14-24-11-17-26(18-12-24)29(5,6)22-8-2/h7-12,15-18H,1-2,13-14,19-22H2,3-6H3/q+2
DMQ3AC0 CS C[N+](C)(CC=C)C1=CC=C(C=C1)CCC(=O)CCC2=CC=C(C=C2)[N+](C)(C)CC=C
DMQ3AC0 IK ZAEXMNKDGJNLTA-UHFFFAOYSA-N
DMQ3AC0 IU [4-[5-[4-[dimethyl(prop-2-enyl)azaniumyl]phenyl]-3-oxopentyl]phenyl]-dimethyl-prop-2-enylazanium
DMQ3AC0 DE Discovery agent
DME15JU ID DME15JU
DME15JU DN BW723C86
DME15JU HS Investigative
DME15JU SN BW-72386
DME15JU DT Small molecular drug
DME15JU PC 5311036
DME15JU MW 322.9
DME15JU FM C16H19ClN2OS
DME15JU IC InChI=1S/C16H18N2OS.ClH/c1-11(17)7-12-9-18-16-5-4-13(8-15(12)16)19-10-14-3-2-6-20-14;/h2-6,8-9,11,18H,7,10,17H2,1H3;1H
DME15JU CS CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl
DME15JU IK PYJBJMIBANAOFJ-UHFFFAOYSA-N
DME15JU IU 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine;hydrochloride
DME15JU CA CAS 160521-72-2
DME15JU DE Discovery agent
DMM2WPH ID DMM2WPH
DMM2WPH DN BW-858C
DMM2WPH HS Investigative
DMM2WPH CP Burroughs Wellcome Inc
DMM2WPH DE Asthma
DM7SNU0 ID DM7SNU0
DM7SNU0 DN BW-A137C
DM7SNU0 HS Investigative
DM7SNU0 SN 106328-28-3
DM7SNU0 DT Small molecular drug
DM7SNU0 PC 129265
DM7SNU0 MW 271.31
DM7SNU0 FM C16H17NO3
DM7SNU0 IC InChI=1S/C16H17NO3/c1-13(18)17(19)11-14-7-9-16(10-8-14)20-12-15-5-3-2-4-6-15/h2-10,19H,11-12H2,1H3
DM7SNU0 CS CC(=O)N(CC1=CC=C(C=C1)OCC2=CC=CC=C2)O
DM7SNU0 IK LWIAYVCOMRXMSJ-UHFFFAOYSA-N
DM7SNU0 IU N-hydroxy-N-[(4-phenylmethoxyphenyl)methyl]acetamide
DM7SNU0 CA CAS 106328-28-3
DM7SNU0 DE Discovery agent
DMU9LQW ID DMU9LQW
DMU9LQW DN BWA868C
DMU9LQW HS Investigative
DMU9LQW SN 3-Benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; BW A868C; 118675-50-6; BW-A868C; BW A 868C; BW-A-868C; C25H37N3O5; (+/-)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin; 4-Imidazolidineheptanoic acid, 3-((2-cyclohexyl-2-hydroxyethyl)amino)-2,5-dioxo-1-(phenylmethyl)-; 4-Imidazolidineheptanoicacid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-; 3-[(2-Cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- 4-imidazolidineheptanoic; BWA-868C; BWA 868C; [3H]BWA868C
DMU9LQW DT Small molecular drug
DMU9LQW PC 122021
DMU9LQW MW 459.6
DMU9LQW FM C25H37N3O5
DMU9LQW IC InChI=1S/C25H37N3O5/c29-22(20-13-7-4-8-14-20)17-26-28-21(15-9-1-2-10-16-23(30)31)24(32)27(25(28)33)18-19-11-5-3-6-12-19/h3,5-6,11-12,20-22,26,29H,1-2,4,7-10,13-18H2,(H,30,31)
DMU9LQW CS C1CCC(CC1)C(CNN2C(C(=O)N(C2=O)CC3=CC=CC=C3)CCCCCCC(=O)O)O
DMU9LQW IK YZJVWSKJHGEIBL-UHFFFAOYSA-N
DMU9LQW IU 7-[1-benzyl-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxoimidazolidin-4-yl]heptanoic acid
DMU9LQW CA CAS 118675-50-6
DMU9LQW DE Discovery agent
DMA2B1C ID DMA2B1C
DMA2B1C DN BX 048
DMA2B1C HS Investigative
DMA2B1C SN BX-048; BX048
DMA2B1C DT Small molecular drug
DMA2B1C PC 16741348
DMA2B1C MW 558.6
DMA2B1C FM C27H34N4O9
DMA2B1C IC InChI=1S/C27H34N4O9/c1-5-39-26(38)31-12-10-30(11-13-31)24(35)18(8-9-22(32)33)29-23(34)20-15-21(40-27(3,4)25(36)37)17-7-6-16(2)14-19(17)28-20/h6-7,14-15,18H,5,8-13H2,1-4H3,(H,29,34)(H,32,33)(H,36,37)
DMA2B1C CS CCOC(=O)N1CCN(CC1)C(=O)C(CCC(=O)O)NC(=O)C2=NC3=C(C=CC(=C3)C)C(=C2)OC(C)(C)C(=O)O
DMA2B1C IK MCBLPJPMVOVJCO-UHFFFAOYSA-N
DMA2B1C IU 4-[[4-(2-carboxypropan-2-yloxy)-7-methylquinoline-2-carbonyl]amino]-5-(4-ethoxycarbonylpiperazin-1-yl)-5-oxopentanoic acid
DMA2B1C DE Discovery agent
DM5CGXB ID DM5CGXB
DM5CGXB DN BX 471
DM5CGXB HS Investigative
DM5CGXB SN 217645-70-0; BX471; BX-471; BX 471; BX-471 free base; BX-741; UNII-76K17ZG4ZN; ZK-811752; CHEMBL232656; 76K17ZG4ZN; CHEMBL535607; (R)-1-(5-chloro-2-(2-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-2-oxoethoxy)phenyl)urea; Urea, N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-; N-[5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]phenyl]-Urea; [5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea; Urea, N-
DM5CGXB DT Small molecular drug
DM5CGXB PC 512282
DM5CGXB MW 434.9
DM5CGXB FM C21H24ClFN4O3
DM5CGXB IC InChI=1S/C21H24ClFN4O3/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29)/t14-/m1/s1
DM5CGXB CS C[C@@H]1CN(CCN1C(=O)COC2=C(C=C(C=C2)Cl)NC(=O)N)CC3=CC=C(C=C3)F
DM5CGXB IK XQYASZNUFDVMFH-CQSZACIVSA-N
DM5CGXB IU [5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]urea
DM5CGXB CA CAS 217645-70-0
DM5CGXB DE Discovery agent
DMBKVN9 ID DMBKVN9
DMBKVN9 DN BX 667
DMBKVN9 HS Investigative
DMBKVN9 SN BX-667; BX667
DMBKVN9 DT Small molecular drug
DMBKVN9 PC 16681707
DMBKVN9 MW 586.6
DMBKVN9 FM C29H38N4O9
DMBKVN9 IC InChI=1S/C29H38N4O9/c1-6-40-27(38)29(4,5)42-23-17-22(30-21-16-18(3)8-9-19(21)23)25(36)31-20(10-11-24(34)35)26(37)32-12-14-33(15-13-32)28(39)41-7-2/h8-9,16-17,20H,6-7,10-15H2,1-5H3,(H,31,36)(H,34,35)/t20-/m0/s1
DMBKVN9 CS CCOC(=O)C(C)(C)OC1=CC(=NC2=C1C=CC(=C2)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N3CCN(CC3)C(=O)OCC
DMBKVN9 IK PHDMSNZRDFPYNQ-FQEVSTJZSA-N
DMBKVN9 IU (4S)-5-(4-ethoxycarbonylpiperazin-1-yl)-4-[[4-(1-ethoxy-2-methyl-1-oxopropan-2-yl)oxy-7-methylquinoline-2-carbonyl]amino]-5-oxopentanoic acid
DMBKVN9 DE Discovery agent
DMGK7U5 ID DMGK7U5
DMGK7U5 DN BX-201
DMGK7U5 HS Investigative
DMGK7U5 SN BX-201; indolinone based inhibitor, 3l; CHEMBL442229; SCHEMBL5728132; BDBM16981
DMGK7U5 DT Small molecular drug
DMGK7U5 PC 11311693
DMGK7U5 MW 268.27
DMGK7U5 FM C14H12N4O2
DMGK7U5 IC InChI=1S/C14H12N4O2/c15-14(20)17-9-3-4-12-10(7-9)11(13(19)18-12)6-8-2-1-5-16-8/h1-7,16H,(H,18,19)(H3,15,17,20)/b11-6-
DMGK7U5 CS C1=CNC(=C1)/C=C\\2/C3=C(C=CC(=C3)NC(=O)N)NC2=O
DMGK7U5 IK SOVOJYOIAXOTIM-WDZFZDKYSA-N
DMGK7U5 IU [(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-5-yl]urea
DMGK7U5 DE Discovery agent
DMBQIEF ID DMBQIEF
DMBQIEF DN BX-517
DMBQIEF HS Investigative
DMBQIEF SN BX517; BX-517; 850717-64-5; UNII-SYV8VN8W5K; SYV8VN8W5K; pdk-1 inhibitors; BX517(PDK1 inhibitor2); Indolinone based inhibitor, 4i; SCHEMBL5567818; CHEMBL228654; 5-Ureido-3-(1-(pyrrol-2-yl)ethylidene)indolin-2-one; BDBM17004; MolPort-046-033-615; BCP16225; EX-A2243; ZINC14962724; AKOS032945106; CS-6066; Urea, N-(2,3-dihydro-2-oxo-3-((3Z)-1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, N-(2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-yl)-; Urea, (2,3-dihydro-2-oxo-3-(1-(1H-pyrrol-2-yl)ethylidene)-1H-indol-5-
DMBQIEF DT Small molecular drug
DMBQIEF PC 11161844
DMBQIEF MW 282.3
DMBQIEF FM C15H14N4O2
DMBQIEF IC InChI=1S/C15H14N4O2/c1-8(11-3-2-6-17-11)13-10-7-9(18-15(16)21)4-5-12(10)19-14(13)20/h2-7,17H,1H3,(H,19,20)(H3,16,18,21)/b13-8-
DMBQIEF CS C/C(=C/1\\C2=C(C=CC(=C2)NC(=O)N)NC1=O)/C3=CC=CN3
DMBQIEF IK DFURSNCTQGJRRX-JYRVWZFOSA-N
DMBQIEF IU [(3Z)-2-oxo-3-[1-(1H-pyrrol-2-yl)ethylidene]-1H-indol-5-yl]urea
DMBQIEF CA CAS 946843-63-6
DMBQIEF DE Discovery agent
DMRIMLJ ID DMRIMLJ
DMRIMLJ DN BX-795
DMRIMLJ HS Investigative
DMRIMLJ SN BX795; BX 795
DMRIMLJ DT Small molecular drug
DMRIMLJ PC 10077147
DMRIMLJ MW 591.5
DMRIMLJ FM C23H26IN7O2S
DMRIMLJ IC InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)
DMRIMLJ CS C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCCNC(=O)C4=CC=CS4)I
DMRIMLJ IK VAVXGGRQQJZYBL-UHFFFAOYSA-N
DMRIMLJ IU N-[3-[[5-iodo-4-[3-(thiophene-2-carbonylamino)propylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide
DMRIMLJ CA CAS 702675-74-9
DMRIMLJ CB CHEBI:91439
DMRIMLJ DE Discovery agent
DMZA45C ID DMZA45C
DMZA45C DN BX-912
DMZA45C HS Investigative
DMZA45C SN BX 912; BX912
DMZA45C DT Small molecular drug
DMZA45C PC 11754511
DMZA45C MW 471.4
DMZA45C FM C20H23BrN8O
DMZA45C IC InChI=1S/C20H23BrN8O/c21-17-12-24-19(28-18(17)23-7-6-16-11-22-13-25-16)26-14-4-3-5-15(10-14)27-20(30)29-8-1-2-9-29/h3-5,10-13H,1-2,6-9H2,(H,22,25)(H,27,30)(H2,23,24,26,28)
DMZA45C CS C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br
DMZA45C IK DMMILYKXNCVKOJ-UHFFFAOYSA-N
DMZA45C IU N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]pyrimidin-2-yl]amino]phenyl]pyrrolidine-1-carboxamide
DMZA45C CA CAS 702674-56-4
DMZA45C CB CHEBI:91357
DMZA45C DE Discovery agent
DMAWMDN ID DMAWMDN
DMAWMDN DN BYK-191023
DMAWMDN HS Investigative
DMAWMDN SN INOS inhibitors (inflammatory diseases); INOS inhibitors (inflammatory diseases), Altana; INOS inhibitors (inflammatory diseases), Nycomed
DMAWMDN CP Nycomed
DMAWMDN DT Small molecular drug
DMAWMDN PC 10308091
DMAWMDN MW 254.29
DMAWMDN FM C14H14N4O
DMAWMDN IC InChI=1S/C14H14N4O/c1-19-11-6-8-15-10(9-11)4-5-13-17-12-3-2-7-16-14(12)18-13/h2-3,6-9H,4-5H2,1H3,(H,16,17,18)
DMAWMDN CS COC1=CC(=NC=C1)CCC2=NC3=C(N2)C=CC=N3
DMAWMDN IK YBOCDKFRGBOOFO-UHFFFAOYSA-N
DMAWMDN IU 2-[2-(4-methoxypyridin-2-yl)ethyl]-1H-imidazo[4,5-b]pyridine
DMAWMDN CA CAS 608880-48-4
DMAWMDN DE Inflammation
DMN5X17 ID DMN5X17
DMN5X17 DN BZ3
DMN5X17 HS Investigative
DMN5X17 SN 5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; BZ3; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T
DMN5X17 DT Small molecular drug
DMN5X17 PC 13872
DMN5X17 MW 147.17
DMN5X17 FM C9H9NO
DMN5X17 IC InChI=1S/C9H9NO/c1-11-8-2-3-9-7(6-8)4-5-10-9/h2-6,10H,1H3
DMN5X17 CS COC1=CC2=C(C=C1)NC=C2
DMN5X17 IK DWAQDRSOVMLGRQ-UHFFFAOYSA-N
DMN5X17 IU 5-methoxy-1H-indole
DMN5X17 CA CAS 1006-94-6
DMN5X17 DE Discovery agent
DMRXPFM ID DMRXPFM
DMRXPFM DN BZ5
DMRXPFM HS Investigative
DMRXPFM PC 46241905
DMRXPFM MW 336.4
DMRXPFM FM C16H16O6S
DMRXPFM IC InChI=1S/C16H16O6S/c17-11-7-16(22,15(20)21)10(13(18)14(11)19)6-8-1-2-12-9(5-8)3-4-23-12/h1-5,10-11,14,17,19,22H,6-7H2,(H,20,21)/t10-,11+,14-,16+/m0/s1
DMRXPFM CS C1[C@H]([C@@H](C(=O)[C@@H]([C@]1(C(=O)O)O)CC2=CC3=C(C=C2)SC=C3)O)O
DMRXPFM IK WFQJMZIPFQUOBR-FJXFWJLJSA-N
DMRXPFM IU (1R,2R,4S,5R)-2-(1-benzothiophen-5-ylmethyl)-1,4,5-trihydroxy-3-oxocyclohexane-1-carboxylic acid
DMRXPFM DE Discovery agent
DMF8UWE ID DMF8UWE
DMF8UWE DN BZ6
DMF8UWE HS Investigative
DMF8UWE DT Small molecular drug
DMF8UWE PC 41673734
DMF8UWE MW 330.4
DMF8UWE FM C20H18N4O
DMF8UWE IC InChI=1S/C20H18N4O/c1-25-19-9-7-16(8-10-19)20-17(13-23-12-11-21-15-23)14-24(22-20)18-5-3-2-4-6-18/h2-12,14-15H,13H2,1H3
DMF8UWE CS COC1=CC=C(C=C1)C2=NN(C=C2CN3C=CN=C3)C4=CC=CC=C4
DMF8UWE IK CZOCKHTYPCJURT-UHFFFAOYSA-N
DMF8UWE IU 4-(imidazol-1-ylmethyl)-3-(4-methoxyphenyl)-1-phenylpyrazole
DMF8UWE DE Ataxia-telangiectasia
DM37GYA ID DM37GYA
DM37GYA DN BzATP
DM37GYA HS Investigative
DM37GYA SN BzATP; 3'-O-(4-Benzoyl)benzoyl ATP; 3'-O-(4-Benzoylbenzoyl)ATP; 3'-O-(4-Benzoyl)benzoyladenosine 5'-triphosphate; UNII-4P5DXU1F8Q; 81790-82-1; 4P5DXU1F8Q; CHEBI:34316; Adenosine 5'-(tetrahydrogen triphosphate), 3'-(4-benzoylbenzoate); C24H24N5O15P3; ATP, Bz; AC1L3GPW; AC1Q6S3N; SCHEMBL3682844; GTPL1757; CHEMBL2407634; BDBM86488; ZINC8295154; 3'-o-(4-benzoylbenzoyl)adenosine 5'-(tetrahydrogen triphosphate); LS-177651; CAS_81790-82-1; C13744; 3'-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate
DM37GYA DT Small molecular drug
DM37GYA PC 115205
DM37GYA MW 715.4
DM37GYA FM C24H24N5O15P3
DM37GYA IC InChI=1S/C24H24N5O15P3/c25-21-17-22(27-11-26-21)29(12-28-17)23-19(31)20(16(41-23)10-40-46(36,37)44-47(38,39)43-45(33,34)35)42-24(32)15-8-6-14(7-9-15)18(30)13-4-2-1-3-5-13/h1-9,11-12,16,19-20,23,31H,10H2,(H,36,37)(H,38,39)(H2,25,26,27)(H2,33,34,35)/t16-,19-,20-,23-/m1/s1
DM37GYA CS C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C(=O)O[C@@H]3[C@H](O[C@H]([C@@H]3O)N4C=NC5=C(N=CN=C54)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O
DM37GYA IK AWJJLYZBWRIBCZ-UGTJMOTHSA-N
DM37GYA IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] 4-benzoylbenzoate
DM37GYA CA CAS 81790-82-1
DM37GYA CB CHEBI:34316
DM37GYA DE Discovery agent
DMUW87A ID DMUW87A
DMUW87A DN Bz--RYYRIK-NH2
DMUW87A HS Investigative
DMUW87A SN CHEMBL257921
DMUW87A DT Small molecular drug
DMUW87A PC 44456187
DMUW87A MW 985.2
DMUW87A FM C49H72N14O8
DMUW87A IC InChI=1S/C49H72N14O8/c1-3-30(2)40(47(71)58-35(41(51)65)18-10-11-25-50)63-44(68)37(20-13-27-57-49(54)55)60-45(69)39(29-32-21-23-34(64)24-22-32)62-46(70)38(28-31-14-6-4-7-15-31)61-43(67)36(19-12-26-56-48(52)53)59-42(66)33-16-8-5-9-17-33/h4-9,14-17,21-24,30,35-40,64H,3,10-13,18-20,25-29,50H2,1-2H3,(H2,51,65)(H,58,71)(H,59,66)(H,60,69)(H,61,67)(H,62,70)(H,63,68)(H4,52,53,56)(H4,54,55,57)/t30-,35-,36-,37-,38-,39-,40-/m0/s1
DMUW87A CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C3=CC=CC=C3
DMUW87A IK OBDOGETZOBOLDY-GCFINZEGSA-N
DMUW87A IU N-[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S,3S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]benzamide
DMUW87A DE Discovery agent
DMU13BY ID DMU13BY
DMU13BY DN BzT-7
DMU13BY HS Investigative
DMU13BY SN CHEMBL1958337; 8-Chloro-1,4-Dimethyl-6-Phenyl-4h-[1,2,4]triazolo[4,3-A][1,3,4]benzotriazepine; BzT-7; 3u5l; GTPL7515; SCHEMBL11468349; UYIVCPRWMLOCSB-UHFFFAOYSA-N; BDBM50365263; 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4)benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a)(1,3,4 )benzotriazepine; 8-chloro-1,4-dimethyl-6-phenyl-4H-s-triazolo(4,3-a) (1,3,4)benzotriazepine
DMU13BY DT Small molecular drug
DMU13BY PC 20350618
DMU13BY MW 323.8
DMU13BY FM C17H14ClN5
DMU13BY IC InChI=1S/C17H14ClN5/c1-11-19-20-17-22(2)21-16(12-6-4-3-5-7-12)14-10-13(18)8-9-15(14)23(11)17/h3-10H,1-2H3
DMU13BY CS CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NN2C)C4=CC=CC=C4
DMU13BY IK UYIVCPRWMLOCSB-UHFFFAOYSA-N
DMU13BY IU 8-chloro-1,4-dimethyl-6-phenyl-[1,2,4]triazolo[4,3-a][1,3,4]benzotriazepine
DMU13BY DE Discovery agent
DMA0GSY ID DMA0GSY
DMA0GSY DN BZYX
DMA0GSY HS Investigative
DMA0GSY SN Acetylcholinesterase inhibitors (neurodegenerative disease), Zhejiang University
DMA0GSY CP Zhejiang University
DMA0GSY DE Neurodegenerative disorder
DMMPXHQ ID DMMPXHQ
DMMPXHQ DN C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide
DMMPXHQ HS Investigative
DMMPXHQ DE Discovery agent
DMDLK9G ID DMDLK9G
DMDLK9G DN C-(1H-Indol-3-yl)-methylamine
DMDLK9G HS Investigative
DMDLK9G SN (1H-Indol-3-yl)methanamine; 22259-53-6; 1H-Indole-3-methanamine; 3-(aminomethyl)indole; 1H-indol-3-ylmethanamine; Indol-3-ylmethylamine; 1H-Indol-3-ylmethylamine; 3-aminomethylindole; CHEBI:65009; CHEMBL6509; C-(1H-Indol-3-yl)-methylamine; 3-Indolylmethylamine; Indole-3-methanamine; 3-Aminomethyl indole; AC1LAOER; 3-(aminomethyl) indole; 1H-indol-3-ylmethyl amine; Indole, 3-(aminomethyl)-; 1H-indol-3-yl-methyl-amine; SCHEMBL701395; AC1Q548H; C-(1H-indol-3-yl)methylamine; 1-(1H-indol-3-yl)methanamine; JXYGLMATGAAIBU-UHFFFAOYSA-
DMDLK9G DT Small molecular drug
DMDLK9G PC 472107
DMDLK9G MW 146.19
DMDLK9G FM C9H10N2
DMDLK9G IC InChI=1S/C9H10N2/c10-5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5,10H2
DMDLK9G CS C1=CC=C2C(=C1)C(=CN2)CN
DMDLK9G IK JXYGLMATGAAIBU-UHFFFAOYSA-N
DMDLK9G IU 1H-indol-3-ylmethanamine
DMDLK9G CA CAS 22259-53-6
DMDLK9G CB CHEBI:65009
DMDLK9G DE Discovery agent
DM3VF9M ID DM3VF9M
DM3VF9M DN C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide
DM3VF9M HS Investigative
DM3VF9M SN C-(1-HYDROGYL-BETA-D-GLUCOPYRANOSYL) FORMAMIDE; CBF; alpha-D-gluco-2-Heptulopyranosonamide; AC1L9L7Q; DB02719; 361440-32-6; (1-Hydroxy-beta-D-glucopyranosyl)formamide; (2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxane-2-carboxamide; (2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxamide (non-preferred name)
DM3VF9M DT Small molecular drug
DM3VF9M PC 447771
DM3VF9M MW 223.18
DM3VF9M FM C7H13NO7
DM3VF9M IC InChI=1S/C7H13NO7/c8-6(13)7(14)5(12)4(11)3(10)2(1-9)15-7/h2-5,9-12,14H,1H2,(H2,8,13)/t2-,3-,4+,5-,7-/m1/s1
DM3VF9M CS C([C@@H]1[C@H]([C@@H]([C@H]([C@@](O1)(C(=O)N)O)O)O)O)O
DM3VF9M IK DTZYCNDAJQDPQC-UHKLXPPTSA-N
DM3VF9M IU (2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxane-2-carboxamide
DM3VF9M CA CAS 361440-32-6
DM3VF9M DE Discovery agent
DMNMYWI ID DMNMYWI
DMNMYWI DN C-(2'-Chloro-biphenyl-2-yl)-methylamine
DMNMYWI HS Investigative
DMNMYWI SN CHEMBL206496; 2'-Chlorobiphenyl-2-methylamine; [2-(2-chlorophenyl)phenyl]methanamine; AC1LRCRY; SCHEMBL6862516; BDBM50178431; AKOS010258410; 876170-46-6
DMNMYWI DT Small molecular drug
DMNMYWI PC 1393052
DMNMYWI MW 217.69
DMNMYWI FM C13H12ClN
DMNMYWI IC InChI=1S/C13H12ClN/c14-13-8-4-3-7-12(13)11-6-2-1-5-10(11)9-15/h1-8H,9,15H2
DMNMYWI CS C1=CC=C(C(=C1)CN)C2=CC=CC=C2Cl
DMNMYWI IK CQHFRBPHEMVDPT-UHFFFAOYSA-N
DMNMYWI IU [2-(2-chlorophenyl)phenyl]methanamine
DMNMYWI DE Discovery agent
DM0VKFO ID DM0VKFO
DM0VKFO DN C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine
DM0VKFO HS Investigative
DM0VKFO SN 2CB-Ind; CHEMBL424890; 912342-23-5; C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine; DTXSID70582080; BDBM50194751; 1H-Indene-1-methanamine, 5-bromo-2,3-dihydro-4,7-dimethoxy-
DM0VKFO DT Small molecular drug
DM0VKFO PC 16086368
DM0VKFO MW 286.16
DM0VKFO FM C12H16BrNO2
DM0VKFO IC InChI=1S/C12H16BrNO2/c1-15-10-5-9(13)12(16-2)8-4-3-7(6-14)11(8)10/h5,7H,3-4,6,14H2,1-2H3
DM0VKFO CS COC1=CC(=C(C2=C1C(CC2)CN)OC)Br
DM0VKFO IK HCLPGYNQMVSQIM-UHFFFAOYSA-N
DM0VKFO IU (5-bromo-4,7-dimethoxy-2,3-dihydro-1H-inden-1-yl)methanamine
DM0VKFO CA CAS 912342-23-5
DM0VKFO DE Discovery agent
DMDHVY0 ID DMDHVY0
DMDHVY0 DN C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine
DMDHVY0 HS Investigative
DMDHVY0 SN CHEMBL46619; AC1L4MLR; C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine; SCHEMBL11335219; CTK7E4003; BKZVRYQHIBSITO-UHFFFAOYSA-N; ZINC3622666; BDBM50097217; 5-aminomethyl-5H-dibenzo[a,d]cycloheptene; 5H-Dibenzo[a,d]cycloheptene-5-methanamine
DMDHVY0 DT Small molecular drug
DMDHVY0 PC 209436
DMDHVY0 MW 221.3
DMDHVY0 FM C16H15N
DMDHVY0 IC InChI=1S/C16H15N/c17-11-16-14-7-3-1-5-12(14)9-10-13-6-2-4-8-15(13)16/h1-10,16H,11,17H2
DMDHVY0 CS C1=CC=C2C(C3=CC=CC=C3C=CC2=C1)CN
DMDHVY0 IK BKZVRYQHIBSITO-UHFFFAOYSA-N
DMDHVY0 IU 2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylmethanamine
DMDHVY0 DE Discovery agent
DMJ6SYI ID DMJ6SYI
DMJ6SYI DN C-(6-Methoxy-naphthalen-1-yl)-methylamine
DMJ6SYI HS Investigative
DMJ6SYI SN CHEMBL131412; 57382-44-2; 6-methoxy-1-naphthalenemethanamine; C-(6-Methoxy-naphthalen-1-yl)-methylamine; SCHEMBL15345391; BDBM50061312; 1-(Aminomethyl)-6-methoxynaphthalene; 6-Methoxynaphthalene-1-(methanamine)
DMJ6SYI DT Small molecular drug
DMJ6SYI PC 44352202
DMJ6SYI MW 187.24
DMJ6SYI FM C12H13NO
DMJ6SYI IC InChI=1S/C12H13NO/c1-14-11-5-6-12-9(7-11)3-2-4-10(12)8-13/h2-7H,8,13H2,1H3
DMJ6SYI CS COC1=CC2=C(C=C1)C(=CC=C2)CN
DMJ6SYI IK HOVVWANIDLIBGI-UHFFFAOYSA-N
DMJ6SYI IU (6-methoxynaphthalen-1-yl)methanamine
DMJ6SYI DE Discovery agent
DMDMA4Z ID DMDMA4Z
DMDMA4Z DN C-(9H-Thioxanthen-9-yl)-methylamine
DMDMA4Z HS Investigative
DMDMA4Z SN CHEMBL152509; (9H-thioxanthen-9-ylmethyl)amine; C-(9H-Thioxanthen-9-yl)-methylamine; 9H-Thioxanthene-9-methanamine; SCHEMBL7001557; ZINC6928031; BDBM50097225
DMDMA4Z DT Small molecular drug
DMDMA4Z PC 13167699
DMDMA4Z MW 227.33
DMDMA4Z FM C14H13NS
DMDMA4Z IC InChI=1S/C14H13NS/c15-9-12-10-5-1-3-7-13(10)16-14-8-4-2-6-11(12)14/h1-8,12H,9,15H2
DMDMA4Z CS C1=CC=C2C(=C1)C(C3=CC=CC=C3S2)CN
DMDMA4Z IK MYNBESFWFGVQQB-UHFFFAOYSA-N
DMDMA4Z IU 9H-thioxanthen-9-ylmethanamine
DMDMA4Z DE Discovery agent
DMN5YOR ID DMN5YOR
DMN5YOR DN C-(9H-Xanthen-9-yl)-methylamine
DMN5YOR HS Investigative
DMN5YOR SN 100866-28-2; XANTHENE-9-METHYLAMINE; 9H-Xanthene-9-methanamine; CHEMBL155276; 1-(9H-Xanthen-9-yl)methanamine; C-(9H-Xanthen-9-yl)-methylamine; 9-aminomethylxanthene; ACMC-20m3ww; 9-AMINOMETHYL XANTHENE; SCHEMBL4667689; CTK0H2362; DTXSID20576237; VYDDHEPARBFMGU-UHFFFAOYSA-N; ZINC21984468; BDBM50097214; AKOS015152152; (9H-XANTHEN-9-YL)METHANAMINE; AB24946
DMN5YOR DT Small molecular drug
DMN5YOR PC 15645577
DMN5YOR MW 211.26
DMN5YOR FM C14H13NO
DMN5YOR IC InChI=1S/C14H13NO/c15-9-12-10-5-1-3-7-13(10)16-14-8-4-2-6-11(12)14/h1-8,12H,9,15H2
DMN5YOR CS C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)CN
DMN5YOR IK VYDDHEPARBFMGU-UHFFFAOYSA-N
DMN5YOR IU 9H-xanthen-9-ylmethanamine
DMN5YOR CA CAS 100866-28-2
DMN5YOR DE Discovery agent
DMHNZGP ID DMHNZGP
DMHNZGP DN C(Arg-Gly-Asp-D-Phe-Val)
DMHNZGP HS Investigative
DMHNZGP SN CHEMBL383412
DMHNZGP DT Small molecular drug
DMHNZGP PC 44411994
DMHNZGP MW 574.6
DMHNZGP FM C26H38N8O7
DMHNZGP IC InChI=1S/C26H38N8O7/c1-14(2)21-25(41)32-16(9-6-10-29-26(27)28)22(38)30-13-19(35)31-18(12-20(36)37)23(39)33-17(24(40)34-21)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18,21H,6,9-13H2,1-2H3,(H,30,38)(H,31,35)(H,32,41)(H,33,39)(H,34,40)(H,36,37)(H4,27,28,29)/t16-,17+,18-,21?/m0/s1
DMHNZGP CS CC(C)C1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMHNZGP IK YYQUWEHEBOMRPH-YQMJFVBQSA-N
DMHNZGP IU 2-[(2S,5R,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMHNZGP DE Discovery agent
DMTMJAI ID DMTMJAI
DMTMJAI DN C(-GRGDfL-)
DMTMJAI HS Investigative
DMTMJAI SN CHEMBL235999
DMTMJAI DT Small molecular drug
DMTMJAI PC 15409414
DMTMJAI MW 645.7
DMTMJAI FM C29H43N9O8
DMTMJAI IC InChI=1S/C29H43N9O8/c1-16(2)11-19-26(44)34-14-22(39)35-18(9-6-10-32-29(30)31)25(43)33-15-23(40)36-21(13-24(41)42)28(46)38-20(27(45)37-19)12-17-7-4-3-5-8-17/h3-5,7-8,16,18-21H,6,9-15H2,1-2H3,(H,33,43)(H,34,44)(H,35,39)(H,36,40)(H,37,45)(H,38,46)(H,41,42)(H4,30,31,32)/t18-,19-,20+,21-/m0/s1
DMTMJAI CS CC(C)C[C@H]1C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMTMJAI IK VRTNUMBPIBDYLD-BURNTYAHSA-N
DMTMJAI IU 2-[(2S,5R,8S,14S)-5-benzyl-14-[3-(diaminomethylideneamino)propyl]-8-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetic acid
DMTMJAI DE Discovery agent
DMSLYHQ ID DMSLYHQ
DMSLYHQ DN C(his-D-phe-arg-trp-Abu)
DMSLYHQ HS Investigative
DMSLYHQ SN CHEMBL379531
DMSLYHQ DT Small molecular drug
DMSLYHQ PC 44413577
DMSLYHQ MW 711.8
DMSLYHQ FM C36H45N11O5
DMSLYHQ IC InChI=1S/C36H45N11O5/c37-36(38)41-15-6-12-27-33(50)47-29(17-23-19-42-26-11-5-4-10-25(23)26)32(49)40-14-7-13-31(48)44-30(18-24-20-39-21-43-24)35(52)46-28(34(51)45-27)16-22-8-2-1-3-9-22/h1-5,8-11,19-21,27-30,42H,6-7,12-18H2,(H,39,43)(H,40,49)(H,44,48)(H,45,51)(H,46,52)(H,47,50)(H4,37,38,41)/t27-,28+,29-,30+/m0/s1
DMSLYHQ CS C1CC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC1)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMSLYHQ IK IYMUEULNOLBKRK-RRGQHJHPSA-N
DMSLYHQ IU 2-[3-[(3S,6S,9R,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacycloheptadec-6-yl]propyl]guanidine
DMSLYHQ DE Discovery agent
DM0IJFZ ID DM0IJFZ
DM0IJFZ DN C(his-D-phe-arg-trp-Ahp)
DM0IJFZ HS Investigative
DM0IJFZ SN CHEMBL379959
DM0IJFZ DT Small molecular drug
DM0IJFZ PC 44413536
DM0IJFZ MW 753.9
DM0IJFZ FM C39H51N11O5
DM0IJFZ IC InChI=1S/C39H51N11O5/c40-39(41)44-18-10-15-30-36(53)50-32(20-26-22-45-29-14-8-7-13-28(26)29)35(52)43-17-9-2-1-6-16-34(51)47-33(21-27-23-42-24-46-27)38(55)49-31(37(54)48-30)19-25-11-4-3-5-12-25/h3-5,7-8,11-14,22-24,30-33,45H,1-2,6,9-10,15-21H2,(H,42,46)(H,43,52)(H,47,51)(H,48,54)(H,49,55)(H,50,53)(H4,40,41,44)/t30-,31+,32+,33+/m0/s1
DM0IJFZ CS C1CCCNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)CC1)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54
DM0IJFZ IK YQBUXOUSHPXETO-LDLFXXLYSA-N
DM0IJFZ IU 2-[3-[(3R,6S,9R,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacycloicos-6-yl]propyl]guanidine
DM0IJFZ DE Discovery agent
DMJKHAB ID DMJKHAB
DMJKHAB DN C(his-D-phe-arg-trp-Ahx)
DMJKHAB HS Investigative
DMJKHAB SN CHEMBL379627; c(his-D-phe-arg-trp-Ahx)
DMJKHAB DT Small molecular drug
DMJKHAB PC 44413537
DMJKHAB MW 739.9
DMJKHAB FM C38H49N11O5
DMJKHAB IC InChI=1S/C38H49N11O5/c39-38(40)43-17-9-14-29-35(52)49-31(19-25-21-44-28-13-7-6-12-27(25)28)34(51)42-16-8-2-5-15-33(50)46-32(20-26-22-41-23-45-26)37(54)48-30(36(53)47-29)18-24-10-3-1-4-11-24/h1,3-4,6-7,10-13,21-23,29-32,44H,2,5,8-9,14-20H2,(H,41,45)(H,42,51)(H,46,50)(H,47,53)(H,48,54)(H,49,52)(H4,39,40,43)/t29-,30+,31-,32+/m0/s1
DMJKHAB CS C1CCC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC1)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMJKHAB IK NKDXCOMNRCSRHU-MLMSKLGMSA-N
DMJKHAB IU 2-[3-[(3S,6S,9R,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclononadec-6-yl]propyl]guanidine
DMJKHAB DE Discovery agent
DM5NQUA ID DM5NQUA
DM5NQUA DN C(his-D-phe-arg-trp-Aoc)
DM5NQUA HS Investigative
DM5NQUA SN CHEMBL264120
DM5NQUA DT Small molecular drug
DM5NQUA PC 44413535
DM5NQUA MW 738.9
DM5NQUA FM C40H54N10O4
DM5NQUA IC InChI=1S/C40H54N10O4/c41-40(42)44-19-11-16-33-38(53)50-34(21-28-23-45-32-15-10-9-14-31(28)32)36(51)17-7-2-1-3-8-18-37(52)48-30(22-29-24-43-26-47-29)25-46-35(39(54)49-33)20-27-12-5-4-6-13-27/h4-6,9-10,12-15,23-24,26,30,33-35,45-46H,1-3,7-8,11,16-22,25H2,(H,43,47)(H,48,52)(H,49,54)(H,50,53)(H4,41,42,44)/t30-,33-,34-,35-/m0/s1
DM5NQUA CS C1CCCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC[C@@H](NC(=O)CCC1)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54
DM5NQUA IK VFJZBZLGBBBPQI-RONNFESSSA-N
DM5NQUA IU 2-[3-[(3S,6S,9S,20S)-6-benzyl-9-(1H-imidazol-5-ylmethyl)-20-(1H-indol-3-ylmethyl)-2,5,11,19-tetraoxo-1,4,7,10-tetrazacycloicos-3-yl]propyl]guanidine
DM5NQUA DE Discovery agent
DMEC2PH ID DMEC2PH
DMEC2PH DN C(his-L-phe-arg-trp-Aoc)
DMEC2PH HS Investigative
DMEC2PH SN CHEMBL211131
DMEC2PH DT Small molecular drug
DMEC2PH PC 44413592
DMEC2PH MW 767.9
DMEC2PH FM C40H53N11O5
DMEC2PH IC InChI=1S/C40H53N11O5/c41-40(42)45-19-11-16-31-37(54)51-33(21-27-23-46-30-15-9-8-14-29(27)30)36(53)44-18-10-3-1-2-7-17-35(52)48-34(22-28-24-43-25-47-28)39(56)50-32(38(55)49-31)20-26-12-5-4-6-13-26/h4-6,8-9,12-15,23-25,31-34,46H,1-3,7,10-11,16-22H2,(H,43,47)(H,44,53)(H,48,52)(H,49,55)(H,50,56)(H,51,54)(H4,41,42,45)/t31-,32-,33-,34+/m0/s1
DMEC2PH CS C1CCCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCCC1)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DMEC2PH IK KYHILABVVZODQF-GZXHTMMISA-N
DMEC2PH IU 2-[3-[(3S,6S,9S,12R)-9-benzyl-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohenicos-6-yl]propyl]guanidine
DMEC2PH DE Discovery agent
DMMBESU ID DMMBESU
DMMBESU DN C(RGDfF)
DMMBESU HS Investigative
DMMBESU SN CHEMBL380434
DMMBESU DT Small molecular drug
DMMBESU PC 10699123
DMMBESU MW 622.7
DMMBESU FM C30H38N8O7
DMMBESU IC InChI=1S/C30H38N8O7/c31-30(32)33-13-7-12-20-26(42)34-17-24(39)35-23(16-25(40)41)29(45)38-22(15-19-10-5-2-6-11-19)28(44)37-21(27(43)36-20)14-18-8-3-1-4-9-18/h1-6,8-11,20-23H,7,12-17H2,(H,34,42)(H,35,39)(H,36,43)(H,37,44)(H,38,45)(H,40,41)(H4,31,32,33)/t20-,21-,22+,23-/m0/s1
DMMBESU CS C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC=CC=C2)CC3=CC=CC=C3)CC(=O)O
DMMBESU IK VYLBOUQMYNRGBR-GPJHCHHRSA-N
DMMBESU IU 2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMMBESU DE Discovery agent
DM8DU42 ID DM8DU42
DM8DU42 DN C(RGDfMeF)
DM8DU42 HS Investigative
DM8DU42 SN CHEMBL383747
DM8DU42 DT Small molecular drug
DM8DU42 PC 44408450
DM8DU42 MW 636.7
DM8DU42 FM C31H40N8O7
DM8DU42 IC InChI=1S/C31H40N8O7/c1-39-24(16-20-11-6-3-7-12-20)29(45)37-21(13-8-14-34-31(32)33)27(43)35-18-25(40)36-22(17-26(41)42)28(44)38-23(30(39)46)15-19-9-4-2-5-10-19/h2-7,9-12,21-24H,8,13-18H2,1H3,(H,35,43)(H,36,40)(H,37,45)(H,38,44)(H,41,42)(H4,32,33,34)/t21-,22-,23+,24-/m0/s1
DM8DU42 CS CN1[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C1=O)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N)CC3=CC=CC=C3
DM8DU42 IK ZILGGGDRKNJYPR-XQUALCHDSA-N
DM8DU42 IU 2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM8DU42 DE Discovery agent
DMY2NU8 ID DMY2NU8
DMY2NU8 DN C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine
DMY2NU8 HS Investigative
DMY2NU8 SN CHEMBL292558; C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine; BDBM50127603
DMY2NU8 DT Small molecular drug
DMY2NU8 PC 10942498
DMY2NU8 MW 137.18
DMY2NU8 FM C7H11N3
DMY2NU8 IC InChI=1S/C7H11N3/c8-2-5-1-6(5)7-3-9-4-10-7/h3-6H,1-2,8H2,(H,9,10)/t5-,6+/m1/s1
DMY2NU8 CS C1[C@@H]([C@H]1C2=CN=CN2)CN
DMY2NU8 IK LMFNLINKCDGRTE-RITPCOANSA-N
DMY2NU8 IU [(1S,2S)-2-(1H-imidazol-5-yl)cyclopropyl]methanamine
DMY2NU8 DE Discovery agent
DMPOIDK ID DMPOIDK
DMPOIDK DN C[-Arg-Gly-Asp-Acpca19-]
DMPOIDK HS Investigative
DMPOIDK SN CHEMBL539338
DMPOIDK DT Small molecular drug
DMPOIDK PC 11569720
DMPOIDK MW 471.5
DMPOIDK FM C18H29N7O8
DMPOIDK IC InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8-,9+,10-,13-,14-/m0/s1
DMPOIDK CS C1[C@H]2[C@@H]([C@H]([C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DMPOIDK IK VNLGSUKLIVHSOW-NDCHHBOESA-N
DMPOIDK IU 2-[(1R,4S,10S,13S,14S,15S)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMPOIDK DE Discovery agent
DMJVW1N ID DMJVW1N
DMJVW1N DN C[-Arg-Gly-Asp-Acpca20-]
DMJVW1N HS Investigative
DMJVW1N SN CHEMBL540618
DMJVW1N DT Small molecular drug
DMJVW1N PC 11656381
DMJVW1N MW 471.5
DMJVW1N FM C18H29N7O8
DMJVW1N IC InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8-,9+,10-,13+,14-/m0/s1
DMJVW1N CS C1[C@H]2[C@H]([C@H]([C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DMJVW1N IK VNLGSUKLIVHSOW-RNSQFEBMSA-N
DMJVW1N IU 2-[(1R,4S,10S,13S,14R,15S)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMJVW1N DE Discovery agent
DMXCUDV ID DMXCUDV
DMXCUDV DN C[-Arg-Gly-Asp-Acpca21-]
DMXCUDV HS Investigative
DMXCUDV SN CHEMBL534711
DMXCUDV DT Small molecular drug
DMXCUDV PC 11613122
DMXCUDV MW 471.5
DMXCUDV FM C18H29N7O8
DMXCUDV IC InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8+,9+,10+,13-,14-/m1/s1
DMXCUDV CS C1[C@@H]2[C@H]([C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DMXCUDV IK VNLGSUKLIVHSOW-KOWOESDJSA-N
DMXCUDV IU 2-[(1S,4S,10S,13R,14R,15R)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMXCUDV DE Discovery agent
DM6DV90 ID DM6DV90
DM6DV90 DN C[-Arg-Gly-Asp-Acpca22-]
DM6DV90 HS Investigative
DM6DV90 SN CHEMBL539850
DM6DV90 DT Small molecular drug
DM6DV90 PC 11540715
DM6DV90 MW 471.5
DM6DV90 FM C18H29N7O8
DM6DV90 IC InChI=1S/C18H29N7O8/c19-18(20)21-3-1-2-8-16(32)22-6-11(26)23-10(5-12(27)28)17(33)25-9-4-7(15(31)24-8)13(29)14(9)30/h7-10,13-14,29-30H,1-6H2,(H,22,32)(H,23,26)(H,24,31)(H,25,33)(H,27,28)(H4,19,20,21)/t7-,8+,9+,10+,13+,14-/m1/s1
DM6DV90 CS C1[C@@H]2[C@@H]([C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O)O
DM6DV90 IK VNLGSUKLIVHSOW-BDDFMHDSSA-N
DM6DV90 IU 2-[(1S,4S,10S,13R,14S,15R)-10-[3-(diaminomethylideneamino)propyl]-14,15-dihydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DM6DV90 DE Discovery agent
DML0U8B ID DML0U8B
DML0U8B DN C-[-Arg-Gly-Asp-Acpca30-]
DML0U8B HS Investigative
DML0U8B SN CHEMBL540622
DML0U8B DT Small molecular drug
DML0U8B PC 11712622
DML0U8B MW 439.5
DML0U8B FM C18H29N7O6
DML0U8B IC InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10+,11+,12+/m1/s1
DML0U8B CS C1C[C@H]2C[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DML0U8B IK SLTMEZLQPRTTBL-RHYQMDGZSA-N
DML0U8B IU 2-[(1S,4S,10S,13R)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DML0U8B DE Discovery agent
DMKENFU ID DMKENFU
DMKENFU DN C-[-Arg-Gly-Asp-Acpca31-]
DMKENFU HS Investigative
DMKENFU SN CHEMBL534934
DMKENFU DT Small molecular drug
DMKENFU PC 11533023
DMKENFU MW 439.5
DMKENFU FM C18H29N7O6
DMKENFU IC InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10+,11-,12-/m0/s1
DMKENFU CS C1C[C@@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMKENFU IK SLTMEZLQPRTTBL-USZNOCQGSA-N
DMKENFU IU 2-[(1R,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMKENFU DE Discovery agent
DMVM7B2 ID DMVM7B2
DMVM7B2 DN C-[-Arg-Gly-Asp-Acpca32-]
DMVM7B2 HS Investigative
DMVM7B2 SN CHEMBL556402
DMVM7B2 DT Small molecular drug
DMVM7B2 PC 11583738
DMVM7B2 MW 439.5
DMVM7B2 FM C18H29N7O6
DMVM7B2 IC InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10-,11+,12+/m1/s1
DMVM7B2 CS C1C[C@@H]2C[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMVM7B2 IK SLTMEZLQPRTTBL-WYUUTHIRSA-N
DMVM7B2 IU 2-[(1R,4S,10S,13R)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMVM7B2 DE Discovery agent
DMIBGWO ID DMIBGWO
DMIBGWO DN C-[-Arg-Gly-Asp-Acpca33-]
DMIBGWO HS Investigative
DMIBGWO SN CHEMBL534712
DMIBGWO DT Small molecular drug
DMIBGWO PC 11670104
DMIBGWO MW 439.5
DMIBGWO FM C18H29N7O6
DMIBGWO IC InChI=1S/C18H29N7O6/c19-18(20)21-5-1-2-11-16(30)22-8-13(26)24-12(7-14(27)28)17(31)23-10-4-3-9(6-10)15(29)25-11/h9-12H,1-8H2,(H,22,30)(H,23,31)(H,24,26)(H,25,29)(H,27,28)(H4,19,20,21)/t9-,10-,11-,12-/m0/s1
DMIBGWO CS C1C[C@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMIBGWO IK SLTMEZLQPRTTBL-BJDJZHNGSA-N
DMIBGWO IU 2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMIBGWO DE Discovery agent
DMKHSAV ID DMKHSAV
DMKHSAV DN C[-Arg-Gly-Asp-Acpca34-]
DMKHSAV HS Investigative
DMKHSAV SN CHEMBL534933
DMKHSAV DT Small molecular drug
DMKHSAV PC 11584047
DMKHSAV MW 455.5
DMKHSAV FM C18H29N7O7
DMKHSAV IC InChI=1S/C18H29N7O7/c19-18(20)21-3-1-2-9-16(31)22-7-13(27)23-11(6-14(28)29)17(32)25-10-4-8(5-12(10)26)15(30)24-9/h8-12,26H,1-7H2,(H,22,31)(H,23,27)(H,24,30)(H,25,32)(H,28,29)(H4,19,20,21)/t8-,9-,10-,11-,12-/m0/s1
DMKHSAV CS C1[C@H]2C[C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O
DMKHSAV IK CFCPTSHVAOVLJR-HTFCKZLJSA-N
DMKHSAV IU 2-[(1S,4S,10S,13S,15S)-10-[3-(diaminomethylideneamino)propyl]-15-hydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMKHSAV DE Discovery agent
DMQOY3J ID DMQOY3J
DMQOY3J DN C[-Arg-Gly-Asp-Acpca35-]
DMQOY3J HS Investigative
DMQOY3J SN CHEMBL534713
DMQOY3J DT Small molecular drug
DMQOY3J PC 11540460
DMQOY3J MW 455.5
DMQOY3J FM C18H29N7O7
DMQOY3J IC InChI=1S/C18H29N7O7/c19-18(20)21-3-1-2-9-16(31)22-7-13(27)23-11(6-14(28)29)17(32)25-10-4-8(5-12(10)26)15(30)24-9/h8-12,26H,1-7H2,(H,22,31)(H,23,27)(H,24,30)(H,25,32)(H,28,29)(H4,19,20,21)/t8-,9-,10+,11-,12+/m0/s1
DMQOY3J CS C1[C@H]2C[C@H]([C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O
DMQOY3J IK CFCPTSHVAOVLJR-HHHUOAJASA-N
DMQOY3J IU 2-[(1R,4S,10S,13S,15R)-10-[3-(diaminomethylideneamino)propyl]-15-hydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMQOY3J DE Discovery agent
DM7LCPW ID DM7LCPW
DM7LCPW DN C[-Arg-Gly-Asp-Acpca36-]
DM7LCPW HS Investigative
DM7LCPW SN CHEMBL557157
DM7LCPW DT Small molecular drug
DM7LCPW PC 11518823
DM7LCPW MW 455.5
DM7LCPW FM C18H29N7O7
DM7LCPW IC InChI=1S/C18H29N7O7/c19-18(20)21-3-1-2-9-16(31)22-7-13(27)23-11(6-14(28)29)17(32)25-10-4-8(5-12(10)26)15(30)24-9/h8-12,26H,1-7H2,(H,22,31)(H,23,27)(H,24,30)(H,25,32)(H,28,29)(H4,19,20,21)/t8-,9+,10+,11+,12+/m1/s1
DM7LCPW CS C1[C@@H]2C[C@@H]([C@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)O
DM7LCPW IK CFCPTSHVAOVLJR-DGORSVRFSA-N
DM7LCPW IU 2-[(1S,4S,10S,13R,15S)-10-[3-(diaminomethylideneamino)propyl]-15-hydroxy-3,6,9,12-tetraoxo-2,5,8,11-tetrazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DM7LCPW DE Discovery agent
DMISP20 ID DMISP20
DMISP20 DN C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2
DMISP20 HS Investigative
DMISP20 PC 91935394
DMISP20 MW 3380.7
DMISP20 FM C152H227N41O47
DMISP20 IC InChI=1S/C152H227N41O47/c1-16-77(10)122(149(238)170-80(13)127(216)178-104(59-86-63-162-91-35-24-23-34-89(86)91)138(227)180-100(55-74(4)5)140(229)190-120(75(6)7)147(236)177-93(36-25-27-51-153)130(219)165-67-114(204)171-92(38-29-53-161-152(157)158)129(218)163-65-111(156)201)192-141(230)102(56-83-30-19-17-20-31-83)181-134(223)97(45-49-117(208)209)174-133(222)94-37-26-28-52-160-112(202)61-105(139(228)175-96(43-47-110(155)200)132(221)169-78(11)125(214)168-79(12)126(215)173-94)183-135(224)98(46-50-118(210)211)176-136(225)99(54-73(2)3)179-137(226)101(58-85-39-41-88(199)42-40-85)182-144(233)107(69-194)186-146(235)109(71-196)187-148(237)121(76(8)9)191-143(232)106(62-119(212)213)184-145(234)108(70-195)188-151(240)124(82(15)198)193-142(231)103(57-84-32-21-18-22-33-84)185-150(239)123(81(14)197)189-115(205)68-166-131(220)95(44-48-116(206)207)172-113(203)66-164-128(217)90(154)60-87-64-159-72-167-87/h17-24,30-35,39-42,63-64,72-82,90,92-109,120-124,162,194-199H,16,25-29,36-38,43-62,65-71,153-154H2,1-15H3,(H2,155,200)(H2,156,201)(H,159,167)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,220)(H,168,214)(H,169,221)(H,170,238)(H,171,204)(H,172,203)(H,173,215)(H,174,222)(H,175,228)(H,176,225)(H,177,236)(H,178,216)(H,179,226)(H,180,227)(H,181,223)(H,182,233)(H,183,224)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,205)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,157,158,161)/t77-,78-,79-,80-,81-,82-,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,120-,121-,122-,123-,124-/m0/s1
DMISP20 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMISP20 IK XYYFVCKJZJFHBW-NINLSKNRSA-N
DMISP20 IU (4S)-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,12S,20S)-20-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-9-(3-amino-3-oxopropyl)-3,6-dimethyl-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacycloicos-12-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMISP20 DE Discovery agent
DMHARQX ID DMHARQX
DMHARQX DN C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX HS Investigative
DMHARQX SN CHEMBL267265; c[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2
DMHARQX DT Small molecular drug
DMHARQX PC 44445085
DMHARQX MW 880
DMHARQX FM C46H61N11O7
DMHARQX IC InChI=1S/C46H61N11O7/c47-34-14-5-3-12-32(58)20-21-40(59)51-22-8-7-16-36(41(48)60)54-45(64)39(26-31-27-53-35-15-6-4-13-33(31)35)57-43(62)37(17-9-23-52-46(49)50)55-44(63)38(56-42(34)61)25-28-18-19-29-10-1-2-11-30(29)24-28/h1-2,4,6,10-11,13,15,18-19,24,27,34,36-39,53H,3,5,7-9,12,14,16-17,20-23,25-26,47H2,(H2,48,60)(H,51,59)(H,54,64)(H,55,63)(H,56,61)(H,57,62)(H4,49,50,52)/t34-,36-,37-,38+,39-/m0/s1
DMHARQX CS C1CCC(=O)CCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](C1)N)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N
DMHARQX IK KDTZLQMUHBEBMZ-OUBWENQOSA-N
DMHARQX IU (2R,5S,8S,11S,25S)-25-amino-5-[3-(diaminomethylideneamino)propyl]-8-(1H-indol-3-ylmethyl)-2-(naphthalen-2-ylmethyl)-3,6,9,17,20,26-hexaoxo-1,4,7,10,16-pentazacyclohexacosane-11-carboxamide
DMHARQX DE Discovery agent
DMI3CSJ ID DMI3CSJ
DMI3CSJ DN C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ HS Investigative
DMI3CSJ SN CHEMBL411391; c[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2
DMI3CSJ DT Small molecular drug
DMI3CSJ PC 44445084
DMI3CSJ MW 830
DMI3CSJ FM C42H59N11O7
DMI3CSJ IC InChI=1S/C42H59N11O7/c43-30-15-6-4-13-28(54)19-20-36(55)47-21-9-8-17-32(37(44)56)50-41(60)35(24-27-25-49-31-16-7-5-14-29(27)31)53-39(58)33(18-10-22-48-42(45)46)51-40(59)34(52-38(30)57)23-26-11-2-1-3-12-26/h1-3,5,7,11-12,14,16,25,30,32-35,49H,4,6,8-10,13,15,17-24,43H2,(H2,44,56)(H,47,55)(H,50,60)(H,51,59)(H,52,57)(H,53,58)(H4,45,46,48)/t30-,32-,33-,34+,35-/m0/s1
DMI3CSJ CS C1CCC(=O)CCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](C1)N)CC2=CC=CC=C2)CCCN=C(N)N)CC3=CNC4=CC=CC=C43)C(=O)N
DMI3CSJ IK HWDXGLQUFJWIAC-DIWSUELLSA-N
DMI3CSJ IU (2R,5S,8S,11S,25S)-25-amino-2-benzyl-5-[3-(diaminomethylideneamino)propyl]-8-(1H-indol-3-ylmethyl)-3,6,9,17,20,26-hexaoxo-1,4,7,10,16-pentazacyclohexacosane-11-carboxamide
DMI3CSJ DE Discovery agent
DMYPHVC ID DMYPHVC
DMYPHVC DN C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC HS Investigative
DMYPHVC SN CHEMBL398665; c[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMYPHVC DT Small molecular drug
DMYPHVC PC 44445083
DMYPHVC MW 954.1
DMYPHVC FM C52H63N11O7
DMYPHVC IC InChI=1S/C52H63N11O7/c53-46(65)40-18-7-8-24-56-25-10-21-45(64)37-15-3-4-16-38(37)51(70)63-27-11-20-44(63)50(69)62-42(29-32-22-23-33-12-1-2-13-34(33)28-32)48(67)60-41(19-9-26-57-52(54)55)47(66)61-43(49(68)59-40)30-35-31-58-39-17-6-5-14-36(35)39/h1-6,12-17,22-23,28,31,40-44,56,58H,7-11,18-21,24-27,29-30H2,(H2,53,65)(H,59,68)(H,60,67)(H,61,66)(H,62,69)(H4,54,55,57)/t40-,41-,42+,43-,44-/m0/s1
DMYPHVC CS C1CCNCCCC(=O)C2=CC=CC=C2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC4=CNC5=CC=CC=C54)CCCN=C(N)N)CC6=CC7=CC=CC=C7C=C6
DMYPHVC IK YUUZCRILYWDWPO-PURVKFDZSA-N
DMYPHVC IU (7S,10R,13S,16S,19S)-13-[3-(diaminomethylideneamino)propyl]-16-(1H-indol-3-ylmethyl)-10-(naphthalen-2-ylmethyl)-2,8,11,14,17,28-hexaoxo-3,9,12,15,18,24-hexazatricyclo[27.4.0.03,7]tritriaconta-1(33),29,31-triene-19-carboxamide
DMYPHVC DE Discovery agent
DM0VP79 ID DM0VP79
DM0VP79 DN C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DM0VP79 HS Investigative
DM0VP79 SN CHEMBL398664; c[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DM0VP79 DT Small molecular drug
DM0VP79 PC 44445082
DM0VP79 MW 800
DM0VP79 FM C41H57N11O6
DM0VP79 IC InChI=1S/C41H57N11O6/c42-36(54)30-15-6-7-19-45-20-9-18-35(53)52-22-10-17-34(52)40(58)51-32(23-26-11-2-1-3-12-26)38(56)49-31(16-8-21-46-41(43)44)37(55)50-33(39(57)48-30)24-27-25-47-29-14-5-4-13-28(27)29/h1-5,11-14,25,30-34,45,47H,6-10,15-24H2,(H2,42,54)(H,48,57)(H,49,56)(H,50,55)(H,51,58)(H4,43,44,46)/t30-,31-,32+,33-,34-/m0/s1
DM0VP79 CS C1CCNCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DM0VP79 IK VFHJQMPJMWPJBF-UBLLTGQXSA-N
DM0VP79 IU (11S,14S,17S,20R,23S)-20-benzyl-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-2,13,16,19,22-pentaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxamide
DM0VP79 DE Discovery agent
DM1VCJP ID DM1VCJP
DM1VCJP DN C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP HS Investigative
DM1VCJP SN CHEMBL253789; c[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2
DM1VCJP DT Small molecular drug
DM1VCJP PC 24774438
DM1VCJP MW 816.9
DM1VCJP FM C42H48N12O6
DM1VCJP IC InChI=1S/C42H48N12O6/c43-36(55)30-12-5-6-16-48-40(59)34-35(47-19-18-46-34)41(60)54-32(21-24-14-15-25-8-1-2-9-26(25)20-24)38(57)52-31(13-7-17-49-42(44)45)37(56)53-33(39(58)51-30)22-27-23-50-29-11-4-3-10-28(27)29/h1-4,8-11,14-15,18-20,23,30-33,50H,5-7,12-13,16-17,21-22H2,(H2,43,55)(H,48,59)(H,51,58)(H,52,57)(H,53,56)(H,54,60)(H4,44,45,49)/t30-,31-,32+,33-/m0/s1
DM1VCJP CS C1CCNC(=O)C2=NC=CN=C2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC6=CC=CC=C6C=C5
DM1VCJP IK YIHQUVPRWHIYHB-SSNHPIBPSA-N
DM1VCJP IU (4R,7S,10S,13S)-7-[3-(diaminomethylideneamino)propyl]-10-(1H-indol-3-ylmethyl)-4-(naphthalen-2-ylmethyl)-2,5,8,11,19-pentaoxo-3,6,9,12,18,21,24-heptazabicyclo[18.4.0]tetracosa-1(24),20,22-triene-13-carboxamide
DM1VCJP DE Discovery agent
DM8AMGF ID DM8AMGF
DM8AMGF DN C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2
DM8AMGF HS Investigative
DM8AMGF SN CHEMBL438744; c[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2
DM8AMGF DT Small molecular drug
DM8AMGF PC 24774602
DM8AMGF MW 766.8
DM8AMGF FM C38H46N12O6
DM8AMGF IC InChI=1S/C38H46N12O6/c39-32(51)26-13-6-7-15-44-36(55)30-31(43-18-17-42-30)37(56)50-28(19-22-9-2-1-3-10-22)34(53)48-27(14-8-16-45-38(40)41)33(52)49-29(35(54)47-26)20-23-21-46-25-12-5-4-11-24(23)25/h1-5,9-12,17-18,21,26-29,46H,6-8,13-16,19-20H2,(H2,39,51)(H,44,55)(H,47,54)(H,48,53)(H,49,52)(H,50,56)(H4,40,41,45)/t26-,27-,28+,29-/m0/s1
DM8AMGF CS C1CCNC(=O)C2=NC=CN=C2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DM8AMGF IK JJPMYGFCLXEQSM-FKWFRFQNSA-N
DM8AMGF IU (4R,7S,10S,13S)-4-benzyl-7-[3-(diaminomethylideneamino)propyl]-10-(1H-indol-3-ylmethyl)-2,5,8,11,19-pentaoxo-3,6,9,12,18,21,24-heptazabicyclo[18.4.0]tetracosa-1(24),20,22-triene-13-carboxamide
DM8AMGF DE Discovery agent
DMD6OW4 ID DMD6OW4
DMD6OW4 DN C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4 HS Investigative
DMD6OW4 SN CHEMBL253788; c[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2
DMD6OW4 DT Small molecular drug
DMD6OW4 PC 24774519
DMD6OW4 MW 912
DMD6OW4 FM C49H57N11O7
DMD6OW4 IC InChI=1S/C49H57N11O7/c50-42(61)37-17-7-8-22-53-43(62)34-14-3-4-15-35(34)48(67)60-24-10-19-41(60)47(66)59-39(26-29-20-21-30-11-1-2-12-31(30)25-29)45(64)57-38(18-9-23-54-49(51)52)44(63)58-40(46(65)56-37)27-32-28-55-36-16-6-5-13-33(32)36/h1-6,11-16,20-21,25,28,37-41,55H,7-10,17-19,22-24,26-27H2,(H2,50,61)(H,53,62)(H,56,65)(H,57,64)(H,58,63)(H,59,66)(H4,51,52,54)/t37-,38-,39+,40-,41-/m0/s1
DMD6OW4 CS C1CCNC(=O)C2=CC=CC=C2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC4=CNC5=CC=CC=C54)CCCN=C(N)N)CC6=CC7=CC=CC=C7C=C6
DMD6OW4 IK VWRQHODLDKRSNP-LIZQXKDQSA-N
DMD6OW4 IU (7S,10R,13S,16S,19S)-13-[3-(diaminomethylideneamino)propyl]-16-(1H-indol-3-ylmethyl)-10-(naphthalen-2-ylmethyl)-2,8,11,14,17,25-hexaoxo-3,9,12,15,18,24-hexazatricyclo[24.4.0.03,7]triaconta-1(30),26,28-triene-19-carboxamide
DMD6OW4 DE Discovery agent
DMNKT8J ID DMNKT8J
DMNKT8J DN C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DMNKT8J HS Investigative
DMNKT8J SN CHEMBL253574; c[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2
DMNKT8J DT Small molecular drug
DMNKT8J PC 24774356
DMNKT8J MW 862
DMNKT8J FM C45H55N11O7
DMNKT8J IC InChI=1S/C45H55N11O7/c46-38(57)33-18-8-9-21-49-39(58)30-15-4-5-16-31(30)44(63)56-23-11-20-37(56)43(62)55-35(24-27-12-2-1-3-13-27)41(60)53-34(19-10-22-50-45(47)48)40(59)54-36(42(61)52-33)25-28-26-51-32-17-7-6-14-29(28)32/h1-7,12-17,26,33-37,51H,8-11,18-25H2,(H2,46,57)(H,49,58)(H,52,61)(H,53,60)(H,54,59)(H,55,62)(H4,47,48,50)/t33-,34-,35+,36-,37-/m0/s1
DMNKT8J CS C1CCNC(=O)C2=CC=CC=C2C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC4=CNC5=CC=CC=C54)CCCN=C(N)N)CC6=CC=CC=C6
DMNKT8J IK CLUDKTYPSAGGGT-GJOOVXBSSA-N
DMNKT8J IU (7S,10R,13S,16S,19S)-10-benzyl-13-[3-(diaminomethylideneamino)propyl]-16-(1H-indol-3-ylmethyl)-2,8,11,14,17,25-hexaoxo-3,9,12,15,18,24-hexazatricyclo[24.4.0.03,7]triaconta-1(30),26,28-triene-19-carboxamide
DMNKT8J DE Discovery agent
DMYIJT1 ID DMYIJT1
DMYIJT1 DN C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2
DMYIJT1 HS Investigative
DMYIJT1 PC 91935398
DMYIJT1 MW 3350.6
DMYIJT1 FM C151H225N41O46
DMYIJT1 IC InChI=1S/C151H225N41O46/c1-16-77(10)121(148(236)170-80(13)126(214)178-104(59-87-62-161-91-35-24-23-34-89(87)91)138(226)180-100(55-74(4)5)139(227)189-119(75(6)7)146(234)177-93(36-25-27-51-152)130(218)164-66-112(201)171-92(38-29-53-160-151(156)157)129(217)162-64-110(155)199)191-140(228)102(56-83-30-19-17-20-31-83)181-135(223)98(46-50-117(208)209)176-134(222)94-37-26-28-52-159-127(215)86-41-39-85(40-42-86)58-101(137(225)179-99(54-73(2)3)136(224)175-96(45-49-116(206)207)132(220)165-67-113(202)173-97(43-47-109(154)198)133(221)169-78(11)124(212)168-79(12)125(213)174-94)182-143(231)106(69-193)185-145(233)108(71-195)186-147(235)120(76(8)9)190-142(230)105(61-118(210)211)183-144(232)107(70-194)187-150(238)123(82(15)197)192-141(229)103(57-84-32-21-18-22-33-84)184-149(237)122(81(14)196)188-114(203)68-166-131(219)95(44-48-115(204)205)172-111(200)65-163-128(216)90(153)60-88-63-158-72-167-88/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,161,193-197H,16,25-29,36-38,43-61,64-71,152-153H2,1-15H3,(H2,154,198)(H2,155,199)(H,158,167)(H,159,215)(H,162,217)(H,163,216)(H,164,218)(H,165,220)(H,166,219)(H,168,212)(H,169,221)(H,170,236)(H,171,201)(H,172,200)(H,173,202)(H,174,213)(H,175,224)(H,176,222)(H,177,234)(H,178,214)(H,179,225)(H,180,226)(H,181,223)(H,182,231)(H,183,232)(H,184,237)(H,185,233)(H,186,235)(H,187,238)(H,188,203)(H,189,227)(H,190,230)(H,191,228)(H,192,229)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,156,157,160)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
DMYIJT1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)C5=CC=C(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)CCC(=O)O)CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N)C=C5
DMYIJT1 IK NBZJWICSDFBTTN-RHBBJNDVSA-N
DMYIJT1 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(8S,11S,14S,17S,23S,26S,29S)-8-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-17-(3-amino-3-oxopropyl)-23-(2-carboxyethyl)-11,14-dimethyl-26-(2-methylpropyl)-2,10,13,16,19,22,25,28-octaoxo-3,9,12,15,18,21,24,27-octazabicyclo[29.2.2]pentatriaconta-1(33),31,34-trien-29-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMYIJT1 DE Discovery agent
DMJR5UD ID DMJR5UD
DMJR5UD DN C[Glu18-Lys22][Gly8]GLP-1(7-37)-NH2
DMJR5UD HS Investigative
DMJR5UD PC 91935383
DMJR5UD MW 3435.8
DMJR5UD FM C156H236N42O46
DMJR5UD IC InChI=1S/C156H236N42O46/c1-16-81(10)126(153(242)175-84(13)131(220)185-110(65-90-68-167-95-37-24-23-36-93(90)95)144(233)187-106(61-78(4)5)145(234)195-124(79(6)7)151(240)184-97(38-25-28-56-157)134(223)170-72-118(208)176-96(41-31-59-166-156(162)163)133(222)168-70-115(161)205)197-146(235)108(62-87-32-19-17-20-33-87)189-141(230)104(50-55-122(214)215)181-137(226)98(39-26-29-57-158)178-130(219)83(12)173-129(218)82(11)174-136(225)101(46-51-114(160)204)180-138(227)99-40-27-30-58-165-116(206)52-47-102(140(229)188-107(64-89-42-44-92(203)45-43-89)143(232)186-105(60-77(2)3)142(231)182-103(139(228)179-99)49-54-121(212)213)183-149(238)112(74-199)192-152(241)125(80(8)9)196-148(237)111(67-123(216)217)190-150(239)113(75-200)193-155(244)128(86(15)202)198-147(236)109(63-88-34-21-18-22-35-88)191-154(243)127(85(14)201)194-119(209)73-171-135(224)100(48-53-120(210)211)177-117(207)71-169-132(221)94(159)66-91-69-164-76-172-91/h17-24,32-37,42-45,68-69,76-86,94,96-113,124-128,167,199-203H,16,25-31,38-41,46-67,70-75,157-159H2,1-15H3,(H2,160,204)(H2,161,205)(H,164,172)(H,165,206)(H,168,222)(H,169,221)(H,170,223)(H,171,224)(H,173,218)(H,174,225)(H,175,242)(H,176,208)(H,177,207)(H,178,219)(H,179,228)(H,180,227)(H,181,226)(H,182,231)(H,183,238)(H,184,240)(H,185,220)(H,186,232)(H,187,233)(H,188,229)(H,189,230)(H,190,239)(H,191,243)(H,192,241)(H,193,244)(H,194,209)(H,195,234)(H,196,237)(H,197,235)(H,198,236)(H,210,211)(H,212,213)(H,214,215)(H,216,217)(H4,162,163,166)/t81-,82-,83-,84-,85+,86+,94-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,124-,125-,126-,127-,128-/m0/s1
DMJR5UD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)O)CC(C)C)CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMJR5UD IK GOARADSSYIPKJH-IJFSHCFJSA-N
DMJR5UD IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,12S,21S)-21-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]-3-(2-carboxyethyl)-9-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMJR5UD DE Discovery agent
DM6O4EZ ID DM6O4EZ
DM6O4EZ DN C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2
DM6O4EZ HS Investigative
DM6O4EZ PC 91935384
DM6O4EZ MW 3288.6
DM6O4EZ FM C147H227N41O45
DM6O4EZ IC InChI=1S/C147H227N41O45/c1-16-76(10)118(144(231)166-79(13)123(210)175-101(58-84-61-157-88-37-24-23-36-86(84)88)134(221)177-98(55-73(4)5)135(222)185-116(74(6)7)142(229)174-90(38-25-28-50-148)126(213)160-65-109(197)167-89(41-31-53-156-147(152)153)125(212)158-63-106(151)194)187-136(223)99(56-82-32-19-17-20-33-82)178-132(219)96(45-49-114(204)205)172-130(217)92(39-26-29-51-149)170-122(209)78(12)164-121(208)77(11)165-129(216)91-40-27-30-52-155-107(195)46-42-95(131(218)176-97(54-72(2)3)133(220)171-94(44-48-113(202)203)128(215)161-66-110(198)168-91)173-139(226)103(68-189)181-141(228)105(70-191)182-143(230)117(75(8)9)186-138(225)102(60-115(206)207)179-140(227)104(69-190)183-146(233)120(81(15)193)188-137(224)100(57-83-34-21-18-22-35-83)180-145(232)119(80(14)192)184-111(199)67-162-127(214)93(43-47-112(200)201)169-108(196)64-159-124(211)87(150)59-85-62-154-71-163-85/h17-24,32-37,61-62,71-81,87,89-105,116-120,157,189-193H,16,25-31,38-60,63-70,148-150H2,1-15H3,(H2,151,194)(H,154,163)(H,155,195)(H,158,212)(H,159,211)(H,160,213)(H,161,215)(H,162,214)(H,164,208)(H,165,216)(H,166,231)(H,167,197)(H,168,198)(H,169,196)(H,170,209)(H,171,220)(H,172,217)(H,173,226)(H,174,229)(H,175,210)(H,176,218)(H,177,221)(H,178,219)(H,179,227)(H,180,232)(H,181,228)(H,182,230)(H,183,233)(H,184,199)(H,185,222)(H,186,225)(H,187,223)(H,188,224)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,152,153,156)/t76-,77-,78-,79-,80+,81+,87-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,116-,117-,118-,119-,120-/m0/s1
DM6O4EZ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N4)CCC(=O)O)CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DM6O4EZ IK OCOAZSDHBCONHT-VHWHDJENSA-N
DM6O4EZ IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(6S,9S,12S,21S)-21-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-6-(2-carboxyethyl)-9-(2-methylpropyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM6O4EZ DE Discovery agent
DMA3ZRJ ID DMA3ZRJ
DMA3ZRJ DN C[Glu21-Lys25][Gly8]GLP-1(7-37)-NH2
DMA3ZRJ HS Investigative
DMA3ZRJ PC 91935386
DMA3ZRJ MW 3379.7
DMA3ZRJ FM C153H232N42O45
DMA3ZRJ IC InChI=1S/C153H232N42O45/c1-15-80(10)124(150(238)172-82(12)128(216)181-107(62-88-65-164-93-36-23-22-35-91(88)93)140(228)183-103(58-77(4)5)141(229)192-122(78(6)7)148(236)180-95(37-24-27-53-154)131(219)167-69-116(206)173-94(40-30-56-163-153(159)160)130(218)165-67-113(158)203)194-142(230)105(59-85-31-18-16-19-32-85)184-137(225)101(48-52-120(211)212)179-136(224)97(38-25-28-54-155)177-135(223)96-39-26-29-55-162-114(204)50-46-99(133(221)168-70-117(207)175-100(45-49-112(157)202)134(222)171-81(11)127(215)176-96)178-138(226)102(57-76(2)3)182-139(227)104(61-87-41-43-90(201)44-42-87)185-145(233)109(72-196)188-147(235)111(74-198)189-149(237)123(79(8)9)193-144(232)108(64-121(213)214)186-146(234)110(73-197)190-152(240)126(84(14)200)195-143(231)106(60-86-33-20-17-21-34-86)187-151(239)125(83(13)199)191-118(208)71-169-132(220)98(47-51-119(209)210)174-115(205)68-166-129(217)92(156)63-89-66-161-75-170-89/h16-23,31-36,41-44,65-66,75-84,92,94-111,122-126,164,196-201H,15,24-30,37-40,45-64,67-74,154-156H2,1-14H3,(H2,157,202)(H2,158,203)(H,161,170)(H,162,204)(H,165,218)(H,166,217)(H,167,219)(H,168,221)(H,169,220)(H,171,222)(H,172,238)(H,173,206)(H,174,205)(H,175,207)(H,176,215)(H,177,223)(H,178,226)(H,179,224)(H,180,236)(H,181,216)(H,182,227)(H,183,228)(H,184,225)(H,185,233)(H,186,234)(H,187,239)(H,188,235)(H,189,237)(H,190,240)(H,191,208)(H,192,229)(H,193,232)(H,194,230)(H,195,231)(H,209,210)(H,211,212)(H,213,214)(H4,159,160,163)/t80-,81-,82-,83+,84+,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,122-,123-,124-,125-,126-/m0/s1
DMA3ZRJ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMA3ZRJ IK QOGYXVBERDYIBU-ZKFPJBBCSA-N
DMA3ZRJ IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,12S,21S)-21-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-6-(3-amino-3-oxopropyl)-3-methyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMA3ZRJ DE Discovery agent
DMPK74W ID DMPK74W
DMPK74W DN C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2
DMPK74W HS Investigative
DMPK74W PC 91935397
DMPK74W MW 3322.6
DMPK74W FM C150H225N41O45
DMPK74W IC InChI=1S/C150H225N41O45/c1-16-77(10)121(147(234)169-80(13)126(213)177-104(59-86-62-160-91-35-24-23-34-89(86)91)137(224)179-100(55-74(4)5)138(225)188-119(75(6)7)145(232)176-93(36-25-27-51-151)129(216)163-66-113(202)170-92(38-29-53-159-150(155)156)128(215)161-64-110(154)199)190-139(226)102(56-83-30-19-17-20-31-83)180-134(221)98(46-50-117(207)208)175-133(220)94-37-26-28-52-158-111(200)48-44-96(131(218)164-67-114(203)172-97(43-47-109(153)198)132(219)168-78(11)124(211)167-79(12)125(212)173-94)174-135(222)99(54-73(2)3)178-136(223)101(58-85-39-41-88(197)42-40-85)181-142(229)106(69-192)184-144(231)108(71-194)185-146(233)120(76(8)9)189-141(228)105(61-118(209)210)182-143(230)107(70-193)186-149(236)123(82(15)196)191-140(227)103(57-84-32-21-18-22-33-84)183-148(235)122(81(14)195)187-115(204)68-165-130(217)95(45-49-116(205)206)171-112(201)65-162-127(214)90(152)60-87-63-157-72-166-87/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,160,192-197H,16,25-29,36-38,43-61,64-71,151-152H2,1-15H3,(H2,153,198)(H2,154,199)(H,157,166)(H,158,200)(H,161,215)(H,162,214)(H,163,216)(H,164,218)(H,165,217)(H,167,211)(H,168,219)(H,169,234)(H,170,202)(H,171,201)(H,172,203)(H,173,212)(H,174,222)(H,175,220)(H,176,232)(H,177,213)(H,178,223)(H,179,224)(H,180,221)(H,181,229)(H,182,230)(H,183,235)(H,184,231)(H,185,233)(H,186,236)(H,187,204)(H,188,225)(H,189,228)(H,190,226)(H,191,227)(H,205,206)(H,207,208)(H,209,210)(H4,155,156,159)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
DMPK74W CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMPK74W IK YLHNVPBGRUSXJQ-RHBBJNDVSA-N
DMPK74W IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,15S,24S)-24-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-9-(3-amino-3-oxopropyl)-3,6-dimethyl-2,5,8,11,14,18-hexaoxo-1,4,7,10,13,19-hexazacyclotetracos-15-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMPK74W DE Discovery agent
DM8I0CZ ID DM8I0CZ
DM8I0CZ DN C[Glu22-Lys26][Gly8]GLP-1(7-37)-NH2
DM8I0CZ HS Investigative
DM8I0CZ DE Discovery agent
DMMA9GE ID DMMA9GE
DMMA9GE DN C[Glu22-Orn26][Gly8]GLP-1(7-37)-NH2
DMMA9GE HS Investigative
DMMA9GE PC 91935393
DMMA9GE MW 3380.7
DMMA9GE FM C152H227N41O47
DMMA9GE IC InChI=1S/C152H227N41O47/c1-16-77(10)122(149(238)170-80(13)127(216)179-105(60-86-63-162-91-34-24-23-33-89(86)91)139(228)181-101(56-74(4)5)140(229)190-120(75(6)7)147(236)178-93(35-25-26-52-153)130(219)165-67-114(204)171-92(36-28-54-161-152(157)158)129(218)163-65-111(156)201)192-141(230)103(57-83-29-19-17-20-30-83)182-136(225)99(46-51-118(210)211)176-133(222)94-37-27-53-160-112(202)48-43-97(134(223)174-96(42-47-110(155)200)132(221)169-78(11)125(214)168-79(12)126(215)173-94)175-135(224)98(45-50-117(208)209)177-137(226)100(55-73(2)3)180-138(227)102(59-85-38-40-88(199)41-39-85)183-144(233)107(69-194)186-146(235)109(71-196)187-148(237)121(76(8)9)191-143(232)106(62-119(212)213)184-145(234)108(70-195)188-151(240)124(82(15)198)193-142(231)104(58-84-31-21-18-22-32-84)185-150(239)123(81(14)197)189-115(205)68-166-131(220)95(44-49-116(206)207)172-113(203)66-164-128(217)90(154)61-87-64-159-72-167-87/h17-24,29-34,38-41,63-64,72-82,90,92-109,120-124,162,194-199H,16,25-28,35-37,42-62,65-71,153-154H2,1-15H3,(H2,155,200)(H2,156,201)(H,159,167)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,220)(H,168,214)(H,169,221)(H,170,238)(H,171,204)(H,172,203)(H,173,215)(H,174,223)(H,175,224)(H,176,222)(H,177,226)(H,178,236)(H,179,216)(H,180,227)(H,181,228)(H,182,225)(H,183,233)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,205)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,157,158,161)/t77-,78-,79-,80-,81-,82-,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,120-,121-,122-,123-,124-/m0/s1
DMMA9GE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMMA9GE IK KMMGHNYLBGRIJN-NINLSKNRSA-N
DMMA9GE IU (4S)-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,5S,8S,11S,19S)-11-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-2-(3-amino-3-oxopropyl)-5,8-dimethyl-3,6,9,16,20-pentaoxo-1,4,7,10,15-pentazacycloicos-19-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMMA9GE DE Discovery agent
DMWYN87 ID DMWYN87
DMWYN87 DN C[Glu23-Lys27][Gly8]GLP-1(7-37)-NH2
DMWYN87 HS Investigative
DMWYN87 PC 91935389
DMWYN87 MW 3322.7
DMWYN87 FM C151H229N41O44
DMWYN87 IC InChI=1S/C151H229N41O44/c1-16-79(10)122(148(234)170-82(13)127(213)178-106(61-88-64-161-93-37-24-23-36-91(88)93)138(224)180-102(57-76(4)5)139(225)189-120(77(6)7)146(232)177-95(38-25-28-52-152)130(216)164-68-114(202)171-94(41-31-55-160-151(156)157)129(215)162-66-111(155)199)191-140(226)104(58-85-32-19-17-20-33-85)181-135(221)97-40-27-30-54-159-112(200)49-46-100(133(219)169-80(11)125(211)168-81(12)126(212)174-96(134(220)175-97)39-26-29-53-153)173-115(203)69-165-132(218)99(48-51-118(207)208)176-136(222)101(56-75(2)3)179-137(223)103(60-87-42-44-90(198)45-43-87)182-143(229)108(71-193)185-145(231)110(73-195)186-147(233)121(78(8)9)190-142(228)107(63-119(209)210)183-144(230)109(72-194)187-150(236)124(84(15)197)192-141(227)105(59-86-34-21-18-22-35-86)184-149(235)123(83(14)196)188-116(204)70-166-131(217)98(47-50-117(205)206)172-113(201)67-163-128(214)92(154)62-89-65-158-74-167-89/h17-24,32-37,42-45,64-65,74-84,92,94-110,120-124,161,193-198H,16,25-31,38-41,46-63,66-73,152-154H2,1-15H3,(H2,155,199)(H,158,167)(H,159,200)(H,162,215)(H,163,214)(H,164,216)(H,165,218)(H,166,217)(H,168,211)(H,169,219)(H,170,234)(H,171,202)(H,172,201)(H,173,203)(H,174,212)(H,175,220)(H,176,222)(H,177,232)(H,178,213)(H,179,223)(H,180,224)(H,181,221)(H,182,229)(H,183,230)(H,184,235)(H,185,231)(H,186,233)(H,187,236)(H,188,204)(H,189,225)(H,190,228)(H,191,226)(H,192,227)(H,205,206)(H,207,208)(H,209,210)(H4,156,157,160)/t79-,80-,81-,82-,83+,84+,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,120-,121-,122-,123-,124-/m0/s1
DMWYN87 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCCCN)C)C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMWYN87 IK WPXDPFYLELBEJH-MAGRMNHLSA-N
DMWYN87 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(3S,6S,9S,12S,21S)-21-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]-3-(4-aminobutyl)-6,9-dimethyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMWYN87 DE Discovery agent
DMKZXV3 ID DMKZXV3
DMKZXV3 DN C[Glu24-Lys28][Gly8]GLP-1(7-37)-NH2
DMKZXV3 HS Investigative
DMKZXV3 PC 91935387
DMKZXV3 MW 3361.7
DMKZXV3 FM C149H230N42O47
DMKZXV3 IC InChI=1S/C149H230N42O47/c1-15-76(10)120(146(236)168-78(12)124(214)178-102(58-83-61-160-88-31-20-19-30-86(83)88)137(227)180-99(55-73(4)5)138(228)188-118(74(6)7)144(234)177-90(32-21-24-50-150)127(217)163-65-111(202)169-89(35-27-53-159-149(155)156)126(216)161-63-108(154)199)190-134(224)92-34-23-26-52-158-109(200)46-41-96(130(220)167-77(11)123(213)172-91(33-22-25-51-151)131(221)176-97(133(223)173-92)44-49-116(209)210)175-132(222)95(40-45-107(153)198)171-112(203)66-164-129(219)94(43-48-115(207)208)174-135(225)98(54-72(2)3)179-136(226)100(57-82-36-38-85(197)39-37-82)181-141(231)104(68-192)184-143(233)106(70-194)185-145(235)119(75(8)9)189-140(230)103(60-117(211)212)182-142(232)105(69-193)186-148(238)122(80(14)196)191-139(229)101(56-81-28-17-16-18-29-81)183-147(237)121(79(13)195)187-113(204)67-165-128(218)93(42-47-114(205)206)170-110(201)64-162-125(215)87(152)59-84-62-157-71-166-84/h16-20,28-31,36-39,61-62,71-80,87,89-106,118-122,160,192-197H,15,21-27,32-35,40-60,63-70,150-152H2,1-14H3,(H2,153,198)(H2,154,199)(H,157,166)(H,158,200)(H,161,216)(H,162,215)(H,163,217)(H,164,219)(H,165,218)(H,167,220)(H,168,236)(H,169,202)(H,170,201)(H,171,203)(H,172,213)(H,173,223)(H,174,225)(H,175,222)(H,176,221)(H,177,234)(H,178,214)(H,179,226)(H,180,227)(H,181,231)(H,182,232)(H,183,237)(H,184,233)(H,185,235)(H,186,238)(H,187,204)(H,188,228)(H,189,230)(H,190,224)(H,191,229)(H,205,206)(H,207,208)(H,209,210)(H,211,212)(H4,155,156,159)/t76-,77-,78-,79+,80-,87-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,118-,119-,120-,121-,122-/m0/s1
DMKZXV3 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@@H]3CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCC(=O)O)CCCCN)C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC6=CN=CN6)N
DMKZXV3 IK KPGVUBCFEGSCNW-NNIIIAALSA-N
DMKZXV3 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(3S,6S,9S,12S,21S)-21-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]-6-(4-aminobutyl)-3-(2-carboxyethyl)-9-methyl-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMKZXV3 DE Discovery agent
DMX2WCZ ID DMX2WCZ
DMX2WCZ DN C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2
DMX2WCZ HS Investigative
DMX2WCZ PC 91935391
DMX2WCZ MW 3380.7
DMX2WCZ FM C152H227N41O47
DMX2WCZ IC InChI=1S/C152H227N41O47/c1-15-78(10)123-149(238)178-94(134(223)183-105(60-86-63-162-91-34-23-22-33-89(86)91)139(228)180-101(56-75(4)5)140(229)190-121(76(6)7)147(236)177-93(35-24-26-52-153)130(219)165-67-114(204)171-92(37-28-54-161-152(157)158)129(218)163-65-111(156)201)36-25-27-53-160-112(202)48-43-98(135(224)176-99(46-51-119(211)212)136(225)181-103(141(230)192-123)57-83-29-18-16-19-30-83)174-127(216)80(12)169-126(215)79(11)170-133(222)97(42-47-110(155)200)173-115(205)68-166-132(221)96(45-50-118(209)210)175-137(226)100(55-74(2)3)179-138(227)102(59-85-38-40-88(199)41-39-85)182-144(233)107(70-194)186-146(235)109(72-196)187-148(237)122(77(8)9)191-143(232)106(62-120(213)214)184-145(234)108(71-195)188-151(240)125(82(14)198)193-142(231)104(58-84-31-20-17-21-32-84)185-150(239)124(81(13)197)189-116(206)69-167-131(220)95(44-49-117(207)208)172-113(203)66-164-128(217)90(154)61-87-64-159-73-168-87/h16-23,29-34,38-41,63-64,73-82,90,92-109,121-125,162,194-199H,15,24-28,35-37,42-62,65-72,153-154H2,1-14H3,(H2,155,200)(H2,156,201)(H,159,168)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,221)(H,167,220)(H,169,215)(H,170,222)(H,171,204)(H,172,203)(H,173,205)(H,174,216)(H,175,226)(H,176,224)(H,177,236)(H,178,238)(H,179,227)(H,180,228)(H,181,225)(H,182,233)(H,183,223)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,206)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,207,208)(H,209,210)(H,211,212)(H,213,214)(H4,157,158,161)/t78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,121-,122-,123-,124-,125-/m0/s1
DMX2WCZ CS CC[C@H](C)[C@H]1C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMX2WCZ IK JGAQRLVKKDZZTH-KXYXCEFHSA-N
DMX2WCZ IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(3S,6S,9S,12S,21S)-21-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]-6-benzyl-3-[(2S)-butan-2-yl]-9-(2-carboxyethyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMX2WCZ DE Discovery agent
DMTP5YZ ID DMTP5YZ
DMTP5YZ DN C[hGlu22-Lys26][Gly8]GLP-1(7-37)-NH2
DMTP5YZ HS Investigative
DMTP5YZ PC 91935395
DMTP5YZ MW 3408.7
DMTP5YZ FM C154H231N41O47
DMTP5YZ IC InChI=1S/C154H231N41O47/c1-16-79(10)124(151(240)172-82(13)129(218)181-107(62-88-65-164-93-36-24-23-35-91(88)93)141(230)183-103(58-76(4)5)142(231)192-122(77(6)7)149(238)180-95(37-25-27-54-155)132(221)167-69-116(206)173-94(40-30-56-163-154(159)160)131(220)165-67-113(158)203)194-143(232)105(59-85-31-19-17-20-32-85)184-138(227)101(49-53-120(212)213)178-135(224)96-38-26-28-55-162-114(204)41-29-39-97(136(225)177-99(46-50-112(157)202)134(223)171-80(11)127(216)170-81(12)128(217)175-96)176-137(226)100(48-52-119(210)211)179-139(228)102(57-75(2)3)182-140(229)104(61-87-42-44-90(201)45-43-87)185-146(235)109(71-196)188-148(237)111(73-198)189-150(239)123(78(8)9)193-145(234)108(64-121(214)215)186-147(236)110(72-197)190-153(242)126(84(15)200)195-144(233)106(60-86-33-21-18-22-34-86)187-152(241)125(83(14)199)191-117(207)70-168-133(222)98(47-51-118(208)209)174-115(205)68-166-130(219)92(156)63-89-66-161-74-169-89/h17-24,31-36,42-45,65-66,74-84,92,94-111,122-126,164,196-201H,16,25-30,37-41,46-64,67-73,155-156H2,1-15H3,(H2,157,202)(H2,158,203)(H,161,169)(H,162,204)(H,165,220)(H,166,219)(H,167,221)(H,168,222)(H,170,216)(H,171,223)(H,172,240)(H,173,206)(H,174,205)(H,175,217)(H,176,226)(H,177,225)(H,178,224)(H,179,228)(H,180,238)(H,181,218)(H,182,229)(H,183,230)(H,184,227)(H,185,235)(H,186,236)(H,187,241)(H,188,237)(H,189,239)(H,190,242)(H,191,207)(H,192,231)(H,193,234)(H,194,232)(H,195,233)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H4,159,160,163)/t79-,80-,81-,82-,83-,84-,92-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,122-,123-,124-,125-,126-/m0/s1
DMTP5YZ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]4CCCCNC(=O)CCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)C)C)CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DMTP5YZ IK FZOFJRYZQZCXIG-XPPJIRRWSA-N
DMTP5YZ IU (4S)-5-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,5S,8S,11S,21S)-11-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]carbamoyl]-2-(3-amino-3-oxopropyl)-5,8-dimethyl-3,6,9,17,22-pentaoxo-1,4,7,10,16-pentazacyclodocos-21-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMTP5YZ DE Discovery agent
DM8HK0J ID DM8HK0J
DM8HK0J DN C[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2
DM8HK0J HS Investigative
DM8HK0J SN CHEMBL410408; c[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2
DM8HK0J DT Small molecular drug
DM8HK0J PC 44428818
DM8HK0J MW 963
DM8HK0J FM C46H58N8O15
DM8HK0J IC InChI=1S/C46H58N8O15/c1-24(2)18-33-45(67)53-32(14-17-40(61)62)43(65)49-27(21-36(47)56)9-15-37(57)50-31(12-8-25-6-4-3-5-7-25)44(66)54-34(19-26-20-41(63)69-35-22-28(55)10-11-29(26)35)46(68)52-30(13-16-39(59)60)42(64)48-23-38(58)51-33/h3-7,10-11,20,22,24,27,30-34,55H,8-9,12-19,21,23H2,1-2H3,(H2,47,56)(H,48,64)(H,49,65)(H,50,57)(H,51,58)(H,52,68)(H,53,67)(H,54,66)(H,59,60)(H,61,62)/t27-,30-,31-,32-,33-,34-/m0/s1
DM8HK0J CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CCC(=O)O)CC2=CC(=O)OC3=C2C=CC(=C3)O)CCC4=CC=CC=C4)CC(=O)N)CCC(=O)O
DM8HK0J IK TZBPOQODYKOULE-HDARCNCQSA-N
DM8HK0J IU 3-[(2S,5S,8S,14S,17S,20S)-20-(2-amino-2-oxoethyl)-17-(2-carboxyethyl)-5-[(7-hydroxy-2-oxochromen-4-yl)methyl]-14-(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-2-(2-phenylethyl)-1,4,7,10,13,16,19-heptazacyclotricos-8-yl]propanoic acid
DM8HK0J DE Discovery agent
DMHXTWK ID DMHXTWK
DMHXTWK DN C[L-Ala-D-pro-L-Phe-D-trp]
DMHXTWK HS Investigative
DMHXTWK SN CHEMBL499595; c[L-Ala-D-pro-L-Phe-D-trp]; SCHEMBL7991248
DMHXTWK DT Small molecular drug
DMHXTWK PC 44583393
DMHXTWK MW 501.6
DMHXTWK FM C28H31N5O4
DMHXTWK IC InChI=1S/C28H31N5O4/c1-17-28(37)33-13-7-12-24(33)27(36)32-22(14-18-8-3-2-4-9-18)26(35)31-23(25(34)30-17)15-19-16-29-21-11-6-5-10-20(19)21/h2-6,8-11,16-17,22-24,29H,7,12-15H2,1H3,(H,30,34)(H,31,35)(H,32,36)/t17-,22-,23+,24+/m0/s1
DMHXTWK CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5
DMHXTWK IK OTUDCPUMJPNZRR-UYGLSEIWSA-N
DMHXTWK IU (3S,6R,9S,12R)-9-benzyl-6-(1H-indol-3-ylmethyl)-3-methyl-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMHXTWK DE Discovery agent
DMNHSR0 ID DMNHSR0
DMNHSR0 DN C[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0 HS Investigative
DMNHSR0 SN CHEMBL510506; c[L-mTyr-D-pro-L-Phe-D-trp]
DMNHSR0 DT Small molecular drug
DMNHSR0 PC 44583376
DMNHSR0 MW 593.7
DMNHSR0 FM C34H35N5O5
DMNHSR0 IC InChI=1S/C34H35N5O5/c40-24-11-6-10-22(16-24)18-29-34(44)39-15-7-14-30(39)33(43)37-27(17-21-8-2-1-3-9-21)31(41)36-28(32(42)38-29)19-23-20-35-26-13-5-4-12-25(23)26/h1-6,8-13,16,20,27-30,35,40H,7,14-15,17-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DMNHSR0 CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC(=CC=C3)O)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DMNHSR0 IK NMGCCCXRAFVYBR-RRGQHJHPSA-N
DMNHSR0 IU (3S,6R,9S,12R)-9-benzyl-3-[(3-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMNHSR0 DE Discovery agent
DM82ZOM ID DM82ZOM
DM82ZOM DN C[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM HS Investigative
DM82ZOM SN CHEMBL509201; c[L-Phe-D-pro-L-mTyr-D-trp]
DM82ZOM DT Small molecular drug
DM82ZOM PC 44583386
DM82ZOM MW 593.7
DM82ZOM FM C34H35N5O5
DM82ZOM IC InChI=1S/C34H35N5O5/c40-24-11-6-10-22(16-24)18-27-31(41)36-28(19-23-20-35-26-13-5-4-12-25(23)26)32(42)38-29(17-21-8-2-1-3-9-21)34(44)39-15-7-14-30(39)33(43)37-27/h1-6,8-13,16,20,27-30,35,40H,7,14-15,17-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DM82ZOM CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC(=CC=C6)O
DM82ZOM IK NXAWTNITTPJQAL-RRGQHJHPSA-N
DM82ZOM IU (3S,6R,9S,12R)-3-benzyl-9-[(3-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM82ZOM DE Discovery agent
DM0NTU5 ID DM0NTU5
DM0NTU5 DN C[L-Phe-D-pro-L-Phe-D-trp]
DM0NTU5 HS Investigative
DM0NTU5 SN CHEMBL502411; c[L-Phe-D-pro-L-Phe-D-trp]; SCHEMBL7980647
DM0NTU5 DT Small molecular drug
DM0NTU5 PC 44583373
DM0NTU5 MW 577.7
DM0NTU5 FM C34H35N5O4
DM0NTU5 IC InChI=1S/C34H35N5O4/c40-31-27(18-22-10-3-1-4-11-22)37-33(42)30-16-9-17-39(30)34(43)29(19-23-12-5-2-6-13-23)38-32(41)28(36-31)20-24-21-35-26-15-8-7-14-25(24)26/h1-8,10-15,21,27-30,35H,9,16-20H2,(H,36,40)(H,37,42)(H,38,41)/t27-,28+,29-,30+/m0/s1
DM0NTU5 CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DM0NTU5 IK GIZJWWQFOGQPRY-RRGQHJHPSA-N
DM0NTU5 IU (3S,6R,9S,12R)-3,9-dibenzyl-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM0NTU5 DE Discovery agent
DMCY4L0 ID DMCY4L0
DMCY4L0 DN C[L-Phe-D-pro-L-Phe-L-trp]
DMCY4L0 HS Investigative
DMCY4L0 SN CHEMBL506616; CJ-15208; c[L-Phe-D-pro-L-Phe-L-trp]; SCHEMBL12368055
DMCY4L0 DT Small molecular drug
DMCY4L0 PC 44583372
DMCY4L0 MW 577.7
DMCY4L0 FM C34H35N5O4
DMCY4L0 IC InChI=1S/C34H35N5O4/c40-31-27(18-22-10-3-1-4-11-22)37-33(42)30-16-9-17-39(30)34(43)29(19-23-12-5-2-6-13-23)38-32(41)28(36-31)20-24-21-35-26-15-8-7-14-25(24)26/h1-8,10-15,21,27-30,35H,9,16-20H2,(H,36,40)(H,37,42)(H,38,41)/t27-,28-,29-,30+/m0/s1
DMCY4L0 CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DMCY4L0 IK GIZJWWQFOGQPRY-GCXHJFECSA-N
DMCY4L0 IU (3S,6S,9S,12R)-3,9-dibenzyl-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMCY4L0 DE Discovery agent
DM4M3OP ID DM4M3OP
DM4M3OP DN C[L-Phe-D-pro-L-Tyr(OMe)-D-trp]
DM4M3OP HS Investigative
DM4M3OP SN CHEMBL506211; c[L-Phe-D-pro-L-Tyr(OMe)-D-trp]
DM4M3OP DT Small molecular drug
DM4M3OP PC 44583388
DM4M3OP MW 607.7
DM4M3OP FM C35H37N5O5
DM4M3OP IC InChI=1S/C35H37N5O5/c1-45-25-15-13-23(14-16-25)18-28-32(41)37-29(20-24-21-36-27-11-6-5-10-26(24)27)33(42)39-30(19-22-8-3-2-4-9-22)35(44)40-17-7-12-31(40)34(43)38-28/h2-6,8-11,13-16,21,28-31,36H,7,12,17-20H2,1H3,(H,37,41)(H,38,43)(H,39,42)/t28-,29+,30-,31+/m0/s1
DM4M3OP CS COC1=CC=C(C=C1)C[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N3CCC[C@@H]3C(=O)N2)CC4=CC=CC=C4)CC5=CNC6=CC=CC=C65
DM4M3OP IK UWYXKSHDABLYGG-XFBWMNOSSA-N
DM4M3OP IU (3S,6R,9S,12R)-3-benzyl-6-(1H-indol-3-ylmethyl)-9-[(4-methoxyphenyl)methyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM4M3OP DE Discovery agent
DMADSBT ID DMADSBT
DMADSBT DN C[L-Phe-D-pro-L-Tyr-D-trp]
DMADSBT HS Investigative
DMADSBT SN CHEMBL486388; c[L-Phe-D-pro-L-Tyr-D-trp]
DMADSBT DT Small molecular drug
DMADSBT PC 44583375
DMADSBT MW 593.7
DMADSBT FM C34H35N5O5
DMADSBT IC InChI=1S/C34H35N5O5/c40-24-14-12-22(13-15-24)17-27-31(41)36-28(19-23-20-35-26-10-5-4-9-25(23)26)32(42)38-29(18-21-7-2-1-3-8-21)34(44)39-16-6-11-30(39)33(43)37-27/h1-5,7-10,12-15,20,27-30,35,40H,6,11,16-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DMADSBT CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CC6=CC=C(C=C6)O
DMADSBT IK YMZQUJVCPUZHJG-RRGQHJHPSA-N
DMADSBT IU (3S,6R,9S,12R)-3-benzyl-9-[(4-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMADSBT DE Discovery agent
DMLB6UA ID DMLB6UA
DMLB6UA DN C[L-Tyr(OMe)-D-pro-L-Phe-D-trp]
DMLB6UA HS Investigative
DMLB6UA SN CHEMBL507127; c[L-Tyr(OMe)-D-pro-L-Phe-D-trp]
DMLB6UA DT Small molecular drug
DMLB6UA PC 44583387
DMLB6UA MW 607.7
DMLB6UA FM C35H37N5O5
DMLB6UA IC InChI=1S/C35H37N5O5/c1-45-25-15-13-23(14-16-25)19-30-35(44)40-17-7-12-31(40)34(43)38-28(18-22-8-3-2-4-9-22)32(41)37-29(33(42)39-30)20-24-21-36-27-11-6-5-10-26(24)27/h2-6,8-11,13-16,21,28-31,36H,7,12,17-20H2,1H3,(H,37,41)(H,38,43)(H,39,42)/t28-,29+,30-,31+/m0/s1
DMLB6UA CS COC1=CC=C(C=C1)C[C@H]2C(=O)N3CCC[C@@H]3C(=O)N[C@H](C(=O)N[C@@H](C(=O)N2)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DMLB6UA IK OGVYQAXJPKYKOQ-XFBWMNOSSA-N
DMLB6UA IU (3S,6R,9S,12R)-9-benzyl-6-(1H-indol-3-ylmethyl)-3-[(4-methoxyphenyl)methyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMLB6UA DE Discovery agent
DM7OIY8 ID DM7OIY8
DM7OIY8 DN C[L-Tyr-D-pro-L-Phe-D-trp]
DM7OIY8 HS Investigative
DM7OIY8 SN CHEMBL506217; c[L-Tyr-D-pro-L-Phe-D-trp]
DM7OIY8 DT Small molecular drug
DM7OIY8 PC 44583374
DM7OIY8 MW 593.7
DM7OIY8 FM C34H35N5O5
DM7OIY8 IC InChI=1S/C34H35N5O5/c40-24-14-12-22(13-15-24)18-29-34(44)39-16-6-11-30(39)33(43)37-27(17-21-7-2-1-3-8-21)31(41)36-28(32(42)38-29)19-23-20-35-26-10-5-4-9-25(23)26/h1-5,7-10,12-15,20,27-30,35,40H,6,11,16-19H2,(H,36,41)(H,37,43)(H,38,42)/t27-,28+,29-,30+/m0/s1
DM7OIY8 CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=C(C=C3)O)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6
DM7OIY8 IK YTXYSUHLDDXFGK-RRGQHJHPSA-N
DM7OIY8 IU (3S,6R,9S,12R)-9-benzyl-3-[(4-hydroxyphenyl)methyl]-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DM7OIY8 DE Discovery agent
DMX7IVO ID DMX7IVO
DMX7IVO DN C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2
DMX7IVO HS Investigative
DMX7IVO SN CHEMBL204263; BDBM50184365
DMX7IVO DT Small molecular drug
DMX7IVO PC 44408515
DMX7IVO MW 937.1
DMX7IVO FM C47H64N14O7
DMX7IVO IC InChI=1S/C47H64N14O7/c1-2-3-13-34-41(64)58-35(15-8-21-53-46(49)50)42(65)60-37(24-27-17-18-28-10-4-5-11-29(28)23-27)44(67)59-36(16-9-22-54-47(51)52)43(66)61-38(25-30-26-55-32-14-7-6-12-31(30)32)45(68)57-33(40(48)63)19-20-39(62)56-34/h4-7,10-12,14,17-18,23,26,33-38,55H,2-3,8-9,13,15-16,19-22,24-25H2,1H3,(H2,48,63)(H,56,62)(H,57,68)(H,58,64)(H,59,67)(H,60,65)(H,61,66)(H4,49,50,53)(H4,51,52,54)/t33-,34-,35+,36-,37+,38-/m0/s1
DMX7IVO CS CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCCN=C(N)N
DMX7IVO IK UHCXNXMBPAFWDS-VRHOQGROSA-N
DMX7IVO IU (2S,5R,8R,11S,14S,17S)-2-butyl-5,11-bis[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMX7IVO DE Discovery agent
DMUESCH ID DMUESCH
DMUESCH DN C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH HS Investigative
DMUESCH SN CHEMBL263822; c[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2
DMUESCH DT Small molecular drug
DMUESCH PC 44408443
DMUESCH MW 887
DMUESCH FM C43H62N14O7
DMUESCH IC InChI=1S/C43H62N14O7/c1-2-3-14-30-37(60)54-31(16-9-20-49-42(45)46)38(61)56-33(22-25-11-5-4-6-12-25)40(63)55-32(17-10-21-50-43(47)48)39(62)57-34(23-26-24-51-28-15-8-7-13-27(26)28)41(64)53-29(36(44)59)18-19-35(58)52-30/h4-8,11-13,15,24,29-34,51H,2-3,9-10,14,16-23H2,1H3,(H2,44,59)(H,52,58)(H,53,64)(H,54,60)(H,55,63)(H,56,61)(H,57,62)(H4,45,46,49)(H4,47,48,50)/t29-,30-,31+,32-,33+,34-/m0/s1
DMUESCH CS CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCCN=C(N)N
DMUESCH IK OVCXMKITXFVUSL-AIQTWYNVSA-N
DMUESCH IU (2S,5R,8R,11S,14S,17S)-8-benzyl-2-butyl-5,11-bis[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMUESCH DE Discovery agent
DM8SXLR ID DM8SXLR
DM8SXLR DN C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2
DM8SXLR HS Investigative
DM8SXLR SN CHEMBL409144; BDBM50184350
DM8SXLR DT Small molecular drug
DM8SXLR PC 44408400
DM8SXLR MW 896
DM8SXLR FM C45H57N11O9
DM8SXLR IC InChI=1S/C45H57N11O9/c1-2-3-12-32-40(61)56-36(23-38(58)59)44(65)54-34(21-25-15-16-26-9-4-5-10-27(26)20-25)42(63)53-33(14-8-19-49-45(47)48)41(62)55-35(22-28-24-50-30-13-7-6-11-29(28)30)43(64)52-31(39(46)60)17-18-37(57)51-32/h4-7,9-11,13,15-16,20,24,31-36,50H,2-3,8,12,14,17-19,21-23H2,1H3,(H2,46,60)(H,51,57)(H,52,64)(H,53,63)(H,54,65)(H,55,62)(H,56,61)(H,58,59)(H4,47,48,49)/t31-,32-,33-,34+,35-,36+/m0/s1
DM8SXLR CS CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CC(=O)O
DM8SXLR IK VKDMHINLWUJYEZ-XBWXEZBPSA-N
DM8SXLR IU 2-[(2S,5R,8R,11S,14S,17S)-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]acetic acid
DM8SXLR DE Discovery agent
DMXJAOI ID DMXJAOI
DMXJAOI DN C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2
DMXJAOI HS Investigative
DMXJAOI SN CHEMBL203170; c[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2
DMXJAOI DT Small molecular drug
DMXJAOI PC 11629290
DMXJAOI MW 845.9
DMXJAOI FM C41H55N11O9
DMXJAOI IC InChI=1S/C41H55N11O9/c1-2-3-13-28-36(57)52-32(21-34(54)55)40(61)50-30(19-23-10-5-4-6-11-23)38(59)49-29(15-9-18-45-41(43)44)37(58)51-31(20-24-22-46-26-14-8-7-12-25(24)26)39(60)48-27(35(42)56)16-17-33(53)47-28/h4-8,10-12,14,22,27-32,46H,2-3,9,13,15-21H2,1H3,(H2,42,56)(H,47,53)(H,48,60)(H,49,59)(H,50,61)(H,51,58)(H,52,57)(H,54,55)(H4,43,44,45)/t27-,28-,29-,30+,31-,32-/m0/s1
DMXJAOI CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC(=O)O
DMXJAOI IK HUAMIBCEKZFYST-BCLKUREPSA-N
DMXJAOI IU 2-[(2S,5S,8R,11S,14S,17S)-8-benzyl-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]acetic acid
DMXJAOI DE Discovery agent
DMM19SJ ID DMM19SJ
DMM19SJ DN C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2
DMM19SJ HS Investigative
DMM19SJ SN CHEMBL204310; BDBM50184355
DMM19SJ DT Small molecular drug
DMM19SJ PC 11498895
DMM19SJ MW 909
DMM19SJ FM C46H60N12O8
DMM19SJ IC InChI=1S/C46H60N12O8/c1-2-3-12-33-41(62)56-35(17-19-38(47)59)43(64)57-36(23-26-15-16-27-9-4-5-10-28(27)22-26)44(65)55-34(14-8-21-51-46(49)50)42(63)58-37(24-29-25-52-31-13-7-6-11-30(29)31)45(66)54-32(40(48)61)18-20-39(60)53-33/h4-7,9-11,13,15-16,22,25,32-37,52H,2-3,8,12,14,17-21,23-24H2,1H3,(H2,47,59)(H2,48,61)(H,53,60)(H,54,66)(H,55,65)(H,56,62)(H,57,64)(H,58,63)(H4,49,50,51)/t32-,33-,34-,35-,36+,37-/m0/s1
DMM19SJ CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCC(=O)N
DMM19SJ IK TUOOEJAUOYDGGA-BWBQVKFQSA-N
DMM19SJ IU (2S,5S,8R,11S,14S,17S)-5-(3-amino-3-oxopropyl)-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMM19SJ DE Discovery agent
DMSGWZE ID DMSGWZE
DMSGWZE DN C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE HS Investigative
DMSGWZE SN CHEMBL203602; c[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2
DMSGWZE DT Small molecular drug
DMSGWZE PC 44408413
DMSGWZE MW 859
DMSGWZE FM C42H58N12O8
DMSGWZE IC InChI=1S/C42H58N12O8/c1-2-3-13-29-37(58)52-31(16-18-34(43)55)39(60)53-32(21-24-10-5-4-6-11-24)40(61)51-30(15-9-20-47-42(45)46)38(59)54-33(22-25-23-48-27-14-8-7-12-26(25)27)41(62)50-28(36(44)57)17-19-35(56)49-29/h4-8,10-12,14,23,28-33,48H,2-3,9,13,15-22H2,1H3,(H2,43,55)(H2,44,57)(H,49,56)(H,50,62)(H,51,61)(H,52,58)(H,53,60)(H,54,59)(H4,45,46,47)/t28-,29-,30-,31+,32+,33-/m0/s1
DMSGWZE CS CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCC(=O)N
DMSGWZE IK RNMRQCPIALKVBK-HSPZZYPGSA-N
DMSGWZE IU (2S,5R,8R,11S,14S,17S)-5-(3-amino-3-oxopropyl)-8-benzyl-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMSGWZE DE Discovery agent
DMHNCAG ID DMHNCAG
DMHNCAG DN C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2
DMHNCAG HS Investigative
DMHNCAG SN CHEMBL383250; BDBM50184354
DMHNCAG DT Small molecular drug
DMHNCAG PC 11520823
DMHNCAG MW 910
DMHNCAG FM C46H59N11O9
DMHNCAG IC InChI=1S/C46H59N11O9/c1-2-3-12-33-41(62)55-35(18-20-39(59)60)43(64)56-36(23-26-15-16-27-9-4-5-10-28(27)22-26)44(65)54-34(14-8-21-50-46(48)49)42(63)57-37(24-29-25-51-31-13-7-6-11-30(29)31)45(66)53-32(40(47)61)17-19-38(58)52-33/h4-7,9-11,13,15-16,22,25,32-37,51H,2-3,8,12,14,17-21,23-24H2,1H3,(H2,47,61)(H,52,58)(H,53,66)(H,54,65)(H,55,62)(H,56,64)(H,57,63)(H,59,60)(H4,48,49,50)/t32-,33-,34-,35-,36+,37-/m0/s1
DMHNCAG CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCC(=O)O
DMHNCAG IK PAILFUNFWZLMMN-BWBQVKFQSA-N
DMHNCAG IU 3-[(2S,5S,8R,11S,14S,17S)-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]propanoic acid
DMHNCAG DE Discovery agent
DMVWOPG ID DMVWOPG
DMVWOPG DN C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2
DMVWOPG HS Investigative
DMVWOPG SN CHEMBL382369; c[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2
DMVWOPG DT Small molecular drug
DMVWOPG PC 44408399
DMVWOPG MW 860
DMVWOPG FM C42H57N11O9
DMVWOPG IC InChI=1S/C42H57N11O9/c1-2-3-13-29-37(58)51-31(17-19-35(55)56)39(60)52-32(21-24-10-5-4-6-11-24)40(61)50-30(15-9-20-46-42(44)45)38(59)53-33(22-25-23-47-27-14-8-7-12-26(25)27)41(62)49-28(36(43)57)16-18-34(54)48-29/h4-8,10-12,14,23,28-33,47H,2-3,9,13,15-22H2,1H3,(H2,43,57)(H,48,54)(H,49,62)(H,50,61)(H,51,58)(H,52,60)(H,53,59)(H,55,56)(H4,44,45,46)/t28-,29-,30-,31+,32+,33-/m0/s1
DMVWOPG CS CCCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCC(=O)O
DMVWOPG IK ZIKRFHYQHLHVCP-HSPZZYPGSA-N
DMVWOPG IU 3-[(2S,5R,8R,11S,14S,17S)-8-benzyl-2-butyl-17-carbamoyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicos-5-yl]propanoic acid
DMVWOPG DE Discovery agent
DM36HBK ID DM36HBK
DM36HBK DN C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2
DM36HBK HS Investigative
DM36HBK SN CHEMBL425591; BDBM50184356
DM36HBK DT Small molecular drug
DM36HBK PC 11672424
DM36HBK MW 918.1
DM36HBK FM C47H59N13O7
DM36HBK IC InChI=1S/C47H59N13O7/c1-2-3-12-35-42(63)60-39(23-31-25-51-26-54-31)46(67)58-37(21-27-15-16-28-9-4-5-10-29(28)20-27)44(65)57-36(14-8-19-52-47(49)50)43(64)59-38(22-30-24-53-33-13-7-6-11-32(30)33)45(66)56-34(41(48)62)17-18-40(61)55-35/h4-7,9-11,13,15-16,20,24-26,34-39,53H,2-3,8,12,14,17-19,21-23H2,1H3,(H2,48,62)(H,51,54)(H,55,61)(H,56,66)(H,57,65)(H,58,67)(H,59,64)(H,60,63)(H4,49,50,52)/t34-,35-,36-,37+,38-,39-/m0/s1
DM36HBK CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CC6=CN=CN6
DM36HBK IK AYKQERUAGGPJLP-WYLITWLFSA-N
DM36HBK IU (2S,5S,8R,11S,14S,17S)-2-butyl-11-[3-(diaminomethylideneamino)propyl]-5-(1H-imidazol-5-ylmethyl)-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM36HBK DE Discovery agent
DM5HRNM ID DM5HRNM
DM5HRNM DN C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM HS Investigative
DM5HRNM SN CHEMBL446185; c[Nle-His-D-Phe-Arg-Trp-Glu]-NH2
DM5HRNM DT Small molecular drug
DM5HRNM PC 11535237
DM5HRNM MW 868
DM5HRNM FM C43H57N13O7
DM5HRNM IC InChI=1S/C43H57N13O7/c1-2-3-13-31-38(59)56-35(21-27-23-47-24-50-27)42(63)54-33(19-25-10-5-4-6-11-25)40(61)53-32(15-9-18-48-43(45)46)39(60)55-34(20-26-22-49-29-14-8-7-12-28(26)29)41(62)52-30(37(44)58)16-17-36(57)51-31/h4-8,10-12,14,22-24,30-35,49H,2-3,9,13,15-21H2,1H3,(H2,44,58)(H,47,50)(H,51,57)(H,52,62)(H,53,61)(H,54,63)(H,55,60)(H,56,59)(H4,45,46,48)/t30-,31-,32-,33+,34-,35-/m0/s1
DM5HRNM CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5
DM5HRNM IK JWVUTJWCWBNVDW-CXJNCMCBSA-N
DM5HRNM IU (2S,5S,8R,11S,14S,17S)-8-benzyl-2-butyl-11-[3-(diaminomethylideneamino)propyl]-5-(1H-imidazol-5-ylmethyl)-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM5HRNM DE Discovery agent
DM73ZMG ID DM73ZMG
DM73ZMG DN C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2
DM73ZMG HS Investigative
DM73ZMG SN CHEMBL204864; BDBM50184360
DM73ZMG DT Small molecular drug
DM73ZMG PC 11700739
DM73ZMG MW 894.1
DM73ZMG FM C47H63N11O7
DM73ZMG IC InChI=1S/C47H63N11O7/c1-3-5-15-35-42(61)55-36(16-6-4-2)43(62)57-38(25-28-19-20-29-12-7-8-13-30(29)24-28)45(64)56-37(18-11-23-51-47(49)50)44(63)58-39(26-31-27-52-33-17-10-9-14-32(31)33)46(65)54-34(41(48)60)21-22-40(59)53-35/h7-10,12-14,17,19-20,24,27,34-39,52H,3-6,11,15-16,18,21-23,25-26H2,1-2H3,(H2,48,60)(H,53,59)(H,54,65)(H,55,61)(H,56,64)(H,57,62)(H,58,63)(H4,49,50,51)/t34-,35-,36-,37-,38+,39-/m0/s1
DM73ZMG CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)CCCC
DM73ZMG IK TYFFXNLNRYRUAU-LFSOJSGESA-N
DM73ZMG IU (2S,5S,8R,11S,14S,17S)-2,5-dibutyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM73ZMG DE Discovery agent
DMDPBVS ID DMDPBVS
DMDPBVS DN C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS HS Investigative
DMDPBVS SN CHEMBL380638; c[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2
DMDPBVS DT Small molecular drug
DMDPBVS PC 11707715
DMDPBVS MW 844
DMDPBVS FM C43H61N11O7
DMDPBVS IC InChI=1S/C43H61N11O7/c1-3-5-16-31-38(57)51-32(17-6-4-2)39(58)53-34(23-26-13-8-7-9-14-26)41(60)52-33(19-12-22-47-43(45)46)40(59)54-35(24-27-25-48-29-18-11-10-15-28(27)29)42(61)50-30(37(44)56)20-21-36(55)49-31/h7-11,13-15,18,25,30-35,48H,3-6,12,16-17,19-24H2,1-2H3,(H2,44,56)(H,49,55)(H,50,61)(H,51,57)(H,52,60)(H,53,58)(H,54,59)(H4,45,46,47)/t30-,31-,32-,33-,34+,35-/m0/s1
DMDPBVS CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CCCC
DMDPBVS IK WGLOHHGRWPHJBM-MAVCTHMOSA-N
DMDPBVS IU (2S,5S,8R,11S,14S,17S)-8-benzyl-2,5-dibutyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMDPBVS DE Discovery agent
DMPZ4VB ID DMPZ4VB
DMPZ4VB DN C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
DMPZ4VB HS Investigative
DMPZ4VB SN CHEMBL203760; BDBM50184366
DMPZ4VB DT Small molecular drug
DMPZ4VB PC 11629326
DMPZ4VB MW 878
DMPZ4VB FM C46H59N11O7
DMPZ4VB IC InChI=1S/C46H59N11O7/c1-2-3-13-35-45(64)57-22-9-16-38(57)44(63)56-36(24-27-17-18-28-10-4-5-11-29(28)23-27)42(61)54-34(15-8-21-50-46(48)49)41(60)55-37(25-30-26-51-32-14-7-6-12-31(30)32)43(62)53-33(40(47)59)19-20-39(58)52-35/h4-7,10-12,14,17-18,23,26,33-38,51H,2-3,8-9,13,15-16,19-22,24-25H2,1H3,(H2,47,59)(H,52,58)(H,53,62)(H,54,61)(H,55,60)(H,56,63)(H4,48,49,50)/t33-,34-,35-,36+,37-,38-/m0/s1
DMPZ4VB CS CCCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC6=CC=CC=C6C=C5
DMPZ4VB IK QQCJWXXVYXUARZ-ZPRVLUMXSA-N
DMPZ4VB IU (3S,8S,11S,14S,17R,20S)-3-butyl-14-[3-(diaminomethylideneamino)propyl]-11-(1H-indol-3-ylmethyl)-17-(naphthalen-2-ylmethyl)-2,5,10,13,16,19-hexaoxo-1,4,9,12,15,18-hexazabicyclo[18.3.0]tricosane-8-carboxamide
DMPZ4VB DE Discovery agent
DMZWMV0 ID DMZWMV0
DMZWMV0 DN C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0 HS Investigative
DMZWMV0 SN CHEMBL381739; c[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2
DMZWMV0 DT Small molecular drug
DMZWMV0 PC 44408408
DMZWMV0 MW 828
DMZWMV0 FM C42H57N11O7
DMZWMV0 IC InChI=1S/C42H57N11O7/c1-2-3-14-31-41(60)53-21-10-17-34(53)40(59)52-32(22-25-11-5-4-6-12-25)38(57)50-30(16-9-20-46-42(44)45)37(56)51-33(23-26-24-47-28-15-8-7-13-27(26)28)39(58)49-29(36(43)55)18-19-35(54)48-31/h4-8,11-13,15,24,29-34,47H,2-3,9-10,14,16-23H2,1H3,(H2,43,55)(H,48,54)(H,49,58)(H,50,57)(H,51,56)(H,52,59)(H4,44,45,46)/t29-,30-,31-,32+,33-,34+/m0/s1
DMZWMV0 CS CCCC[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DMZWMV0 IK AKNCBPIMUGVGES-IPLXUGDNSA-N
DMZWMV0 IU (3S,8S,11S,14S,17R,20R)-17-benzyl-3-butyl-14-[3-(diaminomethylideneamino)propyl]-11-(1H-indol-3-ylmethyl)-2,5,10,13,16,19-hexaoxo-1,4,9,12,15,18-hexazabicyclo[18.3.0]tricosane-8-carboxamide
DMZWMV0 DE Discovery agent
DMSIGJW ID DMSIGJW
DMSIGJW DN C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2
DMSIGJW HS Investigative
DMSIGJW SN CHEMBL413573; BDBM50184361
DMSIGJW DT Small molecular drug
DMSIGJW PC 11700730
DMSIGJW MW 880
DMSIGJW FM C46H61N11O7
DMSIGJW IC InChI=1S/C46H61N11O7/c1-4-5-14-34-42(61)57-39(26(2)3)45(64)56-36(23-27-17-18-28-11-6-7-12-29(28)22-27)43(62)54-35(16-10-21-50-46(48)49)41(60)55-37(24-30-25-51-32-15-9-8-13-31(30)32)44(63)53-33(40(47)59)19-20-38(58)52-34/h6-9,11-13,15,17-18,22,25-26,33-37,39,51H,4-5,10,14,16,19-21,23-24H2,1-3H3,(H2,47,59)(H,52,58)(H,53,63)(H,54,62)(H,55,60)(H,56,64)(H,57,61)(H4,48,49,50)/t33-,34-,35-,36+,37-,39-/m0/s1
DMSIGJW CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4)C(C)C
DMSIGJW IK GVZTZLFKKLVBJF-JDABYTJISA-N
DMSIGJW IU (2S,5S,8R,11S,14S,17S)-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-8-(naphthalen-2-ylmethyl)-3,6,9,12,15,20-hexaoxo-5-propan-2-yl-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DMSIGJW DE Discovery agent
DM45ZLW ID DM45ZLW
DM45ZLW DN C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW HS Investigative
DM45ZLW SN CHEMBL427205; c[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2
DM45ZLW DT Small molecular drug
DM45ZLW PC 11593084
DM45ZLW MW 830
DM45ZLW FM C42H59N11O7
DM45ZLW IC InChI=1S/C42H59N11O7/c1-4-5-15-30-38(57)53-35(24(2)3)41(60)52-32(21-25-12-7-6-8-13-25)39(58)50-31(17-11-20-46-42(44)45)37(56)51-33(22-26-23-47-28-16-10-9-14-27(26)28)40(59)49-29(36(43)55)18-19-34(54)48-30/h6-10,12-14,16,23-24,29-33,35,47H,4-5,11,15,17-22H2,1-3H3,(H2,43,55)(H,48,54)(H,49,59)(H,50,58)(H,51,56)(H,52,60)(H,53,57)(H4,44,45,46)/t29-,30-,31-,32+,33-,35-/m0/s1
DM45ZLW CS CCCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N1)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)C(C)C
DM45ZLW IK STHTUYXXUBUJIE-NMIKHESWSA-N
DM45ZLW IU (2S,5S,8R,11S,14S,17S)-8-benzyl-2-butyl-11-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,20-hexaoxo-5-propan-2-yl-1,4,7,10,13,16-hexazacycloicosane-17-carboxamide
DM45ZLW DE Discovery agent
DMF091Y ID DMF091Y
DMF091Y DN C[RGD-(R)-alpha-TfmfV]
DMF091Y HS Investigative
DMF091Y SN CHEMBL377066; c[RGD-(R)-alpha-TfmfV]
DMF091Y DT Small molecular drug
DMF091Y PC 44408397
DMF091Y MW 690.7
DMF091Y FM C31H37F3N8O7
DMF091Y IC InChI=1S/C31H37F3N8O7/c32-31(33,34)30(16-19-10-5-2-6-11-19)28(49)41-21(14-18-8-3-1-4-9-18)26(47)40-20(12-7-13-37-29(35)36)25(46)38-17-23(43)39-22(15-24(44)45)27(48)42-30/h1-6,8-11,20-22H,7,12-17H2,(H,38,46)(H,39,43)(H,40,47)(H,41,49)(H,42,48)(H,44,45)(H4,35,36,37)/t20-,21-,22-,30+/m0/s1
DMF091Y CS C1C(=O)N[C@H](C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC=CC=C2)(CC3=CC=CC=C3)C(F)(F)F)CC(=O)O
DMF091Y IK UVOUWFPJSKSTMI-YNJMIAMQSA-N
DMF091Y IU 2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-5-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMF091Y DE Discovery agent
DMC9G2Y ID DMC9G2Y
DMC9G2Y DN C[RGD-(S)-alpha-TfmfV]
DMC9G2Y HS Investigative
DMC9G2Y SN CHEMBL379056; c[RGD-(S)-alpha-TfmfV]
DMC9G2Y DT Small molecular drug
DMC9G2Y PC 9986643
DMC9G2Y MW 642.6
DMC9G2Y FM C27H37F3N8O7
DMC9G2Y IC InChI=1S/C27H37F3N8O7/c1-14(2)20-23(44)36-16(9-6-10-33-25(31)32)21(42)34-13-18(39)35-17(11-19(40)41)22(43)38-26(24(45)37-20,27(28,29)30)12-15-7-4-3-5-8-15/h3-5,7-8,14,16-17,20H,6,9-13H2,1-2H3,(H,34,42)(H,35,39)(H,36,44)(H,37,45)(H,38,43)(H,40,41)(H4,31,32,33)/t16-,17-,20-,26-/m0/s1
DMC9G2Y CS CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@](C(=O)N1)(CC2=CC=CC=C2)C(F)(F)F)CC(=O)O)CCCN=C(N)N
DMC9G2Y IK IIJWLNNXJHIKND-CVJKZBOTSA-N
DMC9G2Y IU 2-[(2S,5S,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-5-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMC9G2Y DE Discovery agent
DM1DMR2 ID DM1DMR2
DM1DMR2 DN C[RGDf-(3R)-Carboxymorpholine]
DM1DMR2 HS Investigative
DM1DMR2 SN CHEMBL443362; c[RGDf-(3R)-Carboxymorpholine]
DM1DMR2 DT Small molecular drug
DM1DMR2 PC 44123805
DM1DMR2 MW 588.6
DM1DMR2 FM C26H36N8O8
DM1DMR2 IC InChI=1S/C26H36N8O8/c27-26(28)29-8-4-7-16-22(38)30-13-20(35)31-17(12-21(36)37)23(39)33-18(11-15-5-2-1-3-6-15)25(41)34-9-10-42-14-19(34)24(40)32-16/h1-3,5-6,16-19H,4,7-14H2,(H,30,38)(H,31,35)(H,32,40)(H,33,39)(H,36,37)(H4,27,28,29)/t16-,17-,18+,19+/m0/s1
DM1DMR2 CS C1COC[C@H]2N1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DM1DMR2 IK HKLGBIAIHDSNGD-INDMIFKZSA-N
DM1DMR2 IU 2-[(3R,6S,12S,15R)-3-benzyl-12-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14-pentaoxo-17-oxa-1,4,7,10,13-pentazabicyclo[13.4.0]nonadecan-6-yl]acetic acid
DM1DMR2 DE Discovery agent
DM0ULZM ID DM0ULZM
DM0ULZM DN C[RGDf-(3S)-Carboxymorpholine]
DM0ULZM HS Investigative
DM0ULZM SN CHEMBL452724; c[RGDf-(3S)-Carboxymorpholine]
DM0ULZM DT Small molecular drug
DM0ULZM PC 44123804
DM0ULZM MW 588.6
DM0ULZM FM C26H36N8O8
DM0ULZM IC InChI=1S/C26H36N8O8/c27-26(28)29-8-4-7-16-22(38)30-13-20(35)31-17(12-21(36)37)23(39)33-18(11-15-5-2-1-3-6-15)25(41)34-9-10-42-14-19(34)24(40)32-16/h1-3,5-6,16-19H,4,7-14H2,(H,30,38)(H,31,35)(H,32,40)(H,33,39)(H,36,37)(H4,27,28,29)/t16-,17-,18+,19-/m0/s1
DM0ULZM CS C1COC[C@@H]2N1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC2=O)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DM0ULZM IK HKLGBIAIHDSNGD-OKYOBFRVSA-N
DM0ULZM IU 2-[(3R,6S,12S,15S)-3-benzyl-12-[3-(diaminomethylideneamino)propyl]-2,5,8,11,14-pentaoxo-17-oxa-1,4,7,10,13-pentazabicyclo[13.4.0]nonadecan-6-yl]acetic acid
DM0ULZM DE Discovery agent
DMXA0JB ID DMXA0JB
DMXA0JB DN C[RGDf-(R)-alpha-TfmF]
DMXA0JB HS Investigative
DMXA0JB SN CHEMBL381589; c[RGDf-(R)-alpha-TfmF]
DMXA0JB DT Small molecular drug
DMXA0JB PC 11636164
DMXA0JB MW 690.7
DMXA0JB FM C31H37F3N8O7
DMXA0JB IC InChI=1S/C31H37F3N8O7/c32-31(33,34)30(16-19-10-5-2-6-11-19)28(49)41-20(12-7-13-37-29(35)36)25(46)38-17-23(43)39-22(15-24(44)45)26(47)40-21(27(48)42-30)14-18-8-3-1-4-9-18/h1-6,8-11,20-22H,7,12-17H2,(H,38,46)(H,39,43)(H,40,47)(H,41,49)(H,42,48)(H,44,45)(H4,35,36,37)/t20-,21+,22-,30+/m0/s1
DMXA0JB CS C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)(CC2=CC=CC=C2)C(F)(F)F)CC3=CC=CC=C3)CC(=O)O
DMXA0JB IK QAYABLFYSHKUBR-ULBBTDGDSA-N
DMXA0JB IU 2-[(2S,5R,8R,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMXA0JB DE Discovery agent
DM8FGMA ID DM8FGMA
DM8FGMA DN C[RGDf-(R)-alpha-TfmV]
DM8FGMA HS Investigative
DM8FGMA SN CHEMBL203077; c[RGDf-(R)-alpha-TfmV]
DM8FGMA DT Small molecular drug
DM8FGMA PC 11505585
DM8FGMA MW 642.6
DM8FGMA FM C27H37F3N8O7
DM8FGMA IC InChI=1S/C27H37F3N8O7/c1-14(2)26(27(28,29)30)24(45)37-16(9-6-10-33-25(31)32)21(42)34-13-19(39)35-18(12-20(40)41)22(43)36-17(23(44)38-26)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18H,6,9-13H2,1-2H3,(H,34,42)(H,35,39)(H,36,43)(H,37,45)(H,38,44)(H,40,41)(H4,31,32,33)/t16-,17+,18-,26+/m0/s1
DM8FGMA CS CC(C)[C@@]1(C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N)C(F)(F)F
DM8FGMA IK VYIBTYZRYKIMKX-ORVYPBFBSA-N
DM8FGMA IU 2-[(2S,5R,8R,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM8FGMA DE Discovery agent
DM4ZWOD ID DM4ZWOD
DM4ZWOD DN C[RGDf-(R)-N-Me-alpha-TfmF]
DM4ZWOD HS Investigative
DM4ZWOD SN CHEMBL381590; c[RGDf-(R)-N-Me-alpha-TfmF]
DM4ZWOD DT Small molecular drug
DM4ZWOD PC 11643340
DM4ZWOD MW 704.7
DM4ZWOD FM C32H39F3N8O7
DM4ZWOD IC InChI=1S/C32H39F3N8O7/c1-43-28(49)23(15-19-9-4-2-5-10-19)41-27(48)22(16-25(45)46)40-24(44)18-39-26(47)21(13-8-14-38-30(36)37)42-29(50)31(43,32(33,34)35)17-20-11-6-3-7-12-20/h2-7,9-12,21-23H,8,13-18H2,1H3,(H,39,47)(H,40,44)(H,41,48)(H,42,50)(H,45,46)(H4,36,37,38)/t21-,22-,23+,31+/m0/s1
DM4ZWOD CS CN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@]1(CC2=CC=CC=C2)C(F)(F)F)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DM4ZWOD IK IKBMFRHCMUKOBA-ZAUAPEEVSA-N
DM4ZWOD IU 2-[(2S,5R,8R,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM4ZWOD DE Discovery agent
DMCXJOL ID DMCXJOL
DMCXJOL DN C[RGDf-(S)-alpha-TfmF]
DMCXJOL HS Investigative
DMCXJOL SN CHEMBL204309; c[RGDf-(S)-alpha-TfmF]
DMCXJOL DT Small molecular drug
DMCXJOL PC 9831456
DMCXJOL MW 690.7
DMCXJOL FM C31H37F3N8O7
DMCXJOL IC InChI=1S/C31H37F3N8O7/c32-31(33,34)30(16-19-10-5-2-6-11-19)28(49)41-20(12-7-13-37-29(35)36)25(46)38-17-23(43)39-22(15-24(44)45)26(47)40-21(27(48)42-30)14-18-8-3-1-4-9-18/h1-6,8-11,20-22H,7,12-17H2,(H,38,46)(H,39,43)(H,40,47)(H,41,49)(H,42,48)(H,44,45)(H4,35,36,37)/t20-,21+,22-,30-/m0/s1
DMCXJOL CS C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)(CC2=CC=CC=C2)C(F)(F)F)CC3=CC=CC=C3)CC(=O)O
DMCXJOL IK QAYABLFYSHKUBR-QKFZZCAYSA-N
DMCXJOL IU 2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMCXJOL DE Discovery agent
DMLRYXK ID DMLRYXK
DMLRYXK DN C[RGDf-(S)-alpha-TfmV]
DMLRYXK HS Investigative
DMLRYXK SN CHEMBL203693; c[RGDf-(S)-alpha-TfmV]
DMLRYXK DT Small molecular drug
DMLRYXK PC 10416726
DMLRYXK MW 642.6
DMLRYXK FM C27H37F3N8O7
DMLRYXK IC InChI=1S/C27H37F3N8O7/c1-14(2)26(27(28,29)30)24(45)37-16(9-6-10-33-25(31)32)21(42)34-13-19(39)35-18(12-20(40)41)22(43)36-17(23(44)38-26)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18H,6,9-13H2,1-2H3,(H,34,42)(H,35,39)(H,36,43)(H,37,45)(H,38,44)(H,40,41)(H4,31,32,33)/t16-,17+,18-,26-/m0/s1
DMLRYXK CS CC(C)[C@]1(C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N)C(F)(F)F
DMLRYXK IK VYIBTYZRYKIMKX-KTJGCZTMSA-N
DMLRYXK IU 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMLRYXK DE Discovery agent
DMNS3HC ID DMNS3HC
DMNS3HC DN C[RGDf-(S)-N-Me-alpha-TfmF]
DMNS3HC HS Investigative
DMNS3HC SN CHEMBL413574; c[RGDf-(S)-N-Me-alpha-TfmF]
DMNS3HC DT Small molecular drug
DMNS3HC PC 10372586
DMNS3HC MW 704.7
DMNS3HC FM C32H39F3N8O7
DMNS3HC IC InChI=1S/C32H39F3N8O7/c1-43-28(49)23(15-19-9-4-2-5-10-19)41-27(48)22(16-25(45)46)40-24(44)18-39-26(47)21(13-8-14-38-30(36)37)42-29(50)31(43,32(33,34)35)17-20-11-6-3-7-12-20/h2-7,9-12,21-23H,8,13-18H2,1H3,(H,39,47)(H,40,44)(H,41,48)(H,42,50)(H,45,46)(H4,36,37,38)/t21-,22-,23+,31-/m0/s1
DMNS3HC CS CN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@]1(CC2=CC=CC=C2)C(F)(F)F)CCCN=C(N)N)CC(=O)O)CC3=CC=CC=C3
DMNS3HC IK IKBMFRHCMUKOBA-KAFAUTGVSA-N
DMNS3HC IU 2-[(2S,5R,8S,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-8-(trifluoromethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMNS3HC DE Discovery agent
DMAILK8 ID DMAILK8
DMAILK8 DN C[RGDf-(S,R)-alpha-Dfm-F]
DMAILK8 HS Investigative
DMAILK8 SN c[RGDf-(S,R)-alpha-Dfm-F]; CHEMBL379911
DMAILK8 DT Small molecular drug
DMAILK8 PC 11614485
DMAILK8 MW 672.7
DMAILK8 FM C31H38F2N8O7
DMAILK8 IC InChI=1S/C31H38F2N8O7/c32-28(33)31(16-19-10-5-2-6-11-19)29(48)40-20(12-7-13-36-30(34)35)25(45)37-17-23(42)38-22(15-24(43)44)26(46)39-21(27(47)41-31)14-18-8-3-1-4-9-18/h1-6,8-11,20-22,28H,7,12-17H2,(H,37,45)(H,38,42)(H,39,46)(H,40,48)(H,41,47)(H,43,44)(H4,34,35,36)/t20-,21+,22-,31?/m0/s1
DMAILK8 CS C1C(=O)N[C@H](C(=O)N[C@@H](C(=O)NC(C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)(CC2=CC=CC=C2)C(F)F)CC3=CC=CC=C3)CC(=O)O
DMAILK8 IK DZUCEYPUEFNCRE-ZONASRJLSA-N
DMAILK8 IU 2-[(2S,5R,11S)-5,8-dibenzyl-11-[3-(diaminomethylideneamino)propyl]-8-(difluoromethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMAILK8 DE Discovery agent
DMO7BMZ ID DMO7BMZ
DMO7BMZ DN C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]
DMO7BMZ HS Investigative
DMO7BMZ SN CHEMBL438596; c[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro]
DMO7BMZ PC 44406905
DMO7BMZ MW 1289.4
DMO7BMZ FM C63H84N16O14
DMO7BMZ IC InChI=1S/C63H84N16O14/c1-5-33(2)50-62(93)79-24-12-18-49(79)59(90)75-48(31-80)58(89)72-45(26-37-19-21-40(83)22-20-37)56(87)77-51(34(3)81)60(91)74-47(28-39-30-66-32-69-39)55(86)71-44(25-36-13-7-6-8-14-36)54(85)70-43(17-11-23-67-63(64)65)53(84)73-46(57(88)78-52(35(4)82)61(92)76-50)27-38-29-68-42-16-10-9-15-41(38)42/h6-10,13-16,19-22,29-30,32-35,43-52,68,80-83H,5,11-12,17-18,23-28,31H2,1-4H3,(H,66,69)(H,70,85)(H,71,86)(H,72,89)(H,73,84)(H,74,91)(H,75,90)(H,76,92)(H,77,87)(H,78,88)(H4,64,65,67)/t33-,34-,35-,43+,44-,45+,46-,47+,48+,49+,50-,51+,52-/m1/s1
DMO7BMZ CS CC[C@@H](C)[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)[C@@H](C)O)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5)CC6=CN=CN6)[C@@H](C)O)CC7=CC=C(C=C7)O)CO
DMO7BMZ IK FTGJNWCPPLBYMR-VTQDGRDPSA-N
DMO7BMZ IU 2-[3-[(3R,6R,9R,12S,15R,18S,21S,24S,27S,30S)-15-benzyl-3-[(2R)-butan-2-yl]-6,21-bis[(1R)-1-hydroxyethyl]-27-(hydroxymethyl)-24-[(4-hydroxyphenyl)methyl]-18-(1H-imidazol-5-ylmethyl)-9-(1H-indol-3-ylmethyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-12-yl]propyl]guanidine
DMO7BMZ DE Discovery agent
DMRY95I ID DMRY95I
DMRY95I DN C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]
DMRY95I HS Investigative
DMRY95I SN CHEMBL267492; c[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro]
DMRY95I PC 44406884
DMRY95I MW 1353.5
DMRY95I FM C68H88N16O14
DMRY95I IC InChI=1S/C68H88N16O14/c1-6-35(2)54-67(98)84-27-13-21-53(84)63(94)83-56(37(4)86)65(96)78-49(28-39-22-24-44(88)25-23-39)61(92)81-55(36(3)85)64(95)79-52(31-43-33-71-34-74-43)60(91)77-50(29-41-16-11-15-40-14-7-8-17-45(40)41)59(90)75-48(20-12-26-72-68(69)70)58(89)76-51(62(93)82-57(38(5)87)66(97)80-54)30-42-32-73-47-19-10-9-18-46(42)47/h7-11,14-19,22-25,32-38,48-57,73,85-88H,6,12-13,20-21,26-31H2,1-5H3,(H,71,74)(H,75,90)(H,76,89)(H,77,91)(H,78,96)(H,79,95)(H,80,97)(H,81,92)(H,82,93)(H,83,94)(H4,69,70,72)/t35-,36-,37-,38-,48+,49+,50-,51-,52+,53-,54-,55+,56+,57-/m1/s1
DMRY95I CS CC[C@@H](C)[C@@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)[C@@H](C)O)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC6=CC=CC=C65)CC7=CN=CN7)[C@@H](C)O)CC8=CC=C(C=C8)O)[C@@H](C)O
DMRY95I IK JUOTYAXVJMXIJJ-RTWQMTKCSA-N
DMRY95I IU 2-[3-[(3R,6R,9R,12S,15R,18S,21S,24S,27S,30R)-3-[(2R)-butan-2-yl]-6,21,27-tris[(1R)-1-hydroxyethyl]-24-[(4-hydroxyphenyl)methyl]-18-(1H-imidazol-5-ylmethyl)-9-(1H-indol-3-ylmethyl)-15-(naphthalen-1-ylmethyl)-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-12-yl]propyl]guanidine
DMRY95I DE Discovery agent
DM0YLPV ID DM0YLPV
DM0YLPV DN C[YYAEGLEE]-NH2
DM0YLPV HS Investigative
DM0YLPV SN CHEMBL1082940; c[YYAEGLEE]-NH2
DM0YLPV DT Small molecular drug
DM0YLPV PC 46831062
DM0YLPV MW 954
DM0YLPV FM C44H59N9O15
DM0YLPV IC InChI=1S/C44H59N9O15/c1-22(2)18-31-43(67)52-30(14-17-37(60)61)41(65)50-28(38(45)62)12-15-34(56)48-32(19-24-4-8-26(54)9-5-24)44(68)53-33(20-25-6-10-27(55)11-7-25)42(66)47-23(3)39(63)51-29(13-16-36(58)59)40(64)46-21-35(57)49-31/h4-11,22-23,28-33,54-55H,12-21H2,1-3H3,(H2,45,62)(H,46,64)(H,47,66)(H,48,56)(H,49,57)(H,50,65)(H,51,63)(H,52,67)(H,53,68)(H,58,59)(H,60,61)/t23-,28-,29-,30-,31-,32-,33-/m0/s1
DM0YLPV CS C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)C(=O)N)CCC(=O)O)CC(C)C)CCC(=O)O
DM0YLPV IK WSKHBZRJCGPPOH-RKNQSKIKSA-N
DM0YLPV IU 3-[(2S,5S,8S,11S,17S,20S,23S)-23-carbamoyl-20-(2-carboxyethyl)-2,5-bis[(4-hydroxyphenyl)methyl]-8-methyl-17-(2-methylpropyl)-3,6,9,12,15,18,21,26-octaoxo-1,4,7,10,13,16,19,22-octazacyclohexacos-11-yl]propanoic acid
DM0YLPV DE Discovery agent
DMSKW8H ID DMSKW8H
DMSKW8H DN C[YYDEGLEE]-NH2
DMSKW8H HS Investigative
DMSKW8H SN CHEMBL389147; c[YYDEGLEE]-NH2; BDBM50223446
DMSKW8H DT Small molecular drug
DMSKW8H PC 23630507
DMSKW8H MW 998
DMSKW8H FM C45H59N9O17
DMSKW8H IC InChI=1S/C45H59N9O17/c1-22(2)17-30-42(68)52-29(13-16-37(61)62)41(67)50-27(39(46)65)11-14-34(57)48-31(18-23-3-7-25(55)8-4-23)43(69)53-32(19-24-5-9-26(56)10-6-24)44(70)54-33(20-38(63)64)45(71)51-28(12-15-36(59)60)40(66)47-21-35(58)49-30/h3-10,22,27-33,55-56H,11-21H2,1-2H3,(H2,46,65)(H,47,66)(H,48,57)(H,49,58)(H,50,67)(H,51,71)(H,52,68)(H,53,69)(H,54,70)(H,59,60)(H,61,62)(H,63,64)/t27-,28-,29-,30-,31-,32-,33-/m0/s1
DMSKW8H CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CCC(=O)O)CC(=O)O)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)C(=O)N)CCC(=O)O
DMSKW8H IK FRCBDVBWQMWQOW-MRNVWEPHSA-N
DMSKW8H IU 3-[(3S,6S,12S,15S,18S,21S,26S)-26-carbamoyl-12-(2-carboxyethyl)-15-(carboxymethyl)-18,21-bis[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazacyclohexacos-3-yl]propanoic acid
DMSKW8H DE Discovery agent
DMTHGMR ID DMTHGMR
DMTHGMR DN C[YYDEKLEE]-NH2
DMTHGMR HS Investigative
DMTHGMR SN CHEMBL1082946
DMTHGMR PC 46831676
DMTHGMR MW 1069.1
DMTHGMR FM C49H68N10O17
DMTHGMR IC InChI=1S/C49H68N10O17/c1-25(2)21-34-46(73)55-32(15-18-39(63)64)44(71)53-30(42(51)69)14-17-38(62)52-35(22-26-6-10-28(60)11-7-26)47(74)58-36(23-27-8-12-29(61)13-9-27)48(75)59-37(24-41(67)68)49(76)56-33(16-19-40(65)66)45(72)54-31(43(70)57-34)5-3-4-20-50/h6-13,25,30-37,60-61H,3-5,14-24,50H2,1-2H3,(H2,51,69)(H,52,62)(H,53,71)(H,54,72)(H,55,73)(H,56,76)(H,57,70)(H,58,74)(H,59,75)(H,63,64)(H,65,66)(H,67,68)/t30-,31-,32-,33-,34-,35-,36-,37-/m0/s1
DMTHGMR CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CCC(=O)O)CC(=O)O)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)C(=O)N)CCC(=O)O
DMTHGMR IK UHCDRMNHCPWMSL-MDKUUQCZSA-N
DMTHGMR IU 3-[(3S,6S,9S,12S,15S,18S,21S,26S)-9-(4-aminobutyl)-26-carbamoyl-12-(2-carboxyethyl)-15-(carboxymethyl)-18,21-bis[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazacyclohexacos-3-yl]propanoic acid
DMTHGMR DE Discovery agent
DMD7OQA ID DMD7OQA
DMD7OQA DN C-014C
DMD7OQA HS Investigative
DMD7OQA SN C-014C; CHEMBL509396; BDBM50244050
DMD7OQA DT Small molecular drug
DMD7OQA PC 44561260
DMD7OQA MW 384.5
DMD7OQA FM C22H32N4O2
DMD7OQA IC InChI=1S/C22H32N4O2/c1-27-19-13-17-18(14-20(19)28-2)25-22(24-16-11-7-8-12-16)26-21(17)23-15-9-5-3-4-6-10-15/h13-16H,3-12H2,1-2H3,(H2,23,24,25,26)
DMD7OQA CS COC1=C(C=C2C(=C1)C(=NC(=N2)NC3CCCC3)NC4CCCCCC4)OC
DMD7OQA IK HZBKRPBMAVNOCZ-UHFFFAOYSA-N
DMD7OQA IU 4-N-cycloheptyl-2-N-cyclopentyl-6,7-dimethoxyquinazoline-2,4-diamine
DMD7OQA DE Discovery agent
DMNV1ST ID DMNV1ST
DMNV1ST DN C-10068
DMNV1ST HS Investigative
DMNV1ST SN Deuterated sigma-1 agonists (epilepsy/brain injury/neuropathic pain); Deuterated sigma-1 agonists (epilepsy/brain injury/neuropathic pain), CoNCERT/Walter Reed Army Institute
DMNV1ST CP CoNCERT Pharmaceuticals Inc
DMNV1ST DE Brain injury
DMZXE6O ID DMZXE6O
DMZXE6O DN C-16-(S)-3-methylindolerapamycin
DMZXE6O HS Investigative
DMZXE6O SN CHEMBL503885; C-16-(S)-3-methylindolerapamycin
DMZXE6O PC 44576240
DMZXE6O MW 1013.3
DMZXE6O FM C59H84N2O12
DMZXE6O IC InChI=1S/C59H84N2O12/c1-34-17-12-11-13-18-35(2)46(45-20-16-19-44-40(7)33-60-52(44)45)31-43-24-22-41(8)59(69,73-43)56(66)57(67)61-26-15-14-21-47(61)58(68)72-50(37(4)29-42-23-25-48(62)51(30-42)70-9)32-49(63)36(3)28-39(6)54(65)55(71-10)53(64)38(5)27-34/h11-13,16-20,28,33-34,36-38,41-43,46-48,50-51,54-55,60,62,65,69H,14-15,21-27,29-32H2,1-10H3/b13-11+,17-12+,35-18+,39-28+/t34-,36-,37-,38-,41-,42+,43+,46+,47+,48-,50+,51-,54-,55+,59-/m1/s1
DMZXE6O CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)C5=CC=CC6=C5NC=C6C
DMZXE6O IK MYMSKXFGXABEON-OYYFJIJNSA-N
DMZXE6O IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19-methoxy-15,17,21,23,29,35-hexamethyl-30-(3-methyl-1H-indol-7-yl)-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DMZXE6O DE Discovery agent
DM23KNC ID DM23KNC
DM23KNC DN C16-Fatty-Acyl-Substrate-Mimic
DM23KNC HS Investigative
DM23KNC SN C16-FATTY-ACYL-SUBSTRATE-MIMIC; TRANS-2-HEXADECENOYL-(N-ACETYL-CYSTEAMINE)-THIOESTER; AC1MP1RZ; S-Palmitoyl-N-acetylcysteamine; SCHEMBL5088794; DB02990; S-(2-acetamidoethyl) hexadecanethioate; S-[2-(acetylamino)ethyl] hexadecanethioate
DM23KNC DT Small molecular drug
DM23KNC PC 3378216
DM23KNC MW 357.6
DM23KNC FM C20H39NO2S
DM23KNC IC InChI=1S/C20H39NO2S/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(23)24-18-17-21-19(2)22/h3-18H2,1-2H3,(H,21,22)
DM23KNC CS CCCCCCCCCCCCCCCC(=O)SCCNC(=O)C
DM23KNC IK GDVZALUOXPTSHD-UHFFFAOYSA-N
DM23KNC IU S-(2-acetamidoethyl) hexadecanethioate
DM23KNC DE Discovery agent
DMKGSRZ ID DMKGSRZ
DMKGSRZ DN C-176
DMKGSRZ HS Investigative
DMKGSRZ SN 314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; STING inhibitor C-176; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1
DMKGSRZ DT Small molecular drug
DMKGSRZ PC 1103958
DMKGSRZ MW 358.09
DMKGSRZ FM C11H7IN2O4
DMKGSRZ IC InChI=1S/C11H7IN2O4/c12-7-1-3-8(4-2-7)13-11(15)9-5-6-10(18-9)14(16)17/h1-6H,(H,13,15)
DMKGSRZ CS C1=CC(=CC=C1NC(=O)C2=CC=C(O2)[N+](=O)[O-])I
DMKGSRZ IK JBIKQXOZLBLMKI-UHFFFAOYSA-N
DMKGSRZ IU N-(4-iodophenyl)-5-nitrofuran-2-carboxamide
DMKGSRZ DE Aicardi-Goutieres syndrome
DM4FEU8 ID DM4FEU8
DM4FEU8 DN C-178
DM4FEU8 HS Investigative
DM4FEU8 SN 329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide
DM4FEU8 DT Small molecular drug
DM4FEU8 PC 2866412
DM4FEU8 MW 322.27
DM4FEU8 FM C17H10N2O5
DM4FEU8 IC InChI=1S/C17H10N2O5/c20-17(14-7-8-16(24-14)19(21)22)18-10-5-6-12-11-3-1-2-4-13(11)23-15(12)9-10/h1-9H,(H,18,20)
DM4FEU8 CS C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)NC(=O)C4=CC=C(O4)[N+](=O)[O-]
DM4FEU8 IK URUVDCCYSJEGQQ-UHFFFAOYSA-N
DM4FEU8 IU N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide
DM4FEU8 DE Aicardi-Goutieres syndrome
DMCAO3V ID DMCAO3V
DMCAO3V DN C-21191
DMCAO3V HS Investigative
DMCAO3V SN Deuterium-modified GABA-A modulator (spasticity/neuropathic pain/anxiety), CoNCERT Pharmaceuticals
DMCAO3V CP CoNCERT Pharmaceuticals Inc
DMCAO3V DE Anxiety disorder
DMS87IF ID DMS87IF
DMS87IF DN C2-MAD
DMS87IF HS Investigative
DMS87IF SN C2-MYCOPHENOLIC ADENINE DINUCLEOTIDE; CHEMBL410744; {[5-(6-AMINO-PURIN-7-YL)-3,4-DIHYDROXY-TETRAHYDRO-FURAN-2-YLMETHOXY]-HYDROXY-PHOSPHORYLMETHYL}-PHOSPHONIC ACID MONO-[2-(4-HYDROXY-6-METHOXY-7-METHYL-3-OXO-1,3-DIHYDRO-ISOBENZOFURAN-5-YL)-ETHYL] ESTER; C2-MAD; AC1L9X62; BDBM19265; C2-Mycophenolic Adenine Dinucleotide (C2-MDA); MYD; 4-Methyl-5-methoxy-6-[2-(5'-adenylylmethylphosphonyloxy)ethyl]-7-hydroxyisobenzofuran-1(3H)-one
DMS87IF DT Small molecular drug
DMS87IF PC 477579
DMS87IF MW 645.4
DMS87IF FM C23H29N5O13P2
DMS87IF IC InChI=1S/C23H29N5O13P2/c1-10-12-5-38-23(32)14(12)16(29)11(19(10)37-2)3-4-39-42(33,34)9-43(35,36)40-6-13-17(30)18(31)22(41-13)28-8-27-15-20(24)25-7-26-21(15)28/h7-8,13,17-18,22,29-31H,3-6,9H2,1-2H3,(H,33,34)(H,35,36)(H2,24,25,26)/t13-,17-,18-,22-/m1/s1
DMS87IF CS CC1=C2COC(=O)C2=C(C(=C1OC)CCOP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DMS87IF IK AMYUZLUBFKOUEX-JKWAKEATSA-N
DMS87IF IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)ethoxy]phosphoryl]methyl]phosphinic acid
DMS87IF DE Discovery agent
DMTCOY9 ID DMTCOY9
DMTCOY9 DN C3
DMTCOY9 HS Investigative
DMTCOY9 SN 4-[2-[2-[3-acetamido-2-[[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoylamino]-5-[[6-amino-1-[[1-[(1-hydroxy-1-oxopropan-2-yl)amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid; AC1L18UY
DMTCOY9 DT Small molecular drug
DMTCOY9 PC 268
DMTCOY9 MW 1149.9
DMTCOY9 FM C40H65N9O26P2
DMTCOY9 IC InChI=1S/C40H65N9O26P2/c1-16(32(58)44-18(3)38(63)64)43-35(61)21(8-6-7-12-41)47-36(62)22(9-10-26(53)54)46-33(59)17(2)42-34(60)19(4)71-31-27(45-20(5)51)39(73-23(14-50)29(31)56)74-77(68,69)75-76(66,67)70-15-24-28(55)30(57)37(72-24)49-13-11-25(52)48-40(49)65/h11,13,16-19,21-24,27-31,37,39,50,55-57H,6-10,12,14-15,41H2,1-5H3,(H,42,60)(H,43,61)(H,44,58)(H,45,51)(H,46,59)(H,47,62)(H,53,54)(H,63,64)(H,66,67)(H,68,69)(H,48,52,65)
DMTCOY9 CS CC(C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NC(C)C(=O)O)NC(=O)C(C)OC1C(C(OC(C1O)CO)OP(=O)(O)OP(=O)(O)OCC2C(C(C(O2)N3C=CC(=O)NC3=O)O)O)NC(=O)C
DMTCOY9 IK QAXSYKNMKWGHOF-UHFFFAOYSA-N
DMTCOY9 IU 4-[2-[2-[3-acetamido-2-[[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoylamino]-5-[[6-amino-1-[[1-(1-carboxyethylamino)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
DMTCOY9 DE Discovery agent
DMGA9U7 ID DMGA9U7
DMGA9U7 DN C4-MAD
DMGA9U7 HS Investigative
DMGA9U7 SN C4-MAD; AC1O51QQ; CHEMBL1170847; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-[[hydroxy-[(E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-2-methyl-but-2-enoxy]phosphoryl]methyl]phosphinic acid; 9H-Purin-6-amine, 9-[5-O-[[[[[(2E)-4-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-2-methyl-2-butenyl]oxy]hydroxyphosphinyl]methyl]hydroxyphosphinyl]pentofuranosyl]-
DMGA9U7 DT Small molecular drug
DMGA9U7 PC 6475540
DMGA9U7 MW 685.5
DMGA9U7 FM C26H33N5O13P2
DMGA9U7 IC InChI=1S/C26H33N5O13P2/c1-12(4-5-14-19(32)17-15(7-41-26(17)35)13(2)22(14)40-3)6-42-45(36,37)11-46(38,39)43-8-16-20(33)21(34)25(44-16)31-10-30-18-23(27)28-9-29-24(18)31/h4,9-10,16,20-21,25,32-34H,5-8,11H2,1-3H3,(H,36,37)(H,38,39)(H2,27,28,29)/b12-4+/t16-,20-,21-,25-/m1/s1
DMGA9U7 CS CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/COP(=O)(CP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O
DMGA9U7 IK MCYWJNDIVYMDSF-AWOYCZEKSA-N
DMGA9U7 IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[hydroxy-[(E)-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-2-methylbut-2-enoxy]phosphoryl]methyl]phosphinic acid
DMGA9U7 DE Discovery agent
DM5971G ID DM5971G
DM5971G DN C4X-101
DM5971G HS Investigative
DM5971G SN TRH inhibitors (anxiety disorder/nutritional disorder/endocrine disease), Conformetrix
DM5971G CP Conformetrix
DM5971G DE Endocrine disease
DMEK4HZ ID DMEK4HZ
DMEK4HZ DN C5aR pepducins
DMEK4HZ HS Investigative
DMEK4HZ SN C5aR pepducins ((lipopeptide, inflammatory diseases); Component 5a receptor modulators (lipopeptide, inflammatory diseases), Anchor Therapeutics; C5aR pepducins ((lipopeptide, inflammatory diseases), Anchor Therapeutics
DMEK4HZ CP Anchor Therapeutics Inc
DMEK4HZ DE Inflammation
DMCOQKH ID DMCOQKH
DMCOQKH DN C646
DMCOQKH HS Investigative
DMCOQKH SN 328968-36-1; CHEMBL1797936; 4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid; C24H19N3O6; 4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid; C 646; AC1LPE4V; GTPL7004; SCHEMBL12092858; QCR-235; DTXSID30361651; MolPort-002-171-380; CHEBI:132974; ZINC8780879; s7152; 2295AH; AKOS000113052; SB19338; ST020490; C646, > J-018925; BRD-K73383190-001-03-1
DMCOQKH DT Small molecular drug
DMCOQKH PC 1285940
DMCOQKH MW 445.4
DMCOQKH FM C24H19N3O6
DMCOQKH IC InChI=1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12H,1-3H3,(H,29,30)/b19-12+
DMCOQKH CS CC1=CC(=C(C=C1C)[N+](=O)[O-])C2=CC=C(O2)/C=C/3\\C(=NN(C3=O)C4=CC=C(C=C4)C(=O)O)C
DMCOQKH IK HEKJYZZSCQBJGB-XDHOZWIPSA-N
DMCOQKH IU 4-[(4E)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid
DMCOQKH CA CAS 328968-36-1
DMCOQKH DE Discovery agent
DM4LIHQ ID DM4LIHQ
DM4LIHQ DN C6S
DM4LIHQ HS Investigative
DM4LIHQ SN CHEMBL1417
DM4LIHQ DT Small molecular drug
DM4LIHQ PC 44414814
DM4LIHQ MW 379.4
DM4LIHQ FM C18H21NO6S
DM4LIHQ IC InChI=1S/C18H21NO6S/c1-19-8-7-18-11-4-6-14(25-26(20,21)22)17(18)24-16-13(23-2)5-3-10(15(16)18)9-12(11)19/h3-6,11-12,14,17H,7-9H2,1-2H3,(H,20,21,22)/t11-,12+,14-,17-,18-/m0/s1
DM4LIHQ CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)OS(=O)(=O)O
DM4LIHQ IK JIYGLXDCNSTUSY-XSSYPUMDSA-N
DM4LIHQ IU [(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] hydrogen sulfate
DM4LIHQ DE Discovery agent
DM7MNOX ID DM7MNOX
DM7MNOX DN C7/3-phth
DM7MNOX HS Investigative
DM7MNOX SN heptane-1,7-bis(dimethyl-3'-phthalimidopropylammonium)
DM7MNOX DT Small molecular drug
DM7MNOX PC 168057
DM7MNOX MW 562.7
DM7MNOX FM C33H46N4O4+2
DM7MNOX IC InChI=1S/C33H46N4O4/c1-36(2,24-14-20-34-30(38)26-16-8-9-17-27(26)31(34)39)22-12-6-5-7-13-23-37(3,4)25-15-21-35-32(40)28-18-10-11-19-29(28)33(35)41/h8-11,16-19H,5-7,12-15,20-25H2,1-4H3/q+2
DM7MNOX CS C[N+](C)(CCCCCCC[N+](C)(C)CCCN1C(=O)C2=CC=CC=C2C1=O)CCCN3C(=O)C4=CC=CC=C4C3=O
DM7MNOX IK OSALRKZRWVYPFR-UHFFFAOYSA-N
DM7MNOX IU 3-(1,3-dioxoisoindol-2-yl)propyl-[7-[3-(1,3-dioxoisoindol-2-yl)propyl-dimethylazaniumyl]heptyl]-dimethylazanium
DM7MNOX CA CAS 22664-47-7
DM7MNOX DE Discovery agent
DMHGX1N ID DMHGX1N
DMHGX1N DN C75
DMHGX1N HS Investigative
DMHGX1N SN C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-
DMHGX1N DT Small molecular drug
DMHGX1N PC 4248455
DMHGX1N MW 254.32
DMHGX1N FM C14H22O4
DMHGX1N IC InChI=1S/C14H22O4/c1-3-4-5-6-7-8-9-11-12(13(15)16)10(2)14(17)18-11/h11-12H,2-9H2,1H3,(H,15,16)
DMHGX1N CS CCCCCCCCC1C(C(=C)C(=O)O1)C(=O)O
DMHGX1N IK VCWLZDVWHQVAJU-UHFFFAOYSA-N
DMHGX1N IU 4-methylidene-2-octyl-5-oxooxolane-3-carboxylic acid
DMHGX1N CA CAS 218137-86-1
DMHGX1N CB CHEBI:95108
DMHGX1N DE Obesity
DMX85E7 ID DMX85E7
DMX85E7 DN Ca(2+) chelator
DMX85E7 HS Investigative
DMX85E7 DE Discovery agent
DMP5OSK ID DMP5OSK
DMP5OSK DN CA-327
DMP5OSK HS Investigative
DMP5OSK DT Small molecule immunotherapy
DMCLN6M ID DMCLN6M
DMCLN6M DN CA-50040
DMCLN6M HS Investigative
DMCLN6M CP POZEN Inc
DMCLN6M DE Colorectal cancer
DMQATPN ID DMQATPN
DMQATPN DN CAA0225
DMQATPN HS Investigative
DMQATPN SN CAA0225; CAA-0225; GTPL6532; (2S,3S)-2-N-[(1S)-1-(benzylcarbamoyl)-2-phenylethyl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide
DMQATPN DT Small molecular drug
DMQATPN PC 50909779
DMQATPN MW 487.5
DMQATPN FM C28H29N3O5
DMQATPN IC InChI=1S/C28H29N3O5/c32-22-13-11-19(12-14-22)15-16-29-27(34)24-25(36-24)28(35)31-23(17-20-7-3-1-4-8-20)26(33)30-18-21-9-5-2-6-10-21/h1-14,23-25,32H,15-18H2,(H,29,34)(H,30,33)(H,31,35)/t23-,24-,25-/m0/s1
DMQATPN CS C1=CC=C(C=C1)C[C@@H](C(=O)NCC2=CC=CC=C2)NC(=O)[C@@H]3[C@H](O3)C(=O)NCCC4=CC=C(C=C4)O
DMQATPN IK ZMZQYVMNDRBKLO-SDHOMARFSA-N
DMQATPN IU (2S,3S)-2-N-[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]-3-N-[2-(4-hydroxyphenyl)ethyl]oxirane-2,3-dicarboxamide
DMQATPN DE Discovery agent
DMPKFYZ ID DMPKFYZ
DMPKFYZ DN CACA
DMPKFYZ HS Investigative
DMPKFYZ SN cis-aminocrotonic acid; 4-aminocrotonic acid
DMPKFYZ DT Small molecular drug
DMPKFYZ PC 6603697
DMPKFYZ MW 101.1
DMPKFYZ FM C4H7NO2
DMPKFYZ IC InChI=1S/C4H7NO2/c5-3-1-2-4(6)7/h1-2H,3,5H2,(H,6,7)/b2-1-
DMPKFYZ CS C(/C=C\\C(=O)O)N
DMPKFYZ IK FMKJUUQOYOHLTF-UPHRSURJSA-N
DMPKFYZ IU (Z)-4-aminobut-2-enoic acid
DMPKFYZ CA CAS 55199-25-2
DMPKFYZ DE Discovery agent
DMK4XLD ID DMK4XLD
DMK4XLD DN Cacodylate Ion
DMK4XLD HS Investigative
DMK4XLD SN Dimethylarsinate; Arsinic acid, dimethyl-, ion(1-); Bolate; Bolls; 15132-04-4; Dimethylarsonic Acid; rad-e-cat 25; Cacodylate ions; Cacodylic acid, free acid; Kakodylat; DMAV; Dimethylarsinic acidanion; AC1L4ZLM; CAC; Me2AsO2(-); AC1Q1WC3; CHEBI:16223; CTK4C7002; BDBM92451; DTXSID60164758; OGGXGZAMXPVRFZ-UHFFFAOYSA-M; Scotts Stop Weeds After They Start; Scotts Spot Grass and Weed Control; [As(CH3)2O2](-); AKOS032954710; Arsinic acid,dimethyl-, ion(1-) (9CI)
DMK4XLD DT Small molecular drug
DMK4XLD PC 167250
DMK4XLD MW 136.99
DMK4XLD FM C2H6AsO2-
DMK4XLD IC InChI=1S/C2H7AsO2/c1-3(2,4)5/h1-2H3,(H,4,5)/p-1
DMK4XLD CS C[As](=O)(C)[O-]
DMK4XLD IK OGGXGZAMXPVRFZ-UHFFFAOYSA-M
DMK4XLD IU dimethylarsinate
DMK4XLD CA CAS 15132-04-4
DMK4XLD CB CHEBI:16223
DMK4XLD DE Discovery agent
DMIPJUS ID DMIPJUS
DMIPJUS DN CACOSPONGIONOLIDE
DMIPJUS HS Investigative
DMIPJUS SN cacospongionolide; CHEMBL480681
DMIPJUS DT Small molecular drug
DMIPJUS PC 21774960
DMIPJUS MW 400.5
DMIPJUS FM C25H36O4
DMIPJUS IC InChI=1S/C25H36O4/c1-16-8-12-25-15-23(25,2)10-4-5-20(25)24(16,3)11-9-17-6-7-19(28-14-17)18-13-21(26)29-22(18)27/h6,13,16,19-20,22,27H,4-5,7-12,14-15H2,1-3H3/t16-,19+,20+,22+,23-,24-,25-/m0/s1
DMIPJUS CS C[C@H]1CC[C@@]23C[C@@]2(CCC[C@@H]3[C@@]1(C)CCC4=CC[C@@H](OC4)C5=CC(=O)O[C@H]5O)C
DMIPJUS IK FPUWYDSKOKLTDH-FRMRWZTPSA-N
DMIPJUS IU (2R)-3-[(2R)-5-[2-[(1aS,4aR,5S,6S,8aS)-1a,5,6-trimethyl-1,2,3,4,4a,6,7,8-octahydrocyclopropa[e]naphthalen-5-yl]ethyl]-3,6-dihydro-2H-pyran-2-yl]-2-hydroxy-2H-furan-5-one
DMIPJUS DE Discovery agent
DMCSXNW ID DMCSXNW
DMCSXNW DN CACOSPONGIONOLIDE B
DMCSXNW HS Investigative
DMCSXNW SN cacospongionolide B; CHEMBL111739
DMCSXNW DT Small molecular drug
DMCSXNW PC 10386285
DMCSXNW MW 400.5
DMCSXNW FM C25H36O4
DMCSXNW IC InChI=1S/C25H36O4/c1-16-6-5-7-21-24(16,3)12-10-17(2)25(21,4)13-11-18-8-9-20(28-15-18)19-14-22(26)29-23(19)27/h8,14,17,20-21,23,27H,1,5-7,9-13,15H2,2-4H3/t17-,20?,21-,23?,24-,25-/m1/s1
DMCSXNW CS C[C@@H]1CC[C@]2([C@H]([C@]1(C)CCC3=CCC(OC3)C4=CC(=O)OC4O)CCCC2=C)C
DMCSXNW IK CVAZWHZRZNYCOV-ILKJNQADSA-N
DMCSXNW IU 3-[5-[2-[(1R,2R,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]ethyl]-3,6-dihydro-2H-pyran-2-yl]-2-hydroxy-2H-furan-5-one
DMCSXNW DE Discovery agent
DM2DYAV ID DM2DYAV
DM2DYAV DN Cacospongionolide E
DM2DYAV HS Investigative
DM2DYAV SN cacospongionolide E; CHEMBL480874; BDBM50259952
DM2DYAV DT Small molecular drug
DM2DYAV PC 23243376
DM2DYAV MW 400.5
DM2DYAV FM C25H36O4
DM2DYAV IC InChI=1S/C25H36O4/c1-16-6-5-7-21-24(16,3)12-10-17(2)25(21,4)13-11-18-8-9-20(28-15-18)19-14-22(26)29-23(19)27/h6,8,14,17,20-21,23,27H,5,7,9-13,15H2,1-4H3/t17-,20+,21-,23+,24-,25-/m0/s1
DM2DYAV CS C[C@H]1CC[C@@]2([C@@H]([C@@]1(C)CCC3=CC[C@@H](OC3)C4=CC(=O)O[C@H]4O)CCC=C2C)C
DM2DYAV IK WBDQPITVPUAHAN-DRCQBYJMSA-N
DM2DYAV IU (2R)-3-[(2R)-5-[2-[(1S,2S,4aR,8aR)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]ethyl]-3,6-dihydro-2H-pyran-2-yl]-2-hydroxy-2H-furan-5-one
DM2DYAV DE Discovery agent
DMLKZQH ID DMLKZQH
DMLKZQH DN cADPR
DMLKZQH HS Investigative
DMLKZQH SN cyclic ADP ribose
DMLKZQH DT Small molecular drug
DMLKZQH PC 123847
DMLKZQH MW 541.3
DMLKZQH FM C15H21N5O13P2
DMLKZQH IC InChI=1S/C15H21N5O13P2/c16-12-7-13-18-4-19(12)14-10(23)8(21)5(31-14)1-29-34(25,26)33-35(27,28)30-2-6-9(22)11(24)15(32-6)20(13)3-17-7/h3-6,8-11,14-16,21-24H,1-2H2,(H,25,26)(H,27,28)/t5-,6-,8-,9-,10-,11-,14-,15-/m1/s1
DMLKZQH CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=CN(C4=N)[C@H]5[C@@H]([C@@H]([C@H](O5)COP(=O)(OP(=O)(O1)O)O)O)O)O)O
DMLKZQH IK BQOHYSXSASDCEA-KEOHHSTQSA-N
DMLKZQH IU (2R,3R,4S,5R,13R,14S,15R,16R)-8,10-dihydroxy-24-imino-8,10-dioxo-7,9,11,25,26-pentaoxa-1,17,19,22-tetraza-8lambda5,10lambda5-diphosphapentacyclo[18.3.1.12,5.113,16.017,21]hexacosa-18,20,22-triene-3,4,14,15-tetrol
DMLKZQH CA CAS 119340-53-3
DMLKZQH CB CHEBI:31445
DMLKZQH DE Discovery agent
DMRJKIV ID DMRJKIV
DMRJKIV DN Caffeic acid phenethyl ester
DMRJKIV HS Investigative
DMRJKIV SN Caffeic acid phenethyl ester; Phenethyl caffeate; 104594-70-9; CAPE; phenethyl 3-(3,4-dihydroxyphenyl)acrylate; Capeee; Phenylethyl caffeate; 115610-29-2; caffeic acid phenylethyl ester; UNII-G960R9S5SK; 2-phenylethyl caffeate; PHENETHYL CAFFEATE (CAPE); Caffeic acid-phenethyl ester; CHEBI:8062; G960R9S5SK; CHEMBL319244; 100981-80-4; Caffeic acid 2-phenylethyl ester; SWUARLUWKZWEBQ-VQHVLOKHSA-N; 2-phenylethyl 3-(3,4-dihydroxyphenyl)-2-propenoate; Caffeic Acid Phenethyl Ester, Synthetic; 2-Phenylethyl (2e)-3-(3,4-Dihydroxyphenyl
DMRJKIV DT Small molecular drug
DMRJKIV PC 5281787
DMRJKIV MW 284.31
DMRJKIV FM C17H16O4
DMRJKIV IC InChI=1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-7+
DMRJKIV CS C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O
DMRJKIV IK SWUARLUWKZWEBQ-VQHVLOKHSA-N
DMRJKIV IU 2-phenylethyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMRJKIV CA CAS 115610-29-2
DMRJKIV CB CHEBI:8062
DMRJKIV DE Discovery agent
DM6NPUM ID DM6NPUM
DM6NPUM DN CALCEOLARIOSIDE A
DM6NPUM HS Investigative
DM6NPUM SN Calceolarioside A; CHEMBL481635; 84744-28-5; AC1NRV65; MEGxp0_000507; ACon1_000369; MolPort-001-740-672; ZINC31156700; BDBM50259819; MCULE-7153533238; NCGC00169142-01; Calceolarioside A, > [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-(hydroxymethyl)tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), (E)-; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 4-O-[(2E)-3-(3
DM6NPUM DT Small molecular drug
DM6NPUM PC 5273566
DM6NPUM MW 478.4
DM6NPUM FM C23H26O11
DM6NPUM IC InChI=1S/C23H26O11/c24-11-18-22(34-19(29)6-3-12-1-4-14(25)16(27)9-12)20(30)21(31)23(33-18)32-8-7-13-2-5-15(26)17(28)10-13/h1-6,9-10,18,20-28,30-31H,7-8,11H2/b6-3+/t18-,20-,21-,22-,23-/m1/s1
DM6NPUM CS C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O)O)O
DM6NPUM IK UHIGZYLCYRQESL-VJWFJHQPSA-N
DM6NPUM IU [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DM6NPUM CA CAS 84744-28-5
DM6NPUM DE Discovery agent
DMEAUK5 ID DMEAUK5
DMEAUK5 DN CALCEOLARIOSIDE B
DMEAUK5 HS Investigative
DMEAUK5 SN Calceolarioside B; 105471-98-5; Calceorioside B; CHEMBL518414; CHEBI:68345; Nuomioside A; Calceolarioside-B; AC1NRV68; MEGxp0_000508; ACon1_000407; DTXSID70414938; MolPort-001-740-673; ZINC14512219; BDBM50269516; AKOS016010662; MCULE-4912944466; NCGC00169106-01; AJ-64948; KB-279900; ST24046273; Y0045; 3,4-Dihydroxyphenethyl 6-O-[3-(3,4-dihydroxyphenyl)propenoyl]-beta-D-glucopyranoside; NCGC00169106-02![(2R,3S,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMEAUK5 DT Small molecular drug
DMEAUK5 PC 5273567
DMEAUK5 MW 478.4
DMEAUK5 FM C23H26O11
DMEAUK5 IC InChI=1S/C23H26O11/c24-14-4-1-12(9-16(14)26)3-6-19(28)33-11-18-20(29)21(30)22(31)23(34-18)32-8-7-13-2-5-15(25)17(27)10-13/h1-6,9-10,18,20-27,29-31H,7-8,11H2/b6-3+/t18-,20-,21+,22-,23-/m1/s1
DMEAUK5 CS C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O)O)O)O
DMEAUK5 IK LFKQVVDFNHDYNK-FOXCETOMSA-N
DMEAUK5 IU [(2R,3S,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMEAUK5 CA CAS 105471-98-5
DMEAUK5 CB CHEBI:68345
DMEAUK5 DE Discovery agent
DML562D ID DML562D
DML562D DN Calcineurin
DML562D HS Investigative
DML562D DE T-cell mediated immune dysfunction
DMZ45M6 ID DMZ45M6
DMZ45M6 DN calcitriol-26,23-lactone
DMZ45M6 HS Investigative
DMZ45M6 SN (23S,25R)-1alpha,25-(OH)2D3-26,23-lactone; 1,25-dihydroxyvitamin D3-26,23-lactone; 1,25-lactone
DMZ45M6 DT Small molecular drug
DMZ45M6 PC 6438368
DMZ45M6 MW 444.6
DMZ45M6 FM C27H40O5
DMZ45M6 IC InChI=1S/C27H40O5/c1-16(12-21-15-27(4,31)25(30)32-21)22-9-10-23-18(6-5-11-26(22,23)3)7-8-19-13-20(28)14-24(29)17(19)2/h7-8,16,20-24,28-29,31H,2,5-6,9-15H2,1,3-4H3/b18-7+,19-8-/t16-,20-,21+,22-,23+,24+,26-,27-/m1/s1
DMZ45M6 CS C[C@H](C[C@H]1C[C@@](C(=O)O1)(C)O)[C@H]2CC[C@@H]\\3[C@@]2(CCC/C3=C\\C=C/4\\C[C@H](C[C@@H](C4=C)O)O)C
DMZ45M6 IK WMYIVSWWSRCZFA-RWVJFQLJSA-N
DMZ45M6 IU (3R,5S)-5-[(2R)-2-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]propyl]-3-hydroxy-3-methyloxolan-2-one
DMZ45M6 CA CAS 81203-50-1
DMZ45M6 CB CHEBI:156153
DMZ45M6 DE Discovery agent
DMJXZD5 ID DMJXZD5
DMJXZD5 DN calhex 231
DMJXZD5 HS Investigative
DMJXZD5 SN calhex-231
DMJXZD5 DT Small molecular drug
DMJXZD5 PC 11849514
DMJXZD5 MW 406.9
DMJXZD5 FM C25H27ClN2O
DMJXZD5 IC InChI=1S/C25H27ClN2O/c1-17(21-10-6-8-18-7-2-3-9-22(18)21)27-23-11-4-5-12-24(23)28-25(29)19-13-15-20(26)16-14-19/h2-3,6-10,13-17,23-24,27H,4-5,11-12H2,1H3,(H,28,29)/t17-,23+,24+/m1/s1
DMJXZD5 CS C[C@H](C1=CC=CC2=CC=CC=C21)N[C@H]3CCCC[C@@H]3NC(=O)C4=CC=C(C=C4)Cl
DMJXZD5 IK YTFUQWWKTIWYEY-CQLNOVPUSA-N
DMJXZD5 IU 4-chloro-N-[(1S,2S)-2-[[(1R)-1-naphthalen-1-ylethyl]amino]cyclohexyl]benzamide
DMJXZD5 DE Discovery agent
DMY9P6E ID DMY9P6E
DMY9P6E DN calindol
DMY9P6E HS Investigative
DMY9P6E SN calindol; CHEMBL2092942; Clindol; GTPL719; SCHEMBL4103949; CHEMBL1801356; ZINC1494434; BDBM50404271; NCGC00344505-01
DMY9P6E DT Small molecular drug
DMY9P6E PC 9882793
DMY9P6E MW 300.4
DMY9P6E FM C21H20N2
DMY9P6E IC InChI=1S/C21H20N2/c1-15(19-11-6-9-16-7-2-4-10-20(16)19)22-14-18-13-17-8-3-5-12-21(17)23-18/h2-13,15,22-23H,14H2,1H3/t15-/m1/s1
DMY9P6E CS C[C@H](C1=CC=CC2=CC=CC=C21)NCC3=CC4=CC=CC=C4N3
DMY9P6E IK JLPWXRZETODYFC-OAHLLOKOSA-N
DMY9P6E IU (1R)-N-(1H-indol-2-ylmethyl)-1-naphthalen-1-ylethanamine
DMY9P6E CA CAS 374933-30-9
DMY9P6E DE Discovery agent
DM5ZTJL ID DM5ZTJL
DM5ZTJL DN Calmidazolium
DM5ZTJL HS Investigative
DM5ZTJL SN Calmidazolium ion; 95013-41-5; CHEBI:75400; R24571; MLS002172477; CHEMBL1208858; SMR001254103; SR-01000075486; Probes1_000251; Probes2_000292; Lopac0_000272; methoxy]ethyl]-1H-imidazolium; cid_644274; SCHEMBL8224791; CHEMBL1229168; BDBM76238; DTXSID30915173; BDBM50323389; HSCI1_000319; CCG-204367; NCGC00015233-02; NCGC00015233-03; NCGC00015233-04; NCGC00015233-08; NCGC00162113-01; NCGC00167775-01; 1-(Bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-1H-imidazolium; 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium; 1-[bis(4-chlorophenyl)methyl]-3-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium; 1H-Imidazolium, 1-(bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-; SR-01000075486-7; SR-01000075486-8; BRD-A26199074-003-01-2; Q27145276; 3-[bis(4-chlorophenyl)methyl]-1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl); 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorobenzyl)oxy-2-(2,4-dichlorophenyl)ethyl]imidazol-3-ium;chloride; 1-[Bis(4-chlorophenyl)methyl]-3-{2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl}-1H-imidazol-3-ium
DM5ZTJL DT Small molecular drug
DM5ZTJL PC 2531
DM5ZTJL MW 652.2
DM5ZTJL FM C31H23Cl6N2O+
DM5ZTJL IC InChI=1S/C31H23Cl6N2O/c32-23-6-1-20(2-7-23)31(21-3-8-24(33)9-4-21)39-14-13-38(19-39)17-30(27-12-11-26(35)16-29(27)37)40-18-22-5-10-25(34)15-28(22)36/h1-16,19,30-31H,17-18H2/q+1
DM5ZTJL CS C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)N3C=C[N+](=C3)CC(C4=C(C=C(C=C4)Cl)Cl)OCC5=C(C=C(C=C5)Cl)Cl)Cl
DM5ZTJL IK CTKNMSVWMRRCPW-UHFFFAOYSA-N
DM5ZTJL IU 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium
DM5ZTJL CA CAS 95013-41-5
DM5ZTJL CB CHEBI:75400
DM5ZTJL DE Huntington disease
DMVXKLF ID DMVXKLF
DMVXKLF DN CALOPOCARPIN
DMVXKLF HS Investigative
DMVXKLF SN calopocarpin; CHEMBL1096407; MolPort-005-945-433; ZINC15115178; BDBM50317436; MCULE-1067987266; NCGC00347827-02; NCGC00347827-02_C20H20O4_6H-Benzofuro[3,2-c][1]benzopyran-3,9-diol, 6a,11a-dihydro-2-(3-methyl-2-buten-1-yl)-, (6aR,11aR)-
DMVXKLF DT Small molecular drug
DMVXKLF PC 11709595
DMVXKLF MW 324.4
DMVXKLF FM C20H20O4
DMVXKLF IC InChI=1S/C20H20O4/c1-11(2)3-4-12-7-15-18(9-17(12)22)23-10-16-14-6-5-13(21)8-19(14)24-20(15)16/h3,5-9,16,20-22H,4,10H2,1-2H3/t16-,20-/m0/s1
DMVXKLF CS CC(=CCC1=CC2=C(C=C1O)OC[C@@H]3[C@H]2OC4=C3C=CC(=C4)O)C
DMVXKLF IK CYXCYFYWIZXENQ-JXFKEZNVSA-N
DMVXKLF IU (6aR,11aR)-2-(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMVXKLF DE Discovery agent
DMR0CNQ ID DMR0CNQ
DMR0CNQ DN Calpastatin
DMR0CNQ HS Investigative
DMR0CNQ SN Acacetin-7-O-glucuronide methyl ester; AC1NUQS7; 79076-87-2; beta-D-Glucopyranosiduronic acid, 5-hydroxy-2-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-7-yl, methyl ester; methyl (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[5-hydroxy-2-(4-methoxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylate
DMR0CNQ DT Small molecular drug
DMR0CNQ PC 90488788
DMR0CNQ MW 3177.6
DMR0CNQ FM C142H230N36O44S
DMR0CNQ IC InChI=1S/C142H230N36O44S/c1-18-74(11)111(172-129(211)97(65-81-38-42-83(185)43-39-81)168-136(218)113(77(14)181)174-131(213)100(69-180)170-130(212)99(68-179)169-124(206)92(52-60-223-17)162-132(214)101-33-26-57-176(101)138(220)98(66-109(195)196)154-79(16)183)135(217)163-90(46-50-107(191)192)121(203)159-88(44-48-105(187)188)122(204)164-93(61-70(3)4)116(198)152-67-104(186)155-84(29-20-22-53-143)117(199)156-86(31-24-55-150-141(146)147)118(200)160-91(47-51-108(193)194)125(207)171-110(73(9)10)134(216)175-114(78(15)182)137(219)173-112(75(12)19-2)140(222)178-59-28-35-103(178)139(221)177-58-27-34-102(177)133(215)161-85(30-21-23-54-144)120(202)167-96(64-80-36-40-82(184)41-37-80)128(210)157-87(32-25-56-151-142(148)149)119(201)158-89(45-49-106(189)190)123(205)165-95(63-72(7)8)127(209)166-94(62-71(5)6)126(208)153-76(13)115(145)197/h36-43,70-78,84-103,110-114,179-182,184-185H,18-35,44-69,143-144H2,1-17H3,(H2,145,197)(H,152,198)(H,153,208)(H,154,183)(H,155,186)(H,156,199)(H,157,210)(H,158,201)(H,159,203)(H,160,200)(H,161,215)(H,162,214)(H,163,217)(H,164,204)(H,165,205)(H,166,209)(H,167,202)(H,168,218)(H,169,206)(H,170,212)(H,171,207)(H,172,211)(H,173,219)(H,174,213)(H,175,216)(H,187,188)(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H4,146,147,150)(H4,148,149,151)/t74-,75-,76-,77+,78+,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,110-,111-,112-,113-,114-/m0/s1
DMR0CNQ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(=O)O)NC(=O)C
DMR0CNQ IK ZXJCOYBPXOBJMU-HSQGJUDPSA-N
DMR0CNQ IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-1-[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-acetamido-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-6-aminohexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMR0CNQ CA CAS 79079-11-1
DMR0CNQ CB CHEBI:131884
DMR0CNQ DE Discovery agent
DMBK2S8 ID DMBK2S8
DMBK2S8 DN Calusterone
DMBK2S8 HS Investigative
DMBK2S8 SN CALUSTERONE; Methosarb; Dimethyltestosterone; Calusteronum; Calusterona; 7-beta,17-Dimethyltestosterone; Calusteronum [INN-Latin]; Calusterona [INN-Spanish]; 7beta,17alpha-Dimethyltestosterone; 17021-26-0; 7beta,17-Dimethyltestosterone; Calusteron; 7-beta,17-alpha-Dimethyl testosterone; Calusterone [USAN:INN]; NSC-88536; UNII-0678G6Q58A; HSDB 3210; 17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one; U 22550; U-22,550; BRN 3212336; 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one
DMBK2S8 DT Small molecular drug
DMBK2S8 PC 28204
DMBK2S8 MW 316.5
DMBK2S8 FM C21H32O2
DMBK2S8 IC InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1
DMBK2S8 CS C[C@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C)O)C
DMBK2S8 IK IVFYLRMMHVYGJH-PVPPCFLZSA-N
DMBK2S8 IU (7S,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,10,13,17-tetramethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMBK2S8 CA CAS 17021-26-0
DMBK2S8 CB CHEBI:135356
DMBK2S8 DE Discovery agent
DMY29Q8 ID DMY29Q8
DMY29Q8 DN Calyculin-A
DMY29Q8 HS Investigative
DMY29Q8 SN calyculin A; C05370; 101932-71-2; [(3R,5R,7R,8S,9S)-2-[(1S,3S,4S,5R,6R,7E,9E,11E,13Z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyl-tetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[(1S)-3-[[(2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxy-pentanoyl]amino]-1-methyl-propyl]oxazol-4-yl]allyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate
DMY29Q8 DT Small molecular drug
DMY29Q8 PC 5311365
DMY29Q8 MW 1009.2
DMY29Q8 FM C50H81N4O15P
DMY29Q8 IC InChI=1S/C50H81N4O15P/c1-29(20-22-51)16-14-17-30(2)32(4)24-33(5)42(57)35(7)38(55)25-41(65-13)45-46(69-70(61,62)63)49(8,9)50(68-45)26-39(56)34(6)40(67-50)19-15-18-36-27-66-48(53-36)31(3)21-23-52-47(60)44(59)43(58)37(28-64-12)54(10)11/h14-18,20,24,27,31,33-35,37-46,55-59H,19,21,23,25-26,28H2,1-13H3,(H,52,60)(H2,61,62,63)/b16-14+,18-15+,29-20-,30-17+,32-24+/t31-,33+,34-,35-,37-,38-,39+,40-,41-,42+,43-,44-,45+,46-,50+/m0/s1
DMY29Q8 CS C[C@H]1[C@@H](C[C@@]2(C([C@H]([C@H](O2)[C@H](C[C@@H]([C@H](C)[C@@H]([C@H](C)/C=C(\\C)/C(=C/C=C/C(=C\\C#N)/C)/C)O)O)OC)OP(=O)(O)O)(C)C)O[C@H]1C/C=C/C3=COC(=N3)[C@@H](C)CCNC(=O)[C@H]([C@H]([C@H](COC)N(C)C)O)O)O
DMY29Q8 IK FKAWLXNLHHIHLA-YCBIHMBMSA-N
DMY29Q8 IU [(2R,3R,5R,7R,8S,9S)-2-[(1S,3S,4S,5R,6R,7E,9E,11E,13Z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(E)-3-[2-[(2S)-4-[[(2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4-yl]prop-2-enyl]-7-hydroxy-4,4,8-trimethyl-1,10-dioxaspiro[4.5]decan-3-yl] dihydrogen phosphate
DMY29Q8 CA CAS 101932-71-2
DMY29Q8 DE Discovery agent
DMMBA70 ID DMMBA70
DMMBA70 DN CALYSTEGINE B2
DMMBA70 HS Investigative
DMMBA70 SN Calystegine B2; (1S,2R,3S,4R,5S)-8-AZABICYCLO[3.2.1]OCTANE-1,2,3,4-TETROL; 8-Aza-bicyclo[3.2.1]octane-1,2,3,4-tetraol; (1R,2S,3R,4S,5R)-8-azabicyclo[3.2.1]octane-1,2,3,4-tetrol; 127414-85-1; CGB; Calystegine B(2); 2cbv; 1,2,3,4-Tetrahydroxy-nor-tropane; CID124434; SCHEMBL2435745; CHEMBL526330; BDBM36389; MolPort-006-169-861; ZINC12504453; (2-endo,3-exo,4-endo)-8-Azabicyclo(3.2.1)octane-1,2,3,4-tetrol; AKOS030531595; DB04658; LS-190985; W-200999; 8-Aza-bicyclo[3.2.1]octane-1,2,3,4-tetraol, 14
DMMBA70 DT Small molecular drug
DMMBA70 PC 124434
DMMBA70 MW 175.18
DMMBA70 FM C7H13NO4
DMMBA70 IC InChI=1S/C7H13NO4/c9-4-3-1-2-7(12,8-3)6(11)5(4)10/h3-6,8-12H,1-2H2/t3-,4+,5-,6+,7-/m1/s1
DMMBA70 CS C1C[C@]2([C@H]([C@@H]([C@H]([C@@H]1N2)O)O)O)O
DMMBA70 IK FXFBVZOJVHCEDO-IBISWUOJSA-N
DMMBA70 IU (1R,2S,3R,4S,5R)-8-azabicyclo[3.2.1]octane-1,2,3,4-tetrol
DMMBA70 CA CAS 127414-85-1
DMMBA70 DE Discovery agent
DM4FVDS ID DM4FVDS
DM4FVDS DN CAM-2036
DM4FVDS HS Investigative
DM4FVDS SN Glucagon-like peptide 1 agonist (sustained release subcutaneous injection, type 2 diabetes), Camurus
DM4FVDS CP Camurus AB
DM4FVDS DE Non-insulin dependent diabetes
DMVAP4T ID DMVAP4T
DMVAP4T DN Camrelizumab
DMVAP4T HS Investigative
DMVAP4T SN GTPL9758; SHR-1210
DMVAP4T TC Antiviral Agents
DMVAP4T DT Monoclonal antibody
DMVAP4T DE Coronavirus Disease 2019 (COVID-19)
DMNLTGF ID DMNLTGF
DMNLTGF DN Canaline
DMNLTGF HS Investigative
DMNLTGF SN L-Canaline; 496-93-5; (S)-2-Amino-4-(aminooxy)butanoic acid; O-Amino-L-homoserine; L-Homoserine, O-amino-; UNII-T7H2XP1ZNS; T7H2XP1ZNS; (2S)-2-amino-4-(aminooxy)butanoic acid; L-2-amino-4-(aminooxy)butyrate; L-2-amino-4-(aminooxy)butyric acid; L-a-amino-g-(aminooxy)-n-butyric acid; 2-Amino-4-(aminooxy)butyric acid; L-Canaline base; 1-Amino-3-amino-oxybutyric acid; AC1L9B6J; SCHEMBL440859; CHEMBL1231652; CTK1D6980; DTXSID60197925; MolPort-019-904-731; FQPGMQABJNQLLF-VKHMYHEASA-N; ZINC1531042; ANW-63284; AKOS006274866; L-canaline
DMNLTGF DT Small molecular drug
DMNLTGF PC 441443
DMNLTGF MW 134.13
DMNLTGF FM C4H10N2O3
DMNLTGF IC InChI=1S/C4H10N2O3/c5-3(4(7)8)1-2-9-6/h3H,1-2,5-6H2,(H,7,8)/t3-/m0/s1
DMNLTGF CS C(CON)[C@@H](C(=O)O)N
DMNLTGF IK FQPGMQABJNQLLF-VKHMYHEASA-N
DMNLTGF IU (2S)-2-amino-4-aminooxybutanoic acid
DMNLTGF CA CAS 496-93-5
DMNLTGF CB CHEBI:41401
DMNLTGF DE Discovery agent
DMM6A7P ID DMM6A7P
DMM6A7P DN cannabinol
DMM6A7P HS Investigative
DMM6A7P SN cannabinol; 521-35-7; Cannabinolo [DCIT]; Cannabinolum [INN-Latin]; Cannabinol [INN:BAN]; UNII-7UYP6MC9GH; 6H-Dibenzo(b,d)pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; NSC 134455; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo(b,d)pyran; 7UYP6MC9GH; BRN 0237145; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; CHEMBL74415; CHEBI:3360; VBGLYOIFKLUMQG-UHFFFAOYSA-N; 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-
DMM6A7P DT Small molecular drug
DMM6A7P PC 2543
DMM6A7P MW 310.4
DMM6A7P FM C21H26O2
DMM6A7P IC InChI=1S/C21H26O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9-13,22H,5-8H2,1-4H3
DMM6A7P CS CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O
DMM6A7P IK VBGLYOIFKLUMQG-UHFFFAOYSA-N
DMM6A7P IU 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol
DMM6A7P CA CAS 521-35-7
DMM6A7P CB CHEBI:3360
DMM6A7P DE Discovery agent
DME32XU ID DME32XU
DME32XU DN CANTHARIDIC_ACID
DME32XU HS Investigative
DME32XU SN cantharidic acid; 2,3-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid; exo-1,6-Dicarboxy-endo-1,6-dimethyl-7-oxabicylco[2,2,1]heptane; 2,3-Dicarboxy-2,3-dimethyl-1,4-epoxycyclohexane; NSC115503; AC1L1DX2; Lopac0_000318; SCHEMBL943636; BMK1-G11; CHEMBL275516; CTK7I5696; HMS3260P18; Tox21_500318; HSCI1_000263; CCG-204413; NSC-115503; LP00318; NCGC00093763-02; NCGC00015272-04; NCGC00015272-03; NCGC00015272-02; NCGC00261003-01; NCGC00093763-01; EU-0100318; C 8088; SR-01000075783; SR-01000075783-1
DME32XU DT Small molecular drug
DME32XU PC 2544
DME32XU MW 214.21
DME32XU FM C10H14O5
DME32XU IC InChI=1S/C10H14O5/c1-9(7(11)12)5-3-4-6(15-5)10(9,2)8(13)14/h5-6H,3-4H2,1-2H3,(H,11,12)(H,13,14)
DME32XU CS CC1(C2CCC(C1(C)C(=O)O)O2)C(=O)O
DME32XU IK NMTNUQBORQILRK-UHFFFAOYSA-N
DME32XU IU 2,3-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid
DME32XU DE Discovery agent
DM9IG2P ID DM9IG2P
DM9IG2P DN Cantide + Cisplatin
DM9IG2P HS Investigative
DM9IG2P SN cis-Diaminedichloroplatinum; CPDC; cis-Diamminedichlorplatine; cis-Dichlorodiamine platinum; Diamminedichloroplatinum; Platinum diamine dichloride; Platinum, diamminedichloro-; trans-Diaminedichloroplatinum; NCGC00090759-01; DSSTox_CID_4983; DSSTox_RID_77611; DSSTox_GSID_24983; CAS-15663-27-1; Platiblastin; cisplatin complex; DDPt; cis-Platinum(II); Pt(II) Complex; cis Pt II; CPDD; dichloroplatinumdiamine; Platinum(IV) Complex; Platinum (II) complex; Neuro_000055; cis-Platinum diamminedichloride; DTXSID4024983; MolPort-003-983-464
DM9IG2P TC Antisense
DM9IG2P DT Combination drug (Antisense drug)
DM9IG2P PC 2767
DM9IG2P MW 298.03
DM9IG2P FM Cl2H4N2Pt
DM9IG2P IC InChI=1S/2ClH.2H2N.Pt/h2*1H;2*1H2;/q;;2*-1;+4/p-2
DM9IG2P CS [NH2-].[NH2-].Cl[Pt+2]Cl
DM9IG2P IK DQLATGHUWYMOKM-UHFFFAOYSA-L
DM9IG2P IU azanide;dichloroplatinum(2+)
DM9IG2P CA CAS 26035-31-4
DM9IG2P DE Tumour
DMDZE8N ID DMDZE8N
DMDZE8N DN CAPROCTAMINE
DMDZE8N HS Investigative
DMDZE8N SN CAPROCTAMINE; CHEMBL11805; SCHEMBL18398791; BDBM50067482; N,N''''-(octane-1,8-diyl)bis(6-((2-methoxybenzyl)(methyl)amino)-N-methylhexanamide); 6-[(2-Methoxy-benzyl)-methyl-amino]-hexanoic acid [8-({6-[(2-methoxy-benzyl)-methyl-amino]-hexanoyl}-methyl-amino)-octyl]-methyl-amide
DMDZE8N DT Small molecular drug
DMDZE8N PC 10055202
DMDZE8N MW 667
DMDZE8N FM C40H66N4O4
DMDZE8N IC InChI=1S/C40H66N4O4/c1-41(33-35-23-15-17-25-37(35)47-5)29-19-11-13-27-39(45)43(3)31-21-9-7-8-10-22-32-44(4)40(46)28-14-12-20-30-42(2)34-36-24-16-18-26-38(36)48-6/h15-18,23-26H,7-14,19-22,27-34H2,1-6H3
DMDZE8N CS CN(CCCCCC(=O)N(C)CCCCCCCCN(C)C(=O)CCCCCN(C)CC1=CC=CC=C1OC)CC2=CC=CC=C2OC
DMDZE8N IK HDAQKLAKMZNBQB-UHFFFAOYSA-N
DMDZE8N IU 6-[(2-methoxyphenyl)methyl-methylamino]-N-[8-[6-[(2-methoxyphenyl)methyl-methylamino]hexanoyl-methylamino]octyl]-N-methylhexanamide
DMDZE8N DE Discovery agent
DMLGS82 ID DMLGS82
DMLGS82 DN Caprylic acid
DMLGS82 HS Investigative
DMLGS82 SN octanoic acid; caprylic acid; 124-07-2; n-octanoic acid; n-caprylic acid; Octylic acid; octoic acid; n-octylic acid; n-Octoic acid; neo-fat 8; 1-heptanecarboxylic acid; Enantic acid; Octic acid; C-8 acid; Caprylsaeure; capryloate; Kaprylsaeure; Hexacid 898; Acido octanoico; Acide octanoique; 0ctanoic acid; Acidum octanocium; Caprylic acid (natural); Kyselina kaprylova; Fatty acids, C6-10; octylate; Octansaeure; Acide octanoique [French]; 1-octanoic acid; Acidum octanocium [Latin]; Acido octanoico [Spanish]; NSC 5024; Kyselina kaprylova [C
DMLGS82 DT Small molecular drug
DMLGS82 PC 379
DMLGS82 MW 144.21
DMLGS82 FM C8H16O2
DMLGS82 IC InChI=1S/C8H16O2/c1-2-3-4-5-6-7-8(9)10/h2-7H2,1H3,(H,9,10)
DMLGS82 CS CCCCCCCC(=O)O
DMLGS82 IK WWZKQHOCKIZLMA-UHFFFAOYSA-N
DMLGS82 IU octanoic acid
DMLGS82 CA CAS 124-07-2
DMLGS82 CB CHEBI:28837
DMLGS82 DE Discovery agent
DM4ATCI ID DM4ATCI
DM4ATCI DN CAPSAZEPINE
DM4ATCI HS Investigative
DM4ATCI SN capsazepine; 138977-28-3; capsazepin; N-[2-(4-Chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide; UNII-LFW48MY844; N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2-benzazepine-2-carbothioamide; CHEMBL391997; LFW48MY844; ST50826300; CHEBI:70773; N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carbothioamide; N-(2-[4-chlorophenyl]ethyl)-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide
DM4ATCI DT Small molecular drug
DM4ATCI PC 2733484
DM4ATCI MW 376.9
DM4ATCI FM C19H21ClN2O2S
DM4ATCI IC InChI=1S/C19H21ClN2O2S/c20-16-5-3-13(4-6-16)7-8-21-19(25)22-9-1-2-14-10-17(23)18(24)11-15(14)12-22/h3-6,10-11,23-24H,1-2,7-9,12H2,(H,21,25)
DM4ATCI CS C1CC2=CC(=C(C=C2CN(C1)C(=S)NCCC3=CC=C(C=C3)Cl)O)O
DM4ATCI IK DRCMAZOSEIMCHM-UHFFFAOYSA-N
DM4ATCI IU N-[2-(4-chlorophenyl)ethyl]-7,8-dihydroxy-1,3,4,5-tetrahydro-2-benzazepine-2-carbothioamide
DM4ATCI CA CAS 138977-28-3
DM4ATCI CB CHEBI:70773
DM4ATCI DE Discovery agent
DMJFPA9 ID DMJFPA9
DMJFPA9 DN CARAMIPEN
DMJFPA9 HS Investigative
DMJFPA9 SN Caramiphen; Parpanil; 77-22-5; Pentaphen (pharmaceutical); Caramiphen [INN:BAN]; Caramiphenum [INN-Latin]; Caramiphene [INN-French]; UNII-97J7NP0XJY; Caramifenio [INN-Spanish]; EINECS 201-013-6; BRN 2144901; 97J7NP0XJY; CYCLOPENTANECARBOXYLIC ACID, 1-PHENYL-, 2-(DIETHYLAMINO)ETHYL ESTER; CHEMBL61946; 1-Phenylcyclopentanecarboxylic acid 2-(diethylamino)ethyl ester; 2-Diethylaminoethyl 1-phenylcyclopentancarboxylat; 2-(Diethylamino)ethyl 1-phenylcyclopentanecarboxylate; 2-Diethylaminoethyl 1-phenylcyclopentane-1-carboxylate
DMJFPA9 DT Small molecular drug
DMJFPA9 PC 6472
DMJFPA9 MW 289.4
DMJFPA9 FM C18H27NO2
DMJFPA9 IC InChI=1S/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3
DMJFPA9 CS CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2
DMJFPA9 IK OFAIGZWCDGNZGT-UHFFFAOYSA-N
DMJFPA9 IU 2-(diethylamino)ethyl 1-phenylcyclopentane-1-carboxylate
DMJFPA9 CA CAS 77-22-5
DMJFPA9 CB CHEBI:135204
DMJFPA9 DE Discovery agent
DMEKI1J ID DMEKI1J
DMEKI1J DN Carazolol
DMEKI1J HS Investigative
DMEKI1J SN Carazolol; 57775-29-8; Conducton; Suacron; corazolol; Carazolol [INN:BAN]; 1-((9H-Carbazol-4-yl)oxy)-3-(isopropylamino)propan-2-ol; Carazololum [INN-Latin]; CCRIS 1047; Conducton hydrochloride; 1-(Carbazol-4-yloxy)-3-(isopropylamino)-2-propanol; 1-(9H-carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol; EINECS 260-945-1; BRN 3620576; BM-51052; BM 51052; CHEMBL324665; 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-(4-Carbazolyloxy)-3-isopropylamino-2-propanol
DMEKI1J DT Small molecular drug
DMEKI1J PC 71739
DMEKI1J MW 298.4
DMEKI1J FM C18H22N2O2
DMEKI1J IC InChI=1S/C18H22N2O2/c1-12(2)19-10-13(21)11-22-17-9-5-8-16-18(17)14-6-3-4-7-15(14)20-16/h3-9,12-13,19-21H,10-11H2,1-2H3
DMEKI1J CS CC(C)NCC(COC1=CC=CC2=C1C3=CC=CC=C3N2)O
DMEKI1J IK BQXQGZPYHWWCEB-UHFFFAOYSA-N
DMEKI1J IU 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
DMEKI1J CA CAS 57775-29-8
DMEKI1J CB CHEBI:135261
DMEKI1J DE Discovery agent
DMMBQYE ID DMMBQYE
DMMBQYE DN carbacyclin
DMMBQYE HS Investigative
DMMBQYE SN carboprostacyclin
DMMBQYE DT Small molecular drug
DMMBQYE PC 5311242
DMMBQYE MW 350.5
DMMBQYE FM C21H34O4
DMMBQYE IC InChI=1S/C21H34O4/c1-2-3-4-8-17(22)10-11-18-19-13-15(7-5-6-9-21(24)25)12-16(19)14-20(18)23/h7,10-11,16-20,22-23H,2-6,8-9,12-14H2,1H3,(H,24,25)/b11-10+,15-7-/t16-,17-,18+,19-,20+/m0/s1
DMMBQYE CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C\\CCCC(=O)O)/C2)O)O
DMMBQYE IK XZFRIPGNUQRGPI-WLPVIMDJSA-N
DMMBQYE IU (5Z)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
DMMBQYE DE Discovery agent
DMJQ3LN ID DMJQ3LN
DMJQ3LN DN Carbamic Acid
DMJQ3LN HS Investigative
DMJQ3LN SN Aminoformic acid; 463-77-4; UNII-O0UC6XOS4H; O0UC6XOS4H; CHEBI:28616; OUT; Carbamidsaeure; Aminoformate; ammoniocarboxylate; Aminoameisensaeure; imidocarbonic acid; Aminomethanoic Acid; aminocarboxylic acid; AC1L18VM; CHEMBL125278; DTXSID5048009; CTK1D6698; 1111-78-0 (ammonium salt); KXDHJXZQYSOELW-UHFFFAOYSA-N; 4366-93-2 (potassium salt); ZINC8383199; BDBM50369454; ABP000336; Carbamic acid(6CI,7CI,8CI,9CI); ACM463774; AKOS006223007; DB04261; NCGC00166327-01; LS-69662; KB-75881; DB-011502; FT-0689176
DMJQ3LN DT Small molecular drug
DMJQ3LN PC 277
DMJQ3LN MW 61.04
DMJQ3LN FM CH3NO2
DMJQ3LN IC InChI=1S/CH3NO2/c2-1(3)4/h2H2,(H,3,4)
DMJQ3LN CS C(=O)(N)O
DMJQ3LN IK KXDHJXZQYSOELW-UHFFFAOYSA-N
DMJQ3LN IU carbamic acid
DMJQ3LN CA CAS 463-77-4
DMJQ3LN CB CHEBI:28616
DMJQ3LN DE Discovery agent
DMZYK1W ID DMZYK1W
DMZYK1W DN Carbamoyl phosphate disodium
DMZYK1W HS Investigative
DMZYK1W DE Discovery agent
DMGP4M3 ID DMGP4M3
DMGP4M3 DN Carba-Nicotinamide-Adenine-Dinucleotide
DMGP4M3 HS Investigative
DMGP4M3 SN Carba-NAD; Carbanicotinamide adenine dinucleotide; 112345-60-5; AC1L4TS7; AC1Q5J0L; SCHEMBL16445201; 5'-o-{[({[(1r,2r,3s,4r)-4-(3-carbamoylpyridinium-1-yl)-2,3-dihydroxycyclopentyl]methoxy}phosphinato)oxy](hydroxy)phosphoryl}adenosine; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-((4-(3-(aminocarbonyl)pyridinio)-2,3-dihydroxycyclopentyl)m
DMGP4M3 DT Small molecular drug
DMGP4M3 PC 163884
DMGP4M3 MW 662.5
DMGP4M3 FM C22H30N7O13P2+
DMGP4M3 IC InChI=1S/C22H29N7O13P2/c23-19-14-21(26-8-25-19)29(9-27-14)22-18(33)17(32)13(41-22)7-40-44(37,38)42-43(35,36)39-6-11-4-12(16(31)15(11)30)28-3-1-2-10(5-28)20(24)34/h1-3,5,8-9,11-13,15-18,22,30-33H,4,6-7H2,(H5-,23,24,25,26,34,35,36,37,38)/p+1/t11-,12-,13-,15-,16+,17-,18-,22-/m1/s1
DMGP4M3 CS C1[C@@H]([C@H]([C@H]([C@@H]1[N+]2=CC=CC(=C2)C(=O)N)O)O)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O
DMGP4M3 IK DGPLSUKWXXSBCU-VGXGLJSLSA-O
DMGP4M3 IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(1R,2R,3S,4R)-4-(3-carbamoylpyridin-1-ium-1-yl)-2,3-dihydroxycyclopentyl]methyl hydrogen phosphate
DMGP4M3 DE Discovery agent
DMGFLI7 ID DMGFLI7
DMGFLI7 DN Carbaphosphonate
DMGFLI7 HS Investigative
DMGFLI7 SN carbaphosphonate; CRB; [1R-(1ALPHA,3BETA,4ALPHA,5BETA)]-5-(PHOSPHONOMETHYL)-1,3,4-TRIHYDROXYCYCLOHEXANE-1-CARBOXYLIC ACID; AC1L9HHC; DB02592; (1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexanecarboxylic acid; 1,3beta,4alpha-Trihydroxy-5beta-(phosphonomethyl)cyclohexane-1beta-carboxylic acid; (1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexane-1-carboxylic acid
DMGFLI7 DT Small molecular drug
DMGFLI7 PC 445131
DMGFLI7 MW 270.17
DMGFLI7 FM C8H15O8P
DMGFLI7 IC InChI=1S/C8H15O8P/c9-5-2-8(13,7(11)12)1-4(6(5)10)3-17(14,15)16/h4-6,9-10,13H,1-3H2,(H,11,12)(H2,14,15,16)/t4-,5-,6-,8+/m1/s1
DMGFLI7 CS C1[C@@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)O)O)CP(=O)(O)O
DMGFLI7 IK BKLICLLAHMTUPK-UNGCPHIMSA-N
DMGFLI7 IU (1S,3R,4R,5S)-1,3,4-trihydroxy-5-(phosphonomethyl)cyclohexane-1-carboxylic acid
DMGFLI7 DE Discovery agent
DMO648T ID DMO648T
DMO648T DN Carbenoxolone
DMO648T HS Investigative
DMO648T SN carbenoxolone; 5697-56-3; UNII-MM6384NG73; OBZHEBDUNPOCJG-WBXJDKIVSA-N; MM6384NG73; Carbenoxolone [INN:BAN]; Carbenoxolonum [INN-Latin]; Carbenoxolona [INN-Spanish]; Carbenoxolona; Carbenoxolonum; EINECS 227-174-2; CBO; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-(4-hydroxy-4-oxobutanoyl)oxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-saeure hydogensuccinat; 3beta-(3-Carboxypropionyloxy)-11-oxo-olean-12-en-30-saeure
DMO648T DT Small molecular drug
DMO648T PC 636403
DMO648T MW 570.8
DMO648T FM C34H50O7
DMO648T IC InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1
DMO648T CS C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)O)C)(C)C(=O)O
DMO648T IK OBZHEBDUNPOCJG-WBXJDKIVSA-N
DMO648T IU (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-(3-carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid
DMO648T CA CAS 5697-56-3
DMO648T DE Discovery agent
DM87SOX ID DM87SOX
DM87SOX DN Carbocyclic Peptidomimetic
DM87SOX HS Investigative
DM87SOX SN Carbocyclic Peptidomimetic; CHEMBL434943; OM99-2 cyclopentano analog 3; BDBM16049; N-{[(1R,2R)-2-{(1S,2S)-2-[(L-alpha-glutamyl-L-valyl-L-asparaginyl)amino]-1-hydroxy-4-methylpentyl}cyclopentyl]carbonyl}-L-alanyl-L-alpha-glutamyl-L-phenylalanine; (4S)-4-[(2S)-2-{[(1R,2R)-2-[(1S,2S)-2-[(2S)-2-[(2S)-2-[(4S)-4-amino-4-formamidobutanoic acid]-3-methylbutanamido]butanediamido]-1-hydroxy-4-methylpentyl]cyclopentyl]formamido}propanamido]-4-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}butanoic acid
DM87SOX DT Small molecular drug
DM87SOX PC 11205295
DM87SOX MW 919
DM87SOX FM C43H66N8O14
DM87SOX IC InChI=1S/C43H66N8O14/c1-21(2)18-29(48-41(62)30(20-32(45)52)49-42(63)35(22(3)4)51-39(60)27(44)14-16-33(53)54)36(57)25-12-9-13-26(25)38(59)46-23(5)37(58)47-28(15-17-34(55)56)40(61)50-31(43(64)65)19-24-10-7-6-8-11-24/h6-8,10-11,21-23,25-31,35-36,57H,9,12-20,44H2,1-5H3,(H2,45,52)(H,46,59)(H,47,58)(H,48,62)(H,49,63)(H,50,61)(H,51,60)(H,53,54)(H,55,56)(H,64,65)/t23-,25+,26+,27-,28-,29-,30-,31-,35-,36-/m0/s1
DM87SOX CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@@H]2CCC[C@H]2[C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)N)O
DM87SOX IK SEJYUEISOCTKKB-SABPYFDQSA-N
DM87SOX IU (4S)-4-amino-5-[[(2S)-1-[[(2S)-4-amino-1-[[(1S,2S)-1-[(1R,2R)-2-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]cyclopentyl]-1-hydroxy-4-methylpentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM87SOX DE Discovery agent
DMGKSVF ID DMGKSVF
DMGKSVF DN carbocyclic thromboxane A2
DMGKSVF HS Investigative
DMGKSVF SN 9alpha,11alpha,11a-dicarba-TXA2; CTA-2
DMGKSVF DT Small molecular drug
DMGKSVF PC 5311387
DMGKSVF MW 348.5
DMGKSVF FM C22H36O3
DMGKSVF IC InChI=1S/C22H36O3/c1-2-3-6-9-20(23)13-12-18-14-17-15-19(16-17)21(18)10-7-4-5-8-11-22(24)25/h4,7,12-13,17-21,23H,2-3,5-6,8-11,14-16H2,1H3,(H,24,25)/b7-4-,13-12+/t17?,18-,19?,20-,21+/m0/s1
DMGKSVF CS CCCCC[C@@H](/C=C/[C@H]1CC2CC(C2)[C@@H]1C/C=C\\CCCC(=O)O)O
DMGKSVF IK ZIWNJZLXPXFNGN-GXTQQWMXSA-N
DMGKSVF IU (Z)-7-[(2S,3R)-3-[(E,3S)-3-hydroxyoct-1-enyl]-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMGKSVF CA CAS 74034-56-3
DMGKSVF DE Discovery agent
DMA3FZR ID DMA3FZR
DMA3FZR DN Carbodine
DMA3FZR HS Investigative
DMA3FZR SN Carbocyclic cytidine; 4-amino-1-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]pyrimidin-2-one; 71184-20-8; (-)-Carbodine; (+/-)-Carbodine; AC1LA1FO; C-ARC-C; SCHEMBL3333453; CHEMBL1089302; 2(1H)-Pyrimidinone, 4-amino-1-[2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-, (2:1),(1alpha,2beta,3beta, 4alpha)-(+/-)-
DMA3FZR DT Small molecular drug
DMA3FZR PC 459903
DMA3FZR MW 241.24
DMA3FZR FM C10H15N3O4
DMA3FZR IC InChI=1S/C10H15N3O4/c11-7-1-2-13(10(17)12-7)6-3-5(4-14)8(15)9(6)16/h1-2,5-6,8-9,14-16H,3-4H2,(H2,11,12,17)/t5-,6-,8-,9+/m1/s1
DMA3FZR CS C1[C@@H]([C@H]([C@H]([C@@H]1N2C=CC(=NC2=O)N)O)O)CO
DMA3FZR IK UAZJPMMKWBPACD-GCXDCGAKSA-N
DMA3FZR IU 4-amino-1-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]pyrimidin-2-one
DMA3FZR DE Discovery agent
DMCNV68 ID DMCNV68
DMCNV68 DN Carboron Cluster with phenol
DMCNV68 HS Investigative
DMCNV68 DE Discovery agent
DMEORTQ ID DMEORTQ
DMEORTQ DN Carboxyatractyloside
DMEORTQ HS Investigative
DMEORTQ SN Carboxyatractyloside; CATR; SCHEMBL1612956; GTPL4572; AQFATIOBERWBDY-LNQSNDDKSA-N; (2alpha,8alpha,10alpha,13alpha,15beta)-15-hydroxy-2-{[2-O-(3-methylbutanoyl)-3,4-di-O-sulfo-beta-D-glucopyranosyl]oxy}kaur-16-ene-18,19-dioic acid; (1R,4S,7S,9S,10S,13R,15S)-15-hydroxy-7-{[(2R,3R,4R,5R,6R)-6-(hydroxymethyl)-3-[(3-methylbutanoyl)oxy]-4,5-bis(sulfooxy)oxan-2-yl]oxy}-9-methyl-14-methylidenetetracyclo[11.2.1.0^{1,10}.0^{4,9}]hexadecane-5,5-dicarboxylic acid
DMEORTQ DT Small molecular drug
DMEORTQ PC 20055804
DMEORTQ MW 770.8
DMEORTQ FM C31H46O18S2
DMEORTQ IC InChI=1S/C31H46O18S2/c1-14(2)9-21(33)47-24-23(49-51(42,43)44)22(48-50(39,40)41)18(13-32)46-26(24)45-17-11-29(4)19-6-5-16-10-30(19,25(34)15(16)3)8-7-20(29)31(12-17,27(35)36)28(37)38/h14,16-20,22-26,32,34H,3,5-13H2,1-2,4H3,(H,35,36)(H,37,38)(H,39,40,41)(H,42,43,44)/t16-,17+,18-,19+,20+,22-,23+,24-,25+,26-,29+,30-/m1/s1
DMEORTQ CS CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2C[C@]3([C@@H]4CC[C@@H]5C[C@@]4(CC[C@@H]3C(C2)(C(=O)O)C(=O)O)[C@H](C5=C)O)C)CO)OS(=O)(=O)O)OS(=O)(=O)O
DMEORTQ IK AQFATIOBERWBDY-LNQSNDDKSA-N
DMEORTQ IU (1R,4S,7S,9S,10S,13R,15S)-15-hydroxy-7-[(2R,3R,4R,5R,6R)-6-(hydroxymethyl)-3-(3-methylbutanoyloxy)-4,5-disulfooxyoxan-2-yl]oxy-9-methyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5,5-dicarboxylic acid
DMEORTQ DE Discovery agent
DMTAYMR ID DMTAYMR
DMTAYMR DN Carboxydichlorofluorescein
DMTAYMR HS Investigative
DMTAYMR SN 5,6-carboxydichlorofluorescein
DMTAYMR PC 129670681
DMTAYMR MW 445.204
DMTAYMR FM C21H10Cl2O7
DMTAYMR IC InChI=1S/C21H10Cl2O7/c22-16-12(25)7-13-15(17(16)23)21(9-4-2-1-3-8(9)20(28)30-21)10-5-6-11(24)14(19(26)27)18(10)29-13/h1-7,24-25H,(H,26,27)
DMTAYMR CS C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)C(=O)O)OC5=CC(=C(C(=C35)Cl)Cl)O
DMTAYMR IK SQVCXKJBMHVPIO-UHFFFAOYSA-N
DMTAYMR IU 7',8'-dichloro-3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-carboxylic acid
DMI7Q61 ID DMI7Q61
DMI7Q61 DN CARBOXYFENTANYL
DMI7Q61 HS Investigative
DMI7Q61 SN CARBOXYFENTANYL; CHEBI:61106; CHEMBL216239; 4-oxo-4-{phenyl[1-(2-phenylethyl)piperidin-4-yl]amino}butanoic acid; 4-anilidopiperidine, 8; Epitope ID:153518; SCHEMBL5163413; BDBM21114; ZINC14975441; 4-Oxo-4-[N-(1-phenethylpiperidine-4-yl)anilino]butyric acid; 3-{phenyl[1-(2-phenylethyl)piperidin-4-yl]carbamoyl}propanoic acid
DMI7Q61 DT Small molecular drug
DMI7Q61 PC 23635044
DMI7Q61 MW 380.5
DMI7Q61 FM C23H28N2O3
DMI7Q61 IC InChI=1S/C23H28N2O3/c26-22(11-12-23(27)28)25(20-9-5-2-6-10-20)21-14-17-24(18-15-21)16-13-19-7-3-1-4-8-19/h1-10,21H,11-18H2,(H,27,28)
DMI7Q61 CS C1CN(CCC1N(C2=CC=CC=C2)C(=O)CCC(=O)O)CCC3=CC=CC=C3
DMI7Q61 IK MEVFKTVEGJUHHI-UHFFFAOYSA-N
DMI7Q61 IU 4-oxo-4-(N-[1-(2-phenylethyl)piperidin-4-yl]anilino)butanoic acid
DMI7Q61 CB CHEBI:61106
DMI7Q61 DE Discovery agent
DM105YR ID DM105YR
DM105YR DN Carboxylated glucosamine
DM105YR HS Investigative
DM105YR SN carboxylated glucosamine
DM105YR DT Small molecular drug
DM105YR PC 44411803
DM105YR MW 305.32
DM105YR FM C13H23NO7
DM105YR IC InChI=1S/C13H23NO7/c1-2-7-8(5-15)21-9(6-16)12(13(7)20)14-10(17)3-4-11(18)19/h7-9,12-13,15-16,20H,2-6H2,1H3,(H,14,17)(H,18,19)/t7-,8-,9+,12+,13+/m1/s1
DM105YR CS CC[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)NC(=O)CCC(=O)O)CO)CO
DM105YR IK PTKIBGLZJSEXPT-KOOJSXSQSA-N
DM105YR IU 4-[[(2R,3R,4S,5S,6S)-5-ethyl-4-hydroxy-2,6-bis(hydroxymethyl)oxan-3-yl]amino]-4-oxobutanoic acid
DM105YR DE Discovery agent
DMCTUR1 ID DMCTUR1
DMCTUR1 DN Carboxylic PRPP
DMCTUR1 HS Investigative
DMCTUR1 SN CARBOXYLIC PRPP; CPRPP; 1-ALPHA-PYROPHOSPHORYL-2-ALPHA,3-ALPHA-DIHYDROXY-4-BETA-CYCLOPENTANE-METHANOL-5-PHOSPHATE; AC1L9FVP; CARBOXYLIC PRPP; CPRPP; DB03942; (1S,2R,3R,4R)-2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl trihydrogen diphosphate; [(1S,2R,3R,4R)-2,3-dihydroxy-4-(phosphonooxymethyl)cyclopentyl] phosphono hydrogen phosphate
DMCTUR1 DT Small molecular drug
DMCTUR1 PC 444189
DMCTUR1 MW 388.1
DMCTUR1 FM C6H15O13P3
DMCTUR1 IC InChI=1S/C6H15O13P3/c7-5-3(2-17-20(9,10)11)1-4(6(5)8)18-22(15,16)19-21(12,13)14/h3-8H,1-2H2,(H,15,16)(H2,9,10,11)(H2,12,13,14)/t3-,4+,5-,6+/m1/s1
DMCTUR1 CS C1[C@@H]([C@H]([C@H]([C@H]1OP(=O)(O)OP(=O)(O)O)O)O)COP(=O)(O)O
DMCTUR1 IK OICBXEWBKALHHB-MOJAZDJTSA-N
DMCTUR1 IU [(1S,2R,3R,4R)-2,3-dihydroxy-4-(phosphonooxymethyl)cyclopentyl] phosphono hydrogen phosphate
DMCTUR1 DE Discovery agent
DMQUKBG ID DMQUKBG
DMQUKBG DN CARCININE
DMQUKBG HS Investigative
DMQUKBG SN Carcinine; 56897-53-1; N-(2-(1H-Imidazol-5-yl)ethyl)-3-aminopropanamide; beta-Alanylhistamine; UNII-WIV0W167TC; WIV0W167TC; N-[2-(1H-imidazol-5-yl)ethyl]-beta-alaninamide; SPBio_002343; beta-alaninylhistamine; N-beta-alanylhistamine; AC1L1DZE; Prestwick2_000422; Prestwick1_000422; Prestwick0_000422; Prestwick3_000422; Lopac-C-2321; AC1Q5P6Q; n-[2-(1h-imidazol-5-yl)ethyl]-; A-alaninamide; Lopac0_000210; BSPBio_000404; KSC921E6R; MLS002153803; SCHEMBL2819350; CHEMBL461024; BPBio1_000446; SCHEMBL19051459; CHEBI:95262; CTK8C1268
DMQUKBG DT Small molecular drug
DMQUKBG PC 2574
DMQUKBG MW 182.22
DMQUKBG FM C8H14N4O
DMQUKBG IC InChI=1S/C8H14N4O/c9-3-1-8(13)11-4-2-7-5-10-6-12-7/h5-6H,1-4,9H2,(H,10,12)(H,11,13)
DMQUKBG CS C1=C(NC=N1)CCNC(=O)CCN
DMQUKBG IK ANRUJJLGVODXIK-UHFFFAOYSA-N
DMQUKBG IU 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide
DMQUKBG CA CAS 56897-53-1
DMQUKBG CB CHEBI:95262
DMQUKBG DE Discovery agent
DMCSMX4 ID DMCSMX4
DMCSMX4 DN Cardiolipin
DMCSMX4 HS Investigative
DMCSMX4 SN Cardiolipins(20:4w3/20:4w6/18:2w6/18:2w6); Cardiolipins(20:4n3/20:4n6/18:2n6/18:2n6); Cardiolipin(20:4w3/20:4w6/18:2w6/18:2w6); Cardiolipin(20:4n3/20:4n6/18:2n6/18:2n6); CL(20:4w3/20:4w6/18:2w6/18:2w6); CL(20:4n3/20:4n6/18:2n6/18:2n6); CL(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)/16:0); CL(1'-[20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)],3'-[18:2(9Z,12Z)/18:2(9Z,12Z)])
DMCSMX4 DT Small molecular drug
DMCSMX4 PC 75228679
DMCSMX4 MW 1493.9
DMCSMX4 FM C81H140Na2O17P2
DMCSMX4 IC InChI=1S/C81H142O17P2.2Na/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2;;/h21-28,33-40,75-77,82H,5-20,29-32,41-74H2,1-4H3,(H,87,88)(H,89,90);;/q;2*+1/p-2
DMCSMX4 CS CCCCCC=CCC=CCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCC=CCC=CCCCCC)OC(=O)CCCCCCCC=CCC=CCCCCC)O)OC(=O)CCCCCCCC=CCC=CCCCCC.[Na+].[Na+]
DMCSMX4 IK ZGSPNIOCEDOHGS-UHFFFAOYSA-L
DMCSMX4 IU disodium;[3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate
DMCSMX4 DE Discovery agent
DMUSGYQ ID DMUSGYQ
DMUSGYQ DN Carinatumins B (2)
DMUSGYQ HS Investigative
DMUSGYQ SN carinatumins B (2); CHEMBL241838
DMUSGYQ DT Small molecular drug
DMUSGYQ PC 44428320
DMUSGYQ MW 272.34
DMUSGYQ FM C16H20N2O2
DMUSGYQ IC InChI=1S/C16H20N2O2/c1-9-6-10-7-12-11(2-3-14(20)18-12)16(8-9)15(10)13(19)4-5-17-16/h2-3,6,10,13,15,17,19H,4-5,7-8H2,1H3,(H,18,20)/t10-,13+,15-,16-/m0/s1
DMUSGYQ CS CC1=C[C@H]2CC3=C(C=CC(=O)N3)[C@@]4(C1)[C@@H]2[C@@H](CCN4)O
DMUSGYQ IK RGJUWLMFRYLAOJ-UXVLEFJLSA-N
DMUSGYQ IU (1R,9R,10R,11R)-11-hydroxy-16-methyl-6,14-diazatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,16-trien-5-one
DMUSGYQ DE Discovery agent
DMFYCB4 ID DMFYCB4
DMFYCB4 DN Carnosine
DMFYCB4 HS Investigative
DMFYCB4 SN beta-alanyl-L-histidine; L-carnosine
DMFYCB4 DT Small molecular drug
DMFYCB4 PC 439224
DMFYCB4 MW 226.23
DMFYCB4 FM C9H14N4O3
DMFYCB4 IC InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/t7-/m0/s1
DMFYCB4 CS C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CCN
DMFYCB4 IK CQOVPNPJLQNMDC-ZETCQYMHSA-N
DMFYCB4 IU (2S)-2-(3-aminopropanoylamino)-3-(1H-imidazol-5-yl)propanoic acid
DMFYCB4 CA CAS 305-84-0
DMFYCB4 CB CHEBI:15727
DMFYCB4 DE Discovery agent
DMBKQ03 ID DMBKQ03
DMBKQ03 DN Carpropamid
DMBKQ03 HS Investigative
DMBKQ03 SN Carpropamid; 104030-54-8; 2,2-Dichloro-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide; 2,2-dichloro-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropane-1-carboxamide; Carpropamid [ISO]; AC1L4B6R; SCHEMBL22262; CHEBI:3434; DTXSID4057922; RXDMAYSSBPYBFW-UHFFFAOYSA-N; KTU-3616; AKOS015888200; Cyclopropanecarboxamide, 2,2-dichloro-N-(1-(4-chlorophenyl)ethyl)-1-ethyl-3-methyl-; AN-34090; TR-000928; Carpropamid, PESTANAL(R), analytical standard; C10932; SR-01000883725; SR-01000883725-1; I01-10136
DMBKQ03 DT Small molecular drug
DMBKQ03 PC 153847
DMBKQ03 MW 334.7
DMBKQ03 FM C15H18Cl3NO
DMBKQ03 IC InChI=1S/C15H18Cl3NO/c1-4-14(10(3)15(14,17)18)13(20)19-9(2)11-5-7-12(16)8-6-11/h5-10H,4H2,1-3H3,(H,19,20)
DMBKQ03 CS CCC1(C(C1(Cl)Cl)C)C(=O)NC(C)C2=CC=C(C=C2)Cl
DMBKQ03 IK RXDMAYSSBPYBFW-UHFFFAOYSA-N
DMBKQ03 IU 2,2-dichloro-N-[1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropane-1-carboxamide
DMBKQ03 CA CAS 104030-54-8
DMBKQ03 CB CHEBI:3434
DMBKQ03 DE Discovery agent
DMSKT8G ID DMSKT8G
DMSKT8G DN Cartazolate
DMSKT8G HS Investigative
DMSKT8G SN CARTAZOLATE; 34966-41-1; UNII-8K93Z46WPY; CHEMBL8184; SQ 65396; 8K93Z46WPY; SQ-65396; Cartazolato; Cartazolatum; Ethyl 4-(butylamino)-1-ethyl-1H-pyrazolo(3,4-b)-pyridine-5-carboxylate; 4-Butylamino-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester; Cartazolatum [INN-Latin]; Cartazolate [USAN:INN]; Cartazolato [INN-Spanish]; Ethyl 4-(butylamino)-1-ethyl-1H-pyrazolo[3,4-b]-pyridine-5-carboxylate; NSC 166873; AC1L1WUF; Cartazolate (USAN/INN); SCHEMBL123839; DTXSID20188511; IQNQAOGGWGCROX-UHFFFAOYSA-N; BDBM50098221
DMSKT8G DT Small molecular drug
DMSKT8G PC 37015
DMSKT8G MW 290.36
DMSKT8G FM C15H22N4O2
DMSKT8G IC InChI=1S/C15H22N4O2/c1-4-7-8-16-13-11-10-18-19(5-2)14(11)17-9-12(13)15(20)21-6-3/h9-10H,4-8H2,1-3H3,(H,16,17)
DMSKT8G CS CCCCNC1=C2C=NN(C2=NC=C1C(=O)OCC)CC
DMSKT8G IK IQNQAOGGWGCROX-UHFFFAOYSA-N
DMSKT8G IU ethyl 4-(butylamino)-1-ethylpyrazolo[3,4-b]pyridine-5-carboxylate
DMSKT8G CA CAS 34966-41-1
DMSKT8G DE Discovery agent
DMINM2D ID DMINM2D
DMINM2D DN carvacrol
DMINM2D HS Investigative
DMINM2D SN CARVACROL; 5-Isopropyl-2-methylphenol; 499-75-2; Isopropyl-o-cresol; Karvakrol; o-Thymol; Antioxine; 5-Isopropyl-o-cresol; 2-p-Cymenol; 2-Hydroxy-p-cymene; Isothymol; Phenol, 2-methyl-5-(1-methylethyl)-; p-Cymen-2-ol; 2-Methyl-5-isopropylphenol; 3-Isopropyl-6-methylphenol; p-Cymene, 2-hydroxy-; 5-Isopropyl-2-methyl-phenol; 2-Methyl-5-(Propan-2-Yl)Phenol; 2-Methyl-5-(1-methylethyl)phenol; o-Cresol, 5-isopropyl-; 1-Hydroxy-2-methyl-5-isopropylbenzene; 6-Methyl-3-isopropylphenol; Phenol, 5-isopropyl-2-methyl-; Cymene-2-ol, p-
DMINM2D DT Small molecular drug
DMINM2D PC 10364
DMINM2D MW 150.22
DMINM2D FM C10H14O
DMINM2D IC InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3
DMINM2D CS CC1=C(C=C(C=C1)C(C)C)O
DMINM2D IK RECUKUPTGUEGMW-UHFFFAOYSA-N
DMINM2D IU 2-methyl-5-propan-2-ylphenol
DMINM2D CA CAS 499-75-2
DMINM2D CB CHEBI:3440
DMINM2D DE Discovery agent
DMXTCE7 ID DMXTCE7
DMXTCE7 DN Carvedilol
DMXTCE7 HS Investigative
DMXTCE7 SN Coreg; Dilatrend; Eucardic; Carvedilolum [Latin]; BM 14190; Carvedilolum; SKF 105517; BM-14190; Coreg CR; DQ 2466; HSDB 7044; DQ-2466
DMXTCE7 TC Antiviral Agents
DMXTCE7 DT Small molecular drug
DMXTCE7 PC 2585
DMXTCE7 MW 406.5
DMXTCE7 FM C24H26N2O4
DMXTCE7 IC InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
DMXTCE7 CS COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
DMXTCE7 IK OGHNVEJMJSYVRP-UHFFFAOYSA-N
DMXTCE7 IU 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
DMXTCE7 CA CAS 72956-09-3
DMXTCE7 CB CHEBI:3441
DMXTCE7 DE Coronavirus Disease 2019 (COVID-19)
DMGIZ5U ID DMGIZ5U
DMGIZ5U DN carveol
DMGIZ5U HS Investigative
DMGIZ5U SN L-carveol
DMGIZ5U DT Small molecular drug
DMGIZ5U PC 7438
DMGIZ5U MW 152.23
DMGIZ5U FM C10H16O
DMGIZ5U IC InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3
DMGIZ5U CS CC1=CCC(CC1O)C(=C)C
DMGIZ5U IK BAVONGHXFVOKBV-UHFFFAOYSA-N
DMGIZ5U IU 2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol
DMGIZ5U CA CAS 99-48-9
DMGIZ5U CB CHEBI:23046
DMGIZ5U DE Discovery agent
DMVD481 ID DMVD481
DMVD481 DN Carzenide
DMVD481 HS Investigative
DMVD481 SN Para-Carboxybenzenesulfonamide (Weak Carbonic Anhydrase Inhibitor)
DMVD481 DT Small molecular drug
DMVD481 PC 8739
DMVD481 MW 201.2
DMVD481 FM C7H7NO4S
DMVD481 IC InChI=1S/C7H7NO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)(H2,8,11,12)
DMVD481 CS C1=CC(=CC=C1C(=O)O)S(=O)(=O)N
DMVD481 IK UCAGLBKTLXCODC-UHFFFAOYSA-N
DMVD481 IU 4-sulfamoylbenzoic acid
DMVD481 CA CAS 138-41-0
DMVD481 DE Discovery agent
DMW6P4A ID DMW6P4A
DMW6P4A DN casp 4 inhib
DMW6P4A HS Investigative
DMW6P4A SN 5-nitro-isatin 1 [PMID: 11384246]
DMW6P4A DT Small molecular drug
DMW6P4A PC 515950
DMW6P4A MW 206.15
DMW6P4A FM C9H6N2O4
DMW6P4A IC InChI=1S/C9H6N2O4/c1-10-7-3-2-5(11(14)15)4-6(7)8(12)9(10)13/h2-4H,1H3
DMW6P4A CS CN1C2=C(C=C(C=C2)[N+](=O)[O-])C(=O)C1=O
DMW6P4A IK JPTDPTOWOMFBRY-UHFFFAOYSA-N
DMW6P4A IU 1-methyl-5-nitroindole-2,3-dione
DMW6P4A CA CAS 3484-32-0
DMW6P4A DE Discovery agent
DM5E21C ID DM5E21C
DM5E21C DN CASUARIIN
DM5E21C HS Investigative
DM5E21C SN Casuariin; CHEMBL509562; SCHEMBL1883046
DM5E21C DT Small molecular drug
DM5E21C PC 14035442
DM5E21C MW 784.5
DM5E21C FM C34H24O22
DM5E21C IC InChI=1S/C34H24O22/c35-8-1-5-12(21(42)18(8)39)13-6(2-9(36)19(40)22(13)43)32(50)54-28(11(38)4-53-31(5)49)30-29-26(47)17-16(34(52)55-29)15(24(45)27(48)25(17)46)14-7(33(51)56-30)3-10(37)20(41)23(14)44/h1-3,11,26,28-30,35-48H,4H2/t11-,26-,28-,29+,30+/m1/s1
DM5E21C CS C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)[C@H]4[C@@H]5[C@@H](C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)O)O
DM5E21C IK CHBITXAMNKHJCR-JNUHSSLSSA-N
DM5E21C IU (14R,15S,19R)-14-[(10R,11R)-3,4,5,11,17,18,19-heptahydroxy-8,14-dioxo-9,13-dioxatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]-2,3,4,7,8,9,19-heptahydroxy-13,16-dioxatetracyclo[13.3.1.05,18.06,11]nonadeca-1,3,5(18),6,8,10-hexaene-12,17-dione
DM5E21C DE Discovery agent
DMWHP52 ID DMWHP52
DMWHP52 DN CAT-2200
DMWHP52 HS Investigative
DMWHP52 SN MEDI-571; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), MedImmune; Anti-IL-17 antibody (rheumatoid arthritis/systemic lupus erythematosus (SLE)), Cambridge Antibody Technology (CAT)
DMWHP52 CP Cambridge Antibody Technology Group plc
DMWHP52 DT Antibody
DMWHP52 DE Rheumatoid arthritis
DMY38SB ID DMY38SB
DMY38SB DN CATECHIN
DMY38SB HS Investigative
DMY38SB SN Cianidanol; (+)-catechin; 154-23-4; Catechuic acid; Cyanidanol; Catechinic acid; D-Catechin; Catergen; Cianidol; (+)-Cyanidanol; (+)-Cyanidan-3-ol; Biocatechin; (+)-Catechin Hydrate; D-(+)-Catechin; Dexcyanidanol; Catechin (flavan); Catechol (flavan); D-Catechol; (2R,3S)-Catechin; (2R,3S)-2-(3,4-Dihydroxyphenyl)chroman-3,5,7-triol; Gambier; 3-Cyanidanol, (+)-; Cianidanolum; Catechu; Transepar; Katha; (2R,3S)-(+)-Catechin; Cutch (dye); (+)-Cianidanol; 3,3',4',5,7-Flavanpentol; KB-53; (+)-Cyanidanol-3; CCRIS 6855
DMY38SB DT Small molecular drug
DMY38SB PC 9064
DMY38SB MW 290.27
DMY38SB FM C15H14O6
DMY38SB IC InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1
DMY38SB CS C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O
DMY38SB IK PFTAWBLQPZVEMU-DZGCQCFKSA-N
DMY38SB IU (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
DMY38SB CA CAS 7295-85-4
DMY38SB CB CHEBI:15600
DMY38SB DE Discovery agent
DML0YEK ID DML0YEK
DML0YEK DN Catechol
DML0YEK HS Investigative
DML0YEK SN pyrocatechol; 1,2-dihydroxybenzene; 120-80-9; 1,2-benzenediol; benzene-1,2-diol; pyrocatechin; 2-hydroxyphenol; o-Benzenediol; Pyrocatechine; o-Dihydroxybenzene; Oxyphenic acid; o-Hydroxyphenol; o-Hydroquinone; o-Dioxybenzene; o-Phenylenediol; Phthalhydroquinone; Fouramine PCH; Durafur developer C; Pelagol Grey C; benzenediol; Catechin (phenol); Fourrine 68; Benzene, o-dihydroxy-; Catechol (phenol); o-Diphenol; ortho-Hydroxyphenol; Pyrokatechol; Pyrokatechin; Katechol; ortho-Dihydroxybenzene; C.I. Oxidation Base 26
DML0YEK DT Small molecular drug
DML0YEK PC 289
DML0YEK MW 110.11
DML0YEK FM C6H6O2
DML0YEK IC InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H
DML0YEK CS C1=CC=C(C(=C1)O)O
DML0YEK IK YCIMNLLNPGFGHC-UHFFFAOYSA-N
DML0YEK IU benzene-1,2-diol
DML0YEK CA CAS 120-80-9
DML0YEK CB CHEBI:18135
DML0YEK DE Discovery agent
DMLEJHF ID DMLEJHF
DMLEJHF DN Cation chloride
DMLEJHF HS Investigative
DMF7TBW ID DMF7TBW
DMF7TBW DN CATPB
DMF7TBW HS Investigative
DMF7TBW SN (s)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic acid; GTPL6487; SCHEMBL2312533; CATPB, > ZINC118616157; AKOS030210965; 1322598-09-3; (3S)-3-[2-(3-chlorophenyl)acetamido]-4-[4-(trifluoromethyl)phenyl]butanoic acid
DMF7TBW DT Small molecular drug
DMF7TBW PC 53308747
DMF7TBW MW 399.8
DMF7TBW FM C19H17ClF3NO3
DMF7TBW IC InChI=1S/C19H17ClF3NO3/c20-15-3-1-2-13(8-15)10-17(25)24-16(11-18(26)27)9-12-4-6-14(7-5-12)19(21,22)23/h1-8,16H,9-11H2,(H,24,25)(H,26,27)/t16-/m0/s1
DMF7TBW CS C1=CC(=CC(=C1)Cl)CC(=O)N[C@@H](CC2=CC=C(C=C2)C(F)(F)F)CC(=O)O
DMF7TBW IK QOSIJVVNNGXEKE-INIZCTEOSA-N
DMF7TBW IU (3S)-3-[[2-(3-chlorophenyl)acetyl]amino]-4-[4-(trifluoromethyl)phenyl]butanoic acid
DMF7TBW DE Discovery agent
DM4QKVN ID DM4QKVN
DM4QKVN DN CAULERPIN
DM4QKVN HS Investigative
DM4QKVN SN Caulerpin; 26612-48-6; CHEMBL377236; CHEBI:80923; Cycloocta(1,2-b:5,6-b')diindole-6,13-dicarboxylic acid, 5,12-dihydro-, dimethyl ester; Cycloocta[1,2-b:5,6-b']diindole-6,13-dicarboxylic acid, 5,12-dihydro-, dimethyl ester; SCHEMBL13808752; NSC719624; BDBM50184688; NSC-719624
DM4QKVN DT Small molecular drug
DM4QKVN PC 5326018
DM4QKVN MW 398.4
DM4QKVN FM C24H18N2O4
DM4QKVN IC InChI=1S/C24H18N2O4/c1-29-23(27)17-11-15-13-7-3-6-10-20(13)26-22(15)18(24(28)30-2)12-16-14-8-4-5-9-19(14)25-21(16)17/h3-12,25-26H,1-2H3/b15-11?,16-12?,17-11+,18-12+,21-17?,22-18?
DM4QKVN CS COC(=O)/C/1=C/C2=C(NC3=CC=CC=C23)/C(=C\\C4=C1NC5=CC=CC=C45)/C(=O)OC
DM4QKVN IK PVWALMHWUOWPPA-RPLHEXBESA-N
DM4QKVN IU dimethyl (2E,13E)-11,22-diazapentacyclo[13.7.0.04,12.05,10.016,21]docosa-1(15),2,4(12),5,7,9,13,16,18,20-decaene-2,13-dicarboxylate
DM4QKVN CB CHEBI:80923
DM4QKVN DE Discovery agent
DM4O69H ID DM4O69H
DM4O69H DN CAY 10471
DM4O69H HS Investigative
DM4O69H SN CAY10471; CAY-10471
DM4O69H CP 7TM Pharma A/S
DM4O69H DT Small molecular drug
DM4O69H PC 11384493
DM4O69H MW 416.5
DM4O69H FM C21H21FN2O4S
DM4O69H IC InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
DM4O69H CS CN(C1CCC2=C(C1)C3=CC=CC=C3N2CC(=O)O)S(=O)(=O)C4=CC=C(C=C4)F
DM4O69H IK CANCTKXGRVNXFP-UHFFFAOYSA-N
DM4O69H IU 2-[3-[(4-fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid
DM4O69H DE Allergy
DMT3MBD ID DMT3MBD
DMT3MBD DN CAY10583
DMT3MBD HS Investigative
DMT3MBD SN compound A [PMID:15866883]; CAY 10583; CAY-10583
DMT3MBD DT Small molecular drug
DMT3MBD PC 51529932
DMT3MBD MW 387.5
DMT3MBD FM C25H25NO3
DMT3MBD IC InChI=1S/C25H25NO3/c1-2-3-13-24(27)26(21-9-5-4-6-10-21)18-19-14-16-20(17-15-19)22-11-7-8-12-23(22)25(28)29/h4-12,14-17H,2-3,13,18H2,1H3,(H,28,29)
DMT3MBD CS CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C(=O)O)C3=CC=CC=C3
DMT3MBD IK IUJTVDNJFPZYBL-UHFFFAOYSA-N
DMT3MBD IU 2-[4-[(N-pentanoylanilino)methyl]phenyl]benzoic acid
DMT3MBD CA CAS 862891-27-8
DMT3MBD DE Discovery agent
DMSFXZU ID DMSFXZU
DMSFXZU DN CB-1922
DMSFXZU HS Investigative
DMSFXZU SN HIV replication inhibitor (synthetic steroid), Canopus
DMSFXZU CP Canopus BioPharma Inc
DMSFXZU DE Human immunodeficiency virus infection
DMXON4L ID DMXON4L
DMXON4L DN CB-676475
DMXON4L HS Investigative
DMXON4L SN 690206-97-4; ZM 306416; ZM306416; ZM-306416; N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine; ZM-306416(CB 676475); CB-676475; CHEMBL150315; AK174923; CB 676475; Anilinoquinazoline deriv. 4; AC1NS5UJ; SCHEMBL3012896; BDBM4621; GTPL8245; CTK8E8823; CHEBI:92732; DTXSID90416176; AOB6790; MolPort-035-395-727; HMS3651N06; BCP06445; ZINC2583789; HSCI1_000042; s2897; 2820AH; AKOS025404926; SB16593; CS-1349; KS-00000T57; NCGC00167747-01; SC-95590; DA-41680; CB676475; HY-13785; AB0165814; RT-016341; KB-299318; SW219943-1; FT-0706412; S-7773
DMXON4L DT Small molecular drug
DMXON4L PC 5329006
DMXON4L MW 333.74
DMXON4L FM C16H13ClFN3O2
DMXON4L IC InChI=1S/C16H13ClFN3O2/c1-22-14-6-10-13(7-15(14)23-2)19-8-20-16(10)21-12-4-3-9(17)5-11(12)18/h3-8H,1-2H3,(H,19,20,21)
DMXON4L CS COC1=C(C=C2C(=C1)C(=NC=N2)NC3=C(C=C(C=C3)Cl)F)OC
DMXON4L IK YHUIUSRCUKUUQA-UHFFFAOYSA-N
DMXON4L IU N-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine
DMXON4L CA CAS 690206-97-4
DMXON4L CB CHEBI:92732
DMXON4L DE Discovery agent
DMALVY7 ID DMALVY7
DMALVY7 DN CBiPES
DMALVY7 HS Investigative
DMALVY7 SN CBiPES; LY-566332; 856702-40-4; GTPL3372; DTXSID70432071; ZINC43201133; NCGC00370754-01; LY566332
DMALVY7 DT Small molecular drug
DMALVY7 PC 9864510
DMALVY7 MW 377.5
DMALVY7 FM C21H19N3O2S
DMALVY7 IC InChI=1S/C21H19N3O2S/c1-2-27(25,26)24(16-18-5-4-12-23-15-18)21-7-3-6-20(13-21)19-10-8-17(14-22)9-11-19/h3-13,15H,2,16H2,1H3
DMALVY7 CS CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=CC=C(C=C3)C#N
DMALVY7 IK HDVYXILCBYGKGU-UHFFFAOYSA-N
DMALVY7 IU N-[3-(4-cyanophenyl)phenyl]-N-(pyridin-3-ylmethyl)ethanesulfonamide
DMALVY7 CA CAS 353235-01-5
DMALVY7 DE Discovery agent
DMDIW1M ID DMDIW1M
DMDIW1M DN CBIQ
DMDIW1M HS Investigative
DMDIW1M SN 4-Chlorobenzo[f]isoquinoline; 32081-28-0; SCHEMBL610880; GTPL4152; CHEMBL1372588; CTK8F8501; DTXSID30464737; HMS3260E20; ZINC2577904; Tox21_500109; CBIQ, > MFCD02179769; AKOS017550392; CCG-221413; LP00109; NCGC00093606-01; NCGC00093606-05; NCGC00260794-01; NCGC00093606-03; NCGC00093606-04; NCGC00093606-02; KB-38182; UX00000203; FT-0618182
DMDIW1M DT Small molecular drug
DMDIW1M PC 11401613
DMDIW1M MW 213.66
DMDIW1M FM C13H8ClN
DMDIW1M IC InChI=1S/C13H8ClN/c14-13-12-6-5-9-3-1-2-4-10(9)11(12)7-8-15-13/h1-8H
DMDIW1M CS C1=CC=C2C(=C1)C=CC3=C2C=CN=C3Cl
DMDIW1M IK SHQLTRRYZVBEMR-UHFFFAOYSA-N
DMDIW1M IU 4-chlorobenzo[f]isoquinoline
DMDIW1M CA CAS 32081-28-0
DMDIW1M DE Discovery agent
DMCFR8U ID DMCFR8U
DMCFR8U DN CBLB-612
DMCFR8U HS Investigative
DMCFR8U SN Recombinant flagellin proteins (injectable, radiation induced bone marrow deficiency), Cleveland BioLabs; CBLB-600 series (injectable, radiation sickness), Cleveland BioLabs
DMCFR8U CP Cleveland BioLabs Inc
DMCFR8U DE Radiation syndrome
DMITY0H ID DMITY0H
DMITY0H DN CBOBNEA
DMITY0H HS Investigative
DMITY0H SN carboxybiphenyloxy-butoxy-naphthalen-ethylacetamide
DMITY0H DT Small molecular drug
DMITY0H PC 9957516
DMITY0H MW 497.6
DMITY0H FM C31H31NO5
DMITY0H IC InChI=1S/C31H31NO5/c1-22(33)32-18-17-26-6-4-5-25-13-16-29(21-30(25)26)37-20-3-2-19-36-28-14-11-24(12-15-28)23-7-9-27(10-8-23)31(34)35/h4-16,21H,2-3,17-20H2,1H3,(H,32,33)(H,34,35)
DMITY0H CS CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OCCCCOC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)O
DMITY0H IK VTMXSWVEWDJSKG-UHFFFAOYSA-N
DMITY0H IU 4-[4-[4-[8-(2-acetamidoethyl)naphthalen-2-yl]oxybutoxy]phenyl]benzoic acid
DMITY0H DE Discovery agent
DM21JVF ID DM21JVF
DM21JVF DN Cbz-Glu(OtBu)-Ala-LeuVSMe
DM21JVF HS Investigative
DM21JVF SN CHEMBL208015; Cbz-Glu(OtBu)-Ala-LeuVSMe
DM21JVF DT Small molecular drug
DM21JVF PC 11621207
DM21JVF MW 581.7
DM21JVF FM C28H43N3O8S
DM21JVF IC InChI=1S/C28H43N3O8S/c1-19(2)17-22(15-16-40(7,36)37)30-25(33)20(3)29-26(34)23(13-14-24(32)39-28(4,5)6)31-27(35)38-18-21-11-9-8-10-12-21/h8-12,15-16,19-20,22-23H,13-14,17-18H2,1-7H3,(H,29,34)(H,30,33)(H,31,35)/b16-15+/t20-,22+,23-/m0/s1
DM21JVF CS C[C@@H](C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1
DM21JVF IK LRSBIKVQDTUNIU-DSNMTOQLSA-N
DM21JVF IU tert-butyl (4S)-5-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-5-oxo-4-(phenylmethoxycarbonylamino)pentanoate
DM21JVF DE Discovery agent
DMV8CJK ID DMV8CJK
DMV8CJK DN Cbz-Ile-hPhe-Ala-LeuVSMe
DMV8CJK HS Investigative
DMV8CJK SN CHEMBL446443; Cbz-Ile-hPhe-Ala-LeuVSMe
DMV8CJK DT Small molecular drug
DMV8CJK PC 11714476
DMV8CJK MW 670.9
DMV8CJK FM C35H50N4O7S
DMV8CJK IC InChI=1S/C35H50N4O7S/c1-7-25(4)31(39-35(43)46-23-28-16-12-9-13-17-28)34(42)38-30(19-18-27-14-10-8-11-15-27)33(41)36-26(5)32(40)37-29(22-24(2)3)20-21-47(6,44)45/h8-17,20-21,24-26,29-31H,7,18-19,22-23H2,1-6H3,(H,36,41)(H,37,40)(H,38,42)(H,39,43)/b21-20+/t25-,26-,29+,30-,31-/m0/s1
DMV8CJK CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC2=CC=CC=C2
DMV8CJK IK BZKLWACICJITOJ-QBZCPKQRSA-N
DMV8CJK IU benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMV8CJK DE Discovery agent
DMBFLHD ID DMBFLHD
DMBFLHD DN Cbz-Ile-Leu-Ala-LeuVSMe
DMBFLHD HS Investigative
DMBFLHD SN CHEMBL207403; Cbz-Ile-Leu-Ala-LeuVSMe
DMBFLHD DT Small molecular drug
DMBFLHD PC 11534625
DMBFLHD MW 622.8
DMBFLHD FM C31H50N4O7S
DMBFLHD IC InChI=1S/C31H50N4O7S/c1-9-22(6)27(35-31(39)42-19-24-13-11-10-12-14-24)30(38)34-26(18-21(4)5)29(37)32-23(7)28(36)33-25(17-20(2)3)15-16-43(8,40)41/h10-16,20-23,25-27H,9,17-19H2,1-8H3,(H,32,37)(H,33,36)(H,34,38)(H,35,39)/b16-15+/t22-,23-,25+,26-,27-/m0/s1
DMBFLHD CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMBFLHD IK PXJWGKDQRNBYKI-HUHPYHTRSA-N
DMBFLHD IU benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-4-methyl-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMBFLHD DE Discovery agent
DMI53WR ID DMI53WR
DMI53WR DN Cbz-Ile-Leu-L-(difluoro)aminobutyric acid
DMI53WR HS Investigative
DMI53WR SN CHEMBL175623; Cbz-Ile-Leu-L-(difluoro)aminobutyric acid
DMI53WR DT Small molecular drug
DMI53WR PC 44388151
DMI53WR MW 527.6
DMI53WR FM C25H35F2N3O7
DMI53WR IC InChI=1S/C25H35F2N3O7/c1-5-15(4)20(30-25(36)37-13-16-9-7-6-8-10-16)23(33)29-18(11-14(2)3)22(32)28-17(12-19(26)27)21(31)24(34)35/h6-10,14-15,17-20H,5,11-13H2,1-4H3,(H,28,32)(H,29,33)(H,30,36)(H,34,35)/t15?,17?,18-,20-/m0/s1
DMI53WR CS CCC(C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NC(CC(F)F)C(=O)C(=O)O)NC(=O)OCC1=CC=CC=C1
DMI53WR IK IXLOEMUNKMDCDV-IVJQXSGXSA-N
DMI53WR IU 5,5-difluoro-3-[[(2S)-4-methyl-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]-2-oxopentanoic acid
DMI53WR DE Discovery agent
DMY4M3J ID DMY4M3J
DMY4M3J DN Cbz-Ile-MetO2-Ala-LeuVSMe
DMY4M3J HS Investigative
DMY4M3J SN CHEMBL383730; Cbz-Ile-MetO2-Ala-LeuVSMe
DMY4M3J DT Small molecular drug
DMY4M3J PC 11585523
DMY4M3J MW 658.8
DMY4M3J FM C29H46N4O9S2
DMY4M3J IC InChI=1S/C29H46N4O9S2/c1-8-20(4)25(33-29(37)42-17-22-12-10-9-11-13-22)28(36)32-24(18-44(7,40)41)27(35)30-21(5)26(34)31-23(16-19(2)3)14-15-43(6,38)39/h9-15,19-21,23-25H,8,16-18H2,1-7H3,(H,30,35)(H,31,34)(H,32,36)(H,33,37)/b15-14+/t20-,21-,23+,24-,25-/m0/s1
DMY4M3J CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CS(=O)(=O)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMY4M3J IK HIMUOMBMABFMIW-VHISICEBSA-N
DMY4M3J IU benzyl N-[(2S,3S)-3-methyl-1-[[(2R)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-3-methylsulfonyl-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DMY4M3J DE Discovery agent
DM1OAW3 ID DM1OAW3
DM1OAW3 DN Cbz-Ile-Phe-Ala-LeuVSMe
DM1OAW3 HS Investigative
DM1OAW3 SN CHEMBL207284; Cbz-Ile-Phe-Ala-LeuVSMe
DM1OAW3 DT Small molecular drug
DM1OAW3 PC 11534772
DM1OAW3 MW 656.8
DM1OAW3 FM C34H48N4O7S
DM1OAW3 IC InChI=1S/C34H48N4O7S/c1-7-24(4)30(38-34(42)45-22-27-16-12-9-13-17-27)33(41)37-29(21-26-14-10-8-11-15-26)32(40)35-25(5)31(39)36-28(20-23(2)3)18-19-46(6,43)44/h8-19,23-25,28-30H,7,20-22H2,1-6H3,(H,35,40)(H,36,39)(H,37,41)(H,38,42)/b19-18+/t24-,25-,28+,29-,30-/m0/s1
DM1OAW3 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC2=CC=CC=C2
DM1OAW3 IK NDQAQUAWHJQVGE-HZPWIFGKSA-N
DM1OAW3 IU benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]carbamate
DM1OAW3 DE Discovery agent
DM1KDWE ID DM1KDWE
DM1KDWE DN Cbz-Ile-Pro-Ala-LeuVSMe
DM1KDWE HS Investigative
DM1KDWE SN CHEMBL207670; Cbz-Ile-Pro-Ala-LeuVSMe
DM1KDWE DT Small molecular drug
DM1KDWE PC 11505372
DM1KDWE MW 606.8
DM1KDWE FM C30H46N4O7S
DM1KDWE IC InChI=1S/C30H46N4O7S/c1-7-21(4)26(33-30(38)41-19-23-12-9-8-10-13-23)29(37)34-16-11-14-25(34)28(36)31-22(5)27(35)32-24(18-20(2)3)15-17-42(6,39)40/h8-10,12-13,15,17,20-22,24-26H,7,11,14,16,18-19H2,1-6H3,(H,31,36)(H,32,35)(H,33,38)/b17-15+/t21-,22-,24+,25-,26-/m0/s1
DM1KDWE CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC2=CC=CC=C2
DM1KDWE IK QUUKVNWZLKQWBG-DHJGLREUSA-N
DM1KDWE IU benzyl N-[(2S,3S)-3-methyl-1-[(2S)-2-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]carbamate
DM1KDWE DE Discovery agent
DMGTFON ID DMGTFON
DMGTFON DN Cbz-Ile-t-ButylGln-Ala-LeuVSMe
DMGTFON HS Investigative
DMGTFON SN CHEMBL438612; Cbz-Ile-t-ButylGln-Ala-LeuVSMe
DMGTFON DT Small molecular drug
DMGTFON PC 11621748
DMGTFON MW 693.9
DMGTFON FM C34H55N5O8S
DMGTFON IC InChI=1S/C34H55N5O8S/c1-10-23(4)29(38-33(44)47-21-25-14-12-11-13-15-25)32(43)37-27(16-17-28(40)39-34(6,7)8)31(42)35-24(5)30(41)36-26(20-22(2)3)18-19-48(9,45)46/h11-15,18-19,22-24,26-27,29H,10,16-17,20-21H2,1-9H3,(H,35,42)(H,36,41)(H,37,43)(H,38,44)(H,39,40)/b19-18+/t23-,24-,26+,27-,29-/m0/s1
DMGTFON CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)NC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMGTFON IK YIFPZVMURBGBNU-NHVLHDLVSA-N
DMGTFON IU benzyl N-[(2S,3S)-1-[[(2S)-5-(tert-butylamino)-1-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamate
DMGTFON DE Discovery agent
DMNKC9J ID DMNKC9J
DMNKC9J DN Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
DMNKC9J HS Investigative
DMNKC9J SN CHEMBL207196; Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe
DMNKC9J DT Small molecular drug
DMNKC9J PC 11513217
DMNKC9J MW 708.9
DMNKC9J FM C35H56N4O9S
DMNKC9J IC InChI=1S/C35H56N4O9S/c1-10-24(4)30(39-34(44)47-22-26-15-12-11-13-16-26)33(43)38-28(17-14-18-29(40)48-35(6,7)8)32(42)36-25(5)31(41)37-27(21-23(2)3)19-20-49(9,45)46/h11-13,15-16,19-20,23-25,27-28,30H,10,14,17-18,21-22H2,1-9H3,(H,36,42)(H,37,41)(H,38,43)(H,39,44)/b20-19+/t24-,25-,27+,28-,30-/m0/s1
DMNKC9J CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCC(=O)OC(C)(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)/C=C/S(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
DMNKC9J IK JWIOGOVPAFUFAB-OKNAZKIESA-N
DMNKC9J IU tert-butyl (5S)-6-[[(2S)-1-[[(E,3S)-5-methyl-1-methylsulfonylhex-1-en-3-yl]amino]-1-oxopropan-2-yl]amino]-5-[[(2S,3S)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-6-oxohexanoate
DMNKC9J DE Discovery agent
DM6TYRA ID DM6TYRA
DM6TYRA DN Cbz-Val-Pro-Val-(2-benzoxazole)
DM6TYRA HS Investigative
DM6TYRA SN CHEMBL108783; Cbz-Val-Pro-Val-(2-benzoxazole); BDBM50031199; ((S)-1-{(S)-2-[(S)-1-(Benzooxazole-2-carbonyl)-2-methyl-propylcarbamoyl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid benzyl ester
DM6TYRA DT Small molecular drug
DM6TYRA PC 10053241
DM6TYRA MW 548.6
DM6TYRA FM C30H36N4O6
DM6TYRA IC InChI=1S/C30H36N4O6/c1-18(2)24(26(35)28-31-21-13-8-9-15-23(21)40-28)32-27(36)22-14-10-16-34(22)29(37)25(19(3)4)33-30(38)39-17-20-11-6-5-7-12-20/h5-9,11-13,15,18-19,22,24-25H,10,14,16-17H2,1-4H3,(H,32,36)(H,33,38)/t22-,24-,25-/m0/s1
DM6TYRA CS CC(C)[C@@H](C(=O)C1=NC2=CC=CC=C2O1)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)OCC4=CC=CC=C4
DM6TYRA IK MRIBOSDZTNAJSS-HVCNVCAESA-N
DM6TYRA IU benzyl N-[(2S)-1-[(2S)-2-[[(2S)-1-(1,3-benzoxazol-2-yl)-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
DM6TYRA DE Discovery agent
DMSE20Y ID DMSE20Y
DMSE20Y DN CCACSSKWCRDHSRCC
DMSE20Y HS Investigative
DMSE20Y SN CHEMBL508113
DMSE20Y PC 44560054
DMSE20Y MW 1841.1
DMSE20Y FM C69H105N27O21S6
DMSE20Y IC InChI=1S/C69H105N27O21S6/c1-31-53(103)93-48-27-121-119-25-46(52(72)102)92-67(117)50-29-123-122-26-47(64(114)82-31)94-54(104)35(71)24-118-120-28-49(96-58(108)40(16-32-19-80-36-9-3-2-8-34(32)36)86-55(105)37(10-4-5-13-70)83-62(112)44(22-98)90-63(113)45(23-99)91-66(48)116)65(115)85-38(11-6-14-78-68(73)74)56(106)88-42(18-51(100)101)60(110)87-41(17-33-20-77-30-81-33)59(109)89-43(21-97)61(111)84-39(57(107)95-50)12-7-15-79-69(75)76/h2-3,8-9,19-20,30-31,35,37-50,80,97-99H,4-7,10-18,21-29,70-71H2,1H3,(H2,72,102)(H,77,81)(H,82,114)(H,83,112)(H,84,111)(H,85,115)(H,86,105)(H,87,110)(H,88,106)(H,89,109)(H,90,113)(H,91,116)(H,92,117)(H,93,103)(H,94,104)(H,95,107)(H,96,108)(H,100,101)(H4,73,74,78)(H4,75,76,79)/t31-,35+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+/m1/s1
DMSE20Y CS C[C@@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H]3CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCNC(=N)N)CO)CC4=CN=CN4)CC(=O)O)CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CO)CCCCN)CC5=CNC6=CC=CC=C65)N)C(=O)N
DMSE20Y IK DSVGHPDROAIMFA-YDQMBMOMSA-N
DMSE20Y IU 2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-42-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMSE20Y DE Discovery agent
DMUQJ6X ID DMUQJ6X
DMUQJ6X DN CCG-50014
DMUQJ6X HS Investigative
DMUQJ6X SN CCG 50014; compound 1a; CCG50014
DMUQJ6X DT Small molecular drug
DMUQJ6X PC 2733079
DMUQJ6X MW 316.4
DMUQJ6X FM C16H13FN2O2S
DMUQJ6X IC InChI=1S/C16H13FN2O2S/c1-11-2-8-14(9-3-11)19-15(20)18(16(21)22-19)10-12-4-6-13(17)7-5-12/h2-9H,10H2,1H3
DMUQJ6X CS CC1=CC=C(C=C1)N2C(=O)N(C(=O)S2)CC3=CC=C(C=C3)F
DMUQJ6X IK QUIIIYITNGOFEI-UHFFFAOYSA-N
DMUQJ6X IU 4-[(4-fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione
DMUQJ6X CA CAS 883050-24-6
DMUQJ6X DE Discovery agent
DM1N0ED ID DM1N0ED
DM1N0ED DN CCK-33
DM1N0ED HS Investigative
DM1N0ED SN CCRIS 3307; cholecystokinin 33
DM1N0ED DT Small molecular drug
DM1N0ED PC 16129670
DM1N0ED MW 3931
DM1N0ED FM C166H261N51O52S4
DM1N0ED IC InChI=1S/C166H261N51O52S4/c1-15-84(9)130(159(261)211-116(78-220)154(256)206-110(68-125(227)228)150(252)191-97(38-27-54-182-165(176)177)139(241)205-112(70-127(231)232)152(254)215-132(88-42-44-91(45-43-88)269-273(266,267)268)161(263)197-100(48-58-270-12)135(237)185-75-124(226)190-106(64-89-72-184-94-35-21-20-33-92(89)94)146(248)195-101(49-59-271-13)141(243)204-111(69-126(229)230)151(253)198-103(133(173)235)63-87-31-18-17-19-32-87)213-143(245)98(39-28-55-183-166(178)179)192-147(249)107(65-90-73-180-80-187-90)201-153(255)115(77-219)210-157(259)119-41-30-57-217(119)163(265)113(71-128(233)234)207-145(247)105(62-82(5)6)200-149(251)109(67-122(172)224)203-140(242)99(46-47-120(170)222)193-144(246)104(61-81(3)4)199-148(250)108(66-121(171)223)202-138(240)96(36-23-25-52-168)196-158(260)129(83(7)8)212-160(262)131(85(10)16-2)214-155(257)117(79-221)208-142(244)102(50-60-272-14)194-137(239)95(37-26-53-181-164(174)175)189-123(225)74-186-136(238)114(76-218)209-156(258)118-40-29-56-216(118)162(264)86(11)188-134(236)93(169)34-22-24-51-167/h17-21,31-33,35,42-45,72-73,80-86,93,95-119,129-132,184,218-221H,15-16,22-30,34,36-41,46-71,74-79,167-169H2,1-14H3,(H2,170,222)(H2,171,223)(H2,172,224)(H2,173,235)(H,180,187)(H,185,237)(H,186,238)(H,188,236)(H,189,225)(H,190,226)(H,191,252)(H,192,249)(H,193,246)(H,194,239)(H,195,248)(H,196,260)(H,197,263)(H,198,253)(H,199,250)(H,200,251)(H,201,255)(H,202,240)(H,203,242)(H,204,243)(H,205,241)(H,206,256)(H,207,247)(H,208,244)(H,209,258)(H,210,259)(H,211,261)(H,212,262)(H,213,245)(H,214,257)(H,215,254)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H4,174,175,181)(H4,176,177,182)(H4,178,179,183)(H,266,267,268)
DM1N0ED CS CCC(C)C(C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(C1=CC=C(C=C1)OS(=O)(=O)O)C(=O)NC(CCSC)C(=O)NCC(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC4=CC=CC=C4)C(=O)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC5=CNC=N5)NC(=O)C(CO)NC(=O)C6CCCN6C(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(CO)NC(=O)C7CCCN7C(=O)C(C)NC(=O)C(CCCCN)N
DM1N0ED IK QFLBZJPOIZFFJQ-UHFFFAOYSA-N
DM1N0ED IU 3-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[2-[[2-[[4-amino-2-[[5-amino-2-[[2-[[4-amino-2-[[6-amino-2-[[2-[[2-[[2-[[2-[[5-carbamimidamido-2-[[2-[[2-[[1-[2-(2,6-diaminohexanoylamino)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]pentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-carboxypropanoyl]amino]-2-(4-sulfooxyphenyl)acetyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-oxobutanoic acid
DM1N0ED CA CAS 9011-97-6
DM1N0ED DE Discovery agent
DMN0J4W ID DMN0J4W
DMN0J4W DN CCK-8
DMN0J4W HS Investigative
DMN0J4W SN cholecystokinin 8; cholecystokinin fragment 26-33 amide (sulphated); CCK-8 (sulphated)
DMN0J4W DT Small molecular drug
DMN0J4W PC 9833444
DMN0J4W MW 1143.3
DMN0J4W FM C49H62N10O16S3
DMN0J4W IC InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
DMN0J4W CS CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
DMN0J4W IK IZTQOLKUZKXIRV-YRVFCXMDSA-N
DMN0J4W IU (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DMN0J4W CA CAS 25126-32-3
DMN0J4W CB CHEBI:135946
DMRFA5O ID DMRFA5O
DMRFA5O DN CCNCASKWCRDHSRCC
DMRFA5O HS Investigative
DMRFA5O SN CHEMBL524481
DMRFA5O PC 44560055
DMRFA5O MW 1868.2
DMRFA5O FM C70H106N28O21S6
DMRFA5O IC InChI=1S/C70H106N28O21S6/c1-31-54(105)92-44(22-99)63(114)85-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)59(110)98-49-28-122-120-24-35(72)55(106)95-48-27-124-125-29-50(68(119)94-46(53(74)104)25-121-123-26-47(65(116)84-31)97-61(112)42(18-51(73)101)90-67(48)118)96-58(109)39(12-7-15-81-70(77)78)86-64(115)45(23-100)93-60(111)41(17-33-21-79-30-83-33)89-62(113)43(19-52(102)103)91-57(108)38(87-66(49)117)11-6-14-80-69(75)76/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,116)(H,85,114)(H,86,115)(H,87,117)(H,88,107)(H,89,113)(H,90,118)(H,91,108)(H,92,105)(H,93,111)(H,94,119)(H,95,106)(H,96,109)(H,97,112)(H,98,110)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMRFA5O CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H]3CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](NC3=O)CC(=O)N)C(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CCCNC(=N)N)CC(=O)O)CC4=CN=CN4)CO)CCCNC(=N)N)N)CC5=CNC6=CC=CC=C65)CCCCN)CO
DMRFA5O IK SAPIXEQVQIRZOT-CPQFHPGLSA-N
DMRFA5O IU 2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,33-bis(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-36-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMRFA5O DE Discovery agent
DMZKJ37 ID DMZKJ37
DMZKJ37 DN CCNCSAKWCRDHSRCC
DMZKJ37 HS Investigative
DMZKJ37 SN CHEMBL503290
DMZKJ37 PC 44560056
DMZKJ37 MW 1868.2
DMZKJ37 FM C70H106N28O21S6
DMZKJ37 IC InChI=1S/C70H106N28O21S6/c1-31-54(105)85-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)59(110)97-48-27-122-120-24-35(72)55(106)95-47-26-124-125-29-50(68(119)94-46(53(74)104)25-121-123-28-49(67(118)93-44(22-99)63(114)84-31)98-61(112)42(18-51(73)101)90-66(47)117)96-58(109)39(12-7-15-81-70(77)78)86-64(115)45(23-100)92-60(111)41(17-33-21-79-30-83-33)89-62(113)43(19-52(102)103)91-57(108)38(87-65(48)116)11-6-14-80-69(75)76/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,114)(H,85,105)(H,86,115)(H,87,116)(H,88,107)(H,89,113)(H,90,117)(H,91,108)(H,92,111)(H,93,118)(H,94,119)(H,95,106)(H,96,109)(H,97,110)(H,98,112)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMZKJ37 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H]3CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CO)NC(=O)[C@H](NC3=O)CC(=O)N)C(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CCCNC(=N)N)CC(=O)O)CC4=CN=CN4)CO)CCCNC(=N)N)N)CC5=CNC6=CC=CC=C65)CCCCN
DMZKJ37 IK AOAFXQNJFCOYGE-CPQFHPGLSA-N
DMZKJ37 IU 2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-12,36-bis(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-33-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMZKJ37 DE Discovery agent
DM96YR2 ID DM96YR2
DM96YR2 DN CCNCSSKWCRAHSRCC
DM96YR2 HS Investigative
DM96YR2 SN CHEMBL524475
DM96YR2 PC 44560061
DM96YR2 MW 1840.2
DM96YR2 FM C69H106N28O20S6
DM96YR2 IC InChI=1S/C69H106N28O20S6/c1-31-53(103)87-41(17-33-20-78-30-82-33)59(109)90-43(21-98)61(111)85-39(12-7-15-80-69(76)77)57(107)95-50-29-123-122-26-47-65(115)89-42(18-51(72)101)60(110)97-49(28-121-119-25-46(52(73)102)93-67(50)117)66(116)92-45(23-100)63(113)91-44(22-99)62(112)84-37(10-4-5-13-70)56(106)88-40(16-32-19-81-36-9-3-2-8-34(32)36)58(108)96-48(27-120-118-24-35(71)54(104)94-47)64(114)86-38(55(105)83-31)11-6-14-79-68(74)75/h2-3,8-9,19-20,30-31,35,37-50,81,98-100H,4-7,10-18,21-29,70-71H2,1H3,(H2,72,101)(H2,73,102)(H,78,82)(H,83,105)(H,84,112)(H,85,111)(H,86,114)(H,87,103)(H,88,106)(H,89,115)(H,90,109)(H,91,113)(H,92,116)(H,93,117)(H,94,104)(H,95,107)(H,96,108)(H,97,110)(H4,74,75,79)(H4,76,77,80)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DM96YR2 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC2=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC4=CNC5=CC=CC=C54)CCCCN)CO)CO)CC(=O)N)CCCNC(=N)N)CO)CC6=CN=CN6
DM96YR2 IK RFBOHZPDDZVGLQ-CPQFHPGLSA-N
DM96YR2 IU (1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-18-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontane-56-carboxamide
DM96YR2 DE Discovery agent
DMP0C7B ID DMP0C7B
DMP0C7B DN CCNCSSKWCRDHARCC
DMP0C7B HS Investigative
DMP0C7B SN CHEMBL525208
DMP0C7B PC 44560063
DMP0C7B MW 1868.2
DMP0C7B FM C70H106N28O21S6
DMP0C7B IC InChI=1S/C70H106N28O21S6/c1-31-54(105)85-38(11-6-14-80-69(75)76)58(109)96-50-29-125-124-26-47-66(117)90-42(18-51(73)101)61(112)98-49(28-123-121-25-46(53(74)104)94-68(50)119)67(118)93-45(23-100)64(115)92-44(22-99)63(114)86-37(10-4-5-13-71)56(107)88-40(16-32-20-82-36-9-3-2-8-34(32)36)60(111)97-48(27-122-120-24-35(72)55(106)95-47)65(116)87-39(12-7-15-81-70(77)78)57(108)91-43(19-52(102)103)62(113)89-41(59(110)84-31)17-33-21-79-30-83-33/h2-3,8-9,20-21,30-31,35,37-50,82,99-100H,4-7,10-19,22-29,71-72H2,1H3,(H2,73,101)(H2,74,104)(H,79,83)(H,84,110)(H,85,105)(H,86,114)(H,87,116)(H,88,107)(H,89,113)(H,90,117)(H,91,108)(H,92,115)(H,93,118)(H,94,119)(H,95,106)(H,96,109)(H,97,111)(H,98,112)(H,102,103)(H4,75,76,80)(H4,77,78,81)/t31-,35-,37-,38-,39-,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMP0C7B CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](NC2=O)C(=O)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CN=CN4)CC(=O)O)CCCNC(=N)N)CC5=CNC6=CC=CC=C65)CCCCN)CO)CO)CC(=O)N)CCCNC(=N)N
DMP0C7B IK ILMKBHRRAVBBMV-CPQFHPGLSA-N
DMP0C7B IU 2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-9,21-bis(3-carbamimidamidopropyl)-56-carbamoyl-33,36-bis(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-12-methyl-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMP0C7B DE Discovery agent
DMBGHTW ID DMBGHTW
DMBGHTW DN CCNCSSKWCRDHSRCC
DMBGHTW HS Investigative
DMBGHTW PC 91935560
DMBGHTW MW 1884.2
DMBGHTW FM C70H106N28O22S6
DMBGHTW IC InChI=1S/C70H106N28O22S6/c71-12-4-3-9-36-55(107)87-39(15-31-19-82-35-8-2-1-7-33(31)35)58(110)97-48-27-123-121-24-34(72)54(106)95-47-26-125-126-29-50(68(120)94-46(53(74)105)25-122-124-28-49(98-60(112)41(17-51(73)102)89-66(47)118)67(119)93-45(23-101)64(116)92-44(22-100)63(115)84-36)96-57(109)38(11-6-14-81-70(77)78)85-62(114)43(21-99)91-59(111)40(16-32-20-79-30-83-32)88-61(113)42(18-52(103)104)90-56(108)37(86-65(48)117)10-5-13-80-69(75)76/h1-2,7-8,19-20,30,34,36-50,82,99-101H,3-6,9-18,21-29,71-72H2,(H2,73,102)(H2,74,105)(H,79,83)(H,84,115)(H,85,114)(H,86,117)(H,87,107)(H,88,113)(H,89,118)(H,90,108)(H,91,111)(H,92,116)(H,93,119)(H,94,120)(H,95,106)(H,96,109)(H,97,110)(H,98,112)(H,103,104)(H4,75,76,80)(H4,77,78,81)/t34-,36-,37-,38-,39-,40-,41+,42-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMBGHTW CS C1[C@@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)CCCN=C(N)N)CO)CC4=CN=CN4)CC(=O)O)CCCN=C(N)N)CC5=CNC6=CC=CC=C65)CCCCN)CO)CO)NC(=O)[C@H](NC2=O)CC(=O)N)C(=O)N)N
DMBGHTW IK PRXVBAUMWHTDJW-HEDOAMBMSA-N
DMBGHTW IU 2-[(1R,6R,9S,12S,15S,18S,21S,24R,27S,30S,33S,36S,39R,42R,47R,56R)-47-amino-30-(4-aminobutyl)-42-(2-amino-2-oxoethyl)-56-carbamoyl-9,21-bis[3-(diaminomethylideneamino)propyl]-12,33,36-tris(hydroxymethyl)-15-(1H-imidazol-5-ylmethyl)-27-(1H-indol-3-ylmethyl)-8,11,14,17,20,23,26,29,32,35,38,41,44,46,58-pentadecaoxo-3,4,49,50,53,54-hexathia-7,10,13,16,19,22,25,28,31,34,37,40,43,45,57-pentadecazatricyclo[22.20.7.76,39]octapentacontan-18-yl]acetic acid
DMBGHTW DE Discovery agent
DM2UJM8 ID DM2UJM8
DM2UJM8 DN CCP
DM2UJM8 HS Investigative
DM2UJM8 SN N-Pentadecylcyclohexanecarboxamide; CHEMBL190662; Cyclohexanecarboxylic acid pentadecylamide; GTPL5161; MolPort-009-019-076; VMFXYTSKMWPHQH-UHFFFAOYSA-N; N-Pentadecyl-cyclohexanecarboxamide; HMS3650I19; BDBM50171299; 1921AH; ZINC38140992; AKOS027276373; RT-014383; SR-01000946796
DM2UJM8 DT Small molecular drug
DM2UJM8 PC 44398718
DM2UJM8 MW 337.6
DM2UJM8 FM C22H43NO
DM2UJM8 IC InChI=1S/C22H43NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-20-23-22(24)21-18-15-14-16-19-21/h21H,2-20H2,1H3,(H,23,24)
DM2UJM8 CS CCCCCCCCCCCCCCCNC(=O)C1CCCCC1
DM2UJM8 IK VMFXYTSKMWPHQH-UHFFFAOYSA-N
DM2UJM8 IU N-pentadecylcyclohexanecarboxamide
DM2UJM8 DE Discovery agent
DMZXFT9 ID DMZXFT9
DMZXFT9 DN CCT-241533
DMZXFT9 HS Investigative
DMZXFT9 SN Chk2 inhibitors (cancer); Chk2 inhibitors (cancer), Cancer Research Technology
DMZXFT9 CP Cancer Research Technology Ltd
DMZXFT9 DT Small molecular drug
DMZXFT9 PC 135564841
DMZXFT9 MW 442.5
DMZXFT9 FM C23H27FN4O4
DMZXFT9 IC InChI=1S/C23H27FN4O4/c1-23(2,30)15-10-25-11-17(15)27-21-13-8-19(31-3)20(32-4)9-16(13)26-22(28-21)14-7-12(24)5-6-18(14)29/h5-9,15,17,25,29-30H,10-11H2,1-4H3,(H,26,27,28)/t15-,17-/m1/s1
DMZXFT9 CS CC(C)([C@@H]1CNC[C@H]1NC2=NC(=NC3=CC(=C(C=C32)OC)OC)C4=C(C=CC(=C4)F)O)O
DMZXFT9 IK HZASIAXCPXTISQ-NVXWUHKLSA-N
DMZXFT9 IU 4-fluoro-2-[4-[[(3S,4R)-4-(2-hydroxypropan-2-yl)pyrrolidin-3-yl]amino]-6,7-dimethoxyquinazolin-2-yl]phenol
DMZXFT9 CA CAS 1262849-73-9
DMZXFT9 DE Solid tumour/cancer
DMSDH3A ID DMSDH3A
DMSDH3A DN CCT244747
DMSDH3A HS Investigative
DMSDH3A SN compound 26 [PMID 23082860]
DMSDH3A DT Small molecular drug
DMSDH3A PC 54758482
DMSDH3A MW 408.5
DMSDH3A FM C20H24N8O2
DMSDH3A IC InChI=1S/C20H24N8O2/c1-13(11-27(2)3)30-20-16(7-21)22-10-19(26-20)25-18-6-17(29-5)15(9-23-18)14-8-24-28(4)12-14/h6,8-10,12-13H,11H2,1-5H3,(H,23,25,26)/t13-/m1/s1
DMSDH3A CS C[C@H](CN(C)C)OC1=NC(=CN=C1C#N)NC2=NC=C(C(=C2)OC)C3=CN(N=C3)C
DMSDH3A IK IENLGMOXAQMNEH-CYBMUJFWSA-N
DMSDH3A IU 3-[(2R)-1-(dimethylamino)propan-2-yl]oxy-5-[[4-methoxy-5-(1-methylpyrazol-4-yl)pyridin-2-yl]amino]pyrazine-2-carbonitrile
DMSDH3A DE Discovery agent
DM6WX1A ID DM6WX1A
DM6WX1A DN CCX-662
DM6WX1A HS Investigative
DM6WX1A SN CCX-733; CCX-754; CXCR7 antagonists, ChemoCentryx
DM6WX1A CP ChemoCentryx Inc
DM6WX1A DE Solid tumour/cancer
DM9BMDO ID DM9BMDO
DM9BMDO DN CD154
DM9BMDO HS Investigative
DM9BMDO DE Discovery agent
DMT6M5E ID DMT6M5E
DMT6M5E DN CD-160130
DMT6M5E HS Investigative
DMT6M5E SN PDE-4 inhibitor (oral, B-CLL), Curacyte Discovery; PDE-4 inhibitor (oral, B-cell chronic lymphocytic leukemia), Curacyte Discovery
DMT6M5E CP Curacyte AG
DMT6M5E PC 24990553
DMT6M5E MW 374.4
DMT6M5E FM C21H22N6O
DMT6M5E IC InChI=1S/C21H22N6O/c1-2-28-20-19-18(25-21(26-20)27-11-9-23-10-12-27)16-4-3-15(13-17(16)24-19)14-5-7-22-8-6-14/h3-8,13,23-24H,2,9-12H2,1H3
DMT6M5E CS CCOC1=NC(=NC2=C1NC3=C2C=CC(=C3)C4=CC=NC=C4)N5CCNCC5
DMT6M5E IK HFGHRUCCKVYFKL-UHFFFAOYSA-N
DMT6M5E IU 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole
DMT6M5E DE Chronic lymphocytic leukaemia
DM05M9X ID DM05M9X
DM05M9X DN CD2665
DM05M9X HS Investigative
DM05M9X SN CD 2665; CD-2665
DM05M9X DT Small molecular drug
DM05M9X PC 216241
DM05M9X MW 486.6
DM05M9X FM C31H34O5
DM05M9X IC InChI=1S/C31H34O5/c1-34-8-9-35-19-36-29-15-26-7-6-25(23-2-4-24(5-3-23)30(32)33)13-27(26)14-28(29)31-16-20-10-21(17-31)12-22(11-20)18-31/h2-7,13-15,20-22H,8-12,16-19H2,1H3,(H,32,33)
DM05M9X CS COCCOCOC1=C(C=C2C=C(C=CC2=C1)C3=CC=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
DM05M9X IK JBALRFFXKQPVLT-UHFFFAOYSA-N
DM05M9X IU 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic acid
DM05M9X CA CAS 170355-78-9
DM05M9X DE Discovery agent
DM38MU1 ID DM38MU1
DM38MU1 DN CD3254
DM38MU1 HS Investigative
DM38MU1 SN CD 3254; CD-3254
DM38MU1 DT Small molecular drug
DM38MU1 PC 44566110
DM38MU1 MW 364.5
DM38MU1 FM C24H28O3
DM38MU1 IC InChI=1S/C24H28O3/c1-15-12-19-20(24(4,5)11-10-23(19,2)3)14-17(15)18-13-16(6-8-21(18)25)7-9-22(26)27/h6-9,12-14,25H,10-11H2,1-5H3,(H,26,27)/b9-7+
DM38MU1 CS CC1=CC2=C(C=C1C3=C(C=CC(=C3)/C=C/C(=O)O)O)C(CCC2(C)C)(C)C
DM38MU1 IK DYLLZSVPAUUSSB-VQHVLOKHSA-N
DM38MU1 IU (E)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid
DM38MU1 CA CAS 196961-43-0
DM38MU1 DE Discovery agent
DMIV82T ID DMIV82T
DMIV82T DN CD4 red blood cell electroinsertion
DMIV82T HS Investigative
DMIV82T SN RBC-CD4, Sheffield
DMIV82T DE Discovery agent
DMFQVLW ID DMFQVLW
DMFQVLW DN CD45RB
DMFQVLW HS Investigative
DMFQVLW SN Abeta amyloid agonist (peptide, glioma); Abeta amyloid agonist (peptide, glioma), Lee Moffitt Cancer Center
DMFQVLW CP H Lee Moffitt Cancer Center and Research Institute
DMFQVLW DE Glioma
DMZ2LPO ID DMZ2LPO
DMZ2LPO DN CD564
DMZ2LPO HS Investigative
DMZ2LPO SN cd564; CHEMBL309282; 110952-26-6; 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)naphthalene-2-carboxylic acid; 2-Naphthalenecarboxylicacid, 6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]-; 1fcy; ACMC-20mdu5; AC1L1E1W; SCHEMBL2391376; CTK0I1187; BDBM31886; DTXSID60274381; DB02741; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthoyl)-2-naphthoic acid; 6-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]naphthalene-2-carboxylic acid
DMZ2LPO DT Small molecular drug
DMZ2LPO PC 2605
DMZ2LPO MW 386.5
DMZ2LPO FM C26H26O3
DMZ2LPO IC InChI=1S/C26H26O3/c1-25(2)11-12-26(3,4)22-15-19(9-10-21(22)25)23(27)18-7-5-17-14-20(24(28)29)8-6-16(17)13-18/h5-10,13-15H,11-12H2,1-4H3,(H,28,29)
DMZ2LPO CS CC1(CCC(C2=C1C=CC(=C2)C(=O)C3=CC4=C(C=C3)C=C(C=C4)C(=O)O)(C)C)C
DMZ2LPO IK RWYREGSYPCNZTL-UHFFFAOYSA-N
DMZ2LPO IU 6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)naphthalene-2-carboxylic acid
DMZ2LPO CA CAS 110952-26-6
DMZ2LPO DE Discovery agent
DMC8X9Y ID DMC8X9Y
DMC8X9Y DN CD666
DMC8X9Y HS Investigative
DMC8X9Y SN CD-666; CD 666
DMC8X9Y DT Small molecular drug
DMC8X9Y PC 10090192
DMC8X9Y MW 364.5
DMC8X9Y FM C24H28O3
DMC8X9Y IC InChI=1S/C24H28O3/c1-23(2)13-14-24(3,4)20-15-18(10-11-19(20)23)21(25)12-7-16-5-8-17(9-6-16)22(26)27/h5-12,15,21,25H,13-14H2,1-4H3,(H,26,27)/b12-7+
DMC8X9Y CS CC1(CCC(C2=C1C=CC(=C2)C(/C=C/C3=CC=C(C=C3)C(=O)O)O)(C)C)C
DMC8X9Y IK QCSYBKHFYYISTQ-KPKJPENVSA-N
DMC8X9Y IU 4-[(E)-3-hydroxy-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid
DMC8X9Y DE Discovery agent
DMWP63C ID DMWP63C
DMWP63C DN CD79-targeted immunotoxins
DMWP63C HS Investigative
DMWP63C SN Anti-CD79b-MC-MMAF; Anti-CD79b-MCC-DM1; Anti-CD79b-vc-MMAE; Anti-CD79b-vc-vedotin; CD79-targeted immunotoxins (non-Hodgkin's lymphoma); CD79-targeted immunotoxins (non-Hodgkin's lymphoma), Genentech; Anti-CD79 antibody-drug conjugates (non-Hodgkin's lymphoma), Genentech
DMWP63C CP Genentech Inc
DMWP63C DT Antibody
DMWP63C DE Non-hodgkin lymphoma
DMFYWE3 ID DMFYWE3
DMFYWE3 DN CD-832.HCL
DMFYWE3 HS Investigative
DMFYWE3 SN 129904-55-8; 2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 5-(3-nitrooxypropyl) 3-[2-(3-pyridylcarbonylamino)ethyl] diester monohydrochloride; CD-832.HCl
DMFYWE3 DT Small molecular drug
DMFYWE3 PC 179844
DMFYWE3 MW 606
DMFYWE3 FM C26H28ClN5O10
DMFYWE3 IC InChI=1S/C26H27N5O10.ClH/c1-16-21(25(33)39-11-5-12-41-31(37)38)23(18-6-3-8-20(14-18)30(35)36)22(17(2)29-16)26(34)40-13-10-28-24(32)19-7-4-9-27-15-19;/h3-4,6-9,14-15,23,29H,5,10-13H2,1-2H3,(H,28,32);1H
DMFYWE3 CS CC1=C(C(C(=C(N1)C)C(=O)OCCNC(=O)C2=CN=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCCO[N+](=O)[O-].Cl
DMFYWE3 IK MWVXLKFCDZXILL-UHFFFAOYSA-N
DMFYWE3 IU 3-O-(3-nitrooxypropyl) 5-O-[2-(pyridine-3-carbonylamino)ethyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride
DMFYWE3 CA CAS 129904-55-8
DMFYWE3 DE Discovery agent
DM03NUV ID DM03NUV
DM03NUV DN CDDO
DM03NUV HS Investigative
DM03NUV SN Bardoxolone; CDDO; 218600-44-3; RTA-401; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid; UNII-7HT68L8941; RTA 401; 7HT68L8941; (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid; C31H41NO4; 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid; RTA 402; CCDO;(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid; NSC711193; bardoxolone RTA 401
DM03NUV DT Small molecular drug
DM03NUV PC 400010
DM03NUV MW 491.7
DM03NUV FM C31H41NO4
DM03NUV IC InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1
DM03NUV CS C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)O
DM03NUV IK TXGZJQLMVSIZEI-UQMAOPSPSA-N
DM03NUV IU (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid
DM03NUV CA CAS 218600-44-3
DM03NUV DE Discovery agent
DMNW12R ID DMNW12R
DMNW12R DN Cdk1 inhibitor
DMNW12R HS Investigative
DMNW12R SN cdk1 inhibitor; 3-(2-Chloro-3-indolylmethylene)-1,3-dihydroindol-2-one; CHEMBL261425; 220749-41-7; K00028; AC1NV88J; SCHEMBL1394886; GTPL5944; CHEBI:113538; HMS3229C12; NSC720148; BDBM50375670; HSCI1_000249; CCG-206822; NSC-720148; RT-011955; J-014469; BRD-K81836716-001-01-7; 3-[(2-Chloro-1H-indole-3-yl)methylene]-1H-indole-2(3H)-one; (3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one
DMNW12R DT Small molecular drug
DMNW12R PC 5472558
DMNW12R MW 294.7
DMNW12R FM C17H11ClN2O
DMNW12R IC InChI=1S/C17H11ClN2O/c18-16-12(10-5-1-3-7-14(10)19-16)9-13-11-6-2-4-8-15(11)20-17(13)21/h1-9,19H,(H,20,21)/b13-9+
DMNW12R CS C1=CC=C2C(=C1)/C(=C\\C3=C(NC4=CC=CC=C43)Cl)/C(=O)N2
DMNW12R IK QJKBRWSJWQVKLY-UKTHLTGXSA-N
DMNW12R IU (3E)-3-[(2-chloro-1H-indol-3-yl)methylidene]-1H-indol-2-one
DMNW12R CB CHEBI:113538
DMNW12R DE Discovery agent
DMS62T0 ID DMS62T0
DMS62T0 DN Cdk1/2 inhibitor III
DMS62T0 HS Investigative
DMS62T0 SN Cdk1/2 Inhibitor III; 443798-55-8; CDK 1/2 INHIBITOR; UNII-LFR1253W75; LFR1253W75; 5-AMINO-3-{[4-(AMINOSULFONYL)PHENYL]AMINO}-N-(2,6-DIFLUOROPHENYL)-1H-1,2,4-TRIAZOLE-1-CARBOTHIOAMIDE; 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide; 5-Amino-3-((4-(aminosulfonyl)phenyl)amino)-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide; 2wu6; AC1NS9OB; CHEMBL261720; GTPL5946; BDBM6878; SCHEMBL1394721; CTK8E9250; DTXSID60416209; MolPort-044-561-528; HMS3229C16; ZINC12355112; DB07664
DMS62T0 DT Small molecular drug
DMS62T0 PC 5330812
DMS62T0 MW 425.4
DMS62T0 FM C15H13F2N7O2S2
DMS62T0 IC InChI=1S/C15H13F2N7O2S2/c16-10-2-1-3-11(17)12(10)21-15(27)24-13(18)22-14(23-24)20-8-4-6-9(7-5-8)28(19,25)26/h1-7H,(H,21,27)(H2,19,25,26)(H3,18,20,22,23)
DMS62T0 CS C1=CC(=C(C(=C1)F)NC(=S)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F
DMS62T0 IK ARIOBGGRZJITQX-UHFFFAOYSA-N
DMS62T0 IU 5-amino-N-(2,6-difluorophenyl)-3-(4-sulfamoylanilino)-1,2,4-triazole-1-carbothioamide
DMS62T0 CA CAS 443798-47-8
DMS62T0 DE Discovery agent
DMNZJAX ID DMNZJAX
DMNZJAX DN Cdk4 inhibitor III
DMNZJAX HS Investigative
DMNZJAX SN Ryuvidine; Cdk4 Inhibitor III; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830
DMNZJAX DT Small molecular drug
DMNZJAX PC 481747
DMNZJAX MW 284.3
DMNZJAX FM C15H12N2O2S
DMNZJAX IC InChI=1S/C15H12N2O2S/c1-8-3-5-10(6-4-8)17-11-7-12(18)15-13(14(11)19)16-9(2)20-15/h3-7,17H,1-2H3
DMNZJAX CS CC1=CC=C(C=C1)NC2=CC(=O)C3=C(C2=O)N=C(S3)C
DMNZJAX IK HFPLHASLIOXVGS-UHFFFAOYSA-N
DMNZJAX IU 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione
DMNZJAX CB CHEBI:92119
DMNZJAX DE Discovery agent
DMQDA5W ID DMQDA5W
DMQDA5W DN CDRI-85/92
DMQDA5W HS Investigative
DMQDA5W SN Proton pump inhibitor (gastric ulcer), CDRI
DMQDA5W CP Central Drug Research Institute
DMQDA5W DE Stomach ulcer
DMUKGEA ID DMUKGEA
DMUKGEA DN Cebutolol
DMUKGEA HS Investigative
DMUKGEA DE Discovery agent
DMRYX1P ID DMRYX1P
DMRYX1P DN CEL-1000
DMRYX1P HS Investigative
DMRYX1P SN CEL-1000C; DerG, CEL-SCI; Immunostimulant peptide, CEL-SCI; Peptide vaccine (Vaxcine, oral, herpes simplex virus infection); Peptide vaccine (Vaxcine, oral, herpes simplex virus infection), Infexion
DMRYX1P CP CEL-SCI Corp; Infexion
DMRYX1P DT Vaccine
DMRYX1P DE Solid tumour/cancer
DMQ0HCT ID DMQ0HCT
DMQ0HCT DN CEM-301
DMQ0HCT HS Investigative
DMQ0HCT SN Macrolide motilin agonists, Optimer/Cempra
DMQ0HCT CP Cempra Pharmaceuticals Inc
DMQ0HCT DE Gastric motility disorder
DMCLXO0 ID DMCLXO0
DMCLXO0 DN CENTAUREIDIN
DMCLXO0 HS Investigative
DMCLXO0 SN Centaureidin; Desmethoxycentaureidine; 17313-52-9; 5,7,3'-Trihydroxy-3,6,4'-trimethoxyflavone; NSC-106969; UNII-548R7290J9; CHEMBL77552; MLS002701956; CHEBI:69356; 548R7290J9; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxy-4H-chromen-4-one; centaureidine; NSC106969; NSC 106969; AC1NSTGP; SCHEMBL9953; cid_5315773; DTXSID50169530; MolPort-023-274-268; ZINC3871987; ZINC03871987; LMPK12113000; BDBM50064891; quercetagetin 3,6,4'-trimethyl ether; AKOS027326559; MCULE-7507998415; SMR001565538; 6-hydroxyquercetin 3,6,4''-trimethyl
DMCLXO0 DT Small molecular drug
DMCLXO0 PC 5315773
DMCLXO0 MW 360.3
DMCLXO0 FM C18H16O8
DMCLXO0 IC InChI=1S/C18H16O8/c1-23-11-5-4-8(6-9(11)19)16-18(25-3)15(22)13-12(26-16)7-10(20)17(24-2)14(13)21/h4-7,19-21H,1-3H3
DMCLXO0 CS COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C(=C3O)OC)O)OC)O
DMCLXO0 IK BZXULYMZYPRZOG-UHFFFAOYSA-N
DMCLXO0 IU 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,6-dimethoxychromen-4-one
DMCLXO0 CA CAS 17313-52-9
DMCLXO0 CB CHEBI:69356
DMCLXO0 DE Discovery agent
DMOHELX ID DMOHELX
DMOHELX DN Centratherin
DMOHELX HS Investigative
DMOHELX SN centratherin; CHEMBL382151
DMOHELX DT Small molecular drug
DMOHELX PC 44409502
DMOHELX MW 374.4
DMOHELX FM C20H22O7
DMOHELX IC InChI=1S/C20H22O7/c1-5-10(2)18(23)26-15-8-20(4)16(22)7-13(27-20)12(9-21)6-14-17(15)11(3)19(24)25-14/h5-7,14-15,17,21H,3,8-9H2,1-2,4H3/b10-5-,12-6-/t14-,15+,17+,20-/m1/s1
DMOHELX CS C/C=C(/C)\\C(=O)O[C@H]1C[C@@]2(C(=O)C=C(O2)/C(=C\\[C@@H]3[C@@H]1C(=C)C(=O)O3)/CO)C
DMOHELX IK BMVJFNLJSZHNNS-YUDFMKBLSA-N
DMOHELX IU [(2Z,4R,8R,9S,11R)-2-(hydroxymethyl)-11-methyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (Z)-2-methylbut-2-enoate
DMOHELX CA CAS 71939-83-8
DMOHELX DE Discovery agent
DMA7JO4 ID DMA7JO4
DMA7JO4 DN CEP1348
DMA7JO4 HS Investigative
DMA7JO4 DE Discovery agent
DMOAZX5 ID DMOAZX5
DMOAZX5 DN CEP1349
DMOAZX5 HS Investigative
DMOAZX5 DE Discovery agent
DMCIOSM ID DMCIOSM
DMCIOSM DN CEP-18050
DMCIOSM HS Investigative
DMCIOSM SN ALK inhibitors (anaplastic large cell lymphoma); ALK inhibitors (anaplastic large cell lymphoma), Cephalon; Alk inhibitors (cancer), Cephalon
DMCIOSM CP Cephalon Inc
DMCIOSM DE Lymphoma
DMAY04M ID DMAY04M
DMAY04M DN CEP-28122
DMAY04M HS Investigative
DMAY04M SN ALK inhibitor (cancer), Cephalon
DMAY04M CP Cephalon Inc
DMAY04M DT Small molecular drug
DMAY04M PC 57325421
DMAY04M MW 539.1
DMAY04M FM C28H35ClN6O3
DMAY04M IC InChI=1S/C28H35ClN6O3/c1-37-25-20-8-7-19(35-10-12-38-13-11-35)6-4-16(20)5-9-22(25)32-28-31-15-21(29)27(34-28)33-24-18-3-2-17(14-18)23(24)26(30)36/h2-3,5,9,15,17-19,23-24H,4,6-8,10-14H2,1H3,(H2,30,36)(H2,31,32,33,34)/t17-,18+,19+,23+,24-/m1/s1
DMAY04M CS COC1=C(C=CC2=C1CC[C@H](CC2)N3CCOCC3)NC4=NC=C(C(=N4)N[C@@H]5[C@@H]6C[C@H]([C@@H]5C(=O)N)C=C6)Cl
DMAY04M IK LAJAFFLJAJMYLK-CVOKMOJFSA-N
DMAY04M IU (1S,2S,3R,4R)-3-[[5-chloro-2-[[(7S)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide
DMAY04M CA CAS 1431697-87-8
DMAY04M DE Solid tumour/cancer
DMV43GY ID DMV43GY
DMV43GY DN CEP-5104
DMV43GY HS Investigative
DMV43GY SN C25H22N2O3; 2-Methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-5104; CHEMBL460989; SCHEMBL3264941; BDBM24947; ZINC40861910; 5-oxo dihydronaphthylcarbazole analogue, 14; X7364
DMV43GY DT Small molecular drug
DMV43GY PC 23378546
DMV43GY MW 398.5
DMV43GY FM C25H22N2O3
DMV43GY IC InChI=1S/C25H22N2O3/c1-30-15-7-9-16-14(12-15)6-8-18-21(16)23-19(13-26-25(23)29)22-17-4-2-3-5-20(17)27(10-11-28)24(18)22/h2-5,7,9,12,28H,6,8,10-11,13H2,1H3,(H,26,29)
DMV43GY CS COC1=CC2=C(C=C1)C3=C(CC2)C4=C(C5=C3C(=O)NC5)C6=CC=CC=C6N4CCO
DMV43GY IK QMLALHXGVBGFIC-UHFFFAOYSA-N
DMV43GY IU 3-(2-hydroxyethyl)-20-methoxy-3,13-diazahexacyclo[14.8.0.02,10.04,9.011,15.017,22]tetracosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaen-14-one
DMV43GY DE Discovery agent
DMNXBTD ID DMNXBTD
DMNXBTD DN CEP-6331
DMNXBTD HS Investigative
DMNXBTD SN 2-Isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol[2,1-a]pyrrolo[3,4-c]carbazole-5-one; CEP-6331; CHEMBL460990; BDBM24949; MolPort-027-637-287; ZINC33970297; 5-oxo dihydronaphthylcarbazole analogue, 16; X7365
DMNXBTD DT Small molecular drug
DMNXBTD PC 9823787
DMNXBTD MW 426.5
DMNXBTD FM C27H26N2O3
DMNXBTD IC InChI=1S/C27H26N2O3/c1-15(2)32-17-8-10-18-16(13-17)7-9-20-23(18)25-21(14-28-27(25)31)24-19-5-3-4-6-22(19)29(11-12-30)26(20)24/h3-6,8,10,13,15,30H,7,9,11-12,14H2,1-2H3,(H,28,31)
DMNXBTD CS CC(C)OC1=CC2=C(C=C1)C3=C(CC2)C4=C(C5=C3C(=O)NC5)C6=CC=CC=C6N4CCO
DMNXBTD IK HSWWFIPPMAFLPH-UHFFFAOYSA-N
DMNXBTD IU 3-(2-hydroxyethyl)-20-propan-2-yloxy-3,13-diazahexacyclo[14.8.0.02,10.04,9.011,15.017,22]tetracosa-1(16),2(10),4,6,8,11(15),17(22),18,20-nonaen-14-one
DMNXBTD DE Discovery agent
DMS16BD ID DMS16BD
DMS16BD DN CEP-6800
DMS16BD HS Investigative
DMS16BD SN CEP-6800; UNII-0X7U7SRK9H; 0X7U7SRK9H; CHEMBL247374; 609848-02-4; SCHEMBL12256417; BDBM50197585; 1H-Cyclopenta(a)pyrrolo(3,4-C)carbazole-1,3(2H)-dione, 10-(aminomethyl)-4,5,6,7-tetrahydro-; 8-aminomethyl-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione
DMS16BD DT Small molecular drug
DMS16BD PC 9948440
DMS16BD MW 305.3
DMS16BD FM C18H15N3O2
DMS16BD IC InChI=1S/C18H15N3O2/c19-7-8-4-5-12-11(6-8)13-15-14(17(22)21-18(15)23)9-2-1-3-10(9)16(13)20-12/h4-6,20H,1-3,7,19H2,(H,21,22,23)
DMS16BD CS C1CC2=C(C1)C3=C(C4=C(N3)C=CC(=C4)CN)C5=C2C(=O)NC5=O
DMS16BD IK SDXBGOVSVBZDFL-UHFFFAOYSA-N
DMS16BD IU 15-(aminomethyl)-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione
DMS16BD CA CAS 609848-02-4
DMS16BD DE Discovery agent
DMYW3ZG ID DMYW3ZG
DMYW3ZG DN Cephalosporin C
DMYW3ZG HS Investigative
DMYW3ZG SN cephalosporin C; 7-(5-Amino-5-carboxyvaleramido)cephalosporanic acid; 61-24-5; UNII-3XIY7HJT5L; CHEBI:15776; EINECS 200-501-6; 3XIY7HJT5L; BRN 0065348; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((5-amino-5-carboxy-1-oxopentyl)amino)-8-oxo-, (6R-(6alpha,7beta(R*)))-; (6R,7R)-3-[(acetyloxy)methyl]-7-{[(5R)-5-amino-5-carboxypentanoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(5-amino-5-carboxyvaleramid
DMYW3ZG DT Small molecular drug
DMYW3ZG PC 65536
DMYW3ZG MW 415.4
DMYW3ZG FM C16H21N3O8S
DMYW3ZG IC InChI=1S/C16H21N3O8S/c1-7(20)27-5-8-6-28-14-11(13(22)19(14)12(8)16(25)26)18-10(21)4-2-3-9(17)15(23)24/h9,11,14H,2-6,17H2,1H3,(H,18,21)(H,23,24)(H,25,26)/t9-,11-,14-/m1/s1
DMYW3ZG CS CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)SC1)C(=O)O
DMYW3ZG IK HOKIDJSKDBPKTQ-GLXFQSAKSA-N
DMYW3ZG IU (6R,7R)-3-(acetyloxymethyl)-7-[[(5R)-5-amino-5-carboxypentanoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DMYW3ZG CA CAS 61-24-5
DMYW3ZG CB CHEBI:15776
DMYW3ZG DE Discovery agent
DMCE3NA ID DMCE3NA
DMCE3NA DN CEPHARANTINE
DMCE3NA HS Investigative
DMCE3NA SN cepharantine; CHEMBL500862; BDBM50242977
DMCE3NA DT Small molecular drug
DMCE3NA PC 7098680
DMCE3NA MW 606.7
DMCE3NA FM C37H38N2O6
DMCE3NA IC InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29-/m0/s1
DMCE3NA CS CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
DMCE3NA IK YVPXVXANRNDGTA-VMPREFPWSA-N
DMCE3NA IU (14S,27S)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.216,19.13,10.121,25.04,8.031,35.014,39]nonatriaconta-1(33),3(39),4(8),9,16(38),17,19(37),21,23,25(36),31,34-dodecaene
DMCE3NA DE Discovery agent
DMY8LBO ID DMY8LBO
DMY8LBO DN Ceplene/Peg-Intron/Rebetol
DMY8LBO HS Investigative
DMY8LBO SN Histamine dihydrochloride/peg-interferon alfa-2b/ribavirin
DMY8LBO CP Maxim Pharmaceuticals
DMY8LBO DE Hepatitis C virus infection
DMSL4FQ ID DMSL4FQ
DMSL4FQ DN CFGGFTCARKSARK
DMSL4FQ HS Investigative
DMSL4FQ DE Discovery agent
DM2B0RX ID DM2B0RX
DM2B0RX DN CFGGFTGARKCARK
DM2B0RX HS Investigative
DM2B0RX DE Discovery agent
DMN8B1S ID DMN8B1S
DMN8B1S DN CFMMC
DMN8B1S HS Investigative
DMN8B1S SN CFMMC; 1190598-60-7; 3-cyclohexyl-5-fluoro-6-methyl-7-[2-(morpholin-4-yl)ethoxy]-4H-chromen-4-one; GTPL6340; AKOS028114903; ZINC207688804
DMN8B1S DT Small molecular drug
DMN8B1S PC 73755208
DMN8B1S MW 389.5
DMN8B1S FM C22H28FNO4
DMN8B1S IC InChI=1S/C22H28FNO4/c1-15-18(27-12-9-24-7-10-26-11-8-24)13-19-20(21(15)23)22(25)17(14-28-19)16-5-3-2-4-6-16/h13-14,16H,2-12H2,1H3
DMN8B1S CS CC1=C(C=C2C(=C1F)C(=O)C(=CO2)C3CCCCC3)OCCN4CCOCC4
DMN8B1S IK PHQKNLJAPYWXQQ-UHFFFAOYSA-N
DMN8B1S IU 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)chromen-4-one
DMN8B1S DE Discovery agent
DM9HMP4 ID DM9HMP4
DM9HMP4 DN CFMTI
DM9HMP4 HS Investigative
DM9HMP4 SN CFMTI; 864864-17-5; CHEMBL578995; SCHEMBL1499981; GTPL6341; KS-00001CMY; XZBFQWRAIYRPPZ-UHFFFAOYSA-N; MolPort-044-567-623; BCP18264; ZINC13983188; BDBM50301824; AKOS028114902; CS-5757; 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one; HY-100402; C-365; L023899; 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-3H-isoindol-1-one.; 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-
DM9HMP4 DT Small molecular drug
DM9HMP4 PC 11175501
DM9HMP4 MW 349.4
DM9HMP4 FM C19H16FN5O
DM9HMP4 IC InChI=1S/C19H16FN5O/c1-11-17(22-23-25(11)16-3-2-8-21-18(16)20)12-4-7-15-13(9-12)10-24(19(15)26)14-5-6-14/h2-4,7-9,14H,5-6,10H2,1H3
DM9HMP4 CS CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CC4=C(C=C3)C(=O)N(C4)C5CC5
DM9HMP4 IK XZBFQWRAIYRPPZ-UHFFFAOYSA-N
DM9HMP4 IU 2-cyclopropyl-5-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-3H-isoindol-1-one
DM9HMP4 DE Discovery agent
DM8TJW3 ID DM8TJW3
DM8TJW3 DN CFTRinh-172
DM8TJW3 HS Investigative
DM8TJW3 SN CFTRinh-172; 307510-92-5; 4-({4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene}methyl)benzoic acid; 4-[4-oxo-2-thioxo-3-(3-trifluoromethyl-phenyl)-thiazolidin-(5z)-ylidenemethyl]-benzoic acid; 4-[[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid; AC1L9ZJU; CBMicro_044684; (inh)-172; SCHEMBL919042; GTPL4153; KS-00000NFK; CTK8F1370; CHEBI:131686; 5-[(4-carboxyphenyl)methylene]-2-thioxo-3-[(3-trifluoromethyl)phenyl]-4-thiazolidinone; HMS3653A11
DM8TJW3 DT Small molecular drug
DM8TJW3 PC 504670
DM8TJW3 MW 409.4
DM8TJW3 FM C18H10F3NO3S2
DM8TJW3 IC InChI=1S/C18H10F3NO3S2/c19-18(20,21)12-2-1-3-13(9-12)22-15(23)14(27-17(22)26)8-10-4-6-11(7-5-10)16(24)25/h1-9H,(H,24,25)
DM8TJW3 CS C1=CC(=CC(=C1)N2C(=O)C(=CC3=CC=C(C=C3)C(=O)O)SC2=S)C(F)(F)F
DM8TJW3 IK JIMHYXZZCWVCMI-UHFFFAOYSA-N
DM8TJW3 IU 4-[[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid
DM8TJW3 CA CAS 307510-92-5
DM8TJW3 CB CHEBI:131686
DM8TJW3 DE Discovery agent
DMGW9QL ID DMGW9QL
DMGW9QL DN CG-103065
DMGW9QL HS Investigative
DMGW9QL SN Syk inhibitor (inflammation/cancer); Syk inhibitor (inflammation/cancer), CG Pharmaceuticals; Syk inhibitors (inflammation/cancer), CG Pharmaceuticals; Syk inhibitors (inflammation/cancer), CrystalGenomics
DMGW9QL CP CG Pharmaceuticals Inc
DMGW9QL DT Small molecular drug
DMGW9QL PC 6419747
DMGW9QL MW 353.4
DMGW9QL FM C18H15N3O3S
DMGW9QL IC InChI=1S/C18H15N3O3S/c1-21-10-11(13-4-2-3-5-17(13)21)8-15-14-9-12(25(19,23)24)6-7-16(14)20-18(15)22/h2-10H,1H3,(H,20,22)(H2,19,23,24)/b15-8-
DMGW9QL CS CN1C=C(C2=CC=CC=C21)/C=C\\3/C4=C(C=CC(=C4)S(=O)(=O)N)NC3=O
DMGW9QL IK MLKHXLFEYOOYEY-NVNXTCNLSA-N
DMGW9QL IU (3Z)-3-[(1-methylindol-3-yl)methylidene]-2-oxo-1H-indole-5-sulfonamide
DMGW9QL CA CAS 622387-85-3
DMGW9QL CB CHEBI:92522
DMGW9QL DE Solid tumour/cancer
DMN3YEQ ID DMN3YEQ
DMN3YEQ DN CG-1521
DMN3YEQ HS Investigative
DMN3YEQ SN CG-1521; UNII-028K52V859; 028K52V859; 2,4,6-Heptatrienamide, N-hydroxy-7-phenyl-, (2E,4E,6E)-; 674767-29-4; CHEMBL159249; SCHEMBL10323570; DBBYYRWVNDQECM-CDWOPPGASA-N; N-hydroxy-7-phenylhepta-2,4,6-trienamide
DMN3YEQ DT Small molecular drug
DMN3YEQ PC 10220017
DMN3YEQ MW 215.25
DMN3YEQ FM C13H13NO2
DMN3YEQ IC InChI=1S/C13H13NO2/c15-13(14-16)11-7-2-1-4-8-12-9-5-3-6-10-12/h1-11,16H,(H,14,15)/b2-1+,8-4+,11-7+
DMN3YEQ CS C1=CC=C(C=C1)/C=C/C=C/C=C/C(=O)NO
DMN3YEQ IK DBBYYRWVNDQECM-CDWOPPGASA-N
DMN3YEQ IU (2E,4E,6E)-N-hydroxy-7-phenylhepta-2,4,6-trienamide
DMN3YEQ CA CAS 674767-29-4
DMN3YEQ CB CHEBI:156510
DMN3YEQ DE Solid tumour/cancer
DM4FMPJ ID DM4FMPJ
DM4FMPJ DN CGEN-855
DM4FMPJ HS Investigative
DM4FMPJ SN CGEN-855A; CGEN-855B; FPRL1 G-protein-coupled receptor agonists (peptide, inflammation/cardiac disorder); FPRL1 G-protein-coupled receptor agonists (peptide, inflammation/cardiac disorder), Compugen
DM4FMPJ CP Compugen Ltd
DM4FMPJ DE Inflammation
DMTPRBX ID DMTPRBX
DMTPRBX DN CGI-1316
DMTPRBX HS Investigative
DMTPRBX SN CGI-1746; CGI-2233; CGI-2815; CGI-3130; CGI-560; CGI-676; Btk inhibitors (autoimmune disease/inflammatory disease); Btk inhibitors (autoimmune disease/inflammatory disease), CGI Pharmaceuticals; Btk inhibitors (autoimmune disease/inflammatory disease), Cellular Genomics; Btk inhibitors (autoimmune disease/inflammatory disease), Gilead
DMTPRBX CP CGI Pharmaceuticals Inc
DMTPRBX DT Small molecular drug
DMTPRBX PC 24857323
DMTPRBX MW 579.7
DMTPRBX FM C34H37N5O4
DMTPRBX IC InChI=1S/C34H37N5O4/c1-22-27(7-6-8-28(22)37-31(40)23-9-13-25(14-10-23)34(2,3)4)29-21-38(5)33(42)30(36-29)35-26-15-11-24(12-16-26)32(41)39-17-19-43-20-18-39/h6-16,21H,17-20H2,1-5H3,(H,35,36)(H,37,40)
DMTPRBX CS CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=CN(C(=O)C(=N3)NC4=CC=C(C=C4)C(=O)N5CCOCC5)C
DMTPRBX IK JIFCFQDXHMUPGP-UHFFFAOYSA-N
DMTPRBX IU 4-tert-butyl-N-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide
DMTPRBX CA CAS 910232-84-7
DMTPRBX DE Autoimmune diabetes
DM8OAN9 ID DM8OAN9
DM8OAN9 DN CGK733
DM8OAN9 HS Investigative
DM8OAN9 SN CGK733; 905973-89-9; CGK 733; CGK-733; 2,2-Diphenyl-N-(2,2,2-trichloro-1-(3-(4-fluoro-3-nitrophenyl)thioureido)ethyl)acetamide; CHEMBL1221601; 2,2-Diphenyl-n-(2,2,2-trichloro-1-[3-(4-fluoro-3-nitrophenyl)thioureido]ethyl)acetamide; UNII-L3DGZ99QYM; 2,2-diphenyl-N-(2,2,2-trichloro-1-{[(4-fluoro-3-nitrophenyl)carbamothioyl]amino}ethyl)acetamide; 2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide; L3DGZ99QYM
DM8OAN9 DT Small molecular drug
DM8OAN9 PC 6605258
DM8OAN9 MW 555.8
DM8OAN9 FM C23H18Cl3FN4O3S
DM8OAN9 IC InChI=1S/C23H18Cl3FN4O3S/c24-23(25,26)21(30-22(35)28-16-11-12-17(27)18(13-16)31(33)34)29-20(32)19(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-13,19,21H,(H,29,32)(H2,28,30,35)
DM8OAN9 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC3=CC(=C(C=C3)F)[N+](=O)[O-]
DM8OAN9 IK HLCDNLNLQNYZTK-UHFFFAOYSA-N
DM8OAN9 IU 2,2-diphenyl-N-[2,2,2-trichloro-1-[(4-fluoro-3-nitrophenyl)carbamothioylamino]ethyl]acetamide
DM8OAN9 CA CAS 905973-89-9
DM8OAN9 CB CHEBI:91739
DM8OAN9 DE Discovery agent
DMQ3SAY ID DMQ3SAY
DMQ3SAY DN CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide
DMQ3SAY HS Investigative
DMQ3SAY PC 73352989
DMQ3SAY MW 3431.9
DMQ3SAY FM C146H244N44O47S2
DMQ3SAY IC InChI=1S/C146H244N44O47S2/c1-18-19-27-82(123(215)179-96(51-77-33-35-79(199)36-34-77)144(236)190-45-26-32-103(190)139(231)169-84(30-24-43-158-146(155)156)126(218)187-114(74(15)196)142(234)178-95(55-107(153)203)134(226)186-113(73(14)195)140(232)161-58-109(205)164-97(60-191)120(212)160-59-110(206)184-116(76(17)198)145(237)189-44-25-31-102(189)117(154)209)165-131(223)92(52-78-56-157-66-162-78)174-127(219)88(47-68(4)5)171-122(214)83(29-21-23-42-148)166-132(224)93(53-105(151)201)175-128(220)89(48-69(6)7)172-125(217)86(38-40-111(207)208)167-124(216)85(37-39-104(150)200)168-135(227)99(62-193)181-129(221)90(49-70(8)9)170-121(213)81(28-20-22-41-147)163-108(204)57-159-119(211)87(46-67(2)3)177-141(233)112(72(12)13)185-138(230)101(65-239)183-143(235)115(75(16)197)188-137(229)100(63-194)182-130(222)91(50-71(10)11)173-133(225)94(54-106(152)202)176-136(228)98(61-192)180-118(210)80(149)64-238/h33-36,56,66-76,80-103,112-116,191-199,238-239H,18-32,37-55,57-65,147-149H2,1-17H3,(H2,150,200)(H2,151,201)(H2,152,202)(H2,153,203)(H2,154,209)(H,157,162)(H,159,211)(H,160,212)(H,161,232)(H,163,204)(H,164,205)(H,165,223)(H,166,224)(H,167,216)(H,168,227)(H,169,231)(H,170,213)(H,171,214)(H,172,217)(H,173,225)(H,174,219)(H,175,220)(H,176,228)(H,177,233)(H,178,234)(H,179,215)(H,180,210)(H,181,221)(H,182,222)(H,183,235)(H,184,206)(H,185,230)(H,186,226)(H,187,218)(H,188,229)(H,207,208)(H4,155,156,158)/t73-,74-,75-,76-,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102-,103-,112+,113+,114+,115+,116+/m1/s1
DMQ3SAY CS CCCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N
DMQ3SAY IK YNPHTODKUNFPBE-PQRPONEFSA-N
DMQ3SAY IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQ3SAY DE Discovery agent
DMLA384 ID DMLA384
DMLA384 DN CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide
DMLA384 HS Investigative
DMLA384 PC 73350025
DMLA384 MW 3372.8
DMLA384 FM C152H231N39O44S2
DMLA384 IC InChI=1S/C152H231N39O44S2/c1-17-20-36-94(171-143(226)108(72-237)183-150(233)125(83(16)196)189-142(225)107(70-192)182-135(218)99(56-75(6)7)176-138(221)103(62-113(157)201)169-116(204)67-161-129(212)91(154)71-236)132(215)175-98(55-74(4)5)130(213)162-68-118(206)185-122(80(13)193)148(231)180-101(59-86-40-44-89(197)45-41-86)141(224)188-124(82(15)195)149(232)173-95(48-50-111(155)199)133(216)179-105(64-119(207)208)140(223)177-100(58-85-34-25-22-26-35-85)136(219)178-104(63-114(158)202)139(222)170-92(37-27-28-52-153)126(209)97(57-84-32-23-21-24-33-84)174-137(220)102(61-88-65-160-73-165-88)168-93(31-18-2)131(214)181-106(60-87-42-46-90(198)47-43-87)152(235)191-54-30-39-110(191)144(227)172-96(49-51-112(156)200)134(217)187-123(81(14)194)147(230)167-78(11)128(211)186-121(77(10)19-3)146(229)164-69-117(205)184-120(76(8)9)145(228)163-66-115(203)166-79(12)151(234)190-53-29-38-109(190)127(159)210/h21-26,32-35,40-47,65,73-83,91-110,120-125,168,192-198,236-237H,17-20,27-31,36-39,48-64,66-72,153-154H2,1-16H3,(H2,155,199)(H2,156,200)(H2,157,201)(H2,158,202)(H2,159,210)(H,160,165)(H,161,212)(H,162,213)(H,163,228)(H,164,229)(H,166,203)(H,167,230)(H,169,204)(H,170,222)(H,171,226)(H,172,227)(H,173,232)(H,174,220)(H,175,215)(H,176,221)(H,177,223)(H,178,219)(H,179,216)(H,180,231)(H,181,214)(H,182,218)(H,183,233)(H,184,205)(H,185,206)(H,186,211)(H,187,217)(H,188,224)(H,189,225)(H,207,208)/t77-,78-,79-,80+,81+,82+,83+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102?,103-,104-,105-,106-,107-,108-,109+,110+,120-,121-,122-,123-,124-,125-/m0/s1
DMLA384 CS CCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)[C@H](CC3=CC=CC=C3)NC(=O)C(CC4=CNC=N4)N[C@@H](CCC)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)N6CCC[C@@H]6C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N7CCC[C@@H]7C(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMLA384 IK NUIBIJAKPBPKQM-RQTBQGNLSA-N
DMLA384 IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,4S)-8-amino-2-[[2-[[(2S)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-oxo-1-phenyloctan-4-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DMLA384 DE Discovery agent
DMUGAYT ID DMUGAYT
DMUGAYT DN CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide
DMUGAYT HS Investigative
DMUGAYT PC 73356077
DMUGAYT MW 3354.8
DMUGAYT FM C152H229N39O43S2
DMUGAYT IC InChI=1S/C152H229N39O43S2/c1-16-18-39-94(171-143(225)108(73-236)183-150(232)125(84(15)196)189-142(224)107(71-192)182-135(217)99(57-76(5)6)176-138(220)103(63-113(157)200)169-116(203)68-161-129(211)91(154)72-235)132(214)175-98(56-75(3)4)130(212)162-69-118(205)185-122(81(12)193)148(230)180-101(60-87-37-26-21-27-38-87)141(223)188-124(83(14)195)149(231)173-95(48-50-111(155)198)133(215)179-105(65-119(206)207)140(222)177-100(59-86-35-24-20-25-36-86)136(218)178-104-64-114(201)160-53-30-41-93(168-102(62-89-66-159-74-165-89)137(219)174-97(58-85-33-22-19-23-34-85)126(208)92(170-139(104)221)40-28-29-52-153)131(213)181-106(61-88-44-46-90(197)47-45-88)152(234)191-55-32-43-110(191)144(226)172-96(49-51-112(156)199)134(216)187-123(82(13)194)147(229)167-79(10)128(210)186-121(78(9)17-2)146(228)164-70-117(204)184-120(77(7)8)145(227)163-67-115(202)166-80(11)151(233)190-54-31-42-109(190)127(158)209/h19-27,33-38,44-47,66,74-84,91-110,120-125,168,192-197,235-236H,16-18,28-32,39-43,48-65,67-73,153-154H2,1-15H3,(H2,155,198)(H2,156,199)(H2,157,200)(H2,158,209)(H,159,165)(H,160,201)(H,161,211)(H,162,212)(H,163,227)(H,164,228)(H,166,202)(H,167,229)(H,169,203)(H,170,221)(H,171,225)(H,172,226)(H,173,231)(H,174,219)(H,175,214)(H,176,220)(H,177,222)(H,178,218)(H,179,215)(H,180,230)(H,181,213)(H,182,217)(H,183,232)(H,184,204)(H,185,205)(H,186,210)(H,187,216)(H,188,223)(H,189,224)(H,206,207)/t78-,79-,80-,81+,82+,83+,84+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102?,103-,104-,105-,106-,107-,108-,109+,110+,120-,121-,122-,123-,124-,125-/m0/s1
DMUGAYT CS CCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H]3CC(=O)NCCC[C@H](NC(C(=O)N[C@H](C(=O)[C@@H](NC3=O)CCCCN)CC4=CC=CC=C4)CC5=CNC=N5)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N7CCC[C@@H]7C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N8CCC[C@@H]8C(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMUGAYT IK NRTVMMGXEUIAJK-VZBVTIHGSA-N
DMUGAYT IU (3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(5S,7S,10S,17S)-7-(4-aminobutyl)-17-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-5-benzyl-2-(1H-imidazol-4-ylmethyl)-3,6,9,12-tetraoxo-1,4,8,13-tetrazacycloheptadec-10-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMUGAYT DE Discovery agent
DM3FP47 ID DM3FP47
DM3FP47 DN CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide
DM3FP47 HS Investigative
DM3FP47 PC 73350028
DM3FP47 MW 3372.9
DM3FP47 FM C151H227N39O43S3
DM3FP47 IC InChI=1S/C151H227N39O43S3/c1-16-77(8)120(145(227)163-69-116(203)183-119(76(6)7)144(226)162-66-114(201)165-79(10)150(232)189-52-29-39-108(189)126(157)208)185-127(209)78(9)166-146(228)122(81(12)193)186-133(215)94(46-48-111(155)198)171-143(225)109-40-30-53-190(109)151(233)105(60-86-35-24-19-25-36-86)180-130(212)92-38-28-51-159-113(200)63-103(138(220)169-91(37-26-27-50-152)125(207)96(57-84-31-20-17-21-32-84)173-136(218)101(167-92)61-88-65-158-73-164-88)177-135(217)99(58-85-33-22-18-23-34-85)176-139(221)104(64-118(205)206)178-131(213)93(45-47-110(154)197)172-148(230)123(82(13)194)187-140(222)100(59-87-41-43-89(196)44-42-87)179-147(229)121(80(11)192)184-117(204)68-161-129(211)97(55-74(2)3)174-132(214)95(49-54-236-15)170-142(224)107(72-235)182-149(231)124(83(14)195)188-141(223)106(70-191)181-134(216)98(56-75(4)5)175-137(219)102(62-112(156)199)168-115(202)67-160-128(210)90(153)71-234/h17-25,31-36,41-44,65,73-83,90-109,119-124,167,191-196,234-235H,16,26-30,37-40,45-64,66-72,152-153H2,1-15H3,(H2,154,197)(H2,155,198)(H2,156,199)(H2,157,208)(H,158,164)(H,159,200)(H,160,210)(H,161,211)(H,162,226)(H,163,227)(H,165,201)(H,166,228)(H,168,202)(H,169,220)(H,170,224)(H,171,225)(H,172,230)(H,173,218)(H,174,214)(H,175,219)(H,176,221)(H,177,217)(H,178,213)(H,179,229)(H,180,212)(H,181,216)(H,182,231)(H,183,203)(H,184,204)(H,185,209)(H,186,215)(H,187,222)(H,188,223)(H,205,206)/t77-,78-,79-,80+,81+,82+,83+,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108+,109+,119-,120-,121-,122-,123-,124-/m0/s1
DM3FP47 CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)[C@@H](NC(=O)[C@@H](N4)CC5=CNC=N5)CC6=CC=CC=C6)CCCCN)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DM3FP47 IK QYDBESOJOBAYMS-KPTDGZOOSA-N
DM3FP47 IU (3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S,5S,7S,10S,17S)-7-(4-aminobutyl)-17-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]carbamoyl]-5-benzyl-2-(1H-imidazol-4-ylmethyl)-3,6,9,12-tetraoxo-1,4,8,13-tetrazacycloheptadec-10-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DM3FP47 DE Discovery agent
DMJ9Z31 ID DMJ9Z31
DMJ9Z31 DN CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide
DMJ9Z31 HS Investigative
DMJ9Z31 PC 73351527
DMJ9Z31 MW 3376.8
DMJ9Z31 FM C150H227N39O44S3
DMJ9Z31 IC InChI=1S/C150H227N39O44S3/c1-17-75(8)118(143(226)162-67-114(203)182-117(74(6)7)142(225)161-64-112(201)164-77(10)149(232)188-50-29-38-106(188)125(157)208)184-126(209)76(9)165-144(227)121(80(13)193)185-131(214)92(45-47-109(154)198)170-141(224)107-39-30-51-189(107)150(233)103(58-85-35-25-20-26-36-85)179-145(228)119(78(11)191)167-99(59-87-63-158-71-163-87)134(217)172-94(55-83-31-21-18-22-32-83)124(207)90(37-27-28-49-151)168-136(219)101(61-111(156)200)176-133(216)97(56-84-33-23-19-24-34-84)175-137(220)102(62-116(205)206)177-129(212)91(44-46-108(153)197)171-147(230)122(81(14)194)186-138(221)98(57-86-40-42-88(196)43-41-86)178-146(229)120(79(12)192)183-115(204)66-160-128(211)95(53-72(2)3)173-130(213)93(48-52-236-16)169-140(223)105(70-235)181-148(231)123(82(15)195)187-139(222)104(68-190)180-132(215)96(54-73(4)5)174-135(218)100(60-110(155)199)166-113(202)65-159-127(210)89(152)69-234/h18-26,31-36,40-43,63,71-82,89-107,117-123,167,190-196,234-235H,17,27-30,37-39,44-62,64-70,151-152H2,1-16H3,(H2,153,197)(H2,154,198)(H2,155,199)(H2,156,200)(H2,157,208)(H,158,163)(H,159,210)(H,160,211)(H,161,225)(H,162,226)(H,164,201)(H,165,227)(H,166,202)(H,168,219)(H,169,223)(H,170,224)(H,171,230)(H,172,217)(H,173,213)(H,174,218)(H,175,220)(H,176,216)(H,177,212)(H,178,229)(H,179,228)(H,180,215)(H,181,231)(H,182,203)(H,183,204)(H,184,209)(H,185,214)(H,186,221)(H,187,222)(H,205,206)/t75-,76-,77-,78+,79+,80+,81+,82+,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99?,100-,101-,102-,103-,104-,105-,106+,107+,117-,118-,119-,120-,121-,122-,123-/m0/s1
DMJ9Z31 CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(CC4=CNC=N4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMJ9Z31 IK LHKCIEAVJUMENU-LTFZDLSNSA-N
DMJ9Z31 IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,4S)-8-amino-2-[[2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-oxo-1-phenyloctan-4-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DMJ9Z31 DE Discovery agent
DME84PN ID DME84PN
DME84PN DN CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide
DME84PN HS Investigative
DME84PN PC 73348438
DME84PN MW 3326.8
DME84PN FM C146H225N39O44S3
DME84PN IC InChI=1S/C146H225N39O44S3/c1-17-72(8)114(138(221)158-64-110(199)177-113(71(6)7)137(220)157-61-108(197)160-74(10)144(227)184-48-27-35-102(184)121(153)204)179-122(205)73(9)161-139(222)117(77(13)189)180-127(210)88(42-44-105(150)194)166-136(219)103-36-28-49-185(103)145(228)97(55-81-31-22-19-23-32-81)174-140(223)115(75(11)187)163-98(56-83-60-154-68-159-83)146(229)183-47-26-34-101(183)120(203)86(33-24-25-46-147)164-131(214)95(58-107(152)196)171-129(212)92(53-80-29-20-18-21-30-80)170-132(215)96(59-112(201)202)172-125(208)87(41-43-104(149)193)167-142(225)118(78(14)190)181-133(216)93(54-82-37-39-84(192)40-38-82)173-141(224)116(76(12)188)178-111(200)63-156-124(207)90(51-69(2)3)168-126(209)89(45-50-232-16)165-135(218)100(67-231)176-143(226)119(79(15)191)182-134(217)99(65-186)175-128(211)91(52-70(4)5)169-130(213)94(57-106(151)195)162-109(198)62-155-123(206)85(148)66-230/h18-23,29-32,37-40,60,68-79,85-103,113-119,163,186-192,230-231H,17,24-28,33-36,41-59,61-67,147-148H2,1-16H3,(H2,149,193)(H2,150,194)(H2,151,195)(H2,152,196)(H2,153,204)(H,154,159)(H,155,206)(H,156,207)(H,157,220)(H,158,221)(H,160,197)(H,161,222)(H,162,198)(H,164,214)(H,165,218)(H,166,219)(H,167,225)(H,168,209)(H,169,213)(H,170,215)(H,171,212)(H,172,208)(H,173,224)(H,174,223)(H,175,211)(H,176,226)(H,177,199)(H,178,200)(H,179,205)(H,180,210)(H,181,216)(H,182,217)(H,201,202)/t72-,73-,74-,75+,76+,77+,78+,79+,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102+,103+,113-,114-,115-,116-,117-,118-,119-/m0/s1
DME84PN CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)N[C@@H](CC4=CNC=N4)C(=O)N5CCC[C@H]5C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DME84PN IK NKZSJXPCNXUROW-ZRSYVJPOSA-N
DME84PN IU (3S)-4-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[(2S)-1-[(2S)-2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid
DME84PN DE Discovery agent
DMV7TE4 ID DMV7TE4
DMV7TE4 DN CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide
DMV7TE4 HS Investigative
DMV7TE4 PC 44269042
DMV7TE4 MW 3345.8
DMV7TE4 FM C149H222N38O44S3
DMV7TE4 IC InChI=1S/C149H222N38O44S3/c1-17-74(8)117(141(223)160-66-113(201)179-116(73(6)7)140(222)159-63-111(199)162-76(10)147(229)186-49-28-37-105(186)124(155)206)181-125(207)75(9)163-142(224)120(79(13)191)182-130(212)90(44-46-108(152)196)167-139(221)106-38-29-50-187(106)148(230)100(57-84-34-25-20-26-35-84)176-143(225)118(77(11)189)165-97(58-86-62-156-70-161-86)133(215)169-92(54-82-30-21-18-22-31-82)123(205)104-36-27-48-185(104)149(231)101(60-110(154)198)175-132(214)95(55-83-32-23-19-24-33-83)172-135(217)99(61-115(203)204)173-128(210)89(43-45-107(151)195)168-145(227)121(80(14)192)183-136(218)96(56-85-39-41-87(194)42-40-85)174-144(226)119(78(12)190)180-114(202)65-158-127(209)93(52-71(2)3)170-129(211)91(47-51-234-16)166-138(220)103(69-233)178-146(228)122(81(15)193)184-137(219)102(67-188)177-131(213)94(53-72(4)5)171-134(216)98(59-109(153)197)164-112(200)64-157-126(208)88(150)68-232/h18-26,30-35,39-42,62,70-81,88-106,116-122,165,188-194,232-233H,17,27-29,36-38,43-61,63-69,150H2,1-16H3,(H2,151,195)(H2,152,196)(H2,153,197)(H2,154,198)(H2,155,206)(H,156,161)(H,157,208)(H,158,209)(H,159,222)(H,160,223)(H,162,199)(H,163,224)(H,164,200)(H,166,220)(H,167,221)(H,168,227)(H,169,215)(H,170,211)(H,171,216)(H,172,217)(H,173,210)(H,174,226)(H,175,214)(H,176,225)(H,177,213)(H,178,228)(H,179,201)(H,180,202)(H,181,207)(H,182,212)(H,183,218)(H,184,219)(H,203,204)/t74-,75-,76-,77+,78+,79-,80+,81+,88-,89-,90-,91-,92?,93-,94-,95-,96-,97?,98-,99-,100-,101-,102-,103-,104?,105+,106+,116-,117-,118-,119-,120-,121-,122-/m0/s1
DMV7TE4 CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)NC(CC4=CNC=N4)C(=O)NC(CC5=CC=CC=C5)C(=O)C6CCCN6C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMV7TE4 IK HFYXIJPNTYGTQI-ZAGQHXPESA-N
DMV7TE4 IU (3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-4-amino-1-[2-[2-[[2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMV7TE4 DE Discovery agent
DMMO8A2 ID DMMO8A2
DMMO8A2 DN CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide
DMMO8A2 HS Investigative
DMMO8A2 PC 73354513
DMMO8A2 MW 3255.7
DMMO8A2 FM C142H216N38O44S3
DMMO8A2 IC InChI=1S/C142H216N38O44S3/c1-17-69(8)111(134(216)154-61-107(195)172-110(68(6)7)133(215)153-58-105(193)156-71(10)140(222)179-44-25-32-98(179)117(148)199)174-118(200)70(9)157-135(217)114(74(13)184)175-124(206)84(39-41-102(145)190)161-132(214)99-33-26-45-180(99)141(223)93(51-78-29-22-19-23-30-78)169-136(218)112(72(11)182)159-90(52-80-56-149-65-155-80)121(203)150-57-100(188)97-31-24-43-178(97)142(224)94(54-104(147)192)168-126(208)88(49-77-27-20-18-21-28-77)165-128(210)92(55-109(197)198)166-122(204)83(38-40-101(144)189)162-138(220)115(75(14)185)176-129(211)89(50-79-34-36-81(187)37-35-79)167-137(219)113(73(12)183)173-108(196)60-152-120(202)86(47-66(2)3)163-123(205)85(42-46-227-16)160-131(213)96(64-226)171-139(221)116(76(15)186)177-130(212)95(62-181)170-125(207)87(48-67(4)5)164-127(209)91(53-103(146)191)158-106(194)59-151-119(201)82(143)63-225/h18-23,27-30,34-37,56,65-76,82-99,110-116,159,181-187,225-226H,17,24-26,31-33,38-55,57-64,143H2,1-16H3,(H2,144,189)(H2,145,190)(H2,146,191)(H2,147,192)(H2,148,199)(H,149,155)(H,150,203)(H,151,201)(H,152,202)(H,153,215)(H,154,216)(H,156,193)(H,157,217)(H,158,194)(H,160,213)(H,161,214)(H,162,220)(H,163,205)(H,164,209)(H,165,210)(H,166,204)(H,167,219)(H,168,208)(H,169,218)(H,170,207)(H,171,221)(H,172,195)(H,173,196)(H,174,200)(H,175,206)(H,176,211)(H,177,212)(H,197,198)/t69-,70-,71-,72+,73+,74+,75+,76+,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98+,99+,110-,111-,112-,113-,114-,115-,116-/m0/s1
DMMO8A2 CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H]([C@@H](C)O)N[C@@H](CC4=CNC=N4)C(=O)NCC(=O)[C@@H]5CCCN5C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N
DMMO8A2 IK YYIDQLADSCSELD-ILODDJEPSA-N
DMMO8A2 IU (3S)-3-[[(2S)-5-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-4-amino-1-[(2S)-2-[2-[[(2S)-2-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[2-[[(2S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]pyrrolidin-1-yl]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid
DMMO8A2 DE Discovery agent
DML79NU ID DML79NU
DML79NU DN CGP 20712A
DML79NU HS Investigative
DML79NU SN GKJZEKSHCJELPL-UHFFFAOYSA-N; Cgp 20712; CGP-20712A; CGP-20712; 137888-49-4; CGP20712A; C23H25F3N4O5; 81015-67-0; 2-hydroxy-5-{2-[(2-hydroxy-3-{4-[1-methyl-4-(trifluoromethyl)-1h-imidazol-2-yl]phenoxy}propyl)amino]ethoxy}benzamide; Cgp 26505; CGP 20712-A; 2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide; Cgp-20712-A; SR-01000076208; 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide; CGP 26505
DML79NU DT Small molecular drug
DML79NU PC 10008573
DML79NU MW 590.6
DML79NU FM C24H29F3N4O8S
DML79NU IC InChI=1S/C23H25F3N4O5.CH4O3S/c1-30-12-20(23(24,25)26)29-22(30)14-2-4-16(5-3-14)35-13-15(31)11-28-8-9-34-17-6-7-19(32)18(10-17)21(27)33;1-5(2,3)4/h2-7,10,12,15,28,31-32H,8-9,11,13H2,1H3,(H2,27,33);1H3,(H,2,3,4)
DML79NU CS CN1C=C(N=C1C2=CC=C(C=C2)OCC(CNCCOC3=CC(=C(C=C3)O)C(=O)N)O)C(F)(F)F.CS(=O)(=O)O
DML79NU IK VFPOVCXWKBYDNF-UHFFFAOYSA-N
DML79NU IU 2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide;methanesulfonic acid
DML79NU CA CAS 105737-62-0
DML79NU DE Discovery agent
DMTECXA ID DMTECXA
DMTECXA DN CGP 23996
DMTECXA HS Investigative
DMTECXA SN CGP23996; CGP-23996
DMTECXA DT Small molecular drug
DMTECXA PC 16130961
DMTECXA MW 1474.7
DMTECXA FM C73H99N15O18
DMTECXA IC InChI=1S/C73H99N15O18/c1-41(90)61-71(103)85-55(36-45-28-30-47(92)31-29-45)69(101)88-62(42(2)91)72(104)86-58(40-89)70(102)80-52(73(105)106)26-10-5-11-27-60(94)78-50(24-14-16-32-74)63(95)84-57(38-59(76)93)68(100)82-53(34-43-18-6-3-7-19-43)65(97)81-54(35-44-20-8-4-9-21-44)66(98)83-56(37-46-39-77-49-23-13-12-22-48(46)49)67(99)79-51(64(96)87-61)25-15-17-33-75/h3-4,6-9,12-13,18-23,28-31,39,41-42,50-58,61-62,77,89-92H,5,10-11,14-17,24-27,32-38,40,74-75H2,1-2H3,(H2,76,93)(H,78,94)(H,79,99)(H,80,102)(H,81,97)(H,82,100)(H,83,98)(H,84,95)(H,85,103)(H,86,104)(H,87,96)(H,88,101)(H,105,106)/t41-,42-,50+,51+,52+,53+,54+,55+,56+,57?,58+,61?,62?/m1/s1
DMTECXA CS C[C@H](C1C(=O)N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CCCCCC(=O)N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)C(=O)O)CO)[C@@H](C)O)CC6=CC=C(C=C6)O)O
DMTECXA IK HTEPNQQGQXAYEW-YQENAMKYSA-N
DMTECXA IU (2S,8S,11S,14S,17S,23S,29S,32S)-2,17-bis(4-aminobutyl)-5-(2-amino-2-oxoethyl)-8,11-dibenzyl-20,26-bis[(1R)-1-hydroxyethyl]-29-(hydroxymethyl)-23-[(4-hydroxyphenyl)methyl]-14-(1H-indol-3-ylmethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecazacyclooctatriacontane-32-carboxylic acid
DMTECXA CA CAS 86170-12-9
DMTECXA DE Discovery agent
DMEA5BZ ID DMEA5BZ
DMEA5BZ DN CGP 40336A
DMEA5BZ HS Investigative
DMEA5BZ SN GNF-Pf-5020; CGP40336; AC1LALV6; CHEMBL97338; SCHEMBL8891798; CGP40336A; CGP-40336A; N'-(3-aminopropyl)-N'-[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]butane-1,4-diamine; (4-Aminobutyl)(3-aminopropyl){3-[(6-chloro-2-methyloxyacridin-9-yl)amino]propyl}amine
DMEA5BZ DT Small molecular drug
DMEA5BZ PC 470828
DMEA5BZ MW 444
DMEA5BZ FM C24H34ClN5O
DMEA5BZ IC InChI=1S/C24H34ClN5O/c1-31-19-7-9-22-21(17-19)24(20-8-6-18(25)16-23(20)29-22)28-12-5-15-30(14-4-11-27)13-3-2-10-26/h6-9,16-17H,2-5,10-15,26-27H2,1H3,(H,28,29)
DMEA5BZ CS COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCCN(CCCCN)CCCN
DMEA5BZ IK BIGAHIIWPDZJMX-UHFFFAOYSA-N
DMEA5BZ IU N'-(3-aminopropyl)-N'-[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]butane-1,4-diamine
DMEA5BZ DE Discovery agent
DMXV6RD ID DMXV6RD
DMXV6RD DN CGP 46381
DMXV6RD HS Investigative
DMXV6RD SN CGP-46381; CGP46381
DMXV6RD DT Small molecular drug
DMXV6RD PC 130022
DMXV6RD MW 219.26
DMXV6RD FM C10H22NO2P
DMXV6RD IC InChI=1S/C10H22NO2P/c11-7-4-8-14(12,13)9-10-5-2-1-3-6-10/h10H,1-9,11H2,(H,12,13)
DMXV6RD CS C1CCC(CC1)CP(=O)(CCCN)O
DMXV6RD IK XOESDNIUAWGCLU-UHFFFAOYSA-N
DMXV6RD IU 3-aminopropyl(cyclohexylmethyl)phosphinic acid
DMXV6RD CA CAS 123691-14-5
DMXV6RD DE Discovery agent
DME39UQ ID DME39UQ
DME39UQ DN CGP 47656
DME39UQ HS Investigative
DME39UQ SN (3-Amino-propyl)-difluoromethyl-phosphinic acid; CGP-47656; CHEMBL113553; 3-aminopropyl-(difluoromethyl)phosphinic Acid; CGP47656; SCHEMBL342825; GTPL1066; TXAHGWWWANKBDA-UHFFFAOYSA-N; BDBM50032968; P-(3-aminopropyl)-P-difluoromethyl-phosphinic; CGP-47656
DME39UQ DT Small molecular drug
DME39UQ PC 10154248
DME39UQ MW 173.1
DME39UQ FM C4H10F2NO2P
DME39UQ IC InChI=1S/C4H10F2NO2P/c5-4(6)10(8,9)3-1-2-7/h4H,1-3,7H2,(H,8,9)
DME39UQ CS C(CN)CP(=O)(C(F)F)O
DME39UQ IK TXAHGWWWANKBDA-UHFFFAOYSA-N
DME39UQ IU 3-aminopropyl(difluoromethyl)phosphinic acid
DME39UQ DE Discovery agent
DMEHYVS ID DMEHYVS
DMEHYVS DN CGP 54626A
DMEHYVS HS Investigative
DMEHYVS SN Cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid; Cgp-54626; Cgp 54626; cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid; CGP54626; [3H]CGP54626; [3H]CGP 54626; Tocris-1088; NCGC00024989-01; Biomol-NT_000240; AC1L53OP; GTPL1070; SCHEMBL2957659; GTPL1090; BPBio1_000640; CHEMBL1213187; CGP-54626A; ZINC31544793; NCGC00024989-02; CGP-54626
DMEHYVS DT Small molecular drug
DMEHYVS PC 197584
DMEHYVS MW 408.3
DMEHYVS FM C18H28Cl2NO3P
DMEHYVS IC InChI=1S/C18H28Cl2NO3P/c1-13(15-7-8-17(19)18(20)9-15)21-10-16(22)12-25(23,24)11-14-5-3-2-4-6-14/h7-9,13-14,16,21-22H,2-6,10-12H2,1H3,(H,23,24)/t13-,16-/m0/s1
DMEHYVS CS C[C@@H](C1=CC(=C(C=C1)Cl)Cl)NC[C@@H](CP(=O)(CC2CCCCC2)O)O
DMEHYVS IK JGGVBBYJRQOPPA-BBRMVZONSA-N
DMEHYVS IU cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid
DMEHYVS DE Discovery agent
DMNMG0I ID DMNMG0I
DMNMG0I DN CGP 55845
DMNMG0I HS Investigative
DMNMG0I SN CGP55845; CGP-55845A; CGP-55845
DMNMG0I DT Small molecular drug
DMNMG0I PC 5311042
DMNMG0I MW 402.2
DMNMG0I FM C18H22Cl2NO3P
DMNMG0I IC InChI=1S/C18H22Cl2NO3P/c1-13(15-7-8-17(19)18(20)9-15)21-10-16(22)12-25(23,24)11-14-5-3-2-4-6-14/h2-9,13,16,21-22H,10-12H2,1H3,(H,23,24)/t13-,16-/m0/s1
DMNMG0I CS C[C@@H](C1=CC(=C(C=C1)Cl)Cl)NC[C@@H](CP(=O)(CC2=CC=CC=C2)O)O
DMNMG0I IK ZODSPDOOCZZEIM-BBRMVZONSA-N
DMNMG0I IU benzyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid
DMNMG0I CA CAS 150175-54-5
DMNMG0I CB CHEBI:91949
DMNMG0I DE Discovery agent
DMR708D ID DMR708D
DMR708D DN CGP 56999A
DMR708D HS Investigative
DMR708D SN CGP56999A; CGP-56999A
DMR708D DT Small molecular drug
DMR708D PC 9800175
DMR708D MW 383.4
DMR708D FM C19H30NO5P
DMR708D IC InChI=1S/C19H30NO5P/c1-14(16-8-5-9-17(10-16)19(22)23)20-11-18(21)13-26(24,25)12-15-6-3-2-4-7-15/h5,8-10,14-15,18,20-21H,2-4,6-7,11-13H2,1H3,(H,22,23)(H,24,25)/t14-,18+/m1/s1
DMR708D CS C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CC2CCCCC2)O)O
DMR708D IK JCFULPDIJOVUHP-KDOFPFPSSA-N
DMR708D IU 3-[(1R)-1-[[(2S)-3-[cyclohexylmethyl(hydroxy)phosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid
DMR708D DE Discovery agent
DMYXE39 ID DMYXE39
DMYXE39 DN CGP 62349
DMYXE39 HS Investigative
DMYXE39 SN AKUSEWDIEMJQBM-BEFAXECRSA-N; 3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[(4-methoxyphenyl)methyl]phosphoryl]propyl]-methylamino]ethyl]benzoic acid; 10-31-1; CGP62349; [3H]CGP62349; [3H]CGP 62349; [3H]-CGP 62349; AC1NSJP8; GTPL1072; GTPL3429; SCHEMBL12477448; CGP62349; CGP-62349
DMYXE39 DT Small molecular drug
DMYXE39 PC 5310936
DMYXE39 MW 421.4
DMYXE39 FM C21H28NO6P
DMYXE39 IC InChI=1S/C21H28NO6P/c1-15(17-5-4-6-18(11-17)21(24)25)22(2)12-19(23)14-29(26,27)13-16-7-9-20(28-3)10-8-16/h4-11,15,19,23H,12-14H2,1-3H3,(H,24,25)(H,26,27)/t15-,19+/m1/s1
DMYXE39 CS C[C@H](C1=CC(=CC=C1)C(=O)O)N(C)C[C@@H](CP(=O)(CC2=CC=C(C=C2)OC)O)O
DMYXE39 IK AKUSEWDIEMJQBM-BEFAXECRSA-N
DMYXE39 IU 3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[(4-methoxyphenyl)methyl]phosphoryl]propyl]-methylamino]ethyl]benzoic acid
DMYXE39 CA CAS 10-31-1
DMYXE39 DE Discovery agent
DMR8U1M ID DMR8U1M
DMR8U1M DN CGP 64213
DMR8U1M HS Investigative
DMR8U1M SN CGP64213; CGP-64213
DMR8U1M DT Small molecular drug
DMR8U1M PC 5311043
DMR8U1M MW 646.5
DMR8U1M FM C26H36IN2O7P
DMR8U1M IC InChI=1S/C26H36IN2O7P/c1-18(20-6-5-7-21(15-20)26(33)34)29-16-22(30)17-37(35,36)13-4-2-3-12-28-25(32)11-9-19-8-10-24(31)23(27)14-19/h5-8,10,14-15,18,22,29-31H,2-4,9,11-13,16-17H2,1H3,(H,28,32)(H,33,34)(H,35,36)/t18-,22+/m1/s1
DMR8U1M CS C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)CCC2=CC(=C(C=C2)O)I)O)O
DMR8U1M IK RLYLJDJFHZHCTR-GCJKJVERSA-N
DMR8U1M IU 3-[(1R)-1-[[(2S)-2-hydroxy-3-[hydroxy-[5-[3-(4-hydroxy-3-iodophenyl)propanoylamino]pentyl]phosphoryl]propyl]amino]ethyl]benzoic acid
DMR8U1M DE Discovery agent
DMJWED7 ID DMJWED7
DMJWED7 DN CGP 71872
DMJWED7 HS Investigative
DMJWED7 SN CGP71872; CGP-71872
DMJWED7 DT Small molecular drug
DMJWED7 PC 6324595
DMJWED7 MW 659.4
DMJWED7 FM C24H31IN5O7P
DMJWED7 IC InChI=1S/C24H31IN5O7P/c1-15(16-6-5-7-17(10-16)24(34)35)28-13-18(31)14-38(36,37)9-4-2-3-8-27-23(33)19-11-20(25)21(29-30-26)12-22(19)32/h5-7,10-12,15,18,28,31-32H,2-4,8-9,13-14H2,1H3,(H,27,33)(H,34,35)(H,36,37)/t15-,18+/m1/s1
DMJWED7 CS C[C@H](C1=CC(=CC=C1)C(=O)O)NC[C@@H](CP(=O)(CCCCCNC(=O)C2=CC(=C(C=C2O)N=[N+]=[N-])I)O)O
DMJWED7 IK IHFUJPDKHJTHGQ-QAPCUYQASA-N
DMJWED7 IU 3-[(1R)-1-[[(2S)-3-[5-[(4-azido-2-hydroxy-5-iodobenzoyl)amino]pentyl-hydroxyphosphoryl]-2-hydroxypropyl]amino]ethyl]benzoic acid
DMJWED7 DE Discovery agent
DMXH2R3 ID DMXH2R3
DMXH2R3 DN CGP 77675
DMXH2R3 HS Investigative
DMXH2R3 SN 234772-64-6; CGP-77675; UNII-EQH27E0WRV; 1-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenethyl)piperidin-4-ol; CGP77675; EQH27E0WRV; CHEMBL475584; 1-[2-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]piperidin-4-ol; 4-Piperidinol, 1-(2-(4-(4-amino-5-(3-methoxyphenyl)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)phenyl)ethyl)-; 4-piperidinol, 1-[2-[4-[4-amino-5-(3-methoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]-; AC1NSKIU; SCHEMBL6250604; CTK8E3165; DTXSID20178033
DMXH2R3 DT Small molecular drug
DMXH2R3 PC 5311381
DMXH2R3 MW 443.5
DMXH2R3 FM C26H29N5O2
DMXH2R3 IC InChI=1S/C26H29N5O2/c1-33-22-4-2-3-19(15-22)23-16-31(26-24(23)25(27)28-17-29-26)20-7-5-18(6-8-20)9-12-30-13-10-21(32)11-14-30/h2-8,15-17,21,32H,9-14H2,1H3,(H2,27,28,29)
DMXH2R3 CS COC1=CC=CC(=C1)C2=CN(C3=NC=NC(=C23)N)C4=CC=C(C=C4)CCN5CCC(CC5)O
DMXH2R3 IK WUPXZZWTHIZICK-UHFFFAOYSA-N
DMXH2R3 IU 1-[2-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]piperidin-4-ol
DMXH2R3 CA CAS 234772-64-6
DMXH2R3 DE Discovery agent
DMNUQAG ID DMNUQAG
DMNUQAG DN CGP-029482
DMNUQAG HS Investigative
DMNUQAG SN CGP-029482; CHEMBL92361; (5-OXO-5,6-DIHYDRO-INDOLO[1,2-A]QUINAZOLIN-7-YL)-ACETIC ACID; (5-oxo-5,6-dihydroindolo[1,2-a]quinazolin-7-yl)acetic acid; IQA; 1om1; AC1L9L3Y; SCHEMBL263731; BDBM11319; MolPort-006-167-937; HMS3229D05; ZINC2047511; CGP029482; AKOS005266257; DB01765; {5-oxo-6H-indolo[1,2-a]quinazolin-7-yl}acetic acid; 2-(5-oxo-6H-indolo[1,2-a]quinazolin-7-yl)acetic acid; [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid
DMNUQAG DT Small molecular drug
DMNUQAG PC 447682
DMNUQAG MW 292.29
DMNUQAG FM C17H12N2O3
DMNUQAG IC InChI=1S/C17H12N2O3/c20-15(21)9-12-10-5-1-3-7-13(10)19-14-8-4-2-6-11(14)17(22)18-16(12)19/h1-8H,9H2,(H,18,22)(H,20,21)
DMNUQAG CS C1=CC=C2C(=C1)C(=C3N2C4=CC=CC=C4C(=O)N3)CC(=O)O
DMNUQAG IK INSBKYCYLCEBOD-UHFFFAOYSA-N
DMNUQAG IU 2-(5-oxo-6H-indolo[1,2-a]quinazolin-7-yl)acetic acid
DMNUQAG CA CAS 391670-48-7
DMNUQAG DE Discovery agent
DMCE6WJ ID DMCE6WJ
DMCE6WJ DN CGP-191
DMCE6WJ HS Investigative
DMCE6WJ SN CHEMBL122243; 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine; pyrazolopyrimidine deriv. 1; CGP-191; AC1NS35Q; SCHEMBL2360645; BDBM3003; AKOS028111796; 129852-40-0; 1,3-diphenylpyrazolo[3,4-d]pyrimidin-4-amine; 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1,3-diphenyl-; 1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (11)
DMCE6WJ DT Small molecular drug
DMCE6WJ PC 5327820
DMCE6WJ MW 287.32
DMCE6WJ FM C17H13N5
DMCE6WJ IC InChI=1S/C17H13N5/c18-16-14-15(12-7-3-1-4-8-12)21-22(17(14)20-11-19-16)13-9-5-2-6-10-13/h1-11H,(H2,18,19,20)
DMCE6WJ CS C1=CC=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C4=CC=CC=C4
DMCE6WJ IK CGWOMXNQGSNOHL-UHFFFAOYSA-N
DMCE6WJ IU 1,3-diphenylpyrazolo[3,4-d]pyrimidin-4-amine
DMCE6WJ DE Discovery agent
DMS61KA ID DMS61KA
DMS61KA DN CGP-29030A
DMS61KA HS Investigative
DMS61KA SN 1-[2-(4-Chlorophenyl)ethyl]-4-(3,5-dimethoxybenzoyl)piperazine hydrochloride
DMS61KA DT Small molecular drug
DMS61KA PC 3082655
DMS61KA MW 425.3
DMS61KA FM C21H26Cl2N2O3
DMS61KA IC InChI=1S/C21H25ClN2O3.ClH/c1-26-19-13-17(14-20(15-19)27-2)21(25)24-11-9-23(10-12-24)8-7-16-3-5-18(22)6-4-16;/h3-6,13-15H,7-12H2,1-2H3;1H
DMS61KA CS COC1=CC(=CC(=C1)C(=O)N2CCN(CC2)CCC3=CC=C(C=C3)Cl)OC.Cl
DMS61KA IK OGLXGFIBROXFPU-UHFFFAOYSA-N
DMS61KA IU [4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-(3,5-dimethoxyphenyl)methanone;hydrochloride
DMS61KA CA CAS 113240-27-0
DMS61KA DE Pain
DM84TSH ID DM84TSH
DM84TSH DN CGP-34938
DM84TSH HS Investigative
DM84TSH SN CHEMBL113304; CGP-34938; AC1NOZJY; SCHEMBL185737; MolPort-003-824-912; AKOS006286757; (3-amino-2-hydroxypropyl)-methylphosphinic acid; L013629; (3-amino-2-hydroxypropyl)(methyl)phosphinic acid
DM84TSH DT Small molecular drug
DM84TSH PC 5097016
DM84TSH MW 153.12
DM84TSH FM C4H12NO3P
DM84TSH IC InChI=1S/C4H12NO3P/c1-9(7,8)3-4(6)2-5/h4,6H,2-3,5H2,1H3,(H,7,8)
DM84TSH CS CP(=O)(CC(CN)O)O
DM84TSH IK FUUPFUIGNBPCAY-UHFFFAOYSA-N
DM84TSH IU (3-amino-2-hydroxypropyl)-methylphosphinic acid
DM84TSH DE Discovery agent
DMHKETG ID DMHKETG
DMHKETG DN CGP-35024
DMHKETG HS Investigative
DMHKETG SN 3-Aminopropyl(methyl)phosphinic Acid; 3-Apmpa; 3-aminopropyl(methyl)phosphinic Acid; skf-97541; 127729-35-5; F 97541; CGP 35024; SKF 97541; (3-(Aminopropyl)methyl)phosphinic acid; CHEMBL112710; SKF 97541 hydrochloride; CGP35024; SKF-97,541; (3-aminopropyl)(methyl)phosphinic acid; Phosphinic acid, (3-(aminopropyl)methyl)-; (3-ammoniopropyl)methylphosphinate; SR-01000076225; (3-aminopropyl)methylphosphinic acid; Tocris-0379; Phosphinic acid, (3-aminopropyl)methyl-; Lopac-A-196; AC1L1JVX; Biomol-NT_000257; AC1Q6RJ4; Lopac0_000098; C4H12NO2P; SKF-97541
DMHKETG DT Small molecular drug
DMHKETG PC 5230
DMHKETG MW 137.12
DMHKETG FM C4H12NO2P
DMHKETG IC InChI=1S/C4H12NO2P/c1-8(6,7)4-2-3-5/h2-5H2,1H3,(H,6,7)
DMHKETG CS CP(=O)(CCCN)O
DMHKETG IK NHVRIDDXGZPJTJ-UHFFFAOYSA-N
DMHKETG IU 3-aminopropyl(methyl)phosphinic acid
DMHKETG CA CAS 127729-35-5
DMHKETG DE Discovery agent
DM3J6HM ID DM3J6HM
DM3J6HM DN CGP-35582
DM3J6HM HS Investigative
DM3J6HM SN CGP-35582; CHEMBL113396; SCHEMBL341418; Phosphinic acid, P-(3-amino-1-methylpropyl)-P-methyl-; CCFBFTKQKRGULP-UHFFFAOYSA-N; BDBM50032971; 133345-75-2; P-(4-aminobut-2-yl)-P-methyl-phosphinic acid; (3-Amino-1-methyl-propyl)-methyl-phosphinic acid
DM3J6HM DT Small molecular drug
DM3J6HM PC 10219532
DM3J6HM MW 151.14
DM3J6HM FM C5H14NO2P
DM3J6HM IC InChI=1S/C5H14NO2P/c1-5(3-4-6)9(2,7)8/h5H,3-4,6H2,1-2H3,(H,7,8)
DM3J6HM CS CC(CCN)P(=O)(C)O
DM3J6HM IK CCFBFTKQKRGULP-UHFFFAOYSA-N
DM3J6HM IU 4-aminobutan-2-yl(methyl)phosphinic acid
DM3J6HM DE Discovery agent
DM9U8TO ID DM9U8TO
DM9U8TO DN CGP-36216
DM9U8TO HS Investigative
DM9U8TO SN CGP-36216; CHEMBL325921; 123691-29-2; SCHEMBL2348729; RWCIPYZWXPUGRM-UHFFFAOYSA-N; ethyl(3-aminopropyl)phosphinic acid; 3-aminopropyl(ethyl)phosphinic acid; (3-aminopropyl)ethylphosphinic acid; ZINC13742894; PDSP1_000409; PDSP2_000407; ethyl-(3-aminopropyl)phosphinic acid; BDBM50032972; (3-Amino-propyl)-ethyl-phosphinic acid; Phosphinic acid, P-(3-aminopropyl)-P-ethyl-
DM9U8TO DT Small molecular drug
DM9U8TO PC 9898878
DM9U8TO MW 151.14
DM9U8TO FM C5H14NO2P
DM9U8TO IC InChI=1S/C5H14NO2P/c1-2-9(7,8)5-3-4-6/h2-6H2,1H3,(H,7,8)
DM9U8TO CS CCP(=O)(CCCN)O
DM9U8TO IK RWCIPYZWXPUGRM-UHFFFAOYSA-N
DM9U8TO IU 3-aminopropyl(ethyl)phosphinic acid
DM9U8TO DE Discovery agent
DMKF0GH ID DMKF0GH
DMKF0GH DN CGP-44532
DMKF0GH HS Investigative
DMKF0GH SN CGP-44532; CGP 44532; [(2R)-3-amino-2-hydroxypropyl]-methylphosphinic acid; FUUPFUIGNBPCAY-SCSAIBSYSA-N; AC1NSJP2; 133345-68-3; SCHEMBL185739; GTPL1082; CHEMBL113348; Phosphinic acid, P-[(2R)-3-amino-2-hydroxypropyl]-P-methyl-; CGP 44533; ZINC13742955; LS-106096; P-[3-amino-2(R)-hydroxy-propyl]-P-methyl-phosphinic acid
DMKF0GH DT Small molecular drug
DMKF0GH PC 5310934
DMKF0GH MW 153.12
DMKF0GH FM C4H12NO3P
DMKF0GH IC InChI=1S/C4H12NO3P/c1-9(7,8)3-4(6)2-5/h4,6H,2-3,5H2,1H3,(H,7,8)/t4-/m1/s1
DMKF0GH CS CP(=O)(C[C@@H](CN)O)O
DMKF0GH IK FUUPFUIGNBPCAY-SCSAIBSYSA-N
DMKF0GH IU [(2R)-3-amino-2-hydroxypropyl]-methylphosphinic acid
DMKF0GH CA CAS 133345-68-3
DMKF0GH DE Drug abuse
DM5SATN ID DM5SATN
DM5SATN DN CGP-49870
DM5SATN HS Investigative
DM5SATN SN 186615-82-7; AT1 angiotensin II antagonist, Novartis
DM5SATN DE Discovery agent
DMFPOUC ID DMFPOUC
DMFPOUC DN CGP-57380
DMFPOUC HS Investigative
DMFPOUC SN CGP 57380; 522629-08-9; CGP-57380; MNK1 Inhibitor; N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine; CGP57380; CHEMBL1240885; C11H9FN6; 4-Amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine; SCHEMBL987991; GTPL6010; CHEMBL576817; SCHEMBL16714452; CHEBI:92749; DTXSID50469941; MolPort-006-725-822; HMS3653G22; HMS3269P13; HMS3263L14; HMS3229K20; HMS3648M14; Tox21_501256; BDBM50130693; 2314AH; NSC741567; MFCD03861062; ZINC13816313; s7421; IN1236; BDBM50298223; AKOS024457265; CCG-206868; NSC-741567; LP01256; NCGC00162380-06
DMFPOUC DT Small molecular drug
DMFPOUC PC 11644425
DMFPOUC MW 244.23
DMFPOUC FM C11H9FN6
DMFPOUC IC InChI=1S/C11H9FN6/c12-6-1-3-7(4-2-6)16-11-8-9(13)14-5-15-10(8)17-18-11/h1-5H,(H4,13,14,15,16,17,18)
DMFPOUC CS C1=CC(=CC=C1NC2=C3C(=NC=NC3=NN2)N)F
DMFPOUC IK UQPMANVRZYYQMD-UHFFFAOYSA-N
DMFPOUC IU 3-N-(4-fluorophenyl)-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine
DMFPOUC CA CAS 522629-08-9
DMFPOUC CB CHEBI:92749
DMFPOUC DE Discovery agent
DMYZ72J ID DMYZ72J
DMYZ72J DN CGP-57698
DMYZ72J HS Investigative
DMYZ72J SN 168082-74-4
DMYZ72J DT Small molecular drug
DMYZ72J PC 9888588
DMYZ72J MW 424.5
DMYZ72J FM C24H25FN2O4
DMYZ72J IC InChI=1S/C24H25FN2O4/c1-3-24(4-2,23(29)30)14-22(28)27-18-6-5-7-20(13-18)31-15-19-11-9-16-8-10-17(25)12-21(16)26-19/h5-13H,3-4,14-15H2,1-2H3,(H,27,28)(H,29,30)
DMYZ72J CS CCC(CC)(CC(=O)NC1=CC(=CC=C1)OCC2=NC3=C(C=CC(=C3)F)C=C2)C(=O)O
DMYZ72J IK BFNAFTJCDGWFMQ-UHFFFAOYSA-N
DMYZ72J IU 2,2-diethyl-4-[3-[(7-fluoroquinolin-2-yl)methoxy]anilino]-4-oxobutanoic acid
DMYZ72J CA CAS 168082-74-4
DMYZ72J DE Discovery agent
DM8KFZH ID DM8KFZH
DM8KFZH DN CGP61594
DM8KFZH HS Investigative
DM8KFZH SN 4-[2-(4-Azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; 4-[2-(4-azidophenyl)acetamido]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid; CGP 61594; [3H]CGP61594; CGP-61594; [3H]CGP 61594; GTPL5474; CGP-61594
DM8KFZH DT Small molecular drug
DM8KFZH PC 10025114
DM8KFZH MW 420.2
DM8KFZH FM C18H15Cl2N5O3
DM8KFZH IC InChI=1S/C18H15Cl2N5O3/c19-10-6-12(20)17-13(7-10)22-15(18(27)28)8-14(17)23-16(26)5-9-1-3-11(4-2-9)24-25-21/h1-4,6-7,14-15,22H,5,8H2,(H,23,26)(H,27,28)
DM8KFZH CS C1C(C2=C(C=C(C=C2Cl)Cl)NC1C(=O)O)NC(=O)CC3=CC=C(C=C3)N=[N+]=[N-]
DM8KFZH IK OVAIIHUWSLJJPO-UHFFFAOYSA-N
DM8KFZH IU 4-[[2-(4-azidophenyl)acetyl]amino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
DM8KFZH DE Discovery agent
DMZ34P1 ID DMZ34P1
DMZ34P1 DN CGP-62464
DMZ34P1 HS Investigative
DMZ34P1 SN CGP-62464; CHEMBL169757; 5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; NSC606429; AC1Q4VCQ; 5,7-diphenyl-4-aminopyrrolo[2,3-d]pyrimidine; AC1L74EC; SCHEMBL5936176; ZINC1609260; BDBM50088900; NSC-606429; 121405-24-1; FT-0761196; 5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine; 5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine
DMZ34P1 DT Small molecular drug
DMZ34P1 PC 354471
DMZ34P1 MW 286.3
DMZ34P1 FM C18H14N4
DMZ34P1 IC InChI=1S/C18H14N4/c19-17-16-15(13-7-3-1-4-8-13)11-22(18(16)21-12-20-17)14-9-5-2-6-10-14/h1-12H,(H2,19,20,21)
DMZ34P1 CS C1=CC=C(C=C1)C2=CN(C3=NC=NC(=C23)N)C4=CC=CC=C4
DMZ34P1 IK AFVGAHBUCVDPPI-UHFFFAOYSA-N
DMZ34P1 IU 5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine
DMZ34P1 DE Discovery agent
DMU5984 ID DMU5984
DMU5984 DN CGP74514A
DMU5984 HS Investigative
DMU5984 SN CGP-74514A; CGP 74514A
DMU5984 DT Small molecular drug
DMU5984 PC 2794188
DMU5984 MW 385.9
DMU5984 FM C19H24ClN7
DMU5984 IC InChI=1S/C19H24ClN7/c1-2-27-11-22-16-17(23-13-7-5-6-12(20)10-13)25-19(26-18(16)27)24-15-9-4-3-8-14(15)21/h5-7,10-11,14-15H,2-4,8-9,21H2,1H3,(H2,23,24,25,26)/t14-,15+/m0/s1
DMU5984 CS CCN1C=NC2=C(N=C(N=C21)N[C@@H]3CCCC[C@@H]3N)NC4=CC(=CC=C4)Cl
DMU5984 IK UTBSBSOBZHXMHI-LSDHHAIUSA-N
DMU5984 IU 2-N-[(1R,2S)-2-aminocyclohexyl]-6-N-(3-chlorophenyl)-9-ethylpurine-2,6-diamine
DMU5984 CA CAS 190653-73-7
DMU5984 DE Discovery agent
DMZ0TGY ID DMZ0TGY
DMZ0TGY DN CGS 21680
DMZ0TGY HS Investigative
DMZ0TGY SN 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; Cgs 21680; CGS-21680; 120225-54-9; UNII-T5HB1E831H; T5HB1E831H; CHEMBL331372; CGS21680; 4-(2-((6-Amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)benzenepropanoic acid; CHEBI:73283; CGS 21680 hydrochloride; Benzenepropanoic acid, 4-(2-((6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)-; 2-[p-(2-Carboxyethyl)phenylethyl-Amino]-5'-N-Ethylcarboxamido Adenosine; [3H]CGS 21680
DMZ0TGY DT Small molecular drug
DMZ0TGY PC 3086599
DMZ0TGY MW 499.5
DMZ0TGY FM C23H29N7O6
DMZ0TGY IC InChI=1S/C23H29N7O6/c1-2-25-21(35)18-16(33)17(34)22(36-18)30-11-27-15-19(24)28-23(29-20(15)30)26-10-9-13-5-3-12(4-6-13)7-8-14(31)32/h3-6,11,16-18,22,33-34H,2,7-10H2,1H3,(H,25,35)(H,31,32)(H3,24,26,28,29)/t16-,17+,18-,22+/m0/s1
DMZ0TGY CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O
DMZ0TGY IK PAOANWZGLPPROA-RQXXJAGISA-N
DMZ0TGY IU 3-[4-[2-[[6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxyoxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid
DMZ0TGY CA CAS 120225-54-9
DMZ0TGY CB CHEBI:73283
DMZ0TGY DE Discovery agent
DMRU8G7 ID DMRU8G7
DMRU8G7 DN CGS 24012
DMRU8G7 HS Investigative
DMRU8G7 SN DPMA; CGS-24012; CGS24012
DMRU8G7 DT Small molecular drug
DMRU8G7 PC 10391971
DMRU8G7 MW 521.6
DMRU8G7 FM C27H31N5O6
DMRU8G7 IC InChI=1S/C27H31N5O6/c1-15-6-4-5-7-19(15)20(16-8-17(36-2)10-18(9-16)37-3)11-28-25-22-26(30-13-29-25)32(14-31-22)27-24(35)23(34)21(12-33)38-27/h4-10,13-14,20-21,23-24,27,33-35H,11-12H2,1-3H3,(H,28,29,30)/t20?,21-,23-,24-,27-/m1/s1
DMRU8G7 CS CC1=CC=CC=C1C(CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)C5=CC(=CC(=C5)OC)OC
DMRU8G7 IK BUHVIAUBTBOHAG-FOYDDCNASA-N
DMRU8G7 IU (2R,3R,4S,5R)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMRU8G7 DE Discovery agent
DMCHT27 ID DMCHT27
DMCHT27 DN CGS 35066
DMCHT27 HS Investigative
DMCHT27 SN CGS-35066; CHEMBL34668; SCHEMBL4558321
DMCHT27 DT Small molecular drug
DMCHT27 PC 24868306
DMCHT27 MW 349.27
DMCHT27 FM C16H16NO6P
DMCHT27 IC InChI=1S/C16H16NO6P/c18-16(19)13(17-9-24(20,21)22)7-10-5-6-12-11-3-1-2-4-14(11)23-15(12)8-10/h1-6,8,13,17H,7,9H2,(H,18,19)(H2,20,21,22)
DMCHT27 CS C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)CC(C(=O)O)NCP(=O)(O)O
DMCHT27 IK CRUVAUSVWLATAE-UHFFFAOYSA-N
DMCHT27 IU 3-dibenzofuran-3-yl-2-(phosphonomethylamino)propanoic acid
DMCHT27 DE Discovery agent
DM4DSE7 ID DM4DSE7
DM4DSE7 DN CGS-13767
DM4DSE7 HS Investigative
DM4DSE7 DT Small molecular drug
DM4DSE7 PC 135465884
DM4DSE7 MW 262.27
DM4DSE7 FM C15H10N4O
DM4DSE7 IC InChI=1S/C15H10N4O/c20-15-16-12-9-5-4-8-11(12)14-17-13(18-19(14)15)10-6-2-1-3-7-10/h1-9H,(H,16,20)
DM4DSE7 CS C1=CC=C(C=C1)C2=NN3C(=N2)C4=CC=CC=C4NC3=O
DM4DSE7 IK AXPGZURVLRWNBR-UHFFFAOYSA-N
DM4DSE7 IU 2-phenyl-6H-[1,2,4]triazolo[1,5-c]quinazolin-5-one
DM4DSE7 DE Discovery agent
DM2CS5A ID DM2CS5A
DM2CS5A DN CGS-18320B
DM2CS5A HS Investigative
DM2CS5A SN Cgs-18320B; CHEMBL29482; AC1L33QO; SCHEMBL1507825; ZINC3775824; CGS-18320; BDBM50047260; 4,4''-((1H-imidazol-1-yl)methylene)dibenzonitrile; 4-[4-cyanophenyl(1H-1-imidazolyl)methyl]benzonitrile; 4-[(4-cyanophenyl)-imidazol-1-ylmethyl]benzonitrile
DM2CS5A DT Small molecular drug
DM2CS5A PC 133966
DM2CS5A MW 284.3
DM2CS5A FM C18H12N4
DM2CS5A IC InChI=1S/C18H12N4/c19-11-14-1-5-16(6-2-14)18(22-10-9-21-13-22)17-7-3-15(12-20)4-8-17/h1-10,13,18H
DM2CS5A CS C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=CN=C3
DM2CS5A IK NRXVWQIGPASRKU-UHFFFAOYSA-N
DM2CS5A IU 4-[(4-cyanophenyl)-imidazol-1-ylmethyl]benzonitrile
DM2CS5A DE Discovery agent
DMDB2KJ ID DMDB2KJ
DMDB2KJ DN CGS-19281A
DMDB2KJ HS Investigative
DMDB2KJ SN Cgs-19281A; CHEMBL6409; 31652-37-6; 4,9-Dihydro-7-methoxy-3H-pyrido(3,4b)indole; 3H-Pyrido(3,4-b)indole, 4,9-dihydro-7-methoxy-; AC1L53KC; AC1Q56KK; 7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole; SCHEMBL2930783; CTK4G7530; DTXSID90185537; BDBM50079903; 7-Methoxy-4,9-dihydro-3H-beta-carboline
DMDB2KJ DT Small molecular drug
DMDB2KJ PC 169339
DMDB2KJ MW 200.24
DMDB2KJ FM C12H12N2O
DMDB2KJ IC InChI=1S/C12H12N2O/c1-15-8-2-3-9-10-4-5-13-7-12(10)14-11(9)6-8/h2-3,6-7,14H,4-5H2,1H3
DMDB2KJ CS COC1=CC2=C(C=C1)C3=C(N2)C=NCC3
DMDB2KJ IK VTEZDUSEJVSZGQ-UHFFFAOYSA-N
DMDB2KJ IU 7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indole
DMDB2KJ CA CAS 31652-37-6
DMDB2KJ DE Discovery agent
DMC41UH ID DMC41UH
DMC41UH DN CGS-19480A
DMC41UH HS Investigative
DMC41UH SN 3-(Dipropylamino)-5-ethoxy-3,4-dihydro-2H-[1]-benzothiopyran hydrochloride
DMC41UH DE Anxiety disorder
DM5P7TR ID DM5P7TR
DM5P7TR DN CGS-23885
DM5P7TR HS Investigative
DM5P7TR SN 134822-78-9
DM5P7TR DT Small molecular drug
DM5P7TR PC 131820
DM5P7TR MW 312.32
DM5P7TR FM C17H16N2O4
DM5P7TR IC InChI=1S/C17H16N2O4/c18-17(20)19(21)10-12-8-13-9-15(6-7-16(13)22-11-12)23-14-4-2-1-3-5-14/h1-9,21H,10-11H2,(H2,18,20)
DM5P7TR CS C1C(=CC2=C(O1)C=CC(=C2)OC3=CC=CC=C3)CN(C(=O)N)O
DM5P7TR IK FPOBKZCHKXONBB-UHFFFAOYSA-N
DM5P7TR IU 1-hydroxy-1-[(6-phenoxy-2H-chromen-3-yl)methyl]urea
DM5P7TR CA CAS 134822-78-9
DM5P7TR DE Discovery agent
DM514L0 ID DM514L0
DM514L0 DN CGS-314447
DM514L0 HS Investigative
DM514L0 SN CHEMBL415967; CGS-314447; BDBM50159369; CGS-31,4447; {1-[(S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-2-naphthalen-2-yl-ethyl}-phosphonic acid
DM514L0 DT Small molecular drug
DM514L0 PC 9913857
DM514L0 MW 499.5
DM514L0 FM C27H26N5O3P
DM514L0 IC InChI=1S/C27H26N5O3P/c33-36(34,35)26(18-20-12-15-22-8-4-5-9-24(22)16-20)28-25(27-29-31-32-30-27)17-19-10-13-23(14-11-19)21-6-2-1-3-7-21/h1-16,25-26,28H,17-18H2,(H2,33,34,35)(H,29,30,31,32)/t25-,26?/m0/s1
DM514L0 CS C1=CC=C(C=C1)C2=CC=C(C=C2)C[C@@H](C3=NNN=N3)NC(CC4=CC5=CC=CC=C5C=C4)P(=O)(O)O
DM514L0 IK PIBUIEXHVFJHNQ-PMCHYTPCSA-N
DM514L0 IU [2-naphthalen-2-yl-1-[[(1S)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethyl]amino]ethyl]phosphonic acid
DM514L0 DE Discovery agent
DMZKS6Q ID DMZKS6Q
DMZKS6Q DN CGS-7181
DMZKS6Q HS Investigative
DMZKS6Q SN 200345-93-3; CGS-7184; CGS-7590; CGS-7725
DMZKS6Q DT Small molecular drug
DMZKS6Q PC 656759
DMZKS6Q MW 406.4
DMZKS6Q FM C20H17F3N2O4
DMZKS6Q IC InChI=1S/C20H17F3N2O4/c1-3-29-18(27)16-14-9-6-12(20(21,22)23)10-15(14)25(17(16)26)19(28)24-13-7-4-11(2)5-8-13/h4-10,26H,3H2,1-2H3,(H,24,28)
DMZKS6Q CS CCOC(=O)C1=C(N(C2=C1C=CC(=C2)C(F)(F)F)C(=O)NC3=CC=C(C=C3)C)O
DMZKS6Q IK YMEXYIFTFLKKQK-UHFFFAOYSA-N
DMZKS6Q IU ethyl 2-hydroxy-1-[(4-methylphenyl)carbamoyl]-6-(trifluoromethyl)indole-3-carboxylate
DMZKS6Q CA CAS 200345-93-3
DMZKS6Q CB CHEBI:34601
DMZKS6Q DE Discovery agent
DMKY6CU ID DMKY6CU
DMKY6CU DN CGS-9895
DMKY6CU HS Investigative
DMKY6CU SN Cgs-9895; 77779-50-1; Cgs 9895; MLS003171322; NSC373970; 2-(4-methoxy-phenyl)-1,2-dihydro-pyrazolo[4,3-c]quinolin-3-one; CHEMBL296335; 2-(4-Methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one; FTHGIXILGYJOBQ-UHFFFAOYSA-N; NSC 373970; AC1L2PJC; AC1Q4BZG; SCHEMBL3646887; SCHEMBL1466285; CHEMBL3144739; CTK5E4891; BDBM84956; AOB4750; MolPort-010-675-457; KSKRJZMRHSNRBX-UHFFFAOYSA-N; HMS3436H11; PDSP2_001747; PDSP1_001764; 2,5-Dihydro-2-(4-methoxyphenyl)-3H-pyrazolo(4,3-c)quinolin-3-one; AKOS021660772; ZINC101168346; NSC-373970
DMKY6CU DT Small molecular drug
DMKY6CU PC 100812
DMKY6CU MW 291.3
DMKY6CU FM C17H13N3O2
DMKY6CU IC InChI=1S/C17H13N3O2/c1-22-12-8-6-11(7-9-12)20-17(21)14-10-18-15-5-3-2-4-13(15)16(14)19-20/h2-10,19H,1H3
DMKY6CU CS COC1=CC=C(C=C1)N2C(=O)C3=C(N2)C4=CC=CC=C4N=C3
DMKY6CU IK FTHGIXILGYJOBQ-UHFFFAOYSA-N
DMKY6CU IU 2-(4-methoxyphenyl)-1H-pyrazolo[4,3-c]quinolin-3-one
DMKY6CU CA CAS 77779-50-1
DMKY6CU DE Discovery agent
DMMJZYC ID DMMJZYC
DMMJZYC DN CH-223191
DMMJZYC HS Investigative
DMMJZYC SN 301326-22-7; CH 223191; CH223191; UNII-HYE7315Z4C; HYE7315Z4C; CHEMBL1743245; AhR Antagonist; 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide; 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide; 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide; (E)-1-methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide; 1-methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide; 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide; CBDivE_007629; SCHEMBL363547; DTXSID5058698; AOB1977; EX-A771; SYN5007; CHEBI:125508; HMS3412G22; HMS3676G22; HMS3750E07; BCP12814; ZINC4762981; BDBM50525572; MFCD00377884; s7711; SBB081907; STK837883; 2-Methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azophenyl)-amide; AKOS000629906; AKOS026750492; ZINC100550218; ZINC254429865; CCG-267843; CS-3905; MCULE-3225752823; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-((2-methylphenyl)azo)phenyl)-; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-(2-(2-methylphenyl)diazenyl)phenyl)-; AC-32878; AS-16374; HY-12684; QC-11824; FT-0696668; X3558; J-017795; BRD-K22314899-001-01-6; Q27216129; Q27280162; 1-methyl-N-{2-methyl-4-[2-(2-methylphenyl)diazen-1-yl]phenyl}-1H-pyrazole-5-carboxamide; N-{2-methyl-4-[(2-methylphenyl)diazenyl]phenyl}(1-methylpyrazol-5-yl)carboxami de
DMMJZYC DT Small molecular drug
DMMJZYC PC 3091786
DMMJZYC MW 333.4
DMMJZYC FM C19H19N5O
DMMJZYC IC InChI=1S/C19H19N5O/c1-13-6-4-5-7-17(13)23-22-15-8-9-16(14(2)12-15)21-19(25)18-10-11-20-24(18)3/h4-12H,1-3H3,(H,21,25)
DMMJZYC CS CC1=CC=CC=C1N=NC2=CC(=C(C=C2)NC(=O)C3=CC=NN3C)C
DMMJZYC IK LKTNEXPODAWWFM-UHFFFAOYSA-N
DMMJZYC IU 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide
DMMJZYC CA CAS 301326-22-7
DMMJZYC CB CHEBI:125508
DMMJZYC DE Solid tumour/cancer
DM0RFTJ ID DM0RFTJ
DM0RFTJ DN CH-3697
DM0RFTJ HS Investigative
DM0RFTJ CP Chiroscience R&D Ltd
DM0RFTJ DE Asthma
DMP9UHT ID DMP9UHT
DMP9UHT DN CH4474
DMP9UHT HS Investigative
DMP9UHT SN Methotrexate hydrate; Methotrexate hydrate(1:x); 133073-73-1; L-Amethopterin hydrate; Methotrexate monohydrate; UNII-84DMZ3IHO0; 84DMZ3IHO0; Antifolan hydrate; MTX hydrate; L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- [CAS]; 6745-93-3; Methylaminopterin hydrate; MLS001401431; 4-Amino-10-methylfolic acid hydrate; SMR000449324; Methotrexate trihydrate; Abitrexate(Methotrexate)/; AC1Q5QR4; AC1L4WT9; MLS000758248; L-Amethopterin hydrate, 98%; C20H22N8O5.xH2O; SCHEMBL1230252
DMP9UHT DT Small molecular drug
DMP9UHT PC 165528
DMP9UHT MW 472.5
DMP9UHT FM C20H24N8O6
DMP9UHT IC InChI=1S/C20H22N8O5.H2O/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);1H2/t13-;/m0./s1
DMP9UHT CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O.O
DMP9UHT IK FPJYMUQSRFJSEW-ZOWNYOTGSA-N
DMP9UHT IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid;hydrate
DMP9UHT CA CAS 6745-93-3
DMP9UHT DE Discovery agent
DM1ZF3Y ID DM1ZF3Y
DM1ZF3Y DN CH-4933468
DM1ZF3Y HS Investigative
DM1ZF3Y SN CH-5137291; Androgen receptor antagonists (oral, prostate tumor); Androgen receptor antagonists (oral, prostate tumor), Chugai
DM1ZF3Y CP Chugai Pharmaceutical Co Ltd
DM1ZF3Y DT Small molecular drug
DM1ZF3Y PC 11632731
DM1ZF3Y MW 400.9
DM1ZF3Y FM C15H17ClN4O3S2
DM1ZF3Y IC InChI=1S/C15H17ClN4O3S2/c1-15(2)13(21)20(11-5-4-10(9-17)12(16)8-11)14(24)19(15)6-3-7-25(18,22)23/h4-5,8H,3,6-7H2,1-2H3,(H2,18,22,23)
DM1ZF3Y CS CC1(C(=O)N(C(=S)N1CCCS(=O)(=O)N)C2=CC(=C(C=C2)C#N)Cl)C
DM1ZF3Y IK DSIHXMZSDDJEHM-UHFFFAOYSA-N
DM1ZF3Y IU 3-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]propane-1-sulfonamide
DM1ZF3Y CA CAS 875055-92-8
DM1ZF3Y DE Prostate cancer
DMBK86L ID DMBK86L
DMBK86L DN chaetocin
DMBK86L HS Investigative
DMBK86L SN Chaetocin; Chetocin; 28097-03-2; Chaetocin from Chaetomium minutum; BRN 5722505; AC1L4PPK; GTPL8388; SCHEMBL13662584; CHEBI:94977; MolPort-003-983-881; NSC745363; NSC-745363; LS-52961; Chaetocin from Chaetomium minutum, > J-016970; BRD-A85860691-001-01-4; BRD-A85860691-001-03-0; hydroxymethyl-(hydroxymethyl-methyl-dioxo-[ ]yl)-methyl-[ ]dione; [10b,10'b(11H,11'H)-Bi-3,11a-epidithio-11aH-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole]-1,1',4,4'-tetrone, 2,2',3,3',5a,5'a,6,6'-octahydro-3,3'-bis(hydroxymethyl)-2,2'-dime
DMBK86L DT Small molecular drug
DMBK86L PC 11657687
DMBK86L MW 696.8
DMBK86L FM C30H28N6O6S4
DMBK86L IC InChI=1S/C30H28N6O6S4/c1-33-21(39)27-11-25(15-7-3-5-9-17(15)31-19(25)35(27)23(41)29(33,13-37)45-43-27)26-12-28-22(40)34(2)30(14-38,46-44-28)24(42)36(28)20(26)32-18-10-6-4-8-16(18)26/h3-10,19-20,31-32,37-38H,11-14H2,1-2H3/t19-,20-,25+,26+,27+,28+,29+,30+/m1/s1
DMBK86L CS CN1C(=O)[C@@]23C[C@]4([C@@H](N2C(=O)[C@@]1(SS3)CO)NC5=CC=CC=C54)[C@]67C[C@]89C(=O)N([C@](C(=O)N8[C@H]6NC1=CC=CC=C71)(SS9)CO)C
DMBK86L IK PZPPOCZWRGNKIR-PNVYSBBASA-N
DMBK86L IU (1S,3R,11R,14S)-14-(hydroxymethyl)-3-[(1S,3R,11R,14S)-14-(hydroxymethyl)-18-methyl-13,17-dioxo-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-18-methyl-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione
DMBK86L CA CAS 28097-03-2
DMBK86L DE Discovery agent
DM16QTM ID DM16QTM
DM16QTM DN CHALCONE
DM16QTM HS Investigative
DM16QTM SN Chalcone; (E)-Chalcone; trans-Chalcone; Benzalacetophenone; 614-47-1; 94-41-7; Benzylideneacetophenone; Chalkone; Phenyl styryl ketone; Cinnamophenone; 2-Benzalacetophenone; 2-Benzylideneacetophenone; 1,3-DIPHENYL-2-PROPEN-1-ONE; 1,3-Diphenylpropenone; (2E)-1,3-diphenylprop-2-en-1-one; Styryl phenyl ketone; 3-Phenylacrylophenone; 1-Benzoyl-2-phenylethene; trans-Benzalacetophenone; beta-Benzoylstyrene; Benzylidenecetophenone; Phenyl trans-styryl ketone; 2-Propen-1-one, 1,3-diphenyl-; 1-Benzoyl-1-phenylethene
DM16QTM DT Small molecular drug
DM16QTM PC 637760
DM16QTM MW 208.25
DM16QTM FM C15H12O
DM16QTM IC InChI=1S/C15H12O/c16-15(14-9-5-2-6-10-14)12-11-13-7-3-1-4-8-13/h1-12H/b12-11+
DM16QTM CS C1=CC=C(C=C1)/C=C/C(=O)C2=CC=CC=C2
DM16QTM IK DQFBYFPFKXHELB-VAWYXSNFSA-N
DM16QTM IU (E)-1,3-diphenylprop-2-en-1-one
DM16QTM CA CAS 614-47-1
DM16QTM CB CHEBI:48965
DM16QTM DE Discovery agent
DMBZ0QY ID DMBZ0QY
DMBZ0QY DN CHAP1
DMBZ0QY HS Investigative
DMBZ0QY SN CHEMBL99392; chap-1; CHAP1; AC1OCEVW; BDBM50082325
DMBZ0QY DT Small molecular drug
DMBZ0QY PC 6917986
DMBZ0QY MW 577.7
DMBZ0QY FM C31H39N5O6
DMBZ0QY IC InChI=1S/C31H39N5O6/c37-27(35-42)17-9-3-8-15-23-28(38)33-24(19-21-11-4-1-5-12-21)29(39)34-25(20-22-13-6-2-7-14-22)31(41)36-18-10-16-26(36)30(40)32-23/h1-2,4-7,11-14,23-26,42H,3,8-10,15-20H2,(H,32,40)(H,33,38)(H,34,39)(H,35,37)/t23-,24-,25-,26+/m0/s1
DMBZ0QY CS C1C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CC=CC=C3)CC4=CC=CC=C4)CCCCCC(=O)NO
DMBZ0QY IK FQWUNUXAOHTLLG-ASDGIDEWSA-N
DMBZ0QY IU 6-[(3S,6S,9S,12R)-3,6-dibenzyl-2,5,8,11-tetraoxo-1,4,7,10-tetrazabicyclo[10.3.0]pentadecan-9-yl]-N-hydroxyhexanamide
DMBZ0QY DE Solid tumour/cancer
DMOXRID ID DMOXRID
DMOXRID DN CHAP31
DMOXRID HS Investigative
DMOXRID SN SCHEMBL16585076
DMOXRID DT Small molecular drug
DMOXRID PC 56603758
DMOXRID MW 575.7
DMOXRID FM C29H45N5O7
DMOXRID IC InChI=1S/C29H45N5O7/c1-4-19(2)25(18-35)33-29(39)24(17-20-12-14-21(41-3)15-13-20)32-28(38)23(9-6-5-7-11-26(36)34-40)31-27(37)22-10-8-16-30-22/h12-15,18-19,22-25,30,40H,4-11,16-17H2,1-3H3,(H,31,37)(H,32,38)(H,33,39)(H,34,36)/t19-,22?,23+,24-,25-/m1/s1
DMOXRID CS CC[C@@H](C)[C@@H](C=O)NC(=O)[C@@H](CC1=CC=C(C=C1)OC)NC(=O)[C@H](CCCCCC(=O)NO)NC(=O)C2CCCN2
DMOXRID IK NTGGUMOPMBIWTJ-UIKXIZPHSA-N
DMOXRID IU (2S)-N'-hydroxy-N-[(2R)-3-(4-methoxyphenyl)-1-[[(2S,3R)-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-(pyrrolidine-2-carbonylamino)octanediamide
DMOXRID DE Solid tumour/cancer
DM0H7AV ID DM0H7AV
DM0H7AV DN Chebulagic acid
DM0H7AV HS Investigative
DM0H7AV SN Chebulagic acid; 23094-71-5; NSC 342674; AC1L2HS4; beta-D-Glucopyranose, cyclic 3,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), cyclic 2-5:4-1-ester with (5-carboxy-3,4-dihydro-3,7,8-trihydroxy-2-oxo-2H-1-benzopyran-4-yl)butanedioic acid, stereoisomer
DM0H7AV DT Small molecular drug
DM0H7AV PC 442674
DM0H7AV MW 954.7
DM0H7AV FM C41H30O27
DM0H7AV IC InChI=1S/C41H30O27/c42-13-1-8(2-14(43)24(13)49)35(56)68-41-34-33-31(64-39(60)12(6-19(47)48)22-23-11(38(59)67-34)5-17(46)27(52)32(23)65-40(61)30(22)55)18(63-41)7-62-36(57)9-3-15(44)25(50)28(53)20(9)21-10(37(58)66-33)4-16(45)26(51)29(21)54/h1-5,12,18,22,30-31,33-34,41-46,49-55H,6-7H2,(H,47,48)/t12-,18+,22-,30-,31+,33-,34+,41-/m0/s1
DM0H7AV CS C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O
DM0H7AV IK HGJXAVROWQLCTP-YABCKIEDSA-N
DM0H7AV IU 2-[(4R,5S,7R,25S,26R,29S,30S,31S)-13,14,15,18,19,20,31,35,36-nonahydroxy-2,10,23,28,32-pentaoxo-5-(3,4,5-trihydroxybenzoyl)oxy-3,6,9,24,27,33-hexaoxaheptacyclo[28.7.1.04,25.07,26.011,16.017,22.034,38]octatriaconta-1(37),11,13,15,17,19,21,34(38),35-nonaen-29-yl]acetic acid
DM0H7AV CB CHEBI:3583
DM0H7AV DE Discovery agent
DMR8HKC ID DMR8HKC
DMR8HKC DN Chebulinic acid
DMR8HKC HS Investigative
DMR8HKC SN Chebulinic acid; 18942-26-2; UNII-HVC8VQJ6EK; HVC8VQJ6EK; AC1L2HS1; CHEMBL501154; NSC69862; NSC 69862; CHEBI:3584; ZINC195763592; FT-0697896; C10215; Q-100932; beta-D-Glucopyranose, cyclic 2,4-ester with 3-(6-carboxy-2,3,4-trihydroxyphenyl)-4-hydroxy-1,2,4-butanetricarboxylic acid, 1,3,6-tris(3,4,5-trihydroxybenzoate)
DMR8HKC DT Small molecular drug
DMR8HKC PC 72284
DMR8HKC MW 956.7
DMR8HKC FM C41H32O27
DMR8HKC IC InChI=1S/C41H32O27/c42-15-1-10(2-16(43)26(15)51)35(56)62-9-22-31-33(66-36(57)11-3-17(44)27(52)18(45)4-11)34(41(63-22)68-37(58)12-5-19(46)28(53)20(47)6-12)67-38(59)13-7-21(48)29(54)32-25(13)24(30(55)40(61)65-32)14(8-23(49)50)39(60)64-31/h1-7,14,22,24,30-31,33-34,41-48,51-55H,8-9H2,(H,49,50)/t14-,22+,24-,30-,31+,33-,34+,41-/m0/s1
DMR8HKC CS C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O
DMR8HKC IK YGVHOSGNOYKRIH-FJPMMHPYSA-N
DMR8HKC IU 2-[(4R,5S,7R,8R,11S,12S,13S,21S)-13,17,18-trihydroxy-2,10,14-trioxo-5,21-bis[(3,4,5-trihydroxybenzoyl)oxy]-7-[(3,4,5-trihydroxybenzoyl)oxymethyl]-3,6,9,15-tetraoxatetracyclo[10.7.1.14,8.016,20]henicosa-1(19),16(20),17-trien-11-yl]acetic acid
DMR8HKC CB CHEBI:3584
DMR8HKC DE Discovery agent
DMCP1G9 ID DMCP1G9
DMCP1G9 DN Chelerythrine
DMCP1G9 HS Investigative
DMCP1G9 SN broussonpapyrine; cheleritrine; chelerythrine hydroxide; toddalin
DMCP1G9 DT Small molecular drug
DMCP1G9 PC 2703
DMCP1G9 MW 348.4
DMCP1G9 FM C21H18NO4+
DMCP1G9 IC InChI=1S/C21H18NO4/c1-22-10-16-13(6-7-17(23-2)21(16)24-3)14-5-4-12-8-18-19(26-11-25-18)9-15(12)20(14)22/h4-10H,11H2,1-3H3/q+1
DMCP1G9 CS C[N+]1=C2C(=C3C=CC(=C(C3=C1)OC)OC)C=CC4=CC5=C(C=C42)OCO5
DMCP1G9 IK LLEJIEBFSOEYIV-UHFFFAOYSA-N
DMCP1G9 IU 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium
DMCP1G9 CA CAS 34316-15-9
DMCP1G9 CB CHEBI:78373
DMCP1G9 DE Discovery agent
DMYSG9J ID DMYSG9J
DMYSG9J DN Chemosensitizers
DMYSG9J HS Investigative
DMYSG9J DT Small molecular drug
DMYSG9J PC 24783227
DMYSG9J MW 385.2
DMYSG9J FM C16H18ClN3SZn+2
DMYSG9J IC InChI=1S/C16H18N3S.ClH.Zn/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10H,1-4H3;1H;/q+1;;+2/p-1
DMYSG9J CS CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-].[Zn+2]
DMYSG9J IK LXXWTKZXINWUFR-UHFFFAOYSA-M
DMYSG9J IU zinc;[7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride
DMYSG9J DE Discovery agent
DMLJGVX ID DMLJGVX
DMLJGVX DN CHF-2819
DMLJGVX HS Investigative
DMLJGVX SN CHEMBL539624
DMLJGVX DT Small molecular drug
DMLJGVX PC 23645738
DMLJGVX MW 417.9
DMLJGVX FM C22H28ClN3O3
DMLJGVX IC InChI=1S/C22H27N3O3.ClH/c1-5-15-8-6-7-9-18(15)23-21(26)28-16-10-11-19-17(14-16)22(2)12-13-25(4,27)20(22)24(19)3;/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26);1H/t20-,22-,25?;/m0./s1
DMLJGVX CS CCC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CC[N+]4(C)[O-])C)C.Cl
DMLJGVX IK GPQRGFUTRVNTHA-QFPJJMDASA-N
DMLJGVX IU [(3aS,8bS)-3,4,8b-trimethyl-3-oxido-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-3-ium-7-yl] N-(2-ethylphenyl)carbamate;hydrochloride
DMLJGVX DE Discovery agent
DM5T64L ID DM5T64L
DM5T64L DN CHF-5480
DM5T64L HS Investigative
DM5T64L SN PDE 4 inhibitors (COPD/asthma); PDE 4 inhibitors (COPD/asthma), Chiesi
DM5T64L CP Chiesi Farmaceutici SpA
DM5T64L DE Chronic obstructive pulmonary disease
DMJATBL ID DMJATBL
DMJATBL DN Chimeric small nucleolar RNA-TAR decoy
DMJATBL HS Investigative
DMJATBL DT Small molecular drug
DMJATBL PC 6426938
DMJATBL MW 682.8
DMJATBL FM C37H50N2O10
DMJATBL IC InChI=1S/C37H50N2O10/c1-7-38-17-34(18-49-32(42)20-10-8-9-11-23(20)39-26(40)14-19(2)31(39)41)13-12-25(46-4)36-22-15-21-24(45-3)16-35(43,27(22)28(21)47-5)37(44,33(36)38)30(48-6)29(34)36/h8-11,19,21-22,24-25,27-30,33,43-44H,7,12-18H2,1-6H3/t19?,21?,22?,24?,25?,27?,28?,29?,30-,33?,34?,35+,36?,37-/m0/s1
DMJATBL CS CCN1CC2(CCC(C34C2[C@@H]([C@](C31)([C@]5(CC(C6CC4C5C6OC)OC)O)O)OC)OC)COC(=O)C7=CC=CC=C7N8C(=O)CC(C8=O)C
DMJATBL IK XLTANAWLDBYGFU-SCAXRLHISA-N
DMJATBL IU [(8R,9R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate
DMJATBL CA CAS 1356-60-1
DMJATBL DE Discovery agent
DMVEBT6 ID DMVEBT6
DMVEBT6 DN CHIR-98014
DMVEBT6 HS Investigative
DMVEBT6 SN CHIR98014; CHIR 98014
DMVEBT6 DT Small molecular drug
DMVEBT6 PC 53396311
DMVEBT6 MW 486.3
DMVEBT6 FM C20H17Cl2N9O2
DMVEBT6 IC InChI=1S/C20H17Cl2N9O2/c21-12-1-2-13(14(22)9-12)18-16(30-8-7-24-11-30)10-27-20(29-18)26-6-5-25-17-4-3-15(31(32)33)19(23)28-17/h1-4,7-11H,5-6H2,(H3,23,25,28)(H,26,27,29)
DMVEBT6 CS C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2N3C=CN=C3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N
DMVEBT6 IK MDZCSIDIPDZWKL-UHFFFAOYSA-N
DMVEBT6 IU 6-N-[2-[[4-(2,4-dichlorophenyl)-5-imidazol-1-ylpyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine
DMVEBT6 CA CAS 252935-94-7
DMVEBT6 DE Discovery agent
DMFBW1H ID DMFBW1H
DMFBW1H DN CHIR-98023
DMFBW1H HS Investigative
DMFBW1H SN CT-98014
DMFBW1H DT Small molecular drug
DMFBW1H PC 9847557
DMFBW1H MW 471.3
DMFBW1H FM C20H16Cl2N8O2
DMFBW1H IC InChI=1S/C20H16Cl2N8O2/c21-12-1-3-14(16(22)9-12)18-15(19-24-6-7-25-19)11-28-20(29-18)26-8-5-23-17-4-2-13(10-27-17)30(31)32/h1-4,6-7,9-11H,5,8H2,(H,23,27)(H,24,25)(H,26,28,29)
DMFBW1H CS C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2C3=NC=CN3)NCCNC4=NC=C(C=C4)[N+](=O)[O-]
DMFBW1H IK GUMBZKISKUIHJB-UHFFFAOYSA-N
DMFBW1H IU N'-[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl]-N-(5-nitropyridin-2-yl)ethane-1,2-diamine
DMFBW1H CA CAS 252916-76-0
DMFBW1H DE Discovery agent
DMLCZ3D ID DMLCZ3D
DMLCZ3D DN Chk1-A
DMLCZ3D HS Investigative
DMLCZ3D SN Chk1-B; Chk1-C; Chk 1 inhibitor (oral, cancer); Chk 1 inhibitor (oral, cancer), Array
DMLCZ3D CP Array BioPharma Inc
DMLCZ3D DE Solid tumour/cancer
DMNSPFG ID DMNSPFG
DMNSPFG DN Chk2 inhibitor II
DMNSPFG HS Investigative
DMNSPFG SN BML-277; 516480-79-8; Chk2 Inhibitor II; Chk2 Inhibitor II hydrate; CHEMBL179583; 2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide; C20H14ClN3O2; 2-[4-(4-Chlorophenoxy)phenyl]-1h-Benzimidazole-6-Carboxamide; 2-[4-(4-chlorophenoxy)phenyl]-1H-1,3-benzodiazole-6-carboxamide; 2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide hydrate; 2-arylbenzimidazole; 4a9r; MLS006010751; GTPL5954; BML277; SCHEMBL1723139; CTK8E8283; BDBM34064; DTXSID40433479; MolPort-039-139-575; HMS3229E12; ZINC3815901; EX-A1077; BCP09077
DMNSPFG DT Small molecular drug
DMNSPFG PC 9969021
DMNSPFG MW 363.8
DMNSPFG FM C20H14ClN3O2
DMNSPFG IC InChI=1S/C20H14ClN3O2/c21-14-4-8-16(9-5-14)26-15-6-1-12(2-7-15)20-23-17-10-3-13(19(22)25)11-18(17)24-20/h1-11H,(H2,22,25)(H,23,24)
DMNSPFG CS C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)C(=O)N)OC4=CC=C(C=C4)Cl
DMNSPFG IK UXGJAOIJSROTTN-UHFFFAOYSA-N
DMNSPFG IU 2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide
DMNSPFG CA CAS 516480-79-8
DMNSPFG DE Discovery agent
DMCHGF1 ID DMCHGF1
DMCHGF1 DN CHLORANIL
DMCHGF1 HS Investigative
DMCHGF1 SN Chloranil; 118-75-2; p-Chloranil; Tetrachloro-p-benzoquinone; Tetrachloro-1,4-benzoquinone; Tetrachlorobenzoquinone; 2,3,5,6-tetrachlorocyclohexa-2,5-diene-1,4-dione; Spergon; Coversan; Vulklor; Reranil; 2,3,5,6-TETRACHLORO-1,4-BENZOQUINONE; Psorisan; Khloranil; Tetrachloroparabenzoquinone; Spergon technical; Spergon I; Tetrachloroquinone; Chloranile; Quinone tetrachloride; Tetrachloro-p-quinone; Geigy-444E; 2,3,5,6-Tetrachlorobenzo-1,4-quinone; 2,3,5,6-Tetrachloro-p-benzoquinone; Dow Seed Disinfectant No. 5
DMCHGF1 DT Small molecular drug
DMCHGF1 PC 8371
DMCHGF1 MW 245.9
DMCHGF1 FM C6Cl4O2
DMCHGF1 IC InChI=1S/C6Cl4O2/c7-1-2(8)6(12)4(10)3(9)5(1)11
DMCHGF1 CS C1(=C(C(=O)C(=C(C1=O)Cl)Cl)Cl)Cl
DMCHGF1 IK UGNWTBMOAKPKBL-UHFFFAOYSA-N
DMCHGF1 IU 2,3,5,6-tetrachlorocyclohexa-2,5-diene-1,4-dione
DMCHGF1 CA CAS 118-75-2
DMCHGF1 CB CHEBI:36703
DMCHGF1 DE Discovery agent
DMMHU8G ID DMMHU8G
DMMHU8G DN chlordane
DMMHU8G HS Investigative
DMMHU8G SN Chlorindan; chlordan
DMMHU8G DT Small molecular drug
DMMHU8G PC 5993
DMMHU8G MW 409.8
DMMHU8G FM C10H6Cl8
DMMHU8G IC InChI=1S/C10H6Cl8/c11-3-1-2-4(5(3)12)9(16)7(14)6(13)8(2,15)10(9,17)18/h2-5H,1H2
DMMHU8G CS C1C2C(C(C1Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl
DMMHU8G IK BIWJNBZANLAXMG-UHFFFAOYSA-N
DMMHU8G IU 1,3,4,7,8,9,10,10-octachlorotricyclo[5.2.1.02,6]dec-8-ene
DMMHU8G CA CAS 57-74-9
DMMHU8G CB CHEBI:34623
DMMHU8G DE Discovery agent
DM64K0A ID DM64K0A
DM64K0A DN Chlormadinone
DM64K0A HS Investigative
DM64K0A SN Chlormadinon; Chlormadinone; Chlormadinone (INN); Chlormadinone [INN:BAN]; Chlormadinonum; Chlormadinonum [INN-Latin]; Clormadinona; Clormadinona [INN-Spanish]; Clormadinone; Clormadinone [DCIT]; SDS4N642GG; Tox21_112988; 1961-77-9; 6-Chloro-17-hydroxypregna-4,6-diene-3,20-dione; AC1NR4MV; BCP16136; C21H27ClO3; CHEMBL1697830; CTK8F8596; DSSTox_CID_2796; DSSTox_GSID_22796; DSSTox_RID_76731; DTXSID3022796; EINECS 217-802-3; MLS006010797; NCGC00181768-01; Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-; SCHEMBL37291; UNII-SDS4N642GG
DM64K0A PC 5284533
DM64K0A MW 362.9
DM64K0A FM C21H27ClO3
DM64K0A IC VUHJZBBCZGVNDZ-TTYLFXKOSA-N
DM64K0A CS CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)CCC34C)Cl)C)O
DM64K0A IK 1S/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1
DM64K0A IU (8R,9S,10R,13S,14S,17R)-17-acetyl-6-chloro-17-hydroxy-10,13-dimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DM64K0A CA CAS 1961-77-9
DM64K0A DE Discovery agent
DMY40UB ID DMY40UB
DMY40UB DN Chloroben
DMY40UB HS Investigative
DMY40UB SN Chloroden; Cloroben; Benzene, 1,2-dichloro-; Benzene, dichloro-; Benzene, o-dichloro-; Dichlorobenzene, o-; Dichlorobenzene, ortho, liquid; 2-Dichlorobenzene; Dilantin DB; Dilatin DB; Dizene; Dowtherm E; Orthodichlorobenzene; Orthodichlorobenzol; Special termite fluid; Termitkil; o-Dichlor benzol; o-Dichlorbenzene; o-Dichlorbenzol; o-Dichlorobenzene; o-Dichlorobenzol; ortho-Dichlorobenzene; 1,2-DICHLOROBENZENE; 1,2-Dichlorbenzene; 95-50-1; CCRIS 1360; Caswell No. 301; NCI-C54944; NSC 60644; ODCB; UNII-6PJ93I88XL; o-DCB
DMY40UB PC 7239
DMY40UB MW 147
DMY40UB FM C6H4Cl2
DMY40UB IC RFFLAFLAYFXFSW-UHFFFAOYSA-N
DMY40UB CS C1=CC=C(C(=C1)Cl)Cl
DMY40UB IK 1S/C6H4Cl2/c7-5-3-1-2-4-6(5)8/h1-4H
DMY40UB IU 1,2-dichlorobenzene
DMY40UB CA CAS 95-50-1
DMY40UB CB CHEBI:35290
DMY40UB DE Discovery agent
DMLF7MK ID DMLF7MK
DMLF7MK DN chlorobenzylidene malononitrile
DMLF7MK HS Investigative
DMLF7MK SN 2-chlorobenzylidene malononitrile; alonitrile; CS gas (lacrimator)
DMLF7MK DT Small molecular drug
DMLF7MK PC 17604
DMLF7MK MW 188.61
DMLF7MK FM C10H5ClN2
DMLF7MK IC InChI=1S/C10H5ClN2/c11-10-4-2-1-3-9(10)5-8(6-12)7-13/h1-5H
DMLF7MK CS C1=CC=C(C(=C1)C=C(C#N)C#N)Cl
DMLF7MK IK JJNZXLAFIPKXIG-UHFFFAOYSA-N
DMLF7MK IU 2-[(2-chlorophenyl)methylidene]propanedinitrile
DMLF7MK CA CAS 2698-41-1
DMLF7MK DE Discovery agent
DMZA394 ID DMZA394
DMZA394 DN CHLOROCYCLINONE A
DMZA394 HS Investigative
DMZA394 SN CHLOROCYCLINONE A; CHEMBL253120; BDBM50228358; methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
DMZA394 DT Small molecular drug
DMZA394 PC 24762579
DMZA394 MW 454.9
DMZA394 FM C24H19ClO7
DMZA394 IC InChI=1S/C24H19ClO7/c1-5-11-12(24(30)32-4)8-13-16(20(11)27)22(29)17-14(26)7-10-6-9(2)19(25)23(31-3)15(10)18(17)21(13)28/h6-8,26-27H,5H2,1-4H3
DMZA394 CS CCC1=C(C=C2C(=C1O)C(=O)C3=C(C=C4C=C(C(=C(C4=C3C2=O)OC)Cl)C)O)C(=O)OC
DMZA394 IK NFJVYTZFJNVKBA-UHFFFAOYSA-N
DMZA394 IU methyl 2-chloro-9-ethyl-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxobenzo[a]anthracene-10-carboxylate
DMZA394 DE Discovery agent
DMO78QB ID DMO78QB
DMO78QB DN CHLOROCYCLINONE B
DMO78QB HS Investigative
DMO78QB SN CHLOROCYCLINONE B; CHEMBL254814; BDBM50228360; methyl 9-[1-(acetyloxyethyl)]-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
DMO78QB DT Small molecular drug
DMO78QB PC 24762580
DMO78QB MW 512.9
DMO78QB FM C26H21ClO9
DMO78QB IC InChI=1S/C26H21ClO9/c1-9-6-12-7-15(29)19-20(17(12)25(34-4)21(9)27)22(30)13-8-14(26(33)35-5)16(10(2)36-11(3)28)23(31)18(13)24(19)32/h6-8,10,29,31H,1-5H3
DMO78QB CS CC1=CC2=CC(=C3C(=C2C(=C1Cl)OC)C(=O)C4=CC(=C(C(=C4C3=O)O)C(C)OC(=O)C)C(=O)OC)O
DMO78QB IK MFLXCCWOEBQIHW-UHFFFAOYSA-N
DMO78QB IU methyl 9-(1-acetyloxyethyl)-2-chloro-6,8-dihydroxy-1-methoxy-3-methyl-7,12-dioxobenzo[a]anthracene-10-carboxylate
DMO78QB DE Discovery agent
DMX2DQ5 ID DMX2DQ5
DMX2DQ5 DN CHLOROCYCLINONE C
DMX2DQ5 HS Investigative
DMX2DQ5 SN CHLOROCYCLINONE C; CHEMBL254815; BDBM50228359; methyl 2-chloro-6,8-dihydroxy-9-{1-[(hydroxyacetyl)oxy]ethyl}-1-methoxy-3-methyl-7,12-dioxo-7,12-dihydrotetraphene-10-carboxylate
DMX2DQ5 DT Small molecular drug
DMX2DQ5 PC 24180661
DMX2DQ5 MW 528.9
DMX2DQ5 FM C26H21ClO10
DMX2DQ5 IC InChI=1S/C26H21ClO10/c1-9-5-11-6-14(29)19-20(17(11)25(35-3)21(9)27)22(31)12-7-13(26(34)36-4)16(10(2)37-15(30)8-28)23(32)18(12)24(19)33/h5-7,10,28-29,32H,8H2,1-4H3
DMX2DQ5 CS CC1=CC2=CC(=C3C(=C2C(=C1Cl)OC)C(=O)C4=CC(=C(C(=C4C3=O)O)C(C)OC(=O)CO)C(=O)OC)O
DMX2DQ5 IK LMNHPKWXMIGBEL-UHFFFAOYSA-N
DMX2DQ5 IU methyl 2-chloro-6,8-dihydroxy-9-[1-(2-hydroxyacetyl)oxyethyl]-1-methoxy-3-methyl-7,12-dioxobenzo[a]anthracene-10-carboxylate
DMX2DQ5 DE Discovery agent
DMK7VS1 ID DMK7VS1
DMK7VS1 DN CHLOROCYCLINONE D
DMK7VS1 HS Investigative
DMK7VS1 SN CHLOROCYCLINONE D; CHEMBL400132; BDBM50228361
DMK7VS1 DT Small molecular drug
DMK7VS1 PC 24762578
DMK7VS1 MW 438.8
DMK7VS1 FM C23H15ClO7
DMK7VS1 IC InChI=1S/C23H15ClO7/c1-7-4-9-5-12(25)16-17(14(9)22(30-3)18(7)24)19(26)10-6-11-13(8(2)31-23(11)29)20(27)15(10)21(16)28/h4-6,8,25,27H,1-3H3
DMK7VS1 CS CC1C2=C(C3=C(C=C2C(=O)O1)C(=O)C4=C5C(=CC(=C4C3=O)O)C=C(C(=C5OC)Cl)C)O
DMK7VS1 IK RSSUHOCYQSARQQ-UHFFFAOYSA-N
DMK7VS1 IU 16-chloro-4,21-dihydroxy-15-methoxy-6,17-dimethyl-7-oxapentacyclo[11.8.0.03,11.05,9.014,19]henicosa-1(21),3(11),4,9,13,15,17,19-octaene-2,8,12-trione
DMK7VS1 DE Discovery agent
DMQT3WJ ID DMQT3WJ
DMQT3WJ DN CHLORODEOXYURIDINE
DMQT3WJ HS Investigative
DMQT3WJ SN Chlorodeoxyuridine; 5-Chlorodeoxyuridine; 5-Chloro-2'-deoxyuridine; CldU; 50-90-8; BRN 0546807; CHEMBL505732; Uridine, 5-chloro-2'-deoxy-; Uridine,5-chloro-2'-deoxy-; 5-chloro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; 5-Chloro-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2'-Deoxy-5-chlorouridine; 5-Chloro-dUrd; 5-Chloro-2 -deoxyuridine; AC1L23DV; AC1Q77TD; SCHEMBL1469771; CTK4J3337; NJCXGFKPQSFZIB-RRKCRQDMSA-N; MolPort-001-814-149
DMQT3WJ DT Small molecular drug
DMQT3WJ PC 65510
DMQT3WJ MW 262.65
DMQT3WJ FM C9H11ClN2O5
DMQT3WJ IC InChI=1S/C9H11ClN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
DMQT3WJ CS C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Cl)CO)O
DMQT3WJ IK NJCXGFKPQSFZIB-RRKCRQDMSA-N
DMQT3WJ IU 5-chloro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMQT3WJ CA CAS 50-90-8
DMQT3WJ DE Discovery agent
DMGS3FI ID DMGS3FI
DMGS3FI DN CHLORODYSINOSIN A
DMGS3FI HS Investigative
DMGS3FI SN Chlorodysinosin A; CHEMBL568990
DMGS3FI DT Small molecular drug
DMGS3FI PC 16079152
DMGS3FI MW 667.2
DMGS3FI FM C26H43ClN6O10S
DMGS3FI IC InChI=1S/C26H43ClN6O10S/c1-13(2)21(27)22(31-24(37)20(42-3)12-43-44(39,40)41)25(38)33-16-10-19(35)18(34)9-15(16)8-17(33)23(36)30-6-4-14-5-7-32(11-14)26(28)29/h5,13,15-22,34-35H,4,6-12H2,1-3H3,(H6,28,29,30,31,36,37,39,40,41)/t15-,16+,17+,18+,19+,20-,21-,22-/m1/s1
DMGS3FI CS CC(C)[C@H]([C@H](C(=O)N1[C@H]2C[C@@H]([C@H](C[C@H]2C[C@H]1C(=O)NCCC3=CC[N+](=C(N)N)C3)O)O)NC(=O)[C@@H](COS(=O)(=O)[O-])OC)Cl
DMGS3FI IK DLWZHBAKINZMIF-WNZJUFNWSA-N
DMGS3FI IU [(2R)-3-[[(2S,3R)-1-[(2S,3aR,5S,6S,7aS)-2-[2-[1-(diaminomethylidene)-2,5-dihydropyrrol-1-ium-3-yl]ethylcarbamoyl]-5,6-dihydroxy-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-3-chloro-4-methyl-1-oxopentan-2-yl]amino]-2-methoxy-3-oxopropyl] sulfate
DMGS3FI DE Discovery agent
DMKZIES ID DMKZIES
DMKZIES DN Chloroethylclonidine
DMKZIES HS Investigative
DMKZIES SN Chloroethylclonidine; Chlorethylclonidine; UNII-3X825O680H; N-(2,6-Dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine; 3X825O680H; 98086-36-3; 1h-imidazol-2-amine, n-[2,6-dichloro-4-[[(2-chloroethyl)methylamino]methyl]phenyl]-4,5-dihydro-; 1H-Imidazol-2-amine, N-(2,6-dichloro-4-(((2-chloroethyl)methylamino)methyl)phenyl)-4,5-dihydro-; Lopac-B-003; AC1Q3UQS; AC1L2XTB; Lopac0_000195; C11H12Cl3N3; SCHEMBL4107963; CHEMBL326967; SCHEMBL18154646; CTK3I7576; PDSP2_000070; ZINC27089957
DMKZIES DT Small molecular drug
DMKZIES PC 104973
DMKZIES MW 335.7
DMKZIES FM C13H17Cl3N4
DMKZIES IC InChI=1S/C13H17Cl3N4/c1-20(5-2-14)8-9-6-10(15)12(11(16)7-9)19-13-17-3-4-18-13/h6-7H,2-5,8H2,1H3,(H2,17,18,19)
DMKZIES CS CN(CCCl)CC1=CC(=C(C(=C1)Cl)NC2=NCCN2)Cl
DMKZIES IK XFDVJGKSQRUEEM-UHFFFAOYSA-N
DMKZIES IU N-[2,6-dichloro-4-[[2-chloroethyl(methyl)amino]methyl]phenyl]-4,5-dihydro-1H-imidazol-2-amine
DMKZIES CA CAS 77472-95-8
DMKZIES DE Discovery agent
DM2Y3P4 ID DM2Y3P4
DM2Y3P4 DN Chlorogenic acid
DM2Y3P4 HS Investigative
DM2Y3P4 SN CHLOROGENIC ACID; 327-97-9; 3-Caffeoylquinic acid; 3-O-Caffeoylquinic acid; 3-(3,4-Dihydroxycinnamoyl)quinic acid; Chlorogenate; Heriguard; Hlorogenic acid; Caffeoyl quinic acid; NSC-407296; 3-Caffeoylquinate; UNII-318ADP12RI; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; CCRIS 1400; Chlorogenic acid (8CI); EINECS 206-325-6; NSC 70861; NSC 407296; 3-trans-Caffeoylquinic acid; CHEMBL284616; 318ADP12RI; CHEBI:16112; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); 3-(3,4-Dihydroxycinnamoyl)quinate
DM2Y3P4 DT Small molecular drug
DM2Y3P4 PC 1794427
DM2Y3P4 MW 354.31
DM2Y3P4 FM C16H18O9
DM2Y3P4 IC InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1
DM2Y3P4 CS C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
DM2Y3P4 IK CWVRJTMFETXNAD-JUHZACGLSA-N
DM2Y3P4 IU (1S,3R,4R,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid
DM2Y3P4 CA CAS 202650-88-2
DM2Y3P4 CB CHEBI:16112
DM2Y3P4 DE Discovery agent
DMOA8L2 ID DMOA8L2
DMOA8L2 DN Chlorophenylpiperazine
DMOA8L2 HS Investigative
DMOA8L2 PC 22015046
DMOA8L2 MW 196.67
DMOA8L2 FM C10H13ClN2
DMOA8L2 IC InChI=1S/C10H13ClN2/c11-10-8-12-6-7-13(10)9-4-2-1-3-5-9/h1-5,10,12H,6-8H2
DMOA8L2 CS C1CN(C(CN1)Cl)C2=CC=CC=C2
DMOA8L2 IK JQQKTEXFNXKDIQ-UHFFFAOYSA-N
DMOA8L2 IU 2-chloro-1-phenylpiperazine
DMOA8L2 DE Discovery agent
DMSGBQA ID DMSGBQA
DMSGBQA DN chloropicrin
DMSGBQA HS Investigative
DMSGBQA SN trichloronitromethane; nitrotrichloromethane
DMSGBQA DT Small molecular drug
DMSGBQA PC 6423
DMSGBQA MW 164.37
DMSGBQA FM CCl3NO2
DMSGBQA IC InChI=1S/CCl3NO2/c2-1(3,4)5(6)7
DMSGBQA CS C([N+](=O)[O-])(Cl)(Cl)Cl
DMSGBQA IK LFHISGNCFUNFFM-UHFFFAOYSA-N
DMSGBQA IU trichloro(nitro)methane
DMSGBQA CA CAS 76-06-2
DMSGBQA CB CHEBI:39285
DMSGBQA DE Discovery agent
DM8B0VZ ID DM8B0VZ
DM8B0VZ DN CHLOROPUUPEHENONE
DM8B0VZ HS Investigative
DM8B0VZ SN Chloropuupehenone; (+)-Chloropuupehenone
DM8B0VZ DT Small molecular drug
DM8B0VZ PC 9998777
DM8B0VZ MW 362.9
DM8B0VZ FM C21H27ClO3
DM8B0VZ IC InChI=1S/C21H27ClO3/c1-19(2)7-5-8-20(3)15(19)6-9-21(4)16(20)10-12-14(25-21)11-13(23)18(24)17(12)22/h10-11,15-16,24H,5-9H2,1-4H3/t15-,16+,20-,21-/m0/s1
DM8B0VZ CS C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2C=C4C(=CC(=O)C(=C4Cl)O)O3)C)(C)C
DM8B0VZ IK IVURSJNKOFPQMR-GQSCTRQFSA-N
DM8B0VZ IU (4aS,6aS,12aR,12bS)-11-chloro-10-hydroxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one
DM8B0VZ DE Discovery agent
DMM75WZ ID DMM75WZ
DMM75WZ DN Chloroxylenol
DMM75WZ HS Investigative
DMM75WZ SN Benzytol; Chloro-xylenol; Chloroxylenolum; Chlorxylenolum; Clorossilenolo; Cloroxilenol; Desson; Dettol; Dettol, liquid antiseptic; Espadol; Husept Extra; Nipacide MX; Ottasept; Ottasept Extra; Parametaxylenol; Phenol, 4-chloro-3,5-dimethyl-; RBA 777; Septiderm-Hydrochloride; Willenol V; chloroxylenol; p-Chloro-3,5-xylenol; p-Chloro-m-xylenol; parachlorometaxylenol; 2-Chloro-5-hydroxy-m-xylene; 2-Chloro-m-xylenol; 3,5-Dimethyl-4-chlorophenol; 4-Chloro-3,5-dimethylphenol; 4-Chloro-3,5-xylenol; 4-Chloro-m-xylenol; 88-04-0; PCMX
DMM75WZ PC 2723
DMM75WZ MW 156.61
DMM75WZ FM C8H9ClO
DMM75WZ IC OSDLLIBGSJNGJE-UHFFFAOYSA-N
DMM75WZ CS CC1=CC(=CC(=C1Cl)C)O
DMM75WZ IK 1S/C8H9ClO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,1-2H3
DMM75WZ IU 4-chloro-3,5-dimethylphenol
DMM75WZ CA CAS 88-04-0
DMM75WZ CB CHEBI:34393
DMM75WZ DE Pseudomonas infection
DMGBT68 ID DMGBT68
DMGBT68 DN Chlorphrifos oxon
DMGBT68 HS Investigative
DMGBT68 SN Diethyl 3,5,6-trichloropyridin-2-yl phosphate
DMGBT68 DT Small molecular drug
DMGBT68 PC 21804
DMGBT68 MW 334.5
DMGBT68 FM C9H11Cl3NO4P
DMGBT68 IC InChI=1S/C9H11Cl3NO4P/c1-3-15-18(14,16-4-2)17-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3
DMGBT68 CS CCOP(=O)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl
DMGBT68 IK OTMOUPHCTWPNSL-UHFFFAOYSA-N
DMGBT68 IU diethyl (3,5,6-trichloropyridin-2-yl) phosphate
DMGBT68 CA CAS 5598-15-2
DMGBT68 DE Discovery agent
DMKPUI6 ID DMKPUI6
DMKPUI6 DN Chlorpyrifos
DMKPUI6 HS Investigative
DMKPUI6 SN chlorpyrifos; 2921-88-2; Chlorpyriphos; Dursban; Trichlorpyrphos; Lorsban; Chlorpyrifos-ethyl; Pyrinex; Coroban; Brodan; Killmaster; Piridane; Danusban; Spannit; Lentrek; Geodinfos; Tafaban; Stipend; Bonidel; Zidil; Terial; Durmet; Equity; Suscon green; Suscon blue; suSCon; Dursban R; Dursban F; Lock-On; Dursban 4E; Dowco 179; Chlorpyriphos-ethyl; Ethyl chlorpyriphos; Dursban 10CR; Chlorpyrifos (Dursban); Detmol U.A.; Phosphorothioic acid, O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester; Chloropyrifos; Clorpyrifos; Dhanusban; Grofo; Detmol ua
DMKPUI6 DT Small molecular drug
DMKPUI6 PC 2730
DMKPUI6 MW 350.6
DMKPUI6 FM C9H11Cl3NO3PS
DMKPUI6 IC InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3
DMKPUI6 CS CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl
DMKPUI6 IK SBPBAQFWLVIOKP-UHFFFAOYSA-N
DMKPUI6 IU diethoxy-sulfanylidene-(3,5,6-trichloropyridin-2-yl)oxy-lambda5-phosphane
DMKPUI6 CA CAS 2921-88-2
DMKPUI6 CB CHEBI:34631
DMKPUI6 DE Discovery agent
DMZHO3S ID DMZHO3S
DMZHO3S DN CHO793076
DMZHO3S HS Investigative
DMZHO3S SN CHEMBL493342; CHO793076; SCHEMBL1455615; NPAAFPODGAKMTC-SANMLTNESA-N; BDBM50257522
DMZHO3S DT Small molecular drug
DMZHO3S PC 9981577
DMZHO3S MW 458.5
DMZHO3S FM C26H26N4O4
DMZHO3S IC InChI=1S/C26H26N4O4/c1-3-5-6-10-29-14-27-18-8-7-9-19-21(18)23(29)15-12-30-20(22(15)28-19)11-17-16(24(30)31)13-34-25(32)26(17,33)4-2/h7-9,11,14,33H,3-6,10,12-13H2,1-2H3/t26-/m0/s1
DMZHO3S CS CCCCCN1C=NC2=CC=CC3=C2C1=C4CN5C(=CC6=C(C5=O)COC(=O)[C@@]6(CC)O)C4=N3
DMZHO3S IK NPAAFPODGAKMTC-SANMLTNESA-N
DMZHO3S IU (10S)-10-ethyl-10-hydroxy-23-pentyl-8-oxa-4,15,21,23-tetrazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16(24),17,19,21-octaene-5,9-dione
DMZHO3S DE Discovery agent
DMVJMG8 ID DMVJMG8
DMVJMG8 DN Cholecystokinin-9
DMVJMG8 HS Investigative
DMVJMG8 SN Cholecystokinin-9; CHEMBL414345; Cholecystokinin 9; AC1L4TL1; CCK-9; BDBM50154437; 108050-84-6; Caerulein, 1-de(5-oxo-L-proline)-2-L-arginine-5-L-methionine-
DMVJMG8 PC 163781
DMVJMG8 MW 1299.5
DMVJMG8 FM C55H74N14O17S3
DMVJMG8 IC InChI=1S/C55H74N14O17S3/c1-87-21-18-37(64-51(79)40(24-31-14-16-33(17-15-31)86-89(83,84)85)68-54(82)42(26-45(71)72)67-48(76)35(56)12-8-20-60-55(58)59)49(77)62-29-44(70)63-41(25-32-28-61-36-13-7-6-11-34(32)36)52(80)65-38(19-22-88-2)50(78)69-43(27-46(73)74)53(81)66-39(47(57)75)23-30-9-4-3-5-10-30/h3-7,9-11,13-17,28,35,37-43,61H,8,12,18-27,29,56H2,1-2H3,(H2,57,75)(H,62,77)(H,63,70)(H,64,79)(H,65,80)(H,66,81)(H,67,76)(H,68,82)(H,69,78)(H,71,72)(H,73,74)(H4,58,59,60)(H,83,84,85)/t35-,37-,38-,39-,40-,41-,42-,43-/m0/s1
DMVJMG8 CS CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N
DMVJMG8 IK AOVFOMQIRNOPOR-LVHVEONVSA-N
DMVJMG8 IU (3S)-3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic acid
DMVJMG8 CA CAS 108050-84-6
DMVJMG8 DE Discovery agent
DMKM3WJ ID DMKM3WJ
DMKM3WJ DN cholesten
DMKM3WJ HS Investigative
DMKM3WJ SN cholestane; cholestan; alpha-cholestane
DMKM3WJ DT Small molecular drug
DMKM3WJ PC 6857534
DMKM3WJ MW 372.7
DMKM3WJ FM C27H48
DMKM3WJ IC InChI=1S/C27H48/c1-19(2)9-8-10-20(3)23-14-15-24-22-13-12-21-11-6-7-17-26(21,4)25(22)16-18-27(23,24)5/h19-25H,6-18H2,1-5H3/t20-,21?,22+,23-,24+,25+,26+,27-/m1/s1
DMKM3WJ CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CCCC4)C)C
DMKM3WJ IK XIIAYQZJNBULGD-LDHZKLTISA-N
DMKM3WJ IU (8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene
DMKM3WJ CA CAS 14982-53-7
DMKM3WJ CB CHEBI:35516
DMKM3WJ DE Discovery agent
DMR3J6S ID DMR3J6S
DMR3J6S DN Cholesterol
DMR3J6S HS Investigative
DMR3J6S SN cholesterol; 57-88-5; Cholesterin; Cholest-5-en-3beta-ol; Cholesteryl alcohol; Cholestrin; Dusoran; Cordulan; Dusoline; Cholesterine; Hydrocerin; Cholestrol; Kathro; Dythol; Lanol; Super hartolan; Provitamin D; Cholesterol base H; Lidinite; Nimco cholesterol base H; Lidinit; Wool alcohols B. P.; (-)-Cholesterol; Tegolan (VAN); Cholest-5-en-3-beta-ol; 5:6-Cholesten-3beta-ol; Tegolan; 3beta-Hydroxycholest-5-ene; 5-Cholesten-3beta-ol; Cholest-5-en-3-ol (3beta)-; 3-beta-Hydroxycholest-5-ene; (3beta)-cholest-5-en-3-ol; CCRIS 2834; Dastar; HSDB 7
DMR3J6S DT Small molecular drug
DMR3J6S PC 5997
DMR3J6S MW 386.7
DMR3J6S FM C27H46O
DMR3J6S IC InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMR3J6S CS C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMR3J6S IK HVYWMOMLDIMFJA-DPAQBDIFSA-N
DMR3J6S IU (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMR3J6S CA CAS 57-88-5
DMR3J6S CB CHEBI:16113
DMR3J6S DE Discovery agent
DM5D9YK ID DM5D9YK
DM5D9YK DN Choline
DM5D9YK HS Investigative
DM5D9YK SN choline; Choline ion; Bilineurine; Choline cation; Cholinum; 2-Hydroxy-N,N,N-trimethylethanaminium; 62-49-7; (2-Hydroxyethyl)trimethylammonium; trimethylethanolamine; N-trimethylethanolamine; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-; CCRIS 5847; UNII-N91BDP6H0X; AI3-24208; BRN 1736748; N,N,N-trimethylethanol-ammonium; CHEBI:15354; (beta-hydroxyethyl)trimethylammonium; EINECS 200-535-1; CHEMBL920; N91BDP6H0X; 2-hydroxyethyl(trimethyl)ammonium
DM5D9YK DT Small molecular drug
DM5D9YK PC 305
DM5D9YK MW 104.17
DM5D9YK FM C5H14NO+
DM5D9YK IC InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1
DM5D9YK CS C[N+](C)(C)CCO
DM5D9YK IK OEYIOHPDSNJKLS-UHFFFAOYSA-N
DM5D9YK IU 2-hydroxyethyl(trimethyl)azanium
DM5D9YK CA CAS 62-49-7
DM5D9YK CB CHEBI:15354
DM5D9YK DE Discovery agent
DMW6U7K ID DMW6U7K
DMW6U7K DN CHOLINE IODIDE
DMW6U7K HS Investigative
DMW6U7K SN Choline iodide; 17773-10-3; 2-Hydroxy-N,N,N-trimethylethanaminium iodide; Jodoetano; Dilatol zambon; UNII-39528O55VK; EINECS 241-754-2; (2-Hydroxyethyl)trimethylammonium Iodide; AI3-61505; CHEMBL293410; Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, iodide; 39528O55VK; CholineIodide; AC1L3DCR; AC1Q1TNR; ACMC-209ed9; SCHEMBL315876; CTK4D6569; ANW-22891; MFCD00011900; AKOS027320917; 2-hydroxyethyl(trimethyl)azanium iodide; ACM17773103; KS-0000140P; LS-53247; KB-76072; TC-111636; FT-0623771; C-45721; Ethanaminium,2-hydroxy-N,N,N-trimethyl-, io
DMW6U7K DT Small molecular drug
DMW6U7K PC 87300
DMW6U7K MW 231.08
DMW6U7K FM C5H14INO
DMW6U7K IC InChI=1S/C5H14NO.HI/c1-6(2,3)4-5-7;/h7H,4-5H2,1-3H3;1H/q+1;/p-1
DMW6U7K CS C[N+](C)(C)CCO.[I-]
DMW6U7K IK FNPBHXSBDADRBT-UHFFFAOYSA-M
DMW6U7K IU 2-hydroxyethyl(trimethyl)azanium;iodide
DMW6U7K CA CAS 17773-10-3
DMW6U7K DE Discovery agent
DMVBQ20 ID DMVBQ20
DMVBQ20 DN Cholini alfosceras
DMVBQ20 HS Investigative
DMVBQ20 SN Alfoscerate de choline; Alfoscerato de colina; Choline Alfoscerate; Choline Alphoscerate; Choline glycerophosphate; Glycerophosphorylcholine; Cholini glycerophosphas; Glicerofosfato de colina; Glycerol phosphorylcholine; Glycerophosphate de choline; Glycerophosphocholine; L-alpha-Glycerophosphocholine; L-alpha-Glycerophosphorylcholine; L-alpha-Glycerylphosphorylcholine; SN-glycero-3-phosphocholine; Sn-3-GPC; alpha-Glycerophosphorylcholine; glycerol-3-phosphocholine; 28319-77-9; GPCho; UNII-60M22SGW66
DMVBQ20 PC 657272
DMVBQ20 MW 257.22
DMVBQ20 FM C8H20NO6P
DMVBQ20 IC SUHOQUVVVLNYQR-MRVPVSSYSA-N
DMVBQ20 CS C[N+](C)(C)CCOP(=O)([O-])OCC(CO)O
DMVBQ20 IK 1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1
DMVBQ20 IU [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMVBQ20 CA CAS 28319-77-9
DMVBQ20 CB CHEBI:16870
DMVBQ20 DE Discovery agent
DMZ956E ID DMZ956E
DMZ956E DN CHPG
DMZ956E HS Investigative
DMZ956E SN 2-chloro-5-hydroxyphenylglycine
DMZ956E DT Small molecular drug
DMZ956E PC 3645780
DMZ956E MW 201.61
DMZ956E FM C8H8ClNO3
DMZ956E IC InChI=1S/C8H8ClNO3/c9-6-2-1-4(11)3-5(6)7(10)8(12)13/h1-3,7,11H,10H2,(H,12,13)
DMZ956E CS C1=CC(=C(C=C1O)C(C(=O)O)N)Cl
DMZ956E IK UNIDAFCQFPGYJJ-UHFFFAOYSA-N
DMZ956E IU 2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid
DMZ956E CA CAS 170846-74-9
DMZ956E DE Discovery agent
DMXKU73 ID DMXKU73
DMXKU73 DN CHR-4125
DMXKU73 HS Investigative
DMXKU73 SN CHR-4146; CHR-5010; PLK-1 inhibitors (cancer), Chroma Therapeutics; Polo-like kinase-1 inhibitors (cancer); Polo-likekinase-1 inhibitors (cancer), Chroma Therapeutics
DMXKU73 CP Chroma Therapeutics Ltd
DMXKU73 DE Solid tumour/cancer
DMVDB7S ID DMVDB7S
DMVDB7S DN chroman 28
DMVDB7S HS Investigative
DMVDB7S SN CHEMBL415848; chroman 28; GTPL664; SCHEMBL4136892; BDBM50203200; (R)-3-(naphthalene-7-sulfonamido)-3-phenyl-N-((R)-7-(piperidin-1-ylmethyl)-3,4-dihydro-2H-chromen-4-yl)propanamide; (3R)-3-(naphthalen-2-ylsulfonylamino)-3-phenyl-N-[(4R)-7-(piperidin-1-ylmethyl)chroman-4-yl]propanamide
DMVDB7S DT Small molecular drug
DMVDB7S PC 16108961
DMVDB7S MW 583.7
DMVDB7S FM C34H37N3O4S
DMVDB7S IC InChI=1S/C34H37N3O4S/c38-34(35-31-17-20-41-33-21-25(13-16-30(31)33)24-37-18-7-2-8-19-37)23-32(27-10-3-1-4-11-27)36-42(39,40)29-15-14-26-9-5-6-12-28(26)22-29/h1,3-6,9-16,21-22,31-32,36H,2,7-8,17-20,23-24H2,(H,35,38)/t31-,32-/m1/s1
DMVDB7S CS C1CCN(CC1)CC2=CC3=C(C=C2)[C@@H](CCO3)NC(=O)C[C@H](C4=CC=CC=C4)NS(=O)(=O)C5=CC6=CC=CC=C6C=C5
DMVDB7S IK IQPWKAIEQBOLPJ-ROJLCIKYSA-N
DMVDB7S IU (3R)-3-(naphthalen-2-ylsulfonylamino)-3-phenyl-N-[(4R)-7-(piperidin-1-ylmethyl)-3,4-dihydro-2H-chromen-4-yl]propanamide
DMVDB7S DE Discovery agent
DM5JHUN ID DM5JHUN
DM5JHUN DN CHROMOTROPATE
DM5JHUN HS Investigative
DM5JHUN SN 129-96-4; Chromotropic acid disodium salt; Sodium chromotropate; 2,7-Naphthalenedisulfonic acid, 4,5-dihydroxy-, disodium salt; Disodium chromotropate; Sodium 4,5-dihydroxynaphthalene-2,7-disulfonate; disodium 4,5-dihydroxynaphthalene-2,7-disulfonate; Disodium 4,5-dihydroxynaphthalene-2,7-disulphonate; Mordant Brown 7; Chromotropic acid sodium salt; 3888-44-6; 2,7-Naphthalenedisulfonic acid, 4,5-dihydroxy-, sodium salt (1:2); CHEMBL425511; 148-25-4 (Parent); CHROMOTROPATE; mordantbrown; Chromogen C; NSC 4883; EINECS 204-972-
DM5JHUN DT Small molecular drug
DM5JHUN PC 67220
DM5JHUN MW 364.3
DM5JHUN FM C10H6Na2O8S2
DM5JHUN IC InChI=1S/C10H8O8S2.2Na/c11-8-3-6(19(13,14)15)1-5-2-7(20(16,17)18)4-9(12)10(5)8;;/h1-4,11-12H,(H,13,14,15)(H,16,17,18);;/q;2*+1/p-2
DM5JHUN CS C1=C2C=C(C=C(C2=C(C=C1S(=O)(=O)[O-])O)O)S(=O)(=O)[O-].[Na+].[Na+]
DM5JHUN IK AFGPCIMUGMJQPD-UHFFFAOYSA-L
DM5JHUN IU disodium;4,5-dihydroxynaphthalene-2,7-disulfonate
DM5JHUN CA CAS 129-96-4
DM5JHUN DE Discovery agent
DMLEXN0 ID DMLEXN0
DMLEXN0 DN Chrysamine -G
DMLEXN0 HS Investigative
DMLEXN0 DT Small molecular drug
DMLEXN0 PC 160843
DMLEXN0 MW 482.4
DMLEXN0 FM C26H18N4O6
DMLEXN0 IC InChI=1S/C26H18N4O6/c31-23-11-9-19(13-21(23)25(33)34)29-27-17-5-1-15(2-6-17)16-3-7-18(8-4-16)28-30-20-10-12-24(32)22(14-20)26(35)36/h1-14,31-32H,(H,33,34)(H,35,36)
DMLEXN0 CS C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O)N=NC4=CC(=C(C=C4)O)C(=O)O
DMLEXN0 IK XFFSCOOTVXBLCK-UHFFFAOYSA-N
DMLEXN0 IU 5-[[4-[4-[(3-carboxy-4-hydroxyphenyl)diazenyl]phenyl]phenyl]diazenyl]-2-hydroxybenzoic acid
DMLEXN0 DE Discovery agent
DM7V2LG ID DM7V2LG
DM7V2LG DN Chrysin
DM7V2LG HS Investigative
DM7V2LG SN chrysin; 480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0
DM7V2LG DT Small molecular drug
DM7V2LG PC 5281607
DM7V2LG MW 254.24
DM7V2LG FM C15H10O4
DM7V2LG IC InChI=1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H
DM7V2LG CS C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O
DM7V2LG IK RTIXKCRFFJGDFG-UHFFFAOYSA-N
DM7V2LG IU 5,7-dihydroxy-2-phenylchromen-4-one
DM7V2LG CA CAS 480-40-0
DM7V2LG CB CHEBI:75095
DM7V2LG DE Discovery agent
DM96ECL ID DM96ECL
DM96ECL DN CHRYSOERIOL
DM96ECL HS Investigative
DM96ECL SN Chrysoeriol; 491-71-4; Chryseriol; Luteolin 3'-methyl ether; 3'-O-Methylluteolin; 3'-O-Methyluteolin; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; UNII-Q813145M20; EINECS 207-742-6; BRN 0295004; CHEMBL214321; CHEBI:16514
DM96ECL DT Small molecular drug
DM96ECL PC 5280666
DM96ECL MW 300.26
DM96ECL FM C16H12O6
DM96ECL IC InChI=1S/C16H12O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-7,17-19H,1H3
DM96ECL CS COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DM96ECL IK SCZVLDHREVKTSH-UHFFFAOYSA-N
DM96ECL IU 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
DM96ECL CA CAS 491-71-4
DM96ECL CB CHEBI:16514
DM96ECL DE Discovery agent
DMT27QD ID DMT27QD
DMT27QD DN CHYMOSTATIN
DMT27QD HS Investigative
DMT27QD SN Chymostatin; CHEMBL247767; AC1L9E22; MRXDGVXSWIXTQL-HYHFHBMOSA-N; C11308; 9076-44-2; SCHEMBL8259564; BDBM87059; CHEBI:510447; C31H41N7O6; BDBM222139; LS-187745; X6871; FT-0623815; (2S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-benzyl-2-oxo-ethyl]carbamoyl]-3-methyl-butyl]amino]-1-(2-iminohexahydropyrimidin-4-yl)-2-oxo-ethyl]carbamoylamino]-3-phenyl-propanoic acid
DMT27QD DT Small molecular drug
DMT27QD PC 443119
DMT27QD MW 607.7
DMT27QD FM C31H41N7O6
DMT27QD IC InChI=1S/C31H41N7O6/c1-19(2)15-24(27(40)34-22(18-39)16-20-9-5-3-6-10-20)35-28(41)26(23-13-14-33-30(32)36-23)38-31(44)37-25(29(42)43)17-21-11-7-4-8-12-21/h3-12,18-19,22-26H,13-17H2,1-2H3,(H,34,40)(H,35,41)(H,42,43)(H3,32,33,36)(H2,37,38,44)/t22-,23?,24-,25-,26-/m0/s1
DMT27QD CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](C2CCN=C(N2)N)NC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O
DMT27QD IK MRXDGVXSWIXTQL-HYHFHBMOSA-N
DMT27QD IU (2S)-2-[[(1S)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid
DMT27QD CA CAS 9076-44-2
DMT27QD CB CHEBI:510447
DMT27QD DE Discovery agent
DMQ5CE1 ID DMQ5CE1
DMQ5CE1 DN CI-1015
DMQ5CE1 HS Investigative
DMQ5CE1 SN CI 1015; PD 144598; CI1015
DMQ5CE1 DT Small molecular drug
DMQ5CE1 PC 3074331
DMQ5CE1 MW 493.6
DMQ5CE1 FM C29H39N3O4
DMQ5CE1 IC InChI=1S/C29H39N3O4/c1-28(26(34)31-24-8-4-5-9-25(24)33,16-21-17-30-23-7-3-2-6-22(21)23)32-27(35)36-29-13-18-10-19(14-29)12-20(11-18)15-29/h2-3,6-7,17-20,24-25,30,33H,4-5,8-16H2,1H3,(H,31,34)(H,32,35)/t18?,19?,20?,24-,25-,28+,29?/m0/s1
DMQ5CE1 CS C[C@@](CC1=CNC2=CC=CC=C21)(C(=O)N[C@H]3CCCC[C@@H]3O)NC(=O)OC45CC6CC(C4)CC(C6)C5
DMQ5CE1 IK UOFRODPUIMDZTB-HDCXSGMISA-N
DMQ5CE1 IU 1-adamantyl N-[(2R)-1-[[(1S,2S)-2-hydroxycyclohexyl]amino]-3-(1H-indol-3-yl)-2-methyl-1-oxopropan-2-yl]carbamate
DMQ5CE1 DE Discovery agent
DMTKVDZ ID DMTKVDZ
DMTKVDZ DN CI-1031
DMTKVDZ HS Investigative
DMTKVDZ DT Small molecular drug
DMTKVDZ PC 4322
DMTKVDZ MW 526.5
DMTKVDZ FM C25H24F2N6O5
DMTKVDZ IC InChI=1S/C25H24F2N6O5/c1-32-9-8-30-23(32)14-4-3-5-15(10-14)37-24-19(26)21(33(2)12-18(35)36)20(27)25(31-24)38-17-11-13(22(28)29)6-7-16(17)34/h3-7,10-11,34H,8-9,12H2,1-2H3,(H3,28,29)(H,35,36)
DMTKVDZ CS CN1CCN=C1C2=CC(=CC=C2)OC3=NC(=C(C(=C3F)N(C)CC(=O)O)F)OC4=C(C=CC(=C4)C(=N)N)O
DMTKVDZ IK NPNSVNGQJGRSNR-UHFFFAOYSA-N
DMTKVDZ IU 2-[[2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyridin-4-yl]-methylamino]acetic acid
DMTKVDZ CA CAS 183305-24-0
DMTKVDZ DE Discovery agent
DMF3DZX ID DMF3DZX
DMF3DZX DN CI-1040
DMF3DZX HS Investigative
DMF3DZX DT Small molecular drug
DMF3DZX PC 6918454
DMF3DZX MW 478.7
DMF3DZX FM C17H14ClF2IN2O2
DMF3DZX IC InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)
DMF3DZX CS C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl
DMF3DZX IK GFMMXOIFOQCCGU-UHFFFAOYSA-N
DMF3DZX IU 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
DMF3DZX CA CAS 212631-79-3
DMF3DZX CB CHEBI:91353
DMF3DZX DE Discovery agent
DMG5D6B ID DMG5D6B
DMG5D6B DN CI-1044
DMG5D6B HS Investigative
DMG5D6B SN CI-1044; UNII-O4T475XIIY; O4T475XIIY; 197894-84-1; DSSTox_CID_27291; DSSTox_RID_82245; DSSTox_GSID_47291; CAS-NOCAS_47291; SCHEMBL6441242; CHEMBL342285; DTXSID5047291; NOCAS_47291; Tox21_300455; NCGC00254387-01; NCGC00248057-01; PD-189659; HY-100246; CS-0018397; (+)-CI-1044; 3-Pyridinecarboxamide, N-((3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-; 3-Pyridinecarboxamide, N-(9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-
DMG5D6B DT Small molecular drug
DMG5D6B PC 9843744
DMG5D6B MW 397.4
DMG5D6B FM C23H19N5O2
DMG5D6B IC InChI=1S/C23H19N5O2/c24-17-11-15-8-10-28-20(15)18(12-17)19(14-5-2-1-3-6-14)26-21(23(28)30)27-22(29)16-7-4-9-25-13-16/h1-7,9,11-13,21H,8,10,24H2,(H,27,29)/t21-/m0/s1
DMG5D6B CS C1CN2C(=O)[C@@H](N=C(C3=CC(=CC1=C32)N)C4=CC=CC=C4)NC(=O)C5=CN=CC=C5
DMG5D6B IK XGXOSJSGDNPEEF-NRFANRHFSA-N
DMG5D6B IU N-[(11R)-6-amino-12-oxo-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-11-yl]pyridine-3-carboxamide
DMG5D6B CA CAS 197894-84-1
DMG5D6B DE Discovery agent
DM0RH3S ID DM0RH3S
DM0RH3S DN CI-218872
DM0RH3S HS Investigative
DM0RH3S SN 66548-69-4; CL 218872; CL 218,872; 3-methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; CHEMBL13662; CL-218872; CI-218872; 3-Methyl-6-(3-(trifluoromethyl)phenyl)-1,2,4-triazolo(4,2-b)pyridazine; 1,2,4-Triazolo(4,3-b)pyridazine, 3-methyl-6-(3-(trifluoromethyl)phenyl)-; 3-Methyl-6-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-b]pyridazine; 3-Methyl-6-[-3-(trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine; 3-Methyl-6-[3-(trifluoromethyl)phenyl]-1,2,4-triazolo-(4,3-b)pyridazine
DM0RH3S DT Small molecular drug
DM0RH3S PC 107950
DM0RH3S MW 278.23
DM0RH3S FM C13H9F3N4
DM0RH3S IC InChI=1S/C13H9F3N4/c1-8-17-18-12-6-5-11(19-20(8)12)9-3-2-4-10(7-9)13(14,15)16/h2-7H,1H3
DM0RH3S CS CC1=NN=C2N1N=C(C=C2)C3=CC(=CC=C3)C(F)(F)F
DM0RH3S IK GUOQUXNJZHGPQF-UHFFFAOYSA-N
DM0RH3S IU 3-methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine
DM0RH3S CA CAS 66548-69-4
DM0RH3S CB CHEBI:92018
DM0RH3S DE Discovery agent
DMWE1N8 ID DMWE1N8
DMWE1N8 DN Cibacron blue
DMWE1N8 HS Investigative
DMWE1N8 SN Affi gel blue; Cibacron Blue F 3GA; Cibacron Blue 3G; Cibacronblau F3G-A; Procion Blue H-B; C.I. Reactive Blue 2; UNII-J0A052J6QF; Basilen Blue; CHEBI:34946; EINECS 235-465-0; NSC 328383; J0A052J6QF; C.I. 61211; 26763-68-8; 2-Anthracenesulfonic acid, 1-amino-4-((4-((4-chloro-6-((3(or 4)-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-; Affi-gel blue
DMWE1N8 DT Small molecular drug
DMWE1N8 PC 172469
DMWE1N8 MW 774.2
DMWE1N8 FM C29H20ClN7O11S3
DMWE1N8 IC InChI=1S/C29H20ClN7O11S3/c30-27-35-28(33-16-7-3-4-8-19(16)49(40,41)42)37-29(36-27)34-17-10-9-13(11-20(17)50(43,44)45)32-18-12-21(51(46,47)48)24(31)23-22(18)25(38)14-5-1-2-6-15(14)26(23)39/h1-12,32H,31H2,(H,40,41,42)(H,43,44,45)(H,46,47,48)(H2,33,34,35,36,37)
DMWE1N8 CS C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC(=C(C=C4)NC5=NC(=NC(=N5)NC6=CC=CC=C6S(=O)(=O)O)Cl)S(=O)(=O)O)S(=O)(=O)O)N
DMWE1N8 IK YKCWQPZFAFZLBI-UHFFFAOYSA-N
DMWE1N8 IU 1-amino-4-[4-[[4-chloro-6-(2-sulfoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid
DMWE1N8 CA CAS 84166-13-2
DMWE1N8 DE Discovery agent
DM7ZJ4H ID DM7ZJ4H
DM7ZJ4H DN cicaprost
DM7ZJ4H HS Investigative
DM7ZJ4H SN ZK 96480; ZK-96480
DM7ZJ4H DT Small molecular drug
DM7ZJ4H PC 5311044
DM7ZJ4H MW 374.5
DM7ZJ4H FM C22H30O5
DM7ZJ4H IC InChI=1S/C22H30O5/c1-3-4-5-6-15(2)20(23)8-7-18-19-12-16(9-10-27-14-22(25)26)11-17(19)13-21(18)24/h9,15,17-21,23-24H,3,6,10-14H2,1-2H3,(H,25,26)/b16-9+/t15-,17-,18+,19-,20+,21+/m0/s1
DM7ZJ4H CS CCC#CC[C@H](C)[C@@H](C#C[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/COCC(=O)O)/C2)O)O
DM7ZJ4H IK ARUGKOZUKWAXDS-SEWALLKFSA-N
DM7ZJ4H IU 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid
DM7ZJ4H CA CAS 94079-80-8
DM7ZJ4H CB CHEBI:135578
DM7ZJ4H DE Discovery agent
DM27S6E ID DM27S6E
DM27S6E DN cicloprolol
DM27S6E HS Investigative
DM27S6E SN SL 75-177-10
DM27S6E DT Small molecular drug
DM27S6E PC 146294
DM27S6E MW 323.4
DM27S6E FM C18H29NO4
DM27S6E IC InChI=1S/C18H29NO4/c1-14(2)19-11-16(20)13-23-18-7-5-17(6-8-18)22-10-9-21-12-15-3-4-15/h5-8,14-16,19-20H,3-4,9-13H2,1-2H3
DM27S6E CS CC(C)NCC(COC1=CC=C(C=C1)OCCOCC2CC2)O
DM27S6E IK JNDJPKHYZWRRIS-UHFFFAOYSA-N
DM27S6E IU 1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM27S6E CA CAS 94651-09-9
DM27S6E CB CHEBI:135377
DM27S6E DE Discovery agent
DMP6BU3 ID DMP6BU3
DMP6BU3 DN Ciclosporin
DMP6BU3 HS Investigative
DMP6BU3 SN Cyclosporine A; CSA; CsA; Antibiotic S 7481F1; BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA; BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA; C 3662; CB-01-09 MMX; CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)); Cicloral (TN); Ciclosporin; Ciclosporin (JP15); Cipol N; Cipol-N; Consupren; Consupren S; CsA & IFN-alpha; Cyclokat; Cyclophorine; Cyclosporin; Cyclosporin A; Cyclosporin A & IFN-alpha; Cyclosporin A Implant; Cyclosporin A, Tolypocladium inflatum; Cyclosporine (USP); Cyclosporine A; Cyclosporine [USAN]; DE-076; Equoral; From Tolypocladium inflatum (Trichoderma polysporin); GNF-Pf-2808; Gengraf; Gengraf (TN); Helv Chim Acta 60: 1568 (1977); Mitogard; Modusik-A; Neoplanta; Neoral; Neoral (TN); NeuroSTAT; Nova-22007; OL 27-400; OL-27400; OLO-400; Papilock; Pulminiq; RamihyphinA; Restasis; Restasis (TN); S-Neoral; SDZ-OXL 400; ST-603; Sandimmun; Sandimmun Neoral; Sandimmune; Sandimmune (TN); Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine; Sang-2000; Sang-35; SangCyA; Sigmasporin; Sigmasporin Microoral; TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A); Vekacia; Zyclorin
DMP6BU3 CP Sandoz
DMP6BU3 TC Antiviral Agents
DMP6BU3 DT Protein/peptide drug
DMP6BU3 PC 24883466
DMP6BU3 MW 1202.6
DMP6BU3 FM C62H111N11O12
DMP6BU3 IC InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1
DMP6BU3 CS CC[C@@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
DMP6BU3 IK PMATZTZNYRCHOR-VJRYSDSKSA-N
DMP6BU3 IU (3R,6S,9S,12S,15S,18R,21S,24S,30R,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
DMP6BU3 CA CAS 59865-13-3
DMP6BU3 DE Psoriasis vulgaris; Xerophthalmia; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMK6YOP ID DMK6YOP
DMK6YOP DN CID1172084
DMK6YOP HS Investigative
DMK6YOP SN CID 1172084
DMK6YOP DT Small molecular drug
DMK6YOP PC 1172084
DMK6YOP MW 479.6
DMK6YOP FM C23H18FN5O2S2
DMK6YOP IC InChI=1S/C23H18FN5O2S2/c1-13-9-15-5-8-17(31-2)10-19(15)29-21(13)27-28-23(29)33-12-20(30)26-22-25-18(11-32-22)14-3-6-16(24)7-4-14/h3-11H,12H2,1-2H3,(H,25,26,30)
DMK6YOP CS CC1=CC2=C(C=C(C=C2)OC)N3C1=NN=C3SCC(=O)NC4=NC(=CS4)C5=CC=C(C=C5)F
DMK6YOP IK NQAXYXKWUOWLNN-UHFFFAOYSA-N
DMK6YOP IU N-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-[(8-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinolin-1-yl)sulfanyl]acetamide
DMK6YOP DE Discovery agent
DMLWZRT ID DMLWZRT
DMLWZRT DN CID16020046
DMLWZRT HS Investigative
DMLWZRT SN CID 16020046
DMLWZRT DT Small molecular drug
DMLWZRT PC 16020046
DMLWZRT MW 425.4
DMLWZRT FM C25H19N3O4
DMLWZRT IC InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)
DMLWZRT CS CC1=CC=C(C=C1)C2=NNC3=C2C(N(C3=O)C4=CC=C(C=C4)C(=O)O)C5=CC(=CC=C5)O
DMLWZRT IK VGUQVYZXABOXCX-UHFFFAOYSA-N
DMLWZRT IU 4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-c]pyrazol-5-yl]benzoic acid
DMLWZRT CA CAS 834903-43-4
DMLWZRT DE Discovery agent
DMP6I98 ID DMP6I98
DMP6I98 DN CID16197121
DMP6I98 HS Investigative
DMP6I98 SN MLS000766570; SMR000441998; CID16197121; GTPL8579; CHEMBL1302410; cid_16197121; BDBM114082; HMS2226B08; (4R,5S,6S)-4-(1-benzothiophen-3-yl)-6-ethoxy-5-(3-hydroxypropyl)-N-phenyl-5,6-dihydro-4H-pyran-2-carboxamide; (2S,3S,4R)-4-(benzothiophen-3-yl)-2-ethoxy-3-(3-hydroxypropyl)-N-phenyl-3,4-dihydro-2H-pyran-6-carboxamide; (2S,3S,4R)-4-(1-benzothiophen-3-yl)-2-ethoxy-3-(3-oxidanylpropyl)-N-phenyl-3,4-dihydro-2H-pyran-6-carboxamide
DMP6I98 DT Small molecular drug
DMP6I98 PC 16197121
DMP6I98 MW 437.6
DMP6I98 FM C25H27NO4S
DMP6I98 IC InChI=1S/C25H27NO4S/c1-2-29-25-19(12-8-14-27)20(21-16-31-23-13-7-6-11-18(21)23)15-22(30-25)24(28)26-17-9-4-3-5-10-17/h3-7,9-11,13,15-16,19-20,25,27H,2,8,12,14H2,1H3,(H,26,28)/t19-,20+,25-/m0/s1
DMP6I98 CS CCO[C@@H]1[C@H]([C@@H](C=C(O1)C(=O)NC2=CC=CC=C2)C3=CSC4=CC=CC=C43)CCCO
DMP6I98 IK DPIFUIZFNOZKRB-DFIYOIEZSA-N
DMP6I98 IU (2S,3S,4R)-4-(1-benzothiophen-3-yl)-2-ethoxy-3-(3-hydroxypropyl)-N-phenyl-3,4-dihydro-2H-pyran-6-carboxamide
DMP6I98 DE Discovery agent
DMEGZY7 ID DMEGZY7
DMEGZY7 DN CID1792197
DMEGZY7 HS Investigative
DMEGZY7 SN CID 1792197
DMEGZY7 DT Small molecular drug
DMEGZY7 PC 1792197
DMEGZY7 MW 481.6
DMEGZY7 FM C24H23N3O4S2
DMEGZY7 IC InChI=1S/C24H23N3O4S2/c1-27(20-9-4-3-5-10-20)33(29,30)21-15-13-19(14-16-21)25-24(32)26-23(28)17-12-18-8-6-7-11-22(18)31-2/h3-17H,1-2H3,(H2,25,26,28,32)/b17-12+
DMEGZY7 CS CN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)NC(=S)NC(=O)/C=C/C3=CC=CC=C3OC
DMEGZY7 IK XOMQERYBMDFBAG-SFQUDFHCSA-N
DMEGZY7 IU (E)-3-(2-methoxyphenyl)-N-[[4-[methyl(phenyl)sulfamoyl]phenyl]carbamothioyl]prop-2-enamide
DMEGZY7 DE Discovery agent
DMA3F7S ID DMA3F7S
DMA3F7S DN CID2440433
DMA3F7S HS Investigative
DMA3F7S SN CID 2440433
DMA3F7S DT Small molecular drug
DMA3F7S PC 2440433
DMA3F7S MW 470.6
DMA3F7S FM C25H34N4O3S
DMA3F7S IC InChI=1S/C25H34N4O3S/c1-19-8-7-9-23(20(19)2)28-14-16-29(17-15-28)25(30)22-18-21(33(31,32)26(3)4)10-11-24(22)27-12-5-6-13-27/h7-11,18H,5-6,12-17H2,1-4H3
DMA3F7S CS CC1=C(C(=CC=C1)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)S(=O)(=O)N(C)C)N4CCCC4)C
DMA3F7S IK VRSJAHQGJHDACS-UHFFFAOYSA-N
DMA3F7S IU 3-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-N,N-dimethyl-4-pyrrolidin-1-ylbenzenesulfonamide
DMA3F7S CB CHEBI:93272
DMA3F7S DE Discovery agent
DMSHIQA ID DMSHIQA
DMSHIQA DN CID755673
DMSHIQA HS Investigative
DMSHIQA SN CID755673; 521937-07-5; CID 755673; cid-755673; MLS000043346; 7-Hydroxy-2,3,4,5-tetrahydro-1H-benzofuro[2,3-c]azepin-1-one; 7-hydroxy-2,3,4,5-tetrahydro-1H-[1]benzofuro[2,3-c]azepin-1-one; SMR000019965; 7-hydroxy-2,3,4,5-tetrahydro-[1]benzofuro[2,3-c]azepin-1-one; 2,3,4,5-Tetrahydro-7-hydroxy-1H-benzofuro[2,3-c]azepin-1-one; 3-Hydroxy-5,6,7,8-tetrahydro-10-oxa-8-aza-benzo[a]azulen-9-one; AC1LFLHI; SCHEMBL9904268; cid_755673; REGID_for_CID_755673; CHEMBL1450770; BDBM32334; CTK4J5567; CHEBI:92059; KS-00001CWT; EX-A393
DMSHIQA DT Small molecular drug
DMSHIQA PC 755673
DMSHIQA MW 217.22
DMSHIQA FM C12H11NO3
DMSHIQA IC InChI=1S/C12H11NO3/c14-7-3-4-10-9(6-7)8-2-1-5-13-12(15)11(8)16-10/h3-4,6,14H,1-2,5H2,(H,13,15)
DMSHIQA CS C1CC2=C(C(=O)NC1)OC3=C2C=C(C=C3)O
DMSHIQA IK AACFPJSJOWQNBN-UHFFFAOYSA-N
DMSHIQA IU 7-hydroxy-2,3,4,5-tetrahydro-[1]benzofuro[2,3-c]azepin-1-one
DMSHIQA CA CAS 521937-07-5
DMSHIQA CB CHEBI:92059
DMSHIQA DE Solid tumour/cancer
DMP35OM ID DMP35OM
DMP35OM DN CIFEA
DMP35OM HS Investigative
DMP35OM SN cyclohexylmethyl-indenofurane-ethylacetamide
DMP35OM DT Small molecular drug
DMP35OM PC 53238181
DMP35OM MW 339.5
DMP35OM FM C22H29NO2
DMP35OM IC InChI=1S/C22H29NO2/c1-15(24)23-11-9-19-18(13-16-5-3-2-4-6-16)14-17-7-8-21-20(22(17)19)10-12-25-21/h7-8,16H,2-6,9-14H2,1H3,(H,23,24)
DMP35OM CS CC(=O)NCCC1=C(CC2=C1C3=C(C=C2)OCC3)CC4CCCCC4
DMP35OM IK MMMAALHYEKMNHU-UHFFFAOYSA-N
DMP35OM IU N-[2-[7-(cyclohexylmethyl)-2,6-dihydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]acetamide
DMP35OM DE Discovery agent
DMBVIKY ID DMBVIKY
DMBVIKY DN Cilostamide
DMBVIKY HS Investigative
DMBVIKY SN cilostamide; 68550-75-4; ciloalamide; OPC 3689; Cilostamide [INN]; N-Cyclohexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide; Cilostamidum [INN-Latin]; Cilostamida [INN-Spanish]; UNII-45S5605Q18; OPC 3869; CHEMBL34431; NCGC00015269-03; N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide; 45S5605Q18; Butanamide, N-cyclohexyl-4-((1,2-dihydro-2-oxo-6-quinolinyl)oxy)-N-methyl-; N-Cyclohexyl-N-methyl-4-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)butanamide; DSSTox_RID_80698; DSSTox_CID_25140; DSSTox_GSID_45140
DMBVIKY DT Small molecular drug
DMBVIKY PC 2753
DMBVIKY MW 342.4
DMBVIKY FM C20H26N2O3
DMBVIKY IC InChI=1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23)
DMBVIKY CS CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3
DMBVIKY IK UIAYVIIHMORPSJ-UHFFFAOYSA-N
DMBVIKY IU N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide
DMBVIKY CA CAS 68550-75-4
DMBVIKY CB CHEBI:92503
DMBVIKY DE Discovery agent
DM6TJFU ID DM6TJFU
DM6TJFU DN CINANSERIN
DM6TJFU HS Investigative
DM6TJFU SN CINANSERIN; Cinanserin [INN]; 1166-34-3; Cinanserine [INN-French]; Cinanserinum [INN-Latin]; UNII-KI6J9OY7A3; Cinanserina [INN-Spanish]; KI6J9OY7A3; CHEMBL18786; NCGC00024599-02; 2-Propenamide, N-(2-((3-(dimethylamino)propyl)thio)phenyl)-3-phenyl-; DSSTox_RID_81031; DSSTox_CID_25653; DSSTox_GSID_45653; Cinanserinum; Cinanserina; Cinanserine; CAS-1166-34-3; Cinanserin Monohydrochloride; Cinaserin; SQ 16167; SQ-16,167; SQ-10,643; AC1NUDS4; Biomol-NT_000092; 2'-((3-Dimethylaminopropyl)thio)cinnamanilide; SCHEMBL571561; BPBio1_001097
DM6TJFU DT Small molecular drug
DM6TJFU PC 5475158
DM6TJFU MW 340.5
DM6TJFU FM C20H24N2OS
DM6TJFU IC InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)/b14-13+
DM6TJFU CS CN(C)CCCSC1=CC=CC=C1NC(=O)/C=C/C2=CC=CC=C2
DM6TJFU IK RSUVYMGADVXGOU-BUHFOSPRSA-N
DM6TJFU IU (E)-N-[2-[3-(dimethylamino)propylsulfanyl]phenyl]-3-phenylprop-2-enamide
DM6TJFU CA CAS 1166-34-3
DM6TJFU CB CHEBI:92281
DM6TJFU DE Discovery agent
DMOJ917 ID DMOJ917
DMOJ917 DN Cinchoninic acid
DMOJ917 HS Investigative
DMOJ917 SN Quinoline-4-carboxylic acid; 486-74-8; 4-Quinolinecarboxylic acid; CINCHONINIC ACID; 4-Carboxyquinoline; Cinchonic acid; USAF D-2; NSC 13138; EINECS 207-640-1; MFCD00006782; Quinoline-4-Carboxylicacid; BRN 0005224; 4-QuinolinecarboxylicAcid; Cinchoninsaure; PubChem5843; Chinolin-4-carbonsaeure; AC1L1USE; Maybridge1_002367; quinoline4-carboxylic acid; 4-quinoline carboxylic acid; ACMC-1AM77; WLN: T66 BNJ EVQ; Oprea1_466681; KSC171Q1F; 5-22-03-00204 (Beilstein Handbook Reference); SCHEMBL228713; DivK1c_001119; AC1Q72O9; CHEBI:18311
DMOJ917 DT Small molecular drug
DMOJ917 PC 10243
DMOJ917 MW 173.17
DMOJ917 FM C10H7NO2
DMOJ917 IC InChI=1S/C10H7NO2/c12-10(13)8-5-6-11-9-4-2-1-3-7(8)9/h1-6H,(H,12,13)
DMOJ917 CS C1=CC=C2C(=C1)C(=CC=N2)C(=O)O
DMOJ917 IK VQMSRUREDGBWKT-UHFFFAOYSA-N
DMOJ917 IU quinoline-4-carboxylic acid
DMOJ917 CA CAS 486-74-8
DMOJ917 CB CHEBI:18311
DMOJ917 DE Discovery agent
DMZDUXG ID DMZDUXG
DMZDUXG DN cinnamaldehyde
DMZDUXG HS Investigative
DMZDUXG SN cinnamic aldehyde
DMZDUXG DT Small molecular drug
DMZDUXG PC 637511
DMZDUXG MW 132.16
DMZDUXG FM C9H8O
DMZDUXG IC InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4+
DMZDUXG CS C1=CC=C(C=C1)/C=C/C=O
DMZDUXG IK KJPRLNWUNMBNBZ-QPJJXVBHSA-N
DMZDUXG IU (E)-3-phenylprop-2-enal
DMZDUXG CA CAS 104-55-2
DMZDUXG CB CHEBI:16731
DMZDUXG DE Discovery agent
DM340FH ID DM340FH
DM340FH DN Cinnamic acid
DM340FH HS Investigative
DM340FH SN CINNAMIC ACID; TRANS-CINNAMIC ACID; 140-10-3; 621-82-9; (E)-Cinnamic acid; trans-3-Phenylacrylic acid; 3-Phenylacrylic acid; Phenylacrylic acid; Zimtsaeure; (2E)-3-phenylprop-2-enoic acid; 3-phenylprop-2-enoic acid; E-Cinnamic Acid; 3-Phenylpropenoic acid; (E)-3-phenylprop-2-enoic acid; trans-beta-Carboxystyrene; Benzenepropenoic acid; trans-Cinnamate; (E)-3-Phenyl-2-propenoic acid; (E)-cinnamate; Benzeneacrylic acid; trans-3-Phenyl-2-propenoic acid; Cinnamylic acid; Cinnamic acid, (E)-; t-Cinnamic acid; (2E)-3-Phenyl-2-propenoic
DM340FH DT Small molecular drug
DM340FH PC 444539
DM340FH MW 148.16
DM340FH FM C9H8O2
DM340FH IC InChI=1S/C9H8O2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-7H,(H,10,11)/b7-6+
DM340FH CS C1=CC=C(C=C1)/C=C/C(=O)O
DM340FH IK WBYWAXJHAXSJNI-VOTSOKGWSA-N
DM340FH IU (E)-3-phenylprop-2-enoic acid
DM340FH CA CAS 140-10-3
DM340FH CB CHEBI:35697
DM340FH DE Discovery agent
DMZ2WS9 ID DMZ2WS9
DMZ2WS9 DN CIP-137401
DMZ2WS9 HS Investigative
DMZ2WS9 SN CIP-1374; MEK inhibitors, Cheminpharma; MEK inhibitors (cancer), AlloStem
DMZ2WS9 CP Cheminpharma LLC
DMZ2WS9 DE Solid tumour/cancer
DM9N8WM ID DM9N8WM
DM9N8WM DN Ciproxifan
DM9N8WM HS Investigative
DM9N8WM SN ciproxifan; 184025-18-1; FUB-359; FUB 359; FUB359; UNII-5EVQ7IRG99; 5EVQ7IRG99; CHEMBL14638; ACQBHJXEAYTHCY-UHFFFAOYSA-N; cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone; (4-(3-(1H-imidazol-4-yl)propoxy)phenyl)(cyclopropyl)methanone; Ciproxifan; FUB 359; Methanone, cyclopropyl(4-(3-(1H-imidazol-5-yl)propoxy)phenyl)-; Ciproxifan (FUB-359); AC1O4Y0P; GTPL1265; SCHEMBL3335184; BDBM27213; EX-A077; DTXSID50171532; cyclopropyl-(4-(3-1H-imidazol-4-yl)propyloxyphenyl)ketone; CHEBI:125467; MolPort-027-720-958; ZINC1892860
DM9N8WM DT Small molecular drug
DM9N8WM PC 6422124
DM9N8WM MW 270.33
DM9N8WM FM C16H18N2O2
DM9N8WM IC InChI=1S/C16H18N2O2/c19-16(12-3-4-12)13-5-7-15(8-6-13)20-9-1-2-14-10-17-11-18-14/h5-8,10-12H,1-4,9H2,(H,17,18)
DM9N8WM CS C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
DM9N8WM IK ACQBHJXEAYTHCY-UHFFFAOYSA-N
DM9N8WM IU cyclopropyl-[4-[3-(1H-imidazol-5-yl)propoxy]phenyl]methanone
DM9N8WM CA CAS 184025-18-1
DM9N8WM CB CHEBI:125467
DM9N8WM DE Obesity; Dementia
DMU6JOK ID DMU6JOK
DMU6JOK DN cirazoline
DMU6JOK HS Investigative
DMU6JOK SN cirazoline; Cirazoline [INN]; Cirazolinum [INN-Latin]; Cirazolina [INN-Spanish]; UNII-QK318GVY3Y; 59939-16-1; LD-3098; QK318GVY3Y; CHEMBL13852; NCGC00015196-04; 2-((o-Cyclopropylphenoxy)methyl)-2-imidazoline; DSSTox_CID_25131; DSSTox_RID_80692; DSSTox_GSID_45131; Cirazolina; Cirazolinum; 1H-Imidazole, 2-((2-cyclopropylphenoxy)methyl)-4,5-dihydro-; 2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole; CAS-59939-16-1; LD 3098; Tocris-0888; Lopac-C-223; AC1L1EEZ; Lopac0_000354; KBioGR_000306; BSPBio_001586; KBioSS_000306; GTPL515
DMU6JOK DT Small molecular drug
DMU6JOK PC 2765
DMU6JOK MW 216.28
DMU6JOK FM C13H16N2O
DMU6JOK IC InChI=1S/C13H16N2O/c1-2-4-12(11(3-1)10-5-6-10)16-9-13-14-7-8-15-13/h1-4,10H,5-9H2,(H,14,15)
DMU6JOK CS C1CC1C2=CC=CC=C2OCC3=NCCN3
DMU6JOK IK YAORIDZYZDUZCM-UHFFFAOYSA-N
DMU6JOK IU 2-[(2-cyclopropylphenoxy)methyl]-4,5-dihydro-1H-imidazole
DMU6JOK CA CAS 59939-16-1
DMU6JOK CB CHEBI:92950
DMU6JOK DE Discovery agent
DMM10TG ID DMM10TG
DMM10TG DN Cirsimarin
DMM10TG HS Investigative
DMM10TG SN Cirsimarin; Cirsitakaoside; 13020-19-4; CHEMBL517637; 2-(4-(beta-D-Glucopyranosyloxy)phenyl)-5-hydroxy-6,7-dimethoxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-(beta-D-glucopyranosyloxy)phenyl)-5-hydroxy-6,7-dimethoxy-; AC1L4LVL; AC1Q6CLV; SCHEMBL2016369; MolPort-019-937-034; BDBM50250467; ZINC31459932; MCULE-1339456605; 4-(5-hydroxy-6,7-dimethoxy-4-oxo-4h-chromen-2-yl)phenyl; LS-39681
DMM10TG DT Small molecular drug
DMM10TG PC 159460
DMM10TG MW 476.4
DMM10TG FM C23H24O11
DMM10TG IC InChI=1S/C23H24O11/c1-30-15-8-14-17(19(27)22(15)31-2)12(25)7-13(33-14)10-3-5-11(6-4-10)32-23-21(29)20(28)18(26)16(9-24)34-23/h3-8,16,18,20-21,23-24,26-29H,9H2,1-2H3/t16-,18-,20+,21-,23-/m1/s1
DMM10TG CS COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)OC
DMM10TG IK RETJLKUBHXTIGH-FZFRBNDOSA-N
DMM10TG IU 5-hydroxy-6,7-dimethoxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
DMM10TG CA CAS 13020-19-4
DMM10TG DE Discovery agent
DMA3N9R ID DMA3N9R
DMA3N9R DN CIRSIMARITIN
DMA3N9R HS Investigative
DMA3N9R SN Cirsimaritin; 6601-62-3; Scrophulein; Skrofulein; 4',5-Dihydroxy-6,7-dimethoxyflavone; 7-Methylcapillarisin; cirsimartin; 6,7-Dimethoxyscutellarein; CHEMBL348436; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-chromen-4-one; CHEBI:81337; 4H-1-Benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-; 6-Methoxygenkwanin; Flavone, 4',5-dihydroxy-6,7-dimethoxy-; AC1Q6AIG; AC1L4MLD; MLS000876998; cid_188323; MEGxp0_000498; SCHEMBL1663486; CTK2F4258; ACon1_000850; DTXSID00216220; PubChem SID: 26725076; MolPort-000-779-119
DMA3N9R DT Small molecular drug
DMA3N9R PC 188323
DMA3N9R MW 314.29
DMA3N9R FM C17H14O6
DMA3N9R IC InChI=1S/C17H14O6/c1-21-14-8-13-15(16(20)17(14)22-2)11(19)7-12(23-13)9-3-5-10(18)6-4-9/h3-8,18,20H,1-2H3
DMA3N9R CS COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O)O)OC
DMA3N9R IK ZIIAJIWLQUVGHB-UHFFFAOYSA-N
DMA3N9R IU 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxychromen-4-one
DMA3N9R CA CAS 6601-62-3
DMA3N9R CB CHEBI:81337
DMA3N9R DE Discovery agent
DMWX6J0 ID DMWX6J0
DMWX6J0 DN Cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine
DMWX6J0 HS Investigative
DMWX6J0 SN CHEMBL469024; cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine; SCHEMBL16019175; ZINC13559955
DMWX6J0 DT Small molecular drug
DMWX6J0 PC 11423691
DMWX6J0 MW 151.18
DMWX6J0 FM C9H10FN
DMWX6J0 IC InChI=1S/C9H10FN/c10-9(6-8(9)11)7-4-2-1-3-5-7/h1-5,8H,6,11H2/t8-,9+/m0/s1
DMWX6J0 CS C1[C@@H]([C@@]1(C2=CC=CC=C2)F)N
DMWX6J0 IK UJTQURLMCYMANH-DTWKUNHWSA-N
DMWX6J0 IU (1S,2R)-2-fluoro-2-phenylcyclopropan-1-amine
DMWX6J0 DE Discovery agent
DMV3RYK ID DMV3RYK
DMV3RYK DN Cis-[PtCl(NH3)2(N7-acyclovir)]+
DMV3RYK HS Investigative
DMV3RYK DT Small molecular drug
DMV3RYK PC 56603759
DMV3RYK DE Discovery agent
DMP3F0D ID DMP3F0D
DMP3F0D DN Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea
DMP3F0D HS Investigative
DMP3F0D SN CHEMBL242257; CHEMBL395714; cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea; SCHEMBL3260841; SCHEMBL1066689; SCHEMBL1065034; SCHEMBL1065036; YHZXOUHNBSOYQD-QVTUNDJTSA-N; YHZXOUHNBSOYQD-PIYFJZFMSA-N; BDBM50217474; BDBM50217447; AKOS031057010; AKOS009538033; trans-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea; cis-1-(4-Hydroxy-cyclohexyl)-3-tricyclo[3.3.1.13,7]decan-1-yl-urea
DMP3F0D DT Small molecular drug
DMP3F0D PC 11529433
DMP3F0D MW 292.4
DMP3F0D FM C17H28N2O2
DMP3F0D IC InChI=1S/C17H28N2O2/c20-15-3-1-14(2-4-15)18-16(21)19-17-8-11-5-12(9-17)7-13(6-11)10-17/h11-15,20H,1-10H2,(H2,18,19,21)
DMP3F0D CS C1CC(CCC1NC(=O)NC23CC4CC(C2)CC(C4)C3)O
DMP3F0D IK YHZXOUHNBSOYQD-UHFFFAOYSA-N
DMP3F0D IU 1-(1-adamantyl)-3-(4-hydroxycyclohexyl)urea
DMP3F0D DE Discovery agent
DM8NX3Q ID DM8NX3Q
DM8NX3Q DN Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea
DM8NX3Q HS Investigative
DM8NX3Q SN CHEMBL397669; CHEMBL395987; cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea; SCHEMBL3262525; SCHEMBL3262523; BDBM50217464; BDBM50217445
DM8NX3Q DT Small molecular drug
DM8NX3Q PC 16756626
DM8NX3Q MW 388.6
DM8NX3Q FM C24H40N2O2
DM8NX3Q IC InChI=1S/C24H40N2O2/c27-23(26-24-13-18-10-19(14-24)12-20(11-18)15-24)25-21-6-8-22(9-7-21)28-16-17-4-2-1-3-5-17/h17-22H,1-16H2,(H2,25,26,27)
DM8NX3Q CS C1CCC(CC1)COC2CCC(CC2)NC(=O)NC34CC5CC(C3)CC(C5)C4
DM8NX3Q IK IWFDYFIMYQSEQD-UHFFFAOYSA-N
DM8NX3Q IU 1-(1-adamantyl)-3-[4-(cyclohexylmethoxy)cyclohexyl]urea
DM8NX3Q DE Discovery agent
DMVRF9H ID DMVRF9H
DMVRF9H DN Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMVRF9H HS Investigative
DMVRF9H SN CHEMBL460269; cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine
DMVRF9H DT Small molecular drug
DMVRF9H PC 11390419
DMVRF9H MW 185.62
DMVRF9H FM C9H9ClFN
DMVRF9H IC InChI=1S/C9H9ClFN/c10-7-3-1-6(2-4-7)9(11)5-8(9)12/h1-4,8H,5,12H2/t8-,9+/m1/s1
DMVRF9H CS C1[C@H]([C@]1(C2=CC=C(C=C2)Cl)F)N
DMVRF9H IK UTADHPUNQUNGFZ-BDAKNGLRSA-N
DMVRF9H IU (1R,2S)-2-(4-chlorophenyl)-2-fluorocyclopropan-1-amine
DMVRF9H DE Discovery agent
DMPZ1LY ID DMPZ1LY
DMPZ1LY DN Cis-2-(para-fluorophenyl)cyclopropylamine
DMPZ1LY HS Investigative
DMPZ1LY SN CHEMBL446771; cis-2-(para-fluorophenyl)cyclopropylamine
DMPZ1LY DT Small molecular drug
DMPZ1LY PC 11401479
DMPZ1LY MW 169.17
DMPZ1LY FM C9H9F2N
DMPZ1LY IC InChI=1S/C9H9F2N/c10-7-3-1-6(2-4-7)9(11)5-8(9)12/h1-4,8H,5,12H2/t8-,9+/m1/s1
DMPZ1LY CS C1[C@H]([C@]1(C2=CC=C(C=C2)F)F)N
DMPZ1LY IK JCUGJWBVZNWAIJ-BDAKNGLRSA-N
DMPZ1LY IU (1R,2S)-2-fluoro-2-(4-fluorophenyl)cyclopropan-1-amine
DMPZ1LY DE Discovery agent
DMJ3HG9 ID DMJ3HG9
DMJ3HG9 DN Cis-2,6-dimethyl-1-methyl sulfonyl piperidine
DMJ3HG9 HS Investigative
DMJ3HG9 SN CHEMBL576005; cis-2,6-dimethyl-1-methyl sulfonyl piperidine
DMJ3HG9 DT Small molecular drug
DMJ3HG9 PC 44245252
DMJ3HG9 MW 191.29
DMJ3HG9 FM C8H17NO2S
DMJ3HG9 IC InChI=1S/C8H17NO2S/c1-7-5-4-6-8(2)9(7)12(3,10)11/h7-8H,4-6H2,1-3H3/t7-,8+
DMJ3HG9 CS C[C@@H]1CCC[C@@H](N1S(=O)(=O)C)C
DMJ3HG9 IK NDRNIFSBRLCSCZ-OCAPTIKFSA-N
DMJ3HG9 IU (2R,6S)-2,6-dimethyl-1-methylsulfonylpiperidine
DMJ3HG9 DE Discovery agent
DMF10WT ID DMF10WT
DMF10WT DN Cis-2-aminocyclohexylcarbamoylphosphonic acid
DMF10WT HS Investigative
DMF10WT SN cis-ACCP; cis-2-aminocyclohexylcarbamoylphosphonic acid; 777075-44-2; CHEMBL270083; SCHEMBL569075; C7H15N2O4P; CTK8E9417; MolPort-039-139-066; BDBM50234465; 1683AH; ZINC29134634
DMF10WT DT Small molecular drug
DMF10WT PC 44457233
DMF10WT MW 222.18
DMF10WT FM C7H15N2O4P
DMF10WT IC InChI=1S/C7H15N2O4P/c8-5-3-1-2-4-6(5)9-7(10)14(11,12)13/h5-6H,1-4,8H2,(H,9,10)(H2,11,12,13)/t5-,6+/m0/s1
DMF10WT CS C1CC[C@H]([C@H](C1)N)NC(=O)P(=O)(O)O
DMF10WT IK XHCXISPZIHYKQD-NTSWFWBYSA-N
DMF10WT IU [(1R,2S)-2-aminocyclohexyl]carbamoylphosphonic acid
DMF10WT DE Discovery agent
DMNG9B2 ID DMNG9B2
DMNG9B2 DN Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine
DMNG9B2 HS Investigative
DMNG9B2 SN CHEMBL468854; cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine
DMNG9B2 DT Small molecular drug
DMNG9B2 PC 44577747
DMNG9B2 MW 181.21
DMNG9B2 FM C10H12FNO
DMNG9B2 IC InChI=1S/C10H12FNO/c1-13-8-4-2-7(3-5-8)10(11)6-9(10)12/h2-5,9H,6,12H2,1H3/t9-,10+/m1/s1
DMNG9B2 CS COC1=CC=C(C=C1)[C@]2(C[C@H]2N)F
DMNG9B2 IK IFVJHRWUMHINNO-ZJUUUORDSA-N
DMNG9B2 IU (1R,2S)-2-fluoro-2-(4-methoxyphenyl)cyclopropan-1-amine
DMNG9B2 DE Discovery agent
DMFSPHE ID DMFSPHE
DMFSPHE DN Cis-2-fluoro-2-phenylcyclopropanamine
DMFSPHE HS Investigative
DMFSPHE SN CHEMBL466769; cis-2-fluoro-2-phenylcyclopropanamine; SCHEMBL16010002; ZINC13584960; BDBM50261916; AKOS027415699; 784133-88-6; KB-276212
DMFSPHE DT Small molecular drug
DMFSPHE PC 12098585
DMFSPHE MW 151.18
DMFSPHE FM C9H10FN
DMFSPHE IC InChI=1S/C9H10FN/c10-9(6-8(9)11)7-4-2-1-3-5-7/h1-5,8H,6,11H2/t8-,9+/m1/s1
DMFSPHE CS C1[C@H]([C@]1(C2=CC=CC=C2)F)N
DMFSPHE IK UJTQURLMCYMANH-BDAKNGLRSA-N
DMFSPHE IU (1R,2S)-2-fluoro-2-phenylcyclopropan-1-amine
DMFSPHE DE Discovery agent
DMKZ32J ID DMKZ32J
DMKZ32J DN Cis-2-phenylcyclopropylamine
DMKZ32J HS Investigative
DMKZ32J SN cis-2-phenylcyclopropylamine; Tranylcypromine, cis-; CHEMBL467794; 13531-35-6; cis-Cypromine; CIS-1-AMINO-2-PHENYLCYCLOPROPANE; DL-cis-2-Phenylcyclopropylamine; Cyclopropanamine, 2-phenyl-, cis-; (+/-)-cis-2-Phenylcyclopropylamine; AC1ODZ9B; Tranylcypromine related compound A free base; Cyclopropanamine, 2-phenyl-, (1R,2R)-rel-; cis-2-Phenylcyclopropanamine; SCHEMBL1720497; CTK0F4162; DTXSID80159308; (-) cis-2-phenylcyclopropylamine; AELCINSCMGFISI-RKDXNWHRSA-N; (1R,2R)-2-Phenylcyclopropanamine; ZINC1639567; BDBM50261814
DMKZ32J DT Small molecular drug
DMKZ32J PC 6971118
DMKZ32J MW 133.19
DMKZ32J FM C9H11N
DMKZ32J IC InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9-/m1/s1
DMKZ32J CS C1[C@@H]([C@@H]1N)C2=CC=CC=C2
DMKZ32J IK AELCINSCMGFISI-RKDXNWHRSA-N
DMKZ32J IU (1R,2R)-2-phenylcyclopropan-1-amine
DMKZ32J CA CAS 13531-35-6
DMKZ32J DE Discovery agent
DMQ0EA7 ID DMQ0EA7
DMQ0EA7 DN cis-3-ACPBPA
DMQ0EA7 HS Investigative
DMQ0EA7 SN 3-amino-cyclopentenylbutylphosphonic acid
DMQ0EA7 DT Small molecular drug
DMQ0EA7 PC 23399992
DMQ0EA7 MW 205.23
DMQ0EA7 FM C9H20NO2P
DMQ0EA7 IC InChI=1S/C9H20NO2P/c1-2-3-6-13(11,12)9-5-4-8(10)7-9/h8-9H,2-7,10H2,1H3,(H,11,12)/t8-,9+/m0/s1
DMQ0EA7 CS CCCCP(=O)([C@@H]1CC[C@@H](C1)N)O
DMQ0EA7 IK UQGQAMARAMOEID-DTWKUNHWSA-N
DMQ0EA7 IU [(1R,3S)-3-aminocyclopentyl]-butylphosphinic acid
DMQ0EA7 DE Discovery agent
DMTH4BG ID DMTH4BG
DMTH4BG DN Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG HS Investigative
DMTH4BG SN CHEMBL530334; cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG DT Small molecular drug
DMTH4BG PC 44560576
DMTH4BG MW 225.28
DMTH4BG FM C15H15NO
DMTH4BG IC InChI=1S/C15H15NO/c16-14-10-15(13-9-5-4-8-12(13)14)17-11-6-2-1-3-7-11/h1-9,14-15H,10,16H2/t14-,15+/m1/s1
DMTH4BG CS C1[C@H](C2=CC=CC=C2[C@H]1OC3=CC=CC=C3)N
DMTH4BG IK AFPFOKAYUJMERG-CABCVRRESA-N
DMTH4BG IU (1R,3S)-3-phenoxy-2,3-dihydro-1H-inden-1-amine
DMTH4BG DE Discovery agent
DMX07BG ID DMX07BG
DMX07BG DN Cis-4-hydroxynipecotic acid
DMX07BG HS Investigative
DMX07BG PC 172852
DMX07BG MW 145.16
DMX07BG FM C6H11NO3
DMX07BG IC InChI=1S/C6H11NO3/c8-5-1-2-7-3-4(5)6(9)10/h4-5,7-8H,1-3H2,(H,9,10)/t4-,5+/m1/s1
DMX07BG CS C1CNC[C@H]([C@H]1O)C(=O)O
DMX07BG IK DAMFVOCECLPLSI-UHNVWZDZSA-N
DMX07BG IU (3R,4S)-4-hydroxypiperidine-3-carboxylic acid
DMX07BG CA CAS 71609-37-5
DMX07BG DE Discovery agent
DMRFTB5 ID DMRFTB5
DMRFTB5 DN Cis-4-hydroxytamoxifen
DMRFTB5 HS Investigative
DMRFTB5 SN Afimoxifene, E-isomer; E-4-Hydroxytamoxifen; AKE3PH0IML; SCHEMBL2132301; SCHEMBL640496; ZINC1530090; cis-4-Hydroxytamoxifen; cis/trans-4-Hydroxytamoxifen; (E)-4-Hydroxytamoxifen; (Z)-4-(1-(4-(2-(Dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol; 174592-47-3; 4-((1E)-1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol; AC1NS1S8; ACM174592473; AKOS015894466; API0000886; BCP9000165; BCP9000243; CHEBI:92076; CHEMBL279301; CP-0071; DTXSID10169854; HY-16950B; UNII-AKE3PH0IML
DMRFTB5 PC 5352135
DMRFTB5 MW 387.5
DMRFTB5 FM C26H29NO2
DMRFTB5 IC TXUZVZSFRXZGTL-OCEACIFDSA-N
DMRFTB5 CS CCC(=C(C1=CC=C(C=C1)O)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
DMRFTB5 IK 1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25+
DMRFTB5 IU 4-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
DMRFTB5 CA CAS 174592-47-3
DMRFTB5 CB CHEBI:92076
DMRFTB5 DE Discovery agent
DMQUB19 ID DMQUB19
DMQUB19 DN Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH
DMQUB19 HS Investigative
DMQUB19 SN cDADAE(8); cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; CHEMBL375025; BDBM21125; (5S,8R,10Z,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid
DMQUB19 DT Small molecular drug
DMQUB19 PC 16733485
DMQUB19 MW 551.6
DMQUB19 FM C28H33N5O7
DMQUB19 IC InChI=1S/C28H33N5O7/c29-20(14-18-10-12-19(34)13-11-18)25(36)32-21-8-4-5-9-22(28(39)40)33-27(38)23(15-17-6-2-1-3-7-17)31-24(35)16-30-26(21)37/h1-7,10-13,20-23,34H,8-9,14-16,29H2,(H,30,37)(H,31,35)(H,32,36)(H,33,38)(H,39,40)/b5-4-/t20-,21+,22+,23-/m0/s1
DMQUB19 CS C1/C=C\\C[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)O
DMQUB19 IK VNZCTJLIVONUDE-HOJIFOFPSA-N
DMQUB19 IU (5S,8R,10Z,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxylic acid
DMQUB19 DE Discovery agent
DM75SO4 ID DM75SO4
DM75SO4 DN Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4 HS Investigative
DM75SO4 SN CHEMBL215688; cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4 DT Small molecular drug
DM75SO4 PC 44417210
DM75SO4 MW 324.4
DM75SO4 FM C19H20N2O3
DM75SO4 IC InChI=1S/C19H20N2O3/c22-18(20-12-15-9-5-2-6-10-15)17-13-24-19(23)16(21-17)11-14-7-3-1-4-8-14/h1-10,16-17,21H,11-13H2,(H,20,22)/t16-,17-/m0/s1
DM75SO4 CS C1[C@H](N[C@H](C(=O)O1)CC2=CC=CC=C2)C(=O)NCC3=CC=CC=C3
DM75SO4 IK ORMAGLLOPOBCBO-IRXDYDNUSA-N
DM75SO4 IU (3S,5S)-N,5-dibenzyl-6-oxomorpholine-3-carboxamide
DM75SO4 DE Discovery agent
DM7TU1I ID DM7TU1I
DM7TU1I DN Cis-N-oleoylcyclopropanolamide
DM7TU1I HS Investigative
DM7TU1I SN cyclopropanolamide, 13b; cis-N-oleoylcyclopropanolamide; cyclopropanolamide, rac-10b; CHEMBL472661; BDBM29081
DM7TU1I DT Small molecular drug
DM7TU1I PC 42617985
DM7TU1I MW 337.5
DM7TU1I FM C21H39NO2
DM7TU1I IC InChI=1S/C21H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)22-19-18-20(19)23/h9-10,19-20,23H,2-8,11-18H2,1H3,(H,22,24)/b10-9-/t19-,20+/m1/s1
DM7TU1I CS CCCCCCCC/C=C\\CCCCCCCC(=O)N[C@@H]1C[C@@H]1O
DM7TU1I IK VCMSNKIQHBVCSW-VSEBXTFHSA-N
DM7TU1I IU (Z)-N-[(1R,2S)-2-hydroxycyclopropyl]octadec-9-enamide
DM0N634 ID DM0N634
DM0N634 DN CITCO
DM0N634 HS Investigative
DM0N634 SN CITCO; 338404-52-7; UNII-D77H8321PB; 6-(4-CHLOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBALDEHYDE O-(3,4-DICHLOROBENZYL)OXIME; CHEMBL458603; D77H8321PB; 6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime; CITCO cpd; Spectrum5_001974; BSPBio_001028; SCHEMBL241281; DTXSID4040761; CHEBI:92928; BCBcMAP01_000217; 6-[4-Chlorophenyl]imidazo[2,1-b][1,3]thiazole-5-carbaldehydeo-[3,4-dichlorobenzyl]oxime
DM0N634 DT Small molecular drug
DM0N634 PC 9600409
DM0N634 MW 436.7
DM0N634 FM C19H12Cl3N3OS
DM0N634 IC InChI=1S/C19H12Cl3N3OS/c20-14-4-2-13(3-5-14)18-17(25-7-8-27-19(25)24-18)10-23-26-11-12-1-6-15(21)16(22)9-12/h1-10H,11H2/b23-10+
DM0N634 CS C1=CC(=CC=C1C2=C(N3C=CSC3=N2)/C=N/OCC4=CC(=C(C=C4)Cl)Cl)Cl
DM0N634 IK ZQWBOKJVVYNKTL-AUEPDCJTSA-N
DM0N634 IU (E)-1-[6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]-N-[(3,4-dichlorophenyl)methoxy]methanimine
DM0N634 CA CAS 338404-52-7
DM0N634 CB CHEBI:92928
DM0N634 DE Discovery agent
DMCIM9A ID DMCIM9A
DMCIM9A DN Citraconic acid
DMCIM9A HS Investigative
DMCIM9A SN Citraconic acid; 2-methylmaleic acid; METHYLMALEIC ACID; 498-23-7; 2-Methyl-2-butenedioic acid; cis-Methylbutenedioic acid; Citraconate; (Z)-2-Methyl-2-butenedioic acid; Maleic acid, methyl-; Citraconsaeure; Methyl-maleinsaeure; Kyselina citrakonova; Kyselina citrakonova [Czech]; citraconsaure; UNII-0RQ6CXO9KD; (2Z)-2-methylbut-2-enedioic acid; BRN 1722679; 2-Butenedioic acid, 2-methyl-, (Z)-; 2-Methylmaleate; alpha-methylmaleic acid; EINECS 207-858-7; NSC 32949; 0RQ6CXO9KD; cis-2-methylbutenedioic acid; 2-methyl-2Z-butenedioic ac
DMCIM9A DT Small molecular drug
DMCIM9A PC 643798
DMCIM9A MW 130.1
DMCIM9A FM C5H6O4
DMCIM9A IC InChI=1S/C5H6O4/c1-3(5(8)9)2-4(6)7/h2H,1H3,(H,6,7)(H,8,9)/b3-2-
DMCIM9A CS C/C(=C/C(=O)O)/C(=O)O
DMCIM9A IK HNEGQIOMVPPMNR-IHWYPQMZSA-N
DMCIM9A IU (Z)-2-methylbut-2-enedioic acid
DMCIM9A CA CAS 498-23-7
DMCIM9A CB CHEBI:17626
DMCIM9A DE Discovery agent
DM53ZGY ID DM53ZGY
DM53ZGY DN citral
DM53ZGY HS Investigative
DM53ZGY SN geranial; geranialdehyde; citral a; trans-citral
DM53ZGY DT Small molecular drug
DM53ZGY PC 638011
DM53ZGY MW 152.23
DM53ZGY FM C10H16O
DM53ZGY IC InChI=1S/C10H16O/c1-9(2)5-4-6-10(3)7-8-11/h5,7-8H,4,6H2,1-3H3/b10-7+
DM53ZGY CS CC(=CCC/C(=C/C=O)/C)C
DM53ZGY IK WTEVQBCEXWBHNA-JXMROGBWSA-N
DM53ZGY IU (2E)-3,7-dimethylocta-2,6-dienal
DM53ZGY CA CAS 5392-40-5
DM53ZGY CB CHEBI:16980
DM53ZGY DE Discovery agent
DM80YI7 ID DM80YI7
DM80YI7 DN citric acid
DM80YI7 HS Investigative
DM80YI7 SN Citric acid; 77-92-9; Citric acid, anhydrous; citrate; Citro; Anhydrous citric acid; Aciletten; Citretten; Chemfill; Hydrocerol A; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Kyselina citronova; 2-hydroxy-1,2,3-propanetricarboxylic acid; 2-Hydroxytricarballylic acid; Citric acid anhydrous; Caswell No 221C; F 0001 (polycarboxylic acid); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; 2-Hydroxypropanetricarboxylic acid; beta-Hydroxytricarballylic acid; FEMA Number 2306; K-Lyte
DM80YI7 DT Small molecular drug
DM80YI7 PC 311
DM80YI7 MW 192.12
DM80YI7 FM C6H8O7
DM80YI7 IC InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DM80YI7 CS C(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM80YI7 IK KRKNYBCHXYNGOX-UHFFFAOYSA-N
DM80YI7 IU 2-hydroxypropane-1,2,3-tricarboxylic acid
DM80YI7 CA CAS 77-92-9
DM80YI7 CB CHEBI:30769
DM80YI7 DE Discovery agent
DMH204Y ID DMH204Y
DMH204Y DN CKD-533
DMH204Y HS Investigative
DMH204Y SN PDE 5 inhibitor (oral, erectile dysfunction), Chong Kun Dang
DMH204Y CP Chong Kun Dang Pharmaceutical Corp
DMH204Y DE Erectile dysfunction
DML8MSC ID DML8MSC
DML8MSC DN CL 385319
DML8MSC HS Investigative
DML8MSC SN CHEMBL2088468; cl-385319
DML8MSC DT Small molecular drug
DML8MSC PC 46176195
DML8MSC MW 354.77
DML8MSC FM C15H19ClF4N2O
DML8MSC IC InChI=1S/C15H18F4N2O.ClH/c16-13-9-11(8-12(10-13)15(17,18)19)14(22)20-4-7-21-5-2-1-3-6-21;/h8-10H,1-7H2,(H,20,22);1H
DML8MSC CS C1CCN(CC1)CCNC(=O)C2=CC(=CC(=C2)F)C(F)(F)F.Cl
DML8MSC IK FEMIHMMAZDXYBI-UHFFFAOYSA-N
DML8MSC IU 3-fluoro-N-(2-piperidin-1-ylethyl)-5-(trifluoromethyl)benzamide;hydrochloride
DML8MSC DE Discovery agent
DMB6XUY ID DMB6XUY
DMB6XUY DN CL-205086
DMB6XUY HS Investigative
DMB6XUY SN Imidazole, 4-nitro-; PubChem7615; VYDWQPKRHOGLPA-UHFFFAOYSA-N; Y8U32AZ5O7; 100214-79-7; 1H-4-Nitroimidazole; 1H-5-Nitroimidazole; 1H-Imidazole, 4-nitro-; 1H-Imidazole, 5-nitro-; 3034-38-6; 4(5)-Nitroimidazole; 4-NITRO-1H-IMIDAZOLE; 4-Nitroimidazole; 4-Nitroimidazole, 97%; 4-Nitroimidazole, 98%; 4-nitro-3H-imidazole; 4-nitro-imidazole; 5(4)-nitroimidazole; 5-Nitro-1H-imidazole; 5-Nitroimidazole; 88054-21-1; ACMC-1AIMC; AI3-60154; CHEBI:64635; EC 221-224-7; EINECS 221-224-7; MFCD00005196; NSC 50359; UNII-Y8U32AZ5O7
DMB6XUY PC 18208
DMB6XUY MW 113.08
DMB6XUY FM C3H3N3O2
DMB6XUY IC VYDWQPKRHOGLPA-UHFFFAOYSA-N
DMB6XUY CS C1=C(NC=N1)[N+](=O)[O-]
DMB6XUY IK 1S/C3H3N3O2/c7-6(8)3-1-4-2-5-3/h1-2H,(H,4,5)
DMB6XUY IU 5-nitro-1H-imidazole
DMB6XUY CA CAS 3034-38-6
DMB6XUY CB CHEBI:64635
DMB6XUY DE Amebiasis
DMW3RLB ID DMW3RLB
DMW3RLB DN CL-301
DMW3RLB HS Investigative
DMW3RLB SN CLP-301; CL-301 series, Chlorion
DMW3RLB CP Chlorion Pharma Inc
DMW3RLB DE Neurological disorder
DMLQZGJ ID DMLQZGJ
DMLQZGJ DN CL-385004
DMLQZGJ HS Investigative
DMLQZGJ SN CL-385004; UNII-YS11IQJ45S; YS11IQJ45S; CHEMBL300946; SCHEMBL5738957; BDBM50078663; Benzamide, 5-fluoro-2-methyl-N-(5-(5H-pyrrolo(2,1-C)(1,4)benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl)-; 180416-31-3; L015160
DMLQZGJ DT Small molecular drug
DMLQZGJ PC 9954905
DMLQZGJ MW 440.5
DMLQZGJ FM C26H21FN4O2
DMLQZGJ IC InChI=1S/C26H21FN4O2/c1-17-8-10-20(27)13-22(17)25(32)29-24-11-9-18(14-28-24)26(33)31-16-21-6-4-12-30(21)15-19-5-2-3-7-23(19)31/h2-14H,15-16H2,1H3,(H,28,29,32)
DMLQZGJ CS CC1=C(C=C(C=C1)F)C(=O)NC2=NC=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53
DMLQZGJ IK XJZRYHGTQLKUDO-UHFFFAOYSA-N
DMLQZGJ IU N-[5-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)pyridin-2-yl]-5-fluoro-2-methylbenzamide
DMLQZGJ CA CAS 180416-31-3
DMLQZGJ DE Discovery agent
DMLKFZC ID DMLKFZC
DMLKFZC DN CL-387785
DMLKFZC HS Investigative
DMLKFZC SN cl-387785; 194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide
DMLKFZC DT Small molecular drug
DMLKFZC PC 2776
DMLKFZC MW 381.2
DMLKFZC FM C18H13BrN4O
DMLKFZC IC InChI=1S/C18H13BrN4O/c1-2-4-17(24)22-14-7-8-16-15(10-14)18(21-11-20-16)23-13-6-3-5-12(19)9-13/h3,5-11H,1H3,(H,22,24)(H,20,21,23)
DMLKFZC CS CC#CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br
DMLKFZC IK BTYYWOYVBXILOJ-UHFFFAOYSA-N
DMLKFZC IU N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide
DMLKFZC CA CAS 194423-06-8
DMLKFZC CB CHEBI:90180
DMLKFZC DE Discovery agent
DM9AFZ3 ID DM9AFZ3
DM9AFZ3 DN CL-5343
DM9AFZ3 HS Investigative
DM9AFZ3 SN 5-Amino-1,3,4-thiadiazole-2-sulfonamide; 14949-00-9; Tio-urasin; CL 5343; UNII-F687N81LIZ; NSC 22979; 2-Amino-1,3,4-thiadiazole-5-sulfonamide; CHEMBL265674; F687N81LIZ; 1,3,4-Thiadiazole-2-sulfonamide, 5-amino-; 5-Amino-TDSNH2; PubChem15758; Acetazolamide Impurity D; AC1Q6UUX; 1,3,4-Thiadiazole-5-sulfonamide, 2-amino-; SCHEMBL282413; AC1L382D; CTK4C6227; BDBM10868; DTXSID10164324; MolPort-022-374-081; VGMVBPQOACUDRU-UHFFFAOYSA-N; NSC22979; ZINC16969869; NSC-22979; 1,3,4-thiadiazole-2-sulfonamide 15; aromatic/heteroaromatic; CL-5343; Carbonic anhydrase inhibitors, Universita degli Studi di Firenze; Sulfonamide CA inhibitors, Universita degli Studi di Firenze; Sulfonamide CA inhibitors, University of Florence; Carbonic anhydrase inhibitors (cancer/epilepsy/glaucoma/obesity); Carbonic anhydrase inhibitors (cancer/epilepsy/glaucoma/obesity), University of Florence/ULS; 5-amino-1,3,4-thiadiazole-2-sulfonamide
DM9AFZ3 CP Universita degli Studi di Firenze
DM9AFZ3 DT Small molecular drug
DM9AFZ3 PC 84724
DM9AFZ3 MW 180.21
DM9AFZ3 FM C2H4N4O2S2
DM9AFZ3 IC InChI=1S/C2H4N4O2S2/c3-1-5-6-2(9-1)10(4,7)8/h(H2,3,5)(H2,4,7,8)
DM9AFZ3 CS C1(=NN=C(S1)S(=O)(=O)N)N
DM9AFZ3 IK VGMVBPQOACUDRU-UHFFFAOYSA-N
DM9AFZ3 IU 5-amino-1,3,4-thiadiazole-2-sulfonamide
DM9AFZ3 CA CAS 14949-00-9
DM9AFZ3 DE Solid tumour/cancer
DMP3MDS ID DMP3MDS
DMP3MDS DN CL82198
DMP3MDS HS Investigative
DMP3MDS SN CL-82198; CL 82198
DMP3MDS DT Small molecular drug
DMP3MDS PC 2777
DMP3MDS MW 302.37
DMP3MDS FM C17H22N2O3
DMP3MDS IC InChI=1S/C17H22N2O3/c20-17(16-13-14-5-1-2-6-15(14)22-16)18-7-3-4-8-19-9-11-21-12-10-19/h1-2,5-6,13H,3-4,7-12H2,(H,18,20)
DMP3MDS CS C1COCCN1CCCCNC(=O)C2=CC3=CC=CC=C3O2
DMP3MDS IK KUJQEQAVMNFFAO-UHFFFAOYSA-N
DMP3MDS IU N-(4-morpholin-4-ylbutyl)-1-benzofuran-2-carboxamide
DMP3MDS CA CAS 307002-71-7
DMP3MDS CB CHEBI:92019
DMP3MDS DE Discovery agent
DMRV89X ID DMRV89X
DMRV89X DN Cl-amidine
DMRV89X HS Investigative
DMRV89X SN Cl-amidine; CHEMBL1962361; N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide; 913723-61-2; CHEMBL1910972; GTPL8685; US8969333, CI-amidine; SCHEMBL1979577; BDBM144279; ZINC71746281; BDBM50355657; 4373AJ; NE62957; HY-100574; CS-0019714; FT-0700077; (2S)-5-(2-chloroethanimidamido)-2-(phenylformamido)pentanamide
DMRV89X DT Small molecular drug
DMRV89X PC 24970878
DMRV89X MW 310.78
DMRV89X FM C14H19ClN4O2
DMRV89X IC InChI=1S/C14H19ClN4O2/c15-9-12(16)18-8-4-7-11(13(17)20)19-14(21)10-5-2-1-3-6-10/h1-3,5-6,11H,4,7-9H2,(H2,16,18)(H2,17,20)(H,19,21)/t11-/m0/s1
DMRV89X CS C1=CC=C(C=C1)C(=O)N[C@@H](CCCN=C(CCl)N)C(=O)N
DMRV89X IK BPWATVWOHQZVRP-NSHDSACASA-N
DMRV89X IU N-[(2S)-1-amino-5-[(1-amino-2-chloroethylidene)amino]-1-oxopentan-2-yl]benzamide
DMRV89X DE Discovery agent
DMIX347 ID DMIX347
DMIX347 DN CLAVARINONE
DMIX347 HS Investigative
DMIX347 SN SCHEMBL606234
DMIX347 DT Small molecular drug
DMIX347 PC 10005132
DMIX347 MW 474.7
DMIX347 FM C30H50O4
DMIX347 IC InChI=1S/C30H50O4/c1-18(9-12-24(32)27(4,5)34)19-13-15-30(8)21-10-11-23-26(2,3)25(33)22(31)17-28(23,6)20(21)14-16-29(19,30)7/h18-19,22-24,31-32,34H,9-17H2,1-8H3/t18-,19-,22-,23+,24?,28-,29-,30+/m1/s1
DMIX347 CS C[C@H](CCC(C(C)(C)O)O)[C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(C[C@H](C(=O)C4(C)C)O)C)C)C
DMIX347 IK TZXHHXSEUPQHDR-ITLZUSRVSA-N
DMIX347 IU (2R,5R,10S,13R,14R,17R)-17-[(2R)-5,6-dihydroxy-6-methylheptan-2-yl]-2-hydroxy-4,4,10,13,14-pentamethyl-1,2,5,6,7,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMIX347 DE Discovery agent
DMAJNYM ID DMAJNYM
DMAJNYM DN Clavulanate+Amoxicillin
DMAJNYM HS Investigative
DMAJNYM SN Potassium clavulanate; 61177-45-5; CLAVULANATE POTASSIUM; Amonate; BRL 14151K; UNII-Q42OMW3AT8; EINECS 262-640-9; Q42OMW3AT8; CHEBI:85264; potassium (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate; Potassium (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylate; Potassium clavulanate with microcrystalline cellulose; 4-Oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-(2-hydroxyethylidene)-7-oxo-, monopotassium salt, (2R-(2alpha,3Z,5alpha))-
DMAJNYM CP GlaxoSmithKline
DMAJNYM DT Small molecular drug
DMAJNYM PC 23665591
DMAJNYM MW 237.25
DMAJNYM FM C8H8KNO5
DMAJNYM IC InChI=1S/C8H9NO5.K/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1
DMAJNYM CS C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)[O-].[K+]
DMAJNYM IK ABVRVIZBZKUTMK-JSYANWSFSA-M
DMAJNYM IU potassium;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
DMAJNYM CA CAS 61177-45-5
DMAJNYM CB CHEBI:85264
DMAJNYM DE Infectious disease
DMTLOU6 ID DMTLOU6
DMTLOU6 DN CLEBOPRIDE
DMTLOU6 HS Investigative
DMTLOU6 SN Clebopride; 55905-53-8; Cleboril; Clebopridum [INN-Latin]; Cleboprida [INN-Spanish]; 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide; UNII-I0A84520Y9; LAS 9273; EINECS 259-885-9; C20H24ClN3O2; BRN 0493934; CHEMBL325109; I0A84520Y9; 4-Amino-N-(1-benzyl-4-piperidyl)-5-chloro-o-anisamide; clebopride malate; 4-Amino-5-chloro-2-methoxy-N-(1-benzyl-4-piperidyl)benzamide; Clebopridum; Cleboprida; N-(1'-Benzyl-4'-piperidyl)-2-methoxy-4-amino-5-chlorobenzamide; BENZAMIDE, 4-AMINO-5-CHLORO-2-METHOXY-N-(1-(PHENYLMETHYL)-4
DMTLOU6 DT Small molecular drug
DMTLOU6 PC 2780
DMTLOU6 MW 373.9
DMTLOU6 FM C20H24ClN3O2
DMTLOU6 IC InChI=1S/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)
DMTLOU6 CS COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)N
DMTLOU6 IK BVPWJMCABCPUQY-UHFFFAOYSA-N
DMTLOU6 IU 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide
DMTLOU6 CA CAS 55905-53-8
DMTLOU6 CB CHEBI:92309
DMTLOU6 DE Discovery agent
DM4SKYA ID DM4SKYA
DM4SKYA DN CLEMATOMANDSHURICA SAPONIN A
DM4SKYA HS Investigative
DM4SKYA SN CHEMBL526701; BDBM50241847; 6)-[(3-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-> 3)-alph-L-rhamnopyranosyl-(1-> 2)-alpha-L-arabinopyranosyloleanolicacid 28-O-alph-L-rhamnopyranosyl-(1->
DM4SKYA PC 44559170
DM4SKYA MW 1984.1
DM4SKYA FM C92H142O46
DM4SKYA IC InChI=1S/C92H142O46/c1-34-52(98)60(106)65(111)77(124-34)121-33-47-59(105)74(133-51(97)17-13-37-12-15-42(119-11)40(95)26-37)70(116)84(131-47)136-75-58(104)43(28-93)127-83(71(75)117)130-46-32-123-79(64(110)57(46)103)135-73-54(100)36(3)126-82(69(73)115)137-76-55(101)41(96)30-120-85(76)132-50-19-20-89(8)48(88(50,6)7)18-21-91(10)49(89)16-14-38-39-27-87(4,5)22-24-92(39,25-23-90(38,91)9)86(118)138-81-67(113)62(108)56(102)45(129-81)31-122-78-68(114)63(109)72(44(29-94)128-78)134-80-66(112)61(107)53(99)35(2)125-80/h12-15,17,26,34-36,39,41,43-50,52-85,93-96,98-117H,16,18-25,27-33H2,1-11H3/b17-13+/t34-,35-,36-,39-,41-,43+,44+,45+,46+,47+,48-,49+,50-,52-,53-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74-,75-,76+,77+,78+,79-,80-,81-,82-,83-,84-,85-,89-,90+,91+,92-/m0/s1
DM4SKYA CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@H]3[C@@H]([C@H](O[C@H]([C@@H]3O)O[C@@H]4CO[C@H]([C@@H]([C@@H]4O)O)O[C@@H]5[C@H]([C@@H](O[C@H]([C@@H]5O)O[C@@H]6[C@H]([C@H](CO[C@H]6O[C@H]7CC[C@]8([C@H](C7(C)C)CC[C@@]9([C@@H]8CC=C1[C@]9(CC[C@@]2([C@H]1CC(CC2)(C)C)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)O)O)O)O)O)C)C)C)O)O)C)O)CO)O)O)OC(=O)/C=C/C1=CC(=C(C=C1)OC)O)O)O)O)O
DM4SKYA IK NPRWMYIWVVAUEC-KQFZDZHOSA-N
DM4SKYA IU [(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4S,5R)-5-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DM4SKYA DE Discovery agent
DMNWXOC ID DMNWXOC
DMNWXOC DN CLEMATOMANDSHURICA SAPONIN B
DMNWXOC HS Investigative
DMNWXOC SN CHEMBL525269; BDBM50241848; 6)-[(2-O-isoferuloyl)-beta-D-glucopyranosyl]-(1-> 3)-alpha-L-rhamnopyranosyl-(1-> 2)-alpha-L-arabinopyranosyloleanolic acid-28-O-alpha-L-rhamnopyranosyl-(1->
DMNWXOC PC 11994182
DMNWXOC MW 1984.1
DMNWXOC FM C92H142O46
DMNWXOC IC InChI=1S/C92H142O46/c1-34-52(98)59(105)66(112)77(124-34)121-32-46-57(103)62(108)76(133-51(97)17-13-37-12-15-42(119-11)40(95)26-37)85(131-46)135-73-44(29-94)128-81(70(116)64(73)110)129-47-33-123-79(65(111)58(47)104)136-74-54(100)36(3)126-83(71(74)117)137-75-55(101)41(96)30-120-84(75)132-50-19-20-89(8)48(88(50,6)7)18-21-91(10)49(89)16-14-38-39-27-87(4,5)22-24-92(39,25-23-90(38,91)9)86(118)138-82-68(114)61(107)56(102)45(130-82)31-122-78-69(115)63(109)72(43(28-93)127-78)134-80-67(113)60(106)53(99)35(2)125-80/h12-15,17,26,34-36,39,41,43-50,52-85,93-96,98-117H,16,18-25,27-33H2,1-11H3/b17-13+/t34-,35-,36-,39-,41-,43+,44+,45+,46+,47+,48-,49+,50-,52-,53-,54-,55-,56+,57+,58+,59+,60+,61-,62-,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79-,80-,81-,82-,83-,84-,85-,89-,90+,91+,92-/m0/s1
DMNWXOC CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O[C@@H]4CO[C@H]([C@@H]([C@@H]4O)O)O[C@@H]5[C@H]([C@@H](O[C@H]([C@@H]5O)O[C@@H]6[C@H]([C@H](CO[C@H]6O[C@H]7CC[C@]8([C@H](C7(C)C)CC[C@@]9([C@@H]8CC=C1[C@]9(CC[C@@]2([C@H]1CC(CC2)(C)C)C(=O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)O)O)O)O)O)C)C)C)O)O)C)O)CO)OC(=O)/C=C/C1=CC(=C(C=C1)OC)O)O)O)O)O)O
DMNWXOC IK NMYXWQYOXWOLSB-ZSBIDDPTSA-N
DMNWXOC IU [(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-4-[(2S,3R,4S,5R)-5-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMNWXOC DE Discovery agent
DM9WUHD ID DM9WUHD
DM9WUHD DN Clik60
DM9WUHD HS Investigative
DM9WUHD DE Discovery agent
DMS58P1 ID DMS58P1
DMS58P1 DN Clinopodic acid C
DMS58P1 HS Investigative
DMS58P1 SN Clinopodic acid C; CHEMBL1080779; BDBM50310832; (R)-3-(3,4-Dihydroxyphenyl)-2-[3-[2beta-(3,4-dihydroxyphenyl)-3beta-carboxy-2,3-dihydro-1,4-benzodioxin-6-yl]propenoyloxy]propionic acid
DMS58P1 DT Small molecular drug
DMS58P1 PC 44254596
DMS58P1 MW 538.5
DMS58P1 FM C27H22O12
DMS58P1 IC InChI=1S/C27H22O12/c28-16-5-1-14(9-18(16)30)11-22(26(33)34)37-23(32)8-3-13-2-7-20-21(10-13)39-25(27(35)36)24(38-20)15-4-6-17(29)19(31)12-15/h1-10,12,22,24-25,28-31H,11H2,(H,33,34)(H,35,36)/b8-3+/t22-,24+,25+/m1/s1
DMS58P1 CS C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC3=C(C=C2)O[C@H]([C@H](O3)C(=O)O)C4=CC(=C(C=C4)O)O)O)O
DMS58P1 IK KPKHMGUZUPELJC-RXYMDKBQSA-N
DMS58P1 IU (2S,3S)-6-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-1,4-benzodioxine-3-carboxylic acid
DMS58P1 DE Discovery agent
DM537OH ID DM537OH
DM537OH DN Clobenpropit
DM537OH HS Investigative
DM537OH SN clobenpropit; 145231-45-4; Vuf-9153; Vuf 9153; UNII-RKU631JF4H; S-(3-(4(5)-Imidazolyl))propyl-N-(4-chlorobenzyl)isothiourea; CHEBI:64177; RKU631JF4H; 3-(1h-imidazol-5-yl)propyl n'-(4-chlorobenzyl)carbamimidothioate; 3-(1H-imidazol-4-yl)propyl ((4-chlorophenyl)methyl)carbamimidothioate; Carbamimidothioic acid, ((4-chlorophenyl)methyl)-, 3-(1H-imidazol-4-yl)propyl ester; 3-(1H-imidazol-4-yl)propyl N-(4-chlorobenzyl)carbamimidothioate; Carbamimidothioic acid,N-[(4-chlorophenyl)methyl]-, 3-(1H-imidazol-5-yl)propyl ester
DM537OH DT Small molecular drug
DM537OH PC 2790
DM537OH MW 308.8
DM537OH FM C14H17ClN4S
DM537OH IC InChI=1S/C14H17ClN4S/c15-12-5-3-11(4-6-12)8-18-14(16)20-7-1-2-13-9-17-10-19-13/h3-6,9-10H,1-2,7-8H2,(H2,16,18)(H,17,19)
DM537OH CS C1=CC(=CC=C1CN=C(N)SCCCC2=CN=CN2)Cl
DM537OH IK UCAIEVHKDLMIFL-UHFFFAOYSA-N
DM537OH IU 3-(1H-imidazol-5-yl)propyl N'-[(4-chlorophenyl)methyl]carbamimidothioate
DM537OH CA CAS 145231-45-4
DM537OH CB CHEBI:64177
DM537OH DE Discovery agent
DMZLMJH ID DMZLMJH
DMZLMJH DN Clocinnamox
DMZLMJH HS Investigative
DMZLMJH SN clocinnamox; Methoclocinnamox; C-CAM; 14-beta-(4-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorpmorphine mesylate; Clocinnamox mesylate; 117332-69-1; 2-Propenamide, 3-(4-chlorophenyl)-N-((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-oxomorphinan-14-yl)-, monomethanesulfonate; NIH 10443 mesylate; NIH 10989; SCHEMBL4404383; AKOS024259103
DMZLMJH DT Small molecular drug
DMZLMJH PC 6540640
DMZLMJH MW 505
DMZLMJH FM C29H29ClN2O4
DMZLMJH IC InChI=1S/C29H29ClN2O4/c30-20-7-3-17(4-8-20)5-10-24(35)31-29-12-11-22(34)27-28(29)13-14-32(16-18-1-2-18)23(29)15-19-6-9-21(33)26(36-27)25(19)28/h3-10,18,23,27,33H,1-2,11-16H2,(H,31,35)/b10-5+/t23-,27+,28+,29-/m1/s1
DMZLMJH CS C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)NC(=O)/C=C/C7=CC=C(C=C7)Cl
DMZLMJH IK RAURUSFBVQLAPW-DNIKMYEQSA-N
DMZLMJH IU (E)-N-[(4R,4aS,7aR,12bR)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-chlorophenyl)prop-2-enamide
DMZLMJH DE Discovery agent
DMALRU9 ID DMALRU9
DMALRU9 DN Clodinafop
DMALRU9 HS Investigative
DMALRU9 SN Propanoic acid, 2-[4-[(5-chloro-3-fluoro-2-pyridinyl)oxy]phenoxy]-; 87135-08-8; AC1L3BBN; SCHEMBL1535846; CTK3C5537; DTXSID60275833; YUIKUTLBPMDDNQ-UHFFFAOYSA-N; 2-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenoxy]propanoic acid; 2-[4-(5-chloro-3-fluoropyridin-2-yloxy)phenoxy]propionic acid; 2-[4-(5-chloro-3-fluoropyrdin-2-yloxy)phenoxy]propionic acid; 2-[4-[(5-chloro-3-fluoro-2-pyridyl)oxy]phenoxy]propanoic acid; (+)-[4-(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy]-propionic acid
DMALRU9 DT Small molecular drug
DMALRU9 PC 5483847
DMALRU9 MW 311.69
DMALRU9 FM C14H11ClFNO4
DMALRU9 IC InChI=1S/C14H11ClFNO4/c1-8(14(18)19)20-10-2-4-11(5-3-10)21-13-12(16)6-9(15)7-17-13/h2-8H,1H3,(H,18,19)/t8-/m1/s1
DMALRU9 CS C[C@H](C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)Cl)F
DMALRU9 IK YUIKUTLBPMDDNQ-MRVPVSSYSA-N
DMALRU9 IU (2R)-2-[4-(5-chloro-3-fluoropyridin-2-yl)oxyphenoxy]propanoic acid
DMALRU9 CA CAS 114420-56-3
DMALRU9 CB CHEBI:132841
DMALRU9 DE Discovery agent
DMQ37OP ID DMQ37OP
DMQ37OP DN clofilium
DMQ37OP HS Investigative
DMQ37OP SN Clofilium; 68379-02-2; 4-(4-chlorophenyl)butyl-diethyl-heptylazanium; UNII-847G178BMC; 4-Chloro-N,N-diethyl-N-heptylbenzenebutanaminium; AC1L1EHQ; CHEMBL9484; Benzenebutanaminium, 4-chloro-N,N-diethyl-N-heptyl-; CHEBI:34649; 847G178BMC; MLS002154263; GNF-Pf-3889; SMR001233522; Prestwick2_000319; Prestwick3_000319; Prestwick1_000319; BSPBio_000318; SCHEMBL157537; SPBio_002537; cid_175533; GTPL2507; BPBio1_000350; DTXSID9048568; CTK2F6670; BDBM89440; ZINC8035458; NCGC00168464-02; NCGC00168464-01; 68379-03-3 (phosphate[1:1]); LS-186732
DMQ37OP DT Small molecular drug
DMQ37OP PC 2798
DMQ37OP MW 339
DMQ37OP FM C21H37ClN+
DMQ37OP IC InChI=1S/C21H37ClN/c1-4-7-8-9-11-18-23(5-2,6-3)19-12-10-13-20-14-16-21(22)17-15-20/h14-17H,4-13,18-19H2,1-3H3/q+1
DMQ37OP CS CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(C=C1)Cl
DMQ37OP IK WPSYTTKBGAZSCX-UHFFFAOYSA-N
DMQ37OP IU 4-(4-chlorophenyl)butyl-diethyl-heptylazanium
DMQ37OP CA CAS 68379-02-2
DMQ37OP CB CHEBI:34649
DMQ37OP DE Discovery agent
DMH01JV ID DMH01JV
DMH01JV DN cloprostenol
DMH01JV HS Investigative
DMH01JV SN ICI 80996
DMH01JV DT Small molecular drug
DMH01JV PC 5311053
DMH01JV MW 424.9
DMH01JV FM C22H29ClO6
DMH01JV IC InChI=1S/C22H29ClO6/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1
DMH01JV CS C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\\CCCC(=O)O)O
DMH01JV IK VJGGHXVGBSZVMZ-QIZQQNKQSA-N
DMH01JV IU (Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid
DMH01JV CA CAS 54276-21-0
DMH01JV DE Discovery agent
DMH7GKB ID DMH7GKB
DMH7GKB DN Cloranolol
DMH7GKB HS Investigative
DMH7GKB SN Chloranolol-d9; Cloranolol; Cloranolol (INN); Cloranolol [INN]; Cloranolol-d9; Cloranololum; Cloranololum [INN-Latin]; Tobanum-d9; chloranolol; chlorpropanol; 1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol; 1-(tert-Butylamino)-3-(2,5-dichlorophenoxy)-2-propanol; 1-(tert-butylamino)-3-(2,5-dichlorophenoxy)propan-2-ol; 2-Propanol, 1-(2,5-dichlorophenoxy)-3-((1,1-dimethylethyl)amino)-; 39563-28-5; AC1L240Q; C13H19Cl2NO2; CHEBI:135217; CHEMBL156791; Gyki 41099; SCHEMBL80493; tobanum, hydrochloride, (+-)-isomer
DMH7GKB PC 65814
DMH7GKB MW 292.2
DMH7GKB FM C13H19Cl2NO2
DMH7GKB IC XYCMOTOFHFTUIU-UHFFFAOYSA-N
DMH7GKB CS CC(C)(C)NCC(COC1=C(C=CC(=C1)Cl)Cl)O
DMH7GKB IK 1S/C13H19Cl2NO2/c1-13(2,3)16-7-10(17)8-18-12-6-9(14)4-5-11(12)15/h4-6,10,16-17H,7-8H2,1-3H3
DMH7GKB IU 1-(tert-butylamino)-3-(2,5-dichlorophenoxy)propan-2-ol
DMH7GKB CA CAS 39563-28-5
DMH7GKB CB CHEBI:135217
DMH7GKB DE Discovery agent
DMLPXNC ID DMLPXNC
DMLPXNC DN Clorindione
DMLPXNC HS Investigative
DMLPXNC SN Chlophenadione; Chlor-athrombon; Chlorindione; Chlorindionum; Clorindiona [INN-Spanish]; Clorindione; Clorindione [INN:BAN]; Clorindionum [INN-Latin]; Indaliton; M.G. 2552; 1,3-Indandione, 2-(p-chlorophenyl)-; 1146-99-2; 2-(4-CHLOROPHENYL)INDANE-1,3-DIONE; 2-(4-Chlorophenyl)-1H-indene-1,3(2H)-dione; 2-(4-Chlorophenyl)indan-1,3-dione; 2-(4-chlorophenyl)indene-1,3-dione; 2-(p-Chlorophenyl)-1,3-indandione; 2-(p-Chlorophenyl)indan-1,3-dione; BRN 2052412; CHEMBL278519; EINECS 214-553-2; G 25766; G-25766; UNII-541C7WS64R
DMLPXNC PC 70846
DMLPXNC MW 256.68
DMLPXNC FM C15H9ClO2
DMLPXNC IC NJDUWAXIURWWLN-UHFFFAOYSA-N
DMLPXNC CS C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)Cl
DMLPXNC IK 1S/C15H9ClO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H
DMLPXNC IU 2-(4-chlorophenyl)indene-1,3-dione
DMLPXNC CA CAS 1146-99-2
DMLPXNC CB CHEBI:135057
DMLPXNC DE Hypertriglyceridaemia
DMD5FIU ID DMD5FIU
DMD5FIU DN Clorobiocin
DMD5FIU HS Investigative
DMD5FIU SN Clorobiocin; Chlorobiocin; Antibiotic RP 18,631; NSC 227186; RP 18631; 18631 RP; 39868-96-7; CHEMBL303984; 1H-Pyrrole-2-carboxylic acid, 5-methyl-, 3'-ester with N-(8-chloro-7-((6-deoxy-5-C-methyl-4-O-methyl-alpha-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)-4-hydroxy-3-(3-methyl-2-butenyl)benzamide; [(3R,4S,5R,6S)-6-[8-chloro-4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-2-oxo-chromen-7-yl]oxy-5-hydroxy-3-methoxy-2,2-dimethyl-tetrahydropyran-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
DMD5FIU DT Small molecular drug
DMD5FIU PC 54706138
DMD5FIU MW 697.1
DMD5FIU FM C35H37ClN2O11
DMD5FIU IC InChI=1S/C35H37ClN2O11/c1-16(2)7-9-18-15-19(10-13-22(18)39)31(42)38-25-26(40)20-11-14-23(24(36)28(20)47-33(25)44)46-34-27(41)29(30(45-6)35(4,5)49-34)48-32(43)21-12-8-17(3)37-21/h7-8,10-15,27,29-30,34,37,39-41H,9H2,1-6H3,(H,38,42)/t27-,29+,30-,34-/m1/s1
DMD5FIU CS CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=C(C(=O)O4)NC(=O)C5=CC(=C(C=C5)O)CC=C(C)C)O)Cl)O
DMD5FIU IK FJAQNRBDVKIIKK-LFLQOBSNSA-N
DMD5FIU IU [(3R,4S,5R,6S)-6-[8-chloro-4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-2-oxochromen-7-yl]oxy-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
DMD5FIU CA CAS 39868-96-7
DMD5FIU DE Discovery agent
DMU6FOG ID DMU6FOG
DMU6FOG DN Clorsulon
DMU6FOG HS Investigative
DMU6FOG SN CLORSULON; 60200-06-8; Curatrem; Clorsulonum [Latin]; Clorsulone [French]; Clorsulon [Spanish]; UNII-EG1ZDO6LRD; EG1ZDO6LRD; EINECS 262-100-2; MK 401; MK-401; BRN 2821757; 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide; 4-Amino-6-(trichlorovinyl)-m-benzenedisulfonamide; L 631529; L-631,529; 4-Amino-6-(trichlorovinyl)-1,3-benzenedisulfonamide; 4-Amino-6-(trichloroethenyl)-1,3-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4-amino-6-(trichloroethenyl)-; NCGC00016893-01; NCGC00182084-01
DMU6FOG DT Small molecular drug
DMU6FOG PC 43231
DMU6FOG MW 380.7
DMU6FOG FM C8H8Cl3N3O4S2
DMU6FOG IC InChI=1S/C8H8Cl3N3O4S2/c9-7(8(10)11)3-1-4(12)6(20(14,17)18)2-5(3)19(13,15)16/h1-2H,12H2,(H2,13,15,16)(H2,14,17,18)
DMU6FOG CS C1=C(C(=CC(=C1N)S(=O)(=O)N)S(=O)(=O)N)C(=C(Cl)Cl)Cl
DMU6FOG IK QOVTVIYTBRHADL-UHFFFAOYSA-N
DMU6FOG IU 4-amino-6-(1,2,2-trichloroethenyl)benzene-1,3-disulfonamide
DMU6FOG CA CAS 60200-06-8
DMU6FOG CB CHEBI:94811
DMU6FOG DE Discovery agent
DMWTBG8 ID DMWTBG8
DMWTBG8 DN Clostridial collagenase
DMWTBG8 HS Investigative
DMWTBG8 DE Discovery agent
DM1B0PY ID DM1B0PY
DM1B0PY DN CLP-635
DM1B0PY HS Investigative
DM1B0PY SN CLP-656
DM1B0PY CP Chlorion Pharma Inc
DM1B0PY DE Epilepsy
DM9LSOW ID DM9LSOW
DM9LSOW DN CLR-151
DM9LSOW HS Investigative
DM9LSOW SN CLR-100 series; CLR-136; CLR-155; CLR-161
DM9LSOW CP Clera Inc
DM9LSOW DE Psychotic disorder
DM7TX3D ID DM7TX3D
DM7TX3D DN CM-156
DM7TX3D HS Investigative
DM7TX3D SN Sigma opioid antagonists (addiction); Sigma opioid antagonists (addiction), University of Mississippi; 2(3H)-benzoxalones and 2(3H)-benzothiazolones (addiction), University of Mississippi
DM7TX3D CP University of Mississippi
DM7TX3D DE Drug abuse
DMXA8K1 ID DMXA8K1
DMXA8K1 DN CM-352
DMXA8K1 HS Investigative
DMXA8K1 SN compound 2 [PMID 25686022]
DMXA8K1 DT Small molecular drug
DMXA8K1 PC 91623362
DMXA8K1 MW 487.6
DMXA8K1 FM C24H29N3O6S
DMXA8K1 IC InChI=1S/C24H29N3O6S/c1-25-21(28)17-2-4-18(5-3-17)33-19-6-8-20(9-7-19)34(31,32)24(22(29)27-30)11-10-23(16-24)12-14-26-15-13-23/h2-9,26,30H,10-16H2,1H3,(H,25,28)(H,27,29)/t24-/m1/s1
DMXA8K1 CS CNC(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)[C@@]3(CCC4(C3)CCNCC4)C(=O)NO
DMXA8K1 IK ZUZGJCNWNOCKEB-XMMPIXPASA-N
DMXA8K1 IU (3R)-N-hydroxy-3-[4-[4-(methylcarbamoyl)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carboxamide
DMXA8K1 DE Discovery agent
DM6PFG0 ID DM6PFG0
DM6PFG0 DN CMET Avimer polypeptides
DM6PFG0 HS Investigative
DM6PFG0 SN CMET Avimer polypeptides (cancer); MEDI-555; CMET Avimer polypeptides (cancer), MedImmmue; CMET-targeting anticancer avimers, MedImmune; CMET-targeting avimers (cancer), Avidia/MedImmune
DM6PFG0 CP Medlmmune LLC
DM6PFG0 DE Solid tumour/cancer
DMYPG01 ID DMYPG01
DMYPG01 DN CMI-1145
DMYPG01 HS Investigative
DMYPG01 SN AKOS014861624
DMYPG01 DT Small molecular drug
DMYPG01 PC 100962651
DMYPG01 MW 180.21
DMYPG01 FM C8H12N4O
DMYPG01 IC InChI=1S/C8H12N4O/c9-8-11-7(13-12-8)5-3-4-1-2-6(5)10-4/h4-6,10H,1-3H2,(H2,9,12)/t4-,5-,6+/m1/s1
DMYPG01 CS C1C[C@H]2[C@@H](C[C@@H]1N2)C3=NC(=NO3)N
DMYPG01 IK XODBGPCGVOHHEP-PBXRRBTRSA-N
DMYPG01 IU 5-[(1S,2R,4R)-7-azabicyclo[2.2.1]heptan-2-yl]-1,2,4-oxadiazol-3-amine
DMYPG01 DE Discovery agent
DM4PWDJ ID DM4PWDJ
DM4PWDJ DN CMI-489
DM4PWDJ HS Investigative
DM4PWDJ SN CMI-489; CHEMBL291498; HLNPMOXPJPCMLY-UHFFFAOYSA-N; N-methylepibatidine; N-methyl Epibatidine; SCHEMBL10105083; 222/224 N-Methyl-Epibatidine; BDBM50079453; 7-Methyl-2-(6-chloro-3-pyridyl)-7-azabicyclo[2.2.1]heptane; 2-(6-Chloro-pyridin-3-yl)-7-methyl-7-aza-bicyclo[2.2.1]heptane
DM4PWDJ DT Small molecular drug
DM4PWDJ PC 11601009
DM4PWDJ MW 222.71
DM4PWDJ FM C12H15ClN2
DM4PWDJ IC InChI=1S/C12H15ClN2/c1-15-9-3-4-11(15)10(6-9)8-2-5-12(13)14-7-8/h2,5,7,9-11H,3-4,6H2,1H3
DM4PWDJ CS CN1C2CCC1C(C2)C3=CN=C(C=C3)Cl
DM4PWDJ IK HLNPMOXPJPCMLY-UHFFFAOYSA-N
DM4PWDJ IU 2-(6-chloropyridin-3-yl)-7-methyl-7-azabicyclo[2.2.1]heptane
DM4PWDJ DE Discovery agent
DMT9YKG ID DMT9YKG
DMT9YKG DN CMI-936
DMT9YKG HS Investigative
DMT9YKG SN AKOS014858886
DMT9YKG DT Small molecular drug
DMT9YKG PC 100962650
DMT9YKG MW 179.22
DMT9YKG FM C9H13N3O
DMT9YKG IC InChI=1S/C9H13N3O/c1-5-10-9(13-12-5)7-4-6-2-3-8(7)11-6/h6-8,11H,2-4H2,1H3/t6-,7-,8+/m1/s1
DMT9YKG CS CC1=NOC(=N1)[C@@H]2C[C@H]3CC[C@@H]2N3
DMT9YKG IK DCXSASGOFIVZCG-PRJMDXOYSA-N
DMT9YKG IU 5-[(1S,2R,4R)-7-azabicyclo[2.2.1]heptan-2-yl]-3-methyl-1,2,4-oxadiazole
DMT9YKG DE Discovery agent
DMM9K5S ID DMM9K5S
DMM9K5S DN Cmp-2-Keto-3-Deoxy-Octulosonic Acid
DMM9K5S HS Investigative
DMM9K5S SN CMP-KDO; CMP-2-KETO-3-DEOXY-OCTULOSONIC ACID; AC1L9IPX; CMP-3-deoxy-D-manno-octulosonate; CMP-beta-KDO; cytidine 5'-monophosphate 3-deoxy-beta-d-gulo-oct-2-ulo-pyranosonic acid; C04121; CHEBI:86284; DB04482; CMP-3-deoxy-beta-D-manno-octulosonic acid; cytidine 5'-[(3-deoxy-beta-D-manno-oct-2-ulopyranosonyl) hydrogen phosphate]
DMM9K5S DT Small molecular drug
DMM9K5S PC 445888
DMM9K5S MW 543.4
DMM9K5S FM C17H26N3O15P
DMM9K5S IC InChI=1S/C17H26N3O15P/c18-9-1-2-20(16(29)19-9)14-12(26)11(25)8(33-14)5-32-36(30,31)35-17(15(27)28)3-6(22)10(24)13(34-17)7(23)4-21/h1-2,6-8,10-14,21-26H,3-5H2,(H,27,28)(H,30,31)(H2,18,19,29)/t6-,7-,8-,10-,11-,12-,13-,14-,17-/m1/s1
DMM9K5S CS C1[C@H]([C@H]([C@H](O[C@@]1(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)[C@@H](CO)O)O)O
DMM9K5S IK YWWJKULNWGRYAS-UOVSKDHASA-N
DMM9K5S IU (2R,4R,5R,6R)-2-[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-6-[(1R)-1,2-dihydroxyethyl]-4,5-dihydroxyoxane-2-carboxylic acid
DMM9K5S CB CHEBI:86284
DMM9K5S DE Discovery agent
DMBT2ZW ID DMBT2ZW
DMBT2ZW DN cmp5
DMBT2ZW HS Investigative
DMBT2ZW SN ChemBridge ID 9033823
DMBT2ZW DT Small molecular drug
DMBT2ZW PC 6462334
DMBT2ZW MW 351.9
DMBT2ZW FM C21H22ClN3
DMBT2ZW IC InChI=1S/C21H21N3.ClH/c1-2-24-20-9-4-3-8-18(20)19-13-16(10-11-21(19)24)14-22-15-17-7-5-6-12-23-17;/h3-13,22H,2,14-15H2,1H3;1H
DMBT2ZW CS CCN1C2=C(C=C(C=C2)CNCC3=CC=CC=N3)C4=CC=CC=C41.Cl
DMBT2ZW IK LTMOFUKBECEABM-UHFFFAOYSA-N
DMBT2ZW IU 1-(9-ethylcarbazol-3-yl)-N-(pyridin-2-ylmethyl)methanamine;hydrochloride
DMBT2ZW DE Discovery agent
DM241YW ID DM241YW
DM241YW DN CMP-6
DM241YW HS Investigative
DM241YW SN Pyridone 6; 457081-03-7; JAK Inhibitor I; Merck-5; Merck 5; CMP 6; 2-tert-butyl-9-fluoro-3H-benzo[h]imidazo[4,5-f]isoquinolin-7(6H)-one; CHEMBL21156; 2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one; CHEBI:87103; Compound # 2; 2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE; 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE; IZA; C18H16FN3O; MERk-5
DM241YW DT Small molecular drug
DM241YW PC 5494425
DM241YW MW 309.3
DM241YW FM C18H16FN3O
DM241YW IC InChI=1S/C18H16FN3O/c1-18(2,3)17-21-14-10-5-4-9(19)8-12(10)13-11(15(14)22-17)6-7-20-16(13)23/h4-8H,1-3H3,(H,20,23)(H,21,22)
DM241YW CS CC(C)(C)C1=NC2=C(N1)C3=C(C=C(C=C3)F)C4=C2C=CNC4=O
DM241YW IK VNDWQCSOSCCWIP-UHFFFAOYSA-N
DM241YW IU 4-tert-butyl-15-fluoro-3,5,10-triazatetracyclo[11.4.0.02,6.07,12]heptadeca-1(13),2(6),4,7(12),8,14,16-heptaen-11-one
DM241YW CA CAS 457081-03-7
DM241YW CB CHEBI:87103
DM241YW DE Discovery agent
DMKNUYF ID DMKNUYF
DMKNUYF DN CMPD1
DMKNUYF HS Investigative
DMKNUYF SN MAPKAPK2a inhibitor
DMKNUYF DT Small molecular drug
DMKNUYF PC 11382492
DMKNUYF MW 349.4
DMKNUYF FM C22H20FNO2
DMKNUYF IC InChI=1S/C22H20FNO2/c23-21-6-2-1-5-20(21)17-10-8-16(9-11-17)4-3-7-22(26)24-18-12-14-19(25)15-13-18/h1-2,5-6,8-15,25H,3-4,7H2,(H,24,26)
DMKNUYF CS C1=CC=C(C(=C1)C2=CC=C(C=C2)CCCC(=O)NC3=CC=C(C=C3)O)F
DMKNUYF IK ODYAQBDIXCVKAE-UHFFFAOYSA-N
DMKNUYF IU 4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide
DMKNUYF CA CAS 41179-33-3
DMKNUYF CB CHEBI:92949
DMKNUYF DE Discovery agent
DM9IPH4 ID DM9IPH4
DM9IPH4 DN CMPD-167
DM9IPH4 HS Investigative
DM9IPH4 SN L-167; MRK-167; CCR5 inhibitor (HIV infection), IPM; CCR5 inhibitor (vaginal formulation), IPM; CMPD-167 (HIV infection); CMPD-167 (HIV infection), IPM; CMPD-167 (HIV infection), International Partnership for Microbiocides
DM9IPH4 CP Merck & Co Inc
DM9IPH4 DT Small molecular drug
DM9IPH4 PC 5481119
DM9IPH4 MW 574.8
DM9IPH4 FM C35H47FN4O2
DM9IPH4 IC InChI=1S/C35H47FN4O2/c1-5-40-33(21-30(37-40)18-25-10-7-6-8-11-25)26-14-16-39(17-15-26)23-28-20-31(38(4)34(24(2)3)35(41)42)22-32(28)27-12-9-13-29(36)19-27/h6-13,19,21,24,26,28,31-32,34H,5,14-18,20,22-23H2,1-4H3,(H,41,42)/t28-,31+,32-,34-/m1/s1
DM9IPH4 CS CCN1C(=CC(=N1)CC2=CC=CC=C2)C3CCN(CC3)C[C@H]4C[C@@H](C[C@@H]4C5=CC(=CC=C5)F)N(C)[C@H](C(C)C)C(=O)O
DM9IPH4 IK ZTENZJJCFACIAK-ADWVOTLJSA-N
DM9IPH4 IU (2R)-2-[[(1R,3S,4S)-3-[[4-(5-benzyl-2-ethylpyrazol-3-yl)piperidin-1-yl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methylamino]-3-methylbutanoic acid
DM9IPH4 CA CAS 313994-79-5
DM9IPH4 DE Human immunodeficiency virus-1 infection
DMH48YE ID DMH48YE
DMH48YE DN CMP-sialic acid
DMH48YE HS Investigative
DMH48YE SN CMP-Sialic acid; CMP-N-acetylneuraminate; cytidine monophosphate N-acetylneuraminic acid; CMP-NeuNAc; CYTIDINE-5'-MONOPHOSPHATE-5-N-ACETYLNEURAMINIC ACID; Cmp-D-N-acetylneuraminic acid; CHEBI:16556; Cmp-nana; CMP acetylneuraminic acid; 3063-71-6; CMP-N-acetyl-beta-neuraminate; NCC; (2R,4S,5R,6R)-2-[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]-5-acetamido-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMH48YE DT Small molecular drug
DMH48YE PC 448209
DMH48YE MW 614.5
DMH48YE FM C20H31N4O16P
DMH48YE IC InChI=1S/C20H31N4O16P/c1-7(26)22-12-8(27)4-20(18(32)33,39-16(12)13(29)9(28)5-25)40-41(35,36)37-6-10-14(30)15(31)17(38-10)24-3-2-11(21)23-19(24)34/h2-3,8-10,12-17,25,27-31H,4-6H2,1H3,(H,22,26)(H,32,33)(H,35,36)(H2,21,23,34)/t8-,9+,10+,12+,13+,14+,15+,16+,17+,20+/m0/s1
DMH48YE CS CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)O)O
DMH48YE IK TXCIAUNLDRJGJZ-BILDWYJOSA-N
DMH48YE IU (2R,4S,5R,6R)-5-acetamido-2-[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DMH48YE CA CAS 3063-71-6
DMH48YE CB CHEBI:16556
DMH48YE DE Discovery agent
DMA5Z2G ID DMA5Z2G
DMA5Z2G DN C-myb
DMA5Z2G HS Investigative
DMA5Z2G TC Analgesics
DMA5Z2G DE Pain
DMJA8I4 ID DMJA8I4
DMJA8I4 DN CN-2097
DMJA8I4 HS Investigative
DMJA8I4 SN NMDA receptor 2B modulator (neurological diseases), Ardane Therapeutics; PDZ binding domain-targeting peptidomimetic (neurological diseases), Ardane Therapeutics
DMJA8I4 CP Ardane Therapeutics Inc
DMJA8I4 PC 132608720
DMJA8I4 MW 2376.8
DMJA8I4 FM C96H174N44O23S2
DMJA8I4 IC InChI=1S/C96H174N44O23S2/c1-49(2)71(89(162)163)139-85(158)65-31-32-69(144)118-44-33-70(145)117-36-9-6-19-58(84(157)140-72(50(3)141)88(161)136-65)129-77(150)57(18-5-8-35-98)135-86(159)66(45-51-27-29-52(142)30-28-51)137-87(160)67(46-68(101)143)138-83(156)56(17-4-7-34-97)127-74(147)53(99)47-164-165-48-54(100)75(148)128-59(21-11-38-120-91(105)106)78(151)131-61(23-13-40-122-93(109)110)80(153)133-63(25-15-42-124-95(113)114)82(155)134-64(26-16-43-125-96(115)116)81(154)132-62(24-14-41-123-94(111)112)79(152)130-60(22-12-39-121-92(107)108)76(149)126-55(73(102)146)20-10-37-119-90(103)104/h27-30,49-50,53-67,71-72,141-142H,4-26,31-48,97-100H2,1-3H3,(H2,101,143)(H2,102,146)(H,117,145)(H,118,144)(H,126,149)(H,127,147)(H,128,148)(H,129,150)(H,130,152)(H,131,151)(H,132,154)(H,133,153)(H,134,155)(H,135,159)(H,136,161)(H,137,160)(H,138,156)(H,139,158)(H,140,157)(H,162,163)(H4,103,104,119)(H4,105,106,120)(H4,107,108,121)(H4,109,110,122)(H4,111,112,123)(H4,113,114,124)(H4,115,116,125)/t50-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,71+,72+/m1/s1
DMJA8I4 CS C[C@H]([C@H]1C(=N[C@@H](CCC(=NCCC(=NCCCC[C@@H](C(=N1)O)N=C([C@H](CCCCN)N=C([C@H](CC2=CC=C(C=C2)O)N=C([C@H](CC(=N)O)N=C([C@H](CCCCN)N=C([C@H](CSSC[C@@H](C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N)O)O)O)O)O)O)O)O)N)N)O)O)O)O)O)O)O)C(=N[C@@H](C(C)C)C(=O)O)O)O)O
DMJA8I4 IK YVHNLJSCOYUIPK-YPBSVZMPSA-N
DMJA8I4 IU (2S)-2-[[[(2S,5S,18S)-18-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-[(2S)-5-carbamimidamido-1-hydroxy-1-iminopentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-1-hydroxypentan-2-yl]imino-3-hydroxypropyl]disulfanyl]-1-hydroxypropylidene]amino]-1-hydroxyhexylidene]amino]-1,4-dihydroxy-4-iminobutylidene]amino]-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino]-1-hydroxyhexylidene]amino]-3,8,12,19-tetrahydroxy-2-[(1R)-1-hydroxyethyl]-1,4,9,13-tetrazacyclononadeca-3,8,12,19-tetraen-5-yl]-hydroxymethylidene]amino]-3-methylbutanoic acid
DMJA8I4 DE Neurological disorder
DMFW1JC ID DMFW1JC
DMFW1JC DN C-Naphthalen-1-yl-methylamine
DMFW1JC HS Investigative
DMFW1JC SN 1-Naphthalenemethylamine; 118-31-0; naphthalen-1-ylmethanamine; 1-Naphthylmethylamine; 1-NAPHTHALENEMETHANAMINE; 1-(Aminomethyl)naphthalene; 1-Naphthalenemethyl amine; C-Naphthalen-1-yl-methylamine; 1-Naphthylmethanamine; (1-naphthylmethyl)amine hydrochloride; CHEMBL128633; 1-AMINOMETHYLNAPHTHALENE; naphthylmethylamine; NVSYANRBXPURRQ-UHFFFAOYSA-N; MFCD00004048; 1-Naphthalenemethylamine, 97%; Naphthalene-1-methylamine; naphtalenemethylamine; EINECS 204-244-0; naphth-1-ylmethylamine; 1-naphthylmethyl-amine
DMFW1JC DT Small molecular drug
DMFW1JC PC 8355
DMFW1JC MW 157.21
DMFW1JC FM C11H11N
DMFW1JC IC InChI=1S/C11H11N/c12-8-10-6-3-5-9-4-1-2-7-11(9)10/h1-7H,8,12H2
DMFW1JC CS C1=CC=C2C(=C1)C=CC=C2CN
DMFW1JC IK NVSYANRBXPURRQ-UHFFFAOYSA-N
DMFW1JC IU naphthalen-1-ylmethanamine
DMFW1JC CA CAS 118-31-0
DMFW1JC DE Discovery agent
DMEVM0J ID DMEVM0J
DMEVM0J DN CNICIN
DMEVM0J HS Investigative
DMEVM0J SN Cnicin; 24394-09-0; CTK8F8750
DMEVM0J DT Small molecular drug
DMEVM0J PC 5281435
DMEVM0J MW 378.4
DMEVM0J FM C20H26O7
DMEVM0J IC InChI=1S/C20H26O7/c1-11-5-4-6-14(9-21)8-17-18(13(3)20(25)27-17)16(7-11)26-19(24)12(2)15(23)10-22/h5,8,15-18,21-23H,2-4,6-7,9-10H2,1H3/b11-5+,14-8-/t15-,16-,17+,18+/m0/s1
DMEVM0J CS C/C/1=C\\CC/C(=C/[C@@H]2[C@@H]([C@H](C1)OC(=O)C(=C)[C@H](CO)O)C(=C)C(=O)O2)/CO
DMEVM0J IK ZTDFZLVUIVPZDU-QGNHJMHWSA-N
DMEVM0J IU [(3aR,4S,6E,10Z,11aR)-10-(hydroxymethyl)-6-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (3R)-3,4-dihydroxy-2-methylidenebutanoate
DMEVM0J CA CAS 24394-09-0
DMEVM0J DE Discovery agent
DMTEGNB ID DMTEGNB
DMTEGNB DN CNS-1169
DMTEGNB HS Investigative
DMTEGNB CP CeNeS Pharmaceuticals Inc
DMTEGNB DE Schizophrenia
DMZ57O1 ID DMZ57O1
DMZ57O1 DN CNTO-736
DMZ57O1 HS Investigative
DMZ57O1 SN GLP-1 mimetibody (type 2 diabetes), Centocor
DMZ57O1 CP Centocor Ortho Biotech Inc
DMZ57O1 DE Non-insulin dependent diabetes
DMDK5BL ID DMDK5BL
DMDK5BL DN CNX-010
DMDK5BL HS Investigative
DMDK5BL SN 11-beta hydroxysteroid dehydrogenase 1 inhibitors (type 2 diabetes), Connexios Life Sciences
DMDK5BL CP Connexios Life Sciences Pvt Ltd
DMDK5BL DE Non-insulin dependent diabetes
DM5T401 ID DM5T401
DM5T401 DN CNX-011
DM5T401 HS Investigative
DM5T401 SN GPR 40 agonists (type 2 diabetes); CNX-011-67; GPR 40 agonists (type 2 diabetes), Connexios LifeSciences; G-protein coupled receptor 40 agonists (type 2 diabetes), Connexios Life Sciences
DM5T401 CP Connexios Life Sciences Pvt Ltd
DM5T401 DE Non-insulin dependent diabetes
DMTB965 ID DMTB965
DMTB965 DN Cobalt Hexammine Ion
DMTB965 HS Investigative
DMTB965 SN Cobalt Hexammine Ion; Cobalt Hexammine(Iii); Hexaamminecobalt(3+); Cobalt III hexamine; hexaamminecobalt(III); Co(NH3)6; hexakis(azaniumyl)cobalt(3+); CHEBI:30027; [Co(NH3)6](3+)
DMTB965 DT Small molecular drug
DMTB965 PC 453369
DMTB965 MW 161.12
DMTB965 FM CoH18N6+3
DMTB965 IC InChI=1S/Co.6H3N/h;6*1H3/q+3;;;;;;
DMTB965 CS N.N.N.N.N.N.[Co+3]
DMTB965 IK DYLMFCCYOUSRTK-UHFFFAOYSA-N
DMTB965 IU azane;cobalt(3+)
DMTB965 CB CHEBI:30027
DMTB965 DE Discovery agent
DMJRSIF ID DMJRSIF
DMJRSIF DN COCAINE.HCL
DMJRSIF HS Investigative
DMJRSIF SN Cocaine muriate; Cocaine chloride; Sal de merck; l-Cocaine hydrochloride; Cocain-chlorhydrat [German]; EINECS 200-167-1; Cocaine hydrochloride [JAN]; 1alpha-H,5alpha-H-Tropane-2beta-carboxylic acid, 3beta-hydroxy-,; Methyl 3beta-hydroxy-1alphaH,5alphaH-tropan-2beta-carboxylate, benzoate (ester) hydrochloride; Methyl 3-beta-hydroxy-1-alpha-H,5-alpha-H-tropan-2-beta-carboxylate, benzoate (ester) HCl; 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, hydrochloride, (1R-(exo,exo))-
DMJRSIF DT Small molecular drug
DMJRSIF PC 5871
DMJRSIF MW 339.8
DMJRSIF FM C17H22ClNO4
DMJRSIF IC InChI=1S/C17H21NO4.ClH/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11;/h3-7,12-15H,8-10H2,1-2H3;1H/t12-,13-,14+,15-;/m1./s1
DMJRSIF CS CN1[C@@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3=CC=CC=C3)C(=O)OC.Cl
DMJRSIF IK PIQVDUKEQYOJNR-RWXTUVLLSA-N
DMJRSIF IU methyl (1R,2R,3S,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate;hydrochloride
DMJRSIF DE Discovery agent
DMCSAIJ ID DMCSAIJ
DMCSAIJ DN COCHINCHINENENE B
DMCSAIJ HS Investigative
DMCSAIJ SN COCHINCHINENENE B; CHEMBL399481; BDBM50222765
DMCSAIJ DT Small molecular drug
DMCSAIJ PC 23655936
DMCSAIJ MW 512.6
DMCSAIJ FM C32H32O6
DMCSAIJ IC InChI=1S/C32H32O6/c1-36-27-15-9-22(10-16-27)29(17-11-23-8-14-26(34)19-31(23)38-3)32-24(18-28(37-2)20-30(32)35)7-4-21-5-12-25(33)13-6-21/h4-10,12-16,18-20,29,33-35H,11,17H2,1-3H3/b7-4+
DMCSAIJ CS COC1=CC=C(C=C1)C(CCC2=C(C=C(C=C2)O)OC)C3=C(C=C(C=C3O)OC)/C=C/C4=CC=C(C=C4)O
DMCSAIJ IK XZVDYCHPJWUZFS-QPJJXVBHSA-N
DMCSAIJ IU 2-[3-(4-hydroxy-2-methoxyphenyl)-1-(4-methoxyphenyl)propyl]-3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxyphenol
DMCSAIJ DE Discovery agent
DMIGB7N ID DMIGB7N
DMIGB7N DN COCHINCHINENIN B
DMIGB7N HS Investigative
DMIGB7N SN COCHINCHINENIN B; CHEMBL254648; BDBM50222763
DMIGB7N DT Small molecular drug
DMIGB7N PC 23634523
DMIGB7N MW 542.6
DMIGB7N FM C33H34O7
DMIGB7N IC InChI=1S/C33H34O7/c1-38-31-19-27(36)15-8-23(31)9-16-28(21-4-11-25(34)12-5-21)29-18-24(32(39-2)20-33(29)40-3)10-17-30(37)22-6-13-26(35)14-7-22/h4-8,11-15,18-20,28,34-36H,9-10,16-17H2,1-3H3
DMIGB7N CS COC1=CC(=C(C=C1CCC(=O)C2=CC=C(C=C2)O)C(CCC3=C(C=C(C=C3)O)OC)C4=CC=C(C=C4)O)OC
DMIGB7N IK QFWXEYRQNKRQDH-UHFFFAOYSA-N
DMIGB7N IU 3-[5-[3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)propyl]-2,4-dimethoxyphenyl]-1-(4-hydroxyphenyl)propan-1-one
DMIGB7N DE Discovery agent
DMOUSWN ID DMOUSWN
DMOUSWN DN Cochliobolic acid
DMOUSWN HS Investigative
DMOUSWN SN Cochliobolic acid; CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid
DMOUSWN DT Small molecular drug
DMOUSWN PC 6450172
DMOUSWN MW 426.5
DMOUSWN FM C25H30O6
DMOUSWN IC InChI=1S/C25H30O6/c1-3-19(2)16-17-22(27)21(26)15-13-11-9-7-5-4-6-8-10-12-14-20-18-23(28)24(31-20)25(29)30/h4-17,19-20,23-24,28H,3,18H2,1-2H3,(H,29,30)/b6-4+,7-5+,10-8+,11-9+,14-12+,15-13+,17-16+/t19?,20-,23-,24-/m1/s1
DMOUSWN CS CCC(C)/C=C/C(=O)C(=O)/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H]1C[C@H]([C@@H](O1)C(=O)O)O
DMOUSWN IK UWFRQOWLUPERFN-WUSQRGMKSA-N
DMOUSWN IU (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid
DMOUSWN CA CAS 185846-15-5
DMOUSWN DE Discovery agent
DMZ1VSI ID DMZ1VSI
DMZ1VSI DN COCLAURINE
DMZ1VSI HS Investigative
DMZ1VSI SN (S)-Coclaurine; 486-39-5; UNII-CW1576313Y; (1S)-1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol; CHEMBL446211; CHEBI:15950; CW1576313Y; 1-(p-Hydroxybenzyl)-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline; Coclaurin; (S)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-7-isoquinolinol; 7-Isoquinolinol,1,2,3,4-tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-, (1S)-; AC1L4NPG; AC1Q7A6I; SCHEMBL20683184; CTK4J0916; DTXSID60197561; MolPort-019-904-720; ZINC896120
DMZ1VSI DT Small molecular drug
DMZ1VSI PC 160487
DMZ1VSI MW 285.34
DMZ1VSI FM C17H19NO3
DMZ1VSI IC InChI=1S/C17H19NO3/c1-21-17-9-12-6-7-18-15(14(12)10-16(17)20)8-11-2-4-13(19)5-3-11/h2-5,9-10,15,18-20H,6-8H2,1H3/t15-/m0/s1
DMZ1VSI CS COC1=C(C=C2[C@@H](NCCC2=C1)CC3=CC=C(C=C3)O)O
DMZ1VSI IK LVVKXRQZSRUVPY-HNNXBMFYSA-N
DMZ1VSI IU (1S)-1-[(4-hydroxyphenyl)methyl]-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol
DMZ1VSI CA CAS 486-39-5
DMZ1VSI CB CHEBI:15950
DMZ1VSI DE Discovery agent
DM08WPL ID DM08WPL
DM08WPL DN CODEINONE
DM08WPL HS Investigative
DM08WPL SN Codeinone; 6-Codeinone; 467-13-0; UNII-22B5AW0ANN; (5alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-one; EINECS 207-386-1; BRN 0094188; 22B5AW0ANN; CHEBI:18399; 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-; 6-Oxocodeine; (-)-Codeinone; SCHEMBL100655; CHEMBL257627; DTXSID70196909; XYYVYLMBEZUESM-CMKMFDCUSA-N; ZINC4097036; API0000487; LS-92114; C06171; 7,8-Didehydro-4,5; A-epoxy-3-methoxy-17-methyl-morphinan-6-one
DM08WPL DT Small molecular drug
DM08WPL PC 5459910
DM08WPL MW 297.3
DM08WPL FM C18H19NO3
DM08WPL IC InChI=1S/C18H19NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-12,17H,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
DM08WPL CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)C=C4
DM08WPL IK XYYVYLMBEZUESM-CMKMFDCUSA-N
DM08WPL IU (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM08WPL CA CAS 467-13-0
DM08WPL CB CHEBI:18399
DM08WPL DE Discovery agent
DM1I8LU ID DM1I8LU
DM1I8LU DN Coenzyme A
DM1I8LU HS Investigative
DM1I8LU SN coenzyme A; CoASH; CoA-SH; Zeel; 85-61-0; Depot-Zeel; CoA; HSCoA; Coenzym A; Coenzyme ASH; co-enzyme-A; UNII-SAA04E81UX; HS-CoA; SAA04E81UX; CHEBI:15346; 3'-phosphoadenosine-(5')diphospho(4')pantatheine; Coenzyme A hydrate; co-A; Co-A-SH; Reduced CoA; 3'-phosphoadenosine 5'-{3-[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl] dihydrogen diphosphate}
DM1I8LU DT Small molecular drug
DM1I8LU PC 87642
DM1I8LU MW 767.5
DM1I8LU FM C21H36N7O16P3S
DM1I8LU IC InChI=1S/C21H36N7O16P3S/c1-21(2,16(31)19(32)24-4-3-12(29)23-5-6-48)8-41-47(38,39)44-46(36,37)40-7-11-15(43-45(33,34)35)14(30)20(42-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-31,48H,3-8H2,1-2H3,(H,23,29)(H,24,32)(H,36,37)(H,38,39)(H2,22,25,26)(H2,33,34,35)/t11-,14-,15-,16+,20-/m1/s1
DM1I8LU CS CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@H](C(=O)NCCC(=O)NCCS)O
DM1I8LU IK RGJOEKWQDUBAIZ-IBOSZNHHSA-N
DM1I8LU IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
DM1I8LU CA CAS 85-61-0
DM1I8LU CB CHEBI:15346
DM1I8LU DE Discovery agent
DM0ACL9 ID DM0ACL9
DM0ACL9 DN Coformycin
DM0ACL9 HS Investigative
DM0ACL9 SN coformycin; 11033-22-0; UNII-E49510ZL0H; NSC 277817; (R)-3,4,7,8-Tetrahydro-3-beta-D-ribofuranosylimidazo(4,5-d)(1,3)diazepin-8-ol; CHEBI:16213; E49510ZL0H; (8R)-3-beta-D-ribofuranosyl-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol; Imidazo(4,5-d)(1,3)diazepin-8-ol, 3,4,7,8-tetrahydro-3-beta-D-ribofuranosyl-, (R)-; CHEMBL284483; NSC277817; SCHEMBL442534; YOOVTUPUBVHMPG-LODYRLCVSA-N; AC1L1956; BDBM50367032; LS-77849; C01677; Imidazo[4,5-d][1,3]diazepin-8-ol, 3,4,7,8-tetrahydro-3-.beta.-D-ribofuranosyl-, (8R)
DM0ACL9 DT Small molecular drug
DM0ACL9 PC 25447
DM0ACL9 MW 284.27
DM0ACL9 FM C11H16N4O5
DM0ACL9 IC InChI=1S/C11H16N4O5/c16-2-6-8(18)9(19)11(20-6)15-4-14-7-5(17)1-12-3-13-10(7)15/h3-6,8-9,11,16-19H,1-2H2,(H,12,13)/t5-,6-,8-,9-,11-/m1/s1
DM0ACL9 CS C1[C@H](C2=C(NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O
DM0ACL9 IK YOOVTUPUBVHMPG-LODYRLCVSA-N
DM0ACL9 IU (2R,3R,4S,5R)-2-[(8R)-8-hydroxy-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-3-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM0ACL9 CA CAS 11033-22-0
DM0ACL9 CB CHEBI:16213
DM0ACL9 DE Discovery agent
DM326VN ID DM326VN
DM326VN DN COLCHINOL
DM326VN HS Investigative
DM326VN SN Colchinol; (S)-5-Amino-6,7-dihydro-9,10,11-trimethoxy-5H-dibenzo(a,c)cyclohepten-3-ol; 477-31-6; CHEMBL198808; AC1Q7B91; AC1L4V44; CTK4J0211; 5H-Dibenzo(a,c)cyclohepten-3-ol, 5-amino-6,7-dihydro-9,10,11-trimethoxy-, (S)-
DM326VN DT Small molecular drug
DM326VN PC 164612
DM326VN MW 315.4
DM326VN FM C18H21NO4
DM326VN IC InChI=1S/C18H21NO4/c1-21-15-8-10-4-7-14(19)13-9-11(20)5-6-12(13)16(10)18(23-3)17(15)22-2/h5-6,8-9,14,20H,4,7,19H2,1-3H3/t14-/m0/s1
DM326VN CS COC1=C(C(=C2C(=C1)CC[C@@H](C3=C2C=CC(=C3)O)N)OC)OC
DM326VN IK HSDSUBIABLFGDX-AWEZNQCLSA-N
DM326VN IU (8S)-8-amino-13,14,15-trimethoxytricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,5,11,13-hexaen-5-ol
DM326VN CA CAS 477-31-6
DM326VN DE Discovery agent
DMIKD8X ID DMIKD8X
DMIKD8X DN COMBETASTATIN
DMIKD8X HS Investigative
DMIKD8X DT Small molecular drug
DMIKD8X PC 44303123
DMIKD8X MW 318.4
DMIKD8X FM C18H22O5
DMIKD8X IC InChI=1S/C18H22O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-10,13,19H,11H2,1-4H3/b6-5-
DMIKD8X CS COC1=C(C(=CC(C1)/C=C\\C2=CC(=C(C=C2)OC)O)OC)OC
DMIKD8X IK YHCKDJOSGUSXBN-WAYWQWQTSA-N
DMIKD8X IU 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxycyclohexa-2,4-dien-1-yl)ethenyl]phenol
DMIKD8X DE Discovery agent
DMC2IYH ID DMC2IYH
DMC2IYH DN Conantokin-G
DMC2IYH HS Investigative
DMC2IYH SN Conantokin-G; Conantokin G; UNII-32CFR9L3TD; 93438-65-4; 32CFR9L3TD; Con-G; GTPL4161; Conantokin G, >=75% (HPLC)
DMC2IYH DT Small molecular drug
DMC2IYH PC 16181638
DMC2IYH MW 2264.2
DMC2IYH FM C88H138N26O44
DMC2IYH IC InChI=1S/C88H138N26O44/c1-7-34(6)61(77(138)103-41(12-10-20-98-88(96)97)63(124)107-48(23-35(78(139)140)79(141)142)69(130)100-40(11-8-9-19-89)64(125)113-54(31-115)76(137)104-45(62(95)123)28-57(93)118)114-75(136)47(22-33(4)5)106-70(131)49(24-36(80(143)144)81(145)146)109-67(128)44(14-17-56(92)117)102-74(135)53(29-58(94)119)112-73(134)51(26-38(84(151)152)85(153)154)110-66(127)43(13-16-55(91)116)101-68(129)46(21-32(2)3)105-71(132)52(27-39(86(155)156)87(157)158)111-72(133)50(25-37(82(147)148)83(149)150)108-65(126)42(15-18-60(121)122)99-59(120)30-90/h32-54,61,115H,7-31,89-90H2,1-6H3,(H2,91,116)(H2,92,117)(H2,93,118)(H2,94,119)(H2,95,123)(H,99,120)(H,100,130)(H,101,129)(H,102,135)(H,103,138)(H,104,137)(H,105,132)(H,106,131)(H,107,124)(H,108,126)(H,109,128)(H,110,127)(H,111,133)(H,112,134)(H,113,125)(H,114,136)(H,121,122)(H,139,140)(H,141,142)(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)(H,155,156)(H,157,158)(H4,96,97,98)/t34-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,61-/m0/s1
DMC2IYH CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C(=O)O)C(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN
DMC2IYH IK HTBKFGWATIYCSF-QGXIKSNHSA-N
DMC2IYH IU 2-[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-carboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-oxopropyl]propanedioic acid
DMC2IYH DE Discovery agent
DMN4KJI ID DMN4KJI
DMN4KJI DN Conantokin-R
DMN4KJI HS Investigative
DMN4KJI PC 44560113
DMN4KJI MW 3057.4
DMN4KJI FM C126H202N34O48S3
DMN4KJI IC InChI=1S/C126H202N34O48S3/c1-15-57(8)93(115(189)141-62(13)96(170)145-71(24-16-19-36-127)100(174)136-51-89(165)143-83(52-209)111(185)147-73(26-18-21-38-129)104(178)157-92(56(6)7)114(188)154-80(48-86(131)162)108(182)156-84(53-210)112(186)155-82(43-63-29-31-64(161)32-30-63)116(190)160-40-23-28-85(160)125(207)208)159-110(184)81(49-87(132)163)150-99(173)65(44-66(117(191)192)118(193)194)70(27-22-39-135-126(133)134)144-95(169)60(11)139-105(179)76(42-54(2)3)151-106(180)77(45-67(119(195)196)120(197)198)149-98(172)59(10)137-94(168)58(9)138-101(175)75(35-41-211-14)148-102(176)72(25-17-20-37-128)146-97(171)61(12)140-113(187)91(55(4)5)158-109(183)79(47-69(123(203)204)124(205)206)153-107(181)78(46-68(121(199)200)122(201)202)152-103(177)74(33-34-90(166)167)142-88(164)50-130/h29-32,54-62,65-85,91-93,161,209-210H,15-28,33-53,127-130H2,1-14H3,(H2,131,162)(H2,132,163)(H,136,174)(H,137,168)(H,138,175)(H,139,179)(H,140,187)(H,141,189)(H,142,164)(H,143,165)(H,144,169)(H,145,170)(H,146,171)(H,147,185)(H,148,176)(H,149,172)(H,150,173)(H,151,180)(H,152,177)(H,153,181)(H,154,188)(H,155,186)(H,156,182)(H,157,178)(H,158,183)(H,159,184)(H,166,167)(H,191,192)(H,193,194)(H,195,196)(H,197,198)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,207,208)(H4,133,134,135)/t57-,58-,59-,60-,61-,62-,65?,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,91-,92-,93-/m0/s1
DMN4KJI CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)C(CC(C(=O)O)C(=O)O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CC(C(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN
DMN4KJI IK XIRRXDGMZVHVEG-AZOPZXLDSA-N
DMN4KJI IU 2-[(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]-4-carboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4,4-dicarboxybutanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]propanoyl]amino]-4,4-dicarboxybutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-2-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2R)-1-[[(2S)-1-[(2S)-2-carboxypyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]carbamoyl]-6-carbamimidamidohexyl]propanedioic acid
DMN4KJI DE Discovery agent
DMLHF3E ID DMLHF3E
DMLHF3E DN Conantokins G
DMLHF3E HS Investigative
DMLHF3E DE Discovery agent
DMV6H5S ID DMV6H5S
DMV6H5S DN Conantokins T
DMV6H5S HS Investigative
DMV6H5S DE Discovery agent
DMC5RKY ID DMC5RKY
DMC5RKY DN Concatameric CTLA4Ig
DMC5RKY HS Investigative
DMC5RKY SN Concatameric CTLA4Ig (Immunoadhesin); Concatameric CD152Ig (Immunoadhesin), Medexgen; Concatameric CTLA4Ig (Immunoadhesin), Medexgen
DMC5RKY CP Medexgen Co Ltd
DMC5RKY DE Discovery agent
DMRPV0A ID DMRPV0A
DMRPV0A DN Concatameric LAG3Ig
DMRPV0A HS Investigative
DMRPV0A SN Concatameric LAG3Ig (immunoadhesin); CD223Ig (immunoadhesin), Medexgen; Concatameric LAG3Ig (immunoadhesin),Medexgen
DMRPV0A CP Medexgen Co Ltd
DMRPV0A DE Discovery agent
DM4VYP0 ID DM4VYP0
DM4VYP0 DN CONESSINE
DM4VYP0 HS Investigative
DM4VYP0 SN conessine; Roquessine; Neriine; 546-06-5; Conessinum; Wrightine; Conessin; UNII-EZ38J9BBDF; NSC 119994; EZ38J9BBDF; Konessin; CHEBI:27965; GPLGAQQQNWMVMM-MYAJQUOBSA-N; Conessine [INN]; N,N-dimethylcon-5-enin-3beta-amine; ST066907; Conesina [INN-Spanish]; Conessinum [INN-Latin]; DSSTox_CID_26000; DSSTox_RID_81281; DSSTox_GSID_46000; 3beta-(Dimethylamino)con-5-ene; Conesina; EINECS 208-897-2; BRN 4702160; Con-5-enine, 3.beta.-(dimethylamino)-; ((2S,5S,12S,16S,1R,9R,13R)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0< 2,9> 5, 9>
DM4VYP0 DT Small molecular drug
DM4VYP0 PC 441082
DM4VYP0 MW 356.6
DM4VYP0 FM C24H40N2
DM4VYP0 IC InChI=1S/C24H40N2/c1-16-20-8-9-22-19-7-6-17-14-18(25(3)4)10-12-23(17,2)21(19)11-13-24(20,22)15-26(16)5/h6,16,18-22H,7-15H2,1-5H3/t16-,18-,19+,20+,21-,22-,23-,24-/m0/s1
DM4VYP0 CS C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C)C)CN1C
DM4VYP0 IK GPLGAQQQNWMVMM-MYAJQUOBSA-N
DM4VYP0 IU (1R,2S,5S,6S,9R,12S,13R,16S)-N,N,6,7,13-pentamethyl-7-azapentacyclo[10.8.0.02,9.05,9.013,18]icos-18-en-16-amine
DM4VYP0 CA CAS 546-06-5
DM4VYP0 CB CHEBI:27965
DM4VYP0 DE Discovery agent
DMQG2MC ID DMQG2MC
DMQG2MC DN Conotoxin
DMQG2MC HS Investigative
DMQG2MC DE Discovery agent
DM5DTZR ID DM5DTZR
DM5DTZR DN COOH
DM5DTZR HS Investigative
DM5DTZR SN LS-191838
DM5DTZR DT Small molecular drug
DM5DTZR PC 10025649
DM5DTZR MW 429.5
DM5DTZR FM C27H27NO4
DM5DTZR IC InChI=1S/C27H27NO4/c1-2-6-20-18-24(32-23-7-4-3-5-8-23)10-12-26(20)31-14-13-22-17-21-15-19(16-27(29)30)9-11-25(21)28-22/h3-5,7-12,15,17-18,28H,2,6,13-14,16H2,1H3,(H,29,30)
DM5DTZR CS CCCC1=C(C=CC(=C1)OC2=CC=CC=C2)OCCC3=CC4=C(N3)C=CC(=C4)CC(=O)O
DM5DTZR IK DFFOSEJNFZUOSK-UHFFFAOYSA-N
DM5DTZR IU 2-[2-[2-(4-phenoxy-2-propylphenoxy)ethyl]-1H-indol-5-yl]acetic acid
DM5DTZR CA CAS 209808-51-5
DM5DTZR DE Discovery agent
DMFH5J9 ID DMFH5J9
DMFH5J9 DN cooling agent 10
DMFH5J9 HS Investigative
DMFH5J9 SN (-)-menthoxypropane-1,2-diol
DMFH5J9 DT Small molecular drug
DMFH5J9 PC 5362595
DMFH5J9 MW 230.34
DMFH5J9 FM C13H26O3
DMFH5J9 IC InChI=1S/C13H26O3/c1-9(2)12-5-4-10(3)6-13(12)16-8-11(15)7-14/h9-15H,4-8H2,1-3H3
DMFH5J9 CS CC1CCC(C(C1)OCC(CO)O)C(C)C
DMFH5J9 IK MDVYIGJINBYKOM-UHFFFAOYSA-N
DMFH5J9 IU 3-(5-methyl-2-propan-2-ylcyclohexyl)oxypropane-1,2-diol
DMFH5J9 CA CAS 87061-04-9
DMFH5J9 DE Discovery agent
DMT5SED ID DMT5SED
DMT5SED DN CORDOIN
DMT5SED HS Investigative
DMT5SED SN Cordoin; Derricidin; trans-1-(2-Hydroxy-4-((3-methyl-2-butenyl)oxy)phenyl)-3-phenyl-2-propen-1-one; 2-Propen-1-one, 1-(2-hydroxy-4-((3-methyl-2-butenyl)oxy)phenyl)-3-phenyl-, (E)-; 38965-74-1; substituted chalcone, 5a; AC1NZGI9; AC1Q5EJC; CHEMBL450771; SCHEMBL18265486; BDBM29137; 51619-65-9; 2'-Hydroxy-4'-(prenyloxy)chalcone; NSC270894; LMPK12120040; NSC-270894; 1-{2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-3-phenylprop-2-en-1-one; LS-123926; J3.608.736F
DMT5SED DT Small molecular drug
DMT5SED PC 5961410
DMT5SED MW 308.4
DMT5SED FM C20H20O3
DMT5SED IC InChI=1S/C20H20O3/c1-15(2)12-13-23-17-9-10-18(20(22)14-17)19(21)11-8-16-6-4-3-5-7-16/h3-12,14,22H,13H2,1-2H3/b11-8+
DMT5SED CS CC(=CCOC1=CC(=C(C=C1)C(=O)/C=C/C2=CC=CC=C2)O)C
DMT5SED IK DGUGLZYULGVSIZ-DHZHZOJOSA-N
DMT5SED IU (E)-1-[2-hydroxy-4-(3-methylbut-2-enoxy)phenyl]-3-phenylprop-2-en-1-one
DMT5SED CA CAS 38965-74-1
DMT5SED DE Discovery agent
DM72Y01 ID DM72Y01
DM72Y01 DN Cordycepin
DM72Y01 HS Investigative
DM72Y01 SN 3'-deoxyadenosine
DM72Y01 DT Small molecular drug
DM72Y01 PC 6303
DM72Y01 MW 251.24
DM72Y01 FM C10H13N5O3
DM72Y01 IC InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
DM72Y01 CS C1[C@H](O[C@H]([C@@H]1O)N2C=NC3=C(N=CN=C32)N)CO
DM72Y01 IK OFEZSBMBBKLLBJ-BAJZRUMYSA-N
DM72Y01 IU (2R,3R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
DM72Y01 CA CAS 73-03-0
DM72Y01 CB CHEBI:29014
DM72Y01 DE Discovery agent
DMAC698 ID DMAC698
DMAC698 DN CORILAGIN
DMAC698 HS Investigative
DMAC698 SN Corilagin; 23094-69-1; CHEMBL449392; CHEBI:3884; TUSDEZXZIZRFGC-XIGLUPEJSA-N; Corillagin; Corilagin,(S); AC1Q6PBU; AC1L2K3M; (1s,19r,21s,22r,23r)-6,7,8,11,12,13,22,23-octahydroxy-3,16-dioxo-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-21-yl 3,4,5-trihydroxybenzoate; SCHEMBL329080; Corilagin, analytical standard; CTK4F0871; MolPort-020-005-758; b-D-Glucopyranose, cyclic3,6-[(1R)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate]1-(3,4,5-trihydroxybenzoate); ZINC4098612; BDBM50242279
DMAC698 DT Small molecular drug
DMAC698 PC 73568
DMAC698 MW 634.5
DMAC698 FM C27H22O18
DMAC698 IC InChI=1S/C27H22O18/c28-9-1-6(2-10(29)16(9)32)24(39)45-27-22(38)23-19(35)13(43-27)5-42-25(40)7-3-11(30)17(33)20(36)14(7)15-8(26(41)44-23)4-12(31)18(34)21(15)37/h1-4,13,19,22-23,27-38H,5H2/t13-,19-,22-,23+,27+/m1/s1
DMAC698 CS C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)O)O
DMAC698 IK TUSDEZXZIZRFGC-XIGLUPEJSA-N
DMAC698 IU [(1S,19R,21S,22R,23R)-6,7,8,11,12,13,22,23-octahydroxy-3,16-dioxo-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-21-yl] 3,4,5-trihydroxybenzoate
DMAC698 CA CAS 2088321-44-0
DMAC698 CB CHEBI:3884
DMAC698 DE Discovery agent
DMZBUE7 ID DMZBUE7
DMZBUE7 DN CORONARIDINE
DMZBUE7 HS Investigative
DMZBUE7 SN CORONARIDINE; Coronardine; CHEMBL364613; CHEBI:3887; (-)-Coronaridine; NSC127490; Ibogamine-18-carboxylic acid, methyl ester; Methyl ibogamine-18-carboxylate; 467-77-6; AC1L2JXS; NVVDQMVGALBDGE-KSWFMABOSA-N; BDBM50329102
DMZBUE7 DT Small molecular drug
DMZBUE7 PC 73489
DMZBUE7 MW 338.4
DMZBUE7 FM C21H26N2O2
DMZBUE7 IC InChI=1S/C21H26N2O2/c1-3-14-10-13-11-21(20(24)25-2)18-16(8-9-23(12-13)19(14)21)15-6-4-5-7-17(15)22-18/h4-7,13-14,19,22H,3,8-12H2,1-2H3/t13-,14-,19-,21+/m0/s1
DMZBUE7 CS CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC
DMZBUE7 IK NVVDQMVGALBDGE-KSWFMABOSA-N
DMZBUE7 IU methyl (1S,15S,17S,18S)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMZBUE7 CA CAS 467-77-6
DMZBUE7 CB CHEBI:3887
DMZBUE7 DE Discovery agent
DM563PZ ID DM563PZ
DM563PZ DN Corosolic acid
DM563PZ HS Investigative
DM563PZ SN A,5xi,18; A)-2,3-dihydroxyurs-12-en-28-oic acid; AC1Q5QHO; AC1L4WCO; SCHEMBL1157257; KB-333790; LS-193275; (2a,3b)-2,3-dihydroxy-urs-12-en-28-oic acid; (1S,2R,4aS,6aR,6aS,6bR,10R,11R,12aR,14bR)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM563PZ DT Small molecular drug
DM563PZ PC 6918774
DM563PZ MW 472.7
DM563PZ FM C30H48O4
DM563PZ IC InChI=1S/C30H48O4/c1-17-10-13-30(25(33)34)15-14-28(6)19(23(30)18(17)2)8-9-22-27(5)16-20(31)24(32)26(3,4)21(27)11-12-29(22,28)7/h8,17-18,20-24,31-32H,9-16H2,1-7H3,(H,33,34)/t17-,18+,20-,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1
DM563PZ CS C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5(C)C)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O
DM563PZ IK HFGSQOYIOKBQOW-ZSDYHTTISA-N
DM563PZ IU (1S,2R,4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
DM563PZ CA CAS 4547-24-4
DM563PZ CB CHEBI:67895
DM563PZ DE Discovery agent
DM5ISQK ID DM5ISQK
DM5ISQK DN Correloid
DM5ISQK HS Investigative
DM5ISQK SN Correloid; CHEMBL362198
DM5ISQK DT Small molecular drug
DM5ISQK PC 44389018
DM5ISQK MW 788.8
DM5ISQK FM C40H52O16
DM5ISQK IC InChI=1S/C40H52O16/c1-18-16-39(48)26-14-15-35(8)25-12-13-27(46)50-17-38(25,19(2)51-20(3)41)31(53-22(5)43)28(52-21(4)42)29(35)36(26,9)32(54-23(6)44)33(55-24(7)45)37(39,10)40(30(18)56-40)34(47)49-11/h12-13,19,25-26,28-33,48H,1,14-17H2,2-11H3/t19-,25?,26?,28+,29?,30-,31+,32-,33+,35+,36+,37-,38-,39-,40?/m1/s1
DM5ISQK CS C[C@H]([C@]12COC(=O)C=CC1[C@@]3(CCC4[C@@](C3[C@@H]([C@@H]2OC(=O)C)OC(=O)C)([C@@H]([C@@H]([C@@]5([C@]4(CC(=C)[C@@H]6C5(O6)C(=O)OC)O)C)OC(=O)C)OC(=O)C)C)C)OC(=O)C
DM5ISQK IK VKDXHXWBOARFPD-MDAQDJAWSA-N
DM5ISQK IU methyl (2R,3S,4R,5R,8R,11R,15S,22R,23R,24S)-3,4,23,24-tetraacetyloxy-22-[(1R)-1-acetyloxyethyl]-11-hydroxy-2,5,15-trimethyl-9-methylidene-19-oxo-7,20-dioxahexacyclo[13.9.0.02,12.05,11.06,8.016,22]tetracos-17-ene-6-carboxylate
DM5ISQK DE Discovery agent
DMACH7K ID DMACH7K
DMACH7K DN correolide
DMACH7K HS Investigative
DMACH7K SN Correolide; C13849; GTPL2555
DMACH7K DT Small molecular drug
DMACH7K PC 11643509
DMACH7K MW 788.8
DMACH7K FM C40H52O16
DMACH7K IC InChI=1S/C40H52O16/c1-18-16-39(48)26-14-15-35(8)25-12-13-27(46)50-17-38(25,19(2)51-20(3)41)31(53-22(5)43)28(52-21(4)42)29(35)36(26,9)32(54-23(6)44)33(55-24(7)45)37(39,10)40(30(18)56-40)34(47)49-11/h12-13,19,25-26,28-33,48H,1,14-17H2,2-11H3/t19?,25-,26+,28-,29-,30+,31-,32+,33-,35-,36-,37+,38+,39+,40-/m0/s1
DMACH7K CS CC([C@]12COC(=O)C=C[C@H]1[C@@]3(CC[C@@H]4[C@@]([C@H]3[C@@H]([C@@H]2OC(=O)C)OC(=O)C)([C@@H]([C@@H]([C@@]5([C@]4(CC(=C)[C@@H]6[C@]5(O6)C(=O)OC)O)C)OC(=O)C)OC(=O)C)C)C)OC(=O)C
DMACH7K IK VKDXHXWBOARFPD-IHWRNOMOSA-N
DMACH7K IU methyl (1S,2R,3S,4R,5R,6S,8R,11R,12R,15S,16S,22R,23R,24S)-3,4,23,24-tetraacetyloxy-22-(1-acetyloxyethyl)-11-hydroxy-2,5,15-trimethyl-9-methylidene-19-oxo-7,20-dioxahexacyclo[13.9.0.02,12.05,11.06,8.016,22]tetracos-17-ene-6-carboxylate
DMACH7K CB CHEBI:34654
DMACH7K DE Discovery agent
DM463S2 ID DM463S2
DM463S2 DN CORYMBONE B
DM463S2 HS Investigative
DM463S2 SN corymbone B
DM463S2 DT Small molecular drug
DM463S2 PC 24878741
DM463S2 MW 522.6
DM463S2 FM C31H38O7
DM463S2 IC InChI=1S/C31H38O7/c1-16(2)15-19(22-27(36)30(4,5)29(38)31(6,7)28(22)37)21-24(33)17(3)25(34)23(26(21)35)20(32)14-13-18-11-9-8-10-12-18/h8-12,16,19,33-36H,13-15H2,1-7H3
DM463S2 CS CC1=C(C(=C(C(=C1O)C(=O)CCC2=CC=CC=C2)O)C(CC(C)C)C3=C(C(C(=O)C(C3=O)(C)C)(C)C)O)O
DM463S2 IK LCFIVEWYLOYPOX-UHFFFAOYSA-N
DM463S2 IU 5-hydroxy-2,2,6,6-tetramethyl-4-[3-methyl-1-[2,4,6-trihydroxy-3-methyl-5-(3-phenylpropanoyl)phenyl]butyl]cyclohex-4-ene-1,3-dione
DM463S2 DE Discovery agent
DM18CUZ ID DM18CUZ
DM18CUZ DN CORYNANTHEINE
DM18CUZ HS Investigative
DM18CUZ SN Corynantheine; Hirsuteine; BRN 0096586; 18904-54-6; 17,18-Secoyohimban-16-carboxylic acid, 16,17,18,19-tetradehydro-17-methoxy-, methyl ester, (E)-; AC1MHD3Z; SCHEMBL3084853; MolPort-039-338-502; ZINC85909641; LS-144745; (16E)-16,17,18,19-Tetradehydro-17-methoxycorynan-16-carboxylic acid methyl ester; methyl (Z)-2-[(2S,3R,12bS)-3-vinyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxy-prop-2-enoate; methyl (Z)-2-[(2S,3R,12bS)-3-ethenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methox
DM18CUZ DT Small molecular drug
DM18CUZ PC 3037997
DM18CUZ MW 366.5
DM18CUZ FM C22H26N2O3
DM18CUZ IC InChI=1S/C22H26N2O3/c1-4-14-12-24-10-9-16-15-7-5-6-8-19(15)23-21(16)20(24)11-17(14)18(13-26-2)22(25)27-3/h4-8,13-14,17,20,23H,1,9-12H2,2-3H3/b18-13+/t14-,17-,20-/m0/s1
DM18CUZ CS CO/C=C(\\[C@H]1C[C@H]2C3=C(CCN2C[C@@H]1C=C)C4=CC=CC=C4N3)/C(=O)OC
DM18CUZ IK TZUGIFAYWNNSAO-XPOGPMDLSA-N
DM18CUZ IU methyl (E)-2-[(2S,3R,12bS)-3-ethenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
DM18CUZ CA CAS 18904-54-6
DM18CUZ CB CHEBI:141891
DM18CUZ DE Discovery agent
DMSFXJ8 ID DMSFXJ8
DMSFXJ8 DN Cosalane derivative
DMSFXJ8 HS Investigative
DMSFXJ8 PC 44371300
DMSFXJ8 MW 1123.7
DMSFXJ8 FM C59H70B2Cl2Na4O10
DMSFXJ8 IC InChI=1S/C59H72B2Cl2O10.4Na/c1-35(2)10-6-11-36(3)49-20-21-50-46-19-18-42-26-37(22-24-58(42,4)51(46)23-25-59(49,50)5)12-9-17-45(40-29-47(56(64)65)54(52(62)31-40)72-33-38-13-7-15-43(27-38)60(68)69)41-30-48(57(66)67)55(53(63)32-41)73-34-39-14-8-16-44(28-39)61(70)71;;;;/h7-8,13-17,27-32,35-37,42,46,49-51,68,70H,6,9-12,18-26,33-34H2,1-5H3,(H,64,65)(H,66,67);;;;/q-2;4*+1/p-2/t36?,37-,42?,46?,49+,50?,51?,58-,59+;;;;/m0..../s1
DMSFXJ8 CS B(C1=CC(=CC=C1)COC2=C(C=C(C=C2Cl)C(=CCC[C@H]3CC[C@]4(C(C3)CCC5C4CC[C@]6(C5CC[C@@H]6C(C)CCCC(C)C)C)C)C7=CC(=C(C(=C7)Cl)OCC8=CC=CC(=C8)B(O)[O-])C(=O)[O-])C(=O)[O-])(O)[O-].[Na+].[Na+].[Na+].[Na+]
DMSFXJ8 IK ABZNJZXRGKGMJC-MCUHGXDSSA-L
DMSFXJ8 IU tetrasodium;5-[1-[3-carboxylato-5-chloro-4-[[3-[hydroxy(oxido)boranyl]phenyl]methoxy]phenyl]-4-[(3S,10S,13R,17R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]but-1-enyl]-3-chloro-2-[[3-[hydroxy(oxido)boranyl]phenyl]methoxy]benzoate
DMSFXJ8 DE Discovery agent
DMU6OB4 ID DMU6OB4
DMU6OB4 DN Costunolide
DMU6OB4 HS Investigative
DMU6OB4 SN Costunolide; Costunolid; Costus lactone; Costunlide; AC1NSPGS; HRYLQFBHBWLLLL-GYIATTAWSA-N; Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, [3aS-(3aR*,6E,10E,11aS*)]-; BRD-A49888826-001-01-8; (6E,10E)-3a,4,5,8,9,11a-Hexahydro-6,10-dimethyl-3-methylenecyclodeca[b]furan-2(3H)-one; (E,E)-6-.alpha.-Hydroxygermacra-1(10),4,11(13)-trien-12-oic acid .gamma.-lactone; Germacra-1(10),4,11(13)-trien-12-oic acid, 6.alpha.-hydroxy-, .gamma.-lactone, (E,E)-
DMU6OB4 DT Small molecular drug
DMU6OB4 PC 5281437
DMU6OB4 MW 232.32
DMU6OB4 FM C15H20O2
DMU6OB4 IC InChI=1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,14+/m0/s1
DMU6OB4 CS C/C/1=C\\CC/C(=C/[C@@H]2[C@@H](CC1)C(=C)C(=O)O2)/C
DMU6OB4 IK HRYLQFBHBWLLLL-AHNJNIBGSA-N
DMU6OB4 IU (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one
DMU6OB4 CA CAS 553-21-9
DMU6OB4 CB CHEBI:3900
DMU6OB4 DE Discovery agent
DM7TCPG ID DM7TCPG
DM7TCPG DN Coumaranone
DM7TCPG HS Investigative
DM7TCPG SN Benzofuran-3(2H)-one; Benzofuran-3-one; Coumaran-3-one; Coumaranone; MGKPCLNUSDGXGT-UHFFFAOYSA-N; PubChem7023; benzofuran-3 (2h)-one; benzofuran-3-(2H)-one; 1-Benzofuran-3(2H)-one; 1-benzofuran-3-one; 2,3-Dihydrobenzo[b]furan-3-one; 2,3-dihydro-1-benzofuran-3-one; 2-hydrobenzo[b]furan-3-one; 2H-3-Benzofuranone; 2H-BENZOFURAN-3-ONE; 2H-BEZOFURAN-3-ONE; 3(2H)-BENZOFURANONE; 3-(2H)-benzo[b]furanone; 3-BENZOFURANONE; 3-Coumaranone; 7169-34-8; 71699-34-8; AC1L2MLQ; CCRIS 3596; MFCD00051810; NCIOpen2_003700; SCHEMBL69412
DM7TCPG PC 23556
DM7TCPG MW 134.13
DM7TCPG FM C8H6O2
DM7TCPG IC MGKPCLNUSDGXGT-UHFFFAOYSA-N
DM7TCPG CS C1C(=O)C2=CC=CC=C2O1
DM7TCPG IK 1S/C8H6O2/c9-7-5-10-8-4-2-1-3-6(7)8/h1-4H,5H2
DM7TCPG IU 1-benzofuran-3-one
DM7TCPG CA CAS 7169-34-8
DM7TCPG DE Discovery agent
DM0N8ZM ID DM0N8ZM
DM0N8ZM DN Coumarin
DM0N8ZM HS Investigative
DM0N8ZM SN coumarin; 2H-Chromen-2-one; 91-64-5; 2H-1-Benzopyran-2-one; cumarin; 1,2-Benzopyrone; Rattex; Tonka bean camphor; Coumarinic anhydride; chromen-2-one; Coumarine; Benzo-alpha-pyrone; cis-o-Coumarinic acid lactone; o-Hydroxycinnamic acid lactone; o-Hydroxycinnamic lactone; 2-Oxo-1,2-benzopyran; Coumarinic lactone; Kumarin; Benzo-a-pyrone; Kumarin [Czech]; 5,6-Benzo-2-pyrone; 2H-1-Benzopyran, 2-oxo-; 5,6-Benzo-alpha-pyrone; 2H-Benzo(b)pyran-2-one; 2H-Benzo[b]pyran-2-one; Caswell No. 259C; o-Coumaric acid lactone
DM0N8ZM DT Small molecular drug
DM0N8ZM PC 323
DM0N8ZM MW 146.14
DM0N8ZM FM C9H6O2
DM0N8ZM IC InChI=1S/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H
DM0N8ZM CS C1=CC=C2C(=C1)C=CC(=O)O2
DM0N8ZM IK ZYGHJZDHTFUPRJ-UHFFFAOYSA-N
DM0N8ZM IU chromen-2-one
DM0N8ZM CA CAS 91-64-5
DM0N8ZM CB CHEBI:28794
DM0N8ZM DE Discovery agent
DMAJNPS ID DMAJNPS
DMAJNPS DN Coumermycin
DMAJNPS HS Investigative
DMAJNPS DT Small molecular drug
DMAJNPS PC 54675768
DMAJNPS MW 1110.1
DMAJNPS FM C55H59N5O20
DMAJNPS IC InChI=1S/C55H59N5O20/c1-21-12-16-29(57-21)48(67)77-42-38(63)52(79-54(6,7)44(42)71-10)73-31-18-14-26-36(61)34(50(69)75-40(26)24(31)4)59-46(65)28-20-56-33(23(28)3)47(66)60-35-37(62)27-15-19-32(25(5)41(27)76-51(35)70)74-53-39(64)43(45(72-11)55(8,9)80-53)78-49(68)30-17-13-22(2)58-30/h12-20,38-39,42-45,52-53,56-58,61-64H,1-11H3,(H,59,65)(H,60,66)/t38-,39-,42+,43+,44-,45-,52-,53-/m1/s1
DMAJNPS CS CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=C(C(=O)O4)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(C7=C(C(=C(C=C7)O[C@H]8[C@@H]([C@@H]([C@H](C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)C)OC6=O)O)O)C)O
DMAJNPS IK WTIJXIZOODAMJT-DHFGXMAYSA-N
DMAJNPS IU [(3R,4S,5R,6R)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2R,3R,4S,5R)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1H-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate
DMAJNPS CA CAS 4434-05-3
DMAJNPS CB CHEBI:3907
DMAJNPS DE Discovery agent
DM40TBU ID DM40TBU
DM40TBU DN Coumestrol
DM40TBU HS Investigative
DM40TBU SN COUMESTROL; 479-13-0; Cumoestrol; Cumoesterol; Cumostrol; Coumesterol; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 7,12-Dihydroxycoumestan; 3,9-Dihydroxycoumestan; UNII-V7NW98OB34; NSC 22842; CCRIS 7311; NSC22842; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; EINECS 207-525-6; BRN 0266702; CHEMBL30707; MLS000738006; V7NW98OB34; CHEBI:3908; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-
DM40TBU DT Small molecular drug
DM40TBU PC 5281707
DM40TBU MW 268.22
DM40TBU FM C15H8O5
DM40TBU IC InChI=1S/C15H8O5/c16-7-1-3-9-11(5-7)19-14-10-4-2-8(17)6-12(10)20-15(18)13(9)14/h1-6,16-17H
DM40TBU CS C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O
DM40TBU IK ZZIALNLLNHEQPJ-UHFFFAOYSA-N
DM40TBU IU 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one
DM40TBU CA CAS 479-13-0
DM40TBU CB CHEBI:3908
DM40TBU DE Discovery agent
DM2LWNF ID DM2LWNF
DM2LWNF DN COV08-0064
DM2LWNF HS Investigative
DM2LWNF CP Mallinckrodt Pharma
DM2LWNF DT Small molecular drug
DM2LWNF DE Parkinson disease
DMT2RHV ID DMT2RHV
DMT2RHV DN CP 4010
DMT2RHV HS Investigative
DMT2RHV SN CP-4010
DMT2RHV DE Discovery agent
DMSNVKP ID DMSNVKP
DMSNVKP DN CP 93129
DMSNVKP HS Investigative
DMSNVKP SN CP-93129; CP93129; CP-93,129
DMSNVKP DT Small molecular drug
DMSNVKP PC 124007
DMSNVKP MW 215.25
DMSNVKP FM C12H13N3O
DMSNVKP IC InChI=1S/C12H13N3O/c16-11-2-1-10-12(15-11)9(7-14-10)8-3-5-13-6-4-8/h1-3,7,13-14H,4-6H2,(H,15,16)
DMSNVKP CS C1CNCC=C1C2=CNC3=C2NC(=O)C=C3
DMSNVKP IK PJYVGMRFPFNZCT-UHFFFAOYSA-N
DMSNVKP IU 3-(1,2,3,6-tetrahydropyridin-4-yl)-1,4-dihydropyrrolo[3,2-b]pyridin-5-one
DMSNVKP CA CAS 127792-75-0
DMSNVKP CB CHEBI:93436
DMSNVKP DE Discovery agent
DMLFNTH ID DMLFNTH
DMLFNTH DN CP-100263
DMLFNTH HS Investigative
DMLFNTH SN 3-Piperidinamine,N-[(2-methoxyphenyl)methyl]-2-phenyl-, (2S,3S)-; ACMC-1CCIL; SCHEMBL3951618; CTK4C0571; L007874
DMLFNTH CP Pfizer
DMLFNTH DT Small molecular drug
DMLFNTH PC 9796216
DMLFNTH MW 296.4
DMLFNTH FM C19H24N2O
DMLFNTH IC InChI=1S/C19H24N2O/c1-22-18-12-6-5-10-16(18)14-21-17-11-7-13-20-19(17)15-8-3-2-4-9-15/h2-6,8-10,12,17,19-21H,7,11,13-14H2,1H3/t17-,19-/m1/s1
DMLFNTH CS COC1=CC=CC=C1CN[C@@H]2CCCN[C@@H]2C3=CC=CC=C3
DMLFNTH IK DTQNEFOKTXXQKV-IEBWSBKVSA-N
DMLFNTH IU (2R,3R)-N-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine
DMLFNTH CA CAS 872726-33-5
DMLFNTH DE Vomiting
DM3ZIDT ID DM3ZIDT
DM3ZIDT DN CP-126998
DM3ZIDT HS Investigative
DM3ZIDT SN 3-[2-(1-Benzylpiperidin-4-yl)ethyl]-7-methyl-6,7-dihydro-5H-pyrrolo[3,2-f][1,2-]benzisoxazol-6-one
DM3ZIDT PC 10318177
DM3ZIDT MW 389.5
DM3ZIDT FM C24H27N3O2
DM3ZIDT IC InChI=1S/C24H27N3O2/c1-26-22-15-23-20(13-19(22)14-24(26)28)21(25-29-23)8-7-17-9-11-27(12-10-17)16-18-5-3-2-4-6-18/h2-6,13,15,17H,7-12,14,16H2,1H3
DM3ZIDT CS CN1C(=O)CC2=CC3=C(C=C21)ON=C3CCC4CCN(CC4)CC5=CC=CC=C5
DM3ZIDT IK GBRYDMXCJVBJHH-UHFFFAOYSA-N
DM3ZIDT IU 3-[2-(1-benzylpiperidin-4-yl)ethyl]-7-methyl-5H-pyrrolo[3,2-f][1,2]benzoxazol-6-one
DM3ZIDT DE Discovery agent
DMYHR74 ID DMYHR74
DMYHR74 DN CP154,526
DMYHR74 HS Investigative
DMYHR74 SN CP-154526; 157286-86-7; CP 154,526; CHEMBL9946; CP154526; UNII-9A549FB00R; 9A549FB00R; CHEMBL475903; CP-154526-1; CP-154,526; N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine; N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo(2,3-d)pyrimidin-4-amine; PDSP1_001299; AC1NSJWW; CP154,526; butyl-(2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)ethylamine; SCHEMBL5707848; GTPL3495; FHQYJZCJRZHINA-UHFFFAOYSA-N; ZINC1539133; BCP26372; BDBM50058163; BDBM50369802
DMYHR74 DT Small molecular drug
DMYHR74 PC 5311055
DMYHR74 MW 364.5
DMYHR74 FM C23H32N4
DMYHR74 IC InChI=1S/C23H32N4/c1-8-10-11-26(9-2)22-20-18(6)14-27(23(20)25-19(7)24-22)21-16(4)12-15(3)13-17(21)5/h12-14H,8-11H2,1-7H3
DMYHR74 CS CCCCN(CC)C1=NC(=NC2=C1C(=CN2C3=C(C=C(C=C3C)C)C)C)C
DMYHR74 IK FHQYJZCJRZHINA-UHFFFAOYSA-N
DMYHR74 IU N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
DMYHR74 CA CAS 157286-86-7
DMYHR74 DE Depression
DMGLO2X ID DMGLO2X
DMGLO2X DN CP-226269
DMGLO2X HS Investigative
DMGLO2X SN CP-226,269; CP 226269; CP226269
DMGLO2X DT Small molecular drug
DMGLO2X PC 9796720
DMGLO2X MW 310.4
DMGLO2X FM C18H19FN4
DMGLO2X IC InChI=1S/C18H19FN4/c19-15-4-5-17-14(11-15)12-16(21-17)13-22-7-9-23(10-8-22)18-3-1-2-6-20-18/h1-6,11-12,21H,7-10,13H2
DMGLO2X CS C1CN(CCN1CC2=CC3=C(N2)C=CC(=C3)F)C4=CC=CC=N4
DMGLO2X IK PQOIDBZLMJMYCD-UHFFFAOYSA-N
DMGLO2X IU 5-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-indole
DMGLO2X CA CAS 220941-93-5
DMGLO2X DE Discovery agent
DMGN38F ID DMGN38F
DMGN38F DN CP-271485
DMGN38F HS Investigative
DMGN38F SN CP-271485; 2-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL) ETHYL-4-(4'-ETHOXY [1,1'-BIPHENYL]-4-YL)-4-OXOBUTANOIC ACID; CP8; (6R)-4-BENZYL-6-(1-METHYL-2,2-DIOXIDO-1,3-DIHYDRO-2,1-BENZISOTHIAZOL-5-YL)MORPHOLIN-3-ONE; 1utt; AC1L9MIT; DB02118; CP 271485; (6S)-4-benzyl-6-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)morpholin-3-one; 3-Morpholinone, 6-(1,3-dihydro-1-methyl-2,1-benzisothiazol-5-yl)-4-(phenylmethyl)-, S,S-dioxid; 35580-46-2; (6S)-4-benzyl-6-(1-methyl-2,2-dioxido-1,3-dihydro-2,1-benzisothiazol-5-yl)morpholin-3-one
DMGN38F DT Small molecular drug
DMGN38F PC 448940
DMGN38F MW 372.4
DMGN38F FM C19H20N2O4S
DMGN38F IC InChI=1S/C19H20N2O4S/c1-20-17-8-7-15(9-16(17)13-26(20,23)24)18-11-21(19(22)12-25-18)10-14-5-3-2-4-6-14/h2-9,18H,10-13H2,1H3/t18-/m1/s1
DMGN38F CS CN1C2=C(CS1(=O)=O)C=C(C=C2)[C@H]3CN(C(=O)CO3)CC4=CC=CC=C4
DMGN38F IK CIUMOGWIMXNXSQ-GOSISDBHSA-N
DMGN38F IU (6S)-4-benzyl-6-(1-methyl-2,2-dioxo-3H-2,1-benzothiazol-5-yl)morpholin-3-one
DMGN38F CA CAS 35580-46-2
DMGN38F DE Discovery agent
DM6BRLA ID DM6BRLA
DM6BRLA DN CP-294838
DM6BRLA HS Investigative
DM6BRLA SN CP 294838; CP294838
DM6BRLA DT Small molecular drug
DM6BRLA PC 9889227
DM6BRLA MW 436.3
DM6BRLA FM C22H23Cl2NO4
DM6BRLA IC InChI=1S/C22H23Cl2NO4/c1-22(2,3)12-25-17-9-8-13(23)10-15(17)20(14-6-4-5-7-16(14)24)29-18(21(25)28)11-19(26)27/h4-10,18,20H,11-12H2,1-3H3,(H,26,27)
DM6BRLA CS CC(C)(C)CN1C2=C(C=C(C=C2)Cl)C(OC(C1=O)CC(=O)O)C3=CC=CC=C3Cl
DM6BRLA IK BHDQOMHFEOHAQK-UHFFFAOYSA-N
DM6BRLA IU 2-[7-chloro-5-(2-chlorophenyl)-1-(2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetic acid
DM6BRLA DE Discovery agent
DMME6K2 ID DMME6K2
DMME6K2 DN CP-305202
DMME6K2 HS Investigative
DMME6K2 SN CP-305202; CHEMBL1276497; BDBM50330342
DMME6K2 DT Small molecular drug
DMME6K2 PC 52948369
DMME6K2 MW 512.7
DMME6K2 FM C30H44N2O5
DMME6K2 IC InChI=1S/C30H44N2O5/c1-21(2)18-25(33)29(34)24(19-22-10-5-4-6-11-22)32-30(35)28-26(36-3)14-7-15-27(28)37-17-9-13-23-12-8-16-31-20-23/h7-8,12,14-16,20-22,24-25,29,33-34H,4-6,9-11,13,17-19H2,1-3H3,(H,32,35)/t24-,25-,29+/m0/s1
DMME6K2 CS CC(C)C[C@@H]([C@@H]([C@H](CC1CCCCC1)NC(=O)C2=C(C=CC=C2OCCCC3=CN=CC=C3)OC)O)O
DMME6K2 IK PJZBKGNAKHKHSH-IALVYGIMSA-N
DMME6K2 IU N-[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]-2-methoxy-6-(3-pyridin-3-ylpropoxy)benzamide
DMME6K2 DE Discovery agent
DMY8O0B ID DMY8O0B
DMY8O0B DN CP-320626
DMY8O0B HS Investigative
DMY8O0B SN CP-320626; UNII-FKX709RK3Q; FKX709RK3Q; CHEMBL99889; 5-CHLORO-1H-INDOLE-2-CARBOXYLIC ACID [1-(4-FLUOROBENZYL)-2-(4-HYDROXYPIPERIDIN-1YL)-2-OXOETHYL]AMIDE; 5-chloro-N-[(2S)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide; YDCGVASFVACWKF-NRFANRHFSA-N; AC1L9GTI; 1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-; 186430-23-9; SCHEMBL7234251; BDBM35346; DB03383; 1H-Indole-2-carboxamide, 5-chloro-N-(1-((4-fluorophenyl)methyl)-
DMY8O0B DT Small molecular drug
DMY8O0B PC 444746
DMY8O0B MW 443.9
DMY8O0B FM C23H23ClFN3O3
DMY8O0B IC InChI=1S/C23H23ClFN3O3/c24-16-3-6-19-15(12-16)13-20(26-19)22(30)27-21(11-14-1-4-17(25)5-2-14)23(31)28-9-7-18(29)8-10-28/h1-6,12-13,18,21,26,29H,7-11H2,(H,27,30)/t21-/m0/s1
DMY8O0B CS C1CN(CCC1O)C(=O)[C@H](CC2=CC=C(C=C2)F)NC(=O)C3=CC4=C(N3)C=CC(=C4)Cl
DMY8O0B IK YDCGVASFVACWKF-NRFANRHFSA-N
DMY8O0B IU 5-chloro-N-[(2S)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-1H-indole-2-carboxamide
DMY8O0B CA CAS 186430-23-9
DMY8O0B DE Discovery agent
DMTJOWH ID DMTJOWH
DMTJOWH DN CP-339818
DMTJOWH HS Investigative
DMTJOWH SN CHEMBL281622; AC1LCVJB; CP 339818; Tocris-1399; C13847; (1-Benzyl-1H-quinolin-4-ylidene)-pentyl-amine; SureCN12648579; GTPL2558; SCHEMBL12648579; CHEBI:34602; 1-benzyl-N-pentylquinolin-4-imine; 1-benzyl-N-pentyl-quinolin-4-imine; ZINC17919916; BDBM50083523; ZINC100002080; ZINC253533285; NCGC00025144-01; AJ-70179; CP339818; AJ-70180; N-pentyl-1-(phenylmethyl)quinolin-4-imine
DMTJOWH DT Small molecular drug
DMTJOWH PC 656767
DMTJOWH MW 304.4
DMTJOWH FM C21H24N2
DMTJOWH IC InChI=1S/C21H24N2/c1-2-3-9-15-22-20-14-16-23(17-18-10-5-4-6-11-18)21-13-8-7-12-19(20)21/h4-8,10-14,16H,2-3,9,15,17H2,1H3
DMTJOWH CS CCCCCN=C1C=CN(C2=CC=CC=C12)CC3=CC=CC=C3
DMTJOWH IK MMGAVKCAGQCFHS-UHFFFAOYSA-N
DMTJOWH IU 1-benzyl-N-pentylquinolin-4-imine
DMTJOWH CA CAS 185855-91-8
DMTJOWH CB CHEBI:34602
DMTJOWH DE Discovery agent
DM93CA4 ID DM93CA4
DM93CA4 DN CP-376395
DM93CA4 HS Investigative
DM93CA4 SN CP-376395; CP 376395; 175140-00-8; UNII-5113G7FP34; 3,6-Dimethyl-N-(Pentan-3-Yl)-2-(2,4,6-Trimethylphenoxy)pyridin-4-Amine; 5113G7FP34; VIZBSVDBNLAVAW-UHFFFAOYSA-N; 1Q5; CP376395; 4k5y; SCHEMBL123421; GTPL3496; CHEMBL270948; DTXSID0047298; BDBM20966; MolPort-009-194-134; KS-00002WT7; 2-Aryloxy-4-alkylaminopyridine, 3a; ZINC14975027; AKOS015994585; 4-Pyridinamine, N-(1-ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-; GD-0065; CS-7833; API0007847; compound 3a [PMID: 18288792]; HY-14130; KB-76174; CP-376,395; CP 376,395
DM93CA4 DT Small molecular drug
DM93CA4 PC 9862166
DM93CA4 MW 326.5
DM93CA4 FM C21H30N2O
DM93CA4 IC InChI=1S/C21H30N2O/c1-8-18(9-2)23-19-12-16(6)22-21(17(19)7)24-20-14(4)10-13(3)11-15(20)5/h10-12,18H,8-9H2,1-7H3,(H,22,23)
DM93CA4 CS CCC(CC)NC1=C(C(=NC(=C1)C)OC2=C(C=C(C=C2C)C)C)C
DM93CA4 IK VIZBSVDBNLAVAW-UHFFFAOYSA-N
DM93CA4 IU 3,6-dimethyl-N-pentan-3-yl-2-(2,4,6-trimethylphenoxy)pyridin-4-amine
DM93CA4 CA CAS 175140-00-8
DM93CA4 DE Discovery agent
DMDPH3W ID DMDPH3W
DMDPH3W DN CP-394531
DMDPH3W HS Investigative
DMDPH3W SN CP-394531; UNII-227D9ED2SI; CHEMBL77779; 227D9ED2SI; 305822-63-3; SCHEMBL3111189; BDBM50113783; 2,7-Phenanthrenediol, 2-(chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 2,7-Phenanthrenediol, 2-(2-chloroethynyl)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-, (2R,4aS,10aR)-; 4a-Benzyl-2-chloroethynyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-2,7-diol(CP-394531)
DMDPH3W DT Small molecular drug
DMDPH3W PC 9820558
DMDPH3W MW 366.9
DMDPH3W FM C23H23ClO2
DMDPH3W IC InChI=1S/C23H23ClO2/c24-13-12-22(26)10-11-23(15-17-4-2-1-3-5-17)19(16-22)7-6-18-14-20(25)8-9-21(18)23/h1-5,8-9,14,19,25-26H,6-7,10-11,15-16H2/t19-,22+,23+/m1/s1
DMDPH3W CS C1CC2=C(C=CC(=C2)O)[C@]3([C@H]1C[C@](CC3)(C#CCl)O)CC4=CC=CC=C4
DMDPH3W IK CNOAOQSZNOTZLQ-OIBXWCBGSA-N
DMDPH3W IU (2R,4aS,10aR)-4a-benzyl-2-(2-chloroethynyl)-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol
DMDPH3W CA CAS 305822-63-3
DMDPH3W DE Discovery agent
DM1U6P7 ID DM1U6P7
DM1U6P7 DN CP-409069
DM1U6P7 HS Investigative
DM1U6P7 SN CHEMBL78625; CP-409069; SCHEMBL3114566; BDBM50113780; (2R,4aS,10aR)-4a-benzyl-2-(prop-1-ynyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-2,7-diol
DM1U6P7 DT Small molecular drug
DM1U6P7 PC 9819614
DM1U6P7 MW 346.5
DM1U6P7 FM C24H26O2
DM1U6P7 IC InChI=1S/C24H26O2/c1-2-12-23(26)13-14-24(16-18-6-4-3-5-7-18)20(17-23)9-8-19-15-21(25)10-11-22(19)24/h3-7,10-11,15,20,25-26H,8-9,13-14,16-17H2,1H3/t20-,23-,24+/m1/s1
DM1U6P7 CS CC#C[C@]1(CC[C@@]2([C@@H](C1)CCC3=C2C=CC(=C3)O)CC4=CC=CC=C4)O
DM1U6P7 IK WDSPVCXWXOIFRA-HUVFLSCGSA-N
DM1U6P7 IU (2R,4aS,10aR)-4a-benzyl-2-prop-1-ynyl-1,3,4,9,10,10a-hexahydrophenanthrene-2,7-diol
DM1U6P7 DE Discovery agent
DMROYD7 ID DMROYD7
DMROYD7 DN CP-409092
DMROYD7 HS Investigative
DMROYD7 SN GABA(A) partial agonists (anxiety), Pfizer
DMROYD7 PC 9839190
DMROYD7 MW 297.35
DMROYD7 FM C17H19N3O2
DMROYD7 IC InChI=1S/C17H19N3O2/c1-18-9-11-5-7-12(8-6-11)20-17(22)13-10-19-14-3-2-4-15(21)16(13)14/h5-8,10,18-19H,2-4,9H2,1H3,(H,20,22)
DMROYD7 CS CNCC1=CC=C(C=C1)NC(=O)C2=CNC3=C2C(=O)CCC3
DMROYD7 IK XFJIYNUISLDNLP-UHFFFAOYSA-N
DMROYD7 IU N-[4-(methylaminomethyl)phenyl]-4-oxo-1,5,6,7-tetrahydroindole-3-carboxamide
DMROYD7 CA CAS 194098-25-4
DMROYD7 DE Discovery agent
DMZMKAQ ID DMZMKAQ
DMZMKAQ DN CP-4200
DMZMKAQ HS Investigative
DMZMKAQ SN Lipidated azacitidine (cancer, Lipid Vector), Clavis Pharma; 5-azacytidine-5'-elaidate
DMZMKAQ CP Clavis Pharma AS
DMZMKAQ DE Solid tumour/cancer
DMTHVCA ID DMTHVCA
DMTHVCA DN CP-4497
DMTHVCA HS Investigative
DMTHVCA SN CP-47497
DMTHVCA PC 15942731
DMTHVCA MW 318.5
DMTHVCA FM C21H34O2
DMTHVCA IC InChI=1S/C21H34O2/c1-4-5-6-7-13-21(2,3)17-11-12-19(20(23)15-17)16-9-8-10-18(22)14-16/h11-12,15-16,18,22-23H,4-10,13-14H2,1-3H3/t16-,18+/m0/s1
DMTHVCA CS CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@H](C2)O)O
DMTHVCA IK ZWWRREXSUJTKNN-FUHWJXTLSA-N
DMTHVCA IU 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol
DMTHVCA CA CAS 114753-51-4
DMTHVCA DE Discovery agent
DMS2RHE ID DMS2RHE
DMS2RHE DN CP-470,711
DMS2RHE HS Investigative
DMS2RHE SN CP-470711; CHEMBL36514; SCHEMBL6294633; BDBM50113494; LS-135453
DMS2RHE DT Small molecular drug
DMS2RHE PC 9841731
DMS2RHE MW 358.4
DMS2RHE FM C18H26N6O2
DMS2RHE IC InChI=1S/C18H26N6O2/c1-11-9-23(15-5-7-19-17(21-15)13(3)25)10-12(2)24(11)16-6-8-20-18(22-16)14(4)26/h5-8,11-14,25-26H,9-10H2,1-4H3/t11-,12+,13-,14-/m1/s1
DMS2RHE CS C[C@@H]1CN(C[C@@H](N1C2=NC(=NC=C2)[C@@H](C)O)C)C3=NC(=NC=C3)[C@@H](C)O
DMS2RHE IK ATNZXIACLONSSN-XJFOESAGSA-N
DMS2RHE IU (1R)-1-[4-[(3S,5R)-4-[2-[(1R)-1-hydroxyethyl]pyrimidin-4-yl]-3,5-dimethylpiperazin-1-yl]pyrimidin-2-yl]ethanol
DMS2RHE DE Discovery agent
DMZT7C1 ID DMZT7C1
DMZT7C1 DN CP-481,715
DMZT7C1 HS Investigative
DMZT7C1 SN CP481715; CP 481715; CP-481715
DMZT7C1 DT Small molecular drug
DMZT7C1 PC 5311123
DMZT7C1 MW 482.5
DMZT7C1 FM C26H31FN4O4
DMZT7C1 IC InChI=1S/C26H31FN4O4/c1-26(2,35)11-10-17(24(28)33)14-23(32)21(13-16-6-5-7-18(27)12-16)31-25(34)22-15-29-19-8-3-4-9-20(19)30-22/h3-9,12,15,17,21,23,32,35H,10-11,13-14H2,1-2H3,(H2,28,33)(H,31,34)/t17-,21+,23+/m1/s1
DMZT7C1 CS CC(C)(CC[C@H](C[C@@H]([C@H](CC1=CC(=CC=C1)F)NC(=O)C2=NC3=CC=CC=C3N=C2)O)C(=O)N)O
DMZT7C1 IK YEQJVHQCUDMXFG-FHZYATBESA-N
DMZT7C1 IU N-[(2S,3S,5R)-5-carbamoyl-1-(3-fluorophenyl)-3,8-dihydroxy-8-methylnonan-2-yl]quinoxaline-2-carboxamide
DMZT7C1 CA CAS 212790-31-3
DMZT7C1 DE Discovery agent
DMKWB31 ID DMKWB31
DMKWB31 DN CP55,244
DMKWB31 HS Investigative
DMKWB31 SN CP 55244; CP-55,244; CP 55,244; CP55244; CP-55244
DMKWB31 DT Small molecular drug
DMKWB31 PC 9844074
DMKWB31 MW 402.6
DMKWB31 FM C26H42O3
DMKWB31 IC InChI=1S/C26H42O3/c1-4-5-6-7-12-26(2,3)20-10-11-22(25(29)15-20)24-16-21(28)14-19-9-8-18(17-27)13-23(19)24/h10-11,15,18-19,21,23-24,27-29H,4-9,12-14,16-17H2,1-3H3/t18-,19-,21+,23+,24-/m0/s1
DMKWB31 CS CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2C[C@@H](C[C@H]3[C@H]2C[C@H](CC3)CO)O)O
DMKWB31 IK ZAELPWSCABXXAB-NWXGMGMZSA-N
DMKWB31 IU (2R,4R,4aR,6S,8aS)-6-(hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl]-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol
DMKWB31 CA CAS 79678-32-3
DMKWB31 DE Discovery agent
DMNLD6E ID DMNLD6E
DMNLD6E DN CP55,667
DMNLD6E HS Investigative
DMNLD6E SN CP 55,667; CP-55,667
DMNLD6E DT Small molecular drug
DMNLD6E PC 4412255
DMNLD6E MW 376.6
DMNLD6E FM C24H40O3
DMNLD6E IC InChI=1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3
DMNLD6E CS CCCCCCC(C)(C)C1=CC(=C(C=C1)C2CC(CCC2CCCO)O)O
DMNLD6E IK YNZFFALZMRAPHQ-UHFFFAOYSA-N
DMNLD6E IU 2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
DMNLD6E CB CHEBI:91490
DMNLD6E DE Discovery agent
DMTKO7P ID DMTKO7P
DMTKO7P DN CP608,039
DMTKO7P HS Investigative
DMTKO7P SN CP-608,039
DMTKO7P DT Small molecular drug
DMTKO7P PC 73977920
DMTKO7P MW 528.9
DMTKO7P FM C23H25ClN8O5
DMTKO7P IC InChI=1S/C23H25ClN8O5/c1-11-5-15(37-31-11)35-8-12-3-4-14(24)6-13(12)7-27-20-17-21(29-9-28-20)32(10-30-17)23-18(33)16(25)19(36-23)22(34)26-2/h3-6,9-10,16,18-19,23,33H,7-8,25H2,1-2H3,(H,26,34)(H,27,28,29)/t16-,18+,19-,23+/m0/s1
DMTKO7P CS CC1=NOC(=C1)OCC2=C(C=C(C=C2)Cl)CNC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)C(=O)NC)N)O
DMTKO7P IK KXDJDMIUJGBFAV-QYUDBREXSA-N
DMTKO7P IU (2S,3S,4R,5R)-3-amino-5-[6-[[5-chloro-2-[(3-methyl-1,2-oxazol-5-yl)oxymethyl]phenyl]methylamino]purin-9-yl]-4-hydroxy-N-methyloxolane-2-carboxamide
DMTKO7P DE Discovery agent
DMO0PS9 ID DMO0PS9
DMO0PS9 DN CP-640186
DMO0PS9 HS Investigative
DMO0PS9 SN CP-640186; 591778-68-6; UNII-04L1E4J3ZT; CP640186; (R)-anthracen-9-yl(3-(morpholine-4-carbonyl)-[1,4'-bipiperidin]-1'-yl)methanone; CHEMBL208943; 04L1E4J3ZT; CHEBI:45293; (3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine; (3R)-1'-(anthracen-9-ylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine; RCP; CP 640186; {(3R)-1'-(anthracen-9-ylcarbonyl)[1,4'-bipiperidin]-3-yl}(morpholin-4-yl)methanone; [(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]piperidin-3-yl]-morpholin-4-ylmethanone; 591778-70-0
DMO0PS9 DT Small molecular drug
DMO0PS9 PC 449097
DMO0PS9 MW 485.6
DMO0PS9 FM C30H35N3O3
DMO0PS9 IC InChI=1S/C30H35N3O3/c34-29(32-16-18-36-19-17-32)24-8-5-13-33(21-24)25-11-14-31(15-12-25)30(35)28-26-9-3-1-6-22(26)20-23-7-2-4-10-27(23)28/h1-4,6-7,9-10,20,24-25H,5,8,11-19,21H2/t24-/m1/s1
DMO0PS9 CS C1C[C@H](CN(C1)C2CCN(CC2)C(=O)C3=C4C=CC=CC4=CC5=CC=CC=C53)C(=O)N6CCOCC6
DMO0PS9 IK LDQKDRLEMKIYMC-XMMPIXPASA-N
DMO0PS9 IU [(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]piperidin-3-yl]-morpholin-4-ylmethanone
DMO0PS9 CA CAS 591778-68-6
DMO0PS9 CB CHEBI:45293
DMO0PS9 DE Discovery agent
DMVBPRO ID DMVBPRO
DMVBPRO DN CP-673451
DMVBPRO HS Investigative
DMVBPRO SN CP-673,451
DMVBPRO DT Small molecular drug
DMVBPRO PC 10158940
DMVBPRO MW 417.5
DMVBPRO FM C24H27N5O2
DMVBPRO IC InChI=1S/C24H27N5O2/c1-30-13-14-31-19-6-7-21-20(15-19)26-16-29(21)23-8-5-17-3-2-4-22(24(17)27-23)28-11-9-18(25)10-12-28/h2-8,15-16,18H,9-14,25H2,1H3
DMVBPRO CS COCCOC1=CC2=C(C=C1)N(C=N2)C3=NC4=C(C=CC=C4N5CCC(CC5)N)C=C3
DMVBPRO IK DEEOXSOLTLIWMG-UHFFFAOYSA-N
DMVBPRO IU 1-[2-[5-(2-methoxyethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
DMVBPRO CA CAS 343787-29-1
DMVBPRO CB CHEBI:131173
DMVBPRO DE Discovery agent
DMBQTZG ID DMBQTZG
DMBQTZG DN CP-70949
DMBQTZG HS Investigative
DMBQTZG SN PFI-367; PFI-856; GSK-3-beta inhibitor, Pfizer; Glycogen synthase kinase-3-beta inhibitor, Pfizer
DMBQTZG CP Pfizer Inc
DMBQTZG DE Diabetic complication
DM9LYJT ID DM9LYJT
DM9LYJT DN CP734432
DM9LYJT HS Investigative
DM9LYJT SN CP 734432; CP-734432
DM9LYJT DT Small molecular drug
DM9LYJT PC 73755071
DM9LYJT MW 468.5
DM9LYJT FM C23H25F3NO4S-
DM9LYJT IC InChI=1S/C23H26F3NO4S/c24-23(25,26)16-4-1-3-15(13-16)14-18(28)8-6-17-7-11-21(29)27(17)12-2-5-19-9-10-20(32-19)22(30)31/h1,3-4,9-10,13,17-18,28H,2,5-8,11-12,14H2,(H,30,31)/p-1/t17-,18+/m0/s1
DM9LYJT CS C1CC(=O)N([C@H]1CC[C@H](CC2=CC(=CC=C2)C(F)(F)F)O)CCCC3=CC=C(S3)C(=O)[O-]
DM9LYJT IK JYZXGURJKNAFPT-ZWKOTPCHSA-M
DM9LYJT IU 5-[3-[(2S)-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]-5-oxopyrrolidin-1-yl]propyl]thiophene-2-carboxylate
DM9LYJT DE Discovery agent
DMANV7R ID DMANV7R
DMANV7R DN CP-775146
DMANV7R HS Investigative
DMANV7R SN CP775146
DMANV7R DT Small molecular drug
DMANV7R PC 10410059
DMANV7R MW 423.5
DMANV7R FM C26H33NO4
DMANV7R IC InChI=1S/C26H33NO4/c1-18(2)20-12-10-19(11-13-20)15-24(28)27-14-6-8-22(17-27)21-7-5-9-23(16-21)31-26(3,4)25(29)30/h5,7,9-13,16,18,22H,6,8,14-15,17H2,1-4H3,(H,29,30)/t22-/m1/s1
DMANV7R CS CC(C)C1=CC=C(C=C1)CC(=O)N2CCC[C@H](C2)C3=CC(=CC=C3)OC(C)(C)C(=O)O
DMANV7R IK OISHBINQIFNIPV-JOCHJYFZSA-N
DMANV7R IU 2-methyl-2-[3-[(3S)-1-[2-(4-propan-2-ylphenyl)acetyl]piperidin-3-yl]phenoxy]propanoic acid
DMANV7R CA CAS 702680-17-9
DMANV7R DE Discovery agent
DM3M1LA ID DM3M1LA
DM3M1LA DN CP-809101
DM3M1LA HS Investigative
DM3M1LA SN PF-3246799; PHA-181731A; PHA-57378; PHA-670080; PNU-181731A; PNU-57378; PNU-57378E; 5-HT 2 agonists, Pharmacia
DM3M1LA CP Pharmacia Corp
DM3M1LA DT Small molecular drug
DM3M1LA PC 9901086
DM3M1LA MW 304.77
DM3M1LA FM C15H17ClN4O
DM3M1LA IC InChI=1S/C15H17ClN4O/c16-13-3-1-2-12(8-13)11-21-15-10-18-9-14(19-15)20-6-4-17-5-7-20/h1-3,8-10,17H,4-7,11H2
DM3M1LA CS C1CN(CCN1)C2=CN=CC(=N2)OCC3=CC(=CC=C3)Cl
DM3M1LA IK PCWGGOVOEWHPMG-UHFFFAOYSA-N
DM3M1LA IU 2-[(3-chlorophenyl)methoxy]-6-piperazin-1-ylpyrazine
DM3M1LA CA CAS 479683-64-2
DM3M1LA DE Neurological disorder
DMXDG13 ID DMXDG13
DMXDG13 DN CP-810123
DMXDG13 HS Investigative
DMXDG13 SN CP-810123; UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
DMXDG13 DT Small molecular drug
DMXDG13 PC 11184481
DMXDG13 MW 258.32
DMXDG13 FM C14H18N4O
DMXDG13 IC InChI=1S/C14H18N4O/c1-10-2-3-12-13(15-10)16-14(19-12)18-9-8-17-6-4-11(18)5-7-17/h2-3,11H,4-9H2,1H3
DMXDG13 CS CC1=NC2=C(C=C1)OC(=N2)N3CCN4CCC3CC4
DMXDG13 IK BSNKYWSMUAGMDO-UHFFFAOYSA-N
DMXDG13 IU 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-methyl-[1,3]oxazolo[4,5-b]pyridine
DMXDG13 CA CAS 439608-12-5
DMXDG13 DE Discovery agent
DMHN2LT ID DMHN2LT
DMHN2LT DN CP-94,253
DMHN2LT HS Investigative
DMHN2LT SN CP-94253; CP-94,253; Tocris-1317; NCGC00025108-01; AC1N1FU8; SCHEMBL9695044; GTPL3221; CHEMBL1570196; CHEBI:92591; ZINC1894220; BCP28082; AKOS022184337; CP94253; CP94253NIEaNI/CP94253NIEaNI; AJ-32224; LS-139500; L003950; BRD-K33860217-003-01-6; 4-{5-propoxypyrrolo[3,2-b]pyridin-3-yl}-1,2,3,6-tetrahydropyridine
DMHN2LT DT Small molecular drug
DMHN2LT PC 4029677
DMHN2LT MW 257.329
DMHN2LT FM C15H19N3O
DMHN2LT IC InChI=1S/C15H19N3O/c1-2-9-19-14-4-3-13-15(18-14)12(10-17-13)11-5-7-16-8-6-11/h3-5,10,16-17H,2,6-9H2,1H3
DMHN2LT CS CCCOC1=NC2=C(C=C1)NC=C2C3=CCNCC3
DMHN2LT IK KWQWBZIGHIOKIO-UHFFFAOYSA-N
DMHN2LT IU 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine
DMHN2LT CA CAS 131084-35-0
DMHN2LT CB CHEBI:92591
DMHN2LT DE Discovery agent
DMVJX21 ID DMVJX21
DMVJX21 DN CP-99,994
DMVJX21 HS Investigative
DMVJX21 SN CP-99994; CHEMBL441225; CP99994; CP 99994; (2S,3S)-N-(2-methoxybenzyl)-2-phenylpiperidin-3-amine; (2S,3S)-N-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine; (2~{S},3~{S})-~{N}-[(2-methoxyphenyl)methyl]-2-phenyl-piperidin-3-amine; UNII-5KM4QA7RZC; 5KM4QA7RZC; AC1NSJX2; (2-Methoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine; SCHEMBL1282327; GTPL2102; DTQNEFOKTXXQKV-HKUYNNGSSA-N; ZINC22441784; BDBM50000041; AKOS027453648; NCGC00370844-01; Cis-3-(2-methoxybenzylamino)-2-phenylpiperidine
DMVJX21 DT Small molecular drug
DMVJX21 PC 5311057
DMVJX21 MW 296.4
DMVJX21 FM C19H24N2O
DMVJX21 IC InChI=1S/C19H24N2O/c1-22-18-12-6-5-10-16(18)14-21-17-11-7-13-20-19(17)15-8-3-2-4-9-15/h2-6,8-10,12,17,19-21H,7,11,13-14H2,1H3/t17-,19-/m0/s1
DMVJX21 CS COC1=CC=CC=C1CN[C@H]2CCCN[C@H]2C3=CC=CC=C3
DMVJX21 IK DTQNEFOKTXXQKV-HKUYNNGSSA-N
DMVJX21 IU (2S,3S)-N-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine
DMVJX21 CA CAS 136982-36-0
DMVJX21 DE Discovery agent
DMI4WVE ID DMI4WVE
DMI4WVE DN CPCCOEt
DMI4WVE HS Investigative
DMI4WVE SN CHEMBL327783; 179067-99-3; AC1O3E8H; 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester; SCHEMBL12648369; MolPort-003-940-874; CPCCOEt, > AKOS024456339; LP00300; NCGC00024948-02; KB-49121; AS-16761; L000202; SR-01000597466; SR-01000597466-1; BRD-A05729358-001-01-2; ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate
DMI4WVE DT Small molecular drug
DMI4WVE PC 6278000
DMI4WVE MW 247.25
DMI4WVE FM C13H13NO4
DMI4WVE IC InChI=1S/C13H13NO4/c1-2-17-12(15)13-7-9(13)11(14-16)8-5-3-4-6-10(8)18-13/h3-6,9,16H,2,7H2,1H3/b14-11-
DMI4WVE CS CCOC(=O)C12CC1/C(=N\\O)/C3=CC=CC=C3O2
DMI4WVE IK FXCTZFMSAHZQTR-KAMYIIQDSA-N
DMI4WVE IU ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate
DMI4WVE DE Discovery agent
DMFE5GX ID DMFE5GX
DMFE5GX DN CPFPX
DMFE5GX HS Investigative
DMFE5GX SN CHEMBL2311146; 8-cyclopentyl-3-(3-fluoranylpropyl)-1-propyl-7H-purine-2,6-dione; CPFPX; [18F]CPFPX; AC1NUVWE; GTPL5603
DMFE5GX DT Small molecular drug
DMFE5GX PC 5461879
DMFE5GX MW 321.38
DMFE5GX FM C16H23FN4O2
DMFE5GX IC InChI=1S/C16H23FN4O2/c1-2-9-21-15(22)12-14(20(16(21)23)10-5-8-17)19-13(18-12)11-6-3-4-7-11/h11H,2-10H2,1H3,(H,18,19)/i17-1
DMFE5GX CS CCCN1C(=O)C2=C(N=C(N2)C3CCCC3)N(C1=O)CCC[18F]
DMFE5GX IK GGGMDKJPUXTDAW-SJPDSGJFSA-N
DMFE5GX IU 8-cyclopentyl-3-(3-(18F)fluoranylpropyl)-1-propyl-7H-purine-2,6-dione
DMFE5GX DE Discovery agent
DMXSYTA ID DMXSYTA
DMXSYTA DN CPI-203
DMXSYTA HS Investigative
DMXSYTA SN CPI203; CPI 203
DMXSYTA DT Small molecular drug
DMXSYTA PC 71291068
DMXSYTA MW 399.9
DMXSYTA FM C19H18ClN5OS
DMXSYTA IC InChI=1S/C19H18ClN5OS/c1-9-10(2)27-19-16(9)17(12-4-6-13(20)7-5-12)22-14(8-15(21)26)18-24-23-11(3)25(18)19/h4-7,14H,8H2,1-3H3,(H2,21,26)/t14-/m0/s1
DMXSYTA CS CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)N)C4=CC=C(C=C4)Cl)C
DMXSYTA IK QECMENZMDBOLDR-AWEZNQCLSA-N
DMXSYTA IU 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamide
DMXSYTA DE Discovery agent
DMVHX5T ID DMVHX5T
DMVHX5T DN CPPG
DMVHX5T HS Investigative
DMVHX5T SN cyclopropyl-4-phosphonophenylglycine
DMVHX5T DT Small molecular drug
DMVHX5T PC 2878
DMVHX5T MW 271.21
DMVHX5T FM C11H14NO5P
DMVHX5T IC InChI=1S/C11H14NO5P/c12-11(10(13)14,7-1-2-7)8-3-5-9(6-4-8)18(15,16)17/h3-7H,1-2,12H2,(H,13,14)(H2,15,16,17)
DMVHX5T CS C1CC1C(C2=CC=C(C=C2)P(=O)(O)O)(C(=O)O)N
DMVHX5T IK IGODGTDUQSMDQU-UHFFFAOYSA-N
DMVHX5T IU 2-amino-2-cyclopropyl-2-(4-phosphonophenyl)acetic acid
DMVHX5T CB CHEBI:125380
DMVHX5T DE Discovery agent
DMDG2Y9 ID DMDG2Y9
DMDG2Y9 DN CPPHA
DMDG2Y9 HS Investigative
DMDG2Y9 SN 693288-97-0; CHEMBL366217; C22H15ClN2O4; N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide; N-(4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide; N-[4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide; N-[4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl]-2-hydroxybenzamide; SCHEMBL1821580; GTPL1423; AOB4169; DTXSID80433014; UFOUABRZSDGGAZ-UHFFFAOYSA-N; MolPort-028-748-388; CPPHA, >
DMDG2Y9 DT Small molecular drug
DMDG2Y9 PC 9931205
DMDG2Y9 MW 406.8
DMDG2Y9 FM C22H15ClN2O4
DMDG2Y9 IC InChI=1S/C22H15ClN2O4/c23-14-9-10-18(24-20(27)17-7-3-4-8-19(17)26)13(11-14)12-25-21(28)15-5-1-2-6-16(15)22(25)29/h1-11,26H,12H2,(H,24,27)
DMDG2Y9 CS C1=CC=C2C(=C1)C(=O)N(C2=O)CC3=C(C=CC(=C3)Cl)NC(=O)C4=CC=CC=C4O
DMDG2Y9 IK UFOUABRZSDGGAZ-UHFFFAOYSA-N
DMDG2Y9 IU N-[4-chloro-2-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-2-hydroxybenzamide
DMDG2Y9 CA CAS 693288-97-0
DMDG2Y9 DE Discovery agent
DM9OWG5 ID DM9OWG5
DM9OWG5 DN CPPZ
DM9OWG5 HS Investigative
DM9OWG5 SN CHEMBL1289113; 1-(4-(2-chloro-4-fluorophenyl)piperazin-1-yl)-2-(pyridin-4-ylmethoxy)ethanone; CPPZ; 1-[4-(2-chloro-4-fluorophenyl)piperazin-1-yl]-2-(pyridin-4-ylmethoxy)ethanone; SCHEMBL1904664; GTPL6416; BDBM50331975
DM9OWG5 DT Small molecular drug
DM9OWG5 PC 24763119
DM9OWG5 MW 363.8
DM9OWG5 FM C18H19ClFN3O2
DM9OWG5 IC InChI=1S/C18H19ClFN3O2/c19-16-11-15(20)1-2-17(16)22-7-9-23(10-8-22)18(24)13-25-12-14-3-5-21-6-4-14/h1-6,11H,7-10,12-13H2
DM9OWG5 CS C1CN(CCN1C2=C(C=C(C=C2)F)Cl)C(=O)COCC3=CC=NC=C3
DM9OWG5 IK XNOMHUDLVRWWLV-UHFFFAOYSA-N
DM9OWG5 IU 1-[4-(2-chloro-4-fluorophenyl)piperazin-1-yl]-2-(pyridin-4-ylmethoxy)ethanone
DM9OWG5 DE Discovery agent
DMG2NI9 ID DMG2NI9
DMG2NI9 DN CPS125
DMG2NI9 HS Investigative
DMG2NI9 SN CPS125; GTPL6369; SCHEMBL15257793
DMG2NI9 DT Small molecular drug
DMG2NI9 PC 56929387
DMG2NI9 MW 416.5
DMG2NI9 FM C21H28N4O3S
DMG2NI9 IC InChI=1S/C21H28N4O3S/c1-14(2)18-10-5-15(3)13-19(18)20(26)24-16-6-8-17(9-7-16)29(27,28)25-21-22-11-4-12-23-21/h4,6-9,11-12,14-15,18-19H,5,10,13H2,1-3H3,(H,24,26)(H,22,23,25)/t15-,18+,19-/m1/s1
DMG2NI9 CS C[C@@H]1CC[C@H]([C@@H](C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC=CC=N3)C(C)C
DMG2NI9 IK IIVDSKOVPRNBND-AYOQOUSVSA-N
DMG2NI9 IU (1R,2S,5R)-5-methyl-2-propan-2-yl-N-[4-(pyrimidin-2-ylsulfamoyl)phenyl]cyclohexane-1-carboxamide
DMG2NI9 DE Discovery agent
DMM8FUT ID DMM8FUT
DMM8FUT DN CPU-228
DMM8FUT HS Investigative
DMM8FUT SN Dofetilide analog (cardiac failure), China Pharmaceutical University
DMM8FUT CP China Pharmaceutical University
DMM8FUT DT Small molecular drug
DMM8FUT PC 10025495
DMM8FUT MW 426.5
DMM8FUT FM C23H26N2O4S
DMM8FUT IC InChI=1S/C23H26N2O4S/c1-18(26)25(15-14-19-10-12-21(13-11-19)24-30(2,27)28)16-17-29-23-9-5-7-20-6-3-4-8-22(20)23/h3-13,24H,14-17H2,1-2H3
DMM8FUT CS CC(=O)N(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=CC3=CC=CC=C32
DMM8FUT IK NSXHCQYUSBIMAJ-UHFFFAOYSA-N
DMM8FUT IU N-[2-[4-(methanesulfonamido)phenyl]ethyl]-N-(2-naphthalen-1-yloxyethyl)acetamide
DMM8FUT CA CAS 446877-42-5
DMM8FUT DE Cardiac failure
DMFG0XS ID DMFG0XS
DMFG0XS DN CR-2345
DMFG0XS HS Investigative
DMFG0XS SN CHEMBL558614
DMFG0XS DT Small molecular drug
DMFG0XS PC 45265542
DMFG0XS MW 560
DMFG0XS FM C26H37Cl3N4O3
DMFG0XS IC InChI=1S/C26H36Cl2N4O3.ClH/c1-30-12-14-31(15-13-30)23(33)5-4-22(29-24(34)19-16-20(27)18-21(28)17-19)25(35)32-10-8-26(9-11-32)6-2-3-7-26;/h16-18,22H,2-15H2,1H3,(H,29,34);1H
DMFG0XS CS CN1CCN(CC1)C(=O)CCC(C(=O)N2CCC3(CCCC3)CC2)NC(=O)C4=CC(=CC(=C4)Cl)Cl.Cl
DMFG0XS IK FXORBQJCRPUVDJ-UHFFFAOYSA-N
DMFG0XS IU N-[1-(8-azaspiro[4.5]decan-8-yl)-5-(4-methylpiperazin-1-yl)-1,5-dioxopentan-2-yl]-3,5-dichlorobenzamide;hydrochloride
DMFG0XS DE Discovery agent
DM3M5AW ID DM3M5AW
DM3M5AW DN CR-4174
DM3M5AW HS Investigative
DM3M5AW SN NO-COX-2 inhibitors (osteoarthritis/inflammatory disease), Rottapharm Madaus
DM3M5AW CP Rottapharm Madaus
DM3M5AW DE Inflammation
DMXHIFZ ID DMXHIFZ
DMXHIFZ DN CR-4892
DMXHIFZ HS Investigative
DMXHIFZ SN Nav 1.8 blockers (pain), Rottapharm Madaus
DMXHIFZ CP Rottapharm Madaus
DMXHIFZ DE Pain
DME5IJQ ID DME5IJQ
DME5IJQ DN CR-5259
DME5IJQ HS Investigative
DME5IJQ SN CR-4144 series; CR-4152 series; CR-4153 series; CR-4167 series; Aggrecanase (ADAMTS-4 and 5) inhibitors (osteoarthritis),Rottapharm Madaus
DME5IJQ CP Rottapharm Madaus
DME5IJQ DE Osteoarthritis
DMY2P5C ID DMY2P5C
DMY2P5C DN CR-5790
DMY2P5C HS Investigative
DMY2P5C SN EP4 receptor antagonist (osteoarthritis), Rottapharm Madaus
DMY2P5C CP Rottapharm Madaus
DMY2P5C DE Osteoarthritis
DM70YRT ID DM70YRT
DM70YRT DN CRA_10655
DM70YRT HS Investigative
DM70YRT SN AC1O4QGF
DM70YRT DT Small molecular drug
DM70YRT PC 447480
DM70YRT MW 336.4
DM70YRT FM C19H20N4O2
DM70YRT IC InChI=1S/C19H20N4O2/c20-18(21)11-8-9-14-15(10-11)23-19(22-14)13-6-3-7-16(17(13)24)25-12-4-1-2-5-12/h3,6-10,12,24H,1-2,4-5H2,(H3,20,21)(H,22,23)
DM70YRT CS C1CCC(C1)OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C=C4)C(=N)N
DM70YRT IK WCFWDBPDMBXMTQ-UHFFFAOYSA-N
DM70YRT IU 2-(3-cyclopentyloxy-2-hydroxyphenyl)-3H-benzimidazole-5-carboximidamide
DM70YRT DE Discovery agent
DMK54RM ID DMK54RM
DMK54RM DN CRA_1144
DMK54RM HS Investigative
DMK54RM SN AC1O4QI2
DMK54RM DT Small molecular drug
DMK54RM PC 1506
DMK54RM MW 252.27
DMK54RM FM C14H12N4O
DMK54RM IC InChI=1S/C14H12N4O/c15-13(16)8-5-6-10-11(7-8)18-14(17-10)9-3-1-2-4-12(9)19/h1-7,19H,(H3,15,16)(H,17,18)
DMK54RM CS C1=CC=C(C(=C1)C2=NC3=C(N2)C=C(C=C3)C(=N)N)O
DMK54RM IK URJKRCBBKTXOHS-UHFFFAOYSA-N
DMK54RM IU 2-(2-hydroxyphenyl)-3H-benzimidazole-5-carboximidamide
DMK54RM CA CAS 220955-03-3
DMK54RM DE Discovery agent
DM3IZOP ID DM3IZOP
DM3IZOP DN CRA_8696
DM3IZOP HS Investigative
DM3IZOP SN AC1O4QGN
DM3IZOP DT Small molecular drug
DM3IZOP PC 447476
DM3IZOP MW 327.4
DM3IZOP FM C21H17N3O
DM3IZOP IC InChI=1S/C21H17N3O/c22-21(23)14-9-10-18-15(11-14)12-19(24-18)17-8-4-7-16(20(17)25)13-5-2-1-3-6-13/h1-12,24-25H,(H3,22,23)
DM3IZOP CS C1=CC=C(C=C1)C2=C(C(=CC=C2)C3=CC4=C(N3)C=CC(=C4)C(=N)N)O
DM3IZOP IK GAVRMVQHHVMXFD-UHFFFAOYSA-N
DM3IZOP IU 2-(2-hydroxy-3-phenylphenyl)-1H-indole-5-carboximidamide
DM3IZOP DE Discovery agent
DMPWZOK ID DMPWZOK
DMPWZOK DN CRB-0022
DMPWZOK HS Investigative
DMPWZOK SN Anti-NGF monoclonal antibody (osteoarthritis pain/chronic pain), Rottapharm Madaus; Anti-nerve growth factor monoclonal antibody (osteoarthritis pain/chronic pain), Rottapharm Madaus
DMPWZOK CP Rottapharm Madaus
DMPWZOK DT Antibody
DMPWZOK DE Pain
DMLJOGK ID DMLJOGK
DMLJOGK DN Cremastrine
DMLJOGK HS Investigative
DMLJOGK SN cremastrine; CHEMBL480464; AC1LCUUY; BDBM50259847; pentanoic acid, 2-hydroxy-3-methyl-, [(1S,7aS)-hexahydro-1H-pyrrolizin-1-yl]methyl ester, (2R,3R)-; [(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl (2R,3R)-2-hydroxy-3-methylpentanoate
DMLJOGK DT Small molecular drug
DMLJOGK PC 656392
DMLJOGK MW 255.35
DMLJOGK FM C14H25NO3
DMLJOGK IC InChI=1S/C14H25NO3/c1-3-10(2)13(16)14(17)18-9-11-6-8-15-7-4-5-12(11)15/h10-13,16H,3-9H2,1-2H3/t10-,11-,12+,13-/m1/s1
DMLJOGK CS CC[C@@H](C)[C@H](C(=O)OC[C@H]1CCN2[C@H]1CCC2)O
DMLJOGK IK AVBKRVFZNFJQBK-FVCCEPFGSA-N
DMLJOGK IU [(1S,8S)-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methyl (2R,3R)-2-hydroxy-3-methylpentanoate
DMLJOGK DE Discovery agent
DMY0GXM ID DMY0GXM
DMY0GXM DN CRISNATOL MESILATE
DMY0GXM HS Investigative
DMY0GXM SN 2-[(6-Chrysenylmethyl)amino]-2-methyl-1,3-propanediol methanesulfonate; 770U82 mesylate; 96389-69-4; BW-A770U mesylate; Crisnatol mesilate < Rec INNM
DMY0GXM DT Small molecular drug
DMY0GXM PC 57061
DMY0GXM MW 441.5
DMY0GXM FM C24H27NO5S
DMY0GXM IC InChI=1S/C23H23NO2.CH4O3S/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20;1-5(2,3)4/h2-12,24-26H,13-15H2,1H3;1H3,(H,2,3,4)
DMY0GXM CS CC(CO)(CO)NCC1=CC2=C(C=CC3=CC=CC=C32)C4=CC=CC=C41.CS(=O)(=O)O
DMY0GXM IK NJWBUDCAWGTQAS-UHFFFAOYSA-N
DMY0GXM IU 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid
DMY0GXM CA CAS 96389-69-4
DMY0GXM DE Discovery agent
DMYPLZ8 ID DMYPLZ8
DMYPLZ8 DN Cristacarpin
DMYPLZ8 HS Investigative
DMYPLZ8 SN Cristacarpin; Erythrabyssin I; 74515-47-2; Crystacarpin; CHEMBL454849; CHEBI:3917; AC1L2QIR; AC1Q70TT; SCHEMBL4740053; MolPort-005-945-627; ZINC4098607; LMPK12070114; BDBM50317430; 9166AF; 6h-benzofuro(3,2-c)(1)benzopyran-3,6a(11ah)-diol, 9-methoxy-10-(3-methyl-2-butenyl)-,(6as-cis)-; C10206; 6H-Benzofuro(3,2-c)(1)benzopyran-3,6a(11aH)-diol, 9-methoxy-10-(3-methyl-2-butenyl)-, (6aS-cis)-; 6H-Benzofuro[3,2-c][1]benzopyran-3,6a(11aH)-diol,9-methoxy-10-(3-methyl-2-buten-1-yl)-, (6aS,11aS)-
DMYPLZ8 DT Small molecular drug
DMYPLZ8 PC 126540
DMYPLZ8 MW 354.4
DMYPLZ8 FM C21H22O5
DMYPLZ8 IC InChI=1S/C21H22O5/c1-12(2)4-6-14-17(24-3)9-8-16-19(14)26-20-15-7-5-13(22)10-18(15)25-11-21(16,20)23/h4-5,7-10,20,22-23H,6,11H2,1-3H3/t20-,21+/m0/s1
DMYPLZ8 CS CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@]2(COC4=C3C=CC(=C4)O)O)OC)C
DMYPLZ8 IK ZHPYEBFYLDGZKF-LEWJYISDSA-N
DMYPLZ8 IU (6aS,11aS)-9-methoxy-10-(3-methylbut-2-enyl)-6,11a-dihydro-[1]benzofuro[3,2-c]chromene-3,6a-diol
DMYPLZ8 CA CAS 74515-47-2
DMYPLZ8 CB CHEBI:3917
DMYPLZ8 DE Discovery agent
DMERKU2 ID DMERKU2
DMERKU2 DN CRL-37212
DMERKU2 HS Investigative
DMERKU2 SN Anaplastic lymphoma kinase inhibitors (cancer); CRL-43425; CRL-82007; ALK inihibitors (cancer), ChemBridge Research; Anaplastic lymphoma kinase inhibitors (cancer), ChemBridge Research
DMERKU2 CP ChemBridge Research Laboratories LLC
DMERKU2 DE Solid tumour/cancer
DMELUG5 ID DMELUG5
DMELUG5 DN Crocusatin-K
DMELUG5 HS Investigative
DMELUG5 SN Crocusatin K; CHEMBL446756; Crocusatin-K; AC1LD3L5; BDBM50250531
DMELUG5 DT Small molecular drug
DMELUG5 PC 641786
DMELUG5 MW 184.23
DMELUG5 FM C10H16O3
DMELUG5 IC InChI=1S/C10H16O3/c1-6-4-8(12)9(13)10(2,3)7(6)5-11/h5,8-9,12-13H,4H2,1-3H3/t8-,9+/m1/s1
DMELUG5 CS CC1=C(C([C@H]([C@@H](C1)O)O)(C)C)C=O
DMELUG5 IK YDOIHIWSLMXTHV-BDAKNGLRSA-N
DMELUG5 IU (4R,5R)-4,5-dihydroxy-2,6,6-trimethylcyclohexene-1-carbaldehyde
DMELUG5 DE Discovery agent
DMTWRQI ID DMTWRQI
DMTWRQI DN crotylaldehyde
DMTWRQI HS Investigative
DMTWRQI SN Crotonaldehyde; CROTONALDEHYDE; 2-Butenal; Crotylaldehyde; Crotonal; (2E)-but-2-enal; trans-Crotonaldehyde; 123-73-9; Crotonic aldehyde; (E)-Crotonaldehyde; (E)-but-2-enal; trans-2-Butenal; Methylpropenal; Propylene aldehyde; 1-Formylpropene; beta-Methylacrolein; 4170-30-3; 2-Butenal, (2E)-; Aldehyde crotonique; 2-Butenaldehyde; but-2-enal; Topanel; trans- Crotonal; 2-Butenal, (E)-; Topanel CA; trans-but-2-enal; RCRA waste number U053; E-2-Butenal; beta-Methyl acrolein; trans-2-butenaldehyde; Krotonaldehyd [Czech]; (E)-2-Butenal; CROTONALDEHYDE, (E)-; 2-butenal; crotonal; trans-crotonaldehyde
DMTWRQI DT Small molecular drug
DMTWRQI PC 447466
DMTWRQI MW 70.09
DMTWRQI FM C4H6O
DMTWRQI IC InChI=1S/C4H6O/c1-2-3-4-5/h2-4H,1H3/b3-2+
DMTWRQI CS C/C=C/C=O
DMTWRQI IK MLUCVPSAIODCQM-NSCUHMNNSA-N
DMTWRQI IU (E)-but-2-enal
DMTWRQI CA CAS 4170-30-3
DMTWRQI CB CHEBI:41607
DMTWRQI DE Discovery agent
DMVYSAZ ID DMVYSAZ
DMVYSAZ DN CRT-0004592
DMVYSAZ HS Investigative
DMVYSAZ SN CRT-0066854; CRT-0099431; Protein kinase C iota inhibitors (cancer); PKCi inhibitors (cancer), CRT; Protein kinase C iota inhibitors (cancer), Cancer Research Technology
DMVYSAZ CP Cancer Research Technology Ltd
DMVYSAZ DE Solid tumour/cancer
DMX09KI ID DMX09KI
DMX09KI DN CRT0066101
DMX09KI HS Investigative
DMX09KI DT Small molecular drug
DMX09KI PC 136664697
DMX09KI MW 411.3
DMX09KI FM C18H24Cl2N6O
DMX09KI IC InChI=1S/C18H22N6O.2ClH/c1-3-14(19)10-21-17-6-7-20-18(23-17)15-8-12(4-5-16(15)25)13-9-22-24(2)11-13;;/h4-9,11,14,25H,3,10,19H2,1-2H3,(H,20,21,23);2*1H/t14-;;/m1../s1
DMX09KI CS CC[C@H](CNC1=NC(=NC=C1)C2=C(C=CC(=C2)C3=CN(N=C3)C)O)N.Cl.Cl
DMX09KI IK CXYCRYGNFKDPRH-FMOMHUKBSA-N
DMX09KI IU 2-[4-[[(2R)-2-aminobutyl]amino]pyrimidin-2-yl]-4-(1-methylpyrazol-4-yl)phenol;dihydrochloride
DMX09KI DE Solid tumour/cancer
DMBV79R ID DMBV79R
DMBV79R DN CRTX-070
DMBV79R HS Investigative
DMBV79R CP Cornerstone Therapeutics Inc
DMBV79R DE Allergic rhinitis
DMW61UK ID DMW61UK
DMW61UK DN CRX-526
DMW61UK HS Investigative
DMW61UK SN CRX-526; UNII-8NLO017HHA; 8NLO017HHA; CHEMBL505526; BDBM50275658; 245515-64-4; Hexanoic acid, (1R)-1-(2-(((1S)-1-carboxy-2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)-2-(((3R)-1-oxo-3-((1-oxohexyl)oxy)tetradecyl)amino)-4-O-phosphono-beta-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester; N-[(3R)-3-(Hexanoyloxy)myristoyl]-O-[2-[[(3R)-3-(hexanoyloxy)myristoyl]amino]-3-O-[(3R)-3-(hexanoyloxy)myristoyl]-4-O-phosphono-2-deoxy-beta-D-glucopyranosyl]-L-serine
DMW61UK PC 24849153
DMW61UK MW 1319.7
DMW61UK FM C69H127N2O19P
DMW61UK IC InChI=1S/C69H127N2O19P/c1-7-13-19-22-25-28-31-34-40-43-54(85-61(75)46-37-16-10-4)49-59(73)70-57(68(79)80)53-84-69-65(71-60(74)50-55(86-62(76)47-38-17-11-5)44-41-35-32-29-26-23-20-14-8-2)67(66(58(52-72)88-69)90-91(81,82)83)89-64(78)51-56(87-63(77)48-39-18-12-6)45-42-36-33-30-27-24-21-15-9-3/h54-58,65-67,69,72H,7-53H2,1-6H3,(H,70,73)(H,71,74)(H,79,80)(H2,81,82,83)/t54-,55-,56-,57+,58-,65-,66-,67-,69-/m1/s1
DMW61UK CS CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC[C@@H](C(=O)O)NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCC)CO)OP(=O)(O)O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCC)OC(=O)CCCCC
DMW61UK IK PRIXXGNJDNLMBH-DPGPRPECSA-N
DMW61UK IU (2S)-2-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-3-[(2R,3R,4R,5S,6R)-3-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-4-[(3R)-3-hexanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid
DMW61UK CA CAS 245515-64-4
DMW61UK DE Discovery agent
DM92IK8 ID DM92IK8
DM92IK8 DN CRYPTADINE B
DM92IK8 HS Investigative
DM92IK8 SN cryptadine B; CHEMBL240094
DM92IK8 DT Small molecular drug
DM92IK8 PC 24809844
DM92IK8 MW 467.7
DM92IK8 FM C30H49N3O
DM92IK8 IC InChI=1S/C30H49N3O/c1-20-14-23(27-10-6-12-32(4)29(27)16-20)18-25-8-5-9-26(31-25)19-24-15-21(2)17-30-28(24)11-7-13-33(30)22(3)34/h20-21,25-26,29-31H,5-19H2,1-4H3/t20-,21+,25-,26-,29+,30+/m1/s1
DM92IK8 CS C[C@H]1C[C@H]2C(=C(C1)C[C@H]3CCC[C@@H](N3)CC4=C5CCCN([C@H]5C[C@H](C4)C)C(=O)C)CCCN2C
DM92IK8 IK GNBIIUGCLQZEQB-QERBKSRWSA-N
DM92IK8 IU 1-[(7S,8aS)-5-[[(2R,6R)-6-[[(7R,8aS)-1,7-dimethyl-3,4,6,7,8,8a-hexahydro-2H-quinolin-5-yl]methyl]piperidin-2-yl]methyl]-7-methyl-3,4,6,7,8,8a-hexahydro-2H-quinolin-1-yl]ethanone
DM92IK8 DE Discovery agent
DM8W7VL ID DM8W7VL
DM8W7VL DN CS-6969
DM8W7VL HS Investigative
DM8W7VL SN Hydroxycholesterol; 24-hydroxycholesterol; IOWMKBFJCNLRTC-GHMQSXNDSA-N; SCHEMBL200705; cholest-5-ene-3beta,24-diol; 30271-38-6; 474-73-7; CHEBI:50515; CS-6969; CTK4J0024; HY-N2370
DM8W7VL PC 12302757
DM8W7VL MW 402.7
DM8W7VL FM C27H46O2
DM8W7VL IC IOWMKBFJCNLRTC-GHMQSXNDSA-N
DM8W7VL CS CC(C)C(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)O
DM8W7VL IK 1S/C27H46O2/c1-17(2)25(29)11-6-18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20+,21+,22-,23+,24+,25?,26+,27-/m1/s1
DM8W7VL IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM8W7VL CA CAS 474-73-7
DM8W7VL CB CHEBI:50515
DM8W7VL DE Alzheimer disease
DM6K123 ID DM6K123
DM6K123 DN CSC-500297
DM6K123 HS Investigative
DM6K123 SN CSC-500204; CSC-500 series, Cascade; 5-HT2c receptor agonists (obesity/obsessive compulsive disorder), Cascade
DM6K123 CP Cascade Therapeutics Inc
DM6K123 DE Obesity
DMTN1P2 ID DMTN1P2
DMTN1P2 DN CSL-324
DMTN1P2 HS Investigative
DMTN1P2 SN Anti-GCSF human mAb (inflammation), CSL; Anti-GCSF human monoclonal antibody (inflammation), CSL; Soluble human GCSFR extracellular domain-Fc (inflammation), CSL; Soluble human GCSFR extracellular domain-Fc (arthritis), MuriGen/CSL LTd; Soluble human granulocyte-colony stimulating factor receptor extracellular domain-Fc (arthritis), MuriGen/CSL LTd; Soluble human granulocyte-colony stimulating factor receptor extracellular domain-Fc (arthritis), MuriGen/Zenyth
DMTN1P2 CP MuriGen Therapeutics
DMTN1P2 DT Antibody
DMTN1P2 DE Inflammation
DMYDTO8 ID DMYDTO8
DMYDTO8 DN CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide
DMYDTO8 HS Investigative
DMYDTO8 PC 73346944
DMYDTO8 MW 3433.9
DMYDTO8 FM C145H242N44O48S2
DMYDTO8 IC InChI=1S/C145H242N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99(63-239)181-142(235)114(74(16)197)187-135(228)98(61-193)180-129(222)90(49-69(9)10)172-131(224)92(52-104(151)202)174-134(227)96(59-191)178-117(210)79(148)62-238)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199,238-239H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)/t71-,72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100-,101-,110+,111+,112+,113+,114+,115+/m1/s1
DMYDTO8 CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMYDTO8 IK AZCMZZXDDMAXIT-KOYPLZMPSA-N
DMYDTO8 IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMYDTO8 DE Discovery agent
DMQXEHJ ID DMQXEHJ
DMQXEHJ DN CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide
DMQXEHJ HS Investigative
DMQXEHJ PC 73346940
DMQXEHJ MW 3430.9
DMQXEHJ FM C145H241N45O47S2
DMQXEHJ IC InChI=1S/C145H241N45O47S2/c1-66(2)45-86(176-140(233)111(71(11)12)184-137(230)100(64-239)182-142(235)114(74(15)197)187-136(229)99(62-194)181-129(222)90(49-70(9)10)172-131(224)92(52-104(150)201)174-135(228)97(60-192)179-117(210)79(148)63-238)118(211)158-55-107(204)162-80(25-17-19-39-146)120(213)169-89(48-69(7)8)128(221)180-98(61-193)134(227)167-84(35-37-103(149)200)123(216)166-85(36-38-110(207)208)124(217)171-88(47-68(5)6)127(220)175-94-54-106(203)156-41-21-27-82(165-130(223)91(51-77-58-188(155)65-161-77)173-126(219)87(46-67(3)4)170-121(214)81(164-132(94)225)26-18-20-40-147)122(215)178-95(50-76-31-33-78(199)34-32-76)143(236)190-44-24-30-102(190)138(231)168-83(28-22-42-157-145(153)154)125(218)186-113(73(14)196)141(234)177-93(53-105(151)202)133(226)185-112(72(13)195)139(232)160-56-108(205)163-96(59-191)119(212)159-57-109(206)183-115(75(16)198)144(237)189-43-23-29-101(189)116(152)209/h31-34,58,65-75,79-102,111-115,191-199,238-239H,17-30,35-57,59-64,146-148,155H2,1-16H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,209)(H,156,203)(H,158,211)(H,159,212)(H,160,232)(H,162,204)(H,163,205)(H,164,225)(H,165,223)(H,166,216)(H,167,227)(H,168,231)(H,169,213)(H,170,214)(H,171,217)(H,172,224)(H,173,219)(H,174,228)(H,175,220)(H,176,233)(H,177,234)(H,178,215)(H,179,210)(H,180,221)(H,181,222)(H,182,235)(H,183,206)(H,184,230)(H,185,226)(H,186,218)(H,187,229)(H,207,208)(H4,153,154,157)/t72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101-,102-,111+,112+,113+,114+,115+/m1/s1
DMQXEHJ CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@@H]4CCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC5=CN(C=N5)N)CC(C)C)CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMQXEHJ IK YQLRYCAIJODBIC-AIKTXAPFSA-N
DMQXEHJ IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(3S,6S,9S,12S,19S)-9-(4-aminobutyl)-19-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-3-[(1-aminoimidazol-4-yl)methyl]-6-(2-methylpropyl)-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacyclononadec-12-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMQXEHJ DE Discovery agent
DMMZK89 ID DMMZK89
DMMZK89 DN CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide
DMMZK89 HS Investigative
DMMZK89 PC 73351528
DMMZK89 MW 3406.8
DMMZK89 FM C144H241N43O48S2
DMMZK89 IC InChI=1S/C144H241N43O48S2/c1-65(2)47-85(174-139(231)110(70(11)12)182-136(228)98(64-237)180-141(233)113(73(15)194)185-135(227)97(62-191)179-129(221)89(51-69(9)10)171-130(222)90(53-103(150)199)172-134(226)95(60-189)177-116(208)77(147)63-236)117(209)157-56-106(202)160-78(25-17-19-41-145)119(211)168-88(50-68(7)8)128(220)178-96(61-190)133(225)166-83(36-39-102(149)198)123(215)164-84(37-40-109(205)206)124(216)170-87(49-67(5)6)127(219)173-92-55-105(201)155-43-21-27-80(162-122(214)82(35-38-101(148)197)165-126(218)86(48-66(3)4)169-120(212)79(163-131(92)223)26-18-20-42-146)121(213)176-93(52-75-31-33-76(196)34-32-75)142(234)187-46-24-30-100(187)137(229)167-81(28-22-44-156-144(153)154)125(217)184-112(72(14)193)140(232)175-91(54-104(151)200)132(224)183-111(71(13)192)138(230)159-57-107(203)161-94(59-188)118(210)158-58-108(204)181-114(74(16)195)143(235)186-45-23-29-99(186)115(152)207/h31-34,65-74,77-100,110-114,188-196,236-237H,17-30,35-64,145-147H2,1-16H3,(H2,148,197)(H2,149,198)(H2,150,199)(H2,151,200)(H2,152,207)(H,155,201)(H,157,209)(H,158,210)(H,159,230)(H,160,202)(H,161,203)(H,162,214)(H,163,223)(H,164,215)(H,165,218)(H,166,225)(H,167,229)(H,168,211)(H,169,212)(H,170,216)(H,171,222)(H,172,226)(H,173,219)(H,174,231)(H,175,232)(H,176,213)(H,177,208)(H,178,220)(H,179,221)(H,180,233)(H,181,204)(H,182,228)(H,183,224)(H,184,217)(H,185,227)(H,205,206)(H4,153,154,156)/t71-,72-,73-,74-,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99-,100-,110+,111+,112+,113+,114+/m1/s1
DMMZK89 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@@H]4CCCNC(=O)C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CCC(=O)N)CC(C)C)CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMMZK89 IK PPKRHPCXCVMULC-IFCDPWAYSA-N
DMMZK89 IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(3S,6S,9S,12S,19S)-9-(4-aminobutyl)-19-[[(2S)-1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-3-(3-amino-3-oxopropyl)-6-(2-methylpropyl)-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacyclononadec-12-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMMZK89 DE Discovery agent
DMTL2BA ID DMTL2BA
DMTL2BA DN CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide
DMTL2BA HS Investigative
DMTL2BA PC 44269048
DMTL2BA MW 3433.9
DMTL2BA FM C145H242N44O48S2
DMTL2BA IC InChI=1S/C145H242N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99(63-239)181-142(235)114(74(16)197)187-135(228)98(61-193)180-129(222)90(49-69(9)10)172-131(224)92(52-104(151)202)174-134(227)96(59-191)178-117(210)79(148)62-238)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199,238-239H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)/t71-,72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94?,95+,96+,97+,98+,99+,100-,101-,110+,111+,112+,113+,114+,115+/m1/s1
DMTL2BA CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O
DMTL2BA IK AZCMZZXDDMAXIT-SLFAFRAOSA-N
DMTL2BA IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S,3R)-1-[[1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMTL2BA DE Discovery agent
DM61V5W ID DM61V5W
DM61V5W DN CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide
DM61V5W HS Investigative
DM61V5W PC 44269080
DM61V5W MW 3431.9
DM61V5W FM C146H244N44O47S2
DM61V5W IC InChI=1S/C146H244N44O47S2/c1-18-19-27-82(123(215)179-96(51-77-33-35-79(199)36-34-77)144(236)190-45-26-32-103(190)139(231)169-84(30-24-43-158-146(155)156)126(218)187-114(74(15)196)142(234)178-95(55-107(153)203)134(226)186-113(73(14)195)140(232)161-58-109(205)164-97(60-191)120(212)160-59-110(206)184-116(76(17)198)145(237)189-44-25-31-102(189)117(154)209)165-131(223)92(52-78-56-157-66-162-78)174-127(219)88(47-68(4)5)171-122(214)83(29-21-23-42-148)166-132(224)93(53-105(151)201)175-128(220)89(48-69(6)7)172-125(217)86(38-40-111(207)208)167-124(216)85(37-39-104(150)200)168-135(227)99(62-193)181-129(221)90(49-70(8)9)170-121(213)81(28-20-22-41-147)163-108(204)57-159-119(211)87(46-67(2)3)177-141(233)112(72(12)13)185-138(230)101(65-239)183-143(235)115(75(16)197)188-137(229)100(63-194)182-130(222)91(50-71(10)11)173-133(225)94(54-106(152)202)176-136(228)98(61-192)180-118(210)80(149)64-238/h33-36,56,66-76,80-103,112-116,191-199,238-239H,18-32,37-55,57-65,147-149H2,1-17H3,(H2,150,200)(H2,151,201)(H2,152,202)(H2,153,203)(H2,154,209)(H,157,162)(H,159,211)(H,160,212)(H,161,232)(H,163,204)(H,164,205)(H,165,223)(H,166,224)(H,167,216)(H,168,227)(H,169,231)(H,170,213)(H,171,214)(H,172,217)(H,173,225)(H,174,219)(H,175,220)(H,176,228)(H,177,233)(H,178,234)(H,179,215)(H,180,210)(H,181,221)(H,182,222)(H,183,235)(H,184,206)(H,185,230)(H,186,226)(H,187,218)(H,188,229)(H,207,208)(H4,155,156,158)/t73-,74-,75-,76-,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96?,97+,98+,99+,100+,101+,102-,103-,112+,113+,114+,115+,116+/m1/s1
DM61V5W CS CCCC[C@@H](C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N
DM61V5W IK YNPHTODKUNFPBE-HJMCUHAQSA-N
DM61V5W IU (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[1-[(2R)-2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[2-[[(2S)-1-[[2-[[(2S,3R)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DM61V5W DE Discovery agent
DM3W6PQ ID DM3W6PQ
DM3W6PQ DN CT-003230
DM3W6PQ HS Investigative
DM3W6PQ SN CT-0011; CT-007640; CT-007650; CT-007660; CT-007670; CT-007680; CT-008650; CT-0093; CT-0107; CT-0109; Amyloid beta 1-42 inhibitors (Alzheimers/mild cognitive impairment/Downs' syndrome); Amyloid beta 1-42 inhibitors (Alzheimers/mild cognitive impairment/Downs' syndrome), Cognition
DM3W6PQ CP Cognition Therapeutics Inc
DM3W6PQ DE Cognitive impairment
DMIVNMJ ID DMIVNMJ
DMIVNMJ DN CT-10
DMIVNMJ HS Investigative
DMIVNMJ SN GGTase inhibitors (cancer); GGTase inhibitors (cancer), Cellona Therapeutics/Duke University; Geranylgeranyl transferase inhibitors (cancer), Cellona Therapeutics/Duke University
DMIVNMJ CP Duke University
DMIVNMJ DE Solid tumour/cancer
DMUVQFW ID DMUVQFW
DMUVQFW DN CT301
DMUVQFW HS Investigative
DMUVQFW DE Discovery agent
DM6W9LA ID DM6W9LA
DM6W9LA DN CT-5357
DM6W9LA HS Investigative
DM6W9LA DE Discovery agent
DM6F8DM ID DM6F8DM
DM6F8DM DN CT-98024
DM6F8DM HS Investigative
DM6F8DM SN 556813-39-9; N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine; CHEMBL1080901; CHIR-98024; N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]-3-nitro-2,6-pyridinediamine; NDFXSHIIGXVOKT-UHFFFAOYSA-N; SCHEMBL4394521; CTK8E8250; DTXSID90433308; MolPort-006-393-166; BCP13710; BDBM50313013; ABP000489; ZINC44136098; AKOS016011284; KB-76042; CHIR98014(CT98014)/; AK120785; RT-011992; AX8246201; AJ-109287; FT-0664506; Z-3284
DM6F8DM DT Small molecular drug
DM6F8DM PC 9957049
DM6F8DM MW 486.3
DM6F8DM FM C20H17Cl2N9O2
DM6F8DM IC InChI=1S/C20H17Cl2N9O2/c21-11-1-2-12(14(22)9-11)17-13(19-25-6-7-26-19)10-28-20(30-17)27-8-5-24-16-4-3-15(31(32)33)18(23)29-16/h1-4,6-7,9-10H,5,8H2,(H,25,26)(H3,23,24,29)(H,27,28,30)
DM6F8DM CS C1=CC(=C(C=C1Cl)Cl)C2=NC(=NC=C2C3=NC=CN3)NCCNC4=NC(=C(C=C4)[N+](=O)[O-])N
DM6F8DM IK NDFXSHIIGXVOKT-UHFFFAOYSA-N
DM6F8DM IU 6-N-[2-[[4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine
DM6F8DM CA CAS 556813-39-9
DM6F8DM DE Discovery agent
DMLON9K ID DMLON9K
DMLON9K DN CTAP
DMLON9K HS Investigative
DMLON9K SN CTAP
DMLON9K DT Small molecular drug
DMLON9K PC 44309215
DMLON9K MW 1104.3
DMLON9K FM C51H69N13O11S2
DMLON9K IC InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33+,35+,36+,37+,38+,39+,40+,41-/m1/s1
DMLON9K CS C[C@H]([C@H]1C(=O)N[C@@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMLON9K IK OFMQLVRLOGHAJI-RWMSPKCPSA-N
DMLON9K IU (4R,7S,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2S)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMLON9K DE Discovery agent
DMEGZHF ID DMEGZHF
DMEGZHF DN CTCE-0324
DMEGZHF HS Investigative
DMEGZHF SN Vascular disease therapeutic, Chemokine Therapeutics
DMEGZHF CP Chemokine Therapeutics Corp
DMEGZHF DE Peripheral vascular disease
DMYRVZ8 ID DMYRVZ8
DMYRVZ8 DN CTEP
DMYRVZ8 HS Investigative
DMYRVZ8 SN 2-Chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine; 871362-31-1; CTEP (RO4956371); 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine; CHEMBL3410223; 2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine; [3H]CTEP; mGluR5 inhibitor; C19H13ClF3N3O; SCHEMBL608379; GTPL6409; GTPL6408; DTXSID50469986; EX-A095; MolPort-035-395-697; HMS3651N19; BCP06140; AOB87758; ZINC35996961; BDBM50071375; s2861; 2340AH; AKOS027301517; compound 3 [PMID: 25565255]; CS-0974; KS-000006G1; NCGC00386156-06; KB-76209; HY-15445; MGluR5 antagonist (oral), Roche; Metabotropic glutamate receptor 5 antagonist (oral), Roche
DMYRVZ8 CP F Hoffmann-La Roche Ltd
DMYRVZ8 DT Small molecular drug
DMYRVZ8 PC 11646823
DMYRVZ8 MW 391.8
DMYRVZ8 FM C19H13ClF3N3O
DMYRVZ8 IC InChI=1S/C19H13ClF3N3O/c1-12-17(8-3-14-9-10-24-18(20)11-14)25-13(2)26(12)15-4-6-16(7-5-15)27-19(21,22)23/h4-7,9-11H,1-2H3
DMYRVZ8 CS CC1=C(N=C(N1C2=CC=C(C=C2)OC(F)(F)F)C)C#CC3=CC(=NC=C3)Cl
DMYRVZ8 IK GOHCTCOGYKAJLZ-UHFFFAOYSA-N
DMYRVZ8 IU 2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]imidazol-4-yl]ethynyl]pyridine
DMYRVZ8 CA CAS 871362-31-1
DMYRVZ8 DE Fragile X syndrome
DMI3J0F ID DMI3J0F
DMI3J0F DN CTK1G9578
DMI3J0F HS Investigative
DMI3J0F SN Delta(5)-androstene-3,17-dione; HEE11L5C3G; SCHEMBL1419434; SQGZFRITSMYKRH-QAGGRKNESA-N; ZINC100041759; delta5-ADD; delta5-Androstene-3,17-dione; .DELTA.5-Androsten-3,17-dione; .DELTA.5-Androstene-3,17-dione; 5-Androsten-3,17-dione; 5-Androstene-3,17-dione; 5-Androstenedione; 571-36-8; AC1L4NSA; AC1Q6OKV; Androst-5-en-3,17-dione; Androst-5-ene-3,17-dione; Androst-5-ene-3,17-dione (8CI)(9CI); C20252; CHEBI:83865; CHEMBL1743203; DB01456; NSC 12873; NSC-12873; NSC12873; UNII-HEE11L5C3G
DMI3J0F PC 160531
DMI3J0F MW 286.4
DMI3J0F FM C19H26O2
DMI3J0F IC SQGZFRITSMYKRH-QAGGRKNESA-N
DMI3J0F CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(=O)C4)C
DMI3J0F IK 1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,14-16H,4-11H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1
DMI3J0F IU (8R,9S,10R,13S,14S)-10,13-dimethyl-2,4,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMI3J0F CA CAS 571-36-8
DMI3J0F CB CHEBI:83865
DMI3J0F DE Discovery agent
DMKEIAS ID DMKEIAS
DMKEIAS DN CTLA-4-XTEN
DMKEIAS HS Investigative
DMKEIAS SN Cytotoxic T-lymphocyte protein 4 modulator (XTEN, rheumatoid arthritis/transplant rejection), Amunix
DMKEIAS CP Amunix Inc
DMKEIAS DE Rheumatoid arthritis
DM7VAJX ID DM7VAJX
DM7VAJX DN CTOP
DM7VAJX HS Investigative
DM7VAJX SN Ctop-NH2; CTOPA; CHEMBL507214; 103429-31-8; AC1NSJX5; H-D-Phe-c[Cys-Tyr-DTrp-Orn-Thr-Pen]-Thr-NH2; GTPL1674; CTOP, > BDBM50252861; (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM7VAJX DT Small molecular drug
DM7VAJX PC 2884
DM7VAJX MW 1062.3
DM7VAJX FM C50H67N11O11S2
DM7VAJX IC InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-38(58-43(66)33(52)21-28-11-6-5-7-12-28)47(70)56-36(22-29-16-18-31(64)19-17-29)45(68)57-37(23-30-24-54-34-14-9-8-13-32(30)34)46(69)55-35(15-10-20-51)44(67)60-40(27(2)63)48(71)61-41/h5-9,11-14,16-19,24,26-27,33,35-41,54,62-64H,10,15,20-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,72)(H,60,67)(H,61,71)
DM7VAJX CS CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O
DM7VAJX IK PZWWYAHWHHNCHO-UHFFFAOYSA-N
DM7VAJX IU N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-phenylpropanoyl)amino]-10-(3-aminopropyl)-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM7VAJX CA CAS 103429-31-8
DM7VAJX DE Discovery agent
DM4T62U ID DM4T62U
DM4T62U DN CTP
DM4T62U HS Investigative
DM4T62U SN cytidine triphosphate
DM4T62U DT Small molecular drug
DM4T62U PC 6176
DM4T62U MW 483.16
DM4T62U FM C9H16N3O14P3
DM4T62U IC InChI=1S/C9H16N3O14P3/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DM4T62U CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DM4T62U IK PCDQPRRSZKQHHS-XVFCMESISA-N
DM4T62U IU [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM4T62U CA CAS 65-47-4
DM4T62U CB CHEBI:17677
DM4T62U DE Discovery agent
DMQ5JX8 ID DMQ5JX8
DMQ5JX8 DN CTT-54
DMQ5JX8 HS Investigative
DMQ5JX8 CP Cancer Targeted Technology Llc
DMQ5JX8 DE Solid tumour/cancer
DMDPJWF ID DMDPJWF
DMDPJWF DN CU201 (B9870)
DMDPJWF HS Investigative
DMDPJWF DE Discovery agent
DMY1WEM ID DMY1WEM
DMY1WEM DN CU-906
DMY1WEM HS Investigative
DMY1WEM CP Curis Inc
DMY1WEM DE Solid tumour/cancer
DMBL46A ID DMBL46A
DMBL46A DN CUDRATRICUSXANTHONE
DMBL46A HS Investigative
DMBL46A DT Small molecular drug
DMBL46A PC 44592062
DMBL46A MW 398.4
DMBL46A FM C23H26O6
DMBL46A IC InChI=1S/C23H26O6/c1-6-23(4,5)19-14(25)9-13(24)18-21(28)17-12(8-7-11(2)3)20(27)15(26)10-16(17)29-22(18)19/h6-7,9-10,18,22,24-27H,1,8H2,2-5H3
DMBL46A CS CC(=CCC1=C(C(=CC2=C1C(=O)C3C(O2)C(=C(C=C3O)O)C(C)(C)C=C)O)O)C
DMBL46A IK RAIAMYMZPGRUDU-UHFFFAOYSA-N
DMBL46A IU 1,3,6,7-tetrahydroxy-4-(2-methylbut-3-en-2-yl)-8-(3-methylbut-2-enyl)-4a,9a-dihydroxanthen-9-one
DMBL46A DE Discovery agent
DM10BOC ID DM10BOC
DM10BOC DN Cudratricusxanthone F
DM10BOC HS Investigative
DM10BOC DT Small molecular drug
DM10BOC PC 44592092
DM10BOC MW 412.5
DM10BOC FM C24H28O6
DM10BOC IC InChI=1S/C24H28O6/c1-7-24(4,5)20-17(29-6)10-14(25)19-22(28)18-13(9-8-12(2)3)21(27)15(26)11-16(18)30-23(19)20/h7-8,10-11,19,23,25-27H,1,9H2,2-6H3
DM10BOC CS CC(=CCC1=C(C(=CC2=C1C(=O)C3C(O2)C(=C(C=C3O)OC)C(C)(C)C=C)O)O)C
DM10BOC IK WIZSEOVKPIAUIS-UHFFFAOYSA-N
DM10BOC IU 1,6,7-trihydroxy-3-methoxy-4-(2-methylbut-3-en-2-yl)-8-(3-methylbut-2-enyl)-4a,9a-dihydroxanthen-9-one
DM10BOC DE Discovery agent
DMBQ1VO ID DMBQ1VO
DMBQ1VO DN Cudraxanthone D
DMBQ1VO HS Investigative
DMBQ1VO SN cudraxanthone D; 96552-41-9; CHEMBL425926; MolPort-035-706-470; ZINC13411981; BDBM50175019; AKOS032948528; 4CN-1670; W2633; 2,3,8-trihydroxy-6-methoxy-5-(2-methyl-3-buten-2-yl)-1-(3-methyl- 2-buten-1-yl)-9h-xanthen-9-one
DMBQ1VO DT Small molecular drug
DMBQ1VO PC 11611248
DMBQ1VO MW 410.5
DMBQ1VO FM C24H26O6
DMBQ1VO IC InChI=1S/C24H26O6/c1-7-24(4,5)20-17(29-6)10-14(25)19-22(28)18-13(9-8-12(2)3)21(27)15(26)11-16(18)30-23(19)20/h7-8,10-11,25-27H,1,9H2,2-6H3
DMBQ1VO CS CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(O2)C(=C(C=C3O)OC)C(C)(C)C=C)O)O)C
DMBQ1VO IK UIIGEZZURHDEDK-UHFFFAOYSA-N
DMBQ1VO IU 2,3,8-trihydroxy-6-methoxy-5-(2-methylbut-3-en-2-yl)-1-(3-methylbut-2-enyl)xanthen-9-one
DMBQ1VO DE Discovery agent
DMP1D5Q ID DMP1D5Q
DMP1D5Q DN Cudraxanthone L
DMP1D5Q HS Investigative
DMP1D5Q SN cudraxanthone L; 135541-40-1; CHEMBL197916; MolPort-035-706-469; BDBM50175013; ZINC13412042; AKOS032948133; W2632; 1,3,6,7-tetrahydroxy-5-(3-methylbut-2-enyl)-2-(2-methylbut-3-en-2-yl)-9H-xanthen-9-one
DMP1D5Q DT Small molecular drug
DMP1D5Q PC 11486277
DMP1D5Q MW 396.4
DMP1D5Q FM C23H24O6
DMP1D5Q IC InChI=1S/C23H24O6/c1-6-23(4,5)18-14(24)10-16-17(21(18)28)20(27)13-9-15(25)19(26)12(22(13)29-16)8-7-11(2)3/h6-7,9-10,24-26,28H,1,8H2,2-5H3
DMP1D5Q CS CC(=CCC1=C2C(=CC(=C1O)O)C(=O)C3=C(O2)C=C(C(=C3O)C(C)(C)C=C)O)C
DMP1D5Q IK LVKPSBFBKBJJOB-UHFFFAOYSA-N
DMP1D5Q IU 1,3,6,7-tetrahydroxy-2-(2-methylbut-3-en-2-yl)-5-(3-methylbut-2-enyl)xanthen-9-one
DMP1D5Q DE Discovery agent
DMIQFAU ID DMIQFAU
DMIQFAU DN Cudraxanthone M
DMIQFAU HS Investigative
DMIQFAU SN cudraxanthone M; CHEMBL371024; BDBM50175018
DMIQFAU DT Small molecular drug
DMIQFAU PC 11689770
DMIQFAU MW 396.4
DMIQFAU FM C23H24O6
DMIQFAU IC InChI=1S/C23H24O6/c1-10(2)6-7-12-19(25)14(24)8-13-20(26)17-15(29-22(12)13)9-16-18(21(17)27)23(4,5)11(3)28-16/h6,8-9,11,24-25,27H,7H2,1-5H3
DMIQFAU CS CC1C(C2=C(O1)C=C3C(=C2O)C(=O)C4=CC(=C(C(=C4O3)CC=C(C)C)O)O)(C)C
DMIQFAU IK ZYJVDWWKUSJAQY-UHFFFAOYSA-N
DMIQFAU IU 4,7,8-trihydroxy-2,3,3-trimethyl-9-(3-methylbut-2-enyl)-2H-furo[3,2-b]xanthen-5-one
DMIQFAU DE Discovery agent
DMEB0FX ID DMEB0FX
DMEB0FX DN CV-11194
DMEB0FX HS Investigative
DMEB0FX SN CV-11194; CV 11194; 136284-47-4; CHEMBL48242; 1H-Benzimidazole-7-carboxylicacid, 2-butyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; FLOKGHWIQFCIJW-UHFFFAOYSA-N; AC1MHFWM; ACMC-1CI8P; SCHEMBL905714; SCHEMBL12787593; CTK0H7043; DTXSID70159756; BDBM50044402; 2-Butyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid; 2-Butyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-benzimidazole-7-carboxylic acid; L005054
DMEB0FX DT Small molecular drug
DMEB0FX PC 3025727
DMEB0FX MW 452.5
DMEB0FX FM C26H24N6O2
DMEB0FX IC InChI=1S/C26H24N6O2/c1-2-3-11-23-27-22-10-6-9-21(26(33)34)24(22)32(23)16-17-12-14-18(15-13-17)19-7-4-5-8-20(19)25-28-30-31-29-25/h4-10,12-15H,2-3,11,16H2,1H3,(H,33,34)(H,28,29,30,31)
DMEB0FX CS CCCCC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
DMEB0FX IK FLOKGHWIQFCIJW-UHFFFAOYSA-N
DMEB0FX IU 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
DMEB0FX CA CAS 136284-47-4
DMEB0FX DE Discovery agent
DM9AL7W ID DM9AL7W
DM9AL7W DN CV-1674
DM9AL7W HS Investigative
DM9AL7W SN 2-(4-methoxyphenyl)adenosine; CV 1674; NSC 310669; CV1674
DM9AL7W DT Small molecular drug
DM9AL7W PC 10067935
DM9AL7W MW 373.4
DM9AL7W FM C17H19N5O5
DM9AL7W IC InChI=1S/C17H19N5O5/c1-26-9-4-2-8(3-5-9)15-20-14(18)11-16(21-15)22(7-19-11)17-13(25)12(24)10(6-23)27-17/h2-5,7,10,12-13,17,23-25H,6H2,1H3,(H2,18,20,21)/t10-,12-,13-,17-/m1/s1
DM9AL7W CS COC1=CC=C(C=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM9AL7W IK VKSRAKNPXOTFAX-CNEMSGBDSA-N
DM9AL7W IU (2R,3R,4S,5R)-2-[6-amino-2-(4-methoxyphenyl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM9AL7W CA CAS 37151-17-0
DM9AL7W DE Discovery agent
DM07VRS ID DM07VRS
DM07VRS DN CV-1808
DM07VRS HS Investigative
DM07VRS SN 2-phenylaminoadenosine; CV1808; CV 1808
DM07VRS DT Small molecular drug
DM07VRS PC 6917803
DM07VRS MW 358.35
DM07VRS FM C16H18N6O4
DM07VRS IC InChI=1S/C16H18N6O4/c17-13-10-14(21-16(20-13)19-8-4-2-1-3-5-8)22(7-18-10)15-12(25)11(24)9(6-23)26-15/h1-5,7,9,11-12,15,23-25H,6H2,(H3,17,19,20,21)/t9-,11-,12-,15-/m1/s1
DM07VRS CS C1=CC=C(C=C1)NC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
DM07VRS IK SCNILGOVBBRMBK-SDBHATRESA-N
DM07VRS IU (2R,3R,4S,5R)-2-(6-amino-2-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DM07VRS CA CAS 53296-10-9
DM07VRS DE Discovery agent
DMM7RAD ID DMM7RAD
DMM7RAD DN CV-3988
DMM7RAD HS Investigative
DMM7RAD SN CV 3988; CV3988
DMM7RAD DT Small molecular drug
DMM7RAD PC 107681
DMM7RAD MW 592.8
DMM7RAD FM C28H53N2O7PS
DMM7RAD IC InChI=1S/C28H53N2O7PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-29-28(31)35-24-27(34-2)25-37-38(32,33)36-22-20-30-21-23-39-26-30/h21,23,26-27H,3-20,22,24-25H2,1-2H3,(H-,29,31,32,33)
DMM7RAD CS CCCCCCCCCCCCCCCCCCNC(=O)OCC(COP(=O)([O-])OCC[N+]1=CSC=C1)OC
DMM7RAD IK NMHKTASGTFXJPL-UHFFFAOYSA-N
DMM7RAD IU [2-methoxy-3-(octadecylcarbamoyloxy)propyl] 2-(1,3-thiazol-3-ium-3-yl)ethyl phosphate
DMM7RAD CA CAS 85703-73-7
DMM7RAD DE Discovery agent
DM983QP ID DM983QP
DM983QP DN CV-4093
DM983QP HS Investigative
DM983QP SN Manidipine dihydrochloride; 89226-75-5; Manidipine 2HCl; manidipine hydrochloride; Calslot; Franidipine hydrochloride; Manidipine.2HCl; Manidipine (dihydrochloride); (+-)-Manidipine hydrochloride; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride; DSSTox_CID_796; DSSTox_RID_75794; DSSTox_GSID_20796; 3-(2-(4-Benzhydrylpiperazin-1-yl)ethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-
DM983QP DT Small molecular drug
DM983QP PC 150762
DM983QP MW 683.6
DM983QP FM C35H40Cl2N4O6
DM983QP IC InChI=1S/C35H38N4O6.2ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;;/h4-16,23,32-33,36H,17-22H2,1-3H3;2*1H
DM983QP CS CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC.Cl.Cl
DM983QP IK JINNGBXKBDUGQT-UHFFFAOYSA-N
DM983QP IU 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;dihydrochloride
DM983QP CA CAS 89226-75-5
DM983QP CB CHEBI:31800
DM983QP DE Discovery agent
DMO9WZN ID DMO9WZN
DMO9WZN DN CV-6504.HCL
DMO9WZN HS Investigative
DMO9WZN SN 117585-83-8; 2,3,5-Trimethyl-6-(3-pyridylmethyl)-2,5-cyclohexane-1,4-dione hydrochloride; 3,5,6-Trimethyl-2-(3-pyridylmethyl)-1,4-benzoquinone hydrochloride; CV-6504.HCl
DMO9WZN DT Small molecular drug
DMO9WZN PC 9817080
DMO9WZN MW 277.74
DMO9WZN FM C15H16ClNO2
DMO9WZN IC InChI=1S/C15H15NO2.ClH/c1-9-10(2)15(18)13(11(3)14(9)17)7-12-5-4-6-16-8-12;/h4-6,8H,7H2,1-3H3;1H
DMO9WZN CS CC1=C(C(=O)C(=C(C1=O)C)CC2=CN=CC=C2)C.Cl
DMO9WZN IK FBOCJGYMOAAFSO-UHFFFAOYSA-N
DMO9WZN IU 2,3,5-trimethyl-6-(pyridin-3-ylmethyl)cyclohexa-2,5-diene-1,4-dione;hydrochloride
DMO9WZN DE Discovery agent
DMO9UMK ID DMO9UMK
DMO9UMK DN CVS-1578
DMO9UMK HS Investigative
DMO9UMK SN 174960-52-2; 186318-81-0; CV-1778; CVS-1778; CVS-1832; CVS-1897; CVS-2097
DMO9UMK DT Small molecular drug
DMO9UMK PC 9869156
DMO9UMK MW 466.6
DMO9UMK FM C20H30N6O5S
DMO9UMK IC InChI=1S/C20H30N6O5S/c21-20(22)26-11-5-8-15(19(26)29)23-17(27)12-25-10-4-9-16(18(25)28)24-32(30,31)13-14-6-2-1-3-7-14/h1-3,6-7,15-16,19,24,29H,4-5,8-13H2,(H3,21,22)(H,23,27)/t15-,16-,19?/m0/s1
DMO9UMK CS C1C[C@@H](C(N(C1)C(=N)N)O)NC(=O)CN2CCC[C@@H](C2=O)NS(=O)(=O)CC3=CC=CC=C3
DMO9UMK IK SPUAEQJRVQHWKF-NRAVZPKASA-N
DMO9UMK IU 2-[(3S)-3-(benzylsulfonylamino)-2-oxopiperidin-1-yl]-N-[(3S)-1-carbamimidoyl-2-hydroxypiperidin-3-yl]acetamide
DMO9UMK DE Discovery agent
DMT5R1Q ID DMT5R1Q
DMT5R1Q DN CVS-2139
DMT5R1Q HS Investigative
DMT5R1Q SN CVS-2139; CHEMBL19599; BDBM50111717
DMT5R1Q DT Small molecular drug
DMT5R1Q PC 44272797
DMT5R1Q MW 496.5
DMT5R1Q FM C20H25FN6O6S
DMT5R1Q IC InChI=1S/C20H25FN6O6S/c21-14-6-2-1-5-13(14)12-34(32,33)26-15-8-4-10-27(18(15)29)11-17(28)25-16(19(30)31)7-3-9-24-20(22)23/h1-2,4-6,8,10,16,26H,3,7,9,11-12H2,(H,25,28)(H,30,31)(H4,22,23,24)/t16-/m1/s1
DMT5R1Q CS C1=CC=C(C(=C1)CS(=O)(=O)NC2=CC=CN(C2=O)CC(=O)N[C@H](CCCN=C(N)N)C(=O)O)F
DMT5R1Q IK OFDAQIKHAJYTBV-MRXNPFEDSA-N
DMT5R1Q IU (2R)-5-(diaminomethylideneamino)-2-[[2-[3-[(2-fluorophenyl)methylsulfonylamino]-2-oxopyridin-1-yl]acetyl]amino]pentanoic acid
DMT5R1Q DE Discovery agent
DM3KB4H ID DM3KB4H
DM3KB4H DN CVS-2359
DM3KB4H HS Investigative
DM3KB4H SN CVS-2359; CHEMBL431292; BDBM50111730
DM3KB4H DT Small molecular drug
DM3KB4H PC 44272875
DM3KB4H MW 510.5
DM3KB4H FM C21H27FN6O6S
DM3KB4H IC InChI=1S/C21H27FN6O6S/c1-13-8-9-16(27-35(33,34)12-14-5-2-3-6-15(14)22)19(30)28(13)11-18(29)26-17(20(31)32)7-4-10-25-21(23)24/h2-3,5-6,8-9,17,27H,4,7,10-12H2,1H3,(H,26,29)(H,31,32)(H4,23,24,25)/t17-/m1/s1
DM3KB4H CS CC1=CC=C(C(=O)N1CC(=O)N[C@H](CCCN=C(N)N)C(=O)O)NS(=O)(=O)CC2=CC=CC=C2F
DM3KB4H IK QTGRXIGBXXVLEH-QGZVFWFLSA-N
DM3KB4H IU (2R)-5-(diaminomethylideneamino)-2-[[2-[3-[(2-fluorophenyl)methylsulfonylamino]-6-methyl-2-oxopyridin-1-yl]acetyl]amino]pentanoic acid
DM3KB4H DE Discovery agent
DMDH6PJ ID DMDH6PJ
DMDH6PJ DN CVT-10216
DMDH6PJ HS Investigative
DMDH6PJ SN CVT-10083; CVT-10200; CVT-10992; ALDH2 antagonists (alcoholism), CV Therapeutics; ALDH2 antagonists (alcoholism), Gilead Palo Alto; Aldehyde dehydrogenase-2 antagonists (alcoholism), CV Therapeutics
DMDH6PJ CP Gilead Palo Alto Inc
DMDH6PJ DT Small molecular drug
DMDH6PJ PC 23661666
DMDH6PJ MW 465.5
DMDH6PJ FM C24H19NO7S
DMDH6PJ IC InChI=1S/C24H19NO7S/c1-33(29,30)25-18-7-5-16(6-8-18)21-14-32-22-12-19(9-10-20(22)23(21)26)31-13-15-3-2-4-17(11-15)24(27)28/h2-12,14,25H,13H2,1H3,(H,27,28)
DMDH6PJ CS CS(=O)(=O)NC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C(=O)O
DMDH6PJ IK YYOOFJZTRCPVFD-UHFFFAOYSA-N
DMDH6PJ IU 3-[[3-[4-(methanesulfonamido)phenyl]-4-oxochromen-7-yl]oxymethyl]benzoic acid
DMDH6PJ CA CAS 1005334-57-5
DMDH6PJ DE Alcohol dependence
DMOCKMZ ID DMOCKMZ
DMOCKMZ DN CVT-12012
DMOCKMZ HS Investigative
DMOCKMZ SN CVT-12012; UNII-OH3J29Q653; 1018675-35-8; CHEMBL573829; OH3J29Q653; SCHEMBL906403; EX-A2767; BDBM50298898; HY-11034; 2-Hydroxy-N-(2-(3-methyl-2-oxo-7-(((3-(trifluoromethyl)phenyl)methyl)amino)-1,2-dihydroquinoxalin-1-yl)ethyl)acetamide; Acetamide, 2-hydroxy-N-(2-(3-methyl-2-oxo-7-(((3-(trifluoromethyl)phenyl)methyl)amino)-1(2H)-quinoxalinyl)ethyl)-; CS-0003005; 2-hydroxy-N-(2-(3-methyl-2-oxo-7-(3-(trifluoromethyl)benzylamino)quinoxalin-1(2H)-yl)ethyl)acetamide
DMOCKMZ DT Small molecular drug
DMOCKMZ PC 25195516
DMOCKMZ MW 434.4
DMOCKMZ FM C21H21F3N4O3
DMOCKMZ IC InChI=1S/C21H21F3N4O3/c1-13-20(31)28(8-7-25-19(30)12-29)18-10-16(5-6-17(18)27-13)26-11-14-3-2-4-15(9-14)21(22,23)24/h2-6,9-10,26,29H,7-8,11-12H2,1H3,(H,25,30)
DMOCKMZ CS CC1=NC2=C(C=C(C=C2)NCC3=CC(=CC=C3)C(F)(F)F)N(C1=O)CCNC(=O)CO
DMOCKMZ IK HRAQDVZJYIAWOV-UHFFFAOYSA-N
DMOCKMZ IU 2-hydroxy-N-[2-[3-methyl-2-oxo-7-[[3-(trifluoromethyl)phenyl]methylamino]quinoxalin-1-yl]ethyl]acetamide
DMOCKMZ CA CAS 1018675-35-8
DMOCKMZ DE Diabetic complication
DMSEK5W ID DMSEK5W
DMSEK5W DN CVT-313
DMSEK5W HS Investigative
DMSEK5W SN AC1OCFD4; NG 26
DMSEK5W DT Small molecular drug
DMSEK5W PC 6918386
DMSEK5W MW 400.5
DMSEK5W FM C20H28N6O3
DMSEK5W IC InChI=1S/C20H28N6O3/c1-14(2)26-13-22-17-18(21-12-15-4-6-16(29-3)7-5-15)23-20(24-19(17)26)25(8-10-27)9-11-28/h4-7,13-14,27-28H,8-12H2,1-3H3,(H,21,23,24)
DMSEK5W CS CC(C)N1C=NC2=C(N=C(N=C21)N(CCO)CCO)NCC3=CC=C(C=C3)OC
DMSEK5W IK NQVIIUBWMBHLOZ-UHFFFAOYSA-N
DMSEK5W IU 2-[2-hydroxyethyl-[6-[(4-methoxyphenyl)methylamino]-9-propan-2-ylpurin-2-yl]amino]ethanol
DMSEK5W CA CAS 199986-75-9
DMSEK5W DE Discovery agent
DMYC1DW ID DMYC1DW
DMYC1DW DN CVT-6694
DMYC1DW HS Investigative
DMYC1DW SN CVT-6694; CHEMBL252048; SCHEMBL242234; BDBM50233086
DMYC1DW DT Small molecular drug
DMYC1DW PC 10226014
DMYC1DW MW 452.9
DMYC1DW FM C20H17ClN8O3
DMYC1DW IC InChI=1S/C20H17ClN8O3/c1-2-7-29-19(30)15-17(26-20(29)31)25-16(24-15)12-8-22-28(9-12)10-14-23-18(32-27-14)11-3-5-13(21)6-4-11/h3-6,8-9H,2,7,10H2,1H3,(H,24,25)(H,26,31)
DMYC1DW CS CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CN(N=C3)CC4=NOC(=N4)C5=CC=C(C=C5)Cl
DMYC1DW IK HWHLLTUJISZFDN-UHFFFAOYSA-N
DMYC1DW IU 8-[1-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]pyrazol-4-yl]-1-propyl-3,7-dihydropurine-2,6-dione
DMYC1DW DE Discovery agent
DM53VA8 ID DM53VA8
DM53VA8 DN CVT-7124
DM53VA8 HS Investigative
DM53VA8 SN CVT-7124; CHEMBL251876; SCHEMBL1945825; BDBM50233088; 1-ethyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione
DM53VA8 DT Small molecular drug
DM53VA8 PC 11774068
DM53VA8 MW 404.3
DM53VA8 FM C18H15F3N6O2
DM53VA8 IC InChI=1S/C18H15F3N6O2/c1-2-27-16(28)13-15(25-17(27)29)24-14(23-13)11-7-22-26(9-11)8-10-4-3-5-12(6-10)18(19,20)21/h3-7,9H,2,8H2,1H3,(H,23,24)(H,25,29)
DM53VA8 CS CCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CN(N=C3)CC4=CC(=CC=C4)C(F)(F)F
DM53VA8 IK OFXKKKKJJGJUBD-UHFFFAOYSA-N
DM53VA8 IU 1-ethyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione
DM53VA8 DE Discovery agent
DMXMIT4 ID DMXMIT4
DMXMIT4 DN CX-02
DMXMIT4 HS Investigative
DMXMIT4 SN CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics
DMXMIT4 CP Northwest Biotherapeutics Inc
DMXMIT4 DT Antibody
DMXMIT4 DE Solid tumour/cancer
DM7293Q ID DM7293Q
DM7293Q DN CX-1001
DM7293Q HS Investigative
DM7293Q SN SERT ligand (cancer), Celentyx; Reprofiled marketed drug (B-cell cancers), Celentyx
DM7293Q CP Celentyx Ltd
DM7293Q DE Solid tumour/cancer
DMCNEXF ID DMCNEXF
DMCNEXF DN CX4
DMCNEXF HS Investigative
DMCNEXF SN AC1MBGFP; Maybridge4_002933; CX-4; GTPL7663; CCG-196; MolPort-002-912-245; HMS1529F07; MCULE-4373871510; NCGC00176395-01; BRD-A62325689-001-01-9; 1-(2-chloro-6-methylphenyl)-3-(1,2-diphenylethyl)thiourea
DMCNEXF DT Small molecular drug
DMCNEXF PC 2725220
DMCNEXF MW 380.9
DMCNEXF FM C22H21ClN2S
DMCNEXF IC InChI=1S/C22H21ClN2S/c1-16-9-8-14-19(23)21(16)25-22(26)24-20(18-12-6-3-7-13-18)15-17-10-4-2-5-11-17/h2-14,20H,15H2,1H3,(H2,24,25,26)
DMCNEXF CS CC1=C(C(=CC=C1)Cl)NC(=S)NC(CC2=CC=CC=C2)C3=CC=CC=C3
DMCNEXF IK LHTLPGOZLLOCIS-UHFFFAOYSA-N
DMCNEXF IU 1-(2-chloro-6-methylphenyl)-3-(1,2-diphenylethyl)thiourea
DMCNEXF DE Discovery agent
DMXD1IN ID DMXD1IN
DMXD1IN DN CX-5011
DMXD1IN HS Investigative
DMXD1IN SN 1333382-30-1; UNII-2F5JG09KS6; CX-5011; 2F5JG09KS6; sodium 5-(3-ethynylphenylamino)pyrimido[4,5-c]quinoline-8-carboxylate; AOB1816; AKOS027422619; Pyrimido(4,5-C)quinoline-8-carboxylic acid, 5-((3-ethynylphenyl)amino)-, sodium salt (1:1)
DMXD1IN CP Cylene Pharmaceuticals Inc
DMXD1IN DT Small molecular drug
DMXD1IN PC 70702100
DMXD1IN MW 362.3
DMXD1IN FM C20H11N4NaO2
DMXD1IN IC InChI=1S/C20H12N4O2.Na/c1-2-12-4-3-5-14(8-12)23-19-18-16(10-21-11-22-18)15-7-6-13(20(25)26)9-17(15)24-19;/h1,3-11H,(H,23,24)(H,25,26);/q;+1/p-1
DMXD1IN CS C#CC1=CC(=CC=C1)NC2=NC3=C(C=CC(=C3)C(=O)[O-])C4=CN=CN=C42.[Na+]
DMXD1IN IK FSIFELDKZUCPMJ-UHFFFAOYSA-M
DMXD1IN IU sodium;5-(3-ethynylanilino)pyrimido[4,5-c]quinoline-8-carboxylate
DMXD1IN CA CAS 1333382-30-1
DMXD1IN DE Solid tumour/cancer
DMNTAV8 ID DMNTAV8
DMNTAV8 DN CX-7000
DMNTAV8 HS Investigative
DMNTAV8 SN Second generation CK2 inhibitors (cancer), Cylene
DMNTAV8 CP Cylene Pharmaceuticals Inc
DMNTAV8 DE Solid tumour/cancer
DM526C9 ID DM526C9
DM526C9 DN CX-9051
DM526C9 HS Investigative
DM526C9 SN J-13016; COX-2 inhibitors (cancer); COX-2 inhibitors (cancer), National Taiwan University
DM526C9 CP National Taiwan University
DM526C9 DE Solid tumour/cancer
DMAPRDE ID DMAPRDE
DMAPRDE DN CXB-029
DMAPRDE HS Investigative
DMAPRDE SN CB1 antagonist (pain/obesity/glaucoma/CNS-related disease), CeNeRx
DMAPRDE CP PharmaNess Neurosciences
DMAPRDE DE Central nervous system disease
DMG1SXD ID DMG1SXD
DMG1SXD DN CXCL8
DMG1SXD HS Investigative
DMG1SXD SN Interleukin-8; CHEMBL411250; interleukin-8; IL-8
DMG1SXD DT Small molecular drug
DMG1SXD PC 74974005
DMG1SXD MW 2504.7
DMG1SXD FM C112H150N24O38S2
DMG1SXD IC InChI=1S/C112H150N24O38S2/c1-55(2)41-69(122-103(165)77(49-89(149)150)131-106(168)79(51-91(153)154)129-98(160)70(42-59-19-10-8-11-20-59)123-105(167)78(50-90(151)152)130-100(162)73(45-62-52-115-65-24-15-14-23-64(62)65)126-96(158)67(34-39-175-6)118-58(5)139)97(159)127-74(46-84(113)141)101(163)125-72(43-60-21-12-9-13-22-60)107(169)133-92(57(4)138)109(171)116-53-85(142)119-68(35-40-176-7)110(172)136-38-18-27-83(136)112(174)135-37-17-26-82(135)108(170)117-56(3)94(156)121-75(47-87(145)146)102(164)120-66(32-33-86(143)144)95(157)128-76(48-88(147)148)104(166)124-71(44-61-28-30-63(140)31-29-61)99(161)132-80(54-137)111(173)134-36-16-25-81(134)93(114)155/h8-15,19-24,28-31,52,55-57,66-83,92,115,137-138,140H,16-18,25-27,32-51,53-54H2,1-7H3,(H2,113,141)(H2,114,155)(H,116,171)(H,117,170)(H,118,139)(H,119,142)(H,120,164)(H,121,156)(H,122,165)(H,123,167)(H,124,166)(H,125,163)(H,126,158)(H,127,159)(H,128,157)(H,129,160)(H,130,162)(H,131,168)(H,132,161)(H,133,169)(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)
DMG1SXD CS CC(C)CC(C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCSC)C(=O)N2CCCC2C(=O)N3CCCC3C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)NC(CO)C(=O)N5CCCC5C(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(=O)O)NC(=O)C(CC7=CNC8=CC=CC=C87)NC(=O)C(CCSC)NC(=O)C
DMG1SXD IK XKTZWUACRZHVAN-UHFFFAOYSA-N
DMG1SXD IU 4-[[2-[2-[[1-[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-acetamido-4-methylsulfanylbutanoyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoylamino]-3-carboxypropanoyl]amino]-5-[[1-[[1-[[1-(2-carbamoylpyrrolidin-1-yl)-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMG1SXD DE Psoriasis vulgaris
DMNSUD9 ID DMNSUD9
DMNSUD9 DN CXCR4 gene disrupted T cells
DMNSUD9 HS Investigative
DMNSUD9 SN CXCR4 gene disrupted T cells (HIV infection)
DMNSUD9 CP Scripps Research Institute
DMNSUD9 DE Human immunodeficiency virus infection
DMBKTHI ID DMBKTHI
DMBKTHI DN Cy3B-telenzepine
DMBKTHI HS Investigative
DMBKTHI SN Cy3B-telenzepine
DMBKTHI DT Small molecular drug
DMBKTHI PC 91827377
DMBKTHI MW 1054.4
DMBKTHI FM C59H71N7O7S2-2
DMBKTHI IC InChI=1S/C59H73N7O7S2/c1-38-54-43(37-74-38)57(69)61-46-16-12-13-17-49(46)66(54)53(68)36-63-30-28-62(29-31-63)25-15-11-9-7-6-8-10-14-24-60-52(67)33-39-18-20-47-44(32-39)58(2,3)55-41-35-42-51(73-50(41)22-26-64(47)55)23-27-65-48-21-19-40(75(70,71)72)34-45(48)59(4,5)56(42)65/h12-13,16-21,32,34-35,37,50-51H,6-11,14-15,22-31,33,36H2,1-5H3,(H4-,60,61,67,69,70,71,72)/p-2
DMBKTHI CS CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)CCCCCCCCCCNC(=O)CC5=CC6=C(C=C5)N7CCC8C(=C7C6(C)C)C=C9C(O8)CC[N+]1=C9C(C2=C1C=CC(=C2)S([O-])([O-])[O-])(C)C
DMBKTHI IK DGPHRPUJPHDIPO-UHFFFAOYSA-L
DMBKTHI IU N-[10-[4-[2-(1-methyl-4-oxo-5H-thieno[3,4-b][1,5]benzodiazepin-10-yl)-2-oxoethyl]piperazin-1-yl]decyl]-2-[5,5,27,27-tetramethyl-24-(trioxido-lambda4-sulfanyl)-16-oxa-12-aza-20-azoniaheptacyclo[15.11.0.03,15.04,12.06,11.020,28.021,26]octacosa-1,3,6(11),7,9,20(28),21(26),22,24-nonaen-8-yl]acetamide
DMBKTHI DE Discovery agent
DMZ6YPV ID DMZ6YPV
DMZ6YPV DN Cyamemazine
DMZ6YPV HS Investigative
DMZ6YPV SN cyamepromazine; RP-7204
DMZ6YPV DT Small molecular drug
DMZ6YPV PC 62865
DMZ6YPV MW 323.5
DMZ6YPV FM C19H21N3S
DMZ6YPV IC InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3
DMZ6YPV CS CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N)CN(C)C
DMZ6YPV IK SLFGIOIONGJGRT-UHFFFAOYSA-N
DMZ6YPV IU 10-[3-(dimethylamino)-2-methylpropyl]phenothiazine-2-carbonitrile
DMZ6YPV CA CAS 3546-03-0
DMZ6YPV CB CHEBI:135379
DMZ6YPV DE Discovery agent
DM6HQDL ID DM6HQDL
DM6HQDL DN CYANATE
DM6HQDL HS Investigative
DM6HQDL SN cyanate; ISOCYANATE; UNII-YML51WA0FW; YML51WA0FW; 661-20-1; 71000-82-3; UN2206; Cyanate ion(1-); Isocyanate ion(1-); Isocyanate ion (1-); Isocyanic acid, ion(1-); isocynate; Zyanat; Cyanat; carbonyl amide; hydrogen cyanate; UN3080; nitridooxidocarbonate(1-); AC1L2XX2; OCN(-); CHEBI:29195; CTK5I4582; CTK2H4173; BDBM26982; CNO(-1); IQPQWNKOIGAROB-UHFFFAOYSA-N; XLJMAIOERFSOGZ-UHFFFAOYSA-M; AC1Q2283; BDBM50098562; [C(N)O](-); Isocyanates, toxic, n.o.s. or isocyanate solutions, toxic, n.o.s., Fp 61 C and Bp 300 C; Isocyanates, toxic, n.o.s. o
DM6HQDL DT Small molecular drug
DM6HQDL PC 105034
DM6HQDL MW 42.017
DM6HQDL FM CNO-
DM6HQDL IC InChI=1S/CNO/c2-1-3/q-1
DM6HQDL CS C(=[N-])=O
DM6HQDL IK IQPQWNKOIGAROB-UHFFFAOYSA-N
DM6HQDL IU isocyanate
DM6HQDL CA CAS 71000-82-3
DM6HQDL CB CHEBI:29195
DM6HQDL DE Discovery agent
DMJE4HK ID DMJE4HK
DMJE4HK DN Cyanide
DMJE4HK HS Investigative
DMJE4HK SN cyanide; CYANIDE ION; Isocyanide; Cyanide anion; Nitrile anion; Cyanide ions; 57-12-5; Cyanure [French]; Cyanide(1-) ion; Cyanide(1-); Cyanide (anion); UNII-OXN4E7L11K; RCRA waste number P030; Cyanide (CN(sup 1-)); Carbon nitride ion (CN1-); Hydrocyanic acid, ion(1-)-; Carbon nitride ion (CN(sup 1-)); UN1935; RCRA waste no. P030; BRN 1900509; OXN4E7L11K; CN-; Cyanides (soluble salts and complexes) not otherwise specified; Cyanure; Cyanide, free; iminomethanide; isonitrile; Prussiate; Zyanid; Cyano; nitridocarbonate(1-); Cyanide with pota
DMJE4HK DT Small molecular drug
DMJE4HK PC 5975
DMJE4HK MW 26.017
DMJE4HK FM CN-
DMJE4HK IC InChI=1S/CN/c1-2/q-1
DMJE4HK CS [C-]#N
DMJE4HK IK XFXPMWWXUTWYJX-UHFFFAOYSA-N
DMJE4HK IU cyanide
DMJE4HK CA CAS 57-12-5
DMJE4HK CB CHEBI:17514
DMJE4HK DE Discovery agent
DMZBDO1 ID DMZBDO1
DMZBDO1 DN CYANIDIN
DMZBDO1 HS Investigative
DMZBDO1 SN Cyanidin; 13306-05-3; UNII-7732ZHU564; 3,5,7,3',4'-Pentahydroxyflavylium; 2-(3,4-dihydroxyphenyl)chromenylium-3,5,7-triol; CHEMBL404515; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-1-Benzopyrylium; CHEBI:27843; 3,3',4',5,7-pentahydroxyflavylium; 7732ZHU564; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromenylium; cyanidin cation; 3,3',4,5,7-Pentahydroxyflavylium chloride; cyanidin(1+); Flavylium, 3,3',4',5,7-pentahydroxy-; AC1L2UL2; SCHEMBL20799; 528-58-5 (chloride); DTXSID10157933; MolPort-044-559-814
DMZBDO1 DT Small molecular drug
DMZBDO1 PC 128861
DMZBDO1 MW 287.24
DMZBDO1 FM C15H11O6+
DMZBDO1 IC InChI=1S/C15H10O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-6H,(H4-,16,17,18,19,20)/p+1
DMZBDO1 CS C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O)O)O)O)O
DMZBDO1 IK VEVZSMAEJFVWIL-UHFFFAOYSA-O
DMZBDO1 IU 2-(3,4-dihydroxyphenyl)chromenylium-3,5,7-triol
DMZBDO1 CA CAS 13306-05-3
DMZBDO1 CB CHEBI:27843
DMZBDO1 DE Discovery agent
DMIBLGH ID DMIBLGH
DMIBLGH DN Cyanopindolol
DMIBLGH HS Investigative
DMIBLGH SN Cyanopindolol; 69906-85-0; CYANOPINDOLOL HEMIFUMARATE; 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile; (+-)-Cyanopindolol; (-)-Cyanopindolol; AC1L4E3D; CYANOPINDOLOL(+/-); GTPL132; SCHEMBL353756; CHEMBL378501; CTK8E9328; BDBM81499; CHEBI:125406; PDSP1_001601; PDSP2_001585; PDSP1_001094; PDSP2_001078; NSC707473; CAS_155346; NSC_155346; NSC-707473; 1H-Indole-2-carbonitrile, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-; NCI60_038172; RT-012114; SR-01000597973; L000210; SR-01000597973-1; BRD-A47884604-001-01-7
DMIBLGH DT Small molecular drug
DMIBLGH PC 155346
DMIBLGH MW 287.36
DMIBLGH FM C16H21N3O2
DMIBLGH IC InChI=1S/C16H21N3O2/c1-16(2,3)18-9-12(20)10-21-15-6-4-5-14-13(15)7-11(8-17)19-14/h4-7,12,18-20H,9-10H2,1-3H3
DMIBLGH CS CC(C)(C)NCC(COC1=CC=CC2=C1C=C(N2)C#N)O
DMIBLGH IK QXIUMMLTJVHILT-UHFFFAOYSA-N
DMIBLGH IU 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile
DMIBLGH CA CAS 69906-85-0
DMIBLGH CB CHEBI:125406
DMIBLGH DE Discovery agent
DMC6DAZ ID DMC6DAZ
DMC6DAZ DN CYCLAZOCINE
DMC6DAZ HS Investigative
DMC6DAZ SN (-)-cyclazocine; 7313-86-2; l-Cyclazocine; (-)-cis-Cyclazocine; A-Cyclazocine; AC1L55DZ; GTPL1604; CTK8F1400; DTXSID20617937; MCV 4512; (2R,6R,11R)-3-(Cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol; NIH 10450; AKOS030242899; FT-0665329
DMC6DAZ DT Small molecular drug
DMC6DAZ PC 19143
DMC6DAZ MW 271.4
DMC6DAZ FM C18H25NO
DMC6DAZ IC InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3
DMC6DAZ CS CC1C2CC3=C(C1(CCN2CC4CC4)C)C=C(C=C3)O
DMC6DAZ IK YQYVFVRQLZMJKJ-UHFFFAOYSA-N
DMC6DAZ IU 10-(cyclopropylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMC6DAZ CA CAS 3572-80-3
DMC6DAZ DE Discovery agent
DMPXHO8 ID DMPXHO8
DMPXHO8 DN Cyclazosin
DMPXHO8 HS Investigative
DMPXHO8 SN Cyclazosin; (+)-cyclazosin; 139953-73-4; CHEBI:63937; cis-1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)decahydroquinoxaline; [(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)octahydroquinoxalin-1(2H)-yl](2-furyl)methanone; AC1L30OJ; GTPL486; (4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)octahydroquinoxalin-1-yl)furan-2-ylmethanone hydrochloride; CHEMBL423294; ZINC2385764; BDBM50403649; [(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(furan-2-yl)methanone
DMPXHO8 DT Small molecular drug
DMPXHO8 PC 132266
DMPXHO8 MW 437.5
DMPXHO8 FM C23H27N5O4
DMPXHO8 IC InChI=1S/C23H27N5O4/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1
DMPXHO8 CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN([C@@H]4[C@H]3CCCC4)C(=O)C5=CC=CO5)N)OC
DMPXHO8 IK XBRXTUGRUXGBPX-DLBZAZTESA-N
DMPXHO8 IU [(4aR,8aS)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(furan-2-yl)methanone
DMPXHO8 CA CAS 139953-73-4
DMPXHO8 CB CHEBI:63937
DMPXHO8 DE Discovery agent
DMVJL8H ID DMVJL8H
DMVJL8H DN cyclic CMP
DMVJL8H HS Investigative
DMVJL8H SN cytidine, cyclic 3',5'-(hydrogen phosphate)
DMVJL8H DT Small molecular drug
DMVJL8H PC 19236
DMVJL8H MW 305.18
DMVJL8H FM C9H12N3O7P
DMVJL8H IC InChI=1S/C9H12N3O7P/c10-5-1-2-12(9(14)11-5)8-6(13)7-4(18-8)3-17-20(15,16)19-7/h1-2,4,6-8,13H,3H2,(H,15,16)(H2,10,11,14)/t4-,6-,7-,8-/m1/s1
DMVJL8H CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=NC3=O)N)O)OP(=O)(O1)O
DMVJL8H IK WCPTXJJVVDAEMW-XVFCMESISA-N
DMVJL8H IU 1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one
DMVJL8H CA CAS 3616-08-8
DMVJL8H CB CHEBI:17065
DMVJL8H DE Discovery agent
DMOU93V ID DMOU93V
DMOU93V DN Cyclic guanosine monophosphate
DMOU93V HS Investigative
DMOU93V DT Small molecular drug
DMOU93V PC 135398570
DMOU93V MW 345.21
DMOU93V FM C10H12N5O7P
DMOU93V IC InChI=1S/C10H12N5O7P/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,16H,1H2,(H,18,19)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1
DMOU93V CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=C(NC4=O)N)O)OP(=O)(O1)O
DMOU93V IK ZOOGRGPOEVQQDX-UUOKFMHZSA-N
DMOU93V IU 9-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-amino-1H-purin-6-one
DMOU93V CA CAS 7665-99-8
DMOU93V CB CHEBI:16356
DMOU93V DE Discovery agent
DM2JE5F ID DM2JE5F
DM2JE5F DN Cyclic LVVYPWT
DM2JE5F HS Investigative
DM2JE5F SN CHEMBL397926; cyclic LVVYPWT
DM2JE5F DT Small molecular drug
DM2JE5F PC 17756317
DM2JE5F MW 859
DM2JE5F FM C45H62N8O9
DM2JE5F IC InChI=1S/C45H62N8O9/c1-23(2)19-32-39(56)50-37(25(5)6)43(60)51-36(24(3)4)42(59)49-34(20-27-14-16-29(55)17-15-27)45(62)53-18-10-13-35(53)41(58)47-33(40(57)52-38(26(7)54)44(61)48-32)21-28-22-46-31-12-9-8-11-30(28)31/h8-9,11-12,14-17,22-26,32-38,46,54-55H,10,13,18-21H2,1-7H3,(H,47,58)(H,48,61)(H,49,59)(H,50,56)(H,51,60)(H,52,57)/t26-,32+,33+,34+,35+,36+,37+,38+/m1/s1
DM2JE5F CS C[C@H]([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N1)CC3=CNC4=CC=CC=C43)CC5=CC=C(C=C5)O)C(C)C)C(C)C)CC(C)C)O
DM2JE5F IK COEPOBZXGUREGL-BYZYSQTKSA-N
DM2JE5F IU (3S,6S,9S,12S,15S,18S,21S)-15-[(1R)-1-hydroxyethyl]-3-[(4-hydroxyphenyl)methyl]-18-(1H-indol-3-ylmethyl)-12-(2-methylpropyl)-6,9-di(propan-2-yl)-1,4,7,10,13,16,19-heptazabicyclo[19.3.0]tetracosane-2,5,8,11,14,17,20-heptone
DM2JE5F DE Discovery agent
DMFUG05 ID DMFUG05
DMFUG05 DN Cyclo(1,10)EIYDPGDDIK
DMFUG05 HS Investigative
DMFUG05 SN CHEMBL499996
DMFUG05 PC 44571079
DMFUG05 MW 1146.2
DMFUG05 FM C51H75N11O19
DMFUG05 IC InChI=1S/C51H75N11O19/c1-5-25(3)41-49(79)56-29(10-7-8-18-52)43(73)55-30(16-17-37(65)66)44(74)60-42(26(4)6-2)50(80)58-31(20-27-12-14-28(63)15-13-27)45(75)59-34(23-40(71)72)51(81)62-19-9-11-35(62)48(78)53-24-36(64)54-32(21-38(67)68)46(76)57-33(22-39(69)70)47(77)61-41/h12-15,25-26,29-35,41-42,63H,5-11,16-24,52H2,1-4H3,(H,53,78)(H,54,64)(H,55,73)(H,56,79)(H,57,76)(H,58,80)(H,59,75)(H,60,74)(H,61,77)(H,65,66)(H,67,68)(H,69,70)(H,71,72)/t25-,26-,29-,30-,31-,32+,33-,34-,35-,41-,42-/m0/s1
DMFUG05 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCC(=O)O)CCCCN)[C@@H](C)CC)CC(=O)O)CC(=O)O)CC(=O)O)CC3=CC=C(C=C3)O
DMFUG05 IK JDTPYTFDRAQKHK-ZHDLRRBESA-N
DMFUG05 IU 3-[(3S,6S,9S,12S,15S,18S,21S,24R,30S)-15-(4-aminobutyl)-9,18-bis[(2S)-butan-2-yl]-3,21,24-tris(carboxymethyl)-6-[(4-hydroxyphenyl)methyl]-2,5,8,11,14,17,20,23,26,29-decaoxo-1,4,7,10,13,16,19,22,25,28-decazabicyclo[28.3.0]tritriacontan-12-yl]propanoic acid
DMFUG05 DE Discovery agent
DM5CBQ9 ID DM5CBQ9
DM5CBQ9 DN Cyclo(1,10)H-EIYDPGDDIK-OH
DM5CBQ9 HS Investigative
DM5CBQ9 SN CHEMBL506798
DM5CBQ9 PC 44571080
DM5CBQ9 MW 1146.2
DM5CBQ9 FM C51H75N11O19
DM5CBQ9 IC InChI=1S/C51H75N11O19/c1-5-25(3)41-49(78)58-31(20-27-12-14-28(63)15-13-27)44(73)59-34(23-40(70)71)50(79)62-19-9-11-35(62)47(76)54-24-37(65)55-32(21-38(66)67)45(74)57-33(22-39(68)69)46(75)61-42(26(4)6-2)48(77)56-30(51(80)81)10-7-8-18-53-36(64)17-16-29(52)43(72)60-41/h12-15,25-26,29-35,41-42,63H,5-11,16-24,52H2,1-4H3,(H,53,64)(H,54,76)(H,55,65)(H,56,77)(H,57,74)(H,58,78)(H,59,73)(H,60,72)(H,61,75)(H,66,67)(H,68,69)(H,70,71)(H,80,81)/t25-,26-,29-,30-,31-,32-,33-,34-,35-,41-,42-/m0/s1
DM5CBQ9 CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N1)N)C(=O)O)[C@@H](C)CC)CC(=O)O)CC(=O)O)CC(=O)O)CC3=CC=C(C=C3)O
DM5CBQ9 IK NYVKKYBROIXDPN-ZGHCNQEKSA-N
DM5CBQ9 IU (3S,6S,9S,12S,21S,24S,27S,30S,36S)-12-amino-9,24-bis[(2S)-butan-2-yl]-3,27,30-tris(carboxymethyl)-6-[(4-hydroxyphenyl)methyl]-2,5,8,11,15,23,26,29,32,35-decaoxo-1,4,7,10,16,22,25,28,31,34-decazabicyclo[34.3.0]nonatriacontane-21-carboxylic acid
DM5CBQ9 DE Discovery agent
DM4A1TF ID DM4A1TF
DM4A1TF DN Cyclo(1,11)H-ESIYDPGDDIK-OH
DM4A1TF HS Investigative
DM4A1TF SN CHEMBL525597
DM4A1TF PC 44571078
DM4A1TF MW 1233.3
DM4A1TF FM C54H80N12O21
DM4A1TF IC InChI=1S/C54H80N12O21/c1-5-26(3)43-51(83)59-31(54(86)87)10-7-8-18-56-38(69)17-16-30(55)45(77)63-36(25-67)49(81)65-44(27(4)6-2)52(84)61-32(20-28-12-14-29(68)15-13-28)46(78)62-35(23-42(75)76)53(85)66-19-9-11-37(66)50(82)57-24-39(70)58-33(21-40(71)72)47(79)60-34(22-41(73)74)48(80)64-43/h12-15,26-27,30-37,43-44,67-68H,5-11,16-25,55H2,1-4H3,(H,56,69)(H,57,82)(H,58,70)(H,59,83)(H,60,79)(H,61,84)(H,62,78)(H,63,77)(H,64,80)(H,65,81)(H,71,72)(H,73,74)(H,75,76)(H,86,87)/t26-,27-,30-,31-,32-,33-,34-,35-,36-,37-,43-,44-/m0/s1
DM4A1TF CS CC[C@H](C)[C@H]1C(=O)N[C@@H](CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)O)CC(=O)O)CC(=O)O)CC3=CC=C(C=C3)O)[C@@H](C)CC)CO)N)C(=O)O
DM4A1TF IK QVRGILAZQGYCSV-ZGJOQXBESA-N
DM4A1TF IU (3S,6S,9S,12S,15S,24S,27S,30S,33S,39S)-15-amino-9,27-bis[(2S)-butan-2-yl]-3,30,33-tris(carboxymethyl)-12-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-2,5,8,11,14,18,26,29,32,35,38-undecaoxo-1,4,7,10,13,19,25,28,31,34,37-undecazabicyclo[37.3.0]dotetracontane-24-carboxylic acid
DM4A1TF DE Discovery agent
DMVDS8B ID DMVDS8B
DMVDS8B DN Cyclo(1,12)PenIYDTKGKNVLC-OH
DMVDS8B HS Investigative
DMVDS8B PC 44403758
DMVDS8B MW 1382.7
DMVDS8B FM C60H99N15O18S2
DMVDS8B IC InChI=1S/C60H99N15O18S2/c1-10-31(6)46-56(89)71-38(24-33-17-19-34(77)20-18-33)52(85)69-40(26-44(80)81)54(87)75-47(32(7)76)57(90)67-35(15-11-13-21-61)49(82)65-27-43(79)66-36(16-12-14-22-62)50(83)68-39(25-42(63)78)53(86)73-45(30(4)5)55(88)70-37(23-29(2)3)51(84)72-41(59(92)93)28-94-95-60(8,9)48(64)58(91)74-46/h17-20,29-32,35-41,45-48,76-77H,10-16,21-28,61-62,64H2,1-9H3,(H2,63,78)(H,65,82)(H,66,79)(H,67,90)(H,68,83)(H,69,85)(H,70,88)(H,71,89)(H,72,84)(H,73,86)(H,74,91)(H,75,87)(H,80,81)(H,92,93)/t31-,32+,35-,36-,37+,38+,39+,40-,41+,45-,46-,47+,48?/m0/s1
DMVDS8B CS CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC(C(C(=O)N1)N)(C)C)C(=O)O)CC(C)C)C(C)C)CC(=O)N)CCCCN)CCCCN)[C@@H](C)O)CC(=O)O)CC2=CC=C(C=C2)O
DMVDS8B IK PADTZYYZHQSVHY-JPKRNNDPSA-N
DMVDS8B IU (4S,7R,10S,13R,16S,22S,25R,28S,31R,34S)-37-amino-16,22-bis(4-aminobutyl)-13-(2-amino-2-oxoethyl)-34-[(2S)-butan-2-yl]-28-(carboxymethyl)-25-[(1R)-1-hydroxyethyl]-31-[(4-hydroxyphenyl)methyl]-38,38-dimethyl-7-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DMVDS8B DE Discovery agent
DMLY8CU ID DMLY8CU
DMLY8CU DN Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)
DMLY8CU HS Investigative
DMLY8CU SN CHEMBL373440; cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-)
DMLY8CU DT Small molecular drug
DMLY8CU PC 44418868
DMLY8CU MW 637.7
DMLY8CU FM C30H43N11O5
DMLY8CU IC InChI=1S/C30H43N11O5/c1-17-25(43)37-16-24(42)39-23(15-18-10-11-19-6-2-3-7-20(19)14-18)28(46)41-22(9-5-13-36-30(33)34)27(45)40-21(26(44)38-17)8-4-12-35-29(31)32/h2-3,6-7,10-11,14,17,21-23H,4-5,8-9,12-13,15-16H2,1H3,(H,37,43)(H,38,44)(H,39,42)(H,40,45)(H,41,46)(H4,31,32,35)(H4,33,34,36)/t17-,21-,22+,23+/m1/s1
DMLY8CU CS C[C@@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CCCN=C(N)N)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2
DMLY8CU IK SSVKJORMBVSSPN-DZWOVHDNSA-N
DMLY8CU IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMLY8CU DE Discovery agent
DMBKRQ9 ID DMBKRQ9
DMBKRQ9 DN Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)
DMBKRQ9 HS Investigative
DMBKRQ9 SN CHEMBL375993; cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-)
DMBKRQ9 DT Small molecular drug
DMBKRQ9 PC 44418891
DMBKRQ9 MW 743.9
DMBKRQ9 FM C37H49N11O6
DMBKRQ9 IC InChI=1S/C37H49N11O6/c1-48-30(20-22-11-14-26(49)15-12-22)34(53)44-21-31(50)45-29(19-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(8-4-16-42-36(38)39)32(51)47-28(35(48)54)9-5-17-43-37(40)41/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,53)(H,45,50)(H,46,52)(H,47,51)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m0/s1
DMBKRQ9 CS CN1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C1=O)CCCN=C(N)N)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DMBKRQ9 IK KKHZUKILPGNUFR-RRGQHJHPSA-N
DMBKRQ9 IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-7-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMBKRQ9 DE Discovery agent
DMHI0UL ID DMHI0UL
DMHI0UL DN Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)
DMHI0UL HS Investigative
DMHI0UL SN CHEMBL219096; cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-)
DMHI0UL DT Small molecular drug
DMHI0UL PC 44418886
DMHI0UL MW 743.9
DMHI0UL FM C37H49N11O6
DMHI0UL IC InChI=1S/C37H49N11O6/c1-48-30(20-22-11-14-26(49)15-12-22)34(53)44-21-31(50)45-29(19-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(8-4-16-42-36(38)39)32(51)47-28(35(48)54)9-5-17-43-37(40)41/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,53)(H,45,50)(H,46,52)(H,47,51)(H4,38,39,42)(H4,40,41,43)/t27-,28-,29-,30+/m0/s1
DMHI0UL CS CN1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C1=O)CCCN=C(N)N)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DMHI0UL IK KKHZUKILPGNUFR-GCXHJFECSA-N
DMHI0UL IU 2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-7-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMHI0UL DE Discovery agent
DM82C6Q ID DM82C6Q
DM82C6Q DN Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)
DM82C6Q HS Investigative
DM82C6Q SN Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-); Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine
DM82C6Q DT Small molecular drug
DM82C6Q PC 5275843
DM82C6Q MW 729.8
DM82C6Q FM C36H47N11O6
DM82C6Q IC InChI=1S/C36H47N11O6/c37-35(38)41-15-3-7-26-32(51)45-27(8-4-16-42-36(39)40)33(52)47-28(19-22-9-12-23-5-1-2-6-24(23)17-22)31(50)43-20-30(49)44-29(34(53)46-26)18-21-10-13-25(48)14-11-21/h1-2,5-6,9-14,17,26-29,48H,3-4,7-8,15-16,18-20H2,(H,43,50)(H,44,49)(H,45,51)(H,46,53)(H,47,52)(H4,37,38,41)(H4,39,40,42)/t26-,27-,28-,29+/m0/s1
DM82C6Q CS C1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CCCN=C(N)N)CC4=CC=C(C=C4)O
DM82C6Q IK MBXBICVKLVYNKD-XFTNXAEASA-N
DM82C6Q IU 2-[3-[(2S,5S,8S,14R)-5-[3-(diaminomethylideneamino)propyl]-14-[(4-hydroxyphenyl)methyl]-8-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM82C6Q DE Discovery agent
DM8RKT1 ID DM8RKT1
DM8RKT1 DN Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)
DM8RKT1 HS Investigative
DM8RKT1 SN CHEMBL384429; cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-)
DM8RKT1 DT Small molecular drug
DM8RKT1 PC 44418869
DM8RKT1 MW 644.7
DM8RKT1 FM C33H40N8O6
DM8RKT1 IC InChI=1S/C33H40N8O6/c1-19-29(44)41-26(16-20-9-12-24(42)13-10-20)30(45)37-18-28(43)39-27(17-21-8-11-22-5-2-3-6-23(22)15-21)32(47)40-25(31(46)38-19)7-4-14-36-33(34)35/h2-3,5-6,8-13,15,19,25-27,42H,4,7,14,16-18H2,1H3,(H,37,45)(H,38,46)(H,39,43)(H,40,47)(H,41,44)(H4,34,35,36)/t19-,25+,26-,27+/m1/s1
DM8RKT1 CS C[C@@H]1C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DM8RKT1 IK KSQLRHSLMODJAS-ABXDHCHGSA-N
DM8RKT1 IU 2-[3-[(2S,5R,8R,14S)-8-[(4-hydroxyphenyl)methyl]-5-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM8RKT1 DE Discovery agent
DM8XVAW ID DM8XVAW
DM8XVAW DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)
DM8XVAW HS Investigative
DM8XVAW SN CHEMBL426169; cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-)
DM8XVAW DT Small molecular drug
DM8XVAW PC 44418894
DM8XVAW MW 743.9
DM8XVAW FM C37H49N11O6
DM8XVAW IC InChI=1S/C37H49N11O6/c1-48-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-28(9-5-17-43-37(40)41)33(52)45-27(8-4-16-42-36(38)39)34(53)47-29(32(51)44-21-31(48)50)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,52)(H,46,54)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m1/s1
DM8XVAW CS CN1[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC1=O)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM8XVAW IK XUKFERKCRCTLBJ-ATIZSFMBSA-N
DM8XVAW IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-13-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM8XVAW DE Discovery agent
DMWFITM ID DMWFITM
DMWFITM DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)
DMWFITM HS Investigative
DMWFITM SN CHEMBL219135; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-)
DMWFITM DT Small molecular drug
DMWFITM PC 44418885
DMWFITM MW 743.9
DMWFITM FM C37H49N11O6
DMWFITM IC InChI=1S/C37H49N11O6/c38-36(39)43-16-3-7-27-33(52)46-28(8-4-17-44-37(40)41)34(53)48-29(20-22-10-13-26(49)14-11-22)32(51)42-18-15-31(50)45-30(35(54)47-27)21-23-9-12-24-5-1-2-6-25(24)19-23/h1-2,5-6,9-14,19,27-30,49H,3-4,7-8,15-18,20-21H2,(H,42,51)(H,45,50)(H,46,52)(H,47,54)(H,48,53)(H4,38,39,43)(H4,40,41,44)/t27-,28+,29+,30-/m0/s1
DMWFITM CS C1CNC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CCCN=C(N)N)CC4=CC=C(C=C4)O
DMWFITM IK LMVXXKJNXQKPHR-KJHMZRPRSA-N
DMWFITM IU 2-[3-[(2S,5S,8R,11R)-8-[3-(diaminomethylideneamino)propyl]-11-[(4-hydroxyphenyl)methyl]-2-(naphthalen-2-ylmethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]propyl]guanidine
DMWFITM DE Discovery agent
DMSA0IW ID DMSA0IW
DMSA0IW DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)
DMSA0IW HS Investigative
DMSA0IW SN CHEMBL373636; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-)
DMSA0IW DT Small molecular drug
DMSA0IW PC 44418880
DMSA0IW MW 743.9
DMSA0IW FM C37H49N11O6
DMSA0IW IC InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27+,28-,29-,30+/m1/s1
DMSA0IW CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMSA0IW IK VWZBFEAQYFTPKH-UIMYGGOYSA-N
DMSA0IW IU 2-[3-[(2S,5R,8R,11R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMSA0IW DE Discovery agent
DMGOW1E ID DMGOW1E
DMGOW1E DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)
DMGOW1E HS Investigative
DMGOW1E SN CHEMBL219339; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-)
DMGOW1E DT Small molecular drug
DMGOW1E PC 11331592
DMGOW1E MW 729.8
DMGOW1E FM C36H47N11O6
DMGOW1E IC InChI=1S/C36H47N11O6/c37-35(38)41-15-3-7-26-32(51)45-27(8-4-16-42-36(39)40)33(52)47-28(18-21-10-13-25(48)14-11-21)31(50)43-20-30(49)44-29(34(53)46-26)19-22-9-12-23-5-1-2-6-24(23)17-22/h1-2,5-6,9-14,17,26-29,48H,3-4,7-8,15-16,18-20H2,(H,43,50)(H,44,49)(H,45,51)(H,46,53)(H,47,52)(H4,37,38,41)(H4,39,40,42)/t26-,27+,28+,29-/m0/s1
DMGOW1E CS C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMGOW1E IK YASYVKCWJGCXLS-AUAHOFGGSA-N
DMGOW1E IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMGOW1E DE Discovery agent
DM3PRHF ID DM3PRHF
DM3PRHF DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)
DM3PRHF HS Investigative
DM3PRHF SN CHEMBL376811; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-)
DM3PRHF DT Small molecular drug
DM3PRHF PC 44418879
DM3PRHF MW 743.9
DM3PRHF FM C37H49N11O6
DM3PRHF IC InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27-,28+,29+,30-/m0/s1
DM3PRHF CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM3PRHF IK VWZBFEAQYFTPKH-DXQNDIIUSA-N
DM3PRHF IU 2-[3-[(2S,5R,8R,11S,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM3PRHF DE Discovery agent
DMS9QHI ID DMS9QHI
DMS9QHI DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)
DMS9QHI HS Investigative
DMS9QHI SN CHEMBL373637; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-)
DMS9QHI DT Small molecular drug
DMS9QHI PC 44418883
DMS9QHI MW 783.9
DMS9QHI FM C40H53N11O6
DMS9QHI IC InChI=1S/C40H53N11O6/c41-39(42)45-18-5-9-29-34(53)47-30(10-6-19-46-40(43)44)35(54)50-32(22-24-13-16-28(52)17-14-24)38(57)51-20-4-3-11-33(51)37(56)49-31(36(55)48-29)23-25-12-15-26-7-1-2-8-27(26)21-25/h1-2,7-8,12-17,21,29-33,52H,3-6,9-11,18-20,22-23H2,(H,47,53)(H,48,55)(H,49,56)(H,50,54)(H4,41,42,45)(H4,43,44,46)/t29-,30+,31-,32+,33-/m0/s1
DMS9QHI CS C1CCN2[C@@H](C1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C2=O)CC3=CC=C(C=C3)O)CCCN=C(N)N)CCCN=C(N)N)CC4=CC5=CC=CC=C5C=C4
DMS9QHI IK OGLLNRFCXLYAMK-AUURQCAXSA-N
DMS9QHI IU 2-[3-[(3R,6R,9S,12S,15S)-6-[3-(diaminomethylideneamino)propyl]-3-[(4-hydroxyphenyl)methyl]-12-(naphthalen-2-ylmethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazabicyclo[13.4.0]nonadecan-9-yl]propyl]guanidine
DMS9QHI DE Discovery agent
DM3Y1TZ ID DM3Y1TZ
DM3Y1TZ DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)
DM3Y1TZ HS Investigative
DM3Y1TZ SN CHEMBL374862; cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-)
DM3Y1TZ DT Small molecular drug
DM3Y1TZ PC 44418895
DM3Y1TZ MW 743.9
DM3Y1TZ FM C37H49N11O6
DM3Y1TZ IC InChI=1S/C37H49N11O6/c1-48-21-31(50)44-29(20-23-10-13-24-6-2-3-7-25(24)18-23)34(53)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)47-30(35(48)54)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,50)(H,45,51)(H,46,53)(H,47,52)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m0/s1
DM3Y1TZ CS CN1CC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C1=O)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM3Y1TZ IK RVFLZIGZHRQETC-RRGQHJHPSA-N
DM3Y1TZ IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-10-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM3Y1TZ DE Discovery agent
DMUWC5O ID DMUWC5O
DMUWC5O DN Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)
DMUWC5O HS Investigative
DMUWC5O SN CHEMBL376219; cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-)
DMUWC5O DT Small molecular drug
DMUWC5O PC 44418893
DMUWC5O MW 743.9
DMUWC5O FM C37H49N11O6
DMUWC5O IC InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)46-27(8-4-16-42-36(38)39)33(52)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(35(48)54)20-23-10-13-24-6-2-3-7-25(24)18-23/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,53)(H,47,52)(H4,38,39,42)(H4,40,41,43)/t27-,28-,29+,30+/m1/s1
DMUWC5O CS CN1[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C1=O)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N)CCCN=C(N)N
DMUWC5O IK UYLRGPNGYHIOPK-XAZDILKDSA-N
DMUWC5O IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-1-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMUWC5O DE Discovery agent
DM8F5DY ID DM8F5DY
DM8F5DY DN Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)
DM8F5DY HS Investigative
DM8F5DY SN CHEMBL218806; cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-)
DM8F5DY DT Small molecular drug
DM8F5DY PC 44418892
DM8F5DY MW 743.9
DM8F5DY FM C37H49N11O6
DM8F5DY IC InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(20-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(35(48)54)8-4-16-42-36(38)39/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,52)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30+/m0/s1
DM8F5DY CS CN1[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C1=O)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N
DM8F5DY IK ACYXHFQQOQRMGX-RRGQHJHPSA-N
DM8F5DY IU 2-[3-[(2S,5R,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-4-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM8F5DY DE Discovery agent
DMPW9SD ID DMPW9SD
DMPW9SD DN Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)
DMPW9SD HS Investigative
DMPW9SD SN CHEMBL374108; cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-)
DMPW9SD DT Small molecular drug
DMPW9SD PC 44418865
DMPW9SD MW 644.7
DMPW9SD FM C33H40N8O6
DMPW9SD IC InChI=1S/C33H40N8O6/c1-19-29(44)41-26(16-20-9-12-24(42)13-10-20)30(45)37-18-28(43)39-27(17-21-8-11-22-5-2-3-6-23(22)15-21)32(47)40-25(31(46)38-19)7-4-14-36-33(34)35/h2-3,5-6,8-13,15,19,25-27,42H,4,7,14,16-18H2,1H3,(H,37,45)(H,38,46)(H,39,43)(H,40,47)(H,41,44)(H4,34,35,36)/t19-,25-,26+,27-/m0/s1
DMPW9SD CS C[C@H]1C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O
DMPW9SD IK KSQLRHSLMODJAS-OQVMAISDSA-N
DMPW9SD IU 2-[3-[(2S,5S,8R,14S)-8-[(4-hydroxyphenyl)methyl]-5-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMPW9SD DE Discovery agent
DMOWT4H ID DMOWT4H
DMOWT4H DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)
DMOWT4H HS Investigative
DMOWT4H SN CHEMBL219075; cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-)
DMOWT4H DT Small molecular drug
DMOWT4H PC 44418890
DMOWT4H MW 617.7
DMOWT4H FM C27H43N11O6
DMOWT4H IC InChI=1S/C27H43N11O6/c1-15-22(41)35-18(5-3-11-32-26(28)29)23(42)36-19(6-4-12-33-27(30)31)24(43)37-20(13-16-7-9-17(39)10-8-16)25(44)38(2)14-21(40)34-15/h7-10,15,18-20,39H,3-6,11-14H2,1-2H3,(H,34,40)(H,35,41)(H,36,42)(H,37,43)(H4,28,29,32)(H4,30,31,33)/t15-,18-,19-,20+/m0/s1
DMOWT4H CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N1)C)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N
DMOWT4H IK DUPFTLXKUNVZDO-MVJPYGJCSA-N
DMOWT4H IU 2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-10,14-dimethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMOWT4H DE Discovery agent
DMPZ316 ID DMPZ316
DMPZ316 DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)
DMPZ316 HS Investigative
DMPZ316 SN CHEMBL375850; cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-)
DMPZ316 DT Small molecular drug
DMPZ316 PC 44418889
DMPZ316 MW 743.9
DMPZ316 FM C37H49N11O6
DMPZ316 IC InChI=1S/C37H49N11O6/c1-48-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-28(9-5-17-43-37(40)41)33(52)45-27(8-4-16-42-36(38)39)34(53)47-29(32(51)44-21-31(48)50)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,52)(H,46,54)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28-,29+,30-/m0/s1
DMPZ316 CS CN1[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC1=O)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMPZ316 IK XUKFERKCRCTLBJ-ZXYZSCNASA-N
DMPZ316 IU 2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-13-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMPZ316 DE Discovery agent
DMNQWBS ID DMNQWBS
DMNQWBS DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)
DMNQWBS HS Investigative
DMNQWBS SN CHEMBL375991; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-)
DMNQWBS DT Small molecular drug
DMNQWBS PC 44418878
DMNQWBS MW 743.9
DMNQWBS FM C37H49N11O6
DMNQWBS IC InChI=1S/C37H49N11O6/c38-36(39)43-16-3-7-27-33(52)46-28(8-4-17-44-37(40)41)34(53)48-29(20-22-10-13-26(49)14-11-22)32(51)42-18-15-31(50)45-30(35(54)47-27)21-23-9-12-24-5-1-2-6-25(24)19-23/h1-2,5-6,9-14,19,27-30,49H,3-4,7-8,15-18,20-21H2,(H,42,51)(H,45,50)(H,46,52)(H,47,54)(H,48,53)(H4,38,39,43)(H4,40,41,44)/t27-,28-,29+,30-/m0/s1
DMNQWBS CS C1CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC2=CC3=CC=CC=C3C=C2)CCCN=C(N)N)CCCN=C(N)N)CC4=CC=C(C=C4)O
DMNQWBS IK LMVXXKJNXQKPHR-ZXYZSCNASA-N
DMNQWBS IU 2-[3-[(2S,5S,8S,11R)-8-[3-(diaminomethylideneamino)propyl]-11-[(4-hydroxyphenyl)methyl]-2-(naphthalen-2-ylmethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]propyl]guanidine
DMNQWBS DE Discovery agent
DMV6C9N ID DMV6C9N
DMV6C9N DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)
DMV6C9N HS Investigative
DMV6C9N SN CHEMBL375990; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-)
DMV6C9N DT Small molecular drug
DMV6C9N PC 44418873
DMV6C9N MW 743.9
DMV6C9N FM C37H49N11O6
DMV6C9N IC InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27+,28+,29-,30+/m1/s1
DMV6C9N CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMV6C9N IK VWZBFEAQYFTPKH-CSHHCLTFSA-N
DMV6C9N IU 2-[3-[(2S,5S,8R,11R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMV6C9N DE Discovery agent
DMH9VMO ID DMH9VMO
DMH9VMO DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)
DMH9VMO HS Investigative
DMH9VMO SN CHEMBL219474; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-)
DMH9VMO DT Small molecular drug
DMH9VMO PC 11158428
DMH9VMO MW 729.8
DMH9VMO FM C36H47N11O6
DMH9VMO IC InChI=1S/C36H47N11O6/c37-35(38)41-15-3-7-26-32(51)45-27(8-4-16-42-36(39)40)33(52)47-28(18-21-10-13-25(48)14-11-21)31(50)43-20-30(49)44-29(34(53)46-26)19-22-9-12-23-5-1-2-6-24(23)17-22/h1-2,5-6,9-14,17,26-29,48H,3-4,7-8,15-16,18-20H2,(H,43,50)(H,44,49)(H,45,51)(H,46,53)(H,47,52)(H4,37,38,41)(H4,39,40,42)/t26-,27-,28+,29-/m0/s1
DMH9VMO CS C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DMH9VMO IK YASYVKCWJGCXLS-FKWFRFQNSA-N
DMH9VMO IU 2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMH9VMO DE Discovery agent
DM72HW3 ID DM72HW3
DM72HW3 DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)
DM72HW3 HS Investigative
DM72HW3 SN CHEMBL387120; cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-)
DM72HW3 DT Small molecular drug
DM72HW3 PC 44418872
DM72HW3 MW 743.9
DM72HW3 FM C37H49N11O6
DM72HW3 IC InChI=1S/C37H49N11O6/c1-21-31(50)47-30(20-23-10-13-24-6-2-3-7-25(24)18-23)35(54)46-27(8-4-16-42-36(38)39)32(51)45-28(9-5-17-43-37(40)41)33(52)48-29(34(53)44-21)19-22-11-14-26(49)15-12-22/h2-3,6-7,10-15,18,21,27-30,49H,4-5,8-9,16-17,19-20H2,1H3,(H,44,53)(H,45,51)(H,46,54)(H,47,50)(H,48,52)(H4,38,39,42)(H4,40,41,43)/t21-,27-,28-,29+,30-/m0/s1
DM72HW3 CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)O)CCCN=C(N)N)CCCN=C(N)N)CC3=CC4=CC=CC=C4C=C3
DM72HW3 IK VWZBFEAQYFTPKH-JTIXJMNMSA-N
DM72HW3 IU 2-[3-[(2S,5S,8R,11S,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-11-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DM72HW3 DE Discovery agent
DMSPKWD ID DMSPKWD
DMSPKWD DN Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)
DMSPKWD HS Investigative
DMSPKWD SN CHEMBL436536; cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-)
DMSPKWD DT Small molecular drug
DMSPKWD PC 44418888
DMSPKWD MW 743.9
DMSPKWD FM C37H49N11O6
DMSPKWD IC InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)46-27(8-4-16-42-36(38)39)33(52)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(35(48)54)20-23-10-13-24-6-2-3-7-25(24)18-23/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,53)(H,47,52)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30-/m0/s1
DMSPKWD CS CN1[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C1=O)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N)CCCN=C(N)N
DMSPKWD IK UYLRGPNGYHIOPK-XJYHXZFBSA-N
DMSPKWD IU 2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-1-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMSPKWD DE Discovery agent
DMIUVQ6 ID DMIUVQ6
DMIUVQ6 DN Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)
DMIUVQ6 HS Investigative
DMIUVQ6 SN CHEMBL374421; cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-)
DMIUVQ6 DT Small molecular drug
DMIUVQ6 PC 44418887
DMIUVQ6 MW 743.9
DMIUVQ6 FM C37H49N11O6
DMIUVQ6 IC InChI=1S/C37H49N11O6/c1-48-30(9-5-17-43-37(40)41)34(53)47-28(19-22-11-14-26(49)15-12-22)32(51)44-21-31(50)45-29(20-23-10-13-24-6-2-3-7-25(24)18-23)33(52)46-27(35(48)54)8-4-16-42-36(38)39/h2-3,6-7,10-15,18,27-30,49H,4-5,8-9,16-17,19-21H2,1H3,(H,44,51)(H,45,50)(H,46,52)(H,47,53)(H4,38,39,42)(H4,40,41,43)/t27-,28+,29-,30-/m0/s1
DMIUVQ6 CS CN1[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C1=O)CCCN=C(N)N)CC2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)O)CCCN=C(N)N
DMIUVQ6 IK ACYXHFQQOQRMGX-XJYHXZFBSA-N
DMIUVQ6 IU 2-[3-[(2S,5S,8R,14S)-5-[3-(diaminomethylideneamino)propyl]-8-[(4-hydroxyphenyl)methyl]-4-methyl-14-(naphthalen-2-ylmethyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]propyl]guanidine
DMIUVQ6 DE Discovery agent
DMZF35W ID DMZF35W
DMZF35W DN Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W HS Investigative
DMZF35W SN CHEMBL394261; cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-)
DMZF35W DT Small molecular drug
DMZF35W PC 44437869
DMZF35W MW 595.8
DMZF35W FM C30H37N5O4S2
DMZF35W IC InChI=1S/C30H37N5O4S2/c1-20-28(38)35-16-9-13-24(35)27(37)33-23(12-3-2-8-17-40-41-25-14-6-7-15-31-25)26(36)34-30(29(39)32-20)18-21-10-4-5-11-22(21)19-30/h4-7,10-11,14-15,20,23-24H,2-3,8-9,12-13,16-19H2,1H3,(H,32,39)(H,33,37)(H,34,36)/t20-,23-,24+/m0/s1
DMZF35W CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)NC3(CC4=CC=CC=C4C3)C(=O)N1)CCCCCSSC5=CC=CC=N5
DMZF35W IK RKZORBYVFSJNHI-NKKJXINNSA-N
DMZF35W IU (3'S,9'S,12'R)-3'-methyl-9'-[5-(pyridin-2-yldisulfanyl)pentyl]spiro[1,3-dihydroindene-2,6'-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane]-2',5',8',11'-tetrone
DMZF35W DE Discovery agent
DMIVREK ID DMIVREK
DMIVREK DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-)
DMIVREK HS Investigative
DMIVREK SN CHEMBL238596; cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-); BDBM50222727
DMIVREK DT Small molecular drug
DMIVREK PC 44437883
DMIVREK MW 521.7
DMIVREK FM C24H35N5O4S2
DMIVREK IC InChI=1S/C24H35N5O4S2/c1-16-22(32)29-14-9-11-18(29)21(31)27-17(20(30)28-24(2,3)23(33)26-16)10-5-4-8-15-34-35-19-12-6-7-13-25-19/h6-7,12-13,16-18H,4-5,8-11,14-15H2,1-3H3,(H,26,33)(H,27,31)(H,28,30)/t16-,17-,18+/m0/s1
DMIVREK CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)NC(C(=O)N1)(C)C)CCCCCSSC3=CC=CC=N3
DMIVREK IK SNOZDSAKXKVXTD-OKZBNKHCSA-N
DMIVREK IU (3S,9S,12R)-3,6,6-trimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMIVREK DE Discovery agent
DMLBECR ID DMLBECR
DMLBECR DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR HS Investigative
DMLBECR SN CHEMBL238587; cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-)
DMLBECR DT Small molecular drug
DMLBECR PC 44437875
DMLBECR MW 569.8
DMLBECR FM C29H39N5O3S2
DMLBECR IC InChI=1S/C29H39N5O3S2/c1-20-18-34-19-22-12-7-6-11-21(22)17-24(34)27(36)32-23(26(35)33-29(2,3)28(37)31-20)13-5-4-10-16-38-39-25-14-8-9-15-30-25/h6-9,11-12,14-15,20,23-24H,4-5,10,13,16-19H2,1-3H3,(H,31,37)(H,32,36)(H,33,35)/t20-,23-,24+/m0/s1
DMLBECR CS C[C@H]1CN2CC3=CC=CC=C3C[C@@H]2C(=O)N[C@H](C(=O)NC(C(=O)N1)(C)C)CCCCCSSC4=CC=CC=N4
DMLBECR IK ALYDIERJMKHYLO-NKKJXINNSA-N
DMLBECR IU (3S,9S,12R)-3,6,6-trimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazatricyclo[10.8.0.014,19]icosa-14,16,18-triene-5,8,11-trione
DMLBECR DE Discovery agent
DMA76KW ID DMA76KW
DMA76KW DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW HS Investigative
DMA76KW SN CHEMBL391383; cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-)
DMA76KW DT Small molecular drug
DMA76KW PC 44437877
DMA76KW MW 611.8
DMA76KW FM C31H41N5O4S2
DMA76KW IC InChI=1S/C31H41N5O4S2/c1-31(2)30(40)34-24(18-17-22-12-5-3-6-13-22)29(39)36-20-11-15-25(36)28(38)33-23(27(37)35-31)14-7-4-10-21-41-42-26-16-8-9-19-32-26/h3,5-6,8-9,12-13,16,19,23-25H,4,7,10-11,14-15,17-18,20-21H2,1-2H3,(H,33,38)(H,34,40)(H,35,37)/t23-,24-,25+/m0/s1
DMA76KW CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CCC4=CC=CC=C4)C
DMA76KW IK VOORCQROXYSHCG-CCDWMCETSA-N
DMA76KW IU (3S,9S,12R)-6,6-dimethyl-3-(2-phenylethyl)-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMA76KW DE Discovery agent
DMLNJ0O ID DMLNJ0O
DMLNJ0O DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O HS Investigative
DMLNJ0O SN CHEMBL391384; cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-)
DMLNJ0O DT Small molecular drug
DMLNJ0O PC 44437878
DMLNJ0O MW 625.8
DMLNJ0O FM C32H43N5O4S2
DMLNJ0O IC InChI=1S/C32H43N5O4S2/c1-32(2)31(41)35-25(17-11-15-23-13-5-3-6-14-23)30(40)37-21-12-18-26(37)29(39)34-24(28(38)36-32)16-7-4-10-22-42-43-27-19-8-9-20-33-27/h3,5-6,8-9,13-14,19-20,24-26H,4,7,10-12,15-18,21-22H2,1-2H3,(H,34,39)(H,35,41)(H,36,38)/t24-,25-,26+/m0/s1
DMLNJ0O CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CCCC4=CC=CC=C4)C
DMLNJ0O IK DIIWIWBDXZTFQP-KKUQBAQOSA-N
DMLNJ0O IU (3S,9S,12R)-6,6-dimethyl-3-(3-phenylpropyl)-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMLNJ0O DE Discovery agent
DMTVMWA ID DMTVMWA
DMTVMWA DN Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-)
DMTVMWA HS Investigative
DMTVMWA SN CHEMBL238829; cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-); BDBM50222732
DMTVMWA DT Small molecular drug
DMTVMWA PC 44437868
DMTVMWA MW 597.8
DMTVMWA FM C30H39N5O4S2
DMTVMWA IC InChI=1S/C30H39N5O4S2/c1-30(2)29(39)33-23(20-21-12-5-3-6-13-21)28(38)35-18-11-15-24(35)27(37)32-22(26(36)34-30)14-7-4-10-19-40-41-25-16-8-9-17-31-25/h3,5-6,8-9,12-13,16-17,22-24H,4,7,10-11,14-15,18-20H2,1-2H3,(H,32,37)(H,33,39)(H,34,36)/t22-,23-,24+/m0/s1
DMTVMWA CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CC4=CC=CC=C4)C
DMTVMWA IK GNIYZHFLRFNYMZ-KMDXXIMOSA-N
DMTVMWA IU (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMTVMWA DE Discovery agent
DMUSEDF ID DMUSEDF
DMUSEDF DN Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF HS Investigative
DMUSEDF SN CHEMBL428737; cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-)
DMUSEDF DT Small molecular drug
DMUSEDF PC 44437876
DMUSEDF MW 583.8
DMUSEDF FM C29H37N5O4S2
DMUSEDF IC InChI=1S/C29H37N5O4S2/c1-29(2)28(38)32-24(20-12-5-3-6-13-20)27(37)34-18-11-15-22(34)26(36)31-21(25(35)33-29)14-7-4-10-19-39-40-23-16-8-9-17-30-23/h3,5-6,8-9,12-13,16-17,21-22,24H,4,7,10-11,14-15,18-19H2,1-2H3,(H,31,36)(H,32,38)(H,33,35)/t21-,22+,24-/m0/s1
DMUSEDF CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)C4=CC=CC=C4)C
DMUSEDF IK MAESVPGWPSVAHM-ZDXQCDESSA-N
DMUSEDF IU (3S,9S,12R)-6,6-dimethyl-3-phenyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMUSEDF DE Discovery agent
DMSEQ0W ID DMSEQ0W
DMSEQ0W DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W HS Investigative
DMSEQ0W SN CHEMBL241555; cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-)
DMSEQ0W DT Small molecular drug
DMSEQ0W PC 44437879
DMSEQ0W MW 627.8
DMSEQ0W FM C31H41N5O5S2
DMSEQ0W IC InChI=1S/C31H41N5O5S2/c1-31(2)30(40)34-24(21-41-20-22-12-5-3-6-13-22)29(39)36-18-11-15-25(36)28(38)33-23(27(37)35-31)14-7-4-10-19-42-43-26-16-8-9-17-32-26/h3,5-6,8-9,12-13,16-17,23-25H,4,7,10-11,14-15,18-21H2,1-2H3,(H,33,38)(H,34,40)(H,35,37)/t23-,24-,25+/m0/s1
DMSEQ0W CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)COCC4=CC=CC=C4)C
DMSEQ0W IK UAUCMCUCWAXYRK-CCDWMCETSA-N
DMSEQ0W IU (3S,9S,12R)-6,6-dimethyl-3-(phenylmethoxymethyl)-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMSEQ0W DE Discovery agent
DMBKP48 ID DMBKP48
DMBKP48 DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48 HS Investigative
DMBKP48 SN CHEMBL393961; cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-)
DMBKP48 DT Small molecular drug
DMBKP48 PC 44437880
DMBKP48 MW 537.7
DMBKP48 FM C24H35N5O5S2
DMBKP48 IC InChI=1S/C24H35N5O5S2/c1-24(2)23(34)27-17(15-30)22(33)29-13-8-10-18(29)21(32)26-16(20(31)28-24)9-4-3-7-14-35-36-19-11-5-6-12-25-19/h5-6,11-12,16-18,30H,3-4,7-10,13-15H2,1-2H3,(H,26,32)(H,27,34)(H,28,31)/t16-,17-,18+/m0/s1
DMBKP48 CS CC1(C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N1)CCCCCSSC3=CC=CC=N3)CO)C
DMBKP48 IK HNLHPMBNXUOXHG-OKZBNKHCSA-N
DMBKP48 IU (3S,9S,12R)-3-(hydroxymethyl)-6,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMBKP48 DE Discovery agent
DMVY89X ID DMVY89X
DMVY89X DN Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X HS Investigative
DMVY89X SN CHEMBL393261; cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
DMVY89X DT Small molecular drug
DMVY89X PC 44437873
DMVY89X MW 597.8
DMVY89X FM C30H39N5O4S2
DMVY89X IC InChI=1S/C30H39N5O4S2/c1-21-28(38)35-18-11-15-24(35)27(37)33-23(14-7-4-10-19-40-41-25-16-8-9-17-31-25)26(36)34-30(2,29(39)32-21)20-22-12-5-3-6-13-22/h3,5-6,8-9,12-13,16-17,21,23-24H,4,7,10-11,14-15,18-20H2,1-2H3,(H,32,39)(H,33,37)(H,34,36)/t21-,23-,24+,30+/m0/s1
DMVY89X CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@](C(=O)N1)(C)CC3=CC=CC=C3)CCCCCSSC4=CC=CC=N4
DMVY89X IK ITTWBEZYTYPCGB-HVGAQBFTSA-N
DMVY89X IU (3S,6R,9S,12R)-6-benzyl-3,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMVY89X DE Discovery agent
DMTDIM9 ID DMTDIM9
DMTDIM9 DN Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9 HS Investigative
DMTDIM9 SN CHEMBL390991; cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-)
DMTDIM9 DT Small molecular drug
DMTDIM9 PC 44437870
DMTDIM9 MW 595.8
DMTDIM9 FM C30H37N5O4S2
DMTDIM9 IC InChI=1S/C30H37N5O4S2/c1-20-28(38)35-18-9-13-24(35)27(37)33-23(12-3-2-8-19-40-41-25-14-6-7-17-31-25)26(36)34-30(29(39)32-20)16-15-21-10-4-5-11-22(21)30/h4-7,10-11,14,17,20,23-24H,2-3,8-9,12-13,15-16,18-19H2,1H3,(H,32,39)(H,33,37)(H,34,36)/t20-,23-,24+,30-/m0/s1
DMTDIM9 CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@]3(CCC4=CC=CC=C43)C(=O)N1)CCCCCSSC5=CC=CC=N5
DMTDIM9 IK ZGCIQVPLYZBUHQ-KGPFVPCYSA-N
DMTDIM9 IU (3S,3'S,9'S,12'R)-3'-methyl-9'-[5-(pyridin-2-yldisulfanyl)pentyl]spiro[1,2-dihydroindene-3,6'-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane]-2',5',8',11'-tetrone
DMTDIM9 DE Discovery agent
DMV23XD ID DMV23XD
DMV23XD DN Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD HS Investigative
DMV23XD SN CHEMBL393464; cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-)
DMV23XD DT Small molecular drug
DMV23XD PC 44437874
DMV23XD MW 597.8
DMV23XD FM C30H39N5O4S2
DMV23XD IC InChI=1S/C30H39N5O4S2/c1-21-28(38)35-18-11-15-24(35)27(37)33-23(14-7-4-10-19-40-41-25-16-8-9-17-31-25)26(36)34-30(2,29(39)32-21)20-22-12-5-3-6-13-22/h3,5-6,8-9,12-13,16-17,21,23-24H,4,7,10-11,14-15,18-20H2,1-2H3,(H,32,39)(H,33,37)(H,34,36)/t21-,23-,24+,30-/m0/s1
DMV23XD CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@](C(=O)N1)(C)CC3=CC=CC=C3)CCCCCSSC4=CC=CC=N4
DMV23XD IK ITTWBEZYTYPCGB-GAOIQBMKSA-N
DMV23XD IU (3S,6S,9S,12R)-6-benzyl-3,6-dimethyl-9-[5-(pyridin-2-yldisulfanyl)pentyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
DMV23XD DE Discovery agent
DM0VIH4 ID DM0VIH4
DM0VIH4 DN Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4 HS Investigative
DM0VIH4 SN CHEMBL393260; cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-)
DM0VIH4 DT Small molecular drug
DM0VIH4 PC 44437872
DM0VIH4 MW 595.8
DM0VIH4 FM C30H37N5O4S2
DM0VIH4 IC InChI=1S/C30H37N5O4S2/c1-20-28(38)35-18-9-13-24(35)27(37)33-23(12-3-2-8-19-40-41-25-14-6-7-17-31-25)26(36)34-30(29(39)32-20)16-15-21-10-4-5-11-22(21)30/h4-7,10-11,14,17,20,23-24H,2-3,8-9,12-13,15-16,18-19H2,1H3,(H,32,39)(H,33,37)(H,34,36)/t20-,23-,24+,30+/m0/s1
DM0VIH4 CS C[C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@]3(CCC4=CC=CC=C43)C(=O)N1)CCCCCSSC5=CC=CC=N5
DM0VIH4 IK ZGCIQVPLYZBUHQ-AEPSZFNXSA-N
DM0VIH4 IU (3R,3'S,9'S,12'R)-3'-methyl-9'-[5-(pyridin-2-yldisulfanyl)pentyl]spiro[1,2-dihydroindene-3,6'-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane]-2',5',8',11'-tetrone
DM0VIH4 DE Discovery agent
DM3QVOB ID DM3QVOB
DM3QVOB DN Cyclo(RGDfV) (control)
DM3QVOB HS Investigative
DM3QVOB SN CHEMBL206344; cyclo(RGDfV) (control)
DM3QVOB DT Small molecular drug
DM3QVOB PC 44409460
DM3QVOB MW 574.6
DM3QVOB FM C26H38N8O7
DM3QVOB IC InChI=1S/C26H38N8O7/c1-14(2)21-25(41)32-16(9-6-10-29-26(27)28)23(39)33-18(12-20(36)37)22(38)30-13-19(35)31-17(24(40)34-21)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18,21H,6,9-13H2,1-2H3,(H,30,38)(H,31,35)(H,32,41)(H,33,39)(H,34,40)(H,36,37)(H4,27,28,29)/t16-,17+,18+,21+/m1/s1
DM3QVOB CS CC(C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DM3QVOB IK PWWDFRZRXPLJAN-WKRCXCSHSA-N
DM3QVOB IU 2-[(2S,8S,11S,14R)-8-benzyl-14-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-11-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM3QVOB DE Discovery agent
DM9ZCWV ID DM9ZCWV
DM9ZCWV DN Cyclo[(6-bromotryptophan)arginine]
DM9ZCWV HS Investigative
DM9ZCWV SN CHEMBL511609; cyclo[(6-bromotryptophan)arginine]
DM9ZCWV DT Small molecular drug
DM9ZCWV PC 44559159
DM9ZCWV MW 421.3
DM9ZCWV FM C17H21BrN6O2
DM9ZCWV IC InChI=1S/C17H21BrN6O2/c18-10-3-4-11-9(8-22-13(11)7-10)6-14-16(26)23-12(15(25)24-14)2-1-5-21-17(19)20/h3-4,7-8,12,14,22H,1-2,5-6H2,(H,23,26)(H,24,25)(H4,19,20,21)/t12-,14-/m0/s1
DM9ZCWV CS C1=CC2=C(C=C1Br)NC=C2C[C@H]3C(=O)N[C@H](C(=O)N3)CCCN=C(N)N
DM9ZCWV IK HVWYYWIRLPBRTO-JSGCOSHPSA-N
DM9ZCWV IU 2-[3-[(2S,5S)-5-[(6-bromo-1H-indol-3-yl)methyl]-3,6-dioxopiperazin-2-yl]propyl]guanidine
DM9ZCWV DE Discovery agent
DM67CAY ID DM67CAY
DM67CAY DN Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr
DM67CAY HS Investigative
DM67CAY DT Small molecular drug
DM67CAY PC 44412126
DM67CAY MW 919.1
DM67CAY FM C45H58N8O11S
DM67CAY IC InChI=1S/C45H58N8O11S/c1-3-25(2)38-43(61)53-39(28-11-13-29(14-12-28)47-36(56)19-20-37(57)48-35(24-65)42(60)52-38)44(62)49-32(6-4-5-21-46)40(58)50-33(22-26-7-15-30(54)16-8-26)41(59)51-34(45(63)64)23-27-9-17-31(55)18-10-27/h7-18,25,32-35,38-39,54-55,65H,3-6,19-24,46H2,1-2H3,(H,47,56)(H,48,57)(H,49,62)(H,50,58)(H,51,59)(H,52,60)(H,53,61)(H,63,64)/t25?,32-,33-,34-,35+,38-,39-/m0/s1
DM67CAY CS CCC(C)[C@H]1C(=O)N[C@@H](C2=CC=C(C=C2)NC(=O)CCC(=O)N[C@@H](C(=O)N1)CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O
DM67CAY IK HFHVOHKEMBUZCY-GKLJNLTASA-N
DM67CAY IU (2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(8S,11S,14S)-11-butan-2-yl-3,6,9,12-tetraoxo-8-(sulfanylmethyl)-2,7,10,13-tetrazabicyclo[13.2.2]nonadeca-1(17),15,18-triene-14-carbonyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid
DM67CAY DE Discovery agent
DMB2DV1 ID DMB2DV1
DMB2DV1 DN Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]
DMB2DV1 HS Investigative
DMB2DV1 SN Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]; CHEMBL380288
DMB2DV1 DT Small molecular drug
DMB2DV1 PC 44412084
DMB2DV1 MW 933.1
DMB2DV1 FM C46H60N8O11S
DMB2DV1 IC InChI=1S/C46H60N8O11S/c1-3-26(2)40-45(63)52-35(23-29-11-17-32(56)18-12-29)42(60)50-33(6-4-5-21-47)41(59)51-34(22-28-9-15-31(55)16-10-28)43(61)53-36(46(64)65)24-27-7-13-30(14-8-27)48-38(57)19-20-39(58)49-37(25-66)44(62)54-40/h7-18,26,33-37,40,55-56,66H,3-6,19-25,47H2,1-2H3,(H,48,57)(H,49,58)(H,50,60)(H,51,59)(H,52,63)(H,53,61)(H,54,62)(H,64,65)/t26-,33-,34-,35-,36-,37-,40?/m0/s1
DMB2DV1 CS CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC2=CC=C(C=C2)NC(=O)CCC(=O)N[C@H](C(=O)N1)CS)C(=O)O)CC3=CC=C(C=C3)O)CCCCN)CC4=CC=C(C=C4)O
DMB2DV1 IK QMRXULYAQQEMJC-FYDLKOHDSA-N
DMB2DV1 IU (8R,14S,17S,20S,23S)-17-(4-aminobutyl)-11-[(2S)-butan-2-yl]-14,20-bis[(4-hydroxyphenyl)methyl]-3,6,9,12,15,18,21-heptaoxo-8-(sulfanylmethyl)-2,7,10,13,16,19,22-heptazabicyclo[23.2.2]nonacosa-1(27),25,28-triene-23-carboxylic acid
DMB2DV1 DE Discovery agent
DMO5V9M ID DMO5V9M
DMO5V9M DN Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]
DMO5V9M HS Investigative
DMO5V9M SN CHEMBL429525; Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]
DMO5V9M DT Small molecular drug
DMO5V9M PC 11643573
DMO5V9M MW 834
DMO5V9M FM C42H55N7O9S
DMO5V9M IC InChI=1S/C42H55N7O9S/c1-3-24(2)36-42(58)47-34(22-27-11-17-30(52)18-12-27)38(54)44-31(6-4-5-19-43)37(53)45-32(20-25-7-13-28(50)14-8-25)39(55)46-33(21-26-9-15-29(51)16-10-26)40(56)48-35(23-59)41(57)49-36/h7-18,24,31-36,50-52,59H,3-6,19-23,43H2,1-2H3,(H,44,54)(H,45,53)(H,46,55)(H,47,58)(H,48,56)(H,49,57)/t24-,31-,32-,33-,34-,35-,36-/m0/s1
DMO5V9M CS CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CS)CC2=CC=C(C=C2)O)CC3=CC=C(C=C3)O)CCCCN)CC4=CC=C(C=C4)O
DMO5V9M IK FFQZQESXYOBYDZ-AAWCNGQVSA-N
DMO5V9M IU (3S,6S,9S,12R,15S,18S)-3-(4-aminobutyl)-9-[(2S)-butan-2-yl]-6,15,18-tris[(4-hydroxyphenyl)methyl]-12-(sulfanylmethyl)-1,4,7,10,13,16-hexazacyclooctadecane-2,5,8,11,14,17-hexone
DMO5V9M DE Discovery agent
DMVXPUB ID DMVXPUB
DMVXPUB DN Cyclo-[-Arg-Gly-Asp-Amp21-]
DMVXPUB HS Investigative
DMVXPUB SN CHEMBL411863; BDBM50372589
DMVXPUB DT Small molecular drug
DMVXPUB PC 24822953
DMVXPUB MW 440.5
DMVXPUB FM C17H28N8O6
DMVXPUB IC InChI=1S/C17H28N8O6/c18-17(19)20-3-1-2-9-14(29)22-7-12(26)24-11(5-13(27)28)16(31)23-8-4-10(21-6-8)15(30)25-9/h8-11,21H,1-7H2,(H,22,29)(H,23,31)(H,24,26)(H,25,30)(H,27,28)(H4,18,19,20)/t8-,9-,10-,11-/m0/s1
DMVXPUB CS C1[C@H]2CN[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMVXPUB IK RLABYQGJZRFBJA-NAKRPEOUSA-N
DMVXPUB IU 2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMVXPUB DE Discovery agent
DMBELJK ID DMBELJK
DMBELJK DN Cyclo-[-Arg-Gly-Asp-Amp22-]
DMBELJK HS Investigative
DMBELJK SN CHEMBL406912
DMBELJK DT Small molecular drug
DMBELJK PC 24822283
DMBELJK MW 544.6
DMBELJK FM C24H32N8O7
DMBELJK IC InChI=1S/C24H32N8O7/c25-24(26)27-8-4-7-15-20(36)28-11-18(33)30-16(10-19(34)35)21(37)29-14-9-17(22(38)31-15)32(12-14)23(39)13-5-2-1-3-6-13/h1-3,5-6,14-17H,4,7-12H2,(H,28,36)(H,29,37)(H,30,33)(H,31,38)(H,34,35)(H4,25,26,27)/t14-,15-,16-,17-/m0/s1
DMBELJK CS C1[C@H]2CN([C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N)C(=O)C3=CC=CC=C3
DMBELJK IK UIBGFNHGJUQMPO-QAETUUGQSA-N
DMBELJK IU 2-[(1S,4S,10S,13S)-14-benzoyl-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMBELJK DE Discovery agent
DMT29VJ ID DMT29VJ
DMT29VJ DN Cyclo-[-Arg-Gly-Asp-Amp23-]
DMT29VJ HS Investigative
DMT29VJ SN CHEMBL410050
DMT29VJ DT Small molecular drug
DMT29VJ PC 24822282
DMT29VJ MW 496.5
DMT29VJ FM C20H32N8O7
DMT29VJ IC InChI=1S/C20H32N8O7/c1-2-15(30)28-9-10-6-13(28)19(35)27-11(4-3-5-23-20(21)22)17(33)24-8-14(29)26-12(7-16(31)32)18(34)25-10/h10-13H,2-9H2,1H3,(H,24,33)(H,25,34)(H,26,29)(H,27,35)(H,31,32)(H4,21,22,23)/t10-,11-,12-,13-/m0/s1
DMT29VJ CS CCC(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMT29VJ IK BGIHRGIMRVRYKO-CYDGBPFRSA-N
DMT29VJ IU 2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-14-propanoyl-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMT29VJ DE Discovery agent
DM35ZLK ID DM35ZLK
DM35ZLK DN Cyclo-[-Arg-Gly-Asp-Amp24-]
DM35ZLK HS Investigative
DM35ZLK SN CHEMBL437072
DM35ZLK DT Small molecular drug
DM35ZLK PC 24823110
DM35ZLK MW 538.6
DM35ZLK FM C24H42N8O6
DM35ZLK IC InChI=1S/C24H42N8O6/c1-2-3-4-5-6-10-32-14-15-11-18(32)23(38)31-16(8-7-9-27-24(25)26)21(36)28-13-19(33)30-17(12-20(34)35)22(37)29-15/h15-18H,2-14H2,1H3,(H,28,36)(H,29,37)(H,30,33)(H,31,38)(H,34,35)(H4,25,26,27)/t15-,16-,17-,18-/m0/s1
DM35ZLK CS CCCCCCCN1C[C@@H]2C[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DM35ZLK IK JNEZPOFKGHMQAC-XSLAGTTESA-N
DM35ZLK IU 2-[(1S,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-14-heptyl-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DM35ZLK DE Discovery agent
DMEIXUQ ID DMEIXUQ
DMEIXUQ DN Cyclo-[-Arg-Gly-Asp-Amp25-]
DMEIXUQ HS Investigative
DMEIXUQ SN CHEMBL270690
DMEIXUQ DT Small molecular drug
DMEIXUQ PC 24822784
DMEIXUQ MW 440.5
DMEIXUQ FM C17H28N8O6
DMEIXUQ IC InChI=1S/C17H28N8O6/c18-17(19)20-3-1-2-9-14(29)22-7-12(26)24-11(5-13(27)28)16(31)23-8-4-10(21-6-8)15(30)25-9/h8-11,21H,1-7H2,(H,22,29)(H,23,31)(H,24,26)(H,25,30)(H,27,28)(H4,18,19,20)/t8-,9+,10+,11+/m1/s1
DMEIXUQ CS C1[C@@H]2CN[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMEIXUQ IK RLABYQGJZRFBJA-RCWTZXSCSA-N
DMEIXUQ IU 2-[(1R,4S,10S,13S)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMEIXUQ DE Discovery agent
DME5HRW ID DME5HRW
DME5HRW DN Cyclo-[-Arg-Gly-Asp-Amp26-]
DME5HRW HS Investigative
DME5HRW SN CHEMBL406680
DME5HRW DT Small molecular drug
DME5HRW PC 24822444
DME5HRW MW 544.6
DME5HRW FM C24H32N8O7
DME5HRW IC InChI=1S/C24H32N8O7/c25-24(26)27-8-4-7-15-20(36)28-11-18(33)30-16(10-19(34)35)21(37)29-14-9-17(22(38)31-15)32(12-14)23(39)13-5-2-1-3-6-13/h1-3,5-6,14-17H,4,7-12H2,(H,28,36)(H,29,37)(H,30,33)(H,31,38)(H,34,35)(H4,25,26,27)/t14-,15+,16+,17+/m1/s1
DME5HRW CS C1[C@@H]2CN([C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N)C(=O)C3=CC=CC=C3
DME5HRW IK UIBGFNHGJUQMPO-QZWWFDLISA-N
DME5HRW IU 2-[(1R,4S,10S,13S)-14-benzoyl-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DME5HRW DE Discovery agent
DMBNJZ0 ID DMBNJZ0
DMBNJZ0 DN Cyclo-[-Arg-Gly-Asp-Amp27-]
DMBNJZ0 HS Investigative
DMBNJZ0 SN CHEMBL272436
DMBNJZ0 DT Small molecular drug
DMBNJZ0 PC 44456982
DMBNJZ0 MW 440.5
DMBNJZ0 FM C17H28N8O6
DMBNJZ0 IC InChI=1S/C17H28N8O6/c18-9-5-12(26)23-8-4-11(21-6-8)15(29)25-17(19)20-3-1-2-10(16(30)31)24-13(27)7-22-14(9)28/h8-11,21H,1-7,18H2,(H,22,28)(H,23,26)(H,24,27)(H,30,31)(H3,19,20,25,29)/t8-,9?,10-,11+/m0/s1
DMBNJZ0 CS C1C[C@H](NC(=O)CNC(=O)C(CC(=O)N[C@H]2C[C@H](C(=O)NC(=NC1)N)NC2)N)C(=O)O
DMBNJZ0 IK HWQCIVMCAIEOPT-OFLUOSHYSA-N
DMBNJZ0 IU (1S,11S,19R)-5,16-diamino-3,6,9,18-tetraoxo-2,7,10,15,17,20-hexazabicyclo[17.2.1]docos-15-ene-11-carboxylic acid
DMBNJZ0 DE Discovery agent
DMJMHAV ID DMJMHAV
DMJMHAV DN Cyclo-[-Arg-Gly-Asp-Amp28-]
DMJMHAV HS Investigative
DMJMHAV SN CHEMBL270683
DMJMHAV DT Small molecular drug
DMJMHAV PC 24824620
DMJMHAV MW 440.5
DMJMHAV FM C17H28N8O6
DMJMHAV IC InChI=1S/C17H28N8O6/c18-17(19)20-3-1-2-9-14(29)22-7-12(26)24-11(5-13(27)28)16(31)23-8-4-10(21-6-8)15(30)25-9/h8-11,21H,1-7H2,(H,22,29)(H,23,31)(H,24,26)(H,25,30)(H,27,28)(H4,18,19,20)/t8-,9+,10-,11+/m1/s1
DMJMHAV CS C1[C@@H]2CN[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N2)CC(=O)O)CCCN=C(N)N
DMJMHAV IK RLABYQGJZRFBJA-YTWAJWBKSA-N
DMJMHAV IU 2-[(1R,4S,10S,13R)-10-[3-(diaminomethylideneamino)propyl]-3,6,9,12-tetraoxo-2,5,8,11,14-pentazabicyclo[11.2.1]hexadecan-4-yl]acetic acid
DMJMHAV DE Discovery agent
DMWD5RK ID DMWD5RK
DMWD5RK DN Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2
DMWD5RK HS Investigative
DMWD5RK SN CHEMBL1162357
DMWD5RK PC 25084507
DMWD5RK MW 1462.7
DMWD5RK FM C66H107N23O15
DMWD5RK IC InChI=1S/C66H107N23O15/c1-37(55(95)84-46(25-16-30-76-65(71)72)59(99)83-43(54(70)94)22-10-13-27-67)80-58(98)44-24-12-15-29-75-50(91)34-49(62(102)81-38(2)56(96)85-47(26-17-31-77-66(73)74)61(101)87-45(60(100)86-44)23-11-14-28-68)88-64(104)53(39(3)90)89-63(103)48(33-41-20-8-5-9-21-41)82-52(93)36-78-51(92)35-79-57(97)42(69)32-40-18-6-4-7-19-40/h4-9,18-21,37-39,42-49,53,90H,10-17,22-36,67-69H2,1-3H3,(H2,70,94)(H,75,91)(H,78,92)(H,79,97)(H,80,98)(H,81,102)(H,82,93)(H,83,99)(H,84,95)(H,85,96)(H,86,100)(H,87,101)(H,88,104)(H,89,103)(H4,71,72,76)(H4,73,74,77)/t37-,38-,39+,42-,43-,44-,45-,46-,47-,48-,49-,53-/m0/s1
DMWD5RK CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(=O)N1)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CCCN=C(N)N
DMWD5RK IK QRTPPIOAYQKBJN-WYNMOEERSA-N
DMWD5RK IU (3S,6S,9S,12S,20S)-3-(4-aminobutyl)-12-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-6-[3-(diaminomethylideneamino)propyl]-9-methyl-2,5,8,11,14-pentaoxo-1,4,7,10,15-pentazacycloicosane-20-carboxamide
DMWD5RK DE Discovery agent
DMSMH6T ID DMSMH6T
DMSMH6T DN Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2
DMSMH6T HS Investigative
DMSMH6T SN CHEMBL269029; cyclo[Cys6,Cys10]N/OFQ(1-13)NH2
DMSMH6T PC 25088989
DMSMH6T MW 1441.7
DMSMH6T FM C62H100N22O14S2
DMSMH6T IC InChI=1S/C62H100N22O14S2/c1-34(51(89)79-42(22-14-26-71-61(67)68)54(92)78-40(50(66)88)20-10-12-24-63)75-58(96)45-32-99-100-33-46(59(97)76-35(2)52(90)80-43(23-15-27-72-62(69)70)55(93)81-41(56(94)82-45)21-11-13-25-64)83-60(98)49(36(3)85)84-57(95)44(29-38-18-8-5-9-19-38)77-48(87)31-73-47(86)30-74-53(91)39(65)28-37-16-6-4-7-17-37/h4-9,16-19,34-36,39-46,49,85H,10-15,20-33,63-65H2,1-3H3,(H2,66,88)(H,73,86)(H,74,91)(H,75,96)(H,76,97)(H,77,87)(H,78,92)(H,79,89)(H,80,90)(H,81,93)(H,82,94)(H,83,98)(H,84,95)(H4,67,68,71)(H4,69,70,72)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,45-,46-,49-/m0/s1
DMSMH6T CS C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CCCN=C(N)N
DMSMH6T IK YCXQOGDEHMJXPM-JOEKKRFNSA-N
DMSMH6T IU (4R,7S,10S,13S,16R)-7-(4-aminobutyl)-16-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-13-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide
DMSMH6T DE Discovery agent
DMI9C57 ID DMI9C57
DMI9C57 DN Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2
DMI9C57 HS Investigative
DMI9C57 SN CHEMBL1162359
DMI9C57 PC 25080768
DMI9C57 MW 1427.7
DMI9C57 FM C61H98N22O14S2
DMI9C57 IC InChI=1S/C61H98N22O14S2/c1-34(51(89)79-41(21-13-25-70-60(66)67)53(91)78-39(50(65)88)19-9-11-23-62)75-57(95)45-33-99-98-32-44(58(96)81-42(22-14-26-71-61(68)69)54(92)80-40(55(93)82-45)20-10-12-24-63)77-48(87)31-74-59(97)49(35(2)84)83-56(94)43(28-37-17-7-4-8-18-37)76-47(86)30-72-46(85)29-73-52(90)38(64)27-36-15-5-3-6-16-36/h3-8,15-18,34-35,38-45,49,84H,9-14,19-33,62-64H2,1-2H3,(H2,65,88)(H,72,85)(H,73,90)(H,74,97)(H,75,95)(H,76,86)(H,77,87)(H,78,91)(H,79,89)(H,80,92)(H,81,96)(H,82,93)(H,83,94)(H4,66,67,70)(H4,68,69,71)/t34-,35+,38-,39-,40-,41-,42-,43-,44-,45-,49-/m0/s1
DMI9C57 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCN=C(N)N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMI9C57 IK ZCRGDVZWIYXXNX-QAOCYNJESA-N
DMI9C57 IU (4R,7S,10S,13R)-7-(4-aminobutyl)-13-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMI9C57 DE Discovery agent
DM39UMT ID DM39UMT
DM39UMT DN Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2
DM39UMT HS Investigative
DM39UMT SN CHEMBL1162358
DM39UMT PC 44578000
DM39UMT MW 1448.7
DM39UMT FM C65H105N23O15
DM39UMT IC InChI=1S/C65H105N23O15/c1-37(55(95)84-45(24-15-29-75-64(70)71)58(98)83-42(54(69)94)21-9-12-26-66)80-57(97)43-23-11-14-28-74-49(90)33-48(61(101)87-46(25-16-30-76-65(72)73)60(100)86-44(59(99)85-43)22-10-13-27-67)82-52(93)36-79-63(103)53(38(2)89)88-62(102)47(32-40-19-7-4-8-20-40)81-51(92)35-77-50(91)34-78-56(96)41(68)31-39-17-5-3-6-18-39/h3-8,17-20,37-38,41-48,53,89H,9-16,21-36,66-68H2,1-2H3,(H2,69,94)(H,74,90)(H,77,91)(H,78,96)(H,79,103)(H,80,97)(H,81,92)(H,82,93)(H,83,98)(H,84,95)(H,85,99)(H,86,100)(H,87,101)(H,88,102)(H4,70,71,75)(H4,72,73,76)/t37-,38+,41-,42-,43-,44-,45-,46-,47-,48-,53-/m0/s1
DM39UMT CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCN=C(N)N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DM39UMT IK MUJYKGBDMXOPCE-CFUMCULZSA-N
DM39UMT IU (3S,6S,9S,17S)-3-(4-aminobutyl)-9-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-6-[3-(diaminomethylideneamino)propyl]-2,5,8,11-tetraoxo-1,4,7,12-tetrazacycloheptadecane-17-carboxamide
DM39UMT DE Discovery agent
DMWYFLD ID DMWYFLD
DMWYFLD DN Cyclo[RGDfK(cypate)]
DMWYFLD HS Investigative
DMWYFLD SN CHEMBL407126; cyclo[RGDfK(cypate)]
DMWYFLD PC 44409643
DMWYFLD MW 1181.4
DMWYFLD FM C67H78N11O9+
DMWYFLD IC InChI=1S/C67H77N11O9/c1-66(2)54-28-11-6-5-7-12-29-55-67(3,4)60-46-25-16-14-23-44(46)31-33-52(60)78(55)41-57(81)73-48(27-19-36-71-65(69)70)62(85)72-40-56(80)74-50(39-58(82)83)64(87)76-49(38-42-20-9-8-10-21-42)63(86)75-47(26-17-18-35-68)61(84)53(79)34-37-77(54)51-32-30-43-22-13-15-24-45(43)59(51)66/h5-16,20-25,28-33,47-50H,17-19,26-27,34-41,68H2,1-4H3,(H9-,69,70,71,72,73,74,75,76,80,81,82,83,85,86,87)/p+1/t47-,48+,49+,50-/m1/s1
DMWYFLD CS CC1(C/2=[N+](CC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)C(=O)CCN\\3C4=C(C5=CC=CC=C5C=C4)C(/C3=C\\C=C\\C=C\\C=C2)(C)C)CCCCN)CC6=CC=CC=C6)CC(=O)O)CCCN=C(N)N)C7=C1C8=CC=CC=C8C=C7)C
DMWYFLD IK GCUFPHJXORLRLN-CZFAESEUSA-O
DMWYFLD IU 2-[(1E,3E,5E,7E,25S,31R,34S,37R)-37-(4-aminobutyl)-34-benzyl-25-[3-(diaminomethylideneamino)propyl]-10,10,53,53-tetramethyl-23,26,29,32,35,38,39-heptaoxo-24,27,30,33,36,42-hexaza-21-azoniaheptacyclo[40.11.0.09,21.011,20.012,17.043,52.046,51]tripentaconta-1,3,5,7,9(21),11(20),12,14,16,18,43(52),44,46,48,50-pentadecaen-31-yl]acetic acid
DMWYFLD DE Discovery agent
DM35PIJ ID DM35PIJ
DM35PIJ DN Cyclobutyl
DM35PIJ HS Investigative
DM35PIJ SN Cyclobutyl radical; cyclobutanyl; cyclobutan-1-yl; 4548-06-5; Cyclobutylradical; AC1L3CHP; DTXSID90196522; 16188-EP2281563A1; 16097-EP2316459A1; 16097-EP2275401A1; 16188-EP2316459A1; 16188-EP2308873A1; 16097-EP2308848A1
DM35PIJ DT Small molecular drug
DM35PIJ PC 138291
DM35PIJ MW 55.1
DM35PIJ FM C4H7
DM35PIJ IC InChI=1S/C4H7/c1-2-4-3-1/h1H,2-4H2
DM35PIJ CS C1C[CH]C1
DM35PIJ IK ZAEBLFKQMDEPDM-UHFFFAOYSA-N
DM35PIJ CA CAS 4548-06-5
DM35PIJ DE Discovery agent
DMYLA7F ID DMYLA7F
DMYLA7F DN Cyclobutylcarbamic Acid Biphenyl-3-yl Ester
DMYLA7F HS Investigative
DMYLA7F SN CHEMBL451441; Cyclobutylcarbamic Acid Biphenyl-3-yl Ester
DMYLA7F DT Small molecular drug
DMYLA7F PC 24881673
DMYLA7F MW 267.32
DMYLA7F FM C17H17NO2
DMYLA7F IC InChI=1S/C17H17NO2/c19-17(18-15-9-5-10-15)20-16-11-4-8-14(12-16)13-6-2-1-3-7-13/h1-4,6-8,11-12,15H,5,9-10H2,(H,18,19)
DMYLA7F CS C1CC(C1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMYLA7F IK CACLVJBQOQELCV-UHFFFAOYSA-N
DMYLA7F IU (3-phenylphenyl) N-cyclobutylcarbamate
DMYLA7F DE Discovery agent
DMC520D ID DMC520D
DMC520D DN Cycloguanil
DMC520D HS Investigative
DMC520D SN Cycloguanil; Cycloguanyl; Cycloguanilum; 516-21-2; Chlorcycloguanil; Chlorguanide triazine; UNII-26RM326WVN; BN2410; WR 5473; BN-24-10; CHEMBL747; BRN 0229760; 1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine; 26RM326WVN; QMNFFXRFOJIOKZ-UHFFFAOYSA-N; 1-(p-Chlorophenyl)-4,6-diamino-2,2-dimethyl-1,2-dihydro-s-triazine; 1-(4-chlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine; 1-p-Chlorophenyl-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine
DMC520D DT Small molecular drug
DMC520D PC 9049
DMC520D MW 251.71
DMC520D FM C11H14ClN5
DMC520D IC InChI=1S/C11H14ClN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-7(12)4-6-8/h3-6H,1-2H3,(H4,13,14,15,16)
DMC520D CS CC1(N=C(N=C(N1C2=CC=C(C=C2)Cl)N)N)C
DMC520D IK QMNFFXRFOJIOKZ-UHFFFAOYSA-N
DMC520D IU 1-(4-chlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine
DMC520D CA CAS 516-21-2
DMC520D CB CHEBI:135029
DMC520D DE Malaria
DMGDA3C ID DMGDA3C
DMGDA3C DN Cycloheximide
DMGDA3C HS Investigative
DMGDA3C SN naramycin A; NSC 185; FT 3422-2; NM-MCD 80
DMGDA3C DT Small molecular drug
DMGDA3C PC 6197
DMGDA3C MW 281.35
DMGDA3C FM C15H23NO4
DMGDA3C IC InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1
DMGDA3C CS C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C
DMGDA3C IK YPHMISFOHDHNIV-FSZOTQKASA-N
DMGDA3C IU 4-[(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione
DMGDA3C CA CAS 66-81-9
DMGDA3C CB CHEBI:27641
DMGDA3C DE Discovery agent
DMZKH4R ID DMZKH4R
DMZKH4R DN Cyclohexyl biphenyl-4-ylcarbamate
DMZKH4R HS Investigative
DMZKH4R SN cyclohexyl biphenyl-4-ylcarbamate; CHEMBL541244; SCHEMBL12166742; URB602, 3k
DMZKH4R DT Small molecular drug
DMZKH4R PC 45272494
DMZKH4R MW 295.4
DMZKH4R FM C19H21NO2
DMZKH4R IC InChI=1S/C19H21NO2/c21-19(22-18-9-5-2-6-10-18)20-17-13-11-16(12-14-17)15-7-3-1-4-8-15/h1,3-4,7-8,11-14,18H,2,5-6,9-10H2,(H,20,21)
DMZKH4R CS C1CCC(CC1)OC(=O)NC2=CC=C(C=C2)C3=CC=CC=C3
DMZKH4R IK SSVRRVRYQFRADL-UHFFFAOYSA-N
DMZKH4R IU cyclohexyl N-(4-phenylphenyl)carbamate
DMZKH4R DE Discovery agent
DM84ZX5 ID DM84ZX5
DM84ZX5 DN Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine
DM84ZX5 HS Investigative
DM84ZX5 SN CHEMBL363419; Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine; SCHEMBL935805; ZINC13648479; BDBM50170816
DM84ZX5 DT Small molecular drug
DM84ZX5 PC 11771279
DM84ZX5 MW 309.4
DM84ZX5 FM C17H19N5O
DM84ZX5 IC InChI=1S/C17H19N5O/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)21-17(22-16)23-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H2,18,19,20,21,22)
DM84ZX5 CS C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)OC4=CC=CC=C4
DM84ZX5 IK OGCQBCHLFMBCCE-UHFFFAOYSA-N
DM84ZX5 IU N-cyclohexyl-2-phenoxy-7H-purin-6-amine
DM84ZX5 DE Discovery agent
DMLREDJ ID DMLREDJ
DMLREDJ DN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ HS Investigative
DMLREDJ SN CHEMBL191270; Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine
DMLREDJ DT Small molecular drug
DMLREDJ PC 11450197
DMLREDJ MW 325.4
DMLREDJ FM C17H19N5S
DMLREDJ IC InChI=1S/C17H19N5S/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)21-17(22-16)23-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H2,18,19,20,21,22)
DMLREDJ CS C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)SC4=CC=CC=C4
DMLREDJ IK NFXCEGOWTIZWIH-UHFFFAOYSA-N
DMLREDJ IU N-cyclohexyl-2-phenylsulfanyl-7H-purin-6-amine
DMLREDJ DE Discovery agent
DMJEN45 ID DMJEN45
DMJEN45 DN Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile
DMJEN45 HS Investigative
DMJEN45 SN CHEMBL432482; Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile; SCHEMBL5903164; BDBM50126935
DMJEN45 DT Small molecular drug
DMJEN45 PC 10084369
DMJEN45 MW 268.2
DMJEN45 FM C14H15Cl2N
DMJEN45 IC InChI=1S/C14H15Cl2N/c15-13-7-6-11(8-14(13)16)12(9-17)10-4-2-1-3-5-10/h6-8,10,12H,1-5H2
DMJEN45 CS C1CCC(CC1)C(C#N)C2=CC(=C(C=C2)Cl)Cl
DMJEN45 IK HAXWFRNRCIQCDM-UHFFFAOYSA-N
DMJEN45 IU 2-cyclohexyl-2-(3,4-dichlorophenyl)acetonitrile
DMJEN45 DE Discovery agent
DM1F7I5 ID DM1F7I5
DM1F7I5 DN Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine
DM1F7I5 HS Investigative
DM1F7I5 SN CHEMBL321753; Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine; BDBM50009690
DM1F7I5 DT Small molecular drug
DM1F7I5 PC 15693949
DM1F7I5 MW 245.32
DM1F7I5 FM C13H19N5
DM1F7I5 IC InChI=1S/C13H19N5/c1-2-18-9-16-11-12(14-8-15-13(11)18)17-10-6-4-3-5-7-10/h8-10H,2-7H2,1H3,(H,14,15,17)
DM1F7I5 CS CCN1C=NC2=C(N=CN=C21)NC3CCCCC3
DM1F7I5 IK ZKBBSCAFNVXZSZ-UHFFFAOYSA-N
DM1F7I5 IU N-cyclohexyl-9-ethylpurin-6-amine
DM1F7I5 DE Discovery agent
DMIUCSW ID DMIUCSW
DMIUCSW DN Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine
DMIUCSW HS Investigative
DMIUCSW SN CHEMBL95332; 109292-93-5; 9H-Purin-6-amine, N-cyclohexyl-9-methyl-; N6-Cyclohexyl-9-methyladenine; Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine; ACMC-20mc61; SCHEMBL14564552; CTK0D5868; DTXSID10576963; BDBM50009683; 6-Cyclohexylamino-9-methyl-9H-purine; AKOS030562210
DMIUCSW DT Small molecular drug
DMIUCSW PC 15693939
DMIUCSW MW 231.3
DMIUCSW FM C12H17N5
DMIUCSW IC InChI=1S/C12H17N5/c1-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-2-4-6-9/h7-9H,2-6H2,1H3,(H,13,14,16)
DMIUCSW CS CN1C=NC2=C(N=CN=C21)NC3CCCCC3
DMIUCSW IK YWCWGJZQICOVCA-UHFFFAOYSA-N
DMIUCSW IU N-cyclohexyl-9-methylpurin-6-amine
DMIUCSW CA CAS 109292-93-5
DMIUCSW DE Discovery agent
DMYQH2N ID DMYQH2N
DMYQH2N DN Cyclohexylammonium Ion
DMYQH2N HS Investigative
DMYQH2N SN CYCLOHEXYLAMMONIUM ION; cyclohexylammonium; cyclohexylazanium; cyclohexanaminium; Cyclohexaniminium; cyclohexyl-ammonium; cyclohexyl ammonium; AC1LU7QN; SAMPL4, C7; CHEBI:42939; PAFZNILMFXTMIY-UHFFFAOYSA-O; BDBM197294; DB02995; NCGC00249017-01; CJ-13833; A801941
DMYQH2N DT Small molecular drug
DMYQH2N PC 1549093
DMYQH2N MW 100.18
DMYQH2N FM C6H14N+
DMYQH2N IC InChI=1S/C6H13N/c7-6-4-2-1-3-5-6/h6H,1-5,7H2/p+1
DMYQH2N CS C1CCC(CC1)[NH3+]
DMYQH2N IK PAFZNILMFXTMIY-UHFFFAOYSA-O
DMYQH2N IU cyclohexylazanium
DMYQH2N CB CHEBI:42939
DMYQH2N DE Discovery agent
DM06OLY ID DM06OLY
DM06OLY DN Cyclohexylcarbamic acidbiphenyl-3-yl ester
DM06OLY HS Investigative
DM06OLY SN CHEMBL431202; biphenyl-N-cyclopentyl-carbamate; 546141-07-5; URB524; URB-524; cyclohexylcarbamic acidbiphenyl-3-yl ester; SCHEMBL530169; 3-Biphenylyl cyclohexylcarbamate; biphenyl-3-yl-cyclohexylcarbamate; biphenyl-3-yl cyclohexylcarbamate; ZINC3816417; BDBM50128585; AKOS015909861; KB-48012; Cyclohexyl-carbamic acid biphenyl-3-yl ester
DM06OLY DT Small molecular drug
DM06OLY PC 10108554
DM06OLY MW 295.4
DM06OLY FM C19H21NO2
DM06OLY IC InChI=1S/C19H21NO2/c21-19(20-17-11-5-2-6-12-17)22-18-13-7-10-16(14-18)15-8-3-1-4-9-15/h1,3-4,7-10,13-14,17H,2,5-6,11-12H2,(H,20,21)
DM06OLY CS C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DM06OLY IK KGKDDSYRBQOMLE-UHFFFAOYSA-N
DM06OLY IU (3-phenylphenyl) N-cyclohexylcarbamate
DM06OLY DE Discovery agent
DMNG4B1 ID DMNG4B1
DMNG4B1 DN Cyclohexylglycine-(2S)-cyanopyrrolidine
DMNG4B1 HS Investigative
DMNG4B1 SN Chg-Pro-CN; CHEMBL307636; cyclohexylglycine-(2S)-cyanopyrrolidine; BMCL15687 Compound 3; SCHEMBL14392566; BDBM11694; Cyclohexylglycine-(2S)-cyanopyrolidine 3; Cyclohexylglycine-(2S)-cyanopyrrolidine 2
DMNG4B1 DT Small molecular drug
DMNG4B1 PC 11075394
DMNG4B1 MW 235.33
DMNG4B1 FM C13H21N3O
DMNG4B1 IC InChI=1S/C13H21N3O/c14-9-11-7-4-8-16(11)13(17)12(15)10-5-2-1-3-6-10/h10-12H,1-8,15H2/t11-,12-/m0/s1
DMNG4B1 CS C1CCC(CC1)[C@@H](C(=O)N2CCC[C@H]2C#N)N
DMNG4B1 IK SXNUNNAPZNTPQV-RYUDHWBXSA-N
DMNG4B1 IU (2S)-1-[(2S)-2-amino-2-cyclohexylacetyl]pyrrolidine-2-carbonitrile
DMNG4B1 DE Discovery agent
DMEW7AY ID DMEW7AY
DMEW7AY DN Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester
DMEW7AY HS Investigative
DMEW7AY SN CHEMBL485685; Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester
DMEW7AY DT Small molecular drug
DMEW7AY PC 24881675
DMEW7AY MW 309.4
DMEW7AY FM C20H23NO2
DMEW7AY IC InChI=1S/C20H23NO2/c22-20(21-15-16-8-3-1-4-9-16)23-19-13-7-12-18(14-19)17-10-5-2-6-11-17/h2,5-7,10-14,16H,1,3-4,8-9,15H2,(H,21,22)
DMEW7AY CS C1CCC(CC1)CNC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMEW7AY IK AARHPAICPBZNBZ-UHFFFAOYSA-N
DMEW7AY IU (3-phenylphenyl) N-(cyclohexylmethyl)carbamate
DMEW7AY DE Discovery agent
DM0L6E1 ID DM0L6E1
DM0L6E1 DN Cycloleucine
DM0L6E1 HS Investigative
DM0L6E1 SN cycloleucine; 1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442
DM0L6E1 DT Small molecular drug
DM0L6E1 PC 2901
DM0L6E1 MW 129.16
DM0L6E1 FM C6H11NO2
DM0L6E1 IC InChI=1S/C6H11NO2/c7-6(5(8)9)3-1-2-4-6/h1-4,7H2,(H,8,9)
DM0L6E1 CS C1CCC(C1)(C(=O)O)N
DM0L6E1 IK NILQLFBWTXNUOE-UHFFFAOYSA-N
DM0L6E1 IU 1-aminocyclopentane-1-carboxylic acid
DM0L6E1 CA CAS 52-52-8
DM0L6E1 CB CHEBI:40547
DM0L6E1 DE Discovery agent
DMEM2SW ID DMEM2SW
DMEM2SW DN CYCLOPAMINE
DMEM2SW HS Investigative
DMEM2SW SN CYCLOPAMINE; 11-Deoxojervine; 4449-51-8; UNII-ZH658AJ192; CHEMBL254129; CHEBI:4021; 11-Deoxyjervine; ZH658AJ192; HSDB 3505; Jervine, 11-deoxo-; Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)- (9CI); (3beta,22S,23R)-17,23-epoxyveratraman-3-ol; Veratraman-3-ol, 17,23-epoxy-, (3beta,23beta)-; CY8; [3H]-Cyclopamine; AC1L9DRQ; DSSTox_CID_23709; DSSTox_RID_80067; SCHEMBL29153
DMEM2SW DT Small molecular drug
DMEM2SW PC 442972
DMEM2SW MW 411.6
DMEM2SW FM C27H41NO2
DMEM2SW IC InChI=1S/C27H41NO2/c1-15-11-24-25(28-14-15)17(3)27(30-24)10-8-20-21-6-5-18-12-19(29)7-9-26(18,4)23(21)13-22(20)16(27)2/h5,15,17,19-21,23-25,28-29H,6-14H2,1-4H3/t15-,17+,19-,20-,21-,23-,24+,25-,26-,27-/m0/s1
DMEM2SW CS C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@]6([C@H]5CC4=C3C)C)O)C)NC1
DMEM2SW IK QASFUMOKHFSJGL-LAFRSMQTSA-N
DMEM2SW IU (3S,3'R,3'aS,6'S,6aS,6bS,7'aR,9R,11aS,11bR)-3',6',10,11b-tetramethylspiro[2,3,4,6,6a,6b,7,8,11,11a-decahydro-1H-benzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-ol
DMEM2SW CA CAS 4449-51-8
DMEM2SW CB CHEBI:4021
DMEM2SW DE Discovery agent
DM78PR5 ID DM78PR5
DM78PR5 DN Cyclopentane amide derivatives 1
DM78PR5 HS Investigative
DM78PR5 DT Small molecular drug
DM78PR5 PC 56603762
DM78PR5 MW 328.41
DM78PR5 FM C15H28N4O4
DM78PR5 IC InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9?,10-,11-,12?,13?/m1/s1
DM78PR5 CS CCC(CC)C([C@H]1[C@@H](CC(C1O)C(=O)O)N=C(N)N)NC(=O)C
DM78PR5 IK XRQDFNLINLXZLB-WFNKCNOUSA-N
DM78PR5 IU (3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DM78PR5 DE Discovery agent
DMGU97P ID DMGU97P
DMGU97P DN Cyclopentane amide derivatives 2
DMGU97P HS Investigative
DMGU97P DT Small molecular drug
DMGU97P PC 56603763
DMGU97P MW 312.41
DMGU97P FM C15H28N4O3
DMGU97P IC InChI=1S/C15H28N4O3/c1-4-9(5-2)13(18-8(3)20)11-6-10(14(21)22)7-12(11)19-15(16)17/h9-13H,4-7H2,1-3H3,(H,18,20)(H,21,22)(H4,16,17,19)/t10?,11-,12-,13?/m1/s1
DMGU97P CS CCC(CC)C([C@@H]1CC(C[C@H]1N=C(N)N)C(=O)O)NC(=O)C
DMGU97P IK FOCBRFMNUQOMCY-QZQSVVMZSA-N
DMGU97P IU (3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMGU97P DE Discovery agent
DMHTVRL ID DMHTVRL
DMHTVRL DN Cyclopentane amide derivatives 3
DMHTVRL HS Investigative
DMHTVRL DT Small molecular drug
DMHTVRL PC 56603764
DMHTVRL MW 340.5
DMHTVRL FM C17H32N4O3
DMHTVRL IC InChI=1S/C17H32N4O3/c1-4-6-11(7-5-2)15(20-10(3)22)13-8-12(16(23)24)9-14(13)21-17(18)19/h11-15H,4-9H2,1-3H3,(H,20,22)(H,23,24)(H4,18,19,21)/t12?,13-,14-,15?/m1/s1
DMHTVRL CS CCCC(CCC)C([C@@H]1CC(C[C@H]1N=C(N)N)C(=O)O)NC(=O)C
DMHTVRL IK VUROMZOEXLKRSQ-PIOWNMBXSA-N
DMHTVRL IU (3S,4R)-3-(1-acetamido-2-propylpentyl)-4-(diaminomethylideneamino)cyclopentane-1-carboxylic acid
DMHTVRL DE Discovery agent
DMOA7EP ID DMOA7EP
DMOA7EP DN Cyclopentane amide derivatives 4
DMOA7EP HS Investigative
DMOA7EP DT Small molecular drug
DMOA7EP PC 56603765
DMOA7EP MW 356.5
DMOA7EP FM C17H32N4O4
DMOA7EP IC InChI=1S/C17H32N4O4/c1-4-6-10(7-5-2)14(20-9(3)22)13-12(21-17(18)19)8-11(15(13)23)16(24)25/h10-15,23H,4-8H2,1-3H3,(H,20,22)(H,24,25)(H4,18,19,21)/t11?,12-,13-,14?,15?/m1/s1
DMOA7EP CS CCCC(CCC)C([C@H]1[C@@H](CC(C1O)C(=O)O)N=C(N)N)NC(=O)C
DMOA7EP IK IIZTWIZWLKRAMW-YATPQJKZSA-N
DMOA7EP IU (3S,4R)-3-(1-acetamido-2-propylpentyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
DMOA7EP DE Discovery agent
DMMV2LN ID DMMV2LN
DMMV2LN DN Cyclopentyl 10H-phenothiazine-10-carboxylate
DMMV2LN HS Investigative
DMMV2LN SN CHEMBL520588; cyclopentyl 10H-phenothiazine-10-carboxylate
DMMV2LN DT Small molecular drug
DMMV2LN PC 24905535
DMMV2LN MW 311.4
DMMV2LN FM C18H17NO2S
DMMV2LN IC InChI=1S/C18H17NO2S/c20-18(21-13-7-1-2-8-13)19-14-9-3-5-11-16(14)22-17-12-6-4-10-15(17)19/h3-6,9-13H,1-2,7-8H2
DMMV2LN CS C1CCC(C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMMV2LN IK NFZAMIJBLBLKQJ-UHFFFAOYSA-N
DMMV2LN IU cyclopentyl phenothiazine-10-carboxylate
DMMV2LN DE Discovery agent
DMAKT65 ID DMAKT65
DMAKT65 DN Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile
DMAKT65 HS Investigative
DMAKT65 SN CHEMBL39241; Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile; SCHEMBL5903239; BDBM50126930
DMAKT65 DT Small molecular drug
DMAKT65 PC 10244015
DMAKT65 MW 254.15
DMAKT65 FM C13H13Cl2N
DMAKT65 IC InChI=1S/C13H13Cl2N/c14-12-6-5-10(7-13(12)15)11(8-16)9-3-1-2-4-9/h5-7,9,11H,1-4H2
DMAKT65 CS C1CCC(C1)C(C#N)C2=CC(=C(C=C2)Cl)Cl
DMAKT65 IK MWISMDNUXLOMTQ-UHFFFAOYSA-N
DMAKT65 IU 2-cyclopentyl-2-(3,4-dichlorophenyl)acetonitrile
DMAKT65 DE Discovery agent
DM0J9I5 ID DM0J9I5
DM0J9I5 DN Cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone
DM0J9I5 HS Investigative
DM0J9I5 SN alpha-ketooxazole, 14e; cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone; SCHEMBL711639; CHEMBL376397; BDBM23134; CZXHLRXAHDZQJF-UHFFFAOYSA-N
DM0J9I5 DT Small molecular drug
DM0J9I5 PC 16737623
DM0J9I5 MW 242.27
DM0J9I5 FM C14H14N2O2
DM0J9I5 IC InChI=1S/C14H14N2O2/c17-13(10-5-1-2-6-10)14-16-9-12(18-14)11-7-3-4-8-15-11/h3-4,7-10H,1-2,5-6H2
DM0J9I5 CS C1CCC(C1)C(=O)C2=NC=C(O2)C3=CC=CC=N3
DM0J9I5 IK CZXHLRXAHDZQJF-UHFFFAOYSA-N
DM0J9I5 IU cyclopentyl-(5-pyridin-2-yl-1,3-oxazol-2-yl)methanone
DM0J9I5 DE Discovery agent
DMBDTFQ ID DMBDTFQ
DMBDTFQ DN Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine
DMBDTFQ HS Investigative
DMBDTFQ SN CHEMBL95617; Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine; BDBM50009696
DMBDTFQ DT Small molecular drug
DMBDTFQ PC 15693951
DMBDTFQ MW 271.36
DMBDTFQ FM C15H21N5
DMBDTFQ IC InChI=1S/C15H21N5/c1-2-6-11(5-1)19-14-13-15(17-9-16-14)20(10-18-13)12-7-3-4-8-12/h9-12H,1-8H2,(H,16,17,19)
DMBDTFQ CS C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)C4CCCC4
DMBDTFQ IK TYMGLHAHNFQONV-UHFFFAOYSA-N
DMBDTFQ IU N,9-dicyclopentylpurin-6-amine
DMBDTFQ DE Discovery agent
DMQ6BS2 ID DMQ6BS2
DMQ6BS2 DN Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine
DMQ6BS2 HS Investigative
DMQ6BS2 SN CHEMBL301574; Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine; BDBM50009684; 6-Cyclopentylamino-9-ethyl-9H-purine
DMQ6BS2 DT Small molecular drug
DMQ6BS2 PC 15693948
DMQ6BS2 MW 231.3
DMQ6BS2 FM C12H17N5
DMQ6BS2 IC InChI=1S/C12H17N5/c1-2-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-4-6-9/h7-9H,2-6H2,1H3,(H,13,14,16)
DMQ6BS2 CS CCN1C=NC2=C(N=CN=C21)NC3CCCC3
DMQ6BS2 IK CDVHQRUOORNLKE-UHFFFAOYSA-N
DMQ6BS2 IU N-cyclopentyl-9-ethylpurin-6-amine
DMQ6BS2 DE Discovery agent
DM9DHNZ ID DM9DHNZ
DM9DHNZ DN Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine
DM9DHNZ HS Investigative
DM9DHNZ SN N6-Cyclopentyl-9-methyladenine; N(6)-Cyclopentyl-9-methyladenine; N-0840; n-cyclopentyl-9-methyl-9h-purin-6-amine; CHEMBL48278; 109292-91-3; Lopac-N-154; 9H-Purin-6-amine,N-cyclopentyl-9-methyl-; AC1Q4XZM; Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine; Lopac0_000921; ZINC5203; SCHEMBL1322040; AC1L1I31; DTXSID60148871; LZMRVYPPUVMKOI-UHFFFAOYSA-N; N6 -Cyclopentyl-9-Methyl Adenine; N-cyclopentyl-9-methylpurin-6-amine; n0840; BDBM50009698; CCG-205003; NCGC00094232-01; NCGC00015717-03; NCGC00094232-03; NCGC00015717-02; NCGC00015717-01
DM9DHNZ DT Small molecular drug
DM9DHNZ PC 4401
DM9DHNZ MW 217.27
DM9DHNZ FM C11H15N5
DM9DHNZ IC InChI=1S/C11H15N5/c1-16-7-14-9-10(12-6-13-11(9)16)15-8-4-2-3-5-8/h6-8H,2-5H2,1H3,(H,12,13,15)
DM9DHNZ CS CN1C=NC2=C(N=CN=C21)NC3CCCC3
DM9DHNZ IK LZMRVYPPUVMKOI-UHFFFAOYSA-N
DM9DHNZ IU N-cyclopentyl-9-methylpurin-6-amine
DM9DHNZ CA CAS 109292-91-3
DM9DHNZ DE Discovery agent
DMBJV90 ID DMBJV90
DMBJV90 DN Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine
DMBJV90 HS Investigative
DMBJV90 SN CHEMBL319010; Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine; BDBM50009699
DMBJV90 DT Small molecular drug
DMBJV90 PC 15693952
DMBJV90 MW 279.34
DMBJV90 FM C16H17N5
DMBJV90 IC InChI=1S/C16H17N5/c1-2-8-13(9-3-1)21-11-19-14-15(17-10-18-16(14)21)20-12-6-4-5-7-12/h1-3,8-12H,4-7H2,(H,17,18,20)
DMBJV90 CS C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)C4=CC=CC=C4
DMBJV90 IK HMTXZOPPYXBLIU-UHFFFAOYSA-N
DMBJV90 IU N-cyclopentyl-9-phenylpurin-6-amine
DMBJV90 DE Discovery agent
DMQLGFH ID DMQLGFH
DMQLGFH DN Cyclopentylcarbamic Acid Biphenyl-3-yl Ester
DMQLGFH HS Investigative
DMQLGFH SN CHEMBL448753; Cyclopentylcarbamic Acid Biphenyl-3-yl Ester; BDBM50256913; Cyclopentyl-carbamic acid biphenyl-3-yl ester
DMQLGFH DT Small molecular drug
DMQLGFH PC 24881674
DMQLGFH MW 281.3
DMQLGFH FM C18H19NO2
DMQLGFH IC InChI=1S/C18H19NO2/c20-18(19-16-10-4-5-11-16)21-17-12-6-9-15(13-17)14-7-2-1-3-8-14/h1-3,6-9,12-13,16H,4-5,10-11H2,(H,19,20)
DMQLGFH CS C1CCC(C1)NC(=O)OC2=CC=CC(=C2)C3=CC=CC=C3
DMQLGFH IK ASBRBCNHGJSXLE-UHFFFAOYSA-N
DMQLGFH IU (3-phenylphenyl) N-cyclopentylcarbamate
DMQLGFH DE Discovery agent
DM4KZ1W ID DM4KZ1W
DM4KZ1W DN Cyclopentylcytosine
DM4KZ1W HS Investigative
DM4KZ1W SN cyclopentylcytosine
DM4KZ1W DT Small molecular drug
DM4KZ1W PC 129775084
DM4KZ1W MW 455.06
DM4KZ1W FM C9H4N3O13P3
DM4KZ1W IC InChI=1S/C9H4N3O13P3/c13-6-10-4-3-5-11(6)7-1-2-8-9(7,22-27(15,20-8)21-8)23-28(16,19-7)25-12(5)24-26(14,17-3)18-4/h1-2H2
DM4KZ1W CS C1CC23C4(C15N6C7=C8C(=NC6=O)OP(=O)(O8)ON7OP(=O)(O5)O4)OP(=O)(O2)O3
DM4KZ1W IK VLAUHALXFDMKAB-UHFFFAOYSA-N
DM4KZ1W IU 7,13,17-trioxo-6,8,12,14,16,18,22,23,24-nonaoxa-2,4,11-triaza-7lambda5,13lambda5,17lambda5-triphosphaoctacyclo[11.8.1.17,11.117,19.01,15.02,10.05,9.015,19]tetracosa-4,9-dien-3-one
DM4KZ1W DE Discovery agent
DMPJ08G ID DMPJ08G
DMPJ08G DN Cyclopiazonic acid
DMPJ08G HS Investigative
DMPJ08G SN 2o9j; 2oa0; BSPBio_001303; GTPL5350; SCHEMBL1471247; MolPort-003-983-745; BS0055; ZINC100061481; ZINC100067111; ZINC110970687; FT-0624278; J-011619; (2R,3S,9R)-5-acetyl-4-hydroxy-8,8-dimethyl-7,16-diazapentacyclo[9.6.1.0^{2,9}.0^{3,7}.0^{15,18}]octadeca-1(17),4,11(18),12,14-pentaen-6-one
DMPJ08G DT Small molecular drug
DMPJ08G PC 54682463
DMPJ08G MW 336.4
DMPJ08G FM C20H20N2O3
DMPJ08G IC InChI=1S/C20H20N2O3/c1-9(23)14-18(24)17-16-11-8-21-13-6-4-5-10(15(11)13)7-12(16)20(2,3)22(17)19(14)25/h4-6,8,12,16-17,21,24H,7H2,1-3H3/t12-,16+,17+/m1/s1
DMPJ08G CS CC(=O)C1=C([C@@H]2[C@@H]3[C@@H](CC4=C5C3=CNC5=CC=C4)C(N2C1=O)(C)C)O
DMPJ08G IK SZINUGQCTHLQAZ-DQYPLSBCSA-N
DMPJ08G IU (2R,3S,9R)-5-acetyl-4-hydroxy-8,8-dimethyl-7,16-diazapentacyclo[9.6.1.02,9.03,7.015,18]octadeca-1(17),4,11(18),12,14-pentaen-6-one
DMPJ08G CA CAS 18172-33-3
DMPJ08G DE Discovery agent
DMGFEPJ ID DMGFEPJ
DMGFEPJ DN Cyclopropyl
DMGFEPJ HS Investigative
DMGFEPJ SN Cyclopropyl; Cyclopropyl radical; cyclopropan-1-yl; 2417-82-5; AC1L3VZL; AC1Q1GU5; DTXSID30178882; 16084-EP2281563A1; 16084-EP2275401A1; 16084-EP2316459A1
DMGFEPJ DT Small molecular drug
DMGFEPJ PC 123162
DMGFEPJ MW 41.07
DMGFEPJ FM C3H5
DMGFEPJ IC InChI=1S/C3H5/c1-2-3-1/h1H,2-3H2
DMGFEPJ CS C1C[CH]1
DMGFEPJ IK XIPUIGPNIDKXJU-UHFFFAOYSA-N
DMGFEPJ CA CAS 2417-82-5
DMGFEPJ DE Discovery agent
DMGZ0KM ID DMGZ0KM
DMGZ0KM DN Cyclorgdfv
DMGZ0KM HS Investigative
DMGZ0KM SN CYCLORGDFV; cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid
DMGZ0KM DT Small molecular drug
DMGZ0KM PC 9851104
DMGZ0KM MW 574.6
DMGZ0KM FM C26H38N8O7
DMGZ0KM IC InChI=1S/C26H38N8O7/c1-14(2)21-25(41)32-16(9-6-10-29-26(27)28)22(38)30-13-19(35)31-18(12-20(36)37)23(39)33-17(24(40)34-21)11-15-7-4-3-5-8-15/h3-5,7-8,14,16-18,21H,6,9-13H2,1-2H3,(H,30,38)(H,31,35)(H,32,41)(H,33,39)(H,34,40)(H,36,37)(H4,27,28,29)/t16-,17+,18-,21-/m0/s1
DMGZ0KM CS CC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
DMGZ0KM IK YYQUWEHEBOMRPH-NYUBLWNDSA-N
DMGZ0KM IU 2-[(2S,5R,8S,11S)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMB1U8V ID DMB1U8V
DMB1U8V DN CYCLORPHAN
DMB1U8V HS Investigative
DMB1U8V SN 17-(Cyclopropylmethyl)morphinan-3-ol; 4163-15-9; UNII-U6Z73N36V0; EINECS 224-007-5; CHEMBL49269; (-)-3-Hydroxy-N-cyclopropylmethylmorphinan; U6Z73N36V0; Morphinan, (-)-3-hydroxy-N-cyclopropylmethyl-; Morphinan-3-ol, 17-(cyclopropylmethyl)- (8CI,9CI); SCHEMBL159134; CTK4I5050; ZINC4215487; PDSP2_000668; BDBM50135800; N-cyclopropylmethyl 3-hydroxymorphinan; 3-Hydroxy-N-cyclopropylmethylmorphinan; LS-91818; (-)-17-(Cyclopropylmethyl)morphinan-3-ol; (-)-3-Hydroxy-N-cycloproypylmethylmorphinan Mandelate
DMB1U8V DT Small molecular drug
DMB1U8V PC 5359966
DMB1U8V MW 297.4
DMB1U8V FM C20H27NO
DMB1U8V IC InChI=1S/C20H27NO/c22-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-21(19)13-14-4-5-14/h6-7,12,14,17,19,22H,1-5,8-11,13H2/t17-,19+,20+/m0/s1
DMB1U8V CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC5CC5
DMB1U8V IK NLBUEDSBXVNAPB-DFQSSKMNSA-N
DMB1U8V IU (1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMB1U8V CA CAS 4163-15-9
DMB1U8V DE Discovery agent
DMLC041 ID DMLC041
DMLC041 DN Cyclosal-d4TMP
DMLC041 HS Investigative
DMLC041 SN CycloSal-d4TMP; cycosal-d4TMP; CHEMBL375767; AC1LABYX; BDBM50206637; 5-methyl-1-[(2R,5S)-5-[(2-oxo-4H-1,3,2; 5-Methyl-1-{5-[(2-oxo(4H-benzo[e]1,3,2-dioxaphosphan-2-yloxy))methyl](2-2,5-dihydrofuryl)}-1,3-dihydropyrimidine-2,4-dione; 5-methyl-1-[(2R,5S)-5-[(2-oxo-4H-1,3,2$l^{5}-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione; 5-methyl-1-[(2R,5R)-5-(2-oxo-4H-2lambda5-benzo[1,3,2]dioxaphosphinin-2-yloxy)-2,5-dihydro-furan-2-yl]-1H-pyrimidine-2,4-dione
DMLC041 DT Small molecular drug
DMLC041 PC 465614
DMLC041 MW 392.3
DMLC041 FM C17H17N2O7P
DMLC041 IC InChI=1S/C17H17N2O7P/c1-11-8-19(17(21)18-16(11)20)15-7-6-13(25-15)10-24-27(22)23-9-12-4-2-3-5-14(12)26-27/h2-8,13,15H,9-10H2,1H3,(H,18,20,21)/t13-,15+,27?/m0/s1
DMLC041 CS CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)COP3(=O)OCC4=CC=CC=C4O3
DMLC041 IK NEUXRWCLDPVEMR-OHDXJBIGSA-N
DMLC041 IU 5-methyl-1-[(2R,5S)-5-[(2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
DMLC041 DE Discovery agent
DMFTDPQ ID DMFTDPQ
DMFTDPQ DN Cyclostellettamine derivative
DMFTDPQ HS Investigative
DMFTDPQ SN CHEMBL88332
DMFTDPQ DT Small molecular drug
DMFTDPQ PC 23327627
DMFTDPQ MW 744.9
DMFTDPQ FM C40H58F6N2O4
DMFTDPQ IC InChI=1S/C36H58N2.2C2HF3O2/c1-2-5-9-13-17-21-29-37-31-24-28-36(34-37)26-20-16-12-8-4-6-10-14-18-22-30-38-32-23-27-35(33-38)25-19-15-11-7-3-1;2*3-2(4,5)1(6)7/h1-2,23-24,27-28,31-34H,3-22,25-26,29-30H2;2*(H,6,7)/q+2;;/p-2/b2-1+;;
DMFTDPQ CS C1CCCCCC[N+]2=CC=CC(=C2)CCCCCC/C=C/CCCCCC[N+]3=CC=CC(=C3)CCCCC1.C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-]
DMFTDPQ IK LUAUOMZCZVKFMM-SEPHDYHBSA-L
DMFTDPQ IU (25E)-1,18-diazoniatricyclo[31.3.1.114,18]octatriaconta-1(36),14(38),15,17,25,33(37),34-heptaene;2,2,2-trifluoroacetate
DMFTDPQ DE Discovery agent
DM8HG0K ID DM8HG0K
DM8HG0K DN Cyclotheonamide E
DM8HG0K HS Investigative
DM8HG0K SN Cyclotheonamide E; CHEMBL507449
DM8HG0K DT Small molecular drug
DM8HG0K PC 44584171
DM8HG0K MW 859
DM8HG0K FM C43H58N10O9
DM8HG0K IC InChI=1S/C43H58N10O9/c1-4-25(2)36-40(60)49-29(22-28-14-17-30(54)18-15-28)16-19-34(55)47-24-32(51-38(58)26(3)48-35(56)23-27-10-6-5-7-11-27)42(62)53-21-9-13-33(53)39(59)50-31(37(57)41(61)52-36)12-8-20-46-43(44)45/h5-7,10-11,14-19,25-26,29,31-33,36,54H,4,8-9,12-13,20-24H2,1-3H3,(H,47,55)(H,48,56)(H,49,60)(H,50,59)(H,51,58)(H,52,61)(H4,44,45,46)/b19-16+/t25-,26+,29-,31+,32+,33+,36+/m1/s1
DM8HG0K CS CC[C@@H](C)[C@H]1C(=O)N[C@H](/C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)O
DM8HG0K IK JAVOTTCUBDNFEA-YFQACERUSA-N
DM8HG0K IU (2S)-N-[(3S,7E,9S,12S,16S,19S)-12-[(2R)-butan-2-yl]-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]-2-[(2-phenylacetyl)amino]propanamide
DM8HG0K DE Discovery agent
DM2E5VZ ID DM2E5VZ
DM2E5VZ DN Cyclotheonamide E4
DM2E5VZ HS Investigative
DM2E5VZ SN cyclotheonamide E4; CHEMBL448961
DM2E5VZ DT Small molecular drug
DM2E5VZ PC 44584172
DM2E5VZ MW 839
DM2E5VZ FM C41H62N10O9
DM2E5VZ IC InChI=1S/C41H62N10O9/c1-6-23(3)20-33(54)46-25(5)36(56)49-30-22-45-32(53)17-14-27(21-26-12-15-28(52)16-13-26)47-38(58)34(24(4)7-2)50-39(59)35(55)29(10-8-18-44-41(42)43)48-37(57)31-11-9-19-51(31)40(30)60/h12-17,23-25,27,29-31,34,52H,6-11,18-22H2,1-5H3,(H,45,53)(H,46,54)(H,47,58)(H,48,57)(H,49,56)(H,50,59)(H4,42,43,44)/b17-14+/t23?,24-,25+,27-,29+,30+,31+,34+/m1/s1
DM2E5VZ CS CC[C@@H](C)[C@H]1C(=O)N[C@H](/C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CC(C)CC)CC3=CC=C(C=C3)O
DM2E5VZ IK SJGLOQSIMVYUEK-BJQFAPFESA-N
DM2E5VZ IU N-[(2S)-1-[[(3S,7E,9S,12S,16S,19S)-12-[(2R)-butan-2-yl]-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]amino]-1-oxopropan-2-yl]-3-methylpentanamide
DM2E5VZ DE Discovery agent
DMCA76M ID DMCA76M
DMCA76M DN Cyclotheonamide E5
DMCA76M HS Investigative
DMCA76M SN Cyclotheonamide E5; CHEMBL502059
DMCA76M DT Small molecular drug
DMCA76M PC 44584173
DMCA76M MW 855
DMCA76M FM C41H62N10O10
DMCA76M IC InChI=1S/C41H62N10O10/c1-6-22(3)18-33(55)46-24(5)36(57)49-28-21-45-32(54)15-13-26(19-25-12-14-30(52)31(53)20-25)47-38(59)34(23(4)7-2)50-39(60)35(56)27(10-8-16-44-41(42)43)48-37(58)29-11-9-17-51(29)40(28)61/h12-15,20,22-24,26-29,34,52-53H,6-11,16-19,21H2,1-5H3,(H,45,54)(H,46,55)(H,47,59)(H,48,58)(H,49,57)(H,50,60)(H4,42,43,44)/b15-13+/t22?,23-,24+,26-,27+,28+,29+,34+/m1/s1
DMCA76M CS CC[C@@H](C)[C@H]1C(=O)N[C@H](/C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)C(=O)N1)CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CC(C)CC)CC3=CC(=C(C=C3)O)O
DMCA76M IK GPMPQICWVQKULK-TUTRKGMZSA-N
DMCA76M IU N-[(2S)-1-[[(3S,7E,9S,12S,16S,19S)-12-[(2R)-butan-2-yl]-16-[3-(diaminomethylideneamino)propyl]-9-[(3,4-dihydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]amino]-1-oxopropan-2-yl]-3-methylpentanamide
DMCA76M DE Discovery agent
DMTS8D5 ID DMTS8D5
DMTS8D5 DN CYLINDOL A
DMTS8D5 HS Investigative
DMTS8D5 SN cylindol A; CHEBI:65709; dimethyl 3,3'-oxybis(4-hydroxybenzoate); methyl 4-hydroxy-3-(2-hydroxy-5-methoxycarbonylphenoxy)benzoate
DMTS8D5 DT Small molecular drug
DMTS8D5 PC 10425993
DMTS8D5 MW 318.28
DMTS8D5 FM C16H14O7
DMTS8D5 IC InChI=1S/C16H14O7/c1-21-15(19)9-3-5-11(17)13(7-9)23-14-8-10(16(20)22-2)4-6-12(14)18/h3-8,17-18H,1-2H3
DMTS8D5 CS COC(=O)C1=CC(=C(C=C1)O)OC2=C(C=CC(=C2)C(=O)OC)O
DMTS8D5 IK OEYSNLOOZVNLRA-UHFFFAOYSA-N
DMTS8D5 IU methyl 4-hydroxy-3-(2-hydroxy-5-methoxycarbonylphenoxy)benzoate
DMTS8D5 CB CHEBI:65709
DMTS8D5 DE Discovery agent
DMCRU4H ID DMCRU4H
DMCRU4H DN CYLINDROL A
DMCRU4H HS Investigative
DMCRU4H SN CYLINDROL A; CHEMBL318783; BDBM50059845; Propionic acid (E)-(R)-4-(3-formyl-2,6-dihydroxy-4-methyl-phenyl)-2-methyl-1-((1S,2R,6R)-1,2,6-trimethyl-3-oxo-cyclohexylmethyl)-but-2-enyl ester
DMCRU4H DT Small molecular drug
DMCRU4H PC 10456134
DMCRU4H MW 444.6
DMCRU4H FM C26H36O6
DMCRU4H IC InChI=1S/C26H36O6/c1-7-24(30)32-23(13-26(6)17(4)9-11-21(28)18(26)5)15(2)8-10-19-22(29)12-16(3)20(14-27)25(19)31/h8,12,14,17-18,23,29,31H,7,9-11,13H2,1-6H3/b15-8+/t17-,18+,23-,26+/m1/s1
DMCRU4H CS CCC(=O)O[C@H](C[C@]1([C@@H](CCC(=O)[C@@H]1C)C)C)/C(=C/CC2=C(C=C(C(=C2O)C=O)C)O)/C
DMCRU4H IK VLFRJRBSRCFKPU-AXNCTASFSA-N
DMCRU4H IU [(E,2R)-5-(3-formyl-2,6-dihydroxy-4-methylphenyl)-3-methyl-1-[(1S,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl]pent-3-en-2-yl] propanoate
DMCRU4H DE Discovery agent
DMQWLIC ID DMQWLIC
DMQWLIC DN Cylopentenyl cytosine
DMQWLIC HS Investigative
DMQWLIC DE Discovery agent
DM5NFEA ID DM5NFEA
DM5NFEA DN CYM2503
DM5NFEA HS Investigative
DM5NFEA SN CYM-2503
DM5NFEA DT Small molecular drug
DM5NFEA PC 91827369
DM5NFEA MW 765.9
DM5NFEA FM C44H55N5O7
DM5NFEA IC InChI=1S/C44H55N5O7/c1-27-23-39(50)47-37-25-29(20-21-30(27)37)46-40(51)36(19-12-22-45-42(53)56-44(2,3)4)48-41(52)38(24-28-13-6-5-7-14-28)49-43(54)55-26-35-33-17-10-8-15-31(33)32-16-9-11-18-34(32)35/h8-11,15-18,20-21,23,25,28,31,33,35-36,38H,5-7,12-14,19,22,24,26H2,1-4H3,(H,45,53)(H,46,51)(H,47,50)(H,48,52)(H,49,54)/t31?,33?,35?,36-,38-/m0/s1
DM5NFEA CS CC1=CC(=O)NC2=C1C=CC(=C2)NC(=O)[C@H](CCCNC(=O)OC(C)(C)C)NC(=O)[C@H](CC3CCCCC3)NC(=O)OCC4C5C=CC=CC5C6=CC=CC=C46
DM5NFEA IK DSRPDMJWEFCXMI-GHKFOJCISA-N
DM5NFEA IU tert-butyl N-[(4S)-4-[[(2S)-2-(9,9a-dihydro-4aH-fluoren-9-ylmethoxycarbonylamino)-3-cyclohexylpropanoyl]amino]-5-[(4-methyl-2-oxo-1H-quinolin-7-yl)amino]-5-oxopentyl]carbamate
DM5NFEA DE Discovery agent
DMGTZ9Q ID DMGTZ9Q
DMGTZ9Q DN CYM5181
DMGTZ9Q HS Investigative
DMGTZ9Q SN CYM-5181
DMGTZ9Q DT Small molecular drug
DMGTZ9Q PC 976135
DMGTZ9Q MW 311.33
DMGTZ9Q FM C17H17N3O3
DMGTZ9Q IC InChI=1S/C17H17N3O3/c1-3-21-14-6-5-13(11-15(14)22-4-2)17-19-16(20-23-17)12-7-9-18-10-8-12/h5-11H,3-4H2,1-2H3
DMGTZ9Q CS CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=NC=C3)OCC
DMGTZ9Q IK MMKXHTDCKLZHIM-UHFFFAOYSA-N
DMGTZ9Q IU 5-(3,4-diethoxyphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole
DMGTZ9Q CB CHEBI:92489
DMGTZ9Q DE Discovery agent
DMURD2E ID DMURD2E
DMURD2E DN CYM5442
DMURD2E HS Investigative
DMURD2E SN CYM-5442
DMURD2E DT Small molecular drug
DMURD2E PC 25110406
DMURD2E MW 409.5
DMURD2E FM C23H27N3O4
DMURD2E IC InChI=1S/C23H27N3O4/c1-3-28-20-11-8-15(14-21(20)29-4-2)23-25-22(26-30-23)18-7-5-6-17-16(18)9-10-19(17)24-12-13-27/h5-8,11,14,19,24,27H,3-4,9-10,12-13H2,1-2H3
DMURD2E CS CCOC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)OCC
DMURD2E IK NUIKTBLZSPQGCP-UHFFFAOYSA-N
DMURD2E IU 2-[[4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl]amino]ethanol
DMURD2E CA CAS 1094042-01-9
DMURD2E DE Discovery agent
DMG0PHU ID DMG0PHU
DMG0PHU DN CYNAROPICRIN
DMG0PHU HS Investigative
DMG0PHU SN Cynaropicrin; aguerin; 35730-78-0; CHEMBL374146; CHEBI:4038; UNII-M9233789I9; M9233789I9; [(3aR,4S,6aR,8S,9aR,9bR)-8-hydroxy-3,6,9-trimethylidene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-4-yl] 2-(hydroxymethyl)prop-2-enoate; AC1Q69JD; AC1L3O6W; SCHEMBL1711811; MEGxp0_001095; ACon1_000045; MolPort-001-741-258; ZINC4098049; HY-N2350; BDBM50194430; AKOS032971358; MCULE-5051144608; CS-8041; NCGC00168845-01; NCGC00168845-02; 2-Propenoic acid, 2-(hydroxymethyl)-, (3aR,4S,6aR,8S,9aR,9bR)-dodecahydro-8-hydroxy-3,6,9-tris(m
DMG0PHU DT Small molecular drug
DMG0PHU PC 119093
DMG0PHU MW 346.4
DMG0PHU FM C19H22O6
DMG0PHU IC InChI=1S/C19H22O6/c1-8-5-14(24-18(22)9(2)7-20)16-11(4)19(23)25-17(16)15-10(3)13(21)6-12(8)15/h12-17,20-21H,1-7H2/t12-,13-,14-,15-,16+,17+/m0/s1
DMG0PHU CS C=C1C[C@@H]([C@@H]2[C@@H]([C@@H]3[C@H]1C[C@@H](C3=C)O)OC(=O)C2=C)OC(=O)C(=C)CO
DMG0PHU IK KHSCYOFDKADJDJ-NQLMQOPMSA-N
DMG0PHU IU [(3aR,4S,6aR,8S,9aR,9bR)-8-hydroxy-3,6,9-trimethylidene-2-oxo-3a,4,5,6a,7,8,9a,9b-octahydroazuleno[4,5-b]furan-4-yl] 2-(hydroxymethyl)prop-2-enoate
DMG0PHU CA CAS 35730-78-0
DMG0PHU CB CHEBI:4038
DMG0PHU DE Discovery agent
DMZCA15 ID DMZCA15
DMZCA15 DN Cynooxide anion
DMZCA15 HS Investigative
DMZCA15 SN Fulminic acid; formonitrile oxide; Knallsaeure; HCNO; Hydrogen cyanide N-oxide; H-C#NO; formonitrile-N-oxide; [C(H)NO]; [CH(NO)]; (methylidyneammoniumyl)oxidanide; methylidyne(oxo)-lambda(5)-azane; hydrido(oxidonitrato-N)carbon; hydrido(nitrosyl-kappaN)carbon; CHEMBL185198; CHEBI:29813; 51060-05-0; Cynooxide anion; Formnitrile oxide; AC1LAVEA; CTK1G9581; DTXSID30334603; BDBM50152965; formonitrile oxideformonitrile-N-oxidehydrido(nitrosyl-kappaN)carbonhydrido(oxidonitrato-N)carbon
DMZCA15 DT Small molecular drug
DMZCA15 PC 521293
DMZCA15 MW 43.025
DMZCA15 FM CHNO
DMZCA15 IC InChI=1S/CHNO/c1-2-3/h1H
DMZCA15 CS C#[N+][O-]
DMZCA15 IK UXKUODQYLDZXDL-UHFFFAOYSA-N
DMZCA15 IU formonitrile oxide
DMZCA15 CA CAS 506-85-4
DMZCA15 CB CHEBI:29813
DMZCA15 DE Discovery agent
DMBTU7G ID DMBTU7G
DMBTU7G DN Cypate-[(RGD)2-NH2]1
DMBTU7G HS Investigative
DMBTU7G SN CHEMBL438186; cypate-[(RGD)2-NH2]1
DMBTU7G PC 44409497
DMBTU7G MW 1267.4
DMBTU7G FM C64H80N15O13+
DMBTU7G IC InChI=1S/C64H79N15O13/c1-63(2)47(78(31-28-52(83)84)45-26-24-37-16-10-12-18-39(37)55(45)63)22-8-6-5-7-9-23-48-64(3,4)56-40-19-13-11-17-38(40)25-27-46(56)79(48)36-51(82)74-41(20-14-29-70-61(66)67)58(90)72-35-50(81)76-44(33-54(87)88)60(92)77-42(21-15-30-71-62(68)69)59(91)73-34-49(80)75-43(57(65)89)32-53(85)86/h5-13,16-19,22-27,41-44H,14-15,20-21,28-36H2,1-4H3,(H18-,65,66,67,68,69,70,71,72,73,74,75,76,77,80,81,82,83,84,85,86,87,88,89,90,91,92)/p+1/t41-,42-,43+,44+/m0/s1
DMBTU7G CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)O)C=CC6=CC=CC=C65)(C)C)C
DMBTU7G IK LXIIZUXXHZFFKQ-IYTFMMMVSA-O
DMBTU7G IU (3R)-4-amino-3-[[2-[[(2S)-2-[[(2R)-3-carboxy-2-[[2-[[(2S)-2-[[2-[2-[(1E,3E,5E,7E)-7-[3-(2-carboxyethyl)-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMBTU7G DE Discovery agent
DMJNW9P ID DMJNW9P
DMJNW9P DN Cypate-[(RGD)2-NH2]2
DMJNW9P HS Investigative
DMJNW9P PC 91936295
DMJNW9P MW 1923.1
DMJNW9P FM C88H121N28O22+
DMJNW9P IC InChI=1S/C88H120N28O22/c1-87(2)61(115(59-30-28-47-18-10-12-20-49(47)73(59)87)37-32-63(117)107-51(22-14-33-99-83(91)92)77(133)103-44-66(120)111-57(40-71(127)128)81(137)113-53(24-16-35-101-85(95)96)79(135)105-42-64(118)109-55(75(89)131)38-69(123)124)26-8-6-5-7-9-27-62-88(3,4)74-50-21-13-11-19-48(50)29-31-60(74)116(62)46-68(122)108-52(23-15-34-100-84(93)94)78(134)104-45-67(121)112-58(41-72(129)130)82(138)114-54(25-17-36-102-86(97)98)80(136)106-43-65(119)110-56(76(90)132)39-70(125)126/h5-13,18-21,26-31,51-58H,14-17,22-25,32-46H2,1-4H3,(H35-,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138)/p+1/t51-,52-,53-,54-,55+,56+,57+,58+/m0/s1
DMJNW9P CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C=CC6=CC=CC=C65)(C)C)C
DMJNW9P IK UFEFOGNPPROIQU-SESQYOPQSA-O
DMJNW9P IU (3R)-4-amino-3-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[3-[(2E)-2-[(2E,4E,6E)-7-[3-[2-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoylamino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMJNW9P DE Discovery agent
DMWINK5 ID DMWINK5
DMWINK5 DN Cypate-[(RGD)3-NH2]1
DMWINK5 HS Investigative
DMWINK5 PC 91936298
DMWINK5 MW 1595.7
DMWINK5 FM C76H100N21O18+
DMWINK5 IC InChI=1S/C76H99N21O18/c1-75(2)54(96(34-30-61(103)104)52-28-26-42-17-10-12-19-44(42)64(52)75)24-8-6-5-7-9-25-55-76(3,4)65-45-20-13-11-18-43(45)27-29-53(65)97(55)41-60(102)90-46(21-14-31-84-72(78)79)66(109)87-38-57(99)91-49(36-62(105)106)69(112)94-47(22-15-32-85-73(80)81)67(110)88-39-58(100)92-50(37-63(107)108)70(113)95-48(23-16-33-86-74(82)83)68(111)89-40-59(101)93-51(71(114)115)35-56(77)98/h5-13,17-20,24-29,46-51H,14-16,21-23,30-41H2,1-4H3,(H26-,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115)/p+1/t46-,47-,48-,49+,50+,51+/m0/s1
DMWINK5 CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)O)C=CC6=CC=CC=C65)(C)C)C
DMWINK5 IK JDBLOSLZCJNMOD-QCWHUYCXSA-O
DMWINK5 IU (2R)-4-amino-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[[2-[2-[(1E,3E,5E,7E)-7-[3-(2-carboxyethyl)-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]acetyl]amino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMWINK5 DE Discovery agent
DM1SAIX ID DM1SAIX
DM1SAIX DN Cypate-[(RGD)3-NH2]2
DM1SAIX HS Investigative
DM1SAIX PC 91936296
DM1SAIX MW 2579.7
DM1SAIX FM C112H161N40O32+
DM1SAIX IC InChI=1S/C112H160N40O32/c1-111(2)75(151(73-34-32-57-20-10-12-22-59(57)91(73)111)43-36-79(155)139-61(24-14-37-127-105(115)116)93(171)133-50-80(156)141-67(46-87(163)164)99(177)147-63(26-16-39-129-107(119)120)95(173)135-52-82(158)143-69(48-89(167)168)101(179)149-65(28-18-41-131-109(123)124)97(175)137-54-84(160)145-71(103(181)182)44-77(113)153)30-8-6-5-7-9-31-76-112(3,4)92-60-23-13-11-21-58(60)33-35-74(92)152(76)56-86(162)140-62(25-15-38-128-106(117)118)94(172)134-51-81(157)142-68(47-88(165)166)100(178)148-64(27-17-40-130-108(121)122)96(174)136-53-83(159)144-70(49-90(169)170)102(180)150-66(29-19-42-132-110(125)126)98(176)138-55-85(161)146-72(104(183)184)45-78(114)154/h5-13,20-23,30-35,61-72H,14-19,24-29,36-56H2,1-4H3,(H51-,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184)/p+1/t61-,62-,63-,64-,65-,66-,67+,68+,69+,70+,71+,72+/m0/s1
DM1SAIX CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N)C(=O)O)C=CC6=CC=CC=C65)(C)C)C
DM1SAIX IK RXCTZKKSKSPTFA-PRPZEPFNSA-O
DM1SAIX IU (2R)-4-amino-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[3-[(2E)-2-[(2E,4E,6E)-7-[3-[2-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(1R)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoylamino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DM1SAIX DE Discovery agent
DM3GLMP ID DM3GLMP
DM3GLMP DN Cypate-[(RGD)4-NH2]1
DM3GLMP HS Investigative
DM3GLMP PC 91936299
DM3GLMP MW 1924.1
DM3GLMP FM C88H120N27O23+
DM3GLMP IC InChI=1S/C88H119N27O23/c1-87(2)61(26-8-6-5-7-9-27-62-88(3,4)74-50-21-13-11-19-48(50)29-31-60(74)115(62)46-72(128)129)114(59-30-28-47-18-10-12-20-49(47)73(59)87)37-32-63(116)106-51(22-14-33-98-83(90)91)76(131)103-43-66(119)109-56(40-70(124)125)80(135)112-53(24-16-35-100-85(94)95)78(133)104-44-67(120)110-57(41-71(126)127)81(136)113-54(25-17-36-101-86(96)97)79(134)105-45-68(121)111-58(82(137)138)38-64(117)107-52(23-15-34-99-84(92)93)77(132)102-42-65(118)108-55(75(89)130)39-69(122)123/h5-13,18-21,26-31,51-58H,14-17,22-25,32-46H2,1-4H3,(H34-,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138)/p+1/t51-,52-,53-,54-,55+,56+,57+,58+/m0/s1
DM3GLMP CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CC(=O)O)C=CC6=CC=CC=C65)(C)C)C
DM3GLMP IK GOWQHAYGNUHKIR-SESQYOPQSA-O
DM3GLMP IU (2R)-4-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2R)-2-[[2-[[(2S)-5-carbamimidamido-2-[3-[2-[(1E,3E,5E,7E)-7-[3-(carboxymethyl)-1,1-dimethylbenzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]propanoylamino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DM3GLMP DE Discovery agent
DMR74OM ID DMR74OM
DMR74OM DN Cypate-[(RGD)4-NH2]2
DMR74OM HS Investigative
DMR74OM PC 91936297
DMR74OM MW 3236.4
DMR74OM FM C136H201N52O42+
DMR74OM IC InChI=1S/C136H200N52O42/c1-135(2)89(187(87-38-36-67-22-10-12-24-69(67)109(87)135)49-40-91(189)171-71(26-14-41-155-127(139)140)113(215)165-60-96(194)177-81(54-105(205)206)121(223)183-75(30-18-45-159-131(147)148)117(219)167-62-98(196)179-83(56-107(209)210)123(225)185-77(32-20-47-161-133(151)152)119(221)169-64-100(198)181-85(125(227)228)50-92(190)172-72(27-15-42-156-128(141)142)114(216)163-58-94(192)175-79(111(137)213)52-103(201)202)34-8-6-5-7-9-35-90-136(3,4)110-70-25-13-11-23-68(70)37-39-88(110)188(90)66-102(200)174-74(29-17-44-158-130(145)146)116(218)166-61-97(195)178-82(55-106(207)208)122(224)184-76(31-19-46-160-132(149)150)118(220)168-63-99(197)180-84(57-108(211)212)124(226)186-78(33-21-48-162-134(153)154)120(222)170-65-101(199)182-86(126(229)230)51-93(191)173-73(28-16-43-157-129(143)144)115(217)164-59-95(193)176-80(112(138)214)53-104(203)204/h5-13,22-25,34-39,71-86H,14-21,26-33,40-66H2,1-4H3,(H67-,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230)/p+1/t71-,72-,73-,74-,75-,76-,77-,78-,79+,80+,81+,82+,83+,84+,85+,86+/m0/s1
DMR74OM CS CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C(=O)O)/C=C/C=C/C=C/C=C/4\\C(C5=C(N4CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@H](CC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(=O)O)C(=O)N)C(=O)O)C=CC6=CC=CC=C65)(C)C)C
DMR74OM IK ZQQKMIYGRGPTIR-LKERAZDISA-O
DMR74OM IU (2R)-4-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[(2S)-2-[3-[(2E)-2-[(2E,4E,6E)-7-[3-[2-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(2R)-1-[[(2S)-1-[[2-[[(1R)-3-[[(2S)-1-[[2-[[(2R)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]-1,1-dimethylbenzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]propanoylamino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DMR74OM DE Discovery agent
DM64L9I ID DM64L9I
DM64L9I DN CyPPA
DM64L9I HS Investigative
DM64L9I SN 73029-73-9; N-cyclohexyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidin-4-amine; CHEMBL453730; cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine; C16H23N5; N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine; AC1LIR5Q; SCHEMBL3233745; GTPL2323; CTK8F8875; DTXSID20358676; USEMRPYUFJNFQN-UHFFFAOYSA-N; MolPort-000-762-862; ZINC492516; HMS3262M15; Tox21_500707; STK052676; MFCD01550586; BDBM50275157; CyPPA, >
DM64L9I DT Small molecular drug
DM64L9I PC 909822
DM64L9I MW 285.39
DM64L9I FM C16H23N5
DM64L9I IC InChI=1S/C16H23N5/c1-11-10-15(18-14-7-5-4-6-8-14)19-16(17-11)21-13(3)9-12(2)20-21/h9-10,14H,4-8H2,1-3H3,(H,17,18,19)
DM64L9I CS CC1=CC(=NC(=N1)N2C(=CC(=N2)C)C)NC3CCCCC3
DM64L9I IK USEMRPYUFJNFQN-UHFFFAOYSA-N
DM64L9I IU N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine
DM64L9I CA CAS 73029-73-9
DM64L9I DE Discovery agent
DME9LPO ID DME9LPO
DME9LPO DN cyPPTS
DME9LPO HS Investigative
DME9LPO SN CHEMBL321968; cyPPTS; SCHEMBL6733000; GTPL6257; BDBM50147156; 2,2,2-Trifluoro-ethanesulfonic acid (3-cyclopentyloxy-phenyl)-pyridin-3-ylmethyl-amide; N-[3-(cyclopentyloxy)phenyl]-2,2,2-trifluoro-N-(pyridin-3-ylmethyl)ethane-1-sulfonamide
DME9LPO DT Small molecular drug
DME9LPO PC 44335556
DME9LPO MW 414.4
DME9LPO FM C19H21F3N2O3S
DME9LPO IC InChI=1S/C19H21F3N2O3S/c20-19(21,22)14-28(25,26)24(13-15-5-4-10-23-12-15)16-6-3-9-18(11-16)27-17-7-1-2-8-17/h3-6,9-12,17H,1-2,7-8,13-14H2
DME9LPO CS C1CCC(C1)OC2=CC=CC(=C2)N(CC3=CN=CC=C3)S(=O)(=O)CC(F)(F)F
DME9LPO IK WCYYNLFGFUQJMF-UHFFFAOYSA-N
DME9LPO IU N-(3-cyclopentyloxyphenyl)-2,2,2-trifluoro-N-(pyridin-3-ylmethyl)ethanesulfonamide
DME9LPO DE Discovery agent
DMJXCVA ID DMJXCVA
DMJXCVA DN CYPRODIME
DMJXCVA HS Investigative
DMJXCVA SN Cyprodime; CHEMBL322796; N-(Cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one; SCHEMBL3619261; BDBM50148071; ZINC13580323; NCGC00344512-01; Morphinan-6-one, 17-(cyclopropylmethyl)-4,14-dimethoxy-; (-)-N-(Cycloproylmethyl)-4,14-dimethoxymorphinan-6-one(Cyprodime); 17-cyclopropylmethyl-3,10-dimethoxy-(1R,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one; 17-cyclopropylmethyl-10-hydroxy-4,14-dimethoxy-(1S,9R,10S)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3-dien-6-one(cyprodime)
DMJXCVA DT Small molecular drug
DMJXCVA PC 5748293
DMJXCVA MW 355.5
DMJXCVA FM C22H29NO3
DMJXCVA IC InChI=1S/C22H29NO3/c1-25-18-5-3-4-16-12-19-22(26-2)9-8-17(24)13-21(22,20(16)18)10-11-23(19)14-15-6-7-15/h3-5,15,19H,6-14H2,1-2H3/t19-,21-,22-/m1/s1
DMJXCVA CS COC1=CC=CC2=C1[C@]34CCN([C@H](C2)[C@@]3(CCC(=O)C4)OC)CC5CC5
DMJXCVA IK INUCRGMCKDQKNA-CEMLEFRQSA-N
DMJXCVA IU (1R,9R,10S)-17-(cyclopropylmethyl)-3,10-dimethoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one
DMJXCVA CA CAS 118111-54-9
DMJXCVA DE Discovery agent
DM7T96M ID DM7T96M
DM7T96M DN Cyprodine
DM7T96M HS Investigative
DM7T96M DT Small molecular drug
DM7T96M PC 24758534
DM7T96M MW 1492.5
DM7T96M FM C67H97CoN14O17PS
DM7T96M IC InChI=1S/C62H90N13O14P.C5H9NO3S.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;1-3(7)6-4(2-10)5(8)9;/h20-21,23,28,31,34-37,41,52-53,56-57,71,76,84H,12-19,22,24-27H2,1-11H3,(H2,63,77)(H2,64,78)(H2,65,79)(H2,66,80)(H2,67,81)(H2,68,82)(H,69,83)(H,85,86);4,10H,2H2,1H3,(H,6,7)(H,8,9);/q;;+2/p-2/b38-23-,50-32-,55-33-;;/t31-,34+,35+,36+,37-,41+,52+,53+,56+,57-,59+,60-,61-,62-;4-;/m00./s1
DM7T96M CS CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@@H](C)CNC(=O)CC[C@@]4([C@H]([C@@H]5[C@]6([C@@]([C@@H](C(=N6)/C(=C\\7/[C@@]([C@@H](/C(=C/C8=N/C(=C(\\C4=N5)/C)/[C@H](C8(C)C)CCC(=O)N)/N7)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.CC(=O)N[C@@H](CS)C(=O)[O-].[Co+2]
DM7T96M IK BZLYFDSDKLBOFC-SFSIFEIQSA-L
DM7T96M IU (2R)-2-acetamido-3-sulfanylpropanoate;cobalt(2+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2S)-1-[3-[(1R,2R,3R,5Z,7S,10Z,12S,13S,14Z,17S,18S,19R)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-1,2,7,12,17,23-hexahydrocorrin-3-yl]propanoylamino]propan-2-yl] phosphate
DM7T96M DE Parkinson disease
DMS5DHY ID DMS5DHY
DMS5DHY DN Cystamine
DMS5DHY HS Investigative
DMS5DHY SN Cystamine dihydrochloride; 56-17-7; 2,2'-Disulfanediyldiethanamine dihydrochloride; Ethanamine, 2,2'-dithiobis-, dihydrochloride; Cystamin dihydrochloride; Bis(2-aminoethyl) disulfide dihydrochloride; USAF CB-34; 2-Aminoethyl disulfide dihydrochloride; Cystamine 2HCL; UNII-I90T518457; EINECS 200-260-7; NSC 39322; 2,2'-Dithiodi(ethylammonium) dichloride; Decarboxycystine dihydrochloride; 2,2'-Dithio-bis-(ethylamine) dihydrochloride; Usafcb-34; MFCD00012905; 2-Aminoethyl Dislufide Dihydrochloride
DMS5DHY DT Small molecular drug
DMS5DHY PC 2915
DMS5DHY MW 152.3
DMS5DHY FM C4H12N2S2
DMS5DHY IC InChI=1S/C4H12N2S2/c5-1-3-7-8-4-2-6/h1-6H2
DMS5DHY CS C(CSSCCN)N
DMS5DHY IK APQPRKLAWCIJEK-UHFFFAOYSA-N
DMS5DHY IU 2-(2-aminoethyldisulfanyl)ethanamine
DMS5DHY CA CAS 51-85-4
DMS5DHY CB CHEBI:78757
DMS5DHY DE Discovery agent
DM4GZUJ ID DM4GZUJ
DM4GZUJ DN Cysteine Sulfenic Acid
DM4GZUJ HS Investigative
DM4GZUJ SN S-Hydroxycysteine; s-hydroxy-l-cysteine; Cysteinesulfenic acid; Cys-sulfenic acid; L-cysteinesulfenic acid; UNII-FB8KIA847T; L-Cysteinsulfensaeure; Alanine, 3-sulfeno-; Cys(OH); FB8KIA847T; L-2-amino-3-sulfeno-propionic acid; 5722-80-5; 2-amino-3-hydroxysulfanylpropionic acid; Cysteine-sulfenic acid; L-Alanine, 3-sulfeno-; S-(Propylcarbamoyl)cysteine; AC1Q5QNT; AC1L4WIO; SCHEMBL333356; CHEBI:41710; CTK1H0247; AKOS006339917; DB01915; L-Cysteine, S-[(propylamino)carbonyl]-; 73243-12-6
DM4GZUJ DT Small molecular drug
DM4GZUJ PC 165339
DM4GZUJ MW 137.16
DM4GZUJ FM C3H7NO3S
DM4GZUJ IC InChI=1S/C3H7NO3S/c4-2(1-8-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
DM4GZUJ CS C([C@@H](C(=O)O)N)SO
DM4GZUJ IK FXIRVRPOOYSARH-REOHCLBHSA-N
DM4GZUJ IU (2R)-2-amino-3-hydroxysulfanylpropanoic acid
DM4GZUJ CA CAS 5722-80-5
DM4GZUJ CB CHEBI:41710
DMXI8FP ID DMXI8FP
DMXI8FP DN Cysteinesulfonic Acid
DMXI8FP HS Investigative
DMXI8FP SN Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889
DMXI8FP DT Small molecular drug
DMXI8FP PC 72886
DMXI8FP MW 169.16
DMXI8FP FM C3H7NO5S
DMXI8FP IC InChI=1S/C3H7NO5S/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)/t2-/m0/s1
DMXI8FP CS C([C@@H](C(=O)O)N)S(=O)(=O)O
DMXI8FP IK XVOYSCVBGLVSOL-REOHCLBHSA-N
DMXI8FP IU (2R)-2-amino-3-sulfopropanoic acid
DMXI8FP CA CAS 498-40-8
DMXI8FP CB CHEBI:17285
DMXI8FP DE Discovery agent
DMK0W8E ID DMK0W8E
DMK0W8E DN Cytidine
DMK0W8E HS Investigative
DMK0W8E SN cytidine; 65-46-3; Cytosine riboside; 1-beta-D-Ribofuranosylcytosine; 4-Amino-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone; 1beta-Ribofuranosylcytosine; beta-D-Ribofuranoside, cytosine-1; 1-beta-Ribofuranosylcytosine; Zytidin; Cytidin; 4-Amino-1beta-D-ribofuranosyl-2(1H)-pyrimidinone; Cytosine, 1-beta-D-ribofuranosyl-; 1beta-2'-Ribofuranosylcytosine, d-; UNII-5CSZ8459RP; NSC 20258; Cyd; CHEBI:17562; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-ribofuranosyl-; EINECS 200-610-9; 2(1H)-Pyrimidinone, 4-amino-1beta-D-ribofuranosyl-
DMK0W8E DT Small molecular drug
DMK0W8E PC 6175
DMK0W8E MW 243.22
DMK0W8E FM C9H13N3O5
DMK0W8E IC InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1
DMK0W8E CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
DMK0W8E IK UHDGCWIWMRVCDJ-XVFCMESISA-N
DMK0W8E IU 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
DMK0W8E CA CAS 65-46-3
DMK0W8E CB CHEBI:17562
DMK0W8E DE Discovery agent
DMA5FGS ID DMA5FGS
DMA5FGS DN Cytidine-5'-Diphosphate
DMA5FGS HS Investigative
DMA5FGS SN CDP trianion; cytidine 5'-diphosphate(2-); cytidine 5'-pyrophosphate(2-); CHEBI:58069; CDP(3-); 5'-O-[(phosphonatooxy)phosphinato]cytidine; A834354; [[(2R,3S,4R,5R)-5-(4-azanyl-2-oxidanylidene-pyrimidin-1-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanidyl-phosphoryl] phosphate; [[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]methoxy-oxidophosphoryl] phosphate
DMA5FGS DT Small molecular drug
DMA5FGS PC 6132
DMA5FGS MW 403.18
DMA5FGS FM C9H15N3O11P2
DMA5FGS IC InChI=1S/C9H15N3O11P2/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(22-8)3-21-25(19,20)23-24(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DMA5FGS CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O
DMA5FGS IK ZWIADYZPOWUWEW-XVFCMESISA-N
DMA5FGS IU [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMA5FGS CA CAS 63-38-7
DMA5FGS CB CHEBI:17239
DMA5FGS DE Discovery agent
DM6PAXD ID DM6PAXD
DM6PAXD DN Cytidine-5'-Monophosphate
DM6PAXD HS Investigative
DM6PAXD SN cytidine-monophosphate; CMP dianion; AC1OEJZP; CMP; 5'-O-phosphonatocytidine; cytidine 5'-monophosphate(2-); Cytidine-5-monophosphate dianion; CHEBI:60377; CMP(2-); CJ-10966; LS-190174; A834351; [(2R,3S,4R,5R)-5-(4-amino-2-oxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]methyl phosphate; [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate; [(2R,3S,4R,5R)-5-(4-azanyl-2-oxidanylidene-pyrimidin-1-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methyl phosphate
DM6PAXD DT Small molecular drug
DM6PAXD PC 6131
DM6PAXD MW 323.2
DM6PAXD FM C9H14N3O8P
DM6PAXD IC InChI=1S/C9H14N3O8P/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1
DM6PAXD CS C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DM6PAXD IK IERHLVCPSMICTF-XVFCMESISA-N
DM6PAXD IU [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM6PAXD CA CAS 63-37-6
DM6PAXD CB CHEBI:17361
DM6PAXD DE Discovery agent
DMPT4WM ID DMPT4WM
DMPT4WM DN Cytosine Arabinose-5'-Phosphate
DMPT4WM HS Investigative
DMPT4WM SN 7075-11-8; Ara-5'-CMP; Ara-CMP; Cytarabine 5'-monophosphate; ((2R,3S,4S,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; CYTOSINE ARABINOSE-5'-PHOSPHATE; AraCMP; Cytosine arabinoside monophosphate; Aracytidine 5'-phosphate; Cytosine arabinoside 5'MP; Aracytidine 5'-monophosphate; UNII-Y73692GHI4; Y73692GHI4; NSC 99445; 1-beta-D-Arabinofuranosylcytosine 5'-phosphate; Cytosine-beta-D-arabinofuranoside-5'-monophosphate; Cytosine beta-D-arabinofuranoside 5'-monophosphate
DMPT4WM DT Small molecular drug
DMPT4WM PC 65177
DMPT4WM MW 323.2
DMPT4WM FM C9H14N3O8P
DMPT4WM IC InChI=1S/C9H14N3O8P/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/t4-,6-,7+,8-/m1/s1
DMPT4WM CS C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O
DMPT4WM IK IERHLVCPSMICTF-CCXZUQQUSA-N
DMPT4WM IU [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMPT4WM CA CAS 7075-11-8
DMPT4WM DE Discovery agent
DM7SVLZ ID DM7SVLZ
DM7SVLZ DN Cytotoxin Peptide Conjugate
DM7SVLZ HS Investigative
DM7SVLZ DE Discovery agent
DMLBYFG ID DMLBYFG
DMLBYFG DN CZC 24832
DMLBYFG HS Investigative
DMLBYFG SN CZC24832; CZC-24832
DMLBYFG DT Small molecular drug
DMLBYFG PC 42623951
DMLBYFG MW 364.4
DMLBYFG FM C15H17FN6O2S
DMLBYFG IC InChI=1S/C15H17FN6O2S/c1-15(2,3)21-25(23,24)11-4-9(6-18-7-11)10-5-12(16)13-19-14(17)20-22(13)8-10/h4-8,21H,1-3H3,(H2,17,20)
DMLBYFG CS CC(C)(C)NS(=O)(=O)C1=CN=CC(=C1)C2=CN3C(=NC(=N3)N)C(=C2)F
DMLBYFG IK RXRZPHQBTHQXSV-UHFFFAOYSA-N
DMLBYFG IU 5-(2-amino-8-fluoro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-tert-butylpyridine-3-sulfonamide
DMLBYFG CA CAS 1159824-67-5
DMLBYFG DE Discovery agent
DMYBL5G ID DMYBL5G
DMYBL5G DN CZC-19091
DMYBL5G HS Investigative
DMYBL5G SN PI3K gamma inhibitors (inflammation); PI3K gamma inhibitors (inflammation), Cellzome
DMYBL5G CP Cellzome
DMYBL5G DE Inflammation
DM1E5C4 ID DM1E5C4
DM1E5C4 DN D 2343
DM1E5C4 HS Investigative
DM1E5C4 SN D-2343; AC1OCEM5; SCHEMBL11327703; 4-[1-hydroxy-2-[[4-(2-methoxyphenyl)-2-methylbutan-2-yl]amino]ethyl]phenol hydrochloride
DM1E5C4 DT Small molecular drug
DM1E5C4 PC 166295
DM1E5C4 MW 329.4
DM1E5C4 FM C20H27NO3
DM1E5C4 IC InChI=1S/C20H27NO3/c1-20(2,13-12-16-6-4-5-7-19(16)24-3)21-14-18(23)15-8-10-17(22)11-9-15/h4-11,18,21-23H,12-14H2,1-3H3
DM1E5C4 CS CC(C)(CCC1=CC=CC=C1OC)NCC(C2=CC=C(C=C2)O)O
DM1E5C4 IK QQNHGKXYJUREIZ-UHFFFAOYSA-N
DM1E5C4 IU 4-[1-hydroxy-2-[[4-(2-methoxyphenyl)-2-methylbutan-2-yl]amino]ethyl]phenol
DM1E5C4 CA CAS 72734-63-5
DM1E5C4 DE Discovery agent
DMAX7LW ID DMAX7LW
DMAX7LW DN d(CH2)5[D-Ile2,Ile4]AVP
DMAX7LW HS Investigative
DMAX7LW SN beta-mercapto-beta,beta,cyclopentamethylenepropionyl[D-Ile2,Ile4]AVP; d(CH2)5[D-Ile2,Ile4]VP
DMAX7LW DT Small molecular drug
DMAX7LW PC 3080966
DMAX7LW MW 1072.4
DMAX7LW FM C49H77N13O10S2
DMAX7LW IC InChI=1S/C49H77N13O10S2/c1-5-27(3)40(60-39(65)23-30-16-10-11-19-36(30)74)46(70)57-32(22-29-14-8-7-9-15-29)44(68)61-41(28(4)6-2)47(71)58-33(24-37(50)63)43(67)59-34(26-73)48(72)62-21-13-18-35(62)45(69)56-31(17-12-20-54-49(52)53)42(66)55-25-38(51)64/h7-9,14-15,27-28,30-35,40-41,73H,5-6,10-13,16-26H2,1-4H3,(H2,50,63)(H2,51,64)(H,55,66)(H,56,69)(H,57,70)(H,58,71)(H,59,67)(H,60,65)(H,61,68)(H4,52,53,54)/t27-,28+,30?,31-,32-,33-,34-,35-,40-,41+/m0/s1
DMAX7LW CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)CC3CCCCC3=S
DMAX7LW IK CNWFVLCMGVAHSD-HAEBMLOOSA-N
DMAX7LW IU (2S)-N-[(2R)-1-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylpropan-2-yl]-2-[[(2R,3R)-3-methyl-2-[[(2S)-2-[[(2S,3S)-3-methyl-2-[[2-(2-sulfanylidenecyclohexyl)acetyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]butanediamide
DMAX7LW CA CAS 103529-95-9
DMAX7LW DE Discovery agent
DMVHMGA ID DMVHMGA
DMVHMGA DN D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT
DMVHMGA HS Investigative
DMVHMGA PC 44320911
DMVHMGA MW 1484.7
DMVHMGA FM C73H85N11O19S2
DMVHMGA IC InChI=1S/C73H85N11O19S2/c1-5-37(2)58-66(97)80-59(38(3)85)67(98)78-51(34-56(74)90)64(95)79-52(36-104-105-72(27-7-6-8-28-72)35-57(91)83-71(4,70(101)82-58)41-16-20-43(87)21-17-41)68(99)84-30-10-12-53(84)65(96)77-50(63(94)81-60(61(75)92)39-13-18-42(86)19-14-39)11-9-29-76-62(93)40-15-24-46-49(31-40)73(103-69(46)100)47-25-22-44(88)32-54(47)102-55-33-45(89)23-26-48(55)73/h13-26,31-33,37-38,50-53,58-60,85-89H,5-12,27-30,34-36H2,1-4H3,(H2,74,90)(H2,75,92)(H,76,93)(H,77,96)(H,78,98)(H,79,95)(H,80,97)(H,81,94)(H,82,101)(H,83,91)/t37?,38?,50-,51+,52+,53+,58+,59+,60-,71+/m0/s1
DMVHMGA CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC2(CCCCC2)CC(=O)N[C@](C(=O)N1)(C)C3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCNC(=O)C5=CC6=C(C=C5)C(=O)OC67C8=C(C=C(C=C8)O)OC9=C7C=CC(=C9)O)C(=O)N[C@@H](C1=CC=C(C=C1)O)C(=O)N)CC(=O)N)C(C)O
DMVHMGA IK BBABDJYQAOTGDM-JEIVZFIASA-N
DMVHMGA IU (2R)-N-[(2S)-1-[[(1S)-2-amino-1-(4-hydroxyphenyl)-2-oxoethyl]amino]-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(10S,13R,16R,19R,22R)-13-(2-amino-2-oxoethyl)-19-butan-2-yl-16-(1-hydroxyethyl)-22-(4-hydroxyphenyl)-22-methyl-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
DMVHMGA DE Discovery agent
DM1BMT7 ID DM1BMT7
DM1BMT7 DN D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT
DM1BMT7 HS Investigative
DM1BMT7 PC 44320910
DM1BMT7 MW 1126.4
DM1BMT7 FM C52H75N11O13S2
DM1BMT7 IC InChI=1S/C52H75N11O13S2/c1-5-28(2)40-47(73)59-41(29(3)64)48(74)57-35(25-38(54)67)45(71)58-36(27-77-78-52(21-7-6-8-22-52)26-39(68)62-51(4,50(76)61-40)31-15-19-33(66)20-16-31)49(75)63-24-10-12-37(63)46(72)56-34(11-9-23-53)44(70)60-42(43(55)69)30-13-17-32(65)18-14-30/h13-20,28-29,34-37,40-42,64-66H,5-12,21-27,53H2,1-4H3,(H2,54,67)(H2,55,69)(H,56,72)(H,57,74)(H,58,71)(H,59,73)(H,60,70)(H,61,76)(H,62,68)/t28?,29?,34-,35+,36+,37+,40+,41+,42-,51+/m0/s1
DM1BMT7 CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC2(CCCCC2)CC(=O)N[C@](C(=O)N1)(C)C3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCN)C(=O)N[C@@H](C5=CC=C(C=C5)O)C(=O)N)CC(=O)N)C(C)O
DM1BMT7 IK MRGPBAZYRUEDDT-YHXQAOAKSA-N
DM1BMT7 IU (2R)-N-[(2S)-5-amino-1-[[(1S)-2-amino-1-(4-hydroxyphenyl)-2-oxoethyl]amino]-1-oxopentan-2-yl]-1-[(10S,13R,16R,19R,22R)-13-(2-amino-2-oxoethyl)-19-butan-2-yl-16-(1-hydroxyethyl)-22-(4-hydroxyphenyl)-22-methyl-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
DM1BMT7 DE Discovery agent
DMHTSAX ID DMHTSAX
DMHTSAX DN d(CH2)5[Tyr(Me)2]AVP
DMHTSAX HS Investigative
DMHTSAX SN Pmp[Tyr(Me)2]AVP; SKF-100273; d(CH2)5[O-methyl-Tyr2]AVP
DMHTSAX DT Small molecular drug
DMHTSAX PC 6917952
DMHTSAX MW 1151.4
DMHTSAX FM C52H74N14O12S2
DMHTSAX IC InChI=1S/C52H74N14O12S2/c1-78-32-16-14-31(15-17-32)25-35-46(73)63-36(24-30-10-4-2-5-11-30)47(74)61-34(18-19-40(53)67)45(72)64-37(26-41(54)68)48(75)65-38(29-79-80-52(27-43(70)60-35)20-6-3-7-21-52)50(77)66-23-9-13-39(66)49(76)62-33(12-8-22-58-51(56)57)44(71)59-28-42(55)69/h2,4-5,10-11,14-17,33-39H,3,6-9,12-13,18-29H2,1H3,(H2,53,67)(H2,54,68)(H2,55,69)(H,59,71)(H,60,70)(H,61,74)(H,62,76)(H,63,73)(H,64,72)(H,65,75)(H4,56,57,58)/t33-,34-,35+,36-,37-,38-,39+/m0/s1
DMHTSAX CS COC1=CC=C(C=C1)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC3(CCCCC3)CC(=O)N2)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC5=CC=CC=C5
DMHTSAX IK QVQOGNOOAMQKCE-OVSZNHMYSA-N
DMHTSAX IU (2R)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(10R,13S,16S,19S,22R)-13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-benzyl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
DMHTSAX DE Discovery agent
DMCU8HK ID DMCU8HK
DMCU8HK DN D[Arg4,Dab8]VP
DMCU8HK HS Investigative
DMCU8HK SN CHEMBL385739; d[Arg4,Dab8]VP
DMCU8HK PC 16109443
DMCU8HK MW 1041.2
DMCU8HK FM C45H64N14O11S2
DMCU8HK IC InChI=1S/C45H64N14O11S2/c46-16-14-29(38(64)52-23-36(48)62)55-43(69)34-9-5-18-59(34)44(70)33-24-72-71-19-15-37(63)53-30(21-26-10-12-27(60)13-11-26)40(66)56-31(20-25-6-2-1-3-7-25)41(67)54-28(8-4-17-51-45(49)50)39(65)57-32(22-35(47)61)42(68)58-33/h1-3,6-7,10-13,28-34,60H,4-5,8-9,14-24,46H2,(H2,47,61)(H2,48,62)(H,52,64)(H,53,63)(H,54,67)(H,55,69)(H,56,66)(H,57,65)(H,58,68)(H4,49,50,51)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
DMCU8HK CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCN)C(=O)NCC(=O)N
DMCU8HK IK JTUSVVYBCYZYRH-NXBWRCJVSA-N
DMCU8HK IU (2S)-N-[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxobutan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMCU8HK DE Discovery agent
DM69OVM ID DM69OVM
DM69OVM DN D[Arg4,Lys8]VP
DM69OVM HS Investigative
DM69OVM SN CHEMBL375325; d[Arg4,Lys8]VP
DM69OVM PC 16109442
DM69OVM MW 1069.3
DM69OVM FM C47H68N14O11S2
DM69OVM IC InChI=1S/C47H68N14O11S2/c48-18-5-4-10-30(40(66)54-25-38(50)64)57-45(71)36-12-7-20-61(36)46(72)35-26-74-73-21-17-39(65)55-32(23-28-13-15-29(62)16-14-28)42(68)58-33(22-27-8-2-1-3-9-27)43(69)56-31(11-6-19-53-47(51)52)41(67)59-34(24-37(49)63)44(70)60-35/h1-3,8-9,13-16,30-36,62H,4-7,10-12,17-26,48H2,(H2,49,63)(H2,50,64)(H,54,66)(H,55,65)(H,56,69)(H,57,71)(H,58,68)(H,59,67)(H,60,70)(H4,51,52,53)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DM69OVM CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DM69OVM IK KYQCNVIVUUQTRA-QJCLFNHPSA-N
DM69OVM IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM69OVM DE Discovery agent
DM8D4QT ID DM8D4QT
DM8D4QT DN D[Arg4,Orn8]VP
DM8D4QT HS Investigative
DM8D4QT SN CHEMBL385068; d[Arg4,Orn8]VP
DM8D4QT PC 16109448
DM8D4QT MW 1055.2
DM8D4QT FM C46H66N14O11S2
DM8D4QT IC InChI=1S/C46H66N14O11S2/c47-17-4-9-29(39(65)53-24-37(49)63)56-44(70)35-11-6-19-60(35)45(71)34-25-73-72-20-16-38(64)54-31(22-27-12-14-28(61)15-13-27)41(67)57-32(21-26-7-2-1-3-8-26)42(68)55-30(10-5-18-52-46(50)51)40(66)58-33(23-36(48)62)43(69)59-34/h1-3,7-8,12-15,29-35,61H,4-6,9-11,16-25,47H2,(H2,48,62)(H2,49,63)(H,53,65)(H,54,64)(H,55,68)(H,56,70)(H,57,67)(H,58,66)(H,59,69)(H4,50,51,52)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DM8D4QT CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N
DM8D4QT IK FEMJEHRQGCUGEY-POFDKVPJSA-N
DM8D4QT IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM8D4QT DE Discovery agent
DM76Q2B ID DM76Q2B
DM76Q2B DN D[Arg4]AVP
DM76Q2B HS Investigative
DM76Q2B SN CHEMBL375324; d[Arg4]AVP
DM76Q2B PC 44419039
DM76Q2B MW 1097.3
DM76Q2B FM C47H68N16O11S2
DM76Q2B IC InChI=1S/C47H68N16O11S2/c48-36(65)23-33-43(72)62-34(45(74)63-19-6-11-35(63)44(73)59-29(9-4-17-54-46(50)51)39(68)56-24-37(49)66)25-76-75-20-16-38(67)57-31(22-27-12-14-28(64)15-13-27)41(70)60-32(21-26-7-2-1-3-8-26)42(71)58-30(40(69)61-33)10-5-18-55-47(52)53/h1-3,7-8,12-15,29-35,64H,4-6,9-11,16-25H2,(H2,48,65)(H2,49,66)(H,56,68)(H,57,67)(H,58,71)(H,59,73)(H,60,70)(H,61,69)(H,62,72)(H4,50,51,54)(H4,52,53,55)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DM76Q2B CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN=C(N)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DM76Q2B IK NZPQDNABVFGPNI-POFDKVPJSA-N
DM76Q2B IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM76Q2B DE Discovery agent
DMCLUXI ID DMCLUXI
DMCLUXI DN D[Cha4,Dab8]VP
DMCLUXI HS Investigative
DMCLUXI SN CHEMBL412742; d[Cha4,Dab8]VP
DMCLUXI PC 16109444
DMCLUXI MW 1038.2
DMCLUXI FM C48H67N11O11S2
DMCLUXI IC InChI=1S/C48H67N11O11S2/c49-19-17-32(42(64)52-26-40(51)62)54-47(69)38-12-7-20-59(38)48(70)37-27-72-71-21-18-41(63)53-33(24-30-13-15-31(60)16-14-30)43(65)55-34(22-28-8-3-1-4-9-28)44(66)56-35(23-29-10-5-2-6-11-29)45(67)57-36(25-39(50)61)46(68)58-37/h1,3-4,8-9,13-16,29,32-38,60H,2,5-7,10-12,17-27,49H2,(H2,50,61)(H2,51,62)(H,52,64)(H,53,63)(H,54,69)(H,55,65)(H,56,66)(H,57,67)(H,58,68)/t32-,33-,34-,35-,36-,37-,38-/m0/s1
DMCLUXI CS C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCN)C(=O)NCC(=O)N)CC(=O)N
DMCLUXI IK DPVYQFBOSXXNLG-CXWHUAPYSA-N
DMCLUXI IU (2S)-N-[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxobutan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMCLUXI DE Discovery agent
DMAPZKB ID DMAPZKB
DMAPZKB DN D[Cha4,Dap8]VP
DMAPZKB HS Investigative
DMAPZKB SN CHEMBL375187; d[Cha4,Dap8]VP
DMAPZKB PC 16109439
DMAPZKB MW 1024.2
DMAPZKB FM C47H65N11O11S2
DMAPZKB IC InChI=1S/C47H65N11O11S2/c48-24-35(41(63)51-25-39(50)61)56-46(68)37-12-7-18-58(37)47(69)36-26-71-70-19-17-40(62)52-31(22-29-13-15-30(59)16-14-29)42(64)53-32(20-27-8-3-1-4-9-27)43(65)54-33(21-28-10-5-2-6-11-28)44(66)55-34(23-38(49)60)45(67)57-36/h1,3-4,8-9,13-16,28,31-37,59H,2,5-7,10-12,17-26,48H2,(H2,49,60)(H2,50,61)(H,51,63)(H,52,62)(H,53,64)(H,54,65)(H,55,66)(H,56,68)(H,57,67)/t31-,32-,33-,34-,35-,36-,37-/m0/s1
DMAPZKB CS C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CN)C(=O)NCC(=O)N)CC(=O)N
DMAPZKB IK XABCPBOFMBSCDK-PEAOEFARSA-N
DMAPZKB IU (2S)-N-[(2S)-3-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMAPZKB DE Discovery agent
DM0GO7U ID DM0GO7U
DM0GO7U DN D[Cha4,Lys8]VP
DM0GO7U HS Investigative
DM0GO7U SN CHEMBL221485; d[Cha4,Lys8]VP
DM0GO7U PC 16109437
DM0GO7U MW 1066.3
DM0GO7U FM C50H71N11O11S2
DM0GO7U IC InChI=1S/C50H71N11O11S2/c51-21-8-7-14-34(44(66)54-28-42(53)64)56-49(71)40-15-9-22-61(40)50(72)39-29-74-73-23-20-43(65)55-35(26-32-16-18-33(62)19-17-32)45(67)57-36(24-30-10-3-1-4-11-30)46(68)58-37(25-31-12-5-2-6-13-31)47(69)59-38(27-41(52)63)48(70)60-39/h1,3-4,10-11,16-19,31,34-40,62H,2,5-9,12-15,20-29,51H2,(H2,52,63)(H2,53,64)(H,54,66)(H,55,65)(H,56,71)(H,57,67)(H,58,68)(H,59,69)(H,60,70)/t34-,35-,36-,37-,38-,39-,40-/m0/s1
DM0GO7U CS C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N)CC(=O)N
DM0GO7U IK RJWLIPGRNZUUNS-OAKHNGAUSA-N
DM0GO7U IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM0GO7U DE Discovery agent
DMZWTJK ID DMZWTJK
DMZWTJK DN D[Cha4,Orn8]VP
DMZWTJK HS Investigative
DMZWTJK SN CHEMBL263090; d[Cha4,Orn8]VP
DMZWTJK PC 16109438
DMZWTJK MW 1052.3
DMZWTJK FM C49H69N11O11S2
DMZWTJK IC InChI=1S/C49H69N11O11S2/c50-20-7-13-33(43(65)53-27-41(52)63)55-48(70)39-14-8-21-60(39)49(71)38-28-73-72-22-19-42(64)54-34(25-31-15-17-32(61)18-16-31)44(66)56-35(23-29-9-3-1-4-10-29)45(67)57-36(24-30-11-5-2-6-12-30)46(68)58-37(26-40(51)62)47(69)59-38/h1,3-4,9-10,15-18,30,33-39,61H,2,5-8,11-14,19-28,50H2,(H2,51,62)(H2,52,63)(H,53,65)(H,54,64)(H,55,70)(H,56,66)(H,57,67)(H,58,68)(H,59,69)/t33-,34-,35-,36-,37-,38-,39-/m0/s1
DMZWTJK CS C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N
DMZWTJK IK CADGMGWLZUBCQD-ZTYVOHGWSA-N
DMZWTJK IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMZWTJK DE Discovery agent
DM8FCX5 ID DM8FCX5
DM8FCX5 DN D[Cha4]AVP
DM8FCX5 HS Investigative
DM8FCX5 SN d[Cha4]AVP; CHEMBL265858; BDBM50205312
DM8FCX5 PC 44419028
DM8FCX5 MW 1094.3
DM8FCX5 FM C50H71N13O11S2
DM8FCX5 IC InChI=1S/C50H71N13O11S2/c51-40(65)26-37-47(72)62-38(49(74)63-21-8-14-39(63)48(73)58-33(13-7-20-55-50(53)54)43(68)56-27-41(52)66)28-76-75-22-19-42(67)57-34(25-31-15-17-32(64)18-16-31)44(69)59-35(23-29-9-3-1-4-10-29)45(70)60-36(46(71)61-37)24-30-11-5-2-6-12-30/h1,3-4,9-10,15-18,30,33-39,64H,2,5-8,11-14,19-28H2,(H2,51,65)(H2,52,66)(H,56,68)(H,57,67)(H,58,73)(H,59,69)(H,60,70)(H,61,71)(H,62,72)(H4,53,54,55)/t33-,34-,35-,36-,37-,38-,39-/m0/s1
DM8FCX5 CS C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DM8FCX5 IK ZKYCVZNKBXGNEK-ZTYVOHGWSA-N
DM8FCX5 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-10-(cyclohexylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM8FCX5 DE Discovery agent
DMD4V6U ID DMD4V6U
DMD4V6U DN D[D-3-Pal2]AVP
DMD4V6U HS Investigative
DMD4V6U SN CHEMBL414074; 136105-89-0; D3PVP; d[D-3-Pal2]AVP; [deamino-Cys1, D-3-Pyridyl-Ala2, Arg8]-Vasopressin; (Deamino-Cys1,b-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin; MFCD00214667
DMD4V6U PC 44419027
DMD4V6U MW 1054.2
DMD4V6U FM C45H63N15O11S2
DMD4V6U IC InChI=1S/C45H63N15O11S2/c46-34(61)13-12-28-39(66)58-31(21-35(47)62)42(69)59-32(44(71)60-17-6-11-33(60)43(70)56-27(10-5-16-52-45(49)50)38(65)53-23-36(48)63)24-73-72-18-14-37(64)54-29(20-26-9-4-15-51-22-26)40(67)57-30(41(68)55-28)19-25-7-2-1-3-8-25/h1-4,7-9,15,22,27-33H,5-6,10-14,16-21,23-24H2,(H2,46,61)(H2,47,62)(H2,48,63)(H,53,65)(H,54,64)(H,55,68)(H,56,70)(H,57,67)(H,58,66)(H,59,69)(H4,49,50,52)/t27-,28-,29+,30-,31-,32-,33-/m0/s1
DMD4V6U CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CN=CC=C4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMD4V6U IK KEAHYTRPVNOHKL-ZHFJCBJKSA-N
DMD4V6U IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-6,9,12,15,18-pentaoxo-16-(pyridin-3-ylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMD4V6U DE Discovery agent
DMNSXG9 ID DMNSXG9
DMNSXG9 DN D[Leu4,Dab8]VP
DMNSXG9 HS Investigative
DMNSXG9 SN CHEMBL412973; d[Leu4,Dab8]VP
DMNSXG9 DT Small molecular drug
DMNSXG9 PC 16109440
DMNSXG9 MW 998.2
DMNSXG9 FM C45H63N11O11S2
DMNSXG9 IC InChI=1S/C45H63N11O11S2/c1-25(2)19-30-40(62)54-33(22-36(47)58)43(65)55-34(45(67)56-17-6-9-35(56)44(66)51-29(14-16-46)39(61)49-23-37(48)59)24-69-68-18-15-38(60)50-31(21-27-10-12-28(57)13-11-27)41(63)53-32(42(64)52-30)20-26-7-4-3-5-8-26/h3-5,7-8,10-13,25,29-35,57H,6,9,14-24,46H2,1-2H3,(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,64)(H,53,63)(H,54,62)(H,55,65)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DMNSXG9 CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCN)C(=O)NCC(=O)N)CC(=O)N
DMNSXG9 IK VIYXBPSZIAMFAA-POFDKVPJSA-N
DMNSXG9 IU (2S)-N-[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxobutan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMNSXG9 DE Discovery agent
DME3HK8 ID DME3HK8
DME3HK8 DN D[Leu4,Dap8]VP
DME3HK8 HS Investigative
DME3HK8 SN CHEMBL373968; d[Leu4,Dap8]VP
DME3HK8 DT Small molecular drug
DME3HK8 PC 16109446
DME3HK8 MW 984.2
DME3HK8 FM C44H61N11O11S2
DME3HK8 IC InChI=1S/C44H61N11O11S2/c1-24(2)17-28-39(61)52-31(20-35(46)57)42(64)54-33(44(66)55-15-6-9-34(55)43(65)53-32(21-45)38(60)48-22-36(47)58)23-68-67-16-14-37(59)49-29(19-26-10-12-27(56)13-11-26)40(62)51-30(41(63)50-28)18-25-7-4-3-5-8-25/h3-5,7-8,10-13,24,28-34,56H,6,9,14-23,45H2,1-2H3,(H2,46,57)(H2,47,58)(H,48,60)(H,49,59)(H,50,63)(H,51,62)(H,52,61)(H,53,65)(H,54,64)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
DME3HK8 CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CN)C(=O)NCC(=O)N)CC(=O)N
DME3HK8 IK ZAOGZAMKKBQERK-NXBWRCJVSA-N
DME3HK8 IU (2S)-N-[(2S)-3-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopropan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DME3HK8 DE Discovery agent
DMDBU7Q ID DMDBU7Q
DMDBU7Q DN D[Leu4,Lys8]VP
DMDBU7Q HS Investigative
DMDBU7Q SN 42061-33-6; CHEMBL412972; d[Leu4,Lys8]-VP; d[Leu4,Lys8]VP; 1-Deamino-4-leu-8-lys-vasopressin; Vasopressin, 1-deamino-leu(4)-lys(8)-; Vasopressin, 1-deamino-leucyl(4)-lysine(8)-; BDBM50205309; AKOS024457446; (Deamino-Cys1,Leu4,Lys8)-Vasopressin; Vasopressin, 1-(3-mercaptopropanoic acid)-4-L-leucine-8-L-lysine-
DMDBU7Q PC 44419030
DMDBU7Q MW 1026.2
DMDBU7Q FM C47H67N11O11S2
DMDBU7Q IC InChI=1S/C47H67N11O11S2/c1-27(2)21-32-42(64)56-35(24-38(49)60)45(67)57-36(47(69)58-19-8-12-37(58)46(68)53-31(11-6-7-18-48)41(63)51-25-39(50)61)26-71-70-20-17-40(62)52-33(23-29-13-15-30(59)16-14-29)43(65)55-34(44(66)54-32)22-28-9-4-3-5-10-28/h3-5,9-10,13-16,27,31-37,59H,6-8,11-12,17-26,48H2,1-2H3,(H2,49,60)(H2,50,61)(H,51,63)(H,52,62)(H,53,68)(H,54,66)(H,55,65)(H,56,64)(H,57,67)/t31-,32-,33-,34-,35-,36-,37-/m0/s1
DMDBU7Q CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N)CC(=O)N
DMDBU7Q IK QGZMLGLFLYCDQT-PEAOEFARSA-N
DMDBU7Q IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMDBU7Q CA CAS 42061-33-6
DMDBU7Q DE Discovery agent
DMJCW8Y ID DMJCW8Y
DMJCW8Y DN D[Leu4,Orn8]VP
DMJCW8Y HS Investigative
DMJCW8Y SN CHEMBL375188; d[Leu4,Orn8]VP
DMJCW8Y PC 16109445
DMJCW8Y MW 1012.2
DMJCW8Y FM C46H65N11O11S2
DMJCW8Y IC InChI=1S/C46H65N11O11S2/c1-26(2)20-31-41(63)55-34(23-37(48)59)44(66)56-35(46(68)57-18-7-11-36(57)45(67)52-30(10-6-17-47)40(62)50-24-38(49)60)25-70-69-19-16-39(61)51-32(22-28-12-14-29(58)15-13-28)42(64)54-33(43(65)53-31)21-27-8-4-3-5-9-27/h3-5,8-9,12-15,26,30-36,58H,6-7,10-11,16-25,47H2,1-2H3,(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,67)(H,53,65)(H,54,64)(H,55,63)(H,56,66)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DMJCW8Y CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N
DMJCW8Y IK FVVIZMMVAAKOOP-QJCLFNHPSA-N
DMJCW8Y IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMJCW8Y DE Discovery agent
DMREZT7 ID DMREZT7
DMREZT7 DN D[Leu4]AVP
DMREZT7 HS Investigative
DMREZT7 SN CHEMBL265859; d[Leu4]AVP
DMREZT7 PC 44419029
DMREZT7 MW 1054.3
DMREZT7 FM C47H67N13O11S2
DMREZT7 IC InChI=1S/C47H67N13O11S2/c1-26(2)20-31-41(66)58-34(23-37(48)62)44(69)59-35(46(71)60-18-7-11-36(60)45(70)55-30(10-6-17-52-47(50)51)40(65)53-24-38(49)63)25-73-72-19-16-39(64)54-32(22-28-12-14-29(61)15-13-28)42(67)57-33(43(68)56-31)21-27-8-4-3-5-9-27/h3-5,8-9,12-15,26,30-36,61H,6-7,10-11,16-25H2,1-2H3,(H2,48,62)(H2,49,63)(H,53,65)(H,54,64)(H,55,70)(H,56,68)(H,57,67)(H,58,66)(H,59,69)(H4,50,51,52)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DMREZT7 CS CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DMREZT7 IK CYOLRNSRVHAZDY-QJCLFNHPSA-N
DMREZT7 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-10-(2-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMREZT7 DE Discovery agent
DME2PKB ID DME2PKB
DME2PKB DN D[Lys8(5/6-Flu)]VT
DME2PKB HS Investigative
DME2PKB PC 44320997
DME2PKB MW 1323.5
DME2PKB FM C62H74N12O17S2
DME2PKB IC InChI=1S/C62H74N12O17S2/c1-3-31(2)51-58(86)69-42(19-20-48(64)78)55(83)70-43(28-49(65)79)56(84)71-44(29-93-92-24-21-50(80)72-52(59(87)73-51)32-9-12-34(75)13-10-32)60(88)74-23-6-8-45(74)57(85)68-41(54(82)67-30-63)7-4-5-22-66-53(81)33-11-16-37-40(25-33)62(91-61(37)89)38-17-14-35(76)26-46(38)90-47-27-36(77)15-18-39(47)62/h9-18,25-27,31,41-45,51-52,75-77H,3-8,19-24,28-30,63H2,1-2H3,(H2,64,78)(H2,65,79)(H,66,81)(H,67,82)(H,68,85)(H,69,86)(H,70,83)(H,71,84)(H,72,80)(H,73,87)/t31?,41-,42+,43+,44+,45+,51+,52-/m0/s1
DME2PKB CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DME2PKB IK OXFDSXJSRLFTMF-NRQFMKBZSA-N
DME2PKB IU (2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DME2PKB DE Discovery agent
DMNQTBU ID DMNQTBU
DMNQTBU DN D[Orn4,Lys8]VP
DMNQTBU HS Investigative
DMNQTBU SN CHEMBL375323; d[Orn4,Lys8]VP
DMNQTBU PC 16109441
DMNQTBU MW 1027.2
DMNQTBU FM C46H66N12O11S2
DMNQTBU IC InChI=1S/C46H66N12O11S2/c47-18-5-4-10-30(40(63)51-25-38(50)61)54-45(68)36-12-7-20-58(36)46(69)35-26-71-70-21-17-39(62)52-32(23-28-13-15-29(59)16-14-28)42(65)55-33(22-27-8-2-1-3-9-27)43(66)53-31(11-6-19-48)41(64)56-34(24-37(49)60)44(67)57-35/h1-3,8-9,13-16,30-36,59H,4-7,10-12,17-26,47-48H2,(H2,49,60)(H2,50,61)(H,51,63)(H,52,62)(H,53,66)(H,54,68)(H,55,65)(H,56,64)(H,57,67)/t30-,31-,32-,33-,34-,35-,36-/m0/s1
DMNQTBU CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
DMNQTBU IK MYTIGVSAVZNLKG-QJCLFNHPSA-N
DMNQTBU IU (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-aminopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMNQTBU DE Discovery agent
DMONV0M ID DMONV0M
DMONV0M DN D[Orn4,Orn8]VP
DMONV0M HS Investigative
DMONV0M SN CHEMBL219272; d[Orn4,Orn8]VP
DMONV0M PC 16109447
DMONV0M MW 1013.2
DMONV0M FM C45H64N12O11S2
DMONV0M IC InChI=1S/C45H64N12O11S2/c46-17-4-9-29(39(62)50-24-37(49)60)53-44(67)35-11-6-19-57(35)45(68)34-25-70-69-20-16-38(61)51-31(22-27-12-14-28(58)15-13-27)41(64)54-32(21-26-7-2-1-3-8-26)42(65)52-30(10-5-18-47)40(63)55-33(23-36(48)59)43(66)56-34/h1-3,7-8,12-15,29-35,58H,4-6,9-11,16-25,46-47H2,(H2,48,59)(H2,49,60)(H,50,62)(H,51,61)(H,52,65)(H,53,67)(H,54,64)(H,55,63)(H,56,66)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DMONV0M CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N
DMONV0M IK NLYHQDXERCUYHP-POFDKVPJSA-N
DMONV0M IU (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-aminopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMONV0M DE Discovery agent
DMJNT95 ID DMJNT95
DMJNT95 DN D[Orn4]AVP
DMJNT95 HS Investigative
DMJNT95 SN CHEMBL375096; d[Orn4]AVP
DMJNT95 PC 11366713
DMJNT95 MW 1055.2
DMJNT95 FM C46H66N14O11S2
DMJNT95 IC InChI=1S/C46H66N14O11S2/c47-17-4-9-30-40(66)58-33(23-36(48)62)43(69)59-34(45(71)60-19-6-11-35(60)44(70)56-29(10-5-18-52-46(50)51)39(65)53-24-37(49)63)25-73-72-20-16-38(64)54-31(22-27-12-14-28(61)15-13-27)41(67)57-32(42(68)55-30)21-26-7-2-1-3-8-26/h1-3,7-8,12-15,29-35,61H,4-6,9-11,16-25,47H2,(H2,48,62)(H2,49,63)(H,53,65)(H,54,64)(H,55,68)(H,56,70)(H,57,67)(H,58,66)(H,59,69)(H4,50,51,52)/t29-,30-,31-,32-,33-,34-,35-/m0/s1
DMJNT95 CS C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCCN)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N
DMJNT95 IK HBVZQPKQFUSYKR-POFDKVPJSA-N
DMJNT95 IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-aminopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMJNT95 DE Discovery agent
DMH791N ID DMH791N
DMH791N DN D[Orn8(5/6C-Flu)]VT
DMH791N HS Investigative
DMH791N PC 44321042
DMH791N MW 1309.4
DMH791N FM C61H72N12O17S2
DMH791N IC InChI=1S/C61H72N12O17S2/c1-3-30(2)50-57(85)68-41(18-19-47(63)77)54(82)69-42(27-48(64)78)55(83)70-43(28-92-91-23-20-49(79)71-51(58(86)72-50)31-8-11-33(74)12-9-31)59(87)73-22-5-7-44(73)56(84)67-40(53(81)66-29-62)6-4-21-65-52(80)32-10-15-36-39(24-32)61(90-60(36)88)37-16-13-34(75)25-45(37)89-46-26-35(76)14-17-38(46)61/h8-17,24-26,30,40-44,50-51,74-76H,3-7,18-23,27-29,62H2,1-2H3,(H2,63,77)(H2,64,78)(H,65,80)(H,66,81)(H,67,84)(H,68,85)(H,69,82)(H,70,83)(H,71,79)(H,72,86)/t30?,40-,41+,42+,43+,44+,50+,51-/m0/s1
DMH791N CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)CCC(=O)N
DMH791N IK JOVDCZXVGAWIKQ-VUINKVIFSA-N
DMH791N IU (2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-butan-2-yl-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMH791N DE Discovery agent
DMT8KI6 ID DMT8KI6
DMT8KI6 DN d[Pen1,Tyr(Me)2]AVP
DMT8KI6 HS Investigative
DMT8KI6 SN 1-deaminopenicillamine-2-(O-methyl-tyr)-argipressin; dPTyr(Me)AVP
DMT8KI6 DT Small molecular drug
DMT8KI6 PC 119517
DMT8KI6 MW 1111.3
DMT8KI6 FM C49H70N14O12S2
DMT8KI6 IC InChI=1S/C49H70N14O12S2/c1-49(2)24-40(67)57-32(22-28-13-15-29(75-3)16-14-28)43(70)60-33(21-27-9-5-4-6-10-27)44(71)58-31(17-18-37(50)64)42(69)61-34(23-38(51)65)45(72)62-35(26-76-77-49)47(74)63-20-8-12-36(63)46(73)59-30(11-7-19-55-48(53)54)41(68)56-25-39(52)66/h4-6,9-10,13-16,30-36H,7-8,11-12,17-26H2,1-3H3,(H2,50,64)(H2,51,65)(H2,52,66)(H,56,68)(H,57,67)(H,58,71)(H,59,73)(H,60,70)(H,61,69)(H,62,72)(H4,53,54,55)
DMT8KI6 CS CC1(CC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSS1)C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)OC)C
DMT8KI6 IK HNOGCDKPALYUIG-UHFFFAOYSA-N
DMT8KI6 IU N-[1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-methoxyphenyl)methyl]-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMT8KI6 CA CAS 67269-08-3
DMT8KI6 DE Discovery agent
DMS4F8O ID DMS4F8O
DMS4F8O DN D[Thr4,Lys8(5/6C-Flu)]VT
DMS4F8O HS Investigative
DMS4F8O PC 44321256
DMS4F8O MW 1296.4
DMS4F8O FM C61H73N11O17S2
DMS4F8O IC InChI=1S/C61H73N11O17S2/c1-4-30(2)49-56(83)71-50(31(3)73)57(84)67-42(27-47(63)77)54(81)68-43(28-91-90-23-20-48(78)69-51(58(85)70-49)32-10-13-34(74)14-11-32)59(86)72-22-7-9-44(72)55(82)66-41(53(80)65-29-62)8-5-6-21-64-52(79)33-12-17-37-40(24-33)61(89-60(37)87)38-18-15-35(75)25-45(38)88-46-26-36(76)16-19-39(46)61/h10-19,24-26,30-31,41-44,49-51,73-76H,4-9,20-23,27-29,62H2,1-3H3,(H2,63,77)(H,64,79)(H,65,80)(H,66,82)(H,67,84)(H,68,81)(H,69,78)(H,70,85)(H,71,83)/t30?,31?,41-,42+,43+,44+,49+,50+,51-/m0/s1
DMS4F8O CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DMS4F8O IK NBPSKZJBUIXUIP-IAPRXICDSA-N
DMS4F8O IU (2R)-N-[(2S)-1-(aminomethylamino)-6-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxohexan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMS4F8O DE Discovery agent
DMBDZQA ID DMBDZQA
DMBDZQA DN D[Thr4,Orn8(5/6C-Flu)]VT
DMBDZQA HS Investigative
DMBDZQA PC 44320890
DMBDZQA MW 1282.4
DMBDZQA FM C60H71N11O17S2
DMBDZQA IC InChI=1S/C60H71N11O17S2/c1-4-29(2)48-55(82)70-49(30(3)72)56(83)66-41(26-46(62)76)53(80)67-42(27-90-89-22-19-47(77)68-50(57(84)69-48)31-9-12-33(73)13-10-31)58(85)71-21-6-8-43(71)54(81)65-40(52(79)64-28-61)7-5-20-63-51(78)32-11-16-36-39(23-32)60(88-59(36)86)37-17-14-34(74)24-44(37)87-45-25-35(75)15-18-38(45)60/h9-18,23-25,29-30,40-43,48-50,72-75H,4-8,19-22,26-28,61H2,1-3H3,(H2,62,76)(H,63,78)(H,64,79)(H,65,81)(H,66,83)(H,67,80)(H,68,77)(H,69,84)(H,70,82)/t29?,30?,40-,41+,42+,43+,48+,49+,50-/m0/s1
DMBDZQA CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSCCC(=O)N[C@H](C(=O)N1)C2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)N[C@@H](CCCNC(=O)C4=CC5=C(C=C4)C(=O)OC56C7=C(C=C(C=C7)O)OC8=C6C=CC(=C8)O)C(=O)NCN)CC(=O)N)C(C)O
DMBDZQA IK JFIITURTLJMTOM-OPCZXTJTSA-N
DMBDZQA IU (2R)-N-[(2S)-1-(aminomethylamino)-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]-1-oxopentan-2-yl]-1-[(4S,7R,10R,13R,16S)-7-(2-amino-2-oxoethyl)-13-butan-2-yl-10-(1-hydroxyethyl)-16-(4-hydroxyphenyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DMBDZQA DE Discovery agent
DM3GM8E ID DM3GM8E
DM3GM8E DN D[Val4]AVP
DM3GM8E HS Investigative
DM3GM8E SN CHEMBL221436; d[Val4]AVP
DM3GM8E PC 44419025
DM3GM8E MW 1040.2
DM3GM8E FM C46H65N13O11S2
DM3GM8E IC InChI=1S/C46H65N13O11S2/c1-25(2)38-44(69)56-32(22-35(47)61)41(66)57-33(45(70)59-18-7-11-34(59)43(68)54-29(10-6-17-51-46(49)50)39(64)52-23-36(48)62)24-72-71-19-16-37(63)53-30(21-27-12-14-28(60)15-13-27)40(65)55-31(42(67)58-38)20-26-8-4-3-5-9-26/h3-5,8-9,12-15,25,29-34,38,60H,6-7,10-11,16-24H2,1-2H3,(H2,47,61)(H2,48,62)(H,52,64)(H,53,63)(H,54,68)(H,55,65)(H,56,69)(H,57,66)(H,58,67)(H4,49,50,51)/t29-,30-,31-,32-,33-,34-,38-/m0/s1
DM3GM8E CS CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DM3GM8E IK KEBRFHAVFOSSOX-CDKUOFBKSA-N
DM3GM8E IU (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM3GM8E DE Discovery agent
DMQJD4P ID DMQJD4P
DMQJD4P DN D-166A
DMQJD4P HS Investigative
DMQJD4P SN D-166A; CHEMBL260151
DMQJD4P DT Small molecular drug
DMQJD4P PC 44450666
DMQJD4P MW 426.6
DMQJD4P FM C29H34N2O
DMQJD4P IC InChI=1S/C29H34N2O/c32-27(20-23-10-4-1-5-11-23)22-30-18-19-31-21-26(30)16-17-28(31)29(24-12-6-2-7-13-24)25-14-8-3-9-15-25/h1-15,26-29,32H,16-22H2/t26-,27+,28-/m0/s1
DMQJD4P CS C1C[C@H](N2CCN([C@@H]1C2)C[C@@H](CC3=CC=CC=C3)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DMQJD4P IK WRZZCPUVRXRVCC-IARZGTGTSA-N
DMQJD4P IU (2R)-1-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-3-phenylpropan-2-ol
DMQJD4P DE Discovery agent
DMSON1P ID DMSON1P
DMSON1P DN D17.4
DMSON1P HS Investigative
DMSON1P SN 26482-53-1; 2-(1-adamantyl)ethanamine; 2-(adamantan-1-yl)ethanamine; 1-C-Ethylaminoadamantane; Tricyclo[3.3.1.13,7]decane-1-ethanamine; 1-Adamantanethylamine; 1-adamantaneethanamine; 2-Adamantan-1-yl-ethylamine; 2-adamantanylethylamine; Tricyclo(3.3.1.13,7)decane-1-ethanamine; PubChem21555; Enamine_005504; D-174; 2-(1-adamantyl)ethylamine; AC1L20RI; 2-(2-amino)ethyladamantane; Oprea1_362282; 2-(Adamant-1-yl)ethylamine; SCHEMBL973650; CHEMBL341013; Mrz-2/174; CTK1A4494; DTXSID50181075; MolPort-002-464-537
DMSON1P DT Aptamer
DMSON1P DE Myasthenia gravis
DMU8BJH ID DMU8BJH
DMU8BJH DN D-189
DMU8BJH HS Investigative
DMU8BJH SN CHEMBL468834; D-189; SCHEMBL7877095; BDBM50261304
DMU8BJH DT Small molecular drug
DMU8BJH PC 24866288
DMU8BJH MW 367.5
DMU8BJH FM C22H33N5
DMU8BJH IC InChI=1S/C22H33N5/c1-2-10-26(21-8-9-22-19(17-21)18-23-24-22)14-11-25-12-15-27(16-13-25)20-6-4-3-5-7-20/h3-7,18,21H,2,8-17H2,1H3,(H,23,24)
DMU8BJH CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)C=NN4
DMU8BJH IK LHOJVHKKDRWEEV-UHFFFAOYSA-N
DMU8BJH IU N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-1H-indazol-5-amine
DMU8BJH DE Discovery agent
DMUMNSW ID DMUMNSW
DMUMNSW DN D-190
DMUMNSW HS Investigative
DMUMNSW SN CHEMBL467767; D-190; BDBM50261335
DMUMNSW DT Small molecular drug
DMUMNSW PC 24866294
DMUMNSW MW 432.5
DMUMNSW FM C21H31N5Se
DMUMNSW IC InChI=1S/C21H31N5Se/c1-2-10-25(19-8-9-20-21(17-19)27-23-22-20)14-11-24-12-15-26(16-13-24)18-6-4-3-5-7-18/h3-7,19H,2,8-17H2,1H3
DMUMNSW CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)[Se]N=N4
DMUMNSW IK PFIKDGAKWFWZIM-UHFFFAOYSA-N
DMUMNSW IU N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-1,2,3-benzoselenadiazol-6-amine
DMUMNSW DE Discovery agent
DM8D26T ID DM8D26T
DM8D26T DN D-192
DM8D26T HS Investigative
DM8D26T SN CHEMBL469182; D-192; SCHEMBL7885003; BDBM50261306
DM8D26T DT Small molecular drug
DM8D26T PC 24866118
DM8D26T MW 368.5
DM8D26T FM C22H32N4O
DM8D26T IC InChI=1S/C22H32N4O/c1-2-10-25(21-8-9-22-19(17-21)18-27-23-22)14-11-24-12-15-26(16-13-24)20-6-4-3-5-7-20/h3-7,18,21H,2,8-17H2,1H3
DM8D26T CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=NOC=C4C3
DM8D26T IK FVLVETKUEQQGET-UHFFFAOYSA-N
DM8D26T IU N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-2,1-benzoxazol-5-amine
DM8D26T DE Discovery agent
DMU83T7 ID DMU83T7
DMU83T7 DN D-193
DMU83T7 HS Investigative
DMU83T7 SN CHEMBL469181; D-193; BDBM50261305
DMU83T7 DT Small molecular drug
DMU83T7 PC 24866290
DMU83T7 MW 368.5
DMU83T7 FM C22H32N4O
DMU83T7 IC InChI=1S/C22H32N4O/c1-2-10-25(21-8-9-22-19(17-21)18-23-27-22)14-11-24-12-15-26(16-13-24)20-6-4-3-5-7-20/h3-7,18,21H,2,8-17H2,1H3
DMU83T7 CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)C=NO4
DMU83T7 IK SYVXHALPVYBOLF-UHFFFAOYSA-N
DMU83T7 IU N-[2-(4-phenylpiperazin-1-yl)ethyl]-N-propyl-4,5,6,7-tetrahydro-1,2-benzoxazol-5-amine
DMU83T7 DE Discovery agent
DMKPIH0 ID DMKPIH0
DMKPIH0 DN D-203
DMKPIH0 HS Investigative
DMKPIH0 SN CHEMBL468022; BDBM50261280
DMKPIH0 DT Small molecular drug
DMKPIH0 PC 24866616
DMKPIH0 MW 427.7
DMKPIH0 FM C24H37N5S
DMKPIH0 IC InChI=1S/C24H37N5S/c1-2-12-28(21-10-11-22-23(19-21)30-24(25)26-22)14-7-6-13-27-15-17-29(18-16-27)20-8-4-3-5-9-20/h3-5,8-9,21H,2,6-7,10-19H2,1H3,(H2,25,26)
DMKPIH0 CS CCCN(CCCCN1CCN(CC1)C2=CC=CC=C2)C3CCC4=C(C3)SC(=N4)N
DMKPIH0 IK AHNMVVBJGPOWFW-UHFFFAOYSA-N
DMKPIH0 IU 6-N-[4-(4-phenylpiperazin-1-yl)butyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMKPIH0 DE Discovery agent
DMNLE4S ID DMNLE4S
DMNLE4S DN D-210
DMNLE4S HS Investigative
DMNLE4S SN CHEMBL468016; D-210; BDBM50261278; N6-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiaxole-2,6-diamine; (+)-N6-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
DMNLE4S DT Small molecular drug
DMNLE4S PC 24866614
DMNLE4S MW 429.6
DMNLE4S FM C23H35N5OS
DMNLE4S IC InChI=1S/C23H35N5OS/c1-3-10-27(18-8-9-19-22(17-18)30-23(24)25-19)14-11-26-12-15-28(16-13-26)20-6-4-5-7-21(20)29-2/h4-7,18H,3,8-17H2,1-2H3,(H2,24,25)
DMNLE4S CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2OC)C3CCC4=C(C3)SC(=N4)N
DMNLE4S IK WIZIUHWXARABLD-UHFFFAOYSA-N
DMNLE4S IU 6-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMNLE4S DE Discovery agent
DMIBOAK ID DMIBOAK
DMIBOAK DN D-211A
DMIBOAK HS Investigative
DMIBOAK SN D-211A; CHEMBL263636; SCHEMBL10291414
DMIBOAK DT Small molecular drug
DMIBOAK PC 44450649
DMIBOAK MW 444.6
DMIBOAK FM C29H33FN2O
DMIBOAK IC InChI=1S/C29H33FN2O/c30-25-13-11-22(12-14-25)28(33)17-18-31-19-20-32-21-26(31)15-16-27(32)29(23-7-3-1-4-8-23)24-9-5-2-6-10-24/h1-14,26-29,33H,15-21H2/t26-,27-,28+/m0/s1
DMIBOAK CS C1C[C@H](N2CCN([C@@H]1C2)CC[C@H](C3=CC=C(C=C3)F)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DMIBOAK IK GAKAYJNKCDLKCE-HZFUHODCSA-N
DMIBOAK IU (1R)-3-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-(4-fluorophenyl)propan-1-ol
DMIBOAK DE Discovery agent
DM54CKZ ID DM54CKZ
DM54CKZ DN D-211B
DM54CKZ HS Investigative
DM54CKZ SN D-211B; CHEMBL260682
DM54CKZ DT Small molecular drug
DM54CKZ PC 44450635
DM54CKZ MW 444.6
DM54CKZ FM C29H33FN2O
DM54CKZ IC InChI=1S/C29H33FN2O/c30-25-13-11-22(12-14-25)28(33)17-18-31-19-20-32-21-26(31)15-16-27(32)29(23-7-3-1-4-8-23)24-9-5-2-6-10-24/h1-14,26-29,33H,15-21H2/t26-,27-,28-/m0/s1
DM54CKZ CS C1C[C@H](N2CCN([C@@H]1C2)CC[C@@H](C3=CC=C(C=C3)F)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM54CKZ IK GAKAYJNKCDLKCE-KCHLEUMXSA-N
DM54CKZ IU (1S)-3-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-(4-fluorophenyl)propan-1-ol
DM54CKZ DE Discovery agent
DMQLT84 ID DMQLT84
DMQLT84 DN D-218
DMQLT84 HS Investigative
DMQLT84 SN CHEMBL513352; D-218; BDBM50261302
DMQLT84 DT Small molecular drug
DMQLT84 PC 44577151
DMQLT84 MW 425.6
DMQLT84 FM C23H31N5OS
DMQLT84 IC InChI=1S/C23H31N5OS/c1-3-10-27(18-8-9-19-22(17-18)30-23(24)25-19)14-11-26-12-15-28(16-13-26)20-6-4-5-7-21(20)29-2/h1,4-7,18H,8-17H2,2H3,(H2,24,25)
DMQLT84 CS COC1=CC=CC=C1N2CCN(CC2)CCN(CC#C)C3CCC4=C(C3)SC(=N4)N
DMQLT84 IK GUCAXHFLECNGRL-UHFFFAOYSA-N
DMQLT84 IU 6-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-6-N-prop-2-ynyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMQLT84 DE Discovery agent
DMQ2U4G ID DMQ2U4G
DMQ2U4G DN D-219
DMQ2U4G HS Investigative
DMQ2U4G SN CHEMBL468017; D-219; BDBM50261279; N6-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiaxole-2,6-diamine; (-)-N6-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
DMQ2U4G DT Small molecular drug
DMQ2U4G PC 24866114
DMQ2U4G MW 468.5
DMQ2U4G FM C22H31Cl2N5S
DMQ2U4G IC InChI=1S/C22H31Cl2N5S/c1-2-8-28(16-6-7-18-20(15-16)30-22(25)26-18)12-9-27-10-13-29(14-11-27)19-5-3-4-17(23)21(19)24/h3-5,16H,2,6-15H2,1H3,(H2,25,26)
DMQ2U4G CS CCCN(CCN1CCN(CC1)C2=C(C(=CC=C2)Cl)Cl)C3CCC4=C(C3)SC(=N4)N
DMQ2U4G IK MTSRJJUOIYINNP-UHFFFAOYSA-N
DMQ2U4G IU 6-N-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMQ2U4G DE Discovery agent
DMTUJWN ID DMTUJWN
DMTUJWN DN D-220
DMTUJWN HS Investigative
DMTUJWN SN CHEMBL468833; D-220; BDBM50261303
DMTUJWN DT Small molecular drug
DMTUJWN PC 44577152
DMTUJWN MW 464.5
DMTUJWN FM C22H27Cl2N5S
DMTUJWN IC InChI=1S/C22H27Cl2N5S/c1-2-8-28(16-6-7-18-20(15-16)30-22(25)26-18)12-9-27-10-13-29(14-11-27)19-5-3-4-17(23)21(19)24/h1,3-5,16H,6-15H2,(H2,25,26)
DMTUJWN CS C#CCN(CCN1CCN(CC1)C2=C(C(=CC=C2)Cl)Cl)C3CCC4=C(C3)SC(=N4)N
DMTUJWN IK AWFHSDHVMOYPMI-UHFFFAOYSA-N
DMTUJWN IU 6-N-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]-6-N-prop-2-ynyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMTUJWN DE Discovery agent
DMGA48T ID DMGA48T
DMGA48T DN D-237
DMGA48T HS Investigative
DMGA48T SN CHEMBL457025; BDBM50273939; (R)-6-((2-(4-phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
DMGA48T DT Small molecular drug
DMGA48T PC 24754478
DMGA48T MW 393.6
DMGA48T FM C25H35N3O
DMGA48T IC InChI=1S/C25H35N3O/c1-2-13-27(23-11-12-24-21(20-23)7-6-10-25(24)29)17-14-26-15-18-28(19-16-26)22-8-4-3-5-9-22/h3-10,23,29H,2,11-20H2,1H3/t23-/m1/s1
DMGA48T CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2)[C@@H]3CCC4=C(C3)C=CC=C4O
DMGA48T IK ACDYFMOSSUKHJD-HSZRJFAPSA-N
DMGA48T IU (6R)-6-[2-(4-phenylpiperazin-1-yl)ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol
DMGA48T DE Discovery agent
DM6KFCO ID DM6KFCO
DM6KFCO DN D-254C
DM6KFCO HS Investigative
DM6KFCO SN D-254C; CHEMBL258725; SCHEMBL4886148
DM6KFCO DT Small molecular drug
DM6KFCO PC 16040321
DM6KFCO MW 400.6
DM6KFCO FM C27H32N2O
DM6KFCO IC InChI=1S/C27H32N2O/c30-25(18-21-10-4-1-5-11-21)20-28-24-16-17-26(29-19-24)27(22-12-6-2-7-13-22)23-14-8-3-9-15-23/h1-15,24-30H,16-20H2/t24-,25+,26-/m0/s1
DM6KFCO CS C1C[C@H](NC[C@H]1NC[C@@H](CC2=CC=CC=C2)O)C(C3=CC=CC=C3)C4=CC=CC=C4
DM6KFCO IK YKFRXVGLZNKBAS-NXCFDTQHSA-N
DM6KFCO IU (2R)-1-[[(3S,6S)-6-benzhydrylpiperidin-3-yl]amino]-3-phenylpropan-2-ol
DM6KFCO DE Discovery agent
DMN7E6Y ID DMN7E6Y
DMN7E6Y DN D-257A
DMN7E6Y HS Investigative
DMN7E6Y SN D-257A; CHEMBL409881
DMN7E6Y DT Small molecular drug
DMN7E6Y PC 44450664
DMN7E6Y MW 412.6
DMN7E6Y FM C28H32N2O
DMN7E6Y IC InChI=1S/C28H32N2O/c31-27(22-10-4-1-5-11-22)21-29-18-19-30-20-25(29)16-17-26(30)28(23-12-6-2-7-13-23)24-14-8-3-9-15-24/h1-15,25-28,31H,16-21H2/t25-,26-,27-/m0/s1
DMN7E6Y CS C1C[C@H](N2CCN([C@@H]1C2)C[C@@H](C3=CC=CC=C3)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DMN7E6Y IK OWLHXXQEBCXCEF-QKDODKLFSA-N
DMN7E6Y IU (1R)-2-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-phenylethanol
DMN7E6Y DE Discovery agent
DM5GLJ2 ID DM5GLJ2
DM5GLJ2 DN D-257C
DM5GLJ2 HS Investigative
DM5GLJ2 SN D-257C; CHEMBL408950
DM5GLJ2 DT Small molecular drug
DM5GLJ2 PC 44450651
DM5GLJ2 MW 430.6
DM5GLJ2 FM C28H31FN2O
DM5GLJ2 IC InChI=1S/C28H31FN2O/c29-24-13-11-21(12-14-24)27(32)20-30-17-18-31-19-25(30)15-16-26(31)28(22-7-3-1-4-8-22)23-9-5-2-6-10-23/h1-14,25-28,32H,15-20H2/t25-,26-,27-/m0/s1
DM5GLJ2 CS C1C[C@H](N2CCN([C@@H]1C2)C[C@@H](C3=CC=C(C=C3)F)O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM5GLJ2 IK FESQDZTUIIZPPV-QKDODKLFSA-N
DM5GLJ2 IU (1R)-2-[(5S,8S)-8-benzhydryl-1,4-diazabicyclo[3.3.1]nonan-4-yl]-1-(4-fluorophenyl)ethanol
DM5GLJ2 DE Discovery agent
DMWLHBQ ID DMWLHBQ
DMWLHBQ DN D-264
DMWLHBQ HS Investigative
DMWLHBQ SN D-264; CHEMBL514885; SCHEMBL10075564; BDBM50273996; (S)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
DMWLHBQ DT Small molecular drug
DMWLHBQ PC 24866612
DMWLHBQ MW 475.7
DMWLHBQ FM C28H37N5S
DMWLHBQ IC InChI=1S/C28H37N5S/c1-2-14-32(25-12-13-26-27(21-25)34-28(29)30-26)18-15-31-16-19-33(20-17-31)24-10-8-23(9-11-24)22-6-4-3-5-7-22/h3-11,25H,2,12-21H2,1H3,(H2,29,30)/t25-/m0/s1
DMWLHBQ CS CCCN(CCN1CCN(CC1)C2=CC=C(C=C2)C3=CC=CC=C3)[C@H]4CCC5=C(C4)SC(=N5)N
DMWLHBQ IK YDLWLYDTYNHXBM-VWLOTQADSA-N
DMWLHBQ IU (6S)-6-N-[2-[4-(4-phenylphenyl)piperazin-1-yl]ethyl]-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
DMWLHBQ DE Discovery agent
DMG1CD5 ID DMG1CD5
DMG1CD5 DN D-315
DMG1CD5 HS Investigative
DMG1CD5 SN CHEMBL456825; D-315; SCHEMBL10075562; BDBM50273937; (R)-7-((2-(4-phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-2-ol
DMG1CD5 DT Small molecular drug
DMG1CD5 PC 44588498
DMG1CD5 MW 393.6
DMG1CD5 FM C25H35N3O
DMG1CD5 IC InChI=1S/C25H35N3O/c1-2-12-27(24-10-8-21-9-11-25(29)20-22(21)19-24)16-13-26-14-17-28(18-15-26)23-6-4-3-5-7-23/h3-7,9,11,20,24,29H,2,8,10,12-19H2,1H3/t24-/m1/s1
DMG1CD5 CS CCCN(CCN1CCN(CC1)C2=CC=CC=C2)[C@@H]3CCC4=C(C3)C=C(C=C4)O
DMG1CD5 IK POVCSYONXDMZKL-XMMPIXPASA-N
DMG1CD5 IU (7R)-7-[2-(4-phenylpiperazin-1-yl)ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-2-ol
DMG1CD5 DE Discovery agent
DMZAM3G ID DMZAM3G
DMZAM3G DN D-366
DMZAM3G HS Investigative
DMZAM3G SN CHEMBL569746; D-366; BDBM50303793; (S)-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)(1H-indol-2-yl)methanone
DMZAM3G DT Small molecular drug
DMZAM3G PC 45486362
DMZAM3G MW 460.6
DMZAM3G FM C28H36N4O2
DMZAM3G IC InChI=1S/C28H36N4O2/c1-2-12-31(23-10-11-24-21(19-23)7-5-9-27(24)33)16-13-30-14-17-32(18-15-30)28(34)26-20-22-6-3-4-8-25(22)29-26/h3-9,20,23,29,33H,2,10-19H2,1H3/t23-/m0/s1
DMZAM3G CS CCCN(CCN1CCN(CC1)C(=O)C2=CC3=CC=CC=C3N2)[C@H]4CCC5=C(C4)C=CC=C5O
DMZAM3G IK DQMMOHPPKACCQN-QHCPKHFHSA-N
DMZAM3G IU [4-[2-[[(2S)-5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]-propylamino]ethyl]piperazin-1-yl]-(1H-indol-2-yl)methanone
DMZAM3G DE Discovery agent
DM048OG ID DM048OG
DM048OG DN D-420720
DM048OG HS Investigative
DM048OG SN Dipeptidyl peptidase inhibitor (diabetes), Development Centre for Biotechnology
DM048OG CP Development Centre for Biotechnology
DM048OG DE Diabetic complication
DM0M81E ID DM0M81E
DM0M81E DN D609
DM0M81E HS Investigative
DM0M81E SN D609; O-(Octahydro-4,7-methano-1H-inden-5-yl) carbonopotassium dithioate; D609 potassium salt; Carbonodithioic acid, O-(octahydro-4,7-methano-1H-inden-5-yl) ester potassium; SCHEMBL15720168; tricyclodecan-9-yl xanthogenate k; Tricyclodecan-9-yl xanthogenate potassium salt; o-tricyclo[5.2.1.0(2,6)]dec-9-yl dithiocarbonate potassium salt
DM0M81E DT Small molecular drug
DM0M81E PC 4234241
DM0M81E MW 266.5
DM0M81E FM C11H15KOS2
DM0M81E IC InChI=1S/C11H16OS2.K/c13-11(14)12-10-5-6-4-9(10)8-3-1-2-7(6)8;/h6-10H,1-5H2,(H,13,14);/q;+1/p-1
DM0M81E CS C1CC2C(C1)C3CC2CC3OC(=S)[S-].[K+]
DM0M81E IK IGULCCCBGBDZKQ-UHFFFAOYSA-M
DM0M81E IU potassium;8-tricyclo[5.2.1.02,6]decanyloxymethanedithioate
DM0M81E CA CAS 83373-60-8
DM0M81E DE Discovery agent
DM0A54V ID DM0A54V
DM0A54V DN D-65476
DM0A54V HS Investigative
DM0A54V SN bis(1H-2-indolyl)methanone deriv. 52
DM0A54V DT Small molecular drug
DM0A54V PC 5330548
DM0A54V MW 346.4
DM0A54V FM C21H18N2O3
DM0A54V IC InChI=1S/C21H18N2O3/c1-2-5-20(24)26-15-8-9-17-14(10-15)12-19(23-17)21(25)18-11-13-6-3-4-7-16(13)22-18/h3-4,6-12,22-23H,2,5H2,1H3
DM0A54V CS CCCC(=O)OC1=CC2=C(C=C1)NC(=C2)C(=O)C3=CC4=CC=CC=C4N3
DM0A54V IK CZDUJGOCEPWCNA-UHFFFAOYSA-N
DM0A54V IU [2-(1H-indole-2-carbonyl)-1H-indol-5-yl] butanoate
DM0A54V DE Discovery agent
DM54T8J ID DM54T8J
DM54T8J DN DAB-486-IL-2
DM54T8J HS Investigative
DM54T8J SN 153641-26-0
DM54T8J DE Discovery agent
DMHZKMG ID DMHZKMG
DMHZKMG DN DABCO
DMHZKMG HS Investigative
DMHZKMG SN 1,4-Diazabicyclo[2.2.2]octane; Triethylenediamine; 280-57-9; Dabco; Dabco 33LV; 1,4-Ethylenepiperazine; 1,4-DIAZABICYCLO(2.2.2)OCTANE; Dabco crystal; TEDA; Texacat TD 100; N,N'-endo-Ethylenepiperazine; Dabco S-25; D 33LV; Dabco EG; 1,4-Diazabicyclo-octane; Dabco R-8020; 1,4-Diazobicyclo(2.2.2)octane; Thancat TD 33; Bicyclo(2,2,2)-1,4-diazaoctane; 1,4-diazabicyclooctane; 1,4-diazabicyclo[2,2,2]octane; 1,4-diaza-bicyclo[2.2.2]octane; UNII-X8M57R0JS5; NSC 56362; CCRIS 6692; TED; HSDB 5556; 1,4-Diaza[2.2.2]bicyclooctane; EINECS 205-999-9
DMHZKMG DT Small molecular drug
DMHZKMG PC 9237
DMHZKMG MW 112.17
DMHZKMG FM C6H12N2
DMHZKMG IC InChI=1S/C6H12N2/c1-2-8-5-3-7(1)4-6-8/h1-6H2
DMHZKMG CS C1CN2CCN1CC2
DMHZKMG IK IMNIMPAHZVJRPE-UHFFFAOYSA-N
DMHZKMG IU 1,4-diazabicyclo[2.2.2]octane
DMHZKMG CA CAS 280-57-9
DMHZKMG CB CHEBI:151129
DMHZKMG DE Discovery agent
DMN3GTF ID DMN3GTF
DMN3GTF DN DABCO-C16
DMN3GTF HS Investigative
DMN3GTF SN TA279; C16-1,4-Diazabicyclo[2.2.2]octane
DMN3GTF DT Small molecular drug
DMN3GTF PC 11611423
DMN3GTF MW 337.6
DMN3GTF FM C22H45N2+
DMN3GTF IC InChI=1S/C22H45N2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-24-20-16-23(17-21-24)18-22-24/h2-22H2,1H3/q+1
DMN3GTF CS CCCCCCCCCCCCCCCC[N+]12CCN(CC1)CC2
DMN3GTF IK YPKLQHHICPWJRD-UHFFFAOYSA-N
DMN3GTF IU 1-hexadecyl-4-aza-1-azoniabicyclo[2.2.2]octane
DMN3GTF DE Discovery agent
DMCNAME ID DMCNAME
DMCNAME DN DACTHF
DMCNAME HS Investigative
DMCNAME SN Deazaacyclotetrahydrofolate; 5-deazaacyclotetrahydrofolate; 5-DACTHF
DMCNAME DE Discovery agent
DMRM0OW ID DMRM0OW
DMRM0OW DN Dadle
DMRM0OW HS Investigative
DMRM0OW SN Dadle; 63631-40-3; H-TYR-D-ALA-GLY-PHE-D-LEU-OH; DADL; (D-Ala2,D-Leu5)-Enkephalin; [D-Ala2, D-Leu5]-enkephalin; CHEMBL340032; BW-180C; Tyr-D-Ala-Gly-Phe-D-Leu; (2R,5S,11R,14S)-14-Amino-5-benzyl-15-(4-hydroxyphenyl)-2-isobutyl-11-methyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecan-1-oic acid; (2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; UNII-HB4QD9GL6F; HB4QD9GL6F; DADLE-OH; AC1OCEJN; ZINC14952092; H-Tyr-D-Ala-Gly-Phe-D-Leu
DMRM0OW DT Small molecular drug
DMRM0OW PC 6917707
DMRM0OW MW 569.6
DMRM0OW FM C29H39N5O7
DMRM0OW IC InChI=1S/C29H39N5O7/c1-17(2)13-24(29(40)41)34-28(39)23(15-19-7-5-4-6-8-19)33-25(36)16-31-26(37)18(3)32-27(38)22(30)14-20-9-11-21(35)12-10-20/h4-12,17-18,22-24,35H,13-16,30H2,1-3H3,(H,31,37)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t18-,22+,23+,24-/m1/s1
DMRM0OW CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMRM0OW IK ZHUJMSMQIPIPTF-IBURTVSXSA-N
DMRM0OW IU (2R)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMRM0OW CA CAS 63631-40-3
DMRM0OW DE Discovery agent
DMJIFY3 ID DMJIFY3
DMJIFY3 DN DADMe-ImmG
DMJIFY3 HS Investigative
DMJIFY3 PC 135415984
DMJIFY3 MW 279.3
DMJIFY3 FM C12H17N5O3
DMJIFY3 IC InChI=1S/C12H17N5O3/c13-12-15-9-6(1-14-10(9)11(20)16-12)2-17-3-7(5-18)8(19)4-17/h1,7-8,14,18-19H,2-5H2,(H3,13,15,16,20)/t7-,8+/m1/s1
DMJIFY3 CS C1[C@@H]([C@H](CN1CC2=CNC3=C2N=C(NC3=O)N)O)CO
DMJIFY3 IK GSPTUGDLYPMLCQ-SFYZADRCSA-N
DMJIFY3 IU 2-amino-7-[[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMJIFY3 CA CAS 548486-61-9
DMJIFY3 DE Discovery agent
DMWR3XL ID DMWR3XL
DMWR3XL DN DAEDALIN A
DMWR3XL HS Investigative
DMWR3XL SN CHEMBL602533; CHEBI:65721; (2R)-2-(hydroxymethyl)-2-methyl-2H-chromen-6-ol
DMWR3XL DT Small molecular drug
DMWR3XL PC 46216805
DMWR3XL MW 192.21
DMWR3XL FM C11H12O3
DMWR3XL IC InChI=1S/C11H12O3/c1-11(7-12)5-4-8-6-9(13)2-3-10(8)14-11/h2-6,12-13H,7H2,1H3/t11-/m1/s1
DMWR3XL CS C[C@@]1(C=CC2=C(O1)C=CC(=C2)O)CO
DMWR3XL IK LTKJWSBGTNWRNP-LLVKDONJSA-N
DMWR3XL IU (2R)-2-(hydroxymethyl)-2-methylchromen-6-ol
DMWR3XL CB CHEBI:65721
DMWR3XL DE Discovery agent
DMRFTJX ID DMRFTJX
DMRFTJX DN Daidzein
DMRFTJX HS Investigative
DMRFTJX SN Daidzein; 486-66-8; 4',7-Dihydroxyisoflavone; Daidzeol; 7,4'-Dihydroxyisoflavone; 7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-; 7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7-Hydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; UNII-6287WC5J2L; CCRIS 7600; K 251b; 4,7-Dihydroxyisoflavone; EINECS 207-635-4; BRN 0231523; CHEMBL8145; 4',7-Dihydroxy-iso-flavone; d-(+)-alpha-methylbenzylamine; ,7-Dihydroxyisoflavone; 7,4'-dihydroxyisoflavone; DIADZEIN
DMRFTJX DT Small molecular drug
DMRFTJX PC 5281708
DMRFTJX MW 254.24
DMRFTJX FM C15H10O4
DMRFTJX IC InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H
DMRFTJX CS C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O
DMRFTJX IK ZQSIJRDFPHDXIC-UHFFFAOYSA-N
DMRFTJX IU 7-hydroxy-3-(4-hydroxyphenyl)chromen-4-one
DMRFTJX CA CAS 486-66-8
DMRFTJX CB CHEBI:28197
DMRFTJX DE Discovery agent
DM3M652 ID DM3M652
DM3M652 DN Daio-Orengedokuto (DOT)
DM3M652 HS Investigative
DM3M652 SN 26159-34-2; Miranax; Naproxen sodium salt; Synflex; Naprodol; Naprodil; Leniartril; Gibixen; Floxalin; Flogogin; Aprowell; Anapran; Primeral; Pactens; Naprovite; Gibinap; Floneks; Anaprotab; Monarit; Karoksen; Sodimax; Natrioxen; Floginex; Opraks; Kapnax; Tandax; Flogen; Nixal; Aprol; Naprux Gesic; Causalon Pro; Naproxen natrium; Axer Alfa; Dysmenalgit; Veradol; Naprium; Diocodal; Proxen; Prexan; Naprux; A-Nox; Xenar; Laser; Apo-Napro-NA; UNII-9TN87S3A3C; sodium na
DM3M652 DT Small molecular drug
DM3M652 PC 23681059
DM3M652 MW 252.24
DM3M652 FM C14H13NaO3
DM3M652 IC InChI=1S/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1
DM3M652 CS C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-].[Na+]
DM3M652 IK CDBRNDSHEYLDJV-FVGYRXGTSA-M
DM3M652 IU sodium;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
DM3M652 CA CAS 26159-34-2
DM3M652 CB CHEBI:7477
DM3M652 DE Discovery agent
DMVIDQL ID DMVIDQL
DMVIDQL DN D-alanine
DMVIDQL HS Investigative
DMVIDQL SN D-alanine; 338-69-2; H-D-Ala-OH; (2R)-2-aminopropanoic acid; (R)-Alanine; (R)-2-aminopropanoic acid; D-2-Aminopropionic acid; D-alpha-Alanine; Alanine, D-; Alanine D-form; D-Alanin; (R)-2-Aminopropionic acid; D-alpha-Aminopropionsaeure; (R)-2-Aminopropionsaeure; Ba 2776; D-alpha-aminopropionic acid; UNII-E3UDS4613U; D-.alpha.-Alanine; D-(-)-Alanine; CHEMBL66693; E3UDS4613U; CHEBI:15570; QNAYBMKLOCPYGJ-UWTATZPHSA-N; MFCD00008077; DAL; NCGC00024493-02; D-Alanine, 99+%; DSSTox_RID_81027; DSSTox_CID_25649; DSSTox_GSID_45649
DMVIDQL DT Small molecular drug
DMVIDQL PC 71080
DMVIDQL MW 89.09
DMVIDQL FM C3H7NO2
DMVIDQL IC InChI=1S/C3H7NO2/c1-2(4)3(5)6/h2H,4H2,1H3,(H,5,6)/t2-/m1/s1
DMVIDQL CS C[C@H](C(=O)O)N
DMVIDQL IK QNAYBMKLOCPYGJ-UWTATZPHSA-N
DMVIDQL IU (2R)-2-aminopropanoic acid
DMVIDQL CA CAS 338-69-2
DMVIDQL CB CHEBI:15570
DMVIDQL DE Discovery agent
DMS1DVA ID DMS1DVA
DMS1DVA DN DAMGO
DMS1DVA HS Investigative
DMS1DVA SN DAMGO; DAGO; glyol; Dagol; DAMGE; 78123-71-4; 2-Ala-4-mephe-5-gly-enkephalin; Tyr-ala-gly-(nme)phe-gly-ol; Enkephalin, ala(2)-mephe(4)-gly(5)-; RX 783006; (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin; Ala(2)-mephe(4)-gly-ol(5) enkephalin; CHEBI:272; CHEMBL38874; Tyr-D-Ala-Gly-MePhe-Gly-ol; Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-; H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol; Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-; [3H]DAMGO; L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-
DMS1DVA DT Small molecular drug
DMS1DVA PC 5462471
DMS1DVA MW 513.6
DMS1DVA FM C26H35N5O6
DMS1DVA IC InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1
DMS1DVA CS C[C@H](C(=O)NCC(=O)N(C)[C@@H](CC1=CC=CC=C1)C(=O)NCCO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMS1DVA IK HPZJMUBDEAMBFI-WTNAPCKOSA-N
DMS1DVA IU (2S)-2-amino-N-[(2R)-1-[[2-[[(2S)-1-(2-hydroxyethylamino)-1-oxo-3-phenylpropan-2-yl]-methylamino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMS1DVA CA CAS 78123-71-4
DMS1DVA CB CHEBI:272
DMS1DVA DE Discovery agent
DMXM7JR ID DMXM7JR
DMXM7JR DN daminozide
DMXM7JR HS Investigative
DMXM7JR SN DMASA; SADH; B 995; Alar; Kylar; B-NINE
DMXM7JR DT Small molecular drug
DMXM7JR PC 15331
DMXM7JR MW 160.17
DMXM7JR FM C6H12N2O3
DMXM7JR IC InChI=1S/C6H12N2O3/c1-8(2)7-5(9)3-4-6(10)11/h3-4H2,1-2H3,(H,7,9)(H,10,11)
DMXM7JR CS CN(C)NC(=O)CCC(=O)O
DMXM7JR IK NOQGZXFMHARMLW-UHFFFAOYSA-N
DMXM7JR IU 4-(2,2-dimethylhydrazinyl)-4-oxobutanoic acid
DMXM7JR CA CAS 1596-84-5
DMXM7JR CB CHEBI:4312
DMXM7JR DE Discovery agent
DMQ4L1I ID DMQ4L1I
DMQ4L1I DN Dansylamide
DMQ4L1I HS Investigative
DMQ4L1I SN Dansylamide; 1431-39-6; 5-(dimethylamino)naphthalene-1-sulfonamide; 5-DIMETHYLAMINO-1-NAPHTHALENESULFONAMIDE; Dansyl amide; 5-Dimethylaminonaphthalene-1-sulfonamide; 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONAMIDE; TYNBFJJKZPTRKS-UHFFFAOYSA-N; 5-[Dimethylamino]-1-naphthalenesulfonamide; 1-Naphthalenesulfonamide, 5-(dimethylamino)-; 1okl; EINECS 215-854-1; AC1Q3WHH; 5-(Dimethylamino)naphthalene-1-sulphonamide; AC1L22JG; Oprea1_628153; SCHEMBL108421; CHEMBL119489; ZINC56543; BDBM11402; TYNBFJJKZPTRKS-UHFFFAOYSA-; DTXSID70162306
DMQ4L1I DT Small molecular drug
DMQ4L1I PC 65077
DMQ4L1I MW 250.32
DMQ4L1I FM C12H14N2O2S
DMQ4L1I IC InChI=1S/C12H14N2O2S/c1-14(2)11-7-3-6-10-9(11)5-4-8-12(10)17(13,15)16/h3-8H,1-2H3,(H2,13,15,16)
DMQ4L1I CS CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N
DMQ4L1I IK TYNBFJJKZPTRKS-UHFFFAOYSA-N
DMQ4L1I IU 5-(dimethylamino)naphthalene-1-sulfonamide
DMQ4L1I CA CAS 1431-39-6
DMQ4L1I DE Discovery agent
DM2WS8B ID DM2WS8B
DM2WS8B DN D-AP4
DM2WS8B HS Investigative
DM2WS8B SN D-AP4; 78739-01-2; (2R)-2-amino-4-phosphonobutanoic acid; (R)-2-Amino-4-phosphonobutanoic acid; d(-)-2-amino-4-phosphonobutyric acid; Tocris-0101; Tocris-0102; D-APB; AC1LT3KN; Lopac-A-1910; GTPL1443; SCHEMBL12648443; CHEMBL1319383; CTK2I0929; BDBM82006; MolPort-004-956-473; ZINC1656225; PDSP1_000361; PDSP2_000359; BN0083; (r)-2-amino-4-phosphonobutyric acid; AKOS024456336; FCH3604711; API0009835; NCGC00024467-01; D-(-)-2-Amino-4-phosphonobutyric acid; NCGC00024466-01; NCGC00015041-02; NCGC00015041-01; B6201; FT-0772107; Butanoic acid, 2
DM2WS8B DT Small molecular drug
DM2WS8B PC 1550579
DM2WS8B MW 183.1
DM2WS8B FM C4H10NO5P
DM2WS8B IC InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)/t3-/m1/s1
DM2WS8B CS C(CP(=O)(O)O)[C@H](C(=O)O)N
DM2WS8B IK DDOQBQRIEWHWBT-GSVOUGTGSA-N
DM2WS8B IU (2R)-2-amino-4-phosphonobutanoic acid
DM2WS8B DE Discovery agent
DMY5OTN ID DMY5OTN
DMY5OTN DN d-AP5
DMY5OTN HS Investigative
DMY5OTN SN D-AP-5; D-aminophosphonovaleric acid
DMY5OTN DT Small molecular drug
DMY5OTN PC 135342
DMY5OTN MW 197.13
DMY5OTN FM C5H12NO5P
DMY5OTN IC InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)/t4-/m1/s1
DMY5OTN CS C(C[C@H](C(=O)O)N)CP(=O)(O)O
DMY5OTN IK VOROEQBFPPIACJ-SCSAIBSYSA-N
DMY5OTN IU (2R)-2-amino-5-phosphonopentanoic acid
DMY5OTN CA CAS 79055-68-8
DMY5OTN DE Discovery agent
DMZ4Q0B ID DMZ4Q0B
DMZ4Q0B DN Dasatinib
DMZ4Q0B HS Investigative
DMZ4Q0B SN Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
DMZ4Q0B CP Bristol Myers Squibb
DMZ4Q0B TC Antiviral Agents
DMZ4Q0B DT Small molecular drug
DMZ4Q0B PC 3062316
DMZ4Q0B MW 488
DMZ4Q0B FM C22H26ClN7O2S
DMZ4Q0B IC InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
DMZ4Q0B CS CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
DMZ4Q0B IK ZBNZXTGUTAYRHI-UHFFFAOYSA-N
DMZ4Q0B IU N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
DMZ4Q0B CA CAS 302962-49-8
DMZ4Q0B CB CHEBI:49375
DMZ4Q0B DE Chronic myelogenous leukaemia; Multiple myeloma; Parkinson disease; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM7Z892 ID DM7Z892
DM7Z892 DN D-aspartic acid
DM7Z892 HS Investigative
DM7Z892 SN D-Aspartic acid; 1783-96-6; (R)-2-aminosuccinic acid; D-Aspartate; H-D-Asp-OH; (-)-Aspartic acid; (R)-Aspartic acid; Aspartic acid D-form; (2R)-2-aminobutanedioic acid; Aspartic acid, D-; D-(-)-Aspartic acid; (R)-(-)-Aminosuccinic acid; D-Asp; D-Aminosuccinic acid; NSC 97922; D-Asparaginsaeure; UNII-4SR0Q8YD1X; BRN 1723529; Tocris-0213; EINECS 217-234-6; 4SR0Q8YD1X; (R)-2-aminobutanedioic acid; CHEMBL29757; CHEBI:17364; CKLJMWTZIZZHCS-UWTATZPHSA-N; MFCD00063081; NCGC00024498-02; (R)-2-Aminobutanedioate; D(-)-Aspartic acid, 99+%; D-aspartate; [3H]D-aspartic acid
DM7Z892 DT Small molecular drug
DM7Z892 PC 83887
DM7Z892 MW 133.1
DM7Z892 FM C4H7NO4
DM7Z892 IC InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m1/s1
DM7Z892 CS C([C@H](C(=O)O)N)C(=O)O
DM7Z892 IK CKLJMWTZIZZHCS-UWTATZPHSA-N
DM7Z892 IU (2R)-2-aminobutanedioic acid
DM7Z892 CA CAS 1783-96-6
DM7Z892 CB CHEBI:17364
DM7Z892 DE Discovery agent
DMMXFBJ ID DMMXFBJ
DMMXFBJ DN dATP
DMMXFBJ HS Investigative
DMMXFBJ SN deoxyadenosine triphosphate
DMMXFBJ DT Small molecular drug
DMMXFBJ PC 15993
DMMXFBJ MW 491.18
DMMXFBJ FM C10H16N5O12P3
DMMXFBJ IC InChI=1S/C10H16N5O12P3/c11-9-8-10(13-3-12-9)15(4-14-8)7-1-5(16)6(25-7)2-24-29(20,21)27-30(22,23)26-28(17,18)19/h3-7,16H,1-2H2,(H,20,21)(H,22,23)(H2,11,12,13)(H2,17,18,19)/t5-,6+,7+/m0/s1
DMMXFBJ CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
DMMXFBJ IK SUYVUBYJARFZHO-RRKCRQDMSA-N
DMMXFBJ IU [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMMXFBJ CA CAS 1927-31-7
DMMXFBJ CB CHEBI:16284
DMMXFBJ DE Discovery agent
DMRDX8U ID DMRDX8U
DMRDX8U DN dATPalphaS
DMRDX8U HS Investigative
DMRDX8U SN Datpalphas; [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate; 2'-Deoxyadenosine 5'-O-(1-thiotriphosphate); alpha-Thio-datp; Sp-Datp alpha S; Sp-dATP-.alpha.-S; AC1L51OG; SCHEMBL222923; GTPL1715; CHEMBL2390988; alpha-Thiodeoxyadenosine triphosphate; Deoxyadenosine 5'-(alpha-thio)triphosphate; 2'-deoxyadenosine-5'-O-(1-thiotriphosphate); (Sp-)2'- Deoxyadenosine- 5'- O- (.alpha.-thiotriphosphate); Adenosine, 2'-deoxy-, 5'-P''-ester with thiotriphosphoric ac
DMRDX8U DT Small molecular drug
DMRDX8U PC 196416
DMRDX8U MW 507.25
DMRDX8U FM C10H16N5O11P3S
DMRDX8U IC InChI=1S/C10H16N5O11P3S/c11-9-8-10(13-3-12-9)15(4-14-8)7-1-5(16)6(24-7)2-23-29(22,30)26-28(20,21)25-27(17,18)19/h3-7,16H,1-2H2,(H,20,21)(H,22,30)(H2,11,12,13)(H2,17,18,19)/t5-,6+,7+,29?/m0/s1
DMRDX8U CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)COP(=S)(O)OP(=O)(O)OP(=O)(O)O)O
DMRDX8U IK CCPIKNHZOWQALM-DLQJRSQOSA-N
DMRDX8U IU [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate
DMRDX8U CA CAS 64145-28-4
DMRDX8U DE Discovery agent
DMT14A7 ID DMT14A7
DMT14A7 DN DAU-5750
DMT14A7 HS Investigative
DMT14A7 SN Dau-5750; Dau 5750; AC1Q6M3K; AC1L4RM2; (1r,5s)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl(3s)-3-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-3-carboxylate; 164575-86-4; [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (3S)-3-methyl-2-oxo-1,4-dihydroquinoline-3-carboxylate; 3-Quinolinecarboxylic acid, 1,2,3,4-tetrahydro-3-methyl-2-oxo-, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (3(S)-endo)-
DMT14A7 DT Small molecular drug
DMT14A7 PC 190973
DMT14A7 MW 328.4
DMT14A7 FM C19H24N2O3
DMT14A7 IC InChI=1S/C19H24N2O3/c1-19(11-12-5-3-4-6-16(12)20-17(19)22)18(23)24-15-9-13-7-8-14(10-15)21(13)2/h3-6,13-15H,7-11H2,1-2H3,(H,20,22)/t13-,14+,15?,19-/m0/s1
DMT14A7 CS C[C@@]1(CC2=CC=CC=C2NC1=O)C(=O)OC3C[C@H]4CC[C@@H](C3)N4C
DMT14A7 IK HQZQXIVKGOJOLP-FKGKKHCZSA-N
DMT14A7 IU [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (3S)-3-methyl-2-oxo-1,4-dihydroquinoline-3-carboxylate
DMT14A7 CA CAS 164575-86-4
DMT14A7 DE Discovery agent
DMEZVGK ID DMEZVGK
DMEZVGK DN DAU-5884
DMEZVGK HS Investigative
DMEZVGK SN 131780-47-7
DMEZVGK PC 16759154
DMEZVGK MW 351.8
DMEZVGK FM C17H22ClN3O3
DMEZVGK IC InChI=1S/C17H21N3O3.ClH/c1-19-12-6-7-13(19)9-14(8-12)23-17(22)20-10-11-4-2-3-5-15(11)18-16(20)21;/h2-5,12-14H,6-10H2,1H3,(H,18,21);1H/t12-,13+,14?;
DMEZVGK CS CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)N3CC4=CC=CC=C4NC3=O.Cl
DMEZVGK IK FDERDDSQHZRNGC-LIWIJTDLSA-N
DMEZVGK IU [(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-oxo-1,4-dihydroquinazoline-3-carboxylate;hydrochloride
DMEZVGK CA CAS 131780-47-7
DMEZVGK DE Discovery agent
DMM5SI1 ID DMM5SI1
DMM5SI1 DN DAU-6202
DMM5SI1 HS Investigative
DMM5SI1 SN 131780-83-1
DMM5SI1 PC 9905592
DMM5SI1 MW 331.4
DMM5SI1 FM C17H21N3O4
DMM5SI1 IC InChI=1S/C17H21N3O4/c1-19-10-6-7-11(19)9-12(8-10)24-17(23)20-15(21)13-4-2-3-5-14(13)18-16(20)22/h2-5,10-12,15,21H,6-9H2,1H3,(H,18,22)
DMM5SI1 CS CN1C2CCC1CC(C2)OC(=O)N3C(C4=CC=CC=C4NC3=O)O
DMM5SI1 IK DCNXOLLXJNMTQB-UHFFFAOYSA-N
DMM5SI1 IU (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-hydroxy-2-oxo-1,4-dihydroquinazoline-3-carboxylate
DMM5SI1 DE Discovery agent
DMEST0R ID DMEST0R
DMEST0R DN DB-160
DMEST0R HS Investigative
DMEST0R SN Dipeptidyl peptidase IV inhibitor (oral, type 2 diabetes), DARA BioSciences
DMEST0R CP DARA BioSciences
DMEST0R DE Non-insulin dependent diabetes
DMGRUN1 ID DMGRUN1
DMGRUN1 DN DB-900
DMGRUN1 HS Investigative
DMGRUN1 CP DARA BioSciences
DMGRUN1 DE Type-2 diabetes
DMFYCQ1 ID DMFYCQ1
DMFYCQ1 DN DBT-066
DMFYCQ1 HS Investigative
DMFYCQ1 SN RAGE modulator (dementia), Digital Biotech
DMFYCQ1 CP Seoul National University
DMFYCQ1 DE Dementia
DM09YI7 ID DM09YI7
DM09YI7 DN DBT-1339
DM09YI7 HS Investigative
DM09YI7 SN DBTA-1339; DBTAI-1339; DWJ-501; DWK-1339; Beta-amyloid aggregation inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid deposition inhibitors (Alzheimer's), Digital Biotech; Beta-amyloid aggregation/deposition inhibitors (Alzheimer's), Digital Biotech
DM09YI7 CP Digital Biotech Co Ltd
DM09YI7 DE Alzheimer disease
DMX9FOB ID DMX9FOB
DMX9FOB DN DC6S
DMX9FOB HS Investigative
DMX9FOB SN DC6S
DMX9FOB DT Small molecular drug
DMX9FOB PC 44414725
DMX9FOB MW 381.4
DMX9FOB FM C18H23NO6S
DMX9FOB IC InChI=1S/C18H23NO6S/c1-19-8-7-18-11-4-6-14(25-26(20,21)22)17(18)24-16-13(23-2)5-3-10(15(16)18)9-12(11)19/h3,5,11-12,14,17H,4,6-9H2,1-2H3,(H,20,21,22)/t11-,12+,14-,17-,18-/m0/s1
DMX9FOB CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)OS(=O)(=O)O
DMX9FOB IK UFGYWOICNCSHBB-XSSYPUMDSA-N
DMX9FOB IU [(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] hydrogen sulfate
DMX9FOB DE Discovery agent
DM62IBX ID DM62IBX
DM62IBX DN DC-9703
DM62IBX HS Investigative
DM62IBX CP Obio Pharmaceutical Holdings Ltd
DM62IBX DE Non-insulin dependent diabetes
DMHNAJ7 ID DMHNAJ7
DMHNAJ7 DN D-carnitine
DMHNAJ7 HS Investigative
DMHNAJ7 SN (+)-Carnitine; (3S)-3-hydroxy-4-(trimethylammonio)butanoate; (3S)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (S)-3-Hydroxy-4-(trimethylammonio)butanoate; CHEBI:11060; Carnitine D-form; D-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; D-carnitine; U9VY0ZOK7A; UNII-U9VY0ZOK7A
DMHNAJ7 DT Small molecular drug
DMHNAJ7 PC 2724480
DMHNAJ7 MW 161.201
DMHNAJ7 FM C7H15NO3
DMHNAJ7 IC InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m0/s1
DMHNAJ7 CS C[N+](C)(C)CC(CC(=O)[O-])O
DMHNAJ7 IK PHIQHXFUZVPYII-LURJTMIESA-N
DMHNAJ7 IU (3S)-3-hydroxy-4-(trimethylazaniumyl)butanoate
DMHNAJ7 CA CAS 541-14-0
DMHNAJ7 CB ChEBI:11060
DMPRYTW ID DMPRYTW
DMPRYTW DN DCB-3503
DMPRYTW HS Investigative
DMPRYTW SN DCB-3503; UNII-TXF835U41K; NSC-716802; CHEMBL399454; TXF835U41K; NSC716802; AC1L8JU6; (13aS,14S)-Tylophorinine; 87302-58-7; SCHEMBL12389871; CTK7A0055; BDBM50213933; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13aS,14S)-; NCI60_040362; Dibenzo(f,H)pyrrolo(1,2-b)isoquinolin-14-ol, 9,11,12,13,13a,14-hexahydro-2,3,6,7-tetramethoxy-, (13as-trans)-; (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol; Dibenzo[f,2-b]isoquinolin-14-ol, 9
DMPRYTW DT Small molecular drug
DMPRYTW PC 402628
DMPRYTW MW 409.5
DMPRYTW FM C24H27NO5
DMPRYTW IC InChI=1S/C24H27NO5/c1-27-19-8-13-14-9-20(28-2)22(30-4)11-16(14)23-17(15(13)10-21(19)29-3)12-25-7-5-6-18(25)24(23)26/h8-11,18,24,26H,5-7,12H2,1-4H3/t18-,24+/m0/s1
DMPRYTW CS COC1=C(C=C2C(=C1)C3=C([C@@H]([C@@H]4CCCN4C3)O)C5=CC(=C(C=C25)OC)OC)OC
DMPRYTW IK JWHWLMNMGLICQZ-MHECFPHRSA-N
DMPRYTW IU (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizin-14-ol
DMPRYTW CA CAS 87302-58-7
DMPRYTW DE Discovery agent
DM36D0F ID DM36D0F
DM36D0F DN d-CCPene
DM36D0F HS Investigative
DM36D0F SN Cppene; 137424-80-7; 4-(3-Phosphonoprop-2-enyl)piperazine-2-carboxylic acid; 3-(2-Carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid; C8H15N2O5P; 2-Piperazinecarboxylic acid, 4-(3-phosphono-2-propenyl)-; Midafotee; SDZ EAA 494, (E)-isomer; AC1O5NJ1; SCHEMBL726553; GTPL4170; CHEMBL224678; RT-012176; LS-172991; LS-172816; J-003616; (e)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid; 4-[(E)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
DM36D0F DT Small molecular drug
DM36D0F PC 6437356
DM36D0F MW 250.19
DM36D0F FM C8H15N2O5P
DM36D0F IC InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+
DM36D0F CS C1CN(CC(N1)C(=O)O)C/C=C/P(=O)(O)O
DM36D0F IK VZXMZMJSGLFKQI-ORCRQEGFSA-N
DM36D0F IU 4-[(E)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
DM36D0F CA CAS 132014-88-1
DM36D0F DE Discovery agent
DMG9BFR ID DMG9BFR
DMG9BFR DN DCDPC
DMG9BFR HS Investigative
DMG9BFR SN dichloro-diphenylamine 2-carboxylic acid
DMG9BFR DT Small molecular drug
DMG9BFR PC 87345
DMG9BFR MW 282.12
DMG9BFR FM C13H9Cl2NO2
DMG9BFR IC InChI=1S/C13H9Cl2NO2/c14-8-2-1-3-10(6-8)16-12-7-9(15)4-5-11(12)13(17)18/h1-7,16H,(H,17,18)
DMG9BFR CS C1=CC(=CC(=C1)Cl)NC2=C(C=CC(=C2)Cl)C(=O)O
DMG9BFR IK GSDQYSSLIKJJOG-UHFFFAOYSA-N
DMG9BFR IU 4-chloro-2-(3-chloroanilino)benzoic acid
DMG9BFR CA CAS 17870-85-8
DMG9BFR DE Discovery agent
DM2T5OV ID DM2T5OV
DM2T5OV DN DC-EBIO
DM2T5OV HS Investigative
DM2T5OV SN dichloro-EBIO
DM2T5OV DT Small molecular drug
DM2T5OV PC 656765
DM2T5OV MW 231.08
DM2T5OV FM C9H8Cl2N2O
DM2T5OV IC InChI=1S/C9H8Cl2N2O/c1-2-13-8-4-6(11)5(10)3-7(8)12-9(13)14/h3-4H,2H2,1H3,(H,12,14)
DM2T5OV CS CCN1C2=CC(=C(C=C2NC1=O)Cl)Cl
DM2T5OV IK LKHRMULASXZCLG-UHFFFAOYSA-N
DM2T5OV IU 5,6-dichloro-3-ethyl-1H-benzimidazol-2-one
DM2T5OV CA CAS 60563-36-2
DM2T5OV CB CHEBI:34662
DM2T5OV DE Discovery agent
DM9HG1Y ID DM9HG1Y
DM9HG1Y DN DCG IV
DM9HG1Y HS Investigative
DM9HG1Y SN Dcg-IV; DCG IV; 147782-19-2; CHEMBL284193; (1r,2r)-3-[(S)-Amino(Carboxy)methyl]cyclopropane-1,2-Dicarboxylic Acid; (1R,2R)-3-[(1S)-1-amino-2-hydroxy-2-oxoethyl]cyclopropane-1,2-dicarboxylic acid; DCGIV; AC1NSJRH; (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine; SCHEMBL658075; GTPL1377; 1,2-Cyclopropanedicarboxylicacid, 3-[(S)-aminocarboxymethyl]-, (1R,2R)-; CTK0H7426; MATPZHBYOVDBLI-JJYYJPOSSA-N; ZINC3995770; BDBM50034503; AKOS030230932; API0015797; B5039; CS-0021174; (2S,2''R,3''R)-2-(2'',3'')-dicarboxycyclopropylglycine
DM9HG1Y DT Small molecular drug
DM9HG1Y PC 5310979
DM9HG1Y MW 203.15
DM9HG1Y FM C7H9NO6
DM9HG1Y IC InChI=1S/C7H9NO6/c8-4(7(13)14)1-2(5(9)10)3(1)6(11)12/h1-4H,8H2,(H,9,10)(H,11,12)(H,13,14)/t2-,3-,4+/m1/s1
DM9HG1Y CS [C@@H]1([C@@H](C1[C@@H](C(=O)O)N)C(=O)O)C(=O)O
DM9HG1Y IK MATPZHBYOVDBLI-JJYYJPOSSA-N
DM9HG1Y IU (1R,2R)-3-[(S)-amino(carboxy)methyl]cyclopropane-1,2-dicarboxylic acid
DM9HG1Y CA CAS 147782-19-2
DM9HG1Y DE Discovery agent
DMU287Q ID DMU287Q
DMU287Q DN Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q HS Investigative
DMU287Q SN CHEMBL373489; Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMU287Q DT Small molecular drug
DMU287Q PC 44415255
DMU287Q MW 673.8
DMU287Q FM C29H35N7O8S2
DMU287Q IC InChI=1S/C29H35N7O8S2/c1-15-9-18(26(30)39)10-16(2)20(15)7-8-24(37)34-23-14-46-45-13-22(27(31)40)35-29(42)21(33-25(38)12-32-28(23)41)11-17-3-5-19(6-4-17)36(43)44/h3-6,9-10,21-23H,7-8,11-14H2,1-2H3,(H2,30,39)(H2,31,40)(H,32,41)(H,33,38)(H,34,37)(H,35,42)/t21-,22-,23-/m0/s1
DMU287Q CS CC1=CC(=CC(=C1CCC(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC2=O)CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)N)C)C(=O)N
DMU287Q IK IPRXWMYVCKZIQS-VABKMULXSA-N
DMU287Q IU (4R,7S,13R)-13-[3-(4-carbamoyl-2,6-dimethylphenyl)propanoylamino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMU287Q DE Discovery agent
DM9NMIY ID DM9NMIY
DM9NMIY DN DCPIB
DM9NMIY HS Investigative
DM9NMIY SN 4-(2-butyl-6,7-dichlor-2-cyclopentyl-indan-1-on-5-yl) oxybutyric acid
DM9NMIY DT Small molecular drug
DM9NMIY PC 10071166
DM9NMIY MW 427.4
DM9NMIY FM C22H28Cl2O4
DM9NMIY IC InChI=1S/C22H28Cl2O4/c1-2-3-10-22(15-7-4-5-8-15)13-14-12-16(28-11-6-9-17(25)26)19(23)20(24)18(14)21(22)27/h12,15H,2-11,13H2,1H3,(H,25,26)
DM9NMIY CS CCCCC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCCCC(=O)O)C3CCCC3
DM9NMIY IK KHKGTPJPBOQECW-UHFFFAOYSA-N
DM9NMIY IU 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]butanoic acid
DM9NMIY CA CAS 82749-70-0
DM9NMIY CB CHEBI:91677
DM9NMIY DE Discovery agent
DMV0JQG ID DMV0JQG
DMV0JQG DN DD7
DMV0JQG HS Investigative
DMV0JQG DT Aptamer
DMV0JQG DE Acute respiratory distress syndrome; Myocardial reperfusion injury; Sepsis
DM6GWAC ID DM6GWAC
DM6GWAC DN DDATHF
DM6GWAC HS Investigative
DM6GWAC SN DATHF; 95693-76-8; 5,10-dideazatetrahydrofolate; 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid; 5,10-dideazatetrahydrofolic acid; L-Glutamic acid,N-[4-[2-(2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]-; L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-; C21H25N5O6; AC1L2XXH; Pyrido(2,3-d)pyrimidine, L-glutamic acid deriv; CHEMBL142806; SCHEMBL9045915; ZUQBAQVRAURMCL-CVRLYYSRSA-N; 5,10-Dideazatetrahydrofolic Acid
DM6GWAC DT Small molecular drug
DM6GWAC PC 135436405
DM6GWAC MW 443.5
DM6GWAC FM C21H25N5O6
DM6GWAC IC InChI=1S/C21H25N5O6/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)
DM6GWAC CS C1C(CNC2=C1C(=O)NC(=N2)N)CCC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
DM6GWAC IK ZUQBAQVRAURMCL-UHFFFAOYSA-N
DM6GWAC IU 2-[[4-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioic acid
DM6GWAC DE Discovery agent
DMHLNA2 ID DMHLNA2
DMHLNA2 DN DdCTP SODIUM
DMHLNA2 HS Investigative
DMHLNA2 SN ddCTP SODIUM; CHEMBL486991; 132619-66-0; 2',3'-Dideoxycytidine 5'-triphosphate sodium salt; DTXSID60635554; PUBCHEM_23679072; FT-0643179; J-006199; 2',3'-Dideoxycytidine 5'-triphosphate sodium salt, > 2',3'-Dideoxycytidine 5'-triphosphate sodium salt solution, for MALDI MS, > =98.0% (HPLC); 2 inverted exclamation marka,3 inverted exclamation marka-Dideoxycytidine 5 inverted exclamation marka-triphosphate sodium salt solution; 2 inverted exclamation marka,3 inverted exclamation marka-Dideoxycytidine 5
DMHLNA2 DT Small molecular drug
DMHLNA2 PC 23679072
DMHLNA2 MW 473.14
DMHLNA2 FM C9H15N3NaO12P3
DMHLNA2 IC InChI=1S/C9H16N3O12P3.Na/c10-7-3-4-12(9(13)11-7)8-2-1-6(22-8)5-21-26(17,18)24-27(19,20)23-25(14,15)16;/h3-4,6,8H,1-2,5H2,(H,17,18)(H,19,20)(H2,10,11,13)(H2,14,15,16);/q;+1/p-1/t6-,8+;/m0./s1
DMHLNA2 CS C1C[C@@H](O[C@@H]1COP(=O)([O-])OP(=O)(O)OP(=O)(O)O)N2C=CC(=NC2=O)N.[Na+]
DMHLNA2 IK LOOMQRBEBYCFPP-QDOHZIMISA-M
DMHLNA2 IU sodium;[(2S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [hydroxy(phosphonooxy)phosphoryl] phosphate
DMHLNA2 CA CAS 132619-66-0
DMHLNA2 DE Discovery agent
DMDFRTI ID DMDFRTI
DMDFRTI DN Deamido-NAD
DMDFRTI HS Investigative
DMDFRTI SN Nicotinic acid adenine dinucleotide sodium salt; 104809-30-5; Nicotinic acid adenine dinucleotide sodium salt, >
DMDFRTI DT Small molecular drug
DMDFRTI PC 165491
DMDFRTI MW 665.4
DMDFRTI FM C21H27N6O15P2+
DMDFRTI IC InChI=1S/C21H26N6O15P2/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(31)14(29)11(41-20)6-39-44(36,37)42-43(34,35)38-5-10-13(28)15(30)19(40-10)26-3-1-2-9(4-26)21(32)33/h1-4,7-8,10-11,13-16,19-20,28-31H,5-6H2,(H4-,22,23,24,32,33,34,35,36,37)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1
DMDFRTI CS C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)O
DMDFRTI IK SENPVEZBRZQVST-HISDBWNOSA-O
DMDFRTI IU 1-[(2R,3R,4S,5R)-5-[[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid
DMDFRTI CA CAS 6450-77-7
DMDFRTI CB CHEBI:18304
DMFTNAP ID DMFTNAP
DMFTNAP DN Debio-0930
DMFTNAP HS Investigative
DMFTNAP SN MT-63-78; AMPK stimulator (oral, cancer), Mercury Therapeutics/Debiopharm SA; Adenosine monophosphate activated protein kinase stimulator (oral, cancer), Mercury Therapeutics/Debiopharm SA
DMFTNAP CP Mercury Therapeutics Inc
DMFTNAP DE Metabolic disorder
DMDLER8 ID DMDLER8
DMDLER8 DN DEBROMOHYMENIALDISINE
DMDLER8 HS Investigative
DMDLER8 DT Small molecular drug
DMDLER8 PC 135451156
DMDLER8 MW 245.24
DMDLER8 FM C11H11N5O2
DMDLER8 IC InChI=1S/C11H11N5O2/c12-11-15-8(10(18)16-11)6-2-4-14-9(17)7-5(6)1-3-13-7/h1,3,13H,2,4H2,(H,14,17)(H3,12,15,16,18)/b8-6-
DMDLER8 CS C\\1CNC(=O)C2=C(/C1=C\\3/C(=O)NC(=N3)N)C=CN2
DMDLER8 IK JYRJOQGKGMHTOO-VURMDHGXSA-N
DMDLER8 IU (4Z)-4-(2-amino-5-oxo-1H-imidazol-4-ylidene)-1,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one
DMDLER8 CA CAS 125118-55-0
DMDLER8 DE Discovery agent
DMWZKLM ID DMWZKLM
DMWZKLM DN Decanal
DMWZKLM HS Investigative
DMWZKLM SN Aldehyde C-10; Aldehyde C10; Capraldehyde; Capric aldehyde; Caprinaldehyde; Caprinic aldehyde; DECALDEHYDE; Decanal; Decanal (natural); Decanaldehyde; Decyl aldehyde; Decyl aldehyde, 95%; Decylic aldehyde; KSMVZQYAVGTKIV-UHFFFAOYSA-N; decylaldehyde; n-DECYLALDEHYDE; n-Decaldehyde; n-Decanal; n-Decyl aldehyde; 1-Decanal; 1-Decanal(mixed isomers); 1-Decyl aldehyde; 112-31-2; 31Z90Q7KQJ; AC1L1QFM; AI3-04860; BRN 1362530; C-10 aldehyde; CHEBI:31457; EINECS 203-957-4; FEMA No. 2362; HSDB 288; MFCD00007031; NSC 6087; NSC6087; UNII-31Z90Q7KQJ
DMWZKLM PC 8175
DMWZKLM MW 156.26
DMWZKLM FM C10H20O
DMWZKLM IC KSMVZQYAVGTKIV-UHFFFAOYSA-N
DMWZKLM CS CCCCCCCCCC=O
DMWZKLM IK 1S/C10H20O/c1-2-3-4-5-6-7-8-9-10-11/h10H,2-9H2,1H3
DMWZKLM IU decanal
DMWZKLM CA CAS 112-31-2
DMWZKLM CB CHEBI:31457
DMWZKLM DE Discovery agent
DM1ESVR ID DM1ESVR
DM1ESVR DN Decane-1,10-diyl disulfamate
DM1ESVR HS Investigative
DM1ESVR SN Sulfamic acid, decamethylene ester; Decane-1,10-Diyl Disulfamate; 1,10-Decanediol, bisulfamate (ester); BRN 2290905; CHEMBL171476; 60548-61-0; 10-sulfamoyloxydecyl sulfamate; 3ibn; bis-sulfamate, 4; 1,10-decanediol disulfamate; AC1L3Y02; SCHEMBL11592779; BDBM33282; DTXSID80209296; XPDWKENHTJHZSC-UHFFFAOYSA-N; Bis(sulfamic acid)1,10-decanediyl ester; 1,10-Bis-O-sulfamyl-1,10-decanediol; LS-147672
DM1ESVR DT Small molecular drug
DM1ESVR PC 148885
DM1ESVR MW 332.4
DM1ESVR FM C10H24N2O6S2
DM1ESVR IC InChI=1S/C10H24N2O6S2/c11-19(13,14)17-9-7-5-3-1-2-4-6-8-10-18-20(12,15)16/h1-10H2,(H2,11,13,14)(H2,12,15,16)
DM1ESVR CS C(CCCCCOS(=O)(=O)N)CCCCOS(=O)(=O)N
DM1ESVR IK XPDWKENHTJHZSC-UHFFFAOYSA-N
DM1ESVR IU 10-sulfamoyloxydecyl sulfamate
DM1ESVR CA CAS 60548-61-0
DM1ESVR DE Discovery agent
DM8FMYL ID DM8FMYL
DM8FMYL DN Decanoic Acid
DM8FMYL HS Investigative
DM8FMYL SN Decanoic acid; CAPRIC ACID; 334-48-5; n-Decanoic acid; n-Capric acid; Decylic acid; Caprinic acid; Decoic acid; n-Decylic acid; n-Decoic acid; 1-Nonanecarboxylic acid; Caprynic acid; Neo-fat 10; Hexacid 1095; decanoate; tert-DECANOIC ACID; C10 fatty acid; Versatic 10 acid; Versatic 10; Fatty acid(C10); NSC 5025; Econosan Acid Sanitizer; Decanoic acid (natural); UNII-4G9EDB6V73; FEMA No. 2364; CCRIS 4610; HSDB 2751; Emery 659; C10:0; EINECS 206-376-4; EPA Pesticide Chemical Code 128955; BRN 1754556; AI3-04453; 4G9EDB6V73; CHEBI:30813
DM8FMYL DT Small molecular drug
DM8FMYL PC 2969
DM8FMYL MW 172.26
DM8FMYL FM C10H20O2
DM8FMYL IC InChI=1S/C10H20O2/c1-2-3-4-5-6-7-8-9-10(11)12/h2-9H2,1H3,(H,11,12)
DM8FMYL CS CCCCCCCCCC(=O)O
DM8FMYL IK GHVNFZFCNZKVNT-UHFFFAOYSA-N
DM8FMYL IU decanoic acid
DM8FMYL CA CAS 334-48-5
DM8FMYL CB CHEBI:30813
DM8FMYL DE Discovery agent
DMLT1N3 ID DMLT1N3
DMLT1N3 DN decavanadate
DMLT1N3 HS Investigative
DMLT1N3 SN Decavanidate
DMLT1N3 DT Small molecular drug
DMLT1N3 PC 5311062
DMLT1N3 MW 957.4
DMLT1N3 FM O28V10-6
DMLT1N3 IC InChI=1S/28O.10V/q;;;;;;;;;;;;;;;;;;;;;;6*-1;;;;;;;;;;
DMLT1N3 CS [O-][V](=O)([O-])O[V]1(=O)O[V]2(=O)O[V]3(=O)O[V](=O)(O[V](=O)(O3)O[V](=O)([O-])[O-])O[V](=O)(O[V](=O)(O2)O1)O[V](=O)([O-])[O-]
DMLT1N3 IK OSBWBKHFRWKREF-UHFFFAOYSA-N
DMLT1N3 IU [5,13-bis[(dioxido(oxo)vanadio)oxy]-1,3,5,7,9,11,13-heptaoxo-2,4,6,8,10,12,14,15,16-nonaoxa-1lambda5,3lambda5,5lambda5,7lambda5,9lambda5,11lambda5,13lambda5-heptavanadatricyclo[9.3.1.13,7]hexadecan-9-yl]oxy-dioxido-oxovanadium
DMLT1N3 DE Discovery agent
DM4SWYX ID DM4SWYX
DM4SWYX DN DECIDIUM
DM4SWYX HS Investigative
DM4SWYX SN Decidium diiodide; AC1L2WE8; 123048-04-4; 3,8-Diamino-5,10'-(trimethylammonium)decyl-6-phenyl phenanthridium diiodide; 4-Phenanthrenedecanaminium, 1,6-diamino-N,N,N-trimethyl-3-phenyl-, iodide, monohydriodide; 10-(1,6-diamino-3-phenylphenanthren-4-yl)decyl-trimethylazanium iodide hydroiodide
DM4SWYX DT Small molecular drug
DM4SWYX PC 129883
DM4SWYX MW 737.5
DM4SWYX FM C33H45I2N3
DM4SWYX IC InChI=1S/C33H44N3.2HI/c1-36(2,3)22-14-9-7-5-4-6-8-13-17-28-30(25-15-11-10-12-16-25)24-32(35)29-21-19-26-18-20-27(34)23-31(26)33(28)29;;/h10-12,15-16,18-21,23-24H,4-9,13-14,17,22,34-35H2,1-3H3;2*1H/q+1;;/p-1
DM4SWYX CS C[N+](C)(C)CCCCCCCCCCC1=C2C(=C(C=C1C3=CC=CC=C3)N)C=CC4=C2C=C(C=C4)N.I.[I-]
DM4SWYX IK RJEYFBQMUHTEAX-UHFFFAOYSA-M
DM4SWYX IU 10-(1,6-diamino-3-phenylphenanthren-4-yl)decyl-trimethylazanium;iodide;hydroiodide
DM4SWYX CA CAS 123048-04-4
DM4SWYX DE Discovery agent
DMHO3N1 ID DMHO3N1
DMHO3N1 DN Decoyinine
DMHO3N1 HS Investigative
DMHO3N1 SN AC1L1EVQ; UPCMLD-DP098; CBiol_001975; KBioSS_000329; KBioGR_000329; CHEMBL2360461; UPCMLD-DP098:002; UPCMLD-DP098:001; KBio3_000657; KBio2_002897; KBio3_000658; KBio2_005465; KBio2_000329; CTK8A2092; Bio2_000805; Bio2_000325; Bio1_000261; Bio1_001239; HMS1362A11; Bio1_000750; SMP2_000077; IDI1_002080; NCGC00161649-01; NCGC00161649-02
DMHO3N1 DT Small molecular drug
DMHO3N1 PC 121578
DMHO3N1 MW 279.25
DMHO3N1 FM C11H13N5O4
DMHO3N1 IC InChI=1S/C11H13N5O4/c1-5-7(18)8(19)11(2-17,20-5)16-4-15-6-9(12)13-3-14-10(6)16/h3-4,7-8,17-19H,1-2H2,(H2,12,13,14)/t7-,8-,11-/m1/s1
DMHO3N1 CS C=C1[C@H]([C@H]([C@](O1)(CO)N2C=NC3=C(N=CN=C32)N)O)O
DMHO3N1 IK UZSSGAOAYPICBZ-SOCHQFKDSA-N
DMHO3N1 IU (2R,3R,4S)-2-(6-aminopurin-9-yl)-2-(hydroxymethyl)-5-methylideneoxolane-3,4-diol
DMHO3N1 CA CAS 2004-04-8
DMHO3N1 DE Discovery agent
DMNKDT5 ID DMNKDT5
DMNKDT5 DN decyl dihydrogen phosphate
DMNKDT5 HS Investigative
DMNKDT5 SN FAP10; decanol phosphate; FAP-10; decyl phosphate; n-decyl phosphoric acid
DMNKDT5 DT Small molecular drug
DMNKDT5 PC 62532
DMNKDT5 MW 238.26
DMNKDT5 FM C10H23O4P
DMNKDT5 IC InChI=1S/C10H23O4P/c1-2-3-4-5-6-7-8-9-10-14-15(11,12)13/h2-10H2,1H3,(H2,11,12,13)
DMNKDT5 CS CCCCCCCCCCOP(=O)(O)O
DMNKDT5 IK SCIGVHCNNXTQDB-UHFFFAOYSA-N
DMNKDT5 IU decyl dihydrogen phosphate
DMNKDT5 CA CAS 3921-30-0
DMNKDT5 DE Discovery agent
DMIERWO ID DMIERWO
DMIERWO DN Decyl sulfamate
DMIERWO HS Investigative
DMIERWO SN Decyl Sulfamate; CHEMBL153094; Sulfamic acid, decyl ester; n-decyl sulfamate; 3ibu; aliphatic sulfamate, 2; BDBM33280; 475562-13-1
DMIERWO DT Small molecular drug
DMIERWO PC 19772348
DMIERWO MW 237.36
DMIERWO FM C10H23NO3S
DMIERWO IC InChI=1S/C10H23NO3S/c1-2-3-4-5-6-7-8-9-10-14-15(11,12)13/h2-10H2,1H3,(H2,11,12,13)
DMIERWO CS CCCCCCCCCCOS(=O)(=O)N
DMIERWO IK JBKMRMOTMJVNML-UHFFFAOYSA-N
DMIERWO IU decyl sulfamate
DMIERWO DE Discovery agent
DMQMR3P ID DMQMR3P
DMQMR3P DN DECYL(DIMETHYL)PHOSPHINE OXIDE
DMQMR3P HS Investigative
DMQMR3P SN Dimethyldecylphosphine oxide; APO-10; Decyl(Dimethyl)phosphine Oxide; Decyldimethylphosphine oxide; 2190-95-6; 1-(dimethylphosphoryl)decane; decyl(dimethyl)phosphane oxide; Phosphine oxide, decyldimethyl-; decyldimethylphosphino-1-one; DCX; AC1MRFCU; 1-dimethylphosphoryldecane; Dimethyldecyl phosphine oxide; Phosphine oxide,decyldimethyl-; SCHEMBL158223; CTK4E7952; DTXSID90176309; MolPort-000-474-112; ZINC3130911; STK954185; SBB039895; MFCD00226006; AKOS000271378; MCULE-7993897252; DB07641; ST50109137; Dimethyldecylphosphine oxide,
DMQMR3P DT Small molecular drug
DMQMR3P PC 3492020
DMQMR3P MW 218.32
DMQMR3P FM C12H27OP
DMQMR3P IC InChI=1S/C12H27OP/c1-4-5-6-7-8-9-10-11-12-14(2,3)13/h4-12H2,1-3H3
DMQMR3P CS CCCCCCCCCCP(=O)(C)C
DMQMR3P IK GSVLCKASFMVUSW-UHFFFAOYSA-N
DMQMR3P IU 1-dimethylphosphoryldecane
DMQMR3P CA CAS 2190-95-6
DMQMR3P DE Discovery agent
DM2WEB9 ID DM2WEB9
DM2WEB9 DN Decylamine-N,N-Dimethyl-N-Oxide
DM2WEB9 HS Investigative
DM2WEB9 SN 2605-79-0; N,N-Dimethyldecylamine N-oxide; N,N-Dimethyldecylamine oxide; 1-Decanamine, N,N-dimethyl-, N-oxide; DECYLAMINE-N,N-DIMETHYL-N-OXIDE; decyl(dimethyl)amine oxide; UNII-G387VUT5EZ; Capric dimethyl amine oxide; N,N-Dimethyldecylamine-N-oxide; N,N-dimethyldecan-1-amine oxide; Decyl dimethyl amine oxide; N,N-dimethyldecanamine oxide; G387VUT5EZ; CHEBI:41899; N,N-Dimethyl-1-decanamine-N-oxide; 1-Decanamine,N,N-dimethyl-, N-oxide; Alkyldimethylamine oxides, commercial grade; 3nok; EINECS 220-020-5; decyldimethylamine oxide
DM2WEB9 DT Small molecular drug
DM2WEB9 PC 62452
DM2WEB9 MW 201.35
DM2WEB9 FM C12H27NO
DM2WEB9 IC InChI=1S/C12H27NO/c1-4-5-6-7-8-9-10-11-12-13(2,3)14/h4-12H2,1-3H3
DM2WEB9 CS CCCCCCCCCC[N+](C)(C)[O-]
DM2WEB9 IK ZRKZFNZPJKEWPC-UHFFFAOYSA-N
DM2WEB9 IU N,N-dimethyldecan-1-amine oxide
DM2WEB9 CA CAS 2605-79-0
DM2WEB9 CB CHEBI:41899
DM2WEB9 DE Discovery agent
DMFT3J2 ID DMFT3J2
DMFT3J2 DN Decyl-phosphonic acid
DMFT3J2 HS Investigative
DMFT3J2 SN Decylphosphonic acid; 6874-60-8; Decanephosphonic acid; Phosphonic acid, decyl-; 1-Decanephosphonic acid; n-Decylphosphonic acid; 1-DECYLPHOSPHONIC ACID; Phosphonic acid, P-decyl-; EINECS 229-975-2; NSC 407850; BRN 1771572; AI3-23065; CHEMBL188083; DZQISOJKASMITI-UHFFFAOYSA-N; C10H23O3P; DecylphosphonicAcid; 1-decanephosphonicacid; n-Decanephosphonic acid; ACMC-1CUHV; Phosphonic acid,P-decyl-; Decylphosphonic acid, 97%; AC1Q6RQ2; 10; 4-04-00-03564 (Beilstein Handbook Reference); SCHEMBL110008
DMFT3J2 DT Small molecular drug
DMFT3J2 PC 81309
DMFT3J2 MW 222.26
DMFT3J2 FM C10H23O3P
DMFT3J2 IC InChI=1S/C10H23O3P/c1-2-3-4-5-6-7-8-9-10-14(11,12)13/h2-10H2,1H3,(H2,11,12,13)
DMFT3J2 CS CCCCCCCCCCP(=O)(O)O
DMFT3J2 IK DZQISOJKASMITI-UHFFFAOYSA-N
DMFT3J2 IU decylphosphonic acid
DMFT3J2 CA CAS 6874-60-8
DMFT3J2 DE Discovery agent
DM1ITJ5 ID DM1ITJ5
DM1ITJ5 DN Decyltrimethylammonium
DM1ITJ5 HS Investigative
DM1ITJ5 SN Decyltrimethylammonium; Trimethyldecylammonium; 15053-09-5; n-decyltrimethylammonium; CHEBI:55325; Ammonium, decyltrimethyl-; Decyltrimethylaminium; decyl(trimethyl)azanium; trimethyl-n-decylammonium; decyltrimethylammonium ion; AC1L27UL; SCHEMBL363068; N,N,N-trimethyldecan-1-aminium; N,N,N-trimethyl-1-decanaminium; CHEMBL1180301; 2082-84-0 (bromide); CTK4C6688; 10108-87-9 (chloride); DTXSID10164566; 1-Decanaminium,N,N,N-trimethyl-; 1-Decanaminium, N,N,N-trimethyl-; ZINC1700269; MCULE-3384760582; 65059-98-5 (methyl sulfate salt)
DM1ITJ5 DT Small molecular drug
DM1ITJ5 PC 16389
DM1ITJ5 MW 200.38
DM1ITJ5 FM C13H30N+
DM1ITJ5 IC InChI=1S/C13H30N/c1-5-6-7-8-9-10-11-12-13-14(2,3)4/h5-13H2,1-4H3/q+1
DM1ITJ5 CS CCCCCCCCCC[N+](C)(C)C
DM1ITJ5 IK RKMJXTWHATWGNX-UHFFFAOYSA-N
DM1ITJ5 IU decyl(trimethyl)azanium
DM1ITJ5 CA CAS 15053-09-5
DM1ITJ5 CB CHEBI:55325
DM1ITJ5 DE Discovery agent
DMWCTZ7 ID DMWCTZ7
DMWCTZ7 DN Decynium 22
DMWCTZ7 HS Investigative
DMWCTZ7 SN Pseudoisocyanine; 1,1'-Diethyl-2,2'-cyanine; 1-Ethyl-2-((1-ethyl-2(1H)-quinolylidene)methyl)quinolinium; 20766-49-8; CHEMBL1197556; CHEBI:37994; Pseudocyanine; 1-ethyl-2-[(E)-(1-ethylquinolin-2(1H)-ylidene)methyl]quinolinium; Diethylpseudoisocyanine; MLS000532635; AC1NUNMU; AC1Q1IYW; SMR000137574; AC1L2OT9; CBDivE_000769; SCHEMBL737002; 977-96-8 (iodide); 2402-42-8 (chloride); SCHEMBL13619260; 1613-31-6 (bromide); BDBM39687; cid_5717105; CHEBI:38002; DTXSID40174835; MolPort-006-385-585; STK396423; (E)-1,1'-diethyl-2,2'-cyanine; Dy22; 1,1'-diethyl-2,2'-cyanine; NSC-97374
DMWCTZ7 DT Small molecular drug
DMWCTZ7 PC 5484462
DMWCTZ7 MW 454.3
DMWCTZ7 FM C23H23IN2
DMWCTZ7 IC InChI=1S/C23H23N2.HI/c1-3-24-20(15-13-18-9-5-7-11-22(18)24)17-21-16-14-19-10-6-8-12-23(19)25(21)4-2;/h5-17H,3-4H2,1-2H3;1H/q+1;/p-1
DMWCTZ7 CS CCN1/C(=C/C2=[N+](C3=CC=CC=C3C=C2)CC)/C=CC4=CC=CC=C41.[I-]
DMWCTZ7 IK GMYRVMSXMHEDTL-UHFFFAOYSA-M
DMWCTZ7 IU (2E)-1-ethyl-2-[(1-ethylquinolin-1-ium-2-yl)methylidene]quinoline;iodide
DMWCTZ7 CA CAS 977-96-8
DMWCTZ7 CB CHEBI:37993
DMWCTZ7 DE Discovery agent
DMKRT20 ID DMKRT20
DMKRT20 DN Degraded Cephaloridine
DMKRT20 HS Investigative
DMKRT20 SN DEGRADED CEPHALORIDINE; 5-METHYL-2-[2-OXO-1-(2-THIOPHEN-2-YL-ACETYLAMINO)-ETHYL]-3,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID; 4ivk; AC1NRAIF; DB04133; FT-0771180; (2R)-5-methyl-2-[(1R)-2-oxo-1-[2-(thiophen-2-yl)acetamido]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2R)-5-methyl-2-{(1R)-2-oxo-1-[(thiophen-2-ylacetyl)amino]ethyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2R)-5-methyl-2-[(1R)-2-oxo-1-[(2-thiophen-2-ylacetyl)amino]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMKRT20 DT Small molecular drug
DMKRT20 PC 5287902
DMKRT20 MW 340.4
DMKRT20 FM C14H16N2O4S2
DMKRT20 IC InChI=1S/C14H16N2O4S2/c1-8-7-22-13(16-12(8)14(19)20)10(6-17)15-11(18)5-9-3-2-4-21-9/h2-4,6,10,13,16H,5,7H2,1H3,(H,15,18)(H,19,20)/t10-,13-/m1/s1
DMKRT20 CS CC1=C(N[C@H](SC1)[C@@H](C=O)NC(=O)CC2=CC=CS2)C(=O)O
DMKRT20 IK SFVACKBZMIZHCK-ZWNOBZJWSA-N
DMKRT20 IU (2R)-5-methyl-2-[(1R)-2-oxo-1-[(2-thiophen-2-ylacetyl)amino]ethyl]-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMKRT20 DE Discovery agent
DMXT7WG ID DMXT7WG
DMXT7WG DN Deguelin
DMXT7WG HS Investigative
DMXT7WG SN 522-17-8; (-)-Deguelin; (-)-cis-deguelin; DEGUELIN(-); UNII-K5Z93K66IE; CHEBI:4357; K5Z93K66IE; MFCD01740600; C23H22O6; (7as,13as)-13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-3h-bis[1]benzopyrano[3,4-b:6',5'-e]pyran-7(7ah)-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one; (7aS,13aS)-9,10-dimethoxy-3,3-dimethyl-13,13a-dihydro-3H-pyrano[2,3-c:6,5-f']dichromen-7(7aH)-one.; SR-01000597503; CCRIS 8104; Deguelin/; (-)-Deguelin, Mundulea sericea; Spectrum_001044; Tocris-1770; Spectrum2_000298; Spectrum3_001122; Spectrum4_001965; Spectrum5_001852; SCHEMBL73183; BSPBio_002583; KBioGR_002434; KBioSS_001524; SPECTRUM201138; MLS006010295; SPBio_000236; CHEMBL393417; KBio2_001524; KBio2_004092; KBio2_006660; KBio3_002083; DTXSID10200231; HMS1923A05; HMS3268E12; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS-cis)-; EX-A4158; ZINC3978987; 1702AH; ABP000411; BDBM50505204; CCG-39856; LMPK12060019; s8132; AKOS024456769; ACN-053693; BCP9000596; CS-1802; SDCCGMLS-0066380.P001; NCGC00025288-01; NCGC00025288-02; NCGC00025288-03; (-)-Deguelin, >98% (HPLC), powder; AS-56004; HY-13425; SMR004701363; C10417; Q5251862; SR-01000597503-1; SR-01000597503-3; SR-01000597503-4; BRD-K61401890-001-02-0; BRD-K61401890-001-03-8; BRD-K61401890-001-04-6; (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one; (7aS,13aS)-9,10-Dimethoxy-3,3-dimethyl-13,13a-dihydro-3H,7aH-pyrano[2,3-c;6,5-f']dichromen-7-one; 13,13aS-Dihydro-9,10-dimethoxy-3,3-dimethyl-3H-[1]benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aS)-one; 3H-[1]Benzopyrano[3,4-b]pyrano[2,3-h][1]benzopyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-; 3H-Bis(1)benzopyrano(3,4-b:6',5'-e)pyran-7(7aH)-one, 13,13a-dihydro-9,10-dimethoxy-3,3-dimethyl-, (7aS,13aS)-
DMXT7WG DT Small molecular drug
DMXT7WG PC 107935
DMXT7WG MW 394.4
DMXT7WG FM C23H22O6
DMXT7WG IC InChI=1S/C23H22O6/c1-23(2)8-7-12-15(29-23)6-5-13-21(24)20-14-9-17(25-3)18(26-4)10-16(14)27-11-19(20)28-22(12)13/h5-10,19-20H,11H2,1-4H3/t19-,20+/m1/s1
DMXT7WG CS CC1(C=CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC)C
DMXT7WG IK ORDAZKGHSNRHTD-UXHICEINSA-N
DMXT7WG IU (1S,14S)-17,18-dimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.03,12.04,9.015,20]docosa-3(12),4(9),5,10,15,17,19-heptaen-13-one
DMXT7WG CA CAS 522-17-8
DMXT7WG CB CHEBI:4357
DMXT7WG DE Esophageal squamous cell carcinoma
DMKYQO4 ID DMKYQO4
DMKYQO4 DN Dehydroascorbic acid
DMKYQO4 HS Investigative
DMKYQO4 SN dehydroascorbate
DMKYQO4 DT Small molecular drug
DMKYQO4 PC 440667
DMKYQO4 MW 174.11
DMKYQO4 FM C6H6O6
DMKYQO4 IC InChI=1S/C6H6O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-8H,1H2/t2-,5+/m0/s1
DMKYQO4 CS C([C@@H]([C@@H]1C(=O)C(=O)C(=O)O1)O)O
DMKYQO4 IK SBJKKFFYIZUCET-JLAZNSOCSA-N
DMKYQO4 IU (5R)-5-[(1S)-1,2-dihydroxyethyl]oxolane-2,3,4-trione
DMKYQO4 CA CAS 490-83-5
DMKYQO4 CB CHEBI:27956
DMKYQO4 DE Discovery agent
DMCDLH2 ID DMCDLH2
DMCDLH2 DN Dehydrocholic acid
DMCDLH2 HS Investigative
DMCDLH2 SN Acolen; Bilidren; Bilostat; Biochol; Cholagon; Cholan DH; Cholic acid, dehydro-; Cholimed; Chologon; Decholin; Dee-Co; Dehychol; Dehycol; Dehycon; Dehydrocholsaeure; Dehystolin; Deidrocolico Vita; Didocol; Didrocolo; Dilabil; Doxycholpotassium; Drenobyl; Erebile; Felacrinos; Hykolex; Ketochol; Ketocholanic acid; Khologon; Novocolin; Oxycholin; Procholon; Sanocholen; Triketocholanic acid; dehydrocholate; dehydrocholic acid; 3,7,12-Triketocholanic acid; 3,7,12-Trioxo-5beta-cholanic acid; 3,7,12-Trioxocholanic acid; 81-23-2
DMCDLH2 PC 6674
DMCDLH2 MW 402.5
DMCDLH2 FM C24H34O5
DMCDLH2 IC OHXPGWPVLFPUSM-KLRNGDHRSA-N
DMCDLH2 CS CC(CCC(=O)O)C1CCC2C1(C(=O)CC3C2C(=O)CC4C3(CCC(=O)C4)C)C
DMCDLH2 IK 1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1
DMCDLH2 IU (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
DMCDLH2 CA CAS 81-23-2
DMCDLH2 CB CHEBI:31459
DMCDLH2 DE Asthma
DM48KMB ID DM48KMB
DM48KMB DN Dehydrocorticosterone
DM48KMB HS Investigative
DM48KMB SN Corticosterone, 11-dehydro-; Corticosterone, dehydro-; Cortisone, 17-deoxy-; 11-Dehydrocorticosterone; Dehydrocortocicosterone; FO4V44A3G3; Kendall's compound A; SCHEMBL141610; 11-DEHYDROCORTICOSTERONE; 11-DHC; 11-Dehydrocorticosteron; 11-Oxo-11-deoxycorticosterone; 17-Deoxycortisone; 21-Hydroxypregn-4-ene-3,11,20-trione; 21-Hydroxypregn-4-ene-3,11-20-trione; 4-Pregnen-21-ol-3,11,20-trione; 4qf7; 72-23-1; AC1NSKHU; CHEBI:78600; EINECS 200-776-2; NSC 9702; NSC-9702; Pregn-4-ene-3,11,20-trione, 21-hydroxy-; UNII-FO4V44A3G3
DM48KMB PC 5311364
DM48KMB MW 344.4
DM48KMB FM C21H28O4
DM48KMB IC FUFLCEKSBBHCMO-KJQYFISQSA-N
DM48KMB CS CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4C(=O)CO)C
DM48KMB IK 1S/C21H28O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-16,19,22H,3-8,10-11H2,1-2H3/t14-,15-,16+,19+,20-,21-/m0/s1
DM48KMB IU (8S,9S,10R,13S,14S,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-dione
DM48KMB CA CAS 72-23-1
DM48KMB CB CHEBI:78600
DM48KMB DE Discovery agent
DM0V1NH ID DM0V1NH
DM0V1NH DN DEHYDROLEUCODIN
DM0V1NH HS Investigative
DM0V1NH SN Dehydroleucodin; Dehydroleucodine; 36150-07-9; NSC 180034; CHEMBL441260; Azuleno(4,5-b)furan-2,7-dione, 3,3a,4,5,9a,9b-hexahydro-6,9-dimethyl-3-methylene-, (3aS-(3aalpha,9aalpha,9bbeta))-; Lidbeckialactone; Mesatlantin E; 11,13-Dehydroleucodin; AC1L2JV1; AC1Q69JZ; (3as,9as,9bs)-6,9-dimethyl-3-methylidene-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione; SCHEMBL4998391; CTK4H5993; ZINC5202250; Dehydroleucodine, > BDBM50318392; NCGC00485131-01; LS-182153
DM0V1NH DT Small molecular drug
DM0V1NH PC 73440
DM0V1NH MW 244.28
DM0V1NH FM C15H16O3
DM0V1NH IC InChI=1S/C15H16O3/c1-7-4-5-10-9(3)15(17)18-14(10)13-8(2)6-11(16)12(7)13/h6,10,13-14H,3-5H2,1-2H3/t10-,13-,14-/m0/s1
DM0V1NH CS CC1=C2[C@@H]([C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C(=CC2=O)C
DM0V1NH IK SKNVIAFTENCNGB-BPNCWPANSA-N
DM0V1NH IU (3aS,9aS,9bS)-6,9-dimethyl-3-methylidene-4,5,9a,9b-tetrahydro-3aH-azuleno[4,5-b]furan-2,7-dione
DM0V1NH CA CAS 36150-07-9
DM0V1NH DE Discovery agent
DMIOA9M ID DMIOA9M
DMIOA9M DN Dehydropipernonaline
DMIOA9M HS Investigative
DMIOA9M SN Dehydropipernonaline; 107584-38-3; Dehydropipernoline; Piperidine, 1-[9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl]-, (E,E,E)-; Piperidine, 1-(9-(1,3-benzodioxol-5-yl)-1-oxo-2,4,8-nonatrienyl)-, (E,E,E)-; AC1O5SQM; CHEMBL483708; MolPort-039-101-180; KAYVDASZRFLFRZ-PQECNABGSA-N; N-(9-(3,4-Methylenedioxyphenyl)-2,4,8-nonatrienoyl)piperidine; ZINC14658239; 9-(3,4-Methylenedioxy)-2,4,8-nonatrienoic acid piperidide; (2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one; Piperidine, 1-[(2E,4E,8E)-9-(1
DMIOA9M DT Small molecular drug
DMIOA9M PC 6439947
DMIOA9M MW 339.4
DMIOA9M FM C21H25NO3
DMIOA9M IC InChI=1S/C21H25NO3/c23-21(22-14-8-5-9-15-22)11-7-4-2-1-3-6-10-18-12-13-19-20(16-18)25-17-24-19/h2,4,6-7,10-13,16H,1,3,5,8-9,14-15,17H2/b4-2+,10-6+,11-7+
DMIOA9M CS C1CCN(CC1)C(=O)/C=C/C=C/CC/C=C/C2=CC3=C(C=C2)OCO3
DMIOA9M IK KAYVDASZRFLFRZ-PQECNABGSA-N
DMIOA9M IU (2E,4E,8E)-9-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylnona-2,4,8-trien-1-one
DMIOA9M CA CAS 107584-38-3
DMIOA9M DE Discovery agent
DM9TWR7 ID DM9TWR7
DM9TWR7 DN DEHYDROZINGERONE
DM9TWR7 HS Investigative
DM9TWR7 SN Dehydrozingerone; 1080-12-2; Feruloylmethane; 4-(4-Hydroxy-3-methoxyphenyl)-3-buten-2-one; 4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one; Vanillalacetone; Dehydro(O)-paradol; MHSK; Dehydrogingerone; Vanylidenacetone; 3-BUTEN-2-ONE, 4-(4-HYDROXY-3-METHOXYPHENYL)-; (O)-Paradol, dehydro-; Vanillidene acetone; 3-Methoxy-4-hydroxybenzalacetone; (O)-Dehydroparadol; (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one; 4-Hydroxy-3-methoxystyryl methyl ketone; NSC 5316; NSC 4019; Vanillylidene acetone; UNII-8CJX5I27B7; Vanillylideneacetone
DM9TWR7 DT Small molecular drug
DM9TWR7 PC 5354238
DM9TWR7 MW 192.21
DM9TWR7 FM C11H12O3
DM9TWR7 IC InChI=1S/C11H12O3/c1-8(12)3-4-9-5-6-10(13)11(7-9)14-2/h3-7,13H,1-2H3/b4-3+
DM9TWR7 CS CC(=O)/C=C/C1=CC(=C(C=C1)O)OC
DM9TWR7 IK AFWKBSMFXWNGRE-ONEGZZNKSA-N
DM9TWR7 IU (E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one
DM9TWR7 CA CAS 1080-12-2
DM9TWR7 CB CHEBI:81361
DM9TWR7 DE Discovery agent
DMGZ2H5 ID DMGZ2H5
DMGZ2H5 DN Del 60 tetramer
DMGZ2H5 HS Investigative
DMGZ2H5 DT Aptamer
DMGZ2H5 DE Solid tumour/cancer
DM5ARHI ID DM5ARHI
DM5ARHI DN DELTA 8-TETRAHYDROCANNOBINOL
DM5ARHI HS Investigative
DM5ARHI SN 5957-75-5; UNII-B49D0HH807; DELTA 8-TETRAHYDROCANNOBINOL; CHEMBL267227; B49D0HH807; delta8-THC; delta(sup 8)-Thc; delta(sup 6)-Thc; delta-(sup6)-THC; delta-(sup8)-THC; delta6-Tetrahydrocannabinol; delta-6-THC; (-)-delta8-Tetrahydrocannabinol; Cannabinol, delta1(6)-tetrahydro-; delta1(6)-trans-Tetrahydrocannabinol; BRN 0023921; 1-trans-delta-(sup8)-Tetrahydrocannabinol; 1-trans-delta(sup 8)-Tetrahydrocannabinol; (-)-delta(sup 8)-trans-Tetrahydrocannabinol; (-)-delta-(sup8)-trans-Tetrahydrocannabinol; Cannabinol, 1-trans-delta(s
DM5ARHI DT Small molecular drug
DM5ARHI PC 638026
DM5ARHI MW 314.5
DM5ARHI FM C21H30O2
DM5ARHI IC InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9,12-13,16-17,22H,5-8,10-11H2,1-4H3/t16-,17-/m1/s1
DM5ARHI CS CCCCCC1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)C)O
DM5ARHI IK HCAWPGARWVBULJ-IAGOWNOFSA-N
DM5ARHI IU (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DM5ARHI CA CAS 5957-75-5
DM5ARHI DE Discovery agent
DMB6ADI ID DMB6ADI
DMB6ADI DN Delta12-PGJ2
DMB6ADI HS Investigative
DMB6ADI SN Dddd-PGD2; delta(12)-PGJ2; delta-12-prostaglandin D2
DMB6ADI DT Small molecular drug
DMB6ADI PC 5280885
DMB6ADI MW 334.4
DMB6ADI FM C20H30O4
DMB6ADI IC InChI=1S/C20H30O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h4,7,12,14-17,21H,2-3,5-6,8-11,13H2,1H3,(H,23,24)/b7-4-,18-14+/t16-,17-/m0/s1
DMB6ADI CS CCCCC[C@@H](C/C=C/1\\[C@H](C=CC1=O)C/C=C\\CCCC(=O)O)O
DMB6ADI IK TUXFWOHFPFBNEJ-GJGHEGAFSA-N
DMB6ADI IU (Z)-7-[(1S,5E)-5-[(3S)-3-hydroxyoctylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid
DMB6ADI CA CAS 87893-54-7
DMB6ADI CB CHEBI:28130
DMB6ADI DE Discovery agent
DML6MVH ID DML6MVH
DML6MVH DN Delta1-dihydrotestosterone
DML6MVH HS Investigative
DML6MVH SN 1-testosterone; Delta1-dihydrotestosterone; 1-Testo; 65-06-5; 17beta-Hydroxy-5alpha-androst-1-en-3-one; UNII-Y984BV1Q0G; Y984BV1Q0G; 5alpha-androst-1-en-17beta-ol-3-one; 1-T [Steroid]; 5.alpha.-Androst-1-en-3-one, 17.beta.-hydroxy-; AC1L5X4C; Delta(1)-dihydrotestosterone; SCHEMBL867595; CHEBI:59714; DTXSID80215312; OKJCFMUGMSVJBG-ABEVXSGRSA-N; NSC39366; ZINC4791927; NSC121140; NSC-39366; LMST02020110; NSC-121140; DB01481; LS-193302; (5alpha,17beta)-hydroxyandrost-1-en-3-one; C15377; 171T609; 1-T
DML6MVH DT Small molecular drug
DML6MVH PC 236666
DML6MVH MW 288.4
DML6MVH FM C19H28O2
DML6MVH IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-17,21H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
DML6MVH CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C=CC(=O)C4)C
DML6MVH IK OKJCFMUGMSVJBG-ABEVXSGRSA-N
DML6MVH IU (5S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DML6MVH CA CAS 65-06-5
DML6MVH CB CHEBI:59714
DML6MVH DE Discovery agent
DMV7IAK ID DMV7IAK
DMV7IAK DN Delta-Amino Valeric Acid
DMV7IAK HS Investigative
DMV7IAK SN DELTA-AMINO VALERIC ACID; 4-Carboxybutylammonium; AC1L9NAD; 4-carboxybutan-1-aminium; (5-hydroxy-5-oxopentyl)azanium; DB02068
DMV7IAK DT Small molecular drug
DMV7IAK PC 449593
DMV7IAK MW 118.15
DMV7IAK FM C5H12NO2+
DMV7IAK IC InChI=1S/C5H11NO2/c6-4-2-1-3-5(7)8/h1-4,6H2,(H,7,8)/p+1
DMV7IAK CS C(CC[NH3+])CC(=O)O
DMV7IAK IK JJMDCOVWQOJGCB-UHFFFAOYSA-O
DMV7IAK IU 4-carboxybutylazanium
DMV7IAK DE Discovery agent
DMHOT9P ID DMHOT9P
DMHOT9P DN DELTORPHIN
DMHOT9P HS Investigative
DMHOT9P SN Deltorphin; Dermenkephalin; Deltorphin A; 119975-64-3; CHEMBL20775; CHEBI:81455; Tyr-met-phe-his-leu-met-asp-NH2; AC1MHYOS; DTXSID60152630; BDBM50000518; Tyrosyl-methionyl-phenylalanyl-histidyl-leucyl-methionyl-aspartamide; ZINC169301619
DMHOT9P DT Small molecular drug
DMHOT9P PC 3035060
DMHOT9P MW 955.2
DMHOT9P FM C44H62N10O10S2
DMHOT9P IC InChI=1S/C44H62N10O10S2/c1-25(2)18-34(42(62)50-32(15-17-66-4)40(60)51-33(38(46)58)22-37(56)57)52-44(64)36(21-28-23-47-24-48-28)54-43(63)35(20-26-8-6-5-7-9-26)53-41(61)31(14-16-65-3)49-39(59)30(45)19-27-10-12-29(55)13-11-27/h5-13,23-25,30-36,55H,14-22,45H2,1-4H3,(H2,46,58)(H,47,48)(H,49,59)(H,50,62)(H,51,60)(H,52,64)(H,53,61)(H,54,63)(H,56,57)/t30-,31+,32-,33-,34-,35-,36-/m0/s1
DMHOT9P CS CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCSC)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMHOT9P IK BHSURCCZOBVHJJ-NWOHMYAQSA-N
DMHOT9P IU (3S)-4-amino-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
DMHOT9P CA CAS 119975-64-3
DMHOT9P CB CHEBI:81455
DMHOT9P DE Discovery agent
DM9ZWRK ID DM9ZWRK
DM9ZWRK DN DELTORPHIN-II
DM9ZWRK HS Investigative
DM9ZWRK SN Deltorphin-II; Delt II; Delt-II; (Ala(2))deltorphin II; deltorphin II, Ala(2)-; (Ala(2),glu(4))deltorphin; Deltorphin, ala(2)-glu(4)-; Tyr-ala-phe-glu-val-val-gly-NH2; Deltorphin, alanyl(2)-glutamyl(4)-; Glycinamide, L-tyrosyl-D-alanyl-L-phenylalanyl-L-alpha-glutamyl-L-valyl-L-valyl-; AC1L3XB1; LS-72217
DM9ZWRK DT Small molecular drug
DM9ZWRK PC 123795
DM9ZWRK MW 782.9
DM9ZWRK FM C38H54N8O10
DM9ZWRK IC InChI=1S/C38H54N8O10/c1-20(2)31(37(55)41-19-29(40)48)46-38(56)32(21(3)4)45-35(53)27(15-16-30(49)50)43-36(54)28(18-23-9-7-6-8-10-23)44-33(51)22(5)42-34(52)26(39)17-24-11-13-25(47)14-12-24/h6-14,20-22,26-28,31-32,47H,15-19,39H2,1-5H3,(H2,40,48)(H,41,55)(H,42,52)(H,43,54)(H,44,51)(H,45,53)(H,46,56)(H,49,50)/t22-,26+,27+,28+,31+,32?/m1/s1
DM9ZWRK CS C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)NC(C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM9ZWRK IK NUNBRHVOPFWRRG-MPNDMYOWSA-N
DM9ZWRK IU (4S)-4-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-5-[[1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DM9ZWRK CA CAS 122752-16-3
DM9ZWRK DE Discovery agent
DMO5UGV ID DMO5UGV
DMO5UGV DN DEMETHOXYCURCUMIN
DMO5UGV HS Investigative
DMO5UGV SN Demethoxycurcumin; monodemethoxycurcumin; 22608-11-3; BHCFM; 24939-17-1; 4-Hydroxycinnamoyl(feroyl)methane; desmethoxycurcumin; Feruloyl-P-hydroxycinnnamoylmethane; curcuminII; UNII-W2F8059T80; 33171-16-3; 4-hydroxycinnamoyl(feruloyl)methane; NSC687841; W2F8059T80; 1,6-Heptadiene-3,5-dione, 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)-; 1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; demethoxy-curcumin
DMO5UGV DT Small molecular drug
DMO5UGV PC 5469424
DMO5UGV MW 338.4
DMO5UGV FM C20H18O5
DMO5UGV IC InChI=1S/C20H18O5/c1-25-20-12-15(6-11-19(20)24)5-10-18(23)13-17(22)9-4-14-2-7-16(21)8-3-14/h2-12,21,24H,13H2,1H3/b9-4+,10-5+
DMO5UGV CS COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC=C(C=C2)O)O
DMO5UGV IK HJTVQHVGMGKONQ-LUZURFALSA-N
DMO5UGV IU (1E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione
DMO5UGV CA CAS 22608-11-3
DMO5UGV CB CHEBI:65737
DMO5UGV DE Discovery agent
DMJBAEP ID DMJBAEP
DMJBAEP DN DEMETHYLDEBROMOFLUSTRAMINE B
DMJBAEP HS Investigative
DMJBAEP SN demethyldebromoflustramine B; CHEMBL446242
DMJBAEP DT Small molecular drug
DMJBAEP PC 11173982
DMJBAEP MW 296.4
DMJBAEP FM C20H28N2
DMJBAEP IC InChI=1S/C20H28N2/c1-15(2)9-11-20-12-13-21-19(20)22(14-10-16(3)4)18-8-6-5-7-17(18)20/h5-10,19,21H,11-14H2,1-4H3
DMJBAEP CS CC(=CCC12CCNC1N(C3=CC=CC=C23)CC=C(C)C)C
DMJBAEP IK TWRZIFGLJFJQJK-UHFFFAOYSA-N
DMJBAEP IU 4,8b-bis(3-methylbut-2-enyl)-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole
DMJBAEP DE Discovery agent
DMUVR5T ID DMUVR5T
DMUVR5T DN DEMETHYLMEDICARPIN
DMUVR5T HS Investigative
DMUVR5T SN 3,9-Dihydroxypterocarpan; demethylmedicarpin; 61135-91-9; (6aR,11aR)-3,9-Dihydroxypterocarpan; CHEMBL1098413; CHEBI:15648; (6aR-cis)-6a,11a-Dihydro-6H-benzofuro(3,2-c)(1)benzopyran-3,9-diol; (6aR,11aR)-6a,11a-dihydro-6H-benzo[4,5]furo[3,2-c]chromene-3,9-diol; C04271; AC1Q70TU; AC1L4S7L; (-)-3,9-dihydroxypterocarpan; DTXSID80210024; ZINC902004; BDBM50317431; AKOS032948673; 6h-benzofuro(3,2-c)(1)benzopyran-3,9-diol, 6a,11a-dihydro-,(6ar-cis)-; W2072; (6aR,11aR)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMUVR5T DT Small molecular drug
DMUVR5T PC 162933
DMUVR5T MW 256.25
DMUVR5T FM C15H12O4
DMUVR5T IC InChI=1S/C15H12O4/c16-8-2-4-11-13(5-8)18-7-12-10-3-1-9(17)6-14(10)19-15(11)12/h1-6,12,15-17H,7H2/t12-,15-/m0/s1
DMUVR5T CS C1[C@@H]2[C@H](C3=C(O1)C=C(C=C3)O)OC4=C2C=CC(=C4)O
DMUVR5T IK ODMIEGVTNZNSLD-WFASDCNBSA-N
DMUVR5T IU (6aR,11aR)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMUVR5T CA CAS 61135-91-9
DMUVR5T CB CHEBI:15648
DMUVR5T DE Discovery agent
DMAMS7R ID DMAMS7R
DMAMS7R DN DEMETHYLZEYLASTERONE
DMAMS7R HS Investigative
DMAMS7R SN demethylzeylasterone; CHEMBL465251
DMAMS7R DT Small molecular drug
DMAMS7R PC 10391130
DMAMS7R MW 496.6
DMAMS7R FM C29H36O7
DMAMS7R IC InChI=1S/C29H36O7/c1-25-6-7-26(2,24(35)36)14-19(25)29(5)11-9-27(3)15-12-17(31)22(32)21(23(33)34)20(15)16(30)13-18(27)28(29,4)10-8-25/h12-13,19,31-32H,6-11,14H2,1-5H3,(H,33,34)(H,35,36)/t19-,25-,26-,27+,28-,29+/m1/s1
DMAMS7R CS C[C@]12CC[C@@](C[C@H]1[C@@]3(CC[C@]4(C5=CC(=C(C(=C5C(=O)C=C4[C@]3(CC2)C)C(=O)O)O)O)C)C)(C)C(=O)O
DMAMS7R IK IGEUWSSSLAVCIX-GPQUBRLFSA-N
DMAMS7R IU (2R,4aS,6aR,6aS,14aS,14bR)-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2,9-dicarboxylic acid
DMAMS7R DE Discovery agent
DMRICV6 ID DMRICV6
DMRICV6 DN Demotensin 1
DMRICV6 HS Investigative
DMRICV6 PC 11847007
DMRICV6 MW 1060.3
DMRICV6 FM C48H85N17O10
DMRICV6 IC InChI=1S/C48H85N17O10/c1-5-29(4)39(44(72)63-36(46(74)75)23-28(2)3)64-42(70)35(24-30-12-14-32(66)15-13-30)62-43(71)37-11-8-22-65(37)45(73)34(10-7-19-58-48(53)54)61-41(69)33(9-6-18-57-47(51)52)60-38(67)27-59-40(68)31(25-55-20-16-49)26-56-21-17-50/h12-15,28-29,31,33-37,39,55-56,66H,5-11,16-27,49-50H2,1-4H3,(H,59,68)(H,60,67)(H,61,69)(H,62,71)(H,63,72)(H,64,70)(H,74,75)(H4,51,52,57)(H4,53,54,58)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
DMRICV6 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMRICV6 IK HMOSHXNVAPZVAT-INYUMPDKSA-N
DMRICV6 IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMRICV6 DE Discovery agent
DMW2GA4 ID DMW2GA4
DMW2GA4 DN Demotensin 2
DMW2GA4 HS Investigative
DMW2GA4 PC 56661177
DMW2GA4 MW 1018.3
DMW2GA4 FM C48H87N15O9
DMW2GA4 IC InChI=1S/C48H87N15O9/c1-5-31(4)41(45(69)61-38(47(71)72)24-30(2)3)62-43(67)37(25-32-13-15-35(64)16-14-32)60-44(68)39-12-9-23-63(39)46(70)36(11-8-20-56-48(52)53)57-28-34(10-6-7-17-49)59-40(65)29-58-42(66)33(26-54-21-18-50)27-55-22-19-51/h13-16,30-31,33-34,36-39,41,54-55,57,64H,5-12,17-29,49-51H2,1-4H3,(H,58,66)(H,59,65)(H,60,68)(H,61,69)(H,62,67)(H,71,72)(H4,52,53,56)/t31-,34?,36-,37-,38-,39-,41-/m0/s1
DMW2GA4 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NCC(CCCCN)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMW2GA4 IK DMDCNLGMRLTMHD-PLXGHWBHSA-N
DMW2GA4 IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[6-amino-2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]hexyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMW2GA4 DE Discovery agent
DMS0V84 ID DMS0V84
DMS0V84 DN Demotensin 3
DMS0V84 HS Investigative
DMS0V84 SN Demotensin 3; CHEMBL219862
DMS0V84 PC 44413846
DMS0V84 MW 1018.3
DMS0V84 FM C48H87N15O9
DMS0V84 IC InChI=1S/C48H87N15O9/c1-30(2)24-37(46(71)72)61-44(69)40(48(3,4)5)62-42(67)36(25-31-13-15-34(64)16-14-31)60-43(68)38-12-9-23-63(38)45(70)35(11-8-20-56-47(52)53)57-28-33(10-6-7-17-49)59-39(65)29-58-41(66)32(26-54-21-18-50)27-55-22-19-51/h13-16,30,32-33,35-38,40,54-55,57,64H,6-12,17-29,49-51H2,1-5H3,(H,58,66)(H,59,65)(H,60,68)(H,61,69)(H,62,67)(H,71,72)(H4,52,53,56)/t33?,35-,36-,37-,38-,40+/m0/s1
DMS0V84 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NCC(CCCCN)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMS0V84 IK XXQNJIPZSZMHCW-FZJJICHOSA-N
DMS0V84 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[6-amino-2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]hexyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoic acid
DMS0V84 DE Discovery agent
DMB2HXM ID DMB2HXM
DMB2HXM DN Demotensin 4
DMB2HXM HS Investigative
DMB2HXM SN Demotensin 4; CHEMBL375002
DMB2HXM PC 44413847
DMB2HXM MW 1046.3
DMB2HXM FM C48H87N17O9
DMB2HXM IC InChI=1S/C48H87N17O9/c1-29(2)23-36(45(73)74)63-43(71)39(48(3,4)5)64-41(69)35(24-30-12-14-33(66)15-13-30)62-42(70)37-11-8-22-65(37)44(72)34(10-7-19-58-47(53)54)59-27-32(9-6-18-57-46(51)52)61-38(67)28-60-40(68)31(25-55-20-16-49)26-56-21-17-50/h12-15,29,31-32,34-37,39,55-56,59,66H,6-11,16-28,49-50H2,1-5H3,(H,60,68)(H,61,67)(H,62,70)(H,63,71)(H,64,69)(H,73,74)(H4,51,52,57)(H4,53,54,58)/t32?,34-,35-,36-,37-,39+/m0/s1
DMB2HXM CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NCC(CCCN=C(N)N)NC(=O)CNC(=O)C(CNCCN)CNCCN
DMB2HXM IK GDXILVHURHRHQL-DTKPYEPFSA-N
DMB2HXM IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[2-[[3-(2-aminoethylamino)-2-[(2-aminoethylamino)methyl]propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoic acid
DMB2HXM DE Discovery agent
DMNWRV9 ID DMNWRV9
DMNWRV9 DN De-O-sulfonated kotalanol
DMNWRV9 HS Investigative
DMNWRV9 SN De-O-Sulfonated Kotalanol
DMNWRV9 DT Small molecular drug
DMNWRV9 PC 52942310
DMNWRV9 MW 380.84
DMNWRV9 FM C12H25ClO9S
DMNWRV9 IC InChI=1S/C12H25O9S.ClH/c13-1-5(15)10(19)12(21)11(20)7(17)4-22-3-6(16)9(18)8(22)2-14;/h5-21H,1-4H2;1H/q+1;/p-1/t5-,6+,7+,8+,9-,10+,11+,12+,22?;/m0./s1
DMNWRV9 CS C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H]([C@@H]([C@@H]([C@H](CO)O)O)O)O)O)CO)O)O.[Cl-]
DMNWRV9 IK RCIVZPJZNIFSOZ-RDZATYDKSA-M
DMNWRV9 IU (2S,3R,4R,5S,6S)-7-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]heptane-1,2,3,4,5,6-hexol;chloride
DMNWRV9 DE Discovery agent
DM5JFKX ID DM5JFKX
DM5JFKX DN DEOXY SALVINORIN A
DM5JFKX HS Investigative
DM5JFKX SN deoxy salvinorin A; CHEMBL378635; SCHEMBL13044189; BDBM50189165; (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-ethoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-benzo[f]isochromene-7-carboxylate
DM5JFKX DT Small molecular drug
DM5JFKX PC 44415858
DM5JFKX MW 418.5
DM5JFKX FM C23H30O7
DM5JFKX IC InChI=1S/C23H30O7/c1-5-29-16-10-15(20(25)27-4)22(2)8-6-14-21(26)30-17(13-7-9-28-12-13)11-23(14,3)19(22)18(16)24/h7,9,12,14-17,19H,5-6,8,10-11H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1
DM5JFKX CS CCO[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
DM5JFKX IK IYIKKRWPZJDFNB-AGQYDFLVSA-N
DM5JFKX IU methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-ethoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DM5JFKX DE Discovery agent
DMS6X1I ID DMS6X1I
DMS6X1I DN DEOXYADENOSINE
DMS6X1I HS Investigative
DMS6X1I SN CHEMBL416340; 9H-Purin-6-amine, 9-(2-deoxy-.beta.-D-ribofuranosyl)-; 9-(2-deoxypentofuranosyl)-9H-purin-6-amine; .beta.-D-erythro-Pentofuranoside, adenine-9 2-deoxy-; .beta.-D-Ribofuranose,2-dideoxy-; 9H-Purin-6-amine, 9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-; SR-01000397552; 13276-53-4; dAdo
DMS6X1I DT Small molecular drug
DMS6X1I PC 13730
DMS6X1I MW 251.24
DMS6X1I FM C10H13N5O3
DMS6X1I IC InChI=1S/C10H13N5O3/c11-9-8-10(13-3-12-9)15(4-14-8)7-1-5(17)6(2-16)18-7/h3-7,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,7+/m0/s1
DMS6X1I CS C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)CO)O
DMS6X1I IK OLXZPDWKRNYJJZ-RRKCRQDMSA-N
DMS6X1I IU (2R,3S,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
DMS6X1I CA CAS 958-09-8
DMS6X1I CB CHEBI:17256
DMYAJCG ID DMYAJCG
DMYAJCG DN Deoxy-Bigchap
DMYAJCG HS Investigative
DMYAJCG SN Big CHAP, Deoxy; N,N-bis-(3-D-Gluconamidopropyl)deoxycholamide; AC1MTX5H; DTXSID70394140; AN-35629; FT-0629429; N,N -Bis(3-D -gluconamidopropyl)- deoxy-cholamide; N-[3-[4-(3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide
DMYAJCG DT Small molecular drug
DMYAJCG PC 446320
DMYAJCG MW 862.1
DMYAJCG FM C42H75N3O15
DMYAJCG IC InChI=1S/C42H75N3O15/c1-22(26-9-10-27-25-8-7-23-18-24(48)12-13-41(23,2)28(25)19-31(51)42(26,27)3)6-11-32(52)45(16-4-14-43-39(59)37(57)35(55)33(53)29(49)20-46)17-5-15-44-40(60)38(58)36(56)34(54)30(50)21-47/h22-31,33-38,46-51,53-58H,4-21H2,1-3H3,(H,43,59)(H,44,60)/t22-,23-,24-,25+,26-,27+,28+,29-,30-,31+,33-,34-,35+,36+,37-,38-,41+,42-/m1/s1
DMYAJCG CS C[C@H](CCC(=O)N(CCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)CCCNC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DMYAJCG IK OJSUWTDDXLCUFR-HGZMBBKESA-N
DMYAJCG IU (2R,3S,4R,5R)-N-[3-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]-[3-[[(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl]amino]propyl]-2,3,4,5,6-pentahydroxyhexanamide
DMYAJCG CA CAS 86303-23-3
DMYAJCG DE Discovery agent
DMW6YLS ID DMW6YLS
DMW6YLS DN Deoxycorticosterone
DMW6YLS HS Investigative
DMW6YLS SN 11-deoxycorticosterone; 21-hydroxyprogesterone
DMW6YLS DT Small molecular drug
DMW6YLS PC 6166
DMW6YLS MW 330.5
DMW6YLS FM C21H30O3
DMW6YLS IC InChI=1S/C21H30O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h11,15-18,22H,3-10,12H2,1-2H3/t15-,16-,17-,18+,20-,21-/m0/s1
DMW6YLS CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)CO)CCC4=CC(=O)CC[C@]34C
DMW6YLS IK ZESRJSPZRDMNHY-YFWFAHHUSA-N
DMW6YLS IU (8S,9S,10R,13S,14S,17S)-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DMW6YLS CA CAS 64-85-7
DMW6YLS CB CHEBI:16973
DMW6YLS DE Discovery agent
DMKFMRY ID DMKFMRY
DMKFMRY DN Deoxyfluorothymidine
DMKFMRY HS Investigative
DMKFMRY PC 66659296
DMKFMRY MW 244.22
DMKFMRY FM C10H13FN2O4
DMKFMRY IC InChI=1S/C10H13FN2O4/c1-6-4-13(9(16)12-8(6)15)10(11)3-2-7(5-14)17-10/h4,7,14H,2-3,5H2,1H3,(H,12,15,16)/t7-,10-/m0/s1
DMKFMRY CS CC1=CN(C(=O)NC1=O)[C@]2(CC[C@H](O2)CO)F
DMKFMRY IK KKBCCKWJPCJQLO-XVKPBYJWSA-N
DMKFMRY IU 1-[(2S,5S)-2-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMKFMRY DE Discovery agent
DMR90HY ID DMR90HY
DMR90HY DN Deoxythymidine
DMR90HY HS Investigative
DMR90HY SN Thymidine; thymidine; 50-89-5; deoxythymidine; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748
DMR90HY DT Small molecular drug
DMR90HY PC 5789
DMR90HY MW 242.23
DMR90HY FM C10H14N2O5
DMR90HY IC InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m0/s1
DMR90HY CS CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
DMR90HY IK IQFYYKKMVGJFEH-XLPZGREQSA-N
DMR90HY IU 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
DMR90HY CA CAS 146183-25-7
DMR90HY CB CHEBI:17748
DMR90HY DE Discovery agent
DMIFMDC ID DMIFMDC
DMIFMDC DN Deoxyuridine-5'-Diphosphate
DMIFMDC HS Investigative
DMIFMDC SN dUDP; DEOXYURIDINE-5'-DIPHOSPHATE; 2'-Deoxyuridine 5'-diphosphate; 4208-67-7; deoxyuridine-diphosphate; Deoxyuridine diphosphate; Uridine 5'-(trihydrogen diphosphate), 2'-deoxy-; CHEMBL9519; CHEBI:28850; 2'-deoxyuridine-5'-diphosphate; 2'-deoxyuridine 5'-(trihydrogen diphosphate); DUD; 1dud; Deoxyuridine 5'-diphosphate; AC1L3RS9; SCHEMBL156694; Uridine, 2'-deoxy-, 5'-(trihydrogen pyrophosphate); DTXSID90194922; 2''-Deoxyuridine-5''-diphosphate; ZINC8217150; DEOXYURIDINE-5''-DIPHOSPHATE; BDBM50179185; DB03413
DMIFMDC DT Small molecular drug
DMIFMDC PC 145729
DMIFMDC MW 388.16
DMIFMDC FM C9H14N2O11P2
DMIFMDC IC InChI=1S/C9H14N2O11P2/c12-5-3-8(11-2-1-7(13)10-9(11)14)21-6(5)4-20-24(18,19)22-23(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,18,19)(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMIFMDC CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)OP(=O)(O)O)O
DMIFMDC IK QHWZTVCCBMIIKE-SHYZEUOFSA-N
DMIFMDC IU [(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DMIFMDC CA CAS 4208-67-7
DMIFMDC CB CHEBI:28850
DMIFMDC DE Discovery agent
DMCG5V2 ID DMCG5V2
DMCG5V2 DN Deoxyuridine-5'-Triphosphate
DMCG5V2 HS Investigative
DMCG5V2 SN dUTP; Deoxyuridine triphosphate; deoxy-UTP; DEOXYURIDINE-5'-TRIPHOSPHATE; 2'-Deoxyuridine 5'-triphosphate; Deoxyuridine 5'-triphosphate; 2'-deoxy-UTP; 2'-Deoxyuracil 5'-triphosphate; 1173-82-6; 102814-08-4; CHEMBL374361; CHEBI:17625; N(4)-Methoxydeoxycytidine triphosphate; 2'-deoxyuridine 5'-(tetrahydrogen triphosphate); Uridine 5'-(tetrahydrogen triphosphate), 2'-deoxy-; 2'-Deoxyuridine-5'-triphosphate trisodium salt; [[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosp
DMCG5V2 DT Small molecular drug
DMCG5V2 PC 65070
DMCG5V2 MW 468.14
DMCG5V2 FM C9H15N2O14P3
DMCG5V2 IC InChI=1S/C9H15N2O14P3/c12-5-3-8(11-2-1-7(13)10-9(11)14)23-6(5)4-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,18,19)(H,20,21)(H,10,13,14)(H2,15,16,17)/t5-,6+,8+/m0/s1
DMCG5V2 CS C1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
DMCG5V2 IK AHCYMLUZIRLXAA-SHYZEUOFSA-N
DMCG5V2 IU [[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMCG5V2 CA CAS 1173-82-6
DMCG5V2 CB CHEBI:17625
DMCG5V2 DE Discovery agent
DMGHM1L ID DMGHM1L
DMGHM1L DN Dephospho Coenzyme A
DMGHM1L HS Investigative
DMGHM1L SN 3'-dephospho-CoA; 3-dephospho-CoA; 3633-59-8; 3'-dephospho-CoA(2-); CHEBI:57328; adenosine 5'-{3-[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl] diphosphate}
DMGHM1L DT Small molecular drug
DMGHM1L PC 444485
DMGHM1L MW 687.6
DMGHM1L FM C21H35N7O13P2S
DMGHM1L IC InChI=1S/C21H35N7O13P2S/c1-21(2,16(32)19(33)24-4-3-12(29)23-5-6-44)8-39-43(36,37)41-42(34,35)38-7-11-14(30)15(31)20(40-11)28-10-27-13-17(22)25-9-26-18(13)28/h9-11,14-16,20,30-32,44H,3-8H2,1-2H3,(H,23,29)(H,24,33)(H,34,35)(H,36,37)(H2,22,25,26)/t11-,14-,15-,16+,20-/m1/s1
DMGHM1L CS CC(C)(COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)[C@H](C(=O)NCCC(=O)NCCS)O
DMGHM1L IK KDTSHFARGAKYJN-IBOSZNHHSA-N
DMGHM1L IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-sulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
DMGHM1L CA CAS 3633-59-8
DMGHM1L CB CHEBI:15468
DMGHM1L DE Discovery agent
DMRFBD0 ID DMRFBD0
DMRFBD0 DN Deprenyl
DMRFBD0 HS Investigative
DMRFBD0 SN 2323-36-6; CHEBI:50217; N,alpha-Dimethyl-N-2-propynylphenethylamine; N,alpha-Dimethyl-N-2-propynylbenzeneethanamine; methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine; PHENETHYLAMINE, N,alpha-DIMETHYL-N-2-PROPYNYL-; N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine; dl-Deprenyl; phenylisopropyl-n-methylpropinylamine; AC1L1JT6; CHEMBL8663; SCHEMBL74753; cid_92913; 4-fluorodeprenyl, (-)-isomer; BDBM39862; MEZLKOACVSPNER-UHFFFAOYSA-N; HMS2089B08; AC1Q2862; MCULE-3188554308; ACM2323366
DMRFBD0 DT Small molecular drug
DMRFBD0 PC 5195
DMRFBD0 MW 187.28
DMRFBD0 FM C13H17N
DMRFBD0 IC InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3
DMRFBD0 CS CC(CC1=CC=CC=C1)N(C)CC#C
DMRFBD0 IK MEZLKOACVSPNER-UHFFFAOYSA-N
DMRFBD0 IU N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
DMRFBD0 CA CAS 2323-36-6
DMRFBD0 CB CHEBI:50217
DMRFBD0 DE Discovery agent
DMH340E ID DMH340E
DMH340E DN Deprotected cogener of M6G
DMH340E HS Investigative
DMH340E SN Deprotected cogener of M6G; CHEMBL362202
DMH340E DT Small molecular drug
DMH340E PC 44390358
DMH340E MW 504.6
DMH340E FM C26H36N2O8
DMH340E IC InChI=1S/C26H36N2O8/c1-28-8-7-26-15(18(28)9-13-3-4-14(30)10-16(13)26)5-6-17(25(26)35-2)27-21(31)11-19-22(32)24(34)23(33)20(12-29)36-19/h3-6,10,15,17-20,22-25,29-30,32-34H,7-9,11-12H2,1-2H3,(H,27,31)/t15-,17+,18+,19?,20?,22?,23?,24?,25?,26-/m0/s1
DMH340E CS CN1CC[C@]23[C@H]([C@H]1CC4=C2C=C(C=C4)O)C=C[C@H](C3OC)NC(=O)CC5C(C(C(C(O5)CO)O)O)O
DMH340E IK RSJUYYKJXWPIQQ-LEBYPUKTSA-N
DMH340E IU N-[(1S,9R,10R,13R)-4-hydroxy-14-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-yl]-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide
DMH340E DE Discovery agent
DM4JM50 ID DM4JM50
DM4JM50 DN DEPX
DM4JM50 HS Investigative
DM4JM50 SN 1,3-Diethyl-8-phenylxanthine; 75922-48-4; UNII-2KCV39GKGL; 2KCV39GKGL; 1,3-Dithyl-8-phenylxanthine; CHEMBL11348; 1,3-diethyl-8-phenyl-7H-purine-2,6-dione; 1H-Purine-2,6-dione,1,3-diethyl-3,9-dihydro-8-phenyl-; Lopac-A-003; AC1Q6LCB; AC1L1B8H; Lopac0_000125; GTPL445; 8-Phenyl-1,3-diethylxanthine; SCHEMBL1321894; AC1Q312F; 1,3-Diethyl-8-phenyl-3,7-dihydro-purine-2,6-dione; BDBM81971; CTK5E2202; CAS_1328; ZINC9229229; NSC_1328; PDSP2_000975; PDSP1_000991; PDSP2_000324; PDSP2_000321; PDSP1_000326; PDSP1_000323; AKOS027378654; 1,3-diethyl-8-phenylxanthine; DPX
DM4JM50 DT Small molecular drug
DM4JM50 PC 1328
DM4JM50 MW 284.31
DM4JM50 FM C15H16N4O2
DM4JM50 IC InChI=1S/C15H16N4O2/c1-3-18-13-11(14(20)19(4-2)15(18)21)16-12(17-13)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3,(H,16,17)
DM4JM50 CS CCN1C2=C(C(=O)N(C1=O)CC)NC(=N2)C3=CC=CC=C3
DM4JM50 IK LVSWNSHUTPWCNF-UHFFFAOYSA-N
DM4JM50 IU 1,3-diethyl-8-phenyl-7H-purine-2,6-dione
DM4JM50 CA CAS 75922-48-4
DM4JM50 DE Discovery agent
DM2XT7S ID DM2XT7S
DM2XT7S DN D-Eritadenine
DM2XT7S HS Investigative
DM2XT7S SN AC1O59J4; ZINC3872190; (2S,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid; (2S,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxy-butanoic acid; 9H-Purine-9-propanoic acid, 6-amino-alpha-hydroxy-, (alphaR)-
DM2XT7S DT Small molecular drug
DM2XT7S PC 159961
DM2XT7S MW 253.22
DM2XT7S FM C9H11N5O4
DM2XT7S IC InChI=1S/C9H11N5O4/c10-7-5-8(12-2-11-7)14(3-13-5)1-4(15)6(16)9(17)18/h2-4,6,15-16H,1H2,(H,17,18)(H2,10,11,12)/t4-,6-/m1/s1
DM2XT7S CS C1=NC(=C2C(=N1)N(C=N2)C[C@H]([C@H](C(=O)O)O)O)N
DM2XT7S IK LIEMBEWXEZJEEZ-INEUFUBQSA-N
DM2XT7S IU (2R,3R)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid
DM2XT7S CA CAS 23918-98-1
DMCYQHO ID DMCYQHO
DMCYQHO DN DERMORPHIN
DMCYQHO HS Investigative
DMCYQHO SN Dermorphin; 77614-16-5; H-Tyr-D-ala-phe-gly-tyr-pro-ser-NH2; UNII-2SEC01B703; DERMORPHIN ACETATE; Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide; CHEMBL278789; 2SEC01B703; Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2; AC1NUNYZ; YAFGYPS-NH2; SCHEMBL237169; Tyr-Ala-Phe-Gly-Tyr-Pro-Ser; DTXSID40228281; HY-P0244
DMCYQHO DT Small molecular drug
DMCYQHO PC 5485199
DMCYQHO MW 802.9
DMCYQHO FM C40H50N8O10
DMCYQHO IC InChI=1S/C40H50N8O10/c1-23(44-37(55)29(41)18-25-9-13-27(50)14-10-25)36(54)46-30(19-24-6-3-2-4-7-24)38(56)43-21-34(52)45-31(20-26-11-15-28(51)16-12-26)40(58)48-17-5-8-33(48)39(57)47-32(22-49)35(42)53/h2-4,6-7,9-16,23,29-33,49-51H,5,8,17-22,41H2,1H3,(H2,42,53)(H,43,56)(H,44,55)(H,45,52)(H,46,54)(H,47,57)/t23-,29+,30+,31+,32+,33+/m1/s1
DMCYQHO CS C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMCYQHO IK FHZPGIUBXYVUOY-VWGYHWLBSA-N
DMCYQHO IU (2S)-N-[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]-1-[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMCYQHO CA CAS 77614-16-5
DMCYQHO DE Discovery agent
DMMWDC5 ID DMMWDC5
DMMWDC5 DN Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5 HS Investigative
DMMWDC5 SN CHEMBL263587; Des-AA1,2,4,12,13-[D-Trp8]SRIF
DMMWDC5 PC 44388046
DMMWDC5 MW 1193.4
DMMWDC5 FM C58H72N12O12S2
DMMWDC5 IC InChI=1S/C58H72N12O12S2/c1-33(71)49-57(80)68-44(27-36-19-9-4-10-20-36)54(77)69-47(58(81)82)32-84-83-31-39(60)50(73)64-46(29-48(61)72)56(79)66-42(25-34-15-5-2-6-16-34)52(75)65-43(26-35-17-7-3-8-18-35)53(76)67-45(28-37-30-62-40-22-12-11-21-38(37)40)55(78)63-41(51(74)70-49)23-13-14-24-59/h2-12,15-22,30,33,39,41-47,49,62,71H,13-14,23-29,31-32,59-60H2,1H3,(H2,61,72)(H,63,78)(H,64,73)(H,65,75)(H,66,79)(H,67,76)(H,68,80)(H,69,77)(H,70,74)(H,81,82)/t33-,39-,41+,42-,43+,44+,45+,46+,47+,49-/m1/s1
DMMWDC5 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)N)C(=O)O)CC6=CC=CC=C6)O
DMMWDC5 IK LAZNVYHNZZBPSL-ZXQPUDBWSA-N
DMMWDC5 IU (4R,7S,10R,13S,16S,19S,22R,25S,28S)-28-amino-13-(4-aminobutyl)-25-(2-amino-2-oxoethyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMMWDC5 DE Discovery agent
DMR6Z2N ID DMR6Z2N
DMR6Z2N DN Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N HS Investigative
DMR6Z2N SN CHEMBL410047; Des-AA1,2,4,13-[D-Trp8]SRIF
DMR6Z2N PC 44388125
DMR6Z2N MW 1294.5
DMR6Z2N FM C62H79N13O14S2
DMR6Z2N IC InChI=1S/C62H79N13O14S2/c1-34(76)51-60(86)72-46(28-38-20-10-5-11-21-38)59(85)75-52(35(2)77)61(87)73-49(62(88)89)33-91-90-32-41(64)53(79)68-48(30-50(65)78)58(84)70-44(26-36-16-6-3-7-17-36)55(81)69-45(27-37-18-8-4-9-19-37)56(82)71-47(29-39-31-66-42-23-13-12-22-40(39)42)57(83)67-43(54(80)74-51)24-14-15-25-63/h3-13,16-23,31,34-35,41,43-49,51-52,66,76-77H,14-15,24-30,32-33,63-64H2,1-2H3,(H2,65,78)(H,67,83)(H,68,79)(H,69,81)(H,70,84)(H,71,82)(H,72,86)(H,73,87)(H,74,80)(H,75,85)(H,88,89)/t34-,35-,41-,43+,44-,45+,46+,47+,48+,49+,51-,52-/m1/s1
DMR6Z2N CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)N)C(=O)O)[C@@H](C)O)CC6=CC=CC=C6)O
DMR6Z2N IK AQDRYTXOCJPYQG-WJYXJFIFSA-N
DMR6Z2N IU (4R,7R,10S,13R,16S,19S,22S,25R,28S,31S)-31-amino-16-(4-aminobutyl)-28-(2-amino-2-oxoethyl)-10,22,25-tribenzyl-7,13-bis[(1R)-1-hydroxyethyl]-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carboxylic acid
DMR6Z2N DE Discovery agent
DMEVOD2 ID DMEVOD2
DMEVOD2 DN Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF
DMEVOD2 HS Investigative
DMEVOD2 SN CHEMBL438285; Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF
DMEVOD2 DT Small molecular drug
DMEVOD2 PC 44388051
DMEVOD2 MW 978.2
DMEVOD2 FM C50H59N9O8S2
DMEVOD2 IC InChI=1S/C50H59N9O8S2/c51-23-13-12-22-38-45(61)56-41(26-33-18-8-3-9-19-33)48(64)59-43(50(66)67)30-69-68-29-36(52)44(60)55-39(24-31-14-4-1-5-15-31)46(62)57-40(25-32-16-6-2-7-17-32)47(63)58-42(49(65)54-38)27-34-28-53-37-21-11-10-20-35(34)37/h1-11,14-21,28,36,38-43,53H,12-13,22-27,29-30,51-52H2,(H,54,65)(H,55,60)(H,56,61)(H,57,62)(H,58,63)(H,59,64)(H,66,67)/t36-,38+,39-,40+,41+,42+,43+/m1/s1
DMEVOD2 CS C1[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)O)CC2=CC=CC=C2)CCCCN)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)N
DMEVOD2 IK NQJATBPHPBJDPZ-CEDQUOLKSA-N
DMEVOD2 IU (4R,7S,10S,13S,16S,19R,22S)-22-amino-10-(4-aminobutyl)-7,16,19-tribenzyl-13-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxylic acid
DMEVOD2 DE Discovery agent
DMJI6BK ID DMJI6BK
DMJI6BK DN Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF
DMJI6BK HS Investigative
DMJI6BK SN CHEMBL368304; Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF
DMJI6BK DT Small molecular drug
DMJI6BK PC 44388050
DMJI6BK MW 932.1
DMJI6BK FM C45H57N9O9S2
DMJI6BK IC InChI=1S/C45H57N9O9S2/c1-26(55)38-44(61)53-37(45(62)63)25-65-64-24-31(47)39(56)50-34(20-27-12-4-2-5-13-27)41(58)51-35(21-28-14-6-3-7-15-28)42(59)52-36(22-29-23-48-32-17-9-8-16-30(29)32)43(60)49-33(40(57)54-38)18-10-11-19-46/h2-9,12-17,23,26,31,33-38,48,55H,10-11,18-22,24-25,46-47H2,1H3,(H,49,60)(H,50,56)(H,51,58)(H,52,59)(H,53,61)(H,54,57)(H,62,63)/t26-,31-,33+,34-,35+,36+,37+,38-/m1/s1
DMJI6BK CS C[C@H]([C@@H]1C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)O
DMJI6BK IK SEXJHXQMYWDZHJ-CNNVYZKHSA-N
DMJI6BK IU (4R,7R,10S,13S,16S,19R,22S)-22-amino-10-(4-aminobutyl)-16,19-dibenzyl-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxylic acid
DMJI6BK DE Discovery agent
DMYZXEO ID DMYZXEO
DMYZXEO DN Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO HS Investigative
DMYZXEO SN CHEMBL386784; Des-AA1,2,4,5,13-[D-Trp8]-SRIF
DMYZXEO PC 44388023
DMYZXEO MW 1180.4
DMYZXEO FM C58H73N11O12S2
DMYZXEO IC InChI=1S/C58H73N11O12S2/c1-33(70)48-56(78)66-45(28-37-20-10-5-11-21-37)55(77)69-49(34(2)71)57(79)67-47(58(80)81)32-83-82-31-40(60)50(72)63-43(26-35-16-6-3-7-17-35)52(74)64-44(27-36-18-8-4-9-19-36)53(75)65-46(29-38-30-61-41-23-13-12-22-39(38)41)54(76)62-42(51(73)68-48)24-14-15-25-59/h3-13,16-23,30,33-34,40,42-49,61,70-71H,14-15,24-29,31-32,59-60H2,1-2H3,(H,62,76)(H,63,72)(H,64,74)(H,65,75)(H,66,78)(H,67,79)(H,68,73)(H,69,77)(H,80,81)/t33-,34-,40-,42+,43-,44+,45+,46+,47+,48-,49-/m1/s1
DMYZXEO CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)[C@@H](C)O)CC6=CC=CC=C6)O
DMYZXEO IK IHKVTDBEFCOKGW-FNLAWZLKSA-N
DMYZXEO IU (4R,7R,10S,13R,16S,19S,22S,25R,28S)-28-amino-16-(4-aminobutyl)-10,22,25-tribenzyl-7,13-bis[(1R)-1-hydroxyethyl]-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMYZXEO DE Discovery agent
DM6HZ8D ID DM6HZ8D
DM6HZ8D DN Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF
DM6HZ8D HS Investigative
DM6HZ8D SN CHEMBL367125; Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF
DM6HZ8D DT Small molecular drug
DM6HZ8D PC 44388049
DM6HZ8D MW 932.1
DM6HZ8D FM C45H57N9O9S2
DM6HZ8D IC InChI=1S/C45H57N9O9S2/c1-26(55)38-44(61)52-35(21-28-14-6-3-7-15-28)42(59)53-37(45(62)63)25-65-64-24-31(47)39(56)50-34(20-27-12-4-2-5-13-27)41(58)51-36(22-29-23-48-32-17-9-8-16-30(29)32)43(60)49-33(40(57)54-38)18-10-11-19-46/h2-9,12-17,23,26,31,33-38,48,55H,10-11,18-22,24-25,46-47H2,1H3,(H,49,60)(H,50,56)(H,51,58)(H,52,61)(H,53,59)(H,54,57)(H,62,63)/t26-,31-,33+,34+,35+,36+,37+,38-/m1/s1
DM6HZ8D CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)N)C(=O)O)CC5=CC=CC=C5)O
DM6HZ8D IK GGSHKARHPHVZOO-KLCDHWPJSA-N
DM6HZ8D IU (4R,7S,10R,13S,16S,19S,22S)-22-amino-13-(4-aminobutyl)-7,19-dibenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxylic acid
DM6HZ8D DE Discovery agent
DMEN4G8 ID DMEN4G8
DMEN4G8 DN Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8 HS Investigative
DMEN4G8 SN CHEMBL436962; Des-AA1,2,4,5-[D-Trp8]SRIF
DMEN4G8 PC 44388022
DMEN4G8 MW 1267.5
DMEN4G8 FM C61H78N12O14S2
DMEN4G8 IC InChI=1S/C61H78N12O14S2/c1-34(75)50-59(84)69-46(28-38-20-10-5-11-21-38)57(82)73-51(35(2)76)60(85)70-48(31-74)58(83)71-49(61(86)87)33-89-88-32-41(63)52(77)66-44(26-36-16-6-3-7-17-36)54(79)67-45(27-37-18-8-4-9-19-37)55(80)68-47(29-39-30-64-42-23-13-12-22-40(39)42)56(81)65-43(53(78)72-50)24-14-15-25-62/h3-13,16-23,30,34-35,41,43-51,64,74-76H,14-15,24-29,31-33,62-63H2,1-2H3,(H,65,81)(H,66,77)(H,67,79)(H,68,80)(H,69,84)(H,70,85)(H,71,83)(H,72,78)(H,73,82)(H,86,87)/t34-,35-,41-,43+,44-,45+,46+,47+,48+,49+,50-,51-/m1/s1
DMEN4G8 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=CC=C6)O
DMEN4G8 IK CGHVCXMPDMMIFL-JFJBRMBESA-N
DMEN4G8 IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31S)-31-amino-19-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carboxylic acid
DMEN4G8 DE Discovery agent
DMZPXGY ID DMZPXGY
DMZPXGY DN Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY HS Investigative
DMZPXGY SN CHEMBL265836; Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF
DMZPXGY PC 44388048
DMZPXGY MW 1297.6
DMZPXGY FM C67H84N12O11S2
DMZPXGY IC InChI=1S/C67H84N12O11S2/c1-40(2)70-36-46-28-26-45(27-29-46)34-55-65(87)79-58(41(3)80)66(88)77-54(33-44-21-11-6-12-22-44)63(85)78-57(67(89)90)39-92-91-38-49(69)59(81)72-51(25-15-16-30-68)60(82)73-52(31-42-17-7-4-8-18-42)61(83)74-53(32-43-19-9-5-10-20-43)62(84)76-56(64(86)75-55)35-47-37-71-50-24-14-13-23-48(47)50/h4-14,17-24,26-29,37,40-41,49,51-58,70-71,80H,15-16,25,30-36,38-39,68-69H2,1-3H3,(H,72,81)(H,73,82)(H,74,83)(H,75,86)(H,76,84)(H,77,88)(H,78,85)(H,79,87)(H,89,90)/t41-,49-,51-,52-,53+,54+,55+,56+,57+,58-/m1/s1
DMZPXGY CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CC7=CC=CC=C7)O
DMZPXGY IK CRBKELXXBMEXSB-BHKHLLRWSA-N
DMZPXGY IU (4R,7S,10R,13S,16S,19S,22R,25R,28S)-28-amino-25-(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-13-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMZPXGY DE Discovery agent
DM1KJAE ID DM1KJAE
DM1KJAE DN Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE HS Investigative
DM1KJAE SN CHEMBL216992; Des-AA1,2,5,12,13-[D-Trp8]SRIF
DM1KJAE PC 44388047
DM1KJAE MW 1207.5
DM1KJAE FM C60H78N12O11S2
DM1KJAE IC InChI=1S/C60H78N12O11S2/c1-36(73)51-59(81)70-48(31-39-21-9-4-10-22-39)57(79)71-50(60(82)83)35-85-84-34-42(63)52(74)65-44(25-13-15-27-61)53(75)67-46(29-37-17-5-2-6-18-37)55(77)68-47(30-38-19-7-3-8-20-38)56(78)69-49(32-40-33-64-43-24-12-11-23-41(40)43)58(80)66-45(54(76)72-51)26-14-16-28-62/h2-12,17-24,33,36,42,44-51,64,73H,13-16,25-32,34-35,61-63H2,1H3,(H,65,74)(H,66,80)(H,67,75)(H,68,77)(H,69,78)(H,70,81)(H,71,79)(H,72,76)(H,82,83)/t36-,42-,44-,45+,46-,47+,48+,49+,50+,51-/m1/s1
DM1KJAE CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)N)C(=O)O)CC6=CC=CC=C6)O
DM1KJAE IK ANCUAJMQRRZZNC-JFMJRBFYSA-N
DM1KJAE IU (4R,7S,10R,13S,16S,19S,22R,25R,28S)-28-amino-13,25-bis(4-aminobutyl)-7,19,22-tribenzyl-10-[(1R)-1-hydroxyethyl]-16-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DM1KJAE DE Discovery agent
DMVYHGI ID DMVYHGI
DMVYHGI DN Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF
DMVYHGI HS Investigative
DMVYHGI SN CHEMBL408611; Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF
DMVYHGI PC 44388131
DMVYHGI MW 1510.8
DMVYHGI FM C77H99N13O15S2
DMVYHGI IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-59-71(98)89-65(46(3)92)75(102)86-60(38-50-23-13-8-14-24-50)72(99)90-66(47(4)93)76(103)87-62(42-91)73(100)88-64(77(104)105)44-107-106-43-63(79-5)74(101)81-56(27-17-18-34-78)67(94)82-57(36-48-19-9-6-10-20-48)68(95)83-58(37-49-21-11-7-12-22-49)69(96)85-61(70(97)84-59)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,79-80,91-93H,17-18,27,34,36-44,78H2,1-5H3,(H,81,101)(H,82,94)(H,83,95)(H,84,97)(H,85,96)(H,86,102)(H,87,103)(H,88,100)(H,89,98)(H,90,99)(H,104,105)/t46-,47-,56-,57-,58+,59+,60+,61+,62+,63-,64+,65-,66-/m1/s1
DMVYHGI CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMVYHGI IK ZXYYWYGCHOCUCC-TWURSWGVSA-N
DMVYHGI IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-34-(methylamino)-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMVYHGI DE Discovery agent
DMY6NID ID DMY6NID
DMY6NID DN Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF
DMY6NID HS Investigative
DMY6NID SN CHEMBL265120; Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF
DMY6NID PC 44388071
DMY6NID MW 1499.8
DMY6NID FM C75H98N14O15S2
DMY6NID IC InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-57-69(97)88-63(44(3)91)73(101)85-58(35-48-23-13-8-14-24-48)70(98)89-64(45(4)92)74(102)86-60(40-90)71(99)87-62(75(103)104)42-106-105-41-61(77-5)72(100)80-54(27-17-18-32-76)65(93)81-55(33-46-19-9-6-10-20-46)66(94)82-56(34-47-21-11-7-12-22-47)67(95)84-59(68(96)83-57)37-51-39-79-53-26-16-15-25-52(51)53/h6-16,19-26,28-31,39,43-45,54-64,77-79,90-92H,17-18,27,32-38,40-42,76H2,1-5H3,(H,80,100)(H,81,93)(H,82,94)(H,83,96)(H,84,95)(H,85,101)(H,86,102)(H,87,99)(H,88,97)(H,89,98)(H,103,104)/t44-,45-,54-,55-,56+,57+,58+,59+,60+,61-,62+,63-,64-/m1/s1
DMY6NID CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMY6NID IK TUTDPAIJDZFFHJ-NLGCSLGGSA-N
DMY6NID IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-34-(methylamino)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMY6NID DE Discovery agent
DMQPVGO ID DMQPVGO
DMQPVGO DN Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF
DMQPVGO HS Investigative
DMQPVGO SN CHEMBL407125; Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF
DMQPVGO PC 44388041
DMQPVGO MW 1510.8
DMQPVGO FM C77H99N13O15S2
DMQPVGO IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)38-59-70(97)88-65(46(3)92)74(101)84-60(37-49-21-11-7-12-22-49)71(98)89-66(47(4)93)75(102)86-62(42-91)72(99)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)85-61(39-50-23-13-8-14-24-50)76(103)90(5)64(73(100)83-59)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,100)(H,84,101)(H,85,96)(H,86,102)(H,87,99)(H,88,97)(H,89,98)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMQPVGO CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)C)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMQPVGO IK QWPPERHSUFQZTH-PCKPOTSRSA-N
DMQPVGO IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-23-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMQPVGO DE Discovery agent
DM478XZ ID DM478XZ
DM478XZ DN Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF
DM478XZ HS Investigative
DM478XZ SN CHEMBL406559; Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF
DM478XZ PC 44388034
DM478XZ MW 1510.8
DM478XZ FM C77H99N13O15S2
DM478XZ IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-59-70(97)88-65(46(3)92)74(101)85-60(38-50-23-13-8-14-24-50)71(98)89-66(47(4)93)75(102)86-62(42-91)72(99)87-63(77(104)105)44-107-106-43-56(79)76(103)90(5)64(27-17-18-34-78)73(100)84-58(37-49-21-11-7-12-22-49)68(95)81-57(36-48-19-9-6-10-20-48)67(94)83-61(69(96)82-59)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,95)(H,82,96)(H,83,94)(H,84,100)(H,85,101)(H,86,102)(H,87,99)(H,88,97)(H,89,98)(H,104,105)/t46-,47-,56-,57+,58-,59+,60+,61+,62+,63+,64-,65-,66-/m1/s1
DM478XZ CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)C)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DM478XZ IK MQVPKOMHWCOKLK-DXVDGIIASA-N
DM478XZ IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-32-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM478XZ DE Discovery agent
DMQOL73 ID DMQOL73
DMQOL73 DN Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF
DMQOL73 HS Investigative
DMQOL73 SN CHEMBL384195; Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF
DMQOL73 PC 44388111
DMQOL73 MW 1526.8
DMQOL73 FM C77H99N13O16S2
DMQOL73 IC InChI=1S/C77H99N13O16S2/c1-44(2)80-40-51-25-23-50(24-26-51)39-64-73(101)89-66(46(4)93)74(102)84-60(37-49-28-31-55(94)32-29-49)71(99)88-65(45(3)92)75(103)86-62(41-91)72(100)87-63(77(105)106)43-108-107-42-56(79)67(95)81-57(22-14-15-33-78)68(96)82-58(35-47-16-8-6-9-17-47)69(97)83-59(36-48-18-10-7-11-19-48)70(98)85-61(76(104)90(64)5)38-52-27-30-53-20-12-13-21-54(53)34-52/h6-13,16-21,23-32,34,44-46,56-66,80,91-94H,14-15,22,33,35-43,78-79H2,1-5H3,(H,81,95)(H,82,96)(H,83,97)(H,84,102)(H,85,98)(H,86,103)(H,87,100)(H,88,99)(H,89,101)(H,105,106)/t45-,46-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMQOL73 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CC5=CC=CC=C5C=C4)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMQOL73 IK UJXURZZWDWWNQY-SKAXSEQXSA-N
DMQOL73 IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-20-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMQOL73 DE Discovery agent
DMN4ZYO ID DMN4ZYO
DMN4ZYO DN Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF
DMN4ZYO HS Investigative
DMN4ZYO SN CHEMBL427658; Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF
DMN4ZYO PC 44388042
DMN4ZYO MW 1510.8
DMN4ZYO FM C77H99N13O15S2
DMN4ZYO IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)40-64-73(100)89-66(47(4)93)74(101)84-60(38-50-23-13-8-14-24-50)71(98)88-65(46(3)92)75(102)86-62(42-91)72(99)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-61(76(103)90(64)5)39-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,101)(H,85,97)(H,86,102)(H,87,99)(H,88,98)(H,89,100)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMN4ZYO CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CC5=CC=CC=C5C=C4)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMN4ZYO IK JNLTXZJTSBQWNR-PCKPOTSRSA-N
DMN4ZYO IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-20-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMN4ZYO DE Discovery agent
DMXD60K ID DMXD60K
DMXD60K DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF
DMXD60K HS Investigative
DMXD60K SN CHEMBL438576; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF
DMXD60K PC 44388056
DMXD60K MW 1510.8
DMXD60K FM C77H99N13O15S2
DMXD60K IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-60-72(99)88-65(46(3)92)74(101)86-61(38-50-23-13-8-14-24-50)73(100)89-66(47(4)93)75(102)87-63(42-91)76(103)90(5)64(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-62(71(98)84-60)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,101)(H,87,102)(H,88,99)(H,89,100)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMXD60K CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)C)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMXD60K IK OCBPOFXOMWHIND-PCKPOTSRSA-N
DMXD60K IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMXD60K DE Discovery agent
DM0574W ID DM0574W
DM0574W DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF
DM0574W HS Investigative
DM0574W SN CHEMBL415143; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF
DM0574W PC 44388044
DM0574W MW 1510.8
DM0574W FM C77H99N13O15S2
DM0574W IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)38-60-72(99)89-66(47(4)93)76(103)90(5)64(40-50-23-13-8-14-24-50)74(101)88-65(46(3)92)75(102)86-62(42-91)73(100)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-61(71(98)84-60)39-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,102)(H,87,100)(H,88,101)(H,89,99)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DM0574W CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N1)CC2=CC=CC=C2)C)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)CC4=CC5=CC=CC=C5C=C4)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DM0574W IK VSHSVJQIYKFIKJ-PCKPOTSRSA-N
DM0574W IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-14-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM0574W DE Discovery agent
DMOZ9WC ID DMOZ9WC
DMOZ9WC DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF
DMOZ9WC HS Investigative
DMOZ9WC SN CHEMBL264839; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF
DMOZ9WC PC 44388055
DMOZ9WC MW 1510.8
DMOZ9WC FM C77H99N13O15S2
DMOZ9WC IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)39-60-72(99)88-65(46(3)92)75(102)86-61(38-50-23-13-8-14-24-50)73(100)89-66(47(4)93)76(103)90(5)64(42-91)74(101)87-63(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-62(71(98)84-60)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,102)(H,87,101)(H,88,99)(H,89,100)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMOZ9WC CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)C)[C@@H](C)O)CC7=CC=CC=C7)O
DMOZ9WC IK XJZZHUHCSZMQGG-PCKPOTSRSA-N
DMOZ9WC IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-8-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMOZ9WC DE Discovery agent
DMYFCB0 ID DMYFCB0
DMYFCB0 DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF
DMYFCB0 HS Investigative
DMYFCB0 SN CHEMBL437905; Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF
DMYFCB0 PC 44388045
DMYFCB0 MW 1510.8
DMYFCB0 FM C77H99N13O15S2
DMYFCB0 IC InChI=1S/C77H99N13O15S2/c1-45(2)80-41-52-30-28-51(29-31-52)38-60-72(99)89-65(46(3)92)74(101)86-62(39-50-23-13-8-14-24-50)76(103)90(5)66(47(4)93)75(102)87-63(42-91)73(100)88-64(77(104)105)44-107-106-43-56(79)67(94)81-57(27-17-18-34-78)68(95)82-58(36-48-19-9-6-10-20-48)69(96)83-59(37-49-21-11-7-12-22-49)70(97)85-61(71(98)84-60)40-53-32-33-54-25-15-16-26-55(54)35-53/h6-16,19-26,28-33,35,45-47,56-66,80,91-93H,17-18,27,34,36-44,78-79H2,1-5H3,(H,81,94)(H,82,95)(H,83,96)(H,84,98)(H,85,97)(H,86,101)(H,87,102)(H,88,100)(H,89,99)(H,104,105)/t46-,47-,56-,57-,58-,59+,60+,61+,62+,63+,64+,65-,66-/m1/s1
DMYFCB0 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)C)CC7=CC=CC=C7)O
DMYFCB0 IK NJKZOMFLMSOAAY-PCKPOTSRSA-N
DMYFCB0 IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-11-methyl-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMYFCB0 DE Discovery agent
DM6JAFM ID DM6JAFM
DM6JAFM DN Des-AA1,2,5-[D-Nal8,IAmp9]SRIF
DM6JAFM HS Investigative
DM6JAFM SN CHEMBL410428; Des-AA1,2,5-[D-Nal8,IAmp9]SRIF
DM6JAFM PC 44388130
DM6JAFM MW 1496.8
DM6JAFM FM C76H97N13O15S2
DM6JAFM IC InChI=1S/C76H97N13O15S2/c1-44(2)79-40-51-29-27-50(28-30-51)38-59-71(98)88-64(45(3)91)74(101)85-60(37-49-22-12-7-13-23-49)72(99)89-65(46(4)92)75(102)86-62(41-90)73(100)87-63(76(103)104)43-106-105-42-55(78)66(93)80-56(26-16-17-33-77)67(94)81-57(35-47-18-8-5-9-19-47)68(95)82-58(36-48-20-10-6-11-21-48)69(96)84-61(70(97)83-59)39-52-31-32-53-24-14-15-25-54(53)34-52/h5-15,18-25,27-32,34,44-46,55-65,79,90-92H,16-17,26,33,35-43,77-78H2,1-4H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,101)(H,86,102)(H,87,100)(H,88,98)(H,89,99)(H,103,104)/t45-,46-,55-,56-,57-,58+,59+,60+,61+,62+,63+,64-,65-/m1/s1
DM6JAFM CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CC4=CC=CC=C4C=C3)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DM6JAFM IK VQFBJGSUDSOXIC-MKQNODHSSA-N
DM6JAFM IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(naphthalen-2-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM6JAFM DE Discovery agent
DMLHUPY ID DMLHUPY
DMLHUPY DN Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF
DMLHUPY HS Investigative
DMLHUPY SN CHEMBL411860; Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF
DMLHUPY PC 44388074
DMLHUPY MW 1515.8
DMLHUPY FM C75H98N14O16S2
DMLHUPY IC InChI=1S/C75H98N14O16S2/c1-42(2)78-37-49-25-23-48(24-26-49)35-62-71(100)88-64(44(4)92)72(101)83-58(34-47-27-29-51(93)30-28-47)69(98)87-63(43(3)91)73(102)85-60(39-90)70(99)86-61(75(104)105)41-107-106-40-53(77)65(94)80-55(22-14-15-31-76)66(95)81-56(32-45-16-8-6-9-17-45)67(96)82-57(33-46-18-10-7-11-19-46)68(97)84-59(74(103)89(62)5)36-50-38-79-54-21-13-12-20-52(50)54/h6-13,16-21,23-30,38,42-44,53,55-64,78-79,90-93H,14-15,22,31-37,39-41,76-77H2,1-5H3,(H,80,94)(H,81,95)(H,82,96)(H,83,101)(H,84,97)(H,85,102)(H,86,99)(H,87,98)(H,88,100)(H,104,105)/t43-,44-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMLHUPY CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMLHUPY IK HLFGUCDHVNBZCJ-SQPHWWHVSA-N
DMLHUPY IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMLHUPY DE Discovery agent
DMX2I4P ID DMX2I4P
DMX2I4P DN Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P HS Investigative
DMX2I4P SN CHEMBL425465; Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF
DMX2I4P PC 44388072
DMX2I4P MW 1499.8
DMX2I4P FM C75H98N14O15S2
DMX2I4P IC InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-62-71(99)88-64(45(4)92)72(100)83-58(35-48-23-13-8-14-24-48)69(97)87-63(44(3)91)73(101)85-60(40-90)70(98)86-61(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-59(74(102)89(62)5)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,100)(H,84,96)(H,85,101)(H,86,98)(H,87,97)(H,88,99)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMX2I4P CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)N)C(=O)O)CO)O
DMX2I4P IK SRQXVUQUEBDWHI-YNBIXHCXSA-N
DMX2I4P IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMX2I4P DE Discovery agent
DMFXKRO ID DMFXKRO
DMFXKRO DN Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF
DMFXKRO HS Investigative
DMFXKRO SN CHEMBL414716; Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF
DMFXKRO PC 44388065
DMFXKRO MW 1499.8
DMFXKRO FM C75H98N14O15S2
DMFXKRO IC InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-58-70(98)87-63(44(3)91)72(100)85-59(35-48-23-13-8-14-24-48)71(99)88-64(45(4)92)73(101)86-61(40-90)74(102)89(5)62(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-60(69(97)83-58)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,100)(H,86,101)(H,87,98)(H,88,99)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMFXKRO CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)C)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMFXKRO IK ZLXHFZGOMNAVTA-YNBIXHCXSA-N
DMFXKRO IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-5-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMFXKRO DE Discovery agent
DM9EN01 ID DM9EN01
DM9EN01 DN Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF
DM9EN01 HS Investigative
DM9EN01 SN CHEMBL413442; Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF
DM9EN01 PC 44388064
DM9EN01 MW 1499.8
DM9EN01 FM C75H98N14O15S2
DM9EN01 IC InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)36-58-70(98)87-63(44(3)91)73(101)85-59(35-48-23-13-8-14-24-48)71(99)88-64(45(4)92)74(102)89(5)62(40-90)72(100)86-61(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-60(69(97)83-58)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,101)(H,86,100)(H,87,98)(H,88,99)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DM9EN01 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)C)[C@@H](C)O)CC7=CC=CC=C7)O
DM9EN01 IK LSNMSNQCPXUTAH-YNBIXHCXSA-N
DM9EN01 IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-8-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM9EN01 DE Discovery agent
DMB10GV ID DMB10GV
DMB10GV DN Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF
DMB10GV HS Investigative
DMB10GV SN CHEMBL268448; Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF
DMB10GV PC 44388073
DMB10GV MW 1499.8
DMB10GV FM C75H98N14O15S2
DMB10GV IC InChI=1S/C75H98N14O15S2/c1-43(2)78-38-50-30-28-49(29-31-50)35-58-70(98)88-63(44(3)91)72(100)85-60(36-48-23-13-8-14-24-48)74(102)89(5)64(45(4)92)73(101)86-61(40-90)71(99)87-62(75(103)104)42-106-105-41-53(77)65(93)80-55(27-17-18-32-76)66(94)81-56(33-46-19-9-6-10-20-46)67(95)82-57(34-47-21-11-7-12-22-47)68(96)84-59(69(97)83-58)37-51-39-79-54-26-16-15-25-52(51)54/h6-16,19-26,28-31,39,43-45,53,55-64,78-79,90-92H,17-18,27,32-38,40-42,76-77H2,1-5H3,(H,80,93)(H,81,94)(H,82,95)(H,83,97)(H,84,96)(H,85,100)(H,86,101)(H,87,99)(H,88,98)(H,103,104)/t44-,45-,53-,55-,56-,57+,58+,59+,60+,61+,62+,63-,64-/m1/s1
DMB10GV CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)C)CC7=CC=CC=C7)O
DMB10GV IK YZXQZTRDHNBZMS-YNBIXHCXSA-N
DMB10GV IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-11-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMB10GV DE Discovery agent
DMH0DLZ ID DMH0DLZ
DMH0DLZ DN Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF
DMH0DLZ HS Investigative
DMH0DLZ SN CHEMBL413419; Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF
DMH0DLZ PC 44388094
DMH0DLZ MW 1626.7
DMH0DLZ FM C74H96IN15O15S2
DMH0DLZ IC InChI=1S/C74H96IN15O15S2/c1-40(2)79-35-46-24-22-45(23-25-46)31-57-70(101)89-62(41(3)92)73(104)86-58(32-47-26-27-49(94)34-51(47)75)71(102)90-63(42(4)93)74(105)87-60(37-91)72(103)88-61(64(78)95)39-107-106-38-52(77)65(96)81-54(21-13-14-28-76)66(97)82-55(29-43-15-7-5-8-16-43)67(98)83-56(30-44-17-9-6-10-18-44)68(99)85-59(69(100)84-57)33-48-36-80-53-20-12-11-19-50(48)53/h5-12,15-20,22-27,34,36,40-42,52,54-63,79-80,91-94H,13-14,21,28-33,35,37-39,76-77H2,1-4H3,(H2,78,95)(H,81,96)(H,82,97)(H,83,98)(H,84,100)(H,85,99)(H,86,104)(H,87,105)(H,88,103)(H,89,101)(H,90,102)/t41-,42-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1
DMH0DLZ CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)N)CO)[C@@H](C)O)CC7=C(C=C(C=C7)O)I)O
DMH0DLZ IK LLJHRJNXPMGDKL-JFAFYCKWSA-N
DMH0DLZ IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-13-[(4-hydroxy-2-iodophenyl)methyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMH0DLZ DE Discovery agent
DMXWF2Z ID DMXWF2Z
DMXWF2Z DN Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF
DMXWF2Z HS Investigative
DMXWF2Z SN CHEMBL414717; Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF
DMXWF2Z PC 44388092
DMXWF2Z MW 1500.8
DMXWF2Z FM C74H97N15O15S2
DMXWF2Z IC InChI=1S/C74H97N15O15S2/c1-41(2)78-36-48-24-22-46(23-25-48)33-57-70(100)88-62(42(3)91)73(103)85-58(34-47-26-28-50(93)29-27-47)71(101)89-63(43(4)92)74(104)86-60(38-90)72(102)87-61(64(77)94)40-106-105-39-52(76)65(95)80-54(21-13-14-30-75)66(96)81-55(31-44-15-7-5-8-16-44)67(97)82-56(32-45-17-9-6-10-18-45)68(98)84-59(69(99)83-57)35-49-37-79-53-20-12-11-19-51(49)53/h5-12,15-20,22-29,37,41-43,52,54-63,78-79,90-93H,13-14,21,30-36,38-40,75-76H2,1-4H3,(H2,77,94)(H,80,95)(H,81,96)(H,82,97)(H,83,99)(H,84,98)(H,85,103)(H,86,104)(H,87,102)(H,88,100)(H,89,101)/t42-,43-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1
DMXWF2Z CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)N)CO)[C@@H](C)O)CC7=CC=C(C=C7)O)O
DMXWF2Z IK CLYXKNIFFVWQGI-HXVVHKOFSA-N
DMXWF2Z IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMXWF2Z DE Discovery agent
DMSXILZ ID DMSXILZ
DMSXILZ DN Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
DMSXILZ HS Investigative
DMSXILZ SN CHEMBL386023; Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275
DMSXILZ PC 44388129
DMSXILZ MW 1485.8
DMSXILZ FM C74H96N14O15S2
DMSXILZ IC InChI=1S/C74H96N14O15S2/c1-42(2)77-37-49-29-27-48(28-30-49)35-57-69(97)87-62(43(3)90)72(100)84-58(34-47-22-12-7-13-23-47)70(98)88-63(44(4)91)73(101)85-60(39-89)71(99)86-61(74(102)103)41-105-104-40-52(76)64(92)79-54(26-16-17-31-75)65(93)80-55(32-45-18-8-5-9-19-45)66(94)81-56(33-46-20-10-6-11-21-46)67(95)83-59(68(96)82-57)36-50-38-78-53-25-15-14-24-51(50)53/h5-15,18-25,27-30,38,42-44,52,54-63,77-78,89-91H,16-17,26,31-37,39-41,75-76H2,1-4H3,(H,79,92)(H,80,93)(H,81,94)(H,82,96)(H,83,95)(H,84,100)(H,85,101)(H,86,99)(H,87,97)(H,88,98)(H,102,103)/t43-,44-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1
DMSXILZ CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=CC=C7)O
DMSXILZ IK SYHQUPOPQRNSKD-ZDFJKKNGSA-N
DMSXILZ IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMSXILZ DE Discovery agent
DM7MZ2V ID DM7MZ2V
DM7MZ2V DN Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V HS Investigative
DM7MZ2V SN CHEMBL262379; Des-AA1,2,5-[D-Trp8,Tyr11]SRIF
DM7MZ2V PC 44388115
DM7MZ2V MW 1411.6
DM7MZ2V FM C67H90N14O16S2
DM7MZ2V IC InChI=1S/C67H90N14O16S2/c1-37(83)55-65(94)77-51(31-41-23-25-43(85)26-24-41)63(92)81-56(38(2)84)66(95)78-53(34-82)64(93)79-54(67(96)97)36-99-98-35-45(70)57(86)72-47(21-11-13-27-68)58(87)74-49(29-39-15-5-3-6-16-39)60(89)75-50(30-40-17-7-4-8-18-40)61(90)76-52(32-42-33-71-46-20-10-9-19-44(42)46)62(91)73-48(59(88)80-55)22-12-14-28-69/h3-10,15-20,23-26,33,37-38,45,47-56,71,82-85H,11-14,21-22,27-32,34-36,68-70H2,1-2H3,(H,72,86)(H,73,91)(H,74,87)(H,75,89)(H,76,90)(H,77,94)(H,78,95)(H,79,93)(H,80,88)(H,81,92)(H,96,97)/t37-,38-,45-,47-,48+,49-,50+,51+,52+,53+,54+,55-,56-/m1/s1
DM7MZ2V CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=C(C=C6)O)O
DM7MZ2V IK NIVBKEGMFSFLSD-KGVPGVLISA-N
DM7MZ2V IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-34-amino-19,31-bis(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DM7MZ2V DE Discovery agent
DMQRUF6 ID DMQRUF6
DMQRUF6 DN Des-AA1,2,5-[IAmp9,Tyr11]-SRIF
DMQRUF6 HS Investigative
DMQRUF6 SN CHEMBL436887; Des-AA1,2,5-[IAmp9,Tyr11]-SRIF; BDBM50100745
DMQRUF6 PC 44311674
DMQRUF6 MW 1501.8
DMQRUF6 FM C74H96N14O16S2
DMQRUF6 IC InChI=1S/C74H96N14O16S2/c1-41(2)77-36-48-24-22-46(23-25-48)33-57-69(98)87-62(42(3)90)72(101)84-58(34-47-26-28-50(92)29-27-47)70(99)88-63(43(4)91)73(102)85-60(38-89)71(100)86-61(74(103)104)40-106-105-39-52(76)64(93)79-54(21-13-14-30-75)65(94)80-55(31-44-15-7-5-8-16-44)66(95)81-56(32-45-17-9-6-10-18-45)67(96)83-59(68(97)82-57)35-49-37-78-53-20-12-11-19-51(49)53/h5-12,15-20,22-29,37,41-43,52,54-63,77-78,89-92H,13-14,21,30-36,38-40,75-76H2,1-4H3,(H,79,93)(H,80,94)(H,81,95)(H,82,97)(H,83,96)(H,84,101)(H,85,102)(H,86,100)(H,87,98)(H,88,99)(H,103,104)/t42-,43-,52-,54-,55-,56+,57+,58+,59-,60+,61+,62-,63-/m1/s1
DMQRUF6 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)N)C(=O)O)CO)[C@@H](C)O)CC7=CC=C(C=C7)O)O
DMQRUF6 IK FJRAPOZDHJLSPN-KVMFXWMESA-N
DMQRUF6 IU (4R,7S,10R,13S,16R,19S,22R,25S,28R,31R,34S)-34-amino-31-(4-aminobutyl)-25,28-dibenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-13-[(4-hydroxyphenyl)methyl]-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMQRUF6 DE Discovery agent
DMPMAXI ID DMPMAXI
DMPMAXI DN Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF
DMPMAXI HS Investigative
DMPMAXI SN CHEMBL438630; Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF
DMPMAXI PC 44388024
DMPMAXI MW 1433.7
DMPMAXI FM C74H88N12O14S2
DMPMAXI IC InChI=1S/C74H88N12O14S2/c1-42(2)76-38-50-26-24-49(25-27-50)36-58-69(94)85-63(43(3)87)72(97)82-59(35-47-20-12-7-13-21-47)70(95)86-64(44(4)88)73(98)84-62(74(99)100)41-102-101-40-61(83-65(90)54(75)32-48-28-30-52(89)31-29-48)71(96)80-57(34-46-18-10-6-11-19-46)66(91)78-56(33-45-16-8-5-9-17-45)67(92)81-60(68(93)79-58)37-51-39-77-55-23-15-14-22-53(51)55/h5-31,39,42-44,54,56-64,76-77,87-89H,32-38,40-41,75H2,1-4H3,(H,78,91)(H,79,93)(H,80,96)(H,81,92)(H,82,97)(H,83,90)(H,84,98)(H,85,94)(H,86,95)(H,99,100)/t43-,44-,54+,56+,57-,58+,59+,60+,61-,62+,63-,64-/m1/s1
DMPMAXI CS C[C@H]([C@@H]1C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)NC(=O)[C@H](CC8=CC=C(C=C8)O)N)C(=O)O)O
DMPMAXI IK GYAXOXYXFASSKI-GAZSGENXSA-N
DMPMAXI IU (4R,7R,10S,13R,16S,19S,22S,25R,28S)-28-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-10,22,25-tribenzyl-7,13-bis[(1R)-1-hydroxyethyl]-19-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27-octaoxo-16-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26-octazacyclononacosane-4-carboxylic acid
DMPMAXI DE Discovery agent
DMFCA05 ID DMFCA05
DMFCA05 DN Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF
DMFCA05 HS Investigative
DMFCA05 SN CHEMBL262790; Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF
DMFCA05 PC 44388113
DMFCA05 MW 1662
DMFCA05 FM C84H108N16O16S2
DMFCA05 IC InChI=1S/C84H108N16O16S2/c1-48(2)88-43-56-30-28-55(29-31-56)41-70-81(113)99-72(50(4)103)82(114)93-65(40-53-23-13-8-14-24-53)78(110)98-71(49(3)102)83(115)95-67(45-101)79(111)96-68(73(87)105)46-117-118-47-69(97-74(106)60(86)37-54-32-34-58(104)35-33-54)80(112)90-62(27-17-18-36-85)75(107)91-63(38-51-19-9-6-10-20-51)76(108)92-64(39-52-21-11-7-12-22-52)77(109)94-66(84(116)100(70)5)42-57-44-89-61-26-16-15-25-59(57)61/h6-16,19-26,28-35,44,48-50,60,62-72,88-89,101-104H,17-18,27,36-43,45-47,85-86H2,1-5H3,(H2,87,105)(H,90,112)(H,91,107)(H,92,108)(H,93,114)(H,94,109)(H,95,115)(H,96,111)(H,97,106)(H,98,110)(H,99,113)/t49-,50-,60+,62-,63-,64+,65+,66+,67+,68+,69-,70+,71-,72-/m1/s1
DMFCA05 CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)NC(=O)[C@H](CC8=CC=C(C=C8)O)N)C(=O)N)CO)O
DMFCA05 IK UTASAEBFJXWNHX-PIBSBZCFSA-N
DMFCA05 IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMFCA05 DE Discovery agent
DMW56NI ID DMW56NI
DMW56NI DN Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF
DMW56NI HS Investigative
DMW56NI SN CHEMBL414692; Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF
DMW56NI PC 44388102
DMW56NI MW 1663
DMW56NI FM C84H107N15O17S2
DMW56NI IC InChI=1S/C84H107N15O17S2/c1-48(2)87-43-56-30-28-55(29-31-56)41-70-80(111)98-72(50(4)102)81(112)92-65(40-53-23-13-8-14-24-53)77(108)97-71(49(3)101)82(113)94-67(45-100)78(109)96-69(84(115)116)47-118-117-46-68(95-73(104)60(86)37-54-32-34-58(103)35-33-54)79(110)89-62(27-17-18-36-85)74(105)90-63(38-51-19-9-6-10-20-51)75(106)91-64(39-52-21-11-7-12-22-52)76(107)93-66(83(114)99(70)5)42-57-44-88-61-26-16-15-25-59(57)61/h6-16,19-26,28-35,44,48-50,60,62-72,87-88,100-103H,17-18,27,36-43,45-47,85-86H2,1-5H3,(H,89,110)(H,90,105)(H,91,106)(H,92,112)(H,93,107)(H,94,113)(H,95,104)(H,96,109)(H,97,108)(H,98,111)(H,115,116)/t49-,50-,60+,62-,63-,64+,65+,66+,67+,68-,69+,70+,71-,72-/m1/s1
DMW56NI CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)[C@@H](C)O)CC3=CC=C(C=C3)CNC(C)C)C)CC4=CNC5=CC=CC=C54)CC6=CC=CC=C6)CC7=CC=CC=C7)CCCCN)NC(=O)[C@H](CC8=CC=C(C=C8)O)N)C(=O)O)CO)O
DMW56NI IK MGQOSJMBSMGOOM-DNKCOYOSSA-N
DMW56NI IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-20-methyl-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMW56NI DE Discovery agent
DMV8EWF ID DMV8EWF
DMV8EWF DN Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF
DMV8EWF HS Investigative
DMV8EWF SN CHEMBL385811; Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF
DMV8EWF PC 44388103
DMV8EWF MW 1648
DMV8EWF FM C83H106N16O16S2
DMV8EWF IC InChI=1S/C83H106N16O16S2/c1-47(2)87-42-55-29-27-54(28-30-55)40-64-78(110)98-70(48(3)101)82(114)94-65(39-52-22-12-7-13-23-52)79(111)99-71(49(4)102)83(115)95-67(44-100)80(112)96-68(72(86)104)45-116-117-46-69(97-73(105)59(85)36-53-31-33-57(103)34-32-53)81(113)89-61(26-16-17-35-84)74(106)90-62(37-50-18-8-5-9-19-50)75(107)91-63(38-51-20-10-6-11-21-51)76(108)93-66(77(109)92-64)41-56-43-88-60-25-15-14-24-58(56)60/h5-15,18-25,27-34,43,47-49,59,61-71,87-88,100-103H,16-17,26,35-42,44-46,84-85H2,1-4H3,(H2,86,104)(H,89,113)(H,90,106)(H,91,107)(H,92,109)(H,93,108)(H,94,114)(H,95,115)(H,96,112)(H,97,105)(H,98,110)(H,99,111)/t48-,49-,59+,61-,62-,63+,64+,65+,66+,67+,68+,69-,70-,71-/m1/s1
DMV8EWF CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC(=O)[C@H](CC7=CC=C(C=C7)O)N)C(=O)N)CO)[C@@H](C)O)CC8=CC=CC=C8)O
DMV8EWF IK GIGRDXKZXVSPEN-OFTQGXSVSA-N
DMV8EWF IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxamide
DMV8EWF DE Discovery agent
DMLY7DC ID DMLY7DC
DMLY7DC DN Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288
DMLY7DC HS Investigative
DMLY7DC SN CHEMBL411002; Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288
DMLY7DC PC 44388059
DMLY7DC MW 1648.9
DMLY7DC FM C83H105N15O17S2
DMLY7DC IC InChI=1S/C83H105N15O17S2/c1-47(2)86-42-55-29-27-54(28-30-55)40-64-77(108)97-70(48(3)100)81(112)93-65(39-52-22-12-7-13-23-52)78(109)98-71(49(4)101)82(113)94-67(44-99)79(110)96-69(83(114)115)46-117-116-45-68(95-72(103)59(85)36-53-31-33-57(102)34-32-53)80(111)88-61(26-16-17-35-84)73(104)89-62(37-50-18-8-5-9-19-50)74(105)90-63(38-51-20-10-6-11-21-51)75(106)92-66(76(107)91-64)41-56-43-87-60-25-15-14-24-58(56)60/h5-15,18-25,27-34,43,47-49,59,61-71,86-87,99-102H,16-17,26,35-42,44-46,84-85H2,1-4H3,(H,88,111)(H,89,104)(H,90,105)(H,91,107)(H,92,106)(H,93,112)(H,94,113)(H,95,103)(H,96,110)(H,97,108)(H,98,109)(H,114,115)/t48-,49-,59+,61-,62-,63+,64+,65+,66+,67+,68-,69+,70-,71-/m1/s1
DMLY7DC CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)CNC(C)C)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC6=CC=CC=C6)CCCCN)NC(=O)[C@H](CC7=CC=C(C=C7)O)N)C(=O)O)CO)[C@@H](C)O)CC8=CC=CC=C8)O
DMLY7DC IK UKGIKHPFMXOGRF-UXDQVZPXSA-N
DMLY7DC IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-31-(4-aminobutyl)-34-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-19-[[4-[(propan-2-ylamino)methyl]phenyl]methyl]-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMLY7DC DE Discovery agent
DMO3CFV ID DMO3CFV
DMO3CFV DN Des-AA5-[D-Trp8]SRIF
DMO3CFV HS Investigative
DMO3CFV SN CHEMBL408338; Des-AA5-[D-Trp8]SRIF
DMO3CFV PC 44388128
DMO3CFV MW 1523.8
DMO3CFV FM C72H98N16O17S2
DMO3CFV IC InChI=1S/C72H98N16O17S2/c1-40(75)61(93)77-36-58(92)78-56-38-106-107-39-57(72(104)105)86-68(100)55(37-89)85-71(103)60(42(3)91)88-67(99)53(33-45-23-11-6-12-24-45)84-70(102)59(41(2)90)87-63(95)50(28-16-18-30-74)79-66(98)54(34-46-35-76-48-26-14-13-25-47(46)48)83-65(97)52(32-44-21-9-5-10-22-44)82-64(96)51(31-43-19-7-4-8-20-43)81-62(94)49(80-69(56)101)27-15-17-29-73/h4-14,19-26,35,40-42,49-57,59-60,76,89-91H,15-18,27-34,36-39,73-75H2,1-3H3,(H,77,93)(H,78,92)(H,79,98)(H,80,101)(H,81,94)(H,82,96)(H,83,97)(H,84,102)(H,85,103)(H,86,100)(H,87,95)(H,88,99)(H,104,105)/t40-,41+,42+,49+,50-,51+,52-,53-,54-,55-,56+,57-,59+,60+/m0/s1
DMO3CFV CS C[C@H]([C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CCCCN)NC(=O)CNC(=O)[C@H](C)N)C(=O)O)CO)[C@@H](C)O)CC6=CC=CC=C6)O
DMO3CFV IK ZIHRAPFYJSDXSV-BVGUNDCQSA-N
DMO3CFV IU (4R,7S,10R,13S,16R,19S,22S,25S,28R,31R,34S)-19,31-bis(4-aminobutyl)-34-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
DMO3CFV DE Discovery agent
DMVX9I0 ID DMVX9I0
DMVX9I0 DN Des-Arg(9)-[Leu(8)]-BK
DMVX9I0 HS Investigative
DMVX9I0 SN 5-Chloro-4-(N-(cyclopropyl)methyl-N-propylamino)-2-methyl-6-(2,4,6-trichlorophenyl)aminopyridine; NBI 27914; NBI27914; NBI-27914; CHEMBL45281; SR-01000075865; Tocris-1591; Lopac-N-3911; AC1L41YH; Lopac0_000493; MLS000860080; cid_176157; GTPL3512; SCHEMBL16606734; CHEBI:93069; DTXSID20171549; HMS3261D07; HMS3371C20; HMS2230I15; ZINC2511843; Tox21_500493; BDBM50054245; CCG-204584; API0008466; LP00493; 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine; NCGC00261178-01; NCGC00015737-05
DMVX9I0 DT Small molecular drug
DMVX9I0 PC 176157
DMVX9I0 MW 434.2
DMVX9I0 FM C18H20Cl4N4
DMVX9I0 IC InChI=1S/C18H20Cl4N4/c1-3-6-26(9-11-4-5-11)18-15(22)17(23-10(2)24-18)25-16-13(20)7-12(19)8-14(16)21/h7-8,11H,3-6,9H2,1-2H3,(H,23,24,25)
DMVX9I0 CS CCCN(CC1CC1)C2=NC(=NC(=C2Cl)NC3=C(C=C(C=C3Cl)Cl)Cl)C
DMVX9I0 IK KNADXBVKFAUMCR-UHFFFAOYSA-N
DMVX9I0 IU 5-chloro-4-N-(cyclopropylmethyl)-2-methyl-4-N-propyl-6-N-(2,4,6-trichlorophenyl)pyrimidine-4,6-diamine
DMVX9I0 CA CAS 184241-44-9
DMVX9I0 CB CHEBI:93069
DMVX9I0 DE Depression
DMZ5Y94 ID DMZ5Y94
DMZ5Y94 DN Des-Arg10-Kallidin
DMZ5Y94 HS Investigative
DMZ5Y94 SN des-Arg10-Kallidin; 71800-36-7; kallidin, des-Arg(10)-; Lys-[Des-Arg9]Bradykinin; CHEMBL264100; [des-Arg10]kallidin; (Des-Arg10)kallidin; Lys-[des-Arg9]-bradykinin; Lys-(Des-Arg9)-Bradykinin; Bradykinin, lys-desarg(9); 10-De-arg-kallidin; Lys-des-arg(9)-BK; Des-arg(10)-kallidin
DMZ5Y94 DT Small molecular drug
DMZ5Y94 PC 122227
DMZ5Y94 MW 1032.2
DMZ5Y94 FM C50H73N13O11
DMZ5Y94 IC InChI=1S/C50H73N13O11/c51-22-8-7-17-33(52)42(66)58-34(18-9-23-55-50(53)54)46(70)63-26-12-21-40(63)48(72)62-25-10-19-38(62)44(68)56-29-41(65)57-35(27-31-13-3-1-4-14-31)43(67)60-37(30-64)47(71)61-24-11-20-39(61)45(69)59-36(49(73)74)28-32-15-5-2-6-16-32/h1-6,13-16,33-40,64H,7-12,17-30,51-52H2,(H,56,68)(H,57,65)(H,58,66)(H,59,69)(H,60,67)(H,73,74)(H4,53,54,55)/t33-,34-,35-,36-,37-,38-,39-,40-/m0/s1
DMZ5Y94 CS C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O
DMZ5Y94 IK AILVBOHFGXNHCC-TZPCGENMSA-N
DMZ5Y94 IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
DMZ5Y94 CA CAS 71800-36-7
DMZ5Y94 DE Discovery agent
DMWO4EI ID DMWO4EI
DMWO4EI DN Des-Arg10-Leu9-Kallidin
DMWO4EI HS Investigative
DMWO4EI SN 71800-37-8; Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt; Lys-(Des-Arg9,Leu8)-Bradykinin; AC1NSJPW; Lys-[Leu...8...][des-Arg...9...]Bradykinin; des(Arg10, Leu9)-Kallidin; CHEMBL384721; ZINC169731077; CP-0298; [Leu8]des-Arg10-Kallidin (Lys-[Leu8]des-Arg9-Bradykinin); Lys-(des-Arg9, Leu8)-Bradykinin trifluoroacetate salt, >
DMWO4EI DT Small molecular drug
DMWO4EI PC 5310951
DMWO4EI MW 998.2
DMWO4EI FM C47H75N13O11
DMWO4EI IC InChI=1S/C47H75N13O11/c1-28(2)24-33(46(70)71)56-42(66)36-17-10-21-58(36)44(68)34(27-61)57-40(64)32(25-29-12-4-3-5-13-29)54-38(62)26-53-41(65)35-16-9-22-59(35)45(69)37-18-11-23-60(37)43(67)31(15-8-20-52-47(50)51)55-39(63)30(49)14-6-7-19-48/h3-5,12-13,28,30-37,61H,6-11,14-27,48-49H2,1-2H3,(H,53,65)(H,54,62)(H,55,63)(H,56,66)(H,57,64)(H,70,71)(H4,50,51,52)/t30-,31-,32-,33-,34-,35-,36-,37-/m0/s1
DMWO4EI CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N
DMWO4EI IK AGTPZUQKOYEAOH-MDKUUQCZSA-N
DMWO4EI IU (2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoic acid
DMWO4EI DE Discovery agent
DMIKUBY ID DMIKUBY
DMIKUBY DN Des-bromoaplysamine-1
DMIKUBY HS Investigative
DMIKUBY SN des-bromoaplysamine-1; CHEMBL204377; BDBM50177732; SY246342; MFCD30297079 (95%); 3-[4-[2-(Dimethylamino)ethyl]phenoxy-2,6-D2]-N,N-dimethyl-1-propanamine
DMIKUBY DT Small molecular drug
DMIKUBY PC 44407803
DMIKUBY MW 250.38
DMIKUBY FM C15H26N2O
DMIKUBY IC InChI=1S/C15H26N2O/c1-16(2)11-5-13-18-15-8-6-14(7-9-15)10-12-17(3)4/h6-9H,5,10-13H2,1-4H3
DMIKUBY CS CN(C)CCCOC1=CC=C(C=C1)CCN(C)C
DMIKUBY IK DXZMBOOTLSIFGN-UHFFFAOYSA-N
DMIKUBY IU 3-[4-[2-(dimethylamino)ethyl]phenoxy]-N,N-dimethylpropan-1-amine
DMIKUBY DE Discovery agent
DMQER8D ID DMQER8D
DMQER8D DN Deschloroflavopiridol
DMQER8D HS Investigative
DMQER8D DT Small molecular drug
DMQER8D PC 102397231
DMQER8D MW 368.4
DMQER8D FM C21H22NO5+
DMQER8D IC InChI=1S/C21H21NO5/c1-22-8-7-13(17(26)11-22)19-14(23)9-15(24)20-16(25)10-18(27-21(19)20)12-5-3-2-4-6-12/h2-6,9-10,13,17,23-24,26H,7-8,11H2,1H3/p+1
DMQER8D CS C[NH+]1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4)O)O
DMQER8D IK PGWURUYAKNYOPM-UHFFFAOYSA-O
DMQER8D IU 5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-1-ium-4-yl)-2-phenylchromen-4-one
DMQER8D DE Discovery agent
DMAB9KG ID DMAB9KG
DMAB9KG DN Desclasinose Azithromycinarylalkyl Hydroxamate
DMAB9KG HS Investigative
DMAB9KG SN Desclasinose Azithromycinarylalkyl Hydroxamate; CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10
DMAB9KG DT Small molecular drug
DMAB9KG PC 25151110
DMAB9KG MW 853.1
DMAB9KG FM C44H76N4O12
DMAB9KG IC InChI=1S/C44H76N4O12/c1-11-34-44(8,56)39(53)30(6)47(9)24-26(2)23-43(7,55)40(28(4)37(51)29(5)41(54)59-34)60-42-38(52)33(22-27(3)58-42)48(10)25-31-18-20-32(21-19-31)45-35(49)16-14-12-13-15-17-36(50)46-57/h18-21,26-30,33-34,37-40,42,51-53,55-57H,11-17,22-25H2,1-10H3,(H,45,49)(H,46,50)/t26-,27-,28+,29-,30-,33+,34-,37+,38-,39-,40-,42+,43-,44-/m1/s1
DMAB9KG CS CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O)C)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)CC3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO)O)(C)O)C)C)C)O)(C)O
DMAB9KG IK DJGOCARXUHEYRZ-AYWHDHSOSA-N
DMAB9KG IU N-[4-[[[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]-methylamino]methyl]phenyl]-N'-hydroxyoctanediamide
DMAB9KG DE Discovery agent
DM47JFS ID DM47JFS
DM47JFS DN Desethyl isoquine
DM47JFS HS Investigative
DM47JFS SN desethyl isoquine; CHEMBL146826; ZINC1912679; BDBM50134934
DM47JFS DT Small molecular drug
DM47JFS PC 11450263
DM47JFS MW 327.8
DM47JFS FM C18H18ClN3O
DM47JFS IC InChI=1S/C18H18ClN3O/c1-2-20-11-12-3-5-14(10-18(12)23)22-16-7-8-21-17-9-13(19)4-6-15(16)17/h3-10,20,23H,2,11H2,1H3,(H,21,22)
DM47JFS CS CCNCC1=C(C=C(C=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O
DM47JFS IK XWBLHPDICBKAEX-UHFFFAOYSA-N
DM47JFS IU 5-[(7-chloroquinolin-4-yl)amino]-2-(ethylaminomethyl)phenol
DM47JFS DE Discovery agent
DMJK0H5 ID DMJK0H5
DMJK0H5 DN DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT
DMJK0H5 HS Investigative
DMJK0H5 PC 44321093
DMJK0H5 MW 1322.5
DMJK0H5 FM C64H75N9O18S2
DMJK0H5 IC InChI=1S/C64H75N9O18S2/c1-4-32(2)51-57(83)72-52(33(3)74)58(84)68-44(29-49(65)78)55(81)69-45(31-92-93-63(22-6-5-7-23-63)30-50(79)70-53(59(85)71-51)34-12-15-36(75)16-13-34)60(86)73-25-9-11-46(73)56(82)67-43(61(87)88)10-8-24-66-54(80)35-14-19-39-42(26-35)64(91-62(39)89)40-20-17-37(76)27-47(40)90-48-28-38(77)18-21-41(48)64/h12-21,26-28,32-33,43-46,51-53,74-77H,4-11,22-25,29-31H2,1-3H3,(H2,65,78)(H,66,80)(H,67,82)(H,68,84)(H,69,81)(H,70,79)(H,71,85)(H,72,83)(H,87,88)/t32?,33?,43-,44+,45+,46+,51+,52+,53-/m0/s1
DMJK0H5 CS CCC(C)[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CSSC2(CCCCC2)CC(=O)N[C@H](C(=O)N1)C3=CC=C(C=C3)O)C(=O)N4CCC[C@@H]4C(=O)N[C@@H](CCCNC(=O)C5=CC6=C(C=C5)C(=O)OC67C8=C(C=C(C=C8)O)OC9=C7C=CC(=C9)O)C(=O)O)CC(=O)N)C(C)O
DMJK0H5 IK YDQFMQKHNPCEQF-AMPJLWALSA-N
DMJK0H5 IU (2S)-2-[[(2R)-1-[(10S,13R,16R,19R,22S)-13-(2-amino-2-oxoethyl)-19-butan-2-yl-16-(1-hydroxyethyl)-22-(4-hydroxyphenyl)-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carbonyl]amino]-5-[(3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carbonyl)amino]pentanoic acid
DMJK0H5 DE Discovery agent
DMGTAZ4 ID DMGTAZ4
DMGTAZ4 DN Des-His1[Glu9]glucagon-NH2
DMGTAZ4 HS Investigative
DMGTAZ4 PC 44389629
DMGTAZ4 MW 3509.8
DMGTAZ4 FM C155H230N44O48S
DMGTAZ4 IC InChI=1S/C155H230N44O48S/c1-74(2)55-100(137(231)180-98(50-54-248-12)135(229)188-107(63-117(160)212)146(240)198-123(78(8)204)126(161)220)183-141(235)106(61-85-66-170-90-30-20-19-29-89(85)90)187-133(227)96(44-48-116(159)211)181-151(245)122(76(5)6)197-144(238)104(57-81-25-15-13-16-26-81)186-142(236)108(64-120(216)217)189-132(226)95(43-47-115(158)210)174-127(221)77(7)173-129(223)92(32-23-52-168-154(162)163)175-130(224)93(33-24-53-169-155(164)165)177-148(242)112(71-202)194-143(237)109(65-121(218)219)190-138(232)101(56-75(3)4)182-139(233)102(59-83-34-38-87(207)39-35-83)184-131(225)91(31-21-22-51-156)176-147(241)111(70-201)193-140(234)103(60-84-36-40-88(208)41-37-84)185-134(228)97(45-49-119(214)215)179-150(244)113(72-203)195-153(247)125(80(10)206)199-145(239)105(58-82-27-17-14-18-28-82)191-152(246)124(79(9)205)196-118(213)68-171-128(222)94(42-46-114(157)209)178-149(243)110(69-200)192-136(230)99(166-11)62-86-67-167-73-172-86/h13-20,25-30,34-41,66-67,73-80,91-113,122-125,166,170,200-208H,21-24,31-33,42-65,68-72,156H2,1-12H3,(H2,157,209)(H2,158,210)(H2,159,211)(H2,160,212)(H2,161,220)(H,167,172)(H,171,222)(H,173,223)(H,174,221)(H,175,224)(H,176,241)(H,177,242)(H,178,243)(H,179,244)(H,180,231)(H,181,245)(H,182,233)(H,183,235)(H,184,225)(H,185,228)(H,186,236)(H,187,227)(H,188,229)(H,189,226)(H,190,232)(H,191,246)(H,192,230)(H,193,234)(H,194,237)(H,195,247)(H,196,213)(H,197,238)(H,198,240)(H,199,239)(H,214,215)(H,216,217)(H,218,219)(H4,162,163,168)(H4,164,165,169)/t77-,78+,79+,80+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,122-,123-,124-,125-/m0/s1
DMGTAZ4 CS C[C@H]([C@@H](C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CNC=N7)NC)O
DMGTAZ4 IK QAFHHWFRTULWIL-OQZBCNBHSA-N
DMGTAZ4 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-3-(1H-imidazol-4-yl)-2-(methylamino)propanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid
DMGTAZ4 DE Discovery agent
DMB07WE ID DMB07WE
DMB07WE DN Desirudine
DMB07WE HS Investigative
DMB07WE DE Discovery agent
DM58XJN ID DM58XJN
DM58XJN DN Desmethylastemizole
DM58XJN HS Investigative
DM58XJN SN O-Desmethyl Astemizole; 73736-50-2; UNII-L460QHM1YN; L460QHM1YN; CHEMBL60796; Demethylastemizole; 4-[2-[4-[[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]amino]piperidin-1-yl]ethyl]phenol; Desmethylasteizole; R-44-271; R 44 271; O-Demethylastemizole; O-Desmethylastemizole; AC1L4F06; SCHEMBL1152697; CTK8G2140; DTXSID10224058; LAGYWHSFHIMTPE-UHFFFAOYSA-N; ZINC13537287; BDBM50131433; AKOS030240026; Phenol, 4-(2-(4-((1-((4-fluorophenyl)methyl)-1H-benzimidazol-2-yl)amino)-1-piperidinyl)ethyl)-; FT-0666079; R 44271; DESMETHEYLASTEMIZOLE
DM58XJN DT Small molecular drug
DM58XJN PC 155805
DM58XJN MW 444.5
DM58XJN FM C27H29FN4O
DM58XJN IC InChI=1S/C27H29FN4O/c28-22-9-5-21(6-10-22)19-32-26-4-2-1-3-25(26)30-27(32)29-23-14-17-31(18-15-23)16-13-20-7-11-24(33)12-8-20/h1-12,23,33H,13-19H2,(H,29,30)
DM58XJN CS C1CN(CCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)CCC5=CC=C(C=C5)O
DM58XJN IK LAGYWHSFHIMTPE-UHFFFAOYSA-N
DM58XJN IU 4-[2-[4-[[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]amino]piperidin-1-yl]ethyl]phenol
DM58XJN CA CAS 73736-50-2
DM58XJN DE Discovery agent
DMIESYM ID DMIESYM
DMIESYM DN Desmethylclomipramine
DMIESYM HS Investigative
DMIESYM SN Desmethylclomipramine; Norclomipramine; UNII-01DN47PPQG; 01DN47PPQG; N-Demethylclomipramine; Demethylchlorimipramine; Desmethylchlorimipramine; AC1LDNXR; SCHEMBL11384662; VPIXQGUBUKFLRF-UHFFFAOYSA-N; CHEBI:124969; ZINC2570877; API0007900; BRD-K52696183-003-01-0; 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N-methyl-; 3-Chloro-10,11-dihydro-N-methyl-5H-dibenz(b,f)azepine-5-propanamine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMIESYM DT Small molecular drug
DMIESYM PC 622606
DMIESYM MW 300.8
DMIESYM FM C18H21ClN2
DMIESYM IC InChI=1S/C18H21ClN2/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3
DMIESYM CS CNCCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
DMIESYM IK VPIXQGUBUKFLRF-UHFFFAOYSA-N
DMIESYM IU 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
DMIESYM CA CAS 303-48-0
DMIESYM CB CHEBI:124969
DMIESYM DE Discovery agent
DMLKBNR ID DMLKBNR
DMLKBNR DN DESMETHYLOLANZAPINE
DMLKBNR HS Investigative
DMLKBNR DT Small molecular drug
DMLKBNR PC 135446209
DMLKBNR MW 298.4
DMLKBNR FM C16H18N4S
DMLKBNR IC InChI=1S/C16H18N4S/c1-11-10-12-15(20-8-6-17-7-9-20)18-13-4-2-3-5-14(13)19-16(12)21-11/h2-5,10,17,19H,6-9H2,1H3
DMLKBNR CS CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCNCC4
DMLKBNR IK FHPIXVHJEIZKJW-UHFFFAOYSA-N
DMLKBNR IU 2-methyl-4-piperazin-1-yl-10H-thieno[2,3-b][1,5]benzodiazepine
DMLKBNR CA CAS 161696-76-0
DMLKBNR DE Discovery agent
DMV8SUM ID DMV8SUM
DMV8SUM DN Desmosterol
DMV8SUM HS Investigative
DMV8SUM SN DESMOSTEROL; 24-Dehydrocholesterol; 313-04-2; UNII-ANP93865R8; cholest-5,24-dien-3beta-ol; Cholesta-5,24-dien-3beta-ol; NSC 226126; CHEBI:17737; 3beta-cholesta-5,24-dien-3-ol; ANP93865R8; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesta-5,24-dien-3-ol; desmesterol; EINECS 206-236-2; 24-dehydro Cholesterol; 24,25-Dehydrocholesterol; AC1L97ME; Cholesta-5,24-dien-3b-ol; 5,24-Cholestadien-3beta-ol; 5,24-Cholestadien-3
DMV8SUM DT Small molecular drug
DMV8SUM PC 439577
DMV8SUM MW 384.6
DMV8SUM FM C27H44O
DMV8SUM IC InChI=1S/C27H44O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h7,9,19,21-25,28H,6,8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
DMV8SUM CS C[C@H](CCC=C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DMV8SUM IK AVSXSVCZWQODGV-DPAQBDIFSA-N
DMV8SUM IU (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DMV8SUM CA CAS 313-04-2
DMV8SUM CB CHEBI:17737
DMV8SUM DE Discovery agent
DMW740T ID DMW740T
DMW740T DN desulfated cholecystokinin-8
DMW740T HS Investigative
DMW740T SN des-CCK-8; desulfated sincalide
DMW740T DT Small molecular drug
DMW740T PC 3084441
DMW740T MW 1063.2
DMW740T FM C49H62N10O13S2
DMW740T IC InChI=1S/C49H62N10O13S2/c1-73-18-16-34(46(69)56-36(20-28-12-14-30(60)15-13-28)44(67)43(66)32(50)23-41(62)63)54-40(61)26-53-45(68)37(22-29-25-52-33-11-7-6-10-31(29)33)57-47(70)35(17-19-74-2)55-48(71)38(24-42(64)65)58-49(72)39(59-51)21-27-8-4-3-5-9-27/h3-15,25,32,34-39,52,59-60H,16-24,26,50-51H2,1-2H3,(H,53,68)(H,54,61)(H,55,71)(H,56,69)(H,57,70)(H,58,72)(H,62,63)(H,64,65)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
DMW740T CS CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)C(=O)[C@H](CC(=O)O)N)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC4=CC=CC=C4)NN
DMW740T IK ZBTPHEHKAHBSMT-YRVFCXMDSA-N
DMW740T IU (3S,6S)-3-amino-6-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-hydrazinyl-3-phenylpropanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]-4-methylsulfanylbutanoyl]amino]-7-(4-hydroxyphenyl)-4,5-dioxoheptanoic acid
DMW740T CA CAS 25679-24-7
DMW740T DE Discovery agent
DMFWDNJ ID DMFWDNJ
DMFWDNJ DN detirelix
DMFWDNJ HS Investigative
DMFWDNJ SN 102583-46-0; 89662-30-6; RS-68439; detirelix acetate
DMFWDNJ DT Small molecular drug
DMFWDNJ PC 16129698
DMFWDNJ MW 1538.2
DMFWDNJ FM C78H105ClN18O13
DMFWDNJ IC InChI=1S/C78H105ClN18O13/c1-7-83-78(84-8-2)86-34-14-13-21-58(68(102)92-60(37-45(3)4)69(103)91-59(22-15-35-85-77(81)82)76(110)97-36-16-23-66(97)75(109)88-46(5)67(80)101)90-71(105)62(40-49-27-32-55(100)33-28-49)94-74(108)65(44-98)96-73(107)64(42-53-43-87-57-20-12-11-19-56(53)57)95-72(106)63(39-48-25-30-54(79)31-26-48)93-70(104)61(89-47(6)99)41-50-24-29-51-17-9-10-18-52(51)38-50/h9-12,17-20,24-33,38,43,45-46,58-66,87,98,100H,7-8,13-16,21-23,34-37,39-42,44H2,1-6H3,(H2,80,101)(H,88,109)(H,89,99)(H,90,105)(H,91,103)(H,92,102)(H,93,104)(H,94,108)(H,95,106)(H,96,107)(H4,81,82,85)(H2,83,84,86)/t46-,58-,59+,60+,61-,62+,63-,64-,65+,66+/m1/s1
DMFWDNJ CS CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C)NCC
DMFWDNJ IK OFQNFLLLCMQNEP-MIPXGPCFSA-N
DMFWDNJ IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMFWDNJ CA CAS 89662-30-6
DMFWDNJ DE Discovery agent
DMPCRSY ID DMPCRSY
DMPCRSY DN Detrothyronine
DMPCRSY HS Investigative
DMPCRSY SN DT-3; 3,5,3'-Triiodo-D-thyronine; CHEMBL557; UNII-46XII7C16X; 46XII7C16X; Detrothyronin; dt 3; 5714/8/9; Dextro-3:5:3'-triiodothyronine; Detrothyroninum; Detrotironina; D-Trijodthyronin; DEXTROTHYRONINE; Triiodothyronine, D-; Detrothyronine [INN]; AC1L2FR4; SCHEMBL8301; AC1Q5R0T; DT 3 (hormone) (VAN); Detrotironina [INN-Spanish]; Detrothyroninum [INN-Latin]; DT3 (VAN); D-3,5,3'-Triiodothyronine; CTK4G9296; (2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; SKF D 2623
DMPCRSY DT Small molecular drug
DMPCRSY PC 71212
DMPCRSY MW 650.97
DMPCRSY FM C15H12I3NO4
DMPCRSY IC InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m1/s1
DMPCRSY CS C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@H](C(=O)O)N)I)I)O
DMPCRSY IK AUYYCJSJGJYCDS-GFCCVEGCSA-N
DMPCRSY IU (2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
DMPCRSY CA CAS 5714-08-9
DMPCRSY DE Discovery agent
DMD4N2F ID DMD4N2F
DMD4N2F DN Devazepide
DMD4N2F HS Investigative
DMD4N2F SN DEVAZEPIDE; 103420-77-5; MK-329; Devazepidum; Devazepida; MK 329; L-364,718; UNII-JE6P7QY7NH; L 364718; (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide; JE6P7QY7NH; CHEMBL9506; CHEBI:4460; L-364718; 3(S)-(-)-1,3-Dihydro-3-(2-indolecarbonylamino)-1-methyl-5-phenyl-2H-(1,4)benzodiazepin-2-one; NCGC00159551-01; DSSTox_RID_81331; DSSTox_CID_26092; DSSTox_GSID_46092; 1H-Indole-2-carboxamide,
DMD4N2F DT Small molecular drug
DMD4N2F PC 443375
DMD4N2F MW 408.5
DMD4N2F FM C25H20N4O2
DMD4N2F IC InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
DMD4N2F CS CN1C2=CC=CC=C2C(=N[C@@H](C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5
DMD4N2F IK NFHRQQKPEBFUJK-HSZRJFAPSA-N
DMD4N2F IU N-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-1H-indole-2-carboxamide
DMD4N2F CA CAS 103420-77-5
DMD4N2F CB CHEBI:4460
DMD4N2F DE Gastrointestinal disease
DM9P4JW ID DM9P4JW
DM9P4JW DN Dexverapamil
DM9P4JW HS Investigative
DM9P4JW SN Dexverapamil; Dexverapamil [INN]; Dexverapamilo; Dexverapamilo [INN-Spanish]; Dexverapamilum; Dexverapamilum [INN-Latin]; QR5PYD126V; R(+)-VERAPAMIL; Verapramil; verapamil-r; (+)-(R)-5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; (+)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; (+)-verapamil; (R)-5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile; 38321-02-7; CHEBI:77734; UNII-QR5PYD126V
DM9P4JW PC 65808
DM9P4JW MW 454.6
DM9P4JW FM C27H38N2O4
DM9P4JW IC SGTNSNPWRIOYBX-HHHXNRCGSA-N
DM9P4JW CS CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
DM9P4JW IK 1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1
DM9P4JW IU (2R)-2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
DM9P4JW CA CAS 38321-02-7
DM9P4JW CB CHEBI:77734
DM9P4JW DE Discovery agent
DMR8M19 ID DMR8M19
DMR8M19 DN DFGYVAE
DMR8M19 HS Investigative
DMR8M19 SN DFGYVAE; CHEMBL1163804; GTPL3023; BDBM50321104; (2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-phenylpropanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]pentanedioic acid
DMR8M19 DT Small molecular drug
DMR8M19 PC 46906168
DMR8M19 MW 799.8
DMR8M19 FM C37H49N7O13
DMR8M19 IC InChI=1S/C37H49N7O13/c1-19(2)31(36(55)40-20(3)32(51)42-25(37(56)57)13-14-29(47)48)44-35(54)27(16-22-9-11-23(45)12-10-22)41-28(46)18-39-34(53)26(15-21-7-5-4-6-8-21)43-33(52)24(38)17-30(49)50/h4-12,19-20,24-27,31,45H,13-18,38H2,1-3H3,(H,39,53)(H,40,55)(H,41,46)(H,42,51)(H,43,52)(H,44,54)(H,47,48)(H,49,50)(H,56,57)/t20-,24-,25-,26-,27-,31-/m0/s1
DMR8M19 CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)N
DMR8M19 IK RRCWAJVJCDGGKS-UQPWSHDPSA-N
DMR8M19 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]pentanedioic acid
DMR8M19 DE Discovery agent
DMNX5VI ID DMNX5VI
DMNX5VI DN D-fructose
DMNX5VI HS Investigative
DMNX5VI SN D-Arabino-Hex-2-ulo-Pyranose; D-Fructopyranose; D-Fructopyranoside; D-Fructose; D-arabino-Hex-2-ulopyranose; Fructopyranose; Fructopyranoside; Fructose; LKDRXBCSQODPBY-VRPWFDPXSA-N; Q27117234; SCHEMBL239448; AKOS004910390; C05003; CHEBI:37714; CHEMBL2325229; CTK2F9011; D-Fru; EB37038E-44A6-4AF7-B0D8-47A315AD2F74; F0317; Fru; [14C]-Fructose
DMNX5VI PC 2723872
DMNX5VI MW 180.16
DMNX5VI FM C6H12O6
DMNX5VI IC LKDRXBCSQODPBY-VRPWFDPXSA-N
DMNX5VI CS C1C(C(C(C(O1)(CO)O)O)O)O
DMNX5VI IK 1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6?/m1/s1
DMNX5VI IU (3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMNX5VI CA CAS 7660-25-5
DMNX5VI CB CHEBI:37714
DMNX5VI DE Functional nausea/vomiting
DMUM84K ID DMUM84K
DMUM84K DN DFU
DMUM84K HS Investigative
DMUM84K SN Deoxyfuconojirimycin; 1,2,6-Trideoxy-2,6-imino-D-galactitol; (2S,3R,4S,5R)-2-methylpiperidine-3,4,5-triol; 99212-30-3; 1,5-Dideoxy-1,5-iminofucitol; CHEMBL314772; 1-Deoxyfuconojirimycin HCl; 1,5-Dideoxy-1,5-imino-L-fucitol; L-fuco-Deoxynojirimycin; Fucosidase Inhibitor, 3; AC1L3UXS; AC1Q59GC; SCHEMBL4378188; 3,4,5-Piperidinetriol, 2-methyl-, (2S,3R,4S,5R)-; CHEBI:132866; 1-Deoxyfuconojirimycin hydrochloride; ZINC2585424; BDBM50065258; AKOS006283710; D-Galactitol, 1,2,6-trideoxy-2,6-imino-; FT-0624513
DMUM84K TC Analgesics
DMUM84K DT Small molecular drug
DMUM84K PC 9906892
DMUM84K MW 360.4
DMUM84K FM C19H17FO4S
DMUM84K IC InChI=1S/C19H17FO4S/c1-19(2)17(12-7-9-15(10-8-12)25(3,22)23)16(18(21)24-19)13-5-4-6-14(20)11-13/h4-11H,1-3H3
DMUM84K CS CC1(C(=C(C(=O)O1)C2=CC(=CC=C2)F)C3=CC=C(C=C3)S(=O)(=O)C)C
DMUM84K IK NXERGIJHYVUXHM-UHFFFAOYSA-N
DMUM84K IU 3-(3-fluorophenyl)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one
DMUM84K CA CAS 178402-36-3
DMUM84K DE Pain
DM527XP ID DM527XP
DM527XP DN D-Gluconhydroximo-1,5-Lactam
DM527XP HS Investigative
DM527XP SN D-GLUCONHYDROXIMO-1,5-LACTAM; CHEMBL1213470; (Z)-D-Gluconhydroximo-1,5-lactam; GOX; (2S,3S,4R,5R)-6-(HYDROXYAMINO)-2-(HYDROXYMETHYL)-2,3,4,5-TETRAHYDROPYRIDINE-3,4,5-TRIOL; CID445248; GHIL; 1e6s; AC1L9HO3; BDBM36390; 3d51; 2j78; BDBM50120840; DB02376; (Z)-D-Gluconhydroximo-1,5-lactam, 15; (2Z,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one oxime
DM527XP DT Small molecular drug
DM527XP PC 445248
DM527XP MW 192.17
DM527XP FM C6H12N2O5
DM527XP IC InChI=1S/C6H12N2O5/c9-1-2-3(10)4(11)5(12)6(7-2)8-13/h2-5,9-13H,1H2,(H,7,8)/t2-,3-,4+,5-/m1/s1
DM527XP CS C([C@@H]1[C@H]([C@@H]([C@H](C(=N1)NO)O)O)O)O
DM527XP IK VBXHGXTYZGYTQG-SQOUGZDYSA-N
DM527XP IU (2R,3R,4S,5S)-6-(hydroxyamino)-2-(hydroxymethyl)-2,3,4,5-tetrahydropyridine-3,4,5-triol
DM527XP DE Discovery agent
DMPMYTE ID DMPMYTE
DMPMYTE DN D-glucosamine-phosphate
DMPMYTE HS Investigative
DMPMYTE SN D-glucosamine 6-phosphate; D-glucosamine phosphate; EN300-258467; XHMJOUIAFHJHBW-IVMDWMLBSA-N; glucosamine-6-phosphate; 2-Amino-2-deoxy-D-glucopyranose 6-phosphoric acid; D-GLUCOSAMINE6-PHOSPHATE; 2-amino-2-deoxy-6-O-phosphono-D-glucopyranose; 2-amino-2-deoxy-D-glucopyranose 6-(dihydrogen phosphate); 2-amino-2-deoxy-D-glucopyranose 6-phosphate; 6590AH; AC1L9AD1; C00352; C6H14NO8P; CHEBI:47987; CHEMBL3426569; MFCD00067382; SCHEMBL13321929; WURCS=2.0/1,1,0/[a2122h-1x_1-5_2*N_6*OPO/3O/3=O]/1/
DMPMYTE PC 440997
DMPMYTE MW 259.149
DMPMYTE FM C6H14NO8P
DMPMYTE IC XHMJOUIAFHJHBW-IVMDWMLBSA-N
DMPMYTE CS C(C1C(C(C(C(O1)O)N)O)O)OP(=O)(O)O
DMPMYTE IK 1S/C6H14NO8P/c7-3-5(9)4(8)2(15-6(3)10)1-14-16(11,12)13/h2-6,8-10H,1,7H2,(H2,11,12,13)/t2-,3-,4-,5-,6?/m1/s1
DMPMYTE IU [(2R,3S,4R,5R)-5-amino-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMPMYTE CA CAS 3616-42-0
DMPMYTE CB CHEBI:47987
DMPMYTE DE Discovery agent
DMMG2TO ID DMMG2TO
DMMG2TO DN D-glucose
DMMG2TO HS Investigative
DMMG2TO SN D-Glucopyranose; Glucopyranose; D-Glc; D-Glcp; Glucodin; Meritose; Clintose L; Roferose ST; CPC hydrate; Clearsweet 95; 2280-44-6; Staleydex 95M; CHEBI:4167; Glucopyranoside; D-Glucopyranoside; Glc; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Glucopyranose, D-; DSSTox_CID_2910; Glucose solution; D-Glucopyranose, anhydrous; glc-ring; D-glucose-ring; Cartose Cerelose; Staleydex 130; Glucose 40; EINECS 218-914-5; Meritose 200; Glc-OH
DMMG2TO DT Small molecular drug
DMMG2TO PC 5793
DMMG2TO MW 180.16
DMMG2TO FM C6H12O6
DMMG2TO IC InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1
DMMG2TO CS C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O
DMMG2TO IK WQZGKKKJIJFFOK-GASJEMHNSA-N
DMMG2TO IU (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMMG2TO CA CAS 2280-44-6
DMMG2TO CB CHEBI:4167
DMMG2TO DE Discovery agent
DMPW46G ID DMPW46G
DMPW46G DN D-glucose 1-phosphate
DMPW46G HS Investigative
DMPW46G SN CIX3U01VAU; D-Glucose alpha-1-phosphate; Glucos P; Glucose 1-(dihydrogen phosphate); Glucose monophosphate; Glucose-1-phosphate; alpha-glucose-1-phosphate; .alpha.-D-Glucopyranose, 1-(dihydrogen phosphate); 1-O-phosphono-alpha-D-glucopyranose; 59-56-3; CHEBI:29042; G1P; HXXFSFRBOHSIMQ-VFUOTHLCSA-N; UNII-CIX3U01VAU; alpha-D-Glucopyranose, 1-(dihydrogen phosphate); alpha-D-Glucopyranosyl phosphate; alpha-D-Glucose 1-phosphate; alpha-D-glucose-1-phosphate
DMPW46G PC 65533
DMPW46G MW 260.14
DMPW46G FM C6H13O9P
DMPW46G IC HXXFSFRBOHSIMQ-VFUOTHLCSA-N
DMPW46G CS C(C1C(C(C(C(O1)OP(=O)(O)O)O)O)O)O
DMPW46G IK 1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6-/m1/s1
DMPW46G IU [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DMPW46G CA CAS 59-56-3
DMPW46G CB CHEBI:29042
DMPW46G DE Discovery agent
DMNRW57 ID DMNRW57
DMNRW57 DN D-glucose 6-phosphate
DMNRW57 HS Investigative
DMNRW57 SN Aldohexose 6-phosphate; D(+)-Glucopyranose 6-phosphate; D-Glucose 6-phosphate; D-Glucose 6-phosphoric acid; D-glucose-6-phosphate; SCHEMBL6599; VFRROHXSMXFLSN-SLPGGIOYSA-N; ZINC19850142; glucose-6 phosphate; (2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl dihydrogen phosphate; 375AW34SQA; 56-73-5; 6-O-phosphono-D-glucose; AC1L98E0; CHEBI:15954; CTK3I9725; UNII-375AW34SQA; [(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate; aldehydo-D-glucose 6-(dihydrogen phosphate); aldehydo-D-glucose 6-phosphate
DMNRW57 PC 439958
DMNRW57 MW 260.14
DMNRW57 FM C6H13O9P
DMNRW57 IC VFRROHXSMXFLSN-SLPGGIOYSA-N
DMNRW57 CS C(C(C(C(C(C=O)O)O)O)O)OP(=O)(O)O
DMNRW57 IK 1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h1,3-6,8-11H,2H2,(H2,12,13,14)/t3-,4+,5+,6+/m0/s1
DMNRW57 IU [(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] dihydrogen phosphate
DMNRW57 CA CAS 56-73-5
DMNRW57 CB CHEBI:15954
DMNRW57 DE Discovery agent
DM1YBTC ID DM1YBTC
DM1YBTC DN D-glucuronate
DM1YBTC HS Investigative
DM1YBTC SN AEMOLEFTQBMNLQ-AQKNRBDQSA-N; D-GlcA; D-Glucopyranuronate; D-Glucopyranuronic Acid; D-Glucuronate; D-Glucuronic Acid; Glucopyranuronate; Glucopyranuronic Acid; Glucosiduronic acid; Glucuronate; Glucuronic Acid; Maybridge1_004154; O_FULL_00000000001000_GS_791; SR-01000639202-1; AC1L3SRL; AC1Q5R59; AKOS015955920; C00191; CCG-49770; CHEBI:47952; CHEMBL496672; DTXSID50894097; EINECS 208-429-7; Epitope ID:115136; GlcA; HMS553E20; SCHEMBL30411; WURCS=2.0/1,1,0/[a2122A-1x_1-5]/1/; bmse000140
DM1YBTC PC 94715
DM1YBTC MW 194.14
DM1YBTC FM C6H10O7
DM1YBTC IC AEMOLEFTQBMNLQ-AQKNRBDQSA-N
DM1YBTC CS C1(C(C(OC(C1O)O)C(=O)O)O)O
DM1YBTC IK 1S/C6H10O7/c7-1-2(8)4(5(10)11)13-6(12)3(1)9/h1-4,6-9,12H,(H,10,11)/t1-,2-,3+,4-,6?/m0/s1
DM1YBTC IU (2S,3S,4S,5R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid
DM1YBTC CA CAS 528-16-5
DM1YBTC CB CHEBI:47952
DM1YBTC DE Discovery agent
DMAYPLE ID DMAYPLE
DMAYPLE DN D-glyceraldehyde
DMAYPLE HS Investigative
DMAYPLE SN D(+)-Glyceraldehyde; D-(+)-Glyceraldehyde; D-2,3-dihydroxypropanal; D-2,3-dihydroxypropionaldehyde; D-aldotriose; D-glyceraldehyde; D-glycerose; Glyceraldehyde, D-; J-502403; Propanal, 2,3-dihydroxy-, (2R)-; Propanal, 2,3-dihydroxy-, (r)-; PubChem6338; Triose; (2R)-2,3-DIHYDROXYPROPANAL; (R)-2,3-Dihydroxypropanal; (R)-glyceraldehyde; (R);-2,3-Dihydroxypropanal; 41A680M0WB; 453-17-8; AC1L2WGP; AC1Q6A7Z; AK122382; EINECS 207-217-1; NSC 91534; Propanal, 2,3-dihydroxy-, (R)- (9CI); UNII-41A680M0WB; bmse000298
DMAYPLE PC 79014
DMAYPLE MW 90.08
DMAYPLE FM C3H6O3
DMAYPLE IC MNQZXJOMYWMBOU-VKHMYHEASA-N
DMAYPLE CS C(C(C=O)O)O
DMAYPLE IK 1S/C3H6O3/c4-1-3(6)2-5/h1,3,5-6H,2H2/t3-/m0/s1
DMAYPLE IU (2R)-2,3-dihydroxypropanal
DMAYPLE CA CAS 497-09-6
DMAYPLE CB CHEBI:17378
DMAYPLE DE Discovery agent
DM7UVOD ID DM7UVOD
DM7UVOD DN DH97
DM7UVOD HS Investigative
DM7UVOD SN DH 97; DH97; 343263-95-6; N-[2-(2-benzyl-1H-indol-3-yl)ethyl]pentanamide; N-(2-(2-Benzyl-1H-indol-3-yl)ethyl)pentanamide; Luzindole,N-pentanoyl; Tocris-1218; AC1MRF3Z; 220339-00-4; N-pentanoyl 2-benzyltryptamine; N-Pentanoyl-2-benzyltryptamine; SCHEMBL1626901; GTPL3366; CHEMBL1327247; CHEBI:92107; CTK8E7620; BDBM85384; DTXSID90392749; MolPort-003-983-554; HMS3267D11; ZINC2581407; BN0182; AKOS024456472; NCGC00025049-01; NCGC00025049-02; ACM343263956; RT-012298; FT-0763744; SR-01000597373; SR-01000597373-1; J-019556
DM7UVOD DT Small molecular drug
DM7UVOD PC 3467177
DM7UVOD MW 334.5
DM7UVOD FM C22H26N2O
DM7UVOD IC InChI=1S/C22H26N2O/c1-2-3-13-22(25)23-15-14-19-18-11-7-8-12-20(18)24-21(19)16-17-9-5-4-6-10-17/h4-12,24H,2-3,13-16H2,1H3,(H,23,25)
DM7UVOD CS CCCCC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3
DM7UVOD IK HDOIPCLEKCEANF-UHFFFAOYSA-N
DM7UVOD IU N-[2-(2-benzyl-1H-indol-3-yl)ethyl]pentanamide
DM7UVOD CB CHEBI:92107
DM7UVOD DE Discovery agent
DMSN87T ID DMSN87T
DMSN87T DN Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T HS Investigative
DMSN87T SN CHEMBL386043; Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2
DMSN87T DT Small molecular drug
DMSN87T PC 44415281
DMSN87T MW 646.7
DMSN87T FM C28H34N6O8S2
DMSN87T IC InChI=1S/C28H34N6O8S2/c1-15-9-19(35)10-16(2)20(15)7-8-24(36)32-23-14-44-43-13-22(26(29)38)33-28(40)21(31-25(37)12-30-27(23)39)11-17-3-5-18(6-4-17)34(41)42/h3-6,9-10,21-23,35H,7-8,11-14H2,1-2H3,(H2,29,38)(H,30,39)(H,31,37)(H,32,36)(H,33,40)/t21-,22-,23-/m0/s1
DMSN87T CS CC1=CC(=CC(=C1CCC(=O)N[C@H]2CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC2=O)CC3=CC=C(C=C3)[N+](=O)[O-])C(=O)N)C)O
DMSN87T IK UHOUPDXHBXXBLE-VABKMULXSA-N
DMSN87T IU (4R,7S,13R)-13-[3-(4-hydroxy-2,6-dimethylphenyl)propanoylamino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMSN87T DE Discovery agent
DM3DR6J ID DM3DR6J
DM3DR6J DN Di(1H-indol-2-yl)methanone
DM3DR6J HS Investigative
DM3DR6J SN CHEMBL207483; 200706-56-5; di(1H-indol-2-yl)methanone; indolyl ketone; Di(1H-indole-2-yl) ketone; SCHEMBL370573; Methanone, di-1H-indol-2-yl-; ZINC24262; CTK0J0872; DTXSID70436953
DM3DR6J DT Small molecular drug
DM3DR6J PC 10220822
DM3DR6J MW 260.29
DM3DR6J FM C17H12N2O
DM3DR6J IC InChI=1S/C17H12N2O/c20-17(15-9-11-5-1-3-7-13(11)18-15)16-10-12-6-2-4-8-14(12)19-16/h1-10,18-19H
DM3DR6J CS C1=CC=C2C(=C1)C=C(N2)C(=O)C3=CC4=CC=CC=C4N3
DM3DR6J IK GQJIQKLWZMQQGO-UHFFFAOYSA-N
DM3DR6J IU bis(1H-indol-2-yl)methanone
DM3DR6J CA CAS 200706-56-5
DM3DR6J DE Discovery agent
DMG21PZ ID DMG21PZ
DMG21PZ DN Di(2,6-diisopropylphenol)
DMG21PZ HS Investigative
DMG21PZ SN 3,3',5,5'-Tetraisopropylbiphenyl-4,4'-diol; 2416-95-7; Dipropofo; UNII-H9GE6HX42A; di(2,6-diisopropylphenol); H9GE6HX42A; CHEMBL478518; 3,3',5,5'-Tetrakis(1-methylethyl)biphenyl-4,4'-diol; AK-51092; 3,3',5,5'-Tetraisopropyl-[1,1'-biphenyl]-4,4'-diol; Propofol related compound A; Dipropofol; Propofol related compound A [USP]; Propofol specified impurity E [EP]; Propofol Impurity E; Propofol related compound A RS [USP]; 3,3',5,5'-Tetraisopropyl-4,4'-dihydroxybiphenyl; SCHEMBL275427; CTK4F3066; DTXSID30178867
DMG21PZ DT Small molecular drug
DMG21PZ PC 11602828
DMG21PZ MW 354.5
DMG21PZ FM C24H34O2
DMG21PZ IC InChI=1S/C24H34O2/c1-13(2)19-9-17(10-20(14(3)4)23(19)25)18-11-21(15(5)6)24(26)22(12-18)16(7)8/h9-16,25-26H,1-8H3
DMG21PZ CS CC(C)C1=CC(=CC(=C1O)C(C)C)C2=CC(=C(C(=C2)C(C)C)O)C(C)C
DMG21PZ IK QAISRHCMPQROAX-UHFFFAOYSA-N
DMG21PZ IU 4-[4-hydroxy-3,5-di(propan-2-yl)phenyl]-2,6-di(propan-2-yl)phenol
DMG21PZ CA CAS 2416-95-7
DMG21PZ DE Discovery agent
DMZ3EML ID DMZ3EML
DMZ3EML DN Di(2,6-dimethylphenol)
DMZ3EML HS Investigative
DMZ3EML SN 2417-04-1; 2,2',6,6'-tetramethyl-4,4'-biphenol; 3,3',5,5'-tetramethylbiphenyl-4,4'-diol; di(2,6-dimethylphenol); 2,2',6,6'-Tetramethyl-p,p'-biphenol; CHEMBL449983; [1,1'-Biphenyl]-4,4'-diol, 3,3',5,5'-tetramethyl-; 3,3',5,5'-tetramethyl-4,4'-diallyloxybiphenyl; 3,3,5,5-Tetramehtyl [1,1'-biphenyl] 4,4'-diol; 4-(4-hydroxy-3,5-dimethylphenyl)-2,6-dimethylphenol; 3,3',5,5'-TETRAMETHYL-4,4'-DIHYDROXYBIPHENYL; 3,3,5,5-Tetramethylbiphenyl-4,4-diol; 4,4'-dihydroxy-3,3',5,5'-tetramethyl-biphenyl
DMZ3EML DT Small molecular drug
DMZ3EML PC 75490
DMZ3EML MW 242.31
DMZ3EML FM C16H18O2
DMZ3EML IC InChI=1S/C16H18O2/c1-9-5-13(6-10(2)15(9)17)14-7-11(3)16(18)12(4)8-14/h5-8,17-18H,1-4H3
DMZ3EML CS CC1=CC(=CC(=C1O)C)C2=CC(=C(C(=C2)C)O)C
DMZ3EML IK YGYPMFPGZQPETF-UHFFFAOYSA-N
DMZ3EML IU 4-(4-hydroxy-3,5-dimethylphenyl)-2,6-dimethylphenol
DMZ3EML CA CAS 2417-04-1
DMZ3EML DE Discovery agent
DMO6Z02 ID DMO6Z02
DMO6Z02 DN Di(2,6-di-t-butylphenol)
DMO6Z02 HS Investigative
DMO6Z02 SN 128-38-1; Ethyl 712; 3,3',5,5'-Tetra-tert-butylbiphenyl-4,4'-diol; UNII-D85N5VOL1N; 3,3',5,5'-tetra(tert-butyl)[1,1'-biphenyl]-4,4'-diol; D85N5VOL1N; CHEMBL1662; 4,4-Bis(2,6-di-tert-butylphenol); [1,1'-Biphenyl]-4,4'-diol, 3,3',5,5'-tetrakis(1,1-dimethylethyl)-; 3,3',5,5'-Tetra-tert-butyl-[1,1'-biphenyl]-4,4'-diol; Inter008513,3',5,5'-Tetra-tert-butyl-4,4'-dihydroxybiphenyl; 2,6-bis(tert-butyl)-4-[3,5-bis(tert-butyl)-4-hydroxyphenyl]phenol; 4, 3,3',5,5'-tetra-tert-butyl-; [1,4'-diol, 3,3',5,5'-tetrakis(1,1-dimethylethyl
DMO6Z02 DT Small molecular drug
DMO6Z02 PC 67185
DMO6Z02 MW 410.6
DMO6Z02 FM C28H42O2
DMO6Z02 IC InChI=1S/C28H42O2/c1-25(2,3)19-13-17(14-20(23(19)29)26(4,5)6)18-15-21(27(7,8)9)24(30)22(16-18)28(10,11)12/h13-16,29-30H,1-12H3
DMO6Z02 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
DMO6Z02 IK GSOYMOAPJZYXTB-UHFFFAOYSA-N
DMO6Z02 IU 2,6-ditert-butyl-4-(3,5-ditert-butyl-4-hydroxyphenyl)phenol
DMO6Z02 CA CAS 128-38-1
DMO6Z02 DE Discovery agent
DMOCQ9J ID DMOCQ9J
DMOCQ9J DN Diamide
DMOCQ9J HS Investigative
DMOCQ9J SN N1,N1,N2,N2-Tetramethyldiazene-1,2-dicarboxamide; CHEBI:48958; VLSDXINSOMDCBK-BQYQJAHWSA-N; N,N',N'-Tetramethylazodicarboxamide; AC1L1HSY; ACMC-2098cn; Lopac0_000397; MLS002153343; DTXSID6040456; CHEMBL1338900; CTK8A9086; CTK8E8363; VLSDXINSOMDCBK-UHFFFAOYSA-N; HMS2234I06; 1,1-azobis(n,n-dimethylformamide); KS-00000EC9; ANW-15093; ZINC13552228; ZINC100005746; 1,1'-azobis(N,N'-dimethylformamide); ZINC253921216; AKOS028108436; n,n,n',n'-tetramethylazo-dicarboxamide; n,n,n',n'-tetramethyl azodicarboxamide
DMOCQ9J DT Small molecular drug
DMOCQ9J PC 5353800
DMOCQ9J MW 172.19
DMOCQ9J FM C6H12N4O2
DMOCQ9J IC InChI=1S/C6H12N4O2/c1-9(2)5(11)7-8-6(12)10(3)4/h1-4H3/b8-7+
DMOCQ9J CS CN(C)C(=O)/N=N/C(=O)N(C)C
DMOCQ9J IK VLSDXINSOMDCBK-BQYQJAHWSA-N
DMOCQ9J IU (3E)-3-(dimethylcarbamoylimino)-1,1-dimethylurea
DMOCQ9J CA CAS 10465-78-8
DMOCQ9J CB CHEBI:48963
DMOCQ9J DE Discovery agent
DM4EX8Y ID DM4EX8Y
DM4EX8Y DN diamide 7
DM4EX8Y HS Investigative
DM4EX8Y SN CHEMBL1770298; diamide 7; GTPL5830; BDBM50418334
DM4EX8Y DT Small molecular drug
DM4EX8Y PC 53233899
DM4EX8Y MW 394.5
DM4EX8Y FM C22H22N2O3S
DM4EX8Y IC InChI=1S/C22H22N2O3S/c1-13-7-6-8-14(2)19(13)23-22(27)20(18-12-11-15(3)28-18)24-21(26)16-9-4-5-10-17(16)25/h4-12,20,25H,1-3H3,(H,23,27)(H,24,26)
DM4EX8Y CS CC1=C(C(=CC=C1)C)NC(=O)C(C2=CC=C(S2)C)NC(=O)C3=CC=CC=C3O
DM4EX8Y IK AHTURLVFIJHCLS-UHFFFAOYSA-N
DM4EX8Y IU N-[2-(2,6-dimethylanilino)-1-(5-methylthiophen-2-yl)-2-oxoethyl]-2-hydroxybenzamide
DM4EX8Y DE Discovery agent
DMDGIT6 ID DMDGIT6
DMDGIT6 DN Diaminopropyl sulfate
DMDGIT6 HS Investigative
DMDGIT6 DE Discovery agent
DM14X29 ID DM14X29
DM14X29 DN diarylpropionitril
DM14X29 HS Investigative
DM14X29 SN 1428-67-7; diarylpropionitrile; 2,3-bis(4-hydroxyphenyl)propionitrile; 2,3-bis(4-hydroxyphenyl)propanenitrile; 2,3-bis(4-hydroxyphenyl)-propionitrile; 2,3-Bis(p-hydroxyphenyl)propionitrile; CHEMBL334773; CHEBI:63949; DPN compound; Benzenepropanenitrile,4-hydroxy-a-(4-hydroxyphenyl)-; SR-01000597601; BRN 3337109; SC-4473; 2,3-Bis(p-hydroxyphenyl)-propionitrile; Propionitrile, 2,3-bis(p-hydroxyphenyl); Propionitrile, 2,3-bis(p-hydroxyphenyl)-; AC1L2T6L; GTPL2825; SCHEMBL1940848; DTXSID0040387; CTK8F9375; MolPort-003-983-761
DM14X29 DT Small molecular drug
DM14X29 PC 102614
DM14X29 MW 239.27
DM14X29 FM C15H13NO2
DM14X29 IC InChI=1S/C15H13NO2/c16-10-13(12-3-7-15(18)8-4-12)9-11-1-5-14(17)6-2-11/h1-8,13,17-18H,9H2
DM14X29 CS C1=CC(=CC=C1CC(C#N)C2=CC=C(C=C2)O)O
DM14X29 IK GHZHWDWADLAOIQ-UHFFFAOYSA-N
DM14X29 IU 2,3-bis(4-hydroxyphenyl)propanenitrile
DM14X29 CA CAS 1428-67-7
DM14X29 CB CHEBI:63949
DM14X29 DE Discovery agent
DM3CQV6 ID DM3CQV6
DM3CQV6 DN DIASTEREOMER 2
DM3CQV6 HS Investigative
DM3CQV6 SN 571170-81-5; 2-(4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; DIASTEREOMER 2; CHEMBL221007; 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-Cyclopent[b]indole-3-acetic acid; MK-0524 Laropiprant; SCHEMBL1044552; CTK8C2002; DTXSID00436805; CS-M1273; KS-00001EH0; ANW-67605; BDBM50205278; AKOS016006816; KB-71920; CS-13849; AX8238513; TC-156350; 126596-EP2295409A1; 1-(4-Chlorobenzyl)-5-fluoro-7-mesyl-2,3-propano-1H-indole-10-ylacetic acid
DM3CQV6 DT Small molecular drug
DM3CQV6 PC 10216733
DM3CQV6 MW 435.9
DM3CQV6 FM C21H19ClFNO4S
DM3CQV6 IC InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)
DM3CQV6 CS CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F
DM3CQV6 IK NXFFJDQHYLNEJK-UHFFFAOYSA-N
DM3CQV6 IU 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
DM3CQV6 CA CAS 571170-81-5
DM3CQV6 DE Discovery agent
DM5UFZX ID DM5UFZX
DM5UFZX DN Diazaborines
DM5UFZX HS Investigative
DM5UFZX SN KBPMSEXASFSGEI-WRBBICKQSA-N; Neomycin B-arginine conjugate; NeoR; AC1LAWYH; Hexaarginine-Neomycin B Conjugate; [D-Streptamine, O-2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1fwdarw4)-O-[O-2,6-diamino-2,6-dideoxy-beta-L-idopyranyl- (1fwdarw3)-beta-D-ribofuranosyl-(1fwdarw5)]-2-deoxy]-arginine
DM5UFZX DT Small molecular drug
DM5UFZX PC 496913
DM5UFZX MW 1551.8
DM5UFZX FM C59H118N30O19
DM5UFZX IC InChI=1S/C59H118N30O19/c60-23(7-1-13-78-54(66)67)45(97)84-20-31-37(92)39(94)34(88-49(101)27(64)11-5-17-82-58(74)75)51(103-31)106-42-30(87-48(100)26(63)10-4-16-81-57(72)73)19-29(86-47(99)25(62)9-3-15-80-56(70)71)36(91)44(42)108-53-41(96)43(33(22-90)105-53)107-52-35(89-50(102)28(65)12-6-18-83-59(76)77)40(95)38(93)32(104-52)21-85-46(98)24(61)8-2-14-79-55(68)69/h23-44,51-53,90-96H,1-22,60-65H2,(H,84,97)(H,85,98)(H,86,99)(H,87,100)(H,88,101)(H,89,102)(H4,66,67,78)(H4,68,69,79)(H4,70,71,80)(H4,72,73,81)(H4,74,75,82)(H4,76,77,83)/t23-,24-,25-,26-,27-,28-,29+,30-,31+,32-,33+,34+,35+,36-,37+,38+,39+,40+,41+,42+,43+,44+,51+,52?,53-/m0/s1
DM5UFZX CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1NC(=O)[C@H](CCCN=C(N)N)N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CNC(=O)[C@H](CCCN=C(N)N)N)O)O)NC(=O)[C@H](CCCN=C(N)N)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)OC4[C@@H]([C@H]([C@@H]([C@@H](O4)CNC(=O)[C@H](CCCN=C(N)N)N)O)O)NC(=O)[C@H](CCCN=C(N)N)N)O)O)NC(=O)[C@H](CCCN=C(N)N)N
DM5UFZX IK KBPMSEXASFSGEI-WRBBICKQSA-N
DM5UFZX IU (2S)-2-amino-N-[[(2R,3S,4R,5R,6R)-5-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-6-[(1R,2R,3S,4R,6S)-4,6-bis[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-2-[(2S,3R,4S,5R)-4-[(3R,4R,5S,6S)-3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-6-[[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]methyl]-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxy-3,4-dihydroxyoxan-2-yl]methyl]-5-(diaminomethylideneamino)pentanamide
DM5UFZX DE Discovery agent
DM5DPM4 ID DM5DPM4
DM5DPM4 DN Diazacholesterol
DM5DPM4 HS Investigative
DM5DPM4 PC 129632053
DM5DPM4 MW 388.6
DM5DPM4 FM C25H44N2O
DM5DPM4 IC InChI=1S/C25H44N2O/c1-17(6-5-15-27(4)26)21-9-10-22-20-8-7-18-16-19(28)11-13-24(18,2)23(20)12-14-25(21,22)3/h7,17,19-23,28H,5-6,8-16,26H2,1-4H3/t17-,19+,20+,21-,22+,23+,24+,25-/m1/s1
DM5DPM4 CS C[C@H](CCCN(C)N)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C
DM5DPM4 IK CAVTXXDDLXAFFB-NMQWMWRVSA-N
DM5DPM4 IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-[amino(methyl)amino]pentan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM5DPM4 DE Discovery agent
DM9KPHZ ID DM9KPHZ
DM9KPHZ DN diBA-(5)-C4
DM9KPHZ HS Investigative
DM9KPHZ SN bis-(1,3-dibutylbarbituric acid)pentamethine oxanol; oxalon dye
DM9KPHZ DT Small molecular drug
DM9KPHZ PC 2733616
DM9KPHZ MW 542.7
DM9KPHZ FM C29H42N4O6
DM9KPHZ IC InChI=1S/C29H42N4O6/c1-5-9-18-30-24(34)22(25(35)31(28(30)38)19-10-6-2)16-14-13-15-17-23-26(36)32(20-11-7-3)29(39)33(27(23)37)21-12-8-4/h13-17,34H,5-12,18-21H2,1-4H3
DM9KPHZ CS CCCCN1C(=C(C(=O)N(C1=O)CCCC)C=CC=CC=C2C(=O)N(C(=O)N(C2=O)CCCC)CCCC)O
DM9KPHZ IK CQAPPGVBCMJDML-UHFFFAOYSA-N
DM9KPHZ IU 1,3-dibutyl-5-[5-(1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidin-5-yl)penta-2,4-dienylidene]-1,3-diazinane-2,4,6-trione
DM9KPHZ DE Discovery agent
DMOKNXE ID DMOKNXE
DMOKNXE DN Dibenzo-p-dioxin-2-carboxylic acid
DMOKNXE HS Investigative
DMOKNXE SN Oxanthrene-2-carboxylic acid; 17054-75-0; SCHEMBL18288092; ZINC34729704; AKOS000276725
DMOKNXE DT Small molecular drug
DMOKNXE PC 15728264
DMOKNXE MW 228.2
DMOKNXE FM C13H8O4
DMOKNXE IC InChI=1S/C13H8O4/c14-13(15)8-5-6-11-12(7-8)17-10-4-2-1-3-9(10)16-11/h1-7H,(H,14,15)
DMOKNXE CS C1=CC=C2C(=C1)OC3=C(O2)C=C(C=C3)C(=O)O
DMOKNXE IK MCNODAPWJQPAIE-UHFFFAOYSA-N
DMOKNXE IU dibenzo-p-dioxin-2-carboxylic acid
DMOKNXE DE Discovery agent
DMEDKA3 ID DMEDKA3
DMEDKA3 DN Dibenzothiazepines
DMEDKA3 HS Investigative
DMEDKA3 SN Cannabinoid CB1 inverse agonists (CNS disorder); Cannabinoid CB1 inverse agonists (CNS disorder), ACADIA; CB1 inverse agonists (obesity, substance abuse), ACADIA
DMEDKA3 CP ACADIA Pharmaceuticals Inc
DMEDKA3 DE Drug abuse
DMD8TWC ID DMD8TWC
DMD8TWC DN dibenzoxazepine
DMD8TWC HS Investigative
DMD8TWC SN CR gas
DMD8TWC DT Small molecular drug
DMD8TWC PC 66624158
DMD8TWC MW 195.22
DMD8TWC FM C13H9NO
DMD8TWC IC InChI=1S/C13H9NO/c1-2-6-11-10(5-1)9-14-15-13-8-4-3-7-12(11)13/h1-9H
DMD8TWC CS C1=CC=C2C(=C1)C=NOC3=CC=CC=C23
DMD8TWC IK RVSGRNKUJJUAPV-UHFFFAOYSA-N
DMD8TWC IU benzo[d][1,2]benzoxazepine
DMD8TWC DE Discovery agent
DMAYSGI ID DMAYSGI
DMAYSGI DN Di-Benzyloxycarbonyl-guanidino acetylryanodine
DMAYSGI HS Investigative
DMAYSGI SN CHEMBL416926; Di-Benzyloxycarbonyl-guanidino acetylryanodine
DMAYSGI DT Small molecular drug
DMAYSGI PC 44275895
DMAYSGI MW 860.9
DMAYSGI FM C44H52N4O14
DMAYSGI IC InChI=1S/C44H52N4O14/c1-25(2)41(55)33(61-32(50)29-17-12-20-45-29)42(56)37(4)24-40(54)38(41,5)44(42,57)43(62-40)31(26(3)18-19-39(37,43)53)60-30(49)21-46-34(47-35(51)58-22-27-13-8-6-9-14-27)48-36(52)59-23-28-15-10-7-11-16-28/h6-17,20,25-26,31,33,45,53-57H,18-19,21-24H2,1-5H3,(H2,46,47,48,51,52)/t26?,31-,33-,37+,38?,39?,40?,41?,42?,43?,44?/m1/s1
DMAYSGI CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CN=C(NC(=O)OCC6=CC=CC=C6)NC(=O)OCC7=CC=CC=C7)O4)O)O)OC(=O)C8=CC=CN8)(C(C)C)O)C)O)C)O
DMAYSGI IK NQGUDUOLYOZNBB-UTTPSZOSSA-N
DMAYSGI IU [(2R,7S,12R)-2-[2-[bis(phenylmethoxycarbonylamino)methylideneamino]acetyl]oxy-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMAYSGI DE Discovery agent
DM2G8ON ID DM2G8ON
DM2G8ON DN Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate
DM2G8ON HS Investigative
DM2G8ON SN CHEMBL573979; Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate
DM2G8ON DT Small molecular drug
DM2G8ON PC 14026658
DM2G8ON MW 368.33
DM2G8ON FM C16H24F3O4P
DM2G8ON IC InChI=1S/C16H24F3O4P/c1-3-5-12-21-24(20,22-13-6-4-2)23-15(16(17,18)19)14-10-8-7-9-11-14/h7-11,15H,3-6,12-13H2,1-2H3
DM2G8ON CS CCCCOP(=O)(OCCCC)OC(C1=CC=CC=C1)C(F)(F)F
DM2G8ON IK BREZEIOVGIZIOU-UHFFFAOYSA-N
DM2G8ON IU dibutyl (2,2,2-trifluoro-1-phenylethyl) phosphate
DM2G8ON DE Discovery agent
DMEDGKO ID DMEDGKO
DMEDGKO DN Dibutyl phthalate
DMEDGKO HS Investigative
DMEDGKO SN di-n-butyl phthalate; n-butyl phthalate; nutyl phthalate
DMEDGKO DT Small molecular drug
DMEDGKO PC 3026
DMEDGKO MW 278.34
DMEDGKO FM C16H22O4
DMEDGKO IC InChI=1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3
DMEDGKO CS CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC
DMEDGKO IK DOIRQSBPFJWKBE-UHFFFAOYSA-N
DMEDGKO IU dibutyl benzene-1,2-dicarboxylate
DMEDGKO CA CAS 84-74-2
DMEDGKO CB CHEBI:34687
DMEDGKO DE Discovery agent
DM4I5Z3 ID DM4I5Z3
DM4I5Z3 DN Dicaffeoylquinic acids
DM4I5Z3 HS Investigative
DM4I5Z3 DE Human immunodeficiency virus infection
DMAV0BX ID DMAV0BX
DMAV0BX DN Dicaffeoyltartaric acids
DMAV0BX HS Investigative
DMAV0BX DE Human immunodeficiency virus infection
DML3HEM ID DML3HEM
DML3HEM DN Dicarboxylate
DML3HEM HS Investigative
DML3HEM SN 1,3-Propanedioic acid; 9KX7ZMG0MK; AI3-15375; BRN 1751370; CHEBI:30794; Carboxyacetic acid; DICARBOXYLIC ACID C3; Dicarboxylate; Dicarboxylic acid; Dicarboxymethane; EINECS 205-503-0; Kyselina malonova; Kyselina malonova [Czech]; METAHNEDICARBOXYLIC ACID; MFCD00002707; Malonic acid; Malonic acid, 99%; Methanedicarbonic acid; Methanedicarboxylic acid; NSC 8124; NSC8124; OFOBLEOULBTSOW-UHFFFAOYSA-N; PROPANEDIOLIC ACID; Thallium malonate; UNII-9KX7ZMG0MK; USAF EK-695; alpha,omega-Dicarboxylic acid; malonic acid; propanedioic acid
DML3HEM DT Small molecular drug
DML3HEM PC 867
DML3HEM MW 104.061
DML3HEM FM C3H4O4
DML3HEM IC InChI=1S/C3H4O4/c4-2(5)1-3(6)7/h1H2,(H,4,5)(H,6,7)
DML3HEM CS C(C(=O)O)C(=O)O
DML3HEM IK OFOBLEOULBTSOW-UHFFFAOYSA-N
DML3HEM IU propanedioic acid
DML3HEM CA CAS 141-82-2
DML3HEM CB CHEBI:30794
DMXGV63 ID DMXGV63
DMXGV63 DN Dichloroallyl lawsone
DMXGV63 HS Investigative
DMXGV63 SN Dichloroallyl lawsone; Dichlorolapachol; Dichlorolawsone; Dichloroallyllawsone; Lawsone, dichlorallyl-; 36417-16-0; NSC 126771; NSC-126771; 2-Hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone; UNII-ZE2BI297KA; BRN 1977648; ZE2BI297KA; 1,4-Naphthoquinone, 2-(3,3-dichloroallyl)-3-hydroxy-; MLS002701983; 1,4-NAPHTHALENEDIONE, 2-(3,3-DICHLORO-2-PROPENYL)-3-HYDROXY-; NSC126771; 3-(3,3-Dichloroallyl)-2-hydroxy-1,4-naphthoquinone; AC1L5MNX; AC1Q3FFX; NCIMech_000041; Dichloroallyl lawsone (DCL); C13H8Cl2O3
DMXGV63 DT Small molecular drug
DMXGV63 PC 277767
DMXGV63 MW 283.1
DMXGV63 FM C13H8Cl2O3
DMXGV63 IC InChI=1S/C13H8Cl2O3/c14-10(15)6-5-9-11(16)7-3-1-2-4-8(7)12(17)13(9)18/h1-4,6,16H,5H2
DMXGV63 CS C1=CC=C2C(=C1)C(=C(C(=O)C2=O)CC=C(Cl)Cl)O
DMXGV63 IK LWQZLQISFLBSGW-UHFFFAOYSA-N
DMXGV63 IU 3-(3,3-dichloroprop-2-enyl)-4-hydroxynaphthalene-1,2-dione
DMXGV63 CA CAS 36417-16-0
DMXGV63 DE Discovery agent
DMAU5VM ID DMAU5VM
DMAU5VM DN Dichloroally-lawsone
DMAU5VM HS Investigative
DMAU5VM DE Discovery agent
DMAEI51 ID DMAEI51
DMAEI51 DN Dichloroindophenol
DMAEI51 HS Investigative
DMAEI51 SN Dichlorophenolindophenol; Indochlorophenol; Tillmans Reagent; 2,5-Cyclohexadien-1-one, 2,6-dichloro-4-((4-hydroxyphenyl)imino)-; 2,6-Dichlorophenolindophenol; 2,5-cyclohexadien-1-one, 2,6-dichloro-4-[(4-hydroxyphenyl)imino]-; 2,6-DICHLOROINDOPHENOL; 2,6-Dichloro-N-4-hydroxyphenyl-p-benzoquinone monoimine; 4-[(3,5-dichloro-4-hydroxyphenyl)imino]cyclohexa-2,5-dien-1-one; 956-48-9; C35QN2Z58B; CHEBI:27451; CHEBI:945; DCPIP; DPIP; N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine; UNII-C35QN2Z58B
DMAEI51 PC 13726
DMAEI51 MW 268.09
DMAEI51 FM C12H7Cl2NO2
DMAEI51 IC FBWADIKARMIWNM-UHFFFAOYSA-N
DMAEI51 CS C1=CC(=O)C=CC1=NC2=CC(=C(C(=C2)Cl)O)Cl
DMAEI51 IK 1S/C12H7Cl2NO2/c13-10-5-8(6-11(14)12(10)17)15-7-1-3-9(16)4-2-7/h1-6,17H
DMAEI51 IU 4-(3,5-dichloro-4-hydroxyphenyl)iminocyclohexa-2,5-dien-1-one
DMAEI51 CA CAS 956-48-9
DMAEI51 CB CHEBI:945
DMAEI51 DE Discovery agent
DMSZ7UE ID DMSZ7UE
DMSZ7UE DN Dichloroisoproterenol
DMSZ7UE HS Investigative
DMSZ7UE SN Dichloroisoproterenol; Dichlorisoproterenol; Dichloroisoprenaline; Dichlorisoprenaline [German]; 59-61-0; 3,4-Dichlor-isoproterenol [German]; 1-(3,4-Dichlorophenyl)-2-isopropylaminoethanol; BRN 2807251; CHEMBL30816; beta-Hydroxy-N-isopropyl-3,4-dichlorophenethylamine; 3,4-Dichloro-alpha-(isopropylaminomethyl)benzyl alcohol; N-(beta-(3,4-Dichlorophenyl)-beta-hydroxyethyl)isopropylamine; 3,4-Dichloro-alpha-(((1-methylethyl)amino)methyl)benzenemethanol; 1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol; BENZYL ALCOHOL, 3,4-D
DMSZ7UE DT Small molecular drug
DMSZ7UE PC 5806
DMSZ7UE MW 248.15
DMSZ7UE FM C11H15Cl2NO
DMSZ7UE IC InChI=1S/C11H15Cl2NO/c1-7(2)14-6-11(15)8-3-4-9(12)10(13)5-8/h3-5,7,11,14-15H,6H2,1-2H3
DMSZ7UE CS CC(C)NCC(C1=CC(=C(C=C1)Cl)Cl)O
DMSZ7UE IK VKMGSWIFEHZQRS-UHFFFAOYSA-N
DMSZ7UE IU 1-(3,4-dichlorophenyl)-2-(propan-2-ylamino)ethanol
DMSZ7UE CA CAS 59-61-0
DMSZ7UE DE Discovery agent
DMWADLM ID DMWADLM
DMWADLM DN Diclofenac glucuronide
DMWADLM HS Investigative
DMWADLM SN Diclofenac acyl glucuronide; Diclofenac glucuronide; CHEBI:59609; Diclofenac beta-D-glucosiduronic acid; UNII-C8BEZ13XEN; C8BEZ13XEN; CHEMBL3527338; 64118-81-6; 1-O-({2-[(2,6-dichlorophenyl)amino]phenyl}acetyl)-beta-D-glucopyranuronic acid; Diclofenac acyl-D-glucuronide; Diclofenac O-glucuronide; Epitope ID:131803; Diclofenac-beta-D-glucuronide; SCHEMBL4258872; Diclofenac-acyl-beta-D-glucuronide; BDBM50088512; ZINC35048352; Q27126801; 2-(2,6-Dichloroanilino)phenylacetic acid beta-D-glucopyranuronosyl ester
DMWADLM PC 16084218
DMWADLM MW 472.3
DMWADLM FM C20H19Cl2NO8
DMWADLM IC JXIKYYSIYCILNG-HBWRTXEVSA-N
DMWADLM CS C1=CC=C(C(=C1)CC(=O)OC2C(C(C(C(O2)C(=O)O)O)O)O)NC3=C(C=CC=C3Cl)Cl
DMWADLM IK 1S/C20H19Cl2NO8/c21-10-5-3-6-11(22)14(10)23-12-7-2-1-4-9(12)8-13(24)30-20-17(27)15(25)16(26)18(31-20)19(28)29/h1-7,15-18,20,23,25-27H,8H2,(H,28,29)/t15-,16-,17+,18-,20+/m0/s1
DMWADLM IU (2S,3S,4S,5R,6S)-6-[2-[2-(2,6-dichloroanilino)phenyl]acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMWADLM CA CAS 64118-81-6
DMWADLM CB CHEBI:59609
DMWADLM DE Discovery agent
DMO3KU5 ID DMO3KU5
DMO3KU5 DN Diclosan
DMO3KU5 HS Investigative
DMO3KU5 SN SONECLOSAN; DICLOSAN; 3380-30-1; 5-chloro-2-(4-chlorophenoxy)phenol; 5-Chloro-2-(p-chlorophenoxy)phenol; UNII-814H7B74XK; hydroxydichlorodiphenyl ether; Phenol, 5-chloro-2-(p-chlorophenoxy)-; 814H7B74XK; Snoclosan; Soneclosan [INN]; DCN; Tinosan HP-100; Phenol, 5-chloro-2-(4-chlorophenoxy)-; AC1L2CUC; AC1Q3QSN; EC 429-290-0; SCHEMBL465591; CHEMBL1232142; CTK1C4131; DTXSID80187464; ZINC2027016; ACT08242; AKOS027382858; DB04393; 4,4'-dichloro-2-hydroxydiphenyl ether
DMO3KU5 DT Small molecular drug
DMO3KU5 PC 18807
DMO3KU5 MW 255.09
DMO3KU5 FM C12H8Cl2O2
DMO3KU5 IC InChI=1S/C12H8Cl2O2/c13-8-1-4-10(5-2-8)16-12-6-3-9(14)7-11(12)15/h1-7,15H
DMO3KU5 CS C1=CC(=CC=C1OC2=C(C=C(C=C2)Cl)O)Cl
DMO3KU5 IK BYNQFCJOHGOKSS-UHFFFAOYSA-N
DMO3KU5 IU 5-chloro-2-(4-chlorophenoxy)phenol
DMO3KU5 CA CAS 3380-30-1
DMO3KU5 DE Discovery agent
DM9WU3R ID DM9WU3R
DM9WU3R DN Dideazaacyclotetrahydrofolic acid
DM9WU3R HS Investigative
DM9WU3R DT Small molecular drug
DM9WU3R PC 135884475
DM9WU3R MW 431.4
DM9WU3R FM C20H25N5O6
DM9WU3R IC InChI=1S/C20H25N5O6/c21-16-13(18(29)25-20(22)24-16)4-2-1-3-11-5-7-12(8-6-11)17(28)23-14(19(30)31)9-10-15(26)27/h5-8,14H,1-4,9-10H2,(H,23,28)(H,26,27)(H,30,31)(H5,21,22,24,25,29)/t14-/m0/s1
DM9WU3R CS C1=CC(=CC=C1CCCCC2=C(N=C(NC2=O)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM9WU3R IK LNUHUIPUTGDPDG-AWEZNQCLSA-N
DM9WU3R IU (2S)-2-[[4-[4-(2,4-diamino-6-oxo-1H-pyrimidin-5-yl)butyl]benzoyl]amino]pentanedioic acid
DM9WU3R DE Discovery agent
DMAIOC9 ID DMAIOC9
DMAIOC9 DN Dideazafolate
DMAIOC9 HS Investigative
DMAIOC9 DT Small molecular drug
DMAIOC9 PC 135517463
DMAIOC9 MW 439.4
DMAIOC9 FM C21H21N5O6
DMAIOC9 IC InChI=1S/C21H21N5O6/c22-21-25-15-6-1-11(9-14(15)19(30)26-21)10-23-13-4-2-12(3-5-13)18(29)24-16(20(31)32)7-8-17(27)28/h1-6,9,16,23H,7-8,10H2,(H,24,29)(H,27,28)(H,31,32)(H3,22,25,26,30)
DMAIOC9 CS C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CC3=C(C=C2)N=C(NC3=O)N
DMAIOC9 IK UQFCLENKCDVITL-UHFFFAOYSA-N
DMAIOC9 IU 2-[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DMAIOC9 DE Discovery agent
DM2FLRQ ID DM2FLRQ
DM2FLRQ DN DIDODECANOYLPHLOROGLUCINOL
DM2FLRQ HS Investigative
DM2FLRQ SN DIDODECANOYLPHLOROGLUCINOL; CHEMBL470757; SCHEMBL9188500; MolPort-044-550-959; BDBM50256011; ZINC44417494; 1,1''-(2,4,6-trihydroxy-1,3-phenylene)didodecan-1-one; 1,1'-(2,4,6-trihydroxy-1,3-phenylene)bis-1-dodecanone; 1,1'-(2,4,6-Trihydroxy-1,3-phenylene)bis(dodecan-1-one)
DM2FLRQ DT Small molecular drug
DM2FLRQ PC 9957245
DM2FLRQ MW 490.7
DM2FLRQ FM C30H50O5
DM2FLRQ IC InChI=1S/C30H50O5/c1-3-5-7-9-11-13-15-17-19-21-24(31)28-26(33)23-27(34)29(30(28)35)25(32)22-20-18-16-14-12-10-8-6-4-2/h23,33-35H,3-22H2,1-2H3
DM2FLRQ CS CCCCCCCCCCCC(=O)C1=C(C(=C(C=C1O)O)C(=O)CCCCCCCCCCC)O
DM2FLRQ IK AIKYCZDMJFKXLS-UHFFFAOYSA-N
DM2FLRQ IU 1-(3-dodecanoyl-2,4,6-trihydroxyphenyl)dodecan-1-one
DM2FLRQ DE Discovery agent
DMKSQUB ID DMKSQUB
DMKSQUB DN DIDS
DMKSQUB HS Investigative
DMKSQUB SN 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid
DMKSQUB DT Small molecular drug
DMKSQUB PC 5281951
DMKSQUB MW 454.5
DMKSQUB FM C16H10N2O6S4
DMKSQUB IC InChI=1S/C16H10N2O6S4/c19-27(20,21)15-7-13(17-9-25)5-3-11(15)1-2-12-4-6-14(18-10-26)8-16(12)28(22,23)24/h1-8H,(H,19,20,21)(H,22,23,24)/b2-1+
DMKSQUB CS C1=CC(=C(C=C1N=C=S)S(=O)(=O)O)/C=C/C2=C(C=C(C=C2)N=C=S)S(=O)(=O)O
DMKSQUB IK YSCNMFDFYJUPEF-OWOJBTEDSA-N
DMKSQUB IU 5-isothiocyanato-2-[(E)-2-(4-isothiocyanato-2-sulfophenyl)ethenyl]benzenesulfonic acid
DMKSQUB CA CAS 152216-76-7
DMKSQUB CB CHEBI:4286
DMKSQUB DE Discovery agent
DMBCK4G ID DMBCK4G
DMBCK4G DN DIECKOL
DMBCK4G HS Investigative
DMBCK4G SN Dieckol; UNII-ZU0ESU4399; CHEMBL508791; ZU0ESU4399; CHEBI:65769; 88095-77-6; 4-(4-{[6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxyoxanthren-2-yl]oxy}-3,5-dihydroxyphenoxy)oxanthrene-1,3,6,8-tetrol; 4-[4-[[6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxydibenzo[b,e][1,4]dioxin-2-yl]oxy]-3,5-dihydroxyphenoxy]-dibenzo[b,e][1,4]dioxin-1,3,6,8-tetrol; Dibenzo(b,E)(1,4)dioxin-1,3,6,8-tetrol, 4-(4-((6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxydibenzo(b,E)(1,4)dioxin-2-yl)oxy)-3,5-dihydroxyphenoxy)-
DMBCK4G DT Small molecular drug
DMBCK4G PC 3008868
DMBCK4G MW 742.5
DMBCK4G FM C36H22O18
DMBCK4G IC InChI=1S/C36H22O18/c37-12-1-13(38)3-15(2-12)49-31-22(44)10-25(47)34-35(31)54-30-21(43)8-17(9-27(30)52-34)48-28-19(41)6-16(7-20(28)42)50-32-23(45)11-24(46)33-36(32)53-29-18(40)4-14(39)5-26(29)51-33/h1-11,37-47H
DMBCK4G CS C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)OC5=C(C=C(C=C5O)OC6=C(C=C(C7=C6OC8=C(C=C(C=C8O7)O)O)O)O)O)O)O)O)O
DMBCK4G IK DRZQFGYIIYNNEC-UHFFFAOYSA-N
DMBCK4G IU 4-[4-[6-(3,5-dihydroxyphenoxy)-4,7,9-trihydroxydibenzo-p-dioxin-2-yl]oxy-3,5-dihydroxyphenoxy]dibenzo-p-dioxin-1,3,6,8-tetrol
DMBCK4G CA CAS 88095-77-6
DMBCK4G CB CHEBI:65769
DMBCK4G DE Discovery agent
DMK7QXA ID DMK7QXA
DMK7QXA DN DIETHOXYFLOURESCEIN
DMK7QXA HS Investigative
DMK7QXA SN DIETHOXYFLOURESCEIN; CHEMBL1257567; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 3',6'-diethoxy-; 21934-70-3; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-diethoxy-; AC1Q6MMX; AC1L4PB7; 3',6'-Diethoxyfluorescein; SCHEMBL6404797; XAPFGEPPWZRGFN-UHFFFAOYSA-N; BDBM50328442; AKOS028111348
DMK7QXA DT Small molecular drug
DMK7QXA PC 161373
DMK7QXA MW 388.4
DMK7QXA FM C24H20O5
DMK7QXA IC InChI=1S/C24H20O5/c1-3-26-15-9-11-19-21(13-15)28-22-14-16(27-4-2)10-12-20(22)24(19)18-8-6-5-7-17(18)23(25)29-24/h5-14H,3-4H2,1-2H3
DMK7QXA CS CCOC1=CC2=C(C=C1)C3(C4=C(O2)C=C(C=C4)OCC)C5=CC=CC=C5C(=O)O3
DMK7QXA IK XAPFGEPPWZRGFN-UHFFFAOYSA-N
DMK7QXA IU 3',6'-diethoxyspiro[2-benzofuran-3,9'-xanthene]-1-one
DMK7QXA CA CAS 21934-70-3
DMK7QXA DE Discovery agent
DM7YHBR ID DM7YHBR
DM7YHBR DN Diethyl 2-((biphenyl-3-ylamino)methylene)malonate
DM7YHBR HS Investigative
DM7YHBR SN CHEMBL217897; ZINC14956351; diethyl [(biphenyl-3-ylamino)methylidene]propanedioate
DM7YHBR DT Small molecular drug
DM7YHBR PC 91895907
DM7YHBR MW 339.4
DM7YHBR FM C20H21NO4
DM7YHBR IC InChI=1S/C20H21NO4/c1-3-24-19(22)18(20(23)25-4-2)14-21-17-12-8-11-16(13-17)15-9-6-5-7-10-15/h5-14,18H,3-4H2,1-2H3
DM7YHBR CS CCOC(=O)C(C=NC1=CC=CC(=C1)C2=CC=CC=C2)C(=O)OCC
DM7YHBR IK WHQSBENLMFJXRC-UHFFFAOYSA-N
DM7YHBR IU diethyl 2-[(3-phenylphenyl)iminomethyl]propanedioate
DM7YHBR DE Discovery agent
DMDJ9QA ID DMDJ9QA
DMDJ9QA DN Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMDJ9QA HS Investigative
DMDJ9QA SN CHEMBL575301; Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMDJ9QA DT Small molecular drug
DMDJ9QA PC 14026656
DMDJ9QA MW 312.22
DMDJ9QA FM C12H16F3O4P
DMDJ9QA IC InChI=1S/C12H16F3O4P/c1-3-17-20(16,18-4-2)19-11(12(13,14)15)10-8-6-5-7-9-10/h5-9,11H,3-4H2,1-2H3
DMDJ9QA CS CCOP(=O)(OCC)OC(C1=CC=CC=C1)C(F)(F)F
DMDJ9QA IK LLGREQYHEQMYRW-UHFFFAOYSA-N
DMDJ9QA IU diethyl (2,2,2-trifluoro-1-phenylethyl) phosphate
DMDJ9QA CA CAS 120245-10-5
DMDJ9QA DE Discovery agent
DMM4QFL ID DMM4QFL
DMM4QFL DN Diethylphosphono Group
DMM4QFL HS Investigative
DMM4QFL SN Diethyl phosphonate; 762-04-9; Phosphonic acid, diethyl ester; Phosphonic acid diethyl ester; Diethoxyphosphine oxide; Hydrogen diethyl phosphite; Diethyl acid phosphite; O,O-Diethyl phosphonate; Phosphorous acid, diethyl ester; Ethyl phosphonate ((EtO)2HPO); Diethylfosfit [Czech]; UNII-U9X9YBA22W; NSC 2665; DIETHYLPHOSPHONO GROUP; HSDB 2591; diethoxyphosphino-1-one; diethoxy(oxo)phosphonium; Diethyl phosphite, 98%; EINECS 212-091-6; BRN 0605759; U9X9YBA22W; MJUJXFBTEFXVKU-UHFFFAOYSA-N; Diethylfosfit; MFCD00044573
DMM4QFL DT Small molecular drug
DMM4QFL PC 6327654
DMM4QFL MW 137.09
DMM4QFL FM C4H10O3P+
DMM4QFL IC InChI=1S/C4H10O3P/c1-3-6-8(5)7-4-2/h3-4H2,1-2H3/q+1
DMM4QFL CS CCO[P+](=O)OCC
DMM4QFL IK LXCYSACZTOKNNS-UHFFFAOYSA-N
DMM4QFL IU diethoxy(oxo)phosphanium
DMM4QFL CA CAS 762-04-9
DMM4QFL CB CHEBI:41962
DMM4QFL DE Discovery agent
DM8AZQ3 ID DM8AZQ3
DM8AZQ3 DN difluoroagomelatine
DM8AZQ3 HS Investigative
DM8AZQ3 SN difluoroagomelatine; GTPL7776; CHEMBL1946221
DM8AZQ3 DT Small molecular drug
DM8AZQ3 PC 57381112
DM8AZQ3 MW 279.28
DM8AZQ3 FM C15H15F2NO2
DM8AZQ3 IC InChI=1S/C15H15F2NO2/c1-20-12-6-5-10-3-2-4-11(13(10)9-12)7-8-18-15(19)14(16)17/h2-6,9,14H,7-8H2,1H3,(H,18,19)
DM8AZQ3 CS COC1=CC2=C(C=CC=C2CCNC(=O)C(F)F)C=C1
DM8AZQ3 IK UTLRQLQDJLNKNY-UHFFFAOYSA-N
DM8AZQ3 IU 2,2-difluoro-N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
DM8AZQ3 DE Discovery agent
DM8ABD6 ID DM8ABD6
DM8ABD6 DN Difluorobenztropine
DM8ABD6 HS Investigative
DM8ABD6 SN CHEMBL317757; DIFLUOROBENZTROPINE; 4,4'-DifluoroBZT; AC1MZYZJ; Biomol-NT_000053; Lopac0_000439; SCHEMBL6478352; BPBio1_001309; SCHEMBL12648564; BDBM86701; CHEBI:110199; NCGC00024872-02; LS-190982; BRD-A85216385-003-01-6; 3-[bis(4-fluorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane; 3-[Bis-(4-fluoro-phenyl)-methoxy]-8-methyl-8-azonia-bicyclo[3.2.1]octane; 3-(bis(4-fluorophenyl)methoxy)-8-methyl-8-aza-bicyclo[3.2.1]octane
DM8ABD6 DT Small molecular drug
DM8ABD6 PC 3929516
DM8ABD6 MW 343.4
DM8ABD6 FM C21H23F2NO
DM8ABD6 IC InChI=1S/C21H23F2NO/c1-24-18-10-11-19(24)13-20(12-18)25-21(14-2-6-16(22)7-3-14)15-4-8-17(23)9-5-15/h2-9,18-21H,10-13H2,1H3
DM8ABD6 CS CN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM8ABD6 IK MHNSOBBJZCWUGS-UHFFFAOYSA-N
DM8ABD6 IU 3-[bis(4-fluorophenyl)methoxy]-8-methyl-8-azabicyclo[3.2.1]octane
DM8ABD6 CB CHEBI:110199
DM8ABD6 DE Discovery agent
DM8TG41 ID DM8TG41
DM8TG41 DN Difluoromethionine
DM8TG41 HS Investigative
DM8TG41 SN DIFLUOROMETHIONINE; S-(Difluoromethyl)homocysteine; 2FM; difluoro-L-methionine; AC1L9LA0; S-difluoromethyl-l-homocysteine; SCHEMBL2977180; DB03816; (2S)-2-amino-4-(difluoromethylsulfanyl)butanoic acid
DM8TG41 DT Small molecular drug
DM8TG41 PC 447827
DM8TG41 MW 185.19
DM8TG41 FM C5H9F2NO2S
DM8TG41 IC InChI=1S/C5H9F2NO2S/c6-5(7)11-2-1-3(8)4(9)10/h3,5H,1-2,8H2,(H,9,10)/t3-/m0/s1
DM8TG41 CS C(CSC(F)F)[C@@H](C(=O)O)N
DM8TG41 IK YHBNXKYHZMAFED-VKHMYHEASA-N
DM8TG41 IU (2S)-2-amino-4-(difluoromethylsulfanyl)butanoic acid
DM8TG41 DE Discovery agent
DMXK8BH ID DMXK8BH
DMXK8BH DN digeranyl bisphosphonate
DMXK8BH HS Investigative
DMXK8BH SN digeranyl bisphosphonate; [(6E,11E)-2,6,12,16-tetramethyl-9-phosphonoheptadeca-2,6,11,15-tetraen-9-yl]phosphonic acid; bisphosphonate, 5; CHEMBL258994; GTPL3187; SCHEMBL14408741
DMXK8BH DT Small molecular drug
DMXK8BH PC 11606263
DMXK8BH MW 448.5
DMXK8BH FM C21H38O6P2
DMXK8BH IC InChI=1S/C21H38O6P2/c1-17(2)9-7-11-19(5)13-15-21(28(22,23)24,29(25,26)27)16-14-20(6)12-8-10-18(3)4/h9-10,13-14H,7-8,11-12,15-16H2,1-6H3,(H2,22,23,24)(H2,25,26,27)/b19-13+,20-14+
DMXK8BH CS CC(=CCC/C(=C/CC(P(=O)(O)O)(P(=O)(O)O)C/C=C(/CCC=C(C)C)\\C)/C)C
DMXK8BH IK SQERRIVHBWCION-IWGRKNQJSA-N
DMXK8BH IU [(6E,11E)-2,6,12,16-tetramethyl-9-phosphonoheptadeca-2,6,11,15-tetraen-9-yl]phosphonic acid
DMXK8BH DE Discovery agent
DM5AOFW ID DM5AOFW
DM5AOFW DN Digitoxigenin
DM5AOFW HS Investigative
DM5AOFW SN Uzarigenin; 466-09-1; UNII-K9ZR7LI283; EINECS 207-373-0; NSC 119993; BRN 0095446; K9ZR7LI283; 3-beta-14-beta-5-Allo-cardenolid [German]; 3beta,14-Dihydroxy-5alpha-card-20(22)-enolide; 3-beta,14-Dihydroxy-5-alpha-card-20(22)-enolide; 4-18-00-01470 (Beilstein Handbook Reference); Urarigenin; Odorigeni; 3-beta-14-beta-5-Allo-cardenolid; AC1L3OS7; CHEMBL109863; SCHEMBL1152953; XZTUSOXSLKTKJQ-CIXPXFMPSA-N; MolPort-006-111-351; ZINC4073972; MCULE-2541512222; NCGC00384854-01; BC271971; 3,14-Dihydroxycard-20(22)-enolide #
DM5AOFW DT Small molecular drug
DM5AOFW PC 4369270
DM5AOFW MW 374.5
DM5AOFW FM C23H34O4
DM5AOFW IC InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1
DM5AOFW CS C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O
DM5AOFW IK XZTUSOXSLKTKJQ-CESUGQOBSA-N
DM5AOFW IU 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
DM5AOFW CA CAS 143-62-4
DM5AOFW CB CHEBI:42219
DM5AOFW DE Discovery agent
DMBAY7P ID DMBAY7P
DMBAY7P DN Diheptan-3-yl 5-(hydroxymethyl)isophthalate
DMBAY7P HS Investigative
DMBAY7P SN CHEMBL494361; diheptan-3-yl 5-(hydroxymethyl)isophthalate; SCHEMBL13625629
DMBAY7P DT Small molecular drug
DMBAY7P PC 44186619
DMBAY7P MW 392.5
DMBAY7P FM C23H36O5
DMBAY7P IC InChI=1S/C23H36O5/c1-5-9-11-20(7-3)27-22(25)18-13-17(16-24)14-19(15-18)23(26)28-21(8-4)12-10-6-2/h13-15,20-21,24H,5-12,16H2,1-4H3
DMBAY7P CS CCCCC(CC)OC(=O)C1=CC(=CC(=C1)CO)C(=O)OC(CC)CCCC
DMBAY7P IK ZBGSOGNHNSNOLN-UHFFFAOYSA-N
DMBAY7P IU diheptan-3-yl 5-(hydroxymethyl)benzene-1,3-dicarboxylate
DMBAY7P DE Discovery agent
DM8TBQ9 ID DM8TBQ9
DM8TBQ9 DN Dihexan-3-yl 5-(hydroxymethyl)isophthalate
DM8TBQ9 HS Investigative
DM8TBQ9 SN CHEMBL523053; dihexan-3-yl 5-(hydroxymethyl)isophthalate; SCHEMBL13625642
DM8TBQ9 DT Small molecular drug
DM8TBQ9 PC 44186618
DM8TBQ9 MW 364.5
DM8TBQ9 FM C21H32O5
DM8TBQ9 IC InChI=1S/C21H32O5/c1-5-9-18(7-3)25-20(23)16-11-15(14-22)12-17(13-16)21(24)26-19(8-4)10-6-2/h11-13,18-19,22H,5-10,14H2,1-4H3
DM8TBQ9 CS CCCC(CC)OC(=O)C1=CC(=CC(=C1)CO)C(=O)OC(CC)CCC
DM8TBQ9 IK ONMFJTSDBZIFTK-UHFFFAOYSA-N
DM8TBQ9 IU dihexan-3-yl 5-(hydroxymethyl)benzene-1,3-dicarboxylate
DM8TBQ9 DE Discovery agent
DMW1ALX ID DMW1ALX
DMW1ALX DN DIHYDROAKUAMMINE
DMW1ALX HS Investigative
DMW1ALX SN Dihydroakuammine
DMW1ALX DT Small molecular drug
DMW1ALX PC 44576039
DMW1ALX MW 384.5
DMW1ALX FM C22H28N2O4
DMW1ALX IC InChI=1S/C22H28N2O4/c1-4-14-12-24-10-9-21-17-11-15(26)5-6-18(17)23(2)22(21,24)8-7-16(14)20(21,13-25)19(27)28-3/h4-6,11,16,25-26H,7-10,12-13H2,1-3H3/b14-4-/t16-,20+,21+,22+/m1/s1
DMW1ALX CS C/C=C\\1/CN2CC[C@@]34[C@@]2(CC[C@H]1[C@@]3(CO)C(=O)OC)N(C5=C4C=C(C=C5)O)C
DMW1ALX IK SJFXTBHAODZALL-PEZZAXBTSA-N
DMW1ALX IU methyl (1S,9R,12R,13E,18R)-13-ethylidene-4-hydroxy-18-(hydroxymethyl)-8-methyl-8,15-diazapentacyclo[10.5.1.01,9.02,7.09,15]octadeca-2(7),3,5-triene-18-carboxylate
DMW1ALX DE Discovery agent
DMS4U68 ID DMS4U68
DMS4U68 DN dihydrocarveol
DMS4U68 HS Investigative
DMS4U68 SN neodihydrocarveol
DMS4U68 DT Small molecular drug
DMS4U68 PC 12072
DMS4U68 MW 154.25
DMS4U68 FM C10H18O
DMS4U68 IC InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3
DMS4U68 CS CC1CCC(CC1O)C(=C)C
DMS4U68 IK KRCZYMFUWVJCLI-UHFFFAOYSA-N
DMS4U68 IU 2-methyl-5-prop-1-en-2-ylcyclohexan-1-ol
DMS4U68 CA CAS 619-01-2
DMS4U68 CB CHEBI:50215
DMS4U68 DE Discovery agent
DMGLX1R ID DMGLX1R
DMGLX1R DN Dihydrocoumarin
DMGLX1R HS Investigative
DMGLX1R SN Benzodihydropyrone; Benzopyranone, dihydro-; Chroman, 2-oxo-; Coumarin, 3,4-dihydro-; Dihydrobenzopyrone; Melilotic acid lactone; Melilotine; Meliotine; Oxochroman; Usaf do-12; chroman-2-one; dihydrocoumarin; hydrocoumarin; melilotic lactone; melilotin; melilotol; 1,2-benzodihydropyrone; 119-84-6; 2-Hydroxydihydrocinnamic acid lactone; 2-chromanone; 2H-1-Benzopyran-2-one, 3,4-dihydro-; 3,4-Dihydro-2H-1-benzopyran-2-one; 3,4-Dyhydrocoumarin; 3,4-dihydro-2H-chromen-2-one; 3,4-dihydrocoumarin; NCI-C55890
DMGLX1R PC 660
DMGLX1R MW 148.16
DMGLX1R FM C9H8O2
DMGLX1R IC VMUXSMXIQBNMGZ-UHFFFAOYSA-N
DMGLX1R CS C1CC(=O)OC2=CC=CC=C21
DMGLX1R IK 1S/C9H8O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-4H,5-6H2
DMGLX1R IU 3,4-dihydrochromen-2-one
DMGLX1R CA CAS 119-84-6
DMGLX1R CB CHEBI:16151
DMGLX1R DE Discovery agent
DMZL7R6 ID DMZL7R6
DMZL7R6 DN DIHYDROCUBEBIN
DMZL7R6 HS Investigative
DMZL7R6 SN Dihydrocubebin; (-)-Dihydrocubebin; 24563-03-9; (2R,3R)-2,3-bis(1,3-benzodioxol-5-ylmethyl)butane-1,4-diol; CHEMBL486597; CHEBI:543841; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, (R-(R*,R*))-; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, [R-(R*,R*)]-; Cubebin, dihydro-; AC1Q6ZWV; AC1L4VHK; SCHEMBL15775181; CTK4F3896; DTXSID00179301; JKCVMTYNARDGET-HOTGVXAUSA-N; ZINC899938; BDBM50241937; 1,4-Butanediol, 2,3-bis(1,3-benzodioxol-5-ylmethyl)-, (R*,R*)-(-)-; 1,4-Butanediol, 2,3-dipiperonyl-, (-)-; C10558
DMZL7R6 DT Small molecular drug
DMZL7R6 PC 193042
DMZL7R6 MW 358.4
DMZL7R6 FM C20H22O6
DMZL7R6 IC InChI=1S/C20H22O6/c21-9-15(5-13-1-3-17-19(7-13)25-11-23-17)16(10-22)6-14-2-4-18-20(8-14)26-12-24-18/h1-4,7-8,15-16,21-22H,5-6,9-12H2/t15-,16-/m0/s1
DMZL7R6 CS C1OC2=C(O1)C=C(C=C2)C[C@@H](CO)[C@@H](CC3=CC4=C(C=C3)OCO4)CO
DMZL7R6 IK JKCVMTYNARDGET-HOTGVXAUSA-N
DMZL7R6 IU (2R,3R)-2,3-bis(1,3-benzodioxol-5-ylmethyl)butane-1,4-diol
DMZL7R6 CA CAS 24563-03-9
DMZL7R6 CB CHEBI:543841
DMZL7R6 DE Discovery agent
DMDW2NL ID DMDW2NL
DMDW2NL DN dihydroergocryptine
DMDW2NL HS Investigative
DMDW2NL SN dihydroergokryptine
DMDW2NL DT Small molecular drug
DMDW2NL PC 114948
DMDW2NL MW 577.7
DMDW2NL FM C32H43N5O5
DMDW2NL IC InChI=1S/C32H43N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38)/t20-,22-,24-,25+,26+,31-,32+/m1/s1
DMDW2NL CS CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@H]5[C@@H](CC6=CNC7=CC=CC5=C67)N(C4)C)O
DMDW2NL IK PBUNVLRHZGSROC-VTIMJTGVSA-N
DMDW2NL IU (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
DMDW2NL CA CAS 25447-66-9
DMDW2NL CB CHEBI:59919
DMDW2NL DE Discovery agent
DM1BDM8 ID DM1BDM8
DM1BDM8 DN Dihydrofolic Acid
DM1BDM8 HS Investigative
DM1BDM8 DT Small molecular drug
DM1BDM8 PC 135398604
DM1BDM8 MW 443.4
DM1BDM8 FM C19H21N7O6
DM1BDM8 IC InChI=1S/C19H21N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,12,21H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t12-/m0/s1
DM1BDM8 CS C1C(=NC2=C(N1)N=C(NC2=O)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM1BDM8 IK OZRNSSUDZOLUSN-LBPRGKRZSA-N
DM1BDM8 IU (2S)-2-[[4-[(2-amino-4-oxo-7,8-dihydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DM1BDM8 CA CAS 4033-27-6
DM1BDM8 CB CHEBI:15633
DM1BDM8 DE Discovery agent
DM73OTF ID DM73OTF
DM73OTF DN DIHYDROKAEMPFEROL
DM73OTF HS Investigative
DM73OTF SN aromadendrin; 480-20-6; (+)-Dihydrokaempferol; dihydrokaempferol; katuranin; (+)-aromadendrin; Aromadendrol; (2R,3R)-3,5,7-Trihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (+)-Aromadendrol; UNII-7YA4640575; (2R,3R)-3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; CHEMBL9323; CHEBI:15401; PADQINQHPQKXNL-LSDHHAIUSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-, (2R,3R)-; 7YA4640575; Arbo 14; AC1L3VDW; AC1Q6KIF; (2R,3R)-dihydrokaempferol; MLS000697722
DM73OTF DT Small molecular drug
DM73OTF PC 122850
DM73OTF MW 288.25
DM73OTF FM C15H12O6
DM73OTF IC InChI=1S/C15H12O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,14-18,20H/t14-,15+/m0/s1
DM73OTF CS C1=CC(=CC=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DM73OTF IK PADQINQHPQKXNL-LSDHHAIUSA-N
DM73OTF IU (2R,3R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DM73OTF CA CAS 480-20-6
DM73OTF CB CHEBI:15401
DM73OTF DE Discovery agent
DM9NO6F ID DM9NO6F
DM9NO6F DN DIHYDROKAINATE
DM9NO6F HS Investigative
DM9NO6F SN GTPL4571
DM9NO6F DT Small molecular drug
DM9NO6F PC 107883
DM9NO6F MW 215.25
DM9NO6F FM C10H17NO4
DM9NO6F IC InChI=1S/C10H17NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h5-7,9,11H,3-4H2,1-2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1
DM9NO6F CS CC(C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O
DM9NO6F IK JQPDCKOQOOQUSC-OOZYFLPDSA-N
DM9NO6F IU (2S,3S,4R)-3-(carboxymethyl)-4-propan-2-ylpyrrolidine-2-carboxylic acid
DM9NO6F CA CAS 52497-36-6
DM9NO6F CB CHEBI:43562
DM9NO6F DE Discovery agent
DMG0PXI ID DMG0PXI
DMG0PXI DN Dihydrolanosterol
DMG0PXI HS Investigative
DMG0PXI SN Dihydrolanosterin; Dihydrolanosterol; Lanost-8-en-3-ol; Lanost-8-en-3-ol #; Lanost-8-en-3-ol, (3.beta.)-; Lanost-8-en-3.beta.-ol; Lanost-8-en-3beta-ol; Lanostenol; Lanosterol, dihydro-; MBZYKEVPFYHDOH-BQNIITSRSA-N; SCHEMBL288306; (3beta)-Lanost-8-en-3-ol; 24,25-Dihydrolanosterol; 24-dihydrolanosterol; 3beta-Hydroxylanost-8-ene; 5alpha-Lanost-8-en-3 beta-ol; 5alpha-Lanost-8-en-3beta-ol; 79-62-9; 9H273A8B2X; CHEBI:28113; CHEMBL4213010; DTXSID101000181; UNII-9H273A8B2X
DMG0PXI PC 440560
DMG0PXI MW 428.7
DMG0PXI FM C30H52O
DMG0PXI IC MBZYKEVPFYHDOH-BQNIITSRSA-N
DMG0PXI CS CC(C)CCCC(C)C1CCC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)O)C)C)C
DMG0PXI IK 1S/C30H52O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h20-22,25-26,31H,9-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1
DMG0PXI IU (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMG0PXI CA CAS 79-62-9
DMG0PXI CB CHEBI:28113
DMG0PXI DE Discovery agent
DM4TR0D ID DM4TR0D
DM4TR0D DN Dihydromorphine
DM4TR0D HS Investigative
DM4TR0D SN Dihydromorphine; Paramorphan; 7,8-DIHYDROMORPHINE; 6-alpha-Hydromorphol; 509-60-4; Dihydromorfin [Czech]; UNII-C3S5FRP6JW; Hydromorphine; Paramorfan; Morphine, dihydro-; EINECS 208-100-8; C3S5FRP6JW; NSC 117865; Dihydromorfin; CHEBI:4575; DEA No. 9145; Morphinan-3,6alpha-diol, 4,5alpha-epoxy-17-methyl-; Morphinan-3,6-alpha-diol, 4,5-alpha-epoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; 7,8-Dihydromorphin; 1421-28-9; dihydromorphin
DM4TR0D DT Small molecular drug
DM4TR0D PC 5359421
DM4TR0D MW 287.35
DM4TR0D FM C17H21NO3
DM4TR0D IC InChI=1S/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
DM4TR0D CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](CC4)O
DM4TR0D IK IJVCSMSMFSCRME-KBQPJGBKSA-N
DM4TR0D IU (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DM4TR0D CA CAS 509-60-4
DM4TR0D CB CHEBI:4575
DM4TR0D DE Discovery agent
DM76BGZ ID DM76BGZ
DM76BGZ DN Dihydroorotate
DM76BGZ HS Investigative
DM76BGZ SN Dihydroorotic acid; hydroorotic acid; 4,5-dihydroorotic acid; DL-Dihydroorotic acid; 155-54-4; 5,6-dihydroorotate; dihydroorotate; 2,6-dioxohexahydropyrimidine-4-carboxylic acid; 2,6-dioxo-1,3-diazinane-4-carboxylic acid; hexahydro-2,6-dioxo-4-Pyrimidinecarboxylic acid; 6202/10/4; CHEBI:30865; L-Hydroorotic acid; 4,5-dihydroorotate; 2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid; Orotic acid, 4,5-dihydro-; L-hydroorotate; R,S-Hydroorotate; 2,6-dioxohexahydro-4-pyrimidincarbons; DL-dihydroortotic acid; AC1Q6GGT; Dihydroorotic Acid
DM76BGZ DT Small molecular drug
DM76BGZ PC 5461056
DM76BGZ MW 157.1
DM76BGZ FM C5H5N2O4-
DM76BGZ IC InChI=1S/C5H6N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h2H,1H2,(H,9,10)(H2,6,7,8,11)/p-1
DM76BGZ CS C1C(NC(=O)NC1=O)C(=O)[O-]
DM76BGZ IK UFIVEPVSAGBUSI-UHFFFAOYSA-M
DM76BGZ IU 2,6-dioxo-1,3-diazinane-4-carboxylate
DM76BGZ CB CHEBI:30867
DM76BGZ DE Discovery agent
DM0W64U ID DM0W64U
DM0W64U DN Dihydropyridines
DM0W64U HS Investigative
DM0W64U SN 1,2-dihydropyridine; UNII-YA306KG67U; 22694-45-7; YA306KG67U; Pyridine, 1,2-dihydro-; AC1L8RRH; CTK1A1117; MMWRGWQTAMNAFC-UHFFFAOYSA-N; AKOS006352484; 27183-EP2311806A2; 27183-EP2308562A2; 27183-EP2301911A1; 27183-EP2292593A2; 27183-EP2314575A1; 27183-EP2295427A1; 27183-EP2270010A1; 27183-EP2269990A1; 27617-EP2270006A1; 27183-EP2371811A2; 27183-EP2308510A1; 27183-EP2295426A1; 27183-EP2275404A1; 27617-EP2314587A1; 27183-EP2292611A1; 27183-EP2284149A1
DM0W64U DT Small molecular drug
DM0W64U PC 407038
DM0W64U MW 81.12
DM0W64U FM C5H7N
DM0W64U IC InChI=1S/C5H7N/c1-2-4-6-5-3-1/h1-4,6H,5H2
DM0W64U CS C1C=CC=CN1
DM0W64U IK MMWRGWQTAMNAFC-UHFFFAOYSA-N
DM0W64U IU 1,2-dihydropyridine
DM0W64U CA CAS 22694-45-7
DM0W64U DE Discovery agent
DMYSPMH ID DMYSPMH
DMYSPMH DN Dihydropyrone
DMYSPMH HS Investigative
DMYSPMH SN Butopyronoxyl; INDALONE; 532-34-3; Dihydropyrone; BMOO; Indalon; Butyl mesityl oxide oxalate; ENT 9; n-Butylmesityloxid oxalate; Butyl mesityl oxide; n-Butyl mesityl oxide oxalate; Caswell No. 128; Butylmesityl oxide oxalate; UNII-4I5PG5VZ0V; NSC 404420; HSDB 1526; EINECS 208-535-3; Butyl 3,4-dihydro-2,2-dimethyl-4-oxo-2H-pyran-6-carboxylate; EPA Pesticide Chemical Code 046801; 2,2-Dimethyl-6-carbobutoxy-2,3-dihydro-4-pyrone; BRN 0160461; 4I5PG5VZ0V; Butyl dimethyl dihydro-pyrone carboxylate; 2H-Pyran-6-carboxylic acid, 3,4-dihyd
DMYSPMH DT Small molecular drug
DMYSPMH PC 10760
DMYSPMH MW 226.27
DMYSPMH FM C12H18O4
DMYSPMH IC InChI=1S/C12H18O4/c1-4-5-6-15-11(14)10-7-9(13)8-12(2,3)16-10/h7H,4-6,8H2,1-3H3
DMYSPMH CS CCCCOC(=O)C1=CC(=O)CC(O1)(C)C
DMYSPMH IK OKIJSNGRQAOIGZ-UHFFFAOYSA-N
DMYSPMH IU butyl 2,2-dimethyl-4-oxo-3H-pyran-6-carboxylate
DMYSPMH CA CAS 532-34-3
DMYSPMH CB CHEBI:82262
DMYSPMH DE Hepatovirus infection
DM9UK6D ID DM9UK6D
DM9UK6D DN Dihydro-quinolinone
DM9UK6D HS Investigative
DM9UK6D SN 553-03-7; 3,4-Dihydro-2(1H)-quinolinone; 3,4-Dihydroquinolin-2(1H)-one; Hydrocarbostyril; 1,2,3,4-tetrahydroquinolin-2-one; 3,4-Dihydrocarbostyril; 3,4-dihydro-1H-quinolin-2-one; 2-Oxo-1,2,3,4-tetrahydroquinoline; Dihydro-quinolinone; 3,4-Dihydro-2-quinolinol; o-Aminohydrocinnamic acid lactam; UNII-2CKG6TX32F; 3,4-Dihydro-2(1H)quinolinone; 2(1H)-Quinolinone, 3,4-dihydro-; NSC 49170; 2CKG6TX32F; CHEMBL388582; TZOYXRMEFDYWDQ-UHFFFAOYSA-N; 3,4-DIHYDRO-2-QUINOLONE; MFCD00016722; 3,4-Dihydro-2(1H)-quinolinone, 98%
DM9UK6D DT Small molecular drug
DM9UK6D PC 64796
DM9UK6D MW 147.17
DM9UK6D FM C9H9NO
DM9UK6D IC InChI=1S/C9H9NO/c11-9-6-5-7-3-1-2-4-8(7)10-9/h1-4H,5-6H2,(H,10,11)
DM9UK6D CS C1CC(=O)NC2=CC=CC=C21
DM9UK6D IK TZOYXRMEFDYWDQ-UHFFFAOYSA-N
DM9UK6D IU 3,4-dihydro-1H-quinolin-2-one
DM9UK6D CA CAS 553-03-7
DM9UK6D DE Discovery agent
DM70OIC ID DM70OIC
DM70OIC DN DIHYDRORALOXIFENE
DM70OIC HS Investigative
DM70OIC SN DIHYDRORALOXIFENE; CHEMBL14955; BDBM50217538; ZINC15919388
DM70OIC DT Small molecular drug
DM70OIC PC 15788490
DM70OIC MW 475.6
DM70OIC FM C28H29NO4S
DM70OIC IC InChI=1S/C28H29NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,26,28,30-31H,1-3,14-17H2/t26-,28-/m1/s1
DM70OIC CS C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)[C@@H]3[C@H](SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
DM70OIC IK IKZMTNSYXDOFJH-IXCJQBJRSA-N
DM70OIC IU [(2S,3R)-6-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
DM70OIC DE Discovery agent
DM58KHY ID DM58KHY
DM58KHY DN dihydrosphingosine-1-phosphate
DM58KHY HS Investigative
DM58KHY SN sphinganine-phosphate; dihydroS1P
DM58KHY DT Small molecular drug
DM58KHY PC 644260
DM58KHY MW 381.5
DM58KHY FM C18H40NO5P
DM58KHY IC InChI=1S/C18H40NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)17(19)16-24-25(21,22)23/h17-18,20H,2-16,19H2,1H3,(H2,21,22,23)/t17-,18+/m0/s1
DM58KHY CS CCCCCCCCCCCCCCC[C@H]([C@H](COP(=O)(O)O)N)O
DM58KHY IK YHEDRJPUIRMZMP-ZWKOTPCHSA-N
DM58KHY IU [(2S,3R)-2-amino-3-hydroxyoctadecyl] dihydrogen phosphate
DM58KHY CA CAS 19794-97-9
DM58KHY CB CHEBI:16893
DMPDQSV ID DMPDQSV
DMPDQSV DN Dihydrostreptomycin
DMPDQSV HS Investigative
DMPDQSV SN Dihidroestreptomicina; Dihydrostreptomycin [INN:BAN]; Dihydrostreptomycine; Dihydrostreptomycine [INN-French]; Dihydrostreptomycinum; Diidrostreptomicina; Diidrostreptomicina [DCIT]; P2I6R8W6UA; Streptomycin, dihydro-; Vibriomycin; dihydrostreptomycin; 128-46-1; Abiocine; CHEBI:38291; DHMS; N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine; UNII-P2I6R8W6UA
DMPDQSV PC 439369
DMPDQSV MW 583.6
DMPDQSV FM C21H41N7O12
DMPDQSV IC ASXBYYWOLISCLQ-HZYVHMACSA-N
DMPDQSV CS CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(CO)O
DMPDQSV IK 1S/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1
DMPDQSV IU 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
DMPDQSV CA CAS 128-46-1
DMPDQSV CB CHEBI:38291
DMPDQSV DE Pulmonary tuberculosis
DMFKWRM ID DMFKWRM
DMFKWRM DN DIHYDROXANTHOHUMOL
DMFKWRM HS Investigative
DMFKWRM SN dihydroxanthohumol; alpha,beta-dihydroxanthohumol; MLS000863606; 4,2',4'-Trihydroxy-6'-methoxy-3'-prenyldihydrochalcone; CHEBI:66332; SMR000440746; a,b-Dihydroxanthohumol; MEGxp0_001797; CHEMBL510279; SCHEMBL15704299; BDBM76566; ACon1_000059; cid_10450920; HMS2267A19; LMPK12120536; 1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)propan-1-one; NCGC00168833-01; BRD-K15951006-001-01-4; 2',4,4'-Trihydroxy-6'-methoxy-3'-prenyldihydrochalcone
DMFKWRM DT Small molecular drug
DMFKWRM PC 10450920
DMFKWRM MW 356.4
DMFKWRM FM C21H24O5
DMFKWRM IC InChI=1S/C21H24O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-6,8-9,12,22,24-25H,7,10-11H2,1-3H3
DMFKWRM CS CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)CCC2=CC=C(C=C2)O)O)C
DMFKWRM IK SVTCZHIDEDUTBH-UHFFFAOYSA-N
DMFKWRM IU 1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)propan-1-one
DMFKWRM CA CAS 102448-00-0
DMFKWRM CB CHEBI:66332
DMFKWRM DE Discovery agent
DME4NH1 ID DME4NH1
DME4NH1 DN Di-imidazole lexitropsin
DME4NH1 HS Investigative
DME4NH1 SN DIIMIDAZOLE LEXITROPSIN; AC1NDQQ9; [1-amino-3-[[4-[(4-formamido-1-methylimidazole-2-carbonyl)amino]-1-methylimidazole-2-carbonyl]amino]propylidene]azanium
DME4NH1 DT Small molecular drug
DME4NH1 PC 449424
DME4NH1 MW 361.36
DME4NH1 FM C14H19N9O3
DME4NH1 IC InChI=1S/C14H19N9O3/c1-22-5-9(18-7-24)19-12(22)14(26)21-10-6-23(2)11(20-10)13(25)17-4-3-8(15)16/h5-7H,3-4H2,1-2H3,(H3,15,16)(H,17,25)(H,18,24)(H,21,26)
DME4NH1 CS CN1C=C(N=C1C(=O)NC2=CN(C(=N2)C(=O)NCCC(=N)N)C)NC=O
DME4NH1 IK WISSDOJERIUENW-UHFFFAOYSA-N
DME4NH1 IU N-[2-[(3-amino-3-iminopropyl)carbamoyl]-1-methylimidazol-4-yl]-4-formamido-1-methylimidazole-2-carboxamide
DME4NH1 CA CAS 114139-02-5
DME4NH1 DE Discovery agent
DM917FE ID DM917FE
DM917FE DN Diiodo-l-thyronine
DM917FE HS Investigative
DM917FE SN L-3,3'-Diiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]propanoic acid; (S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl)propanoic acid; 3,3'-DEIODO-THYROXINE; 3,3'-Diiodo-L-thyronine; 3,3'-Diiodothyronine; 3,3'-Diiodothyronine, L-; 3,3'-T2; 3,3'-Diiodo-l-thyronine; 3L9U2Z4602; 4604-41-5; AC1L32DA; CHEBI:45698; CHEMBL1236140; EINECS 225-005-7; MFCD01863378; O-(4-Hydroxy-3-iodophenyl)-3-iodo-L-tyrosine; Tyrosine, O-(4-hydroxy-3-iodophenyl)-3-iodo-; UNII-3L9U2Z4602
DM917FE PC 107564
DM917FE MW 525.08
DM917FE FM C15H13I2NO4
DM917FE IC CPCJBZABTUOGNM-LBPRGKRZSA-N
DM917FE CS C1=CC(=C(C=C1CC(C(=O)O)N)I)OC2=CC(=C(C=C2)O)I
DM917FE IK 1S/C15H13I2NO4/c16-10-7-9(2-3-13(10)19)22-14-4-1-8(5-11(14)17)6-12(18)15(20)21/h1-5,7,12,19H,6,18H2,(H,20,21)/t12-/m0/s1
DM917FE IU (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3-iodophenyl]propanoic acid
DM917FE CA CAS 4604-41-5
DM917FE CB CHEBI:45698
DM917FE DE Discovery agent
DMNR439 ID DMNR439
DMNR439 DN Diisopropyl 1-mercaptopropylphosphonate
DMNR439 HS Investigative
DMNR439 SN diisopropyl 1-mercaptopropylphosphonate; CHEMBL1173339
DMNR439 DT Small molecular drug
DMNR439 PC 21576786
DMNR439 MW 240.3
DMNR439 FM C9H21O3PS
DMNR439 IC InChI=1S/C9H21O3PS/c1-6-9(14)13(10,11-7(2)3)12-8(4)5/h7-9,14H,6H2,1-5H3
DMNR439 CS CCC(P(=O)(OC(C)C)OC(C)C)S
DMNR439 IK SGAGKIQXGMCPPU-UHFFFAOYSA-N
DMNR439 IU 1-di(propan-2-yloxy)phosphorylpropane-1-thiol
DMNR439 DE Discovery agent
DMVFJAH ID DMVFJAH
DMVFJAH DN Diisopropyl 2-(sulfanylmethyl)phenylphosphonate
DMVFJAH HS Investigative
DMVFJAH SN CHEMBL1173337; Diisopropyl 2-(sulfanylmethyl)phenylphosphonate; Bis(1-Methylethyl) [2-(Sulfanylmethyl)phenyl]phosphonate; 3iof; BDBM50322605; dipropan-2-yl [2-(sulfanylmethyl)phenyl]phosphonate
DMVFJAH DT Small molecular drug
DMVFJAH PC 46173032
DMVFJAH MW 288.34
DMVFJAH FM C13H21O3PS
DMVFJAH IC InChI=1S/C13H21O3PS/c1-10(2)15-17(14,16-11(3)4)13-8-6-5-7-12(13)9-18/h5-8,10-11,18H,9H2,1-4H3
DMVFJAH CS CC(C)OP(=O)(C1=CC=CC=C1CS)OC(C)C
DMVFJAH IK JFZVPWMZPZJUTE-UHFFFAOYSA-N
DMVFJAH IU [2-di(propan-2-yloxy)phosphorylphenyl]methanethiol
DMVFJAH DE Discovery agent
DMHKE3M ID DMHKE3M
DMHKE3M DN Diisopropyl mercapto(phenyl)methylphosphonate
DMHKE3M HS Investigative
DMHKE3M SN diisopropyl mercapto(phenyl)methylphosphonate; CHEMBL1170023
DMHKE3M DT Small molecular drug
DMHKE3M PC 21576785
DMHKE3M MW 288.34
DMHKE3M FM C13H21O3PS
DMHKE3M IC InChI=1S/C13H21O3PS/c1-10(2)15-17(14,16-11(3)4)13(18)12-8-6-5-7-9-12/h5-11,13,18H,1-4H3
DMHKE3M CS CC(C)OP(=O)(C(C1=CC=CC=C1)S)OC(C)C
DMHKE3M IK NOPVXMUUBWYONO-UHFFFAOYSA-N
DMHKE3M IU di(propan-2-yloxy)phosphoryl-phenylmethanethiol
DMHKE3M DE Discovery agent
DMND2AS ID DMND2AS
DMND2AS DN Diisopropylphosphono Group
DMND2AS HS Investigative
DMND2AS SN Diisopropyl phosphonate; Phosphonic acid, bis(1-methylethyl) ester; Diisopropylphosphine oxide; Phosphonic acid, diisopropyl ester; O,O-Diisopropyl phosphonate; Isopropyl phosphonate; Diisopropyl hydrogen phosphonate; Isopropyl phosphonate ((C3H7O)2HPO); Diisopropylphosphonate; DIISOPROPYLPHOSPHONO GROUP; NSC 82344; O,O-Diisopropyl phosphite; bis(propan-2-yl) phosphonate; BLKXLEPPVDUHBY-UHFFFAOYSA-N; EINECS 217-317-7; BRN 1703675; diisopropylphosponate; di-i-Propylphosphite; AC1O3FKK; diisopropoxy(oxo)phosphonium
DMND2AS DT Small molecular drug
DMND2AS PC 6327350
DMND2AS MW 165.15
DMND2AS FM C6H14O3P+
DMND2AS IC InChI=1S/C6H14O3P/c1-5(2)8-10(7)9-6(3)4/h5-6H,1-4H3/q+1
DMND2AS CS CC(C)O[P+](=O)OC(C)C
DMND2AS IK BJLZAAWLLPMZQR-UHFFFAOYSA-N
DMND2AS IU oxo-di(propan-2-yloxy)phosphanium
DMND2AS CA CAS 1809-20-7
DMND2AS DE Discovery agent
DMPKQER ID DMPKQER
DMPKQER DN Diketonitrile
DMPKQER HS Investigative
DMPKQER PC 15461303
DMPKQER MW 359.3
DMPKQER FM C15H12F3NO4S
DMPKQER IC InChI=1S/C15H12F3NO4S/c1-24(22,23)12-6-9(15(16,17)18)4-5-10(12)14(21)11(7-19)13(20)8-2-3-8/h4-6,8,11H,2-3H2,1H3
DMPKQER CS CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C(C#N)C(=O)C2CC2
DMPKQER IK ZTTKDUXKVPEXCG-UHFFFAOYSA-N
DMPKQER IU 2-(cyclopropanecarbonyl)-3-[2-methylsulfonyl-4-(trifluoromethyl)phenyl]-3-oxopropanenitrile
DMPKQER CA CAS 143701-75-1
DMPKQER CB CHEBI:141214
DMPKQER DE Discovery agent
DMOD5Y0 ID DMOD5Y0
DMOD5Y0 DN Dilazep
DMOD5Y0 HS Investigative
DMOD5Y0 SN Dilazep; 35898-87-4; Dilazep [INN]; Dilazepum [INN-Latin]; UNII-F8KLC2BD5Z; Dilazepam [INN-Spanish]; F8KLC2BD5Z; CHEMBL126075; Dilazep (INN); Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester; NCGC00016747-03; AS 05; DSSTox_RID_80871; DSSTox_CID_25425; DSSTox_GSID_45425; Dilazepum; Dilazepam; Tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropanol 3,4,5-trimethoxybenzoate (diester); 3-{4-[3-(3,4,5-trimethoxybenzoyloxy)propyl]-1,4-diazepan-1-yl}propyl 3,4,5-trimethoxybenzoate
DMOD5Y0 DT Small molecular drug
DMOD5Y0 PC 3074
DMOD5Y0 MW 604.7
DMOD5Y0 FM C31H44N2O10
DMOD5Y0 IC InChI=1S/C31H44N2O10/c1-36-24-18-22(19-25(37-2)28(24)40-5)30(34)42-16-8-12-32-10-7-11-33(15-14-32)13-9-17-43-31(35)23-20-26(38-3)29(41-6)27(21-23)39-4/h18-21H,7-17H2,1-6H3
DMOD5Y0 CS COC1=CC(=CC(=C1OC)OC)C(=O)OCCCN2CCCN(CC2)CCCOC(=O)C3=CC(=C(C(=C3)OC)OC)OC
DMOD5Y0 IK QVZCXCJXTMIDME-UHFFFAOYSA-N
DMOD5Y0 IU 3-[4-[3-(3,4,5-trimethoxybenzoyl)oxypropyl]-1,4-diazepan-1-yl]propyl 3,4,5-trimethoxybenzoate
DMOD5Y0 CA CAS 35898-87-4
DMOD5Y0 CB CHEBI:92842
DMOD5Y0 DE Discovery agent
DMA4NI2 ID DMA4NI2
DMA4NI2 DN Dimaprit
DMA4NI2 HS Investigative
DMA4NI2 SN Dimaprit; 65119-89-3; UNII-ZZQ699148P; BRN 2350552; CHEMBL12344; 3-(dimethylamino)propyl imidothiocarbamate; 3-(dimethylamino)propyl carbamimidothioate; CARBAMIMIDOTHIOIC ACID, 3-(DIMETHYLAMINO)PROPYL ESTER; CHEBI:81389; ZZQ699148P; Pseudourea, 2-(3-(dimethylamino)propyl)-2-thio-; [3-(carbamimidoylsulfanyl)propyl]dimethylamine; Carbamimidothioicacid, 3-(dimethylamino)propyl ester; C6H15N3S; AE-641/25069014; Tocris-0506; AC1Q1UAQ; Prestwick0_000983; Prestwick3_000983; Prestwick2_000983; Prestwick1_000983; AC1L1F4E; BSPBio_001045
DMA4NI2 DT Small molecular drug
DMA4NI2 PC 3077
DMA4NI2 MW 161.27
DMA4NI2 FM C6H15N3S
DMA4NI2 IC InChI=1S/C6H15N3S/c1-9(2)4-3-5-10-6(7)8/h3-5H2,1-2H3,(H3,7,8)
DMA4NI2 CS CN(C)CCCSC(=N)N
DMA4NI2 IK OLHQOJYVQUNWPL-UHFFFAOYSA-N
DMA4NI2 IU 3-(dimethylamino)propyl carbamimidothioate
DMA4NI2 CA CAS 65119-89-3
DMA4NI2 CB CHEBI:81389
DMA4NI2 DE Discovery agent
DMV8ZQG ID DMV8ZQG
DMV8ZQG DN DIMEBOLIN
DMV8ZQG HS Investigative
DMV8ZQG SN Dimebolin; Dimebon; 3613-73-8; Latrepirdine; Dimebone; Dimeboline; Preparation 84; UNII-OD9237K1Z6; C21H25N3; BRN 0622478; CHEMBL589390; JNODQFNWMXFMEV-UHFFFAOYSA-N; OD9237K1Z6; 2,8-Dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole; 2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole; 2,3,4,5-Tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-pyrido(4,3-b)indole; 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
DMV8ZQG DT Small molecular drug
DMV8ZQG PC 197033
DMV8ZQG MW 319.4
DMV8ZQG FM C21H25N3
DMV8ZQG IC InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3
DMV8ZQG CS CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
DMV8ZQG IK JNODQFNWMXFMEV-UHFFFAOYSA-N
DMV8ZQG IU 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole
DMV8ZQG CA CAS 3613-73-8
DMV8ZQG CB CHEBI:92976
DMV8ZQG DE Discovery agent
DM2Q3CL ID DM2Q3CL
DM2Q3CL DN Dimemorfan
DM2Q3CL HS Investigative
DM2Q3CL SN Dimemorfan (INN); 36309-01-0; SCHEMBL509122
DM2Q3CL DT Small molecular drug
DM2Q3CL PC 3037918
DM2Q3CL MW 255.4
DM2Q3CL FM C18H25N
DM2Q3CL IC InChI=1S/C18H25N/c1-13-6-7-14-12-17-15-5-3-4-8-18(15,16(14)11-13)9-10-19(17)2/h6-7,11,15,17H,3-5,8-10,12H2,1-2H3/t15-,17+,18+/m1/s1
DM2Q3CL CS CC1=CC2=C(C[C@H]3[C@@H]4[C@]2(CCCC4)CCN3C)C=C1
DM2Q3CL IK KBEZZLAAKIIPFK-NJAFHUGGSA-N
DM2Q3CL IU (1S,9S,10S)-4,17-dimethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DM2Q3CL CA CAS 36309-01-0
DM2Q3CL CB CHEBI:135048
DM2Q3CL DE Discovery agent
DMRMHE8 ID DMRMHE8
DMRMHE8 DN Dimepheptanol
DMRMHE8 HS Investigative
DMRMHE8 SN Dimepheptanol; Methadol; Racemethadol; Pangerin; Bimethadol; 545-90-4; NIH 2933; Betamethadol; Betametadol; 6-DIMETHYLAMINO-4,4-DIPHENYL-3-HEPTANOL; 3-HEPTANOL, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-; Dimepheptanolum; Dimefeptanol; Dimefeptanolo; Bimethadolum; (-)-beta-Methadol; Betametadolo [DCIT]; (3S,6R)-Methadol; beta-Methadol, (-)-; Betametadol [INN-Spanish]; Dimefeptanolo [DCIT]; Betamethadolum [INN-Latin]; 3-Heptanol,4-diphenyl-, hydrochloride; Betamethadol [INN:BAN:DCF]; DEA No. 9609; Dimefeptanol [INN-Spanish]; Dimepheptanolum [IN
DMRMHE8 DT Small molecular drug
DMRMHE8 PC 28397
DMRMHE8 MW 311.5
DMRMHE8 FM C21H29NO
DMRMHE8 IC InChI=1S/C21H29NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20,23H,5,16H2,1-4H3
DMRMHE8 CS CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)O
DMRMHE8 IK QIRAYNIFEOXSPW-UHFFFAOYSA-N
DMRMHE8 IU 6-(dimethylamino)-4,4-diphenylheptan-3-ol
DMRMHE8 CA CAS 545-90-4
DMRMHE8 CB CHEBI:135332
DMRMHE8 DE Discovery agent
DMTVA49 ID DMTVA49
DMTVA49 DN Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMTVA49 HS Investigative
DMTVA49 SN CHEMBL575281; Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate
DMTVA49 DT Small molecular drug
DMTVA49 PC 11666354
DMTVA49 MW 284.17
DMTVA49 FM C10H12F3O4P
DMTVA49 IC InChI=1S/C10H12F3O4P/c1-15-18(14,16-2)17-9(10(11,12)13)8-6-4-3-5-7-8/h3-7,9H,1-2H3
DMTVA49 CS COP(=O)(OC)OC(C1=CC=CC=C1)C(F)(F)F
DMTVA49 IK LEDQZLXLDMICCN-UHFFFAOYSA-N
DMTVA49 IU dimethyl (2,2,2-trifluoro-1-phenylethyl) phosphate
DMTVA49 DE Discovery agent
DMP5I47 ID DMP5I47
DMP5I47 DN Dimethylallyl Diphosphate
DMP5I47 HS Investigative
DMP5I47 SN di-CH3-allyl-PPi; dimethylallyl-PP; prenyl diphosphate trianion; delta-Prenyl diphosphate; prenyl-diphosphate; delta2-isopentenyl-diphosphate; prenyl diphosphate(3-); prenyl pyrophosphate trianion; polycis-polyprenyl diphosphate; GTPL3049; CHEBI:83374; CHEBI:57623; CTK4H5497; CHEBI:58914; CBIDRCWHNCKSTO-UHFFFAOYSA-K; Dimethylallyl pyrophosphate trianion; an all-trans-polyprenyl diphosphate; 3-methylbut-2-en-1-yl diphosphate; all-cis-polyprenyl diphosphate(3-); poly-cis-polyprenyl diphosphate(3-); all-trans-polyprenyl diphospha
DMP5I47 DT Small molecular drug
DMP5I47 PC 647
DMP5I47 MW 246.09
DMP5I47 FM C5H12O7P2
DMP5I47 IC InChI=1S/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h3H,4H2,1-2H3,(H,9,10)(H2,6,7,8)
DMP5I47 CS CC(=CCOP(=O)(O)OP(=O)(O)O)C
DMP5I47 IK CBIDRCWHNCKSTO-UHFFFAOYSA-N
DMP5I47 IU 3-methylbut-2-enyl phosphono hydrogen phosphate
DMP5I47 CA CAS 358-72-5
DMP5I47 CB CHEBI:16057
DMP5I47 DE Discovery agent
DM2HYEN ID DM2HYEN
DM2HYEN DN dimethylethylamine
DM2HYEN HS Investigative
DM2HYEN SN N,N-DIMETHYLETHYLAMINE; 598-56-1; Dimethylethylamine; N,N-Dimethylethanamine; N-Ethyldimethylamine; Ethanamine, N,N-dimethyl-; Ethyldimethylamine; Ethylamine, N,N-dimethyl-; Methanamine, N-ethyl-N-methyl-; UNII-9N5384XVEM; HSDB 5712; EINECS 209-940-8; N,N-Dimethylethylamine, 99%; AI3-52225; 9N5384XVEM; DAZXVJBJRMWXJP-UHFFFAOYSA-N; C13-15-Alkyldimethylamines; Amines, C13-15-alkyldimethyl; dimethylaminoethane; dimethylethyl amine; EINECS 275-053-8; NEtMe2; NMe2Et; EtNMe2; n,n-dimethylaminoethane; PubChem10322; N,N-dimethyl-ethanamine
DM2HYEN DT Small molecular drug
DM2HYEN PC 11723
DM2HYEN MW 73.14
DM2HYEN FM C4H11N
DM2HYEN IC InChI=1S/C4H11N/c1-4-5(2)3/h4H2,1-3H3
DM2HYEN CS CCN(C)C
DM2HYEN IK DAZXVJBJRMWXJP-UHFFFAOYSA-N
DM2HYEN IU N,N-dimethylethanamine
DM2HYEN CA CAS 598-56-1
DM2HYEN DE Discovery agent
DML6O4N ID DML6O4N
DML6O4N DN Dimethylformamide
DML6O4N HS Investigative
DML6O4N SN N,N-DIMETHYLFORMAMIDE; Dimethylformamide; 68-12-2; N,N-Dimethylmethanamide; Dimethyl formamide; N-Formyldimethylamine; Formamide, N,N-dimethyl-; DMF; Dimethylformamid; Dimetilformamide; Dwumetyloformamid; DMFA; Formyldimethylamine; N,N-Dimethyl formamide; Dimethylforamide; Dimetylformamidu; DMF (amide); NCI-C60913; N,N-Dimethylformamid; n,n,dimethylformamide; Dimethylamid kyseliny mravenci; Caswell No. 366A; Dimetylformamidu [Czech]; Dimethylformamid [German]; Dimetilformamide [Italian]; Dwumetyloformamid [Polish]
DML6O4N DT Small molecular drug
DML6O4N PC 6228
DML6O4N MW 73.09
DML6O4N FM C3H7NO
DML6O4N IC InChI=1S/C3H7NO/c1-4(2)3-5/h3H,1-2H3
DML6O4N CS CN(C)C=O
DML6O4N IK ZMXDDKWLCZADIW-UHFFFAOYSA-N
DML6O4N IU N,N-dimethylformamide
DML6O4N CA CAS 68-12-2
DML6O4N CB CHEBI:17741
DML6O4N DE Discovery agent
DMW0MTV ID DMW0MTV
DMW0MTV DN DIMETHYLGRISABINE
DMW0MTV HS Investigative
DMW0MTV SN Dimethylgrisabine; CHEMBL450147; Grisabine dimethyl ether
DMW0MTV DT Small molecular drug
DMW0MTV PC 14137099
DMW0MTV MW 638.8
DMW0MTV FM C39H46N2O6
DMW0MTV IC InChI=1S/C39H46N2O6/c1-40-16-14-27-21-35(43-4)37(45-6)23-30(27)32(40)18-25-8-11-29(12-9-25)47-39-20-26(10-13-34(39)42-3)19-33-31-24-38(46-7)36(44-5)22-28(31)15-17-41(33)2/h8-13,20-24,32-33H,14-19H2,1-7H3/t32-,33+/m1/s1
DMW0MTV CS CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@H]5C6=CC(=C(C=C6CCN5C)OC)OC)OC)OC)OC
DMW0MTV IK UHYCXSGUNAWVBW-SAIUNTKASA-N
DMW0MTV IU (1R)-1-[[4-[5-[[(1S)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline
DMW0MTV DE Discovery agent
DMY0FVU ID DMY0FVU
DMY0FVU DN dimethylhistaprodifen
DMY0FVU HS Investigative
DMY0FVU SN dimethylhistaprodifen; CHEMBL11553; GTPL1203; BDBM86170; PDSP1_001311; PDSP2_001295; N,N-Dimethyl-2-(3,3-diphenylpropyl)-1H-imidazole-4-(ethanamine)
DMY0FVU DT Small molecular drug
DMY0FVU PC 10042467
DMY0FVU MW 333.5
DMY0FVU FM C22H27N3
DMY0FVU IC InChI=1S/C22H27N3/c1-25(2)16-15-20-17-23-22(24-20)14-13-21(18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17,21H,13-16H2,1-2H3,(H,23,24)
DMY0FVU CS CN(C)CCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3
DMY0FVU IK GNBOIGBQIBQOIA-UHFFFAOYSA-N
DMY0FVU IU 2-[2-(3,3-diphenylpropyl)-1H-imidazol-5-yl]-N,N-dimethylethanamine
DMY0FVU DE Discovery agent
DMG3WTE ID DMG3WTE
DMG3WTE DN Dimethylnordihydroguarierate acid
DMG3WTE HS Investigative
DMG3WTE SN dimethylnordihydroguarierate acid; CHEMBL103600; AC1L9VQY; CTK7A7114; ZINC13780579; BDBM50065997; meso-1,4-Bis-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutane; 5,5'-[(2R,3S)-2,3-Dimethyl-1,4-butanediyl]bis(2-methoxyphenol); 5-[(2S,3R)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol; 5-[(2r,3s)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol; 5-[4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethyl-(2R,3S)-butyl]-2-methoxyphenol
DMG3WTE DT Small molecular drug
DMG3WTE PC 476857
DMG3WTE MW 330.4
DMG3WTE FM C20H26O4
DMG3WTE IC InChI=1S/C20H26O4/c1-13(9-15-5-7-19(23-3)17(21)11-15)14(2)10-16-6-8-20(24-4)18(22)12-16/h5-8,11-14,21-22H,9-10H2,1-4H3/t13-,14+
DMG3WTE CS C[C@H](CC1=CC(=C(C=C1)OC)O)[C@@H](C)CC2=CC(=C(C=C2)OC)O
DMG3WTE IK FHAGEYRSWPQEQJ-OKILXGFUSA-N
DMG3WTE IU 5-[(2S,3R)-4-(3-hydroxy-4-methoxyphenyl)-2,3-dimethylbutyl]-2-methoxyphenol
DMG3WTE DE Discovery agent
DMO0UI8 ID DMO0UI8
DMO0UI8 DN Dimethyl-pent-4-enyl-ammonium bromide
DMO0UI8 HS Investigative
DMO0UI8 DE Discovery agent
DM1OKN0 ID DM1OKN0
DM1OKN0 DN DIMETHYLSPINGOSINE
DM1OKN0 HS Investigative
DM1OKN0 SN N,N-Dimethylsphing-4-enine; D-erythro-N,N-dimethylsphingosine; N,N-Dimethylspingosine; CHEMBL322333; CHEBI:78759; D-erythro-Sphingosine, N,N-Dimethyl-; N,N-Dimethylsphingenine; N,N-dimethyl-erythro-sphingosine; N,N-Dimethyl-D-erythrosphingenine; N-dimethylsphingosine; AC1NQZUP; C13914; N,N-Dimethyl-4-sphingenine; BSPBio_001420; N,N-Dimethylsphingosine, oil; SCHEMBL121927; SCHEMBL5493697; BML3-C12; Dimethyl Sphingosine (d18:1)
DM1OKN0 DT Small molecular drug
DM1OKN0 PC 5282309
DM1OKN0 MW 327.5
DM1OKN0 FM C20H41NO2
DM1OKN0 IC InChI=1S/C20H41NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)19(18-22)21(2)3/h16-17,19-20,22-23H,4-15,18H2,1-3H3/b17-16+/t19-,20+/m0/s1
DM1OKN0 CS CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)N(C)C)O
DM1OKN0 IK YRXOQXUDKDCXME-YIVRLKKSSA-N
DM1OKN0 IU (E,2S,3R)-2-(dimethylamino)octadec-4-ene-1,3-diol
DM1OKN0 CA CAS 119567-63-4
DM1OKN0 CB CHEBI:78759
DM7EKAF ID DM7EKAF
DM7EKAF DN Dimethylthiambutene
DM7EKAF HS Investigative
DM7EKAF SN Dimethylthiambutene; Dimethibutin; Ohton; Dimetiltiambuteno; Aminobutene; Dimethylthiambutenum; Kobaton; N,N,1-Trimethyl-3,3-di-2-thienylallylamine; 3-Dimethylamino-1,1-bis(2-thienyl)-1-butene; 524-84-5; 3-Dimethylamino-1,1-di-(2'-thienyl)-1-butene; Dimetiltiambutene [DCIT]; N,N,1-Trimethyl-3,3-di(2-thienyl)-2-propenylamine; Dimetiltiambuteno [INN-Spanish]; Dimethylthiambutenum [INN-Latin]; Dimethylthiambutene [INN:BAN:DCF]; 338C48; Allylamine, N,N,1-trimethyl-3,3-di-2-thienyl-; BRN 0084891; DEA No. 9619; CHEBI:59781; NIH4542
DM7EKAF DT Small molecular drug
DM7EKAF PC 10668
DM7EKAF MW 263.4
DM7EKAF FM C14H17NS2
DM7EKAF IC InChI=1S/C14H17NS2/c1-11(15(2)3)10-12(13-6-4-8-16-13)14-7-5-9-17-14/h4-11H,1-3H3
DM7EKAF CS CC(C=C(C1=CC=CS1)C2=CC=CS2)N(C)C
DM7EKAF IK CANBGVXYBPOLRR-UHFFFAOYSA-N
DM7EKAF IU N,N-dimethyl-4,4-dithiophen-2-ylbut-3-en-2-amine
DM7EKAF CA CAS 524-84-5
DM7EKAF CB CHEBI:59781
DM7EKAF DE Discovery agent
DM2Y0AI ID DM2Y0AI
DM2Y0AI DN Diminazene
DM2Y0AI HS Investigative
DM2Y0AI SN DIMINAZENE; 536-71-0; berenil; Diminazenum; Diminazeno; Diminazine; Azidin; Pirocide; Diminazene [INN:BAN]; Diminazenum [INN-Latin]; Diminazeno [INN-Spanish]; UNII-Y5G36EEA5Z; 4,4'-(Diazoamino)benzamidine; CHEBI:81724; 4,4'-(1-Triazene-1,3-diyl)bis-benzenecarboximidamide; Benzenecarboximidamide, 4,4'-(1-triazene-1,3-diyl)bis-; EINECS 208-644-6; Y5G36EEA5Z; C14H15N7; Bevenil; 1,3-TRIS-(4'AMIDINOPHENYL)TRIAZINE; 4,4'-(Triaz-1-ene-1,3-diyl)dibenzimidamide; 4,4'-(1-Triazene-1,3-diyl)bisbenzenecarboximidamide
DM2Y0AI DT Small molecular drug
DM2Y0AI PC 2354
DM2Y0AI MW 281.32
DM2Y0AI FM C14H15N7
DM2Y0AI IC InChI=1S/C14H15N7/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18/h1-8H,(H3,15,16)(H3,17,18)(H,19,20)
DM2Y0AI CS C1=CC(=CC=C1C(=N)N)NN=NC2=CC=C(C=C2)C(=N)N
DM2Y0AI IK XNYZHCFCZNMTFY-UHFFFAOYSA-N
DM2Y0AI IU 4-[2-(4-carbamimidoylphenyl)iminohydrazinyl]benzenecarboximidamide
DM2Y0AI CA CAS 536-71-0
DM2Y0AI CB CHEBI:81724
DM2Y0AI DE Discovery agent
DMJGKND ID DMJGKND
DMJGKND DN DIMS-9054
DMJGKND HS Investigative
DMJGKND SN DNA-based immunomodulatory sequence (multiple sclerosis/infectious disease), InDex
DMJGKND CP InDex Pharmaceuticals AB
DMJGKND DE Infectious disease
DM8CSOJ ID DM8CSOJ
DM8CSOJ DN Dinoterb
DM8CSOJ HS Investigative
DM8CSOJ SN DINOTERB; Dinoterb [BSI:ISO]; Dinoterbe; Dinoterbe [ISO-French]; EPA Pesticide Chemical Code 228400; Herbogil; Phenol, 2-tert-butyl-4,6-dinitro-; Phenol, o-t-butyl-4,6-dinitro-; Phenol, o-tert-butyl-4,6-dinitro-; Stirpan forte; 1420-07-1; 2,4-Dinitro-6-tert-butylphenol; 2-(1,1-Dimethylethyl)-4,6-dinitrophenol; 2-tert-Butyl-4,6-dinitrophenol; 2-tert-Butyl-4,6-dinitrophenol [ISO]; 2O5H456CFI; BRN 1887173; Caswell No. 392F; Dntbp; EINECS 215-813-8; HSDB 1598; NSC 166496; Phenol, 2-(1,1-dimethylethyl)-4,6-dinitro-; UNII-2O5H456CFI
DM8CSOJ PC 14994
DM8CSOJ MW 240.21
DM8CSOJ FM C10H12N2O5
DM8CSOJ IC IIPZYDQGBIWLBU-UHFFFAOYSA-N
DM8CSOJ CS CC(C)(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O
DM8CSOJ IK 1S/C10H12N2O5/c1-10(2,3)7-4-6(11(14)15)5-8(9(7)13)12(16)17/h4-5,13H,1-3H3
DM8CSOJ IU 2-tert-butyl-4,6-dinitrophenol
DM8CSOJ CA CAS 1420-07-1
DM8CSOJ CB CHEBI:81883
DM8CSOJ DE Discovery agent
DMBKJL8 ID DMBKJL8
DMBKJL8 DN DIOA
DMBKJL8 HS Investigative
DMBKJL8 SN dihydroindenyl-oxyalkanoic acid
DMBKJL8 DT Small molecular drug
DMBKJL8 PC 5017
DMBKJL8 MW 399.3
DMBKJL8 FM C20H24Cl2O4
DMBKJL8 IC InChI=1S/C20H24Cl2O4/c1-2-3-8-20(13-6-4-5-7-13)10-12-9-14(26-11-15(23)24)17(21)18(22)16(12)19(20)25/h9,13H,2-8,10-11H2,1H3,(H,23,24)
DMBKJL8 CS CCCCC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3CCCC3
DMBKJL8 IK YAWWQIFONIPBKT-UHFFFAOYSA-N
DMBKJL8 IU 2-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]acetic acid
DMBKJL8 CA CAS 106105-17-3
DMBKJL8 DE Discovery agent
DM0QY1V ID DM0QY1V
DM0QY1V DN dioctanoylglycerol pyrophosphate
DM0QY1V HS Investigative
DM0QY1V SN DGPP 8:0
DM0QY1V DT Small molecular drug
DM0QY1V PC 10051843
DM0QY1V MW 504.4
DM0QY1V FM C19H38O11P2
DM0QY1V IC InChI=1S/C19H38O11P2/c1-3-5-7-9-11-13-18(20)27-15-17(16-28-32(25,26)30-31(22,23)24)29-19(21)14-12-10-8-6-4-2/h17H,3-16H2,1-2H3,(H,25,26)(H2,22,23,24)/t17-/m1/s1
DM0QY1V CS CCCCCCCC(=O)OC[C@H](COP(=O)(O)OP(=O)(O)O)OC(=O)CCCCCCC
DM0QY1V IK MBDSUZSCJLRKPC-QGZVFWFLSA-N
DM0QY1V IU [(2R)-3-[hydroxy(phosphonooxy)phosphoryl]oxy-2-octanoyloxypropyl] octanoate
DM0QY1V CB CHEBI:77961
DM0QY1V DE Discovery agent
DM7D6JV ID DM7D6JV
DM7D6JV DN dioleoylphosphatidic acid
DM7D6JV HS Investigative
DM7D6JV SN doPA; dioleoyl phosphatidic acid
DM7D6JV DT Small molecular drug
DM7D6JV PC 9547172
DM7D6JV MW 701
DM7D6JV FM C39H73O8P
DM7D6JV IC InChI=1S/C39H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,37H,3-16,21-36H2,1-2H3,(H2,42,43,44)/b19-17-,20-18-
DM7D6JV CS CCCCCCCC/C=C\\CCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCC/C=C\\CCCCCCCC
DM7D6JV IK MHUWZNTUIIFHAS-CLFAGFIQSA-N
DM7D6JV IU [2-[(Z)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate
DM7D6JV CA CAS 14268-17-8
DM7D6JV CB CHEBI:60427
DM7D6JV DE Discovery agent
DM5G4O7 ID DM5G4O7
DM5G4O7 DN DI-O-METHYLENDIANDRIN A
DM5G4O7 HS Investigative
DM5G4O7 SN di-O-methylendiandrin A; CHEMBL388363
DM5G4O7 DT Small molecular drug
DM5G4O7 PC 16756782
DM5G4O7 MW 356.5
DM5G4O7 FM C22H28O4
DM5G4O7 IC InChI=1S/C22H28O4/c1-13-14(2)22(16-8-10-18(24-4)20(12-16)26-6)21(13)15-7-9-17(23-3)19(11-15)25-5/h7-14,21-22H,1-6H3/t13-,14-,21-,22-/m0/s1
DM5G4O7 CS C[C@H]1[C@@H]([C@H]([C@@H]1C2=CC(=C(C=C2)OC)OC)C3=CC(=C(C=C3)OC)OC)C
DM5G4O7 IK IOTXFXWARGNLEJ-WJWAULOUSA-N
DM5G4O7 IU 4-[(1R,2R,3S,4S)-2-(3,4-dimethoxyphenyl)-3,4-dimethylcyclobutyl]-1,2-dimethoxybenzene
DM5G4O7 DE Discovery agent
DM4KXIM ID DM4KXIM
DM4KXIM DN DIOSMETIN
DM4KXIM HS Investigative
DM4KXIM SN Diosmetin; 520-34-3; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; Salinigricoflavonol; 4'-Methylluteolin; 5,7,3'-Trihydroxy-4'-methoxyflavone; UNII-TWZ37241OT; Luteolin 4-methyl ether; 5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; 3',5,7-trihydroxy-4'-methoxyflavone; CHEBI:4630; TWZ37241OT; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-; MFCD00017425; AK111246
DM4KXIM DT Small molecular drug
DM4KXIM PC 5281612
DM4KXIM MW 300.26
DM4KXIM FM C16H12O6
DM4KXIM IC InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3
DM4KXIM CS COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
DM4KXIM IK MBNGWHIJMBWFHU-UHFFFAOYSA-N
DM4KXIM IU 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
DM4KXIM CA CAS 520-34-3
DM4KXIM CB CHEBI:4630
DM4KXIM DE Discovery agent
DML2B04 ID DML2B04
DML2B04 DN DIOXINODEHYDROECKOL
DML2B04 HS Investigative
DML2B04 SN DIOXINODEHYDROECKOL; Eckstolonol; UNII-N5P71K0GE3; CHEMBL559870; N5P71K0GE3; CHEBI:65820; 5,8,13,14-tetraoxa-pentaphene-1,3,6,9,11-pentol; [1,4]benzodioxino[2,3-a]oxanthrene-1,3,6,9,11-pentol; SCHEMBL14848420; BDBM50319629; 5,8,13,14-Tetraoxa-pentaphene-1,3,6,9,11-pentaol; Benzo(1,2-b:3,4-b')bis(1,4)benzodioxin-1,3,6,9,11-pentol
DML2B04 DT Small molecular drug
DML2B04 PC 10429214
DML2B04 MW 370.3
DML2B04 FM C18H10O9
DML2B04 IC InChI=1S/C18H10O9/c19-6-1-8(21)14-11(3-6)26-17-13(24-14)5-10(23)16-18(17)27-15-9(22)2-7(20)4-12(15)25-16/h1-5,19-23H
DML2B04 CS C1=C(C=C2C(=C1O)OC3=C(O2)C4=C(C(=C3)O)OC5=CC(=CC(=C5O4)O)O)O
DML2B04 IK LBHQACSAGWCMAB-UHFFFAOYSA-N
DML2B04 IU [1,4]benzodioxino[2,3-a]oxanthrene-1,3,6,9,11-pentol
DML2B04 CA CAS 639514-05-9
DML2B04 CB CHEBI:65820
DML2B04 DE Discovery agent
DM93MAB ID DM93MAB
DM93MAB DN Dioxothiomolybdenum(VI) ion
DM93MAB HS Investigative
DM93MAB SN DIOXOTHIOMOLYBDENUM(VI) ION; dioxo(sulfanyl)molybdenum; CHEBI:47566
DM93MAB DT Small molecular drug
DM93MAB PC 5162682
DM93MAB MW 161.02
DM93MAB FM HMoO2S-
DM93MAB IC InChI=1S/Mo.2O.H2S/h;;;1H2/p-1
DM93MAB CS O=[Mo]=O.[SH-]
DM93MAB IK LMGKUBJWYNQHBP-UHFFFAOYSA-M
DM93MAB IU dioxomolybdenum;sulfanide
DM93MAB CB CHEBI:47566
DM93MAB DE Discovery agent
DMO4XUC ID DMO4XUC
DMO4XUC DN Diphenyl(piperidin-4-yl)methanol
DMO4XUC HS Investigative
DMO4XUC SN Azacyclonol; 115-46-8; diphenyl(piperidin-4-yl)methanol; alpha,alpha-diphenyl-4-piperidinomethanol; Frenquel; alpha,alpha-Diphenyl-4-piperidinemethanol; alpha-(4-Piperidyl)benzhydrol; gamma-Pipradol; Calmeran; Ataractan; Diphenyl-piperidin-4-yl-methanol; Diphenyl(4-piperidinyl)methanol; 4-Piperidinemethanol, alpha,alpha-diphenyl-; Azaciclonolo [DCIT]; Azacyklonol; Psychosan; MER 17; Frenoton; Azacyclonol [INN:BAN]; UNII-2MMR990PEM; Azacyclonolum [INN-Latin]; EINECS 204-092-5; Diphenyl-4-piperidylmethanol; BRN 0230221; 2MMR990PEM
DMO4XUC DT Small molecular drug
DMO4XUC PC 15723
DMO4XUC MW 267.4
DMO4XUC FM C18H21NO
DMO4XUC IC InChI=1S/C18H21NO/c20-18(15-7-3-1-4-8-15,16-9-5-2-6-10-16)17-11-13-19-14-12-17/h1-10,17,19-20H,11-14H2
DMO4XUC CS C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O
DMO4XUC IK ZMISODWVFHHWNR-UHFFFAOYSA-N
DMO4XUC IU diphenyl(piperidin-4-yl)methanol
DMO4XUC CA CAS 115-46-8
DMO4XUC CB CHEBI:93706
DMO4XUC DE Discovery agent
DMP6IHR ID DMP6IHR
DMP6IHR DN Diphenylacetic Acid
DMP6IHR HS Investigative
DMP6IHR SN DIPHENYLACETIC ACID; 2,2-diphenylacetic acid; 117-34-0; Diphenylethanoic acid; Acetic acid, diphenyl-; Benzeneacetic acid, .alpha.-phenyl-; 1,1-Diphenylacetic acid; UNII-658NCZ0NKO; Diphenyl-acetic acid; alpha-Toluic acid, alpha-phenyl-; Benzeneacetic acid, alpha-phenyl-; EINECS 204-185-0; NSC 120417; BRN 1910978; 658NCZ0NKO; AI3-23777; CHEBI:41967; PYHXGXCGESYPCW-UHFFFAOYSA-N; .alpha.,.alpha.-Diphenylacetic acid; MFCD00004251; .alpha.-Toluic acid, .alpha.-phenyl-; A-Toluic Acid, A-Phenyl-; Diphenylacetic acid, 99+%
DMP6IHR DT Small molecular drug
DMP6IHR PC 8333
DMP6IHR MW 212.24
DMP6IHR FM C14H12O2
DMP6IHR IC InChI=1S/C14H12O2/c15-14(16)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13H,(H,15,16)
DMP6IHR CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)O
DMP6IHR IK PYHXGXCGESYPCW-UHFFFAOYSA-N
DMP6IHR IU 2,2-diphenylacetic acid
DMP6IHR CA CAS 117-34-0
DMP6IHR CB CHEBI:41967
DMP6IHR DE Discovery agent
DMBV19T ID DMBV19T
DMBV19T DN diphenylamine-2-carboxylic acid
DMBV19T HS Investigative
DMBV19T SN N-phenylanthranilic acid; fenamic acid
DMBV19T DT Small molecular drug
DMBV19T PC 4386
DMBV19T MW 213.23
DMBV19T FM C13H11NO2
DMBV19T IC InChI=1S/C13H11NO2/c15-13(16)11-8-4-5-9-12(11)14-10-6-2-1-3-7-10/h1-9,14H,(H,15,16)
DMBV19T CS C1=CC=C(C=C1)NC2=CC=CC=C2C(=O)O
DMBV19T IK ZWJINEZUASEZBH-UHFFFAOYSA-N
DMBV19T IU 2-anilinobenzoic acid
DMBV19T CA CAS 91-40-7
DMBV19T CB CHEBI:34756
DMBV19T DE Discovery agent
DMRQZTS ID DMRQZTS
DMRQZTS DN diphenylboronic anhydride
DMRQZTS HS Investigative
DMRQZTS SN diphenylborinic anhydride
DMRQZTS DT Small molecular drug
DMRQZTS PC 596810
DMRQZTS MW 346
DMRQZTS FM C24H20B2O
DMRQZTS IC InChI=1S/C24H20B2O/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22)27-26(23-17-9-3-10-18-23)24-19-11-4-12-20-24/h1-20H
DMRQZTS CS B(C1=CC=CC=C1)(C2=CC=CC=C2)OB(C3=CC=CC=C3)C4=CC=CC=C4
DMRQZTS IK SNQFEECGHGUHBK-UHFFFAOYSA-N
DMRQZTS IU diphenylboranyloxy(diphenyl)borane
DMRQZTS CA CAS 4426-21-5
DMRQZTS DE Discovery agent
DMB75PV ID DMB75PV
DMB75PV DN diphenyleneiodonium chloride
DMB75PV HS Investigative
DMB75PV SN Diphenyleneiodonium chloride; 4673-26-1; Dibenziodolium chloride; UNII-7M9D81YZ2N; DPI; 7M9D81YZ2N; CHEBI:77967; CHEMBL397686; SR-01000075494; Dibenziodolium, chloride; AC1MBZ20; C12H8I.Cl; dibenzo[b,d]iodolium chloride; SCHEMBL159318; GTPL7802; CTK8F9249; DTXSID00196932; MolPort-003-983-758; MolPort-023-275-892; HMS3266G10; HMS3261I15; 2,2'-biphenylyleneiodonium chloride; Diphenyleneiodonium chloride, 97+%; BCP08692; Tox21_500367; Diphenyleneiodonium chloride, > MFCD00214165; 1726AH; AKOS015903219; LP00367; CCG-221671
DMB75PV DT Small molecular drug
DMB75PV PC 2733504
DMB75PV MW 314.55
DMB75PV FM C12H8ClI
DMB75PV IC InChI=1S/C12H8I.ClH/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11;/h1-8H;1H/q+1;/p-1
DMB75PV CS C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2.[Cl-]
DMB75PV IK FCFZKAVCDNTYID-UHFFFAOYSA-M
DMB75PV IU 8-iodoniatricyclo[7.4.0.02,7]trideca-1(13),2,4,6,9,11-hexaene;chloride
DMB75PV CA CAS 4673-26-1
DMB75PV CB CHEBI:77967
DMB75PV DE Discovery agent
DMK8T61 ID DMK8T61
DMK8T61 DN diphenyltetrahydrofuran
DMK8T61 HS Investigative
DMK8T61 SN 2,2-Diphenyltetrahydrofuran; 887-15-0; 2,2-diphenyloxolane; diphenyltetrahydrofuran; NSC89761; EINECS 212-957-3; 2,2-di(phenyl)oxolane; AC1L2DIK; AC1Q1IAM; AC1Q70T2; GTPL2498; SCHEMBL1569110; Furan,tetrahydro-2,2-diphenyl-; CTK5G1253; DTXSID70237245; Furan, tetrahydro-2,2-diphenyl-; ZINC1575610; NSC-89761; AKOS024323254; MCULE-6052973560; X4640
DMK8T61 DT Small molecular drug
DMK8T61 PC 70175
DMK8T61 MW 224.3
DMK8T61 FM C16H16O
DMK8T61 IC InChI=1S/C16H16O/c1-3-8-14(9-4-1)16(12-7-13-17-16)15-10-5-2-6-11-15/h1-6,8-11H,7,12-13H2
DMK8T61 CS C1CC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3
DMK8T61 IK ONRSPOWNRLCCGF-UHFFFAOYSA-N
DMK8T61 IU 2,2-diphenyloxolane
DMK8T61 CA CAS 887-15-0
DMK8T61 DE Discovery agent
DMHY30B ID DMHY30B
DMHY30B DN Diphosphate
DMHY30B HS Investigative
DMHY30B SN Pyrophosphate ion; 14000-31-8; UNII-X3SSV2V6L3; Diphosphate(4-); X3SSV2V6L3; phosphonato phosphate; diphospate; Pyrophosphat; Diphosphat; Pyrophosphate(4-); 2o1c; mu-oxo-hexaoxodiphosphate; AC1LD8JZ; Phosphate (P2O74-); Diphosphate (P2O74-); Pyrophosphate (P2O74-); Diphosphoric acid tetraanion; diphosphoric acid, ion(4-); DTXSID4074514; CHEBI:18361; CTK0H7511; 3c14; XPPKVPWEQAFLFU-UHFFFAOYSA-J; [O3POPO3](4-); mu-oxido-bis(trioxidophosphate)(4-); BDBM50278316; P2O7(4-)
DMHY30B DT Small molecular drug
DMHY30B PC 644102
DMHY30B MW 173.94
DMHY30B FM O7P2-4
DMHY30B IC InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)/p-4
DMHY30B CS [O-]P(=O)([O-])OP(=O)([O-])[O-]
DMHY30B IK XPPKVPWEQAFLFU-UHFFFAOYSA-J
DMHY30B IU phosphonato phosphate
DMHY30B CA CAS 14000-31-8
DMHY30B CB CHEBI:18361
DMHY30B DE Discovery agent
DM28NIU ID DM28NIU
DM28NIU DN diphosphoglycolyl proline
DM28NIU HS Investigative
DM28NIU SN diphosphoglycolyproline; (R,S)-diphosphoglycolyl proline
DM28NIU DT Small molecular drug
DM28NIU PC 73755030
DM28NIU MW 335.14
DM28NIU FM C7H15NO10P2
DM28NIU IC InChI=1S/C7H15NO10P2/c9-5(10)4-2-1-3-8(4)6(11)7(12,19(13,14)15)20(16,17)18/h4,6,11-12H,1-3H2,(H,9,10)(H2,13,14,15)(H2,16,17,18)
DM28NIU CS C1CC(N(C1)C(C(O)(P(=O)(O)O)P(=O)(O)O)O)C(=O)O
DM28NIU IK CDFDGXYBANXCPC-UHFFFAOYSA-N
DM28NIU IU 1-(1,2-dihydroxy-2,2-diphosphonoethyl)pyrrolidine-2-carboxylic acid
DM28NIU DE Discovery agent
DMYWL89 ID DMYWL89
DMYWL89 DN diphosphoric acid
DMYWL89 HS Investigative
DMYWL89 SN pyrophosphoric acid; phosphonooxyphosphonic acid
DMYWL89 DT Small molecular drug
DMYWL89 PC 1023
DMYWL89 MW 177.98
DMYWL89 FM H4O7P2
DMYWL89 IC InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)
DMYWL89 CS OP(=O)(O)OP(=O)(O)O
DMYWL89 IK XPPKVPWEQAFLFU-UHFFFAOYSA-N
DMYWL89 IU phosphono dihydrogen phosphate
DMYWL89 CA CAS 2466-09-3
DMYWL89 CB CHEBI:29888
DMYWL89 DE Discovery agent
DMRWD9M ID DMRWD9M
DMRWD9M DN Diphthamide
DMRWD9M HS Investigative
DMRWD9M SN 2-(3-Carboxyamido-3-(trimethylammonio)propyl)histidine
DMRWD9M DT Small molecular drug
DMRWD9M PC 6438375
DMRWD9M MW 297.35
DMRWD9M FM C13H23N5O3
DMRWD9M IC InChI=1S/C13H23N5O3/c1-18(2,3)10(12(15)19)4-5-11-16-7-8(17-11)6-9(14)13(20)21/h7,9-10H,4-6,14H2,1-3H3,(H3-,15,16,17,19,20,21)
DMRWD9M CS C[N+](C)(C)C(CCC1=NC=C(N1)CC(C(=O)[O-])N)C(=O)N
DMRWD9M IK FOOBQHKMWYGHCE-UHFFFAOYSA-N
DMRWD9M IU 2-amino-3-[2-[4-amino-4-oxo-3-(trimethylazaniumyl)butyl]-1H-imidazol-5-yl]propanoate
DMRWD9M CA CAS 75645-22-6
DMRWD9M DE Discovery agent
DMIXPU6 ID DMIXPU6
DMIXPU6 DN Diprenorphine
DMIXPU6 HS Investigative
DMIXPU6 SN Diprenorphine; 14357-78-9; UNII-1F0L5N25ZZ; CHEMBL281786; CHEBI:4650; 1F0L5N25ZZ; DEA No. 9058; M50-50 Injection; Diprenorphine [INN:BAN]; Diprenorphinum [INN-Latin]; Diprenorfina [INN-Spanish]; Diprenorphinum; Diprenorfina; EINECS 238-325-7; 21-Cyclopropyl-6,7,8,14-tetrahydro-7alpha-(1-hydroxy-1-methylethyl)-6,14-endo-ethanooripavine; Diprenorfin; (5 ,7 )-17-(Cyclopropylmethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- , -dimethyl-6,14-ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4
DMIXPU6 DT Small molecular drug
DMIXPU6 PC 443408
DMIXPU6 MW 425.6
DMIXPU6 FM C26H35NO4
DMIXPU6 IC InChI=1S/C26H35NO4/c1-23(2,29)18-13-24-8-9-26(18,30-3)22-25(24)10-11-27(14-15-4-5-15)19(24)12-16-6-7-17(28)21(31-22)20(16)25/h6-7,15,18-19,22,28-29H,4-5,8-14H2,1-3H3/t18-,19-,22-,24-,25+,26-/m1/s1
DMIXPU6 CS CC(C)([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
DMIXPU6 IK OIJXLIIMXHRJJH-KNLIIKEYSA-N
DMIXPU6 IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxypropan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
DMIXPU6 CA CAS 14357-78-9
DMIXPU6 CB CHEBI:4650
DMIXPU6 DE Discovery agent
DM9VKXC ID DM9VKXC
DM9VKXC DN dipropyl-5-CT
DM9VKXC HS Investigative
DM9VKXC SN DP-5-CT; DP5CT; N,N-dipropylcarboxamidotryptamine
DM9VKXC DT Small molecular drug
DM9VKXC PC 156314
DM9VKXC MW 287.4
DM9VKXC FM C17H25N3O
DM9VKXC IC InChI=1S/C17H25N3O/c1-3-8-20(9-4-2)10-7-14-12-19-16-6-5-13(17(18)21)11-15(14)16/h5-6,11-12,19H,3-4,7-10H2,1-2H3,(H2,18,21)
DM9VKXC CS CCCN(CCC)CCC1=CNC2=C1C=C(C=C2)C(=O)N
DM9VKXC IK DPXOFRGRKPFZOD-UHFFFAOYSA-N
DM9VKXC IU 3-[2-(dipropylamino)ethyl]-1H-indole-5-carboxamide
DM9VKXC CA CAS 74885-25-9
DM9VKXC CB CHEBI:92566
DM9VKXC DE Discovery agent
DMGBCP0 ID DMGBCP0
DMGBCP0 DN DIPROTIN A
DMGBCP0 HS Investigative
DMGBCP0 SN diprotin A; MLS002207185; NSC602337; HIV inhibitor; AC1Q5KXE; AC1L1F6Q; DivK1c_000899; CHEMBL158110; SCHEMBL17867000; KBio1_000899; HMS502M21; NINDS_000899; Ile-Pro-Ile, > BDBM50085083; NSC-602337; IDI1_000899; AN-25068; SMR001306756; Bacillus cereus BMF673-RF1 culture filtrate; 2-[[1-(2-amino-3-methyl-pentanoyl)pyrrolidine-2-carbonyl]amino]-3-methyl-pentanoic acid; 2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid
DMGBCP0 DT Small molecular drug
DMGBCP0 PC 94701
DMGBCP0 MW 341.4
DMGBCP0 FM C17H31N3O4
DMGBCP0 IC InChI=1S/C17H31N3O4/c1-5-10(3)13(18)16(22)20-9-7-8-12(20)15(21)19-14(17(23)24)11(4)6-2/h10-14H,5-9,18H2,1-4H3,(H,19,21)(H,23,24)/t10-,11-,12-,13-,14-/m0/s1
DMGBCP0 CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N
DMGBCP0 IK JNTMAZFVYNDPLB-PEDHHIEDSA-N
DMGBCP0 IU (2S,3S)-2-[[(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid
DMGBCP0 CA CAS 90614-48-5
DMGBCP0 CB CHEBI:93213
DMGBCP0 DE Discovery agent
DM2MV9O ID DM2MV9O
DM2MV9O DN DIRLOTAPIDE
DM2MV9O HS Investigative
DM2MV9O SN Dirlotapide; Slentrol; UNII-578H0RMP25; 481658-94-0; CHEMBL410414; 578H0RMP25; Dirlotapide [USAN:INN]; CP 742033; Dirlotapide (USAN/INN); Slentrol [veterinary] (TN); SCHEMBL37781; TUOSYWCFRFNJBS-BHVANESWSA-N; HY-U00070; BDBM50204367; CS-6779; CP-742033; CP-742,033; D03867; N-((1S)-2-(Benzylmethylamino)-2-oxo-1-phenylethyl)-1-methyl-5-(((4'-(trifluoromethyl)biphenyl-2-yl)carbonyl)amino)-1H-indole-2-carboxamide; 1H-Indole-2-carboxamide, 1-methyl-N-((1S)-2-(methyl(phenylmethyl)amino)-2-oxo-1-phenylethyl)-5-(((4'-(trifluoromethyl
DM2MV9O DT Small molecular drug
DM2MV9O PC 9917862
DM2MV9O MW 674.7
DM2MV9O FM C40H33F3N4O3
DM2MV9O IC InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1
DM2MV9O CS CN1C2=C(C=C(C=C2)NC(=O)C3=CC=CC=C3C4=CC=C(C=C4)C(F)(F)F)C=C1C(=O)N[C@@H](C5=CC=CC=C5)C(=O)N(C)CC6=CC=CC=C6
DM2MV9O IK TUOSYWCFRFNJBS-BHVANESWSA-N
DM2MV9O IU N-[(1S)-2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]-1-methyl-5-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]indole-2-carboxamide
DM2MV9O CA CAS 481658-94-0
DM2MV9O DE Discovery agent
DMPVNDK ID DMPVNDK
DMPVNDK DN Distamycin A
DMPVNDK HS Investigative
DMPVNDK SN distamycin a; Stallimycin; Distamycin; Herperetin; 636-47-5; DST-A; UNII-80O63P88IS; NSC82150; FI 6426; CHEMBL11252; 80O63P88IS; NCGC00018292-04; NSC 150528; Stallimycinum; Stallimycine; Estalimicina; Stallimicina; Distamicina A; DISTAMYCIN HYDROCHLORIDE; NSC150528; Dst-3; AC1Q5M1Q; AC1L1F7B; DSSTox_RID_81018; DSSTox_CID_25637; DSSTox_GSID_45637; DISTAMYCIN; STALLIMYCIN; SCHEMBL108585; DTXSID9045637; cid_6602691; UPBAOYRENQEPJO-UHFFFAOYSA-N; ZINC3872327; Tox21_110857; 6576-51-8 (mono-hydrochloride); NSC-82150; CCG-36393; BDBM50055659
DMPVNDK DT Small molecular drug
DMPVNDK PC 3115
DMPVNDK MW 481.5
DMPVNDK FM C22H27N9O4
DMPVNDK IC InChI=1S/C22H27N9O4/c1-29-9-13(26-12-32)6-17(29)21(34)28-15-8-18(31(3)11-15)22(35)27-14-7-16(30(2)10-14)20(33)25-5-4-19(23)24/h6-12H,4-5H2,1-3H3,(H3,23,24)(H,25,33)(H,26,32)(H,27,35)(H,28,34)
DMPVNDK CS CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NC=O
DMPVNDK IK UPBAOYRENQEPJO-UHFFFAOYSA-N
DMPVNDK IU N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide
DMPVNDK CA CAS 636-47-5
DMPVNDK DE Discovery agent
DM0GQJ2 ID DM0GQJ2
DM0GQJ2 DN Di-Stearoyl-3-Sn-Phosphatidylcholine
DM0GQJ2 HS Investigative
DM0GQJ2 SN DI-STEAROYL-3-SN-PHOSPHATIDYLCHOLINE; DSPC;L-,-Distearoyl--lecithin; Distearoylphosphatidylcholine; AC1L3RPB; SCHEMBL10001505; ZINC85433138; DB04178; DB-027511; 816D944; O-(1-O,2-O-Distearoyl-L-glycero-3-phospho)choline
DM0GQJ2 DT Small molecular drug
DM0GQJ2 PC 94191
DM0GQJ2 MW 791.2
DM0GQJ2 FM C44H89NO8P+
DM0GQJ2 IC InChI=1S/C44H88NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h42H,6-41H2,1-5H3/p+1/t42-/m1/s1
DM0GQJ2 CS CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC
DM0GQJ2 IK NRJAVPSFFCBXDT-HUESYALOSA-O
DM0GQJ2 IU 2-[[(2R)-2,3-di(octadecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
DM0GQJ2 DE Discovery agent
DM6TVAX ID DM6TVAX
DM6TVAX DN Disulergine
DM6TVAX HS Investigative
DM6TVAX SN Disulergine; UNII-1Q3CYC1YR6; 1Q3CYC1YR6; CHEMBL95067; 59032-40-5; Disulergina; Disulerginum; Sulergin; disulergine[inn]; Disulergine [INN]; Disulerginum [INN-Latin]; Disulergina [INN-Spanish]; Compound 71; SULERGINE; CM 29717; CH 29-717; CH-29717; AC1Q6V4Q; AC1L2AG4; SCHEMBL1841646; BDBM50130260; CH 29717; N,N-Dimethyl-N'-(6-methylergolin-8alpha-yl)sulfamide; N,N-Dimethyl-N'-((8 alpha)-6-methylergolin-8-yl)sulfamide
DM6TVAX DT Small molecular drug
DM6TVAX PC 68788
DM6TVAX MW 348.5
DM6TVAX FM C17H24N4O2S
DM6TVAX IC InChI=1S/C17H24N4O2S/c1-20(2)24(22,23)19-12-8-14-13-5-4-6-15-17(13)11(9-18-15)7-16(14)21(3)10-12/h4-6,9,12,14,16,18-19H,7-8,10H2,1-3H3/t12-,14+,16+/m0/s1
DM6TVAX CS CN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NS(=O)(=O)N(C)C
DM6TVAX IK VUEGYUOUAAVYAS-JGGQBBKZSA-N
DM6TVAX IU (6aR,9S,10aR)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DM6TVAX CA CAS 59032-40-5
DM6TVAX DE Discovery agent
DMVJYKG ID DMVJYKG
DMVJYKG DN Dithiazoline
DMVJYKG HS Investigative
DMVJYKG SN dithiazoline
DMVJYKG PC 17990703
DMVJYKG MW 105.19
DMVJYKG FM C2H3NS2
DMVJYKG IC WPEVFLXBCFUSFF-UHFFFAOYSA-N
DMVJYKG CS C1C=NSS1
DMVJYKG IK 1S/C2H3NS2/c1-2-4-5-3-1/h1H,2H2
DMVJYKG IU 5H-dithiazole
DMVJYKG CA CAS 504-79-0
DMVJYKG DE Gonococcal infection
DMK0VFS ID DMK0VFS
DMK0VFS DN dithiipin-1,1,4,4-tetroxide analogue 7
DMK0VFS HS Investigative
DMK0VFS SN dithiipin-1,1,4,4-tetroxide analogue 7; GTPL6124; CHEMBL3906195; 2-(4-methylphenyl)-6,7-dihydro-5H-1,4-dithiepine 1,1,4,4-tetraoxide; 2-(4-Methylphenyl)-6,7-dihydro-5H-1,4-dithiepin 1,1,4,4-tetraoxide
DMK0VFS DT Small molecular drug
DMK0VFS PC 9947811
DMK0VFS MW 286.4
DMK0VFS FM C12H14O4S2
DMK0VFS IC InChI=1S/C12H14O4S2/c1-10-3-5-11(6-4-10)12-9-17(13,14)7-2-8-18(12,15)16/h3-6,9H,2,7-8H2,1H3
DMK0VFS CS CC1=CC=C(C=C1)C2=CS(=O)(=O)CCCS2(=O)=O
DMK0VFS IK KZYCUCAZAITGMW-UHFFFAOYSA-N
DMK0VFS IU 2-(4-methylphenyl)-6,7-dihydro-5H-1,4-dithiepine 1,1,4,4-tetraoxide
DMK0VFS DE Discovery agent
DM0QZ6I ID DM0QZ6I
DM0QZ6I DN D-kynurenine
DM0QZ6I HS Investigative
DM0QZ6I SN D-Kynurenine; 13441-51-5; (R)-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid; UNII-DK8PQD0WC5; DK8PQD0WC5; CHEBI:86262; (2R)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid; K-8980; Kynurenine, D-; D-2-Amino-4-[2-aminophenyl]-4-oxobutanoic acid; D-2-Amino-4-(2-aminophenyl)-4-oxobutanoic acid; D-KYN; D-Kynurenine, free base; AC1LMC0V; GTPL5799; SCHEMBL13969610; CHEMBL1233899; Benzenebutanoic acid, alpha,2-diamino-gamma-oxo-, (R)-; CTK8C4802; DTXSID50360767; Benzenebutanoic acid, alpha,2-diamino-gamma-oxo-, (alphaR)-; ZINC901103
DM0QZ6I DT Small molecular drug
DM0QZ6I PC 1152206
DM0QZ6I MW 208.21
DM0QZ6I FM C10H12N2O3
DM0QZ6I IC InChI=1S/C10H12N2O3/c11-7-4-2-1-3-6(7)9(13)5-8(12)10(14)15/h1-4,8H,5,11-12H2,(H,14,15)/t8-/m1/s1
DM0QZ6I CS C1=CC=C(C(=C1)C(=O)C[C@H](C(=O)O)N)N
DM0QZ6I IK YGPSJZOEDVAXAB-MRVPVSSYSA-N
DM0QZ6I IU (2R)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid
DM0QZ6I CA CAS 13441-51-5
DM0QZ6I CB CHEBI:86262
DM0QZ6I DE Discovery agent
DME9ODX ID DME9ODX
DME9ODX DN DL-3
DME9ODX HS Investigative
DME9ODX CP University of Cincinnati
DME9ODX DE Prostate cancer
DMBNFQ8 ID DMBNFQ8
DMBNFQ8 DN D-lactic acid
DMBNFQ8 HS Investigative
DMBNFQ8 SN R-lactic acid; D-lactate
DMBNFQ8 DT Small molecular drug
DMBNFQ8 PC 61503
DMBNFQ8 MW 90.08
DMBNFQ8 FM C3H6O3
DMBNFQ8 IC InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m1/s1
DMBNFQ8 CS C[C@H](C(=O)O)O
DMBNFQ8 IK JVTAAEKCZFNVCJ-UWTATZPHSA-N
DMBNFQ8 IU (2R)-2-hydroxypropanoic acid
DMBNFQ8 CA CAS 10326-41-7
DMBNFQ8 CB CHEBI:42111
DMBNFQ8 DE Discovery agent
DMHI9ZJ ID DMHI9ZJ
DMHI9ZJ DN DL-benzylsuccinic acid
DMHI9ZJ HS Investigative
DMHI9ZJ SN 2-Benzylsuccinic acid; 884-33-3; Benzylsuccinic acid; 2-benzylbutanedioic acid; DL-Benzylsuccinic acid; alpha-Benzylsuccinic acid; 36092-42-9; (phenylmethyl)butanedioic acid; beta-carboxybenzenebutanoic acid; D,L-Benzylsuccinic Acid; Butanedioic acid,2-(phenylmethyl)-; NSC20708; .alpha.-Benzylsuccinic acid; CHEMBL151284; CHEBI:16054; GTOFKXZQQDSVFH-UHFFFAOYSA-N; MFCD00055798; Benzenebutanoic acid, .beta.-carboxy-; 2-Benzyl-succinic acid; NSC-20708; NSC 20708; mono benzyl succinic acid; AC1L1GVE; 2-Benzylsuccinic acid #
DMHI9ZJ DT Small molecular drug
DMHI9ZJ PC 3858
DMHI9ZJ MW 208.21
DMHI9ZJ FM C11H12O4
DMHI9ZJ IC InChI=1S/C11H12O4/c12-10(13)7-9(11(14)15)6-8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H,12,13)(H,14,15)
DMHI9ZJ CS C1=CC=C(C=C1)CC(CC(=O)O)C(=O)O
DMHI9ZJ IK GTOFKXZQQDSVFH-UHFFFAOYSA-N
DMHI9ZJ IU 2-benzylbutanedioic acid
DMHI9ZJ CA CAS 884-33-3
DMHI9ZJ CB CHEBI:16054
DMHI9ZJ DE Discovery agent
DMVN93B ID DMVN93B
DMVN93B DN D-leucyl-N-(3-chlorobenzyl)-L-prolinamide
DMVN93B HS Investigative
DMVN93B SN D-Leucyl-N-(3-Chlorobenzyl)-L-Prolinamide; CHEMBL1229801; DB06911; N-(3-Chlorobenzyl)-1-[(2R)-2-amino-4-methylpentanoyl]-L-prolinamide; (2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide
DMVN93B DT Small molecular drug
DMVN93B PC 25113127
DMVN93B MW 351.9
DMVN93B FM C18H26ClN3O2
DMVN93B IC InChI=1S/C18H26ClN3O2/c1-12(2)9-15(20)18(24)22-8-4-7-16(22)17(23)21-11-13-5-3-6-14(19)10-13/h3,5-6,10,12,15-16H,4,7-9,11,20H2,1-2H3,(H,21,23)/t15-,16+/m1/s1
DMVN93B CS CC(C)C[C@H](C(=O)N1CCC[C@H]1C(=O)NCC2=CC(=CC=C2)Cl)N
DMVN93B IK FHVBVJXZKNCSLP-CVEARBPZSA-N
DMVN93B IU (2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide
DMVN93B DE Discovery agent
DMIFCHL ID DMIFCHL
DMIFCHL DN D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
DMIFCHL HS Investigative
DMIFCHL SN D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide; CHEMBL1230016; DB06996; N-(4-Amidinobenzyl)-1-[(2R)-2-amino-4-methylpentanoyl]-L-prolinamide; 31U
DMIFCHL DT Small molecular drug
DMIFCHL PC 25220914
DMIFCHL MW 359.5
DMIFCHL FM C19H29N5O2
DMIFCHL IC InChI=1S/C19H29N5O2/c1-12(2)10-15(20)19(26)24-9-3-4-16(24)18(25)23-11-13-5-7-14(8-6-13)17(21)22/h5-8,12,15-16H,3-4,9-11,20H2,1-2H3,(H3,21,22)(H,23,25)/t15-,16+/m1/s1
DMIFCHL CS CC(C)C[C@H](C(=O)N1CCC[C@H]1C(=O)NCC2=CC=C(C=C2)C(=N)N)N
DMIFCHL IK XFNMDMGNNKIXBT-CVEARBPZSA-N
DMIFCHL IU (2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide
DMIFCHL CA CAS 1186647-77-7
DMIFCHL DE Discovery agent
DMM1GXI ID DMM1GXI
DMM1GXI DN DL-guanidinoethylmercaptosuccinic acid
DMM1GXI HS Investigative
DMM1GXI SN 77482-44-1; gemsa; guanidinoethylmercaptosuccinic acid; DL-guanidinoethylmercaptosuccinic acid; CHEMBL560871; GUANIDINOETHYLMERCAPTO-SUCCINIC ACID; Butanedioic acid,2-[[2-[(aminoiminomethyl)amino]ethyl]thio]-; 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid; Guanidinoethyl-Mercaptosuccinic Acid; AC1L1FZW; AC1Q5SXD; 2-[(2-carbamimidamidoethyl)sulfanyl]succinic acid; AC1Q50E8; SCHEMBL1765999; CTK5E4534; 2-Guanidinoethylthiosuccinic acid; MolPort-004-964-125; (2-Guanidinoethylthio)succinic acid; BDBM50296412
DMM1GXI DT Small molecular drug
DMM1GXI PC 3464
DMM1GXI MW 235.26
DMM1GXI FM C7H13N3O4S
DMM1GXI IC InChI=1S/C7H13N3O4S/c8-7(9)10-1-2-15-4(6(13)14)3-5(11)12/h4H,1-3H2,(H,11,12)(H,13,14)(H4,8,9,10)
DMM1GXI CS C(CSC(CC(=O)O)C(=O)O)N=C(N)N
DMM1GXI IK VKVCLXDFOQQABP-UHFFFAOYSA-N
DMM1GXI IU 2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid
DMM1GXI CA CAS 77482-44-1
DMM1GXI DE Discovery agent
DM2HGNU ID DM2HGNU
DM2HGNU DN DL-TBOA
DM2HGNU HS Investigative
DM2HGNU SN dl-threo-beta-benzyloxyaspartate
DM2HGNU DT Small molecular drug
DM2HGNU PC 5311218
DM2HGNU MW 239.22
DM2HGNU FM C11H13NO5
DM2HGNU IC InChI=1S/C11H13NO5/c12-8(10(13)14)9(11(15)16)17-6-7-4-2-1-3-5-7/h1-5,8-9H,6,12H2,(H,13,14)(H,15,16)/t8-,9-/m0/s1
DM2HGNU CS C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O
DM2HGNU IK BYOBCYXURWDEDS-IUCAKERBSA-N
DM2HGNU IU (2S,3S)-2-amino-3-phenylmethoxybutanedioic acid
DM2HGNU CA CAS 208706-75-6
DM2HGNU DE Discovery agent
DMPD2XF ID DMPD2XF
DMPD2XF DN DLX-521
DMPD2XF HS Investigative
DMPD2XF SN Anti-ALK antibody fragment, Delenex; Anti-CD246 antibody fragment, Delenex
DMPD2XF CP Delenex Therapeutics AG
DMPD2XF DT Antibody
DMPD2XF DE Discovery agent
DMRYQVJ ID DMRYQVJ
DMRYQVJ DN DM-107
DMRYQVJ HS Investigative
DMRYQVJ SN MDPK-67; MDPK-67b; Kallikrein 2 inhibitor (anticancer), Med Discovery; Kallikrein 2 inhibitor (dermatological disorders), Dermadis
DMRYQVJ CP Med Discovery SA
DMRYQVJ DE Atopic dermatitis
DMM0VDK ID DMM0VDK
DMM0VDK DN DM-1451
DMM0VDK HS Investigative
DMM0VDK SN DM 1451
DMM0VDK DT Small molecular drug
DMM0VDK PC 9847259
DMM0VDK MW 464.4
DMM0VDK FM C23H27Cl2N3O3
DMM0VDK IC InChI=1S/C23H27Cl2N3O3/c24-22-19(6-7-20(29)23(22)25)28-12-10-27(11-13-28)9-1-2-14-31-17-5-3-16-4-8-21(30)26-18(16)15-17/h3,5-7,15,29H,1-2,4,8-14H2,(H,26,30)
DMM0VDK CS C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=C(C=C4)O)Cl)Cl
DMM0VDK IK YZIVLADPQQPFLO-UHFFFAOYSA-N
DMM0VDK IU 7-[4-[4-(2,3-dichloro-4-hydroxyphenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
DMM0VDK CA CAS 173456-49-0
DMM0VDK DE Discovery agent
DMSXI6W ID DMSXI6W
DMSXI6W DN DM-204
DMSXI6W HS Investigative
DMSXI6W SN Anti-GSK-3beta mAbs, DiaMedica; Anti-GSK-3beta mAbs, Sanomune; Anti-GSK-3beta monoclonal antibodies, DiaMedica; Anti-GSK-3beta monoclonal antibodies, Sanomune
DMSXI6W CP Sanomune Inc
DMSXI6W DT Antibody
DMSXI6W DE Solid tumour/cancer
DM7YXKL ID DM7YXKL
DM7YXKL DN DM3A6S
DM7YXKL HS Investigative
DM7YXKL SN CHEMBL437682
DM7YXKL DT Small molecular drug
DM7YXKL PC 44414785
DM7YXKL MW 409.5
DM7YXKL FM C19H23NO7S
DM7YXKL IC InChI=1S/C19H23NO7S/c1-10(21)25-14-5-3-11-9-13-12-4-6-15(27-28(22,23)24)18-19(12,7-8-20(13)2)16(11)17(14)26-18/h3,5,12-13,15,18H,4,6-9H2,1-2H3,(H,22,23,24)/t12-,13+,15-,18-,19-/m0/s1
DM7YXKL CS CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](CC5)OS(=O)(=O)[O-])C=C1
DM7YXKL IK YATYBWXTHXFYJT-SSTWWWIQSA-N
DM7YXKL IU [(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DM7YXKL DE Discovery agent
DML68UF ID DML68UF
DML68UF DN DM3B6S
DML68UF HS Investigative
DML68UF SN CHEMBL213737
DML68UF DT Small molecular drug
DML68UF PC 44414801
DML68UF MW 471.5
DML68UF FM C24H25NO7S
DML68UF IC InChI=1S/C24H25NO7S/c1-25-12-11-24-16-8-10-19(32-33(27,28)29)22(24)31-21-18(9-7-15(20(21)24)13-17(16)25)30-23(26)14-5-3-2-4-6-14/h2-7,9,16-17,19,22H,8,10-13H2,1H3,(H,27,28,29)/t16-,17+,19-,22-,24-/m0/s1
DML68UF CS C[NH+]1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC(=O)C6=CC=CC=C6)O[C@H]3[C@H](CC4)OS(=O)(=O)[O-]
DML68UF IK YEYZQNSVGVDYOU-MJFIPZRTSA-N
DML68UF IU [(4R,4aR,7S,7aR,12bS)-9-benzoyloxy-3-methyl-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DML68UF DE Discovery agent
DMAJ0Q8 ID DMAJ0Q8
DMAJ0Q8 DN DM6S
DMAJ0Q8 HS Investigative
DMAJ0Q8 SN CHEMBL385448
DMAJ0Q8 DT Small molecular drug
DMAJ0Q8 PC 44414783
DMAJ0Q8 MW 367.4
DMAJ0Q8 FM C17H21NO6S
DMAJ0Q8 IC InChI=1S/C17H21NO6S/c1-18-7-6-17-10-3-5-13(24-25(20,21)22)16(17)23-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19H,3,5-8H2,1H3,(H,20,21,22)/t10-,11+,13-,16-,17-/m0/s1
DMAJ0Q8 CS C[NH+]1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](CC4)OS(=O)(=O)[O-]
DMAJ0Q8 IK QTALQTUQMLSRSG-KBQPJGBKSA-N
DMAJ0Q8 IU [(4R,4aR,7S,7aR,12bS)-9-hydroxy-3-methyl-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMAJ0Q8 DE Discovery agent
DMT6X03 ID DMT6X03
DMT6X03 DN D-mannose
DMT6X03 HS Investigative
DMT6X03 SN D-Mannose; Mannose; D-Mannopyranose; Seminose; Carubinose; Mannopyranose; Mannopyranoside; D-(+)-Mannose; 530-26-7; CHEBI:4208; DL-Mannose; D(+)-Mannose; (+-)-Mannose; (3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; D-Mannopyranoside; D-Man; WQZGKKKJIJFFOK-QTVWNMPRSA-N; Man; Mannopyranose, D-; SMR000857125; EINECS 208-474-2; D-Mannose,(S); alpha,beta-D-mannopyranose; bmse000018; bmse000882; Epitope ID:152206; bmse000874; AC1L2D5C; SCHEMBL38300; MLS001332528; MLS001332527; GTPL4650; CHEMBL469448; DTXSID5040463
DMT6X03 DT Small molecular drug
DMT6X03 PC 18950
DMT6X03 MW 180.16
DMT6X03 FM C6H12O6
DMT6X03 IC InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1
DMT6X03 CS C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)O)O)O)O)O
DMT6X03 IK WQZGKKKJIJFFOK-QTVWNMPRSA-N
DMT6X03 IU (3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
DMT6X03 CA CAS 530-26-7
DMT6X03 CB CHEBI:4208
DMT6X03 DE Discovery agent
DM7O1IW ID DM7O1IW
DM7O1IW DN D-mannose 1-phosphate
DM7O1IW HS Investigative
DM7O1IW SN D-Mannose 1-phosphate; Mannose 1-phosphate; mannose-1-P; D-mannose-1-phosphate; D-mannose 1-phosphates; CHEBI:35374; 27251-84-9; AC1LD8PO; delta-mannose-1-phosphate; Mannose 1-phosphoric acid; delta-mannose 1-phosphates; Epitope ID:145013; D-Mannopyranose-1-phosphate; D-Mannopyranose, 1-phosphate; SCHEMBL284741; alpha-delta-Mannose 1-phosphate; Mannose 1-phosphate-Mannopyranose; D-Mannose, 1-(dihydrogen phosphate); DB02867; D-mannopyranose 1-(dihydrogen phosphate); 1-(dihydrogen phosphate)-D-Mannopyranose; D-Mannopyranose, 1-(d
DM7O1IW DT Small molecular drug
DM7O1IW PC 644175
DM7O1IW MW 260.14
DM7O1IW FM C6H13O9P
DM7O1IW IC InChI=1S/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5+,6?/m1/s1
DM7O1IW CS C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)OP(=O)(O)O)O)O)O)O
DM7O1IW IK HXXFSFRBOHSIMQ-QTVWNMPRSA-N
DM7O1IW IU [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DM7O1IW CA CAS 27251-84-9
DM7O1IW CB CHEBI:35374
DM7O1IW DE Discovery agent
DMK3WY4 ID DMK3WY4
DMK3WY4 DN DMCM
DMK3WY4 HS Investigative
DMK3WY4 SN DMCM; Methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate; UNII-1309288N1J; 82499-00-1; CHEMBL17468; METHYL-6,7-DIMETHOXY-4-ETHYL-BETA-CARBOLINE-3-CARBOXYLATE; methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylate; 1309288N1J; Methyl 4-ethyl-6,7-dimethoxy-9H-pyrido(3,4-b)indole-3-carboxylate; 4-Ethyl-6,7-dimethoxy-9H-pyrido(3,4-b)indole-3-carboxylic acid, methyl ester; 9H-Pyrido(3,4-b)indole-3-carboxylic acid, 4-ethyl-6,7-dimethoxy-, methyl ester; C17H18N2O4; Lopac-E-007; Biomol-NT_000249; AC1Q5ZP9
DMK3WY4 DT Small molecular drug
DMK3WY4 PC 104999
DMK3WY4 MW 314.34
DMK3WY4 FM C17H18N2O4
DMK3WY4 IC InChI=1S/C17H18N2O4/c1-5-9-15-10-6-13(21-2)14(22-3)7-11(10)19-12(15)8-18-16(9)17(20)23-4/h6-8,19H,5H2,1-4H3
DMK3WY4 CS CCC1=C2C3=CC(=C(C=C3NC2=CN=C1C(=O)OC)OC)OC
DMK3WY4 IK GADIKQPUNWAMEB-UHFFFAOYSA-N
DMK3WY4 IU methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-carboxylate
DMK3WY4 CA CAS 82499-00-1
DMK3WY4 CB CHEBI:92263
DMK3WY4 DE Discovery agent
DMOJ92D ID DMOJ92D
DMOJ92D DN DMI-bisphosphate
DMOJ92D HS Investigative
DMOJ92D SN D-myo-inositol 3,4-bisphosphate; Inositol 3,4-bisphosphate; SCHEMBL2044892; 1D-myo-Inositol 3,4-bisphosphate; 1D-myo-inositol 3,4-bis(dihydrogen phosphate); 1L-myo-inositol 1,6-bis(dihydrogen phosphate); 23410-61-9; 69256-53-7; AC1L98W7; C04063; CHEBI:28858; CTK2F6528; [(1S,2R,3S,4S,5S,6S)-2,3,4,5-tetrahydroxy-6-phosphonooxy-cyclohexyl]oxyphosphonic acid; [(1S,2S,3S,4S,5R,6S)-2,3,4,5-tetrahydroxy-6-phosphonooxycyclohexyl] dihydrogen phosphate
DMOJ92D PC 440211
DMOJ92D MW 340.12
DMOJ92D FM C6H14O12P2
DMOJ92D IC MCKAJXMRULSUKI-CNWJWELYSA-N
DMOJ92D CS C1(C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)O)O)O
DMOJ92D IK 1S/C6H14O12P2/c7-1-2(8)4(10)6(18-20(14,15)16)5(3(1)9)17-19(11,12)13/h1-10H,(H2,11,12,13)(H2,14,15,16)/t1-,2-,3-,4+,5-,6-/m0/s1
DMOJ92D IU [(1S,2R,3S,4S,5S,6S)-2,3,4,5-tetrahydroxy-6-phosphonooxycyclohexyl] dihydrogen phosphate
DMOJ92D CA CAS 69256-53-7
DMOJ92D CB CHEBI:28858
DMOJ92D DE Discovery agent
DM3GYFZ ID DM3GYFZ
DM3GYFZ DN DMI-trisphosphate
DM3GYFZ HS Investigative
DM3GYFZ SN D-myo-inositol 1,3,4-trisphosphate; D-myo-Inositol-1,3,4-triphosphate; Inositol 1,3,4-triphosphate; SCHEMBL9382320; ZINC4095596; inositol 1,3,4-trisphosphate; myo-inositol 1,3,4-trisphosphate; (1S,3S,4S)-1,3,4-TRIPHOSPHO-MYO-INOSITOL; 1,3,4-Itp; 1D-myo-Inositol 1,3,4-trisphosphate; 1D-myo-inositol 1,3,4-tris(dihydrogen phosphate); AC1L97DW; C01243; CHEBI:18228; CHEMBL329137; DB01729; I3S; MMWCIQZXVOZEGG-MLQGYMEPSA-N; d-myo-inositol-1,3,4-tris(dihydrogen phosphate)
DM3GYFZ PC 439455
DM3GYFZ MW 420.1
DM3GYFZ FM C6H15O15P3
DM3GYFZ IC MMWCIQZXVOZEGG-MLQGYMEPSA-N
DM3GYFZ CS C1(C(C(C(C(C1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DM3GYFZ IK 1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3+,4+,5+,6+/m1/s1
DM3GYFZ IU [(1S,2R,3R,4S,5S,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
DM3GYFZ CA CAS 98102-63-7
DM3GYFZ CB CHEBI:18228
DM3GYFZ DE Discovery agent
DMNRLA7 ID DMNRLA7
DMNRLA7 DN DMP-695/696
DMNRLA7 HS Investigative
DMNRLA7 DT Small molecular drug
DMNRLA7 PC 56603766
DMNRLA7 MW 410.3
DMNRLA7 FM C18H21Cl2N5O2
DMNRLA7 IC InChI=1S/C18H21Cl2N5O2/c1-10-16(12-5-13(19)7-14(20)6-12)17-21-11(2)22-18(25(17)24-10)23-15(8-26-3)9-27-4/h5-7,15H,8-9H2,1-4H3,(H,21,22,23)
DMNRLA7 CS CC1=NN2C(=C1C3=CC(=CC(=C3)Cl)Cl)N=C(N=C2NC(COC)COC)C
DMNRLA7 IK RHSNHBGJLLYGNA-UHFFFAOYSA-N
DMNRLA7 IU 8-(3,5-dichlorophenyl)-N-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine
DMNRLA7 DE Depression
DMUGPD1 ID DMUGPD1
DMUGPD1 DN DM-PPP
DMUGPD1 HS Investigative
DMUGPD1 SN CHEMBL232052; DM-PPP; GTPL1383; BDBM50204428; D-255; O4-(3,3-dimethylbutan-2-yl) O2-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate; (S)-4-(3,3-dimethylbutan-2-yl) 2-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate; 4-O-[(2S)-3,3-dimethylbutan-2-yl] 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate.
DMUGPD1 DT Small molecular drug
DMUGPD1 PC 44431042
DMUGPD1 MW 309.4
DMUGPD1 FM C17H27NO4
DMUGPD1 IC InChI=1S/C17H27NO4/c1-8-9-21-16(20)14-10(2)13(11(3)18-14)15(19)22-12(4)17(5,6)7/h12,18H,8-9H2,1-7H3/t12-/m0/s1
DMUGPD1 CS CCCOC(=O)C1=C(C(=C(N1)C)C(=O)O[C@@H](C)C(C)(C)C)C
DMUGPD1 IK DOYZAIRDDZPMQZ-LBPRGKRZSA-N
DMUGPD1 IU 4-O-[(2S)-3,3-dimethylbutan-2-yl] 2-O-propyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate
DMUGPD1 DE Discovery agent
DM5WEFK ID DM5WEFK
DM5WEFK DN Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK HS Investigative
DM5WEFK SN CHEMBL389949; Dmt-Pro-3,5Dmp-Phe-NH2
DM5WEFK DT Small molecular drug
DM5WEFK PC 16736676
DM5WEFK MW 627.8
DM5WEFK FM C36H45N5O5
DM5WEFK IC InChI=1S/C36H45N5O5/c1-21-13-22(2)15-26(14-21)19-31(34(44)39-30(33(38)43)18-25-9-6-5-7-10-25)40-35(45)32-11-8-12-41(32)36(46)29(37)20-28-23(3)16-27(42)17-24(28)4/h5-7,9-10,13-17,29-32,42H,8,11-12,18-20,37H2,1-4H3,(H2,38,43)(H,39,44)(H,40,45)/t29-,30-,31-,32-/m0/s1
DM5WEFK CS CC1=CC(=CC(=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)C
DM5WEFK IK GBRVPIBAPYVZMY-YDPTYEFTSA-N
DM5WEFK IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(3,5-dimethylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM5WEFK DE Discovery agent
DMGUIR1 ID DMGUIR1
DMGUIR1 DN Dmt-Pro-Dmp-Phe-NH2
DMGUIR1 HS Investigative
DMGUIR1 SN CHEMBL228409; Dmt-Pro-Dmp-Phe-NH2
DMGUIR1 DT Small molecular drug
DMGUIR1 PC 16736727
DMGUIR1 MW 627.8
DMGUIR1 FM C36H45N5O5
DMGUIR1 IC InChI=1S/C36H45N5O5/c1-21-10-8-11-22(2)28(21)20-31(34(44)39-30(33(38)43)18-25-12-6-5-7-13-25)40-35(45)32-14-9-15-41(32)36(46)29(37)19-27-23(3)16-26(42)17-24(27)4/h5-8,10-13,16-17,29-32,42H,9,14-15,18-20,37H2,1-4H3,(H2,38,43)(H,39,44)(H,40,45)/t29-,30-,31-,32-/m0/s1
DMGUIR1 CS CC1=C(C(=CC=C1)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N
DMGUIR1 IK KIPQYPCUMMQKJB-YDPTYEFTSA-N
DMGUIR1 IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2,6-dimethylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMGUIR1 DE Discovery agent
DM4VEU2 ID DM4VEU2
DM4VEU2 DN Dmt-Pro-Dmt-Phe-NH2
DM4VEU2 HS Investigative
DM4VEU2 SN CHEMBL388800; Dmt-Pro-Dmt-Phe-NH2
DM4VEU2 DT Small molecular drug
DM4VEU2 PC 44424810
DM4VEU2 MW 629.7
DM4VEU2 FM C35H43N5O6
DM4VEU2 IC InChI=1S/C35H43N5O6/c1-20-14-25(41)12-11-24(20)18-30(33(44)38-29(32(37)43)17-23-8-5-4-6-9-23)39-34(45)31-10-7-13-40(31)35(46)28(36)19-27-21(2)15-26(42)16-22(27)3/h4-6,8-9,11-12,14-16,28-31,41-42H,7,10,13,17-19,36H2,1-3H3,(H2,37,43)(H,38,44)(H,39,45)/t28-,29-,30-,31-/m0/s1
DM4VEU2 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=C(C=C(C=C3)O)C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)N)C)O
DM4VEU2 IK VSPCTLNQMKBUFW-ORYMTKCHSA-N
DM4VEU2 IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxy-2-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM4VEU2 DE Discovery agent
DM06VGY ID DM06VGY
DM06VGY DN Dmt-Pro-Emp-Phe-NH2
DM06VGY HS Investigative
DM06VGY SN CHEMBL374818; Dmt-Pro-Emp-Phe-NH2
DM06VGY DT Small molecular drug
DM06VGY PC 16736880
DM06VGY MW 641.8
DM06VGY FM C37H47N5O5
DM06VGY IC InChI=1S/C37H47N5O5/c1-5-26-14-9-11-22(2)29(26)21-32(35(45)40-31(34(39)44)19-25-12-7-6-8-13-25)41-36(46)33-15-10-16-42(33)37(47)30(38)20-28-23(3)17-27(43)18-24(28)4/h6-9,11-14,17-18,30-33,43H,5,10,15-16,19-21,38H2,1-4H3,(H2,39,44)(H,40,45)(H,41,46)/t30-,31-,32-,33-/m0/s1
DM06VGY CS CCC1=CC=CC(=C1C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)C
DM06VGY IK FZEQHIVEBCRYJC-YRCZKMHPSA-N
DM06VGY IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-ethyl-6-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM06VGY DE Discovery agent
DMXUI1J ID DMXUI1J
DMXUI1J DN Dmt-Pro-Imp-Phe-NH2
DMXUI1J HS Investigative
DMXUI1J SN CHEMBL228516; Dmt-Pro-Imp-Phe-NH2
DMXUI1J DT Small molecular drug
DMXUI1J PC 16737137
DMXUI1J MW 655.8
DMXUI1J FM C38H49N5O5
DMXUI1J IC InChI=1S/C38H49N5O5/c1-22(2)28-14-9-11-23(3)30(28)21-33(36(46)41-32(35(40)45)19-26-12-7-6-8-13-26)42-37(47)34-15-10-16-43(34)38(48)31(39)20-29-24(4)17-27(44)18-25(29)5/h6-9,11-14,17-18,22,31-34,44H,10,15-16,19-21,39H2,1-5H3,(H2,40,45)(H,41,46)(H,42,47)/t31-,32-,33-,34-/m0/s1
DMXUI1J CS CC1=C(C(=CC=C1)C(C)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N
DMXUI1J IK PUIMPGYMFMJIOK-CUPIEXAXSA-N
DMXUI1J IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-methyl-6-propan-2-ylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMXUI1J DE Discovery agent
DM78PFN ID DM78PFN
DM78PFN DN Dmt-Pro-Mmp-Phe-NH2
DM78PFN HS Investigative
DM78PFN SN CHEMBL389948; Dmt-Pro-Mmp-Phe-NH2
DM78PFN DT Small molecular drug
DM78PFN PC 16737287
DM78PFN MW 613.7
DM78PFN FM C35H43N5O5
DM78PFN IC InChI=1S/C35H43N5O5/c1-21-10-7-8-13-25(21)19-30(33(43)38-29(32(37)42)18-24-11-5-4-6-12-24)39-34(44)31-14-9-15-40(31)35(45)28(36)20-27-22(2)16-26(41)17-23(27)3/h4-8,10-13,16-17,28-31,41H,9,14-15,18-20,36H2,1-3H3,(H2,37,42)(H,38,43)(H,39,44)/t28-,29-,30-,31-/m0/s1
DM78PFN CS CC1=CC=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N
DM78PFN IK ILQNJTWDEDHFTC-ORYMTKCHSA-N
DM78PFN IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(2-methylphenyl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM78PFN DE Discovery agent
DM0VCWA ID DM0VCWA
DM0VCWA DN Dmt-Pro-Phe-D-1-Nal-NH2
DM0VCWA HS Investigative
DM0VCWA SN CHEMBL385583; Dmt-Pro-Phe-D-1-Nal-NH2
DM0VCWA DT Small molecular drug
DM0VCWA PC 16105560
DM0VCWA MW 649.8
DM0VCWA FM C38H43N5O5
DM0VCWA IC InChI=1S/C38H43N5O5/c1-23-18-26(19-24(2)34(23)44)20-30(39)38(48)43-17-9-16-33(43)37(47)42-32(21-25-10-4-3-5-11-25)36(46)41-31(35(40)45)22-28-14-8-13-27-12-6-7-15-29(27)28/h3-8,10-15,18-19,30-33,44H,9,16-17,20-22,39H2,1-2H3,(H2,40,45)(H,41,46)(H,42,47)/t30-,31+,32-,33-/m0/s1
DM0VCWA CS CC1=CC(=CC(=C1O)C)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@H](CC4=CC=CC5=CC=CC=C54)C(=O)N)N
DM0VCWA IK UOSWQKPDVGZIDQ-YGXYGYJOSA-N
DM0VCWA IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-3,5-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-1-yl-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM0VCWA DE Discovery agent
DMRJVE8 ID DMRJVE8
DMRJVE8 DN Dmt-Pro-Phe-D-2-Nal-NH2
DMRJVE8 HS Investigative
DMRJVE8 DE Discovery agent
DMM8BIE ID DMM8BIE
DMM8BIE DN Dmt-Pro-Phe-Phe-NH2
DMM8BIE HS Investigative
DMM8BIE SN CHEMBL331325; 596792-36-8; Dmt-Pro-Phe-Phe-NH2; Dmt-endomorphin-2; CTK1E6813; DTXSID10435187; BDBM50149384; AKOS030610408; L-Phenylalaninamide, 2,6-dimethyl-L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-1-[(S)-2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide
DMM8BIE DT Small molecular drug
DMM8BIE PC 10077295
DMM8BIE MW 599.7
DMM8BIE FM C34H41N5O5
DMM8BIE IC InChI=1S/C34H41N5O5/c1-21-16-25(40)17-22(2)26(21)20-27(35)34(44)39-15-9-14-30(39)33(43)38-29(19-24-12-7-4-8-13-24)32(42)37-28(31(36)41)18-23-10-5-3-6-11-23/h3-8,10-13,16-17,27-30,40H,9,14-15,18-20,35H2,1-2H3,(H2,36,41)(H,37,42)(H,38,43)/t27-,28-,29-,30-/m0/s1
DMM8BIE CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)N)C)O
DMM8BIE IK PJAMNQXPYIKTPE-KRCBVYEFSA-N
DMM8BIE IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMM8BIE CA CAS 596792-36-8
DMM8BIE DE Discovery agent
DMEMQAK ID DMEMQAK
DMEMQAK DN Dmt-Pro-Tmp-Phe-NH2
DMEMQAK HS Investigative
DMEMQAK SN CHEMBL228503; Dmt-Pro-Tmp-Phe-NH2
DMEMQAK DT Small molecular drug
DMEMQAK PC 16737135
DMEMQAK MW 641.8
DMEMQAK FM C37H47N5O5
DMEMQAK IC InChI=1S/C37H47N5O5/c1-21-14-22(2)29(23(3)15-21)20-32(35(45)40-31(34(39)44)18-26-10-7-6-8-11-26)41-36(46)33-12-9-13-42(33)37(47)30(38)19-28-24(4)16-27(43)17-25(28)5/h6-8,10-11,14-17,30-33,43H,9,12-13,18-20,38H2,1-5H3,(H2,39,44)(H,40,45)(H,41,46)/t30-,31-,32-,33-/m0/s1
DMEMQAK CS CC1=CC(=C(C(=C1)C)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)C
DMEMQAK IK NHSNBLRALWOIIA-YRCZKMHPSA-N
DMEMQAK IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-(2,4,6-trimethylphenyl)propan-2-yl]pyrrolidine-2-carboxamide
DMEMQAK DE Discovery agent
DMKEV5U ID DMKEV5U
DMKEV5U DN Dmt-Pro-Trp-D-2-Nal-NH2
DMKEV5U HS Investigative
DMKEV5U SN CHEMBL218433; Dmt-Pro-Trp-D-2-Nal-NH2
DMKEV5U DT Small molecular drug
DMKEV5U PC 16105563
DMKEV5U MW 688.8
DMKEV5U FM C40H44N6O5
DMKEV5U IC InChI=1S/C40H44N6O5/c1-23-16-26(17-24(2)36(23)47)19-31(41)40(51)46-15-7-12-35(46)39(50)45-34(21-29-22-43-32-11-6-5-10-30(29)32)38(49)44-33(37(42)48)20-25-13-14-27-8-3-4-9-28(27)18-25/h3-6,8-11,13-14,16-18,22,31,33-35,43,47H,7,12,15,19-21,41H2,1-2H3,(H2,42,48)(H,44,49)(H,45,50)/t31-,33+,34-,35-/m0/s1
DMKEV5U CS CC1=CC(=CC(=C1O)C)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC6=CC=CC=C6C=C5)C(=O)N)N
DMKEV5U IK DAHITVLHYSLLFU-ZFOKTMFVSA-N
DMKEV5U IU (2S)-1-[(2S)-2-amino-3-(4-hydroxy-3,5-dimethylphenyl)propanoyl]-N-[(2S)-1-[[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMKEV5U DE Discovery agent
DMHRT0F ID DMHRT0F
DMHRT0F DN Dmt-Sar-Phe-D-2-Nal-NH
DMHRT0F HS Investigative
DMHRT0F SN CHEMBL254927; Dmt-Sar-Phe-D-2-Nal-NH; BDBM50232770
DMHRT0F DT Small molecular drug
DMHRT0F PC 44447368
DMHRT0F MW 623.7
DMHRT0F FM C36H41N5O5
DMHRT0F IC InChI=1S/C36H41N5O5/c1-22-15-28(42)16-23(2)29(22)20-30(37)36(46)41(3)21-33(43)39-32(18-24-9-5-4-6-10-24)35(45)40-31(34(38)44)19-25-13-14-26-11-7-8-12-27(26)17-25/h4-17,30-32,42H,18-21,37H2,1-3H3,(H2,38,44)(H,39,43)(H,40,45)/t30-,31+,32-/m0/s1
DMHRT0F CS CC1=CC(=CC(=C1C[C@@H](C(=O)N(C)CC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC3=CC4=CC=CC=C4C=C3)C(=O)N)N)C)O
DMHRT0F IK LCSGBFCHAFMKLD-QAXCHELISA-N
DMHRT0F IU (2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-methylamino]acetyl]amino]-N-[(2R)-1-amino-3-naphthalen-2-yl-1-oxopropan-2-yl]-3-phenylpropanamide
DMHRT0F DE Discovery agent
DMNUKIX ID DMNUKIX
DMNUKIX DN D-myo-inositol 1,4,5-trisphosphate
DMNUKIX HS Investigative
DMNUKIX SN d-Myo-inositol-1,4,5-triphosphate; inositol 1,4,5-trisphosphate; 1,4,5-Insp3; InsP3; d-myo-inositol-1,4,5-triphosphate; 1D-myo-Inositol 1,4,5-trisphosphate; D-myo-Inositol 1,4,5-trisphosphate; IP3; Ins(1,4,5)P3; 85166-31-0; CHEMBL279107; CHEBI:16595; Triphosphoinositol; I3P; 1D-myo-inositol 1,4,5-tris(dihydrogen phosphate); D-myo-Inositol, 1,4,5-tris(dihydrogen phosphate); {[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-bis(phosphonooxy)cyclohexyl]oxy}phosphonic acid; D-myo-Inositol 1,4,5-triphosphate; 1btn; 1mai; Inositol trisphosphate; 1n4k; 1h0a; D-Myo-Inositol-1,4,5-Triphosphate
DMNUKIX DT Small molecular drug
DMNUKIX PC 439456
DMNUKIX MW 420.1
DMNUKIX FM C6H15O15P3
DMNUKIX IC InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2+,3+,4-,5-,6-/m1/s1
DMNUKIX CS [C@H]1([C@@H]([C@H]([C@@H]([C@H]([C@@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DMNUKIX IK MMWCIQZXVOZEGG-XJTPDSDZSA-N
DMNUKIX IU [(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
DMNUKIX CA CAS 85166-31-0
DMNUKIX CB CHEBI:16595
DMNUKIX DE Discovery agent
DMQXPA5 ID DMQXPA5
DMQXPA5 DN DNQX
DMQXPA5 HS Investigative
DMQXPA5 SN dnqx; 2379-57-9; 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione; FG-9041; FG 9041; UNII-62T278S1MX; 6,7-Dinitroquinoxaline-2,3-dione (DNQX); 2,3-Quinoxalinedione, 1,4-dihydro-6,7-dinitro-; 6,7-Dinitroquinoxaline-2,3(1H,4H)-dione; 62T278S1MX; 6,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione; SR-01000075442; 1ftl; Tocris-0189; AC1MZKE9; Lopac-D-0540; Biomol-NT_000182; Oprea1_127694; Lopac0_000345; MLS000705107; SCHEMBL594575; SCHEMBL8128055; BPBio1_001176; CHEMBL155265; C8H4N4O6; CHEBI:93492; CTK8F7031; DTXSID60178476; MolPort-003-846-931
DMQXPA5 DT Small molecular drug
DMQXPA5 PC 3899541
DMQXPA5 MW 252.14
DMQXPA5 FM C8H4N4O6
DMQXPA5 IC InChI=1S/C8H4N4O6/c13-7-8(14)10-4-2-6(12(17)18)5(11(15)16)1-3(4)9-7/h1-2H,(H,9,13)(H,10,14)
DMQXPA5 CS C1=C2C(=CC(=C1[N+](=O)[O-])[N+](=O)[O-])NC(=O)C(=O)N2
DMQXPA5 IK RWVIMCIPOAXUDG-UHFFFAOYSA-N
DMQXPA5 IU 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione
DMQXPA5 CA CAS 2379-57-9
DMQXPA5 CB CHEBI:93492
DMQXPA5 DE Discovery agent
DMC5RL7 ID DMC5RL7
DMC5RL7 DN DNX-2000
DMC5RL7 HS Investigative
DMC5RL7 SN SYK kinase inhibitor (autoimmune disorders), Dynamix/Teva Pharmaceutical
DMC5RL7 CP Dynamix Pharmaceuticals Ltd
DMC5RL7 DE Autoimmune diabetes
DMVCP6X ID DMVCP6X
DMVCP6X DN Docosapentaenoic acid
DMVCP6X HS Investigative
DMVCP6X SN Docosa-4,7,10,13,16-pentaenoic acid; 2313-14-6; 25182-74-5; 4-7-10-13-16 Docsapentaenoic acid; CTK1A5509; CTK1A4905; AVKOENOBFIYBSA-UHFFFAOYSA-N; 4,7,10,13,16-Docosapentaenoicacid; 4,7,10,13,16-Docosapentaenoicacid, (4Z,7Z,10Z,13Z,16Z)-; CH3(CH2)4-CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)2COOH
DMVCP6X DT Small molecular drug
DMVCP6X PC 5497182
DMVCP6X MW 330.5
DMVCP6X FM C22H34O2
DMVCP6X IC InChI=1S/C22H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMVCP6X CS CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCCC(=O)O
DMVCP6X IK YUFFSWGQGVEMMI-JLNKQSITSA-N
DMVCP6X IU (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoic acid
DMVCP6X CA CAS 24880-45-3
DMVCP6X CB CHEBI:53488
DMVCP6X DE Discovery agent
DMEKU71 ID DMEKU71
DMEKU71 DN Dodeca-2E,4E-dienoic acid isobutylamide
DMEKU71 HS Investigative
DMEKU71 SN UNII-5F4WO3BVS9; dodeca-2E,4E-dienoic acid isobutylamide; N-isobutyl-(2E,4E)-dodecadienamide; N-Isobutyldodeca-trans-2,4-dienamide; 5F4WO3BVS9; CHEMBL426912; CHEBI:70101; 2,4-Dodecadienamide, N-(2-methylpropyl)-, (2E,4E)-; Kalecide; Dodecatetraenoic acid isobutylamide, (2E,4E)-; AC1O5Y9Z; (2E,4E)-N-(2-methylpropyl)dodeca-2,4-dienamide; SCHEMBL2262688; MolPort-005-944-951; BBRMJCAPNGJKEM-AQASXUMVSA-N; BDBM50212599; ZINC36294914; 2,4-(E,E)-Dodecadienoylisobutylamide; MCULE-7934862818; (E,E)-N-Isobutyl-2,4-dodecadienamide
DMEKU71 DT Small molecular drug
DMEKU71 PC 6443006
DMEKU71 MW 251.41
DMEKU71 FM C16H29NO
DMEKU71 IC InChI=1S/C16H29NO/c1-4-5-6-7-8-9-10-11-12-13-16(18)17-14-15(2)3/h10-13,15H,4-9,14H2,1-3H3,(H,17,18)/b11-10+,13-12+
DMEKU71 CS CCCCCCC/C=C/C=C/C(=O)NCC(C)C
DMEKU71 IK BBRMJCAPNGJKEM-AQASXUMVSA-N
DMEKU71 IU (2E,4E)-N-(2-methylpropyl)dodeca-2,4-dienamide
DMEKU71 CA CAS 24738-51-0
DMEKU71 CB CHEBI:70101
DMEKU71 DE Discovery agent
DME9CGK ID DME9CGK
DME9CGK DN Dodecane-1-sulfonyl fluoride
DME9CGK HS Investigative
DME9CGK SN dodecane-1-sulfonyl fluoride; Dodecanesulfonyl fluoride; CHEMBL97038; dodecyl sulfonyl fluoride; 1-(Fluorosulfonyl)dodecane; SCHEMBL1470419; BDBM50132715
DME9CGK DT Small molecular drug
DME9CGK PC 18516661
DME9CGK MW 252.39
DME9CGK FM C12H25FO2S
DME9CGK IC InChI=1S/C12H25FO2S/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3
DME9CGK CS CCCCCCCCCCCCS(=O)(=O)F
DME9CGK IK UVLRFDMRDPQRSM-UHFFFAOYSA-N
DME9CGK IU dodecane-1-sulfonyl fluoride
DME9CGK DE Discovery agent
DMCNFEL ID DMCNFEL
DMCNFEL DN Dodecanesulfonate ion
DMCNFEL HS Investigative
DMCNFEL SN 1-DODECANESULFONIC ACID; 1510-16-3; Dodecane-1-sulphonic acid; Dodecylsulfonic acid; dodecane-1-sulfonic acid; UNII-YGB5540EYF; YGB5540EYF; NSC238164; 38480-64-7; Dodecylsulfonate; Benzenemethanaminium, N-(C12-C16-alkyl)-N,N-dimethyl-, 1-dodecanesulfonate; 3300-34-3; dodecyl sulfonic acid; NSC29062; 1-Dodecanesulfonic acid, ion(1-); EINECS 216-146-5; NSC 29062; NSC 238164; dodecane sulfonic acid; AC1L25CW; SCHEMBL16659; CHEMBL1208337; DTXSID3073262; CTK0H6625; LDMOEFOXLIZJOW-UHFFFAOYSA-N; ZINC1651926; 2386-53-0 (hydrochloride salt)
DMCNFEL DT Small molecular drug
DMCNFEL PC 3383616
DMCNFEL MW 249.39
DMCNFEL FM C12H25O3S-
DMCNFEL IC InChI=1S/C12H26O3S/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3,(H,13,14,15)/p-1
DMCNFEL CS CCCCCCCCCCCCS(=O)(=O)[O-]
DMCNFEL IK LDMOEFOXLIZJOW-UHFFFAOYSA-M
DMCNFEL IU dodecane-1-sulfonate
DMCNFEL DE Discovery agent
DMUPMCZ ID DMUPMCZ
DMUPMCZ DN Dodecane-Trimethylamine
DMUPMCZ HS Investigative
DMUPMCZ SN DODECANE-TRIMETHYLAMINE; n-Dodecyltrimethylammonium; Dotac compound; Dodecyltrimethylammonium; N,N,N-trimethyldodecan-1-aminium; UNII-GT3793XV5S; 10182-91-9; DODECYLTRIMETHYLAMMONIUM ION; N,N,N-Trimethyl-1-dodecanaminium; dodecyl(trimethyl)azanium; GT3793XV5S; CHEBI:41378; 1-Dodecanaminium, N,N,N-trimethyl-; CHEMBL109873; Lauryltrimethylaminium; dodecyl-trimethyl-azanium; AC1L1QDV; dodecyl(trimethyl)ammonium; AC1Q28RJ; SCHEMBL93498; 112-00-5 (chloride); DTXSID4045008; CHEMBL1180004; 1119-94-4 (bromide); CTK4A0283
DMUPMCZ DT Small molecular drug
DMUPMCZ PC 8153
DMUPMCZ MW 228.44
DMUPMCZ FM C15H34N+
DMUPMCZ IC InChI=1S/C15H34N/c1-5-6-7-8-9-10-11-12-13-14-15-16(2,3)4/h5-15H2,1-4H3/q+1
DMUPMCZ CS CCCCCCCCCCCC[N+](C)(C)C
DMUPMCZ IK VICYBMUVWHJEFT-UHFFFAOYSA-N
DMUPMCZ IU dodecyl(trimethyl)azanium
DMUPMCZ CA CAS 10182-91-9
DMUPMCZ CB CHEBI:41378
DMUPMCZ DE Discovery agent
DM6TIQX ID DM6TIQX
DM6TIQX DN Dodecanoic acid adamantan-1-ylamide
DM6TIQX HS Investigative
DM6TIQX SN N-(1-adamantyl)dodecanamide; Dodecanoic acid adamantan-1-ylamide; CHEMBL192273; AC1NNKRI; N-adamantyl n-dodecanamide; SCHEMBL12931877; ZINC36330560; BDBM50167054
DM6TIQX DT Small molecular drug
DM6TIQX PC 5071820
DM6TIQX MW 333.6
DM6TIQX FM C22H39NO
DM6TIQX IC InChI=1S/C22H39NO/c1-2-3-4-5-6-7-8-9-10-11-21(24)23-22-15-18-12-19(16-22)14-20(13-18)17-22/h18-20H,2-17H2,1H3,(H,23,24)
DM6TIQX CS CCCCCCCCCCCC(=O)NC12CC3CC(C1)CC(C3)C2
DM6TIQX IK FRFKXRWIBACCCN-UHFFFAOYSA-N
DM6TIQX IU N-(1-adamantyl)dodecanamide
DM6TIQX DE Discovery agent
DMMDG92 ID DMMDG92
DMMDG92 DN Dodecyl-Alpha-D-Maltoside
DMMDG92 HS Investigative
DMMDG92 SN DODECYL-ALPHA-D-MALTOSIDE; 116183-64-3; N-Dodecylmaltoside; Dodecyl a-D-maltopyranoside; n-Dodecyl alpha-D-maltoside; LMU; (2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6S)-6-(Dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; AC1L9I0U; Dodecyl alpha-D-maltopyranoside; SCHEMBL17817178; Dodecyl-I+/--D-maltopyranoside; ZINC14253923; GC5636; AKOS030567697; DB03279; W0537; K-1145; 183D643; W-200893; dodecyl 4-O-alpha-D-glucopyranosyl-alpha-D-glucopyranoside
DMMDG92 DT Small molecular drug
DMMDG92 PC 445456
DMMDG92 MW 510.6
DMMDG92 FM C24H46O11
DMMDG92 IC InChI=1S/C24H46O11/c1-2-3-4-5-6-7-8-9-10-11-12-32-23-21(31)19(29)22(16(14-26)34-23)35-24-20(30)18(28)17(27)15(13-25)33-24/h15-31H,2-14H2,1H3/t15-,16-,17-,18+,19-,20-,21-,22-,23+,24-/m1/s1
DMMDG92 CS CCCCCCCCCCCCO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O
DMMDG92 IK NLEBIOOXCVAHBD-YHBSTRCHSA-N
DMMDG92 IU (2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMMDG92 DE Discovery agent
DMPCLTW ID DMPCLTW
DMPCLTW DN dodecylphosphate
DMPCLTW HS Investigative
DMPCLTW SN FAP12; dodecanol phosphate; FAP-12; lauryl phosphate
DMPCLTW DT Small molecular drug
DMPCLTW PC 1550836
DMPCLTW MW 264.3
DMPCLTW FM C12H25O4P-2
DMPCLTW IC InChI=1S/C12H27O4P/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h2-12H2,1H3,(H2,13,14,15)/p-2
DMPCLTW CS CCCCCCCCCCCCOP(=O)([O-])[O-]
DMPCLTW IK TVACALAUIQMRDF-UHFFFAOYSA-L
DMPCLTW IU dodecyl phosphate
DMPCLTW DE Discovery agent
DMLHKI9 ID DMLHKI9
DMLHKI9 DN Dodecyl-phosphonic acid
DMLHKI9 HS Investigative
DMLHKI9 SN Dodecylphosphonic acid; n-Dodecylphosphonic acid; 5137-70-2; Phosphonic acid, dodecyl-; n-Dodecanephosphonic acid; Dodecane phosphonic acid; 1-Dodecanephosphonic acid; n-Dodecyl phosphonic acid; Phosphonic acid, P-dodecyl-; 1-Dodecylphosphonic Acid; EINECS 225-897-8; NSC 407872; BRN 1778341; CHEMBL363067; N-DODECYLPHOSPHONICACID; AC1L2W0V; 12; SCHEMBL194178; DTXSID2063715; CTK3J3207; MolPort-004-285-423; KS-00000W0I; ZINC1600143; MFCD00015832; BDBM50170845; SBB057480; NSC407872; AKOS015899842
DMLHKI9 DT Small molecular drug
DMLHKI9 PC 78816
DMLHKI9 MW 250.31
DMLHKI9 FM C12H27O3P
DMLHKI9 IC InChI=1S/C12H27O3P/c1-2-3-4-5-6-7-8-9-10-11-12-16(13,14)15/h2-12H2,1H3,(H2,13,14,15)
DMLHKI9 CS CCCCCCCCCCCCP(=O)(O)O
DMLHKI9 IK SVMUEEINWGBIPD-UHFFFAOYSA-N
DMLHKI9 IU dodecylphosphonic acid
DMLHKI9 CA CAS 5137-70-2
DMLHKI9 DE Discovery agent
DMAJVPI ID DMAJVPI
DMAJVPI DN dodecyl-thiophosphate
DMAJVPI HS Investigative
DMAJVPI SN Dodecyl-thiophosphate; Thiophosphoric acid dodecyl ester; CHEMBL191365; Phosphorothioic acid, O-dodecyl ester; SCHEMBL40052; GTPL6990; thiophosphoric acid o-dodecyl ester; BDBM50170860
DMAJVPI DT Small molecular drug
DMAJVPI PC 10468943
DMAJVPI MW 282.38
DMAJVPI FM C12H27O3PS
DMAJVPI IC InChI=1S/C12H27O3PS/c1-2-3-4-5-6-7-8-9-10-11-12-15-16(13,14)17/h2-12H2,1H3,(H2,13,14,17)
DMAJVPI CS CCCCCCCCCCCCOP(=S)(O)O
DMAJVPI IK ISWBBUXCFWZBKC-UHFFFAOYSA-N
DMAJVPI IU dodecoxy-dihydroxy-sulfanylidene-lambda5-phosphane
DMAJVPI CA CAS 710277-85-3
DMAJVPI DE Discovery agent
DM1YCQF ID DM1YCQF
DM1YCQF DN dolichol phosphate
DM1YCQF HS Investigative
DM1YCQF SN Dolichol-P; dolichol-phosphate; dolichyl-phosphate; Dolychol phosphate; Dolichol-PO4; AC1NQWWQ; GTPL3214; [(6E)-3,7,11-trimethyldodeca-6,10-dienyl] dihydrogen phosphate; {[(6E)-3,7,11-trimethyldodeca-6,10-dien-1-yl]oxy}phosphonic acid
DM1YCQF DT Small molecular drug
DM1YCQF PC 5280322
DM1YCQF MW 304.36
DM1YCQF FM C15H29O4P
DM1YCQF IC InChI=1S/C15H29O4P/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-19-20(16,17)18/h7,9,15H,5-6,8,10-12H2,1-4H3,(H2,16,17,18)/b14-9+
DM1YCQF CS CC(CC/C=C(\\C)/CCC=C(C)C)CCOP(=O)(O)O
DM1YCQF IK DZHSRPJGCZHWOM-NTEUORMPSA-N
DM1YCQF IU [(6E)-3,7,11-trimethyldodeca-6,10-dienyl] dihydrogen phosphate
DM1YCQF CA CAS 34457-14-2
DM1YCQF DE Discovery agent
DM53KZX ID DM53KZX
DM53KZX DN DOM
DM53KZX HS Investigative
DM53KZX SN 2,5-Dimethoxy-4-methylamphetamine; STP (hallucinogen); (RS)-DOM; DOM; 15588-95-1; dl-2,5-Dimethoxy-4-methylamphetamine; 2,5-Dimethoxymethylamphetamine; 4-Methyl-2,5-dimethoxyamphetamine; (+-)-DOM; dl-4-Methyl-2,5-dimethoxyamphetamine; 2',5'-Dimethoxy-4'-methylamphetamine; CHEMBL8600; (+-)-2,5-Dimethoxy-4-methylamphetamine; 2,5-Dimethoxy-4-methylphenylisopropylamine; 2,5-Dimethoxy-4,alpha-dimethylphenethylamin; DEA No. 7395; 2,5-Dimethoxy-alpha,4-dimethylphenylethylamine; 2-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane
DM53KZX DT Small molecular drug
DM53KZX PC 85875
DM53KZX MW 209.28
DM53KZX FM C12H19NO2
DM53KZX IC InChI=1S/C12H19NO2/c1-8-5-12(15-4)10(6-9(2)13)7-11(8)14-3/h5,7,9H,6,13H2,1-4H3
DM53KZX CS CC1=CC(=C(C=C1OC)CC(C)N)OC
DM53KZX IK NTJQREUGJKIARY-UHFFFAOYSA-N
DM53KZX IU 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine
DM53KZX CA CAS 15588-95-1
DM53KZX DE Discovery agent
DMXJOYH ID DMXJOYH
DMXJOYH DN DOM-0215
DMXJOYH HS Investigative
DMXJOYH SN dual anti-TNFalpha/unspecified target human dAb (rheumatoid arthritis), Domantis; dual-targeting domain antibody therapy (rheumatoid arthritis), Domantis
DMXJOYH DE Discovery agent
DMYPVO0 ID DMYPVO0
DMYPVO0 DN domoic acid
DMYPVO0 HS Investigative
DMYPVO0 SN domoate; NSC 288031
DMYPVO0 DT Small molecular drug
DMYPVO0 PC 5282253
DMYPVO0 MW 311.33
DMYPVO0 FM C15H21NO6
DMYPVO0 IC InChI=1S/C15H21NO6/c1-8(4-3-5-9(2)14(19)20)11-7-16-13(15(21)22)10(11)6-12(17)18/h3-5,9-11,13,16H,6-7H2,1-2H3,(H,17,18)(H,19,20)(H,21,22)/b5-3+,8-4-/t9-,10+,11-,13+/m1/s1
DMYPVO0 CS C[C@H](/C=C/C=C(/C)\\[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O)C(=O)O
DMYPVO0 IK VZFRNCSOCOPNDB-AOKDLOFSSA-N
DMYPVO0 IU (2S,3S,4S)-4-[(2Z,4E,6R)-6-carboxyhepta-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
DMYPVO0 CA CAS 14277-97-5
DMYPVO0 CB CHEBI:34727
DMYPVO0 DE Discovery agent
DMOJF6D ID DMOJF6D
DMOJF6D DN Domoric acid
DMOJF6D HS Investigative
DMOJF6D SN domoric acid; CHEMBL482097; E,E-Isodomoic acid; ISODOMOIC ACID E; ( )-Isodomoic acid E; (-)-Isodomoic acid E; SCHEMBL13319904; ZINC4521465; (2S,3S,4S)-2-CARBOXY-4-[(1Z,3E,5R)-5-CARBOXY-1-METHYL-1,3-HEXADIENYL]-3-PYRROLIDINEACETIC ACID; BDBM50252103
DMOJF6D DT Small molecular drug
DMOJF6D PC 44568340
DMOJF6D MW 311.33
DMOJF6D FM C15H21NO6
DMOJF6D IC InChI=1S/C15H21NO6/c1-8(4-3-5-9(2)14(19)20)11-7-16-13(15(21)22)10(11)6-12(17)18/h3-5,9-11,13,16H,6-7H2,1-2H3,(H,17,18)(H,19,20)(H,21,22)/b5-3+,8-4+/t9-,10+,11-,13+/m1/s1
DMOJF6D CS C[C@H](/C=C/C=C(\\C)/[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O)C(=O)O
DMOJF6D IK VZFRNCSOCOPNDB-JIUSADRUSA-N
DMOJF6D IU (2S,3S,4S)-4-[(2E,4E,6R)-6-carboxyhepta-2,4-dien-2-yl]-3-(carboxymethyl)pyrrolidine-2-carboxylic acid
DMOJF6D CA CAS 133005-85-3
DMOJF6D DE Discovery agent
DMKYXJW ID DMKYXJW
DMKYXJW DN Dorsomorphin
DMKYXJW HS Investigative
DMKYXJW SN dorsomorphin; 866405-64-3; 6-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine; BML-275; Compound C; AMPK Inhibitor, Compound C; 6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine; CHEMBL478629; CHEBI:78510; 4-(6-{4-[2-(piperidin-1-yl)ethoxy]phenyl}pyrazolo[1,5-a]pyrimidin-3-yl)pyridine; 6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine; AMPK Inhibitor
DMKYXJW DT Small molecular drug
DMKYXJW PC 11524144
DMKYXJW MW 399.5
DMKYXJW FM C24H25N5O
DMKYXJW IC InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2
DMKYXJW CS C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3
DMKYXJW IK XHBVYDAKJHETMP-UHFFFAOYSA-N
DMKYXJW IU 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
DMKYXJW CA CAS 866405-64-3
DMKYXJW CB CHEBI:78510
DMKYXJW DE Discovery agent
DM6TU84 ID DM6TU84
DM6TU84 DN Double Oxidized Cysteine
DM6TU84 HS Investigative
DM6TU84 DT Small molecular drug
DM6TU84 PC 6398956
DM6TU84 MW 152.15
DM6TU84 FM C3H6NO4S-
DM6TU84 IC InChI=1S/C3H7NO4S/c4-2(3(5)6)1-9(7)8/h2H,1,4H2,(H,5,6)(H,7,8)/p-1/t2-/m0/s1
DM6TU84 CS C([C@@H](C(=O)O)N)S(=O)[O-]
DM6TU84 IK ADVPTQAUNPRNPO-REOHCLBHSA-M
DM6TU84 IU (2R)-2-amino-3-hydroxy-3-oxopropane-1-sulfinate
DM6TU84 CB CHEBI:41721
DM6TU84 DE Discovery agent
DMQIK9S ID DMQIK9S
DMQIK9S DN DOV-51892
DMQIK9S HS Investigative
DMQIK9S SN DOV-22047; GABA-A modulators, DOV
DMQIK9S CP DOV Pharmaceutical Inc
DMQIK9S DE Panic disorder
DMJF6AQ ID DMJF6AQ
DMJF6AQ DN Doxorubicin-Formaldehyde Conjugate
DMJF6AQ HS Investigative
DMJF6AQ PC 44397072
DMJF6AQ MW 1140.1
DMJF6AQ FM C57H56F3N5O17
DMJF6AQ IC InChI=1S/C57H56F3N5O17/c1-6-10-41(68)81-37-16-13-29(26-79-18-8-7-17-64-54(76)65(53(75)55(64,3)4)31-15-14-30(24-61)35(20-31)57(58,59)60)19-33(37)52(74)63-27-62-36-21-42(80-28(2)47(36)69)82-39-23-56(77,40(67)25-66)22-34-44(39)51(73)46-45(49(34)71)48(70)32-11-9-12-38(78-5)43(32)50(46)72/h9,11-16,19-20,28,36,39,42,47,62,66,69,71,73,77H,6,10,17-18,21-23,25-27H2,1-5H3,(H,63,74)/t28-,36-,39?,42?,47+,56-/m0/s1
DMJF6AQ CS CCCC(=O)OC1=C(C=C(C=C1)COCC#CCN2C(=O)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)C(=O)NCN[C@H]4CC(O[C@H]([C@H]4O)C)OC5C[C@@](CC6=C5C(=C7C(=C6O)C(=O)C8=C(C7=O)C(=CC=C8)OC)O)(C(=O)CO)O
DMJF6AQ IK WLZCINFVVNITPX-ZJLMMONESA-N
DMJF6AQ IU [4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]but-2-ynoxymethyl]-2-[[[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]amino]methylcarbamoyl]phenyl] butanoate
DMJF6AQ DE Discovery agent
DMNJBF8 ID DMNJBF8
DMNJBF8 DN doxorubicin-LL2 conjugate
DMNJBF8 HS Investigative
DMNJBF8 SN DOX-LL2, Immunomedics
DMNJBF8 DE Discovery agent
DM2OCZ8 ID DM2OCZ8
DM2OCZ8 DN doxorubicin-peptide-PEG conjugate
DM2OCZ8 HS Investigative
DM2OCZ8 DE Discovery agent
DMXEVA2 ID DMXEVA2
DMXEVA2 DN DP-3005
DMXEVA2 HS Investigative
DMXEVA2 SN TCCB (hypertension/angina), Diakron Pharmaceuticals; T-type calcium channel blocker (hypertension/angina), Diakron Pharmaceuticals
DMXEVA2 CP Diakron Pharmaceuticals Inc
DMXEVA2 DE Angina pectoris
DMFZML9 ID DMFZML9
DMFZML9 DN DP-3590
DMFZML9 HS Investigative
DMFZML9 SN DP-4157; DP-4693; DP-4756; C-Met kinase inhibitors (solid tumor/metastatic cancer); C-Met kinase inhibitors (solid tumor/metastatic cancer), Deciphera
DMFZML9 CP Deciphera Pharmaceuticals Inc
DMFZML9 DE Solid tumour/cancer
DMARTC2 ID DMARTC2
DMARTC2 DN DP-802
DMARTC2 HS Investigative
DMARTC2 SN P38-alpha inhibitors (inflammation); P38-alpha inhibitors (inflammation), Deciphera
DMARTC2 CP Deciphera Pharmaceuticals Inc
DMARTC2 DE Inflammation
DMIRSNA ID DMIRSNA
DMIRSNA DN DPDPE
DMIRSNA HS Investigative
DMIRSNA SN DPDPE; 2,5-Pen-enkephalin; (D-Pen2,D-Pen5)-Enkephalin; Enkephalin, D-penicillamine (2,5)-; (4s,7s,13s)-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-13-(l-tyrosylamino)-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid; DPLPE; c[D-Pen(2,5)]-enkephalin; CHEMBL31421; CHEBI:73356; Enkephalin, penicillamine(2,5)-; cyclo-[D-Pen(2,5)]-enkephalin; 88373-73-3; D-penicillamine-(2,5)-enkephalin; H-Tyr-c(D-Pen-Gly-Phe-D-Pen)-OH; [D-Pen(2)-D-Pen(5)]-enkephaline; H-Tyr-cyclo-(D-Pen-Gly-Phe-D-Pen)-OH; [3H]DPDPE; D-Valine, L-tyros
DMIRSNA DT Small molecular drug
DMIRSNA PC 104787
DMIRSNA MW 645.8
DMIRSNA FM C30H39N5O7S2
DMIRSNA IC InChI=1S/C30H39N5O7S2/c1-29(2)23(34-25(38)20(31)14-18-10-12-19(36)13-11-18)27(40)32-16-22(37)33-21(15-17-8-6-5-7-9-17)26(39)35-24(28(41)42)30(3,4)44-43-29/h5-13,20-21,23-24,36H,14-16,31H2,1-4H3,(H,32,40)(H,33,37)(H,34,38)(H,35,39)(H,41,42)/t20-,21-,23-,24-/m0/s1
DMIRSNA CS CC1([C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C
DMIRSNA IK MCMMCRYPQBNCPH-WMIMKTLMSA-N
DMIRSNA IU (4S,7S,13S)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
DMIRSNA CA CAS 88373-73-3
DMIRSNA CB CHEBI:73356
DMIRSNA DE Discovery agent
DMLK428 ID DMLK428
DMLK428 DN D-Phe-Arg-2-Nal-NHCH3
DMLK428 HS Investigative
DMLK428 DE Discovery agent
DM0YQHM ID DM0YQHM
DM0YQHM DN D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2
DM0YQHM HS Investigative
DM0YQHM SN CHEMBL269532; D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2
DM0YQHM PC 44403231
DM0YQHM MW 1060.3
DM0YQHM FM C50H65N11O11S2
DM0YQHM IC InChI=1S/C50H65N11O11S2/c1-27(2)42-50(72)60-40(48(70)56-36(43(53)65)23-41(63)64)26-74-73-25-39(59-44(66)33(52)20-28-10-4-3-5-11-28)49(71)57-37(21-29-15-17-31(62)18-16-29)46(68)58-38(22-30-24-54-34-13-7-6-12-32(30)34)47(69)55-35(45(67)61-42)14-8-9-19-51/h3-7,10-13,15-18,24,27,33,35-40,42,54,62H,8-9,14,19-23,25-26,51-52H2,1-2H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,71)(H,58,68)(H,59,66)(H,60,72)(H,61,67)(H,63,64)/t33-,35-,36-,37-,38+,39-,40+,42+/m0/s1
DM0YQHM CS CC(C)[C@@H]1C(=O)N[C@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CC(=O)O)C(=O)N
DM0YQHM IK HFLJXACCXCUGOQ-OZHBEKPPSA-N
DM0YQHM IU (3S)-4-amino-3-[[(4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-4-oxobutanoic acid
DM0YQHM DE Discovery agent
DM2EFLA ID DM2EFLA
DM2EFLA DN D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)
DM2EFLA HS Investigative
DM2EFLA SN CHEMBL413950; D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP)
DM2EFLA PC 44316483
DM2EFLA MW 1104.3
DM2EFLA FM C51H69N13O11S2
DM2EFLA IC InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40-,41+/m1/s1
DM2EFLA CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DM2EFLA IK OFMQLVRLOGHAJI-JGPYJKKXSA-N
DM2EFLA IU (4S,7R,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM2EFLA DE Discovery agent
DMPQHRC ID DMPQHRC
DMPQHRC DN D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)
DMPQHRC HS Investigative
DMPQHRC SN CHEMBL437283; D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)
DMPQHRC PC 44316364
DMPQHRC MW 1076.3
DMPQHRC FM C51H69N11O11S2
DMPQHRC IC InChI=1S/C51H69N11O11S2/c1-27(63)40(43(54)66)60-50(73)42-51(3,4)75-74-26-39(59-44(67)34(53)22-29-12-6-5-7-13-29)48(71)57-37(23-30-17-19-32(65)20-18-30)46(69)58-38(24-31-25-55-35-15-9-8-14-33(31)35)47(70)56-36(16-10-11-21-52)45(68)61-41(28(2)64)49(72)62-42/h5-9,12-15,17-20,25,27-28,34,36-42,55,63-65H,10-11,16,21-24,26,52-53H2,1-4H3,(H2,54,66)(H,56,70)(H,57,71)(H,58,69)(H,59,67)(H,60,73)(H,61,68)(H,62,72)/t27-,28-,34-,36+,37+,38-,39+,40+,41-,42+/m1/s1
DMPQHRC CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMPQHRC IK VSEYLDNPHYTJMJ-MHKBYQEDSA-N
DMPQHRC IU (4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMPQHRC DE Discovery agent
DMX1IYO ID DMX1IYO
DMX1IYO DN D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP)
DMX1IYO HS Investigative
DMX1IYO SN CHEMBL406014
DMX1IYO PC 44316520
DMX1IYO MW 1062.3
DMX1IYO FM C50H67N11O11S2
DMX1IYO IC InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-38(58-43(66)33(52)21-28-11-6-5-7-12-28)47(70)56-36(22-29-16-18-31(64)19-17-29)45(68)57-37(23-30-24-54-34-14-9-8-13-32(30)34)46(69)55-35(15-10-20-51)44(67)60-40(27(2)63)48(71)61-41/h5-9,11-14,16-19,24,26-27,33,35-41,54,62-64H,10,15,20-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,72)(H,60,67)(H,61,71)/t26-,27-,33-,35+,36+,37-,38+,39+,40-,41+/m1/s1
DMX1IYO CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMX1IYO IK PZWWYAHWHHNCHO-JGPYJKKXSA-N
DMX1IYO IU (4S,7R,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMX1IYO DE Discovery agent
DMUJC97 ID DMUJC97
DMUJC97 DN D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2
DMUJC97 HS Investigative
DMUJC97 SN CHEMBL274400; D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2
DMUJC97 PC 44316657
DMUJC97 MW 1076.3
DMUJC97 FM C51H69N11O11S2
DMUJC97 IC InChI=1S/C51H69N11O11S2/c1-27(63)40(43(54)66)60-50(73)42-51(3,4)75-74-26-39(59-44(67)34(53)22-29-12-6-5-7-13-29)48(71)57-37(23-30-17-19-32(65)20-18-30)46(69)58-38(24-31-25-55-35-15-9-8-14-33(31)35)47(70)56-36(16-10-11-21-52)45(68)61-41(28(2)64)49(72)62-42/h5-9,12-15,17-20,25,27-28,34,36-42,55,63-65H,10-11,16,21-24,26,52-53H2,1-4H3,(H2,54,66)(H,56,70)(H,57,71)(H,58,69)(H,59,67)(H,60,73)(H,61,68)(H,62,72)/t27-,28-,34-,36+,37+,38+,39+,40+,41-,42+/m1/s1
DMUJC97 CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMUJC97 IK VSEYLDNPHYTJMJ-AVTOYXFISA-N
DMUJC97 IU (4S,7R,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMUJC97 DE Discovery agent
DMTUHFX ID DMTUHFX
DMTUHFX DN D-Phenylalanine
DMTUHFX HS Investigative
DMTUHFX SN D-phenylalanine; 673-06-3; H-D-Phe-OH; (2R)-2-amino-3-phenylpropanoic acid; Sabiden; Phenylalanine D-form; D-Phe; (R)-2-AMINO-3-PHENYLPROPANOIC ACID; Alanine, phenyl-, D-; NCI-C60195; UNII-032K16VRCU; (R)-2-Amino-3-phenylpropionic acid; D-alpha-Amino-beta-phenylpropionic acid; CCRIS 6267; EINECS 211-603-5; NSC 25005; 032K16VRCU; CHEBI:16998; COLNVLDHVKWLRT-MRVPVSSYSA-N; MFCD00004270; D-Phenylalanine, 99+%; d-phenylalanin; D-.beta.-Phenylalanine; Phenylalanine,d-; DPhe; l-3-phenylalanine; HDPheOH; (D)-Phenylalanine; Phenylalanine,(S)
DMTUHFX DT Small molecular drug
DMTUHFX PC 71567
DMTUHFX MW 165.19
DMTUHFX FM C9H11NO2
DMTUHFX IC InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1
DMTUHFX CS C1=CC=C(C=C1)C[C@H](C(=O)O)N
DMTUHFX IK COLNVLDHVKWLRT-MRVPVSSYSA-N
DMTUHFX IU (2R)-2-amino-3-phenylpropanoic acid
DMTUHFX CA CAS 673-06-3
DMTUHFX CB CHEBI:16998
DMTUHFX DE Discovery agent
DMGD7JM ID DMGD7JM
DMGD7JM DN D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide
DMGD7JM HS Investigative
DMGD7JM SN D-Phenylalanyl-N-(3-Chlorobenzyl)-L-Prolinamide; CHEMBL321130; CHEMBL599035; 628262-82-8; 22U; CTK1I8953; DTXSID70648418; BDBM50133531; BDBM50307858; DB06919; D-Phenylalanyl-N-[(3-chlorophenyl)methyl]-L-prolinamide; L-Prolinamide, D-phenylalanyl-N-[(3-chlorophenyl)methyl]-; N-(3-Chlorobenzyl)-1-[(2R)-2-amino-3-phenylpropionyl]-L-prolinamide; (S)-1-((R)-2-Amino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid 3-chloro-benzylamide; (S)-1-((R)-2-amino-3-phenylpropanoyl)-N-(3-chlorobenzyl)pyrrolidine-2-carboxamide hydrochlo
DMGD7JM DT Small molecular drug
DMGD7JM PC 25011732
DMGD7JM MW 385.9
DMGD7JM FM C21H24ClN3O2
DMGD7JM IC InChI=1S/C21H24ClN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1
DMGD7JM CS C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)NCC3=CC(=CC=C3)Cl
DMGD7JM IK CJHLRGCXPGIPCB-MOPGFXCFSA-N
DMGD7JM IU (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-chlorophenyl)methyl]pyrrolidine-2-carboxamide
DMGD7JM CA CAS 628262-82-8
DMGD7JM DE Discovery agent
DM5XHA6 ID DM5XHA6
DM5XHA6 DN D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide
DM5XHA6 HS Investigative
DM5XHA6 SN D-Phenylalanyl-N-(3-Fluorobenzyl)-L-Prolinamide; DB07027; 37U; (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxamide
DM5XHA6 DT Small molecular drug
DM5XHA6 PC 25011733
DM5XHA6 MW 369.4
DM5XHA6 FM C21H24FN3O2
DM5XHA6 IC InChI=1S/C21H24FN3O2/c22-17-9-4-8-16(12-17)14-24-20(26)19-10-5-11-25(19)21(27)18(23)13-15-6-2-1-3-7-15/h1-4,6-9,12,18-19H,5,10-11,13-14,23H2,(H,24,26)/t18-,19+/m1/s1
DM5XHA6 CS C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)NCC3=CC(=CC=C3)F
DM5XHA6 IK JGZSVYZIJHGHMA-MOPGFXCFSA-N
DM5XHA6 IU (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxamide
DM5XHA6 DE Discovery agent
DMV9RAN ID DMV9RAN
DMV9RAN DN D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide
DMV9RAN HS Investigative
DMV9RAN SN D-Phenylalanyl-N-(3-Methylbenzyl)-L-Prolinamide; DB07133; 51U
DMV9RAN DT Small molecular drug
DMV9RAN PC 25021183
DMV9RAN MW 365.5
DMV9RAN FM C22H27N3O2
DMV9RAN IC InChI=1S/C22H27N3O2/c1-16-7-5-10-18(13-16)15-24-21(26)20-11-6-12-25(20)22(27)19(23)14-17-8-3-2-4-9-17/h2-5,7-10,13,19-20H,6,11-12,14-15,23H2,1H3,(H,24,26)/t19-,20+/m1/s1
DMV9RAN CS CC1=CC(=CC=C1)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC3=CC=CC=C3)N
DMV9RAN IK CHKWABXWPATIIG-UXHICEINSA-N
DMV9RAN IU (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[(3-methylphenyl)methyl]pyrrolidine-2-carboxamide
DMV9RAN DE Discovery agent
DMHNR63 ID DMHNR63
DMHNR63 DN D-phenylalanyl-N-benzyl-L-prolinamide
DMHNR63 HS Investigative
DMHNR63 SN D-Phenylalanyl-N-Benzyl-L-Prolinamide; CHEMBL116597; BDBM50133518; DB07143; (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-benzylpyrrolidine-2-carboxamide; (S)-1-((R)-2-Amino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid benzylamide; (2S)-1-((2R)-2-amino-3-phenyl-propanoyl)-N-(phenylmethyl)pyrrolidine-2-carboxamide
DMHNR63 DT Small molecular drug
DMHNR63 PC 25113125
DMHNR63 MW 351.4
DMHNR63 FM C21H25N3O2
DMHNR63 IC InChI=1S/C21H25N3O2/c22-18(14-16-8-3-1-4-9-16)21(26)24-13-7-12-19(24)20(25)23-15-17-10-5-2-6-11-17/h1-6,8-11,18-19H,7,12-15,22H2,(H,23,25)/t18-,19+/m1/s1
DMHNR63 CS C1C[C@H](N(C1)C(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)NCC3=CC=CC=C3
DMHNR63 IK MEPJWLFTTFHOQO-MOPGFXCFSA-N
DMHNR63 IU (2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-benzylpyrrolidine-2-carboxamide
DMHNR63 DE Discovery agent
DMMXA5K ID DMMXA5K
DMMXA5K DN D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
DMMXA5K HS Investigative
DMMXA5K SN CHEMBL384284; D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2
DMMXA5K PC 44316656
DMMXA5K MW 1062.3
DMMXA5K FM C50H67N11O11S2
DMMXA5K IC InChI=1S/C50H67N11O11S2/c1-26(62)39(42(53)65)59-49(72)41-50(3,4)74-73-25-37(58-47(70)38(52)29-12-6-5-7-13-29)46(69)56-35(22-28-17-19-31(64)20-18-28)44(67)57-36(23-30-24-54-33-15-9-8-14-32(30)33)45(68)55-34(16-10-11-21-51)43(66)60-40(27(2)63)48(71)61-41/h5-9,12-15,17-20,24,26-27,34-41,54,62-64H,10-11,16,21-23,25,51-52H2,1-4H3,(H2,53,65)(H,55,68)(H,56,69)(H,57,67)(H,58,70)(H,59,72)(H,60,66)(H,61,71)/t26-,27-,34+,35+,36-,37+,38-,39+,40-,41+/m1/s1
DMMXA5K CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](C5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMMXA5K IK MAYLVNQSAJCEEF-XGMLMNQMSA-N
DMMXA5K IU (4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-2-phenylacetyl]amino]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMMXA5K DE Discovery agent
DME5S3C ID DME5S3C
DME5S3C DN DPI-221
DME5S3C HS Investigative
DME5S3C CP Ardent Pharmaceuticals Inc
DME5S3C DE Urinary incontinence
DMTHZ3B ID DMTHZ3B
DMTHZ3B DN DPI59
DMTHZ3B HS Investigative
DMTHZ3B SN DPI59; HYDROXY(1-NAPHTHYL)METHYLPHOSPHONIC ACID; [(S)-hydroxy(naphthalen-1-yl)methyl]phosphonic acid; I59; 1o4g; AC1L9KXU
DMTHZ3B DT Small molecular drug
DMTHZ3B PC 447531
DMTHZ3B MW 238.18
DMTHZ3B FM C11H11O4P
DMTHZ3B IC InChI=1S/C11H11O4P/c12-11(16(13,14)15)10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11-12H,(H2,13,14,15)/t11-/m0/s1
DMTHZ3B CS C1=CC=C2C(=C1)C=CC=C2[C@@H](O)P(=O)(O)O
DMTHZ3B IK AXIBZLYWMBUYRV-NSHDSACASA-N
DMTHZ3B IU [(S)-hydroxy(naphthalen-1-yl)methyl]phosphonic acid
DMTHZ3B DE Discovery agent
DMSRUKQ ID DMSRUKQ
DMSRUKQ DN DPN-205-734
DMSRUKQ HS Investigative
DMSRUKQ SN 5-(4-Cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
DMSRUKQ DT Small molecular drug
DMSRUKQ PC 145915
DMSRUKQ MW 235.24
DMSRUKQ FM C14H9N3O
DMSRUKQ IC InChI=1S/C14H9N3O/c1-9-13(6-12(8-16)14(18)17-9)11-4-2-10(7-15)3-5-11/h2-6H,1H3,(H,17,18)
DMSRUKQ CS CC1=C(C=C(C(=O)N1)C#N)C2=CC=C(C=C2)C#N
DMSRUKQ IK NMIRAZSAZYNODX-UHFFFAOYSA-N
DMSRUKQ IU 5-(4-cyanophenyl)-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
DMSRUKQ CA CAS 88594-78-9
DMSRUKQ DE Cardiac disease
DMHCZP0 ID DMHCZP0
DMHCZP0 DN DPO-1
DMHCZP0 HS Investigative
DMHCZP0 SN IKur blockers (atrial arrythmia), Merck & Co; Kv1.5 voltage-gated potassium channel antagonists (atrial arrythmia); Kv1.5 voltage-gated potassium channel antagonists (atrial arrythmia), Merck & Co
DMHCZP0 CP Merck & Co Inc
DMHCZP0 DT Small molecular drug
DMHCZP0 PC 21678144
DMHCZP0 MW 340.4
DMHCZP0 FM C22H29OP
DMHCZP0 IC InChI=1S/C22H29OP/c1-17(2)21-15-14-18(3)16-22(21)24(23,19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,17-18,21-22H,14-16H2,1-3H3/t18-,21+,22+/m1/s1
DMHCZP0 CS C[C@@H]1CC[C@H]([C@H](C1)P(=O)(C2=CC=CC=C2)C3=CC=CC=C3)C(C)C
DMHCZP0 IK BPCNGVCAHAIZEE-COPCDDAFSA-N
DMHCZP0 IU [[(1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene
DMHCZP0 CA CAS 43077-30-1
DMHCZP0 CB CHEBI:93748
DMHCZP0 DE Atrial fibrillation
DMRJQ8X ID DMRJQ8X
DMRJQ8X DN D-Pro-Phe-Arg chloromethyl ketone
DMRJQ8X HS Investigative
DMRJQ8X SN H-D-Pro-Phe-Arg-chloromethylketone; 88546-74-1; CHEMBL521527; BDBM23569; CTK8G0139; DTXSID90440219; ZINC13507825; D-Pro-Phe-Arg chloromethyl ketone (PCK); (R)-N-((S)-1-((S)-1-chloro-6-guanidino-2-oxohexan-3-ylamino)-1-oxo-3-phenylpropan-2-yl)pyrrolidine-2-carboxamide
DMRJQ8X DT Small molecular drug
DMRJQ8X PC 10456438
DMRJQ8X MW 451
DMRJQ8X FM C21H31ClN6O3
DMRJQ8X IC InChI=1S/C21H31ClN6O3/c22-13-18(29)15(8-4-11-26-21(23)24)27-20(31)17(12-14-6-2-1-3-7-14)28-19(30)16-9-5-10-25-16/h1-3,6-7,15-17,25H,4-5,8-13H2,(H,27,31)(H,28,30)(H4,23,24,26)/t15-,16+,17-/m0/s1
DMRJQ8X CS C1C[C@@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)CCl
DMRJQ8X IK HCCRRLVJBLDSLL-BBWFWOEESA-N
DMRJQ8X IU (2R)-N-[(2S)-1-[[(3S)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMRJQ8X CA CAS 88546-74-1
DMRJQ8X DE Discovery agent
DM35CKE ID DM35CKE
DM35CKE DN DprwFwLL-NH2
DM35CKE HS Investigative
DM35CKE SN CHEMBL507636; DprwFwLL-NH2
DM35CKE PC 44576250
DM35CKE MW 1131.3
DM35CKE FM C58H78N14O10
DM35CKE IC InChI=1S/C58H78N14O10/c1-32(2)24-43(50(60)75)67-52(77)44(25-33(3)4)68-54(79)47(28-36-31-65-41-19-11-9-17-38(36)41)71-53(78)45(26-34-14-6-5-7-15-34)69-55(80)46(27-35-30-64-40-18-10-8-16-37(35)40)70-51(76)42(20-12-22-63-58(61)62)66-56(81)48-21-13-23-72(48)57(82)39(59)29-49(73)74/h5-11,14-19,30-33,39,42-48,64-65H,12-13,20-29,59H2,1-4H3,(H2,60,75)(H,66,81)(H,67,77)(H,68,79)(H,69,80)(H,70,76)(H,71,78)(H,73,74)(H4,61,62,63)/t39-,42+,43-,44-,45-,46+,47+,48+/m0/s1
DM35CKE CS CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H]6CCCN6C(=O)[C@H](CC(=O)O)N
DM35CKE IK CZJDWLOOIMAJCD-JXDKTPIUSA-N
DM35CKE IU (3S)-3-amino-4-[(2R)-2-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acid
DM35CKE DE Discovery agent
DMQLJ3Y ID DMQLJ3Y
DMQLJ3Y DN DQP-1105
DMQLJ3Y HS Investigative
DMQLJ3Y SN KB-272091
DMQLJ3Y DT Small molecular drug
DMQLJ3Y PC 76849261
DMQLJ3Y MW 558.4
DMQLJ3Y FM C29H24BrN3O4
DMQLJ3Y IC InChI=1S/C29H24BrN3O4/c1-17-7-12-22-21(15-17)27(19-5-3-2-4-6-19)28(29(37)31-22)23-16-24(18-8-10-20(30)11-9-18)33(32-23)25(34)13-14-26(35)36/h2-12,15,24,28H,13-14,16H2,1H3,(H,35,36)
DMQLJ3Y CS CC1=CC2=C(C(C(=O)N=C2C=C1)C3=NN(C(C3)C4=CC=C(C=C4)Br)C(=O)CCC(=O)O)C5=CC=CC=C5
DMQLJ3Y IK ACUGSRUCGXYFTL-UHFFFAOYSA-N
DMQLJ3Y IU 4-[3-(4-bromophenyl)-5-(6-methyl-2-oxo-4-phenyl-3H-quinolin-3-yl)-3,4-dihydropyrazol-2-yl]-4-oxobutanoic acid
DMQLJ3Y DE Discovery agent
DM1AV5R ID DM1AV5R
DM1AV5R DN DR2313
DM1AV5R HS Investigative
DM1AV5R DT Small molecular drug
DM1AV5R PC 135522417
DM1AV5R MW 182.25
DM1AV5R FM C8H10N2OS
DM1AV5R IC InChI=1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11)
DM1AV5R CS CC1=NC2=C(CSCC2)C(=O)N1
DM1AV5R IK HRYKZAKEAVZGJD-UHFFFAOYSA-N
DM1AV5R IU 2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one
DM1AV5R CA CAS 284028-90-6
DM1AV5R DE Stroke
DMW8ORN ID DMW8ORN
DMW8ORN DN DR-4004
DMW8ORN HS Investigative
DMW8ORN SN compound 7 [PMID 10052959]
DMW8ORN DT Small molecular drug
DMW8ORN PC 9843179
DMW8ORN MW 386.5
DMW8ORN FM C26H30N2O
DMW8ORN IC InChI=1S/C26H30N2O/c29-25-26(16-7-11-22-10-6-12-23(27-25)24(22)26)15-4-5-17-28-18-13-21(14-19-28)20-8-2-1-3-9-20/h1-3,6,8-10,12-13H,4-5,7,11,14-19H2,(H,27,29)
DMW8ORN CS C1CC2=C3C(=CC=C2)NC(=O)C3(C1)CCCCN4CCC(=CC4)C5=CC=CC=C5
DMW8ORN IK JBQOYPLKTTXLSQ-UHFFFAOYSA-N
DMW8ORN IU 2a-[4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1,3,4,5-tetrahydrobenzo[cd]indol-2-one
DMW8ORN CA CAS 201608-41-5
DMW8ORN DE Discovery agent
DMX2TZD ID DMX2TZD
DMX2TZD DN DR-5/DR-4 cross reactive mabs
DMX2TZD HS Investigative
DMX2TZD SN DR-5/DR-4 cross reactive mAbs (cancer); Death receptor-5/4 cross reactive mAbs (cancer), Crystal Bioscience; DR-5/DR-4 cross reactive mAbs (cancer), Crystal Bioscience
DMX2TZD CP Crystal Bioscience Inc
DMX2TZD DT Antibody
DMX2TZD DE Solid tumour/cancer
DMTFQG3 ID DMTFQG3
DMTFQG3 DN DRF 2519
DMTFQG3 HS Investigative
DMTFQG3 SN DRF 2519; 5-[[4-[2-(4-Oxo-2H-1,3-benzoxazin3(4H)-yl)ethoxy]phenyl]methyl2,4-thiazolidinedione; SCHEMBL6953746; GTPL2671; CHEMBL1491825; DTXSID5040754; NOCAS_40754; CTK8F9377; API0008459; NCGC00165785-01; NCGC00164420-01; SR-05000000444; SR-05000000444-2
DMTFQG3 DT Small molecular drug
DMTFQG3 PC 9908833
DMTFQG3 MW 398.4
DMTFQG3 FM C20H18N2O5S
DMTFQG3 IC InChI=1S/C20H18N2O5S/c23-18-17(28-20(25)21-18)11-13-5-7-14(8-6-13)26-10-9-22-12-27-16-4-2-1-3-15(16)19(22)24/h1-8,17H,9-12H2,(H,21,23,25)
DMTFQG3 CS C1N(C(=O)C2=CC=CC=C2O1)CCOC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
DMTFQG3 IK RFMNEXVCPAPDRA-UHFFFAOYSA-N
DMTFQG3 IU 5-[[4-[2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
DMTFQG3 DE Discovery agent
DMYOLEV ID DMYOLEV
DMYOLEV DN D-ribosylnicotinate
DMYOLEV HS Investigative
DMYOLEV SN D-ribosylnicotinate; Beta-D-ribosylnicotinate; Nicotinate ribonucleoside; Nicotinate ribose; Nicotinate riboside; Nicotinic Riboside; Nicotinic acid ribonucleoside; beta-D-Ribosylnicotinate; nicotinic acid ribose; nicotinic acid riboside; ribosylnicotinate; 1-(; 1-(beta-D-ribofuranosyl)pyridinium-3-carboxylate; 1-Pentofuranosylpyridin-1-ium-3-carboxylate; 17720-18-2; 3-Carboxy-1-; A-D-ribofuranosylpyridinium Inner Salt; A-d-ribofuranosyl)pyridinium-3-carboxylate; AC1L4P1J; AC1Q22CH; CHEBI:58527; DTXSID20938912; SCHEMBL20152239
DMYOLEV PC 161233
DMYOLEV MW 255.22
DMYOLEV FM C11H13NO6
DMYOLEV IC PUEDDPCUCPRQNY-ZYUZMQFOSA-N
DMYOLEV CS C1=CC(=C[N+](=C1)C2C(C(C(O2)CO)O)O)C(=O)[O-]
DMYOLEV IK 1S/C11H13NO6/c13-5-7-8(14)9(15)10(18-7)12-3-1-2-6(4-12)11(16)17/h1-4,7-10,13-15H,5H2/t7-,8-,9-,10-/m1/s1
DMYOLEV IU 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylate
DMYOLEV CA CAS 17720-18-2
DMYOLEV CB CHEBI:58527
DMYOLEV DE Discovery agent
DM5IA9W ID DM5IA9W
DM5IA9W DN droxinostat
DM5IA9W HS Investigative
DM5IA9W SN NS-41080; NS41080
DM5IA9W DT Small molecular drug
DM5IA9W PC 568416
DM5IA9W MW 243.68
DM5IA9W FM C11H14ClNO3
DM5IA9W IC InChI=1S/C11H14ClNO3/c1-8-7-9(12)4-5-10(8)16-6-2-3-11(14)13-15/h4-5,7,15H,2-3,6H2,1H3,(H,13,14)
DM5IA9W CS CC1=C(C=CC(=C1)Cl)OCCCC(=O)NO
DM5IA9W IK JHSXDAWGLCZYSM-UHFFFAOYSA-N
DM5IA9W IU 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide
DM5IA9W CA CAS 99873-43-5
DM5IA9W CB CHEBI:94504
DM5IA9W DE Discovery agent
DMBUH02 ID DMBUH02
DMBUH02 DN DRP-049
DMBUH02 HS Investigative
DMBUH02 SN TGF-beta inhibitor (fibrosis), Sosei Group
DMBUH02 CP Sosei Group Corp
DMBUH02 DE Fibrosis
DM5QUJV ID DM5QUJV
DM5QUJV DN Drug 311383
DM5QUJV HS Investigative
DM5QUJV SN 311383
DM5QUJV DE Discovery agent
DMOIFBK ID DMOIFBK
DMOIFBK DN Drug 311440
DMOIFBK HS Investigative
DMOIFBK SN 311440
DMOIFBK DE Discovery agent
DMXTCJ1 ID DMXTCJ1
DMXTCJ1 DN Drug 311951
DMXTCJ1 HS Investigative
DMXTCJ1 SN 311951
DMXTCJ1 DE Discovery agent
DM27ILS ID DM27ILS
DM27ILS DN Drug 311952
DM27ILS HS Investigative
DM27ILS SN 311952
DM27ILS DE Discovery agent
DML4V73 ID DML4V73
DML4V73 DN Drug 7684380
DML4V73 HS Investigative
DML4V73 SN 7684380
DML4V73 DE Discovery agent
DME3WBQ ID DME3WBQ
DME3WBQ DN DS-437
DME3WBQ HS Investigative
DME3WBQ SN DS437
DME3WBQ DT Small molecular drug
DME3WBQ PC 91827358
DME3WBQ MW 397.5
DME3WBQ FM C15H23N7O4S
DME3WBQ IC InChI=1S/C15H23N7O4S/c1-2-17-15(25)18-3-4-27-5-8-10(23)11(24)14(26-8)22-7-21-9-12(16)19-6-20-13(9)22/h6-8,10-11,14,23-24H,2-5H2,1H3,(H2,16,19,20)(H2,17,18,25)/t8-,10+,11-,14?/m1/s1
DME3WBQ CS CCNC(=O)NCCSC[C@@H]1[C@@H]([C@H](C(O1)N2C=NC3=C(N=CN=C32)N)O)O
DME3WBQ IK CACMCLIHCDTJHL-XLAISSFRSA-N
DME3WBQ IU 1-[2-[[(2S,3R,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]ethyl]-3-ethylurea
DME3WBQ DE Discovery agent
DMZGWQA ID DMZGWQA
DMZGWQA DN DS-AH-14
DMZGWQA HS Investigative
DMZGWQA CP Boehringer Ingelheim Corp
DMZGWQA PC 19801656
DMZGWQA MW 363.4
DMZGWQA FM C20H21N5O2
DMZGWQA IC InChI=1S/C20H21N5O2/c1-23-11-8-17-16(23)9-12-24(17)20(27)25-15-7-3-2-5-13(15)19(26)22-14-6-4-10-21-18(14)25/h2-7,10,16-17H,8-9,11-12H2,1H3,(H,22,26)
DMZGWQA CS CN1CCC2C1CCN2C(=O)N3C4=CC=CC=C4C(=O)NC5=C3N=CC=C5
DMZGWQA IK QBUPWEMXZYDTRC-UHFFFAOYSA-N
DMZGWQA IU 11-(1-methyl-2,3,3a,5,6,6a-hexahydropyrrolo[3,2-b]pyrrole-4-carbonyl)-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
DMZGWQA DE Asthma
DMSTOB0 ID DMSTOB0
DMSTOB0 DN DSLET
DMSTOB0 HS Investigative
DMSTOB0 SN DSTLE; Dislet; [D-Ser2, Leu5, Thr6]-enkephalin
DMSTOB0 DT Small molecular drug
DMSTOB0 PC 107847
DMSTOB0 MW 686.8
DMSTOB0 FM C33H46N6O10
DMSTOB0 IC InChI=1S/C33H46N6O10/c1-18(2)13-24(32(47)39-28(19(3)41)33(48)49)37-31(46)25(15-20-7-5-4-6-8-20)36-27(43)16-35-30(45)26(17-40)38-29(44)23(34)14-21-9-11-22(42)12-10-21/h4-12,18-19,23-26,28,40-42H,13-17,34H2,1-3H3,(H,35,45)(H,36,43)(H,37,46)(H,38,44)(H,39,47)(H,48,49)/t19-,23+,24+,25+,26-,28+/m1/s1
DMSTOB0 CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O
DMSTOB0 IK PKSODCLCMBUCPW-LVNBQDLPSA-N
DMSTOB0 IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMSTOB0 CA CAS 75644-90-5
DMSTOB0 DE Discovery agent
DM1LK0C ID DM1LK0C
DM1LK0C DN DSM1
DM1LK0C HS Investigative
DM1LK0C DE Malaria
DMZYQOB ID DMZYQOB
DMZYQOB DN DSM2
DMZYQOB HS Investigative
DMZYQOB DE Malaria
DM4EKHR ID DM4EKHR
DM4EKHR DN DSR-17759
DM4EKHR HS Investigative
DM4EKHR SN Glucagon receptor antagonist (type 2 diabetes), Dainippon Sumitomo
DM4EKHR CP Dainippon Sumitomo Pharma Co Ltd
DM4EKHR DE Non-insulin dependent diabetes
DMSVP1K ID DMSVP1K
DMSVP1K DN DSTBULET
DMSVP1K HS Investigative
DMSVP1K SN Dstbulet; CHEMBL298972; Tyrosyl-seryl(O-tert-butyl)-glycyl-phenylalanyl-leucyl-threonine; 111035-56-4; (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2-methylpropan-2-yl)oxy]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid; Tyr-ser(O-tert-Bu)-gly-phe-leu-thr; AC1L2XS7; (Ser(2)(O-t-butyl)-leu(5))enkephalyl-thr(6); Leu(5) enkephalin, ser(2)(O-tert-butyl)-thr(6); GTPL3873; DTXSID40149447
DMSVP1K DT Small molecular drug
DMSVP1K PC 130662
DMSVP1K MW 742.9
DMSVP1K FM C37H54N6O10
DMSVP1K IC InChI=1S/C37H54N6O10/c1-21(2)16-27(35(50)43-31(22(3)44)36(51)52)41-34(49)28(18-23-10-8-7-9-11-23)40-30(46)19-39-33(48)29(20-53-37(4,5)6)42-32(47)26(38)17-24-12-14-25(45)15-13-24/h7-15,21-22,26-29,31,44-45H,16-20,38H2,1-6H3,(H,39,48)(H,40,46)(H,41,49)(H,42,47)(H,43,50)(H,51,52)/t22-,26+,27+,28+,29-,31+/m1/s1
DMSVP1K CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O
DMSVP1K IK DOMQMNWQZKXZCU-GUVNKXFDSA-N
DMSVP1K IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2-methylpropan-2-yl)oxy]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMSVP1K CA CAS 111035-56-4
DMSVP1K DE Discovery agent
DMCKQF7 ID DMCKQF7
DMCKQF7 DN DT-2228
DMCKQF7 HS Investigative
DMCKQF7 SN MGluR2 NAMs (Alzheimer's disease/depression), DomainTherapeutics; Metabotropic glutamate receptor 2 modulators (Alzheimer's disease/depression), DomainTherapeutics
DMCKQF7 CP Domain Therapeutics SA
DMCKQF7 DE Major depressive disorder
DM3TMUK ID DM3TMUK
DM3TMUK DN DT-831j
DM3TMUK HS Investigative
DM3TMUK SN Factor Xa antagonists, Daiichi Sankyo
DM3TMUK CP Daiichi Sankyo Co Ltd
DM3TMUK DE Thrombosis
DM376J2 ID DM376J2
DM376J2 DN D-tartaric acid
DM376J2 HS Investigative
DM376J2 SN d-Tartaric acid; 147-71-7; D-(-)-Tartaric acid; (2S,3S)-2,3-Dihydroxysuccinic acid; D(-)-TARTARIC ACID; (2S,3S)-2,3-dihydroxybutanedioic acid; D-threaric acid; (-)-D-Tartaric acid; (-)-Tartaric acid; (2S,3S)-(-)-Tartaric acid; (S,S)-Tartaric acid; (-)-(S,S)-Tartaric acid; (S,S)-(-)-Tartaric acid; UNII-RRX6A4PL3C; Butanedioic acid, 2,3-dihydroxy-, (2S,3S)-; D-(-)-tartaricacid; (2S,3S)-Tartaric acid; RRX6A4PL3C; CHEBI:15672; MFCD00004238; D-Tartrate; (S,S)-Tartrate; D(-)-Tartaric acid, 99%; levo-Tartaric acid
DM376J2 DT Small molecular drug
DM376J2 PC 439655
DM376J2 MW 150.09
DM376J2 FM C4H6O6
DM376J2 IC InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m0/s1
DM376J2 CS [C@H]([C@@H](C(=O)O)O)(C(=O)O)O
DM376J2 IK FEWJPZIEWOKRBE-LWMBPPNESA-N
DM376J2 IU (2S,3S)-2,3-dihydroxybutanedioic acid
DM376J2 CA CAS 133-37-9
DM376J2 CB CHEBI:15672
DM376J2 DE Discovery agent
DMPKTB4 ID DMPKTB4
DMPKTB4 DN DTD
DMPKTB4 HS Investigative
DMPKTB4 SN DITHIANE DIOL; trans-1,2-Dithiane-4,5-diol; Oxidized dithiothreitol; (4R,5R)-1,2-dithiane-4,5-diol; D-4,5-Dihydroxy-1,2-dithiane; 16096-98-3; NSC 667089; trans-4,5-Dihydroxy-1,2-dithiane; o-DITHIANE, 4,5-DIHYDROXY-, D-; 14193-38-5; 51621-02-4; DTD; 1qtn; 2izx; AC1L97AN; trans-O-Dithiane-4,5-diol; Threo-O-dithiane-4,5-diol; SCHEMBL1628862; (4R,5R)-dithiane-4,5-diol; YPGMOWHXEQDBBV-IMJSIDKUSA-; CHEBI:42147; 1,2-Dithiane-4alpha,5beta-diol; YPGMOWHXEQDBBV-IMJSIDKUSA-N; 1,2-Dithiane-4,5-diol, trans-; ZINC4095547; AKOS022180307; DB01822
DMPKTB4 DT Small molecular drug
DMPKTB4 PC 439407
DMPKTB4 MW 152.2
DMPKTB4 FM C4H8O2S2
DMPKTB4 IC InChI=1S/C4H8O2S2/c5-3-1-7-8-2-4(3)6/h3-6H,1-2H2/t3-,4-/m0/s1
DMPKTB4 CS C1[C@@H]([C@H](CSS1)O)O
DMPKTB4 IK YPGMOWHXEQDBBV-IMJSIDKUSA-N
DMPKTB4 IU (4R,5R)-dithiane-4,5-diol
DMPKTB4 CA CAS 16096-98-3
DMPKTB4 CB CHEBI:42147
DMPKTB4 DE Discovery agent
DMNS265 ID DMNS265
DMNS265 DN DTPA Conjugate
DMNS265 HS Investigative
DMNS265 SN CHEMBL415548; DTPA Conjugate
DMNS265 PC 44403823
DMNS265 MW 3127.4
DMNS265 FM C123H180N26O53S8
DMNS265 IC InChI=1S/C123H180N26O53S8/c1-122(2,41-19-23-57-201-105-69-88(84-29-9-5-10-30-84)67-91(130-105)86-33-13-7-14-34-86)120-139-141-143-148(120)47-21-17-37-101(150)124-43-25-53-195-59-63-199-65-61-197-55-27-45-126-111(162)93(76-203(171,172)173)132-115(166)97(80-207(183,184)185)136-118(169)99(82-209(189,190)191)135-114(165)95(78-205(177,178)179)129-103(152)40-39-90(128-104(153)71-146(73-108(156)157)51-49-145(72-107(154)155)50-52-147(74-109(158)159)75-110(160)161)113(164)134-96(79-206(180,181)182)117(168)138-100(83-210(192,193)194)119(170)137-98(81-208(186,187)188)116(167)133-94(77-204(174,175)176)112(163)127-46-28-56-198-62-66-200-64-60-196-54-26-44-125-102(151)38-18-22-48-149-121(140-142-144-149)123(3,4)42-20-24-58-202-106-70-89(85-31-11-6-12-32-85)68-92(131-106)87-35-15-8-16-36-87/h5-16,29-36,67-70,90,93-100H,17-28,37-66,71-83H2,1-4H3,(H,124,150)(H,125,151)(H,126,162)(H,127,163)(H,128,153)(H,129,152)(H,132,166)(H,133,167)(H,134,164)(H,135,165)(H,136,169)(H,137,170)(H,138,168)(H,154,155)(H,156,157)(H,158,159)(H,160,161)(H,171,172,173)(H,174,175,176)(H,177,178,179)(H,180,181,182)(H,183,184,185)(H,186,187,188)(H,189,190,191)(H,192,193,194)/t90-,93-,94-,95-,96-,97-,98-,99-,100-/m0/s1
DMNS265 CS CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CC[C@@H](C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN5C(=NN=N5)C(C)(C)CCCCOC6=CC(=CC(=N6)C7=CC=CC=C7)C8=CC=CC=C8)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O
DMNS265 IK DIGMLMRBDDSXMD-MSOXLDFBSA-N
DMNS265 IU 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[[2-[[(2S)-1,5-bis[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylamino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1-oxo-3-sulfopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]-(carboxymethyl)amino]ethyl]amino]acetic acid
DMNS265 DE Discovery agent
DM1JL5W ID DM1JL5W
DM1JL5W DN D-Trp8-SRIF-14
DM1JL5W HS Investigative
DM1JL5W PC 44400604
DM1JL5W MW 1637.9
DM1JL5W FM C76H104N18O19S2
DM1JL5W IC InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42?,43?,50-,51+,52-,53+,54-,55-,56+,57-,58-,59-,62+,63+/m0/s1
DM1JL5W CS C[C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCCCN)CC(=O)N)CC2=CC=CC=C2)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CCCCN)C(C)O)CC6=CC=CC=C6)C(C)O)CO)C(=O)O)N
DM1JL5W IK NHXLMOGPVYXJNR-VOWFNQDTSA-N
DM1JL5W IU (4R,7S,10R,13S,16R,19R,22S,25R,28S,31R,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis(1-hydroxyethyl)-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
DM1JL5W DE Discovery agent
DMKIML1 ID DMKIML1
DMKIML1 DN D-tryptophan
DMKIML1 HS Investigative
DMKIML1 SN D-Tryptophan; 153-94-6; H-D-Trp-OH; D(+)-Tryptophan; (R)-Tryptophan; D-TRYPTOPHANE; (2R)-2-amino-3-(1H-indol-3-yl)propanoic acid; D-Trytophane; H-D-Typ-OH; Tryptophan, D-; D-Trp; UNII-7NS97N9H1G; D-(+)-Tryptophan; (R)-2-Amino-3-(3-indolyl)propionic acid; EINECS 205-819-9; NSC 97942; (R)-(+)-2-Amino-3-(3-indolyl)propionic Acid; 7NS97N9H1G; CHEMBL292303; DTR; CHEBI:16296; QIVBCDIJIAJPQS-SECBINFHSA-N; MFCD00005647; D-alpha-Amino-3-indolepropionic acid; NCGC00093372-02; DSSTox_RID_82038; DSSTox_CID_26989; D(+)-Tryptophan,
DMKIML1 DT Small molecular drug
DMKIML1 PC 9060
DMKIML1 MW 204.22
DMKIML1 FM C11H12N2O2
DMKIML1 IC InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m1/s1
DMKIML1 CS C1=CC=C2C(=C1)C(=CN2)C[C@H](C(=O)O)N
DMKIML1 IK QIVBCDIJIAJPQS-SECBINFHSA-N
DMKIML1 IU (2R)-2-amino-3-(1H-indol-3-yl)propanoic acid
DMKIML1 CA CAS 153-94-6
DMKIML1 CB CHEBI:16296
DMKIML1 DE Discovery agent
DM7PNOK ID DM7PNOK
DM7PNOK DN DTS-108
DM7PNOK HS Investigative
DM7PNOK SN SN-38 prodrug (cancer), Diatos
DM7PNOK CP Diatos SA
DM7PNOK DE Solid tumour/cancer
DMUKPO3 ID DMUKPO3
DMUKPO3 DN Duo3
DMUKPO3 HS Investigative
DMUKPO3 SN DUO3
DMUKPO3 DT Small molecular drug
DMUKPO3 PC 86277833
DMUKPO3 MW 604.3
DMUKPO3 FM C29H26Cl4N4O2+2
DMUKPO3 IC InChI=1S/C29H26Cl4N4O2/c30-26-4-1-5-27(31)24(26)20-38-34-18-22-8-14-36(15-9-22)12-3-13-37-16-10-23(11-17-37)19-35-39-21-25-28(32)6-2-7-29(25)33/h1-2,4-11,14-19H,3,12-13,20-21H2/q+2/b34-18-,35-19-
DMUKPO3 CS C1=CC(=C(C(=C1)Cl)CO/N=C\\C2=CC=[N+](C=C2)CCC[N+]3=CC=C(C=C3)/C=N\\OCC4=C(C=CC=C4Cl)Cl)Cl
DMUKPO3 IK RAHLDBGBLYIYDN-OQWDZDEYSA-N
DMUKPO3 IU (Z)-N-[(2,6-dichlorophenyl)methoxy]-1-[1-[3-[4-[(Z)-(2,6-dichlorophenyl)methoxyiminomethyl]pyridin-1-ium-1-yl]propyl]pyridin-1-ium-4-yl]methanimine
DMUKPO3 DE Discovery agent
DM0CQIP ID DM0CQIP
DM0CQIP DN Duocarmycin
DM0CQIP HS Investigative
DM0CQIP SN AC1L1FCB; CTK7A0066; methyl 4-hydroxy-2,8-dimethyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-1,2,3,6,7,8-hexahydropyrrolo[3,2-e]indole-2-carboxylate; methyl 4-hydroxy-2,8-dimethyl-1-oxo-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-2-carboxylate
DM0CQIP DT Small molecular drug
DM0CQIP PC 3175
DM0CQIP MW 509.5
DM0CQIP FM C26H27N3O8
DM0CQIP IC InChI=1S/C26H27N3O8/c1-11-10-29(14-9-15(30)20-18(17(11)14)23(31)26(2,28-20)25(33)37-6)24(32)13-7-12-8-16(34-3)21(35-4)22(36-5)19(12)27-13/h7-9,11,27-28,30H,10H2,1-6H3
DM0CQIP CS CC1CN(C2=CC(=C3C(=C12)C(=O)C(N3)(C)C(=O)OC)O)C(=O)C4=CC5=CC(=C(C(=C5N4)OC)OC)OC
DM0CQIP IK WQAYQZWERWNDPV-UHFFFAOYSA-N
DM0CQIP IU methyl 4-hydroxy-2,8-dimethyl-1-oxo-6-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-7,8-dihydro-3H-pyrrolo[3,2-e]indole-2-carboxylate
DM0CQIP DE Discovery agent
DM29PTO ID DM29PTO
DM29PTO DN Durhamycin A
DM29PTO HS Investigative
DM29PTO SN AC1LCSNY
DM29PTO DT Small molecular drug
DM29PTO PC 6478419
DM29PTO MW 1285.4
DM29PTO FM C62H92O28
DM29PTO IC InChI=1S/C62H92O28/c1-12-22(2)47-36(85-43-18-37(53(70)26(6)80-43)86-41-16-34(65)51(68)24(4)78-41)15-32-13-31-14-33(61(77-11)59(76)50(67)23(3)63)62(58(75)49(31)57(74)48(32)56(47)73)90-46-20-39(55(72)28(8)82-46)88-45-21-40(60(29(9)83-45)84-30(10)64)89-44-19-38(54(71)27(7)81-44)87-42-17-35(66)52(69)25(5)79-42/h13,15,22-29,33-35,37-46,50-55,60-63,65-74H,12,14,16-21H2,1-11H3/t22?,23?,24-,25-,26-,27-,28-,29-,33?,34-,35-,37-,38-,39-,40-,41+,42+,43+,44+,45+,46+,50?,51-,52-,53-,54-,55-,60+,61?,62?/m1/s1
DM29PTO CS CCC(C)C1=C(C2=C(C3=C(CC(C(C3=O)O[C@H]4C[C@H]([C@@H]([C@H](O4)C)O)O[C@H]5C[C@H]([C@H]([C@H](O5)C)OC(=O)C)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7C[C@H]([C@@H]([C@H](O7)C)O)O)C(C(=O)C(C(C)O)O)OC)C=C2C=C1O[C@H]8C[C@H]([C@@H]([C@H](O8)C)O)O[C@H]9C[C@H]([C@@H]([C@H](O9)C)O)O)O)O
DM29PTO IK GKQPKEYSNFSHDQ-XQGPSDOPSA-N
DM29PTO IU [(2R,3S,4R,6S)-6-[(2R,3R,4R,6S)-6-[[7-butan-2-yl-3-(3,4-dihydroxy-1-methoxy-2-oxopentyl)-6-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-1-oxo-3,4-dihydro-2H-anthracen-2-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]oxy-4-[(2S,4R,5R,6R)-4-[(2S,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate
DM29PTO DE Discovery agent
DML7YPS ID DML7YPS
DML7YPS DN Duroquinone
DML7YPS HS Investigative
DML7YPS SN Duroquinone; 527-17-3; Tetramethyl-1,4-benzoquinone; Tetramethyl-p-benzoquinone; Tetramethylquinone; 2,3,5,6-Tetramethyl-1,4-benzoquinone; 2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione; Tetramethyl-p-quinone; 2,3,5,6-Tetramethylbenzoquinone; p-Benzoquinone, tetramethyl-; p-Benzoquinone, 2,3,5,6-tetramethyl-; 2,3,5,6-Tetramethyl-p-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetramethyl-; NSC 2068; CCRIS 2989; p-Benzoquinone, tetramethyl-, semiquinone; UNII-X0Q8791R69; EINECS 208-409-8
DML7YPS DT Small molecular drug
DML7YPS PC 68238
DML7YPS MW 164.2
DML7YPS FM C10H12O2
DML7YPS IC InChI=1S/C10H12O2/c1-5-6(2)10(12)8(4)7(3)9(5)11/h1-4H3
DML7YPS CS CC1=C(C(=O)C(=C(C1=O)C)C)C
DML7YPS IK WAMKWBHYPYBEJY-UHFFFAOYSA-N
DML7YPS IU 2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione
DML7YPS CA CAS 527-17-3
DML7YPS CB CHEBI:42023
DML7YPS DE Discovery agent
DML4G6K ID DML4G6K
DML4G6K DN D-Val-L-boroPro
DML4G6K HS Investigative
DML4G6K DT Small molecular drug
DML4G6K PC 44422921
DML4G6K MW 215.08
DML4G6K FM C9H20BN2O3+
DML4G6K IC InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/p+1/t7-,8+/m0/s1
DML4G6K CS B([C@@H]1CCCN1C(=O)[C@@H](C(C)C)[NH3+])(O)O
DML4G6K IK FKCMADOPPWWGNZ-JGVFFNPUSA-O
DML4G6K IU [(2R)-1-[(2R)-2-boronopyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]azanium
DML4G6K DE Discovery agent
DM53079 ID DM53079
DM53079 DN DVDAVP
DM53079 HS Investigative
DM53079 SN 1-Deamino-4-val-8-arg-vasopressin; Vasopressin, 1-deamino-4-val-8-arg-; 1-Deamino-4-valyl-8-arginine vasopressin; Vasopressin, 1-deamino-4-valyl-8-arginine-; (1-Deamino,4-valine)-8-D-argininevasopressin; 51980-16-6; Vasopressin 1-(3-mercaptopropanoic acid)-4-L-valine-8-L-arginine-
DM53079 DT Small molecular drug
DM53079 PC 44419026
DM53079 MW 1040.2
DM53079 FM C46H65N13O11S2
DM53079 IC InChI=1S/C46H65N13O11S2/c1-25(2)38-44(69)56-32(22-35(47)61)41(66)57-33(45(70)59-18-7-11-34(59)43(68)54-29(10-6-17-51-46(49)50)39(64)52-23-36(48)62)24-72-71-19-16-37(63)53-30(21-27-12-14-28(60)15-13-27)40(65)55-31(42(67)58-38)20-26-8-4-3-5-9-26/h3-5,8-9,12-15,25,29-34,38,60H,6-7,10-11,16-24H2,1-2H3,(H2,47,61)(H2,48,62)(H,52,64)(H,53,63)(H,54,68)(H,55,65)(H,56,69)(H,57,66)(H,58,67)(H4,49,50,51)/t29-,30+,31+,32+,33+,34+,38+/m1/s1
DM53079 CS CC(C)[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N
DM53079 IK KEBRFHAVFOSSOX-WSFLLCRESA-N
DM53079 IU (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
DM53079 CA CAS 43157-23-9
DM53079 DE Discovery agent
DMWF9GQ ID DMWF9GQ
DMWF9GQ DN DVD-Ig
DMWF9GQ HS Investigative
DMWF9GQ SN DVD-Ig (arthritis); DVD-Ig (arthritis), Abbott; Dual anti-CD20/CD3 immunoglobulin, Abbott; Dual anti-TNF/PGE2 innunoglobulin, Abbott; Dual anti-IL-1 alpha/beta immunoglobulin (arthritis), Abbott; Dual anti-IL-12/IL-18 immunoglobulin, Abbott; 1D4.1-2.5; 1D4.1-ABT325
DMWF9GQ CP Abbott Laboratories
DMWF9GQ DE Solid tumour/cancer
DMEUVIP ID DMEUVIP
DMEUVIP DN DwFwLL-NH2
DMEUVIP HS Investigative
DMEUVIP SN CHEMBL449590; DwFwLL-NH2
DMEUVIP DT Small molecular drug
DMEUVIP PC 44576251
DMEUVIP MW 878
DMEUVIP FM C47H59N9O8
DMEUVIP IC InChI=1S/C47H59N9O8/c1-26(2)18-36(42(49)59)52-44(61)37(19-27(3)4)54-47(64)40(22-30-25-51-35-17-11-9-15-32(30)35)56-45(62)38(20-28-12-6-5-7-13-28)55-46(63)39(53-43(60)33(48)23-41(57)58)21-29-24-50-34-16-10-8-14-31(29)34/h5-17,24-27,33,36-40,50-51H,18-23,48H2,1-4H3,(H2,49,59)(H,52,61)(H,53,60)(H,54,64)(H,55,63)(H,56,62)(H,57,58)/t33-,36-,37-,38-,39+,40+/m0/s1
DMEUVIP CS CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC(=O)O)N
DMEUVIP IK AYYVHEGPWNZVTO-YAQHVWCZSA-N
DMEUVIP IU (3S)-3-amino-4-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMEUVIP DE Discovery agent
DMW9GT7 ID DMW9GT7
DMW9GT7 DN DwLIP-GCGRrx
DMW9GT7 HS Investigative
DMW9GT7 SN UNII-T450D0Q71D; 1-Nitro-9-(3-dimethylaminopropylamino)-acridine dihydrochloride; 6514-85-8; Nitracrine HCl; ACRIDINE, 9-((3-(DIMETHYLAMINO)PROPYL)AMINO)-1-NITRO-, DIHYDROCHLORIDE; T450D0Q71D; 1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)-, dihydrochloride; CCRIS 9297; AC1L2LHF; SCHEMBL1652148; LS-14357; 1-NITRO-9-(DIMETHYLAMINOPROPYLAMINO)ACRIDINE DIHYDROCHLORIDE; dimethyl-[3-[(1-nitroacridin-9-yl)azaniumyl]propyl]azanium dichloride
DMW9GT7 CP ISIS
DMW9GT7 DT Small molecular drug
DMW9GT7 PC 23015
DMW9GT7 MW 397.3
DMW9GT7 FM C18H22Cl2N4O2
DMW9GT7 IC InChI=1S/C18H20N4O2.2ClH/c1-21(2)12-6-11-19-18-13-7-3-4-8-14(13)20-15-9-5-10-16(17(15)18)22(23)24;;/h3-5,7-10H,6,11-12H2,1-2H3,(H,19,20);2*1H
DMW9GT7 CS C[NH+](C)CCC[NH2+]C1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-].[Cl-].[Cl-]
DMW9GT7 IK XBHIADYHFGJGSK-UHFFFAOYSA-N
DMW9GT7 IU dimethyl-[3-[(1-nitroacridin-9-yl)azaniumyl]propyl]azanium;dichloride
DMW9GT7 CA CAS 6514-85-8
DMW9GT7 DE Diabetic complication
DMF9M06 ID DMF9M06
DMF9M06 DN DX-2400
DMF9M06 HS Investigative
DMF9M06 SN DX-2410; MMP inhibitors (fully human antibodies), Dyax
DMF9M06 CP Dyax Corp
DMF9M06 DE Solid tumour/cancer
DM3BWTM ID DM3BWTM
DM3BWTM DN DX-2500
DM3BWTM HS Investigative
DM3BWTM SN Anti-FcRn antibody (autoimmune disorder), Dyax Corp
DM3BWTM CP Dyax Corp
DM3BWTM DT Antibody
DM3BWTM DE Ischemic heart disease
DMZWAQ3 ID DMZWAQ3
DMZWAQ3 DN DXL-625
DMZWAQ3 HS Investigative
DMZWAQ3 SN DXLr-120; Anti-CD20 monoclonal antibodies (DXL, cancer), InNexus; Autophilic peptide conjuagted rituximab (rheumatoid arthritis/NHL/CLL), InNexus; Anti-CD20 monoclonal antibodies (DXL, non-Hodgkin's lymphoma/ rheumatoid arthritis), InNexus
DMZWAQ3 CP InNexus Biotechnology Inc
DMZWAQ3 DE Chronic lymphocytic leukaemia
DM1ROU7 ID DM1ROU7
DM1ROU7 DN D-xylulose
DM1ROU7 HS Investigative
DM1ROU7 SN D-threo-2-Pentulose; D-threo-pent-2-ulose; D-xylulose; HY-W010256; Lyxulose; Threo-2-pentulose (9CI); Threo-2-pentulose(9ci); Threo-2-pentulose, D-; Xylulose D-isomer [MI]; Xylulose, D-; YSC9WAF8X1; ZAQJHHRNXZUBTE-WUJLRWPWSA-N; ZINC100028356; threo-2-Pentulose; xylulose; (3S,4R)-1,3,4,5-tetrahydroxypentan-2-one; 551-84-8; 5962-29-8; AC1NRDJS; AKOS027320628; CHEBI:17140; CHEMBL195094; CS-W010972; CTK5A3156; D-Xul; DTXSID70415364; FCH4007851; FT-0625634; SCHEMBL37387; UNII-YSC9WAF8X1; XUL
DM1ROU7 PC 5289590
DM1ROU7 MW 150.13
DM1ROU7 FM C5H10O5
DM1ROU7 IC ZAQJHHRNXZUBTE-WUJLRWPWSA-N
DM1ROU7 CS C(C(C(C(=O)CO)O)O)O
DM1ROU7 IK 1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h3,5-8,10H,1-2H2/t3-,5+/m1/s1
DM1ROU7 IU (3S,4R)-1,3,4,5-tetrahydroxypentan-2-one
DM1ROU7 CA CAS 551-84-8
DM1ROU7 CB CHEBI:17140
DM1ROU7 DE Discovery agent
DMFJ3VC ID DMFJ3VC
DMFJ3VC DN DY131
DMFJ3VC HS Investigative
DMFJ3VC SN DY-131; GSK9089
DMFJ3VC DT Small molecular drug
DMFJ3VC PC 5497124
DMFJ3VC MW 311.4
DMFJ3VC FM C18H21N3O2
DMFJ3VC IC InChI=1S/C18H21N3O2/c1-3-21(4-2)16-9-5-14(6-10-16)13-19-20-18(23)15-7-11-17(22)12-8-15/h5-13,22H,3-4H2,1-2H3,(H,20,23)/b19-13+
DMFJ3VC CS CCN(CC)C1=CC=C(C=C1)/C=N/NC(=O)C2=CC=C(C=C2)O
DMFJ3VC IK WLKOCYWYAWBGKY-CPNJWEJPSA-N
DMFJ3VC IU N-[(E)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide
DMFJ3VC CA CAS 95167-41-2
DMFJ3VC CB CHEBI:93087
DMFJ3VC DE Discovery agent
DMSPVLM ID DMSPVLM
DMSPVLM DN dynorphin B
DMSPVLM HS Investigative
DMSPVLM SN rimorphin
DMSPVLM DT Small molecular drug
DMSPVLM PC 25075991
DMSPVLM MW 1570.8
DMSPVLM FM C74H115N21O17
DMSPVLM IC InChI=1S/C74H115N21O17/c1-40(2)34-53(91-68(107)54(36-44-18-10-8-11-19-44)86-58(100)39-84-57(99)38-85-62(101)48(76)35-46-25-27-47(97)28-26-46)67(106)89-51(24-17-33-83-74(80)81)63(102)87-50(23-16-32-82-73(78)79)64(103)90-52(29-30-56(77)98)65(104)92-55(37-45-20-12-9-13-21-45)69(108)88-49(22-14-15-31-75)66(105)93-59(41(3)4)70(109)94-60(42(5)6)71(110)95-61(43(7)96)72(111)112/h8-13,18-21,25-28,40-43,48-55,59-61,96-97H,14-17,22-24,29-39,75-76H2,1-7H3,(H2,77,98)(H,84,99)(H,85,101)(H,86,100)(H,87,102)(H,88,108)(H,89,106)(H,90,103)(H,91,107)(H,92,104)(H,93,105)(H,94,109)(H,95,110)(H,111,112)(H4,78,79,82)(H4,80,81,83)/t43-,48+,49+,50+,51+,52+,53+,54+,55+,59+,60+,61+/m1/s1
DMSPVLM CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N)O
DMSPVLM IK AGTSSZRZBSNTGQ-ITZCFHCWSA-N
DMSPVLM IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoic acid
DMSPVLM CA CAS 83335-41-5
DMSPVLM DE Discovery agent
DMM92LG ID DMM92LG
DMM92LG DN Dynorphin(1-8)
DMM92LG HS Investigative
DMM92LG DT Small molecular drug
DMM92LG PC 44273338
DMM92LG DE Discovery agent
DMIZQTX ID DMIZQTX
DMIZQTX DN DYSIDENIN
DMIZQTX HS Investigative
DMIZQTX SN Isodysidenin; Dysidenine; Isodysidenine; (+)-Isodysidenin; 67528-34-1; 65647-65-6; AC1L2TGX; AC1Q5L6U; 5,5,5-trichloro-n2-methyl-n-[1-(1,3-thiazol-2-yl)ethyl]-n2-(4,4,4-trichloro-3-methylbutanoyl)leucinamide; A836069; 5,5,5-trichloro-4-methyl-2-[methyl-(4,4,4-trichloro-3-methylbutanoyl)amino]-N-[1-(1,3-thiazol-2-yl)ethyl]pentanamide; 5,5,5-trichloro-4-methyl-2-[methyl-(4,4,4-trichloro-3-methyl-1-oxobutyl)amino]-N-[1-(2-thiazolyl)ethyl]pentanamide; Pentanamide, 5,5,5-trichloro-4-methyl-2-(methyl(4,4,4-trichloro-3-methyl
DMIZQTX DT Small molecular drug
DMIZQTX PC 10007601
DMIZQTX MW 546.2
DMIZQTX FM C17H23Cl6N3O2S
DMIZQTX IC InChI=1S/C17H23Cl6N3O2S/c1-9(16(18,19)20)7-12(14(28)25-11(3)15-24-5-6-29-15)26(4)13(27)8-10(2)17(21,22)23/h5-6,9-12H,7-8H2,1-4H3,(H,25,28)/t9-,10-,11-,12-/m0/s1
DMIZQTX CS C[C@@H](C[C@@H](C(=O)N[C@@H](C)C1=NC=CS1)N(C)C(=O)C[C@H](C)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl
DMIZQTX IK BFVRAKVNXYQMID-BJDJZHNGSA-N
DMIZQTX IU (2S,4S)-5,5,5-trichloro-4-methyl-2-[methyl-[(3S)-4,4,4-trichloro-3-methylbutanoyl]amino]-N-[(1S)-1-(1,3-thiazol-2-yl)ethyl]pentanamide
DMIZQTX DE Discovery agent
DMNYQL9 ID DMNYQL9
DMNYQL9 DN DYSIDINE
DMNYQL9 HS Investigative
DMNYQL9 SN Dysidine; CHEBI:65816; 2-[(4-hydroxy-3,6-dioxo-5-{[(1R,2R,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-2-yl]methyl}cyclohexa-1,4-dien-1-yl)amino]ethanesulfonic acid; dicidin
DMNYQL9 DT Small molecular drug
DMNYQL9 PC 10321583
DMNYQL9 MW 451.6
DMNYQL9 FM C23H33NO6S
DMNYQL9 IC InChI=1S/C23H33NO6S/c1-14-6-5-7-17-15(2)22(3,8-9-23(14,17)4)13-16-20(26)18(12-19(25)21(16)27)24-10-11-31(28,29)30/h6,12,15,17,24,26H,5,7-11,13H2,1-4H3,(H,28,29,30)/t15-,17+,22-,23-/m1/s1
DMNYQL9 CS C[C@@H]1[C@@H]2CCC=C([C@]2(CC[C@]1(C)CC3=C(C(=CC(=O)C3=O)NCCS(=O)(=O)O)O)C)C
DMNYQL9 IK JUZCKAMLAZUOHD-CIVZFWGOSA-N
DMNYQL9 IU 2-[[5-[[(1R,2R,4aS,8aS)-1,2,4a,5-tetramethyl-1,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]ethanesulfonic acid
DMNYQL9 CB CHEBI:65816
DMNYQL9 DE Discovery agent
DM0EBAF ID DM0EBAF
DM0EBAF DN dysiherbaine
DM0EBAF HS Investigative
DM0EBAF SN dysiherbaine; (2r,3ar,6s,7r,7ar)-2-[(2s)-2-Amino-2-Carboxyethyl]-6-Hydroxy-7-(Methylamino)hexahydro-2h-Furo[3,2-B]pyran-2-Carboxylic Acid; DYH; CHEMBL221142; GTPL4185; SCHEMBL12409079; BDBM85740; (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid (non-preferred name); (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)-hexahydro-2H-furo[3,2-b]pyran-2-carboxylic acid
DM0EBAF DT Small molecular drug
DM0EBAF PC 9839436
DM0EBAF MW 304.3
DM0EBAF FM C12H20N2O7
DM0EBAF IC InChI=1S/C12H20N2O7/c1-14-8-6(15)4-20-7-3-12(11(18)19,21-9(7)8)2-5(13)10(16)17/h5-9,14-15H,2-4,13H2,1H3,(H,16,17)(H,18,19)/t5-,6+,7+,8+,9-,12+/m0/s1
DM0EBAF CS CN[C@@H]1[C@@H](CO[C@H]2[C@@H]1O[C@@](C2)(C[C@@H](C(=O)O)N)C(=O)O)O
DM0EBAF IK YUSZFKPLFIQTGF-FDNSHYBFSA-N
DM0EBAF IU (2R,3aR,6S,7R,7aR)-2-[(2S)-2-amino-2-carboxyethyl]-6-hydroxy-7-(methylamino)-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylic acid
DM0EBAF DE Discovery agent
DMU42C1 ID DMU42C1
DMU42C1 DN DYSINOSIN A
DMU42C1 HS Investigative
DMU42C1 SN dysinosin A; CHEMBL502639
DMU42C1 DT Small molecular drug
DMU42C1 PC 10439038
DMU42C1 MW 632.7
DMU42C1 FM C26H44N6O10S
DMU42C1 IC InChI=1S/C26H44N6O10S/c1-14(2)8-17(30-24(36)22(41-3)13-42-43(38,39)40)25(37)32-18-11-21(34)20(33)10-16(18)9-19(32)23(35)29-6-4-15-5-7-31(12-15)26(27)28/h5,14,16-22,33-34H,4,6-13H2,1-3H3,(H6,27,28,29,30,35,36,38,39,40)/t16-,17-,18+,19+,20+,21+,22-/m1/s1
DMU42C1 CS CC(C)C[C@H](C(=O)N1[C@H]2C[C@@H]([C@H](C[C@H]2C[C@H]1C(=O)NCCC3=CC[N+](=C(N)N)C3)O)O)NC(=O)[C@@H](COS(=O)(=O)[O-])OC
DMU42C1 IK FJKGWCOVORXKMM-FAWMDMTCSA-N
DMU42C1 IU [(2R)-3-[[(2R)-1-[(2S,3aR,5S,6S,7aS)-2-[2-[1-(diaminomethylidene)-2,5-dihydropyrrol-1-ium-3-yl]ethylcarbamoyl]-5,6-dihydroxy-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-2-methoxy-3-oxopropyl] sulfate
DMU42C1 DE Discovery agent
DM0JXBK ID DM0JXBK
DM0JXBK DN DZNep
DM0JXBK HS Investigative
DM0JXBK SN 3-deazaneplanocin A
DM0JXBK DT Small molecular drug
DM0JXBK PC 73087
DM0JXBK MW 262.26
DM0JXBK FM C12H14N4O3
DM0JXBK IC InChI=1S/C12H14N4O3/c13-12-9-7(1-2-14-12)16(5-15-9)8-3-6(4-17)10(18)11(8)19/h1-3,5,8,10-11,17-19H,4H2,(H2,13,14)/t8-,10-,11+/m1/s1
DM0JXBK CS C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N
DM0JXBK IK OMKHWTRUYNAGFG-IEBDPFPHSA-N
DM0JXBK IU (1S,2R,5R)-5-(4-aminoimidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DM0JXBK CA CAS 102052-95-9
DM0JXBK DE Discovery agent
DM76UJY ID DM76UJY
DM76UJY DN E[c(RGDyK)]2
DM76UJY HS Investigative
DM76UJY SN E[c(RGDyK)]2; CHEMBL414385
DM76UJY PC 44388431
DM76UJY MW 1422.5
DM76UJY FM C62H91N19O20
DM76UJY IC InChI=1S/C62H91N19O20/c63-61(64)69-24-5-9-37-53(94)71-31-48(87)74-44(29-50(89)90)59(100)80-42(27-33-11-15-35(83)16-12-33)57(98)78-39(55(96)76-37)7-1-3-22-67-46(85)20-19-41(73-47(86)21-26-82)52(93)68-23-4-2-8-40-56(97)77-38(10-6-25-70-62(65)66)54(95)72-32-49(88)75-45(30-51(91)92)60(101)81-43(58(99)79-40)28-34-13-17-36(84)18-14-34/h11-18,37-45,82-84H,1-10,19-32H2,(H,67,85)(H,68,93)(H,71,94)(H,72,95)(H,73,86)(H,74,87)(H,75,88)(H,76,96)(H,77,97)(H,78,98)(H,79,99)(H,80,100)(H,81,101)(H,89,90)(H,91,92)(H4,63,64,69)(H4,65,66,70)/t37-,38-,39-,40?,41?,42+,43+,44-,45-/m1/s1
DM76UJY CS C1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN=C(N)N)CCCCNC(=O)CCC(C(=O)NCCCCC2C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N2)CC3=CC=C(C=C3)O)CC(=O)O)CCCN=C(N)N)NC(=O)CCO)CC4=CC=C(C=C4)O)CC(=O)O
DM76UJY IK ACEBGKIPKRNNIW-JMIOTQLUSA-N
DM76UJY IU 2-[(2R,5S,8R,11R)-8-[4-[[5-[4-[(5R,11R,14S)-11-(carboxymethyl)-5-[3-(diaminomethylideneamino)propyl]-14-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]butylamino]-4-(3-hydroxypropanoylamino)-5-oxopentanoyl]amino]butyl]-11-[3-(diaminomethylideneamino)propyl]-5-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DM76UJY DE Discovery agent
DMS1LZI ID DMS1LZI
DMS1LZI DN E[c(RGDyK)]2-PTX conjugate
DMS1LZI HS Investigative
DMS1LZI PC 91933274
DMS1LZI MW 2258.4
DMS1LZI FM C109H140N20O33
DMS1LZI IC InChI=1S/C109H140N20O33/c1-57-76(53-109(156)91(161-102(154)64-26-14-9-15-27-64)89-107(6,77(134)52-78-108(89,56-158-78)162-59(3)131)90(143)87(159-58(2)130)85(57)106(109,4)5)160-103(155)88(86(62-22-10-7-11-23-62)129-92(144)63-24-12-8-13-25-63)157-47-42-80(136)120-71(93(145)115-44-19-17-29-70-97(149)124-68(31-21-46-117-105(112)113)95(147)119-55-82(138)122-75(51-84(141)142)101(153)128-73(99(151)126-70)49-61-34-38-66(133)39-35-61)40-41-79(135)114-43-18-16-28-69-96(148)123-67(30-20-45-116-104(110)111)94(146)118-54-81(137)121-74(50-83(139)140)100(152)127-72(98(150)125-69)48-60-32-36-65(132)37-33-60/h7-15,22-27,32-39,67-78,86-89,91,132-134,156H,16-21,28-31,40-56H2,1-6H3,(H,114,135)(H,115,145)(H,118,146)(H,119,147)(H,120,136)(H,121,137)(H,122,138)(H,123,148)(H,124,149)(H,125,150)(H,126,151)(H,127,152)(H,128,153)(H,129,144)(H,139,140)(H,141,142)(H4,110,111,116)(H4,112,113,117)/t67-,68-,69-,70?,71?,72+,73+,74-,75-,76?,77+,78?,86+,87-,88+,89?,91+,107-,108+,109-/m1/s1
DMS1LZI CS CC1=C2[C@H](C(=O)[C@@]3([C@H](CC4[C@](C3[C@@H]([C@@](C2(C)C)(CC1OC(=O)[C@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)OCCC(=O)NC(CCC(=O)NCCCC[C@@H]7C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N7)CC8=CC=C(C=C8)O)CC(=O)O)CCCNC(=N)N)C(=O)NCCCCC9C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N9)CC1=CC=C(C=C1)O)CC(=O)O)CCCNC(=N)N)O)OC(=O)C1=CC=CC=C1)(CO4)OC(=O)C)O)C)OC(=O)C
DMS1LZI IK YUHVDRZERRVMDC-XLKUZTQTSA-N
DMS1LZI IU 2-[(2R,5S,8R,11R)-8-[4-[[4-[3-[(1S,2S)-1-benzamido-3-[[(1S,2S,4S,9S,10S,12R)-4,12-diacetyloxy-2-benzoyloxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-15-yl]oxy]-3-oxo-1-phenylpropan-2-yl]oxypropanoylamino]-5-[4-[(5R,11R,14S)-5-(3-carbamimidamidopropyl)-11-(carboxymethyl)-14-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]butylamino]-5-oxopentanoyl]amino]butyl]-11-(3-carbamimidamidopropyl)-5-[(4-hydroxyphenyl)methyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
DMS1LZI DE Discovery agent
DMA9CZV ID DMA9CZV
DMA9CZV DN E-003
DMA9CZV HS Investigative
DMA9CZV SN Bcl-xL modulators (oral, cancer); Ensemblin macrocycle (oral, cancer), Ensemble Therapeutics; Bcl-xL modulators (oral, cancer), Ensemble
DMA9CZV CP Ensemble Therapeutics Corp
DMA9CZV DE Solid tumour/cancer
DMHPFMV ID DMHPFMV
DMHPFMV DN E-1455
DMHPFMV HS Investigative
DMHPFMV SN E-1043; Clozapine prodrug (oral, ECLYPS), ProCor Pharmaceuticals
DMHPFMV CP ProCor Pharmaceuticals
DMHPFMV PC 74890720
DMHPFMV MW 277.2
DMHPFMV FM C14H20BNO2S
DMHPFMV IC InChI=1S/C14H20BNO2S/c1-13(2)14(3,4)18-15(17-13)9-8-11-6-7-12(19-5)16-10-11/h6-10H,1-5H3/b9-8+
DMHPFMV CS B1(OC(C(O1)(C)C)(C)C)/C=C/C2=CN=C(C=C2)SC
DMHPFMV IK MTGNTJQBNWXEMY-CMDGGOBGSA-N
DMHPFMV IU 2-methylsulfanyl-5-[(E)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]pyridine
DMHPFMV DE Schizophrenia
DME5JBH ID DME5JBH
DME5JBH DN E-3024
DME5JBH HS Investigative
DME5JBH SN DPP-IV inhibitors (type 2 diabetes), Eisai; ER-260891; IDDBCP150088; IDDBCP150131
DME5JBH DE Discovery agent
DMGPRT7 ID DMGPRT7
DMGPRT7 DN E339-3D6
DMGPRT7 HS Investigative
DMGPRT7 SN E339-3D6; GTPL6187; 4-{[(1-{[2-(1-benzyl-3-methyl-1H-imidazol-3-ium-4-yl)-1-[(1-methylpiperidin-1-ium-4-yl)carbamoyl]ethyl]carbamoyl}-5-({[12-({4-[6-(diethylamino)-3-(diethyliminiumyl)-3H-xanthen-9-yl]-3-sulfobenzene}sulfonamido)dodecyl]carbamoyl}amino)pentyl)carbamoyl]methyl}-2-imino-3-methyl-2,3-dihydro-1,3-thiazol-3-ium tritrifluoroacetate
DMGPRT7 DT Small molecular drug
DMGPRT7 PC 73755182
DMGPRT7 MW 1747.9
DMGPRT7 FM C78H105F9N13O16S3+
DMGPRT7 IC InChI=1S/C72H101N13O10S3.3C2HF3O2/c1-8-84(9-2)54-30-33-59-64(44-54)95-65-45-55(85(10-3)11-4)31-34-60(65)68(59)61-35-32-58(47-66(61)98(92,93)94)97(90,91)76-40-25-19-17-15-13-12-14-16-18-24-38-74-72(89)75-39-26-23-29-62(78-67(86)46-57-50-96-71(73)82(57)7)69(87)79-63(70(88)77-53-36-41-80(5)42-37-53)43-56-49-83(51-81(56)6)48-52-27-21-20-22-28-52;3*3-2(4,5)1(6)7/h20-22,27-28,30-35,44-45,47,49-51,53,62-63,73,76H,8-19,23-26,29,36-43,46,48H2,1-7H3,(H4-2,74,75,77,78,79,86,87,88,89,92,93,94);3*(H,6,7)/p+1
DMGPRT7 CS CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=C(C=C4)S(=O)(=O)NCCCCCCCCCCCCNC(=O)NCCCCC(C(=O)NC(CC5=C[N+](=CN5C)CC6=CC=CC=C6)C(=O)NC7CC[NH+](CC7)C)NC(=O)CC8=CSC(=N)[NH+]8C)S(=O)(=O)O.C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-].C(=O)(C(F)(F)F)[O-]
DMGPRT7 IK SEZVZMIKECAWEG-UHFFFAOYSA-O
DMGPRT7 IU [9-[4-[12-[[6-[[3-(1-benzyl-3-methylimidazol-1-ium-4-yl)-1-[(1-methylpiperidin-1-ium-4-yl)amino]-1-oxopropan-2-yl]amino]-5-[[2-(2-imino-3-methyl-3H-1,3-thiazol-3-ium-4-yl)acetyl]amino]-6-oxohexyl]carbamoylamino]dodecylsulfamoyl]-2-sulfophenyl]-6-(diethylamino)xanthen-3-ylidene]-diethylazanium;2,2,2-trifluoroacetate
DMGPRT7 DE Discovery agent
DMLZU09 ID DMLZU09
DMLZU09 DN E-52862
DMLZU09 HS Investigative
DMLZU09 SN S1RA; UNII-ZW18DSD1H4; ZW18DSD1H4; GTPL10431; MR309; BCP08990; AOB87704; sigma 1 receptor antagonist (S1RA); ZINC95000617; s6754; BDBM50396352; AKOS026750239; SB17181; MCULE-6623106441; CS-2187; compound 28 [PMID: 22784008]; NCGC00371119-04; DA-40938; HY-18099; FT-0700391; E52862; A12504; Q7388203
DMLZU09 TC Antiviral Agents
DMLZU09 DT Small molecular drug
DMLZU09 PC 44247568
DMLZU09 MW 337.4
DMLZU09 FM C20H23N3O2
DMLZU09 IC InChI=1S/C20H23N3O2/c1-16-14-20(25-13-10-22-8-11-24-12-9-22)21-23(16)19-7-6-17-4-2-3-5-18(17)15-19/h2-7,14-15H,8-13H2,1H3
DMLZU09 CS CC1=CC(=NN1C2=CC3=CC=CC=C3C=C2)OCCN4CCOCC4
DMLZU09 IK DGPGXHRHNRYVDH-UHFFFAOYSA-N
DMLZU09 IU 4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine
DMLZU09 CA CAS 878141-96-9
DMLZU09 DE Coronavirus Disease 2019 (COVID-19)
DM0O8KR ID DM0O8KR
DM0O8KR DN E55888
DM0O8KR HS Investigative
DM0O8KR SN E-55888; E 55888
DM0O8KR DT Small molecular drug
DM0O8KR PC 24825775
DM0O8KR MW 257.37
DM0O8KR FM C16H23N3
DM0O8KR IC InChI=1S/C16H23N3/c1-12-16(13(2)19(5)17-12)15-8-6-7-14(11-15)9-10-18(3)4/h6-8,11H,9-10H2,1-5H3
DM0O8KR CS CC1=C(C(=NN1C)C)C2=CC=CC(=C2)CCN(C)C
DM0O8KR IK MFUWRMRKXKCSPL-UHFFFAOYSA-N
DM0O8KR IU N,N-dimethyl-2-[3-(1,3,5-trimethylpyrazol-4-yl)phenyl]ethanamine
DM0O8KR CA CAS 1034142-33-0
DM0O8KR DE Discovery agent
DM8LPBF ID DM8LPBF
DM8LPBF DN E5700
DM8LPBF HS Investigative
DM8LPBF SN E 5700; E-5700
DM8LPBF DT Small molecular drug
DM8LPBF PC 56947067
DM8LPBF MW 433.5
DM8LPBF FM C26H31N3O3
DM8LPBF IC InChI=1S/C26H31N3O3/c1-32-24-17-29(16-23(24)30)25-8-7-20(22(27-25)15-19-5-3-2-4-6-19)9-12-26(31)18-28-13-10-21(26)11-14-28/h2-8,21,23-24,30-31H,10-11,13-18H2,1H3/t23-,24+,26-/m0/s1
DM8LPBF CS CO[C@@H]1CN(C[C@@H]1O)C2=NC(=C(C=C2)C#C[C@@]3(CN4CCC3CC4)O)CC5=CC=CC=C5
DM8LPBF IK NDEOTZXSBKCQLS-GSLIJJQTSA-N
DM8LPBF IU (3S)-3-[2-[2-benzyl-6-[(3S,4R)-3-hydroxy-4-methoxypyrrolidin-1-yl]pyridin-3-yl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol
DM8LPBF DE Discovery agent
DMMOPAK ID DMMOPAK
DMMOPAK DN E-64
DMMOPAK HS Investigative
DMMOPAK SN e-64; 66701-25-5; CHEMBL189382; AC1NEEQI; SCHEMBL13283063; HMS3369L13; trans-Epoxysuccinyl-leucylamido-[4-guanidino]butane; [L-3-trans-carboxy-oxiran-2-carbonyl]-Leu-agmatin; trans-Epoxysuccinyl-leucylamido- [4-guanidino]butane; [L -3-trans-carboxy- oxiran-2-carbonyl]-Leu-agmatin; 3-({1-[(4-carbamimidamidobutyl)carbamoyl]-3-methylbutyl}carbamoyl)oxirane-2-carboxylic acid; 3-[[1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMMOPAK DT Small molecular drug
DMMOPAK PC 123985
DMMOPAK MW 357.41
DMMOPAK FM C15H27N5O5
DMMOPAK IC InChI=1S/C15H27N5O5/c1-8(2)7-9(20-13(22)10-11(25-10)14(23)24)12(21)18-5-3-4-6-19-15(16)17/h8-11H,3-7H2,1-2H3,(H,18,21)(H,20,22)(H,23,24)(H4,16,17,19)/t9-,10-,11-/m0/s1
DMMOPAK CS CC(C)C[C@@H](C(=O)NCCCCN=C(N)N)NC(=O)[C@@H]1[C@H](O1)C(=O)O
DMMOPAK IK LTLYEAJONXGNFG-DCAQKATOSA-N
DMMOPAK IU (2S,3S)-3-[[(2S)-1-[4-(diaminomethylideneamino)butylamino]-4-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid
DMMOPAK CA CAS 66701-25-5
DMMOPAK CB CHEBI:30270
DMMOPAK DE Discovery agent
DM7LGAF ID DM7LGAF
DM7LGAF DN E6801
DM7LGAF HS Investigative
DM7LGAF SN E 6801; E-6801
DM7LGAF DT Small molecular drug
DM7LGAF PC 10202564
DM7LGAF MW 423.9
DM7LGAF FM C17H18ClN5O2S2
DM7LGAF IC InChI=1S/C17H18ClN5O2S2/c1-22(2)6-5-11-10-19-14-4-3-12(9-13(11)14)21-27(24,25)16-15(18)20-17-23(16)7-8-26-17/h3-4,7-10,19,21H,5-6H2,1-2H3
DM7LGAF CS CN(C)CCC1=CNC2=C1C=C(C=C2)NS(=O)(=O)C3=C(N=C4N3C=CS4)Cl
DM7LGAF IK RZAXUKVIIWUIOM-UHFFFAOYSA-N
DM7LGAF IU 6-chloro-N-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide
DM7LGAF CA CAS 528859-04-3
DM7LGAF DE Discovery agent
DMJ2P0N ID DMJ2P0N
DMJ2P0N DN E-6837
DMJ2P0N HS Investigative
DMJ2P0N SN E-6837; E 6837; CHEMBL175835; 528859-61-2; AC1OCFY6; SCHEMBL1423485; BDBM34143; ZINC13611722; AKOS032954248; KB-76740
DMJ2P0N DT Small molecular drug
DMJ2P0N PC 6918836
DMJ2P0N MW 427.9
DMJ2P0N FM C22H22ClN3O2S
DMJ2P0N IC InChI=1S/C22H22ClN3O2S/c1-26(2)11-10-16-14-24-22-9-6-17(13-20(16)22)25-29(27,28)18-7-8-19-15(12-18)4-3-5-21(19)23/h3-9,12-14,24-25H,10-11H2,1-2H3
DMJ2P0N CS CN(C)CCC1=CNC2=C1C=C(C=C2)NS(=O)(=O)C3=CC4=C(C=C3)C(=CC=C4)Cl
DMJ2P0N IK OOIQBABUMXSCPC-UHFFFAOYSA-N
DMJ2P0N IU 5-chloro-N-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]naphthalene-2-sulfonamide
DMJ2P0N CA CAS 528859-61-2
DMJ2P0N DE Discovery agent
DM7ROJI ID DM7ROJI
DM7ROJI DN E-6-O-p-methoxycinnamoyl scandoside methyl ester
DM7ROJI HS Investigative
DM7ROJI SN CHEMBL447012; E-6-O-p-methoxycinnamoyl scandoside methyl ester; BDBM50305815; 6-O-E-p-methoxycinnamoyl scandoside methyl ester; (1S)-1alpha-(beta-D-Glucopyranosyloxy)-1,4aalpha,5,7aalpha-tetrahydro-5alpha-[[(E)-4-methoxycinnamoyl]oxy]-7-hydroxymethylcyclopenta[c]pyran-4-carboxylic acid methyl ester
DM7ROJI DT Small molecular drug
DM7ROJI PC 44584782
DM7ROJI MW 564.5
DM7ROJI FM C27H32O13
DM7ROJI IC InChI=1S/C27H32O13/c1-35-15-6-3-13(4-7-15)5-8-19(30)38-17-9-14(10-28)20-21(17)16(25(34)36-2)12-37-26(20)40-27-24(33)23(32)22(31)18(11-29)39-27/h3-9,12,17-18,20-24,26-29,31-33H,10-11H2,1-2H3/b8-5+/t17-,18-,20-,21+,22-,23+,24-,26+,27+/m1/s1
DM7ROJI CS COC1=CC=C(C=C1)/C=C/C(=O)O[C@@H]2C=C([C@@H]3[C@H]2C(=CO[C@H]3O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C(=O)OC)CO
DM7ROJI IK VBHBNHXZBKWQNO-BIIYMWGFSA-N
DM7ROJI IU methyl (1S,4aS,5R,7aS)-7-(hydroxymethyl)-5-[(E)-3-(4-methoxyphenyl)prop-2-enoyl]oxy-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
DM7ROJI DE Discovery agent
DMY6DM5 ID DMY6DM5
DMY6DM5 DN E-758
DMY6DM5 HS Investigative
DMY6DM5 SN E-759; E-761; Lycobetaine analogs (cancer); Lycobetaine analogs (cancer), Oncotest; Topoisomerase inhibitors (cancer), Oncotest
DMY6DM5 CP Oncotest GmbH
DMY6DM5 DE Solid tumour/cancer
DMB7685 ID DMB7685
DMB7685 DN EAPB0203
DMB7685 HS Investigative
DMB7685 SN UNII-KXZ9LA2QV7; KXZ9LA2QV7; EAPB-0203; N-Methyl-1-(2-phenylethyl)imidazo(1,2-a)quinoxalin-4-amine; n-methyl-1-(2-phenylethyl)imidazo[1,2-a]quinoxalin-4-amine; CHEMBL488644; SCHEMBL2815787; EAPB 0203; Imidazo(1,2-a)quinoxalin-4-amine, N-methyl-1-(2-phenylethyl)-; 681284-86-6
DMB7685 DT Small molecular drug
DMB7685 PC 24779760
DMB7685 MW 302.4
DMB7685 FM C19H18N4
DMB7685 IC InChI=1S/C19H18N4/c1-20-18-19-21-13-15(12-11-14-7-3-2-4-8-14)23(19)17-10-6-5-9-16(17)22-18/h2-10,13H,11-12H2,1H3,(H,20,22)
DMB7685 CS CNC1=NC2=CC=CC=C2N3C1=NC=C3CCC4=CC=CC=C4
DMB7685 IK HOACPUXUWCASLE-UHFFFAOYSA-N
DMB7685 IU N-methyl-1-(2-phenylethyl)imidazo[1,2-a]quinoxalin-4-amine
DMB7685 CA CAS 681284-86-6
DMB7685 DE T-cell leukaemia
DM4UZ6V ID DM4UZ6V
DM4UZ6V DN EB-47
DM4UZ6V HS Investigative
DM4UZ6V SN EB 47; 366454-36-6; 5'-Deoxy-5'-[4-[2-[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5'-oxoadenosine Dihydrochloride; DTXSID40692822; ZINC98052573; NCGC00370771-01; KB-76747; FT-0667818; 4-[1-(6-Amino-9H-purin-9-yl)-1-deoxy-; A-D-ribofuranuronoyl]-N-(2,3-dihydro-1-oxo-1H-isoindol-4-yl)-1-piperazineacetamide Dihydrochloride; 2-{4-[(2R,3R,4S,5S)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl}-N-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)acetamide (non-preferred name)
DM4UZ6V DT Small molecular drug
DM4UZ6V PC 9871899
DM4UZ6V MW 537.5
DM4UZ6V FM C24H27N9O6
DM4UZ6V IC InChI=1S/C24H27N9O6/c25-20-16-21(28-10-27-20)33(11-29-16)24-18(36)17(35)19(39-24)23(38)32-6-4-31(5-7-32)9-15(34)30-14-3-1-2-12-13(14)8-26-22(12)37/h1-3,10-11,17-19,24,35-36H,4-9H2,(H,26,37)(H,30,34)(H2,25,27,28)/t17-,18+,19-,24+/m0/s1
DM4UZ6V CS C1CN(CCN1CC(=O)NC2=CC=CC3=C2CNC3=O)C(=O)[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O
DM4UZ6V IK DDFLFKTXUWPNMV-UAKAABGRSA-N
DM4UZ6V IU 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolane-2-carbonyl]piperazin-1-yl]-N-(1-oxo-2,3-dihydroisoindol-4-yl)acetamide
DM4UZ6V DE Discovery agent
DMPKI0N ID DMPKI0N
DMPKI0N DN EBIO
DMPKI0N HS Investigative
DMPKI0N SN 10045-45-1; 1-Ethyl-2-benzimidazolinone; 1-EBIO; 1-ethyl-1H-benzo[d]imidazol-2(3H)-one; 1-Ethylbenzimidazolinone; 1-Ethylbenzimidazolin-2-one; 1-ethyl-1,3-dihydro-2h-benzimidazol-2-one; 2H-Benzimidazol-2-one, 1-ethyl-1,3-dihydro-; 1-Ethyl-Benzimidazolinone; UNII-M82W79SS4W; 3-ethyl-1H-benzimidazol-2-one; EINECS 233-148-1; CHEMBL452887; M82W79SS4W; CHEBI:34076; CXUCKELNYMZTRT-UHFFFAOYSA-N; 1-ethyl-2,3-dihydro-1H-1,3-benzodiazol-2-one; 1-EB10; EBIO; 1-ethyl-1,3-dihydrobenzimidazol-2-one; Tocris-1041; AC1Q2ZX3; AC1Q2ZX4
DMPKI0N DT Small molecular drug
DMPKI0N PC 82320
DMPKI0N MW 162.19
DMPKI0N FM C9H10N2O
DMPKI0N IC InChI=1S/C9H10N2O/c1-2-11-8-6-4-3-5-7(8)10-9(11)12/h3-6H,2H2,1H3,(H,10,12)
DMPKI0N CS CCN1C2=CC=CC=C2NC1=O
DMPKI0N IK CXUCKELNYMZTRT-UHFFFAOYSA-N
DMPKI0N IU 3-ethyl-1H-benzimidazol-2-one
DMPKI0N CA CAS 10045-45-1
DMPKI0N CB CHEBI:34076
DMPKI0N DE Discovery agent
DMIC372 ID DMIC372
DMIC372 DN EC-0565
DMIC372 HS Investigative
DMIC372 SN Folate-everolimus conjugate (inflammation), Endocyte
DMIC372 CP Endocyte Inc
DMIC372 DE Solid tumour/cancer
DMK6E10 ID DMK6E10
DMK6E10 DN EC-0845
DMK6E10 HS Investigative
DMK6E10 SN MTOR modulator (inflammatory disease), Endocyte
DMK6E10 CP Endocyte Inc
DMK6E10 DE Inflammation
DM61FB0 ID DM61FB0
DM61FB0 DN EC18
DM61FB0 HS Investigative
DM61FB0 SN EC18; SCHEMBL1028017; GTPL6262
DM61FB0 DT Small molecular drug
DM61FB0 PC 50902958
DM61FB0 MW 496.6
DM61FB0 FM C29H40N2O5
DM61FB0 IC InChI=1S/C29H40N2O5/c1-30(13-11-20-9-10-25(33-2)26(15-20)34-3)23-7-6-8-24(19-23)31-14-12-21-16-27(35-4)28(36-5)17-22(21)18-29(31)32/h9-10,15-17,23-24H,6-8,11-14,18-19H2,1-5H3
DM61FB0 CS CN(CCC1=CC(=C(C=C1)OC)OC)C2CCCC(C2)N3CCC4=CC(=C(C=C4CC3=O)OC)OC
DM61FB0 IK IUAVZEYOWYFRAS-UHFFFAOYSA-N
DM61FB0 IU 3-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]cyclohexyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
DM61FB0 DE Discovery agent
DM67549 ID DM67549
DM67549 DN EC33
DM67549 HS Investigative
DM67549 DE Discovery agent
DMIVY0Q ID DMIVY0Q
DMIVY0Q DN Eckol
DMIVY0Q HS Investigative
DMIVY0Q SN Eckol; 88798-74-7; 4-(3,5-dihydroxyphenoxy)dibenzo-p-dioxin-1,3,6,8-tetrol; 1-(3,5-Dihydroxyphenoxy)-2,4,7,9-tetrahydroxydibenzo-1,4-dioxin; UNII-4A5E8354UB; CHEMBL471187; CHEBI:65819; 4A5E8354UB; 4-(3,5-dihydroxyphenoxy)oxanthrene-1,3,6,8-tetrol; 4-(3,5-dihydroxyphenoxy)-dibenzo(b,e)(1,4)dioxin-1,3,6,8-tetrol; AC1L3S7Z; SCHEMBL2562621; DTXSID40237333; ZINC6091359; BDBM50259982; Dibenzo[b,e][1,4]dioxin-1,3,6,8-tetrol, 4-(3,5-dihydroxyphenoxy)-; Dibenzo(b,e)(1,4)-dioxin-1,3,6,8-tetrol, 4-(3,5-dihydroxyphenoxy)-
DMIVY0Q DT Small molecular drug
DMIVY0Q PC 145937
DMIVY0Q MW 372.3
DMIVY0Q FM C18H12O9
DMIVY0Q IC InChI=1S/C18H12O9/c19-7-1-8(20)3-10(2-7)25-16-12(23)6-13(24)17-18(16)27-15-11(22)4-9(21)5-14(15)26-17/h1-6,19-24H
DMIVY0Q CS C1=C(C=C(C=C1O)OC2=C(C=C(C3=C2OC4=C(C=C(C=C4O3)O)O)O)O)O
DMIVY0Q IK PCZZRBGISTUIOA-UHFFFAOYSA-N
DMIVY0Q IU 4-(3,5-dihydroxyphenoxy)dibenzo-p-dioxin-1,3,6,8-tetrol
DMIVY0Q CA CAS 88798-74-7
DMIVY0Q CB CHEBI:65819
DMIVY0Q DE Discovery agent
DMWKS29 ID DMWKS29
DMWKS29 DN ECOPLADIB
DMWKS29 HS Investigative
DMWKS29 SN Ecopladib; UNII-48TI67E57Q; PLA-725; CHEMBL269787; 48TI67E57Q; 381683-92-7; Ecopladib [USAN:INN]; Ecopladib (USAN/INN); AC1L4BXD; SCHEMBL1500755; DTXSID70191555; BDBM50205515; HY-U00037; CS-6742; D03938; Benzoic acid, 4-(2-(5-chloro-2-(2-((((3,4-dichlorophenyl)methyl)sulfonyl)amino)ethyl)-1-(diphenylmethyl)-1H-indol-3-yl)ethoxy)-; 4-(2-(5-Chloro-2-(2-(((3,4-dichlorobenzyl)sulfonyl)amino)ethyl)-1-(diphenylmethyl)-1H-indol-3-yl)ethoxy)benzoic acid
DMWKS29 DT Small molecular drug
DMWKS29 PC 204106
DMWKS29 MW 748.1
DMWKS29 FM C39H33Cl3N2O5S
DMWKS29 IC InChI=1S/C39H33Cl3N2O5S/c40-30-14-18-36-33(24-30)32(20-22-49-31-15-12-29(13-16-31)39(45)46)37(19-21-43-50(47,48)25-26-11-17-34(41)35(42)23-26)44(36)38(27-7-3-1-4-8-27)28-9-5-2-6-10-28/h1-18,23-24,38,43H,19-22,25H2,(H,45,46)
DMWKS29 CS C1=CC=C(C=C1)C(C2=CC=CC=C2)N3C4=C(C=C(C=C4)Cl)C(=C3CCNS(=O)(=O)CC5=CC(=C(C=C5)Cl)Cl)CCOC6=CC=C(C=C6)C(=O)O
DMWKS29 IK FMMCHWHNSUBYAV-UHFFFAOYSA-N
DMWKS29 IU 4-[2-[1-benzhydryl-5-chloro-2-[2-[(3,4-dichlorophenyl)methylsulfonylamino]ethyl]indol-3-yl]ethoxy]benzoic acid
DMWKS29 CA CAS 381683-92-7
DMWKS29 DE Discovery agent
DMYZVLN ID DMYZVLN
DMYZVLN DN EC-SOD
DMYZVLN HS Investigative
DMYZVLN DE Discovery agent
DM5QS17 ID DM5QS17
DM5QS17 DN ED1
DM5QS17 HS Investigative
DM5QS17 SN ethylenediamine scaffold, 10; BDBM31426; ED1; 3-{2'-[{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(2-{(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino}ethyl)sulfamoyl]biphenyl-3-yl}propanoic acid
DM5QS17 DT Aptamer
DM5QS17 PC 25181318
DM5QS17 MW 740.9
DM5QS17 FM C40H48N6O6S
DM5QS17 IC InChI=1S/C40H48N6O6S/c1-40(2,3)52-39(49)44-20-18-32(19-21-44)27-46(23-22-45(28-35-26-42-29-43(35)4)34-15-12-31(25-41)13-16-34)53(50,51)37-11-6-5-10-36(37)33-9-7-8-30(24-33)14-17-38(47)48/h5-13,15-16,24,26,29,32H,14,17-23,27-28H2,1-4H3,(H,47,48)
DM5QS17 CS CC(C)(C)OC(=O)N1CCC(CC1)CN(CCN(CC2=CN=CN2C)C3=CC=C(C=C3)C#N)S(=O)(=O)C4=CC=CC=C4C5=CC=CC(=C5)CCC(=O)O
DM5QS17 IK IQLSFMXNAXIRFW-UHFFFAOYSA-N
DM5QS17 IU 3-[3-[2-[2-[4-cyano-N-[(3-methylimidazol-4-yl)methyl]anilino]ethyl-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]sulfamoyl]phenyl]phenyl]propanoic acid
DM5QS17 DE Acute respiratory distress syndrome; Myocardial reperfusion injury; Sepsis
DMX32JY ID DMX32JY
DMX32JY DN ED45
DMX32JY HS Investigative
DMX32JY DT Aptamer
DMX32JY DE Acute respiratory distress syndrome; Myocardial reperfusion injury; Sepsis
DM32O0L ID DM32O0L
DM32O0L DN Edatrexate
DM32O0L HS Investigative
DM32O0L SN EDATREXATE; 80576-83-6; TCMDC-137768; GNF-Pf-63; CHEMBL296373; 10-Ethyl-10-deazaaminopterin; CGP-30694; Edatrexate [USAN:INN]; Edatrexatum [INN-Latin]; Edatrexato [INN-Spanish]; Edatrexatum; Edatrexato; CGP 30694; EDX; psylliumseed; N-(p-(1-((2,4-Diamino-6-pteridinyl)methyl)propyl)benzoyl)-L-glutamic acid; L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-; AC1OCESK; Edatrexate (USAN/INN); SCHEMBL4676; 10-ethyl-10-deazaaminopterine; CHEBI:135757
DM32O0L DT Small molecular drug
DM32O0L PC 6917908
DM32O0L MW 467.5
DM32O0L FM C22H25N7O5
DM32O0L IC InChI=1S/C22H25N7O5/c1-2-11(9-14-10-25-19-17(26-14)18(23)28-22(24)29-19)12-3-5-13(6-4-12)20(32)27-15(21(33)34)7-8-16(30)31/h3-6,10-11,15H,2,7-9H2,1H3,(H,27,32)(H,30,31)(H,33,34)(H4,23,24,25,28,29)/t11?,15-/m0/s1
DM32O0L CS CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM32O0L IK FSIRXIHZBIXHKT-MHTVFEQDSA-N
DM32O0L IU (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid
DM32O0L CA CAS 80576-83-6
DM32O0L CB CHEBI:135757
DM32O0L DE Discovery agent
DM10D85 ID DM10D85
DM10D85 DN Edetic acid
DM10D85 HS Investigative
DM10D85 SN Ethylenediaminetetraacetic acid; EDTA; 60-00-4; Edathamil; Versene; Titriplex; Havidote; EDTA acid; Sequestrol; Cheelox; Sequestric acid; Warkeelate acid; Gluma cleanser; Sequestrene aa; Komplexon ii; Versene acid; Tetrine acid; Quastal Special; Metaquest A; Trilon bw; Complexon II; Titriplex II; Hamp-ene acid; Cheelox BF acid; Trilon BS; Celon A; Questex 4H; Chelest 3A; Celon ATH; Chemcolox 340; Versenate; Acidum edeticum; Universne acid; Acido edetico; Acide edetique; Vinkeil 100; Dissolvine E; Nullapon B acid; Perma
DM10D85 DT Small molecular drug
DM10D85 PC 6049
DM10D85 MW 292.24
DM10D85 FM C10H16N2O8
DM10D85 IC InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)
DM10D85 CS C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
DM10D85 IK KCXVZYZYPLLWCC-UHFFFAOYSA-N
DM10D85 IU 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid
DM10D85 CA CAS 60-00-4
DM10D85 CB CHEBI:42191
DM10D85 DE Discovery agent
DMS3AXK ID DMS3AXK
DMS3AXK DN EDMT
DMS3AXK HS Investigative
DMS3AXK SN 2-Ethyl-5-methoxy-N,N-dimethyltryptamine; EMDT; 2-ethyl-5-methoxy-N,N-dimethyltryptamine; CHEMBL267615; 2-(2-ethyl-5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine; AC1OCFIZ; GTPL12; SCHEMBL2537573; BDBM34142; ZINC13805803; PDSP1_001417; PDSP2_001401; AKOS027422828; NCGC00387149-01; N,N-Dimethyl-2-ethyl-5-methoxy-1H-indole-3-ethanamine; [2-(2-ethyl-5-methoxy-1H-indol-3-yl)ethyl]dimethylamine,
DMS3AXK DT Small molecular drug
DMS3AXK PC 6918513
DMS3AXK MW 246.35
DMS3AXK FM C15H22N2O
DMS3AXK IC InChI=1S/C15H22N2O/c1-5-14-12(8-9-17(2)3)13-10-11(18-4)6-7-15(13)16-14/h6-7,10,16H,5,8-9H2,1-4H3
DMS3AXK CS CCC1=C(C2=C(N1)C=CC(=C2)OC)CCN(C)C
DMS3AXK IK ZEYRDXUWJDGTLD-UHFFFAOYSA-N
DMS3AXK IU 2-(2-ethyl-5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
DMS3AXK DE Discovery agent
DMHCGIS ID DMHCGIS
DMHCGIS DN EDN-OL1
DMHCGIS HS Investigative
DMHCGIS SN Amyloid beta oligonucleotide (Alzheimer's disease/Down syndrome), Edunn
DMHCGIS CP Edunn Biotechnology Inc
DMHCGIS DE Alzheimer disease
DMC7DYX ID DMC7DYX
DMC7DYX DN Edoxudine
DMC7DYX HS Investigative
DMC7DYX SN 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine ; Edoxudine; MCULE-3445830855; ST056929
DMC7DYX DT Small molecular drug
DMC7DYX PC 66377
DMC7DYX MW 256.25
DMC7DYX FM C11H16N2O5
DMC7DYX IC InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1
DMC7DYX CS CCC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)O
DMC7DYX IK XACKNLSZYYIACO-DJLDLDEBSA-N
DMC7DYX IU 5-ethyl-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMC7DYX CA CAS 15176-29-1
DMC7DYX CB CHEBI:135051
DMC7DYX DE Discovery agent
DMLSMBI ID DMLSMBI
DMLSMBI DN EDP-13
DMLSMBI HS Investigative
DMLSMBI SN Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma
DMLSMBI CP BioLineRx Ltd
DMLSMBI DE Solid tumour/cancer
DMTVRKG ID DMTVRKG
DMTVRKG DN EDP-18
DMTVRKG HS Investigative
DMTVRKG SN TRPV3 agonist (depression), Biolinerx
DMTVRKG CP BioLineRx Ltd
DMTVRKG DE Major depressive disorder
DMMN0GO ID DMMN0GO
DMMN0GO DN EDP-21
DMMN0GO HS Investigative
DMMN0GO SN Recombinant leptin analogs (obesity), BioLineRx
DMMN0GO CP BioLineRx Ltd
DMMN0GO DE Obesity
DMN8JKX ID DMN8JKX
DMN8JKX DN E-EBU-dM
DMN8JKX HS Investigative
DMN8JKX SN 132774-45-9; 136011-43-3; E-EPU; E-EPU-S
DMN8JKX DT Small molecular drug
DMN8JKX PC 453151
DMN8JKX MW 316.4
DMN8JKX FM C18H24N2O3
DMN8JKX IC InChI=1S/C18H24N2O3/c1-5-15-16(10-14-8-12(3)7-13(4)9-14)20(11-23-6-2)18(22)19-17(15)21/h7-9H,5-6,10-11H2,1-4H3,(H,19,21,22)
DMN8JKX CS CCC1=C(N(C(=O)NC1=O)COCC)CC2=CC(=CC(=C2)C)C
DMN8JKX IK LNEPZLRCYLNOIU-UHFFFAOYSA-N
DMN8JKX IU 6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethylpyrimidine-2,4-dione
DMN8JKX CA CAS 136160-30-0
DMN8JKX DE Discovery agent
DMXZRND ID DMXZRND
DMXZRND DN EFFUSOL
DMXZRND HS Investigative
DMXZRND SN EFFUSOL; 73166-28-6; NSC 371300; 5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol; UNII-S436Y000RU; CHEMBL205119; S436Y000RU; 1-methyl-5-vinyl-9,10-dihydrophenanthrene-2,7-diol; NSC-371300; 2,7-Phenanthrenediol, 5-ethenyl-9,10-dihydro-1-methyl-; NSC371300; AC1L2PII; AC1Q7B8H; CTK8D4698; DTXSID00223419; MolPort-042-624-482; ZINC1588038; BDBM50180512; FT-0667825
DMXZRND DT Small molecular drug
DMXZRND PC 100801
DMXZRND MW 252.31
DMXZRND FM C17H16O2
DMXZRND IC InChI=1S/C17H16O2/c1-3-11-8-13(18)9-12-4-5-14-10(2)16(19)7-6-15(14)17(11)12/h3,6-9,18-19H,1,4-5H2,2H3
DMXZRND CS CC1=C(C=CC2=C1CCC3=C2C(=CC(=C3)O)C=C)O
DMXZRND IK GEXAPRXWKRZPCK-UHFFFAOYSA-N
DMXZRND IU 5-ethenyl-1-methyl-9,10-dihydrophenanthrene-2,7-diol
DMXZRND CA CAS 73166-28-6
DMXZRND DE Discovery agent
DMOKX76 ID DMOKX76
DMOKX76 DN Efomycine M
DMOKX76 HS Investigative
DMOKX76 DE Discovery agent
DMZ2XOH ID DMZ2XOH
DMZ2XOH DN EFPPEA
DMZ2XOH HS Investigative
DMZ2XOH SN ethyl-furo-pyrazolo-pyridine-ethyl-acetamide; N-[2-(2-Ethyl-8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridin-1-yl)ethyl]acetamide
DMZ2XOH DT Small molecular drug
DMZ2XOH PC 24954989
DMZ2XOH MW 273.33
DMZ2XOH FM C15H19N3O2
DMZ2XOH IC InChI=1S/C15H19N3O2/c1-3-13-11(4-7-16-10(2)19)15-12-6-9-20-14(12)5-8-18(15)17-13/h5,8H,3-4,6-7,9H2,1-2H3,(H,16,19)
DMZ2XOH CS CCC1=NN2C=CC3=C(C2=C1CCNC(=O)C)CCO3
DMZ2XOH IK IZDHETWMKYCGAU-UHFFFAOYSA-N
DMZ2XOH IU N-[2-(4-ethyl-10-oxa-5,6-diazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7-tetraen-3-yl)ethyl]acetamide
DMZ2XOH DE Discovery agent
DMRP9K3 ID DMRP9K3
DMRP9K3 DN EG-10
DMRP9K3 HS Investigative
DMRP9K3 SN IL-10 human gene therapy (nanoparticle , inflammatory bowel disease), enGene
DMRP9K3 CP EnGene Inc
DMRP9K3 DE Inflammatory bowel disease
DM7AYH4 ID DM7AYH4
DM7AYH4 DN EGFR inhibitor
DM7AYH4 HS Investigative
DM7AYH4 SN EGFR Inhibitor; 879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01
DM7AYH4 DT Small molecular drug
DM7AYH4 PC 9549299
DM7AYH4 MW 413.4
DM7AYH4 FM C21H18F3N5O
DM7AYH4 IC InChI=1S/C21H18F3N5O/c22-21(23,24)14-3-1-4-15(9-14)27-18-11-19(26-12-25-18)28-16-5-2-6-17(10-16)29-20(30)13-7-8-13/h1-6,9-13H,7-8H2,(H,29,30)(H2,25,26,27,28)
DM7AYH4 CS C1CC1C(=O)NC2=CC=CC(=C2)NC3=NC=NC(=C3)NC4=CC=CC(=C4)C(F)(F)F
DM7AYH4 IK YOHYSYJDKVYCJI-UHFFFAOYSA-N
DM7AYH4 IU N-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide
DM7AYH4 CA CAS 879127-07-8
DM7AYH4 DE Discovery agent
DMLK4X5 ID DMLK4X5
DMLK4X5 DN EGIS-7625
DMLK4X5 HS Investigative
DMLK4X5 SN UNII-ZD6AG3N96D; ZD6AG3N96D; EGIS-7625; EGIS-7625 free base; GTPL176; SCHEMBL7430234; Benzenamine, 2-methyl-4-nitro-5-(4-(phenylmethyl)-1-piperazinyl)-; 751462-86-9; L017292
DMLK4X5 DT Small molecular drug
DMLK4X5 PC 9930788
DMLK4X5 MW 399.3
DMLK4X5 FM C18H24Cl2N4O2
DMLK4X5 IC InChI=1S/C18H22N4O2.2ClH/c1-14-11-18(22(23)24)17(12-16(14)19)21-9-7-20(8-10-21)13-15-5-3-2-4-6-15;;/h2-6,11-12H,7-10,13,19H2,1H3;2*1H
DMLK4X5 CS CC1=CC(=C(C=C1N)N2CCN(CC2)CC3=CC=CC=C3)[N+](=O)[O-].Cl.Cl
DMLK4X5 IK AYRFPZMTRYDWGP-UHFFFAOYSA-N
DMLK4X5 IU 5-(4-benzylpiperazin-1-yl)-2-methyl-4-nitroaniline;dihydrochloride
DMLK4X5 CA CAS 755040-97-2
DMLK4X5 DE Discovery agent
DMKW0Q3 ID DMKW0Q3
DMKW0Q3 DN eGlu
DMKW0Q3 HS Investigative
DMKW0Q3 SN EGLU; (s)-alpha-ethylglutamate
DMKW0Q3 DT Small molecular drug
DMKW0Q3 PC 5311079
DMKW0Q3 MW 175.18
DMKW0Q3 FM C7H13NO4
DMKW0Q3 IC InChI=1S/C7H13NO4/c1-2-7(8,6(11)12)4-3-5(9)10/h2-4,8H2,1H3,(H,9,10)(H,11,12)/t7-/m0/s1
DMKW0Q3 CS CC[C@](CCC(=O)O)(C(=O)O)N
DMKW0Q3 IK QFYBYZLHPIALCZ-ZETCQYMHSA-N
DMKW0Q3 IU (2S)-2-amino-2-ethylpentanedioic acid
DMKW0Q3 CA CAS 170984-72-2
DMKW0Q3 DE Discovery agent
DMW9MRO ID DMW9MRO
DMW9MRO DN EGTA
DMW9MRO HS Investigative
DMW9MRO SN EGTA; 67-42-5; Egtazic acid; Ethylenebis(oxyethylenenitrilo)tetraacetic acid; Gedta; Ebonta; 6,9-Dioxa-3,12-diazatetradecanedioic acid, 3,12-bis(carboxymethyl)-; 1,2-Bis[2-[bis(carboxymethyl)amino]ethoxy]ethane; Ethylene Glycol Tetraacetic Acid; H4egta; Egtazic acid [USAN:INN]; Ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid; NSC 615010; Acide egtazique [INN-French]; Acido egtazico [INN-Spanish]; Acidum egtazicum [INN-Latin]; Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid; Ethylene glyc
DMW9MRO DT Small molecular drug
DMW9MRO PC 6207
DMW9MRO MW 380.35
DMW9MRO FM C14H24N2O10
DMW9MRO IC InChI=1S/C14H24N2O10/c17-11(18)7-15(8-12(19)20)1-3-25-5-6-26-4-2-16(9-13(21)22)10-14(23)24/h1-10H2,(H,17,18)(H,19,20)(H,21,22)(H,23,24)
DMW9MRO CS C(COCCOCCN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
DMW9MRO IK DEFVIWRASFVYLL-UHFFFAOYSA-N
DMW9MRO IU 2-[2-[2-[2-[bis(carboxymethyl)amino]ethoxy]ethoxy]ethyl-(carboxymethyl)amino]acetic acid
DMW9MRO CA CAS 67-42-5
DMW9MRO CB CHEBI:30740
DMW9MRO DE Discovery agent
DM014WS ID DM014WS
DM014WS DN EHNA
DM014WS HS Investigative
DM014WS SN erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride
DM014WS DT Small molecular drug
DM014WS PC 3206
DM014WS MW 277.37
DM014WS FM C14H23N5O
DM014WS IC InChI=1S/C14H23N5O/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17)
DM014WS CS CCCCCCC(C(C)O)N1C=NC2=C(N=CN=C21)N
DM014WS IK IOSAAWHGJUZBOG-UHFFFAOYSA-N
DM014WS IU 3-(6-aminopurin-9-yl)nonan-2-ol
DM014WS CA CAS 59262-86-1
DM014WS DE Discovery agent
DMBQCMU ID DMBQCMU
DMBQCMU DN EI1
DMBQCMU HS Investigative
DMBQCMU SN KB-145943
DMBQCMU DT Small molecular drug
DMBQCMU PC 72199293
DMBQCMU MW 390.5
DMBQCMU FM C23H26N4O2
DMBQCMU IC InChI=1S/C23H26N4O2/c1-5-17(6-2)27-8-7-18-19(10-16(12-24)11-21(18)27)22(28)25-13-20-14(3)9-15(4)26-23(20)29/h7-11,17H,5-6,13H2,1-4H3,(H,25,28)(H,26,29)
DMBQCMU CS CCC(CC)N1C=CC2=C(C=C(C=C21)C#N)C(=O)NCC3=C(C=C(NC3=O)C)C
DMBQCMU IK PFHDWRIVDDIFRP-UHFFFAOYSA-N
DMBQCMU IU 6-cyano-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide
DMBQCMU CA CAS 1418308-27-6
DMBQCMU DE Discovery agent
DMVJK9W ID DMVJK9W
DMVJK9W DN Eicosadienoic acid
DMVJK9W HS Investigative
DMVJK9W SN Eicosadienoic acid; HOMO-GAMMA-LINOLEICACID; Homo-gamma-linoleic acid; Icosadienoic acid; SCHEMBL416181; cis-11,14-Eicosadienoic acid; cis-11,14-eicosadienoicacid; (11Z,14Z)-Eicosa-11,14-dienoic acid; (11Z,14Z)-Icosa-11,14-dienoic acid; (11Z,14Z)-icosadienoic acid; 11, 14-icosadienoate; 11, 14-icosadienoic acid; 11,14-Eicosadienoate; 11,14-Eicosadienoic acid, (Z,Z)-; 11,14-Icosadienoic acid; 11C,14C-Eicosadienoic acid; 11Z,14Z-eicosadienoic acid; 2091-39-6; 5598-38-9; AC1O5SJA; BSPBio_001326; CHEBI:73731; CHEMBL464983; FA 20:2
DMVJK9W PC 6439848
DMVJK9W MW 308.5
DMVJK9W FM C20H36O2
DMVJK9W IC XSXIVVZCUAHUJO-HZJYTTRNSA-N
DMVJK9W CS CCCCCC=CCC=CCCCCCCCCCC(=O)O
DMVJK9W IK 1S/C20H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10H,2-5,8,11-19H2,1H3,(H,21,22)/b7-6-,10-9-
DMVJK9W IU (11Z,14Z)-icosa-11,14-dienoic acid
DMVJK9W CA CAS 5598-38-9
DMVJK9W CB CHEBI:73731
DMVJK9W DE Discovery agent
DMAKP20 ID DMAKP20
DMAKP20 DN eicosatetranoic acid
DMAKP20 HS Investigative
DMAKP20 SN ETYA; 5,8,11,14-eicosatetraynoic acid; 1191-85-1; icosa-5,8,11,14-tetraynoic acid; Octadehydroarachidonic acid; eicosatetranoic acid; MLS000069514; SMR000058640; MLS-0002886.0001; Ro 31428; Ro 3-1428; Opera_ID_402; AC1Q5VYB; Spectrum5_001952; cid_1780; CBiol_001864; SCHEMBL68751; KBioSS_000169; BSPBio_001449; KBioGR_000169; GTPL2669; CHEMBL458328; BML2-F04; AC1L1C80; CTK0H5766; CHEBI:94483; KBio3_000338; KBio2_002737; KBio3_000337; KBio2_005305; KBio2_000169; BDBM31752; DTXSID20152318; MGLDCXPLYOWQRP-UHFFFAOYSA-N; HMS3402I11; Bio1_001128
DMAKP20 DT Small molecular drug
DMAKP20 PC 1780
DMAKP20 MW 296.4
DMAKP20 FM C20H24O2
DMAKP20 IC InChI=1S/C20H24O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h2-5,8,11,14,17-19H2,1H3,(H,21,22)
DMAKP20 CS CCCCCC#CCC#CCC#CCC#CCCCC(=O)O
DMAKP20 IK MGLDCXPLYOWQRP-UHFFFAOYSA-N
DMAKP20 IU icosa-5,8,11,14-tetraynoic acid
DMAKP20 CA CAS 1191-85-1
DMAKP20 CB CHEBI:94483
DMAKP20 DE Discovery agent
DM03X7D ID DM03X7D
DM03X7D DN EISAI-1
DM03X7D HS Investigative
DM03X7D SN Malptll; EISAI-1; NT-1; (Me)Arg-lys-pro-trp-tert-leu-leu-oet; H(CH3)-Arg-lys-pro-trp-tert-leu-leu-oet; AC1L2XGU; 125600-60-4; GTPL1566; Methylarginyl-lysyl-prolyl-tryptophyl-tert-leucyl-leucyl-ethyl ester; (Methyl)-arginyl-lysyl-prolyl-tryptophyl-tert-leucyl-leucine ethyl ester; ethyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-(methylamino)pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoate
DM03X7D DT Small molecular drug
DM03X7D PC 130482
DM03X7D MW 854.1
DM03X7D FM C43H71N11O7
DM03X7D IC InChI=1S/C43H71N11O7/c1-8-61-41(60)33(23-26(2)3)52-39(58)35(43(4,5)6)53-37(56)32(24-27-25-49-29-16-10-9-15-28(27)29)51-38(57)34-19-14-22-54(34)40(59)31(17-11-12-20-44)50-36(55)30(47-7)18-13-21-48-42(45)46/h9-10,15-16,25-26,30-35,47,49H,8,11-14,17-24,44H2,1-7H3,(H,50,55)(H,51,57)(H,52,58)(H,53,56)(H4,45,46,48)/t30-,31-,32-,33-,34-,35+/m0/s1
DM03X7D CS CCOC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC
DM03X7D IK BLWANJSERJECRU-ULWXFTFZSA-N
DM03X7D IU ethyl (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-(methylamino)pentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3,3-dimethylbutanoyl]amino]-4-methylpentanoate
DM03X7D CA CAS 125600-60-4
DM03X7D DE Discovery agent
DMRHSCQ ID DMRHSCQ
DMRHSCQ DN ELAEOCARPENINE
DMRHSCQ HS Investigative
DMRHSCQ SN elaeocarpenine
DMRHSCQ DT Small molecular drug
DMRHSCQ PC 16747727
DMRHSCQ MW 257.329
DMRHSCQ FM C16H19NO2
DMRHSCQ IC InChI=1S/C16H19NO2/c1-11-5-2-8-14(18)15(11)16(19)12-6-3-9-17-10-4-7-13(12)17/h2,5-6,8,13,18H,3-4,7,9-10H2,1H3/t13-/m1/s1
DMRHSCQ CS CC1=C(C(=CC=C1)O)C(=O)C2=CCCN3[C@@H]2CCC3
DMRHSCQ IK KNSLYJICIDVPEX-CYBMUJFWSA-N
DMRHSCQ IU [(8aR)-1,2,3,5,6,8a-hexahydroindolizin-8-yl]-(2-hydroxy-6-methylphenyl)methanone
DMRHSCQ DE Discovery agent
DMP8VDT ID DMP8VDT
DMP8VDT DN Elaidoylamide
DMP8VDT HS Investigative
DMP8VDT SN Oleamide; Oleic acid amide; 301-02-0; Oleylamide; Oleyl amide; Adogen 73; Crodamide O; Slip-eze; Armoslip CP; Crodamide OR; cis-9,10-Octadecenoamide; (Z)-9-OCTADECENAMIDE; (9Z)-octadec-9-enamide; 9-Octadecenamide, (Z)-; (Z)-octadec-9-enamide; ELAIDOYLAMIDE; 9Z-octadecenamide; 9,10-octadecenamide; Unislip 1759; Kemamide O; Petrac Slip-Eze; UNII-7L25QK8BWO; Armid O; Amide O; trans-9,10-octadecenoamide; cis-9-Octadecenamide; 9-Octadecenamide, (9Z)-; 14C-labeled oleamide; Diamide O 200; HSDB 5560; (9E)-OCTADEC-9-ENAMIDE; oleamide
DMP8VDT DT Small molecular drug
DMP8VDT PC 5283387
DMP8VDT MW 281.5
DMP8VDT FM C18H35NO
DMP8VDT IC InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H2,19,20)/b10-9-
DMP8VDT CS CCCCCCCC/C=C\\CCCCCCCC(=O)N
DMP8VDT IK FATBGEAMYMYZAF-KTKRTIGZSA-N
DMP8VDT IU (Z)-octadec-9-enamide
DMP8VDT CA CAS 301-02-0
DMP8VDT CB CHEBI:116314
DMP8VDT DE Discovery agent
DMEOJ9W ID DMEOJ9W
DMEOJ9W DN eledoisin
DMEOJ9W HS Investigative
DMEOJ9W SN ELD 950; eledone peptide; ELD-950
DMEOJ9W DT Small molecular drug
DMEOJ9W PC 10328936
DMEOJ9W MW 1188.4
DMEOJ9W FM C54H85N13O15S
DMEOJ9W IC InChI=1S/C54H85N13O15S/c1-7-30(4)44(53(81)57-27-42(70)60-36(24-29(2)3)49(77)61-33(45(56)73)20-23-83-6)66-50(78)37(25-32-14-9-8-10-15-32)63-46(74)31(5)58-48(76)38(26-43(71)72)64-47(75)34(16-11-12-21-55)62-51(79)39(28-68)65-52(80)40-17-13-22-67(40)54(82)35-18-19-41(69)59-35/h8-10,14-15,29-31,33-40,44,68H,7,11-13,16-28,55H2,1-6H3,(H2,56,73)(H,57,81)(H,58,76)(H,59,69)(H,60,70)(H,61,77)(H,62,79)(H,63,74)(H,64,75)(H,65,80)(H,66,78)(H,71,72)/t30-,31-,33-,34-,35-,36-,37-,38-,39-,40-,44-/m0/s1
DMEOJ9W CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCC(=O)N3
DMEOJ9W IK AYLPVIWBPZMVSH-FCKMLYJASA-N
DMEOJ9W IU (3S)-3-[[(2S)-6-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMEOJ9W CA CAS 69-25-0
DMEOJ9W CB CHEBI:135903
DMEOJ9W DE Discovery agent
DMMVZU0 ID DMMVZU0
DMMVZU0 DN Eleutherobin
DMMVZU0 HS Investigative
DMMVZU0 SN Eleutherobin; 174545-76-7; CHEMBL504387; SCHEMBL12015046
DMMVZU0 DT Small molecular drug
DMMVZU0 PC 6918335
DMMVZU0 MW 656.8
DMMVZU0 FM C35H48N2O10
DMMVZU0 IC InChI=1S/C35H48N2O10/c1-20(2)25-10-8-21(3)26-15-29(46-30(40)11-9-24-16-37(6)19-36-24)34(5)12-13-35(42-7,47-34)23(14-27(25)26)17-43-33-32(45-22(4)38)31(41)28(39)18-44-33/h8-9,11-14,16,19-20,25-29,31-33,39,41H,10,15,17-18H2,1-7H3/b11-9+,23-14-/t25-,26+,27-,28-,29+,31-,32+,33-,34+,35-/m1/s1
DMMVZU0 CS CC1=CC[C@@H]([C@@H]/2[C@H]1C[C@@H]([C@@]3(C=C[C@@](O3)(/C(=C2)/CO[C@H]4[C@H]([C@@H]([C@@H](CO4)O)O)OC(=O)C)OC)C)OC(=O)/C=C/C5=CN(C=N5)C)C(C)C
DMMVZU0 IK XOPYFXBZMVTEJF-PDACKIITSA-N
DMMVZU0 IU [(1S,2S,4R,8R,9S,10Z,12R)-11-[[(2R,3S,4R,5R)-3-acetyloxy-4,5-dihydroxyoxan-2-yl]oxymethyl]-12-methoxy-1,5-dimethyl-8-propan-2-yl-15-oxatricyclo[10.2.1.04,9]pentadeca-5,10,13-trien-2-yl] (E)-3-(1-methylimidazol-4-yl)prop-2-enoate
DMMVZU0 CA CAS 174545-76-7
DMMVZU0 DE Discovery agent
DMX8BS5 ID DMX8BS5
DMX8BS5 DN ELLAGIC ACID
DMX8BS5 HS Investigative
DMX8BS5 SN ellagic acid; 476-66-4; Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728
DMX8BS5 DT Small molecular drug
DMX8BS5 PC 5281855
DMX8BS5 MW 302.19
DMX8BS5 FM C14H6O8
DMX8BS5 IC InChI=1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-18H
DMX8BS5 CS C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O
DMX8BS5 IK AFSDNFLWKVMVRB-UHFFFAOYSA-N
DMX8BS5 IU 6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),4,6,8(16),11,13-hexaene-3,10-dione
DMX8BS5 CA CAS 476-66-4
DMX8BS5 CB CHEBI:4775
DMX8BS5 DE Discovery agent
DMHPYSM ID DMHPYSM
DMHPYSM DN Ellipticine
DMHPYSM HS Investigative
DMHPYSM SN ellipticine; 519-23-3; Elliptisine; 5,11-Dimethyl-6H-pyrido[4,3-b]carbazole; NSC 71795; TCMDC-125546; NSC-71795; 5,11-Dimethyl-6H-pyrido(4,3-b)carbazole; ICIG 770; 5,11-Dimethylpyrido[4,3-b]carbazole; CCRIS 2003; CP 5; UNII-117VLW7484; NSC71795; EINECS 208-264-0; CHEMBL123; BRN 0221300; MLS000736786; MLS000028487; CHEBI:4776; 6H-Pyrido(4,3-b)carbazole, 5,11-dimethyl-; CCG-36483; 117VLW7484; SMR000058370; 6H-Pyrido[4,3-b]carbazole,5,11-dimethyl-; 6H-Pyrido[4,3-b]carbazole, 5,11-dimethyl-; SR-01000003083; elliptecine; Ellipticin
DMHPYSM DT Small molecular drug
DMHPYSM PC 3213
DMHPYSM MW 246.31
DMHPYSM FM C17H14N2
DMHPYSM IC InChI=1S/C17H14N2/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17/h3-9,19H,1-2H3
DMHPYSM CS CC1=C2C=CN=CC2=C(C3=C1NC4=CC=CC=C43)C
DMHPYSM IK CTSPAMFJBXKSOY-UHFFFAOYSA-N
DMHPYSM IU 5,11-dimethyl-6H-pyrido[4,3-b]carbazole
DMHPYSM CA CAS 519-23-3
DMHPYSM CB CHEBI:4776
DMHPYSM DE Discovery agent
DM2DERW ID DM2DERW
DM2DERW DN ELN-864709
DM2DERW HS Investigative
DM2DERW SN ELN-330977; ELN-678033; JNK3 inhibitors (neuronal injury), Elan; JNK3 inhibitors (neuronalinjury/neurodegenerative disease); JNK3 inhibitors (neuronal injury/neurodegenerative disease), Elan
DM2DERW CP Elan Corp plc
DM2DERW DE Central nervous system injury
DM5G1SF ID DM5G1SF
DM5G1SF DN ELND-007
DM5G1SF HS Investigative
DM5G1SF SN ELN-318463; ELN-318611; ELN-44989; ELN-475513; ELN-475516; ELN-480271; ELN-481090; ELN-481970; ELND-006; Gamma secretase inhibitors (Alzheimer's disease), Elan
DM5G1SF CP Elan Pharmaceuticals Inc
DM5G1SF DT Small molecular drug
DM5G1SF PC 53308121
DM5G1SF MW 455.4
DM5G1SF FM C20H14F5N3O2S
DM5G1SF IC InChI=1S/C20H14F5N3O2S/c21-15-7-13-17(8-16(15)22)28(19(10-1-2-10)14-9-26-27-18(13)14)31(29,30)12-5-3-11(4-6-12)20(23,24)25/h3-10,19H,1-2H2,(H,26,27)/t19-/m1/s1
DM5G1SF CS C1CC1[C@@H]2C3=C(C4=CC(=C(C=C4N2S(=O)(=O)C5=CC=C(C=C5)C(F)(F)F)F)F)NN=C3
DM5G1SF IK XODSHWXKSMPDRP-LJQANCHMSA-N
DM5G1SF IU (4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline
DM5G1SF CA CAS 959997-22-9
DM5G1SF DE Alzheimer disease
DMQ63J2 ID DMQ63J2
DMQ63J2 DN EM-101
DMQ63J2 HS Investigative
DMQ63J2 SN EM-100 series; LY-3; LY-303511; MTOR pathway inhibitors (cancer), Emiliem; MTOR pathway inhibitors (cancer), NIH
DMQ63J2 CP National Institutes of Health
DMQ63J2 DT Small molecular drug
DMQ63J2 PC 3971
DMQ63J2 MW 306.4
DMQ63J2 FM C19H18N2O2
DMQ63J2 IC InChI=1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2
DMQ63J2 CS C1CN(CCN1)C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
DMQ63J2 IK NGAGMBNBKCDCDJ-UHFFFAOYSA-N
DMQ63J2 IU 8-phenyl-2-piperazin-1-ylchromen-4-one
DMQ63J2 CA CAS 154447-38-8
DMQ63J2 CB CHEBI:92399
DMQ63J2 DE Solid tumour/cancer
DMZ2EL1 ID DMZ2EL1
DMZ2EL1 DN EM1396
DMZ2EL1 HS Investigative
DMZ2EL1 SN EM-1396; CHEMBL490979
DMZ2EL1 DT Small molecular drug
DMZ2EL1 PC 44576211
DMZ2EL1 MW 451.6
DMZ2EL1 FM C28H37NO4
DMZ2EL1 IC InChI=1S/C28H37NO4/c1-26(2)11-12-28(33-25(26)30)10-8-23-21-6-5-18-16-24(32-14-13-31-4)19(17-29)15-22(18)20(21)7-9-27(23,28)3/h15-16,20-21,23H,5-14H2,1-4H3/t20-,21+,23-,27-,28+/m0/s1
DMZ2EL1 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24CCC(C(=O)O4)(C)C)CCC5=CC(=C(C=C35)C#N)OCCOC
DMZ2EL1 IK DBERIEFIHOJVNL-NOPJHZOQSA-N
DMZ2EL1 IU (8R,9S,13S,14S,17R)-3-(2-methoxyethoxy)-5',5',13-trimethyl-6'-oxospiro[7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17,2'-oxane]-2-carbonitrile
DMZ2EL1 DE Discovery agent
DMSLHDN ID DMSLHDN
DMSLHDN DN EM-1424
DMSLHDN HS Investigative
DMSLHDN SN CHEMBL490978
DMSLHDN DT Small molecular drug
DMSLHDN PC 23647683
DMSLHDN MW 485.6
DMSLHDN FM C28H39NO6
DMSLHDN IC InChI=1S/C28H39NO6/c1-26(2)11-12-28(34-25(26)31)10-8-22-19-6-5-17-15-23(33-14-13-32-4)21(24(30)35-29)16-20(17)18(19)7-9-27(22,28)3/h15-16,18-19,22H,5-14,29H2,1-4H3/t18?,19?,22?,27-,28+/m0/s1
DMSLHDN CS C[C@]12CCC3C(C1CC[C@@]24CCC(C(=O)O4)(C)C)CCC5=CC(=C(C=C35)C(=O)ON)OCCOC
DMSLHDN IK CUTJLDJFYWQIRX-LFCNJKSUSA-N
DMSLHDN IU amino (13S,17R)-3-(2-methoxyethoxy)-5',5',13-trimethyl-6'-oxospiro[7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17,2'-oxane]-2-carboxylate
DMSLHDN DE Discovery agent
DM3RSYO ID DM3RSYO
DM3RSYO DN EM-1745
DM3RSYO HS Investigative
DM3RSYO SN BDBM17290; E2-adenosine hybrid compound, 8; EM1745; [5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl 9-[(1S,10R,11S,14S,15S)-5,14-dihydroxy-15-methyltetracyclo[8.7.0.0; {11,15}]heptadeca-2,4,6-trien-13-yl]nonanoate
DM3RSYO DT Small molecular drug
DM3RSYO PC 446201
DM3RSYO MW 677.8
DM3RSYO FM C37H51N5O7
DM3RSYO IC InChI=1S/C37H51N5O7/c1-37-15-14-25-24-13-11-23(43)16-21(24)10-12-26(25)27(37)17-22(33(37)47)8-6-4-2-3-5-7-9-29(44)48-18-28-31(45)32(46)36(49-28)42-20-41-30-34(38)39-19-40-35(30)42/h11,13,16,19-20,22,25-28,31-33,36,43,45-47H,2-10,12,14-15,17-18H2,1H3,(H2,38,39,40)/t22-,25+,26+,27-,28+,31+,32+,33-,36+,37-/m0/s1
DM3RSYO CS C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@@H]([C@@H]2O)CCCCCCCCC(=O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)CCC7=C3C=CC(=C7)O
DM3RSYO IK CKSDYJASHNGOOS-KTXOUVACSA-N
DM3RSYO IU [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl 9-[(8R,9S,13S,14S,16S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]nonanoate
DM3RSYO DE Discovery agent
DMC4XJ6 ID DMC4XJ6
DMC4XJ6 DN EM-523
DMC4XJ6 HS Investigative
DMC4XJ6 SN N-ethyl,N-methyl EM-A enolether; erythromycin analogue (523)
DMC4XJ6 DT Small molecular drug
DMC4XJ6 PC 184178
DMC4XJ6 MW 729.9
DMC4XJ6 FM C38H67NO12
DMC4XJ6 IC InChI=1S/C38H67NO12/c1-14-26-38(11,44)31(41)21(5)29-19(3)17-37(10,51-29)33(50-35-28(40)25(39(12)15-2)16-20(4)46-35)22(6)30(23(7)34(43)48-26)49-27-18-36(9,45-13)32(42)24(8)47-27/h20-28,30-33,35,40-42,44H,14-18H2,1-13H3/t20-,21+,22+,23-,24+,25+,26-,27+,28-,30+,31-,32+,33-,35+,36-,37+,38-/m1/s1
DMC4XJ6 CS CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)CC)O)C)C)C)O)(C)O
DMC4XJ6 IK UTTLXGDLSXWDJI-OTELOYJSSA-N
DMC4XJ6 IU (2R,3R,4S,5R,8R,9S,10S,11R,12S)-5-ethyl-11-[(2S,3R,4S,6R)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3,4-dihydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMC4XJ6 DE Discovery agent
DMFQX1U ID DMFQX1U
DMFQX1U DN EMATE
DMFQX1U HS Investigative
DMFQX1U SN Emate compound; Estrone 3-O-Sulfamate; EMATE; Estrone-3-O-sulfamate; Oestrone-3-O-sulphamate; 148672-09-7; Estra-1,3,5(10)-trien-17-one-3-sulfamate; CHEMBL122708; 3-((Aminosulfonyl)oxy)estra-1,3,5(10)-trien-17-one; C18H23NO4S; 3-[(Aminosulfonyl)oxy]estra-1,3,5(10)-trien-17-one; Estra-1,3,5(10)-trien-17-one, 3-((aminosulfonyl)oxy)-; Estrone Sulfamate; estrone3-O-sulfamate; NSC685426; Estrone O-Sulfamate; Estrone 3-Sulfamate; AC1L2SFZ; SCHEMBL305660; CTK8F0296; RVKFQAJIXCZXQY-CBZIJGRNSA-N; ZINC5832614; BDBM50134329; AKOS030241107
DMFQX1U DT Small molecular drug
DMFQX1U PC 127676
DMFQX1U MW 349.4
DMFQX1U FM C18H23NO4S
DMFQX1U IC InChI=1S/C18H23NO4S/c1-18-9-8-14-13-5-3-12(23-24(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,18+/m1/s1
DMFQX1U CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMFQX1U IK RVKFQAJIXCZXQY-CBZIJGRNSA-N
DMFQX1U IU [(8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] sulfamate
DMFQX1U CA CAS 148672-09-7
DMFQX1U DE Discovery agent
DMUH1JX ID DMUH1JX
DMUH1JX DN EMC-0901
DMUH1JX HS Investigative
DMUH1JX SN EMC-0902; Dipeptidyl peptidase IV inhibitors (diabetes), EMC Microcollections; DPP-IV inhibitors (diabetes), EMC Microcollections
DMUH1JX CP EMC Microcollections GmbH
DMUH1JX DE Diabetic complication
DM4SEMA ID DM4SEMA
DM4SEMA DN EMD 56551
DM4SEMA HS Investigative
DM4SEMA DE Discovery agent
DM3AGUQ ID DM3AGUQ
DM3AGUQ DN EMD-386088
DM3AGUQ HS Investigative
DM3AGUQ SN compound 18 [PMID 16055331]; EMD 386088; EMD386088
DM3AGUQ DT Small molecular drug
DM3AGUQ PC 10131112
DM3AGUQ MW 246.73
DM3AGUQ FM C14H15ClN2
DM3AGUQ IC InChI=1S/C14H15ClN2/c1-9-14(10-4-6-16-7-5-10)12-8-11(15)2-3-13(12)17-9/h2-4,8,16-17H,5-7H2,1H3
DM3AGUQ CS CC1=C(C2=C(N1)C=CC(=C2)Cl)C3=CCNCC3
DM3AGUQ IK BPPGPYJBCVXILI-UHFFFAOYSA-N
DM3AGUQ IU 5-chloro-2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
DM3AGUQ CA CAS 54635-62-0
DM3AGUQ CB CHEBI:92829
DM3AGUQ DE Discovery agent
DM6O2BR ID DM6O2BR
DM6O2BR DN EMPA
DM6O2BR HS Investigative
DM6O2BR SN EMPA; 680590-49-2; CHEMBL2385132; N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonyl-amino]-N-(pyridin-3-ylmethyl)ethanamide; 7MA; GTPL4037; SCHEMBL1040297; MolPort-035-765-760; KJPHTXTWFHVJIG-UHFFFAOYSA-N; BCP23952; ZINC95617557; BDBM50434481; AKOS024458223; API0017731; NCGC00386678-02; N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonylamino]-N-(pyridin-3-ylmethyl)acetamide; N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide
DM6O2BR DT Small molecular drug
DM6O2BR PC 9981404
DM6O2BR MW 454.5
DM6O2BR FM C23H26N4O4S
DM6O2BR IC InChI=1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3
DM6O2BR CS CCN(CC1=CN=CC=C1)C(=O)CN(C2=CN=C(C=C2)OC)S(=O)(=O)C3=CC=CC=C3C
DM6O2BR IK KJPHTXTWFHVJIG-UHFFFAOYSA-N
DM6O2BR IU N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl)sulfonylamino]-N-(pyridin-3-ylmethyl)acetamide
DM6O2BR CA CAS 680590-49-2
DM6O2BR DE Discovery agent
DMQLNZC ID DMQLNZC
DMQLNZC DN Empagli ozin
DMQLNZC HS Investigative
DMQLNZC CP Boehringer ingelheim pharmaceuticals; eli lilly
DMQLNZC DE Type-2 diabetes
DMASQWV ID DMASQWV
DMASQWV DN enantio PAF C-16
DMASQWV HS Investigative
DMASQWV SN enantio platelet-activating factor C-16
DMASQWV DT Small molecular drug
DMASQWV PC 2499
DMASQWV MW 523.7
DMASQWV FM C26H54NO7P
DMASQWV IC InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3
DMASQWV CS CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)C
DMASQWV IK HVAUUPRFYPCOCA-UHFFFAOYSA-N
DMASQWV IU (2-acetyloxy-3-hexadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
DMASQWV CA CAS 77286-68-1
DMASQWV DE Discovery agent
DMUCZPJ ID DMUCZPJ
DMUCZPJ DN ENDG-4010
DMUCZPJ HS Investigative
DMUCZPJ SN ENDG-1620; Imaging agent (tumor), EndogenX
DMUCZPJ CP EndogenX Inc
DMUCZPJ DE Solid tumour/cancer
DM7RDGH ID DM7RDGH
DM7RDGH DN ENDIANDRIN A
DM7RDGH HS Investigative
DM7RDGH SN ENDIANDRIN A; CHEMBL228274; BDBM50216277; 4,4''-((1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl)bis(2-methoxyphenol)
DM7RDGH DT Small molecular drug
DM7RDGH PC 16756780
DM7RDGH MW 328.4
DM7RDGH FM C20H24O4
DM7RDGH IC InChI=1S/C20H24O4/c1-11-12(2)20(14-6-8-16(22)18(10-14)24-4)19(11)13-5-7-15(21)17(9-13)23-3/h5-12,19-22H,1-4H3/t11-,12-,19-,20-/m0/s1
DM7RDGH CS C[C@H]1[C@@H]([C@H]([C@@H]1C2=CC(=C(C=C2)O)OC)C3=CC(=C(C=C3)O)OC)C
DM7RDGH IK QDBUCXMBHJMGCN-HIGYNYDNSA-N
DM7RDGH IU 4-[(1R,2R,3S,4S)-2-(4-hydroxy-3-methoxyphenyl)-3,4-dimethylcyclobutyl]-2-methoxyphenol
DM7RDGH DE Discovery agent
DM4AI91 ID DM4AI91
DM4AI91 DN Endo-CD
DM4AI91 HS Investigative
DM4AI91 SN Endostatin-cytosine deaminase fusion protein
DM4AI91 DE Discovery agent
DMOQWBU ID DMOQWBU
DMOQWBU DN ENDOMORPHIN 2
DMOQWBU HS Investigative
DMOQWBU SN Endomorphin 2; Endomorphin-2; 141801-26-5; H-Tyr-Pro-Phe-Phe-NH2; UNII-3PH5M0466G; CHEMBL333357; 3PH5M0466G; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-phenylalanyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMOQWBU DT Small molecular drug
DMOQWBU PC 5311081
DMOQWBU MW 571.7
DMOQWBU FM C32H37N5O5
DMOQWBU IC InChI=1S/C32H37N5O5/c33-25(18-23-13-15-24(38)16-14-23)32(42)37-17-7-12-28(37)31(41)36-27(20-22-10-5-2-6-11-22)30(40)35-26(29(34)39)19-21-8-3-1-4-9-21/h1-6,8-11,13-16,25-28,38H,7,12,17-20,33H2,(H2,34,39)(H,35,40)(H,36,41)/t25-,26-,27-,28-/m0/s1
DMOQWBU CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N
DMOQWBU IK XIJHWXXXIMEHKW-LJWNLINESA-N
DMOQWBU IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMOQWBU CA CAS 141801-26-5
DMOQWBU DE Discovery agent
DMBJUEM ID DMBJUEM
DMBJUEM DN ENDOMORPHIN-1
DMBJUEM HS Investigative
DMBJUEM SN Endomorphin 1; Endomorphin-1; 189388-22-5; Tyr-Pro-Trp-Phe-Nh2; H-Tyr-Pro-Trp-Phe-NH2; CHEMBL316446; L-Phenylalaninamide,L-tyrosyl-L-prolyl-L-tryptophyl-; (S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide; (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMBJUEM DT Small molecular drug
DMBJUEM PC 5311080
DMBJUEM MW 610.7
DMBJUEM FM C34H38N6O5
DMBJUEM IC InChI=1S/C34H38N6O5/c35-26(17-22-12-14-24(41)15-13-22)34(45)40-16-6-11-30(40)33(44)39-29(19-23-20-37-27-10-5-4-9-25(23)27)32(43)38-28(31(36)42)18-21-7-2-1-3-8-21/h1-5,7-10,12-15,20,26,28-30,37,41H,6,11,16-19,35H2,(H2,36,42)(H,38,43)(H,39,44)/t26-,28-,29-,30-/m0/s1
DMBJUEM CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N
DMBJUEM IK ZEXLJFNSKAHNFH-SYKYGTKKSA-N
DMBJUEM IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMBJUEM CA CAS 189388-22-5
DMBJUEM DE Discovery agent
DMI2RQS ID DMI2RQS
DMI2RQS DN Endomorphins
DMI2RQS HS Investigative
DMI2RQS SN EM-1; EM-2; Endomorphins (chronic inflammation); Endomorphin EM-1, University of Bristol; Endomorphin EM-2, University of Bristol; Endomorphins (chronic inflammation), University of Bristol
DMI2RQS CP University of Bristol
DMI2RQS DE Inflammation
DMOEIYQ ID DMOEIYQ
DMOEIYQ DN Endothelin-2
DMOEIYQ HS Investigative
DMOEIYQ SN Endothelin 2, human; ET-2; CHEMBL3774897; Endothelin-2; endothelin-2 human; Endothelin 2 human; GTPL990
DMOEIYQ DT Small molecular drug
DMOEIYQ PC 16219332
DMOEIYQ MW 2546.9
DMOEIYQ FM C115H160N26O32S4
DMOEIYQ IC InChI=1S/C115H160N26O32S4/c1-11-59(9)93(113(170)132-82(115(172)173)41-64-46-120-71-27-19-17-25-68(64)71)141-114(171)94(60(10)12-2)140-105(162)81(44-91(150)151)130-99(156)75(37-57(5)6)125-103(160)79(42-65-47-118-55-121-65)128-109(166)86-52-175-174-51-69(117)95(152)133-83(48-142)108(165)138-87-53-176-177-54-88(111(168)139-92(58(7)8)112(169)131-77(39-62-29-31-66(145)32-30-62)100(157)126-76(101(158)137-86)38-61-22-14-13-15-23-61)136-97(154)73(33-34-89(146)147)123-96(153)72(28-20-21-35-116)122-104(161)80(43-90(148)149)129-98(155)74(36-56(3)4)124-102(159)78(40-63-45-119-70-26-18-16-24-67(63)70)127-106(163)84(49-143)134-107(164)85(50-144)135-110(87)167/h13-19,22-27,29-32,45-47,55-60,69,72-88,92-94,119-120,142-145H,11-12,20-21,28,33-44,48-54,116-117H2,1-10H3,(H,118,121)(H,122,161)(H,123,153)(H,124,159)(H,125,160)(H,126,157)(H,127,163)(H,128,166)(H,129,155)(H,130,156)(H,131,169)(H,132,170)(H,133,152)(H,134,164)(H,135,167)(H,136,154)(H,137,158)(H,138,165)(H,139,168)(H,140,162)(H,141,171)(H,146,147)(H,148,149)(H,150,151)(H,172,173)/t59-,60-,69-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,92-,93-,94-/m0/s1
DMOEIYQ CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC5=O)CO)CO)CC8=CNC9=CC=CC=C98)CC(C)C)CC(=O)O)CCCCN)CCC(=O)O)CO)N
DMOEIYQ IK MLFJHYIHIKEBTQ-IYRKOGFYSA-N
DMOEIYQ IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-7-(4-aminobutyl)-39-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-19,22,28-tris(hydroxymethyl)-42-[(4-hydroxyphenyl)methyl]-16-(1H-indol-3-ylmethyl)-13-(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-45-propan-2-yl-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DMOEIYQ DE Discovery agent
DM0DM6X ID DM0DM6X
DM0DM6X DN Endothelin-3
DM0DM6X HS Investigative
DM0DM6X SN ET-3; Endothelin 3 human, rat; 117399-93-6; Endothelin 3 human, rat, > =97% (HPLC), powder
DM0DM6X DT Small molecular drug
DM0DM6X PC 16219334
DM0DM6X MW 2643.1
DM0DM6X FM C121H168N26O33S4
DM0DM6X IC InChI=1S/C121H168N26O33S4/c1-11-62(7)97(117(175)139-89(121(179)180)49-70-53-126-77-25-17-16-24-75(70)77)145-118(176)98(63(8)12-2)144-112(170)88(52-95(157)158)136-105(163)81(44-60(3)4)131-109(167)86(50-71-54-125-59-127-71)134-113(171)90-56-182-181-55-76(124)101(159)146-99(64(9)148)120(178)142-91-57-183-184-58-92(115(173)143-96(61(5)6)116(174)137-84(48-69-32-38-74(152)39-33-69)107(165)132-82(108(166)141-90)46-67-28-34-72(150)35-29-67)140-104(162)80(40-41-93(153)154)130-102(160)78(26-18-20-42-122)129-110(168)87(51-94(155)156)135-103(161)79(27-19-21-43-123)128-106(164)83(47-68-30-36-73(151)37-31-68)138-119(177)100(65(10)149)147-111(169)85(133-114(91)172)45-66-22-14-13-15-23-66/h13-17,22-25,28-39,53-54,59-65,76,78-92,96-100,126,148-152H,11-12,18-21,26-27,40-52,55-58,122-124H2,1-10H3,(H,125,127)(H,128,164)(H,129,168)(H,130,160)(H,131,167)(H,132,165)(H,133,172)(H,134,171)(H,135,161)(H,136,163)(H,137,174)(H,138,177)(H,139,175)(H,140,162)(H,141,166)(H,142,178)(H,143,173)(H,144,170)(H,145,176)(H,146,159)(H,147,169)(H,153,154)(H,155,156)(H,157,158)(H,179,180)/t62-,63-,64?,65?,76-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,96-,97-,98-,99-,100-/m0/s1
DM0DM6X CS CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=C(C=C6)O)CC7=CC=C(C=C7)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC5=O)CC8=CC=CC=C8)C(C)O)CC9=CC=C(C=C9)O)CCCCN)CC(=O)O)CCCCN)CCC(=O)O)C(C)O)N
DM0DM6X IK OQGZWNZGVYLIFX-XKIQDWPYSA-N
DM0DM6X IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16S,19S,22S,25R,28S,31R,36R,39S,42S,45S)-31-amino-7,13-bis(4-aminobutyl)-22-benzyl-4-(2-carboxyethyl)-10-(carboxymethyl)-19,28-bis(1-hydroxyethyl)-16,39,42-tris[(4-hydroxyphenyl)methyl]-3,6,9,12,15,18,21,24,27,30,38,41,44,47-tetradecaoxo-45-propan-2-yl-33,34,49,50-tetrathia-2,5,8,11,14,17,20,23,26,29,37,40,43,46-tetradecazabicyclo[23.22.4]henpentacontane-36-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
DM0DM6X CA CAS 117399-93-6
DM0DM6X DE Discovery agent
DM0STFR ID DM0STFR
DM0STFR DN ENHYDRIN
DM0STFR HS Investigative
DM0STFR SN Enhydrin; enhydrine; CHEMBL206765
DM0STFR DT Small molecular drug
DM0STFR PC 5281441
DM0STFR MW 464.5
DM0STFR FM C23H28O10
DM0STFR IC InChI=1S/C23H28O10/c1-10-14-16(31-21(27)23(5)11(2)32-23)15(29-12(3)24)13(20(26)28-6)8-7-9-22(4)18(33-22)17(14)30-19(10)25/h8,11,14-18H,1,7,9H2,2-6H3/b13-8+/t11-,14-,15+,16+,17+,18-,22-,23-/m1/s1
DM0STFR CS C[C@@H]1[C@](O1)(C)C(=O)O[C@H]2[C@@H]3[C@@H]([C@@H]4[C@](O4)(CC/C=C(\\[C@@H]2OC(=O)C)/C(=O)OC)C)OC(=O)C3=C
DM0STFR IK VCBNPTWPJQLHQN-FQAPAZNFSA-N
DM0STFR IU methyl (1S,2R,4R,7E,9S,10S,11R)-9-acetyloxy-10-[(2R,3R)-2,3-dimethyloxirane-2-carbonyl]oxy-4-methyl-12-methylidene-13-oxo-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-ene-8-carboxylate
DM0STFR CA CAS 33880-85-2
DM0STFR DE Discovery agent
DMYJ8ZB ID DMYJ8ZB
DMYJ8ZB DN Enoxaprin
DMYJ8ZB HS Investigative
DMYJ8ZB DE Discovery agent
DMSPIF2 ID DMSPIF2
DMSPIF2 DN EP 157
DMSPIF2 HS Investigative
DMSPIF2 SN EP-157; EP157
DMSPIF2 DT Small molecular drug
DMSPIF2 PC 73755162
DMSPIF2 MW 443.6
DMSPIF2 FM C29H33NO3
DMSPIF2 IC InChI=1S/C29H33NO3/c31-28(32)16-10-2-1-9-15-26-22-17-19-23(20-18-22)27(26)21-30-33-29(24-11-5-3-6-12-24)25-13-7-4-8-14-25/h1,3-9,11-14,17,19,21-23,26-27,29H,2,10,15-16,18,20H2,(H,31,32)/b9-1-,30-21-/t22-,23+,26+,27+/m0/s1
DMSPIF2 CS C1C[C@H]2C=C[C@@H]1[C@H]([C@@H]2/C=N\\OC(C3=CC=CC=C3)C4=CC=CC=C4)C/C=C\\CCCC(=O)O
DMSPIF2 IK NBBRUBRIVJNCKV-WXGDQWFLSA-N
DMSPIF2 IU (Z)-7-[(1R,2R,3R,4S)-3-[(Z)-benzhydryloxyiminomethyl]-2-bicyclo[2.2.2]oct-5-enyl]hept-5-enoic acid
DMSPIF2 DE Discovery agent
DM7YION ID DM7YION
DM7YION DN EP 171
DM7YION HS Investigative
DM7YION SN EP-171; EP171
DM7YION DT Small molecular drug
DM7YION PC 5311384
DM7YION MW 404.5
DM7YION FM C23H29FO5
DM7YION IC InChI=1S/C23H29FO5/c24-16-7-10-18(11-8-16)28-15-17(25)9-12-20-19(21-13-14-22(20)29-21)5-3-1-2-4-6-23(26)27/h1,3,7-12,17,19-22,25H,2,4-6,13-15H2,(H,26,27)/b3-1-,12-9+/t17-,19+,20+,21-,22+/m0/s1
DM7YION CS C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)C/C=C\\CCCC(=O)O)/C=C/[C@@H](COC3=CC=C(C=C3)F)O
DM7YION IK JEUSDRLWFSRHSX-XUEDOEMRSA-N
DM7YION IU (Z)-7-[(1S,2R,3R,4R)-3-[(E,3S)-4-(4-fluorophenoxy)-3-hydroxybut-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DM7YION DE Discovery agent
DMAURX5 ID DMAURX5
DMAURX5 DN EP-200
DMAURX5 HS Investigative
DMAURX5 SN HCG targeted oncolytic peptide (iv, CLYP, multiple cancers), Esperance Pharmaceuticals; Luteinizing hormone receptor targeted oncolytic peptide (iv/CLYP, multiple cancers), Esperance Pharmaceuticals
DMAURX5 CP Esperance Pharmaceuticals Inc
DMAURX5 DE Solid tumour/cancer
DMHN82B ID DMHN82B
DMHN82B DN EP-37
DMHN82B HS Investigative
DMHN82B SN Factor Xa antagonist (oral, stroke prevention in atrial fibrillation), Endotis
DMHN82B CP Endotis Pharma
DMHN82B DE Cerebrovascular ischaemia
DM01MW7 ID DM01MW7
DM01MW7 DN EPALRESTATE
DM01MW7 HS Investigative
DM01MW7 SN CHEMBL449204; AC1Q1J87; [5-(2-Methyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid; ZINC967120
DM01MW7 DT Small molecular drug
DM01MW7 PC 1201332
DM01MW7 MW 319.4
DM01MW7 FM C15H13NO3S2
DM01MW7 IC InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7-,12-8+
DM01MW7 CS C/C(=C/C1=CC=CC=C1)/C=C/2\\C(=O)N(C(=S)S2)CC(=O)O
DM01MW7 IK CHNUOJQWGUIOLD-MITUOZDPSA-N
DM01MW7 IU 2-[(5E)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
DM01MW7 DE Discovery agent
DMBLSX3 ID DMBLSX3
DMBLSX3 DN EPB-415
DMBLSX3 HS Investigative
DMBLSX3 SN Ribavirin prodrug (hepatitis C virus infection), Epiphany
DMBLSX3 CP Epiphany Biosciences
DMBLSX3 DE Hepatitis C virus infection
DMT7RXZ ID DMT7RXZ
DMT7RXZ DN E-pentenylbutanedioic acid 32
DMT7RXZ HS Investigative
DMT7RXZ DT Small molecular drug
DMT7RXZ PC 56603767
DMT7RXZ MW 210.1
DMT7RXZ FM C10H12Li2O4
DMT7RXZ IC InChI=1S/C10H14O4.2Li/c1-7(2)4-3-5-8(10(13)14)6-9(11)12;;/h6H,1,3-5H2,2H3,(H,11,12)(H,13,14);;/q;2*+1/p-2/b8-6+;;
DMT7RXZ CS [Li+].[Li+].CC(=C)CCC/C(=C\\C(=O)[O-])/C(=O)[O-]
DMT7RXZ IK GPRQQRASSGZCNY-OVGXCEQFSA-L
DMT7RXZ IU dilithium;(E)-2-(4-methylpent-4-enyl)but-2-enedioate
DMT7RXZ DE Discovery agent
DM3F427 ID DM3F427
DM3F427 DN EphB4-131
DM3F427 HS Investigative
DM3F427 SN EphB4 neutralizing antibody, Vasgene
DM3F427 CP VasGene Therapeutics Inc
DM3F427 DT Antibody
DM3F427 DE Solid tumour/cancer
DMYWV81 ID DMYWV81
DMYWV81 DN EPI-001
DMYWV81 HS Investigative
DMYWV81 SN 227947-06-0; BADGE-HCl-H2O; Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether; 3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol; 3-(4-{2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl}phenoxy)propane-1,2-diol; EPI 001; AC1N56RN; SCHEMBL12267194; CTK8F8201; CHEBI:59642; DTXSID30400170; MolPort-003-939-733; BCP18361; EX-A2389; s7955; AKOS030573303; ACM227947060; AC-29035; RT-011557; EPI-001, > J-014857
DMYWV81 CP British Columbia Cancer Agency
DMYWV81 DT Small molecular drug
DMYWV81 PC 4166922
DMYWV81 MW 394.9
DMYWV81 FM C21H27ClO5
DMYWV81 IC InChI=1S/C21H27ClO5/c1-21(2,15-3-7-19(8-4-15)26-13-17(24)11-22)16-5-9-20(10-6-16)27-14-18(25)12-23/h3-10,17-18,23-25H,11-14H2,1-2H3
DMYWV81 CS CC(C)(C1=CC=C(C=C1)OCC(CO)O)C2=CC=C(C=C2)OCC(CCl)O
DMYWV81 IK HDTYUHNZRYZEEB-UHFFFAOYSA-N
DMYWV81 IU 3-[4-[2-[4-(3-chloro-2-hydroxypropoxy)phenyl]propan-2-yl]phenoxy]propane-1,2-diol
DMYWV81 CA CAS 227947-06-0
DMYWV81 CB CHEBI:59642
DMYWV81 DE Prostate cancer
DM72DO1 ID DM72DO1
DM72DO1 DN EPI-0030
DM72DO1 HS Investigative
DM72DO1 SN APX-003; SIM-BD-0801; Humanized anti-VEGF mAbs (RabMab/MLG, cancer), Apexigen/Simcere; Humanized anti-VEGF mAbs (RabMab/MLG, cancer), Epitomics/Simcere
DM72DO1 CP Epitomics Inc
DM72DO1 DE Solid tumour/cancer
DMAGZD8 ID DMAGZD8
DMAGZD8 DN Epibatidine
DMAGZD8 HS Investigative
DMAGZD8 SN ( inverted exclamation markA)-Epibatidine; CHEMBL298517; (1S,2S,4R)-Epibatidine; CMI 477; 152378-30-8; 148152-66-3; (1S-exo)-2-(6-Chloro-3-pyridinyl)-7-azabicyclo(2.2.1)heptane; 7-Azabicyclo(2.2.1)heptane, 2-(6-chloro-3-pyridinyl)-, (1S-exo)-; (-)-1-epidatidine; Tocris-0684; SCHEMBL316977; (1S,2S,4R)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane; GTPL5348; CMI 488; ZINC967913; BDBM50143320
DMAGZD8 DT Small molecular drug
DMAGZD8 PC 854023
DMAGZD8 MW 208.69
DMAGZD8 FM C11H13ClN2
DMAGZD8 IC InChI=1S/C11H13ClN2/c12-11-4-1-7(6-13-11)9-5-8-2-3-10(9)14-8/h1,4,6,8-10,14H,2-3,5H2/t8-,9+,10+/m0/s1
DMAGZD8 CS C1C[C@@H]2[C@H](C[C@H]1N2)C3=CN=C(C=C3)Cl
DMAGZD8 IK NLPRAJRHRHZCQQ-IVZWLZJFSA-N
DMAGZD8 IU (1R,2R,4S)-2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane
DMAGZD8 CA CAS 140111-52-0
DMAGZD8 DE Discovery agent
DMFMWA7 ID DMFMWA7
DMFMWA7 DN EpiCept
DMFMWA7 HS Investigative
DMFMWA7 TC Analgesics
DMFMWA7 DE Neuropathic pain
DMGKIYE ID DMGKIYE
DMGKIYE DN EPIDEPRIDE
DMGKIYE HS Investigative
DMGKIYE SN Epidepride; CHEMBL44237; 107188-87-4; N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2,3-dimethoxybenzamide; AC1L3AWQ; SCHEMBL8961795; DTXSID00147929; CHEBI:125687; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-iodo-2,3-dimethoxybenzamide; BDBM50008782; PDSP2_001484; BRD-K99502674-001-01-5; (s)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxy-benzamide; N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2,3-dimethoxy-benzamide (epidepride); Epidepride;N-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-iodo-2,3-dimethoxy-benzamide; Benzamide, N-((1-
DMGKIYE DT Small molecular drug
DMGKIYE PC 86101
DMGKIYE MW 418.27
DMGKIYE FM C16H23IN2O3
DMGKIYE IC InChI=1S/C16H23IN2O3/c1-4-19-7-5-6-12(19)10-18-16(20)13-8-11(17)9-14(21-2)15(13)22-3/h8-9,12H,4-7,10H2,1-3H3,(H,18,20)/t12-/m0/s1
DMGKIYE CS CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2)I)OC)OC
DMGKIYE IK APNNSBJHVTUORL-LBPRGKRZSA-N
DMGKIYE IU N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2,3-dimethoxybenzamide
DMGKIYE CA CAS 107188-87-4
DMGKIYE CB CHEBI:125687
DMGKIYE DE Discovery agent
DMVZW92 ID DMVZW92
DMVZW92 DN Epierenone
DMVZW92 HS Investigative
DMVZW92 SN epierenone; CHEMBL237122; SCHEMBL13806060
DMVZW92 DT Small molecular drug
DMVZW92 PC 44433505
DMVZW92 MW 414.5
DMVZW92 FM C24H30O6
DMVZW92 IC InChI=1S/C24H30O6/c1-22-7-4-13(25)10-12(22)11-14(21(27)28-3)17-15-5-8-24(9-6-16(26)30-24)23(15,2)20-19(29-20)18(17)22/h10,14-15,17-20H,4-9,11H2,1-3H3/t14-,15?,17?,18?,19+,20+,22+,23-,24-/m1/s1
DMVZW92 CS C[C@]12CCC(=O)C=C1C[C@H](C3C2[C@H]4[C@H](O4)[C@]5(C3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMVZW92 IK QBIRIYASLUPKQB-CBHLJOAQSA-N
DMVZW92 IU methyl (2S,4R,5R,6R,11R,18R)-5,18-dimethyl-5',15-dioxospiro[3-oxapentacyclo[8.8.0.02,4.05,9.013,18]octadec-13-ene-6,2'-oxolane]-11-carboxylate
DMVZW92 DE Discovery agent
DMQAEU8 ID DMQAEU8
DMQAEU8 DN EPIMER A
DMQAEU8 HS Investigative
DMQAEU8 SN CHEMBL564088; EPIMER A; BDBM50296787; N-((S)-2''-oxo-1,1'',2'',3-tetrahydrospiro[indene-2,3''-pyrrolo[2,3-b]pyridine]-5-yl)-2-(4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetamide 2; N-((S)-2''-oxo-1,1'',2'',3-tetrahydrospiro[indene-2,3''-pyrrolo[2,3-b]pyridine]-5-yl)-2-(4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetamide 1
DMQAEU8 DT Small molecular drug
DMQAEU8 PC 23582940
DMQAEU8 MW 465.5
DMQAEU8 FM C27H23N5O3
DMQAEU8 IC InChI=1S/C27H23N5O3/c33-22-10-17-13-32(21-5-1-4-20(30-22)24(17)21)14-23(34)29-18-7-6-15-11-27(12-16(15)9-18)19-3-2-8-28-25(19)31-26(27)35/h1-9,17H,10-14H2,(H,29,34)(H,30,33)(H,28,31,35)/t17?,27-/m0/s1
DMQAEU8 CS C1C2CN(C3=CC=CC(=C23)NC1=O)CC(=O)NC4=CC5=C(C[C@]6(C5)C7=C(NC6=O)N=CC=C7)C=C4
DMQAEU8 IK YMMTXWRRJUTBEI-LYTHVRBOSA-N
DMQAEU8 IU 2-(6-oxo-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(11),8(12),9-trien-2-yl)-N-[(2S)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
DMQAEU8 DE Discovery agent
DMW271Q ID DMW271Q
DMW271Q DN epipregnanolone sulphate
DMW271Q HS Investigative
DMW271Q SN epipregnanolone sulfate
DMW271Q DT Small molecular drug
DMW271Q PC 73755084
DMW271Q MW 398.6
DMW271Q FM C21H34O5S
DMW271Q IC InChI=1S/C21H34O5S/c1-13(22)17-6-7-18-16-5-4-14-12-15(26-27(23,24)25)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19H,4-12H2,1-3H3,(H,23,24,25)/t14-,15+,16?,17?,18?,19?,20+,21-/m1/s1
DMW271Q CS CC(=O)C1CCC2[C@@]1(CCC3C2CC[C@H]4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C)C
DMW271Q IK MENQCIVHHONJLU-ACWDEBGSSA-N
DMW271Q IU [(3S,5R,10S,13S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
DMW271Q DE Discovery agent
DM1C8FW ID DM1C8FW
DM1C8FW DN Epitinib
DM1C8FW HS Investigative
DM1C8FW SN HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma
DM1C8FW CP Hutchison Medipharma Enterprises Ltd
DM1C8FW DT Small molecular drug
DM1C8FW PC 59142777
DM1C8FW MW 430.5
DM1C8FW FM C24H26N6O2
DM1C8FW IC InChI=1S/C24H26N6O2/c1-4-17-7-6-8-18(13-17)27-23-19-14-21(22(32-3)15-20(19)25-16-26-23)28-24(31)30-11-9-29(5-2)10-12-30/h1,6-8,13-16H,5,9-12H2,2-3H3,(H,28,31)(H,25,26,27)
DM1C8FW CS CCN1CCN(CC1)C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=CC=CC(=C4)C#C)OC
DM1C8FW IK DQAZPZIYEOGZAF-UHFFFAOYSA-N
DM1C8FW IU 4-ethyl-N-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide
DM1C8FW CA 1203902-67-3
DM1C8FW DE Solid tumour/cancer
DMVOD03 ID DMVOD03
DMVOD03 DN Eplerenone
DMVOD03 HS Investigative
DMVOD03 SN Epoxymexrenone; Inspra; Selara; SC-66110; Epleremone; CGP-30083; UNII-6995V82D0B; Cgp 30083
DMVOD03 TC Antiviral Agents
DMVOD03 DT Small molecular drug
DMVOD03 PC 443872
DMVOD03 MW 414.5
DMVOD03 FM C24H30O6
DMVOD03 IC InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
DMVOD03 CS C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC
DMVOD03 IK JUKPWJGBANNWMW-VWBFHTRKSA-N
DMVOD03 IU methyl (1R,2S,9R,10R,11S,14R,15S,17R)-2,15-dimethyl-5,5'-dioxospiro[18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadec-6-ene-14,2'-oxolane]-9-carboxylate
DMVOD03 CA CAS 107724-20-9
DMVOD03 CB CHEBI:31547
DMVOD03 DE Coronavirus Disease 2019 (COVID-19)
DMDOR0L ID DMDOR0L
DMDOR0L DN EPLIVANSERIN MESILATE
DMDOR0L HS Investigative
DMDOR0L SN 1(Z)-[2-(Dimethylamino)ethoxyimino]-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2(E)-propene methanesulfonate; Eplivanserin mesilate; SR-46349C
DMDOR0L DE Discovery agent
DMP2QF0 ID DMP2QF0
DMP2QF0 DN EPO peptide mimetics
DMP2QF0 HS Investigative
DMP2QF0 SN HemoMer; SESTide; AGE-49C; AGE-53C; EPO peptide mimetics (anemia); AG-EM-0040; EPO peptide mimetics (anemia), AplaGen; Erythropoietin peptide mimetics (anemia), AplaGen
DMP2QF0 CP AplaGen GmbH
DMP2QF0 DE Anemia
DMHQDLX ID DMHQDLX
DMHQDLX DN EPO-derived peptide
DMHQDLX HS Investigative
DMHQDLX SN EPO-derived peptide (diabetic retinopathy); EPO helix-B domain peptide (diabetic retinopathy), Araim Pharmaceuticals; EPO-derived peptide (diabetic retinopathy), Araim Pharmaceuticals; Erythropoietin-derived peptide (diabetic retinopathy), Araim Pharmaceuticals
DMHQDLX CP Araim Pharmaceuticals Inc
DMHQDLX DE Diabetic retinopathy
DMV8PB4 ID DMV8PB4
DMV8PB4 DN Epostane
DMV8PB4 HS Investigative
DMV8PB4 SN Epostane; Epostanum [Latin]; Epostano [Spanish]; WIN 32729; AC1L1HB6; Epostane [USAN:BAN:INN]; 4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile (4alpha,5alpha,17beta); Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-4,17-dimethyl-, (4alpha,5alpha,17beta)-; LS-19418; Androst-2-ene-2-carbonitrile, 3,17-dihydroxy-4,17-dimethyl-4,5-epoxy-, (4-alpha,5-alpha,17-beta)-
DMV8PB4 DT Small molecular drug
DMV8PB4 PC 6917713
DMV8PB4 MW 357.5
DMV8PB4 FM C22H31NO3
DMV8PB4 IC InChI=1S/C22H31NO3/c1-18-8-6-16-14(15(18)7-9-20(18,3)25)5-10-22-19(16,2)11-13(12-23)17(24)21(22,4)26-22/h14-16,24-25H,5-11H2,1-4H3/t14-,15-,16-,18-,19+,20-,21+,22-/m0/s1
DMV8PB4 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@]45[C@@]3(CC(=C([C@]4(O5)C)O)C#N)C
DMV8PB4 IK CETKWEWBSMKADK-GSXVSZIWSA-N
DMV8PB4 IU (1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,6,15,16-tetramethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
DMV8PB4 CA CAS 80471-63-2
DMV8PB4 DE Abortion
DMK3VID ID DMK3VID
DMK3VID DN EPPTB
DMK3VID HS Investigative
DMK3VID SN Ro 5212773; Ro5212773; Ro-5212773
DMK3VID DT Small molecular drug
DMK3VID PC 25175634
DMK3VID MW 378.4
DMK3VID FM C20H21F3N2O2
DMK3VID IC InChI=1S/C20H21F3N2O2/c1-2-27-16-7-5-6-15(13-16)24-19(26)14-8-9-18(25-10-3-4-11-25)17(12-14)20(21,22)23/h5-9,12-13H,2-4,10-11H2,1H3,(H,24,26)
DMK3VID CS CCOC1=CC=CC(=C1)NC(=O)C2=CC(=C(C=C2)N3CCCC3)C(F)(F)F
DMK3VID IK KLFVWQCQUXXLOU-UHFFFAOYSA-N
DMK3VID IU N-(3-ethoxyphenyl)-4-pyrrolidin-1-yl-3-(trifluoromethyl)benzamide
DMK3VID DE Discovery agent
DMLN4V5 ID DMLN4V5
DMLN4V5 DN EPZ-004777
DMLN4V5 HS Investigative
DMLN4V5 SN DOT1L inhibitors (mixed lineage leukemia); DOT1L inhibitors (leukemia), Epizyme/GSK; DOT1L inhibitors (mixed lineage leukemia), Epizyme/GlaxoSmithKline
DMLN4V5 CP Epizyme Inc
DMLN4V5 DT Small molecular drug
DMLN4V5 PC 56962336
DMLN4V5 MW 539.7
DMLN4V5 FM C28H41N7O4
DMLN4V5 IC InChI=1S/C28H41N7O4/c1-17(2)34(13-6-12-30-27(38)33-19-9-7-18(8-10-19)28(3,4)5)15-21-22(36)23(37)26(39-21)35-14-11-20-24(29)31-16-32-25(20)35/h7-11,14,16-17,21-23,26,36-37H,6,12-13,15H2,1-5H3,(H2,29,31,32)(H2,30,33,38)/t21-,22-,23-,26-/m1/s1
DMLN4V5 CS CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)C[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC4=C(N=CN=C43)N)O)O
DMLN4V5 IK WXRGFPHDRFQODR-ICLZECGLSA-N
DMLN4V5 IU 1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea
DMLN4V5 CA CAS 1338466-77-5
DMLN4V5 CB CHEBI:124920
DMLN4V5 DE leukaemia
DMYISTE ID DMYISTE
DMYISTE DN EPZ005687
DMYISTE HS Investigative
DMYISTE SN EPZ-005687; EPZ 005687
DMYISTE DT Small molecular drug
DMYISTE PC 60160561
DMYISTE MW 539.7
DMYISTE FM C32H37N5O3
DMYISTE IC InChI=1S/C32H37N5O3/c1-21-15-22(2)35-32(39)28(21)18-33-31(38)27-16-25(17-30-29(27)19-34-37(30)26-5-3-4-6-26)24-9-7-23(8-10-24)20-36-11-13-40-14-12-36/h7-10,15-17,19,26H,3-6,11-14,18,20H2,1-2H3,(H,33,38)(H,35,39)
DMYISTE CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC=C(C=C4)CN5CCOCC5)C6CCCC6)C
DMYISTE IK ZOIBZSZLMJDVDQ-UHFFFAOYSA-N
DMYISTE IU 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(morpholin-4-ylmethyl)phenyl]indazole-4-carboxamide
DMYISTE CA CAS 1396772-26-1
DMYISTE CB CHEBI:124922
DMYISTE DE Discovery agent
DM3INX7 ID DM3INX7
DM3INX7 DN EPZ015666
DM3INX7 HS Investigative
DM3INX7 SN EPZ-015666; EPZ 015666
DM3INX7 DT Small molecular drug
DM3INX7 PC 90241673
DM3INX7 MW 383.4
DM3INX7 FM C20H25N5O3
DM3INX7 IC InChI=1S/C20H25N5O3/c26-17(10-25-6-5-14-3-1-2-4-15(14)9-25)8-21-20(27)18-7-19(23-13-22-18)24-16-11-28-12-16/h1-4,7,13,16-17,26H,5-6,8-12H2,(H,21,27)(H,22,23,24)/t17-/m0/s1
DM3INX7 CS C1CN(CC2=CC=CC=C21)C[C@H](CNC(=O)C3=CC(=NC=N3)NC4COC4)O
DM3INX7 IK ZKXZLIFRWWKZRY-KRWDZBQOSA-N
DM3INX7 IU N-[(2S)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide
DM3INX7 DE Discovery agent
DM2KMNU ID DM2KMNU
DM2KMNU DN EQ-1280
DM2KMNU HS Investigative
DM2KMNU SN 11-beta hydroxysteroid dehydrogenase 1 inhibitor (diabetes), Equispharm
DM2KMNU CP Equispharm Co Ltd
DM2KMNU DE Diabetic complication
DMHO56W ID DMHO56W
DMHO56W DN Equilenin
DMHO56W HS Investigative
DMHO56W SN EQUILENIN; 517-09-9; UNII-W8FTJ17C4J; 3-Hydroxyestra-1,3,5(10),6,8-pentaen-17-one; W8FTJ17C4J; Equilenina [Spanish]; 3-hydroxy-estra-1,3,5(10),6,8-pentaen-17-one; CCRIS 9075; Equilenin solution; EINECS 208-230-5; (13S,14S)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthren-17-one; BRN 2335367; EQU; 3-Hydroxyoestra-1,3,5(10),6,8-pentaen-17-one; 1ogz; 1ogx; 1w6y; AC1L9H0U; 4-08-00-01420 (Beilstein Handbook Reference); SCHEMBL120922; CHEMBL225546; DTXSID2052156; CTK8F9475; ZINC393154; LMST02010007; BDBM50423545
DMHO56W DT Small molecular drug
DMHO56W PC 444865
DMHO56W MW 266.3
DMHO56W FM C18H18O2
DMHO56W IC InChI=1S/C18H18O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2-5,10,16,19H,6-9H2,1H3/t16-,18-/m0/s1
DMHO56W CS C[C@]12CCC3=C([C@@H]1CCC2=O)C=CC4=C3C=CC(=C4)O
DMHO56W IK PDRGHUMCVRDZLQ-WMZOPIPTSA-N
DMHO56W IU (13S,14S)-3-hydroxy-13-methyl-12,14,15,16-tetrahydro-11H-cyclopenta[a]phenanthren-17-one
DMHO56W CA CAS 517-09-9
DMHO56W CB CHEBI:34739
DMHO56W DE Discovery agent
DM2Q19U ID DM2Q19U
DM2Q19U DN Equilin
DM2Q19U HS Investigative
DM2Q19U SN 7-Dehydroestrone; Dihydroequilenin; Equilin [USP]; UNII-08O86EX0J4; CCRIS 9074; EINECS 207-488-6; NSC 10971; BRN 2624302
DM2Q19U TC Antiviral Agents
DM2Q19U DT Small molecular drug
DM2Q19U PC 223368
DM2Q19U MW 268.3
DM2Q19U FM C18H20O2
DM2Q19U IC InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1
DM2Q19U CS C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O
DM2Q19U IK WKRLQDKEXYKHJB-HFTRVMKXSA-N
DM2Q19U IU (9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
DM2Q19U CA CAS 474-86-2
DM2Q19U CB CHEBI:42309
DM2Q19U DE Coronavirus Disease 2019 (COVID-19)
DM9PT03 ID DM9PT03
DM9PT03 DN Equilin
DM9PT03 HS Investigative
DM9PT03 SN equilin; 7-Dehydroestrone; 474-86-2; Dihydroequilenin; 3-HYDROXYESTRA-1,3,5(10),7-TETRAEN-17-ONE; 1,3,5,7-Estratetraen-3-ol-17-one; Equilin [USP]; UNII-08O86EX0J4; MLS000028624; CHEBI:42309; WKRLQDKEXYKHJB-HFTRVMKXSA-N; 08O86EX0J4; Equilin (USP); SMR000058656; 3-hydroxy-estra-1,3,5(10),7tetraen-17-one; Estra-1,3,5(10),7-tetraen-17-one,3-hydroxy-; CCRIS 9074; EINECS 207-488-6; NSC 10971; BRN 2624302; (9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
DM9PT03 DT Small molecular drug
DM9PT03 PC 223368
DM9PT03 MW 268.3
DM9PT03 FM C18H20O2
DM9PT03 IC InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1
DM9PT03 CS C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O
DM9PT03 IK WKRLQDKEXYKHJB-HFTRVMKXSA-N
DM9PT03 IU (9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one
DM9PT03 CA CAS 474-86-2
DM9PT03 CB CHEBI:42309
DM9PT03 DE Discovery agent
DMIQ801 ID DMIQ801
DMIQ801 DN ER-119884
DMIQ801 HS Investigative
DMIQ801 SN ER-119884; CHEMBL258503; (3r)-3-{[2-Benzyl-6-(3-Methoxypropoxy)pyridin-3-Yl]ethynyl}-1-Azabicyclo[2.2.2]octan-3-Ol; ER4; SCHEMBL6377294; BDBM50208577; (R)-3-(2-(2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl)ethynyl)quinuclidin-3-ol; (R)-3-((2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl)ethynyl)quinuclidin-3-ol; (3r)-3-[[2-benzyl-6-(3-methoxypropyloxy)-pyridin-3-yl]ethynyl] quinuclidin-3-ol
DMIQ801 DT Small molecular drug
DMIQ801 PC 9844255
DMIQ801 MW 406.5
DMIQ801 FM C25H30N2O3
DMIQ801 IC InChI=1S/C25H30N2O3/c1-29-16-5-17-30-24-9-8-21(23(26-24)18-20-6-3-2-4-7-20)10-13-25(28)19-27-14-11-22(25)12-15-27/h2-4,6-9,22,28H,5,11-12,14-19H2,1H3/t25-/m1/s1
DMIQ801 CS COCCCOC1=NC(=C(C=C1)C#C[C@]2(CN3CCC2CC3)O)CC4=CC=CC=C4
DMIQ801 IK HVIKCINYHLGLMN-RUZDIDTESA-N
DMIQ801 IU (3R)-3-[2-[2-benzyl-6-(3-methoxypropoxy)pyridin-3-yl]ethynyl]-1-azabicyclo[2.2.2]octan-3-ol
DMIQ801 DE Discovery agent
DMUNO4R ID DMUNO4R
DMUNO4R DN ER-21018
DMUNO4R HS Investigative
DMUNO4R SN 5-HT 4 receptor agonist (sustained release/tablet, gastrointestinal disease), Eurapharm
DMUNO4R CP Eurapharm Inc
DMUNO4R DE Gastrointestinal disease
DMAO6JS ID DMAO6JS
DMAO6JS DN ER-23006
DMAO6JS HS Investigative
DMAO6JS CP Eurapharm Inc
DMAO6JS DE Asthma
DMSG91J ID DMSG91J
DMSG91J DN ER819762
DMSG91J HS Investigative
DMSG91J SN ER-819762; ER 819762
DMSG91J DT Small molecular drug
DMSG91J PC 42596951
DMSG91J MW 489.6
DMSG91J FM C30H39N3O3
DMSG91J IC InChI=1S/C30H39N3O3/c1-7-33-29(34)32-19-24-16-25(35-5)17-26(36-6)28(24)22(4)15-27(32)30(33)8-10-31(11-9-30)18-23-13-20(2)12-21(3)14-23/h12-17,22H,7-11,18-19H2,1-6H3/t22-/m0/s1
DMSG91J CS CCN1C(=O)N2CC3=C([C@H](C=C2C14CCN(CC4)CC5=CC(=CC(=C5)C)C)C)C(=CC(=C3)OC)OC
DMSG91J IK ANKFBAJRCGOKJJ-QFIPXVFZSA-N
DMSG91J IU (5S)-1'-[(3,5-dimethylphenyl)methyl]-2-ethyl-6,8-dimethoxy-5-methylspiro[5,10-dihydroimidazo[1,5-b][2]benzazepine-3,4'-piperidine]-1-one
DMSG91J DE Discovery agent
DMYRDBX ID DMYRDBX
DMYRDBX DN ERB-002
DMYRDBX HS Investigative
DMYRDBX SN ERB-131; ERb agonists, ACADIA; Estrogen receptor beta agonists, ACADIA
DMYRDBX CP ACADIA Pharmaceuticals Inc
DMYRDBX DE Inflammation
DMD3BEQ ID DMD3BEQ
DMD3BEQ DN ERIODICTYOL
DMD3BEQ HS Investigative
DMD3BEQ SN (+/-)-Eriodictyol; 4049-38-1; MLS000877024; 5,7,3',4'-Tetrahydroxyflavanone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-4-one; SMR000440624; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one; Eriodictyol, (+/-)-; Eriodicytol; ERIODYCTOL; Flavanone, 3',4',5,7-tetrahydroxy-; AC1L1WLT
DMD3BEQ DT Small molecular drug
DMD3BEQ PC 440735
DMD3BEQ MW 288.25
DMD3BEQ FM C15H12O6
DMD3BEQ IC InChI=1S/C15H12O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-5,13,16-19H,6H2/t13-/m0/s1
DMD3BEQ CS C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O
DMD3BEQ IK SBHXYTNGIZCORC-ZDUSSCGKSA-N
DMD3BEQ IU (2S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMD3BEQ CA CAS 552-58-9
DMD3BEQ CB CHEBI:28412
DMD3BEQ DE Discovery agent
DMB3ROZ ID DMB3ROZ
DMB3ROZ DN ERK inhibitor III
DMB3ROZ HS Investigative
DMB3ROZ SN AC1NSSSU; 1-nitro-2-[(Z)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine
DMB3ROZ DT Small molecular drug
DMB3ROZ PC 5721470
DMB3ROZ MW 318.25
DMB3ROZ FM C12H10N6O5
DMB3ROZ IC InChI=1S/C12H10N6O5/c13-12(16-18(21)22)15-14-7-10-4-5-11(23-10)8-2-1-3-9(6-8)17(19)20/h1-7H,(H3,13,15,16)/b14-7+
DMB3ROZ CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(O2)/C=N/N=C(/N)\\N[N+](=O)[O-]
DMB3ROZ IK RODAAYVFYDKHGT-VGOFMYFVSA-N
DMB3ROZ IU 1-nitro-2-[(E)-[5-(3-nitrophenyl)furan-2-yl]methylideneamino]guanidine
DMB3ROZ DE Discovery agent
DM27FRY ID DM27FRY
DM27FRY DN Erybreadin b
DM27FRY HS Investigative
DM27FRY SN ERYBREADIN B; CHEMBL561967
DM27FRY DT Small molecular drug
DM27FRY PC 45268827
DM27FRY MW 390.5
DM27FRY FM C25H26O4
DM27FRY IC InChI=1S/C25H26O4/c1-14(2)5-6-16-20(26)9-7-18-22(16)27-13-19-15-8-10-21-17(23(15)28-24(18)19)11-12-25(3,4)29-21/h5,7-12,19,24,26H,6,13H2,1-4H3/t19-,24-/m0/s1
DM27FRY CS CC(=CCC1=C(C=CC2=C1OC[C@@H]3[C@H]2OC4=C3C=CC5=C4C=CC(O5)(C)C)O)C
DM27FRY IK XDRMVDDOBVPELW-CYFREDJKSA-N
DM27FRY IU (2R,11R)-17,17-dimethyl-6-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaen-7-ol
DM27FRY DE Discovery agent
DMNS976 ID DMNS976
DMNS976 DN Erybreadin C
DMNS976 HS Investigative
DMNS976 SN Erybreadin C; CHEMBL1086765
DMNS976 DT Small molecular drug
DMNS976 PC 21147013
DMNS976 MW 392.5
DMNS976 FM C25H28O4
DMNS976 IC InChI=1S/C25H28O4/c1-14(2)5-7-16-11-19-20-13-28-24-17(8-6-15(3)4)21(26)10-9-18(24)25(20)29-23(19)12-22(16)27/h5-6,9-12,20,25-27H,7-8,13H2,1-4H3/t20-,25-/m0/s1
DMNS976 CS CC(=CCC1=CC2=C(C=C1O)O[C@@H]3[C@H]2COC4=C3C=CC(=C4CC=C(C)C)O)C
DMNS976 IK SAXBNTXROWQAKX-CPJSRVTESA-N
DMNS976 IU (6aR,11aR)-4,8-bis(3-methylbut-2-enyl)-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene-3,9-diol
DMNS976 DE Discovery agent
DMYG7BM ID DMYG7BM
DMYG7BM DN Erybreadin D
DMYG7BM HS Investigative
DMYG7BM SN Erybreadin D; CHEMBL1087148
DMYG7BM DT Small molecular drug
DMYG7BM PC 46880036
DMYG7BM MW 390.5
DMYG7BM FM C25H26O4
DMYG7BM IC InChI=1S/C25H26O4/c1-14(2)5-7-17-20(26)10-9-18-22(17)27-13-19-16-8-6-15-11-12-25(3,4)29-21(15)24(16)28-23(18)19/h5-6,8-12,19,23,26H,7,13H2,1-4H3/t19-,23-/m0/s1
DMYG7BM CS CC(=CCC1=C(C=CC2=C1OC[C@@H]3[C@H]2OC4=C3C=CC5=C4OC(C=C5)(C)C)O)C
DMYG7BM IK YODBFZQPDZJGJG-CVDCTZTESA-N
DMYG7BM IU (2R,11R)-16,16-dimethyl-6-(3-methylbut-2-enyl)-4,12,15-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),17,20-heptaen-7-ol
DMYG7BM DE Discovery agent
DMCHVIG ID DMCHVIG
DMCHVIG DN ERYSTAGALLIN A
DMCHVIG HS Investigative
DMCHVIG SN Erystagallin A; CHEMBL1088462
DMCHVIG DT Small molecular drug
DMCHVIG PC 10410005
DMCHVIG MW 422.5
DMCHVIG FM C26H30O5
DMCHVIG IC InChI=1S/C26H30O5/c1-15(2)6-8-17-12-19-23(13-21(17)27)30-14-26(28)20-10-11-22(29-5)18(9-7-16(3)4)24(20)31-25(19)26/h6-7,10-13,25,27-28H,8-9,14H2,1-5H3/t25-,26+/m0/s1
DMCHVIG CS CC(=CCC1=CC2=C(C=C1O)OC[C@@]3([C@H]2OC4=C3C=CC(=C4CC=C(C)C)OC)O)C
DMCHVIG IK OOAXWUFECWLVEQ-IZZNHLLZSA-N
DMCHVIG IU (6aS,11aS)-9-methoxy-2,10-bis(3-methylbut-2-enyl)-6,11a-dihydro-[1]benzofuro[3,2-c]chromene-3,6a-diol
DMCHVIG DE Discovery agent
DMVA9F7 ID DMVA9F7
DMVA9F7 DN Erysubin D
DMVA9F7 HS Investigative
DMVA9F7 SN erysubin D; CHEMBL1095422
DMVA9F7 DT Small molecular drug
DMVA9F7 PC 12051846
DMVA9F7 MW 408.5
DMVA9F7 FM C25H28O5
DMVA9F7 IC InChI=1S/C25H28O5/c1-13(2)5-6-14-9-16-21(11-19(14)26)28-12-18-15-7-8-20-17(23(15)29-24(16)18)10-22(27)25(3,4)30-20/h5,7-9,11,18,22,24,26-27H,6,10,12H2,1-4H3/t18-,22?,24-/m0/s1
DMVA9F7 CS CC(=CCC1=CC2=C(C=C1O)OC[C@@H]3[C@H]2OC4=C3C=CC5=C4CC(C(O5)(C)C)O)C
DMVA9F7 IK UNODSKHATHZQGW-HRKCMRQESA-N
DMVA9F7 IU (2R,11R)-17,17-dimethyl-8-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),20-hexaene-7,16-diol
DMVA9F7 DE Discovery agent
DMXWK1A ID DMXWK1A
DMXWK1A DN Erysubin E
DMXWK1A HS Investigative
DMXWK1A SN Erysubin E; CHEMBL1086764; AC1LCTGM; BDBM50311581; InChI=1/C25H26O5/c1-14(2)5-6-15-11-17-21(12-19(15)26)28-13-25(27)18-7-8-20-16(22(18)29-23(17)25)9-10-24(3,4)30-20/h5,7-12,23,26-27H,6,13H2,1-4H3/t23-,25+/m0/s; 3H,7H-pyrano[2',3':6,7]benzofuro[3,2-c][1]benzopyran-6b,10(12bH)-diol, 3,3-dimethyl-11-(3-methyl-2-butenyl)-, (6bS,12bS)-; 3,3-Dimethyl-11-(3-methyl-but-2-enyl)-3H,12bH-4,8,13-trioxa-dibenzo[a,i]fluorene-6b,10-diol
DMXWK1A DT Small molecular drug
DMXWK1A PC 637080
DMXWK1A MW 406.5
DMXWK1A FM C25H26O5
DMXWK1A IC InChI=1S/C25H26O5/c1-14(2)5-6-15-11-17-21(12-19(15)26)28-13-25(27)18-7-8-20-16(22(18)29-23(17)25)9-10-24(3,4)30-20/h5,7-12,23,26-27H,6,13H2,1-4H3/t23-,25+/m0/s1
DMXWK1A CS CC(=CCC1=CC2=C(C=C1O)OC[C@@]3([C@H]2OC4=C3C=CC5=C4C=CC(O5)(C)C)O)C
DMXWK1A IK CMHGFGMNRHHGSN-UKILVPOCSA-N
DMXWK1A IU (2S,11S)-17,17-dimethyl-8-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaene-2,7-diol
DMXWK1A DE Discovery agent
DMLT7FQ ID DMLT7FQ
DMLT7FQ DN Erythose-4-Phosphate
DMLT7FQ HS Investigative
DMLT7FQ SN D-Erythrose 4-phosphate; erythrose 4-phosphate; threose 4-phosphate; ERYTHOSE-4-PHOSPHATE; D-erythrose-4-phosphate; 585-18-2; erythrose-4-phosphate; erythrose-4P; erythrose-4-P; D-erythrose-4-P; UNII-2156QF7O8M; CHEBI:48153; 2156QF7O8M; (2R,3R)-2,3-dihydroxy-4-oxobutyl dihydrogen phosphate; E4P; Butanal, 2,3-dihydroxy-4-(phosphonooxy)-, (R-(R*,R*))-; 4-D-erythrosephosphoric acid; Erythrose 4-PO4; D-Erythrose 4-PO4; AC1L3UFJ; 4-O-phosphono-D-erythrose; SCHEMBL50110; AC1Q6S62; butanal, 2,3-dihydroxy-4-(phosphonooxy)-,(2r,3r)-
DMLT7FQ DT Small molecular drug
DMLT7FQ PC 122357
DMLT7FQ MW 200.08
DMLT7FQ FM C4H9O7P
DMLT7FQ IC InChI=1S/C4H9O7P/c5-1-3(6)4(7)2-11-12(8,9)10/h1,3-4,6-7H,2H2,(H2,8,9,10)/t3-,4+/m0/s1
DMLT7FQ CS C([C@H]([C@H](C=O)O)O)OP(=O)(O)O
DMLT7FQ IK NGHMDNPXVRFFGS-IUYQGCFVSA-N
DMLT7FQ IU [(2R,3R)-2,3-dihydroxy-4-oxobutyl] dihydrogen phosphate
DMLT7FQ CA CAS 585-18-2
DMLT7FQ CB CHEBI:48153
DMLT7FQ DE Discovery agent
DM5GEUN ID DM5GEUN
DM5GEUN DN ERYTHRIBYSSIN A
DM5GEUN HS Investigative
DM5GEUN SN Erythribyssin A; CHEMBL1076430
DM5GEUN DT Small molecular drug
DM5GEUN PC 46879996
DM5GEUN MW 368.4
DM5GEUN FM C22H24O5
DM5GEUN IC InChI=1S/C22H24O5/c1-13(2)5-7-15-18(24-3)10-9-17-20(15)27-21-16-8-6-14(23)11-19(16)26-12-22(17,21)25-4/h5-6,8-11,21,23H,7,12H2,1-4H3/t21-,22+/m0/s1
DM5GEUN CS CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@]2(COC4=C3C=CC(=C4)O)OC)OC)C
DM5GEUN IK IGSYALWDCAHJEF-FCHUYYIVSA-N
DM5GEUN IU (6aS,11aS)-6a,9-dimethoxy-10-(3-methylbut-2-enyl)-6,11a-dihydro-[1]benzofuro[3,2-c]chromen-3-ol
DM5GEUN DE Discovery agent
DMBVSKZ ID DMBVSKZ
DMBVSKZ DN Erythribyssin D
DMBVSKZ HS Investigative
DMBVSKZ SN Erythribyssin D; CHEMBL1099089
DMBVSKZ DT Small molecular drug
DMBVSKZ PC 46887822
DMBVSKZ MW 340.4
DMBVSKZ FM C20H20O5
DMBVSKZ IC InChI=1S/C20H20O5/c1-20(2)17(22)8-13-15(25-20)6-5-11-14-9-23-16-7-10(21)3-4-12(16)19(14)24-18(11)13/h3-7,14,17,19,21-22H,8-9H2,1-2H3/t14-,17?,19-/m0/s1
DMBVSKZ CS CC1(C(CC2=C(O1)C=CC3=C2O[C@@H]4[C@H]3COC5=C4C=CC(=C5)O)O)C
DMBVSKZ IK ZCLUCQDBFSBCJB-OZIHFDBSSA-N
DMBVSKZ IU (2R,11R)-17,17-dimethyl-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),20-hexaene-7,16-diol
DMBVSKZ DE Discovery agent
DMUL4AP ID DMUL4AP
DMUL4AP DN Erythribyssin L
DMUL4AP HS Investigative
DMUL4AP SN Erythribyssin L; CHEMBL1096408
DMUL4AP DT Small molecular drug
DMUL4AP PC 46887764
DMUL4AP MW 408.5
DMUL4AP FM C25H28O5
DMUL4AP IC InChI=1S/C25H28O5/c1-13(2)5-6-16-19(26)8-7-15-18-12-28-21-11-20-14(10-22(27)25(3,4)30-20)9-17(21)24(18)29-23(15)16/h5,7-9,11,18,22,24,26-27H,6,10,12H2,1-4H3/t18-,22?,24-/m0/s1
DMUL4AP CS CC(=CCC1=C(C=CC2=C1O[C@@H]3[C@H]2COC4=C3C=C5CC(C(OC5=C4)(C)C)O)O)C
DMUL4AP IK HAOOQCMPFMLAJM-HRKCMRQESA-N
DMUL4AP IU (2R,10R)-17,17-dimethyl-5-(3-methylbut-2-enyl)-3,12,16-trioxapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(13),4(9),5,7,14,20-hexaene-6,18-diol
DMUL4AP DE Discovery agent
DMWEK8I ID DMWEK8I
DMWEK8I DN Erythribyssin M
DMWEK8I HS Investigative
DMWEK8I SN Erythribyssin M; CHEMBL1099090
DMWEK8I DT Small molecular drug
DMWEK8I PC 46887823
DMWEK8I MW 340.4
DMWEK8I FM C20H20O5
DMWEK8I IC InChI=1S/C20H20O5/c1-20(2)17(22)8-13-15(25-20)6-5-11-14-9-23-16-7-10(21)3-4-12(16)19(14)24-18(11)13/h3-7,14,17,19,21-22H,8-9H2,1-2H3/t14-,17?,19-/m1/s1
DMWEK8I CS CC1(C(CC2=C(O1)C=CC3=C2O[C@H]4[C@@H]3COC5=C4C=CC(=C5)O)O)C
DMWEK8I IK ZCLUCQDBFSBCJB-LJMFKLJISA-N
DMWEK8I IU (2S,11S)-17,17-dimethyl-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),20-hexaene-7,16-diol
DMWEK8I DE Discovery agent
DM8LEJ4 ID DM8LEJ4
DM8LEJ4 DN Erythribyssin O
DM8LEJ4 HS Investigative
DM8LEJ4 SN Erythribyssin O; CHEMBL1096406
DM8LEJ4 DT Small molecular drug
DM8LEJ4 PC 46861837
DM8LEJ4 MW 350.4
DM8LEJ4 FM C21H18O5
DM8LEJ4 IC InChI=1S/C21H18O5/c1-11(2)3-4-14-17(23)6-5-13-16-10-25-19-8-18(24)12(9-22)7-15(19)21(16)26-20(13)14/h3,5-9,23-24H,4,10H2,1-2H3
DM8LEJ4 CS CC(=CCC1=C(C=CC2=C1OC3=C2COC4=C3C=C(C(=C4)O)C=O)O)C
DM8LEJ4 IK AGFXXWXSPAYWMF-UHFFFAOYSA-N
DM8LEJ4 IU 3,9-dihydroxy-10-(3-methylbut-2-enyl)-6H-[1]benzofuro[3,2-c]chromene-2-carbaldehyde
DM8LEJ4 DE Discovery agent
DM8UVI3 ID DM8UVI3
DM8UVI3 DN Erythro-3,4-dichloromethylphenidate hydrochloride
DM8UVI3 HS Investigative
DM8UVI3 SN CHEMBL537654; Erythro-3,4-Dichloromethylphenidate HCl
DM8UVI3 DT Small molecular drug
DM8UVI3 PC 16719762
DM8UVI3 MW 302.2
DM8UVI3 FM C14H17Cl2NO2
DM8UVI3 IC InChI=1S/C14H17Cl2NO2/c1-19-14(18)13(12-4-2-3-7-17-12)9-5-6-10(15)11(16)8-9/h5-6,8,12-13,17H,2-4,7H2,1H3/t12-,13+/m1/s1
DM8UVI3 CS COC(=O)[C@H]([C@H]1CCCCN1)C2=CC(=C(C=C2)Cl)Cl
DM8UVI3 IK JUKMAYKVHWKRKY-OLZOCXBDSA-N
DM8UVI3 IU methyl (2S)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetate
DM8UVI3 DE Discovery agent
DM0PHEW ID DM0PHEW
DM0PHEW DN Erythromycin salnacedin
DM0PHEW HS Investigative
DM0PHEW SN Actagen; G 101
DM0PHEW DT Small molecular drug
DM0PHEW PC 9854689
DM0PHEW MW 1017.2
DM0PHEW FM C49H80N2O18S
DM0PHEW IC InChI=1S/C37H67NO13.C12H13NO5S/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-7(14)13-9(11(16)17)6-19-12(18)8-4-2-3-5-10(8)15/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-5,9,15H,6H2,1H3,(H,13,14)(H,16,17)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;9-/m10/s1
DM0PHEW CS CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.CC(=O)N[C@@H](CSC(=O)C1=CC=CC=C1O)C(=O)O
DM0PHEW IK CEKAAZRHRXXWDX-CQWDQVLCSA-N
DM0PHEW IU (2R)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DM0PHEW CA CAS 87573-04-4
DM0PHEW DE Discovery agent
DM3R8YL ID DM3R8YL
DM3R8YL DN Erythropoietin
DM3R8YL HS Investigative
DM3R8YL SN NuPIAO; Erythropoietin (second generation, anemia/blood cell mobilization); Erythropoietin (second generation, anemia/blood cell mobilization), 3SBio
DM3R8YL CP 3SBio Inc
DM3R8YL SQ DB00016 (Erythropoietin) sequence: APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR
DM3R8YL PC 11751549
DM3R8YL MW 461
DM3R8YL FM C22H22ClKN6O
DM3R8YL IC InChI=1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
DM3R8YL CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+]
DM3R8YL IK OXCMYAYHXIHQOA-UHFFFAOYSA-N
DM3R8YL IU potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
DM3R8YL CA CAS 124750-99-8
DM3R8YL DE Anemia
DM8BS5C ID DM8BS5C
DM8BS5C DN Eryvarin D
DM8BS5C HS Investigative
DM8BS5C SN eryvarin D; CHEMBL1097045
DM8BS5C DT Small molecular drug
DM8BS5C PC 15546808
DM8BS5C MW 336.4
DM8BS5C FM C21H20O4
DM8BS5C IC InChI=1S/C21H20O4/c1-12(2)4-6-15-18(23-3)9-8-14-17-11-24-19-10-13(22)5-7-16(19)21(17)25-20(14)15/h4-5,7-10,22H,6,11H2,1-3H3
DM8BS5C CS CC(=CCC1=C(C=CC2=C1OC3=C2COC4=C3C=CC(=C4)O)OC)C
DM8BS5C IK BYZVMAQRPFEPSV-UHFFFAOYSA-N
DM8BS5C IU 9-methoxy-10-(3-methylbut-2-enyl)-6H-[1]benzofuro[3,2-c]chromen-3-ol
DM8BS5C DE Discovery agent
DMSNM5O ID DMSNM5O
DMSNM5O DN ES-6864
DMSNM5O HS Investigative
DMSNM5O SN N-[N-[3-(Morpholinocarbonyl)-2(R)-(1-naphthylmethyl)propionyl]-3-(4-thiazolyl)-L-alanyl]cyclostatin-(2-morpholinoethyl)amide; 4(S)-[N-[3-(Morpholinocarbonyl)-2(R)-(1-naphthylmethyl)propionyl]-3-(4-thiazolyl)-L-alanylamino]-5-cyclohexyl-3(S)-hydroxypentanoic acid 2-morpholinoethylamide
DMSNM5O DT Small molecular drug
DMSNM5O PC 6918071
DMSNM5O MW 791
DMSNM5O FM C42H58N6O7S
DMSNM5O IC InChI=1S/C42H58N6O7S/c49-38(27-39(50)43-13-14-47-15-19-54-20-16-47)36(23-30-7-2-1-3-8-30)45-42(53)37(26-34-28-56-29-44-34)46-41(52)33(25-40(51)48-17-21-55-22-18-48)24-32-11-6-10-31-9-4-5-12-35(31)32/h4-6,9-12,28-30,33,36-38,49H,1-3,7-8,13-27H2,(H,43,50)(H,45,53)(H,46,52)/t33-,36+,37+,38+/m1/s1
DMSNM5O CS C1CCC(CC1)C[C@@H]([C@H](CC(=O)NCCN2CCOCC2)O)NC(=O)[C@H](CC3=CSC=N3)NC(=O)[C@H](CC4=CC=CC5=CC=CC=C54)CC(=O)N6CCOCC6
DMSNM5O IK UACWUNAXAAUHDZ-MVPOBJIPSA-N
DMSNM5O IU (3S,4S)-5-cyclohexyl-3-hydroxy-N-(2-morpholin-4-ylethyl)-4-[[(2S)-2-[[(2R)-4-morpholin-4-yl-2-(naphthalen-1-ylmethyl)-4-oxobutanoyl]amino]-3-(1,3-thiazol-4-yl)propanoyl]amino]pentanamide
DMSNM5O DE Hypertension
DMIVZ3W ID DMIVZ3W
DMIVZ3W DN ES-936
DMIVZ3W HS Investigative
DMIVZ3W SN 192820-78-3; ES 936; UNII-1XI90I177M; 5-METHOXY-1,2-DIMETHYL-3-(4-NITROPHENOXYMETHYL)INDOLE-4,7-DIONE; 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione; 1XI90I177M; 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione; AC1NBNHW; CHEMBL357217; SCHEMBL3991028; CTK8E6509; DTXSID20172879; MolPort-006-168-362; ZINC587989; AKOS024457934; 1H-Indole-4,7-dione, 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)-; API0010300; DB02400; ES936, > LS-191843; B5514; KS-00000189; J-012477
DMIVZ3W DT Small molecular drug
DMIVZ3W PC 4470790
DMIVZ3W MW 356.3
DMIVZ3W FM C18H16N2O6
DMIVZ3W IC InChI=1S/C18H16N2O6/c1-10-13(9-26-12-6-4-11(5-7-12)20(23)24)16-17(19(10)2)14(21)8-15(25-3)18(16)22/h4-8H,9H2,1-3H3
DMIVZ3W CS CC1=C(C2=C(N1C)C(=O)C=C(C2=O)OC)COC3=CC=C(C=C3)[N+](=O)[O-]
DMIVZ3W IK IBLWSLZYYZHSRG-UHFFFAOYSA-N
DMIVZ3W IU 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione
DMIVZ3W CA CAS 192820-78-3
DMIVZ3W DE Discovery agent
DMPTDHC ID DMPTDHC
DMPTDHC DN ESCHOLTZINE
DMPTDHC HS Investigative
DMPTDHC SN escholtzine; Escholzine; Crychine; 4040-75-9; CHEMBL481839; BDBM50259677; ZINC27865962
DMPTDHC DT Small molecular drug
DMPTDHC PC 12304178
DMPTDHC MW 323.3
DMPTDHC FM C19H17NO4
DMPTDHC IC InChI=1S/C19H17NO4/c1-20-14-2-10-4-16-18(23-8-21-16)6-12(10)15(20)3-11-5-17-19(7-13(11)14)24-9-22-17/h4-7,14-15H,2-3,8-9H2,1H3/t14-,15-/m0/s1
DMPTDHC CS CN1[C@H]2CC3=CC4=C(C=C3[C@@H]1CC5=CC6=C(C=C25)OCO6)OCO4
DMPTDHC IK PGINMPJZCWDQNT-GJZGRUSLSA-N
DMPTDHC IU (1S,12S)-23-methyl-5,7,16,18-tetraoxa-23-azahexacyclo[10.10.1.02,10.04,8.013,21.015,19]tricosa-2,4(8),9,13,15(19),20-hexaene
DMPTDHC CA CAS 4040-75-9
DMPTDHC DE Discovery agent
DMANEC9 ID DMANEC9
DMANEC9 DN Esculin
DMANEC9 HS Investigative
DMANEC9 SN Aesculetin glukosid; Aesculinum; Esculetin 6-O-glucoside; Esculetin 6-beta-D-glucoside; Esculin; Esculin hydrate; Esculin hydrate, 97%; Esculine; Esculoside; Polychrome; Venoplant; XHCADAYNFIFUHF-TVKJYDDYSA-N; aesculin; (-)-Esculin; 1Y1L18LQAF; 531-75-9; 6,7-Dihydroxycoumarin 6-glucoside; 6,7-Dihydroxycoumarin-6-O-glucoside; 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one; 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-cumarin; 7-Hydroxy-6-cumarinyl-glucosid; 7-Hydroxy-6-glucosyloxy-2H-chromene; CHEBI:4853; UNII-1Y1L18LQAF
DMANEC9 PC 5281417
DMANEC9 MW 340.28
DMANEC9 FM C15H16O9
DMANEC9 IC XHCADAYNFIFUHF-TVKJYDDYSA-N
DMANEC9 CS C1=CC(=O)OC2=CC(=C(C=C21)OC3C(C(C(C(O3)CO)O)O)O)O
DMANEC9 IK 1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17/h1-4,10,12-17,19-21H,5H2/t10-,12-,13+,14-,15-/m1/s1
DMANEC9 IU 7-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
DMANEC9 CA CAS 531-75-9
DMANEC9 CB CHEBI:4853
DMANEC9 DE Appendicitis
DMTJDXY ID DMTJDXY
DMTJDXY DN ESI-09
DMTJDXY HS Investigative
DMTJDXY SN ESI 09; ESI09
DMTJDXY DT Small molecular drug
DMTJDXY PC 5704083
DMTJDXY MW 330.77
DMTJDXY FM C16H15ClN4O2
DMTJDXY IC InChI=1S/C16H15ClN4O2/c1-16(2,3)14-8-12(21-23-14)15(22)13(9-18)20-19-11-6-4-5-10(17)7-11/h4-8,19H,1-3H3/b20-13-
DMTJDXY CS CC(C)(C)C1=CC(=NO1)C(=O)/C(=N\\NC2=CC(=CC=C2)Cl)/C#N
DMTJDXY IK DXEATJQGQHDURZ-MOSHPQCFSA-N
DMTJDXY IU (1Z)-2-(5-tert-butyl-1,2-oxazol-3-yl)-N-(3-chloroanilino)-2-oxoethanimidoyl cyanide
DMTJDXY DE Discovery agent
DM7K14V ID DM7K14V
DM7K14V DN Estradiol 17-O-sulfamate
DM7K14V HS Investigative
DM7K14V SN CHEMBL220493; estradiol 17-O-sulfamate; Estradiol-17-O-Sulfamate; SCHEMBL628173; BDBM50200938
DM7K14V DT Small molecular drug
DM7K14V PC 20718630
DM7K14V MW 351.5
DM7K14V FM C18H25NO4S
DM7K14V IC InChI=1S/C18H25NO4S/c1-18-9-8-14-13-5-3-12(20)10-11(13)2-4-15(14)16(18)6-7-17(18)23-24(19,21)22/h3,5,10,14-17,20H,2,4,6-9H2,1H3,(H2,19,21,22)/t14-,15-,16+,17+,18+/m1/s1
DM7K14V CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=C3C=CC(=C4)O
DM7K14V IK NALROBPVVYUESB-ZBRFXRBCSA-N
DM7K14V IU [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DM7K14V DE Discovery agent
DMPM8I5 ID DMPM8I5
DMPM8I5 DN Estradiol 3,17-O,O-bis-sulfamate
DMPM8I5 HS Investigative
DMPM8I5 SN CHEMBL221802; estradiol 3,17-O,O-bis-sulfamate; SCHEMBL5167329; ZINC3825541; BDBM50159804; Sulfamic acid (8R,9S,13S,14S,17S)-13-methyl-3-sulfamoyloxy-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl ester
DMPM8I5 DT Small molecular drug
DMPM8I5 PC 9954405
DMPM8I5 MW 430.5
DMPM8I5 FM C18H26N2O6S2
DMPM8I5 IC InChI=1S/C18H26N2O6S2/c1-18-9-8-14-13-5-3-12(25-27(19,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)26-28(20,23)24/h3,5,10,14-17H,2,4,6-9H2,1H3,(H2,19,21,22)(H2,20,23,24)/t14-,15-,16+,17+,18+/m1/s1
DMPM8I5 CS C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OS(=O)(=O)N)CCC4=C3C=CC(=C4)OS(=O)(=O)N
DMPM8I5 IK ZVSCPWTWOPVEDW-ZBRFXRBCSA-N
DMPM8I5 IU [(8R,9S,13S,14S,17S)-13-methyl-3-sulfamoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] sulfamate
DMPM8I5 DE Discovery agent
DMNXO9C ID DMNXO9C
DMNXO9C DN Estriol E3
DMNXO9C HS Investigative
DMNXO9C SN Estriol E3 (oral formulation, multiple sclerosis)
DMNXO9C CP Effective Pharmaceuticals Inc
DMNXO9C DE Multiple sclerosis
DMH4MBW ID DMH4MBW
DMH4MBW DN ET bromodomain inhibitor
DMH4MBW HS Investigative
DMH4MBW SN Methyl (2r)-2-[(4s)-6-(4-Chlorophenyl)-8-Methoxy-1-Methyl-4h-[1,2,4]triazolo[4,3-A][1,4]benzodiazepin-4-Yl]butanoate; ET bromodomain inhibitor; GTPL7808; SCHEMBL16771873
DMH4MBW DT Small molecular drug
DMH4MBW PC 86277843
DMH4MBW MW 438.9
DMH4MBW FM C23H23ClN4O3
DMH4MBW IC InChI=1S/C23H23ClN4O3/c1-5-17(23(29)31-4)21-22-27-26-13(2)28(22)19-11-10-16(30-3)12-18(19)20(25-21)14-6-8-15(24)9-7-14/h6-12,17,21H,5H2,1-4H3/t17-,21+/m1/s1
DMH4MBW CS CC[C@H]([C@H]1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C)C(=O)OC
DMH4MBW IK WGMDCNPABCIZCD-UTKZUKDTSA-N
DMH4MBW IU methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]butanoate
DMH4MBW DE Discovery agent
DM0IYLS ID DM0IYLS
DM0IYLS DN EtBut-RYYRIK-NH2
DM0IYLS HS Investigative
DM0IYLS SN CHEMBL443765
DM0IYLS DT Small molecular drug
DM0IYLS PC 44456217
DM0IYLS MW 979.2
DM0IYLS FM C48H78N14O8
DM0IYLS IC InChI=1S/C48H78N14O8/c1-5-29(4)39(46(70)57-34(40(50)64)17-11-12-24-49)62-43(67)36(19-14-26-56-48(53)54)59-44(68)38(28-31-20-22-33(63)23-21-31)61-45(69)37(27-30-15-9-8-10-16-30)60-42(66)35(18-13-25-55-47(51)52)58-41(65)32(6-2)7-3/h8-10,15-16,20-23,29,32,34-39,63H,5-7,11-14,17-19,24-28,49H2,1-4H3,(H2,50,64)(H,57,70)(H,58,65)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t29-,34-,35-,36-,37-,38-,39-/m0/s1
DM0IYLS CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(CC)CC
DM0IYLS IK ZOGNSEAXOALIEC-ICJZXESVSA-N
DM0IYLS IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-ethylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DM0IYLS DE Discovery agent
DMMEQUR ID DMMEQUR
DMMEQUR DN Ethidium
DMMEQUR HS Investigative
DMMEQUR SN Ethidium; homidium; Ethidium cation; Novidium; 3546-21-2; UNII-EN464416SI; 3,8-Diamino-5-ethyl-6-phenylphenanthridinium; Phenanthridinium, 3,8-diamino-5-ethyl-6-phenyl-; BRN 3627183; CHEBI:42478; EN464416SI; AB00053825_07; CHEMBL284328; NSC84423; NSC522843; 5-ethyl-6-phenyl-phenanthridin-5-ium-3,8-diamine; 5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine; C21H20N3; Spectrum_001500; AC1L1GCK; Spectrum2_001587; Spectrum5_001263; Spectrum4_000198; UPCMLD-DP076; NCIMech_000529; cid_3624; Piperine & Ethidium bromide; NCIOpen2_009324
DMMEQUR DT Small molecular drug
DMMEQUR PC 3624
DMMEQUR MW 314.4
DMMEQUR FM C21H20N3+
DMMEQUR IC InChI=1S/C21H19N3/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14/h3-13,23H,2,22H2,1H3/p+1
DMMEQUR CS CC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N
DMMEQUR IK QTANTQQOYSUMLC-UHFFFAOYSA-O
DMMEQUR IU 5-ethyl-6-phenylphenanthridin-5-ium-3,8-diamine
DMMEQUR CA CAS 3546-21-2
DMMEQUR CB CHEBI:42478
DMMEQUR DE Discovery agent
DMQTEDP ID DMQTEDP
DMQTEDP DN ETHIOFENCARB
DMQTEDP HS Investigative
DMQTEDP SN Ethiofencarb; 29973-13-5; CRONETON; Arylmate; Kronetone; Croneton 500; Ethiophencarbe; Ethiofencarb [BSI:ISO]; alpha-Ethylthio-o-tolyl methylcarbamate; Hox 1901; 2-((Ethylthio)methyl)phenol methylcarbamate; 2-((Ethylthio)methyl)phenyl methylcarbamate; BAY-HOX-1901; Caswell No. 263AA; CHOX 1901; alpha-(Ethylthio)-o-tolyl methylcarbamate; UNII-FY0YB813XV; Ethiophencarbe [ISO-French]; 2-Ethylthiomethylphenyl N-methylcarbamate; HSDB 7140; (2-Ethylthiomethyl-phenyl)-N-methylcarbamate; EINECS 249-981-9
DMQTEDP DT Small molecular drug
DMQTEDP PC 34766
DMQTEDP MW 225.31
DMQTEDP FM C11H15NO2S
DMQTEDP IC InChI=1S/C11H15NO2S/c1-3-15-8-9-6-4-5-7-10(9)14-11(13)12-2/h4-7H,3,8H2,1-2H3,(H,12,13)
DMQTEDP CS CCSCC1=CC=CC=C1OC(=O)NC
DMQTEDP IK HEZNVIYQEUHLNI-UHFFFAOYSA-N
DMQTEDP IU [2-(ethylsulfanylmethyl)phenyl] N-methylcarbamate
DMQTEDP CA CAS 29973-13-5
DMQTEDP CB CHEBI:38483
DMQTEDP DE Discovery agent
DMGESUH ID DMGESUH
DMGESUH DN ETHIONINE
DMGESUH HS Investigative
DMGESUH SN L-Ethionine; Ethionine; 13073-35-3; S-Ethyl-L-homocysteine; (S)-2-amino-4-(ethylthio)butanoic acid; L-S-Ethylhomocysteine; Homocysteine, S-ethyl-; L-Homocysteine, S-ethyl-; Ethionine (VAN); L-2-Amino-4-(ethylthio)butyric acid; UNII-WX1BN24WZT; (L)-Ethionine; (+)-ethionine; NSC 82393; CCRIS 289; C6H13NO2S; HSDB 5080; Butyric acid, 2-amino-4-(ethylthio)-, L-; EINECS 235-966-4; WX1BN24WZT; Butanoic acid, 2-amino-4-(ethylthio)-, (S)-; BRN 1722528; (+)-S-ethyl-L-homocysteine; CHEMBL203187; CHEBI:4886; Butyric acid, 2-amino-4-(ethylene)-
DMGESUH DT Small molecular drug
DMGESUH PC 25674
DMGESUH MW 163.24
DMGESUH FM C6H13NO2S
DMGESUH IC InChI=1S/C6H13NO2S/c1-2-10-4-3-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1
DMGESUH CS CCSCC[C@@H](C(=O)O)N
DMGESUH IK GGLZPLKKBSSKCX-YFKPBYRVSA-N
DMGESUH IU (2S)-2-amino-4-ethylsulfanylbutanoic acid
DMGESUH CA CAS 13073-35-3
DMGESUH CB CHEBI:4886
DMGESUH DE Discovery agent
DMDXRP1 ID DMDXRP1
DMDXRP1 DN ETHISTERONE
DMDXRP1 HS Investigative
DMDXRP1 SN 17-Hydroxypregn-4-en-20-yn-3-one; Syngestrotabs; Aethisteron; Progestolets; Pregneninolone; Progestoral; Gestoral; Ethinone; Colutoid; Trosinone; Prolutol; Progestab; Produxan; Nalutoral; Prodroxan; Prodoxan; Nugestoral; Pregnin; Prone; Lucorteum Oral; Lutidon Oral; Progestin P; Proluton C; Primolut C; Ora-Lutin; Ethinyltestosterone; Anhydroxyprogesterone; 17.alpha.-Ethynyltestosterone; Anhydrohydroxyprogesterone; Ethynyltestosterone; Testosterone, 17-ethynyl-; NSC-9565; 17-Ethinyltestosterone; 17.alpha.-Pregn-4-en-20-yn-3-one, 17-hydroxy-
DMDXRP1 DT Small molecular drug
DMDXRP1 PC 5284557
DMDXRP1 MW 312.4
DMDXRP1 FM C21H28O2
DMDXRP1 IC InChI=1S/C21H28O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,13,16-18,23H,5-12H2,2-3H3/t16-,17+,18+,19+,20+,21+/m1/s1
DMDXRP1 CS C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C
DMDXRP1 IK CHNXZKVNWQUJIB-CEGNMAFCSA-N
DMDXRP1 IU (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
DMDXRP1 CA CAS 434-03-7
DMDXRP1 CB CHEBI:34749
DMDXRP1 DE Discovery agent
DM1MGTX ID DM1MGTX
DM1MGTX DN ETHOXYCLUSIN
DM1MGTX HS Investigative
DM1MGTX SN ethoxyclusin; CHEMBL480295
DM1MGTX DT Small molecular drug
DM1MGTX PC 44575400
DM1MGTX MW 446.5
DM1MGTX FM C24H30O8
DM1MGTX IC InChI=1S/C24H30O8/c1-5-29-20-10-14(11-21-23(20)32-13-31-21)6-16-12-30-24(25)17(16)7-15-8-18(26-2)22(28-4)19(9-15)27-3/h8-11,16-17,24-25H,5-7,12-13H2,1-4H3/t16-,17+,24?/m0/s1
DM1MGTX CS CCOC1=CC(=CC2=C1OCO2)C[C@H]3COC([C@@H]3CC4=CC(=C(C(=C4)OC)OC)OC)O
DM1MGTX IK PPKABVGOUVBEEX-HSQXHLSASA-N
DM1MGTX IU (3R,4R)-4-[(7-ethoxy-1,3-benzodioxol-5-yl)methyl]-3-[(3,4,5-trimethoxyphenyl)methyl]oxolan-2-ol
DM1MGTX DE Discovery agent
DMSKU4M ID DMSKU4M
DMSKU4M DN ETHOXYCOUMARIN
DMSKU4M HS Investigative
DMSKU4M SN 7-ETHOXYCOUMARIN; 31005-02-4; 7-ethoxy-2H-chromen-2-one; Ethylumbelliferone; 2H-1-Benzopyran-2-one, 7-ethoxy-; 7-ethoxychromen-2-one; 7-ethoxy-2H-1-benzopyran-2-one; CHEMBL191528; CHEBI:28184; LIFAQMGORKPVDH-UHFFFAOYSA-N; 7-Ethoxycoumarine; EINECS 250-429-4; 7 - Ethoxycoumarin; PubChem8680; Coumarin, 7-ethoxy-; ACMC-209hjx; 7-Ethoxy-chromen-2-one; 7-Ethoxycoumarin, 99.5%; SCHEMBL119072; 7-Ethoxy-1-benzopyran-2-one; AC1L1U91; ZINC57719; CTK4G6277; DTXSID30184983; MolPort-001-759-189; HMS1722P19; KS-000014EB
DMSKU4M DT Small molecular drug
DMSKU4M PC 182475
DMSKU4M MW 190.19
DMSKU4M FM C11H10O3
DMSKU4M IC InChI=1S/C11H10O3/c1-2-13-10-7-8-5-3-4-6-9(8)14-11(10)12/h3-7H,2H2,1H3
DMSKU4M CS CCOC1=CC2=CC=CC=C2OC1=O
DMSKU4M IK PPGXDBJURPEKDZ-UHFFFAOYSA-N
DMSKU4M IU 3-ethoxychromen-2-one
DMSKU4M CA CAS 65216-93-5
DMSKU4M DE Discovery agent
DMNOTH5 ID DMNOTH5
DMNOTH5 DN ETHOXY-IDAZOXAN
DMNOTH5 HS Investigative
DMNOTH5 SN RX-811059; 2-(2-Ethoxy-1,4-benzodioxan-2-yl)-1-imidazoline
DMNOTH5 DT Small molecular drug
DMNOTH5 PC 125992
DMNOTH5 MW 248.28
DMNOTH5 FM C13H16N2O3
DMNOTH5 IC InChI=1S/C13H16N2O3/c1-2-17-13(12-14-7-8-15-12)9-16-10-5-3-4-6-11(10)18-13/h3-6H,2,7-9H2,1H3,(H,14,15)
DMNOTH5 CS CCOC1(COC2=CC=CC=C2O1)C3=NCCN3
DMNOTH5 IK PXTLRBYNGGDZBN-UHFFFAOYSA-N
DMNOTH5 IU 2-(3-ethoxy-2H-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole
DMNOTH5 CA CAS 96576-24-8
DMNOTH5 DE Poison intoxication
DM7390Y ID DM7390Y
DM7390Y DN ethyketazocine
DM7390Y HS Investigative
DM7390Y SN WIN-35,197-2
DM7390Y DT Small molecular drug
DM7390Y PC 135018
DM7390Y MW 299.4
DM7390Y FM C19H25NO2
DM7390Y IC InChI=1S/C19H25NO2/c1-3-19-8-9-20(11-13-4-5-13)17(12(19)2)18(22)15-7-6-14(21)10-16(15)19/h6-7,10,12-13,17,21H,3-5,8-9,11H2,1-2H3/t12-,17-,19-/m1/s1
DM7390Y CS CC[C@@]12CCN([C@H]([C@H]1C)C(=O)C3=C2C=C(C=C3)O)CC4CC4
DM7390Y IK SEJUQQOPVAUETF-QHLBDZCJSA-N
DM7390Y IU (1R,9R,13S)-10-(cyclopropylmethyl)-1-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
DM7390Y CA CAS 6036-52-8
DM7390Y DE Discovery agent
DM0O4A2 ID DM0O4A2
DM0O4A2 DN ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE
DM0O4A2 HS Investigative
DM0O4A2 SN ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE; S-BENZYL PHENYLACETOTHIOHYDROXIMATE-O-SULFATE; DB04779; ethyl (1Z)-2-phenyl-N-(sulfooxy)ethanimidothioate; [(Z)-[1-(ethylsulfanyl)-2-phenylethylidene]amino]oxysulfonic acid
DM0O4A2 DT Small molecular drug
DM0O4A2 PC 9600421
DM0O4A2 MW 275.3
DM0O4A2 FM C10H13NO4S2
DM0O4A2 IC InChI=1S/C10H13NO4S2/c1-2-16-10(11-15-17(12,13)14)8-9-6-4-3-5-7-9/h3-7H,2,8H2,1H3,(H,12,13,14)/b11-10-
DM0O4A2 CS CCS/C(=N\\OS(=O)(=O)O)/CC1=CC=CC=C1
DM0O4A2 IK VZFUNHITNWTQFU-KHPPLWFESA-N
DM0O4A2 IU ethyl (1Z)-2-phenyl-N-sulfooxyethanimidothioate
DM0O4A2 DE Discovery agent
DM3FH02 ID DM3FH02
DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM3FH02 HS Investigative
DM3FH02 SN 2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893
DM3FH02 DT Small molecular drug
DM3FH02 PC 9860529
DM3FH02 MW 281.3
DM3FH02 FM C17H15NO3
DM3FH02 IC InChI=1S/C17H15NO3/c19-15-11-16(18-7-9-20-10-8-18)21-17-13-4-2-1-3-12(13)5-6-14(15)17/h1-6,11H,7-10H2
DM3FH02 CS C1COCCN1C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
DM3FH02 IK KKTZALUTXUZPSN-UHFFFAOYSA-N
DM3FH02 IU 2-morpholin-4-ylbenzo[h]chromen-4-one
DM3FH02 CA CAS 154447-35-5
DM3FH02 CB CHEBI:92165
DM3FH02 DE Discovery agent
DMQ0XYH ID DMQ0XYH
DMQ0XYH DN Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DMQ0XYH HS Investigative
DMQ0XYH SN ethyl 1-(3H-benzimidazol-5-ylsulfonyl)pyrrole-2-carboxylate; AC1LA3ZP; CTK6F6830; ZINC5884309; 1h-pyrrole-2-carboxylic acid,1-(1h-benzimidazol-6-ylsulfonyl)-,ethyl ester; 306964-90-9; KB-266409; ethyl 1-(1h-benzimidazol-6-ylsulfonyl)-1h-pyrrole-2-carboxylate; 1-(3H-Benzoimidazole-5-sulfonyl)-1H-pyrrole-2-carboxylic acid ethyl ester; 1-[(1H-Benzimidazole-5-yl)sulfonyl]1H-pyrrole-2-carboxylic acid ethyl ester
DMQ0XYH DT Small molecular drug
DMQ0XYH PC 481117
DMQ0XYH MW 319.34
DMQ0XYH FM C14H13N3O4S
DMQ0XYH IC InChI=1S/C14H13N3O4S/c1-2-21-14(18)13-4-3-7-17(13)22(19,20)10-5-6-11-12(8-10)16-9-15-11/h3-9H,2H2,1H3,(H,15,16)
DMQ0XYH CS CCOC(=O)C1=CC=CN1S(=O)(=O)C2=CC3=C(C=C2)N=CN3
DMQ0XYH IK UVYMCWVOZHENRB-UHFFFAOYSA-N
DMQ0XYH IU ethyl 1-(3H-benzimidazol-5-ylsulfonyl)pyrrole-2-carboxylate
DMQ0XYH DE Discovery agent
DM82X3J ID DM82X3J
DM82X3J DN Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate
DM82X3J HS Investigative
DM82X3J DE Discovery agent
DM762HQ ID DM762HQ
DM762HQ DN Ethyl 2-(2-oxohexadecanamido)acetate
DM762HQ HS Investigative
DM762HQ SN Ethyl 2-(2-oxohexadecanamido)acetate
DM762HQ DT Small molecular drug
DM762HQ PC 16118320
DM762HQ MW 355.5
DM762HQ FM C20H37NO4
DM762HQ IC InChI=1S/C20H37NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-18(22)20(24)21-17-19(23)25-4-2/h3-17H2,1-2H3,(H,21,24)
DM762HQ CS CCCCCCCCCCCCCCC(=O)C(=O)NCC(=O)OCC
DM762HQ IK OUAFHJCWFYXWSR-UHFFFAOYSA-N
DM762HQ IU ethyl 2-(2-oxohexadecanoylamino)acetate
DM762HQ DE Discovery agent
DMPUCMV ID DMPUCMV
DMPUCMV DN Ethyl 2beta-hydroxyolean-12-en-28-oate
DMPUCMV HS Investigative
DMPUCMV SN CHEMBL1077973; Ethyl 2beta-hydroxyolean-12-en-28-oate
DMPUCMV DT Small molecular drug
DMPUCMV PC 44254513
DMPUCMV MW 484.8
DMPUCMV FM C32H52O3
DMPUCMV IC InChI=1S/C32H52O3/c1-9-35-26(34)32-16-14-27(2,3)20-23(32)22-10-11-25-29(6)19-21(33)18-28(4,5)24(29)12-13-31(25,8)30(22,7)15-17-32/h10,21,23-25,33H,9,11-20H2,1-8H3/t21-,23+,24+,25-,29+,30-,31-,32+/m1/s1
DMPUCMV CS CCOC(=O)[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H](CC5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C
DMPUCMV IK ZGVDWCUGEWKVJU-UMIBNUPHSA-N
DMPUCMV IU ethyl (4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMPUCMV DE Discovery agent
DM06AQZ ID DM06AQZ
DM06AQZ DN Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate
DM06AQZ HS Investigative
DM06AQZ SN AC1NVSSE; MLS000104229; CHEMBL3197417; MolPort-002-136-693; MolPort-019-735-612; HMS2400I13; CCG-2361; ZINC18045921; STL321690; AKOS022107323; SMR000051278; SR-01000198931; SR-01000198931-1; ethyl (2Z)-cyano(quinoxalin-2(1H)-ylidene)ethanoate; ethyl (2Z)-2-cyano-2-(1H-quinoxalin-2-ylidene)acetate
DM06AQZ DT Small molecular drug
DM06AQZ PC 607092
DM06AQZ MW 241.24
DM06AQZ FM C13H11N3O2
DM06AQZ IC InChI=1S/C13H11N3O2/c1-2-18-13(17)9(7-14)12-8-15-10-5-3-4-6-11(10)16-12/h3-6,8-9H,2H2,1H3
DM06AQZ CS CCOC(=O)C(C#N)C1=NC2=CC=CC=C2N=C1
DM06AQZ IK KKQBQZXMEPUMLX-UHFFFAOYSA-N
DM06AQZ IU ethyl 2-cyano-2-quinoxalin-2-ylacetate
DM06AQZ DE Discovery agent
DM5XYFN ID DM5XYFN
DM5XYFN DN Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate
DM5XYFN HS Investigative
DM5XYFN SN CHEMBL387254; ethyl (2z)-3-(biphenyl-3-ylamino)-2-cyanoprop-2-enoate
DM5XYFN DT Small molecular drug
DM5XYFN PC 91895906
DM5XYFN MW 292.3
DM5XYFN FM C18H16N2O2
DM5XYFN IC InChI=1S/C18H16N2O2/c1-2-22-18(21)16(12-19)13-20-17-10-6-9-15(11-17)14-7-4-3-5-8-14/h3-11,13,16H,2H2,1H3
DM5XYFN CS CCOC(=O)C(C=NC1=CC=CC(=C1)C2=CC=CC=C2)C#N
DM5XYFN IK ADNKWYMTGWSRNK-UHFFFAOYSA-N
DM5XYFN IU ethyl 2-cyano-3-(3-phenylphenyl)iminopropanoate
DM5XYFN DE Discovery agent
DM4UWYF ID DM4UWYF
DM4UWYF DN Ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate
DM4UWYF HS Investigative
DM4UWYF SN CHEMBL208261; ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate
DM4UWYF DT Small molecular drug
DM4UWYF PC 44410730
DM4UWYF MW 266.29
DM4UWYF FM C16H14N2O2
DM4UWYF IC InChI=1S/C16H14N2O2/c1-2-20-16(19)12-3-4-13-14(10-18-15(13)9-12)11-5-7-17-8-6-11/h3-10,18H,2H2,1H3
DM4UWYF CS CCOC(=O)C1=CC2=C(C=C1)C(=CN2)C3=CC=NC=C3
DM4UWYF IK HFXZBVKGWWNQBD-UHFFFAOYSA-N
DM4UWYF IU ethyl 3-pyridin-4-yl-1H-indole-6-carboxylate
DM4UWYF DE Discovery agent
DMKJGLO ID DMKJGLO
DMKJGLO DN ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE
DMKJGLO HS Investigative
DMKJGLO SN Ethyl 3-[4-(Aminosulfonyl)phenyl]propanoate; ethyl 3-(4-sulfamoylphenyl)propanoate; 2nnv; M29; 2nn7; AKOS009166834; DB08157; 4-PROPYL BENZENESULFONAMIDE ETHYL ESTER
DMKJGLO DT Small molecular drug
DMKJGLO PC 16122582
DMKJGLO MW 257.31
DMKJGLO FM C11H15NO4S
DMKJGLO IC InChI=1S/C11H15NO4S/c1-2-16-11(13)8-5-9-3-6-10(7-4-9)17(12,14)15/h3-4,6-7H,2,5,8H2,1H3,(H2,12,14,15)
DMKJGLO CS CCOC(=O)CCC1=CC=C(C=C1)S(=O)(=O)N
DMKJGLO IK OJBJALUJMRMNIR-UHFFFAOYSA-N
DMKJGLO IU ethyl 3-(4-sulfamoylphenyl)propanoate
DMKJGLO DE Discovery agent
DM5GLP7 ID DM5GLP7
DM5GLP7 DN Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate
DM5GLP7 HS Investigative
DM5GLP7 SN YD-3; CHEMBL125021; SCHEMBL363569; GTPL9458; LPROLPQTWKDPNU-UHFFFAOYSA-N; BDBM50024254; 1-benzyl-3-(4'-ethoxycarbonylphenyl)indazole; ethyl 4-(1-benzyl-1h-indazol-3-yl)-benzoate
DM5GLP7 DT Small molecular drug
DM5GLP7 PC 10132921
DM5GLP7 MW 356.4
DM5GLP7 FM C23H20N2O2
DM5GLP7 IC InChI=1S/C23H20N2O2/c1-2-27-23(26)19-14-12-18(13-15-19)22-20-10-6-7-11-21(20)25(24-22)16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3
DM5GLP7 CS CCOC(=O)C1=CC=C(C=C1)C2=NN(C3=CC=CC=C32)CC4=CC=CC=C4
DM5GLP7 IK LPROLPQTWKDPNU-UHFFFAOYSA-N
DM5GLP7 IU ethyl 4-(1-benzylindazol-3-yl)benzoate
DM5GLP7 DE Discovery agent
DMQ3LMF ID DMQ3LMF
DMQ3LMF DN Ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate
DMQ3LMF HS Investigative
DMQ3LMF SN 111947-24-1; ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate; AC1LHTSN; CBMicro_028869; 3-carboxamido coumarin, 15; Oprea1_481544; ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate; CHEMBL470419; BDBM29165; MolPort-000-375-263; MISJYZJMFQOBPG-UHFFFAOYSA-N; ZINC434162; STK401564; AKOS001279407; MCULE-7936571021; LS-38062; BIM-0028988.P001; ST4083371; ethyl 4-(2-oxo-2H-chromene-3-amido)benzoate; ethyl 4-[(2-oxochromen-3-yl)carbonylamino]benzoate; ethyl 4-[(2-oxochromene-3-carbonyl)amino]benzoate; Z30248586; F1006-0090
DMQ3LMF DT Small molecular drug
DMQ3LMF PC 869109
DMQ3LMF MW 337.3
DMQ3LMF FM C19H15NO5
DMQ3LMF IC InChI=1S/C19H15NO5/c1-2-24-18(22)12-7-9-14(10-8-12)20-17(21)15-11-13-5-3-4-6-16(13)25-19(15)23/h3-11H,2H2,1H3,(H,20,21)
DMQ3LMF CS CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMQ3LMF IK MISJYZJMFQOBPG-UHFFFAOYSA-N
DMQ3LMF IU ethyl 4-[(2-oxochromene-3-carbonyl)amino]benzoate
DMQ3LMF DE Discovery agent
DMB12M7 ID DMB12M7
DMB12M7 DN Ethyl 4-(2-oxohexadecanamido)benzoate
DMB12M7 HS Investigative
DMB12M7 SN CHEMBL460083
DMB12M7 DT Small molecular drug
DMB12M7 PC 44562728
DMB12M7 MW 417.6
DMB12M7 FM C25H39NO4
DMB12M7 IC InChI=1S/C25H39NO4/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-23(27)24(28)26-22-19-17-21(18-20-22)25(29)30-4-2/h17-20H,3-16H2,1-2H3,(H,26,28)
DMB12M7 CS CCCCCCCCCCCCCCC(=O)C(=O)NC1=CC=C(C=C1)C(=O)OCC
DMB12M7 IK HUIFVZXXYFVZMD-UHFFFAOYSA-N
DMB12M7 IU ethyl 4-(2-oxohexadecanoylamino)benzoate
DMB12M7 DE Discovery agent
DMK4T5Y ID DMK4T5Y
DMK4T5Y DN Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate
DMK4T5Y HS Investigative
DMK4T5Y SN CHEMBL603129; MLS000537589; Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate; AC1OJ6S4; cid_7315331; REGID_for_CID_7315331; HMS2189O04; BDBM50308501; SMR000161712; MLS-0103498.0001; ethyl 5-benzoyl-4-phenyl-1,3-thiazol-2-ylcarbamate; ethyl N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)carbamate
DMK4T5Y DT Small molecular drug
DMK4T5Y PC 7315331
DMK4T5Y MW 352.4
DMK4T5Y FM C19H16N2O3S
DMK4T5Y IC InChI=1S/C19H16N2O3S/c1-2-24-19(23)21-18-20-15(13-9-5-3-6-10-13)17(25-18)16(22)14-11-7-4-8-12-14/h3-12H,2H2,1H3,(H,20,21,23)
DMK4T5Y CS CCOC(=O)NC1=NC(=C(S1)C(=O)C2=CC=CC=C2)C3=CC=CC=C3
DMK4T5Y IK VMTZCTQCFMWSEO-UHFFFAOYSA-N
DMK4T5Y IU ethyl N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)carbamate
DMK4T5Y DE Discovery agent
DM5G91Z ID DM5G91Z
DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z HS Investigative
DM5G91Z SN CHEMBL1269786; iodo-betaCCE; ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate; SCHEMBL7380021; LTYUPBZLKIUGQX-UHFFFAOYSA-N; BDBM50329629; 6-iodo-beta-carboline-3-carboxylic-acid-ethylester; 6-Iodo-beta-carbolin-3-carboxylic acid ethyl ester
DM5G91Z DT Small molecular drug
DM5G91Z PC 13037317
DM5G91Z MW 366.15
DM5G91Z FM C14H11IN2O2
DM5G91Z IC InChI=1S/C14H11IN2O2/c1-2-19-14(18)12-6-10-9-5-8(15)3-4-11(9)17-13(10)7-16-12/h3-7,17H,2H2,1H3
DM5G91Z CS CCOC(=O)C1=NC=C2C(=C1)C3=C(N2)C=CC(=C3)I
DM5G91Z IK LTYUPBZLKIUGQX-UHFFFAOYSA-N
DM5G91Z IU ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate
DM5G91Z DE Discovery agent
DM7FPX8 ID DM7FPX8
DM7FPX8 DN Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate
DM7FPX8 HS Investigative
DM7FPX8 SN 6093-71-6; ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate; 3-CARBETHOXYUMBELIFERONE; ethyl 7-hydroxy-2-oxochromene-3-carboxylate; 7-Hydroxycoumarin-3-carboxylic acid ethyl ester; 3-carbethoxy-7-hydroxycoumarin; YZ9; 2H-1-Benzopyran-3-carboxylic acid, 7-hydroxy-2-oxo-, ethyl ester; CHEMBL155103; 7-HYDROXY-2-OXO-CHROMENE-3-CARBOXYLIC ACID ETHYL ESTER; Ethyl umbelliferone-3-carboxylate; Ethyl 7-hydroxy-2-oxo-2H-1-benzopyran-3-carboxylate; AK146029; 7-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid ethyl ester; 1gcz; AC1NRDLP
DM7FPX8 DT Small molecular drug
DM7FPX8 PC 5289613
DM7FPX8 MW 234.2
DM7FPX8 FM C12H10O5
DM7FPX8 IC InChI=1S/C12H10O5/c1-2-16-11(14)9-5-7-3-4-8(13)6-10(7)17-12(9)15/h3-6,13H,2H2,1H3
DM7FPX8 CS CCOC(=O)C1=CC2=C(C=C(C=C2)O)OC1=O
DM7FPX8 IK IETDBZQIWIJQJG-UHFFFAOYSA-N
DM7FPX8 IU ethyl 7-hydroxy-2-oxochromene-3-carboxylate
DM7FPX8 CA CAS 6093-71-6
DM7FPX8 DE Discovery agent
DMWIB0V ID DMWIB0V
DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
DMWIB0V HS Investigative
DMWIB0V SN ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate; 6093-72-7; CHEMBL568385; ethyl 7-methoxy-2-oxochromene-3-carboxylate; 7-Methoxy-2-oxo-2H-chromene-3-carboxylic acid ethyl ester; MLS000554938; AC1LIZL3; Oprea1_386697; AC1Q645E; SCHEMBL1406462; CTK8D4125; CHEBI:108321; MolPort-000-258-049; ZINC499358; HMS2332G10; STK527622; BDBM50303495; AKOS002230558; MCULE-3724351908; AJ-23200; SMR000147055; TC-069558; KB-296861; AX8285479; ST50114633; 2-Oxo-7-methoxy-2H-1-benzopyran-3-carboxylic acid ethyl ester; 2H-1-Benzopyran-3-carboxylic acid,
DMWIB0V DT Small molecular drug
DMWIB0V PC 914298
DMWIB0V MW 248.23
DMWIB0V FM C13H12O5
DMWIB0V IC InChI=1S/C13H12O5/c1-3-17-12(14)10-6-8-4-5-9(16-2)7-11(8)18-13(10)15/h4-7H,3H2,1-2H3
DMWIB0V CS CCOC(=O)C1=CC2=C(C=C(C=C2)OC)OC1=O
DMWIB0V IK FWFVXBZXJKTVGL-UHFFFAOYSA-N
DMWIB0V IU ethyl 7-methoxy-2-oxochromene-3-carboxylate
DMWIB0V CA CAS 6093-72-7
DMWIB0V CB CHEBI:108321
DMWIB0V DE Discovery agent
DMJQTIK ID DMJQTIK
DMJQTIK DN Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate
DMJQTIK HS Investigative
DMJQTIK SN CHEMBL571926
DMJQTIK DT Small molecular drug
DMJQTIK PC 54736443
DMJQTIK MW 394.3
DMJQTIK FM C21H14O8
DMJQTIK IC InChI=1S/C21H14O8/c1-27-19(24)14(15-17(22)10-6-2-4-8-12(10)28-20(15)25)16-18(23)11-7-3-5-9-13(11)29-21(16)26/h2-9,14,22-23H,1H3
DMJQTIK CS COC(=O)C(C1=C(C2=CC=CC=C2OC1=O)O)C3=C(C4=CC=CC=C4OC3=O)O
DMJQTIK IK XCIPOAZOZKLEOW-UHFFFAOYSA-N
DMJQTIK IU methyl 2,2-bis(4-hydroxy-2-oxochromen-3-yl)acetate
DMJQTIK DE Discovery agent
DMR5Z2A ID DMR5Z2A
DMR5Z2A DN Ethyl biscoumacetate
DMR5Z2A HS Investigative
DMR5Z2A SN Aethyli biscumacetas; Aethylis biscumacetas; Aethylum biscumaceticum; Dicumacyl; ETHYL BISCOUMACETATE; Ethyl biscumacetate; Ethyldicoumarol; Ethyldicoumarol acetate; Neodicoumarin; Neodicoumarol; Neodicumarinum; Neodicumarol; Neodikumarin; Pelentan; Trombarin; Trombil; Trombolysan; Tromexan; Tromexan ethyl acetate; 548-00-5; BOEA; Bis(4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)acetic acid ethyl ester; Bis-(4-hydroxy-3-coumarinyl)ethyl acetate; Ethyl bis(4-hydroxy-3-coumarinyl)acetate; Ethyl bis(4-hydroxycoumarinyl)acetate; NSC 36366
DMR5Z2A PC 54685524
DMR5Z2A MW 408.4
DMR5Z2A FM C22H16O8
DMR5Z2A IC JCLHQFUTFHUXNN-UHFFFAOYSA-N
DMR5Z2A CS CCOC(=O)C(C1=C(C2=CC=CC=C2OC1=O)O)C3=C(C4=CC=CC=C4OC3=O)O
DMR5Z2A IK 1S/C22H16O8/c1-2-28-20(25)15(16-18(23)11-7-3-5-9-13(11)29-21(16)26)17-19(24)12-8-4-6-10-14(12)30-22(17)27/h3-10,15,23-24H,2H2,1H3
DMR5Z2A IU ethyl 2,2-bis(4-hydroxy-2-oxochromen-3-yl)acetate
DMR5Z2A CA CAS 548-00-5
DMR5Z2A CB CHEBI:135659
DMR5Z2A DE Thrombosis
DMW0J3D ID DMW0J3D
DMW0J3D DN Ethyl Dihydrogen Phosphate
DMW0J3D HS Investigative
DMW0J3D SN Ethyl dihydrogen phosphate; Monoethyl phosphate; O-Ethyl dihydrogen phosphate; Monoethyl acid phosphate; 1623-14-9; ethylphosphate; Ethyl phosphate, mono-; PHOSPHORIC ACID, MONOETHYL ESTER; UNII-BMH1WT204A; Phosphoric acid monoethyl ester; EINECS 216-603-9; Phosphoric Acid Ethyl Ester; BRN 1702252; BMH1WT204A; AI3-15046; CHEBI:42383; EFS; ethanol-phosphate; mono-ethyl phosphate; ethoxyphosphonic acid; AC1L2LDP; ETHYLPHOSPHORIC ACID; Epitope ID:143619; AC1Q6S7W; SCHEMBL40792; CTK6G4379; Ethyl phosphate ((eto)(ho)2po)
DMW0J3D DT Small molecular drug
DMW0J3D PC 74190
DMW0J3D MW 126.05
DMW0J3D FM C2H7O4P
DMW0J3D IC InChI=1S/C2H7O4P/c1-2-6-7(3,4)5/h2H2,1H3,(H2,3,4,5)
DMW0J3D CS CCOP(=O)(O)O
DMW0J3D IK ZJXZSIYSNXKHEA-UHFFFAOYSA-N
DMW0J3D IU ethyl dihydrogen phosphate
DMW0J3D CA CAS 1623-14-9
DMW0J3D CB CHEBI:42383
DMW0J3D DE Discovery agent
DMXTLJE ID DMXTLJE
DMXTLJE DN Ethyl estrone-16-methylcarboxylate
DMXTLJE HS Investigative
DMXTLJE SN SCHEMBL12379501
DMXTLJE DT Small molecular drug
DMXTLJE PC 53319855
DMXTLJE MW 356.5
DMXTLJE FM C22H28O4
DMXTLJE IC InChI=1S/C22H28O4/c1-3-26-20(24)12-14-11-19-18-6-4-13-10-15(23)5-7-16(13)17(18)8-9-22(19,2)21(14)25/h5,7,10,14,17-19,23H,3-4,6,8-9,11-12H2,1-2H3/t14?,17-,18-,19+,22+/m1/s1
DMXTLJE CS CCOC(=O)CC1C[C@H]2[C@@H]3CCC4=C([C@H]3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMXTLJE IK SRWMNPAYNHYCEU-LRHWGCDKSA-N
DMXTLJE IU ethyl 2-[(8R,9S,13S,14S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetate
DMXTLJE DE Discovery agent
DMT4XJM ID DMT4XJM
DMT4XJM DN ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE
DMT4XJM HS Investigative
DMT4XJM SN Ethyl Hydrogen Diethylamidophosphate; SCHEMBL3141511; diethylamino(ethoxy)phosphinic acid; DB08658; N,N-Diethylamidophosphoric acid hydrogen ethyl ester
DMT4XJM DT Small molecular drug
DMT4XJM PC 15083623
DMT4XJM MW 181.17
DMT4XJM FM C6H16NO3P
DMT4XJM IC InChI=1S/C6H16NO3P/c1-4-7(5-2)11(8,9)10-6-3/h4-6H2,1-3H3,(H,8,9)
DMT4XJM CS CCN(CC)P(=O)(O)OCC
DMT4XJM IK DUNFIZRDIMDMIH-UHFFFAOYSA-N
DMT4XJM IU ethoxy-N,N-diethylphosphonamidic acid
DMT4XJM DE Discovery agent
DMXMRK7 ID DMXMRK7
DMXMRK7 DN Ethyl octylfluorophosphonate
DMXMRK7 HS Investigative
DMXMRK7 SN CHEMBL1222256
DMXMRK7 DT Small molecular drug
DMXMRK7 PC 49864679
DMXMRK7 MW 238.28
DMXMRK7 FM C11H24FO2P
DMXMRK7 IC InChI=1S/C11H24FO2P/c1-4-5-6-7-8-9-10-15(12,13)14-11(2)3/h11H,4-10H2,1-3H3
DMXMRK7 CS CCCCCCCCP(=O)(OC(C)C)F
DMXMRK7 IK GLHLEAFTUHVDCD-UHFFFAOYSA-N
DMXMRK7 IU 1-[fluoro(propan-2-yloxy)phosphoryl]octane
DMXMRK7 DE Discovery agent
DM9KF0H ID DM9KF0H
DM9KF0H DN Ethyl Oxo(Piperidin-1-Yl)Acetate
DM9KF0H HS Investigative
DM9KF0H SN 53074-96-7; Ethyl 1-piperidineglyoxylate; Ethyl 1-piperidineoxoacetate; ETHYL OXO(PIPERIDIN-1-YL)ACETATE; ethyl 2-oxo-2-(piperidin-1-yl)acetate; ASBDXHCMVYVJQQ-UHFFFAOYSA-N; 1-Piperidineaceticacid, a-oxo-, ethyl ester; E1P; Ethyl1-piperidineglyoxylate; EINECS 258-343-9; N-ethoxalylpiperidine; 1w8m; AI3-26189; AC1L2WQF; ethyl 2-oxo-2-piperidylacetate; SCHEMBL1819086; CTK4J7020; DTXSID60201157; MolPort-001-510-784; Ethyl oxo(1-piperidinyl)acetate #; ZINC2149356; ALBB-030316; ethyl 2-oxo-2-piperidin-1-ylacetate; AKOS000444140
DM9KF0H DT Small molecular drug
DM9KF0H PC 104406
DM9KF0H MW 185.22
DM9KF0H FM C9H15NO3
DM9KF0H IC InChI=1S/C9H15NO3/c1-2-13-9(12)8(11)10-6-4-3-5-7-10/h2-7H2,1H3
DM9KF0H CS CCOC(=O)C(=O)N1CCCCC1
DM9KF0H IK ASBDXHCMVYVJQQ-UHFFFAOYSA-N
DM9KF0H IU ethyl 2-oxo-2-piperidin-1-ylacetate
DM9KF0H CA CAS 53074-96-7
DM9KF0H DE Discovery agent
DMYFK4L ID DMYFK4L
DMYFK4L DN Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMYFK4L HS Investigative
DMYFK4L SN CHEMBL77421; 2H-Indazol-5-amine, N-ethyl-4,5,6,7-tetrahydro-; 121867-55-8; Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine
DMYFK4L DT Small molecular drug
DMYFK4L PC 14539718
DMYFK4L MW 165.24
DMYFK4L FM C9H15N3
DMYFK4L IC InChI=1S/C9H15N3/c1-2-10-8-3-4-9-7(5-8)6-11-12-9/h6,8,10H,2-5H2,1H3,(H,11,12)
DMYFK4L CS CCNC1CCC2=C(C1)C=NN2
DMYFK4L IK DDFOVLJCDZCIIF-UHFFFAOYSA-N
DMYFK4L IU N-ethyl-4,5,6,7-tetrahydro-1H-indazol-5-amine
DMYFK4L DE Discovery agent
DMBULX4 ID DMBULX4
DMBULX4 DN Ethylene diamine
DMBULX4 HS Investigative
DMBULX4 SN ethylenediamine; Ethane-1,2-diamine; 1,2-Ethanediamine; 107-15-3; 1,2-Diaminoethane; Ethylene diamine; Ethylendiamine; Dimethylenediamine; edamine; 1,2-Ethylenediamine; Aethaldiamin; Ethyleendiamine; Aethylenediamin; Ethylene-diamine; beta-Aminoethylamine; 1,2-Diaminoaethan; Amerstat 274; Algicode 106L; 1,2-Diamino-ethano; 1,2-Diamino-ethaan; Aethaldiamin [German]; Caswell No. 437; Ethylenediamine [JAN]; Ethyleendiamine [Dutch]; 1,2-Ethanediamine, homopolymer; Aethylenediamin [German]; Ethylene-diamine [French]; NCI-C60402
DMBULX4 DT Small molecular drug
DMBULX4 PC 3301
DMBULX4 MW 60.1
DMBULX4 FM C2H8N2
DMBULX4 IC InChI=1S/C2H8N2/c3-1-2-4/h1-4H2
DMBULX4 CS C(CN)N
DMBULX4 IK PIICEJLVQHRZGT-UHFFFAOYSA-N
DMBULX4 IU ethane-1,2-diamine
DMBULX4 CA CAS 107-15-3
DMBULX4 CB CHEBI:30347
DMBULX4 DE Tuberculosis
DMJ6PB8 ID DMJ6PB8
DMJ6PB8 DN Ethylgallate
DMJ6PB8 HS Investigative
DMJ6PB8 SN ETHYL GALLATE; 831-61-8; Ethyl 3,4,5-trihydroxybenzoate; Gallic acid ethyl ester; Phyllemblin; Nipagallin A; Progallin A; Ethylgallate; Nipa No. 48; Gallic acid, ethyl ester; Benzoic acid, 3,4,5-trihydroxy-, ethyl ester; NIPA 48; 3,4,5-Trihydroxybenzoic acid ethyl ester; Ethyl-3,4,5-trihydroxybenzoate; Ethylester kyseliny gallove; UNII-235I6UDD3L; NSC 402626; Ethylester kyseliny gallove [Czech]; EINECS 212-608-5; BRN 2116014; CHEMBL453196; 235I6UDD3L; CHEBI:87247; VFPFQHQNJCMNBZ-UHFFFAOYSA-N; NSC402626; AK-94174; Q-100846; Gallic aci
DMJ6PB8 DT Small molecular drug
DMJ6PB8 PC 13250
DMJ6PB8 MW 198.17
DMJ6PB8 FM C9H10O5
DMJ6PB8 IC InChI=1S/C9H10O5/c1-2-14-9(13)5-3-6(10)8(12)7(11)4-5/h3-4,10-12H,2H2,1H3
DMJ6PB8 CS CCOC(=O)C1=CC(=C(C(=C1)O)O)O
DMJ6PB8 IK VFPFQHQNJCMNBZ-UHFFFAOYSA-N
DMJ6PB8 IU ethyl 3,4,5-trihydroxybenzoate
DMJ6PB8 CA CAS 831-61-8
DMJ6PB8 CB CHEBI:87247
DMJ6PB8 DE Discovery agent
DM3CWFR ID DM3CWFR
DM3CWFR DN Ethyl-indol-1-yl-pyridin-4-yl-amine
DM3CWFR HS Investigative
DM3CWFR SN CHEMBL154541; Ethyl-indol-1-yl-pyridin-4-yl-amine; SCHEMBL7613957; BDBM50048600
DM3CWFR DT Small molecular drug
DM3CWFR PC 10561859
DM3CWFR MW 237.3
DM3CWFR FM C15H15N3
DM3CWFR IC InChI=1S/C15H15N3/c1-2-17(14-7-10-16-11-8-14)18-12-9-13-5-3-4-6-15(13)18/h3-12H,2H2,1H3
DM3CWFR CS CCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DM3CWFR IK RBKZPZVPVZNIMS-UHFFFAOYSA-N
DM3CWFR IU N-ethyl-N-pyridin-4-ylindol-1-amine
DM3CWFR DE Discovery agent
DMV9OCU ID DMV9OCU
DMV9OCU DN Ethylisothiourea
DMV9OCU HS Investigative
DMV9OCU SN etiron; 2-Ethyl-2-thiopseudourea; ethyron; ETHYLISOTHIOUREA; 2-Ethyl-isothiourea; 2986-20-1; Carbamimidothioic acid, ethyl ester; UNII-236P47H4VR; Pseudourea, 2-ethyl-2-thio-; CHEMBL321691; VFIZBHJTOHUOEK-UHFFFAOYSA-N; 236P47H4VR; S-ethyl-thioureum; Ethiron (Salt/Mix); Ethyl imidothiocarbamate; Tocris-0873; ethylsulfanyl-formamidine; AC1L1JOU; Lopac-E-3149; Ethyl imidothiocarbamate #; AC1Q1UA8; WR 539 (Salt/Mix); Lopac0_000491; SCHEMBL160501
DMV9OCU DT Small molecular drug
DMV9OCU PC 5139
DMV9OCU MW 104.18
DMV9OCU FM C3H8N2S
DMV9OCU IC InChI=1S/C3H8N2S/c1-2-6-3(4)5/h2H2,1H3,(H3,4,5)
DMV9OCU CS CCSC(=N)N
DMV9OCU IK VFIZBHJTOHUOEK-UHFFFAOYSA-N
DMV9OCU IU ethyl carbamimidothioate
DMV9OCU CA CAS 2986-20-1
DM9YRCU ID DM9YRCU
DM9YRCU DN ethylketocyclazocine
DM9YRCU HS Investigative
DM9YRCU SN CHEMBL71301; AC1L28LJ; GTPL1602; BDBM50017232; L024009
DM9YRCU DT Small molecular drug
DM9YRCU PC 443409
DM9YRCU MW 299.4
DM9YRCU FM C19H25NO2
DM9YRCU IC InChI=1S/C19H25NO2/c1-3-19-8-9-20(11-13-4-5-13)17(12(19)2)18(22)15-7-6-14(21)10-16(15)19/h6-7,10,12-13,17,21H,3-5,8-9,11H2,1-2H3/t12?,17-,19+/m0/s1
DM9YRCU CS CC[C@@]12CCN([C@@H](C1C)C(=O)C3=C2C=C(C=C3)O)CC4CC4
DM9YRCU IK SEJUQQOPVAUETF-SCTOPSOGSA-N
DM9YRCU IU (1R,9S)-10-(cyclopropylmethyl)-1-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
DM9YRCU CA CAS 6036-52-8
DM9YRCU CB CHEBI:4901
DM9YRCU DE Discovery agent
DM0YROF ID DM0YROF
DM0YROF DN Ethylmorphine
DM0YROF HS Investigative
DM0YROF SN Ethylmorphine; Codethyline; DIONINE; 76-58-4; Morphine, ethyl-; Ethyl morphine; UNII-RWO67D87EU; Ethylmorphine [BAN]; 3-O-Ethylmorphine; EINECS 200-970-7; RWO67D87EU; CHEBI:4902; DEA No. 9190; Dionin; Ethylmorphine (BAN); NCGC00168251-01; Ethomorphine; Morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-ethoxy-17-methyl-; (4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol; Morphine 3-ethyl ether; AC1Q37UW; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-ethoxy-17-methyl-
DM0YROF DT Small molecular drug
DM0YROF PC 5359271
DM0YROF MW 313.4
DM0YROF FM C19H23NO3
DM0YROF IC InChI=1S/C19H23NO3/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18/h4-7,12-14,18,21H,3,8-10H2,1-2H3/t12-,13+,14-,18-,19-/m0/s1
DM0YROF CS CCOC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1
DM0YROF IK OGDVEMNWJVYAJL-LEPYJNQMSA-N
DM0YROF IU (4R,4aR,7S,7aR,12bS)-9-ethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
DM0YROF CA CAS 76-58-4
DM0YROF CB CHEBI:4902
DM0YROF DE Discovery agent
DMT51QD ID DMT51QD
DMT51QD DN ETHYLPHENSERINE
DMT51QD HS Investigative
DMT51QD SN 2-ethylphenserine.tartaric acid; ETHYLPHENSERINE; homotolserine; 2-ethylphenserine; eseroline 2-ethylphenylcarbamate; CHEMBL340391; BDBM10961; (3aS,8aR)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-(2-ethylphenyl)carbamate
DMT51QD DT Small molecular drug
DMT51QD PC 9976105
DMT51QD MW 365.5
DMT51QD FM C22H27N3O2
DMT51QD IC InChI=1S/C22H27N3O2/c1-5-15-8-6-7-9-18(15)23-21(26)27-16-10-11-19-17(14-16)22(2)12-13-24(3)20(22)25(19)4/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)/t20-,22+/m1/s1
DMT51QD CS CCC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN4C)C)C
DMT51QD IK NRKKZJALIFDZIJ-IRLDBZIGSA-N
DMT51QD IU [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(2-ethylphenyl)carbamate
DMT51QD DE Discovery agent
DM4FW3H ID DM4FW3H
DM4FW3H DN ETICLOPRIDE
DM4FW3H HS Investigative
DM4FW3H SN Eticlopride; Eticlopride [INN]; Eticlopridum [Latin]; Eticloprida [Spanish]; CHEMBL8946; UNII-J8M468HBH4; J8M468HBH4; FLB 131; FLB-131; 3-Chloro-5-Ethyl-N-{[(2s)-1-Ethylpyrrolidin-2-Yl]methyl}-6-Hydroxy-2-Methoxybenzamide; C17H25ClN2O3; 5-chloro-3-ethyl-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide; (-)-(S)-5-Chloro-3-ethyl-N-((1-ethyl-2-pyrrolidinyl)methyl)-6-methoxysalicylamide; NCGC00016963-01; NCGC00161393-01; CAS-97612-24-3; Eticlopridum; Eticloprida; Prestwick3_000932; ETICLOPRIDE,S(-); AC1L1MN4
DM4FW3H DT Small molecular drug
DM4FW3H PC 57267
DM4FW3H MW 340.8
DM4FW3H FM C17H25ClN2O3
DM4FW3H IC InChI=1S/C17H25ClN2O3/c1-4-11-9-13(18)16(23-3)14(15(11)21)17(22)19-10-12-7-6-8-20(12)5-2/h9,12,21H,4-8,10H2,1-3H3,(H,19,22)/t12-/m0/s1
DM4FW3H CS CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)Cl
DM4FW3H IK AADCDMQTJNYOSS-LBPRGKRZSA-N
DM4FW3H IU 5-chloro-3-ethyl-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide
DM4FW3H CA CAS 84226-12-0
DM4FW3H CB CHEBI:92874
DM4FW3H DE Discovery agent
DMR9YL6 ID DMR9YL6
DMR9YL6 DN Etilamfetamine
DMR9YL6 HS Investigative
DMR9YL6 SN Apetinil; Ethylamphetamine; Etilamfetamina [INN-Spanish]; Etilamfetamine; Etilamfetamine (INN); Etilamfetamine [INN]; Etilamfetaminum [INN-Latin]; Etilamfetaminum [Latin]; Etilanfetamina [Spanish]; N-Ethylamphetamine; N-ethyl-1-phenylpropan-2-amine; 1-Phenyl-2-aethylamino-propan; 1-Phenyl-2-aethylamino-propan [German]; 1-Phenyl-2-ethylaminopropane; 457-87-4; BRN 2357701; Benzeneethanamine, N-ethyl-.alpha.-methyl-; DEA No. 1475; N-Ethyl-alpha-methylphenethylamine; alpha-Phenyl-beta-ethylaminopropane
DMR9YL6 PC 9982
DMR9YL6 MW 163.26
DMR9YL6 FM C11H17N
DMR9YL6 IC YAGBSNMZQKEFCO-UHFFFAOYSA-N
DMR9YL6 CS CCNC(C)CC1=CC=CC=C1
DMR9YL6 IK 1S/C11H17N/c1-3-12-10(2)9-11-7-5-4-6-8-11/h4-8,10,12H,3,9H2,1-2H3
DMR9YL6 IU N-ethyl-1-phenylpropan-2-amine
DMR9YL6 CA CAS 457-87-4
DMR9YL6 CB CHEBI:134796
DMR9YL6 DE Pulmonary hypertension
DMVI9DM ID DMVI9DM
DMVI9DM DN ETIOCHOLANOLONE
DMVI9DM HS Investigative
DMVI9DM SN etiocholanolone; 5-Isoandrosterone; 53-42-9; Etiocholan-3alpha-ol-17-one; Aetiocholanolone; 3alpha-Etiocholanolone; 5beta-Androsterone; 3alpha-Hydroxy-5beta-androstan-17-one; 5b-androsterone; Androsterone, (5beta)-; UNII-97CGB1M48I; alpha-Etiocholanolone; 5.beta.-Androsterone; 5beta-Androstan-3alpha-ol-17-one; 3.alpha.-Etiocholanolone; NSC 50908; Androsterone, (5.beta.)-; CHEMBL85799; 97CGB1M48I; 3alpha-Hydroxyetiocholan-17-one; CHEBI:28195; Etiocholan-3.alpha.-ol-17-one; 3a-Hydroxy-5b-androstan-17-one
DMVI9DM DT Small molecular drug
DMVI9DM PC 5880
DMVI9DM MW 290.4
DMVI9DM FM C19H30O2
DMVI9DM IC InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14+,15+,16+,18+,19+/m1/s1
DMVI9DM CS C[C@]12CC[C@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
DMVI9DM IK QGXBDMJGAMFCBF-BNSUEQOYSA-N
DMVI9DM IU (3R,5R,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
DMVI9DM CA CAS 53-42-9
DMVI9DM CB CHEBI:28195
DMVI9DM DE Discovery agent
DMKH8TC ID DMKH8TC
DMKH8TC DN Etisulergine
DMKH8TC HS Investigative
DMKH8TC SN Etisulergine; UNII-28N73Q6O7Y; 64795-23-9; 28N73Q6O7Y; Etisulerginum; Etisulergina; etisulergine[inn]; Etisulergine [INN]; Etisulerginum [INN-Latin]; Etisulergina [INN-Spanish]; CQ 32-084; AC1L2AKJ; AC1Q6V8T; SCHEMBL219311; CHEMBL38992; BDBM50225361; 72782-54-8 (mono-hydrochloride)
DMKH8TC DT Small molecular drug
DMKH8TC PC 68847
DMKH8TC MW 376.5
DMKH8TC FM C19H28N4O2S
DMKH8TC IC InChI=1S/C19H28N4O2S/c1-4-23(5-2)26(24,25)21-14-10-16-15-7-6-8-17-19(15)13(11-20-17)9-18(16)22(3)12-14/h6-8,11,14,16,18,20-21H,4-5,9-10,12H2,1-3H3/t14-,16+,18+/m0/s1
DMKH8TC CS CCN(CC)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
DMKH8TC IK YHEIHLVIKSTGJE-YXJHDRRASA-N
DMKH8TC IU (6aR,9S,10aR)-9-(diethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
DMKH8TC CA CAS 64795-23-9
DMKH8TC DE Discovery agent
DMDOX1Z ID DMDOX1Z
DMDOX1Z DN Etoloxamine
DMDOX1Z HS Investigative
DMDOX1Z SN Etoloxamine; UNII-NEZ417265P; CHEMBL366265; 1157-87-5; NEZ417265P; Etoloxaminum; Etoloxamina; Aetholoxaminum; etoloxamine[inn]; Etoloxamine [INN]; Etoloxaminum [INN-Latin]; Etoloxamina [INN-Spanish]; 2-(2-benzylphenoxy)-N,N-diethylethanamine; AC1L2ASA; AC1Q57OP; SCHEMBL2110223; ZINC1407; BPXIOWINQPQVOY-UHFFFAOYSA-N; BDBM50151052; 2-((alpha-Phenyl-o-tolyl)oxy)triethylamine
DMDOX1Z DT Small molecular drug
DMDOX1Z PC 68950
DMDOX1Z MW 283.4
DMDOX1Z FM C19H25NO
DMDOX1Z IC InChI=1S/C19H25NO/c1-3-20(4-2)14-15-21-19-13-9-8-12-18(19)16-17-10-6-5-7-11-17/h5-13H,3-4,14-16H2,1-2H3
DMDOX1Z CS CCN(CC)CCOC1=CC=CC=C1CC2=CC=CC=C2
DMDOX1Z IK BPXIOWINQPQVOY-UHFFFAOYSA-N
DMDOX1Z IU 2-(2-benzylphenoxy)-N,N-diethylethanamine
DMDOX1Z CA CAS 1157-87-5
DMDOX1Z DE Discovery agent
DMFR1SE ID DMFR1SE
DMFR1SE DN ETONITAZENE
DMFR1SE HS Investigative
DMFR1SE SN Etonitazene; Etonitazine; Etonitazinum; Ciba 20-684BA; ARC 1G2; Etobedolum; 911-65-9; Etonitazenum [INN-Latin]; NIH 7607; Etonitazeno [INN-Spanish]; Etonitazene [INN:BAN:DCF]; UNII-9U3GT3353T; EINECS 213-009-1; Ba-20684; Ba 20684; BRN 0363324; CHEMBL312040; DEA No. 9624; PXDBZSCGSQSKST-UHFFFAOYSA-N; C22H28N4O3; 9U3GT3353T; 1-(2-(Diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1-(2-Diethylaminoethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; 1H-Benzimidazole-1-ethanamine, 2-((4-ethoxyphenyl)methyl)-N,N-diethyl-5-nitro-
DMFR1SE DT Small molecular drug
DMFR1SE PC 13493
DMFR1SE MW 396.5
DMFR1SE FM C22H28N4O3
DMFR1SE IC InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3
DMFR1SE CS CCN(CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)OCC
DMFR1SE IK PXDBZSCGSQSKST-UHFFFAOYSA-N
DMFR1SE IU 2-[2-[(4-ethoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]-N,N-diethylethanamine
DMFR1SE CA CAS 911-65-9
DMFR1SE DE Discovery agent
DM79YZN ID DM79YZN
DM79YZN DN Etorphine
DM79YZN HS Investigative
DM79YZN SN Etorphine; 19-Propylorvinol; 6,14-Ethenomorphinan-7-methanol, 4,5-epoxy-3-hydroxy-6-methoxy-.alpha.,17-dimethyl-.alpha.-propyl-, [5.alpha.,7.alpha.(R)]-; 7.alpha.-Etorphine; AC1LARGT; ETORPHINE - HCI; GTPL1625; SCHEMBL10031275; Oripavine, 6,14-endo-ethylenetetrahydro-7-(1-hydroxy-1-methylbutyl)-; BDBM82425; CAHCBJPUTCKATP-UHFFFAOYSA-N; M99; CAS_61677; NSC_61677; FT-0668440; L024016; Tetrahydro-7-.alpha.-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine; 6,14-endo-Ethenotetrahydrooripavine, 7.alpha.-(1-hydroxy-1-methylbuty
DM79YZN DT Small molecular drug
DM79YZN PC 644209
DM79YZN MW 411.5
DM79YZN FM C25H33NO4
DM79YZN IC InChI=1S/C25H33NO4/c1-5-8-22(2,28)17-14-23-9-10-25(17,29-4)21-24(23)11-12-26(3)18(23)13-15-6-7-16(27)20(30-21)19(15)24/h6-7,9-10,17-18,21,27-28H,5,8,11-14H2,1-4H3/t17-,18-,21-,22-,23-,24+,25-/m1/s1
DM79YZN CS CCC[C@](C)([C@H]1C[C@@]23C=C[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)C)OC)O
DM79YZN IK CAHCBJPUTCKATP-FAWZKKEFSA-N
DM79YZN IU (1R,2S,6R,14R,15R,19R)-19-[(2R)-2-hydroxypentan-2-yl]-15-methoxy-5-methyl-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11,16-tetraen-11-ol
DM79YZN CA CAS 14521-96-1
DM79YZN CB CHEBI:4912
DM79YZN DE Discovery agent
DM79XSF ID DM79XSF
DM79XSF DN ETP-45658
DM79XSF HS Investigative
DM79XSF SN 1198357-79-7; ETP 45658; 3-(1-methyl-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl)phenol; 3-(4-Morpholino-1-methyl-1H-pyrazolo[3,4-d]pyrimidine-6-yl)phenol; 3-[1-Methyl-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenol; CHEMBL4303351; SCHEMBL12684765; BDBM92585; ETP45658; ZINC59155589; AKOS025293482; ETP-45658, 13; 3-[1-Methyl-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-6-ylphenol
DM79XSF DT Small molecular drug
DM79XSF PC 25229608
DM79XSF MW 311.34
DM79XSF FM C16H17N5O2
DM79XSF IC InChI=1S/C16H17N5O2/c1-20-15-13(10-17-20)16(21-5-7-23-8-6-21)19-14(18-15)11-3-2-4-12(22)9-11/h2-4,9-10,22H,5-8H2,1H3
DM79XSF CS CN1C2=C(C=N1)C(=NC(=N2)C3=CC(=CC=C3)O)N4CCOCC4
DM79XSF IK BJVRNXSHJLDZJR-UHFFFAOYSA-N
DM79XSF IU 3-(1-methyl-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl)phenol
DM79XSF DE Breast cancer
DMO2PY8 ID DMO2PY8
DMO2PY8 DN ETP-46321
DMO2PY8 HS Investigative
DMO2PY8 SN 1252594-99-2; CHEMBL2087474; 5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine; SCHEMBL10100315; BCP19935; ETP46321; EX-A1284; BDBM50420714; ZINC68247289; CS-3350; ETP 46321;ETP46321; HY-12340; 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-yl-imidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine
DMO2PY8 DT Small molecular drug
DMO2PY8 PC 46927938
DMO2PY8 MW 473.6
DMO2PY8 FM C20H27N9O3S
DMO2PY8 IC InChI=1S/C20H27N9O3S/c1-33(30,31)29-4-2-26(3-5-29)12-16-13-28-14-17(15-10-22-20(21)23-11-15)25-19(18(28)24-16)27-6-8-32-9-7-27/h10-11,13-14H,2-9,12H2,1H3,(H2,21,22,23)
DMO2PY8 CS CS(=O)(=O)N1CCN(CC1)CC2=CN3C=C(N=C(C3=N2)N4CCOCC4)C5=CN=C(N=C5)N
DMO2PY8 IK OHKDVDMWRKFZRB-UHFFFAOYSA-N
DMO2PY8 IU 5-[2-[(4-methylsulfonylpiperazin-1-yl)methyl]-8-morpholin-4-ylimidazo[1,2-a]pyrazin-6-yl]pyrimidin-2-amine
DMO2PY8 DE Rheumatoid arthritis
DMZ1FCJ ID DMZ1FCJ
DMZ1FCJ DN EU-517
DMZ1FCJ HS Investigative
DMZ1FCJ SN Mcl-1 inhibitors (cancer), Eutropics; BH3 mimetics/Mcl-1 inhibitors (cancer), Eutropics
DMZ1FCJ CP Harvard Medical School
DMZ1FCJ DE Solid tumour/cancer
DMR3487 ID DMR3487
DMR3487 DN EU-C-001
DMR3487 HS Investigative
DMR3487 CP James Cook University of North Queensland
DMR3487 DE Brain injury
DME5CK3 ID DME5CK3
DME5CK3 DN eucalyptol
DME5CK3 HS Investigative
DME5CK3 SN Eucalyptol; cineole; 1,8-Cineole; 1,8-Cineol; Cajeputol; 470-82-6; 1,8-Epoxy-p-menthane; Eucalyptole; Zineol; Eucapur; Terpan; p-Cineole; 1,8-Oxido-p-menthane; 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane; Eukalyptol; CINEOL; Cucalyptol; Soledum; Eukalyptol [Czech]; Zedoary oil; Eucalyptol (natural); EUCALYPTUS OIL; p-Menthane, 1,8-epoxy-; Cineole (VAN); 2-Oxabicyclo[2.2.2]octane, 1,3,3-trimethyl-; NCI-C56575; Eucalyptol [USAN]; UNII-RV6J6604TK; FEMA No. 2465; 2-Oxabicyclo(2.2.2)octane, 1,3,3-trimethyl-; NSC 6171
DME5CK3 DT Small molecular drug
DME5CK3 PC 2758
DME5CK3 MW 154.25
DME5CK3 FM C10H18O
DME5CK3 IC InChI=1S/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H3
DME5CK3 CS CC1(C2CCC(O1)(CC2)C)C
DME5CK3 IK WEEGYLXZBRQIMU-UHFFFAOYSA-N
DME5CK3 IU 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane
DME5CK3 CA CAS 470-82-6
DME5CK3 CB CHEBI:27961
DME5CK3 DE Discovery agent
DMUA485 ID DMUA485
DMUA485 DN EUGENIIN
DMUA485 HS Investigative
DMUA485 SN beta-D-Glucopyranose, cyclic 4,6-((1S)-4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,3-tris(3,4,5-trihydroxybenzoate); 81571-72-4; 58970-75-5; SCHEMBL618555; AC1L46N3; LS-71467; 1,2,3-Tri-O-galloyl-4,6-(S)-hexahydroxydiphenoyl-b-D-glucopyranose; beta-D-Glucopyranose, cyclic 4,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1,2,3-tris(3,4,5-trihydroxybenzoate)
DMUA485 DT Small molecular drug
DMUA485 PC 442679
DMUA485 MW 938.7
DMUA485 FM C41H30O26
DMUA485 IC InChI=1S/C41H30O26/c42-15-1-10(2-16(43)26(15)50)36(57)65-34-33-23(9-62-39(60)13-7-21(48)29(53)31(55)24(13)25-14(40(61)64-33)8-22(49)30(54)32(25)56)63-41(67-38(59)12-5-19(46)28(52)20(47)6-12)35(34)66-37(58)11-3-17(44)27(51)18(45)4-11/h1-8,23,33-35,41-56H,9H2/t23-,33-,34+,35-,41+/m1/s1
DMUA485 CS C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O
DMUA485 IK JCGHAEBIBSEQAD-UUUCSUBKSA-N
DMUA485 IU [(10R,11S,12R,13S,15R)-3,4,5,21,22,23-hexahydroxy-8,18-dioxo-12,13-bis[(3,4,5-trihydroxybenzoyl)oxy]-9,14,17-trioxatetracyclo[17.4.0.02,7.010,15]tricosa-1(23),2,4,6,19,21-hexaen-11-yl] 3,4,5-trihydroxybenzoate
DMUA485 CB CHEBI:4916
DMUA485 DE Discovery agent
DMLXKZH ID DMLXKZH
DMLXKZH DN EUPAFOLIN
DMLXKZH HS Investigative
DMLXKZH SN 6-Methoxyluteolin; 520-11-6; Nepetin; EUPAFOLIN; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one; Eurafolin; UNII-I3O7LF3GED; I3O7LF3GED; CHEMBL172350; NSC122416; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxy-; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one; SMR000440634; Pedaltin; NSC 122416; AC1NSVCV; MLS000728561; MLS000877025; SCHEMBL828390; MEGxp0_000458; cid_5317284; ACon1_000516; BDBM23412; DTXSID10199959; FHHSEFRSDKWJKJ-UHFFFAOYSA-N; REGID_for_CID_5317284
DMLXKZH DT Small molecular drug
DMLXKZH PC 5317284
DMLXKZH MW 316.26
DMLXKZH FM C16H12O7
DMLXKZH IC InChI=1S/C16H12O7/c1-22-16-11(20)6-13-14(15(16)21)10(19)5-12(23-13)7-2-3-8(17)9(18)4-7/h2-6,17-18,20-21H,1H3
DMLXKZH CS COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O
DMLXKZH IK FHHSEFRSDKWJKJ-UHFFFAOYSA-N
DMLXKZH IU 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-methoxychromen-4-one
DMLXKZH CA CAS 520-11-6
DMLXKZH DE Discovery agent
DM068CY ID DM068CY
DM068CY DN EUPATORIOPICRIN
DM068CY HS Investigative
DM068CY SN Eupatoriopicrin; CHEMBL221283; 6856-01-5; Eupatoriopicrine; AC1NQYHY; CHEBI:4937; BDBM50194428; C09442; [(3aR,4R,6E,10E,11aR)-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-(hydroxymethyl)but-2-enoate
DM068CY DT Small molecular drug
DM068CY PC 5281461
DM068CY MW 362.4
DM068CY FM C20H26O6
DM068CY IC InChI=1S/C20H26O6/c1-12-5-4-6-13(2)10-17(26-20(24)15(11-22)7-8-21)18-14(3)19(23)25-16(18)9-12/h6-7,9,16-18,21-22H,3-5,8,10-11H2,1-2H3/b12-9+,13-6+,15-7+/t16-,17-,18+/m1/s1
DM068CY CS C/C/1=C\\[C@@H]2[C@@H]([C@@H](C/C(=C/CC1)/C)OC(=O)/C(=C/CO)/CO)C(=C)C(=O)O2
DM068CY IK VWJYWGYJIDQUEG-DKDOXNMLSA-N
DM068CY IU [(3aR,4R,6E,10E,11aR)-6,10-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-(hydroxymethyl)but-2-enoate
DM068CY CA CAS 6856-01-5
DM068CY CB CHEBI:4937
DM068CY DE Discovery agent
DMO3AZ6 ID DMO3AZ6
DMO3AZ6 DN Euro-Celtique 1
DMO3AZ6 HS Investigative
DMO3AZ6 TC Analgesics
DMO3AZ6 DE Pain
DMJH4BF ID DMJH4BF
DMJH4BF DN Euro-Celtique 2
DMJH4BF HS Investigative
DMJH4BF TC Analgesics
DMJH4BF DE Pain
DM8VI3T ID DM8VI3T
DM8VI3T DN Euro-Celtique 3
DM8VI3T HS Investigative
DM8VI3T TC Analgesics
DM8VI3T DE Pain
DMO4CEL ID DMO4CEL
DMO4CEL DN Euro-Celtique 4
DMO4CEL HS Investigative
DMO4CEL TC Analgesics
DMO4CEL DE Pain
DMXBGSL ID DMXBGSL
DMXBGSL DN EUSYNSTYELAMIDE B
DMXBGSL HS Investigative
DMXBGSL PC 70685496
DMXBGSL MW 802.6
DMXBGSL FM C33H42Br2N10O4
DMXBGSL IC InChI=1S/C33H42Br2N10O4/c34-21-5-7-23-19(17-43-25(23)14-21)13-27-32(48,16-20-18-44-26-15-22(35)6-8-24(20)26)29(47)45(12-4-3-11-42-31(38)39)33(27,49)28(46)40-9-1-2-10-41-30(36)37/h5-8,14-15,17-18,27,43-44,48-49H,1-4,9-13,16H2,(H,40,46)(H4,36,37,41)(H4,38,39,42)/t27-,32+,33+/m1/s1
DMXBGSL CS C1=CC2=C(C=C1Br)NC=C2C[C@@H]3[C@](C(=O)N([C@]3(C(=O)NCCCCN=C(N)N)O)CCCCN=C(N)N)(CC4=CNC5=C4C=CC(=C5)Br)O
DMXBGSL IK FWIZAEZOEFOBCD-LGBXHZPNSA-N
DMXBGSL IU (2S,3R,4S)-3,4-bis[(6-bromo-1H-indol-3-yl)methyl]-N,1-bis[4-(diaminomethylideneamino)butyl]-2,4-dihydroxy-5-oxopyrrolidine-2-carboxamide
DMXBGSL DE Discovery agent
DM6ODAS ID DM6ODAS
DM6ODAS DN Eusynstyelamide C
DM6ODAS HS Investigative
DM6ODAS DE Discovery agent
DMNMEAW ID DMNMEAW
DMNMEAW DN Evatak
DMNMEAW HS Investigative
DMNMEAW SN Echovirus type 1 cancer therapy, Psiron; Echovirus type 1 cancer therapy, Viralytics
DMNMEAW CP University of Newcastle
DMNMEAW DE Solid tumour/cancer
DM17TYR ID DM17TYR
DM17TYR DN Everolimus
DM17TYR HS Investigative
DM17TYR SN Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
DM17TYR CP Novartis
DM17TYR TC Antiviral Agents
DM17TYR DT Small molecular drug
DM17TYR PC 6442177
DM17TYR MW 958.2
DM17TYR FM C53H83NO14
DM17TYR IC InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DM17TYR CS C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
DM17TYR IK HKVAMNSJSFKALM-GKUWKFKPSA-N
DM17TYR IU (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
DM17TYR CA CAS 159351-69-6
DM17TYR CB CHEBI:68478
DM17TYR DE Advanced kidney cancer; Diffuse large B-cell lymphoma; Renal cell carcinoma; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMHMFKE ID DMHMFKE
DMHMFKE DN EVP-4473
DMHMFKE HS Investigative
DMHMFKE CP Bayer AG
DMHMFKE DE Alzheimer disease
DM4Q2HZ ID DM4Q2HZ
DM4Q2HZ DN EVT-501
DM4Q2HZ HS Investigative
DM4Q2HZ SN H3 antagonists (cognitive/sleep disorders), Evotec
DM4Q2HZ CP Evotec AG
DM4Q2HZ DE Sleep-wake disorder
DMBKM30 ID DMBKM30
DMBKM30 DN EX-1311
DMBKM30 HS Investigative
DMBKM30 SN EX-1350; EX-1365; EX-1832; EX-51; Ghrelin antagonists (metabolic disease); Ghrelin antagonists (metabolic disease), Elixir; Ghrelin antagonists (metabolic disease), Elixir/Novartis
DMBKM30 CP Elixir Pharmaceuticals Inc
DMBKM30 DE Metabolic disorder
DMWF8U5 ID DMWF8U5
DMWF8U5 DN EX-1314
DMWF8U5 HS Investigative
DMWF8U5 SN BMS-317180; BMS-604992; BMS-606056; Ghrelin agonists, BMS; Ghrelin agonists, Elixir; Growth hormone secretagogues, BMS; Growthhormone secretagogues, Elixir
DMWF8U5 CP Bristol-Myers Squibb Co
DMWF8U5 DT Small molecular drug
DMWF8U5 PC 72941845
DMWF8U5 MW 534
DMWF8U5 FM C24H32ClN7O5
DMWF8U5 IC InChI=1S/C24H31N7O5.ClH/c1-24(2,26)22(33)27-18(15-35-13-16-8-5-4-6-9-16)21-29-28-20-11-7-10-17(31(20)21)14-36-23(34)30(3)12-19(25)32;/h4-11,18H,12-15,26H2,1-3H3,(H2,25,32)(H,27,33);1H/t18-;/m1./s1
DMWF8U5 CS CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C2=NN=C3N2C(=CC=C3)COC(=O)N(C)CC(=O)N)N.Cl
DMWF8U5 IK DFDPBEQMMOYQHK-GMUIIQOCSA-N
DMWF8U5 IU [3-[(1S)-1-[(2-amino-2-methylpropanoyl)amino]-2-phenylmethoxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-5-yl]methyl N-(2-amino-2-oxoethyl)-N-methylcarbamate;hydrochloride
DMWF8U5 CA CAS 674343-47-6
DMWF8U5 DE Cachexia
DMNI6YU ID DMNI6YU
DMNI6YU DN EX5
DMNI6YU HS Investigative
DMNI6YU TC Antisense
DMNI6YU DT Antisense drug
DMNI6YU DE Discovery agent
DMSG8RI ID DMSG8RI
DMSG8RI DN example 131 [WO2009133348]
DMSG8RI HS Investigative
DMSG8RI SN example 131 [WO2009133348]; SCHEMBL1431769; GTPL8489
DMSG8RI DT Small molecular drug
DMSG8RI PC 44468926
DMSG8RI MW 431.5
DMSG8RI FM C22H27F2N5O2
DMSG8RI IC InChI=1S/C22H27F2N5O2/c1-2-29-9-3-4-19(29)22(31)28-18(11-14-5-7-16(23)17(24)10-14)21(30)27-13-15-6-8-20(25)26-12-15/h5-8,10,12,18-19H,2-4,9,11,13H2,1H3,(H2,25,26)(H,27,30)(H,28,31)/t18-,19+/m0/s1
DMSG8RI CS CCN1CCC[C@@H]1C(=O)N[C@@H](CC2=CC(=C(C=C2)F)F)C(=O)NCC3=CN=C(C=C3)N
DMSG8RI IK ALLYUHIQZKTLFG-RBUKOAKNSA-N
DMSG8RI IU (2R)-N-[(2S)-1-[(6-aminopyridin-3-yl)methylamino]-3-(3,4-difluorophenyl)-1-oxopropan-2-yl]-1-ethylpyrrolidine-2-carboxamide
DMSG8RI DE Discovery agent
DMY3CKG ID DMY3CKG
DMY3CKG DN example 166 (WO2014154727)
DMY3CKG HS Investigative
DMY3CKG SN GTPL7892; SCHEMBL18725165; example 166 [WO2014154727]; 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid
DMY3CKG DT Small molecular drug
DMY3CKG PC 78426198
DMY3CKG MW 414.9
DMY3CKG FM C21H19ClN2O3S
DMY3CKG IC InChI=1S/C21H19ClN2O3S/c1-12-11-24-21(28-12)18(10-20(26)27)16-7-15(8-17(22)9-16)14-4-2-3-13(5-14)6-19(23)25/h2-5,7-9,11,18H,6,10H2,1H3,(H2,23,25)(H,26,27)
DMY3CKG CS CC1=CN=C(S1)C(CC(=O)O)C2=CC(=CC(=C2)C3=CC=CC(=C3)CC(=O)N)Cl
DMY3CKG IK SRVXSISGYBMIHR-UHFFFAOYSA-N
DMY3CKG IU 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid
DMY3CKG DE Discovery agent
DMU25HZ ID DMU25HZ
DMU25HZ DN example 2 (WO2013004676)
DMU25HZ HS Investigative
DMU25HZ SN entry 2 [PMID: 24900681]
DMU25HZ DT Small molecular drug
DMU25HZ PC 71202307
DMU25HZ MW 390.9
DMU25HZ FM C18H16ClFN4OS
DMU25HZ IC InChI=1S/C18H16ClFN4OS/c19-11-1-4-15(22-9-11)16(25)23-12-2-3-14(20)13(7-12)18-8-10(18)5-6-26-17(21)24-18/h1-4,7,9-10H,5-6,8H2,(H2,21,24)(H,23,25)/t10-,18+/m1/s1
DMU25HZ CS C1CSC(=N[C@@]2([C@H]1C2)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)Cl)F)N
DMU25HZ IK COCAUCFPFHUGAA-MGNBDDOMSA-N
DMU25HZ IU N-[3-[(1S,7S)-3-amino-4-thia-2-azabicyclo[5.1.0]oct-2-en-1-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide
DMU25HZ DE Discovery agent
DMF9W41 ID DMF9W41
DMF9W41 DN example 20 (WO2010128058)
DMF9W41 HS Investigative
DMF9W41 SN SCHEMBL297687; GTPL7853; example 20 [WO2010128058]
DMF9W41 DT Small molecular drug
DMF9W41 PC 46944265
DMF9W41 MW 372.8
DMF9W41 FM C17H17ClN6O2
DMF9W41 IC InChI=1S/C17H17ClN6O2/c1-17(7-13(25)24(2)16(19)23-17)10-4-3-5-12(6-10)22-15(26)14-20-8-11(18)9-21-14/h3-6,8-9H,7H2,1-2H3,(H2,19,23)(H,22,26)/t17-/m0/s1
DMF9W41 CS C[C@]1(CC(=O)N(C(=N1)N)C)C2=CC(=CC=C2)NC(=O)C3=NC=C(C=N3)Cl
DMF9W41 IK VZUGBLTVBZJZOE-KRWDZBQOSA-N
DMF9W41 IU N-[3-[(4S)-2-amino-1,4-dimethyl-6-oxo-5H-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide
DMF9W41 DE Discovery agent
DMP8A5R ID DMP8A5R
DMP8A5R DN example 373 [WO2012093101]
DMP8A5R HS Investigative
DMP8A5R SN CHEMBL2180765; example 373 [WO2012093101]; GTPL8296; SCHEMBL19210538; BDBM50400274
DMP8A5R DT Small molecular drug
DMP8A5R PC 57412074
DMP8A5R MW 524.9
DMP8A5R FM C25H22ClFN6O4
DMP8A5R IC InChI=1S/C25H22ClFN6O4/c26-17-3-1-2-13(22(17)27)11-30-23(34)21-9-14-8-20(14)33(21)25(36)31-18-12-32(24(29)35)19-5-4-15(10-16(18)19)37-7-6-28/h1-5,10,12,14,20-21H,7-9,11H2,(H2,29,35)(H,30,34)(H,31,36)/t14-,20-,21+/m1/s1
DMP8A5R CS C1[C@H]2[C@@H]1N([C@@H](C2)C(=O)NCC3=C(C(=CC=C3)Cl)F)C(=O)NC4=CN(C5=C4C=C(C=C5)OCC#N)C(=O)N
DMP8A5R IK SOCAXRLFGRNEPK-IFZYUDKTSA-N
DMP8A5R IU (1R,3S,5R)-2-N-[1-carbamoyl-5-(cyanomethoxy)indol-3-yl]-3-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide
DMP8A5R DE Discovery agent
DM2N9Y8 ID DM2N9Y8
DM2N9Y8 DN example 41 (WO2012028563)
DM2N9Y8 HS Investigative
DM2N9Y8 SN SCHEMBL719875; GTPL7855; example 41 [WO2012028563]
DM2N9Y8 DT Small molecular drug
DM2N9Y8 PC 56846820
DM2N9Y8 MW 759.9
DM2N9Y8 FM C36H40F3N5O6S2
DM2N9Y8 IC InChI=1S/C36H40F3N5O6S2/c1-23-22-51-34(41-23)31-13-8-14-44(31)35(47)27-17-26(18-28(19-27)43(2)52(3,48)49)33(46)42-30(16-24-9-5-4-6-10-24)32(45)21-40-20-25-11-7-12-29(15-25)50-36(37,38)39/h4-7,9-12,15,17-19,22,30-32,40,45H,8,13-14,16,20-21H2,1-3H3,(H,42,46)/t30-,31+,32+/m0/s1
DM2N9Y8 CS CC1=CSC(=N1)[C@H]2CCCN2C(=O)C3=CC(=CC(=C3)C(=O)N[C@@H](CC4=CC=CC=C4)[C@@H](CNCC5=CC(=CC=C5)OC(F)(F)F)O)N(C)S(=O)(=O)C
DM2N9Y8 IK GUOONOJYWQOJJP-DCMFLLSESA-N
DM2N9Y8 IU N-[(2S,3R)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethoxy)phenyl]methylamino]butan-2-yl]-3-[methyl(methylsulfonyl)amino]-5-[(2R)-2-(4-methyl-1,3-thiazol-2-yl)pyrrolidine-1-carbonyl]benzamide
DM2N9Y8 DE Discovery agent
DMFSHXW ID DMFSHXW
DMFSHXW DN example 8 [WO1999033801A1]
DMFSHXW HS Investigative
DMFSHXW SN example 8 [WO1999033801A1]; GTPL8581
DMFSHXW DT Small molecular drug
DMFSHXW PC 57180216
DMFSHXW MW 347.31
DMFSHXW FM C15H17F4N3O2
DMFSHXW IC InChI=1S/C15H17F4N3O2/c1-2-10(20)14(24)22-11-5-3-4-9(16)8(11)6-12(22)13(23)21-7-15(17,18)19/h3-5,10,12H,2,6-7,20H2,1H3,(H,21,23)/t10-,12+/m0/s1
DMFSHXW CS CC[C@@H](C(=O)N1[C@H](CC2=C1C=CC=C2F)C(=O)NCC(F)(F)F)N
DMFSHXW IK GNYDXSHWPPTVEX-CMPLNLGQSA-N
DMFSHXW IU (2R)-1-[(2S)-2-aminobutanoyl]-4-fluoro-N-(2,2,2-trifluoroethyl)-2,3-dihydroindole-2-carboxamide
DMFSHXW DE Discovery agent
DMU42CR ID DMU42CR
DMU42CR DN example 92 (WO2012095521)
DMU42CR HS Investigative
DMU42CR SN US8846658, 92; SCHEMBL363629; GTPL7856; CHEMBL3653509; BDBM18751; example 92 [WO2012095521]; US8846658, 93
DMU42CR DT Small molecular drug
DMU42CR PC 50913216
DMU42CR MW 394.8
DMU42CR FM C18H17ClF2N4O2
DMU42CR IC InChI=1S/C18H17ClF2N4O2/c1-10-4-11(19)6-23-16(10)17(26)24-12-2-3-14(21)13(5-12)18(8-20)9-27-7-15(22)25-18/h2-6H,7-9H2,1H3,(H2,22,25)(H,24,26)/t18-/m0/s1
DMU42CR CS CC1=CC(=CN=C1C(=O)NC2=CC(=C(C=C2)F)[C@@]3(COCC(=N3)N)CF)Cl
DMU42CR IK NQNLROFWOGGJGK-SFHVURJKSA-N
DMU42CR IU N-[3-[(3R)-5-amino-3-(fluoromethyl)-2,6-dihydro-1,4-oxazin-3-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide
DMU42CR DE Discovery agent
DMMZH3Q ID DMMZH3Q
DMMZH3Q DN Exiguamine A
DMMZH3Q HS Investigative
DMMZH3Q SN CHEMBL468547; BDBM21975
DMMZH3Q DT Small molecular drug
DMMZH3Q PC 16066751
DMMZH3Q MW 492.5
DMMZH3Q FM C25H26N5O6+
DMMZH3Q IC InChI=1S/C25H25N5O6/c1-28-23(34)25(29(2)24(28)35)18-17(21(33)19-15(20(18)32)11(5-7-26)10-27-19)16-12-6-8-30(3,4)13(12)9-14(31)22(16)36-25/h9-10H,5-8,26H2,1-4H3,(H-,27,31,32,33)/p+1/t25-/m1/s1
DMMZH3Q CS CN1C(=O)[C@]2(C3=C(C4=C5CC[N+](C5=CC(=C4O2)O)(C)C)C(=O)C6=C(C3=O)C(=CN6)CCN)N(C1=O)C
DMMZH3Q IK UEKKREMMIOJMRO-RUZDIDTESA-O
DMMZH3Q IU (12R)-16-(2-aminoethyl)-9-hydroxy-1',3',6,6-tetramethylspiro[11-oxa-18-aza-6-azoniapentacyclo[11.7.0.02,10.03,7.015,19]icosa-1(13),2,7,9,15(19),16-hexaene-12,5'-imidazolidine]-2',4',14,20-tetrone
DMMZH3Q CB CHEBI:50655
DMMZH3Q DE Discovery agent
DME1TGM ID DME1TGM
DME1TGM DN EXIGUAMINE B
DME1TGM HS Investigative
DME1TGM SN CHEMBL1221412
DME1TGM DT Small molecular drug
DME1TGM PC 24856337
DME1TGM MW 508.5
DME1TGM FM C25H26N5O7+
DME1TGM IC InChI=1S/C25H25N5O7/c1-28-23(35)25(29(2)24(28)36)18-17(21(34)19-14(20(18)33)10(5-6-26)8-27-19)16-15-11(7-12(31)22(16)37-25)30(3,4)9-13(15)32/h7-8,13,32H,5-6,9,26H2,1-4H3,(H-,27,31,33,34)/p+1/t13-,25-/m1/s1
DME1TGM CS CN1C(=O)[C@]2(C3=C(C4=C5[C@@H](C[N+](C5=CC(=C4O2)O)(C)C)O)C(=O)C6=C(C3=O)C(=CN6)CCN)N(C1=O)C
DME1TGM IK YOXFPJITBOPKPN-YMXBGEKHSA-O
DME1TGM IU (4S,12R)-16-(2-aminoethyl)-4,9-dihydroxy-1',3',6,6-tetramethylspiro[11-oxa-18-aza-6-azoniapentacyclo[11.7.0.02,10.03,7.015,19]icosa-1(13),2,7,9,15(19),16-hexaene-12,5'-imidazolidine]-2',4',14,20-tetrone
DME1TGM CB CHEBI:50657
DME1TGM DE Discovery agent
DMWIBFM ID DMWIBFM
DMWIBFM DN EXP3174
DMWIBFM HS Investigative
DMWIBFM SN Losartan carboxylic acid; 124750-92-1; EXP-3174; Exp3174; EXP 3174; E-3174; UNII-GD76OCH73X; CHEBI:74125; CHEMBL907; GD76OCH73X; L-158641; 2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid; 2-Butyl-4-chloro-1-[(2'-(1-H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-1-H-imidazole-5-carboxylic acid; 1H-Imidazole-5-carboxylicacid, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; EXP-3174; Carboxylic Acid Metabolite (E-3174)
DMWIBFM DT Small molecular drug
DMWIBFM PC 108185
DMWIBFM MW 436.9
DMWIBFM FM C22H21ClN6O2
DMWIBFM IC InChI=1S/C22H21ClN6O2/c1-2-3-8-18-24-20(23)19(22(30)31)29(18)13-14-9-11-15(12-10-14)16-6-4-5-7-17(16)21-25-27-28-26-21/h4-7,9-12H,2-3,8,13H2,1H3,(H,30,31)(H,25,26,27,28)
DMWIBFM CS CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)Cl
DMWIBFM IK ZEUXAIYYDDCIRX-UHFFFAOYSA-N
DMWIBFM IU 2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
DMWIBFM CA CAS 124750-92-1
DMWIBFM CB CHEBI:74125
DMWIBFM DE Discovery agent
DMY96KO ID DMY96KO
DMY96KO DN EXRD-4605
DMY96KO HS Investigative
DMY96KO SN DIRA-7471; Epoxide hydrolase inhibitors (hypertension); Epoxide hydrolase inhibitors (hypertension), Boehringer Ingelheim
DMY96KO CP Boehringer Ingelheim Corp
DMY96KO DE Hypertension
DM5V3S7 ID DM5V3S7
DM5V3S7 DN Ezetimibe-glucuronide
DM5V3S7 HS Investigative
DM5V3S7 SN ezetimibe-glucuronide; 190448-57-8; Ezetimibe b-D-glucuronide; CHEMBL321017; Ezetimibe beta-D-Glucuronide; Ezetimibe Phenoxy Glucuronide; EZM-G; Sch-58235 Glucuronide; Sch 58235 Glucuronide; A-D-Glucuronide; Ezetimibe Phenexy Glucuronide; Sch 60663; SCHEMBL10027374; CTK8F0579; DTXSID10432454; ZINC3975560; Ezetimibe Phenoxy; BDBM50240720; AKOS030241675; B-D-GLUCOPYRANOSIDURONIC ACID,4-[(2S,3R)-1-(4-FLUOROPHENYL)-3-[(3S)-3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL]-4-OXO-2-AZETIDINYL]PHENYL; RT-012671
DM5V3S7 DT Small molecular drug
DM5V3S7 PC 9894653
DM5V3S7 MW 585.5
DM5V3S7 FM C30H29F2NO9
DM5V3S7 IC InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(34)14-13-21-23(33(28(21)38)19-9-7-18(32)8-10-19)16-3-11-20(12-4-16)41-30-26(37)24(35)25(36)27(42-30)29(39)40/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1
DM5V3S7 CS C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O
DM5V3S7 IK UOFYCFMTERCNEW-ADEYADIWSA-N
DM5V3S7 IU (2S,3S,4S,5R,6S)-6-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DM5V3S7 CA CAS 190448-57-8
DM5V3S7 DE Discovery agent
DMXV5PM ID DMXV5PM
DMXV5PM DN EZN-3920
DMXV5PM HS Investigative
DMXV5PM SN SPC-3920; ERBB3 RNA inhibitor (cancer), Enzon/Santaris
DMXV5PM CP Santaris Pharma A/S
DMXV5PM DE Solid tumour/cancer
DMTW571 ID DMTW571
DMTW571 DN F(4-Fluoro)VAE
DMTW571 HS Investigative
DMTW571 SN CHEMBL258583; F(4-Fluoro)VAE; F(4-fluro)VAE
DMTW571 DT Small molecular drug
DMTW571 PC 44452269
DMTW571 MW 482.5
DMTW571 FM C22H31FN4O7
DMTW571 IC InChI=1S/C22H31FN4O7/c1-11(2)18(27-20(31)15(24)10-13-4-6-14(23)7-5-13)21(32)25-12(3)19(30)26-16(22(33)34)8-9-17(28)29/h4-7,11-12,15-16,18H,8-10,24H2,1-3H3,(H,25,32)(H,26,30)(H,27,31)(H,28,29)(H,33,34)/t12-,15-,16-,18-/m0/s1
DMTW571 CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)F)N
DMTW571 IK HREKBPJJOGCVRC-RPZXMPESSA-N
DMTW571 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]pentanedioic acid
DMTW571 DE Discovery agent
DMXHKE3 ID DMXHKE3
DMXHKE3 DN F-12458
DMXHKE3 HS Investigative
DMXHKE3 SN CAAX tetrapeptide analogs, Pierre Fabre; Farnesyl transferase inhibitors, Pierre Fabre; Ras inhibitor, Pierre Fabre
DMXHKE3 CP Pierre Fabre SA
DMXHKE3 DE Solid tumour/cancer
DMHETZN ID DMHETZN
DMHETZN DN F-18 exendin-4 derivative PET tracers
DMHETZN HS Investigative
DMHETZN SN [18F]FB12-Ex4; [18F]FB40-Ex4; F-18 exendin-4 derivative PET tracers (diabetes); F-18 exendin-4 derivative PET tracers (diabetes), Kyoto University/Arkray
DMHETZN CP Kyoto University
DMHETZN DE Diabetic complication
DM69MKU ID DM69MKU
DM69MKU DN F3
DM69MKU HS Investigative
DM69MKU SN 1-Chloro-1,2,2-trifluorocyclobutane; 661-71-2; Cyclobutane, 1-chloro-1,2,2-trifluoro-; 1-Ctfcb; AC1Q4KXO; AC1L2WN1; GTPL2400; SCHEMBL3123282; CTK5C3598; MolPort-001-773-111; ZX-AP007208; 7606AE; PC2028; 7607AE; FCH917920; SBB086362; MFCD00042139; AKOS006230600; Cyclobutane,1-chloro-1,2,2-trifluoro-; TR-022419; FT-0607576; C-47497; I14-28177
DM69MKU DT Small molecular drug
DM69MKU PC 79091
DM69MKU MW 144.52
DM69MKU FM C4H4ClF3
DM69MKU IC InChI=1S/C4H4ClF3/c5-3(6)1-2-4(3,7)8/h1-2H2
DM69MKU CS C1CC(C1(F)F)(F)Cl
DM69MKU IK ZZQYDYODFHABLC-UHFFFAOYSA-N
DM69MKU IU 1-chloro-1,2,2-trifluorocyclobutane
DM69MKU CA CAS 661-71-2
DM69MKU DE Discovery agent
DMD7HO8 ID DMD7HO8
DMD7HO8 DN F61F12
DMD7HO8 HS Investigative
DMD7HO8 SN Anti-Fas mAb (cancer), IMED
DMD7HO8 CP IMED AB
DMD7HO8 DT Antibody
DMD7HO8 DE Solid tumour/cancer
DMYWERO ID DMYWERO
DMYWERO DN F-9TG
DMYWERO HS Investigative
DMYWERO SN Recombinant human coagulation factor IX (type B hemophilia), ProGenetics; Recombinant human coagulation factor IX (type B hemophilia), GTC/LFB
DMYWERO CP Progenetics LLC
DMYWERO DE Factor IX deficiency
DMDBO89 ID DMDBO89
DMDBO89 DN FA-70
DMDBO89 HS Investigative
DMDBO89 CP Universitat Autonoma de Barcelona
DMDBO89 PC 9816234
DMDBO89 MW 242.32
DMDBO89 FM C15H18N2O
DMDBO89 IC InChI=1S/C15H18N2O/c1-4-5-8-16(2)11-13-9-12-10-14(18)6-7-15(12)17(13)3/h6-7,9-10,18H,8,11H2,1-3H3
DMDBO89 CS CC#CCN(C)CC1=CC2=C(N1C)C=CC(=C2)O
DMDBO89 IK VJSXYTMXFSBYDX-UHFFFAOYSA-N
DMDBO89 IU 2-[[but-2-ynyl(methyl)amino]methyl]-1-methylindol-5-ol
DMDBO89 CA CAS 133846-05-6
DMDBO89 DE Major depressive disorder
DMSQ3I9 ID DMSQ3I9
DMSQ3I9 DN Factor IX-XTEN
DMSQ3I9 HS Investigative
DMSQ3I9 SN FIX-XTEN; Coagulation factor IX modulator (XTEN, hemophilia), Amunix/Biogen
DMSQ3I9 CP Amunix Inc
DMSQ3I9 DE Hemophilia
DM1AYVU ID DM1AYVU
DM1AYVU DN Factor VIII-XTEN
DM1AYVU HS Investigative
DM1AYVU SN FVIII-XTEN; Factor VIII modulator (XTEN, hemophilia), Amunix/Biogen
DM1AYVU CP Amunix Inc
DM1AYVU DE Hemophilia
DMDWSH1 ID DMDWSH1
DMDWSH1 DN Factor-VIIa-XTEN
DMDWSH1 HS Investigative
DMDWSH1 SN FVIIa-XTEN; Factor VIIa modulator (XTEN, hemophilia), Amunix/Biogen
DMDWSH1 CP Amunix Inc
DMDWSH1 DE Hemophilia
DMJFKSU ID DMJFKSU
DMJFKSU DN FAICAR
DMJFKSU HS Investigative
DMJFKSU SN Faicar; phosphoribosyl formamidocarboxamide; 5-Formamidoimidazole-4-carboxamide ribotide; 13018-54-7; CHEBI:18381; 5-Formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide; 5'-Phosphoribosyl-5-formamido-4-imidazolecarboxamide; 5-Formamido-1-(5-phosphoribosyl)imidazole-4-carboxamide; 1-(5'-Phosphoribosyl)-5-formamido-4-imidazolecarboxamide; 5-(Formylamino)-1-(5-O-Phosphono-Beta-D-Ribofuranosyl)-1h-Imidazole-4-Carboxamide
DMJFKSU DT Small molecular drug
DMJFKSU PC 166760
DMJFKSU MW 366.22
DMJFKSU FM C10H15N4O9P
DMJFKSU IC InChI=1S/C10H15N4O9P/c11-8(18)5-9(13-3-15)14(2-12-5)10-7(17)6(16)4(23-10)1-22-24(19,20)21/h2-4,6-7,10,16-17H,1H2,(H2,11,18)(H,13,15)(H2,19,20,21)/t4-,6-,7-,10-/m1/s1
DMJFKSU CS C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O)NC=O)C(=O)N
DMJFKSU IK ABCOOORLYAOBOZ-KQYNXXCUSA-N
DMJFKSU IU [(2R,3S,4R,5R)-5-(4-carbamoyl-5-formamidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMJFKSU CA CAS 13018-54-7
DMJFKSU CB CHEBI:18381
DMJFKSU DE Discovery agent
DMLOV18 ID DMLOV18
DMLOV18 DN FALCARINDIOL
DMLOV18 HS Investigative
DMLOV18 SN Falcarindiol; 55297-87-5; 1,9-Heptadecadiene-4,6-diyne-3,8-diol; Heptadeca-1,9-diene-4,6-diyne-3,8-diol; AC1L1FO2; SCHEMBL16680213; CTK1C6414; 225110-25-8; AKOS030230026; AN-40378; 4CN-1774
DMLOV18 DT Small molecular drug
DMLOV18 PC 5281148
DMLOV18 MW 260.399
DMLOV18 FM C17H24O2
DMLOV18 IC InChI=1S/C17H24O2/c1-3-5-6-7-8-9-10-14-17(19)15-12-11-13-16(18)4-2/h4,10,14,16-19H,2-3,5-9H2,1H3/b14-10-/t16-,17+/m1/s1
DMLOV18 CS CCCCCCC/C=C\\[C@@H](C#CC#C[C@@H](C=C)O)O
DMLOV18 IK QWCNQXNAFCBLLV-YWALDVPYSA-N
DMLOV18 IU (3R,8S,9Z)-heptadeca-1,9-dien-4,6-diyne-3,8-diol
DMLOV18 DE Discovery agent
DMJYNMC ID DMJYNMC
DMJYNMC DN FAMOXADONE
DMJYNMC HS Investigative
DMJYNMC SN (S)-famoxadone; (-)-famoxadone; (S)-(-)-famoxadone; CHEBI:106738; (5S)-5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione; (5S)-3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dione; (S)-5-Methyl-5-(4-phenoxy-phenyl)-3-phenylamino-oxazolidine-2,4-dione; 5-METHYL-5-(4-PHENOXYPHENYL)-3-(PHENYLAMINO)-2,4-OXAZOLIDINEDIONE; FMX; AC1L9K5S; CHEMBL10118; SCHEMBL673443; PCCSBWNGDMYFCW-QFIPXVFZSA-N; ZINC6491064; DB07778; AJ-56253; UNII-V1C07OR6II component PCCSBWNGDMYFCW-QFIPXVFZSA-N
DMJYNMC DT Small molecular drug
DMJYNMC PC 213032
DMJYNMC MW 374.4
DMJYNMC FM C22H18N2O4
DMJYNMC IC InChI=1S/C22H18N2O4/c1-22(16-12-14-19(15-13-16)27-18-10-6-3-7-11-18)20(25)24(21(26)28-22)23-17-8-4-2-5-9-17/h2-15,23H,1H3
DMJYNMC CS CC1(C(=O)N(C(=O)O1)NC2=CC=CC=C2)C3=CC=C(C=C3)OC4=CC=CC=C4
DMJYNMC IK PCCSBWNGDMYFCW-UHFFFAOYSA-N
DMJYNMC IU 3-anilino-5-methyl-5-(4-phenoxyphenyl)-1,3-oxazolidine-2,4-dione
DMJYNMC CA CAS 131807-57-3
DMJYNMC CB CHEBI:83250
DMJYNMC DE Discovery agent
DM45K8W ID DM45K8W
DM45K8W DN FANA
DM45K8W HS Investigative
DM45K8W DT Small molecular drug
DM45K8W PC 56603768
DM45K8W MW 345.23
DM45K8W FM C11H14F3NO8
DM45K8W IC InChI=1S/C11H14F3NO8/c12-11(13,14)10(22)15-6-3(17)1-5(9(20)21)23-8(6)7(19)4(18)2-16/h1,3-4,6-8,16-19H,2H2,(H,15,22)(H,20,21)/t3-,4-,6+,7+,8?/m0/s1
DM45K8W CS C1=C(OC([C@@H]([C@H]1O)NC(=O)C(F)(F)F)[C@@H]([C@H](CO)O)O)C(=O)O
DM45K8W IK GEGPMWUYMRCINJ-DELVFIHMSA-N
DM45K8W IU (3R,4S)-4-hydroxy-3-[(2,2,2-trifluoroacetyl)amino]-2-[(1R,2S)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
DM45K8W DE Discovery agent
DMV2X1B ID DMV2X1B
DMV2X1B DN Farnesol
DMV2X1B HS Investigative
DMV2X1B SN farnesol; 4602-84-0; Farnesyl alcohol; 3,7,11-trimethyldodeca-2,6,10-trien-1-ol; Spectrum_001282; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, (2Z,6Z)-; ACMC-20aplp; ACMC-209ukw; SpecPlus_000549; AC1L1FOK; Spectrum3_001070; Spectrum2_001397; Spectrum4_001221; KBioSS_001762; KBioGR_001682; 2,6,10-Dodecatrien-1-ol, 3,7,11-trimethyl-, (2E,6Z)-; DivK1c_006645; SPBio_001414; GTPL3215; DTXSID3032389; KBio2_006898; KBio1_001589; KBio3_001880; KBio2_004330; CTK1B4647; CTK1D5922; KBio2_001762; CTK0H6624; CTK0E6577; MolPort-006-116-336
DMV2X1B DT Small molecular drug
DMV2X1B PC 445070
DMV2X1B MW 222.37
DMV2X1B FM C15H26O
DMV2X1B IC InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9+,15-11+
DMV2X1B CS CC(=CCC/C(=C/CC/C(=C/CO)/C)/C)C
DMV2X1B IK CRDAMVZIKSXKFV-YFVJMOTDSA-N
DMV2X1B IU (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol
DMV2X1B CA CAS 4602-84-0
DMV2X1B CB CHEBI:16619
DMV2X1B DE Discovery agent
DMXYWD7 ID DMXYWD7
DMXYWD7 DN FARNESYL
DMXYWD7 HS Investigative
DMXYWD7 SN FARNESYL; (6E,10E)-2,6,10-trimethyldodeca-2,6,10-triene; 2,6E,10E-Trimethyl-2,6,10-dodecatriene; CHEBI:36534; 2,6,10-trimethyldodeca-2,6,10-triene; 2,6,10-Farnesatriene; AC1L9FQ4; CHEBI:42362; LMFA11000034; (2E)-3,7,11-Trimethyl-2,6,10-dodecatriene; (6E)-3,7,11-Trimethyl-2,6,10-dodecatriene; (2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatriene; (6E,10E)-2,6,10-trimethyl-dodeca-2,6,10-triene
DMXYWD7 DT Small molecular drug
DMXYWD7 PC 444108
DMXYWD7 MW 206.37
DMXYWD7 FM C15H26
DMXYWD7 IC InChI=1S/C15H26/c1-6-14(4)10-8-12-15(5)11-7-9-13(2)3/h6,9,12H,7-8,10-11H2,1-5H3/b14-6+,15-12+
DMXYWD7 CS C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMXYWD7 IK JXBSHSBNOVLGHF-BUJBXKITSA-N
DMXYWD7 IU (6E,10E)-2,6,10-trimethyldodeca-2,6,10-triene
DMXYWD7 CB CHEBI:36534
DMXYWD7 DE Discovery agent
DMRMI0V ID DMRMI0V
DMRMI0V DN FAS-031
DMRMI0V HS Investigative
DMRMI0V SN FASi; FAS inhibitors (cancer); FAS-093; FAS-31; FAS-93; FAS inhibitors (cancer), FASgen/Johns Hopkins; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins; FAS inhibitors (cancer), FASgen/Johns Hopkins/Johnson & Johnson; Fatty acid synthase inhibitors (cancer), FASgen/Johns Hopkins/ Johnson & Johnson
DMRMI0V CP Johns Hopkins University
DMRMI0V DE Solid tumour/cancer
DMG5OZP ID DMG5OZP
DMG5OZP DN Fascaplysin
DMG5OZP HS Investigative
DMG5OZP SN Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6
DMG5OZP DT Small molecular drug
DMG5OZP PC 73292
DMG5OZP MW 306.7
DMG5OZP FM C18H11ClN2O
DMG5OZP IC InChI=1S/C18H10N2O.ClH/c21-18-13-6-2-4-8-15(13)20-10-9-12-11-5-1-3-7-14(11)19-16(12)17(18)20;/h1-10H;1H
DMG5OZP CS C1=CC=C2C(=C1)C3=C(N2)C4=[N+](C=C3)C5=CC=CC=C5C4=O.[Cl-]
DMG5OZP IK PWUOOJVYZQILBG-UHFFFAOYSA-N
DMG5OZP IU 3-aza-13-azoniapentacyclo[11.7.0.02,10.04,9.014,19]icosa-1(13),2(10),4,6,8,11,14,16,18-nonaen-20-one;chloride
DMG5OZP CA CAS 114719-57-2
DMG5OZP DE Discovery agent
DMC8G7X ID DMC8G7X
DMC8G7X DN fasidotrilat
DMC8G7X HS Investigative
DMC8G7X SN AC1O52DL; DTXSID20159221; (2R)-2-[[(2R)-2-(1,3-benzodioxol-5-ylmethyl)-3-sulfanylpropanoyl]amino]propanoic acid
DMC8G7X DT Small molecular drug
DMC8G7X PC 9818189
DMC8G7X MW 311.36
DMC8G7X FM C14H17NO5S
DMC8G7X IC InChI=1S/C14H17NO5S/c1-8(14(17)18)15-13(16)10(6-21)4-9-2-3-11-12(5-9)20-7-19-11/h2-3,5,8,10,21H,4,6-7H2,1H3,(H,15,16)(H,17,18)/t8-,10+/m0/s1
DMC8G7X CS C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC2=C(C=C1)OCO2)CS
DMC8G7X IK TXSINLUUGRGAJO-WCBMZHEXSA-N
DMC8G7X IU (2S)-2-[[(2S)-2-(1,3-benzodioxol-5-ylmethyl)-3-sulfanylpropanoyl]amino]propanoic acid
DMC8G7X CA CAS 135038-59-4
DMC8G7X DE Discovery agent
DMTCNOM ID DMTCNOM
DMTCNOM DN Fasudil
DMTCNOM HS Investigative
DMTCNOM SN 103745-39-7; HA1077; ha-1077; HA 1077; Fasudil [INN]; AT 877; Fasudilum [INN-Latin]; 1-(5-Isoquinolinesulfonyl)homopiperazine; 1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-; UNII-Q0CH43PGXS; 5-(1,4-diazepane-1-sulfonyl)isoquinoline; 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline; (5-ISOQUINOLINESULFONYL)HOMOPIPERAZINE; AT-877; AT877; Q0CH43PGXS; 5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE; CHEMBL38380; Hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine; Fasudil (INN); Fasudilhydrochloride
DMTCNOM DT Small molecular drug
DMTCNOM PC 3547
DMTCNOM MW 291.37
DMTCNOM FM C14H17N3O2S
DMTCNOM IC InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2
DMTCNOM CS C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3
DMTCNOM IK NGOGFTYYXHNFQH-UHFFFAOYSA-N
DMTCNOM IU 5-(1,4-diazepan-1-ylsulfonyl)isoquinoline
DMTCNOM CA CAS 103745-39-7
DMTCNOM DE Discovery agent
DMC6J3B ID DMC6J3B
DMC6J3B DN FAUC 113
DMC6J3B HS Investigative
DMC6J3B SN fauc-113; CHEMBL7927; FAUC 113; 221470-50-4; SCHEMBL1058707; CTK0I8746; DTXSID50439407; ZINC13438692; BDBM50073805; KB-272556; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)H-pyrazolo[1,5-a]pyridine; 3-[4-(4-Chloro-phenyl)-piperazin-1-ylmethyl]-pyrazolo[1,5-a]pyridine; 4-(4-Chloro-phenyl)-1-pyrazolo[1,5-a]pyridin-3-ylmethyl-piperazin-1-ium; Pyrazolo[1,5-a]pyridine, 3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-
DMC6J3B DT Small molecular drug
DMC6J3B PC 10404144
DMC6J3B MW 326.8
DMC6J3B FM C18H19ClN4
DMC6J3B IC InChI=1S/C18H19ClN4/c19-16-4-6-17(7-5-16)22-11-9-21(10-12-22)14-15-13-20-23-8-2-1-3-18(15)23/h1-8,13H,9-12,14H2
DMC6J3B CS C1CN(CCN1CC2=C3C=CC=CN3N=C2)C4=CC=C(C=C4)Cl
DMC6J3B IK XVPRVMIFXXOEFR-UHFFFAOYSA-N
DMC6J3B IU 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine
DMC6J3B CA CAS 221470-50-4
DMC6J3B DE Discovery agent
DM1LMFG ID DM1LMFG
DM1LMFG DN FAUC213
DM1LMFG HS Investigative
DM1LMFG SN FAUC 213; 337972-47-1; FAUC-213; UNII-G8F040299R; CHEMBL310843; G8F040299R; 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine; GTPL974; CTK8E8281; DTXSID40187460; HMS3263F09; Tox21_501144; BDBM50102712; ZINC52541476; MFCD06798338; Pyrazolo(1,5-a)pyridine, 2-((4-(4-chlorophenyl)-1-piperazinyl)methyl)-; CCG-222448; LP01144; API0002679; NCGC00261829-01; NCGC00165795-01; NCGC00165795-02; RT-012699; FAUC 213, > J-019326; 2-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-pyrazolo[1,5-a]pyridine
DM1LMFG DT Small molecular drug
DM1LMFG PC 10336538
DM1LMFG MW 326.8
DM1LMFG FM C18H19ClN4
DM1LMFG IC InChI=1S/C18H19ClN4/c19-15-4-6-17(7-5-15)22-11-9-21(10-12-22)14-16-13-18-3-1-2-8-23(18)20-16/h1-8,13H,9-12,14H2
DM1LMFG CS C1CN(CCN1CC2=NN3C=CC=CC3=C2)C4=CC=C(C=C4)Cl
DM1LMFG IK DTRXURJDKOYCCD-UHFFFAOYSA-N
DM1LMFG IU 2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine
DM1LMFG CA CAS 337972-47-1
DM1LMFG DE Discovery agent
DM7IEL2 ID DM7IEL2
DM7IEL2 DN FD-1
DM7IEL2 HS Investigative
DM7IEL2 SN GTPL1182
DM7IEL2 DT Small molecular drug
DM7IEL2 PC 10279142
DM7IEL2 MW 509.6
DM7IEL2 FM C28H35N3O6
DM7IEL2 IC InChI=1S/C28H35N3O6/c1-15-12-18-17(27(3,4)14-16(2)28(18,5)6)13-20(15)37-21-11-10-19(36-21)23(32)29-22-24(33-7)30-26(35-9)31-25(22)34-8/h10-13,16H,14H2,1-9H3,(H,29,32)
DM7IEL2 CS CC1CC(C2=C(C1(C)C)C=C(C(=C2)OC3=CC=C(O3)C(=O)NC4=C(N=C(N=C4OC)OC)OC)C)(C)C
DM7IEL2 IK JTFNDUMPCFHPFC-UHFFFAOYSA-N
DM7IEL2 IU 5-[(3,5,5,6,8,8-hexamethyl-6,7-dihydronaphthalen-2-yl)oxy]-N-(2,4,6-trimethoxypyrimidin-5-yl)furan-2-carboxamide
DM7IEL2 DE Discovery agent
DMYXA7E ID DMYXA7E
DMYXA7E DN FdG
DMYXA7E HS Investigative
DMYXA7E DE Discovery agent
DMKVA6Z ID DMKVA6Z
DMKVA6Z DN FE 999011
DMKVA6Z HS Investigative
DMKVA6Z SN Tle-Pro-CN; UNII-I17T1J33X6; CHEMBL363250; I17T1J33X6; FE-999011; 171092-64-1; SCHEMBL369343; fe999011; BDBM50151003; ZINC53122800; 2-Pyrrolidinecarbonitrile, 1-(2-amino-3,3-dimethyl-1-oxobutyl)-, (S-(R*,R*))-; 2-Pyrrolidinecarbonitrile, 1-((2S)-2-amino-3,3-dimethyl-1-oxobutyl)-, (2S)-
DMKVA6Z DT Small molecular drug
DMKVA6Z PC 10130510
DMKVA6Z MW 209.29
DMKVA6Z FM C11H19N3O
DMKVA6Z IC InChI=1S/C11H19N3O/c1-11(2,3)9(13)10(15)14-6-4-5-8(14)7-12/h8-9H,4-6,13H2,1-3H3/t8-,9+/m0/s1
DMKVA6Z CS CC(C)(C)[C@@H](C(=O)N1CCC[C@H]1C#N)N
DMKVA6Z IK XGNBIYXILDDDQR-DTWKUNHWSA-N
DMKVA6Z IU (2S)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]pyrrolidine-2-carbonitrile
DMKVA6Z CA CAS 171092-64-1
DMKVA6Z DE Discovery agent
DMBX81R ID DMBX81R
DMBX81R DN FE-203799
DMBX81R HS Investigative
DMBX81R SN GLP-2 analog (gastrointestinal disease), Ferring; Glucagon-like peptide 2 analog (gastrointestinal disease), Ferring
DMBX81R CP Ferring Pharmaceuticals Inc
DMBX81R DE Gastrointestinal disease
DM3UCWM ID DM3UCWM
DM3UCWM DN FE-999040
DM3UCWM HS Investigative
DM3UCWM SN FAP inhibitors, Vantia; Fibroblast activation protein inhibitors (sc/oral, cancer/pulmonary fibrosis/IBD), Vantia
DM3UCWM CP Vantia Therapeutics
DM3UCWM DE Solid tumour/cancer
DMN1579 ID DMN1579
DMN1579 DN Fedratinib
DMN1579 HS Investigative
DMN1579 SN Tg-101348; TG101348; TG 101348; SAR302503; UNII-6L1XP550I6; SAR-302503; Fedratinib (SAR302503, TG101348); TG101348 (SAR302503); SAR 302503; CHEMBL1287853; C27H36N6O3S; 6L1XP550I6
DMN1579 TC Antiviral Agents
DMN1579 DT Small molecular drug
DMN1579 PC 16722836
DMN1579 MW 524.7
DMN1579 FM C27H36N6O3S
DMN1579 IC InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
DMN1579 CS CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
DMN1579 IK JOOXLOJCABQBSG-UHFFFAOYSA-N
DMN1579 IU N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
DMN1579 CA CAS 936091-26-8
DMN1579 CB CHEBI:91408
DMN1579 DE Coronavirus Disease 2019 (COVID-19)
DMUBO3E ID DMUBO3E
DMUBO3E DN fenclonine
DMUBO3E HS Investigative
DMUBO3E SN 4-chlorophenylalanine; para-chlorophenylalanine; PCPA
DMUBO3E DT Small molecular drug
DMUBO3E PC 4652
DMUBO3E MW 199.63
DMUBO3E FM C9H10ClNO2
DMUBO3E IC InChI=1S/C9H10ClNO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)
DMUBO3E CS C1=CC(=CC=C1CC(C(=O)O)N)Cl
DMUBO3E IK NIGWMJHCCYYCSF-UHFFFAOYSA-N
DMUBO3E IU 2-amino-3-(4-chlorophenyl)propanoic acid
DMUBO3E CA CAS 7424-00-2
DMUBO3E CB CHEBI:110187
DMUBO3E DE Discovery agent
DM34V5W ID DM34V5W
DM34V5W DN Fenethylline
DM34V5W HS Investigative
DM34V5W SN Amfetyline; Amphetaminoethyltheophylline; Captagon; Ethylteophylline amphetamine; FENETHYLLINE; Fenetilina; Fenetilina [INN-Spanish]; Fenetillina; Fenetillina [DCIT]; Fenetylinum; Fenetyllin; Fenetylline; Fenetylline (INN); Fenetylline [INN:BAN]; Fenetyllinum; Fenetyllinum [INN-Latin]; Humburg 814; Phenethylline; Theophyllineethylamphetamine; 7-(2-((alpha-Methylphenethyl)amino)ethyl)theophylline; BRN 1169517; C18H23N5O2; D323; DEA No. 1503; NCGC00247730-01; Theophylline, 7-(2-((alpha-methylphenethyl)amino)ethyl)-
DM34V5W PC 19527
DM34V5W MW 341.4
DM34V5W FM C18H23N5O2
DM34V5W IC NMCHYWGKBADVMK-UHFFFAOYSA-N
DM34V5W CS CC(CC1=CC=CC=C1)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C
DM34V5W IK 1S/C18H23N5O2/c1-13(11-14-7-5-4-6-8-14)19-9-10-23-12-20-16-15(23)17(24)22(3)18(25)21(16)2/h4-8,12-13,19H,9-11H2,1-3H3
DM34V5W IU 1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione
DM34V5W CA CAS 3736-08-1
DM34V5W CB CHEBI:135451
DM34V5W DE Narcolepsy
DMKEG49 ID DMKEG49
DMKEG49 DN Fenthion
DMKEG49 HS Investigative
DMKEG49 SN Baytex; ENT 25,540; Fenthion 4E; Fenthion [BAN]; Fenthion [BSI:ISO]; Fenthion-methyl; Fenthione; Figuron; Lebaycid; Lebayeid; MPP (pesticide); Mercaptophos; Mosquitocide 700; Phenthion; Pro-Spot; Queletox; S 1752; Spotton; Sulfidophos; Talodex; Tiguvon; fenthion; 4-Methylmercapto-3-methylphenyl dimethyl thiophosphate; 55-38-9; B 29493; BAY 29493; Bay-Bassa; Baycid; Bayer 29493; Bayer 9007; Bayer S-1752; BL0L45OVKT; C10H15O3PS2; CCRIS 310; Caswell No. 456F; EINECS 200-231-9; Entex; HSDB 1403; NCI-C08651; OMS 2; UNII-BL0L45OVKT
DMKEG49 PC 3346
DMKEG49 MW 278.3
DMKEG49 FM C10H15O3PS2
DMKEG49 IC PNVJTZOFSHSLTO-UHFFFAOYSA-N
DMKEG49 CS CC1=C(C=CC(=C1)OP(=S)(OC)OC)SC
DMKEG49 IK 1S/C10H15O3PS2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7H,1-4H3
DMKEG49 IU dimethoxy-(3-methyl-4-methylsulfanylphenoxy)-sulfanylidene-lambda5-phosphane
DMKEG49 CA CAS 55-38-9
DMKEG49 CB CHEBI:34761
DMKEG49 DE Discovery agent
DM4OLRS ID DM4OLRS
DM4OLRS DN Fenthion sulfoxide
DM4OLRS HS Investigative
DM4OLRS SN FENTHION SULFOXIDE; FENTHION-SULFOXIDE; Fensulfoxide; Fenthionsulfoxide; Mesulfenfos; Mesulfenfos [ISO]; Mesulfenfos, (+)-; Mesulfenfos, (R)-; Mesulfenfos, (S)-; Mesulfenos; TM8HKU4HKN; 3761-41-9; BRN 2136026; O,O-Dimethyl O-((4-methylthio)-m-tolyl)phosphorothioate sulfoxide; O,O-Dimethyl O-(4-(methylsulfinyl)-m-tolyl) phosphorothioate; Phosphorothioic acid, O,O-dimethyl O-(3-methyl-4-(methylsulfinyl)phenyl) ester; Phosphorothioic acid, O,O-dimethyl O-(4-(methylsulfinyl)-m-tolyl) ester; UNII-J04Q566L5K; UNII-TM8HKU4HKN
DM4OLRS PC 19577
DM4OLRS MW 294.3
DM4OLRS FM C10H15O4PS2
DM4OLRS IC DLAPIMGBBDILHJ-UHFFFAOYSA-N
DM4OLRS CS CC1=C(C=CC(=C1)OP(=S)(OC)OC)S(=O)C
DM4OLRS IK 1S/C10H15O4PS2/c1-8-7-9(5-6-10(8)17(4)11)14-15(16,12-2)13-3/h5-7H,1-4H3
DM4OLRS IU dimethoxy-(3-methyl-4-methylsulfinylphenoxy)-sulfanylidene-lambda5-phosphane
DM4OLRS CA CAS 3761-41-9
DM4OLRS DE Discovery agent
DM1TH08 ID DM1TH08
DM1TH08 DN Ferricyanide
DM1TH08 HS Investigative
DM1TH08 SN Ferric hexacyanide; Ferricyanide; Hexacyanoferrate(III); Hexazyanoferrat(III); hexacyanidoferrate(3-); hexacyanidoferrate(III); hexacyanoferrate III; hexacyanoferrate(3-); hexacyanoiron(3-); 13408-62-3; CHEBI:5020; CRWNKXHVYMVLCY-UHFFFAOYSA-N; [Fe(CN)6](3-)
DM1TH08 PC 439210
DM1TH08 MW 211.95
DM1TH08 FM C6FeN6-3
DM1TH08 IC YAGKRVSRTSUGEY-UHFFFAOYSA-N
DM1TH08 CS [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+3]
DM1TH08 IK 1S/6CN.Fe/c6*1-2;/q6*-1;+3
DM1TH08 IU iron(3+);hexacyanide
DM1TH08 CA CAS 13408-62-3
DM1TH08 CB CHEBI:5020
DM1TH08 DE Discovery agent
DMO1N2T ID DMO1N2T
DMO1N2T DN FETAV
DMO1N2T HS Investigative
DMO1N2T SN FETAV; CHEMBL492642
DMO1N2T DT Small molecular drug
DMO1N2T PC 44568793
DMO1N2T MW 565.6
DMO1N2T FM C26H39N5O9
DMO1N2T IC InChI=1S/C26H39N5O9/c1-13(2)20(26(39)40)30-22(35)14(3)28-25(38)21(15(4)32)31-24(37)18(10-11-19(33)34)29-23(36)17(27)12-16-8-6-5-7-9-16/h5-9,13-15,17-18,20-21,32H,10-12,27H2,1-4H3,(H,28,38)(H,29,36)(H,30,35)(H,31,37)(H,33,34)(H,39,40)/t14-,15?,17-,18-,20-,21-/m0/s1
DMO1N2T CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N
DMO1N2T IK ILLATSRMKXLBOS-HWJJFRRQSA-N
DMO1N2T IU (4S)-4-[[(2S)-2-amino-3-phenylpropanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMO1N2T DE Discovery agent
DMWCLQ5 ID DMWCLQ5
DMWCLQ5 DN Fexaramine
DMWCLQ5 HS Investigative
DMWCLQ5 SN 574013-66-4; CHEMBL192966; CHEBI:80003; FEX; (E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate; C32H36N2O3; AC1NS0YI; A1-01872; GTPL2744; Fexaramine, > SCHEMBL17083218; AOB5017; MolPort-023-276-486; EX-A2246; BCP15784; ZINC13831232; 3671AH; BDBM50167161; AKOS024457169; DB02545; CS-3884; NCGC00167776-01; HY-10912; AS-35318; AK175872; BC600742; KB-69557; RT-012704; B7108; C15649; BRD-K34170797-001-01-1
DMWCLQ5 DT Small molecular drug
DMWCLQ5 PC 5326713
DMWCLQ5 MW 496.6
DMWCLQ5 FM C32H36N2O3
DMWCLQ5 IC InChI=1S/C32H36N2O3/c1-33(2)29-19-17-27(18-20-29)26-15-12-25(13-16-26)23-34(32(36)28-9-5-4-6-10-28)30-11-7-8-24(22-30)14-21-31(35)37-3/h7-8,11-22,28H,4-6,9-10,23H2,1-3H3/b21-14+
DMWCLQ5 CS CN(C)C1=CC=C(C=C1)C2=CC=C(C=C2)CN(C3=CC=CC(=C3)/C=C/C(=O)OC)C(=O)C4CCCCC4
DMWCLQ5 IK VLQTUNDJHLEFEQ-KGENOOAVSA-N
DMWCLQ5 IU methyl (E)-3-[3-[cyclohexanecarbonyl-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]amino]phenyl]prop-2-enoate
DMWCLQ5 CA CAS 574013-66-4
DMWCLQ5 CB CHEBI:80003
DMWCLQ5 DE Discovery agent
DM1NL3Z ID DM1NL3Z
DM1NL3Z DN FG-5893
DM1NL3Z HS Investigative
DM1NL3Z SN FG5893; FG 5893
DM1NL3Z DT Small molecular drug
DM1NL3Z PC 127728
DM1NL3Z MW 465.5
DM1NL3Z FM C27H29F2N3O2
DM1NL3Z IC InChI=1S/C27H29F2N3O2/c1-34-27(33)25-4-2-14-30-26(25)32-18-16-31(17-19-32)15-3-5-24(20-6-10-22(28)11-7-20)21-8-12-23(29)13-9-21/h2,4,6-14,24H,3,5,15-19H2,1H3
DM1NL3Z CS COC(=O)C1=C(N=CC=C1)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM1NL3Z IK NDCPNKXUTJGQQC-UHFFFAOYSA-N
DM1NL3Z IU methyl 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]pyridine-3-carboxylate
DM1NL3Z CA CAS 150527-23-4
DM1NL3Z DE Discovery agent
DML9IGY ID DML9IGY
DML9IGY DN FGGFTCARKCARK
DML9IGY HS Investigative
DML9IGY SN CHEMBL442113
DML9IGY PC 10986104
DML9IGY MW 1443.7
DML9IGY FM C62H102N22O14S2
DML9IGY IC InChI=1S/C62H102N22O14S2/c1-34(51(89)79-42(22-14-26-71-61(67)68)54(92)78-40(50(66)88)20-10-12-24-63)75-58(96)45(32-99)82-56(94)41(21-11-13-25-64)81-55(93)43(23-15-27-72-62(69)70)80-52(90)35(2)76-59(97)46(33-100)83-60(98)49(36(3)85)84-57(95)44(29-38-18-8-5-9-19-38)77-48(87)31-73-47(86)30-74-53(91)39(65)28-37-16-6-4-7-17-37/h4-9,16-19,34-36,39-46,49,85,99-100H,10-15,20-33,63-65H2,1-3H3,(H2,66,88)(H,73,86)(H,74,91)(H,75,96)(H,76,97)(H,77,87)(H,78,92)(H,79,89)(H,80,90)(H,81,93)(H,82,94)(H,83,98)(H,84,95)(H4,67,68,71)(H4,69,70,72)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,45-,46-,49-/m0/s1
DML9IGY CS C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DML9IGY IK APYUYQWYKXKSOW-JOEKKRFNSA-N
DML9IGY IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide
DML9IGY DE Discovery agent
DMMV061 ID DMMV061
DMMV061 DN F-G-G-F-T-G-Aib-R-K-S-Aib-R-K-L-A-N-Q-CONH2
DMMV061 HS Investigative
DMMV061 PC 91932083
DMMV061 MW 1836.1
DMMV061 FM C81H134N28O21
DMMV061 IC InChI=1S/C81H134N28O21/c1-7-49(98-64(116)41-96-79(130)65(45(6)111)109-77(128)57(37-47-23-13-10-14-24-47)99-63(115)40-94-62(114)39-95-68(119)48(84)36-46-21-11-9-12-22-46)69(120)102-54(27-19-33-92-80(88)89)71(122)105-53(26-16-18-32-83)74(125)108-59(42-110)78(129)100-50(8-2)70(121)103-55(28-20-34-93-81(90)91)72(123)104-52(25-15-17-31-82)73(124)107-56(35-43(3)4)75(126)97-44(5)67(118)106-58(38-61(86)113)76(127)101-51(66(87)117)29-30-60(85)112/h9-14,21-24,43-45,48-59,65,110-111H,7-8,15-20,25-42,82-84H2,1-6H3,(H2,85,112)(H2,86,113)(H2,87,117)(H,94,114)(H,95,119)(H,96,130)(H,97,126)(H,98,116)(H,99,115)(H,100,129)(H,101,127)(H,102,120)(H,103,121)(H,104,123)(H,105,122)(H,106,118)(H,107,124)(H,108,125)(H,109,128)(H4,88,89,92)(H4,90,91,93)/t44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMMV061 CS CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMMV061 IK JDXIHEXWMPKRIL-METNDEIASA-N
DMMV061 IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMMV061 DE Discovery agent
DMN7501 ID DMN7501
DMN7501 DN F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-CONH2
DMN7501 HS Investigative
DMN7501 PC 91932085
DMN7501 MW 1822.1
DMN7501 FM C80H132N28O21
DMN7501 IC InChI=1S/C80H132N28O21/c1-7-49(98-63(115)40-95-78(129)64(45(6)110)108-76(127)56(36-47-22-12-9-13-23-47)99-62(114)39-93-61(113)38-94-68(119)48(83)35-46-20-10-8-11-21-46)69(120)102-54(27-19-33-92-80(89)90)71(122)104-52(25-15-17-31-82)73(124)107-58(41-109)77(128)97-43(4)66(117)101-53(26-18-32-91-79(87)88)70(121)103-51(24-14-16-30-81)72(123)106-55(34-42(2)3)74(125)96-44(5)67(118)105-57(37-60(85)112)75(126)100-50(65(86)116)28-29-59(84)111/h8-13,20-23,42-45,48-58,64,109-110H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,119)(H,95,129)(H,96,125)(H,97,128)(H,98,115)(H,99,114)(H,100,126)(H,101,117)(H,102,120)(H,103,121)(H,104,122)(H,105,118)(H,106,123)(H,107,124)(H,108,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMN7501 CS CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMN7501 IK UWYRKSVDCJMXNB-KMOVSZGYSA-N
DMN7501 IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMN7501 DE Discovery agent
DMU3IJL ID DMU3IJL
DMU3IJL DN F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH
DMU3IJL HS Investigative
DMU3IJL PC 91932082
DMU3IJL MW 1823.1
DMU3IJL FM C80H131N27O22
DMU3IJL IC InChI=1S/C80H131N27O22/c1-7-49(97-63(114)40-94-77(127)64(45(6)109)107-75(125)56(36-47-22-12-9-13-23-47)98-62(113)39-92-61(112)38-93-67(117)48(83)35-46-20-10-8-11-21-46)68(118)100-53(27-19-33-91-80(88)89)70(120)102-51(25-15-17-31-82)72(122)106-58(41-108)76(126)96-43(4)65(115)99-52(26-18-32-90-79(86)87)69(119)101-50(24-14-16-30-81)71(121)105-55(34-42(2)3)73(123)95-44(5)66(116)104-57(37-60(85)111)74(124)103-54(78(128)129)28-29-59(84)110/h8-13,20-23,42-45,48-58,64,108-109H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,117)(H,94,127)(H,95,123)(H,96,126)(H,97,114)(H,98,113)(H,99,115)(H,100,118)(H,101,119)(H,102,120)(H,103,124)(H,104,116)(H,105,121)(H,106,122)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMU3IJL CS CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMU3IJL IK XQBWITORWNZMQG-KMOVSZGYSA-N
DMU3IJL IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMU3IJL DE Discovery agent
DMTEO35 ID DMTEO35
DMTEO35 DN FGGFTGARKCARKC
DMTEO35 HS Investigative
DMTEO35 DE Discovery agent
DMIFKPE ID DMIFKPE
DMIFKPE DN FGGFTGARKRKRKLANQ
DMIFKPE HS Investigative
DMIFKPE PC 91934902
DMIFKPE MW 1935.2
DMIFKPE FM C85H143N31O21
DMIFKPE IC InChI=1S/C85H143N31O21/c1-46(2)39-60(78(132)105-48(4)70(124)114-62(42-64(91)119)79(133)113-59(82(136)137)31-32-63(90)118)115-77(131)55(27-14-17-35-88)110-76(130)58(30-20-38-100-85(96)97)112-73(127)54(26-13-16-34-87)109-75(129)57(29-19-37-99-84(94)95)111-72(126)53(25-12-15-33-86)108-74(128)56(28-18-36-98-83(92)93)107-69(123)47(3)104-66(121)45-103-81(135)68(49(5)117)116-80(134)61(41-51-23-10-7-11-24-51)106-67(122)44-101-65(120)43-102-71(125)52(89)40-50-21-8-6-9-22-50/h6-11,21-24,46-49,52-62,68,117H,12-20,25-45,86-89H2,1-5H3,(H2,90,118)(H2,91,119)(H,101,120)(H,102,125)(H,103,135)(H,104,121)(H,105,132)(H,106,122)(H,107,123)(H,108,128)(H,109,129)(H,110,130)(H,111,126)(H,112,127)(H,113,133)(H,114,124)(H,115,131)(H,116,134)(H,136,137)(H4,92,93,98)(H4,94,95,99)(H4,96,97,100)/t47-,48-,49+,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,68-/m0/s1
DMIFKPE CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMIFKPE IK OPYGIVVZZPRQCO-BANXXPNRSA-N
DMIFKPE IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMIFKPE DE Discovery agent
DM9H80P ID DM9H80P
DM9H80P DN F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-CONH2
DM9H80P HS Investigative
DM9H80P PC 91932091
DM9H80P MW 1822.1
DM9H80P FM C80H132N28O21
DM9H80P IC InChI=1S/C80H132N28O21/c1-7-49(69(120)102-54(27-19-33-92-80(89)90)71(122)103-51(24-14-16-30-81)72(123)106-55(34-42(2)3)74(125)97-44(5)67(118)105-57(37-60(85)112)75(126)100-50(65(86)116)28-29-59(84)111)99-77(128)58(41-109)107-73(124)52(25-15-17-31-82)104-70(121)53(26-18-32-91-79(87)88)101-66(117)43(4)96-62(114)40-95-78(129)64(45(6)110)108-76(127)56(36-47-22-12-9-13-23-47)98-63(115)39-93-61(113)38-94-68(119)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,109-110H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,119)(H,95,129)(H,96,114)(H,97,125)(H,98,115)(H,99,128)(H,100,126)(H,101,117)(H,102,120)(H,103,122)(H,104,121)(H,105,118)(H,106,123)(H,107,124)(H,108,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DM9H80P CS CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DM9H80P IK BMXJNWVYNYOAHC-KMOVSZGYSA-N
DM9H80P IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DM9H80P DE Discovery agent
DMPRZ8N ID DMPRZ8N
DMPRZ8N DN F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH
DMPRZ8N HS Investigative
DMPRZ8N PC 91932088
DMPRZ8N MW 1823.1
DMPRZ8N FM C80H131N27O22
DMPRZ8N IC InChI=1S/C80H131N27O22/c1-7-49(68(118)100-53(27-19-33-91-80(88)89)70(120)101-50(24-14-16-30-81)71(121)105-55(34-42(2)3)73(123)96-44(5)66(116)104-57(37-60(85)111)74(124)103-54(78(128)129)28-29-59(84)110)98-76(126)58(41-108)106-72(122)51(25-15-17-31-82)102-69(119)52(26-18-32-90-79(86)87)99-65(115)43(4)95-62(113)40-94-77(127)64(45(6)109)107-75(125)56(36-47-22-12-9-13-23-47)97-63(114)39-92-61(112)38-93-67(117)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,108-109H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,117)(H,94,127)(H,95,113)(H,96,123)(H,97,114)(H,98,126)(H,99,115)(H,100,118)(H,101,120)(H,102,119)(H,103,124)(H,104,116)(H,105,121)(H,106,122)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMPRZ8N CS CC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMPRZ8N IK FBSIFFHLVXSJIC-KMOVSZGYSA-N
DMPRZ8N IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMPRZ8N DE Discovery agent
DM5W1VF ID DM5W1VF
DM5W1VF DN FGGFTGARKSARKAANQ
DM5W1VF HS Investigative
DM5W1VF PC 91934910
DM5W1VF MW 1767
DM5W1VF FM C76H123N27O22
DM5W1VF IC InChI=1S/C76H123N27O22/c1-39(91-58(109)37-90-73(123)60(43(5)105)103-71(121)52(33-45-20-10-7-11-21-45)95-59(110)36-88-57(108)35-89-65(115)46(79)32-44-18-8-6-9-19-44)62(112)96-49(24-16-30-86-75(82)83)68(118)99-48(23-13-15-29-78)69(119)102-54(38-104)72(122)94-42(4)63(113)97-50(25-17-31-87-76(84)85)67(117)98-47(22-12-14-28-77)66(116)93-40(2)61(111)92-41(3)64(114)101-53(34-56(81)107)70(120)100-51(74(124)125)26-27-55(80)106/h6-11,18-21,39-43,46-54,60,104-105H,12-17,22-38,77-79H2,1-5H3,(H2,80,106)(H2,81,107)(H,88,108)(H,89,115)(H,90,123)(H,91,109)(H,92,111)(H,93,116)(H,94,122)(H,95,110)(H,96,112)(H,97,113)(H,98,117)(H,99,118)(H,100,120)(H,101,114)(H,102,119)(H,103,121)(H,124,125)(H4,82,83,86)(H4,84,85,87)/t39-,40-,41-,42-,43+,46-,47-,48-,49-,50-,51-,52-,53-,54-,60-/m0/s1
DM5W1VF CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM5W1VF IK FMVUBOOWCUPBBL-OVWUADNCSA-N
DM5W1VF IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM5W1VF DE Discovery agent
DMYJTZ7 ID DMYJTZ7
DMYJTZ7 DN FGGFTGARKSARKFANQ
DMYJTZ7 HS Investigative
DMYJTZ7 PC 91934912
DMYJTZ7 MW 1843.1
DMYJTZ7 FM C82H127N27O22
DMYJTZ7 IC InChI=1S/C82H127N27O22/c1-44(97-64(115)42-96-79(129)66(47(4)111)109-77(127)57(37-49-22-10-6-11-23-49)100-65(116)41-94-63(114)40-95-70(120)51(85)36-48-20-8-5-9-21-48)67(117)101-54(28-18-34-92-81(88)89)71(121)104-53(27-15-17-33-84)74(124)108-60(43-110)78(128)99-45(2)68(118)102-55(29-19-35-93-82(90)91)72(122)103-52(26-14-16-32-83)73(123)107-58(38-50-24-12-7-13-25-50)75(125)98-46(3)69(119)106-59(39-62(87)113)76(126)105-56(80(130)131)30-31-61(86)112/h5-13,20-25,44-47,51-60,66,110-111H,14-19,26-43,83-85H2,1-4H3,(H2,86,112)(H2,87,113)(H,94,114)(H,95,120)(H,96,129)(H,97,115)(H,98,125)(H,99,128)(H,100,116)(H,101,117)(H,102,118)(H,103,122)(H,104,121)(H,105,126)(H,106,119)(H,107,123)(H,108,124)(H,109,127)(H,130,131)(H4,88,89,92)(H4,90,91,93)/t44-,45-,46-,47+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMYJTZ7 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMYJTZ7 IK XBCTWRVAMOVPCA-UUKLZGIWSA-N
DMYJTZ7 IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMYJTZ7 DE Discovery agent
DMHG2TB ID DMHG2TB
DMHG2TB DN FGGFTGARKSARKKANQ
DMHG2TB HS Investigative
DMHG2TB PC 91934909
DMHG2TB MW 1824.1
DMHG2TB FM C79H130N28O22
DMHG2TB IC InChI=1S/C79H130N28O22/c1-42(95-61(113)40-94-76(127)63(45(4)109)107-74(125)55(36-47-21-9-6-10-22-47)98-62(114)39-92-60(112)38-93-67(118)48(83)35-46-19-7-5-8-20-46)64(115)99-52(26-17-33-90-78(86)87)70(121)103-51(25-13-16-32-82)72(123)106-57(41-108)75(126)97-43(2)65(116)100-53(27-18-34-91-79(88)89)71(122)102-50(24-12-15-31-81)69(120)101-49(23-11-14-30-80)68(119)96-44(3)66(117)105-56(37-59(85)111)73(124)104-54(77(128)129)28-29-58(84)110/h5-10,19-22,42-45,48-57,63,108-109H,11-18,23-41,80-83H2,1-4H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,127)(H,95,113)(H,96,119)(H,97,126)(H,98,114)(H,99,115)(H,100,116)(H,101,120)(H,102,122)(H,103,121)(H,104,124)(H,105,117)(H,106,123)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
DMHG2TB CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMHG2TB IK OYXJMSJHGINGKM-SMFNREODSA-N
DMHG2TB IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMHG2TB DE Discovery agent
DMY347Q ID DMY347Q
DMY347Q DN FGGFTGARKSARKKKNQ
DMY347Q HS Investigative
DMY347Q PC 91934907
DMY347Q MW 1881.1
DMY347Q FM C82H137N29O22
DMY347Q IC InChI=1S/C82H137N29O22/c1-45(99-64(117)43-98-79(131)66(47(3)113)111-77(129)58(39-49-22-8-5-9-23-49)101-65(118)42-96-63(116)41-97-69(121)50(87)38-48-20-6-4-7-21-48)67(119)102-55(28-18-36-94-81(90)91)72(124)107-54(27-13-17-35-86)75(127)110-60(44-112)78(130)100-46(2)68(120)103-56(29-19-37-95-82(92)93)73(125)105-52(25-11-15-33-84)70(122)104-51(24-10-14-32-83)71(123)106-53(26-12-16-34-85)74(126)109-59(40-62(89)115)76(128)108-57(80(132)133)30-31-61(88)114/h4-9,20-23,45-47,50-60,66,112-113H,10-19,24-44,83-87H2,1-3H3,(H2,88,114)(H2,89,115)(H,96,116)(H,97,121)(H,98,131)(H,99,117)(H,100,130)(H,101,118)(H,102,119)(H,103,120)(H,104,122)(H,105,125)(H,106,123)(H,107,124)(H,108,128)(H,109,126)(H,110,127)(H,111,129)(H,132,133)(H4,90,91,94)(H4,92,93,95)/t45-,46-,47+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMY347Q CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMY347Q IK UDQRAMWZBFAZAV-WBMOPDPASA-N
DMY347Q IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMY347Q DE Discovery agent
DMPG8NC ID DMPG8NC
DMPG8NC DN FGGFTGARKSARKKRNQ
DMPG8NC HS Investigative
DMPG8NC PC 91934905
DMPG8NC MW 1909.2
DMPG8NC FM C82H137N31O22
DMPG8NC IC InChI=1S/C82H137N31O22/c1-44(101-63(119)42-100-78(133)65(46(3)115)113-76(131)57(38-48-21-8-5-9-22-48)103-64(120)41-98-62(118)40-99-68(123)49(86)37-47-19-6-4-7-20-47)66(121)104-53(26-16-34-95-80(89)90)71(126)108-52(25-12-15-33-85)74(129)112-59(43-114)77(132)102-45(2)67(122)105-54(27-17-35-96-81(91)92)72(127)107-50(23-10-13-31-83)69(124)106-51(24-11-14-32-84)70(125)109-55(28-18-36-97-82(93)94)73(128)111-58(39-61(88)117)75(130)110-56(79(134)135)29-30-60(87)116/h4-9,19-22,44-46,49-59,65,114-115H,10-18,23-43,83-86H2,1-3H3,(H2,87,116)(H2,88,117)(H,98,118)(H,99,123)(H,100,133)(H,101,119)(H,102,132)(H,103,120)(H,104,121)(H,105,122)(H,106,124)(H,107,127)(H,108,126)(H,109,125)(H,110,130)(H,111,128)(H,112,129)(H,113,131)(H,134,135)(H4,89,90,95)(H4,91,92,96)(H4,93,94,97)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMPG8NC CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMPG8NC IK LIKGHYIDQTYXFY-VUXBHJHDSA-N
DMPG8NC IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMPG8NC DE Discovery agent
DMHD6N7 ID DMHD6N7
DMHD6N7 DN FGGFTGARKSARKKWNQ
DMHD6N7 HS Investigative
DMHD6N7 PC 91934382
DMHD6N7 MW 1939.2
DMHD6N7 FM C87H135N29O22
DMHD6N7 IC InChI=1S/C87H135N29O22/c1-47(104-69(122)45-103-84(136)71(49(3)118)116-82(134)62(39-51-22-8-5-9-23-51)106-70(123)44-101-68(121)43-102-74(126)54(91)38-50-20-6-4-7-21-50)72(124)107-59(29-18-36-98-86(94)95)76(128)111-58(28-14-17-35-90)79(131)115-65(46-117)83(135)105-48(2)73(125)108-60(30-19-37-99-87(96)97)77(129)109-56(26-12-15-33-88)75(127)110-57(27-13-16-34-89)78(130)113-63(40-52-42-100-55-25-11-10-24-53(52)55)80(132)114-64(41-67(93)120)81(133)112-61(85(137)138)31-32-66(92)119/h4-11,20-25,42,47-49,54,56-65,71,100,117-118H,12-19,26-41,43-46,88-91H2,1-3H3,(H2,92,119)(H2,93,120)(H,101,121)(H,102,126)(H,103,136)(H,104,122)(H,105,135)(H,106,123)(H,107,124)(H,108,125)(H,109,129)(H,110,127)(H,111,128)(H,112,133)(H,113,130)(H,114,132)(H,115,131)(H,116,134)(H,137,138)(H4,94,95,98)(H4,96,97,99)/t47-,48-,49+,54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,71-/m0/s1
DMHD6N7 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMHD6N7 IK URYINPOXJIHSDS-PBUARHPHSA-N
DMHD6N7 IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMHD6N7 DE Discovery agent
DM78I2W ID DM78I2W
DM78I2W DN FGGFTGARKSARKL
DM78I2W HS Investigative
DM78I2W SN CHEMBL437915; FGGFTGARKSARKL
DM78I2W PC 44352919
DM78I2W MW 1494.7
DM78I2W FM C67H111N23O16
DM78I2W IC InChI=1S/C67H111N23O16/c1-37(2)30-48(55(71)96)88-61(102)44(22-12-14-26-68)86-60(101)47(25-17-29-77-67(74)75)85-57(98)39(4)82-64(105)50(36-91)89-62(103)45(23-13-15-27-69)87-59(100)46(24-16-28-76-66(72)73)84-56(97)38(3)81-52(94)35-80-65(106)54(40(5)92)90-63(104)49(32-42-20-10-7-11-21-42)83-53(95)34-78-51(93)33-79-58(99)43(70)31-41-18-8-6-9-19-41/h6-11,18-21,37-40,43-50,54,91-92H,12-17,22-36,68-70H2,1-5H3,(H2,71,96)(H,78,93)(H,79,99)(H,80,106)(H,81,94)(H,82,105)(H,83,95)(H,84,97)(H,85,98)(H,86,101)(H,87,100)(H,88,102)(H,89,103)(H,90,104)(H4,72,73,76)(H4,74,75,77)/t38-,39-,40+,43-,44-,45-,46-,47-,48-,49-,50-,54-/m0/s1
DM78I2W CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM78I2W IK LZQNOYOFRMAEJW-SYMNRJDYSA-N
DM78I2W IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]hexanamide
DM78I2W DE Discovery agent
DMS5AH4 ID DMS5AH4
DMS5AH4 DN FGGFTGARKSARKLADE
DMS5AH4 HS Investigative
DMS5AH4 PC 91931808
DMS5AH4 MW 1810
DMS5AH4 FM C79H128N26O23
DMS5AH4 IC InChI=1S/C79H128N26O23/c1-41(2)33-54(73(124)94-44(5)67(118)102-56(36-62(113)114)74(125)97-49(64(83)115)27-28-61(111)112)103-71(122)50(23-13-15-29-80)100-70(121)53(26-18-32-89-79(86)87)99-66(117)43(4)95-76(127)57(40-106)104-72(123)51(24-14-16-30-81)101-69(120)52(25-17-31-88-78(84)85)98-65(116)42(3)93-59(109)39-92-77(128)63(45(6)107)105-75(126)55(35-47-21-11-8-12-22-47)96-60(110)38-90-58(108)37-91-68(119)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,106-107H,13-18,23-40,80-82H2,1-6H3,(H2,83,115)(H,90,108)(H,91,119)(H,92,128)(H,93,109)(H,94,124)(H,95,127)(H,96,110)(H,97,125)(H,98,116)(H,99,117)(H,100,121)(H,101,120)(H,102,118)(H,103,122)(H,104,123)(H,105,126)(H,111,112)(H,113,114)(H4,84,85,88)(H4,86,87,89)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1
DMS5AH4 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMS5AH4 IK PUPSFQBPHILNGY-SMFNREODSA-N
DMS5AH4 IU (4S)-5-amino-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-5-oxopentanoic acid
DMS5AH4 DE Discovery agent
DMKLSBN ID DMKLSBN
DMKLSBN DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-CONH2
DMKLSBN HS Investigative
DMKLSBN PC 91932087
DMKLSBN MW 1822.1
DMKLSBN FM C80H132N28O21
DMKLSBN IC InChI=1S/C80H132N28O21/c1-7-49(69(120)106-57(37-60(85)112)75(126)100-50(65(86)116)28-29-59(84)111)99-74(125)55(34-42(2)3)105-72(123)51(24-14-16-30-81)103-71(122)54(27-19-33-92-80(89)90)102-67(118)44(5)97-77(128)58(41-109)107-73(124)52(25-15-17-31-82)104-70(121)53(26-18-32-91-79(87)88)101-66(117)43(4)96-62(114)40-95-78(129)64(45(6)110)108-76(127)56(36-47-22-12-9-13-23-47)98-63(115)39-93-61(113)38-94-68(119)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,109-110H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,119)(H,95,129)(H,96,114)(H,97,128)(H,98,115)(H,99,125)(H,100,126)(H,101,117)(H,102,118)(H,103,122)(H,104,121)(H,105,123)(H,106,120)(H,107,124)(H,108,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMKLSBN CS CC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMKLSBN IK FNRHKDQQWGJCOM-KMOVSZGYSA-N
DMKLSBN IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMKLSBN DE Discovery agent
DMPDMFA ID DMPDMFA
DMPDMFA DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH
DMPDMFA HS Investigative
DMPDMFA PC 91932094
DMPDMFA MW 1823.1
DMPDMFA FM C80H131N27O22
DMPDMFA IC InChI=1S/C80H131N27O22/c1-7-49(68(118)105-57(37-60(85)111)74(124)103-54(78(128)129)28-29-59(84)110)98-73(123)55(34-42(2)3)104-71(121)50(24-14-16-30-81)101-70(120)53(27-19-33-91-80(88)89)100-66(116)44(5)96-76(126)58(41-108)106-72(122)51(25-15-17-31-82)102-69(119)52(26-18-32-90-79(86)87)99-65(115)43(4)95-62(113)40-94-77(127)64(45(6)109)107-75(125)56(36-47-22-12-9-13-23-47)97-63(114)39-92-61(112)38-93-67(117)48(83)35-46-20-10-8-11-21-46/h8-13,20-23,42-45,48-58,64,108-109H,7,14-19,24-41,81-83H2,1-6H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,117)(H,94,127)(H,95,113)(H,96,126)(H,97,114)(H,98,123)(H,99,115)(H,100,116)(H,101,120)(H,102,119)(H,103,124)(H,104,121)(H,105,118)(H,106,122)(H,107,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMPDMFA CS CC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N
DMPDMFA IK CBBZIEAUVSBRPS-KMOVSZGYSA-N
DMPDMFA IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMPDMFA DE Discovery agent
DMSMK70 ID DMSMK70
DMSMK70 DN FGGFTGARKSARKLARK
DMSMK70 HS Investigative
DMSMK70 SN CHEMBL499157; FGGFTGARKSARKLARK
DMSMK70 PC 44588828
DMSMK70 MW 1704
DMSMK70 FM C73H130N28O19
DMSMK70 IC InChI=1S/C73H130N28O19/c1-39(2)33-52(67(116)91-41(4)59(108)95-50(26-18-32-86-73(82)83)64(113)98-51(70(119)120)23-12-15-29-76)99-65(114)46(21-10-13-27-74)96-63(112)49(25-17-31-85-72(80)81)94-60(109)42(5)92-68(117)53(38-102)100-66(115)47(22-11-14-28-75)97-62(111)48(24-16-30-84-71(78)79)93-58(107)40(3)90-55(105)37-89-69(118)57(43(6)103)101-56(106)36-87-54(104)35-88-61(110)45(77)34-44-19-8-7-9-20-44/h7-9,19-20,39-43,45-53,57,102-103H,10-18,21-38,74-77H2,1-6H3,(H,87,104)(H,88,110)(H,89,118)(H,90,105)(H,91,116)(H,92,117)(H,93,107)(H,94,109)(H,95,108)(H,96,112)(H,97,111)(H,98,113)(H,99,114)(H,100,115)(H,101,106)(H,119,120)(H4,78,79,84)(H4,80,81,85)(H4,82,83,86)/t40-,41-,42-,43+,45-,46-,47-,48-,49-,50-,51-,52-,53-,57-/m0/s1
DMSMK70 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CNC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)N)O
DMSMK70 IK UNHQLKTVYYARAV-VKORATPISA-N
DMSMK70 IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoic acid
DMSMK70 DE Discovery agent
DMLDWFE ID DMLDWFE
DMLDWFE DN FGGFTGARKSARKLFNQ
DMLDWFE HS Investigative
DMLDWFE PC 91934919
DMLDWFE MW 1885.1
DMLDWFE FM C85H133N27O22
DMLDWFE IC InChI=1S/C85H133N27O22/c1-46(2)37-59(77(127)109-61(40-52-25-13-8-14-26-52)78(128)110-62(41-65(90)116)79(129)107-58(83(133)134)31-32-64(89)115)108-75(125)54(27-15-17-33-86)105-74(124)57(30-20-36-96-85(93)94)104-71(121)48(4)101-81(131)63(45-113)111-76(126)55(28-16-18-34-87)106-73(123)56(29-19-35-95-84(91)92)103-70(120)47(3)100-67(118)44-99-82(132)69(49(5)114)112-80(130)60(39-51-23-11-7-12-24-51)102-68(119)43-97-66(117)42-98-72(122)53(88)38-50-21-9-6-10-22-50/h6-14,21-26,46-49,53-63,69,113-114H,15-20,27-45,86-88H2,1-5H3,(H2,89,115)(H2,90,116)(H,97,117)(H,98,122)(H,99,132)(H,100,118)(H,101,131)(H,102,119)(H,103,120)(H,104,121)(H,105,124)(H,106,123)(H,107,129)(H,108,125)(H,109,127)(H,110,128)(H,111,126)(H,112,130)(H,133,134)(H4,91,92,95)(H4,93,94,96)/t47-,48-,49+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,69-/m0/s1
DMLDWFE CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMLDWFE IK KCPGYTKGECMLMX-UAOIWBIESA-N
DMLDWFE IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMLDWFE DE Discovery agent
DMIA2XJ ID DMIA2XJ
DMIA2XJ DN FGGFTGARKSARKLKNQ
DMIA2XJ HS Investigative
DMIA2XJ PC 91934916
DMIA2XJ MW 1866.1
DMIA2XJ FM C82H136N28O22
DMIA2XJ IC InChI=1S/C82H136N28O22/c1-44(2)36-57(75(126)105-52(25-13-16-32-84)73(124)108-59(39-62(88)114)76(127)106-56(80(131)132)29-30-61(87)113)107-72(123)51(24-12-15-31-83)103-71(122)55(28-19-35-94-82(91)92)102-68(119)46(4)99-78(129)60(43-111)109-74(125)53(26-14-17-33-85)104-70(121)54(27-18-34-93-81(89)90)101-67(118)45(3)98-64(116)42-97-79(130)66(47(5)112)110-77(128)58(38-49-22-10-7-11-23-49)100-65(117)41-95-63(115)40-96-69(120)50(86)37-48-20-8-6-9-21-48/h6-11,20-23,44-47,50-60,66,111-112H,12-19,24-43,83-86H2,1-5H3,(H2,87,113)(H2,88,114)(H,95,115)(H,96,120)(H,97,130)(H,98,116)(H,99,129)(H,100,117)(H,101,118)(H,102,119)(H,103,122)(H,104,121)(H,105,126)(H,106,127)(H,107,123)(H,108,124)(H,109,125)(H,110,128)(H,131,132)(H4,89,90,93)(H4,91,92,94)/t45-,46-,47+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMIA2XJ CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMIA2XJ IK PODXIWAAMNUDTK-WBMOPDPASA-N
DMIA2XJ IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMIA2XJ DE Discovery agent
DMRVSXG ID DMRVSXG
DMRVSXG DN FGGFTGARKSARKLLNQ
DMRVSXG HS Investigative
DMRVSXG PC 91934917
DMRVSXG MW 1851.1
DMRVSXG FM C82H135N27O22
DMRVSXG IC InChI=1S/C82H135N27O22/c1-43(2)34-56(74(124)106-57(35-44(3)4)75(125)107-59(38-62(87)113)76(126)104-55(80(130)131)28-29-61(86)112)105-72(122)51(24-14-16-30-83)102-71(121)54(27-19-33-93-82(90)91)101-68(118)46(6)98-78(128)60(42-110)108-73(123)52(25-15-17-31-84)103-70(120)53(26-18-32-92-81(88)89)100-67(117)45(5)97-64(115)41-96-79(129)66(47(7)111)109-77(127)58(37-49-22-12-9-13-23-49)99-65(116)40-94-63(114)39-95-69(119)50(85)36-48-20-10-8-11-21-48/h8-13,20-23,43-47,50-60,66,110-111H,14-19,24-42,83-85H2,1-7H3,(H2,86,112)(H2,87,113)(H,94,114)(H,95,119)(H,96,129)(H,97,115)(H,98,128)(H,99,116)(H,100,117)(H,101,118)(H,102,121)(H,103,120)(H,104,126)(H,105,122)(H,106,124)(H,107,125)(H,108,123)(H,109,127)(H,130,131)(H4,88,89,92)(H4,90,91,93)/t45-,46-,47+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DMRVSXG CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMRVSXG IK OQBMVKTZJNOYNF-WBMOPDPASA-N
DMRVSXG IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMRVSXG DE Discovery agent
DMD9SOF ID DMD9SOF
DMD9SOF DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-CONH2
DMD9SOF HS Investigative
DMD9SOF PC 91932084
DMD9SOF MW 1822.1
DMD9SOF FM C80H132N28O21
DMD9SOF IC InChI=1S/C80H132N28O21/c1-42(2)34-57(78(129)108(7)45(5)68(119)104-56(37-60(85)112)74(125)99-50(65(86)116)28-29-59(84)111)105-72(123)51(24-14-16-30-81)102-71(122)54(27-19-33-92-80(89)90)101-67(118)44(4)97-76(127)58(41-109)106-73(124)52(25-15-17-31-82)103-70(121)53(26-18-32-91-79(87)88)100-66(117)43(3)96-62(114)40-95-77(128)64(46(6)110)107-75(126)55(36-48-22-12-9-13-23-48)98-63(115)39-93-61(113)38-94-69(120)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,109-110H,14-19,24-41,81-83H2,1-7H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,120)(H,95,128)(H,96,114)(H,97,127)(H,98,115)(H,99,125)(H,100,117)(H,101,118)(H,102,122)(H,103,121)(H,104,119)(H,105,123)(H,106,124)(H,107,126)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMD9SOF CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMD9SOF IK DLMXQMKGBYRHOA-FKPOJLNCSA-N
DMD9SOF IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]-methylamino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMD9SOF DE Discovery agent
DMCSN9M ID DMCSN9M
DMCSN9M DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH
DMCSN9M HS Investigative
DMCSN9M PC 91932086
DMCSN9M MW 1823.1
DMCSN9M FM C80H131N27O22
DMCSN9M IC InChI=1S/C80H131N27O22/c1-42(2)34-57(77(127)107(7)45(5)67(117)103-56(37-60(85)111)73(123)102-54(78(128)129)28-29-59(84)110)104-71(121)50(24-14-16-30-81)100-70(120)53(27-19-33-91-80(88)89)99-66(116)44(4)96-75(125)58(41-108)105-72(122)51(25-15-17-31-82)101-69(119)52(26-18-32-90-79(86)87)98-65(115)43(3)95-62(113)40-94-76(126)64(46(6)109)106-74(124)55(36-48-22-12-9-13-23-48)97-63(114)39-92-61(112)38-93-68(118)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,108-109H,14-19,24-41,81-83H2,1-7H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,126)(H,95,113)(H,96,125)(H,97,114)(H,98,115)(H,99,116)(H,100,120)(H,101,119)(H,102,123)(H,103,117)(H,104,121)(H,105,122)(H,106,124)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMCSN9M CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMCSN9M IK NQIPFWOYZKKZKS-FKPOJLNCSA-N
DMCSN9M IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]-methylamino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMCSN9M DE Discovery agent
DMCSTP5 ID DMCSTP5
DMCSTP5 DN FGGFTGARKSARKLRNQ
DMCSTP5 HS Investigative
DMCSTP5 PC 91934915
DMCSTP5 MW 1894.1
DMCSTP5 FM C82H136N30O22
DMCSTP5 IC InChI=1S/C82H136N30O22/c1-43(2)35-56(74(128)107-54(27-18-34-96-82(92)93)72(126)110-58(38-61(87)116)75(129)108-55(79(133)134)28-29-60(86)115)109-71(125)50(23-12-14-30-83)105-70(124)53(26-17-33-95-81(90)91)104-67(121)45(4)101-77(131)59(42-113)111-73(127)51(24-13-15-31-84)106-69(123)52(25-16-32-94-80(88)89)103-66(120)44(3)100-63(118)41-99-78(132)65(46(5)114)112-76(130)57(37-48-21-10-7-11-22-48)102-64(119)40-97-62(117)39-98-68(122)49(85)36-47-19-8-6-9-20-47/h6-11,19-22,43-46,49-59,65,113-114H,12-18,23-42,83-85H2,1-5H3,(H2,86,115)(H2,87,116)(H,97,117)(H,98,122)(H,99,132)(H,100,118)(H,101,131)(H,102,119)(H,103,120)(H,104,121)(H,105,124)(H,106,123)(H,107,128)(H,108,129)(H,109,125)(H,110,126)(H,111,127)(H,112,130)(H,133,134)(H4,88,89,94)(H4,90,91,95)(H4,92,93,96)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DMCSTP5 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMCSTP5 IK YWJIJXCRNQLPGY-VUXBHJHDSA-N
DMCSTP5 IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMCSTP5 DE Discovery agent
DMDEJS6 ID DMDEJS6
DMDEJS6 DN FGGFTGARKSARKLVNQ
DMDEJS6 HS Investigative
DMDEJS6 PC 91934918
DMDEJS6 MW 1837.1
DMDEJS6 FM C81H133N27O22
DMDEJS6 IC InChI=1S/C81H133N27O22/c1-42(2)34-55(74(124)107-64(43(3)4)78(128)105-57(37-60(86)112)73(123)103-54(79(129)130)28-29-59(85)111)104-71(121)50(24-14-16-30-82)101-70(120)53(27-19-33-92-81(89)90)100-67(117)45(6)97-76(126)58(41-109)106-72(122)51(25-15-17-31-83)102-69(119)52(26-18-32-91-80(87)88)99-66(116)44(5)96-62(114)40-95-77(127)65(46(7)110)108-75(125)56(36-48-22-12-9-13-23-48)98-63(115)39-93-61(113)38-94-68(118)49(84)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64-65,109-110H,14-19,24-41,82-84H2,1-7H3,(H2,85,111)(H2,86,112)(H,93,113)(H,94,118)(H,95,127)(H,96,114)(H,97,126)(H,98,115)(H,99,116)(H,100,117)(H,101,120)(H,102,119)(H,103,123)(H,104,121)(H,105,128)(H,106,122)(H,107,124)(H,108,125)(H,129,130)(H4,87,88,91)(H4,89,90,92)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-,65-/m0/s1
DMDEJS6 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMDEJS6 IK ONIQWXAYTYHYLD-BEIYNOPZSA-N
DMDEJS6 IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMDEJS6 DE Discovery agent
DMV34KQ ID DMV34KQ
DMV34KQ DN FGGFTGARKSARKLWNQ
DMV34KQ HS Investigative
DMV34KQ PC 91934921
DMV34KQ MW 1924.2
DMV34KQ FM C87H134N28O22
DMV34KQ IC InChI=1S/C87H134N28O22/c1-46(2)36-61(79(130)112-63(39-52-41-99-55-25-13-12-24-53(52)55)80(131)113-64(40-67(92)119)81(132)110-60(85(136)137)30-31-66(91)118)111-77(128)56(26-14-16-32-88)108-76(127)59(29-19-35-98-87(95)96)107-73(124)48(4)104-83(134)65(45-116)114-78(129)57(27-15-17-33-89)109-75(126)58(28-18-34-97-86(93)94)106-72(123)47(3)103-69(121)44-102-84(135)71(49(5)117)115-82(133)62(38-51-22-10-7-11-23-51)105-70(122)43-100-68(120)42-101-74(125)54(90)37-50-20-8-6-9-21-50/h6-13,20-25,41,46-49,54,56-65,71,99,116-117H,14-19,26-40,42-45,88-90H2,1-5H3,(H2,91,118)(H2,92,119)(H,100,120)(H,101,125)(H,102,135)(H,103,121)(H,104,134)(H,105,122)(H,106,123)(H,107,124)(H,108,127)(H,109,126)(H,110,132)(H,111,128)(H,112,130)(H,113,131)(H,114,129)(H,115,133)(H,136,137)(H4,93,94,97)(H4,95,96,98)/t47-,48-,49+,54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,71-/m0/s1
DMV34KQ CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMV34KQ IK IXCVHRQJQPARCV-PBUARHPHSA-N
DMV34KQ IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMV34KQ DE Discovery agent
DMG5LXT ID DMG5LXT
DMG5LXT DN FGGFTGARKSARKLYNQ
DMG5LXT HS Investigative
DMG5LXT PC 91934920
DMG5LXT MW 1901.1
DMG5LXT FM C85H133N27O23
DMG5LXT IC InChI=1S/C85H133N27O23/c1-45(2)36-59(77(128)109-61(39-51-26-28-52(115)29-27-51)78(129)110-62(40-65(90)117)79(130)107-58(83(134)135)30-31-64(89)116)108-75(126)54(22-12-14-32-86)105-74(125)57(25-17-35-96-85(93)94)104-71(122)47(4)101-81(132)63(44-113)111-76(127)55(23-13-15-33-87)106-73(124)56(24-16-34-95-84(91)92)103-70(121)46(3)100-67(119)43-99-82(133)69(48(5)114)112-80(131)60(38-50-20-10-7-11-21-50)102-68(120)42-97-66(118)41-98-72(123)53(88)37-49-18-8-6-9-19-49/h6-11,18-21,26-29,45-48,53-63,69,113-115H,12-17,22-25,30-44,86-88H2,1-5H3,(H2,89,116)(H2,90,117)(H,97,118)(H,98,123)(H,99,133)(H,100,119)(H,101,132)(H,102,120)(H,103,121)(H,104,122)(H,105,125)(H,106,124)(H,107,130)(H,108,126)(H,109,128)(H,110,129)(H,111,127)(H,112,131)(H,134,135)(H4,91,92,95)(H4,93,94,96)/t46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,69-/m0/s1
DMG5LXT CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DMG5LXT IK BDVDLXKNELSDGP-RLSGEJHXSA-N
DMG5LXT IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMG5LXT DE Discovery agent
DM21XBO ID DM21XBO
DM21XBO DN FGGFTGARKSARKRANQ
DM21XBO HS Investigative
DM21XBO PC 91934908
DM21XBO MW 1852.1
DM21XBO FM C79H130N30O22
DM21XBO IC InChI=1S/C79H130N30O22/c1-41(97-60(115)39-96-75(129)62(44(4)111)109-73(127)54(35-46-20-9-6-10-21-46)100-61(116)38-94-59(114)37-95-66(120)47(82)34-45-18-7-5-8-19-45)63(117)101-51(25-16-32-92-78(87)88)69(123)104-49(23-12-14-30-81)71(125)108-56(40-110)74(128)99-42(2)64(118)102-52(26-17-33-93-79(89)90)70(124)103-48(22-11-13-29-80)68(122)105-50(24-15-31-91-77(85)86)67(121)98-43(3)65(119)107-55(36-58(84)113)72(126)106-53(76(130)131)27-28-57(83)112/h5-10,18-21,41-44,47-56,62,110-111H,11-17,22-40,80-82H2,1-4H3,(H2,83,112)(H2,84,113)(H,94,114)(H,95,120)(H,96,129)(H,97,115)(H,98,121)(H,99,128)(H,100,116)(H,101,117)(H,102,118)(H,103,124)(H,104,123)(H,105,122)(H,106,126)(H,107,119)(H,108,125)(H,109,127)(H,130,131)(H4,85,86,91)(H4,87,88,92)(H4,89,90,93)/t41-,42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,62-/m0/s1
DM21XBO CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM21XBO IK YTLZMPJDUFYROB-YRFUXTPFSA-N
DM21XBO IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM21XBO DE Discovery agent
DM9RHXC ID DM9RHXC
DM9RHXC DN FGGFTGARKSARKRKNQ
DM9RHXC HS Investigative
DM9RHXC SN [Arg14,Lys15]Nociceptin; 236098-40-1
DM9RHXC PC 91934903
DM9RHXC MW 1909.2
DM9RHXC FM C82H137N31O22
DM9RHXC IC InChI=1S/C82H137N31O22/c1-44(101-63(119)42-100-78(133)65(46(3)115)113-76(131)57(38-48-21-8-5-9-22-48)103-64(120)41-98-62(118)40-99-68(123)49(86)37-47-19-6-4-7-20-47)66(121)104-53(26-16-34-95-80(89)90)70(125)108-52(25-12-15-33-85)74(129)112-59(43-114)77(132)102-45(2)67(122)105-54(27-17-35-96-81(91)92)71(126)106-50(23-10-13-31-83)69(124)109-55(28-18-36-97-82(93)94)72(127)107-51(24-11-14-32-84)73(128)111-58(39-61(88)117)75(130)110-56(79(134)135)29-30-60(87)116/h4-9,19-22,44-46,49-59,65,114-115H,10-18,23-43,83-86H2,1-3H3,(H2,87,116)(H2,88,117)(H,98,118)(H,99,123)(H,100,133)(H,101,119)(H,102,132)(H,103,120)(H,104,121)(H,105,122)(H,106,126)(H,107,127)(H,108,125)(H,109,124)(H,110,130)(H,111,128)(H,112,129)(H,113,131)(H,134,135)(H4,89,90,95)(H4,91,92,96)(H4,93,94,97)/t44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,65-/m0/s1
DM9RHXC CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM9RHXC IK VULLMZOQBGUKAT-VUXBHJHDSA-N
DM9RHXC IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM9RHXC DE Discovery agent
DMWK0Z6 ID DMWK0Z6
DMWK0Z6 DN FGGFTGARKSARKRKRK
DMWK0Z6 HS Investigative
DMWK0Z6 PC 91934904
DMWK0Z6 MW 1951.3
DMWK0Z6 FM C85H147N33O20
DMWK0Z6 IC InChI=1S/C85H147N33O20/c1-48(106-65(122)46-105-80(136)67(50(3)120)118-78(134)62(43-52-24-8-5-9-25-52)108-66(123)45-103-64(121)44-104-70(126)53(90)42-51-22-6-4-7-23-51)68(124)109-57(30-18-38-99-82(91)92)73(129)113-56(28-12-16-36-88)77(133)117-63(47-119)79(135)107-49(2)69(125)110-58(31-19-39-100-83(93)94)74(130)111-54(26-10-14-34-86)71(127)114-59(32-20-40-101-84(95)96)75(131)112-55(27-11-15-35-87)72(128)115-60(33-21-41-102-85(97)98)76(132)116-61(81(137)138)29-13-17-37-89/h4-9,22-25,48-50,53-63,67,119-120H,10-21,26-47,86-90H2,1-3H3,(H,103,121)(H,104,126)(H,105,136)(H,106,122)(H,107,135)(H,108,123)(H,109,124)(H,110,125)(H,111,130)(H,112,131)(H,113,129)(H,114,127)(H,115,128)(H,116,132)(H,117,133)(H,118,134)(H,137,138)(H4,91,92,99)(H4,93,94,100)(H4,95,96,101)(H4,97,98,102)/t48-,49-,50+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,67-/m0/s1
DMWK0Z6 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMWK0Z6 IK UJJPEJMTOWTFSE-VDORGCAASA-N
DMWK0Z6 IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoic acid
DMWK0Z6 DE Discovery agent
DMDMT5U ID DMDMT5U
DMDMT5U DN FGGFTGARKSARKRRNQ
DMDMT5U HS Investigative
DMDMT5U PC 91934906
DMDMT5U MW 1937.2
DMDMT5U FM C82H137N33O22
DMDMT5U IC InChI=1S/C82H137N33O22/c1-43(103-62(121)41-102-77(135)64(45(3)117)115-75(133)56(37-47-20-8-5-9-21-47)105-63(122)40-100-61(120)39-101-67(125)48(85)36-46-18-6-4-7-19-46)65(123)106-51(24-14-32-96-79(88)89)69(127)109-50(23-11-13-31-84)73(131)114-58(42-116)76(134)104-44(2)66(124)107-52(25-15-33-97-80(90)91)70(128)108-49(22-10-12-30-83)68(126)110-53(26-16-34-98-81(92)93)71(129)111-54(27-17-35-99-82(94)95)72(130)113-57(38-60(87)119)74(132)112-55(78(136)137)28-29-59(86)118/h4-9,18-21,43-45,48-58,64,116-117H,10-17,22-42,83-85H2,1-3H3,(H2,86,118)(H2,87,119)(H,100,120)(H,101,125)(H,102,135)(H,103,121)(H,104,134)(H,105,122)(H,106,123)(H,107,124)(H,108,128)(H,109,127)(H,110,126)(H,111,129)(H,112,132)(H,113,130)(H,114,131)(H,115,133)(H,136,137)(H4,88,89,96)(H4,90,91,97)(H4,92,93,98)(H4,94,95,99)/t43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMDMT5U CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMDMT5U IK DJPBHOCLMOWQPP-KMOVSZGYSA-N
DMDMT5U IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMDMT5U DE Discovery agent
DMEGW7F ID DMEGW7F
DMEGW7F DN FGGFTGARKSARKRWNQ
DMEGW7F HS Investigative
DMEGW7F PC 91934381
DMEGW7F MW 1967.2
DMEGW7F FM C87H135N31O22
DMEGW7F IC InChI=1S/C87H135N31O22/c1-46(106-68(124)44-105-83(138)70(48(3)120)118-81(136)61(38-50-21-8-5-9-22-50)108-69(125)43-103-67(123)42-104-73(128)53(90)37-49-19-6-4-7-20-49)71(126)109-57(27-16-34-99-85(93)94)75(130)112-56(26-13-15-33-89)78(133)117-64(45-119)82(137)107-47(2)72(127)110-58(28-17-35-100-86(95)96)76(131)111-55(25-12-14-32-88)74(129)113-59(29-18-36-101-87(97)98)77(132)115-62(39-51-41-102-54-24-11-10-23-52(51)54)79(134)116-63(40-66(92)122)80(135)114-60(84(139)140)30-31-65(91)121/h4-11,19-24,41,46-48,53,55-64,70,102,119-120H,12-18,25-40,42-45,88-90H2,1-3H3,(H2,91,121)(H2,92,122)(H,103,123)(H,104,128)(H,105,138)(H,106,124)(H,107,137)(H,108,125)(H,109,126)(H,110,127)(H,111,131)(H,112,130)(H,113,129)(H,114,135)(H,115,132)(H,116,134)(H,117,133)(H,118,136)(H,139,140)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t46-,47-,48+,53-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,70-/m0/s1
DMEGW7F CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMEGW7F IK HCNFEYAQXGBVLO-UWALROLSSA-N
DMEGW7F IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMEGW7F DE Discovery agent
DM1QTN5 ID DM1QTN5
DM1QTN5 DN FGGFTGARKSARKVANQ
DM1QTN5 HS Investigative
DM1QTN5 PC 91934911
DM1QTN5 MW 1795
DM1QTN5 FM C78H127N27O22
DM1QTN5 IC InChI=1S/C78H127N27O22/c1-40(2)61(75(125)95-43(5)65(115)102-54(35-57(83)109)71(121)101-52(76(126)127)27-28-56(82)108)104-70(120)49(24-14-16-30-80)100-68(118)51(26-18-32-89-78(86)87)98-64(114)42(4)94-73(123)55(39-106)103-69(119)48(23-13-15-29-79)99-67(117)50(25-17-31-88-77(84)85)97-63(113)41(3)93-59(111)38-92-74(124)62(44(6)107)105-72(122)53(34-46-21-11-8-12-22-46)96-60(112)37-90-58(110)36-91-66(116)47(81)33-45-19-9-7-10-20-45/h7-12,19-22,40-44,47-55,61-62,106-107H,13-18,23-39,79-81H2,1-6H3,(H2,82,108)(H2,83,109)(H,90,110)(H,91,116)(H,92,124)(H,93,111)(H,94,123)(H,95,125)(H,96,112)(H,97,113)(H,98,114)(H,99,117)(H,100,118)(H,101,121)(H,102,115)(H,103,119)(H,104,120)(H,105,122)(H,126,127)(H4,84,85,88)(H4,86,87,89)/t41-,42-,43-,44+,47-,48-,49-,50-,51-,52-,53-,54-,55-,61-,62-/m0/s1
DM1QTN5 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DM1QTN5 IK PLDGJAGJBNNRQP-OTYLYHRBSA-N
DM1QTN5 IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM1QTN5 DE Discovery agent
DMM17AO ID DMM17AO
DMM17AO DN FGGFTGARKSARKWANQ
DMM17AO HS Investigative
DMM17AO PC 91934914
DMM17AO MW 1882.1
DMM17AO FM C84H128N28O22
DMM17AO IC InChI=1S/C84H128N28O22/c1-44(100-66(118)42-99-81(132)68(47(4)114)112-79(130)59(36-49-21-9-6-10-22-49)103-67(119)41-97-65(117)40-98-72(123)52(87)35-48-19-7-5-8-20-48)69(120)104-56(27-17-33-94-83(90)91)73(124)107-55(26-14-16-32-86)76(127)111-62(43-113)80(131)102-45(2)70(121)105-57(28-18-34-95-84(92)93)74(125)106-54(25-13-15-31-85)75(126)110-60(37-50-39-96-53-24-12-11-23-51(50)53)77(128)101-46(3)71(122)109-61(38-64(89)116)78(129)108-58(82(133)134)29-30-63(88)115/h5-12,19-24,39,44-47,52,54-62,68,96,113-114H,13-18,25-38,40-43,85-87H2,1-4H3,(H2,88,115)(H2,89,116)(H,97,117)(H,98,123)(H,99,132)(H,100,118)(H,101,128)(H,102,131)(H,103,119)(H,104,120)(H,105,121)(H,106,125)(H,107,124)(H,108,129)(H,109,122)(H,110,126)(H,111,127)(H,112,130)(H,133,134)(H4,90,91,94)(H4,92,93,95)/t44-,45-,46-,47+,52-,54-,55-,56-,57-,58-,59-,60-,61-,62-,68-/m0/s1
DMM17AO CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMM17AO IK MRPJNGQFWWZSQY-FMCSKRGOSA-N
DMM17AO IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMM17AO DE Discovery agent
DM1YN0F ID DM1YN0F
DM1YN0F DN FGGFTGARKSARKWKNQ
DM1YN0F HS Investigative
DM1YN0F PC 91934380
DM1YN0F MW 1939.2
DM1YN0F FM C87H135N29O22
DM1YN0F IC InChI=1S/C87H135N29O22/c1-47(104-69(122)45-103-84(136)71(49(3)118)116-82(134)62(39-51-22-8-5-9-23-51)106-70(123)44-101-68(121)43-102-74(126)54(91)38-50-20-6-4-7-21-50)72(124)107-59(29-18-36-98-86(94)95)75(127)110-58(28-14-17-35-90)79(131)115-65(46-117)83(135)105-48(2)73(125)108-60(30-19-37-99-87(96)97)76(128)109-56(26-12-15-33-88)77(129)113-63(40-52-42-100-55-25-11-10-24-53(52)55)80(132)111-57(27-13-16-34-89)78(130)114-64(41-67(93)120)81(133)112-61(85(137)138)31-32-66(92)119/h4-11,20-25,42,47-49,54,56-65,71,100,117-118H,12-19,26-41,43-46,88-91H2,1-3H3,(H2,92,119)(H2,93,120)(H,101,121)(H,102,126)(H,103,136)(H,104,122)(H,105,135)(H,106,123)(H,107,124)(H,108,125)(H,109,128)(H,110,127)(H,111,132)(H,112,133)(H,113,129)(H,114,130)(H,115,131)(H,116,134)(H,137,138)(H4,94,95,98)(H4,96,97,99)/t47-,48-,49+,54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,71-/m0/s1
DM1YN0F CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DM1YN0F IK ZXXWZZVFRTXDSC-PBUARHPHSA-N
DM1YN0F IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM1YN0F DE Discovery agent
DMRLZKJ ID DMRLZKJ
DMRLZKJ DN FGGFTGARKSARKWRNQ
DMRLZKJ HS Investigative
DMRLZKJ PC 91934379
DMRLZKJ MW 1967.2
DMRLZKJ FM C87H135N31O22
DMRLZKJ IC InChI=1S/C87H135N31O22/c1-46(106-68(124)44-105-83(138)70(48(3)120)118-81(136)61(38-50-21-8-5-9-22-50)108-69(125)43-103-67(123)42-104-73(128)53(90)37-49-19-6-4-7-20-49)71(126)109-57(27-16-34-99-85(93)94)74(129)112-56(26-13-15-33-89)78(133)117-64(45-119)82(137)107-47(2)72(127)110-58(28-17-35-100-86(95)96)75(130)111-55(25-12-14-32-88)76(131)115-62(39-51-41-102-54-24-11-10-23-52(51)54)79(134)113-59(29-18-36-101-87(97)98)77(132)116-63(40-66(92)122)80(135)114-60(84(139)140)30-31-65(91)121/h4-11,19-24,41,46-48,53,55-64,70,102,119-120H,12-18,25-40,42-45,88-90H2,1-3H3,(H2,91,121)(H2,92,122)(H,103,123)(H,104,128)(H,105,138)(H,106,124)(H,107,137)(H,108,125)(H,109,126)(H,110,127)(H,111,130)(H,112,129)(H,113,134)(H,114,135)(H,115,131)(H,116,132)(H,117,133)(H,118,136)(H,139,140)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t46-,47-,48+,53-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,70-/m0/s1
DMRLZKJ CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=CC=C4)N)O
DMRLZKJ IK KUDFNAMEWORXOZ-UWALROLSSA-N
DMRLZKJ IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMRLZKJ DE Discovery agent
DM5FRXN ID DM5FRXN
DM5FRXN DN FGGFTGARKSARKYANQ
DM5FRXN HS Investigative
DM5FRXN PC 91934913
DM5FRXN MW 1859.1
DM5FRXN FM C82H127N27O23
DM5FRXN IC InChI=1S/C82H127N27O23/c1-43(97-64(116)41-96-79(130)66(46(4)111)109-77(128)57(36-48-19-9-6-10-20-48)100-65(117)40-94-63(115)39-95-70(121)51(85)35-47-17-7-5-8-18-47)67(118)101-54(23-15-33-92-81(88)89)71(122)104-53(22-12-14-32-84)74(125)108-60(42-110)78(129)99-44(2)68(119)102-55(24-16-34-93-82(90)91)72(123)103-52(21-11-13-31-83)73(124)107-58(37-49-25-27-50(112)28-26-49)75(126)98-45(3)69(120)106-59(38-62(87)114)76(127)105-56(80(131)132)29-30-61(86)113/h5-10,17-20,25-28,43-46,51-60,66,110-112H,11-16,21-24,29-42,83-85H2,1-4H3,(H2,86,113)(H2,87,114)(H,94,115)(H,95,121)(H,96,130)(H,97,116)(H,98,126)(H,99,129)(H,100,117)(H,101,118)(H,102,119)(H,103,123)(H,104,122)(H,105,127)(H,106,120)(H,107,124)(H,108,125)(H,109,128)(H,131,132)(H4,88,89,92)(H4,90,91,93)/t43-,44-,45-,46+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1
DM5FRXN CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=CC=C3)N)O
DM5FRXN IK NTZGMAAQXGNGFH-VDVVPONDSA-N
DM5FRXN IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DM5FRXN DE Discovery agent
DMV3ZF1 ID DMV3ZF1
DMV3ZF1 DN F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2
DMV3ZF1 HS Investigative
DMV3ZF1 PC 91932089
DMV3ZF1 MW 1822.1
DMV3ZF1 FM C80H132N28O21
DMV3ZF1 IC InChI=1S/C80H132N28O21/c1-42(2)34-55(74(125)97-44(4)67(118)104-57(37-60(85)112)75(126)99-50(65(86)116)28-29-59(84)111)105-72(123)51(24-14-16-30-81)102-71(122)54(27-19-33-92-80(89)90)101-68(119)45(5)108(7)78(129)58(41-109)106-73(124)52(25-15-17-31-82)103-70(121)53(26-18-32-91-79(87)88)100-66(117)43(3)96-62(114)40-95-77(128)64(46(6)110)107-76(127)56(36-48-22-12-9-13-23-48)98-63(115)39-93-61(113)38-94-69(120)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,109-110H,14-19,24-41,81-83H2,1-7H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,120)(H,95,128)(H,96,114)(H,97,125)(H,98,115)(H,99,126)(H,100,117)(H,101,119)(H,102,122)(H,103,121)(H,104,118)(H,105,123)(H,106,124)(H,107,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMV3ZF1 CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMV3ZF1 IK JRFVGOSSKZWBRX-FKPOJLNCSA-N
DMV3ZF1 IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMV3ZF1 DE Discovery agent
DMZI6RD ID DMZI6RD
DMZI6RD DN F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH
DMZI6RD HS Investigative
DMZI6RD PC 91932092
DMZI6RD MW 1823.1
DMZI6RD FM C80H131N27O22
DMZI6RD IC InChI=1S/C80H131N27O22/c1-42(2)34-55(73(123)96-44(4)66(116)103-57(37-60(85)111)74(124)102-54(78(128)129)28-29-59(84)110)104-71(121)50(24-14-16-30-81)100-70(120)53(27-19-33-91-80(88)89)99-67(117)45(5)107(7)77(127)58(41-108)105-72(122)51(25-15-17-31-82)101-69(119)52(26-18-32-90-79(86)87)98-65(115)43(3)95-62(113)40-94-76(126)64(46(6)109)106-75(125)56(36-48-22-12-9-13-23-48)97-63(114)39-92-61(112)38-93-68(118)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,108-109H,14-19,24-41,81-83H2,1-7H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,126)(H,95,113)(H,96,123)(H,97,114)(H,98,115)(H,99,117)(H,100,120)(H,101,119)(H,102,124)(H,103,116)(H,104,121)(H,105,122)(H,106,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMZI6RD CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMZI6RD IK MJZVYHXPHQEPQQ-FKPOJLNCSA-N
DMZI6RD IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMZI6RD DE Discovery agent
DM2PYE7 ID DM2PYE7
DM2PYE7 DN FGGFTGCRKSARKC
DM2PYE7 HS Investigative
DM2PYE7 DE Discovery agent
DMQX2GK ID DMQX2GK
DMQX2GK DN FGGFTGCRKSCRK
DMQX2GK HS Investigative
DMQX2GK DE Discovery agent
DMPHIBZ ID DMPHIBZ
DMPHIBZ DN F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2
DMPHIBZ HS Investigative
DMPHIBZ PC 91932090
DMPHIBZ MW 1822.1
DMPHIBZ FM C80H132N28O21
DMPHIBZ IC InChI=1S/C80H132N28O21/c1-42(2)34-55(74(125)96-44(4)67(118)104-57(37-60(85)112)75(126)99-50(65(86)116)28-29-59(84)111)105-72(123)51(24-14-16-30-81)102-70(121)53(26-18-32-91-79(87)88)100-66(117)43(3)97-77(128)58(41-109)106-73(124)52(25-15-17-31-82)103-71(122)54(27-19-33-92-80(89)90)101-68(119)45(5)108(7)63(115)40-95-78(129)64(46(6)110)107-76(127)56(36-48-22-12-9-13-23-48)98-62(114)39-93-61(113)38-94-69(120)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,109-110H,14-19,24-41,81-83H2,1-7H3,(H2,84,111)(H2,85,112)(H2,86,116)(H,93,113)(H,94,120)(H,95,129)(H,96,125)(H,97,128)(H,98,114)(H,99,126)(H,100,117)(H,101,119)(H,102,121)(H,103,122)(H,104,118)(H,105,123)(H,106,124)(H,107,127)(H4,87,88,91)(H4,89,90,92)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMPHIBZ CS C[C@H]([C@@H](C(=O)NCC(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMPHIBZ IK JKAMREUJRZWECK-FKPOJLNCSA-N
DMPHIBZ IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]pentanediamide
DMPHIBZ DE Discovery agent
DMXH2D8 ID DMXH2D8
DMXH2D8 DN F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH
DMXH2D8 HS Investigative
DMXH2D8 PC 91932093
DMXH2D8 MW 1823.1
DMXH2D8 FM C80H131N27O22
DMXH2D8 IC InChI=1S/C80H131N27O22/c1-42(2)34-55(73(123)95-44(4)66(116)103-57(37-60(85)111)74(124)102-54(78(128)129)28-29-59(84)110)104-71(121)50(24-14-16-30-81)100-69(119)52(26-18-32-90-79(86)87)98-65(115)43(3)96-76(126)58(41-108)105-72(122)51(25-15-17-31-82)101-70(120)53(27-19-33-91-80(88)89)99-67(117)45(5)107(7)63(114)40-94-77(127)64(46(6)109)106-75(125)56(36-48-22-12-9-13-23-48)97-62(113)39-92-61(112)38-93-68(118)49(83)35-47-20-10-8-11-21-47/h8-13,20-23,42-46,49-58,64,108-109H,14-19,24-41,81-83H2,1-7H3,(H2,84,110)(H2,85,111)(H,92,112)(H,93,118)(H,94,127)(H,95,123)(H,96,126)(H,97,113)(H,98,115)(H,99,117)(H,100,119)(H,101,120)(H,102,124)(H,103,116)(H,104,121)(H,105,122)(H,106,125)(H,128,129)(H4,86,87,90)(H4,88,89,91)/t43-,44-,45-,46+,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-/m0/s1
DMXH2D8 CS C[C@H]([C@@H](C(=O)NCC(=O)N(C)[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMXH2D8 IK AZDMRQCLZWWKEK-FKPOJLNCSA-N
DMXH2D8 IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]-methylamino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMXH2D8 DE Discovery agent
DMD9UQN ID DMD9UQN
DMD9UQN DN FGGFTRKRKSARKLANQ
DMD9UQN HS Investigative
DMD9UQN PC 91934901
DMD9UQN MW 1965.3
DMD9UQN FM C86H145N31O22
DMD9UQN IC InChI=1S/C86H145N31O22/c1-46(2)39-60(78(133)104-48(4)70(125)114-62(42-65(92)121)79(134)113-59(83(138)139)31-32-64(91)120)115-76(131)54(26-13-16-34-88)109-73(128)56(28-18-36-99-84(93)94)107-69(124)47(3)105-81(136)63(45-118)116-77(132)55(27-14-17-35-89)110-74(129)57(29-19-37-100-85(95)96)111-72(127)53(25-12-15-33-87)108-75(130)58(30-20-38-101-86(97)98)112-82(137)68(49(5)119)117-80(135)61(41-51-23-10-7-11-24-51)106-67(123)44-102-66(122)43-103-71(126)52(90)40-50-21-8-6-9-22-50/h6-11,21-24,46-49,52-63,68,118-119H,12-20,25-45,87-90H2,1-5H3,(H2,91,120)(H2,92,121)(H,102,122)(H,103,126)(H,104,133)(H,105,136)(H,106,123)(H,107,124)(H,108,130)(H,109,128)(H,110,129)(H,111,127)(H,112,137)(H,113,134)(H,114,125)(H,115,131)(H,116,132)(H,117,135)(H,138,139)(H4,93,94,99)(H4,95,96,100)(H4,97,98,101)/t47-,48-,49+,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-/m0/s1
DMD9UQN CS C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMD9UQN IK SNTZLYOXEWYFBE-UTPVZXCMSA-N
DMD9UQN IU (2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoic acid
DMD9UQN DE Discovery agent
DM4T5DY ID DM4T5DY
DM4T5DY DN FGIN-1-27
DM4T5DY HS Investigative
DM4T5DY SN FGIN-1-27; 142720-24-9; N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide; Fgin 1 27; Fgin 1-27; N,N-Di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide; CHEMBL63154; 1H-Indole-3-acetamide, 2-(4-fluorophenyl)-N,N-dihexyl-; 2-(2-(4-fluorophenyl)-1H-indol-3-yl)-N,N-dihexylacetamide; 2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide; SR-01000075838; Tocris-0658; Lopac-D-8555; Biomol-NT_000279; Lopac0_000453; MLS002153299; SCHEMBL1229718; BPBio1_001277; AC1L313J; FGIN1-27; CHEBI:92171; CTK8E7869; DTXSID90162141
DM4T5DY DT Small molecular drug
DM4T5DY PC 132496
DM4T5DY MW 436.6
DM4T5DY FM C28H37FN2O
DM4T5DY IC InChI=1S/C28H37FN2O/c1-3-5-7-11-19-31(20-12-8-6-4-2)27(32)21-25-24-13-9-10-14-26(24)30-28(25)22-15-17-23(29)18-16-22/h9-10,13-18,30H,3-8,11-12,19-21H2,1-2H3
DM4T5DY CS CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)F
DM4T5DY IK VUWXAQFLTSBUDB-UHFFFAOYSA-N
DM4T5DY IU 2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide
DM4T5DY CA CAS 142720-24-9
DM4T5DY CB CHEBI:92171
DM4T5DY DE Discovery agent
DMH7LDX ID DMH7LDX
DMH7LDX DN FHT-2107
DMH7LDX HS Investigative
DMH7LDX SN EGFR-targeting siRNA agent, ForHumanTech
DMH7LDX CP ForHumanTech Co Ltd
DMH7LDX DT siRNA drug
DMH7LDX DE Discovery agent
DMFNTMY ID DMFNTMY
DMFNTMY DN Fibrates
DMFNTMY HS Investigative
DMFNTMY SN clofibric acid; 882-09-7; 2-(4-Chlorophenoxy)-2-methylpropanoic acid; Chlorofibrinic acid; Clofibrinic acid; Chlorfibrinic acid; Clofibrin; 2-(4-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID; Chlorophibrinic acid; PCIB; Clofibrate free acid; Clofibrinsaeure; Regulipid; Regadrin; PCPIB; 2-(p-Chlorophenoxy)-2-methylpropionic acid; 2-(4-Chlorophenoxy)isobutyric Acid; 4-CPIB; 2-(p-Chlorophenoxy)isobutyric acid; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-; alpha-(p-Chlorophenoxy)isobutyric acid; Acido clofibrico; Acide clofibrique; Acidum c
DMFNTMY DT Small molecular drug
DMFNTMY PC 2797
DMFNTMY MW 214.64
DMFNTMY FM C10H11ClO3
DMFNTMY IC InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)
DMFNTMY CS CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl
DMFNTMY IK TXCGAZHTZHNUAI-UHFFFAOYSA-N
DMFNTMY IU 2-(4-chlorophenoxy)-2-methylpropanoic acid
DMFNTMY CA CAS 882-09-7
DMFNTMY CB CHEBI:34648
DMFNTMY DE Dyslipidemia
DMUX702 ID DMUX702
DMUX702 DN Fibronectin extra domain A
DMUX702 HS Investigative
DMUX702 SN Fibronectin extra domain A (vaccine adjuvant); Fibronectin extra domain A (vaccine adjuvant), Digna Biotech; TLR-4 antagonist (protein recombinant, vaccination), Digna Biotech/University of Navarra
DMUX702 CP University of Navarra
DMUX702 DT Vaccine
DMUX702 DE Discovery agent
DMETVLB ID DMETVLB
DMETVLB DN Fidarestat(Stereoisomer)
DMETVLB HS Investigative
DMETVLB SN FIDARESTAT(STEREOISOMER); CHEMBL84060; (2R,4S)-2-AMINOFORMYL-6-FLUORO-SPIRO[CHROMAN-4,4'-IMIDAZOLIDINE]-2',5'-DIONE; Fir; AC1L9MSJ; (R,S)-FIDARESTAT; SCHEMBL48828; ZINC5704; BDBM50089423; (2R,4S)-6-Fluoro-2',5'-dioxospiro[2H-1-benzopyran-4(3H),4'-imidazolidine]-2-carboxamide; (2R,4S)-6-fluoro-2',5'-dioxo-2,3-dihydrospiro[chromene-4,4'-imidazolidine]-2-carboxamide; (2R,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMETVLB DT Small molecular drug
DMETVLB PC 449157
DMETVLB MW 279.22
DMETVLB FM C12H10FN3O4
DMETVLB IC InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12+/m0/s1
DMETVLB CS C1[C@H](OC2=C([C@@]13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N
DMETVLB IK WAAPEIZFCHNLKK-QPUJVOFHSA-N
DMETVLB IU (2S,4R)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
DMETVLB DE Discovery agent
DM29TVC ID DM29TVC
DM29TVC DN FIG 1
DM29TVC HS Investigative
DM29TVC SN CHEMBL428429; FIG 1; SCHEMBL5095865; BDBM50239276
DM29TVC DT Small molecular drug
DM29TVC PC 10193044
DM29TVC MW 293.4
DM29TVC FM C19H23N3
DM29TVC IC InChI=1S/C19H23N3/c1-22-17(16-5-3-2-4-6-16)20-21-18(22)19-10-13-7-14(11-19)9-15(8-13)12-19/h2-6,13-15H,7-12H2,1H3
DM29TVC CS CN1C(=NN=C1C23CC4CC(C2)CC(C4)C3)C5=CC=CC=C5
DM29TVC IK SPLKSRDVCTUAGF-UHFFFAOYSA-N
DM29TVC IU 3-(1-adamantyl)-4-methyl-5-phenyl-1,2,4-triazole
DM29TVC DE Discovery agent
DMP6GNY ID DMP6GNY
DMP6GNY DN Firocoxib
DMP6GNY HS Investigative
DMP6GNY SN Firocoxib; 189954-96-9; Equioxx; Previcox; Equixx; Librens; UNII-Y6V2W4S4WT; Y6V2W4S4WT; CHEMBL69998; CHEBI:76136; 3-(CYCLOPROPYLMETHOXY)-5,5-DIMETHYL-4-[4-(METHYLSULFONYL)PHENYL]-2(5H)-FURANONE; ML 1785713; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one; 3-(Cyclopropylmethoxy)-5,5-dimethyl-4-(4-(methylsulfonyl)phenyl)furan-2(5H)-one; Firocoxib [USAN:INN]; firocoxibum; 3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one; Firocoxib (USAN/INN); AC1L4LLA; ML-1,785,713
DMP6GNY DT Small molecular drug
DMP6GNY PC 208910
DMP6GNY MW 336.4
DMP6GNY FM C17H20O5S
DMP6GNY IC InChI=1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
DMP6GNY CS CC1(C(=C(C(=O)O1)OCC2CC2)C3=CC=C(C=C3)S(=O)(=O)C)C
DMP6GNY IK FULAPETWGIGNMT-UHFFFAOYSA-N
DMP6GNY IU 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one
DMP6GNY CA CAS 189954-96-9
DMP6GNY CB CHEBI:76136
DMP6GNY DE Discovery agent
DMW2VOX ID DMW2VOX
DMW2VOX DN FITC-LMNNAEHINQFYMFI
DMW2VOX HS Investigative
DMW2VOX PC 44577018
DMW2VOX MW 2258.6
DMW2VOX FM C107H136N22O27S3
DMW2VOX IC InChI=1S/C107H136N22O27S3/c1-10-55(5)88(103(151)125-79(51-85(111)135)99(147)116-68(35-37-82(108)132)91(139)119-73(44-58-21-14-12-15-22-58)98(146)121-74(46-60-29-31-62(130)32-30-60)97(145)118-70(39-41-158-8)93(141)120-75(45-59-23-16-13-17-24-59)101(149)129-89(104(152)153)56(6)11-2)128-102(150)76(47-61-52-112-53-113-61)122-92(140)69(36-38-86(136)137)115-90(138)57(7)114-95(143)77(49-83(109)133)124-100(148)78(50-84(110)134)123-94(142)71(40-42-159-9)117-96(144)72(43-54(3)4)127-106(157)126-67-27-20-26-66-87(67)105(154)156-107(66)64-25-18-19-28-80(64)155-81-48-63(131)33-34-65(81)107/h12-34,48,52-57,68-79,88-89,130-131H,10-11,35-47,49-51H2,1-9H3,(H2,108,132)(H2,109,133)(H2,110,134)(H2,111,135)(H,112,113)(H,114,143)(H,115,138)(H,116,147)(H,117,144)(H,118,145)(H,119,139)(H,120,141)(H,121,146)(H,122,140)(H,123,142)(H,124,148)(H,125,151)(H,128,150)(H,129,149)(H,136,137)(H,152,153)(H2,126,127,157)/t55-,56-,57-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,88?,89?,107?/m0/s1
DMW2VOX CS CC[C@H](C)C(C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NC([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=S)NC5=CC=CC6=C5C(=O)OC67C8=C(C=C(C=C8)O)OC9=CC=CC=C79
DMW2VOX IK IHNJXISEZYRUDB-YDQBPDQJSA-N
DMW2VOX IU (3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[(3'-hydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-yl)carbamothioylamino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoic acid
DMW2VOX DE Discovery agent
DM9K834 ID DM9K834
DM9K834 DN FKB-001
DM9K834 HS Investigative
DM9K834 SN FKB-001; 1-[2,2-DIFLUORO-2-(3,4,5-TRIMETHOXY-PHENYL)-ACETYL]-PIPERIDINE-2-CARBOXYLIC ACID 4-PHENYL-1-(3-PYRIDIN-3-YL-PROPYL)-BUTYL ESTER; (S)-4-phenyl-1-[3-(3-pyridyl)propyl]butyl N-[difluoro(3,4,5-trimethoxy)acetyl]-L-pipecolate; (1S)-4-phenyl-1-(3-pyridin-3-ylpropyl)butyl (2S)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate; (4S)-1-phenyl-7-(pyridin-3-yl)heptan-4-yl (2S)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate; 1j4r; AC1L9JNT; CHEBI:39485; DB02888
DM9K834 DT Small molecular drug
DM9K834 PC 446414
DM9K834 MW 624.7
DM9K834 FM C35H42F2N2O6
DM9K834 IC InChI=1S/C35H42F2N2O6/c1-42-30-22-27(23-31(43-2)32(30)44-3)35(36,37)34(41)39-21-8-7-19-29(39)33(40)45-28(17-9-14-25-12-5-4-6-13-25)18-10-15-26-16-11-20-38-24-26/h4-6,11-13,16,20,22-24,28-29H,7-10,14-15,17-19,21H2,1-3H3/t28-,29-/m0/s1
DM9K834 CS COC1=CC(=CC(=C1OC)OC)C(C(=O)N2CCCC[C@H]2C(=O)O[C@@H](CCCC3=CC=CC=C3)CCCC4=CN=CC=C4)(F)F
DM9K834 IK NBYCDVVSYOMFMS-VMPREFPWSA-N
DM9K834 IU [(4S)-1-phenyl-7-pyridin-3-ylheptan-4-yl] (2S)-1-[2,2-difluoro-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
DM9K834 CA CAS 251909-04-3
DM9K834 CB CHEBI:39485
DM9K834 DE Discovery agent
DMO7U62 ID DMO7U62
DMO7U62 DN FL104
DMO7U62 HS Investigative
DMO7U62 SN 885672-81-1; CHEMBL583981; [1,1'-Biphenyl]-4-carboxamide,N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-; FL104; CHEMBL204989; GTPL3501; SCHEMBL14204301; BDBM50414782; KB-63706
DMO7U62 DT Small molecular drug
DMO7U62 PC 11663047
DMO7U62 MW 392.9
DMO7U62 FM C24H25ClN2O
DMO7U62 IC InChI=1S/C24H25ClN2O/c1-27(2)17-16-23(20-12-14-22(25)15-13-20)26-24(28)21-10-8-19(9-11-21)18-6-4-3-5-7-18/h3-15,23H,16-17H2,1-2H3,(H,26,28)
DMO7U62 CS CN(C)CCC(C1=CC=C(C=C1)Cl)NC(=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMO7U62 IK JXJCJZNVWYQHIF-UHFFFAOYSA-N
DMO7U62 IU N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide
DMO7U62 DE Discovery agent
DMNWIYM ID DMNWIYM
DMNWIYM DN Flavanone
DMNWIYM HS Investigative
DMNWIYM SN FLAVANONE; 487-26-3; 2-Phenylchroman-4-one; 2,3-Dihydroflavone; 2-Phenyl-4-chromanone; 4-Flavanone; 2,3-Dihydro-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-2-phenyl-; 2-Phenyl-2,3-dihydro-4H-chromen-4-one; NSC-50393; 2,3-Dihydro-2-phenyl-4H-benzopyran-4-one; 2-Phenyl-chroman-4-one; 2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one; EINECS 207-654-8; NSC 50393; BRN 0183227; MLS002667384; CHEMBL274318; CHEBI:5070; ZONYXWQDUYMKFB-UHFFFAOYSA-N; NSC50393; 2-phenyl-2,3-dihydrochromen-4-one; MFCD00006841; (-)-Flavanone
DMNWIYM DT Small molecular drug
DMNWIYM PC 10251
DMNWIYM MW 224.25
DMNWIYM FM C15H12O2
DMNWIYM IC InChI=1S/C15H12O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-9,15H,10H2
DMNWIYM CS C1C(OC2=CC=CC=C2C1=O)C3=CC=CC=C3
DMNWIYM IK ZONYXWQDUYMKFB-UHFFFAOYSA-N
DMNWIYM IU 2-phenyl-2,3-dihydrochromen-4-one
DMNWIYM CA CAS 487-26-3
DMNWIYM CB CHEBI:5070
DMNWIYM DE Discovery agent
DM5S4GK ID DM5S4GK
DM5S4GK DN Flavin-Adenine Dinucleotide
DM5S4GK HS Investigative
DM5S4GK SN flavin adenine dinucleotide; Flavin-adenine dinucleotide; 146-14-5; FAD; flavitan; Flavine-adenine dinucleotide; Flanin F; UNII-ZC44YTI8KK; Flamitajin B; Adenine-flavin dinucleotide; Adenine-flavine dinucleotide; ZC44YTI8KK; Flavine adenosine diphosphate; Riboflavin 5'-adenosine diphosphate; Flaziren (free acid); Riboflavin-adenine dinucleotide; Adenine-riboflavin dinucleotide; Adenine-riboflavine dinucleotide; Riboflavine-adenine dinucleotide; Isoalloxazine-adenine dinucleotide; Flavin adenin dinucleotide; CHEBI:16238; flavin a
DM5S4GK DT Small molecular drug
DM5S4GK PC 643975
DM5S4GK MW 785.5
DM5S4GK FM C27H33N9O15P2
DM5S4GK IC InChI=1S/C27H33N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1
DM5S4GK CS CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O
DM5S4GK IK VWWQXMAJTJZDQX-UYBVJOGSSA-N
DM5S4GK IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] hydrogen phosphate
DM5S4GK CA CAS 146-14-5
DM5S4GK CB CHEBI:16238
DM5S4GK DE Discovery agent
DMEQH6J ID DMEQH6J
DMEQH6J DN Flavone
DMEQH6J HS Investigative
DMEQH6J SN Flavone; FLAVONE; 525-82-6; 2-Phenylchromone; 2-Phenyl-4H-chromen-4-one; 2-Phenyl-4-chromone; Asmacoril; 2-Phenyl-4H-1-benzopyran-4-one; 2-Phenyl-4-benzopyron; 4H-1-Benzopyran-4-one, 2-phenyl-; Chromocor; Cromaril; 2-phenylchromen-4-one; Phenylchromone; 2-Phenyl-chromen-4-one; 2-Phenyl-gamma-benzopyrone; 2-Phenylbenzopyran-4-one; Cromarile; 2-Phenyl-4H-benzopyran-4-one; Flavon; 2-Phenylchrome; UNII-S2V45N7G3B; NSC 19028; 2-Phenyl-4H-chromen-4-on; CCRIS 4288; NSC19028; EINECS 208-383-8; NSC-19028; BRN 0157598
DMEQH6J DT Small molecular drug
DMEQH6J PC 10680
DMEQH6J MW 222.24
DMEQH6J FM C15H10O2
DMEQH6J IC InChI=1S/C15H10O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-10H
DMEQH6J CS C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2
DMEQH6J IK VHBFFQKBGNRLFZ-UHFFFAOYSA-N
DMEQH6J IU 2-phenylchromen-4-one
DMEQH6J CA CAS 525-82-6
DMEQH6J CB CHEBI:42491
DMEQH6J DE Discovery agent
DMQSDM7 ID DMQSDM7
DMQSDM7 DN FLUANISONE
DMQSDM7 HS Investigative
DMQSDM7 SN Fluanisone; Haloanisone; Haloanison; Sedalande; Fluanison; 1480-19-9; Anti-Pica; Metorin; MD 2028; NSC 170977; R 2028; 2028 MD; R 2167; Fluanisonum [INN-Latin]; Fluanisona [INN-Spanish]; Fluanisone [INN:BAN:DCF]; UNII-1D0W98U1I4; EINECS 216-038-8; BRN 0707524; 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one; CHEMBL58792; 4-(4-(o-Methoxyphenyl)-1-piperazinyl)-p-fluorobutyrophenone; 4'-Fluoro-4-(4-(o-methoxyphenyl)-1-piperazinyl)butyrophenone; C21H25FN2O2; 1D0W98U1I4; Butyrophenone, 4'-fluoro-4-[4-(o-methoxyphenyl
DMQSDM7 DT Small molecular drug
DMQSDM7 PC 15139
DMQSDM7 MW 356.4
DMQSDM7 FM C21H25FN2O2
DMQSDM7 IC InChI=1S/C21H25FN2O2/c1-26-21-7-3-2-5-19(21)24-15-13-23(14-16-24)12-4-6-20(25)17-8-10-18(22)11-9-17/h2-3,5,7-11H,4,6,12-16H2,1H3
DMQSDM7 CS COC1=CC=CC=C1N2CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F
DMQSDM7 IK IRYFCWPNDIUQOW-UHFFFAOYSA-N
DMQSDM7 IU 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one
DMQSDM7 CA CAS 1480-19-9
DMQSDM7 DE Discovery agent
DMN8AP0 ID DMN8AP0
DMN8AP0 DN flufenamate
DMN8AP0 HS Investigative
DMN8AP0 SN Flufenamate; 2-[3-(trifluoromethyl)anilino]benzoate; 2-{[3-(trifluoromethyl)phenyl]amino}benzoate; 2-[[3-(trifluoromethyl)phenyl]amino]benzoate; 2pix; AC1MU9L1; GTPL4191; BDBM85514; CHEBI:520819; NSC_27881; ZB003097; CAS_530-78-9; CJ-00698; 2-(3-(trifluoromethyl)phenylamino)benzoate
DMN8AP0 DT Small molecular drug
DMN8AP0 PC 3637398
DMN8AP0 MW 280.22
DMN8AP0 FM C14H9F3NO2-
DMN8AP0 IC InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)/p-1
DMN8AP0 CS C1=CC=C(C(=C1)C(=O)[O-])NC2=CC=CC(=C2)C(F)(F)F
DMN8AP0 IK LPEPZBJOKDYZAD-UHFFFAOYSA-M
DMN8AP0 IU 2-[3-(trifluoromethyl)anilino]benzoate
DMN8AP0 CB CHEBI:520819
DMN8AP0 DE Discovery agent
DMW0HOG ID DMW0HOG
DMW0HOG DN FLUMEZAPINE
DMW0HOG HS Investigative
DMW0HOG DT Small molecular drug
DMW0HOG PC 135413528
DMW0HOG MW 330.4
DMW0HOG FM C17H19FN4S
DMW0HOG IC InChI=1S/C17H19FN4S/c1-11-9-13-16(22-7-5-21(2)6-8-22)19-15-10-12(18)3-4-14(15)20-17(13)23-11/h3-4,9-10,20H,5-8H2,1-2H3
DMW0HOG CS CC1=CC2=C(S1)NC3=C(C=C(C=C3)F)N=C2N4CCN(CC4)C
DMW0HOG IK JBHUBOISLBWHAR-UHFFFAOYSA-N
DMW0HOG IU 7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
DMW0HOG CA CAS 61325-80-2
DMW0HOG DE Discovery agent
DMLO9FU ID DMLO9FU
DMLO9FU DN Fluo-3
DMLO9FU HS Investigative
DMLO9FU SN 121714-13-4; 123632-39-3; 23D4W0B50Y; AC1L2XTQ; AKOS015894386; C11369; CHEBI:5107; CHEMBL509919; CTK8F0793; Fluo 3; Fluo-3; Fluo-3, suitable for fluorescence, ~70%; Fluo-3-AM; Glycine,N-[2-[2-[2-[bis(carboxymethyl)amino]-5-(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)phenoxy]ethoxy]-4-methylphenyl]-N-(carboxymethyl)-; OZLGRUXZXMRXGP-UHFFFAOYSA-N; SCHEMBL28109; UNII-23D4W0B50Y; ZINC8295051
DMLO9FU DT Small molecular drug
DMLO9FU PC 104978
DMLO9FU MW 769.537
DMLO9FU FM C36H30Cl2N2O13
DMLO9FU IC InChI=1S/C36H30Cl2N2O13/c1-18-2-4-24(39(14-32(43)44)15-33(45)46)30(8-18)51-6-7-52-31-9-19(3-5-25(31)40(16-34(47)48)17-35(49)50)36-20-10-22(37)26(41)12-28(20)53-29-13-27(42)23(38)11-21(29)36/h2-5,8-13,41H,6-7,14-17H2,1H3,(H,43,44)(H,45,46)(H,47,48)(H,49,50)
DMLO9FU CS CC1=CC(=C(C=C1)N(CC(=O)O)CC(=O)O)OCCOC2=C(C=CC(=C2)C3=C4C=C(C(=O)C=C4OC5=CC(=C(C=C53)Cl)O)Cl)N(CC(=O)O)CC(=O)O
DMLO9FU IK OZLGRUXZXMRXGP-UHFFFAOYSA-N
DMLO9FU IU 2-[2-[2-[2-[bis(carboxymethyl)amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-N-(carboxymethyl)-4-methylanilino]acetic acid
DMLO9FU CA CAS 123632-39-3
DMLO9FU CB ChEBI:5107
DMJS62X ID DMJS62X
DMJS62X DN Fluoro loxoprofen
DMJS62X HS Investigative
DMJS62X SN fluoro loxoprofen
DMJS62X DT Small molecular drug
DMJS62X PC 49837499
DMJS62X MW 286.27
DMJS62X FM C15H16FNaO3
DMJS62X IC InChI=1S/C15H17FO3.Na/c1-9(15(18)19)12-6-5-10(8-13(12)16)7-11-3-2-4-14(11)17;/h5-6,8-9,11H,2-4,7H2,1H3,(H,18,19);/q;+1/p-1
DMJS62X CS CC(C1=C(C=C(C=C1)CC2CCCC2=O)F)C(=O)[O-].[Na+]
DMJS62X IK ISLFLEUBAXYHSW-UHFFFAOYSA-M
DMJS62X IU sodium;2-[2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl]propanoate
DMJS62X DE Discovery agent
DM0LR7G ID DM0LR7G
DM0LR7G DN FLUORO-NEPLANOCIN A
DM0LR7G HS Investigative
DM0LR7G SN CHEMBL64718; (1s,2r,5s)-5-(6-amino-9h-purin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; FLUORO-NEPLANOCIN A; AC1LAYBA; SCHEMBL9215628; ZINC3801483; BDBM50144206; KB-77273; 5-(6-Amino-purin-9-yl)-4-fluoro-3-hydroxymethyl-cyclopent-3-ene-1,2-diol; (1S,2R,5S)-5-(6-aminopurin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DM0LR7G DT Small molecular drug
DM0LR7G PC 498018
DM0LR7G MW 281.24
DM0LR7G FM C11H12FN5O3
DM0LR7G IC InChI=1S/C11H12FN5O3/c12-5-4(1-18)8(19)9(20)7(5)17-3-16-6-10(13)14-2-15-11(6)17/h2-3,7-9,18-20H,1H2,(H2,13,14,15)/t7-,8-,9+/m1/s1
DM0LR7G CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H](C(=C3F)CO)O)O)N
DM0LR7G IK RWUXFWACUXDNKY-HLTSFMKQSA-N
DM0LR7G IU (1S,2R,5S)-5-(6-aminopurin-9-yl)-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DM0LR7G DE Discovery agent
DMIRBYE ID DMIRBYE
DMIRBYE DN Fluoro-Phosphite Ion
DMIRBYE HS Investigative
DMIRBYE SN Fluorophosphate; FLUORO-PHOSPHITE ION; Phosphorofluoridate; UNII-4964UZ79MI; 15181-43-8; 4964UZ79MI; Monofluorophosphate(2-); Fluorotrioxophosphate(2-); Fluorophosphate (FPO32-); Monofluorophostae (PO3F2-); fluoridophosphate; Fluorophosphate ion (PFO32-); fluoro-dioxido-oxo-; AC1L22VV; fluoridotrioxidophosphate(2-); Phosphorofluoridate(8CI,9CI); CHEBI:42699; CTK0H6578; DTXSID90164882; 7789-74-4 (calcium salt); 15600-53-0 (barium salt); DB02348; [PFO3](2-); 10163-15-2 (di-hydrochloride salt); 7631-97-2 (unspecified hydrochloride sa
DMIRBYE DT Small molecular drug
DMIRBYE PC 65241
DMIRBYE MW 97.97
DMIRBYE FM FO3P-2
DMIRBYE IC InChI=1S/FH2O3P/c1-5(2,3)4/h(H2,2,3,4)/p-2
DMIRBYE CS [O-]P(=O)([O-])F
DMIRBYE IK DWYMPOCYEZONEA-UHFFFAOYSA-L
DMIRBYE IU fluoro-dioxido-oxo-lambda5-phosphane
DMIRBYE CA CAS 15181-43-8
DMIRBYE CB CHEBI:42699
DMIRBYE DE Discovery agent
DMELB5S ID DMELB5S
DMELB5S DN Flupentixole
DMELB5S HS Investigative
DMELB5S SN (E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DMELB5S DT Small molecular drug
DMELB5S PC 5281878
DMELB5S MW 434.5
DMELB5S FM C23H25F3N2OS
DMELB5S IC InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5+
DMELB5S CS C1CN(CCN1CC/C=C/2\\C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DMELB5S IK NJMYODHXAKYRHW-BLLMUTORSA-N
DMELB5S IU 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DMELB5S CA CAS 53772-85-3
DMELB5S CB CHEBI:93235
DMELB5S DE Discovery agent
DMEGL84 ID DMEGL84
DMEGL84 DN FLUPERAMIDE
DMEGL84 HS Investigative
DMEGL84 SN Fluperamide; UNII-6H13T09362; 53179-10-5; CHEMBL421665; 6H13T09362; R-18910; Fluperamide [USAN:INN]; AC1L2ZCI; AC1Q4JI5; SCHEMBL120826; ZINC4216287; BDBM50017686; R 18,910; 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; 4-(4-Chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-1-piperidinebutyramide; 4-[4-(4-Chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide; 1-Piperidinebutanamide, 4-(4-
DMEGL84 DT Small molecular drug
DMEGL84 PC 131534
DMEGL84 MW 545
DMEGL84 FM C30H32ClF3N2O2
DMEGL84 IC InChI=1S/C30H32ClF3N2O2/c1-35(2)27(37)29(22-9-5-3-6-10-22,23-11-7-4-8-12-23)17-20-36-18-15-28(38,16-19-36)24-13-14-26(31)25(21-24)30(32,33)34/h3-14,21,38H,15-20H2,1-2H3
DMEGL84 CS CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)(C3=CC=CC=C3)C4=CC=CC=C4
DMEGL84 IK WPYGCZCMGMVGNO-UHFFFAOYSA-N
DMEGL84 IU 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
DMEGL84 CA CAS 53179-10-5
DMEGL84 DE Discovery agent
DM9KIPU ID DM9KIPU
DM9KIPU DN fluperlapine
DM9KIPU HS Investigative
DM9KIPU SN C10967
DM9KIPU DT Small molecular drug
DM9KIPU PC 49381
DM9KIPU MW 309.4
DM9KIPU FM C19H20FN3
DM9KIPU IC InChI=1S/C19H20FN3/c1-22-8-10-23(11-9-22)19-17-5-3-2-4-14(17)12-15-6-7-16(20)13-18(15)21-19/h2-7,13H,8-12H2,1H3
DM9KIPU CS CN1CCN(CC1)C2=NC3=C(CC4=CC=CC=C42)C=CC(=C3)F
DM9KIPU IK OBWGMKKHCLHVIE-UHFFFAOYSA-N
DM9KIPU IU 3-fluoro-6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine
DM9KIPU CA CAS 67121-76-0
DM9KIPU CB CHEBI:5122
DM9KIPU DE Discovery agent
DM496RP ID DM496RP
DM496RP DN Fluphenazine
DM496RP HS Investigative
DM496RP SN FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
DM496RP CP Bristol-Myers Squibb
DM496RP TC Antiviral Agents
DM496RP DT Small molecular drug
DM496RP PC 3372
DM496RP MW 437.5
DM496RP FM C22H26F3N3OS
DM496RP IC InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
DM496RP CS C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
DM496RP IK PLDUPXSUYLZYBN-UHFFFAOYSA-N
DM496RP IU 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
DM496RP CA CAS 69-23-8
DM496RP CB CHEBI:5123
DM496RP DE Psychotic disorders; Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DM9Q2PG ID DM9Q2PG
DM9Q2PG DN fluprostenol
DM9Q2PG HS Investigative
DM9Q2PG SN Fluprostenol; travoprost acid; (+)-fluprostenol; Fluprostenolum; travoprost free acid; ICI 81,008; UNII-MEH3MCE8X1; EINECS 255-029-3; 40666-16-8; CHEBI:60782; MEH3MCE8X1; 54276-17-4; NCGC00160386-01; Fluprostenol [INN:BAN]; ICI 81008; Fluprostenolum [INN-Latin]; AL-5848; rac-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoic acid; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic; ICI 81008; [3H](+)-fluprostenol
DM9Q2PG DT Small molecular drug
DM9Q2PG PC 5311100
DM9Q2PG MW 458.5
DM9Q2PG FM C23H29F3O6
DM9Q2PG IC InChI=1S/C23H29F3O6/c24-23(25,26)15-6-5-7-17(12-15)32-14-16(27)10-11-19-18(20(28)13-21(19)29)8-3-1-2-4-9-22(30)31/h1,3,5-7,10-12,16,18-21,27-29H,2,4,8-9,13-14H2,(H,30,31)/b3-1-,11-10+/t16-,18-,19-,20+,21-/m1/s1
DM9Q2PG CS C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)C/C=C\\CCCC(=O)O)O
DM9Q2PG IK WWSWYXNVCBLWNZ-QIZQQNKQSA-N
DM9Q2PG IU (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid
DM9Q2PG CA CAS 40666-16-8
DM9Q2PG CB CHEBI:60782
DM9Q2PG DE Discovery agent
DMUOHVL ID DMUOHVL
DMUOHVL DN FLUTROLINE
DMUOHVL HS Investigative
DMUOHVL SN FLUTROLINE; 70801-02-4; CP-36,584; Flutrolinum; Flutrolino; 2H-Pyrido(4,3-b)indole-2-butanol, 8-fluoro-alpha,5-bis(4-fluorophenyl)-1,3,4,5-tetrahydro-, (+-)-; Flutroline [USAN:INN]; Flutrolinum [INN-Latin]; Flutrolino [INN-Spanish]; 62655-22-5; CP 36,584; AC1L1ALJ; Flutroline (USAN/INN); CHEMBL57241; SCHEMBL121860; OYGDOCFZQVGFIP-UHFFFAOYSA-N; (2-Parafluorophenyl-4-hydroxybutyl)-5-parafluorophenyl-8-fluoro-1,2,3,4-tetrahydro-gamma-carboline
DMUOHVL DT Small molecular drug
DMUOHVL PC 51174
DMUOHVL MW 450.5
DMUOHVL FM C27H25F3N2O
DMUOHVL IC InChI=1S/C27H25F3N2O/c28-19-5-3-18(4-6-19)27(33)2-1-14-31-15-13-26-24(17-31)23-16-21(30)9-12-25(23)32(26)22-10-7-20(29)8-11-22/h3-12,16,27,33H,1-2,13-15,17H2
DMUOHVL CS C1CN(CC2=C1N(C3=C2C=C(C=C3)F)C4=CC=C(C=C4)F)CCCC(C5=CC=C(C=C5)F)O
DMUOHVL IK OYGDOCFZQVGFIP-UHFFFAOYSA-N
DMUOHVL IU 4-[8-fluoro-5-(4-fluorophenyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)butan-1-ol
DMUOHVL CA CAS 70801-02-4
DMUOHVL DE Discovery agent
DMXK6EI ID DMXK6EI
DMXK6EI DN FM-101
DMXK6EI HS Investigative
DMXK6EI CP Femta Pharmaceuticals Inc
DMXK6EI DE Multiple myeloma
DM5782Z ID DM5782Z
DM5782Z DN FM1-10
DM5782Z HS Investigative
DM5782Z SN CHEMBL257643; 4-((E)-2-[4-(DIETHYLAMINO)PHENYL]ETHENYL)-1-[3-(TRIETHYLAMMONIO)PROPYL]PYRIDINIUM DIBROMIDE; AC1O6V5O; SCHEMBL1527145; AKOS000814322; ACM336185207; (E)-4-(4-(diethylamino)styryl)-1-(3-(triethylammonio)propyl)pyridinium bromide; 336185-20-7; 3-[4-[(E)-2-[4-(diethylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propyl-triethylazanium dibromide
DM5782Z DT Small molecular drug
DM5782Z PC 6508730
DM5782Z MW 555.4
DM5782Z FM C26H41Br2N3
DM5782Z IC InChI=1S/C26H41N3.2BrH/c1-6-28(7-2)26-16-14-24(15-17-26)12-13-25-18-21-27(22-19-25)20-11-23-29(8-3,9-4)10-5;;/h12-19,21-22H,6-11,20,23H2,1-5H3;2*1H/q+2;;/p-2
DM5782Z CS CCN(CC)C1=CC=C(C=C1)/C=C/C2=CC=[N+](C=C2)CCC[N+](CC)(CC)CC.[Br-].[Br-]
DM5782Z IK HLNKJDYNEWLULB-UHFFFAOYSA-L
DM5782Z IU 3-[4-[(E)-2-[4-(diethylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propyl-triethylazanium;dibromide
DM5782Z DE Discovery agent
DMAP8VY ID DMAP8VY
DMAP8VY DN FM1-43
DMAP8VY HS Investigative
DMAP8VY SN 149838-22-2; UNII-83IGZ86I9D; 83IGZ86I9D; CHEBI:52077; N-(3-(triethylammonium)propyl)-4-(4-(dibutylamino)styryl)pyridinium; Fm1 43; CHEMBL257431; FM 1-43; SynaptoGreen& C4; FM 1-43 dye; AC1O6V5E; SCHEMBL1527120; N-(3-(triethylammonium)propyl)-4-(2-(4-dibutylaminophenyl)vinyl)pyridinium; AKOS000814323; SynaptoGreen(TM) C4, > =95% (HPLC), solid; n-(3-triethylammoniumpropyl)-4-(4-(dibutylamino)styryl)pyridinium dibromide; 4-[2-[4-(dibutylamino)phenyl]ethenyl]-1-[3-(triethylammonio)propyl]-pyridiniumbromide
DMAP8VY DT Small molecular drug
DMAP8VY PC 6508724
DMAP8VY MW 611.5
DMAP8VY FM C30H49Br2N3
DMAP8VY IC InChI=1S/C30H49N3.2BrH/c1-6-11-23-32(24-12-7-2)30-18-16-28(17-19-30)14-15-29-20-25-31(26-21-29)22-13-27-33(8-3,9-4)10-5;;/h14-21,25-26H,6-13,22-24,27H2,1-5H3;2*1H/q+2;;/p-2
DMAP8VY CS CCCCN(CCCC)C1=CC=C(C=C1)/C=C/C2=CC=[N+](C=C2)CCC[N+](CC)(CC)CC.[Br-].[Br-]
DMAP8VY IK VZUVCAGXYLMFEC-UHFFFAOYSA-L
DMAP8VY IU 3-[4-[(E)-2-[4-(dibutylamino)phenyl]ethenyl]pyridin-1-ium-1-yl]propyl-triethylazanium;dibromide
DMAP8VY CA CAS 149838-22-2
DMAP8VY CB CHEBI:52077
DMAP8VY DE Discovery agent
DMZRI6H ID DMZRI6H
DMZRI6H DN FM-303
DMZRI6H HS Investigative
DMZRI6H SN IL-23 antagonist (ATLAb antibody technology, IBD), Femta Pharmaceuticals
DMZRI6H CP Femta Pharmaceuticals Inc
DMZRI6H DT Antibody
DMZRI6H DE Inflammatory bowel disease
DMQ391A ID DMQ391A
DMQ391A DN Fmet-leu-phe
DMQ391A HS Investigative
DMQ391A SN fMetLeuPhe; formyl-Met-Leu-Phe
DMQ391A DT Small molecular drug
DMQ391A PC 443295
DMQ391A MW 437.6
DMQ391A FM C21H31N3O5S
DMQ391A IC InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1
DMQ391A CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)NC=O
DMQ391A IK PRQROPMIIGLWRP-BZSNNMDCSA-N
DMQ391A IU (2S)-2-[[(2S)-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
DMQ391A CA CAS 59880-97-6
DMQ391A CB CHEBI:53490
DMW5V9U ID DMW5V9U
DMW5V9U DN FMP-825
DMW5V9U HS Investigative
DMW5V9U SN Obesity therapeutics, MDI; Anti-obesity agent, MDI; Beta-3 adrenoceptor agonist, Molecular Design International; Beta-3 adrenoceptor agonists (obesity/diabetes); Beta-3 adrenoceptor agonists (obesity/diabetes), MDI
DMW5V9U CP Molecular Design International Inc
DMW5V9U DE Diabetic complication
DMQBTL3 ID DMQBTL3
DMQBTL3 DN FMS586
DMQBTL3 HS Investigative
DMQBTL3 SN FMS 586; FMS-586
DMQBTL3 DT Small molecular drug
DMQBTL3 PC 11589975
DMQBTL3 MW 390.5
DMQBTL3 FM C24H30N4O
DMQBTL3 IC InChI=1S/C24H30N4O/c1-17(2)28-22-7-5-4-6-20(22)21-16-19(8-9-23(21)28)26-24(29)27(3)15-12-18-10-13-25-14-11-18/h8-11,13-14,16-17H,4-7,12,15H2,1-3H3,(H,26,29)
DMQBTL3 CS CC(C)N1C2=C(CCCC2)C3=C1C=CC(=C3)NC(=O)N(C)CCC4=CC=NC=C4
DMQBTL3 IK YLNOMVNCZMWDST-UHFFFAOYSA-N
DMQBTL3 IU 1-methyl-3-(9-propan-2-yl-5,6,7,8-tetrahydrocarbazol-3-yl)-1-(2-pyridin-4-ylethyl)urea
DMQBTL3 DE Discovery agent
DMJ4F3Q ID DMJ4F3Q
DMJ4F3Q DN Folate gamma-hydroxamic acid
DMJ4F3Q HS Investigative
DMJ4F3Q DT Small molecular drug
DMJ4F3Q PC 136177317
DMJ4F3Q MW 456.4
DMJ4F3Q FM C19H20N8O6
DMJ4F3Q IC InChI=1S/C19H20N8O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(28)27-33/h1-4,8,12,21,33H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1
DMJ4F3Q CS C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)NO)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N
DMJ4F3Q IK TZBJIYPNYFAUQG-LBPRGKRZSA-N
DMJ4F3Q IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-(hydroxyamino)-5-oxopentanoic acid
DMJ4F3Q DE Discovery agent
DM76AUO ID DM76AUO
DM76AUO DN Folate gamma-L-phenylalaninehydroxamic acid
DM76AUO HS Investigative
DM76AUO DT Small molecular drug
DM76AUO PC 136117931
DM76AUO MW 603.6
DM76AUO FM C28H29N9O7
DM76AUO IC InChI=1S/C28H29N9O7/c29-28-35-23-22(26(41)36-28)32-18(14-31-23)13-30-17-8-6-16(7-9-17)24(39)34-19(27(42)43)10-11-21(38)33-20(25(40)37-44)12-15-4-2-1-3-5-15/h1-9,14,19-20,30,44H,10-13H2,(H,33,38)(H,34,39)(H,37,40)(H,42,43)(H3,29,31,35,36,41)/t19-,20-/m0/s1
DM76AUO CS C1=CC=C(C=C1)C[C@@H](C(=O)NO)NC(=O)CC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=CN=C4C(=N3)C(=O)NC(=N4)N
DM76AUO IK WYBGJFMKGROIBY-PMACEKPBSA-N
DM76AUO IU (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DM76AUO DE Discovery agent
DMH5SQV ID DMH5SQV
DMH5SQV DN Folate gamma-L-proline-hydroxamic acid
DMH5SQV HS Investigative
DMH5SQV SN CHEMBL388878
DMH5SQV DT Small molecular drug
DMH5SQV PC 44428663
DMH5SQV MW 553.5
DMH5SQV FM C24H27N9O7
DMH5SQV IC InChI=1S/C24H27N9O7/c25-24-30-19-18(22(37)31-24)28-14(11-27-19)10-26-13-5-3-12(4-6-13)20(35)29-15(23(38)39)7-8-17(34)33-9-1-2-16(33)21(36)32-40/h3-6,11,15-16,18,26,40H,1-2,7-10H2,(H,29,35)(H,32,36)(H,38,39)(H2,25,31,37)/t15-,16-,18?/m0/s1
DMH5SQV CS C1C[C@H](N(C1)C(=O)CC[C@@H](C(=O)O)NC(=O)C2=CC=C(C=C2)NCC3=NC4C(=NC(=NC4=O)N)N=C3)C(=O)NO
DMH5SQV IK RDZUJKVCOZNTDE-MZQXSQAVSA-N
DMH5SQV IU (2S)-2-[[4-[(2-amino-4-oxo-4aH-pteridin-6-yl)methylamino]benzoyl]amino]-5-[(2S)-2-(hydroxycarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid
DMH5SQV DE Discovery agent
DMEPZ2I ID DMEPZ2I
DMEPZ2I DN folipastatin
DMEPZ2I HS Investigative
DMEPZ2I SN 139959-71-0
DMEPZ2I DT Small molecular drug
DMEPZ2I PC 6439424
DMEPZ2I MW 380.4
DMEPZ2I FM C23H24O5
DMEPZ2I IC InChI=1S/C23H24O5/c1-7-11(3)15-9-17(24)13(5)20-19(15)23(26)28-21-14(6)18(25)10-16(12(4)8-2)22(21)27-20/h7-10,24-25H,1-6H3/b11-7-,12-8-
DMEPZ2I CS C/C=C(/C)\\C1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=CC(=C3C)O)/C(=C\\C)/C)C)O
DMEPZ2I IK JJMKBGPTPXPMBH-OXAWKVHCSA-N
DMEPZ2I IU 1,7-bis[(Z)-but-2-en-2-yl]-3,9-dihydroxy-4,10-dimethylbenzo[b][1,4]benzodioxepin-6-one
DMEPZ2I CA CAS 139959-71-0
DMEPZ2I DE Discovery agent
DMSBQL0 ID DMSBQL0
DMSBQL0 DN FOLITENOL
DMSBQL0 HS Investigative
DMSBQL0 SN folitenol; CHEMBL551155; BDBM50311579
DMSBQL0 DT Small molecular drug
DMSBQL0 PC 15840592
DMSBQL0 MW 390.5
DMSBQL0 FM C25H26O4
DMSBQL0 IC InChI=1S/C25H26O4/c1-14(2)5-6-15-11-18-22(12-20(15)26)27-13-19-16-7-8-21-17(23(16)28-24(18)19)9-10-25(3,4)29-21/h5,7-12,19,24,26H,6,13H2,1-4H3/t19-,24-/m0/s1
DMSBQL0 CS CC(=CCC1=CC2=C(C=C1O)OC[C@@H]3[C@H]2OC4=C3C=CC5=C4C=CC(O5)(C)C)C
DMSBQL0 IK XERSCIKBWOLVNC-CYFREDJKSA-N
DMSBQL0 IU (2R,11R)-17,17-dimethyl-8-(3-methylbut-2-enyl)-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaen-7-ol
DMSBQL0 DE Discovery agent
DM7Q6M0 ID DM7Q6M0
DM7Q6M0 DN Formaldehyde
DM7Q6M0 HS Investigative
DM7Q6M0 SN formalin; methanal; formol; Paraformaldehyde; Methylene oxide; 50-00-0; Oxomethane; Paraform; Formic aldehyde; Oxymethylene; Methyl aldehyde; Formalith; Fannoform; Formaldehyde solution; Superlysoform; Methaldehyde; Morbicid; Formalina; Lysoform; Karsan; Formaline; Oxomethylene; Formaldehyd; Polyoxymethylene; Aldehyde formique; FYDE; Formaldehyde, gas; Formalin 40; Aldeide formica; 30525-89-4; Oplossingen; Dormol; Polyformaldehyde; Formalin-loesungen; Paraformic aldehyde; Rcra waste number U122; Aldacide; Paraformaldehydum
DM7Q6M0 DT Small molecular drug
DM7Q6M0 PC 712
DM7Q6M0 MW 30.026
DM7Q6M0 FM CH2O
DM7Q6M0 IC InChI=1S/CH2O/c1-2/h1H2
DM7Q6M0 CS C=O
DM7Q6M0 IK WSFSSNUMVMOOMR-UHFFFAOYSA-N
DM7Q6M0 IU formaldehyde
DM7Q6M0 CA CAS 50-00-0
DM7Q6M0 CB CHEBI:16842
DM7Q6M0 DE Discovery agent
DMNFZC6 ID DMNFZC6
DMNFZC6 DN Formic Acid
DMNFZC6 HS Investigative
DMNFZC6 SN formate; Formic acid, ion(1-); HCO2 anion; 71-47-6; formylate; aminate; methanoate; hydrogen carboxylate; CHEMBL183491; formiate; Formate ion; a carboxyl group; Hydrogencarboxylic acid; HCOO-; AC1L18W4; GTPL4540; CTK5I5292; CHEBI:15740; DTXSID60221219; BDAGIHXWWSANSR-UHFFFAOYSA-M; BDBM50155538; STL483235
DMNFZC6 DT Small molecular drug
DMNFZC6 PC 284
DMNFZC6 MW 46.025
DMNFZC6 FM CH2O2
DMNFZC6 IC InChI=1S/CH2O2/c2-1-3/h1H,(H,2,3)
DMNFZC6 CS C(=O)O
DMNFZC6 IK BDAGIHXWWSANSR-UHFFFAOYSA-N
DMNFZC6 IU formic acid
DMNFZC6 CA CAS 64-18-6
DMNFZC6 CB CHEBI:30751
DMNFZC6 DE Discovery agent
DM7WFZ8 ID DM7WFZ8
DM7WFZ8 DN Formononetin
DM7WFZ8 HS Investigative
DM7WFZ8 SN formononetin; 485-72-3; Biochanin B; Formononetol; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-4'-methoxyisoflavone; 4'-O-methyldaidzein; 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; UNII-295DQC67BJ; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; CHEBI:18088; Isoflavone, 7-hydroxy-4'-methoxy-; EINECS 207-623-9; NSC 93360; NSC-93360; 7-Hydroxy-3-(4-methoxyphenyl)chromone; 295DQC67BJ; HKQYGTCOTHHOMP-UHFFFAOYSA-N; NSC93360; AK106172
DM7WFZ8 DT Small molecular drug
DM7WFZ8 PC 5280378
DM7WFZ8 MW 268.26
DM7WFZ8 FM C16H12O4
DM7WFZ8 IC InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3
DM7WFZ8 CS COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O
DM7WFZ8 IK HKQYGTCOTHHOMP-UHFFFAOYSA-N
DM7WFZ8 IU 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one
DM7WFZ8 CA CAS 485-72-3
DM7WFZ8 CB CHEBI:18088
DM7WFZ8 DE Discovery agent
DMWG0P3 ID DMWG0P3
DMWG0P3 DN Formycin
DMWG0P3 HS Investigative
DMWG0P3 SN Formycin; formycin A; CHEBI:42452; 6742-12-7; (1S)-1-(7-amino-1H-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-D-ribitol; FMC; 2qtt; NSC 102811; BRN 0624229; 1nc3; 8-Aza-9-deazaadenosine; AC1L9KKW; 7-Amino-3-beta-D-ribofuranosyl-1H-pyrazolo(4,3-d)pyrimidine; SCHEMBL980049; 1H-Pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-D-ribofuranosyl-; CHEMBL471524; KBHMEHLJSZMEMI-KSYZLYKTSA-N; ZINC18275505; API0010090; DB02281; D-Ribitol, 1-C-(7-amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-, (S)- (9CI); D-Ribitol, 1-C-(7-amino-1H-pyrazolo[4
DMWG0P3 DT Small molecular drug
DMWG0P3 PC 447199
DMWG0P3 MW 267.24
DMWG0P3 FM C10H13N5O4
DMWG0P3 IC InChI=1S/C10H13N5O4/c11-10-6-4(12-2-13-10)5(14-15-6)9-8(18)7(17)3(1-16)19-9/h2-3,7-9,16-18H,1H2,(H,14,15)(H2,11,12,13)/t3-,7-,8-,9+/m1/s1
DMWG0P3 CS C1=NC2=C(NN=C2C(=N1)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMWG0P3 IK KBHMEHLJSZMEMI-KSYZLYKTSA-N
DMWG0P3 IU (2S,3R,4S,5R)-2-(7-amino-2H-pyrazolo[4,3-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMWG0P3 CA CAS 6742-12-7
DMWG0P3 CB CHEBI:42452
DMWG0P3 DE Discovery agent
DMHLYUM ID DMHLYUM
DMHLYUM DN Formycin B
DMHLYUM HS Investigative
DMHLYUM DT Small molecular drug
DMHLYUM PC 135449281
DMHLYUM MW 268.23
DMHLYUM FM C10H12N4O5
DMHLYUM IC InChI=1S/C10H12N4O5/c15-1-3-7(16)8(17)9(19-3)5-4-6(14-13-5)10(18)12-2-11-4/h2-3,7-9,15-17H,1H2,(H,13,14)(H,11,12,18)/t3-,7-,8-,9+/m1/s1
DMHLYUM CS C1=NC2=C(NN=C2C(=O)N1)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMHLYUM IK MTCJZZBQNCXKAP-KSYZLYKTSA-N
DMHLYUM IU 3-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
DMHLYUM CA CAS 13877-76-4
DMHLYUM CB CHEBI:42654
DMHLYUM DE Discovery agent
DMFOU92 ID DMFOU92
DMFOU92 DN FORMYLCHROMONE
DMFOU92 HS Investigative
DMFOU92 SN CHEMBL559311; BDBM50296368
DMFOU92 DT Small molecular drug
DMFOU92 PC 45273571
DMFOU92 MW 326.3
DMFOU92 FM C22H14O3
DMFOU92 IC InChI=1S/C22H14O3/c23-13-19-14-25-21-12-18(10-11-20(21)22(19)24)17-8-6-16(7-9-17)15-4-2-1-3-5-15/h1-14H
DMFOU92 CS C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)C(=CO4)C=O
DMFOU92 IK LWZMEMOPULJQIN-UHFFFAOYSA-N
DMFOU92 IU 4-oxo-7-(4-phenylphenyl)chromene-3-carbaldehyde
DMFOU92 DE Discovery agent
DMVBGAT ID DMVBGAT
DMVBGAT DN For-RYYRIK-NH2
DMVBGAT HS Investigative
DMVBGAT SN CHEMBL271478
DMVBGAT DT Small molecular drug
DMVBGAT PC 44456296
DMVBGAT MW 909.1
DMVBGAT FM C43H68N14O8
DMVBGAT IC InChI=1S/C43H68N14O8/c1-3-26(2)35(41(65)53-30(36(45)60)13-7-8-20-44)57-38(62)32(15-10-22-51-43(48)49)54-39(63)34(24-28-16-18-29(59)19-17-28)56-40(64)33(23-27-11-5-4-6-12-27)55-37(61)31(52-25-58)14-9-21-50-42(46)47/h4-6,11-12,16-19,25-26,30-35,59H,3,7-10,13-15,20-24,44H2,1-2H3,(H2,45,60)(H,52,58)(H,53,65)(H,54,63)(H,55,61)(H,56,64)(H,57,62)(H4,46,47,50)(H4,48,49,51)/t26-,30-,31-,32-,33-,34-,35-/m0/s1
DMVBGAT CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC=O
DMVBGAT IK ZABHXVCIKRRWGE-OLPQHFNPSA-N
DMVBGAT IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-formamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMVBGAT DE Discovery agent
DM6ITNG ID DM6ITNG
DM6ITNG DN Forskolin
DM6ITNG HS Investigative
DM6ITNG SN forskolin; Colforsin; 66575-29-9; Coleonol; colforsina; colforsinum; colforsine; Boforsin; Colforsinum [Latin]; Colforsine [French]; Colforsina [Spanish]; Coleonolk; Colforsin [USAN:INN]; UNII-1F7A44V6OU; 7beta-Acetoxy-8,13-epoxy-1alpha,6beta,9alpha-trihydroxylabd-14-en-11-one; EINECS 266-410-9; HL 362; (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate; NSC 357088; NSC 375489; Forskolin, Coleus forskohlii; CHEMBL52606; 1F7A44V6OU; L 75 1362B
DM6ITNG DT Small molecular drug
DM6ITNG PC 47936
DM6ITNG MW 410.5
DM6ITNG FM C22H34O7
DM6ITNG IC InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1
DM6ITNG CS CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)O
DM6ITNG IK OHCQJHSOBUTRHG-KGGHGJDLSA-N
DM6ITNG IU [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate
DM6ITNG CA CAS 66575-29-9
DM6ITNG CB CHEBI:42471
DM6ITNG DE Solid tumour/cancer
DMPC568 ID DMPC568
DMPC568 DN FORSYTHIASIDE
DMPC568 HS Investigative
DMPC568 SN Forsythoside A; Forsythiaside; 79916-77-1; UNII-OUH5BQ893P; CHEMBL504363; AC1NQZ1W; OUH5BQ893P; CHEBI:5160; MEGxp0_001187; [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; Forsythoside A; Forsythoside-A; SureCN3318896; SCHEMBL3318896; ACon1_001402; EBD9590; MolPort-001-741-410; ZINC8234345; BDBM50269517; NSC729638; AKOS015897128; NSC-729638; MCULE-6865459907
DMPC568 DT Small molecular drug
DMPC568 PC 5281773
DMPC568 MW 624.6
DMPC568 FM C29H36O15
DMPC568 IC InChI=1S/C29H36O15/c1-13-22(35)23(36)25(38)29(42-13)41-12-20-27(44-21(34)7-4-14-2-5-16(30)18(32)10-14)24(37)26(39)28(43-20)40-9-8-15-3-6-17(31)19(33)11-15/h2-7,10-11,13,20,22-33,35-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29+/m0/s1
DMPC568 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OCCC3=CC(=C(C=C3)O)O)O)O)OC(=O)/C=C/C4=CC(=C(C=C4)O)O)O)O)O
DMPC568 IK DTOUWTJYUCZJQD-UJERWXFOSA-N
DMPC568 IU [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
DMPC568 CA CAS 79916-77-1
DMPC568 CB CHEBI:5160
DMPC568 DE Discovery agent
DMYBQN9 ID DMYBQN9
DMYBQN9 DN FP0429
DMYBQN9 HS Investigative
DMYBQN9 SN FP 0429; FP-0429
DMYBQN9 DT Small molecular drug
DMYBQN9 PC 11565290
DMYBQN9 MW 272.21
DMYBQN9 FM C10H12N2O7
DMYBQN9 IC InChI=1S/C10H12N2O7/c11-10(9(18)19)3-5(8(16)17)12(4-10)6(13)1-2-7(14)15/h1-2,5H,3-4,11H2,(H,14,15)(H,16,17)(H,18,19)/b2-1+/t5-,10-/m0/s1
DMYBQN9 CS C1[C@H](N(C[C@@]1(C(=O)O)N)C(=O)/C=C/C(=O)O)C(=O)O
DMYBQN9 IK ZALHFQNLXQORTH-FGLATXDZSA-N
DMYBQN9 IU (2S,4S)-4-amino-1-[(E)-3-carboxyprop-2-enoyl]pyrrolidine-2,4-dicarboxylic acid
DMYBQN9 DE Discovery agent
DMGID4T ID DMGID4T
DMGID4T DN FP-1102
DMGID4T HS Investigative
DMGID4T SN Farbetics; FP-1101; AOC3 protein inhibitors (incipient vasculopathies), Faron Pharmaceuticals; Vascular adhesion protein 1 inhibitor (incipient vasculopathies), Faron Pharmaceuticals; Vitamin B1 analog (incipient vasculopathies), Faron Pharmaceuticals
DMGID4T CP Faron Pharmaceuticals Ltd
DMGID4T DE Vascular disease
DMB8U4F ID DMB8U4F
DMB8U4F DN FPL64176
DMB8U4F HS Investigative
DMB8U4F SN FPL-64176; FPL 64176
DMB8U4F DT Small molecular drug
DMB8U4F PC 3423
DMB8U4F MW 347.4
DMB8U4F FM C22H21NO3
DMB8U4F IC InChI=1S/C22H21NO3/c1-14-19(20(15(2)23-14)22(25)26-3)21(24)18-12-8-7-11-17(18)13-16-9-5-4-6-10-16/h4-12,23H,13H2,1-3H3
DMB8U4F CS CC1=C(C(=C(N1)C)C(=O)OC)C(=O)C2=CC=CC=C2CC3=CC=CC=C3
DMB8U4F IK MDMWHKZANMNXTF-UHFFFAOYSA-N
DMB8U4F IU methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
DMB8U4F CA CAS 120934-96-5
DMB8U4F CB CHEBI:249982
DMB8U4F DE Discovery agent
DM0T2LQ ID DM0T2LQ
DM0T2LQ DN FPT-038
DM0T2LQ HS Investigative
DM0T2LQ SN Hypoglycemic recombinant secreted protein (type 2 diabetes), Five Prime Therapeutics
DM0T2LQ CP FivePrime Therapeutics Inc
DM0T2LQ DE Non-insulin dependent diabetes
DMR2NBK ID DMR2NBK
DMR2NBK DN FPTQ
DMR2NBK HS Investigative
DMR2NBK SN FPTQ; 864863-72-9; CHEMBL1645352; 6-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]quinoline; SCHEMBL1499977; GTPL6353; MolPort-044-724-493; KS-00001CM0; BDBM50333367; ZINC66251948; AKOS028114901; CS-5754; HY-100382; F-185; 6-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]quinolone.
DMR2NBK DT Small molecular drug
DMR2NBK PC 11301185
DMR2NBK MW 305.31
DMR2NBK FM C17H12FN5
DMR2NBK IC InChI=1S/C17H12FN5/c1-11-16(13-6-7-14-12(10-13)4-2-8-19-14)21-22-23(11)15-5-3-9-20-17(15)18/h2-10H,1H3
DMR2NBK CS CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CC4=C(C=C3)N=CC=C4
DMR2NBK IK RTUBNVSZHGWRCV-UHFFFAOYSA-N
DMR2NBK IU 6-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]quinoline
DMR2NBK DE Discovery agent
DMDUR4C ID DMDUR4C
DMDUR4C DN FPYVAE peptide
DMDUR4C HS Investigative
DMDUR4C SN CHEMBL1165259; FPYVAE; GTPL3024; BDBM50321107; FPYVAE peptide [PMID: 20494585]; (2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]propanamido]pentanedioic acid
DMDUR4C DT Small molecular drug
DMDUR4C PC 46906163
DMDUR4C MW 724.8
DMDUR4C FM C36H48N6O10
DMDUR4C IC InChI=1S/C36H48N6O10/c1-20(2)30(34(49)38-21(3)31(46)39-26(36(51)52)15-16-29(44)45)41-32(47)27(19-23-11-13-24(43)14-12-23)40-33(48)28-10-7-17-42(28)35(50)25(37)18-22-8-5-4-6-9-22/h4-6,8-9,11-14,20-21,25-28,30,43H,7,10,15-19,37H2,1-3H3,(H,38,49)(H,39,46)(H,40,48)(H,41,47)(H,44,45)(H,51,52)/t21-,25-,26-,27-,28-,30-/m0/s1
DMDUR4C CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)N
DMDUR4C IK QKSOHTFYHNYHRK-YFVDCHTDSA-N
DMDUR4C IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]pentanedioic acid
DMDUR4C DE Discovery agent
DM7UP4E ID DM7UP4E
DM7UP4E DN FR-104
DM7UP4E HS Investigative
DM7UP4E SN Anti-CD28 (PEGylated formulation, transplant rejection/autoimmune disease), TcL Pharma
DM7UP4E CP TcL Pharma
DM7UP4E DT Antibody
DM7UP4E DE Autoimmune diabetes
DM6UWVB ID DM6UWVB
DM6UWVB DN FR117016
DM6UWVB HS Investigative
DM6UWVB SN FR117016; CHEMBL93647; 2-(4-{5-[(1H-1,3-benzodiazol-2-ylamino)methyl]thiophen-2-yl}-1,3-thiazol-2-yl)guanidine; N''-(4-(5-((1H-BENZIMIDAZOL-2-YLAMINO)METHYL)-2-THIENYL)-1,3-THIAZOL-2-YL)GUANIDINE; 1ndv; 2-(4-{5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl}-1,3-thiazol-2-yl)guanidine; 2-[4-[5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl]-1,3-thiazol-2-yl]guanidine; AC1L9KQW; BDBM22918; BDBM50170632; DB02616; FR0; N-(4-{5-[(1H-Benzoimidazol-2-ylamino)-methyl]-thiophen-2-yl}-thiazol-2-yl)-guanidine
DM6UWVB DT Small molecular drug
DM6UWVB PC 447339
DM6UWVB MW 369.5
DM6UWVB FM C16H15N7S2
DM6UWVB IC InChI=1S/C16H15N7S2/c17-14(18)23-16-22-12(8-24-16)13-6-5-9(25-13)7-19-15-20-10-3-1-2-4-11(10)21-15/h1-6,8H,7H2,(H2,19,20,21)(H4,17,18,22,23)
DM6UWVB CS C1=CC=C2C(=C1)NC(=N2)NCC3=CC=C(S3)C4=CSC(=N4)N=C(N)N
DM6UWVB IK CKJGKHXCUDWFDC-UHFFFAOYSA-N
DM6UWVB IU 2-[4-[5-[(1H-benzimidazol-2-ylamino)methyl]thiophen-2-yl]-1,3-thiazol-2-yl]guanidine
DM6UWVB DE Discovery agent
DMAYTWN ID DMAYTWN
DMAYTWN DN FR122047
DMAYTWN HS Investigative
DMAYTWN SN FR 122047; FR 122047 hydrochloride; FR-122047
DMAYTWN DT Small molecular drug
DMAYTWN PC 196840
DMAYTWN MW 460
DMAYTWN FM C23H26ClN3O3S
DMAYTWN IC InChI=1S/C23H25N3O3S.ClH/c1-25-12-14-26(15-13-25)23(27)22-24-20(16-4-8-18(28-2)9-5-16)21(30-22)17-6-10-19(29-3)11-7-17;/h4-11H,12-15H2,1-3H3;1H
DMAYTWN CS CN1CCN(CC1)C(=O)C2=NC(=C(S2)C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC.Cl
DMAYTWN IK YWMAVHIKOAOSFM-UHFFFAOYSA-N
DMAYTWN IU [4,5-bis(4-methoxyphenyl)-1,3-thiazol-2-yl]-(4-methylpiperazin-1-yl)methanone;hydrochloride
DMAYTWN CA CAS 130717-51-0
DMAYTWN DE Discovery agent
DMNMO83 ID DMNMO83
DMNMO83 DN FR-122788
DMNMO83 HS Investigative
DMNMO83 DE Discovery agent
DMZSFEP ID DMZSFEP
DMZSFEP DN FR161282
DMZSFEP HS Investigative
DMZSFEP SN SCHEMBL6701281; IOISKVCNGOOFMR-UHFFFAOYSA-N; L011765; 1-[2-Oxo-2-(4-methylpiperazino)ethyl]-5-[4-(4'-methyl-2-biphenylylcarbonylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-2-one; 5-{4-[2-(4-methylphenyl)benzoylamino]benzoyl}-1-[(4-methyl-1-piperazinyl)carbonylmethyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2(2H)-one
DMZSFEP DT Small molecular drug
DMZSFEP PC 9873768
DMZSFEP MW 615.7
DMZSFEP FM C37H37N5O4
DMZSFEP IC InChI=1S/C37H37N5O4/c1-26-11-13-27(14-12-26)30-7-3-4-8-31(30)36(45)38-29-17-15-28(16-18-29)37(46)41-20-19-34(43)42(33-10-6-5-9-32(33)41)25-35(44)40-23-21-39(2)22-24-40/h3-18H,19-25H2,1-2H3,(H,38,45)
DMZSFEP CS CC1=CC=C(C=C1)C2=CC=CC=C2C(=O)NC3=CC=C(C=C3)C(=O)N4CCC(=O)N(C5=CC=CC=C54)CC(=O)N6CCN(CC6)C
DMZSFEP IK IOISKVCNGOOFMR-UHFFFAOYSA-N
DMZSFEP IU 2-(4-methylphenyl)-N-[4-[5-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-4-oxo-2,3-dihydro-1,5-benzodiazepine-1-carbonyl]phenyl]benzamide
DMZSFEP DE Discovery agent
DMPCBXT ID DMPCBXT
DMPCBXT DN FR-166124
DMPCBXT HS Investigative
DMPCBXT SN FR-166124; CHEMBL59673; SCHEMBL6050347; AHLONZJYCGNSFG-UHFFFAOYSA-N; BDBM50079650; L013227; {2-[6-Oxo-3-(2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)-6H-pyridazin-1-yl]-cyclohex-1-enyl}-acetic acid
DMPCBXT DT Small molecular drug
DMPCBXT PC 9910335
DMPCBXT MW 426.5
DMPCBXT FM C25H22N4O3
DMPCBXT IC InChI=1S/C25H22N4O3/c30-22-14-13-19(26-29(22)20-11-5-4-10-18(20)16-23(31)32)24-21-12-6-7-15-28(21)27-25(24)17-8-2-1-3-9-17/h1-3,6-9,12-15H,4-5,10-11,16H2,(H,31,32)
DMPCBXT CS C1CCC(=C(C1)CC(=O)O)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMPCBXT IK AHLONZJYCGNSFG-UHFFFAOYSA-N
DMPCBXT IU 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]cyclohexen-1-yl]acetic acid
DMPCBXT DE Discovery agent
DM2W5VA ID DM2W5VA
DM2W5VA DN FR167344
DM2W5VA HS Investigative
DM2W5VA SN FR-167344; FR 167344
DM2W5VA DT Small molecular drug
DM2W5VA PC 9810391
DM2W5VA MW 673.4
DM2W5VA FM C30H28BrCl2N5O4
DM2W5VA IC InChI=1S/C30H28BrCl2N5O4/c1-18-28(31)38-15-5-6-24(29(38)35-18)42-17-21-22(32)12-13-23(27(21)33)37(4)26(40)16-34-25(39)14-9-19-7-10-20(11-8-19)30(41)36(2)3/h5-15H,16-17H2,1-4H3,(H,34,39)/b14-9+
DM2W5VA CS CC1=C(N2C=CC=C(C2=N1)OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CC=C(C=C4)C(=O)N(C)C)Cl)Br
DM2W5VA IK NDOBHDUXUJNXHX-NTEUORMPSA-N
DM2W5VA IU 4-[(E)-3-[[2-[3-[(3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl)oxymethyl]-2,4-dichloro-N-methylanilino]-2-oxoethyl]amino]-3-oxoprop-1-enyl]-N,N-dimethylbenzamide
DM2W5VA DE Discovery agent
DMQDP23 ID DMQDP23
DMQDP23 DN FR-175985
DMQDP23 HS Investigative
DMQDP23 SN CHEMBL49085; FR-175985; BDBM50290398; L014760
DMQDP23 DT Small molecular drug
DMQDP23 PC 9872735
DMQDP23 MW 567.7
DMQDP23 FM C33H34FN5O3
DMQDP23 IC InChI=1S/C33H34FN5O3/c1-21-7-6-8-24(17-21)35-33(42)37-31-32(41)39(20-29(40)38-18-22-13-14-23(19-38)16-15-22)28-12-5-3-10-26(28)30(36-31)25-9-2-4-11-27(25)34/h2-12,17,22-23,31H,13-16,18-20H2,1H3,(H2,35,37,42)
DMQDP23 CS CC1=CC(=CC=C1)NC(=O)NC2C(=O)N(C3=CC=CC=C3C(=N2)C4=CC=CC=C4F)CC(=O)N5CC6CCC(C5)CC6
DMQDP23 IK GWKWFUNKYXSZQP-UHFFFAOYSA-N
DMQDP23 IU 1-[1-[2-(3-azabicyclo[3.2.2]nonan-3-yl)-2-oxoethyl]-5-(2-fluorophenyl)-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMQDP23 DE Discovery agent
DM051PI ID DM051PI
DM051PI DN FR-180204
DM051PI HS Investigative
DM051PI SN 865362-74-9; FR 180204; FR180204; FR-180204; ERK Inhibitor II, FR180204; 5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine; CHEMBL259551; 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE; C18H13N7; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-1H-pyrazolo[3,4-c]pyridazin-3-amine; 5-{2-phenylpyrazolo[1,5-a]pyridin-3-yl}-2H-pyrazolo[3,4-c]pyridazin-3-amine; 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine; ERK inhibitor II; MLS002607685
DM051PI DT Small molecular drug
DM051PI PC 11493598
DM051PI MW 327.3
DM051PI FM C18H13N7
DM051PI IC InChI=1S/C18H13N7/c19-17-12-10-13(20-22-18(12)23-21-17)15-14-8-4-5-9-25(14)24-16(15)11-6-2-1-3-7-11/h1-10H,(H3,19,21,22,23)
DM051PI CS C1=CC=C(C=C1)C2=NN3C=CC=CC3=C2C4=CC5=C(NN=C5N=N4)N
DM051PI IK XVECMUKVOMUNLE-UHFFFAOYSA-N
DM051PI IU 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine
DM051PI CA CAS 865362-74-9
DM051PI CB CHEBI:91383
DM051PI DE Discovery agent
DM2V7U1 ID DM2V7U1
DM2V7U1 DN FR-181157
DM2V7U1 HS Investigative
DM2V7U1 SN SCHEMBL7960020; GTPL5854; FR181157; FR 181157; 2-[3-[[2-[4,5-di(phenyl)-1,3-oxazol-2-yl]-1-cyclohex-2-enyl]methyl]phenoxy]acetic acid
DM2V7U1 DT Small molecular drug
DM2V7U1 PC 23685469
DM2V7U1 MW 487.5
DM2V7U1 FM C30H26NNaO4
DM2V7U1 IC InChI=1S/C30H27NO4.Na/c32-27(33)20-34-25-16-9-10-21(19-25)18-24-15-7-8-17-26(24)30-31-28(22-11-3-1-4-12-22)29(35-30)23-13-5-2-6-14-23;/h1-6,9-14,16-17,19,24H,7-8,15,18,20H2,(H,32,33);/q;+1/p-1/t24-;/m0./s1
DM2V7U1 CS C1CC=C([C@@H](C1)CC2=CC(=CC=C2)OCC(=O)[O-])C3=NC(=C(O3)C4=CC=CC=C4)C5=CC=CC=C5.[Na+]
DM2V7U1 IK DPECFBBZFTXROT-JIDHJSLPSA-M
DM2V7U1 IU sodium;2-[3-[[(1S)-2-(4,5-diphenyl-1,3-oxazol-2-yl)cyclohex-2-en-1-yl]methyl]phenoxy]acetate
DM2V7U1 CA CAS 171046-15-4
DM2V7U1 DE Discovery agent
DM0G4HP ID DM0G4HP
DM0G4HP DN FR190997
DM0G4HP HS Investigative
DM0G4HP SN FR-190997; FR 190997
DM0G4HP DT Small molecular drug
DM0G4HP PC 5311114
DM0G4HP MW 698.6
DM0G4HP FM C37H33Cl2N5O5
DM0G4HP IC InChI=1S/C37H33Cl2N5O5/c1-23-19-32(48-21-26-7-4-5-18-41-26)27-8-6-9-31(36(27)43-23)49-22-28-29(38)15-16-30(35(28)39)44(3)34(46)20-42-33(45)17-12-24-10-13-25(14-11-24)37(47)40-2/h4-19H,20-22H2,1-3H3,(H,40,47)(H,42,45)/b17-12+
DM0G4HP CS CC1=CC(=C2C=CC=C(C2=N1)OCC3=C(C=CC(=C3Cl)N(C)C(=O)CNC(=O)/C=C/C4=CC=C(C=C4)C(=O)NC)Cl)OCC5=CC=CC=N5
DM0G4HP IK YFMDLMSUZMRKKH-SFQUDFHCSA-N
DM0G4HP IU 4-[(E)-3-[[2-[2,4-dichloro-N-methyl-3-[[2-methyl-4-(pyridin-2-ylmethoxy)quinolin-8-yl]oxymethyl]anilino]-2-oxoethyl]amino]-3-oxoprop-1-enyl]-N-methylbenzamide
DM0G4HP DE Discovery agent
DM75VHN ID DM75VHN
DM75VHN DN FR191413
DM75VHN HS Investigative
DM75VHN SN FR-191413; FR 191413
DM75VHN DT Small molecular drug
DM75VHN PC 10394861
DM75VHN MW 688.6
DM75VHN FM C34H31Cl2N7O5
DM75VHN IC InChI=1S/C34H31Cl2N7O5/c1-21(44)40-29-14-10-22(17-38-29)11-15-30(45)39-18-31(46)42(2)26-13-12-25(35)24(32(26)36)20-48-28-9-6-8-27-33(28)41-34(47-3)43(27)19-23-7-4-5-16-37-23/h4-17H,18-20H2,1-3H3,(H,39,45)(H,38,40,44)/b15-11+
DM75VHN CS CC(=O)NC1=NC=C(C=C1)/C=C/C(=O)NCC(=O)N(C)C2=C(C(=C(C=C2)Cl)COC3=CC=CC4=C3N=C(N4CC5=CC=CC=N5)OC)Cl
DM75VHN IK KXMCFJQQOFOBKN-RVDMUPIBSA-N
DM75VHN IU (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-3-[[2-methoxy-1-(pyridin-2-ylmethyl)benzimidazol-4-yl]oxymethyl]-N-methylanilino]-2-oxoethyl]prop-2-enamide
DM75VHN DE Discovery agent
DM9BS3W ID DM9BS3W
DM9BS3W DN FR-193262
DM9BS3W HS Investigative
DM9BS3W SN FR-193262; UNII-6799C86Z0K; 6799C86Z0K; CHEMBL190497; Acetic acid, (((5R)-5-((2R)-2-(4,5-diphenyl-2-oxazolyl)-1-pyrrolidinyl)-5,6,7,8-tetrahydro-1-naphthalenyl)oxy)-, sodium salt; Acetic acid, ((5-(2-(4,5-diphenyl-2-oxazolyl)-1-pyrrolidinyl)-5,6,7,8-tetrahydro-1-naphthalenyl)oxy)-, sodium salt, (R-(R*,R*))-; 187992-22-9; Acetic acid, 2-(((5R)-5-((2R)-2-(4,5-diphenyl-2-oxazolyl)-1-pyrrolidinyl)-5,6,7,8-tetrahydro-1-naphthalenyl)oxy)-, sodium salt (1:1)
DM9BS3W DT Small molecular drug
DM9BS3W PC 23664784
DM9BS3W MW 516.6
DM9BS3W FM C31H29N2NaO4
DM9BS3W IC InChI=1S/C31H30N2O4.Na/c34-28(35)20-36-27-18-8-14-23-24(27)15-7-16-25(23)33-19-9-17-26(33)31-32-29(21-10-3-1-4-11-21)30(37-31)22-12-5-2-6-13-22;/h1-6,8,10-14,18,25-26H,7,9,15-17,19-20H2,(H,34,35);/q;+1/p-1/t25-,26-;/m1./s1
DM9BS3W CS C1C[C@H](C2=C(C1)C(=CC=C2)OCC(=O)[O-])N3CCC[C@@H]3C4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6.[Na+]
DM9BS3W IK NRXVVCOCESTRSY-JUJAXGASSA-M
DM9BS3W IU sodium;2-[[(5R)-5-[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetate
DM9BS3W CA CAS 187992-22-9
DM9BS3W DE Discovery agent
DMISP7G ID DMISP7G
DMISP7G DN FR194921
DMISP7G HS Investigative
DMISP7G SN FR-194921; FR 194921
DMISP7G DT Small molecular drug
DMISP7G PC 9821511
DMISP7G MW 385.5
DMISP7G FM C23H23N5O
DMISP7G IC InChI=1S/C23H23N5O/c1-26-15-12-18(13-16-26)28-21(29)11-10-19(24-28)22-20-9-5-6-14-27(20)25-23(22)17-7-3-2-4-8-17/h2-11,14,18H,12-13,15-16H2,1H3
DMISP7G CS CN1CCC(CC1)N2C(=O)C=CC(=N2)C3=C4C=CC=CN4N=C3C5=CC=CC=C5
DMISP7G IK YHDRUTMZCJZJAL-UHFFFAOYSA-N
DMISP7G IU 2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3-one
DMISP7G CA CAS 202646-80-8
DMISP7G DE Discovery agent
DM70UQR ID DM70UQR
DM70UQR DN FR221647
DM70UQR HS Investigative
DM70UQR SN FR-221647; CHEMBL13696; 256461-28-6; 1H-Imidazole-4-carboxamide, 1-[1-(hydroxymethyl)-3-phenylpropyl]-; 1H-Imidazole-4-carboxamide, 1-(1-(hydroxymethyl)-3-phenylpropyl)-; FR221647; ZUYUIKKHHBEVHL-UHFFFAOYSA-N; AC1MHQ05; SCHEMBL7659103; CTK0J3882; BDBM22917; imidazole-4-carboxamide derivative, 1; AKOS030619368; 1-(1-hydroxy-4-phenyl-2-butyl)imidazole-4-carboxamide; 1-(1-hydroxy-4-phenylbutan-2-yl)imidazole-4-carboxamide; 1-[1-(hydroxymethyl)-3-phenyl-propyl]imidazole-4-carboxamide
DM70UQR DT Small molecular drug
DM70UQR PC 447340
DM70UQR MW 259.3
DM70UQR FM C14H17N3O2
DM70UQR IC InChI=1S/C14H17N3O2/c15-14(19)13-8-17(10-16-13)12(9-18)7-6-11-4-2-1-3-5-11/h1-5,8,10,12,18H,6-7,9H2,(H2,15,19)/t12-/m1/s1
DM70UQR CS C1=CC=C(C=C1)CC[C@H](CO)N2C=C(N=C2)C(=O)N
DM70UQR IK ZUYUIKKHHBEVHL-GFCCVEGCSA-N
DM70UQR IU 1-[(2R)-1-hydroxy-4-phenylbutan-2-yl]imidazole-4-carboxamide
DM70UQR CA CAS 256461-28-6
DM70UQR DE Discovery agent
DMBY3T5 ID DMBY3T5
DMBY3T5 DN FR-226928
DMBY3T5 HS Investigative
DMBY3T5 SN FR-226928; CHEMBL350620; FR-226928 free base; BDBM50110416; 1-Naphthalenesulfonamide, N-(2-(4-((((6,7,8,9-tetrahydro-3-methoxy-5H-benzocyclohepten-6-yl)methyl)amino)methyl)-1-piperidinyl)ethyl)-; 765261-46-9; Naphthalene-1-sulfonic acid [2-(4-{[(3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl)-amino]-methyl}-piperidin-1-yl)-ethyl]-amide
DMBY3T5 DT Small molecular drug
DMBY3T5 PC 10007341
DMBY3T5 MW 535.7
DMBY3T5 FM C31H41N3O3S
DMBY3T5 IC InChI=1S/C31H41N3O3S/c1-37-29-13-12-26-8-4-6-25(20-28(26)21-29)23-32-22-24-14-17-34(18-15-24)19-16-33-38(35,36)31-11-5-9-27-7-2-3-10-30(27)31/h2-3,5,7,9-13,21,24-25,32-33H,4,6,8,14-20,22-23H2,1H3
DMBY3T5 CS COC1=CC2=C(CCCC(C2)CNCC3CCN(CC3)CCNS(=O)(=O)C4=CC=CC5=CC=CC=C54)C=C1
DMBY3T5 IK ITJLZSOZZWEOJL-UHFFFAOYSA-N
DMBY3T5 IU N-[2-[4-[[(3-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)methylamino]methyl]piperidin-1-yl]ethyl]naphthalene-1-sulfonamide
DMBY3T5 CA CAS 765261-46-9
DMBY3T5 DE Discovery agent
DMKJQWR ID DMKJQWR
DMKJQWR DN FR-230481
DMKJQWR HS Investigative
DMKJQWR SN FR-230481; CHEMBL167991; BDBM50110571; FR230481; Naphthalene-1-sulfonic acid [2-(4-{[(1-hydroxy-7-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-amino]-methyl}-piperidin-1-yl)-ethyl]-amide
DMKJQWR DT Small molecular drug
DMKJQWR PC 10030142
DMKJQWR MW 537.7
DMKJQWR FM C30H39N3O4S
DMKJQWR IC InChI=1S/C30H39N3O4S/c1-37-26-12-11-25-8-5-15-30(34,28(25)20-26)22-31-21-23-13-17-33(18-14-23)19-16-32-38(35,36)29-10-4-7-24-6-2-3-9-27(24)29/h2-4,6-7,9-12,20,23,31-32,34H,5,8,13-19,21-22H2,1H3
DMKJQWR CS COC1=CC2=C(CCCC2(CNCC3CCN(CC3)CCNS(=O)(=O)C4=CC=CC5=CC=CC=C54)O)C=C1
DMKJQWR IK HROMPGSHGXAFBQ-UHFFFAOYSA-N
DMKJQWR IU N-[2-[4-[[(1-hydroxy-7-methoxy-3,4-dihydro-2H-naphthalen-1-yl)methylamino]methyl]piperidin-1-yl]ethyl]naphthalene-1-sulfonamide
DMKJQWR DE Discovery agent
DM3V0HA ID DM3V0HA
DM3V0HA DN FR230513
DM3V0HA HS Investigative
DM3V0HA SN FR230513; 1-((1R)-1-(HYDROXYMETHYL)-3-(1-NAPHTHYL)PROPYL)-1H-IMIDAZOLE-4-CARBOXAMIDE; 1ndy; AC1L9KR0; DB03572; 1-[(2R)-1-hydroxy-4-naphthalen-1-ylbutan-2-yl]imidazole-4-carboxamide; 1-[(2R)-1-hydroxy-4-(naphthalen-1-yl)butan-2-yl]imidazole-4-carboxamide; 1-[(1R)-1-(hydroxymethyl)-3-(1-naphthyl)propyl]imidazole-4-carboxamide; 1-[(1R)-1-(hydroxymethyl)-3-naphthalen-1-ylpropyl]-1H-imidazole-4-carboxamide; 1H-Imidazole-4-carboxamide, 1-[1-(hydroxymethyl)-3-(1-naphthalenyl)propyl]-
DM3V0HA DT Small molecular drug
DM3V0HA PC 447341
DM3V0HA MW 309.4
DM3V0HA FM C18H19N3O2
DM3V0HA IC InChI=1S/C18H19N3O2/c19-18(23)17-10-21(12-20-17)15(11-22)9-8-14-6-3-5-13-4-1-2-7-16(13)14/h1-7,10,12,15,22H,8-9,11H2,(H2,19,23)/t15-/m1/s1
DM3V0HA CS C1=CC=C2C(=C1)C=CC=C2CC[C@H](CO)N3C=C(N=C3)C(=O)N
DM3V0HA IK URGFTPMACWKJKU-OAHLLOKOSA-N
DM3V0HA IU 1-[(2R)-1-hydroxy-4-naphthalen-1-ylbutan-2-yl]imidazole-4-carboxamide
DM3V0HA DE Discovery agent
DMPD16N ID DMPD16N
DMPD16N DN FR-233118
DMPD16N HS Investigative
DMPD16N SN FR-233118; CHEMBL166606; BDBM50110562
DMPD16N DT Small molecular drug
DMPD16N PC 10052173
DMPD16N MW 514.1
DMPD16N FM C27H32ClN3O3S
DMPD16N IC InChI=1S/C27H32ClN3O3S/c1-34-23-7-5-19-3-2-4-22(13-20(19)14-23)29-16-18-9-11-30(12-10-18)26(32)17-31-24-15-21(28)6-8-25(24)35-27(31)33/h5-8,14-15,18,22,29H,2-4,9-13,16-17H2,1H3
DMPD16N CS COC1=CC2=C(CCCC(C2)NCC3CCN(CC3)C(=O)CN4C5=C(C=CC(=C5)Cl)SC4=O)C=C1
DMPD16N IK RYHPEQQPQCIMIB-UHFFFAOYSA-N
DMPD16N IU 5-chloro-3-[2-[4-[[(3-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)amino]methyl]piperidin-1-yl]-2-oxoethyl]-1,3-benzothiazol-2-one
DMPD16N DE Discovery agent
DMR251H ID DMR251H
DMR251H DN FR233623
DMR251H HS Investigative
DMR251H SN UNII-10302WQ21V; FR233623; CHEMBL93560; 10302WQ21V; 1H-Imidazole-4-carboxamide, 1-((1R,2S)-2-hydroxy-1-(2-(1-naphthalenyl)ethyl)propyl)-; 1-{(1R,2S)-2-HYDROXY-1-[2-(1-NAPHTHYL)ETHYL]PROPYL}-1H-IMIDAZOLE-4-CARBOXAMIDE; 1-[(1R,2S)-2-hydroxy-1-(2-naphthalen-1-ylethyl)propyl]-1H-imidazole-4-carboxamide; 1H-Imidazole-4-carboxamide, 1-[(1R,2S)-2-hydroxy-1-[2-(1-naphthalenyl)ethyl]propyl]-; OODDZQQDDOVCFD-SCLBCKFNSA-N; 2e1w; FR-234938; AC1L9MM5; (+)-FR-234938; 256461-79-7; SCHEMBL6172027; BDBM22948; imidazole-4-carboxamide analog
DMR251H DT Small molecular drug
DMR251H PC 449013
DMR251H MW 323.4
DMR251H FM C19H21N3O2
DMR251H IC InChI=1S/C19H21N3O2/c1-13(23)18(22-11-17(19(20)24)21-12-22)10-9-15-7-4-6-14-5-2-3-8-16(14)15/h2-8,11-13,18,23H,9-10H2,1H3,(H2,20,24)/t13-,18+/m0/s1
DMR251H CS C[C@@H]([C@@H](CCC1=CC=CC2=CC=CC=C21)N3C=C(N=C3)C(=O)N)O
DMR251H IK OODDZQQDDOVCFD-SCLBCKFNSA-N
DMR251H IU 1-[(3R,4S)-4-hydroxy-1-naphthalen-1-ylpentan-3-yl]imidazole-4-carboxamide
DMR251H CA CAS 256461-79-7
DMR251H DE Discovery agent
DMLH546 ID DMLH546
DMLH546 DN FR236913
DMLH546 HS Investigative
DMLH546 DT Small molecular drug
DMLH546 PC 447546
DMLH546 MW 446.5
DMLH546 FM C24H26N6O3
DMLH546 IC InChI=1S/C24H26N6O3/c25-23(32)21-14-30(16-27-21)20(15-31)9-11-29-10-8-18-6-7-19(12-22(18)29)28-24(33)26-13-17-4-2-1-3-5-17/h1-8,10,12,14,16,20,31H,9,11,13,15H2,(H2,25,32)(H2,26,28,33)/t20-/m1/s1
DMLH546 CS C1=CC=C(C=C1)CNC(=O)NC2=CC3=C(C=C2)C=CN3CC[C@H](CO)N4C=C(N=C4)C(=O)N
DMLH546 IK KCCUBLLGAMGDJL-HXUWFJFHSA-N
DMLH546 IU 1-[(2R)-4-[6-(benzylcarbamoylamino)indol-1-yl]-1-hydroxybutan-2-yl]imidazole-4-carboxamide
DMLH546 DE Discovery agent
DMMJDXT ID DMMJDXT
DMMJDXT DN FR239087
DMMJDXT HS Investigative
DMMJDXT SN AC1NRB3Z
DMMJDXT DT Small molecular drug
DMMJDXT PC 449014
DMMJDXT MW 342.2
DMMJDXT FM C15H17Cl2N3O2
DMMJDXT IC InChI=1S/C15H17Cl2N3O2/c1-9(21)13(20-7-12(15(18)22)19-8-20)6-5-10-3-2-4-11(16)14(10)17/h2-4,7-9,13,21H,5-6H2,1H3,(H2,18,22)/t9-,13+/m0/s1
DMMJDXT CS C[C@@H]([C@@H](CCC1=C(C(=CC=C1)Cl)Cl)N2C=C(N=C2)C(=O)N)O
DMMJDXT IK HCJYSIGJDKNVRU-TVQRCGJNSA-N
DMMJDXT IU 1-[(3R,4S)-1-(2,3-dichlorophenyl)-4-hydroxypentan-3-yl]imidazole-4-carboxamide
DMMJDXT DE Discovery agent
DMSQ6CV ID DMSQ6CV
DMSQ6CV DN FR260010
DMSQ6CV HS Investigative
DMSQ6CV SN FR-260010; FR 260010
DMSQ6CV DT Small molecular drug
DMSQ6CV PC 9968450
DMSQ6CV MW 353.4
DMSQ6CV FM C22H19N5
DMSQ6CV IC InChI=1S/C22H19N5/c1-15-12-27(14-25-15)18-7-4-6-17(11-18)26-22-20-10-9-16-5-2-3-8-19(16)21(20)23-13-24-22/h2-8,11-14H,9-10H2,1H3,(H,23,24,26)
DMSQ6CV CS CC1=CN(C=N1)C2=CC=CC(=C2)NC3=NC=NC4=C3CCC5=CC=CC=C54
DMSQ6CV IK LFKNMCJSJZOQJF-UHFFFAOYSA-N
DMSQ6CV IU N-[3-(4-methylimidazol-1-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine
DMSQ6CV DE Discovery agent
DMV0UM2 ID DMV0UM2
DMV0UM2 DN FR-73966
DMV0UM2 HS Investigative
DMV0UM2 SN FR-73966; CHEMBL279073; BDBM50110568; FR73966; 1-[2-(5-Chloro-2-oxo-benzothiazol-3-yl)-acetyl]-piperidine-4-carboxylic acid thiazol-2-ylamide
DMV0UM2 DT Small molecular drug
DMV0UM2 PC 9889267
DMV0UM2 MW 436.9
DMV0UM2 FM C18H17ClN4O3S2
DMV0UM2 IC InChI=1S/C18H17ClN4O3S2/c19-12-1-2-14-13(9-12)23(18(26)28-14)10-15(24)22-6-3-11(4-7-22)16(25)21-17-20-5-8-27-17/h1-2,5,8-9,11H,3-4,6-7,10H2,(H,20,21,25)
DMV0UM2 CS C1CN(CCC1C(=O)NC2=NC=CS2)C(=O)CN3C4=C(C=CC(=C4)Cl)SC3=O
DMV0UM2 IK MYSZTUDXDIGAGW-UHFFFAOYSA-N
DMV0UM2 IU 1-[2-(5-chloro-2-oxo-1,3-benzothiazol-3-yl)acetyl]-N-(1,3-thiazol-2-yl)piperidine-4-carboxamide
DMV0UM2 DE Discovery agent
DMMGWXQ ID DMMGWXQ
DMMGWXQ DN FR-900452
DMMGWXQ HS Investigative
DMMGWXQ SN 101706-33-6
DMMGWXQ DT Small molecular drug
DMMGWXQ PC 3035856
DMMGWXQ MW 411.5
DMMGWXQ FM C22H25N3O3S
DMMGWXQ IC InChI=1S/C22H25N3O3S/c1-12(18-13-7-4-5-9-16(13)25(2)22(18)28)19-20(14-8-6-10-17(14)26)23-15(11-29-3)21(27)24-19/h4-7,9-10,12,15,18-19,23H,8,11H2,1-3H3,(H,24,27)/b20-14+/t12-,15-,18-,19-/m0/s1
DMMGWXQ CS C[C@@H]([C@H]1C2=CC=CC=C2N(C1=O)C)[C@H]3/C(=C\\4/CC=CC4=O)/N[C@H](C(=O)N3)CSC
DMMGWXQ IK UAPDNDKYPBHNQT-WVPMBWLTSA-N
DMMGWXQ IU (3S)-1-methyl-3-[(1S)-1-[(2S,3E,5R)-5-(methylsulfanylmethyl)-6-oxo-3-(2-oxocyclopent-3-en-1-ylidene)piperazin-2-yl]ethyl]-3H-indol-2-one
DMMGWXQ CA CAS 101706-33-6
DMMGWXQ DE Discovery agent
DMEYNGP ID DMEYNGP
DMEYNGP DN frescolat MGA
DMEYNGP HS Investigative
DMEYNGP SN menthone 1,2-glycerol ketal
DMEYNGP DT Small molecular drug
DMEYNGP PC 162184
DMEYNGP MW 228.33
DMEYNGP FM C13H24O3
DMEYNGP IC InChI=1S/C13H24O3/c1-9(2)12-5-4-10(3)6-13(12)15-8-11(7-14)16-13/h9-12,14H,4-8H2,1-3H3
DMEYNGP CS CC1CCC(C2(C1)OCC(O2)CO)C(C)C
DMEYNGP IK ZBJCYZPANVLBRK-UHFFFAOYSA-N
DMEYNGP IU (9-methyl-6-propan-2-yl-1,4-dioxaspiro[4.5]decan-3-yl)methanol
DMEYNGP CA CAS 63187-91-7
DMEYNGP DE Discovery agent
DMIBCZJ ID DMIBCZJ
DMIBCZJ DN frescolat ML
DMIBCZJ HS Investigative
DMIBCZJ SN (-)-menthyl lactate
DMIBCZJ DT Small molecular drug
DMIBCZJ PC 62151
DMIBCZJ MW 228.33
DMIBCZJ FM C13H24O3
DMIBCZJ IC InChI=1S/C13H24O3/c1-8(2)11-6-5-9(3)7-12(11)16-13(15)10(4)14/h8-12,14H,5-7H2,1-4H3/t9-,10?,11+,12-/m1/s1
DMIBCZJ CS C[C@@H]1CC[C@H]([C@@H](C1)OC(=O)C(C)O)C(C)C
DMIBCZJ IK UJNOLBSYLSYIBM-SGUBAKSOSA-N
DMIBCZJ IU [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] 2-hydroxypropanoate
DMIBCZJ CA CAS 61597-98-6
DMIBCZJ DE Discovery agent
DMU5SAF ID DMU5SAF
DMU5SAF DN Fructose-6-phosphate
DMU5SAF HS Investigative
DMU5SAF SN Fructose 6-Phosphate; D-fructose-6-phosphate; fructose-6P; fructose-6-P; D-fructose-6-P; FRUCTOSE -6-PHOSPHATE; fru-6-P; UNII-2012QM764Y; 2012QM764Y; 6814-87-5; keto-D-fructose 6-phosphate; F6R; D-fructose-6P; D-Fructose 6-phosphorate; 6-O-phosphono-D-fructose; Fructose 6-phosphoric acid; SCHEMBL8230; AC1Q28E6; AC1L2C15; CTK5C7413; CHEBI:15946; GSXOAOHZAIYLCY-HSUXUTPPSA-N; Fructose 6-(dihydrogen phosphate); Fructose, 6-(dihydrogen phosphate); EINECS 211-395-6; d-fructose-6-phosphate (open form); ZINC85994845; DB04493; AJ-127870
DMU5SAF DT Small molecular drug
DMU5SAF PC 69507
DMU5SAF MW 260.14
DMU5SAF FM C6H13O9P
DMU5SAF IC InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h4-7,9-11H,1-2H2,(H2,12,13,14)/t4-,5-,6-/m1/s1
DMU5SAF CS C([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)OP(=O)(O)O
DMU5SAF IK GSXOAOHZAIYLCY-HSUXUTPPSA-N
DMU5SAF IU [(2R,3R,4S)-2,3,4,6-tetrahydroxy-5-oxohexyl] dihydrogen phosphate
DMU5SAF CA CAS 643-13-0
DMU5SAF CB CHEBI:15946
DMU5SAF DE Discovery agent
DMPRMOD ID DMPRMOD
DMPRMOD DN FSHR NAM
DMPRMOD HS Investigative
DMPRMOD SN ADX-68692; ADX-68693
DMPRMOD CP Addex Pharmaceuticals SA
DMPRMOD DE Contraception
DM2KUEV ID DM2KUEV
DM2KUEV DN Fsn-0503
DM2KUEV HS Investigative
DM2KUEV SN Cathepsin S mAb (cancer), Fusion
DM2KUEV CP Fusion Antibodies Ltd
DM2KUEV DT Antibody
DM2KUEV DE Solid tumour/cancer
DMN2Q7Y ID DMN2Q7Y
DMN2Q7Y DN FTI 276
DMN2Q7Y HS Investigative
DMN2Q7Y SN FTI-276; FTI276
DMN2Q7Y DT Small molecular drug
DMN2Q7Y PC 395754
DMN2Q7Y MW 433.6
DMN2Q7Y FM C21H27N3O3S2
DMN2Q7Y IC InChI=1S/C21H27N3O3S2/c1-29-10-9-19(21(26)27)24-20(25)17-8-7-16(23-12-15(22)13-28)11-18(17)14-5-3-2-4-6-14/h2-8,11,15,19,23,28H,9-10,12-13,22H2,1H3,(H,24,25)(H,26,27)/t15-,19+/m1/s1
DMN2Q7Y CS CSCC[C@@H](C(=O)O)NC(=O)C1=C(C=C(C=C1)NC[C@H](CS)N)C2=CC=CC=C2
DMN2Q7Y IK ZIXDDEATQSBHHL-BEFAXECRSA-N
DMN2Q7Y IU (2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
DMN2Q7Y CA CAS 170006-72-1
DMN2Q7Y CB CHEBI:94119
DMN2Q7Y DE Discovery agent
DM65VLB ID DM65VLB
DM65VLB DN FTIDC
DM65VLB HS Investigative
DM65VLB SN FTIDC; 873551-53-2; CHEMBL502882; 4-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-N-methyl-N-propan-2-yl-3,6-dihydro-2H-pyridine-1-carboxamide; SCHEMBL658737; GTPL6363; MolPort-035-941-181; BCP18262; BDBM50273942; ZINC40979996; AKOS025142035; NCGC00387221-01; F-190; 4-[1-(2-Fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-3,6-dihydro-N-methyl-N-(1-methylethyl)-1(2H)-pyridinecarboxamide; 4-(1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl)-N-isopropyl-N-methyl-5,6-dihydropyridine-1(2H)-carboxamide
DM65VLB DT Small molecular drug
DM65VLB PC 11245287
DM65VLB MW 358.4
DM65VLB FM C18H23FN6O
DM65VLB IC InChI=1S/C18H23FN6O/c1-12(2)23(4)18(26)24-10-7-14(8-11-24)16-13(3)25(22-21-16)15-6-5-9-20-17(15)19/h5-7,9,12H,8,10-11H2,1-4H3
DM65VLB CS CC1=C(N=NN1C2=C(N=CC=C2)F)C3=CCN(CC3)C(=O)N(C)C(C)C
DM65VLB IK CJTLKLBSIFQKNT-UHFFFAOYSA-N
DM65VLB IU 4-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-N-methyl-N-propan-2-yl-3,6-dihydro-2H-pyridine-1-carboxamide
DM65VLB DE Discovery agent
DMDZBQH ID DMDZBQH
DMDZBQH DN FTY720-phosphate
DMDZBQH HS Investigative
DMDZBQH SN fingolimod phosphate
DMDZBQH DT Small molecular drug
DMDZBQH PC 9908268
DMDZBQH MW 387.5
DMDZBQH FM C19H34NO5P
DMDZBQH IC InChI=1S/C19H34NO5P/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-25-26(22,23)24/h9-12,21H,2-8,13-16,20H2,1H3,(H2,22,23,24)
DMDZBQH CS CCCCCCCCC1=CC=C(C=C1)CCC(CO)(COP(=O)(O)O)N
DMDZBQH IK LRFKWQGGENFBFO-UHFFFAOYSA-N
DMDZBQH IU [2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate
DMDZBQH CA CAS 402616-23-3
DMDZBQH CB CHEBI:73420
DMDZBQH DE Discovery agent
DMUAYWX ID DMUAYWX
DMUAYWX DN FUB 349
DMUAYWX HS Investigative
DMUAYWX SN 4-(4-Phenyl-butyl)-1H-imidazole; FUB-349; CHEMBL296450; FUB349; 4-(4-phenylbutyl)-3H-imidazole; GTPL1259; BDBM50071197; ZINC29405823; FUB-349
DMUAYWX DT Small molecular drug
DMUAYWX PC 9990388
DMUAYWX MW 200.28
DMUAYWX FM C13H16N2
DMUAYWX IC InChI=1S/C13H16N2/c1-2-6-12(7-3-1)8-4-5-9-13-10-14-11-15-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,14,15)
DMUAYWX CS C1=CC=C(C=C1)CCCCC2=CN=CN2
DMUAYWX IK BQTXNCXSCSNHGA-UHFFFAOYSA-N
DMUAYWX IU 5-(4-phenylbutyl)-1H-imidazole
DMUAYWX DE Discovery agent
DMCLSE0 ID DMCLSE0
DMCLSE0 DN FUB-130
DMCLSE0 HS Investigative
DMCLSE0 SN FUB-132; FUB-250; FUB-465; FUB-86; UCL-1860; UCL-2065; UCL-2283; H3 antagonists, Bioprojet/Berlin Free University/INSERM/UCL
DMCLSE0 CP BioProjet; Societe Civile de Recherche
DMCLSE0 DT Small molecular drug
DMCLSE0 PC 9989449
DMCLSE0 MW 154.21
DMCLSE0 FM C8H14N2O
DMCLSE0 IC InChI=1S/C8H14N2O/c1-2-11-5-3-4-8-6-9-7-10-8/h6-7H,2-5H2,1H3,(H,9,10)
DMCLSE0 CS CCOCCCC1=CN=CN1
DMCLSE0 IK RSHKAUMLIJVWFJ-UHFFFAOYSA-N
DMCLSE0 IU 5-(3-ethoxypropyl)-1H-imidazole
DMCLSE0 DE Neurological disorder
DMAHMSV ID DMAHMSV
DMAHMSV DN Fucose
DMAHMSV HS Investigative
DMAHMSV SN L-galactomethylose; 6-Desoxygalactose; SCHEMBL13092958; AKOS030212707
DMAHMSV DT Small molecular drug
DMAHMSV PC 17106
DMAHMSV MW 164.16
DMAHMSV FM C6H12O5
DMAHMSV IC InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1
DMAHMSV CS C[C@H]1[C@H]([C@H]([C@@H](C(O1)O)O)O)O
DMAHMSV IK SHZGCJCMOBCMKK-DHVFOXMCSA-N
DMAHMSV IU (3S,4R,5S,6S)-6-methyloxane-2,3,4,5-tetrol
DMAHMSV CA CAS 87-96-7
DMAHMSV CB CHEBI:2181
DMWF82O ID DMWF82O
DMWF82O DN FUKUGETIN
DMWF82O HS Investigative
DMWF82O SN CHEMBL446790; BDBM50292533
DMWF82O DT Small molecular drug
DMWF82O PC 12110448
DMWF82O MW 556.5
DMWF82O FM C30H20O11
DMWF82O IC InChI=1S/C30H20O11/c31-14-4-1-12(2-5-14)29-27(28(39)25-18(35)8-15(32)9-23(25)41-29)26-20(37)10-19(36)24-21(38)11-22(40-30(24)26)13-3-6-16(33)17(34)7-13/h1-11,27,29,31-37H/t27-,29+/m1/s1
DMWF82O CS C1=CC(=CC=C1[C@H]2[C@@H](C(=O)C3=C(C=C(C=C3O2)O)O)C4=C(C=C(C5=C4OC(=CC5=O)C6=CC(=C(C=C6)O)O)O)O)O
DMWF82O IK GFWPWSNIXRDQJC-PXJZQJOASA-N
DMWF82O IU 8-[(2R,3S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
DMWF82O CA CAS 16851-21-1
DMWF82O CB CHEBI:70331
DMWF82O DE Discovery agent
DM4M91Z ID DM4M91Z
DM4M91Z DN Full-length Factor VIII molecule
DM4M91Z HS Investigative
DM4M91Z SN Full-length Factor VIII molecule (hemophilia)
DM4M91Z CP Bayer Schering Pharma AG
DM4M91Z DE Hemophilia
DMA3Y8C ID DMA3Y8C
DMA3Y8C DN Fumagillin
DMA3Y8C HS Investigative
DMA3Y8C SN MLS002702991; SMR001566800; NCGC00163699-01; AC1NS4EN; SCHEMBL6953272; MEGxm0_000010; CHEMBL1396346; BDBM95462; ACon0_000963; MolPort-044-567-755; cid_45281154; MolPort-001-739-223; MCULE-6695017352; NCGC00163699-03; J-014992; Fumagillin from Aspergillus fumigatus, > =90%, powder; NCGC00163699-03_C26H34O7_2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-buten-1-yl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, (2E,4E,6E,8E)-
DMA3Y8C DT Small molecular drug
DMA3Y8C PC 6917655
DMA3Y8C MW 458.5
DMA3Y8C FM C26H34O7
DMA3Y8C IC InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)/b7-5+,8-6+,11-9+,12-10+/t19-,20-,23-,24-,25+,26+/m1/s1
DMA3Y8C CS CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)OC)C
DMA3Y8C IK NGGMYCMLYOUNGM-CSDLUJIJSA-N
DMA3Y8C IU (2E,4E,6E,8E)-10-[[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxy]-10-oxodeca-2,4,6,8-tetraenoic acid
DMA3Y8C CA CAS 23110-15-8
DMA3Y8C CB CHEBI:48635
DMA3Y8C DE Discovery agent
DM9VLS2 ID DM9VLS2
DM9VLS2 DN Fumarate
DM9VLS2 HS Investigative
DM9VLS2 SN Fumarate(2-); (2E)-but-2-enedioate; 142-42-7; (E)-2-Butenedioate; (E)-Butenedioic acid; but-2-enedioate; Fumarate dianion; (E)-but-2-enedioate; butenedioate; Fumerate; 2-Butenedioic acid (E)-, ion(2-); AC1NUT2F; Fumaric acid, ion(2-); AC1Q22C1; DTXSID9037660; CHEBI:36180; CHEBI:29806; VZCYOOQTPOCHFL-OWOJBTEDSA-L; trans-1,2-Ethenedicarboxylic acid; (E)-1,2-Ethylenedicarboxylic acid; (E)-2-butenedioic acid, ion(2-); trans-1,2-Ethylenediccarboxylic acid; CJ-10837; 3861-EP2371811A2; 3861-EP2316829A1; 3861-EP2316450A1
DM9VLS2 DT Small molecular drug
DM9VLS2 PC 5460307
DM9VLS2 MW 114.06
DM9VLS2 FM C4H2O4-2
DM9VLS2 IC InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/p-2/b2-1+
DM9VLS2 CS C(=C/C(=O)[O-])\\C(=O)[O-]
DM9VLS2 IK VZCYOOQTPOCHFL-OWOJBTEDSA-L
DM9VLS2 IU (E)-but-2-enedioate
DM9VLS2 CA CAS 142-42-7
DM9VLS2 CB CHEBI:29806
DM9VLS2 DE Discovery agent
DMCFEBW ID DMCFEBW
DMCFEBW DN furan-1
DMCFEBW HS Investigative
DMCFEBW DT Small molecular drug
DMCFEBW PC 9957278
DMCFEBW MW 491.6
DMCFEBW FM C30H37NO5
DMCFEBW IC InChI=1S/C30H37NO5/c1-18-13-22-23(30(4,5)12-11-29(22,2)3)15-19(18)14-20-9-10-24(36-20)28(32)31-27-25(34-7)16-21(33-6)17-26(27)35-8/h9-10,13,15-17H,11-12,14H2,1-8H3,(H,31,32)
DMCFEBW CS CC1=CC2=C(C=C1CC3=CC=C(O3)C(=O)NC4=C(C=C(C=C4OC)OC)OC)C(CCC2(C)C)(C)C
DMCFEBW IK IPEMCIBPDYCJLO-UHFFFAOYSA-N
DMCFEBW IU 5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-N-(2,4,6-trimethoxyphenyl)furan-2-carboxamide
DMCFEBW CA CAS 263847-55-8
DMCFEBW DE Discovery agent
DM9XPUN ID DM9XPUN
DM9XPUN DN Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester
DM9XPUN HS Investigative
DM9XPUN SN CHEMBL449538; Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester
DM9XPUN DT Small molecular drug
DM9XPUN PC 24881738
DM9XPUN MW 293.3
DM9XPUN FM C18H15NO3
DM9XPUN IC InChI=1S/C18H15NO3/c20-18(19-13-17-10-5-11-21-17)22-16-9-4-8-15(12-16)14-6-2-1-3-7-14/h1-12H,13H2,(H,19,20)
DM9XPUN CS C1=CC=C(C=C1)C2=CC(=CC=C2)OC(=O)NCC3=CC=CO3
DM9XPUN IK OLMUNVAXPITDSI-UHFFFAOYSA-N
DM9XPUN IU (3-phenylphenyl) N-(furan-2-ylmethyl)carbamate
DM9XPUN DE Discovery agent
DMPC6YL ID DMPC6YL
DMPC6YL DN Furan-3-yl(4-(methylsulfonyl)phenyl)methanone
DMPC6YL HS Investigative
DMPC6YL SN CHEMBL1240537; 3-(p-methylsulfonylbenzoyl)furan; 1244038-62-7; furan-3-yl(4-(methylsulfonyl)phenyl)methanone
DMPC6YL DT Small molecular drug
DMPC6YL PC 46939837
DMPC6YL MW 250.27
DMPC6YL FM C12H10O4S
DMPC6YL IC InChI=1S/C12H10O4S/c1-17(14,15)11-4-2-9(3-5-11)12(13)10-6-7-16-8-10/h2-8H,1H3
DMPC6YL CS CS(=O)(=O)C1=CC=C(C=C1)C(=O)C2=COC=C2
DMPC6YL IK ULFFSZMVURLRPK-UHFFFAOYSA-N
DMPC6YL IU furan-3-yl-(4-methylsulfonylphenyl)methanone
DMPC6YL DE Discovery agent
DM78NOM ID DM78NOM
DM78NOM DN furin inhibitor peptide
DM78NOM HS Investigative
DM78NOM SN CHEMBL502642; furin inhibitor peptide; GTPL8668
DM78NOM DT Small molecular drug
DM78NOM PC 44584947
DM78NOM MW 1424.7
DM78NOM FM C58H113N29O13
DM78NOM IC InChI=1S/C58H113N29O13/c1-30(78-45(92)35(16-8-24-73-54(63)64)85-52(99)40-21-13-29-87(40)53(100)41(61)31(2)88)44(91)79-36(17-9-25-74-55(65)66)48(95)82-38(19-11-27-76-57(69)70)50(97)83-37(18-10-26-75-56(67)68)49(96)81-33(14-4-6-22-59)46(93)80-34(15-5-7-23-60)47(94)84-39(20-12-28-77-58(71)72)51(98)86-42(32(3)89)43(62)90/h30-42,88-89H,4-29,59-61H2,1-3H3,(H2,62,90)(H,78,92)(H,79,91)(H,80,93)(H,81,96)(H,82,95)(H,83,97)(H,84,94)(H,85,99)(H,86,98)(H4,63,64,73)(H4,65,66,74)(H4,67,68,75)(H4,69,70,76)(H4,71,72,77)/t30-,31+,32+,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m0/s1
DM78NOM CS C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
DM78NOM IK XIHRZTWKTVFWSV-HQSWAJDZSA-N
DM78NOM IU (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carboxamide
DM78NOM DE Discovery agent
DMVYEZ1 ID DMVYEZ1
DMVYEZ1 DN Furo[2,3d]Pyrimidine Antifolate
DMVYEZ1 HS Investigative
DMVYEZ1 SN Dpmmabg; furo[2,3d]pyrimidine antifolate; CHEMBL104829; 156595-85-6; N-[4-[(2,4-DIAMINOFURO[2,3D]PYRIMIDIN-5-YL)METHYL]METHYLAMINO]-BENZOYL]-L-GLUTAMATE; MOT; MTXO; AC1L4JTH; CTK4C9124; DTXSID50166105; 2-{4-[(2,4-Diamino-furo[2,3-d]pyrimidin-5-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid; BDBM50091145; AKOS030607152; DB02026; N-(4-(((2,4-Diaminofuro(2,3-d)pyrimidin-5-yl)methyl)methylamino)benzoyl)-L-glutamic acid; N-(4-(N-((2,4-Diamino-furo(2,3-d)pyrimidin-5-yl)methyl)methylamino)benzoyl)glutamic acid
DMVYEZ1 DT Small molecular drug
DMVYEZ1 PC 158376
DMVYEZ1 MW 442.4
DMVYEZ1 FM C20H22N6O6
DMVYEZ1 IC InChI=1S/C20H22N6O6/c1-26(8-11-9-32-18-15(11)16(21)24-20(22)25-18)12-4-2-10(3-5-12)17(29)23-13(19(30)31)6-7-14(27)28/h2-5,9,13H,6-8H2,1H3,(H,23,29)(H,27,28)(H,30,31)(H4,21,22,24,25)/t13-/m0/s1
DMVYEZ1 CS CN(CC1=COC2=NC(=NC(=C12)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMVYEZ1 IK WXINNGCGSCFUCR-ZDUSSCGKSA-N
DMVYEZ1 IU (2S)-2-[[4-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
DMVYEZ1 CA CAS 156595-85-6
DMVYEZ1 DE Discovery agent
DMVT0JO ID DMVT0JO
DMVT0JO DN FUROSIN
DMVT0JO HS Investigative
DMVT0JO SN Furosin; CHEMBL447361
DMVT0JO DT Small molecular drug
DMVT0JO PC 10416810
DMVT0JO MW 650.5
DMVT0JO FM C27H22O19
DMVT0JO IC InChI=1S/C27H22O19/c28-5-12-19-18(35)21(25(42-12)45-22(36)6-1-9(29)16(33)10(30)2-6)44-23(37)7-3-11(31)17(34)20-14(7)15-8(24(38)43-19)4-13(32)26(39,40)27(15,41)46-20/h1-4,12,15,18-19,21,25,28-31,33-35,39-41H,5H2/t12-,15+,18+,19-,21-,25+,27?/m1/s1
DMVT0JO CS C1=C(C=C(C(=C1O)O)O)C(=O)O[C@H]2[C@H]3[C@H]([C@@H]([C@H](O2)CO)OC(=O)C4=CC(=O)C(C5([C@@H]4C6=C(O5)C(=C(C=C6C(=O)O3)O)O)O)(O)O)O
DMVT0JO IK CXTMLIMZRPKULL-YXYYPBJFSA-N
DMVT0JO IU [(1S,9R,18R,19S,21R,22S)-7,7,8,12,13,22-hexahydroxy-21-(hydroxymethyl)-3,6,16-trioxo-2,17,20,23-tetraoxapentacyclo[16.3.1.18,11.04,9.010,15]tricosa-4,10,12,14-tetraen-19-yl] 3,4,5-trihydroxybenzoate
DMVT0JO DE Discovery agent
DM4M3C8 ID DM4M3C8
DM4M3C8 DN furtrethonium
DM4M3C8 HS Investigative
DM4M3C8 SN furmethide
DM4M3C8 DT Small molecular drug
DM4M3C8 PC 10938
DM4M3C8 MW 140.2
DM4M3C8 FM C8H14NO+
DM4M3C8 IC InChI=1S/C8H14NO/c1-9(2,3)7-8-5-4-6-10-8/h4-6H,7H2,1-3H3/q+1
DM4M3C8 CS C[N+](C)(C)CC1=CC=CO1
DM4M3C8 IK HEDXEAAVEOJUCR-UHFFFAOYSA-N
DM4M3C8 IU furan-2-ylmethyl(trimethyl)azanium
DM4M3C8 CA CAS 7618-86-2
DM4M3C8 CB CHEBI:134764
DM4M3C8 DE Discovery agent
DMP3BZH ID DMP3BZH
DMP3BZH DN Fusion peptide EK1
DMP3BZH HS Investigative
DMP3BZH SN EK1 peptide
DMP3BZH TC Antiviral Agents
DMP3BZH DT Protein/peptide drug
DMP3BZH SQ SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL
DMP3BZH DE Middle East Respiratory Syndrome (MERS); Severe acute respiratory syndrome (SARS)
DMFBP7C ID DMFBP7C
DMFBP7C DN FUTOENONE
DMFBP7C HS Investigative
DMFBP7C SN Futoenone; 19913-01-0; (-)-Futoenone; SCHEMBL3468519; CHEMBL295191; SXHVHWXETMBKPP-KXXATPMCSA-N; CHEBI:132647; OAS 1136; BDBM50213210; ZINC29395822; AKOS032949051; (2S,4S,5R,5aS)-4-(2H-1,3-benzodioxol-5-yl)-7-methoxy-5-methyl-2,3,4,5-tetrahydro-8H-2,5a-methano-1-benzoxepin-8-one
DMFBP7C DT Small molecular drug
DMFBP7C PC 9819306
DMFBP7C MW 340.4
DMFBP7C FM C20H20O5
DMFBP7C IC InChI=1S/C20H20O5/c1-11-14(12-3-4-16-17(5-12)24-10-23-16)6-13-8-20(11)9-18(22-2)15(21)7-19(20)25-13/h3-5,7,9,11,13-14H,6,8,10H2,1-2H3/t11-,13+,14+,20-/m1/s1
DMFBP7C CS C[C@@H]1[C@H](C[C@H]2C[C@@]13C=C(C(=O)C=C3O2)OC)C4=CC5=C(C=C4)OCO5
DMFBP7C IK SXHVHWXETMBKPP-KXXATPMCSA-N
DMFBP7C IU (1S,8S,10S,11R)-10-(1,3-benzodioxol-5-yl)-3-methoxy-11-methyl-7-oxatricyclo[6.3.1.01,6]dodeca-2,5-dien-4-one
DMFBP7C CA CAS 19913-01-0
DMFBP7C CB CHEBI:132647
DMFBP7C DE Discovery agent
DMEI890 ID DMEI890
DMEI890 DN FV-Aib-TDVGPFAF
DMEI890 HS Investigative
DMEI890 SN [Aib29,Asp31,Pro34,Phe35]CGRP(27-37)
DMEI890 PC 44406785
DMEI890 MW 1184.3
DMEI890 FM C59H81N11O15
DMEI890 IC InChI=1S/C59H81N11O15/c1-32(2)46(67-52(78)41(30-45(73)74)64-55(81)48(35(6)71)68-58(85)59(7,8)69-56(82)47(33(3)4)66-50(76)39(60)27-36-19-12-9-13-20-36)54(80)61-31-44(72)70-26-18-25-43(70)53(79)63-40(28-37-21-14-10-15-22-37)51(77)62-34(5)49(75)65-42(57(83)84)29-38-23-16-11-17-24-38/h9-17,19-24,32-35,39-43,46-48,71H,18,25-31,60H2,1-8H3,(H,61,80)(H,62,77)(H,63,79)(H,64,81)(H,65,75)(H,66,76)(H,67,78)(H,68,85)(H,69,82)(H,73,74)(H,83,84)/t34-,35+,39-,40-,41-,42-,43-,46-,47-,48-/m0/s1
DMEI890 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N)O
DMEI890 IK GUILBDPDYMIGBQ-GBWZQAKSSA-N
DMEI890 IU (3S)-3-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-2-methylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMEI890 DE Discovery agent
DMDG1ZX ID DMDG1ZX
DMDG1ZX DN FVATDVGPFAF
DMDG1ZX HS Investigative
DMDG1ZX SN CHEMBL385986; FVATDVGPFAF
DMDG1ZX PC 44406786
DMDG1ZX MW 1170.3
DMDG1ZX FM C58H79N11O15
DMDG1ZX IC InChI=1S/C58H79N11O15/c1-31(2)46(67-53(78)41(29-45(72)73)64-57(82)48(35(7)70)68-50(75)34(6)62-56(81)47(32(3)4)66-51(76)39(59)26-36-18-11-8-12-19-36)55(80)60-30-44(71)69-25-17-24-43(69)54(79)63-40(27-37-20-13-9-14-21-37)52(77)61-33(5)49(74)65-42(58(83)84)28-38-22-15-10-16-23-38/h8-16,18-23,31-35,39-43,46-48,70H,17,24-30,59H2,1-7H3,(H,60,80)(H,61,77)(H,62,81)(H,63,79)(H,64,82)(H,65,74)(H,66,76)(H,67,78)(H,68,75)(H,72,73)(H,83,84)/t33-,34-,35+,39-,40-,41-,42-,43-,46-,47-,48-/m0/s1
DMDG1ZX CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N)O
DMDG1ZX IK WMTZDAHGKCEIAT-ILJNECBNSA-N
DMDG1ZX IU (3S)-3-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMDG1ZX DE Discovery agent
DMXQC6H ID DMXQC6H
DMXQC6H DN FV-Hyp-TDVGPFAF
DMXQC6H HS Investigative
DMXQC6H PC 73348632
DMXQC6H MW 1212.3
DMXQC6H FM C60H81N11O16
DMXQC6H IC InChI=1S/C60H81N11O16/c1-32(2)48(57(83)62-30-46(74)70-24-16-23-44(70)55(81)64-41(26-37-19-12-8-13-20-37)53(79)63-34(5)51(77)66-43(60(86)87)27-38-21-14-9-15-22-38)67-54(80)42(29-47(75)76)65-58(84)50(35(6)72)69-56(82)45-28-39(73)31-71(45)59(85)49(33(3)4)68-52(78)40(61)25-36-17-10-7-11-18-36/h7-15,17-22,32-35,39-45,48-50,72-73H,16,23-31,61H2,1-6H3,(H,62,83)(H,63,79)(H,64,81)(H,65,84)(H,66,77)(H,67,80)(H,68,78)(H,69,82)(H,75,76)(H,86,87)/t34-,35+,39+,40-,41-,42-,43-,44-,45-,48-,49-,50-/m0/s1
DMXQC6H CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)N)O)O
DMXQC6H IK RYURPNQKLUHMSX-UVHAUATQSA-N
DMXQC6H IU (3S)-3-[[(2S,3R)-2-[[(2S,4R)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMXQC6H DE Discovery agent
DMSD7B1 ID DMSD7B1
DMSD7B1 DN FVPTDVGAFAF
DMSD7B1 HS Investigative
DMSD7B1 SN CHEMBL406459; FVPTDVGAFAF
DMSD7B1 PC 44274034
DMSD7B1 MW 1170.3
DMSD7B1 FM C58H79N11O15
DMSD7B1 IC InChI=1S/C58H79N11O15/c1-31(2)46(55(80)60-30-44(71)61-33(5)49(74)63-40(27-37-20-13-9-14-21-37)52(77)62-34(6)50(75)65-42(58(83)84)28-38-22-15-10-16-23-38)66-53(78)41(29-45(72)73)64-56(81)48(35(7)70)68-54(79)43-24-17-25-69(43)57(82)47(32(3)4)67-51(76)39(59)26-36-18-11-8-12-19-36/h8-16,18-23,31-35,39-43,46-48,70H,17,24-30,59H2,1-7H3,(H,60,80)(H,61,71)(H,62,77)(H,63,74)(H,64,81)(H,65,75)(H,66,78)(H,67,76)(H,68,79)(H,72,73)(H,83,84)/t33-,34-,35+,39-,40-,41-,42-,43-,46-,47-,48-/m0/s1
DMSD7B1 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C(C)C)NC(=O)[C@H](CC4=CC=CC=C4)N)O
DMSD7B1 IK SQQZSWBNZZDEAJ-ILJNECBNSA-N
DMSD7B1 IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMSD7B1 DE Discovery agent
DMUVXZQ ID DMUVXZQ
DMUVXZQ DN FVPTDVGPFAF
DMUVXZQ HS Investigative
DMUVXZQ SN CHEMBL264010; FVPTDVGPFAF
DMUVXZQ PC 44274033
DMUVXZQ MW 1196.3
DMUVXZQ FM C60H81N11O15
DMUVXZQ IC InChI=1S/C60H81N11O15/c1-33(2)48(67-54(79)42(31-47(74)75)65-58(83)50(36(6)72)69-56(81)45-25-17-27-71(45)59(84)49(34(3)4)68-52(77)40(61)28-37-18-10-7-11-19-37)57(82)62-32-46(73)70-26-16-24-44(70)55(80)64-41(29-38-20-12-8-13-21-38)53(78)63-35(5)51(76)66-43(60(85)86)30-39-22-14-9-15-23-39/h7-15,18-23,33-36,40-45,48-50,72H,16-17,24-32,61H2,1-6H3,(H,62,82)(H,63,78)(H,64,80)(H,65,83)(H,66,76)(H,67,79)(H,68,77)(H,69,81)(H,74,75)(H,85,86)/t35-,36+,40-,41-,42-,43-,44-,45-,48-,49-,50-/m0/s1
DMUVXZQ CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC5=CC=CC=C5)N)O
DMUVXZQ IK COFTYEBEOOYCDC-KTHKGSMISA-N
DMUVXZQ IU (3S)-3-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMUVXZQ DE Discovery agent
DM58JFR ID DM58JFR
DM58JFR DN FVPTDVG-Tic-FAF-Tic
DM58JFR HS Investigative
DM58JFR PC 73353193
DM58JFR MW 1417.6
DM58JFR FM C75H92N12O16
DM58JFR IC InChI=1S/C75H92N12O16/c1-42(2)62(82-68(95)55(38-61(90)91)80-72(99)64(45(6)88)84-69(96)57-31-20-32-85(57)74(101)63(43(3)4)83-66(93)53(76)33-46-21-10-7-11-22-46)71(98)77-39-60(89)86-40-51-29-18-16-27-49(51)36-58(86)70(97)79-54(34-47-23-12-8-13-24-47)67(94)78-44(5)65(92)81-56(35-48-25-14-9-15-26-48)73(100)87-41-52-30-19-17-28-50(52)37-59(87)75(102)103/h7-19,21-30,42-45,53-59,62-64,88H,20,31-41,76H2,1-6H3,(H,77,98)(H,78,94)(H,79,97)(H,80,99)(H,81,92)(H,82,95)(H,83,93)(H,84,96)(H,90,91)(H,102,103)/t44-,45+,53-,54-,55-,56-,57-,58-,59-,62-,63-,64-/m0/s1
DM58JFR CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N5CC6=CC=CC=C6C[C@H]5C(=O)O)NC(=O)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)[C@H](CC8=CC=CC=C8)N)O
DM58JFR IK LZESRBNZLWMEIJ-GKKQDZIBSA-N
DM58JFR IU (3S)-2-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S)-2-[2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]acetyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM58JFR DE Discovery agent
DMBOE1U ID DMBOE1U
DMBOE1U DN FV-Tic-TDVGPFAF
DMBOE1U HS Investigative
DMBOE1U PC 11956141
DMBOE1U MW 1258.4
DMBOE1U FM C65H83N11O15
DMBOE1U IC InChI=1S/C65H83N11O15/c1-36(2)53(62(87)67-34-51(78)75-28-18-27-49(75)60(85)69-46(30-41-21-12-8-13-22-41)58(83)68-38(5)56(81)71-48(65(90)91)31-42-23-14-9-15-24-42)72-59(84)47(33-52(79)80)70-63(88)55(39(6)77)74-61(86)50-32-43-25-16-17-26-44(43)35-76(50)64(89)54(37(3)4)73-57(82)45(66)29-40-19-10-7-11-20-40/h7-17,19-26,36-39,45-50,53-55,77H,18,27-35,66H2,1-6H3,(H,67,87)(H,68,83)(H,69,85)(H,70,88)(H,71,81)(H,72,84)(H,73,82)(H,74,86)(H,79,80)(H,90,91)/t38-,39+,45-,46-,47-,48-,49-,50-,53-,54-,55-/m0/s1
DMBOE1U CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@@H]4CC5=CC=CC=C5CN4C(=O)[C@H](C(C)C)NC(=O)[C@H](CC6=CC=CC=C6)N)O
DMBOE1U IK RFOPIEIJLKLOPX-HGULNMISSA-N
DMBOE1U IU (3S)-3-[[(2S,3R)-2-[[(3S)-2-[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMBOE1U DE Discovery agent
DMAZ1NW ID DMAZ1NW
DMAZ1NW DN FXI-AS1
DMAZ1NW HS Investigative
DMAZ1NW SN FXI antisense oligonucleotides (thrombosis); FXI-AS2; FXI-ASO; ISIS-404071; FXI antisense oligonucleotides (thrombosis), Isis Pharmaceuticals; Factor XI antisense oligonucleotides (thrombosis), Isis Pharmaceuticals
DMAZ1NW CP Isis Pharmaceuticals Inc
DMAZ1NW DT Antisense drug
DMAZ1NW DE Thrombosis
DMUC0F5 ID DMUC0F5
DMUC0F5 DN G(D-Pen)-G-H-R-G-D-L-R-C-A
DMUC0F5 HS Investigative
DMUC0F5 SN CHEMBL437813; G(D-Pen)-G-H-R-G-D-L-R-C-A
DMUC0F5 PC 44379110
DMUC0F5 MW 1170.3
DMUC0F5 FM C45H75N19O14S2
DMUC0F5 IC InChI=1S/C45H75N19O14S2/c1-21(2)12-26-37(72)62-25(9-7-11-53-44(49)50)36(71)64-29(40(75)58-22(3)42(77)78)19-79-80-45(4,5)34(46)41(76)56-16-30(65)54-17-31(66)59-27(13-23-15-51-20-57-23)38(73)61-24(8-6-10-52-43(47)48)35(70)55-18-32(67)60-28(14-33(68)69)39(74)63-26/h15,20-22,24-29,34H,6-14,16-19,46H2,1-5H3,(H,51,57)(H,54,65)(H,55,70)(H,56,76)(H,58,75)(H,59,66)(H,60,67)(H,61,73)(H,62,72)(H,63,74)(H,64,71)(H,68,69)(H,77,78)(H4,47,48,52)(H4,49,50,53)/t22-,24-,25-,26+,27+,28-,29-,34-/m0/s1
DMUC0F5 CS C[C@@H](C(=O)O)NC(=O)[C@@H]1CSSC([C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC(C)C)CC(=O)O)CCCN=C(N)N)CC2=CN=CN2)N)(C)C
DMUC0F5 IK RGCFJZZTHIGGDJ-UHZMXWKHSA-N
DMUC0F5 IU (2S)-2-[[(4R,7S,10R,13S,19S,22R,31S)-31-amino-13-(carboxymethyl)-7,19-bis[3-(diaminomethylideneamino)propyl]-22-(1H-imidazol-5-ylmethyl)-32,32-dimethyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30-nonaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]propanoic acid
DMUC0F5 DE Discovery agent
DMXZGKI ID DMXZGKI
DMXZGKI DN G009
DMXZGKI HS Investigative
DMXZGKI SN Beta-(1-3)-Glucan with beta-(1-6) side chain isolated from the Basidiomycetes Ganoderma lucidum
DMXZGKI DE Immune System disease
DMMEC9D ID DMMEC9D
DMMEC9D DN G15
DMMEC9D HS Investigative
DMMEC9D SN G-15
DMMEC9D DT Small molecular drug
DMMEC9D PC 7433743
DMMEC9D MW 370.2
DMMEC9D FM C19H16BrNO2
DMMEC9D IC InChI=1S/C19H16BrNO2/c20-15-9-18-17(22-10-23-18)8-14(15)19-13-6-3-5-11(13)12-4-1-2-7-16(12)21-19/h1-5,7-9,11,13,19,21H,6,10H2/t11-,13-,19+/m0/s1
DMMEC9D CS C1C=C[C@@H]2[C@H]1[C@@H](NC3=CC=CC=C23)C4=CC5=C(C=C4Br)OCO5
DMMEC9D IK YOLTZIVRJAPVPH-MJLGCCKJSA-N
DMMEC9D IU (3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline
DMMEC9D CA CAS 1161002-05-6
DMMEC9D DE Discovery agent
DMADOK6 ID DMADOK6
DMADOK6 DN G-25
DMADOK6 HS Investigative
DMADOK6 SN SCHEMBL16529235; BDBM286896; US9567304, Compound G-25
DMADOK6 DT Small molecular drug
DMADOK6 PC 117921588
DMADOK6 MW 687.5
DMADOK6 FM C25H27Cl2F3N4O7S2
DMADOK6 IC InChI=1S/C25H27Cl2F3N4O7S2/c1-3-43(39,40)20-7-6-15(26)9-14(20)12-34-23(35)17-10-19(41-25(28,29)30)18(21(27)22(17)32-24(34)36)13-33-8-4-5-16(33)11-31-42(2,37)38/h6-7,9-10,16,31H,3-5,8,11-13H2,1-2H3,(H,32,36)/t16-/m0/s1
DMADOK6 CS CCS(=O)(=O)C1=C(C=C(C=C1)Cl)CN2C(=O)C3=CC(=C(C(=C3NC2=O)Cl)CN4CCC[C@H]4CNS(=O)(=O)C)OC(F)(F)F
DMADOK6 IK ADNJLXQZOZXZJU-INIZCTEOSA-N
DMADOK6 IU N-[[(2S)-1-[[8-chloro-3-[(5-chloro-2-ethylsulfonylphenyl)methyl]-2,4-dioxo-6-(trifluoromethoxy)-1H-quinazolin-7-yl]methyl]pyrrolidin-2-yl]methyl]methanesulfonamide
DMADOK6 DE Discovery agent
DM3ZBGQ ID DM3ZBGQ
DM3ZBGQ DN G3139 + cytarabine (ARA-C)
DM3ZBGQ HS Investigative
DM3ZBGQ TC Antisense
DM3ZBGQ DT Combination drug (Antisense drug)
DM3ZBGQ PC 91865905; 6253
DM3ZBGQ DE Acute leukaemia
DMFJ1EI ID DMFJ1EI
DMFJ1EI DN G3139 + Dacarbazine
DMFJ1EI HS Investigative
DMFJ1EI TC Antisense
DMFJ1EI DT Combination drug (Antisense drug)
DMFJ1EI PC 91865905; 5353562
DMFJ1EI DE Melanoma
DMJ9DN3 ID DMJ9DN3
DMJ9DN3 DN G3139 + Dexamethasone
DMJ9DN3 HS Investigative
DMJ9DN3 TC Antisense
DMJ9DN3 DT Combination drug (Antisense drug)
DMJ9DN3 PC 91865905; 5743
DMJ9DN3 DE Multiple myeloma
DMRVLZ4 ID DMRVLZ4
DMRVLZ4 DN G3139 + Fludarabine
DMRVLZ4 HS Investigative
DMRVLZ4 TC Antisense
DMRVLZ4 DT Combination drug (Antisense drug)
DMRVLZ4 PC 91865905; 657237
DMRVLZ4 DE Acute leukaemia
DMH6UOL ID DMH6UOL
DMH6UOL DN G3139 + G-CSF
DMH6UOL HS Investigative
DMH6UOL TC Antisense
DMH6UOL DT Combination drug (Antisense drug)
DMH6UOL PC 91865905;
DMH6UOL DE Acute leukaemia
DMZLJ21 ID DMZLJ21
DMZLJ21 DN G3139 + Irinotecan
DMZLJ21 HS Investigative
DMZLJ21 TC Antisense
DMZLJ21 DT Combination drug (Antisense drug)
DMZLJ21 PC 91865905; 60838
DMZLJ21 DE Metastatic colorectal cancer
DM3MK9Z ID DM3MK9Z
DM3MK9Z DN G3139 + Paclitaxel
DM3MK9Z HS Investigative
DM3MK9Z CP Genta
DM3MK9Z TC Antisense
DM3MK9Z DT Combination drug (Antisense drug)
DM3MK9Z PC 91865905; 36314
DM3MK9Z DE Small-cell lung cancer
DM5KO80 ID DM5KO80
DM5KO80 DN G3139 + Thalidomide
DM5KO80 HS Investigative
DM5KO80 TC Antisense
DM5KO80 DT Combination drug (Antisense drug)
DM5KO80 PC 91865905; 5426
DM5KO80 DE Multiple myeloma
DMDJCIP ID DMDJCIP
DMDJCIP DN G36
DMDJCIP HS Investigative
DMDJCIP SN G-36
DMDJCIP DT Small molecular drug
DMDJCIP PC 73755224
DMDJCIP MW 412.3
DMDJCIP FM C22H22BrNO2
DMDJCIP IC InChI=1S/C22H22BrNO2/c1-12(2)13-6-7-19-16(8-13)14-4-3-5-15(14)22(24-19)17-9-20-21(10-18(17)23)26-11-25-20/h3-4,6-10,12,14-15,22,24H,5,11H2,1-2H3/t14-,15+,22-/m1/s1
DMDJCIP CS CC(C)C1=CC2=C(C=C1)N[C@H]([C@@H]3[C@H]2C=CC3)C4=CC5=C(C=C4Br)OCO5
DMDJCIP IK QTOCPACSSHFGOY-ZCCHDVMBSA-N
DMDJCIP IU (3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-8-propan-2-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline
DMDJCIP DE Discovery agent
DMKTJBU ID DMKTJBU
DMKTJBU DN G418
DMKTJBU HS Investigative
DMKTJBU SN Geneticin; geneticin; antibiotic G 418; antibiotic G-418; UNII-A08F5XTI6G; 49863-47-0; BRN 1669188; A08F5XTI6G; O-2-Amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-D-streptamine; G 418 sulfate; G 418; G-418; C20H40N4O10; GET; D-Streptamine, O-2-amino-2,7-dideoxy-D-glycero-alpha-D-gluco-heptopyranosyl-(1-4)-O-(3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6))-; AC1L3XFV; SCHEMBL5006573; CHEMBL215226; DTXSID10198129
DMKTJBU DT Small molecular drug
DMKTJBU PC 123865
DMKTJBU MW 496.6
DMKTJBU FM C20H40N4O10
DMKTJBU IC InChI=1S/C20H40N4O10/c1-6(25)14-11(27)10(26)9(23)18(32-14)33-15-7(21)4-8(22)16(12(15)28)34-19-13(29)17(24-3)20(2,30)5-31-19/h6-19,24-30H,4-5,21-23H2,1-3H3/t6-,7+,8-,9-,10-,11+,12+,13-,14-,15-,16+,17-,18-,19-,20+/m1/s1
DMKTJBU CS C[C@H]([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)O)O)O
DMKTJBU IK BRZYSWJRSDMWLG-DJWUNRQOSA-N
DMKTJBU IU (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
DMKTJBU CA CAS 49863-47-0
DMKTJBU DE Discovery agent
DMC54UG ID DMC54UG
DMC54UG DN G-573
DMC54UG HS Investigative
DMC54UG SN G-573; CHEMBL2087078; CHEBI:83404; 1009333-44-1; 7-Fluoro-3-[(2-Fluoro-4-Iodophenyl)amino]-N-{[(2s)-2-Hydroxypropyl]oxy}furo[3,2-C]pyridine-2-Carboxamide; SCHEMBL12164599; ZINC43207624; BDBM50420694; KB-77496
DMC54UG CP Genentech Inc
DMC54UG DT Small molecular drug
DMC54UG PC 46926364
DMC54UG MW 489.21
DMC54UG FM C17H14F2IN3O4
DMC54UG IC InChI=1S/C17H14F2IN3O4/c1-8(24)7-26-23-17(25)16-14(10-5-21-6-12(19)15(10)27-16)22-13-3-2-9(20)4-11(13)18/h2-6,8,22,24H,7H2,1H3,(H,23,25)/t8-/m0/s1
DMC54UG CS C[C@@H](CONC(=O)C1=C(C2=CN=CC(=C2O1)F)NC3=C(C=C(C=C3)I)F)O
DMC54UG IK ZEZHPEIEEFTILY-QMMMGPOBSA-N
DMC54UG IU 7-fluoro-3-(2-fluoro-4-iodoanilino)-N-[(2S)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide
DMC54UG CB CHEBI:83404
DMC54UG DE Solid tumour/cancer
DMEZO4M ID DMEZO4M
DMEZO4M DN G6976
DMEZO4M HS Investigative
DMEZO4M SN 12H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; Go 6976; 136194-77-9; GO6976; Go-6976; Goe 6976; UNII-B9IQO7JZ16; 6976; Go 6976, Solution; B9IQO7JZ16; 5,6,7,13-Tetrahydro-13-Methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile; CHEMBL302449; CHEBI:51913; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole; Go6976
DMEZO4M DT Small molecular drug
DMEZO4M PC 3501
DMEZO4M MW 378.4
DMEZO4M FM C24H18N4O
DMEZO4M IC InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)
DMEZO4M CS CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O
DMEZO4M IK VWVYILCFSYNJHF-UHFFFAOYSA-N
DMEZO4M IU 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile
DMEZO4M CA CAS 136194-77-9
DMEZO4M CB CHEBI:51913
DMEZO4M DE Solid tumour/cancer
DMC7HIS ID DMC7HIS
DMC7HIS DN G749
DMC7HIS HS Investigative
DMC7HIS SN G-749
DMC7HIS DT Small molecular drug
DMC7HIS PC 78357765
DMC7HIS MW 521.4
DMC7HIS FM C25H25BrN6O2
DMC7HIS IC InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)
DMC7HIS CS CN1CCC(CC1)NC2=NC3=C(C(=O)NC=C3Br)C(=N2)NC4=CC=C(C=C4)OC5=CC=CC=C5
DMC7HIS IK SXWMIXPJPNCXQQ-UHFFFAOYSA-N
DMC7HIS IU 8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one
DMC7HIS CA CAS 1457983-28-6
DMC7HIS DE Discovery agent
DMOF7JL ID DMOF7JL
DMOF7JL DN GABA-B receptor PAM
DMOF7JL HS Investigative
DMOF7JL SN ADX-1; ADX-1a; ADX-1b; ADX-71441; ADX-1 program (GABA b positive allosteric modulators), Addex; GABA-B receptor PAM (pain/fragile X syndrome/urinary incontinence/GERD); GABA-B receptor PAM (pain/fragile X syndrome/urinary incontinence/GERD), Addex
DMOF7JL CP Addex Pharmaceuticals SA
DMOF7JL DE Anxiety disorder
DMDEAWS ID DMDEAWS
DMDEAWS DN Gababutin
DMDEAWS HS Investigative
DMDEAWS SN Gababutin; CHEMBL610734; 60142-99-6; Cyclopentaneacetic acid, 1-(aminomethyl)-; 2-[1-(aminomethyl)cyclopentyl]acetic Acid; SCHEMBL25615; CTK2F1329; DTXSID70432495; ZINC34016806; BDBM50304691
DMDEAWS DT Small molecular drug
DMDEAWS PC 9898895
DMDEAWS MW 157.21
DMDEAWS FM C8H15NO2
DMDEAWS IC InChI=1S/C8H15NO2/c9-6-8(5-7(10)11)3-1-2-4-8/h1-6,9H2,(H,10,11)
DMDEAWS CS C1CCC(C1)(CC(=O)O)CN
DMDEAWS IK MKGSCDBHUPQQMX-UHFFFAOYSA-N
DMDEAWS IU 2-[1-(aminomethyl)cyclopentyl]acetic acid
DMDEAWS CA CAS 60142-99-6
DMDEAWS DE Discovery agent
DMH17MU ID DMH17MU
DMH17MU DN Gabaculine
DMH17MU HS Investigative
DMH17MU SN DL-Gabaculine; 3-Amino-2,3-dihydrobenzoic acid; GABACULINE, D.L-; Gabaculin; 59556-18-2; 5-Amino-1,3-cyclohexadienylcarboxylic acid; 5-aminocyclohexa-1,3-diene-1-carboxylic acid; NSC-329502; 87980-11-8; C7H9NO2; (+-)-Gabaculine; AC1L1FYB; AC1Q5RCE; Biomol-NT_000232; Lopac0_000006; SCHEMBL2024044; BPBio1_000639; CHEMBL1394922; CTK1H1588; DTXSID90274399; KFNRJXCQEJIBER-UHFFFAOYSA-N; CPD0-1467; NSC329502; Benzoic acid, 3-amino-2,3-dihydro-; NSC 329502; CCG-204102; NCGC00015051-04; NCGC00015051-03; NCGC00162040-01; NCGC00015051-02
DMH17MU DT Small molecular drug
DMH17MU PC 3445
DMH17MU MW 139.15
DMH17MU FM C7H9NO2
DMH17MU IC InChI=1S/C7H9NO2/c8-6-3-1-2-5(4-6)7(9)10/h1-3,6H,4,8H2,(H,9,10)
DMH17MU CS C1C(C=CC=C1C(=O)O)N
DMH17MU IK KFNRJXCQEJIBER-UHFFFAOYSA-N
DMH17MU IU 5-aminocyclohexa-1,3-diene-1-carboxylic acid
DMH17MU CA CAS 59556-18-2
DMH17MU CB CHEBI:29585
DMH17MU DE Discovery agent
DM5TQ2O ID DM5TQ2O
DM5TQ2O DN Galangin
DM5TQ2O HS Investigative
DM5TQ2O SN Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one
DM5TQ2O DT Small molecular drug
DM5TQ2O PC 5281616
DM5TQ2O MW 270.24
DM5TQ2O FM C15H10O5
DM5TQ2O IC InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H
DM5TQ2O CS C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DM5TQ2O IK VCCRNZQBSJXYJD-UHFFFAOYSA-N
DM5TQ2O IU 3,5,7-trihydroxy-2-phenylchromen-4-one
DM5TQ2O CA CAS 548-83-4
DM5TQ2O CB CHEBI:5262
DM5TQ2O DE Discovery agent
DMHPV8A ID DMHPV8A
DMHPV8A DN GALANIN
DMHPV8A HS Investigative
DMHPV8A DE Discovery agent
DMAFE24 ID DMAFE24
DMAFE24 DN Galanthamine derivative
DMAFE24 HS Investigative
DMAFE24 SN GALANTHAMINE DERIVATIVE; (4AR,6S,8AR)-11-[8-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)OCTYL]-6-HYDROXY-3-METHOXY-5,6,9,10-TETRAHYDRO-4AH-[1]BENZOFURO[3A,3,2-EF][2]BENZAZEPIN-11-IUM; galanthamine deriv. 4d; 1w4l; Galanthamine derivative 3; CHEMBL490866; BDBM10406; DB02673; (4aS,8aS)-3-Methoxy-6beta-hydroxy-11-[8-(1,3-dioxo-1,3-dihydro-2H-isoindole-2-yl)octyl]-4aalpha,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef][2]benzazepine-11-ium
DMAFE24 DT Small molecular drug
DMAFE24 PC 5288394
DMAFE24 MW 529.6
DMAFE24 FM C32H37N2O5+
DMAFE24 IC InChI=1S/C32H37N2O5/c1-38-26-13-12-22-21-33(19-16-32-15-14-23(35)20-27(32)39-29(26)28(22)32)17-8-4-2-3-5-9-18-34-30(36)24-10-6-7-11-25(24)31(34)37/h6-7,10-15,21,23,27,35H,2-5,8-9,16-20H2,1H3/q+1/t23-,27-,32-/m0/s1
DMAFE24 CS COC1=C2C3=C(C=C1)C=[N+](CC[C@]34C=C[C@@H](C[C@@H]4O2)O)CCCCCCCCN5C(=O)C6=CC=CC=C6C5=O
DMAFE24 IK VLGAHTYYCHWLNI-BHRZLAGCSA-N
DMAFE24 IU 2-[8-[(1S,12S,14R)-14-hydroxy-9-methoxy-11-oxa-4-azoniatetracyclo[8.6.1.01,12.06,17]heptadeca-4,6(17),7,9,15-pentaen-4-yl]octyl]isoindole-1,3-dione
DMAFE24 DE Discovery agent
DMDZHEO ID DMDZHEO
DMDZHEO DN GALANTIDE
DMDZHEO HS Investigative
DMDZHEO SN 52364-71-3; 4'-Pentyloxy-[1,1'-Biphenyl]-4-carbonitrile; 4-Pentyloxy-4'-cyanobiphenyl; 4-Cyano-4'-pentyloxybiphenyl; 4-Amyloxycyanodiphenyl; 5OCB; 4'-(pentyloxy)biphenyl-4-carbonitrile; [1,1'-Biphenyl]-4-carbonitrile, 4'-(pentyloxy)-; 5COB; M 15 (liquid crystal); NZh K 1; 4-Cyano-4'-pentoxybiphenyl; D 105 (stationary phase); Ro CB 5315; m 15; 4-Pentyloxy-[1,1'-biphenyl]-4'-carbonitrile; EINECS 257-875-9; BRN 2215500; 4-(4-pentoxyphenyl)benzonitrile; D 105; 4'-(Pentyloxy)-(1,1'-biphenyl)-4-carbonitrile
DMDZHEO DT Small molecular drug
DMDZHEO PC 16132126
DMDZHEO MW 2199.5
DMDZHEO FM C104H151N25O26S
DMDZHEO IC InChI=1S/C104H151N25O26S/c1-54(2)39-70(91(142)113-52-87(139)129-37-20-27-80(129)103(154)120-69(33-35-82(107)134)93(144)119-68(32-34-81(106)133)94(145)124-76(44-61-23-16-13-17-24-61)99(150)123-74(43-60-21-14-12-15-22-60)92(143)112-51-86(138)116-71(40-55(3)4)95(146)118-67(89(109)140)36-38-156-11)121-96(147)72(41-56(5)6)122-98(149)75(45-62-28-30-64(132)31-29-62)117-85(137)50-111-90(141)58(9)114-102(153)79(53-130)127-100(151)78(47-83(108)135)125-97(148)73(42-57(7)8)126-104(155)88(59(10)131)128-101(152)77(115-84(136)48-105)46-63-49-110-66-26-19-18-25-65(63)66/h12-19,21-26,28-31,49,54-59,67-80,88,110,130-132H,20,27,32-48,50-53,105H2,1-11H3,(H2,106,133)(H2,107,134)(H2,108,135)(H2,109,140)(H,111,141)(H,112,143)(H,113,142)(H,114,153)(H,115,136)(H,116,138)(H,117,137)(H,118,146)(H,119,144)(H,120,154)(H,121,147)(H,122,149)(H,123,150)(H,124,145)(H,125,148)(H,126,155)(H,127,151)(H,128,152)/t58-,59+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,88-/m0/s1
DMDZHEO CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)CN)O
DMDZHEO IK TZOJVPDIYKRJSM-GKPUQKAJSA-N
DMDZHEO IU (2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMDZHEO CA CAS 138579-66-5
DMDZHEO DE Discovery agent
DMGX6UH ID DMGX6UH
DMGX6UH DN GalB2
DMGX6UH HS Investigative
DMGX6UH SN GalB2; CHEMBL578514
DMGX6UH PC 24760995
DMGX6UH MW 2113.6
DMGX6UH FM C104H173N23O23
DMGX6UH IC InChI=1S/C104H173N23O23/c1-11-12-13-14-15-16-17-18-19-20-21-22-23-42-86(132)110-50-33-29-39-74(95(140)120-76(104(149)150)40-28-32-49-107)118-93(138)73(37-26-30-47-105)117-94(139)75(38-27-31-48-106)119-102(147)84-41-34-51-127(84)89(135)61-113-92(137)77(52-63(2)3)121-96(141)78(53-64(4)5)122-98(143)80(55-68-43-45-70(130)46-44-68)115-88(134)60-112-91(136)66(8)114-101(146)83(62-128)125-99(144)82(57-85(108)131)123-97(142)79(54-65(6)7)124-103(148)90(67(9)129)126-100(145)81(116-87(133)59-109-10)56-69-58-111-72-36-25-24-35-71(69)72/h24-25,35-36,43-46,58,63-67,73-84,90,109,111,128-130H,11-23,26-34,37-42,47-57,59-62,105-107H2,1-10H3,(H2,108,131)(H,110,132)(H,112,136)(H,113,137)(H,114,146)(H,115,134)(H,116,133)(H,117,139)(H,118,138)(H,119,147)(H,120,140)(H,121,141)(H,122,143)(H,123,142)(H,124,148)(H,125,144)(H,126,145)(H,149,150)/t66-,67+,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,90-/m0/s1
DMGX6UH CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)CNC
DMGX6UH IK DWLPZUABYQBJIQ-CMDPNKGGSA-N
DMGX6UH IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-3-hydroxy-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]hexanoyl]amino]-6-(hexadecanoylamino)hexanoyl]amino]hexanoic acid
DMGX6UH DE Discovery agent
DM7PR5E ID DM7PR5E
DM7PR5E DN Gal-B5
DM7PR5E HS Investigative
DM7PR5E SN Gal-B5; CHEMBL506495
DM7PR5E PC 25180495
DM7PR5E MW 2041.6
DM7PR5E FM C101H169N23O21
DM7PR5E IC InChI=1S/C101H169N23O21/c1-10-11-12-13-14-15-16-17-18-19-20-21-22-41-84(129)108-49-32-28-39-74(92(136)114-72(88(107)132)36-25-29-46-102)116-93(137)73(37-26-30-47-103)115-94(138)75(38-27-31-48-104)117-100(144)82-40-33-50-124(82)86(131)59-111-91(135)76(51-61(2)3)118-95(139)77(52-62(4)5)119-97(141)79(54-66-42-44-68(127)45-43-66)113-85(130)58-110-89(133)64(8)112-99(143)81(60-125)122-98(142)80(56-83(106)128)120-96(140)78(53-63(6)7)121-101(145)87(65(9)126)123-90(134)70(105)55-67-57-109-71-35-24-23-34-69(67)71/h23-24,34-35,42-45,57,61-65,70,72-82,87,109,125-127H,10-22,25-33,36-41,46-56,58-60,102-105H2,1-9H3,(H2,106,128)(H2,107,132)(H,108,129)(H,110,133)(H,111,135)(H,112,143)(H,113,130)(H,114,136)(H,115,138)(H,116,137)(H,117,144)(H,118,139)(H,119,141)(H,120,140)(H,121,145)(H,122,142)(H,123,134)/t64-,65+,70-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,87-/m0/s1
DM7PR5E CS CCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N
DM7PR5E IK CYRNKOJFIDMNMV-WCXAHCKYSA-N
DM7PR5E IU (2S)-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-6-(hexadecanoylamino)-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]butanediamide
DM7PR5E DE Discovery agent
DMNWU83 ID DMNWU83
DMNWU83 DN Gallic acid 5,6-dihydroxy-3-carboxyphenylester
DMNWU83 HS Investigative
DMNWU83 SN gallic acid 5,6-dihydroxy-3-carboxyphenylester; SCHEMBL2280107; CHEMBL498103
DMNWU83 DT Small molecular drug
DMNWU83 PC 44592636
DMNWU83 MW 322.22
DMNWU83 FM C14H10O9
DMNWU83 IC InChI=1S/C14H10O9/c15-7-2-1-6(10(17)12(7)19)14(22)23-9-4-5(13(20)21)3-8(16)11(9)18/h1-4,15-19H,(H,20,21)
DMNWU83 CS C1=CC(=C(C(=C1C(=O)OC2=CC(=CC(=C2O)O)C(=O)O)O)O)O
DMNWU83 IK PTBZQGDFAUQSCW-UHFFFAOYSA-N
DMNWU83 IU 3,4-dihydroxy-5-(2,3,4-trihydroxybenzoyl)oxybenzoic acid
DMNWU83 DE Discovery agent
DM6Y3A0 ID DM6Y3A0
DM6Y3A0 DN GALLICACID
DM6Y3A0 HS Investigative
DM6Y3A0 SN Gallic acid; 3,4,5-Trihydroxybenzoic acid; 149-91-7; gallate; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.; GALOP; Pyrogallol-5-carboxylic acid; Kyselina gallova; HSDB 2117; 3,4,5-Trihydroxybenzoate; CCRIS 5523; Kyselina gallova [Czech]; Gallic acid polymer; UNII-632XD903SP; NSC 674319; Gallicum acidum; CHEBI:30778; AI3-16412; Kyselina 3,4,5-trihydroxybenzoova; EINECS 205-749-9; NSC 20103; BRN 2050274; GALLIC ACID ANHYDROUS; Kyselina 3,4,5-trihydroxybenzoova [Czech]; CHEMBL288114; LNTHITQWFMADLM-UHFFFAOYSA-N; 632XD903SP
DM6Y3A0 DT Small molecular drug
DM6Y3A0 PC 370
DM6Y3A0 MW 170.12
DM6Y3A0 FM C7H6O5
DM6Y3A0 IC InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)
DM6Y3A0 CS C1=C(C=C(C(=C1O)O)O)C(=O)O
DM6Y3A0 IK LNTHITQWFMADLM-UHFFFAOYSA-N
DM6Y3A0 IU 3,4,5-trihydroxybenzoic acid
DM6Y3A0 CA CAS 149-91-7
DM6Y3A0 CB CHEBI:30778
DM6Y3A0 DE Discovery agent
DMX2084 ID DMX2084
DMX2084 DN GALLOCATECHIN GALLATE
DMX2084 HS Investigative
DMX2084 SN (-)-Gallocatechin gallate; 4233-96-9; Gallocatechin gallate; (-)-Gallocatechol gallate; UNII-IRW3C4Y31Q; (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Gallocatechin gallate (Gcg); IRW3C4Y31Q; CHEMBL264938; (-)-gallocatechin-3-O-gallate; (2S,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-(3,4,5-trihydroxybenzoate); [(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, 3,
DMX2084 DT Small molecular drug
DMX2084 PC 5276890
DMX2084 MW 458.4
DMX2084 FM C22H18O11
DMX2084 IC InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21+/m0/s1
DMX2084 CS C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
DMX2084 IK WMBWREPUVVBILR-GHTZIAJQSA-N
DMX2084 IU [(2R,3S)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
DMX2084 CA CAS 5127-64-0
DMX2084 CB CHEBI:156284
DMX2084 DE Discovery agent
DML9DH8 ID DML9DH8
DML9DH8 DN galmic
DML9DH8 HS Investigative
DML9DH8 SN galmic; CHEMBL1187471; GTPL6119
DML9DH8 DT Small molecular drug
DML9DH8 PC 24748735
DML9DH8 MW 989.1
DML9DH8 FM C51H60N10O11
DML9DH8 IC InChI=1S/C51H60N10O11/c1-26-36-41(64)61-51(6,45(68)55-38-32-21-13-11-19-30(32)31-20-12-14-22-33(31)38)48-58-37(28(3)72-48)40(63)60-50(5,44(67)54-34(42(65)69-7)23-15-16-24-52)47-57-35(27(2)71-47)39(62)59-49(4,46(56-36)70-26)43(66)53-25-29-17-9-8-10-18-29/h11-14,19-22,29,34,38H,8-10,15-18,23-25,52H2,1-7H3,(H,53,66)(H,54,67)(H,55,68)(H,59,62)(H,60,63)(H,61,64)/t34-,49-,50-,51-/m0/s1
DML9DH8 CS CC1=C2C(=O)N[C@@](C3=NC(=C(O3)C)C(=O)N[C@@](C4=NC(=C(O4)C)C(=O)N[C@@](C(=N2)O1)(C)C(=O)NCC5CCCCC5)(C)C(=O)N[C@@H](CCCCN)C(=O)OC)(C)C(=O)NC6C7=CC=CC=C7C8=CC=CC=C68
DML9DH8 IK DOHGPSDHRIKTDB-KBAHWNQNSA-N
DML9DH8 IU methyl (2S)-6-amino-2-[[(4R,11R,18R)-11-(cyclohexylmethylcarbamoyl)-18-(9H-fluoren-9-ylcarbamoyl)-4,7,11,14,18,21-hexamethyl-2,9,16-trioxo-6,13,20-trioxa-3,10,17,22,23,24-hexazatetracyclo[17.2.1.15,8.112,15]tetracosa-1(21),5(24),7,12(23),14,19(22)-hexaene-4-carbonyl]amino]hexanoate
DML9DH8 DE Discovery agent
DMB8HCW ID DMB8HCW
DMB8HCW DN Galnon
DMB8HCW HS Investigative
DMB8HCW SN Galnon; 475115-35-6; CHEMBL592414; 9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate; AC1NSKC5; SCHEMBL4464884; GTPL6118; CHEMBL451433; MolPort-023-276-322; ZINC49756387; AKOS024456937; NCGC00165798-01; B5256
DMB8HCW DT Small molecular drug
DMB8HCW PC 5311268
DMB8HCW MW 678.8
DMB8HCW FM C40H46N4O6
DMB8HCW IC InChI=1S/C40H46N4O6/c1-25-21-37(45)50-36-23-27(18-19-28(25)36)42-38(46)34(17-9-10-20-41)43-39(47)35(22-26-11-3-2-4-12-26)44-40(48)49-24-33-31-15-7-5-13-29(31)30-14-6-8-16-32(30)33/h5-8,13-16,18-19,21,23,26,33-35H,2-4,9-12,17,20,22,24,41H2,1H3,(H,42,46)(H,43,47)(H,44,48)/t34-,35-/m0/s1
DMB8HCW CS CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3CCCCC3)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46
DMB8HCW IK IKNOZZKXIDSTRN-PXLJZGITSA-N
DMB8HCW IU 9H-fluoren-9-ylmethyl N-[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]carbamate
DMB8HCW CA CAS 475115-35-6
DMB8HCW DE Discovery agent
DMI7RPT ID DMI7RPT
DMI7RPT DN GalR3ant
DMI7RPT HS Investigative
DMI7RPT SN GalR3ant; GTPL6127; SCHEMBL5362026; 3-(3,4-dichlorophenyl)imino-1-(6-methoxypyridin-3-yl)indol-2-one
DMI7RPT DT Small molecular drug
DMI7RPT PC 9800980
DMI7RPT MW 398.2
DMI7RPT FM C20H13Cl2N3O2
DMI7RPT IC InChI=1S/C20H13Cl2N3O2/c1-27-18-9-7-13(11-23-18)25-17-5-3-2-4-14(17)19(20(25)26)24-12-6-8-15(21)16(22)10-12/h2-11H,1H3
DMI7RPT CS COC1=NC=C(C=C1)N2C3=CC=CC=C3C(=NC4=CC(=C(C=C4)Cl)Cl)C2=O
DMI7RPT IK YZFBJQVMOLTGFZ-UHFFFAOYSA-N
DMI7RPT IU 3-(3,4-dichlorophenyl)imino-1-(6-methoxypyridin-3-yl)indol-2-one
DMI7RPT DE Discovery agent
DMFSXOM ID DMFSXOM
DMFSXOM DN Gamma-acetylenic GABA
DMFSXOM HS Investigative
DMFSXOM SN gamma-Acetylenic gaba; 4-Aminohex-5-ynoic acid; gamma-Acetylinic GABA; 4-Amino-5-hexynoic acid; 57659-38-8; RMI 71645; 5-Hexynoic acid, 4-amino-; RMI-71645; 4-aminohexynoate; gamma-acetylenic-GABA; Acetylenic GABA-7; AC1L1FYW; 4-ami-nohex-5-ynoic acid; AC1Q5VT0; 4-Amino-hex-5-ynoic acid; Lopac0_000138; SCHEMBL690785; CHEMBL330129; 4-Amino-5-hexynoic acid, solid; CTK5A7233; BDBM81477; HMS3260K18; Tox21_500138; PDSP2_000141; PDSP1_000142; AKOS006272245; LP00138; CCG-204233; NCGC00015019-02; NCGC00093628-02; NCGC00260823-01
DMFSXOM DT Small molecular drug
DMFSXOM PC 3452
DMFSXOM MW 127.14
DMFSXOM FM C6H9NO2
DMFSXOM IC InChI=1S/C6H9NO2/c1-2-5(7)3-4-6(8)9/h1,5H,3-4,7H2,(H,8,9)
DMFSXOM CS C#CC(CCC(=O)O)N
DMFSXOM IK BJNIHWSOVCDBHS-UHFFFAOYSA-N
DMFSXOM IU 4-aminohex-5-ynoic acid
DMFSXOM CA CAS 57659-38-8
DMFSXOM DE Discovery agent
DMDCZWY ID DMDCZWY
DMDCZWY DN Gamma-butyrolactone
DMDCZWY HS Investigative
DMDCZWY SN 4-butanolide; 2-oxolanone
DMDCZWY DT Small molecular drug
DMDCZWY PC 7302
DMDCZWY MW 86.09
DMDCZWY FM C4H6O2
DMDCZWY IC InChI=1S/C4H6O2/c5-4-2-1-3-6-4/h1-3H2
DMDCZWY CS C1CC(=O)OC1
DMDCZWY IK YEJRWHAVMIAJKC-UHFFFAOYSA-N
DMDCZWY IU oxolan-2-one
DMDCZWY CA CAS 96-48-0
DMDCZWY CB CHEBI:42639
DMDCZWY DE Discovery agent
DMZMCT0 ID DMZMCT0
DMZMCT0 DN Gamma-Carboxy-Glutamic Acid
DMZMCT0 HS Investigative
DMZMCT0 SN H-GLA-OH; 53861-57-7; gamma-Carboxyglutamic acid; Gamma-Carboxy-Glutamic Acid; g-carboxyglutamic acid; gamma-Carboxy-L-glutamic acid; L-Gla-OH; H-L-Gla-OH; (S)-3-Aminopropane-1,1,3-tricarboxylic acid; (3S)-3-aminopropane-1,1,3-tricarboxylic acid; CHEMBL38397; CHEBI:41450; (3S)-3-amino-1,1,3-propanetricarboxylic acid; gamma-carboxy-glutamic acid zwitterion; EINECS 258-825-9; AC1Q5RNZ; H-Gamma-Carboxy-Glu-OH; AC1L2X6R; SCHEMBL39093; 1,1,3-Propanetricarboxylic acid, 3-amino-, (3S)-; CTK1H2562; UHBYWPGGCSDKFX-VKHMYHEASA-N
DMZMCT0 DT Small molecular drug
DMZMCT0 PC 104625
DMZMCT0 MW 191.14
DMZMCT0 FM C6H9NO6
DMZMCT0 IC InChI=1S/C6H9NO6/c7-3(6(12)13)1-2(4(8)9)5(10)11/h2-3H,1,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m0/s1
DMZMCT0 CS C([C@@H](C(=O)O)N)C(C(=O)O)C(=O)O
DMZMCT0 IK UHBYWPGGCSDKFX-VKHMYHEASA-N
DMZMCT0 IU (3S)-3-aminopropane-1,1,3-tricarboxylic acid
DMZMCT0 CA CAS 53861-57-7
DMZMCT0 CB CHEBI:41450
DMZMCT0 DE Discovery agent
DMHNJDE ID DMHNJDE
DMHNJDE DN Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine
DMHNJDE HS Investigative
DMHNJDE SN GAMMA-GLUTAMYL[S-(2-IODOBENZYL)CYSTEINYL]GLYCINE; IBG; AC1L9KH0; SCHEMBL433962; DB03597; L-gamma-glutamyl-S-(2-iodobenzyl)-L-cysteinylglycine; (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(2-iodophenyl)methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMHNJDE DT Small molecular drug
DMHNJDE PC 447108
DMHNJDE MW 523.299
DMHNJDE FM C17H22IN3O6S
DMHNJDE IC InChI=1S/C17H22IN3O6S/c18-11-4-2-1-3-10(11)8-28-9-13(16(25)20-7-15(23)24)21-14(22)6-5-12(19)17(26)27/h1-4,12-13H,5-9,19H2,(H,20,25)(H,21,22)(H,23,24)(H,26,27)/t12-,13-/m0/s1
DMHNJDE CS C1=CC=C(C(=C1)CSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)I
DMHNJDE IK QFYJAEOZTBVJQM-STQMWFEESA-N
DMHNJDE IU (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[(2-iodophenyl)methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMHNJDE DE Discovery agent
DMC0OVP ID DMC0OVP
DMC0OVP DN Gamma-mangostin
DMC0OVP HS Investigative
DMC0OVP SN gamma-Mangostin; 31271-07-5; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; CHEMBL260553; CHEBI:67548; Q-100393; 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6,7-tetrahydroxy-2,8-bis(3-methyl-2-butenyl)-; Normangostin; g-Mangostin; gamma- Mangostin; Mangostin, gamma-; AC1NUYXQ; 1,3,6,7-Tetrahydroxy-2,5-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; SCHEMBL3753526; DTXSID50185194; VEZXFTKZUMARDU-UHFFFAOYSA-N; MolPort-019-937-259; ZINC5195818; gamma-Mangostin, >
DMC0OVP DT Small molecular drug
DMC0OVP PC 5464078
DMC0OVP MW 396.4
DMC0OVP FM C23H24O6
DMC0OVP IC InChI=1S/C23H24O6/c1-11(2)5-7-13-15(24)9-18-20(22(13)27)23(28)19-14(8-6-12(3)4)21(26)16(25)10-17(19)29-18/h5-6,9-10,24-27H,7-8H2,1-4H3
DMC0OVP CS CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)O)CC=C(C)C)O)C
DMC0OVP IK VEZXFTKZUMARDU-UHFFFAOYSA-N
DMC0OVP IU 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one
DMC0OVP CA CAS 31271-07-5
DMC0OVP CB CHEBI:67548
DMC0OVP DE Discovery agent
DMG7UPR ID DMG7UPR
DMG7UPR DN Gamma-secretase modulators
DMG7UPR HS Investigative
DMG7UPR SN Gamma-secretase modulators (Alzheimer's disease); Gamma-secretase modulators (Alzheimer's disease), F Hoffmann-La Roche
DMG7UPR CP F Hoffmann-La Roche Ltd
DMG7UPR DT Small molecular drug
DMG7UPR PC 24781184
DMG7UPR MW 483.5
DMG7UPR FM C26H24F3N3O3
DMG7UPR IC InChI=1S/C26H24F3N3O3/c1-15-11-31(14-30-15)22-6-3-16(8-24(22)34-2)7-17-4-5-19-12-35-13-23(32(19)26(17)33)18-9-20(27)25(29)21(28)10-18/h3,6-11,14,19,23H,4-5,12-13H2,1-2H3/b17-7+/t19-,23-/m0/s1
DMG7UPR CS CC1=CN(C=N1)C2=C(C=C(C=C2)/C=C/3\\CC[C@H]4COC[C@H](N4C3=O)C5=CC(=C(C(=C5)F)F)F)OC
DMG7UPR IK VHNYOQKVZQVBLC-RTCGXNAVSA-N
DMG7UPR IU (4R,7E,9aS)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one
DMG7UPR CA CAS 937812-80-1
DMG7UPR DE Alzheimer disease
DM83HUI ID DM83HUI
DM83HUI DN Gamma-thiobutyrolactone
DM83HUI HS Investigative
DM83HUI SN Dihydro-2(3H)-thiophenone; Dihydro-2-(3H)-thiophenone; KMSNYNIWEORQDJ-UHFFFAOYSA-N; Tetrahydro-2-thiophenone; Thiacyclopentan-2-one; Thiacyclopentanone-2; Thiolan-2-one; dihydrothiophen-2(3H)-one; gamma-Thiobutyrolactone; thiolanone; .gamma.-Thiobutyrolactone; 1003-10-7; 2(3H)-Thiophenone, dihydro-; 2-Oxothiolane; 2-THIOPHENONE, TETRAHYDRO-; 2-Thiolanone; 2-oxotetrahydrothiophene; 4-Butyrothiolactone; 4-Thiobutyrolactone; A3ERZ734SN; AC1L22MB; BRN 0105273; CHEBI:89059; EINECS 213-700-8; NSC 54087; SCHEMBL13480; UNII-A3ERZ734SN
DM83HUI PC 13852
DM83HUI MW 102.16
DM83HUI FM C4H6OS
DM83HUI IC KMSNYNIWEORQDJ-UHFFFAOYSA-N
DM83HUI CS C1CC(=O)SC1
DM83HUI IK 1S/C4H6OS/c5-4-2-1-3-6-4/h1-3H2
DM83HUI IU thiolan-2-one
DM83HUI CA CAS 1003-10-7
DM83HUI CB CHEBI:89059
DM83HUI DE Discovery agent
DM42EVG ID DM42EVG
DM42EVG DN Ganoderic acid A
DM42EVG HS Investigative
DM42EVG SN Ganoderic acid A; 81907-62-2; UNII-548G37DF65; 548G37DF65; (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid; (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxo-heptanoic acid; CHEMBL602899; Ganoderic-acid-A; AC1LAM6R; HY-N1447; ZINC49767216; CS-5856; Lanost-8-en-26-oic
DM42EVG DT Small molecular drug
DM42EVG PC 471002
DM42EVG MW 516.7
DM42EVG FM C30H44O7
DM42EVG IC InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,23,32,35H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,23+,28+,29-,30+/m1/s1
DM42EVG CS C[C@H](CC(=O)C[C@@H](C)C(=O)O)[C@H]1C[C@@H]([C@@]2([C@@]1(CC(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)O)C)C)O
DM42EVG IK DYOKDAQBNHPJFD-JNTBEZBXSA-N
DM42EVG IU (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
DM42EVG CA CAS 81907-62-2
DM42EVG DE Discovery agent
DMFT4GU ID DMFT4GU
DMFT4GU DN GANSTIGMINE
DMFT4GU HS Investigative
DMFT4GU DT Small molecular drug
DMFT4GU PC 9823294
DMFT4GU MW 381.5
DMFT4GU FM C22H27N3O3
DMFT4GU IC InChI=1S/C22H27N3O3/c1-5-15-8-6-7-9-18(15)23-21(26)27-16-10-11-19-17(14-16)22(2)12-13-24(3)28-20(22)25(19)4/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)/t20-,22-/m0/s1
DMFT4GU CS CCC1=CC=CC=C1NC(=O)OC2=CC3=C(C=C2)N([C@@H]4[C@]3(CCN(O4)C)C)C
DMFT4GU IK ZOBDWFRKFSPCRB-UNMCSNQZSA-N
DMFT4GU IU [(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-(2-ethylphenyl)carbamate
DMFT4GU CA CAS 457075-21-7
DMFT4GU DE Discovery agent
DM6B9ZG ID DM6B9ZG
DM6B9ZG DN garcinol
DM6B9ZG HS Investigative
DM6B9ZG SN Garcinol; Camboginol; 78824-30-3; AC1Q1NUM; GTPL7001; QDKLRKZQSOQWJQ-SMDXAGPFSA-N; ZINC4098424; AKOS025142024; (1S,5R,7R)-3-[(3,4-dihydroxyphenyl)(hydroxy)methylidene]-6,6-dimethyl-1-[(2S)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-5,7-bis(3-methylbut-2-en-1-yl)bicyclo[3.3.1]nonane-2,4,9-trione; (1R,5R,7R)-3-(3,4-Dihydroxybenzoyl)-4-hydroxy-8,8-dimethyl-1,7-bis(3-methyl-2-buten-1-yl)-5-[(2S)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-Bicyclo[3.3.1]non-3-ene-2,9-dione
DM6B9ZG DT Small molecular drug
DM6B9ZG PC 5281560
DM6B9ZG MW 602.8
DM6B9ZG FM C38H50O6
DM6B9ZG IC InChI=1S/C38H50O6/c1-22(2)11-13-27(25(7)8)20-37-21-28(15-12-23(3)4)36(9,10)38(35(37)44,18-17-24(5)6)34(43)31(33(37)42)32(41)26-14-16-29(39)30(40)19-26/h11-12,14,16-17,19,27-28,39-41H,7,13,15,18,20-21H2,1-6,8-10H3/b32-31-/t27-,28+,37+,38-/m0/s1
DM6B9ZG CS CC(=CC[C@@H]1C[C@@]2(C(=O)/C(=C(\\C3=CC(=C(C=C3)O)O)/O)/C(=O)[C@@](C2=O)(C1(C)C)CC=C(C)C)C[C@H](CC=C(C)C)C(=C)C)C
DM6B9ZG IK DTTONLKLWRTCAB-BZSUNBQASA-N
DM6B9ZG IU (1S,3Z,5R,7R)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2S)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione
DM6B9ZG CA CAS 78824-30-3
DM6B9ZG CB CHEBI:5276
DM6B9ZG DE Discovery agent
DMQDV3U ID DMQDV3U
DMQDV3U DN GARCINONE D
DMQDV3U HS Investigative
DMQDV3U SN GARCINONE D; 107390-08-9; CHEMBL462879; Q-100046; Garcinone-D; AC1NUY2Y; Garcinia mangostana (Mangosteen); DTXSID00420547; MolPort-039-142-002; ZINC14727633; 9439AF; BDBM50250510; AB3000023; N2173; FT-0686619; 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-8-(3-hydroxy-3-methyl-butyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one; 9H-Xanthen-9-one, 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methyl-2-butenyl)-
DMQDV3U DT Small molecular drug
DMQDV3U PC 5495926
DMQDV3U MW 428.5
DMQDV3U FM C24H28O7
DMQDV3U IC InChI=1S/C24H28O7/c1-12(2)6-7-13-15(25)10-18-20(21(13)27)22(28)19-14(8-9-24(3,4)29)23(30-5)16(26)11-17(19)31-18/h6,10-11,25-27,29H,7-9H2,1-5H3
DMQDV3U CS CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CCC(C)(C)O)O)C
DMQDV3U IK TYALNCRUIKOKGP-UHFFFAOYSA-N
DMQDV3U IU 1,3,6-trihydroxy-8-(3-hydroxy-3-methylbutyl)-7-methoxy-2-(3-methylbut-2-enyl)xanthen-9-one
DMQDV3U CA CAS 107390-08-9
DMQDV3U DE Discovery agent
DMZ5AD8 ID DMZ5AD8
DMZ5AD8 DN GARTANIN
DMZ5AD8 HS Investigative
DMZ5AD8 SN Gartanin; 33390-42-0; 1,3,5,8-Tetrahydroxy-2,4-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; Gartinin; 9H-Xanthen-9-one, 1,3,5,8-tetrahydroxy-2,4-bis(3-methyl-2-butenyl)-; CHEBI:5279; CHEMBL487992; 1,3,5,8-Tetrahydroxy-2,4-diprenylxanthone; 1,3,5,8-TETRAHYDROXY-2,4-BIS(3-METHYL-2-BUTENYL)-9H-XANTHEN-9-ONE; Q-100408; 1,3,5,8-tetrahydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one; AC1NQYRY; C10063; SCHEMBL1516414; DTXSID20187024; MolPort-023-221-573; ZINC5854400; BDBM50311743; NSC692946; AKOS016009589; NSC-692946; P165; AK111266
DMZ5AD8 DT Small molecular drug
DMZ5AD8 PC 5281633
DMZ5AD8 MW 396.4
DMZ5AD8 FM C23H24O6
DMZ5AD8 IC InChI=1S/C23H24O6/c1-11(2)5-7-13-19(26)14(8-6-12(3)4)22-18(20(13)27)21(28)17-15(24)9-10-16(25)23(17)29-22/h5-6,9-10,24-27H,7-8H2,1-4H3
DMZ5AD8 CS CC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=C(C=CC(=C3O2)O)O)CC=C(C)C)O)C
DMZ5AD8 IK OJXQLGQIDIPMTE-UHFFFAOYSA-N
DMZ5AD8 IU 1,3,5,8-tetrahydroxy-2,4-bis(3-methylbut-2-enyl)xanthen-9-one
DMZ5AD8 CA CAS 33390-42-0
DMZ5AD8 CB CHEBI:5279
DMZ5AD8 DE Discovery agent
DM7GX1S ID DM7GX1S
DM7GX1S DN GARVEATIN A
DM7GX1S HS Investigative
DM7GX1S SN garveatin A; SCHEMBL3090239
DM7GX1S DT Small molecular drug
DM7GX1S PC 15940065
DM7GX1S MW 340.4
DM7GX1S FM C20H20O5
DM7GX1S IC InChI=1S/C20H20O5/c1-8-6-11-7-12-15(16(22)9(2)19(25)20(12,4)5)18(24)14(11)17(23)13(8)10(3)21/h6-7,22-24H,1-5H3
DM7GX1S CS CC1=CC2=CC3=C(C(=C(C(=O)C3(C)C)C)O)C(=C2C(=C1C(=O)C)O)O
DM7GX1S IK WVQSFFSLBOWMAA-UHFFFAOYSA-N
DM7GX1S IU 6-acetyl-4,5,10-trihydroxy-1,1,3,7-tetramethylanthracen-2-one
DM7GX1S DE Discovery agent
DMXNQ15 ID DMXNQ15
DMXNQ15 DN Garveatin C
DMXNQ15 HS Investigative
DMXNQ15 SN Garveatin C; NSC611985; CHEMBL505049; AC1L78CY; AC1Q1K0O; SCHEMBL3086612; BDBM50241725; NSC-611985; 7-acetyl-9-hydroxy-8-methoxy-2,2,4,4,6-pentamethylanthracene-1,3-dione; 1,3(2H,4H)-anthracenedione, 7-acetyl-9-hydroxy-8-methoxy-2,2,4,4,6-pentamethyl-
DMXNQ15 DT Small molecular drug
DMXNQ15 PC 356405
DMXNQ15 MW 368.4
DMXNQ15 FM C22H24O5
DMXNQ15 IC InChI=1S/C22H24O5/c1-10-8-12-9-13-16(19(25)22(5,6)20(26)21(13,3)4)17(24)15(12)18(27-7)14(10)11(2)23/h8-9,24H,1-7H3
DMXNQ15 CS CC1=CC2=CC3=C(C(=C2C(=C1C(=O)C)OC)O)C(=O)C(C(=O)C3(C)C)(C)C
DMXNQ15 IK BRECKZGJFRHNPM-UHFFFAOYSA-N
DMXNQ15 IU 7-acetyl-9-hydroxy-8-methoxy-2,2,4,4,6-pentamethylanthracene-1,3-dione
DMXNQ15 DE Discovery agent
DMUFZ18 ID DMUFZ18
DMUFZ18 DN Garveatin E
DMUFZ18 HS Investigative
DMUFZ18 SN garveatin E
DMUFZ18 DT Small molecular drug
DMUFZ18 PC 16091659
DMUFZ18 MW 340.4
DMUFZ18 FM C20H20O5
DMUFZ18 IC InChI=1S/C20H20O5/c1-6-10-8(2)15(21)11-7-12-14(18(24)13(11)17(10)23)16(22)9(3)19(25)20(12,4)5/h7,22,24H,6H2,1-5H3
DMUFZ18 CS CCC1=C(C(=O)C2=CC3=C(C(=C(C(=O)C3(C)C)C)O)C(=C2C1=O)O)C
DMUFZ18 IK XUTUGWZITVPISM-UHFFFAOYSA-N
DMUFZ18 IU 2-ethyl-8,9-dihydroxy-3,5,5,7-tetramethylanthracene-1,4,6-trione
DMUFZ18 DE Discovery agent
DMWFYJ4 ID DMWFYJ4
DMWFYJ4 DN GB110
DMWFYJ4 HS Investigative
DMWFYJ4 SN GB 110; GB-110
DMWFYJ4 DT Small molecular drug
DMWFYJ4 PC 49843508
DMWFYJ4 MW 608.8
DMWFYJ4 FM C33H48N6O5
DMWFYJ4 IC InChI=1S/C33H48N6O5/c1-3-22(2)29(38-30(40)27(19-23-8-5-4-6-9-23)37-31(41)28-12-15-36-44-28)32(42)35-21-25-10-7-11-26(18-25)33(43)39-16-13-24(20-34)14-17-39/h7,10-12,15,18,22-24,27,29H,3-6,8-9,13-14,16-17,19-21,34H2,1-2H3,(H,35,42)(H,37,41)(H,38,40)/t22?,27-,29-/m0/s1
DMWFYJ4 CS CCC(C)[C@@H](C(=O)NCC1=CC(=CC=C1)C(=O)N2CCC(CC2)CN)NC(=O)[C@H](CC3CCCCC3)NC(=O)C4=CC=NO4
DMWFYJ4 IK HXLQLJFWNKMGET-KCPQSXFMSA-N
DMWFYJ4 IU N-[(2S)-1-[[(2S)-1-[[3-[4-(aminomethyl)piperidine-1-carbonyl]phenyl]methylamino]-3-methyl-1-oxopentan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]-1,2-oxazole-5-carboxamide
DMWFYJ4 DE Discovery agent
DM7B5HA ID DM7B5HA
DM7B5HA DN GB-12819
DM7B5HA HS Investigative
DM7B5HA SN GB-12819; CHEMBL433138; BDBM50116806; 4-{2-[bis-(4-fluoro-phenyl)-methoxy]-ethyl}-1-(3-phenyl-propyl)-piperazin-1-ium
DM7B5HA DT Small molecular drug
DM7B5HA PC 44316307
DM7B5HA MW 449.6
DM7B5HA FM C29H33F2NO
DM7B5HA IC InChI=1S/C29H33F2NO/c30-27-13-9-25(10-14-27)29(26-11-15-28(31)16-12-26)33-22-21-32-19-17-24(18-20-32)8-4-7-23-5-2-1-3-6-23/h1-3,5-6,9-16,24,29H,4,7-8,17-22H2
DM7B5HA CS C1CN(CCC1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM7B5HA IK VMIZSAUBUHOYHI-UHFFFAOYSA-N
DM7B5HA IU 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperidine
DM7B5HA DE Discovery agent
DMLDVFM ID DMLDVFM
DMLDVFM DN GB88
DMLDVFM HS Investigative
DMLDVFM SN GB 88; GB-88
DMLDVFM DT Small molecular drug
DMLDVFM PC 73755230
DMLDVFM MW 546.7
DMLDVFM FM C32H42N4O4
DMLDVFM IC InChI=1S/C32H42N4O4/c1-3-22(2)28(31(39)36-19-16-32(17-20-36)15-13-24-11-7-8-12-25(24)32)35-29(37)26(21-23-9-5-4-6-10-23)34-30(38)27-14-18-33-40-27/h7-8,11-15,18,22-23,26,28H,3-6,9-10,16-17,19-21H2,1-2H3,(H,34,38)(H,35,37)/t22-,26+,28+/m1/s1
DMLDVFM CS CC[C@@H](C)[C@@H](C(=O)N1CCC2(CC1)C=CC3=CC=CC=C23)NC(=O)[C@H](CC4CCCCC4)NC(=O)C5=CC=NO5
DMLDVFM IK DCUDDCGUKZLQLN-ZEZZXZOMSA-N
DMLDVFM IU N-[(2S)-3-cyclohexyl-1-[[(2S,3R)-3-methyl-1-oxo-1-spiro[indene-1,4'-piperidine]-1'-ylpentan-2-yl]amino]-1-oxopropan-2-yl]-1,2-oxazole-5-carboxamide
DMLDVFM DE Discovery agent
DMPOML4 ID DMPOML4
DMPOML4 DN GBR 12530
DMPOML4 HS Investigative
DMPOML4 SN GBR 12530; CHEMBL203446
DMPOML4 DT Small molecular drug
DMPOML4 PC 44409554
DMPOML4 MW 326.5
DMPOML4 FM C25H26
DMPOML4 IC InChI=1S/C25H26/c1-17-21-12-13-22(17)15-18(14-21)16-25-23-8-4-2-6-19(23)10-11-20-7-3-5-9-24(20)25/h2-9,14,16-17,21-22H,10-13,15H2,1H3
DMPOML4 CS CC1C2CCC1C=C(C2)C=C3C4=CC=CC=C4CCC5=CC=CC=C53
DMPOML4 IK RMNZMKPVCVYBDK-UHFFFAOYSA-N
DMPOML4 IU 2-[(8-methyl-3-bicyclo[3.2.1]oct-2-enyl)methylidene]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene
DMPOML4 DE Discovery agent
DM2CUNP ID DM2CUNP
DM2CUNP DN GBR-12289
DM2CUNP HS Investigative
DM2CUNP SN GBR-12289; CHEMBL381386; BDBM50185251
DM2CUNP DT Small molecular drug
DM2CUNP PC 44409490
DM2CUNP MW 290.4
DM2CUNP FM C19H18N2O
DM2CUNP IC InChI=1S/C19H18N2O/c1-21-13-12-20-19(21)18(22)14-17(15-8-4-2-5-9-15)16-10-6-3-7-11-16/h2-14,18,22H,1H3
DM2CUNP CS CN1C=CN=C1C(C=C(C2=CC=CC=C2)C3=CC=CC=C3)O
DM2CUNP IK ZNOUJOFQAABUAP-UHFFFAOYSA-N
DM2CUNP IU 1-(1-methylimidazol-2-yl)-3,3-diphenylprop-2-en-1-ol
DM2CUNP DE Discovery agent
DMYMGBA ID DMYMGBA
DMYMGBA DN GC-14
DMYMGBA HS Investigative
DMYMGBA DT Small molecular drug
DMYMGBA PC 23724977
DMYMGBA MW 1989.1
DMYMGBA FM C86H103Cl3N10O34P2
DMYMGBA IC InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66+,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1
DMYMGBA CS C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O.OP(=O)(O)O.OP(=O)(O)O
DMYMGBA IK PWTROOMOPLCZHB-UBFSLMEUSA-N
DMYMGBA IU (1S,2R,18R,19R,22S,25R,28R,40R)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid;phosphoric acid
DMYMGBA DE Discovery agent
DM46HAS ID DM46HAS
DM46HAS DN GC-2107
DM46HAS HS Investigative
DM46HAS SN Factor Xa inhibitor (oral/injectable, thrombosis), Green Cross/ LegoChem
DM46HAS CP LegoChem Bioscience Inc
DM46HAS DE Thrombosis
DMSF8B9 ID DMSF8B9
DMSF8B9 DN GC-24
DMSF8B9 HS Investigative
DMSF8B9 SN GC 24; N-[2-(dimethylamino)ethyl]-2-methylpropanamide; Propanamide, N-(2-(dimethylamino)ethyl)-2-methyl-; BRN 2350680; 63224-17-9; N-(2-(Dimethylamino)ethyl)-2-methylpropanamide; AC1MIL8W; SCHEMBL2624391; DTXSID70212592; MolPort-008-439-279; ZINC11638438; AKOS009104316; MCULE-5485385679; NE11932; LS-119191; N-(2-dimethylaminoethyl)-2-methylpropanamide; EN300-86303
DMSF8B9 DT Small molecular drug
DMSF8B9 PC 448011
DMSF8B9 MW 376.4
DMSF8B9 FM C24H24O4
DMSF8B9 IC InChI=1S/C24H24O4/c1-16-10-21(28-15-24(26)27)11-17(2)22(16)14-19-8-9-23(25)20(13-19)12-18-6-4-3-5-7-18/h3-11,13,25H,12,14-15H2,1-2H3,(H,26,27)
DMSF8B9 CS CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)CC3=CC=CC=C3)C)OCC(=O)O
DMSF8B9 IK JYHIGYLGYNCMGI-UHFFFAOYSA-N
DMSF8B9 IU 2-[4-[(3-benzyl-4-hydroxyphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
DMSF8B9 DE Hyperthyroidism
DM4BZEC ID DM4BZEC
DM4BZEC DN GCCSHPACAGNNQHIC*
DM4BZEC HS Investigative
DM4BZEC SN CHEMBL437423; GCCSHPACAGNNQHIC*
DM4BZEC PC 44274422
DM4BZEC MW 1613.8
DM4BZEC FM C61H96N24O20S4
DM4BZEC IC InChI=1S/C61H96N24O20S4/c1-5-26(2)47(60(104)81-37(20-106)48(66)92)84-54(98)32(11-29-16-67-24-70-29)77-51(95)31(8-9-42(63)87)76-53(97)34(14-44(65)89)78-52(96)33(13-43(64)88)74-46(91)18-69-49(93)27(3)72-56(100)39(22-108)82-50(94)28(4)73-59(103)41-7-6-10-85(41)61(105)35(12-30-17-68-25-71-30)79-55(99)36(19-86)80-58(102)40(23-109)83-57(101)38(21-107)75-45(90)15-62/h16-17,24-28,31-41,47,86,106-109H,5-15,18-23,62H2,1-4H3,(H2,63,87)(H2,64,88)(H2,65,89)(H2,66,92)(H,67,70)(H,68,71)(H,69,93)(H,72,100)(H,73,103)(H,74,91)(H,75,90)(H,76,97)(H,77,95)(H,78,96)(H,79,99)(H,80,102)(H,81,104)(H,82,94)(H,83,101)(H,84,98)/t26-,27-,28-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,47-/m0/s1
DM4BZEC CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CN
DM4BZEC IK UCMCIMRDJCGRNT-KLMBZYLCSA-N
DM4BZEC IU (2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]propanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-N-[(2S)-1-[[(2S,3S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]pentanediamide
DM4BZEC DE Discovery agent
DMJ0ICN ID DMJ0ICN
DMJ0ICN DN GCCSNPVCHLEHSNLC*
DMJ0ICN HS Investigative
DMJ0ICN SN CHEMBL265198; GCCSNPVCHLEHSNLC*
DMJ0ICN PC 44274190
DMJ0ICN MW 1715
DMJ0ICN FM C67H107N23O22S4
DMJ0ICN IC InChI=1S/C67H107N23O22S4/c1-29(2)12-35(55(100)77-34(9-10-51(96)97)54(99)80-38(15-33-20-73-28-75-33)58(103)84-41(21-91)60(105)82-39(16-48(69)93)59(104)79-36(13-30(3)4)56(101)86-43(23-113)53(71)98)78-57(102)37(14-32-19-72-27-74-32)81-63(108)46(26-116)88-66(111)52(31(5)6)89-65(110)47-8-7-11-90(47)67(112)40(17-49(70)94)83-61(106)42(22-92)85-64(109)45(25-115)87-62(107)44(24-114)76-50(95)18-68/h19-20,27-31,34-47,52,91-92,113-116H,7-18,21-26,68H2,1-6H3,(H2,69,93)(H2,70,94)(H2,71,98)(H,72,74)(H,73,75)(H,76,95)(H,77,100)(H,78,102)(H,79,104)(H,80,99)(H,81,108)(H,82,105)(H,83,106)(H,84,103)(H,85,109)(H,86,101)(H,87,107)(H,88,111)(H,89,110)(H,96,97)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,52-/m0/s1
DMJ0ICN CS CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CN
DMJ0ICN IK MLPOWHAMUPIMTC-XCQLYXDWSA-N
DMJ0ICN IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMJ0ICN DE Discovery agent
DMVFDYU ID DMVFDYU
DMVFDYU DN G-CSF
DMVFDYU HS Investigative
DMVFDYU SN G-CSF (leukemia)
DMVFDYU CP Medexgen Co Ltd
DMVFDYU DE leukaemia
DMF6MUB ID DMF6MUB
DMF6MUB DN GDP-alpha-D-glucose
DMF6MUB HS Investigative
DMF6MUB SN GDP-D-glucose; GDP-alpha-D-glucose; GDP-alpha-delta-glucose; GDP-glucose; Guanosine 5-pyrophosphate; Guanosine diphosphate glucose; Guanosine diphosphoglucose; P-alpha-D-glucopyranosyl ester; ZINC8215895; (GDP-Glc)1; 5750-57-2; AC1LD8KB; CHEBI:62254; CHEMBL228228; GDG; GDPG; Guanosine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester; Guanosine 5-(trihydrogen diphosphate); P-alpha-delta-glucopyranosyl ester; guanosine 5'-[3-(alpha-D-glucopyranosyl) dihydrogen diphosphate]
DMF6MUB PC 135398625
DMF6MUB MW 605.3
DMF6MUB FM C16H25N5O16P2
DMF6MUB IC MVMSCBBUIHUTGJ-LRJDVEEWSA-N
DMF6MUB CS C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OC4C(C(C(C(O4)CO)O)O)O)O)O)N=C(NC2=O)N
DMF6MUB IK 1S/C16H25N5O16P2/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28)/t4-,5-,7-,8-,9+,10-,11-,14-,15-/m1/s1
DMF6MUB IU [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMF6MUB CA CAS 5750-57-2
DMF6MUB CB CHEBI:62254
DMF6MUB DE Discovery agent
DMZMULS ID DMZMULS
DMZMULS DN Gdp-Fucose
DMZMULS HS Investigative
DMZMULS SN guanosine diphosphate fucose; GDP-L-fucose
DMZMULS DT Small molecular drug
DMZMULS PC 135412609
DMZMULS MW 589.3
DMZMULS FM C16H25N5O15P2
DMZMULS IC InChI=1S/C16H25N5O15P2/c1-4-7(22)9(24)11(26)15(33-4)35-38(30,31)36-37(28,29)32-2-5-8(23)10(25)14(34-5)21-3-18-6-12(21)19-16(17)20-13(6)27/h3-5,7-11,14-15,22-26H,2H2,1H3,(H,28,29)(H,30,31)(H3,17,19,20,27)/t4-,5+,7+,8+,9+,10+,11-,14+,15?/m0/s1
DMZMULS CS C[C@H]1[C@H]([C@H]([C@@H](C(O1)OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=C(NC4=O)N)O)O)O)O)O
DMZMULS IK LQEBEXMHBLQMDB-QIXZNPMTSA-N
DMZMULS IU [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl] hydrogen phosphate
DMZMULS CA CAS 15839-70-0
DMZMULS CB CHEBI:17009
DMZMULS DE Discovery agent
DM9ARQ1 ID DM9ARQ1
DM9ARQ1 DN GDP-l-fucose
DM9ARQ1 HS Investigative
DM9ARQ1 SN GDP-L-fucose; GDP-fucose; Gdp fucose; guanosine diphosphate fucose; (6-deoxy-beta-l-galactopyranosyl) ester; AC1L96W5; CHEBI:17009; GTPL4578; [(2R,3S,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl] hydrogen phosphate; guanosine 5'-[3-(6-deoxy-L-galactopyranosyl) dihydrogen diphosphate]
DM9ARQ1 PC 135412609
DM9ARQ1 MW 589.3
DM9ARQ1 FM C16H25N5O15P2
DM9ARQ1 IC LQEBEXMHBLQMDB-QIXZNPMTSA-N
DM9ARQ1 CS CC1C(C(C(C(O1)OP(=O)(O)OP(=O)(O)OCC2C(C(C(O2)N3C=NC4=C3N=C(NC4=O)N)O)O)O)O)O
DM9ARQ1 IK 1S/C16H25N5O15P2/c1-4-7(22)9(24)11(26)15(33-4)35-38(30,31)36-37(28,29)32-2-5-8(23)10(25)14(34-5)21-3-18-6-12(21)19-16(17)20-13(6)27/h3-5,7-11,14-15,22-26H,2H2,1H3,(H,28,29)(H,30,31)(H3,17,19,20,27)/t4-,5+,7+,8+,9+,10+,11-,14+,15?/m0/s1
DM9ARQ1 IU [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl] hydrogen phosphate
DM9ARQ1 CA CAS 15839-70-0
DM9ARQ1 CB CHEBI:17009
DM9ARQ1 DE Discovery agent
DMOC25M ID DMOC25M
DMOC25M DN GDP-mannose
DMOC25M HS Investigative
DMOC25M SN GDP-D-mannose; GDP-alpha-D-mannose; GDP-mannose; Gdp mannose; SA0B77H8CS; guanosine diphosphate mannose; guanosine diphosphomannose; guanosine pyrophosphate mannose; 3123-67-9; GUANOSINE-5'-DIPHOSPHATE-ALPHA-D-MANNOSE; Guanosine 5'-(trihydrogen diphosphate) P'-mannosyl ester; Guanosine 5'-(trihydrogen pyrophosphate) mono-D-mannosyl ester; Guanosine 5'-(trihydrogen pyrophosphate) monomannopyranosyl ester; Guanosine 5'-diphosphate D-mannose; Guanosine 5'-pyrophosphate D-mannosyl ester; UNII-SA0B77H8CS
DMOC25M PC 135398627
DMOC25M MW 605.3
DMOC25M FM C16H25N5O16P2
DMOC25M IC MVMSCBBUIHUTGJ-GDJBGNAASA-N
DMOC25M CS C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OC4C(C(C(C(O4)CO)O)O)O)O)O)N=C(NC2=O)N
DMOC25M IK 1S/C16H25N5O16P2/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28)/t4-,5-,7-,8-,9+,10-,11+,14-,15-/m1/s1
DMOC25M IU [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
DMOC25M CA CAS 3123-67-9
DMOC25M CB CHEBI:15820
DMOC25M DE Discovery agent
DMB813H ID DMB813H
DMB813H DN GE-137
DMB813H HS Investigative
DMB813H SN GE-137
DMB813H DT Small molecular drug
DMB813H PC 91827375
DMB813H MW 3652
DMB813H FM C156H212N34O52S8
DMB813H IC InChI=1S/C156H212N34O52S8/c1-85(169-88(4)195)135(212)165-76-126(202)171-111(80-192)145(222)184-114-83-245-244-82-113(183-144(221)109(69-92-72-162-100-31-17-16-30-97(92)100)179-148(225)112-81-243-246-84-115(182-143(220)108(178-147(114)224)68-91-41-45-94(197)46-42-91)149(226)180-110(79-191)137(214)168-78-128(204)189-62-27-35-119(189)153(230)190-63-26-34-118(190)150(227)174-102(33-25-59-161-154(158)159)138(215)176-106(66-89-28-11-8-12-29-89)141(218)172-104(139(216)181-112)50-55-130(207)208)146(223)177-107(67-90-39-43-93(196)44-40-90)142(219)173-105(51-56-131(209)210)140(217)186-133(87(3)194)152(229)175-103(49-54-129(205)206)136(213)166-77-127(203)185-132(86(2)193)151(228)167-74-124(200)163-73-123(199)164-75-125(201)170-101(134(157)211)32-18-20-58-160-122(198)38-15-10-21-60-187-116-52-47-95(249(237,238)239)70-98(116)155(5,6)120(187)36-13-9-14-37-121-156(7,57-19-23-64-247(231,232)233)99-71-96(250(240,241)242)48-53-117(99)188(121)61-22-24-65-248(234,235)236/h8-9,11-14,16-17,28-31,36-37,39-48,52-53,70-72,85-87,101-115,118-119,132-133,162,191-194H,10,15,18-27,32-35,38,49-51,54-69,73-84H2,1-7H3,(H39-,157,158,159,160,161,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,195,196,197,198,199,200,201,202,203,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,231,232,233,234,235,236,237,238,239,240,241,242)/t85-,86+,87+,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,118-,119-,132-,133-,156?/m0/s1
DMB813H CS C[C@H]([C@@H](C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCCCCN\\1C2=C(C=C(C=C2)S(=O)(=O)O)C(/C1=C/C=C/C=C/C3=[N+](C4=C(C3(C)CCCCS(=O)(=O)O)C=C(C=C4)S(=O)(=O)[O-])CCCCS(=O)(=O)O)(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@@H]6CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]7CSSC[C@@H](C(=O)N[C@H](C(=O)N6)CC8=CNC9=CC=CC=C98)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC7=O)CO)CCCNC(=N)N)CC1=CC=CC=C1)CCC(=O)O)CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)C)O
DMB813H IK UQYUYHHXESUXGH-ABPLELQPSA-N
DMB813H IU 2-[(1E,3E,5Z)-5-[1-[6-[[(5S)-5-[[2-[[2-[[2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(1R,4S,13S,19S,22S,25S,28S,31R,34S,37R,42R,45S)-42-[[(2S)-2-[[2-[[(2S)-2-acetamidopropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-25-benzyl-22-(3-carbamimidamidopropyl)-28-(2-carboxyethyl)-4-(hydroxymethyl)-45-[(4-hydroxyphenyl)methyl]-34-(1H-indol-3-ylmethyl)-2,5,8,14,20,23,26,29,32,35,43,46-dodecaoxo-39,40,49,50-tetrathia-3,6,9,15,21,24,27,30,33,36,44,47-dodecazatetracyclo[29.16.4.09,13.015,19]henpentacontane-37-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-6-amino-6-oxohexyl]amino]-6-oxohexyl]-3,3-dimethyl-5-sulfoindol-2-ylidene]penta-1,3-dienyl]-3-methyl-1,3-bis(4-sulfobutyl)indol-1-ium-5-sulfonate
DMB813H DE Discovery agent
DMBGWEK ID DMBGWEK
DMBGWEK DN GEA 3162
DMBGWEK HS Investigative
DMBGWEK SN GEA-3162; GEA3162
DMBGWEK DT Small molecular drug
DMBGWEK PC 3035443
DMBGWEK MW 231.04
DMBGWEK FM C7H4Cl2N4O
DMBGWEK IC InChI=1S/C7H4Cl2N4O/c8-5-2-1-4(3-6(5)9)13-11-7(10)14-12-13/h1-3,10H
DMBGWEK CS C1=CC(=C(C=C1[N+]2=NOC(=N)[N-]2)Cl)Cl
DMBGWEK IK VXGYFEOSZYEJBK-UHFFFAOYSA-N
DMBGWEK IU 3-(3,4-dichlorophenyl)-1-oxa-2-aza-3-azonia-4-azanidacyclopent-2-en-5-imine
DMBGWEK CA CAS 144576-10-3
DMBGWEK DE Discovery agent
DMUSJ96 ID DMUSJ96
DMUSJ96 DN Geldanamycin-estradiol hybrid
DMUSJ96 HS Investigative
DMUSJ96 DE Discovery agent
DML0OUY ID DML0OUY
DML0OUY DN Gelsolin
DML0OUY HS Investigative
DML0OUY SN OYQRWBFWLSYDIZ-NATPOTRJSA-N; GEM 231
DML0OUY DT Antibody
DML0OUY DE Discovery agent
DMETRIS ID DMETRIS
DMETRIS DN gemini
DMETRIS HS Investigative
DMETRIS SN 1R,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)vitamin D3; KH
DMETRIS DT Small molecular drug
DMETRIS PC 10436120
DMETRIS MW 502.8
DMETRIS FM C32H54O4
DMETRIS IC InChI=1S/C32H54O4/c1-22-25(20-26(33)21-29(22)34)14-13-24-12-9-19-32(6)27(15-16-28(24)32)23(10-7-17-30(2,3)35)11-8-18-31(4,5)36/h13-14,23,26-29,33-36H,1,7-12,15-21H2,2-6H3/b24-13+,25-14-/t26-,27-,28+,29+,32-/m1/s1
DMETRIS CS C[C@]12CCC/C(=C\\C=C/3\\C[C@H](C[C@@H](C3=C)O)O)/[C@@H]1CC[C@@H]2C(CCCC(C)(C)O)CCCC(C)(C)O
DMETRIS IK WTQXZYVWLNPNEX-LKUPKUSPSA-N
DMETRIS IU (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-(2,10-dihydroxy-2,10-dimethylundecan-6-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DMETRIS DE Discovery agent
DMAUFLQ ID DMAUFLQ
DMAUFLQ DN GENESERINE
DMAUFLQ HS Investigative
DMAUFLQ SN Eseridine; Geneserine; Eserine oxide; Eserine aminoxide; Eseridinum [Latin]; Eseridina [Spanish]; Eseridine [INN]; UNII-LW9S78L4M8; 25573-43-7; EINECS 247-111-2; NSC 340071; CHEBI:4855; LW9S78L4M8; Eseridine (INN); Eseridinum; C15H21N3O3; Eseridina; [(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-methylcarbamate; (4aS,9aS)-2,3,4,4a,9,9a-Hexahydro-2,4a,9-trimethyl-1,2-oxazino(6,5-b)indol-6-ylmethylcarbamate; eseridin; geneserine oxazine; 1,2-Oxazino(6,5-b)indol-6-ol, 2,3,4,4a,9,9a-hexahydro-2,4a,9-trimeth
DMAUFLQ DT Small molecular drug
DMAUFLQ PC 65719
DMAUFLQ MW 291.35
DMAUFLQ FM C15H21N3O3
DMAUFLQ IC InChI=1S/C15H21N3O3/c1-15-7-8-17(3)21-13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15-/m0/s1
DMAUFLQ CS C[C@@]12CCN(O[C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
DMAUFLQ IK CNBHDDBNEKKMJH-ZFWWWQNUSA-N
DMAUFLQ IU [(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-methylcarbamate
DMAUFLQ CA CAS 25573-43-7
DMAUFLQ CB CHEBI:4855
DMAUFLQ DE Discovery agent
DMMLNTW ID DMMLNTW
DMMLNTW DN Genistein-7-glucoside
DMMLNTW HS Investigative
DMMLNTW SN 1POG3SCN5T; 4',5,7-trihydroxyisoflavone 7-D-glucoside; BRN 0064479; C21H20O10; CHEBI:27514; Genistein 7-O-beta-D-glucoside; Genistein 7-glucoside; Genistein glucoside; Genistein, 7-O-beta-D-glucoside; Genistein, 7-beta-D-glucopyranoside; Genistein-7-glucoside; Genisteol 7-monoglucoside; Genistin; Genistine; Genistoside; Glucopyranoside, genistein-7, beta-D-; Glucosyl-7-genistein; Isoflavone, 4',5,7-trihydroxy-, 7-D-glucoside; MFCD00016883; NSC 5112; UNII-1POG3SCN5T; ZCOLJUOHXJRHDI-CMWLGVBASA-N; genistein 7-O-glucoside
DMMLNTW DT Small molecular drug
DMMLNTW PC 5281377
DMMLNTW MW 432.381
DMMLNTW FM C21H20O10
DMMLNTW IC InChI=1S/C21H20O10/c22-7-15-18(26)19(27)20(28)21(31-15)30-11-5-13(24)16-14(6-11)29-8-12(17(16)25)9-1-3-10(23)4-2-9/h1-6,8,15,18-24,26-28H,7H2/t15-,18-,19+,20-,21-/m1/s1
DMMLNTW CS C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)OC4C(C(C(C(O4)CO)O)O)O)O
DMMLNTW IK ZCOLJUOHXJRHDI-CMWLGVBASA-N
DMMLNTW IU 5-hydroxy-3-(4-hydroxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
DMMLNTW CA CAS 529-59-9
DMMLNTW CB CHEBI:27514
DMMLNTW DE Cancer; Rotavirus infections
DMB70WC ID DMB70WC
DMB70WC DN Genz-10850
DMB70WC HS Investigative
DMB70WC SN Genz-10850; 5-{[4-(9H-FLUOREN-9-YL)PIPERAZIN-1-YL]CARBONYL}-1H-INDOLE; [4-(9H-fluoren-9-yl)piperazin-1-yl]-(1H-indol-5-yl)methanone; [4-(9H-Fluoren-9-yl)-piperazin-1-yl]-(1H-indol-5-yl)-methanone; GEQ; piperazine, p3; AC1L9L7I; SCHEMBL7664894; CHEMBL216579; BDBM25796; YYMZSGIXLQPFAC-UHFFFAOYSA-N; DB04289
DMB70WC DT Small molecular drug
DMB70WC PC 447767
DMB70WC MW 393.5
DMB70WC FM C26H23N3O
DMB70WC IC InChI=1S/C26H23N3O/c30-26(19-9-10-24-18(17-19)11-12-27-24)29-15-13-28(14-16-29)25-22-7-3-1-5-20(22)21-6-2-4-8-23(21)25/h1-12,17,25,27H,13-16H2
DMB70WC CS C1CN(CCN1C2C3=CC=CC=C3C4=CC=CC=C24)C(=O)C5=CC6=C(C=C5)NC=C6
DMB70WC IK YYMZSGIXLQPFAC-UHFFFAOYSA-N
DMB70WC IU [4-(9H-fluoren-9-yl)piperazin-1-yl]-(1H-indol-5-yl)methanone
DMB70WC DE Discovery agent
DMB5I03 ID DMB5I03
DMB5I03 DN GERANIIN
DMB5I03 HS Investigative
DMB5I03 SN Geraniin; 60976-49-0; AC1L3GGN; AC1Q6OHG; SCHEMBL13242673; HY-N0472; AN-8034; 3,4,4,6,7,15,16,17,18,19,20-undecahydroxy-2,9,13,22,27-pentaoxo-2,3,4,4a,9,11a,13,22,24,25,25a,27-dodecahydro-11h-3,5-epoxy-25,11-(epoxymethano)dibenzo[h,j]dibenzo[7,8:9,10][1,5]dioxacycloundecino[3,2-b][1,6]dioxacyclododecin-29-yl 3,4,5-trihydroxybenzoate; beta-D-Glucopyranose, cyclic 3,6-(4,4',5,5',6,6'-hexahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), cyclic 2-2:4-1-ester with 2-(2-carboxy-4,5,6-trioxo-2-cycl
DMB5I03 DT Small molecular drug
DMB5I03 PC 3001497
DMB5I03 MW 952.6
DMB5I03 FM C41H28O27
DMB5I03 IC InChI=1S/C41H28O27/c42-13-1-8(2-14(43)24(13)48)34(54)67-39-33-32-30(64-38(58)12-6-19(47)41(61)40(59,60)23(12)22-11(37(57)66-33)5-17(46)27(51)31(22)68-41)18(63-39)7-62-35(55)9-3-15(44)25(49)28(52)20(9)21-10(36(56)65-32)4-16(45)26(50)29(21)53/h1-6,18,23,30,32-33,39,42-46,48-53,59-61H,7H2/t18-,23+,30-,32+,33-,39+,41+/m1/s1
DMB5I03 CS C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@@H]7C(=CC(=O)[C@@](C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O
DMB5I03 IK JQQBXPCJFAKSPG-SVYIMCMUSA-N
DMB5I03 IU [(1R,7R,8S,26R,28S,29R,38R)-1,13,14,15,18,19,20,34,35,39,39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl] 3,4,5-trihydroxybenzoate
DMB5I03 CB CHEBI:5328
DMB5I03 DE Discovery agent
DMS3CBD ID DMS3CBD
DMS3CBD DN geraniol
DMS3CBD HS Investigative
DMS3CBD SN GERANIOL; 106-24-1; Lemonol; Geranyl alcohol; trans-Geraniol; (E)-Geraniol; (2E)-3,7-dimethylocta-2,6-dien-1-ol; (E)-Nerol; trans-3,7-Dimethyl-2,6-octadien-1-ol; (E)-3,7-Dimethylocta-2,6-dien-1-ol; Geraniol Extra; Geraniol alcohol; 3,7-Dimethyl-2,6-octadien-1-ol; (E)-3,7-Dimethyl-2,6-octadien-1-ol; beta-Geraniol; 3,7-Dimethyl-trans-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-, (2E)-; Guaniol; t-geraniol; 2E-geraniol; Geraniol (natural); 2-trans-3,7-Dimethyl-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-; CHEBI:17447
DMS3CBD DT Small molecular drug
DMS3CBD PC 637566
DMS3CBD MW 154.25
DMS3CBD FM C10H18O
DMS3CBD IC InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,7,11H,4,6,8H2,1-3H3/b10-7+
DMS3CBD CS CC(=CCC/C(=C/CO)/C)C
DMS3CBD IK GLZPCOQZEFWAFX-JXMROGBWSA-N
DMS3CBD IU (2E)-3,7-dimethylocta-2,6-dien-1-ol
DMS3CBD CA CAS 106-24-1
DMS3CBD CB CHEBI:17447
DMS3CBD DE Discovery agent
DMB9LE1 ID DMB9LE1
DMB9LE1 DN Geranyl Diphosphate
DMB9LE1 HS Investigative
DMB9LE1 SN Geranyl diphosphate; geranyl pyrophosphate; 763-10-0; Neryl pyrophosphate; Polyprenyl diphosphate; CHEBI:17211; Polyisopentenyldiphosphate; Polyisopentenylpyrophosphate; trans-Geranyl pyrophosphate; trans-Polyisopentenyldiphosphate; geranyl-PP; all-trans-Polyprenyl diphosphate; GPP; GVVPGTZRZFNKDS-JXMROGBWSA-N; geranyl-diphosphate; (2E)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate; geranyl-pyrophosphate; trans-3,7-Dimethyl-2,6-octadienyl pyrophosphate; [(2E)-3,7-dimethylocta-2,6-dienyl] phosphono hydrogen phosphate
DMB9LE1 DT Small molecular drug
DMB9LE1 PC 445995
DMB9LE1 MW 314.21
DMB9LE1 FM C10H20O7P2
DMB9LE1 IC InChI=1S/C10H20O7P2/c1-9(2)5-4-6-10(3)7-8-16-19(14,15)17-18(11,12)13/h5,7H,4,6,8H2,1-3H3,(H,14,15)(H2,11,12,13)/b10-7+
DMB9LE1 CS CC(=CCC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)C
DMB9LE1 IK GVVPGTZRZFNKDS-JXMROGBWSA-N
DMB9LE1 IU [(2E)-3,7-dimethylocta-2,6-dienyl] phosphono hydrogen phosphate
DMB9LE1 CA CAS 763-10-0
DMB9LE1 CB CHEBI:17211
DMB9LE1 DE Discovery agent
DMRPWGL ID DMRPWGL
DMRPWGL DN Geranylcoumarin
DMRPWGL HS Investigative
DMRPWGL SN geranylcoumarin; CHEMBL241896
DMRPWGL DT Small molecular drug
DMRPWGL PC 44429171
DMRPWGL MW 298.4
DMRPWGL FM C19H22O3
DMRPWGL IC InChI=1S/C19H22O3/c1-14(2)5-4-6-15(3)11-12-21-17-9-7-16-8-10-19(20)22-18(16)13-17/h4-5,7-11,13-14H,6,12H2,1-3H3/b5-4+,15-11+
DMRPWGL CS CC(C)/C=C/C/C(=C/COC1=CC2=C(C=C1)C=CC(=O)O2)/C
DMRPWGL IK KAYCKFWCZGZEHA-WEPZFIBGSA-N
DMRPWGL IU 7-[(2E,5E)-3,7-dimethylocta-2,5-dienoxy]chromen-2-one
DMRPWGL DE Discovery agent
DMJZ0AM ID DMJZ0AM
DMJZ0AM DN GERANYLGERANYL DIPHOSPHATE
DMJZ0AM HS Investigative
DMJZ0AM SN Geranylgeranyl pyrophosphate; Geranylgeranyl diphosphate; GGDP; 6699-20-3; geranylgeranyl-PP; GGPP; UNII-N21T0D88LX; (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl trihydrogen diphosphate; N21T0D88LX; Geranylgeraniol diphosphate; CHEBI:48861; all-trans-Geranylgeranyl pyrophosphate; all-trans-Geranylgeranyl diphosphate; Diphosphoric acid, mono(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl) ester, (E,E,E)-; Geranylgeranyl pyrophosphate ammonium salt; 2-trans,6-trans,10-trans-geranylgeranyl diphosphate
DMJZ0AM DT Small molecular drug
DMJZ0AM PC 447277
DMJZ0AM MW 450.4
DMJZ0AM FM C20H36O7P2
DMJZ0AM IC InChI=1S/C20H36O7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13,15H,6-8,10,12,14,16H2,1-5H3,(H,24,25)(H2,21,22,23)/b18-11+,19-13+,20-15+
DMJZ0AM CS CC(=CCC/C(=C/CC/C(=C/CC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)/C)/C)C
DMJZ0AM IK OINNEUNVOZHBOX-QIRCYJPOSA-N
DMJZ0AM IU phosphono [(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl] hydrogen phosphate
DMJZ0AM CA CAS 6699-20-3
DMJZ0AM CB CHEBI:48861
DMJZ0AM DE Discovery agent
DMLM02I ID DMLM02I
DMLM02I DN GFPDGG
DMLM02I HS Investigative
DMLM02I SN CHEMBL261622; GFPDGG
DMLM02I DT Small molecular drug
DMLM02I PC 24873518
DMLM02I MW 548.5
DMLM02I FM C24H32N6O9
DMLM02I IC InChI=1S/C24H32N6O9/c25-11-18(31)28-16(9-14-5-2-1-3-6-14)24(39)30-8-4-7-17(30)23(38)29-15(10-20(33)34)22(37)27-12-19(32)26-13-21(35)36/h1-3,5-6,15-17H,4,7-13,25H2,(H,26,32)(H,27,37)(H,28,31)(H,29,38)(H,33,34)(H,35,36)/t15-,16-,17-/m0/s1
DMLM02I CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)NCC(=O)O
DMLM02I IK NLYXJKKWVSCTSP-ULQDDVLXSA-N
DMLM02I IU (3S)-3-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-[[2-(carboxymethylamino)-2-oxoethyl]amino]-4-oxobutanoic acid
DMLM02I DE Discovery agent
DMGZTQW ID DMGZTQW
DMGZTQW DN GFPEGG
DMGZTQW HS Investigative
DMGZTQW SN CHEMBL261621; GFPEGG
DMGZTQW DT Small molecular drug
DMGZTQW PC 24873519
DMGZTQW MW 562.6
DMGZTQW FM C25H34N6O9
DMGZTQW IC InChI=1S/C25H34N6O9/c26-12-19(32)29-17(11-15-5-2-1-3-6-15)25(40)31-10-4-7-18(31)24(39)30-16(8-9-21(34)35)23(38)28-13-20(33)27-14-22(36)37/h1-3,5-6,16-18H,4,7-14,26H2,(H,27,33)(H,28,38)(H,29,32)(H,30,39)(H,34,35)(H,36,37)/t16-,17-,18-/m0/s1
DMGZTQW CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)O
DMGZTQW IK WXUQGIGEEDNHIW-BZSNNMDCSA-N
DMGZTQW IU (4S)-4-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-[[2-(carboxymethylamino)-2-oxoethyl]amino]-5-oxopentanoic acid
DMGZTQW DE Discovery agent
DM9D8VH ID DM9D8VH
DM9D8VH DN GFPTGG
DM9D8VH HS Investigative
DM9D8VH SN CHEMBL258999; GFPTGG
DM9D8VH DT Small molecular drug
DM9D8VH PC 25254902
DM9D8VH MW 534.6
DM9D8VH FM C24H34N6O8
DM9D8VH IC InChI=1S/C24H34N6O8/c1-14(31)21(23(37)27-12-19(33)26-13-20(34)35)29-22(36)17-8-5-9-30(17)24(38)16(28-18(32)11-25)10-15-6-3-2-4-7-15/h2-4,6-7,14,16-17,21,31H,5,8-13,25H2,1H3,(H,26,33)(H,27,37)(H,28,32)(H,29,36)(H,34,35)/t14-,16+,17+,21+/m1/s1
DM9D8VH CS C[C@H]([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)O
DM9D8VH IK JWBSOWVZSDHJSP-IOFRSVQKSA-N
DM9D8VH IU 2-[[2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetic acid
DM9D8VH DE Discovery agent
DMU82JV ID DMU82JV
DMU82JV DN GG-818
DMU82JV HS Investigative
DMU82JV SN GI-231818; GW-1818
DMU82JV CP Glaxo Wellcome plc
DMU82JV DE Prostate disease
DMU92RC ID DMU92RC
DMU92RC DN GI-3000
DMU92RC HS Investigative
DMU92RC SN GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune
DMU92RC CP GlobeImmune Inc
DMU92RC DT Vaccine
DMU92RC DE Non-small-cell lung cancer
DMASR6T ID DMASR6T
DMASR6T DN GIDAZEPAM
DMASR6T HS Investigative
DMASR6T SN 2-(7-Bromo-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)acetic acid hydrazide
DMASR6T DT Small molecular drug
DMASR6T PC 121919
DMASR6T MW 387.2
DMASR6T FM C17H15BrN4O2
DMASR6T IC InChI=1S/C17H15BrN4O2/c18-12-6-7-14-13(8-12)17(11-4-2-1-3-5-11)20-9-16(24)22(14)10-15(23)21-19/h1-8H,9-10,19H2,(H,21,23)
DMASR6T CS C1C(=O)N(C2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=C3)CC(=O)NN
DMASR6T IK XLGCMZLSEXRBSG-UHFFFAOYSA-N
DMASR6T IU 2-(7-bromo-2-oxo-5-phenyl-3H-1,4-benzodiazepin-1-yl)acetohydrazide
DMASR6T CA CAS 129186-29-4
DMASR6T DE Anxiety disorder
DMNXYSM ID DMNXYSM
DMNXYSM DN gingerol
DMNXYSM HS Investigative
DMNXYSM SN [6]-Gingerol; 6-Gingerol
DMNXYSM DT Small molecular drug
DMNXYSM PC 442793
DMNXYSM MW 294.4
DMNXYSM FM C17H26O4
DMNXYSM IC InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-16(20)17(11-13)21-2/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3/t14-/m0/s1
DMNXYSM CS CCCCC[C@@H](CC(=O)CCC1=CC(=C(C=C1)O)OC)O
DMNXYSM IK NLDDIKRKFXEWBK-AWEZNQCLSA-N
DMNXYSM IU (5S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one
DMNXYSM CA CAS 23513-14-6
DMNXYSM CB CHEBI:10136
DMNXYSM DE Discovery agent
DMKZJ7T ID DMKZJ7T
DMKZJ7T DN GINKGOLIDE A
DMKZJ7T HS Investigative
DMKZJ7T SN Ginkgolide A; 15291-75-5; CHEBI:5355; SCHEMBL340234; GTPL1861; LMPR0104540001; AB2000432; C07601
DMKZJ7T DT Small molecular drug
DMKZJ7T PC 9909368
DMKZJ7T MW 408.4
DMKZJ7T FM C20H24O9
DMKZJ7T IC InChI=1S/C20H24O9/c1-7-12(22)26-10-6-17-9-5-8(16(2,3)4)18(17)11(21)13(23)28-15(18)29-20(17,14(24)27-9)19(7,10)25/h7-11,15,21,25H,5-6H2,1-4H3/t7-,8+,9-,10+,11+,15+,17-,18+,19-,20-/m1/s1
DMKZJ7T CS C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3(C2)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMKZJ7T IK FPUXKXIZEIDQKW-VKMVSBOZSA-N
DMKZJ7T IU (1R,3R,6R,7S,8S,10R,11S,13S,16S,17R)-8-tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMKZJ7T CA CAS 15291-75-5
DMKZJ7T DE Discovery agent
DMVN374 ID DMVN374
DMVN374 DN Ginkgolide C
DMVN374 HS Investigative
DMVN374 SN Ginkgolide C; BN 52022; SCHEMBL500086; GTPL1863; 15291-76-6; AKOS032961923; LMPR0104540003; C07603
DMVN374 DT Small molecular drug
DMVN374 PC 24721502
DMVN374 MW 440.4
DMVN374 FM C20H24O11
DMVN374 IC InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5-,6-,7+,8-,9+,10-,11+,15+,17+,18-,19-,20-/m1/s1
DMVN374 CS C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3([C@@H]2O)[C@@]6([C@@H]([C@H]5O)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMVN374 IK AMOGMTLMADGEOQ-PYLUGNSCSA-N
DMVN374 IU (1R,3R,6R,7S,8S,9R,10S,11R,12S,13S,16S,17R)-8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMVN374 CA CAS 15291-76-6
DMVN374 DE Discovery agent
DMUOMP1 ID DMUOMP1
DMUOMP1 DN Ginkgolide J
DMUOMP1 HS Investigative
DMUOMP1 SN Ginkgolide J; BN 52024; GTPL1864; 107438-79-9; LMPR0104540004; C07604
DMUOMP1 DT Small molecular drug
DMUOMP1 PC 24721483
DMUOMP1 MW 424.4
DMUOMP1 FM C20H24O10
DMUOMP1 IC InChI=1S/C20H24O10/c1-6-12(23)27-7-5-17-11-8(21)9(16(2,3)4)18(17)10(22)13(24)29-15(18)30-20(17,14(25)28-11)19(6,7)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11-,15+,17?,18+,19-,20-/m1/s1
DMUOMP1 CS C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3(C2)[C@@]6([C@@H]([C@H]5O)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O
DMUOMP1 IK LMEHVEUFNRJAAV-XNSMQBOTSA-N
DMUOMP1 IU (1R,3R,6R,7S,8S,9R,10S,13S,16S,17R)-8-tert-butyl-6,9,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMUOMP1 DE Discovery agent
DMHWIG6 ID DMHWIG6
DMHWIG6 DN Ginkgolide M
DMHWIG6 HS Investigative
DMHWIG6 SN Ginkgolide M; 15291-78-8
DMHWIG6 DT Small molecular drug
DMHWIG6 PC 12310208
DMHWIG6 MW 424.4
DMHWIG6 FM C20H24O10
DMHWIG6 IC InChI=1S/C20H24O10/c1-5-6-8(27-13(5)24)10(22)19-12-7(21)9(17(2,3)4)18(19)11(23)14(25)29-16(18)30-20(6,19)15(26)28-12/h5-12,16,21-23H,1-4H3
DMHWIG6 CS CC1C2C(C(C34C25C(=O)OC3C(C(C46C(C(=O)OC6O5)O)C(C)(C)C)O)O)OC1=O
DMHWIG6 IK KDKROYXEHCYLJQ-UHFFFAOYSA-N
DMHWIG6 IU 8-tert-butyl-6,9,12-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
DMHWIG6 CA CAS 15291-78-8
DMHWIG6 DE Discovery agent
DMK543E ID DMK543E
DMK543E DN ginkgolide X
DMK543E HS Investigative
DMK543E SN ginkgolide X; GTPL4201
DMK543E DT Small molecular drug
DMK543E PC 73755085
DMK543E MW 376.4
DMK543E FM C20H24O7
DMK543E IC InChI=1S/C20H24O7/c1-8-9-5-13-19(7-10(9)25-15(8)23)12(21)6-11(18(2,3)4)20(19)14(22)16(24)27-17(20)26-13/h5,10-12,14,17,21-22H,6-7H2,1-4H3/t10-,11-,12-,14-,17+,19-,20-/m0/s1
DMK543E CS CC1=C2C=C3[C@]4(C[C@@H]2OC1=O)[C@H](C[C@H]([C@@]45[C@H](C(=O)O[C@H]5O3)O)C(C)(C)C)O
DMK543E IK SPCYYGUOUYOYPX-FUDPCSHESA-N
DMK543E IU (1S,2S,4S,5S,6R,9R,17S)-4-tert-butyl-2,6-dihydroxy-14-methyl-8,10,16-trioxapentacyclo[9.7.0.01,5.05,9.013,17]octadeca-11,13-diene-7,15-dione
DMK543E DE Discovery agent
DMF70AB ID DMF70AB
DMF70AB DN Ginsenoside Rb1
DMF70AB HS Investigative
DMF70AB SN Arasaponin E1; Ginsenoside rb1; Gynosaponin C; Panax saponin E; Panaxsaponin E; Pseudoginsenoside D; Sanchinoside E1; ginsenoside-Rb1; (20S)-ginsenoside Rb1; 2-O-beta-Glucopyranosyl-(3beta,12beta)-20-((6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl-beta-D-glucopyranoside; 20(S)-ginsenoside Rb1; 41753-43-9; 7413S0WMH6; BIDD:ER0108; C54H92O23; CHEBI:67989; CHEMBL501515; GRb 1; GS-Rb1; GSRb1; GZYPWOGIYAIIPV-JBDTYSNRSA-N; Gypenoside III; NSC 310103; UNII-7413S0WMH6
DMF70AB PC 9898279
DMF70AB MW 1109.3
DMF70AB FM C54H92O23
DMF70AB IC GZYPWOGIYAIIPV-JBDTYSNRSA-N
DMF70AB CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(C(O8)CO)O)O)O)O)O)O)C
DMF70AB IK 1S/C54H92O23/c1-23(2)10-9-14-54(8,77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3,4)30(51)12-17-52(31,53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10,24-49,55-69H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34+,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,51-,52+,53+,54-/m0/s1
DMF70AB IU (2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6S)-6-[(2S)-2-[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-3-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
DMF70AB CA CAS 41753-43-9
DMF70AB CB CHEBI:67989
DMF70AB DE Obesity
DMES9Q2 ID DMES9Q2
DMES9Q2 DN Ginsenoside Rc
DMES9Q2 HS Investigative
DMES9Q2 SN Ginsenoside Rc; Panaxoside RC; ginsenoside-Rc; 0K83B0L786; 11021-14-0; 20-((6-O-alpha-L-Arabinofuranosyl-beta-D-glucopyranosyl)oxy)-12beta-hydroxydammar-24-en-3beta-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; 20-[(6-O-a-L-arabinofuranosyl-ss-D-glucopyranosyl)oxy]-12ss-hydroxydammar-24-en-3ss-yl 2-O-ss-D-glucopyranosyl-ss-D-glucopyranoside; AB0029025; AKOS037514670; AS-56539; BRN 1677618; CHEBI:77154; CHEMBL451702; CS-3837; EINECS 234-253-5; HY-N0042; MFCD00133368; NCGC00485983-01; NSC 310104; UNII-0K83B0L786; s9266
DMES9Q2 PC 12855889
DMES9Q2 MW 1079.3
DMES9Q2 FM C53H90O22
DMES9Q2 IC JDCPEKQWFDWQLI-LUQKBWBOSA-N
DMES9Q2 CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)OC7C(C(C(C(O7)COC8C(C(C(O8)CO)O)O)O)O)O)C
DMES9Q2 IK 1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1
DMES9Q2 IU (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMES9Q2 CA CAS 11021-14-0
DMES9Q2 CB CHEBI:77154
DMES9Q2 DE Diabetes mellitus
DM46FVD ID DM46FVD
DM46FVD DN Ginsenoside Re
DM46FVD HS Investigative
DM46FVD SN Chikusetsusaponin IVc; Ginsenoside B2; Ginsenoside Re; PWAOOJDMFUQOKB-WCZZMFLVSA-N; Panaxoside RE; SCHEMBL669738; TR-036967; ZINC242620164; ginsenoside-Re; (20S)-ginsenoside Re; 2-O-(6-Deoxy-alpha-L-mannopyranosyl)-(3beta,6alpha,12beta)-20-(beta-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl-beta-D-glucopyranoside; 46F3R0BL3I; 51542-56-4; 52286-59-6; AKOS025310861; BDBM50378779; CHEBI:77148; CHEMBL510095; CS-3838; CTK8F0918; DB14815; EINECS 257-814-6; HY-N0044; MFCD00133369; NSC 308877; NSC-308877; UNII-46F3R0BL3I; s3811
DM46FVD PC 441921
DM46FVD MW 947.2
DM46FVD FM C48H82O18
DM46FVD IC PWAOOJDMFUQOKB-WCZZMFLVSA-N
DM46FVD CS CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)C)CO)O)O)O)O)O
DM46FVD IK 1S/C48H82O18/c1-21(2)11-10-14-48(9,66-42-38(60)35(57)32(54)26(19-49)63-42)23-12-16-46(7)30(23)24(51)17-28-45(6)15-13-29(52)44(4,5)40(45)25(18-47(28,46)8)62-43-39(36(58)33(55)27(20-50)64-43)65-41-37(59)34(56)31(53)22(3)61-41/h11,22-43,49-60H,10,12-20H2,1-9H3/t22-,23-,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34+,35-,36-,37+,38+,39+,40-,41-,42-,43+,45+,46+,47+,48-/m0/s1
DM46FVD IU (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
DM46FVD CA CAS 52286-59-6
DM46FVD CB CHEBI:77148
DM46FVD DE Lung cancer
DMYE2SR ID DMYE2SR
DMYE2SR DN Ginsenoside Rg1
DMYE2SR HS Investigative
DMYE2SR SN Chikusetsusaponin Ia; ginsenoside-Rg(1); sanchinoside C(1); C17544; CHEBI:81171
DMYE2SR PC 13386145
DMYE2SR MW 755
DMYE2SR FM C41H70O12
DMYE2SR IC DGSOBIYFLJXVQZ-UHFFFAOYSA-N
DMYE2SR CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)COC6C(C(C(CO6)O)O)O)O)O)O)C)C)O)C)O)C
DMYE2SR IK 1S/C41H70O12/c1-21(2)10-9-14-41(8,49)22-11-16-40(7)29(22)23(42)18-27-38(5)15-13-28(37(3,4)26(38)12-17-39(27,40)6)53-36-34(48)32(46)31(45)25(52-36)20-51-35-33(47)30(44)24(43)19-50-35/h10,22-36,42-49H,9,11-20H2,1-8H3
DMYE2SR IU 2-[[12-hydroxy-17-(2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxane-3,4,5-triol
DMYE2SR CA CAS 59252-86-7
DMYE2SR CB CHEBI:81171
DMYE2SR DE Insomnia
DMFN58T ID DMFN58T
DMFN58T DN Ginsenoside RG3
DMFN58T HS Investigative
DMFN58T SN (20S)-ginsenoside Rg3
DMFN58T DT Small molecular drug
DMFN58T PC 9918693
DMFN58T MW 785
DMFN58T FM C42H72O13
DMFN58T IC InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1
DMFN58T CS CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C
DMFN58T IK RWXIFXNRCLMQCD-JBVRGBGGSA-N
DMFN58T IU (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMFN58T CA CAS 14197-60-5
DMFN58T CB CHEBI:67991
DMFN58T DE Discovery agent
DM9P62Y ID DM9P62Y
DM9P62Y DN GKA1
DM9P62Y HS Investigative
DM9P62Y SN CHEMBL381434; GKA1; SCHEMBL1794696; RTMFZNZPHCZAFG-UHFFFAOYSA-N; ZINC28523790; BDBM50165037; 6-(3-Isobutoxy-5-isopropoxy-benzoylamino)-nicotinic acid; 6-[(3-isobutoxy-5-isopropoxybenzoyl)amino]-3-pyridinecarboxylic acid; 6-[(3-isobutoxy-5-isopropoxvbenzoyl)amino]-3-pyridinecarboxylic acid
DM9P62Y DT Small molecular drug
DM9P62Y PC 10044792
DM9P62Y MW 372.4
DM9P62Y FM C20H24N2O5
DM9P62Y IC InChI=1S/C20H24N2O5/c1-12(2)11-26-16-7-15(8-17(9-16)27-13(3)4)19(23)22-18-6-5-14(10-21-18)20(24)25/h5-10,12-13H,11H2,1-4H3,(H,24,25)(H,21,22,23)
DM9P62Y CS CC(C)COC1=CC(=CC(=C1)C(=O)NC2=NC=C(C=C2)C(=O)O)OC(C)C
DM9P62Y IK RTMFZNZPHCZAFG-UHFFFAOYSA-N
DM9P62Y IU 6-[[3-(2-methylpropoxy)-5-propan-2-yloxybenzoyl]amino]pyridine-3-carboxylic acid
DM9P62Y DE Discovery agent
DMIENSW ID DMIENSW
DMIENSW DN GKA-23
DMIENSW HS Investigative
DMIENSW SN GKA-21; GKA-22; GKA-30; GKA-31; GKA-50; GKA-60; Glucokinase activators (diabetes); Glucokinase activators (diabetes), AstraZeneca
DMIENSW CP AstraZeneca plc
DMIENSW PC 25235270
DMIENSW MW 468.6
DMIENSW FM C21H20N6O3S2
DMIENSW IC InChI=1S/C21H20N6O3S2/c1-12-6-7-16(13(2)24-12)30-17-9-14(31-18-5-3-4-8-22-18)10-23-20(17)26-21-25-19(27-32-21)15(29)11-28/h3-10,15,28-29H,11H2,1-2H3,(H,23,25,26,27)/t15-/m1/s1
DMIENSW CS CC1=NC(=C(C=C1)OC2=C(N=CC(=C2)SC3=CC=CC=N3)NC4=NC(=NS4)[C@@H](CO)O)C
DMIENSW IK NARRNXGFBLOLIN-OAHLLOKOSA-N
DMIENSW IU (1S)-1-[5-[[3-(2,6-dimethylpyridin-3-yl)oxy-5-pyridin-2-ylsulfanylpyridin-2-yl]amino]-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
DMIENSW DE Diabetic complication
DMSP7V8 ID DMSP7V8
DMSP7V8 DN GLAUCINE
DMSP7V8 HS Investigative
DMSP7V8 SN Glaucine; d-Glaucine; 475-81-0; Bromcholitin; Boldine dimethyl ether; Glauvent; S-(+)-Glaucine; (S)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline; Glaucine fumarate; UNII-NU19306XA7; 1,2,9,10-Tetramethoxy-6a-alpha-aporphine; NSC34396; EINECS 207-501-5; NSC 34396; (+)-Glaucine; CHEMBL228082; CHEBI:5373; NU19306XA7; (S)-5,6,6a7-Tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo(de,g)quinoline; 6a-alpha-APORPHINE, 1,2,9,10-TETRAMETHOXY-; Glaucine, d
DMSP7V8 DT Small molecular drug
DMSP7V8 PC 16754
DMSP7V8 MW 355.4
DMSP7V8 FM C21H25NO4
DMSP7V8 IC InChI=1S/C21H25NO4/c1-22-7-6-12-9-18(25-4)21(26-5)20-14-11-17(24-3)16(23-2)10-13(14)8-15(22)19(12)20/h9-11,15H,6-8H2,1-5H3/t15-/m0/s1
DMSP7V8 CS CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC)OC)OC
DMSP7V8 IK RUZIUYOSRDWYQF-HNNXBMFYSA-N
DMSP7V8 IU (6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline
DMSP7V8 CA CAS 475-81-0
DMSP7V8 CB CHEBI:5373
DMSP7V8 DE Discovery agent
DM4QJPU ID DM4QJPU
DM4QJPU DN Glaxo-11p
DM4QJPU HS Investigative
DM4QJPU SN CHEMBL345869; Glaxo-11p; GTPL866; CHEMBL1184355; BDBM50422153; N-Isopropyl-N-[4-(dimethylamino)phenyl]-2-[[2,3,4,5-tetrahydro-2,4-dioxo-5-phenyl-3-(3-phenylureido)-1H-1,5-benzodiazepin]-1-yl]acetamide
DM4QJPU DT Small molecular drug
DM4QJPU PC 10348659
DM4QJPU MW 604.7
DM4QJPU FM C35H36N6O4
DM4QJPU IC InChI=1S/C35H36N6O4/c1-24(2)40(28-21-19-26(20-22-28)38(3)4)31(42)23-39-29-17-11-12-18-30(29)41(27-15-9-6-10-16-27)34(44)32(33(39)43)37-35(45)36-25-13-7-5-8-14-25/h5-22,24,32H,23H2,1-4H3,(H2,36,37,45)
DM4QJPU CS CC(C)N(C1=CC=C(C=C1)N(C)C)C(=O)CN2C3=CC=CC=C3N(C(=O)C(C2=O)NC(=O)NC4=CC=CC=C4)C5=CC=CC=C5
DM4QJPU IK GESRVUYUMYPJBC-UHFFFAOYSA-N
DM4QJPU IU N-[4-(dimethylamino)phenyl]-2-[2,4-dioxo-5-phenyl-3-(phenylcarbamoylamino)-1,5-benzodiazepin-1-yl]-N-propan-2-ylacetamide
DM4QJPU DE Discovery agent
DMNEML0 ID DMNEML0
DMNEML0 DN GlaxoSmithKline compound 5h
DMNEML0 HS Investigative
DMNEML0 DT Small molecular drug
DMNEML0 PC 46911435
DMNEML0 MW 440.6
DMNEML0 FM C29H32N2O2
DMNEML0 IC InChI=1S/C29H32N2O2/c1-4-5-6-10-21-15-17-23(18-16-21)30-29(32)31-26-14-9-11-22-19-27(33-28(22)26)25-13-8-7-12-24(25)20(2)3/h7-9,11-20H,4-6,10H2,1-3H3,(H2,30,31,32)
DMNEML0 CS CCCCCC1=CC=C(C=C1)NC(=O)NC2=CC=CC3=C2OC(=C3)C4=CC=CC=C4C(C)C
DMNEML0 IK ASCJIAKBYVUVNZ-UHFFFAOYSA-N
DMNEML0 IU 1-(4-pentylphenyl)-3-[2-(2-propan-2-ylphenyl)-1-benzofuran-7-yl]urea
DMNEML0 DE Discovery agent
DM1UAWP ID DM1UAWP
DM1UAWP DN GlaxoSmithKline compound 6i
DM1UAWP HS Investigative
DM1UAWP DT Small molecular drug
DM1UAWP PC 73755157
DM1UAWP MW 439.4
DM1UAWP FM C25H24Cl2N2O
DM1UAWP IC InChI=1S/C25H24Cl2N2O/c1-3-22-16(2)24(28-20-9-5-4-6-10-20)21-11-7-8-12-23(21)29(22)25(30)17-13-18(26)15-19(27)14-17/h4-16,22,24,28H,3H2,1-2H3/t16-,22-,24+/m1/s1
DM1UAWP CS CC[C@@H]1[C@H]([C@@H](C2=CC=CC=C2N1C(=O)C3=CC(=CC(=C3)Cl)Cl)NC4=CC=CC=C4)C
DM1UAWP IK DKLLTFTXYHJXHK-OAEOJWKDSA-N
DM1UAWP IU [(2R,3S,4S)-4-anilino-2-ethyl-3-methyl-3,4-dihydro-2H-quinolin-1-yl]-(3,5-dichlorophenyl)methanone
DM1UAWP DE Discovery agent
DM98CSW ID DM98CSW
DM98CSW DN Glionitrin A
DM98CSW HS Investigative
DM98CSW SN Glionitrin A; CHEMBL550491
DM98CSW CP Korea Institute of Science and Technology
DM98CSW DT Small molecular drug
DM98CSW PC 25243252
DM98CSW MW 353.4
DM98CSW FM C13H11N3O5S2
DM98CSW IC InChI=1S/C13H11N3O5S2/c1-14-10(18)12-5-7-2-3-8(16(20)21)4-9(7)15(12)11(19)13(14,6-17)23-22-12/h2-4,17H,5-6H2,1H3/t12-,13-/m0/s1
DM98CSW CS CN1C(=O)[C@@]23CC4=C(N2C(=O)[C@@]1(SS3)CO)C=C(C=C4)[N+](=O)[O-]
DM98CSW IK VRFJINVAZRAFHH-STQMWFEESA-N
DM98CSW IU (1S,11S)-11-(hydroxymethyl)-15-methyl-6-nitro-12,13-dithia-9,15-diazatetracyclo[9.2.2.01,9.03,8]pentadeca-3(8),4,6-triene-10,14-dione
DM98CSW CA CAS 1116153-15-1
DM98CSW CB CHEBI:65967
DM98CSW DE Solid tumour/cancer
DMBH18C ID DMBH18C
DMBH18C DN GLP-17-(7-36) derivative
DMBH18C HS Investigative
DMBH18C PC 91933043
DMBH18C MW 3297.6
DMBH18C FM C149H226N40O45
DMBH18C IC InChI=1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMBH18C CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMBH18C IK DTHNMHAUYICORS-KTKZVXAJSA-N
DMBH18C IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMBH18C DE Discovery agent
DMGTPDA ID DMGTPDA
DMGTPDA DN GLPDGG peptide
DMGTPDA HS Investigative
DMGTPDA SN CHEMBL412295; GLPDGG; GTPL2980; BDBM50226164; GLPDGG peptide [PMID: 20494585]; (3S)-3-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-4-methylpentanoyl]pyrrolidin-2-yl]formamido}-3-({[(carboxymethyl)carbamoyl]methyl}carbamoyl)propanoic acid
DMGTPDA DT Small molecular drug
DMGTPDA PC 44452237
DMGTPDA MW 514.5
DMGTPDA FM C21H34N6O9
DMGTPDA IC InChI=1S/C21H34N6O9/c1-11(2)6-13(25-15(28)8-22)21(36)27-5-3-4-14(27)20(35)26-12(7-17(30)31)19(34)24-9-16(29)23-10-18(32)33/h11-14H,3-10,22H2,1-2H3,(H,23,29)(H,24,34)(H,25,28)(H,26,35)(H,30,31)(H,32,33)/t12-,13-,14-/m0/s1
DMGTPDA CS CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)NCC(=O)O)NC(=O)CN
DMGTPDA IK SKODABHETMRRBC-IHRRRGAJSA-N
DMGTPDA IU (3S)-3-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-[[2-(carboxymethylamino)-2-oxoethyl]amino]-4-oxobutanoic acid
DMGTPDA DE Discovery agent
DME2YL6 ID DME2YL6
DME2YL6 DN GLPTGG
DME2YL6 HS Investigative
DME2YL6 SN CHEMBL261334; GLPTGG
DME2YL6 DT Small molecular drug
DME2YL6 PC 25254901
DME2YL6 MW 500.5
DME2YL6 FM C21H36N6O8
DME2YL6 IC InChI=1S/C21H36N6O8/c1-11(2)7-13(25-15(29)8-22)21(35)27-6-4-5-14(27)19(33)26-18(12(3)28)20(34)24-9-16(30)23-10-17(31)32/h11-14,18,28H,4-10,22H2,1-3H3,(H,23,30)(H,24,34)(H,25,29)(H,26,33)(H,31,32)/t12-,13+,14+,18+/m1/s1
DME2YL6 CS C[C@H]([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN)O
DME2YL6 IK FYPRIKVHHVQETD-COJSNBRMSA-N
DME2YL6 IU 2-[[2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]acetic acid
DME2YL6 DE Discovery agent
DM0HWB1 ID DM0HWB1
DM0HWB1 DN Glu20-Lys24][Gly8][GLP-1(7-37)-NH2
DM0HWB1 HS Investigative
DM0HWB1 PC 91935385
DM0HWB1 MW 3395.7
DM0HWB1 FM C152H228N42O47
DM0HWB1 IC InChI=1S/C152H228N42O47/c1-13-78(8)123(149(239)171-80(10)127(217)181-105(61-86-64-163-91-34-21-20-33-89(86)91)139(229)182-101(57-75(2)3)140(230)191-121(76(4)5)147(237)180-93(35-22-25-53-153)130(220)166-68-114(205)172-92(38-28-56-162-152(158)159)129(219)164-66-111(157)202)193-141(231)103(58-83-29-16-14-17-30-83)183-137(227)100(47-52-119(212)213)178-134(224)95(36-23-26-54-154)175-126(216)79(9)170-133(223)94-37-24-27-55-161-112(203)49-44-99(136(226)177-97(46-51-118(210)211)132(222)167-69-115(206)174-98(135(225)176-94)43-48-110(156)201)179-138(228)102(60-85-39-41-88(200)42-40-85)184-144(234)107(71-195)187-146(236)109(73-197)188-148(238)122(77(6)7)192-143(233)106(63-120(214)215)185-145(235)108(72-196)189-151(241)125(82(12)199)194-142(232)104(59-84-31-18-15-19-32-84)186-150(240)124(81(11)198)190-116(207)70-168-131(221)96(45-50-117(208)209)173-113(204)67-165-128(218)90(155)62-87-65-160-74-169-87/h14-21,29-34,39-42,64-65,74-82,90,92-109,121-125,163,195-200H,13,22-28,35-38,43-63,66-73,153-155H2,1-12H3,(H2,156,201)(H2,157,202)(H,160,169)(H,161,203)(H,164,219)(H,165,218)(H,166,220)(H,167,222)(H,168,221)(H,170,223)(H,171,239)(H,172,205)(H,173,204)(H,174,206)(H,175,216)(H,176,225)(H,177,226)(H,178,224)(H,179,228)(H,180,237)(H,181,217)(H,182,229)(H,183,227)(H,184,234)(H,185,235)(H,186,240)(H,187,236)(H,188,238)(H,189,241)(H,190,207)(H,191,230)(H,192,233)(H,193,231)(H,194,232)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H4,158,159,162)/t78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,121-,122-,123-,124-,125-/m0/s1
DM0HWB1 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]4CCCCNC(=O)CC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N4)CCC(=O)N)CCC(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CC7=CN=CN7)N
DM0HWB1 IK PAMPKNPMNUNCAF-KXYXCEFHSA-N
DM0HWB1 IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3S,9S,12S,21S)-21-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-3-(3-amino-3-oxopropyl)-9-(2-carboxyethyl)-2,5,8,11,15-pentaoxo-1,4,7,10,16-pentazacyclohenicos-12-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DM0HWB1 DE Discovery agent
DMVWDHM ID DMVWDHM
DMVWDHM DN glucagon-(1-6)
DMVWDHM HS Investigative
DMVWDHM SN glucagon 1-6
DMVWDHM DT Small molecular drug
DMVWDHM PC 194323
DMVWDHM MW 675.7
DMVWDHM FM C29H41N9O10
DMVWDHM IC InChI=1S/C29H41N9O10/c1-15(40)24(28(46)36-20(29(47)48)9-16-5-3-2-4-6-16)38-23(42)12-33-26(44)19(7-8-22(31)41)35-27(45)21(13-39)37-25(43)18(30)10-17-11-32-14-34-17/h2-6,11,14-15,18-21,24,39-40H,7-10,12-13,30H2,1H3,(H2,31,41)(H,32,34)(H,33,44)(H,35,45)(H,36,46)(H,37,43)(H,38,42)(H,47,48)/t15-,18+,19+,20+,21+,24+/m1/s1
DMVWDHM CS C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)O
DMVWDHM IK VDWWLJRQDNTHJB-MXAMYCJDSA-N
DMVWDHM IU (2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoic acid
DMVWDHM CA CAS 69658-84-0
DMVWDHM DE Discovery agent
DMZLRY2 ID DMZLRY2
DMZLRY2 DN Glucagon-like peptide-1 analog
DMZLRY2 HS Investigative
DMZLRY2 SN GLP-1 analog (type 2 diabetes), Arisaph; Glucagon-like peptide-1 analog (type 2 diabetes); Glucagon-like peptide-1 analog (type 2 diabetes), Arisaph
DMZLRY2 CP Arisaph Pharmaceuticals Inc
DMZLRY2 DE Non-insulin dependent diabetes
DMO071E ID DMO071E
DMO071E DN Gluconolactone
DMO071E HS Investigative
DMO071E SN gluconolactone; delta-gluconolactone; 90-80-2; D-glucono-1,5-lactone; D-Gluconolactone; 1,5-Gluconolactone; D-Gluconic acid lactone; Glucono delta-lactone; Gluconic acid lactone; 1,5-D-Gluconolactone; Gluconic lactone; Glucono delta lactone; (3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one; Gluconic delta-lactone; D-Gluconic acid delta-lactone; d-(+)-Glucono-1,5-lactone; D-delta-Gluconolactone; delta-D-Gluconolactone; Deltagluconolactone; D-Gluconic delta-lactone; Glucarolactone; D-Aldonolactone
DMO071E DT Small molecular drug
DMO071E PC 7027
DMO071E MW 178.14
DMO071E FM C6H10O6
DMO071E IC InChI=1S/C6H10O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-5,7-10H,1H2/t2-,3-,4+,5-/m1/s1
DMO071E CS C([C@@H]1[C@H]([C@@H]([C@H](C(=O)O1)O)O)O)O
DMO071E IK PHOQVHQSTUBQQK-SQOUGZDYSA-N
DMO071E IU (3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-one
DMO071E CA CAS 90-80-2
DMO071E CB CHEBI:16217
DMO071E DE Discovery agent
DMRHYU8 ID DMRHYU8
DMRHYU8 DN Glucopyranosyl oleanolate
DMRHYU8 HS Investigative
DMRHYU8 SN Beta-D-glucopyranosyl oleanolate; Oleanolic acid 28-O-beta-D-glucopyranoside; Compound O; Beta-D-glucopyranosyl oleanolate; oleanolic acid beta-D-glucopyranosyl ester; SCHEMBL2999839; BDBM50235153; ZINC49898882; 162H539; Q27136470; CHEBI:67985; CHEMBL510111; 14162-53-9
DMRHYU8 PC 14189384
DMRHYU8 MW 618.8
DMRHYU8 FM C36H58O8
DMRHYU8 IC KMKFOIBUKYMVRJ-YHFBEQRYSA-N
DMRHYU8 CS CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)OC6C(C(C(C(O6)CO)O)O)O)C
DMRHYU8 IK 1S/C36H58O8/c1-31(2)14-16-36(30(42)44-29-28(41)27(40)26(39)22(19-37)43-29)17-15-34(6)20(21(36)18-31)8-9-24-33(5)12-11-25(38)32(3,4)23(33)10-13-35(24,34)7/h8,21-29,37-41H,9-19H2,1-7H3/t21-,22+,23-,24+,25-,26+,27-,28+,29-,33-,34+,35+,36-/m0/s1
DMRHYU8 IU [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMRHYU8 CA CAS 14162-53-9
DMRHYU8 CB CHEBI:67985
DMRHYU8 DE Discovery agent
DMY590Q ID DMY590Q
DMY590Q DN Glucosamine 6-Phosphate
DMY590Q HS Investigative
DMY590Q SN glucosamine 6-phosphate; glucosamine-6-phosphate; D-glucosamine phosphate; D-glucosamine 6-phosphate; 2-amino-2-deoxy-6-O-phosphono-alpha-D-glucopyranose; GlcN-6-P; 1moq; Glucose-6-phosphorate; bmse000189; AC1L96WN; SCHEMBL4363568; CHEBI:15873; XHMJOUIAFHJHBW-UKFBFLRUSA-N; ZINC4097103; alpha-D-Glucosamine 6-phosphoric acid; DB02657; alpha-D-glucosamine 6-(dihydrogen phosphate); 2-amino-2-deoxy-alpha-D-glucopyranose 6-(dihydrogen phosphate); WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*N_6*OPO/3O/3=O]/1/
DMY590Q DT Small molecular drug
DMY590Q PC 439217
DMY590Q MW 259.149
DMY590Q FM C6H14NO8P
DMY590Q IC InChI=1S/C6H14NO8P/c7-3-5(9)4(8)2(15-6(3)10)1-14-16(11,12)13/h2-6,8-10H,1,7H2,(H2,11,12,13)/t2-,3-,4-,5-,6+/m1/s1
DMY590Q CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)N)O)O)OP(=O)(O)O
DMY590Q IK XHMJOUIAFHJHBW-UKFBFLRUSA-N
DMY590Q IU [(2R,3S,4R,5R,6S)-5-amino-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
DMY590Q CA CAS 3616-42-0
DMY590Q CB CHEBI:15873
DMY590Q DE Discovery agent
DMLISP2 ID DMLISP2
DMLISP2 DN Glucose analogue
DMLISP2 HS Investigative
DMLISP2 DE Infection of P. falciparum
DMMJQ7O ID DMMJQ7O
DMMJQ7O DN Glucose-bisphosphate
DMMJQ7O HS Investigative
DMMJQ7O SN Glucose 1,6-bisphosphate; Alpha-D-Glucose 1,6-bisphosphate; 10139-18-1; alpha-D-Glucose 1,6-bis(dihydrogen phosphate); Glucose 1,6-diphosphate; glucose-1,6-bisphosphate; alpha-D-Glucose 1,6-diphosphate; UNII-DRX17R6AM2; D-Glucose 1,6-biphosphate; D-Glucose 1,6-diphosphate; DRX17R6AM2; alpha-D-Glucose 1,6-biphosphate; alpha-D-Glucose-1,6-diphosphate; RWHOZGRAXYWRNX-VFUOTHLCSA-N; alpha-D-glucopyranose, 1,6-bis(dihydrogen phosphate); 1,6-di-O-phosphono-alpha-D-glucopyranose; 2fkf; Glc-1,6P; G16; EINECS 233-395-5; Glucose-1,3-bisphosphate; glucose 1, 6-diphosphate; bmse000087; a-D-Glucose 1,6-diphosphate; a-D-Glucose 1,6-bisphosphate; alpha-Glucose 1,6-diphosphate; delta-Glucose 1,6-diphosphate; SCHEMBL1266885; CHEBI:18148; alpha-D-Glucose-1,6-bisphosphate; ZINC4095589; .alpha.-D-Glucose 1,6-bisphosphate; alpha-delta-Glucose 1,6-diphosphate; alpha-delta-Glucose 1,6-bisphosphate; Glucose 1,6-diphosphate (6CI,7CI); DB02835; a-D-Glucose 1,6-bis(dihydrogen phosphate); C01231; alpha-delta-Glucose 1,6-bis(dihydrogen phosphate); Alpha-D-1,6-bis(dihydrogen phosphate) Glucopyranose; alpha-D-glucopyranose 1,6-bis(dihydrogen phosphate); Q4122197; Alpha-delta-1,6-bis(dihydrogen phosphate) Glucopyranose; .alpha.-D-Glucose 1,6-bisphosphate potassium salt hydrate; FFE24833-162C-479C-90C5-CDF93D1E899A; alpha-D-Glucopyranose, 1,6-bis(dihydrogen phosphate) (9CI); Glucopyranose, 1,6-bis(dihydrogen phosphate), alpha-D- (8CI); {[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[(phosphonooxy)methyl]oxan-2-yl]oxy}phosphonic acid
DMMJQ7O PC 82400
DMMJQ7O IU [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(phosphonooxymethyl)oxan-2-yl] dihydrogen phosphate
DMMJQ7O DE Discovery agent
DMXBQRJ ID DMXBQRJ
DMXBQRJ DN Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe
DMXBQRJ HS Investigative
DMXBQRJ SN CHEMBL363255; Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe
DMXBQRJ DT Small molecular drug
DMXBQRJ PC 44397266
DMXBQRJ MW 979.1
DMXBQRJ FM C45H70N8O16
DMXBQRJ IC InChI=1S/C45H70N8O16/c1-22(2)17-29(49-43(66)31(20-36(59)60)51-42(65)30(18-23(3)4)50-40(63)27(46)13-15-34(55)56)38(61)33(54)21-47-25(7)39(62)53-37(24(5)6)44(67)48-28(14-16-35(57)58)41(64)52-32(45(68)69)19-26-11-9-8-10-12-26/h8-12,22-25,27-33,37,47,54H,13-21,46H2,1-7H3,(H,48,67)(H,49,66)(H,50,63)(H,51,65)(H,52,64)(H,53,62)(H,55,56)(H,57,58)(H,59,60)(H,68,69)/t25-,27-,28-,29-,30-,31-,32-,33?,37-/m0/s1
DMXBQRJ CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NCC(C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)N)O
DMXBQRJ IK WAHCXYBUKGOGCQ-SHELQGHFSA-N
DMXBQRJ IU (4S)-4-amino-5-[[(2S)-1-[[(2S)-3-carboxy-1-[[(4S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-hydroxy-6-methyl-3-oxoheptan-4-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
DMXBQRJ DE Discovery agent
DM6EA9B ID DM6EA9B
DM6EA9B DN Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DM6EA9B HS Investigative
DM6EA9B SN CHEMBL413629; Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DM6EA9B PC 44300176
DM6EA9B MW 1507.5
DM6EA9B FM C67H97F2N12O23P
DM6EA9B IC InChI=1S/C67H97F2N12O23P/c1-7-35(5)54(63(97)76-46(33-38-15-19-40(82)20-16-38)60(94)77-47(66(100)101)31-34(3)4)78-62(96)49-12-10-30-81(49)65(99)55(36(6)8-2)79-58(92)44(24-28-53(88)89)72-56(90)43(23-27-52(86)87)73-59(93)45(32-37-13-17-39(18-14-37)67(68,69)105(102,103)104)75-57(91)42(22-25-50(71)83)74-61(95)48-11-9-29-80(48)64(98)41(70)21-26-51(84)85/h13-20,34-36,41-49,54-55,82H,7-12,21-33,70H2,1-6H3,(H2,71,83)(H,72,90)(H,73,93)(H,74,95)(H,75,91)(H,76,97)(H,77,94)(H,78,96)(H,79,92)(H,84,85)(H,86,87)(H,88,89)(H,100,101)(H2,102,103,104)/t35-,36-,41-,42-,43-,44-,45-,46-,47-,48-,49-,54-,55-/m0/s1
DM6EA9B CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)C(F)(F)P(=O)(O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)N
DM6EA9B IK FOSUHZNVGWOSJD-VBIHGRSYSA-N
DM6EA9B IU (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-amino-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]propanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DM6EA9B DE Discovery agent
DMYZO37 ID DMYZO37
DMYZO37 DN Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu
DMYZO37 HS Investigative
DMYZO37 SN CHEMBL414123; Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu; BDBM50289749; 147612-86-0
DMYZO37 PC 44300143
DMYZO37 MW 1473.5
DMYZO37 FM C66H97N12O24P
DMYZO37 IC InChI=1S/C66H97N12O24P/c1-7-35(5)54(63(94)73-46(32-37-13-17-39(79)18-14-37)60(91)74-47(66(97)98)31-34(3)4)75-62(93)49-12-10-30-78(49)65(96)55(36(6)8-2)76-58(89)44(24-28-53(85)86)69-56(87)43(23-27-52(83)84)70-59(90)45(33-38-15-19-40(20-16-38)102-103(99,100)101)72-57(88)42(22-25-50(68)80)71-61(92)48-11-9-29-77(48)64(95)41(67)21-26-51(81)82/h13-20,34-36,41-49,54-55,79H,7-12,21-33,67H2,1-6H3,(H2,68,80)(H,69,87)(H,70,90)(H,71,92)(H,72,88)(H,73,94)(H,74,91)(H,75,93)(H,76,89)(H,81,82)(H,83,84)(H,85,86)(H,97,98)(H2,99,100,101)/t35-,36-,41-,42-,43-,44-,45-,46-,47-,48-,49-,54-,55-/m0/s1
DMYZO37 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)OP(=O)(O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)N
DMYZO37 IK DLNQPUNIZRZGQD-VBIHGRSYSA-N
DMYZO37 IU (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-amino-4-carboxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-(4-phosphonooxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
DMYZO37 DE Discovery agent
DMT7K0U ID DMT7K0U
DMT7K0U DN Glutamine Hydroxamate
DMT7K0U HS Investigative
DMT7K0U SN glutamine hydroxamate; N-Hydroxy-L-glutamine; 1955-67-5; Glutamyl-gamma-hydroxamate; gamma-Glutamyl hydroxamate; Glutamate-gamma-hydroxamate; L-gamma-Glutamyl hydroxamate; Glutamate-gamma-hydroxamic acid; Glutamic acid gamma-monohydroxamate; CHEMBL63893; CHEBI:75305; HGA; Glunhoh; Amino acid hydroxamates L-glutamic acid gamma- monohydroxamate; AC1L9MTD; gamma-glutamylhydroxylamine; SCHEMBL4321249; L-Glutamic acid -monohydroxamate; L-Glutamic acid gamma-hydroxamate; ZINC2522574; FCH838713; BDBM50129196; L-glutamic acid gamma-hydr
DMT7K0U DT Small molecular drug
DMT7K0U PC 449178
DMT7K0U MW 162.14
DMT7K0U FM C5H10N2O4
DMT7K0U IC InChI=1S/C5H10N2O4/c6-3(5(9)10)1-2-4(8)7-11/h3,11H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
DMT7K0U CS C(CC(=O)NO)[C@@H](C(=O)O)N
DMT7K0U IK YVGZXTQJQNXIAU-VKHMYHEASA-N
DMT7K0U IU (2S)-2-amino-5-(hydroxyamino)-5-oxopentanoic acid
DMT7K0U CA CAS 1955-67-5
DMT7K0U CB CHEBI:75305
DMT7K0U DE Discovery agent
DMPUFDS ID DMPUFDS
DMPUFDS DN Glutarate
DMPUFDS HS Investigative
DMPUFDS SN GLUTARIC ACID; Pentanedioic acid; 110-94-1; 1,5-Pentanedioic acid; 1,3-Propanedicarboxylic acid; Pentandioic acid; glutarate; n-Pyrotartaric acid; UNII-H849F7N00B; propane-1,3-dicarboxylic acid; Carboxylic acids, di-, C4-6; HSDB 5542; Glutaric acid, 99%; Carboxylic acids, C6-18 and C5-15-di-; NSC 9238; EINECS 203-817-2; (C4-C6) Dibasic acids; BRN 1209725; AI3-24247; CHEBI:17859; NSC9238; JFCQEDHGNNZCLN-UHFFFAOYSA-N; H849F7N00B; MFCD00004410; DSSTox_CID_1654; DSSTox_RID_76266; DSSTox_GSID_21654; CAS-110-94-1; Pentandioate; Glutarsaeure
DMPUFDS DT Small molecular drug
DMPUFDS PC 743
DMPUFDS MW 132.11
DMPUFDS FM C5H8O4
DMPUFDS IC InChI=1S/C5H8O4/c6-4(7)2-1-3-5(8)9/h1-3H2,(H,6,7)(H,8,9)
DMPUFDS CS C(CC(=O)O)CC(=O)O
DMPUFDS IK JFCQEDHGNNZCLN-UHFFFAOYSA-N
DMPUFDS IU pentanedioic acid
DMPUFDS CA CAS 110-94-1
DMPUFDS CB CHEBI:17859
DMPUFDS DE Discovery agent
DMAV2I7 ID DMAV2I7
DMAV2I7 DN Glutathione ester
DMAV2I7 HS Investigative
DMAV2I7 SN Glutathione S-methyl ester; S-Methylglutathione; OOW3025SR1; QTQDDTSVRVWHMO-BQBZGAKWSA-N; S-METHYL-GLUTATHIONE; S-Methyl GSH; S-Methyl glutathione; SCHEMBL1767370; ZINC1532230; 2922-56-7; AC1L3GTT; BDBM225232; C11347; CHEBI:141472; CHEMBL1233129; CTK4G2973; DB04701; DTXSID10183479; GSM; Glycine, L-g-glutamyl-S-methyl-L-cysteinyl-; Glycine, N-(N-L-gamma-glutamyl-S-methyl-L-cysteinyl)-; L-GAMMA-GLUTAMYL-S-METHYLCYSTEINYLGLYCINE; L-gamma-Glutamyl-S-methyl-L-cysteinylglycine; UNII-OOW3025SR1
DMAV2I7 PC 115260
DMAV2I7 MW 321.35
DMAV2I7 FM C11H19N3O6S
DMAV2I7 IC QTQDDTSVRVWHMO-BQBZGAKWSA-N
DMAV2I7 CS CSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N
DMAV2I7 IK 1S/C11H19N3O6S/c1-21-5-7(10(18)13-4-9(16)17)14-8(15)3-2-6(12)11(19)20/h6-7H,2-5,12H2,1H3,(H,13,18)(H,14,15)(H,16,17)(H,19,20)/t6-,7-/m0/s1
DMAV2I7 IU (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-methylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMAV2I7 CA CAS 2922-56-7
DMAV2I7 CB CHEBI:141472
DMAV2I7 DE Discovery agent
DMPX7FR ID DMPX7FR
DMPX7FR DN Glutathionylspermidine Disulfide
DMPX7FR HS Investigative
DMPX7FR SN GLUTATHIONYLSPERMIDINE DISULFIDE; TS4; AC1L9N8X; DB02553; (2R)-2-amino-5-[[(2R)-1-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-3-[[(2R)-3-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-2-[[(4R)-4-amino-5-hydroxy-5-oxopentanoyl]amino]-3-oxopropyl]disulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMPX7FR DT Small molecular drug
DMPX7FR PC 449555
DMPX7FR MW 867.1
DMPX7FR FM C34H66N12O10S2
DMPX7FR IC InChI=1S/C34H66N12O10S2/c35-11-1-3-13-39-15-5-17-41-29(49)19-43-31(51)25(45-27(47)9-7-23(37)33(53)54)21-57-58-22-26(46-28(48)10-8-24(38)34(55)56)32(52)44-20-30(50)42-18-6-16-40-14-4-2-12-36/h23-26,39-40H,1-22,35-38H2,(H,41,49)(H,42,50)(H,43,51)(H,44,52)(H,45,47)(H,46,48)(H,53,54)(H,55,56)/t23-,24-,25+,26+/m1/s1
DMPX7FR CS C(CCNCCCNC(=O)CNC(=O)[C@H](CSSC[C@@H](C(=O)NCC(=O)NCCCNCCCCN)NC(=O)CC[C@H](C(=O)O)N)NC(=O)CC[C@H](C(=O)O)N)CN
DMPX7FR IK HCMZDPYSWPSKSP-XPGKHFPBSA-N
DMPX7FR IU (2R)-2-amino-5-[[(2R)-1-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-3-[[(2R)-3-[[2-[3-(4-aminobutylamino)propylamino]-2-oxoethyl]amino]-2-[[(4R)-4-amino-4-carboxybutanoyl]amino]-3-oxopropyl]disulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMPX7FR DE Discovery agent
DM1Q83B ID DM1Q83B
DM1Q83B DN Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
DM1Q83B HS Investigative
DM1Q83B SN Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro; CHEMBL216386; BDBM50027353
DM1Q83B PC 44346192
DM1Q83B MW 1119.3
DM1Q83B FM C53H78N14O13
DM1Q83B IC InChI=1S/C53H78N14O13/c1-3-29(2)43(51(78)66-25-9-16-39(66)50(77)67-26-10-17-40(67)52(79)80)63-45(72)34(19-20-41(55)68)60-46(73)37-14-7-23-64(37)48(75)35(13-6-22-58-53(56)57)61-47(74)38-15-8-24-65(38)49(76)36(62-44(71)32(54)18-21-42(69)70)27-30-28-59-33-12-5-4-11-31(30)33/h4-5,11-12,28-29,32,34-40,43,59H,3,6-10,13-27,54H2,1-2H3,(H2,55,68)(H,60,73)(H,61,74)(H,62,71)(H,63,72)(H,69,70)(H,79,80)(H4,56,57,58)/t29-,32-,34-,35-,36-,37-,38-,39-,40-,43-/m0/s1
DM1Q83B CS CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCC(=O)O)N
DM1Q83B IK RDZJYRCUGADIDN-AXPLDACSSA-N
DM1Q83B IU (2S)-1-[(2S)-1-[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid
DM1Q83B DE Discovery agent
DMO8LAC ID DMO8LAC
DMO8LAC DN Gly-Amp-Glu
DMO8LAC HS Investigative
DMO8LAC SN Gly-Amp-Glu
DMO8LAC DT Small molecular drug
DMO8LAC PC 44408739
DMO8LAC MW 316.31
DMO8LAC FM C12H20N4O6
DMO8LAC IC InChI=1S/C12H20N4O6/c13-4-9(17)16-5-6(14)3-8(16)11(20)15-7(12(21)22)1-2-10(18)19/h6-8H,1-5,13-14H2,(H,15,20)(H,18,19)(H,21,22)/t6-,7-,8-/m0/s1
DMO8LAC CS C1[C@@H](CN([C@@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)CN)N
DMO8LAC IK FVOTXFYXMKNJIH-FXQIFTODSA-N
DMO8LAC IU (2S)-2-[[(2S,4S)-4-amino-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid
DMO8LAC DE Discovery agent
DMACT8D ID DMACT8D
DMACT8D DN Gly-Arg-Gly-Asp-Ser
DMACT8D HS Investigative
DMACT8D SN Gly-arg-gly-asp-ser; 96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, > LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-
DMACT8D DT Small molecular drug
DMACT8D PC 123811
DMACT8D MW 490.5
DMACT8D FM C17H30N8O9
DMACT8D IC InChI=1S/C17H30N8O9/c18-5-11(27)23-8(2-1-3-21-17(19)20)14(31)22-6-12(28)24-9(4-13(29)30)15(32)25-10(7-26)16(33)34/h8-10,26H,1-7,18H2,(H,22,31)(H,23,27)(H,24,28)(H,25,32)(H,29,30)(H,33,34)(H4,19,20,21)/t8-,9-,10-/m0/s1
DMACT8D CS C(C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)CN)CN=C(N)N
DMACT8D IK RGNVSYKVCGAEHK-GUBZILKMSA-N
DMACT8D IU (3S)-3-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid
DMACT8D CA CAS 96426-21-0
DMACT8D DE Discovery agent
DMGOIME ID DMGOIME
DMGOIME DN Gly-Arg-Gly-Asp-Ser-Pro-Lys
DMGOIME HS Investigative
DMGOIME SN Grgdspk; Gly-arg-gly-asp-ser-pro-lys; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, > glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-
DMGOIME DT Small molecular drug
DMGOIME PC 130667
DMGOIME MW 715.8
DMGOIME FM C28H49N11O11
DMGOIME IC InChI=1S/C28H49N11O11/c29-8-2-1-5-16(27(49)50)37-25(47)19-7-4-10-39(19)26(48)18(14-40)38-24(46)17(11-22(43)44)36-21(42)13-34-23(45)15(35-20(41)12-30)6-3-9-33-28(31)32/h15-19,40H,1-14,29-30H2,(H,34,45)(H,35,41)(H,36,42)(H,37,47)(H,38,46)(H,43,44)(H,49,50)(H4,31,32,33)/t15-,16-,17-,18-,19-/m0/s1
DMGOIME CS C1C[C@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)O
DMGOIME IK ZRVZOBGMZWVJOS-VMXHOPILSA-N
DMGOIME IU (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DMGOIME CA CAS 111119-28-9
DMGOIME DE Discovery agent
DM8L09J ID DM8L09J
DM8L09J DN Gly-b7Pro-Glu
DM8L09J HS Investigative
DM8L09J SN Gly-b7Pro-Glu
DM8L09J DT Small molecular drug
DM8L09J PC 44408837
DM8L09J MW 327.33
DM8L09J FM C14H21N3O6
DM8L09J IC InChI=1S/C14H21N3O6/c15-7-10(18)17-8-3-5-14(17,6-4-8)13(23)16-9(12(21)22)1-2-11(19)20/h8-9H,1-7,15H2,(H,16,23)(H,19,20)(H,21,22)/t8?,9-,14?/m0/s1
DM8L09J CS C1CC2(CCC1N2C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DM8L09J IK AXVZKZJJSLXCSR-PUUHTONNSA-N
DM8L09J IU (2S)-2-[[7-(2-aminoacetyl)-7-azabicyclo[2.2.1]heptane-1-carbonyl]amino]pentanedioic acid
DM8L09J DE Discovery agent
DM0J5KF ID DM0J5KF
DM0J5KF DN Glycerol-2-Phosphate
DM0J5KF HS Investigative
DM0J5KF SN 1,3-dihydroxypropan-2-yl phosphate; Glycerol 2-phosphate; 2-glycerophosphate; NCGC00166037-02; b-glycerol-phosphate; beta-glycerol-phosphate; AC1MU1UF; glycerol 2-phosphate(2-); glycerol 2-phosphate dianion; CHEBI:58083; STL280277; 2-(phosphonatooxy)propane-1,3-diol; AKOS022142160
DM0J5KF DT Small molecular drug
DM0J5KF PC 2526
DM0J5KF MW 172.07
DM0J5KF FM C3H9O6P
DM0J5KF IC InChI=1S/C3H9O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)
DM0J5KF CS C(C(CO)OP(=O)(O)O)O
DM0J5KF IK DHCLVCXQIBBOPH-UHFFFAOYSA-N
DM0J5KF IU 1,3-dihydroxypropan-2-yl dihydrogen phosphate
DM0J5KF CA CAS 17181-54-3
DM0J5KF CB CHEBI:17270
DM0J5KF DE Discovery agent
DMTCEFV ID DMTCEFV
DMTCEFV DN Glycinamid
DMTCEFV HS Investigative
DMTCEFV SN Glycinamide; 2-Aminoacetamide; 598-41-4; Glycine amide; Acetamide, 2-amino-; GLYCINAMID; AMINOMETHYLAMIDE; 2-Amino-Acetamide; CHEBI:42843; BEBCJVAWIBVWNZ-UHFFFAOYSA-N; Glycinamide HCl; AI3-60342; aminoacetamide; glycineamide; glycinamidehcl; glycine-amide; glycine imine; Glycinimidic acid; alpha-aminoacetamide; EINECS 209-932-4; GlyNH2; 2-Aminoacetamide #; Gly-NH2; Glycineamide, G-NH2; AC1L2AXY; H2NCH2CONH2; Glycine amide hydrobromide; AC1Q53MT; CHEMBL86954; 598-41-4 (Parent); DTXSID1060508; 1668-10-6 (hydrochloride); CTK1H1328; CTK1D7741
DMTCEFV DT Small molecular drug
DMTCEFV PC 69020
DMTCEFV MW 74.08
DMTCEFV FM C2H6N2O
DMTCEFV IC InChI=1S/C2H6N2O/c3-1-2(4)5/h1,3H2,(H2,4,5)
DMTCEFV CS C(C(=O)N)N
DMTCEFV IK BEBCJVAWIBVWNZ-UHFFFAOYSA-N
DMTCEFV IU 2-aminoacetamide
DMTCEFV CA CAS 598-41-4
DMTCEFV CB CHEBI:42843
DMTCEFV DE Discovery agent
DMW180Y ID DMW180Y
DMW180Y DN Glycinamide Ribonucleotide
DMW180Y HS Investigative
DMW180Y SN Glycineamide ribonucleotide; Glycineamideribotide; glycinamide ribonucleotide; 10074-18-7; 5'-phosphoribosylglycineamide; GAR; 5'-phosphoribosylglycinamide; N1-(5-Phospho-D-ribosyl)glycinamide; {[(2R,3S,4R,5R)-5-(2-aminoacetamido)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid; N1-(5-phospho-beta-D-ribosyl)glycinamide; Glycineamide ribotide; AC1Q5JNA; AC1L4OGM; n-glycyl-5-o-phosphono-; A-d-ribofuranosylamine; 5'-Phosphoribosyl-glycineamide; SCHEMBL4366354; BDBM22589; DTXSID70143478; C03838
DMW180Y DT Small molecular drug
DMW180Y PC 160913
DMW180Y MW 286.18
DMW180Y FM C7H15N2O8P
DMW180Y IC InChI=1S/C7H15N2O8P/c8-1-4(10)9-7-6(12)5(11)3(17-7)2-16-18(13,14)15/h3,5-7,11-12H,1-2,8H2,(H,9,10)(H2,13,14,15)/t3-,5-,6-,7-/m1/s1
DMW180Y CS C([C@@H]1[C@H]([C@H]([C@@H](O1)NC(=O)CN)O)O)OP(=O)(O)O
DMW180Y IK OBQMLSFOUZUIOB-SHUUEZRQSA-N
DMW180Y IU [(2R,3S,4R,5R)-5-[(2-aminoacetyl)amino]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DMW180Y CA CAS 10074-18-7
DMW180Y DE Discovery agent
DM0SXNM ID DM0SXNM
DM0SXNM DN Glycocholic acid
DM0SXNM HS Investigative
DM0SXNM SN glycocholate; cholylglycine
DM0SXNM DT Small molecular drug
DM0SXNM PC 10140
DM0SXNM MW 465.6
DM0SXNM FM C26H43NO6
DM0SXNM IC InChI=1S/C26H43NO6/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29/h14-21,24,28-30H,4-13H2,1-3H3,(H,27,31)(H,32,33)/t14-,15+,16-,17-,18+,19+,20-,21+,24+,25+,26-/m1/s1
DM0SXNM CS C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
DM0SXNM IK RFDAIACWWDREDC-FRVQLJSFSA-N
DM0SXNM IU 2-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
DM0SXNM CA CAS 475-31-0
DM0SXNM CB CHEBI:17687
DM0SXNM DE Discovery agent
DM1XEJV ID DM1XEJV
DM1XEJV DN Glycodeoxycholic acid
DM1XEJV HS Investigative
DM1XEJV SN glycodeoxycholate
DM1XEJV DT Small molecular drug
DM1XEJV PC 3035026
DM1XEJV MW 449.6
DM1XEJV FM C26H43NO5
DM1XEJV IC InChI=1S/C26H43NO5/c1-15(4-9-23(30)27-14-24(31)32)19-7-8-20-18-6-5-16-12-17(28)10-11-25(16,2)21(18)13-22(29)26(19,20)3/h15-22,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16-,17-,18+,19-,20+,21+,22+,25+,26-/m1/s1
DM1XEJV CS C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
DM1XEJV IK WVULKSPCQVQLCU-BUXLTGKBSA-N
DM1XEJV IU 2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid
DM1XEJV CA CAS 360-65-6
DM1XEJV CB CHEBI:27471
DM1XEJV DE Discovery agent
DM0SCK8 ID DM0SCK8
DM0SCK8 DN Glycyl-H 1152
DM0SCK8 HS Investigative
DM0SCK8 SN glycyl-H 1152
DM0SCK8 DT Small molecular drug
DM0SCK8 PC 11976582
DM0SCK8 MW 376.5
DM0SCK8 FM C18H24N4O3S
DM0SCK8 IC InChI=1S/C18H24N4O3S/c1-13-10-20-11-15-5-3-6-16(18(13)15)26(24,25)22-8-4-7-21(12-14(22)2)17(23)9-19/h3,5-6,10-11,14H,4,7-9,12,19H2,1-2H3/t14-/m0/s1
DM0SCK8 CS C[C@H]1CN(CCCN1S(=O)(=O)C2=CC=CC3=C2C(=CN=C3)C)C(=O)CN
DM0SCK8 IK CMKMGFAUKPAOMG-AWEZNQCLSA-N
DM0SCK8 IU 2-amino-1-[(3S)-3-methyl-4-(4-methylisoquinolin-5-yl)sulfonyl-1,4-diazepan-1-yl]ethanone
DM0SCK8 DE Discovery agent
DM8FTJN ID DM8FTJN
DM8FTJN DN Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine
DM8FTJN HS Investigative
DM8FTJN SN GLYCYL-L-ALPHA-AMINO-EPSILON-PIMELYL-D-ALANINE; REY; AC1L9JH9; DB03927; (2S)-2-[(2-aminoacetyl)amino]-7-[[(2R)-1-hydroxy-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid
DM8FTJN DT Small molecular drug
DM8FTJN PC 446307
DM8FTJN MW 303.31
DM8FTJN FM C12H21N3O6
DM8FTJN IC InChI=1S/C12H21N3O6/c1-7(11(18)19)14-9(16)5-3-2-4-8(12(20)21)15-10(17)6-13/h7-8H,2-6,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t7-,8+/m1/s1
DM8FTJN CS C[C@H](C(=O)O)NC(=O)CCCC[C@@H](C(=O)O)NC(=O)CN
DM8FTJN IK ZMQJQOKNTYQVHO-SFYZADRCSA-N
DM8FTJN IU (2S)-2-[(2-aminoacetyl)amino]-7-[[(1R)-1-carboxyethyl]amino]-7-oxoheptanoic acid
DM8FTJN DE Discovery agent
DMTOCXZ ID DMTOCXZ
DMTOCXZ DN GLYCYLRYANODINE
DMTOCXZ HS Investigative
DMTOCXZ SN glycylryanodine; CHEMBL283836
DMTOCXZ DT Small molecular drug
DMTOCXZ PC 44275859
DMTOCXZ MW 550.6
DMTOCXZ FM C27H38N2O10
DMTOCXZ IC InChI=1S/C27H38N2O10/c1-13(2)24(34)19(38-18(31)15-7-6-10-29-15)25(35)20(4)12-23(33)21(24,5)27(25,36)26(39-23)17(37-16(30)11-28)14(3)8-9-22(20,26)32/h6-7,10,13-14,17,19,29,32-36H,8-9,11-12,28H2,1-5H3/t14?,17-,19-,20+,21?,22?,23?,24?,25?,26?,27?/m1/s1
DMTOCXZ CS CC1CCC2([C@@]3(CC4(C5(C([C@H](C3(C5(C2([C@@H]1OC(=O)CN)O4)O)O)OC(=O)C6=CC=CN6)(C(C)C)O)C)O)C)O
DMTOCXZ IK XNUMBOKCFNVRAL-MPGPDOFNSA-N
DMTOCXZ IU [(2R,7S,12R)-2-(2-aminoacetyl)oxy-6,9,11,13,14-pentahydroxy-3,7,10-trimethyl-11-propan-2-yl-15-oxapentacyclo[7.5.1.01,6.07,13.010,14]pentadecan-12-yl] 1H-pyrrole-2-carboxylate
DMTOCXZ DE Discovery agent
DM67FQ1 ID DM67FQ1
DM67FQ1 DN GlyH-101
DM67FQ1 HS Investigative
DM67FQ1 SN CTK8E9894; AGN-PC-005HH0
DM67FQ1 DT Small molecular drug
DM67FQ1 PC 135476586
DM67FQ1 MW 493.1
DM67FQ1 FM C19H15Br2N3O3
DM67FQ1 IC InChI=1S/C19H15Br2N3O3/c20-15-8-13(18(26)17(21)19(15)27)9-23-24-16(25)10-22-14-6-5-11-3-1-2-4-12(11)7-14/h1-9,22,26-27H,10H2,(H,24,25)/b23-9+
DM67FQ1 CS C1=CC=C2C=C(C=CC2=C1)NCC(=O)N/N=C/C3=CC(=C(C(=C3O)Br)O)Br
DM67FQ1 IK RMBDLOATEPYBSI-NUGSKGIGSA-N
DM67FQ1 IU N-[(E)-(3,5-dibromo-2,4-dihydroxyphenyl)methylideneamino]-2-(naphthalen-2-ylamino)acetamide
DM67FQ1 DE Discovery agent
DM8XR4Y ID DM8XR4Y
DM8XR4Y DN Gly-Hyp-Glu
DM8XR4Y HS Investigative
DM8XR4Y SN Gly-Hyp-Glu; CHEMBL380624; SCHEMBL2084290; MPZCPLJCORMPJI-CSMHCCOUSA-N; glycyl-l-hydroxyprolyl-l-glutamic acid; Glycyl-trans-4-hydroxy-L-prolyl-L-glutamic acid
DM8XR4Y DT Small molecular drug
DM8XR4Y PC 11902976
DM8XR4Y MW 317.3
DM8XR4Y FM C12H19N3O7
DM8XR4Y IC InChI=1S/C12H19N3O7/c13-4-9(17)15-5-6(16)3-8(15)11(20)14-7(12(21)22)1-2-10(18)19/h6-8,16H,1-5,13H2,(H,14,20)(H,18,19)(H,21,22)/t6-,7+,8+/m1/s1
DM8XR4Y CS C1[C@H](CN([C@@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)CN)O
DM8XR4Y IK MPZCPLJCORMPJI-CSMHCCOUSA-N
DM8XR4Y IU (2S)-2-[[(2S,4R)-1-(2-aminoacetyl)-4-hydroxypyrrolidine-2-carbonyl]amino]pentanedioic acid
DM8XR4Y CA CAS 32302-79-7
DM8XR4Y DE Discovery agent
DMQUP7O ID DMQUP7O
DMQUP7O DN Glyoxalate, Glyoxylate
DMQUP7O HS Investigative
DMQUP7O SN glyoxylic acid; 298-12-4; 2-Oxoacetic Acid; Glyoxalic acid; Oxoacetic acid; Oxoethanoic acid; Formylformic acid; Acetic acid, oxo-; Oxalaldehydic acid; glyoxylate; alpha-Ketoacetic acid; glyoxalate; 2-Oxoacetic acid(50% in water); Formic acid, formyl-; oxaldehydic acid; Kyselina glyoxylova; GLYOXALATE, GLYOXYLATE; 563-96-2; CCRIS 1455; Acetic acid, 2-oxo-; HSDB 5559; Oxo-acetic acid; Kyselina glyoxylova [Czech]; UNII-JQ39C92HH6; NSC 27785; OCHCOOH; .alpha.-Ketoacetic acid; EINECS 206-058-5; BRN 0741891; JQ39C92HH6; Glyoxylic acid, 50% i
DMQUP7O DT Small molecular drug
DMQUP7O PC 760
DMQUP7O MW 74.04
DMQUP7O FM C2H2O3
DMQUP7O IC InChI=1S/C2H2O3/c3-1-2(4)5/h1H,(H,4,5)
DMQUP7O CS C(=O)C(=O)O
DMQUP7O IK HHLFWLYXYJOTON-UHFFFAOYSA-N
DMQUP7O IU oxaldehydic acid
DMQUP7O CA CAS 298-12-4
DMQUP7O CB CHEBI:16891
DMQUP7O DE Discovery agent
DMJ9XZO ID DMJ9XZO
DMJ9XZO DN Glyoxylate
DMJ9XZO HS Investigative
DMJ9XZO SN Glyoxylat; HHLFWLYXYJOTON-UHFFFAOYSA-M; glyoxylate; oxaldehydate; oxoacetate; AC1MU8DW; CHEBI:36655; glyox
DMJ9XZO PC 3614358
DMJ9XZO MW 73.03
DMJ9XZO FM C2HO3-
DMJ9XZO IC HHLFWLYXYJOTON-UHFFFAOYSA-M
DMJ9XZO CS C(=O)C(=O)[O-]
DMJ9XZO IK 1S/C2H2O3/c3-1-2(4)5/h1H,(H,4,5)/p-1
DMJ9XZO IU oxaldehydate
DMJ9XZO CA CAS 298-12-4
DMJ9XZO CB CHEBI:36655
DMJ9XZO DE Discovery agent
DM0AFY7 ID DM0AFY7
DM0AFY7 DN Glyphosate
DM0AFY7 HS Investigative
DM0AFY7 SN glyphosate; 1071-83-6; N-(Phosphonomethyl)glycine; Glyphosphate; Roundup; Glycine, N-(phosphonomethyl)-; N-Phosphonomethyl-glycine; 2-(phosphonomethylamino)acetic acid; Silglif; Pondmaster; Roundup Max; N-Phosphonomethylglycine; N-Phosphomethylglycine; Caswell No. 661A; MON 2139; C3H8NO5P; N-(Phosphonomethyl) Glycine; NSC151063; Glialka; Phosphonomethyliminoacetic acid; Mon 6000; Glyphosate [ANSI:BSI:ISO]; UNII-4632WW1X5A; CCRIS 1587; CP 67573; HSDB 3432; XDDAORKBJWWYJS-UHFFFAOYSA-N; EINECS 213-997-4; 2-((Phosphonomethyl)amino)acetic
DM0AFY7 DT Small molecular drug
DM0AFY7 PC 3496
DM0AFY7 MW 169.07
DM0AFY7 FM C3H8NO5P
DM0AFY7 IC InChI=1S/C3H8NO5P/c5-3(6)1-4-2-10(7,8)9/h4H,1-2H2,(H,5,6)(H2,7,8,9)
DM0AFY7 CS C(C(=O)O)NCP(=O)(O)O
DM0AFY7 IK XDDAORKBJWWYJS-UHFFFAOYSA-N
DM0AFY7 IU 2-(phosphonomethylamino)acetic acid
DM0AFY7 CA CAS 1071-83-6
DM0AFY7 CB CHEBI:27744
DM0AFY7 DE Malaria
DMM0JA4 ID DMM0JA4
DMM0JA4 DN Gly-Pip-Glu
DMM0JA4 HS Investigative
DMM0JA4 SN Gly-Pip-Glu; SCHEMBL2084204
DMM0JA4 DT Small molecular drug
DMM0JA4 PC 25055596
DMM0JA4 MW 315.32
DMM0JA4 FM C13H21N3O6
DMM0JA4 IC InChI=1S/C13H21N3O6/c14-7-10(17)16-6-2-1-3-9(16)12(20)15-8(13(21)22)4-5-11(18)19/h8-9H,1-7,14H2,(H,15,20)(H,18,19)(H,21,22)/t8-,9-/m0/s1
DMM0JA4 CS C1CCN([C@@H](C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)CN
DMM0JA4 IK NEMPLRJUKFPLSV-IUCAKERBSA-N
DMM0JA4 IU (2S)-2-[[(2S)-1-(2-aminoacetyl)piperidine-2-carbonyl]amino]pentanedioic acid
DMM0JA4 DE Discovery agent
DMMDU0K ID DMMDU0K
DMMDU0K DN GM-109
DMMDU0K HS Investigative
DMMDU0K SN GM109; GM 109
DMMDU0K DT Small molecular drug
DMMDU0K PC 9850904
DMMDU0K MW 565.7
DMMDU0K FM C31H43N5O5
DMMDU0K IC InChI=1S/C31H43N5O5/c1-31(2,3)22-17-21(12-13-26(22)37)19-25-29(40)34-16-14-27(38)33-15-8-7-11-24(30(41)36-25)35-28(39)23(32)18-20-9-5-4-6-10-20/h4-6,9-10,12-13,17,23-25,37H,7-8,11,14-16,18-19,32H2,1-3H3,(H,33,38)(H,34,40)(H,35,39)(H,36,41)/t23-,24-,25-/m0/s1
DMMDU0K CS CC(C)(C)C1=C(C=CC(=C1)C[C@H]2C(=O)NCCC(=O)NCCCC[C@@H](C(=O)N2)NC(=O)[C@H](CC3=CC=CC=C3)N)O
DMMDU0K IK RRXAKVUZGASTMY-SDHOMARFSA-N
DMMDU0K IU (2S)-2-amino-N-[(2S,13S)-2-[(3-tert-butyl-4-hydroxyphenyl)methyl]-3,7,14-trioxo-1,4,8-triazacyclotetradec-13-yl]-3-phenylpropanamide
DMMDU0K DE Discovery agent
DMM0ZKQ ID DMM0ZKQ
DMM0ZKQ DN GMQ
DMM0ZKQ HS Investigative
DMM0ZKQ SN 2-guanidine-4-methylquinazoline; GNF-Pf-3515; 2-GMQ
DMM0ZKQ DT Small molecular drug
DMM0ZKQ PC 345657
DMM0ZKQ MW 201.23
DMM0ZKQ FM C10H11N5
DMM0ZKQ IC InChI=1S/C10H11N5/c1-6-7-4-2-3-5-8(7)14-10(13-6)15-9(11)12/h2-5H,1H3,(H4,11,12,13,14,15)
DMM0ZKQ CS CC1=NC(=NC2=CC=CC=C12)N=C(N)N
DMM0ZKQ IK ONQKSKDLYYDFLL-UHFFFAOYSA-N
DMM0ZKQ IU 2-(4-methylquinazolin-2-yl)guanidine
DMM0ZKQ CA CAS 716-11-0
DMM0ZKQ DE Discovery agent
DMYWM56 ID DMYWM56
DMYWM56 DN GNE-7915
DMYWM56 HS Investigative
DMYWM56 SN GNE7915; GNE 7915
DMYWM56 DT Small molecular drug
DMYWM56 PC 58539171
DMYWM56 MW 443.4
DMYWM56 FM C19H21F4N5O3
DMYWM56 IC InChI=1S/C19H21F4N5O3/c1-3-24-16-12(19(21,22)23)10-25-18(27-16)26-14-9-13(20)11(8-15(14)30-2)17(29)28-4-6-31-7-5-28/h8-10H,3-7H2,1-2H3,(H2,24,25,26,27)
DMYWM56 CS CCNC1=NC(=NC=C1C(F)(F)F)NC2=C(C=C(C(=C2)F)C(=O)N3CCOCC3)OC
DMYWM56 IK XCFLWTZSJYBCPF-UHFFFAOYSA-N
DMYWM56 IU [4-[[4-(ethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-2-fluoro-5-methoxyphenyl]-morpholin-4-ylmethanone
DMYWM56 DE Discovery agent
DMLXR90 ID DMLXR90
DMLXR90 DN GNE-9605
DMLXR90 HS Investigative
DMLXR90 SN GNE 9605; GNE9605
DMLXR90 DT Small molecular drug
DMLXR90 PC 76328936
DMLXR90 MW 449.8
DMLXR90 FM C17H20ClF4N7O
DMLXR90 IC InChI=1S/C17H20ClF4N7O/c1-23-15-10(17(20,21)22)4-24-16(27-15)26-12-5-25-29(14(12)18)13-2-3-28(6-11(13)19)9-7-30-8-9/h4-5,9,11,13H,2-3,6-8H2,1H3,(H2,23,24,26,27)/t11-,13-/m0/s1
DMLXR90 CS CNC1=NC(=NC=C1C(F)(F)F)NC2=C(N(N=C2)[C@H]3CCN(C[C@@H]3F)C4COC4)Cl
DMLXR90 IK PUXPEQJKNAWNQA-AAEUAGOBSA-N
DMLXR90 IU 2-N-[5-chloro-1-[(3S,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl]pyrazol-4-yl]-4-N-methyl-5-(trifluoromethyl)pyrimidine-2,4-diamine
DMLXR90 DE Discovery agent
DMGLIPV ID DMGLIPV
DMGLIPV DN GNF-5
DMGLIPV HS Investigative
DMGLIPV SN GNF5; GNF 5
DMGLIPV DT Small molecular drug
DMGLIPV PC 44129660
DMGLIPV MW 418.4
DMGLIPV FM C20H17F3N4O3
DMGLIPV IC InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-6-4-15(5-7-16)27-18-11-17(25-12-26-18)13-2-1-3-14(10-13)19(29)24-8-9-28/h1-7,10-12,28H,8-9H2,(H,24,29)(H,25,26,27)
DMGLIPV CS C1=CC(=CC(=C1)C(=O)NCCO)C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F
DMGLIPV IK IIQUYGWWHIHOCF-UHFFFAOYSA-N
DMGLIPV IU N-(2-hydroxyethyl)-3-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
DMGLIPV CA CAS 778277-15-9
DMGLIPV DE Discovery agent
DMYJO13 ID DMYJO13
DMYJO13 DN GNF-5837
DMYJO13 HS Investigative
DMYJO13 SN GNF 5837; GNF5837
DMYJO13 DT Small molecular drug
DMYJO13 PC 59397065
DMYJO13 MW 535.5
DMYJO13 FM C28H21F4N5O2
DMYJO13 IC InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-
DMYJO13 CS CC1=C(C=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)NC3=CC4=C(C=C3)/C(=C/C5=CC=CN5)/C(=O)N4
DMYJO13 IK YYDUWLSETXNJJT-MTJSOVHGSA-N
DMYJO13 IU 1-[2-fluoro-5-(trifluoromethyl)phenyl]-3-[4-methyl-3-[[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-6-yl]amino]phenyl]urea
DMYJO13 DE Discovery agent
DM3INUK ID DM3INUK
DM3INUK DN GNF-PF-117
DM3INUK HS Investigative
DM3INUK SN 4-Hydroxy-6-methoxy-2-phenylquinoline; 17282-70-1; GNF-PF-117; 6-methoxy-2-phenylquinolin-4-ol; 6-Methoxy-2-phenyl-4-quinolinol; 6-Methoxy-2-phenyl-1H-quinolin-4-one; CHEMBL14120; 6-Methoxy-2-phenyl-quinolin-4-ol; Maybridge3_005419; AC1L3YAP; Oprea1_238017; SCHEMBL6534282; SCHEMBL10610678; CTK8F6034; CTK7A7980; MolPort-000-677-170; KUC100231N; HMS1446G07; ZINC8649323; 2-Phenyl-4-oxy-6-methoxy-chinolin; KUC100231; BDBM50041130; SBB016283; AKOS009868047; AKOS000273771; MCULE-6727803755; AB10684; CCG-252411; IDI1_016806
DM3INUK DT Small molecular drug
DM3INUK PC 124348
DM3INUK MW 251.28
DM3INUK FM C16H13NO2
DM3INUK IC InChI=1S/C16H13NO2/c1-19-12-7-8-14-13(9-12)16(18)10-15(17-14)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
DM3INUK CS COC1=CC2=C(C=C1)NC(=CC2=O)C3=CC=CC=C3
DM3INUK IK CKFBIYVXNYYXAI-UHFFFAOYSA-N
DM3INUK IU 6-methoxy-2-phenyl-1H-quinolin-4-one
DM3INUK CA CAS 57183-50-3
DM3INUK DE Discovery agent
DM183RV ID DM183RV
DM183RV DN GNF-PF-1399
DM183RV HS Investigative
DM183RV SN GNF-PF-2708; GNF-PF-4643
DM183RV DT Small molecular drug
DM183RV PC 107464
DM183RV MW 380.27
DM183RV FM C17H21IN2
DM183RV IC InChI=1S/C17H21N2.HI/c1-4-19-14-6-5-7-17(19)13-10-15-8-11-16(12-9-15)18(2)3;/h5-14H,4H2,1-3H3;1H/q+1;/p-1
DM183RV CS CC[N+]1=CC=CC=C1C=CC2=CC=C(C=C2)N(C)C.[I-]
DM183RV IK AMAXNNVXIBDEMV-UHFFFAOYSA-M
DM183RV IU 4-[2-(1-ethylpyridin-1-ium-2-yl)ethenyl]-N,N-dimethylaniline;iodide
DM183RV CA CAS 3785-01-1
DM183RV CB CHEBI:38007
DM183RV DE Discovery agent
DMVUBGF ID DMVUBGF
DMVUBGF DN GNF-PF-1550
DMVUBGF HS Investigative
DMVUBGF SN GNF-PF-1550; CHEMBL196573; MolPort-007-587-167; HMS1621O13; ZINC13671923; BDBM50172447; AKOS001782657; SR-01000549061; SR-01000549061-1; (2E)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]-3-(4-methoxyphenyl)acrylamide
DMVUBGF DT Small molecular drug
DMVUBGF PC 44403742
DMVUBGF MW 430.5
DMVUBGF FM C26H30N4O2
DMVUBGF IC InChI=1S/C26H30N4O2/c1-4-29-13-15-30(16-14-29)25-17-19(2)23-18-21(8-11-24(23)28-25)27-26(31)12-7-20-5-9-22(32-3)10-6-20/h5-12,17-18H,4,13-16H2,1-3H3,(H,27,31)/b12-7+
DMVUBGF CS CCN1CCN(CC1)C2=NC3=C(C=C(C=C3)NC(=O)/C=C/C4=CC=C(C=C4)OC)C(=C2)C
DMVUBGF IK BYSCWUNLAIWJED-KPKJPENVSA-N
DMVUBGF IU (E)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]-3-(4-methoxyphenyl)prop-2-enamide
DMVUBGF DE Discovery agent
DMHCGBZ ID DMHCGBZ
DMHCGBZ DN GNF-PF-1591
DMHCGBZ HS Investigative
DMHCGBZ SN GNF-Pf-1591; MLS000554446; SMR000171400; AC1LKBEY; ChemDiv2_001930; CBMicro_025972; MAIM-1; CHEMBL588954; HDOKKAMQZREOLG-XQNSMLJCSA-N; 4-methyl-N-[4-oxo-3-(1H-1,2,4-triazol-5-ylsulfanyl)naphthalen-1-ylidene]benzenesulfonamide; HMS2542H12; ZINC18213201; ZINC100480724; MCULE-5187110916; J3.505.787K; SR-01000708580; SR-01000708580-2
DMHCGBZ DT Small molecular drug
DMHCGBZ PC 1015540
DMHCGBZ MW 410.5
DMHCGBZ FM C19H14N4O3S2
DMHCGBZ IC InChI=1S/C19H14N4O3S2/c1-12-6-8-13(9-7-12)28(25,26)23-16-10-17(27-19-20-11-21-22-19)18(24)15-5-3-2-4-14(15)16/h2-11H,1H3,(H,20,21,22)
DMHCGBZ CS CC1=CC=C(C=C1)S(=O)(=O)N=C2C=C(C(=O)C3=CC=CC=C32)SC4=NC=NN4
DMHCGBZ IK HDOKKAMQZREOLG-UHFFFAOYSA-N
DMHCGBZ IU 4-methyl-N-[4-oxo-3-(1H-1,2,4-triazol-5-ylsulfanyl)naphthalen-1-ylidene]benzenesulfonamide
DMHCGBZ CA CAS 315698-91-0
DMHCGBZ DE Discovery agent
DM4JZ9A ID DM4JZ9A
DM4JZ9A DN GNF-PF-1694
DM4JZ9A HS Investigative
DM4JZ9A SN GNF-PF-1694; CHEMBL513104; Oprea1_332906; Oprea1_089499; BDBM50274012
DM4JZ9A DT Small molecular drug
DM4JZ9A PC 23968266
DM4JZ9A MW 313.4
DM4JZ9A FM C19H23NO3
DM4JZ9A IC InChI=1S/C19H23NO3/c1-19(2,3)20-11-13(21)12-22-16-9-6-10-17-18(16)14-7-4-5-8-15(14)23-17/h4-10,13,20-21H,11-12H2,1-3H3
DM4JZ9A CS CC(C)(C)NCC(COC1=CC=CC2=C1C3=CC=CC=C3O2)O
DM4JZ9A IK HGDYQUMVUUMEFM-UHFFFAOYSA-N
DM4JZ9A IU 1-(tert-butylamino)-3-dibenzofuran-1-yloxypropan-2-ol
DM4JZ9A DE Discovery agent
DMUSAYG ID DMUSAYG
DMUSAYG DN GNF-PF-173
DMUSAYG HS Investigative
DMUSAYG SN 10-Deazaaminopterin; 10-Deazaminopterin; 10-Deaza-aminopterin; GNF-PF-173; UNII-PXJ16PPE04; NSC 311469; PXJ16PPE04; CHEMBL293263; L-Glutamic acid, N-(4-(2-(2,4-diamino-6-pteridinyl)ethyl)benzoyl)-; L-Glutamic acid, N-[4-[2-(2,4-diamino-6-pteridinyl)ethyl]benzoyl]-; 52454-37-2; AC1L2OWJ; AC1Q5QQQ; 10-DAM; SCHEMBL7081697; BDBM50016461; LS-187417; LS-186724; (2S)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]pentanedioic acid; (S)-2-{4-[2-(2,4-Diamino-pteridin-6-yl)-ethyl]-benzoylamino}-pentanedioic acid
DMUSAYG DT Small molecular drug
DMUSAYG PC 100516
DMUSAYG MW 439.4
DMUSAYG FM C20H21N7O5
DMUSAYG IC InChI=1S/C20H21N7O5/c21-16-15-17(27-20(22)26-16)23-9-12(24-15)6-3-10-1-4-11(5-2-10)18(30)25-13(19(31)32)7-8-14(28)29/h1-2,4-5,9,13H,3,6-8H2,(H,25,30)(H,28,29)(H,31,32)(H4,21,22,23,26,27)/t13-/m0/s1
DMUSAYG CS C1=CC(=CC=C1CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMUSAYG IK LGFLRHWJJKLPCC-ZDUSSCGKSA-N
DMUSAYG IU (2S)-2-[[4-[2-(2,4-diaminopteridin-6-yl)ethyl]benzoyl]amino]pentanedioic acid
DMUSAYG CA CAS 52454-37-2
DMUSAYG DE Discovery agent
DMGSRLA ID DMGSRLA
DMGSRLA DN GNF-PF-1967
DMGSRLA HS Investigative
DMGSRLA SN GNF-PF-1967; AC1NEHJX; CHEMBL374744; MolPort-007-587-747; AKOS021661170; AKOS001495347; MCULE-7181472168; SR-01000549442; SR-01000549442-1; N-[2-(diethylamino)ethyl]-2-(4-fluorobenzyl)-3-(4-methoxyphenyl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide
DMGSRLA DT Small molecular drug
DMGSRLA PC 4617502
DMGSRLA MW 503.6
DMGSRLA FM C30H34FN3O3
DMGSRLA IC InChI=1S/C30H34FN3O3/c1-4-33(5-2)19-18-32-29(35)27-25-8-6-7-9-26(25)30(36)34(20-21-10-14-23(31)15-11-21)28(27)22-12-16-24(37-3)17-13-22/h6-17,27-28H,4-5,18-20H2,1-3H3,(H,32,35)
DMGSRLA CS CCN(CC)CCNC(=O)C1C(N(C(=O)C2=CC=CC=C12)CC3=CC=C(C=C3)F)C4=CC=C(C=C4)OC
DMGSRLA IK ACZABABCHZPYHY-UHFFFAOYSA-N
DMGSRLA IU N-[2-(diethylamino)ethyl]-2-[(4-fluorophenyl)methyl]-3-(4-methoxyphenyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
DMGSRLA DE Discovery agent
DM9J35R ID DM9J35R
DM9J35R DN GNF-PF-2094
DM9J35R HS Investigative
DM9J35R SN GNF-Pf-2094; CHEMBL578928; AC1LF3VX; ChemDiv3_003176; MLS000555549; REGID_for_CID_697226; ZINC73452; MolPort-002-569-783; HMS2595H06; HMS3382F08; HMS1482A08; DNDI1388215; CCG-20329; BDBM50304834; STK839621; AKOS005624964; MCULE-1058130285; IDI1_021086; SMR000147266; SR-01000110418; SR-01000110418-1; BRD-K84805375-001-01-1; N2-benzyl-N4-cyclohexyl-6-methylpyrimidine-2,4-diamine; 2-N-benzyl-4-N-cyclohexyl-6-methylpyrimidine-2,4-diamine; N*2*-Benzyl-N*4*-cyclohexyl-6-methyl-pyrimidine-2,4-diamine
DM9J35R DT Small molecular drug
DM9J35R PC 697226
DM9J35R MW 296.4
DM9J35R FM C18H24N4
DM9J35R IC InChI=1S/C18H24N4/c1-14-12-17(21-16-10-6-3-7-11-16)22-18(20-14)19-13-15-8-4-2-5-9-15/h2,4-5,8-9,12,16H,3,6-7,10-11,13H2,1H3,(H2,19,20,21,22)
DM9J35R CS CC1=CC(=NC(=N1)NCC2=CC=CC=C2)NC3CCCCC3
DM9J35R IK GDKCAAWSNQLXNX-UHFFFAOYSA-N
DM9J35R IU 2-N-benzyl-4-N-cyclohexyl-6-methylpyrimidine-2,4-diamine
DM9J35R DE Discovery agent
DM26UKN ID DM26UKN
DM26UKN DN GNF-PF-2224
DM26UKN HS Investigative
DM26UKN SN 8-Cyclopentyl-1,3-dipropylxanthine; DPCPX; 102146-07-6; 8-cyclopentyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione; 1,3-Dpcpx; 1,3-dipropyl-8-cyclopentylxanthine; PD-116,948; PD-116948; UNII-9PTP4FOI9E; dipropylcyclopentylxanthine; 9PTP4FOI9E; CHEMBL183; MLS000069347; CHEBI:73282; 8-Cyclopentyl-3,7-dihydro-1,3-dipropyl-1H-purin-2,6-dione; 8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE [DPCPX]; SMR000058434; DPCPX, 1,3-Dipropyl-8-cyclopentylxanthine
DM26UKN DT Small molecular drug
DM26UKN PC 1329
DM26UKN MW 304.39
DM26UKN FM C16H24N4O2
DM26UKN IC InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)
DM26UKN CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3CCCC3
DM26UKN IK FFBDFADSZUINTG-UHFFFAOYSA-N
DM26UKN IU 8-cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione
DM26UKN CA CAS 102146-07-6
DM26UKN CB CHEBI:73282
DM26UKN DE Discovery agent
DMONK0F ID DMONK0F
DMONK0F DN GNF-PF-2272
DMONK0F HS Investigative
DMONK0F SN 3-Methyltoxoflavin; GNF-Pf-2272; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117
DMONK0F DT Small molecular drug
DMONK0F PC 460747
DMONK0F MW 207.19
DMONK0F FM C8H9N5O2
DMONK0F IC InChI=1S/C8H9N5O2/c1-4-9-5-6(13(3)11-4)10-8(15)12(2)7(5)14/h1-3H3
DMONK0F CS CC1=NN(C2=NC(=O)N(C(=O)C2=N1)C)C
DMONK0F IK CPXHNWKHOFNPDO-UHFFFAOYSA-N
DMONK0F IU 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
DMONK0F CB CHEBI:95315
DMONK0F DE Discovery agent
DMP6DBX ID DMP6DBX
DMP6DBX DN GNF-PF-2307
DMP6DBX HS Investigative
DMP6DBX SN 3-Phenyl-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-2307; NSC663883; 77152-22-8; CHEMBL421088; 3-phenylindeno[1,2-c]pyridazin-5-one; 5H-Indeno[1,2-c]pyridazin-5-one, 3-phenyl-; AC1Q6KMU; AC1L8E6X; Oprea1_571099; MLS000539984; cid_379337; Aza-heterocyclic Derivative, 1b; KS-00001QSP; CTK2G0333; BDBM19164; DTXSID40327521; MolPort-002-851-051; HMS2177H12; ZINC1383534; STK336084; AKOS005075114; NSC-663883; MCULE-8078785196; SMR000125442; NCI60_021916; 3-(Phenyl)-5H-indeno[1,2-c]pyridazin-5-one; SR-01000694335; 10K-057
DMP6DBX DT Small molecular drug
DMP6DBX PC 379337
DMP6DBX MW 258.269
DMP6DBX FM C17H10N2O
DMP6DBX IC InChI=1S/C17H10N2O/c20-17-13-9-5-4-8-12(13)16-14(17)10-15(18-19-16)11-6-2-1-3-7-11/h1-10H
DMP6DBX CS C1=CC=C(C=C1)C2=NN=C3C4=CC=CC=C4C(=O)C3=C2
DMP6DBX IK ORLUBUYLVCUFDE-UHFFFAOYSA-N
DMP6DBX IU 3-phenylindeno[1,2-c]pyridazin-5-one
DMP6DBX CA CAS 77152-22-8
DMP6DBX DE Discovery agent
DMW93IO ID DMW93IO
DMW93IO DN GNF-PF-2322
DMW93IO HS Investigative
DMW93IO SN GNF-PF-2322; CHEMBL194986; SR-01000548998
DMW93IO DT Small molecular drug
DMW93IO PC 44403736
DMW93IO MW 442.5
DMW93IO FM C26H26N4O3
DMW93IO IC InChI=1S/C26H26N4O3/c1-3-29-10-12-30(13-11-29)25-14-17(2)20-15-18(8-9-21(20)28-25)27-26(32)24-16-22(31)19-6-4-5-7-23(19)33-24/h4-9,14-16H,3,10-13H2,1-2H3,(H,27,32)
DMW93IO CS CCN1CCN(CC1)C2=NC3=C(C=C(C=C3)NC(=O)C4=CC(=O)C5=CC=CC=C5O4)C(=C2)C
DMW93IO IK GDOKGIIKPLGRMR-UHFFFAOYSA-N
DMW93IO IU N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]-4-oxochromene-2-carboxamide
DMW93IO DE Discovery agent
DMC56YJ ID DMC56YJ
DMC56YJ DN GNF-PF-2700
DMC56YJ HS Investigative
DMC56YJ SN 5361-37-5; GNF-Pf-2700; N-(8-ethoxy-4-methylquinazolin-2-yl)guanidine; 1-(8-ethoxy-4-methylquinazolin-2-yl)guanidine; CHEMBL602578; N-(8-Ethoxy-4-methyl-quinazolin-2-yl)-guanidine; Guanidine, N-(8-ethoxy-4-methyl-2-quinazolinyl)-; amino(8-ethoxy-4-methylquinazolin-2-yl)carboxamidine; BAS 00364218; 2-(8-ethoxy-4-methylquinazolin-2-yl)guanidine; AC1MDO65; SCHEMBL4104976; MolPort-000-870-551; ZX-AN037437; ALBB-021848; BDBM50322849; STK091313; SBB041931; ZINC19314134; AKOS000270455; MCULE-2552194685; ST4052426; R3533
DMC56YJ DT Small molecular drug
DMC56YJ PC 2840092
DMC56YJ MW 245.28
DMC56YJ FM C12H15N5O
DMC56YJ IC InChI=1S/C12H15N5O/c1-3-18-9-6-4-5-8-7(2)15-12(16-10(8)9)17-11(13)14/h4-6H,3H2,1-2H3,(H4,13,14,15,16,17)
DMC56YJ CS CCOC1=CC=CC2=C(N=C(N=C21)N=C(N)N)C
DMC56YJ IK NNFBJZLFJMBVGQ-UHFFFAOYSA-N
DMC56YJ IU 2-(8-ethoxy-4-methylquinazolin-2-yl)guanidine
DMC56YJ DE Discovery agent
DMD1QOH ID DMD1QOH
DMD1QOH DN GNF-PF-2812
DMD1QOH HS Investigative
DMD1QOH SN 3-(4-Methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-2812; NSC663884; CHEMBL125044; 147508-58-5; 3-(4-methoxyphenyl)indeno[1,2-c]pyridazin-5-one; 5H-indeno[1,2-c]pyridazin-5-one, 3-(4-methoxyphenyl)-; AC1Q6KMT; AC1L8E6Y; Oprea1_523550; CBDivE_007579; MLS000691948; cid_379338; CTK7A3357; BDBM21618; KS-00001QSJ; MolPort-002-851-046; HMS2631I03; ZINC196663; STK336082; MMV666026; Indeno[1,2-c]pyridazin-5-one, 6; AKOS005075095; MCULE-6151549558; NSC-663884; SMR000333991; NCI60_021917
DMD1QOH DT Small molecular drug
DMD1QOH PC 379338
DMD1QOH MW 288.3
DMD1QOH FM C18H12N2O2
DMD1QOH IC InChI=1S/C18H12N2O2/c1-22-12-8-6-11(7-9-12)16-10-15-17(20-19-16)13-4-2-3-5-14(13)18(15)21/h2-10H,1H3
DMD1QOH CS COC1=CC=C(C=C1)C2=NN=C3C4=CC=CC=C4C(=O)C3=C2
DMD1QOH IK HXQRIHGYIOARQJ-UHFFFAOYSA-N
DMD1QOH IU 3-(4-methoxyphenyl)indeno[1,2-c]pyridazin-5-one
DMD1QOH DE Discovery agent
DML5QFZ ID DML5QFZ
DML5QFZ DN GNF-PF-2857
DML5QFZ HS Investigative
DML5QFZ SN GNF-PF-2857; CHEMBL217665; ChemDiv1_019259; N-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4-amine; N-[4-(4-methylpiperazin-1-yl)phenyl]quinolin-4-amine; AC1NCZHO; Oprea1_484208; SCHEMBL7129284; HMS641L09; ZINC1507915; BDBM50196110; AKOS024359777; MCULE-1778420008; ST50989409; [4-(4-methylpiperazinyl)phenyl]-4-quinolylamine; SR-01000394477; SR-01000394477-1
DML5QFZ DT Small molecular drug
DML5QFZ PC 4567175
DML5QFZ MW 318.4
DML5QFZ FM C20H22N4
DML5QFZ IC InChI=1S/C20H22N4/c1-23-12-14-24(15-13-23)17-8-6-16(7-9-17)22-20-10-11-21-19-5-3-2-4-18(19)20/h2-11H,12-15H2,1H3,(H,21,22)
DML5QFZ CS CN1CCN(CC1)C2=CC=C(C=C2)NC3=CC=NC4=CC=CC=C43
DML5QFZ IK RXXDJBWYJTWSKV-UHFFFAOYSA-N
DML5QFZ IU N-[4-(4-methylpiperazin-1-yl)phenyl]quinolin-4-amine
DML5QFZ DE Discovery agent
DMLP241 ID DMLP241
DMLP241 DN GNF-PF-2893
DMLP241 HS Investigative
DMLP241 SN GNF-PF-2893; MLS001098045; SMR000657694; ({[4-(dimethylamino)anilino]carbonyl}amino)(4-methylphenyl)dioxo-lambda~6~-sulfane; AC1MDRKI; CHEMBL312032; cid_2815701; BDBM71503; MolPort-002-902-750; ZINC158170; HMS2998H18; CCG-43375; AKOS024379092; MCULE-5924445847; 1-[4-(dimethylamino)phenyl]-3-tosyl-urea; ST51023936; SR-01000633302-1; 1-[4-Dimethylaminophenyl]-3-(4-methylphenylsulfonyl)urea; 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea; 1-(4-dimethylaminophenyl)-3-(4-methylphenyl)sulfonylurea
DMLP241 DT Small molecular drug
DMLP241 PC 2815701
DMLP241 MW 333.4
DMLP241 FM C16H19N3O3S
DMLP241 IC InChI=1S/C16H19N3O3S/c1-12-4-10-15(11-5-12)23(21,22)18-16(20)17-13-6-8-14(9-7-13)19(2)3/h4-11H,1-3H3,(H2,17,18,20)
DMLP241 CS CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2=CC=C(C=C2)N(C)C
DMLP241 IK GRIAZRCYPXFJJF-UHFFFAOYSA-N
DMLP241 IU 1-[4-(dimethylamino)phenyl]-3-(4-methylphenyl)sulfonylurea
DMLP241 DE Discovery agent
DM4RZSB ID DM4RZSB
DM4RZSB DN GNF-PF-3037
DM4RZSB HS Investigative
DM4RZSB SN GNF-Pf-3037; SMR000116549; MLS000526075; Oprea1_099756; Oprea1_432483; Oprea1_261700; CHEMBL600336; cid_1160447; BDBM40315; MolPort-001-513-008; MolPort-001-991-899; C23H16N4O2S2; HMS2507A20; ZINC8671257; STK223484; AKOS003264843; AKOS000636670; MCULE-7239362503; BAS 03422558; MLS-0072644.0001; N-[4-[6-(2-thenoylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide; N-(4-{5-[(thiophen-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)thiophene-2-carboxamide
DM4RZSB DT Small molecular drug
DM4RZSB PC 1160447
DM4RZSB MW 444.5
DM4RZSB FM C23H16N4O2S2
DM4RZSB IC InChI=1S/C23H16N4O2S2/c28-22(19-3-1-11-30-19)24-15-7-5-14(6-8-15)21-26-17-10-9-16(13-18(17)27-21)25-23(29)20-4-2-12-31-20/h1-13H,(H,24,28)(H,25,29)(H,26,27)
DM4RZSB CS C1=CSC(=C1)C(=O)NC2=CC=C(C=C2)C3=NC4=C(N3)C=C(C=C4)NC(=O)C5=CC=CS5
DM4RZSB IK ALZVAGBHXQHAIA-UHFFFAOYSA-N
DM4RZSB IU N-[4-[6-(thiophene-2-carbonylamino)-1H-benzimidazol-2-yl]phenyl]thiophene-2-carboxamide
DM4RZSB DE Discovery agent
DMWAKHD ID DMWAKHD
DMWAKHD DN GNF-PF-3464
DMWAKHD HS Investigative
DMWAKHD SN GNF-Pf-3464; MLS000080647; SMR000035446; 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile; AC1LDF42; MLS002584786; cid_666034; CHEMBL602213; BDBM54721; MolPort-002-638-170; HMS2390G20; CCG-29223; STK849599; AKOS001814539; AKOS022041133; MCULE-2552432292; SR-01000096914; SR-01000096914-1; 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-3,4,7,8-tetrahydro-2H,6H-pyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile
DMWAKHD DT Small molecular drug
DMWAKHD PC 666034
DMWAKHD MW 430.3
DMWAKHD FM C19H16BrN3O2S
DMWAKHD IC InChI=1S/C19H16BrN3O2S/c1-12-2-7-17(25-12)15-8-18(24)23-10-22(11-26-19(23)16(15)9-21)14-5-3-13(20)4-6-14/h2-7,15H,8,10-11H2,1H3
DMWAKHD CS CC1=CC=C(O1)C2CC(=O)N3CN(CSC3=C2C#N)C4=CC=C(C=C4)Br
DMWAKHD IK DCNZODDMKOTPHQ-UHFFFAOYSA-N
DMWAKHD IU 3-(4-bromophenyl)-8-(5-methylfuran-2-yl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile
DMWAKHD DE Discovery agent
DM17GIV ID DM17GIV
DM17GIV DN GNF-PF-3645
DM17GIV HS Investigative
DM17GIV SN GNF-PF-3645; ethyl 6-isopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylate; ethyl 4-hydroxy-6-isopropyl-3-quinolinecarboxylate; AC1LEPYU; Oprea1_718373; CHEMBL202969; SCHEMBL11065820; MolPort-002-693-403; ZINC9761170; STK040682; AKOS005383459; MCULE-2719488867; ST085537; 64321-61-5; EU-0017663; CS-0061597; ethyl 4-hydroxy-6-isopropylquinoline-3-carboxylate; SR-01000511952; AG-670/08515048; SR-01000511952-1; ethyl 4-hydroxy-6-(propan-2-yl)quinoline-3-carboxylate; ethyl 4-oxo-6-propan-2-yl-1H-quinoline-3-carboxylate; ethyl 4-hydroxy-
DM17GIV DT Small molecular drug
DM17GIV PC 690399
DM17GIV MW 259.3
DM17GIV FM C15H17NO3
DM17GIV IC InChI=1S/C15H17NO3/c1-4-19-15(18)12-8-16-13-6-5-10(9(2)3)7-11(13)14(12)17/h5-9H,4H2,1-3H3,(H,16,17)
DM17GIV CS CCOC(=O)C1=CNC2=C(C1=O)C=C(C=C2)C(C)C
DM17GIV IK JBFFEVKDAYLOKF-UHFFFAOYSA-N
DM17GIV IU ethyl 4-oxo-6-propan-2-yl-1H-quinoline-3-carboxylate
DM17GIV DE Discovery agent
DMIY79U ID DMIY79U
DMIY79U DN GNF-PF-3832
DMIY79U HS Investigative
DMIY79U SN 3-(4-methylphenyl)-5H-indeno[1,2-c]pyridazin-5-one; GNF-PF-3832; 300843-87-2; AC1MCE1I; Cambridge id 5215436; Oprea1_419211; CBDivE_007454; MLS000104226; CHEMBL261693; cid_2767330; KS-00001RTF; BDBM21629; MolPort-002-136-671; HMS1578F11; HMS2748H23; ZINC196662; STK746982; MMV666021; AKOS001704735; MCULE-6620780852; SMR000051275; SR-01000507948; 3-(4-methylphenyl)indeno[1,2-c]pyridazin-5-one; 11K-012; SR-01000507948-1
DMIY79U DT Small molecular drug
DMIY79U PC 2767330
DMIY79U MW 272.3
DMIY79U FM C18H12N2O
DMIY79U IC InChI=1S/C18H12N2O/c1-11-6-8-12(9-7-11)16-10-15-17(20-19-16)13-4-2-3-5-14(13)18(15)21/h2-10H,1H3
DMIY79U CS CC1=CC=C(C=C1)C2=NN=C3C4=CC=CC=C4C(=O)C3=C2
DMIY79U IK ITHVHASAWMAMQC-UHFFFAOYSA-N
DMIY79U IU 3-(4-methylphenyl)indeno[1,2-c]pyridazin-5-one
DMIY79U CA CAS 300843-87-2
DMIY79U DE Discovery agent
DM7BXHQ ID DM7BXHQ
DM7BXHQ DN GNF-PF-3878
DM7BXHQ HS Investigative
DM7BXHQ SN 143069-08-3; GNF-PF-3878; TCMDC-124255; 9-Acridinamine, N-(4-(4-ethyl-1-piperazinyl)phenyl)-; CHEMBL217366; N-(4-(4-Ethyl-1-piperazinyl)phenyl)-9-acridinamine; N-[4-(4-ethylpiperazin-1-yl)phenyl]acridin-9-amine; 9-Acridinamine,N-[4-(4-ethyl-1-piperazinyl)phenyl]-; N-(4-(4-ethylpiperazin-1-yl)phenyl)acridin-9-amine; CBDivE_005028; AC1MILKO; ACMC-20n23a; CTK4C3465; DTXSID10162300; BDBM50196122; AKOS030561802
DM7BXHQ DT Small molecular drug
DM7BXHQ PC 3072540
DM7BXHQ MW 382.5
DM7BXHQ FM C25H26N4
DM7BXHQ IC InChI=1S/C25H26N4/c1-2-28-15-17-29(18-16-28)20-13-11-19(12-14-20)26-25-21-7-3-5-9-23(21)27-24-10-6-4-8-22(24)25/h3-14H,2,15-18H2,1H3,(H,26,27)
DM7BXHQ CS CCN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
DM7BXHQ IK CUVBGWMAORETGV-UHFFFAOYSA-N
DM7BXHQ IU N-[4-(4-ethylpiperazin-1-yl)phenyl]acridin-9-amine
DM7BXHQ CA CAS 143069-08-3
DM7BXHQ DE Discovery agent
DMOJL61 ID DMOJL61
DMOJL61 DN GNF-PF-3955
DMOJL61 HS Investigative
DMOJL61 SN GNF-Pf-3955; MLS000073091; SMR000013108; 500276-85-7; 2-Imino-8-methyl-10-oxo-1-phenethyl-1,10-dihydro-2H-1,9,10a-triaza-anthracene-3-carboxylic acid (furan-2-ylmethyl)-amide; BAS 04995279; regid844814; AC1LDF87; MLS001385288; CHEMBL605747; cid_647145; BDBM49996; MolPort-000-197-560; HMS2774A18; STK703431; ZINC100662448; AKOS001655389; MCULE-3107531902; EU-0080883; Z57780857; N-(furan-2-ylmethyl)-2-imino-10-methyl-5-oxo-1-(2-phenylethyl)dipyrido[3,4-c:1'',2''-f]pyrimidine-3-carboxamide
DMOJL61 DT Small molecular drug
DMOJL61 PC 647145
DMOJL61 MW 453.5
DMOJL61 FM C26H23N5O3
DMOJL61 IC InChI=1S/C26H23N5O3/c1-17-7-5-12-31-23(17)29-24-21(26(31)33)15-20(25(32)28-16-19-10-6-14-34-19)22(27)30(24)13-11-18-8-3-2-4-9-18/h2-10,12,14-15,27H,11,13,16H2,1H3,(H,28,32)
DMOJL61 CS CC1=CC=CN2C1=NC3=C(C2=O)C=C(C(=N)N3CCC4=CC=CC=C4)C(=O)NCC5=CC=CO5
DMOJL61 IK AINLDDVHMMTZDO-UHFFFAOYSA-N
DMOJL61 IU N-(furan-2-ylmethyl)-6-imino-11-methyl-2-oxo-7-(2-phenylethyl)-1,7,9-triazatricyclo[8.4.0.03,8]tetradeca-3(8),4,9,11,13-pentaene-5-carboxamide
DMOJL61 DE Discovery agent
DMXWYMH ID DMXWYMH
DMXWYMH DN GNF-PF-4292
DMXWYMH HS Investigative
DMXWYMH SN Hydrocinchonine; GNF-PF-4292; CHEMBL428695; Cinchotine; (8alpha,9R)-10,11-Dihydrocinchonan-9-ol; 485-64-3; Cinchonifine; Pseudocinchonine; y-Cinchonine; 10,11-dihydrocinchonan-9-ol; (9S)-10,11-Dihydrocinchonan-9-ol; 10,11-dihydrocinchonine; AC1Q4XW7; AC1L2RE5; Oprea1_425428; SCHEMBL312806; MolPort-003-871-861; WFJNHVWTKZUUTR-UHFFFAOYSA-N; BDBM50047001; NCGC00142479-01; AC-30196; ST056343; FT-0700733; (9S)-10,11-Dihydrocinchonan-9-ol, 9CI; (1R)(5-ethylquinuclidin-2-yl)-4-quinolylmethan-1-ol; Quinoline 4-(alpha-(7-ethyl-1,4-ethanopip
DMXWYMH DT Small molecular drug
DMXWYMH PC 101711
DMXWYMH MW 296.4
DMXWYMH FM C19H24N2O
DMXWYMH IC InChI=1S/C19H24N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h3-7,9,13-14,18-19,22H,2,8,10-12H2,1H3
DMXWYMH CS CCC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O
DMXWYMH IK WFJNHVWTKZUUTR-UHFFFAOYSA-N
DMXWYMH IU (5-ethyl-1-azabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol
DMXWYMH CA CAS 485-64-3
DMXWYMH DE Discovery agent
DMV10UH ID DMV10UH
DMV10UH DN GNF-PF-4421
DMV10UH HS Investigative
DMV10UH SN GNF-PF-4421; 85418-73-1; 6-Ethyl-4-hydroxyquinoline-3-carboxylic acid ethyl ester; AURORA 17945; ethyl 6-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate; ethyl 6-ethyl-4-hydroxyquinoline-3-carboxylate; AC1LECY7; Oprea1_563397; Oprea1_408052; CHEMBL206540; SCHEMBL7291769; SCHEMBL11066821; CTK8F7131; DTXSID00350618; ZFOFJXFVCJQXBL-UHFFFAOYSA-N; MolPort-003-761-637; MolPort-000-653-080; ZINC9761169; STK791819; MMV007116; STK942448; 3-Quinolinecarboxylic acid, 6-ethyl-1,4-dihydro-4-oxo-, ethyl ester; AKOS002674049; AKOS001717599
DMV10UH DT Small molecular drug
DMV10UH PC 684193
DMV10UH MW 245.27
DMV10UH FM C14H15NO3
DMV10UH IC InChI=1S/C14H15NO3/c1-3-9-5-6-12-10(7-9)13(16)11(8-15-12)14(17)18-4-2/h5-8H,3-4H2,1-2H3,(H,15,16)
DMV10UH CS CCC1=CC2=C(C=C1)NC=C(C2=O)C(=O)OCC
DMV10UH IK ZFOFJXFVCJQXBL-UHFFFAOYSA-N
DMV10UH IU ethyl 6-ethyl-4-oxo-1H-quinoline-3-carboxylate
DMV10UH CA CAS 85418-73-1
DMV10UH DE Discovery agent
DMPYIA3 ID DMPYIA3
DMPYIA3 DN GNF-PF-4453
DMPYIA3 HS Investigative
DMPYIA3 SN GNF-Pf-4453; TCMDC-125689; 4-{[3-(3,5-dimethylpiperidin-1-yl)propyl]amino}-N-(3-methoxyphenyl)-3-nitrobenzamide; MLS000689410; CHEMBL579424; MolPort-007-928-102; HMS2706G13; AKOS021653715; AKOS002143414; MCULE-1668730596; SMR000311209; SR-01000581321
DMPYIA3 DT Small molecular drug
DMPYIA3 PC 16194189
DMPYIA3 MW 440.5
DMPYIA3 FM C24H32N4O4
DMPYIA3 IC InChI=1S/C24H32N4O4/c1-17-12-18(2)16-27(15-17)11-5-10-25-22-9-8-19(13-23(22)28(30)31)24(29)26-20-6-4-7-21(14-20)32-3/h4,6-9,13-14,17-18,25H,5,10-12,15-16H2,1-3H3,(H,26,29)
DMPYIA3 CS CC1CC(CN(C1)CCCNC2=C(C=C(C=C2)C(=O)NC3=CC(=CC=C3)OC)[N+](=O)[O-])C
DMPYIA3 IK LRAMWMMVZIGQPU-UHFFFAOYSA-N
DMPYIA3 IU 4-[3-(3,5-dimethylpiperidin-1-yl)propylamino]-N-(3-methoxyphenyl)-3-nitrobenzamide
DMPYIA3 DE Discovery agent
DMCDU8K ID DMCDU8K
DMCDU8K DN GNF-PF-4478
DMCDU8K HS Investigative
DMCDU8K SN GNF-Pf-4478; CHEMBL597857; SMR000042305; AC1LD5U9; MLS000036444; cid_661700; MolPort-002-590-307; HMS2349M09; ZINC20191037; MMV006587; STK552090; BDBM50322743; AKOS005479117; MCULE-5579816479; NCGC00019462-02; NCGC00019462-01; 8-chloro-N-(3-morpholinopropyl)-5H-pyrimido[5,4-b]indol-4-amine; 8-chloro-N-[3-(morpholin-4-yl)propyl]-5H-pyrimido[5,4-b]indol-4-amine; 8-chloro-N-(3-morpholin-4-ylpropyl)-5H-pyrimido[5,4-b]indol-4-amine
DMCDU8K DT Small molecular drug
DMCDU8K PC 661700
DMCDU8K MW 345.8
DMCDU8K FM C17H20ClN5O
DMCDU8K IC InChI=1S/C17H20ClN5O/c18-12-2-3-14-13(10-12)15-16(22-14)17(21-11-20-15)19-4-1-5-23-6-8-24-9-7-23/h2-3,10-11,22H,1,4-9H2,(H,19,20,21)
DMCDU8K CS C1COCCN1CCCNC2=NC=NC3=C2NC4=C3C=C(C=C4)Cl
DMCDU8K IK ULJISGNQAXNPOC-UHFFFAOYSA-N
DMCDU8K IU 8-chloro-N-(3-morpholin-4-ylpropyl)-5H-pyrimido[5,4-b]indol-4-amine
DMCDU8K DE Discovery agent
DM1ZMUN ID DM1ZMUN
DM1ZMUN DN GNF-PF-4599
DM1ZMUN HS Investigative
DM1ZMUN SN GNF-PF-4599; TCMDC-125680; CHEMBL227704; MolPort-007-928-115; AKOS021616514; AKOS001585537; MCULE-4162592697; SR-01000581334; SR-01000581334-1
DM1ZMUN DT Small molecular drug
DM1ZMUN PC 44422654
DM1ZMUN MW 478.5
DM1ZMUN FM C24H29F3N4O3
DM1ZMUN IC InChI=1S/C24H29F3N4O3/c1-16-12-17(2)15-30(14-16)11-3-10-28-21-9-4-18(13-22(21)31(33)34)23(32)29-20-7-5-19(6-8-20)24(25,26)27/h4-9,13,16-17,28H,3,10-12,14-15H2,1-2H3,(H,29,32)
DM1ZMUN CS CC1CC(CN(C1)CCCNC2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)C(F)(F)F)[N+](=O)[O-])C
DM1ZMUN IK VWDZICDNGXUIKB-UHFFFAOYSA-N
DM1ZMUN IU 4-[3-(3,5-dimethylpiperidin-1-yl)propylamino]-3-nitro-N-[4-(trifluoromethyl)phenyl]benzamide
DM1ZMUN DE Discovery agent
DM7850H ID DM7850H
DM7850H DN GNF-PF-5134
DM7850H HS Investigative
DM7850H SN GNF-Pf-5134; SMR000176391; MLS000567447; 1-ethyl-2,3-dimethyl-2-phenylbenzimidazole; 1-Ethyl-2,3-dimethyl-2-phenyl-2,3-dihydro-1H-benzoimidazole; AC1MK4BC; Oprea1_386360; Oprea1_275132; CHEMBL602969; cid_3124417; BDBM34775; MolPort-001-953-343; HMS2514O12; 1-ethyl-2,3-dimethyl-2-phenyl-2,3-dihydro-1H-benzimidazole; AKOS030484368; AKOS000562909; MCULE-9973053606; BAS 01044600; 1-ethyl-2,3-dimethyl-2-phenyl-benzimidazole
DM7850H DT Small molecular drug
DM7850H PC 3124417
DM7850H MW 252.35
DM7850H FM C17H20N2
DM7850H IC InChI=1S/C17H20N2/c1-4-19-16-13-9-8-12-15(16)18(3)17(19,2)14-10-6-5-7-11-14/h5-13H,4H2,1-3H3
DM7850H CS CCN1C2=CC=CC=C2N(C1(C)C3=CC=CC=C3)C
DM7850H IK QWPMTQMHWWDYRA-UHFFFAOYSA-N
DM7850H IU 1-ethyl-2,3-dimethyl-2-phenylbenzimidazole
DM7850H DE Discovery agent
DMVI4JG ID DMVI4JG
DMVI4JG DN GNF-PF-5188
DMVI4JG HS Investigative
DMVI4JG SN GNF-PF-5188; CHEMBL525381; BAS 02081013; AC1MJHV1; HMS1682E16; ZINC4976718; BDBM50265648; AKOS000639707; 8-hexyl-3,5,5-trimethyl-2,4-dihydro-1H-chromeno[3,4-c]pyridin-10-ol; 8-Hexyl-3,5,5-trimethyl-1,3,4,5-tetrahydro-2H-chromeno[3,4-c]pyridin-10-ol
DMVI4JG DT Small molecular drug
DMVI4JG PC 3137700
DMVI4JG MW 329.5
DMVI4JG FM C21H31NO2
DMVI4JG IC InChI=1S/C21H31NO2/c1-5-6-7-8-9-15-12-18(23)20-16-10-11-22(4)14-17(16)21(2,3)24-19(20)13-15/h12-13,23H,5-11,14H2,1-4H3
DMVI4JG CS CCCCCCC1=CC(=C2C3=C(CN(CC3)C)C(OC2=C1)(C)C)O
DMVI4JG IK CXLQUCPRQKBNSP-UHFFFAOYSA-N
DMVI4JG IU 8-hexyl-3,5,5-trimethyl-2,4-dihydro-1H-chromeno[3,4-c]pyridin-10-ol
DMVI4JG DE Discovery agent
DMZNAEQ ID DMZNAEQ
DMZNAEQ DN GNF-PF-5411
DMZNAEQ HS Investigative
DMZNAEQ SN CINCHONIDINE; Cinchonan-9-ol; cinchonine; alpha-Quinidine; 485-71-2; GNF-PF-5411; 118-10-5; MLS002637808; NSC5364; .alpha.-Quinidine; NSC 5364; Cinchonan-9-ol, (8.alpha.,9R)-; Cinchonan-9-ol, (9S)-; (8alpha,9R)Cinchonan-9-ol; a-quinidine; (8-alpha,9R)-Cinchonan-9-ol; EINECS 207-622-3; {5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(quinolin-4-yl)methanol; SMR001488502; AI3-15317; 4-quinolyl-(5-vinylquinuclidin-2-yl)methanol; 2-Quinuclidinemethanol, alpha-4-quinolyl-5-vinyl-; (+)-Quinolin-4-yl(5-vinylquinuclidin-2-yl)methanol
DMZNAEQ DT Small molecular drug
DMZNAEQ PC 2757
DMZNAEQ MW 294.4
DMZNAEQ FM C19H22N2O
DMZNAEQ IC InChI=1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2
DMZNAEQ CS C=CC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O
DMZNAEQ IK KMPWYEUPVWOPIM-UHFFFAOYSA-N
DMZNAEQ IU (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol
DMZNAEQ CA CAS 485-71-2
DMZNAEQ DE Discovery agent
DMP9AIH ID DMP9AIH
DMP9AIH DN GNF-PF-5434
DMP9AIH HS Investigative
DMP9AIH SN GNF-PF-5434; CHEMBL486232; N~2~-(MORPHOLIN-4-YLCARBONYL)-N~1~-[(1S,2E)-1-(2-PHENYLETHYL)-3-(PHENYLSULFONYL)PROP-2-ENYL]-D-LEUCINAMIDE; MORPHOLINE-4-CARBOXYLIC ACID (1-(3-BENZENESULFONYL-1-PHENETHYLALLYLCARBAMOYL)-3-METHYLBUTYL)-AMIDE; N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide; AC1NRAGB; SCHEMBL7352997; BDBM50243232; K-11017; 4-Morpholinecarboxamide, N-[(1S)-3-methyl-1-[[[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl]amino]carbonyl]butyl]-
DMP9AIH DT Small molecular drug
DMP9AIH PC 5287864
DMP9AIH MW 527.7
DMP9AIH FM C28H37N3O5S
DMP9AIH IC InChI=1S/C28H37N3O5S/c1-22(2)21-26(30-28(33)31-16-18-36-19-17-31)27(32)29-24(14-13-23-9-5-3-6-10-23)15-20-37(34,35)25-11-7-4-8-12-25/h3-12,15,20,22,24,26H,13-14,16-19,21H2,1-2H3,(H,29,32)(H,30,33)/b20-15+/t24-,26-/m0/s1
DMP9AIH CS CC(C)C[C@@H](C(=O)N[C@@H](CCC1=CC=CC=C1)/C=C/S(=O)(=O)C2=CC=CC=C2)NC(=O)N3CCOCC3
DMP9AIH IK YUMYYTORLYHUFW-MSKIIMLESA-N
DMP9AIH IU N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-4-methyl-1-oxopentan-2-yl]morpholine-4-carboxamide
DMP9AIH DE Discovery agent
DMT8VUS ID DMT8VUS
DMT8VUS DN GNF-PF-5618
DMT8VUS HS Investigative
DMT8VUS DT Small molecular drug
DMT8VUS PC 3013846
DMT8VUS MW 757.9
DMT8VUS FM C39H59N5O10
DMT8VUS IC InChI=1S/C39H59N5O10/c1-4-5-6-7-8-9-10-11-12-23-34(27(2)35(47)40-30-20-15-18-25-44(52)38(30)49)54-39(50)31(21-16-17-24-43(51)28(3)45)41-36(48)32-26-53-37(42-32)29-19-13-14-22-33(29)46/h13-14,19,22,26-27,30-31,34,46,51-52H,4-12,15-18,20-21,23-25H2,1-3H3,(H,40,47)(H,41,48)
DMT8VUS CS CCCCCCCCCCCC(C(C)C(=O)NC1CCCCN(C1=O)O)OC(=O)C(CCCCN(C(=O)C)O)NC(=O)C2=COC(=N2)C3=CC=CC=C3O
DMT8VUS IK QFWVGKDFYOXTQO-UHFFFAOYSA-N
DMT8VUS IU [1-[(1-hydroxy-2-oxoazepan-3-yl)amino]-2-methyl-1-oxotetradecan-3-yl] 6-[acetyl(hydroxy)amino]-2-[[2-(2-hydroxyphenyl)-1,3-oxazole-4-carbonyl]amino]hexanoate
DMT8VUS DE Discovery agent
DMWGXBF ID DMWGXBF
DMWGXBF DN GNF-PF-600
DMWGXBF HS Investigative
DMWGXBF SN GNF-PF-600; BAS 00282408; CHEMBL199659; BDBM8464; SCHEMBL13056375; ZINC880427; Thiobarbituric acid-furan analogue 29; SR-01000369489; SR-01000369489-1
DMWGXBF DT Small molecular drug
DMWGXBF PC 1138119
DMWGXBF MW 362.8
DMWGXBF FM C16H11ClN2O4S
DMWGXBF IC InChI=1S/C16H11ClN2O4S/c1-22-13-4-2-8(6-11(13)17)12-5-3-9(23-12)7-10-14(20)18-16(24)19-15(10)21/h2-7H,1H3,(H2,18,19,20,21,24)
DMWGXBF CS COC1=C(C=C(C=C1)C2=CC=C(O2)C=C3C(=O)NC(=S)NC3=O)Cl
DMWGXBF IK PKLIDAWVQNGMRD-UHFFFAOYSA-N
DMWGXBF IU 5-[[5-(3-chloro-4-methoxyphenyl)furan-2-yl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
DMWGXBF DE Discovery agent
DMJXE6K ID DMJXE6K
DMJXE6K DN GNF-PF-607
DMJXE6K HS Investigative
DMJXE6K SN GNF-PF-607; CHEMBL113999; 13794-67-7; N6-[(3,4,5-trimethoxyphenyl)methyl]quinazoline-2,4,6-triamine; NSC156246; AC1L6FHM; AC1Q4YN2; n6-(3,4,5-trimethoxybenzyl)quinazoline-2,4,6-triamine; CTK0I1910; DTXSID70303050; BDBM50066492; NSC-156246; 6-[(3,4,5-Trimethoxybenzyl)amino]quinazoline-2,4-diamine; N*6*-(3,4,5-Trimethoxy-benzyl)-quinazoline-2,4,6-triamine; 6-N-[(3,4,5-trimethoxyphenyl)methyl]quinazoline-2,4,6-triamine
DMJXE6K DT Small molecular drug
DMJXE6K PC 291270
DMJXE6K MW 355.4
DMJXE6K FM C18H21N5O3
DMJXE6K IC InChI=1S/C18H21N5O3/c1-24-14-6-10(7-15(25-2)16(14)26-3)9-21-11-4-5-13-12(8-11)17(19)23-18(20)22-13/h4-8,21H,9H2,1-3H3,(H4,19,20,22,23)
DMJXE6K CS COC1=CC(=CC(=C1OC)OC)CNC2=CC3=C(C=C2)N=C(N=C3N)N
DMJXE6K IK YYJWQABXDCUJEF-UHFFFAOYSA-N
DMJXE6K IU 6-N-[(3,4,5-trimethoxyphenyl)methyl]quinazoline-2,4,6-triamine
DMJXE6K CA CAS 13794-67-7
DMJXE6K DE Discovery agent
DM3SYH5 ID DM3SYH5
DM3SYH5 DN GNF-PF-67
DM3SYH5 HS Investigative
DM3SYH5 SN Toxoflavin; Toxoflavine; Xanthothricin; Xanthotricin; 84-82-2; Xanthothricin (VAN); UNII-5N5YI4IP1P; GNF-Pf-67; NSC 67078; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,6-Dimethylpyrimido(5,4-e)-as-triazine-5,7(1H,6H)-dione; 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; BRN 0021014; 5N5YI4IP1P; MLS000087831; CHEBI:80729; NSC67078; 1,6-Dimethyl-5,7-dioxo-1,5,6,7-tetrahydropyrimido(5,4-E)-as-triazine-5,7(1H,6H)-dione; SMR000024051; Pyrimido(5,4-e)-as-triazine-5,7-(1H,6H)-dione, 1,6-dimethyl-
DM3SYH5 DT Small molecular drug
DM3SYH5 PC 66541
DM3SYH5 MW 193.16
DM3SYH5 FM C7H7N5O2
DM3SYH5 IC InChI=1S/C7H7N5O2/c1-11-6(13)4-5(10-7(11)14)12(2)9-3-8-4/h3H,1-2H3
DM3SYH5 CS CN1C2=NC(=O)N(C(=O)C2=NC=N1)C
DM3SYH5 IK SLGRAIAQIAUZAQ-UHFFFAOYSA-N
DM3SYH5 IU 1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
DM3SYH5 CA CAS 84-82-2
DM3SYH5 CB CHEBI:80729
DM3SYH5 DE Discovery agent
DM7SPRJ ID DM7SPRJ
DM7SPRJ DN GNF-PF-78
DM7SPRJ HS Investigative
DM7SPRJ SN GNF-Pf-78; MLS000724706; SMR000237577; 2-methyl-4,9-dioxo-N-(pyridin-3-ylmethyl)benzo[f][1]benzofuran-3-carboxamide; 2-methyl-4,9-dioxo-N-(pyridin-3-ylmethyl)-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide; 867135-78-2; AC1M2EUB; CHEMBL579318; cid_2142309; BDBM63230; MolPort-000-336-147; HMS2252C13; STL228961; ZINC37867960; AKOS002232614; MCULE-2786712757; AB00637219-02; BRD-K01762812-001-08-0; F1654-0382; 4,9-diketo-2-methyl-N-(3-pyridylmethyl)benzo[f]benzofuran-3-carboxamide
DM7SPRJ DT Small molecular drug
DM7SPRJ PC 2142309
DM7SPRJ MW 346.3
DM7SPRJ FM C20H14N2O4
DM7SPRJ IC InChI=1S/C20H14N2O4/c1-11-15(20(25)22-10-12-5-4-8-21-9-12)16-17(23)13-6-2-3-7-14(13)18(24)19(16)26-11/h2-9H,10H2,1H3,(H,22,25)
DM7SPRJ CS CC1=C(C2=C(O1)C(=O)C3=CC=CC=C3C2=O)C(=O)NCC4=CN=CC=C4
DM7SPRJ IK HSYUWLOZMGPYKC-UHFFFAOYSA-N
DM7SPRJ IU 2-methyl-4,9-dioxo-N-(pyridin-3-ylmethyl)benzo[f][1]benzofuran-3-carboxamide
DM7SPRJ DE Discovery agent
DM37ORC ID DM37ORC
DM37ORC DN GNF-PF-826
DM37ORC HS Investigative
DM37ORC SN GNF-Pf-826; AC1M65LM; CHEMBL599946; N-[3-(4-hydroxyanilino)-4-oxonaphthalen-1-ylidene]thiophene-2-sulfonamide; HMS2671P22; MCULE-4006851150
DM37ORC DT Small molecular drug
DM37ORC PC 2391700
DM37ORC MW 410.5
DM37ORC FM C20H14N2O4S2
DM37ORC IC InChI=1S/C20H14N2O4S2/c23-14-9-7-13(8-10-14)21-18-12-17(15-4-1-2-5-16(15)20(18)24)22-28(25,26)19-6-3-11-27-19/h1-12,21,23H
DM37ORC CS C1=CC=C2C(=C1)C(=NS(=O)(=O)C3=CC=CS3)C=C(C2=O)NC4=CC=C(C=C4)O
DM37ORC IK YXKCWSSSTBYFQS-UHFFFAOYSA-N
DM37ORC IU N-[3-(4-hydroxyanilino)-4-oxonaphthalen-1-ylidene]thiophene-2-sulfonamide
DM37ORC DE Discovery agent
DMB6FN7 ID DMB6FN7
DMB6FN7 DN GNF-PF-85
DMB6FN7 HS Investigative
DMB6FN7 SN GNF-PF-85; 3-[(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]naphthalen-2-ol; 3-({5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}amino)naphthalen-2-ol; BAS 01083131; AC1LFFF4; Oprea1_463466; Oprea1_430691; SCHEMBL4939616; CHEMBL487518; BDBM24409; ZINC267589; AKOS024371314; Triazolopyrimidine-Based Compound, 16; MCULE-8335313178; ST51007753; SR-01000326143; SR-01000326143-1; 3-(5-Methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamino)-naphthalen-2-ol
DMB6FN7 DT Small molecular drug
DMB6FN7 PC 777193
DMB6FN7 MW 291.31
DMB6FN7 FM C16H13N5O
DMB6FN7 IC InChI=1S/C16H13N5O/c1-10-6-15(21-16(19-10)17-9-18-21)20-13-7-11-4-2-3-5-12(11)8-14(13)22/h2-9,20,22H,1H3
DMB6FN7 CS CC1=NC2=NC=NN2C(=C1)NC3=CC4=CC=CC=C4C=C3O
DMB6FN7 IK OMQCQQGZRWJBCI-UHFFFAOYSA-N
DMB6FN7 IU 3-[(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]naphthalen-2-ol
DMB6FN7 DE Discovery agent
DMKVTZN ID DMKVTZN
DMKVTZN DN Go 6983
DMKVTZN HS Investigative
DMKVTZN SN Goe 6983; Go-6893
DMKVTZN DT Small molecular drug
DMKVTZN PC 3499
DMKVTZN MW 442.5
DMKVTZN FM C26H26N4O3
DMKVTZN IC InChI=1S/C26H26N4O3/c1-29(2)11-6-12-30-15-20(18-13-16(33-3)9-10-22(18)30)24-23(25(31)28-26(24)32)19-14-27-21-8-5-4-7-17(19)21/h4-5,7-10,13-15,27H,6,11-12H2,1-3H3,(H,28,31,32)
DMKVTZN CS CN(C)CCCN1C=C(C2=C1C=CC(=C2)OC)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54
DMKVTZN IK LLJJDLHGZUOMQP-UHFFFAOYSA-N
DMKVTZN IU 3-[1-[3-(dimethylamino)propyl]-5-methoxyindol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione
DMKVTZN CA CAS 133053-19-7
DMKVTZN CB CHEBI:91455
DMKVTZN DE Discovery agent
DMS91OR ID DMS91OR
DMS91OR DN Go7874
DMS91OR HS Investigative
DMS91OR SN Go 7874; Go-7874
DMS91OR DT Small molecular drug
DMS91OR PC 3500
DMS91OR MW 470.5
DMS91OR FM C27H26N4O4
DMS91OR IC InChI=1S/C27H26N4O4/c1-29(2)12-14(32)13-31-19-10-9-15(35-4)11-17(19)21-23-22(26(33)28-27(23)34)20-16-7-5-6-8-18(16)30(3)24(20)25(21)31/h5-11,14,32H,12-13H2,1-4H3,(H,28,33,34)
DMS91OR CS CN1C2=CC=CC=C2C3=C4C(=C5C6=C(C=CC(=C6)OC)N(C5=C31)CC(CN(C)C)O)C(=O)NC4=O
DMS91OR IK NYBAPNLYWRMTJL-UHFFFAOYSA-N
DMS91OR IU 3-[3-(dimethylamino)-2-hydroxypropyl]-7-methoxy-23-methyl-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione
DMS91OR DE Discovery agent
DMS97A1 ID DMS97A1
DMS97A1 DN Gold trichloride sodium chloride
DMS97A1 HS Investigative
DMS97A1 DE Discovery agent
DMMT05U ID DMMT05U
DMMT05U DN GOSSYPETIN
DMMT05U HS Investigative
DMMT05U SN Gossypetin; Articulatidin; Equisporol; 489-35-0; 3,5,7,8,3',4'-Hexahydroxyflavone; UNII-SET4M23ZTM; 3,3',4',5,7,8-Hexahydroxyflavone; SET4M23ZTM; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxy-4H-chromen-4-one; CHEMBL253570; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one; CHEBI:16400; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-; 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-chromen-4-one; PubChem9855; AC1NQXCW; BSPBio_002552; SPECTRUM1505143; SCHEMBL157033; BDBM26655; DTXSID50197631
DMMT05U DT Small molecular drug
DMMT05U PC 5280647
DMMT05U MW 318.23
DMMT05U FM C15H10O8
DMMT05U IC InChI=1S/C15H10O8/c16-6-2-1-5(3-7(6)17)14-13(22)12(21)10-8(18)4-9(19)11(20)15(10)23-14/h1-4,16-20,22H
DMMT05U CS C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O)O)O)O
DMMT05U IK YRRAGUMVDQQZIY-UHFFFAOYSA-N
DMMT05U IU 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one
DMMT05U CA CAS 489-35-0
DMMT05U CB CHEBI:16400
DMMT05U DE Discovery agent
DMZNUAD ID DMZNUAD
DMZNUAD DN Go-Y022
DMZNUAD HS Investigative
DMZNUAD SN Go-Y022; CHEMBL128729; 1,5-Bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one; (1E,4E)-1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one; Hylin; AC1O6FK4; 1,5-Bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one; SCHEMBL1493282; ZINC6483730; BDBM50067028; 1,5-Bis-(4-hydroxy-3-methoxy-phenyl)-penta-1,4-dien-3-one; 1,5-bis-(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one; (1E,4E)-1,5-bis(4-hydroxy-3-methoxy-phenyl)penta-1,4-dien-3-one
DMZNUAD DT Small molecular drug
DMZNUAD PC 6474893
DMZNUAD MW 326.3
DMZNUAD FM C19H18O5
DMZNUAD IC InChI=1S/C19H18O5/c1-23-18-11-13(5-9-16(18)21)3-7-15(20)8-4-14-6-10-17(22)19(12-14)24-2/h3-12,21-22H,1-2H3/b7-3+,8-4+
DMZNUAD CS COC1=C(C=CC(=C1)/C=C/C(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
DMZNUAD IK ISIMGBQRFXXNON-FCXRPNKRSA-N
DMZNUAD IU (1E,4E)-1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one
DMZNUAD CA CAS 131359-25-6
DMZNUAD DE Discovery agent
DMUNSLJ ID DMUNSLJ
DMUNSLJ DN Go-Y026
DMUNSLJ HS Investigative
DMUNSLJ SN Go-Y026; CHEMBL493001; SCHEMBL2743841; SCHEMBL2743839; GO-Y-026; BDBM50258200; 1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one; 1,5-Bis(3,5-dimethoxy-4-hydroxyphenyl)-1,4-pentadien-3-one
DMUNSLJ DT Small molecular drug
DMUNSLJ PC 10691533
DMUNSLJ MW 386.4
DMUNSLJ FM C21H22O7
DMUNSLJ IC InChI=1S/C21H22O7/c1-25-16-9-13(10-17(26-2)20(16)23)5-7-15(22)8-6-14-11-18(27-3)21(24)19(12-14)28-4/h5-12,23-24H,1-4H3/b7-5+,8-6+
DMUNSLJ CS COC1=CC(=CC(=C1O)OC)/C=C/C(=O)/C=C/C2=CC(=C(C(=C2)OC)O)OC
DMUNSLJ IK DDGVRFAFSCAHHH-KQQUZDAGSA-N
DMUNSLJ IU (1E,4E)-1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one
DMUNSLJ DE Discovery agent
DMRUIX3 ID DMRUIX3
DMRUIX3 DN GP515
DMRUIX3 HS Investigative
DMRUIX3 SN 1H-Pyrazolo(3,4-d)pyrimidin-4-amine, 1-(5-amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-; GP 1-515; CHEMBL356141; 144928-48-3; GP-515; Adenosine kinase inhibitor GP515; GP-1-515; SCHEMBL2053010; AC1L31E2; DTXSID30162847; BDBM50134744; 1-(5-Amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-1H-pyrazolo(3,4-d)pyrimidin-4-amine; 4-Amino-1-(5-amino-5-deoxy-1-beta-D-ribofuranosyl)-3-bromopyrazolo(3,4-d)pyrimidine; (2R,3R,4S,5R)-2-(4-amino-3-bromopyrazolo[3,4-d]pyrimidin-1-yl)-5-(aminomethyl)oxolane-3,4-diol; 19-nor-10-azasteroid skeleton
DMRUIX3 DT Small molecular drug
DMRUIX3 PC 132663
DMRUIX3 MW 345.15
DMRUIX3 FM C10H13BrN6O3
DMRUIX3 IC InChI=1S/C10H13BrN6O3/c11-7-4-8(13)14-2-15-9(4)17(16-7)10-6(19)5(18)3(1-12)20-10/h2-3,5-6,10,18-19H,1,12H2,(H2,13,14,15)/t3-,5-,6-,10-/m1/s1
DMRUIX3 CS C1=NC(=C2C(=N1)N(N=C2Br)[C@H]3[C@@H]([C@@H]([C@H](O3)CN)O)O)N
DMRUIX3 IK LTTBFVDMHCIDPM-BHBWVORQSA-N
DMRUIX3 IU (2R,3R,4S,5R)-2-(4-amino-3-bromopyrazolo[3,4-d]pyrimidin-1-yl)-5-(aminomethyl)oxolane-3,4-diol
DMRUIX3 CA CAS 144928-48-3
DMRUIX3 DE Discovery agent
DM1W5G9 ID DM1W5G9
DM1W5G9 DN GPCR39 pepducins
DM1W5G9 HS Investigative
DM1W5G9 SN GPCR39 pepducins (lipopeptide, diabetes/obesity); GPCR39 pepducins (lipopeptide, diabetes/obesity), Anchor Therapeutics; GPCR39 pepducins (lipopeptide, diabetes/obesity), Anchor/Janssen; G-protein coupled receptor-39 modulators (lipopeptide, diabetes/obesity), Anchor Therapeutics; GPCR39 pepducins (lipopeptide, diabetes/obesity), Anchor Therapeutics/ Ortho-McNeil-Janssen
DM1W5G9 CP Anchor Therapeutics Inc
DM1W5G9 DE Diabetic complication
DMRJ5OD ID DMRJ5OD
DMRJ5OD DN GPG-290
DMRJ5OD HS Investigative
DMRJ5OD SN Platelet adhesion inhibitor, Aarvon Biosciences
DMRJ5OD CP Wyeth
DMRJ5OD DE Angina pectoris
DMAY48N ID DMAY48N
DMAY48N DN GPI 18214
DMAY48N HS Investigative
DMAY48N DE Discovery agent
DMLRTPH ID DMLRTPH
DMLRTPH DN GPYRMEHFRWGSPPKD-NH2
DMLRTPH HS Investigative
DMLRTPH PC 91936746
DMLRTPH MW 1959.2
DMLRTPH FM C89H127N27O22S
DMLRTPH IC InChI=1S/C89H127N27O22S/c1-139-37-30-60(107-76(127)57(19-9-32-98-88(93)94)104-82(133)63(39-50-24-26-53(118)27-25-50)113-84(135)67-21-11-34-114(67)71(120)43-91)80(131)106-59(28-29-72(121)122)79(130)112-65(41-52-45-97-48-102-52)83(134)110-62(38-49-14-3-2-4-15-49)81(132)105-58(20-10-33-99-89(95)96)78(129)111-64(40-51-44-100-55-17-6-5-16-54(51)55)75(126)101-46-70(119)103-66(47-117)86(137)116-36-13-23-69(116)87(138)115-35-12-22-68(115)85(136)108-56(18-7-8-31-90)77(128)109-61(74(92)125)42-73(123)124/h2-6,14-17,24-27,44-45,48,56-69,100,117-118H,7-13,18-23,28-43,46-47,90-91H2,1H3,(H2,92,125)(H,97,102)(H,101,126)(H,103,119)(H,104,133)(H,105,132)(H,106,131)(H,107,127)(H,108,136)(H,109,128)(H,110,134)(H,111,129)(H,112,130)(H,113,135)(H,121,122)(H,123,124)(H4,93,94,98)(H4,95,96,99)/t56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-/m0/s1
DMLRTPH CS CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CO)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@@H]8CCCN8C(=O)CN
DMLRTPH IK XQMPAWYRHAOJTE-JLQTWWGSSA-N
DMLRTPH IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[[(2S)-6-amino-1-[[(2S)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMLRTPH DE Discovery agent
DMMX7KL ID DMMX7KL
DMMX7KL DN GR 125,743
DMMX7KL HS Investigative
DMMX7KL SN GR125743; GR 125743
DMMX7KL DT Small molecular drug
DMMX7KL PC 5311130
DMMX7KL MW 416.5
DMMX7KL FM C25H28N4O2
DMMX7KL IC InChI=1S/C25H28N4O2/c1-18-16-20(4-6-22(18)19-8-10-26-11-9-19)25(30)27-21-5-7-24(31-3)23(17-21)29-14-12-28(2)13-15-29/h4-11,16-17H,12-15H2,1-3H3,(H,27,30)
DMMX7KL CS CC1=C(C=CC(=C1)C(=O)NC2=CC(=C(C=C2)OC)N3CCN(CC3)C)C4=CC=NC=C4
DMMX7KL IK GNOXPYACARZYMW-UHFFFAOYSA-N
DMMX7KL IU N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-4-pyridin-4-ylbenzamide
DMMX7KL DE Discovery agent
DM72B86 ID DM72B86
DM72B86 DN GR 125487
DM72B86 HS Investigative
DM72B86 SN GR-125487; GR125487
DM72B86 DT Small molecular drug
DM72B86 PC 4284721
DM72B86 MW 427.5
DM72B86 FM C19H26FN3O5S
DM72B86 IC InChI=1S/C19H26FN3O5S/c1-27-18-17(15-11-14(20)3-4-16(15)22-18)19(24)28-12-13-5-8-23(9-6-13)10-7-21-29(2,25)26/h3-4,11,13,21-22H,5-10,12H2,1-2H3
DM72B86 CS COC1=C(C2=C(N1)C=CC(=C2)F)C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C
DM72B86 IK SSPCCAYAIDNNJX-UHFFFAOYSA-N
DM72B86 IU [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate
DM72B86 CA CAS 144625-67-2
DM72B86 DE Discovery agent
DMAI9Y0 ID DMAI9Y0
DMAI9Y0 DN GR 128107
DMAI9Y0 HS Investigative
DMAI9Y0 SN L000276; GR-128107; GR128107
DMAI9Y0 DT Small molecular drug
DMAI9Y0 PC 44208891
DMAI9Y0 MW 272.34
DMAI9Y0 FM C16H20N2O2
DMAI9Y0 IC InChI=1S/C16H20N2O2/c1-11(19)18-7-3-4-12(10-18)15-9-17-16-6-5-13(20-2)8-14(15)16/h5-6,8-9,12,17H,3-4,7,10H2,1-2H3
DMAI9Y0 CS CC(=O)N1CCCC(C1)C2=CNC3=C2C=C(C=C3)OC
DMAI9Y0 IK RBINAFTXZHPTNU-UHFFFAOYSA-N
DMAI9Y0 IU 1-[3-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]ethanone
DMAI9Y0 DE Discovery agent
DMHAWYJ ID DMHAWYJ
DMHAWYJ DN GR 196429
DMHAWYJ HS Investigative
DMHAWYJ SN GR196429; GR-196429
DMHAWYJ DT Small molecular drug
DMHAWYJ PC 5311134
DMHAWYJ MW 246.3
DMHAWYJ FM C14H18N2O2
DMHAWYJ IC InChI=1S/C14H18N2O2/c1-10(17)15-6-8-16-7-4-11-2-3-13-12(14(11)16)5-9-18-13/h2-3H,4-9H2,1H3,(H,15,17)
DMHAWYJ CS CC(=O)NCCN1CCC2=C1C3=C(C=C2)OCC3
DMHAWYJ IK LTYWTNUOUBBVNZ-UHFFFAOYSA-N
DMHAWYJ IU N-[2-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)ethyl]acetamide
DMHAWYJ CA CAS 170729-12-1
DMHAWYJ DE Discovery agent
DMP1DO4 ID DMP1DO4
DMP1DO4 DN GR100679
DMP1DO4 HS Investigative
DMP1DO4 SN GR 100679; GR-100679
DMP1DO4 DT Small molecular drug
DMP1DO4 PC 5311129
DMP1DO4 MW 616.7
DMP1DO4 FM C34H44N6O5
DMP1DO4 IC InChI=1S/C34H44N6O5/c1-22(37-30(41)21-36-32(43)24-14-8-5-9-15-24)31(42)38-28(19-25-20-35-27-17-11-10-16-26(25)27)33(44)39-29(34(45)40(2)3)18-23-12-6-4-7-13-23/h4,6-7,10-13,16-17,20,22,24,28-29,35H,5,8-9,14-15,18-19,21H2,1-3H3,(H,36,43)(H,37,41)(H,38,42)(H,39,44)/t22-,28+,29-/m0/s1
DMP1DO4 CS C[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N(C)C)NC(=O)CNC(=O)C4CCCCC4
DMP1DO4 IK IBHXDZADSPABSD-GJDOKZOISA-N
DMP1DO4 IU N-[2-[[(2S)-1-[[(2R)-1-[[(2S)-1-(dimethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]cyclohexanecarboxamide
DMP1DO4 DE Discovery agent
DMFU9VH ID DMFU9VH
DMFU9VH DN GR-113808
DMFU9VH HS Investigative
DMFU9VH SN CHEMBL518682; GTPL259; [3H]GR 113808; GR 125487 [H3]; [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-(tritritiomethyl)indole-3-carboxylate
DMFU9VH DT Small molecular drug
DMFU9VH PC 119376
DMFU9VH MW 393.5
DMFU9VH FM C19H27N3O4S
DMFU9VH IC InChI=1S/C19H27N3O4S/c1-21-13-17(16-5-3-4-6-18(16)21)19(23)26-14-15-7-10-22(11-8-15)12-9-20-27(2,24)25/h3-6,13,15,20H,7-12,14H2,1-2H3
DMFU9VH CS CN1C=C(C2=CC=CC=C21)C(=O)OCC3CCN(CC3)CCNS(=O)(=O)C
DMFU9VH IK MOZPSIXKYJUTKI-UHFFFAOYSA-N
DMFU9VH IU [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-methylindole-3-carboxylate
DMFU9VH CA CAS 144625-51-4
DMFU9VH CB CHEBI:73380
DMFU9VH DE Discovery agent
DMQH8PK ID DMQH8PK
DMQH8PK DN GR-133686
DMQH8PK HS Investigative
DMQH8PK PC 10696098
DMQH8PK MW 480.6
DMQH8PK FM C30H40O5
DMQH8PK IC InChI=1S/C30H40O5/c1-16(2)13-17(31)14-18-24-21(34-25(18)32)15-29(5)20-7-8-22-27(3,19(20)9-12-28(24,29)4)11-10-23-30(22,6)26(33)35-23/h7,13,18-19,21-24H,8-12,14-15H2,1-6H3/t18-,19+,21+,22-,23-,24-,27-,28+,29-,30+/m1/s1
DMQH8PK CS CC(=CC(=O)C[C@@H]1[C@@H]2[C@H](C[C@]3([C@]2(CC[C@H]4C3=CC[C@@H]5[C@@]4(CC[C@@H]6[C@]5(C(=O)O6)C)C)C)C)OC1=O)C
DMQH8PK IK UAKRLLAUOQEYFN-PQNCNOJFSA-N
DMQH8PK IU (2S,4S,7R,8S,9S,12R,13R,16R,19S,20R)-2,9,13,19-tetramethyl-7-(4-methyl-2-oxopent-3-enyl)-5,17-dioxahexacyclo[10.10.0.02,9.04,8.013,20.016,19]docos-1(22)-ene-6,18-dione
DMQH8PK DE Discovery agent
DMW8YDR ID DMW8YDR
DMW8YDR DN GR138676
DMW8YDR HS Investigative
DMW8YDR SN GR 138676; GR-138676
DMW8YDR DT Small molecular drug
DMW8YDR PC 25088319
DMW8YDR MW 1433.7
DMW8YDR FM C75H92N12O15S
DMW8YDR IC InChI=1S/C75H92N12O15S/c1-47(2)33-63(73(98)79-55(44-101-42-51-25-15-7-16-26-51)45-102-43-52-27-17-8-18-28-52)87-41-53-29-31-86(66(53)75(87)100)74(99)62(36-50-23-13-6-14-24-50)85-70(95)59(35-49-21-11-5-12-22-49)81-69(94)58(34-48-19-9-4-10-20-48)82-72(97)61(39-65(90)91)84-71(96)60(37-54-40-77-46-78-54)83-68(93)57(30-32-103-3)80-67(92)56(76)38-64(88)89/h4-28,40,46-47,53,55-63,66H,29-39,41-45,76H2,1-3H3,(H,77,78)(H,79,98)(H,80,92)(H,81,94)(H,82,97)(H,83,93)(H,84,96)(H,85,95)(H,88,89)(H,90,91)/t53-,56+,57+,58+,59+,60+,61+,62+,63-,66-/m1/s1
DMW8YDR CS CC(C)C[C@H](C(=O)NC(COCC1=CC=CC=C1)COCC2=CC=CC=C2)N3C[C@H]4CCN([C@H]4C3=O)C(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)N
DMW8YDR IK SHZVIDXXKGEHEF-QEPUNBJPSA-N
DMW8YDR IU (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(3aR,6aR)-5-[(2R)-1-[1,3-bis(phenylmethoxy)propan-2-ylamino]-4-methyl-1-oxopentan-2-yl]-6-oxo-3,3a,4,6a-tetrahydro-2H-pyrrolo[2,3-c]pyrrol-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-amino-4-oxobutanoic acid
DMW8YDR DE Discovery agent
DMIY9UF ID DMIY9UF
DMIY9UF DN GR-38414
DMIY9UF HS Investigative
DMIY9UF SN 138155-21-2
DMIY9UF DE Discovery agent
DM5UOYM ID DM5UOYM
DM5UOYM DN GR-45809
DM5UOYM HS Investigative
DM5UOYM SN 125104-16-7
DM5UOYM DT Small molecular drug
DM5UOYM PC 9955378
DM5UOYM MW 413.3
DM5UOYM FM C20H26Cl2N2O3
DM5UOYM IC InChI=1S/C20H26Cl2N2O3/c21-17-4-3-15(11-18(17)22)12-19(25)24-8-5-20(26-9-10-27-20)13-16(24)14-23-6-1-2-7-23/h3-4,11,16H,1-2,5-10,12-14H2
DM5UOYM CS C1CCN(C1)CC2CC3(CCN2C(=O)CC4=CC(=C(C=C4)Cl)Cl)OCCO3
DM5UOYM IK LWUQHEXXEFUHHQ-UHFFFAOYSA-N
DM5UOYM IU 2-(3,4-dichlorophenyl)-1-[7-(pyrrolidin-1-ylmethyl)-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]ethanone
DM5UOYM DE Discovery agent
DM8L1Z2 ID DM8L1Z2
DM8L1Z2 DN GR55562
DM8L1Z2 HS Investigative
DM8L1Z2 SN GR55562; GR-55562; CHEMBL119264; GR 55562; Tocris-1054; Biomol-NT_000120; AC1L2T1B; GTPL113; SCHEMBL3366363; BPBio1_000002; CHEBI:92813; ZINC599925; BDBM50060519; AKOS028111023; NCGC00024970-02; NCGC00024970-01; NCGC00024970-03; L000279; BRD-K46441700-300-01-4; BRD-K46441700-001-01-8; 3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide; 3-[3-(dimethylamino)pro-pyl]-4-hydroxy-N-[4-(4-pyridinyl)phenyl]benzamide; 3-(3-dimethylaminopropyl)-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide
DM8L1Z2 DT Small molecular drug
DM8L1Z2 PC 128018
DM8L1Z2 MW 375.5
DM8L1Z2 FM C23H25N3O2
DM8L1Z2 IC InChI=1S/C23H25N3O2/c1-26(2)15-3-4-19-16-20(7-10-22(19)27)23(28)25-21-8-5-17(6-9-21)18-11-13-24-14-12-18/h5-14,16,27H,3-4,15H2,1-2H3,(H,25,28)
DM8L1Z2 CS CN(C)CCCC1=C(C=CC(=C1)C(=O)NC2=CC=C(C=C2)C3=CC=NC=C3)O
DM8L1Z2 IK ZAGAUUVCYGSPBP-UHFFFAOYSA-N
DM8L1Z2 IU 3-[3-(dimethylamino)propyl]-4-hydroxy-N-(4-pyridin-4-ylphenyl)benzamide
DM8L1Z2 CA CAS 159533-26-3
DM8L1Z2 CB CHEBI:92813
DM8L1Z2 DE Discovery agent
DMEO7CP ID DMEO7CP
DMEO7CP DN GR-86014
DMEO7CP HS Investigative
DMEO7CP SN 132537-24-7
DMEO7CP DE Discovery agent
DM9WY1D ID DM9WY1D
DM9WY1D DN GR-91272
DM9WY1D HS Investigative
DM9WY1D SN 132537-23-6
DM9WY1D DE Discovery agent
DMBYK0X ID DMBYK0X
DMBYK0X DN GR94800
DMBYK0X HS Investigative
DMBYK0X SN GR-94800; GR 94800
DMBYK0X DT Small molecular drug
DMBYK0X PC 6324620
DMBYK0X MW 904.1
DMBYK0X FM C49H61N9O8
DMBYK0X IC InChI=1S/C49H61N9O8/c1-5-29(2)41(42(50)59)56-47(64)39-22-14-24-57(39)49(66)40-23-15-25-58(40)48(65)38(26-32-16-8-6-9-17-32)55-46(63)37(27-34-28-51-36-21-13-12-20-35(34)36)54-44(61)31(4)52-43(60)30(3)53-45(62)33-18-10-7-11-19-33/h6-13,16-21,28-31,37-41,51H,5,14-15,22-27H2,1-4H3,(H2,50,59)(H,52,60)(H,53,62)(H,54,61)(H,55,63)(H,56,64)/t29-,30-,31-,37+,38-,39-,40+,41-/m0/s1
DMBYK0X CS CC[C@H](C)[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)C6=CC=CC=C6
DMBYK0X IK KIPTYYXCLIQOHM-KKMBCTKYSA-N
DMBYK0X IU (2S)-N-[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-1-[(2R)-1-[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-benzamidopropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide
DMBYK0X DE Discovery agent
DMVLQUP ID DMVLQUP
DMVLQUP DN Grandisine C
DMVLQUP HS Investigative
DMVLQUP SN Grandisine C; CHEMBL509995; BDBM50269339
DMVLQUP DT Small molecular drug
DMVLQUP PC 16086540
DMVLQUP MW 277.36
DMVLQUP FM C16H23NO3
DMVLQUP IC InChI=1S/C16H23NO3/c1-9-7-10(18)8-13-14(9)16(19)15-11-3-2-5-17(11)6-4-12(15)20-13/h9-12,15,18H,2-8H2,1H3/t9-,10-,11-,12+,15-/m0/s1
DMVLQUP CS C[C@H]1C[C@@H](CC2=C1C(=O)[C@H]3[C@@H]4CCCN4CC[C@H]3O2)O
DMVLQUP IK WNDBXOYUMYCREE-NAYUARGSSA-N
DMVLQUP IU (6aR,9S,11S,12aS,12bS)-9-hydroxy-11-methyl-1,2,3,5,6,6a,8,9,10,11,12a,12b-dodecahydrochromeno[2,3-g]indolizin-12-one
DMVLQUP DE Discovery agent
DM0JHYF ID DM0JHYF
DM0JHYF DN Grandisine D
DM0JHYF HS Investigative
DM0JHYF SN grandisine D; (+)-Grandisine D
DM0JHYF DT Small molecular drug
DM0JHYF PC 16040172
DM0JHYF MW 259.339
DM0JHYF FM C16H21NO2
DM0JHYF IC InChI=1S/C16H21NO2/c1-11-5-2-8-14(18)15(11)16(19)12-6-3-9-17-10-4-7-13(12)17/h2,6,8,11,13,15H,3-5,7,9-10H2,1H3/t11-,13-,15+/m0/s1
DM0JHYF CS C[C@H]1CC=CC(=O)[C@@H]1C(=O)C2=CCCN3[C@H]2CCC3
DM0JHYF IK FKYCJVGMJYUVIJ-CORIIIEPSA-N
DM0JHYF IU (5S,6R)-6-[(8aS)-1,2,3,5,6,8a-hexahydroindolizine-8-carbonyl]-5-methylcyclohex-2-en-1-one
DM0JHYF DE Discovery agent
DM04S2P ID DM04S2P
DM04S2P DN Grandisine F
DM04S2P HS Investigative
DM04S2P SN Grandisine F; CHEMBL497516; BDBM50269337
DM04S2P DT Small molecular drug
DM04S2P PC 16086543
DM04S2P MW 276.37
DM04S2P FM C16H24N2O2
DM04S2P IC InChI=1S/C16H24N2O2/c1-9-7-10(17)8-13-14(9)16(19)15-11-3-2-5-18(11)6-4-12(15)20-13/h9-12,15H,2-8,17H2,1H3/t9-,10-,11-,12+,15-/m0/s1
DM04S2P CS C[C@H]1C[C@@H](CC2=C1C(=O)[C@H]3[C@@H]4CCCN4CC[C@H]3O2)N
DM04S2P IK AOYSDZUESPFRDD-NAYUARGSSA-N
DM04S2P IU (6aR,9S,11S,12aS,12bS)-9-amino-11-methyl-1,2,3,5,6,6a,8,9,10,11,12a,12b-dodecahydrochromeno[2,3-g]indolizin-12-one
DM04S2P DE Discovery agent
DM65SQK ID DM65SQK
DM65SQK DN GRANULATIMIDE
DM65SQK HS Investigative
DM65SQK SN GRANULATIMIDE; CHEMBL240747; 219828-99-6; SCHEMBL4238896; CTK1A7209; DTXSID90415922; BDBM50216165; 1,11-dihydro-1,3,5,11-tetraaza-benzo[a]trindene-4,6-dione; 3,11-Dihydro-1,3,5,11-tetraaza-benzo[a]trindene-4,6-dione; 1H-Imidazo[4,5-a]pyrrolo[3,4-c]carbazole-4,6(5H,11H)-dione
DM65SQK DT Small molecular drug
DM65SQK PC 5324595
DM65SQK MW 276.25
DM65SQK FM C15H8N4O2
DM65SQK IC InChI=1S/C15H8N4O2/c20-14-9-8-6-3-1-2-4-7(6)18-12(8)13-11(16-5-17-13)10(9)15(21)19-14/h1-5,18H,(H,16,17)(H,19,20,21)
DM65SQK CS C1=CC=C2C(=C1)C3=C4C(=C5C(=C3N2)NC=N5)C(=O)NC4=O
DM65SQK IK LBTREMHIJGMYQN-UHFFFAOYSA-N
DM65SQK IU 3,5,9,19-tetrazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1,4,6,11,13,15,17-heptaene-8,10-dione
DM65SQK CA CAS 219828-99-6
DM65SQK DE Discovery agent
DM1PWX2 ID DM1PWX2
DM1PWX2 DN Grassystatin a
DM1PWX2 HS Investigative
DM1PWX2 SN Grassystatin A; CHEMBL567893; GTPL8674
DM1PWX2 DT Small molecular drug
DM1PWX2 PC 44255320
DM1PWX2 MW 1174.4
DM1PWX2 FM C58H95N9O16
DM1PWX2 IC InChI=1S/C58H95N9O16/c1-30(2)25-38(43(69)29-45(71)64-46(36(12)68)52(74)60-35(11)54(76)66(15)42(27-37-21-18-17-19-22-37)55(77)67-24-20-23-41(67)56(78)81-16)61-51(73)40(28-44(59)70)62-50(72)39(26-31(3)4)63-53(75)48(33(7)8)82-58(80)49(34(9)10)83-57(79)47(32(5)6)65(13)14/h17-19,21-22,30-36,38-43,46-49,68-69H,20,23-29H2,1-16H3,(H2,59,70)(H,60,74)(H,61,73)(H,62,72)(H,63,75)(H,64,71)/t35-,36+,38-,39-,40-,41-,42+,43-,46-,47-,48+,49-/m0/s1
DM1PWX2 CS C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N(C)[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)OC)NC(=O)C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)OC(=O)[C@H](C(C)C)N(C)C)O)O
DM1PWX2 IK JZYWSTGTBRHGTL-BIXXXADNSA-N
DM1PWX2 IU methyl (2S)-1-[(2R)-2-[[(2S)-2-[[(2S,3R)-2-[[(3S,4S)-4-[[(2S)-4-amino-2-[[(2S)-2-[[(2R)-2-[(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanoyl]oxy-3-methylbutanoyl]oxy-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]-methylamino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate
DM1PWX2 DE Discovery agent
DMXSWF6 ID DMXSWF6
DMXSWF6 DN grayanotoxin III
DMXSWF6 HS Investigative
DMXSWF6 SN grayanotoxin III; UNII-ZKR09NT58C; Andromedol; ZKR09NT58C; Deacylasebotoxin I; Deacetylandromedotoxin; 4678-45-9; NSC 323778; BRN 2059374; Grayanotoxane-3,5,6,10,14,16-hexol, (3-beta,6-beta,14R)-; grayanotoxin-III; (3beta,6beta,14R)-Grayanotoxane-3,5,6,10,14,16-hexol; GTPL2628; CHEMBL454313; SCHEMBL1008212; 7,9a-Methano-9aH-cyclopenta(b)heptalene-2,4,8,11,11a,12(1H)-hexol, dodecahydro-1,1,4,8-tetramethyl-, (2S,3as,4R,4ar,7R,8R,9as,11R,11aR,12R)-; ZINC33913426; Grayanotoxane-3,5,6,10,14,16-hexol, (3beta,6beta,14R)- (9CI)
DMXSWF6 DT Small molecular drug
DMXSWF6 PC 11057730
DMXSWF6 MW 370.5
DMXSWF6 FM C20H34O6
DMXSWF6 IC InChI=1S/C20H34O6/c1-16(2)13(21)7-12-18(4,25)11-6-5-10-15(23)19(11,9-17(10,3)24)8-14(22)20(12,16)26/h10-15,21-26H,5-9H2,1-4H3/t10-,11+,12+,13+,14-,15-,17-,18-,19+,20+/m1/s1
DMXSWF6 CS C[C@]1(C[C@@]23C[C@H]([C@]4([C@@H](C[C@@H](C4(C)C)O)[C@]([C@@H]2CC[C@@H]1[C@H]3O)(C)O)O)O)O
DMXSWF6 IK BWMFRQKICHXLSH-FIRPSQKQSA-N
DMXSWF6 IU (1S,3R,4R,6S,8S,9R,10R,13R,14R,16R)-5,5,9,14-tetramethyltetracyclo[11.2.1.01,10.04,8]hexadecane-3,4,6,9,14,16-hexol
DMXSWF6 CA CAS 4678-45-9
DMXSWF6 DE Discovery agent
DMQHJTF ID DMQHJTF
DMQHJTF DN Green tea
DMQHJTF HS Investigative
DMQHJTF SN Oxotremorine; Oxytremorine; Oxotremorin; Tremorine, oxo-; 70-22-4; 2'-Oxopyrrolidino-1-pyrrolidino-4-butyne; MLS000766260; UNII-5RY0UWH1JL; EINECS 200-728-0; 5RY0UWH1JL; NSC 330497; 1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one; BRN 1530948; CHEMBL7634; 1-(4-(Pyrrolidin-1-yl)but-2-ynyl)pyrrolidin-2-one; CHEBI:7851; 2-PYRROLIDINONE, 1-(4-(1-PYRROLIDINYL)-2-BUTYNYL)-; RSDOPYMFZBJHRL-UHFFFAOYSA-N; 2-Pyrrolidinone, 1-[4-(1-pyrrolidinyl)-2-butynyl]-; Tocris-0843; Spectrum_001875; Spectrum_001448; AC1L1ILJ; Spectrum5_001099
DMQHJTF DT Small molecular drug
DMQHJTF PC 4630
DMQHJTF MW 206.28
DMQHJTF FM C12H18N2O
DMQHJTF IC InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2
DMQHJTF CS C1CCN(C1)CC#CCN2CCCC2=O
DMQHJTF IK RSDOPYMFZBJHRL-UHFFFAOYSA-N
DMQHJTF IU 1-(4-pyrrolidin-1-ylbut-2-ynyl)pyrrolidin-2-one
DMQHJTF CA CAS 70-22-4
DMQHJTF CB CHEBI:7851
DMQHJTF DE Discovery agent
DM3A0TE ID DM3A0TE
DM3A0TE DN GRI977143
DM3A0TE HS Investigative
DM3A0TE SN GRI-977143
DM3A0TE DT Small molecular drug
DM3A0TE PC 73755227
DM3A0TE MW 375.4
DM3A0TE FM C22H17NO3S
DM3A0TE IC InChI=1S/C22H17NO3S/c24-14-16-6-1-2-11-19(16)27-13-5-12-23-21(25)17-9-3-7-15-8-4-10-18(20(15)17)22(23)26/h1-4,6-11,14H,5,12-13H2
DM3A0TE CS C1=CC=C(C(=C1)C=O)SCCCN2C(=O)C3=CC=CC4=C3C(=CC=C4)C2=O
DM3A0TE IK IYUOFUODBWFCBK-UHFFFAOYSA-N
DM3A0TE IU 2-[3-(1,3-dioxobenzo[de]isoquinolin-2-yl)propylsulfanyl]benzaldehyde
DM3A0TE DE Discovery agent
DMGTRZE ID DMGTRZE
DMGTRZE DN grifolic acid
DMGTRZE HS Investigative
DMGTRZE SN ilicicolinic acid B
DMGTRZE DT Small molecular drug
DMGTRZE PC 9976563
DMGTRZE MW 372.5
DMGTRZE FM C23H32O4
DMGTRZE IC InChI=1S/C23H32O4/c1-15(2)8-6-9-16(3)10-7-11-17(4)12-13-19-20(24)14-18(5)21(22(19)25)23(26)27/h8,10,12,14,24-25H,6-7,9,11,13H2,1-5H3,(H,26,27)/b16-10+,17-12+
DMGTRZE CS CC1=CC(=C(C(=C1C(=O)O)O)C/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C)O
DMGTRZE IK QPIZDZGIXDKCRC-JTCWOHKRSA-N
DMGTRZE IU 2,4-dihydroxy-6-methyl-3-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzoic acid
DMGTRZE DE Discovery agent
DML09OS ID DML09OS
DML09OS DN GRL-0667
DML09OS HS Investigative
DML09OS SN BDBM50007789; CHEMBL1173044; GRM; Q27460878; SCHEMBL7938638
DML09OS TC Antiviral Agents
DML09OS DT Small molecular drug
DML09OS PC 46174170
DML09OS MW 416.5
DML09OS FM C26H28N2O3
DML09OS IC InChI=1S/C26H28N2O3/c1-18(22-8-4-6-20-5-2-3-7-23(20)22)28-13-11-21(12-14-28)26(29)27-16-19-9-10-24-25(15-19)31-17-30-24/h2-10,15,18,21H,11-14,16-17H2,1H3,(H,27,29)/t18-/m1/s1
DML09OS CS C[C@H](C1=CC=CC2=CC=CC=C21)N3CCC(CC3)C(=O)NCC4=CC5=C(C=C4)OCO5
DML09OS IK IVXBCFLWMPMSAP-GOSISDBHSA-N
DML09OS IU N-(1,3-benzodioxol-5-ylmethyl)-1-[(1R)-1-naphthalen-1-ylethyl]piperidine-4-carboxamide
DML09OS CB CHEBI:149790
DML09OS DE Severe acute respiratory syndrome (SARS)
DMR93MK ID DMR93MK
DMR93MK DN GRL-7234
DMR93MK HS Investigative
DMR93MK SN GRL-7234; N-[(1s,2s,4r)-2-Hydroxy-1-Isobutyl-5-({(1s)-1-[(Isopropylamino)carbonyl]-2-Methylpropyl}amino)-4-Methyl-5-Oxopentyl]-5-[methyl(Methylsulfonyl)amino]-N'-[(1r)-1-Phenylethyl]isophthalamide; 2p4j; Isophthalamide Derivative 5d; CHEMBL387771; BDBM16259; 23I; 1-N-[(1R,3S,4S)-3-hydroxy-1,6-dimethyl-1-{[(1S)-2-methyl-1-(propan-2-ylcarbamoyl)propyl]carbamoyl}heptan-4-yl]-5-(N-methylmethanesulfonamido)-3-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
DMR93MK DT Small molecular drug
DMR93MK PC 16659106
DMR93MK MW 701.9
DMR93MK FM C36H55N5O7S
DMR93MK IC InChI=1S/C36H55N5O7S/c1-21(2)16-30(31(42)17-24(7)33(43)40-32(22(3)4)36(46)37-23(5)6)39-35(45)28-18-27(19-29(20-28)41(9)49(10,47)48)34(44)38-25(8)26-14-12-11-13-15-26/h11-15,18-25,30-32,42H,16-17H2,1-10H3,(H,37,46)(H,38,44)(H,39,45)(H,40,43)/t24-,25-,30+,31+,32+/m1/s1
DMR93MK CS C[C@H](C[C@@H]([C@H](CC(C)C)NC(=O)C1=CC(=CC(=C1)C(=O)N[C@H](C)C2=CC=CC=C2)N(C)S(=O)(=O)C)O)C(=O)N[C@@H](C(C)C)C(=O)NC(C)C
DMR93MK IK BJOCXJJVELLFKM-LLWRDSBASA-N
DMR93MK IU 3-N-[(4S,5S,7R)-5-hydroxy-2,7-dimethyl-8-[[(2S)-3-methyl-1-oxo-1-(propan-2-ylamino)butan-2-yl]amino]-8-oxooctan-4-yl]-5-[methyl(methylsulfonyl)amino]-1-N-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide
DMR93MK DE Discovery agent
DMJ47DM ID DMJ47DM
DMJ47DM DN GRN-529
DMJ47DM HS Investigative
DMJ47DM SN IDDBCP263385
DMJ47DM CP Pfizer Inc
DMJ47DM DT Small molecular drug
DMJ47DM PC 59548652
DMJ47DM MW 391.4
DMJ47DM FM C22H15F2N3O2
DMJ47DM IC InChI=1S/C22H15F2N3O2/c23-22(24)29-20-9-7-16(12-15(20)6-8-18-5-1-2-10-25-18)21(28)27-13-17-4-3-11-26-19(17)14-27/h1-5,7,9-12,22H,13-14H2
DMJ47DM CS C1C2=C(CN1C(=O)C3=CC(=C(C=C3)OC(F)F)C#CC4=CC=CC=N4)N=CC=C2
DMJ47DM IK JITMSIRHBAVREW-UHFFFAOYSA-N
DMJ47DM IU [4-(difluoromethoxy)-3-(2-pyridin-2-ylethynyl)phenyl]-(5,7-dihydropyrrolo[3,4-b]pyridin-6-yl)methanone
DMJ47DM CA CAS 1253291-12-1
DMJ47DM DE Major depressive disorder
DMO6IM1 ID DMO6IM1
DMO6IM1 DN group E 1682-2106
DMO6IM1 HS Investigative
DMO6IM1 SN CHEMBL1770295; 3-methyl-2-[(5Z)-5-(1-methyl-2-oxoindol-3-ylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid; AC1NT1C6; GTPL5827; MolPort-000-500-334; BDBM50418364; AKOS016308025; AKOS002200571; ST50147548; UNM000000513101; group E 1682-2106 [PMID:16118363]; 3-METHYL-2-[(5Z)-5-(1-METHYL-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)-4-OXO-2-THIOXO-1,3-THIAZOLIDIN-3-YL]BUTANOIC ACID; 3-methyl-2-[5-(1-methyl-2-oxobenzo[d]azolin-3-ylidene)-4-oxo-2-thioxo(1,3-thia zolidin-3-yl)]butanoic acid
DMO6IM1 DT Small molecular drug
DMO6IM1 PC 5322194
DMO6IM1 MW 376.5
DMO6IM1 FM C17H16N2O4S2
DMO6IM1 IC InChI=1S/C17H16N2O4S2/c1-8(2)12(16(22)23)19-15(21)13(25-17(19)24)11-9-6-4-5-7-10(9)18(3)14(11)20/h4-8,12H,1-3H3,(H,22,23)/b13-11-
DMO6IM1 CS CC(C)C(C(=O)O)N1C(=O)/C(=C/2\\C3=CC=CC=C3N(C2=O)C)/SC1=S
DMO6IM1 IK ICRQMQBVDGOOFY-QBFSEMIESA-N
DMO6IM1 IU 3-methyl-2-[(5Z)-5-(1-methyl-2-oxoindol-3-ylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid
DMO6IM1 DE Discovery agent
DMG0OUD ID DMG0OUD
DMG0OUD DN GS4071
DMG0OUD HS Investigative
DMG0OUD SN Oseltamivir acid; 187227-45-8; Oseltamivir carboxylate; Oseltamivir (acid); GS 4071; Ro 64-0802; UNII-K6106LV5Q8; CHEMBL674; CHEBI:73139; K6106LV5Q8; GS-4071; (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid; 5-N-ACETYL-3-(1-ETHYLPROPYL)-1-CYCLOHEXENE-1-CARBOXYLIC ACID; 1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, (3R,4R,5S)-; (3r,4r,5s)-4-(Acetylamino)-5-Amino-3-(Pentan-3-Yloxy)cyclohex-1-Ene-1-Carboxylic Acid; G39; Oseltamivir-carboxylate; 2,4-diamino triazine
DMG0OUD DT Small molecular drug
DMG0OUD PC 449381
DMG0OUD MW 284.35
DMG0OUD FM C14H24N2O4
DMG0OUD IC InChI=1S/C14H24N2O4/c1-4-10(5-2)20-12-7-9(14(18)19)6-11(15)13(12)16-8(3)17/h7,10-13H,4-6,15H2,1-3H3,(H,16,17)(H,18,19)/t11-,12+,13+/m0/s1
DMG0OUD CS CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)O
DMG0OUD IK NENPYTRHICXVCS-YNEHKIRRSA-N
DMG0OUD IU (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylic acid
DMG0OUD CA CAS 187227-45-8
DMG0OUD CB CHEBI:73139
DMG0OUD DE Discovery agent
DMEGY3Q ID DMEGY3Q
DMEGY3Q DN GS-9256 + tegobuvir
DMEGY3Q HS Investigative
DMEGY3Q DE Discovery agent
DMTKGA3 ID DMTKGA3
DMTKGA3 DN GSC-1
DMTKGA3 HS Investigative
DMTKGA3 SN Alpha-glucosidase inhibitor (hyperglycemia), Dharma Biomedical
DMTKGA3 CP Dharma Biomedical
DMTKGA3 DE Hyperglycemia
DMC2ZF6 ID DMC2ZF6
DMC2ZF6 DN GSK-008A
DMC2ZF6 HS Investigative
DMC2ZF6 SN Progesterone receptor agonists (gynecological disorder); Progesterone receptor agonists (gynecological disorder), GSK
DMC2ZF6 CP GlaxoSmithKline plc
DMC2ZF6 DE Gynecological disease
DMNIVOX ID DMNIVOX
DMNIVOX DN GSK-0660
DMNIVOX HS Investigative
DMNIVOX SN GSK0660; 1014691-61-2; GSK 0660; GSK-0660; CHEMBL592652; 3-[[[2-Methoxy-4-(phenylamino)phenyl]amino]sulfonyl]-2-thiophenecarboxylicacidmethylester; methyl 3-[(4-anilino-2-methoxyphenyl)sulfamoyl]thiophene-2-carboxylate; C19H18N2O5S2; methyl 3-(N-(2-methoxy-4-(phenylamino)phenyl)sulfamoyl)thiophene-2-carboxylate; 3-(((2-Methoxy-4-(phenylamino)phenyl)amino]sulfonyl)-2-thiophenecarboxylic acid methyl ester; 3-[[[2-METHOXY-4-(PHENYLAMINO)PHENYL]AMINO]SULFONYL]-2-THIOPHENECARBOXYLIC ACID METHYL ESTER
DMNIVOX DT Small molecular drug
DMNIVOX PC 46233311
DMNIVOX MW 418.5
DMNIVOX FM C19H18N2O5S2
DMNIVOX IC InChI=1S/C19H18N2O5S2/c1-25-16-12-14(20-13-6-4-3-5-7-13)8-9-15(16)21-28(23,24)17-10-11-27-18(17)19(22)26-2/h3-12,20-21H,1-2H3
DMNIVOX CS COC1=C(C=CC(=C1)NC2=CC=CC=C2)NS(=O)(=O)C3=C(SC=C3)C(=O)OC
DMNIVOX IK NDFKBGWLUHKMFY-UHFFFAOYSA-N
DMNIVOX IU methyl 3-[(4-anilino-2-methoxyphenyl)sulfamoyl]thiophene-2-carboxylate
DMNIVOX CA CAS 1014691-61-2
DMNIVOX CB CHEBI:94813
DMNIVOX DE Discovery agent
DMDHZR1 ID DMDHZR1
DMDHZR1 DN GSK1016790A
DMDHZR1 HS Investigative
DMDHZR1 SN GSK1016790A; 942206-85-1; GSK 1016790A; GSK-1016790A; GSK101; (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide; IVYQPSHHYIAUFO-VXKWHMMOSA-N; GTPL4205; SCHEMBL5007988; DTXSID30635248; CHEBI:140524; MolPort-044-560-329; EX-A1885; s8107; MFCD12912413; ZINC95571016; AKOS030527025; CS-5660; NCGC00250409-01
DMDHZR1 DT Small molecular drug
DMDHZR1 PC 23630211
DMDHZR1 MW 655.6
DMDHZR1 FM C28H32Cl2N4O6S2
DMDHZR1 IC InChI=1S/C28H32Cl2N4O6S2/c1-17(2)13-21(31-26(36)24-14-18-5-3-4-6-23(18)41-24)27(37)33-9-11-34(12-10-33)28(38)22(16-35)32-42(39,40)25-8-7-19(29)15-20(25)30/h3-8,14-15,17,21-22,32,35H,9-13,16H2,1-2H3,(H,31,36)/t21-,22-/m0/s1
DMDHZR1 CS CC(C)C[C@@H](C(=O)N1CCN(CC1)C(=O)[C@H](CO)NS(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(=O)C3=CC4=CC=CC=C4S3
DMDHZR1 IK IVYQPSHHYIAUFO-VXKWHMMOSA-N
DMDHZR1 IU N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide
DMDHZR1 CA CAS 942206-85-1
DMDHZR1 CB CHEBI:140524
DMDHZR1 DE Discovery agent
DMIWY7Q ID DMIWY7Q
DMIWY7Q DN GSK1331268
DMIWY7Q HS Investigative
DMIWY7Q SN GSK 1331268; GSK-1331268
DMIWY7Q DT Small molecular drug
DMIWY7Q PC 46190878
DMIWY7Q MW 342.8
DMIWY7Q FM C17H19ClN6
DMIWY7Q IC InChI=1S/C17H19ClN6/c1-22-15-5-3-2-4-14(15)21-16(22)12-23-6-8-24(9-7-23)17-19-10-13(18)11-20-17/h2-5,10-11H,6-9,12H2,1H3
DMIWY7Q CS CN1C2=CC=CC=C2N=C1CN3CCN(CC3)C4=NC=C(C=N4)Cl
DMIWY7Q IK IXXZGBOSQDVMTC-UHFFFAOYSA-N
DMIWY7Q IU 2-[[4-(5-chloropyrimidin-2-yl)piperazin-1-yl]methyl]-1-methylbenzimidazole
DMIWY7Q CA CAS 1207197-70-3
DMIWY7Q DE Discovery agent
DMHBUG5 ID DMHBUG5
DMHBUG5 DN GSK-1344386B
DMHBUG5 HS Investigative
DMHBUG5 SN CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline
DMHBUG5 CP GlaxoSmithKline plc
DMHBUG5 DE Arteriosclerosis
DMZUTXW ID DMZUTXW
DMZUTXW DN GSK1511931
DMZUTXW HS Investigative
DMZUTXW SN GSK1511931A; GSK-1511931; compound 14 [PMID: 19081716]
DMZUTXW DT Small molecular drug
DMZUTXW PC 44581765
DMZUTXW MW 508.6
DMZUTXW FM C29H32N8O
DMZUTXW IC InChI=1S/C29H32N8O/c1-19(2)36-14-16-37(17-15-36)20-9-10-25(26(18-20)38-3)33-29-34-27-22(11-13-31-27)28(35-29)32-24-8-4-7-23-21(24)6-5-12-30-23/h4-13,18-19H,14-17H2,1-3H3,(H3,31,32,33,34,35)
DMZUTXW CS CC(C)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)NC5=CC=CC6=C5C=CC=N6)OC
DMZUTXW IK PEPOAPKYASCEKL-UHFFFAOYSA-N
DMZUTXW IU 2-N-[2-methoxy-4-(4-propan-2-ylpiperazin-1-yl)phenyl]-4-N-quinolin-5-yl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
DMZUTXW DE Discovery agent
DMKN76P ID DMKN76P
DMKN76P DN GSK-1564023A
DMKN76P HS Investigative
DMKN76P SN CHEMBL1093774; GSK-1564023A; SCHEMBL17963371; GSK1564023A
DMKN76P DT Small molecular drug
DMKN76P PC 46830196
DMKN76P MW 409.9
DMKN76P FM C21H20ClN5O2
DMKN76P IC InChI=1S/C21H20ClN5O2/c1-11-18-19(22)16(10-23-20(18)27(4)25-11)21(28)24-9-14-5-7-15(8-6-14)17-12(2)26-29-13(17)3/h5-8,10H,9H2,1-4H3,(H,24,28)
DMKN76P CS CC1=C(C(=NO1)C)C2=CC=C(C=C2)CNC(=O)C3=CN=C4C(=C3Cl)C(=NN4C)C
DMKN76P IK QWZQPWUWGYGVOC-UHFFFAOYSA-N
DMKN76P IU 4-chloro-N-[[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methyl]-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxamide
DMKN76P DE Discovery agent
DMG6TL7 ID DMG6TL7
DMG6TL7 DN GSK1614343
DMG6TL7 HS Investigative
DMG6TL7 SN GSK-1614343; GSK 1614343
DMG6TL7 DT Small molecular drug
DMG6TL7 PC 25124566
DMG6TL7 MW 487.4
DMG6TL7 FM C22H23F6N5O
DMG6TL7 IC InChI=1S/C22H23F6N5O/c23-21(24,25)15-9-16(22(26,27)28)11-17(10-15)30-31-20(34)19(14-3-1-5-29-12-14)33-8-7-32-6-2-4-18(32)13-33/h1,3,5,9-12,18-19,30H,2,4,6-8,13H2,(H,31,34)/t18-,19-/m1/s1
DMG6TL7 CS C1C[C@@H]2CN(CCN2C1)[C@H](C3=CN=CC=C3)C(=O)NNC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
DMG6TL7 IK QNOSCJDGJKVFJR-RTBURBONSA-N
DMG6TL7 IU (2R)-2-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-N'-[3,5-bis(trifluoromethyl)phenyl]-2-pyridin-3-ylacetohydrazide
DMG6TL7 DE Discovery agent
DM9IZNP ID DM9IZNP
DM9IZNP DN GSK-172981
DM9IZNP HS Investigative
DM9IZNP SN GSK-256471; SB-218795; SB-235375; SB-244487; SB-400238; SB-414240; SK-797230; NK-2 antagonists, GSK; NK-3 antagonists, GlaxoSmithKline; NK-3 antagonists, SB
DM9IZNP CP SmithKline Beecham SpA
DM9IZNP DT Small molecular drug
DM9IZNP PC 25195091
DM9IZNP MW 411.5
DM9IZNP FM C26H22FN3O
DM9IZNP IC InChI=1S/C26H22FN3O/c27-19-10-6-9-18(15-19)25-23(28)22(20-11-4-5-12-21(20)29-25)26(31)30-24(17-13-14-17)16-7-2-1-3-8-16/h1-12,15,17,24H,13-14,28H2,(H,30,31)/t24-/m1/s1
DM9IZNP CS C1CC1[C@@H](C2=CC=CC=C2)NC(=O)C3=C(C(=NC4=CC=CC=C43)C5=CC(=CC=C5)F)N
DM9IZNP IK ZKGNLARKIMWKFE-XMMPIXPASA-N
DM9IZNP IU 3-amino-N-[(S)-cyclopropyl(phenyl)methyl]-2-(3-fluorophenyl)quinoline-4-carboxamide
DM9IZNP DE Asthma
DM4HLK3 ID DM4HLK3
DM4HLK3 DN GSK-1838705A
DM4HLK3 HS Investigative
DM4HLK3 SN GSK 1838705A; GSK1838705A
DM4HLK3 DT Small molecular drug
DM4HLK3 PC 25182616
DM4HLK3 MW 532.6
DM4HLK3 FM C27H29FN8O3
DM4HLK3 IC InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)
DM4HLK3 CS CNC(=O)C1=C(C=CC=C1F)NC2=NC(=NC3=C2C=CN3)NC4=C(C=C5CCN(C5=C4)C(=O)CN(C)C)OC
DM4HLK3 IK HZTYDQRUAWIZRE-UHFFFAOYSA-N
DM4HLK3 IU 2-[[2-[[1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide
DM4HLK3 CA CAS 1116235-97-2
DM4HLK3 CB CHEBI:93768
DM4HLK3 DE Discovery agent
DM2KT17 ID DM2KT17
DM2KT17 DN GSK-1842799C
DM2KT17 HS Investigative
DM2KT17 SN PPI-4691; S1P1 agonists, Praecis
DM2KT17 CP Praecis Pharmaceuticals Inc
DM2KT17 DE Cardiovascular disease
DMMWBU6 ID DMMWBU6
DMMWBU6 DN GSK-188909
DMMWBU6 HS Investigative
DMMWBU6 SN GSK188909; CHEMBL253641; SCHEMBL5222560; BMCL181022 Compound 23; BDBM26788
DMMWBU6 DT Small molecular drug
DMMWBU6 DE Discovery agent
DMKXPOL ID DMKXPOL
DMKXPOL DN GSK189254A
DMKXPOL HS Investigative
DMKXPOL SN 720690-73-3; GSK 189254A; GSK-189254; GSK189254A; UNII-5T4TX6CO53; GSK189254; CHEMBL517140; 5T4TX6CO53; 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide; 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide; WROHEWWOCPRMIA-UHFFFAOYSA-N; 854485-15-7; GSK-189254A; SCHEMBL169579; ZINC3961799; AOB87474; EX-A1905; ABP000814; BDBM50247054; AKOS032944981; CS-6206; BCP9000737; GSK-189,254; KB-77605; HY-14111
DMKXPOL CP GlaxoSmithKline
DMKXPOL DT Small molecular drug
DMKXPOL PC 9798547
DMKXPOL MW 351.4
DMKXPOL FM C21H25N3O2
DMKXPOL IC InChI=1S/C21H25N3O2/c1-22-21(25)17-6-8-20(23-14-17)26-19-7-5-15-9-11-24(18-3-2-4-18)12-10-16(15)13-19/h5-8,13-14,18H,2-4,9-12H2,1H3,(H,22,25)
DMKXPOL CS CNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
DMKXPOL IK WROHEWWOCPRMIA-UHFFFAOYSA-N
DMKXPOL IU 6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide
DMKXPOL CA CAS 720690-73-3
DMKXPOL DE Cognitive impairment
DM9GPAU ID DM9GPAU
DM9GPAU DN GSK2033
DM9GPAU HS Investigative
DM9GPAU SN GSK 2033; GSK-2033
DM9GPAU DT Small molecular drug
DM9GPAU PC 46203250
DM9GPAU MW 591.7
DM9GPAU FM C29H28F3NO5S2
DM9GPAU IC InChI=1S/C29H28F3NO5S2/c1-19-14-20(2)28(21(3)15-19)40(36,37)33(18-25-12-13-27(38-25)29(30,31)32)17-22-8-10-23(11-9-22)24-6-5-7-26(16-24)39(4,34)35/h5-16H,17-18H2,1-4H3
DM9GPAU CS CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C
DM9GPAU IK PSOXOVKYGWBTPB-UHFFFAOYSA-N
DM9GPAU IU 2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide
DM9GPAU DE Discovery agent
DMY2XV3 ID DMY2XV3
DMY2XV3 DN GSK2193874
DMY2XV3 HS Investigative
DMY2XV3 SN GSK 2193874; GSK-2193874
DMY2XV3 DT Small molecular drug
DMY2XV3 PC 53464483
DMY2XV3 MW 691.6
DMY2XV3 FM C37H38BrF3N4O
DMY2XV3 IC InChI=1S/C37H38BrF3N4O/c38-28-12-13-30-32(23-28)42-34(25-8-7-11-27(22-25)37(39,40)41)31(24-44-20-14-29(15-21-44)45-18-5-2-6-19-45)33(30)35(46)43-36(16-17-36)26-9-3-1-4-10-26/h1,3-4,7-13,22-23,29H,2,5-6,14-21,24H2,(H,43,46)
DMY2XV3 CS C1CCN(CC1)C2CCN(CC2)CC3=C(C4=C(C=C(C=C4)Br)N=C3C5=CC(=CC=C5)C(F)(F)F)C(=O)NC6(CC6)C7=CC=CC=C7
DMY2XV3 IK UIVOZBSCHXCGPS-UHFFFAOYSA-N
DMY2XV3 IU 7-bromo-N-(1-phenylcyclopropyl)-3-[(4-piperidin-1-ylpiperidin-1-yl)methyl]-2-[3-(trifluoromethyl)phenyl]quinoline-4-carboxamide
DMY2XV3 DE Discovery agent
DMZ2TD9 ID DMZ2TD9
DMZ2TD9 DN GSK2194069
DMZ2TD9 HS Investigative
DMZ2TD9 SN GSK-2194069; GSK 2194069
DMZ2TD9 DT Small molecular drug
DMZ2TD9 PC 67376285
DMZ2TD9 MW 428.5
DMZ2TD9 FM C25H24N4O3
DMZ2TD9 IC InChI=1S/C25H24N4O3/c30-24(18-1-2-18)28-11-9-16(15-28)13-23-26-27-25(31)29(23)21-6-3-17(4-7-21)19-5-8-22-20(14-19)10-12-32-22/h3-8,10,12,14,16,18H,1-2,9,11,13,15H2,(H,27,31)/t16-/m0/s1
DMZ2TD9 CS C1CN(C[C@@H]1CC2=NNC(=O)N2C3=CC=C(C=C3)C4=CC5=C(C=C4)OC=C5)C(=O)C6CC6
DMZ2TD9 IK AQTPWCUIYUOEMG-INIZCTEOSA-N
DMZ2TD9 IU 4-[4-(1-benzofuran-5-yl)phenyl]-3-[[(3S)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl]methyl]-1H-1,2,4-triazol-5-one
DMZ2TD9 DE Discovery agent
DM0DKQN ID DM0DKQN
DM0DKQN DN GSK-2210875
DM0DKQN HS Investigative
DM0DKQN SN GSK-1222392; GSK-1331258; GSK-1635157; GSK-329771; GSK-355089; GSK-817755
DM0DKQN CP GlaxoSmithKline plc
DM0DKQN DT Small molecular drug
DM0DKQN PC 1489963
DM0DKQN MW 302.35
DM0DKQN FM C14H14N4O2S
DM0DKQN IC InChI=1S/C14H14N4O2S/c1-9-12(21-13-15-8-16-18(9)13)10(2)20-14(19)17-11-6-4-3-5-7-11/h3-8,10H,1-2H3,(H,17,19)/t10-/m1/s1
DM0DKQN CS CC1=C(SC2=NC=NN12)[C@@H](C)OC(=O)NC3=CC=CC=C3
DM0DKQN IK AOUUMBPBMVOBSP-SNVBAGLBSA-N
DM0DKQN IU [(1R)-1-(6-methyl-[1,3]thiazolo[3,2-b][1,2,4]triazol-5-yl)ethyl] N-phenylcarbamate
DM0DKQN DE Anxiety disorder
DM3BI7R ID DM3BI7R
DM3BI7R DN GSK-2334470
DM3BI7R HS Investigative
DM3BI7R SN PDK1 inhibitors, GlaxoSmithKline
DM3BI7R CP GlaxoSmithKline plc
DM3BI7R DT Small molecular drug
DM3BI7R PC 46215815
DM3BI7R MW 462.6
DM3BI7R FM C25H34N8O
DM3BI7R IC InChI=1S/C25H34N8O/c1-15-8-9-17(24(34)28-18-6-4-3-5-7-18)14-33(15)22-13-20(29-25(27-2)30-22)16-10-11-19-21(12-16)31-32-23(19)26/h10-13,15,17-18H,3-9,14H2,1-2H3,(H,28,34)(H3,26,31,32)(H,27,29,30)/t15-,17+/m1/s1
DM3BI7R CS C[C@@H]1CC[C@@H](CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5
DM3BI7R IK QLPHOXTXAKOFMU-WBVHZDCISA-N
DM3BI7R IU (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide
DM3BI7R CA CAS 1227911-45-6
DM3BI7R CB CHEBI:91465
DM3BI7R DE Solid tumour/cancer
DMLASOF ID DMLASOF
DMLASOF DN GSK2606414
DMLASOF HS Investigative
DMLASOF SN GSK PERK Inhibitor; 3-fluoro-GSK2606414; compound 38 [PMID: 22827572]
DMLASOF DT Small molecular drug
DMLASOF PC 53469448
DMLASOF MW 451.4
DMLASOF FM C24H20F3N5O
DMLASOF IC InChI=1S/C24H20F3N5O/c1-31-12-18(21-22(28)29-13-30-23(21)31)15-5-6-19-16(11-15)7-8-32(19)20(33)10-14-3-2-4-17(9-14)24(25,26)27/h2-6,9,11-13H,7-8,10H2,1H3,(H2,28,29,30)
DMLASOF CS CN1C=C(C2=C(N=CN=C21)N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F
DMLASOF IK SIXVRXARNAVBTC-UHFFFAOYSA-N
DMLASOF IU 1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydroindol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone
DMLASOF CA CAS 1337531-36-8
DMLASOF DE Discovery agent
DM325YR ID DM325YR
DM325YR DN GSK-280
DM325YR HS Investigative
DM325YR SN P38 kinase inhibitors (inflammation), GSK
DM325YR CP GlaxoSmithKline plc
DM325YR DE Inflammation
DMDSK9N ID DMDSK9N
DMDSK9N DN GSK2801
DMDSK9N HS Investigative
DMDSK9N SN KB-146016
DMDSK9N DT Small molecular drug
DMDSK9N PC 73010930
DMDSK9N MW 371.5
DMDSK9N FM C20H21NO4S
DMDSK9N IC InChI=1S/C20H21NO4S/c1-4-11-25-15-9-10-21-18(14(2)22)13-17(19(21)12-15)16-7-5-6-8-20(16)26(3,23)24/h5-10,12-13H,4,11H2,1-3H3
DMDSK9N CS CCCOC1=CC2=C(C=C(N2C=C1)C(=O)C)C3=CC=CC=C3S(=O)(=O)C
DMDSK9N IK KHWCPNJRJCNVRI-UHFFFAOYSA-N
DMDSK9N IU 1-[1-(2-methylsulfonylphenyl)-7-propoxyindolizin-3-yl]ethanone
DMDSK9N DE Discovery agent
DM1865H ID DM1865H
DM1865H DN GSK-325971A
DM1865H HS Investigative
DM1865H SN CHEMBL1093602; GSK-325971A; SCHEMBL4938465; GSK325971A
DM1865H DT Small molecular drug
DM1865H PC 46883841
DM1865H MW 342.8
DM1865H FM C18H19ClN4O
DM1865H IC InChI=1S/C18H19ClN4O/c1-4-23-17-14(10-22-23)16(19)15(9-20-17)18(24)21-8-13-6-5-11(2)7-12(13)3/h5-7,9-10H,4,8H2,1-3H3,(H,21,24)
DM1865H CS CCN1C2=NC=C(C(=C2C=N1)Cl)C(=O)NCC3=C(C=C(C=C3)C)C
DM1865H IK XLMANSLWCIMZAE-UHFFFAOYSA-N
DM1865H IU 4-chloro-N-[(2,4-dimethylphenyl)methyl]-1-ethylpyrazolo[3,4-b]pyridine-5-carboxamide
DM1865H DE Discovery agent
DM5EO3F ID DM5EO3F
DM5EO3F DN GSK-334429
DM5EO3F HS Investigative
DM5EO3F SN GSK-357868; GSK-678103; H3 antagonists (cognitive disorder); H3 antagonists (cognitive disorder), GlaxoSmithKline
DM5EO3F CP GlaxoSmithKline plc
DM5EO3F PC 11452311
DM5EO3F MW 398.5
DM5EO3F FM C20H29F3N4O
DM5EO3F IC InChI=1S/C20H29F3N4O/c1-15(2)25-8-3-9-27(13-12-25)19(28)16-6-10-26(11-7-16)17-4-5-18(24-14-17)20(21,22)23/h4-5,14-16H,3,6-13H2,1-2H3
DM5EO3F CS CC(C)N1CCCN(CC1)C(=O)C2CCN(CC2)C3=CN=C(C=C3)C(F)(F)F
DM5EO3F IK AHHPKVQYHXNBQN-UHFFFAOYSA-N
DM5EO3F IU (4-propan-2-yl-1,4-diazepan-1-yl)-[1-[6-(trifluoromethyl)pyridin-3-yl]piperidin-4-yl]methanone
DM5EO3F DE Cognitive impairment
DM9QU5Y ID DM9QU5Y
DM9QU5Y DN GSK343
DM9QU5Y HS Investigative
DM9QU5Y SN compound 6 [PMID 24900432]; GSK 343
DM9QU5Y DT Small molecular drug
DM9QU5Y PC 71268957
DM9QU5Y MW 541.7
DM9QU5Y FM C31H39N7O2
DM9QU5Y IC InChI=1S/C31H39N7O2/c1-6-7-23-14-21(4)35-31(40)26(23)18-33-30(39)25-15-24(16-28-27(25)19-34-38(28)20(2)3)22-8-9-32-29(17-22)37-12-10-36(5)11-13-37/h8-9,14-17,19-20H,6-7,10-13,18H2,1-5H3,(H,33,39)(H,35,40)
DM9QU5Y CS CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C
DM9QU5Y IK ULNXAWLQFZMIHX-UHFFFAOYSA-N
DM9QU5Y IU N-[(6-methyl-2-oxo-4-propyl-1H-pyridin-3-yl)methyl]-6-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1-propan-2-ylindazole-4-carboxamide
DM9QU5Y CA CAS 1346704-33-3
DM9QU5Y DE Discovery agent
DMKDLB7 ID DMKDLB7
DMKDLB7 DN GSK-3787
DMKDLB7 HS Investigative
DMKDLB7 SN GSK3787; 188591-46-0; GSK 3787; GSK-3787; 4-Chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]ethyl]benzamide; CHEMBL598608; 4-Chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide; 4-chloro-N-[2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylethyl]benzamide; Benzamide, 4-chloro-N-[2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]ethyl]-; Maybridge3_000547; AC1MCTIO; C15H12ClF3N2O3S; MLS006012025; SCHEMBL14968834; CTK8E8261; KS-00000XJC; AOB6285; QCR-146; EX-A704; DTXSID00384175; MolPort-002-892-395; HMS1432I19
DMKDLB7 DT Small molecular drug
DMKDLB7 PC 2800647
DMKDLB7 MW 392.8
DMKDLB7 FM C15H12ClF3N2O3S
DMKDLB7 IC InChI=1S/C15H12ClF3N2O3S/c16-12-4-1-10(2-5-12)14(22)20-7-8-25(23,24)13-6-3-11(9-21-13)15(17,18)19/h1-6,9H,7-8H2,(H,20,22)
DMKDLB7 CS C1=CC(=CC=C1C(=O)NCCS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)Cl
DMKDLB7 IK JFUIMTGOQCQTPF-UHFFFAOYSA-N
DMKDLB7 IU 4-chloro-N-[2-[5-(trifluoromethyl)pyridin-2-yl]sulfonylethyl]benzamide
DMKDLB7 CA CAS 188591-46-0
DMKDLB7 DE Discovery agent
DMQR7TZ ID DMQR7TZ
DMQR7TZ DN GSK-3beta inhibitor II
DMQR7TZ HS Investigative
DMQR7TZ SN GSK-3b inhibitor II
DMQR7TZ DT Small molecular drug
DMQR7TZ PC 6539732
DMQR7TZ MW 395.22
DMQR7TZ FM C14H10IN3OS
DMQR7TZ IC InChI=1S/C14H10IN3OS/c15-12-3-1-2-10(8-12)9-20-14-18-17-13(19-14)11-4-6-16-7-5-11/h1-8H,9H2
DMQR7TZ CS C1=CC(=CC(=C1)I)CSC2=NN=C(O2)C3=CC=NC=C3
DMQR7TZ IK ZRHRPGSSSVYBRG-UHFFFAOYSA-N
DMQR7TZ IU 2-[(3-iodophenyl)methylsulfanyl]-5-pyridin-4-yl-1,3,4-oxadiazole
DMQR7TZ CA CAS 478482-75-6
DMQR7TZ CB CHEBI:91342
DMQR7TZ DE Discovery agent
DM734QB ID DM734QB
DM734QB DN GSK-3beta inhibitor XI
DM734QB HS Investigative
DM734QB SN GSK-3b inhibitor XI
DM734QB DT Small molecular drug
DM734QB PC 10020713
DM734QB MW 349.3
DM734QB FM C18H15N5O3
DM734QB IC InChI=1S/C18H15N5O3/c24-8-2-7-23-10-12(11-3-1-4-21-16(11)23)14-15(18(26)22-17(14)25)13-9-19-5-6-20-13/h1,3-6,9-10,24H,2,7-8H2,(H,22,25,26)
DM734QB CS C1=CC2=C(N=C1)N(C=C2C3=C(C(=O)NC3=O)C4=NC=CN=C4)CCCO
DM734QB IK ZDEJZKULWCZIHL-UHFFFAOYSA-N
DM734QB IU 3-[1-(3-hydroxypropyl)pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-ylpyrrole-2,5-dione
DM734QB CA CAS 626604-39-5
DM734QB DE Discovery agent
DMHUMP9 ID DMHUMP9
DMHUMP9 DN GSK4716
DMHUMP9 HS Investigative
DMHUMP9 SN GSK 4716; GSK-4716
DMHUMP9 DT Small molecular drug
DMHUMP9 PC 5331325
DMHUMP9 MW 282.34
DMHUMP9 FM C17H18N2O2
DMHUMP9 IC InChI=1S/C17H18N2O2/c1-12(2)14-5-3-13(4-6-14)11-18-19-17(21)15-7-9-16(20)10-8-15/h3-12,20H,1-2H3,(H,19,21)/b18-11+
DMHUMP9 CS CC(C)C1=CC=C(C=C1)/C=N/NC(=O)C2=CC=C(C=C2)O
DMHUMP9 IK IKPPIUNQWSRCOZ-WOJGMQOQSA-N
DMHUMP9 IU 4-hydroxy-N-[(E)-(4-propan-2-ylphenyl)methylideneamino]benzamide
DMHUMP9 CA CAS 101574-65-6
DMHUMP9 CB CHEBI:80000
DMHUMP9 DE Discovery agent
DMMIWHV ID DMMIWHV
DMMIWHV DN GSK494581A
DMMIWHV HS Investigative
DMMIWHV SN GSK494581A; GTPL5562; SCHEMBL4940960; CHEMBL3746420
DMMIWHV DT Small molecular drug
DMMIWHV PC 11855860
DMMIWHV MW 514.6
DMMIWHV FM C27H28F2N2O4S
DMMIWHV IC InChI=1S/C27H28F2N2O4S/c1-18(35-2)20-6-11-26(25(29)16-20)30-12-14-31(15-13-30)27(32)24-17-22(36(3,33)34)9-10-23(24)19-4-7-21(28)8-5-19/h4-11,16-18H,12-15H2,1-3H3
DMMIWHV CS CC(C1=CC(=C(C=C1)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)S(=O)(=O)C)C4=CC=C(C=C4)F)F)OC
DMMIWHV IK JQXZHDOSMUZLML-UHFFFAOYSA-N
DMMIWHV IU [4-[2-fluoro-4-(1-methoxyethyl)phenyl]piperazin-1-yl]-[2-(4-fluorophenyl)-5-methylsulfonylphenyl]methanone
DMMIWHV DE Discovery agent
DMNGEAY ID DMNGEAY
DMNGEAY DN GSK-5182
DMNGEAY HS Investigative
DMNGEAY SN GSK5182; GSK-5182; GSK 5182; 877387-37-6; (Z)-4-(1-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-HYDROXY-2-PHENYLPENT-1-ENYL)PHENOL; TXF; 4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-5-hydroxy-2-phenylpent-1-en-1-yl]phenol; 2ewp; AC1OA9V8; GTPL8908; CHEMBL201013; SCHEMBL20534177; BDBM22435; AOB1629; EX-A2580; ZINC14978677; 4-hydroxytamoxifen (4-OHT) analog, 15; 4-[(z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-hydroxy-2-phenylpent-1-enyl]phenol; 4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol
DMNGEAY DT Small molecular drug
DMNGEAY PC 6852176
DMNGEAY MW 417.5
DMNGEAY FM C27H31NO3
DMNGEAY IC InChI=1S/C27H31NO3/c1-28(2)18-20-31-25-16-12-23(13-17-25)27(22-10-14-24(30)15-11-22)26(9-6-19-29)21-7-4-3-5-8-21/h3-5,7-8,10-17,29-30H,6,9,18-20H2,1-2H3/b27-26-
DMNGEAY CS CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCO)\\C2=CC=CC=C2)/C3=CC=C(C=C3)O
DMNGEAY IK ZVSFNBNLNLXEFQ-RQZHXJHFSA-N
DMNGEAY IU 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol
DMNGEAY DE Discovery agent
DM1I0AN ID DM1I0AN
DM1I0AN DN GSK575594A
DM1I0AN HS Investigative
DM1I0AN SN SCHEMBL4938360; GTPL5561; CHEMBL3747673; DAPKZHQMEQRNPY-UHFFFAOYSA-N; ZINC86012924; GSK575594A, > 3-fluoro-4-(4-{[4'-fluoro-4-(methylsulfonyl)-2-biphenylyl]carbonyl}-1-piperazinyl)aniline
DM1I0AN DT Small molecular drug
DM1I0AN PC 59822766
DM1I0AN MW 471.5
DM1I0AN FM C24H23F2N3O3S
DM1I0AN IC InChI=1S/C24H23F2N3O3S/c1-33(31,32)19-7-8-20(16-2-4-17(25)5-3-16)21(15-19)24(30)29-12-10-28(11-13-29)23-9-6-18(27)14-22(23)26/h2-9,14-15H,10-13,27H2,1H3
DM1I0AN CS CS(=O)(=O)C1=CC(=C(C=C1)C2=CC=C(C=C2)F)C(=O)N3CCN(CC3)C4=C(C=C(C=C4)N)F
DM1I0AN IK DAPKZHQMEQRNPY-UHFFFAOYSA-N
DM1I0AN IU [4-(4-amino-2-fluorophenyl)piperazin-1-yl]-[2-(4-fluorophenyl)-5-methylsulfonylphenyl]methanone
DM1I0AN DE Discovery agent
DMJXHU8 ID DMJXHU8
DMJXHU8 DN GSK579289A
DMJXHU8 HS Investigative
DMJXHU8 SN compound 25 [PMID 19237286]; GSK-579289A
DMJXHU8 DT Small molecular drug
DMJXHU8 PC 16051023
DMJXHU8 MW 511
DMJXHU8 FM C26H27ClN4O3S
DMJXHU8 IC InChI=1S/C26H27ClN4O3S/c1-16(19-5-3-4-6-20(19)27)33-23-14-24(35-25(23)26(28)32)31-15-29-21-8-7-18(13-22(21)31)34-17-9-11-30(2)12-10-17/h3-8,13-17H,9-12H2,1-2H3,(H2,28,32)/t16-/m1/s1
DMJXHU8 CS C[C@H](C1=CC=CC=C1Cl)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)OC5CCN(CC5)C)C(=O)N
DMJXHU8 IK GILNGUYOGYOZMP-MRXNPFEDSA-N
DMJXHU8 IU 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]thiophene-2-carboxamide
DMJXHU8 CA CAS 929095-23-8
DMJXHU8 DE Discovery agent
DMNRP2L ID DMNRP2L
DMNRP2L DN GSK-650394
DMNRP2L HS Investigative
DMNRP2L SN SGK-1 inhibitor (prostate cancer), GlaxoSmithKline
DMNRP2L CP GlaxoSmithKline plc
DMNRP2L DT Small molecular drug
DMNRP2L PC 25022668
DMNRP2L MW 382.5
DMNRP2L FM C25H22N2O2
DMNRP2L IC InChI=1S/C25H22N2O2/c28-25(29)20-11-10-18(12-21(20)17-8-4-5-9-17)23-15-27-24-22(23)13-19(14-26-24)16-6-2-1-3-7-16/h1-3,6-7,10-15,17H,4-5,8-9H2,(H,26,27)(H,28,29)
DMNRP2L CS C1CCC(C1)C2=C(C=CC(=C2)C3=CNC4=C3C=C(C=N4)C5=CC=CC=C5)C(=O)O
DMNRP2L IK WVSBGSNVCDAMCF-UHFFFAOYSA-N
DMNRP2L IU 2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid
DMNRP2L CA CAS 890842-28-1
DMNRP2L CB CHEBI:95066
DMNRP2L DE Prostate cancer
DMGW42V ID DMGW42V
DMGW42V DN GSK-8062
DMGW42V HS Investigative
DMGW42V SN UNII-37IS6K16XE; 37IS6K16XE; 6-(4-{[3-(2,6-Dichlorophenyl)-5-(1-Methylethyl)isoxazol-4-Yl]methoxy}phenyl)naphthalene-1-Carboxylic Acid; GSK-8062; TUOXXRMLFZBSTB-UHFFFAOYSA-N; 943549-47-1; SCHEMBL2115258; CHEMBL476302; Naphthoic acid-based analog, 1b; BDBM30329; GSK8062; 1-Naphthalenecarboxylic acid, 6-(4-((3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl)methoxy)phenyl)-; 6-[4-({[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1-naphthalenecarboxylic acid
DMGW42V DT Small molecular drug
DMGW42V PC 16214849
DMGW42V MW 532.4
DMGW42V FM C30H23Cl2NO4
DMGW42V IC InChI=1S/C30H23Cl2NO4/c1-17(2)29-24(28(33-37-29)27-25(31)7-4-8-26(27)32)16-36-21-12-9-18(10-13-21)19-11-14-22-20(15-19)5-3-6-23(22)30(34)35/h3-15,17H,16H2,1-2H3,(H,34,35)
DMGW42V CS CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC=C(C=C3)C4=CC5=C(C=C4)C(=CC=C5)C(=O)O
DMGW42V IK TUOXXRMLFZBSTB-UHFFFAOYSA-N
DMGW42V IU 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]naphthalene-1-carboxylic acid
DMGW42V CA CAS 943549-47-1
DMGW42V DE Discovery agent
DMT98PA ID DMT98PA
DMT98PA DN GSK-812397
DMT98PA HS Investigative
DMT98PA SN CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline
DMT98PA CP GlaxoSmithKline plc
DMT98PA DT Small molecular drug
DMT98PA PC 11718722
DMT98PA MW 420.6
DMT98PA FM C24H32N6O
DMT98PA IC InChI=1S/C24H32N6O/c1-27-12-14-29(15-13-27)23-10-4-9-22-26-19(21(17-31)30(22)23)16-28(2)20-8-3-6-18-7-5-11-25-24(18)20/h4-5,7,9-11,20,31H,3,6,8,12-17H2,1-2H3/t20-/m0/s1
DMT98PA CS CN1CCN(CC1)C2=CC=CC3=NC(=C(N32)CO)CN(C)[C@H]4CCCC5=C4N=CC=C5
DMT98PA IK QUDMHFVRKBVGBY-FQEVSTJZSA-N
DMT98PA IU [5-(4-methylpiperazin-1-yl)-2-[[methyl-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]imidazo[1,2-a]pyridin-3-yl]methanol
DMT98PA CA CAS 878197-98-9
DMT98PA DE Human immunodeficiency virus-1 infection
DMSOWPE ID DMSOWPE
DMSOWPE DN GSK-894281
DMSOWPE HS Investigative
DMSOWPE SN Ghrelin agonists (gastric motility disorder); SB-791016; Ghrelin agonists (gastric motility disorder), GlaxoSmithKline; Ghrelin agonists (gastric motility disorders), GSK
DMSOWPE CP GlaxoSmithKline plc
DMSOWPE DT Small molecular drug
DMSOWPE PC 24803511
DMSOWPE MW 473.6
DMSOWPE FM C24H28FN3O4S
DMSOWPE IC InChI=1S/C24H28FN3O4S/c1-15-13-28(14-16(2)26-15)18-6-10-24(31-4)22(11-18)27-33(29,30)19-7-8-20(21(25)12-19)23-9-5-17(3)32-23/h5-12,15-16,26-27H,13-14H2,1-4H3/t15-,16+
DMSOWPE CS C[C@@H]1CN(C[C@@H](N1)C)C2=CC(=C(C=C2)OC)NS(=O)(=O)C3=CC(=C(C=C3)C4=CC=C(O4)C)F
DMSOWPE IK OIWVNMRPHUCLHN-IYBDPMFKSA-N
DMSOWPE IU N-[5-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-methoxyphenyl]-3-fluoro-4-(5-methylfuran-2-yl)benzenesulfonamide
DMSOWPE CA CAS 874958-63-1
DMSOWPE DE Gastric motility disorder
DMIDQ8B ID DMIDQ8B
DMIDQ8B DN GSK931145
DMIDQ8B HS Investigative
DMIDQ8B SN GSK931145; GTPL4598
DMIDQ8B DT Small molecular drug
DMIDQ8B PC 73755100
DMIDQ8B MW 350.5
DMIDQ8B FM C23H30N2O
DMIDQ8B IC InChI=1S/C23H30N2O/c1-17-11-10-12-18(2)20(17)22(26)24-21(19-13-6-5-7-14-19)23(25(3)4)15-8-9-16-23/h5-7,10-14,21H,8-9,15-16H2,1-4H3,(H,24,26)/t21-/m0/s1
DMIDQ8B CS CC1=C(C(=CC=C1)C)C(=O)N[C@@H](C2=CC=CC=C2)C3(CCCC3)N(C)C
DMIDQ8B IK BMXRRRIDMAIEKX-NRFANRHFSA-N
DMIDQ8B IU N-[(S)-[1-(dimethylamino)cyclopentyl]-phenylmethyl]-2,6-dimethylbenzamide
DMIDQ8B DE Discovery agent
DMW9AN1 ID DMW9AN1
DMW9AN1 DN GSK-9578
DMW9AN1 HS Investigative
DMW9AN1 SN KYQNYMXQHLMADB-UHFFFAOYSA-N; GW 9578; GW9578; 247923-29-1; GW-9578; UNII-H32ABL87X4; H32ABL87X4; CHEMBL278590; SCHEMBL68327; GTPL2673; BDBM28799; CTK8E7867; GSK9578; DTXSID10179493; MolPort-009-019-367; ZINC14115100; Propanoic acid, 2-((4-(2-((((2,4-difluorophenyl)amino)carbonyl)heptylamino)ethyl)phenyl)thio)-2-methyl-; RT-013144; J-015674; 289722-11-8; 2-{[4-(2-{[(2,4-difluorophenyl)carbamoyl](heptyl)amino}ethyl)phenyl]sulfanyl}-2-methylpropanoic acid; 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic
DMW9AN1 DT Small molecular drug
DMW9AN1 PC 9870304
DMW9AN1 MW 492.6
DMW9AN1 FM C26H34F2N2O3S
DMW9AN1 IC InChI=1S/C26H34F2N2O3S/c1-4-5-6-7-8-16-30(25(33)29-23-14-11-20(27)18-22(23)28)17-15-19-9-12-21(13-10-19)34-26(2,3)24(31)32/h9-14,18H,4-8,15-17H2,1-3H3,(H,29,33)(H,31,32)
DMW9AN1 CS CCCCCCCN(CCC1=CC=C(C=C1)SC(C)(C)C(=O)O)C(=O)NC2=C(C=C(C=C2)F)F
DMW9AN1 IK KYQNYMXQHLMADB-UHFFFAOYSA-N
DMW9AN1 IU 2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenyl]sulfanyl-2-methylpropanoic acid
DMW9AN1 CA CAS 247923-29-1
DMW9AN1 DE Discovery agent
DMNOU59 ID DMNOU59
DMNOU59 DN GSK'963
DMNOU59 HS Investigative
DMNOU59 CP GlaxoSmithKline
DMNOU59 DT Small molecular drug
DMNOU59 DE Myeloid leukaemia
DM4WS3R ID DM4WS3R
DM4WS3R DN GSK-9772
DM4WS3R HS Investigative
DM4WS3R SN GSK-9772; CHEMBL493241; 928035-84-1; GSK9772; 4-[[Butyl[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]amino]methyl]-2,6-dichlorophenol; 4-[(Butyl{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}amino)methyl]-2,6-dichlorophenol; SCHEMBL4629551; GTPL8693; GSK 9772; BDBM50252940; ZINC34946707; KB-71932
DM4WS3R DT Small molecular drug
DM4WS3R PC 16049480
DM4WS3R MW 490.3
DM4WS3R FM C20H19Cl2F6NO2
DM4WS3R IC InChI=1S/C20H19Cl2F6NO2/c1-2-3-8-29(11-12-9-15(21)17(30)16(22)10-12)14-6-4-13(5-7-14)18(31,19(23,24)25)20(26,27)28/h4-7,9-10,30-31H,2-3,8,11H2,1H3
DM4WS3R CS CCCCN(CC1=CC(=C(C(=C1)Cl)O)Cl)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O
DM4WS3R IK TYYLMKBOWXDDCT-UHFFFAOYSA-N
DM4WS3R IU 4-[[N-butyl-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)anilino]methyl]-2,6-dichlorophenol
DM4WS3R DE Discovery agent
DMY3SEN ID DMY3SEN
DMY3SEN DN GSK-J1
DMY3SEN HS Investigative
DMY3SEN SN GSK-J1; GSK J1; 1373422-53-7; 3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid; 3-((6-(4,5-Dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid; 3-[[2-Pyridin-2-Yl-6-(1,2,4,5-Tetrahydro-3-Benzazepin-3-Yl)pyrimidin-4-Yl]amino]propanoic Acid; GSKJ1; GSKJ1; GSK-J1; MLS006010249; GTPL7027; SCHEMBL10157115; CHEMBL3188597; BDBM60875; EX-A571; AOB3940; CHEBI:131152; MolPort-023-278-906; EX-A1744; BCP08262; ZINC95616592; s7581; 2442AH; AKOS024458240
DMY3SEN DT Small molecular drug
DMY3SEN PC 56963315
DMY3SEN MW 389.4
DMY3SEN FM C22H23N5O2
DMY3SEN IC InChI=1S/C22H23N5O2/c28-21(29)8-12-24-19-15-20(26-22(25-19)18-7-3-4-11-23-18)27-13-9-16-5-1-2-6-17(16)10-14-27/h1-7,11,15H,8-10,12-14H2,(H,28,29)(H,24,25,26)
DMY3SEN CS C1CN(CCC2=CC=CC=C21)C3=NC(=NC(=C3)NCCC(=O)O)C4=CC=CC=N4
DMY3SEN IK AVZCPICCWKMZDT-UHFFFAOYSA-N
DMY3SEN IU 3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoic acid
DMY3SEN CB CHEBI:131152
DMY3SEN DE Discovery agent
DMHJU7A ID DMHJU7A
DMHJU7A DN GSK-LSD1
DMHJU7A HS Investigative
DMHJU7A SN GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, > NCGC00356416-07; US9487512, 3
DMHJU7A DT Small molecular drug
DMHJU7A PC 71522234
DMHJU7A MW 216.32
DMHJU7A FM C14H20N2
DMHJU7A IC InChI=1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1
DMHJU7A CS C1CNCCC1N[C@@H]2C[C@H]2C3=CC=CC=C3
DMHJU7A IK BASFYRLYJAZPPL-UONOGXRCSA-N
DMHJU7A IU N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine
DMHJU7A DE Discovery agent
DMNMITH ID DMNMITH
DMNMITH DN GT-1282
DMNMITH HS Investigative
DMNMITH SN DDVVRHNNOPQPGB-UHFFFAOYSA-N; NIBR-1282; CHEMBL255858; SCHEMBL619811; BDBM50234723; SB16769; (2,4-dimethyl-1-oxy-pyridin-3-yl)-[4''-methyl-4-(phenyl-pyridin-3-yl-amino)-[1,4'']bipiperidinyl-1''-yl]-methanone; NIBR-1282
DMNMITH DT Small molecular drug
DMNMITH PC 10278617
DMNMITH MW 499.6
DMNMITH FM C30H37N5O2
DMNMITH IC InChI=1S/C30H37N5O2/c1-23-11-19-34(37)24(2)28(23)29(36)32-20-14-30(3,15-21-32)33-17-12-26(13-18-33)35(25-8-5-4-6-9-25)27-10-7-16-31-22-27/h4-11,16,19,22,26H,12-15,17-18,20-21H2,1-3H3
DMNMITH CS CC1=C(C(=[N+](C=C1)[O-])C)C(=O)N2CCC(CC2)(C)N3CCC(CC3)N(C4=CC=CC=C4)C5=CN=CC=C5
DMNMITH IK DDVVRHNNOPQPGB-UHFFFAOYSA-N
DMNMITH IU (2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)-[4-methyl-4-[4-(N-pyridin-3-ylanilino)piperidin-1-yl]piperidin-1-yl]methanone
DMNMITH DE Autoimmune diabetes
DMH3PDG ID DMH3PDG
DMH3PDG DN GT2394
DMH3PDG HS Investigative
DMH3PDG SN GT2394; SCHEMBL649448; GTPL1261; gt-2394; Cyclohexylmethyl N-[(1R,2R)-2-(3H-imidazol-4-yl)cyclopropyl]carbamate
DMH3PDG DT Small molecular drug
DMH3PDG PC 9860053
DMH3PDG MW 263.34
DMH3PDG FM C14H21N3O2
DMH3PDG IC InChI=1S/C14H21N3O2/c18-14(19-8-10-4-2-1-3-5-10)17-12-6-11(12)13-7-15-9-16-13/h7,9-12H,1-6,8H2,(H,15,16)(H,17,18)/t11-,12-/m1/s1
DMH3PDG CS C1CCC(CC1)COC(=O)N[C@@H]2C[C@H]2C3=CN=CN3
DMH3PDG IK SLQAVEDMASVHTL-VXGBXAGGSA-N
DMH3PDG IU cyclohexylmethyl N-[(1R,2R)-2-(1H-imidazol-5-yl)cyclopropyl]carbamate
DMH3PDG DE Discovery agent
DMW23Y9 ID DMW23Y9
DMW23Y9 DN GTP-14564
DMW23Y9 HS Investigative
DMW23Y9 SN GTP-14564; GTP 14564; 34823-86-4; 3-Phenyl-1H-benzofuro[3,2-c]pyrazole; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden; CHEMBL406375; 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole; 3-Phenyl-1H-benzofuro(3,2-c)pyrazole; AC1MPHAI; SCHEMBL2550165; GTPL5982; CHEBI:92300; DTXSID10188363; MolPort-002-816-012; HMS3268J15; HMS3229E17; ZINC5387628; HSCI1_000176; BDBM50375646; AKOS024456938; MCULE-3563628731; CCG-206757; NCGC00159539-01; AI-204/33265070; J-019773; BRD-K16664969-001-02-5; BRD-K16664969-001-01-7
DMW23Y9 DT Small molecular drug
DMW23Y9 PC 3385203
DMW23Y9 MW 234.25
DMW23Y9 FM C15H10N2O
DMW23Y9 IC InChI=1S/C15H10N2O/c1-2-6-10(7-3-1)13-15-14(17-16-13)11-8-4-5-9-12(11)18-15/h1-9H,(H,16,17)
DMW23Y9 CS C1=CC=C(C=C1)C2=NNC3=C2OC4=CC=CC=C43
DMW23Y9 IK DZQLVVLATXPWBK-UHFFFAOYSA-N
DMW23Y9 IU 3-phenyl-1H-[1]benzofuro[3,2-c]pyrazole
DMW23Y9 CA CAS 34823-86-4
DMW23Y9 CB CHEBI:92300
DMW23Y9 DE Discovery agent
DMJUXKY ID DMJUXKY
DMJUXKY DN GTPgammaS
DMJUXKY HS Investigative
DMJUXKY DT Small molecular drug
DMJUXKY PC 135476260
DMJUXKY MW 539.25
DMJUXKY FM C10H16N5O13P3S
DMJUXKY IC InChI=1S/C10H16N5O13P3S/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(26-9)1-25-29(19,20)27-30(21,22)28-31(23,24)32/h2-3,5-6,9,16-17H,1H2,(H,19,20)(H,21,22)(H2,23,24,32)(H3,11,13,14,18)
DMJUXKY CS C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N=C(NC2=O)N
DMJUXKY IK XOFLBQFBSOEHOG-UHFFFAOYSA-N
DMJUXKY IU [[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphinothioyl hydrogen phosphate
DMJUXKY CA CAS 108964-33-6
DMJUXKY DE Discovery agent
DMZQETV ID DMZQETV
DMZQETV DN GTPL8662
DMZQETV HS Investigative
DMZQETV SN 43574
DMZQETV DT Small molecular drug
DMZQETV PC 54596718
DMZQETV MW 322.5
DMZQETV FM C21H32F2
DMZQETV IC InChI=1S/C21H32F2/c1-13-4-7-17-16-6-5-14-12-15(22)8-10-20(14,2)18(16)9-11-21(17,3)19(13)23/h5,13,15-19H,4,6-12H2,1-3H3/t13-,15+,16?,17?,18?,19+,20+,21+/m1/s1
DMZQETV CS C[C@@H]1CCC2C3CC=C4C[C@H](CC[C@@]4(C3CC[C@@]2([C@H]1F)C)C)F
DMZQETV IK UEILQXVVJHZGQK-KYFJQHFKSA-N
DMZQETV IU (1S,2R,8S,10aR,12aS)-1,8-difluoro-2,10a,12a-trimethyl-1,2,3,4,4a,4b,5,7,8,9,10,10b,11,12-tetradecahydrochrysene
DMZQETV DE Discovery agent
DM315VL ID DM315VL
DM315VL DN GTx-027
DM315VL HS Investigative
DM315VL CP GTx Inc
DM315VL DE Solid tumour/cancer
DMEIMVW ID DMEIMVW
DMEIMVW DN GTx-822
DMEIMVW HS Investigative
DMEIMVW SN Selective estrogen receptor beta modulator (ocular disease), GTx
DMEIMVW CP GTx Inc
DMEIMVW DE Ocular disease
DMP9OGC ID DMP9OGC
DMP9OGC DN GTx-878
DMP9OGC HS Investigative
DMP9OGC SN Estrogen receptor beta agonist (prostatitis/BPH), GTx
DMP9OGC CP GTx Inc
DMP9OGC DE Prostate hyperplasia
DMGYMW4 ID DMGYMW4
DMGYMW4 DN Guajazulen
DMGYMW4 HS Investigative
DMGYMW4 SN AZ-8 beris; Azulen-beris; Azulol; Azulon; Azunol; Azunol (TN); Cuteazul; Eucazulen; Guaiazulene, 99%; Guajazulene; Guiazulene; Gurjunazulen; Kessazulen; Purazulen; S-Guaiazulene; Silazulon; Uroazulen; Vaumigan; Vetivazulen; guaiazulen; guaiazulene; hepatoprotectant; 1,4-Dimethyl-7-(1-methylethyl)azulene; 1,4-Dimethyl-7-isopropylazulene; 1,4-dimethyl-7-(propan-2-yl)azulene; 3,8-Dimethyl-5-(2-propyl)azulene; 489-84-9; 7-Isopropyl-1,4-dimethylazulene; Azulene, 1,4-dimethyl-7-(1-methylethyl)-; NSC 4714; UNII-2OZ1K9JKQC
DMGYMW4 PC 3515
DMGYMW4 MW 198.3
DMGYMW4 FM C15H18
DMGYMW4 IC FWKQNCXZGNBPFD-UHFFFAOYSA-N
DMGYMW4 CS CC1=C2C=CC(=C2C=C(C=C1)C(C)C)C
DMGYMW4 IK 1S/C15H18/c1-10(2)13-7-5-11(3)14-8-6-12(4)15(14)9-13/h5-10H,1-4H3
DMGYMW4 IU 1,4-dimethyl-7-propan-2-ylazulene
DMGYMW4 CA CAS 489-84-9
DMGYMW4 CB CHEBI:5550
DMGYMW4 DE Allergy
DM4GO8H ID DM4GO8H
DM4GO8H DN Guanidine
DM4GO8H HS Investigative
DM4GO8H SN (NH2)2C=NH; 4-03-00-00148 (Beilstein Handbook Reference); AC1L1G4E; AC1Q50DT; AC1Q50DU; Aminoformamidine; Aminomethanamidine; Carbamamidine; Carbamidine; GAI; Gu; Guanidin; Guanidine, Hydrochloride; Guanidine, free base;BRN 0506044; H2N-C(=NH)-NH2; HSDB 7603; Imidourea; Iminourea; JU58VJ6Y3B; NCIOpen2_007946; UNII-JU58VJ6Y3B; ZRALSGWEFCBTJO-UHFFFAOYSA-N; guanidine
DM4GO8H DT Small molecular drug
DM4GO8H PC 3520
DM4GO8H MW 59.072
DM4GO8H FM CH5N3
DM4GO8H IC InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)
DM4GO8H CS C(=N)(N)N
DM4GO8H IK ZRALSGWEFCBTJO-UHFFFAOYSA-N
DM4GO8H IU guanidine
DM4GO8H CA CAS 113-00-8
DM4GO8H CB CHEBI:42820
DM4GO8H DE Myasthenic syndrome
DMCN56S ID DMCN56S
DMCN56S DN GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
DMCN56S HS Investigative
DMCN56S DT Small molecular drug
DMCN56S PC 135464486
DMCN56S MW 389.26
DMCN56S FM C12H16N5O8P
DMCN56S IC InChI=1S/C12H16N5O8P/c13-12-15-9-6(10(19)16-12)14-3-17(9)11-8-7(4(1-18)23-11)24-5(25-8)2-26(20,21)22/h3-5,7-8,11,18H,1-2H2,(H2,20,21,22)(H3,13,15,16,19)/t4-,5-,7-,8-,11-/m1/s1
DMCN56S CS C1=NC2=C(N1[C@H]3[C@H]4[C@@H]([C@H](O3)CO)O[C@H](O4)CP(=O)(O)O)N=C(NC2=O)N
DMCN56S IK HYAPEMYRVFIHDJ-QWEIRQIHSA-N
DMCN56S IU [(2R,3aR,4R,6R,6aR)-4-(2-amino-6-oxo-1H-purin-9-yl)-6-(hydroxymethyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]methylphosphonic acid
DMCN56S DE Discovery agent
DMRITFU ID DMRITFU
DMRITFU DN GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE
DMRITFU HS Investigative
DMRITFU DT Small molecular drug
DMRITFU PC 135464488
DMRITFU MW 375.23
DMRITFU FM C11H14N5O8P
DMRITFU IC InChI=1S/C11H14N5O8P/c12-10-14-7-4(8(18)15-10)13-2-16(7)9-6-5(3(1-17)22-9)23-11(24-6)25(19,20)21/h2-3,5-6,9,11,17H,1H2,(H2,19,20,21)(H3,12,14,15,18)/t3-,5-,6-,9-,11+/m1/s1
DMRITFU CS C1=NC2=C(N1[C@H]3[C@H]4[C@@H]([C@H](O3)CO)O[C@@H](O4)P(=O)(O)O)N=C(NC2=O)N
DMRITFU IK GKAPYWCOOQBBHV-KXSYMAMXSA-N
DMRITFU IU [(2S,3aR,4R,6R,6aR)-4-(2-amino-6-oxo-1H-purin-9-yl)-6-(hydroxymethyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-2-yl]phosphonic acid
DMRITFU DE Discovery agent
DMG2ZFV ID DMG2ZFV
DMG2ZFV DN Guanosine-5',3'-Tetraphosphate
DMG2ZFV HS Investigative
DMG2ZFV DT Small molecular drug
DMG2ZFV PC 135398637
DMG2ZFV MW 603.16
DMG2ZFV FM C10H17N5O17P4
DMG2ZFV IC InChI=1S/C10H17N5O17P4/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6(30-36(26,27)32-34(21,22)23)3(29-9)1-28-35(24,25)31-33(18,19)20/h2-3,5-6,9,16H,1H2,(H,24,25)(H,26,27)(H2,18,19,20)(H2,21,22,23)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1
DMG2ZFV CS C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)OP(=O)(O)OP(=O)(O)O)O)N=C(NC2=O)N
DMG2ZFV IK BUFLLCUFNHESEH-UUOKFMHZSA-N
DMG2ZFV IU [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-[[hydroxy(phosphonooxy)phosphoryl]oxymethyl]oxolan-3-yl] phosphono hydrogen phosphate
DMG2ZFV CA CAS 32452-17-8
DMG2ZFV CB CHEBI:17633
DMG2ZFV DE Discovery agent
DM0MUKQ ID DM0MUKQ
DM0MUKQ DN Guanosine-5'-Diphosphate
DM0MUKQ HS Investigative
DM0MUKQ DT Small molecular drug
DM0MUKQ PC 135398619
DM0MUKQ MW 443.2
DM0MUKQ FM C10H15N5O11P2
DM0MUKQ IC InChI=1S/C10H15N5O11P2/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DM0MUKQ CS C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N
DM0MUKQ IK QGWNDRXFNXRZMB-UUOKFMHZSA-N
DM0MUKQ IU [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM0MUKQ CA CAS 146-91-8
DM0MUKQ CB CHEBI:17552
DM0MUKQ DE Discovery agent
DM3SLZK ID DM3SLZK
DM3SLZK DN Guanosine-5'-Monophosphate
DM3SLZK HS Investigative
DM3SLZK SN 5'-Guanylic acid; guanylic acid; guanosine-5'-monophosphate; guanosine monophosphate; Guanosine 5'-monophosphate; 85-32-5; 5'-Gmp; Guanosine 5'-phosphate; Guanidine monophosphate; guanylate; CHEBI:17345; guanosine-phosphate; guanosine-monophosphate; Guanosine 5'-monophosphoric acid; AI3-28539; guanosine-5'-phosphate; UNII-16597955EP; EINECS 201-598-8; Guanosine 5'-phosphoric acid; CHEMBL283807; GMP; ((2R,3S,4R,5R)-5-(2-Amino-6-oxo-1H-purin-9(6H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; E 626; 16597955EP
DM3SLZK DT Small molecular drug
DM3SLZK PC 135398631
DM3SLZK MW 363.22
DM3SLZK FM C10H14N5O8P
DM3SLZK IC InChI=1S/C10H14N5O8P/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,16-17H,1H2,(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DM3SLZK CS C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N=C(NC2=O)N
DM3SLZK IK RQFCJASXJCIDSX-UUOKFMHZSA-N
DM3SLZK IU [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
DM3SLZK CA CAS 85-32-5
DM3SLZK CB CHEBI:17345
DM3SLZK DE Discovery agent
DMV2OJX ID DMV2OJX
DMV2OJX DN Guanosine-5'-Triphosphate
DMV2OJX HS Investigative
DMV2OJX DT Small molecular drug
DMV2OJX PC 135398633
DMV2OJX MW 523.179
DMV2OJX FM C10H16N5O14P3
DMV2OJX IC InChI=1S/C10H16N5O14P3/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(27-9)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1
DMV2OJX CS C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N
DMV2OJX IK XKMLYUALXHKNFT-UUOKFMHZSA-N
DMV2OJX IU [[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMV2OJX CA CAS 86-01-1
DMV2OJX CB CHEBI:15996
DMV2OJX DE Discovery agent
DMOUQLB ID DMOUQLB
DMOUQLB DN guanylpirenzepine
DMOUQLB HS Investigative
DMOUQLB SN 4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazine-1-carboximidamide dihydrochloride
DMOUQLB DT Small molecular drug
DMOUQLB PC 129786
DMOUQLB MW 379.4
DMOUQLB FM C19H21N7O2
DMOUQLB IC InChI=1S/C19H21N7O2/c20-19(21)25-10-8-24(9-11-25)12-16(27)26-15-6-2-1-4-13(15)18(28)23-14-5-3-7-22-17(14)26/h1-7H,8-12H2,(H3,20,21)(H,23,28)
DMOUQLB CS C1CN(CCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4)C(=N)N
DMOUQLB IK YGBQWISDDSXPRF-UHFFFAOYSA-N
DMOUQLB IU 4-[2-oxo-2-(6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-11-yl)ethyl]piperazine-1-carboximidamide
DMOUQLB CA CAS 122858-76-8
DMOUQLB DE Discovery agent
DM89KNT ID DM89KNT
DM89KNT DN Gue1654
DM89KNT HS Investigative
DM89KNT SN Gue 1654
DM89KNT DT Small molecular drug
DM89KNT PC 5066134
DM89KNT MW 447.6
DM89KNT FM C23H17N3OS3
DM89KNT IC InChI=1S/C23H17N3OS3/c1-28-23-25-17-13-12-16-19(20(17)30-23)29-22(24-16)26-21(27)18(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-13,18H,1H3,(H,24,26,27)
DM89KNT CS CSC1=NC2=C(S1)C3=C(C=C2)N=C(S3)NC(=O)C(C4=CC=CC=C4)C5=CC=CC=C5
DM89KNT IK UFOBDFMYJABXGK-UHFFFAOYSA-N
DM89KNT IU N-(2-methylsulfanyl-[1,3]thiazolo[4,5-g][1,3]benzothiazol-7-yl)-2,2-diphenylacetamide
DM89KNT DE Discovery agent
DMBXGVH ID DMBXGVH
DMBXGVH DN Guttiferone I
DMBXGVH HS Investigative
DMBXGVH SN Guttiferone I
DMBXGVH DT Small molecular drug
DMBXGVH PC 44584005
DMBXGVH MW 670.9
DMBXGVH FM C43H58O6
DMBXGVH IC InChI=1S/C43H58O6/c1-27(2)13-11-15-31(9)16-18-33-26-42(23-20-29(5)6)38(47)36(37(46)32-17-19-34(44)35(45)25-32)39(48)43(40(42)49,24-21-30(7)8)41(33,10)22-12-14-28(3)4/h13-14,16-17,19-21,25,33,44-46H,11-12,15,18,22-24,26H2,1-10H3/b31-16+,37-36+/t33-,41+,42-,43+/m0/s1
DMBXGVH CS CC(=CCC/C(=C/C[C@H]1C[C@]2(C(=O)/C(=C(/C3=CC(=C(C=C3)O)O)\\O)/C(=O)[C@](C2=O)([C@]1(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)/C)C
DMBXGVH IK HIGOXQQRSUDJCL-KJLWUZBSSA-N
DMBXGVH IU (1R,3E,5S,6R,7S)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-methyl-1,5-bis(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)bicyclo[3.3.1]nonane-2,4,9-trione
DMBXGVH DE Discovery agent
DM78KYC ID DM78KYC
DM78KYC DN GW 627368
DM78KYC HS Investigative
DM78KYC SN saccharic acid; GW627368; GW-627368
DM78KYC DT Small molecular drug
DM78KYC PC 5312130
DM78KYC MW 544.6
DM78KYC FM C30H28N2O6S
DM78KYC IC InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)
DM78KYC CS CCOC1=C2CN(C(=O)C2=C(C3=CC=CC=C31)OCC)C4=CC=C(C=C4)CC(=O)NS(=O)(=O)C5=CC=CC=C5
DM78KYC IK XREWXJVMYAXCJV-UHFFFAOYSA-N
DM78KYC IU N-(benzenesulfonyl)-2-[4-(4,9-diethoxy-3-oxo-1H-benzo[f]isoindol-2-yl)phenyl]acetamide
DM78KYC CA CAS 439288-66-1
DM78KYC DE Discovery agent
DM3D2R4 ID DM3D2R4
DM3D2R4 DN GW0072
DM3D2R4 HS Investigative
DM3D2R4 SN GW 0072
DM3D2R4 DT Small molecular drug
DM3D2R4 PC 449532
DM3D2R4 MW 614.8
DM3D2R4 FM C37H46N2O4S
DM3D2R4 IC InChI=1S/C37H46N2O4S/c1-2-3-4-5-12-20-35-39(25-14-13-15-29-21-23-32(24-22-29)37(42)43)36(41)33(44-35)26-34(40)38(27-30-16-8-6-9-17-30)28-31-18-10-7-11-19-31/h6-11,16-19,21-24,33,35H,2-5,12-15,20,25-28H2,1H3,(H,42,43)/t33-,35-/m0/s1
DM3D2R4 CS CCCCCCC[C@H]1N(C(=O)[C@@H](S1)CC(=O)N(CC2=CC=CC=C2)CC3=CC=CC=C3)CCCCC4=CC=C(C=C4)C(=O)O
DM3D2R4 IK GHJJBEKMPCOSRH-LRHLLKFHSA-N
DM3D2R4 IU 4-[4-[(2S,5S)-5-[2-(dibenzylamino)-2-oxoethyl]-2-heptyl-4-oxo-1,3-thiazolidin-3-yl]butyl]benzoic acid
DM3D2R4 DE Discovery agent
DMGKEO5 ID DMGKEO5
DMGKEO5 DN GW0742X
DMGKEO5 HS Investigative
DMGKEO5 SN GW0742; GW-0742X
DMGKEO5 DT Small molecular drug
DMGKEO5 PC 9934458
DMGKEO5 MW 471.5
DMGKEO5 FM C21H17F4NO3S2
DMGKEO5 IC InChI=1S/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)
DMGKEO5 CS CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC(=C(C=C3)C(F)(F)F)F)C)OCC(=O)O
DMGKEO5 IK HWVNEWGKWRGSRK-UHFFFAOYSA-N
DMGKEO5 IU 2-[4-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid
DMGKEO5 CA CAS 317318-84-6
DMGKEO5 CB CHEBI:79991
DMGKEO5 DE Discovery agent
DM3DXM0 ID DM3DXM0
DM3DXM0 DN GW1100
DM3DXM0 HS Investigative
DM3DXM0 SN GW 1100; GW-1100
DM3DXM0 DT Small molecular drug
DM3DXM0 PC 11692123
DM3DXM0 MW 520.6
DM3DXM0 FM C27H25FN4O4S
DM3DXM0 IC InChI=1S/C27H25FN4O4S/c1-3-35-25(34)20-7-11-23(12-8-20)32-16-21(13-19-14-29-26(30-15-19)36-4-2)24(33)31-27(32)37-17-18-5-9-22(28)10-6-18/h5-12,14-16H,3-4,13,17H2,1-2H3
DM3DXM0 CS CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC
DM3DXM0 IK PTPNCCWOTBBVJR-UHFFFAOYSA-N
DM3DXM0 IU ethyl 4-[5-[(2-ethoxypyrimidin-5-yl)methyl]-2-[(4-fluorophenyl)methylsulfanyl]-4-oxopyrimidin-1-yl]benzoate
DM3DXM0 CA CAS 306974-70-9
DM3DXM0 DE Discovery agent
DMOV980 ID DMOV980
DMOV980 DN GW1929
DMOV980 HS Investigative
DMOV980 SN GW 1929; GW-1929
DMOV980 DT Small molecular drug
DMOV980 PC 6518171
DMOV980 MW 495.6
DMOV980 FM C30H29N3O4
DMOV980 IC InChI=1S/C30H29N3O4/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23/h2-18,27,32H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
DMOV980 CS CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4
DMOV980 IK QTQMRBZOBKYXCG-MHZLTWQESA-N
DMOV980 IU (2S)-2-(2-benzoylanilino)-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]propanoic acid
DMOV980 CA CAS 196808-24-9
DMOV980 CB CHEBI:79992
DMOV980 DE Discovery agent
DMM8V9E ID DMM8V9E
DMM8V9E DN GW-2331
DMM8V9E HS Investigative
DMM8V9E SN 190844-95-2; PPAR ligand, Glaxo Wellcome
DMM8V9E DT Small molecular drug
DMM8V9E PC 657048
DMM8V9E MW 490.6
DMM8V9E FM C27H36F2N2O4
DMM8V9E IC InChI=1S/C27H36F2N2O4/c1-4-6-7-8-9-17-31(26(34)30-24-15-12-21(28)19-23(24)29)18-16-20-10-13-22(14-11-20)35-27(3,5-2)25(32)33/h10-15,19H,4-9,16-18H2,1-3H3,(H,30,34)(H,32,33)/t27-/m0/s1
DMM8V9E CS CCCCCCCN(CCC1=CC=C(C=C1)O[C@@](C)(CC)C(=O)O)C(=O)NC2=C(C=C(C=C2)F)F
DMM8V9E IK VGSJXSLGVQINOL-MHZLTWQESA-N
DMM8V9E IU (2S)-2-[4-[2-[(2,4-difluorophenyl)carbamoyl-heptylamino]ethyl]phenoxy]-2-methylbutanoic acid
DMM8V9E DE Discovery agent
DMEAIQC ID DMEAIQC
DMEAIQC DN GW2433
DMEAIQC HS Investigative
DMEAIQC SN GW 2433; GW-2433
DMEAIQC DT Small molecular drug
DMEAIQC PC 1517
DMEAIQC MW 581.9
DMEAIQC FM C28H28Cl3FN2O4
DMEAIQC IC InChI=1S/C28H28Cl3FN2O4/c1-28(2,26(35)36)38-19-13-11-18(12-14-19)6-5-16-34(17-15-20-21(29)7-3-9-23(20)32)27(37)33-24-10-4-8-22(30)25(24)31/h3-4,7-14H,5-6,15-17H2,1-2H3,(H,33,37)(H,35,36)
DMEAIQC CS CC(C)(C(=O)O)OC1=CC=C(C=C1)CCCN(CCC2=C(C=CC=C2Cl)F)C(=O)NC3=C(C(=CC=C3)Cl)Cl
DMEAIQC IK YMWJDWJXIXITMD-UHFFFAOYSA-N
DMEAIQC IU 2-[4-[3-[2-(2-chloro-6-fluorophenyl)ethyl-[(2,3-dichlorophenyl)carbamoyl]amino]propyl]phenoxy]-2-methylpropanoic acid
DMEAIQC DE Discovery agent
DMTW9GM ID DMTW9GM
DMTW9GM DN GW-2580
DMTW9GM HS Investigative
DMTW9GM SN GW2580; cFMS receptor tyrosine kinase inhibitor; GW632580X
DMTW9GM DT Small molecular drug
DMTW9GM PC 11617559
DMTW9GM MW 366.4
DMTW9GM FM C20H22N4O3
DMTW9GM IC InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)
DMTW9GM CS COC1=CC=C(C=C1)COC2=C(C=C(C=C2)CC3=CN=C(N=C3N)N)OC
DMTW9GM IK MYQAUKPBNJWPIE-UHFFFAOYSA-N
DMTW9GM IU 5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine
DMTW9GM CA CAS 870483-87-7
DMTW9GM DE Discovery agent
DMG60ET ID DMG60ET
DMG60ET DN GW-3965
DMG60ET HS Investigative
DMG60ET SN GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A
DMG60ET DT Small molecular drug
DMG60ET PC 447905
DMG60ET MW 582
DMG60ET FM C33H31ClF3NO3
DMG60ET IC InChI=1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40)
DMG60ET CS C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4
DMG60ET IK NAXSRXHZFIBFMI-UHFFFAOYSA-N
DMG60ET IU 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid
DMG60ET CA CAS 405911-09-3
DMG60ET CB CHEBI:79995
DMG60ET DE Major depressive disorder
DMFRP7H ID DMFRP7H
DMFRP7H DN GW4065
DMFRP7H HS Investigative
DMFRP7H DE Discovery agent
DMIHOYF ID DMIHOYF
DMIHOYF DN GW-5074
DMIHOYF HS Investigative
DMIHOYF SN gw5074; 220904-83-6; GW 5074; Raf1 Kinase Inhibitor I; UNII-B7W8RS1GG2; B7W8RS1GG2; CHEMBL72365; 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone; 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one; (3Z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one; (Z)-3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodoindolin-2-one; SR-01000075897; STO521; 3-(3,5-Dibromo-4-hydroxybenzyliden)-5-iodo-1,3-dihydroindol-2-one; Tocris-1381
DMIHOYF DT Small molecular drug
DMIHOYF PC 5924208
DMIHOYF MW 520.94
DMIHOYF FM C15H8Br2INO2
DMIHOYF IC InChI=1S/C15H8Br2INO2/c16-11-4-7(5-12(17)14(11)20)3-10-9-6-8(18)1-2-13(9)19-15(10)21/h1-6,20H,(H,19,21)/b10-3-
DMIHOYF CS C1=CC2=C(C=C1I)/C(=C/C3=CC(=C(C(=C3)Br)O)Br)/C(=O)N2
DMIHOYF IK LMXYVLFTZRPNRV-KMKOMSMNSA-N
DMIHOYF IU (3Z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
DMIHOYF CA CAS 1233748-60-1
DMIHOYF DE Discovery agent
DMGRKT4 ID DMGRKT4
DMGRKT4 DN GW-559768X
DMGRKT4 HS Investigative
DMGRKT4 SN GW-569998X; GW-578257A; GW-585550A; RET tyrosine kinase inhibitors (cancer); RET tyrosine kinase inhibitors (cancer), GlaxoSmithKline
DMGRKT4 CP GlaxoSmithKline plc
DMGRKT4 DE Solid tumour/cancer
DMCOYF9 ID DMCOYF9
DMCOYF9 DN GW-5823
DMCOYF9 HS Investigative
DMCOYF9 SN GW5823; GW 5823
DMCOYF9 DT Small molecular drug
DMCOYF9 PC 5311148
DMCOYF9 MW 587.7
DMCOYF9 FM C35H33N5O4
DMCOYF9 IC InChI=1S/C35H33N5O4/c1-23(2)39(25-17-19-26(44-3)20-18-25)33(41)22-38-31-15-9-10-16-32(31)40(24-11-5-4-6-12-24)35(43)28(34(38)42)21-30-27-13-7-8-14-29(27)36-37-30/h4-20,23,28H,21-22H2,1-3H3,(H,36,37)
DMCOYF9 CS CC(C)N(C1=CC=C(C=C1)OC)C(=O)CN2C3=CC=CC=C3N(C(=O)C(C2=O)CC4=C5C=CC=CC5=NN4)C6=CC=CC=C6
DMCOYF9 IK LGYKPDHARJMLQN-UHFFFAOYSA-N
DMCOYF9 IU 2-[3-(2H-indazol-3-ylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-1-yl]-N-(4-methoxyphenyl)-N-propan-2-ylacetamide
DMCOYF9 DE Discovery agent
DMX59A0 ID DMX59A0
DMX59A0 DN GW-637185X
DMX59A0 HS Investigative
DMX59A0 SN CHEMBL539663; GW-637185X; GW637185X; BDBM50297670
DMX59A0 DT Small molecular drug
DMX59A0 PC 45268661
DMX59A0 MW 373.4
DMX59A0 FM C16H18F3N3O2S
DMX59A0 IC InChI=1S/C16H18F3N3O2S/c1-4-10(2)20-15-21-13(9-14(22-15)16(17,18)19)11-5-7-12(8-6-11)25(3,23)24/h5-10H,4H2,1-3H3,(H,20,21,22)
DMX59A0 CS CCC(C)NC1=NC(=CC(=N1)C(F)(F)F)C2=CC=C(C=C2)S(=O)(=O)C
DMX59A0 IK BHAFHAMADYHYPJ-UHFFFAOYSA-N
DMX59A0 IU N-butan-2-yl-4-(4-methylsulfonylphenyl)-6-(trifluoromethyl)pyrimidin-2-amine
DMX59A0 DE Discovery agent
DMCA4RM ID DMCA4RM
DMCA4RM DN GW7604
DMCA4RM HS Investigative
DMCA4RM DT Small molecular drug
DMCA4RM PC 9799518
DMCA4RM MW 370.4
DMCA4RM FM C25H22O3
DMCA4RM IC InChI=1S/C25H22O3/c1-2-23(19-6-4-3-5-7-19)25(21-13-15-22(26)16-14-21)20-11-8-18(9-12-20)10-17-24(27)28/h3-17,26H,2H2,1H3,(H,27,28)/b17-10+,25-23+
DMCA4RM CS CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\\C2=CC=C(C=C2)O)/C3=CC=CC=C3
DMCA4RM IK SCVIEONTACSLJA-YGCRUXFTSA-N
DMCA4RM IU (E)-3-[4-[(E)-1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenyl]prop-2-enoic acid
DMCA4RM DE Discovery agent
DM9RD0C ID DM9RD0C
DM9RD0C DN GW7647
DM9RD0C HS Investigative
DM9RD0C SN GW-7647; GW 7647
DM9RD0C DT Small molecular drug
DM9RD0C PC 3392731
DM9RD0C MW 502.8
DM9RD0C FM C29H46N2O3S
DM9RD0C IC InChI=1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)
DM9RD0C CS CC(C)(C(=O)O)SC1=CC=C(C=C1)CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3
DM9RD0C IK PKNYXWMTHFMHKD-UHFFFAOYSA-N
DM9RD0C IU 2-[4-[2-[4-cyclohexylbutyl(cyclohexylcarbamoyl)amino]ethyl]phenyl]sulfanyl-2-methylpropanoic acid
DM9RD0C CA CAS 265129-71-3
DM9RD0C CB CHEBI:70778
DM9RD0C DE Discovery agent
DMEK2I4 ID DMEK2I4
DMEK2I4 DN GW7845
DMEK2I4 HS Investigative
DMEK2I4 SN GW7845; GW-7845; GW 7845; CHEMBL106666; 196809-22-0; SCHEMBL614392; GTPL2704; BDBM50085046; ZINC49748569; GW 845; GW 347845; UNII-23Y783RURX component KEGOAFNIGUBYHZ-SANMLTNESA-N; N-(2-(Methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine; 2-((S)-1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester; 720711-63-7; 2-(1-Carboxy-2-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-ethylamino)-benzoic acid methyl ester(GW 7845)
DMEK2I4 DT Small molecular drug
DMEK2I4 PC 9870584
DMEK2I4 MW 500.5
DMEK2I4 FM C29H28N2O6
DMEK2I4 IC InChI=1S/C29H28N2O6/c1-19-24(31-27(37-19)21-8-4-3-5-9-21)16-17-36-22-14-12-20(13-15-22)18-26(28(32)33)30-25-11-7-6-10-23(25)29(34)35-2/h3-15,26,30H,16-18H2,1-2H3,(H,32,33)/t26-/m0/s1
DMEK2I4 CS CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)C[C@@H](C(=O)O)NC4=CC=CC=C4C(=O)OC
DMEK2I4 IK KEGOAFNIGUBYHZ-SANMLTNESA-N
DMEK2I4 IU (2S)-2-(2-methoxycarbonylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid
DMEK2I4 CA CAS 196809-22-0
DMEK2I4 DE Discovery agent
DMIBUW5 ID DMIBUW5
DMIBUW5 DN GW-788388
DMIBUW5 HS Investigative
DMIBUW5 SN 452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW-788388; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606
DMIBUW5 DT Small molecular drug
DMIBUW5 PC 10202642
DMIBUW5 MW 425.5
DMIBUW5 FM C25H23N5O2
DMIBUW5 IC InChI=1S/C25H23N5O2/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31)
DMIBUW5 CS C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=CC=CC=N5
DMIBUW5 IK SAGZIBJAQGBRQA-UHFFFAOYSA-N
DMIBUW5 IU N-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1H-pyrazol-4-yl)pyridin-2-yl]benzamide
DMIBUW5 CA CAS 452342-67-5
DMIBUW5 DE Solid tumour/cancer
DMWAEJ3 ID DMWAEJ3
DMWAEJ3 DN GW803430
DMWAEJ3 HS Investigative
DMWAEJ3 SN 6-(4-Chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one; 515141-51-2; GW 803430; GW-3430; UNII-4R0136W1PR; GW-803430; Thieno[3,2-d]pyrimidin-4(3H)-one, 6-(4-chlorophenyl)-3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-; CHEMBL214957; GW-803,430; 4R0136W1PR; GW3430; 6-(4-Chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno(3,2-d)pyrimidin-4(3H)-one; 6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one; Thieno(3,2-d)pyrimidin-4(3H)-one,; GW-803,430
DMWAEJ3 DT Small molecular drug
DMWAEJ3 PC 9826520
DMWAEJ3 MW 482
DMWAEJ3 FM C25H24ClN3O3S
DMWAEJ3 IC InChI=1S/C25H24ClN3O3S/c1-31-22-14-19(8-9-21(22)32-13-12-28-10-2-3-11-28)29-16-27-20-15-23(33-24(20)25(29)30)17-4-6-18(26)7-5-17/h4-9,14-16H,2-3,10-13H2,1H3
DMWAEJ3 CS COC1=C(C=CC(=C1)N2C=NC3=C(C2=O)SC(=C3)C4=CC=C(C=C4)Cl)OCCN5CCCC5
DMWAEJ3 IK MWULMTACIBZPGN-UHFFFAOYSA-N
DMWAEJ3 IU 6-(4-chlorophenyl)-3-[3-methoxy-4-(2-pyrrolidin-1-ylethoxy)phenyl]thieno[3,2-d]pyrimidin-4-one
DMWAEJ3 CA CAS 515141-51-2
DMWAEJ3 DE Discovery agent
DMRL9IN ID DMRL9IN
DMRL9IN DN GW841819X
DMRL9IN HS Investigative
DMRL9IN SN KB-75882
DMRL9IN DT Small molecular drug
DMRL9IN PC 13953710
DMRL9IN MW 423.5
DMRL9IN FM C25H21N5O2
DMRL9IN IC InChI=1S/C25H21N5O2/c1-17-28-29-24-23(27-25(31)32-16-18-10-4-2-5-11-18)26-22(19-12-6-3-7-13-19)20-14-8-9-15-21(20)30(17)24/h2-15,23H,16H2,1H3,(H,27,31)
DMRL9IN CS CC1=NN=C2N1C3=CC=CC=C3C(=NC2NC(=O)OCC4=CC=CC=C4)C5=CC=CC=C5
DMRL9IN IK TUWDLUFFAHHNEF-UHFFFAOYSA-N
DMRL9IN IU benzyl N-(1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl)carbamate
DMRL9IN DE Discovery agent
DMXA5M9 ID DMXA5M9
DMXA5M9 DN GW848687X
DMXA5M9 HS Investigative
DMXA5M9 SN GW 848687X; GW-848687X
DMXA5M9 DT Small molecular drug
DMXA5M9 PC 10238338
DMXA5M9 MW 441.9
DMXA5M9 FM C24H18ClF2NO3
DMXA5M9 IC InChI=1S/C24H18ClF2NO3/c25-15-8-10-23(31-13-14-7-9-16(26)12-20(14)27)19(11-15)17-3-1-4-18(17)21-5-2-6-22(28-21)24(29)30/h2,5-12H,1,3-4,13H2,(H,29,30)
DMXA5M9 CS C1CC(=C(C1)C2=C(C=CC(=C2)Cl)OCC3=C(C=C(C=C3)F)F)C4=NC(=CC=C4)C(=O)O
DMXA5M9 IK PFODPHDNBFSMOX-UHFFFAOYSA-N
DMXA5M9 IU 6-[2-[5-chloro-2-[(2,4-difluorophenyl)methoxy]phenyl]cyclopenten-1-yl]pyridine-2-carboxylic acid
DMXA5M9 CA CAS 612831-24-0
DMXA5M9 DE Discovery agent
DML4UMT ID DML4UMT
DML4UMT DN GW-8510
DML4UMT HS Investigative
DML4UMT DT Small molecular drug
DML4UMT PC 3536
DML4UMT MW 449.5
DML4UMT FM C21H15N5O3S2
DML4UMT IC InChI=1S/C21H15N5O3S2/c27-21-15(19-16(25-21)8-9-17-20(19)30-12-24-17)11-23-13-4-6-14(7-5-13)31(28,29)26-18-3-1-2-10-22-18/h1-12,25,27H,(H,22,26)
DML4UMT CS C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=CC3=C(NC4=C3C5=C(C=C4)N=CS5)O
DML4UMT IK CDNIYBIKHDLGMT-UHFFFAOYSA-N
DML4UMT IU 4-[(7-hydroxy-6H-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-N-pyridin-2-ylbenzenesulfonamide
DML4UMT CB CHEBI:95283
DML4UMT DE Discovery agent
DMITKX8 ID DMITKX8
DMITKX8 DN GW853606
DMITKX8 HS Investigative
DMITKX8 SN GW853606X; compound 22 [PMID: 19097784]
DMITKX8 DT Small molecular drug
DMITKX8 PC 25263088
DMITKX8 MW 496.3
DMITKX8 FM C20H13BrF3N3O2S
DMITKX8 IC InChI=1S/C20H13BrF3N3O2S/c21-13-4-2-1-3-11(13)9-29-16-8-17(30-18(16)19(25)28)27-10-26-14-6-5-12(7-15(14)27)20(22,23)24/h1-8,10H,9H2,(H2,25,28)
DMITKX8 CS C1=CC=C(C(=C1)COC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)C(F)(F)F)C(=O)N)Br
DMITKX8 IK LOKKVFGDJAVMLU-UHFFFAOYSA-N
DMITKX8 IU 3-[(2-bromophenyl)methoxy]-5-[6-(trifluoromethyl)benzimidazol-1-yl]thiophene-2-carboxamide
DMITKX8 DE Discovery agent
DMVKZ5I ID DMVKZ5I
DMVKZ5I DN GW9508
DMVKZ5I HS Investigative
DMVKZ5I SN GW-9508; GW 9508
DMVKZ5I DT Small molecular drug
DMVKZ5I PC 11595431
DMVKZ5I MW 347.4
DMVKZ5I FM C22H21NO3
DMVKZ5I IC InChI=1S/C22H21NO3/c24-22(25)14-11-17-9-12-19(13-10-17)23-16-18-5-4-8-21(15-18)26-20-6-2-1-3-7-20/h1-10,12-13,15,23H,11,14,16H2,(H,24,25)
DMVKZ5I CS C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC3=CC=C(C=C3)CCC(=O)O
DMVKZ5I IK DGENZVKCTGIDRZ-UHFFFAOYSA-N
DMVKZ5I IU 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid
DMVKZ5I CA CAS 885101-89-3
DMVKZ5I CB CHEBI:93259
DMVKZ5I DE Discovery agent
DMPIRE0 ID DMPIRE0
DMPIRE0 DN GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2
DMPIRE0 HS Investigative
DMPIRE0 PC 91934075
DMPIRE0 MW 3156.4
DMPIRE0 FM C139H211N43O42
DMPIRE0 IC InChI=1S/C139H211N43O42/c1-65(2)38-84(166-122(208)86(40-67(5)6)167-124(210)88(43-75-31-33-79(189)34-32-75)162-106(194)55-152-115(201)70(11)158-132(218)98(60-184)177-128(214)95(49-104(144)192)171-123(209)87(41-68(7)8)174-137(223)112(72(13)187)181-131(217)90(160-105(193)51-141)44-76-52-151-81-27-19-18-26-80(76)81)117(203)155-58-109(197)182-37-23-30-101(182)135(221)173-91(45-77-53-148-63-156-77)121(207)159-71(12)116(202)179-111(69(9)10)136(222)154-57-108(196)163-94(48-103(143)191)127(213)169-92(46-78-54-149-64-157-78)126(212)165-83(29-22-36-150-139(146)147)120(206)176-99(61-185)133(219)168-89(42-74-24-16-15-17-25-74)125(211)178-100(62-186)134(220)172-96(50-110(198)199)129(215)164-82(28-20-21-35-140)119(205)170-93(47-102(142)190)118(204)153-56-107(195)161-85(39-66(3)4)130(216)180-113(73(14)188)138(224)175-97(59-183)114(145)200/h15-19,24-27,31-34,52-54,63-73,82-101,111-113,151,183-189H,20-23,28-30,35-51,55-62,140-141H2,1-14H3,(H2,142,190)(H2,143,191)(H2,144,192)(H2,145,200)(H,148,156)(H,149,157)(H,152,201)(H,153,204)(H,154,222)(H,155,203)(H,158,218)(H,159,207)(H,160,193)(H,161,195)(H,162,194)(H,163,196)(H,164,215)(H,165,212)(H,166,208)(H,167,210)(H,168,219)(H,169,213)(H,170,205)(H,171,209)(H,172,220)(H,173,221)(H,174,223)(H,175,224)(H,176,206)(H,177,214)(H,178,211)(H,179,202)(H,180,216)(H,181,217)(H,198,199)(H4,146,147,150)/t70-,71-,72+,73+,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,111-,112-,113-/m0/s1
DMPIRE0 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)NC(=O)CN)O
DMPIRE0 IK VYHIHGYPAVCHDV-RUKUCZSXSA-N
DMPIRE0 IU (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMPIRE0 DE Discovery agent
DMZPRIG ID DMZPRIG
DMZPRIG DN GWTLNSAGYLLGPHAV-NH2
DMZPRIG HS Investigative
DMZPRIG SN CHEMBL508083; GWTLNSAGYLLGPHAV-NH2
DMZPRIG PC 44587982
DMZPRIG MW 1654.9
DMZPRIG FM C77H115N21O20
DMZPRIG IC InChI=1S/C77H115N21O20/c1-37(2)23-50(68(109)84-34-62(105)98-22-14-17-58(98)76(117)93-55(28-46-32-81-36-85-46)69(110)87-42(10)67(108)96-63(40(7)8)65(80)106)90-70(111)51(24-38(3)4)91-72(113)53(26-44-18-20-47(101)21-19-44)89-61(104)33-83-66(107)41(9)86-75(116)57(35-99)95-73(114)56(29-59(79)102)92-71(112)52(25-39(5)6)94-77(118)64(43(11)100)97-74(115)54(88-60(103)30-78)27-45-31-82-49-16-13-12-15-48(45)49/h12-13,15-16,18-21,31-32,36-43,50-58,63-64,82,99-101H,14,17,22-30,33-35,78H2,1-11H3,(H2,79,102)(H2,80,106)(H,81,85)(H,83,107)(H,84,109)(H,86,116)(H,87,110)(H,88,103)(H,89,104)(H,90,111)(H,91,113)(H,92,112)(H,93,117)(H,94,118)(H,95,114)(H,96,108)(H,97,115)/t41-,42-,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,63-,64-/m0/s1
DMZPRIG CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CC4=CNC5=CC=CC=C54)NC(=O)CN)O
DMZPRIG IK QWMBNRVWDTXENF-LJQDGMHUSA-N
DMZPRIG IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMZPRIG DE Discovery agent
DMKFMQ5 ID DMKFMQ5
DMKFMQ5 DN GWTLNSAGYLLGPPPALALA-CONH2
DMKFMQ5 HS Investigative
DMKFMQ5 SN 143896-17-7; CHEMBL604990; M40; GWTLNSAGYLLGPPPALALA-CONH2; GALANIN RECEPTOR LIGAND M40; BDBM50307254; AKOS024457623; Galanin (1-13)-Pro-Pro-(Ala-Leu-)2Ala amide
DMKFMQ5 PC 16133821
DMKFMQ5 MW 1981.3
DMKFMQ5 FM C94H145N23O24
DMKFMQ5 IC InChI=1S/C94H145N23O24/c1-46(2)33-61(82(129)100-44-76(124)115-30-19-24-71(115)93(140)117-32-20-25-72(117)94(141)116-31-18-23-70(116)91(138)104-54(14)81(128)108-63(35-48(5)6)84(131)103-53(13)80(127)107-62(34-47(3)4)83(130)101-51(11)78(97)125)109-85(132)64(36-49(7)8)110-87(134)66(38-56-26-28-58(120)29-27-56)106-75(123)43-99-79(126)52(12)102-90(137)69(45-118)113-88(135)68(40-73(96)121)111-86(133)65(37-50(9)10)112-92(139)77(55(15)119)114-89(136)67(105-74(122)41-95)39-57-42-98-60-22-17-16-21-59(57)60/h16-17,21-22,26-29,42,46-55,61-72,77,98,118-120H,18-20,23-25,30-41,43-45,95H2,1-15H3,(H2,96,121)(H2,97,125)(H,99,126)(H,100,129)(H,101,130)(H,102,137)(H,103,131)(H,104,138)(H,105,122)(H,106,123)(H,107,127)(H,108,128)(H,109,132)(H,110,134)(H,111,133)(H,112,139)(H,113,135)(H,114,136)/t51-,52-,53-,54-,55+,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,77-/m0/s1
DMKFMQ5 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)CN)O
DMKFMQ5 IK OSGCBUDLRBUEGW-JZCUZNMGSA-N
DMKFMQ5 IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMKFMQ5 DE Discovery agent
DMVWGM2 ID DMVWGM2
DMVWGM2 DN GWTLNSAGYLLGPPPGFSPFR-CONH2
DMVWGM2 HS Investigative
DMVWGM2 SN M35 Peptide; Galanin-(1-13)-bradykinin-(2-9)-amide; 142846-71-7; M-35; L-Argininamide, glycyl-L-tryptophyl-L-threonyl-L-leucyl-L-asparaginyl-L-seryl-L-alanylglycyl-L-tyrosyl-L-leucyl-L-leucylglycyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-; M 35; Galanin(1-13)-bradykinin(2-9)amide; NCGC00167245-01
DMVWGM2 PC 91934871
DMVWGM2 MW 2233.5
DMVWGM2 FM C107H153N27O26
DMVWGM2 IC InChI=1S/C107H153N27O26/c1-57(2)42-70(123-93(147)71(43-58(3)4)124-95(149)74(47-64-33-35-66(138)36-34-64)121-86(141)52-115-91(145)60(7)118-100(154)78(55-135)128-98(152)77(49-84(109)139)125-94(148)72(44-59(5)6)127-103(157)89(61(8)137)130-99(153)76(119-85(140)50-108)48-65-51-114-68-27-16-15-26-67(65)68)92(146)117-54-88(143)131-38-20-31-82(131)105(159)134-41-21-32-83(134)106(160)133-40-18-29-80(133)101(155)116-53-87(142)120-73(45-62-22-11-9-12-23-62)96(150)129-79(56-136)104(158)132-39-19-30-81(132)102(156)126-75(46-63-24-13-10-14-25-63)97(151)122-69(90(110)144)28-17-37-113-107(111)112/h9-16,22-27,33-36,51,57-61,69-83,89,114,135-138H,17-21,28-32,37-50,52-56,108H2,1-8H3,(H2,109,139)(H2,110,144)(H,115,145)(H,116,155)(H,117,146)(H,118,154)(H,119,140)(H,120,142)(H,121,141)(H,122,151)(H,123,147)(H,124,149)(H,125,148)(H,126,156)(H,127,157)(H,128,152)(H,129,150)(H,130,153)(H4,111,112,113)/t60-,61+,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DMVWGM2 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)NCC(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CO)C(=O)N6CCC[C@H]6C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)NC(=O)CN)O
DMVWGM2 IK JWMXJVFGTXYBFM-AEXVMZOXSA-N
DMVWGM2 IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]butanediamide
DMVWGM2 DE Discovery agent
DM5YR4S ID DM5YR4S
DM5YR4S DN GWTLNSAGYLLGPRHYINLITRQRY-CONH2
DM5YR4S HS Investigative
DM5YR4S PC 91934077
DM5YR4S MW 2849.2
DM5YR4S FM C130H198N40O33
DM5YR4S IC InChI=1S/C130H198N40O33/c1-14-67(10)104(125(201)165-95(55-100(134)179)118(194)160-89(48-66(8)9)120(196)168-105(69(12)172)126(202)156-83(25-19-43-145-130(140)141)110(186)154-84(39-40-98(132)177)113(189)153-81(23-17-41-143-128(136)137)111(187)157-85(107(135)183)49-71-27-33-76(174)34-28-71)167-121(197)91(51-73-31-37-78(176)38-32-73)161-117(193)93(53-75-58-142-62-149-75)162-112(188)82(24-18-42-144-129(138)139)155-124(200)97-26-20-44-170(97)103(182)60-148-109(185)86(45-63(2)3)158-114(190)87(46-64(4)5)159-116(192)90(50-72-29-35-77(175)36-30-72)152-102(181)59-147-108(184)68(11)150-123(199)96(61-171)166-119(195)94(54-99(133)178)163-115(191)88(47-65(6)7)164-127(203)106(70(13)173)169-122(198)92(151-101(180)56-131)52-74-57-146-80-22-16-15-21-79(74)80/h15-16,21-22,27-38,57-58,62-70,81-97,104-106,146,171-176H,14,17-20,23-26,39-56,59-61,131H2,1-13H3,(H2,132,177)(H2,133,178)(H2,134,179)(H2,135,183)(H,142,149)(H,147,184)(H,148,185)(H,150,199)(H,151,180)(H,152,181)(H,153,189)(H,154,186)(H,155,200)(H,156,202)(H,157,187)(H,158,190)(H,159,192)(H,160,194)(H,161,193)(H,162,188)(H,163,191)(H,164,203)(H,165,201)(H,166,195)(H,167,197)(H,168,196)(H,169,198)(H4,136,137,143)(H4,138,139,144)(H4,140,141,145)/t67-,68-,69+,70+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,104-,105-,106-/m0/s1
DM5YR4S CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)NC(=O)CN
DM5YR4S IK SQXQKSDIKGRBPX-MNFZLFQXSA-N
DM5YR4S IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DM5YR4S DE Discovery agent
DM48AV3 ID DM48AV3
DM48AV3 DN GWTLNSAGYLLGPrPKPQQwFwLL-CONH2
DM48AV3 HS Investigative
DM48AV3 SN NCGC00167329-01
DM48AV3 PC 91934078
DM48AV3 MW 2828.3
DM48AV3 FM C138H199N35O30
DM48AV3 IC InChI=1S/C138H199N35O30/c1-72(2)54-95(117(144)183)160-122(188)97(56-74(5)6)163-127(193)104(63-83-68-150-90-35-21-18-32-87(83)90)166-126(192)101(59-79-28-14-13-15-29-79)164-128(194)103(62-82-67-149-89-34-20-17-31-86(82)89)165-121(187)91(45-47-110(141)177)156-120(186)92(46-48-111(142)178)157-133(199)108-39-26-52-172(108)136(202)93(36-22-23-49-139)158-134(200)109-40-27-53-173(109)137(203)94(37-24-50-147-138(145)146)159-132(198)107-38-25-51-171(107)115(182)70-152-119(185)96(55-73(3)4)161-123(189)98(57-75(7)8)162-125(191)100(60-80-41-43-84(176)44-42-80)155-114(181)69-151-118(184)77(11)153-131(197)106(71-174)169-129(195)105(64-112(143)179)167-124(190)99(58-76(9)10)168-135(201)116(78(12)175)170-130(196)102(154-113(180)65-140)61-81-66-148-88-33-19-16-30-85(81)88/h13-21,28-35,41-44,66-68,72-78,91-109,116,148-150,174-176H,22-27,36-40,45-65,69-71,139-140H2,1-12H3,(H2,141,177)(H2,142,178)(H2,143,179)(H2,144,183)(H,151,184)(H,152,185)(H,153,197)(H,154,180)(H,155,181)(H,156,186)(H,157,199)(H,158,200)(H,159,198)(H,160,188)(H,161,189)(H,162,191)(H,163,193)(H,164,194)(H,165,187)(H,166,192)(H,167,190)(H,168,201)(H,169,195)(H,170,196)(H4,145,146,147)/t77-,78+,91-,92-,93-,94+,95-,96-,97-,98-,99-,100-,101-,102-,103+,104+,105-,106-,107-,108-,109-,116-/m0/s1
DM48AV3 CS C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H](CCCN=C(N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N[C@H](CC8=CNC9=CC=CC=C98)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN)O
DM48AV3 IK LTAFNTKZCARRFJ-HPWFANMZSA-N
DM48AV3 IU (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-[[(2S)-1-[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DM48AV3 DE Discovery agent
DM8GFJP ID DM8GFJP
DM8GFJP DN GX-C4
DM8GFJP HS Investigative
DM8GFJP SN CTLA-4/Fc region of a hybrid IgG4/IgD antibody (fusion protein, autoimmune disease), Genexine
DM8GFJP CP Genexine Co Ltd
DM8GFJP DT Antibody
DM8GFJP DE Autoimmune diabetes
DM1RY6Q ID DM1RY6Q
DM1RY6Q DN GX-G6
DM1RY6Q HS Investigative
DM1RY6Q SN GX-G9; GLP-1/Fc antibody (fusion protein, diabetes), Genexine; GLP-1/Fc antibody fusion protein (diabetes), Genexine/ IlDong
DM1RY6Q CP Genexine Co Ltd
DM1RY6Q DT Antibody
DM1RY6Q DE Diabetic complication
DM7SLAM ID DM7SLAM
DM7SLAM DN Gymnochrome E
DM7SLAM HS Investigative
DM7SLAM DT Small molecular drug
DM7SLAM PC 135894458
DM7SLAM MW 778.4
DM7SLAM FM C36H26Br2O10
DM7SLAM IC InChI=1S/C36H26Br2O10/c1-3-4-10(40)6-12-18-17-11(5-9(2)39)31(37)35(47)29-23(17)27-25-19(13(41)7-15(43)21(25)33(29)45)20-14(42)8-16(44)22-26(20)28(27)24(18)30(34(22)46)36(48)32(12)38/h7-10,39-40,43-48H,3-6H2,1-2H3/t9-,10+/m0/s1
DM7SLAM CS CCC[C@H](CC1=C2C3=C(C(=C(C4=C(C5=C6C(=C7C(=O)C=C(C8=C7C(=C2C(=C8O)C(=C1Br)O)C6=C34)O)C(=O)C=C5O)O)O)Br)C[C@H](C)O)O
DM7SLAM IK PGSCEVFXDRXNMP-VHSXEESVSA-N
DM7SLAM IU 12,17-dibromo-7,9,11,18,20,22-hexahydroxy-13-[(2R)-2-hydroxypentyl]-16-[(2S)-2-hydroxypropyl]octacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(27),2(28),3(8),4(25),6,9,11,13,15,17,19,21(26),22-tridecaene-5,24-dione
DM7SLAM DE Discovery agent
DM8ENQZ ID DM8ENQZ
DM8ENQZ DN Gypenoside XVII
DM8ENQZ HS Investigative
DM8ENQZ SN Ginsenoside XVII; Gynosaponin S; Q27146716; ZINC253387973; 80321-69-3; AKOS027251125; C20736; CHEBI:77155; CHEMBL504441; CS-4163; GYPENOSIDE-XVII; Gypenoside XVII; HY-N0553; N2767; Y0100; s9207
DM8ENQZ PC 44584555
DM8ENQZ MW 947.2
DM8ENQZ FM C48H82O18
DM8ENQZ IC ZRBFCAALKKNCJG-SJYBZOGZSA-N
DM8ENQZ CS CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)C)O)C)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)O)O)O)O)O)O)C
DM8ENQZ IK 1S/C48H82O18/c1-22(2)10-9-14-48(8,66-43-40(60)37(57)34(54)27(64-43)21-61-41-38(58)35(55)32(52)25(19-49)62-41)23-11-16-47(7)31(23)24(51)18-29-45(5)15-13-30(44(3,4)28(45)12-17-46(29,47)6)65-42-39(59)36(56)33(53)26(20-50)63-42/h10,23-43,49-60H,9,11-21H2,1-8H3/t23-,24+,25+,26+,27+,28-,29+,30-,31-,32+,33+,34+,35-,36-,37-,38+,39+,40+,41+,42-,43-,45-,46+,47+,48-/m0/s1
DM8ENQZ IU (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol
DM8ENQZ CA CAS 80321-69-3
DM8ENQZ CB CHEBI:77155
DM8ENQZ DE Arteriosclerosis obliterans
DM9XK05 ID DM9XK05
DM9XK05 DN H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05 HS Investigative
DM9XK05 SN CHEMBL408891; H-[Trp-Arg-Nva-Arg-Tyr]2-NH2
DM9XK05 PC 44409452
DM9XK05 MW 1538.8
DM9XK05 FM C74H107N25O12
DM9XK05 IC InChI=1S/C74H107N25O12/c1-3-13-52(92-65(106)54(19-9-31-85-71(77)78)91-62(103)49(75)37-43-39-89-50-17-7-5-15-47(43)50)64(105)95-57(22-12-34-88-74(83)84)68(109)98-59(36-42-25-29-46(101)30-26-42)69(110)99-60(38-44-40-90-51-18-8-6-16-48(44)51)70(111)96-55(20-10-32-86-72(79)80)66(107)93-53(14-4-2)63(104)94-56(21-11-33-87-73(81)82)67(108)97-58(61(76)102)35-41-23-27-45(100)28-24-41/h5-8,15-18,23-30,39-40,49,52-60,89-90,100-101H,3-4,9-14,19-22,31-38,75H2,1-2H3,(H2,76,102)(H,91,103)(H,92,106)(H,93,107)(H,94,104)(H,95,105)(H,96,111)(H,97,108)(H,98,109)(H,99,110)(H4,77,78,85)(H4,79,80,86)(H4,81,82,87)(H4,83,84,88)/t49-,52-,53-,54-,55-,56-,57-,58-,59-,60-/m0/s1
DM9XK05 CS CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)N
DM9XK05 IK QTWWWOBSQULXHE-MTVPJWGZSA-N
DM9XK05 IU (2S)-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DM9XK05 DE Discovery agent
DMKH8PF ID DMKH8PF
DMKH8PF DN H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF HS Investigative
DMKH8PF SN CHEMBL413871; H-[Trp-Arg-Nva-Arg-Tyr]3-NH2
DMKH8PF PC 44409453
DMKH8PF MW 2299.7
DMKH8PF FM C111H159N37O18
DMKH8PF IC InChI=1S/C111H159N37O18/c1-4-19-77(136-96(157)80(28-13-46-126-106(114)115)135-92(153)73(112)55-64-58-132-74-25-10-7-22-70(64)74)94(155)140-84(32-17-50-130-110(122)123)100(161)145-87(53-62-36-42-68(150)43-37-62)102(163)148-90(57-66-60-134-76-27-12-9-24-72(66)76)105(166)143-82(30-15-48-128-108(118)119)98(159)138-79(21-6-3)95(156)141-85(33-18-51-131-111(124)125)101(162)146-88(54-63-38-44-69(151)45-39-63)103(164)147-89(56-65-59-133-75-26-11-8-23-71(65)75)104(165)142-81(29-14-47-127-107(116)117)97(158)137-78(20-5-2)93(154)139-83(31-16-49-129-109(120)121)99(160)144-86(91(113)152)52-61-34-40-67(149)41-35-61/h7-12,22-27,34-45,58-60,73,77-90,132-134,149-151H,4-6,13-21,28-33,46-57,112H2,1-3H3,(H2,113,152)(H,135,153)(H,136,157)(H,137,158)(H,138,159)(H,139,154)(H,140,155)(H,141,156)(H,142,165)(H,143,166)(H,144,160)(H,145,161)(H,146,162)(H,147,164)(H,148,163)(H4,114,115,126)(H4,116,117,127)(H4,118,119,128)(H4,120,121,129)(H4,122,123,130)(H4,124,125,131)/t73-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-/m0/s1
DMKH8PF CS CCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC8=CNC9=CC=CC=C98)N
DMKH8PF IK DRBRBJSYRQHXHE-TWUBVJIJSA-N
DMKH8PF IU (2S)-N-[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]pentanoyl]amino]-5-(diaminomethylideneamino)pentanamide
DMKH8PF DE Discovery agent
DMYOADQ ID DMYOADQ
DMYOADQ DN H-2',6'-dimethyltyrosine-Tic-OH
DMYOADQ HS Investigative
DMYOADQ SN CHEMBL571492; 2,6-Dimethyl-L-Tyr-L-Tic-OH; BDBM50299565; H-2'',6''-dimethyltyrosine-Tic-OH; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
DMYOADQ DT Small molecular drug
DMYOADQ PC 15384271
DMYOADQ MW 368.4
DMYOADQ FM C21H24N2O4
DMYOADQ IC InChI=1S/C21H24N2O4/c1-12-7-16(24)8-13(2)17(12)10-18(22)20(25)23-11-15-6-4-3-5-14(15)9-19(23)21(26)27/h3-8,18-19,24H,9-11,22H2,1-2H3,(H,26,27)/t18-,19-/m0/s1
DMYOADQ CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O)N)C)O
DMYOADQ IK QBLVXTMPLLWZDE-OALUTQOASA-N
DMYOADQ IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DM7IEU2 ID DM7IEU2
DM7IEU2 DN H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH
DM7IEU2 HS Investigative
DM7IEU2 SN CHEMBL555206; BDBM50299557; H-2'',6''-dimethyltyrosine-Tic-Phe-Phe-OH; (S)-2-((S)-2-((S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-phenylpropanamido)-3-phenylpropanoic acid
DM7IEU2 DT Small molecular drug
DM7IEU2 PC 45273695
DM7IEU2 MW 662.8
DM7IEU2 FM C39H42N4O6
DM7IEU2 IC InChI=1S/C39H42N4O6/c1-24-17-30(44)18-25(2)31(24)22-32(40)38(47)43-23-29-16-10-9-15-28(29)21-35(43)37(46)41-33(19-26-11-5-3-6-12-26)36(45)42-34(39(48)49)20-27-13-7-4-8-14-27/h3-18,32-35,44H,19-23,40H2,1-2H3,(H,41,46)(H,42,45)(H,48,49)/t32-,33-,34-,35-/m0/s1
DM7IEU2 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DM7IEU2 IK SZIMPGYQGJRODH-BBACVFHCSA-N
DM7IEU2 IU (2S)-2-[[(2S)-2-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DM7IEU2 DE Discovery agent
DMOJI0N ID DMOJI0N
DMOJI0N DN H22xKi-4
DMOJI0N HS Investigative
DMOJI0N DT Antibody
DMOJI0N DE Discovery agent
DM80QF9 ID DM80QF9
DM80QF9 DN H-8
DM80QF9 HS Investigative
DM80QF9 SN 84478-11-5; Protein kinase inhibitor H-8; h-8; H-8 Protein kinase inhibitor; N-(2-(Methylamino)ethyl)-5-isoquinolinesulfonamide; N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE; N-[2-(methylamino)ethyl]isoquinoline-5-sulfonamide; (5-Isoquinolylsulfonyl)[2-(methylamino)ethyl]amine; Lopac-M-9656; CHEMBL148333; CHEBI:43561; H8; N-(2-methylaminoethyl)isoquinoline-5-sulfonamide; (5-Isoquinolylsulfonyl)(2-(methylamino)ethyl)amine; 5-Isoquinolinesulfonamide, N-(2-(methylamino)ethyl)-; N-(2-(Methylamino)ethyl)isoquinoline- 5-s
DM80QF9 DT Small molecular drug
DM80QF9 PC 3540
DM80QF9 MW 265.33
DM80QF9 FM C12H15N3O2S
DM80QF9 IC InChI=1S/C12H15N3O2S/c1-13-7-8-15-18(16,17)12-4-2-3-10-9-14-6-5-11(10)12/h2-6,9,13,15H,7-8H2,1H3
DM80QF9 CS CNCCNS(=O)(=O)C1=CC=CC2=C1C=CN=C2
DM80QF9 IK PJWUXKNZVMEPPH-UHFFFAOYSA-N
DM80QF9 IU N-[2-(methylamino)ethyl]isoquinoline-5-sulfonamide
DM80QF9 CA CAS 84478-11-5
DM80QF9 CB CHEBI:43561
DM80QF9 DE Discovery agent
DM43ODJ ID DM43ODJ
DM43ODJ DN H87/07
DM43ODJ HS Investigative
DM43ODJ SN H 87-07
DM43ODJ DT Small molecular drug
DM43ODJ PC 193122
DM43ODJ MW 283.36
DM43ODJ FM C15H25NO4
DM43ODJ IC InChI=1S/C15H25NO4/c1-12(2)16-10-13(17)11-20-15-6-4-14(5-7-15)19-9-8-18-3/h4-7,12-13,16-17H,8-11H2,1-3H3
DM43ODJ CS CC(C)NCC(COC1=CC=C(C=C1)OCCOC)O
DM43ODJ IK FGAPARDHTDKREN-UHFFFAOYSA-N
DM43ODJ IU 1-[4-(2-methoxyethoxy)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DM43ODJ CA CAS 30311-37-6
DM43ODJ DE Discovery agent
DM4RVGO ID DM4RVGO
DM4RVGO DN H-89
DM4RVGO HS Investigative
DM4RVGO SN H 89
DM4RVGO DT Small molecular drug
DM4RVGO PC 449241
DM4RVGO MW 446.4
DM4RVGO FM C20H20BrN3O2S
DM4RVGO IC InChI=1S/C20H20BrN3O2S/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20/h1-10,12,15,22,24H,11,13-14H2/b3-2+
DM4RVGO CS C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCNC/C=C/C3=CC=C(C=C3)Br
DM4RVGO IK ZKZXNDJNWUTGDK-NSCUHMNNSA-N
DM4RVGO IU N-[2-[[(E)-3-(4-bromophenyl)prop-2-enyl]amino]ethyl]isoquinoline-5-sulfonamide
DM4RVGO CA CAS 127243-85-0
DM4RVGO CB CHEBI:47495
DM4RVGO DE Discovery agent
DM61G0I ID DM61G0I
DM61G0I DN H-Aba-ala-Gly-Phe-leu-OH
DM61G0I HS Investigative
DM61G0I SN CHEMBL247064; H-Aba-ala-Gly-Phe-leu-OH
DM61G0I DT Small molecular drug
DM61G0I PC 44439877
DM61G0I MW 625.7
DM61G0I FM C30H39N7O6S
DM61G0I IC InChI=1S/C30H39N7O6S/c1-16(2)11-23(29(42)43)36-28(41)22(13-18-7-5-4-6-8-18)35-25(38)15-33-26(39)17(3)34-27(40)20(31)12-19-9-10-21-24(14-19)44-30(32)37-21/h4-10,14,16-17,20,22-23H,11-13,15,31H2,1-3H3,(H2,32,37)(H,33,39)(H,34,40)(H,35,38)(H,36,41)(H,42,43)/t17-,20-,22-,23-/m0/s1
DM61G0I CS C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N
DM61G0I IK VLIQMZUUPDOVAM-NWZJSZKRSA-N
DM61G0I IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM61G0I DE Discovery agent
DMKD94Q ID DMKD94Q
DMKD94Q DN H-Aba-ala-Gly-Phe-Met-OH
DMKD94Q HS Investigative
DMKD94Q SN CHEMBL246572; H-Aba-ala-Gly-Phe-Met-OH
DMKD94Q DT Small molecular drug
DMKD94Q PC 44439910
DMKD94Q MW 643.8
DMKD94Q FM C29H37N7O6S2
DMKD94Q IC InChI=1S/C29H37N7O6S2/c1-16(33-26(39)19(30)12-18-8-9-20-23(14-18)44-29(31)36-20)25(38)32-15-24(37)34-22(13-17-6-4-3-5-7-17)27(40)35-21(28(41)42)10-11-43-2/h3-9,14,16,19,21-22H,10-13,15,30H2,1-2H3,(H2,31,36)(H,32,38)(H,33,39)(H,34,37)(H,35,40)(H,41,42)/t16-,19-,21-,22-/m0/s1
DMKD94Q CS C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N
DMKD94Q IK NQZMBRNFTRPOCP-PWZKMPOXSA-N
DMKD94Q IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DMKD94Q DE Discovery agent
DMH1L3P ID DMH1L3P
DMH1L3P DN H-Aba-Gly-Gly-Phe-Leu-OH
DMH1L3P HS Investigative
DMH1L3P SN CHEMBL247759; H-Aba-Gly-Gly-Phe-Leu-OH
DMH1L3P DT Small molecular drug
DMH1L3P PC 44439882
DMH1L3P MW 611.7
DMH1L3P FM C29H37N7O6S
DMH1L3P IC InChI=1S/C29H37N7O6S/c1-16(2)10-22(28(41)42)35-27(40)21(12-17-6-4-3-5-7-17)34-25(38)15-32-24(37)14-33-26(39)19(30)11-18-8-9-20-23(13-18)43-29(31)36-20/h3-9,13,16,19,21-22H,10-12,14-15,30H2,1-2H3,(H2,31,36)(H,32,37)(H,33,39)(H,34,38)(H,35,40)(H,41,42)/t19-,21-,22-/m0/s1
DMH1L3P CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N
DMH1L3P IK AHRIYJIWFATUOS-BVSLBCMMSA-N
DMH1L3P IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMH1L3P DE Discovery agent
DMFE3J4 ID DMFE3J4
DMFE3J4 DN H-Aba-ser-Gly-Phe-Leu-Thr-OH
DMFE3J4 HS Investigative
DMFE3J4 SN CHEMBL246479; H-Aba-ser-Gly-Phe-Leu-Thr-OH
DMFE3J4 DT Small molecular drug
DMFE3J4 PC 44439907
DMFE3J4 MW 742.8
DMFE3J4 FM C34H46N8O9S
DMFE3J4 IC InChI=1S/C34H46N8O9S/c1-17(2)11-23(32(49)42-28(18(3)44)33(50)51)39-31(48)24(13-19-7-5-4-6-8-19)38-27(45)15-37-30(47)25(16-43)40-29(46)21(35)12-20-9-10-22-26(14-20)52-34(36)41-22/h4-10,14,17-18,21,23-25,28,43-44H,11-13,15-16,35H2,1-3H3,(H2,36,41)(H,37,47)(H,38,45)(H,39,48)(H,40,46)(H,42,49)(H,50,51)/t18-,21+,23+,24+,25+,28+/m1/s1
DMFE3J4 CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC3=C(C=C2)N=C(S3)N)N)O
DMFE3J4 IK XSYMBKQKMSKFJU-LEKCGIOJSA-N
DMFE3J4 IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(2-amino-1,3-benzothiazol-6-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMFE3J4 DE Discovery agent
DMQCGRI ID DMQCGRI
DMQCGRI DN HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2
DMQCGRI HS Investigative
DMQCGRI PC 16200894
DMQCGRI MW 3354.7
DMQCGRI FM C151H229N41O46
DMQCGRI IC InChI=1S/C151H229N41O46/c1-17-77(10)121(148(236)170-81(14)127(215)178-105(60-87-63-161-92-36-25-24-35-90(87)92)138(226)180-101(56-74(4)5)139(227)189-119(75(6)7)146(234)177-94(37-26-28-52-152)130(218)163-66-112(201)171-93(39-30-54-160-151(157)158)129(217)162-65-111(156)200)191-140(228)103(57-84-31-20-18-21-32-84)181-135(223)99(47-51-117(208)209)176-134(222)95(38-27-29-53-153)173-125(213)79(12)167-124(212)78(11)169-133(221)98(44-48-110(155)199)172-113(202)67-164-132(220)97(46-50-116(206)207)175-136(224)100(55-73(2)3)179-137(225)102(59-86-40-42-89(198)43-41-86)182-143(231)107(69-193)185-145(233)109(71-195)186-147(235)120(76(8)9)190-142(230)106(62-118(210)211)183-144(232)108(70-194)187-150(238)123(83(16)197)192-141(229)104(58-85-33-22-19-23-34-85)184-149(237)122(82(15)196)188-114(203)68-165-131(219)96(45-49-115(204)205)174-126(214)80(13)168-128(216)91(154)61-88-64-159-72-166-88/h18-25,31-36,40-43,63-64,72-83,91,93-109,119-123,161,193-198H,17,26-30,37-39,44-62,65-71,152-154H2,1-16H3,(H2,155,199)(H2,156,200)(H,159,166)(H,162,217)(H,163,218)(H,164,220)(H,165,219)(H,167,212)(H,168,216)(H,169,221)(H,170,236)(H,171,201)(H,172,202)(H,173,213)(H,174,214)(H,175,224)(H,176,222)(H,177,234)(H,178,215)(H,179,225)(H,180,226)(H,181,223)(H,182,231)(H,183,232)(H,184,237)(H,185,233)(H,186,235)(H,187,238)(H,188,203)(H,189,227)(H,190,230)(H,191,228)(H,192,229)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,157,158,160)/t77-,78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,119-,120-,121-,122-,123-/m0/s1
DMQCGRI CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMQCGRI IK FZWMHWVGNYURLN-AAEALURTSA-N
DMQCGRI IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMQCGRI DE Discovery agent
DMN54LS ID DMN54LS
DMN54LS DN HAEGTFTSDVSSYLEGQAAKEIFAWLVKGR
DMN54LS HS Investigative
DMN54LS PC 91934873
DMN54LS MW 3298.6
DMN54LS FM C149H225N39O46
DMN54LS IC InChI=1S/C149H225N39O46/c1-17-76(10)119(145(230)179-101(57-83-31-20-18-21-32-83)133(218)166-80(14)125(210)174-104(60-86-63-158-91-36-25-24-35-89(86)91)136(221)176-100(56-73(4)5)137(222)185-117(74(6)7)143(228)173-92(37-26-28-52-150)127(212)159-66-111(197)168-98(148(233)234)39-30-54-157-149(154)155)187-132(217)97(47-51-115(203)204)172-131(216)93(38-27-29-53-151)169-123(208)78(12)163-122(207)77(11)165-130(215)96(44-48-109(153)195)167-110(196)65-160-129(214)95(46-50-114(201)202)171-134(219)99(55-72(2)3)175-135(220)102(59-85-40-42-88(194)43-41-85)177-140(225)106(68-189)181-142(227)108(70-191)182-144(229)118(75(8)9)186-139(224)105(62-116(205)206)178-141(226)107(69-190)183-147(232)121(82(16)193)188-138(223)103(58-84-33-22-19-23-34-84)180-146(231)120(81(15)192)184-112(198)67-161-128(213)94(45-49-113(199)200)170-124(209)79(13)164-126(211)90(152)61-87-64-156-71-162-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,158,189-194H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,195)(H,156,162)(H,159,212)(H,160,214)(H,161,213)(H,163,207)(H,164,211)(H,165,215)(H,166,218)(H,167,196)(H,168,197)(H,169,208)(H,170,209)(H,171,219)(H,172,216)(H,173,228)(H,174,210)(H,175,220)(H,176,221)(H,177,225)(H,178,226)(H,179,230)(H,180,231)(H,181,227)(H,182,229)(H,183,232)(H,184,198)(H,185,222)(H,186,224)(H,187,217)(H,188,223)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,233,234)(H4,154,155,157)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1
DMN54LS CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
DMN54LS IK UVENJQHDPZDEHP-KTKZVXAJSA-N
DMN54LS IU (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid
DMN54LS DE Discovery agent
DMO6MGJ ID DMO6MGJ
DMO6MGJ DN Haempatch
DMO6MGJ HS Investigative
DMO6MGJ SN Haemepatch; Q-8009; Q-8010
DMO6MGJ CP University of Queensland
DMO6MGJ DE Bleeding disorder
DM5S4AO ID DM5S4AO
DM5S4AO DN H-Ala-Pro-Phe-Phe-NH2
DM5S4AO HS Investigative
DM5S4AO SN CHEMBL589082; H-Ala-Pro-Phe-Phe-NH2
DM5S4AO DT Small molecular drug
DM5S4AO PC 46229263
DM5S4AO MW 479.6
DM5S4AO FM C26H33N5O4
DM5S4AO IC InChI=1S/C26H33N5O4/c1-17(27)26(35)31-14-8-13-22(31)25(34)30-21(16-19-11-6-3-7-12-19)24(33)29-20(23(28)32)15-18-9-4-2-5-10-18/h2-7,9-12,17,20-22H,8,13-16,27H2,1H3,(H2,28,32)(H,29,33)(H,30,34)/t17-,20+,21+,22+/m1/s1
DM5S4AO CS C[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)N
DM5S4AO IK PYBNVPBCTAEKPN-MNAPGUCWSA-N
DM5S4AO IU (2S)-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[(2R)-2-aminopropanoyl]pyrrolidine-2-carboxamide
DM5S4AO DE Discovery agent
DMJB87Q ID DMJB87Q
DMJB87Q DN Halisulfate 1
DMJB87Q HS Investigative
DMJB87Q SN CHEBI:69280; CHEMBL387584; halisulfate 1, (rel)-
DMJB87Q DT Small molecular drug
DMJB87Q PC 23662099
DMJB87Q MW 570.8
DMJB87Q FM C31H47NaO6S
DMJB87Q IC InChI=1S/C31H48O6S.Na/c1-21(11-13-24-19-25(32)14-15-27(24)33)9-7-10-23(3)28(37-38(34,35)36)20-26-22(2)12-16-29-30(4,5)17-8-18-31(26,29)6;/h11-12,14-15,19,23,26,28-29,32-33H,7-10,13,16-18,20H2,1-6H3,(H,34,35,36);/q;+1/p-1/b21-11+;/t23-,26+,28-,29+,31-;/m1./s1
DMJB87Q CS CC1=CC[C@@H]2[C@@]([C@H]1C[C@H]([C@H](C)CCC/C(=C/CC3=C(C=CC(=C3)O)O)/C)OS(=O)(=O)[O-])(CCCC2(C)C)C.[Na+]
DMJB87Q IK MWESFEYZPAHLCJ-NHDYRKAGSA-M
DMJB87Q IU sodium;[(E,2R,3R)-1-[(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-9-(2,5-dihydroxyphenyl)-3,7-dimethylnon-7-en-2-yl] sulfate
DMJB87Q CB CHEBI:69280
DMJB87Q DE Discovery agent
DMF6V8W ID DMF6V8W
DMF6V8W DN HALOPEMIDE
DMF6V8W HS Investigative
DMF6V8W SN Halopemide; 59831-65-1; UNII-65Q28TV0ZY; R 34,301; MLS003171133; 65Q28TV0ZY; CHEMBL245621; R-34301; N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide; Halopemida; Halopemidum; Halopemide [USAN:INN]; Halopemidum [INN-Latin]; Halopemida [INN-Spanish]; C21H22ClFN4O2; N-[2-[4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino]ethyl]-p-fluorobenzamide; Halopemide, 8; NSC 354856; Halopemide (USAN/INN); AC1L23CG; R 34301; MLS006012046; cid_65490; SCHEMBL121267; Halopemide, > CTK8G0128; AOB5520
DMF6V8W DT Small molecular drug
DMF6V8W PC 65490
DMF6V8W MW 416.9
DMF6V8W FM C21H22ClFN4O2
DMF6V8W IC InChI=1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29)
DMF6V8W CS C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCNC(=O)C4=CC=C(C=C4)F
DMF6V8W IK NBHPRWLFLUBAIE-UHFFFAOYSA-N
DMF6V8W IU N-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide
DMF6V8W CA CAS 59831-65-1
DMF6V8W DE Discovery agent
DMWCXPK ID DMWCXPK
DMWCXPK DN Haloperidol
DMWCXPK HS Investigative
DMWCXPK SN Haldol; Aloperidin; Serenace; Aloperidol; Eukystol; Brotopon; Einalon S; Ulcolind; Serenase; Uliolind; Serenelfi; Aloperidolo; Vesalium; Halopoidol; Galoperidol; Halojust; Pernox; Mixidol; Halopal; Linton; Sernel; Sernas; Dozic; Aldo; Lealgin compositum; Keselan; Peluces; Bioperidolo; Haldol Solutab; McN-JR-1625; Haloperidolum; Aloperidon; Fortunan; Aloperidolo [DCIT]; Aloperidolo [Italian]; Haloperidolum [INN-Latin]
DMWCXPK TC Antiviral Agents
DMWCXPK DT Small molecular drug
DMWCXPK PC 3559
DMWCXPK MW 375.9
DMWCXPK FM C21H23ClFNO2
DMWCXPK IC InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
DMWCXPK CS C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
DMWCXPK IK LNEPOXFFQSENCJ-UHFFFAOYSA-N
DMWCXPK IU 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
DMWCXPK CA CAS 52-86-8
DMWCXPK CB CHEBI:5613
DMWCXPK DE Coronavirus Disease 2019 (COVID-19)
DM5SULN ID DM5SULN
DM5SULN DN Haloxyfop
DM5SULN HS Investigative
DM5SULN SN HALOXYFOP; 69806-34-4; 2-(4-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)phenoxy)propanoic acid; Haloxyfop [ANSI:BSI:ISO]; Haloxyfop-P; GOCUAJYOYBLQRH-UHFFFAOYSA-N; 2-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenoxy]propanoic acid; 2-[4-[[3-chloro-5-(trifluoromethyl)-2-pyridyl]oxy]phenoxy]propanoic acid; 2-(4-((3-Chloro-5-(trifluoromethyl)-2-pyridinyl)oxy)phenoxy)propanoic acid; Propanoic acid, 2-[4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy]-
DM5SULN DT Small molecular drug
DM5SULN PC 50895
DM5SULN MW 361.7
DM5SULN FM C15H11ClF3NO4
DM5SULN IC InChI=1S/C15H11ClF3NO4/c1-8(14(21)22)23-10-2-4-11(5-3-10)24-13-12(16)6-9(7-20-13)15(17,18)19/h2-8H,1H3,(H,21,22)
DM5SULN CS CC(C(=O)O)OC1=CC=C(C=C1)OC2=C(C=C(C=N2)C(F)(F)F)Cl
DM5SULN IK GOCUAJYOYBLQRH-UHFFFAOYSA-N
DM5SULN IU 2-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenoxy]propanoic acid
DM5SULN CA CAS 69806-34-4
DM5SULN CB CHEBI:365
DM5SULN DE Discovery agent
DM4AEGQ ID DM4AEGQ
DM4AEGQ DN HALOXYSTEROL A
DM4AEGQ HS Investigative
DM4AEGQ SN haloxysterol A; CHEMBL202221
DM4AEGQ DT Small molecular drug
DM4AEGQ PC 44407168
DM4AEGQ MW 446.7
DM4AEGQ FM C29H50O3
DM4AEGQ IC InChI=1S/C29H50O3/c1-7-19(17(2)3)14-26(31)18(4)23-10-11-24-22-9-8-20-15-21(30)16-27(32)29(20,6)25(22)12-13-28(23,24)5/h8,17-19,21-27,30-32H,7,9-16H2,1-6H3/t18-,19+,21+,22?,23+,24?,25?,26+,27-,28+,29-/m0/s1
DM4AEGQ CS CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CCC3C2CC=C4[C@@]3([C@H](C[C@@H](C4)O)O)C)C)O)C(C)C
DM4AEGQ IK UNBKHVKAEFBHAN-IWAMNEIESA-N
DM4AEGQ IU (1S,3R,10R,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1,3-diol
DM4AEGQ DE Discovery agent
DMD8O7S ID DMD8O7S
DMD8O7S DN HALOXYSTEROL B
DMD8O7S HS Investigative
DMD8O7S SN haloxysterol B; CHEMBL202223
DMD8O7S DT Small molecular drug
DMD8O7S PC 11690845
DMD8O7S MW 444.7
DMD8O7S FM C29H48O3
DMD8O7S IC InChI=1S/C29H48O3/c1-7-19(17(2)3)14-26(31)18(4)23-10-11-24-22-9-8-20-15-21(30)16-27(32)29(20,6)25(22)12-13-28(23,24)5/h8-9,15,17-19,21-27,30-32H,7,10-14,16H2,1-6H3/t18-,19+,21+,22?,23+,24?,25?,26+,27-,28+,29-/m0/s1
DMD8O7S CS CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CCC3C2C=CC4=C[C@H](C[C@@H]([C@]34C)O)O)C)O)C(C)C
DMD8O7S IK MVMHIMFXUANMIR-IWAMNEIESA-N
DMD8O7S IU (1S,3S,10R,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-1,3-diol
DMD8O7S DE Discovery agent
DMU1DHM ID DMU1DHM
DMU1DHM DN Haloxysterol C
DMU1DHM HS Investigative
DMU1DHM SN haloxysterol C; CHEMBL382961
DMU1DHM DT Small molecular drug
DMU1DHM PC 44407175
DMU1DHM MW 426.7
DMU1DHM FM C29H46O2
DMU1DHM IC InChI=1S/C29H46O2/c1-7-20(18(2)3)16-27(31)19(4)24-10-11-25-23-9-8-21-17-22(30)12-14-28(21,5)26(23)13-15-29(24,25)6/h13,17-20,23-25,27,31H,7-12,14-16H2,1-6H3/t19-,20+,23?,24+,25?,27+,28-,29+/m0/s1
DMU1DHM CS CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CC=C3C2CCC4=CC(=O)CC[C@@]43C)C)O)C(C)C
DMU1DHM IK AHQRPBWVJHINRW-XHVUHYHXSA-N
DMU1DHM IU (10S,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,6,7,8,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
DMU1DHM DE Discovery agent
DMWCZLT ID DMWCZLT
DMWCZLT DN Haloxysterol D
DMWCZLT HS Investigative
DMWCZLT SN haloxysterol D; CHEMBL201253; SCHEMBL16227159
DMWCZLT DT Small molecular drug
DMWCZLT PC 44407203
DMWCZLT MW 480.7
DMWCZLT FM C29H52O5
DMWCZLT IC InChI=1S/C29H52O5/c1-7-18(16(2)3)12-24(31)17(4)21-8-9-22-20-14-26(33)29(34)15-19(30)13-25(32)28(29,6)23(20)10-11-27(21,22)5/h16-26,30-34H,7-15H2,1-6H3/t17-,18+,19-,20?,21+,22?,23?,24+,25-,26+,27+,28-,29-/m0/s1
DMWCZLT CS CC[C@H](C[C@H]([C@@H](C)[C@H]1CCC2[C@@]1(CCC3C2C[C@H]([C@@]4([C@@]3([C@H](C[C@@H](C4)O)O)C)O)O)C)O)C(C)C
DMWCZLT IK SENGWVUFOJLNFP-QDQFXZLYSA-N
DMWCZLT IU (1S,3S,5R,6R,10S,13S,17R)-17-[(2S,3R,5R)-5-ethyl-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-1,3,5,6-tetrol
DMWCZLT DE Discovery agent
DMJN0BL ID DMJN0BL
DMJN0BL DN HAMI3379
DMJN0BL HS Investigative
DMJN0BL SN HAMI3379; CHEMBL3342944; 712313-35-4; GTPL6197; SCHEMBL4518791; DTXSID80439859; MolPort-027-641-329; BDBM50033098; 3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic Acid
DMJN0BL DT Small molecular drug
DMJN0BL PC 10438479
DMJN0BL MW 595.7
DMJN0BL FM C34H45NO8
DMJN0BL IC InChI=1S/C34H45NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h13-18,23,25,27-28H,1-12,19-22H2,(H,35,36)(H,37,38)(H,39,40)
DMJN0BL CS C1CCC(CC1)OCCCCOC2=CC=C(C=C2)CCCOC3=C(C=C(C=C3)C(=O)O)C(=O)NC4CCCC(C4)C(=O)O
DMJN0BL IK HRJWSEPIRZRGCL-UHFFFAOYSA-N
DMJN0BL IU 3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic acid
DMJN0BL CA CAS 712313-35-4
DMJN0BL DE Discovery agent
DM5SUYP ID DM5SUYP
DM5SUYP DN H-Apa-ala-Gly-Phe-leu-OH
DM5SUYP HS Investigative
DM5SUYP SN CHEMBL247363; H-Apa-ala-Gly-Phe-leu-OH
DM5SUYP DT Small molecular drug
DM5SUYP PC 44439872
DM5SUYP MW 568.7
DM5SUYP FM C29H40N6O6
DM5SUYP IC InChI=1S/C29H40N6O6/c1-17(2)13-24(29(40)41)35-28(39)23(15-19-7-5-4-6-8-19)34-25(36)16-32-26(37)18(3)33-27(38)22(31)14-20-9-11-21(30)12-10-20/h4-12,17-18,22-24H,13-16,30-31H2,1-3H3,(H,32,37)(H,33,38)(H,34,36)(H,35,39)(H,40,41)/t18-,22-,23-,24-/m0/s1
DM5SUYP CS C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)N)N
DM5SUYP IK DFYAWCYXKNEWBW-IMNFJDCFSA-N
DM5SUYP IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-aminophenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM5SUYP DE Discovery agent
DM9K6H5 ID DM9K6H5
DM9K6H5 DN HAp-IFN
DM9K6H5 HS Investigative
DM9K6H5 SN Hydroxyapatite-IFN (hepatitis C), LTT Bio-Pharma
DM9K6H5 CP LTT Bio-Pharma Co Ltd
DM9K6H5 DE Hepatitis C virus infection
DMENVKA ID DMENVKA
DMENVKA DN H-Arg-Arg-Pro-Tyr-Ile-Aac-OH
DMENVKA HS Investigative
DMENVKA SN CHEMBL507382; H-Arg-Arg-Pro-Tyr-Ile-Aac-OH
DMENVKA DT Small molecular drug
DMENVKA PC 44578945
DMENVKA MW 881.1
DMENVKA FM C43H68N12O8
DMENVKA IC InChI=1S/C43H68N12O8/c1-3-23(2)34(38(60)54-43(40(62)63)27-18-25-17-26(20-27)21-28(43)19-25)53-36(58)32(22-24-10-12-29(56)13-11-24)52-37(59)33-9-6-16-55(33)39(61)31(8-5-15-50-42(47)48)51-35(57)30(44)7-4-14-49-41(45)46/h10-13,23,25-28,30-34,56H,3-9,14-22,44H2,1-2H3,(H,51,57)(H,52,59)(H,53,58)(H,54,60)(H,62,63)(H4,45,46,49)(H4,47,48,50)/t23-,25?,26?,27?,28?,30-,31-,32-,33-,34-,43?/m0/s1
DMENVKA CS CC[C@H](C)[C@@H](C(=O)NC1(C2CC3CC(C2)CC1C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DMENVKA IK CMCIRTPGPAKLJS-YTNDVNQYSA-N
DMENVKA IU 2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]adamantane-2-carboxylic acid
DMENVKA DE Discovery agent
DM4FKR1 ID DM4FKR1
DM4FKR1 DN H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH
DM4FKR1 HS Investigative
DM4FKR1 SN CHEMBL508130; H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH
DM4FKR1 DT Small molecular drug
DM4FKR1 PC 44578943
DM4FKR1 MW 831
DM4FKR1 FM C39H66N12O8
DM4FKR1 IC InChI=1S/C39H66N12O8/c1-6-23(4)31(36(57)50(5)30(37(58)59)20-22(2)3)49-33(54)28(21-24-13-15-25(52)16-14-24)48-34(55)29-12-9-19-51(29)35(56)27(11-8-18-46-39(43)44)47-32(53)26(40)10-7-17-45-38(41)42/h13-16,22-23,26-31,52H,6-12,17-21,40H2,1-5H3,(H,47,53)(H,48,55)(H,49,54)(H,58,59)(H4,41,42,45)(H4,43,44,46)/t23-,26-,27-,28-,29-,30-,31-/m0/s1
DM4FKR1 CS CC[C@H](C)[C@@H](C(=O)N(C)[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DM4FKR1 IK DUYQEARXOLBXOJ-VGPFALITSA-N
DM4FKR1 IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]-methylamino]-4-methylpentanoic acid
DM4FKR1 DE Discovery agent
DM107RT ID DM107RT
DM107RT DN H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH
DM107RT HS Investigative
DM107RT SN CHEMBL503059; H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH
DM107RT DT Small molecular drug
DM107RT PC 44578944
DM107RT MW 831
DM107RT FM C39H66N12O8
DM107RT IC InChI=1S/C39H66N12O8/c1-6-23(4)31(34(55)49-29(37(58)59)20-22(2)3)50(5)35(56)28(21-24-13-15-25(52)16-14-24)48-33(54)30-12-9-19-51(30)36(57)27(11-8-18-46-39(43)44)47-32(53)26(40)10-7-17-45-38(41)42/h13-16,22-23,26-31,52H,6-12,17-21,40H2,1-5H3,(H,47,53)(H,48,54)(H,49,55)(H,58,59)(H4,41,42,45)(H4,43,44,46)/t23-,26-,27-,28-,29-,30-,31-/m0/s1
DM107RT CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)N(C)C(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DM107RT IK AGCKRBKIEACUSP-VGPFALITSA-N
DM107RT IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]-methylamino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DM107RT DE Discovery agent
DMSXLKJ ID DMSXLKJ
DMSXLKJ DN H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH
DMSXLKJ HS Investigative
DMSXLKJ SN CHEMBL443967; H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH
DMSXLKJ DT Small molecular drug
DMSXLKJ PC 10102003
DMSXLKJ MW 831
DMSXLKJ FM C39H66N12O8
DMSXLKJ IC InChI=1S/C39H66N12O8/c1-6-23(4)31(34(55)48-28(37(58)59)20-22(2)3)49-32(53)27(21-24-13-15-25(52)16-14-24)47-33(54)29-12-9-19-51(29)36(57)30(11-8-18-46-39(43)44)50(5)35(56)26(40)10-7-17-45-38(41)42/h13-16,22-23,26-31,52H,6-12,17-21,40H2,1-5H3,(H,47,54)(H,48,55)(H,49,53)(H,58,59)(H4,41,42,45)(H4,43,44,46)/t23-,26-,27-,28-,29-,30-,31-/m0/s1
DMSXLKJ CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)N
DMSXLKJ IK FMWPNVFPKCUWHA-VGPFALITSA-N
DMSXLKJ IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]-methylamino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMSXLKJ DE Discovery agent
DMJ6N1X ID DMJ6N1X
DMJ6N1X DN H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH
DMJ6N1X HS Investigative
DMJ6N1X SN Substance P (1-7); CHEMBL589979; H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH; 68060-49-1; 1-7-SubstanceP; Substance P(1-7); SCHEMBL17887920; HY-P1485; BDBM50308381; MFCD00076789; ZINC169311322; NCGC00167124-01; CS-0044424
DMJ6N1X DT Small molecular drug
DMJ6N1X PC 10440769
DMJ6N1X MW 900
DMJ6N1X FM C41H65N13O10
DMJ6N1X IC InChI=1S/C41H65N13O10/c42-19-5-4-12-28(51-37(60)30-13-7-21-53(30)38(61)25(43)11-6-20-48-41(46)47)39(62)54-22-8-14-31(54)36(59)50-27(16-18-33(45)56)34(57)49-26(15-17-32(44)55)35(58)52-29(40(63)64)23-24-9-2-1-3-10-24/h1-3,9-10,25-31H,4-8,11-23,42-43H2,(H2,44,55)(H2,45,56)(H,49,57)(H,50,59)(H,51,60)(H,52,58)(H,63,64)(H4,46,47,48)/t25-,26-,27-,28-,29-,30-,31-/m0/s1
DMJ6N1X CS C1C[C@H](N(C1)C(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O
DMJ6N1X IK KPHDBQWTCKBKIL-XIJWKTHWSA-N
DMJ6N1X IU (2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoic acid
DMJ6N1X DE Discovery agent
DM5VDU2 ID DM5VDU2
DM5VDU2 DN HBN-2
DM5VDU2 HS Investigative
DM5VDU2 CP University of North Carolina
DM5VDU2 DE Neurological disorder
DMKDBFL ID DMKDBFL
DMKDBFL DN HBR-985
DMKDBFL HS Investigative
DMKDBFL SN Glicondamide; 52994-25-9; UNII-876SH4764F; C18H20ClN3O5S; 876SH4764F; 1-[[p-[2-(5-chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-methylurea; Glicondamide [INN]; 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-methylurea; AC1Q3LT7; CHEMBL12806; AC1L562G; SCHEMBL1818252; CTK4J6836; DTXSID10201026; ZINC537790; HB-985; AKOS030573774; ACM52994259; W0037; 5-chloro-2-methoxy-N-[2-[4-(methylcarbamoylsulfamoyl)phenyl]ethyl]benzamide
DMKDBFL DT Small molecular drug
DMKDBFL PC 219108
DMKDBFL MW 425.9
DMKDBFL FM C18H20ClN3O5S
DMKDBFL IC InChI=1S/C18H20ClN3O5S/c1-20-18(24)22-28(25,26)14-6-3-12(4-7-14)9-10-21-17(23)15-11-13(19)5-8-16(15)27-2/h3-8,11H,9-10H2,1-2H3,(H,21,23)(H2,20,22,24)
DMKDBFL CS CNC(=O)NS(=O)(=O)C1=CC=C(C=C1)CCNC(=O)C2=C(C=CC(=C2)Cl)OC
DMKDBFL IK RXOBKRPNVDTZQF-UHFFFAOYSA-N
DMKDBFL IU 5-chloro-2-methoxy-N-[2-[4-(methylcarbamoylsulfamoyl)phenyl]ethyl]benzamide
DMKDBFL CA CAS 52994-25-9
DMKDBFL DE Discovery agent
DMCQH23 ID DMCQH23
DMCQH23 DN H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH
DMCQH23 HS Investigative
DMCQH23 SN CHEMBL438247; H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH
DMCQH23 DT Small molecular drug
DMCQH23 PC 10581102
DMCQH23 MW 784.9
DMCQH23 FM C36H48N8O8S2
DMCQH23 IC InChI=1S/C36H48N8O8S2/c1-20(45)30-35(50)43-29(36(51)52)19-54-53-18-24(38)31(46)41-27(15-21-9-3-2-4-10-21)33(48)42-28(16-22-17-39-25-12-6-5-11-23(22)25)34(49)40-26(32(47)44-30)13-7-8-14-37/h2-6,9-12,17,20,24,26-30,39,45H,7-8,13-16,18-19,37-38H2,1H3,(H,40,49)(H,41,46)(H,42,48)(H,43,50)(H,44,47)(H,51,52)/t20-,24+,26+,27+,28-,29+,30+/m1/s1
DMCQH23 CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)N)C(=O)O)O
DMCQH23 IK XNCLQDHGWMNJRY-XJVQTVDVSA-N
DMCQH23 IU (4R,7S,10S,13R,16S,19R)-19-amino-10-(4-aminobutyl)-16-benzyl-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxylic acid
DMCQH23 DE Discovery agent
DMOY2AI ID DMOY2AI
DMOY2AI DN HC-030031
DMOY2AI HS Investigative
DMOY2AI SN TRPA1 inhibitor (pain/inflammation), Hydra Biosciences/Cubist Pharmaceuticals
DMOY2AI CP Hydra Biosciences Inc
DMOY2AI DT Small molecular drug
DMOY2AI PC 1150897
DMOY2AI MW 355.4
DMOY2AI FM C18H21N5O3
DMOY2AI IC InChI=1S/C18H21N5O3/c1-11(2)12-5-7-13(8-6-12)20-14(24)9-23-10-19-16-15(23)17(25)22(4)18(26)21(16)3/h5-8,10-11H,9H2,1-4H3,(H,20,24)
DMOY2AI CS CC(C)C1=CC=C(C=C1)NC(=O)CN2C=NC3=C2C(=O)N(C(=O)N3C)C
DMOY2AI IK HEQDZPHDVAOBLN-UHFFFAOYSA-N
DMOY2AI IU 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-N-(4-propan-2-ylphenyl)acetamide
DMOY2AI CA CAS 349085-38-7
DMOY2AI DE Inflammation
DMOG1Q4 ID DMOG1Q4
DMOG1Q4 DN HC-056456
DMOG1Q4 HS Investigative
DMOG1Q4 SN HC056456
DMOG1Q4 DT Small molecular drug
DMOG1Q4 PC 573747
DMOG1Q4 MW 306.3
DMOG1Q4 FM C12H6N2O4S2
DMOG1Q4 IC InChI=1S/C12H6N2O4S2/c15-11(7-3-1-5-19-7)9-10(14(17)18-13-9)12(16)8-4-2-6-20-8/h1-6H
DMOG1Q4 CS C1=CSC(=C1)C(=O)C2=NO[N+](=C2C(=O)C3=CC=CS3)[O-]
DMOG1Q4 IK RUQGCDMXFBOTMW-UHFFFAOYSA-N
DMOG1Q4 IU [5-oxido-4-(thiophene-2-carbonyl)-1,2,5-oxadiazol-5-ium-3-yl]-thiophen-2-ylmethanone
DMOG1Q4 CA CAS 7733-96-2
DMOG1Q4 DE Discovery agent
DMIXY1O ID DMIXY1O
DMIXY1O DN HC067047
DMIXY1O HS Investigative
DMIXY1O SN HC 067047
DMIXY1O DT Small molecular drug
DMIXY1O PC 2742550
DMIXY1O MW 471.5
DMIXY1O FM C26H28F3N3O2
DMIXY1O IC InChI=1S/C26H28F3N3O2/c1-19-23(25(33)30-22-10-5-9-21(17-22)26(27,28)29)18-24(20-7-3-2-4-8-20)32(19)12-6-11-31-13-15-34-16-14-31/h2-5,7-10,17-18H,6,11-16H2,1H3,(H,30,33)
DMIXY1O CS CC1=C(C=C(N1CCCN2CCOCC2)C3=CC=CC=C3)C(=O)NC4=CC=CC(=C4)C(F)(F)F
DMIXY1O IK NCZYSQOTAYFTNM-UHFFFAOYSA-N
DMIXY1O IU 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-N-[3-(trifluoromethyl)phenyl]pyrrole-3-carboxamide
DMIXY1O CA CAS 883031-03-6
DMIXY1O DE Discovery agent
DM1BLCX ID DM1BLCX
DM1BLCX DN HC3-1496
DM1BLCX HS Investigative
DM1BLCX SN RC3 Decomplase; RC3-1
DM1BLCX CP InCode BioPharmaceutics Inc
DM1BLCX DE Autoimmune diabetes
DMV751G ID DMV751G
DMV751G DN H-Cdp-ala-Gly-Phe-leu-OH
DMV751G HS Investigative
DMV751G SN CHEMBL247758; H-Cdp-ala-Gly-Phe-leu-OH
DMV751G DT Small molecular drug
DMV751G PC 44439876
DMV751G MW 624.7
DMV751G FM C32H44N6O7
DMV751G IC InChI=1S/C32H44N6O7/c1-17(2)11-26(32(44)45)38-31(43)25(14-21-9-7-6-8-10-21)37-27(39)16-35-29(41)20(5)36-30(42)24(33)15-23-18(3)12-22(28(34)40)13-19(23)4/h6-10,12-13,17,20,24-26H,11,14-16,33H2,1-5H3,(H2,34,40)(H,35,41)(H,36,42)(H,37,39)(H,38,43)(H,44,45)/t20-,24-,25-,26-/m0/s1
DMV751G CS CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)N)C)C(=O)N
DMV751G IK MNNRFUWQCDJULI-CGIBELHQSA-N
DMV751G IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMV751G DE Discovery agent
DMVEB8C ID DMVEB8C
DMVEB8C DN H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C HS Investigative
DMVEB8C SN CHEMBL246739; H-Cdp-Gly-Gly-Phe-Leu-OH
DMVEB8C DT Small molecular drug
DMVEB8C PC 44439880
DMVEB8C MW 610.7
DMVEB8C FM C31H42N6O7
DMVEB8C IC InChI=1S/C31H42N6O7/c1-17(2)10-25(31(43)44)37-30(42)24(13-20-8-6-5-7-9-20)36-27(39)16-34-26(38)15-35-29(41)23(32)14-22-18(3)11-21(28(33)40)12-19(22)4/h5-9,11-12,17,23-25H,10,13-16,32H2,1-4H3,(H2,33,40)(H,34,38)(H,35,41)(H,36,39)(H,37,42)(H,43,44)/t23-,24-,25-/m0/s1
DMVEB8C CS CC1=CC(=CC(=C1C[C@@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)O)N)C)C(=O)N
DMVEB8C IK AYRRYHMNASIQTF-SDHOMARFSA-N
DMVEB8C IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMVEB8C DE Discovery agent
DMCDLTV ID DMCDLTV
DMCDLTV DN H-Cdp-ser-Gly-Phe-Leu-Thr-OH
DMCDLTV HS Investigative
DMCDLTV SN CHEMBL247760; H-Cdp-ser-Gly-Phe-Leu-Thr-OH
DMCDLTV DT Small molecular drug
DMCDLTV PC 44439905
DMCDLTV MW 741.8
DMCDLTV FM C36H51N7O10
DMCDLTV IC InChI=1S/C36H51N7O10/c1-18(2)11-26(35(51)43-30(21(5)45)36(52)53)41-34(50)27(14-22-9-7-6-8-10-22)40-29(46)16-39-33(49)28(17-44)42-32(48)25(37)15-24-19(3)12-23(31(38)47)13-20(24)4/h6-10,12-13,18,21,25-28,30,44-45H,11,14-17,37H2,1-5H3,(H2,38,47)(H,39,49)(H,40,46)(H,41,50)(H,42,48)(H,43,51)(H,52,53)/t21-,25+,26+,27+,28+,30+/m1/s1
DMCDLTV CS CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)C)C(=O)N
DMCDLTV IK OCIDAPABHMBEIS-VVPQYXBXSA-N
DMCDLTV IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DMCDLTV DE Discovery agent
DM415ZX ID DM415ZX
DM415ZX DN HCGRPalpha
DM415ZX HS Investigative
DM415ZX PC 44308929
DM415ZX MW 3789.3
DM415ZX FM C163H267N51O49S2
DM415ZX IC InChI=1S/C163H267N51O49S2/c1-73(2)52-97(186-116(226)65-179-131(233)82(18)183-139(241)98(53-74(3)4)193-137(239)94(44-35-49-176-162(171)172)188-142(244)101(57-91-62-175-72-182-91)199-159(261)128(88(24)221)213-156(258)123(79(13)14)207-151(253)110-71-265-264-70-109(203-130(232)81(17)166)150(252)198-105(61-119(229)230)147(249)211-125(85(21)218)157(259)185-84(20)133(235)210-126(86(22)219)160(262)204-110)140(242)194-99(54-75(5)6)141(243)202-108(69-217)149(251)190-95(45-36-50-177-163(173)174)138(240)201-106(67-215)134(236)180-63-115(225)178-64-118(228)205-121(77(9)10)155(257)208-122(78(11)12)154(256)191-93(43-32-34-48-165)136(238)196-102(58-112(167)222)144(246)197-103(59-113(168)223)143(245)195-100(56-90-40-29-26-30-41-90)145(247)209-124(80(15)16)161(263)214-51-37-46-111(214)152(254)212-127(87(23)220)158(260)200-104(60-114(169)224)146(248)206-120(76(7)8)153(255)181-66-117(227)187-107(68-216)148(250)189-92(42-31-33-47-164)135(237)184-83(19)132(234)192-96(129(170)231)55-89-38-27-25-28-39-89/h25-30,38-41,62,72-88,92-111,120-128,215-221H,31-37,42-61,63-71,164-166H2,1-24H3,(H2,167,222)(H2,168,223)(H2,169,224)(H2,170,231)(H,175,182)(H,178,225)(H,179,233)(H,180,236)(H,181,255)(H,183,241)(H,184,237)(H,185,259)(H,186,226)(H,187,227)(H,188,244)(H,189,250)(H,190,251)(H,191,256)(H,192,234)(H,193,239)(H,194,242)(H,195,245)(H,196,238)(H,197,246)(H,198,252)(H,199,261)(H,200,260)(H,201,240)(H,202,243)(H,203,232)(H,204,262)(H,205,228)(H,206,248)(H,207,253)(H,208,257)(H,209,247)(H,210,235)(H,211,249)(H,212,254)(H,213,258)(H,229,230)(H4,171,172,176)(H4,173,174,177)/t81-,82+,83+,84-,85+,86+,87-,88-,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105-,106+,107+,108+,109-,110+,111?,120+,121+,122+,123+,124+,125+,126+,127+,128+/m1/s1
DM415ZX CS C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)CC(=O)O)NC(=O)[C@@H](C)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N4CCCC4C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)[C@H](C)O
DM415ZX IK JMJJWZFCOWFIBU-NFAXDPBFSA-N
DM415ZX IU 2-[(4R,7S,10R,13S,16R,19S)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[2-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-19-[[(2R)-2-aminopropanoyl]amino]-7,13-bis[(1S)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-16-yl]acetic acid
DM415ZX DE Discovery agent
DM3V4XG ID DM3V4XG
DM3V4XG DN H-Cpa-c[pen-Gly-Phe-pen]OH
DM3V4XG HS Investigative
DM3V4XG DT Small molecular drug
DM3V4XG PC 73354725
DM3V4XG MW 672.8
DM3V4XG FM C31H40N6O7S2
DM3V4XG IC InChI=1S/C31H40N6O7S2/c1-30(2)23(36-26(40)20(32)14-18-10-12-19(13-11-18)25(33)39)28(42)34-16-22(38)35-21(15-17-8-6-5-7-9-17)27(41)37-24(29(43)44)31(3,4)46-45-30/h5-13,20-21,23-24H,14-16,32H2,1-4H3,(H2,33,39)(H,34,42)(H,35,38)(H,36,40)(H,37,41)(H,43,44)/t20-,21-,23-,24-/m0/s1
DM3V4XG CS CC1([C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)C(=O)N)N)C
DM3V4XG IK KFLVOLBPEGAIIK-WMIMKTLMSA-N
DM3V4XG IU (4S,7S,13S)-13-[[(2S)-2-amino-3-(4-carbamoylphenyl)propanoyl]amino]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
DM3V4XG DE Discovery agent
DMU6PV8 ID DMU6PV8
DMU6PV8 DN H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8 HS Investigative
DMU6PV8 SN CHEMBL246956; H-Cpa-Gly-Gly-Phe-Met-NH2
DMU6PV8 DT Small molecular drug
DMU6PV8 PC 44439866
DMU6PV8 MW 599.7
DMU6PV8 FM C28H37N7O6S
DMU6PV8 IC InChI=1S/C28H37N7O6S/c1-42-12-11-21(26(31)39)35-28(41)22(14-17-5-3-2-4-6-17)34-24(37)16-32-23(36)15-33-27(40)20(29)13-18-7-9-19(10-8-18)25(30)38/h2-10,20-22H,11-16,29H2,1H3,(H2,30,38)(H2,31,39)(H,32,36)(H,33,40)(H,34,37)(H,35,41)/t20-,21-,22-/m0/s1
DMU6PV8 CS CSCC[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)C(=O)N)N
DMU6PV8 IK WVSXHGGHIPRNNC-FKBYEOEOSA-N
DMU6PV8 IU 4-[(2S)-2-amino-3-[[2-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-oxopropyl]benzamide
DMU6PV8 DE Discovery agent
DM154G2 ID DM154G2
DM154G2 DN H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2 HS Investigative
DM154G2 SN CHEMBL391580; H-Cpa-Gly-Gly-Phe-Met-OH
DM154G2 DT Small molecular drug
DM154G2 PC 11250396
DM154G2 MW 600.7
DM154G2 FM C28H36N6O7S
DM154G2 IC InChI=1S/C28H36N6O7S/c1-42-12-11-21(28(40)41)34-27(39)22(14-17-5-3-2-4-6-17)33-24(36)16-31-23(35)15-32-26(38)20(29)13-18-7-9-19(10-8-18)25(30)37/h2-10,20-22H,11-16,29H2,1H3,(H2,30,37)(H,31,35)(H,32,38)(H,33,36)(H,34,39)(H,40,41)/t20-,21-,22-/m0/s1
DM154G2 CS CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)C(=O)N)N
DM154G2 IK OOJZMMQHNUJUPF-FKBYEOEOSA-N
DM154G2 IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-carbamoylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid
DM154G2 DE Discovery agent
DMPL0BR ID DMPL0BR
DMPL0BR DN H-Cxp-ala-Gly-Phe-leu-OH
DMPL0BR HS Investigative
DMPL0BR SN CHEMBL247163; H-Cxp-ala-Gly-Phe-leu-OH
DMPL0BR DT Small molecular drug
DMPL0BR PC 44439873
DMPL0BR MW 597.7
DMPL0BR FM C30H39N5O8
DMPL0BR IC InChI=1S/C30H39N5O8/c1-17(2)13-24(30(42)43)35-28(39)23(15-19-7-5-4-6-8-19)34-25(36)16-32-26(37)18(3)33-27(38)22(31)14-20-9-11-21(12-10-20)29(40)41/h4-12,17-18,22-24H,13-16,31H2,1-3H3,(H,32,37)(H,33,38)(H,34,36)(H,35,39)(H,40,41)(H,42,43)/t18-,22-,23-,24-/m0/s1
DMPL0BR CS C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)C(=O)O)N
DMPL0BR IK YGSPIRVSMFDGND-IMNFJDCFSA-N
DMPL0BR IU 4-[(2S)-2-amino-3-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-3-methylbutyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]benzoic acid
DMPL0BR DE Discovery agent
DM6839G ID DM6839G
DM6839G DN H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638)
DM6839G HS Investigative
DM6839G SN CHEMBL216618; H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638); JMV 1638
DM6839G PC 44316621
DM6839G MW 1092.2
DM6839G FM C49H69N15O12S
DM6839G IC InChI=1S/C49H69N15O12S/c50-30(10-5-15-55-48(51)52)41(70)58-31(11-6-16-56-49(53)54)45(74)62-17-7-13-35(62)47(76)63-22-29(66)20-36(63)43(72)57-21-38(67)61-40(28-18-26-8-1-2-9-27(26)19-28)44(73)59-32(24-65)42(71)60-33-25-77-37-14-4-3-12-34(37)64(46(33)75)23-39(68)69/h1-4,8-9,12,14,28-33,35-36,40,65-66H,5-7,10-11,13,15-25,50H2,(H,57,72)(H,58,70)(H,59,73)(H,60,71)(H,61,67)(H,68,69)(H4,51,52,55)(H4,53,54,56)/t29?,30?,31-,32+,33-,35+,36+,40?/m1/s1
DM6839G CS C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(C3CC4=CC=CC=C4C3)C(=O)N[C@@H](CO)C(=O)N[C@@H]5CSC6=CC=CC=C6N(C5=O)CC(=O)O)O
DM6839G IK BBKUNIDRTSPPPW-XBNUIVHSSA-N
DM6839G IU 2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-2-(2,3-dihydro-1H-inden-2-yl)acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DM6839G DE Discovery agent
DM9WJZK ID DM9WJZK
DM9WJZK DN H-Dmt-Aba-Gly-NH-CH2-Bid
DM9WJZK HS Investigative
DM9WJZK SN CHEMBL211543; H-Dmt-Aba-Gly-NH-CH2-Bid
DM9WJZK DT Small molecular drug
DM9WJZK PC 11721803
DM9WJZK MW 497.6
DM9WJZK FM C29H31N5O3
DM9WJZK IC InChI=1S/C29H31N5O3/c1-17-11-21(35)12-18(2)22(17)14-23(30)28(36)33-26-13-19-7-3-4-8-20(19)15-34(29(26)37)16-27-31-24-9-5-6-10-25(24)32-27/h3-12,23,26,35H,13-16,30H2,1-2H3,(H,31,32)(H,33,36)/t23-,26-/m0/s1
DM9WJZK CS CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CC4=NC5=CC=CC=C5N4)N)C)O
DM9WJZK IK KNVMNIVKKSUNLC-OZXSUGGESA-N
DM9WJZK IU (2S)-2-amino-N-[(4S)-2-(1H-benzimidazol-2-ylmethyl)-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxy-2,6-dimethylphenyl)propanamide
DM9WJZK DE Discovery agent
DM61CMS ID DM61CMS
DM61CMS DN H-Dmt-Aba-Gly-NH-CH2-Ph
DM61CMS HS Investigative
DM61CMS SN CHEMBL208683; H-Dmt-Aba-Gly-NH-CH2-Ph; BDBM50189920
DM61CMS DT Small molecular drug
DM61CMS PC 11664525
DM61CMS MW 514.6
DM61CMS FM C30H34N4O4
DM61CMS IC InChI=1S/C30H34N4O4/c1-19-12-24(35)13-20(2)25(19)15-26(31)29(37)33-27-14-22-10-6-7-11-23(22)17-34(30(27)38)18-28(36)32-16-21-8-4-3-5-9-21/h3-13,26-27,35H,14-18,31H2,1-2H3,(H,32,36)(H,33,37)/t26-,27-/m0/s1
DM61CMS CS CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CC(=O)NCC4=CC=CC=C4)N)C)O
DM61CMS IK HAQFBGNRXYPSQF-SVBPBHIXSA-N
DM61CMS IU (2S)-2-amino-N-[(4S)-2-[2-(benzylamino)-2-oxoethyl]-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxy-2,6-dimethylphenyl)propanamide
DM61CMS DE Discovery agent
DMCQYIJ ID DMCQYIJ
DMCQYIJ DN H-Dmt-Aba-Gly-NH-Ph
DMCQYIJ HS Investigative
DMCQYIJ SN CHEMBL377392; H-Dmt-Aba-Gly-NH-Ph
DMCQYIJ DT Small molecular drug
DMCQYIJ PC 11635818
DMCQYIJ MW 500.6
DMCQYIJ FM C29H32N4O4
DMCQYIJ IC InChI=1S/C29H32N4O4/c1-18-12-23(34)13-19(2)24(18)15-25(30)28(36)32-26-14-20-8-6-7-9-21(20)16-33(29(26)37)17-27(35)31-22-10-4-3-5-11-22/h3-13,25-26,34H,14-17,30H2,1-2H3,(H,31,35)(H,32,36)/t25-,26-/m0/s1
DMCQYIJ CS CC1=CC(=CC(=C1C[C@@H](C(=O)N[C@H]2CC3=CC=CC=C3CN(C2=O)CC(=O)NC4=CC=CC=C4)N)C)O
DMCQYIJ IK JYNUREYKNAJNLW-UIOOFZCWSA-N
DMCQYIJ IU (2S)-2-amino-N-[(4S)-2-(2-anilino-2-oxoethyl)-3-oxo-4,5-dihydro-1H-2-benzazepin-4-yl]-3-(4-hydroxy-2,6-dimethylphenyl)propanamide
DMCQYIJ DE Discovery agent
DMHK70B ID DMHK70B
DMHK70B DN H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2
DMHK70B HS Investigative
DMHK70B SN CHEMBL371856; H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2
DMHK70B DT Small molecular drug
DMHK70B PC 44399141
DMHK70B MW 818.9
DMHK70B FM C40H54N10O9
DMHK70B IC InChI=1S/C40H54N10O9/c1-25-20-29(51)21-26(2)30(25)23-31(41)36(53)47-33(17-11-19-44-39(43)49-50(57)58)37(54)48-34(22-27-12-5-3-6-13-27)38(55)46-32(35(42)52)16-9-10-18-45-40(56)59-24-28-14-7-4-8-15-28/h3-8,12-15,20-21,31-34,51H,9-11,16-19,22-24,41H2,1-2H3,(H2,42,52)(H,45,56)(H,46,55)(H,47,53)(H,48,54)(H3,43,44,49)/t31?,32-,33+,34-/m0/s1
DMHK70B CS CC1=CC(=CC(=C1CC(C(=O)N[C@H](CCCN=C(N)N[N+](=O)[O-])C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCNC(=O)OCC3=CC=CC=C3)C(=O)N)N)C)O
DMHK70B IK LMMJRHRZYGSRLK-OPTRWXFLSA-N
DMHK70B IU benzyl N-[(5S)-6-amino-5-[[(2S)-2-[[(2R)-2-[[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-5-[[amino(nitramido)methylidene]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-6-oxohexyl]carbamate
DMHK70B DE Discovery agent
DMM9EPQ ID DMM9EPQ
DMM9EPQ DN H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
DMM9EPQ HS Investigative
DMM9EPQ SN CHEMBL370701; H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH
DMM9EPQ DT Small molecular drug
DMM9EPQ PC 44399025
DMM9EPQ MW 819.9
DMM9EPQ FM C40H53N9O10
DMM9EPQ IC InChI=1S/C40H53N9O10/c1-25-20-29(50)21-26(2)30(25)23-31(41)35(51)45-32(17-11-19-43-39(42)48-49(57)58)36(52)47-34(22-27-12-5-3-6-13-27)37(53)46-33(38(54)55)16-9-10-18-44-40(56)59-24-28-14-7-4-8-15-28/h3-8,12-15,20-21,31-34,50H,9-11,16-19,22-24,41H2,1-2H3,(H,44,56)(H,45,51)(H,46,53)(H,47,52)(H,54,55)(H3,42,43,48)/t31?,32-,33+,34+/m1/s1
DMM9EPQ CS CC1=CC(=CC(=C1CC(C(=O)N[C@H](CCCN=C(N)N[N+](=O)[O-])C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCCNC(=O)OCC3=CC=CC=C3)C(=O)O)N)C)O
DMM9EPQ IK DTKHPEUFGZLWTF-OYKWTTPJSA-N
DMM9EPQ IU (2S)-2-[[(2S)-2-[[(2R)-2-[[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-5-[[amino(nitramido)methylidene]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]-6-(phenylmethoxycarbonylamino)hexanoic acid
DMM9EPQ DE Discovery agent
DM1ZDJ6 ID DM1ZDJ6
DM1ZDJ6 DN H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2
DM1ZDJ6 HS Investigative
DM1ZDJ6 SN CHEMBL218781; H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2
DM1ZDJ6 DT Small molecular drug
DM1ZDJ6 PC 44418916
DM1ZDJ6 MW 681.9
DM1ZDJ6 FM C40H51N5O5
DM1ZDJ6 IC InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33+,34+,35?,36-/m1/s1
DM1ZDJ6 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DM1ZDJ6 IK KIHHZGQBWZPIMS-RUXLTPPNSA-N
DM1ZDJ6 IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2R,3R)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM1ZDJ6 DE Discovery agent
DMC3APN ID DMC3APN
DMC3APN DN H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH
DMC3APN HS Investigative
DMC3APN SN CHEMBL375094; H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH
DMC3APN DT Small molecular drug
DMC3APN PC 44418912
DMC3APN MW 682.8
DMC3APN FM C40H50N4O6
DMC3APN IC InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33+,34+,35?,36-/m1/s1
DMC3APN CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMC3APN IK GWHRSTGESQKJIQ-RUXLTPPNSA-N
DMC3APN IU (2S)-2-[[(2R,3R)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMC3APN DE Discovery agent
DMY97TN ID DMY97TN
DMY97TN DN H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2
DMY97TN HS Investigative
DMY97TN SN CHEMBL218782; H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2
DMY97TN DT Small molecular drug
DMY97TN PC 44418918
DMY97TN MW 681.9
DMY97TN FM C40H51N5O5
DMY97TN IC InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33-,34-,35?,36+/m0/s1
DMY97TN CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DMY97TN IK KIHHZGQBWZPIMS-FVTMYMNWSA-N
DMY97TN IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2R,3S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMY97TN DE Discovery agent
DMGPAM0 ID DMGPAM0
DMGPAM0 DN H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH
DMGPAM0 HS Investigative
DMGPAM0 SN CHEMBL376453; H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH
DMGPAM0 DT Small molecular drug
DMGPAM0 PC 44418914
DMGPAM0 MW 682.8
DMGPAM0 FM C40H50N4O6
DMGPAM0 IC InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33-,34-,35?,36+/m0/s1
DMGPAM0 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMGPAM0 IK GWHRSTGESQKJIQ-FVTMYMNWSA-N
DMGPAM0 IU (2S)-2-[[(2R,3S)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMGPAM0 DE Discovery agent
DMOI1U5 ID DMOI1U5
DMOI1U5 DN H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2
DMOI1U5 HS Investigative
DMOI1U5 SN CHEMBL415426; H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2
DMOI1U5 DT Small molecular drug
DMOI1U5 PC 44418917
DMOI1U5 MW 681.9
DMOI1U5 FM C40H51N5O5
DMOI1U5 IC InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33+,34+,35?,36+/m1/s1
DMOI1U5 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DMOI1U5 IK KIHHZGQBWZPIMS-IAEIRYAQSA-N
DMOI1U5 IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S,3R)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMOI1U5 DE Discovery agent
DMZBFJ5 ID DMZBFJ5
DMZBFJ5 DN H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH
DMZBFJ5 HS Investigative
DMZBFJ5 SN CHEMBL375095; H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH
DMZBFJ5 DT Small molecular drug
DMZBFJ5 PC 44418913
DMZBFJ5 MW 682.8
DMZBFJ5 FM C40H50N4O6
DMZBFJ5 IC InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33+,34+,35?,36+/m1/s1
DMZBFJ5 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMZBFJ5 IK GWHRSTGESQKJIQ-IAEIRYAQSA-N
DMZBFJ5 IU (2S)-2-[[(2S,3R)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMZBFJ5 DE Discovery agent
DMNS1GX ID DMNS1GX
DMNS1GX DN H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2
DMNS1GX HS Investigative
DMNS1GX SN CHEMBL269314; H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2
DMNS1GX DT Small molecular drug
DMNS1GX PC 44418915
DMNS1GX MW 681.9
DMNS1GX FM C40H51N5O5
DMNS1GX IC InChI=1S/C40H51N5O5/c1-24-18-31(46)19-25(2)32(24)22-33(41)40(50)45-23-30-17-11-10-16-29(30)21-35(45)38(48)44-36(26(3)28-14-8-5-9-15-28)39(49)43-34(37(42)47)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,46H,5,8-9,14-15,20-23,41H2,1-3H3,(H2,42,47)(H,43,49)(H,44,48)/t26-,33-,34-,35?,36-/m0/s1
DMNS1GX CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N)C)O
DMNS1GX IK KIHHZGQBWZPIMS-VERNRBRGSA-N
DMNS1GX IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(2S,3S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxobutan-2-yl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMNS1GX DE Discovery agent
DMM9TUR ID DMM9TUR
DMM9TUR DN H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH
DMM9TUR HS Investigative
DMM9TUR SN CHEMBL219482; H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH
DMM9TUR DT Small molecular drug
DMM9TUR PC 44418911
DMM9TUR MW 682.8
DMM9TUR FM C40H50N4O6
DMM9TUR IC InChI=1S/C40H50N4O6/c1-24-18-31(45)19-25(2)32(24)22-33(41)39(48)44-23-30-17-11-10-16-29(30)21-35(44)37(46)43-36(26(3)28-14-8-5-9-15-28)38(47)42-34(40(49)50)20-27-12-6-4-7-13-27/h4,6-7,10-13,16-19,26,28,33-36,45H,5,8-9,14-15,20-23,41H2,1-3H3,(H,42,47)(H,43,46)(H,49,50)/t26-,33-,34-,35?,36-/m0/s1
DMM9TUR CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H]([C@@H](C)C4CCCCC4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O)N)C)O
DMM9TUR IK GWHRSTGESQKJIQ-VERNRBRGSA-N
DMM9TUR IU (2S)-2-[[(2S,3S)-2-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylbutanoyl]amino]-3-phenylpropanoic acid
DMM9TUR DE Discovery agent
DM4JP8L ID DM4JP8L
DM4JP8L DN H-Dmt-Tic-Asp-N(Me)-Ph
DM4JP8L HS Investigative
DM4JP8L SN CHEMBL448360; H-Dmt-Tic-Asp-N(Me)-Ph
DM4JP8L DT Small molecular drug
DM4JP8L PC 25034014
DM4JP8L MW 572.7
DM4JP8L FM C32H36N4O6
DM4JP8L IC InChI=1S/C32H36N4O6/c1-19-13-24(37)14-20(2)25(19)16-26(33)31(41)36-18-22-10-8-7-9-21(22)15-28(36)30(40)34-27(17-29(38)39)32(42)35(3)23-11-5-4-6-12-23/h4-14,26-28,37H,15-18,33H2,1-3H3,(H,34,40)(H,38,39)/t26-,27-,28-/m0/s1
DM4JP8L CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)N(C)C4=CC=CC=C4)N)C)O
DM4JP8L IK HEKBLCZSNQVJKZ-KCHLEUMXSA-N
DM4JP8L IU (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-(N-methylanilino)-4-oxobutanoic acid
DM4JP8L DE Discovery agent
DMBKOJG ID DMBKOJG
DMBKOJG DN H-Dmt-Tic-Asp-NH-Bzl
DMBKOJG HS Investigative
DMBKOJG SN CHEMBL450566; H-Dmt-Tic-Asp-NH-Bzl
DMBKOJG DT Small molecular drug
DMBKOJG PC 25034010
DMBKOJG MW 572.7
DMBKOJG FM C32H36N4O6
DMBKOJG IC InChI=1S/C32H36N4O6/c1-19-12-24(37)13-20(2)25(19)15-26(33)32(42)36-18-23-11-7-6-10-22(23)14-28(36)31(41)35-27(16-29(38)39)30(40)34-17-21-8-4-3-5-9-21/h3-13,26-28,37H,14-18,33H2,1-2H3,(H,34,40)(H,35,41)(H,38,39)/t26-,27-,28-/m0/s1
DMBKOJG CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)NCC4=CC=CC=C4)N)C)O
DMBKOJG IK RBFLTKCFTXQSNZ-KCHLEUMXSA-N
DMBKOJG IU (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-(benzylamino)-4-oxobutanoic acid
DMBKOJG DE Discovery agent
DM3W9FQ ID DM3W9FQ
DM3W9FQ DN H-Dmt-Tic-Asp-NH-Ph
DM3W9FQ HS Investigative
DM3W9FQ SN CHEMBL501202; H-Dmt-Tic-Asp-NH-Ph
DM3W9FQ DT Small molecular drug
DM3W9FQ PC 25033885
DM3W9FQ MW 558.6
DM3W9FQ FM C31H34N4O6
DM3W9FQ IC InChI=1S/C31H34N4O6/c1-18-12-23(36)13-19(2)24(18)15-25(32)31(41)35-17-21-9-7-6-8-20(21)14-27(35)30(40)34-26(16-28(37)38)29(39)33-22-10-4-3-5-11-22/h3-13,25-27,36H,14-17,32H2,1-2H3,(H,33,39)(H,34,40)(H,37,38)/t25-,26-,27-/m0/s1
DM3W9FQ CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C(=O)NC4=CC=CC=C4)N)C)O
DM3W9FQ IK ISUHYDNNFIRLMN-QKDODKLFSA-N
DM3W9FQ IU (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-anilino-4-oxobutanoic acid
DM3W9FQ DE Discovery agent
DM483BG ID DM483BG
DM483BG DN H-Dmt-Tic-D-Asp-N(Me)-Ph
DM483BG HS Investigative
DM483BG SN CHEMBL502302; H-Dmt-Tic-D-Asp-N(Me)-Ph
DM483BG DT Small molecular drug
DM483BG PC 25033947
DM483BG MW 572.7
DM483BG FM C32H36N4O6
DM483BG IC InChI=1S/C32H36N4O6/c1-19-13-24(37)14-20(2)25(19)16-26(33)31(41)36-18-22-10-8-7-9-21(22)15-28(36)30(40)34-27(17-29(38)39)32(42)35(3)23-11-5-4-6-12-23/h4-14,26-28,37H,15-18,33H2,1-3H3,(H,34,40)(H,38,39)/t26-,27+,28-/m0/s1
DM483BG CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C(=O)N(C)C4=CC=CC=C4)N)C)O
DM483BG IK HEKBLCZSNQVJKZ-IARZGTGTSA-N
DM483BG IU (3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-(N-methylanilino)-4-oxobutanoic acid
DM483BG DE Discovery agent
DMUG7X1 ID DMUG7X1
DMUG7X1 DN H-Dmt-Tic-D-Asp-NH-Ph
DMUG7X1 HS Investigative
DMUG7X1 SN CHEMBL498799; H-Dmt-Tic-D-Asp-NH-Ph
DMUG7X1 DT Small molecular drug
DMUG7X1 PC 25033945
DMUG7X1 MW 558.6
DMUG7X1 FM C31H34N4O6
DMUG7X1 IC InChI=1S/C31H34N4O6/c1-18-12-23(36)13-19(2)24(18)15-25(32)31(41)35-17-21-9-7-6-8-20(21)14-27(35)30(40)34-26(16-28(37)38)29(39)33-22-10-4-3-5-11-22/h3-13,25-27,36H,14-17,32H2,1-2H3,(H,33,39)(H,34,40)(H,37,38)/t25-,26+,27-/m0/s1
DMUG7X1 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C(=O)NC4=CC=CC=C4)N)C)O
DMUG7X1 IK ISUHYDNNFIRLMN-VJGNERBWSA-N
DMUG7X1 IU (3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-anilino-4-oxobutanoic acid
DMUG7X1 DE Discovery agent
DMQSRPD ID DMQSRPD
DMQSRPD DN H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)
DMQSRPD HS Investigative
DMQSRPD SN CHEMBL208916; H-Dmt-Tic-Glu-Dap(6DMN)-NH(2)
DMQSRPD DT Small molecular drug
DMQSRPD PC 44412290
DMQSRPD MW 805.9
DMQSRPD FM C43H47N7O9
DMQSRPD IC InChI=1S/C43H47N7O9/c1-21-13-27(51)14-22(2)29(21)19-32(44)38(54)37-28-8-6-5-7-24(28)18-34(46-37)41(57)47-33(11-12-36(52)53)40(56)48-35(39(45)55)20-50-42(58)30-16-23-9-10-26(49(3)4)15-25(23)17-31(30)43(50)59/h5-10,13-17,32-35,37,46,51H,11-12,18-20,44H2,1-4H3,(H2,45,55)(H,47,57)(H,48,56)(H,52,53)/t32-,33-,34?,35?,37?/m0/s1
DMQSRPD CS CC1=CC(=CC(=C1C[C@@H](C(=O)C2C3=CC=CC=C3CC(N2)C(=O)N[C@@H](CCC(=O)O)C(=O)NC(CN4C(=O)C5=C(C4=O)C=C6C=C(C=CC6=C5)N(C)C)C(=O)N)N)C)O
DMQSRPD IK XJJAERVDDMSANL-TXQDRJNYSA-N
DMQSRPD IU (4S)-5-[[1-amino-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]amino]-4-[[1-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino]-5-oxopentanoic acid
DMQSRPD DE Discovery agent
DMF52SH ID DMF52SH
DMF52SH DN H-Dmt-Tic-Glu-NH-(CH2)5-NH2
DMF52SH HS Investigative
DMF52SH SN CHEMBL225479; H-Dmt-Tic-Glu-NH-(CH2)5-NH2
DMF52SH DT Small molecular drug
DMF52SH PC 44421433
DMF52SH MW 581.7
DMF52SH FM C31H43N5O6
DMF52SH IC InChI=1S/C31H43N5O6/c1-19-14-23(37)15-20(2)24(19)17-25(33)31(42)36-18-22-9-5-4-8-21(22)16-27(36)30(41)35-26(10-11-28(38)39)29(40)34-13-7-3-6-12-32/h4-5,8-9,14-15,25-27,37H,3,6-7,10-13,16-18,32-33H2,1-2H3,(H,34,40)(H,35,41)(H,38,39)/t25-,26-,27?/m0/s1
DMF52SH CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@@H](CCC(=O)O)C(=O)NCCCCCN)N)C)O
DMF52SH IK JKBJCPFUZMWEMK-TXIPYEPDSA-N
DMF52SH IU (4S)-4-[[2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(5-aminopentylamino)-5-oxopentanoic acid
DMF52SH DE Discovery agent
DM8A573 ID DM8A573
DM8A573 DN H-Dmt-Tic-Glu-NH2
DM8A573 HS Investigative
DM8A573 DT Small molecular drug
DM8A573 PC 11156202
DM8A573 MW 496.6
DM8A573 FM C26H32N4O6
DM8A573 IC InChI=1S/C26H32N4O6/c1-14-9-18(31)10-15(2)19(14)12-20(27)26(36)30-13-17-6-4-3-5-16(17)11-22(30)25(35)29-21(24(28)34)7-8-23(32)33/h3-6,9-10,20-22,31H,7-8,11-13,27H2,1-2H3,(H2,28,34)(H,29,35)(H,32,33)/t20-,21-,22-/m0/s1
DM8A573 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CCC(=O)O)C(=O)N)N)C)O
DM8A573 IK CXJVHAFXBCEOKB-FKBYEOEOSA-N
DM8A573 IU (4S)-5-amino-4-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-oxopentanoic acid
DM8A573 DE Discovery agent
DMHYKBC ID DMHYKBC
DMHYKBC DN H-Dmt-Tic-Gly-N(Me)-Ph
DMHYKBC HS Investigative
DMHYKBC SN CHEMBL500937; H-Dmt-Tic-Gly-N(Me)-Ph
DMHYKBC DT Small molecular drug
DMHYKBC PC 25034012
DMHYKBC MW 514.6
DMHYKBC FM C30H34N4O4
DMHYKBC IC InChI=1S/C30H34N4O4/c1-19-13-24(35)14-20(2)25(19)16-26(31)30(38)34-18-22-10-8-7-9-21(22)15-27(34)29(37)32-17-28(36)33(3)23-11-5-4-6-12-23/h4-14,26-27,35H,15-18,31H2,1-3H3,(H,32,37)/t26-,27-/m0/s1
DMHYKBC CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC(=O)N(C)C4=CC=CC=C4)N)C)O
DMHYKBC IK CADRNJIFUDEZBB-SVBPBHIXSA-N
DMHYKBC IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-(N-methylanilino)-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMHYKBC DE Discovery agent
DMM39YW ID DMM39YW
DMM39YW DN H-Dmt-Tic-Gly-NH-Bzl
DMM39YW HS Investigative
DMM39YW SN H-Dmt-Tic-Gly-NH-Bzl; CHEMBL458631; H-Dmt-Tic-Gly-NH-CH2-Ph; GTPL9838; BDBM50266025; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (benzylcarbamoyl-methyl)-amide; (S)-2-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl)-N-(2-(benzylamino)-2-oxoethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; (3S)-N-(Benzylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMM39YW DT Small molecular drug
DMM39YW PC 10864183
DMM39YW MW 514.6
DMM39YW FM C30H34N4O4
DMM39YW IC InChI=1S/C30H34N4O4/c1-19-12-24(35)13-20(2)25(19)15-26(31)30(38)34-18-23-11-7-6-10-22(23)14-27(34)29(37)33-17-28(36)32-16-21-8-4-3-5-9-21/h3-13,26-27,35H,14-18,31H2,1-2H3,(H,32,36)(H,33,37)/t26-,27-/m0/s1
DMM39YW CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC(=O)NCC4=CC=CC=C4)N)C)O
DMM39YW IK SYOVEDOWOXNOJG-SVBPBHIXSA-N
DMM39YW IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-(benzylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMM39YW DE Discovery agent
DMH6JOU ID DMH6JOU
DMH6JOU DN H-Dmt-Tic-Gly-NH-CH2-Bid
DMH6JOU HS Investigative
DMH6JOU SN (3S)-N-[(1H-Benzimidazole-2-ylmethyl)carbamoylmethyl]-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
DMH6JOU DT Small molecular drug
DMH6JOU PC 44375729
DMH6JOU MW 554.6
DMH6JOU FM C31H34N6O4
DMH6JOU IC InChI=1S/C31H34N6O4/c1-18-11-22(38)12-19(2)23(18)14-24(32)31(41)37-17-21-8-4-3-7-20(21)13-27(37)30(40)34-16-29(39)33-15-28-35-25-9-5-6-10-26(25)36-28/h3-12,24,27,38H,13-17,32H2,1-2H3,(H,33,39)(H,34,40)(H,35,36)/t24-,27?/m0/s1
DMH6JOU CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCC(=O)NCC4=NC5=CC=CC=C5N4)N)C)O
DMH6JOU IK LKKOHYJIXKBADA-BXXZMZEQSA-N
DMH6JOU IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-(1H-benzimidazol-2-ylmethylamino)-2-oxoethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMH6JOU DE Discovery agent
DMIZ28H ID DMIZ28H
DMIZ28H DN H-Dmt-Tic-Gly-NH-Ph
DMIZ28H HS Investigative
DMIZ28H SN CHEMBL501451; H-Dmt-Tic-Gly-NH-Ph; BDBM50272081; (3S)-N-(Phenylcarbamoylmethyl)-2-[(S)-3-(2,6-dimethyl-4-hydroxyphenyl)-2-aminopropionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; 2-[2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid phenylcarbamoylmethyl-amide
DMIZ28H DT Small molecular drug
DMIZ28H PC 11016572
DMIZ28H MW 500.6
DMIZ28H FM C29H32N4O4
DMIZ28H IC InChI=1S/C29H32N4O4/c1-18-12-23(34)13-19(2)24(18)15-25(30)29(37)33-17-21-9-7-6-8-20(21)14-26(33)28(36)31-16-27(35)32-22-10-4-3-5-11-22/h3-13,25-26,34H,14-17,30H2,1-2H3,(H,31,36)(H,32,35)/t25-,26-/m0/s1
DMIZ28H CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC(=O)NC4=CC=CC=C4)N)C)O
DMIZ28H IK JQERUKPESNWSQA-UIOOFZCWSA-N
DMIZ28H IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(2-anilino-2-oxoethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMIZ28H DE Discovery agent
DM2TY43 ID DM2TY43
DM2TY43 DN H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph
DM2TY43 HS Investigative
DM2TY43 SN SCHEMBL8222648
DM2TY43 DT Small molecular drug
DM2TY43 PC 25050225
DM2TY43 MW 627.8
DM2TY43 FM C36H45N5O5
DM2TY43 IC InChI=1S/C36H45N5O5/c1-23-17-29(43)18-24(2)30(23)20-31(37)36(46)41-22-28-14-8-7-13-27(28)19-33(41)35(45)40-32(15-9-10-16-38-25(3)42)34(44)39-21-26-11-5-4-6-12-26/h4-8,11-14,17-18,31-33,43H,9-10,15-16,19-22,37H2,1-3H3,(H,38,42)(H,39,44)(H,40,45)
DM2TY43 CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)C)C(=O)NCC4=CC=CC=C4)N)C)O
DM2TY43 IK FSIMYSAKEXUAHH-UHFFFAOYSA-N
DM2TY43 IU N-[6-acetamido-1-(benzylamino)-1-oxohexan-2-yl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM2TY43 DE Discovery agent
DMZH9P5 ID DMZH9P5
DMZH9P5 DN H-Dmt-Tic-Lys(Ac)-NH-Ph
DMZH9P5 HS Investigative
DMZH9P5 SN SCHEMBL8228366
DMZH9P5 DT Small molecular drug
DMZH9P5 PC 25050226
DMZH9P5 MW 613.7
DMZH9P5 FM C35H43N5O5
DMZH9P5 IC InChI=1S/C35H43N5O5/c1-22-17-28(42)18-23(2)29(22)20-30(36)35(45)40-21-26-12-8-7-11-25(26)19-32(40)34(44)39-31(15-9-10-16-37-24(3)41)33(43)38-27-13-5-4-6-14-27/h4-8,11-14,17-18,30-32,42H,9-10,15-16,19-21,36H2,1-3H3,(H,37,41)(H,38,43)(H,39,44)
DMZH9P5 CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)C)C(=O)NC4=CC=CC=C4)N)C)O
DMZH9P5 IK VCTWEJIUVCJXEY-UHFFFAOYSA-N
DMZH9P5 IU N-(6-acetamido-1-anilino-1-oxohexan-2-yl)-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMZH9P5 DE Discovery agent
DMP8HFA ID DMP8HFA
DMP8HFA DN H-Dmt-Tic-Lys(Z)-NH-CH2-Ph
DMP8HFA HS Investigative
DMP8HFA DT Small molecular drug
DMP8HFA PC 44415603
DMP8HFA MW 719.9
DMP8HFA FM C42H49N5O6
DMP8HFA IC InChI=1S/C42H49N5O6/c1-28-21-34(48)22-29(2)35(28)24-36(43)41(51)47-26-33-18-10-9-17-32(33)23-38(47)40(50)46-37(39(49)45-25-30-13-5-3-6-14-30)19-11-12-20-44-42(52)53-27-31-15-7-4-8-16-31/h3-10,13-18,21-22,36-38,48H,11-12,19-20,23-27,43H2,1-2H3,(H,44,52)(H,45,49)(H,46,50)
DMP8HFA CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)OCC4=CC=CC=C4)C(=O)NCC5=CC=CC=C5)N)C)O
DMP8HFA IK MVEIALIQEDSFAK-UHFFFAOYSA-N
DMP8HFA IU benzyl N-[5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-6-(benzylamino)-6-oxohexyl]carbamate
DMP8HFA DE Discovery agent
DMBXGLA ID DMBXGLA
DMBXGLA DN H-Dmt-Tic-Lys(Z)-NH-Ph
DMBXGLA HS Investigative
DMBXGLA DT Small molecular drug
DMBXGLA PC 25050066
DMBXGLA MW 705.8
DMBXGLA FM C41H47N5O6
DMBXGLA IC InChI=1S/C41H47N5O6/c1-27-21-33(47)22-28(2)34(27)24-35(42)40(50)46-25-31-16-10-9-15-30(31)23-37(46)39(49)45-36(38(48)44-32-17-7-4-8-18-32)19-11-12-20-43-41(51)52-26-29-13-5-3-6-14-29/h3-10,13-18,21-22,35-37,47H,11-12,19-20,23-26,42H2,1-2H3,(H,43,51)(H,44,48)(H,45,49)
DMBXGLA CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)OCC4=CC=CC=C4)C(=O)NC5=CC=CC=C5)N)C)O
DMBXGLA IK MJVSDWUKXXUPBE-UHFFFAOYSA-N
DMBXGLA IU benzyl N-[5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-6-anilino-6-oxohexyl]carbamate
DMBXGLA DE Discovery agent
DMDJ9PE ID DMDJ9PE
DMDJ9PE DN H-Dmt-Tic-Lys-NH-CH2-Ph
DMDJ9PE HS Investigative
DMDJ9PE DT Small molecular drug
DMDJ9PE PC 44415604
DMDJ9PE MW 585.7
DMDJ9PE FM C34H43N5O4
DMDJ9PE IC InChI=1S/C34H43N5O4/c1-22-16-27(40)17-23(2)28(22)19-29(36)34(43)39-21-26-13-7-6-12-25(26)18-31(39)33(42)38-30(14-8-9-15-35)32(41)37-20-24-10-4-3-5-11-24/h3-7,10-13,16-17,29-31,40H,8-9,14-15,18-21,35-36H2,1-2H3,(H,37,41)(H,38,42)
DMDJ9PE CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCN)C(=O)NCC4=CC=CC=C4)N)C)O
DMDJ9PE IK RMSWGJUPLHHSPI-UHFFFAOYSA-N
DMDJ9PE IU N-[6-amino-1-(benzylamino)-1-oxohexan-2-yl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMDJ9PE DE Discovery agent
DMT3Y6E ID DMT3Y6E
DMT3Y6E DN H-Dmt-Tic-Lys-NH-Ph
DMT3Y6E HS Investigative
DMT3Y6E SN SCHEMBL8224099
DMT3Y6E DT Small molecular drug
DMT3Y6E PC 25050067
DMT3Y6E MW 571.7
DMT3Y6E FM C33H41N5O4
DMT3Y6E IC InChI=1S/C33H41N5O4/c1-21-16-26(39)17-22(2)27(21)19-28(35)33(42)38-20-24-11-7-6-10-23(24)18-30(38)32(41)37-29(14-8-9-15-34)31(40)36-25-12-4-3-5-13-25/h3-7,10-13,16-17,28-30,39H,8-9,14-15,18-20,34-35H2,1-2H3,(H,36,40)(H,37,41)
DMT3Y6E CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCN)C(=O)NC4=CC=CC=C4)N)C)O
DMT3Y6E IK RTMKKGXDPBYWCA-UHFFFAOYSA-N
DMT3Y6E IU N-(6-amino-1-anilino-1-oxohexan-2-yl)-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMT3Y6E DE Discovery agent
DMMJ9YN ID DMMJ9YN
DMMJ9YN DN H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H
DMMJ9YN HS Investigative
DMMJ9YN SN CHEMBL372130; H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H
DMMJ9YN DT Small molecular drug
DMMJ9YN PC 44405653
DMMJ9YN MW 657.8
DMMJ9YN FM C38H51N5O5
DMMJ9YN IC InChI=1S/C38H51N5O5/c1-23-15-29(44)16-24(2)31(23)20-33(39)36(46)41-13-9-5-6-10-14-42-37(47)35-19-27-11-7-8-12-28(27)22-43(35)38(48)34(40)21-32-25(3)17-30(45)18-26(32)4/h7-8,11-12,15-18,33-35,44-45H,5-6,9-10,13-14,19-22,39-40H2,1-4H3,(H,41,46)(H,42,47)/t33-,34-,35?/m0/s1
DMMJ9YN CS CC1=CC(=CC(=C1C[C@@H](C(=O)NCCCCCCNC(=O)C2CC3=CC=CC=C3CN2C(=O)[C@H](CC4=C(C=C(C=C4C)O)C)N)N)C)O
DMMJ9YN IK PKRAENCMWFWKSB-IEKJTBOOSA-N
DMMJ9YN IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMMJ9YN DE Discovery agent
DM0BGNE ID DM0BGNE
DM0BGNE DN H-Dmt-Tic-NH-(CH2)6-NH-Phe-H
DM0BGNE HS Investigative
DM0BGNE SN CHEMBL198909; H-Dmt-Tic-NH-(CH2)6-NH-Phe-H
DM0BGNE DT Small molecular drug
DM0BGNE PC 44405656
DM0BGNE MW 613.8
DM0BGNE FM C36H47N5O4
DM0BGNE IC InChI=1S/C36H47N5O4/c1-24-18-29(42)19-25(2)30(24)22-32(38)36(45)41-23-28-15-9-8-14-27(28)21-33(41)35(44)40-17-11-4-3-10-16-39-34(43)31(37)20-26-12-6-5-7-13-26/h5-9,12-15,18-19,31-33,42H,3-4,10-11,16-17,20-23,37-38H2,1-2H3,(H,39,43)(H,40,44)/t31-,32-,33?/m0/s1
DM0BGNE CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)[C@H](CC4=CC=CC=C4)N)N)C)O
DM0BGNE IK VWEMLWZEBKVSHE-KOPQTXDBSA-N
DM0BGNE IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-[[(2S)-2-amino-3-phenylpropanoyl]amino]hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM0BGNE DE Discovery agent
DMQ586T ID DMQ586T
DMQ586T DN H-Dmt-Tic-NH-(CH2)6-NH-Tic-H
DMQ586T HS Investigative
DMQ586T SN CHEMBL380590; H-Dmt-Tic-NH-(CH2)6-NH-Tic-H
DMQ586T DT Small molecular drug
DMQ586T PC 44405654
DMQ586T MW 625.8
DMQ586T FM C37H47N5O4
DMQ586T IC InChI=1S/C37H47N5O4/c1-24-17-30(43)18-25(2)31(24)21-32(38)37(46)42-23-29-14-8-6-12-27(29)20-34(42)36(45)40-16-10-4-3-9-15-39-35(44)33-19-26-11-5-7-13-28(26)22-41-33/h5-8,11-14,17-18,32-34,41,43H,3-4,9-10,15-16,19-23,38H2,1-2H3,(H,39,44)(H,40,45)/t32-,33?,34?/m0/s1
DMQ586T CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCCCCCNC(=O)C4CC5=CC=CC=C5CN4)N)C)O
DMQ586T IK SIUMEPYYYNRSSX-BGVJURHFSA-N
DMQ586T IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[6-(1,2,3,4-tetrahydroisoquinoline-3-carbonylamino)hexyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMQ586T DE Discovery agent
DMAU2H6 ID DMAU2H6
DMAU2H6 DN H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid
DMAU2H6 HS Investigative
DMAU2H6 SN H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid; CHEMBL212172
DMAU2H6 DT Small molecular drug
DMAU2H6 PC 16082947
DMAU2H6 MW 702.8
DMAU2H6 FM C41H46N6O5
DMAU2H6 IC InChI=1S/C41H46N6O5/c1-26-20-31(48)21-27(2)32(26)23-33(42)40(50)47-24-30-15-7-6-14-29(30)22-37(47)39(49)46-36(38-44-34-16-8-9-17-35(34)45-38)18-10-11-19-43-41(51)52-25-28-12-4-3-5-13-28/h3-9,12-17,20-21,33,36-37,48H,10-11,18-19,22-25,42H2,1-2H3,(H,43,51)(H,44,45)(H,46,49)/t33?,36-,37?/m1/s1
DMAU2H6 CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)N[C@H](CCCCNC(=O)OCC4=CC=CC=C4)C5=NC6=CC=CC=C6N5)N)C)O
DMAU2H6 IK ZHRKDWCBKIOLKI-QNUATKLTSA-N
DMAU2H6 IU benzyl N-[(5R)-5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(1H-benzimidazol-2-yl)pentyl]carbamate
DMAU2H6 DE Discovery agent
DM5TZ1J ID DM5TZ1J
DM5TZ1J DN H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid
DM5TZ1J HS Investigative
DM5TZ1J SN CHEMBL444197; H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid
DM5TZ1J DT Small molecular drug
DM5TZ1J PC 25033951
DM5TZ1J MW 555.6
DM5TZ1J FM C31H33N5O5
DM5TZ1J IC InChI=1S/C31H33N5O5/c1-17-11-21(37)12-18(2)22(17)14-23(32)31(41)36-16-20-8-4-3-7-19(20)13-27(36)30(40)35-26(15-28(38)39)29-33-24-9-5-6-10-25(24)34-29/h3-12,23,26-27,37H,13-16,32H2,1-2H3,(H,33,34)(H,35,40)(H,38,39)/t23-,26+,27-/m0/s1
DM5TZ1J CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C4=NC5=CC=CC=C5N4)N)C)O
DM5TZ1J IK USVQTDLSVBRMCR-RNJDCESWSA-N
DM5TZ1J IU (3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1H-benzimidazol-2-yl)propanoic acid
DM5TZ1J DE Discovery agent
DMIDLPT ID DMIDLPT
DMIDLPT DN H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me)
DMIDLPT HS Investigative
DMIDLPT SN CHEMBL499099; BDBM50272228
DMIDLPT DT Small molecular drug
DMIDLPT PC 25034016
DMIDLPT MW 569.6
DMIDLPT FM C32H35N5O5
DMIDLPT IC InChI=1S/C32H35N5O5/c1-18-12-22(38)13-19(2)23(18)15-24(33)32(42)37-17-21-9-5-4-8-20(21)14-28(37)31(41)35-26(16-29(39)40)30-34-25-10-6-7-11-27(25)36(30)3/h4-13,24,26,28,38H,14-17,33H2,1-3H3,(H,35,41)(H,39,40)/t24-,26+,28-/m0/s1
DMIDLPT CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@H](CC(=O)O)C4=NC5=CC=CC=C5N4C)N)C)O
DMIDLPT IK XFKPEXYNTQLONY-YIOBJHAYSA-N
DMIDLPT IU (3R)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1-methylbenzimidazol-2-yl)propanoic acid
DMIDLPT DE Discovery agent
DMNEAQ9 ID DMNEAQ9
DMNEAQ9 DN H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me)
DMNEAQ9 HS Investigative
DMNEAQ9 SN XFKPEXYNTQLONY-MPYJOUPCSA-N; CHEMBL450263
DMNEAQ9 DT Small molecular drug
DMNEAQ9 PC 25033949
DMNEAQ9 MW 569.6
DMNEAQ9 FM C32H35N5O5
DMNEAQ9 IC InChI=1S/C32H35N5O5/c1-18-12-22(38)13-19(2)23(18)15-24(33)32(42)37-17-21-9-5-4-8-20(21)14-28(37)31(41)35-26(16-29(39)40)30-34-25-10-6-7-11-27(25)36(30)3/h4-13,24,26,28,38H,14-17,33H2,1-3H3,(H,35,41)(H,39,40)/t24-,26-,28-/m0/s1
DMNEAQ9 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)N[C@@H](CC(=O)O)C4=NC5=CC=CC=C5N4C)N)C)O
DMNEAQ9 IK XFKPEXYNTQLONY-MPYJOUPCSA-N
DMNEAQ9 IU (3S)-3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-(1-methylbenzimidazol-2-yl)propanoic acid
DMNEAQ9 DE Discovery agent
DMQEDP5 ID DMQEDP5
DMQEDP5 DN H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid
DMQEDP5 HS Investigative
DMQEDP5 SN H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid; SCHEMBL8230993; CHEMBL377960
DMQEDP5 DT Small molecular drug
DMQEDP5 PC 25050224
DMQEDP5 MW 568.7
DMQEDP5 FM C33H40N6O3
DMQEDP5 IC InChI=1S/C33H40N6O3/c1-20-15-24(40)16-21(2)25(20)18-26(35)33(42)39-19-23-10-4-3-9-22(23)17-30(39)32(41)38-29(13-7-8-14-34)31-36-27-11-5-6-12-28(27)37-31/h3-6,9-12,15-16,26,29-30,40H,7-8,13-14,17-19,34-35H2,1-2H3,(H,36,37)(H,38,41)
DMQEDP5 CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCN)C4=NC5=CC=CC=C5N4)N)C)O
DMQEDP5 IK GDHJQGJCKHJHHZ-UHFFFAOYSA-N
DMQEDP5 IU N-[5-amino-1-(1H-benzimidazol-2-yl)pentyl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMQEDP5 DE Discovery agent
DM8PJ92 ID DM8PJ92
DM8PJ92 DN H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid
DM8PJ92 HS Investigative
DM8PJ92 SN H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid; CHEMBL378082
DM8PJ92 DT Small molecular drug
DM8PJ92 PC 25050370
DM8PJ92 MW 610.7
DM8PJ92 FM C35H42N6O4
DM8PJ92 IC InChI=1S/C35H42N6O4/c1-21-16-26(43)17-22(2)27(21)19-28(36)35(45)41-20-25-11-5-4-10-24(25)18-32(41)34(44)40-31(14-8-9-15-37-23(3)42)33-38-29-12-6-7-13-30(29)39-33/h4-7,10-13,16-17,28,31-32,43H,8-9,14-15,18-20,36H2,1-3H3,(H,37,42)(H,38,39)(H,40,44)
DM8PJ92 CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)C)C4=NC5=CC=CC=C5N4)N)C)O
DM8PJ92 IK IOSGXZKTOLVOTQ-UHFFFAOYSA-N
DM8PJ92 IU N-[5-acetamido-1-(1H-benzimidazol-2-yl)pentyl]-2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM8PJ92 DE Discovery agent
DMQ4ILK ID DMQ4ILK
DMQ4ILK DN H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid
DMQ4ILK HS Investigative
DMQ4ILK SN H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid; CHEMBL386309; SCHEMBL8228625
DMQ4ILK DT Small molecular drug
DMQ4ILK PC 25050223
DMQ4ILK MW 702.8
DMQ4ILK FM C41H46N6O5
DMQ4ILK IC InChI=1S/C41H46N6O5/c1-26-20-31(48)21-27(2)32(26)23-33(42)40(50)47-24-30-15-7-6-14-29(30)22-37(47)39(49)46-36(38-44-34-16-8-9-17-35(34)45-38)18-10-11-19-43-41(51)52-25-28-12-4-3-5-13-28/h3-9,12-17,20-21,33,36-37,48H,10-11,18-19,22-25,42H2,1-2H3,(H,43,51)(H,44,45)(H,46,49)
DMQ4ILK CS CC1=CC(=CC(=C1CC(C(=O)N2CC3=CC=CC=C3CC2C(=O)NC(CCCCNC(=O)OCC4=CC=CC=C4)C5=NC6=CC=CC=C6N5)N)C)O
DMQ4ILK IK ZHRKDWCBKIOLKI-UHFFFAOYSA-N
DMQ4ILK IU benzyl N-[5-[[2-[2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-5-(1H-benzimidazol-2-yl)pentyl]carbamate
DMQ4ILK DE Discovery agent
DM4IUCW ID DM4IUCW
DM4IUCW DN H-Dmt-Tic-NH-CH2-Boa
DM4IUCW HS Investigative
DM4IUCW SN CHEMBL258458
DM4IUCW DT Small molecular drug
DM4IUCW PC 44451689
DM4IUCW MW 498.6
DM4IUCW FM C29H30N4O4
DM4IUCW IC InChI=1S/C29H30N4O4/c1-17-11-21(34)12-18(2)22(17)14-23(30)29(36)33-16-20-8-4-3-7-19(20)13-25(33)28(35)31-15-27-32-24-9-5-6-10-26(24)37-27/h3-12,23,25,34H,13-16,30H2,1-2H3,(H,31,35)/t23-,25-/m0/s1
DM4IUCW CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC5=CC=CC=C5O4)N)C)O
DM4IUCW IK JBEVAWMNEBELDV-ZCYQVOJMSA-N
DM4IUCW IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1,3-benzoxazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DM4IUCW DE Discovery agent
DMZ8C0U ID DMZ8C0U
DMZ8C0U DN H-Dmt-Tic-NH-CH2-Bta
DMZ8C0U HS Investigative
DMZ8C0U SN CHEMBL258704
DMZ8C0U DT Small molecular drug
DMZ8C0U PC 44451667
DMZ8C0U MW 514.6
DMZ8C0U FM C29H30N4O3S
DMZ8C0U IC InChI=1S/C29H30N4O3S/c1-17-11-21(34)12-18(2)22(17)14-23(30)29(36)33-16-20-8-4-3-7-19(20)13-25(33)28(35)31-15-27-32-24-9-5-6-10-26(24)37-27/h3-12,23,25,34H,13-16,30H2,1-2H3,(H,31,35)/t23-,25-/m0/s1
DMZ8C0U CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC5=CC=CC=C5S4)N)C)O
DMZ8C0U IK AWMRTINMSUQIBM-ZCYQVOJMSA-N
DMZ8C0U IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1,3-benzothiazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMZ8C0U DE Discovery agent
DMYJAW4 ID DMYJAW4
DMYJAW4 DN H-Dmt-Tic-NH-CH2-CH2-NH2
DMYJAW4 HS Investigative
DMYJAW4 SN CHEMBL241010; H-Dmt-Tic-NH-CH2-CH2-NH2
DMYJAW4 DT Small molecular drug
DMYJAW4 PC 44436392
DMYJAW4 MW 410.5
DMYJAW4 FM C23H30N4O3
DMYJAW4 IC InChI=1S/C23H30N4O3/c1-14-9-18(28)10-15(2)19(14)12-20(25)23(30)27-13-17-6-4-3-5-16(17)11-21(27)22(29)26-8-7-24/h3-6,9-10,20-21,28H,7-8,11-13,24-25H2,1-2H3,(H,26,29)/t20-,21?/m0/s1
DMYJAW4 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCN)N)C)O
DMYJAW4 IK VIPTXSCSZKOVSA-BGERDNNASA-N
DMYJAW4 IU N-(2-aminoethyl)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMYJAW4 DE Discovery agent
DMJ2F8M ID DMJ2F8M
DMJ2F8M DN H-Dmt-Tic-NH-CH2-Imid
DMJ2F8M HS Investigative
DMJ2F8M SN CHEMBL407957
DMJ2F8M DT Small molecular drug
DMJ2F8M PC 44451610
DMJ2F8M MW 447.5
DMJ2F8M FM C25H29N5O3
DMJ2F8M IC InChI=1S/C25H29N5O3/c1-15-9-19(31)10-16(2)20(15)12-21(26)25(33)30-14-18-6-4-3-5-17(18)11-22(30)24(32)29-13-23-27-7-8-28-23/h3-10,21-22,31H,11-14,26H2,1-2H3,(H,27,28)(H,29,32)/t21-,22-/m0/s1
DMJ2F8M CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC=CN4)N)C)O
DMJ2F8M IK PFUVPVAVWLKTQT-VXKWHMMOSA-N
DMJ2F8M IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1H-imidazol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMJ2F8M DE Discovery agent
DMKGIQJ ID DMKGIQJ
DMKGIQJ DN H-Dmt-Tic-NH-CH2-ImidPh
DMKGIQJ HS Investigative
DMKGIQJ SN CHEMBL259917
DMKGIQJ DT Small molecular drug
DMKGIQJ PC 44451637
DMKGIQJ MW 523.6
DMKGIQJ FM C31H33N5O3
DMKGIQJ IC InChI=1S/C31H33N5O3/c1-19-12-24(37)13-20(2)25(19)15-26(32)31(39)36-18-23-11-7-6-10-22(23)14-28(36)30(38)34-17-29-33-16-27(35-29)21-8-4-3-5-9-21/h3-13,16,26,28,37H,14-15,17-18,32H2,1-2H3,(H,33,35)(H,34,38)/t26-,28-/m0/s1
DMKGIQJ CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=NC=C(N4)C5=CC=CC=C5)N)C)O
DMKGIQJ IK LKMAEHUMCHTBER-XCZPVHLTSA-N
DMKGIQJ IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[(5-phenyl-1H-imidazol-2-yl)methyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMKGIQJ DE Discovery agent
DMNY3A1 ID DMNY3A1
DMNY3A1 DN H-Dmt-Tic-NH-CH2-Indl
DMNY3A1 HS Investigative
DMNY3A1 SN CHEMBL408975
DMNY3A1 DT Small molecular drug
DMNY3A1 PC 44451665
DMNY3A1 MW 496.6
DMNY3A1 FM C30H32N4O3
DMNY3A1 IC InChI=1S/C30H32N4O3/c1-18-11-24(35)12-19(2)25(18)15-26(31)30(37)34-17-22-9-4-3-7-20(22)14-28(34)29(36)32-16-23-13-21-8-5-6-10-27(21)33-23/h3-13,26,28,33,35H,14-17,31H2,1-2H3,(H,32,36)/t26-,28-/m0/s1
DMNY3A1 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4=CC5=CC=CC=C5N4)N)C)O
DMNY3A1 IK WOVWFYGUXKNNEL-XCZPVHLTSA-N
DMNY3A1 IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(1H-indol-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMNY3A1 DE Discovery agent
DMZWUFK ID DMZWUFK
DMZWUFK DN H-Dmt-Tic-NH-CH2-Indn
DMZWUFK HS Investigative
DMZWUFK SN CHEMBL260127
DMZWUFK DT Small molecular drug
DMZWUFK PC 44451639
DMZWUFK MW 497.6
DMZWUFK FM C31H35N3O3
DMZWUFK IC InChI=1S/C31H35N3O3/c1-19-11-26(35)12-20(2)27(19)16-28(32)31(37)34-18-25-10-6-5-9-24(25)15-29(34)30(36)33-17-21-13-22-7-3-4-8-23(22)14-21/h3-12,21,28-29,35H,13-18,32H2,1-2H3,(H,33,36)/t28-,29-/m0/s1
DMZWUFK CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCC4CC5=CC=CC=C5C4)N)C)O
DMZWUFK IK DDWRUPXWANOFLU-VMPREFPWSA-N
DMZWUFK IU (3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-(2,3-dihydro-1H-inden-2-ylmethyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMZWUFK DE Discovery agent
DML8S7J ID DML8S7J
DML8S7J DN H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J HS Investigative
DML8S7J SN CHEMBL376703; H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2
DML8S7J DT Small molecular drug
DML8S7J PC 11847438
DML8S7J MW 956.1
DML8S7J FM C43H61N11O10S2
DML8S7J IC InChI=1S/C43H61N11O10S2/c1-22-37(58)50-31(18-26-19-47-29-14-8-7-13-27(26)29)40(61)49-30(15-9-10-16-44)39(60)54-35(24(3)56)43(64)52-33(42(63)53-34(23(2)55)36(46)57)21-66-65-20-32(41(62)48-22)51-38(59)28(45)17-25-11-5-4-6-12-25/h4-8,11-14,19,22-24,28,30-35,47,55-56H,9-10,15-18,20-21,44-45H2,1-3H3,(H2,46,57)(H,48,62)(H,49,61)(H,50,58)(H,51,59)(H,52,64)(H,53,63)(H,54,60)/t22-,23+,24+,28+,30-,31+,32-,33-,34-,35-/m0/s1
DML8S7J CS C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@@H](CC2=CC=CC=C2)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)[C@@H](C)O)CCCCN)CC3=CNC4=CC=CC=C43
DML8S7J IK DNIBTKHTGSPUNA-RHSAGAAYSA-N
DML8S7J IU (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-16-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DML8S7J DE Discovery agent
DMLCIZ8 ID DMLCIZ8
DMLCIZ8 DN H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2
DMLCIZ8 HS Investigative
DMLCIZ8 SN CHEMBL219375; H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2; BDBM50191271; H-DPhe2-c[Cys3-Phe7-DTrp8-Lys9-Thr10-Cys14]-Thr15-NH2
DMLCIZ8 PC 11847588
DMLCIZ8 MW 1032.2
DMLCIZ8 FM C49H65N11O10S2
DMLCIZ8 IC InChI=1S/C49H65N11O10S2/c1-27(61)40(42(52)63)59-48(69)39-26-72-71-25-38(57-43(64)33(51)21-29-13-5-3-6-14-29)47(68)55-36(22-30-15-7-4-8-16-30)45(66)56-37(23-31-24-53-34-18-10-9-17-32(31)34)46(67)54-35(19-11-12-20-50)44(65)60-41(28(2)62)49(70)58-39/h3-10,13-18,24,27-28,33,35-41,53,61-62H,11-12,19-23,25-26,50-51H2,1-2H3,(H2,52,63)(H,54,67)(H,55,68)(H,56,66)(H,57,64)(H,58,70)(H,59,69)(H,60,65)/t27-,28-,33-,35+,36+,37-,38+,39+,40+,41+/m1/s1
DMLCIZ8 CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMLCIZ8 IK SGYDRBBPYPDBRO-WNIOSIORSA-N
DMLCIZ8 IU (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMLCIZ8 DE Discovery agent
DM1EGC3 ID DM1EGC3
DM1EGC3 DN H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
DM1EGC3 HS Investigative
DM1EGC3 SN CHEMBL262017; H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
DM1EGC3 PC 44403230
DM1EGC3 MW 1031.3
DM1EGC3 FM C50H66N10O10S2
DM1EGC3 IC InChI=1S/C50H66N10O10S2/c1-28(2)43-50(70)59-42(49(69)57-40(25-61)29(3)62)27-72-71-26-41(58-44(64)35(52)21-30-11-5-4-6-12-30)48(68)55-38(22-31-16-18-33(63)19-17-31)46(66)56-39(23-32-24-53-36-14-8-7-13-34(32)36)47(67)54-37(45(65)60-43)15-9-10-20-51/h4-8,11-14,16-19,24-25,28-29,35,37-43,53,62-63H,9-10,15,20-23,26-27,51-52H2,1-3H3,(H,54,67)(H,55,68)(H,56,66)(H,57,69)(H,58,64)(H,59,70)(H,60,65)/t29-,35+,37+,38+,39-,40-,41+,42-,43-/m1/s1
DM1EGC3 CS C[C@H]([C@@H](C=O)NC(=O)[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H](CC5=CC=CC=C5)N)O
DM1EGC3 IK KBXJEGQBFLLJFL-ILNSAXFWSA-N
DM1EGC3 IU (4S,7R,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2S)-2-amino-3-phenylpropanoyl]amino]-N-[(2S,3R)-3-hydroxy-1-oxobutan-2-yl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM1EGC3 DE Discovery agent
DMLRUVA ID DMLRUVA
DMLRUVA DN HDS-029
DMLRUVA HS Investigative
DMLRUVA SN HDS 029
DMLRUVA DT Small molecular drug
DMLRUVA PC 11566580
DMLRUVA MW 355.8
DMLRUVA FM C17H11ClFN5O
DMLRUVA IC InChI=1S/C17H11ClFN5O/c1-2-3-16(25)24-15-7-11-14(8-20-15)21-9-22-17(11)23-10-4-5-13(19)12(18)6-10/h4-9H,1H3,(H,20,24,25)(H,21,22,23)
DMLRUVA CS CC#CC(=O)NC1=NC=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl
DMLRUVA IK DLPSDPPZXRJQOY-UHFFFAOYSA-N
DMLRUVA IU N-[4-(3-chloro-4-fluoroanilino)pyrido[3,4-d]pyrimidin-6-yl]but-2-ynamide
DMLRUVA CA CAS 881001-19-0
DMLRUVA DE Discovery agent
DMY4QE6 ID DMY4QE6
DMY4QE6 DN H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMY4QE6 HS Investigative
DMY4QE6 PC 91931233
DMY4QE6 MW 1082.3
DMY4QE6 FM C47H63N13O11S3
DMY4QE6 IC InChI=1S/C47H63N13O11S3/c1-23(61)35(38(48)64)58-45(71)37-47(3,4)74-73-22-34(57-42(68)33-21-72-17-16-51-33)43(69)55-31(18-25-11-13-27(63)14-12-25)40(66)56-32(19-26-20-53-29-9-6-5-8-28(26)29)41(67)54-30(10-7-15-52-46(49)50)39(65)59-36(24(2)62)44(70)60-37/h5-6,8-9,11-14,16,20-21,23-24,30-32,34-37,53,61-63H,7,10,15,17-19,22H2,1-4H3,(H2,48,64)(H,54,67)(H,55,69)(H,56,66)(H,57,68)(H,58,71)(H,59,65)(H,60,70)(H4,49,50,52)/t23-,24-,30+,31+,32+,34+,35+,36-,37+/m1/s1
DMY4QE6 CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C5=CSCC=N5)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMY4QE6 IK AVXONNNWRZHIKA-HVLWERHHSA-N
DMY4QE6 IU (4S,7R,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-(2H-1,4-thiazine-5-carbonylamino)-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMY4QE6 DE Discovery agent
DM8GC36 ID DM8GC36
DM8GC36 DN H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DM8GC36 HS Investigative
DM8GC36 SN CHEMBL268162; H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DM8GC36 PC 44369523
DM8GC36 MW 1116.3
DM8GC36 FM C52H69N13O11S2
DM8GC36 IC InChI=1S/C52H69N13O11S2/c1-26(66)40(43(53)69)63-50(76)42-52(3,4)78-77-25-39(62-45(71)36-21-29-10-5-6-11-30(29)23-58-36)48(74)60-37(20-28-15-17-32(68)18-16-28)46(72)61-38(22-31-24-57-34-13-8-7-12-33(31)34)47(73)59-35(14-9-19-56-51(54)55)44(70)64-41(27(2)67)49(75)65-42/h5-8,10-13,15-18,24,26-27,35-42,57-58,66-68H,9,14,19-23,25H2,1-4H3,(H2,53,69)(H,59,73)(H,60,74)(H,61,72)(H,62,71)(H,63,76)(H,64,70)(H,65,75)(H4,54,55,56)/t26-,27-,35+,36-,37+,38+,39+,40+,41-,42+/m1/s1
DM8GC36 CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@H]5CC6=CC=CC=C6CN5)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DM8GC36 IK VZDYOAZXFPOIMZ-MDTUBHLHSA-N
DM8GC36 IU (4S,7R,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-19-[[(3R)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DM8GC36 DE Discovery agent
DMNAE6J ID DMNAE6J
DMNAE6J DN H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMNAE6J HS Investigative
DMNAE6J SN CHEMBL384571; H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2
DMNAE6J PC 44369487
DMNAE6J MW 1143.3
DMNAE6J FM C53H70N14O11S2
DMNAE6J IC InChI=1S/C53H70N14O11S2/c1-26(68)41(44(55)71)65-51(78)43-53(3,4)80-79-25-40(64-45(72)34(54)21-29-23-59-35-12-7-5-10-32(29)35)49(76)62-38(20-28-15-17-31(70)18-16-28)47(74)63-39(22-30-24-60-36-13-8-6-11-33(30)36)48(75)61-37(14-9-19-58-52(56)57)46(73)66-42(27(2)69)50(77)67-43/h5-8,10-13,15-18,23-24,26-27,34,37-43,59-60,68-70H,9,14,19-22,25,54H2,1-4H3,(H2,55,71)(H,61,75)(H,62,76)(H,63,74)(H,64,72)(H,65,78)(H,66,73)(H,67,77)(H4,56,57,58)/t26-,27-,34-,37+,38+,39+,40+,41+,42-,43+/m1/s1
DMNAE6J CS C[C@H]([C@@H]1C(=O)N[C@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CNC6=CC=CC=C65)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O
DMNAE6J IK UGJHJTQROKIYLL-CCDPMWLASA-N
DMNAE6J IU (4S,7R,10S,13S,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMNAE6J DE Discovery agent
DM9I5Y0 ID DM9I5Y0
DM9I5Y0 DN Heberkinasa
DM9I5Y0 HS Investigative
DM9I5Y0 SN cardiovascular therapy, York Medical; recombinant streptokinase, York Medical
DM9I5Y0 DE Discovery agent
DMZ4A0R ID DMZ4A0R
DMZ4A0R DN Hebervis
DMZ4A0R HS Investigative
DMZ4A0R SN CIGB-400; EGF (buccal local, mucositis), CIGB; EGF (rectal, proctitis), CIGB
DMZ4A0R CP Center for Genetic Engineering and Biotechnology
DMZ4A0R DE Oral mucositis
DMQPCDG ID DMQPCDG
DMQPCDG DN Helenalin-2-methylbutyrate
DMQPCDG HS Investigative
DMQPCDG SN helenalin-2-methylbutyrate
DMQPCDG DT Small molecular drug
DMQPCDG PC 44409560
DMQPCDG MW 346.4
DMQPCDG FM C20H26O5
DMQPCDG IC InChI=1S/C20H26O5/c1-6-10(2)18(22)25-17-16-12(4)19(23)24-14(16)9-11(3)13-7-8-15(21)20(13,17)5/h7-8,10-11,13-14,16-17H,4,6,9H2,1-3,5H3/t10?,11-,13+,14-,16-,17-,20+/m1/s1
DMQPCDG CS CCC(C)C(=O)O[C@@H]1[C@H]2[C@@H](C[C@H]([C@H]3[C@]1(C(=O)C=C3)C)C)OC(=O)C2=C
DMQPCDG IK IFEHNUQNAATZSJ-MXCJSKHRSA-N
DMQPCDG IU [(3aR,5R,5aR,8aR,9R,9aR)-5,8a-dimethyl-1-methylidene-2,8-dioxo-3a,4,5,5a,9,9a-hexahydroazuleno[6,5-b]furan-9-yl] 2-methylbutanoate
DMQPCDG DE Discovery agent
DMPOALD ID DMPOALD
DMPOALD DN HELENALINMETHACRYLATE
DMPOALD HS Investigative
DMPOALD SN helenalinmethacrylate
DMPOALD DT Small molecular drug
DMPOALD PC 25845235
DMPOALD MW 330.4
DMPOALD FM C19H22O5
DMPOALD IC InChI=1S/C19H22O5/c1-9(2)17(21)24-16-15-11(4)18(22)23-13(15)8-10(3)12-6-7-14(20)19(12,16)5/h6-7,10,12-13,15-16H,1,4,8H2,2-3,5H3/t10-,12+,13-,15-,16-,19+/m1/s1
DMPOALD CS C[C@@H]1C[C@@H]2[C@H]([C@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C(=C)C)C(=C)C(=O)O2
DMPOALD IK USRAFFQOAADTTD-OJIWXCRVSA-N
DMPOALD IU [(3aR,5R,5aR,8aR,9R,9aR)-5,8a-dimethyl-1-methylidene-2,8-dioxo-3a,4,5,5a,9,9a-hexahydroazuleno[6,5-b]furan-9-yl] 2-methylprop-2-enoate
DMPOALD DE Discovery agent
DM5MOLY ID DM5MOLY
DM5MOLY DN HELENAQUINONE
DM5MOLY HS Investigative
DM5MOLY SN Halenaquinone; 86690-14-4; CHEMBL513747; NSC643407; helenaquinone; AC1Q6BZF; (12bs)-12b-methyl-1h-tetrapheno[5,4-bc]furan-3,6,8,11(2h,12bh)-tetrone; AC1L80TG; SCHEMBL12464240; CTK5F7104; DTXSID50235769; BDBM50323927; NSC-643407
DM5MOLY DT Small molecular drug
DM5MOLY PC 370346
DM5MOLY MW 332.3
DM5MOLY FM C20H12O5
DM5MOLY IC InChI=1S/C20H12O5/c1-20-5-4-16(23)12-8-25-19(17(12)20)18(24)11-6-9-10(7-13(11)20)15(22)3-2-14(9)21/h2-3,6-8H,4-5H2,1H3/t20-/m0/s1
DM5MOLY CS C[C@@]12CCC(=O)C3=COC(=C31)C(=O)C4=C2C=C5C(=O)C=CC(=O)C5=C4
DM5MOLY IK SMGBXXZKAPMTBB-FQEVSTJZSA-N
DM5MOLY IU (1S)-1-methyl-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2(11),3,6,9,13(20),15-hexaene-5,8,12,17-tetrone
DM5MOLY CA CAS 86690-14-4
DM5MOLY DE Discovery agent
DMIUABO ID DMIUABO
DMIUABO DN helodermin
DMIUABO HS Investigative
DMIUABO SN Exendin 2
DMIUABO DT Small molecular drug
DMIUABO PC 16132369
DMIUABO MW 3843
DMIUABO FM C176H285N47O49
DMIUABO IC InChI=1S/C176H285N47O49/c1-23-93(15)138(217-146(243)98(20)194-159(256)124(78-137(237)238)210-167(264)126(82-225)214-147(244)107(180)77-104-79-187-86-190-104)169(266)212-123(74-101-38-26-25-27-39-101)164(261)220-140(99(21)229)171(268)202-114(57-60-135(183)235)153(250)200-113(56-59-134(182)234)154(251)209-122(76-103-49-53-106(232)54-50-103)163(260)215-127(83-226)166(263)198-110(42-30-33-63-179)150(247)205-120(73-92(13)14)161(258)206-117(70-89(7)8)157(254)191-95(17)143(240)196-108(40-28-31-61-177)149(246)204-116(69-88(5)6)156(253)192-96(18)144(241)203-119(72-91(11)12)160(257)201-112(55-58-133(181)233)152(249)197-109(41-29-32-62-178)151(248)208-121(75-102-47-51-105(231)52-48-102)162(259)207-118(71-90(9)10)158(255)193-97(19)145(242)213-128(84-227)168(265)218-139(94(16)24-2)170(267)211-115(68-87(3)4)148(245)189-80-136(236)195-125(81-224)165(262)199-111(43-34-64-188-176(185)186)155(252)219-141(100(22)230)172(269)216-129(85-228)173(270)222-66-36-45-131(222)175(272)223-67-37-46-132(223)174(271)221-65-35-44-130(221)142(184)239/h25-27,38-39,47-54,79,86-100,107-132,138-141,224-232H,23-24,28-37,40-46,55-78,80-85,177-180H2,1-22H3,(H2,181,233)(H2,182,234)(H2,183,235)(H2,184,239)(H,187,190)(H,189,245)(H,191,254)(H,192,253)(H,193,255)(H,194,256)(H,195,236)(H,196,240)(H,197,249)(H,198,263)(H,199,262)(H,200,250)(H,201,257)(H,202,268)(H,203,241)(H,204,246)(H,205,247)(H,206,258)(H,207,259)(H,208,248)(H,209,251)(H,210,264)(H,211,267)(H,212,266)(H,213,242)(H,214,244)(H,215,260)(H,216,269)(H,217,243)(H,218,265)(H,219,252)(H,220,261)(H,237,238)(H4,185,186,188)/t93-,94-,95-,96-,97-,98-,99+,100+,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,138-,139-,140-,141-/m0/s1
DMIUABO CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CN=CN7)N
DMIUABO IK SSAAJZQUEUTACT-MDBKHZGBSA-N
DMIUABO IU (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S,3R)-1-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-carbamoylpyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid
DMIUABO CA CAS 89468-62-2
DMIUABO DE Discovery agent
DMVK36Q ID DMVK36Q
DMVK36Q DN Hematoporphyrin
DMVK36Q HS Investigative
DMVK36Q SN 1,3,5,8-Tetramethyl-2,4-bis(alpha-hydroxyethyl)prophine-6,7-dipropionic acid; 2,18-Porphinedipropionic acid, 7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-bis(1-hydroxyethyl); 7,12-Bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid; HEMATOPORPHYRIN; HP; HP (VAN); Haematoporphyrin; Hematoporphyrin I; Hematoporphyrin IX; ISOHEMATOPORPHYRIN IX; NSC 267084; NSC 59265; NSC59265; Photodyn
DMVK36Q TC Antiasthenia Agents
DMVK36Q DT Small molecular drug
DMVK36Q PC 11103
DMVK36Q MW 598.7
DMVK36Q FM C34H38N4O6
DMVK36Q IC InChI=1S/C34H38N4O6/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27/h11-14,19-20,37-40H,7-10H2,1-6H3,(H,41,42)(H,43,44)
DMVK36Q CS CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O
DMVK36Q IK KFKRXESVMDBTNQ-UHFFFAOYSA-N
DMVK36Q IU 3-[18-(2-carboxyethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid
DMVK36Q CA CAS 14459-29-1
DMVK36Q CB ChEBI:36162
DMGC287 ID DMGC287
DMGC287 DN Heme
DMGC287 HS Investigative
DMGC287 SN heme; protoheme; Haem; ferroprotoporphyrin; UNII-42VZT0U6YR; Iron protoporphyrin ix; Protohaem; Ferroheme; Reduced hematin; Ferrous protoheme; Iron protoporphyrin; Ferrous protoheme IX; Ferroprotoporphyrin IX; 14875-96-8; 42VZT0U6YR; Iron(II) protoporphyrin IX; Protoheme IX (VAN); Ferroheme (VAN); Heme (VAN); 85758-EP2305825A1; 85758-EP2305243A1; 85758-EP2270505A1; 85758-EP2270016A1; 3-[18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoic acid; iron(2+); NSC 16669; NSC 267100; AC1L9FPJ; Hemin
DMGC287 DT Small molecular drug
DMGC287 PC 26945
DMGC287 MW 616.5
DMGC287 FM C34H32FeN4O4
DMGC287 IC InChI=1S/C34H34N4O4.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2
DMGC287 CS CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[Fe+2]
DMGC287 IK KABFMIBPWCXCRK-UHFFFAOYSA-L
DMGC287 IU 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(2+)
DMGC287 CA CAS 14875-96-8
DMGC287 DE Discovery agent
DMXP276 ID DMXP276
DMXP276 DN Hemi-Babim
DMXP276 HS Investigative
DMXP276 SN HEMI-BABIM; CHEMBL46148; (5-amidino-2-benzimidazolyl)(2-benzimidazolyl)methane; 1c1r; 1c1u; AC1L1B4Q; APD-1; SCHEMBL6163820; CTK7D1925; BDBM16303; ZINC2047318; DB01767; 2-(1H-Benzoimidazole-2-ylmethyl)-6-amidino-1H-benzoimidazole; 2-(1H-benzimidazol-2-ylmethyl)-1H-benzimidazole-5-carboximidamide; 2-(1H-benzimidazol-2-ylmethyl)-3H-benzimidazole-5-carboximidamide; 2-(1H-benzimidazol-2-ylmethyl)-1H-benzimidazole-6-carboximidamide
DMXP276 DT Small molecular drug
DMXP276 PC 1282
DMXP276 MW 290.32
DMXP276 FM C16H14N6
DMXP276 IC InChI=1S/C16H14N6/c17-16(18)9-5-6-12-13(7-9)22-15(21-12)8-14-19-10-3-1-2-4-11(10)20-14/h1-7H,8H2,(H3,17,18)(H,19,20)(H,21,22)
DMXP276 CS C1=CC=C2C(=C1)NC(=N2)CC3=NC4=C(N3)C=C(C=C4)C(=N)N
DMXP276 IK KKJYVDXDZURHMA-UHFFFAOYSA-N
DMXP276 IU 2-(1H-benzimidazol-2-ylmethyl)-3H-benzimidazole-5-carboximidamide
DMXP276 DE Discovery agent
DMF7X31 ID DMF7X31
DMF7X31 DN Hemoparatide
DMF7X31 HS Investigative
DMF7X31 SN hPTH 1-37 (metabolic/bone/skin diseases), Haemopep
DMF7X31 DE Discovery agent
DMY16VG ID DMY16VG
DMY16VG DN Heparin Pentasaccharide
DMY16VG HS Investigative
DMY16VG SN Heparin pentasaccharide; 1azx; AC1L9G9S; 1e03; methyl 3,4-di-O-methyl-2,6-di-O-sulfo-alpha-D-glucopyranosyl-(1->4)-2,3-di-O-methyl-beta-D-glucopyranuronosyl-(1->4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranosyl-(1->4)-3-O-methyl-2-O-sulfo-alpha-L-idopyranuronosyl-(1->4)-2,3,6-tri-O-sulfo-alpha-D-glucopyranoside
DMY16VG DT Small molecular drug
DMY16VG PC 444410
DMY16VG MW 1661.4
DMY16VG FM C36H60O55S9
DMY16VG IC InChI=1S/C36H60O55S9/c1-68-13-10(7-74-92(41,42)43)78-34(26(16(13)69-2)88-97(56,57)58)82-19-17(70-3)25(72-5)33(84-23(19)30(37)38)80-15-12(9-76-94(47,48)49)79-35(29(91-100(65,66)67)22(15)87-96(53,54)55)83-20-18(71-4)27(89-98(59,60)61)36(85-24(20)31(39)40)81-14-11(8-75-93(44,45)46)77-32(73-6)28(90-99(62,63)64)21(14)86-95(50,51)52/h10-29,32-36H,7-9H2,1-6H3,(H,37,38)(H,39,40)(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)/t10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26-,27-,28-,29-,32+,33-,34-,35-,36-/m1/s1
DMY16VG CS CO[C@@H]1[C@H](O[C@@H]([C@@H]([C@H]1OC)OS(=O)(=O)O)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]4[C@@H]([C@H]([C@@H](O[C@H]4C(=O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5OS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OS(=O)(=O)O)OC)COS(=O)(=O)O)OC)OC)COS(=O)(=O)O
DMY16VG IK MQLWHPBUPXUQHM-XAYBSJBFSA-N
DMY16VG IU (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4-methoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[(2R,3R,4S,5R,6R)-4,5-dimethoxy-3-sulfooxy-6-(sulfooxymethyl)oxan-2-yl]oxy-4,5-dimethoxyoxane-2-carboxylic acid
DMY16VG DE Discovery agent
DM7U491 ID DM7U491
DM7U491 DN Heparin-Cantithrombin III
DM7U491 HS Investigative
DM7U491 SN 212391-63-4; PD 166285 dihydrochloride; 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-onedihydrochloride; PD166285/PD-166285; SCHEMBL15106017; CHEMBL3545196; CTK8E7972; DTXSID80432749; MolPort-023-219-121; PD 166285 2HCl; EX-A1369; AKOS024457798; BCP9001063; BCP0726000019; KB-309461; RT-014958; FT-0673536; J-013945; 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one dihydrochloride
DM7U491 DT Small molecular drug
DM7U491 PC 9916391
DM7U491 MW 585.3
DM7U491 FM C26H29Cl4N5O2
DM7U491 IC InChI=1S/C26H27Cl2N5O2.2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H
DM7U491 CS CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl
DM7U491 IK NADLBPWBFGTESN-UHFFFAOYSA-N
DM7U491 IU 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one;dihydrochloride
DM7U491 CA CAS 212391-63-4
DM7U491 DE Discovery agent
DMK846H ID DMK846H
DMK846H DN HEPT
DMK846H HS Investigative
DMK846H SN HEPT; 6-Hept; HMPTT; 123027-56-5; 1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE; 1-((2-Hydroxyethoxy)methyl)-6-(phenylthio)thymine; 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine; CHEMBL31871; CHEBI:43060; 1-((2-Hydroxyethoxy)methyl)-6-phenylthiothymine; 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine; 1-[(2-hydroxyethoxy)methyl]-5-methyl-6-(phenylsulfanyl)pyrimidine-2,4(1H,3H)-dione; 1-((2-Hydroxyethoxy)methyl)-5-methyl-6-(phenylthio)-2,4(1H,3H)-pyrimidinedione
DMK846H DT Small molecular drug
DMK846H PC 64993
DMK846H MW 308.35
DMK846H FM C14H16N2O4S
DMK846H IC InChI=1S/C14H16N2O4S/c1-10-12(18)15-14(19)16(9-20-8-7-17)13(10)21-11-5-3-2-4-6-11/h2-6,17H,7-9H2,1H3,(H,15,18,19)
DMK846H CS CC1=C(N(C(=O)NC1=O)COCCO)SC2=CC=CC=C2
DMK846H IK HDMHBHNRWDNNCD-UHFFFAOYSA-N
DMK846H IU 1-(2-hydroxyethoxymethyl)-5-methyl-6-phenylsulfanylpyrimidine-2,4-dione
DMK846H CA CAS 123027-56-5
DMK846H CB CHEBI:43060
DMK846H DE Discovery agent
DMV4GDI ID DMV4GDI
DMV4GDI DN Heptane-1,2,3-Triol
DMV4GDI HS Investigative
DMV4GDI SN (2R,3R)-heptane-1,2,3-triol; HTO; AC1L9G8Y; CHEBI:43208; ZINC2043148; LMFA05000549; DB04079
DMV4GDI DT Small molecular drug
DMV4GDI PC 124604
DMV4GDI MW 148.2
DMV4GDI FM C7H16O3
DMV4GDI IC InChI=1S/C7H16O3/c1-2-3-4-6(9)7(10)5-8/h6-10H,2-5H2,1H3
DMV4GDI CS CCCCC(C(CO)O)O
DMV4GDI IK HXYCHJFUBNTKQR-UHFFFAOYSA-N
DMV4GDI IU heptane-1,2,3-triol
DMV4GDI CA CAS 103404-57-5
DMV4GDI CB CHEBI:67095
DMV4GDI DE Discovery agent
DMCFTB8 ID DMCFTB8
DMCFTB8 DN Heptane-2,3-dione
DMCFTB8 HS Investigative
DMCFTB8 SN 2,3-HEPTANEDIONE; 96-04-8; Acetyl valeryl; Heptane-2,3-dione; Valerylacetyl; Acetylvaleryl; Acetyl pentanoyl; UNII-DK55DDE86P; DK55DDE86P; Benzil-related compound, 47; CHEBI:88623; MFCD00036550; FR-2294; Heptanedione; FEMA No. 2543; 2,3-Dioxoheptane; EINECS 202-472-5; 2,3-heptane dione; NSC 31668; 2,3 - Heptanedione; AC1L1UAC; SCHEMBL109416; ACMC-20978p; CHEMBL364588; DTXSID4059128; KS-00000YJN; FEMA 2543; CTK0C6666; BDBM22769; MolPort-002-501-994; FJPGAMCQJNLTJC-UHFFFAOYSA-N; NSC31668; ZINC1663926; 2,3-Heptanedione, >=97%, FG
DMCFTB8 DT Small molecular drug
DMCFTB8 PC 60983
DMCFTB8 MW 128.169
DMCFTB8 FM C7H12O2
DMCFTB8 IC InChI=1S/C7H12O2/c1-3-4-5-7(9)6(2)8/h3-5H2,1-2H3
DMCFTB8 CS CCCCC(=O)C(=O)C
DMCFTB8 IK FJPGAMCQJNLTJC-UHFFFAOYSA-N
DMCFTB8 IU heptane-2,3-dione
DMCFTB8 CA CAS 96-04-8
DMCFTB8 CB CHEBI:88623
DMCFTB8 DE Discovery agent
DMGEO8N ID DMGEO8N
DMGEO8N DN HEPTANOATE
DMGEO8N HS Investigative
DMGEO8N SN Heptanoate; enanthate; Heptanoic acid, ion(1-); oenanthate; oenanthylate; heptoate; enanthylate; n-heptylate; n-heptanoate; n-heptoate; heptylate; 1-hexanecarboxylate; 7563-37-3; CH3-[CH2]5-COO(-); EINECS 231-459-7; AC1L3PEG; AC1Q2VSF; AC1Q22DU; CTK5E1803; CHEBI:32362; MNWFXJYAOYHMED-UHFFFAOYSA-M; STL483842; BDBM50240408; AKOS024438002; CJ-25028; 9187-EP2316836A1; 9187-EP2316835A1; 9187-EP2316834A1; 9187-EP2298734A2; 9187-EP2295437A1; 9187-EP2295426A1; 9187-EP2295413A1; 9187-EP2292614A1; 9187-EP2292227A2; 9187-EP2275412A1; 9187-EP2270004A1
DMGEO8N DT Small molecular drug
DMGEO8N PC 93052
DMGEO8N MW 129.18
DMGEO8N FM C7H13O2-
DMGEO8N IC InChI=1S/C7H14O2/c1-2-3-4-5-6-7(8)9/h2-6H2,1H3,(H,8,9)/p-1
DMGEO8N CS CCCCCCC(=O)[O-]
DMGEO8N IK MNWFXJYAOYHMED-UHFFFAOYSA-M
DMGEO8N IU heptanoate
DMGEO8N CA CAS 7563-37-3
DMGEO8N CB CHEBI:32362
DMGEO8N DE Discovery agent
DM4NY9H ID DM4NY9H
DM4NY9H DN Heptanoic Acid
DM4NY9H HS Investigative
DM4NY9H SN 2(3H)-Furanone, dihydro-5,5-dimethyl-4-(3-oxobutyl)-; 4436-81-1; NSC45645; 4,5-Dihydro-5,5-dimethyl-4-(3-oxobutyl)furan-2(3H)-one; 16091-70-6; HEPTANOIC ACID,; HEPTANOIC ACID LACTONE DERIV; AC1L3CDV; AC1Q1K5S; SCHEMBL7128855; Heptanoic acid lactone derivative; AWQSAIIDOMEEOD-UHFFFAOYSA-N; NSC36847; NSC140633; NSC-36847; NSC140621; NSC127945; NSC-45645; AKOS006346009; NSC-127945; MCULE-6610625549; NSC-140621; NSC-140633; 5,5-dimethyl-4-(3-oxobutyl)oxolan-2-one; C06066; 2(3H)-Furanone,5-dimethyl-4-(3-oxobutyl)-
DM4NY9H DT Small molecular drug
DM4NY9H PC 8094
DM4NY9H MW 130.18
DM4NY9H FM C7H14O2
DM4NY9H IC InChI=1S/C7H14O2/c1-2-3-4-5-6-7(8)9/h2-6H2,1H3,(H,8,9)
DM4NY9H CS CCCCCCC(=O)O
DM4NY9H IK MNWFXJYAOYHMED-UHFFFAOYSA-N
DM4NY9H IU heptanoic acid
DM4NY9H CA CAS 111-14-8
DM4NY9H CB CHEBI:45571
DM4NY9H DE Discovery agent
DMIAQX4 ID DMIAQX4
DMIAQX4 DN Heptulose-2-Phosphate
DMIAQX4 HS Investigative
DMIAQX4 SN Heptulose-2-Phosphate; 6gpb; H2P; Heptulose-2-P; 1-Deoxygluco-heptulose 2-phosphate; Heptulose 2-phosphate; AC1Q6S5N; AC1L3Z5G; SCHEMBL4312544; 1-deoxy-2-o-phosphono-; A-d-gluco-hept-2-ulopyranose; 1-Deoxy-D-gluco-heptulose 2-phosphate; DB04195; 92642-58-5; 1-deoxy-2-O-phosphono-alpha-D-gluco-hept-2-ulopyranose; alpha-D-gluco-2-Heptulopyranose, 1-deoxy-, 2-(dihydrogen phosphate); [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-methyloxan-2-yl] dihydrogen phosphate
DMIAQX4 DT Small molecular drug
DMIAQX4 PC 124823
DMIAQX4 MW 274.16
DMIAQX4 FM C7H15O9P
DMIAQX4 IC InChI=1S/C7H15O9P/c1-7(16-17(12,13)14)6(11)5(10)4(9)3(2-8)15-7/h3-6,8-11H,2H2,1H3,(H2,12,13,14)/t3-,4-,5+,6-,7-/m1/s1
DMIAQX4 CS C[C@]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)OP(=O)(O)O
DMIAQX4 IK QZBAZODTRUGOQS-XUUWZHRGSA-N
DMIAQX4 IU [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-methyloxan-2-yl] dihydrogen phosphate
DMIAQX4 CA CAS 92642-58-5
DMIAQX4 DE Discovery agent
DMKF762 ID DMKF762
DMKF762 DN Heptyl 1-Thiohexopyranoside
DMKF762 HS Investigative
DMKF762 SN 85618-20-8; Heptyl b-D-thioglucopyranoside; Heptyl 1-thiohexopyranoside; Heptyl beta-D-thioglucopyranoside; Heptyl-beta-D-1-thioglucopyranoside; N-HEPTYL-BETA-D-THIOGLUCOPYRANOSIDE; Heptyl 1-thioglucoside; HTG; N-Heptylthioglucoside; Heptyl thioglucoside; AC1LCVPH; SCHEMBL137948; Heptyl -D-thioglucopyranoside; C13H26O5S; ZINC16052385; n-Heptyl-I(2)-D-thioglucopyranoside; Heptyl-1-thio-beta-D-glucopyranoside; heptyl 1-thio-beta-D-glucopyranoside; GC8635; MFCD00043236; AKOS016846196; beta-D-Glucopyranoside,heptyl 1-thio-
DMKF762 DT Small molecular drug
DMKF762 PC 656917
DMKF762 MW 294.41
DMKF762 FM C13H26O5S
DMKF762 IC InChI=1S/C13H26O5S/c1-2-3-4-5-6-7-19-13-12(17)11(16)10(15)9(8-14)18-13/h9-17H,2-8H2,1H3/t9-,10-,11+,12-,13+/m1/s1
DMKF762 CS CCCCCCCS[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMKF762 IK HPEGNLMTTNTJSP-LBELIVKGSA-N
DMKF762 IU (2S,3R,4S,5S,6R)-2-heptylsulfanyl-6-(hydroxymethyl)oxane-3,4,5-triol
DMKF762 CA CAS 85618-20-8
DMKF762 DE Discovery agent
DMPQBN0 ID DMPQBN0
DMPQBN0 DN Heptyl-Beta-D-Glucopyranoside
DMPQBN0 HS Investigative
DMPQBN0 SN 78617-12-6; HEPTYL-BETA-D-GLUCOPYRANOSIDE; Heptyl beta-D-glucopyranoside; (2R,3R,4S,5S,6R)-2-(Heptyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Heptyl-b-D-glucopyranoside; Heptyl b-D-glucopyranoside; B7G; n-Heptyl-I(2)-D-glucopyranoside; AC1L9LOI; heptyl-; n-Heptyl-ss-D-glucopyranosid; SCHEMBL333088; MolPort-003-935-703; C13H26O6; ZINC48016017; MFCD00063299; GC5331; AKOS027251086; DB03338; API0002901; AK187162; W0562; FT-0626931; n-Heptyl beta-D-glucopyranoside, ~98% (GC); A-7798; n-Heptyl beta-D-gluc
DMPQBN0 DT Small molecular drug
DMPQBN0 PC 448173
DMPQBN0 MW 278.34
DMPQBN0 FM C13H26O6
DMPQBN0 IC InChI=1S/C13H26O6/c1-2-3-4-5-6-7-18-13-12(17)11(16)10(15)9(8-14)19-13/h9-17H,2-8H2,1H3/t9-,10-,11+,12-,13-/m1/s1
DMPQBN0 CS CCCCCCCO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMPQBN0 IK NIDYWHLDTIVRJT-UJPOAAIJSA-N
DMPQBN0 IU (2R,3R,4S,5S,6R)-2-heptoxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMPQBN0 CA CAS 78617-12-6
DMPQBN0 DE Discovery agent
DM1NUO5 ID DM1NUO5
DM1NUO5 DN Heptyl-methyl-prop-2-ynyl-amine hydrochloride
DM1NUO5 HS Investigative
DM1NUO5 DE Discovery agent
DM0VC84 ID DM0VC84
DM0VC84 DN Her2- and PSA-targeted TGX-D1
DM0VC84 HS Investigative
DM0VC84 SN KCC-TGX; Her2- and PSA-targeted TGX-D1 (prostate cancer); Her2-and PSA-targeted TGX-D1 (prostate cancer), University of Missouri
DM0VC84 CP University of Missouri
DM0VC84 DE Prostate cancer
DM8MD52 ID DM8MD52
DM8MD52 DN HERBACETIN
DM8MD52 HS Investigative
DM8MD52 SN Herbacetin; 527-95-7; CHEMBL611029; 8-Hydroxykaempferol; 3,5,7,8-tetrahydroxy-2-(4-hydroxyphenyl)chromen-4-one; 3,4',5,7,8-Pentahydroxyflavone; 2-(4-hydroxyphenyl)-3,5,7,8-tetrakis(oxidanyl)chromen-4-one; PubChem9861; C02806; AC1NQX74; SCHEMBL872691; Herbacetin, > DTXSID70415061; ZDOTZEDNGNPOEW-UHFFFAOYSA-N; MolPort-019-998-217; 3,5,7,8,4'-Pentahydroxyflavone; ZINC6536276; 8144AH; LMPK12113149; BDBM50304350; AKOS030573690; FT-0688291; A829256; 3,5,7,8-tetrahydroxy-2-(4-hydroxyphenyl)-1-benzopyran-4-one
DM8MD52 DT Small molecular drug
DM8MD52 PC 5280544
DM8MD52 MW 302.23
DM8MD52 FM C15H10O7
DM8MD52 IC InChI=1S/C15H10O7/c16-7-3-1-6(2-4-7)14-13(21)12(20)10-8(17)5-9(18)11(19)15(10)22-14/h1-5,16-19,21H
DM8MD52 CS C1=CC(=CC=C1C2=C(C(=O)C3=C(O2)C(=C(C=C3O)O)O)O)O
DM8MD52 IK ZDOTZEDNGNPOEW-UHFFFAOYSA-N
DM8MD52 IU 3,5,7,8-tetrahydroxy-2-(4-hydroxyphenyl)chromen-4-one
DM8MD52 CA CAS 527-95-7
DM8MD52 CB CHEBI:27673
DM8MD52 DE Discovery agent
DMJXBWV ID DMJXBWV
DMJXBWV DN HERKINORIN
DMJXBWV HS Investigative
DMJXBWV SN herkinorin; CHEMBL363324; 862073-77-6; BF3DNCA methyl ester; 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester; SCHEMBL3540059; DTXSID30235444; MolPort-003-983-869; PYDQMXRFUVDCHC-XAGHGKQISA-N; ZINC28461930; BDBM50170678; (3S,4aR,4bS,6S,8R,8aR,10aR)-6-Benzoyloxy-3-furan-3-yl-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester
DMJXBWV DT Small molecular drug
DMJXBWV PC 11431898
DMJXBWV MW 494.5
DMJXBWV FM C28H30O8
DMJXBWV IC InChI=1S/C28H30O8/c1-27-11-9-18-26(32)36-21(17-10-12-34-15-17)14-28(18,2)23(27)22(29)20(13-19(27)25(31)33-3)35-24(30)16-7-5-4-6-8-16/h4-8,10,12,15,18-21,23H,9,11,13-14H2,1-3H3/t18-,19-,20-,21-,23-,27-,28-/m0/s1
DMJXBWV CS C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)OC(=O)C4=CC=CC=C4)C)C5=COC=C5
DMJXBWV IK PYDQMXRFUVDCHC-XAGHGKQISA-N
DMJXBWV IU methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-benzoyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
DMJXBWV CA CAS 862073-77-6
DMJXBWV DE Discovery agent
DM9UASM ID DM9UASM
DM9UASM DN HERNIARIN
DM9UASM HS Investigative
DM9UASM SN 7-Methoxycoumarin; Herniarin; 531-59-9; 7-Methoxy-2H-chromen-2-one; Ayapanin; Herniarine; Methylumbelliferone; 7-Methoxy-2H-1-benzopyran-2-one; 7-methoxychromen-2-one; 2H-1-BENZOPYRAN-2-ONE, 7-METHOXY-; Coumarin, 7-methoxy-; METHOXYCOURMARIN, 7-; Herniarin (6CI); Methyl umbelliferyl ether; UNII-DGK72G008A; 7-methoxy-coumarin; 7-Methoxy Coumarin; NSC 404559; 7-(methyloxy)-2H-chromen-2-one; EINECS 208-513-3; 7-methoxy-chromen-2-one; BRN 0141728; CHEMBL49732; CHEBI:5679; DGK72G008A; Coumarin, 7-methoxy- (8CI)
DM9UASM DT Small molecular drug
DM9UASM PC 10748
DM9UASM MW 176.17
DM9UASM FM C10H8O3
DM9UASM IC InChI=1S/C10H8O3/c1-12-8-4-2-7-3-5-10(11)13-9(7)6-8/h2-6H,1H3
DM9UASM CS COC1=CC2=C(C=C1)C=CC(=O)O2
DM9UASM IK LIIALPBMIOVAHH-UHFFFAOYSA-N
DM9UASM IU 7-methoxychromen-2-one
DM9UASM CA CAS 531-59-9
DM9UASM CB CHEBI:5679
DM9UASM DE Discovery agent
DM2CK7B ID DM2CK7B
DM2CK7B DN HESPERADIN
DM2CK7B HS Investigative
DM2CK7B DT Small molecular drug
DM2CK7B PC 135421442
DM2CK7B MW 516.7
DM2CK7B FM C29H32N4O3S
DM2CK7B IC InChI=1S/C29H32N4O3S/c1-2-37(35,36)32-24-15-16-26-25(19-24)27(29(34)31-26)28(22-9-5-3-6-10-22)30-23-13-11-21(12-14-23)20-33-17-7-4-8-18-33/h3,5-6,9-16,19,31-32,34H,2,4,7-8,17-18,20H2,1H3
DM2CK7B CS CCS(=O)(=O)NC1=CC2=C(C=C1)NC(=C2C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5)O
DM2CK7B IK HYHIYZMIFPJROG-UHFFFAOYSA-N
DM2CK7B IU N-[2-hydroxy-3-[C-phenyl-N-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1H-indol-5-yl]ethanesulfonamide
DM2CK7B CA CAS 422513-13-1
DM2CK7B CB CHEBI:70726
DM2CK7B DE Discovery agent
DMJCHE1 ID DMJCHE1
DMJCHE1 DN Hexadecanal
DMJCHE1 HS Investigative
DMJCHE1 SN hexadecanal; palmitaldehyde; 629-80-1; N-hexadecanal; palmitoyl aldehyde; 1-hexadecanal; 16-Hexadecanal; UNII-WQD27655QE; EINECS 211-111-0; AI3-24252; WQD27655QE; CHEBI:17600; NIOYUNMRJMEDGI-UHFFFAOYSA-N; PLY; Hexadecanaldehyde; Palmitic aldehyde; Palmityl Aldehyde; ACMC-209nbe; AC1L1AGZ; SCHEMBL4481; AC1Q6QL1; GTPL6627; QSPL 064; Palmitaldehyde, 16-Hexadecanal; DTXSID5042039; CHEMBL1235338; CTK2F4087; MolPort-001-784-298; ZINC8216082; KS-000016GB; ANW-34488; RB3019; 6369AF; LMFA06000088; AKOS005145523; TRA0026585; DB03381; MCULE-1337115097
DMJCHE1 DT Small molecular drug
DMJCHE1 PC 984
DMJCHE1 MW 240.42
DMJCHE1 FM C16H32O
DMJCHE1 IC InChI=1S/C16H32O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h16H,2-15H2,1H3
DMJCHE1 CS CCCCCCCCCCCCCCCC=O
DMJCHE1 IK NIOYUNMRJMEDGI-UHFFFAOYSA-N
DMJCHE1 IU hexadecanal
DMJCHE1 CA CAS 629-80-1
DMJCHE1 CB CHEBI:17600
DMJCHE1 DE Discovery agent
DMWUXDZ ID DMWUXDZ
DMWUXDZ DN Hexadecanoic acid
DMWUXDZ HS Investigative
DMWUXDZ SN Palmitic acid; palmitic acid; 1957/10/3; Cetylic acid; palmitate; n-Hexadecanoic acid; Hexadecylic acid; Hydrofol; n-Hexadecoic acid; 1-Pentadecanecarboxylic acid; Pentadecanecarboxylic acid; Palmitinic acid; C16 fatty acid; hexaectylic acid; Industrene 4516; Emersol 143; Emersol 140; Hystrene 8016; Hystrene 9016; 1-Hexyldecanoic Acid; hexadecoic acid; Palmitinsaeure; Palmitic acid (natural); Palmitic acid, pure; Palmitic acid 95%; Prifac 2960; FEMA No 2832; Fatty acids, C14-18; Pristerene 4934; Edenor C16; Kortacid 1698; Lunac P; Palmitic Acid
DMWUXDZ DT Small molecular drug
DMWUXDZ PC 985
DMWUXDZ MW 256.42
DMWUXDZ FM C16H32O2
DMWUXDZ IC InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)
DMWUXDZ CS CCCCCCCCCCCCCCCC(=O)O
DMWUXDZ IK IPCSVZSSVZVIGE-UHFFFAOYSA-N
DMWUXDZ IU hexadecanoic acid
DMWUXDZ CA CAS 57-10-3
DMWUXDZ CB CHEBI:15756
DMWUXDZ DE Discovery agent
DMNZLD6 ID DMNZLD6
DMNZLD6 DN Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine
DMNZLD6 HS Investigative
DMNZLD6 SN CHEMBL361419; Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine; BDBM50150921
DMNZLD6 DT Small molecular drug
DMNZLD6 PC 44393534
DMNZLD6 MW 124.18
DMNZLD6 FM C7H12N2
DMNZLD6 IC InChI=1S/C7H12N2/c8-7-4-5-2-1-3-6(5)9-7/h5-6H,1-4H2,(H2,8,9)
DMNZLD6 CS C1CC2CC(=NC2C1)N
DMNZLD6 IK BJTCDQQHCOHHOO-UHFFFAOYSA-N
DMNZLD6 IU 3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-amine
DMNZLD6 DE Discovery agent
DMG0UVT ID DMG0UVT
DMG0UVT DN Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine
DMG0UVT HS Investigative
DMG0UVT SN CHEMBL365849; Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine; BDBM50150935
DMG0UVT DT Small molecular drug
DMG0UVT PC 19049158
DMG0UVT MW 124.18
DMG0UVT FM C7H12N2
DMG0UVT IC InChI=1S/C7H12N2/c8-7-6-3-1-2-5(6)4-9-7/h5-6H,1-4H2,(H2,8,9)
DMG0UVT CS C1CC2CN=C(C2C1)N
DMG0UVT IK QRVPYEUERURUGX-UHFFFAOYSA-N
DMG0UVT IU 1,3a,4,5,6,6a-hexahydrocyclopenta[c]pyrrol-3-amine
DMG0UVT DE Discovery agent
DMH25OD ID DMH25OD
DMH25OD DN hexahydrodifenidol
DMH25OD HS Investigative
DMH25OD SN Hexahydrodifenidol; 1-cyclohexyl-1-phenyl-4-piperidin-1-ylbutan-1-ol; 113010-69-8; Hexahydro-diphenidol; GTPL322; AC1L3Y37; BDBM81960; CAS_113010-69-8; Piperidinebutanol, alpha-cyclohexyl-alpha-phenyl-
DMH25OD DT Small molecular drug
DMH25OD PC 124226
DMH25OD MW 315.5
DMH25OD FM C21H33NO
DMH25OD IC InChI=1S/C21H33NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1,4-5,11-12,20,23H,2-3,6-10,13-18H2
DMH25OD CS C1CCC(CC1)C(CCCN2CCCCC2)(C3=CC=CC=C3)O
DMH25OD IK ILHSFCNKNNNPRN-UHFFFAOYSA-N
DMH25OD IU 1-cyclohexyl-1-phenyl-4-piperidin-1-ylbutan-1-ol
DMH25OD CA CAS 113010-69-8
DMH25OD DE Discovery agent
DMIB3J2 ID DMIB3J2
DMIB3J2 DN Hexahydro-pyrrolizin-(3E)-ylideneamine
DMIB3J2 HS Investigative
DMIB3J2 SN Hexahydro-pyrrolizin-(3E)-ylideneamine; CHEMBL185535; 765304-80-1; 3h-pyrrolizin-3-imine,hexahydro-; BDBM50150910
DMIB3J2 DT Small molecular drug
DMIB3J2 PC 44393480
DMIB3J2 MW 124.18
DMIB3J2 FM C7H12N2
DMIB3J2 IC InChI=1S/C7H12N2/c8-7-4-3-6-2-1-5-9(6)7/h6,8H,1-5H2
DMIB3J2 CS C1CC2CCC(=N)N2C1
DMIB3J2 IK IGTGCXXJCCYMRS-UHFFFAOYSA-N
DMIB3J2 IU 1,2,5,6,7,8-hexahydropyrrolizin-3-imine
DMIB3J2 DE Discovery agent
DM6UAV7 ID DM6UAV7
DM6UAV7 DN hexahydrosiladifenidol
DM6UAV7 HS Investigative
DM6UAV7 SN Hhsi-difenidol; hexahydro-sila-diphenidol; GNF-Pf-5565
DM6UAV7 DT Small molecular drug
DM6UAV7 PC 3602
DM6UAV7 MW 331.6
DM6UAV7 FM C20H33NOSi
DM6UAV7 IC InChI=1S/C20H33NOSi/c22-23(19-11-4-1-5-12-19,20-13-6-2-7-14-20)18-10-17-21-15-8-3-9-16-21/h1,4-5,11-12,20,22H,2-3,6-10,13-18H2
DM6UAV7 CS C1CCC(CC1)[Si](CCCN2CCCCC2)(C3=CC=CC=C3)O
DM6UAV7 IK QTBCATBNRIYMPB-UHFFFAOYSA-N
DM6UAV7 IU cyclohexyl-hydroxy-phenyl-(3-piperidin-1-ylpropyl)silane
DM6UAV7 CA CAS 98299-40-2
DM6UAV7 DE Discovery agent
DMSHF0K ID DMSHF0K
DMSHF0K DN Hexane-1,6-diamine
DMSHF0K HS Investigative
DMSHF0K SN 1,6-Hexanediamine; 1,6-Diaminohexane; Hexamethylenediamine; 124-09-4; HEXANE-1,6-DIAMINE; HMDA; 1,6-Hexylenediamine; 1,6-Hexamethylenediamine; 1,6-Diamino-n-hexane; HEXAMETHYLENE DIAMINE; Hexylenediamine; 1,6-Hexanediamine (solution); Hexane, 1,6-diamino-; UNII-ZRA5J5B2QW; NCI-C61405; NSC 9257; H2N(CH2)6NH2; CCRIS 6224; HSDB 189; EINECS 204-679-6; HEX-NH2; UN2280; UN1783; ZRA5J5B2QW; Hexamethylenediamine solution; BRN 1098307; AI3-37283; CHEMBL303004; CHEBI:39618; NAQMVNRVTILPCV-UHFFFAOYSA-N; MFCD00008243; DSSTox_CID_4922
DMSHF0K DT Small molecular drug
DMSHF0K PC 16402
DMSHF0K MW 116.2
DMSHF0K FM C6H16N2
DMSHF0K IC InChI=1S/C6H16N2/c7-5-3-1-2-4-6-8/h1-8H2
DMSHF0K CS C(CCCN)CCN
DMSHF0K IK NAQMVNRVTILPCV-UHFFFAOYSA-N
DMSHF0K IU hexane-1,6-diamine
DMSHF0K CA CAS 124-09-4
DMSHF0K CB CHEBI:39618
DMSHF0K DE Discovery agent
DMWAPGI ID DMWAPGI
DMWAPGI DN Hexane-1,6-Diol
DMWAPGI HS Investigative
DMWAPGI SN 1,6-HEXANEDIOL; Hexane-1,6-diol; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; 1,6-Hexylene Glycol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6hexanediol; 1.6-hexanediol; 1,6 hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; hexan-1,6-diol; 1,6-hexan-diol
DMWAPGI DT Small molecular drug
DMWAPGI PC 12374
DMWAPGI MW 118.17
DMWAPGI FM C6H14O2
DMWAPGI IC InChI=1S/C6H14O2/c7-5-3-1-2-4-6-8/h7-8H,1-6H2
DMWAPGI CS C(CCCO)CCO
DMWAPGI IK XXMIOPMDWAUFGU-UHFFFAOYSA-N
DMWAPGI IU hexane-1,6-diol
DMWAPGI CA CAS 629-11-8
DMWAPGI CB CHEBI:43078
DMWAPGI DE Discovery agent
DMJOZYG ID DMJOZYG
DMJOZYG DN Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide
DMJOZYG HS Investigative
DMJOZYG SN CHEMBL222432; 820961-43-1; hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide; CTK3E2660; DTXSID20464908; BDBM50157668; Pentanamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DMJOZYG DT Small molecular drug
DMJOZYG PC 11404772
DMJOZYG MW 331.4
DMJOZYG FM C21H21N3O
DMJOZYG IC InChI=1S/C21H21N3O/c1-2-3-14-20(25)23-19-15-18(16-10-6-4-7-11-16)22-21(24-19)17-12-8-5-9-13-17/h4-13,15H,2-3,14H2,1H3,(H,22,23,24,25)
DMJOZYG CS CCCCC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMJOZYG IK AJUVVGPOXGXRAI-UHFFFAOYSA-N
DMJOZYG IU N-(2,6-diphenylpyrimidin-4-yl)pentanamide
DMJOZYG CA CAS 820961-43-1
DMJOZYG DE Discovery agent
DM4U0L1 ID DM4U0L1
DM4U0L1 DN Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester
DM4U0L1 HS Investigative
DM4U0L1 SN CHEMBL67589; Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester; BDBM50012391; Hexanoic acid 2,5-diphenyl-4-thiazolyl ester
DM4U0L1 DT Small molecular drug
DM4U0L1 PC 15691796
DM4U0L1 MW 351.5
DM4U0L1 FM C21H21NO2S
DM4U0L1 IC InChI=1S/C21H21NO2S/c1-2-3-6-15-18(23)24-20-19(16-11-7-4-8-12-16)25-21(22-20)17-13-9-5-10-14-17/h4-5,7-14H,2-3,6,15H2,1H3
DM4U0L1 CS CCCCCC(=O)OC1=C(SC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM4U0L1 IK HQKAVFKKTZEFLJ-UHFFFAOYSA-N
DM4U0L1 IU (2,5-diphenyl-1,3-thiazol-4-yl) hexanoate
DM4U0L1 DE Discovery agent
DM0HS7L ID DM0HS7L
DM0HS7L DN hexocyclium
DM0HS7L HS Investigative
DM0HS7L SN Tral
DM0HS7L DT Small molecular drug
DM0HS7L PC 24199
DM0HS7L MW 317.5
DM0HS7L FM C20H33N2O+
DM0HS7L IC InChI=1S/C20H33N2O/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3/q+1
DM0HS7L CS C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C
DM0HS7L IK ZRYHPQCHHOKSMD-UHFFFAOYSA-N
DM0HS7L IU 1-cyclohexyl-2-(4,4-dimethylpiperazin-4-ium-1-yl)-1-phenylethanol
DM0HS7L CA CAS 6004-98-4
DM0HS7L CB CHEBI:5707
DM0HS7L DE Discovery agent
DMHTWN9 ID DMHTWN9
DMHTWN9 DN Hex-RYYRIK-NH2
DMHTWN9 HS Investigative
DMHTWN9 SN CHEMBL438383
DMHTWN9 DT Small molecular drug
DMHTWN9 PC 44456339
DMHTWN9 MW 979.2
DMHTWN9 FM C48H78N14O8
DMHTWN9 IC InChI=1S/C48H78N14O8/c1-4-6-8-20-39(64)57-35(18-13-26-55-47(51)52)42(66)60-37(28-31-15-9-7-10-16-31)45(69)61-38(29-32-21-23-33(63)24-22-32)44(68)59-36(19-14-27-56-48(53)54)43(67)62-40(30(3)5-2)46(70)58-34(41(50)65)17-11-12-25-49/h7,9-10,15-16,21-24,30,34-38,40,63H,4-6,8,11-14,17-20,25-29,49H2,1-3H3,(H2,50,65)(H,57,64)(H,58,70)(H,59,68)(H,60,66)(H,61,69)(H,62,67)(H4,51,52,55)(H4,53,54,56)/t30-,34-,35-,36-,37-,38-,40-/m0/s1
DMHTWN9 CS CCCCCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N
DMHTWN9 IK BULLVLNXUBKWQF-GCRPBELOSA-N
DMHTWN9 IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(hexanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMHTWN9 DE Discovery agent
DMBC8KM ID DMBC8KM
DMBC8KM DN Hexylacrolein
DMBC8KM HS Investigative
DMBC8KM SN Heptylideneacetaldehyde; 2-Nonenal; Non-2-enal; alpha-Nonenyl aldehyde; beta-Hexylacrolein; trans-2-Nonen-1-al; trans-2-Nonenal; trans-2-Nonenal (natural); (E)-2-Nonenal; (E)-2-nonen-1-al; (E)-Non-2-enal; 18829-56-6; 2-NONENAL; 2-Nonen-1-al; 2-Nonenal, (2E)-; 2-Nonenal, (E)-; 2-trans-Nonenal; 2463-53-8; 3-Hexyl-2-propenal; 3-Hexylacrolein; 3-hexyl-acrolein; 8VEO649985; AI3-36268; BRN 1722170; BSAIUMLZVGUGKX-BQYQJAHWSA-N; CCRIS 3326; CCRIS 9203; EINECS 219-562-5; EINECS 242-609-6; FEMA No. 3213; MFCD00007012; NSC 20746; UNII-8VEO649985
DMBC8KM PC 5283335
DMBC8KM MW 140.22
DMBC8KM FM C9H16O
DMBC8KM IC BSAIUMLZVGUGKX-BQYQJAHWSA-N
DMBC8KM CS CCCCCCC=CC=O
DMBC8KM IK 1S/C9H16O/c1-2-3-4-5-6-7-8-9-10/h7-9H,2-6H2,1H3/b8-7+
DMBC8KM IU (E)-non-2-enal
DMBC8KM CA CAS 18829-56-6
DMBC8KM CB CHEBI:61726
DMBC8KM DE Discovery agent
DM3YFG9 ID DM3YFG9
DM3YFG9 DN Hexylcarbamoyl fluorouracil
DM3YFG9 HS Investigative
DM3YFG9 SN Carmofur; HCFU; Yamaful; 1-hexylcarbamoyl-5-fluorouracil
DM3YFG9 TC Antiviral Agents
DM3YFG9 DT Small molecular drug
DM3YFG9 PC 2577
DM3YFG9 MW 257.26
DM3YFG9 FM C11H16FN3O3
DM3YFG9 IC InChI=1S/C11H16FN3O3/c1-2-3-4-5-6-13-10(17)15-7-8(12)9(16)14-11(15)18/h7H,2-6H2,1H3,(H,13,17)(H,14,16,18)
DM3YFG9 CS CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F
DM3YFG9 IK AOCCBINRVIKJHY-UHFFFAOYSA-N
DM3YFG9 IU 5-fluoro-N-hexyl-2,4-dioxopyrimidine-1-carboxamide
DM3YFG9 CA CAS 61422-45-5
DM3YFG9 CB CHEBI:31360
DM3YFG9 DE Cancer; Coronavirus Disease 2019 (COVID-19)
DM9EW7V ID DM9EW7V
DM9EW7V DN Hexyl-trimethyl-ammonium
DM9EW7V HS Investigative
DM9EW7V DT Small molecular drug
DM9EW7V PC 84774
DM9EW7V MW 144.28
DM9EW7V FM C9H22N+
DM9EW7V IC InChI=1S/C9H22N/c1-5-6-7-8-9-10(2,3)4/h5-9H2,1-4H3/q+1
DM9EW7V CS CCCCCC[N+](C)(C)C
DM9EW7V IK XTPRURKTXNFVQT-UHFFFAOYSA-N
DM9EW7V IU hexyl(trimethyl)azanium
DM9EW7V CA CAS 16208-27-8
DM9EW7V DE Discovery agent
DMM4JCA ID DMM4JCA
DMM4JCA DN HG-1051
DMM4JCA HS Investigative
DMM4JCA SN CD136 modulator (inflammation/immune disorders), Human Genome Sciences; CD137 antigen modulator (inflammation/immune disorders), Human Genome Sciences; CDw137 modulator (inflammation/immune disorders), Human Genome Sciences; Homolog of mouse Ly63 modulator (inflammation/immune disorders), Human Genome Sciences; ILA modulator (inflammation/immune disorders), Human Genome Sciences; MGC2172 modulator (inflammation/immune disorders), Human Genome Sciences; T cell antigen ILA modulator (inflammation/immune disorders), Human Genome Sciences; TNFRSF9 modulator (inflammation/immune disorders), Human Genome Sciences; Tumor necrosis factor receptor superfamily member 9 modulator (inflammation/immune disorders), Human Genome Sciences; Homolog of mouse 4-1BB modulator (inflammation/immune disorders), Human Genome Sciences; Human 4-1BB receptor splicing varifant modulator (inflammation/immune disorders), Human Genome Sciences; Induced by lymphocyte activation (ILA) modulator (inflammation/immune disorders), Human Genome Sciences; Interleukin-activated receptor modulator (inflammation/immune disorders), Human Genome Sciences; 4-1BB ligand receptor modulator (inflammation/immune disorders), Human Genome Sciences; 4-1BB modulator (inflammation/immune disorders), Human Genome Sciences
DMM4JCA CP Human Genome Sciences Inc
DMM4JCA DE Immune System disease
DM8FD3Z ID DM8FD3Z
DM8FD3Z DN HG-9-91-01
DM8FD3Z HS Investigative
DM8FD3Z SN HY-15776
DM8FD3Z DT Small molecular drug
DM8FD3Z PC 78357808
DM8FD3Z MW 567.7
DM8FD3Z FM C32H37N7O3
DM8FD3Z IC InChI=1S/C32H37N7O3/c1-22-7-6-8-23(2)31(22)36-32(40)39(27-14-13-26(41-4)19-28(27)42-5)30-20-29(33-21-34-30)35-24-9-11-25(12-10-24)38-17-15-37(3)16-18-38/h6-14,19-21H,15-18H2,1-5H3,(H,36,40)(H,33,34,35)
DM8FD3Z CS CC1=C(C(=CC=C1)C)NC(=O)N(C2=C(C=C(C=C2)OC)OC)C3=NC=NC(=C3)NC4=CC=C(C=C4)N5CCN(CC5)C
DM8FD3Z IK UYUHRKLITDJEHB-UHFFFAOYSA-N
DM8FD3Z IU 1-(2,4-dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea
DM8FD3Z CB CHEBI:133818
DM8FD3Z DE Discovery agent
DMOIPYD ID DMOIPYD
DMOIPYD DN hGCGR antagonist
DMOIPYD HS Investigative
DMOIPYD SN acylated aminothiophene nitrile; glucagon receptor antagonist I
DMOIPYD DT Small molecular drug
DMOIPYD PC 619101
DMOIPYD MW 346.5
DMOIPYD FM C20H30N2OS
DMOIPYD IC InChI=1S/C20H30N2OS/c1-6-13(7-2)18(23)22-19-16(12-21)15-10-9-14(11-17(15)24-19)20(4,5)8-3/h13-14H,6-11H2,1-5H3,(H,22,23)
DMOIPYD CS CCC(CC)C(=O)NC1=C(C2=C(S1)CC(CC2)C(C)(C)CC)C#N
DMOIPYD IK SWIBDWBSJSJQHL-UHFFFAOYSA-N
DMOIPYD IU N-[3-cyano-6-(2-methylbutan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-2-ethylbutanamide
DMOIPYD CA CAS 438618-32-7
DMOIPYD DE Discovery agent
DMX2TGD ID DMX2TGD
DMX2TGD DN H-Gly-D-dmP-Glu-OH
DMX2TGD HS Investigative
DMX2TGD SN CHEMBL212694
DMX2TGD DT Small molecular drug
DMX2TGD PC 44413487
DMX2TGD MW 329.35
DMX2TGD FM C14H23N3O6
DMX2TGD IC InChI=1S/C14H23N3O6/c1-14(2)6-5-9(17(14)10(18)7-15)12(21)16-8(13(22)23)3-4-11(19)20/h8-9H,3-7,15H2,1-2H3,(H,16,21)(H,19,20)(H,22,23)/t8-,9+/m0/s1
DMX2TGD CS CC1(CC[C@@H](N1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C
DMX2TGD IK KNUZCBVWBGSPRA-DTWKUNHWSA-N
DMX2TGD IU (2S)-2-[[(2R)-1-(2-aminoacetyl)-5,5-dimethylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMX2TGD DE Discovery agent
DMOYQPM ID DMOYQPM
DMOYQPM DN H-Gly-dmP-Glu-OH
DMOYQPM HS Investigative
DMOYQPM SN SCHEMBL2085656; CHEMBL193486
DMOYQPM DT Small molecular drug
DMOYQPM PC 11515428
DMOYQPM MW 329.35
DMOYQPM FM C14H23N3O6
DMOYQPM IC InChI=1S/C14H23N3O6/c1-14(2)6-5-9(17(14)10(18)7-15)12(21)16-8(13(22)23)3-4-11(19)20/h8-9H,3-7,15H2,1-2H3,(H,16,21)(H,19,20)(H,22,23)/t8-,9-/m0/s1
DMOYQPM CS CC1(CC[C@H](N1C(=O)CN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C
DMOYQPM IK KNUZCBVWBGSPRA-IUCAKERBSA-N
DMOYQPM IU (2S)-2-[[(2S)-1-(2-aminoacetyl)-5,5-dimethylpyrrolidine-2-carbonyl]amino]pentanedioic acid
DMOYQPM CA CAS 853400-77-8
DMOYQPM DE Discovery agent
DMCKAWY ID DMCKAWY
DMCKAWY DN HI-172
DMCKAWY HS Investigative
DMCKAWY SN HI-172; CHEMBL288626; BDBM50078260
DMCKAWY DT Small molecular drug
DMCKAWY PC 44287426
DMCKAWY MW 329.26
DMCKAWY FM C12H17BrN4S
DMCKAWY IC InChI=1S/C12H17BrN4S/c13-10-4-5-11(14-8-10)16-12(18)15-9-17-6-2-1-3-7-17/h4-5,8H,1-3,6-7,9H2,(H2,14,15,16,18)
DMCKAWY CS C1CCN(CC1)CNC(=S)NC2=NC=C(C=C2)Br
DMCKAWY IK QIWYYZPJZHMEPR-UHFFFAOYSA-N
DMCKAWY IU 1-(5-bromopyridin-2-yl)-3-(piperidin-1-ylmethyl)thiourea
DMCKAWY DE Discovery agent
DM3R4ZF ID DM3R4ZF
DM3R4ZF DN HI-236
DM3R4ZF HS Investigative
DM3R4ZF SN HI-236; CHEMBL240416; D-PBT; AC1MHD7C; DDE236; SCHEMBL6246077; BDBM50206060; 1-(5-bromopyridin-2-yl)-3-(2,5-dimethoxyphenethyl)thiourea; 1-(2,5-dimethoxyphenethyl)-3-(5-bromopyridin-2-yl)thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(2,5-dimethoxyphenyl)ethyl]thiourea; N-[2-(2,5-Dimethoxyphenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea; 1-(5-bromopyridin-2-yl)-3-[2-(2,5-dimethoxyphenyl)ethyl]thiourea
DM3R4ZF DT Small molecular drug
DM3R4ZF PC 3000498
DM3R4ZF MW 396.3
DM3R4ZF FM C16H18BrN3O2S
DM3R4ZF IC InChI=1S/C16H18BrN3O2S/c1-21-13-4-5-14(22-2)11(9-13)7-8-18-16(23)20-15-6-3-12(17)10-19-15/h3-6,9-10H,7-8H2,1-2H3,(H2,18,19,20,23)
DM3R4ZF CS COC1=CC(=C(C=C1)OC)CCNC(=S)NC2=NC=C(C=C2)Br
DM3R4ZF IK GNLVRKKIIIVZHZ-UHFFFAOYSA-N
DM3R4ZF IU 1-(5-bromopyridin-2-yl)-3-[2-(2,5-dimethoxyphenyl)ethyl]thiourea
DM3R4ZF DE Discovery agent
DMQK5RM ID DMQK5RM
DMQK5RM DN HI-240
DMQK5RM HS Investigative
DMQK5RM SN HI-240; CHEMBL295585; AC1MHDYL; F-PBT; SCHEMBL5390696; DDE240; BDBM50078263; AKOS030056312; 1-(5-bromo-2-pyridyl)-3-[2-(2-fluorophenyl)ethyl]thiourea; N-[2-(2-Fluorophenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; 1-(5-bromopyridin-2-yl)-3-[2-(2-fluorophenyl)ethyl]thiourea
DMQK5RM DT Small molecular drug
DMQK5RM PC 3001767
DMQK5RM MW 354.24
DMQK5RM FM C14H13BrFN3S
DMQK5RM IC InChI=1S/C14H13BrFN3S/c15-11-5-6-13(18-9-11)19-14(20)17-8-7-10-3-1-2-4-12(10)16/h1-6,9H,7-8H2,(H2,17,18,19,20)
DMQK5RM CS C1=CC=C(C(=C1)CCNC(=S)NC2=NC=C(C=C2)Br)F
DMQK5RM IK MIJLSRZJDIBHJU-UHFFFAOYSA-N
DMQK5RM IU 1-(5-bromopyridin-2-yl)-3-[2-(2-fluorophenyl)ethyl]thiourea
DMQK5RM DE Discovery agent
DMTKCW6 ID DMTKCW6
DMTKCW6 DN HI-241
DMTKCW6 HS Investigative
DMTKCW6 SN HI-241; CHEMBL40625; N-[2-(3-Fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea; DDE241; AC1MHDYO; SCHEMBL5888383; OEBGVSGGLQGGNH-UHFFFAOYSA-N; BDBM50078255; AKOS030056592; 1-(5-bromopyridin-2-yl)-3-[2-(3-fluorophenyl)ethyl]thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(3-fluorophenyl)ethyl]thiourea
DMTKCW6 DT Small molecular drug
DMTKCW6 PC 3001770
DMTKCW6 MW 354.24
DMTKCW6 FM C14H13BrFN3S
DMTKCW6 IC InChI=1S/C14H13BrFN3S/c15-11-4-5-13(18-9-11)19-14(20)17-7-6-10-2-1-3-12(16)8-10/h1-5,8-9H,6-7H2,(H2,17,18,19,20)
DMTKCW6 CS C1=CC(=CC(=C1)F)CCNC(=S)NC2=NC=C(C=C2)Br
DMTKCW6 IK OEBGVSGGLQGGNH-UHFFFAOYSA-N
DMTKCW6 IU 1-(5-bromopyridin-2-yl)-3-[2-(3-fluorophenyl)ethyl]thiourea
DMTKCW6 DE Discovery agent
DM0QYLP ID DM0QYLP
DM0QYLP DN HI-242
DM0QYLP HS Investigative
DM0QYLP SN HI-242; CHEMBL287978; DDE242; AC1MHDYR; SCHEMBL5888407; BDBM50078254; AKOS030051128; 1-(5-bromopyridin-2-yl)-3-[2-(4-fluorophenyl)ethyl]thiourea; 1-(5-bromo-2-pyridyl)-3-[2-(4-fluorophenyl)ethyl]thiourea; N-[2-(4-Fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea
DM0QYLP DT Small molecular drug
DM0QYLP PC 3001773
DM0QYLP MW 354.24
DM0QYLP FM C14H13BrFN3S
DM0QYLP IC InChI=1S/C14H13BrFN3S/c15-11-3-6-13(18-9-11)19-14(20)17-8-7-10-1-4-12(16)5-2-10/h1-6,9H,7-8H2,(H2,17,18,19,20)
DM0QYLP CS C1=CC(=CC=C1CCNC(=S)NC2=NC=C(C=C2)Br)F
DM0QYLP IK SDMLMNPOMWSLBF-UHFFFAOYSA-N
DM0QYLP IU 1-(5-bromopyridin-2-yl)-3-[2-(4-fluorophenyl)ethyl]thiourea
DM0QYLP DE Discovery agent
DMG36BD ID DMG36BD
DMG36BD DN HI-244
DMG36BD HS Investigative
DMG36BD SN CHEMBL144604; HI-256; AC1MHE9N; SCHEMBL6847403; BDBM50097041; AKOS030007896; 1-(5-bromo-2-pyridyl)-3-[2-(4-hydroxyphenyl)ethyl]thiourea; N-[2-(4-Hydroxyphenethyl)]-N'-[2-(5-bromopyridyl)]thiourea; 1-(5-bromopyridin-2-yl)-3-[2-(4-hydroxyphenyl)ethyl]thiourea
DMG36BD DT Small molecular drug
DMG36BD PC 3002300
DMG36BD MW 352.25
DMG36BD FM C14H14BrN3OS
DMG36BD IC InChI=1S/C14H14BrN3OS/c15-11-3-6-13(17-9-11)18-14(20)16-8-7-10-1-4-12(19)5-2-10/h1-6,9,19H,7-8H2,(H2,16,17,18,20)
DMG36BD CS C1=CC(=CC=C1CCNC(=S)NC2=NC=C(C=C2)Br)O
DMG36BD IK UAUYJJLEWDLTLK-UHFFFAOYSA-N
DMG36BD IU 1-(5-bromopyridin-2-yl)-3-[2-(4-hydroxyphenyl)ethyl]thiourea
DMG36BD DE Discovery agent
DME4SML ID DME4SML
DME4SML DN HI-280
DME4SML HS Investigative
DME4SML SN HI-280; CHEMBL40642; DDE280; AC1LAQRF; SCHEMBL14560609; CTK7B5926; BDBM50078253; 3-(Methylethyl)-6-(methylthiomethylthio)-4-benzylhydropyridin-2-one; 4-benzyl-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one; 4-benzyl-3-isopropyl-6-(methylsulfanylmethylsulfanyl)-1H-pyridin-2-one; 4-Benzyl-3-isopropyl-6-methylsulfanylmethylsulfanyl-1H-pyridin-2-one
DME4SML DT Small molecular drug
DME4SML PC 473270
DME4SML MW 319.5
DME4SML FM C17H21NOS2
DME4SML IC InChI=1S/C17H21NOS2/c1-12(2)16-14(9-13-7-5-4-6-8-13)10-15(18-17(16)19)21-11-20-3/h4-8,10,12H,9,11H2,1-3H3,(H,18,19)
DME4SML CS CC(C)C1=C(C=C(NC1=O)SCSC)CC2=CC=CC=C2
DME4SML IK CCFCAWLPLYLQBS-UHFFFAOYSA-N
DME4SML IU 4-benzyl-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one
DME4SML DE Discovery agent
DM7K0PH ID DM7K0PH
DM7K0PH DN HI-281
DM7K0PH HS Investigative
DM7K0PH SN HI-281; CHEMBL290312; DDE281; AC1LAQRC; CTK7B5925; BDBM50078262; 4-[(3,5-Dimethylphenyl)methyl]-3-(methylethyl)-6-(methylthiomethylthio)hydropyridin-2-one; 4-(3,5-Dimethyl-benzyl)-3-isopropyl-6-methylsulfanylmethylsulfanyl-1H-pyridin-2-one; 4-(3,5-dimethylbenzyl)-3-(1-methylethyl)-6-{[(methylsulfanyl)methyl]sulfanyl}pyridin-2(1h)-one; 4-[(3,5-dimethylphenyl)methyl]-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one
DM7K0PH DT Small molecular drug
DM7K0PH PC 473269
DM7K0PH MW 347.5
DM7K0PH FM C19H25NOS2
DM7K0PH IC InChI=1S/C19H25NOS2/c1-12(2)18-16(9-15-7-13(3)6-14(4)8-15)10-17(20-19(18)21)23-11-22-5/h6-8,10,12H,9,11H2,1-5H3,(H,20,21)
DM7K0PH CS CC1=CC(=CC(=C1)CC2=C(C(=O)NC(=C2)SCSC)C(C)C)C
DM7K0PH IK AGRSTTVMWWVJEL-UHFFFAOYSA-N
DM7K0PH IU 4-[(3,5-dimethylphenyl)methyl]-6-(methylsulfanylmethylsulfanyl)-3-propan-2-yl-1H-pyridin-2-one
DM7K0PH DE Discovery agent
DMSUWD8 ID DMSUWD8
DMSUWD8 DN HI-443
DMSUWD8 HS Investigative
DMSUWD8 SN HI-443; CHEMBL116474; 258340-15-7; AC1MHE5U; SCHEMBL1345282; CTK0J3754; DTXSID40388233; PHI-443; 1-(5-bromopyridin-2-yl)-3-(2-thiophen-2-ylethyl)thiourea; BDBM50083680; AKOS030257616; 1-(5-bromo-2-pyridyl)-3-[2-(2-thienyl)ethyl]thiourea; Thiourea, N-(5-bromo-2-pyridinyl)-N'-[2-(2-thienyl)ethyl]-; 1-(5-Bromo-pyridin-2-yl)-3-(2-thiophen-2-yl-ethyl)-thiourea
DMSUWD8 DT Small molecular drug
DMSUWD8 PC 3002121
DMSUWD8 MW 342.3
DMSUWD8 FM C12H12BrN3S2
DMSUWD8 IC InChI=1S/C12H12BrN3S2/c13-9-3-4-11(15-8-9)16-12(17)14-6-5-10-2-1-7-18-10/h1-4,7-8H,5-6H2,(H2,14,15,16,17)
DMSUWD8 CS C1=CSC(=C1)CCNC(=S)NC2=NC=C(C=C2)Br
DMSUWD8 IK GAIBJCKASOWHGH-UHFFFAOYSA-N
DMSUWD8 IU 1-(5-bromopyridin-2-yl)-3-(2-thiophen-2-ylethyl)thiourea
DMSUWD8 CA CAS 258340-15-7
DMSUWD8 DE Discovery agent
DMYP0DE ID DMYP0DE
DMYP0DE DN HI-445
DMYP0DE HS Investigative
DMYP0DE PC 3001929
DMYP0DE MW 295.8
DMYP0DE FM C14H18ClN3S
DMYP0DE IC InChI=1S/C14H18ClN3S/c15-12-6-7-13(17-10-12)18-14(19)16-9-8-11-4-2-1-3-5-11/h4,6-7,10H,1-3,5,8-9H2,(H2,16,17,18,19)
DMYP0DE CS C1CCC(=CC1)CCNC(=S)NC2=NC=C(C=C2)Cl
DMYP0DE IK DVTYONOGIMBZRG-UHFFFAOYSA-N
DMYP0DE IU 1-(5-chloropyridin-2-yl)-3-[2-(cyclohexen-1-yl)ethyl]thiourea
DMYP0DE DE Discovery agent
DMD6NZO ID DMD6NZO
DMD6NZO DN Hinokinin
DMD6NZO HS Investigative
DMD6NZO SN Hinokinin; (-)-Hinokinin; 26543-89-5; CHEBI:5722; CHEMBL242011; (3R,4R)-3,4-Bis(benzo[d][1,3]dioxol-5-ylmethyl)dihydrofuran-2(3H)-one; (3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-one; (3R-trans)-3,4-bis(1,3-benzodioxol-5-ylmethyl)dihydrofuran-2(3H)-one; hinoquinin; (-)-hinoquinin; AC1L9DKH; Epitope ID:116880; SCHEMBL1121862; MolPort-039-338-821; ZINC1872258; BDBM50218812; AKOS027324070; LS-190466; C10627; (2r,3r)-2,3-di-(3,4-methylenedioxybenzyl)-butyrolactone
DMD6NZO DT Small molecular drug
DMD6NZO PC 442879
DMD6NZO MW 354.4
DMD6NZO FM C20H18O6
DMD6NZO IC InChI=1S/C20H18O6/c21-20-15(6-13-2-4-17-19(8-13)26-11-24-17)14(9-22-20)5-12-1-3-16-18(7-12)25-10-23-16/h1-4,7-8,14-15H,5-6,9-11H2/t14-,15+/m0/s1
DMD6NZO CS C1[C@@H]([C@H](C(=O)O1)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DMD6NZO IK DDWGQGZPYDSYEL-LSDHHAIUSA-N
DMD6NZO IU (3R,4R)-3,4-bis(1,3-benzodioxol-5-ylmethyl)oxolan-2-one
DMD6NZO CA CAS 26543-89-5
DMD6NZO CB CHEBI:5722
DMD6NZO DE Discovery agent
DMHL9Y6 ID DMHL9Y6
DMHL9Y6 DN HINOKITIOL
DMHL9Y6 HS Investigative
DMHL9Y6 SN hinokitiol; beta-Thujaplicin; 499-44-5; 4-Isopropyltropolone; Hinokitol; beta-Thujaplicine; THUJAPLICIN, BETA; Tropolone, 4-isopropyl-; beta-Isopropyltropolon; 2-Hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one; Isopropyltropolone; .beta.-Thujaplicin; beta-Isopropyltropolone; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-4-(1-methylethyl)-; .beta.-Isopropyltropolon; UNII-U5335D6EBI; NSC 18804; .beta.-Thujaplicine; 2-hydroxy-4-(propan-2-yl)cyclohepta-2,4,6-trien-1-one; NSC18804; EINECS 207-880-7
DMHL9Y6 DT Small molecular drug
DMHL9Y6 PC 3611
DMHL9Y6 MW 164.2
DMHL9Y6 FM C10H12O2
DMHL9Y6 IC InChI=1S/C10H12O2/c1-7(2)8-4-3-5-9(11)10(12)6-8/h3-7H,1-2H3,(H,11,12)
DMHL9Y6 CS CC(C)C1=CC(=O)C(=CC=C1)O
DMHL9Y6 IK FUWUEFKEXZQKKA-UHFFFAOYSA-N
DMHL9Y6 IU 2-hydroxy-6-propan-2-ylcyclohepta-2,4,6-trien-1-one
DMHL9Y6 CA CAS 499-44-5
DMHL9Y6 CB CHEBI:10447
DMHL9Y6 DE Discovery agent
DM0PV2Y ID DM0PV2Y
DM0PV2Y DN Hippuristanol
DM0PV2Y HS Investigative
DM0PV2Y SN 80442-78-0; SCHEMBL1374807; CHEMBL1098427; DTXSID50433627; BDBM50235738; Q10861089
DM0PV2Y DT Small molecular drug
DM0PV2Y PC 9981822
DM0PV2Y MW 462.7
DM0PV2Y FM C28H46O5
DM0PV2Y IC InChI=1S/C28H46O5/c1-15-13-28(33-24(15,2)3)27(6,31)23-21(32-28)12-19-18-8-7-16-11-17(29)9-10-25(16,4)22(18)20(30)14-26(19,23)5/h15-23,29-31H,7-14H2,1-6H3/t15-,16-,17+,18-,19-,20-,21-,22+,23-,25-,26-,27+,28+/m0/s1
DM0PV2Y CS C[C@H]1C[C@]2([C@]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(C[C@@H]([C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@H](C6)O)C)O)C)(C)O)OC1(C)C
DM0PV2Y IK HPHXKNOXVBFETI-SHCCRYCOSA-N
DM0PV2Y IU (1S,2S,3'S,4S,6R,7R,8R,9S,11S,12S,13S,16R,18S)-2',2',3',7,9,13-hexamethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,5'-oxolane]-7,11,16-triol
DM0PV2Y CA CAS 80442-78-0
DM0PV2Y DE T-cell leukaemia
DMRJGOP ID DMRJGOP
DMRJGOP DN His-DPhe-Arg-Trp
DMRJGOP HS Investigative
DMRJGOP SN CHEMBL397413; 4289-02-5; His-DPhe-Arg-Trp; Hisetal; Characteristic MSH-Tetrapeptide; ZINC28707608; BDBM50211182; (MSH fragment H-His-Phe-Arg-Trp-OH)2-(2-{2-[2-Amino-3-(3H-imidazol-4-yl)-propionylamino]-3-phenyl-propionylamino}-5-guanidino-pentanoylamino)-3-(1H-indol-3-yl)-propionic acid
DMRJGOP DT Small molecular drug
DMRJGOP PC 10258635
DMRJGOP MW 644.7
DMRJGOP FM C32H40N10O5
DMRJGOP IC InChI=1S/C32H40N10O5/c33-23(15-21-17-36-18-39-21)28(43)41-26(13-19-7-2-1-3-8-19)30(45)40-25(11-6-12-37-32(34)35)29(44)42-27(31(46)47)14-20-16-38-24-10-5-4-9-22(20)24/h1-5,7-10,16-18,23,25-27,38H,6,11-15,33H2,(H,36,39)(H,40,45)(H,41,43)(H,42,44)(H,46,47)(H4,34,35,37)/t23-,25-,26-,27-/m0/s1
DMRJGOP CS C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N
DMRJGOP IK CAYNQHPLZNPBIO-MNUOIFNESA-N
DMRJGOP IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DMRJGOP DE Discovery agent
DMA9YIB ID DMA9YIB
DMA9YIB DN histaprodifen
DMA9YIB HS Investigative
DMA9YIB SN Histaprodifen; SCHEMBL3019488; GTPL4026; CHEMBL275507; BDBM22864; ZINC38881558; 2-[2-(3,3-diphenylpropyl)-1h-imidazol-4-yl]ethanamine; 2-[2-[3,3-di(phenyl)propyl]-3H-imidazol-4-yl]ethanamine
DMA9YIB DT Small molecular drug
DMA9YIB PC 10447834
DMA9YIB MW 305.4
DMA9YIB FM C20H23N3
DMA9YIB IC InChI=1S/C20H23N3/c21-14-13-18-15-22-20(23-18)12-11-19(16-7-3-1-4-8-16)17-9-5-2-6-10-17/h1-10,15,19H,11-14,21H2,(H,22,23)
DMA9YIB CS C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3
DMA9YIB IK BPZGZNLONLANFE-UHFFFAOYSA-N
DMA9YIB IU 2-[2-(3,3-diphenylpropyl)-1H-imidazol-5-yl]ethanamine
DMA9YIB DE Discovery agent
DM7MUJ3 ID DM7MUJ3
DM7MUJ3 DN HITOPK-032
DM7MUJ3 HS Investigative
DM7MUJ3 SN HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J
DM7MUJ3 PC 1936439
DM7MUJ3 MW 369.4
DM7MUJ3 FM C20H11N5OS
DM7MUJ3 IC InChI=1S/C20H11N5OS/c21-11-13-16-10-12(22-20(26)17-6-3-9-27-17)7-8-25(16)19-18(13)23-14-4-1-2-5-15(14)24-19/h1-10H,(H,22,26)
DM7MUJ3 CS C1=CC=C2C(=C1)N=C3C(=C4C=C(C=CN4C3=N2)NC(=O)C5=CC=CS5)C#N
DM7MUJ3 IK BCSBXWKRZUPFHW-UHFFFAOYSA-N
DM7MUJ3 IU N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide
DM7MUJ3 CA CAS 799819-78-6
DM7MUJ3 DE Nasopharyngeal carcinoma
DMNI5FW ID DMNI5FW
DMNI5FW DN HJC 0350
DMNI5FW HS Investigative
DMNI5FW SN HJC0350
DMNI5FW DT Small molecular drug
DMNI5FW PC 22200891
DMNI5FW MW 277.4
DMNI5FW FM C15H19NO2S
DMNI5FW IC InChI=1S/C15H19NO2S/c1-10-6-12(3)15(13(4)7-10)19(17,18)16-9-11(2)8-14(16)5/h6-9H,1-5H3
DMNI5FW CS CC1=CC(=C(C(=C1)C)S(=O)(=O)N2C=C(C=C2C)C)C
DMNI5FW IK AFZWZVLPIMHLSE-UHFFFAOYSA-N
DMNI5FW IU 2,4-dimethyl-1-(2,4,6-trimethylphenyl)sulfonylpyrrole
DMNI5FW DE Discovery agent
DMWIOCY ID DMWIOCY
DMWIOCY DN HJP-272
DMWIOCY HS Investigative
DMWIOCY SN Endothelin type A receptor antagonist (premature birth, inflammation); ETA antagonist (premature birth, lung inflammation), St Johns University; Endothelin type A receptor antagonist (premature birth, inflammation), St Johns University
DMWIOCY CP St Johns University
DMWIOCY DE Premature labour
DME13RQ ID DME13RQ
DME13RQ DN hK2p01 derivative KLK2 inhibitor
DME13RQ HS Investigative
DME13RQ SN CHEMBL2171880; hK2p01 derivative KLK2 inhibitor; GTPL8672; BDBM50396163; 2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]acetic acid
DME13RQ DT Small molecular drug
DME13RQ PC 11700955
DME13RQ MW 1191.4
DME13RQ FM C59H82N16O11
DME13RQ IC InChI=1S/C59H82N16O11/c1-32(2)49(75-54(82)43(22-13-14-24-60)71-56(84)45(26-36-16-7-6-8-17-36)72-53(81)44(70-50(78)33(3)61)23-15-25-64-59(62)63)58(86)74-47(28-38-30-66-42-21-12-10-19-40(38)42)57(85)73-46(27-37-29-65-41-20-11-9-18-39(37)41)55(83)69-35(5)52(80)68-34(4)51(79)67-31-48(76)77/h6-12,16-21,29-30,32-35,43-47,49,65-66H,13-15,22-28,31,60-61H2,1-5H3,(H,67,79)(H,68,80)(H,69,83)(H,70,78)(H,71,84)(H,72,81)(H,73,85)(H,74,86)(H,75,82)(H,76,77)(H4,62,63,64)/t33-,34-,35-,43-,44-,45-,46-,47-,49-/m0/s1
DME13RQ CS C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)O)N
DME13RQ IK BVRWWHKWGPOKPN-NXOPMQQOSA-N
DME13RQ IU 2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]acetic acid
DME13RQ DE Discovery agent
DM5LR2B ID DM5LR2B
DM5LR2B DN HKI-9924129
DM5LR2B HS Investigative
DM5LR2B CP Grunenthal
DM5LR2B DT Small molecular drug
DM5LR2B PC 5311104
DM5LR2B MW 429.3
DM5LR2B FM C21H15Cl2FN4O
DM5LR2B IC InChI=1S/C21H15Cl2FN4O/c1-11-8-13(6-7-17(11)24)26-21-25-10-12-9-14(20(29)28(2)19(12)27-21)18-15(22)4-3-5-16(18)23/h3-10H,1-2H3,(H,25,26,27)
DM5LR2B CS CC1=C(C=CC(=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl)F
DM5LR2B IK SLCFEJAMCRLYRG-UHFFFAOYSA-N
DM5LR2B IU 6-(2,6-dichlorophenyl)-2-(4-fluoro-3-methylanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one
DM5LR2B CA CAS 287204-45-9
DM5LR2B DE Gram-positive bacterial infection
DMDINX9 ID DMDINX9
DMDINX9 DN H-KPPR-OH
DMDINX9 HS Investigative
DMDINX9 SN CHEMBL1091089; H-KPPR-OH
DMDINX9 DT Small molecular drug
DMDINX9 PC 15858500
DMDINX9 MW 496.6
DMDINX9 FM C22H40N8O5
DMDINX9 IC InChI=1S/C22H40N8O5/c23-10-2-1-6-14(24)19(32)30-13-5-9-17(30)20(33)29-12-4-8-16(29)18(31)28-15(21(34)35)7-3-11-27-22(25)26/h14-17H,1-13,23-24H2,(H,28,31)(H,34,35)(H4,25,26,27)/t14-,15-,16-,17-/m0/s1
DMDINX9 CS C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMDINX9 IK CKFCCXJQYNXYHI-QAETUUGQSA-N
DMDINX9 IU (2S)-2-[[(2S)-1-[(2S)-1-[(2S)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMDINX9 DE Discovery agent
DMMW0OF ID DMMW0OF
DMMW0OF DN HL-034
DMMW0OF HS Investigative
DMMW0OF SN Oral TPO agent, HanAll Biopharma
DMMW0OF CP HanAll Biopharma Co Ltd
DMMW0OF DE Discovery agent
DMAPWC2 ID DMAPWC2
DMAPWC2 DN H-Leu-Phe-NH2
DMAPWC2 HS Investigative
DMAPWC2 SN Leucyl-phenylalanine amide; H-Leu-Phe-NH2; L-Leucyl-L-phenylalaninamide; 38678-60-3; CHEMBL590518; Leu-phe-NH2; AC1MIYXY; SCHEMBL2184039; L-Phenylalaninamide, L-leucyl-; DTXSID30191975; HVNQCDIUFGAINF-STQMWFEESA-N; ZINC1605748; BDBM50308392; AKOS027447855; (2S)-2-[[(2S)-2-Amino-4-methylpentanoyl]amino]-3-phenylpropanamide
DMAPWC2 DT Small molecular drug
DMAPWC2 PC 3082491
DMAPWC2 MW 277.36
DMAPWC2 FM C15H23N3O2
DMAPWC2 IC InChI=1S/C15H23N3O2/c1-10(2)8-12(16)15(20)18-13(14(17)19)9-11-6-4-3-5-7-11/h3-7,10,12-13H,8-9,16H2,1-2H3,(H2,17,19)(H,18,20)/t12-,13-/m0/s1
DMAPWC2 CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)N
DMAPWC2 IK HVNQCDIUFGAINF-STQMWFEESA-N
DMAPWC2 IU (2S)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-4-methylpentanamide
DMAPWC2 CA CAS 38678-60-3
DMAPWC2 DE Discovery agent
DM2URWO ID DM2URWO
DM2URWO DN HLL1-Fab-A3B3
DM2URWO HS Investigative
DM2URWO SN Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer); Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer), Immunomedics
DM2URWO CP Immunomedics Inc
DM2URWO DT Vaccine
DM2URWO DE Solid tumour/cancer
DMDXIS7 ID DMDXIS7
DMDXIS7 DN H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645)
DMDXIS7 HS Investigative
DMDXIS7 SN H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645); CHEMBL405182
DMDXIS7 PC 44316376
DMDXIS7 MW 1064.2
DMDXIS7 FM C49H69N13O12S
DMDXIS7 IC InChI=1S/C49H69N13O12S/c50-16-6-5-11-31(51)42(68)56-32(12-7-17-54-49(52)53)46(72)60-18-8-14-36(60)48(74)61-23-30(64)21-37(61)44(70)55-22-39(65)59-41(29-19-27-9-1-2-10-28(27)20-29)45(71)57-33(25-63)43(69)58-34-26-75-38-15-4-3-13-35(38)62(47(34)73)24-40(66)67/h1-4,9-10,13,15,29-34,36-37,41,63-64H,5-8,11-12,14,16-26,50-51H2,(H,55,70)(H,56,68)(H,57,71)(H,58,69)(H,59,65)(H,66,67)(H4,52,53,54)/t30?,31?,32-,33+,34-,36+,37+,41?/m1/s1
DMDXIS7 CS C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCCN)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(C3CC4=CC=CC=C4C3)C(=O)N[C@@H](CO)C(=O)N[C@@H]5CSC6=CC=CC=C6N(C5=O)CC(=O)O)O
DMDXIS7 IK DSKXSKYPLRUWNI-XISDYZNSSA-N
DMDXIS7 IU 2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-(2,6-diaminohexanoylamino)-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-2-(2,3-dihydro-1H-inden-2-yl)acetyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DMDXIS7 DE Discovery agent
DMTGU0L ID DMTGU0L
DMTGU0L DN H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)
DMTGU0L HS Investigative
DMTGU0L SN CHEMBL412824; H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669)
DMTGU0L PC 44316161
DMTGU0L MW 1044.2
DMTGU0L FM C45H65N13O12S2
DMTGU0L IC InChI=1S/C45H65N13O12S2/c46-14-4-3-9-27(47)38(64)53-28(10-5-15-50-45(48)49)42(68)56-16-6-12-33(56)44(70)57-21-25(60)18-34(57)41(67)51-20-36(61)52-29(19-26-8-7-17-71-26)39(65)54-30(23-59)40(66)55-31-24-72-35-13-2-1-11-32(35)58(43(31)69)22-37(62)63/h1-2,7-8,11,13,17,25,27-31,33-34,59-60H,3-6,9-10,12,14-16,18-24,46-47H2,(H,51,67)(H,52,61)(H,53,64)(H,54,65)(H,55,66)(H,62,63)(H4,48,49,50)/t25?,27?,28-,29?,30+,31-,33+,34+/m1/s1
DMTGU0L CS C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCCN)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N[C@@H]4CSC5=CC=CC=C5N(C4=O)CC(=O)O)O
DMTGU0L IK UXMVCNAZMAVIBE-SXGBRQJCSA-N
DMTGU0L IU 2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-(2,6-diaminohexanoylamino)-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DMTGU0L DE Discovery agent
DMKHVUE ID DMKHVUE
DMKHVUE DN HM-5016699
DMKHVUE HS Investigative
DMKHVUE SN Dual PI3K/mTOR inhibitor (cancer); Dual PI3K/mTOR inhibitor (cancer), Hutchison
DMKHVUE CP Hutchison Medipharma Enterprises Ltd
DMKHVUE DE Solid tumour/cancer
DMNOFTX ID DMNOFTX
DMNOFTX DN HM-61713B
DMNOFTX HS Investigative
DMNOFTX SN EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi
DMNOFTX CP Hanmi Pharmaceutical Co Ltd
DMNOFTX DE Solid tumour/cancer
DM17QMV ID DM17QMV
DM17QMV DN H-mCpa-ala-Gly-Phe-leu-OH
DM17QMV HS Investigative
DM17QMV SN CHEMBL246682; H-mCpa-ala-Gly-Phe-leu-OH
DM17QMV DT Small molecular drug
DM17QMV PC 44439875
DM17QMV MW 596.7
DM17QMV FM C30H40N6O7
DM17QMV IC InChI=1S/C30H40N6O7/c1-17(2)12-24(30(42)43)36-29(41)23(15-19-8-5-4-6-9-19)35-25(37)16-33-27(39)18(3)34-28(40)22(31)14-20-10-7-11-21(13-20)26(32)38/h4-11,13,17-18,22-24H,12,14-16,31H2,1-3H3,(H2,32,38)(H,33,39)(H,34,40)(H,35,37)(H,36,41)(H,42,43)/t18-,22-,23-,24-/m0/s1
DM17QMV CS C[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC2=CC(=CC=C2)C(=O)N)N
DM17QMV IK CPTUJVNVSNEVEH-IMNFJDCFSA-N
DM17QMV IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(3-carbamoylphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM17QMV DE Discovery agent
DMKAEQP ID DMKAEQP
DMKAEQP DN H-mCpa-Gly-Gly-Phe-Leu-OH
DMKAEQP HS Investigative
DMKAEQP SN CHEMBL392275; H-mCpa-Gly-Gly-Phe-Leu-OH
DMKAEQP DT Small molecular drug
DMKAEQP PC 44439879
DMKAEQP MW 582.6
DMKAEQP FM C29H38N6O7
DMKAEQP IC InChI=1S/C29H38N6O7/c1-17(2)11-23(29(41)42)35-28(40)22(14-18-7-4-3-5-8-18)34-25(37)16-32-24(36)15-33-27(39)21(30)13-19-9-6-10-20(12-19)26(31)38/h3-10,12,17,21-23H,11,13-16,30H2,1-2H3,(H2,31,38)(H,32,36)(H,33,39)(H,34,37)(H,35,40)(H,41,42)/t21-,22-,23-/m0/s1
DMKAEQP CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC(=CC=C2)C(=O)N)N
DMKAEQP IK MKAKAIMBENCCEJ-VABKMULXSA-N
DMKAEQP IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(3-carbamoylphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMKAEQP DE Discovery agent
DM8OUHV ID DM8OUHV
DM8OUHV DN H-mCpa-ser-Gly-Phe-Leu-Thr-OH
DM8OUHV HS Investigative
DM8OUHV SN CHEMBL393867; H-mCpa-ser-Gly-Phe-Leu-Thr-OH
DM8OUHV DT Small molecular drug
DM8OUHV PC 44439901
DM8OUHV MW 713.8
DM8OUHV FM C34H47N7O10
DM8OUHV IC InChI=1S/C34H47N7O10/c1-18(2)12-24(33(49)41-28(19(3)43)34(50)51)39-32(48)25(15-20-8-5-4-6-9-20)38-27(44)16-37-31(47)26(17-42)40-30(46)23(35)14-21-10-7-11-22(13-21)29(36)45/h4-11,13,18-19,23-26,28,42-43H,12,14-17,35H2,1-3H3,(H2,36,45)(H,37,47)(H,38,44)(H,39,48)(H,40,46)(H,41,49)(H,50,51)/t19-,23+,24+,25+,26+,28+/m1/s1
DM8OUHV CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC(=CC=C2)C(=O)N)N)O
DM8OUHV IK LGORGTYVVSKEOB-KXJTVXFKSA-N
DM8OUHV IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(3-carbamoylphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DM8OUHV DE Discovery agent
DMXMTA9 ID DMXMTA9
DMXMTA9 DN HMR-1556
DMXMTA9 HS Investigative
DMXMTA9 SN GTPL2590
DMXMTA9 DT Small molecular drug
DMXMTA9 PC 9867091
DMXMTA9 MW 425.5
DMXMTA9 FM C18H26F3NO5S
DMXMTA9 IC InChI=1S/C18H26F3NO5S/c1-5-28(24,25)22(4)15-13-11-12(26-10-6-9-18(19,20)21)7-8-14(13)27-17(2,3)16(15)23/h7-8,11,15-16,23H,5-6,9-10H2,1-4H3/t15-,16+/m0/s1
DMXMTA9 CS CCS(=O)(=O)N(C)[C@@H]1[C@H](C(OC2=C1C=C(C=C2)OCCCC(F)(F)F)(C)C)O
DMXMTA9 IK YBZQPPIQXNWGEX-JKSUJKDBSA-N
DMXMTA9 IU N-[(3R,4S)-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydrochromen-4-yl]-N-methylethanesulfonamide
DMXMTA9 DE Discovery agent
DMNXR17 ID DMNXR17
DMNXR17 DN HMR1883
DMNXR17 HS Investigative
DMNXR17 SN Clamikalant; Clamikalant [INN]; 158751-64-5; UNII-94301K998R; CHEMBL12531; HMR-1883; 94301K998R; 1-((5-(2-(5-Chloro-o-anisamido)ethyl)-2-methoxyphenyl)sulfonyl)-3-methyl-2-thiourea; HMR1883; AC1MI3H0; SCHEMBL726268; DTXSID30166522; VXTKXGKPBOLHRY-UHFFFAOYSA-N; ZINC599915; BDBM50099573; AKOS027339538; API0011065; NCGC00386636-01; AS-44931; LS-26123; SR-01000945051; SR-01000945051-1; 5-chloro-2-methoxy-N-[2-[4-methoxy-3-(methylcarbamothioylsulfamoyl)phenyl]ethyl]benzamide
DMNXR17 DT Small molecular drug
DMNXR17 PC 3037766
DMNXR17 MW 472
DMNXR17 FM C19H22ClN3O5S2
DMNXR17 IC InChI=1S/C19H22ClN3O5S2/c1-21-19(29)23-30(25,26)17-10-12(4-6-16(17)28-3)8-9-22-18(24)14-11-13(20)5-7-15(14)27-2/h4-7,10-11H,8-9H2,1-3H3,(H,22,24)(H2,21,23,29)
DMNXR17 CS CNC(=S)NS(=O)(=O)C1=C(C=CC(=C1)CCNC(=O)C2=C(C=CC(=C2)Cl)OC)OC
DMNXR17 IK VXTKXGKPBOLHRY-UHFFFAOYSA-N
DMNXR17 IU 5-chloro-2-methoxy-N-[2-[4-methoxy-3-(methylcarbamothioylsulfamoyl)phenyl]ethyl]benzamide
DMNXR17 CA CAS 158751-64-5
DMNXR17 DE Discovery agent
DMUPS48 ID DMUPS48
DMUPS48 DN HMS3229G13
DMUPS48 HS Investigative
DMUPS48 SN JAK3 Inhibitor VI; CHEMBL2397013; 856436-16-3; GTPL5995; CCG-206764; RT-013395; (3Z)-5-(pyridin-3-yl)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one
DMUPS48 DT Small molecular drug
DMUPS48 PC 16760524
DMUPS48 MW 383.4
DMUPS48 FM C19H17N3O4S
DMUPS48 IC InChI=1S/C18H13N3O.CH4O3S/c22-18-16(10-14-4-2-8-20-14)15-9-12(5-6-17(15)21-18)13-3-1-7-19-11-13;1-5(2,3)4/h1-11,20H,(H,21,22);1H3,(H,2,3,4)/b16-10-;
DMUPS48 CS CS(=O)(=O)O.C1=CC(=CN=C1)C2=CC\\3=C(C=C2)NC(=O)/C3=C\\C4=CC=CN4
DMUPS48 IK ZUDPNBZMAJGYTE-HYMQDMCPSA-N
DMUPS48 IU methanesulfonic acid;(3Z)-5-pyridin-3-yl-3-(1H-pyrrol-2-ylmethylidene)-1H-indol-2-one
DMUPS48 CA CAS 856436-16-3
DMUPS48 DE Discovery agent
DMKOMP2 ID DMKOMP2
DMKOMP2 DN HOE-33258
DMKOMP2 HS Investigative
DMKOMP2 DT Small molecular drug
DMKOMP2 PC 2392
DMKOMP2 MW 424.5
DMKOMP2 FM C25H24N6O
DMKOMP2 IC InChI=1S/C25H24N6O/c1-30-10-12-31(13-11-30)18-5-9-21-23(15-18)29-25(27-21)17-4-8-20-22(14-17)28-24(26-20)16-2-6-19(32)7-3-16/h2-9,14-15,32H,10-13H2,1H3,(H,26,28)(H,27,29)
DMKOMP2 CS CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)O
DMKOMP2 IK INAAIJLSXJJHOZ-UHFFFAOYSA-N
DMKOMP2 IU 4-[6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenol
DMKOMP2 CA CAS 23491-44-3
DMKOMP2 CB CHEBI:52082
DMKOMP2 DE Discovery agent
DMJQI7A ID DMJQI7A
DMJQI7A DN HO-LVA
DMJQI7A HS Investigative
DMJQI7A SN CHEMBL394602
DMJQI7A PC 44428111
DMJQI7A MW 1127.3
DMJQI7A FM C53H74N16O12
DMJQI7A IC InChI=1S/C53H74N16O12/c1-68(44(74)27-32-13-17-35(71)18-14-32)41(26-31-11-15-34(70)16-12-31)50(80)67-39(25-30-7-3-2-4-8-30)48(78)64-37(19-20-42(54)72)47(77)66-40(28-43(55)73)49(79)65-38(10-6-23-62-53(59)60)51(81)69-24-21-33(29-69)46(76)63-36(45(56)75)9-5-22-61-52(57)58/h2-4,7-8,11-18,33,36-41,70-71H,5-6,9-10,19-29H2,1H3,(H2,54,72)(H2,55,73)(H2,56,75)(H,63,76)(H,64,78)(H,65,79)(H,66,77)(H,67,80)(H4,57,58,61)(H4,59,60,62)/t33-,36-,37-,38-,39-,40-,41+/m0/s1
DMJQI7A CS CN([C@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N3CC[C@@H](C3)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)C(=O)CC4=CC=C(C=C4)O
DMJQI7A IK QSWYUUWOWAFPRH-PDQNOIBYSA-N
DMJQI7A IU (2S)-N-[(2S)-4-amino-1-[[(2S)-1-[(3S)-3-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]-2-[[(2S)-2-[[(2R)-3-(4-hydroxyphenyl)-2-[[2-(4-hydroxyphenyl)acetyl]-methylamino]propanoyl]amino]-3-phenylpropanoyl]amino]pentanediamide
DMJQI7A DE Discovery agent
DMZYB3S ID DMZYB3S
DMZYB3S DN Hombreol
DMZYB3S HS Investigative
DMZYB3S SN Dihydroandrosterone; Etiocholane-3alpha,17beta-diol; Hombreol; J34MX0M30Y; (3alpha,5alpha,17beta)-androstane-3,17-diol; 1852-53-5; 3alpha androstanediol; 3alpha,17beta-Dihydroxy-5alpha-androstane; 3alpha-androstanediol; 5-alpha-ANDROSTANE-3-alpha,17-beta-DIOL; 5a-Androstane-3a,17b-diol; 5alpha-Androstan-3alpha,17beta-diol; 5alpha-Androstane-3alpha,17beta-androstanediol; 5alpha-Androstane-3alpha,17beta-diol; BRN 2694353; CHEBI:36713; CHEMBL335062; EINECS 217-447-4; MLS000028362; NSC 9899; UNII-J34MX0M30Y
DMZYB3S PC 15818
DMZYB3S MW 292.5
DMZYB3S FM C19H32O2
DMZYB3S IC CBMYJHIOYJEBSB-KHOSGYARSA-N
DMZYB3S CS CC12CCC(CC1CCC3C2CCC4(C3CCC4O)C)O
DMZYB3S IK 1S/C19H32O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-17,20-21H,3-11H2,1-2H3/t12-,13+,14-,15-,16-,17-,18-,19-/m0/s1
DMZYB3S IU (3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
DMZYB3S CA CAS 1852-53-5
DMZYB3S CB CHEBI:36713
DMZYB3S DE Discovery agent
DMH96AI ID DMH96AI
DMH96AI DN homo-AMPA
DMH96AI HS Investigative
DMH96AI SN CHEMBL107768; homo-AMPA; HomoAMPA; AC1N6KQF; 2-Amino-4-(3-hydroxy-5-methyl-isoxazol-4-yl)-butyric acid; GTPL3359; SCHEMBL3731488; CTK8G0203; HMS3267O13; BDBM50052551; NCGC00024946-02; SR-01000597464; SR-01000597464-1; 2-amino-4-(5-methyl-3-oxo-1,2-oxazol-4-yl)butanoic acid; 2-Amino-4-(3-hydroxy-5-methylisoxazole-4-yl)butyric acid; 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid; a-Amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolebutanoic acid; 2-amino-4-(5-methyl-3-oxo-2,3-dihydro-1,2-oxazol-4-yl)butanoic acid
DMH96AI DT Small molecular drug
DMH96AI PC 4236420
DMH96AI MW 200.19
DMH96AI FM C8H12N2O4
DMH96AI IC InChI=1S/C8H12N2O4/c1-4-5(7(11)10-14-4)2-3-6(9)8(12)13/h6H,2-3,9H2,1H3,(H,10,11)(H,12,13)
DMH96AI CS CC1=C(C(=O)NO1)CCC(C(=O)O)N
DMH96AI IK NZDIZJGEDFARSV-UHFFFAOYSA-N
DMH96AI IU 2-amino-4-(5-methyl-3-oxo-1,2-oxazol-4-yl)butanoic acid
DMH96AI DE Discovery agent
DMIHFQY ID DMIHFQY
DMIHFQY DN HOMOAROMOLINE
DMIHFQY HS Investigative
DMIHFQY SN Homoaromoline; (+)-Homoaromoline; Thalrugosamine; 6,6',12'-Trimethoxy-2,2'-dimethyloxyacanthan-7-ol; 17132-74-0; NSC 251213; CHEMBL509855; NSC-251213; Oxyacanthan-7-ol, 6,6',12'-trimethoxy-2,2'-dimethyl-; (+)-Thalrugosamine; Homothalicrine; Limacusine (R,S); ( )-Thalrugosamine; Homothalicrine (7CI); SCHEMBL2991819; AC1Q58F3; AC1L410X; DTXSID90169059; NSC251213; BDBM50241641; LS-75888; Oxyacanthan-7-ol,6',12'-trimethoxy-2,2'-dimethyl-; Oxyacanthan-7-ol, 6,6',12'-trimethoxy-2,2'-dimethyl- (9CI)
DMIHFQY DT Small molecular drug
DMIHFQY PC 99620
DMIHFQY MW 608.7
DMIHFQY FM C37H40N2O6
DMIHFQY IC InChI=1S/C37H40N2O6/c1-38-14-12-24-19-31(42-4)33-21-27(24)28(38)17-23-8-11-30(41-3)32(18-23)44-26-9-6-22(7-10-26)16-29-35-25(13-15-39(29)2)20-34(43-5)36(40)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m1/s1
DMIHFQY CS CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=CC(=C(C=C7CCN6C)OC)O3)OC)O)OC
DMIHFQY IK YJRWQNIRFXVBRB-WDYNHAJCSA-N
DMIHFQY IU (1R,14S)-6,20,25-trimethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.29,12.13,7.114,18.027,31.022,33]hexatriaconta-3(36),4,6,9(35),10,12(34),18,20,22(33),24,26,31-dodecaen-21-ol
DMIHFQY CA CAS 17132-74-0
DMIHFQY DE Discovery agent
DMCIRY0 ID DMCIRY0
DMCIRY0 DN Homocamptothecins (hCPTs)
DMCIRY0 HS Investigative
DMCIRY0 DE Discovery agent
DM1SDN8 ID DM1SDN8
DM1SDN8 DN HOMOERIODICTYOL
DM1SDN8 HS Investigative
DM1SDN8 SN Homoeriodictyol; (-)-Homoeriodictyol; 446-71-9; Eriodictyonone; UNII-EHE7H3705C; Eriodictyol 3'-methyl ether; 5,7,4'-Trihydroxy-3'-methoxyflavanone; CHEMBL490170; EHE7H3705C; CHEBI:74960; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone; Q-100585; (+/-)-Homoeriodictyol; cyanidanon-3-methyl ether 1625; EINECS 207-173-3; AC1Q6KID; AC1L2K7J; SCHEMBL39497; DTXSID30196243; FTODBIPDTXRIGS-ZDUSSCGKSA-N; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-; ZINC4098322; BDBM50325672
DM1SDN8 DT Small molecular drug
DM1SDN8 PC 73635
DM1SDN8 MW 302.28
DM1SDN8 FM C16H14O6
DM1SDN8 IC InChI=1S/C16H14O6/c1-21-14-4-8(2-3-10(14)18)13-7-12(20)16-11(19)5-9(17)6-15(16)22-13/h2-6,13,17-19H,7H2,1H3/t13-/m0/s1
DM1SDN8 CS COC1=C(C=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O
DM1SDN8 IK FTODBIPDTXRIGS-ZDUSSCGKSA-N
DM1SDN8 IU (2S)-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-2,3-dihydrochromen-4-one
DM1SDN8 CA CAS 446-71-9
DM1SDN8 CB CHEBI:74960
DM1SDN8 DE Discovery agent
DMQD0YW ID DMQD0YW
DMQD0YW DN Homogentisic acid
DMQD0YW HS Investigative
DMQD0YW SN Homogenestic acid lactone; Homogentisic acid lactone; Homogentisic Acid gamma-Lactone; Homogentisic Acid?-Lactone; Homogentisic lactone; 2(3H)-Benzofuranone, 5-hydroxy-; 2,3-Dihydro-5-hydroxybenzofuran-2-one; 2688-48-4; 5-Hydroxy-2(3H)-benzofuranone; 5-Hydroxy-2-coumaranone; 5-Hydroxybenzofuran-2(3H)-one; 5-Hydroxybenzofuran-2-one; 5-hydroxy-1-benzofuran-2(3H)-one; 5-hydroxy-3-hydrobenzo[b]furan-2-one; 5-hydroxy-3H-1-benzofuran-2-one; A-Lactone; AC1L2PRA; AC1Q6ML0; EINECS 220-252-7; MLS002693363; NSC61996
DMQD0YW PC 75898
DMQD0YW MW 150.13
DMQD0YW FM C8H6O3
DMQD0YW IC POUITAHNNRJWMA-UHFFFAOYSA-N
DMQD0YW CS C1C2=C(C=CC(=C2)O)OC1=O
DMQD0YW IK 1S/C8H6O3/c9-6-1-2-7-5(3-6)4-8(10)11-7/h1-3,9H,4H2
DMQD0YW IU 5-hydroxy-3H-1-benzofuran-2-one
DMQD0YW CA CAS 2688-48-4
DMQD0YW CB CHEBI:141343
DMQD0YW DE Discovery agent
DMVBTHA ID DMVBTHA
DMVBTHA DN HOMOPHENYLALANINYLMETHANE
DMVBTHA HS Investigative
DMVBTHA DE Discovery agent
DMBW5DU ID DMBW5DU
DMBW5DU DN homoquinolinic acid
DMBW5DU HS Investigative
DMBW5DU SN HQA
DMBW5DU DT Small molecular drug
DMBW5DU PC 3080554
DMBW5DU MW 181.15
DMBW5DU FM C8H7NO4
DMBW5DU IC InChI=1S/C8H7NO4/c10-6(11)4-5-2-1-3-9-7(5)8(12)13/h1-3H,4H2,(H,10,11)(H,12,13)
DMBW5DU CS C1=CC(=C(N=C1)C(=O)O)CC(=O)O
DMBW5DU IK HQPMJFFEXJELOQ-UHFFFAOYSA-N
DMBW5DU IU 3-(carboxymethyl)pyridine-2-carboxylic acid
DMBW5DU CA CAS 490-75-5
DMBW5DU DE Discovery agent
DMX8DC2 ID DMX8DC2
DMX8DC2 DN Homorisedronate
DMX8DC2 HS Investigative
DMX8DC2 SN NE 58051; 104261-69-0; NE-58051; CHEMBL293522; [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid); HRX; AC1L2TXU; SCHEMBL8710665; 3-(3-Pyridyl)-1-hydroxypropylidene bisphosphonic acid; (1-Hydroxy-3-(3-pyridinyl)propylidene)bisphosphonic acid; DTXSID70146363; 1-hydroxy-3-(3-pyridyl)propylidene-1,1-bisphosphonic acid; ILROXFQHACCDLA-UHFFFAOYSA-N; BDBM50098382; 3-(3-Hydroxy-3,3-bis-phosphono-propyl)-pyridinium; 3-(3-pyridyl)-1-hydroxy-propane-1,1-bisphosphonate
DMX8DC2 DT Small molecular drug
DMX8DC2 PC 128523
DMX8DC2 MW 297.14
DMX8DC2 FM C8H13NO7P2
DMX8DC2 IC InChI=1S/C8H13NO7P2/c10-8(17(11,12)13,18(14,15)16)4-3-7-2-1-5-9-6-7/h1-2,5-6,10H,3-4H2,(H2,11,12,13)(H2,14,15,16)
DMX8DC2 CS C1=CC(=CN=C1)CCC(O)(P(=O)(O)O)P(=O)(O)O
DMX8DC2 IK ILROXFQHACCDLA-UHFFFAOYSA-N
DMX8DC2 IU (1-hydroxy-1-phosphono-3-pyridin-3-ylpropyl)phosphonic acid
DMX8DC2 CA CAS 104261-69-0
DMX8DC2 DE Discovery agent
DMTKN4A ID DMTKN4A
DMTKN4A DN Homoserine Lactone
DMTKN4A HS Investigative
DMTKN4A SN homoserinium lactone; 2-oxooxolan-3-aminium; homoserinium lactone(1+); homoserinium lactone cation; (2-oxooxolan-3-yl)azanium; 2-oxotetrahydrofuran-3-aminium; AC1N129K
DMTKN4A DT Small molecular drug
DMTKN4A PC 73509
DMTKN4A MW 101.1
DMTKN4A FM C4H7NO2
DMTKN4A IC InChI=1S/C4H7NO2/c5-3-1-2-7-4(3)6/h3H,1-2,5H2
DMTKN4A CS C1COC(=O)C1N
DMTKN4A IK QJPWUUJVYOJNMH-UHFFFAOYSA-N
DMTKN4A IU 3-aminooxolan-2-one
DMTKN4A CA CAS 1192-20-7
DMTKN4A CB CHEBI:17289
DMTKN4A DE Discovery agent
DM0SHPY ID DM0SHPY
DM0SHPY DN Homovanillic acid
DM0SHPY HS Investigative
DM0SHPY SN Homovanilic acid; Homovanillate; Homovanillic acid; Homovanillic acid, 98%; Homovanillinic acid; Homovaniuic acid; Vanilacetic acid; Vanillacetic acid; (4-HYDROXY-3-METHOXYPHENYL)ACETIC ACID; 2-(4-hydroxy-3-methoxy-phenyl)acetic acid; 2-(4-hydroxy-3-methoxyphenyl)acetic acid; 3-Methoxy-4-hydroxyphenylacetate; 3-Methoxy-4-hydroxyphenylacetic acid; 306-08-1; 4-Hydroxy-3-methoxybenzeneacetic acid; 4-Hydroxy-3-methoxyphenylacetic acid; Benzeneacetic acid, 4-hydroxy-3-methoxy-; HVA; MFCD00004350; NSC 16682; UNII-X77S6GMS36
DM0SHPY PC 1738
DM0SHPY MW 182.17
DM0SHPY FM C9H10O4
DM0SHPY IC QRMZSPFSDQBLIX-UHFFFAOYSA-N
DM0SHPY CS COC1=C(C=CC(=C1)CC(=O)O)O
DM0SHPY IK 1S/C9H10O4/c1-13-8-4-6(5-9(11)12)2-3-7(8)10/h2-4,10H,5H2,1H3,(H,11,12)
DM0SHPY IU 2-(4-hydroxy-3-methoxyphenyl)acetic acid
DM0SHPY CA CAS 306-08-1
DM0SHPY CB CHEBI:545959
DM0SHPY DE Brain cancer
DMI7258 ID DMI7258
DMI7258 DN Homspera
DMI7258 HS Investigative
DMI7258 SN Homspera (oral, influenza)
DMI7258 CP ImmuneRegen BioSciences Inc
DMI7258 PC 129822097
DMI7258 MW 1393.7
DMI7258 FM C64H100N18O15S
DMI7258 IC InChI=1S/C64H100N18O15S/c1-38(2)34-46(57(89)74-42(54(69)86)28-33-98(4,96)97)73-53(85)37-80(3)62(94)48(36-40-18-9-6-10-19-40)79-58(90)47(35-39-16-7-5-8-17-39)78-56(88)43(24-26-51(67)83)75-55(87)44(25-27-52(68)84)76-59(91)50-23-15-32-82(50)63(95)45(21-11-12-29-65)77-60(92)49-22-14-31-81(49)61(93)41(66)20-13-30-72-64(70)71/h5-10,16-19,38,41-50H,11-15,20-37,65-66H2,1-4H3,(H2,67,83)(H2,68,84)(H2,69,86)(H,73,85)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,88)(H,79,90)(H4,70,71,72)/t41-,42-,43?,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMI7258 CS CC(C)C[C@@H](C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)N)NC(=O)CN(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)C(CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N
DMI7258 IK OUPXSLGGCPUZJJ-HTTPISLZSA-N
DMI7258 IU (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfonyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]pentanediamide
DMI7258 DE Influenza virus infection
DMJWT3X ID DMJWT3X
DMJWT3X DN HONOKIOL
DMJWT3X HS Investigative
DMJWT3X SN Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3& -Diallyl-2,4& Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa
DMJWT3X DT Small molecular drug
DMJWT3X PC 72303
DMJWT3X MW 266.3
DMJWT3X FM C18H18O2
DMJWT3X IC InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
DMJWT3X CS C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C
DMJWT3X IK FVYXIJYOAGAUQK-UHFFFAOYSA-N
DMJWT3X IU 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
DMJWT3X CA CAS 35354-74-6
DMJWT3X CB CHEBI:5759
DMJWT3X DE Discovery agent
DMHW2DU ID DMHW2DU
DMHW2DU DN Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2
DMHW2DU HS Investigative
DMHW2DU DT Small molecular drug
DMHW2DU PC 73347136
DMHW2DU MW 955.1
DMHW2DU FM C49H63FN10O9
DMHW2DU IC InChI=1S/C49H63FN10O9/c1-29(2)17-22-34(43(63)56-38(27-32-18-20-33(50)21-19-32)45(65)55-36(42(52)62)25-30-11-5-3-6-12-30)53-47(67)40-16-10-24-60(40)48(68)35(15-9-23-51)54-44(64)37(26-31-13-7-4-8-14-31)57-46(66)39-28-41(61)59-49(69)58-39/h3-8,11-14,18-21,29,34-40H,9-10,15-17,22-28,51H2,1-2H3,(H2,52,62)(H,53,67)(H,54,64)(H,55,65)(H,56,63)(H,57,66)(H2,58,59,61,69)/t34-,35-,36+,37-,38-,39-,40-/m0/s1
DMHW2DU CS CC(C)CC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)F)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H]5CC(=O)NC(=O)N5
DMHW2DU IK HXKFHHNEFCZKPG-VEKZNEBUSA-N
DMHW2DU IU (4S)-N-[(2S)-1-[[(2S)-5-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-5-methyl-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2,6-dioxo-1,3-diazinane-4-carboxamide
DMHW2DU DE Discovery agent
DM2OZBL ID DM2OZBL
DM2OZBL DN Howiinol A (GHM-10)
DM2OZBL HS Investigative
DM2OZBL SN Howiinol A; (+)-Howiinol A; AC1O5TEF; CHEMBL1170578; D-xylo-Hept-2-enonic acid, 2,3-dideoxy-7-C-phenyl-, delta-lactone, 7-((2E)-3-phenyl-2-propenoate), (7R)-; 190848-69-2; [(1R,2R)-2-hydroxy-2-[(2R,3S)-3-hydroxy-6-oxo-2,3-dihydropyran-2-yl]-1-phenylethyl] (E)-3-phenylprop-2-enoate
DM2OZBL DT Small molecular drug
DM2OZBL PC 6440329
DM2OZBL MW 380.4
DM2OZBL FM C22H20O6
DM2OZBL IC InChI=1S/C22H20O6/c23-17-12-14-19(25)28-22(17)20(26)21(16-9-5-2-6-10-16)27-18(24)13-11-15-7-3-1-4-8-15/h1-14,17,20-23,26H/b13-11+/t17-,20+,21+,22+/m0/s1
DM2OZBL CS C1=CC=C(C=C1)/C=C/C(=O)O[C@H](C2=CC=CC=C2)[C@H]([C@H]3[C@H](C=CC(=O)O3)O)O
DM2OZBL IK HCJURVKKVSCZRL-VTWBULIDSA-N
DM2OZBL IU [(1R,2R)-2-hydroxy-2-[(2R,3S)-3-hydroxy-6-oxo-2,3-dihydropyran-2-yl]-1-phenylethyl] (E)-3-phenylprop-2-enoate
DM2OZBL CA CAS 190848-69-2
DM2OZBL DE Discovery agent
DM9IODG ID DM9IODG
DM9IODG DN H-Phe-NH2
DM9IODG HS Investigative
DM9IODG SN 5241-58-7; Phenylalanine amide; (S)-2-amino-3-phenylpropanamide; L-Phenylalanine amide; phenylalaninamide; (2S)-2-amino-3-phenylpropanamide; Phe-NH2; L-Phe-NH2; Phenh2; UNII-PV9T9B2S11; CHEMBL350320; PV9T9B2S11; CHEBI:21371; AK-46083; phenylalanylamide; L-phenylalanineamide; Benzenepropanamide, alpha-amino-, (alphaS)-; DL-Phenylalanine amide; 2-Amino-3-phenyl-propionamide; phenylalanine imine; (S)-phenylalaninamide; Benzenepropanamide, alpha-amino-, (S)-; H-L-Phe-NH2; AC1L9IEO; SCHEMBL244302
DM9IODG DT Small molecular drug
DM9IODG PC 445694
DM9IODG MW 164.2
DM9IODG FM C9H12N2O
DM9IODG IC InChI=1S/C9H12N2O/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H2,11,12)/t8-/m0/s1
DM9IODG CS C1=CC=C(C=C1)C[C@@H](C(=O)N)N
DM9IODG IK OBSIQMZKFXFYLV-QMMMGPOBSA-N
DM9IODG IU (2S)-2-amino-3-phenylpropanamide
DM9IODG CA CAS 5241-58-7
DM9IODG CB CHEBI:21371
DM9IODG DE Discovery agent
DM0KFW2 ID DM0KFW2
DM0KFW2 DN H-Phe-Phe-NH2
DM0KFW2 HS Investigative
DM0KFW2 SN CHEMBL108438; 15893-46-6; Phe-phe-amide; Phenylalanylphenylalanylamide; L-Phe-L-phe-amide; H-Phe-Phe-NH2; L-Phenylalanine-L-phenylalanylamide; L-Phe-L-Phe-NH2; AC1L38WX; XXPXQEQOAZMUDD-HOTGVXAUSA-N; L-Phenylalaninamide, L-phenylalanyl-; BDBM50188489; (S)-2-Amino-N-((S)-1-carbamoyl-2-phenyl-ethyl)-3-phenyl-propionamide
DM0KFW2 DT Small molecular drug
DM0KFW2 PC 85169
DM0KFW2 MW 311.4
DM0KFW2 FM C18H21N3O2
DM0KFW2 IC InChI=1S/C18H21N3O2/c19-15(11-13-7-3-1-4-8-13)18(23)21-16(17(20)22)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H2,20,22)(H,21,23)/t15-,16-/m0/s1
DM0KFW2 CS C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)N
DM0KFW2 IK XXPXQEQOAZMUDD-HOTGVXAUSA-N
DM0KFW2 IU (2S)-2-amino-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
DM0KFW2 CA CAS 15893-46-6
DM0KFW2 DE Discovery agent
DME1CT9 ID DME1CT9
DME1CT9 DN H-Poa-ser-Gly-Phe-Leu-Thr-OH
DME1CT9 HS Investigative
DME1CT9 SN CHEMBL246740; H-Poa-ser-Gly-Phe-Leu-Thr-OH
DME1CT9 DT Small molecular drug
DME1CT9 PC 44439896
DME1CT9 MW 687.7
DME1CT9 FM C32H45N7O10
DME1CT9 IC InChI=1S/C32H45N7O10/c1-18(2)13-23(31(46)38-27(19(3)41)32(47)48)36-30(45)24(15-20-7-5-4-6-8-20)35-26(42)16-34-29(44)25(17-40)37-28(43)22(33)14-21-9-11-39(49)12-10-21/h4-12,18-19,22-25,27,40-41H,13-17,33H2,1-3H3,(H,34,44)(H,35,42)(H,36,45)(H,37,43)(H,38,46)(H,47,48)/t19-,22+,23+,24+,25+,27+/m1/s1
DME1CT9 CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=[N+](C=C2)[O-])N)O
DME1CT9 IK PDLKKPWJIQINFZ-GQHROEFJSA-N
DME1CT9 IU (2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(1-oxidopyridin-1-ium-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoic acid
DME1CT9 DE Discovery agent
DMXKPQR ID DMXKPQR
DMXKPQR DN H-Pro-Phe-Phe-NH2
DMXKPQR HS Investigative
DMXKPQR SN CHEMBL591489; H-Pro-Phe-Phe-NH2
DMXKPQR DT Small molecular drug
DMXKPQR PC 44611435
DMXKPQR MW 408.5
DMXKPQR FM C23H28N4O3
DMXKPQR IC InChI=1S/C23H28N4O3/c24-21(28)19(14-16-8-3-1-4-9-16)26-23(30)20(15-17-10-5-2-6-11-17)27-22(29)18-12-7-13-25-18/h1-6,8-11,18-20,25H,7,12-15H2,(H2,24,28)(H,26,30)(H,27,29)/t18-,19-,20-/m0/s1
DMXKPQR CS C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N
DMXKPQR IK GQTQFZUTXSDLLQ-UFYCRDLUSA-N
DMXKPQR IU (2S)-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMXKPQR DE Discovery agent
DMRPZD4 ID DMRPZD4
DMRPZD4 DN HPTE
DMRPZD4 HS Investigative
DMRPZD4 SN Hydroxychlor; HPTE; p,p'-Hydroxy-DDT; 2971-36-0; p,p'-HO-DDT; 2,2-Bis(4-hydroxyphenyl)-1,1,1-trichloroethane; 1,1,1-Trichloro-2,2-bis(4-hydroxyphenyl)ethane; 4,4'-(2,2,2-trichloroethane-1,1-diyl)diphenol; 2,2-Bis(p-hydroxyphenyl)-1,1,1-trichloroethane; 4,4'-(2,2,2-Trichloroethylidene)diphenol; 1,1-Bis(4-hydroxyphenyl)-2,2,2-trichloroethane; 1,1-Bis(p-hydroxyphenyl)-2,2,2-trichloroethane; p,p'-(2,2,2-Trichloroethylidene)diphenol; NSC 7045; 1,1,1-Trichloro-2,2-bis(p-hydroxyphenyl)ethane; Phenol, 4,4'-(2,2,2-trichloroethylid
DMRPZD4 DT Small molecular drug
DMRPZD4 PC 76302
DMRPZD4 MW 317.6
DMRPZD4 FM C14H11Cl3O2
DMRPZD4 IC InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H
DMRPZD4 CS C1=CC(=CC=C1C(C2=CC=C(C=C2)O)C(Cl)(Cl)Cl)O
DMRPZD4 IK IUGDILGOLSSKNE-UHFFFAOYSA-N
DMRPZD4 IU 4-[2,2,2-trichloro-1-(4-hydroxyphenyl)ethyl]phenol
DMRPZD4 CA CAS 2971-36-0
DMRPZD4 CB CHEBI:34025
DMRPZD4 DE Discovery agent
DMSHYQ3 ID DMSHYQ3
DMSHYQ3 DN HQL-79
DMSHYQ3 HS Investigative
DMSHYQ3 SN HQL79; HQL 79
DMSHYQ3 DT Small molecular drug
DMSHYQ3 PC 6540277
DMSHYQ3 MW 377.5
DMSHYQ3 FM C22H27N5O
DMSHYQ3 IC InChI=1S/C22H27N5O/c1-3-8-18(9-4-1)22(19-10-5-2-6-11-19)28-20-13-16-27(17-14-20)15-7-12-21-23-25-26-24-21/h1-6,8-11,20,22H,7,12-17H2,(H,23,24,25,26)
DMSHYQ3 CS C1CN(CCC1OC(C2=CC=CC=C2)C3=CC=CC=C3)CCCC4=NNN=N4
DMSHYQ3 IK TZQGXAHOROZEKN-UHFFFAOYSA-N
DMSHYQ3 IU 4-benzhydryloxy-1-[3-(2H-tetrazol-5-yl)propyl]piperidine
DMSHYQ3 CA CAS 162641-16-9
DMSHYQ3 DE Discovery agent
DMSTV96 ID DMSTV96
DMSTV96 DN H-RYYRIK-NH2
DMSTV96 HS Investigative
DMSTV96 SN CHEMBL444110
DMSTV96 DT Small molecular drug
DMSTV96 PC 44456337
DMSTV96 MW 881.1
DMSTV96 FM C42H68N14O7
DMSTV96 IC InChI=1S/C42H68N14O7/c1-3-25(2)34(40(63)52-30(35(45)58)14-7-8-20-43)56-37(60)31(15-10-22-51-42(48)49)53-38(61)33(24-27-16-18-28(57)19-17-27)55-39(62)32(23-26-11-5-4-6-12-26)54-36(59)29(44)13-9-21-50-41(46)47/h4-6,11-12,16-19,25,29-34,57H,3,7-10,13-15,20-24,43-44H2,1-2H3,(H2,45,58)(H,52,63)(H,53,61)(H,54,59)(H,55,62)(H,56,60)(H4,46,47,50)(H4,48,49,51)/t25-,29-,30-,31-,32-,33-,34-/m0/s1
DMSTV96 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N
DMSTV96 IK NJUUHBQLRQTWGG-QQUOXUDESA-N
DMSTV96 IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMSTV96 DE Discovery agent
DMM3FD2 ID DMM3FD2
DMM3FD2 DN HS014
DMM3FD2 HS Investigative
DMM3FD2 DE Discovery agent
DM0A2UF ID DM0A2UF
DM0A2UF DN HS-173
DM0A2UF HS Investigative
DM0A2UF SN HS-173; 1276110-06-5; Ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate; CHEMBL1765463; HS 173; GTPL8243; SCHEMBL20768095; EX-A320; AOB6845; MolPort-035-395-894; HMS3653I16; HS173; BCP09225; BDBM50341493; ZINC71319188; s7356; 2465AH; AKOS026750419; ACN-053037; CS-6015; SB19242; NCGC00386329-02; HY-15868; BC600371; FT-0700155; SW219873-1; J3.560.887G; J-690118; ethyl 6-[5-(benzenesulfonamido)pyridin-3-yl]imidazo[1,2-a]pyridine-3-carboxylate; Ethyl 6-(5-(Phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine
DM0A2UF DT Small molecular drug
DM0A2UF PC 52936849
DM0A2UF MW 422.5
DM0A2UF FM C21H18N4O4S
DM0A2UF IC InChI=1S/C21H18N4O4S/c1-2-29-21(26)19-13-23-20-9-8-15(14-25(19)20)16-10-17(12-22-11-16)24-30(27,28)18-6-4-3-5-7-18/h3-14,24H,2H2,1H3
DM0A2UF CS CCOC(=O)C1=CN=C2N1C=C(C=C2)C3=CC(=CN=C3)NS(=O)(=O)C4=CC=CC=C4
DM0A2UF IK SEKOTFCHZNXZMM-UHFFFAOYSA-N
DM0A2UF IU ethyl 6-[5-(benzenesulfonamido)pyridin-3-yl]imidazo[1,2-a]pyridine-3-carboxylate
DM0A2UF DE Discovery agent
DMA91T4 ID DMA91T4
DMA91T4 DN H-SMGLPCVVM-OH
DMA91T4 HS Investigative
DMA91T4 SN CHEMBL87258; H-SMGLPCVVM-OH
DMA91T4 DT Small molecular drug
DMA91T4 PC 44320675
DMA91T4 MW 936.2
DMA91T4 FM C39H69N9O11S3
DMA91T4 IC InChI=1S/C39H69N9O11S3/c1-20(2)16-26(42-29(50)17-41-33(52)24(11-14-61-7)43-32(51)23(40)18-49)38(57)48-13-9-10-28(48)35(54)45-27(19-60)34(53)46-31(22(5)6)37(56)47-30(21(3)4)36(55)44-25(39(58)59)12-15-62-8/h20-28,30-31,49,60H,9-19,40H2,1-8H3,(H,41,52)(H,42,50)(H,43,51)(H,44,55)(H,45,54)(H,46,53)(H,47,56)(H,58,59)/t23-,24-,25-,26-,27-,28-,30-,31-/m0/s1
DMA91T4 CS CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@H](CO)N
DMA91T4 IK XSTRKZMDUHFCKT-LFPOIMSVSA-N
DMA91T4 IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-methylsulfanylbutanoic acid
DMA91T4 DE Discovery agent
DMZRPM5 ID DMZRPM5
DMZRPM5 DN HT1042
DMZRPM5 HS Investigative
DMZRPM5 SN 5-(3-nitrophenyl)-1,3,4-oxathiazol-2-one; CHEMBL3265177; 23589-77-7; NSC294566; AC1L6WL8; GTPL8649; SCHEMBL1781484; DTXSID10315430; BDBM50010993
DMZRPM5 DT Small molecular drug
DMZRPM5 PC 325597
DMZRPM5 MW 224.2
DMZRPM5 FM C8H4N2O4S
DMZRPM5 IC InChI=1S/C8H4N2O4S/c11-8-14-7(9-15-8)5-2-1-3-6(4-5)10(12)13/h1-4H
DMZRPM5 CS C1=CC(=CC(=C1)[N+](=O)[O-])C2=NSC(=O)O2
DMZRPM5 IK QBAZATRGWRVUFN-UHFFFAOYSA-N
DMZRPM5 IU 5-(3-nitrophenyl)-1,3,4-oxathiazol-2-one
DMZRPM5 CA CAS 23589-77-7
DMZRPM5 DE Discovery agent
DMRF73O ID DMRF73O
DMRF73O DN HT-2678
DMRF73O HS Investigative
DMRF73O SN GABA inverse agonist (cognitive disorder) Helicon; HT-4313; GABA A receptor alpha-5 subunit modulator (cognitive disorder), Helicon Therapeutics
DMRF73O CP Helicon Therapeutics Inc
DMRF73O DE Cognitive impairment
DMPT8JN ID DMPT8JN
DMPT8JN DN HTMT
DMPT8JN HS Investigative
DMPT8JN SN histamine-trifluoromethyl-toluidine; histamine-trifluoromethyltoluide; HTFMT
DMPT8JN DT Small molecular drug
DMPT8JN PC 124846
DMPT8JN MW 382.4
DMPT8JN FM C19H25F3N4O
DMPT8JN IC InChI=1S/C19H25F3N4O/c1-14(24-11-10-17-12-23-13-25-17)4-2-3-5-18(27)26-16-8-6-15(7-9-16)19(20,21)22/h6-9,12-14,24H,2-5,10-11H2,1H3,(H,23,25)(H,26,27)
DMPT8JN CS CC(CCCCC(=O)NC1=CC=C(C=C1)C(F)(F)F)NCCC2=CN=CN2
DMPT8JN IK PMKJGGBYYNEYPA-UHFFFAOYSA-N
DMPT8JN IU 6-[2-(1H-imidazol-5-yl)ethylamino]-N-[4-(trifluoromethyl)phenyl]heptanamide
DMPT8JN CA CAS 103827-16-3
DMPT8JN CB CHEBI:91812
DMPT8JN DE Discovery agent
DMQ8ADE ID DMQ8ADE
DMQ8ADE DN HTS-00213
DMQ8ADE HS Investigative
DMQ8ADE SN HTS-00213; CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole
DMQ8ADE DT Small molecular drug
DMQ8ADE PC 2809539
DMQ8ADE MW 502.3
DMQ8ADE FM C19H12Cl2F3N5O2S
DMQ8ADE IC InChI=1S/C19H12Cl2F3N5O2S/c20-13-2-1-3-14(21)17(13)30-8-15-26-16(31-28-15)9-32-18-27-25-10-29(18)12-6-4-11(5-7-12)19(22,23)24/h1-7,10H,8-9H2
DMQ8ADE CS C1=CC(=C(C(=C1)Cl)OCC2=NOC(=N2)CSC3=NN=CN3C4=CC=C(C=C4)C(F)(F)F)Cl
DMQ8ADE IK UUZRVUXGULNUHU-UHFFFAOYSA-N
DMQ8ADE IU 3-[(2,6-dichlorophenoxy)methyl]-5-[[4-[4-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]sulfanylmethyl]-1,2,4-oxadiazole
DMQ8ADE DE Discovery agent
DMXV379 ID DMXV379
DMXV379 DN HTS-00798
DMXV379 HS Investigative
DMXV379 SN HTS-00798; CHEMBL380201; AC1MDE1P; Maybridge1_004268; MLS000850034; AC1Q78S6; HMS553J24; MolPort-001-806-570; ZINC119025; HMS2791J06; BDBM50191461; AKOS008398059; CCG-233002; MCULE-4306598933; SMR000456052; 1-(4-fluorophenyl)-2-[1-(4-hydroxyphenyl)tetrazol-5-yl]sulfanylethanone; 1-(4-fluorophenyl)-2-(1-(4-hydroxyphenyl)-1H-tetrazol-5-ylthio)ethanone; 1-(4-fluorophenyl)-2-{[1-(4-hydroxyphenyl)-1H-1,2,3,4-tetraazol-5-yl]thio}ethan-1-one
DMXV379 DT Small molecular drug
DMXV379 PC 2809808
DMXV379 MW 330.3
DMXV379 FM C15H11FN4O2S
DMXV379 IC InChI=1S/C15H11FN4O2S/c16-11-3-1-10(2-4-11)14(22)9-23-15-17-18-19-20(15)12-5-7-13(21)8-6-12/h1-8,21H,9H2
DMXV379 CS C1=CC(=CC=C1C(=O)CSC2=NN=NN2C3=CC=C(C=C3)O)F
DMXV379 IK WROGOTHXLJWPOD-UHFFFAOYSA-N
DMXV379 IU 1-(4-fluorophenyl)-2-[1-(4-hydroxyphenyl)tetrazol-5-yl]sulfanylethanone
DMXV379 DE Discovery agent
DMVUTJ5 ID DMVUTJ5
DMVUTJ5 DN HTS-02876
DMVUTJ5 HS Investigative
DMVUTJ5 SN HTS-02876; AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609
DMVUTJ5 DT Small molecular drug
DMVUTJ5 PC 2810910
DMVUTJ5 MW 535.6
DMVUTJ5 FM C24H20F3N3O4S2
DMVUTJ5 IC InChI=1S/C24H20F3N3O4S2/c25-24(26,27)18-7-4-8-21(15-18)36(32,33)14-13-35-23-29-28-22(31)30(23)19-9-11-20(12-10-19)34-16-17-5-2-1-3-6-17/h1-12,15H,13-14,16H2,(H,28,31)
DMVUTJ5 CS C1=CC=C(C=C1)COC2=CC=C(C=C2)N3C(=O)NN=C3SCCS(=O)(=O)C4=CC=CC(=C4)C(F)(F)F
DMVUTJ5 IK PCYFSRWJXFMTSN-UHFFFAOYSA-N
DMVUTJ5 IU 4-(4-phenylmethoxyphenyl)-3-[2-[3-(trifluoromethyl)phenyl]sulfonylethylsulfanyl]-1H-1,2,4-triazol-5-one
DMVUTJ5 DE Discovery agent
DM3F4IQ ID DM3F4IQ
DM3F4IQ DN HTS-05058
DM3F4IQ HS Investigative
DM3F4IQ SN MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; HTS-05058; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988
DM3F4IQ DT Small molecular drug
DM3F4IQ PC 5714572
DM3F4IQ MW 211.22
DM3F4IQ FM C12H9N3O
DM3F4IQ IC InChI=1S/C12H9N3O/c16-12-10(5-8-6-13-7-14-8)9-3-1-2-4-11(9)15-12/h1-7H,(H,13,14)(H,15,16)/b10-5-
DM3F4IQ CS C1=CC=C2C(=C1)/C(=C/C3=CN=CN3)/C(=O)N2
DM3F4IQ IK VEEGZPWAAPPXRB-YHYXMXQVSA-N
DM3F4IQ IU (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one
DM3F4IQ DE Discovery agent
DM70YTF ID DM70YTF
DM70YTF DN HTS-466284
DM70YTF HS Investigative
DM70YTF SN 4-(3-Pyridin-2-YL-1H-pyrazol-4-YL)quinoline; 396129-53-6; LY-364947; LY364947; 4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)quinoline; 4-(3-PYRIDIN-2-YL-1H-PYRAZOL-4-YL)QUINOLINE; TbetaR-I Inhibitor; LY 364947; ALK5 Inhibitor I; TGF-beta RI Kinase Inhibitor; 4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]quinoline; CHEMBL261454; Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor; 4-(3-pyridin-2-yl)(1h)-pyrazol-4-yl quinoline; 4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]quinoline; [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole; 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
DM70YTF DT Small molecular drug
DM70YTF PC 447966
DM70YTF MW 272.3
DM70YTF FM C17H12N4
DM70YTF IC InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21)
DM70YTF CS C1=CC=C2C(=C1)C(=CC=N2)C3=C(NN=C3)C4=CC=CC=N4
DM70YTF IK IBCXZJCWDGCXQT-UHFFFAOYSA-N
DM70YTF IU 4-(5-pyridin-2-yl-1H-pyrazol-4-yl)quinoline
DM70YTF CA CAS 396129-53-6
DM70YTF CB CHEBI:91198
DM70YTF DE Discovery agent
DMX08FL ID DMX08FL
DMX08FL DN H-Tyr(OMe)-Phe(2-Me)-NH2
DMX08FL HS Investigative
DMX08FL SN CHEMBL589543; H-Tyr(OMe)-Phe(2-Me)-NH2; SCHEMBL13538437
DMX08FL DT Small molecular drug
DMX08FL PC 45379600
DMX08FL MW 355.4
DMX08FL FM C20H25N3O3
DMX08FL IC InChI=1S/C20H25N3O3/c1-13-5-3-4-6-15(13)12-18(19(22)24)23-20(25)17(21)11-14-7-9-16(26-2)10-8-14/h3-10,17-18H,11-12,21H2,1-2H3,(H2,22,24)(H,23,25)/t17-,18-/m0/s1
DMX08FL CS CC1=CC=CC=C1C[C@@H](C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)OC)N
DMX08FL IK DZDNCKHJPMLWQZ-ROUUACIJSA-N
DMX08FL IU (2S)-2-amino-N-[(2S)-1-amino-3-(2-methylphenyl)-1-oxopropan-2-yl]-3-(4-methoxyphenyl)propanamide
DMX08FL DE Discovery agent
DMUHBGC ID DMUHBGC
DMUHBGC DN H-Tyr-Ala-Phe-Phe-NH2
DMUHBGC HS Investigative
DMUHBGC SN CHEMBL58178; H-Tyr-Ala-Phe-Phe-NH2; BDBM50308383; NCGC00163200-01
DMUHBGC DT Small molecular drug
DMUHBGC PC 16760005
DMUHBGC MW 545.6
DMUHBGC FM C30H35N5O5
DMUHBGC IC InChI=1S/C30H35N5O5/c1-19(33-29(39)24(31)16-22-12-14-23(36)15-13-22)28(38)35-26(18-21-10-6-3-7-11-21)30(40)34-25(27(32)37)17-20-8-4-2-5-9-20/h2-15,19,24-26,36H,16-18,31H2,1H3,(H2,32,37)(H,33,39)(H,34,40)(H,35,38)/t19-,24-,25-,26-/m0/s1
DMUHBGC CS C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMUHBGC IK MVUYXNQARFGHMJ-UBLBMGLWSA-N
DMUHBGC IU (2S)-2-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide
DMUHBGC DE Discovery agent
DMP8KMV ID DMP8KMV
DMP8KMV DN H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2
DMP8KMV HS Investigative
DMP8KMV SN CHEMBL396356; H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2
DMP8KMV DT Small molecular drug
DMP8KMV PC 44439948
DMP8KMV MW 633.7
DMP8KMV FM C26H31N7O8S2
DMP8KMV IC InChI=1S/C26H31N7O8S2/c27-18(9-14-3-7-17(34)8-4-14)24(37)32-21-13-43-42-12-20(23(28)36)31-26(39)19(30-22(35)11-29-25(21)38)10-15-1-5-16(6-2-15)33(40)41/h1-8,18-21,34H,9-13,27H2,(H2,28,36)(H,29,38)(H,30,35)(H,31,39)(H,32,37)/t18-,19-,20-,21-/m0/s1
DMP8KMV CS C1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N)CC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMP8KMV IK NBZQMFLIMSGMAF-TUFLPTIASA-N
DMP8KMV IU (4R,7S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-[(4-nitrophenyl)methyl]-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMP8KMV DE Discovery agent
DM48XV0 ID DM48XV0
DM48XV0 DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2
DM48XV0 HS Investigative
DM48XV0 SN CHEMBL220219
DM48XV0 DT Small molecular drug
DM48XV0 PC 16116220
DM48XV0 MW 550.6
DM48XV0 FM C28H34N6O6
DM48XV0 IC InChI=1S/C28H34N6O6/c29-20(14-18-10-12-19(35)13-11-18)26(38)34-22-9-5-4-8-21(25(30)37)33-28(40)23(15-17-6-2-1-3-7-17)32-24(36)16-31-27(22)39/h1-7,10-13,20-23,35H,8-9,14-16,29H2,(H2,30,37)(H,31,39)(H,32,36)(H,33,40)(H,34,38)/b5-4+/t20-,21+,22+,23-/m0/s1
DM48XV0 CS C1/C=C/C[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)N
DM48XV0 IK UYBFKIDGDVZVFM-KLGXLVMCSA-N
DM48XV0 IU (5S,8R,10E,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxamide
DM48XV0 DE Discovery agent
DMA2CZL ID DMA2CZL
DMA2CZL DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH
DMA2CZL HS Investigative
DMA2CZL SN rDADAE (11); CHEMBL229441; BDBM21127; single bond H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH; reduced bond-c[2-D-allylglycine, 5-D-allylglycine]enkephalin; (5S,8R,13R)-13-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid
DMA2CZL DT Small molecular drug
DMA2CZL PC 16733489
DMA2CZL MW 553.6
DMA2CZL FM C28H35N5O7
DMA2CZL IC InChI=1S/C28H35N5O7/c29-20(14-18-10-12-19(34)13-11-18)25(36)32-21-8-4-5-9-22(28(39)40)33-27(38)23(15-17-6-2-1-3-7-17)31-24(35)16-30-26(21)37/h1-3,6-7,10-13,20-23,34H,4-5,8-9,14-16,29H2,(H,30,37)(H,31,35)(H,32,36)(H,33,38)(H,39,40)/t20-,21+,22+,23-/m0/s1
DMA2CZL CS C1CC[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)O
DMA2CZL IK GDFBPHMKQXUQTN-AFXVXQJMSA-N
DMA2CZL IU (5S,8R,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradecane-8-carboxylic acid
DMA2CZL DE Discovery agent
DMXPJHB ID DMXPJHB
DMXPJHB DN H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2
DMXPJHB HS Investigative
DMXPJHB SN CHEMBL220333
DMXPJHB DT Small molecular drug
DMXPJHB PC 16116088
DMXPJHB MW 550.6
DMXPJHB FM C28H34N6O6
DMXPJHB IC InChI=1S/C28H34N6O6/c29-20(14-18-10-12-19(35)13-11-18)26(38)34-22-9-5-4-8-21(25(30)37)33-28(40)23(15-17-6-2-1-3-7-17)32-24(36)16-31-27(22)39/h1-7,10-13,20-23,35H,8-9,14-16,29H2,(H2,30,37)(H,31,39)(H,32,36)(H,33,40)(H,34,38)/b5-4-/t20-,21-,22+,23-/m0/s1
DMXPJHB CS C1/C=C\\C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]1NC(=O)[C@H](CC2=CC=C(C=C2)O)N)CC3=CC=CC=C3)C(=O)N
DMXPJHB IK UYBFKIDGDVZVFM-ODCKOUNNSA-N
DMXPJHB IU (5S,8S,10Z,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-benzyl-3,6,14-trioxo-1,4,7-triazacyclotetradec-10-ene-8-carboxamide
DMXPJHB DE Discovery agent
DM7QAES ID DM7QAES
DM7QAES DN H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES HS Investigative
DM7QAES SN CHEMBL220327; H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2
DM7QAES DT Small molecular drug
DM7QAES PC 44420667
DM7QAES MW 588.7
DM7QAES FM C26H32N6O6S2
DM7QAES IC InChI=1S/C26H32N6O6S2/c27-18(10-16-6-8-17(33)9-7-16)24(36)32-21-14-40-39-13-20(23(28)35)31-26(38)19(11-15-4-2-1-3-5-15)30-22(34)12-29-25(21)37/h1-9,18-21,33H,10-14,27H2,(H2,28,35)(H,29,37)(H,30,34)(H,31,38)(H,32,36)/t18-,19-,20-,21-/m0/s1
DM7QAES CS C1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSS1)C(=O)N)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM7QAES IK VUVASMYWPNXOGI-TUFLPTIASA-N
DM7QAES IU (4R,7S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DM7QAES DE Discovery agent
DMZSTL5 ID DMZSTL5
DMZSTL5 DN H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5 HS Investigative
DMZSTL5 SN CHEMBL373572; H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2
DMZSTL5 DT Small molecular drug
DMZSTL5 PC 44420674
DMZSTL5 MW 588.7
DMZSTL5 FM C26H32N6O6S2
DMZSTL5 IC InChI=1S/C26H32N6O6S2/c27-18(10-16-6-8-17(33)9-7-16)24(36)32-21-14-40-39-13-20(23(28)35)31-26(38)19(11-15-4-2-1-3-5-15)30-22(34)12-29-25(21)37/h1-9,18-21,33H,10-14,27H2,(H2,28,35)(H,29,37)(H,30,34)(H,31,38)(H,32,36)/t18-,19-,20+,21-/m0/s1
DMZSTL5 CS C1[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](CSS1)C(=O)N)CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMZSTL5 IK VUVASMYWPNXOGI-BURNTYAHSA-N
DMZSTL5 IU (4S,7S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxamide
DMZSTL5 DE Discovery agent
DMI7CR9 ID DMI7CR9
DMI7CR9 DN H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2
DMI7CR9 HS Investigative
DMI7CR9 DT Small molecular drug
DMI7CR9 PC 15088039
DMI7CR9 MW 578.7
DMI7CR9 FM C30H38N6O6
DMI7CR9 IC InChI=1S/C30H38N6O6/c31-22(16-18-7-9-21(37)10-8-18)27(40)34-24-6-3-15-33-25(38)12-11-23(26(32)39)35-29(42)30(36-28(24)41)14-13-19-4-1-2-5-20(19)17-30/h1-2,4-5,7-10,22-24,37H,3,6,11-17,31H2,(H2,32,39)(H,33,38)(H,34,40)(H,35,42)(H,36,41)/t22-,23-,24+,30-/m0/s1
DMI7CR9 CS C1C[C@H](C(=O)N[C@]2(CCC3=CC=CC=C3C2)C(=O)N[C@@H](CCC(=O)NC1)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMI7CR9 IK IJZIWUAJVCVWNA-WAHOFHFDSA-N
DMI7CR9 IU (2S,5S,13R)-13-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3,8,14-trioxospiro[1,4,9-triazacyclotetradecane-2,3'-2,4-dihydro-1H-naphthalene]-5-carboxamide
DMI7CR9 DE Discovery agent
DMOTI0P ID DMOTI0P
DMOTI0P DN H-Tyr-c[D-Orn-Aic-Glu]-NH2
DMOTI0P HS Investigative
DMOTI0P SN CHEMBL106849; H-Tyr-c[D-Orn-Aic-Glu]-NH2
DMOTI0P DT Small molecular drug
DMOTI0P PC 44336496
DMOTI0P MW 564.6
DMOTI0P FM C29H36N6O6
DMOTI0P IC InChI=1S/C29H36N6O6/c30-21(14-17-7-9-20(36)10-8-17)26(39)33-23-6-3-13-32-24(37)12-11-22(25(31)38)34-28(41)29(35-27(23)40)15-18-4-1-2-5-19(18)16-29/h1-2,4-5,7-10,21-23,36H,3,6,11-16,30H2,(H2,31,38)(H,32,37)(H,33,39)(H,34,41)(H,35,40)/t21-,22+,23-/m0/s1
DMOTI0P CS C1C[C@@H](C(=O)NC2(CC3=CC=CC=C3C2)C(=O)N[C@H](CCC(=O)NC1)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
DMOTI0P IK YFKXNEKIMXIPLT-ZRBLBEILSA-N
DMOTI0P IU (5'R,13'S)-13'-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3',8',14'-trioxospiro[1,3-dihydroindene-2,2'-1,4,9-triazacyclotetradecane]-5'-carboxamide
DMOTI0P DE Discovery agent
DMAKPM1 ID DMAKPM1
DMAKPM1 DN H-Tyr-c[pen-Gly-Phe-pen]OH
DMAKPM1 HS Investigative
DMAKPM1 SN H-Tyr-c[pen-Gly-Phe-pen]OH; CHEMBL396103
DMAKPM1 DT Small molecular drug
DMAKPM1 PC 44439867
DMAKPM1 MW 645.8
DMAKPM1 FM C30H39N5O7S2
DMAKPM1 IC InChI=1S/C30H39N5O7S2/c1-29(2)23(34-25(38)20(31)14-18-10-12-19(36)13-11-18)27(40)32-16-22(37)33-21(15-17-8-6-5-7-9-17)26(39)35-24(28(41)42)30(3,4)44-43-29/h5-13,20-21,23-24,36H,14-16,31H2,1-4H3,(H,32,40)(H,33,37)(H,34,38)(H,35,39)(H,41,42)/t20-,21?,23-,24?/m1/s1
DMAKPM1 CS CC1([C@@H](C(=O)NCC(=O)NC(C(=O)NC(C(SS1)(C)C)C(=O)O)CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=C(C=C3)O)N)C
DMAKPM1 IK MCMMCRYPQBNCPH-ZNNNFZKMSA-N
DMAKPM1 IU (13R)-13-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-7-benzyl-3,3,14,14-tetramethyl-6,9,12-trioxo-1,2-dithia-5,8,11-triazacyclotetradecane-4-carboxylic acid
DMAKPM1 DE Discovery agent
DMN2AQO ID DMN2AQO
DMN2AQO DN H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2
DMN2AQO HS Investigative
DMN2AQO SN CHEMBL124941; H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2; BDBM50001459; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid
DMN2AQO DT Small molecular drug
DMN2AQO PC 44348645
DMN2AQO MW 794.9
DMN2AQO FM C39H54N8O10
DMN2AQO IC InChI=1S/C39H54N8O10/c1-20(2)31(36(55)42-19-29(41)49)46-37(56)32(21(3)4)45-35(54)28(17-30(50)51)44-38(57)39(15-14-24-8-6-7-9-25(24)18-39)47-33(52)22(5)43-34(53)27(40)16-23-10-12-26(48)13-11-23/h6-13,20-22,27-28,31-32,48H,14-19,40H2,1-5H3,(H2,41,49)(H,42,55)(H,43,53)(H,44,57)(H,45,54)(H,46,56)(H,47,52)(H,50,51)/t22-,27+,28+,31+,32+,39?/m1/s1
DMN2AQO CS C[C@H](C(=O)NC1(CCC2=CC=CC=C2C1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMN2AQO IK WCJNWJPRBIKFOI-RKPARCAKSA-N
DMN2AQO IU (3S)-3-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3,4-dihydro-1H-naphthalene-2-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMN2AQO DE Discovery agent
DM6ZHWS ID DM6ZHWS
DM6ZHWS DN H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2
DM6ZHWS HS Investigative
DM6ZHWS SN CHEMBL124435; H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2; BDBM50001462; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-indane-2-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid
DM6ZHWS DT Small molecular drug
DM6ZHWS PC 10010455
DM6ZHWS MW 780.9
DM6ZHWS FM C38H52N8O10
DM6ZHWS IC InChI=1S/C38H52N8O10/c1-19(2)30(35(54)41-18-28(40)48)45-36(55)31(20(3)4)44-34(53)27(15-29(49)50)43-37(56)38(16-23-8-6-7-9-24(23)17-38)46-32(51)21(5)42-33(52)26(39)14-22-10-12-25(47)13-11-22/h6-13,19-21,26-27,30-31,47H,14-18,39H2,1-5H3,(H2,40,48)(H,41,54)(H,42,52)(H,43,56)(H,44,53)(H,45,55)(H,46,51)(H,49,50)/t21-,26+,27+,30+,31+/m1/s1
DM6ZHWS CS C[C@H](C(=O)NC1(CC2=CC=CC=C2C1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM6ZHWS IK QZYUFPDOTMWDCQ-UZHHEQFGSA-N
DM6ZHWS IU (3S)-3-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-1,3-dihydroindene-2-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM6ZHWS DE Discovery agent
DMDF9AS ID DMDF9AS
DMDF9AS DN H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2
DMDF9AS HS Investigative
DMDF9AS SN H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2; CHEMBL261390; BDBM21007; C-terminal modified bifunctional peptide, 1; [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate
DMDF9AS PC 24768351
DMDF9AS MW 1079.1
DMDF9AS FM C54H60F6N8O9
DMDF9AS IC InChI=1S/C54H60F6N8O9/c1-30(2)20-42(49(73)67-44(25-35-27-62-41-13-8-7-12-39(35)41)52(76)77-29-34-21-36(53(55,56)57)26-37(22-34)54(58,59)60)66-50(74)45-14-9-19-68(45)51(75)43(24-32-10-5-4-6-11-32)65-46(70)28-63-47(71)31(3)64-48(72)40(61)23-33-15-17-38(69)18-16-33/h4-8,10-13,15-18,21-22,26-27,30-31,40,42-45,62,69H,9,14,19-20,23-25,28-29,61H2,1-3H3,(H,63,71)(H,64,72)(H,65,70)(H,66,74)(H,67,73)/t31-,40+,42+,43+,44+,45+/m1/s1
DMDF9AS CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)OCC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMDF9AS IK XHJXRHNUFXHMEV-REAJPLCASA-N
DMDF9AS IU [3,5-bis(trifluoromethyl)phenyl]methyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoate
DMDF9AS DE Discovery agent
DM4VBDW ID DM4VBDW
DM4VBDW DN H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac
DM4VBDW HS Investigative
DM4VBDW SN CHEMBL408889; H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac
DM4VBDW PC 44408417
DM4VBDW MW 1090.2
DM4VBDW FM C56H67N9O14
DM4VBDW IC InChI=1S/C56H67N9O14/c1-5-6-20-41(52(73)62-45(56(78)79)29-38-32-65(34(3)66)46-21-14-13-19-40(38)46)59-53(74)42(30-49(69)70)60-54(75)47(28-36-17-11-8-12-18-36)64(4)63-43(26-35-15-9-7-10-16-35)51(72)57-31-48(68)58-33(2)50(71)61-44(55(76)77)27-37-22-24-39(67)25-23-37/h7-19,21-25,32-33,41-45,47,63,67H,5-6,20,26-31H2,1-4H3,(H,57,72)(H,58,68)(H,59,74)(H,60,75)(H,61,71)(H,62,73)(H,69,70)(H,76,77)(H,78,79)/t33-,41+,42+,43+,44+,45+,47+/m1/s1
DM4VBDW CS CCCC[C@@H](C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)N(C)N[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DM4VBDW IK DZRXMQMULMXHKQ-GDYSDZBQSA-N
DM4VBDW IU (3S)-4-[[(2S)-1-[[(1S)-2-(1-acetylindol-3-yl)-1-carboxyethyl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-[[[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-methylamino]-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DM4VBDW DE Discovery agent
DM0J8P6 ID DM0J8P6
DM0J8P6 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H
DM0J8P6 HS Investigative
DM0J8P6 SN CHEMBL375359; H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H
DM0J8P6 PC 16100411
DM0J8P6 MW 1032.099
DM0J8P6 FM C53H65N11O11
DM0J8P6 IC InChI=1S/C53H65N11O11/c1-3-4-18-41(60-49(71)39(55)28-36-27-35-17-11-12-19-40(35)58-36)50(72)62-44(29-46(67)68)51(73)61-43(26-33-15-9-6-10-16-33)53(75)64-63-52(74)42(25-32-13-7-5-8-14-32)59-45(66)30-56-47(69)31(2)57-48(70)38(54)24-34-20-22-37(65)23-21-34/h5-17,19-23,27,31,38-39,41-44,58,65H,3-4,18,24-26,28-30,54-55H2,1-2H3,(H,56,69)(H,57,70)(H,59,66)(H,60,71)(H,61,73)(H,62,72)(H,63,74)(H,64,75)(H,67,68)/t31-,38+,39+,41-,42+,43-,44-/m1/s1
DM0J8P6 CS CCCC[C@H](C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)NNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)NC(=O)[C@H](CC4=CC5=CC=CC=C5N4)N
DM0J8P6 IK NXHWDEQNHXTHJU-KDWYPSCJSA-N
DM0J8P6 IU (3R)-4-[[(2R)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(1H-indol-2-yl)propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid
DM0J8P6 DE Discovery agent
DMW50ZQ ID DMW50ZQ
DMW50ZQ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ HS Investigative
DMW50ZQ SN CHEMBL217957; H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo
DMW50ZQ PC 16100407
DMW50ZQ MW 1132.3
DMW50ZQ FM C58H73N11O13
DMW50ZQ IC InChI=1S/C58H73N11O13/c1-6-7-21-43(64-54(78)47(32-49(72)73)66-53(77)44(28-35-16-10-8-11-17-35)67-57(81)82-58(3,4)5)52(76)65-46(31-39-30-38-20-14-15-22-42(38)62-39)56(80)69-68-55(79)45(29-36-18-12-9-13-19-36)63-48(71)33-60-50(74)34(2)61-51(75)41(59)27-37-23-25-40(70)26-24-37/h8-20,22-26,30,34,41,43-47,62,70H,6-7,21,27-29,31-33,59H2,1-5H3,(H,60,74)(H,61,75)(H,63,71)(H,64,78)(H,65,76)(H,66,77)(H,67,81)(H,68,79)(H,69,80)(H,72,73)/t34-,41+,43+,44+,45+,46-,47+/m1/s1
DMW50ZQ CS CCCC[C@@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2N1)C(=O)NNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)OC(C)(C)C
DMW50ZQ IK FEOAQCGOOODCEB-RXFVQNAMSA-N
DMW50ZQ IU (3S)-4-[[(2S)-1-[[(2R)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMW50ZQ DE Discovery agent
DMF82C1 ID DMF82C1
DMF82C1 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1 HS Investigative
DMF82C1 SN CHEMBL386212; H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H
DMF82C1 PC 16100410
DMF82C1 MW 1032.099
DMF82C1 FM C53H65N11O11
DMF82C1 IC InChI=1S/C53H65N11O11/c1-3-4-18-41(60-51(73)44(29-46(67)68)61-49(71)39(55)24-32-13-7-5-8-14-32)50(72)62-43(28-36-27-35-17-11-12-19-40(35)58-36)53(75)64-63-52(74)42(26-33-15-9-6-10-16-33)59-45(66)30-56-47(69)31(2)57-48(70)38(54)25-34-20-22-37(65)23-21-34/h5-17,19-23,27,31,38-39,41-44,58,65H,3-4,18,24-26,28-30,54-55H2,1-2H3,(H,56,69)(H,57,70)(H,59,66)(H,60,73)(H,61,71)(H,62,72)(H,63,74)(H,64,75)(H,67,68)/t31-,38+,39+,41+,42+,43-,44+/m1/s1
DMF82C1 CS CCCC[C@@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2N1)C(=O)NNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC5=CC=CC=C5)N
DMF82C1 IK KYWMQIRORZGHDH-QOIWPSRPSA-N
DMF82C1 IU (3S)-4-[[(2S)-1-[[(2R)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMF82C1 DE Discovery agent
DM6UWKL ID DM6UWKL
DM6UWKL DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc
DM6UWKL HS Investigative
DM6UWKL SN CHEMBL413644; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc
DM6UWKL PC 44408590
DM6UWKL MW 1134.2
DM6UWKL FM C58H71N9O15
DM6UWKL IC InChI=1S/C58H71N9O15/c1-6-7-21-41(52(74)64-46(56(79)80)30-38-33-67(57(81)82-58(3,4)5)47-22-15-14-20-40(38)47)61-53(75)42(31-49(70)71)62-54(76)44(28-36-18-12-9-13-19-36)66-65-43(27-35-16-10-8-11-17-35)51(73)59-32-48(69)60-34(2)50(72)63-45(55(77)78)29-37-23-25-39(68)26-24-37/h8-20,22-26,33-34,41-46,65-66,68H,6-7,21,27-32H2,1-5H3,(H,59,73)(H,60,69)(H,61,75)(H,62,76)(H,63,72)(H,64,74)(H,70,71)(H,77,78)(H,79,80)/t34-,41+,42+,43+,44+,45+,46-/m1/s1
DM6UWKL CS CCCC[C@@H](C(=O)N[C@H](CC1=CN(C2=CC=CC=C21)C(=O)OC(C)(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DM6UWKL IK IYNMVGGOTRCWGJ-KSEFKAEUSA-N
DM6UWKL IU (3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1R)-1-carboxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]ethyl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DM6UWKL DE Discovery agent
DMSXD63 ID DMSXD63
DMSXD63 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63 HS Investigative
DMSXD63 SN CHEMBL375412; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H
DMSXD63 PC 44408484
DMSXD63 MW 1034.099
DMSXD63 FM C53H63N9O13
DMSXD63 IC InChI=1S/C53H63N9O13/c1-3-4-18-39(49(69)60-44(53(74)75)27-35-29-54-38-19-12-11-17-37(35)38)57-50(70)40(28-46(65)66)58-51(71)42(25-33-15-9-6-10-16-33)62-61-41(24-32-13-7-5-8-14-32)48(68)55-30-45(64)56-31(2)47(67)59-43(52(72)73)26-34-20-22-36(63)23-21-34/h5-17,19-23,29,31,39-44,54,61-63H,3-4,18,24-28,30H2,1-2H3,(H,55,68)(H,56,64)(H,57,70)(H,58,71)(H,59,67)(H,60,69)(H,65,66)(H,72,73)(H,74,75)/t31-,39+,40+,41+,42+,43+,44-/m1/s1
DMSXD63 CS CCCC[C@@H](C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMSXD63 IK LHFDBKUCTFELLO-WMRIFXDUSA-N
DMSXD63 IU (3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMSXD63 DE Discovery agent
DMRUD37 ID DMRUD37
DMRUD37 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37 HS Investigative
DMRUD37 SN CHEMBL442483; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac
DMRUD37 PC 44408525
DMRUD37 MW 1076.2
DMRUD37 FM C55H65N9O14
DMRUD37 IC InChI=1S/C55H65N9O14/c1-4-5-19-40(51(72)61-45(55(77)78)28-37-31-64(33(3)65)46-20-13-12-18-39(37)46)58-52(73)41(29-48(68)69)59-53(74)43(26-35-16-10-7-11-17-35)63-62-42(25-34-14-8-6-9-15-34)50(71)56-30-47(67)57-32(2)49(70)60-44(54(75)76)27-36-21-23-38(66)24-22-36/h6-18,20-24,31-32,40-45,62-63,66H,4-5,19,25-30H2,1-3H3,(H,56,71)(H,57,67)(H,58,73)(H,59,74)(H,60,70)(H,61,72)(H,68,69)(H,75,76)(H,77,78)/t32-,40+,41+,42+,43+,44+,45+/m1/s1
DMRUD37 CS CCCC[C@@H](C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMRUD37 IK RBNPCZIQGBMFDV-FPWNPRTMSA-N
DMRUD37 IU (3S)-4-[[(2S)-1-[[(1S)-2-(1-acetylindol-3-yl)-1-carboxyethyl]amino]-1-oxohexan-2-yl]amino]-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMRUD37 DE Discovery agent
DMIPXCZ ID DMIPXCZ
DMIPXCZ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ HS Investigative
DMIPXCZ SN CHEMBL405192; H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc
DMIPXCZ PC 44408524
DMIPXCZ MW 1134.2
DMIPXCZ FM C58H71N9O15
DMIPXCZ IC InChI=1S/C58H71N9O15/c1-6-7-21-41(52(74)64-46(56(79)80)30-38-33-67(57(81)82-58(3,4)5)47-22-15-14-20-40(38)47)61-53(75)42(31-49(70)71)62-54(76)44(28-36-18-12-9-13-19-36)66-65-43(27-35-16-10-8-11-17-35)51(73)59-32-48(69)60-34(2)50(72)63-45(55(77)78)29-37-23-25-39(68)26-24-37/h8-20,22-26,33-34,41-46,65-66,68H,6-7,21,27-32H2,1-5H3,(H,59,73)(H,60,69)(H,61,75)(H,62,76)(H,63,72)(H,64,74)(H,70,71)(H,77,78)(H,79,80)/t34-,41+,42+,43+,44+,45+,46+/m1/s1
DMIPXCZ CS CCCC[C@@H](C(=O)N[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC(C)(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NN[C@@H](CC4=CC=CC=C4)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CC5=CC=C(C=C5)O)C(=O)O
DMIPXCZ IK IYNMVGGOTRCWGJ-CHAGIDMDSA-N
DMIPXCZ IU (3S)-3-[[(2S)-2-[2-[(2S)-1-[[2-[[(2R)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]hydrazinyl]-3-phenylpropanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]ethyl]amino]-1-oxohexan-2-yl]amino]-4-oxobutanoic acid
DMIPXCZ DE Discovery agent
DMFSKDM ID DMFSKDM
DMFSKDM DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM HS Investigative
DMFSKDM SN CHEMBL218651; H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H
DMFSKDM PC 16100409
DMFSKDM MW 1032.099
DMFSKDM FM C53H65N11O11
DMFSKDM IC InChI=1S/C53H65N11O11/c1-3-4-18-41(60-51(73)44(29-46(67)68)61-49(71)39(55)24-32-13-7-5-8-14-32)50(72)62-43(28-36-27-35-17-11-12-19-40(35)58-36)53(75)64-63-52(74)42(26-33-15-9-6-10-16-33)59-45(66)30-56-47(69)31(2)57-48(70)38(54)25-34-20-22-37(65)23-21-34/h5-17,19-23,27,31,38-39,41-44,58,65H,3-4,18,24-26,28-30,54-55H2,1-2H3,(H,56,69)(H,57,70)(H,59,66)(H,60,73)(H,61,71)(H,62,72)(H,63,74)(H,64,75)(H,67,68)/t31-,38+,39-,41-,42+,43+,44-/m1/s1
DMFSKDM CS CCCC[C@H](C(=O)N[C@@H](CC1=CC2=CC=CC=C2N1)C(=O)NNC(=O)[C@H](CC3=CC=CC=C3)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMFSKDM IK KYWMQIRORZGHDH-KKSWQRHZSA-N
DMFSKDM IU (3R)-4-[[(2R)-1-[[(2S)-1-[2-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]hydrazinyl]-3-(1H-indol-2-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-[[(2R)-2-amino-3-phenylpropanoyl]amino]-4-oxobutanoic acid
DMFSKDM DE Discovery agent
DM2K16M ID DM2K16M
DM2K16M DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2
DM2K16M HS Investigative
DM2K16M SN CHEMBL438389; H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2; BDBM21012; C-terminal modified bifunctional peptide, 5
DM2K16M PC 24768355
DM2K16M MW 1078.1
DM2K16M FM C54H61F6N9O8
DM2K16M IC InChI=1S/C54H61F6N9O8/c1-30(2)20-42(50(75)67-43(25-35-28-62-41-13-8-7-12-39(35)41)49(74)63-27-34-21-36(53(55,56)57)26-37(22-34)54(58,59)60)68-51(76)45-14-9-19-69(45)52(77)44(24-32-10-5-4-6-11-32)66-46(71)29-64-47(72)31(3)65-48(73)40(61)23-33-15-17-38(70)18-16-33/h4-8,10-13,15-18,21-22,26,28,30-31,40,42-45,62,70H,9,14,19-20,23-25,27,29,61H2,1-3H3,(H,63,74)(H,64,72)(H,65,73)(H,66,71)(H,67,75)(H,68,76)/t31-,40+,42+,43+,44+,45+/m1/s1
DM2K16M CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DM2K16M IK LWOMHJBSXPGKKS-REAJPLCASA-N
DM2K16M IU (2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM2K16M DE Discovery agent
DMRE4ZI ID DMRE4ZI
DMRE4ZI DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl
DMRE4ZI HS Investigative
DMRE4ZI SN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl; CHEMBL271619; BDBM21010; C-terminal modified bifunctional peptide, 3
DMRE4ZI DT Small molecular drug
DMRE4ZI PC 24768353
DMRE4ZI MW 942.1
DMRE4ZI FM C52H63N9O8
DMRE4ZI IC InChI=1S/C52H63N9O8/c1-32(2)25-42(50(67)59-43(49(66)55-29-36-15-8-5-9-16-36)28-37-30-54-41-18-11-10-17-39(37)41)60-51(68)45-19-12-24-61(45)52(69)44(27-34-13-6-4-7-14-34)58-46(63)31-56-47(64)33(3)57-48(65)40(53)26-35-20-22-38(62)23-21-35/h4-11,13-18,20-23,30,32-33,40,42-45,54,62H,12,19,24-29,31,53H2,1-3H3,(H,55,66)(H,56,64)(H,57,65)(H,58,63)(H,59,67)(H,60,68)/t33-,40+,42+,43+,44+,45+/m1/s1
DMRE4ZI CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMRE4ZI IK VXHMITAKWYIILS-FDXPNMITSA-N
DMRE4ZI IU (2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-(benzylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DMRE4ZI DE Discovery agent
DM1ESMZ ID DM1ESMZ
DM1ESMZ DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2
DM1ESMZ HS Investigative
DM1ESMZ SN CHEMBL406030; H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2; BDBM21013; C-terminal modified bifunctional peptide, 6
DM1ESMZ PC 24768356
DM1ESMZ MW 1092.1
DM1ESMZ FM C55H63F6N9O8
DM1ESMZ IC InChI=1S/C55H63F6N9O8/c1-31(2)21-43(50(75)68-45(26-36-28-63-42-14-9-8-13-40(36)42)52(77)69(4)30-35-22-37(54(56,57)58)27-38(23-35)55(59,60)61)67-51(76)46-15-10-20-70(46)53(78)44(25-33-11-6-5-7-12-33)66-47(72)29-64-48(73)32(3)65-49(74)41(62)24-34-16-18-39(71)19-17-34/h5-9,11-14,16-19,22-23,27-28,31-32,41,43-46,63,71H,10,15,20-21,24-26,29-30,62H2,1-4H3,(H,64,73)(H,65,74)(H,66,72)(H,67,76)(H,68,75)/t32-,41+,43+,44+,45+,46+/m1/s1
DM1ESMZ CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N(C)CC5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DM1ESMZ IK IRIFESWSRQBRPW-CKWXOEDFSA-N
DM1ESMZ IU (2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl-methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM1ESMZ DE Discovery agent
DM56KDV ID DM56KDV
DM56KDV DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl
DM56KDV HS Investigative
DM56KDV SN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl; CHEMBL272665; BDBM21011; C-terminal modified bifunctional peptide, 4
DM56KDV DT Small molecular drug
DM56KDV PC 24768354
DM56KDV MW 956.1
DM56KDV FM C53H65N9O8
DM56KDV IC InChI=1S/C53H65N9O8/c1-33(2)26-43(50(67)60-45(29-38-30-55-42-19-12-11-18-40(38)42)52(69)61(4)32-37-16-9-6-10-17-37)59-51(68)46-20-13-25-62(46)53(70)44(28-35-14-7-5-8-15-35)58-47(64)31-56-48(65)34(3)57-49(66)41(54)27-36-21-23-39(63)24-22-36/h5-12,14-19,21-24,30,33-34,41,43-46,55,63H,13,20,25-29,31-32,54H2,1-4H3,(H,56,65)(H,57,66)(H,58,64)(H,59,68)(H,60,67)/t34-,41+,43+,44+,45+,46+/m1/s1
DM56KDV CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N(C)CC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DM56KDV IK GYOWORZEZSLHIN-NATPVWCTSA-N
DM56KDV IU (2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]-N-[(2S)-1-[[(2S)-1-[benzyl(methyl)amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
DM56KDV DE Discovery agent
DMH3YKR ID DMH3YKR
DMH3YKR DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl
DMH3YKR HS Investigative
DMH3YKR SN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl; CHEMBL261608; BDBM21009; C-terminal modified bifunctional peptide, 2; benzyl (2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]acetamido}-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-4-methylpentanamido]-3-(1H-indol-3-yl)propanoate
DMH3YKR DT Small molecular drug
DMH3YKR PC 24768352
DMH3YKR MW 943.1
DMH3YKR FM C52H62N8O9
DMH3YKR IC InChI=1S/C52H62N8O9/c1-32(2)25-42(49(65)59-44(52(68)69-31-36-15-8-5-9-16-36)28-37-29-54-41-18-11-10-17-39(37)41)58-50(66)45-19-12-24-60(45)51(67)43(27-34-13-6-4-7-14-34)57-46(62)30-55-47(63)33(3)56-48(64)40(53)26-35-20-22-38(61)23-21-35/h4-11,13-18,20-23,29,32-33,40,42-45,54,61H,12,19,24-28,30-31,53H2,1-3H3,(H,55,63)(H,56,64)(H,57,62)(H,58,66)(H,59,65)/t33-,40+,42+,43+,44+,45+/m1/s1
DMH3YKR CS C[C@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)OCC5=CC=CC=C5)NC(=O)[C@H](CC6=CC=C(C=C6)O)N
DMH3YKR IK AWLKNBWKVMBAKT-FDXPNMITSA-N
DMH3YKR IU benzyl (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoate
DMH3YKR DE Discovery agent
DMSX8CH ID DMSX8CH
DMSX8CH DN H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2
DMSX8CH HS Investigative
DMSX8CH SN CHEMBL330991; H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2; BDBM50001460; 3-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionyl}-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl)-amino]-N-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-2-methyl-propyl}-succinamic acid
DMSX8CH DT Small molecular drug
DMSX8CH PC 10485385
DMSX8CH MW 780.9
DMSX8CH FM C38H52N8O10
DMSX8CH IC InChI=1S/C38H52N8O10/c1-19(2)31(36(54)41-17-29(40)48)45-37(55)32(20(3)4)44-34(52)27(16-30(49)50)43-35(53)28-15-23-8-6-7-9-24(23)18-46(28)38(56)21(5)42-33(51)26(39)14-22-10-12-25(47)13-11-22/h6-13,19-21,26-28,31-32,47H,14-18,39H2,1-5H3,(H2,40,48)(H,41,54)(H,42,51)(H,43,53)(H,44,52)(H,45,55)(H,49,50)/t21-,26+,27+,28+,31+,32+/m1/s1
DMSX8CH CS C[C@H](C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
DMSX8CH IK JOXXADDFFWZHEE-JMZWVCJUSA-N
DMSX8CH IU (3S)-3-[[(3S)-2-[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMSX8CH DE Discovery agent
DM25KZE ID DM25KZE
DM25KZE DN HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2
DM25KZE HS Investigative
DM25KZE SN CHEMBL216640; Dynorphin A (1-11) amide; Dynorphin A(1-11) amide; HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2; 79985-48-1; Dyn A(1-11)-NH2; Linear Dyn A-(1-11)NH2; BDBM50010704; BDBM50033143; H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-NH2; Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-D-Lys-NH2; TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS-TRP-ASP-ASN-GLN-NH2
DM25KZE PC 10677974
DM25KZE MW 1361.6
DM25KZE FM C63H104N22O12
DM25KZE IC InChI=1S/C63H104N22O12/c1-5-37(4)51(59(96)82-45(20-13-29-75-63(71)72)60(97)85-30-14-21-48(85)58(95)79-42(52(66)89)17-9-10-26-64)84-55(92)44(19-12-28-74-62(69)70)80-54(91)43(18-11-27-73-61(67)68)81-56(93)46(31-36(2)3)83-57(94)47(33-38-15-7-6-8-16-38)78-50(88)35-76-49(87)34-77-53(90)41(65)32-39-22-24-40(86)25-23-39/h6-8,15-16,22-25,36-37,41-48,51,86H,5,9-14,17-21,26-35,64-65H2,1-4H3,(H2,66,89)(H,76,87)(H,77,90)(H,78,88)(H,79,95)(H,80,91)(H,81,93)(H,82,96)(H,83,94)(H,84,92)(H4,67,68,73)(H4,69,70,74)(H4,71,72,75)/t37-,41-,42-,43-,44-,45-,46-,47-,48-,51-/m0/s1
DM25KZE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N
DM25KZE IK OKJAOUBQLSWUNX-QFIUEGLPSA-N
DM25KZE IU (2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2S)-1,6-diamino-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
DM25KZE DE Discovery agent
DM6D0ZS ID DM6D0ZS
DM6D0ZS DN H-Tyr-Gly-Gly-Phe-Met-NH2
DM6D0ZS HS Investigative
DM6D0ZS SN H-Tyr-Gly-Gly-Phe-Met-NH2; [Met5]-Enkephalin Amide; [Met5]-Enkephalin, amide; CHEMBL247368; 60117-17-1; Tyr-Gly-Gly-Phe-Met-NH2; Met-enkephalinamide; L-Methioninamide, L-tyrosylglycylglycyl-L-phenylalanyl-; Enkephalinamide-met-; Methionine enkephalinamide; AC1L3X5D; CTK2F3118; HY-P1467; ZINC28893234; BDBM50207823; AKOS030610304; CS-0044396; A833448; (2S)-2-[[(2S)-2-[2-[2-[[(2S)-2-azanyl-3-(4-hydroxyphenyl)propanoyl]amino]ethanoylamino]ethanoylamino]-3-phenyl-propanoyl]amino]-4-methylsulfanyl-butanamide
DM6D0ZS DT Small molecular drug
DM6D0ZS PC 123704
DM6D0ZS MW 572.7
DM6D0ZS FM C27H36N6O6S
DM6D0ZS IC InChI=1S/C27H36N6O6S/c1-40-12-11-21(25(29)37)33-27(39)22(14-17-5-3-2-4-6-17)32-24(36)16-30-23(35)15-31-26(38)20(28)13-18-7-9-19(34)10-8-18/h2-10,20-22,34H,11-16,28H2,1H3,(H2,29,37)(H,30,35)(H,31,38)(H,32,36)(H,33,39)/t20-,21-,22-/m0/s1
DM6D0ZS CS CSCC[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DM6D0ZS IK HBDDEVHKKBWEQT-FKBYEOEOSA-N
DM6D0ZS IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide
DM6D0ZS CA CAS 60117-17-1
DM6D0ZS DE Discovery agent
DM1NT5G ID DM1NT5G
DM1NT5G DN H-Tyr-NMe-D-Ala-Phe-Sar-NH2
DM1NT5G HS Investigative
DM1NT5G SN CHEMBL260120
DM1NT5G DT Small molecular drug
DM1NT5G PC 24853671
DM1NT5G MW 483.6
DM1NT5G FM C25H33N5O5
DM1NT5G IC InChI=1S/C25H33N5O5/c1-16(30(3)24(34)20(26)13-18-9-11-19(31)12-10-18)23(33)28-21(14-17-7-5-4-6-8-17)25(35)29(2)15-22(27)32/h4-12,16,20-21,31H,13-15,26H2,1-3H3,(H2,27,32)(H,28,33)/t16-,20+,21+/m1/s1
DM1NT5G CS C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N(C)CC(=O)N)N(C)C(=O)[C@H](CC2=CC=C(C=C2)O)N
DM1NT5G IK GRHNSLXBGRDMSP-CZAAIQMYSA-N
DM1NT5G IU (2S)-2-amino-N-[(2R)-1-[[(2S)-1-[(2-amino-2-oxoethyl)-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)-N-methylpropanamide
DM1NT5G DE Discovery agent
DMP0CRD ID DMP0CRD
DMP0CRD DN H-Tyr-Pro-Ala-Phe-NH2
DMP0CRD HS Investigative
DMP0CRD SN YPAF-NH2
DMP0CRD PC 44428865
DMP0CRD MW 495.6
DMP0CRD FM C26H33N5O5
DMP0CRD IC InChI=1S/C26H33N5O5/c1-16(24(34)30-21(23(28)33)15-17-6-3-2-4-7-17)29-25(35)22-8-5-13-31(22)26(36)20(27)14-18-9-11-19(32)12-10-18/h2-4,6-7,9-12,16,20-22,32H,5,8,13-15,27H2,1H3,(H2,28,33)(H,29,35)(H,30,34)/t16-,20-,21-,22-/m0/s1
DMP0CRD CS C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)N
DMP0CRD IK RZZXLHCBXYDTOF-KPQYALRZSA-N
DMP0CRD IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMP0CRD DE Discovery agent
DMQUNGC ID DMQUNGC
DMQUNGC DN H-Tyr-Pro-Dap(6DMN)-Phe-NH2
DMQUNGC HS Investigative
DMQUNGC SN CHEMBL207661; H-Tyr-Pro-Dap(6DMN)-Phe-NH2
DMQUNGC DT Small molecular drug
DMQUNGC PC 44412206
DMQUNGC MW 733.8
DMQUNGC FM C40H43N7O7
DMQUNGC IC InChI=1S/C40H43N7O7/c1-45(2)27-13-12-25-20-29-30(21-26(25)19-27)39(53)47(38(29)52)22-33(36(50)43-32(35(42)49)18-23-7-4-3-5-8-23)44-37(51)34-9-6-16-46(34)40(54)31(41)17-24-10-14-28(48)15-11-24/h3-5,7-8,10-15,19-21,31-34,48H,6,9,16-18,22,41H2,1-2H3,(H2,42,49)(H,43,50)(H,44,51)/t31-,32-,33?,34-/m0/s1
DMQUNGC CS CN(C)C1=CC2=CC3=C(C=C2C=C1)C(=O)N(C3=O)CC(C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC6=CC=C(C=C6)O)N
DMQUNGC IK OHGKVUSMHZDAKH-SHROADRVSA-N
DMQUNGC IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMQUNGC DE Discovery agent
DM2F6L9 ID DM2F6L9
DM2F6L9 DN H-Tyr-Pro-Phe-Ala-NH2
DM2F6L9 HS Investigative
DM2F6L9 SN CHEMBL388265; H-Tyr-Pro-Phe-Ala-NH2; BDBM50209300
DM2F6L9 DT Small molecular drug
DM2F6L9 PC 44428877
DM2F6L9 MW 495.6
DM2F6L9 FM C26H33N5O5
DM2F6L9 IC InChI=1S/C26H33N5O5/c1-16(23(28)33)29-24(34)21(15-17-6-3-2-4-7-17)30-25(35)22-8-5-13-31(22)26(36)20(27)14-18-9-11-19(32)12-10-18/h2-4,6-7,9-12,16,20-22,32H,5,8,13-15,27H2,1H3,(H2,28,33)(H,29,34)(H,30,35)/t16-,20-,21-,22-/m0/s1
DM2F6L9 CS C[C@@H](C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=C(C=C3)O)N
DM2F6L9 IK WNYNLZIGNIJEJM-KPQYALRZSA-N
DM2F6L9 IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM2F6L9 DE Discovery agent
DM326GJ ID DM326GJ
DM326GJ DN H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2
DM326GJ HS Investigative
DM326GJ SN CHEMBL411335; H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2
DM326GJ DT Small molecular drug
DM326GJ PC 44412234
DM326GJ MW 994.1
DM326GJ FM C55H63N9O9
DM326GJ IC InChI=1S/C55H63N9O9/c1-62(2)39-22-21-37-31-41-42(32-38(37)30-39)54(72)64(53(41)71)33-46(49(57)67)59-48(66)18-10-5-11-25-58-50(68)44(28-34-13-6-3-7-14-34)60-51(69)45(29-35-15-8-4-9-16-35)61-52(70)47-17-12-26-63(47)55(73)43(56)27-36-19-23-40(65)24-20-36/h3-4,6-9,13-16,19-24,30-32,43-47,65H,5,10-12,17-18,25-29,33,56H2,1-2H3,(H2,57,67)(H,58,68)(H,59,66)(H,60,69)(H,61,70)/t43-,44-,45-,46?,47-/m0/s1
DM326GJ CS CN(C)C1=CC2=CC3=C(C=C2C=C1)C(=O)N(C3=O)CC(C(=O)N)NC(=O)CCCCCNC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CC7=CC=C(C=C7)O)N
DM326GJ IK FATMKOSWYXDNJL-FCTRPSMQSA-N
DM326GJ IU (2S)-N-[(2S)-1-[[(2S)-1-[[6-[[1-amino-3-[6-(dimethylamino)-1,3-dioxobenzo[f]isoindol-2-yl]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM326GJ DE Discovery agent
DMXQUKJ ID DMXQUKJ
DMXQUKJ DN H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H
DMXQUKJ HS Investigative
DMXQUKJ SN CHEMBL392469; H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H
DMXQUKJ DT Small molecular drug
DMXQUKJ PC 44436371
DMXQUKJ MW 965.1
DMXQUKJ FM C55H64N8O8
DMXQUKJ IC InChI=1S/C55H64N8O8/c1-34-26-42(65)27-35(2)43(34)32-45(57)55(71)63-33-40-17-10-9-16-39(40)31-49(63)52(68)59-24-23-58-50(66)46(29-36-12-5-3-6-13-36)60-51(67)47(30-37-14-7-4-8-15-37)61-53(69)48-18-11-25-62(48)54(70)44(56)28-38-19-21-41(64)22-20-38/h3-10,12-17,19-22,26-27,44-49,64-65H,11,18,23-25,28-33,56-57H2,1-2H3,(H,58,66)(H,59,68)(H,60,67)(H,61,69)/t44-,45-,46-,47-,48-,49?/m0/s1
DMXQUKJ CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3CC2C(=O)NCCNC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CC7=CC=C(C=C7)O)N)N)C)O
DMXQUKJ IK CJBITXMCHBQEBZ-PGXNEIGQSA-N
DMXQUKJ IU 2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-N-[2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]ethyl]-3,4-dihydro-1H-isoquinoline-3-carboxamide
DMXQUKJ DE Discovery agent
DMUQLRN ID DMUQLRN
DMUQLRN DN H-Tyr-Pro-Phe-Phe-OH
DMUQLRN HS Investigative
DMUQLRN SN CHEMBL589982; 213768-49-1; H-Tyr-Pro-Phe-Phe-OH; CTK0J7647; DTXSID40649492; BDBM50308384; AKOS030610604; L-Tyrosyl-L-prolyl-L-phenylalanyl-L-phenylalanine; L-Phenylalanine, L-tyrosyl-L-prolyl-L-phenylalanyl-
DMUQLRN DT Small molecular drug
DMUQLRN PC 25254709
DMUQLRN MW 572.7
DMUQLRN FM C32H36N4O6
DMUQLRN IC InChI=1S/C32H36N4O6/c33-25(18-23-13-15-24(37)16-14-23)31(40)36-17-7-12-28(36)30(39)34-26(19-21-8-3-1-4-9-21)29(38)35-27(32(41)42)20-22-10-5-2-6-11-22/h1-6,8-11,13-16,25-28,37H,7,12,17-20,33H2,(H,34,39)(H,35,38)(H,41,42)/t25-,26-,27-,28-/m0/s1
DMUQLRN CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O
DMUQLRN IK SDJCVHZDMZOUDX-LJWNLINESA-N
DMUQLRN IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DMUQLRN CA CAS 213768-49-1
DMUQLRN DE Discovery agent
DM1VFLG ID DM1VFLG
DM1VFLG DN H-Tyr-Tic-Cha-Phe-OH
DM1VFLG HS Investigative
DM1VFLG SN H-Tyr-Tic-Cha-Phe-OH; CHEMBL197937
DM1VFLG DT Small molecular drug
DM1VFLG PC 9809581
DM1VFLG MW 640.8
DM1VFLG FM C37H44N4O6
DM1VFLG IC InChI=1S/C37H44N4O6/c38-30(19-26-15-17-29(42)18-16-26)36(45)41-23-28-14-8-7-13-27(28)22-33(41)35(44)39-31(20-24-9-3-1-4-10-24)34(43)40-32(37(46)47)21-25-11-5-2-6-12-25/h2,5-8,11-18,24,30-33,42H,1,3-4,9-10,19-23,38H2,(H,39,44)(H,40,43)(H,46,47)/t30-,31-,32-,33?/m0/s1
DM1VFLG CS C1CCC(CC1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CC5=CC=C(C=C5)O)N
DM1VFLG IK AFTOYBSNHFSKRV-KSTJSZMBSA-N
DM1VFLG IU (2S)-2-[[(2S)-2-[[2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-cyclohexylpropanoyl]amino]-3-phenylpropanoic acid
DM1VFLG DE Discovery agent
DMIU52O ID DMIU52O
DMIU52O DN H-Tyr-Tic-OH
DMIU52O HS Investigative
DMIU52O SN CHEMBL485576; ZINC13765438; BDBM50060080; 2-({2-[(R)-2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carbonyl}-amino)-propionic acid
DMIU52O DT Small molecular drug
DMIU52O PC 44588783
DMIU52O MW 340.4
DMIU52O FM C19H20N2O4
DMIU52O IC InChI=1S/C19H20N2O4/c20-16(9-12-5-7-15(22)8-6-12)18(23)21-11-14-4-2-1-3-13(14)10-17(21)19(24)25/h1-8,16-17,22H,9-11,20H2,(H,24,25)/t16-,17-/m0/s1
DMIU52O CS C1[C@H](N(CC2=CC=CC=C21)C(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O
DMIU52O IK VUOZTGVYOFFWCN-IRXDYDNUSA-N
DMIU52O IU (3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMIU52O DE Discovery agent
DMI0U87 ID DMI0U87
DMI0U87 DN H-Tyr-Tic-Phe-Phe-OH
DMI0U87 HS Investigative
DMI0U87 SN Tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine; TIPP; 146369-65-5; Tyr-tic-phe-phe-OH; CHEMBL191751; tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-phenylalanyl-phenylalanine; L-Phenylalanine, L-tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-phenylalanyl-; Tyr-Tic-Phe-PheOH; AC1LD8RR; TIPP (opioid antagonist); DTXSID60163362; ZINC3942635; BDBM50068664; tyrosyl-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl- phenylalanyl-phenylalanine; L-Tyrosyl-L-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L- phenylalanyl-L-phenylalanine; 147780-77-6
DMI0U87 DT Small molecular drug
DMI0U87 PC 644210
DMI0U87 MW 634.7
DMI0U87 FM C37H38N4O6
DMI0U87 IC InChI=1S/C37H38N4O6/c38-30(19-26-15-17-29(42)18-16-26)36(45)41-23-28-14-8-7-13-27(28)22-33(41)35(44)39-31(20-24-9-3-1-4-10-24)34(43)40-32(37(46)47)21-25-11-5-2-6-12-25/h1-18,30-33,42H,19-23,38H2,(H,39,44)(H,40,43)(H,46,47)/t30-,31-,32-,33-/m0/s1
DMI0U87 CS C1[C@H](N(CC2=CC=CC=C21)C(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)O
DMI0U87 IK JYOUATXRHWNDDW-YRCZKMHPSA-N
DMI0U87 IU (2S)-2-[[(2S)-2-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid
DMI0U87 CA CAS 146369-65-5
DMI0U87 DE Discovery agent
DM48F3D ID DM48F3D
DM48F3D DN HU210
DM48F3D HS Investigative
DM48F3D SN HU-210; HU 210; 112830-95-2; HU210; UNII-191042422P; CHEMBL307696; (-)-HU-210; 191042422P; (6aR-trans-3-(1, 1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; GTPL731; SCHEMBL1517460; DTXSID30150188; HU-210, solid (air sensitive); ZINC2572463; PDSP2_000201; BDBM50067499; MFCD01074786; AKOS024458716; (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; 924H455
DM48F3D DT Small molecular drug
DM48F3D PC 9821569
DM48F3D MW 386.6
DM48F3D FM C25H38O3
DM48F3D IC InChI=1S/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h10,14-15,19-20,26-27H,6-9,11-13,16H2,1-5H3/t19-,20-/m1/s1
DM48F3D CS CCCCCCC(C)(C)C1=CC(=C2[C@@H]3CC(=CC[C@H]3C(OC2=C1)(C)C)CO)O
DM48F3D IK SSQJFGMEZBFMNV-WOJBJXKFSA-N
DM48F3D IU (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DM48F3D CA CAS 112830-95-2
DM48F3D DE Discovery agent
DMPLG4R ID DMPLG4R
DMPLG4R DN HU-433
DMPLG4R HS Investigative
DMPLG4R SN CB2 activator (osteoporosis); CB2 activator (osteoporosis), Yissum
DMPLG4R CP Yissum Research Development Co
DMPLG4R PC 59386636
DMPLG4R MW 414.6
DMPLG4R FM C27H42O3
DMPLG4R IC InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3/t20?,21-,22+/m0/s1
DMPLG4R CS CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC)C2C=C([C@@H]3C[C@H]2C3(C)C)CO)OC
DMPLG4R IK CFMRIVODIXTERW-JTGIGXABSA-N
DMPLG4R IU [(1R,5R)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl]methanol
DMPLG4R DE Osteoporosis
DM8FLVH ID DM8FLVH
DM8FLVH DN Human CD40 agonist ligand
DM8FLVH HS Investigative
DM8FLVH SN Human CD40 agonist ligand (TNF receptor, cancer); Human CD40 agonist ligand (TNF receptor, cancer), ISA Pharmaceuticals; Agonistic anti-CD40 mAb (adjuvant, cancer), ISA
DM8FLVH CP ISA Pharmaceuticals BV
DM8FLVH DE Discovery agent
DMFV5UL ID DMFV5UL
DMFV5UL DN human monoclonal antibodies (GM-CSF)
DMFV5UL HS Investigative
DMFV5UL DE Discovery agent
DMARY2Z ID DMARY2Z
DMARY2Z DN Human recombinant factor VIIa
DMARY2Z HS Investigative
DMARY2Z SN Human recombinant factor VIIa (hemophilia A and B)
DMARY2Z CP Inspiration Biopharmaceuticals Inc
DMARY2Z DE Factor IX deficiency
DMG1BYH ID DMG1BYH
DMG1BYH DN Human recombinant factor VIII
DMG1BYH HS Investigative
DMG1BYH SN Human recombinant factor VIII (hemophilia A)
DMG1BYH CP Inspiration Biopharmaceuticals Inc
DMG1BYH DE Factor VIII deficiency
DM4FIZJ ID DM4FIZJ
DM4FIZJ DN HuMax-CD38b
DM4FIZJ HS Investigative
DM4FIZJ CP Genmab Inc
DM4FIZJ DE Solid tumour/cancer
DM8AG5R ID DM8AG5R
DM8AG5R DN HuMax-cMet
DM8AG5R HS Investigative
DM8AG5R SN CMet-targeting human IgG1 antibody (cancer), Genmab
DM8AG5R CP Genmab A/S
DM8AG5R DT Antibody
DM8AG5R DE Solid tumour/cancer
DMTPXB6 ID DMTPXB6
DMTPXB6 DN Huprine X
DMTPXB6 HS Investigative
DMTPXB6 SN rac-huprine H7; huprine x; CHEMBL143812; AC1L1GD8; SCHEMBL7115053; CTK6D0420; BDBM10597; NCI60_041180; 3-chloro-9-ethyl-6,7,10,11-tetrahydro-7,11-methanocycloocta[b]quinolin-12-amine; (1S)-7-chloro-15-ethyl-10-azatetracyclo[11.3.1.0^{2,11}.0^{4,9}]heptadeca-2(11),3,5,7,9,14-hexaen-3-amine
DMTPXB6 DT Small molecular drug
DMTPXB6 PC 3632
DMTPXB6 MW 298.8
DMTPXB6 FM C18H19ClN2
DMTPXB6 IC InChI=1S/C18H19ClN2/c1-2-10-5-11-7-12(6-10)17-16(8-11)21-15-9-13(19)3-4-14(15)18(17)20/h3-5,9,11-12H,2,6-8H2,1H3,(H2,20,21)
DMTPXB6 CS CCC1=CC2CC(C1)C3=C(C4=C(C=C(C=C4)Cl)N=C3C2)N
DMTPXB6 IK QTPHSDHUHXUYFE-UHFFFAOYSA-N
DMTPXB6 IU 7-chloro-15-ethyl-10-azatetracyclo[11.3.1.02,11.04,9]heptadeca-2,4(9),5,7,10,14-hexaen-3-amine
DMTPXB6 DE Discovery agent
DMYH0XQ ID DMYH0XQ
DMYH0XQ DN Huprine Y
DMYH0XQ HS Investigative
DMYH0XQ SN CHEMBL140476; rac-huprine H3; BDBM10592; BDBM50200340
DMYH0XQ DT Small molecular drug
DMYH0XQ PC 10107976
DMYH0XQ MW 284.8
DMYH0XQ FM C17H17ClN2
DMYH0XQ IC InChI=1S/C17H17ClN2/c1-9-4-10-6-11(5-9)16-15(7-10)20-14-8-12(18)2-3-13(14)17(16)19/h2-4,8,10-11H,5-7H2,1H3,(H2,19,20)
DMYH0XQ CS CC1=CC2CC(C1)C3=C(C4=C(C=C(C=C4)Cl)N=C3C2)N
DMYH0XQ IK UKCBMHDZLYYTMI-UHFFFAOYSA-N
DMYH0XQ IU 7-chloro-15-methyl-10-azatetracyclo[11.3.1.02,11.04,9]heptadeca-2,4(9),5,7,10,14-hexaen-3-amine
DMJ4ME7 ID DMJ4ME7
DMJ4ME7 DN Huprine-Tacrine Heterodimer
DMJ4ME7 HS Investigative
DMJ4ME7 DE Discovery agent
DM1D5F0 ID DM1D5F0
DM1D5F0 DN HwFwLL-NH2
DM1D5F0 HS Investigative
DM1D5F0 SN CHEMBL502208; HwFwLL-NH2
DM1D5F0 DT Small molecular drug
DM1D5F0 PC 44576249
DM1D5F0 MW 900.1
DM1D5F0 FM C49H61N11O6
DM1D5F0 IC InChI=1S/C49H61N11O6/c1-28(2)18-39(44(51)61)56-46(63)40(19-29(3)4)58-49(66)43(22-32-25-54-38-17-11-9-15-35(32)38)60-47(64)41(20-30-12-6-5-7-13-30)59-48(65)42(21-31-24-53-37-16-10-8-14-34(31)37)57-45(62)36(50)23-33-26-52-27-55-33/h5-17,24-29,36,39-43,53-54H,18-23,50H2,1-4H3,(H2,51,61)(H,52,55)(H,56,63)(H,57,62)(H,58,66)(H,59,65)(H,60,64)/t36-,39-,40-,41-,42+,43+/m0/s1
DM1D5F0 CS CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CC6=CN=CN6)N
DM1D5F0 IK RGMLIBBPSJGIRX-XLAQBFAFSA-N
DM1D5F0 IU (2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanamide
DM1D5F0 DE Discovery agent
DMJ9KNU ID DMJ9KNU
DMJ9KNU DN Hyacinthacine B3
DMJ9KNU HS Investigative
DMJ9KNU SN Hyacinthacine B3; CHEMBL524631
DMJ9KNU DT Small molecular drug
DMJ9KNU PC 10262292
DMJ9KNU MW 203.24
DMJ9KNU FM C9H17NO4
DMJ9KNU IC InChI=1S/C9H17NO4/c1-4-2-6(12)7-9(14)8(13)5(3-11)10(4)7/h4-9,11-14H,2-3H2,1H3/t4-,5-,6-,7-,8-,9+/m1/s1
DMJ9KNU CS C[C@@H]1C[C@H]([C@H]2N1[C@@H]([C@H]([C@H]2O)O)CO)O
DMJ9KNU IK PIBHCJDPQRCONN-MVEQLIQHSA-N
DMJ9KNU IU (1S,2R,3R,5R,7R,8R)-3-(hydroxymethyl)-5-methyl-2,3,5,6,7,8-hexahydro-1H-pyrrolizine-1,2,7-triol
DMJ9KNU DE Discovery agent
DMY5RDI ID DMY5RDI
DMY5RDI DN HYDAMTIQ
DMY5RDI HS Investigative
DMY5RDI SN PARP-1 inhibitor (brain ischemia), University of Perugia
DMY5RDI CP Universita di Perugia
DMY5RDI DE Brain ischaemia
DMOTXP1 ID DMOTXP1
DMOTXP1 DN Hydantocidin-5'-Monophosphate
DMOTXP1 HS Investigative
DMOTXP1 SN Hydantocidin-5'-phosphate; HYDANTOCIDIN-5'-PHOSPHATE; PHOSPHOHYDANTOCIDIN; CHEMBL323799; H5P; 1juy; HYDANTOCIDIN-5'-MONOPHOSPHATE; 5'-phosphohydantocidin; AC1L9JTE; HYDANTOCIDIN-5''-PHOSPHATE; BDBM50149203; HYDANTOCIDIN-5''-MONOPHOSPHATE; DB02493; HNP; Phosphoric acid mono-((5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-6-oxa-1,3-diaza-spiro[44]non-7-ylmethyl) ester; [(1R,2S,3R,5S)-1,2-dihydroxy-6,8-dioxo-4-oxa-7,9-diazaspiro[44]nonan-3-yl]methyl dihydrogen phosphate; [(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-6-oxa-1,3-diazaspiro[44]non-7-yl]methyl; Hydantocidin-5'-Phosphate
DMOTXP1 DT Small molecular drug
DMOTXP1 PC 446561
DMOTXP1 MW 298.14
DMOTXP1 FM C7H11N2O9P
DMOTXP1 IC InChI=1S/C7H11N2O9P/c10-3-2(1-17-19(14,15)16)18-7(4(3)11)5(12)8-6(13)9-7/h2-4,10-11H,1H2,(H2,14,15,16)(H2,8,9,12,13)/t2-,3-,4-,7+/m1/s1
DMOTXP1 CS C([C@@H]1[C@H]([C@H]([C@]2(O1)C(=O)NC(=O)N2)O)O)OP(=O)(O)O
DMOTXP1 IK HVXIMXHBUJADCC-GTBMBKLPSA-N
DMOTXP1 IU [(5S,7R,8S,9R)-8,9-dihydroxy-2,4-dioxo-6-oxa-1,3-diazaspiro[4.4]nonan-7-yl]methyl dihydrogen phosphate
DMOTXP1 DE Discovery agent
DMARWG5 ID DMARWG5
DMARWG5 DN HYDRAZINECARBOXAMIDE
DMARWG5 HS Investigative
DMARWG5 SN Aminourea; 57-56-7; Carbamylhydrazine; Carbazamide; Semikarbazid; Urea, amino-; Aminoharnstoff; Aminomocovina; Hydrazine, carbamoyl-; Carbamoylhydrazine; Carbamic acid, hydrazide; Carbamidsaeurehydrazid; Semikarbazid [Czech]; Aminomocovina [Czech]; UNII-37QUC23K2X; EINECS 200-339-6; CHEMBL903; BRN 0506319; 37QUC23K2X; CHEBI:28306; DUIOPKIIICUYRZ-UHFFFAOYSA-N; 4426-72-6; Hydrazinecarboxamide, hydrochloride (1:1); isosemicarbazide; amino-urea; 1-azanylurea; carbamic acid hydrazide; Lopac-S-2201
DMARWG5 DT Small molecular drug
DMARWG5 PC 5196
DMARWG5 MW 75.07
DMARWG5 FM CH5N3O
DMARWG5 IC InChI=1S/CH5N3O/c2-1(5)4-3/h3H2,(H3,2,4,5)
DMARWG5 CS C(=O)(N)NN
DMARWG5 IK DUIOPKIIICUYRZ-UHFFFAOYSA-N
DMARWG5 IU aminourea
DMARWG5 CA CAS 57-56-7
DMARWG5 CB CHEBI:28306
DMARWG5 DE Discovery agent
DM0HQF6 ID DM0HQF6
DM0HQF6 DN Hydrohalisulfate 1
DM0HQF6 HS Investigative
DM0HQF6 SN hydrohalisulfate 1; CHEMBL230058; BDBM50206259
DM0HQF6 DT Small molecular drug
DM0HQF6 PC 10874329
DM0HQF6 MW 468.7
DM0HQF6 FM C31H48O3
DM0HQF6 IC InChI=1S/C31H48O3/c1-21(11-13-24-19-25(32)14-15-27(24)33)9-7-10-23(3)28(34)20-26-22(2)12-16-29-30(4,5)17-8-18-31(26,29)6/h11-12,14-15,19,23,26,28-29,32-34H,7-10,13,16-18,20H2,1-6H3/b21-11+/t23-,26+,28-,29+,31-/m1/s1
DM0HQF6 CS CC1=CC[C@@H]2[C@@]([C@H]1C[C@H]([C@H](C)CCC/C(=C/CC3=C(C=CC(=C3)O)O)/C)O)(CCCC2(C)C)C
DM0HQF6 IK JZTPEJICPYCDGH-JWMGXGOZSA-N
DM0HQF6 IU 2-[(E,7R,8R)-9-[(1S,4aS,8aS)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-8-hydroxy-3,7-dimethylnon-2-enyl]benzene-1,4-diol
DM0HQF6 DE Discovery agent
DMWH92F ID DMWH92F
DMWH92F DN Hydrolyzed Cephalothin
DMWH92F HS Investigative
DMWH92F SN HYDROLYZED CEPHALOTHIN; 2-[CARBOXY-(2-THIOPHEN-2-YL-ACETYLAMINO)-METHYL]-5-METHYL-3,6-DIHYDRO-2H-[1,3]THIAZINE-4-CARBOXYLIC ACID; AC1NRBVK; DB02247; (2S)-2-[(R)-carboxy[2-(thiophen-2-yl)acetamido]methyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2S)-2-[(1R)-2-hydroxy-2-oxo-1-[(2-thiophen-2-ylacetyl)amino]ethyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; (2S)-2-{(R)-carboxy[(thiophen-2-ylacetyl)amino]methyl}-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMWH92F DT Small molecular drug
DMWH92F PC 5288660
DMWH92F MW 356.4
DMWH92F FM C14H16N2O5S2
DMWH92F IC InChI=1S/C14H16N2O5S2/c1-7-6-23-12(16-10(7)13(18)19)11(14(20)21)15-9(17)5-8-3-2-4-22-8/h2-4,11-12,16H,5-6H2,1H3,(H,15,17)(H,18,19)(H,20,21)/t11-,12-/m0/s1
DMWH92F CS CC1=C(N[C@@H](SC1)[C@@H](C(=O)O)NC(=O)CC2=CC=CS2)C(=O)O
DMWH92F IK JRYZEMHNDUZNMI-RYUDHWBXSA-N
DMWH92F IU (2S)-2-[(R)-carboxy-[(2-thiophen-2-ylacetyl)amino]methyl]-5-methyl-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid
DMWH92F DE Discovery agent
DMO32HN ID DMO32HN
DMO32HN DN HYDROSULFIDE
DMO32HN HS Investigative
DMO32HN SN hydrosulfide; sulfanide; HS anion; CHEMBL38703; CHEBI:29919; 15035-72-0; hydrosulphide; bisulfide; thiolate; Hydridesulfuranion; Hydrosulfide Anion; Hydrogensulfide Ion; hydrogen sulfide ion; sulfur(1-); Sulfide (HS1-); hydrogen(sulfide)(-1); hydrogen(sulfide)(1-); AC1NUTG4; AC1NNM8X; BDBM26990; RWSOTUBLDIXVET-UHFFFAOYSA-M; HS(-); HS(-1)
DMO32HN DT Small molecular drug
DMO32HN PC 5047209
DMO32HN MW 33.08
DMO32HN FM HS-
DMO32HN IC InChI=1S/H2S/h1H2/p-1
DMO32HN CS [SH-]
DMO32HN IK RWSOTUBLDIXVET-UHFFFAOYSA-M
DMO32HN IU sulfanide
DMO32HN CA CAS 15035-72-0
DMO32HN CB CHEBI:29919
DMO32HN DE Discovery agent
DMA4SIN ID DMA4SIN
DMA4SIN DN HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE
DMA4SIN HS Investigative
DMA4SIN SN N-hydroxy-N-[3-(6-methylpyridin-2-yl)propyl]formamide; SB-505684; HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE; SB9; AC1NRD3B; BDBM21685
DMA4SIN DT Small molecular drug
DMA4SIN PC 5289331
DMA4SIN MW 194.23
DMA4SIN FM C10H14N2O2
DMA4SIN IC InChI=1S/C10H14N2O2/c1-9-4-2-5-10(11-9)6-3-7-12(14)8-13/h2,4-5,8,14H,3,6-7H2,1H3
DMA4SIN CS CC1=NC(=CC=C1)CCCN(C=O)O
DMA4SIN IK FJYUGRZKJXCRFF-UHFFFAOYSA-N
DMA4SIN IU N-hydroxy-N-[3-(6-methylpyridin-2-yl)propyl]formamide
DMA4SIN DE Discovery agent
DMQFBH6 ID DMQFBH6
DMQFBH6 DN Hydroxyacetic acid
DMQFBH6 HS Investigative
DMQFBH6 SN glycolic acid; 2-Hydroxyacetic acid; hydroxyacetic acid; 79-14-1; Glycollic acid; Hydroxyethanoic acid; Acetic acid, hydroxy-; glycolate; Caswell No. 470; alpha-Hydroxyacetic acid; Kyselina glykolova; Kyselina glykolova [Czech]; Kyselina hydroxyoctova; HOCH2COOH; 2-Hydroxyethanoic acid; Kyselina hydroxyoctova [Czech]; Glycocide; EPA Pesticide Chemical Code 000101; GlyPure; HSDB 5227; NSC 166; Acetic acid, 2-hydroxy-; AI3-15362; UNII-0WT12SX38S; GlyPure 70; BRN 1209322; GLYCOLLATE; C2H4O3; Acetic acid, hydroxy-, homopolymer; EINECS 201-
DMQFBH6 DT Small molecular drug
DMQFBH6 PC 757
DMQFBH6 MW 76.05
DMQFBH6 FM C2H4O3
DMQFBH6 IC InChI=1S/C2H4O3/c3-1-2(4)5/h3H,1H2,(H,4,5)
DMQFBH6 CS C(C(=O)O)O
DMQFBH6 IK AEMRFAOFKBGASW-UHFFFAOYSA-N
DMQFBH6 IU 2-hydroxyacetic acid
DMQFBH6 CA CAS 79-14-1
DMQFBH6 CB CHEBI:17497
DMQFBH6 DE Discovery agent
DM5HWZY ID DM5HWZY
DM5HWZY DN Hydroxyalanine
DM5HWZY HS Investigative
DM5HWZY PC 18605011
DM5HWZY MW 105.09
DM5HWZY FM C3H7NO3
DM5HWZY IC InChI=1S/C3H7NO3/c1-2(4-7)3(5)6/h2,4,7H,1H3,(H,5,6)/t2-/m0/s1
DM5HWZY CS C[C@@H](C(=O)O)NO
DM5HWZY IK AWOUERYHOVSIAI-REOHCLBHSA-N
DM5HWZY IU (2S)-2-(hydroxyamino)propanoic acid
DM5HWZY CA CAS 21209-71-2
DM5HWZY DE Discovery agent
DMUVCRQ ID DMUVCRQ
DMUVCRQ DN Hydroxyaminovaline
DMUVCRQ HS Investigative
DMUVCRQ SN HYDROXYAMINOVALINE; (2R)-2-amino-N-hydroxy-3-methylbutanamide; 88244-32-0; HAV; n-hydroxy-d-valinamide; AC1L9GKY; SCHEMBL2512211; CTK3B5308; DTXSID10332162; ZINC3997609; AKOS006348422; DB02697; (R)-2-Amino-N-hydroxy-3-methylbutanamide; FT-0772977; Butanamide, 2-amino-N-hydroxy-3-methyl-, (2R)-
DMUVCRQ DT Small molecular drug
DMUVCRQ PC 444599
DMUVCRQ MW 132.16
DMUVCRQ FM C5H12N2O2
DMUVCRQ IC InChI=1S/C5H12N2O2/c1-3(2)4(6)5(8)7-9/h3-4,9H,6H2,1-2H3,(H,7,8)/t4-/m1/s1
DMUVCRQ CS CC(C)[C@H](C(=O)NO)N
DMUVCRQ IK USSBBYRBOWZYSB-SCSAIBSYSA-N
DMUVCRQ IU (2R)-2-amino-N-hydroxy-3-methylbutanamide
DMUVCRQ CA CAS 88244-32-0
DMUVCRQ DE Discovery agent
DM9H5EN ID DM9H5EN
DM9H5EN DN Hydroxybenzo(a)pyrene
DM9H5EN HS Investigative
DM9H5EN SN 3-Hydroxybenzo(a)pyrene; Benzo(a)pyrene, 3-hydroxy-; Benzo[def]chrysen-3-ol; Benzo[pqr]tetraphen-3-ol; SCHEMBL145489; benzo[a]pyren-3-ol; 13345-21-6; 3-Hydroxy Benzopyrene; 3-Hydroxy benzo[a]pyrene; 3-Hydroxy-3,4-benzo[a]pyrene; 3-Hydroxybenzo[a]pyrene; 3-hydroxybenz[a]pyrene; 4-06-00-05133 (Beilstein Handbook Reference); 672ICH1Q4L; 8-Hydroxy-3,4-benzpyrene; BENZO(a)PYREN-3-OL; AC1L19Z3; BIDD:ER0040; BP-3-Hydroxy; BRN 2333868; CCRIS 1071; CHEBI:34337; CHEMBL8020; CTK0H7534; DTXSID7038319; UNII-672ICH1Q4L
DM9H5EN PC 25890
DM9H5EN MW 268.3
DM9H5EN FM C20H12O
DM9H5EN IC SPUUWWRWIAEPDB-UHFFFAOYSA-N
DM9H5EN CS C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)O
DM9H5EN IK 1S/C20H12O/c21-18-10-7-12-5-8-16-15-4-2-1-3-13(15)11-14-6-9-17(18)19(12)20(14)16/h1-11,21H
DM9H5EN IU benzo[a]pyren-3-ol
DM9H5EN CA CAS 13345-21-6
DM9H5EN CB CHEBI:34337
DM9H5EN DE Discovery agent
DMFSKYE ID DMFSKYE
DMFSKYE DN Hydroxybenzo[a]pyrene
DMFSKYE HS Investigative
DMFSKYE SN Benzo[a]pyren-1-ol; 1-Hydroxybenzo(a)pyrene; 1-Hydroxybenzo[a]pyrene; 13345-23-8; 3-06-00-03808 (Beilstein Handbook Reference); AC1L19Z6; BENZO(a)PYREN-1-OL; SCHEMBL3341439; ZINC5935140; BRN 2380732; CCRIS 1070; CHEMBL1907999; CTK0H6930; DTXSID40158115
DMFSKYE PC 25891
DMFSKYE MW 268.3
DMFSKYE FM C20H12O
DMFSKYE IC GPIRWWPRDKGKPS-UHFFFAOYSA-N
DMFSKYE CS C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)O)C=C3
DMFSKYE IK 1S/C20H12O/c21-18-10-7-12-5-6-14-11-13-3-1-2-4-15(13)16-8-9-17(18)19(12)20(14)16/h1-11,21H
DMFSKYE IU benzo[a]pyren-1-ol
DMFSKYE CA CAS 13345-23-8
DMFSKYE DE Discovery agent
DM0PCWZ ID DM0PCWZ
DM0PCWZ DN Hydroxybutyryl-CoA
DM0PCWZ HS Investigative
DM0PCWZ SN CoA(4:0(OH)); Beta-hydroxybutyryl-CoA; Coenzyme A, 3-hydroxybutyryl-; Coenzyme A, S-(3-hydroxybutanoate); LMFA07050212; QHHKKMYHDBRONY-RMNRSTNRSA-N; S-(3-hydroxybutanoyl)-CoA; S-(3-hydroxybutanoyl)-coenzyme A; S-(3-hydroxybutyryl)-CoA; S-(3-hydroxybutyryl)-coenzyme A; beta-Hydroxybutyryl-coenzyme A; beta-hydroxybutyryl-CoA; 2871-66-1; 3-Hydroxybutyryl CoA; 3-Hydroxybutyryl-coenzyme A; 3-hydroxybutanoyl-CoA; 3-hydroxybutanoyl-coenzyme a; 3-hydroxybutyryl-CoA; 3HC; AC1LD8I5; C05116; CHEBI:37050; DB03612; DTXSID90951355; SCHEMBL60564
DM0PCWZ PC 644065
DM0PCWZ MW 853.6
DM0PCWZ FM C25H42N7O18P3S
DM0PCWZ IC QHHKKMYHDBRONY-RMNRSTNRSA-N
DM0PCWZ CS CC(CC(=O)SCCNC(=O)CCNC(=O)C(C(C)(C)COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O)O
DM0PCWZ IK 1S/C25H42N7O18P3S/c1-13(33)8-16(35)54-7-6-27-15(34)4-5-28-23(38)20(37)25(2,3)10-47-53(44,45)50-52(42,43)46-9-14-19(49-51(39,40)41)18(36)24(48-14)32-12-31-17-21(26)29-11-30-22(17)32/h11-14,18-20,24,33,36-37H,4-10H2,1-3H3,(H,27,34)(H,28,38)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t13?,14-,18-,19-,20+,24-/m1/s1
DM0PCWZ IU S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 3-hydroxybutanethioate
DM0PCWZ CA CAS 2871-66-1
DM0PCWZ CB CHEBI:37050
DM0PCWZ DE Discovery agent
DM6IEKW ID DM6IEKW
DM6IEKW DN Hydroxy-cholesten-one
DM6IEKW HS Investigative
DM6IEKW SN A-Hydroxy-4-cholesten-3-one; Cholest-4-en-7alpha-ol-3-one; 7 Alpha-hydroxy-4-cholesten-3-one; (7; (7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 3862-25-7; 4-Cholesten-7-alpha-ol-3-one; 7-Hydroxycholest-4-en-3-one; 7a-hydroxy-cholestene-3-one; 7alpha-Hydroxy-4-cholesten-3-one; 7alpha-Hydroxycholest-4-en-3-one; A)-7-Hydroxycholest-4-en-3-one
DM6IEKW PC 123743
DM6IEKW MW 400.6
DM6IEKW FM C27H44O2
DM6IEKW IC IOIZWEJGGCZDOL-RQDYSCIWSA-N
DM6IEKW CS CC(C)CCCC(C)C1CCC2C1(CCC3C2C(CC4=CC(=O)CCC34C)O)C
DM6IEKW IK 1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h15,17-18,21-25,29H,6-14,16H2,1-5H3/t18-,21-,22+,23+,24-,25+,26+,27-/m1/s1
DM6IEKW IU (7R,8S,9S,10R,13R,14S,17R)-7-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
DM6IEKW CA CAS 3862-25-7
DM6IEKW CB CHEBI:17899
DM6IEKW DE Discovery agent
DMY0A9E ID DMY0A9E
DMY0A9E DN Hydroxycitric acid
DMY0A9E HS Investigative
DMY0A9E SN SCHEMBL4050699; AKOS021667799; AKOS001495053; ES-2021; MCULE-2991610180; EU-0054396; SR-01000546484; SR-01000546484-1
DMY0A9E DT Small molecular drug
DMY0A9E PC 123908
DMY0A9E MW 208.12
DMY0A9E FM C6H8O8
DMY0A9E IC InChI=1S/C6H8O8/c7-2(8)1-6(14,5(12)13)3(9)4(10)11/h3,9,14H,1H2,(H,7,8)(H,10,11)(H,12,13)
DMY0A9E CS C(C(=O)O)C(C(C(=O)O)O)(C(=O)O)O
DMY0A9E IK ZMJBYMUCKBYSCP-UHFFFAOYSA-N
DMY0A9E IU 1,2-dihydroxypropane-1,2,3-tricarboxylic acid
DMY0A9E CA CAS 6205-14-7
DMY0A9E DE Discovery agent
DMFHCV9 ID DMFHCV9
DMFHCV9 DN hydroxycitronellal
DMFHCV9 HS Investigative
DMFHCV9 SN Hydroxycitronellal; 7-Hydroxy-3,7-dimethyloctanal; 107-75-5; 7-Hydroxycitronellal; Citronellal hydrate; 3,7-Dimethyl-7-hydroxyoctanal; Phixia; Laurine; Cyclosia; Cyclalia; Fixol; Lilyl aldehyde; Muguet synthetic; Musuet synthetic; Musuettine principle; Muguettine principle; Octanal, 7-hydroxy-3,7-dimethyl-; Citronellal, hydroxy-; hydroxy citronellal; Oxydihydrocitronellal; 7-Hydroxy-3,7-dimethyloctan-1-al; NSC 406740; FEMA No. 2583; CHEBI:53459; 1-OCTANAL, 3,7-DIMETHYL-7-HYDROXY-; EINECS 203-518-7; BRN 1721290; AI3-05823
DMFHCV9 DT Small molecular drug
DMFHCV9 PC 7888
DMFHCV9 MW 172.26
DMFHCV9 FM C10H20O2
DMFHCV9 IC InChI=1S/C10H20O2/c1-9(6-8-11)5-4-7-10(2,3)12/h8-9,12H,4-7H2,1-3H3
DMFHCV9 CS CC(CCCC(C)(C)O)CC=O
DMFHCV9 IK WPFVBOQKRVRMJB-UHFFFAOYSA-N
DMFHCV9 IU 7-hydroxy-3,7-dimethyloctanal
DMFHCV9 CA CAS 107-75-5
DMFHCV9 CB CHEBI:53459
DMFHCV9 DE Discovery agent
DM5DOEC ID DM5DOEC
DM5DOEC DN Hydroxyclemastine
DM5DOEC HS Investigative
DM5DOEC SN AC1O52GA; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidin-1-ium
DM5DOEC DT Small molecular drug
DM5DOEC PC 6426695
DM5DOEC MW 460
DM5DOEC FM C25H30ClNO5
DM5DOEC IC InChI=1S/C21H26ClNO.C4H4O4/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2;5-3(6)1-2-4(7)8/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t20-,21-;/m1./s1
DM5DOEC CS C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCC[NH+]3C.C(=C/C(=O)[O-])\\C(=O)O
DM5DOEC IK PMGQWSIVQFOFOQ-YKVZVUFRSA-N
DM5DOEC IU (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidin-1-ium;(E)-4-hydroxy-4-oxobut-2-enoate
DM5DOEC CA CAS 14976-57-9
DM5DOEC DE Discovery agent
DMPS2B1 ID DMPS2B1
DMPS2B1 DN Hydroxydimethylarsine Oxide
DMPS2B1 HS Investigative
DMPS2B1 SN Cacodylic acid; cacodylic acid; Dimethylarsinic acid; 75-60-5; Hydroxydimethylarsine oxide; Chexmate; Silvisar; Phytar; Arsan; Erase; DIMETHYLARSENIC ACID; Silvisar 510; Arsinic acid, dimethyl-; Phytar 560; Ansar 138; Sylvicor; Moncide; Dilic; Rad-e-cate 35; Agent Blue; Acide cacodylique; Alkargen; Phytar 138; Acide dimethylarsinique; Cotton aide HC; Kyselina kakodylova; RCRA waste number U136; Phytar 600; Caswell No 133; Arsine oxide, hydroxydimethyl-; Ansar; UNII-AJ2HL7EU8K; Acide cacodylique [French]; Kyselina kakodylova [Czech]
DMPS2B1 DT Small molecular drug
DMPS2B1 PC 2513
DMPS2B1 MW 138
DMPS2B1 FM C2H7AsO2
DMPS2B1 IC InChI=1S/C2H7AsO2/c1-3(2,4)5/h1-2H3,(H,4,5)
DMPS2B1 CS C[As](=O)(C)O
DMPS2B1 IK OGGXGZAMXPVRFZ-UHFFFAOYSA-N
DMPS2B1 IU dimethylarsinic acid
DMPS2B1 CA CAS 75-60-5
DMPS2B1 CB CHEBI:48765
DMPS2B1 DE Discovery agent
DMJXQME ID DMJXQME
DMJXQME DN Hydroxyestradiol
DMJXQME HS Investigative
DMJXQME SN 4-Hydroxy-17-beta-estradiol; 4-Hydroxyestradiol-17beta; 4-OH-Estradiol; 4-hydroxy-estradiol; 4-HYDROXYESTRADIOL; 4-hydroxyestradiol-17 beta; 4OHE2; 5976-61-4; C3ZO03450E; CHEBI:62845; MLS000069567; SMR000058747; UNII-C3ZO03450E; estra-1,3,5(10)-triene-2,4,17beta-triol; 4-Hydroxyestradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,4,17-triol; 1,3,5(10)-Estratriene-3,4,17beta-triol; 1,3,5[10]-ESTRATRIENE-3,4,17BETA-TRIOL; 3,4,17beta-estriol; 3,4,17beta-trihydroxy-1,3,5[10]-estratriene
DMJXQME PC 5282360
DMJXQME MW 288.4
DMJXQME FM C18H24O3
DMJXQME IC QOZFCKXEVSGWGS-ZHIYBZGJSA-N
DMJXQME CS CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4O)O
DMJXQME IK 1S/C18H24O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,16,19-21H,2-3,5,7-9H2,1H3/t11-,12-,14+,16+,18+/m1/s1
DMJXQME IU (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,4,17-triol
DMJXQME CA CAS 5976-61-4
DMJXQME CB CHEBI:62845
DMJXQME DE Discovery agent
DMBO7ZD ID DMBO7ZD
DMBO7ZD DN Hydroxyestrone
DMBO7ZD HS Investigative
DMBO7ZD SN Catecholestrone; LMST02010032; SCHEMBL222517; UQS3A06ILY; ZINC4096681; 2,3-Dihydroxyestra-1,3,5(10)-trien-17-one; 2,3-dihydroxy-estra-1,3,5(10)-trien-17-one; 2-HYDROXYESTRONE; 2-Hydroxy Estrone; 2-Hydroxyestrone; 2-OHE1; 362-06-1; 362H061; AC1L99N9; AKOS030254485; C-44096; C05298; CCRIS 9276; CHEBI:1156; CHEMBL1627343; CTK4H6079; DTXSID80904315; Estra-1,3,5(1)-trien-17-one, 2,3-dihydroxy-; Estra-1,3,5(10)-trien-17-one, 2,3-dihydroxy-; Estra-1,3,5(10)-trien-17-one,2,3-dihydroxy-; UNII-UQS3A06ILY
DMBO7ZD PC 440623
DMBO7ZD MW 286.4
DMBO7ZD FM C18H22O3
DMBO7ZD IC SWINWPBPEKHUOD-JPVZDGGYSA-N
DMBO7ZD CS CC12CCC3C(C1CCC2=O)CCC4=CC(=C(C=C34)O)O
DMBO7ZD IK 1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1
DMBO7ZD IU (8R,9S,13S,14S)-2,3-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
DMBO7ZD CA CAS 362-06-1
DMBO7ZD CB CHEBI:1156
DMBO7ZD DE Discovery agent
DMPGAR2 ID DMPGAR2
DMPGAR2 DN Hydroxymethylpyrene
DMPGAR2 HS Investigative
DMPGAR2 SN 1-Hydroxymethylpyrene; 1-Pyrenemethanol; KSC205I9L; MCULE-5243016090; NGDMLQSGYUCLDC-UHFFFAOYSA-N; Pyrenemethanol; RTR-011298; SCHEMBL505806; TRA0091121; ZINC2143350; pyren-1-ylmethanol; pyrenylmethan-1-ol; (1-pyrenyl)methanol; 1-(1-Hydroxymethyl)pyrene; 1-(Hydroxymethyl)pyrene; 1-Pyrenemethanol, 98%; 1-Pyrenylmethanol; 1-Pyrenylmethanol #; 24463-15-8; AC1L2XTN; AC1Q7C1N; AC1Q7CGU; ACMC-1CIST; AKOS005265175; ANW-25453; BIDD:GT0067; C76UX3EH8M; CCRIS 6510; CHEMBL1743299; CTK1A5495; DTXSID90179219; KS-00000WCR; MFCD00029252; UNII-C76UX3EH8M
DMPGAR2 PC 104977
DMPGAR2 MW 232.28
DMPGAR2 FM C17H12O
DMPGAR2 IC NGDMLQSGYUCLDC-UHFFFAOYSA-N
DMPGAR2 CS C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)CO
DMPGAR2 IK 1S/C17H12O/c18-10-14-7-6-13-5-4-11-2-1-3-12-8-9-15(14)17(13)16(11)12/h1-9,18H,10H2
DMPGAR2 IU pyren-1-ylmethanol
DMPGAR2 CA CAS 24463-15-8
DMPGAR2 DE Discovery agent
DMZN3GP ID DMZN3GP
DMZN3GP DN Hydroxytryptophol
DMZN3GP HS Investigative
DMZN3GP SN SCHEMBL233744; 5-Hydroxytryptophol; 154-02-9; 1H-Indole-3-ethanol, 5-hydroxy-; 3-(2-Hydroxyethyl)-1H-indol-5-ol; 4-21-00-02181 (Beilstein Handbook Reference); Hydroxytryptophol; INDOLE-3-ETHANOL, 5-HYDROXY-; KQROHCSYOGBQGJ-UHFFFAOYSA-N; 5-HTOL; 5-Hydroxy Tryptophol; 5-Hydroxy-1H-indole-3-ethanol; 5-Hydroxyindole-3-ethanol; 5-hydroxy-indole-acetic acid; 5-hydroxyindoacetic acid; 5-hydroxyindolacetate; 5-hydroxyindole-acetic acid; 52MNE52QA1; AC1L1S8D; BRN 0143517; EINECS 205-820-4; NSC 84416; UNII-52MNE52QA1
DMZN3GP PC 9061
DMZN3GP MW 177.2
DMZN3GP FM C10H11NO2
DMZN3GP IC KQROHCSYOGBQGJ-UHFFFAOYSA-N
DMZN3GP CS C1=CC2=C(C=C1O)C(=CN2)CCO
DMZN3GP IK 1S/C10H11NO2/c12-4-3-7-6-11-10-2-1-8(13)5-9(7)10/h1-2,5-6,11-13H,3-4H2
DMZN3GP IU 3-(2-hydroxyethyl)-1H-indol-5-ol
DMZN3GP CA CAS 154-02-9
DMZN3GP CB CHEBI:89825
DMZN3GP DE Discovery agent
DM7XISZ ID DM7XISZ
DM7XISZ DN HYG-440
DM7XISZ HS Investigative
DM7XISZ SN HYG-410; HYG-420; HYG-430; Androgen receptor antagonists (topical, dermatological disorder), hygeia
DM7XISZ CP Yale University
DM7XISZ DE Dermatological disease
DMEZ92A ID DMEZ92A
DMEZ92A DN Hygromycin B
DMEZ92A HS Investigative
DMEZ92A SN AC1NUSSH
DMEZ92A DT Small molecular drug
DMEZ92A PC 56928061
DMEZ92A MW 527.5
DMEZ92A FM C20H37N3O13
DMEZ92A IC InChI=1S/C20H37N3O13/c1-23-7-2-5(21)9(26)15(10(7)27)33-19-17-16(11(28)8(4-25)32-19)35-20(36-17)18(31)13(30)12(29)14(34-20)6(22)3-24/h5-19,23-31H,2-4,21-22H2,1H3/t5-,6+,7+,8-,9+,10-,11+,12-,13+,14-,15-,16+,17+,18-,19+,20?/m1/s1
DMEZ92A CS CN[C@H]1C[C@H]([C@@H]([C@H]([C@@H]1O)O[C@H]2[C@@H]3[C@H]([C@H]([C@H](O2)CO)O)OC4(O3)[C@@H]([C@H]([C@H]([C@H](O4)[C@H](CO)N)O)O)O)O)N
DMEZ92A IK GRRNUXAQVGOGFE-HUCHGKBZSA-N
DMEZ92A IU (3'R,3aS,4S,4'S,5'R,6R,6'R,7S,7aS)-4-[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1S)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol
DMEZ92A CA CAS 31282-04-9
DMEZ92A DE Discovery agent
DMETS37 ID DMETS37
DMETS37 DN HYNIC Analogue
DMETS37 HS Investigative
DMETS37 PC 91936660
DMETS37 MW 1018.2
DMETS37 FM C53H65N10O9S-
DMETS37 IC InChI=1S/C53H66N10O9S/c1-53(2,26-12-14-32-72-50-38-45(41-17-5-3-6-18-41)37-46(58-50)42-19-7-4-8-20-42)52-60-61-62-63(52)29-13-11-23-49(64)54-27-15-30-69-33-35-71-36-34-70-31-16-28-55-51(65)44-24-25-48(56-39-44)59-57-40-43-21-9-10-22-47(43)73(66,67)68/h3-10,17-22,24-25,37-39H,11-16,23,26-36,40H2,1-2H3,(H,54,64)(H,55,65)(H,66,67,68)/p-1
DMETS37 CS CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)C5=CN=C(C=C5)N=NCC6=CC=CC=C6S(=O)(=O)[O-]
DMETS37 IK OPZKREHSQYOWCZ-UHFFFAOYSA-M
DMETS37 IU 2-[[[5-[3-[2-[2-[3-[5-[5-[6-(4,6-diphenylpyridin-2-yl)oxy-2-methylhexan-2-yl]tetrazol-1-yl]pentanoylamino]propoxy]ethoxy]ethoxy]propylcarbamoyl]pyridin-2-yl]diazenyl]methyl]benzenesulfonate
DMETS37 DE Discovery agent
DMSIWD0 ID DMSIWD0
DMSIWD0 DN Hyodeoxycholic acid
DMSIWD0 HS Investigative
DMSIWD0 SN A-Dihydroxy-5; A-cholan-24-oic acid; DGABKXLVXPYZII-SIBKNCMHSA-N; HYODEOXYCHOLIC ACID; Hyodeoxycholate; Hyodeoxycholic acid (HDCA); Hyodesoxycholic acid; Hyodesoxycholsaeure; Iodeoxycholic acid; alpha-Hyodeoxycholic acid; 3alpha,6alpha-Dihydroxy-5beta-cholan-24-oic acid; 3alpha,6alpha-Dihydroxy-5beta-cholanic acid; 3alpha,6alpha-Dihydroxy-5beta-cholanoic acid; 6alpha-Hydroxylithocholate; 7-Deoxyhyocholic acid; 7A33Y6EHYK; 83-49-8; CHEBI:52023; HDCA; MFCD00003681; NSC 60672; UNII-7A33Y6EHYK
DMSIWD0 PC 5283820
DMSIWD0 MW 392.6
DMSIWD0 FM C24H40O4
DMSIWD0 IC DGABKXLVXPYZII-SIBKNCMHSA-N
DMSIWD0 CS CC(CCC(=O)O)C1CCC2C1(CCC3C2CC(C4C3(CCC(C4)O)C)O)C
DMSIWD0 IK 1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1
DMSIWD0 IU (4R)-4-[(3R,5R,6S,8S,9S,10R,13R,14S,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
DMSIWD0 CA CAS 83-49-8
DMSIWD0 CB CHEBI:52023
DMSIWD0 DE Discovery agent
DM0U8IV ID DM0U8IV
DM0U8IV DN hyp 9
DM0U8IV HS Investigative
DM0U8IV SN 2,4-(1-keto-hexyl) phloroglucinol
DM0U8IV DT Small molecular drug
DM0U8IV PC 15659415
DM0U8IV MW 322.4
DM0U8IV FM C18H26O5
DM0U8IV IC InChI=1S/C18H26O5/c1-3-5-7-9-12(19)16-14(21)11-15(22)17(18(16)23)13(20)10-8-6-4-2/h11,21-23H,3-10H2,1-2H3
DM0U8IV CS CCCCCC(=O)C1=C(C(=C(C=C1O)O)C(=O)CCCCC)O
DM0U8IV IK JRHOSBCIYWDGHN-UHFFFAOYSA-N
DM0U8IV IU 1-(3-hexanoyl-2,4,6-trihydroxyphenyl)hexan-1-one
DM0U8IV CA CAS 3118-34-1
DM0U8IV DE Discovery agent
DMW9HTL ID DMW9HTL
DMW9HTL DN HYP-10
DMW9HTL HS Investigative
DMW9HTL SN T-type calcium channel blockers (pain), Ewha Woman's University
DMW9HTL CP Ewha Woman's University
DMW9HTL DE Pain
DM2L3PE ID DM2L3PE
DM2L3PE DN Hyperforin
DM2L3PE HS Investigative
DM2L3PE SN hyperforin; 11079-53-1; hyperforine; hiperforina; UNII-RM741E34FP; CHEBI:5834; RM741E34FP; CHEMBL1237210; (1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione; (1R,5S,6R,7S)-4-hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; HSDB 7646; (+)-Hyperforin; Spectrum5_002025; SCHEMBL98723; CHEMBL501711; GTPL2764; SCHEMBL15557965; Hyperforin, >
DM2L3PE DT Small molecular drug
DM2L3PE PC 441298
DM2L3PE MW 536.8
DM2L3PE FM C35H52O4
DM2L3PE IC InChI=1S/C35H52O4/c1-22(2)13-12-19-33(11)27(16-14-23(3)4)21-34(20-18-25(7)8)30(37)28(17-15-24(5)6)31(38)35(33,32(34)39)29(36)26(9)10/h13-15,18,26-27,37H,12,16-17,19-21H2,1-11H3/t27-,33+,34+,35-/m0/s1
DM2L3PE CS CC(C)C(=O)[C@]12C(=O)C(=C([C@](C1=O)(C[C@@H]([C@@]2(C)CCC=C(C)C)CC=C(C)C)CC=C(C)C)O)CC=C(C)C
DM2L3PE IK KGSZHKRKHXOAMG-HQKKAZOISA-N
DM2L3PE IU (1R,5R,7S,8R)-4-hydroxy-8-methyl-3,5,7-tris(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-1-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione
DM2L3PE CA CAS 11079-53-1
DM2L3PE CB CHEBI:5834
DM2L3PE DE Discovery agent
DMJKIUX ID DMJKIUX
DMJKIUX DN hypoglaucin A
DMJKIUX HS Investigative
DMJKIUX SN (-)-hypoglaucine A
DMJKIUX DT Small molecular drug
DMJKIUX PC 71446540
DMJKIUX MW 867.1
DMJKIUX FM C46H74O15
DMJKIUX IC InChI=1S/C46H74O15/c1-20-9-14-46(55-19-20)22(3)32-29(61-46)17-28-26-8-7-24-16-25(10-12-44(24,5)27(26)11-13-45(28,32)6)57-43-41(58-30-15-21(2)33(48)37(52)35(30)50)40(36(51)31(18-47)59-43)60-42-39(54)38(53)34(49)23(4)56-42/h7,20-23,25-43,47-54H,8-19H2,1-6H3/t20-,21-,22-,23-,25-,26+,27-,28-,29-,30-,31+,32-,33+,34-,35-,36+,37+,38+,39+,40-,41+,42-,43+,44-,45-,46+/m0/s1
DMJKIUX CS C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O[C@H]9C[C@@H]([C@H]([C@H]([C@H]9O)O)O)C)C)C)C)OC1
DMJKIUX IK SRFKCMVQTOGLCC-NSNPDTTGSA-N
DMJKIUX IU (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5R,6R)-3-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'S,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(1S,2R,3R,4R,5S)-2,3,4-trihydroxy-5-methylcyclohexyl]oxyoxan-4-yl]oxy-6-methyloxane-3,4,5-triol
DMJKIUX DE Discovery agent
DMLSABI ID DMLSABI
DMLSABI DN Hypoxanthine
DMLSABI HS Investigative
DMLSABI DT Small molecular drug
DMLSABI PC 135398638
DMLSABI MW 136.11
DMLSABI FM C5H4N4O
DMLSABI IC InChI=1S/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
DMLSABI CS C1=NC2=C(N1)C(=O)NC=N2
DMLSABI IK FDGQSTZJBFJUBT-UHFFFAOYSA-N
DMLSABI IU 1,7-dihydropurin-6-one
DMLSABI CA CAS 68-94-0
DMLSABI CB CHEBI:17368
DMLSABI DE Discovery agent
DMWLJ5S ID DMWLJ5S
DMWLJ5S DN Hyrtiosulawesine
DMWLJ5S HS Investigative
DMWLJ5S SN Hyrtiosulawesine; CHEMBL465767; AC1LCSOD; BDBM50250398; (6-Hydroxy-9H-beta-carbolin-1-yl)-(5-hydroxy-1H-indol-3-yl)-methanone; (6-hydroxy-9H-beta-carbolin-1-yl)(5-hydroxy-1H-indol-3-yl)methanone; methanone, (5-hydroxy-1H-indol-3-yl)(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)-; (5-hydroxy-1H-indol-3-yl)-(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)methanone
DMWLJ5S DT Small molecular drug
DMWLJ5S PC 636664
DMWLJ5S MW 343.3
DMWLJ5S FM C20H13N3O3
DMWLJ5S IC InChI=1S/C20H13N3O3/c24-10-1-3-16-14(8-10)15(9-22-16)20(26)19-18-12(5-6-21-19)13-7-11(25)2-4-17(13)23-18/h1-9,22-25H
DMWLJ5S CS C1=CC2=C(C=C1O)C(=CN2)C(=O)C3=NC=CC4=C3NC5=C4C=C(C=C5)O
DMWLJ5S IK OATSYJQLKPRTBO-UHFFFAOYSA-N
DMWLJ5S IU (5-hydroxy-1H-indol-3-yl)-(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)methanone
DMWLJ5S DE Discovery agent
DMLU6VM ID DMLU6VM
DMLU6VM DN HZ-166
DMLU6VM HS Investigative
DMLU6VM SN Benzodiazepine derivatives (neuropathic pain); Benzodiazepine derivatives (neuropathic pain), Addiction Therapeutix
DMLU6VM CP University of Wisconsin-Milwaukee
DMLU6VM PC 10309028
DMLU6VM MW 356.4
DMLU6VM FM C21H16N4O2
DMLU6VM IC InChI=1S/C21H16N4O2/c1-3-14-8-9-17-15(11-14)19(16-7-5-6-10-22-16)23-12-18-20(21(26)27-4-2)24-13-25(17)18/h1,5-11,13H,4,12H2,2H3
DMLU6VM CS CCOC(=O)C1=C2CN=C(C3=C(N2C=N1)C=CC(=C3)C#C)C4=CC=CC=N4
DMLU6VM IK ZSEDMNMFODMQRD-UHFFFAOYSA-N
DMLU6VM IU ethyl 8-ethynyl-6-pyridin-2-yl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
DMLU6VM DE Neuropathic pain
DM7QE51 ID DM7QE51
DM7QE51 DN I-309
DM7QE51 HS Investigative
DM7QE51 SN 2050-48-8; bis(4-bromophenyl)sulfone; 4,4'-Sulfonylbis(bromobenzene); Bis(p-bromophenyl) sulfone; Sulfone, bis(p-bromophenyl); 4-Bromophenyl sulfone; 4,4'-Dibromodiphenyl sulfone; 1,1'-sulfonylbis(4-bromobenzene); 4,4'-Dibromodiphenylsulfone; Benzene, 1,1'-sulfonylbis[4-bromo-; 4,4'-DIBROMO DIPHENYL SULFONE; Bis(p-bromophenyl)sulfone; Benzene, 1,1'-sulfonylbis(4-bromo-; NSC 43047; BRN 2505841; 1-bromo-4-(4-bromophenyl)sulfonylbenzene; AI3-22602; AK112394; 1-bromo-4-(4-bromophenyl)sulfonyl-benzene
DM7QE51 DT Small molecular drug
DM7QE51 PC 95927
DM7QE51 MW 376.07
DM7QE51 FM C12H8Br2O2S
DM7QE51 IC InChI=1S/C12H8Br2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H
DM7QE51 CS C1=CC(=CC=C1S(=O)(=O)C2=CC=C(C=C2)Br)Br
DM7QE51 IK QBNABJXQGRVIRA-UHFFFAOYSA-N
DM7QE51 IU 1-bromo-4-(4-bromophenyl)sulfonylbenzene
DM7QE51 CA CAS 2050-48-8
DM7QE51 DE Discovery agent
DM1TQ7N ID DM1TQ7N
DM1TQ7N DN I-5
DM1TQ7N HS Investigative
DM1TQ7N SN SB-409513; 2-CHLORO-5-[4-(3-CHLORO-PHENYL)-2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-3-YLAMINO]-BENZOIC ACID; I-5; 2-chloro-5-{[4-(3-chlorophenyl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl]amino}benzoic acid; AC1L9LHU; 4-arylmaleimide deriv. 6-z; CHEMBL156987; BDBM8269; SCHEMBL10059345; HMS3303B04; HMS3305M22; DB01793; NCGC00241937-01; AB01092116-01; 2-(3-Carboxy-4-chlorophenylamino)-3-(3-chlorophenyl)maleimide; 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid
DM1TQ7N DT Small molecular drug
DM1TQ7N PC 448008
DM1TQ7N MW 377.2
DM1TQ7N FM C17H10Cl2N2O4
DM1TQ7N IC InChI=1S/C17H10Cl2N2O4/c18-9-3-1-2-8(6-9)13-14(16(23)21-15(13)22)20-10-4-5-12(19)11(7-10)17(24)25/h1-7H,(H,24,25)(H2,20,21,22,23)
DM1TQ7N CS C1=CC(=CC(=C1)Cl)C2=C(C(=O)NC2=O)NC3=CC(=C(C=C3)Cl)C(=O)O
DM1TQ7N IK ONVZFCHLOZUXRP-UHFFFAOYSA-N
DM1TQ7N IU 2-chloro-5-[[4-(3-chlorophenyl)-2,5-dioxopyrrol-3-yl]amino]benzoic acid
DM1TQ7N DE Discovery agent
DMFSAK3 ID DMFSAK3
DMFSAK3 DN IAA-94
DMFSAK3 HS Investigative
DMFSAK3 SN indanyloxyacetic acid 94; MK-473
DMFSAK3 DT Small molecular drug
DMFSAK3 PC 3667
DMFSAK3 MW 357.2
DMFSAK3 FM C17H18Cl2O4
DMFSAK3 IC InChI=1S/C17H18Cl2O4/c1-17(10-4-2-3-5-10)7-9-6-11(23-8-12(20)21)14(18)15(19)13(9)16(17)22/h6,10H,2-5,7-8H2,1H3,(H,20,21)
DMFSAK3 CS CC1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3CCCC3
DMFSAK3 IK RNOJGTHBMJBOSP-UHFFFAOYSA-N
DMFSAK3 IU 2-[(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-3H-inden-5-yl)oxy]acetic acid
DMFSAK3 CA CAS 53108-00-2
DMFSAK3 DE Discovery agent
DMIJ2GV ID DMIJ2GV
DMIJ2GV DN I-ABA
DMIJ2GV HS Investigative
DMIJ2GV SN N6-(4-amino-3-iodobenzyl)adenosine; IABA
DMIJ2GV DT Small molecular drug
DMIJ2GV PC 125348
DMIJ2GV MW 498.3
DMIJ2GV FM C17H19IN6O4
DMIJ2GV IC InChI=1S/C17H19IN6O4/c18-9-3-8(1-2-10(9)19)4-20-15-12-16(22-6-21-15)24(7-23-12)17-14(27)13(26)11(5-25)28-17/h1-3,6-7,11,13-14,17,25-27H,4-5,19H2,(H,20,21,22)/t11-,13-,14-,17-/m1/s1
DMIJ2GV CS C1=CC(=C(C=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)I)N
DMIJ2GV IK REGZQZHKIFOMRK-LSCFUAHRSA-N
DMIJ2GV IU (2R,3R,4S,5R)-2-[6-[(4-amino-3-iodophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMIJ2GV CA CAS 95523-14-1
DMIJ2GV DE Discovery agent
DM5X0JS ID DM5X0JS
DM5X0JS DN I-ABOPX
DM5X0JS HS Investigative
DM5X0JS SN BW-A522
DM5X0JS DT Small molecular drug
DM5X0JS PC 163889
DM5X0JS MW 575.4
DM5X0JS FM C23H22IN5O5
DM5X0JS IC InChI=1S/C23H22IN5O5/c1-2-9-28-22(32)19-21(29(23(28)33)11-13-3-8-17(25)16(24)10-13)27-20(26-19)14-4-6-15(7-5-14)34-12-18(30)31/h3-8,10H,2,9,11-12,25H2,1H3,(H,26,27)(H,30,31)
DM5X0JS CS CCCN1C(=O)C2=C(N=C(N2)C3=CC=C(C=C3)OCC(=O)O)N(C1=O)CC4=CC(=C(C=C4)N)I
DM5X0JS IK DKJMGIXWGPEEFF-UHFFFAOYSA-N
DM5X0JS IU 2-[4-[3-[(4-amino-3-iodophenyl)methyl]-2,6-dioxo-1-propyl-7H-purin-8-yl]phenoxy]acetic acid
DM5X0JS CA CAS 112533-64-9
DM5X0JS DE Discovery agent
DMOQIDG ID DMOQIDG
DMOQIDG DN IAI-100
DMOQIDG HS Investigative
DMOQIDG SN ADAM inhibitors (cancer); IAI-102; INCB-3531; INCB-3619; A disintegrin and metalloprotease inhibitors (cancer), Incyte;ADAM inhibitors (cancer), Incyte; HER-2 sheddase inhibitors (cancer), Incyte
DMOQIDG CP Incyte Corp
DMOQIDG DT Small molecular drug
DMOQIDG PC 11625778
DMOQIDG MW 413.5
DMOQIDG FM C22H27N3O5
DMOQIDG IC InChI=1S/C22H27N3O5/c1-30-21(28)25-14-22(9-10-22)13-17(19(26)23-29)18(25)20(27)24-11-7-16(8-12-24)15-5-3-2-4-6-15/h2-7,17-18,29H,8-14H2,1H3,(H,23,26)/t17-,18-/m0/s1
DMOQIDG CS COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCC(=CC3)C4=CC=CC=C4)C(=O)NO
DMOQIDG IK CKZHFOKQZRZCPF-ROUUACIJSA-N
DMOQIDG IU methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenyl-3,6-dihydro-2H-pyridine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate
DMOQIDG CA CAS 791826-72-7
DMOQIDG DE Solid tumour/cancer
DM8U4HE ID DM8U4HE
DM8U4HE DN IATX-FVIII
DM8U4HE HS Investigative
DM8U4HE SN ATX-F8 program (hemophilia A); Factor VIII inhibitor apitope (hemophilia A), Apitope; ATX-F8 program (hemophilia A), Apitope Technology
DM8U4HE CP Apitope Technology (Bristol) Ltd
DM8U4HE DE Factor VIII deficiency
DM8J24A ID DM8J24A
DM8J24A DN IBC 293
DM8J24A HS Investigative
DM8J24A SN IBC293; IBC-293
DM8J24A DT Small molecular drug
DM8J24A PC 2736690
DM8J24A MW 205.21
DM8J24A FM C10H11N3O2
DM8J24A IC InChI=1S/C10H11N3O2/c1-6(2)13-9-4-3-7(10(14)15)5-8(9)11-12-13/h3-6H,1-2H3,(H,14,15)
DM8J24A CS CC(C)N1C2=C(C=C(C=C2)C(=O)O)N=N1
DM8J24A IK RUTVRAJKELSHCC-UHFFFAOYSA-N
DM8J24A IU 1-propan-2-ylbenzotriazole-5-carboxylic acid
DM8J24A CA CAS 306935-41-1
DM8J24A CB CHEBI:92275
DM8J24A DE Discovery agent
DMRIG3O ID DMRIG3O
DMRIG3O DN iberiotoxin
DMRIG3O HS Investigative
DMRIG3O SN Iberiotoxin; IbTX; Iberiatoxin; 129203-60-7; Iberiotoxin_Smartox; GTPL4218; 12IBX001; LS-183325; Iberiotoxin, from Buthus tamulus, >
DMRIG3O DT Small molecular drug
DMRIG3O PC 16132435
DMRIG3O MW 4231
DMRIG3O FM C179H274N50O55S7
DMRIG3O IC InChI=1S/C179H274N50O55S7/c1-87(2)65-111-155(261)208-112(66-93-33-15-13-16-34-93)146(252)195-77-133(239)225-139(88(3)4)172(278)213-117(71-136(244)245)158(264)199-100(44-31-62-190-178(186)187)144(250)193-75-131(237)198-102(40-22-27-58-181)148(254)219-124(167(273)205-109(56-64-285-12)145(251)194-76-132(238)197-101(39-21-26-57-180)147(253)200-105(43-25-30-61-184)151(257)220-123-81-286-288-83-125(221-152(258)106(203-166(123)272)45-32-63-191-179(188)189)169(275)210-113(68-95-46-48-97(234)49-47-95)156(262)206-110(177(283)284)50-53-129(185)235)82-287-291-86-128(168(274)202-104(42-24-29-60-183)150(256)212-116(70-135(242)243)159(265)207-111)224-175(281)142(91(9)10)228-164(270)121(79-231)216-157(263)115(69-96-74-192-99-38-20-19-37-98(96)99)211-170(276)126-84-289-290-85-127(171(277)217-122(80-232)165(271)227-141(90(7)8)174(280)218-120(78-230)163(269)201-103(41-23-28-59-182)149(255)204-108(154(260)222-126)52-55-134(240)241)223-160(266)118(72-137(246)247)214-173(279)140(89(5)6)226-162(268)119(73-138(248)249)215-176(282)143(92(11)233)229-161(267)114(67-94-35-17-14-18-36-94)209-153(259)107-51-54-130(236)196-107/h13-20,33-38,46-49,74,87-92,100-128,139-143,192,230-234H,21-32,39-45,50-73,75-86,180-184H2,1-12H3,(H2,185,235)(H,193,250)(H,194,251)(H,195,252)(H,196,236)(H,197,238)(H,198,237)(H,199,264)(H,200,253)(H,201,269)(H,202,274)(H,203,272)(H,204,255)(H,205,273)(H,206,262)(H,207,265)(H,208,261)(H,209,259)(H,210,275)(H,211,276)(H,212,256)(H,213,278)(H,214,279)(H,215,282)(H,216,263)(H,217,277)(H,218,280)(H,219,254)(H,220,257)(H,221,258)(H,222,260)(H,223,266)(H,224,281)(H,225,239)(H,226,268)(H,227,271)(H,228,270)(H,229,267)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H,283,284)(H4,186,187,190)(H4,188,189,191)
DMRIG3O CS CC(C)CC1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CC(=O)O)CCCCN)NC(=O)C(C(C)C)NC(=O)C(CO)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C4CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)CCC(=O)O)CCCCN)CO)C(C)C)CO)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C6CCC(=O)N6)C(=O)NC(CCSC)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC7CSSCC(NC(=O)C(NC7=O)CCCNC(=N)N)C(=O)NC(CC8=CC=C(C=C8)O)C(=O)NC(CCC(=O)N)C(=O)O)CCCCN)CCCNC(=N)N)CC(=O)O)C(C)C)CC9=CC=CC=C9
DMRIG3O IK VDNVVLOBNHIMQA-UHFFFAOYSA-N
DMRIG3O IU 5-amino-2-[[2-[[10-[[6-amino-2-[[6-amino-2-[[2-[[2-[[7,34-bis(4-aminobutyl)-37-[[2-[[2-[[2-[[10-(4-aminobutyl)-22-[[3-carboxy-2-[[2-[[3-carboxy-2-[[3-hydroxy-2-[[2-[(5-oxopyrrolidine-2-carbonyl)amino]-3-phenylpropanoyl]amino]butanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-7-(2-carboxyethyl)-13,19-bis(hydroxymethyl)-6,9,12,15,18,21-hexaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-25-benzyl-13-(3-carbamimidamidopropyl)-16,31-bis(carboxymethyl)-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-19-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-7-(3-carbamimidamidopropyl)-6,9-dioxo-1,2-dithia-5,8-diazacycloundecane-4-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
DMRIG3O CA CAS 129203-60-7
DMRIG3O DE Discovery agent
DMYRUH2 ID DMYRUH2
DMYRUH2 DN I-BET151
DMYRUH2 HS Investigative
DMYRUH2 SN GSK1210151A
DMYRUH2 DT Small molecular drug
DMYRUH2 PC 52912189
DMYRUH2 MW 415.4
DMYRUH2 FM C23H21N5O3
DMYRUH2 IC InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1
DMYRUH2 CS CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC
DMYRUH2 IK VUVUVNZRUGEAHB-CYBMUJFWSA-N
DMYRUH2 IU 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one
DMYRUH2 CA CAS 1300031-49-5
DMYRUH2 CB CHEBI:95083
DMYRUH2 DE Discovery agent
DM3HJX7 ID DM3HJX7
DM3HJX7 DN Ibogaine
DM3HJX7 HS Investigative
DM3HJX7 DT Small molecular drug
DM3HJX7 PC 197060
DM3HJX7 MW 310.4
DM3HJX7 FM C20H26N2O
DM3HJX7 IC InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1
DM3HJX7 CS CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC
DM3HJX7 IK HSIBGVUMFOSJPD-CFDPKNGZSA-N
DM3HJX7 IU (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene
DM3HJX7 CA CAS 83-74-9
DM3HJX7 CB CHEBI:5852
DM3HJX7 DE Discovery agent
DMJAPML ID DMJAPML
DMJAPML DN I-BOP
DMJAPML HS Investigative
DMJAPML SN I-BOP; 128719-90-4; AC1NSK5B; GTPL1938; CHEMBL2113346; C23H29IO5; BDBM82512; ZINC13649924; 1795AH; CAS_128719-90-4; (Z)-7-[(1S,4R,5R,6R)-5-[(E,3R)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid; (Z)-7-[(1S,2R,3R,4R)-3-[(E,3R)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid; 7-[(1S,2R,3R,4R)-3-[(1E,3R)-3-HYDROXY-4-(4-IODOPHENOXY)-1-BUTENYL]-7-OXABICYCLO[2.2.1]HEPT-2-YL]-5Z-HEPTENOIC ACID
DMJAPML DT Small molecular drug
DMJAPML PC 5311175
DMJAPML MW 512.4
DMJAPML FM C23H29IO5
DMJAPML IC InChI=1S/C23H29IO5/c24-16-7-10-18(11-8-16)28-15-17(25)9-12-20-19(21-13-14-22(20)29-21)5-3-1-2-4-6-23(26)27/h1,3,7-12,17,19-22,25H,2,4-6,13-15H2,(H,26,27)/b3-1-,12-9+/t17-,19-,20-,21+,22-/m1/s1
DMJAPML CS C1C[C@@H]2[C@@H]([C@H]([C@H]1O2)C/C=C\\CCCC(=O)O)/C=C/[C@H](COC3=CC=C(C=C3)I)O
DMJAPML IK UYFMSCHBODMWON-HBHIRWTLSA-N
DMJAPML IU (Z)-7-[(1S,2R,3R,4R)-3-[(E,3R)-3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid
DMJAPML DE Discovery agent
DM8RZE0 ID DM8RZE0
DM8RZE0 DN ibotenate
DM8RZE0 HS Investigative
DM8RZE0 SN ibotenic acid
DM8RZE0 DT Small molecular drug
DM8RZE0 PC 1233
DM8RZE0 MW 158.11
DM8RZE0 FM C5H6N2O4
DM8RZE0 IC InChI=1S/C5H6N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h1,4H,6H2,(H,7,8)(H,9,10)
DM8RZE0 CS C1=C(ONC1=O)C(C(=O)O)N
DM8RZE0 IK IRJCBFDCFXCWGO-UHFFFAOYSA-N
DM8RZE0 IU 2-amino-2-(3-oxo-1,2-oxazol-5-yl)acetic acid
DM8RZE0 CA CAS 2552-55-8
DM8RZE0 CB CHEBI:5854
DM8RZE0 DE Discovery agent
DM9C8FP ID DM9C8FP
DM9C8FP DN I-BRD9
DM9C8FP HS Investigative
DM9C8FP SN GSK602; compound 45 [PMID 25856009]
DM9C8FP DT Small molecular drug
DM9C8FP PC 91668541
DM9C8FP MW 497.6
DM9C8FP FM C22H22F3N3O3S2
DM9C8FP IC InChI=1S/C22H22F3N3O3S2/c1-2-28-12-17(13-4-3-5-14(10-13)22(23,24)25)19-16(21(28)29)11-18(32-19)20(26)27-15-6-8-33(30,31)9-7-15/h3-5,10-12,15H,2,6-9H2,1H3,(H2,26,27)
DM9C8FP CS CCN1C=C(C2=C(C1=O)C=C(S2)C(=NC3CCS(=O)(=O)CC3)N)C4=CC(=CC=C4)C(F)(F)F
DM9C8FP IK WRUWGLUCNBMGPS-UHFFFAOYSA-N
DM9C8FP IU N'-(1,1-dioxothian-4-yl)-5-ethyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carboximidamide
DM9C8FP DE Discovery agent
DMUSRJ8 ID DMUSRJ8
DMUSRJ8 DN IBZM
DMUSRJ8 HS Investigative
DMUSRJ8 SN IBZM; Iodobenzamide; UNII-9J5D4ZN1JK; 9J5D4ZN1JK; S(-)-IBZM; CHEMBL267723; 123I-IBZM; (S)-(-)-IBZM; BRN 4322848; C15H21IN2O3; IOLOPRIDE; 3-Iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; (S)-N-(1-Ethyl-2-pyrrolidinyl)methyl-2-hydroxy-3-iodo-6-methoxybenzamide; n-{[(2s)-1-ethylpyrrolidin-2-yl]methyl}-2-hydroxy-3-iodo-6-methoxybenzamide; (S)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-hydroxy-3-iodo-6-methoxybenzamide; 84226-06-2; Benzamide, N-(((2S)-1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-3-iodo-6-methoxy-
DMUSRJ8 DT Small molecular drug
DMUSRJ8 PC 107995
DMUSRJ8 MW 404.24
DMUSRJ8 FM C15H21IN2O3
DMUSRJ8 IC InChI=1S/C15H21IN2O3/c1-3-18-8-4-5-10(18)9-17-15(20)13-12(21-2)7-6-11(16)14(13)19/h6-7,10,19H,3-5,8-9H2,1-2H3,(H,17,20)/t10-/m0/s1
DMUSRJ8 CS CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2O)I)OC
DMUSRJ8 IK CANPFCFJURGKAX-JTQLQIEISA-N
DMUSRJ8 IU N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-3-iodo-6-methoxybenzamide
DMUSRJ8 CA CAS 84226-06-2
DMUSRJ8 DE Discovery agent
DMRF5LU ID DMRF5LU
DMRF5LU DN IC-041
DMRF5LU HS Investigative
DMRF5LU SN Small molecule PDE 1 inhibitors (cognitive disorder), Intra-Cellular Therapies; PDE 1B inhibitor (small molecule therapeutic, cognitive disorder), Intra-Cellular
DMRF5LU CP Intra-Cellular Therapies Inc
DMRF5LU DE Cognitive impairment
DMWRVGE ID DMWRVGE
DMWRVGE DN IC86621
DMWRVGE HS Investigative
DMWRVGE SN DNA-PK Inhibitor III; 404009-40-1; IC86621; 1-(2-HYDROXY-4-MORPHOLINOPHENYL)ETHANONE; 1-(2-Hydroxy-4-morpholin-4-yl-phenyl)ethanone; CHEMBL1317546; Ethanone, 1-[2-hydroxy-4-(4-morpholinyl)phenyl]-; SCHEMBL600210; GTPL5960; CTK1D4579; CHEBI:95245; DTXSID40431950; MolPort-027-354-881; HMS3229C13; BCP08943; ZINC3817773; BDBM50398036; AR2783; 4512AH; IN1363; AKOS017560291; CCG-206744; NCGC00165807-01; AS-45440; IC 86621; RT-012395; 1-(2-hydroxy-4-morpholinophenyl)ethan-1-one; A-8048; 1-[2-hydroxy-4-(morpholin-4-yl)phenyl]ethan-1-one
DMWRVGE DT Small molecular drug
DMWRVGE PC 9859309
DMWRVGE MW 221.25
DMWRVGE FM C12H15NO3
DMWRVGE IC InChI=1S/C12H15NO3/c1-9(14)11-3-2-10(8-12(11)15)13-4-6-16-7-5-13/h2-3,8,15H,4-7H2,1H3
DMWRVGE CS CC(=O)C1=C(C=C(C=C1)N2CCOCC2)O
DMWRVGE IK YHKSBKQXCWHTQL-UHFFFAOYSA-N
DMWRVGE IU 1-(2-hydroxy-4-morpholin-4-ylphenyl)ethanone
DMWRVGE CA CAS 404009-40-1
DMWRVGE CB CHEBI:95245
DMWRVGE DE Discovery agent
DMM50ED ID DMM50ED
DMM50ED DN IC87114
DMM50ED HS Investigative
DMM50ED SN IC-87114; 371242-69-2; IC87114; 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one; IC 87114; UNII-9HC746B1KF; 2-[(6-AMINO-9H-PURIN-9-YL)METHYL]-5-METHYL-3-(2-METHYLPHENYL)-4(3H)-QUINAZOLINONE; 9HC746B1KF; CHEMBL1213082; CHEBI:90686; D-030; 2-[(6-aminopurin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one; 2-[(6-Amino-9h-Purin-9-Yl)methyl]-5-Methyl-3-(2-Methylphenyl)quinazolin-4(3h)-One; BiomolKI2_000002; GNWHRHGTIBRNSM-UHFFFAOYSA-N; PubChem22453; MLS006011148; SCHEMBL360745; GTPL9376; EX-A326
DMM50ED DT Small molecular drug
DMM50ED PC 9908783
DMM50ED MW 397.4
DMM50ED FM C22H19N7O
DMM50ED IC InChI=1S/C22H19N7O/c1-13-6-3-4-9-16(13)29-17(27-15-8-5-7-14(2)18(15)22(29)30)10-28-12-26-19-20(23)24-11-25-21(19)28/h3-9,11-12H,10H2,1-2H3,(H2,23,24,25)
DMM50ED CS CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C=NC5=C(N=CN=C54)N
DMM50ED IK GNWHRHGTIBRNSM-UHFFFAOYSA-N
DMM50ED IU 2-[(6-aminopurin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one
DMM50ED CA CAS 371242-69-2
DMM50ED CB CHEBI:90686
DMM50ED DE Discovery agent
DM8L6WB ID DM8L6WB
DM8L6WB DN IC980033
DM8L6WB HS Investigative
DM8L6WB DT Small molecular drug
DM8L6WB PC 24738776
DM8L6WB MW 541.7
DM8L6WB FM C25H45N6O7-
DM8L6WB IC InChI=1S/C19H32N2O5.C6H14N4O2/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;7-4(5(11)12)2-1-3-10-6(8)9/h12-16,20H,4-11H2,1-3H3,(H,23,24);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/p-1/t12-,13-,14-,15-,16-;4-/m00/s1
DM8L6WB CS CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.C(C[C@@H](C(=O)[O-])N)CN=C(N)N
DM8L6WB IK RYCSJJXKEWBUTI-YDYAIEMNSA-M
DM8L6WB IU (2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;(2S)-2-amino-5-(diaminomethylideneamino)pentanoate
DM8L6WB DE Discovery agent
DMS9H2P ID DMS9H2P
DMS9H2P DN ICA-105574
DMS9H2P HS Investigative
DMS9H2P SN ICA 105574; ICA105574
DMS9H2P DT Small molecular drug
DMS9H2P PC 715924
DMS9H2P MW 334.3
DMS9H2P FM C19H14N2O4
DMS9H2P IC InChI=1S/C19H14N2O4/c22-19(14-5-4-6-16(13-14)21(23)24)20-15-9-11-18(12-10-15)25-17-7-2-1-3-8-17/h1-13H,(H,20,22)
DMS9H2P CS C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
DMS9H2P IK GDWKBKTVROCPNZ-UHFFFAOYSA-N
DMS9H2P IU 3-nitro-N-(4-phenoxyphenyl)benzamide
DMS9H2P CA CAS 316146-57-3
DMS9H2P DE Discovery agent
DMO0N3Q ID DMO0N3Q
DMO0N3Q DN ICA-27243
DMO0N3Q HS Investigative
DMO0N3Q SN ICA 27243; ICA27243
DMO0N3Q DT Small molecular drug
DMO0N3Q PC 9903497
DMO0N3Q MW 268.64
DMO0N3Q FM C12H7ClF2N2O
DMO0N3Q IC InChI=1S/C12H7ClF2N2O/c13-11-4-2-8(6-16-11)17-12(18)7-1-3-9(14)10(15)5-7/h1-6H,(H,17,18)
DMO0N3Q CS C1=CC(=C(C=C1C(=O)NC2=CN=C(C=C2)Cl)F)F
DMO0N3Q IK GDGUOCFTHNGPBK-UHFFFAOYSA-N
DMO0N3Q IU N-(6-chloropyridin-3-yl)-3,4-difluorobenzamide
DMO0N3Q CA CAS 325457-89-4
DMO0N3Q DE Discovery agent
DM3DB8X ID DM3DB8X
DM3DB8X DN Icariside II
DM3DB8X HS Investigative
DM3DB8X SN Baohuoside I; 113558-15-9; Icariside II; CHEBI:82619; Icarlin II; Baohuoside-I; Baohuoside I;; Icarisid II;; AC1NUQWY; 3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside; SCHEMBL4229321; CHEMBL560116; DTXSID40150457; 2h44; MolPort-020-006-007; HY-N0011; ZINC70455423; C27H30O10; CS-3673; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; AK169968; anhydroicaritin-3-O-alpha-L-rhamnopyranoside; N2538; Y0106; FT-0686579; Q-100071
DM3DB8X DT Small molecular drug
DM3DB8X PC 5488822
DM3DB8X MW 514.5
DM3DB8X FM C27H30O10
DM3DB8X IC InChI=1S/C27H30O10/c1-12(2)5-10-16-17(28)11-18(29)19-21(31)26(37-27-23(33)22(32)20(30)13(3)35-27)24(36-25(16)19)14-6-8-15(34-4)9-7-14/h5-9,11,13,20,22-23,27-30,32-33H,10H2,1-4H3/t13-,20-,22+,23+,27-/m0/s1
DM3DB8X CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O)O)O
DM3DB8X IK NGMYNFJANBHLKA-LVKFHIPRSA-N
DM3DB8X IU 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DM3DB8X CA CAS 113558-15-9
DM3DB8X CB CHEBI:82619
DM3DB8X DE Discovery agent
DMQX3W6 ID DMQX3W6
DMQX3W6 DN I-CBP112
DMQX3W6 HS Investigative
DMQX3W6 SN 1640282-31-0; I-CBP 112; CHEMBL3774655; 1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; 1-[7-(3,4-dimethoxyphenyl)-9-{[(3S)-1-methylpiperidin-3-yl]methoxy}-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one; GTPL8236; SCHEMBL17620385; MolPort-035-765-871; EX-A2474; ZINC96024493; BDBM50151663; AKOS024458402; CS-6146; NCGC00350526-04; HY-19541; I-CBP112, >
DMQX3W6 DT Small molecular drug
DMQX3W6 PC 90488984
DMQX3W6 MW 468.6
DMQX3W6 FM C27H36N2O5
DMQX3W6 IC InChI=1S/C27H36N2O5/c1-5-26(30)29-11-12-33-27-22(17-29)13-21(20-8-9-23(31-3)24(14-20)32-4)15-25(27)34-18-19-7-6-10-28(2)16-19/h8-9,13-15,19H,5-7,10-12,16-18H2,1-4H3/t19-/m0/s1
DMQX3W6 CS CCC(=O)N1CCOC2=C(C1)C=C(C=C2OC[C@H]3CCCN(C3)C)C4=CC(=C(C=C4)OC)OC
DMQX3W6 IK YKNAKDFZAWQEEO-IBGZPJMESA-N
DMQX3W6 IU 1-[7-(3,4-dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]propan-1-one
DMQX3W6 DE Discovery agent
DMN6UET ID DMN6UET
DMN6UET DN ICI 154129
DMN6UET HS Investigative
DMN6UET SN ICI 154129; 83420-94-4; ICI-154129; UNII-97BUE7NR2M; ICI 154,129; N,N-Bis(allyl)-tyr-gly-gly-psi-methylthio-phe-leu; 97BUE7NR2M; M 154,129; M-154,129; N,N-Bis(allyl)-tyrosyl-glycyl-glycyl-psi-methylthio-phenylalanyl-leucine; N,N-Di-2-propenyl-L-tyrosylglycyl-(alphaS)-alpha-((2-aminoethyl)thio)benzenepropanoyl-L-leucine; Glycinamide, N,N-di-2-propenyl-L-tyrosyl-N-(2-((2-((1-carboxy-3-methylbutyl)amino)-2-oxo-1-(phenylmethyl)ethyl)thio)ethyl)-, (S-(R*,R*))-; L-Leucine, N,N-di-2-propenyl-L-tyrosylglycyl-(alphaS)-alpha-((2
DMN6UET DT Small molecular drug
DMN6UET PC 3035055
DMN6UET MW 638.8
DMN6UET FM C34H46N4O6S
DMN6UET IC InChI=1S/C34H46N4O6S/c1-5-17-38(18-6-2)29(21-26-12-14-27(39)15-13-26)32(41)36-23-31(40)35-16-19-45-30(22-25-10-8-7-9-11-25)33(42)37-28(34(43)44)20-24(3)4/h5-15,24,28-30,39H,1-2,16-23H2,3-4H3,(H,35,40)(H,36,41)(H,37,42)(H,43,44)/t28-,29-,30-/m0/s1
DMN6UET CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)SCCNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N(CC=C)CC=C
DMN6UET IK CZRZYRKTYLLLRL-DTXPUJKBSA-N
DMN6UET IU (2S)-2-[[(2S)-2-[2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]ethylsulfanyl]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMN6UET CA CAS 83420-94-4
DMN6UET DE Discovery agent
DMLPZ3N ID DMLPZ3N
DMLPZ3N DN ICI 200,355
DMLPZ3N HS Investigative
DMLPZ3N DT Small molecular drug
DMLPZ3N PC 10078636
DMLPZ3N MW 731.6
DMLPZ3N FM C30H34BrF3N4O7S
DMLPZ3N IC InChI=1S/C30H34BrF3N4O7S/c1-16(2)23(25(39)30(32,33)34)35-28(42)22-6-5-15-38(22)29(43)24(17(3)4)36-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,42)(H,36,40)(H,37,41)
DMLPZ3N CS CC(C)C(C(=O)C(F)(F)F)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Br
DMLPZ3N IK UUWIYANOKPHUQZ-UHFFFAOYSA-N
DMLPZ3N IU 4-N-(4-bromophenyl)sulfonyl-1-N-[3-methyl-1-oxo-1-[2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]benzene-1,4-dicarboxamide
DMLPZ3N DE Discovery agent
DM0PQ37 ID DM0PQ37
DM0PQ37 DN ICI 200,880
DM0PQ37 HS Investigative
DM0PQ37 DT Small molecular drug
DM0PQ37 PC 59911
DM0PQ37 MW 687.1
DM0PQ37 FM C30H34ClF3N4O7S
DM0PQ37 IC InChI=1S/C30H34ClF3N4O7S/c1-16(2)23(29(43)36-28(42)22-6-5-15-38(22)24(17(3)4)25(39)30(32,33)34)35-26(40)18-7-9-19(10-8-18)27(41)37-46(44,45)21-13-11-20(31)12-14-21/h7-14,16-17,22-24H,5-6,15H2,1-4H3,(H,35,40)(H,37,41)(H,36,42,43)/t22-,23-,24?/m0/s1
DM0PQ37 CS CC(C)[C@@H](C(=O)NC(=O)[C@@H]1CCCN1C(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C3=CC=C(C=C3)Cl
DM0PQ37 IK SMCMGLCPSSSOQE-NTZARQNWSA-N
DM0PQ37 IU 4-N-(4-chlorophenyl)sulfonyl-1-N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)pyrrolidine-2-carbonyl]amino]butan-2-yl]benzene-1,4-dicarboxamide
DM0PQ37 CA CAS 105080-50-0
DM0PQ37 DE Discovery agent
DM1D6CQ ID DM1D6CQ
DM1D6CQ DN ICI-174864
DM1D6CQ HS Investigative
DM1D6CQ SN Ici-174864; Ici 174864; N,N-Diallyl-tyr-aib-phe-leu; N,N-Diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine; L-Leucine, N-(N-(N-(N,N-di-2-propenyl-L-tyrosyl)-2-methylalanyl)-L-phenylalanyl)-; L-Leucine, N,N-di-2-propenyl-L-tyrosyl-2-methylalanyl-L-phenylalanyl-; AC1Q5QOV; AC1L32KD; SCHEMBL4402752; GTPL1636; PDSP2_001212; PDSP1_001228; n,n-di(prop-2-en-1-yl)-l-tyrosyl-2-methylalanyl-l-phenylalanyl-l-leucine; ICI-174,864; LS-178085
DM1D6CQ DT Small molecular drug
DM1D6CQ PC 107691
DM1D6CQ MW 606.8
DM1D6CQ FM C34H46N4O6
DM1D6CQ IC InChI=1S/C34H46N4O6/c1-7-18-38(19-8-2)29(22-25-14-16-26(39)17-15-25)31(41)37-34(5,6)33(44)36-27(21-24-12-10-9-11-13-24)30(40)35-28(32(42)43)20-23(3)4/h7-17,23,27-29,39H,1-2,18-22H2,3-6H3,(H,35,40)(H,36,44)(H,37,41)(H,42,43)/t27-,28-,29-/m0/s1
DM1D6CQ CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C(C)(C)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(CC=C)CC=C
DM1D6CQ IK BGJPRBZZLWCLJW-AWCRTANDSA-N
DM1D6CQ IU (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DM1D6CQ CA CAS 89352-67-0
DM1D6CQ DE Discovery agent
DMW4L3K ID DMW4L3K
DMW4L3K DN ICI-198583
DMW4L3K HS Investigative
DMW4L3K SN 112887-62-4; CB-3819
DMW4L3K DT Small molecular drug
DMW4L3K PC 135400203
DMW4L3K MW 476.5
DMW4L3K FM C25H24N4O6
DMW4L3K IC InChI=1S/C25H24N4O6/c1-3-12-29(14-16-4-9-20-19(13-16)24(33)27-15(2)26-20)18-7-5-17(6-8-18)23(32)28-21(25(34)35)10-11-22(30)31/h1,4-9,13,21H,10-12,14H2,2H3,(H,28,32)(H,30,31)(H,34,35)(H,26,27,33)/t21-/m0/s1
DMW4L3K CS CC1=NC2=C(C=C(C=C2)CN(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N1
DMW4L3K IK PMTUUSDTAKQWQJ-NRFANRHFSA-N
DMW4L3K IU (2S)-2-[[4-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]benzoyl]amino]pentanedioic acid
DMW4L3K CA CAS 112887-62-4
DMW4L3K DE Discovery agent
DMEWZ80 ID DMEWZ80
DMEWZ80 DN ICI-199441
DMEWZ80 HS Investigative
DMEWZ80 SN 115199-84-3; ICI-199,441 HYDROCHLORIDE; ICI 199,441 hydrochloride; Ici 199441; Ici 199,441; AC1MIZCX; N-(2-(N-Methyl-3,4-dichlorophenylacetamido)-2-phenylethyl)pyrrolidine; SCHEMBL7647023; CTK8E9897; MolPort-023-275-929; AKOS024458644; (S)-3,4-Dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)benzeneacetamide monohydrochloride; RT-013313; B6448; J-003264; Benzeneacetamide, 3,4-dichloro-N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-, monohydrochloride, (S)-
DMEWZ80 DT Small molecular drug
DMEWZ80 PC 3082718
DMEWZ80 MW 391.3
DMEWZ80 FM C21H24Cl2N2O
DMEWZ80 IC InChI=1S/C21H24Cl2N2O/c1-24(21(26)14-16-9-10-18(22)19(23)13-16)20(15-25-11-5-6-12-25)17-7-3-2-4-8-17/h2-4,7-10,13,20H,5-6,11-12,14-15H2,1H3/t20-/m1/s1
DMEWZ80 CS CN([C@H](CN1CCCC1)C2=CC=CC=C2)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DMEWZ80 IK AEJOEPSMZCEYJN-HXUWFJFHSA-N
DMEWZ80 IU 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide
DMEWZ80 CA CAS 116508-24-8
DMEWZ80 CB CHEBI:93291
DMEWZ80 DE Discovery agent
DMNA8RS ID DMNA8RS
DMNA8RS DN ICI-204448
DMNA8RS HS Investigative
DMNA8RS SN 121264-04-8
DMNA8RS DT Small molecular drug
DMNA8RS PC 3683
DMNA8RS MW 465.4
DMNA8RS FM C23H26Cl2N2O4
DMNA8RS IC InChI=1S/C23H26Cl2N2O4/c1-26(22(28)12-16-7-8-19(24)20(25)11-16)21(14-27-9-2-3-10-27)17-5-4-6-18(13-17)31-15-23(29)30/h4-8,11,13,21H,2-3,9-10,12,14-15H2,1H3,(H,29,30)
DMNA8RS CS CN(C(CN1CCCC1)C2=CC(=CC=C2)OCC(=O)O)C(=O)CC3=CC(=C(C=C3)Cl)Cl
DMNA8RS IK JKYJSFISYHSNOE-UHFFFAOYSA-N
DMNA8RS IU 2-[3-[1-[[2-(3,4-dichlorophenyl)acetyl]-methylamino]-2-pyrrolidin-1-ylethyl]phenoxy]acetic acid
DMNA8RS CB CHEBI:91666
DMNA8RS DE Discovery agent
DMYRILU ID DMYRILU
DMYRILU DN ICI-211965
DMYRILU HS Investigative
DMYRILU SN 129424-08-4; ZM-211965
DMYRILU DT Small molecular drug
DMYRILU PC 164272
DMYRILU MW 389.5
DMYRILU FM C24H23NO2S
DMYRILU IC InChI=1S/C24H23NO2S/c1-3-24(26-2,23-25-13-14-28-23)21-9-6-10-22(16-21)27-17-18-11-12-19-7-4-5-8-20(19)15-18/h4-16H,3,17H2,1-2H3
DMYRILU CS CCC(C1=CC(=CC=C1)OCC2=CC3=CC=CC=C3C=C2)(C4=NC=CS4)OC
DMYRILU IK XYRDHZXSQUWVCD-UHFFFAOYSA-N
DMYRILU IU 2-[1-methoxy-1-[3-(naphthalen-2-ylmethoxy)phenyl]propyl]-1,3-thiazole
DMYRILU CA CAS 129424-08-4
DMYRILU DE Discovery agent
DMYVOL9 ID DMYVOL9
DMYVOL9 DN icilin
DMYVOL9 HS Investigative
DMYVOL9 SN Icilin; 36945-98-9; AG 3-5; 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one; Icilin(AG 3-5); UNII-CS70PZQ4QJ; ICILLIN; 2(1H)-Pyrimidinone, 3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-; CS70PZQ4QJ; BRN 0700310; CHEMBL258405; 3,6-Dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-2(1H)-pyrimidinone; AG-3-5; 1-(2-Hydroxyphenyl)-4-(3-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one; 2(1H)-Pyrimidinone,3,6-dihydro-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-
DMYVOL9 DT Small molecular drug
DMYVOL9 PC 161930
DMYVOL9 MW 311.29
DMYVOL9 FM C16H13N3O4
DMYVOL9 IC InChI=1S/C16H13N3O4/c20-15-7-2-1-6-14(15)18-9-8-13(17-16(18)21)11-4-3-5-12(10-11)19(22)23/h1-8,10,20H,9H2,(H,17,21)
DMYVOL9 CS C1C=C(NC(=O)N1C2=CC=CC=C2O)C3=CC(=CC=C3)[N+](=O)[O-]
DMYVOL9 IK RCEFMOGVOYEGJN-UHFFFAOYSA-N
DMYVOL9 IU 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one
DMYVOL9 CA CAS 36945-98-9
DMYVOL9 CB CHEBI:92845
DMYVOL9 DE Discovery agent
DMF1CM7 ID DMF1CM7
DMF1CM7 DN Icosapentum
DMF1CM7 HS Investigative
DMF1CM7 SN Eicosapentaenoic acid; Icosapent; Icosapent [INN]; Icosapentaenoic acid; Icosapento; Cis-5,8,11,14,17-eicosapentaenoic acid; Timnodonic acid; (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid; (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid; (all-Z)-5,8,11,14,17-Eicosapentaenoic acid; 10417-94-4; 5,8,11,14,17-EICOSAPENTAENOIC ACID; 5,8,11,14,17-Icosapentaenoic acid; 5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid; AAN7QOV9EA; C20:5 omega-3; CCRIS 3279; CHEBI:28364; CHEMBL460026; EPA; UNII-AAN7QOV9EA; cis-5,8,11,14,17-Eicosapentaenoic acid
DMF1CM7 PC 446284
DMF1CM7 MW 302.5
DMF1CM7 FM C20H30O2
DMF1CM7 IC JAZBEHYOTPTENJ-JLNKQSITSA-N
DMF1CM7 CS CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O
DMF1CM7 IK 1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
DMF1CM7 IU (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
DMF1CM7 CA CAS 10417-94-4
DMF1CM7 CB CHEBI:28364
DMF1CM7 DE Discovery agent
DMH4KGX ID DMH4KGX
DMH4KGX DN ICR 62
DMH4KGX HS Investigative
DMH4KGX DT Antibody
DMH4KGX DE Discovery agent
DM9DXRL ID DM9DXRL
DM9DXRL DN ICRF-154
DM9DXRL HS Investigative
DM9DXRL SN Ethyliminum; 1506-47-4; Icrf-154; 1,2-Bis(3,5-dioxopiperazin-1-yl)ethane; UNII-QML51S42CD; QML51S42CD; 4-[2-(3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione; 4,4'-ethane-1,2-diyldipiperazine-2,6-dione; NSC-129942; NSC 129942; AI3-52846; AC1Q6LVJ; 2, 4,4'-ethylenedi-; AC1L2IM2; salor-int l163228-1ea; SCHEMBL728996; CHEMBL2361164; CTK4C6725; DTXSID40164579; MolPort-002-546-041; GBLIGNUYGOFIKS-UHFFFAOYSA-N; ZINC19367672; NSC129942; STK700954; 2, 4,4'-(1,2-ethanediyl)bis-; AKOS000646070; MCULE-3427635262; API0009072
DM9DXRL DT Small molecular drug
DM9DXRL PC 72760
DM9DXRL MW 254.24
DM9DXRL FM C10H14N4O4
DM9DXRL IC InChI=1S/C10H14N4O4/c15-7-3-13(4-8(16)11-7)1-2-14-5-9(17)12-10(18)6-14/h1-6H2,(H,11,15,16)(H,12,17,18)
DM9DXRL CS C1C(=O)NC(=O)CN1CCN2CC(=O)NC(=O)C2
DM9DXRL IK GBLIGNUYGOFIKS-UHFFFAOYSA-N
DM9DXRL IU 4-[2-(3,5-dioxopiperazin-1-yl)ethyl]piperazine-2,6-dione
DM9DXRL CA CAS 1506-47-4
DM9DXRL DE Discovery agent
DMPH8E9 ID DMPH8E9
DMPH8E9 DN ICT-037
DMPH8E9 HS Investigative
DMPH8E9 SN Anticancer mAbs, Immunocellular Therapeutics; ICT-37; Monoclonal antibodies (cancer), Immunocellular Therapeutics
DMPH8E9 CP Molecular Discoveries LLC
DMPH8E9 DT Antibody
DMPH8E9 DE Solid tumour/cancer
DM3P7W5 ID DM3P7W5
DM3P7W5 DN IDD552
DM3P7W5 HS Investigative
DM3P7W5 SN IDD552; CHEMBL399598; [5-FLUORO-2-({[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]AMINO}CARBONYL)PHENOXY]ACETIC ACID; ID5; AC1L9M77; SCHEMBL5462044; ZCAGEXZTORJQDZ-UHFFFAOYSA-N; BDBM50222611; DB02834; {5-fluoro-2[(4,5,7-trifluoro-benzothiazol-2-ylmethyl)carbamoyl]-phenoxy}-acetic acid; 5-fluoro-2-{[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]carbamoyl}phenoxyacetic acid; 2-[5-fluoro-2-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methylcarbamoyl]phenoxy]acetic acid
DM3P7W5 DT Small molecular drug
DM3P7W5 PC 448658
DM3P7W5 MW 414.3
DM3P7W5 FM C17H10F4N2O4S
DM3P7W5 IC InChI=1S/C17H10F4N2O4S/c18-7-1-2-8(11(3-7)27-6-13(24)25)17(26)22-5-12-23-15-14(21)9(19)4-10(20)16(15)28-12/h1-4H,5-6H2,(H,22,26)(H,24,25)
DM3P7W5 CS C1=CC(=C(C=C1F)OCC(=O)O)C(=O)NCC2=NC3=C(C(=CC(=C3S2)F)F)F
DM3P7W5 IK ZCAGEXZTORJQDZ-UHFFFAOYSA-N
DM3P7W5 IU 2-[5-fluoro-2-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methylcarbamoyl]phenoxy]acetic acid
DM3P7W5 DE Discovery agent
DMDHLG3 ID DMDHLG3
DMDHLG3 DN IDD594
DMDHLG3 HS Investigative
DMDHLG3 SN IDD594; CHEMBL395347; {2-[(4-bromo-2-fluorobenzyl)carbamothioyl]-5-fluorophenoxy}acetic acid; [2-(4-BROMO-2-FLUORO-BENZYLTHIOCARBAMOYL)-5-FLUORO-PHENOXY]-ACETIC ACID; AC1N9ZWX; SCHEMBL5467958; BDBM16313; IDD 594; IDD-594; ZINC13137482; AKOS032949406; DB08084; 2-[2-[(4-bromo-2-fluorophenyl)methylcarbamothioyl]-5-fluorophenoxy]acetic acid; 2-(2-{[(4-bromo-2-fluorophenyl)methyl]carbamothioyl}-5-fluorophenoxy)acetic acid; 2-{[(4-bromo-2-fluorophenyl)methyl]carbamothioyl}-5-fluorophenoxyacetic acid
DMDHLG3 DT Small molecular drug
DMDHLG3 PC 4369325
DMDHLG3 MW 416.2
DMDHLG3 FM C16H12BrF2NO3S
DMDHLG3 IC InChI=1S/C16H12BrF2NO3S/c17-10-2-1-9(13(19)5-10)7-20-16(24)12-4-3-11(18)6-14(12)23-8-15(21)22/h1-6H,7-8H2,(H,20,24)(H,21,22)
DMDHLG3 CS C1=CC(=C(C=C1F)OCC(=O)O)C(=S)NCC2=C(C=C(C=C2)Br)F
DMDHLG3 IK JCZUIWYXULSXSW-UHFFFAOYSA-N
DMDHLG3 IU 2-[2-[(4-bromo-2-fluorophenyl)methylcarbamothioyl]-5-fluorophenoxy]acetic acid
DMDHLG3 DE Discovery agent
DMBFX5H ID DMBFX5H
DMBFX5H DN IDDBCP226234
DMBFX5H HS Investigative
DMBFX5H SN Serine/threonine-protein kinase PIM-2 inhibitor (inflammation), Boehringer Ingelheim
DMBFX5H CP Boehringer Ingelheim Corp
DMBFX5H DE Inflammation
DMRQSN2 ID DMRQSN2
DMRQSN2 DN IDN-1965
DMRQSN2 HS Investigative
DMRQSN2 SN IDN-1965; GONUYDANRODTCF-IBYPIGCZSA-N; IDN 1965; 204919-14-2; CHEMBL198068; SCHEMBL5668068; LS-101833; N-[(1.3-dimethylindole-2-carbonyl)valinyl]-3-amino-4-oxo-5-fluoropentanoic Acid; N-[(1,3-Dimethylindole-2-Carbonyl)Valinyl]-3-Amino-4-Oxo-5-Fluoropentanoic Acid; Pentanoic acid, 3-(((2S)-2-(((1,3-dimethyl-1H-indol-2-yl)carbonyl)amino)-3-methyl-1-oxobutyl)amino)-5-fluoro-4-oxo-
DMRQSN2 DT Small molecular drug
DMRQSN2 PC 9802179
DMRQSN2 MW 419.4
DMRQSN2 FM C21H26FN3O5
DMRQSN2 IC InChI=1S/C21H26FN3O5/c1-11(2)18(20(29)23-14(9-17(27)28)16(26)10-22)24-21(30)19-12(3)13-7-5-6-8-15(13)25(19)4/h5-8,11,14,18H,9-10H2,1-4H3,(H,23,29)(H,24,30)(H,27,28)/t14?,18-/m0/s1
DMRQSN2 CS CC1=C(N(C2=CC=CC=C12)C)C(=O)N[C@@H](C(C)C)C(=O)NC(CC(=O)O)C(=O)CF
DMRQSN2 IK GONUYDANRODTCF-IBYPIGCZSA-N
DMRQSN2 IU 3-[[(2S)-2-[(1,3-dimethylindole-2-carbonyl)amino]-3-methylbutanoyl]amino]-5-fluoro-4-oxopentanoic acid
DMRQSN2 CA CAS 204919-14-2
DMRQSN2 DE Discovery agent
DMNS9KW ID DMNS9KW
DMNS9KW DN IDN-5174
DMNS9KW HS Investigative
DMNS9KW SN Camptothecin analogs (anticancer); Camptothecin analogs (anticancer), Indena
DMNS9KW CP Indena SpA
DMNS9KW DE Solid tumour/cancer
DM1OMSW ID DM1OMSW
DM1OMSW DN IDN-5390
DM1OMSW HS Investigative
DM1OMSW SN IDN-5868; IDN-5869; IDN-6140; Paclitaxel derivatives, Indena; 14-OH DAB
DM1OMSW CP Indena SpA
DM1OMSW DT Small molecular drug
DM1OMSW PC 44405214
DM1OMSW MW 787.9
DM1OMSW FM C41H57NO14
DM1OMSW IC InChI=1S/C41H57NO14/c1-21(2)18-26(42-37(50)56-38(6,7)8)32(46)36(49)53-27-19-41(51)34(54-35(48)25-14-12-11-13-15-25)30(40(55-24(5)44)20-52-28(40)16-17-43)23(4)31(45)33(47)29(22(27)3)39(41,9)10/h11-15,21,26-28,30,32,34,43,45-46,51H,16-20H2,1-10H3,(H,42,50)/b31-23+/t26-,27-,28+,30+,32+,34-,40-,41+/m0/s1
DM1OMSW CS CC1=C2C(=O)/C(=C(\\[C@H]([C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](CC(C)C)NC(=O)OC(C)(C)C)O)O)OC(=O)C3=CC=CC=C3)[C@@]4(CO[C@@H]4CCO)OC(=O)C)/C)/O
DM1OMSW IK UKFDBDGJFYRBHE-QWSJSTABSA-N
DM1OMSW IU [(1S,2S,3R,4E,9S)-3-[(2R,3S)-3-acetyloxy-2-(2-hydroxyethyl)oxetan-3-yl]-1,5-dihydroxy-9-[(2R,3S)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]oxy-4,8,11,11-tetramethyl-6-oxo-2-bicyclo[5.3.1]undeca-4,7-dienyl] benzoate
DM1OMSW DE Solid tumour/cancer
DM6TEWZ ID DM6TEWZ
DM6TEWZ DN IDN-6384
DM6TEWZ HS Investigative
DM6TEWZ SN Topoisomerase Ib inhibitor (cancer), Indena
DM6TEWZ CP Indena SpA
DM6TEWZ DE Solid tumour/cancer
DMOU234 ID DMOU234
DMOU234 DN IGEL1.2
DMOU234 HS Investigative
DMOU234 DT Aptamer
DMOU234 DE Allergy
DMFMY1L ID DMFMY1L
DMFMY1L DN IGERNELLIN
DMFMY1L HS Investigative
DMFMY1L SN igernellin; CHEMBL442427; SCHEMBL6834704
DMFMY1L DT Small molecular drug
DMFMY1L PC 9947690
DMFMY1L MW 372.6
DMFMY1L FM C25H40O2
DMFMY1L IC InChI=1S/C25H40O2/c1-20(13-14-24-21(2)9-7-16-25(24,3)4)8-5-10-22(18-26)11-6-12-23-15-17-27-19-23/h8-9,15,17,19,22,24,26H,5-7,10-14,16,18H2,1-4H3/b20-8+
DMFMY1L CS CC1=CCCC(C1CC/C(=C/CCC(CCCC2=COC=C2)CO)/C)(C)C
DMFMY1L IK UJVZMYQCMKGVLL-DNTJNYDQSA-N
DMFMY1L IU (E)-2-[3-(furan-3-yl)propyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)oct-5-en-1-ol
DMFMY1L DE Discovery agent
DMLYIBO ID DMLYIBO
DMLYIBO DN IIK7
DMLYIBO HS Investigative
DMLYIBO SN IIK7; CHEMBL10009; IIK7, solid; AC1N5IDZ; Lopac-I-5531; IIK-7; Lopac0_000701; GTPL1350; SCHEMBL19612546; CTK8G0268; ZINC2510569; BDBM50086013; CCG-204786; NCGC00094053-02; NCGC00015557-03; NCGC00015557-02; NCGC00015557-01; NCGC00094053-01; EU-0100701; I 5531; SR-01000075939; L000306; SR-01000075939-1; N-[2-(2-methoxy-6H-isoindolo[2,3-a]indol-11-yl)ethyl]butanamide; N-Butanoyl 2-(9-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine; N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide; N-Butanoyl 2-(9-methoxy-6H-iso-indolo[
DMLYIBO DT Small molecular drug
DMLYIBO PC 4172142
DMLYIBO MW 348.4
DMLYIBO FM C22H24N2O2
DMLYIBO IC InChI=1S/C22H24N2O2/c1-3-6-21(25)23-12-11-18-19-13-16(26-2)9-10-20(19)24-14-15-7-4-5-8-17(15)22(18)24/h4-5,7-10,13H,3,6,11-12,14H2,1-2H3,(H,23,25)
DMLYIBO CS CCCC(=O)NCCC1=C2C3=CC=CC=C3CN2C4=C1C=C(C=C4)OC
DMLYIBO IK RQYIUGOJQFWLAZ-UHFFFAOYSA-N
DMLYIBO IU N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide
DMLYIBO DE Discovery agent
DMJA4UE ID DMJA4UE
DMJA4UE DN IK-862
DMJA4UE HS Investigative
DMJA4UE SN YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK862; IK 862; compound 32; IK-682
DMJA4UE DT Small molecular drug
DMJA4UE PC 6914621
DMJA4UE MW 433.5
DMJA4UE FM C25H27N3O4
DMJA4UE IC InChI=1S/C25H27N3O4/c1-16-14-18(21-6-4-5-7-22(21)26-16)15-32-20-10-8-19(9-11-20)25(3)12-13-28(24(25)30)17(2)23(29)27-31/h4-11,14,17,31H,12-13,15H2,1-3H3,(H,27,29)/t17-,25+/m1/s1
DMJA4UE CS CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)[C@@]4(CCN(C4=O)[C@H](C)C(=O)NO)C
DMJA4UE IK YDMIPBHQKFOFQW-NSYGIPOTSA-N
DMJA4UE IU (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide
DMJA4UE CB CHEBI:40083
DMJA4UE DE Discovery agent
DM2X3EV ID DM2X3EV
DM2X3EV DN IkappaB-alphaM
DM2X3EV HS Investigative
DM2X3EV DE Discovery agent
DM94AIL ID DM94AIL
DM94AIL DN IKH-25
DM94AIL HS Investigative
DM94AIL SN HDAC-6 inhibitors (cancer), Ikerchem
DM94AIL CP Ikerchem
DM94AIL DE Solid tumour/cancer
DM8GQ9X ID DM8GQ9X
DM8GQ9X DN IKI-1
DM8GQ9X HS Investigative
DM8GQ9X SN IKK inhibitors (cancer); I kappa B kinase inhibitors (cancer), Pfizer; IKK inhibitor (cancer), Wyeth; IKK inhibitors (cancer), Pfizer
DM8GQ9X CP Wyeth
DM8GQ9X DE Solid tumour/cancer
DMLY5IF ID DMLY5IF
DMLY5IF DN IKs124
DMLY5IF HS Investigative
DMLY5IF SN IKs124; SCHEMBL6559311; GTPL2591
DMLY5IF DT Small molecular drug
DMLY5IF PC 15338746
DMLY5IF MW 350.5
DMLY5IF FM C18H26N2O3S
DMLY5IF IC InChI=1S/C18H26N2O3S/c1-5-7-10-20(24(21,22)6-2)16-12-18(3,4)23-17-9-8-14(13-19)11-15(16)17/h8-9,11,16H,5-7,10,12H2,1-4H3
DMLY5IF CS CCCCN(C1CC(OC2=C1C=C(C=C2)C#N)(C)C)S(=O)(=O)CC
DMLY5IF IK VTICUGOJGKDYJD-UHFFFAOYSA-N
DMLY5IF IU N-butyl-N-(6-cyano-2,2-dimethyl-3,4-dihydrochromen-4-yl)ethanesulfonamide
DMLY5IF DE Discovery agent
DMU6AMP ID DMU6AMP
DMU6AMP DN IL-2 antibody (anti-tumor)
DMU6AMP HS Investigative
DMU6AMP SN DMS-1.10; anti-human rIL-2 antibody, Hybritech
DMU6AMP DE Discovery agent
DM10Z5W ID DM10Z5W
DM10Z5W DN Il-8((3-73))K11R
DM10Z5W HS Investigative
DM10Z5W DE Discovery agent
DMPNQ27 ID DMPNQ27
DMPNQ27 DN Il-94
DMPNQ27 HS Investigative
DMPNQ27 SN CHEMBL2386715; Il-94; GTPL8132; SCHEMBL15216595; BDBM50434330
DMPNQ27 DT Small molecular drug
DMPNQ27 PC 73348907
DMPNQ27 MW 422.5
DMPNQ27 FM C21H23FN8O
DMPNQ27 IC InChI=1S/C21H23FN8O/c1-31-7-6-30(12-14-8-15(22)9-18-16(14)11-24-27-18)21-23-5-4-19(26-21)25-20-10-17(28-29-20)13-2-3-13/h4-5,8-11,13H,2-3,6-7,12H2,1H3,(H,24,27)(H2,23,25,26,28,29)
DMPNQ27 CS COCCN(CC1=C2C=NNC2=CC(=C1)F)C3=NC=CC(=N3)NC4=NNC(=C4)C5CC5
DMPNQ27 IK FTGUWURNNBVUBC-UHFFFAOYSA-N
DMPNQ27 IU 4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-N-[(6-fluoro-1H-indazol-4-yl)methyl]-2-N-(2-methoxyethyl)pyrimidine-2,4-diamine
DMPNQ27 DE Discovery agent
DMPIV1G ID DMPIV1G
DMPIV1G DN Ilatreotide
DMPIV1G HS Investigative
DMPIV1G SN SDZ-CO-611
DMPIV1G CP Novartis AG
DMPIV1G PC 72046
DMPIV1G MW 1343.5
DMPIV1G FM C61H86N10O20S2
DMPIV1G IC InChI=1S/C61H86N10O20S2/c1-31(74)42(25-72)68-58(86)44-29-93-92-28-43(69-54(82)39(21-33-13-5-3-6-14-33)64-30-61(88)52(80)51(45(76)27-89-61)91-60-50(79)49(78)48(77)46(26-73)90-60)57(85)66-40(22-34-15-7-4-8-16-34)55(83)67-41(23-35-24-63-37-18-10-9-17-36(35)37)56(84)65-38(19-11-12-20-62)53(81)71-47(32(2)75)59(87)70-44/h3-10,13-18,24,31-32,38-52,60,63-64,72-80,88H,11-12,19-23,25-30,62H2,1-2H3,(H,65,84)(H,66,85)(H,67,83)(H,68,86)(H,69,82)(H,70,87)(H,71,81)/t31-,32-,38+,39-,40+,41-,42-,43+,44+,45-,46-,47+,48-,49+,50-,51-,52+,60-,61-/m1/s1
DMPIV1G CS C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC[C@@]6([C@H]([C@@H]([C@@H](CO6)O)O[C@@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)C(=O)N[C@H](CO)[C@@H](C)O)O
DMPIV1G IK FYSDQQZUTAKKQX-CULBQIHKSA-N
DMPIV1G IU (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2R)-3-phenyl-2-[[(2R,3S,4R,5R)-2,3,5-trihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methylamino]propanoyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
DMPIV1G CA CAS 119719-11-8
DMPIV1G DE Duodenal ulcer
DMZW0YO ID DMZW0YO
DMZW0YO DN IM-023911
DMZW0YO HS Investigative
DMZW0YO SN IM-023911; CHEMBL193342; AC1NQ014; A2595/0110399; MolPort-002-710-895; ZINC3672574; BDBM50173049; STK765418; AKOS001757037; MCULE-3428588247; 4-[4-[4-[chloro(difluoro)methoxy]anilino]phthalazin-1-yl]benzamide; 4-(4-{4-[chloro(difluoro)methoxy]anilino}-1-phthalazinyl)benzamide; 4-{4-[4-(Chloro-difluoro-methoxy)-phenylamino]-phthalazin-1-yl}-benzamide; 4-[4-({4-[chloro(difluoro)methoxy]phenyl}amino)phthalazin-1-yl]benzamide
DMZW0YO DT Small molecular drug
DMZW0YO PC 5187941
DMZW0YO MW 440.8
DMZW0YO FM C22H15ClF2N4O2
DMZW0YO IC InChI=1S/C22H15ClF2N4O2/c23-22(24,25)31-16-11-9-15(10-12-16)27-21-18-4-2-1-3-17(18)19(28-29-21)13-5-7-14(8-6-13)20(26)30/h1-12H,(H2,26,30)(H,27,29)
DMZW0YO CS C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=C(C=C4)C(=O)N
DMZW0YO IK GUSAPNPQBHFHSX-UHFFFAOYSA-N
DMZW0YO IU 4-[4-[4-[chloro(difluoro)methoxy]anilino]phthalazin-1-yl]benzamide
DMZW0YO DE Discovery agent
DMTFV65 ID DMTFV65
DMTFV65 DN IM-094261
DMTFV65 HS Investigative
DMTFV65 SN IM-094261; CHEMBL370586; AC1NRUHT; ZINC4624188; STK686670; BDBM50173019; MCULE-9113150619; 4-[4-(4-tert-butylanilino)phthalazin-1-yl]benzamide; 4-(4-(4-tert-butylphenylamino)phthalazin-1-yl)benzamide; A3870/0164436; 4-{4-[(4-tert-butylphenyl)amino]phthalazin-1-yl}benzamide
DMTFV65 DT Small molecular drug
DMTFV65 PC 5298698
DMTFV65 MW 396.5
DMTFV65 FM C25H24N4O
DMTFV65 IC InChI=1S/C25H24N4O/c1-25(2,3)18-12-14-19(15-13-18)27-24-21-7-5-4-6-20(21)22(28-29-24)16-8-10-17(11-9-16)23(26)30/h4-15H,1-3H3,(H2,26,30)(H,27,29)
DMTFV65 CS CC(C)(C)C1=CC=C(C=C1)NC2=NN=C(C3=CC=CC=C32)C4=CC=C(C=C4)C(=O)N
DMTFV65 IK FIQNADOCRLODMD-UHFFFAOYSA-N
DMTFV65 IU 4-[4-(4-tert-butylanilino)phthalazin-1-yl]benzamide
DMTFV65 DE Discovery agent
DMO18YN ID DMO18YN
DMO18YN DN IM-094882
DMO18YN HS Investigative
DMO18YN SN IM-094882; CHEMBL380316; BDBM50179881; N-(4-chlorophenyl)-4-(isoquinolin-5-yl)phthalazin-1-amine
DMO18YN DT Small molecular drug
DMO18YN PC 42609931
DMO18YN MW 382.8
DMO18YN FM C23H15ClN4
DMO18YN IC InChI=1S/C23H15ClN4/c24-16-8-10-17(11-9-16)26-23-21-6-2-1-5-20(21)22(27-28-23)19-7-3-4-15-14-25-13-12-18(15)19/h1-14H,(H,26,28)
DMO18YN CS C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)C4=CC=CC5=C4C=CN=C5
DMO18YN IK RXWBASVYZOFLRF-UHFFFAOYSA-N
DMO18YN IU N-(4-chlorophenyl)-4-isoquinolin-5-ylphthalazin-1-amine
DMO18YN DE Discovery agent
DM58DGY ID DM58DGY
DM58DGY DN IM-12
DM58DGY HS Investigative
DM58DGY SN IM-12; 1129669-05-1; CHEMBL1254896; 3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-(4-fluorophenethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione; IM 12; GTPL8017; SCHEMBL17378682; DTXSID20649091; AOB4090; MolPort-035-789-694; CHEBI:125616; HMS3653F15; BCP10769; EX-A2071; ZINC59086693; s7566; BDBM50326901; 2472AH; AKOS026750397; SB19269; CS-3399; CCG-208085; NCGC00386352-05; BC600587
DM58DGY DT Small molecular drug
DM58DGY PC 25209788
DM58DGY MW 377.4
DM58DGY FM C22H20FN3O2
DM58DGY IC InChI=1S/C22H20FN3O2/c1-13-18(16-5-3-4-6-17(16)25-13)19-20(22(28)26(2)21(19)27)24-12-11-14-7-9-15(23)10-8-14/h3-10,24-25H,11-12H2,1-2H3
DM58DGY CS CC1=C(C2=CC=CC=C2N1)C3=C(C(=O)N(C3=O)C)NCCC4=CC=C(C=C4)F
DM58DGY IK ZKJAZFUFPPSFCO-UHFFFAOYSA-N
DM58DGY IU 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione
DM58DGY CA CAS 1129669-05-1
DM58DGY CB CHEBI:125616
DM58DGY DE Discovery agent
DMUQO86 ID DMUQO86
DMUQO86 DN IM-491
DMUQO86 HS Investigative
DMUQO86 SN IM-491; UNII-UG82Y9C069; CHEMBL134908; UG82Y9C069; SCHEMBL6444631; BDBM50136259; 2,3-Piperidinedicarboxamide, N3-hydroxy-1-methyl-N2-(4-((2-methyl-4-quinolinyl)methoxy)phenyl)-, (2S,3S)-; 252918-63-1; (2S,3S)-N3-hydroxy-1-methyl-N2-(4-((2-methylquinolin-4-yl)methoxy)phenyl)piperidine-2,3-dicarboxamide; (2S,3S)-1-Methyl-piperidine-2,3-dicarboxylic acid 3-hydroxyamide 2-{[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-amide}
DMUQO86 DT Small molecular drug
DMUQO86 PC 9889867
DMUQO86 MW 448.5
DMUQO86 FM C25H28N4O4
DMUQO86 IC InChI=1S/C25H28N4O4/c1-16-14-17(20-6-3-4-8-22(20)26-16)15-33-19-11-9-18(10-12-19)27-25(31)23-21(24(30)28-32)7-5-13-29(23)2/h3-4,6,8-12,14,21,23,32H,5,7,13,15H2,1-2H3,(H,27,31)(H,28,30)/t21-,23-/m0/s1
DMUQO86 CS CC1=NC2=CC=CC=C2C(=C1)COC3=CC=C(C=C3)NC(=O)[C@@H]4[C@H](CCCN4C)C(=O)NO
DMUQO86 IK RJSKOAOWDAMMHR-GMAHTHKFSA-N
DMUQO86 IU (2S,3S)-3-N-hydroxy-1-methyl-2-N-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]piperidine-2,3-dicarboxamide
DMUQO86 CA CAS 252918-63-1
DMUQO86 DE Discovery agent
DMPKWUO ID DMPKWUO
DMPKWUO DN imbutamine
DMPKWUO HS Investigative
DMPKWUO SN Imbutamine; 4-(1H-imidazol-5-yl)butan-1-amine; 40546-47-2; 1H-Imidazole-4-butanamine; imidazole-4-butanamine; 4-(4-aminobutyl)imidazole; CHEMBL90019; GTPL1249; SCHEMBL3885328; CTK8I6140; BDBM22907; DTXSID90542303; 4-(1H-imidazol-4-yl)butanamine; VJSUMPPMFYQOMP-UHFFFAOYSA-N; VUF-4701; 4-(1H-Imidazol-4-yl)-butylamine; BDBM50170164; AKOS032954093; AKOS006310860
DMPKWUO DT Small molecular drug
DMPKWUO PC 13499360
DMPKWUO MW 139.2
DMPKWUO FM C7H13N3
DMPKWUO IC InChI=1S/C7H13N3/c8-4-2-1-3-7-5-9-6-10-7/h5-6H,1-4,8H2,(H,9,10)
DMPKWUO CS C1=C(NC=N1)CCCCN
DMPKWUO IK VJSUMPPMFYQOMP-UHFFFAOYSA-N
DMPKWUO IU 4-(1H-imidazol-5-yl)butan-1-amine
DMPKWUO CA CAS 40546-47-2
DMPKWUO DE Discovery agent
DMMJ6NS ID DMMJ6NS
DMMJ6NS DN Imetit
DMMJ6NS HS Investigative
DMMJ6NS SN imetit; S-(2-(4-Imidazolyl)ethyl)isothiourea; 102203-18-9; UNII-677MJ4VPZC; 2-(1H-Imidazol-4-yl)ethyl carbamimidothioate; 677MJ4VPZC; CHEMBL19439; CHEBI:64156; 2-(1h-imidazol-5-yl)ethyl carbamimidothioate; Carbamimidothioic acid, 2-(1H-imidazol-4-yl)ethyl ester; 2-(3H-imidazol-4-yl)ethylsulfanylmethanimidamide; C6H10N4S; Carbamimidothioic acid,2-(1H-imidazol-5-yl)ethyl ester; S-[2-(4-imidazolyl)ethyl]isothiourea; Tocris-0729; Lopac-I-135; AC1Q7DRW; ACMC-20m57g; AC1L1GI2; Lopac0_000645; SCHEMBL114670; GTPL1250; DTXSID8043737
DMMJ6NS DT Small molecular drug
DMMJ6NS PC 3692
DMMJ6NS MW 170.24
DMMJ6NS FM C6H10N4S
DMMJ6NS IC InChI=1S/C6H10N4S/c7-6(8)11-2-1-5-3-9-4-10-5/h3-4H,1-2H2,(H3,7,8)(H,9,10)
DMMJ6NS CS C1=C(NC=N1)CCSC(=N)N
DMMJ6NS IK PEHSVUKQDJULKE-UHFFFAOYSA-N
DMMJ6NS IU 2-(1H-imidazol-5-yl)ethyl carbamimidothioate
DMMJ6NS CA CAS 102203-18-9
DMMJ6NS CB CHEBI:64156
DMMJ6NS DE Discovery agent
DMTGRAF ID DMTGRAF
DMTGRAF DN Imidazolidin-2-ylidene-o-tolyl-amine
DMTGRAF HS Investigative
DMTGRAF SN 36318-56-6; Imidazolidine, 2-(2-methylphenylimino)-; N-(2-methylphenyl)-4,5-dihydro-1H-imidazol-2-amine; CHEMBL50430; 785724-64-3; (4,5-dihydro-1H-imidazol-2-yl)-o-tolyl-amine; Imidazolidine,2-(2-methylphenylimino)-; AC1L3KDH; Benzenamine,N-2-imidazolidinylidene-2-methyl-; SCHEMBL8020019; CTK5E5913; CTK1C4679; DTXSID30189852; WLQWOUULTDRZTQ-UHFFFAOYSA-N; ZINC13835980; BDBM50213213; 2-(2-Methylphenylimino)imidazolidine; 2-(2-methylphenylimino)-imidazolidine; AKOS027415754; KB-298713
DMTGRAF DT Small molecular drug
DMTGRAF PC 142067
DMTGRAF MW 175.23
DMTGRAF FM C10H13N3
DMTGRAF IC InChI=1S/C10H13N3/c1-8-4-2-3-5-9(8)13-10-11-6-7-12-10/h2-5H,6-7H2,1H3,(H2,11,12,13)
DMTGRAF CS CC1=CC=CC=C1NC2=NCCN2
DMTGRAF IK WLQWOUULTDRZTQ-UHFFFAOYSA-N
DMTGRAF IU N-(2-methylphenyl)-4,5-dihydro-1H-imidazol-2-amine
DMTGRAF CA CAS 36318-56-6
DMTGRAF DE Discovery agent
DMZ5ISH ID DMZ5ISH
DMZ5ISH DN Imidazolidin-2-ylidene-quinoxalin-6-yl-amine
DMZ5ISH HS Investigative
DMZ5ISH SN 91147-43-2; CHEMBL49395; Brimonidine impurity II; 6-Quinoxalinamine, N-(4,5-dihydro-1H-imidazol-2-yl)-; SCHEMBL679239; N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; SCHEMBL12860178; ZINC14042; CTK3I1267; DTXSID00436663; MolPort-039-240-453; N-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)-6-QUINOXALINAMINE; BDBM50213029; N-quinoxalin-6-ylimidazolidin-2-imine; AKOS030240596
DMZ5ISH DT Small molecular drug
DMZ5ISH PC 10198248
DMZ5ISH MW 213.24
DMZ5ISH FM C11H11N5
DMZ5ISH IC InChI=1S/C11H11N5/c1-2-9-10(13-4-3-12-9)7-8(1)16-11-14-5-6-15-11/h1-4,7H,5-6H2,(H2,14,15,16)
DMZ5ISH CS C1CN=C(N1)NC2=CC3=NC=CN=C3C=C2
DMZ5ISH IK PVKUNRLEOHFACD-UHFFFAOYSA-N
DMZ5ISH IU N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
DMZ5ISH CA CAS 91147-43-2
DMZ5ISH DE Discovery agent
DMS4D96 ID DMS4D96
DMS4D96 DN imiloxan
DMS4D96 HS Investigative
DMS4D96 SN RS-21361; GNF-Pf-2156
DMS4D96 DT Small molecular drug
DMS4D96 PC 133621
DMS4D96 MW 244.29
DMS4D96 FM C14H16N2O2
DMS4D96 IC InChI=1S/C14H16N2O2/c1-2-16-8-7-15-14(16)9-11-10-17-12-5-3-4-6-13(12)18-11/h3-8,11H,2,9-10H2,1H3
DMS4D96 CS CCN1C=CN=C1CC2COC3=CC=CC=C3O2
DMS4D96 IK UXABARREKCJULM-UHFFFAOYSA-N
DMS4D96 IU 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole
DMS4D96 CA CAS 81167-16-0
DMS4D96 CB CHEBI:91522
DMS4D96 DE Discovery agent
DMSINGH ID DMSINGH
DMSINGH DN Imino sugars
DMSINGH HS Investigative
DMSINGH SN Imino sugars (dengue virus infection); PBDNJ-0801; PBDNJ-0803; PBDNJ-0804; CM-10-18; CM-7-98; Imino sugars (dengue virus infection), Enantigen
DMSINGH CP Enantigen Therapeutics Inc
DMSINGH DE Dengue fever
DMZKABS ID DMZKABS
DMZKABS DN Imipramine oxide
DMZKABS HS Investigative
DMZKABS SN Elepsin; Imipramine N-oxide; Imipramine oxide; Imipraminoxide; Imipraminoxide (INN); Imipraminoxide [INN]; Imipraminoxido; Imipraminoxidum; 5-(3-(Dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine 5-oxide; 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine N-oxide; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, N-oxide; 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, N-oxide; 6829-98-7; 8MKS280XJW; UNII-8MKS280XJW
DMZKABS PC 65589
DMZKABS MW 296.4
DMZKABS FM C19H24N2O
DMZKABS IC QZIQORUGXBPDSU-UHFFFAOYSA-N
DMZKABS CS C[N+](C)(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)[O-]
DMZKABS IK 1S/C19H24N2O/c1-21(2,22)15-7-14-20-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)20/h3-6,8-11H,7,12-15H2,1-2H3
DMZKABS IU 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine oxide
DMZKABS CA CAS 6829-98-7
DMZKABS CB CHEBI:135256
DMZKABS DE Depression
DMDM3Y1 ID DMDM3Y1
DMDM3Y1 DN Immepip
DMDM3Y1 HS Investigative
DMDM3Y1 SN Immepip; 151070-83-6; 4-(1H-Imidazol-4-ylmethyl)piperidine; 4-(1H-imidazol-5-ylmethyl)piperidine; CHEBI:81390; Piperidine,4-(1H-imidazol-5-ylmethyl)-; 4-(1H-Imidazol-4-ylmethyl)-piperidine; 4-((1H-imidazol-4-yl)methyl)piperidine; Immepip, Dihydrobromide; 4-IMP; Tocris-0932; AC1MI02O; CHEMBL18661; ACMC-20n643; ZINC5777; SCHEMBL3338054; GTPL1251; BDBM22542; CTK4C6867; DTXSID10164703; FCH842654; BDBM50150945; AKOS006273473; AKOS015964158; 4-(3H-imidazol-4-ylmethyl)piperidine; NCGC00024883-01; NCGC00024883-02; CC-16184; KB-33506
DMDM3Y1 DT Small molecular drug
DMDM3Y1 PC 3035842
DMDM3Y1 MW 165.24
DMDM3Y1 FM C9H15N3
DMDM3Y1 IC InChI=1S/C9H15N3/c1-3-10-4-2-8(1)5-9-6-11-7-12-9/h6-8,10H,1-5H2,(H,11,12)
DMDM3Y1 CS C1CNCCC1CC2=CN=CN2
DMDM3Y1 IK MCNGUYXRBCIGOV-UHFFFAOYSA-N
DMDM3Y1 IU 4-(1H-imidazol-5-ylmethyl)piperidine
DMDM3Y1 CA CAS 151070-83-6
DMDM3Y1 CB CHEBI:81390
DMDM3Y1 DE Discovery agent
DM7YQ26 ID DM7YQ26
DM7YQ26 DN Immethridine
DM7YQ26 HS Investigative
DM7YQ26 SN Immethridine; UNII-F8ZT2IBM1X; F8ZT2IBM1X; 87976-03-2; 4-(1H-imidazol-5-ylmethyl)pyridine; 4-(3H-imidazol-4-ylmethyl)pyridine; SCHEMBL845141; CHEMBL82298; GTPL4024; CHEBI:92859; BDBM22910; DFVSGZHJSIEEQQ-UHFFFAOYSA-N; BCP27655; ZINC12956299; SB17136; 4-(1H-imidazol-4-yl-methyl)-pyridine; Pyridine,4-(1H-imidazol-5-ylmethyl)-; NCGC00092368-02; Pyridine, 4-(1H-imidazol-5-ylmethyl)-
DM7YQ26 DT Small molecular drug
DM7YQ26 PC 9989505
DM7YQ26 MW 159.19
DM7YQ26 FM C9H9N3
DM7YQ26 IC InChI=1S/C9H9N3/c1-3-10-4-2-8(1)5-9-6-11-7-12-9/h1-4,6-7H,5H2,(H,11,12)
DM7YQ26 CS C1=CN=CC=C1CC2=CN=CN2
DM7YQ26 IK DFVSGZHJSIEEQQ-UHFFFAOYSA-N
DM7YQ26 IU 4-(1H-imidazol-5-ylmethyl)pyridine
DM7YQ26 CA CAS 87976-03-2
DM7YQ26 CB CHEBI:92859
DM7YQ26 DE Discovery agent
DMX2NKO ID DMX2NKO
DMX2NKO DN Immucillin-G
DMX2NKO HS Investigative
DMX2NKO DT Small molecular drug
DMX2NKO PC 135445969
DMX2NKO MW 281.27
DMX2NKO FM C11H15N5O4
DMX2NKO IC InChI=1S/C11H15N5O4/c12-11-15-5-3(1-13-7(5)10(20)16-11)6-9(19)8(18)4(2-17)14-6/h1,4,6,8-9,13-14,17-19H,2H2,(H3,12,15,16,20)/t4-,6+,8-,9+/m1/s1
DMX2NKO CS C1=C(C2=C(N1)C(=O)NC(=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
DMX2NKO IK KBIDJCVAURJXFG-PVEDRDFWSA-N
DMX2NKO IU 2-amino-7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMX2NKO CB CHEBI:43467
DMX2NKO DE Discovery agent
DM1TQXO ID DM1TQXO
DM1TQXO DN IMP-731
DM1TQXO HS Investigative
DM1TQXO CP Immutep SA
DM1TQXO DE Autoimmune diabetes
DMPJXZN ID DMPJXZN
DMPJXZN DN impentamine
DMPJXZN HS Investigative
DMPJXZN SN PDSP1_000940; PDSP2_000926
DMPJXZN DT Small molecular drug
DMPJXZN PC 9793868
DMPJXZN MW 153.22
DMPJXZN FM C8H15N3
DMPJXZN IC InChI=1S/C8H15N3/c9-5-3-1-2-4-8-6-10-7-11-8/h6-7H,1-5,9H2,(H,10,11)
DMPJXZN CS C1=C(NC=N1)CCCCCN
DMPJXZN IK MZCJWLAXZRFUPI-UHFFFAOYSA-N
DMPJXZN IU 5-(1H-imidazol-5-yl)pentan-1-amine
DMPJXZN CA CAS 34973-91-6
DMPJXZN DE Discovery agent
DMVLW6R ID DMVLW6R
DMVLW6R DN IMPERATORIN
DMVLW6R HS Investigative
DMVLW6R SN IMPERATORIN; 482-44-0; Ammidin; Marmelosin; Pentosalen; 8-Isoamylenoxypsoralen; 8-Isopentenyloxypsoralene; Marmelide; NSC 402949; CCRIS 4346; UNII-K713N25C78; 9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one; HSDB 3497; EINECS 207-581-1; 9-(3-Methylbut-2-enyloxy)furo(3,2-g)chromen-7-one; AI3-61725; CHEBI:5885; CHEMBL453805; OLOOJGVNMBJLLR-UHFFFAOYSA-N; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-[(3-methyl-2-butenyl)oxy]-; 9-(3-Methylbut-2-enyloxy)furo[3,2-g]chromen-7-one; K713N25C78
DMVLW6R DT Small molecular drug
DMVLW6R PC 10212
DMVLW6R MW 270.28
DMVLW6R FM C16H14O4
DMVLW6R IC InChI=1S/C16H14O4/c1-10(2)5-7-19-16-14-12(6-8-18-14)9-11-3-4-13(17)20-15(11)16/h3-6,8-9H,7H2,1-2H3
DMVLW6R CS CC(=CCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2)C
DMVLW6R IK OLOOJGVNMBJLLR-UHFFFAOYSA-N
DMVLW6R IU 9-(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one
DMVLW6R CA CAS 482-44-0
DMVLW6R CB CHEBI:5885
DMVLW6R DE Discovery agent
DMQ4ICU ID DMQ4ICU
DMQ4ICU DN improgan
DMQ4ICU HS Investigative
DMQ4ICU SN improgan; SKF-92374; GTPL1276; CHEMBL2261340
DMQ4ICU DT Small molecular drug
DMQ4ICU PC 10058807
DMQ4ICU MW 206.25
DMQ4ICU FM C9H14N6
DMQ4ICU IC InChI=1S/C9H14N6/c1-11-9(14-6-10)13-4-2-3-8-5-12-7-15-8/h5,7H,2-4H2,1H3,(H,12,15)(H2,11,13,14)
DMQ4ICU CS CN=C(NCCCC1=CN=CN1)NC#N
DMQ4ICU IK CXTGREPICTYOGB-UHFFFAOYSA-N
DMQ4ICU IU 1-cyano-3-[3-(1H-imidazol-5-yl)propyl]-2-methylguanidine
DMQ4ICU DE Discovery agent
DMTDRPM ID DMTDRPM
DMTDRPM DN impromidine
DMTDRPM HS Investigative
DMTDRPM SN SK&F-92676-A3
DMTDRPM DT Small molecular drug
DMTDRPM PC 41376
DMTDRPM MW 321.45
DMTDRPM FM C14H23N7S
DMTDRPM IC InChI=1S/C14H23N7S/c1-11-13(21-10-19-11)8-22-6-5-18-14(15)17-4-2-3-12-7-16-9-20-12/h7,9-10H,2-6,8H2,1H3,(H,16,20)(H,19,21)(H3,15,17,18)
DMTDRPM CS CC1=C(N=CN1)CSCCNC(=NCCCC2=CN=CN2)N
DMTDRPM IK MURRAGMMNAYLNA-UHFFFAOYSA-N
DMTDRPM IU 2-[3-(1H-imidazol-5-yl)propyl]-1-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine
DMTDRPM CA CAS 55273-05-7
DMTDRPM DE Discovery agent
DM3YJXF ID DM3YJXF
DM3YJXF DN IN-1130
DM3YJXF HS Investigative
DM3YJXF SN IN-1130; UNII-KW4O83PQ97; 868612-83-3; CHEMBL492634; KW4O83PQ97; IN 1130; SCHEMBL139815; MolPort-042-665-839; ZINC13985930; BDBM50252542; AKOS032962854; Benzamide, 3-((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; Benzamide, 3-((4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)-; NCGC00386726-01; KB-274188; 3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide
DM3YJXF DT Small molecular drug
DM3YJXF PC 11676119
DM3YJXF MW 420.5
DM3YJXF FM C25H20N6O
DM3YJXF IC InChI=1S/C25H20N6O/c1-15-4-2-7-20(29-15)24-23(17-8-9-19-21(14-17)28-11-10-27-19)30-22(31-24)13-16-5-3-6-18(12-16)25(26)32/h2-12,14H,13H2,1H3,(H2,26,32)(H,30,31)
DM3YJXF CS CC1=NC(=CC=C1)C2=C(N=C(N2)CC3=CC(=CC=C3)C(=O)N)C4=CC5=NC=CN=C5C=C4
DM3YJXF IK RYKSGWSKILPDDY-UHFFFAOYSA-N
DM3YJXF IU 3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1H-imidazol-2-yl]methyl]benzamide
DM3YJXF CA CAS 868612-83-3
DM3YJXF DE Discovery agent
DMMS6D3 ID DMMS6D3
DMMS6D3 DN IN-1166
DMMS6D3 HS Investigative
DMMS6D3 SN UNII-86NAB50A9A; IN-1166; CHEMBL387748; 86NAB50A9A; SCHEMBL373674; BDBM50214857; Benzonitrile, 3-(((5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl)methyl)amino)-; 945244-71-3
DMMS6D3 DT Small molecular drug
DMMS6D3 PC 16654987
DMMS6D3 MW 417.5
DMMS6D3 FM C25H19N7
DMMS6D3 IC InChI=1S/C25H19N7/c1-16-4-2-7-21(30-16)25-24(18-8-9-20-22(13-18)28-11-10-27-20)31-23(32-25)15-29-19-6-3-5-17(12-19)14-26/h2-13,29H,15H2,1H3,(H,31,32)
DMMS6D3 CS CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC(=C3)C#N)C4=CC5=NC=CN=C5C=C4
DMMS6D3 IK SVFWZNDJPVECNU-UHFFFAOYSA-N
DMMS6D3 IU 3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1H-imidazol-2-yl]methylamino]benzonitrile
DMMS6D3 CA CAS 945244-71-3
DMMS6D3 DE Discovery agent
DM4JNUH ID DM4JNUH
DM4JNUH DN IN1479
DM4JNUH HS Investigative
DM4JNUH SN Flt-3 Inhibitor III; IN1479; 5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine; (5-Phenyl-thiazol-2-yl)-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-amine; (5-Phenyl-thiazol-2-yl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine; GTPL5972; SCHEMBL2230201; CHEMBL2218935; MolPort-044-561-828; FNZTULJDGIXMJJ-UHFFFAOYSA-N; HMS3229E21; ZINC35052133; CCG-206753; NCGC00387783-01; 5-phenyl-N-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,3-thiazol-2-amine
DM4JNUH DT Small molecular drug
DM4JNUH PC 11772958
DM4JNUH MW 365.5
DM4JNUH FM C21H23N3OS
DM4JNUH IC InChI=1S/C21H23N3OS/c1-2-6-17(7-3-1)20-16-22-21(26-20)23-18-8-10-19(11-9-18)25-15-14-24-12-4-5-13-24/h1-3,6-11,16H,4-5,12-15H2,(H,22,23)
DM4JNUH CS C1CCN(C1)CCOC2=CC=C(C=C2)NC3=NC=C(S3)C4=CC=CC=C4
DM4JNUH IK FNZTULJDGIXMJJ-UHFFFAOYSA-N
DM4JNUH IU 5-phenyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,3-thiazol-2-amine
DM4JNUH DE Discovery agent
DMKFE6X ID DMKFE6X
DMKFE6X DN IN1535
DMKFE6X HS Investigative
DMKFE6X SN 220792-57-4; CTK8F1119; K00613a; ZINC00582597; NCGC00390411-01; RT-011271
DMKFE6X DT Small molecular drug
DMKFE6X PC 9549304
DMKFE6X MW 403.9
DMKFE6X FM C19H26ClN7O
DMKFE6X IC InChI=1S/C19H26ClN7O/c1-10(2)15(8-28)24-19-25-17(23-14-6-12(20)5-13(21)7-14)16-18(26-19)27(9-22-16)11(3)4/h5-7,9-11,15,28H,8,21H2,1-4H3,(H2,23,24,25,26)
DMKFE6X CS CC(C)C(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NC3=CC(=CC(=C3)N)Cl
DMKFE6X IK RAMROQQYRRQPDL-UHFFFAOYSA-N
DMKFE6X IU 2-[[6-(3-amino-5-chloroanilino)-9-propan-2-ylpurin-2-yl]amino]-3-methylbutan-1-ol
DMKFE6X DE Discovery agent
DMENHMU ID DMENHMU
DMENHMU DN IN-3
DMENHMU HS Investigative
DMENHMU SN IN 3; analogue 24 [PMID: 11551758]
DMENHMU DT Small molecular drug
DMENHMU PC 10231401
DMENHMU MW 562.8
DMENHMU FM C37H46N4O
DMENHMU IC InChI=1S/C37H46N4O/c1-24-18-25(2)20-29(19-24)35-34(26(3)22-39-17-14-27-12-15-38-16-13-27)32-21-30(8-11-33(32)40-35)37(4,5)36(42)41-23-28-6-9-31(41)10-7-28/h8,11-13,15-16,18-21,26,28,31,39-40H,6-7,9-10,14,17,22-23H2,1-5H3/t26-,28?,31?/m1/s1
DMENHMU CS CC1=CC(=CC(=C1)C2=C(C3=C(N2)C=CC(=C3)C(C)(C)C(=O)N4CC5CCC4CC5)[C@H](C)CNCCC6=CC=NC=C6)C
DMENHMU IK GGVFLXSCFPVLMS-WPCLDFDBSA-N
DMENHMU IU 1-(2-azabicyclo[2.2.2]octan-2-yl)-2-[2-(3,5-dimethylphenyl)-3-[(2S)-1-(2-pyridin-4-ylethylamino)propan-2-yl]-1H-indol-5-yl]-2-methylpropan-1-one
DMENHMU DE Discovery agent
DM8E4HB ID DM8E4HB
DM8E4HB DN INC-106
DM8E4HB HS Investigative
DM8E4HB SN Angiotensin II mAb (restenosis), Inncardio/Queen Mary and Westfield College; Angiotensin II type I receptor monoclonal antibody (restenosis), Inncardio/Queen Mary Univeristy
DM8E4HB CP Queen Mary University of London
DM8E4HB DT Antibody
DM8E4HB DE Artery stenosis
DMZCHSD ID DMZCHSD
DMZCHSD DN INCB-10820
DMZCHSD HS Investigative
DMZCHSD SN PF-4178903; Dual CCR2/CCR5 antagonist (inflammation), Pfizer
DMZCHSD CP Incyte Corp
DMZCHSD DE Inflammation
DMONMHK ID DMONMHK
DMONMHK DN incensole acetate
DMONMHK HS Investigative
DMONMHK SN 34701-53-6; Incensol acetate; GTPL4220; 1,5,9-trimethyl-12-(propan-2-yl)-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-yl acetate
DMONMHK DT Small molecular drug
DMONMHK PC 53386731
DMONMHK MW 348.5
DMONMHK FM C22H36O3
DMONMHK IC InChI=1S/C22H36O3/c1-16(2)22-13-12-18(4)9-7-8-17(3)10-11-20(24-19(5)23)21(6,25-22)14-15-22/h8,12,16,20H,7,9-11,13-15H2,1-6H3/b17-8+,18-12+/t20-,21+,22+/m0/s1
DMONMHK CS C/C/1=C\\CC/C(=C/C[C@@]2(CC[C@@](O2)([C@H](CC1)OC(=O)C)C)C(C)C)/C
DMONMHK IK HVBACKJYWZTKCA-XSLBTUIJSA-N
DMONMHK IU [(1R,2S,5E,9E,12S)-1,5,9-trimethyl-12-propan-2-yl-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-yl] acetate
DMONMHK DE Discovery agent
DMMLQZJ ID DMMLQZJ
DMMLQZJ DN Indan-1-ol
DMMLQZJ HS Investigative
DMMLQZJ SN Indan-1-ol; 1-Indanol; Indanol; L-INDANOL; SCHEMBL1747186; YIAPLDFPUUJILH-UHFFFAOYSA-N; (-)-indanol; 1-Hydroxyhydrindene; 1-Hydroxyindan; 1-Hydroxyindane; 1-INDANOL; 1-Indanol, 98%; 1-Indanole; 1H-Inden-1-ol, 2,3-dihydro-; 1H-Inden-1-ol,3-dihydro-; 1H-Indenol, 2,3-dihydro-; 1H-Indenol,2,3-dihydro-; 2,3-Dihydro-1H-inden-1-ol; 36643-74-0; 4-06-00-03824 (Beilstein Handbook Reference); AC1L2L5X; AC1Q7AG7; ACMC-1ATT8; ACMC-20aphe; BRN 2042960; CHEBI:16697; CTK4H6942; EINECS 253-146-4; KS-00000MBA; MFCD00003797; NSC31258; SCHEMBL57132
DMMLQZJ PC 22819
DMMLQZJ MW 134.17
DMMLQZJ FM C9H10O
DMMLQZJ IC YIAPLDFPUUJILH-UHFFFAOYSA-N
DMMLQZJ CS C1CC2=CC=CC=C2C1O
DMMLQZJ IK 1S/C9H10O/c10-9-6-5-7-3-1-2-4-8(7)9/h1-4,9-10H,5-6H2
DMMLQZJ IU 2,3-dihydro-1H-inden-1-ol
DMMLQZJ CA CAS 6351-10-6
DMMLQZJ CB CHEBI:16697
DMMLQZJ DE Discovery agent
DMVZMBU ID DMVZMBU
DMVZMBU DN Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester
DMVZMBU HS Investigative
DMVZMBU SN CHEMBL485886; Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester
DMVZMBU DT Small molecular drug
DMVZMBU PC 24881740
DMVZMBU MW 329.4
DMVZMBU FM C22H19NO2
DMVZMBU IC InChI=1S/C22H19NO2/c24-22(23-20-13-17-9-4-5-10-18(17)14-20)25-21-12-6-11-19(15-21)16-7-2-1-3-8-16/h1-12,15,20H,13-14H2,(H,23,24)
DMVZMBU CS C1C(CC2=CC=CC=C21)NC(=O)OC3=CC=CC(=C3)C4=CC=CC=C4
DMVZMBU IK UEEYQEMKIXZIGW-UHFFFAOYSA-N
DMVZMBU IU (3-phenylphenyl) N-(2,3-dihydro-1H-inden-2-yl)carbamate
DMVZMBU DE Discovery agent
DM4S81A ID DM4S81A
DM4S81A DN indanidine
DM4S81A HS Investigative
DM4S81A SN Sgd 101/75
DM4S81A DT Small molecular drug
DM4S81A PC 121925
DM4S81A MW 215.25
DM4S81A FM C11H13N5
DM4S81A IC InChI=1S/C11H13N5/c1-16-7-8-9(3-2-4-10(8)15-16)14-11-12-5-6-13-11/h2-4,7H,5-6H2,1H3,(H2,12,13,14)
DM4S81A CS CN1C=C2C(=N1)C=CC=C2NC3=NCCN3
DM4S81A IK PNHJTLDBYZVCGW-UHFFFAOYSA-N
DM4S81A IU N-(4,5-dihydro-1H-imidazol-2-yl)-2-methylindazol-4-amine
DM4S81A CA CAS 85392-79-6
DM4S81A DE Discovery agent
DMIP9DN ID DMIP9DN
DMIP9DN DN Indatraline
DMIP9DN HS Investigative
DMIP9DN SN Indatraline; Lu 19005; CHEMBL341898; 86939-10-8; Indatralinum; Indatraline [INN]; (+)-Indatraline; Lu-19-005; (-)-trans-3-(3,4-dichlorophenyl)-n-methyl-1-indanamine; Lopac-I-119; AC1Q3O5Q; Lopac0_000684; SCHEMBL9252640; AC1L2Q22; DTXSID4043981; CHEBI:94467; (+-)-trans-3-(3,4-Dichlorophenyl)-N-methyl-1-indanamine; ZINC3872906; BDBM50095618; PDSP2_001486; PDSP1_001502; CCG-204769; API0009127; NCGC00025223-04; NCGC00025223-03; NCGC00015532-01; NCGC00025223-02; 97229-15-7; 3-(3,4-Dichlorophenyl)-N-methyl-1-indanamine hcl; UNII-4U40Y96J1Z c
DMIP9DN DT Small molecular drug
DMIP9DN PC 126280
DMIP9DN MW 292.2
DMIP9DN FM C16H15Cl2N
DMIP9DN IC InChI=1S/C16H15Cl2N/c1-19-16-9-13(11-4-2-3-5-12(11)16)10-6-7-14(17)15(18)8-10/h2-8,13,16,19H,9H2,1H3/t13-,16+/m0/s1
DMIP9DN CS CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
DMIP9DN IK SVFXPTLYMIXFRX-XJKSGUPXSA-N
DMIP9DN IU (1R,3S)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
DMIP9DN CA CAS 86939-10-8
DMIP9DN CB CHEBI:94467
DMIP9DN DE Discovery agent
DMYLVQF ID DMYLVQF
DMYLVQF DN indirubin deriv. 8a
DMYLVQF HS Investigative
DMYLVQF DT Small molecular drug
DMYLVQF PC 135398521
DMYLVQF MW 398.2
DMYLVQF FM C18H12BrN3O3
DMYLVQF IC InChI=1S/C18H12BrN3O3/c1-9(23)25-22-16-12-4-2-3-5-13(12)20-17(16)15-11-7-6-10(19)8-14(11)21-18(15)24/h2-8,21,24H,1H3/b22-16+
DMYLVQF CS CC(=O)O/N=C/1\\C2=CC=CC=C2N=C1C3=C(NC4=C3C=CC(=C4)Br)O
DMYLVQF IK HUDSYNWJCPDHLL-CJLVFECKSA-N
DMYLVQF IU [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DMYLVQF CA CAS 667463-85-6
DMYLVQF DE Discovery agent
DMFP1C5 ID DMFP1C5
DMFP1C5 DN indirubin derivative E804
DMFP1C5 HS Investigative
DMFP1C5 SN indirubin E804; compound 2 [PMID: 21632247]
DMFP1C5 DT Small molecular drug
DMFP1C5 PC 6419764
DMFP1C5 DE Discovery agent
DM3UR1E ID DM3UR1E
DM3UR1E DN Indirubin-3-acetoxime
DM3UR1E HS Investigative
DM3UR1E DT Small molecular drug
DM3UR1E PC 136043837
DM3UR1E MW 319.3
DM3UR1E FM C18H13N3O3
DM3UR1E IC InChI=1S/C18H13N3O3/c1-10(22)24-21-16-12-7-3-5-9-14(12)19-17(16)15-11-6-2-4-8-13(11)20-18(15)23/h2-9,20,23H,1H3/b21-16-
DM3UR1E CS CC(=O)O/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=CC=CC=C43)O
DM3UR1E IK SPLHCOMFUFSNNE-PGMHBOJBSA-N
DM3UR1E IU [(Z)-[2-(2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate
DM3UR1E DE Discovery agent
DMZ5ODC ID DMZ5ODC
DMZ5ODC DN Indirubin-3-methoxime
DMZ5ODC HS Investigative
DMZ5ODC DT Small molecular drug
DMZ5ODC PC 136043836
DMZ5ODC MW 291.3
DMZ5ODC FM C17H13N3O2
DMZ5ODC IC InChI=1S/C17H13N3O2/c1-22-20-15-11-7-3-5-9-13(11)18-16(15)14-10-6-2-4-8-12(10)19-17(14)21/h2-9,19,21H,1H3/b20-15-
DMZ5ODC CS CO/N=C\\1/C2=CC=CC=C2N=C1C3=C(NC4=CC=CC=C43)O
DMZ5ODC IK DLJNVUXERDSYFS-HKWRFOASSA-N
DMZ5ODC IU 3-[(3Z)-3-methoxyiminoindol-2-yl]-1H-indol-2-ol
DMZ5ODC DE Discovery agent
DMLRQH0 ID DMLRQH0
DMLRQH0 DN Indirubin-3'-monoxime
DMLRQH0 HS Investigative
DMLRQH0 SN INDIRUBIN-3'-MONOXIME; indirubin-3'-oxime; 160807-49-8; indirubin-3-oxime; Indirubin-3monoxime; Indirubin-3-monoxime; 3-[3-(Hydroxyamino)-1H-indol-2-yl]indol-2-one; CHEBI:43645; Indirubin 3'-monoxime; indirubin-3'-monooxime; Indirubin-3& CHEMBL216543; CHEMBL126077; (Z)-1H,1'H-[2,3']BIINDOLYLIDENE-3,2'-DIONE-3-OXIME; UNM-0000305771; 3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one; 667463-82-3; IXM; SR-01000075929; Indirubin-3; Indirubin 3-oxime; Tocris-1813; BiomolKI_000070; Indirubin-3-oxime
DMLRQH0 DT Small molecular drug
DMLRQH0 PC 3707
DMLRQH0 MW 277.28
DMLRQH0 FM C16H11N3O2
DMLRQH0 IC InChI=1S/C16H11N3O2/c20-16-13(9-5-1-3-7-11(9)18-16)15-14(19-21)10-6-2-4-8-12(10)17-15/h1-8,17-18,20H
DMLRQH0 CS C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O
DMLRQH0 IK FQCPPVRJPILDIK-UHFFFAOYSA-N
DMLRQH0 IU 3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
DMLRQH0 CA CAS 160807-49-8
DMLRQH0 CB CHEBI:43645
DMLRQH0 DE Discovery agent
DM08VHZ ID DM08VHZ
DM08VHZ DN Indirubin-5-sulfonate
DM08VHZ HS Investigative
DM08VHZ SN indirubin-5-sulphonate; CHEMBL1207227; 2',3-DIOXO-1,1',2',3-TETRAHYDRO-2,3'-BIINDOLE-5'-SULFONIC ACID; INR; AC1NRBUE; AC1NZHHM; 1v0o; AC1O8NUW; Indirubin derivative, 20; SCHEMBL490806; BDBM84534; A05-A11B1-I; NSC717821; BDBM50023871; NSC-717821; DB02519; NCI60_040625; 2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (3Z)-2-oxo-3-(3-oxoindolin-2-ylidene)indoline-5-sulfonic acid; (3E)-2-oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; (2Z)-2',3-dioxo-1,1',2',3-tetrahydro-2,3'-biindole-5'-sulfonic acid; Indirubin-5-Sulphonate
DM08VHZ DT Small molecular drug
DM08VHZ PC 3708
DM08VHZ MW 342.3
DM08VHZ FM C16H10N2O5S
DM08VHZ IC InChI=1S/C16H10N2O5S/c19-15-9-3-1-2-4-11(9)17-14(15)13-10-7-8(24(21,22)23)5-6-12(10)18-16(13)20/h1-7,18,20H,(H,21,22,23)
DM08VHZ CS C1=CC=C2C(=C1)C(=O)C(=N2)C3=C(NC4=C3C=C(C=C4)S(=O)(=O)O)O
DM08VHZ IK BYYOTMYLPPUWCF-UHFFFAOYSA-N
DM08VHZ IU 2-hydroxy-3-(3-oxoindol-2-yl)-1H-indole-5-sulfonic acid
DM08VHZ CA CAS 244021-67-8
DM08VHZ DE Discovery agent
DMJB876 ID DMJB876
DMJB876 DN Indol-1-yl-methyl-pyridin-4-yl-amine
DMJB876 HS Investigative
DMJB876 SN CHEMBL152842; Indol-1-yl-methyl-pyridin-4-yl-amine; ZINC3997; SCHEMBL7615812; BDBM50048589
DMJB876 DT Small molecular drug
DMJB876 PC 10799123
DMJB876 MW 223.27
DMJB876 FM C14H13N3
DMJB876 IC InChI=1S/C14H13N3/c1-16(13-6-9-15-10-7-13)17-11-8-12-4-2-3-5-14(12)17/h2-11H,1H3
DMJB876 CS CN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMJB876 IK DZLHSFJMKLMKMN-UHFFFAOYSA-N
DMJB876 IU N-methyl-N-pyridin-4-ylindol-1-amine
DMJB876 DE Discovery agent
DMR9GNW ID DMR9GNW
DMR9GNW DN Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine
DMR9GNW HS Investigative
DMR9GNW SN CHEMBL348034; Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine; SCHEMBL7609255; BDBM50048602
DMR9GNW DT Small molecular drug
DMR9GNW PC 10490725
DMR9GNW MW 247.29
DMR9GNW FM C16H13N3
DMR9GNW IC InChI=1S/C16H13N3/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19/h1,3-11,13H,12H2
DMR9GNW CS C#CCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32
DMR9GNW IK KUBLGYWISNGZNK-UHFFFAOYSA-N
DMR9GNW IU N-prop-2-ynyl-N-pyridin-4-ylindol-1-amine
DMR9GNW DE Discovery agent
DM1F53L ID DM1F53L
DM1F53L DN Indol-1-yl-pyridin-4-yl-amine
DM1F53L HS Investigative
DM1F53L SN 119257-33-9; N-(4-pyridinyl)-1H-indol-1-amine; N-(PYRIDIN-4-YL)-1H-INDOL-1-AMINE; CHEMBL154488; 1H-Indol-1-amine,N-4-pyridinyl-; N-pyridin-4-ylindol-1-amine; N-4-Pyridinyl-1H-indol-1-amine; AC1MIWH0; ACMC-1C0H7; SCHEMBL3139425; ZINC24994; CTK4B1164; DTXSID90152360; YFXZWVUZIPQSKX-UHFFFAOYSA-N; BDBM50048608; 1H-Indol-1-amine, N-4-pyridinyl-; AKOS015924421; RP26505; KB-139314; J-523178
DM1F53L DT Small molecular drug
DM1F53L PC 3081186
DM1F53L MW 209.25
DM1F53L FM C13H11N3
DM1F53L IC InChI=1S/C13H11N3/c1-2-4-13-11(3-1)7-10-16(13)15-12-5-8-14-9-6-12/h1-10H,(H,14,15)
DM1F53L CS C1=CC=C2C(=C1)C=CN2NC3=CC=NC=C3
DM1F53L IK YFXZWVUZIPQSKX-UHFFFAOYSA-N
DM1F53L IU N-pyridin-4-ylindol-1-amine
DM1F53L CA CAS 119257-33-9
DM1F53L DE Discovery agent
DMP543H ID DMP543H
DMP543H DN INDOLACTUM
DMP543H HS Investigative
DMP543H SN (-)-Indolactam V; Indolactam V; 90365-57-4; Indolactum; UNII-8CIY9O1323; (-)-ILV; BRN 4711877; CHEMBL27266; 8CIY9O1323; (2s,5s)-5-(hydroxymethyl)-2-isopropyl-1-methyl-1,2,4,5,6,8-hexahydro-3h-[1,4]diazonino[7,6,5-cd]indol-3-one; 3H-Pyrrolo(4,3,2-gh)-1,4-benzodiazonin-3-one, 1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-, (2S-(2R*,5R*))-; 3H-Pyrrolo(4,3,2-gh)-1,4-benzodiazonin-3-one, 1,2,4,5,6,8-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-, (2S,5S)-
DMP543H DT Small molecular drug
DMP543H PC 105000
DMP543H MW 301.4
DMP543H FM C17H23N3O2
DMP543H IC InChI=1S/C17H23N3O2/c1-10(2)16-17(22)19-12(9-21)7-11-8-18-13-5-4-6-14(15(11)13)20(16)3/h4-6,8,10,12,16,18,21H,7,9H2,1-3H3,(H,19,22)/t12-,16-/m0/s1
DMP543H CS CC(C)[C@H]1C(=O)N[C@@H](CC2=CNC3=C2C(=CC=C3)N1C)CO
DMP543H IK LUZOFMGZMUZSSK-LRDDRELGSA-N
DMP543H IU (10S,13S)-13-(hydroxymethyl)-9-methyl-10-propan-2-yl-3,9,12-triazatricyclo[6.6.1.04,15]pentadeca-1,4(15),5,7-tetraen-11-one
DMP543H CA CAS 90365-57-4
DMP543H DE Discovery agent
DMEHI15 ID DMEHI15
DMEHI15 DN Indole N -acetamide
DMEHI15 HS Investigative
DMEHI15 SN 1H-Indole-1-acetamide; 2-(1H-indol-1-yl)acetamide; 39597-63-2; 2-indol-1-ylacetamide; 2(N-indolyl) acetamide; 2-(N-indolyl) acetamide; AC1N9C0U; SCHEMBL1519806; CHEMBL3252106; MolPort-003-001-159; IUUZMSMGSOUFTO-UHFFFAOYSA-N; ZINC6393531; STK319340; AKOS003406817; MCULE-8299376429; VU0526183-1
DMEHI15 DT Small molecular drug
DMEHI15 PC 4408257
DMEHI15 MW 174.2
DMEHI15 FM C10H10N2O
DMEHI15 IC InChI=1S/C10H10N2O/c11-10(13)7-12-6-5-8-3-1-2-4-9(8)12/h1-6H,7H2,(H2,11,13)
DMEHI15 CS C1=CC=C2C(=C1)C=CN2CC(=O)N
DMEHI15 IK IUUZMSMGSOUFTO-UHFFFAOYSA-N
DMEHI15 IU 2-indol-1-ylacetamide
DMEHI15 DE Hepatovirus infection
DMB4ZNW ID DMB4ZNW
DMB4ZNW DN Indole Naphthyridinone
DMB4ZNW HS Investigative
DMB4ZNW SN INDOLE NAPHTHYRIDINONE; (E)-N-METHYL-N-(1-METHYL-1H-INDOL-3-YLMETHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-[1,8]NAPHTHYRIDIN-3-YL)-ACRYLAMIDE; IDN; (2E)-N-methyl-N-[(1-methyl-1H-indol-3-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide; AC1NRBS2; indole naphthyridinone 29; SCHEMBL725906; SCHEMBL725904; CHEMBL42208; BDBM8733; DB01691; (e)-n-methyl-n-(1-methyl-1h-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
DMB4ZNW DT Small molecular drug
DMB4ZNW PC 5288607
DMB4ZNW MW 374.4
DMB4ZNW FM C22H22N4O2
DMB4ZNW IC InChI=1S/C22H22N4O2/c1-25-13-17(18-5-3-4-6-19(18)25)14-26(2)21(28)10-7-15-11-16-8-9-20(27)24-22(16)23-12-15/h3-7,10-13H,8-9,14H2,1-2H3,(H,23,24,27)/b10-7+
DMB4ZNW CS CN1C=C(C2=CC=CC=C21)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3
DMB4ZNW IK VAZMNDXVXVUKFY-JXMROGBWSA-N
DMB4ZNW IU (E)-N-methyl-N-[(1-methylindol-3-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide
DMB4ZNW DE Discovery agent
DMF0VAG ID DMF0VAG
DMF0VAG DN indole-3-propionic acid
DMF0VAG HS Investigative
DMF0VAG SN oxigon; 3-indolepropionicacid
DMF0VAG DT Small molecular drug
DMF0VAG PC 3744
DMF0VAG MW 189.21
DMF0VAG FM C11H11NO2
DMF0VAG IC InChI=1S/C11H11NO2/c13-11(14)6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6H2,(H,13,14)
DMF0VAG CS C1=CC=C2C(=C1)C(=CN2)CCC(=O)O
DMF0VAG IK GOLXRNDWAUTYKT-UHFFFAOYSA-N
DMF0VAG IU 3-(1H-indol-3-yl)propanoic acid
DMF0VAG CA CAS 830-96-6
DMF0VAG CB CHEBI:43580
DMF0VAG DE Discovery agent
DMML9AY ID DMML9AY
DMML9AY DN Indolin-2-one deriv. 4b
DMML9AY HS Investigative
DMML9AY SN indolin-2-one deriv. 4b
DMML9AY DT Small molecular drug
DMML9AY PC 5329155
DMML9AY MW 343.2
DMML9AY FM C17H15BrN2O
DMML9AY IC InChI=1S/C17H15BrN2O/c18-11-5-6-16-13(8-11)14(17(21)20-16)9-12-7-10-3-1-2-4-15(10)19-12/h5-9,19H,1-4H2,(H,20,21)/b14-9-
DMML9AY CS C1CCC2=C(C1)C=C(N2)/C=C\\3/C4=C(C=CC(=C4)Br)NC3=O
DMML9AY IK RFHPWPWVGFSLOP-ZROIWOOFSA-N
DMML9AY IU (3Z)-5-bromo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indol-2-one
DMML9AY CA CAS 288144-20-7
DMML9AY DE Discovery agent
DMSBENK ID DMSBENK
DMSBENK DN Indomethacin glucuronide
DMSBENK HS Investigative
DMSBENK SN Indomethacin acyl glucuronide; INDOMETHACIN GLUCURONIDE; CHEMBL2074828; Indomethacin Acyl-; INDOMETHACIN ACYL-B-D-GLUCURONIDE; 75523-11-4; ZINC84386263
DMSBENK PC 70691027
DMSBENK MW 533.9
DMSBENK FM C25H24ClNO10
DMSBENK IC QCBWEVBGELGABM-CZLVRFMKSA-N
DMSBENK CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OC4C(C(C(C(O4)C(=O)O)O)O)O
DMSBENK IK 1S/C25H24ClNO10/c1-11-15(10-18(28)36-25-21(31)19(29)20(30)22(37-25)24(33)34)16-9-14(35-2)7-8-17(16)27(11)23(32)12-3-5-13(26)6-4-12/h3-9,19-22,25,29-31H,10H2,1-2H3,(H,33,34)/t19-,20-,21+,22-,25+/m0/s1
DMSBENK IU (2S,3S,4S,5R,6S)-6-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
DMSBENK CA CAS 75523-11-4
DMSBENK DE Discovery agent
DMBOQ6M ID DMBOQ6M
DMBOQ6M DN INDUS-815B
DMBOQ6M HS Investigative
DMBOQ6M SN INDUS-815B (kidney disease); INDUS-815B (kidney disease), Indus Biotech; Protein kinase D-2 modulator (kidney disease),Indus Biotech
DMBOQ6M CP Indus Biotech Pvt Ltd
DMBOQ6M DE Kidney disease
DMLJ645 ID DMLJ645
DMLJ645 DN INDUS-815C
DMLJ645 HS Investigative
DMLJ645 SN VEGF modulator (age related macular degeneration/retinopathy), Indus Biotech; INDUS-815C (Huntington's disease), Indus Biotech; INDUS-815C (age related macular degeneration/retinopathy), Indus Biotech; SIRT2 inhibtior (Parkinson's disease/dementia/Huntington's disease), Indus Biotech; NAD-dependent deacetylase sirtuin-2inhibitor (Parkinson's disease/dementia/Huntington's disease), Indus Biotech
DMLJ645 CP Indus Biotech Pvt Ltd
DMLJ645 DE Retinopathy
DMV6UJ5 ID DMV6UJ5
DMV6UJ5 DN Infractopicrin
DMV6UJ5 HS Investigative
DMV6UJ5 SN Infractopicrin
DMV6UJ5 DT Small molecular drug
DMV6UJ5 PC 46228995
DMV6UJ5 MW 296.7
DMV6UJ5 FM C17H13ClN2O
DMV6UJ5 IC InChI=1S/C17H13N2O.ClH/c20-15-10-11-4-3-8-18-9-7-13-12-5-1-2-6-14(12)19(15)17(13)16(11)18;/h1-2,5-7,9-10H,3-4,8H2;1H/q+1;/p-1
DMV6UJ5 CS C1CC2=CC(=O)N3C4=CC=CC=C4C5=C3C2=[N+](C1)C=C5.[Cl-]
DMV6UJ5 IK ANXYOVQDHIBQTM-UHFFFAOYSA-M
DMV6UJ5 IU 1-aza-11-azoniapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),9,11(19),15-heptaen-17-one;chloride
DMV6UJ5 DE Discovery agent
DM487FU ID DM487FU
DM487FU DN Ingenol-3-bezoate
DM487FU HS Investigative
DM487FU SN Ingenol-3-bezoate; CHEMBL46094; Ingenol 3-bezoate; BDBM50099646
DM487FU DT Small molecular drug
DM487FU PC 44292399
DM487FU MW 452.5
DM487FU FM C27H32O6
DM487FU IC InChI=1S/C27H32O6/c1-14-12-26-15(2)10-19-20(25(19,3)4)18(22(26)30)11-17(13-28)21(29)27(26,32)23(14)33-24(31)16-8-6-5-7-9-16/h5-9,11-12,15,18-21,23,28-29,32H,10,13H2,1-4H3/t15-,18+,19-,20+,21-,23+,26?,27+/m1/s1
DM487FU CS C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4(C1(C3=O)C=C([C@@H]4OC(=O)C5=CC=CC=C5)C)O)O)CO
DM487FU IK VYLJAGRINUHTSF-KTOZFIMGSA-N
DM487FU IU [(4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] benzoate
DM487FU DE Discovery agent
DMUQHMP ID DMUQHMP
DMUQHMP DN Inhibitor 1 [Colombo et al., 2012]
DMUQHMP HS Investigative
DMUQHMP SN CHEMBL2086421; inhibitor 1 [Colombo et al., 2012]; GTPL8624; SCHEMBL14232816; BDBM50420334
DMUQHMP DT Small molecular drug
DMUQHMP PC 70689167
DMUQHMP MW 646.8
DMUQHMP FM C27H42N12O5S
DMUQHMP IC InChI=1S/C27H42N12O5S/c1-14(36-24(44)18(10-11-20(29)40)38-23(43)15(28)6-4-12-34-26(30)31)22(42)37-17(8-5-13-35-27(32)33)21(41)25-39-16-7-2-3-9-19(16)45-25/h2-3,7,9,14-15,17-18H,4-6,8,10-13,28H2,1H3,(H2,29,40)(H,36,44)(H,37,42)(H,38,43)(H4,30,31,34)(H4,32,33,35)/t14-,15-,17-,18-/m0/s1
DMUQHMP CS C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)C1=NC2=CC=CC=C2S1)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N
DMUQHMP IK JRNGHBUUFQDBPT-LAQRGFTBSA-N
DMUQHMP IU (2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide
DMUQHMP DE Discovery agent
DMWIHRX ID DMWIHRX
DMWIHRX DN inhibitor 19
DMWIHRX HS Investigative
DMWIHRX SN CHEMBL1782887; GTPL8621; BDBM50346448; inhibitor 19 [PMID: 21476495]; 2-[2-[[[(2S,6S,9E,13S)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid; 2-(2-(((2S,6S,13S,E)-13-Amino-2-(4-hydroxybenzyl)-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carboxamido)methyl)phenyl)acetic Acid
DMWIHRX DT Small molecular drug
DMWIHRX PC 53259050
DMWIHRX MW 536.6
DMWIHRX FM C29H36N4O6
DMWIHRX IC InChI=1S/C29H36N4O6/c30-24-9-3-1-2-4-10-25(29(39)31-18-21-8-6-5-7-20(21)16-27(36)37)33-26(35)17-22(32-28(24)38)15-19-11-13-23(34)14-12-19/h1-2,5-8,11-14,22,24-25,34H,3-4,9-10,15-18,30H2,(H,31,39)(H,32,38)(H,33,35)(H,36,37)/b2-1+/t22-,24-,25-/m0/s1
DMWIHRX CS C\\1C[C@@H](C(=O)N[C@H](CC(=O)N[C@@H](CC/C=C1)C(=O)NCC2=CC=CC=C2CC(=O)O)CC3=CC=C(C=C3)O)N
DMWIHRX IK QUJXIMWUJGTUEG-CLKUPZDLSA-N
DMWIHRX IU 2-[2-[[[(2S,6S,9E,13S)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid
DMWIHRX DE Discovery agent
DMBQY3C ID DMBQY3C
DMBQY3C DN Inhibitor Idd 384
DMBQY3C HS Investigative
DMBQY3C SN INHIBITOR IDD 384; CHEMBL240719; [2,6-dimethyl-4-(2-o-tolyl-acetylamino)-benzenesulfonyl]-glycine; I84; AC1L1CKR; BDBM50222612; DB01689; 2-(2,6-dimethyl-4-(2-o-tolylacetamido)phenylsulfonamido)acetic acid; N-[(2,6-dimethyl-4-{[(2-methylphenyl)acetyl]amino}phenyl)sulfonyl]glycine; 2-[[2,6-dimethyl-4-[[2-(2-methylphenyl)acetyl]amino]phenyl]sulfonylamino]acetic acid
DMBQY3C DT Small molecular drug
DMBQY3C PC 1944
DMBQY3C MW 390.5
DMBQY3C FM C19H22N2O5S
DMBQY3C IC InChI=1S/C19H22N2O5S/c1-12-6-4-5-7-15(12)10-17(22)21-16-8-13(2)19(14(3)9-16)27(25,26)20-11-18(23)24/h4-9,20H,10-11H2,1-3H3,(H,21,22)(H,23,24)
DMBQY3C CS CC1=CC=CC=C1CC(=O)NC2=CC(=C(C(=C2)C)S(=O)(=O)NCC(=O)O)C
DMBQY3C IK CJKKMQCZOLCXAM-UHFFFAOYSA-N
DMBQY3C IU 2-[[2,6-dimethyl-4-[[2-(2-methylphenyl)acetyl]amino]phenyl]sulfonylamino]acetic acid
DMBQY3C DE Discovery agent
DMI5N23 ID DMI5N23
DMI5N23 DN IN-N01
DMI5N23 HS Investigative
DMI5N23 SN ANTISENILIN; Beta-amyloid-specific humanized monoclonal antibodies (Alzheimer's disease/glaucoma/age-related macular degeneration/traumatic brain injury), Intellect Neurosciences/IBL
DMI5N23 CP Immuno-Biological Laboratories Co Ltd
DMI5N23 DT Antibody
DMI5N23 DE Brain injury
DMZEXY9 ID DMZEXY9
DMZEXY9 DN INO-1002
DMZEXY9 HS Investigative
DMZEXY9 SN PARP inhibitors, Inotek; PARP inhibitor (erectile dysfunction), Inotek; PARP inhibitor (prostate nerve damage), Inotek; Poly (ADP ribose) polymerase inhibitor (erectile dysfunction), Inotek; Poly (ADP ribose) polymerase inhibitor (prostate nerve damage), Inotek
DMZEXY9 CP Inotek Pharmaceuticals Corp
DMZEXY9 DE Solid tumour/cancer
DMY65AR ID DMY65AR
DMY65AR DN Inosine
DMY65AR HS Investigative
DMY65AR SN Atorel; Hypoxanthine D-riboside; Hypoxanthine nucleoside; Hypoxanthine ribonucleoside; Hypoxanthine riboside; Hypoxanthosine; INO 495; Inosie; Inosin; Inosina; Inosina [INN-Spanish]; Inosine [INN:JAN]; Inosinum; Inosinum [INN-Latin]; Oxiamin; Panholic-L; Pantholic-L; Ribonosine; Selfer; Trophicardyl; beta-Inosine; hypoxanthine-ribose; inosine; iso-prinosine; (-)-Inosine; 58-63-9; 9-beta-D-Ribofuranosylhypoxanthine; AI3-52241; Hypoxanthine, 9-beta-D-ribofuranosyl-; Hypoxanthine-9-beta-D-ribofuranoside; MFCD00066770; NSC 20262
DMY65AR PC 135398641
DMY65AR MW 268.23
DMY65AR FM C10H12N4O5
DMY65AR IC UGQMRVRMYYASKQ-KQYNXXCUSA-N
DMY65AR CS C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O
DMY65AR IK 1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
DMY65AR IU 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
DMY65AR CA CAS 58-63-9
DMY65AR CB CHEBI:17596
DMY65AR DE Haemorrhagic stroke
DMLR86H ID DMLR86H
DMLR86H DN Inosinic Acid
DMLR86H HS Investigative
DMLR86H DT Small molecular drug
DMLR86H PC 135398640
DMLR86H MW 348.21
DMLR86H FM C10H13N4O8P
DMLR86H IC InChI=1S/C10H13N4O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMLR86H CS C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
DMLR86H IK GRSZFWQUAKGDAV-KQYNXXCUSA-N
DMLR86H IU [(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
DMLR86H CA CAS 131-99-7
DMLR86H CB CHEBI:17202
DMLR86H DE Discovery agent
DMIFD35 ID DMIFD35
DMIFD35 DN Inositol 1,3,4,5-tetrakisphosphate
DMIFD35 HS Investigative
DMIFD35 SN inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetraphosphate; Ins-1,3,4,5-P4; 1D-myo-inositol 1,3,4,5-tetrakisphosphate; Inositol-1,3,4,5-tetrakisphosphate; inositol-(1,3,4,5)-tetrakisphosphate; Inositol 1,3,4,5-tetraphosphate; myo-Inositol-1,3,4,5-tetrakisphosphate; CHEMBL23552; D-myo-inositol 1,3,4,5-tetrakisphosphate; CHEBI:16783; myo-Inositol, 1,3,4,5-tetrakis(dihydrogen phosphate); 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate); Ins(1,3,4,5)P4; 1bwn; 4IP; 102850-29-3; myo-Inositol 1,3,4,5-tetraphosphate
DMIFD35 DT Small molecular drug
DMIFD35 PC 107758
DMIFD35 MW 500.08
DMIFD35 FM C6H16O18P4
DMIFD35 IC InChI=1S/C6H16O18P4/c7-1-3(21-25(9,10)11)2(8)5(23-27(15,16)17)6(24-28(18,19)20)4(1)22-26(12,13)14/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2-,3?,4-,5+,6?/m0/s1
DMIFD35 CS [C@H]1([C@H](C([C@H]([C@H](C1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O
DMIFD35 IK CIPFCGZLFXVXBG-FTSGZOCFSA-N
DMIFD35 IU [(1S,2S,4S,5R)-2,4-dihydroxy-3,5,6-triphosphonooxycyclohexyl] dihydrogen phosphate
DMIFD35 CA CAS 102850-29-3
DMIFD35 CB CHEBI:16783
DMIFD35 DE Discovery agent
DM43G5Z ID DM43G5Z
DM43G5Z DN inositol 2,4,5-trisphosphate
DM43G5Z HS Investigative
DM43G5Z SN Ins(2,4,5)P3
DM43G5Z DT Small molecular drug
DM43G5Z PC 122195
DM43G5Z MW 420.1
DM43G5Z FM C6H15O15P3
DM43G5Z IC InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2-,3-,4-,5+,6+/m0/s1
DM43G5Z CS [C@@H]1([C@@H]([C@H]([C@@H]([C@H]([C@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DM43G5Z IK MMWCIQZXVOZEGG-LKPKBOIGSA-N
DM43G5Z IU [(1R,2S,3S,4S,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
DM43G5Z CA CAS 91840-07-2
DM43G5Z DE Discovery agent
DMAQU71 ID DMAQU71
DMAQU71 DN Ins(3,4,5,6)P4
DMAQU71 HS Investigative
DMAQU71 SN 1D-myo-inositol 3,4,5,6-tetrakisphosphate
DMAQU71 DT Small molecular drug
DMAQU71 PC 121920
DMAQU71 MW 500.08
DMAQU71 FM C6H16O18P4
DMAQU71 IC InChI=1S/C6H16O18P4/c7-1-2(8)4(22-26(12,13)14)6(24-28(18,19)20)5(23-27(15,16)17)3(1)21-25(9,10)11/h1-8H,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)/t1-,2+,3-,4-,5+,6+/m0/s1
DMAQU71 CS [C@H]1([C@@H]([C@@H]([C@H]([C@@H]([C@H]1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
DMAQU71 IK MRVYFOANPDTYBY-UZAAGFTCSA-N
DMAQU71 IU [(1S,2S,3R,4S,5R,6R)-2,3-dihydroxy-4,5,6-triphosphonooxycyclohexyl] dihydrogen phosphate
DMAQU71 CA CAS 112791-61-4
DMAQU71 CB CHEBI:15844
DMAQU71 DE Discovery agent
DMLZFTH ID DMLZFTH
DMLZFTH DN INS48823
DMLZFTH HS Investigative
DMLZFTH SN INS-48823; INS 48823
DMLZFTH DT Small molecular drug
DMLZFTH PC 44457307
DMLZFTH MW 812.5
DMLZFTH FM C26H31N4O20P3
DMLZFTH IC InChI=1S/C26H31N4O20P3/c31-16-6-8-29(25(35)27-16)23-20(34)19(33)14(45-23)11-43-51(37,38)49-53(41,42)50-52(39,40)44-12-15-21-22(24(46-15)30-9-7-17(32)28-26(30)36)48-18(47-21)10-13-4-2-1-3-5-13/h1-9,14-15,18-24,33-34H,10-12H2,(H,37,38)(H,39,40)(H,41,42)(H,27,31,35)(H,28,32,36)/t14-,15+,18?,19-,20-,21+,22+,23-,24+/m0/s1
DMLZFTH CS C1=CC=C(C=C1)CC2O[C@@H]3[C@H](O[C@H]([C@@H]3O2)N4C=CC(=O)NC4=O)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]5[C@@H]([C@@H]([C@H](O5)N6C=CC(=O)NC6=O)O)O
DMLZFTH IK FIZCPSOYGRAJHH-LAJHJGSGSA-N
DMLZFTH IU [[(3aR,4R,6R,6aR)-2-benzyl-4-(2,4-dioxopyrimidin-1-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methoxy-hydroxyphosphoryl] [[(2S,3R,4S,5S)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMLZFTH DE Discovery agent
DM95BL8 ID DM95BL8
DM95BL8 DN INS49266
DM95BL8 HS Investigative
DM95BL8 SN INS49266
DM95BL8 DT Small molecular drug
DM95BL8 PC 91827342
DM95BL8 MW 633.4
DM95BL8 FM C25H25N5O11P2
DM95BL8 IC InChI=1S/C25H25N5O11P2/c31-24(16-9-5-2-6-10-16)29-22-19-23(27-13-26-22)30(14-28-19)25-21-20(39-18(40-21)11-15-7-3-1-4-8-15)17(38-25)12-37-43(35,36)41-42(32,33)34/h1-10,13-14,17-18,20-21,25H,11-12H2,(H,35,36)(H2,32,33,34)(H,26,27,29,31)/t17-,18-,20-,21-,25-/m1/s1
DM95BL8 CS C1=CC=C(C=C1)C[C@@H]2O[C@@H]3[C@H](O[C@H]([C@@H]3O2)N4C=NC5=C(N=CN=C54)NC(=O)C6=CC=CC=C6)COP(=O)(O)OP(=O)(O)O
DM95BL8 IK VXEHVAOFCPIBTQ-XXXKQHFZSA-N
DM95BL8 IU [(2R,3aR,4R,6R,6aR)-4-(6-benzamidopurin-9-yl)-2-benzyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methyl phosphono hydrogen phosphate
DM95BL8 DE Discovery agent
DMFU92Z ID DMFU92Z
DMFU92Z DN Insulin molecules, Novo
DMFU92Z HS Investigative
DMFU92Z SN B10Asp; B28Asp
DMFU92Z DE Discovery agent
DMTPB8A ID DMTPB8A
DMTPB8A DN INT-777
DMTPB8A HS Investigative
DMTPB8A SN TGR5 agonist (oral, metabolic disorder), Intercept
DMTPB8A CP Intercept Pharmaceuticals Inc
DMTPB8A DT Small molecular drug
DMTPB8A PC 45483949
DMTPB8A MW 450.7
DMTPB8A FM C27H46O5
DMTPB8A IC InChI=1S/C27H46O5/c1-6-17-20-12-16(28)9-10-26(20,4)21-13-22(29)27(5)18(14(2)11-15(3)25(31)32)7-8-19(27)23(21)24(17)30/h14-24,28-30H,6-13H2,1-5H3,(H,31,32)/t14-,15+,16-,17-,18-,19+,20+,21+,22+,23+,24-,26+,27-/m1/s1
DMTPB8A CS CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3C[C@@H]([C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)C[C@H](C)C(=O)O)C)O)C)O
DMTPB8A IK NPBCMXATLRCCLF-IRRLEISYSA-N
DMTPB8A IU (2S,4R)-4-[(3R,5S,6R,7R,8R,9S,10S,12S,13R,14S,17R)-6-ethyl-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid
DMTPB8A CA CAS 1199796-29-6
DMTPB8A DE Metabolic disorder
DMB9AIX ID DMB9AIX
DMB9AIX DN Interleukin-1-alpha - Amgen/Roche
DMB9AIX HS Investigative
DMB9AIX SN Interleukin-1-alpha - Immunex
DMB9AIX DE Discovery agent
DM3D9XY ID DM3D9XY
DM3D9XY DN interleukin-2, Roussel Uclaf
DM3D9XY HS Investigative
DM3D9XY SN IL-2, Elf Sanofi; IL-2, Roussel Uclaf; RU-49637; U-49637; interleukin-2, Elf Sanofi
DM3D9XY DE Discovery agent
DM8BZVI ID DM8BZVI
DM8BZVI DN INV-311
DM8BZVI HS Investigative
DM8BZVI SN Myeloperoxidase inhibitors (vascular/inflammatory disease), InVasc Therapeutics
DM8BZVI CP InVasc Therapeutics Inc
DM8BZVI DE Inflammation
DM3FZ6P ID DM3FZ6P
DM3FZ6P DN IODIDE
DM3FZ6P HS Investigative
DM3FZ6P SN Iodide ion; 20461-54-5; Iodide-127; Iodide(1-); iodinane; trihydridoiodine; iodine anion; Iodide anion; Iodide Salt; lambda(3)-iodane; UNII-09G4I6V86Q; I-; CHEMBL185537; CHEBI:16382; 09G4I6V86Q; Colloidal iodine; Iodine ion; Iodide ion(1-); Iodine(1-); Iodine, ion (I1-); AC1L1IXU; hydriodic acid, ion(1-); CTK1A4386; CHEBI:37181; BDBM26981; XMBWDFGMSWQBCA-UHFFFAOYSA-M; Iodide (6CI,7CI,8CI,9CI); Ba 2796; DB12754; LS-193152
DM3FZ6P DT Small molecular drug
DM3FZ6P PC 30165
DM3FZ6P MW 126.904
DM3FZ6P FM I-
DM3FZ6P IC InChI=1S/HI/h1H/p-1
DM3FZ6P CS [I-]
DM3FZ6P IK XMBWDFGMSWQBCA-UHFFFAOYSA-M
DM3FZ6P IU iodide
DM3FZ6P CA CAS 20461-54-5
DM3FZ6P CB CHEBI:16382
DM3FZ6P DE Discovery agent
DMM4XVL ID DMM4XVL
DMM4XVL DN Iodoacetamide
DMM4XVL HS Investigative
DMM4XVL SN iodoacetamide; 2-Iodoacetamide; 144-48-9; Monoiodoacetamide; Surauto; ACETAMIDE, 2-IODO-; 2-Iodo-acetamide; USAF D-1; alpha-Iodoacetamide; CCRIS 7710; C2H4INO; UNII-ZRH8M27S79; N-(3-Methoxy-4-butoxybenzyl)thiobarbituric acid; .alpha.-Iodoacetamide; AI3-51841; NSC 9581; EINECS 205-630-1; BRN 1739080; ZRH8M27S79; PGLTVOMIXTUURA-UHFFFAOYSA-N; MFCD00008028; Iodoacetamide, 98%; deltop; iodoacetoamide; a-iodoacetamide; iodo acetamide; 2-iodanylethanamide; sJYHCaVIKTp@; Alpha-iodo acetamide; Iodoacetamide, BioUltra; PubChem12542; ACMC-209csv
DMM4XVL DT Small molecular drug
DMM4XVL PC 3727
DMM4XVL MW 184.96
DMM4XVL FM C2H4INO
DMM4XVL IC InChI=1S/C2H4INO/c3-1-2(4)5/h1H2,(H2,4,5)
DMM4XVL CS C(C(=O)N)I
DMM4XVL IK PGLTVOMIXTUURA-UHFFFAOYSA-N
DMM4XVL IU 2-iodoacetamide
DMM4XVL CA CAS 144-48-9
DMM4XVL DE Discovery agent
DM7AHNF ID DM7AHNF
DM7AHNF DN iodoaminopotentidine
DM7AHNF HS Investigative
DM7AHNF SN I-APT; CHEMBL72193; 126632-01-7; 4-amino-N-[2-[[N-cyano-N'-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]carbamimidoyl]amino]ethyl]-3-iodobenzamide; AC1L492K; GTPL1232; DTXSID40155260; BDBM50406642; N-(2-(4-Amino-3-iodobenzamido)ethyl)-N'-cyano-N''(3-(3-(1-piperidinylmethyl)phenoxy)propyl)guanidine; L000314; Benzamide, 4-amino-N-(2-(((cyanoamino)((3-(3-(1-piperidinylmethyl)phenoxy)propyl)amino)methylene)amino)ethyl)-3-iodo-
DM7AHNF DT Small molecular drug
DM7AHNF PC 181461
DM7AHNF MW 603.5
DM7AHNF FM C26H34IN7O2
DM7AHNF IC InChI=1S/C26H34IN7O2/c27-23-17-21(8-9-24(23)29)25(35)30-11-12-32-26(33-19-28)31-10-5-15-36-22-7-4-6-20(16-22)18-34-13-2-1-3-14-34/h4,6-9,16-17H,1-3,5,10-15,18,29H2,(H,30,35)(H2,31,32,33)
DM7AHNF CS C1CCN(CC1)CC2=CC(=CC=C2)OCCCN=C(NCCNC(=O)C3=CC(=C(C=C3)N)I)NC#N
DM7AHNF IK VJTYCMQYDRXNNY-UHFFFAOYSA-N
DM7AHNF IU 4-amino-N-[2-[[N-cyano-N'-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]carbamimidoyl]amino]ethyl]-3-iodobenzamide
DM7AHNF CA CAS 126632-01-7
DM7AHNF DE Discovery agent
DMOA2J8 ID DMOA2J8
DMOA2J8 DN iodocyanopindolol
DMOA2J8 HS Investigative
DMOA2J8 SN 4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3-iodo-1H-indole-2-carbonitrile; GTPL562; GTPL540
DMOA2J8 DT Small molecular drug
DMOA2J8 PC 68618
DMOA2J8 MW 399.23
DMOA2J8 FM C15H18IN3O2
DMOA2J8 IC InChI=1S/C15H18IN3O2/c1-9(2)18-7-10(20)8-21-13-5-3-4-11-14(13)15(16)12(6-17)19-11/h3-5,9-10,18-20H,7-8H2,1-2H3
DMOA2J8 CS CC(C)NCC(COC1=CC=CC2=C1C(=C(N2)C#N)I)O
DMOA2J8 IK WGSPBWSPJOBKNT-UHFFFAOYSA-N
DMOA2J8 IU 4-[2-hydroxy-3-(propan-2-ylamino)propoxy]-3-iodo-1H-indole-2-carbonitrile
DMOA2J8 CA CAS 83498-72-0
DMOA2J8 DE Discovery agent
DM3BL0G ID DM3BL0G
DM3BL0G DN IODOINDOMETHACIN
DM3BL0G HS Investigative
DM3BL0G SN Iodoindomethacin; 1-(4-IODOBENZOYL)-5-METHOXY-2-METHYL INDOLE-3-ACETIC ACID; CHEMBL590284; IMM; AC1L9LAG; SCHEMBL13290295; BDBM50308511; DB07983; 1-(4-iodobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid; [1-(4-iodobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; 2-[1-(4-iodobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid; {1-[(4-iodophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
DM3BL0G DT Small molecular drug
DM3BL0G PC 447835
DM3BL0G MW 449.2
DM3BL0G FM C19H16INO4
DM3BL0G IC InChI=1S/C19H16INO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
DM3BL0G CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)I)C=CC(=C2)OC)CC(=O)O
DM3BL0G IK CXBFZYKAVCAPSV-UHFFFAOYSA-N
DM3BL0G IU 2-[1-(4-iodobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
DM3BL0G DE Discovery agent
DMF8EJ6 ID DMF8EJ6
DMF8EJ6 DN Iodo-Phenylalanine
DMF8EJ6 HS Investigative
DMF8EJ6 SN 4-Iodo-L-phenylalanine; 24250-85-9; 4-Iodophenylalanine; L-4-Iodophenylalanine; H-Phe(4-I)-OH; IODO-PHENYLALANINE; (2S)-2-amino-3-(4-iodophenyl)propanoic acid; p-Iodo-l-phenylalanine; (S)-2-Amino-3-(4-iodophenyl)propanoic acid; Phenylalanine, 4-iodo-; p-IODOPHENYLALANINE; L-Phenylalanine, 4-iodo-; UNII-J882Z73MPL; L-4-Iodophe; (L)-4-iodophenylalanine; 1991-81-7; J882Z73MPL; MFCD00002602; (2S)-2-azanyl-3-(4-iodophenyl)propanoic acid; DL-4-iodophenylalanine; para-Iodophenylalanine; 4-iod-l-phenylalanin; 4-Iodo-L-phenylalaine
DMF8EJ6 DT Small molecular drug
DMF8EJ6 PC 134497
DMF8EJ6 MW 291.09
DMF8EJ6 FM C9H10INO2
DMF8EJ6 IC InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m0/s1
DMF8EJ6 CS C1=CC(=CC=C1C[C@@H](C(=O)O)N)I
DMF8EJ6 IK PZNQZSRPDOEBMS-QMMMGPOBSA-N
DMF8EJ6 IU (2S)-2-amino-3-(4-iodophenyl)propanoic acid
DMF8EJ6 CA CAS 1991-81-7
DMF8EJ6 CB CHEBI:44964
DMF8EJ6 DE Discovery agent
DM0749Z ID DM0749Z
DM0749Z DN IODOPRIDE
DM0749Z HS Investigative
DM0749Z SN Iodopride; CHEMBL2115023; 115860-70-3; AC1MIZFL; DTXSID40151207; N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-iodo-2-methoxybenzamide; BDBM50452484; N-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2-methoxybenzamide; Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-iodo-2-methoxy-, (R)-
DM0749Z DT Small molecular drug
DM0749Z PC 3082754
DM0749Z MW 388.24
DM0749Z FM C15H21IN2O2
DM0749Z IC InChI=1S/C15H21IN2O2/c1-3-18-8-4-5-12(18)10-17-15(19)13-9-11(16)6-7-14(13)20-2/h6-7,9,12H,3-5,8,10H2,1-2H3,(H,17,19)/t12-/m1/s1
DM0749Z CS CCN1CCC[C@@H]1CNC(=O)C2=C(C=CC(=C2)I)OC
DM0749Z IK JHMTYLJMPBFCTD-GFCCVEGCSA-N
DM0749Z IU N-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-5-iodo-2-methoxybenzamide
DM0749Z CA CAS 115860-70-3
DM0749Z DE Discovery agent
DMDA6VL ID DMDA6VL
DMDA6VL DN IODOPROXYFAN
DMDA6VL HS Investigative
DMDA6VL SN Iodoproxyfan; CHEMBL19010; 152028-96-1; 5-[3-[(4-iodophenyl)methoxy]propyl]-1H-imidazole; 5-{3-[(4-iodophenyl)methoxy]propyl}-1H-imidazole; 4-[3-[(4-iodophenyl)methoxy]propyl]-3H-imidazole; AC1L31V0; SCHEMBL3089477; GTPL1253; 3-(1H-Imidazol-4-yl)propyl-(4-iodophenyl)methyl ether; BDBM22916; DTXSID30164942; ZINC5117186; PDSP2_000542; PDSP1_000544; L010934; 1H-Imidazole, 4-(3-((4-iodophenyl)methoxy)propyl)-
DMDA6VL DT Small molecular drug
DMDA6VL PC 132937
DMDA6VL MW 342.18
DMDA6VL FM C13H15IN2O
DMDA6VL IC InChI=1S/C13H15IN2O/c14-12-5-3-11(4-6-12)9-17-7-1-2-13-8-15-10-16-13/h3-6,8,10H,1-2,7,9H2,(H,15,16)
DMDA6VL CS C1=CC(=CC=C1COCCCC2=CN=CN2)I
DMDA6VL IK DCQNAFOCXVCDLB-UHFFFAOYSA-N
DMDA6VL IU 5-[3-[(4-iodophenyl)methoxy]propyl]-1H-imidazole
DMDA6VL CA CAS 152028-96-1
DMDA6VL DE Discovery agent
DMXYFMB ID DMXYFMB
DMXYFMB DN IODOSULPIRIDE
DMXYFMB HS Investigative
DMXYFMB SN CHEMBL307023; BDBM50040082; N-(1-Ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-5-sulfamoyl-benzamide(iodosulpiride); N-(1-Ethyl-pyrrolidin-2-ylmethyl)-2-iodo-6-methoxy-3-sulfamoyl-benzamide (iodosulpride)
DMXYFMB DT Small molecular drug
DMXYFMB PC 44312731
DMXYFMB MW 467.3
DMXYFMB FM C15H22IN3O4S
DMXYFMB IC InChI=1S/C15H22IN3O4S/c1-3-19-8-4-5-10(19)9-18-15(20)13-11(23-2)6-7-12(14(13)16)24(17,21)22/h6-7,10H,3-5,8-9H2,1-2H3,(H,18,20)(H2,17,21,22)/t10-/m0/s1
DMXYFMB CS CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2I)S(=O)(=O)N)OC
DMXYFMB IK HCKMONAVUWHQOT-JTQLQIEISA-N
DMXYFMB IU N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-iodo-6-methoxy-3-sulfamoylbenzamide
DMXYFMB DE Discovery agent
DMOE8LT ID DMOE8LT
DMOE8LT DN IODOSUPROFEN
DMOE8LT HS Investigative
DMOE8LT SN Iodosuprofen; CHEMBL589253; AC1NE3NB; BDBM50308510; 2-[4-(5-iodothiophene-2-carbonyl)phenyl]propanoic
DMOE8LT DT Small molecular drug
DMOE8LT PC 4636051
DMOE8LT MW 386.21
DMOE8LT FM C14H11IO3S
DMOE8LT IC InChI=1S/C14H11IO3S/c1-8(14(17)18)9-2-4-10(5-3-9)13(16)11-6-7-12(15)19-11/h2-8H,1H3,(H,17,18)
DMOE8LT CS CC(C1=CC=C(C=C1)C(=O)C2=CC=C(S2)I)C(=O)O
DMOE8LT IK UIZPHGUBGPJBAR-UHFFFAOYSA-N
DMOE8LT IU 2-[4-(5-iodothiophene-2-carbonyl)phenyl]propanoic acid
DMOE8LT DE Discovery agent
DMQMH6S ID DMQMH6S
DMQMH6S DN Iodotubercidin
DMQMH6S HS Investigative
DMQMH6S SN IODOTUBERCIDIN
DMQMH6S DT Small molecular drug
DMQMH6S PC 46875276
DMQMH6S MW 392.15
DMQMH6S FM C11H13IN4O4
DMQMH6S IC InChI=1S/C11H13IN4O4/c12-4-1-16(10-6(4)9(13)14-3-15-10)11-8(19)7(18)5(2-17)20-11/h1,3,5,7-8,11,17-19H,2H2,(H2,13,14,15)/t5-,7-,8-,11?/m1/s1
DMQMH6S CS C1=C(C2=C(N=CN=C2N1C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)I
DMQMH6S IK WHSIXKUPQCKWBY-YNJARDAQSA-N
DMQMH6S IU (3R,4S,5R)-2-(4-amino-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
DMQMH6S DE Discovery agent
DMO73M9 ID DMO73M9
DMO73M9 DN Iodyl-benzene
DMO73M9 HS Investigative
DMO73M9 SN Iodoxybenzene; Iodyl-benzene; Benzene, iodyl-; phenyliodane dioxide; 696-33-3; iodylbenzene; CHEMBL325174; 1-iodylbenzene; NSC 60684; AC1Q6QYY; AC1L2RNB; SCHEMBL751952; CTK2F5229; DTXSID70219869; BDOLQESNFGCNSC-UHFFFAOYSA-N; NSC60684; BDBM50075022; NSC-60684; AKOS000531141; BAS 00121555; SC-90106; FT-0658671; A19070
DMO73M9 DT Small molecular drug
DMO73M9 PC 101840
DMO73M9 MW 236.01
DMO73M9 FM C6H5IO2
DMO73M9 IC InChI=1S/C6H5IO2/c8-7(9)6-4-2-1-3-5-6/h1-5H
DMO73M9 CS C1=CC=C(C=C1)I(=O)=O
DMO73M9 IK BDOLQESNFGCNSC-UHFFFAOYSA-N
DMO73M9 IU iodylbenzene
DMO73M9 CA CAS 696-33-3
DMO73M9 DE Discovery agent
DMYG0M5 ID DMYG0M5
DMYG0M5 DN IOX1
DMYG0M5 HS Investigative
DMYG0M5 SN 5852-78-8; 8-Hydroxyquinoline-5-Carboxylic Acid; 8-Hydroxy-5-quinolinecarboxylic acid; 5-Carboxy-8-hydroxyquinoline; IOX 1; UNII-JM015YQC1C; IOX-1; 5-carboxy-8HQ; 5-Quinolinecarboxylic acid, 8-hydroxy-; JM015YQC1C; CHEMBL1230640; 4bio; 4jht; 8XQ; 4ie4; AC1LA0UV; MLS002729056; GTPL8230; SCHEMBL6068195; KS-00000PPH; CHEBI:93239; CTK1E0142; DTXSID20207236; AOB6499; JGRPKOGHYBAVMW-UHFFFAOYSA-N; MolPort-006-673-354; HMS3653E21; ZINC5933707; BCP16996; s7234; BDBM50396018; 2184AH; IOX1, > AKOS016371793
DMYG0M5 DT Small molecular drug
DMYG0M5 PC 459617
DMYG0M5 MW 189.17
DMYG0M5 FM C10H7NO3
DMYG0M5 IC InChI=1S/C10H7NO3/c12-8-4-3-7(10(13)14)6-2-1-5-11-9(6)8/h1-5,12H,(H,13,14)
DMYG0M5 CS C1=CC2=C(C=CC(=C2N=C1)O)C(=O)O
DMYG0M5 IK JGRPKOGHYBAVMW-UHFFFAOYSA-N
DMYG0M5 IU 8-hydroxyquinoline-5-carboxylic acid
DMYG0M5 CA CAS 5852-78-8
DMYG0M5 CB CHEBI:93239
DMYG0M5 DE Discovery agent
DMQ0X7I ID DMQ0X7I
DMQ0X7I DN IOX2
DMQ0X7I HS Investigative
DMQ0X7I SN compound 6
DMQ0X7I DT Small molecular drug
DMQ0X7I PC 54685215
DMQ0X7I MW 352.3
DMQ0X7I FM C19H16N2O5
DMQ0X7I IC InChI=1S/C19H16N2O5/c22-15(23)10-20-18(25)16-17(24)13-8-4-5-9-14(13)21(19(16)26)11-12-6-2-1-3-7-12/h1-9,24H,10-11H2,(H,20,25)(H,22,23)
DMQ0X7I CS C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O
DMQ0X7I IK CAOSCCRYLYQBES-UHFFFAOYSA-N
DMQ0X7I IU 2-[(1-benzyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]acetic acid
DMQ0X7I CA CAS 931398-72-0
DMQ0X7I CB CHEBI:95087
DMQ0X7I DE Discovery agent
DMIX7CP ID DMIX7CP
DMIX7CP DN IP-1200
DMIX7CP HS Investigative
DMIX7CP CP Shire Pharmaceutical Development Ltd
DMIX7CP DE Erectile dysfunction
DMB2YXN ID DMB2YXN
DMB2YXN DN Ip5I
DMB2YXN HS Investigative
DMB2YXN SN diinosine-5',5"-pentaphosphate
DMB2YXN DT Small molecular drug
DMB2YXN PC 136203454
DMB2YXN MW 913.3
DMB2YXN FM C20H22N8O24P5-5
DMB2YXN IC InChI=1S/C20H27N8O24P5/c29-11-7(47-19(13(11)31)27-5-25-9-15(27)21-3-23-17(9)33)1-45-57(44,52-56(42,43)51-55(40,41)50-54(38,39)49-53(35,36)37)46-2-8-12(30)14(32)20(48-8)28-6-26-10-16(28)22-4-24-18(10)34/h3-8,11-14,19-20,29-32H,1-2H2,(H,38,39)(H,40,41)(H,42,43)(H,21,23,33)(H,22,24,34)(H2,35,36,37)/p-5/t7-,8-,11?,12?,13?,14?,19-,20-,57?/m1/s1
DMB2YXN CS C1=NC2=C(C(=O)N1)N=CN2[C@H]3C(C([C@H](O3)COP(=O)(OC[C@@H]4C(C([C@@H](O4)N5C=NC6=C5N=CNC6=O)O)O)OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-])O)O
DMB2YXN IK GFFAYTMBCSSULP-ICIWVTHHSA-I
DMB2YXN IU [[[bis[[(2R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy]phosphoryloxy-oxidophosphoryl]oxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
DMB2YXN DE Discovery agent
DM6OHVU ID DM6OHVU
DM6OHVU DN iperoxo
DM6OHVU HS Investigative
DM6OHVU SN iperoxo; CHEMBL3121473; GTPL6937; BDBM50448377; [4-(2-Isoxazoline-3-yloxy)-2-butynyl]trimethylaminium
DM6OHVU DT Small molecular drug
DM6OHVU PC 10104167
DM6OHVU MW 197.25
DM6OHVU FM C10H17N2O2+
DM6OHVU IC InChI=1S/C10H17N2O2/c1-12(2,3)7-4-5-8-13-10-6-9-14-11-10/h6-9H2,1-3H3/q+1
DM6OHVU CS C[N+](C)(C)CC#CCOC1=NOCC1
DM6OHVU IK WXXOCGISBCTWPW-UHFFFAOYSA-N
DM6OHVU IU 4-(4,5-dihydro-1,2-oxazol-3-yloxy)but-2-ynyl-trimethylazanium
DM6OHVU DE Discovery agent
DM42ENF ID DM42ENF
DM42ENF DN IPRONIAZIDE
DM42ENF HS Investigative
DM42ENF SN iproniazid; 54-92-2; N'-Isopropylisonicotinohydrazide; Iprazid; Marsilid; Iproniazide; Euphozid; Rivivol; Marsalid; Yatrozide; 4-Pyridinecarboxylic acid, 2-(1-methylethyl)hydrazide; Iproniazyd [Polish]; Propilniazida; Ipronid; Ro 2-4572; N'-Isopropylisonicotinoylhydrazide; Iproniazide [INN-French]; Iproniazidum [INN-Latin]; UNII-D892HFI3XA; Iproniazida [INN-Spanish]; 1-Isonicotinoyl-2-isopropylhydrazine; N'-isopropylpyridine-4-carbohydrazide; CCRIS 9177; C9H13N3O; P 887; EINECS 200-218-8; Isonicotinic acid 2-isopropylhydrazide; BRN 0
DM42ENF DT Small molecular drug
DM42ENF PC 3748
DM42ENF MW 179.22
DM42ENF FM C9H13N3O
DM42ENF IC InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
DM42ENF CS CC(C)NNC(=O)C1=CC=NC=C1
DM42ENF IK NYMGNSNKLVNMIA-UHFFFAOYSA-N
DM42ENF IU N'-propan-2-ylpyridine-4-carbohydrazide
DM42ENF CA CAS 54-92-2
DM42ENF CB CHEBI:5958
DM42ENF DE Discovery agent
DM0T8ZU ID DM0T8ZU
DM0T8ZU DN IPS-01003
DM0T8ZU HS Investigative
DM0T8ZU SN EGFR kinase antagonist (cancer), InnoPharmaScreen
DM0T8ZU CP InnoPharmaScreen Inc
DM0T8ZU DE Solid tumour/cancer
DMYEM59 ID DMYEM59
DMYEM59 DN Ipsalazide
DMYEM59 HS Investigative
DMYEM59 SN Ipsalazida; Ipsalazida [Spanish]; Ipsalazide; Ipsalazide [BAN:INN]; Ipsalazide [INN:BAN]; Ipsalazido; Ipsalazido [Spanish]; Ipsalazidum; Ipsalazidum [Latin]; LS-36378; SCHEMBL596652; ZINC4216628; (E)-5-((4-(((Carboxymethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid; (E)-p-((3-Carboxy-4-hydroxyphenyl)azo)hippuric acid; 499H4332KZ; 80573-03-1; BX 650 A; BX-650A; Benzoic acid, 5-((4-(((carboxymethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-; CHEMBL2104872; SCHEMBL11165440; UNII-499H4332KZ
DMYEM59 PC 72003
DMYEM59 MW 343.29
DMYEM59 FM C16H13N3O6
DMYEM59 IC CQSRTOJJBONKMC-UHFFFAOYSA-N
DMYEM59 CS C1=CC(=CC=C1C(=O)NCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
DMYEM59 IK 1S/C16H13N3O6/c20-13-6-5-11(7-12(13)16(24)25)19-18-10-3-1-9(2-4-10)15(23)17-8-14(21)22/h1-7,20H,8H2,(H,17,23)(H,21,22)(H,24,25)
DMYEM59 IU 5-[[4-(carboxymethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid
DMYEM59 CA CAS 80573-03-1
DMYEM59 DE Inflammatory bowel disease
DM2MXIK ID DM2MXIK
DM2MXIK DN IQM-97423
DM2MXIK HS Investigative
DM2MXIK SN IQM-97,423
DM2MXIK DT Small molecular drug
DM2MXIK PC 11757476
DM2MXIK MW 558.7
DM2MXIK FM C31H38N6O4
DM2MXIK IC InChI=1S/C31H38N6O4/c1-31(2,3)35-29(40)34-25(16-21-18-32-23-13-8-7-12-22(21)23)28(39)33-24-14-9-15-36-26(24)17-27(38)37(30(36)41)19-20-10-5-4-6-11-20/h4-8,10-13,18,24-26,32H,9,14-17,19H2,1-3H3,(H,33,39)(H2,34,35,40)/t24-,25+,26+/m1/s1
DM2MXIK CS CC(C)(C)NC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]3CCCN4[C@H]3CC(=O)N(C4=O)CC5=CC=CC=C5
DM2MXIK IK JQMXXJDAKTTXOB-ZNZIZOMTSA-N
DM2MXIK IU (2S)-N-[(4aS,5R)-2-benzyl-1,3-dioxo-4,4a,5,6,7,8-hexahydropyrido[1,2-c]pyrimidin-5-yl]-2-(tert-butylcarbamoylamino)-3-(1H-indol-3-yl)propanamide
DM2MXIK DE Discovery agent
DMOQBGP ID DMOQBGP
DMOQBGP DN IRAK-1/4 inhibitor
DMOQBGP HS Investigative
DMOQBGP SN IRAK-1-4 Inhibitor I; 509093-47-4; IRAK-1/4 Inhibitor I; IRAK-1/4 Inhibitor; Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor; CHEMBL379787; N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole; N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide; N-[1-[2-(4-morpholinyl)ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide; IRAK-1-4InhibitorI; IRAK1/4 Inhibitor I; MLS006010636; SCHEMBL3600534; GTPL5990; CTK8E9833; DTXSID50475143; QTCFYQHZJIIHBS-UHFFFAOYSA-N; MolPort-028-617-757; HMS3263A20; HMS3229G05
DMOQBGP DT Small molecular drug
DMOQBGP PC 11983295
DMOQBGP MW 395.4
DMOQBGP FM C20H21N5O4
DMOQBGP IC InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
DMOQBGP CS C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-]
DMOQBGP IK QTCFYQHZJIIHBS-UHFFFAOYSA-N
DMOQBGP IU N-[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]-3-nitrobenzamide
DMOQBGP CA CAS 509093-47-4
DMOQBGP DE Discovery agent
DMC80TA ID DMC80TA
DMC80TA DN IRAK4 inhibitor 4b
DMC80TA HS Investigative
DMC80TA SN CHEMBL256713; N-[2-methoxy-4-(morpholin-4-yl)phenyl]-6-(1H-pyrazol-5-yl)pyridine-2-carboxamide; DL1; GTPL8080; SCHEMBL18427794; BDBM50373415; IRAK4 inhibitor 4b [PMID: 18474425]
DMC80TA DT Small molecular drug
DMC80TA PC 44449334
DMC80TA MW 379.4
DMC80TA FM C20H21N5O3
DMC80TA IC InChI=1S/C20H21N5O3/c1-27-19-13-14(25-9-11-28-12-10-25)5-6-17(19)23-20(26)18-4-2-3-15(22-18)16-7-8-21-24-16/h2-8,13H,9-12H2,1H3,(H,21,24)(H,23,26)
DMC80TA CS COC1=C(C=CC(=C1)N2CCOCC2)NC(=O)C3=CC=CC(=N3)C4=CC=NN4
DMC80TA IK RAFFLDOJXQAJPF-UHFFFAOYSA-N
DMC80TA IU N-(2-methoxy-4-morpholin-4-ylphenyl)-6-(1H-pyrazol-5-yl)pyridine-2-carboxamide
DMC80TA DE Discovery agent
DM1XHNW ID DM1XHNW
DM1XHNW DN IRAK4 inhibitor rac-45
DM1XHNW HS Investigative
DM1XHNW SN CHEMBL401633; GTPL8081; SCHEMBL18427753; BDBM50377180; IRAK4 inhibitor rac-45 [PMID: 18501603]
DM1XHNW DT Small molecular drug
DM1XHNW PC 25169383
DM1XHNW MW 313.78
DM1XHNW FM C16H16ClN5
DM1XHNW IC InChI=1S/C16H16ClN5/c17-11-4-5-16-19-9-14(22(16)10-11)13-2-1-3-15(21-13)20-12-6-7-18-8-12/h1-5,9-10,12,18H,6-8H2,(H,20,21)
DM1XHNW CS C1CNCC1NC2=CC=CC(=N2)C3=CN=C4N3C=C(C=C4)Cl
DM1XHNW IK NAMQQRIYZTTYCJ-UHFFFAOYSA-N
DM1XHNW IU 6-(6-chloroimidazo[1,2-a]pyridin-3-yl)-N-pyrrolidin-3-ylpyridin-2-amine
DM1XHNW DE Discovery agent
DM5S7IG ID DM5S7IG
DM5S7IG DN Irbesartan
DM5S7IG HS Investigative
DM5S7IG SN Aprovel; Avapro; Karvea; SR-47436; BMS-186295; BMS 186295; SR 47436; UNII-J0E2756Z7N; CHEMBL1513; YOSHYTLCDANDAN-UHFFFAOYSA-N; J0E2756Z7N; NCGC00095122-01; AK-57149; DSSTox_CID_3169; Irbesartan [USAN:INN]
DM5S7IG TC Antiviral Agents
DM5S7IG DT Small molecular drug
DM5S7IG PC 3749
DM5S7IG MW 428.5
DM5S7IG FM C25H28N6O
DM5S7IG IC InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
DM5S7IG CS CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DM5S7IG IK YOSHYTLCDANDAN-UHFFFAOYSA-N
DM5S7IG IU 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
DM5S7IG CA CAS 138402-11-6
DM5S7IG CB CHEBI:5959
DM5S7IG DE Coronavirus Disease 2019 (COVID-19)
DMMGQZ8 ID DMMGQZ8
DMMGQZ8 DN IRL-1722
DMMGQZ8 HS Investigative
DMMGQZ8 SN CHEMBL418898; IRL-1722; BDBM50287880; (S)-3-(1H-Indol-3-yl)-2-[(2-phenyl-cyclopropanecarbonyl)-amino]-propionic acid
DMMGQZ8 DT Small molecular drug
DMMGQZ8 PC 9863132
DMMGQZ8 MW 348.4
DMMGQZ8 FM C21H20N2O3
DMMGQZ8 IC InChI=1S/C21H20N2O3/c24-20(17-11-16(17)13-6-2-1-3-7-13)23-19(21(25)26)10-14-12-22-18-9-5-4-8-15(14)18/h1-9,12,16-17,19,22H,10-11H2,(H,23,24)(H,25,26)/t16?,17?,19-/m0/s1
DMMGQZ8 CS C1C(C1C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)C4=CC=CC=C4
DMMGQZ8 IK DRPGADQFIJJWNZ-TVPLGVNVSA-N
DMMGQZ8 IU (2S)-3-(1H-indol-3-yl)-2-[(2-phenylcyclopropanecarbonyl)amino]propanoic acid
DMMGQZ8 DE Discovery agent
DML0S7V ID DML0S7V
DML0S7V DN IRL-1841
DML0S7V HS Investigative
DML0S7V SN CHEMBL439759; 169544-71-2; IRL-1841; SCHEMBL8721943; CTK0E5016; DTXSID80431752; BDBM50071431; L-Tryptophan, N-[N-(3,5-dimethylbenzoyl)-N-methyl-D-phenylalanyl]-; (S)-2-{(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-phenyl-propionylamino}-3-(1H-indol-3-yl)-propionic acid
DML0S7V DT Small molecular drug
DML0S7V PC 9848710
DML0S7V MW 497.6
DML0S7V FM C30H31N3O4
DML0S7V IC InChI=1S/C30H31N3O4/c1-19-13-20(2)15-22(14-19)29(35)33(3)27(16-21-9-5-4-6-10-21)28(34)32-26(30(36)37)17-23-18-31-25-12-8-7-11-24(23)25/h4-15,18,26-27,31H,16-17H2,1-3H3,(H,32,34)(H,36,37)/t26-,27+/m0/s1
DML0S7V CS CC1=CC(=CC(=C1)C(=O)N(C)[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)C
DML0S7V IK JFNANCYIHVAEQV-RRPNLBNLSA-N
DML0S7V IU (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid
DML0S7V CA CAS 169544-71-2
DML0S7V DE Discovery agent
DMNF70P ID DMNF70P
DMNF70P DN IS1
DMNF70P HS Investigative
DMNF70P SN N-{2-Furan-2-yl-1-[(pyridin-3-ylmethyl)-carbamoyl]-vinyl}-benzamide; IS1; AC1MFOLV; SMR000176552; Salor-int l253618-1ea; MLS000551960; GTPL8517; CHEMBL1499206; SCHEMBL10092076; MolPort-000-526-523; HMS2374A20; ZINC4892255; AKOS000531713; BAS 01151561; ACM324562018; ST053578; SR-01000425582; SR-01000425582-1; N-[(Z)-1-furan-2-yl-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide; N~1~-((Z)-2-(2-furyl)-1-{[(3-pyridylmethyl)amino]carbonyl}-1-ethenyl)benzamide
DMNF70P DT Small molecular drug
DMNF70P PC 2874943
DMNF70P MW 347.4
DMNF70P FM C20H17N3O3
DMNF70P IC InChI=1S/C20H17N3O3/c24-19(16-7-2-1-3-8-16)23-18(12-17-9-5-11-26-17)20(25)22-14-15-6-4-10-21-13-15/h1-13H,14H2,(H,22,25)(H,23,24)/b18-12-
DMNF70P CS C1=CC=C(C=C1)C(=O)N/C(=C\\C2=CC=CO2)/C(=O)NCC3=CN=CC=C3
DMNF70P IK ANTQNDKESCDJPE-PDGQHHTCSA-N
DMNF70P IU N-[(Z)-1-(furan-2-yl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide
DMNF70P DE Discovery agent
DMQ5GA9 ID DMQ5GA9
DMQ5GA9 DN IS20
DMQ5GA9 HS Investigative
DMQ5GA9 SN N-{2-(4-Methoxy-phenyl)-1-[(pyridin-3-ylmethyl)-carbamoyl]-vinyl}-benzamide; N-[(Z)-1-(4-methoxyphenyl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide; IS20; AC1NU0FP; MLS001215457; GTPL8518; CHEMBL1387323; SCHEMBL10192303; MolPort-019-741-307; HMS2912O06; ZINC13370608; AKOS000531635; SMR000608280; BAS 01151555; ST50247237; SR-01000425577; SR-01000425577-1; (2Z)-3-(4-methoxyphenyl)-2-(phenylcarbonylamino)-N-(3-pyridylmethyl)prop-2-ena mide
DMQ5GA9 DT Small molecular drug
DMQ5GA9 PC 5442665
DMQ5GA9 MW 387.4
DMQ5GA9 FM C23H21N3O3
DMQ5GA9 IC InChI=1S/C23H21N3O3/c1-29-20-11-9-17(10-12-20)14-21(26-22(27)19-7-3-2-4-8-19)23(28)25-16-18-6-5-13-24-15-18/h2-15H,16H2,1H3,(H,25,28)(H,26,27)/b21-14-
DMQ5GA9 CS COC1=CC=C(C=C1)/C=C(/C(=O)NCC2=CN=CC=C2)\\NC(=O)C3=CC=CC=C3
DMQ5GA9 IK KKDANILRTKQMGA-STZFKDTASA-N
DMQ5GA9 IU N-[(Z)-1-(4-methoxyphenyl)-3-oxo-3-(pyridin-3-ylmethylamino)prop-1-en-2-yl]benzamide
DMQ5GA9 DE Discovery agent
DMXPMA6 ID DMXPMA6
DMXPMA6 DN IS20I
DMXPMA6 HS Investigative
DMXPMA6 DE Discovery agent
DMU6QXV ID DMU6QXV
DMU6QXV DN ISA-2011B
DMU6QXV HS Investigative
DMU6QXV SN ISA-2011B; 1395347-24-6; GTPL8444; SCHEMBL10020974; AKOS032946525; CS-6374
DMU6QXV DT Small molecular drug
DMU6QXV PC 49853637
DMU6QXV MW 423.8
DMU6QXV FM C22H18ClN3O4
DMU6QXV IC InChI=1S/C22H18ClN3O4/c1-25-9-20(27)26-17(22(25)28)4-11-5-18-19(30-10-29-18)7-13(11)21(26)15-8-24-16-3-2-12(23)6-14(15)16/h2-3,5-8,17,21,24H,4,9-10H2,1H3/t17-,21-/m0/s1
DMU6QXV CS CN1CC(=O)N2[C@H](C1=O)CC3=CC4=C(C=C3[C@H]2C5=CNC6=C5C=C(C=C6)Cl)OCO4
DMU6QXV IK FSEZESVJDPKRDS-UWJYYQICSA-N
DMU6QXV IU (2S,8S)-2-(5-chloro-1H-indol-3-yl)-6-methyl-13,15-dioxa-3,6-diazatetracyclo[8.7.0.03,8.012,16]heptadeca-1(17),10,12(16)-triene-4,7-dione
DMU6QXV DE Discovery agent
DMD6U4F ID DMD6U4F
DMD6U4F DN ISAINDIGOTONE
DMD6U4F HS Investigative
DMD6U4F DT Small molecular drug
DMD6U4F PC 135433966
DMD6U4F MW 350.4
DMD6U4F FM C20H18N2O4
DMD6U4F IC InChI=1S/C20H18N2O4/c1-25-16-10-12(11-17(26-2)18(16)23)9-13-7-8-22-19(13)21-15-6-4-3-5-14(15)20(22)24/h3-6,9-11,23H,7-8H2,1-2H3/b13-9+
DMD6U4F CS COC1=CC(=CC(=C1O)OC)/C=C/2\\CCN3C2=NC4=CC=CC=C4C3=O
DMD6U4F IK UBCUTNIGHUVICE-UKTHLTGXSA-N
DMD6U4F IU (3E)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-1,2-dihydropyrrolo[2,1-b]quinazolin-9-one
DMD6U4F DE Discovery agent
DMJ2FQA ID DMJ2FQA
DMJ2FQA DN I-SAP
DMJ2FQA HS Investigative
DMJ2FQA SN (Z)-7-[(1R,2S,3S,5S)-3-[(4-iodophenyl)sulfonylamino]-7,7-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMJ2FQA DT Small molecular drug
DMJ2FQA PC 5312147
DMJ2FQA MW 531.4
DMJ2FQA FM C22H30INO4S
DMJ2FQA IC InChI=1S/C22H30INO4S/c1-22(2)15-13-19(22)18(7-5-3-4-6-8-21(25)26)20(14-15)24-29(27,28)17-11-9-16(23)10-12-17/h3,5,9-12,15,18-20,24H,4,6-8,13-14H2,1-2H3,(H,25,26)/b5-3-/t15-,18+,19+,20+/m1/s1
DMJ2FQA CS CC1([C@@H]2C[C@H]1[C@@H]([C@H](C2)NS(=O)(=O)C3=CC=C(C=C3)I)C/C=C\\CCCC(=O)O)C
DMJ2FQA IK SZNMERGTFJHNSM-JAWYFFTGSA-N
DMJ2FQA IU (Z)-7-[(1S,2S,3S,5R)-3-[(4-iodophenyl)sulfonylamino]-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]hept-5-enoic acid
DMJ2FQA DE Discovery agent
DMH6YVD ID DMH6YVD
DMH6YVD DN ISC-4
DMH6YVD HS Investigative
DMH6YVD SN ISC-6; Isoselenocyanate Akt3 inhibitors (cancer); Isoselenocyanate Akt3 inhibitors (cancer), Penn State Hershey Medical Center
DMH6YVD CP Penn State Hershey Medical Center
DMH6YVD DE Solid tumour/cancer
DMM2I9G ID DMM2I9G
DMM2I9G DN ischemin
DMM2I9G HS Investigative
DMM2I9G SN MS120
DMM2I9G DT Small molecular drug
DMM2I9G PC 135566302
DMM2I9G MW 335.4
DMM2I9G FM C15H17N3O4S
DMM2I9G IC InChI=1S/C15H17N3O4S/c1-8-4-10(3)15(23(20,21)22)7-12(8)17-18-13-5-9(2)14(19)6-11(13)16/h4-7,19H,16H2,1-3H3,(H,20,21,22)
DMM2I9G CS CC1=CC(=C(C=C1N=NC2=C(C=C(C(=C2)C)O)N)S(=O)(=O)O)C
DMM2I9G IK UUECJWRVDTUDCB-UHFFFAOYSA-N
DMM2I9G IU 5-[(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-2,4-dimethylbenzenesulfonic acid
DMM2I9G CB CHEBI:95084
DMM2I9G DE Discovery agent
DMIB6JL ID DMIB6JL
DMIB6JL DN ISIS 100742
DMIB6JL HS Investigative
DMIB6JL CP Isis Pharmaceuticals
DMIB6JL DT Antisense drug
DMIB6JL SQ GTCTTCATGTGAGACTGCTC
DMIB6JL DE Discovery agent
DMI7PGZ ID DMI7PGZ
DMI7PGZ DN ISIS 100743
DMI7PGZ HS Investigative
DMI7PGZ CP Isis Pharmaceuticals
DMI7PGZ DT Antisense drug
DMI7PGZ SQ CTACACCAGTCATCTGGTAT
DMI7PGZ DE Discovery agent
DMFW5VK ID DMFW5VK
DMFW5VK DN ISIS 100748
DMFW5VK HS Investigative
DMFW5VK CP Isis Pharmaceuticals
DMFW5VK DT Antisense drug
DMFW5VK SQ AGCAATTCCCATAAGTAATA
DMFW5VK DE Discovery agent
DMSMJ37 ID DMSMJ37
DMSMJ37 DN ISIS 100749
DMSMJ37 HS Investigative
DMSMJ37 CP Isis Pharmaceuticals
DMSMJ37 DT Antisense drug
DMSMJ37 SQ GTGAAGTTTTCCCATTGTAG
DMSMJ37 DE Discovery agent
DMFJES5 ID DMFJES5
DMFJES5 DN ISIS 100750
DMFJES5 HS Investigative
DMFJES5 CP Isis Pharmaceuticals
DMFJES5 DT Antisense drug
DMFJES5 SQ GGTCTGAGGATATGATCTCT
DMFJES5 DE Discovery agent
DMZV5A7 ID DMZV5A7
DMZV5A7 DN ISIS 100913
DMZV5A7 HS Investigative
DMZV5A7 CP Isis Pharmaceuticals
DMZV5A7 DT Antisense drug
DMZV5A7 SQ CTGTAGTAACCATTCTTGCA
DMZV5A7 DE Discovery agent
DMUMVIF ID DMUMVIF
DMUMVIF DN ISIS 100929
DMUMVIF HS Investigative
DMUMVIF CP Isis Pharmaceuticals
DMUMVIF DT Antisense drug
DMUMVIF SQ GAGAAAACTTGCGCTGTGTT
DMUMVIF DE Discovery agent
DMHUC1X ID DMHUC1X
DMHUC1X DN ISIS 100935
DMHUC1X HS Investigative
DMHUC1X CP Isis Pharmaceuticals
DMHUC1X DT Antisense drug
DMHUC1X SQ CCACTGGCCTCGTTCATAGC
DMHUC1X DE Discovery agent
DM67Q3C ID DM67Q3C
DM67Q3C DN ISIS 100939
DM67Q3C HS Investigative
DM67Q3C CP Isis Pharmaceuticals
DM67Q3C DT Antisense drug
DM67Q3C SQ GCACTAGTTTGGGCTTTTGC
DM67Q3C DE Discovery agent
DMS6JD4 ID DMS6JD4
DMS6JD4 DN ISIS 101952
DMS6JD4 HS Investigative
DMS6JD4 CP Isis Pharmaceuticals
DMS6JD4 DT Antisense drug
DMS6JD4 SQ CTACAGGTTGGCCACTCTGG
DMS6JD4 DE Discovery agent
DMEWXR2 ID DMEWXR2
DMEWXR2 DN ISIS 101960
DMEWXR2 HS Investigative
DMEWXR2 CP Isis Pharmaceuticals
DMEWXR2 DT Antisense drug
DMEWXR2 SQ GATCTTGCAGACGGTAGCTG
DMEWXR2 DE Discovery agent
DMV9PI7 ID DMV9PI7
DMV9PI7 DN ISIS 101983
DMV9PI7 HS Investigative
DMV9PI7 CP Isis Pharmaceuticals
DMV9PI7 DT Antisense drug
DMV9PI7 SQ ACTGCCTTCTCTGCCCACTT
DMV9PI7 DE Discovery agent
DMYZ5CX ID DMYZ5CX
DMYZ5CX DN ISIS 101984
DMYZ5CX HS Investigative
DMYZ5CX CP Isis Pharmaceuticals
DMYZ5CX DT Antisense drug
DMYZ5CX SQ CCCGGGCAGCTGAGAGCCCT
DMYZ5CX DE Discovery agent
DM8CN2M ID DM8CN2M
DM8CN2M DN ISIS 101985
DM8CN2M HS Investigative
DM8CN2M CP Isis Pharmaceuticals
DM8CN2M DT Antisense drug
DM8CN2M SQ CACCTGCAGCCGCCCCGTCCA
DM8CN2M DE Discovery agent
DM5PTQX ID DM5PTQX
DM5PTQX DN ISIS 101986
DM5PTQX HS Investigative
DM5PTQX CP Isis Pharmaceuticals
DM5PTQX DT Antisense drug
DM5PTQX SQ AGCGCCACACGCGACAGTAA
DM5PTQX DE Discovery agent
DMWCK8Q ID DMWCK8Q
DMWCK8Q DN ISIS 101987
DMWCK8Q HS Investigative
DMWCK8Q CP Isis Pharmaceuticals
DMWCK8Q DT Antisense drug
DMWCK8Q SQ AGCCAAATGGGAACTCACAG
DMWCK8Q DE Discovery agent
DM3EMLB ID DM3EMLB
DM3EMLB DN ISIS 101995
DM3EMLB HS Investigative
DM3EMLB CP Isis Pharmaceuticals
DM3EMLB DT Antisense drug
DM3EMLB SQ CCATCTATGAGCACACTTCG
DM3EMLB DE Discovery agent
DM5APGL ID DM5APGL
DM5APGL DN ISIS 101996
DM5APGL HS Investigative
DM5APGL CP Isis Pharmaceuticals
DM5APGL DT Antisense drug
DM5APGL SQ AAGTCCAAGACAGAATCTGT
DM5APGL DE Discovery agent
DMUZJCD ID DMUZJCD
DMUZJCD DN ISIS 101997
DMUZJCD HS Investigative
DMUZJCD CP Isis Pharmaceuticals
DMUZJCD DT Antisense drug
DMUZJCD SQ TTTCTATCGTTGAGTTTCTG
DMUZJCD DE Discovery agent
DMEH6G1 ID DMEH6G1
DMEH6G1 DN ISIS 101998
DMEH6G1 HS Investigative
DMEH6G1 CP Isis Pharmaceuticals
DMEH6G1 DT Antisense drug
DMEH6G1 SQ TGCTGTCACTCACGCACTCG
DMEH6G1 DE Discovery agent
DMESKQX ID DMESKQX
DMESKQX DN ISIS 10228
DMESKQX HS Investigative
DMESKQX CP Isis Pharmaceuticals
DMESKQX DT Antisense drug
DMESKQX SQ CATCAGGGCAGAGACGAACA
DMESKQX DE Discovery agent
DML40N3 ID DML40N3
DML40N3 DN ISIS 102450
DML40N3 HS Investigative
DML40N3 CP Isis Pharmaceuticals
DML40N3 DT Antisense drug
DML40N3 SQ GCGTTGCCCATCGCGGCGGC
DML40N3 DE Discovery agent
DMNSEH1 ID DMNSEH1
DMNSEH1 DN ISIS 102454
DMNSEH1 HS Investigative
DMNSEH1 CP Isis Pharmaceuticals
DMNSEH1 DT Antisense drug
DMNSEH1 SQ CGGCGTTGCCCATCGCGGCG
DMNSEH1 DE Discovery agent
DMBUTFN ID DMBUTFN
DMBUTFN DN ISIS 102458
DMBUTFN HS Investigative
DMBUTFN CP Isis Pharmaceuticals
DMBUTFN DT Antisense drug
DMBUTFN SQ GGCGGCGTTGCCCATCGCGG
DMBUTFN DE Discovery agent
DMXNC0B ID DMXNC0B
DMXNC0B DN ISIS 102462
DMXNC0B HS Investigative
DMXNC0B CP Isis Pharmaceuticals
DMXNC0B DT Antisense drug
DMXNC0B SQ GCGGCGGCGTTGCCCATCGC
DMXNC0B DE Discovery agent
DMAG8QO ID DMAG8QO
DMAG8QO DN ISIS 102466
DMAG8QO HS Investigative
DMAG8QO CP Isis Pharmaceuticals
DMAG8QO DT Antisense drug
DMAG8QO SQ CGGCGGCGGCGTTGCCCATC
DMAG8QO DE Discovery agent
DMU70ND ID DMU70ND
DMU70ND DN ISIS 102478
DMU70ND HS Investigative
DMU70ND CP Isis Pharmaceuticals
DMU70ND DT Antisense drug
DMU70ND SQ CAAACTGATCCAAGTGGGCT
DMU70ND DE Discovery agent
DMMBJWK ID DMMBJWK
DMMBJWK DN ISIS 102482
DMMBJWK HS Investigative
DMMBJWK CP Isis Pharmaceuticals
DMMBJWK DT Antisense drug
DMMBJWK SQ CCAGCATCACCCGCCCGAAG
DMMBJWK DE Discovery agent
DMTMBEX ID DMTMBEX
DMTMBEX DN ISIS 102486
DMTMBEX HS Investigative
DMTMBEX CP Isis Pharmaceuticals
DMTMBEX DT Antisense drug
DMTMBEX SQ CTTCTGTTTGTCGAGGATCT
DMTMBEX DE Discovery agent
DMMWVCH ID DMMWVCH
DMMWVCH DN ISIS 102490
DMMWVCH HS Investigative
DMMWVCH CP Isis Pharmaceuticals
DMMWVCH DT Antisense drug
DMMWVCH SQ GCTTGCAGGATGCGCTTTTC
DMMWVCH DE Discovery agent
DMYJO7T ID DMYJO7T
DMYJO7T DN ISIS 102558
DMYJO7T HS Investigative
DMYJO7T CP Isis Pharmaceuticals
DMYJO7T DT Antisense drug
DMYJO7T SQ TGCAGGGATGCCCTCCCCAC
DMYJO7T DE Discovery agent
DMTHMF0 ID DMTHMF0
DMTHMF0 DN ISIS 102563
DMTHMF0 HS Investigative
DMTHMF0 CP Isis Pharmaceuticals
DMTHMF0 DT Antisense drug
DMTHMF0 SQ CCTTGAACCCCGGGCCGTGG
DMTHMF0 DE Discovery agent
DMEDFLA ID DMEDFLA
DMEDFLA DN ISIS 102584
DMEDFLA HS Investigative
DMEDFLA CP Isis Pharmaceuticals
DMEDFLA DT Antisense drug
DMEDFLA SQ CACACAGGTTGAATCGCCCC
DMEDFLA DE Discovery agent
DM3RVUY ID DM3RVUY
DM3RVUY DN ISIS 102599
DM3RVUY HS Investigative
DM3RVUY CP Isis Pharmaceuticals
DM3RVUY DT Antisense drug
DM3RVUY SQ GCGGCGGGTGCTGGCTGCGG
DM3RVUY DE Discovery agent
DMZ6X9B ID DMZ6X9B
DMZ6X9B DN ISIS 102604
DMZ6X9B HS Investigative
DMZ6X9B CP Isis Pharmaceuticals
DMZ6X9B DT Antisense drug
DMZ6X9B SQ TCGCGGCGGCGGCGGCCGGG
DMZ6X9B DE Discovery agent
DM60LT9 ID DM60LT9
DM60LT9 DN ISIS 102609
DM60LT9 HS Investigative
DM60LT9 CP Isis Pharmaceuticals
DM60LT9 DT Antisense drug
DM60LT9 SQ CATCGCGGCGGCGGCGGCCG
DM60LT9 DE Discovery agent
DMEB36I ID DMEB36I
DMEB36I DN ISIS 102614
DMEB36I HS Investigative
DMEB36I CP Isis Pharmaceuticals
DMEB36I DT Antisense drug
DMEB36I SQ CCCATCGCGGCGGCGGCGGC
DMEB36I DE Discovery agent
DMXH9IT ID DMXH9IT
DMXH9IT DN ISIS 102619
DMXH9IT HS Investigative
DMXH9IT CP Isis Pharmaceuticals
DMXH9IT DT Antisense drug
DMXH9IT SQ TGCCCATCGCGGCGGCGGCG
DMXH9IT DE Discovery agent
DMGO4TZ ID DMGO4TZ
DMGO4TZ DN ISIS 102624
DMGO4TZ HS Investigative
DMGO4TZ CP Isis Pharmaceuticals
DMGO4TZ DT Antisense drug
DMGO4TZ SQ GTTGCCCATCGCGGCGGCGG
DMGO4TZ DE Discovery agent
DMNSZPX ID DMNSZPX
DMNSZPX DN ISIS 102629
DMNSZPX HS Investigative
DMNSZPX CP Isis Pharmaceuticals
DMNSZPX DT Antisense drug
DMNSZPX SQ GCGTTGCCCATCGCGGCGGC
DMNSZPX DE Discovery agent
DMWT7BK ID DMWT7BK
DMWT7BK DN ISIS 102633
DMWT7BK HS Investigative
DMWT7BK CP Isis Pharmaceuticals
DMWT7BK DT Antisense drug
DMWT7BK SQ CGGCGTTGCCCATCGCGGCG
DMWT7BK DE Discovery agent
DM6KUV9 ID DM6KUV9
DM6KUV9 DN ISIS 102660
DM6KUV9 HS Investigative
DM6KUV9 CP Isis Pharmaceuticals
DM6KUV9 DT Antisense drug
DM6KUV9 SQ CCAGCATCACCCGCCCGAAG
DM6KUV9 DE Discovery agent
DMKI6L5 ID DMKI6L5
DMKI6L5 DN ISIS 102664
DMKI6L5 HS Investigative
DMKI6L5 CP Isis Pharmaceuticals
DMKI6L5 DT Antisense drug
DMKI6L5 SQ CTTCTGTTTGTCGAGGATCT
DMKI6L5 DE Discovery agent
DMY87QX ID DMY87QX
DMY87QX DN ISIS 102668
DMY87QX HS Investigative
DMY87QX CP Isis Pharmaceuticals
DMY87QX DT Antisense drug
DMY87QX SQ GCTTGCAGGATGCGCTTTTC
DMY87QX DE Discovery agent
DMFP598 ID DMFP598
DMFP598 DN ISIS 102676
DMFP598 HS Investigative
DMFP598 CP Isis Pharmaceuticals
DMFP598 DT Antisense drug
DMFP598 SQ GAACATCTCCCCGCCGGGCA
DMFP598 DE Discovery agent
DM205TE ID DM205TE
DM205TE DN ISIS 10303
DM205TE HS Investigative
DM205TE CP Isis Pharmaceuticals
DM205TE DT Antisense drug
DM205TE SQ TGCAATCCACGTCCTCCAGG
DM205TE DE Discovery agent
DMT6H9S ID DMT6H9S
DMT6H9S DN ISIS 10310
DMT6H9S HS Investigative
DMT6H9S CP Isis Pharmaceuticals
DMT6H9S DT Antisense drug
DMT6H9S SQ GGTGCTGGCCCGGCTCTCCC
DMT6H9S DE Discovery agent
DMQ3KUV ID DMQ3KUV
DMQ3KUV DN ISIS 10311
DMQ3KUV HS Investigative
DMQ3KUV CP Isis Pharmaceuticals
DMQ3KUV DT Antisense drug
DMQ3KUV SQ GGACCCCGAAAGACCACCAG
DMQ3KUV DE Discovery agent
DMX835E ID DMX835E
DMX835E DN ISIS 103375
DMX835E HS Investigative
DMX835E CP Isis Pharmaceuticals
DMX835E DT Antisense drug
DMX835E SQ CCCAGGCCCGCCCCGCAGCA
DMX835E DE Discovery agent
DMBAM5K ID DMBAM5K
DMBAM5K DN ISIS 103386
DMBAM5K HS Investigative
DMBAM5K CP Isis Pharmaceuticals
DMBAM5K DT Antisense drug
DMBAM5K SQ TTGCTGGCGTTGAGGACGTA
DMBAM5K DE Discovery agent
DMW8GIT ID DMW8GIT
DMW8GIT DN ISIS 103387
DMW8GIT HS Investigative
DMW8GIT CP Isis Pharmaceuticals
DMW8GIT DT Antisense drug
DMW8GIT SQ TTTCACAGTAGTTGTCGTTG
DMW8GIT DE Discovery agent
DM86KWU ID DM86KWU
DM86KWU DN ISIS 103471
DM86KWU HS Investigative
DM86KWU CP Isis Pharmaceuticals
DM86KWU DT Antisense drug
DM86KWU SQ CCGGGCACTGCCCAGATAGA
DM86KWU DE Discovery agent
DMQRP32 ID DMQRP32
DMQRP32 DN ISIS 103473
DMQRP32 HS Investigative
DMQRP32 CP Isis Pharmaceuticals
DMQRP32 DT Antisense drug
DMQRP32 SQ AAGAACCGCGACAGGTTCTG
DMQRP32 DE Discovery agent
DM5BSVQ ID DM5BSVQ
DM5BSVQ DN ISIS 103486
DM5BSVQ HS Investigative
DM5BSVQ CP Isis Pharmaceuticals
DM5BSVQ DT Antisense drug
DM5BSVQ SQ AGGCCATGGATGTGGGCGG
DM5BSVQ DE Discovery agent
DM6ZME7 ID DM6ZME7
DM6ZME7 DN ISIS 103489
DM6ZME7 HS Investigative
DM6ZME7 CP Isis Pharmaceuticals
DM6ZME7 DT Antisense drug
DM6ZME7 SQ GGGCCCCGCAGCAGCAAAAG
DM6ZME7 DE Discovery agent
DME9Q8L ID DME9Q8L
DME9Q8L DN ISIS 103582
DME9Q8L HS Investigative
DME9Q8L CP Isis Pharmaceuticals
DME9Q8L DT Antisense drug
DME9Q8L SQ TCCCAGACTGCTGCCGTACA
DME9Q8L DE Discovery agent
DM6BH7K ID DM6BH7K
DM6BH7K DN ISIS 103601
DM6BH7K HS Investigative
DM6BH7K CP Isis Pharmaceuticals
DM6BH7K DT Antisense drug
DM6BH7K SQ CACCATAATCAAGTCCTTCT
DM6BH7K DE Discovery agent
DM298KT ID DM298KT
DM298KT DN ISIS 103612
DM298KT HS Investigative
DM298KT CP Isis Pharmaceuticals
DM298KT DT Antisense drug
DM298KT SQ ACTAGAGTGCTTGTAGGTAC
DM298KT DE Discovery agent
DMNPMW4 ID DMNPMW4
DMNPMW4 DN ISIS 103613
DMNPMW4 HS Investigative
DMNPMW4 CP Isis Pharmaceuticals
DMNPMW4 DT Antisense drug
DMNPMW4 SQ GAGACGGAGATGAAGGTGTG
DMNPMW4 DE Discovery agent
DMGTX6O ID DMGTX6O
DMGTX6O DN ISIS 103615
DMGTX6O HS Investigative
DMGTX6O CP Isis Pharmaceuticals
DMGTX6O DT Antisense drug
DMGTX6O SQ GTTGGTGCAAATGAGGATGA
DMGTX6O DE Discovery agent
DM3PK2G ID DM3PK2G
DM3PK2G DN ISIS 103616
DM3PK2G HS Investigative
DM3PK2G CP Isis Pharmaceuticals
DM3PK2G DT Antisense drug
DM3PK2G SQ TCAGACACTACTGGAGTACC
DM3PK2G DE Discovery agent
DMERJAV ID DMERJAV
DMERJAV DN ISIS 103619
DMERJAV HS Investigative
DMERJAV CP Isis Pharmaceuticals
DMERJAV DT Antisense drug
DMERJAV SQ ATTCCAATTCTGCACTGGTA
DMERJAV DE Discovery agent
DM61FYM ID DM61FYM
DM61FYM DN ISIS 103620
DM61FYM HS Investigative
DM61FYM CP Isis Pharmaceuticals
DM61FYM DT Antisense drug
DM61FYM SQ GAATTAGAGGTGTCAGGCTC
DM61FYM DE Discovery agent
DMP7VJL ID DMP7VJL
DMP7VJL DN ISIS 103621
DMP7VJL HS Investigative
DMP7VJL CP Isis Pharmaceuticals
DMP7VJL DT Antisense drug
DMP7VJL SQ TGTCTTGATTTGGCTGCTTC
DMP7VJL DE Discovery agent
DM9J4I3 ID DM9J4I3
DM9J4I3 DN ISIS 103622
DM9J4I3 HS Investigative
DM9J4I3 CP Isis Pharmaceuticals
DM9J4I3 DT Antisense drug
DM9J4I3 SQ TCCCAGACTGCTGCCGTACA
DM9J4I3 DE Discovery agent
DMST2QW ID DMST2QW
DMST2QW DN ISIS 103624
DMST2QW HS Investigative
DMST2QW CP Isis Pharmaceuticals
DMST2QW DT Antisense drug
DMST2QW SQ GATCCACATAATAGGTTCTA
DMST2QW DE Discovery agent
DMJLHE7 ID DMJLHE7
DMJLHE7 DN ISIS 103629
DMJLHE7 HS Investigative
DMJLHE7 CP Isis Pharmaceuticals
DMJLHE7 DT Antisense drug
DMJLHE7 SQ GCATAGCTCCCTGCAATTGG
DMJLHE7 DE Discovery agent
DMOK9FA ID DMOK9FA
DMOK9FA DN ISIS 103631
DMOK9FA HS Investigative
DMOK9FA CP Isis Pharmaceuticals
DMOK9FA DT Antisense drug
DMOK9FA SQ CCTGGTGGCAAAGGTCCATA
DMOK9FA DE Discovery agent
DMVW7N5 ID DMVW7N5
DMVW7N5 DN ISIS 103635
DMVW7N5 HS Investigative
DMVW7N5 CP Isis Pharmaceuticals
DMVW7N5 DT Antisense drug
DMVW7N5 SQ TCCCATTGCGAGGATCTTTG
DMVW7N5 DE Discovery agent
DM3TIJD ID DM3TIJD
DM3TIJD DN ISIS 103669
DM3TIJD HS Investigative
DM3TIJD CP Isis Pharmaceuticals
DM3TIJD DT Antisense drug
DM3TIJD SQ CAGCCCTCTTTAGCCTTTCT
DM3TIJD DE Discovery agent
DMF9JAH ID DMF9JAH
DMF9JAH DN ISIS 103671
DMF9JAH HS Investigative
DMF9JAH CP Isis Pharmaceuticals
DMF9JAH DT Antisense drug
DMF9JAH SQ CACCTTGGGCTTTGCGGACA
DMF9JAH DE Discovery agent
DMQ48YZ ID DMQ48YZ
DMQ48YZ DN ISIS 103701
DMQ48YZ HS Investigative
DMQ48YZ CP Isis Pharmaceuticals
DMQ48YZ DT Antisense drug
DMQ48YZ SQ GGGCCTCCCAAGGGCTGCGG
DMQ48YZ DE Discovery agent
DMLVPOA ID DMLVPOA
DMLVPOA DN ISIS 103708
DMLVPOA HS Investigative
DMLVPOA CP Isis Pharmaceuticals
DMLVPOA DT Antisense drug
DMLVPOA SQ GGCAAAGACCCTTGGCGCTC
DMLVPOA DE Discovery agent
DM60CBI ID DM60CBI
DM60CBI DN ISIS 10373
DM60CBI HS Investigative
DM60CBI CP Isis Pharmaceuticals
DM60CBI DT Antisense drug
DM60CBI SQ TGCGAGCTCCCCGTACCTCC
DM60CBI DE Discovery agent
DMKI6JF ID DMKI6JF
DMKI6JF DN ISIS 103736
DMKI6JF HS Investigative
DMKI6JF CP Isis Pharmaceuticals
DMKI6JF DT Antisense drug
DMKI6JF SQ CGCCCTCCTTCAGCTCGTGG
DMKI6JF DE Discovery agent
DM7DOY3 ID DM7DOY3
DM7DOY3 DN ISIS 103747
DM7DOY3 HS Investigative
DM7DOY3 CP Isis Pharmaceuticals
DM7DOY3 DT Antisense drug
DM7DOY3 SQ AGAACCTCCTTTGCTGGCAA
DM7DOY3 DE Discovery agent
DMBZVW0 ID DMBZVW0
DMBZVW0 DN ISIS 103752
DMBZVW0 HS Investigative
DMBZVW0 CP Isis Pharmaceuticals
DMBZVW0 DT Antisense drug
DMBZVW0 SQ CACCTTGGGCTTTGCGGACA
DMBZVW0 DE Discovery agent
DM8HDW6 ID DM8HDW6
DM8HDW6 DN ISIS 103771
DM8HDW6 HS Investigative
DM8HDW6 CP Isis Pharmaceuticals
DM8HDW6 DT Antisense drug
DM8HDW6 SQ CAGCATGATGTACTCTTCCT
DM8HDW6 DE Discovery agent
DMVL8O0 ID DMVL8O0
DMVL8O0 DN ISIS 103803
DMVL8O0 HS Investigative
DMVL8O0 CP Isis Pharmaceuticals
DMVL8O0 DT Antisense drug
DMVL8O0 SQ CGTAGGAGTTAATTCGAGGT
DMVL8O0 DE Discovery agent
DMA0D8I ID DMA0D8I
DMA0D8I DN ISIS 103806
DMA0D8I HS Investigative
DMA0D8I CP Isis Pharmaceuticals
DMA0D8I DT Antisense drug
DMA0D8I SQ GGTTCAGGGTCAGCTGCATG
DMA0D8I DE Discovery agent
DMFQ10R ID DMFQ10R
DMFQ10R DN ISIS 103819
DMFQ10R HS Investigative
DMFQ10R CP Isis Pharmaceuticals
DMFQ10R DT Antisense drug
DMFQ10R SQ GTGGTCCGTTGCTACCGATG
DMFQ10R DE Discovery agent
DMPKQ61 ID DMPKQ61
DMPKQ61 DN ISIS 104211
DMPKQ61 HS Investigative
DMPKQ61 CP Isis Pharmaceuticals
DMPKQ61 DT Antisense drug
DMPKQ61 SQ TGGTCCCGGGCGCTCAGGCC
DMPKQ61 DE Discovery agent
DMME8JP ID DMME8JP
DMME8JP DN ISIS 104253
DMME8JP HS Investigative
DMME8JP CP Isis Pharmaceuticals
DMME8JP DT Antisense drug
DMME8JP SQ TTCATGGTCCCGGGCGCTCA
DMME8JP DE Discovery agent
DMDEI9X ID DMDEI9X
DMDEI9X DN ISIS 104254
DMDEI9X HS Investigative
DMDEI9X CP Isis Pharmaceuticals
DMDEI9X DT Antisense drug
DMDEI9X SQ CGTTCATGGTCCCGGGCGCT
DMDEI9X DE Discovery agent
DMAI5B8 ID DMAI5B8
DMAI5B8 DN ISIS 104255
DMAI5B8 HS Investigative
DMAI5B8 CP Isis Pharmaceuticals
DMAI5B8 DT Antisense drug
DMAI5B8 SQ CCCGTTCATGGTCCCGGGCG
DMAI5B8 DE Discovery agent
DMHUX9A ID DMHUX9A
DMHUX9A DN ISIS 104256
DMHUX9A HS Investigative
DMHUX9A CP Isis Pharmaceuticals
DMHUX9A DT Antisense drug
DMHUX9A SQ TCCCCGTTCATGGTCCCGGG
DMHUX9A DE Discovery agent
DMSDCGV ID DMSDCGV
DMSDCGV DN ISIS 104257
DMSDCGV HS Investigative
DMSDCGV CP Isis Pharmaceuticals
DMSDCGV DT Antisense drug
DMSDCGV SQ CCTCCCCGTTCATGGTCCCG
DMSDCGV DE Discovery agent
DMUC3L0 ID DMUC3L0
DMUC3L0 DN ISIS 104258
DMUC3L0 HS Investigative
DMUC3L0 CP Isis Pharmaceuticals
DMUC3L0 DT Antisense drug
DMUC3L0 SQ GGCCTCCCCGTTCATGGTCC
DMUC3L0 DE Discovery agent
DMB5F9H ID DMB5F9H
DMB5F9H DN ISIS 10582
DMB5F9H HS Investigative
DMB5F9H CP Isis Pharmaceuticals
DMB5F9H DT Antisense drug
DMB5F9H SQ TCAGCCCCCGACGGTCTCTC
DMB5F9H DE Discovery agent
DMIGV0H ID DMIGV0H
DMIGV0H DN ISIS 105987
DMIGV0H HS Investigative
DMIGV0H CP Isis Pharmaceuticals
DMIGV0H DT Antisense drug
DMIGV0H SQ AGATCAATCCGTTAAAAGAA
DMIGV0H DE Discovery agent
DMFOSYU ID DMFOSYU
DMFOSYU DN ISIS 105989
DMFOSYU HS Investigative
DMFOSYU CP Isis Pharmaceuticals
DMFOSYU DT Antisense drug
DMFOSYU SQ CAAAAGATCAATCCGTTAAA
DMFOSYU DE Discovery agent
DM8FY3H ID DM8FY3H
DM8FY3H DN ISIS 105990
DM8FY3H HS Investigative
DM8FY3H CP Isis Pharmaceuticals
DM8FY3H DT Antisense drug
DM8FY3H SQ AGCAAAAGATCAATCCGTTA
DM8FY3H DE Discovery agent
DMTY6O9 ID DMTY6O9
DMTY6O9 DN ISIS 106008
DMTY6O9 HS Investigative
DMTY6O9 CP Isis Pharmaceuticals
DMTY6O9 DT Antisense drug
DMTY6O9 SQ TTTGCTGTAATTCACACTGA
DMTY6O9 DE Discovery agent
DM4YJQG ID DM4YJQG
DM4YJQG DN ISIS 10639
DM4YJQG HS Investigative
DM4YJQG CP Isis Pharmaceuticals
DM4YJQG DT Antisense drug
DM4YJQG SQ AAGTCCTTGAGGCCCACAGC
DM4YJQG DE Discovery agent
DMYG5IO ID DMYG5IO
DMYG5IO DN ISIS 10707
DMYG5IO HS Investigative
DMYG5IO CP Isis Pharmaceuticals
DMYG5IO DT Antisense drug
DMYG5IO SQ 3' UTR GCTTCCATTTCCAGGGCAGG
DMYG5IO DE Discovery agent
DMBWCZR ID DMBWCZR
DMBWCZR DN ISIS 107612
DMBWCZR HS Investigative
DMBWCZR CP Isis Pharmaceuticals
DMBWCZR DT Antisense drug
DMBWCZR SQ CTGCTCAGACAGCAGATGCT
DMBWCZR DE Discovery agent
DMPR7OD ID DMPR7OD
DMPR7OD DN ISIS 107642
DMPR7OD HS Investigative
DMPR7OD CP Isis Pharmaceuticals
DMPR7OD DT Antisense drug
DMPR7OD SQ ATCCAGCAGGTTCATGTCAT
DMPR7OD DE Discovery agent
DMOX8JF ID DMOX8JF
DMOX8JF DN ISIS 107652
DMOX8JF HS Investigative
DMOX8JF CP Isis Pharmaceuticals
DMOX8JF DT Antisense drug
DMOX8JF SQ ATTTGGTAAACTTTGTCCAA
DMOX8JF DE Discovery agent
DMUE64H ID DMUE64H
DMUE64H DN ISIS 107676
DMUE64H HS Investigative
DMUE64H CP Isis Pharmaceuticals
DMUE64H DT Antisense drug
DMUE64H SQ ACTGGATGTACCAGGTTCCC
DMUE64H DE Discovery agent
DMB9VFS ID DMB9VFS
DMB9VFS DN ISIS 107681
DMB9VFS HS Investigative
DMB9VFS CP Isis Pharmaceuticals
DMB9VFS DT Antisense drug
DMB9VFS SQ GCTGAGGCATCTGTTTCCCC
DMB9VFS DE Discovery agent
DM37VYR ID DM37VYR
DM37VYR DN ISIS 107772
DM37VYR HS Investigative
DM37VYR CP Isis Pharmaceuticals
DM37VYR DT Antisense drug
DM37VYR SQ CCCGGACTTGTCGATCTGCT
DM37VYR DE Discovery agent
DMA3ZGH ID DMA3ZGH
DMA3ZGH DN ISIS 107773
DMA3ZGH HS Investigative
DMA3ZGH CP Isis Pharmaceuticals
DMA3ZGH DT Antisense drug
DMA3ZGH SQ CTGGCTTCATGTCGGATATC
DMA3ZGH DE Discovery agent
DMFOTQY ID DMFOTQY
DMFOTQY DN ISIS 107774
DMFOTQY HS Investigative
DMFOTQY CP Isis Pharmaceuticals
DMFOTQY DT Antisense drug
DMFOTQY SQ TTGGCCACTCTACATGGGAA
DMFOTQY DE Discovery agent
DMLBX9Z ID DMLBX9Z
DMLBX9Z DN ISIS 107775
DMLBX9Z HS Investigative
DMLBX9Z CP Isis Pharmaceuticals
DMLBX9Z DT Antisense drug
DMLBX9Z SQ GGACTGACGTCTCTGTACCT
DMLBX9Z DE Discovery agent
DMNHBGJ ID DMNHBGJ
DMNHBGJ DN ISIS 107776
DMNHBGJ HS Investigative
DMNHBGJ CP Isis Pharmaceuticals
DMNHBGJ DT Antisense drug
DMNHBGJ SQ GATGTAGTTTAATCCGACTA
DMNHBGJ DE Discovery agent
DMVTU63 ID DMVTU63
DMVTU63 DN ISIS 107791
DMVTU63 HS Investigative
DMVTU63 CP Isis Pharmaceuticals
DMVTU63 DT Antisense drug
DMVTU63 SQ GCAGTGCACCACAACGGGCC
DMVTU63 DE Discovery agent
DMV87MP ID DMV87MP
DMV87MP DN ISIS 107792
DMV87MP HS Investigative
DMV87MP CP Isis Pharmaceuticals
DMV87MP DT Antisense drug
DMV87MP SQ AGGTTCCAGACCTGCCGATG
DMV87MP DE Discovery agent
DM83TLC ID DM83TLC
DM83TLC DN ISIS 109110
DM83TLC HS Investigative
DM83TLC CP Isis Pharmaceuticals
DM83TLC DT Antisense drug
DM83TLC SQ TGCGCTGCCTGGCTCTCGCC
DM83TLC DE Discovery agent
DM0UOL3 ID DM0UOL3
DM0UOL3 DN ISIS 109111
DM0UOL3 HS Investigative
DM0UOL3 CP Isis Pharmaceuticals
DM0UOL3 DT Antisense drug
DM0UOL3 SQ GCAACCATGGTGGCAGCTTC
DM0UOL3 DE Discovery agent
DM6R5YW ID DM6R5YW
DM6R5YW DN ISIS 109112
DM6R5YW HS Investigative
DM6R5YW CP Isis Pharmaceuticals
DM6R5YW DT Antisense drug
DM6R5YW SQ ATCGTCTTCACCACATTCCC
DM6R5YW DE Discovery agent
DM58XT1 ID DM58XT1
DM58XT1 DN ISIS 109113
DM58XT1 HS Investigative
DM58XT1 CP Isis Pharmaceuticals
DM58XT1 DT Antisense drug
DM58XT1 SQ TGCGGCAGGCGTCGTACACC
DM58XT1 DE Discovery agent
DMUDFZN ID DMUDFZN
DMUDFZN DN ISIS 109114
DMUDFZN HS Investigative
DMUDFZN CP Isis Pharmaceuticals
DMUDFZN DT Antisense drug
DMUDFZN SQ AAAGAGCCCAAAGTCGCTGG
DMUDFZN DE Discovery agent
DMBMDG7 ID DMBMDG7
DMBMDG7 DN ISIS 109115
DMBMDG7 HS Investigative
DMBMDG7 CP Isis Pharmaceuticals
DMBMDG7 DT Antisense drug
DMBMDG7 SQ GTAGTAGTCCAAAGCTTTCC
DMBMDG7 DE Discovery agent
DMQ8K9J ID DMQ8K9J
DMQ8K9J DN ISIS 109116
DMQ8K9J HS Investigative
DMQ8K9J CP Isis Pharmaceuticals
DMQ8K9J DT Antisense drug
DMQ8K9J SQ TGTTTCTTCCTGTACTCCAT
DMQ8K9J DE Discovery agent
DM508BS ID DM508BS
DM508BS DN ISIS 109351
DM508BS HS Investigative
DM508BS CP Isis Pharmaceuticals
DM508BS DT Antisense drug
DM508BS SQ TGGCGACATGGTTGCGCCCT
DM508BS DE Discovery agent
DMWK1XC ID DMWK1XC
DMWK1XC DN ISIS 109352
DMWK1XC HS Investigative
DMWK1XC CP Isis Pharmaceuticals
DMWK1XC DT Antisense drug
DMWK1XC SQ AGAAATGGCGACATGGTTGC
DMWK1XC DE Discovery agent
DM6AJMC ID DM6AJMC
DM6AJMC DN ISIS 109353
DM6AJMC HS Investigative
DM6AJMC CP Isis Pharmaceuticals
DM6AJMC DT Antisense drug
DM6AJMC SQ CAATCCGAAGAAATGGCGAC
DM6AJMC DE Discovery agent
DM1REKQ ID DM1REKQ
DM1REKQ DN ISIS 109354
DM1REKQ HS Investigative
DM1REKQ CP Isis Pharmaceuticals
DM1REKQ DT Antisense drug
DM1REKQ SQ CCTGACAAGACTGGCAGGAC
DM1REKQ DE Discovery agent
DMFIQGW ID DMFIQGW
DMFIQGW DN ISIS 109355
DMFIQGW HS Investigative
DMFIQGW CP Isis Pharmaceuticals
DMFIQGW DT Antisense drug
DMFIQGW SQ ATACTCTTTGACGAGCACAG
DMFIQGW DE Discovery agent
DMDVE6A ID DMDVE6A
DMDVE6A DN ISIS 109490
DMDVE6A HS Investigative
DMDVE6A CP Isis Pharmaceuticals
DMDVE6A DT Antisense drug
DMDVE6A SQ TGGAGGAAAAGGCATCAGAG
DMDVE6A DE Discovery agent
DMISNWV ID DMISNWV
DMISNWV DN ISIS 109491
DMISNWV HS Investigative
DMISNWV CP Isis Pharmaceuticals
DMISNWV DT Antisense drug
DMISNWV SQ CCAGGGTCTGCATTTGTCCG
DMISNWV DE Discovery agent
DMRPMN6 ID DMRPMN6
DMRPMN6 DN ISIS 109502
DMRPMN6 HS Investigative
DMRPMN6 CP Isis Pharmaceuticals
DMRPMN6 DT Antisense drug
DMRPMN6 SQ TCTCCTCCAGAGTCAGCAGT
DMRPMN6 DE Discovery agent
DMJ7EDV ID DMJ7EDV
DMJ7EDV DN ISIS 109524
DMJ7EDV HS Investigative
DMJ7EDV CP Isis Pharmaceuticals
DMJ7EDV DT Antisense drug
DMJ7EDV SQ CCAGTGCGGCGGGCTGCTGA
DMJ7EDV DE Discovery agent
DMB28D3 ID DMB28D3
DMB28D3 DN ISIS 109525
DMB28D3 HS Investigative
DMB28D3 CP Isis Pharmaceuticals
DMB28D3 DT Antisense drug
DMB28D3 SQ ATTACTGCTGCGAGTTTGAG
DMB28D3 DE Discovery agent
DMZN60F ID DMZN60F
DMZN60F DN ISIS 109526
DMZN60F HS Investigative
DMZN60F CP Isis Pharmaceuticals
DMZN60F DT Antisense drug
DMZN60F SQ AAAATAGCTGTCATAGTGCC
DMZN60F DE Discovery agent
DMXNG1S ID DMXNG1S
DMXNG1S DN ISIS 110064
DMXNG1S HS Investigative
DMXNG1S CP Isis Pharmaceuticals
DMXNG1S DT Antisense drug
DMXNG1S SQ GGCTCCCTTCTTGCCAGGTG
DMXNG1S DE Discovery agent
DMBOU16 ID DMBOU16
DMBOU16 DN ISIS 110065
DMBOU16 HS Investigative
DMBOU16 CP Isis Pharmaceuticals
DMBOU16 DT Antisense drug
DMBOU16 SQ GCTACCAATGCTTTGCCTGG
DMBOU16 DE Discovery agent
DM4B35Y ID DM4B35Y
DM4B35Y DN ISIS 110066
DM4B35Y HS Investigative
DM4B35Y CP Isis Pharmaceuticals
DM4B35Y DT Antisense drug
DM4B35Y SQ AGCACCCTTCTTACCAGGAG
DM4B35Y DE Discovery agent
DM0EFHM ID DM0EFHM
DM0EFHM DN ISIS 110067
DM0EFHM HS Investigative
DM0EFHM CP Isis Pharmaceuticals
DM0EFHM DT Antisense drug
DM0EFHM SQ ATTCTTGCCATTCTTTGCCC
DM0EFHM DE Discovery agent
DMSLOKM ID DMSLOKM
DMSLOKM DN ISIS 110068
DMSLOKM HS Investigative
DMSLOKM CP Isis Pharmaceuticals
DMSLOKM DT Antisense drug
DMSLOKM SQ ATCACTGTCTTCCTTCTTGG
DMSLOKM DE Discovery agent
DMUG4HJ ID DMUG4HJ
DMUG4HJ DN ISIS 110073
DMUG4HJ HS Investigative
DMUG4HJ CP Isis Pharmaceuticals
DMUG4HJ DT Antisense drug
DMUG4HJ SQ CTTCGTCATCCTCATCGTCC
DMUG4HJ DE Discovery agent
DM2KECW ID DM2KECW
DM2KECW DN ISIS 110074
DM2KECW HS Investigative
DM2KECW CP Isis Pharmaceuticals
DM2KECW DT Antisense drug
DM2KECW SQ GTCATCGTCATCCTCATCAT
DM2KECW DE Discovery agent
DMNKY2R ID DMNKY2R
DMNKY2R DN ISIS 11061
DMNKY2R HS Investigative
DMNKY2R CP Isis Pharmaceuticals
DMNKY2R DT Antisense drug
DMNKY2R SQ 5' UTR ATGCATTCTGCCCCCAAGGA
DMNKY2R DE Discovery agent
DMF4V58 ID DMF4V58
DMF4V58 DN ISIS 111084
DMF4V58 HS Investigative
DMF4V58 CP Isis Pharmaceuticals
DMF4V58 DT Antisense drug
DMF4V58 SQ CAGGCGCTGAATCTCCACCA
DMF4V58 DE Discovery agent
DMJQS5O ID DMJQS5O
DMJQS5O DN ISIS 111085
DMJQS5O HS Investigative
DMJQS5O CP Isis Pharmaceuticals
DMJQS5O DT Antisense drug
DMJQS5O SQ GCTTCACTGAGCTCCTCCCG
DMJQS5O DE Discovery agent
DMJ86U4 ID DMJ86U4
DMJ86U4 DN ISIS 111086
DMJ86U4 HS Investigative
DMJ86U4 CP Isis Pharmaceuticals
DMJ86U4 DT Antisense drug
DMJ86U4 SQ TCGCTCATGGCTTCACTGAG
DMJ86U4 DE Discovery agent
DM2VNUW ID DM2VNUW
DM2VNUW DN ISIS 111105
DM2VNUW HS Investigative
DM2VNUW CP Isis Pharmaceuticals
DM2VNUW DT Antisense drug
DM2VNUW SQ GAGGTCGGTGAACTCATGCA
DM2VNUW DE Discovery agent
DMAVQK3 ID DMAVQK3
DMAVQK3 DN ISIS 111117
DMAVQK3 HS Investigative
DMAVQK3 CP Isis Pharmaceuticals
DMAVQK3 DT Antisense drug
DMAVQK3 SQ ACGTGTCTGTGGACTGGAAA
DMAVQK3 DE Discovery agent
DM2N8JX ID DM2N8JX
DM2N8JX DN ISIS 111118
DM2N8JX HS Investigative
DM2N8JX CP Isis Pharmaceuticals
DM2N8JX DT Antisense drug
DM2N8JX SQ GCACATAGCACGTGTCTGTG
DM2N8JX DE Discovery agent
DM019LA ID DM019LA
DM019LA DN ISIS 111119
DM019LA HS Investigative
DM019LA CP Isis Pharmaceuticals
DM019LA DT Antisense drug
DM019LA SQ CGGCGAAGGACAGCACATAG
DM019LA DE Discovery agent
DM3W8R0 ID DM3W8R0
DM3W8R0 DN ISIS 111120
DM3W8R0 HS Investigative
DM3W8R0 CP Isis Pharmaceuticals
DM3W8R0 DT Antisense drug
DM3W8R0 SQ CATGATGACGGCGAAGGACA
DM3W8R0 DE Discovery agent
DMIHTPC ID DMIHTPC
DMIHTPC DN ISIS 111121
DMIHTPC HS Investigative
DMIHTPC CP Isis Pharmaceuticals
DMIHTPC DT Antisense drug
DMIHTPC SQ ACTGGTGTTGAGCATGATGA
DMIHTPC DE Discovery agent
DMB31GR ID DMB31GR
DMB31GR DN ISIS 11155
DMB31GR HS Investigative
DMB31GR CP Isis Pharmaceuticals
DMB31GR DT Antisense drug
DMB31GR DE Discovery agent
DMX1OI8 ID DMX1OI8
DMX1OI8 DN ISIS 11158
DMX1OI8 HS Investigative
DMX1OI8 CP Isis Pharmaceuticals
DMX1OI8 DT Antisense drug
DMX1OI8 DE Discovery agent
DM9V6FW ID DM9V6FW
DM9V6FW DN ISIS 11159
DM9V6FW HS Investigative
DM9V6FW CP Isis Pharmaceuticals
DM9V6FW DT Antisense drug
DM9V6FW DE Discovery agent
DMNIBTG ID DMNIBTG
DMNIBTG DN ISIS 111992
DMNIBTG HS Investigative
DMNIBTG CP Isis Pharmaceuticals
DMNIBTG DT Antisense drug
DMNIBTG SQ TTTAACGATGCTTCTTCGGC
DMNIBTG DE Discovery agent
DMVMDAZ ID DMVMDAZ
DMVMDAZ DN ISIS 111993
DMVMDAZ HS Investigative
DMVMDAZ CP Isis Pharmaceuticals
DMVMDAZ DT Antisense drug
DMVMDAZ SQ CGGCAGGGTGAAGAGAGACT
DMVMDAZ DE Discovery agent
DMSXTRI ID DMSXTRI
DMSXTRI DN ISIS 111997
DMSXTRI HS Investigative
DMSXTRI CP Isis Pharmaceuticals
DMSXTRI DT Antisense drug
DMSXTRI SQ CTTAGACATGACGGCAGGGT
DMSXTRI DE Discovery agent
DM1NHJ8 ID DM1NHJ8
DM1NHJ8 DN ISIS 112000
DM1NHJ8 HS Investigative
DM1NHJ8 CP Isis Pharmaceuticals
DM1NHJ8 DT Antisense drug
DM1NHJ8 SQ AGACTCTGACTTAGACATGA
DM1NHJ8 DE Discovery agent
DM2K74C ID DM2K74C
DM2K74C DN ISIS 112001
DM2K74C HS Investigative
DM2K74C CP Isis Pharmaceuticals
DM2K74C DT Antisense drug
DM2K74C SQ AGGAGACTCTGACTTAGACA
DM2K74C DE Discovery agent
DMPROW5 ID DMPROW5
DMPROW5 DN ISIS 112002
DMPROW5 HS Investigative
DMPROW5 CP Isis Pharmaceuticals
DMPROW5 DT Antisense drug
DMPROW5 SQ TTTAGGAGACTCTGACTTAG
DMPROW5 DE Discovery agent
DMHRLYJ ID DMHRLYJ
DMHRLYJ DN ISIS 112003
DMHRLYJ HS Investigative
DMHRLYJ CP Isis Pharmaceuticals
DMHRLYJ DT Antisense drug
DMHRLYJ SQ ATGAAGAGCTTCCTCAGCTG
DMHRLYJ DE Discovery agent
DMRJ1L6 ID DMRJ1L6
DMRJ1L6 DN ISIS 112004
DMRJ1L6 HS Investigative
DMRJ1L6 CP Isis Pharmaceuticals
DMRJ1L6 DT Antisense drug
DMRJ1L6 SQ ATCAGTTGTTTCAAAGCTCA
DMRJ1L6 DE Discovery agent
DMDZY8F ID DMDZY8F
DMDZY8F DN ISIS 112005
DMDZY8F HS Investigative
DMDZY8F CP Isis Pharmaceuticals
DMDZY8F DT Antisense drug
DMDZY8F SQ CCATTGCTCAAAATGGCTCC
DMDZY8F DE Discovery agent
DMN6IBS ID DMN6IBS
DMN6IBS DN ISIS 112019
DMN6IBS HS Investigative
DMN6IBS CP Isis Pharmaceuticals
DMN6IBS DT Antisense drug
DMN6IBS SQ CCACGGAGTCATGGTCGTCA
DMN6IBS DE Discovery agent
DMO2FY8 ID DMO2FY8
DMO2FY8 DN ISIS 112020
DMO2FY8 HS Investigative
DMO2FY8 CP Isis Pharmaceuticals
DMO2FY8 DT Antisense drug
DMO2FY8 SQ TGACAATCTTATCCACGGAG
DMO2FY8 DE Discovery agent
DM0E1SH ID DM0E1SH
DM0E1SH DN ISIS 112021
DM0E1SH HS Investigative
DM0E1SH CP Isis Pharmaceuticals
DM0E1SH DT Antisense drug
DM0E1SH SQ CAGTATGGTATTTCTGAATG
DM0E1SH DE Discovery agent
DM7R53M ID DM7R53M
DM7R53M DN ISIS 112022
DM7R53M HS Investigative
DM7R53M CP Isis Pharmaceuticals
DM7R53M DT Antisense drug
DM7R53M SQ TTTCTAACTTCACAGTTGTG
DM7R53M DE Discovery agent
DM5F4Q6 ID DM5F4Q6
DM5F4Q6 DN ISIS 112023
DM5F4Q6 HS Investigative
DM5F4Q6 CP Isis Pharmaceuticals
DM5F4Q6 DT Antisense drug
DM5F4Q6 SQ CACTAGCCATCTCTTGCTTT
DM5F4Q6 DE Discovery agent
DMVLHN9 ID DMVLHN9
DMVLHN9 DN ISIS 112024
DMVLHN9 HS Investigative
DMVLHN9 CP Isis Pharmaceuticals
DMVLHN9 DT Antisense drug
DMVLHN9 SQ AACCACTTCGACCTCTTTGG
DMVLHN9 DE Discovery agent
DMW3145 ID DMW3145
DMW3145 DN ISIS 11219
DMW3145 HS Investigative
DMW3145 CP Isis Pharmaceuticals
DMW3145 DT Antisense drug
DMW3145 SQ CGGGTTCTCCTGGTGGCAAT
DMW3145 DE Discovery agent
DMNJS0K ID DMNJS0K
DMNJS0K DN ISIS 11220
DMNJS0K HS Investigative
DMNJS0K CP Isis Pharmaceuticals
DMNJS0K DT Antisense drug
DMNJS0K SQ CAGTGTCTGGTCATTTCCGA
DMNJS0K DE Discovery agent
DMDUIG3 ID DMDUIG3
DMDUIG3 DN ISIS 11221
DMDUIG3 HS Investigative
DMDUIG3 CP Isis Pharmaceuticals
DMDUIG3 DT Antisense drug
DMDUIG3 SQ AGCCCAGCAGAACCACGCCG
DMDUIG3 DE Discovery agent
DM7LPI4 ID DM7LPI4
DM7LPI4 DN ISIS 11223
DM7LPI4 HS Investigative
DM7LPI4 CP Isis Pharmaceuticals
DM7LPI4 DT Antisense drug
DM7LPI4 SQ CAGTGCCCCGCCGAAGGAGA
DM7LPI4 DE Discovery agent
DMMGA6K ID DMMGA6K
DMMGA6K DN ISIS 11224
DMMGA6K HS Investigative
DMMGA6K CP Isis Pharmaceuticals
DMMGA6K DT Antisense drug
DMMGA6K SQ TCGCCTGCCTCCCTCAGCGC
DMMGA6K DE Discovery agent
DMXHQSG ID DMXHQSG
DMXHQSG DN ISIS 112580
DMXHQSG HS Investigative
DMXHQSG CP Isis Pharmaceuticals
DMXHQSG DT Antisense drug
DMXHQSG SQ CAGCGTGGGTCCCTGCGGCT
DMXHQSG DE Discovery agent
DMU5QRX ID DMU5QRX
DMU5QRX DN ISIS 112590
DMU5QRX HS Investigative
DMU5QRX CP Isis Pharmaceuticals
DMU5QRX DT Antisense drug
DMU5QRX SQ CCAGCGCAGACAGCGTGGGT
DMU5QRX DE Discovery agent
DM9OPJW ID DM9OPJW
DM9OPJW DN ISIS 112592
DM9OPJW HS Investigative
DM9OPJW CP Isis Pharmaceuticals
DM9OPJW DT Antisense drug
DM9OPJW SQ AGCCAGCGCAGACAGCGTGG
DM9OPJW DE Discovery agent
DMIYCMF ID DMIYCMF
DMIYCMF DN ISIS 112599
DMIYCMF HS Investigative
DMIYCMF CP Isis Pharmaceuticals
DMIYCMF DT Antisense drug
DMIYCMF SQ CGGGTGGAGCCAGCGCAGAC
DMIYCMF DE Discovery agent
DM6PO0N ID DM6PO0N
DM6PO0N DN ISIS 112690
DM6PO0N HS Investigative
DM6PO0N CP Isis Pharmaceuticals
DM6PO0N DT Antisense drug
DM6PO0N SQ CCCGCGCAGAGGCACAGACG
DM6PO0N DE Discovery agent
DMA4635 ID DMA4635
DMA4635 DN ISIS 112694
DMA4635 HS Investigative
DMA4635 CP Isis Pharmaceuticals
DMA4635 DT Antisense drug
DMA4635 SQ GAGACCCGCGCAGAGGCACA
DMA4635 DE Discovery agent
DMXZS4Y ID DMXZS4Y
DMXZS4Y DN ISIS 112696
DMXZS4Y HS Investigative
DMXZS4Y CP Isis Pharmaceuticals
DMXZS4Y DT Antisense drug
DMXZS4Y SQ AGGAGACCCGCGCAGAGGCA
DMXZS4Y DE Discovery agent
DMIE0GJ ID DMIE0GJ
DMIE0GJ DN ISIS 112699
DMIE0GJ HS Investigative
DMIE0GJ CP Isis Pharmaceuticals
DMIE0GJ DT Antisense drug
DMIE0GJ SQ ACCAGGAGACCCGCGCAGAG
DMIE0GJ DE Discovery agent
DM52UGS ID DM52UGS
DM52UGS DN ISIS 112711
DM52UGS HS Investigative
DM52UGS CP Isis Pharmaceuticals
DM52UGS DT Antisense drug
DM52UGS SQ TGGCAGAAGGACCAGGAGAC
DM52UGS DE Discovery agent
DMB2O1Y ID DMB2O1Y
DMB2O1Y DN ISIS 112724
DMB2O1Y HS Investigative
DMB2O1Y CP Isis Pharmaceuticals
DMB2O1Y DT Antisense drug
DMB2O1Y SQ AACATCGGCATGATGGCAGA
DMB2O1Y DE Discovery agent
DMVCYBG ID DMVCYBG
DMVCYBG DN ISIS 113019
DMVCYBG HS Investigative
DMVCYBG CP Isis Pharmaceuticals
DMVCYBG DT Antisense drug
DMVCYBG SQ GGTCCAGCCTCCGCTTCACC
DMVCYBG DE Discovery agent
DMUXN8P ID DMUXN8P
DMUXN8P DN ISIS 113020
DMUXN8P HS Investigative
DMUXN8P CP Isis Pharmaceuticals
DMUXN8P DT Antisense drug
DMUXN8P SQ GCCCACTGCTCTCGGCCAGG
DMUXN8P DE Discovery agent
DMQ4GL6 ID DMQ4GL6
DMQ4GL6 DN ISIS 113021
DMQ4GL6 HS Investigative
DMQ4GL6 CP Isis Pharmaceuticals
DMQ4GL6 DT Antisense drug
DMQ4GL6 SQ CACCTTTTCCTGGATGGCGG
DMQ4GL6 DE Discovery agent
DMOQ0XD ID DMOQ0XD
DMOQ0XD DN ISIS 113022
DMOQ0XD HS Investigative
DMOQ0XD CP Isis Pharmaceuticals
DMOQ0XD DT Antisense drug
DMOQ0XD SQ GTGGTCAGATTCAGTGAGGT
DMOQ0XD DE Discovery agent
DMKTNVJ ID DMKTNVJ
DMKTNVJ DN ISIS 113048
DMKTNVJ HS Investigative
DMKTNVJ CP Isis Pharmaceuticals
DMKTNVJ DT Antisense drug
DMKTNVJ SQ GAGTCGGCCGCCACCAGCGG
DMKTNVJ DE Discovery agent
DM063XM ID DM063XM
DM063XM DN ISIS 113131
DM063XM HS Investigative
DM063XM CP Isis Pharmaceuticals
DM063XM DT Antisense drug
DM063XM SQ CGTGTGTCTGTGCTAGTCCC
DM063XM DE Discovery agent
DM5QEP4 ID DM5QEP4
DM5QEP4 DN ISIS 113176
DM5QEP4 HS Investigative
DM5QEP4 CP Isis Pharmaceuticals
DM5QEP4 DT Antisense drug
DM5QEP4 SQ GCTCCAGCATCTGCTGCTTC
DM5QEP4 DE Discovery agent
DM4E6Y8 ID DM4E6Y8
DM4E6Y8 DN ISIS 113187
DM4E6Y8 HS Investigative
DM4E6Y8 CP Isis Pharmaceuticals
DM4E6Y8 DT Antisense drug
DM4E6Y8 SQ CCGCTCCACCACAAAGGCAC
DM4E6Y8 DE Discovery agent
DMGVN7A ID DMGVN7A
DMGVN7A DN ISIS 113209
DMGVN7A HS Investigative
DMGVN7A CP Isis Pharmaceuticals
DMGVN7A DT Antisense drug
DMGVN7A SQ AAAAGTGCCCAGATTGCTCA
DMGVN7A DE Discovery agent
DMZWH6E ID DMZWH6E
DMZWH6E DN ISIS 113210
DMZWH6E HS Investigative
DMZWH6E CP Isis Pharmaceuticals
DMZWH6E DT Antisense drug
DMZWH6E SQ TAAAAGTGCCCAGATTGCTC
DMZWH6E DE Discovery agent
DM9D3F1 ID DM9D3F1
DM9D3F1 DN ISIS 113858
DM9D3F1 HS Investigative
DM9D3F1 CP Isis Pharmaceuticals
DM9D3F1 DT Antisense drug
DM9D3F1 SQ AATCAGCATTCTTTATGGCC
DM9D3F1 DE Discovery agent
DMTEUDL ID DMTEUDL
DMTEUDL DN ISIS 113871
DMTEUDL HS Investigative
DMTEUDL CP Isis Pharmaceuticals
DMTEUDL DT Antisense drug
DMTEUDL SQ CTGATCATCCATTATGGCAA
DMTEUDL DE Discovery agent
DMR05YO ID DMR05YO
DMR05YO DN ISIS 113872
DMR05YO HS Investigative
DMR05YO CP Isis Pharmaceuticals
DMR05YO DT Antisense drug
DMR05YO SQ TTCAAAGCTTGCTGATCATC
DMR05YO DE Discovery agent
DMHUC3Q ID DMHUC3Q
DMHUC3Q DN ISIS 113873
DMHUC3Q HS Investigative
DMHUC3Q CP Isis Pharmaceuticals
DMHUC3Q DT Antisense drug
DMHUC3Q SQ CTTATGAAGGACAGCCAAAT
DMHUC3Q DE Discovery agent
DMEMSW1 ID DMEMSW1
DMEMSW1 DN ISIS 113874
DMEMSW1 HS Investigative
DMEMSW1 CP Isis Pharmaceuticals
DMEMSW1 DT Antisense drug
DMEMSW1 SQ ACTGGCCTTATGAAGGACAG
DMEMSW1 DE Discovery agent
DMI8NYF ID DMI8NYF
DMI8NYF DN ISIS 113902
DMI8NYF HS Investigative
DMI8NYF CP Isis Pharmaceuticals
DMI8NYF DT Antisense drug
DMI8NYF SQ GAGAGACAGATGGTCTGAAG
DMI8NYF DE Discovery agent
DM56A89 ID DM56A89
DM56A89 DN ISIS 113903
DM56A89 HS Investigative
DM56A89 CP Isis Pharmaceuticals
DM56A89 DT Antisense drug
DM56A89 SQ GTGACAGACTTCATTCCTGT
DM56A89 DE Discovery agent
DMBM7HD ID DMBM7HD
DMBM7HD DN ISIS 113904
DMBM7HD HS Investigative
DMBM7HD CP Isis Pharmaceuticals
DMBM7HD DT Antisense drug
DMBM7HD SQ GCAACACTCCAGATGTCTGC
DMBM7HD DE Discovery agent
DMPRDXO ID DMPRDXO
DMPRDXO DN ISIS 113905
DMPRDXO HS Investigative
DMPRDXO CP Isis Pharmaceuticals
DMPRDXO DT Antisense drug
DMPRDXO SQ GGCGGCTTTTCAGTTAGCAT
DMPRDXO DE Discovery agent
DMPJAB5 ID DMPJAB5
DMPJAB5 DN ISIS 113906
DMPJAB5 HS Investigative
DMPJAB5 CP Isis Pharmaceuticals
DMPJAB5 DT Antisense drug
DMPJAB5 SQ AAATTCAGCCCAAGGCGGCT
DMPJAB5 DE Discovery agent
DMP6WE0 ID DMP6WE0
DMP6WE0 DN ISIS 113907
DMP6WE0 HS Investigative
DMP6WE0 CP Isis Pharmaceuticals
DMP6WE0 DT Antisense drug
DMP6WE0 SQ GTTGGCTGAGTGGCGATTTT
DMP6WE0 DE Discovery agent
DMKLZ2H ID DMKLZ2H
DMKLZ2H DN ISIS 113908
DMKLZ2H HS Investigative
DMKLZ2H CP Isis Pharmaceuticals
DMKLZ2H DT Antisense drug
DMKLZ2H SQ ACTGGCTGCTAGTGATAATG
DMKLZ2H DE Discovery agent
DM0B9V5 ID DM0B9V5
DM0B9V5 DN ISIS 113909
DM0B9V5 HS Investigative
DM0B9V5 CP Isis Pharmaceuticals
DM0B9V5 DT Antisense drug
DM0B9V5 SQ ACAGGAGAGGTTACTGGCTG
DM0B9V5 DE Discovery agent
DMUVS0E ID DMUVS0E
DMUVS0E DN ISIS 114170
DMUVS0E HS Investigative
DMUVS0E CP Isis Pharmaceuticals
DMUVS0E DT Antisense drug
DMUVS0E SQ GCTCCTGCTCTTTTTAGTGT
DMUVS0E DE Discovery agent
DM60V4N ID DM60V4N
DM60V4N DN ISIS 114184
DM60V4N HS Investigative
DM60V4N CP Isis Pharmaceuticals
DM60V4N DT Antisense drug
DM60V4N SQ GGGCTTTCACAACTATAACA
DM60V4N DE Discovery agent
DMVJN4B ID DMVJN4B
DMVJN4B DN ISIS 114197
DMVJN4B HS Investigative
DMVJN4B CP Isis Pharmaceuticals
DMVJN4B DT Antisense drug
DMVJN4B SQ GCAGACCTCAAAGACATGCA
DMVJN4B DE Discovery agent
DM2GH8X ID DM2GH8X
DM2GH8X DN ISIS 114232
DM2GH8X HS Investigative
DM2GH8X CP Isis Pharmaceuticals
DM2GH8X DT Antisense drug
DM2GH8X SQ GCATACTTAGTACTTAAAGT
DM2GH8X DE Discovery agent
DMBO3YT ID DMBO3YT
DMBO3YT DN ISIS 114371
DMBO3YT HS Investigative
DMBO3YT CP Isis Pharmaceuticals
DMBO3YT DT Antisense drug
DMBO3YT SQ TGCCACTCTGGTCTTGGAAG
DMBO3YT DE Discovery agent
DMNTRKI ID DMNTRKI
DMNTRKI DN ISIS 114372
DMNTRKI HS Investigative
DMNTRKI CP Isis Pharmaceuticals
DMNTRKI DT Antisense drug
DMNTRKI SQ GCATCACTACACCTCAAAAG
DMNTRKI DE Discovery agent
DMIZH16 ID DMIZH16
DMIZH16 DN ISIS 114388
DMIZH16 HS Investigative
DMIZH16 CP Isis Pharmaceuticals
DMIZH16 DT Antisense drug
DMIZH16 SQ CTGGTTTCCCTGACAGTTGG
DMIZH16 DE Discovery agent
DM1H428 ID DM1H428
DM1H428 DN ISIS 114390
DM1H428 HS Investigative
DM1H428 CP Isis Pharmaceuticals
DM1H428 DT Antisense drug
DM1H428 SQ AGCCAATCCTCTGTAACCAT
DM1H428 DE Discovery agent
DMCBXQK ID DMCBXQK
DMCBXQK DN ISIS 114397
DMCBXQK HS Investigative
DMCBXQK CP Isis Pharmaceuticals
DMCBXQK DT Antisense drug
DMCBXQK SQ CAGTACCAGGCACTTCCTTG
DMCBXQK DE Discovery agent
DMZVE0S ID DMZVE0S
DMZVE0S DN ISIS 114399
DMZVE0S HS Investigative
DMZVE0S CP Isis Pharmaceuticals
DMZVE0S DT Antisense drug
DMZVE0S SQ GGTTGCCCATCTTCTTTCCT
DMZVE0S DE Discovery agent
DMIOWBH ID DMIOWBH
DMIOWBH DN ISIS 114404
DMIOWBH HS Investigative
DMIOWBH CP Isis Pharmaceuticals
DMIOWBH DT Antisense drug
DMIOWBH SQ ATTTGGCAAGCTGCAGTCAC
DMIOWBH DE Discovery agent
DMCVP5G ID DMCVP5G
DMCVP5G DN ISIS 114442
DMCVP5G HS Investigative
DMCVP5G CP Isis Pharmaceuticals
DMCVP5G DT Antisense drug
DMCVP5G SQ CCCGCCCACGCGTCACACGG
DMCVP5G DE Discovery agent
DM1OVSW ID DM1OVSW
DM1OVSW DN ISIS 114527
DM1OVSW HS Investigative
DM1OVSW CP Isis Pharmaceuticals
DM1OVSW DT Antisense drug
DM1OVSW SQ TCAGTGATGGTGTCACTGGT
DM1OVSW DE Discovery agent
DMSEQ61 ID DMSEQ61
DMSEQ61 DN ISIS 114530
DMSEQ61 HS Investigative
DMSEQ61 CP Isis Pharmaceuticals
DMSEQ61 DT Antisense drug
DMSEQ61 SQ TTGTAAGACTTGTCACTCAC
DMSEQ61 DE Discovery agent
DMZSUA9 ID DMZSUA9
DMZSUA9 DN ISIS 114531
DMZSUA9 HS Investigative
DMZSUA9 CP Isis Pharmaceuticals
DMZSUA9 DT Antisense drug
DMZSUA9 SQ TCCGTTGGGCAATTTCTGGA
DMZSUA9 DE Discovery agent
DMJ7BOL ID DMJ7BOL
DMJ7BOL DN ISIS 114532
DMJ7BOL HS Investigative
DMJ7BOL CP Isis Pharmaceuticals
DMJ7BOL DT Antisense drug
DMJ7BOL SQ TTCCTGTCACTTTCGATTGC
DMJ7BOL DE Discovery agent
DMD9O2H ID DMD9O2H
DMD9O2H DN ISIS 114537
DMD9O2H HS Investigative
DMD9O2H CP Isis Pharmaceuticals
DMD9O2H DT Antisense drug
DMD9O2H SQ TCTTCTGAATGTGTGAAGGT
DMD9O2H DE Discovery agent
DMMOPUK ID DMMOPUK
DMMOPUK DN ISIS 114559
DMMOPUK HS Investigative
DMMOPUK CP Isis Pharmaceuticals
DMMOPUK DT Antisense drug
DMMOPUK SQ CTGGGCTGCAGCATATTCAC
DMMOPUK DE Discovery agent
DMD2J3Q ID DMD2J3Q
DMD2J3Q DN ISIS 114563
DMD2J3Q HS Investigative
DMD2J3Q CP Isis Pharmaceuticals
DMD2J3Q DT Antisense drug
DMD2J3Q SQ AGGAGGAGTAACATCCGCCT
DMD2J3Q DE Discovery agent
DM280AE ID DM280AE
DM280AE DN ISIS 116359
DM280AE HS Investigative
DM280AE CP Isis Pharmaceuticals
DM280AE DT Antisense drug
DM280AE SQ GGCTCTTCACTTGCATAAAG
DM280AE DE Discovery agent
DMFEZHM ID DMFEZHM
DMFEZHM DN ISIS 116360
DMFEZHM HS Investigative
DMFEZHM CP Isis Pharmaceuticals
DMFEZHM DT Antisense drug
DMFEZHM SQ GTTTTGATTACTGTCTTGAC
DMFEZHM DE Discovery agent
DMWBQHS ID DMWBQHS
DMWBQHS DN ISIS 116361
DMWBQHS HS Investigative
DMWBQHS CP Isis Pharmaceuticals
DMWBQHS DT Antisense drug
DMWBQHS SQ AACCATGGTACCTCTTGGCC
DMWBQHS DE Discovery agent
DM7M1UB ID DM7M1UB
DM7M1UB DN ISIS 116362
DM7M1UB HS Investigative
DM7M1UB CP Isis Pharmaceuticals
DM7M1UB DT Antisense drug
DM7M1UB SQ AAAAATGCTTTGCAGTGTTG
DM7M1UB DE Discovery agent
DMXKAJP ID DMXKAJP
DMXKAJP DN ISIS 116363
DMXKAJP HS Investigative
DMXKAJP CP Isis Pharmaceuticals
DMXKAJP DT Antisense drug
DMXKAJP SQ CCAGATTCCTGTGGTCGTTG
DMXKAJP DE Discovery agent
DM4Q3JO ID DM4Q3JO
DM4Q3JO DN ISIS 116414
DM4Q3JO HS Investigative
DM4Q3JO CP Isis Pharmaceuticals
DM4Q3JO DT Antisense drug
DM4Q3JO SQ TGCATTAAATGAAGCTGCAG
DM4Q3JO DE Discovery agent
DMVE5UH ID DMVE5UH
DMVE5UH DN ISIS 116505
DMVE5UH HS Investigative
DMVE5UH CP Isis Pharmaceuticals
DMVE5UH DT Antisense drug
DMVE5UH SQ ACCGATTGCATCAACTTCGA
DMVE5UH DE Discovery agent
DM76CYG ID DM76CYG
DM76CYG DN ISIS 116507
DM76CYG HS Investigative
DM76CYG CP Isis Pharmaceuticals
DM76CYG DT Antisense drug
DM76CYG SQ GGTTGCGTCAGTCCCGTGTA
DM76CYG DE Discovery agent
DM3XHBR ID DM3XHBR
DM3XHBR DN ISIS 116508
DM3XHBR HS Investigative
DM3XHBR CP Isis Pharmaceuticals
DM3XHBR DT Antisense drug
DM3XHBR SQ CAGGGCCCGGCTGACAGTTA
DM3XHBR DE Discovery agent
DMIJES1 ID DMIJES1
DMIJES1 DN ISIS 116625
DMIJES1 HS Investigative
DMIJES1 CP Isis Pharmaceuticals
DMIJES1 DT Antisense drug
DMIJES1 SQ CGGACCAACTGCTTTGCACT
DMIJES1 DE Discovery agent
DM2X5RT ID DM2X5RT
DM2X5RT DN ISIS 116631
DM2X5RT HS Investigative
DM2X5RT CP Isis Pharmaceuticals
DM2X5RT DT Antisense drug
DM2X5RT SQ AGCTGGTCCACCCCACTGTC
DM2X5RT DE Discovery agent
DMW2Q4T ID DMW2Q4T
DMW2Q4T DN ISIS 116632
DMW2Q4T HS Investigative
DMW2Q4T CP Isis Pharmaceuticals
DMW2Q4T DT Antisense drug
DMW2Q4T SQ GCTGGGTTCCCAGACATCGC
DMW2Q4T DE Discovery agent
DMUOB3S ID DMUOB3S
DMUOB3S DN ISIS 116648
DMUOB3S HS Investigative
DMUOB3S CP Isis Pharmaceuticals
DMUOB3S DT Antisense drug
DMUOB3S SQ AGCCAATGACACCATACCTT
DMUOB3S DE Discovery agent
DMYWINR ID DMYWINR
DMYWINR DN ISIS 11665
DMYWINR HS Investigative
DMYWINR CP Isis Pharmaceuticals
DMYWINR DT Antisense drug
DMYWINR DE Discovery agent
DMBJU2X ID DMBJU2X
DMBJU2X DN ISIS 116654
DMBJU2X HS Investigative
DMBJU2X CP Isis Pharmaceuticals
DMBJU2X DT Antisense drug
DMBJU2X SQ CAGGCAATCCTCTTACCTGA
DMBJU2X DE Discovery agent
DM9R51M ID DM9R51M
DM9R51M DN ISIS 116670
DM9R51M HS Investigative
DM9R51M CP Isis Pharmaceuticals
DM9R51M DT Antisense drug
DM9R51M SQ CTCAGTTCCTCTCTCTGCTA
DM9R51M DE Discovery agent
DMIS715 ID DMIS715
DMIS715 DN ISIS 119262
DMIS715 HS Investigative
DMIS715 CP Isis Pharmaceuticals
DMIS715 DT Antisense drug
DMIS715 SQ TCATCACGGGATGGATCCAG
DMIS715 DE Discovery agent
DMD3M9J ID DMD3M9J
DMD3M9J DN ISIS 119263
DMD3M9J HS Investigative
DMD3M9J CP Isis Pharmaceuticals
DMD3M9J DT Antisense drug
DMD3M9J SQ ACACTCATCACGGGATGGAT
DMD3M9J DE Discovery agent
DM0P3R5 ID DM0P3R5
DM0P3R5 DN ISIS 119264
DM0P3R5 HS Investigative
DM0P3R5 CP Isis Pharmaceuticals
DM0P3R5 DT Antisense drug
DM0P3R5 SQ TTCAGGACACTCATCACGGG
DM0P3R5 DE Discovery agent
DMFPM5S ID DMFPM5S
DMFPM5S DN ISIS 119281
DMFPM5S HS Investigative
DMFPM5S CP Isis Pharmaceuticals
DMFPM5S DT Antisense drug
DMFPM5S SQ CTCACATCATCCATGTAGCT
DMFPM5S DE Discovery agent
DMLND5S ID DMLND5S
DMLND5S DN ISIS 119282
DMLND5S HS Investigative
DMLND5S CP Isis Pharmaceuticals
DMLND5S DT Antisense drug
DMLND5S SQ TCTGCTCACATCATCCATGT
DMLND5S DE Discovery agent
DMKJ57H ID DMKJ57H
DMKJ57H DN ISIS 119283
DMKJ57H HS Investigative
DMKJ57H CP Isis Pharmaceuticals
DMKJ57H DT Antisense drug
DMKJ57H SQ GTCTCTGCTCACATCATCCA
DMKJ57H DE Discovery agent
DM7CTVE ID DM7CTVE
DM7CTVE DN ISIS 119284
DM7CTVE HS Investigative
DM7CTVE CP Isis Pharmaceuticals
DM7CTVE DT Antisense drug
DM7CTVE SQ ATGCGTCTCTGCTCACATCA
DM7CTVE DE Discovery agent
DMYQR3A ID DMYQR3A
DMYQR3A DN ISIS 119285
DMYQR3A HS Investigative
DMYQR3A CP Isis Pharmaceuticals
DMYQR3A DT Antisense drug
DMYQR3A SQ GTTATGCGTCTCTGCTCACA
DMYQR3A DE Discovery agent
DM42LSO ID DM42LSO
DM42LSO DN ISIS 119286
DM42LSO HS Investigative
DM42LSO CP Isis Pharmaceuticals
DM42LSO DT Antisense drug
DM42LSO SQ GATGTTATGCGTCTCTGCTC
DM42LSO DE Discovery agent
DMZYOPD ID DMZYOPD
DMZYOPD DN ISIS 11929
DMZYOPD HS Investigative
DMZYOPD CP Isis Pharmaceuticals
DMZYOPD DT Antisense drug
DMZYOPD DE Discovery agent
DM0LMQH ID DM0LMQH
DM0LMQH DN ISIS 122970
DM0LMQH HS Investigative
DM0LMQH CP Isis Pharmaceuticals
DM0LMQH DT Antisense drug
DM0LMQH SQ CTTCATGGTCTCATATCCAG
DM0LMQH DE Discovery agent
DM4NBX0 ID DM4NBX0
DM4NBX0 DN ISIS 122971
DM4NBX0 HS Investigative
DM4NBX0 CP Isis Pharmaceuticals
DM4NBX0 DT Antisense drug
DM4NBX0 SQ TGACGTCACTCTGCCTATTT
DM4NBX0 DE Discovery agent
DMLHA6K ID DMLHA6K
DMLHA6K DN ISIS 122974
DMLHA6K HS Investigative
DMLHA6K CP Isis Pharmaceuticals
DMLHA6K DT Antisense drug
DMLHA6K SQ CACATCTTCATATTTCACAG
DMLHA6K DE Discovery agent
DM4Y8EQ ID DM4Y8EQ
DM4Y8EQ DN ISIS 122975
DM4Y8EQ HS Investigative
DM4Y8EQ CP Isis Pharmaceuticals
DM4Y8EQ DT Antisense drug
DM4Y8EQ SQ ACCTTGTGCTCCACATCTTC
DM4Y8EQ DE Discovery agent
DM7OSZI ID DM7OSZI
DM7OSZI DN ISIS 122976
DM7OSZI HS Investigative
DM7OSZI CP Isis Pharmaceuticals
DM7OSZI DT Antisense drug
DM7OSZI SQ TTGTCACCTTGTGCTCCACA
DM7OSZI DE Discovery agent
DMVZS1D ID DMVZS1D
DMVZS1D DN ISIS 122984
DMVZS1D HS Investigative
DMVZS1D CP Isis Pharmaceuticals
DMVZS1D DT Antisense drug
DMVZS1D SQ ATTGGCAGCTTCCAGACAAG
DMVZS1D DE Discovery agent
DM6JVOP ID DM6JVOP
DM6JVOP DN ISIS 122985
DM6JVOP HS Investigative
DM6JVOP CP Isis Pharmaceuticals
DM6JVOP DT Antisense drug
DM6JVOP SQ TCCAAGGATTGGCAGCTTCC
DM6JVOP DE Discovery agent
DMU79FD ID DMU79FD
DMU79FD DN ISIS 122986
DMU79FD HS Investigative
DMU79FD CP Isis Pharmaceuticals
DMU79FD DT Antisense drug
DMU79FD SQ CTGTCCAAGGATTGGCAGCT
DMU79FD DE Discovery agent
DMLN8XS ID DMLN8XS
DMLN8XS DN ISIS 122990
DMLN8XS HS Investigative
DMLN8XS CP Isis Pharmaceuticals
DMLN8XS DT Antisense drug
DMLN8XS SQ GAAGGATGGGCTGTCTGCTG
DMLN8XS DE Discovery agent
DMHAWMV ID DMHAWMV
DMHAWMV DN ISIS 122991
DMHAWMV HS Investigative
DMHAWMV CP Isis Pharmaceuticals
DMHAWMV DT Antisense drug
DMHAWMV SQ TCGTGATTTCCGGAAGGATG
DMHAWMV DE Discovery agent
DMZGKHO ID DMZGKHO
DMZGKHO DN ISIS 12659
DMZGKHO HS Investigative
DMZGKHO CP Isis Pharmaceuticals
DMZGKHO DT Antisense drug
DMZGKHO SQ GGCGTCTCCAGGCGATCTGA
DMZGKHO DE Discovery agent
DMNOPWB ID DMNOPWB
DMNOPWB DN ISIS 12660
DMNOPWB HS Investigative
DMNOPWB CP Isis Pharmaceuticals
DMNOPWB DT Antisense drug
DMNOPWB SQ TGGATGGCGTCTCCAGGCGA
DMNOPWB DE Discovery agent
DMAXB8T ID DMAXB8T
DMAXB8T DN ISIS 12882
DMAXB8T HS Investigative
DMAXB8T CP Isis Pharmaceuticals
DMAXB8T DT Antisense drug
DMAXB8T SQ GTCCCCACCGCCACTCCTGG
DMAXB8T DE Discovery agent
DMND0JL ID DMND0JL
DMND0JL DN ISIS 12883
DMND0JL HS Investigative
DMND0JL CP Isis Pharmaceuticals
DMND0JL DT Antisense drug
DMND0JL SQ GTCCCCACCGCCACTCCTGG
DMND0JL DE Discovery agent
DMS15A3 ID DMS15A3
DMS15A3 DN ISIS 12884
DMS15A3 HS Investigative
DMS15A3 CP Isis Pharmaceuticals
DMS15A3 DT Antisense drug
DMS15A3 SQ GTCCCCACCGCCACTCCTGG
DMS15A3 DE Discovery agent
DMKY5LI ID DMKY5LI
DMKY5LI DN ISIS 133206
DMKY5LI HS Investigative
DMKY5LI CP Isis Pharmaceuticals
DMKY5LI DT Antisense drug
DMKY5LI SQ AAGTCTATTGCTTCTTGAAA
DMKY5LI DE Discovery agent
DMR3KLF ID DMR3KLF
DMR3KLF DN ISIS 133207
DMR3KLF HS Investigative
DMR3KLF CP Isis Pharmaceuticals
DMR3KLF DT Antisense drug
DMR3KLF SQ AGGACCTTGCCTCCCTTTTC
DMR3KLF DE Discovery agent
DMTSKQZ ID DMTSKQZ
DMTSKQZ DN ISIS 133208
DMTSKQZ HS Investigative
DMTSKQZ CP Isis Pharmaceuticals
DMTSKQZ DT Antisense drug
DMTSKQZ SQ GCGGAACTGCTTGGTCTTCA
DMTSKQZ DE Discovery agent
DMCGF2P ID DMCGF2P
DMCGF2P DN ISIS 133211
DMCGF2P HS Investigative
DMCGF2P CP Isis Pharmaceuticals
DMCGF2P DT Antisense drug
DMCGF2P SQ GAAGGCCTCCTTCAGGCGGA
DMCGF2P DE Discovery agent
DMP60XE ID DMP60XE
DMP60XE DN ISIS 133242
DMP60XE HS Investigative
DMP60XE CP Isis Pharmaceuticals
DMP60XE DT Antisense drug
DMP60XE SQ CAACATCTTGCTACTTCAAC
DMP60XE DE Discovery agent
DM2PIAZ ID DM2PIAZ
DM2PIAZ DN ISIS 133243
DM2PIAZ HS Investigative
DM2PIAZ CP Isis Pharmaceuticals
DM2PIAZ DT Antisense drug
DM2PIAZ SQ CATGCCAAAGTCCAAGGTCA
DM2PIAZ DE Discovery agent
DMTGFXI ID DMTGFXI
DMTGFXI DN ISIS 133244
DMTGFXI HS Investigative
DMTGFXI CP Isis Pharmaceuticals
DMTGFXI DT Antisense drug
DMTGFXI SQ AGTTCAAGTATGACTAAGAA
DMTGFXI DE Discovery agent
DMO09DU ID DMO09DU
DMO09DU DN ISIS 133245
DMO09DU HS Investigative
DMO09DU CP Isis Pharmaceuticals
DMO09DU DT Antisense drug
DMO09DU SQ CAAGTTCAAGTATGACTAAG
DMO09DU DE Discovery agent
DMDZ3FU ID DMDZ3FU
DMDZ3FU DN ISIS 133712
DMDZ3FU HS Investigative
DMDZ3FU CP Isis Pharmaceuticals
DMDZ3FU DT Antisense drug
DMDZ3FU SQ AGCTTCTCCATGGTCACGTC
DMDZ3FU DE Discovery agent
DMJ56XU ID DMJ56XU
DMJ56XU DN ISIS 133726
DMJ56XU HS Investigative
DMJ56XU CP Isis Pharmaceuticals
DMJ56XU DT Antisense drug
DMJ56XU SQ GCACTCTGGACCCAAACCAG
DMJ56XU DE Discovery agent
DM90TOR ID DM90TOR
DM90TOR DN ISIS 134499
DM90TOR HS Investigative
DM90TOR CP Isis Pharmaceuticals
DM90TOR DT Antisense drug
DM90TOR SQ CCTTCTGCAACAGAGTAACA
DM90TOR DE Discovery agent
DMFCOA5 ID DMFCOA5
DMFCOA5 DN ISIS 134524
DMFCOA5 HS Investigative
DMFCOA5 CP Isis Pharmaceuticals
DMFCOA5 DT Antisense drug
DMFCOA5 SQ CAAATGCTTATAAATTTTTA
DMFCOA5 DE Discovery agent
DMYZNIW ID DMYZNIW
DMYZNIW DN ISIS 134528
DMYZNIW HS Investigative
DMYZNIW CP Isis Pharmaceuticals
DMYZNIW DT Antisense drug
DMYZNIW SQ CAGCTTTACCTTTTATAGAA
DMYZNIW DE Discovery agent
DMRFMVL ID DMRFMVL
DMRFMVL DN ISIS 134532
DMRFMVL HS Investigative
DMRFMVL CP Isis Pharmaceuticals
DMRFMVL DT Antisense drug
DMRFMVL SQ ATCTGAAAACCTAGTGGTAT
DMRFMVL DE Discovery agent
DMWRYA1 ID DMWRYA1
DMWRYA1 DN ISIS 134563
DMWRYA1 HS Investigative
DMWRYA1 CP Isis Pharmaceuticals
DMWRYA1 DT Antisense drug
DMWRYA1 SQ CCCTACTTTTGTAGAAGCCA
DMWRYA1 DE Discovery agent
DM8J24F ID DM8J24F
DM8J24F DN ISIS 134564
DM8J24F HS Investigative
DM8J24F CP Isis Pharmaceuticals
DM8J24F DT Antisense drug
DM8J24F SQ CTTGTACTGCTCGGCTGGAT
DM8J24F DE Discovery agent
DM9FR3A ID DM9FR3A
DM9FR3A DN ISIS 134565
DM9FR3A HS Investigative
DM9FR3A CP Isis Pharmaceuticals
DM9FR3A DT Antisense drug
DM9FR3A SQ TCCATCTTGTACTGCTCGGC
DM9FR3A DE Discovery agent
DMCM2S4 ID DMCM2S4
DMCM2S4 DN ISIS 134566
DMCM2S4 HS Investigative
DMCM2S4 CP Isis Pharmaceuticals
DMCM2S4 DT Antisense drug
DMCM2S4 SQ TTGTGGTCCATCTTGTACTG
DMCM2S4 DE Discovery agent
DM0HWRN ID DM0HWRN
DM0HWRN DN ISIS 134583
DM0HWRN HS Investigative
DM0HWRN CP Isis Pharmaceuticals
DM0HWRN DT Antisense drug
DM0HWRN SQ CGGGTACGTCATGCTGGCTA
DM0HWRN DE Discovery agent
DMNP8HG ID DMNP8HG
DMNP8HG DN ISIS 134601
DMNP8HG HS Investigative
DMNP8HG CP Isis Pharmaceuticals
DMNP8HG DT Antisense drug
DMNP8HG SQ CTAGGTTTGGGACAGAAATG
DMNP8HG DE Discovery agent
DMDS4BP ID DMDS4BP
DMDS4BP DN ISIS 134602
DMDS4BP HS Investigative
DMDS4BP CP Isis Pharmaceuticals
DMDS4BP DT Antisense drug
DMDS4BP SQ ACCAGCTGGCCTTTGTATAA
DMDS4BP DE Discovery agent
DM01UDZ ID DM01UDZ
DM01UDZ DN ISIS 134603
DM01UDZ HS Investigative
DM01UDZ CP Isis Pharmaceuticals
DM01UDZ DT Antisense drug
DM01UDZ SQ TGGGTGAAAGTCTTCCACCA
DM01UDZ DE Discovery agent
DM32XGR ID DM32XGR
DM32XGR DN ISIS 134604
DM32XGR HS Investigative
DM32XGR CP Isis Pharmaceuticals
DM32XGR DT Antisense drug
DM32XGR SQ TGAAGCAGTTTACATTGATG
DM32XGR DE Discovery agent
DMCPKV9 ID DMCPKV9
DMCPKV9 DN ISIS 134605
DMCPKV9 HS Investigative
DMCPKV9 CP Isis Pharmaceuticals
DMCPKV9 DT Antisense drug
DMCPKV9 SQ GGCATCTACAAAATTGAAGC
DMCPKV9 DE Discovery agent
DM4OF6C ID DM4OF6C
DM4OF6C DN ISIS 134606
DM4OF6C HS Investigative
DM4OF6C CP Isis Pharmaceuticals
DM4OF6C DT Antisense drug
DM4OF6C SQ TTCTATGGCATCTACAAAAT
DM4OF6C DE Discovery agent
DMZDJF3 ID DMZDJF3
DMZDJF3 DN ISIS 134607
DMZDJF3 HS Investigative
DMZDJF3 CP Isis Pharmaceuticals
DMZDJF3 DT Antisense drug
DMZDJF3 SQ AACATTACTTTTCTATGGCA
DMZDJF3 DE Discovery agent
DMVX9IT ID DMVX9IT
DMVX9IT DN ISIS 134608
DMVX9IT HS Investigative
DMVX9IT CP Isis Pharmaceuticals
DMVX9IT DT Antisense drug
DMVX9IT SQ CACGTCCAACATGATTGAAA
DMVX9IT DE Discovery agent
DMYODMN ID DMYODMN
DMYODMN DN ISIS 134609
DMYODMN HS Investigative
DMYODMN CP Isis Pharmaceuticals
DMYODMN DT Antisense drug
DMYODMN SQ CTTCCACCACGTCCAACATG
DMYODMN DE Discovery agent
DMCDW4H ID DMCDW4H
DMCDW4H DN ISIS 13727
DMCDW4H HS Investigative
DMCDW4H CP Isis Pharmaceuticals
DMCDW4H DT Antisense drug
DMCDW4H SQ TGTAACTGCTGAGGTGTAGG
DMCDW4H DE Discovery agent
DMRJBH4 ID DMRJBH4
DMRJBH4 DN ISIS 13730
DMRJBH4 HS Investigative
DMRJBH4 CP Isis Pharmaceuticals
DMRJBH4 DT Antisense drug
DMRJBH4 SQ ATGGAGATGGTGATACAAGC
DMRJBH4 DE Discovery agent
DM5Q12D ID DM5Q12D
DM5Q12D DN ISIS 13740
DM5Q12D HS Investigative
DM5Q12D CP Isis Pharmaceuticals
DM5Q12D DT Antisense drug
DM5Q12D SQ TGGATGGGTGTTTTTGGAGA
DM5Q12D DE Discovery agent
DMC7Q38 ID DMC7Q38
DMC7Q38 DN ISIS 13741
DMC7Q38 HS Investigative
DMC7Q38 CP Isis Pharmaceuticals
DMC7Q38 DT Antisense drug
DMC7Q38 SQ CTGCCTGGATGGGTGTTTTT
DMC7Q38 DE Discovery agent
DMO6R1I ID DMO6R1I
DMO6R1I DN ISIS 13743
DMO6R1I HS Investigative
DMO6R1I CP Isis Pharmaceuticals
DMO6R1I DT Antisense drug
DMO6R1I SQ TTTATTTTCCTTTTGTTGCT
DMO6R1I DE Discovery agent
DMLVKPD ID DMLVKPD
DMLVKPD DN ISIS 13805
DMLVKPD HS Investigative
DMLVKPD CP Isis Pharmaceuticals
DMLVKPD DT Antisense drug
DMLVKPD SQ CCTGCCTCCGTGTGTGGCCC
DMLVKPD DE Discovery agent
DMPXCZ7 ID DMPXCZ7
DMPXCZ7 DN ISIS 13812
DMPXCZ7 HS Investigative
DMPXCZ7 CP Isis Pharmaceuticals
DMPXCZ7 DT Antisense drug
DMPXCZ7 SQ GCCTCATGATCCCCACGATC
DMPXCZ7 DE Discovery agent
DMLE7YQ ID DMLE7YQ
DMLE7YQ DN ISIS 138612
DMLE7YQ HS Investigative
DMLE7YQ CP Isis Pharmaceuticals
DMLE7YQ DT Antisense drug
DMLE7YQ SQ ATAGATCACTTTTACAAGGC
DMLE7YQ DE Discovery agent
DMN3L0Y ID DMN3L0Y
DMN3L0Y DN ISIS 138613
DMN3L0Y HS Investigative
DMN3L0Y CP Isis Pharmaceuticals
DMN3L0Y DT Antisense drug
DMN3L0Y SQ CCTTAGGAAAGTGTCTGTAA
DMN3L0Y DE Discovery agent
DM1FX7N ID DM1FX7N
DM1FX7N DN ISIS 138616
DM1FX7N HS Investigative
DM1FX7N CP Isis Pharmaceuticals
DM1FX7N DT Antisense drug
DM1FX7N SQ GGAAAATTTGTCTCTGGCTT
DM1FX7N DE Discovery agent
DM73NIE ID DM73NIE
DM73NIE DN ISIS 138647
DM73NIE HS Investigative
DM73NIE CP Isis Pharmaceuticals
DM73NIE DT Antisense drug
DM73NIE SQ TCTCATATATGAAAGGCGGC
DM73NIE DE Discovery agent
DMSUKAO ID DMSUKAO
DMSUKAO DN ISIS 138648
DMSUKAO HS Investigative
DMSUKAO CP Isis Pharmaceuticals
DMSUKAO DT Antisense drug
DMSUKAO SQ GCTGACCTTTTTGCTTCTCA
DMSUKAO DE Discovery agent
DMNFYZL ID DMNFYZL
DMNFYZL DN ISIS 138649
DMNFYZL HS Investigative
DMNFYZL CP Isis Pharmaceuticals
DMNFYZL DT Antisense drug
DMNFYZL SQ TACAGTTGCTGACCTTTTTG
DMNFYZL DE Discovery agent
DMB7E4X ID DMB7E4X
DMB7E4X DN ISIS 138678
DMB7E4X HS Investigative
DMB7E4X CP Isis Pharmaceuticals
DMB7E4X DT Antisense drug
DMB7E4X SQ CATAAACATTTCCATCAGTG
DMB7E4X DE Discovery agent
DM4PM1G ID DM4PM1G
DM4PM1G DN ISIS 13920
DM4PM1G HS Investigative
DM4PM1G CP Isis Pharmaceuticals
DM4PM1G TC Anticancer Agents
DM4PM1G DT Antisense drug
DM4PM1G SQ TCCGTCATCGCTCCTCAGGG
DM4PM1G DE Solid tumour/cancer
DMKYWQ2 ID DMKYWQ2
DMKYWQ2 DN ISIS 140148
DMKYWQ2 HS Investigative
DMKYWQ2 CP Isis Pharmaceuticals
DMKYWQ2 DT Antisense drug
DMKYWQ2 SQ CAGTTGTCCCTGCGCTTGCT
DMKYWQ2 DE Discovery agent
DMD60BA ID DMD60BA
DMD60BA DN ISIS 140153
DMD60BA HS Investigative
DMD60BA CP Isis Pharmaceuticals
DMD60BA DT Antisense drug
DMD60BA SQ TCCAGGTGCCCCTGGCCCAC
DMD60BA DE Discovery agent
DMG2P7B ID DMG2P7B
DMG2P7B DN ISIS 140157
DMG2P7B HS Investigative
DMG2P7B CP Isis Pharmaceuticals
DMG2P7B DT Antisense drug
DMG2P7B SQ GTTCTTGGCCACATAATTCC
DMG2P7B DE Discovery agent
DMO87PG ID DMO87PG
DMO87PG DN ISIS 140158
DMO87PG HS Investigative
DMO87PG CP Isis Pharmaceuticals
DMO87PG DT Antisense drug
DMO87PG SQ AACACAGAGGCGGCCCAGGA
DMO87PG DE Discovery agent
DMRHSY6 ID DMRHSY6
DMRHSY6 DN ISIS 140161
DMRHSY6 HS Investigative
DMRHSY6 CP Isis Pharmaceuticals
DMRHSY6 DT Antisense drug
DMRHSY6 SQ GTCATGGACCACCACGTTCC
DMRHSY6 DE Discovery agent
DMP9WOZ ID DMP9WOZ
DMP9WOZ DN ISIS 140180
DMP9WOZ HS Investigative
DMP9WOZ CP Isis Pharmaceuticals
DMP9WOZ DT Antisense drug
DMP9WOZ SQ GTGAACACTTCGCCTTGCAC
DMP9WOZ DE Discovery agent
DMWIKD5 ID DMWIKD5
DMWIKD5 DN ISIS 14144
DMWIKD5 HS Investigative
DMWIKD5 CP Isis Pharmaceuticals
DMWIKD5 DT Antisense drug
DMWIKD5 SQ GGACAGGAAACGCACCATA
DMWIKD5 DE Discovery agent
DMJW4C5 ID DMJW4C5
DMJW4C5 DN ISIS 144368
DMJW4C5 HS Investigative
DMJW4C5 CP Isis Pharmaceuticals
DMJW4C5 DT Antisense drug
DMJW4C5 SQ TCTGCGTCTGAGCATTGCGT
DMJW4C5 DE Discovery agent
DM1QLB0 ID DM1QLB0
DM1QLB0 DN ISIS 144379
DM1QLB0 HS Investigative
DM1QLB0 CP Isis Pharmaceuticals
DM1QLB0 DT Antisense drug
DM1QLB0 SQ ACCTGACACCGGGATCCCTC
DM1QLB0 DE Discovery agent
DMY34RB ID DMY34RB
DMY34RB DN ISIS 144396
DMY34RB HS Investigative
DMY34RB CP Isis Pharmaceuticals
DMY34RB DT Antisense drug
DMY34RB SQ TCCTTACCCACGTTTCAGCT
DMY34RB DE Discovery agent
DMHWGL0 ID DMHWGL0
DMHWGL0 DN ISIS 14548
DMHWGL0 HS Investigative
DMHWGL0 CP Isis Pharmaceuticals
DMHWGL0 DT Antisense drug
DMHWGL0 SQ GGTGAGATTTTGGTCTCAAG
DMHWGL0 DE Discovery agent
DMNMXKC ID DMNMXKC
DMNMXKC DN ISIS 147483
DMNMXKC HS Investigative
DMNMXKC CP Isis Pharmaceuticals
DMNMXKC DT Antisense drug
DMNMXKC SQ ATGTCAATGCCACATGTCCA
DMNMXKC DE Discovery agent
DM1Z5W8 ID DM1Z5W8
DM1Z5W8 DN ISIS 147788
DM1Z5W8 HS Investigative
DM1Z5W8 CP Isis Pharmaceuticals
DM1Z5W8 DT Antisense drug
DM1Z5W8 SQ TTTCTGTTGCCACATTGCCC
DM1Z5W8 DE Discovery agent
DMTE3FJ ID DMTE3FJ
DMTE3FJ DN ISIS 147919
DMTE3FJ HS Investigative
DMTE3FJ CP Isis Pharmaceuticals
DMTE3FJ DT Antisense drug
DMTE3FJ SQ TCAGTGACCC
DMTE3FJ DE Discovery agent
DMSB27R ID DMSB27R
DMSB27R DN ISIS 148715
DMSB27R HS Investigative
DMSB27R CP Isis Pharmaceuticals
DMSB27R DT Antisense drug
DMSB27R SQ TTGTCCCAGTCCCAGGCCTC
DMSB27R DE Discovery agent
DMMBW13 ID DMMBW13
DMMBW13 DN ISIS 150450
DMMBW13 HS Investigative
DMMBW13 CP Isis Pharmaceuticals
DMMBW13 DT Antisense drug
DMMBW13 SQ CAGGCCTTCAGTCAGTCCTT
DMMBW13 DE Discovery agent
DM1DCFP ID DM1DCFP
DM1DCFP DN ISIS 150451
DM1DCFP HS Investigative
DM1DCFP CP Isis Pharmaceuticals
DM1DCFP DT Antisense drug
DM1DCFP SQ TATCTCCAAACTCATGAACA
DM1DCFP DE Discovery agent
DMQE7BH ID DMQE7BH
DMQE7BH DN ISIS 150452
DMQE7BH HS Investigative
DMQE7BH CP Isis Pharmaceuticals
DMQE7BH DT Antisense drug
DMQE7BH SQ GCTGTATTATCTCCAAACTC
DMQE7BH DE Discovery agent
DMKCG41 ID DMKCG41
DMKCG41 DN ISIS 150453
DMKCG41 HS Investigative
DMKCG41 CP Isis Pharmaceuticals
DMKCG41 DT Antisense drug
DMKCG41 SQ GTACAGCCTGCTGTATTATC
DMKCG41 DE Discovery agent
DMW0Y75 ID DMW0Y75
DMW0Y75 DN ISIS 150454
DMW0Y75 HS Investigative
DMW0Y75 CP Isis Pharmaceuticals
DMW0Y75 DT Antisense drug
DMW0Y75 SQ TGCCCAAGTCTCCAACATGC
DMW0Y75 DE Discovery agent
DMFUM62 ID DMFUM62
DMFUM62 DN ISIS 150463
DMFUM62 HS Investigative
DMFUM62 CP Isis Pharmaceuticals
DMFUM62 DT Antisense drug
DMFUM62 SQ GGCGATCCCAATTACACCAC
DMFUM62 DE Discovery agent
DM1IC54 ID DM1IC54
DM1IC54 DN ISIS 150464
DM1IC54 HS Investigative
DM1IC54 CP Isis Pharmaceuticals
DM1IC54 DT Antisense drug
DM1IC54 SQ GGAATGTTTATTGGGCGATC
DM1IC54 DE Discovery agent
DMPB3FH ID DMPB3FH
DMPB3FH DN ISIS 156449
DMPB3FH HS Investigative
DMPB3FH CP Isis Pharmaceuticals
DMPB3FH DT Antisense drug
DMPB3FH SQ GTTCATCTTCTATTCCTGCC
DMPB3FH DE Discovery agent
DMPH2W7 ID DMPH2W7
DMPH2W7 DN ISIS 156451
DMPH2W7 HS Investigative
DMPH2W7 CP Isis Pharmaceuticals
DMPH2W7 DT Antisense drug
DMPH2W7 SQ TTAGTCCAACATTGAGGCAG
DMPH2W7 DE Discovery agent
DMCU6RF ID DMCU6RF
DMCU6RF DN ISIS 156452
DMCU6RF HS Investigative
DMCU6RF CP Isis Pharmaceuticals
DMCU6RF DT Antisense drug
DMCU6RF SQ GCTTCCTAATTAGTCCAACA
DMCU6RF DE Discovery agent
DMQ9018 ID DMQ9018
DMQ9018 DN ISIS 156453
DMQ9018 HS Investigative
DMQ9018 CP Isis Pharmaceuticals
DMQ9018 DT Antisense drug
DMQ9018 SQ CCTTCTTGAGGATCAATAAA
DMQ9018 DE Discovery agent
DMM9ARP ID DMM9ARP
DMM9ARP DN ISIS 156471
DMM9ARP HS Investigative
DMM9ARP CP Isis Pharmaceuticals
DMM9ARP DT Antisense drug
DMM9ARP SQ TCATCTCCATCACTTGAGAA
DMM9ARP DE Discovery agent
DM3U0Z6 ID DM3U0Z6
DM3U0Z6 DN ISIS 156472
DM3U0Z6 HS Investigative
DM3U0Z6 CP Isis Pharmaceuticals
DM3U0Z6 DT Antisense drug
DM3U0Z6 SQ GCAATGAACCATTAGGCATG
DM3U0Z6 DE Discovery agent
DMDFUS8 ID DMDFUS8
DMDFUS8 DN ISIS 156473
DMDFUS8 HS Investigative
DMDFUS8 CP Isis Pharmaceuticals
DMDFUS8 DT Antisense drug
DMDFUS8 SQ CATGTGCCAAGAAAGTGGTG
DMDFUS8 DE Discovery agent
DMCXP9T ID DMCXP9T
DMCXP9T DN ISIS 156474
DMCXP9T HS Investigative
DMCXP9T CP Isis Pharmaceuticals
DMCXP9T DT Antisense drug
DMCXP9T SQ GCACCCTGAGCAATCTTGCA
DMCXP9T DE Discovery agent
DMNB4UJ ID DMNB4UJ
DMNB4UJ DN ISIS 156475
DMNB4UJ HS Investigative
DMNB4UJ CP Isis Pharmaceuticals
DMNB4UJ DT Antisense drug
DMNB4UJ SQ CATTAGCTGCACCCTGAGCA
DMNB4UJ DE Discovery agent
DMJCXHM ID DMJCXHM
DMJCXHM DN ISIS 15770
DMJCXHM HS Investigative
DMJCXHM CP Isis Pharmaceuticals
DMJCXHM TC Anticancer Agents
DMJCXHM DT Antisense drug
DMJCXHM SQ ATGCATTCTGCCCCCAAGGA
DMJCXHM DE Solid tumour/cancer
DMAQ9EB ID DMAQ9EB
DMAQ9EB DN ISIS 15998
DMAQ9EB HS Investigative
DMAQ9EB CP Isis Pharmaceuticals
DMAQ9EB DT Antisense drug
DMAQ9EB SQ TAATAGGGATGGGCTCAACC
DMAQ9EB DE Discovery agent
DMMEP6J ID DMMEP6J
DMMEP6J DN ISIS 15999
DMMEP6J HS Investigative
DMMEP6J CP Isis Pharmaceuticals
DMMEP6J DT Antisense drug
DMMEP6J SQ TCCCGGTTGCTCTGAGACAT
DMMEP6J DE Discovery agent
DMDORHA ID DMDORHA
DMDORHA DN ISIS 16005
DMDORHA HS Investigative
DMDORHA CP Isis Pharmaceuticals
DMDORHA DT Antisense drug
DMDORHA SQ GCCGGTACCGCAGTTCAAAC
DMDORHA DE Discovery agent
DMBRKFC ID DMBRKFC
DMBRKFC DN ISIS 16009
DMBRKFC HS Investigative
DMBRKFC CP Isis Pharmaceuticals
DMBRKFC DT Antisense drug
DMBRKFC SQ CTACGCTTTCCACGCACAGT
DMBRKFC DE Discovery agent
DMZID0W ID DMZID0W
DMZID0W DN ISIS 16010
DMZID0W HS Investigative
DMZID0W CP Isis Pharmaceuticals
DMZID0W DT Antisense drug
DMZID0W SQ TCCAAGCTGCGATCCGACTC
DMZID0W DE Discovery agent
DM7VQH8 ID DM7VQH8
DM7VQH8 DN ISIS 16108
DM7VQH8 HS Investigative
DM7VQH8 CP Isis Pharmaceuticals
DM7VQH8 DT Antisense drug
DM7VQH8 SQ CGGCTGGTTCATTCTCCTGG
DM7VQH8 DE Discovery agent
DMS7HQN ID DMS7HQN
DMS7HQN DN ISIS 16112
DMS7HQN HS Investigative
DMS7HQN CP Isis Pharmaceuticals
DMS7HQN DT Antisense drug
DMS7HQN SQ CCATACGCTCGTGCTGGTGC
DMS7HQN DE Discovery agent
DM71H65 ID DM71H65
DM71H65 DN ISIS 16121
DM71H65 HS Investigative
DM71H65 CP Isis Pharmaceuticals
DM71H65 DT Antisense drug
DM71H65 SQ TCTGACCGCTTCAGCGTTGG
DM71H65 DE Discovery agent
DM0AC3S ID DM0AC3S
DM0AC3S DN ISIS 16123
DM0AC3S HS Investigative
DM0AC3S CP Isis Pharmaceuticals
DM0AC3S DT Antisense drug
DM0AC3S SQ ACCAGGCTGACAGCTGGAGG
DM0AC3S DE Discovery agent
DMYGOT7 ID DMYGOT7
DMYGOT7 DN ISIS 16124
DMYGOT7 HS Investigative
DMYGOT7 CP Isis Pharmaceuticals
DMYGOT7 DT Antisense drug
DMYGOT7 SQ CCTTCAGTGATATGAGAGAC
DMYGOT7 DE Discovery agent
DMOTMVP ID DMOTMVP
DMOTMVP DN ISIS 16179
DMOTMVP HS Investigative
DMOTMVP CP Isis Pharmaceuticals
DMOTMVP DT Antisense drug
DMOTMVP SQ TCTTGACCAAATGCAACCCA
DMOTMVP DE Discovery agent
DMK69ZR ID DMK69ZR
DMK69ZR DN ISIS 16507
DMK69ZR HS Investigative
DMK69ZR CP Isis Pharmaceuticals
DMK69ZR TC Anticancer Agents
DMK69ZR DT Antisense drug
DMK69ZR DE Solid tumour/cancer
DM24L0S ID DM24L0S
DM24L0S DN ISIS 16518
DM24L0S HS Investigative
DM24L0S CP Isis Pharmaceuticals
DM24L0S TC Anticancer Agents
DM24L0S DT Antisense drug
DM24L0S DE Solid tumour/cancer
DMXMHJV ID DMXMHJV
DMXMHJV DN ISIS 17020
DMXMHJV HS Investigative
DMXMHJV CP Isis Pharmaceuticals
DMXMHJV DT Antisense drug
DMXMHJV SQ TCACTCTAGACCAAGCTTTG
DMXMHJV DE Discovery agent
DMPZ9D3 ID DMPZ9D3
DMPZ9D3 DN ISIS 17148
DMPZ9D3 HS Investigative
DMPZ9D3 CP Isis Pharmaceuticals
DMPZ9D3 DT Antisense drug
DMPZ9D3 SQ ACTCAAACTGCCCTCCTGCT
DMPZ9D3 DE Discovery agent
DME7VZG ID DME7VZG
DME7VZG DN ISIS 17152
DME7VZG HS Investigative
DME7VZG CP Isis Pharmaceuticals
DME7VZG DT Antisense drug
DME7VZG SQ AAAAAGTGCCCAGATTGCCC
DME7VZG DE Discovery agent
DMW40NK ID DMW40NK
DMW40NK DN ISIS 17252
DMW40NK HS Investigative
DMW40NK CP Isis Pharmaceuticals
DMW40NK DT Antisense drug
DMW40NK SQ GGACCCCGAAAGACCACCAG
DMW40NK DE Discovery agent
DM8ITFJ ID DM8ITFJ
DM8ITFJ DN ISIS 173813
DM8ITFJ HS Investigative
DM8ITFJ CP Isis Pharmaceuticals
DM8ITFJ DT Antisense drug
DM8ITFJ SQ CTCTCTGCGCAGCTGATGCT
DM8ITFJ DE Discovery agent
DM9Y5NX ID DM9Y5NX
DM9Y5NX DN ISIS 173831
DM9Y5NX HS Investigative
DM9Y5NX CP Isis Pharmaceuticals
DM9Y5NX DT Antisense drug
DM9Y5NX SQ GGAGGGCGCATGCACAGACC
DM9Y5NX DE Discovery agent
DMIU0QJ ID DMIU0QJ
DMIU0QJ DN ISIS 173840
DMIU0QJ HS Investigative
DMIU0QJ CP Isis Pharmaceuticals
DMIU0QJ DT Antisense drug
DMIU0QJ SQ GGCACTGCTACTCTCCCGGC
DMIU0QJ DE Discovery agent
DMSG1NI ID DMSG1NI
DMSG1NI DN ISIS 173848
DMSG1NI HS Investigative
DMSG1NI CP Isis Pharmaceuticals
DMSG1NI DT Antisense drug
DMSG1NI SQ GCCTGGATTTCGATCTCTCT
DMSG1NI DE Discovery agent
DMBFK8A ID DMBFK8A
DMBFK8A DN ISIS 1751
DMBFK8A HS Investigative
DMBFK8A CP Isis Pharmaceuticals
DMBFK8A DT Antisense drug
DMBFK8A DE Discovery agent
DMKWT6F ID DMKWT6F
DMKWT6F DN ISIS 1753
DMKWT6F HS Investigative
DMKWT6F CP Isis Pharmaceuticals
DMKWT6F DT Antisense drug
DMKWT6F DE Discovery agent
DMPAXR4 ID DMPAXR4
DMPAXR4 DN ISIS 175510
DMPAXR4 HS Investigative
DMPAXR4 CP Isis Pharmaceuticals
DMPAXR4 DT Antisense drug
DMPAXR4 SQ TGAGCTGTCTGTGATCCAGC
DMPAXR4 DE Discovery agent
DMHZPJ0 ID DMHZPJ0
DMHZPJ0 DN ISIS 18078
DMHZPJ0 HS Investigative
DMHZPJ0 CP Isis Pharmaceuticals
DMHZPJ0 TC Anticancer Agents
DMHZPJ0 DT Antisense drug
DMHZPJ0 SQ GTGCGCGCGAGCCCGAAATC
DMHZPJ0 DE Solid tumour/cancer
DMQ5A4Y ID DMQ5A4Y
DMQ5A4Y DN ISIS 1820
DMQ5A4Y HS Investigative
DMQ5A4Y CP Isis Pharmaceuticals
DMQ5A4Y DT Antisense drug
DMQ5A4Y DE Discovery agent
DMUG2PN ID DMUG2PN
DMUG2PN DN ISIS 1821
DMUG2PN HS Investigative
DMUG2PN CP Isis Pharmaceuticals
DMUG2PN DT Antisense drug
DMUG2PN SQ 5'-CATGGCGCGGGCCGCGGG-3'
DMUG2PN DE Discovery agent
DMLJBU8 ID DMLJBU8
DMLJBU8 DN ISIS 1822
DMLJBU8 HS Investigative
DMLJBU8 CP Isis Pharmaceuticals
DMLJBU8 DT Antisense drug
DMLJBU8 DE Discovery agent
DMPHWMO ID DMPHWMO
DMPHWMO DN ISIS 1827
DMPHWMO HS Investigative
DMPHWMO CP Isis Pharmaceuticals
DMPHWMO DT Antisense drug
DMPHWMO DE Discovery agent
DM1LWGI ID DM1LWGI
DM1LWGI DN ISIS 1831
DM1LWGI HS Investigative
DM1LWGI CP Isis Pharmaceuticals
DM1LWGI DT Antisense drug
DM1LWGI DE Discovery agent
DMOU9EP ID DMOU9EP
DMOU9EP DN ISIS 183881
DMOU9EP HS Investigative
DMOU9EP CP Isis Pharmaceuticals
DMOU9EP DT Antisense drug
DMOU9EP SQ ATCCAAGTGCTACTGTAGTA
DMOU9EP DE Discovery agent
DMT3YI5 ID DMT3YI5
DMT3YI5 DN ISIS 183882
DMT3YI5 HS Investigative
DMT3YI5 CP Isis Pharmaceuticals
DMT3YI5 DT Antisense drug
DMT3YI5 SQ TTTCCTCAAGATTGAGAGAT
DMT3YI5 DE Discovery agent
DMA46S1 ID DMA46S1
DMA46S1 DN ISIS 183883
DMA46S1 HS Investigative
DMA46S1 CP Isis Pharmaceuticals
DMA46S1 DT Antisense drug
DMA46S1 SQ CAAAGCACAGAATCTCTCTG
DMA46S1 DE Discovery agent
DMS172K ID DMS172K
DMS172K DN ISIS 183897
DMS172K HS Investigative
DMS172K CP Isis Pharmaceuticals
DMS172K DT Antisense drug
DMS172K SQ CAGTTAGGTTTCCACATTGC
DMS172K DE Discovery agent
DMSEJZK ID DMSEJZK
DMSEJZK DN ISIS 183901
DMSEJZK HS Investigative
DMSEJZK CP Isis Pharmaceuticals
DMSEJZK DT Antisense drug
DMSEJZK SQ TACCAGCCAAGGGATCCTCT
DMSEJZK DE Discovery agent
DMMQ2L7 ID DMMQ2L7
DMMQ2L7 DN ISIS 183910
DMMQ2L7 HS Investigative
DMMQ2L7 CP Isis Pharmaceuticals
DMMQ2L7 DT Antisense drug
DMMQ2L7 SQ GAGAAGCCATCAGAATCAGC
DMMQ2L7 DE Discovery agent
DMTB350 ID DMTB350
DMTB350 DN ISIS 183911
DMTB350 HS Investigative
DMTB350 CP Isis Pharmaceuticals
DMTB350 DT Antisense drug
DMTB350 SQ CTCAAGATTGAGAGATGCAG
DMTB350 DE Discovery agent
DM5QWED ID DM5QWED
DM5QWED DN ISIS 183912
DM5QWED HS Investigative
DM5QWED CP Isis Pharmaceuticals
DM5QWED DT Antisense drug
DM5QWED SQ GTTTCTCATGAGCTGCCTTA
DM5QWED DE Discovery agent
DMR6QNA ID DMR6QNA
DMR6QNA DN ISIS 18473
DMR6QNA HS Investigative
DMR6QNA CP Isis Pharmaceuticals
DMR6QNA DT Antisense drug
DMR6QNA SQ GGTCTTCAATGGATGAGGAG
DMR6QNA DE Discovery agent
DM0BAX4 ID DM0BAX4
DM0BAX4 DN ISIS 188755
DM0BAX4 HS Investigative
DM0BAX4 CP Isis Pharmaceuticals
DM0BAX4 DT Antisense drug
DM0BAX4 SQ CCGGCCTGGGCAGCGGCCAG
DM0BAX4 DE Discovery agent
DMFTJD5 ID DMFTJD5
DMFTJD5 DN ISIS 188757
DMFTJD5 HS Investigative
DMFTJD5 CP Isis Pharmaceuticals
DMFTJD5 DT Antisense drug
DMFTJD5 SQ CCCTGGAAGTCCOCGCACAG
DMFTJD5 DE Discovery agent
DMM8G03 ID DMM8G03
DMM8G03 DN ISIS 188759
DMM8G03 HS Investigative
DMM8G03 CP Isis Pharmaceuticals
DMM8G03 DT Antisense drug
DMM8G03 SQ TTGGTGATGAGGTCGGCGTA
DMM8G03 DE Discovery agent
DMTY3N6 ID DMTY3N6
DMTY3N6 DN ISIS 188761
DMTY3N6 HS Investigative
DMTY3N6 CP Isis Pharmaceuticals
DMTY3N6 DT Antisense drug
DMTY3N6 SQ TCTCGATGGCCTTGGTGATG
DMTY3N6 DE Discovery agent
DMOJBHC ID DMOJBHC
DMOJBHC DN ISIS 188763
DMOJBHC HS Investigative
DMOJBHC CP Isis Pharmaceuticals
DMOJBHC DT Antisense drug
DMOJBHC SQ TTGAAGTAGGGCACGCTCTT
DMOJBHC DE Discovery agent
DMP9YD3 ID DMP9YD3
DMP9YD3 DN ISIS 188778
DMP9YD3 HS Investigative
DMP9YD3 CP Isis Pharmaceuticals
DMP9YD3 DT Antisense drug
DMP9YD3 SQ TGAGATGCCTGGCTGCCATA
DMP9YD3 DE Discovery agent
DMVZTU0 ID DMVZTU0
DMVZTU0 DN ISIS 188780
DMVZTU0 HS Investigative
DMVZTU0 CP Isis Pharmaceuticals
DMVZTU0 DT Antisense drug
DMVZTU0 SQ ATCATTTTGTTATGAGATGC
DMVZTU0 DE Discovery agent
DMOYINM ID DMOYINM
DMOYINM DN ISIS 188781
DMOYINM HS Investigative
DMOYINM CP Isis Pharmaceuticals
DMOYINM DT Antisense drug
DMOYINM SQ CAGGGCACTCATCTGCATGG
DMOYINM DE Discovery agent
DM5O4L8 ID DM5O4L8
DM5O4L8 DN ISIS 188782
DM5O4L8 HS Investigative
DM5O4L8 CP Isis Pharmaceuticals
DM5O4L8 DT Antisense drug
DM5O4L8 SQ TAGCCATTGCAGCTGCTCAC
DM5O4L8 DE Discovery agent
DMOQ27M ID DMOQ27M
DMOQ27M DN ISIS 191729
DMOQ27M HS Investigative
DMOQ27M CP Isis Pharmaceuticals
DMOQ27M DT Antisense drug
DMOQ27M SQ CAGCCGCGTCTCGCACCTCG
DMOQ27M DE Discovery agent
DM52ZWB ID DM52ZWB
DM52ZWB DN ISIS 191731
DM52ZWB HS Investigative
DM52ZWB CP Isis Pharmaceuticals
DM52ZWB DT Antisense drug
DM52ZWB SQ CCACGCTGGTCCGCCCGTCT
DM52ZWB DE Discovery agent
DMHWMFP ID DMHWMFP
DMHWMFP DN ISIS 191755
DMHWMFP HS Investigative
DMHWMFP CP Isis Pharmaceuticals
DMHWMFP DT Antisense drug
DMHWMFP SQ GTCTGATGCACCACTTGTGC
DMHWMFP DE Discovery agent
DMQRZX8 ID DMQRZX8
DMQRZX8 DN ISIS 191756
DMQRZX8 HS Investigative
DMQRZX8 CP Isis Pharmaceuticals
DMQRZX8 DT Antisense drug
DMQRZX8 SQ TGCCATGTCTGAGCATAGGC
DMQRZX8 DE Discovery agent
DMHPENR ID DMHPENR
DMHPENR DN ISIS 191759
DMHPENR HS Investigative
DMHPENR CP Isis Pharmaceuticals
DMHPENR DT Antisense drug
DMHPENR SQ ATTGCCATAGTTCCCTTGGA
DMHPENR DE Discovery agent
DM0VAUR ID DM0VAUR
DM0VAUR DN ISIS 191761
DM0VAUR HS Investigative
DM0VAUR CP Isis Pharmaceuticals
DM0VAUR DT Antisense drug
DM0VAUR SQ CCACCGGTTGCCCAATGATG
DM0VAUR DE Discovery agent
DMKFCD5 ID DMKFCD5
DMKFCD5 DN ISIS 19211
DMKFCD5 HS Investigative
DMKFCD5 CP Isis Pharmaceuticals
DMKFCD5 DT Antisense drug
DMKFCD5 SQ CCAGGCGGCAGGACCACT
DMKFCD5 DE Discovery agent
DMLQT5F ID DMLQT5F
DMLQT5F DN ISIS 19212
DMLQT5F HS Investigative
DMLQT5F CP Isis Pharmaceuticals
DMLQT5F DT Antisense drug
DMLQT5F SQ GACCAGGCGGCAGGACCA
DMLQT5F DE Discovery agent
DMD1JVZ ID DMD1JVZ
DMD1JVZ DN ISIS 19213
DMD1JVZ HS Investigative
DMD1JVZ CP Isis Pharmaceuticals
DMD1JVZ DT Antisense drug
DMD1JVZ SQ AGGTGAGACCAGGCGGCA
DMD1JVZ DE Discovery agent
DMQK0AL ID DMQK0AL
DMQK0AL DN ISIS 19217
DMQK0AL HS Investigative
DMQK0AL CP Isis Pharmaceuticals
DMQK0AL DT Antisense drug
DMQK0AL SQ GGTCAGCAAGCAGCCCCA
DMQK0AL DE Discovery agent
DMX4I5A ID DMX4I5A
DMX4I5A DN ISIS 19218
DMX4I5A HS Investigative
DMX4I5A CP Isis Pharmaceuticals
DMX4I5A DT Antisense drug
DMX4I5A SQ GACAGCGGTCAGCAAGCA
DMX4I5A DE Discovery agent
DMFAWGX ID DMFAWGX
DMFAWGX DN ISIS 19219
DMFAWGX HS Investigative
DMFAWGX CP Isis Pharmaceuticals
DMFAWGX DT Antisense drug
DMFAWGX SQ GATGGACAGCGGTCAGCA
DMFAWGX DE Discovery agent
DMIKEXD ID DMIKEXD
DMIKEXD DN ISIS 19220
DMIKEXD HS Investigative
DMIKEXD CP Isis Pharmaceuticals
DMIKEXD DT Antisense drug
DMIKEXD SQ TCTGGATGGACAGCGGTC
DMIKEXD DE Discovery agent
DMKOFNX ID DMKOFNX
DMKOFNX DN ISIS 19221
DMKOFNX HS Investigative
DMKOFNX CP Isis Pharmaceuticals
DMKOFNX DT Antisense drug
DMKOFNX SQ GGTGGTTCTGGATGGACA
DMKOFNX DE Discovery agent
DMBMQNI ID DMBMQNI
DMBMQNI DN ISIS 1931
DMBMQNI HS Investigative
DMBMQNI CP Isis Pharmaceuticals
DMBMQNI DT Antisense drug
DMBMQNI DE Discovery agent
DM1NJD7 ID DM1NJD7
DM1NJD7 DN ISIS 196103
DM1NJD7 HS Investigative
DM1NJD7 CP Isis Pharmaceuticals
DM1NJD7 DT Antisense drug
DM1NJD7 SQ AGCCCATTGCTGGACATGCA
DM1NJD7 DE Discovery agent
DMVOSN1 ID DMVOSN1
DMVOSN1 DN ISIS 19634
DMVOSN1 HS Investigative
DMVOSN1 CP Isis Pharmaceuticals
DMVOSN1 DT Antisense drug
DMVOSN1 SQ ACTGACTGAGAATCGCTG
DMVOSN1 DE Discovery agent
DMAW4OE ID DMAW4OE
DMAW4OE DN ISIS 19639
DMAW4OE HS Investigative
DMAW4OE CP Isis Pharmaceuticals
DMAW4OE DT Antisense drug
DMAW4OE SQ ATTCTCCAGAGGCAGGTA
DMAW4OE DE Discovery agent
DMS5PZ0 ID DMS5PZ0
DMS5PZ0 DN ISIS 19647
DMS5PZ0 HS Investigative
DMS5PZ0 CP Isis Pharmaceuticals
DMS5PZ0 DT Antisense drug
DMS5PZ0 SQ GTCCTTGTCAAAGTCTGG
DMS5PZ0 DE Discovery agent
DMBEPGU ID DMBEPGU
DMBEPGU DN ISIS 19649
DMBEPGU HS Investigative
DMBEPGU CP Isis Pharmaceuticals
DMBEPGU DT Antisense drug
DMBEPGU SQ GCCTCCAGCACATTCTCG
DMBEPGU DE Discovery agent
DMCZLK1 ID DMCZLK1
DMCZLK1 DN ISIS 19650
DMCZLK1 HS Investigative
DMCZLK1 CP Isis Pharmaceuticals
DMCZLK1 DT Antisense drug
DMCZLK1 SQ GGTCCTGAGCAGCCTCCA
DMCZLK1 DE Discovery agent
DM8O7EM ID DM8O7EM
DM8O7EM DN ISIS 19651
DM8O7EM HS Investigative
DM8O7EM CP Isis Pharmaceuticals
DM8O7EM DT Antisense drug
DM8O7EM SQ GGCAAAGCAGTCTGTGTC
DM8O7EM DE Discovery agent
DMGIMH8 ID DMGIMH8
DMGIMH8 DN ISIS 19657
DMGIMH8 HS Investigative
DMGIMH8 CP Isis Pharmaceuticals
DMGIMH8 DT Antisense drug
DMGIMH8 SQ TGATCCTGTGCCAATGCC
DMGIMH8 DE Discovery agent
DM8WC4A ID DM8WC4A
DM8WC4A DN ISIS 19658
DM8WC4A HS Investigative
DM8WC4A CP Isis Pharmaceuticals
DM8WC4A DT Antisense drug
DM8WC4A SQ CTGGGTCTATGGCTTCAA
DM8WC4A DE Discovery agent
DMQ5UA3 ID DMQ5UA3
DMQ5UA3 DN ISIS 19659
DMQ5UA3 HS Investigative
DMQ5UA3 CP Isis Pharmaceuticals
DMQ5UA3 DT Antisense drug
DMQ5UA3 SQ GACGTTCAGTTTCTCTGG
DMQ5UA3 DE Discovery agent
DMB5LNC ID DMB5LNC
DMB5LNC DN ISIS 19675
DMB5LNC HS Investigative
DMB5LNC CP Isis Pharmaceuticals
DMB5LNC DT Antisense drug
DMB5LNC SQ CTGTGCCACTGGGAGTTA
DMB5LNC DE Discovery agent
DMYEMST ID DMYEMST
DMYEMST DN ISIS 19676
DMYEMST HS Investigative
DMYEMST CP Isis Pharmaceuticals
DMYEMST DT Antisense drug
DMYEMST SQ CCAAAAGCACCTGAGCCA
DMYEMST DE Discovery agent
DMN0DR2 ID DMN0DR2
DMN0DR2 DN ISIS 19677
DMN0DR2 HS Investigative
DMN0DR2 CP Isis Pharmaceuticals
DMN0DR2 DT Antisense drug
DMN0DR2 SQ GCCACAGGAATCTTCACA
DMN0DR2 DE Discovery agent
DM76H35 ID DM76H35
DM76H35 DN ISIS 20577
DM76H35 HS Investigative
DM76H35 CP Isis Pharmaceuticals
DM76H35 DT Antisense drug
DM76H35 SQ GCCATGATGGACTCCAGA
DM76H35 DE Discovery agent
DM6X9RQ ID DM6X9RQ
DM6X9RQ DN ISIS 20579
DM6X9RQ HS Investigative
DM6X9RQ CP Isis Pharmaceuticals
DM6X9RQ DT Antisense drug
DM6X9RQ SQ CTCATCGCTCAGGCAACA
DM6X9RQ DE Discovery agent
DMJRNWK ID DMJRNWK
DMJRNWK DN ISIS 20585
DMJRNWK HS Investigative
DMJRNWK CP Isis Pharmaceuticals
DMJRNWK DT Antisense drug
DMJRNWK SQ CCCGCCGCAGCTGCTTCT
DMJRNWK DE Discovery agent
DMHVQ0S ID DMHVQ0S
DMHVQ0S DN ISIS 20586
DMHVQ0S HS Investigative
DMHVQ0S CP Isis Pharmaceuticals
DMHVQ0S DT Antisense drug
DMHVQ0S SQ CTTGAGCTCGCGCCGGGC
DMHVQ0S DE Discovery agent
DMLWO70 ID DMLWO70
DMLWO70 DN ISIS 20990
DMLWO70 HS Investigative
DMLWO70 CP Isis Pharmaceuticals
DMLWO70 DT Antisense drug
DMLWO70 SQ CCCGCCGCAGCTGCTTCT
DMLWO70 DE Discovery agent
DMFYDE4 ID DMFYDE4
DMFYDE4 DN ISIS 20993
DMFYDE4 HS Investigative
DMFYDE4 CP Isis Pharmaceuticals
DMFYDE4 DT Antisense drug
DMFYDE4 SQ GCCCGTGCCGAGCAGCAG
DMFYDE4 DE Discovery agent
DM85EV7 ID DM85EV7
DM85EV7 DN ISIS 20994
DM85EV7 HS Investigative
DM85EV7 CP Isis Pharmaceuticals
DM85EV7 DT Antisense drug
DM85EV7 SQ ACGTGCTCTTCCCGCTCT
DM85EV7 DE Discovery agent
DMCXVPG ID DMCXVPG
DMCXVPG DN ISIS 20995
DMCXVPG HS Investigative
DMCXVPG CP Isis Pharmaceuticals
DMCXVPG DT Antisense drug
DMCXVPG SQ ATCTGCTTGATGAACGTG
DMCXVPG DE Discovery agent
DM4VZPU ID DM4VZPU
DM4VZPU DN ISIS 2177
DM4VZPU HS Investigative
DM4VZPU CP Isis Pharmaceuticals
DM4VZPU DT Antisense drug
DM4VZPU DE Discovery agent
DMD7HA3 ID DMD7HA3
DMD7HA3 DN ISIS 222001
DMD7HA3 HS Investigative
DMD7HA3 CP Isis Pharmaceuticals
DMD7HA3 DT Antisense drug
DMD7HA3 SQ GCAGCTCCTCAGGGTGGTAA
DMD7HA3 DE Discovery agent
DMQY2EA ID DMQY2EA
DMQY2EA DN ISIS 222035
DMQY2EA HS Investigative
DMQY2EA CP Isis Pharmaceuticals
DMQY2EA DT Antisense drug
DMQY2EA SQ GCGCTGCTCCCAAGAACTCT
DMQY2EA DE Discovery agent
DMVL1SN ID DMVL1SN
DMVL1SN DN ISIS 222039
DMVL1SN HS Investigative
DMVL1SN CP Isis Pharmaceuticals
DMVL1SN DT Antisense drug
DMVL1SN SQ GTGCTGCCACCAGGTGGGTC
DMVL1SN DE Discovery agent
DMS03TR ID DMS03TR
DMS03TR DN ISIS 222041
DMS03TR HS Investigative
DMS03TR CP Isis Pharmaceuticals
DMS03TR DT Antisense drug
DMS03TR SQ TGGTCATGTTCTCGGAGTCT
DMS03TR DE Discovery agent
DM26M7E ID DM26M7E
DM26M7E DN ISIS 222043
DM26M7E HS Investigative
DM26M7E CP Isis Pharmaceuticals
DM26M7E DT Antisense drug
DM26M7E SQ TCAGTCTGGTCCATGGAGAA
DM26M7E DE Discovery agent
DMREFCY ID DMREFCY
DMREFCY DN ISIS 2324
DMREFCY HS Investigative
DMREFCY CP Isis Pharmaceuticals
DMREFCY DT Antisense drug
DMREFCY DE Discovery agent
DMYEPV8 ID DMYEPV8
DMYEPV8 DN ISIS 232828
DMYEPV8 HS Investigative
DMYEPV8 CP Isis Pharmaceuticals
DMYEPV8 DT Antisense drug
DMYEPV8 SQ GTCTGTAGTCATCTTAAAAA
DMYEPV8 DE Discovery agent
DMJ0LB1 ID DMJ0LB1
DMJ0LB1 DN ISIS 23412
DMJ0LB1 HS Investigative
DMJ0LB1 CP Isis Pharmaceuticals
DMJ0LB1 DT Antisense drug
DMJ0LB1 SQ ACTGAAGACATTTTGAAT
DMJ0LB1 DE Discovery agent
DMOC0DT ID DMOC0DT
DMOC0DT DN ISIS 23414
DMOC0DT HS Investigative
DMOC0DT CP Isis Pharmaceuticals
DMOC0DT DT Antisense drug
DMOC0DT SQ GCACTTTTATTTCTTAGA
DMOC0DT DE Discovery agent
DMHQD76 ID DMHQD76
DMHQD76 DN ISIS 23416
DMHQD76 HS Investigative
DMHQD76 CP Isis Pharmaceuticals
DMHQD76 DT Antisense drug
DMHQD76 SQ ACCATATTTCACTGATTC
DMHQD76 DE Discovery agent
DM17G39 ID DM17G39
DM17G39 DN ISIS 23452
DM17G39 HS Investigative
DM17G39 CP Isis Pharmaceuticals
DM17G39 DT Antisense drug
DM17G39 SQ ACTGAAGACATTTTGAAT
DM17G39 DE Discovery agent
DM7FPZV ID DM7FPZV
DM7FPZV DN ISIS 23454
DM7FPZV HS Investigative
DM7FPZV CP Isis Pharmaceuticals
DM7FPZV DT Antisense drug
DM7FPZV SQ GCACTTTTATTTCTTAGA
DM7FPZV DE Discovery agent
DM4PGRU ID DM4PGRU
DM4PGRU DN ISIS 23459
DM4PGRU HS Investigative
DM4PGRU CP Isis Pharmaceuticals
DM4PGRU DT Antisense drug
DM4PGRU SQ GCTCTGCTGTCAAGTGTT
DM4PGRU DE Discovery agent
DMDHY37 ID DMDHY37
DMDHY37 DN ISIS 23544
DMDHY37 HS Investigative
DMDHY37 CP Isis Pharmaceuticals
DMDHY37 DT Antisense drug
DMDHY37 SQ TGTGTAAGGCTTATTCTC
DMDHY37 DE Discovery agent
DM7NKRO ID DM7NKRO
DM7NKRO DN ISIS 23559
DM7NKRO HS Investigative
DM7NKRO CP Isis Pharmaceuticals
DM7NKRO DT Antisense drug
DM7NKRO SQ ACATTGCTGCCCTTTGTC
DM7NKRO DE Discovery agent
DM5LBQM ID DM5LBQM
DM5LBQM DN ISIS 23705
DM5LBQM HS Investigative
DM5LBQM CP Isis Pharmaceuticals
DM5LBQM DT Antisense drug
DM5LBQM SQ CGATGGPAPGGCGCACTT
DM5LBQM DE Discovery agent
DMIK0GR ID DMIK0GR
DMIK0GR DN ISIS 23707
DMIK0GR HS Investigative
DMIK0GR CP Isis Pharmaceuticals
DMIK0GR DT Antisense drug
DMIK0GR SQ ACAGGAAGGCTGGTGGCA
DMIK0GR DE Discovery agent
DM1SDN3 ID DM1SDN3
DM1SDN3 DN ISIS 23718
DM1SDN3 HS Investigative
DM1SDN3 CP Isis Pharmaceuticals
DM1SDN3 DT Antisense drug
DM1SDN3 SQ AGGACTGTGACAGCCTCA
DM1SDN3 DE Discovery agent
DMLHQ2J ID DMLHQ2J
DMLHQ2J DN ISIS 24448
DMLHQ2J HS Investigative
DMLHQ2J CP Isis Pharmaceuticals
DMLHQ2J DT Antisense drug
DMLHQ2J SQ ACTGAAGCGTTGGCGAGC
DMLHQ2J DE Discovery agent
DM45WUZ ID DM45WUZ
DM45WUZ DN ISIS 24453
DM45WUZ HS Investigative
DM45WUZ CP Isis Pharmaceuticals
DM45WUZ DT Antisense drug
DM45WUZ SQ GCTTATTTTCATTCTTTA
DM45WUZ DE Discovery agent
DMDE3J1 ID DMDE3J1
DMDE3J1 DN ISIS 24454
DMDE3J1 HS Investigative
DMDE3J1 CP Isis Pharmaceuticals
DMDE3J1 DT Antisense drug
DMDE3J1 SQ TTCTTTTACTCAGTTCTG
DMDE3J1 DE Discovery agent
DMBKZOQ ID DMBKZOQ
DMBKZOQ DN ISIS 24475
DMBKZOQ HS Investigative
DMBKZOQ CP Isis Pharmaceuticals
DMBKZOQ DT Antisense drug
DMBKZOQ SQ GCCCTTATATGAGAAACA
DMBKZOQ DE Discovery agent
DMCNBIL ID DMCNBIL
DMCNBIL DN ISIS 24477
DMCNBIL HS Investigative
DMCNBIL CP Isis Pharmaceuticals
DMCNBIL DT Antisense drug
DMCNBIL SQ TCCATTCTCTCAATTTGA 3'-UTR
DMCNBIL DE Discovery agent
DMYEC3M ID DMYEC3M
DMYEC3M DN ISIS 2490
DMYEC3M HS Investigative
DMYEC3M CP Isis Pharmaceuticals
DMYEC3M DT Antisense drug
DMYEC3M SQ AGCGCGCCATAGTATTGTGG
DMYEC3M DE Discovery agent
DMVI1D0 ID DMVI1D0
DMVI1D0 DN ISIS 2491
DMVI1D0 HS Investigative
DMVI1D0 CP Isis Pharmaceuticals
DMVI1D0 DT Antisense drug
DMVI1D0 SQ GTCCATGCATACTTAATATT
DMVI1D0 DE Discovery agent
DMYTXBS ID DMYTXBS
DMYTXBS DN ISIS 2502
DMYTXBS HS Investigative
DMYTXBS CP Isis Pharmaceuticals
DMYTXBS DT Antisense drug
DMYTXBS SQ CTTATATTCCGTCATCGCTC
DMYTXBS DE Discovery agent
DMUMEST ID DMUMEST
DMUMEST DN ISIS 25073
DMUMEST HS Investigative
DMUMEST CP Isis Pharmaceuticals
DMUMEST DT Antisense drug
DMUMEST SQ CTTCCTCCGGGCCAGCAT
DMUMEST DE Discovery agent
DMM0GUN ID DMM0GUN
DMM0GUN DN ISIS 25074
DMM0GUN HS Investigative
DMM0GUN CP Isis Pharmaceuticals
DMM0GUN DT Antisense drug
DMM0GUN SQ GGTAGGGTTGATGGTGAG
DMM0GUN DE Discovery agent
DM1EPLC ID DM1EPLC
DM1EPLC DN ISIS 25075
DM1EPLC HS Investigative
DM1EPLC CP Isis Pharmaceuticals
DM1EPLC DT Antisense drug
DM1EPLC SQ TCCACCAGGTTTGCCTCG
DM1EPLC DE Discovery agent
DMSZRY0 ID DMSZRY0
DMSZRY0 DN ISIS 25078
DMSZRY0 HS Investigative
DMSZRY0 CP Isis Pharmaceuticals
DMSZRY0 DT Antisense drug
DMSZRY0 SQ TCATCGTCTTTGAGTTCG
DMSZRY0 DE Discovery agent
DMAKTCH ID DMAKTCH
DMAKTCH DN ISIS 25079
DMAKTCH HS Investigative
DMAKTCH CP Isis Pharmaceuticals
DMAKTCH DT Antisense drug
DMAKTCH SQ TTTCGAAGTCATCGTCTT
DMAKTCH DE Discovery agent
DMEI28S ID DMEI28S
DMEI28S DN ISIS 25080
DMEI28S HS Investigative
DMEI28S CP Isis Pharmaceuticals
DMEI28S DT Antisense drug
DMEI28S SQ CCGTTGCCCGCGCCCAGC
DMEI28S DE Discovery agent
DM4AZG9 ID DM4AZG9
DM4AZG9 DN ISIS 25081
DM4AZG9 HS Investigative
DM4AZG9 CP Isis Pharmaceuticals
DM4AZG9 DT Antisense drug
DM4AZG9 SQ CTGTGCTGGACTTTGGTG
DM4AZG9 DE Discovery agent
DM04CUL ID DM04CUL
DM04CUL DN ISIS 25082
DM04CUL HS Investigative
DM04CUL CP Isis Pharmaceuticals
DM04CUL DT Antisense drug
DM04CUL SQ AGCTTCCTGGCCATGATG
DM04CUL DE Discovery agent
DM3IR7W ID DM3IR7W
DM3IR7W DN ISIS 25113
DM3IR7W HS Investigative
DM3IR7W CP Isis Pharmaceuticals
DM3IR7W DT Antisense drug
DM3IR7W SQ CTTCCTCCGGGCCAGCAT
DM3IR7W DE Discovery agent
DMG6SYP ID DMG6SYP
DMG6SYP DN ISIS 25114
DMG6SYP HS Investigative
DMG6SYP CP Isis Pharmaceuticals
DMG6SYP DT Antisense drug
DMG6SYP SQ GGTAGGGTTGATGGTGAG
DMG6SYP DE Discovery agent
DMDH943 ID DMDH943
DMDH943 DN ISIS 25115
DMDH943 HS Investigative
DMDH943 CP Isis Pharmaceuticals
DMDH943 DT Antisense drug
DMDH943 SQ TCCACCAGGTTTGCCTCG
DMDH943 DE Discovery agent
DM8AHJC ID DM8AHJC
DM8AHJC DN ISIS 25116
DM8AHJC HS Investigative
DM8AHJC CP Isis Pharmaceuticals
DM8AHJC DT Antisense drug
DM8AHJC SQ CTTCTGCTGCTCGTCAAG
DM8AHJC DE Discovery agent
DMAN94P ID DMAN94P
DMAN94P DN ISIS 25117
DMAN94P HS Investigative
DMAN94P CP Isis Pharmaceuticals
DMAN94P DT Antisense drug
DMAN94P SQ TTGGCTTTCTGGGTGAGA
DMAN94P DE Discovery agent
DMA7KV8 ID DMA7KV8
DMA7KV8 DN ISIS 25118
DMA7KV8 HS Investigative
DMA7KV8 CP Isis Pharmaceuticals
DMA7KV8 DT Antisense drug
DMA7KV8 SQ TCATCGTCTTTGAGTTCG
DMA7KV8 DE Discovery agent
DMFQO21 ID DMFQO21
DMFQO21 DN ISIS 25123
DMFQO21 HS Investigative
DMFQO21 CP Isis Pharmaceuticals
DMFQO21 DT Antisense drug
DMFQO21 SQ ATCTCAAGGTGGATCAGC
DMFQO21 DE Discovery agent
DMEI8L2 ID DMEI8L2
DMEI8L2 DN ISIS 25124
DMEI8L2 HS Investigative
DMEI8L2 CP Isis Pharmaceuticals
DMEI8L2 DT Antisense drug
DMEI8L2 SQ ATGATCTGGTTCCGGATG
DMEI8L2 DE Discovery agent
DML2F3N ID DML2F3N
DML2F3N DN ISIS 25125
DML2F3N HS Investigative
DML2F3N CP Isis Pharmaceuticals
DML2F3N DT Antisense drug
DML2F3N SQ GATGTACGGCGAGTTGCA
DML2F3N DE Discovery agent
DM8K4DP ID DM8K4DP
DM8K4DP DN ISIS 25126
DM8K4DP HS Investigative
DM8K4DP CP Isis Pharmaceuticals
DM8K4DP DT Antisense drug
DM8K4DP SQ GTCACTGTAGAAGGCCCC
DM8K4DP DE Discovery agent
DM6AQ2X ID DM6AQ2X
DM6AQ2X DN ISIS 25127
DM6AQ2X HS Investigative
DM6AQ2X CP Isis Pharmaceuticals
DM6AQ2X DT Antisense drug
DM6AQ2X SQ TGTGTTCCATGCAAATGC
DM6AQ2X DE Discovery agent
DMH3C01 ID DMH3C01
DMH3C01 DN ISIS 25128
DMH3C01 HS Investigative
DMH3C01 CP Isis Pharmaceuticals
DMH3C01 DT Antisense drug
DMH3C01 SQ TCTTTCAGCACCTGGTCC
DMH3C01 DE Discovery agent
DMD75MP ID DMD75MP
DMD75MP DN ISIS 25237
DMD75MP HS Investigative
DMD75MP CP Isis Pharmaceuticals
DMD75MP DT Antisense drug
DMD75MP SQ GCCCATTGCTGGACATGC
DMD75MP DE Discovery agent
DMB9DWH ID DMB9DWH
DMB9DWH DN ISIS 25544
DMB9DWH HS Investigative
DMB9DWH CP Isis Pharmaceuticals
DMB9DWH DT Antisense drug
DMB9DWH SQ AGAGAACCGACGGAGGAC
DMB9DWH DE Discovery agent
DM4P15C ID DM4P15C
DM4P15C DN ISIS 25547
DM4P15C HS Investigative
DM4P15C CP Isis Pharmaceuticals
DM4P15C DT Antisense drug
DM4P15C SQ AGCTGAAGACCAGACCGT
DM4P15C DE Discovery agent
DMWXQPG ID DMWXQPG
DMWXQPG DN ISIS 25549
DMWXQPG HS Investigative
DMWXQPG CP Isis Pharmaceuticals
DMWXQPG DT Antisense drug
DMWXQPG SQ AATCCGAGTCCAGCCTCT
DMWXQPG DE Discovery agent
DM41B62 ID DM41B62
DM41B62 DN ISIS 25551
DM41B62 HS Investigative
DM41B62 CP Isis Pharmaceuticals
DM41B62 DT Antisense drug
DM41B62 SQ TCAGGCAACGAATCCGAG
DM41B62 DE Discovery agent
DMO8IVA ID DMO8IVA
DMO8IVA DN ISIS 25552
DMO8IVA HS Investigative
DMO8IVA CP Isis Pharmaceuticals
DMO8IVA DT Antisense drug
DMO8IVA SQ CACCAACAATCACCAGTT
DMO8IVA DE Discovery agent
DM5PXN4 ID DM5PXN4
DM5PXN4 DN ISIS 25554
DM5PXN4 HS Investigative
DM5PXN4 CP Isis Pharmaceuticals
DM5PXN4 DT Antisense drug
DM5PXN4 SQ ATACACCTCTGGGAACTG
DM5PXN4 DE Discovery agent
DMBI2PH ID DMBI2PH
DMBI2PH DN ISIS 25563
DMBI2PH HS Investigative
DMBI2PH CP Isis Pharmaceuticals
DMBI2PH DT Antisense drug
DMBI2PH SQ TAGCTCCCGCCTTGTGTG
DMBI2PH DE Discovery agent
DMMZW8J ID DMMZW8J
DMMZW8J DN ISIS 25564
DMMZW8J HS Investigative
DMMZW8J CP Isis Pharmaceuticals
DMMZW8J DT Antisense drug
DMMZW8J SQ CCAATCCTGTTTGCCATA
DMMZW8J DE Discovery agent
DMB0CJ4 ID DMB0CJ4
DMB0CJ4 DN ISIS 25565
DMB0CJ4 HS Investigative
DMB0CJ4 CP Isis Pharmaceuticals
DMB0CJ4 DT Antisense drug
DMB0CJ4 SQ GTCTTTGCTGAACACTCC
DMB0CJ4 DE Discovery agent
DMUR2TH ID DMUR2TH
DMUR2TH DN ISIS 25566
DMUR2TH HS Investigative
DMUR2TH CP Isis Pharmaceuticals
DMUR2TH DT Antisense drug
DMUR2TH SQ AAAACCTCTCTCACTCCA
DMUR2TH DE Discovery agent
DMX72T6 ID DMX72T6
DMX72T6 DN ISIS 25567
DMX72T6 HS Investigative
DMX72T6 CP Isis Pharmaceuticals
DMX72T6 DT Antisense drug
DMX72T6 SQ AAGACAAGGCAACCAGAT
DMX72T6 DE Discovery agent
DMRUEM8 ID DMRUEM8
DMRUEM8 DN ISIS 2674
DMRUEM8 HS Investigative
DMRUEM8 CP Isis Pharmaceuticals
DMRUEM8 DT Antisense drug
DMRUEM8 SQ CACAATCCTTAAGAACTCTTT
DMRUEM8 DE Discovery agent
DMZP5VG ID DMZP5VG
DMZP5VG DN ISIS 2678
DMZP5VG HS Investigative
DMZP5VG CP Isis Pharmaceuticals
DMZP5VG DT Antisense drug
DMZP5VG SQ ACCTCTGCTGTTCTGATCCT
DMZP5VG DE Discovery agent
DM78BDU ID DM78BDU
DM78BDU DN ISIS 2686
DM78BDU HS Investigative
DM78BDU CP Isis Pharmaceuticals
DM78BDU DT Antisense drug
DM78BDU SQ TGAAGCAATCATGACTTCAAG
DM78BDU DE Discovery agent
DMGMKH3 ID DMGMKH3
DMGMKH3 DN ISIS 28405
DMGMKH3 HS Investigative
DMGMKH3 CP Isis Pharmaceuticals
DMGMKH3 DT Antisense drug
DMGMKH3 SQ CTCCGGCTGCCCCACCCC
DMGMKH3 DE Discovery agent
DMXKRWN ID DMXKRWN
DMXKRWN DN ISIS 28407
DMXKRWN HS Investigative
DMXKRWN CP Isis Pharmaceuticals
DMXKRWN DT Antisense drug
DMXKRWN SQ CGAACATGACCTCCGCAC
DMXKRWN DE Discovery agent
DMR24BS ID DMR24BS
DMR24BS DN ISIS 28425
DMR24BS HS Investigative
DMR24BS CP Isis Pharmaceuticals
DMR24BS DT Antisense drug
DMR24BS SQ GCTCAGCTCACGCTCTGT
DMR24BS DE Discovery agent
DMQ5JNT ID DMQ5JNT
DMQ5JNT DN ISIS 28465
DMQ5JNT HS Investigative
DMQ5JNT CP Isis Pharmaceuticals
DMQ5JNT DT Antisense drug
DMQ5JNT SQ GCTCAGCTCACGCTCTGT
DMQ5JNT DE Discovery agent
DMH96UP ID DMH96UP
DMH96UP DN ISIS 28466
DMH96UP HS Investigative
DMH96UP CP Isis Pharmaceuticals
DMH96UP DT Antisense drug
DMH96UP SQ TGCATGAAAAGCAAGCAC
DMH96UP DE Discovery agent
DMA4U2P ID DMA4U2P
DMA4U2P DN ISIS 28472
DMA4U2P HS Investigative
DMA4U2P CP Isis Pharmaceuticals
DMA4U2P DT Antisense drug
DMA4U2P SQ TTGGGACTGCAAACCTC
DMA4U2P DE Discovery agent
DMMOV9U ID DMMOV9U
DMMOV9U DN ISIS 28477
DMMOV9U HS Investigative
DMMOV9U CP Isis Pharmaceuticals
DMMOV9U DT Antisense drug
DMMOV9U SQ ACACACAGGATGGGAGCA
DMMOV9U DE Discovery agent
DMECMA6 ID DMECMA6
DMECMA6 DN ISIS 29112
DMECMA6 HS Investigative
DMECMA6 CP Isis Pharmaceuticals
DMECMA6 DT Antisense drug
DMECMA6 SQ AAATGTGTTTGGCTTTGG
DMECMA6 DE Discovery agent
DMGJURC ID DMGJURC
DMGJURC DN ISIS 29135
DMGJURC HS Investigative
DMGJURC CP Isis Pharmaceuticals
DMGJURC DT Antisense drug
DMGJURC SQ CTGCTCGGCCATAGTCAT
DMGJURC DE Discovery agent
DMAMTLR ID DMAMTLR
DMAMTLR DN ISIS 29136
DMAMTLR HS Investigative
DMAMTLR CP Isis Pharmaceuticals
DMAMTLR DT Antisense drug
DMAMTLR SQ AGTCTACTGCTCGGCCAT
DMAMTLR DE Discovery agent
DMAR1D6 ID DMAR1D6
DMAR1D6 DN ISIS 29137
DMAR1D6 HS Investigative
DMAR1D6 CP Isis Pharmaceuticals
DMAR1D6 DT Antisense drug
DMAR1D6 SQ CTAGGCCCCACCAGTCTA
DMAR1D6 DE Discovery agent
DMBY1RS ID DMBY1RS
DMBY1RS DN ISIS 29138
DMBY1RS HS Investigative
DMBY1RS CP Isis Pharmaceuticals
DMBY1RS DT Antisense drug
DMBY1RS SQ CAACCCCTAGGCCCCACC
DMBY1RS DE Discovery agent
DM2K0RD ID DM2K0RD
DM2K0RD DN ISIS 29139
DM2K0RD HS Investigative
DM2K0RD CP Isis Pharmaceuticals
DM2K0RD DT Antisense drug
DM2K0RD SQ TCATACATGACAACCCCT
DM2K0RD DE Discovery agent
DMT9F15 ID DMT9F15
DMT9F15 DN ISIS 29154
DMT9F15 HS Investigative
DMT9F15 CP Isis Pharmaceuticals
DMT9F15 DT Antisense drug
DMT9F15 SQ GCCCTGAAAGCAATGATT
DMT9F15 DE Discovery agent
DMSVN1B ID DMSVN1B
DMSVN1B DN ISIS 29155
DMSVN1B HS Investigative
DMSVN1B CP Isis Pharmaceuticals
DMSVN1B DT Antisense drug
DMSVN1B SQ ATCAAGAGCCCTGAAAGC
DMSVN1B DE Discovery agent
DMD8KXB ID DMD8KXB
DMD8KXB DN ISIS 29156
DMD8KXB HS Investigative
DMD8KXB CP Isis Pharmaceuticals
DMD8KXB DT Antisense drug
DMD8KXB SQ GATCCTTTATCAAGAGCC
DMD8KXB DE Discovery agent
DMLE1IJ ID DMLE1IJ
DMLE1IJ DN ISIS 29159
DMLE1IJ HS Investigative
DMLE1IJ CP Isis Pharmaceuticals
DMLE1IJ DT Antisense drug
DMLE1IJ SQ CTCCACCAAGGCGTTTAT
DMLE1IJ DE Discovery agent
DM9NB1A ID DM9NB1A
DM9NB1A DN ISIS 29160
DM9NB1A HS Investigative
DM9NB1A CP Isis Pharmaceuticals
DM9NB1A DT Antisense drug
DM9NB1A SQ TCTGGTCCTCCACCAAGG
DM9NB1A DE Discovery agent
DMPS6OQ ID DMPS6OQ
DMPS6OQ DN ISIS 29161
DMPS6OQ HS Investigative
DMPS6OQ CP Isis Pharmaceuticals
DMPS6OQ DT Antisense drug
DMPS6OQ SQ GCGTCATCTGGTCCTCCA
DMPS6OQ DE Discovery agent
DMVLU5J ID DMVLU5J
DMVLU5J DN ISIS 29176
DMVLU5J HS Investigative
DMVLU5J CP Isis Pharmaceuticals
DMVLU5J DT Antisense drug
DMVLU5J SQ AGTCTACTGCTCGGCCAT
DMVLU5J DE Discovery agent
DMSUWVE ID DMSUWVE
DMSUWVE DN ISIS 29177
DMSUWVE HS Investigative
DMSUWVE CP Isis Pharmaceuticals
DMSUWVE DT Antisense drug
DMSUWVE SQ CTAGGCCCCACCAGTCTA
DMSUWVE DE Discovery agent
DMTE7BJ ID DMTE7BJ
DMTE7BJ DN ISIS 29178
DMTE7BJ HS Investigative
DMTE7BJ CP Isis Pharmaceuticals
DMTE7BJ DT Antisense drug
DMTE7BJ SQ CAACCCCTAGGCCCCACC
DMTE7BJ DE Discovery agent
DMJTHXY ID DMJTHXY
DMJTHXY DN ISIS 2918
DMJTHXY HS Investigative
DMJTHXY CP Isis Pharmaceuticals
DMJTHXY DT Antisense drug
DMJTHXY SQ AUGGGGTCCTTCATCTGGGAGAGC
DMJTHXY DE Discovery agent
DMVMF5X ID DMVMF5X
DMVMF5X DN ISIS 2919
DMVMF5X HS Investigative
DMVMF5X CP Isis Pharmaceuticals
DMVMF5X DT Antisense drug
DMVMF5X SQ CGGCTCAGGTCGTCAATCTTG
DMVMF5X DE Discovery agent
DMJFLK0 ID DMJFLK0
DMJFLK0 DN ISIS 2920
DMJFLK0 HS Investigative
DMJFLK0 CP Isis Pharmaceuticals
DMJFLK0 DT Antisense drug
DMJFLK0 SQ GCGCACCATGACCTGTTTGGG
DMJFLK0 DE Discovery agent
DMN1LHI ID DMN1LHI
DMN1LHI DN ISIS 29200
DMN1LHI HS Investigative
DMN1LHI CP Isis Pharmaceuticals
DMN1LHI DT Antisense drug
DMN1LHI SQ TCTGGTCCTCCACCAAGG
DMN1LHI DE Discovery agent
DMSKVWG ID DMSKVWG
DMSKVWG DN ISIS 29201
DMSKVWG HS Investigative
DMSKVWG CP Isis Pharmaceuticals
DMSKVWG DT Antisense drug
DMSKVWG SQ GCGTCATCTGGTCCTCCA
DMSKVWG DE Discovery agent
DMDR8V9 ID DMDR8V9
DMDR8V9 DN ISIS 29202
DMDR8V9 HS Investigative
DMDR8V9 CP Isis Pharmaceuticals
DMDR8V9 DT Antisense drug
DMDR8V9 SQ CTTTTGCGTCATCTGGTC
DMDR8V9 DE Discovery agent
DMDZAKS ID DMDZAKS
DMDZAKS DN ISIS 2921
DMDZAKS HS Investigative
DMDZAKS CP Isis Pharmaceuticals
DMDZAKS DT Antisense drug
DMDZAKS SQ GTTTTGCGCGGTTTCTTACGC
DMDZAKS DE Discovery agent
DM37R5F ID DM37R5F
DM37R5F DN ISIS 29219
DM37R5F HS Investigative
DM37R5F CP Isis Pharmaceuticals
DM37R5F DT Antisense drug
DM37R5F SQ AGCTGGCTGGTGGTCCTG
DM37R5F DE Discovery agent
DMK8FPR ID DMK8FPR
DMK8FPR DN ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine
DMK8FPR HS Investigative
DMK8FPR TC Antisense
DMK8FPR DT Combination drug (Antisense drug)
DMK8FPR DE Virus infection
DMVT2CJ ID DMVT2CJ
DMVT2CJ DN ISIS 2922 + Ganciclovir
DMVT2CJ HS Investigative
DMVT2CJ TC Antisense
DMVT2CJ DT Combination drug (Antisense drug)
DMVT2CJ PC 3454
DMVT2CJ DE Virus infection
DMMQPFE ID DMMQPFE
DMMQPFE DN ISIS 29223
DMMQPFE HS Investigative
DMMQPFE CP Isis Pharmaceuticals
DMMQPFE DT Antisense drug
DMMQPFE SQ GGAGGCTGGGCATGCTGC
DMMQPFE DE Discovery agent
DM9UNWE ID DM9UNWE
DM9UNWE DN ISIS 29224
DM9UNWE HS Investigative
DM9UNWE CP Isis Pharmaceuticals
DM9UNWE DT Antisense drug
DM9UNWE SQ GAAGTCCTCAGGCCGCTT
DM9UNWE DE Discovery agent
DMLES7J ID DMLES7J
DMLES7J DN ISIS 29232
DMLES7J HS Investigative
DMLES7J CP Isis Pharmaceuticals
DMLES7J DT Antisense drug
DMLES7J SQ CAGCTTCTCGTCGTCCTG
DMLES7J DE Discovery agent
DMGV4O7 ID DMGV4O7
DMGV4O7 DN ISIS 29233
DMGV4O7 HS Investigative
DMGV4O7 CP Isis Pharmaceuticals
DMGV4O7 DT Antisense drug
DMGV4O7 SQ AAGGCCGAAATACAGCTT
DMGV4O7 DE Discovery agent
DM1XAPO ID DM1XAPO
DM1XAPO DN ISIS 29234
DM1XAPO HS Investigative
DM1XAPO CP Isis Pharmaceuticals
DM1XAPO DT Antisense drug
DM1XAPO SQ TTTAAGTAGTTCTCCATT
DM1XAPO DE Discovery agent
DMAXD7P ID DMAXD7P
DMAXD7P DN ISIS 29236
DMAXD7P HS Investigative
DMAXD7P CP Isis Pharmaceuticals
DMAXD7P DT Antisense drug
DMAXD7P SQ GGTACAGGTCTCATCGAA
DMAXD7P DE Discovery agent
DMPYJEB ID DMPYJEB
DMPYJEB DN ISIS 29237
DMPYJEB HS Investigative
DMPYJEB CP Isis Pharmaceuticals
DMPYJEB DT Antisense drug
DMPYJEB SQ CGATCTCAGCCGTGTAAA
DMPYJEB DE Discovery agent
DMHQF1J ID DMHQF1J
DMHQF1J DN ISIS 29239
DMHQF1J HS Investigative
DMHQF1J CP Isis Pharmaceuticals
DMHQF1J DT Antisense drug
DMHQF1J SQ GTCCCTGTGAATGATGCC
DMHQF1J DE Discovery agent
DMZ7UM2 ID DMZ7UM2
DMZ7UM2 DN ISIS 29243
DMZ7UM2 HS Investigative
DMZ7UM2 CP Isis Pharmaceuticals
DMZ7UM2 DT Antisense drug
DMZ7UM2 SQ TTGGCCCTGGCTTGTTTG
DMZ7UM2 DE Discovery agent
DMTHVEL ID DMTHVEL
DMTHVEL DN ISIS 29244
DMTHVEL HS Investigative
DMTHVEL CP Isis Pharmaceuticals
DMTHVEL DT Antisense drug
DMTHVEL SQ GCTGTTCCCACGAATGAG
DMTHVEL DE Discovery agent
DM0DG1K ID DM0DG1K
DM0DG1K DN ISIS 29246
DM0DG1K HS Investigative
DM0DG1K CP Isis Pharmaceuticals
DM0DG1K DT Antisense drug
DM0DG1K SQ GGACTTCTCCGTGAGCAG
DM0DG1K DE Discovery agent
DMK2QPU ID DMK2QPU
DMK2QPU DN ISIS 29255
DMK2QPU HS Investigative
DMK2QPU CP Isis Pharmaceuticals
DMK2QPU DT Antisense drug
DMK2QPU SQ CTGGTATCGCTGCCTCCA
DMK2QPU DE Discovery agent
DMF1MJ2 ID DMF1MJ2
DMF1MJ2 DN ISIS 29256
DMF1MJ2 HS Investigative
DMF1MJ2 CP Isis Pharmaceuticals
DMF1MJ2 DT Antisense drug
DMF1MJ2 SQ GCAGGTGTCCTGGCAGCG
DMF1MJ2 DE Discovery agent
DMUM2H1 ID DMUM2H1
DMUM2H1 DN ISIS 29257
DMUM2H1 HS Investigative
DMUM2H1 CP Isis Pharmaceuticals
DMUM2H1 DT Antisense drug
DMUM2H1 SQ CAAGGTTTCCGCCTCTGC
DMUM2H1 DE Discovery agent
DMVCFQ5 ID DMVCFQ5
DMVCFQ5 DN ISIS 29469
DMVCFQ5 HS Investigative
DMVCFQ5 CP Isis Pharmaceuticals
DMVCFQ5 DT Antisense drug
DMVCFQ5 SQ AAGGTCCCTGTGAATGAT
DMVCFQ5 DE Discovery agent
DMPCK7Y ID DMPCK7Y
DMPCK7Y DN ISIS 29470
DMPCK7Y HS Investigative
DMPCK7Y CP Isis Pharmaceuticals
DMPCK7Y DT Antisense drug
DMPCK7Y SQ AGACTTTTGCTGTTCCAA
DMPCK7Y DE Discovery agent
DMG4RMZ ID DMG4RMZ
DMG4RMZ DN ISIS 29471
DMG4RMZ HS Investigative
DMG4RMZ CP Isis Pharmaceuticals
DMG4RMZ DT Antisense drug
DMG4RMZ SQ GAGTTGGCCCTGGCTTGT
DMG4RMZ DE Discovery agent
DMEBQUN ID DMEBQUN
DMEBQUN DN ISIS 29475
DMEBQUN HS Investigative
DMEBQUN CP Isis Pharmaceuticals
DMEBQUN DT Antisense drug
DMEBQUN SQ GGTCTCTTGCCTTAGGGA
DMEBQUN DE Discovery agent
DMKQMXV ID DMKQMXV
DMKQMXV DN ISIS 29477
DMKQMXV HS Investigative
DMKQMXV CP Isis Pharmaceuticals
DMKQMXV DT Antisense drug
DMKQMXV SQ CTTCCATTTCCTCACAGC
DMKQMXV DE Discovery agent
DM7K19L ID DM7K19L
DM7K19L DN ISIS 2974
DM7K19L HS Investigative
DM7K19L CP Isis Pharmaceuticals
DM7K19L DT Antisense drug
DM7K19L DE Discovery agent
DM0WH1L ID DM0WH1L
DM0WH1L DN ISIS 298697
DM0WH1L HS Investigative
DM0WH1L CP Isis Pharmaceuticals
DM0WH1L DT Antisense drug
DM0WH1L SQ TCCTCATGGTCACATGGATG
DM0WH1L DE Discovery agent
DMB28JW ID DMB28JW
DMB28JW DN ISIS 298699
DMB28JW HS Investigative
DMB28JW CP Isis Pharmaceuticals
DMB28JW DT Antisense drug
DMB28JW SQ GCATTTCTCTCATTTCCTCA
DMB28JW DE Discovery agent
DM3DE98 ID DM3DE98
DM3DE98 DN ISIS 298700
DM3DE98 HS Investigative
DM3DE98 CP Isis Pharmaceuticals
DM3DE98 DT Antisense drug
DM3DE98 SQ GTGTGTAAGCATTTCTCTCA
DM3DE98 DE Discovery agent
DMVIXND ID DMVIXND
DMVIXND DN ISIS 298701
DMVIXND HS Investigative
DMVIXND CP Isis Pharmaceuticals
DMVIXND DT Antisense drug
DMVIXND SQ GGCCATTTCTGTGTGTAAGC
DMVIXND DE Discovery agent
DM4L7NE ID DM4L7NE
DM4L7NE DN ISIS 298702
DM4L7NE HS Investigative
DM4L7NE CP Isis Pharmaceuticals
DM4L7NE DT Antisense drug
DM4L7NE SQ TGGTTACTGTTGGTATCATA
DM4L7NE DE Discovery agent
DMCDWSG ID DMCDWSG
DMCDWSG DN ISIS 298711
DMCDWSG HS Investigative
DMCDWSG CP Isis Pharmaceuticals
DMCDWSG DT Antisense drug
DMCDWSG SQ TGGTGACTTGTCCTTTAGTA
DMCDWSG DE Discovery agent
DMGJ4AO ID DMGJ4AO
DMGJ4AO DN ISIS 298712
DMGJ4AO HS Investigative
DMGJ4AO CP Isis Pharmaceuticals
DMGJ4AO DT Antisense drug
DMGJ4AO SQ TCCTGTGGTGACTTGTCCTT
DMGJ4AO DE Discovery agent
DMD3NSQ ID DMD3NSQ
DMD3NSQ DN ISIS 298743
DMD3NSQ HS Investigative
DMD3NSQ CP Isis Pharmaceuticals
DMD3NSQ DT Antisense drug
DMD3NSQ SQ TGAGCCACCAGTGTCCAAAA
DMD3NSQ DE Discovery agent
DM8VMQ4 ID DM8VMQ4
DM8VMQ4 DN ISIS 298744
DM8VMQ4 HS Investigative
DM8VMQ4 CP Isis Pharmaceuticals
DM8VMQ4 DT Antisense drug
DM8VMQ4 SQ CCAGGCTTCTAAAATTAGAT
DM8VMQ4 DE Discovery agent
DM9YMPI ID DM9YMPI
DM9YMPI DN ISIS 298745
DM9YMPI HS Investigative
DM9YMPI CP Isis Pharmaceuticals
DM9YMPI DT Antisense drug
DM9YMPI SQ GTGCAGTATTGTAGCCAGGC
DM9YMPI DE Discovery agent
DMHOJ0Z ID DMHOJ0Z
DMHOJ0Z DN ISIS 298746
DMHOJ0Z HS Investigative
DMHOJ0Z CP Isis Pharmaceuticals
DMHOJ0Z DT Antisense drug
DMHOJ0Z SQ AGTTTGTGCAGTATTGTAGC
DMHOJ0Z DE Discovery agent
DMC9OL7 ID DMC9OL7
DMC9OL7 DN ISIS 3067
DMC9OL7 HS Investigative
DMC9OL7 CP Isis Pharmaceuticals
DMC9OL7 DT Antisense drug
DMC9OL7 SQ TCTGAGTAGCAGAGGAGCTC
DMC9OL7 DE Discovery agent
DMOHZKW ID DMOHZKW
DMOHZKW DN ISIS 31963
DMOHZKW HS Investigative
DMOHZKW CP Isis Pharmaceuticals
DMOHZKW DT Antisense drug
DMOHZKW SQ CACCGCCCAGATGTCAAGGA
DMOHZKW DE Discovery agent
DMP9IR2 ID DMP9IR2
DMP9IR2 DN ISIS 31982
DMP9IR2 HS Investigative
DMP9IR2 CP Isis Pharmaceuticals
DMP9IR2 DT Antisense drug
DMP9IR2 SQ CTTCCCATGAATAGTCAAAC
DMP9IR2 DE Discovery agent
DM21ZCQ ID DM21ZCQ
DM21ZCQ DN ISIS 31996
DM21ZCQ HS Investigative
DM21ZCQ CP Isis Pharmaceuticals
DM21ZCQ DT Antisense drug
DM21ZCQ SQ ACTATGTCTGTCACCAATCC
DM21ZCQ DE Discovery agent
DM0O9WM ID DM0O9WM
DM0O9WM DN ISIS 32000
DM0O9WM HS Investigative
DM0O9WM CP Isis Pharmaceuticals
DM0O9WM DT Antisense drug
DM0O9WM SQ CATTATGAAACTGAAGCACA
DM0O9WM DE Discovery agent
DMEAXV3 ID DMEAXV3
DMEAXV3 DN ISIS 32002
DMEAXV3 HS Investigative
DMEAXV3 CP Isis Pharmaceuticals
DMEAXV3 DT Antisense drug
DMEAXV3 SQ GATGTCTGCCATAGCAGGAG
DMEAXV3 DE Discovery agent
DM7EVQX ID DM7EVQX
DM7EVQX DN ISIS 32003
DM7EVQX HS Investigative
DM7EVQX CP Isis Pharmaceuticals
DM7EVQX DT Antisense drug
DM7EVQX SQ CACCGCCCAGATGTCAAGGA
DM7EVQX DE Discovery agent
DME7VX6 ID DME7VX6
DME7VX6 DN ISIS 32004
DME7VX6 HS Investigative
DME7VX6 CP Isis Pharmaceuticals
DME7VX6 DT Antisense drug
DME7VX6 SQ TGCTATCTGTGAATCCACCG
DME7VX6 DE Discovery agent
DMT8GWX ID DMT8GWX
DMT8GWX DN ISIS 32005
DMT8GWX HS Investigative
DMT8GWX CP Isis Pharmaceuticals
DMT8GWX DT Antisense drug
DMT8GWX SQ AGGTATGGAGCCATCAGATG
DMT8GWX DE Discovery agent
DMFKLUS ID DMFKLUS
DMFKLUS DN ISIS 32006
DMFKLUS HS Investigative
DMFKLUS CP Isis Pharmaceuticals
DMFKLUS DT Antisense drug
DMFKLUS SQ GGGCAAAAGGAAATCCACAG
DMFKLUS DE Discovery agent
DME1KXM ID DME1KXM
DME1KXM DN ISIS 32008
DME1KXM HS Investigative
DME1KXM CP Isis Pharmaceuticals
DME1KXM DT Antisense drug
DME1KXM SQ TTCCCGAGGTACCTCCAACT
DME1KXM DE Discovery agent
DM8PBCA ID DM8PBCA
DM8PBCA DN ISIS 32010
DM8PBCA HS Investigative
DM8PBCA CP Isis Pharmaceuticals
DM8PBCA DT Antisense drug
DM8PBCA SQ CCATAACATCTGCTTAATAT
DM8PBCA DE Discovery agent
DMF5SK8 ID DMF5SK8
DMF5SK8 DN ISIS 32014
DMF5SK8 HS Investigative
DMF5SK8 CP Isis Pharmaceuticals
DMF5SK8 DT Antisense drug
DMF5SK8 SQ ATGCAAACATATAGGAGTCA
DMF5SK8 DE Discovery agent
DMMV4WX ID DMMV4WX
DMMV4WX DN ISIS 32015
DMMV4WX HS Investigative
DMMV4WX CP Isis Pharmaceuticals
DMMV4WX DT Antisense drug
DMMV4WX SQ CTGGAAGAAAAGGTCTGACA
DMMV4WX DE Discovery agent
DMXL9IY ID DMXL9IY
DMXL9IY DN ISIS 32020
DMXL9IY HS Investigative
DMXL9IY CP Isis Pharmaceuticals
DMXL9IY DT Antisense drug
DMXL9IY SQ CATATTAGGAGACACTTGAA
DMXL9IY DE Discovery agent
DMISB5V ID DMISB5V
DMISB5V DN ISIS 32021
DMISB5V HS Investigative
DMISB5V CP Isis Pharmaceuticals
DMISB5V DT Antisense drug
DMISB5V SQ TGCCAATTCATTTACTTTGA
DMISB5V DE Discovery agent
DMPKGIU ID DMPKGIU
DMPKGIU DN ISIS 32024
DMPKGIU HS Investigative
DMPKGIU CP Isis Pharmaceuticals
DMPKGIU DT Antisense drug
DMPKGIU SQ ATTAGTGGATGATCACCAAA
DMPKGIU DE Discovery agent
DMATWDO ID DMATWDO
DMATWDO DN ISIS 32028
DMATWDO HS Investigative
DMATWDO CP Isis Pharmaceuticals
DMATWDO DT Antisense drug
DMATWDO SQ TGTAATATTATGTCTCCAGT
DMATWDO DE Discovery agent
DM47B2O ID DM47B2O
DM47B2O DN ISIS 32035
DM47B2O HS Investigative
DM47B2O CP Isis Pharmaceuticals
DM47B2O DT Antisense drug
DM47B2O SQ AGTAGCCAGCACAGGACAGT
DM47B2O DE Discovery agent
DMY1R0Q ID DMY1R0Q
DMY1R0Q DN ISIS 32039
DMY1R0Q HS Investigative
DMY1R0Q CP Isis Pharmaceuticals
DMY1R0Q DT Antisense drug
DMY1R0Q SQ TTCACTTTAGTAGTCCAGCT
DMY1R0Q DE Discovery agent
DMAFEYG ID DMAFEYG
DMAFEYG DN ISIS 3224
DMAFEYG HS Investigative
DMAFEYG CP Isis Pharmaceuticals
DMAFEYG DT Antisense drug
DMAFEYG DE Discovery agent
DM56EZC ID DM56EZC
DM56EZC DN ISIS 3246
DM56EZC HS Investigative
DM56EZC CP Isis Pharmaceuticals
DM56EZC DT Antisense drug
DM56EZC SQ TGGCGTCTCCAGGCGATCTGA
DM56EZC DE Discovery agent
DMA96KW ID DMA96KW
DMA96KW DN ISIS 329956
DMA96KW HS Investigative
DMA96KW CP Isis Pharmaceuticals
DMA96KW DT Antisense drug
DMA96KW SQ CCTGAGGCGGACTCCCAGCT
DMA96KW DE Discovery agent
DM2TIO1 ID DM2TIO1
DM2TIO1 DN ISIS 3300
DM2TIO1 HS Investigative
DM2TIO1 CP Isis Pharmaceuticals
DM2TIO1 DT Antisense drug
DM2TIO1 SQ TGGCGTCTCCAGGCGATCTGA
DM2TIO1 DE Discovery agent
DMWIVS9 ID DMWIVS9
DMWIVS9 DN ISIS 330012
DMWIVS9 HS Investigative
DMWIVS9 CP Isis Pharmaceuticals
DMWIVS9 DT Antisense drug
DMWIVS9 SQ TCCCATTTCAGGAGACCTGG
DMWIVS9 DE Discovery agent
DM35WFL ID DM35WFL
DM35WFL DN ISIS 330031
DM35WFL HS Investigative
DM35WFL CP Isis Pharmaceuticals
DM35WFL DT Antisense drug
DM35WFL SQ TGGGCTCCTCTGACAGGACA
DM35WFL DE Discovery agent
DM0W47U ID DM0W47U
DM0W47U DN ISIS 3303
DM0W47U HS Investigative
DM0W47U CP Isis Pharmaceuticals
DM0W47U DT Antisense drug
DM0W47U SQ CTTTCCATATTGAATATAATAUG
DM0W47U DE Discovery agent
DM1K6DX ID DM1K6DX
DM1K6DX DN ISIS 3304
DM1K6DX HS Investigative
DM1K6DX CP Isis Pharmaceuticals
DM1K6DX DT Antisense drug
DM1K6DX SQ ACATCCATTCAAATGGTTTGAUG
DM1K6DX DE Discovery agent
DMWD1XH ID DMWD1XH
DMWD1XH DN ISIS 3306
DMWD1XH HS Investigative
DMWD1XH CP Isis Pharmaceuticals
DMWD1XH DT Antisense drug
DMWD1XH SQ GCCTTCATTTTGGTTGTTTTAUG
DMWD1XH DE Discovery agent
DMXRL2J ID DMXRL2J
DMXRL2J DN ISIS 3307
DMXRL2J HS Investigative
DMXRL2J CP Isis Pharmaceuticals
DMXRL2J DT Antisense drug
DMXRL2J SQ GACGCCATGATTTTGATGTCAUG
DMXRL2J DE Discovery agent
DMSIBWP ID DMSIBWP
DMSIBWP DN ISIS 3308
DMSIBWP HS Investigative
DMSIBWP CP Isis Pharmaceuticals
DMSIBWP DT Antisense drug
DMSIBWP SQ GGATTCATTTTAAACCCCTGAUG
DMSIBWP DE Discovery agent
DMDSMJU ID DMDSMJU
DMDSMJU DN ISIS 3309
DMDSMJU HS Investigative
DMDSMJU CP Isis Pharmaceuticals
DMDSMJU DT Antisense drug
DMDSMJU SQ AGACTCATCTTTCAATATCTAUG
DMDSMJU DE Discovery agent
DMOYBFQ ID DMOYBFQ
DMOYBFQ DN ISIS 341881
DMOYBFQ HS Investigative
DMOYBFQ CP Isis Pharmaceuticals
DMOYBFQ DT siRNA drug
DMOYBFQ SQ UUUGAAAAUGUUGAUCUCCTT
DMOYBFQ DE Discovery agent
DMO7492 ID DMO7492
DMO7492 DN ISIS 343867
DMO7492 HS Investigative
DMO7492 CP Isis Pharmaceuticals
DMO7492 DT siRNA drug
DMO7492 SQ 5'-UUUGAAAAUGWUGAUCUCC-3'
DMO7492 DE Discovery agent
DMAFEX8 ID DMAFEX8
DMAFEX8 DN ISIS 347573
DMAFEX8 HS Investigative
DMAFEX8 CP Isis Pharmaceuticals
DMAFEX8 DT Antisense drug
DMAFEX8 SQ AGAGTTGAACTGTTTTCCTC
DMAFEX8 DE Discovery agent
DM36SRT ID DM36SRT
DM36SRT DN ISIS 347577
DM36SRT HS Investigative
DM36SRT CP Isis Pharmaceuticals
DM36SRT DT Antisense drug
DM36SRT SQ AAGGGAAAGCAGCTCTCTTT
DM36SRT DE Discovery agent
DMBE1T8 ID DMBE1T8
DMBE1T8 DN ISIS 3792
DMBE1T8 HS Investigative
DMBE1T8 CP Isis Pharmaceuticals
DMBE1T8 DT Antisense drug
DMBE1T8 SQ GGCATTTTAAGTTGCTGTCG
DMBE1T8 DE Discovery agent
DMJDWX5 ID DMJDWX5
DMJDWX5 DN ISIS 3801
DMJDWX5 HS Investigative
DMJDWX5 CP Isis Pharmaceuticals
DMJDWX5 DT Antisense drug
DMJDWX5 SQ AACCCAGTGCTCCCTTTGCT
DMJDWX5 DE Discovery agent
DM7VAT0 ID DM7VAT0
DM7VAT0 DN ISIS 3804
DM7VAT0 HS Investigative
DM7VAT0 CP Isis Pharmaceuticals
DM7VAT0 DT Antisense drug
DM7VAT0 SQ GGCCACATTGGGAAAGTTGC
DM7VAT0 DE Discovery agent
DMX927V ID DMX927V
DMX927V DN ISIS 3805
DMX927V HS Investigative
DMX927V CP Isis Pharmaceuticals
DMX927V DT Antisense drug
DMX927V SQ CCCGGCATCTTTACAAAACC
DMX927V DE Discovery agent
DMN8OHG ID DMN8OHG
DMN8OHG DN ISIS 4189
DMN8OHG HS Investigative
DMN8OHG CP Isis Pharmaceuticals
DMN8OHG DT Antisense drug
DMN8OHG DE Discovery agent
DMXNBGP ID DMXNBGP
DMXNBGP DN ISIS 4719
DMXNBGP HS Investigative
DMXNBGP CP Isis Pharmaceuticals
DMXNBGP DT Antisense drug
DMXNBGP SQ ACGTTTGGCCTCATGGAAGT
DMXNBGP DE Discovery agent
DMD67YO ID DMD67YO
DMD67YO DN ISIS 4729
DMD67YO HS Investigative
DMD67YO CP Isis Pharmaceuticals
DMD67YO DT Antisense drug
DMD67YO SQ GGGCCAGAGACCCGAGGAGA
DMD67YO DE Discovery agent
DMKU1PN ID DMKU1PN
DMKU1PN DN ISIS 4730
DMKU1PN HS Investigative
DMKU1PN CP Isis Pharmaceuticals
DMKU1PN DT Antisense drug
DMKU1PN SQ TTCCCCAGATGCACCTGTTT
DMKU1PN DE Discovery agent
DMCZK1U ID DMCZK1U
DMCZK1U DN ISIS 4756
DMCZK1U HS Investigative
DMCZK1U CP Isis Pharmaceuticals
DMCZK1U DT Antisense drug
DMCZK1U SQ CCAAAGTGAGAGCTGAGAGA
DMCZK1U DE Discovery agent
DM3PZUX ID DM3PZUX
DM3PZUX DN ISIS 4759
DM3PZUX HS Investigative
DM3PZUX CP Isis Pharmaceuticals
DM3PZUX DT Antisense drug
DM3PZUX SQ ACAGGATCTCTCAGGTGGGT
DM3PZUX DE Discovery agent
DMLA5I9 ID DMLA5I9
DMLA5I9 DN ISIS 4764
DMLA5I9 HS Investigative
DMLA5I9 CP Isis Pharmaceuticals
DMLA5I9 DT Antisense drug
DMLA5I9 SQ GAAGTCAGCCAAGAACAGCT
DMLA5I9 DE Discovery agent
DMYVST6 ID DMYVST6
DMYVST6 DN ISIS 5874
DMYVST6 HS Investigative
DMYVST6 CP Isis Pharmaceuticals
DMYVST6 DT Antisense drug
DMYVST6 SQ CTTGAACAATTAATTCCACCT
DMYVST6 DE Discovery agent
DM8T1Z4 ID DM8T1Z4
DM8T1Z4 DN ISIS 5875
DM8T1Z4 HS Investigative
DM8T1Z4 CP Isis Pharmaceuticals
DM8T1Z4 DT Antisense drug
DM8T1Z4 SQ GTCTTTGTTGTTTTCTCTTCC
DM8T1Z4 DE Discovery agent
DMRATOH ID DMRATOH
DMRATOH DN ISIS 5876
DMRATOH HS Investigative
DMRATOH CP Isis Pharmaceuticals
DMRATOH DT Antisense drug
DMRATOH SQ CTGTGTCTCCTGTCTCCGCT
DMRATOH DE Discovery agent
DME7698 ID DME7698
DME7698 DN ISIS 5884
DME7698 HS Investigative
DME7698 CP Isis Pharmaceuticals
DME7698 DT Antisense drug
DME7698 SQ CGATGCAGATACCGCGGAGT
DME7698 DE Discovery agent
DMH7LPO ID DMH7LPO
DMH7LPO DN ISIS 6186
DMH7LPO HS Investigative
DMH7LPO CP Isis Pharmaceuticals
DMH7LPO DT Antisense drug
DMH7LPO SQ TATTCCGTCATCGCTCCTCA
DMH7LPO DE Discovery agent
DMEUCI2 ID DMEUCI2
DMEUCI2 DN ISIS 6431
DMEUCI2 HS Investigative
DMEUCI2 CP Isis Pharmaceuticals
DMEUCI2 DT Antisense drug
DMEUCI2 SQ CGACATGCCGGCGCCGCTGC
DMEUCI2 DE Discovery agent
DMQHN43 ID DMQHN43
DMQHN43 DN ISIS 6432
DMQHN43 HS Investigative
DMQHN43 CP Isis Pharmaceuticals
DMQHN43 DT Antisense drug
DMQHN43 SQ ACAGGTGCAGGAGTCGAGGC
DMQHN43 DE Discovery agent
DMNVLE2 ID DMNVLE2
DMNVLE2 DN ISIS 6434
DMNVLE2 HS Investigative
DMNVLE2 CP Isis Pharmaceuticals
DMNVLE2 DT Antisense drug
DMNVLE2 SQ CGCCTTCGCATAGCCCTTTG
DMNVLE2 DE Discovery agent
DMI7JQG ID DMI7JQG
DMI7JQG DN ISIS 6435
DMI7JQG HS Investigative
DMI7JQG CP Isis Pharmaceuticals
DMI7JQG DT Antisense drug
DMI7JQG SQ CCTCACCGATGCGGACCCTC
DMI7JQG DE Discovery agent
DM7KSRG ID DM7KSRG
DM7KSRG DN ISIS 6442
DM7KSRG HS Investigative
DM7KSRG CP Isis Pharmaceuticals
DM7KSRG DT Antisense drug
DM7KSRG SQ CAGACGACATGCCGGCGCCG
DM7KSRG DE Discovery agent
DMGN051 ID DMGN051
DMGN051 DN ISIS 6443
DMGN051 HS Investigative
DMGN051 CP Isis Pharmaceuticals
DMGN051 DT Antisense drug
DMGN051 SQ GCCTGCTTCGCAGCGGGAGA
DMGN051 DE Discovery agent
DMXJ4SO ID DMXJ4SO
DMXJ4SO DN ISIS 6445
DMXJ4SO HS Investigative
DMXJ4SO CP Isis Pharmaceuticals
DMXJ4SO DT Antisense drug
DMXJ4SO SQ AACACGCCCATTGCCCACCA
DMXJ4SO DE Discovery agent
DM5L387 ID DM5L387
DM5L387 DN ISIS 6553
DM5L387 HS Investigative
DM5L387 CP Isis Pharmaceuticals
DM5L387 DT Antisense drug
DM5L387 SQ GCGATGGTTCAGCTGGGCCC
DM5L387 DE Discovery agent
DMEAVPQ ID DMEAVPQ
DMEAVPQ DN ISIS 6581
DMEAVPQ HS Investigative
DMEAVPQ CP Isis Pharmaceuticals
DMEAVPQ DT Antisense drug
DMEAVPQ SQ TCTCACTCCCCATAAGGCTA
DMEAVPQ DE Discovery agent
DMVXC7W ID DMVXC7W
DMVXC7W DN ISIS 6603
DMVXC7W HS Investigative
DMVXC7W CP Isis Pharmaceuticals
DMVXC7W DT Antisense drug
DMVXC7W SQ AAGGCTGATGCTGGGAAGGT
DMVXC7W DE Discovery agent
DM5KGQO ID DM5KGQO
DM5KGQO DN ISIS 6717
DM5KGQO HS Investigative
DM5KGQO CP Isis Pharmaceuticals
DM5KGQO DT Antisense drug
DM5KGQO SQ TCCCGCCTGTGACATGCATT
DM5KGQO DE Discovery agent
DMJS6B0 ID DMJS6B0
DMJS6B0 DN ISIS 6720
DMJS6B0 HS Investigative
DMJS6B0 CP Isis Pharmaceuticals
DMJS6B0 DT Antisense drug
DMJS6B0 SQ TCCCGCCTGTGACATGCATT
DMJS6B0 DE Discovery agent
DMWZOQJ ID DMWZOQJ
DMWZOQJ DN ISIS 6729
DMWZOQJ HS Investigative
DMWZOQJ CP Isis Pharmaceuticals
DMWZOQJ DT Antisense drug
DMWZOQJ SQ TCCCGCCTGTGACATGCATT
DMWZOQJ DE Discovery agent
DM0B4RD ID DM0B4RD
DM0B4RD DN ISIS 6739
DM0B4RD HS Investigative
DM0B4RD CP Isis Pharmaceuticals
DM0B4RD DT Antisense drug
DM0B4RD SQ AAAGCCCCCCACCAC
DM0B4RD DE Discovery agent
DMQONPU ID DMQONPU
DMQONPU DN ISIS 6748
DMQONPU HS Investigative
DMQONPU CP Isis Pharmaceuticals
DMQONPU DT Antisense drug
DMQONPU SQ AGAAGGTGGCGTCGCGCGTG
DMQONPU DE Discovery agent
DM4LD1Y ID DM4LD1Y
DM4LD1Y DN ISIS 6755
DM4LD1Y HS Investigative
DM4LD1Y CP Isis Pharmaceuticals
DM4LD1Y DT Antisense drug
DM4LD1Y SQ GCGGCAAAGGCAGCACCCAG
DM4LD1Y DE Discovery agent
DMRM5QH ID DMRM5QH
DMRM5QH DN ISIS 6756
DMRM5QH HS Investigative
DMRM5QH CP Isis Pharmaceuticals
DMRM5QH DT Antisense drug
DMRM5QH SQ GCGCCCCATGGTACTGTGGC
DMRM5QH DE Discovery agent
DMTHO4A ID DMTHO4A
DMTHO4A DN ISIS 6957
DMTHO4A HS Investigative
DMTHO4A DT Antisense drug
DMTHO4A SQ CAGTGCCTGCGCCGCGCTCG
DMTHO4A DE Discovery agent
DM83EK9 ID DM83EK9
DM83EK9 DN ISIS 6958
DM83EK9 HS Investigative
DM83EK9 CP Isis Pharmaceuticals
DM83EK9 DT Antisense drug
DM83EK9 SQ CTGCCTCCGCCGCCGCGGCC
DM83EK9 DE Discovery agent
DMOX7FJ ID DMOX7FJ
DMOX7FJ DN ISIS 7453
DMOX7FJ HS Investigative
DMOX7FJ CP Isis Pharmaceuticals
DMOX7FJ DT Antisense drug
DMOX7FJ SQ TACGCCAACAGCTCC
DMOX7FJ DE Discovery agent
DMTN1D7 ID DMTN1D7
DMTN1D7 DN ISIS 7847
DMTN1D7 HS Investigative
DMTN1D7 CP Isis Pharmaceuticals
DMTN1D7 DT Antisense drug
DMTN1D7 SQ CTGGCTTCTCCTCCTCCCCT
DMTN1D7 DE Discovery agent
DMOXBDT ID DMOXBDT
DMOXBDT DN ISIS 7848
DMOXBDT HS Investigative
DMOXBDT CP Isis Pharmaceuticals
DMOXBDT DT Antisense drug
DMOXBDT SQ TCCTCCTCCCCGCGGCGGGT
DMOXBDT DE Discovery agent
DMQYB7A ID DMQYB7A
DMQYB7A DN ISIS 7849
DMQYB7A HS Investigative
DMQYB7A CP Isis Pharmaceuticals
DMQYB7A DT Antisense drug
DMQYB7A SQ CTCGCCCGCTCCTCCTCCCC
DMQYB7A DE Discovery agent
DMJKC45 ID DMJKC45
DMJKC45 DN ISIS 7851
DMJKC45 HS Investigative
DMJKC45 CP Isis Pharmaceuticals
DMJKC45 DT Antisense drug
DMJKC45 SQ CTCGCCCGCTCCTCCTCCCC
DMJKC45 DE Discovery agent
DM12E76 ID DM12E76
DM12E76 DN ISIS 7853
DM12E76 HS Investigative
DM12E76 CP Isis Pharmaceuticals
DM12E76 DT Antisense drug
DM12E76 SQ CCTGCTGGCTTCTCCTCCTC
DM12E76 DE Discovery agent
DMKAQ6U ID DMKAQ6U
DMKAQ6U DN ISIS 7855
DMKAQ6U HS Investigative
DMKAQ6U CP Isis Pharmaceuticals
DMKAQ6U DT Antisense drug
DMKAQ6U SQ TTCTCGCCCGCTCCTCCTCC
DMKAQ6U DE Discovery agent
DMN0A1R ID DMN0A1R
DMN0A1R DN ISIS 7942
DMN0A1R HS Investigative
DMN0A1R CP Isis Pharmaceuticals
DMN0A1R DT Antisense drug
DMN0A1R SQ CATGAGGGCCGATGTGACCT
DMN0A1R DE Discovery agent
DMYZE8R ID DMYZE8R
DMYZE8R DN ISIS 7948
DMYZE8R HS Investigative
DMYZE8R CP Isis Pharmaceuticals
DMYZE8R DT Antisense drug
DMYZE8R SQ TGCCACACAGCCCAGGCGCA
DMYZE8R DE Discovery agent
DMLIRKY ID DMLIRKY
DMLIRKY DN ISIS 9002
DMLIRKY HS Investigative
DMLIRKY CP Isis Pharmaceuticals
DMLIRKY DT Antisense drug
DMLIRKY SQ GGTCAGGCAGGCTGTCCGGC
DMLIRKY DE Discovery agent
DMBL2CG ID DMBL2CG
DMBL2CG DN ISIS 9003
DMBL2CG HS Investigative
DMBL2CG CP Isis Pharmaceuticals
DMBL2CG DT Antisense drug
DMBL2CG SQ GTCCCCACCGCCACTCCTGG
DMBL2CG DE Discovery agent
DM3PVGC ID DM3PVGC
DM3PVGC DN ISIS 9005
DM3PVGC HS Investigative
DM3PVGC CP Isis Pharmaceuticals
DM3PVGC DT Antisense drug
DM3PVGC SQ GCATGGCAGGTTCCCCTGGA
DM3PVGC DE Discovery agent
DMGK2TQ ID DMGK2TQ
DMGK2TQ DN ISIS 9007
DMGK2TQ HS Investigative
DMGK2TQ CP Isis Pharmaceuticals
DMGK2TQ DT Antisense drug
DMGK2TQ SQ AUGCGCCGCTCCCTTCCATCTTG
DMGK2TQ DE Discovery agent
DMQDZF2 ID DMQDZF2
DMQDZF2 DN ISIS 9008
DMQDZF2 HS Investigative
DMQDZF2 CP Isis Pharmaceuticals
DMQDZF2 DT Antisense drug
DMQDZF2 SQ CCCCGTAATGCGCCTTGAGG
DMQDZF2 DE Discovery agent
DM7TRSB ID DM7TRSB
DM7TRSB DN ISIS 9022
DM7TRSB HS Investigative
DM7TRSB CP Isis Pharmaceuticals
DM7TRSB DT Antisense drug
DM7TRSB SQ GGGCTCGCTGGTGAACTGTG
DM7TRSB DE Discovery agent
DMO2V5C ID DMO2V5C
DMO2V5C DN ISIS 9023
DMO2V5C HS Investigative
DMO2V5C CP Isis Pharmaceuticals
DMO2V5C DT Antisense drug
DMO2V5C SQ 3' UTR GACGCACGCGGCCTCACACC
DMO2V5C DE Discovery agent
DMAQ7XH ID DMAQ7XH
DMAQ7XH DN ISIS 9025
DMAQ7XH HS Investigative
DMAQ7XH CP Isis Pharmaceuticals
DMAQ7XH DT Antisense drug
DMAQ7XH SQ 3' UTR TCGGAGCCGTGCCCAGCCTG
DMAQ7XH DE Discovery agent
DMD1MEZ ID DMD1MEZ
DMD1MEZ DN ISIS 9058
DMD1MEZ HS Investigative
DMD1MEZ CP Isis Pharmaceuticals
DMD1MEZ DT Antisense drug
DMD1MEZ SQ TCCCGCCTGTGACATGCATT
DMD1MEZ DE Discovery agent
DMZL7SW ID DMZL7SW
DMZL7SW DN ISIS 9060
DMZL7SW HS Investigative
DMZL7SW CP Isis Pharmaceuticals
DMZL7SW DT Antisense drug
DMZL7SW SQ GTCAAGATGGGCTGAGGTGG
DMZL7SW DE Discovery agent
DMFAL2E ID DMFAL2E
DMFAL2E DN ISIS 9061
DMFAL2E HS Investigative
DMFAL2E CP Isis Pharmaceuticals
DMFAL2E DT Antisense drug
DMFAL2E SQ CCATCCCGGACAGTCACCAC
DMFAL2E DE Discovery agent
DM5ZGSO ID DM5ZGSO
DM5ZGSO DN ISIS 9062
DM5ZGSO HS Investigative
DM5ZGSO CP Isis Pharmaceuticals
DM5ZGSO DT Antisense drug
DM5ZGSO SQ ATGAGCTCCTCGCCATCCAG
DM5ZGSO DE Discovery agent
DM8E5RO ID DM8E5RO
DM8E5RO DN ISIS 9063
DM8E5RO HS Investigative
DM8E5RO CP Isis Pharmaceuticals
DM8E5RO DT Antisense drug
DM8E5RO SQ AATGCTGGTGGAACTTGTAG
DM8E5RO DE Discovery agent
DMBMTGP ID DMBMTGP
DMBMTGP DN ISIS 9064
DMBMTGP HS Investigative
DMBMTGP CP Isis Pharmaceuticals
DMBMTGP DT Antisense drug
DMBMTGP SQ CCGGTACCCCAGGTTCTTCA
DMBMTGP DE Discovery agent
DMH50RX ID DMH50RX
DMH50RX DN ISIS 9065
DMH50RX HS Investigative
DMH50RX CP Isis Pharmaceuticals
DMH50RX DT Antisense drug
DMH50RX SQ CTGGGCAGTCTGCCGGGCCA
DMH50RX DE Discovery agent
DMB8MH0 ID DMB8MH0
DMB8MH0 DN ISIS 9066
DMB8MH0 HS Investigative
DMB8MH0 CP Isis Pharmaceuticals
DMB8MH0 DT Antisense drug
DMB8MH0 SQ CACCTCAGCTGCCATCCACA
DMB8MH0 DE Discovery agent
DML8HCZ ID DML8HCZ
DML8HCZ DN ISIS 9067
DML8HCZ HS Investigative
DML8HCZ CP Isis Pharmaceuticals
DML8HCZ DT Antisense drug
DML8HCZ SQ GAGATTTTGCTGAGGTCCGG
DML8HCZ DE Discovery agent
DM953VY ID DM953VY
DM953VY DN ISIS 9068
DM953VY HS Investigative
DM953VY CP Isis Pharmaceuticals
DM953VY DT Antisense drug
DM953VY SQ GCACTCCGCTCAATCTTGGG
DM953VY DE Discovery agent
DM5C86M ID DM5C86M
DM5C86M DN ISIS 9069
DM5C86M HS Investigative
DM5C86M CP Isis Pharmaceuticals
DM5C86M DT Antisense drug
DM5C86M SQ CTAAGGCACAAGGCGGGCTG
DM5C86M DE Discovery agent
DMU0HQF ID DMU0HQF
DMU0HQF DN ISIS 9070
DMU0HQF HS Investigative
DMU0HQF CP Isis Pharmaceuticals
DMU0HQF DT Antisense drug
DMU0HQF SQ ACGAACATTGATTGGCTGGT
DMU0HQF DE Discovery agent
DMWY2XB ID DMWY2XB
DMWY2XB DN ISIS 9071
DMWY2XB HS Investigative
DMWY2XB CP Isis Pharmaceuticals
DMWY2XB DT Antisense drug
DMWY2XB SQ GTATCCCCAAAGCCAAGAGG
DMWY2XB DE Discovery agent
DMDKB1I ID DMDKB1I
DMDKB1I DN ISIS 9133
DMDKB1I HS Investigative
DMDKB1I CP Isis Pharmaceuticals
DMDKB1I DT Antisense drug
DMDKB1I SQ TTCCAGGTCATGAGCCATTA
DMDKB1I DE Discovery agent
DMGOPHN ID DMGOPHN
DMGOPHN DN ISIS 9139
DMGOPHN HS Investigative
DMGOPHN CP Isis Pharmaceuticals
DMGOPHN DT Antisense drug
DMGOPHN SQ CCCATAGTGCTGTCACAAAT
DMGOPHN DE Discovery agent
DM052M3 ID DM052M3
DM052M3 DN ISIS 9606
DM052M3 HS Investigative
DM052M3 CP Isis Pharmaceuticals
DM052M3 DT Antisense drug
DM052M3 SQ GTTCTCGCTGGTGAGTTTCA
DM052M3 DE Discovery agent
DM054SL ID DM054SL
DM054SL DN ISIS 9984
DM054SL HS Investigative
DM054SL CP Isis Pharmaceuticals
DM054SL DT Antisense drug
DM054SL SQ GAAGTCAGCCAAGAACAGCT
DM054SL DE Discovery agent
DMGN4OQ ID DMGN4OQ
DMGN4OQ DN ISIS-1939
DMGN4OQ HS Investigative
DMGN4OQ SN 136216-59-6
DMGN4OQ DE Discovery agent
DMU64W8 ID DMU64W8
DMU64W8 DN ISO24
DMU64W8 HS Investigative
DMU64W8 SN ISO24; [(4-ETHYLPHENYL)AMINO]CARBONYLPHOSPHONIC ACID; CHEMBL284362; IS2; 1o4j; AC1L9KY0; CTK8I8170; BDBM14687; 4-Ethylphenylcarbamoylphosphonic acid; AKOS027407805; DB03628; (4-ethylphenyl)carbamoylphosphonic acid; [(4-ethylphenyl)carbamoyl]phosphonic acid
DMU64W8 DT Small molecular drug
DMU64W8 PC 447534
DMU64W8 MW 229.17
DMU64W8 FM C9H12NO4P
DMU64W8 IC InChI=1S/C9H12NO4P/c1-2-7-3-5-8(6-4-7)10-9(11)15(12,13)14/h3-6H,2H2,1H3,(H,10,11)(H2,12,13,14)
DMU64W8 CS CCC1=CC=C(C=C1)NC(=O)P(=O)(O)O
DMU64W8 IK KGNSYMGWPCEFDZ-UHFFFAOYSA-N
DMU64W8 IU (4-ethylphenyl)carbamoylphosphonic acid
DMU64W8 DE Discovery agent
DMGNFXY ID DMGNFXY
DMGNFXY DN isoamyl-agomelatine
DMGNFXY HS Investigative
DMGNFXY SN isoamyl-agomelatine; GTPL7781; CHEMBL1946226
DMGNFXY DT Small molecular drug
DMGNFXY PC 57381997
DMGNFXY MW 313.4
DMGNFXY FM C20H27NO2
DMGNFXY IC InChI=1S/C20H27NO2/c1-14(2)5-6-16-11-17-7-8-19(23-4)13-20(17)18(12-16)9-10-21-15(3)22/h7-8,11-14H,5-6,9-10H2,1-4H3,(H,21,22)
DMGNFXY CS CC(C)CCC1=CC(=C2C=C(C=CC2=C1)OC)CCNC(=O)C
DMGNFXY IK DGWFQLYAVLGONI-UHFFFAOYSA-N
DMGNFXY IU N-[2-[7-methoxy-3-(3-methylbutyl)naphthalen-1-yl]ethyl]acetamide
DMGNFXY DE Discovery agent
DMTEDHP ID DMTEDHP
DMTEDHP DN isoamylamine
DMTEDHP HS Investigative
DMTEDHP SN ISOAMYLAMINE; Isopentylamine; 107-85-7; 3-METHYLBUTAN-1-AMINE; 3-Methylbutylamine; 1-Amino-3-methylbutane; Monoisoamylamine; Leucamine; 1-Butanamine, 3-methyl-; 3-Methylbutanamine; Isovalerylamine; Monoisopentylamine; gamma-Isoamylamine; Isobutylcarbylamine; 3-Methyl-Butylamine; 3-Methyl-1-butylamine; Butylamine, 3-methyl-; 3-Methyl-1-butanamine; 3,3-Dimethylpropylamine; 1-Aminoisopentane; isoamyl amine; UNII-LPO0L33SHY; 2-(2-isopropyl)ethylamine; Propylamine, 3,3-dimethyl-; .gamma.-Isoamylamine; NSC 7907; ISOAMYLAMINE, REAG
DMTEDHP DT Small molecular drug
DMTEDHP PC 7894
DMTEDHP MW 87.16
DMTEDHP FM C5H13N
DMTEDHP IC InChI=1S/C5H13N/c1-5(2)3-4-6/h5H,3-4,6H2,1-2H3
DMTEDHP CS CC(C)CCN
DMTEDHP IK BMFVGAAISNGQNM-UHFFFAOYSA-N
DMTEDHP IU 3-methylbutan-1-amine
DMTEDHP CA CAS 107-85-7
DMTEDHP CB CHEBI:43689
DMTEDHP DE Discovery agent
DM0B7NO ID DM0B7NO
DM0B7NO DN Isoarnebin 4
DM0B7NO HS Investigative
DM0B7NO SN Shikonin; NSC 252844; Shikonin S; Shikonin,(S); Tokyo Violet
DM0B7NO TC Antiviral Agents
DM0B7NO DT Small molecular drug
DM0B7NO PC 479503
DM0B7NO MW 288.29
DM0B7NO FM C16H16O5
DM0B7NO IC InChI=1S/C16H16O5/c1-8(2)3-4-10(17)9-7-13(20)14-11(18)5-6-12(19)15(14)16(9)21/h3,5-7,10,17-19H,4H2,1-2H3/t10-/m1/s1
DM0B7NO CS CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C
DM0B7NO IK NEZONWMXZKDMKF-SNVBAGLBSA-N
DM0B7NO IU 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione
DM0B7NO CA CAS 517-89-5
DM0B7NO CB CHEBI:81068
DM0B7NO DE Coronavirus Disease 2019 (COVID-19)
DMV8OCF ID DMV8OCF
DMV8OCF DN IsoBu-RYYRIK-NH2
DMV8OCF HS Investigative
DMV8OCF SN CHEMBL436852
DMV8OCF DT Small molecular drug
DMV8OCF PC 44456140
DMV8OCF MW 951.2
DMV8OCF FM C46H74N14O8
DMV8OCF IC InChI=1S/C46H74N14O8/c1-5-28(4)37(44(68)55-32(38(48)62)15-9-10-22-47)60-41(65)34(17-12-24-54-46(51)52)57-42(66)36(26-30-18-20-31(61)21-19-30)59-43(67)35(25-29-13-7-6-8-14-29)58-40(64)33(56-39(63)27(2)3)16-11-23-53-45(49)50/h6-8,13-14,18-21,27-28,32-37,61H,5,9-12,15-17,22-26,47H2,1-4H3,(H2,48,62)(H,55,68)(H,56,63)(H,57,66)(H,58,64)(H,59,67)(H,60,65)(H4,49,50,53)(H4,51,52,54)/t28-,32-,33-,34-,35-,36-,37-/m0/s1
DMV8OCF CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)C
DMV8OCF IK WWFAEBUHIGIWNK-KHLMYIKTSA-N
DMV8OCF IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-methylpropanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMV8OCF DE Discovery agent
DM293XH ID DM293XH
DM293XH DN Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine
DM293XH HS Investigative
DM293XH SN CHEMBL380191; isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine; SCHEMBL5996834; BDBM50183166
DM293XH DT Small molecular drug
DM293XH PC 44411213
DM293XH MW 260.399
DM293XH FM C17H28N2
DM293XH IC InChI=1S/C17H28N2/c1-14(2)12-19(17-8-10-18-11-9-17)13-16-6-4-15(3)5-7-16/h4-7,14,17-18H,8-13H2,1-3H3
DM293XH CS CC1=CC=C(C=C1)CN(CC(C)C)C2CCNCC2
DM293XH IK GBWQTSFXTHVNTA-UHFFFAOYSA-N
DM293XH IU N-[(4-methylphenyl)methyl]-N-(2-methylpropyl)piperidin-4-amine
DM293XH DE Discovery agent
DM46F5X ID DM46F5X
DM46F5X DN isobutylmethylxanthine
DM46F5X HS Investigative
DM46F5X SN 3-Isobutyl-1-methylxanthine; IBMX; 28822-58-4; 1-METHYL-3-ISOBUTYLXANTHINE; Methylisobutylxanthine; 3-Isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione; Xanthine, 3-isobutyl-1-methyl-; 3-Isobutyl-1-methyxanthine; 1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-; Methyl-isobutylxanthine; 3-isobutyl-1-methylxanthine (ibmx); UNII-TBT296U68M; 3-Isobutyl 1-methylxanthine; NSC 165960; CCRIS 4290; CHEBI:34795; 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione; 3-isobutyl-1-methyl-7H-xanthine; methylisobutylxanthine; 3-Isobutyl-1-methyl-3,9-dihydro-purine-2,6-dione; 3-ISOBUTYL-1-METHYLXANTHINE
DM46F5X DT Small molecular drug
DM46F5X PC 3758
DM46F5X MW 222.24
DM46F5X FM C10H14N4O2
DM46F5X IC InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
DM46F5X CS CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2
DM46F5X IK APIXJSLKIYYUKG-UHFFFAOYSA-N
DM46F5X IU 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
DM46F5X CA CAS 28822-58-4
DM46F5X CB CHEBI:34795
DM46F5X DE Discovery agent
DMX4VY9 ID DMX4VY9
DMX4VY9 DN isobutyric acid
DMX4VY9 HS Investigative
DMX4VY9 SN isobutyrate
DMX4VY9 DT Small molecular drug
DMX4VY9 PC 6590
DMX4VY9 MW 88.11
DMX4VY9 FM C4H8O2
DMX4VY9 IC InChI=1S/C4H8O2/c1-3(2)4(5)6/h3H,1-2H3,(H,5,6)
DMX4VY9 CS CC(C)C(=O)O
DMX4VY9 IK KQNPFQTWMSNSAP-UHFFFAOYSA-N
DMX4VY9 IU 2-methylpropanoic acid
DMX4VY9 CA CAS 79-31-2
DMX4VY9 CB CHEBI:16135
DMX4VY9 DE Discovery agent
DM861DU ID DM861DU
DM861DU DN Iso-caffeine
DM861DU HS Investigative
DM861DU SN Isocaffeine; 1,3,9-Trimethylxanthine; 519-32-4; 1,3,9-trimethylpurine-2,6-dione; 1,3,9-trimethyl-3,9-dihydro-1H-purine-2,6-dione; CHEMBL74063; MLS002639222; Caffeine Impurity C (Isocaffeine); 2,6-Dihydroxy-1,3,9-trimethylpurine; 1,3,9-Trimethyl-3,9-dihydro-purine-2,6-dione; W-202958; isocaffeine(8ci); Isocoffein; EINECS 208-267-7; NSC 28332; Isocaffeine (8CI); ISOCAFFIENE; 1,9-Trimethylxanthine; AC1L1B8B; AC1Q6KE0; 1,3,9-trimethyl-1H-purine-2,6(3H,9H)-dione; SCHEMBL515995; 3,9-Dihydro-1,3,9-trimethyl-1H-purine-2,6-dione
DM861DU DT Small molecular drug
DM861DU PC 1326
DM861DU MW 194.19
DM861DU FM C8H10N4O2
DM861DU IC InChI=1S/C8H10N4O2/c1-10-4-9-5-6(10)11(2)8(14)12(3)7(5)13/h4H,1-3H3
DM861DU CS CN1C=NC2=C1N(C(=O)N(C2=O)C)C
DM861DU IK LPHGQDQBBGAPDZ-UHFFFAOYSA-N
DM861DU IU 1,3,9-trimethylpurine-2,6-dione
DM861DU CA CAS 519-32-4
DM861DU DE Discovery agent
DMZR7W6 ID DMZR7W6
DMZR7W6 DN isocarbacyclin
DMZR7W6 HS Investigative
DMZR7W6 SN 9-O-methanoprostaglandin I
DMZR7W6 DT Small molecular drug
DMZR7W6 PC 5311244
DMZR7W6 MW 350.5
DMZR7W6 FM C21H34O4
DMZR7W6 IC InChI=1S/C21H34O4/c1-2-3-4-8-17(22)10-11-18-19-13-15(7-5-6-9-21(24)25)12-16(19)14-20(18)23/h10-12,16-20,22-23H,2-9,13-14H2,1H3,(H,24,25)/b11-10+/t16-,17-,18+,19-,20+/m0/s1
DMZR7W6 CS CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=C2)CCCCC(=O)O)O)O
DMZR7W6 IK JANVYOZZTKSZGN-WCAFQOMDSA-N
DMZR7W6 IU 5-[(3aS,5R,6R,6aS)-5-hydroxy-6-[(E,3S)-3-hydroxyoct-1-enyl]-1,3a,4,5,6,6a-hexahydropentalen-2-yl]pentanoic acid
DMZR7W6 CA CAS 88911-35-7
DMZR7W6 DE Discovery agent
DMUB187 ID DMUB187
DMUB187 DN Isochroman mono-carboxylic acid
DMUB187 HS Investigative
DMUB187 SN CHEMBL564124; isochroman mono-carboxylic acid; BDBM50296382; (3S)-7-{4-[(3R)-1,2-Dithiolan-3-yl]butylcarboxamido}-isochroman-3-carboxylic acid
DMUB187 DT Small molecular drug
DMUB187 PC 44139929
DMUB187 MW 381.5
DMUB187 FM C18H23NO4S2
DMUB187 IC InChI=1S/C18H23NO4S2/c20-17(4-2-1-3-15-7-8-24-25-15)19-14-6-5-12-10-16(18(21)22)23-11-13(12)9-14/h5-6,9,15-16H,1-4,7-8,10-11H2,(H,19,20)(H,21,22)/t15-,16+/m1/s1
DMUB187 CS C1CSS[C@@H]1CCCCC(=O)NC2=CC3=C(C[C@H](OC3)C(=O)O)C=C2
DMUB187 IK KRQHPRIBLJFGIT-CVEARBPZSA-N
DMUB187 IU (3S)-7-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-3,4-dihydro-1H-isochromene-3-carboxylic acid
DMUB187 DE Discovery agent
DMJKW4S ID DMJKW4S
DMJKW4S DN Isocitric Acid
DMJKW4S HS Investigative
DMJKW4S SN Citric acid, tetrakis(trimethylsilyl) deriv.; 1,2,3-Propanetricarboxylic acid, 2-[(trimethylsilyl)oxy]-, tris(trimethylsilyl) ester; Citric acid, (4TMS); Citric acid, tetra-TMS; Citric acid, tetrakis-TMS; CITRIC ACID-TETRA-TMS; Citric acid, 4TMS derivative; AC1LB862; CTK7F4886; VFGAVMGYDWDESE-UHFFFAOYSA-N; 14330-97-3; 3-O-Trimethylsilylcitric acid tri(trimethylsilyl) ester; Citric acid, trimethylsilyl ether, tris(trimethylsilyl) ester; tris(trimethylsilyl) 2-trimethylsilyloxypropane-1,2,3-tricarboxylate
DMJKW4S DT Small molecular drug
DMJKW4S PC 1198
DMJKW4S MW 192.12
DMJKW4S FM C6H8O7
DMJKW4S IC InChI=1S/C6H8O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h2,4,9H,1H2,(H,7,8)(H,10,11)(H,12,13)
DMJKW4S CS C(C(C(C(=O)O)O)C(=O)O)C(=O)O
DMJKW4S IK ODBLHEXUDAPZAU-UHFFFAOYSA-N
DMJKW4S IU 1-hydroxypropane-1,2,3-tricarboxylic acid
DMJKW4S CA CAS 320-77-4
DMJKW4S CB CHEBI:30887
DMJKW4S DE Discovery agent
DM52CPU ID DM52CPU
DM52CPU DN ISOCLOZAPINE
DM52CPU HS Investigative
DM52CPU SN ISOCLOZAPINE; BRN 0763655; CHEMBL415300; 1977-08-8; 2-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 2-Chloro-11-(4-methyl-1-piperazinyl)-5H-benzo(b,e)(1,4)diazepine; 5H-DIBENZO(b,e)(1,4)DIAZEPINE, 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-; SCHEMBL140207; AC1L279R; CTK4E2258; DTXSID40173464; MolPort-042-665-648; ZINC25973757; BDBM50010594; 2-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; NCGC00386501-01; LS-60880; 5H-Dibenzo[b,e][1,4]diazepine,2-chloro-11-(4-methyl-1-piperazinyl)-
DM52CPU DT Small molecular drug
DM52CPU PC 16104
DM52CPU MW 326.8
DM52CPU FM C18H19ClN4
DM52CPU IC InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-12-13(19)6-7-15(14)20-16-4-2-3-5-17(16)21-18/h2-7,12,20H,8-11H2,1H3
DM52CPU CS CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(C=C4)Cl
DM52CPU IK APOMSSAGEAOUGO-UHFFFAOYSA-N
DM52CPU IU 8-chloro-6-(4-methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine
DM52CPU CA CAS 1977-08-8
DM52CPU DE Discovery agent
DMMF1HX ID DMMF1HX
DMMF1HX DN ISOCONAZOLE
DMMF1HX HS Investigative
DMMF1HX SN Isoconazole; 27523-40-6; Isoconazolum; Isoconazol; Travogen; Isoconazol [INN-Spanish]; Isoconazolum [INN-Latin]; EINECS 248-508-3; CHEBI:83667; MPIPASJGOJYODL-UHFFFAOYSA-N; 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]imidazole; 1-(2,4-Dichloro-beta-((2,6-dichlorobenzyl)oxy)phenethyl)imidazole; 1-(2-(2,4-Dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)1H-imidazole; DSSTox_CID_25447; DSSTox_RID_80886; DSSTox_GSID_45447; 1H-Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)-
DMMF1HX DT Small molecular drug
DMMF1HX PC 3760
DMMF1HX MW 416.1
DMMF1HX FM C18H14Cl4N2O
DMMF1HX IC InChI=1S/C18H14Cl4N2O/c19-12-4-5-13(17(22)8-12)18(9-24-7-6-23-11-24)25-10-14-15(20)2-1-3-16(14)21/h1-8,11,18H,9-10H2
DMMF1HX CS C1=CC(=C(C(=C1)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
DMMF1HX IK MPIPASJGOJYODL-UHFFFAOYSA-N
DMMF1HX IU 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]imidazole
DMMF1HX CA CAS 27523-40-6
DMMF1HX CB CHEBI:83667
DMMF1HX DE Discovery agent
DM7ZSVD ID DM7ZSVD
DM7ZSVD DN ISODISPAR B
DM7ZSVD HS Investigative
DM7ZSVD SN ISODISPAR B; CHEMBL198873; AC1O5FK1; BDBM50172747; 5,7-dihydroxy-8-(3-methylbutanoyl)-4-phenylchromen-2-one; 5,7-Dihydroxy-8-(3-methyl-butyryl)-4-phenyl-chromen-2-one; 5,7-dihydroxy-8-(3-methylbutanoyl)-4-phenyl-chromen-2-one; 4-Phenyl-5,7-dihydroxy-8-(3-methylbutyryl)-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 5,7-dihydroxy-8-(3-methyl-1-oxobutyl)-4-phenyl-
DM7ZSVD DT Small molecular drug
DM7ZSVD PC 6483316
DM7ZSVD MW 338.4
DM7ZSVD FM C20H18O5
DM7ZSVD IC InChI=1S/C20H18O5/c1-11(2)8-14(21)19-16(23)10-15(22)18-13(9-17(24)25-20(18)19)12-6-4-3-5-7-12/h3-7,9-11,22-23H,8H2,1-2H3
DM7ZSVD CS CC(C)CC(=O)C1=C(C=C(C2=C1OC(=O)C=C2C3=CC=CC=C3)O)O
DM7ZSVD IK GKEWZBRIASMMCY-UHFFFAOYSA-N
DM7ZSVD IU 5,7-dihydroxy-8-(3-methylbutanoyl)-4-phenylchromen-2-one
DM7ZSVD DE Discovery agent
DMSLO71 ID DMSLO71
DMSLO71 DN Isoelaeocarpine
DMSLO71 HS Investigative
DMSLO71 SN Isoelaeocarpine
DMSLO71 DT Small molecular drug
DMSLO71 PC 44423026
DMSLO71 MW 257.329
DMSLO71 FM C16H19NO2
DMSLO71 IC InChI=1S/C16H19NO2/c1-10-4-2-6-12-14(10)16(18)15-11-5-3-8-17(11)9-7-13(15)19-12/h2,4,6,11,13,15H,3,5,7-9H2,1H3/t11-,13+,15-/m1/s1
DMSLO71 CS CC1=C2C(=CC=C1)O[C@H]3CCN4CCC[C@@H]4[C@H]3C2=O
DMSLO71 IK DXTYYNIKCKARPP-OSAQELSMSA-N
DMSLO71 IU (6aS,12aR,12bR)-11-methyl-1,2,3,5,6,6a,12a,12b-octahydrochromeno[2,3-g]indolizin-12-one
DMSLO71 DE Discovery agent
DMN23KT ID DMN23KT
DMN23KT DN isoferulic acid
DMN23KT HS Investigative
DMN23KT SN Isoferulic acid; 3-Hydroxy-4-methoxycinnamic acid; 537-73-5; Hesperetic acid; 25522-33-2; 3-(3-Hydroxy-4-methoxyphenyl)acrylic acid; (2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid; (E)-3-(3-hydroxy-4-methoxyphenyl)acrylic acid; Isoferulate; 2-Propenoic acid, 3-(3-hydroxy-4-methoxyphenyl)-; 3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid; 3-hydroxy-4-methoxy-cinnamic acid; CHEMBL233295; CHEBI:27794; QURCVMIEKCOAJU-HWKANZROSA-N; AK-88788; UNII-XSQ2K2G7MC; Cinnamic acid, 3-hydroxy-4-methoxy-; Q-100609
DMN23KT DT Small molecular drug
DMN23KT PC 736186
DMN23KT MW 194.18
DMN23KT FM C10H10O4
DMN23KT IC InChI=1S/C10H10O4/c1-14-9-4-2-7(6-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
DMN23KT CS COC1=C(C=C(C=C1)/C=C/C(=O)O)O
DMN23KT IK QURCVMIEKCOAJU-HWKANZROSA-N
DMN23KT IU (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid
DMN23KT CA CAS 25522-33-2
DMN23KT CB CHEBI:27794
DMN23KT DE Discovery agent
DM5CMA8 ID DM5CMA8
DM5CMA8 DN ISOFORMONENTIN
DM5CMA8 HS Investigative
DM5CMA8 SN isoformononetin; 486-63-5; 3-(4-Hydroxyphenyl)-7-methoxy-4H-chromen-4-one; 4'-HYDROXY-7-METHOXYISOFLAVONE; 7-methoxy-4'-hydroxyisoflavone; CHEBI:29608; LNIQZRIHAMVRJA-UHFFFAOYSA-N; HMO; 4H-1-Benzopyran-4-one, 3-(4-hydroxyphenyl)-7-methoxy-; ISOFORMONENTIN; 7-O-methyldaidzein; AC1L1GNQ; SCHEMBL73338; CTK8C3880; DTXSID40274405; ZINC968077; LMPK12050039; 6634AB; ANW-70750; AKOS016007909; DB04202; CCG-214134; AJ-24572; AX8239272; 4,(S); 3-(4-hydroxyphenyl)-7-methoxychromen-4-one; C12125; SR-05000002516
DM5CMA8 DT Small molecular drug
DM5CMA8 PC 3764
DM5CMA8 MW 268.26
DM5CMA8 FM C16H12O4
DM5CMA8 IC InChI=1S/C16H12O4/c1-19-12-6-7-13-15(8-12)20-9-14(16(13)18)10-2-4-11(17)5-3-10/h2-9,17H,1H3
DM5CMA8 CS COC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O
DM5CMA8 IK LNIQZRIHAMVRJA-UHFFFAOYSA-N
DM5CMA8 IU 3-(4-hydroxyphenyl)-7-methoxychromen-4-one
DM5CMA8 CA CAS 486-63-5
DM5CMA8 CB CHEBI:29608
DM5CMA8 DE Discovery agent
DM31AXO ID DM31AXO
DM31AXO DN Isogemichalcone C
DM31AXO HS Investigative
DM31AXO SN isogemichalcone C; CHEMBL463638; 3'-(4-Feruloyloxy-3-methylbutyl-2(E)-enyl)-2,4,2',4'-tetrahydroxychalcone; BDBM50250978; LMPK12120123; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[3-(2,4-dihydroxyphenyl)acryloyl]phenyl]-2-butenyl ester; 3-Methoxy-4-hydroxy-trans-cinnamic acid 2-methyl-4-[2,6-dihydroxy-3-[(E)-2,4-dihydroxycinnamoyl]phenyl]-2-butenyl ester
DM31AXO DT Small molecular drug
DM31AXO PC 10143276
DM31AXO MW 532.5
DM31AXO FM C30H28O9
DM31AXO IC InChI=1S/C30H28O9/c1-18(17-39-29(36)14-5-19-4-11-26(34)28(15-19)38-2)3-9-22-25(33)13-10-23(30(22)37)24(32)12-7-20-6-8-21(31)16-27(20)35/h3-8,10-16,31,33-35,37H,9,17H2,1-2H3/b12-7+,14-5+,18-3+
DM31AXO CS C/C(=C\\CC1=C(C=CC(=C1O)C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)/COC(=O)/C=C/C3=CC(=C(C=C3)O)OC
DM31AXO IK OFKHJNZDWNKYOY-MNYVGDBSSA-N
DM31AXO IU [(E)-4-[3-[(E)-3-(2,4-dihydroxyphenyl)prop-2-enoyl]-2,6-dihydroxyphenyl]-2-methylbut-2-enyl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
DM31AXO DE Discovery agent
DMCF1ZD ID DMCF1ZD
DMCF1ZD DN ISOGOIAZENSOLIDE
DMCF1ZD HS Investigative
DMCF1ZD SN isogoiazensolide
DMCF1ZD DT Small molecular drug
DMCF1ZD PC 10247932
DMCF1ZD MW 360.4
DMCF1ZD FM C19H20O7
DMCF1ZD IC InChI=1S/C19H20O7/c1-8(2)17(22)24-12-7-19(5)13(20)6-11(26-19)9(3)15(21)16-14(12)10(4)18(23)25-16/h6,12,14-16,21H,1,3-4,7H2,2,5H3/t12-,14+,15+,16-,19+/m0/s1
DMCF1ZD CS CC(=C)C(=O)O[C@H]1C[C@@]2(C(=O)C=C(O2)C(=C)[C@H]([C@@H]3[C@@H]1C(=C)C(=O)O3)O)C
DMCF1ZD IK QOLGSSCWXRXSJG-FTLZPGDLSA-N
DMCF1ZD IU [(3R,4S,8R,9S,11R)-3-hydroxy-11-methyl-2,7-dimethylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradec-1(13)-en-9-yl] 2-methylprop-2-enoate
DMCF1ZD DE Discovery agent
DMI6NJ1 ID DMI6NJ1
DMI6NJ1 DN Isogranulatimide
DMI6NJ1 HS Investigative
DMI6NJ1 DT Small molecular drug
DMI6NJ1 PC 135418335
DMI6NJ1 MW 276.25
DMI6NJ1 FM C15H8N4O2
DMI6NJ1 IC InChI=1S/C15H8N4O2/c20-14-11-9-5-16-6-19(9)13-10(12(11)15(21)18-14)7-3-1-2-4-8(7)17-13/h1-6,20H,(H,18,21)
DMI6NJ1 CS C1=CC=C2C(=C1)C3=C4C(=C(NC4=O)O)C5=CN=CN5C3=N2
DMI6NJ1 IK KUWAFJHRXZRHJH-UHFFFAOYSA-N
DMI6NJ1 IU 8-hydroxy-2,4,9,19-tetrazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(19),3,5,7,11,13,15,17-octaen-10-one
DMI6NJ1 CA CAS 219829-00-2
DMI6NJ1 DE Discovery agent
DMAFLCJ ID DMAFLCJ
DMAFLCJ DN Isoguanosine
DMAFLCJ HS Investigative
DMAFLCJ SN 2-Hydroxyadenosine; Crotonoside; Isoguanosine; 1818-71-9; Crotonosid; Isoguanine riboside; Adenosine, 1,2-dihydro-2-oxo-; 1,2-Dihydro-2-oxoadenosine; Isoguanosine (7CI,8CI); Isoguanine, 9-beta-D-ribofuranosyl-; NSC 12161; CHEBI:3927; 9H-Purin-2-ol, 6-amino-9-beta-D-ribofuranosyl-; 6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-2-one; Isoguanosin; CCRIS 8240; isoguanineriboside; Isoguanine, 9-.beta.-D-ribofuranosyl-; Isoguanosine (VAN); 2-Oxo-3-hydroadenosine; 2-Oxoado (isoguanosine)
DMAFLCJ DT Small molecular drug
DMAFLCJ PC 65085
DMAFLCJ MW 283.24
DMAFLCJ FM C10H13N5O5
DMAFLCJ IC InChI=1S/C10H13N5O5/c11-7-4-8(14-10(19)13-7)15(2-12-4)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1
DMAFLCJ CS C1=NC2=C(NC(=O)N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N
DMAFLCJ IK MIKUYHXYGGJMLM-UUOKFMHZSA-N
DMAFLCJ IU 6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-2-one
DMAFLCJ CA CAS 1818-71-9
DMAFLCJ CB CHEBI:3927
DMAFLCJ DE Discovery agent
DMZH9PW ID DMZH9PW
DMZH9PW DN Isohelenin
DMZH9PW HS Investigative
DMZH9PW DT Small molecular drug
DMZH9PW PC 605266
DMZH9PW MW 232.32
DMZH9PW FM C15H20O2
DMZH9PW IC InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h11-13H,1-2,4-8H2,3H3
DMZH9PW CS CC12CCCC(=C)C1CC3C(C2)OC(=O)C3=C
DMZH9PW IK CVUANYCQTOGILD-UHFFFAOYSA-N
DMZH9PW IU 8a-methyl-3,5-dimethylidene-3a,4,4a,6,7,8,9,9a-octahydrobenzo[f][1]benzofuran-2-one
DMZH9PW CA CAS 470-17-7
DMZH9PW DE Discovery agent
DMQC4HV ID DMQC4HV
DMQC4HV DN Isoindolinone Urea derivative
DMQC4HV HS Investigative
DMQC4HV SN CHEMBL184971
DMQC4HV DT Small molecular drug
DMQC4HV PC 44394105
DMQC4HV MW 509.6
DMQC4HV FM C32H35N3O3
DMQC4HV IC InChI=1S/C32H35N3O3/c1-19(2)38-18-20-12-13-26-23(15-20)29-25-17-33-32(37)30(25)28-22-10-6-5-9-21(22)16-24(28)31(29)35(26)14-8-7-11-27(36)34(3)4/h5-6,9-10,12-13,15,19H,7-8,11,14,16-18H2,1-4H3,(H,33,37)
DMQC4HV CS CC(C)OCC1=CC2=C(C=C1)N(C3=C2C4=C(C5=C3CC6=CC=CC=C65)C(=O)NC4)CCCCC(=O)N(C)C
DMQC4HV IK FBRQJIGPZJLFIQ-UHFFFAOYSA-N
DMQC4HV IU N,N-dimethyl-5-[14-oxo-7-(propan-2-yloxymethyl)-3,13-diazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-3-yl]pentanamide
DMQC4HV DE Discovery agent
DMHTBDN ID DMHTBDN
DMHTBDN DN Isojaspic acid
DMHTBDN HS Investigative
DMHTBDN SN isojaspic acid; CHEMBL1164369
DMHTBDN DT Small molecular drug
DMHTBDN PC 46907602
DMHTBDN MW 410.6
DMHTBDN FM C27H38O3
DMHTBDN IC InChI=1S/C27H38O3/c1-18(2)8-6-13-26(4)14-7-15-27(5)22(19(3)9-12-24(26)27)17-21-16-20(25(29)30)10-11-23(21)28/h8-11,16,22,24,28H,6-7,12-15,17H2,1-5H3,(H,29,30)/t22-,24+,26+,27-/m1/s1
DMHTBDN CS CC1=CC[C@H]2[C@@](CCC[C@@]2([C@@H]1CC3=C(C=CC(=C3)C(=O)O)O)C)(C)CCC=C(C)C
DMHTBDN IK IIMZFSAVKIVVHG-PPKJMBTNSA-N
DMHTBDN IU 3-[[(1R,4aS,5R,8aS)-2,5,8a-trimethyl-5-(4-methylpent-3-enyl)-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl]-4-hydroxybenzoic acid
DMHTBDN DE Discovery agent
DMYEGBC ID DMYEGBC
DMYEGBC DN ISOLICOFLAVONOL
DMYEGBC HS Investigative
DMYEGBC SN Isolicoflavonol; 94805-83-1; MLS000697735; CHEMBL457679; SMR000470986; 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one; AC1NSX1R; SCHEMBL5614138; cid_5318585; MolPort-039-052-689; PGCKDCPTJAQQSQ-UHFFFAOYSA-N; HMS2271L11; ZINC13130924; LMPK12111984; 9577AF; BDBM50251003; 5,7,4'-trihydroxy-3'-prenylflavonol; 4',5,7-Trihydroxy-3'-prenylflavonol; SR-01000765807; SR-01000765807-2; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-
DMYEGBC DT Small molecular drug
DMYEGBC PC 5318585
DMYEGBC MW 354.4
DMYEGBC FM C20H18O6
DMYEGBC IC InChI=1S/C20H18O6/c1-10(2)3-4-11-7-12(5-6-14(11)22)20-19(25)18(24)17-15(23)8-13(21)9-16(17)26-20/h3,5-9,21-23,25H,4H2,1-2H3
DMYEGBC CS CC(=CCC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)C
DMYEGBC IK PGCKDCPTJAQQSQ-UHFFFAOYSA-N
DMYEGBC IU 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one
DMYEGBC CA CAS 94805-83-1
DMYEGBC DE Discovery agent
DMXWOBE ID DMXWOBE
DMXWOBE DN ISOLONGIFOLOL
DMXWOBE HS Investigative
DMXWOBE SN Longifolol; CHEMBL388140; ISOLONGIFOLOL; 469-27-2; ZINC28645580; BDBM50211775
DMXWOBE DT Small molecular drug
DMXWOBE PC 12311096
DMXWOBE MW 222.37
DMXWOBE FM C15H26O
DMXWOBE IC InChI=1S/C15H26O/c1-14(2)7-4-8-15(3)11-6-5-10(13(11)14)12(15)9-16/h10-13,16H,4-9H2,1-3H3/t10-,11-,12+,13+,15+/m1/s1
DMXWOBE CS C[C@]12CCCC([C@@H]3[C@H]1CC[C@@H]3[C@@H]2CO)(C)C
DMXWOBE IK VZJHQHUOVIDRCF-BIGJJFBESA-N
DMXWOBE IU [(1R,2S,7S,8S,9S)-3,3,7-trimethyl-8-tricyclo[5.4.0.02,9]undecanyl]methanol
DMXWOBE CA CAS 1139-17-9
DMXWOBE DE Discovery agent
DMH1BN4 ID DMH1BN4
DMH1BN4 DN ISOLOXAPINE
DMH1BN4 HS Investigative
DMH1BN4 SN ISOLOXAPINE; CHEMBL7828; 8-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine; SCHEMBL2738975; AWHNHDGHHNGACT-UHFFFAOYSA-N; BDBM50028980; LS-61561; 8-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 3-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DMH1BN4 DT Small molecular drug
DMH1BN4 PC 10381810
DMH1BN4 MW 327.8
DMH1BN4 FM C18H18ClN3O
DMH1BN4 IC InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-4-2-3-5-16(14)23-17-7-6-13(19)12-15(17)20-18/h2-7,12H,8-11H2,1H3
DMH1BN4 CS CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)OC4=CC=CC=C42
DMH1BN4 IK AWHNHDGHHNGACT-UHFFFAOYSA-N
DMH1BN4 IU 3-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
DMH1BN4 DE Discovery agent
DMD1KSW ID DMD1KSW
DMD1KSW DN Isomaltose
DMD1KSW HS Investigative
DMD1KSW SN Brachiose; DLRVVLDZNNYCBX-RTPHMHGBSA-N; ISOMALTOSE; Isomalto-oligosaccharide; Isomaltose, ~98% (TLC); SCHEMBL1782423; 499-40-1; 6-O-alpha-D-glucopyranosyl-D-glucopyranose; 6024AF; AKOS026749917; CHEBI:28189; CHEMBL66675; HMS2236B05; I0231; MFCD00065373; MLS001333223; MLS001333224; SMR000857202; alpha-1,6-Glucobiose; alpha-D-Glc-(1->6)-D-Glc; alpha-D-Glcp-(1->6)-D-Glcp; alpha-D-Glcp-(1-6)-D-Glcp; alpha-D-glucopyranosyl-(1-6)-D-glucopyranose; alpha-D-glucosyl-(1->6)-D-glucose
DMD1KSW PC 439193
DMD1KSW MW 342.3
DMD1KSW FM C12H22O11
DMD1KSW IC DLRVVLDZNNYCBX-RTPHMHGBSA-N
DMD1KSW CS C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)O)O)O)O)O)O
DMD1KSW IK 1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9-,10-,11?,12+/m1/s1
DMD1KSW IU (3R,4S,5S,6R)-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
DMD1KSW CA CAS 499-40-1
DMD1KSW CB CHEBI:28189
DMD1KSW DE Discovery agent
DMOJ52F ID DMOJ52F
DMOJ52F DN ISOMER A
DMOJ52F HS Investigative
DMOJ52F DE Discovery agent
DM69XT3 ID DM69XT3
DM69XT3 DN ISONEORAUTENOL
DM69XT3 HS Investigative
DM69XT3 SN Isoneorautenol; 6H,10H-Furo[3,2-c:4,5-g']bis[1]benzopyran-3-ol, 6a,13a-dihydro-10,10-dimethyl-; 98755-24-9; 3-Hydroxy-6'',6''-dimethylpyrano[2'',3'':9,8]pterocarpan; (-)-Isoneorautenol; 6H,10H-Furo(3,2-c:4,5-g')bis(1)benzopyran-3-ol, 6a,13a-dihydro-10,10-dimethyl-; AC1L2K8A; AC1Q70ZR; CTK5I0056
DM69XT3 DT Small molecular drug
DM69XT3 PC 73649
DM69XT3 MW 322.4
DM69XT3 FM C20H18O4
DM69XT3 IC InChI=1S/C20H18O4/c1-20(2)6-5-11-7-14-15-10-22-17-8-12(21)3-4-13(17)19(15)23-18(14)9-16(11)24-20/h3-9,15,19,21H,10H2,1-2H3
DM69XT3 CS CC1(C=CC2=CC3=C(C=C2O1)OC4C3COC5=C4C=CC(=C5)O)C
DM69XT3 IK WTKJOOHYNMPGLE-UHFFFAOYSA-N
DM69XT3 IU 7,7-dimethyl-8,12,20-trioxapentacyclo[11.8.0.02,11.04,9.014,19]henicosa-2(11),3,5,9,14(19),15,17-heptaen-17-ol
DM69XT3 CA CAS 98755-24-9
DM69XT3 DE Discovery agent
DMUVAIF ID DMUVAIF
DMUVAIF DN ISONICOTINIC ACID
DMUVAIF HS Investigative
DMUVAIF SN ISONICOTINIC ACID; 55-22-1; Pyridine-4-carboxylic acid; 4-Pyridinecarboxylic acid; 4-Picolinic acid; 4-Carboxypyridine; p-Pyridinecarboxylic acid; gamma-Picolinic acid; gamma-Pyridinecarboxylic acid; Acide iso-nicotinique; 1,4-Dihydroisonicotinic acid; Acide iso-nicotinique [French]; UNII-Y8SYN761TQ; AI3-19239; .gamma.-Picolinic acid; NSC 1483; Isonicotinic acid, 99%; EINECS 200-228-2; Y8SYN761TQ; CHEBI:6032; TWBYWOBDOCUKOW-UHFFFAOYSA-N; MFCD00006429; g-picolinic acid; Isonicotinic Acids; isonicotinicacid; isonicotonic acid; MN1
DMUVAIF DT Small molecular drug
DMUVAIF PC 5922
DMUVAIF MW 123.11
DMUVAIF FM C6H5NO2
DMUVAIF IC InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9)
DMUVAIF CS C1=CN=CC=C1C(=O)O
DMUVAIF IK TWBYWOBDOCUKOW-UHFFFAOYSA-N
DMUVAIF IU pyridine-4-carboxylic acid
DMUVAIF CA CAS 55-22-1
DMUVAIF CB CHEBI:6032
DMUVAIF DE Discovery agent
DM5DKUY ID DM5DKUY
DM5DKUY DN ISONIPECOTAMIDE
DM5DKUY HS Investigative
DM5DKUY SN Piperidine-4-carboxamide; Isonipecotamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide
DM5DKUY DT Small molecular drug
DM5DKUY PC 3772
DM5DKUY MW 128.169
DM5DKUY FM C6H12N2O
DM5DKUY IC InChI=1S/C6H12N2O/c7-6(9)5-1-3-8-4-2-5/h5,8H,1-4H2,(H2,7,9)
DM5DKUY CS C1CNCCC1C(=O)N
DM5DKUY IK DPBWFNDFMCCGGJ-UHFFFAOYSA-N
DM5DKUY IU piperidine-4-carboxamide
DM5DKUY CA CAS 39546-32-2
DM5DKUY CB CHEBI:166563
DM5DKUY DE Discovery agent
DMO1ZHE ID DMO1ZHE
DMO1ZHE DN Isonipecotic acid
DMO1ZHE HS Investigative
DMO1ZHE SN Isonipecotic acid; Piperidine-4-carboxylic acid; 498-94-2; 4-Piperidinecarboxylic acid; 4-Carboxypiperidine; Hexahydroisonicotinic acid; h-inp-oh; dl-isopipecolinic acid; Isonicotinic acid, hexahydro-; Acide isonipecotique; 4-Hexahydroisonicotinic acid; NSC 61049; UNII-M5TZP1RWIE; iso-nipecotic acid; Acide isonipecotique [French]; Acide piperidine-carboxylique-4; M5TZP1RWIE; EINECS 207-872-3; BRN 0112553; 4-Piperidine carboxylic acid; Acide piperidine-carboxylique-4 [French]; CHEMBL279998; SRJOCJYGOFTFLH-UHFFFAOYSA-N
DMO1ZHE DT Small molecular drug
DMO1ZHE PC 3773
DMO1ZHE MW 129.16
DMO1ZHE FM C6H11NO2
DMO1ZHE IC InChI=1S/C6H11NO2/c8-6(9)5-1-3-7-4-2-5/h5,7H,1-4H2,(H,8,9)
DMO1ZHE CS C1CNCCC1C(=O)O
DMO1ZHE IK SRJOCJYGOFTFLH-UHFFFAOYSA-N
DMO1ZHE IU piperidine-4-carboxylic acid
DMO1ZHE CA CAS 498-94-2
DMO1ZHE DE Discovery agent
DMFX16H ID DMFX16H
DMFX16H DN Iso-OMPA
DMFX16H HS Investigative
DMFX16H SN iso-OMPA; tetraisopropyl pyrophosphoramide; 513-00-8; TETRAISOPROPYLPYROPHOSPHAMIDE; Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)-; Tetraisopropylpyrophosphoramide; MLS002153308; CHEMBL494887; EINECS 208-149-5; Tetra(monoisopropyl)pyrophosphortetramide; N,N',N'',N'''-Tetraisopropyldiphosphoramide; n,n'-diisopropylphosphorodiamidic anhydride; AC1L1KBH; Lopac-T-1505; Lopac0_001184; Tetraisoproryl Pyrophosphoramide; AC1Q6T49; SCHEMBL6263949; Tetraisopropyl pyrophos-phoramide; IOIMDJXKIMCMIG-UHFFFAOYSA-; BDBM10625
DMFX16H DT Small molecular drug
DMFX16H PC 5420
DMFX16H MW 342.36
DMFX16H FM C12H32N4O3P2
DMFX16H IC InChI=1S/C12H32N4O3P2/c1-9(2)13-20(17,14-10(3)4)19-21(18,15-11(5)6)16-12(7)8/h9-12H,1-8H3,(H2,13,14,17)(H2,15,16,18)
DMFX16H CS CC(C)NP(=O)(NC(C)C)OP(=O)(NC(C)C)NC(C)C
DMFX16H IK IOIMDJXKIMCMIG-UHFFFAOYSA-N
DMFX16H IU N-[bis(propan-2-ylamino)phosphoryloxy-(propan-2-ylamino)phosphoryl]propan-2-amine
DMFX16H CA CAS 513-00-8
DMFX16H DE Discovery agent
DMTU05Y ID DMTU05Y
DMTU05Y DN ISOPENTENYL PYROPHOSPHATE
DMTU05Y HS Investigative
DMTU05Y SN isopentenyl pyrophosphate; isopentenyl diphosphate; 3-Methyl-3-butenyl pyrophosphate; IPPP; Mono(3-methyl-3-butenyl) diphosphate; delta3-Isopentenyl diphosphate; isopentenyl-pp; Diphosphoric acid mono(3-methyl-3-butenyl) ester; delta-3-Isopentenyl pyrophosphat; Isopentenyl-diphosphate; CHEBI:16584; delta3-methyl-3-butenyl diphosphate; 3-methylbut-3-enyl phosphono hydrogen phosphate; 358-71-4; delta-3-Isopentenyl pyrophosphate; 3-methylbut-3-en-1-yl trihydrogen diphosphate; 3-METHYLBUT-3-ENYL TRIHYDROGEN DIPHOSPHATE
DMTU05Y DT Small molecular drug
DMTU05Y PC 1195
DMTU05Y MW 246.09
DMTU05Y FM C5H12O7P2
DMTU05Y IC InChI=1S/C5H12O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h1,3-4H2,2H3,(H,9,10)(H2,6,7,8)
DMTU05Y CS CC(=C)CCOP(=O)(O)OP(=O)(O)O
DMTU05Y IK NUHSROFQTUXZQQ-UHFFFAOYSA-N
DMTU05Y IU 3-methylbut-3-enyl phosphono hydrogen phosphate
DMTU05Y CA CAS 358-71-4
DMTU05Y CB CHEBI:16584
DMTU05Y DE Discovery agent
DM9J5IS ID DM9J5IS
DM9J5IS DN Isopentyl Pyrophosphate
DM9J5IS HS Investigative
DM9J5IS SN ISOPENTYL PYROPHOSPHATE; AC1L9LX1; SCHEMBL155704; IPFXNYPSBSIFOB-UHFFFAOYSA-N; ZINC2579357; 3-methylbutyl trihydrogen diphosphate; DB02508; Diphosphoric acid alpha-isopentyl ester; 3-methylbutyl phosphono hydrogen phosphate; Diphosphoric acid, P,P-bis(3-methylbutyl) ester
DM9J5IS DT Small molecular drug
DM9J5IS PC 448400
DM9J5IS MW 248.11
DM9J5IS FM C5H14O7P2
DM9J5IS IC InChI=1S/C5H14O7P2/c1-5(2)3-4-11-14(9,10)12-13(6,7)8/h5H,3-4H2,1-2H3,(H,9,10)(H2,6,7,8)
DM9J5IS CS CC(C)CCOP(=O)(O)OP(=O)(O)O
DM9J5IS IK IPFXNYPSBSIFOB-UHFFFAOYSA-N
DM9J5IS IU 3-methylbutyl phosphono hydrogen phosphate
DM9J5IS DE Discovery agent
DM9ERD6 ID DM9ERD6
DM9ERD6 DN ISOPILINE
DM9ERD6 HS Investigative
DM9ERD6 SN Isopiline; CHEMBL508011; BDBM50292445
DM9ERD6 DT Small molecular drug
DM9ERD6 PC 13891896
DM9ERD6 MW 297.3
DM9ERD6 FM C18H19NO3
DM9ERD6 IC InChI=1S/C18H19NO3/c1-21-17-12-7-8-19-13-9-10-5-3-4-6-11(10)15(14(12)13)16(20)18(17)22-2/h3-6,13,19-20H,7-9H2,1-2H3/t13-/m1/s1
DM9ERD6 CS COC1=C(C(=C2C3=CC=CC=C3C[C@@H]4C2=C1CCN4)O)OC
DM9ERD6 IK XLXSXOHBVGWKMT-CYBMUJFWSA-N
DM9ERD6 IU (6aR)-2,3-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-1-ol
DM9ERD6 DE Discovery agent
DMWI0M8 ID DMWI0M8
DMWI0M8 DN ISOPPADS
DMWI0M8 HS Investigative
DMWI0M8 DT Small molecular drug
DMWI0M8 PC 3978952
DMWI0M8 MW 511.4
DMWI0M8 FM C14H14N3O12PS2
DMWI0M8 IC InChI=1S/C14H14N3O12PS2/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-4-8(31(23,24)25)2-3-12(11)32(26,27)28/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28)
DMWI0M8 CS CC1=C(C(=C(C(=N1)N=NC2=C(C=CC(=C2)S(=O)(=O)O)S(=O)(=O)O)COP(=O)(O)O)C=O)O
DMWI0M8 IK XYBQYEJAMIDMPT-UHFFFAOYSA-N
DMWI0M8 IU 2-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonooxymethyl)pyridin-2-yl]diazenyl]benzene-1,4-disulfonic acid
DMWI0M8 DE Discovery agent
DMH67J2 ID DMH67J2
DMH67J2 DN Isopropyl 10H-phenothiazine-10-carboxylate
DMH67J2 HS Investigative
DMH67J2 SN CHEMBL450026; isopropyl 10H-phenothiazine-10-carboxylate
DMH67J2 DT Small molecular drug
DMH67J2 PC 44568318
DMH67J2 MW 285.4
DMH67J2 FM C16H15NO2S
DMH67J2 IC InChI=1S/C16H15NO2S/c1-11(2)19-16(18)17-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)17/h3-11H,1-2H3
DMH67J2 CS CC(C)OC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMH67J2 IK FFXIYTTZCCARMF-UHFFFAOYSA-N
DMH67J2 IU propan-2-yl phenothiazine-10-carboxylate
DMH67J2 DE Discovery agent
DMS8MBI ID DMS8MBI
DMS8MBI DN Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate
DMS8MBI HS Investigative
DMS8MBI SN SCHEMBL5812186
DMS8MBI DT Small molecular drug
DMS8MBI PC 11630982
DMS8MBI MW 311.4
DMS8MBI FM C18H17NO2S
DMS8MBI IC InChI=1S/C18H17NO2S/c1-12(2)21-18(20)16-17(22-13-8-4-3-5-9-13)14-10-6-7-11-15(14)19-16/h3-12,19H,1-2H3
DMS8MBI CS CC(C)OC(=O)C1=C(C2=CC=CC=C2N1)SC3=CC=CC=C3
DMS8MBI IK CIEJDDRWESEPGF-UHFFFAOYSA-N
DMS8MBI IU propan-2-yl 3-phenylsulfanyl-1H-indole-2-carboxylate
DMS8MBI DE Discovery agent
DM2VJF4 ID DM2VJF4
DM2VJF4 DN Isopropyl 4-nitrophenyl dodecylphosphonate
DM2VJF4 HS Investigative
DM2VJF4 SN isopropyl 4-nitrophenyl dodecylphosphonate; CHEMBL512224
DM2VJF4 DT Small molecular drug
DM2VJF4 PC 44563663
DM2VJF4 MW 413.5
DM2VJF4 FM C21H36NO5P
DM2VJF4 IC InChI=1S/C21H36NO5P/c1-4-5-6-7-8-9-10-11-12-13-18-28(25,26-19(2)3)27-21-16-14-20(15-17-21)22(23)24/h14-17,19H,4-13,18H2,1-3H3
DM2VJF4 CS CCCCCCCCCCCCP(=O)(OC1=CC=C(C=C1)[N+](=O)[O-])OC(C)C
DM2VJF4 IK VZXZHBVWVCMVBS-UHFFFAOYSA-N
DM2VJF4 IU 1-[dodecyl(propan-2-yloxy)phosphoryl]oxy-4-nitrobenzene
DM2VJF4 DE Discovery agent
DML54EA ID DML54EA
DML54EA DN Isopropyl dodecylfluorophosphonate
DML54EA HS Investigative
DML54EA SN IDFP; Isopropyl dodecylfluorophosphonate; 615250-02-7; CHEMBL333149; Isopropyl Dodecylphosphonofluoridate; isopropyl dodecylphosphonofluoridoate; C15H32FO2P; SCHEMBL6115190; CTK8E7841; DTXSID00647212; MolPort-006-822-693; HMS3648I13; BDBM50132717; 1797AH; Propan-2-yl dodecylphosphonofluoridate; RT-013317; LS-192335; Dodecyl(fluoro)phosphinic acid isopropyl ester; SR-01000946223
DML54EA DT Small molecular drug
DML54EA PC 24762154
DML54EA MW 294.39
DML54EA FM C15H32FO2P
DML54EA IC InChI=1S/C15H32FO2P/c1-4-5-6-7-8-9-10-11-12-13-14-19(16,17)18-15(2)3/h15H,4-14H2,1-3H3
DML54EA CS CCCCCCCCCCCCP(=O)(OC(C)C)F
DML54EA IK SFRALHFBKRAJPW-UHFFFAOYSA-N
DML54EA IU 1-[fluoro(propan-2-yloxy)phosphoryl]dodecane
DML54EA CA CAS 615250-02-7
DML54EA DE Discovery agent
DMBR8P1 ID DMBR8P1
DMBR8P1 DN Isopropylcarbamic Acid Biphenyl-3-yl Ester
DMBR8P1 HS Investigative
DMBR8P1 SN Isopropylcarbamic Acid Biphenyl-3-yl Ester; CHEMBL486494; SCHEMBL12132464
DMBR8P1 DT Small molecular drug
DMBR8P1 PC 11673293
DMBR8P1 MW 255.31
DMBR8P1 FM C16H17NO2
DMBR8P1 IC InChI=1S/C16H17NO2/c1-12(2)17-16(18)19-15-10-6-9-14(11-15)13-7-4-3-5-8-13/h3-12H,1-2H3,(H,17,18)
DMBR8P1 CS CC(C)NC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMBR8P1 IK AOMCLMJYDMDVOF-UHFFFAOYSA-N
DMBR8P1 IU (3-phenylphenyl) N-propan-2-ylcarbamate
DMBR8P1 DE Discovery agent
DM92F6Z ID DM92F6Z
DM92F6Z DN Isopropyl-methyl-prop-2-ynyl-amine hydrochloride
DM92F6Z HS Investigative
DM92F6Z DE Discovery agent
DMPYAMU ID DMPYAMU
DMPYAMU DN isopulegol
DMPYAMU HS Investigative
DMPYAMU SN coolact P
DMPYAMU DT Small molecular drug
DMPYAMU PC 170833
DMPYAMU MW 154.25
DMPYAMU FM C10H18O
DMPYAMU IC InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)6-10(9)11/h8-11H,1,4-6H2,2-3H3/t8-,9+,10-/m1/s1
DMPYAMU CS C[C@@H]1CC[C@H]([C@@H](C1)O)C(=C)C
DMPYAMU IK ZYTMANIQRDEHIO-KXUCPTDWSA-N
DMPYAMU IU (1R,2S,5R)-5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol
DMPYAMU CA CAS 89-79-2
DMPYAMU CB CHEBI:70479
DMPYAMU DE Discovery agent
DMDF26N ID DMDF26N
DMDF26N DN Isoquinolin-1-yl-(3-phenyl-propyl)-amine
DMDF26N HS Investigative
DMDF26N SN CHEMBL289792; Isoquinolin-1-yl-(3-phenyl-propyl)-amine; BDBM50282107
DMDF26N DT Small molecular drug
DMDF26N PC 44288035
DMDF26N MW 262.3
DMDF26N FM C18H18N2
DMDF26N IC InChI=1S/C18H18N2/c1-2-7-15(8-3-1)9-6-13-19-18-17-11-5-4-10-16(17)12-14-20-18/h1-5,7-8,10-12,14H,6,9,13H2,(H,19,20)
DMDF26N CS C1=CC=C(C=C1)CCCNC2=NC=CC3=CC=CC=C32
DMDF26N IK ZRAIUMVYTFUMKD-UHFFFAOYSA-N
DMDF26N IU N-(3-phenylpropyl)isoquinolin-1-amine
DMDF26N DE Discovery agent
DMT4RI2 ID DMT4RI2
DMT4RI2 DN Isoquinoline-1,3,4(2H)-trione
DMT4RI2 HS Investigative
DMT4RI2 SN Phthalonimide; 1,3,4(2H)-Isoquinolinetrione; isoquinoline-1,3,4(2H)-trione; 521-73-3; isoquinoline-1,3,4-trione; 1,3,4-(2H)ISOQUINOLINETRIONE; UNII-BM68CV5X6Q; NSC 407248; BRN 0383773; BM68CV5X6Q; 1,2,3,4-tetrahydroisoquinoline-1,3,4-trione; isoquinoline-1,3,4-(2H)-trione; 3deh; NSC407248; AC1L1VMV; 5-21-11-00575 (Beilstein Handbook Reference); 1,4(2H)-Isoquinolinetrione; SCHEMBL1122624; Isoquinoline-1,3,4-trione 1; CHEMBL206435; CTK1H0848; BDBM10247; DTXSID40200103; ZINC1599708; FCH844329; ACM521733; AKOS006276226; NSC-407248
DMT4RI2 DT Small molecular drug
DMT4RI2 PC 10640
DMT4RI2 MW 175.14
DMT4RI2 FM C9H5NO3
DMT4RI2 IC InChI=1S/C9H5NO3/c11-7-5-3-1-2-4-6(5)8(12)10-9(7)13/h1-4H,(H,10,12,13)
DMT4RI2 CS C1=CC=C2C(=C1)C(=O)C(=O)NC2=O
DMT4RI2 IK YIOFGHHAURBGSJ-UHFFFAOYSA-N
DMT4RI2 IU isoquinoline-1,3,4-trione
DMT4RI2 CA CAS 521-73-3
DMT4RI2 DE Discovery agent
DMWIMUZ ID DMWIMUZ
DMWIMUZ DN Isoquinoline-3-carboxylic acid methyl ester
DMWIMUZ HS Investigative
DMWIMUZ SN methyl isoquinoline-3-carboxylate; 27104-73-0; Methyl 3-isoquinolinecarboxylate; Isoquinoline-3-carboxylic acid methyl ester; 3-Isoquinolinecarboxylic acid, methyl ester; MFCD00075138; PubChem16888; AC1LDU8C; AC1Q5ZLC; Maybridge1_001945; ACMC-1CRQ5; KSC497K1B; SCHEMBL214090; CHEMBL416152; 3-(Methoxycarbonyl)isoquinoline; Methylisoquinoline-3-carboxylate; KS-00000GIP; HMS547A09; CTK3J7510; DTXSID10352385; MolPort-000-141-870; ZBCGBIZQNMVMPC-UHFFFAOYSA-N; methyl isoquinoline-3-carbo-xylate; ZINC132552; BCP05782; ANW-48722; RW2951
DMWIMUZ DT Small molecular drug
DMWIMUZ PC 725374
DMWIMUZ MW 187.19
DMWIMUZ FM C11H9NO2
DMWIMUZ IC InChI=1S/C11H9NO2/c1-14-11(13)10-6-8-4-2-3-5-9(8)7-12-10/h2-7H,1H3
DMWIMUZ CS COC(=O)C1=CC2=CC=CC=C2C=N1
DMWIMUZ IK ZBCGBIZQNMVMPC-UHFFFAOYSA-N
DMWIMUZ IU methyl isoquinoline-3-carboxylate
DMWIMUZ CA CAS 27104-73-0
DMWIMUZ DE Discovery agent
DMQ4Z6E ID DMQ4Z6E
DMQ4Z6E DN ISORHAMNETIN
DMQ4Z6E HS Investigative
DMQ4Z6E SN Isorhamnetin; 480-19-3; 3-Methylquercetin; Isorhamnetol; 3'-Methoxyquercetin; 3'-Methoxy-3,4',5,7-tetrahydroxyflavone; isorhamnetine; 3'-Methylquercetin; C.I. 75680; 3-Methylquercetine; UNII-07X3IB4R4Z; CCRIS 3791; C16H12O7; EINECS 207-545-5; Flavone, 3'-methoxy-3,4',5,7-tetrahydroxy-; BRN 0044723; 3,5,7,4'-Tetrahydroxy-3'-methoxyflavone; CHEMBL379064; CHEBI:6052; 07X3IB4R4Z
DMQ4Z6E DT Small molecular drug
DMQ4Z6E PC 5281654
DMQ4Z6E MW 316.26
DMQ4Z6E FM C16H12O7
DMQ4Z6E IC InChI=1S/C16H12O7/c1-22-11-4-7(2-3-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3
DMQ4Z6E CS COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMQ4Z6E IK IZQSVPBOUDKVDZ-UHFFFAOYSA-N
DMQ4Z6E IU 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
DMQ4Z6E CA CAS 480-19-3
DMQ4Z6E CB CHEBI:6052
DMQ4Z6E DE Discovery agent
DMFKQ0B ID DMFKQ0B
DMFKQ0B DN Isorhamnetin 3,7-disulfate
DMFKQ0B HS Investigative
DMFKQ0B SN Isorhamnetin 3,7-disulfate
DMFKQ0B DT Small molecular drug
DMFKQ0B PC 15290611
DMFKQ0B MW 552.6
DMFKQ0B FM C16H10K2O13S2
DMFKQ0B IC InChI=1S/C16H12O13S2.2K/c1-26-11-4-7(2-3-9(11)17)15-16(29-31(23,24)25)14(19)13-10(18)5-8(6-12(13)27-15)28-30(20,21)22;;/h2-6,17-18H,1H3,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
DMFKQ0B CS COC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O.[K+].[K+]
DMFKQ0B IK JILXHFDBMPFPLQ-UHFFFAOYSA-L
DMFKQ0B IU dipotassium;[5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxo-3-sulfonatooxychromen-7-yl] sulfate
DMFKQ0B DE Discovery agent
DMZQUY4 ID DMZQUY4
DMZQUY4 DN Isorhamnetin 3-O-rhamnoside
DMZQUY4 HS Investigative
DMZQUY4 SN isorhamnetin 3-O-rhamnoside; CHEMBL485261; BDBM50260170
DMZQUY4 DT Small molecular drug
DMZQUY4 PC 23634491
DMZQUY4 MW 462.4
DMZQUY4 FM C22H22O11
DMZQUY4 IC InChI=1S/C22H22O11/c1-8-16(26)18(28)19(29)22(31-8)33-21-17(27)15-12(25)6-10(23)7-14(15)32-20(21)9-3-4-11(24)13(5-9)30-2/h3-8,16,18-19,22-26,28-29H,1-2H3/t8-,16-,18+,19+,22-/m0/s1
DMZQUY4 CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)OC)O)O)O
DMZQUY4 IK UXXAEVMOIUAYQT-UFGFRKJLSA-N
DMZQUY4 IU 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
DMZQUY4 DE Discovery agent
DMJS7MV ID DMJS7MV
DMJS7MV DN ISOSAKUTANETIN
DMJS7MV HS Investigative
DMJS7MV SN Isosakuranetin; 480-43-3; 4'-Methylnaringenin; Isosakutanetin; UNII-U02X7TF8UA; naringenin 4'-methyl ether; U02X7TF8UA; CHEMBL470266; CHEBI:27552; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Citrifoliol; (S)-5,7-dihydroxy-2-(4-methoxyphenyl)chroman-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one; (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-methoxyphenyl)-, (2S)-; 4'-Methoxy-5,7-dihydroxyflavonone
DMJS7MV DT Small molecular drug
DMJS7MV PC 160481
DMJS7MV MW 286.28
DMJS7MV FM C16H14O5
DMJS7MV IC InChI=1S/C16H14O5/c1-20-11-4-2-9(3-5-11)14-8-13(19)16-12(18)6-10(17)7-15(16)21-14/h2-7,14,17-18H,8H2,1H3/t14-/m0/s1
DMJS7MV CS COC1=CC=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O
DMJS7MV IK HMUJXQRRKBLVOO-AWEZNQCLSA-N
DMJS7MV IU (2S)-5,7-dihydroxy-2-(4-methoxyphenyl)-2,3-dihydrochromen-4-one
DMJS7MV CA CAS 480-43-3
DMJS7MV CB CHEBI:27552
DMJS7MV DE Discovery agent
DMNM2SQ ID DMNM2SQ
DMNM2SQ DN ISOSCOPOLETIN
DMNM2SQ HS Investigative
DMNM2SQ SN Isoscopoletin; 776-86-3; 6-Hydroxy-7-methoxycoumarin; 6-hydroxy-7-methoxy-2H-chromen-2-one; 7-Methoxyesculetin; Isoscopoletine; 6-hydroxy-7-methoxychromen-2-one; 2H-1-Benzopyran-2-one, 6-hydroxy-7-methoxy-; 6-hydroxy-7-methoxy-chromen-2-one; CHEMBL390320; CHEBI:81484; iso-scopoletin; 6-Hydroxy-7-methoxy-2-benzopyrone; EINECS 212-282-4; AC1L2CWN; Esculetin 7-methyl ether; Esculetin, 7-methyl ether; AC1Q4EZ0; 6-Hydroxy-7-methylcoumarin; SCHEMBL2790887; AC1Q69W0; CTK7A0381; DTXSID40228266; MolPort-003-927-047
DMNM2SQ DT Small molecular drug
DMNM2SQ PC 69894
DMNM2SQ MW 192.17
DMNM2SQ FM C10H8O4
DMNM2SQ IC InChI=1S/C10H8O4/c1-13-9-5-8-6(4-7(9)11)2-3-10(12)14-8/h2-5,11H,1H3
DMNM2SQ CS COC1=C(C=C2C=CC(=O)OC2=C1)O
DMNM2SQ IK SYTYLPHCLSSCOJ-UHFFFAOYSA-N
DMNM2SQ IU 6-hydroxy-7-methoxychromen-2-one
DMNM2SQ CA CAS 776-86-3
DMNM2SQ CB CHEBI:81484
DMNM2SQ DE Discovery agent
DMTRCSV ID DMTRCSV
DMTRCSV DN Isosorbide-2-(benzylcarbamate)-5-benzoate
DMTRCSV HS Investigative
DMTRCSV SN CHEMBL523830; Isosorbide-2-(benzylcarbamate)-5-benzoate; BDBM50253231; (3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)hexahydrofuro[3,2-b]furan-3-yl benzoate
DMTRCSV DT Small molecular drug
DMTRCSV PC 25129141
DMTRCSV MW 383.4
DMTRCSV FM C21H21NO6
DMTRCSV IC InChI=1S/C21H21NO6/c23-20(15-9-5-2-6-10-15)27-16-12-25-19-17(13-26-18(16)19)28-21(24)22-11-14-7-3-1-4-8-14/h1-10,16-19H,11-13H2,(H,22,24)/t16-,17+,18-,19-/m1/s1
DMTRCSV CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)C4=CC=CC=C4
DMTRCSV IK NIWDLVRLOCHGOV-FCGDIQPGSA-N
DMTRCSV IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] benzoate
DMTRCSV DE Discovery agent
DMG0TW2 ID DMG0TW2
DMG0TW2 DN Isosorbide-2-(benzylcarbamate)-5-mononitrate
DMG0TW2 HS Investigative
DMG0TW2 SN CHEMBL445695; Isosorbide-2-(benzylcarbamate)-5-mononitrate
DMG0TW2 DT Small molecular drug
DMG0TW2 PC 11573367
DMG0TW2 MW 324.29
DMG0TW2 FM C14H16N2O7
DMG0TW2 IC InChI=1S/C14H16N2O7/c17-14(15-6-9-4-2-1-3-5-9)22-10-7-20-13-11(23-16(18)19)8-21-12(10)13/h1-5,10-13H,6-8H2,(H,15,17)/t10-,11+,12+,13+/m0/s1
DMG0TW2 CS C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])OC(=O)NCC3=CC=CC=C3
DMG0TW2 IK XCUJUZNXFHRMEC-UMSGYPCISA-N
DMG0TW2 IU [(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-benzylcarbamate
DMG0TW2 DE Discovery agent
DM1ZH2U ID DM1ZH2U
DM1ZH2U DN Isosorbide-2-(butylcarbamate)-5-benzoate
DM1ZH2U HS Investigative
DM1ZH2U SN CHEMBL494684; Isosorbide-2-(butylcarbamate)-5-benzoate
DM1ZH2U DT Small molecular drug
DM1ZH2U PC 44568823
DM1ZH2U MW 349.4
DM1ZH2U FM C18H23NO6
DM1ZH2U IC InChI=1S/C18H23NO6/c1-3-11(2)19-18(21)25-14-10-23-15-13(9-22-16(14)15)24-17(20)12-7-5-4-6-8-12/h4-8,11,13-16H,3,9-10H2,1-2H3,(H,19,21)/t11?,13-,14+,15-,16-/m1/s1
DM1ZH2U CS CCC(C)NC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2OC(=O)C3=CC=CC=C3
DM1ZH2U IK PEHJQBISUGKFJH-IXCHPVQKSA-N
DM1ZH2U IU [(3R,3aR,6S,6aR)-6-(butan-2-ylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] benzoate
DM1ZH2U DE Discovery agent
DMUDS12 ID DMUDS12
DMUDS12 DN Isosorbide-2-(butylcarbamate)-5-mononitrate
DMUDS12 HS Investigative
DMUDS12 SN Isosorbide-2-(butylcarbamate)-5-mononitrate; CHEMBL494520; BDBM50253227
DMUDS12 DT Small molecular drug
DMUDS12 PC 25133941
DMUDS12 MW 290.27
DMUDS12 FM C11H18N2O7
DMUDS12 IC InChI=1S/C11H18N2O7/c1-2-3-4-12-11(14)19-7-5-17-10-8(20-13(15)16)6-18-9(7)10/h7-10H,2-6H2,1H3,(H,12,14)/t7-,8+,9+,10+/m0/s1
DMUDS12 CS CCCCNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMUDS12 IK ZRPGNSMQMBUVBC-SGIHWFKDSA-N
DMUDS12 IU [(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-butylcarbamate
DMUDS12 DE Discovery agent
DM4ZYRP ID DM4ZYRP
DM4ZYRP DN Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate
DM4ZYRP HS Investigative
DM4ZYRP SN CHEMBL521852; Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate
DM4ZYRP DT Small molecular drug
DM4ZYRP PC 25133942
DM4ZYRP MW 316.31
DM4ZYRP FM C13H20N2O7
DM4ZYRP IC InChI=1S/C13H20N2O7/c16-13(14-8-4-2-1-3-5-8)21-9-6-19-12-10(22-15(17)18)7-20-11(9)12/h8-12H,1-7H2,(H,14,16)/t9-,10+,11+,12+/m0/s1
DM4ZYRP CS C1CCC(CC1)NC(=O)O[C@H]2CO[C@H]3[C@@H]2OC[C@H]3O[N+](=O)[O-]
DM4ZYRP IK HHQBHYZANLCQHI-IRCOFANPSA-N
DM4ZYRP IU [(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-cyclohexylcarbamate
DM4ZYRP DE Discovery agent
DMMH70I ID DMMH70I
DMMH70I DN Isosorbide-2-(ethylcarbamate)-5-mononitrate
DMMH70I HS Investigative
DMMH70I SN CHEMBL494518; Isosorbide-2-(ethylcarbamate)-5-mononitrate
DMMH70I DT Small molecular drug
DMMH70I PC 25133940
DMMH70I MW 262.22
DMMH70I FM C9H14N2O7
DMMH70I IC InChI=1S/C9H14N2O7/c1-2-10-9(12)17-5-3-15-8-6(18-11(13)14)4-16-7(5)8/h5-8H,2-4H2,1H3,(H,10,12)/t5-,6+,7+,8+/m0/s1
DMMH70I CS CCNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMMH70I IK KSNZOFCCDYSKSB-LXGUWJNJSA-N
DMMH70I IU [(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-ethylcarbamate
DMMH70I DE Discovery agent
DMC7MLN ID DMC7MLN
DMC7MLN DN Isosorbide-2-(methylcarbamate)-5-benzoate
DMC7MLN HS Investigative
DMC7MLN SN CHEMBL523500; Isosorbide-2-(methylcarbamate)-5-benzoate
DMC7MLN DT Small molecular drug
DMC7MLN PC 25129490
DMC7MLN MW 307.3
DMC7MLN FM C15H17NO6
DMC7MLN IC InChI=1S/C15H17NO6/c1-16-15(18)22-11-8-20-12-10(7-19-13(11)12)21-14(17)9-5-3-2-4-6-9/h2-6,10-13H,7-8H2,1H3,(H,16,18)/t10-,11+,12-,13-/m1/s1
DMC7MLN CS CNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2OC(=O)C3=CC=CC=C3
DMC7MLN IK XVQSZSYQBPAKTI-YVECIDJPSA-N
DMC7MLN IU [(3R,3aR,6S,6aR)-6-(methylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] benzoate
DMC7MLN DE Discovery agent
DMEKMOF ID DMEKMOF
DMEKMOF DN Isosorbide-2-(methylcarbamate)-5-mononitrate
DMEKMOF HS Investigative
DMEKMOF SN CHEMBL492179; Isosorbide-2-(methylcarbamate)-5-mononitrate
DMEKMOF DT Small molecular drug
DMEKMOF PC 25129843
DMEKMOF MW 248.19
DMEKMOF FM C8H12N2O7
DMEKMOF IC InChI=1S/C8H12N2O7/c1-9-8(11)16-4-2-14-7-5(17-10(12)13)3-15-6(4)7/h4-7H,2-3H2,1H3,(H,9,11)/t4-,5+,6+,7+/m0/s1
DMEKMOF CS CNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMEKMOF IK DEDWFQACIHPQHF-BDVNFPICSA-N
DMEKMOF IU [(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-methylcarbamate
DMEKMOF DE Discovery agent
DMQAEZP ID DMQAEZP
DMQAEZP DN Isosorbide-2-(propylcarbamate)-5-mononitrate
DMQAEZP HS Investigative
DMQAEZP SN CHEMBL494519; Isosorbide-2-(propylcarbamate)-5-mononitrate
DMQAEZP DT Small molecular drug
DMQAEZP PC 25129844
DMQAEZP MW 276.24
DMQAEZP FM C10H16N2O7
DMQAEZP IC InChI=1S/C10H16N2O7/c1-2-3-11-10(13)18-6-4-16-9-7(19-12(14)15)5-17-8(6)9/h6-9H,2-5H2,1H3,(H,11,13)/t6-,7+,8+,9+/m0/s1
DMQAEZP CS CCCNC(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]
DMQAEZP IK HZZGTUOWJWTZKT-JQCXWYLXSA-N
DMQAEZP IU [(3S,3aR,6R,6aS)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-propylcarbamate
DMQAEZP DE Discovery agent
DM6FVDO ID DM6FVDO
DM6FVDO DN Isosorbide-2-benzyl carbamate
DM6FVDO HS Investigative
DM6FVDO SN isosorbide-2-benzyl carbamate; Isosorbide-2-benzylcarbamate; CHEMBL524046
DM6FVDO DT Small molecular drug
DM6FVDO PC 25129492
DM6FVDO MW 279.29
DM6FVDO FM C14H17NO5
DM6FVDO IC InChI=1S/C14H17NO5/c16-10-7-18-13-11(8-19-12(10)13)20-14(17)15-6-9-4-2-1-3-5-9/h1-5,10-13,16H,6-8H2,(H,15,17)/t10-,11+,12-,13-/m1/s1
DM6FVDO CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)O
DM6FVDO IK LYJZFQNPWOVWIJ-YVECIDJPSA-N
DM6FVDO IU [(3R,3aR,6S,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] N-benzylcarbamate
DM6FVDO DE Discovery agent
DM5XEZI ID DM5XEZI
DM5XEZI DN Isosorbide-2-benzylcarbamate-5-(o-toluate)
DM5XEZI HS Investigative
DM5XEZI SN CHEMBL583687; Isosorbide-2-benzylcarbamate-5-(o-toluate)
DM5XEZI DT Small molecular drug
DM5XEZI PC 45487256
DM5XEZI MW 397.4
DM5XEZI FM C22H23NO6
DM5XEZI IC InChI=1S/C22H23NO6/c1-14-7-5-6-10-16(14)21(24)28-17-12-26-20-18(13-27-19(17)20)29-22(25)23-11-15-8-3-2-4-9-15/h2-10,17-20H,11-13H2,1H3,(H,23,25)/t17-,18+,19-,20-/m1/s1
DM5XEZI CS CC1=CC=CC=C1C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DM5XEZI IK XMIPVPSZMVVUST-IYWMVGAKSA-N
DM5XEZI IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] 2-methylbenzoate
DM5XEZI DE Discovery agent
DMD4WRH ID DMD4WRH
DMD4WRH DN Isosorbide-2-benzylcarbamate-5-acetate
DMD4WRH HS Investigative
DMD4WRH SN CHEMBL493460; Isosorbide-2-benzylcarbamate-5-acetate
DMD4WRH DT Small molecular drug
DMD4WRH PC 25128786
DMD4WRH MW 321.32
DMD4WRH FM C16H19NO6
DMD4WRH IC InChI=1S/C16H19NO6/c1-10(18)22-12-8-20-15-13(9-21-14(12)15)23-16(19)17-7-11-5-3-2-4-6-11/h2-6,12-15H,7-9H2,1H3,(H,17,19)/t12-,13+,14-,15-/m1/s1
DMD4WRH CS CC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC3=CC=CC=C3
DMD4WRH IK RMUIRACCZOGQBC-LXTVHRRPSA-N
DMD4WRH IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] acetate
DMD4WRH DE Discovery agent
DMWDQ90 ID DMWDQ90
DMWDQ90 DN Isosorbide-2-benzylcarbamate-5-cyclopentanoate
DMWDQ90 HS Investigative
DMWDQ90 SN CHEMBL492635; Isosorbide-2-benzylcarbamate-5-cyclopentanoate
DMWDQ90 DT Small molecular drug
DMWDQ90 PC 25130201
DMWDQ90 MW 375.4
DMWDQ90 FM C20H25NO6
DMWDQ90 IC InChI=1S/C20H25NO6/c22-19(14-8-4-5-9-14)26-15-11-24-18-16(12-25-17(15)18)27-20(23)21-10-13-6-2-1-3-7-13/h1-3,6-7,14-18H,4-5,8-12H2,(H,21,23)/t15-,16+,17-,18-/m1/s1
DMWDQ90 CS C1CCC(C1)C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DMWDQ90 IK UPLFPBDRBGHRQW-XMTFNYHQSA-N
DMWDQ90 IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] cyclopentanecarboxylate
DMWDQ90 DE Discovery agent
DM8E2L6 ID DM8E2L6
DM8E2L6 DN Isosorbide-2-benzylcarbamate-5-cyclopropanoate
DM8E2L6 HS Investigative
DM8E2L6 SN CHEMBL492432; Isosorbide-2-benzylcarbamate-5-cyclopropanoate
DM8E2L6 DT Small molecular drug
DM8E2L6 PC 25128788
DM8E2L6 MW 347.4
DM8E2L6 FM C18H21NO6
DM8E2L6 IC InChI=1S/C18H21NO6/c20-17(12-6-7-12)24-13-9-22-16-14(10-23-15(13)16)25-18(21)19-8-11-4-2-1-3-5-11/h1-5,12-16H,6-10H2,(H,19,21)/t13-,14+,15-,16-/m1/s1
DM8E2L6 CS C1CC1C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DM8E2L6 IK FEYSXVBUKKSWGH-QKPAOTATSA-N
DM8E2L6 IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] cyclopropanecarboxylate
DM8E2L6 DE Discovery agent
DMQ3Z17 ID DMQ3Z17
DMQ3Z17 DN Isosorbide-2-benzylcarbamate-5-isonicotinate
DMQ3Z17 HS Investigative
DMQ3Z17 SN CHEMBL492481; Isosorbide-2-benzylcarbamate-5-isonicotinate
DMQ3Z17 DT Small molecular drug
DMQ3Z17 PC 25129143
DMQ3Z17 MW 384.4
DMQ3Z17 FM C20H20N2O6
DMQ3Z17 IC InChI=1S/C20H20N2O6/c23-19(14-6-8-21-9-7-14)27-15-11-25-18-16(12-26-17(15)18)28-20(24)22-10-13-4-2-1-3-5-13/h1-9,15-18H,10-12H2,(H,22,24)/t15-,16+,17-,18-/m1/s1
DMQ3Z17 CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)C4=CC=NC=C4
DMQ3Z17 IK CPCJEEMJBNMGOE-XMTFNYHQSA-N
DMQ3Z17 IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] pyridine-4-carboxylate
DMQ3Z17 DE Discovery agent
DMY49DN ID DMY49DN
DMY49DN DN Isosorbide-2-benzylcarbamate-5-nicotinate
DMY49DN HS Investigative
DMY49DN SN CHEMBL492283; Isosorbide-2-benzylcarbamate-5-nicotinate; BDBM50253230; (3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)hexahydrofuro[3,2-b]furan-3-yl nicotinate
DMY49DN DT Small molecular drug
DMY49DN PC 25129142
DMY49DN MW 384.4
DMY49DN FM C20H20N2O6
DMY49DN IC InChI=1S/C20H20N2O6/c23-19(14-7-4-8-21-10-14)27-15-11-25-18-16(12-26-17(15)18)28-20(24)22-9-13-5-2-1-3-6-13/h1-8,10,15-18H,9,11-12H2,(H,22,24)/t15-,16+,17-,18-/m1/s1
DMY49DN CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)C4=CN=CC=C4
DMY49DN IK FYZLBYYWOFEUSZ-XMTFNYHQSA-N
DMY49DN IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] pyridine-3-carboxylate
DMY49DN DE Discovery agent
DMSQ538 ID DMSQ538
DMSQ538 DN Isosorbide-2-benzylcarbamate-5-pentanoate
DMSQ538 HS Investigative
DMSQ538 SN CHEMBL521666; Isosorbide-2-benzylcarbamate-5-pentanoate
DMSQ538 DT Small molecular drug
DMSQ538 PC 25128787
DMSQ538 MW 363.4
DMSQ538 FM C19H25NO6
DMSQ538 IC InChI=1S/C19H25NO6/c1-2-3-9-16(21)25-14-11-23-18-15(12-24-17(14)18)26-19(22)20-10-13-7-5-4-6-8-13/h4-8,14-15,17-18H,2-3,9-12H2,1H3,(H,20,22)/t14-,15+,17-,18-/m1/s1
DMSQ538 CS CCCCC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC3=CC=CC=C3
DMSQ538 IK CFMVNQSTYPRCII-CYGHRXIMSA-N
DMSQ538 IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] pentanoate
DMSQ538 DE Discovery agent
DMP6E34 ID DMP6E34
DMP6E34 DN Isosorbide-2-benzylcarbamate-5-propionate
DMP6E34 HS Investigative
DMP6E34 SN CHEMBL493672; Isosorbide-2-benzylcarbamate-5-propionate
DMP6E34 DT Small molecular drug
DMP6E34 PC 25129847
DMP6E34 MW 335.4
DMP6E34 FM C17H21NO6
DMP6E34 IC InChI=1S/C17H21NO6/c1-2-14(19)23-12-9-21-16-13(10-22-15(12)16)24-17(20)18-8-11-6-4-3-5-7-11/h3-7,12-13,15-16H,2,8-10H2,1H3,(H,18,20)/t12-,13+,15-,16-/m1/s1
DMP6E34 CS CCC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC3=CC=CC=C3
DMP6E34 IK FDUDHTXZERVRTN-OCVGTWLNSA-N
DMP6E34 IU [(3R,3aR,6S,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] propanoate
DMP6E34 DE Discovery agent
DMCHSWQ ID DMCHSWQ
DMCHSWQ DN Isosorbide-2-benzylcarbamate-5-tosylate
DMCHSWQ HS Investigative
DMCHSWQ SN CHEMBL523852
DMCHSWQ DT Small molecular drug
DMCHSWQ PC 44568995
DMCHSWQ MW 461.5
DMCHSWQ FM C22H23NO8S
DMCHSWQ IC InChI=1S/C22H23NO8S/c1-14-7-9-16(10-8-14)32(26,27)22(25)31-18-13-29-19-17(12-28-20(18)19)30-21(24)23-11-15-5-3-2-4-6-15/h2-10,17-20H,11-13H2,1H3,(H,23,24)/t17-,18+,19+,20+/m0/s1
DMCHSWQ CS CC1=CC=C(C=C1)S(=O)(=O)C(=O)O[C@@H]2CO[C@H]3[C@@H]2OC[C@@H]3OC(=O)NCC4=CC=CC=C4
DMCHSWQ IK RGANIXDJVGCBKP-MTQWCTHYSA-N
DMCHSWQ IU [(3S,3aR,6R,6aR)-3-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] (4-methylphenyl)sulfonylformate
DMCHSWQ DE Discovery agent
DMG69IX ID DMG69IX
DMG69IX DN Isosorbide-2-benzylcarbamate-5-triflate
DMG69IX HS Investigative
DMG69IX SN CHEMBL492636; Isosorbide-2-benzylcarbamate-5-triflate
DMG69IX DT Small molecular drug
DMG69IX PC 44568822
DMG69IX MW 455.4
DMG69IX FM C16H16F3NO9S
DMG69IX IC InChI=1S/C16H16F3NO9S/c17-16(18,19)30(23,24)29-15(22)28-11-8-26-12-10(7-25-13(11)12)27-14(21)20-6-9-4-2-1-3-5-9/h1-5,10-13H,6-8H2,(H,20,21)/t10-,11+,12+,13+/m0/s1
DMG69IX CS C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)OC(=O)OS(=O)(=O)C(F)(F)F)OC(=O)NCC3=CC=CC=C3
DMG69IX IK WOSIHMSPFKVEAI-UMSGYPCISA-N
DMG69IX IU [(3S,3aR,6R,6aR)-3-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxycarbonyl trifluoromethanesulfonate
DMG69IX DE Discovery agent
DMPA2ON ID DMPA2ON
DMPA2ON DN Isosorbide-di-(4-nitrophenyl carbamate)
DMPA2ON HS Investigative
DMPA2ON SN CHEMBL603100
DMPA2ON DT Small molecular drug
DMPA2ON PC 46232723
DMPA2ON MW 474.4
DMPA2ON FM C20H18N4O10
DMPA2ON IC InChI=1S/C20H18N4O10/c25-19(21-11-1-5-13(6-2-11)23(27)28)33-15-9-31-18-16(10-32-17(15)18)34-20(26)22-12-3-7-14(8-4-12)24(29)30/h1-8,15-18H,9-10H2,(H,21,25)(H,22,26)/t15-,16+,17-,18-/m1/s1
DMPA2ON CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NC3=CC=C(C=C3)[N+](=O)[O-])OC(=O)NC4=CC=C(C=C4)[N+](=O)[O-]
DMPA2ON IK DHXOUOFGQLLAMG-XMTFNYHQSA-N
DMPA2ON IU [(3S,3aR,6R,6aR)-6-[(4-nitrophenyl)carbamoyloxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-(4-nitrophenyl)carbamate
DMPA2ON DE Discovery agent
DMFVN71 ID DMFVN71
DMFVN71 DN Isosorbide-di-(benzylcarbamate)
DMFVN71 HS Investigative
DMFVN71 SN CHEMBL600013; Isosorbide-di-(benzylcarbamate)
DMFVN71 DT Small molecular drug
DMFVN71 PC 46232725
DMFVN71 MW 412.4
DMFVN71 FM C22H24N2O6
DMFVN71 IC InChI=1S/C22H24N2O6/c25-21(23-11-15-7-3-1-4-8-15)29-17-13-27-20-18(14-28-19(17)20)30-22(26)24-12-16-9-5-2-6-10-16/h1-10,17-20H,11-14H2,(H,23,25)(H,24,26)/t17-,18+,19-,20-/m1/s1
DMFVN71 CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NCC3=CC=CC=C3)OC(=O)NCC4=CC=CC=C4
DMFVN71 IK PERBLOUPRPLYHU-IYWMVGAKSA-N
DMFVN71 IU [(3S,3aR,6R,6aR)-6-(benzylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-benzylcarbamate
DMFVN71 DE Discovery agent
DMNSTKD ID DMNSTKD
DMNSTKD DN Isosorbide-di-(butylcarbamate)
DMNSTKD HS Investigative
DMNSTKD SN Isosorbide-di-(butylcarbamate); CHEMBL606050
DMNSTKD DT Small molecular drug
DMNSTKD PC 46232686
DMNSTKD MW 344.4
DMNSTKD FM C16H28N2O6
DMNSTKD IC InChI=1S/C16H28N2O6/c1-3-5-7-17-15(19)23-11-9-21-14-12(10-22-13(11)14)24-16(20)18-8-6-4-2/h11-14H,3-10H2,1-2H3,(H,17,19)(H,18,20)/t11-,12+,13-,14-/m1/s1
DMNSTKD CS CCCCNC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCCCC
DMNSTKD IK KFJGIBINELGQIA-XJFOESAGSA-N
DMNSTKD IU [(3S,3aR,6R,6aR)-6-(butylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-butylcarbamate
DMNSTKD DE Discovery agent
DMTHWXO ID DMTHWXO
DMTHWXO DN Isosorbide-di-(ethylcarbamate)
DMTHWXO HS Investigative
DMTHWXO SN Isosorbide-di-(ethylcarbamate); CHEMBL600621; BDBM50306694
DMTHWXO DT Small molecular drug
DMTHWXO PC 46232684
DMTHWXO MW 288.3
DMTHWXO FM C12H20N2O6
DMTHWXO IC InChI=1S/C12H20N2O6/c1-3-13-11(15)19-7-5-17-10-8(6-18-9(7)10)20-12(16)14-4-2/h7-10H,3-6H2,1-2H3,(H,13,15)(H,14,16)/t7-,8+,9-,10-/m1/s1
DMTHWXO CS CCNC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCC
DMTHWXO IK IMAKVWCOCNQBSI-UTINFBMNSA-N
DMTHWXO IU [(3S,3aR,6R,6aR)-6-(ethylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-ethylcarbamate
DMTHWXO DE Discovery agent
DMV1GLP ID DMV1GLP
DMV1GLP DN Isosorbide-di-(propylcarbamate)
DMV1GLP HS Investigative
DMV1GLP SN Isosorbide-di-(propylcarbamate); CHEMBL600622
DMV1GLP DT Small molecular drug
DMV1GLP PC 46232685
DMV1GLP MW 316.35
DMV1GLP FM C14H24N2O6
DMV1GLP IC InChI=1S/C14H24N2O6/c1-3-5-15-13(17)21-9-7-19-12-10(8-20-11(9)12)22-14(18)16-6-4-2/h9-12H,3-8H2,1-2H3,(H,15,17)(H,16,18)/t9-,10+,11-,12-/m1/s1
DMV1GLP CS CCCNC(=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC(=O)NCCC
DMV1GLP IK FHZOSQQIPPAAMJ-WRWGMCAJSA-N
DMV1GLP IU [(3S,3aR,6R,6aR)-6-(propylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-propylcarbamate
DMV1GLP DE Discovery agent
DMT1ZGM ID DMT1ZGM
DMT1ZGM DN Isosorbide-di-phenylcarbamate
DMT1ZGM HS Investigative
DMT1ZGM SN Isosorbide-di-phenylcarbamate
DMT1ZGM DT Small molecular drug
DMT1ZGM PC 46232722
DMT1ZGM MW 384.4
DMT1ZGM FM C20H20N2O6
DMT1ZGM IC InChI=1S/C20H20N2O6/c23-19(21-13-7-3-1-4-8-13)27-15-11-25-18-16(12-26-17(15)18)28-20(24)22-14-9-5-2-6-10-14/h1-10,15-18H,11-12H2,(H,21,23)(H,22,24)/t15-,16+,17-,18-/m1/s1
DMT1ZGM CS C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)OC(=O)NC3=CC=CC=C3)OC(=O)NC4=CC=CC=C4
DMT1ZGM IK KDDHNJSIHIMRGH-XMTFNYHQSA-N
DMT1ZGM IU [(3S,3aR,6R,6aR)-6-(phenylcarbamoyloxy)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] N-phenylcarbamate
DMT1ZGM DE Discovery agent
DM21K0E ID DM21K0E
DM21K0E DN ISOTETRANDRINE
DM21K0E HS Investigative
DM21K0E SN O-Methylberbamine; O,O'-Dimethylobamegine; Isosinomenine A; NSC 97338; O,O'-Dimethylstepholine; Isosinomenin A; CHEBI:80898; 1-ISOTETRANDRINE; 6,6',7,12-Tetramethoxy-2,2'-dimethylberbaman; Hanfangchin A; CCRIS 6540; 6,6& ,7,12-Tetramethoxy-2,2& C38H42N2O6; (+)-Isotetrandrine; tetramethoxy(dimethyl)[ ]; Phaeanthin; O,O-Dimethylobamegine; O,O-Dimethylstepholine; AC1L1KBN; AC1Q58ES; (1.beta.)-6,6',7,12-Tetramethoxy-2,2'-dimethylberbaman; SCHEMBL209832; CHEMBL367260; WVTKBKWTSCPRNU-UHFFFAOYSA-N
DM21K0E DT Small molecular drug
DM21K0E PC 457825
DM21K0E MW 622.7
DM21K0E FM C38H42N2O6
DM21K0E IC InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30+/m0/s1
DM21K0E CS CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC
DM21K0E IK WVTKBKWTSCPRNU-XZWHSSHBSA-N
DM21K0E IU (1S,14R)-9,20,21,25-tetramethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene
DM21K0E CA CAS 477-57-6
DM21K0E DE Discovery agent
DMKTBEH ID DMKTBEH
DMKTBEH DN ISOTHIAZOLIDINONE ANALOG
DMKTBEH HS Investigative
DMKTBEH SN ISOTHIAZOLIDINONE ANALOG; CHEMBL382311; IZD; (2S)-N-[(1S)-1-carbamoyl-2-{4-[(5S)-1,1,3-trioxo-1$l^{6},2-thiazolidin-5-yl]phenyl}ethyl]-2-acetamido-3-phenylpropanamide; Saturated (S)-IZD; 2cm7; IZD 8; BDBM13465; Isothiazolidinone (IZD) deriv. 6; DB08003
DMKTBEH DT Small molecular drug
DMKTBEH PC 9547915
DMKTBEH MW 486.5
DMKTBEH FM C23H26N4O6S
DMKTBEH IC InChI=1S/C23H26N4O6S/c1-14(28)25-19(12-15-5-3-2-4-6-15)23(31)26-18(22(24)30)11-16-7-9-17(10-8-16)20-13-21(29)27-34(20,32)33/h2-10,18-20H,11-13H2,1H3,(H2,24,30)(H,25,28)(H,26,31)(H,27,29)/t18-,19-,20-/m0/s1
DMKTBEH CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)[C@@H]3CC(=O)NS3(=O)=O)C(=O)N
DMKTBEH IK UILYPHAKDBTKQV-UFYCRDLUSA-N
DMKTBEH IU (2S)-2-acetamido-N-[(2S)-1-amino-1-oxo-3-[4-[(5S)-1,1,3-trioxo-1,2-thiazolidin-5-yl]phenyl]propan-2-yl]-3-phenylpropanamide
DMKTBEH DE Discovery agent
DMAYOTF ID DMAYOTF
DMAYOTF DN isothiourea-1a
DMAYOTF HS Investigative
DMAYOTF SN IT1a
DMAYOTF DT Small molecular drug
DMAYOTF PC 11176403
DMAYOTF MW 378.6
DMAYOTF FM C19H30N4S2
DMAYOTF IC InChI=1S/C19H30N4S2/c1-3-7-15(8-4-1)21-18(22-16-9-5-2-6-10-16)24-13-17-14-25-19-20-11-12-23(17)19/h14-16H,1-13H2,(H,21,22)
DMAYOTF CS C1CCC(CC1)NC(=NC2CCCCC2)SCC3=CSC4=NCCN34
DMAYOTF IK ZEZPDHKACVMMCD-UHFFFAOYSA-N
DMAYOTF IU 5,6-dihydroimidazo[2,1-b][1,3]thiazol-3-ylmethyl N,N'-dicyclohexylcarbamimidothioate
DMAYOTF DE Discovery agent
DMBX4WR ID DMBX4WR
DMBX4WR DN isothiourea-1t
DMBX4WR HS Investigative
DMBX4WR SN IT1t
DMBX4WR DT Small molecular drug
DMBX4WR PC 25147749
DMBX4WR MW 406.7
DMBX4WR FM C21H34N4S2
DMBX4WR IC InChI=1S/C21H34N4S2/c1-21(2)15-25-18(14-27-20(25)24-21)13-26-19(22-16-9-5-3-6-10-16)23-17-11-7-4-8-12-17/h14,16-17H,3-13,15H2,1-2H3,(H,22,23)
DMBX4WR CS CC1(CN2C(=CSC2=N1)CSC(=NC3CCCCC3)NC4CCCCC4)C
DMBX4WR IK OOSUDWRRWZVFEB-UHFFFAOYSA-N
DMBX4WR IU (6,6-dimethyl-5H-imidazo[2,1-b][1,3]thiazol-3-yl)methyl N,N'-dicyclohexylcarbamimidothioate
DMBX4WR DE Discovery agent
DMNL0BK ID DMNL0BK
DMNL0BK DN IsoVa-RYYRIK-NH2
DMNL0BK HS Investigative
DMNL0BK SN CHEMBL404530
DMNL0BK DT Small molecular drug
DMNL0BK PC 44456028
DMNL0BK MW 965.2
DMNL0BK FM C47H76N14O8
DMNL0BK IC InChI=1S/C47H76N14O8/c1-5-29(4)39(45(69)57-33(40(49)64)15-9-10-22-48)61-42(66)35(17-12-24-55-47(52)53)58-43(67)37(27-31-18-20-32(62)21-19-31)60-44(68)36(26-30-13-7-6-8-14-30)59-41(65)34(16-11-23-54-46(50)51)56-38(63)25-28(2)3/h6-8,13-14,18-21,28-29,33-37,39,62H,5,9-12,15-17,22-27,48H2,1-4H3,(H2,49,64)(H,56,63)(H,57,69)(H,58,67)(H,59,65)(H,60,68)(H,61,66)(H4,50,51,54)(H4,52,53,55)/t29-,33-,34-,35-,36-,37-,39-/m0/s1
DMNL0BK CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC(C)C
DMNL0BK IK WYGLGBXUEUHKTI-INYUMPDKSA-N
DMNL0BK IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(3-methylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMNL0BK DE Discovery agent
DMTRGAP ID DMTRGAP
DMTRGAP DN isovelleral
DMTRGAP HS Investigative
DMTRGAP SN iso-velleral; (+)-isovelleral
DMTRGAP DT Small molecular drug
DMTRGAP PC 37839
DMTRGAP MW 232.32
DMTRGAP FM C15H20O2
DMTRGAP IC InChI=1S/C15H20O2/c1-13(2)5-10-4-11(7-16)15(9-17)8-14(15,3)12(10)6-13/h4,7,9-10,12H,5-6,8H2,1-3H3/t10-,12+,14-,15-/m1/s1
DMTRGAP CS C[C@]12C[C@]1(C(=C[C@H]3[C@@H]2CC(C3)(C)C)C=O)C=O
DMTRGAP IK PJAAESPGJOSQGZ-DZGBDDFRSA-N
DMTRGAP IU (1aS,3aS,6aS,6bR)-5,5,6b-trimethyl-3a,4,6,6a-tetrahydro-1H-cyclopropa[e]indene-1a,2-dicarbaldehyde
DMTRGAP CA CAS 37841-91-1
DMTRGAP CB CHEBI:6070
DMTRGAP DE Discovery agent
DMXAD8E ID DMXAD8E
DMXAD8E DN Isoxazol
DMXAD8E HS Investigative
DMXAD8E SN Isoxazol; C23H33NO2; Azastenum [INN-Latin]; Azasteno [INN-Spanish]; WIN 17625; AC1L19IF; 4,4,17-Trimethylandrosta-2,5-dieno(2,3-d)isoxazol-17beta-ol; 4,4,17-alpha-Trimethylandrost-5-eno(2,3-d)isoxazol-17-ol; 17beta-Hydroxy-4,4,17alpha-trimethylandrost-5-en-(2,3d)-isoxazole; (17beta)-4,4,17-Trimethylandrosta-2,5-diene(3,2-d)isoxazol-17-ol; Androsta-2,5-dieno(2,3-d)isoxazol-17-ol, 4,4,17-trimethyl-, (17beta)-; Win 17,625; LS-19331; ANDROSTA-2,5-DIENO(2,3-d)ISOXAZOL-17-beta-OL, 4,4,17-TRIMETHYL-; (17 beta)-4,4,17-trimethyla
DMXAD8E DT Small molecular drug
DMXAD8E PC 25676
DMXAD8E MW 355.5
DMXAD8E FM C23H33NO2
DMXAD8E IC InChI=1S/C23H33NO2/c1-20(2)18-7-6-15-16(21(18,3)12-14-13-24-26-19(14)20)8-10-22(4)17(15)9-11-23(22,5)25/h7,13,15-17,25H,6,8-12H2,1-5H3/t15?,16-,17-,21?,22?,23-/m0/s1
DMXAD8E CS C[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CC=C4C3(CC5=C(C4(C)C)ON=C5)C)C)O
DMXAD8E IK AXLOCHLTNQDFFS-BELXDXCXSA-N
DMXAD8E IU (1S,14S,17S)-2,9,9,17,18-pentamethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,10-trien-17-ol
DMXAD8E DE Discovery agent
DMAFC3R ID DMAFC3R
DMAFC3R DN isoxazole azepine compound 3
DMAFC3R HS Investigative
DMAFC3R DT Small molecular drug
DMAFC3R PC 57345400
DMAFC3R MW 399.9
DMAFC3R FM C20H18ClN3O2S
DMAFC3R IC InChI=1S/C20H18ClN3O2S/c1-9-11(3)27-20-16(9)18(12-4-6-13(21)7-5-12)23-14(8-15(22)25)19-17(20)10(2)24-26-19/h4-7,14H,8H2,1-3H3,(H2,22,25)/t14-/m0/s1
DMAFC3R CS CC1=C(SC2=C1C(=N[C@H](C3=C2C(=NO3)C)CC(=O)N)C4=CC=C(C=C4)Cl)C
DMAFC3R IK DRSQZZRFHBWKKZ-AWEZNQCLSA-N
DMAFC3R IU 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-11-oxa-3-thia-8,12-diazatricyclo[8.3.0.02,6]trideca-1(10),2(6),4,7,12-pentaen-9-yl]acetamide
DMAFC3R DE Discovery agent
DMPZURH ID DMPZURH
DMPZURH DN Isoxazolecarboxylic acid
DMPZURH HS Investigative
DMPZURH SN CHEMBL133541; SCHEMBL5619846; SCHEMBL5619857; UBNWPQXLFRMMEI-GQCTYLIASA-N; BDBM50133280; isochroman-3-(S)-carboxylic acid methylester; 5-{3-[3-(3-Hydroxy-2-methoxycarbonyl-phenoxy)-propenyl]-phenyl}-isoxazole-3-carboxylic acid; 5-(3-((1e)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid; 5-(3-(3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid
DMPZURH DT Small molecular drug
DMPZURH PC 11286453
DMPZURH MW 113.07
DMPZURH FM C4H3NO3
DMPZURH IC InChI=1S/C4H3NO3/c6-4(7)3-1-2-8-5-3/h1-2H,(H,6,7)
DMPZURH CS C1=CON=C1C(=O)O
DMPZURH IK UXYRXGFUANQKTA-UHFFFAOYSA-N
DMPZURH IU 1,2-oxazole-3-carboxylic acid
DMPZURH CA CAS 3209-71-0
DMPZURH DE Discovery agent
DMA8F4N ID DMA8F4N
DMA8F4N DN ITdU
DMA8F4N HS Investigative
DMA8F4N SN 3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-
DMA8F4N DT Small molecular drug
DMA8F4N PC 76
DMA8F4N MW 288.4
DMA8F4N FM C19H28O2
DMA8F4N IC InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3
DMA8F4N CS CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C
DMA8F4N IK FMGSKLZLMKYGDP-UHFFFAOYSA-N
DMA8F4N IU 3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
DMA8F4N CB CHEBI:95212
DMA8F4N DE Discovery agent
DMVFITX ID DMVFITX
DMVFITX DN ITP
DMVFITX HS Investigative
DMVFITX SN inosine triphosphate
DMVFITX DT Small molecular drug
DMVFITX PC 135398643
DMVFITX MW 508.17
DMVFITX FM C10H15N4O14P3
DMVFITX IC InChI=1S/C10H15N4O14P3/c15-6-4(1-25-30(21,22)28-31(23,24)27-29(18,19)20)26-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,21,22)(H,23,24)(H,11,12,17)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
DMVFITX CS C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMVFITX IK HAEJPQIATWHALX-KQYNXXCUSA-N
DMVFITX IU [[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMVFITX CA CAS 132-06-9
DMVFITX CB CHEBI:16039
DMVFITX DE Discovery agent
DMWTDS8 ID DMWTDS8
DMWTDS8 DN ITRI-305
DMWTDS8 HS Investigative
DMWTDS8 SN RET tyrosine kinase inhibitors, Industrial Technology Research Institute
DMWTDS8 CP Industrial Technology Research Institute
DMWTDS8 DE Thyroid cancer
DMFMYIH ID DMFMYIH
DMFMYIH DN Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2
DMFMYIH HS Investigative
DMFMYIH PC 44295289
DMFMYIH MW 1077.3
DMFMYIH FM C57H80N12O9
DMFMYIH IC InChI=1S/C57H80N12O9/c1-35(2)23-44(53(74)66-43(52(58)73)26-38-17-10-6-11-18-38)63-51(72)30-49(70)42(25-37-15-8-5-9-16-37)65-55(76)46(28-40-31-59-33-61-40)67-54(75)45(27-39-19-12-7-13-20-39)68-56(77)48-21-14-22-69(48)57(78)47(29-41-32-60-34-62-41)64-50(71)24-36(3)4/h6-7,10-13,17-20,31-37,42-49,70H,5,8-9,14-16,21-30H2,1-4H3,(H2,58,73)(H,59,61)(H,60,62)(H,63,72)(H,64,71)(H,65,76)(H,66,74)(H,67,75)(H,68,77)
DMFMYIH CS CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)N)NC(=O)CC(C(CC2CCCCC2)NC(=O)C(CC3=CN=CN3)NC(=O)C(CC4=CC=CC=C4)NC(=O)C5CCCN5C(=O)C(CC6=CN=CN6)NC(=O)CC(C)C)O
DMFMYIH IK ZOAVSRHEYNKAIW-UHFFFAOYSA-N
DMFMYIH IU N-[1-[[1-[[5-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-1-cyclohexyl-3-hydroxy-5-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[3-(1H-imidazol-5-yl)-2-(3-methylbutanoylamino)propanoyl]pyrrolidine-2-carboxamide
DMFMYIH DE Discovery agent
DMZTIU3 ID DMZTIU3
DMZTIU3 DN Iva-His-Pro-Phe-His-AHPPA-Leu-Phe-NH2
DMZTIU3 HS Investigative
DMZTIU3 PC 44295266
DMZTIU3 MW 1071.3
DMZTIU3 FM C57H74N12O9
DMZTIU3 IC InChI=1S/C57H74N12O9/c1-35(2)23-44(53(74)66-43(52(58)73)26-38-17-10-6-11-18-38)63-51(72)30-49(70)42(25-37-15-8-5-9-16-37)65-55(76)46(28-40-31-59-33-61-40)67-54(75)45(27-39-19-12-7-13-20-39)68-56(77)48-21-14-22-69(48)57(78)47(29-41-32-60-34-62-41)64-50(71)24-36(3)4/h5-13,15-20,31-36,42-49,70H,14,21-30H2,1-4H3,(H2,58,73)(H,59,61)(H,60,62)(H,63,72)(H,64,71)(H,65,76)(H,66,74)(H,67,75)(H,68,77)
DMZTIU3 CS CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)N)NC(=O)CC(C(CC2=CC=CC=C2)NC(=O)C(CC3=CN=CN3)NC(=O)C(CC4=CC=CC=C4)NC(=O)C5CCCN5C(=O)C(CC6=CN=CN6)NC(=O)CC(C)C)O
DMZTIU3 IK OXZWHUWYDVRMCP-UHFFFAOYSA-N
DMZTIU3 IU N-[1-[[1-[[5-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-5-oxo-1-phenylpentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-1-[3-(1H-imidazol-5-yl)-2-(3-methylbutanoylamino)propanoyl]pyrrolidine-2-carboxamide
DMZTIU3 DE Discovery agent
DM92QIW ID DM92QIW
DM92QIW DN Iva-His-Pro-Phe-His-Sta-Leu-Phe-NH2
DM92QIW HS Investigative
DM92QIW DT Peptide
DM92QIW PC 44297826
DM92QIW MW 1052.3
DM92QIW FM C54H77N13O9
DM92QIW IC InChI=1S/C54H77N13O9/c1-7-54(6,56)53(76)66-43(26-37-29-58-31-60-37)52(75)67-20-14-19-44(67)51(74)65-41(24-35-17-12-9-13-18-35)49(72)64-42(25-36-28-57-30-59-36)50(73)62-38(21-32(2)3)45(68)27-46(69)61-40(22-33(4)5)48(71)63-39(47(55)70)23-34-15-10-8-11-16-34/h8-13,15-18,28-33,38-45,68H,7,14,19-27,56H2,1-6H3,(H2,55,70)(H,57,59)(H,58,60)(H,61,69)(H,62,73)(H,63,71)(H,64,72)(H,65,74)(H,66,76)/t38?,39-,40-,41-,42-,43-,44-,45?,54-/m0/s1
DM92QIW CS CC[C@@](C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CN=CN4)C(=O)NC(CC(C)C)C(CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)O)N
DM92QIW IK YLFGKFNAVPVWDW-AJEFLBOZSA-N
DM92QIW IU (2S)-1-[(2S)-2-[[(2S)-2-amino-2-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]-N-[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM92QIW DE Discovery agent
DMBTWF0 ID DMBTWF0
DMBTWF0 DN IW-1221
DMBTWF0 HS Investigative
DMBTWF0 SN CRTH2 inhibitor (asthma), Ironwood
DMBTWF0 CP Ironwood Pharmaceuticals Inc
DMBTWF0 DE Asthma
DMQSB6N ID DMQSB6N
DMQSB6N DN J-009747
DMQSB6N HS Investigative
DMQSB6N SN LMFA06000016; LS-75538; RT-005620; S14-1394; SCHEMBL1269927; SR-01000946533; (E)-4-HYDROXYHEXENAL; (E)-4-Hydroxy-2-hexenal; (E)-4-hydroxy-hex-2-enal; 4-Hydroxy-2-hexenal; JYTUBIHWMKQZRB-ONEGZZNKSA-N; (E)-4-hydroxyhex-2-enal; 1086AH; 160708-91-8; 17427-08-6; 17427-21-3; 2-HEXENAL, 4-HYDROXY-; 2-Hexenal, 4-hydroxy-, (2E)-; 2-Hexenal, 4-hydroxy-, (E)-; 4-Hydroxyhexenal; 4-hydroxy-2E-hexenal; AC1NR205; AKOS006273451; CCRIS 9201; HMS3648N12
DMQSB6N PC 5283314
DMQSB6N MW 114.14
DMQSB6N FM C6H10O2
DMQSB6N IC JYTUBIHWMKQZRB-ONEGZZNKSA-N
DMQSB6N CS CCC(C=CC=O)O
DMQSB6N IK 1S/C6H10O2/c1-2-6(8)4-3-5-7/h3-6,8H,2H2,1H3/b4-3+
DMQSB6N IU (E)-4-hydroxyhex-2-enal
DMQSB6N CA CAS 17427-08-6
DMQSB6N DE Discovery agent
DMQ8J3M ID DMQ8J3M
DMQ8J3M DN J-104118
DMQ8J3M HS Investigative
DMQ8J3M SN J 104118
DMQ8J3M DT Small molecular drug
DMQ8J3M PC 10460101
DMQ8J3M MW 546.4
DMQ8J3M FM C28H26Cl2FNO5
DMQ8J3M IC InChI=1S/C28H26Cl2FNO5/c1-16(32-26(33)14-20(28(36)37)15-27(34)35)22(11-17-7-10-23(29)24(30)12-17)19-8-9-21(25(31)13-19)18-5-3-2-4-6-18/h2-10,12-13,16,20,22H,11,14-15H2,1H3,(H,32,33)(H,34,35)(H,36,37)/t16-,20-,22+/m0/s1
DMQ8J3M CS C[C@@H]([C@@H](CC1=CC(=C(C=C1)Cl)Cl)C2=CC(=C(C=C2)C3=CC=CC=C3)F)NC(=O)C[C@@H](CC(=O)O)C(=O)O
DMQ8J3M IK NBRLADMQSZWKGO-XUEUYAKLSA-N
DMQ8J3M IU (2S)-2-[2-[[(2S,3S)-4-(3,4-dichlorophenyl)-3-(3-fluoro-4-phenylphenyl)butan-2-yl]amino]-2-oxoethyl]butanedioic acid
DMQ8J3M DE Discovery agent
DMWF7RO ID DMWF7RO
DMWF7RO DN J-104123
DMWF7RO HS Investigative
DMWF7RO SN CHEMBL143820; J-104123; GTPL3110; SCHEMBL8623891; BDBM50288819; (R)-4-[(E)-(1S,2S)-2-(3,4-Dichloro-benzyl)-1-methyl-4-naphthalen-2-yl-but-3-enylcarbamoyl]-3-methyl-butyric acid; (3R)-4-{[(2S,3S,4E)-3-[(3,4-dichlorophenyl)methyl]-5-(naphthalen-2-yl)pent-4-en-2-yl]carbamoyl}-3-methylbutanoic acid
DMWF7RO DT Small molecular drug
DMWF7RO PC 9848748
DMWF7RO MW 498.4
DMWF7RO FM C28H29Cl2NO3
DMWF7RO IC InChI=1S/C28H29Cl2NO3/c1-18(14-28(33)34)13-27(32)31-19(2)23(16-21-9-12-25(29)26(30)17-21)11-8-20-7-10-22-5-3-4-6-24(22)15-20/h3-12,15,17-19,23H,13-14,16H2,1-2H3,(H,31,32)(H,33,34)/b11-8+/t18-,19+,23-/m1/s1
DMWF7RO CS C[C@H](CC(=O)N[C@@H](C)[C@@H](CC1=CC(=C(C=C1)Cl)Cl)/C=C/C2=CC3=CC=CC=C3C=C2)CC(=O)O
DMWF7RO IK LVRZMZFXRFKCCY-KSYFVSBMSA-N
DMWF7RO IU (3R)-5-[[(E,2S,3S)-3-[(3,4-dichlorophenyl)methyl]-5-naphthalen-2-ylpent-4-en-2-yl]amino]-3-methyl-5-oxopentanoic acid
DMWF7RO DE Discovery agent
DMAEQS9 ID DMAEQS9
DMAEQS9 DN J-104135
DMAEQS9 HS Investigative
DMAEQS9 SN UNII-6137X5QNJF; 6137X5QNJF; J-104871; J-104135; SCHEMBL15207668; SCHEMBL15207665; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-pentenyl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-((((1R,2R,4E)-2-(1,3-benzodioxol-5-yl)-5-(2-benzoxazolyl)-1-methyl-4-penten-1-yl)(2-naphthalenylmethyl)amino)carbonyl)-, (4R,5S)-; 191088-19-4; 1,3-Dioxolane-2,2,4-tricarboxylic acid, 5-(((2-(1,3-benzodioxol-5-yl)-5-(2-benzoxa
DMAEQS9 CP MSD Japan
DMAEQS9 DT Small molecular drug
DMAEQS9 PC 9962301
DMAEQS9 MW 708.7
DMAEQS9 FM C38H32N2O12
DMAEQS9 IC InChI=1S/C38H32N2O12/c1-21(26(25-15-16-29-30(18-25)49-20-48-29)9-6-12-31-39-27-10-4-5-11-28(27)50-31)40(19-22-13-14-23-7-2-3-8-24(23)17-22)34(41)32-33(35(42)43)52-38(51-32,36(44)45)37(46)47/h2-8,10-18,21,26,32-33H,9,19-20H2,1H3,(H,42,43)(H,44,45)(H,46,47)/b12-6+/t21-,26+,32+,33-/m1/s1
DMAEQS9 CS C[C@H]([C@H](C/C=C/C1=NC2=CC=CC=C2O1)C3=CC4=C(C=C3)OCO4)N(CC5=CC6=CC=CC=C6C=C5)C(=O)[C@@H]7[C@@H](OC(O7)(C(=O)O)C(=O)O)C(=O)O
DMAEQS9 IK CXDSZFRIMJUZKT-MRGWGSTCSA-N
DMAEQS9 IU (4R,5S)-5-[[(E,2R,3R)-3-(1,3-benzodioxol-5-yl)-6-(1,3-benzoxazol-2-yl)hex-5-en-2-yl]-(naphthalen-2-ylmethyl)carbamoyl]-1,3-dioxolane-2,2,4-tricarboxylic acid
DMAEQS9 CA CAS 191088-19-4
DMAEQS9 DE Chronic obstructive pulmonary disease
DMCS4BL ID DMCS4BL
DMCS4BL DN J-104870
DMCS4BL HS Investigative
DMCS4BL SN 145-13-1; 3-Hydroxypregn-5-en-20-one; 1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanon; 1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone; .DELTA.5-Pregnenolone; 5-Pregnene-3-ol-20-one; 5-Pregnen-3.beta.-ol-20-one; delta5-Pregnen-3beta-ol-20-one; Pregn-5-en-20-one, 3-hydroxy-; 3.beta.-Hydroxypregn-5-en-20-one; Pregn-5-en-20-one, 3.beta.-hydroxy-; AC1L1AKE; AC1Q1K1J; CHEMBL14116
DMCS4BL DT Small molecular drug
DMCS4BL PC 9807770
DMCS4BL MW 555.7
DMCS4BL FM C27H33N5O4S2
DMCS4BL IC InChI=1S/C27H33N5O4S2/c1-4-8-36-26(33)31-20-11-19(12-23(14-20)34-3)16-28-25-15-22(32-6-9-35-10-7-32)13-21(30-25)18-37-27-29-17-24(5-2)38-27/h4,11-15,17H,1,5-10,16,18H2,2-3H3,(H,28,30)(H,31,33)
DMCS4BL CS CCC1=CN=C(S1)SCC2=NC(=CC(=C2)N3CCOCC3)NCC4=CC(=CC(=C4)OC)NC(=O)OCC=C
DMCS4BL IK JNFARUXJNLDBCZ-UHFFFAOYSA-N
DMCS4BL IU prop-2-enyl N-[3-[[[6-[(5-ethyl-1,3-thiazol-2-yl)sulfanylmethyl]-4-morpholin-4-ylpyridin-2-yl]amino]methyl]-5-methoxyphenyl]carbamate
DMCS4BL DE Discovery agent
DM9SFGB ID DM9SFGB
DM9SFGB DN J-109,390
DM9SFGB HS Investigative
DM9SFGB DE Discovery agent
DMXC319 ID DMXC319
DMXC319 DN J591-Ac-225
DMXC319 HS Investigative
DMXC319 SN PSMA-targeting mAb and Ac-225 conjugate (metastatic prostate cancer), Actinium Pharmaceuticals
DMXC319 CP Actinium Pharmaceuticals Inc
DMXC319 DT Antibody
DMXC319 DE Prostate cancer
DMJAEMT ID DMJAEMT
DMJAEMT DN JASPAQUINOL
DMJAEMT HS Investigative
DMJAEMT SN jaspaquinol; Jasplaquinol; CHEMBL425166; SCHEMBL6833479; BDBM50240936
DMJAEMT DT Small molecular drug
DMJAEMT PC 10110469
DMJAEMT MW 382.6
DMJAEMT FM C26H38O2
DMJAEMT IC InChI=1S/C26H38O2/c1-19(11-13-22-18-23(27)14-16-25(22)28)8-6-9-20(2)12-15-24-21(3)10-7-17-26(24,4)5/h9,11,14,16,18,27-28H,6-8,10,12-13,15,17H2,1-5H3/b19-11+,20-9+
DMJAEMT CS CC1=C(C(CCC1)(C)C)CC/C(=C/CC/C(=C/CC2=C(C=CC(=C2)O)O)/C)/C
DMJAEMT IK KUTRNQZRJBENDY-ZQYJZOSASA-N
DMJAEMT IU 2-[(2E,6E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,6-dienyl]benzene-1,4-diol
DMJAEMT DE Discovery agent
DMOF0TB ID DMOF0TB
DMOF0TB DN Jaspic acid
DMOF0TB HS Investigative
DMOF0TB SN (-)-jaspic acid; jaspic acid; CHEMBL180947; (-)-Jaspic acid; BDBM50240937; 4-Hydroxy-3-[(1S,4aS,5R,8aS)-2,5,8a-trimethyl-5-(4-methyl-pent-3-enyl)-1,4,4a,5,6,7,8,8a-octahydro-naphthalen-1-ylmethyl]-benzoic acid
DMOF0TB DT Small molecular drug
DMOF0TB PC 10179787
DMOF0TB MW 410.6
DMOF0TB FM C27H38O3
DMOF0TB IC InChI=1S/C27H38O3/c1-18(2)8-6-13-26(4)14-7-15-27(5)22(19(3)9-12-24(26)27)17-21-16-20(25(29)30)10-11-23(21)28/h8-11,16,22,24,28H,6-7,12-15,17H2,1-5H3,(H,29,30)/t22-,24-,26-,27+/m0/s1
DMOF0TB CS CC1=CC[C@H]2[C@@](CCC[C@@]2([C@H]1CC3=C(C=CC(=C3)C(=O)O)O)C)(C)CCC=C(C)C
DMOF0TB IK IIMZFSAVKIVVHG-DAANFHMWSA-N
DMOF0TB IU 3-[[(1S,4aS,5R,8aS)-2,5,8a-trimethyl-5-(4-methylpent-3-enyl)-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl]-4-hydroxybenzoic acid
DMOF0TB DE Discovery agent
DMYFNW9 ID DMYFNW9
DMYFNW9 DN JATRORRHIZINE
DMYFNW9 HS Investigative
DMYFNW9 SN Jatrorrhizine; 3621-38-3; neprotin; jateorrhizine; Yatrorizine; UNII-091S1F8V5Q; CHEMBL251055; CHEBI:6087; GNF-PF-220; 7,8,13,13a-tetradehydro-3-hydroxy-2,9,10-trimethoxyberbinium; 091S1F8V5Q; 2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol; Dibenzo[a,g]quinolizinium, 5,6-dihydro-3-hydroxy-2,9,10-trimethoxy-; 3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium; 3-Hydroxy-2,9,10-trimethoxy-5,6-dihydroisoquinolino-[3,2-a]isoquinolin-7-ium; NSC645313; NSC150445; NSC209410
DMYFNW9 DT Small molecular drug
DMYFNW9 PC 72323
DMYFNW9 MW 338.4
DMYFNW9 FM C20H20NO4+
DMYFNW9 IC InChI=1S/C20H19NO4/c1-23-18-5-4-12-8-16-14-10-19(24-2)17(22)9-13(14)6-7-21(16)11-15(12)20(18)25-3/h4-5,8-11H,6-7H2,1-3H3/p+1
DMYFNW9 CS COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC
DMYFNW9 IK MXTLAHSTUOXGQF-UHFFFAOYSA-O
DMYFNW9 IU 2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol
DMYFNW9 CA CAS 3621-38-3
DMYFNW9 CB CHEBI:6087
DMYFNW9 DE Discovery agent
DMPRTVX ID DMPRTVX
DMPRTVX DN JB 98064
DMPRTVX HS Investigative
DMPRTVX SN JB-98064
DMPRTVX DT Small molecular drug
DMPRTVX PC 10810249
DMPRTVX MW 350.9
DMPRTVX FM C19H31ClN4
DMPRTVX IC InChI=1S/C19H31ClN4/c20-18-10-8-17(9-11-18)16-24(19(21)22)15-5-3-1-2-4-12-23-13-6-7-14-23/h8-11H,1-7,12-16H2,(H3,21,22)
DMPRTVX CS C1CCN(C1)CCCCCCCN(CC2=CC=C(C=C2)Cl)C(=N)N
DMPRTVX IK ZRIVDXCYPBUSKL-UHFFFAOYSA-N
DMPRTVX IU 1-[(4-chlorophenyl)methyl]-1-(7-pyrrolidin-1-ylheptyl)guanidine
DMPRTVX CA CAS 485812-42-8
DMPRTVX DE Discovery agent
DM38L1B ID DM38L1B
DM38L1B DN JB-1
DM38L1B HS Investigative
DM38L1B SN JB1
DM38L1B CP Chiron
DM38L1B DT Small molecular drug
DM38L1B PC 25150849
DM38L1B MW 434.7
DM38L1B FM C28H50O3
DM38L1B IC InChI=1S/C28H50O3/c1-5-6-8-21(14-16-29)19(2)25-12-13-26-22(9-7-15-28(25,26)4)10-11-23-17-24(30)18-27(31)20(23)3/h19,21-22,24-27,29-31H,5-18H2,1-4H3/t19-,21+,22?,24-,25-,26+,27+,28-/m1/s1
DM38L1B CS CCCC[C@@H](CCO)[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CCCC2CCC3=C([C@H](C[C@@H](C3)O)O)C)C
DM38L1B IK DHZOGFADXFKXSH-PMMQCNKASA-N
DM38L1B IU (1R,3S)-5-[2-[(1R,3aS,7aS)-1-[(2R,3S)-3-(2-hydroxyethyl)heptan-2-yl]-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-4-yl]ethyl]-4-methylcyclohex-4-ene-1,3-diol
DM38L1B DE Multiple myeloma
DM0KMPN ID DM0KMPN
DM0KMPN DN JBP-1
DM0KMPN HS Investigative
DM0KMPN SN Trypsinogen/chymotrypsinogen/amylase (metastatic cancer), Propanc
DM0KMPN CP Propanc Pty Ltd
DM0KMPN DE Solid tumour/cancer
DMYF7AE ID DMYF7AE
DMYF7AE DN JCF 109
DMYF7AE HS Investigative
DMYF7AE SN JCF109; JCF-109
DMYF7AE DT Small molecular drug
DMYF7AE PC 73755001
DMYF7AE MW 453.6
DMYF7AE FM C24H27N3O4S
DMYF7AE IC InChI=1S/C24H27N3O4S/c28-27(29)23-7-3-4-8-24(23)32(30,31)26-17-19-11-9-18(10-12-19)16-25-22-14-13-20-5-1-2-6-21(20)15-22/h1-8,13-15,18-19,25-26H,9-12,16-17H2
DMYF7AE CS C1CC(CCC1CNC2=CC3=CC=CC=C3C=C2)CNS(=O)(=O)C4=CC=CC=C4[N+](=O)[O-]
DMYF7AE IK BPBPTEVVRMSHTB-UHFFFAOYSA-N
DMYF7AE IU N-[[4-[(naphthalen-2-ylamino)methyl]cyclohexyl]methyl]-2-nitrobenzenesulfonamide
DMYF7AE DE Discovery agent
DMLBX3Q ID DMLBX3Q
DMLBX3Q DN JD-0100
DMLBX3Q HS Investigative
DMLBX3Q SN JD-0100 series; JD-0200 series; JD-0300 series; Monoamine oxidase-B inhibitors (obesity); Monoamine oxidase-B inhibitors (obesity), Jenrin Discovery
DMLBX3Q CP Jenrin Discovery Inc
DMLBX3Q DE Obesity
DMQP4VG ID DMQP4VG
DMQP4VG DN JG-365
DMQP4VG HS Investigative
DMQP4VG SN (S)-JG-365; 127231-42-9; 132748-20-0
DMQP4VG DT Small molecular drug
DMQP4VG PC 131549
DMQP4VG MW 861
DMQP4VG FM C42H68N8O11
DMQP4VG IC InChI=1S/C42H68N8O11/c1-9-25(6)36(41(59)48-35(24(4)5)42(60)61-8)49-40(58)32-16-13-17-50(32)21-33(53)28(19-27-14-11-10-12-15-27)45-38(56)30(20-34(43)54)47-37(55)29(18-23(2)3)46-39(57)31(22-51)44-26(7)52/h10-12,14-15,23-25,28-33,35-36,51,53H,9,13,16-22H2,1-8H3,(H2,43,54)(H,44,52)(H,45,56)(H,46,57)(H,47,55)(H,48,59)(H,49,58)/t25-,28?,29-,30-,31-,32-,33?,35-,36-/m0/s1
DMQP4VG CS CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)OC)NC(=O)[C@@H]1CCCN1CC(C(CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)C)O
DMQP4VG IK MJOXWVYKMFPFPL-AIVXTZMUSA-N
DMQP4VG IU methyl (2S)-2-[[(2S,3S)-2-[[(2S)-1-[3-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-2-hydroxy-4-phenylbutyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoate
DMQP4VG CA CAS 132748-20-0
DMQP4VG DE Discovery agent
DM0LD3F ID DM0LD3F
DM0LD3F DN JL-18
DM0LD3F HS Investigative
DM0LD3F SN NCGC00094013-01
DM0LD3F DT Small molecular drug
DM0LD3F PC 3802
DM0LD3F MW 307.4
DM0LD3F FM C18H21N5
DM0LD3F IC InChI=1S/C18H21N5/c1-13-5-6-15-14(12-13)18(23-10-8-22(2)9-11-23)21-16-4-3-7-19-17(16)20-15/h3-7,12H,8-11H2,1-2H3,(H,19,20)
DM0LD3F CS CC1=CC2=C(C=C1)NC3=C(C=CC=N3)N=C2N4CCN(CC4)C
DM0LD3F IK MMCMKWDIEUZMQB-UHFFFAOYSA-N
DM0LD3F IU 8-methyl-6-(4-methylpiperazin-1-yl)-11H-pyrido[2,3-b][1,4]benzodiazepine
DM0LD3F CA CAS 147395-65-1
DM0LD3F DE Discovery agent
DMWMRO2 ID DMWMRO2
DMWMRO2 DN JM-1232(-)
DMWMRO2 HS Investigative
DMWMRO2 SN Sedative, Maruishi; Benzodiazepine agonist (sedation), Maruishi
DMWMRO2 CP Maruishi Pharmaceutical Co Ltd
DMWMRO2 PC 17755150
DMWMRO2 MW 389.5
DMWMRO2 FM C24H27N3O2
DMWMRO2 IC InChI=1S/C24H27N3O2/c1-25-10-12-26(13-11-25)23(28)16-22-20-14-17-6-5-7-18(17)15-21(20)24(29)27(22)19-8-3-2-4-9-19/h2-4,8-9,14-15,22H,5-7,10-13,16H2,1H3/t22-/m1/s1
DMWMRO2 CS CN1CCN(CC1)C(=O)C[C@@H]2C3=C(C=C4CCCC4=C3)C(=O)N2C5=CC=CC=C5
DMWMRO2 IK MBGOHVUPIPFVMM-JOCHJYFZSA-N
DMWMRO2 IU (3R)-3-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-2-phenyl-3,5,6,7-tetrahydrocyclopenta[f]isoindol-1-one
DMWMRO2 CA CAS 1013427-48-9
DMWMRO2 DE Anaesthesia
DMP1B9D ID DMP1B9D
DMP1B9D DN JMV 1535
DMP1B9D HS Investigative
DMP1B9D SN JMV 1535; CHEMBL437655
DMP1B9D PC 44315745
DMP1B9D MW 1081.3
DMP1B9D FM C54H76N14O10
DMP1B9D IC InChI=1S/C54H76N14O10/c1-30(2)21-41(47(57)71)65-52(76)42(22-31(3)4)66-53(77)44(25-35-27-58-29-60-35)62-46(70)28-68-20-12-11-17-40(54(68)78)64-48(72)32(5)61-51(75)43(24-34-26-59-38-16-10-9-15-36(34)38)67-50(74)39(18-19-45(56)69)63-49(73)37(55)23-33-13-7-6-8-14-33/h6-10,13-16,26-27,29-32,37,39-44,59H,11-12,17-25,28,55H2,1-5H3,(H2,56,69)(H2,57,71)(H,58,60)(H,61,75)(H,62,70)(H,63,73)(H,64,72)(H,65,76)(H,66,77)(H,67,74)/t32?,37-,39?,40?,41?,42?,43?,44?/m1/s1
DMP1B9D CS CC(C)CC(C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMP1B9D IK FTAPYHDWDYGKIH-CJGWHWQJSA-N
DMP1B9D IU N-[1-[[1-[[1-[2-[[1-[[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]pentanediamide
DMP1B9D DE Discovery agent
DMARTN3 ID DMARTN3
DMARTN3 DN JMV 1693
DMARTN3 HS Investigative
DMARTN3 SN JMV 1693; CHEMBL407022
DMARTN3 DT Small molecular drug
DMARTN3 PC 44315690
DMARTN3 MW 984.1
DMARTN3 FM C48H65N13O10
DMARTN3 IC InChI=1S/C48H65N13O10/c1-27(2)19-37(47(69)60-71)58-46(68)39(22-31-24-51-26-53-31)55-41(63)25-61-18-10-9-15-36(48(61)70)57-42(64)28(3)54-45(67)38(21-30-23-52-34-14-8-7-13-32(30)34)59-44(66)35(16-17-40(50)62)56-43(65)33(49)20-29-11-5-4-6-12-29/h4-8,11-14,23-24,26-28,33,35-39,52,71H,9-10,15-22,25,49H2,1-3H3,(H2,50,62)(H,51,53)(H,54,67)(H,55,63)(H,56,65)(H,57,64)(H,58,68)(H,59,66)(H,60,69)/t28?,33-,35?,36?,37-,38?,39?/m1/s1
DMARTN3 CS CC(C)C[C@H](C(=O)NO)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMARTN3 IK FARKOIUETYEQIK-DBJXSMFVSA-N
DMARTN3 IU 2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-N-[1-[[1-[[1-[2-[[1-[[(2R)-1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMARTN3 DE Discovery agent
DM82HW9 ID DM82HW9
DM82HW9 DN JMV 1719
DM82HW9 HS Investigative
DM82HW9 SN JMV 1719; CHEMBL406013
DM82HW9 DT Small molecular drug
DM82HW9 PC 44315688
DM82HW9 MW 985.1
DM82HW9 FM C48H64N12O11
DM82HW9 IC InChI=1S/C48H64N12O11/c1-27(2)20-37(47(69)59-71)57-46(68)39(22-31-24-50-26-52-31)55-42(64)25-60-19-7-6-10-36(48(60)70)56-43(65)28(3)53-45(67)38(21-30-23-51-34-9-5-4-8-33(30)34)58-44(66)35(16-17-40(49)62)54-41(63)18-13-29-11-14-32(61)15-12-29/h4-5,8-9,11-12,14-15,23-24,26-28,35-39,51,61,71H,6-7,10,13,16-22,25H2,1-3H3,(H2,49,62)(H,50,52)(H,53,67)(H,54,63)(H,55,64)(H,56,65)(H,57,68)(H,58,66)(H,59,69)/t28?,35?,36?,37-,38?,39?/m1/s1
DM82HW9 CS CC(C)C[C@H](C(=O)NO)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O
DM82HW9 IK SVDHLNPEHKDLER-PGRJMBAQSA-N
DM82HW9 IU N-[1-[[1-[[1-[2-[[1-[[(2R)-1-(hydroxyamino)-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[3-(4-hydroxyphenyl)propanoylamino]pentanediamide
DM82HW9 DE Discovery agent
DMX3P68 ID DMX3P68
DMX3P68 DN JMV 1799
DMX3P68 HS Investigative
DMX3P68 SN JMV 1799; CHEMBL415110
DMX3P68 DT Small molecular drug
DMX3P68 PC 44315612
DMX3P68 MW 984.1
DMX3P68 FM C49H65N11O11
DMX3P68 IC InChI=1S/C49H65N11O11/c1-28(2)21-40(49(70)71-4)59-47(68)39(23-32-25-51-27-53-32)56-43(64)26-60-20-8-7-11-37(48(60)69)57-44(65)29(3)54-46(67)38(22-31-24-52-35-10-6-5-9-34(31)35)58-45(66)36(17-18-41(50)62)55-42(63)19-14-30-12-15-33(61)16-13-30/h5-6,9-10,12-13,15-16,24-25,27-29,36-40,52,61H,7-8,11,14,17-23,26H2,1-4H3,(H2,50,62)(H,51,53)(H,54,67)(H,55,63)(H,56,64)(H,57,65)(H,58,66)(H,59,68)
DMX3P68 CS CC(C)CC(C(=O)OC)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O
DMX3P68 IK SVPHNBMMYLAPKY-UHFFFAOYSA-N
DMX3P68 IU methyl 2-[[2-[[2-[3-[2-[[2-[[5-amino-2-[3-(4-hydroxyphenyl)propanoylamino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-2-oxoazepan-1-yl]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoate
DMX3P68 DE Discovery agent
DMTX694 ID DMTX694
DMTX694 DN JMV 1801
DMTX694 HS Investigative
DMTX694 SN JMV 1801; CHEMBL411016
DMTX694 PC 44315611
DMTX694 MW 1011.2
DMTX694 FM C52H74N12O9
DMTX694 IC InChI=1S/C52H74N12O9/c1-5-6-19-44(65)41(23-31(2)3)62-51(72)43(26-35-28-55-30-57-35)59-46(67)29-64-22-13-12-18-40(52(64)73)61-47(68)32(4)58-50(71)42(25-34-27-56-38-17-11-10-16-36(34)38)63-49(70)39(20-21-45(54)66)60-48(69)37(53)24-33-14-8-7-9-15-33/h7-11,14-17,27-28,30-32,37,39-44,56,65H,5-6,12-13,18-26,29,53H2,1-4H3,(H2,54,66)(H,55,57)(H,58,71)(H,59,67)(H,60,69)(H,61,68)(H,62,72)(H,63,70)/t32?,37-,39?,40?,41-,42?,43?,44?/m1/s1
DMTX694 CS CCCCC([C@@H](CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N)O
DMTX694 IK FJZSPPBJQIVSSX-SCVQECHTSA-N
DMTX694 IU 2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-N-[1-[[1-[[1-[2-[[1-[[(4R)-5-hydroxy-2-methylnonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide
DMTX694 DE Discovery agent
DMGT6DN ID DMGT6DN
DMGT6DN DN JMV 1802
DMGT6DN HS Investigative
DMGT6DN SN JMV 1802; CHEMBL386480
DMGT6DN PC 44315691
DMGT6DN MW 1012.2
DMGT6DN FM C52H73N11O10
DMGT6DN IC InChI=1S/C52H73N11O10/c1-5-6-14-44(65)41(24-31(2)3)61-51(72)43(26-35-28-54-30-56-35)59-47(68)29-63-23-10-9-13-40(52(63)73)60-48(69)32(4)57-50(71)42(25-34-27-55-38-12-8-7-11-37(34)38)62-49(70)39(20-21-45(53)66)58-46(67)22-17-33-15-18-36(64)19-16-33/h7-8,11-12,15-16,18-19,27-28,30-32,39-44,55,64-65H,5-6,9-10,13-14,17,20-26,29H2,1-4H3,(H2,53,66)(H,54,56)(H,57,71)(H,58,67)(H,59,68)(H,60,69)(H,61,72)(H,62,70)/t32?,39?,40?,41-,42?,43?,44?/m1/s1
DMGT6DN CS CCCCC([C@@H](CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O)O
DMGT6DN IK SXWFVLCWIVAJQD-FUEGDDJLSA-N
DMGT6DN IU N-[1-[[1-[[1-[2-[[1-[[(4R)-5-hydroxy-2-methylnonan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[3-(4-hydroxyphenyl)propanoylamino]pentanediamide
DMGT6DN DE Discovery agent
DM248HC ID DM248HC
DM248HC DN JMV 1803
DM248HC HS Investigative
DM248HC SN JMV 1803; CHEMBL265856
DM248HC PC 44315477
DM248HC MW 1082.3
DM248HC FM C54H75N13O11
DM248HC IC InChI=1S/C54H75N13O11/c1-30(2)22-41(48(56)72)64-52(76)42(23-31(3)4)65-53(77)44(25-35-27-57-29-59-35)62-47(71)28-67-21-9-8-12-40(54(67)78)63-49(73)32(5)60-51(75)43(24-34-26-58-38-11-7-6-10-37(34)38)66-50(74)39(18-19-45(55)69)61-46(70)20-15-33-13-16-36(68)17-14-33/h6-7,10-11,13-14,16-17,26-27,29-32,39-44,58,68H,8-9,12,15,18-25,28H2,1-5H3,(H2,55,69)(H2,56,72)(H,57,59)(H,60,75)(H,61,70)(H,62,71)(H,63,73)(H,64,76)(H,65,77)(H,66,74)
DM248HC CS CC(C)CC(C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)CCC5=CC=C(C=C5)O
DM248HC IK HCLOOVPFXYLTPB-UHFFFAOYSA-N
DM248HC IU N-[1-[[1-[[1-[2-[[1-[[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-2-oxoazepan-3-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[3-(4-hydroxyphenyl)propanoylamino]pentanediamide
DM248HC DE Discovery agent
DMSICYK ID DMSICYK
DMSICYK DN JMV 1813
DMSICYK HS Investigative
DMSICYK SN JMV 1813; CHEMBL415021
DMSICYK DT Small molecular drug
DMSICYK PC 44315476
DMSICYK MW 983.1
DMSICYK FM C49H66N12O10
DMSICYK IC InChI=1S/C49H66N12O10/c1-28(2)20-40(49(70)71-4)60-47(68)39(23-32-25-52-27-54-32)56-42(63)26-61-19-11-10-16-37(48(61)69)58-43(64)29(3)55-46(67)38(22-31-24-53-35-15-9-8-14-33(31)35)59-45(66)36(17-18-41(51)62)57-44(65)34(50)21-30-12-6-5-7-13-30/h5-9,12-15,24-25,27-29,34,36-40,53H,10-11,16-23,26,50H2,1-4H3,(H2,51,62)(H,52,54)(H,55,67)(H,56,63)(H,57,65)(H,58,64)(H,59,66)(H,60,68)/t29?,34-,36?,37?,38?,39?,40?/m1/s1
DMSICYK CS CC(C)CC(C(=O)OC)NC(=O)C(CC1=CN=CN1)NC(=O)CN2CCCCC(C2=O)NC(=O)C(C)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CCC(=O)N)NC(=O)[C@@H](CC5=CC=CC=C5)N
DMSICYK IK LRJRTIDXMDONHY-UEHPUAOMSA-N
DMSICYK IU methyl 2-[[2-[[2-[3-[2-[[2-[[5-amino-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-2-oxoazepan-1-yl]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoate
DMSICYK DE Discovery agent
DMAR3M2 ID DMAR3M2
DMAR3M2 DN JMV1431
DMAR3M2 HS Investigative
DMAR3M2 SN YMROZBYZFLPAPA-RONNJKQASA-N; JMV 1431; CHEMBL408846; JMV-1431; GTPL656; H-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1431); JMV 1431
DMAR3M2 DT Small molecular drug
DMAR3M2 PC 44316620
DMAR3M2 MW 1072.2
DMAR3M2 FM C45H65N15O12S2
DMAR3M2 IC InChI=1S/C45H65N15O12S2/c46-26(8-3-13-51-44(47)48)37(66)55-27(9-4-14-52-45(49)50)41(70)58-15-5-11-32(58)43(72)59-20-24(62)17-33(59)40(69)53-19-35(63)54-28(18-25-7-6-16-73-25)38(67)56-29(22-61)39(68)57-30-23-74-34-12-2-1-10-31(34)60(42(30)71)21-36(64)65/h1-2,6-7,10,12,16,24,26-30,32-33,61-62H,3-5,8-9,11,13-15,17-23,46H2,(H,53,69)(H,54,63)(H,55,66)(H,56,67)(H,57,68)(H,64,65)(H4,47,48,51)(H4,49,50,52)/t24?,26?,27-,28?,29+,30-,32+,33+/m1/s1
DMAR3M2 CS C1C[C@H](N(C1)C(=O)[C@@H](CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)C(=O)N2CC(C[C@H]2C(=O)NCC(=O)NC(CC3=CC=CS3)C(=O)N[C@@H](CO)C(=O)N[C@@H]4CSC5=CC=CC=C5N(C4=O)CC(=O)O)O
DMAR3M2 IK YMROZBYZFLPAPA-RONNJKQASA-N
DMAR3M2 IU 2-[(3S)-3-[[(2S)-2-[[2-[[2-[[(2S)-1-[(2S)-1-[(2R)-2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]acetic acid
DMAR3M2 DE Discovery agent
DM5G0IM ID DM5G0IM
DM5G0IM DN JMV180
DM5G0IM HS Investigative
DM5G0IM SN Boc-Tyr(SO3H)Ahx-Gly-Trp-Ahx-Asp2phenylethyl ester; JMV-180; JMV 180
DM5G0IM DT Small molecular drug
DM5G0IM PC 5311195
DM5G0IM MW 1084.2
DM5G0IM FM C51H73N9O15S
DM5G0IM IC InChI=1S/C51H67N7O15S.2H3N/c1-6-8-18-38(55-47(64)40(58-50(67)72-51(3,4)5)27-33-21-23-35(24-22-33)73-74(68,69)70)45(62)53-31-43(59)54-41(28-34-30-52-37-20-14-13-17-36(34)37)48(65)56-39(19-9-7-2)46(63)57-42(29-44(60)61)49(66)71-26-25-32-15-11-10-12-16-32;;/h10-17,20-24,30,38-42,52H,6-9,18-19,25-29,31H2,1-5H3,(H,53,62)(H,54,59)(H,55,64)(H,56,65)(H,57,63)(H,58,67)(H,60,61)(H,68,69,70);2*1H3/t38-,39-,40-,41-,42-;;/m0../s1
DM5G0IM CS CCCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)OCCC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)OC(C)(C)C.N.N
DM5G0IM IK NKUXFWRTWZIEIT-IKSUPOOSSA-N
DM5G0IM IU azane;(3S)-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[[2-[[(2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxo-4-(2-phenylethoxy)butanoic acid
DM5G0IM DE Discovery agent
DMB9U17 ID DMB9U17
DMB9U17 DN JMV3008
DMB9U17 HS Investigative
DMB9U17 SN JMV3008; GTPL5872
DMB9U17 DT Small molecular drug
DMB9U17 PC 74015851
DMB9U17 MW 603.7
DMB9U17 FM C35H37N7O3
DMB9U17 IC InChI=1S/C35H37N7O3/c1-4-22-21-41(30-14-8-6-11-26(22)30)35-40-39-33(42(35)31-16-15-24(44-2)19-32(31)45-3)29(38-34(43)28-13-9-17-36-28)18-23-20-37-27-12-7-5-10-25(23)27/h5-8,10-12,14-16,19-21,28-29,36-37H,4,9,13,17-18H2,1-3H3,(H,38,43)/t28-,29+/m0/s1
DMB9U17 CS CCC1=CN(C2=CC=CC=C21)C3=NN=C(N3C4=C(C=C(C=C4)OC)OC)[C@@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@@H]7CCCN7
DMB9U17 IK YAWJYESYIAWFJX-URLMMPGGSA-N
DMB9U17 IU (2S)-N-[(1R)-1-[4-(2,4-dimethoxyphenyl)-5-(3-ethylindol-1-yl)-1,2,4-triazol-3-yl]-2-(1H-indol-3-yl)ethyl]pyrrolidine-2-carboxamide
DMB9U17 DE Discovery agent
DME9GF8 ID DME9GF8
DME9GF8 DN JMV449
DME9GF8 HS Investigative
DME9GF8 SN JMV 449; JMV-449
DME9GF8 DT Small molecular drug
DME9GF8 PC 164415
DME9GF8 MW 747
DME9GF8 FM C38H66N8O7
DME9GF8 IC InChI=1S/C38H66N8O7/c1-5-25(4)33(36(50)44-31(38(52)53)21-24(2)3)45-34(48)30(22-26-14-16-28(47)17-15-26)43-35(49)32-13-10-20-46(32)37(51)29(12-7-9-19-40)42-23-27(41)11-6-8-18-39/h14-17,24-25,27,29-33,42,47H,5-13,18-23,39-41H2,1-4H3,(H,43,49)(H,44,50)(H,45,48)(H,52,53)/t25-,27-,29-,30-,31-,32-,33-/m0/s1
DME9GF8 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC[C@H](CCCCN)N
DME9GF8 IK TZCYVPLNMOJUIL-GULBXNHPSA-N
DME9GF8 IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2,6-diaminohexyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DME9GF8 CA CAS 139026-66-7
DME9GF8 DE Discovery agent
DMC1ARG ID DMC1ARG
DMC1ARG DN JMV458
DMC1ARG HS Investigative
DMC1ARG SN JMV 458; JMV-458
DMC1ARG DT Small molecular drug
DMC1ARG PC 5311320
DMC1ARG MW 940.1
DMC1ARG FM C45H73N13O9
DMC1ARG IC InChI=1S/C45H73N13O9/c1-8-26(4)35(39(62)55-33(41(64)65)22-25(2)3)57-37(60)32(23-27-24-52-29-15-10-9-14-28(27)29)54-38(61)34-18-13-21-58(34)40(63)31(17-12-20-51-43(48)49)53-36(59)30(16-11-19-50-42(46)47)56-44(66)67-45(5,6)7/h9-10,14-15,24-26,30-35,52H,8,11-13,16-23H2,1-7H3,(H,53,59)(H,54,61)(H,55,62)(H,56,66)(H,57,60)(H,64,65)(H4,46,47,50)(H4,48,49,51)/t26-,30-,31-,32-,33-,34-,35-/m0/s1
DMC1ARG CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)OC(C)(C)C
DMC1ARG IK KOHSYJYVCLITLX-OLPQHFNPSA-N
DMC1ARG IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DMC1ARG DE Discovery agent
DMFU76I ID DMFU76I
DMFU76I DN JN-711
DMFU76I HS Investigative
DMFU76I SN Alpha-7 nicotinic acetylcholine receptor agonists (CNS disorders); Alpha-7 nicotinic acetylcholine receptor agonists (CNS disorders), Novartis
DMFU76I CP Novartis AG
DMFU76I DE Central nervous system disease
DM6P1UA ID DM6P1UA
DM6P1UA DN JNJ-10191584
DM6P1UA HS Investigative
DM6P1UA SN VUF 6002; JNJ 10191584; VUF6002; VUF-6002; JNJ10191584; compound 12
DM6P1UA DT Small molecular drug
DM6P1UA PC 10446295
DM6P1UA MW 278.74
DM6P1UA FM C13H15ClN4O
DM6P1UA IC InChI=1S/C13H15ClN4O/c1-17-4-6-18(7-5-17)13(19)12-15-10-3-2-9(14)8-11(10)16-12/h2-3,8H,4-7H2,1H3,(H,15,16)
DM6P1UA CS CN1CCN(CC1)C(=O)C2=NC3=C(N2)C=C(C=C3)Cl
DM6P1UA IK MOIWSUQWIOVGRH-UHFFFAOYSA-N
DM6P1UA IU (6-chloro-1H-benzimidazol-2-yl)-(4-methylpiperazin-1-yl)methanone
DM6P1UA CA CAS 73903-17-0
DM6P1UA CB CHEBI:92272
DM6P1UA DE Discovery agent
DM9GDP5 ID DM9GDP5
DM9GDP5 DN JNJ-10198409
DM9GDP5 HS Investigative
DM9GDP5 SN JNJ-10198409; 627518-40-5; PDGFR Tyrosine Kinase Inhibitor IV; PDGF Receptor Tyrosine Kinase Inhibitor IV; CHEMBL120077; N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine; 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine; ZDNURMVOKAERHZ-UHFFFAOYSA-N; SCHEMBL3088170; GTPL6020; CTK8E8807; jnj10198409; DTXSID70430890; MolPort-009-019-131; HMS3650O03; HMS3229I11; ZINC13677843; BDBM50179207; AKOS030525202; RWJ 540973; CCG-206773; NCGC00343986-02; RT-014973; KB-274227; SR-01000946814
DM9GDP5 DT Small molecular drug
DM9GDP5 PC 9797370
DM9GDP5 MW 325.3
DM9GDP5 FM C18H16FN3O2
DM9GDP5 IC InChI=1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)
DM9GDP5 CS COC1=C(C=C2C(=C1)CC3=C2NN=C3NC4=CC(=CC=C4)F)OC
DM9GDP5 IK ZDNURMVOKAERHZ-UHFFFAOYSA-N
DM9GDP5 IU N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine
DM9GDP5 CA CAS 627518-40-5
DM9GDP5 DE Discovery agent
DMBRJ3C ID DMBRJ3C
DMBRJ3C DN JNJ-10329670
DMBRJ3C HS Investigative
DMBRJ3C SN Cathepsin S inhibitors (autoimmune disease); Cathepsin S inhibitors (autoimmune disease), J&J PRD; Cathepsin S inhibitors (autoimmune disease), Johnson & Johnson
DMBRJ3C CP Johnson & Johnson Pharmaceutical Research & Development LLC
DMBRJ3C DT Small molecular drug
DMBRJ3C PC 10168449
DMBRJ3C MW 651.1
DMBRJ3C FM C30H34ClF3N6O3S
DMBRJ3C IC InChI=1S/C30H34ClF3N6O3S/c1-36-26-9-8-22(31)18-27(26)40(29(36)41)23-10-15-37(16-11-23)13-3-14-39-25-12-17-38(44(2,42)43)19-24(25)28(35-39)20-4-6-21(7-5-20)30(32,33)34/h4-9,18,23H,3,10-17,19H2,1-2H3
DMBRJ3C CS CN1C2=C(C=C(C=C2)Cl)N(C1=O)C3CCN(CC3)CCCN4C5=C(CN(CC5)S(=O)(=O)C)C(=N4)C6=CC=C(C=C6)C(F)(F)F
DMBRJ3C IK NVAHQQYCEWEDKM-UHFFFAOYSA-N
DMBRJ3C IU 5-chloro-1-methyl-3-[1-[3-[5-methylsulfonyl-3-[4-(trifluoromethyl)phenyl]-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]propyl]piperidin-4-yl]benzimidazol-2-one
DMBRJ3C CA CAS 400797-24-2
DMBRJ3C DE Autoimmune diabetes
DMZH0K8 ID DMZH0K8
DMZH0K8 DN JNJ-10392980
DMZH0K8 HS Investigative
DMZH0K8 SN 841200-46-2; benzoxazole,2-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-; JNJ-10392980; Benzoxazole compound, 10b; CHEMBL481863; SCHEMBL2170316; BDBM24203; ZIQGASWXUSSORV-UHFFFAOYSA-N; ZINC36377694; KB-306080; 2-[4-(2-Piperidin-1-yl-ethoxy)-phenoxy]-benzooxazole
DMZH0K8 DT Small molecular drug
DMZH0K8 PC 11739248
DMZH0K8 MW 338.4
DMZH0K8 FM C20H22N2O3
DMZH0K8 IC InChI=1S/C20H22N2O3/c1-4-12-22(13-5-1)14-15-23-16-8-10-17(11-9-16)24-20-21-18-6-2-3-7-19(18)25-20/h2-3,6-11H,1,4-5,12-15H2
DMZH0K8 CS C1CCN(CC1)CCOC2=CC=C(C=C2)OC3=NC4=CC=CC=C4O3
DMZH0K8 IK ZIQGASWXUSSORV-UHFFFAOYSA-N
DMZH0K8 IU 2-[4-(2-piperidin-1-ylethoxy)phenoxy]-1,3-benzoxazole
DMZH0K8 DE Discovery agent
DMZ8M0K ID DMZ8M0K
DMZ8M0K DN JNJ-10397049
DMZ8M0K HS Investigative
DMZ8M0K SN JNJ-10397049; JNJ 10397049; 708275-58-5; UNII-1B419P24AV; CHEMBL359632; 1B419P24AV; N-(2,4-Dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-urea; JNJ10397049; SCHEMBL1818251; GTPL1701; MolPort-035-765-717; ZINC3960325; BDBM50412863; AKOS024458089; compound 9 [PMID: 15261275]; 1-(2,4-Dibromophenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-(1,3)dioxan-5-yl)urea; Urea, N-(2,4-dibromophenyl)-N'-((4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-; NCGC00379105-01; KB-77996; B5553; J3.628.691A
DMZ8M0K CP Johnson & Johnson
DMZ8M0K DT Small molecular drug
DMZ8M0K PC 9869934
DMZ8M0K MW 484.2
DMZ8M0K FM C19H20Br2N2O3
DMZ8M0K IC InChI=1S/C19H20Br2N2O3/c1-19(2)25-11-16(17(26-19)12-6-4-3-5-7-12)23-18(24)22-15-9-8-13(20)10-14(15)21/h3-10,16-17H,11H2,1-2H3,(H2,22,23,24)/t16-,17-/m0/s1
DMZ8M0K CS CC1(OC[C@@H]([C@@H](O1)C2=CC=CC=C2)NC(=O)NC3=C(C=C(C=C3)Br)Br)C
DMZ8M0K IK RBKIJGLHFFQHBE-IRXDYDNUSA-N
DMZ8M0K IU 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea
DMZ8M0K CA CAS 708275-58-5
DMZ8M0K DE Insomnia
DMXNFU5 ID DMXNFU5
DMXNFU5 DN JNJ-16567083
DMXNFU5 HS Investigative
DMXNFU5 SN JNJ-16567083; CHEMBL253345; CHEMBL188906; CHEMBL1645348; EMQMCM; GTPL7442; SCHEMBL8352668; BDBM50231750; BDBM50333368; BDBM50171313; L021349; R-193845; (3-ethyl-2-methylquinolin-6-yl)-(4-methoxycyclohexyl)methanone; (3-ethyl-2-methylquinolin-6-yl)(4-methoxycyclohexyl)methanone; (3-ethyl-2-methyl-quinolin-6-yl)(4-methoxy-cyclohexyl)methanone; (3-Ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone
DMXNFU5 DT Small molecular drug
DMXNFU5 PC 9948645
DMXNFU5 MW 311.4
DMXNFU5 FM C20H25NO2
DMXNFU5 IC InChI=1S/C20H25NO2/c1-4-14-11-17-12-16(7-10-19(17)21-13(14)2)20(22)15-5-8-18(23-3)9-6-15/h7,10-12,15,18H,4-6,8-9H2,1-3H3
DMXNFU5 CS CCC1=C(N=C2C=CC(=CC2=C1)C(=O)C3CCC(CC3)OC)C
DMXNFU5 IK VEURHZYLLRSEGL-UHFFFAOYSA-N
DMXNFU5 IU (3-ethyl-2-methylquinolin-6-yl)-(4-methoxycyclohexyl)methanone
DMXNFU5 DE Discovery agent
DM3ZNF9 ID DM3ZNF9
DM3ZNF9 DN JNJ-1661010
DM3ZNF9 HS Investigative
DM3ZNF9 SN 681136-29-8; JNJ-1661010; JNJ 1661010; JNJ1661010; N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide; UNII-62521S57AU; 1-Piperazinecarboxamide, N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)-; N-PHENYL-4-(3-PHENYL-1,2,4-THIADIAZOL-5-YL)-1-PIPERAZINECARBOXAMIDE; CHEMBL460273; 62521S57AU; BHBOSTKQCZEAJM-UHFFFAOYSA-N; ACMC-20emff; AC1MDCTI; AC1Q5LMB; Oprea1_746619; MLS001111246; SCHEMBL1164398; GTPL5206; CTK1J2536; cid_2809273; DTXSID00384599; MolPort-001-806-365; HMS3651L15; HMS1662H10; HMS2801K13; BCP06935; EX-A2218
DM3ZNF9 DT Small molecular drug
DM3ZNF9 PC 2809273
DM3ZNF9 MW 365.5
DM3ZNF9 FM C19H19N5OS
DM3ZNF9 IC InChI=1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)
DM3ZNF9 CS C1CN(CCN1C2=NC(=NS2)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
DM3ZNF9 IK BHBOSTKQCZEAJM-UHFFFAOYSA-N
DM3ZNF9 IU N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide
DM3ZNF9 CA CAS 681136-29-8
DM3ZNF9 DE Discovery agent
DMJ1DE9 ID DMJ1DE9
DMJ1DE9 DN JNJ-17148066
DMJ1DE9 HS Investigative
DMJ1DE9 SN CHEMBL1088485; SCHEMBL14277842; BDBM50310388
DMJ1DE9 DT Small molecular drug
DMJ1DE9 PC 44597742
DMJ1DE9 MW 485.6
DMJ1DE9 FM C30H31NO5
DMJ1DE9 IC InChI=1S/C30H31NO5/c32-21-7-11-26-27(18-21)35-16-12-25-24-10-6-22(33)19-28(24)36-30(29(25)26)20-4-8-23(9-5-20)34-17-15-31-13-2-1-3-14-31/h4-11,18-19,30,32-33H,1-3,12-17H2/t30-/m1/s1
DMJ1DE9 CS C1CCN(CC1)CCOC2=CC=C(C=C2)[C@@H]3C4=C(CCOC5=C4C=CC(=C5)O)C6=C(O3)C=C(C=C6)O
DMJ1DE9 IK OFYZVZJXVRFMIW-SSEXGKCCSA-N
DMJ1DE9 IU (19R)-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaene-5,15-diol
DMJ1DE9 DE Discovery agent
DMIXUNB ID DMIXUNB
DMIXUNB DN JNJ-17156516
DMIXUNB HS Investigative
DMIXUNB SN JNJ 17156516
DMIXUNB DT Small molecular drug
DMIXUNB PC 11488979
DMIXUNB MW 481.4
DMIXUNB FM C26H22Cl2N2O3
DMIXUNB IC InChI=1S/C26H22Cl2N2O3/c1-16-4-3-5-17(12-16)22(26(31)32)14-19-15-25(18-6-11-23(27)24(28)13-18)30(29-19)20-7-9-21(33-2)10-8-20/h3-13,15,22H,14H2,1-2H3,(H,31,32)/t22-/m0/s1
DMIXUNB CS CC1=CC(=CC=C1)[C@H](CC2=NN(C(=C2)C3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OC)C(=O)O
DMIXUNB IK UZCIUKFEIOCAOC-QFIPXVFZSA-N
DMIXUNB IU (2S)-3-[5-(3,4-dichlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-2-(3-methylphenyl)propanoic acid
DMIXUNB CA CAS 649551-06-4
DMIXUNB DE Discovery agent
DMDUWBF ID DMDUWBF
DMDUWBF DN JNJ-17203212
DMDUWBF HS Investigative
DMDUWBF SN JNJ-17203212; 821768-06-3; JNJ 17203212; UNII-71JE0C439X; CHEMBL254778; 71JE0C439X; 4-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide; 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide; JFRYYGVYCWYIDQ-UHFFFAOYSA-N; 4-(3-(trifluoromethyl)pyridin-2-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxamide; JNJ17203212; SCHEMBL138342; GTPL4228; CTK5E9468; C17H15F6N5O; DTXSID50462856; AOB2189; SYN5009; MolPort-006-822-716
DMDUWBF DT Small molecular drug
DMDUWBF PC 11339118
DMDUWBF MW 419.32
DMDUWBF FM C17H15F6N5O
DMDUWBF IC InChI=1S/C17H15F6N5O/c18-16(19,20)11-3-4-13(25-10-11)26-15(29)28-8-6-27(7-9-28)14-12(17(21,22)23)2-1-5-24-14/h1-5,10H,6-9H2,(H,25,26,29)
DMDUWBF CS C1CN(CCN1C2=C(C=CC=N2)C(F)(F)F)C(=O)NC3=NC=C(C=C3)C(F)(F)F
DMDUWBF IK JFRYYGVYCWYIDQ-UHFFFAOYSA-N
DMDUWBF IU 4-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide
DMDUWBF CA CAS 821768-06-3
DMDUWBF DE Cough
DMKH9O7 ID DMKH9O7
DMKH9O7 DN JNJ-1930942
DMKH9O7 HS Investigative
DMKH9O7 SN JNJ-41512549; Alpha-7 nicotinic acetylcholine receptor modulator (cognitive disorder), Johnson & Johnson
DMKH9O7 CP Johnson & Johnson
DMKH9O7 DT Small molecular drug
DMKH9O7 PC 44240744
DMKH9O7 MW 369.3
DMKH9O7 FM C16H11F4N3OS
DMKH9O7 IC InChI=1S/C16H11F4N3OS/c17-12-2-1-10(7-11(12)16(18,19)20)22-15-23-14(13(8-24)25-15)9-3-5-21-6-4-9/h1-7,24H,8H2,(H,22,23)
DMKH9O7 CS C1=CC(=C(C=C1NC2=NC(=C(S2)CO)C3=CC=NC=C3)C(F)(F)F)F
DMKH9O7 IK JBSVHWCIKVSTTH-UHFFFAOYSA-N
DMKH9O7 IU [2-[4-fluoro-3-(trifluoromethyl)anilino]-4-pyridin-4-yl-1,3-thiazol-5-yl]methanol
DMKH9O7 CA CAS 929562-28-7
DMKH9O7 DE Cognitive impairment
DM94IJC ID DM94IJC
DM94IJC DN JNJ-19398990
DM94IJC HS Investigative
DM94IJC SN JNJ-19398990; CHEMBL1085429; BDBM50310424
DM94IJC DT Small molecular drug
DM94IJC PC 10029432
DM94IJC MW 513.6
DM94IJC FM C32H35NO5
DM94IJC IC InChI=1S/C32H35NO5/c1-34-24-11-13-28-29(20-24)37-18-14-27-26-12-10-25(35-2)21-30(26)38-32(31(27)28)22-6-8-23(9-7-22)36-19-17-33-15-4-3-5-16-33/h6-13,20-21,32H,3-5,14-19H2,1-2H3/t32-/m1/s1
DM94IJC CS COC1=CC2=C(C=C1)C3=C([C@H](O2)C4=CC=C(C=C4)OCCN5CCCCC5)C6=C(C=C(C=C6)OC)OCC3
DM94IJC IK IFCSDJGUXGRSFR-JGCGQSQUSA-N
DM94IJC IU 1-[2-[4-[(19R)-5,15-dimethoxy-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-19-yl]phenoxy]ethyl]piperidine
DM94IJC CA CAS 810668-60-1
DM94IJC DE Discovery agent
DMK6TVN ID DMK6TVN
DMK6TVN DN JNJ-26529126
DMK6TVN HS Investigative
DMK6TVN SN JNJ-26529126; CHEMBL1088343; BDBM50310407
DMK6TVN DT Small molecular drug
DMK6TVN PC 9848809
DMK6TVN MW 499.6
DMK6TVN FM C31H33NO5
DMK6TVN IC InChI=1S/C31H33NO5/c1-34-24-10-12-27-28(20-24)36-17-13-26-25-11-7-22(33)19-29(25)37-31(30(26)27)21-5-8-23(9-6-21)35-18-16-32-14-3-2-4-15-32/h5-12,19-20,31,33H,2-4,13-18H2,1H3/t31-/m1/s1
DMK6TVN CS COC1=CC2=C(C=C1)C3=C(CCO2)C4=C(C=C(C=C4)O)O[C@@H]3C5=CC=C(C=C5)OCCN6CCCCC6
DMK6TVN IK BHYFKQDXXVAJEL-WJOKGBTCSA-N
DMK6TVN IU (19R)-5-methoxy-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-15-ol
DMK6TVN DE Discovery agent
DMBZ7MA ID DMBZ7MA
DMBZ7MA DN JNJ-26529152
DMBZ7MA HS Investigative
DMBZ7MA SN JNJ-26529152; CHEMBL1088483; BDBM50310372
DMBZ7MA DT Small molecular drug
DMBZ7MA PC 10323679
DMBZ7MA MW 499.6
DMBZ7MA FM C31H33NO5
DMBZ7MA IC InChI=1S/C31H33NO5/c1-34-24-10-12-25-26-13-17-36-28-19-22(33)7-11-27(28)30(26)31(37-29(25)20-24)21-5-8-23(9-6-21)35-18-16-32-14-3-2-4-15-32/h5-12,19-20,31,33H,2-4,13-18H2,1H3/t31-/m1/s1
DMBZ7MA CS COC1=CC2=C(C=C1)C3=C([C@H](O2)C4=CC=C(C=C4)OCCN5CCCCC5)C6=C(C=C(C=C6)O)OCC3
DMBZ7MA IK MEGWHNJGIHFDSO-WJOKGBTCSA-N
DMBZ7MA IU (19R)-15-methoxy-19-[4-(2-piperidin-1-ylethoxy)phenyl]-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-5-ol
DMBZ7MA DE Discovery agent
DMCMH7O ID DMCMH7O
DMCMH7O DN JNJ-28312141
DMCMH7O HS Investigative
DMCMH7O SN JNJ 28312141
DMCMH7O DT Small molecular drug
DMCMH7O PC 11676971
DMCMH7O MW 460.6
DMCMH7O FM C26H32N6O2
DMCMH7O IC InChI=1S/C26H32N6O2/c1-31(2)17-24(33)32-12-10-18(11-13-32)20-8-9-23(22(14-20)19-6-4-3-5-7-19)30-26(34)25-28-16-21(15-27)29-25/h6,8-9,14,16,18H,3-5,7,10-13,17H2,1-2H3,(H,28,29)(H,30,34)
DMCMH7O CS CN(C)CC(=O)N1CCC(CC1)C2=CC(=C(C=C2)NC(=O)C3=NC=C(N3)C#N)C4=CCCCC4
DMCMH7O IK GUBJNPWVIUFSTR-UHFFFAOYSA-N
DMCMH7O IU 5-cyano-N-[2-(cyclohexen-1-yl)-4-[1-[2-(dimethylamino)acetyl]piperidin-4-yl]phenyl]-1H-imidazole-2-carboxamide
DMCMH7O CA CAS 885692-52-4
DMCMH7O DE Discovery agent
DM84PWI ID DM84PWI
DM84PWI DN JNJ-28318706
DM84PWI HS Investigative
DM84PWI SN JNJ-28318706; CHEMBL572138; SCHEMBL1733714; BDBM50302228
DM84PWI DT Small molecular drug
DM84PWI PC 23627612
DM84PWI MW 485.6
DM84PWI FM C29H31N3O4
DM84PWI IC InChI=1S/C29H31N3O4/c1-20(22-8-5-4-6-9-22)30-14-16-31(17-15-30)24-11-7-10-23-27(24)29(34)32(28(23)33)19-21-12-13-25(35-2)26(18-21)36-3/h4-13,18,20H,14-17,19H2,1-3H3/t20-/m1/s1
DM84PWI CS C[C@H](C1=CC=CC=C1)N2CCN(CC2)C3=CC=CC4=C3C(=O)N(C4=O)CC5=CC(=C(C=C5)OC)OC
DM84PWI IK XVYISGJLURJDNX-HXUWFJFHSA-N
DM84PWI IU 2-[(3,4-dimethoxyphenyl)methyl]-4-[4-[(1R)-1-phenylethyl]piperazin-1-yl]isoindole-1,3-dione
DM84PWI DE Discovery agent
DM5LEOR ID DM5LEOR
DM5LEOR DN JNJ-28583867
DM5LEOR HS Investigative
DM5LEOR SN JNJ-28583867; CHEMBL257917
DM5LEOR DT Small molecular drug
DM5LEOR PC 44456154
DM5LEOR MW 412.6
DM5LEOR FM C24H32N2O2S
DM5LEOR IC InChI=1S/C24H32N2O2S/c1-25-17-20-16-21(28-13-3-10-26-11-14-27-15-12-26)6-9-23(20)24(18-25)19-4-7-22(29-2)8-5-19/h4-9,16,24H,3,10-15,17-18H2,1-2H3/t24-/m0/s1
DM5LEOR CS CN1C[C@H](C2=C(C1)C=C(C=C2)OCCCN3CCOCC3)C4=CC=C(C=C4)SC
DM5LEOR IK XYYGFCDTBHAUSN-DEOSSOPVSA-N
DM5LEOR IU 4-[3-[[(4S)-2-methyl-4-(4-methylsulfanylphenyl)-3,4-dihydro-1H-isoquinolin-7-yl]oxy]propyl]morpholine
DM5LEOR DE Discovery agent
DM48Y9E ID DM48Y9E
DM48Y9E DN JNJ-38158471
DM48Y9E HS Investigative
DM48Y9E SN VEGFR-2 inhibitors (angiogenesis disorder/cancer); VEGFR-2 inhibitors (angiogenesis disorder/cancer), Johnson & Johnson
DM48Y9E CP Johnson & Johnson
DM48Y9E DT Small molecular drug
DM48Y9E PC 16742063
DM48Y9E MW 364.79
DM48Y9E FM C15H17ClN6O3
DM48Y9E IC InChI=1S/C15H17ClN6O3/c1-3-18-15(23)22-12-5-4-9(6-11(12)16)25-14-10(7-21-24-2)13(17)19-8-20-14/h4-8H,3H2,1-2H3,(H2,17,19,20)(H2,18,22,23)/b21-7+
DM48Y9E CS CCNC(=O)NC1=C(C=C(C=C1)OC2=NC=NC(=C2/C=N/OC)N)Cl
DM48Y9E IK BJHCYTJNPVGSBZ-QPSGOUHRSA-N
DM48Y9E IU 1-[4-[6-amino-5-[(E)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea
DM48Y9E DE Angiogenesis disorder
DMLOQ92 ID DMLOQ92
DMLOQ92 DN JNJ-42153605
DMLOQ92 HS Investigative
DMLOQ92 SN JNJ 42153605
DMLOQ92 DT Small molecular drug
DMLOQ92 PC 49765871
DMLOQ92 MW 400.4
DMLOQ92 FM C22H23F3N4
DMLOQ92 IC InChI=1S/C22H23F3N4/c23-22(24,25)20-18(10-13-29-19(14-15-6-7-15)26-27-21(20)29)28-11-8-17(9-12-28)16-4-2-1-3-5-16/h1-5,10,13,15,17H,6-9,11-12,14H2
DMLOQ92 CS C1CC1CC2=NN=C3N2C=CC(=C3C(F)(F)F)N4CCC(CC4)C5=CC=CC=C5
DMLOQ92 IK BQAVZGJJQFJSMW-UHFFFAOYSA-N
DMLOQ92 IU 3-(cyclopropylmethyl)-7-(4-phenylpiperidin-1-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine
DMLOQ92 DE Discovery agent
DMWYU5C ID DMWYU5C
DMWYU5C DN JNJ-5207787
DMWYU5C HS Investigative
DMWYU5C SN JNJ5207787
DMWYU5C DT Small molecular drug
DMWYU5C PC 10324083
DMWYU5C MW 510.7
DMWYU5C FM C32H38N4O2
DMWYU5C IC InChI=1S/C32H38N4O2/c1-24(37)35-20-14-28-10-11-30(22-31(28)35)36(32(38)12-9-26-7-4-8-27(21-26)23-33)29-15-18-34(19-16-29)17-13-25-5-2-3-6-25/h4,7-12,21-22,25,29H,2-3,5-6,13-20H2,1H3/b12-9+
DMWYU5C CS CC(=O)N1CCC2=C1C=C(C=C2)N(C3CCN(CC3)CCC4CCCC4)C(=O)/C=C/C5=CC(=CC=C5)C#N
DMWYU5C IK DSEJCLDJIFTPPH-FMIVXFBMSA-N
DMWYU5C IU (E)-N-(1-acetyl-2,3-dihydroindol-6-yl)-3-(3-cyanophenyl)-N-[1-(2-cyclopentylethyl)piperidin-4-yl]prop-2-enamide
DMWYU5C CA CAS 683746-68-1
DMWYU5C DE Discovery agent
DM5L23N ID DM5L23N
DM5L23N DN JNJ-5207852
DM5L23N HS Investigative
DM5L23N SN 398473-34-2; JNJ-5207852; UNII-4I9OVB1G7D; JNJ 5207852; 1-[4-(3-piperidinopropoxy)benzyl]piperidine; 4I9OVB1G7D; CHEMBL129542; JNJ 5207852 dihydrochloride; 1-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperidine; Piperidine, 1-(3-(4-(1-piperidinylmethyl)phenoxy)propyl)-; 1-(3-(4-((Piperidin-1-yl)methyl)phenoxy)propyl)piperidine; 1-(3-(4-(piperidin-1-ylmethyl)phenoxy)propyl)piperidine; Piperidine, 1-[3-[4-(1-piperidinylmethyl)phenoxy]propyl]-; 1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine; AC1MCCJO
DM5L23N CP Johnson & Johnson
DM5L23N DT Small molecular drug
DM5L23N PC 2766326
DM5L23N MW 316.5
DM5L23N FM C20H32N2O
DM5L23N IC InChI=1S/C20H32N2O/c1-3-12-21(13-4-1)16-7-17-23-20-10-8-19(9-11-20)18-22-14-5-2-6-15-22/h8-11H,1-7,12-18H2
DM5L23N CS C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CCCCC3
DM5L23N IK PTKHFRNHJULJKT-UHFFFAOYSA-N
DM5L23N IU 1-[3-[4-(piperidin-1-ylmethyl)phenoxy]propyl]piperidine
DM5L23N CA CAS 398473-34-2
DM5L23N DE Narcolepsy
DMHTYBS ID DMHTYBS
DMHTYBS DN JNJ-7706621
DMHTYBS HS Investigative
DMHTYBS SN JNJ-7706621; 443797-96-4; JNJ7706621; 4-((5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl)amino)benzenesulfonamide; UNII-74GK72DON8; RWJ-387252; 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide; CHEMBL191003; 74GK72DON8; 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide; JNJ 7706621; 4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide
DMHTYBS DT Small molecular drug
DMHTYBS PC 5330790
DMHTYBS MW 394.4
DMHTYBS FM C15H12F2N6O3S
DMHTYBS IC InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)
DMHTYBS CS C1=CC(=C(C(=C1)F)C(=O)N2C(=NC(=N2)NC3=CC=C(C=C3)S(=O)(=O)N)N)F
DMHTYBS IK KDKUVYLMPJIGKA-UHFFFAOYSA-N
DMHTYBS IU 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
DMHTYBS CA CAS 443797-96-4
DMHTYBS CB CHEBI:94506
DMHTYBS DE Discovery agent
DMLWYJB ID DMLWYJB
DMLWYJB DN JNK-IN-8
DMLWYJB HS Investigative
DMLWYJB SN JNK-IN-8; 1410880-22-6; JNK Inhibitor XVI; 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; JNK-IN8; GTPL8058; CHEMBL2216824; SCHEMBL14979761; BDBM86633; DTXSID40720937; CHEBI:124918; MolPort-035-395-752; EX-A2206; BCP09744; ZINC89464842; s4901; AKOS030526496; SB19427; CS-0601; NCGC00386243-05; HY-13319; BC600656; Y1469; SW219193-1; W-5897; J-007458; 3-{[(2E)-4-(Dimethylamino)but-2-enoyl]amino}-N-(3-methyl-4-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
DMLWYJB DT Small molecular drug
DMLWYJB PC 57340686
DMLWYJB MW 507.6
DMLWYJB FM C29H29N7O2
DMLWYJB IC InChI=1S/C29H29N7O2/c1-20-17-24(11-12-25(20)34-29-31-15-13-26(35-29)22-8-5-14-30-19-22)33-28(38)21-7-4-9-23(18-21)32-27(37)10-6-16-36(2)3/h4-15,17-19H,16H2,1-3H3,(H,32,37)(H,33,38)(H,31,34,35)/b10-6+
DMLWYJB CS CC1=C(C=CC(=C1)NC(=O)C2=CC(=CC=C2)NC(=O)/C=C/CN(C)C)NC3=NC=CC(=N3)C4=CN=CC=C4
DMLWYJB IK GJFCSAPFHAXMSF-UXBLZVDNSA-N
DMLWYJB IU 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
DMLWYJB CA CAS 1410880-22-6
DMLWYJB CB CHEBI:124918
DMLWYJB DE Discovery agent
DMYBJ4K ID DMYBJ4K
DMYBJ4K DN joro toxin
DMYBJ4K HS Investigative
DMYBJ4K SN Joro spider toxin; Joro toxin; JSTX-3; 112163-33-4; Joro Spider Toxin 3; AC1L3P2K; CHEMBL313747; CHEBI:34802; Butanediamide, N1-(5-((3-((4-((3-aminopropyl)amino)butyl)amino)-1-oxopropyl)amino)pentyl)-2-(((2,4-dihydroxyphenyl)acetyl)amino)-, (2S)-; (2S)-N-[5-[3-[4-(3-aminopropylamino)butylamino]propanoylamino]pentyl]-2-[[2-(2,4-dihydroxyphenyl)acetyl]amino]butanediamide; GTPL4229; CTK8E9607; DTXSID50149933; ZINC4654981; BDBM50105843; RT-013407; FT-0771159; C13931; J-002718
DMYBJ4K DT Small molecular drug
DMYBJ4K PC 119582
DMYBJ4K MW 565.7
DMYBJ4K FM C27H47N7O6
DMYBJ4K IC InChI=1S/C27H47N7O6/c28-10-6-13-30-11-4-5-12-31-16-9-25(38)32-14-2-1-3-15-33-27(40)22(19-24(29)37)34-26(39)17-20-7-8-21(35)18-23(20)36/h7-8,18,22,30-31,35-36H,1-6,9-17,19,28H2,(H2,29,37)(H,32,38)(H,33,40)(H,34,39)/t22-/m0/s1
DMYBJ4K CS C1=CC(=C(C=C1O)O)CC(=O)N[C@@H](CC(=O)N)C(=O)NCCCCCNC(=O)CCNCCCCNCCCN
DMYBJ4K IK SJLRBGDPTALRDM-QFIPXVFZSA-N
DMYBJ4K IU (2S)-N-[5-[3-[4-(3-aminopropylamino)butylamino]propanoylamino]pentyl]-2-[[2-(2,4-dihydroxyphenyl)acetyl]amino]butanediamide
DMYBJ4K CA CAS 112163-33-4
DMYBJ4K CB CHEBI:34802
DMYBJ4K DE Discovery agent
DMMVBK6 ID DMMVBK6
DMMVBK6 DN JP1302
DMMVBK6 HS Investigative
DMMVBK6 SN N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine; GNF-PF-3427; TCMDC-123912; BRN 5117597; 80259-18-3; MMV006172; JP 1302; N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine; CHEMBL106525; QZKGUNQLVFEEBA-UHFFFAOYSA-N; 9-Acridinamine, N-(4-(4-methyl-1-piperazinyl)phenyl)-; Acridin-9-yl-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine; N-(4-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine; N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine; 9-Acridinamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-; JP-1302; JP-1302
DMMVBK6 DT Small molecular drug
DMMVBK6 PC 540335
DMMVBK6 MW 368.5
DMMVBK6 FM C24H24N4
DMMVBK6 IC InChI=1S/C24H24N4/c1-27-14-16-28(17-15-27)19-12-10-18(11-13-19)25-24-20-6-2-4-8-22(20)26-23-9-5-3-7-21(23)24/h2-13H,14-17H2,1H3,(H,25,26)
DMMVBK6 CS CN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
DMMVBK6 IK QZKGUNQLVFEEBA-UHFFFAOYSA-N
DMMVBK6 IU N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine
DMMVBK6 CA CAS 80259-18-3
DMMVBK6 DE Discovery agent
DM3XQDH ID DM3XQDH
DM3XQDH DN JQ1
DM3XQDH HS Investigative
DM3XQDH SN JQ1 compound; JQ-1; UNII-1MRH0IMX0W; (S)-JQ1; Bromodomain Inhibitor, (+)-JQ1; 1MRH0IMX0W
DM3XQDH TC Antiviral Agents
DM3XQDH DT Small molecular drug
DM3XQDH PC 46907787
DM3XQDH MW 457
DM3XQDH FM C23H25ClN4O2S
DM3XQDH IC InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1
DM3XQDH CS CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C
DM3XQDH IK DNVXATUJJDPFDM-KRWDZBQOSA-N
DM3XQDH IU tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
DM3XQDH CA CAS 1268524-70-4
DM3XQDH CB CHEBI:95080
DM3XQDH DE Coronavirus Disease 2019 (COVID-19)
DMD9W0B ID DMD9W0B
DMD9W0B DN JT-2724
DMD9W0B HS Investigative
DMD9W0B DE Discovery agent
DMXZ9RF ID DMXZ9RF
DMXZ9RF DN JWB-1-84-1
DMXZ9RF HS Investigative
DMXZ9RF SN Choline analogs (neurodegenerative diseases); Choline analogs (neurodegenerative diseases), Medical College of Georgia; JWB-1-B4-1
DMXZ9RF CP Medical College of Georgia
DMXZ9RF DE Neurological disorder
DMYX30S ID DMYX30S
DMYX30S DN JWH-051
DMYX30S HS Investigative
DMYX30S SN CB2 receptor agonists (pain); CB2 receptor agonists (pain), Merck
DMYX30S CP Merck & Co Inc
DMYX30S PC 9799540
DMYX30S MW 370.6
DMYX30S FM C25H38O2
DMYX30S IC InChI=1S/C25H38O2/c1-6-7-8-9-14-24(2,3)19-11-12-20-21-15-18(17-26)10-13-22(21)25(4,5)27-23(20)16-19/h10-12,16,21-22,26H,6-9,13-15,17H2,1-5H3/t21-,22+/m0/s1
DMYX30S CS CCCCCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)CO
DMYX30S IK ORTVDISIJXKUAV-FCHUYYIVSA-N
DMYX30S IU [(6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl]methanol
DMYX30S DE Pain
DM7JQDS ID DM7JQDS
DM7JQDS DN JWH-120
DM7JQDS HS Investigative
DM7JQDS SN JWH-120; UNII-J6M7L6J6PN; J6M7L6J6PN; CHEMBL497811; 824955-98-8; Methanone, (4-methyl-1-naphthalenyl)(1-propyl-1H-indol-3-yl)-; SCHEMBL6325731; CTK3D9085; DTXSID20466689; (4-methylnaphthalen-1-yl)(1-propyl-1H-indol-3-yl)methanone; BDBM50265747
DM7JQDS DT Small molecular drug
DM7JQDS PC 11461586
DM7JQDS MW 327.4
DM7JQDS FM C23H21NO
DM7JQDS IC InChI=1S/C23H21NO/c1-3-14-24-15-21(19-10-6-7-11-22(19)24)23(25)20-13-12-16(2)17-8-4-5-9-18(17)20/h4-13,15H,3,14H2,1-2H3
DM7JQDS CS CCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=C(C4=CC=CC=C43)C
DM7JQDS IK DUBUGSKBMMXSOU-UHFFFAOYSA-N
DM7JQDS IU (4-methylnaphthalen-1-yl)-(1-propylindol-3-yl)methanone
DM7JQDS CA CAS 824955-98-8
DM7JQDS DE Discovery agent
DM1DEYU ID DM1DEYU
DM1DEYU DN JWH-133
DM1DEYU HS Investigative
DM1DEYU SN JWH-133; 259869-55-1; JWH 133; JWH133; CHEMBL371214; (6AR,10AR)-3-(1,1-DIMETHYLBUTYL)-6A,7,10,10A-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO[B,D]PYRAN; JW-133/JW133; (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene; (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene; (6aR,10aR)-6,6,9-Trimethyl-3-(2-methyl-2-pentanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene; YSBFLLZNALVODA-RBUKOAKNSA-N; JW 133; AC1OCFIJ
DM1DEYU DT Small molecular drug
DM1DEYU PC 6918505
DM1DEYU MW 312.5
DM1DEYU FM C22H32O
DM1DEYU IC InChI=1S/C22H32O/c1-7-12-21(3,4)16-9-10-17-18-13-15(2)8-11-19(18)22(5,6)23-20(17)14-16/h8-10,14,18-19H,7,11-13H2,1-6H3/t18-,19+/m0/s1
DM1DEYU CS CCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)C
DM1DEYU IK YSBFLLZNALVODA-RBUKOAKNSA-N
DM1DEYU IU (6aR,10aR)-6,6,9-trimethyl-3-(2-methylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene
DM1DEYU CA CAS 259869-55-1
DM1DEYU CB CHEBI:146243
DM1DEYU DE Discovery agent
DMZQ31O ID DMZQ31O
DMZQ31O DN JWH-145
DMZQ31O HS Investigative
DMZQ31O SN JWH-145; CHEMBL385940; naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone; JLXYYSHMURZHKI-UHFFFAOYSA-N; JWH 145; ZINC36294590
DMZQ31O DT Small molecular drug
DMZQ31O PC 44418304
DMZQ31O MW 367.5
DMZQ31O FM C26H25NO
DMZQ31O IC InChI=1S/C26H25NO/c1-2-3-9-17-27-19-22(18-25(27)21-12-5-4-6-13-21)26(28)24-16-10-14-20-11-7-8-15-23(20)24/h4-8,10-16,18-19H,2-3,9,17H2,1H3
DMZQ31O CS CCCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMZQ31O IK JLXYYSHMURZHKI-UHFFFAOYSA-N
DMZQ31O IU naphthalen-1-yl-(1-pentyl-5-phenylpyrrol-3-yl)methanone
DMZQ31O CA CAS 914458-19-8
DMZQ31O DE Discovery agent
DMU7E6A ID DMU7E6A
DMU7E6A DN JWH-146
DMU7E6A HS Investigative
DMU7E6A SN JWH-146; CHEMBL219970; 914458-21-2; (1-Heptyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenylmethanone; ZINC36294593; BDBM50192598
DMU7E6A DT Small molecular drug
DMU7E6A PC 44418308
DMU7E6A MW 395.5
DMU7E6A FM C28H29NO
DMU7E6A IC InChI=1S/C28H29NO/c1-2-3-4-5-11-19-29-21-24(20-27(29)23-14-7-6-8-15-23)28(30)26-18-12-16-22-13-9-10-17-25(22)26/h6-10,12-18,20-21H,2-5,11,19H2,1H3
DMU7E6A CS CCCCCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMU7E6A IK JDBFNFBWXVCTSA-UHFFFAOYSA-N
DMU7E6A IU (1-heptyl-5-phenylpyrrol-3-yl)-naphthalen-1-ylmethanone
DMU7E6A CA CAS 914458-21-2
DMU7E6A DE Discovery agent
DMEX9GV ID DMEX9GV
DMEX9GV DN JWH-147
DMEX9GV HS Investigative
DMEX9GV SN JWH-147; 914458-20-1; CHEMBL374982; (1-hexyl-5-phenyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; SCHEMBL15435604; JWH 147; DTXSID00658823; FRMYAMAGHYHNKF-UHFFFAOYSA-N; JWH-147"; ZINC36294592; BDBM50192588; AKOS015950991; AB1006809; FT-0669208; 1-Hexyl-2-phenyl-4-(1-naphthoyl)pyrroleJWH-147; 1-Hexyl-2-phenyl-4-(1-naphthoyl)pyrrole JWH-147; (1-Hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenylmethanone
DMEX9GV DT Small molecular drug
DMEX9GV PC 44418307
DMEX9GV MW 381.5
DMEX9GV FM C27H27NO
DMEX9GV IC InChI=1S/C27H27NO/c1-2-3-4-10-18-28-20-23(19-26(28)22-13-6-5-7-14-22)27(29)25-17-11-15-21-12-8-9-16-24(21)25/h5-9,11-17,19-20H,2-4,10,18H2,1H3
DMEX9GV CS CCCCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMEX9GV IK FRMYAMAGHYHNKF-UHFFFAOYSA-N
DMEX9GV IU (1-hexyl-5-phenylpyrrol-3-yl)-naphthalen-1-ylmethanone
DMEX9GV CA CAS 914458-20-1
DMEX9GV DE Discovery agent
DM86OZD ID DM86OZD
DM86OZD DN JWH-150
DM86OZD HS Investigative
DM86OZD SN JWH-150; CHEMBL216836; BDBM50192593
DM86OZD DT Small molecular drug
DM86OZD PC 44418303
DM86OZD MW 353.5
DM86OZD FM C25H23NO
DM86OZD IC InChI=1S/C25H23NO/c1-2-3-16-26-18-21(17-24(26)20-11-5-4-6-12-20)25(27)23-15-9-13-19-10-7-8-14-22(19)23/h4-15,17-18H,2-3,16H2,1H3
DM86OZD CS CCCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DM86OZD IK PTIAQHRJOQEMCO-UHFFFAOYSA-N
DM86OZD IU (1-butyl-5-phenylpyrrol-3-yl)-naphthalen-1-ylmethanone
DM86OZD DE Discovery agent
DMGPN61 ID DMGPN61
DMGPN61 DN JWH-151
DMGPN61 HS Investigative
DMGPN61 SN JWH-151; CHEMBL522550; SCHEMBL6330271; BDBM50265754; 1-propyl-2-methyl-3-(6-methoxy-1-naphthoyl)indole
DMGPN61 DT Small molecular drug
DMGPN61 PC 11233636
DMGPN61 MW 357.4
DMGPN61 FM C24H23NO2
DMGPN61 IC InChI=1S/C24H23NO2/c1-4-14-25-16(2)23(21-9-5-6-11-22(21)25)24(26)20-10-7-8-17-15-18(27-3)12-13-19(17)20/h5-13,15H,4,14H2,1-3H3
DMGPN61 CS CCCN1C(=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=C3C=CC(=C4)OC)C
DMGPN61 IK PJQIBVPPWAUFQB-UHFFFAOYSA-N
DMGPN61 IU (6-methoxynaphthalen-1-yl)-(2-methyl-1-propylindol-3-yl)methanone
DMGPN61 DE Discovery agent
DMWGSQO ID DMWGSQO
DMWGSQO DN JWH-156
DMWGSQO HS Investigative
DMWGSQO SN JWH-156; CHEMBL217969; BDBM50192590
DMWGSQO DT Small molecular drug
DMWGSQO PC 44418301
DMWGSQO MW 339.4
DMWGSQO FM C24H21NO
DMWGSQO IC InChI=1S/C24H21NO/c1-2-15-25-17-20(16-23(25)19-10-4-3-5-11-19)24(26)22-14-8-12-18-9-6-7-13-21(18)22/h3-14,16-17H,2,15H2,1H3
DMWGSQO CS CCCN1C=C(C=C1C2=CC=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMWGSQO IK CVADUNUZYYADMA-UHFFFAOYSA-N
DMWGSQO IU naphthalen-1-yl-(5-phenyl-1-propylpyrrol-3-yl)methanone
DMWGSQO DE Discovery agent
DMLDOYV ID DMLDOYV
DMLDOYV DN JWH-167
DMLDOYV HS Investigative
DMLDOYV SN 1-(1-Pentyl-1H-indol-3-yl)-2-phenylethanone; JWH-167; 864445-37-4; UNII-LQX1W3537N; CHEMBL365878; LQX1W3537N; 1-pentyl-3-phenylacetylindole; SCHEMBL20552905; DTXSID20235554; JWH 167; AMCPOEOUXQWESI-UHFFFAOYSA-N; 3543AC; BDBM50170338; ZINC28460304; AKOS016000818; AJ-83459; KB-212442; AX8250724
DMLDOYV DT Small molecular drug
DMLDOYV PC 44397502
DMLDOYV MW 305.4
DMLDOYV FM C21H23NO
DMLDOYV IC InChI=1S/C21H23NO/c1-2-3-9-14-22-16-19(18-12-7-8-13-20(18)22)21(23)15-17-10-5-4-6-11-17/h4-8,10-13,16H,2-3,9,14-15H2,1H3
DMLDOYV CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3
DMLDOYV IK AMCPOEOUXQWESI-UHFFFAOYSA-N
DMLDOYV IU 1-(1-pentylindol-3-yl)-2-phenylethanone
DMLDOYV CA CAS 864445-37-4
DMLDOYV DE Discovery agent
DMC2XSU ID DMC2XSU
DMC2XSU DN JWH-201
DMC2XSU HS Investigative
DMC2XSU SN JWH-201; JWH 201; 864445-47-6; CHEMBL188940; 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; DTXSID90658736; KQRKUKYSZPHOKC-UHFFFAOYSA-N; ZINC28459373; BDBM50170353; CCG-208746; FT-0670591; 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one
DMC2XSU DT Small molecular drug
DMC2XSU PC 44397641
DMC2XSU MW 335.4
DMC2XSU FM C22H25NO2
DMC2XSU IC InChI=1S/C22H25NO2/c1-3-4-7-14-23-16-20(19-8-5-6-9-21(19)23)22(24)15-17-10-12-18(25-2)13-11-17/h5-6,8-13,16H,3-4,7,14-15H2,1-2H3
DMC2XSU CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)OC
DMC2XSU IK KQRKUKYSZPHOKC-UHFFFAOYSA-N
DMC2XSU IU 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone
DMC2XSU CA CAS 864445-47-6
DMC2XSU DE Discovery agent
DMQU2SV ID DMQU2SV
DMQU2SV DN JWH-202
DMQU2SV HS Investigative
DMQU2SV SN JWH-202; CHEMBL364111; BDBM50170352; 2-(4-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone
DMQU2SV DT Small molecular drug
DMQU2SV PC 44397671
DMQU2SV MW 349.5
DMQU2SV FM C23H27NO2
DMQU2SV IC InChI=1S/C23H27NO2/c1-4-5-8-15-24-17(2)23(20-9-6-7-10-21(20)24)22(25)16-18-11-13-19(26-3)14-12-18/h6-7,9-14H,4-5,8,15-16H2,1-3H3
DMQU2SV CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)OC)C
DMQU2SV IK RNQWQIZOTKYEKJ-UHFFFAOYSA-N
DMQU2SV IU 2-(4-methoxyphenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMQU2SV DE Discovery agent
DMEJ8YA ID DMEJ8YA
DMEJ8YA DN JWH-203
DMEJ8YA HS Investigative
DMEJ8YA SN JWH-203; 864445-54-5; 2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; UNII-52CP80V8FY; 1-Pentyl-3-(2-chlorophenylacetyl)indole; JWH 203; CHEMBL189035; 52CP80V8FY; 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; JWH203; DEA No. 7203; SCHEMBL16201543; DTXSID00235557; YDINKDBAZJOSLV-UHFFFAOYSA-N; ZINC28457100; BDBM50170357; AKOS022186463; CCG-208745; AJ-83455; AK146159; AX8283836; KB-220910; ST24039182; FT-0670592; A20550; JWH-203 (1-pentyl-3-(2-chlorophenylacetyl)indole; 2-(2-Chlorophenyl)-1-(1-pentylindol-3-yl)methanone
DMEJ8YA DT Small molecular drug
DMEJ8YA PC 44397500
DMEJ8YA MW 339.9
DMEJ8YA FM C21H22ClNO
DMEJ8YA IC InChI=1S/C21H22ClNO/c1-2-3-8-13-23-15-18(17-10-5-7-12-20(17)23)21(24)14-16-9-4-6-11-19(16)22/h4-7,9-12,15H,2-3,8,13-14H2,1H3
DMEJ8YA CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Cl
DMEJ8YA IK YDINKDBAZJOSLV-UHFFFAOYSA-N
DMEJ8YA IU 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMEJ8YA CA CAS 864445-54-5
DMEJ8YA DE Discovery agent
DMDTILC ID DMDTILC
DMDTILC DN JWH-204
DMDTILC HS Investigative
DMDTILC SN JWH-204; CHEMBL361032; 2-(2-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170356
DMDTILC DT Small molecular drug
DMDTILC PC 44397501
DMDTILC MW 353.9
DMDTILC FM C22H24ClNO
DMDTILC IC InChI=1S/C22H24ClNO/c1-3-4-9-14-24-16(2)22(18-11-6-8-13-20(18)24)21(25)15-17-10-5-7-12-19(17)23/h5-8,10-13H,3-4,9,14-15H2,1-2H3
DMDTILC CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Cl)C
DMDTILC IK JUWWNZZHFZTXED-UHFFFAOYSA-N
DMDTILC IU 2-(2-chlorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMDTILC CA CAS 864445-55-6
DMDTILC DE Discovery agent
DMKIR63 ID DMKIR63
DMKIR63 DN JWH-205
DMKIR63 HS Investigative
DMKIR63 SN JWH-205; UNII-13OTY4DTE7; 13OTY4DTE7; CHEMBL186525; 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-phenylethanone; BDBM50170341; Ethanone, 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-phenyl-; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-phenyl-ethanone
DMKIR63 DT Small molecular drug
DMKIR63 PC 44397436
DMKIR63 MW 319.4
DMKIR63 FM C22H25NO
DMKIR63 IC InChI=1S/C22H25NO/c1-3-4-10-15-23-17(2)22(19-13-8-9-14-20(19)23)21(24)16-18-11-6-5-7-12-18/h5-9,11-14H,3-4,10,15-16H2,1-2H3
DMKIR63 CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3)C
DMKIR63 IK BVRXLMVNOFBNCJ-UHFFFAOYSA-N
DMKIR63 IU 1-(2-methyl-1-pentylindol-3-yl)-2-phenylethanone
DMKIR63 CA CAS 864445-38-5
DMKIR63 DE Discovery agent
DMGFSQB ID DMGFSQB
DMGFSQB DN JWH-206
DMGFSQB HS Investigative
DMGFSQB SN JWH-206; UNII-KC06JV2SNX; KC06JV2SNX; CHEMBL188819; 2-(4-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 864445-58-9; JWH 203 4-chlorophenyl isomer; GPMUZXUMSOFDBA-UHFFFAOYSA-N; ZINC28461030; BDBM50170348; 2-(4-Chloro-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(4-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMGFSQB DT Small molecular drug
DMGFSQB PC 44397532
DMGFSQB MW 339.9
DMGFSQB FM C21H22ClNO
DMGFSQB IC InChI=1S/C21H22ClNO/c1-2-3-6-13-23-15-19(18-7-4-5-8-20(18)23)21(24)14-16-9-11-17(22)12-10-16/h4-5,7-12,15H,2-3,6,13-14H2,1H3
DMGFSQB CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)Cl
DMGFSQB IK GPMUZXUMSOFDBA-UHFFFAOYSA-N
DMGFSQB IU 2-(4-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMGFSQB CA CAS 864445-58-9
DMGFSQB DE Discovery agent
DMF70IM ID DMF70IM
DMF70IM DN JWH-207
DMF70IM HS Investigative
DMF70IM SN JWH-207; UNII-828QKW93YY; 828QKW93YY; CHEMBL187813; 2-(4-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170350; Ethanone, 2-(4-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl); 2-(4-Chloro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DMF70IM DT Small molecular drug
DMF70IM PC 44397533
DMF70IM MW 353.9
DMF70IM FM C22H24ClNO
DMF70IM IC InChI=1S/C22H24ClNO/c1-3-4-7-14-24-16(2)22(19-8-5-6-9-20(19)24)21(25)15-17-10-12-18(23)13-11-17/h5-6,8-13H,3-4,7,14-15H2,1-2H3
DMF70IM CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)Cl)C
DMF70IM IK ZFTOVDKPJSCPEE-UHFFFAOYSA-N
DMF70IM IU 2-(4-chlorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMF70IM CA CAS 864445-59-0
DMF70IM DE Discovery agent
DMLYHUN ID DMLYHUN
DMLYHUN DN JWH-208
DMLYHUN HS Investigative
DMLYHUN SN JWH-208; BDU1DA9SRY; UNII-BDU1DA9SRY; CHEMBL187354; JWH 251 4-methylphenyl isomer; 864445-41-0; GSVYYNBRAJBCQS-UHFFFAOYSA-N; ZINC28462048; BDBM50170351; 1-(1-pentyl-1H-indol-3-yl)-2-p-tolylethanone; 1-(1-Pentyl-1H-indol-3-yl)-2-p-tolyl-ethanone; 2-(4-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; Ethanone, 2-(4-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMLYHUN DT Small molecular drug
DMLYHUN PC 44397464
DMLYHUN MW 319.4
DMLYHUN FM C22H25NO
DMLYHUN IC InChI=1S/C22H25NO/c1-3-4-7-14-23-16-20(19-8-5-6-9-21(19)23)22(24)15-18-12-10-17(2)11-13-18/h5-6,8-13,16H,3-4,7,14-15H2,1-2H3
DMLYHUN CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)C
DMLYHUN IK GSVYYNBRAJBCQS-UHFFFAOYSA-N
DMLYHUN IU 2-(4-methylphenyl)-1-(1-pentylindol-3-yl)ethanone
DMLYHUN CA CAS 864445-41-0
DMLYHUN DE Discovery agent
DMDXCIV ID DMDXCIV
DMDXCIV DN JWH-209
DMDXCIV HS Investigative
DMDXCIV SN JWH-209; UNII-2A7P4YEN6H; 2A7P4YEN6H; CHEMBL187771; BDBM50170347; 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-p-tolylethanone; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-p-tolyl-ethanone; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-(4-methylphenyl)ethanone; Ethanone, 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-(4-methylphenyl)-
DMDXCIV DT Small molecular drug
DMDXCIV PC 44397465
DMDXCIV MW 333.5
DMDXCIV FM C23H27NO
DMDXCIV IC InChI=1S/C23H27NO/c1-4-5-8-15-24-18(3)23(20-9-6-7-10-21(20)24)22(25)16-19-13-11-17(2)12-14-19/h6-7,9-14H,4-5,8,15-16H2,1-3H3
DMDXCIV CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)C)C
DMDXCIV IK RDYZLFKKWNGIJS-UHFFFAOYSA-N
DMDXCIV IU 1-(2-methyl-1-pentylindol-3-yl)-2-(4-methylphenyl)ethanone
DMDXCIV CA CAS 864445-42-1
DMDXCIV DE Discovery agent
DMMKYGP ID DMMKYGP
DMMKYGP DN JWH-229
DMMKYGP HS Investigative
DMMKYGP SN JWH-229; UNII-8HHX5B1WP5; 8HHX5B1WP5; CHEMBL498346; 1-Methoxy-3-(1',1'-dimethylhexyl)-Delta(8)-THC; BDBM50265755; 832111-99-6; 6H-Dibenzo(b,d)pyran, 3-(1,1-dimethylhexyl)-6a,7,8,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-, (6aR,10aR)-
DMMKYGP DT Small molecular drug
DMMKYGP PC 44581105
DMMKYGP MW 370.6
DMMKYGP FM C25H38O2
DMMKYGP IC InChI=1S/C25H38O2/c1-8-9-10-13-24(3,4)18-15-21(26-7)23-19-14-17(2)11-12-20(19)25(5,6)27-22(23)16-18/h14-16,19-20H,8-13H2,1-7H3/t19-,20-/m1/s1
DMMKYGP CS CCCCCC(C)(C)C1=CC2=C([C@@H]3C=C(CC[C@H]3C(O2)(C)C)C)C(=C1)OC
DMMKYGP IK PUBXDTLETUTKIJ-WOJBJXKFSA-N
DMMKYGP IU (6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-(2-methylheptan-2-yl)-6a,7,8,10a-tetrahydrobenzo[c]chromene
DMMKYGP CA CAS 832111-99-6
DMMKYGP DE Discovery agent
DMRQOL5 ID DMRQOL5
DMRQOL5 DN JWH-237
DMRQOL5 HS Investigative
DMRQOL5 SN JWH-237; UNII-NR611I7X19; CHEMBL188822; NR611I7X19; 2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 864445-56-7; JWH 203 3-chlorophenyl isomer; KURUPMPUIIQATM-UHFFFAOYSA-N; ZINC28463001; BDBM50170332; 2-(3-Chloro-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMRQOL5 DT Small molecular drug
DMRQOL5 PC 44397713
DMRQOL5 MW 339.9
DMRQOL5 FM C21H22ClNO
DMRQOL5 IC InChI=1S/C21H22ClNO/c1-2-3-6-12-23-15-19(18-10-4-5-11-20(18)23)21(24)14-16-8-7-9-17(22)13-16/h4-5,7-11,13,15H,2-3,6,12,14H2,1H3
DMRQOL5 CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)Cl
DMRQOL5 IK KURUPMPUIIQATM-UHFFFAOYSA-N
DMRQOL5 IU 2-(3-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMRQOL5 CA CAS 864445-56-7
DMRQOL5 DE Discovery agent
DMGD73A ID DMGD73A
DMGD73A DN JWH-243
DMGD73A HS Investigative
DMGD73A SN JWH-243; CHEMBL220413; BDBM50192609
DMGD73A DT Small molecular drug
DMGD73A PC 44418354
DMGD73A MW 397.5
DMGD73A FM C27H27NO2
DMGD73A IC InChI=1S/C27H27NO2/c1-3-4-7-17-28-19-22(18-26(28)21-13-15-23(30-2)16-14-21)27(29)25-12-8-10-20-9-5-6-11-24(20)25/h5-6,8-16,18-19H,3-4,7,17H2,1-2H3
DMGD73A CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)OC)C(=O)C3=CC=CC4=CC=CC=C43
DMGD73A IK IQIAZANEJACDNJ-UHFFFAOYSA-N
DMGD73A IU [5-(4-methoxyphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMGD73A DE Discovery agent
DMETAOU ID DMETAOU
DMETAOU DN JWH-244
DMETAOU HS Investigative
DMETAOU SN JWH-244; CHEMBL385653; BDBM50192596
DMETAOU DT Small molecular drug
DMETAOU PC 44418345
DMETAOU MW 381.5
DMETAOU FM C27H27NO
DMETAOU IC InChI=1S/C27H27NO/c1-3-4-7-17-28-19-23(18-26(28)22-15-13-20(2)14-16-22)27(29)25-12-8-10-21-9-5-6-11-24(21)25/h5-6,8-16,18-19H,3-4,7,17H2,1-2H3
DMETAOU CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)C)C(=O)C3=CC=CC4=CC=CC=C43
DMETAOU IK RZASCFFZBHYWDH-UHFFFAOYSA-N
DMETAOU IU [5-(4-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMETAOU DE Discovery agent
DMC5RZ9 ID DMC5RZ9
DMC5RZ9 DN JWH-245
DMC5RZ9 HS Investigative
DMC5RZ9 SN JWH-245; CHEMBL219027; BDBM50192587
DMC5RZ9 DT Small molecular drug
DMC5RZ9 PC 44418367
DMC5RZ9 MW 401.9
DMC5RZ9 FM C26H24ClNO
DMC5RZ9 IC InChI=1S/C26H24ClNO/c1-2-3-6-16-28-18-21(17-25(28)20-12-14-22(27)15-13-20)26(29)24-11-7-9-19-8-4-5-10-23(19)24/h4-5,7-15,17-18H,2-3,6,16H2,1H3
DMC5RZ9 CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)Cl)C(=O)C3=CC=CC4=CC=CC=C43
DMC5RZ9 IK GBQKSTSSOVRZFN-UHFFFAOYSA-N
DMC5RZ9 IU [5-(4-chlorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMC5RZ9 CA CAS 914458-40-5
DMC5RZ9 DE Discovery agent
DMGTEYB ID DMGTEYB
DMGTEYB DN JWH-246
DMGTEYB HS Investigative
DMGTEYB SN JWH-246; CHEMBL374937; BDBM50192612
DMGTEYB DT Small molecular drug
DMGTEYB PC 44418337
DMGTEYB MW 401.9
DMGTEYB FM C26H24ClNO
DMGTEYB IC InChI=1S/C26H24ClNO/c1-2-3-6-15-28-18-21(17-25(28)20-11-7-12-22(27)16-20)26(29)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMGTEYB CS CCCCCN1C=C(C=C1C2=CC(=CC=C2)Cl)C(=O)C3=CC=CC4=CC=CC=C43
DMGTEYB IK UVJANPIKZUBGAE-UHFFFAOYSA-N
DMGTEYB IU [5-(3-chlorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMGTEYB DE Discovery agent
DMURL8D ID DMURL8D
DMURL8D DN JWH-248
DMURL8D HS Investigative
DMURL8D SN JWH-248; CHEMBL190305; BDBM50170349; 2-(4-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMURL8D DT Small molecular drug
DMURL8D PC 44397610
DMURL8D MW 384.3
DMURL8D FM C21H22BrNO
DMURL8D IC InChI=1S/C21H22BrNO/c1-2-3-6-13-23-15-19(18-7-4-5-8-20(18)23)21(24)14-16-9-11-17(22)12-10-16/h4-5,7-12,15H,2-3,6,13-14H2,1H3
DMURL8D CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)Br
DMURL8D IK BMRAIRSNJUSFSM-UHFFFAOYSA-N
DMURL8D IU 2-(4-bromophenyl)-1-(1-pentylindol-3-yl)ethanone
DMURL8D DE Discovery agent
DMTOUCL ID DMTOUCL
DMTOUCL DN JWH-249
DMTOUCL HS Investigative
DMTOUCL SN JWH-249; 1-pentyl-3-(2-bromophenylacetyl)indole; 864445-60-3; UNII-H988KQV4U9; H988KQV4U9; CHEMBL363471; 2-(2-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; DTXSID30658735; JWH 249; CGQRVOHECAULLB-UHFFFAOYSA-N; ZINC28461369; BDBM50170337; 2-(2-Bromo-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(2-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMTOUCL DT Small molecular drug
DMTOUCL PC 44397335
DMTOUCL MW 384.3
DMTOUCL FM C21H22BrNO
DMTOUCL IC InChI=1S/C21H22BrNO/c1-2-3-8-13-23-15-18(17-10-5-7-12-20(17)23)21(24)14-16-9-4-6-11-19(16)22/h4-7,9-12,15H,2-3,8,13-14H2,1H3
DMTOUCL CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Br
DMTOUCL IK CGQRVOHECAULLB-UHFFFAOYSA-N
DMTOUCL IU 2-(2-bromophenyl)-1-(1-pentylindol-3-yl)ethanone
DMTOUCL CA CAS 864445-60-3
DMTOUCL DE Discovery agent
DMWVS5X ID DMWVS5X
DMWVS5X DN JWH-250
DMWVS5X HS Investigative
DMWVS5X SN 864445-43-2; 2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; UNII-IP9911R8A0; CHEMBL188031; FFLSJIQJQKDDCM-UHFFFAOYSA-N; IP9911R8A0; Q-200139; 1-Pentyl-3-(2-methoxyphenylacetyl)indole; DEA No. 6250; SCHEMBL11983322; CTK8C5059; JWH 250; DTXSID40235556; MolPort-009-019-586; KS-000024QU; ANW-73903; ZINC28465020; MFCD12911796; BDBM50170335; AKOS015999864; DS-3158; CCG-208724; NCGC00386575-01; AJ-83461; CJ-17680; AK-82232; AN-26990; KB-110367; TC-162648; ST24021676
DMWVS5X DT Small molecular drug
DMWVS5X PC 44397540
DMWVS5X MW 335.4
DMWVS5X FM C22H25NO2
DMWVS5X IC InChI=1S/C22H25NO2/c1-3-4-9-14-23-16-19(18-11-6-7-12-20(18)23)21(24)15-17-10-5-8-13-22(17)25-2/h5-8,10-13,16H,3-4,9,14-15H2,1-2H3
DMWVS5X CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3OC
DMWVS5X IK FFLSJIQJQKDDCM-UHFFFAOYSA-N
DMWVS5X IU 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone
DMWVS5X CA CAS 864445-43-2
DMWVS5X DE Discovery agent
DMOJAUI ID DMOJAUI
DMOJAUI DN JWH-251
DMOJAUI HS Investigative
DMOJAUI SN JWH-251; UNII-55H9NDH32M; 1-Pentyl-3-(2-methylphenylacetyl)indole; 864445-39-6; CHEMBL364820; 55H9NDH32M; 2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 2-(2-methylphenyl)-1-(1-pentylindol-3-yl)ethanone; SCHEMBL2473611; JWH 251; DTXSID80235555; YBIPNGRKUAVSBG-UHFFFAOYSA-N; ZINC28463005; BDBM50170339; CCG-208751; FT-0670595; 1-(1-pentyl-1H-indol-3-yl)-2-o-tolylethanone
DMOJAUI DT Small molecular drug
DMOJAUI PC 11616723
DMOJAUI MW 319.4
DMOJAUI FM C22H25NO
DMOJAUI IC InChI=1S/C22H25NO/c1-3-4-9-14-23-16-20(19-12-7-8-13-21(19)23)22(24)15-18-11-6-5-10-17(18)2/h5-8,10-13,16H,3-4,9,14-15H2,1-2H3
DMOJAUI CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3C
DMOJAUI IK YBIPNGRKUAVSBG-UHFFFAOYSA-N
DMOJAUI IU 2-(2-methylphenyl)-1-(1-pentylindol-3-yl)ethanone
DMOJAUI CA CAS 864445-39-6
DMOJAUI DE Discovery agent
DM6IWCZ ID DM6IWCZ
DM6IWCZ DN JWH-252
DM6IWCZ HS Investigative
DM6IWCZ SN JWH-252; CHEMBL188494; BDBM50170343; 1-(2-methyl-1-pentyl-1H-indol-3-yl)-2-o-tolylethanone
DM6IWCZ DT Small molecular drug
DM6IWCZ PC 44397635
DM6IWCZ MW 333.5
DM6IWCZ FM C23H27NO
DM6IWCZ IC InChI=1S/C23H27NO/c1-4-5-10-15-24-18(3)23(20-13-8-9-14-21(20)24)22(25)16-19-12-7-6-11-17(19)2/h6-9,11-14H,4-5,10,15-16H2,1-3H3
DM6IWCZ CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3C)C
DM6IWCZ IK NHQVWPJMCINXPI-UHFFFAOYSA-N
DM6IWCZ IU 1-(2-methyl-1-pentylindol-3-yl)-2-(2-methylphenyl)ethanone
DM6IWCZ DE Discovery agent
DML1UMX ID DML1UMX
DML1UMX DN JWH-253
DML1UMX HS Investigative
DML1UMX SN JWH-253; UNII-E28U9TD6JM; E28U9TD6JM; CHEMBL188887; 2-(3-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170334; Ethanone, 2-(3-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-; 2-(3-Methoxy-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DML1UMX DT Small molecular drug
DML1UMX PC 44397405
DML1UMX MW 349.5
DML1UMX FM C23H27NO2
DML1UMX IC InChI=1S/C23H27NO2/c1-4-5-8-14-24-17(2)23(20-12-6-7-13-21(20)24)22(25)16-18-10-9-11-19(15-18)26-3/h6-7,9-13,15H,4-5,8,14,16H2,1-3H3
DML1UMX CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)OC)C
DML1UMX IK QZLRCHSRCYFMFK-UHFFFAOYSA-N
DML1UMX IU 2-(3-methoxyphenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DML1UMX CA CAS 864445-46-5
DML1UMX DE Discovery agent
DM07XBG ID DM07XBG
DM07XBG DN JWH-268
DM07XBG HS Investigative
DM07XBG SN JWH-268; CHEMBL524822; SCHEMBL6333837; BDBM50265756
DM07XBG DT Small molecular drug
DM07XBG PC 11406508
DM07XBG MW 385.5
DM07XBG FM C26H27NO2
DM07XBG IC InChI=1S/C26H27NO2/c1-4-5-10-17-27-18(2)24(21-13-8-9-14-22(21)27)26(28)25-20-12-7-6-11-19(20)15-16-23(25)29-3/h6-9,11-16H,4-5,10,17H2,1-3H3
DM07XBG CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)C3=C(C=CC4=CC=CC=C43)OC)C
DM07XBG IK POCUOUJJUBHVTI-UHFFFAOYSA-N
DM07XBG IU (2-methoxynaphthalen-1-yl)-(2-methyl-1-pentylindol-3-yl)methanone
DM07XBG DE Discovery agent
DM5FAUY ID DM5FAUY
DM5FAUY DN JWH-292
DM5FAUY HS Investigative
DM5FAUY SN JWH-292; CHEMBL218202; BDBM50192586
DM5FAUY DT Small molecular drug
DM5FAUY PC 44418317
DM5FAUY MW 397.5
DM5FAUY FM C27H27NO2
DM5FAUY IC InChI=1S/C27H27NO2/c1-3-4-9-17-28-19-21(18-25(28)24-14-7-8-16-26(24)30-2)27(29)23-15-10-12-20-11-5-6-13-22(20)23/h5-8,10-16,18-19H,3-4,9,17H2,1-2H3
DM5FAUY CS CCCCCN1C=C(C=C1C2=CC=CC=C2OC)C(=O)C3=CC=CC4=CC=CC=C43
DM5FAUY IK RWYPPHVLXFTKAG-UHFFFAOYSA-N
DM5FAUY IU [5-(2-methoxyphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM5FAUY DE Discovery agent
DMCK1XR ID DMCK1XR
DMCK1XR DN JWH-293
DMCK1XR HS Investigative
DMCK1XR SN JWH-293; CHEMBL218253; BDBM50192600
DMCK1XR DT Small molecular drug
DMCK1XR PC 44418344
DMCK1XR MW 412.5
DMCK1XR FM C26H24N2O3
DMCK1XR IC InChI=1S/C26H24N2O3/c1-2-3-6-15-27-18-21(17-25(27)20-11-7-12-22(16-20)28(30)31)26(29)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMCK1XR CS CCCCCN1C=C(C=C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)C3=CC=CC4=CC=CC=C43
DMCK1XR IK FQGNQKRWZNTBLM-UHFFFAOYSA-N
DMCK1XR IU naphthalen-1-yl-[5-(3-nitrophenyl)-1-pentylpyrrol-3-yl]methanone
DMCK1XR DE Discovery agent
DMTMF8X ID DMTMF8X
DMTMF8X DN JWH-294
DMTMF8X HS Investigative
DMTMF8X SN JWH-294; CHEMBL259293
DMTMF8X DT Small molecular drug
DMTMF8X PC 44452669
DMTMF8X MW 246.4
DMTMF8X FM C17H26O
DMTMF8X IC InChI=1S/C17H26O/c1-4-17(2,3)15-10-8-13(9-11-15)14-6-5-7-16(18)12-14/h8-11,14,16,18H,4-7,12H2,1-3H3/t14-,16+/m0/s1
DMTMF8X CS CCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMTMF8X IK NGNJEMWGXAUJKO-GOEBONIOSA-N
DMTMF8X IU (1R,3S)-3-[4-(2-methylbutan-2-yl)phenyl]cyclohexan-1-ol
DMTMF8X DE Discovery agent
DMUMJGD ID DMUMJGD
DMUMJGD DN JWH-295
DMUMJGD HS Investigative
DMUMJGD SN JWH-295; CHEMBL407763
DMUMJGD DT Small molecular drug
DMUMJGD PC 44452602
DMUMJGD MW 246.4
DMUMJGD FM C17H26O
DMUMJGD IC InChI=1S/C17H26O/c1-4-17(2,3)15-10-8-13(9-11-15)14-6-5-7-16(18)12-14/h8-11,14,16,18H,4-7,12H2,1-3H3/t14-,16-/m1/s1
DMUMJGD CS CCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DMUMJGD IK NGNJEMWGXAUJKO-GDBMZVCRSA-N
DMUMJGD IU (1R,3R)-3-[4-(2-methylbutan-2-yl)phenyl]cyclohexan-1-ol
DMUMJGD DE Discovery agent
DMNRXJU ID DMNRXJU
DMNRXJU DN JWH-296
DMNRXJU HS Investigative
DMNRXJU SN JWH-296; CHEMBL408060
DMNRXJU DT Small molecular drug
DMNRXJU PC 44452670
DMNRXJU MW 260.399
DMNRXJU FM C18H28O
DMNRXJU IC InChI=1S/C18H28O/c1-4-12-18(2,3)16-10-8-14(9-11-16)15-6-5-7-17(19)13-15/h8-11,15,17,19H,4-7,12-13H2,1-3H3/t15-,17+/m0/s1
DMNRXJU CS CCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMNRXJU IK IWAZRTQOOAVKDN-DOTOQJQBSA-N
DMNRXJU IU (1R,3S)-3-[4-(2-methylpentan-2-yl)phenyl]cyclohexan-1-ol
DMNRXJU DE Discovery agent
DM4A761 ID DM4A761
DM4A761 DN JWH-297
DM4A761 HS Investigative
DM4A761 SN JWH-297; CHEMBL260005
DM4A761 DT Small molecular drug
DM4A761 PC 44452601
DM4A761 MW 260.399
DM4A761 FM C18H28O
DM4A761 IC InChI=1S/C18H28O/c1-4-12-18(2,3)16-10-8-14(9-11-16)15-6-5-7-17(19)13-15/h8-11,15,17,19H,4-7,12-13H2,1-3H3/t15-,17-/m1/s1
DM4A761 CS CCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DM4A761 IK IWAZRTQOOAVKDN-NVXWUHKLSA-N
DM4A761 IU (1R,3R)-3-[4-(2-methylpentan-2-yl)phenyl]cyclohexan-1-ol
DM4A761 DE Discovery agent
DMI7LF1 ID DMI7LF1
DMI7LF1 DN JWH-302
DMI7LF1 HS Investigative
DMI7LF1 SN JWH-302; UNII-DQF20NHW2M; DQF20NHW2M; CHEMBL186674; 2-(3-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 864445-45-4; JWH 302; SCHEMBL2471302; DTXSID60467554; XZVYWLVYUAQEIM-UHFFFAOYSA-N; ZINC28456868; BDBM50170333; CCG-208748; 1-pentyl-3-(3-methoxyphenylacetyl)indole; FT-0670596; 2-(3-Methoxy-phenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-
DMI7LF1 DT Small molecular drug
DMI7LF1 PC 11493740
DMI7LF1 MW 335.4
DMI7LF1 FM C22H25NO2
DMI7LF1 IC InChI=1S/C22H25NO2/c1-3-4-7-13-23-16-20(19-11-5-6-12-21(19)23)22(24)15-17-9-8-10-18(14-17)25-2/h5-6,8-12,14,16H,3-4,7,13,15H2,1-2H3
DMI7LF1 CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)OC
DMI7LF1 IK XZVYWLVYUAQEIM-UHFFFAOYSA-N
DMI7LF1 IU 2-(3-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone
DMI7LF1 CA CAS 864445-45-4
DMI7LF1 DE Discovery agent
DMCLAHR ID DMCLAHR
DMCLAHR DN JWH-303
DMCLAHR HS Investigative
DMCLAHR SN JWH-303; UNII-ZW7N2KTX23; ZW7N2KTX23; CHEMBL188910; 2-(3-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone; BDBM50170355; 2-(3-Chloro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone; Ethanone, 2-(3-chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-
DMCLAHR DT Small molecular drug
DMCLAHR PC 44397333
DMCLAHR MW 353.9
DMCLAHR FM C22H24ClNO
DMCLAHR IC InChI=1S/C22H24ClNO/c1-3-4-7-13-24-16(2)22(19-11-5-6-12-20(19)24)21(25)15-17-9-8-10-18(23)14-17/h5-6,8-12,14H,3-4,7,13,15H2,1-2H3
DMCLAHR CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)Cl)C
DMCLAHR IK IVDPZBGEPKPWGK-UHFFFAOYSA-N
DMCLAHR IU 2-(3-chlorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMCLAHR CA CAS 864445-57-8
DMCLAHR DE Discovery agent
DM36W9M ID DM36W9M
DM36W9M DN JWH-305
DM36W9M HS Investigative
DM36W9M SN JWH-305; CHEMBL187559; BDBM50170345; 2-(2-Bromo-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DM36W9M DT Small molecular drug
DM36W9M PC 44397336
DM36W9M MW 398.3
DM36W9M FM C22H24BrNO
DM36W9M IC InChI=1S/C22H24BrNO/c1-3-4-9-14-24-16(2)22(18-11-6-8-13-20(18)24)21(25)15-17-10-5-7-12-19(17)23/h5-8,10-13H,3-4,9,14-15H2,1-2H3
DM36W9M CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3Br)C
DM36W9M IK VCQGIPSJKBCBFO-UHFFFAOYSA-N
DM36W9M IU 2-(2-bromophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DM36W9M DE Discovery agent
DMPDJKG ID DMPDJKG
DMPDJKG DN JWH-306
DMPDJKG HS Investigative
DMPDJKG SN JWH-306; CHEMBL361088; BDBM50170342; 2-(2-methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)ethanone
DMPDJKG DT Small molecular drug
DMPDJKG PC 44397559
DMPDJKG MW 349.5
DMPDJKG FM C23H27NO2
DMPDJKG IC InChI=1S/C23H27NO2/c1-4-5-10-15-24-17(2)23(19-12-7-8-13-20(19)24)21(25)16-18-11-6-9-14-22(18)26-3/h6-9,11-14H,4-5,10,15-16H2,1-3H3
DMPDJKG CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3OC)C
DMPDJKG IK HGGHYEFHTTXEIQ-UHFFFAOYSA-N
DMPDJKG IU 2-(2-methoxyphenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMPDJKG CA CAS 864445-44-3
DMPDJKG DE Discovery agent
DM23RUZ ID DM23RUZ
DM23RUZ DN JWH-307
DM23RUZ HS Investigative
DM23RUZ SN 914458-26-7; (5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; JWH-307; UNII-06QTR14ONW; 06QTR14ONW; CHEMBL216857; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; SCHEMBL17464417; CTK8C0835; DTXSID60581542; ZINC34947163; 5343AC; ANW-65338; BDBM50192607; AKOS016005279; AJ-90459; TC-154083; KB-208480; AX8234389; ST24034774; FT-0747021; (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone
DM23RUZ DT Small molecular drug
DM23RUZ PC 16049783
DM23RUZ MW 385.5
DM23RUZ FM C26H24FNO
DM23RUZ IC InChI=1S/C26H24FNO/c1-2-3-8-16-28-18-20(17-25(28)23-13-6-7-15-24(23)27)26(29)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
DM23RUZ CS CCCCCN1C=C(C=C1C2=CC=CC=C2F)C(=O)C3=CC=CC4=CC=CC=C43
DM23RUZ IK WYNZPDDTQGVCLZ-UHFFFAOYSA-N
DM23RUZ IU [5-(2-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM23RUZ CA CAS 914458-26-7
DM23RUZ DE Discovery agent
DMV5ASE ID DMV5ASE
DMV5ASE DN JWH-308
DMV5ASE HS Investigative
DMV5ASE SN (5-(4-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; 914458-39-2; JWH-308; CHEMBL374292; [5-(4-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; CTK8B4184; DTXSID20658825; ANW-44201; 5345AC; ZINC36294625; BDBM50192602; AKOS015999107; AJ-92571; KB-208490; AX8228513; TC-132946
DMV5ASE DT Small molecular drug
DMV5ASE PC 44418355
DMV5ASE MW 385.5
DMV5ASE FM C26H24FNO
DMV5ASE IC InChI=1S/C26H24FNO/c1-2-3-6-16-28-18-21(17-25(28)20-12-14-22(27)15-13-20)26(29)24-11-7-9-19-8-4-5-10-23(19)24/h4-5,7-15,17-18H,2-3,6,16H2,1H3
DMV5ASE CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)F)C(=O)C3=CC=CC4=CC=CC=C43
DMV5ASE IK PJNACIYIFHTDCK-UHFFFAOYSA-N
DMV5ASE IU [5-(4-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMV5ASE CA CAS 914458-39-2
DMV5ASE DE Discovery agent
DMTV1B9 ID DMTV1B9
DMTV1B9 DN JWH-309
DMTV1B9 HS Investigative
DMTV1B9 SN JWH-309; CHEMBL376028; ZINC36294630; BDBM50192591
DMTV1B9 DT Small molecular drug
DMTV1B9 PC 44418371
DMTV1B9 MW 417.5
DMTV1B9 FM C30H27NO
DMTV1B9 IC InChI=1S/C30H27NO/c1-2-3-8-19-31-21-24(30(32)28-18-10-14-23-12-5-7-16-26(23)28)20-29(31)27-17-9-13-22-11-4-6-15-25(22)27/h4-7,9-18,20-21H,2-3,8,19H2,1H3
DMTV1B9 CS CCCCCN1C=C(C=C1C2=CC=CC3=CC=CC=C32)C(=O)C4=CC=CC5=CC=CC=C54
DMTV1B9 IK WVISOUYKTUUDFW-UHFFFAOYSA-N
DMTV1B9 IU naphthalen-1-yl-(5-naphthalen-1-yl-1-pentylpyrrol-3-yl)methanone
DMTV1B9 DE Discovery agent
DMLABGW ID DMLABGW
DMLABGW DN JWH-311
DMLABGW HS Investigative
DMLABGW SN JWH-311; CHEMBL187883; BDBM50170331; 2-(2-fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMLABGW DT Small molecular drug
DMLABGW PC 44397516
DMLABGW MW 323.4
DMLABGW FM C21H22FNO
DMLABGW IC InChI=1S/C21H22FNO/c1-2-3-8-13-23-15-18(17-10-5-7-12-20(17)23)21(24)14-16-9-4-6-11-19(16)22/h4-7,9-12,15H,2-3,8,13-14H2,1H3
DMLABGW CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3F
DMLABGW IK RLINGXSUWCVHIQ-UHFFFAOYSA-N
DMLABGW IU 2-(2-fluorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMLABGW DE Discovery agent
DMYIGCU ID DMYIGCU
DMYIGCU DN JWH-312
DMYIGCU HS Investigative
DMYIGCU SN JWH-312; CHEMBL189545; BDBM50170344; 2-(3-fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMYIGCU DT Small molecular drug
DMYIGCU PC 44397383
DMYIGCU MW 323.4
DMYIGCU FM C21H22FNO
DMYIGCU IC InChI=1S/C21H22FNO/c1-2-3-6-12-23-15-19(18-10-4-5-11-20(18)23)21(24)14-16-8-7-9-17(22)13-16/h4-5,7-11,13,15H,2-3,6,12,14H2,1H3
DMYIGCU CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)F
DMYIGCU IK ZOBARDBQXUOIQF-UHFFFAOYSA-N
DMYIGCU IU 2-(3-fluorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMYIGCU DE Discovery agent
DMWBHZL ID DMWBHZL
DMWBHZL DN JWH-313
DMWBHZL HS Investigative
DMWBHZL SN JWH-313; CHEMBL187412; BDBM50170330; 2-(4-fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone
DMWBHZL DT Small molecular drug
DMWBHZL PC 44397491
DMWBHZL MW 323.4
DMWBHZL FM C21H22FNO
DMWBHZL IC InChI=1S/C21H22FNO/c1-2-3-6-13-23-15-19(18-7-4-5-8-20(18)23)21(24)14-16-9-11-17(22)12-10-16/h4-5,7-12,15H,2-3,6,13-14H2,1H3
DMWBHZL CS CCCCCN1C=C(C2=CC=CC=C21)C(=O)CC3=CC=C(C=C3)F
DMWBHZL IK QGDPTDVGZNHCIR-UHFFFAOYSA-N
DMWBHZL IU 2-(4-fluorophenyl)-1-(1-pentylindol-3-yl)ethanone
DMWBHZL DE Discovery agent
DMCEKNJ ID DMCEKNJ
DMCEKNJ DN JWH-314
DMCEKNJ HS Investigative
DMCEKNJ SN JWH-314; CHEMBL190469; BDBM50170354; 2-(2-Fluoro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DMCEKNJ DT Small molecular drug
DMCEKNJ PC 44397542
DMCEKNJ MW 337.4
DMCEKNJ FM C22H24FNO
DMCEKNJ IC InChI=1S/C22H24FNO/c1-3-4-9-14-24-16(2)22(18-11-6-8-13-20(18)24)21(25)15-17-10-5-7-12-19(17)23/h5-8,10-13H,3-4,9,14-15H2,1-2H3
DMCEKNJ CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3F)C
DMCEKNJ IK SMBDYSPMOWAQKQ-UHFFFAOYSA-N
DMCEKNJ IU 2-(2-fluorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMCEKNJ DE Discovery agent
DMWHN56 ID DMWHN56
DMWHN56 DN JWH-315
DMWHN56 HS Investigative
DMWHN56 SN JWH-315; CHEMBL427524; BDBM50170336; 2-(3-Fluoro-phenyl)-1-(2-methyl-1-pentyl-1H-indol-3-yl)-ethanone
DMWHN56 DT Small molecular drug
DMWHN56 PC 44397406
DMWHN56 MW 337.4
DMWHN56 FM C22H24FNO
DMWHN56 IC InChI=1S/C22H24FNO/c1-3-4-7-13-24-16(2)22(19-11-5-6-12-20(19)24)21(25)15-17-9-8-10-18(23)14-17/h5-6,8-12,14H,3-4,7,13,15H2,1-2H3
DMWHN56 CS CCCCCN1C(=C(C2=CC=CC=C21)C(=O)CC3=CC(=CC=C3)F)C
DMWHN56 IK STCKLQNFQVHGSM-UHFFFAOYSA-N
DMWHN56 IU 2-(3-fluorophenyl)-1-(2-methyl-1-pentylindol-3-yl)ethanone
DMWHN56 DE Discovery agent
DM63LOX ID DM63LOX
DM63LOX DN JWH-323
DM63LOX HS Investigative
DM63LOX SN JWH-323; CHEMBL263399
DM63LOX DT Small molecular drug
DM63LOX PC 44452648
DM63LOX MW 274.4
DM63LOX FM C19H30O
DM63LOX IC InChI=1S/C19H30O/c1-4-5-13-19(2,3)17-11-9-15(10-12-17)16-7-6-8-18(20)14-16/h9-12,16,18,20H,4-8,13-14H2,1-3H3/t16-,18+/m0/s1
DM63LOX CS CCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DM63LOX IK WMICXNJEJDOUPN-FUHWJXTLSA-N
DM63LOX IU (1R,3S)-3-[4-(2-methylhexan-2-yl)phenyl]cyclohexan-1-ol
DM63LOX DE Discovery agent
DMJ2EI9 ID DMJ2EI9
DMJ2EI9 DN JWH-324
DMJ2EI9 HS Investigative
DMJ2EI9 SN JWH-324; CHEMBL263386; BDBM50323907; (1R,3S)3-[4-(1,1-dimethylheptyl)phenyl]cyclohexanol
DMJ2EI9 DT Small molecular drug
DMJ2EI9 PC 44452650
DMJ2EI9 MW 302.5
DMJ2EI9 FM C21H34O
DMJ2EI9 IC InChI=1S/C21H34O/c1-4-5-6-7-15-21(2,3)19-13-11-17(12-14-19)18-9-8-10-20(22)16-18/h11-14,18,20,22H,4-10,15-16H2,1-3H3/t18-,20+/m0/s1
DMJ2EI9 CS CCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMJ2EI9 IK CICRJVLFNFCUOX-AZUAARDMSA-N
DMJ2EI9 IU (1R,3S)-3-[4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DMJ2EI9 DE Discovery agent
DMHNTZ8 ID DMHNTZ8
DMHNTZ8 DN JWH-325
DMHNTZ8 HS Investigative
DMHNTZ8 SN JWH-325; CHEMBL264412
DMHNTZ8 DT Small molecular drug
DMHNTZ8 PC 44452424
DMHNTZ8 MW 332.5
DMHNTZ8 FM C22H36O2
DMHNTZ8 IC InChI=1S/C22H36O2/c1-4-5-14-22(2,3)19-11-8-18(9-12-19)21-16-20(24)13-10-17(21)7-6-15-23/h8-9,11-12,17,20-21,23-24H,4-7,10,13-16H2,1-3H3/t17-,20-,21-/m1/s1
DMHNTZ8 CS CCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMHNTZ8 IK RSOWKGHGGWKLRF-DUXKGJEZSA-N
DMHNTZ8 IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylhexan-2-yl)phenyl]cyclohexan-1-ol
DMHNTZ8 DE Discovery agent
DMK3DUZ ID DMK3DUZ
DMK3DUZ DN JWH-337
DMK3DUZ HS Investigative
DMK3DUZ SN JWH-337; CHEMBL408777
DMK3DUZ DT Small molecular drug
DMK3DUZ PC 44452712
DMK3DUZ MW 360.6
DMK3DUZ FM C24H40O2
DMK3DUZ IC InChI=1S/C24H40O2/c1-4-5-6-7-16-24(2,3)21-13-10-20(11-14-21)23-18-22(26)15-12-19(23)9-8-17-25/h10-11,13-14,19,22-23,25-26H,4-9,12,15-18H2,1-3H3/t19-,22-,23-/m1/s1
DMK3DUZ CS CCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMK3DUZ IK BTHPTUSWFPTQIG-UEVCKROQSA-N
DMK3DUZ IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DMK3DUZ DE Discovery agent
DMTSZFB ID DMTSZFB
DMTSZFB DN JWH-342
DMTSZFB HS Investigative
DMTSZFB SN CHEMBL260130; JWH-342
DMTSZFB DT Small molecular drug
DMTSZFB PC 49863581
DMTSZFB MW 302.5
DMTSZFB FM C21H34O
DMTSZFB IC InChI=1S/C21H34O/c1-4-5-6-7-15-21(2,3)19-13-11-17(12-14-19)18-9-8-10-20(22)16-18/h11-14,18,20,22H,4-10,15-16H2,1-3H3/t18-,20-/m0/s1
DMTSZFB CS CCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@@H](C2)O
DMTSZFB IK CICRJVLFNFCUOX-ICSRJNTNSA-N
DMTSZFB IU (1S,3S)-3-[4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DMTSZFB DE Discovery agent
DMEU1NS ID DMEU1NS
DMEU1NS DN JWH-343
DMEU1NS HS Investigative
DMEU1NS SN JWH-343; CHEMBL263885
DMEU1NS DT Small molecular drug
DMEU1NS PC 44452446
DMEU1NS MW 304.5
DMEU1NS FM C20H32O2
DMEU1NS IC InChI=1S/C20H32O2/c1-4-20(2,3)17-10-7-16(8-11-17)19-14-18(22)12-9-15(19)6-5-13-21/h7-8,10-11,15,18-19,21-22H,4-6,9,12-14H2,1-3H3/t15-,18-,19-/m1/s1
DMEU1NS CS CCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMEU1NS IK FDSWUKCGXVVOCA-ATZDWAIDSA-N
DMEU1NS IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylbutan-2-yl)phenyl]cyclohexan-1-ol
DMEU1NS DE Discovery agent
DM6VZ3T ID DM6VZ3T
DM6VZ3T DN JWH-344
DM6VZ3T HS Investigative
DM6VZ3T SN JWH-344; CHEMBL260253
DM6VZ3T DT Small molecular drug
DM6VZ3T PC 44452397
DM6VZ3T MW 346.5
DM6VZ3T FM C23H38O2
DM6VZ3T IC InChI=1S/C23H38O2/c1-4-5-6-15-23(2,3)20-12-9-19(10-13-20)22-17-21(25)14-11-18(22)8-7-16-24/h9-10,12-13,18,21-22,24-25H,4-8,11,14-17H2,1-3H3/t18-,21-,22-/m1/s1
DM6VZ3T CS CCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DM6VZ3T IK VAVUZZKKXHPBEZ-STZQEDGTSA-N
DM6VZ3T IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DM6VZ3T DE Discovery agent
DML53SK ID DML53SK
DML53SK DN JWH-345
DML53SK HS Investigative
DML53SK SN JWH-345; CHEMBL259723
DML53SK DT Small molecular drug
DML53SK PC 44452688
DML53SK MW 374.6
DML53SK FM C25H42O2
DML53SK IC InChI=1S/C25H42O2/c1-4-5-6-7-8-17-25(2,3)22-14-11-21(12-15-22)24-19-23(27)16-13-20(24)10-9-18-26/h11-12,14-15,20,23-24,26-27H,4-10,13,16-19H2,1-3H3/t20-,23-,24-/m1/s1
DML53SK CS CCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DML53SK IK RTPUPNNHNNHDQM-AGILITTLSA-N
DML53SK IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol
DML53SK DE Discovery agent
DMHNILP ID DMHNILP
DMHNILP DN JWH-346
DMHNILP HS Investigative
DMHNILP SN JWH-346; CHEMBL219243; BDBM50192613
DMHNILP DT Small molecular drug
DMHNILP PC 44418326
DMHNILP MW 381.5
DMHNILP FM C27H27NO
DMHNILP IC InChI=1S/C27H27NO/c1-3-4-7-16-28-19-23(18-26(28)22-13-8-10-20(2)17-22)27(29)25-15-9-12-21-11-5-6-14-24(21)25/h5-6,8-15,17-19H,3-4,7,16H2,1-2H3
DMHNILP CS CCCCCN1C=C(C=C1C2=CC=CC(=C2)C)C(=O)C3=CC=CC4=CC=CC=C43
DMHNILP IK SHCDXHJKMSBCOQ-UHFFFAOYSA-N
DMHNILP IU [5-(3-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMHNILP DE Discovery agent
DMK2NQ1 ID DMK2NQ1
DMK2NQ1 DN JWH-347
DMK2NQ1 HS Investigative
DMK2NQ1 SN JWH-347; CHEMBL374254; BDBM50192599
DMK2NQ1 DT Small molecular drug
DMK2NQ1 PC 44418372
DMK2NQ1 MW 417.5
DMK2NQ1 FM C30H27NO
DMK2NQ1 IC InChI=1S/C30H27NO/c1-2-3-8-18-31-21-26(30(32)28-15-9-13-23-11-6-7-14-27(23)28)20-29(31)25-17-16-22-10-4-5-12-24(22)19-25/h4-7,9-17,19-21H,2-3,8,18H2,1H3
DMK2NQ1 CS CCCCCN1C=C(C=C1C2=CC3=CC=CC=C3C=C2)C(=O)C4=CC=CC5=CC=CC=C54
DMK2NQ1 IK WYOWIOBJNTYRNN-UHFFFAOYSA-N
DMK2NQ1 IU naphthalen-1-yl-(5-naphthalen-2-yl-1-pentylpyrrol-3-yl)methanone
DMK2NQ1 DE Discovery agent
DMQIVPK ID DMQIVPK
DMQIVPK DN JWH-348
DMQIVPK HS Investigative
DMQIVPK SN JWH-348; CHEMBL375791; BDBM50192605
DMQIVPK DT Small molecular drug
DMQIVPK PC 44418368
DMQIVPK MW 435.5
DMQIVPK FM C27H24F3NO
DMQIVPK IC InChI=1S/C27H24F3NO/c1-2-3-6-16-31-18-21(17-25(31)20-12-14-22(15-13-20)27(28,29)30)26(32)24-11-7-9-19-8-4-5-10-23(19)24/h4-5,7-15,17-18H,2-3,6,16H2,1H3
DMQIVPK CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
DMQIVPK IK KFMFBZYLXNTONN-UHFFFAOYSA-N
DMQIVPK IU naphthalen-1-yl-[1-pentyl-5-[4-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
DMQIVPK DE Discovery agent
DMFLB1Z ID DMFLB1Z
DMFLB1Z DN JWH-363
DMFLB1Z HS Investigative
DMFLB1Z SN JWH-363; CHEMBL219556; BDBM50192611
DMFLB1Z DT Small molecular drug
DMFLB1Z PC 44418338
DMFLB1Z MW 435.5
DMFLB1Z FM C27H24F3NO
DMFLB1Z IC InChI=1S/C27H24F3NO/c1-2-3-6-15-31-18-21(17-25(31)20-11-7-12-22(16-20)27(28,29)30)26(32)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMFLB1Z CS CCCCCN1C=C(C=C1C2=CC(=CC=C2)C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
DMFLB1Z IK GETLFVZYXNFVJS-UHFFFAOYSA-N
DMFLB1Z IU naphthalen-1-yl-[1-pentyl-5-[3-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
DMFLB1Z DE Discovery agent
DMP6C4D ID DMP6C4D
DMP6C4D DN JWH-364
DMP6C4D HS Investigative
DMP6C4D SN JWH-364; CHEMBL426706; BDBM50192606
DMP6C4D DT Small molecular drug
DMP6C4D PC 44418348
DMP6C4D MW 395.5
DMP6C4D FM C28H29NO
DMP6C4D IC InChI=1S/C28H29NO/c1-3-5-8-18-29-20-24(19-27(29)23-16-14-21(4-2)15-17-23)28(30)26-13-9-11-22-10-6-7-12-25(22)26/h6-7,9-17,19-20H,3-5,8,18H2,1-2H3
DMP6C4D CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)CC)C(=O)C3=CC=CC4=CC=CC=C43
DMP6C4D IK VJWBAPGRMUZBEH-UHFFFAOYSA-N
DMP6C4D IU [5-(4-ethylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMP6C4D DE Discovery agent
DM2ZXBR ID DM2ZXBR
DM2ZXBR DN JWH-365
DM2ZXBR HS Investigative
DM2ZXBR SN JWH-365; CHEMBL220352; BDBM50192589
DM2ZXBR DT Small molecular drug
DM2ZXBR PC 44418313
DM2ZXBR MW 395.5
DM2ZXBR FM C28H29NO
DM2ZXBR IC InChI=1S/C28H29NO/c1-3-5-10-18-29-20-23(19-27(29)25-16-9-6-12-21(25)4-2)28(30)26-17-11-14-22-13-7-8-15-24(22)26/h6-9,11-17,19-20H,3-5,10,18H2,1-2H3
DM2ZXBR CS CCCCCN1C=C(C=C1C2=CC=CC=C2CC)C(=O)C3=CC=CC4=CC=CC=C43
DM2ZXBR IK SNWJCZXZSGPAJM-UHFFFAOYSA-N
DM2ZXBR IU [5-(2-ethylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM2ZXBR DE Discovery agent
DMSNLFJ ID DMSNLFJ
DMSNLFJ DN JWH-366
DMSNLFJ HS Investigative
DMSNLFJ SN JWH-366; CHEMBL218956; BDBM50192592
DMSNLFJ DT Small molecular drug
DMSNLFJ PC 44418373
DMSNLFJ MW 368.5
DMSNLFJ FM C25H24N2O
DMSNLFJ IC InChI=1S/C25H24N2O/c1-2-3-6-15-27-18-21(16-24(27)20-11-8-14-26-17-20)25(28)23-13-7-10-19-9-4-5-12-22(19)23/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMSNLFJ CS CCCCCN1C=C(C=C1C2=CN=CC=C2)C(=O)C3=CC=CC4=CC=CC=C43
DMSNLFJ IK MPQYTRCOFXNOTB-UHFFFAOYSA-N
DMSNLFJ IU naphthalen-1-yl-(1-pentyl-5-pyridin-3-ylpyrrol-3-yl)methanone
DMSNLFJ DE Discovery agent
DM7ZF2K ID DM7ZF2K
DM7ZF2K DN JWH-367
DM7ZF2K HS Investigative
DM7ZF2K SN JWH-367; CHEMBL385994; BDBM50192604
DM7ZF2K DT Small molecular drug
DM7ZF2K PC 44418330
DM7ZF2K MW 397.5
DM7ZF2K FM C27H27NO2
DM7ZF2K IC InChI=1S/C27H27NO2/c1-3-4-7-16-28-19-22(18-26(28)21-12-8-13-23(17-21)30-2)27(29)25-15-9-11-20-10-5-6-14-24(20)25/h5-6,8-15,17-19H,3-4,7,16H2,1-2H3
DM7ZF2K CS CCCCCN1C=C(C=C1C2=CC(=CC=C2)OC)C(=O)C3=CC=CC4=CC=CC=C43
DM7ZF2K IK RGYBGMOZXHKLRI-UHFFFAOYSA-N
DM7ZF2K IU [5-(3-methoxyphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM7ZF2K DE Discovery agent
DMK0FNX ID DMK0FNX
DMK0FNX DN JWH-368
DMK0FNX HS Investigative
DMK0FNX SN (5-(3-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone; 914458-31-4; JWH-368; CHEMBL220304; [5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone; CTK8B4185; DTXSID60658824; MolPort-023-278-971; 5344AC; ZINC36294609; BDBM50192608; ANW-44202; AKOS015999106; AJ-92570; AK-88831; DS-18529; TC-132947; KB-208485; AX8228512
DMK0FNX DT Small molecular drug
DMK0FNX PC 44418331
DMK0FNX MW 385.5
DMK0FNX FM C26H24FNO
DMK0FNX IC InChI=1S/C26H24FNO/c1-2-3-6-15-28-18-21(17-25(28)20-11-7-12-22(27)16-20)26(29)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3
DMK0FNX CS CCCCCN1C=C(C=C1C2=CC(=CC=C2)F)C(=O)C3=CC=CC4=CC=CC=C43
DMK0FNX IK OCOICOMCAJNSCA-UHFFFAOYSA-N
DMK0FNX IU [5-(3-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMK0FNX CA CAS 914458-31-4
DMK0FNX DE Discovery agent
DMPDTWY ID DMPDTWY
DMPDTWY DN JWH-369
DMPDTWY HS Investigative
DMPDTWY SN JWH-369; CHEMBL216837; ZINC34947165; BDBM50192601; 1-pentyl-2-(2-chlorophenyl)-4-(1-naphthoyl) pyrrole
DMPDTWY DT Small molecular drug
DMPDTWY PC 16049784
DMPDTWY MW 401.9
DMPDTWY FM C26H24ClNO
DMPDTWY IC InChI=1S/C26H24ClNO/c1-2-3-8-16-28-18-20(17-25(28)23-13-6-7-15-24(23)27)26(29)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
DMPDTWY CS CCCCCN1C=C(C=C1C2=CC=CC=C2Cl)C(=O)C3=CC=CC4=CC=CC=C43
DMPDTWY IK SUELCWQJMQQCTF-UHFFFAOYSA-N
DMPDTWY IU [5-(2-chlorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMPDTWY CA CAS 914458-27-8
DMPDTWY DE Discovery agent
DM6IG7P ID DM6IG7P
DM6IG7P DN JWH-370
DM6IG7P HS Investigative
DM6IG7P SN JWH-370; CHEMBL220180; HZMLAMXVETUEJZ-UHFFFAOYSA-N; 914458-22-3; JWH 370; BDBM50192595; ZINC36294595; [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
DM6IG7P DT Small molecular drug
DM6IG7P PC 44418312
DM6IG7P MW 381.5
DM6IG7P FM C27H27NO
DM6IG7P IC InChI=1S/C27H27NO/c1-3-4-9-17-28-19-22(18-26(28)23-14-7-5-11-20(23)2)27(29)25-16-10-13-21-12-6-8-15-24(21)25/h5-8,10-16,18-19H,3-4,9,17H2,1-2H3
DM6IG7P CS CCCCCN1C=C(C=C1C2=CC=CC=C2C)C(=O)C3=CC=CC4=CC=CC=C43
DM6IG7P IK HZMLAMXVETUEJZ-UHFFFAOYSA-N
DM6IG7P IU [5-(2-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DM6IG7P DE Discovery agent
DME0URP ID DME0URP
DME0URP DN JWH-371
DME0URP HS Investigative
DME0URP SN JWH-371; CHEMBL219580; BDBM50192594
DME0URP DT Small molecular drug
DME0URP PC 44418349
DME0URP MW 423.6
DME0URP FM C30H33NO
DME0URP IC InChI=1S/C30H33NO/c1-3-5-9-20-31-22-26(21-29(31)25-18-16-23(17-19-25)11-6-4-2)30(32)28-15-10-13-24-12-7-8-14-27(24)28/h7-8,10,12-19,21-22H,3-6,9,11,20H2,1-2H3
DME0URP CS CCCCCN1C=C(C=C1C2=CC=C(C=C2)CCCC)C(=O)C3=CC=CC4=CC=CC=C43
DME0URP IK PKNGYYSGLHBRGC-UHFFFAOYSA-N
DME0URP IU [5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DME0URP DE Discovery agent
DM9D3GM ID DM9D3GM
DM9D3GM DN JWH-372
DM9D3GM HS Investigative
DM9D3GM SN JWH-372; CHEMBL384897; BDBM50192610
DM9D3GM DT Small molecular drug
DM9D3GM PC 44418325
DM9D3GM MW 435.5
DM9D3GM FM C27H24F3NO
DM9D3GM IC InChI=1S/C27H24F3NO/c1-2-3-8-16-31-18-20(17-25(31)23-13-6-7-15-24(23)27(28,29)30)26(32)22-14-9-11-19-10-4-5-12-21(19)22/h4-7,9-15,17-18H,2-3,8,16H2,1H3
DM9D3GM CS CCCCCN1C=C(C=C1C2=CC=CC=C2C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
DM9D3GM IK CYPUIQJYGVOHMM-UHFFFAOYSA-N
DM9D3GM IU naphthalen-1-yl-[1-pentyl-5-[2-(trifluoromethyl)phenyl]pyrrol-3-yl]methanone
DM9D3GM DE Discovery agent
DMWP84R ID DMWP84R
DMWP84R DN JWH-373
DMWP84R HS Investigative
DMWP84R SN JWH-373; CHEMBL375802; BDBM50192597
DMWP84R DT Small molecular drug
DMWP84R PC 44418316
DMWP84R MW 423.6
DMWP84R FM C30H33NO
DMWP84R IC InChI=1S/C30H33NO/c1-3-5-11-20-31-22-25(21-29(31)27-18-10-8-15-24(27)13-6-4-2)30(32)28-19-12-16-23-14-7-9-17-26(23)28/h7-10,12,14-19,21-22H,3-6,11,13,20H2,1-2H3
DMWP84R CS CCCCCN1C=C(C=C1C2=CC=CC=C2CCCC)C(=O)C3=CC=CC4=CC=CC=C43
DMWP84R IK LDGBUSJKRUNXPK-UHFFFAOYSA-N
DMWP84R IU [5-(2-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone
DMWP84R DE Discovery agent
DMU1HA7 ID DMU1HA7
DMU1HA7 DN JWH-385
DMU1HA7 HS Investigative
DMU1HA7 SN JWH-385; CHEMBL259518
DMU1HA7 DT Small molecular drug
DMU1HA7 PC 44452687
DMU1HA7 MW 388.6
DMU1HA7 FM C26H44O2
DMU1HA7 IC InChI=1S/C26H44O2/c1-4-5-6-7-8-9-18-26(2,3)23-15-12-22(13-16-23)25-20-24(28)17-14-21(25)11-10-19-27/h12-13,15-16,21,24-25,27-28H,4-11,14,17-20H2,1-3H3/t21-,24-,25-/m1/s1
DMU1HA7 CS CCCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMU1HA7 IK ZWVZYXMEZOIWEQ-NQHRYMMQSA-N
DMU1HA7 IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methyldecan-2-yl)phenyl]cyclohexan-1-ol
DMU1HA7 DE Discovery agent
DMMUBIF ID DMMUBIF
DMMUBIF DN JWH-392
DMMUBIF HS Investigative
DMMUBIF SN JWH-392; CHEMBL260483
DMMUBIF DT Small molecular drug
DMMUBIF PC 44452426
DMMUBIF MW 318.5
DMMUBIF FM C21H34O2
DMMUBIF IC InChI=1S/C21H34O2/c1-4-13-21(2,3)18-10-7-17(8-11-18)20-15-19(23)12-9-16(20)6-5-14-22/h7-8,10-11,16,19-20,22-23H,4-6,9,12-15H2,1-3H3/t16-,19-,20-/m1/s1
DMMUBIF CS CCCC(C)(C)C1=CC=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O
DMMUBIF IK VIGWEDJLUIAROG-NSISKUIASA-N
DMMUBIF IU (1R,3R,4R)-4-(3-hydroxypropyl)-3-[4-(2-methylpentan-2-yl)phenyl]cyclohexan-1-ol
DMMUBIF DE Discovery agent
DMFL6B9 ID DMFL6B9
DMFL6B9 DN JWH-401
DMFL6B9 HS Investigative
DMFL6B9 SN JWH-401; CHEMBL262337
DMFL6B9 DT Small molecular drug
DMFL6B9 PC 44452623
DMFL6B9 MW 330.5
DMFL6B9 FM C23H38O
DMFL6B9 IC InChI=1S/C23H38O/c1-4-5-6-7-8-9-17-23(2,3)21-15-13-19(14-16-21)20-11-10-12-22(24)18-20/h13-16,20,22,24H,4-12,17-18H2,1-3H3/t20-,22+/m0/s1
DMFL6B9 CS CCCCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMFL6B9 IK DQKOXMDLNBLQTB-RBBKRZOGSA-N
DMFL6B9 IU (1R,3S)-3-[4-(2-methyldecan-2-yl)phenyl]cyclohexan-1-ol
DMFL6B9 DE Discovery agent
DM8TQIF ID DM8TQIF
DM8TQIF DN JWH-402
DM8TQIF HS Investigative
DM8TQIF SN JWH-402; CHEMBL265934
DM8TQIF DT Small molecular drug
DM8TQIF PC 44452507
DM8TQIF MW 330.5
DM8TQIF FM C23H38O
DM8TQIF IC InChI=1S/C23H38O/c1-4-5-6-7-8-9-17-23(2,3)21-15-13-19(14-16-21)20-11-10-12-22(24)18-20/h13-16,20,22,24H,4-12,17-18H2,1-3H3/t20-,22-/m1/s1
DM8TQIF CS CCCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DM8TQIF IK DQKOXMDLNBLQTB-IFMALSPDSA-N
DM8TQIF IU (1R,3R)-3-[4-(2-methyldecan-2-yl)phenyl]cyclohexan-1-ol
DM8TQIF DE Discovery agent
DMRG1VI ID DMRG1VI
DMRG1VI DN JWH-403
DMRG1VI HS Investigative
DMRG1VI SN JWH-403; CHEMBL263385
DMRG1VI DT Small molecular drug
DMRG1VI PC 44452649
DMRG1VI MW 288.5
DMRG1VI FM C20H32O
DMRG1VI IC InChI=1S/C20H32O/c1-4-5-6-14-20(2,3)18-12-10-16(11-13-18)17-8-7-9-19(21)15-17/h10-13,17,19,21H,4-9,14-15H2,1-3H3/t17-,19+/m0/s1
DMRG1VI CS CCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DMRG1VI IK RGRMJFXCHLLHAS-PKOBYXMFSA-N
DMRG1VI IU (1R,3S)-3-[4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DMRG1VI DE Discovery agent
DM3KWER ID DM3KWER
DM3KWER DN JWH-404
DM3KWER HS Investigative
DM3KWER SN JWH-404; CHEMBL262336
DM3KWER DT Small molecular drug
DM3KWER PC 44452622
DM3KWER MW 316.5
DM3KWER FM C22H36O
DM3KWER IC InChI=1S/C22H36O/c1-4-5-6-7-8-16-22(2,3)20-14-12-18(13-15-20)19-10-9-11-21(23)17-19/h12-15,19,21,23H,4-11,16-17H2,1-3H3/t19-,21+/m0/s1
DM3KWER CS CCCCCCCC(C)(C)C1=CC=C(C=C1)[C@H]2CCC[C@H](C2)O
DM3KWER IK SHSCKELICBAALI-PZJWPPBQSA-N
DM3KWER IU (1R,3S)-3-[4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol
DM3KWER DE Discovery agent
DM57TN3 ID DM57TN3
DM57TN3 DN JWH-405
DM57TN3 HS Investigative
DM57TN3 SN JWH-405; CHEMBL265933
DM57TN3 DT Small molecular drug
DM57TN3 PC 44452506
DM57TN3 MW 316.5
DM57TN3 FM C22H36O
DM57TN3 IC InChI=1S/C22H36O/c1-4-5-6-7-8-16-22(2,3)20-14-12-18(13-15-20)19-10-9-11-21(23)17-19/h12-15,19,21,23H,4-11,16-17H2,1-3H3/t19-,21-/m1/s1
DM57TN3 CS CCCCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DM57TN3 IK SHSCKELICBAALI-TZIWHRDSSA-N
DM57TN3 IU (1R,3R)-3-[4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol
DM57TN3 DE Discovery agent
DMNP7GD ID DMNP7GD
DMNP7GD DN JWH-406
DMNP7GD HS Investigative
DMNP7GD SN JWH-406; CHEMBL261495
DMNP7GD DT Small molecular drug
DMNP7GD PC 44452581
DMNP7GD MW 288.5
DMNP7GD FM C20H32O
DMNP7GD IC InChI=1S/C20H32O/c1-4-5-6-14-20(2,3)18-12-10-16(11-13-18)17-8-7-9-19(21)15-17/h10-13,17,19,21H,4-9,14-15H2,1-3H3/t17-,19-/m1/s1
DMNP7GD CS CCCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DMNP7GD IK RGRMJFXCHLLHAS-IEBWSBKVSA-N
DMNP7GD IU (1R,3R)-3-[4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DMNP7GD DE Discovery agent
DMZQ0V9 ID DMZQ0V9
DMZQ0V9 DN JWH-407
DMZQ0V9 HS Investigative
DMZQ0V9 SN JWH-407; CHEMBL261494
DMZQ0V9 DT Small molecular drug
DMZQ0V9 PC 44452580
DMZQ0V9 MW 274.4
DMZQ0V9 FM C19H30O
DMZQ0V9 IC InChI=1S/C19H30O/c1-4-5-13-19(2,3)17-11-9-15(10-12-17)16-7-6-8-18(20)14-16/h9-12,16,18,20H,4-8,13-14H2,1-3H3/t16-,18-/m1/s1
DMZQ0V9 CS CCCCC(C)(C)C1=CC=C(C=C1)[C@@H]2CCC[C@H](C2)O
DMZQ0V9 IK WMICXNJEJDOUPN-SJLPKXTDSA-N
DMZQ0V9 IU (1R,3R)-3-[4-(2-methylhexan-2-yl)phenyl]cyclohexan-1-ol
DMZQ0V9 DE Discovery agent
DM89602 ID DM89602
DM89602 DN JWH-440
DM89602 HS Investigative
DM89602 SN JWH-440; CHEMBL1214644; BDBM50323906
DM89602 DT Small molecular drug
DM89602 PC 46918944
DM89602 MW 318.5
DM89602 FM C21H34O2
DM89602 IC InChI=1S/C21H34O2/c1-5-6-7-13-21(2,3)17-11-12-19(20(15-17)23-4)16-9-8-10-18(22)14-16/h11-12,15-16,18,22H,5-10,13-14H2,1-4H3/t16-,18+/m0/s1
DM89602 CS CCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@H](C2)O)OC
DM89602 IK GZSDLXNECOWUFY-FUHWJXTLSA-N
DM89602 IU (1R,3S)-3-[2-methoxy-4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DM89602 DE Discovery agent
DM7R1XS ID DM7R1XS
DM7R1XS DN JWH-441
DM7R1XS HS Investigative
DM7R1XS SN JWH-441; CHEMBL1212958; BDBM50323908
DM7R1XS DT Small molecular drug
DM7R1XS PC 49863973
DM7R1XS MW 332.5
DM7R1XS FM C22H36O2
DM7R1XS IC InChI=1S/C22H36O2/c1-5-6-7-8-14-22(2,3)18-12-13-20(21(16-18)24-4)17-10-9-11-19(23)15-17/h12-13,16-17,19,23H,5-11,14-15H2,1-4H3/t17-,19+/m0/s1
DM7R1XS CS CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@H](C2)O)OC
DM7R1XS IK ZVQYLLPGZZZCSV-PKOBYXMFSA-N
DM7R1XS IU (1R,3S)-3-[2-methoxy-4-(2-methyloctan-2-yl)phenyl]cyclohexan-1-ol
DM7R1XS DE Discovery agent
DMX6F1L ID DMX6F1L
DMX6F1L DN JWH-442
DMX6F1L HS Investigative
DMX6F1L SN JWH-442; CHEMBL1213721; BDBM50323905
DMX6F1L DT Small molecular drug
DMX6F1L PC 49863580
DMX6F1L MW 318.5
DMX6F1L FM C21H34O2
DMX6F1L IC InChI=1S/C21H34O2/c1-5-6-7-13-21(2,3)17-11-12-19(20(15-17)23-4)16-9-8-10-18(22)14-16/h11-12,15-16,18,22H,5-10,13-14H2,1-4H3/t16-,18-/m0/s1
DMX6F1L CS CCCCCC(C)(C)C1=CC(=C(C=C1)[C@H]2CCC[C@@H](C2)O)OC
DMX6F1L IK GZSDLXNECOWUFY-WMZOPIPTSA-N
DMX6F1L IU (1S,3S)-3-[2-methoxy-4-(2-methylheptan-2-yl)phenyl]cyclohexan-1-ol
DMX6F1L DE Discovery agent
DMWA8B0 ID DMWA8B0
DMWA8B0 DN JZL184
DMWA8B0 HS Investigative
DMWA8B0 SN JZL 184; JZL-184
DMWA8B0 DT Small molecular drug
DMWA8B0 PC 25021165
DMWA8B0 MW 520.5
DMWA8B0 FM C27H24N2O9
DMWA8B0 IC InChI=1S/C27H24N2O9/c30-26(38-21-5-3-20(4-6-21)29(32)33)28-11-9-17(10-12-28)27(31,18-1-7-22-24(13-18)36-15-34-22)19-2-8-23-25(14-19)37-16-35-23/h1-8,13-14,17,31H,9-12,15-16H2
DMWA8B0 CS C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC6=CC=C(C=C6)[N+](=O)[O-]
DMWA8B0 IK SEGYOKHGGFKMCX-UHFFFAOYSA-N
DMWA8B0 IU (4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate
DMWA8B0 CA CAS 1101854-58-3
DMWA8B0 CB CHEBI:95015
DMWA8B0 DE Discovery agent
DMEOCKZ ID DMEOCKZ
DMEOCKZ DN JZL195
DMEOCKZ HS Investigative
DMEOCKZ SN JZL-195; JZL 195
DMEOCKZ DT Small molecular drug
DMEOCKZ PC 46232606
DMEOCKZ MW 433.5
DMEOCKZ FM C24H23N3O5
DMEOCKZ IC InChI=1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2
DMEOCKZ CS C1CN(CCN1CC2=CC(=CC=C2)OC3=CC=CC=C3)C(=O)OC4=CC=C(C=C4)[N+](=O)[O-]
DMEOCKZ IK QNYRAEKLMNDRFY-UHFFFAOYSA-N
DMEOCKZ IU (4-nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
DMEOCKZ DE Discovery agent
DMP8M9Q ID DMP8M9Q
DMP8M9Q DN K00024
DMP8M9Q HS Investigative
DMP8M9Q SN indolocarbazole deriv. 4(d)
DMP8M9Q DT Small molecular drug
DMP8M9Q PC 5330797
DMP8M9Q MW 404.2
DMP8M9Q FM C20H10BrN3O2
DMP8M9Q IC InChI=1S/C20H10BrN3O2/c21-8-5-6-10-12(7-8)23-18-14(10)16-15(19(25)24-20(16)26)13-9-3-1-2-4-11(9)22-17(13)18/h1-7,22-23H,(H,24,25,26)
DMP8M9Q CS C1=CC=C2C(=C1)C3=C4C(=C5C6=C(C=C(C=C6)Br)NC5=C3N2)C(=O)NC4=O
DMP8M9Q IK NMFKDDRQSNVETB-UHFFFAOYSA-N
DMP8M9Q IU 6-bromo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17,19,21-nonaene-12,14-dione
DMP8M9Q CA CAS 546102-60-7
DMP8M9Q DE Discovery agent
DM2BKU8 ID DM2BKU8
DM2BKU8 DN K00244
DM2BKU8 HS Investigative
DM2BKU8 SN GSK-3 Inhibitor XIII; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine; GSK3-XIII; K00244; 404828-08-6; CHEMBL359482; (5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine; CHEBI:78544; AC1O4WD1; SCHEMBL462877; GTPL5976; CTK4I3154; HMS3229I06; BDBM228657; BCP12434; BDBM50162083; ZINC16052235; IN1311; AKOS025394676; DB08454; CCG-101293; NCGC00387776-01; ACM404828086; RT-013126; N-(3-methyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-amine; (5-Methyl-1H-pyrazol-3-yl)-(2-phenyl-quinazolin-4-yl)-amine
DM2BKU8 DT Small molecular drug
DM2BKU8 PC 6419766
DM2BKU8 MW 301.3
DM2BKU8 FM C18H15N5
DM2BKU8 IC InChI=1S/C18H15N5/c1-12-11-16(23-22-12)20-18-14-9-5-6-10-15(14)19-17(21-18)13-7-3-2-4-8-13/h2-11H,1H3,(H2,19,20,21,22,23)
DM2BKU8 CS CC1=CC(=NN1)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4
DM2BKU8 IK JYCUVOXSZBECAY-UHFFFAOYSA-N
DM2BKU8 IU N-(5-methyl-1H-pyrazol-3-yl)-2-phenylquinazolin-4-amine
DM2BKU8 CB CHEBI:78544
DM2BKU8 DE Discovery agent
DMWZJG6 ID DMWZJG6
DMWZJG6 DN K00248
DMWZJG6 HS Investigative
DMWZJG6 SN PKCbeta Inhibitor; 257879-35-9; K00248; CHEMBL366266; 3-(1-(3-Imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione; PKC Inhibitor; AC1O4WCS; SCHEMBL7841474; GTPL6025; CHEBI:94140; CTK8F0351; DTXSID20423555; HMS3229K09; BDBM50153461; IN1136; CCG-206785; RT-015068; J-016132; BRD-K89687904-001-01-8; 3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione; 3-[1-[3-(1H-Imidazole-1-yl)propyl]-1H-indole-3-yl]-4-anilino-1H-pyrrole-2,5-dione
DMWZJG6 DT Small molecular drug
DMWZJG6 PC 6419755
DMWZJG6 MW 411.5
DMWZJG6 FM C24H21N5O2
DMWZJG6 IC InChI=1S/C24H21N5O2/c30-23-21(22(24(31)27-23)26-17-7-2-1-3-8-17)19-15-29(20-10-5-4-9-18(19)20)13-6-12-28-14-11-25-16-28/h1-5,7-11,14-16H,6,12-13H2,(H2,26,27,30,31)
DMWZJG6 CS C1=CC=C(C=C1)NC2=C(C(=O)NC2=O)C3=CN(C4=CC=CC=C43)CCCN5C=CN=C5
DMWZJG6 IK KIWODJBCHRADND-UHFFFAOYSA-N
DMWZJG6 IU 3-anilino-4-[1-(3-imidazol-1-ylpropyl)indol-3-yl]pyrrole-2,5-dione
DMWZJG6 CA CAS 257879-35-9
DMWZJG6 CB CHEBI:94140
DMWZJG6 DE Discovery agent
DM1RP5Q ID DM1RP5Q
DM1RP5Q DN K00592a
DM1RP5Q HS Investigative
DM1RP5Q SN K00592a; CHEMBL471901; SCHEMBL1222899; GTPL6047; MolPort-044-561-482; ZINC2007259; BDBM50249319; 2-(2-aminoethylamino)-4-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxamide; 2-[(2-aminoethyl)amino]-4-{[3-(trifluoromethyl)phenyl]amino}pyrimidine-5-carboxamide
DM1RP5Q DT Small molecular drug
DM1RP5Q PC 9549296
DM1RP5Q MW 340.3
DM1RP5Q FM C14H15F3N6O
DM1RP5Q IC InChI=1S/C14H15F3N6O/c15-14(16,17)8-2-1-3-9(6-8)22-12-10(11(19)24)7-21-13(23-12)20-5-4-18/h1-3,6-7H,4-5,18H2,(H2,19,24)(H2,20,21,22,23)
DM1RP5Q CS C1=CC(=CC(=C1)NC2=NC(=NC=C2C(=O)N)NCCN)C(F)(F)F
DM1RP5Q IK FQNFLNSVHWCZML-UHFFFAOYSA-N
DM1RP5Q IU 2-(2-aminoethylamino)-4-[3-(trifluoromethyl)anilino]pyrimidine-5-carboxamide
DM1RP5Q DE Discovery agent
DME65H8 ID DME65H8
DME65H8 DN K185
DME65H8 HS Investigative
DME65H8 SN K-185; K 185
DME65H8 DT Small molecular drug
DME65H8 PC 5311198
DME65H8 MW 376.5
DME65H8 FM C24H28N2O2
DME65H8 IC InChI=1S/C24H28N2O2/c1-3-7-23(27)25-14-13-20-21-16-18(28-2)11-12-22(21)26-15-6-9-17-8-4-5-10-19(17)24(20)26/h4-5,8,10-12,16H,3,6-7,9,13-15H2,1-2H3,(H,25,27)
DME65H8 CS CCCC(=O)NCCC1=C2C3=CC=CC=C3CCCN2C4=C1C=C(C=C4)OC
DME65H8 IK SPIFQXPRSJKRAO-UHFFFAOYSA-N
DME65H8 IU N-[2-(11-methoxy-6,7-dihydro-5H-indolo[2,1-a][2]benzazepin-13-yl)ethyl]butanamide
DME65H8 CA CAS 32223-82-8
DME65H8 DE Discovery agent
DMT68RG ID DMT68RG
DMT68RG DN K252a
DMT68RG HS Investigative
DMT68RG SN K-252a, Nocardiopsis sp.; k-252a; ST50826373; (+)-K-252A; k-252a deriva-tives; AC1LAL9C; GTPL336; BDBM2580; CHEMBL416056; SCHEMBL13485248; HMS3229K08; ZINC3776578; 99533-80-9; CCG-206861; methyl hydroxy-methyl-oxo-[ ]carboxylate; B6828; methyl (15R,16S,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaene-16-carboxylate; methyl (16S,18S,15R)-1
DMT68RG DT Small molecular drug
DMT68RG PC 3035817
DMT68RG MW 467.5
DMT68RG FM C27H21N3O5
DMT68RG IC InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18-,26+,27+/m1/s1
DMT68RG CS C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O
DMT68RG IK KOZFSFOOLUUIGY-SOLYNIJKSA-N
DMT68RG IU methyl (15S,16R,18R)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DMT68RG CA CAS 99533-80-9
DMT68RG CB CHEBI:43616
DMT68RG DE Solid tumour/cancer
DMCZPH4 ID DMCZPH4
DMCZPH4 DN K-252a analogue
DMCZPH4 HS Investigative
DMCZPH4 DT Small molecular drug
DMCZPH4 PC 44400432
DMCZPH4 MW 455.5
DMCZPH4 FM C27H25N3O4
DMCZPH4 IC InChI=1S/C27H25N3O4/c1-26(2)27(33,13-31)11-19(34-26)30-18-10-6-4-8-15(18)21-22-16(12-28-25(22)32)20-14-7-3-5-9-17(14)29-23(20)24(21)30/h3-10,19,29,31,33H,11-13H2,1-2H3,(H,28,32)/t19-,27-/m1/s1
DMCZPH4 CS CC1([C@@](C[C@@H](O1)N2C3=CC=CC=C3C4=C5C(=C6C7=CC=CC=C7NC6=C42)CNC5=O)(CO)O)C
DMCZPH4 IK ONSKSKMJNHEONW-XHCCPWGMSA-N
DMCZPH4 IU 3-[(2R,4R)-4-hydroxy-4-(hydroxymethyl)-5,5-dimethyloxolan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-12-one
DMCZPH4 DE Discovery agent
DMYSMWI ID DMYSMWI
DMYSMWI DN K-454
DMYSMWI HS Investigative
DMYSMWI SN JAK2 kinase inhibitor (cancer), Kyowa
DMYSMWI CP Kyowa Hakko Kirin Co Ltd
DMYSMWI DE Solid tumour/cancer
DMUKTBF ID DMUKTBF
DMUKTBF DN K-6015
DMUKTBF HS Investigative
DMUKTBF SN Thymol-beta-D-glucopyranoside; LS-71596; MCULE-2137662265; THYMOL-B-D-GLUCOPYRANOSIDE; THYMOL-BETA-D-GLUCOPYRANOSIDE; Thymol glucoside; Thymol-beta-D-glucoside; W-201820; ZINC5765311; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-isopropyl-5-methylphenoxy)tetrahydro-2H-pyran-3,4,5-triol; 1-O-Thymyl-beta-D-glucopyranoside; 2-isopropyl-5-methylphenol-O-beta-d-glucopyranoside; 20772-23-0; FT-0771734; Glucopyranoside, 1-O-thymyl-, beta-D-; NCGC00380175-01; beta-D-Glucopyranoside, 5-methyl-2-(1-methylethyl)phenyl
DMUKTBF PC 88687
DMUKTBF MW 312.36
DMUKTBF FM C16H24O6
DMUKTBF IC GKQGIQVSMCHAFX-IBEHDNSVSA-N
DMUKTBF CS CC1=CC(=C(C=C1)C(C)C)OC2C(C(C(C(O2)CO)O)O)O
DMUKTBF IK 1S/C16H24O6/c1-8(2)10-5-4-9(3)6-11(10)21-16-15(20)14(19)13(18)12(7-17)22-16/h4-6,8,12-20H,7H2,1-3H3/t12-,13-,14+,15-,16-/m1/s1
DMUKTBF IU (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(5-methyl-2-propan-2-ylphenoxy)oxane-3,4,5-triol
DMUKTBF CA CAS 20772-23-0
DMUKTBF DE Campylobacter gastroenteritis
DMIFCMW ID DMIFCMW
DMIFCMW DN K-777
DMIFCMW HS Investigative
DMIFCMW SN K-777; UNII-320A4L58IZ; APC-3316; CRA-3316; K777; CHEMBL91704; 320A4L58IZ; K-11777; 4-methyl-N-((S)-1-oxo-3-phenyl-1-((S,E)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-ylamino)propan-2-yl)piperazine-1-carboxamide hydrochloride; APC 3316; K 777; K 11777; 233277-99-1; BDBM50229129; 1-Piperazinecarboxamide, 4-methyl-N-((1S)-2-oxo-2-(((1S)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propen-1-yl)amino)-1-(phenylmethyl)ethyl)-; 1-Piperazinecarboxamide, 4-methyl-N-((1S)-2-oxo-2-(((1S)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propenyl)amino)
DMIFCMW DT Small molecular drug
DMIFCMW PC 9851116
DMIFCMW MW 574.7
DMIFCMW FM C32H38N4O4S
DMIFCMW IC InChI=1S/C32H38N4O4S/c1-35-20-22-36(23-21-35)32(38)34-30(25-27-13-7-3-8-14-27)31(37)33-28(18-17-26-11-5-2-6-12-26)19-24-41(39,40)29-15-9-4-10-16-29/h2-16,19,24,28,30H,17-18,20-23,25H2,1H3,(H,33,37)(H,34,38)/b24-19+/t28-,30-/m0/s1
DMIFCMW CS CN1CCN(CC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC3=CC=CC=C3)/C=C/S(=O)(=O)C4=CC=CC=C4
DMIFCMW IK RHJLQMVZXQKJKB-FPHSVDBKSA-N
DMIFCMW IU N-[(2S)-1-[[(E,3S)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide
DMIFCMW CA CAS 233277-99-1
DMIFCMW DE Discovery agent
DM4GSHY ID DM4GSHY
DM4GSHY DN KA-10X
DM4GSHY HS Investigative
DM4GSHY SN KA-101; KA-102; G3BP antagonist peptides (cancer), Wuhan KatyGen Pharmaceuticals; RasGAP/RasGAP binding protein antagonist peptides (cancer), Wuhan Katygen Pharmaceuticals
DM4GSHY CP Wuhan Katygen Pharmaceuticals Inc
DM4GSHY DE Solid tumour/cancer
DMUWA2G ID DMUWA2G
DMUWA2G DN KAEMPFERIDE
DMUWA2G HS Investigative
DMUWA2G SN Kaempferide; 491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; Kaemperide; Campheride; Kempferide; UNII-508XL61MPD; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 5,7-Dihydroxy-4'-methoxyflavonol; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; EINECS 207-738-4; BRN 0305378; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; Flavone, 3,5,7-trihydroxy-4'-methoxy-; CHEMBL40919; CHEBI:6099; 508XL61MPD
DMUWA2G DT Small molecular drug
DMUWA2G PC 5281666
DMUWA2G MW 300.26
DMUWA2G FM C16H12O6
DMUWA2G IC InChI=1S/C16H12O6/c1-21-10-4-2-8(3-5-10)16-15(20)14(19)13-11(18)6-9(17)7-12(13)22-16/h2-7,17-18,20H,1H3
DMUWA2G CS COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DMUWA2G IK SQFSKOYWJBQGKQ-UHFFFAOYSA-N
DMUWA2G IU 3,5,7-trihydroxy-2-(4-methoxyphenyl)chromen-4-one
DMUWA2G CA CAS 491-54-3
DMUWA2G CB CHEBI:6099
DMUWA2G DE Discovery agent
DMHEMUB ID DMHEMUB
DMHEMUB DN Kaempferol
DMHEMUB HS Investigative
DMHEMUB SN kaempferol; 520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe
DMHEMUB DT Small molecular drug
DMHEMUB PC 5280863
DMHEMUB MW 286.24
DMHEMUB FM C15H10O6
DMHEMUB IC InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H
DMHEMUB CS C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
DMHEMUB IK IYRMWMYZSQPJKC-UHFFFAOYSA-N
DMHEMUB IU 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one
DMHEMUB CA CAS 520-18-3
DMHEMUB CB CHEBI:28499
DMHEMUB DE Discovery agent
DMUCZ3F ID DMUCZ3F
DMUCZ3F DN Kaempferol-3-O-(2''-O-galloyl)-glucoside
DMUCZ3F HS Investigative
DMUCZ3F SN CHEMBL444191; 76343-90-3; AC1NUQQD; Astragalin 2''-gallate; SCHEMBL12470746; BDBM50004199; AKOS030532822; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-((2-O-(3,4,5-trihydroxybenzoyl)-beta-D-glucopyranosyl)oxy)-; [(2S,3R,4S,5S,6R)-2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] 3,4,5-trihydroxybenzoate
DMUCZ3F DT Small molecular drug
DMUCZ3F PC 5488619
DMUCZ3F MW 600.5
DMUCZ3F FM C28H24O15
DMUCZ3F IC InChI=1S/C28H24O15/c29-9-18-21(36)23(38)26(42-27(39)11-5-15(33)20(35)16(34)6-11)28(41-18)43-25-22(37)19-14(32)7-13(31)8-17(19)40-24(25)10-1-3-12(30)4-2-10/h1-8,18,21,23,26,28-36,38H,9H2/t18-,21-,23+,26-,28+/m1/s1
DMUCZ3F CS C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)O
DMUCZ3F IK UWIQWJHBYRTKAL-KQOASZHBSA-N
DMUCZ3F IU [(2S,3R,4S,5S,6R)-2-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] 3,4,5-trihydroxybenzoate
DMUCZ3F CA CAS 76343-90-3
DMUCZ3F DE Discovery agent
DMBG7X1 ID DMBG7X1
DMBG7X1 DN Kaempferol-3-O-methyl ether
DMBG7X1 HS Investigative
DMBG7X1 SN Isokaempferide; 1592-70-7; 3-Methylkaempferol; 3-O-Methylkaempferol; Kaempferol 3-methyl ether; kaempferol-3-O-methyl ether; CHEBI:1579; CHEMBL165064; 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-3-METHOXY-; 3-Methylkempferol; AC1NQXOY; MLS000877008; SCHEMBL4637442; SCHEMBL1628023; MEGxp0_000171; 3-MK; cid_5280862; ACon1_001687; DTXSID90166609; MolPort-001-740-349; HMS2271C11; ZINC5732268; BDBM50240899; LMPK12112688; AKOS032949069
DMBG7X1 DT Small molecular drug
DMBG7X1 PC 5280862
DMBG7X1 MW 300.26
DMBG7X1 FM C16H12O6
DMBG7X1 IC InChI=1S/C16H12O6/c1-21-16-14(20)13-11(19)6-10(18)7-12(13)22-15(16)8-2-4-9(17)5-3-8/h2-7,17-19H,1H3
DMBG7X1 CS COC1=C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O
DMBG7X1 IK VJJZJBUCDWKPLC-UHFFFAOYSA-N
DMBG7X1 IU 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-methoxychromen-4-one
DMBG7X1 CA CAS 1592-70-7
DMBG7X1 CB CHEBI:1579
DMBG7X1 DE Discovery agent
DMN4EUB ID DMN4EUB
DMN4EUB DN KAG-308
DMN4EUB HS Investigative
DMN4EUB SN EP4 agonists (ulcerative colitis), Kaken
DMN4EUB CP Kaken Pharmaceutical Co Ltd
DMN4EUB PC 67108613
DMN4EUB MW 460.5
DMN4EUB FM C24H30F2N4O3
DMN4EUB IC InChI=1S/C24H30F2N4O3/c1-14-6-5-7-16(12-14)15(2)18(31)11-10-17-19(32)13-20-23(17)24(25,26)21(33-20)8-3-4-9-22-27-29-30-28-22/h5-8,10-12,15,17-20,23,31-32H,3-4,9,13H2,1-2H3,(H,27,28,29,30)/b11-10+,21-8-/t15-,17+,18-,19-,20+,23-/m1/s1
DMN4EUB CS CC1=CC(=CC=C1)[C@@H](C)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C(/C(=C/CCCC4=NNN=N4)/O3)(F)F)O)O
DMN4EUB IK KSELABKNBIUMGG-YGBAREPYSA-N
DMN4EUB IU (2Z,3aR,4R,5R,6aS)-3,3-difluoro-4-[(E,3R,4R)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2H-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-5-ol
DMN4EUB DE Ulcerative colitis
DMRT6OP ID DMRT6OP
DMRT6OP DN kallidin
DMRT6OP HS Investigative
DMRT6OP SN Lysyl-bradykinin; [Lys]bradykinin; Lys-BK; kallidin II
DMRT6OP DT Small molecular drug
DMRT6OP PC 5311111
DMRT6OP MW 1188.4
DMRT6OP FM C56H85N17O12
DMRT6OP IC InChI=1S/C56H85N17O12/c57-24-8-7-18-36(58)46(76)67-37(19-9-25-63-55(59)60)51(81)73-29-13-23-44(73)53(83)72-28-11-21-42(72)49(79)65-32-45(75)66-39(30-34-14-3-1-4-15-34)47(77)70-41(33-74)52(82)71-27-12-22-43(71)50(80)69-40(31-35-16-5-2-6-17-35)48(78)68-38(54(84)85)20-10-26-64-56(61)62/h1-6,14-17,36-44,74H,7-13,18-33,57-58H2,(H,65,79)(H,66,75)(H,67,76)(H,68,78)(H,69,80)(H,70,77)(H,84,85)(H4,59,60,63)(H4,61,62,64)/t36-,37-,38-,39-,40-,41-,42-,43-,44-/m0/s1
DMRT6OP CS C1C[C@H](N(C1)C(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
DMRT6OP IK FYSKZKQBTVLYEQ-FSLKYBNLSA-N
DMRT6OP IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMRT6OP CA CAS 342-10-9
DMRT6OP CB CHEBI:6102
DMRT6OP DE Discovery agent
DM7YAE0 ID DM7YAE0
DM7YAE0 DN kallstroemin D
DM7YAE0 HS Investigative
DM7YAE0 SN kallstroemin D
DM7YAE0 DT Small molecular drug
DM7YAE0 PC 73754998
DM7YAE0 MW 1015.2
DM7YAE0 FM C51H82O20
DM7YAE0 IC InChI=1S/C51H82O20/c1-21-10-15-50(63-19-21)22(2)34-32(69-50)17-30-28-9-8-26-16-27(11-13-48(26,6)29(28)12-14-49(30,34)7)66-45-42(60)40(58)38(56)33(67-45)20-62-47-44(41(59)37(55)24(4)65-47)70-51(18-31(52)35(53)25(5)68-51)71-46-43(61)39(57)36(54)23(3)64-46/h8,21-25,27-47,52-61H,9-20H2,1-7H3
DM7YAE0 CS CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)COC8C(C(C(C(O8)C)O)O)OC9(CC(C(C(O9)C)O)O)OC2C(C(C(C(O2)C)O)O)O)O)O)O)C)C)C)OC1
DM7YAE0 IK JXANHBVHGVNOQZ-UHFFFAOYSA-N
DM7YAE0 IU 2-[2-[4,5-dihydroxy-6-methyl-2-[[3,4,5-trihydroxy-6-(5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl)oxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6-methyloxane-3,4,5-triol
DM7YAE0 DE Discovery agent
DMFR79L ID DMFR79L
DMFR79L DN Kaltostat
DMFR79L HS Investigative
DMFR79L SN Polysaccharide alginic acid; Sodium calcium alginate; calginat; Kalrostat; Vocoloid; Xantalgin; copper alginate; C14H22O13; Alloid G; Kalrostat 2; Polymannuronic acid; poly(mannuronic acid); alginic acid, copper salt; Alginic acid, calcium salt; Alginic acid, ammonium salt; polymannuronic-guluronic acid; Landalgine; Nouralgine
DMFR79L DE Gastro-oesophageal reflux disease
DMXAK75 ID DMXAK75
DMXAK75 DN KAR-1880
DMXAK75 HS Investigative
DMXAK75 SN Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus
DMXAK75 CP Karus Therapeutics Ltd
DMXAK75 DE Dermatitis
DMMIA38 ID DMMIA38
DMMIA38 DN kassinin
DMMIA38 HS Investigative
DMMIA38 SN KASSININ; 63968-82-1; UNII-9BOP147TRT; 9BOP147TRT; AC1L2EKC; GTPL2088; SCHEMBL20639320; BDBM81943; NSC_45749; CAS_45749; L-alpha-Aspartyl-L-valyl-L-prolyl-L-lysyl-L-seryl-L-alpha-aspartyl-L-glutaminyl-L-phenylalanyl-L-valylglycyl-L-leucyl-L-methioninamide; LS-187667; LS-187057; L-Methioninamide, L-alpha-aspartyl-L-valyl-L-prolyl-L-lysyl-L-seryl-L-alpha-aspartyl-L-glutaminyl-L-phenylalanyl-L-valylglycyl-L-leucyl-
DMMIA38 DT Small molecular drug
DMMIA38 PC 45749
DMMIA38 MW 1334.5
DMMIA38 FM C59H95N15O18S
DMMIA38 IC InChI=1S/C59H95N15O18S/c1-30(2)24-38(53(86)66-35(49(63)82)20-23-93-7)65-44(77)28-64-58(91)47(31(3)4)72-55(88)39(25-33-14-9-8-10-15-33)69-52(85)37(18-19-43(62)76)67-54(87)40(27-46(80)81)70-56(89)41(29-75)71-51(84)36(16-11-12-21-60)68-57(90)42-17-13-22-74(42)59(92)48(32(5)6)73-50(83)34(61)26-45(78)79/h8-10,14-15,30-32,34-42,47-48,75H,11-13,16-29,60-61H2,1-7H3,(H2,62,76)(H2,63,82)(H,64,91)(H,65,77)(H,66,86)(H,67,87)(H,68,90)(H,69,85)(H,70,89)(H,71,84)(H,72,88)(H,73,83)(H,78,79)(H,80,81)
DMMIA38 CS CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(CC(=O)O)N
DMMIA38 IK NXTPETCPVNEEOP-UHFFFAOYSA-N
DMMIA38 IU 3-amino-4-[[1-[2-[[6-amino-1-[[1-[[1-[[5-amino-1-[[1-[[1-[[2-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DMMIA38 DE Discovery agent
DM513QY ID DM513QY
DM513QY DN KATSUMADAIN A
DM513QY HS Investigative
DM513QY SN katsumadain A; CHEMBL480470
DM513QY DT Small molecular drug
DM513QY PC 9982435
DM513QY MW 476.6
DM513QY FM C32H28O4
DM513QY IC InChI=1S/C32H28O4/c33-26(18-16-23-10-4-1-5-11-23)20-28-21-29(25-14-8-3-9-15-25)31-30(35-28)22-27(36-32(31)34)19-17-24-12-6-2-7-13-24/h1-15,17,19,22,28-29H,16,18,20-21H2/b19-17+/t28-,29+/m1/s1
DM513QY CS C1[C@H](OC2=C([C@@H]1C3=CC=CC=C3)C(=O)OC(=C2)/C=C/C4=CC=CC=C4)CC(=O)CCC5=CC=CC=C5
DM513QY IK IAIGBNIWSBFKNA-FIACUDKOSA-N
DM513QY IU (2S,4S)-2-(2-oxo-4-phenylbutyl)-4-phenyl-7-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrano[3,2-c]pyran-5-one
DM513QY DE Discovery agent
DMS527J ID DMS527J
DMS527J DN Kazinol C
DMS527J HS Investigative
DMS527J SN kazinol C; CHEMBL466200; SCHEMBL14815139
DMS527J DT Small molecular drug
DMS527J PC 21637679
DMS527J MW 464.6
DMS527J FM C30H40O4
DMS527J IC InChI=1S/C30H40O4/c1-8-30(6,7)25-16-22(26(31)18-27(25)32)11-9-10-21-17-28(33)29(34)24(15-13-20(4)5)23(21)14-12-19(2)3/h8,12-13,16-18,31-34H,1,9-11,14-15H2,2-7H3
DMS527J CS CC(=CCC1=C(C(=C(C=C1CCCC2=CC(=C(C=C2O)O)C(C)(C)C=C)O)O)CC=C(C)C)C
DMS527J IK YCJJCTRPAGXWGX-UHFFFAOYSA-N
DMS527J IU 5-[3-[2,4-dihydroxy-5-(2-methylbut-3-en-2-yl)phenyl]propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol
DMS527J DE Discovery agent
DMFVT81 ID DMFVT81
DMFVT81 DN Kazinol F
DMFVT81 HS Investigative
DMFVT81 SN Kazinol F; 104494-35-1; CHEMBL457677; 1,2-Benzenediol, 5-(3-(2,4-dihydroxyphenyl)propyl)-3,4-bis(3-methyl-2-butenyl)-; 5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol; 1,2-Benzenediol,5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methyl-2-buten-1-yl)-; ACMC-20cyyd; AC1L4EMW; AC1Q79FB; SCHEMBL7555982; CTK4A3084; DTXSID10146504; BDBM50251001
DMFVT81 DT Small molecular drug
DMFVT81 PC 184311
DMFVT81 MW 396.5
DMFVT81 FM C25H32O4
DMFVT81 IC InChI=1S/C25H32O4/c1-16(2)8-12-21-19(7-5-6-18-10-11-20(26)15-23(18)27)14-24(28)25(29)22(21)13-9-17(3)4/h8-11,14-15,26-29H,5-7,12-13H2,1-4H3
DMFVT81 CS CC(=CCC1=C(C(=C(C=C1CCCC2=C(C=C(C=C2)O)O)O)O)CC=C(C)C)C
DMFVT81 IK PNQQDEFGJPUAGZ-UHFFFAOYSA-N
DMFVT81 IU 5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol
DMFVT81 CA CAS 104494-35-1
DMFVT81 DE Discovery agent
DMEV2AL ID DMEV2AL
DMEV2AL DN KAZINOL S
DMEV2AL HS Investigative
DMEV2AL SN CHEMBL469113; KAZINOL S; BDBM50254431; 5''-(2-methylbut-3-en-2-yl)-6''''-(3-methylbut-2-enyl)-5''''-(2,3-epoxy-3-methylbytyl)-2'',4'',3'''',4''''-tetrahydroxy diphenylpropane
DMEV2AL DT Small molecular drug
DMEV2AL PC 44569902
DMEV2AL MW 480.6
DMEV2AL FM C30H40O5
DMEV2AL IC InChI=1S/C30H40O5/c1-8-29(4,5)23-14-20(24(31)17-25(23)32)11-9-10-19-15-26(33)28(34)22(16-27-30(6,7)35-27)21(19)13-12-18(2)3/h8,12,14-15,17,27,31-34H,1,9-11,13,16H2,2-7H3
DMEV2AL CS CC(=CCC1=C(C(=C(C=C1CCCC2=CC(=C(C=C2O)O)C(C)(C)C=C)O)O)CC3C(O3)(C)C)C
DMEV2AL IK YTBAFGRFSDPCBF-UHFFFAOYSA-N
DMEV2AL IU 5-[3-[2,4-dihydroxy-5-(2-methylbut-3-en-2-yl)phenyl]propyl]-3-[(3,3-dimethyloxiran-2-yl)methyl]-4-(3-methylbut-2-enyl)benzene-1,2-diol
DMEV2AL DE Discovery agent
DMO72XF ID DMO72XF
DMO72XF DN KB-130015
DMO72XF HS Investigative
DMO72XF SN KB 130015; KB130015
DMO72XF DT Small molecular drug
DMO72XF PC 9872203
DMO72XF MW 548.1
DMO72XF FM C18H14I2O4
DMO72XF IC InChI=1S/C18H14I2O4/c1-10-13(12-4-2-3-5-16(12)24-10)6-11-7-14(19)18(15(20)8-11)23-9-17(21)22/h2-5,7-8H,6,9H2,1H3,(H,21,22)
DMO72XF CS CC1=C(C2=CC=CC=C2O1)CC3=CC(=C(C(=C3)I)OCC(=O)O)I
DMO72XF IK OLIKCJUMYWSDIV-UHFFFAOYSA-N
DMO72XF IU 2-[2,6-diiodo-4-[(2-methyl-1-benzofuran-3-yl)methyl]phenoxy]acetic acid
DMO72XF CA CAS 147030-48-6
DMO72XF DE Discovery agent
DMCQRA3 ID DMCQRA3
DMCQRA3 DN KB-9520
DMCQRA3 HS Investigative
DMCQRA3 SN KB-093823; KB-095285; KB-095508; KB-099520; ER-beta agonists (depression/cancer/inflammation), Karo Bio
DMCQRA3 CP Karo Bio AB
DMCQRA3 DE Solid tumour/cancer
DMMD5W3 ID DMMD5W3
DMMD5W3 DN KB-R7943
DMMD5W3 HS Investigative
DMMD5W3 SN 182004-65-5; KB-R7943 mesylate; KB-R7943; 2-[2-[4-(4-NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA MESYLATE; KB-R7943 (mesylate); 4-((4-Nitrobenzyl)oxy)phenethyl carbamimidothioate methanesulfonate; 4-((4-Nitrobenzyl)oxy)phenethyl carbamimidothioatemethanesulfonate; 2-(2-(4-(4-Nitrobenzyloxy)phenyl)ethyl)isothiourea, methane sulfonate; 4-[(4-Nitrobenzyl)oxy]phenethyl Carbamimidothioate Methanesulfonate; KB-R7943 mesylate; SCHEMBL742683; GTPL4232; CTK0H1228; DTXSID50431360; MolPort-003-983-603; C16H17N3O3S.CH4O3S; HMS3267H09
DMMD5W3 DT Small molecular drug
DMMD5W3 PC 9823846
DMMD5W3 MW 427.5
DMMD5W3 FM C17H21N3O6S2
DMMD5W3 IC InChI=1S/C16H17N3O3S.CH4O3S/c17-16(18)23-10-9-12-3-7-15(8-4-12)22-11-13-1-5-14(6-2-13)19(20)21;1-5(2,3)4/h1-8H,9-11H2,(H3,17,18);1H3,(H,2,3,4)
DMMD5W3 CS CS(=O)(=O)O.C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-]
DMMD5W3 IK WGIKEBHIKKWJLG-UHFFFAOYSA-N
DMMD5W3 IU methanesulfonic acid;2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl carbamimidothioate
DMMD5W3 CA CAS 182004-65-5
DMMD5W3 DE Discovery agent
DMY6QOR ID DMY6QOR
DMY6QOR DN KC-12291
DMY6QOR HS Investigative
DMY6QOR SN KC-12291; CHEMBL452043; SCHEMBL6577701; kc12291; ZINC1545352; NCGC00370808-01
DMY6QOR DT Small molecular drug
DMY6QOR PC 10364418
DMY6QOR MW 413.5
DMY6QOR FM C22H27N3O3S
DMY6QOR IC InChI=1S/C22H27N3O3S/c1-25(14-12-17-10-11-19(26-2)20(16-17)27-3)13-7-15-28-22-23-21(29-24-22)18-8-5-4-6-9-18/h4-6,8-11,16H,7,12-15H2,1-3H3
DMY6QOR CS CN(CCCOC1=NSC(=N1)C2=CC=CC=C2)CCC3=CC(=C(C=C3)OC)OC
DMY6QOR IK RHJGWXNLFGHPHA-UHFFFAOYSA-N
DMY6QOR IU N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-[(5-phenyl-1,2,4-thiadiazol-3-yl)oxy]propan-1-amine
DMY6QOR DE Discovery agent
DMJ2X64 ID DMJ2X64
DMJ2X64 DN KD-7332
DMJ2X64 HS Investigative
DMJ2X64 SN Inducible nitric oxide synthase dimerization inhibitor (oral, inflammatory diseases), Kalypsys; Inducible nitric oxide synthase dimerization inhibitor (oral, neuropathic pain), Kalypsys
DMJ2X64 CP Kalypsys Inc
DMJ2X64 DE Inflammation
DMOX8FD ID DMOX8FD
DMOX8FD DN KELATORPHAN
DMOX8FD HS Investigative
DMOX8FD SN kelatorphan; 92175-57-0; UNII-46BBW2U5D6; n-[(2r)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-l-alanine; 46BBW2U5D6; (3-(N-Hydroxy)carboxamido-2-benzylpropanoyl)alanine; L-Alanine, N-(4-(hydroxyamino)-1,4-dioxo-2-(phenylmethyl)butyl)-, (R)-; 3b7u; AC1L3XO7; CHEMBL85320; SCHEMBL7384459; BDBM92500; DTXSID90238911; ZINC6020153; DB08040; HY-10827; KB-78017; LS-186814; LS-187482; CS-0002846; (2S)-2-[[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]amino]propanoic acid
DMOX8FD DT Small molecular drug
DMOX8FD PC 123982
DMOX8FD MW 294.3
DMOX8FD FM C14H18N2O5
DMOX8FD IC InChI=1S/C14H18N2O5/c1-9(14(19)20)15-13(18)11(8-12(17)16-21)7-10-5-3-2-4-6-10/h2-6,9,11,21H,7-8H2,1H3,(H,15,18)(H,16,17)(H,19,20)/t9-,11+/m0/s1
DMOX8FD CS C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)CC(=O)NO
DMOX8FD IK OJCFZTVYDSKXNM-GXSJLCMTSA-N
DMOX8FD IU (2S)-2-[[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]amino]propanoic acid
DMOX8FD CA CAS 92175-57-0
DMOX8FD DE Discovery agent
DM0RC8M ID DM0RC8M
DM0RC8M DN KETOCYCLAZOCINE
DM0RC8M HS Investigative
DM0RC8M SN Ketocyclazocine
DM0RC8M DT Small molecular drug
DM0RC8M PC 23724935
DM0RC8M MW 285.4
DM0RC8M FM C18H23NO2
DM0RC8M IC InChI=1S/C18H23NO2/c1-11-16-17(21)14-6-5-13(20)9-15(14)18(11,2)7-8-19(16)10-12-3-4-12/h5-6,9,11-12,16,20H,3-4,7-8,10H2,1-2H3/t11-,16-,18-/m0/s1
DM0RC8M CS C[C@H]1[C@H]2C(=O)C3=C([C@]1(CCN2CC4CC4)C)C=C(C=C3)O
DM0RC8M IK HQBZLVPZOGIAIQ-PBQZTSCYSA-N
DM0RC8M IU (1S,9S,13R)-10-(cyclopropylmethyl)-4-hydroxy-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one
DM0RC8M DE Discovery agent
DMX2FL3 ID DMX2FL3
DMX2FL3 DN Ketoprofen glucuronide
DMX2FL3 HS Investigative
DMX2FL3 SN Ketoprofen glucuronide; KETOPROFEN ACYL-B-D-GLUCURONIDE; 76690-94-3; DL-Ketoprofen glucuronide; (R)-Ketoprofen Glucuronide; (S)-Ketoprofen Glucuronide; CHEMBL3526739; DTXSID30998002; FT-0670648; W-203754; 1-O-[2-(3-Benzoylphenyl)propanoyl]hexopyranuronic acid; 1-(3-benzoyl-alpha-methylbenzeneacetate) beta-D-glucopyranuronic acid; beta-D-Glucopyranuronic acid, 1-(3-benzoyl-alpha-methylbenzeneacetate); 1-(3-benzoyl-alpha-methylbenzeneacetate) beta-delta-glucopyranuronic acid
DMX2FL3 PC 131281
DMX2FL3 MW 430.4
DMX2FL3 FM C22H22O9
DMX2FL3 IC PBTXSZZKPHBHMA-LYFYOZKASA-N
DMX2FL3 CS CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)OC3C(C(C(C(O3)C(=O)O)O)O)O
DMX2FL3 IK 1S/C22H22O9/c1-11(13-8-5-9-14(10-13)15(23)12-6-3-2-4-7-12)21(29)31-22-18(26)16(24)17(25)19(30-22)20(27)28/h2-11,16-19,22,24-26H,1H3,(H,27,28)/t11?,16-,17-,18+,19-,22-/m0/s1
DMX2FL3 IU (2S,3S,4S,5R,6S)-6-[2-(3-benzoylphenyl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
DMX2FL3 CA CAS 76690-94-3
DMX2FL3 DE Discovery agent
DM7W9MT ID DM7W9MT
DM7W9MT DN KF 17837S
DM7W9MT HS Investigative
DM7W9MT SN 152881-18-0; 8-(3,4-Dimethoxyphenyl)-7-methyl-1,3-dipropyl-1H-purine-2,6(3H,7H)-dione; 8-(3,4-dimethoxyphenyl)-7-methyl-1,3-dipropylpurine-2,6-dione; 1,3-Dipropyl-7-methyl-8-(3,4-dimethoxystyryl)xanthine; AC1L3X7D; GTPL428; CTK8C1262; DTXSID30165151; ZINC5114737; 7673AA; ANW-66125; AKOS016004661; 8-(3,4-Dimethoxyphenyl)-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione; AJ-53127; AX8236469; L001123; 1H-Purine-2,6-dione, 8-(3,4-dimethoxyphenyl)-3,7-dihydro-7-methyl-1,3-dipropyl-
DM7W9MT DT Small molecular drug
DM7W9MT PC 123739
DM7W9MT MW 386.4
DM7W9MT FM C20H26N4O4
DM7W9MT IC InChI=1S/C20H26N4O4/c1-6-10-23-18-16(19(25)24(11-7-2)20(23)26)22(3)17(21-18)13-8-9-14(27-4)15(12-13)28-5/h8-9,12H,6-7,10-11H2,1-5H3
DM7W9MT CS CCCN1C2=C(C(=O)N(C1=O)CCC)N(C(=N2)C3=CC(=C(C=C3)OC)OC)C
DM7W9MT IK FSUNYKAEJIVAHY-UHFFFAOYSA-N
DM7W9MT IU 8-(3,4-dimethoxyphenyl)-7-methyl-1,3-dipropylpurine-2,6-dione
DM7W9MT CA CAS 152881-18-0
DM7W9MT DE Discovery agent
DMK6SMW ID DMK6SMW
DMK6SMW DN KF24345
DMK6SMW HS Investigative
DMK6SMW SN KF-24345; KF 24345
DMK6SMW DT Small molecular drug
DMK6SMW PC 9938824
DMK6SMW MW 574.7
DMK6SMW FM C31H38N6O5
DMK6SMW IC InChI=1S/C31H38N6O5/c1-5-41-26-18-22-24(19-27(26)42-6-2)32-30(36-13-15-40-16-14-36)33-28(22)35-11-9-21(10-12-35)37-29(38)23-17-20(3)7-8-25(23)34(4)31(37)39/h7-8,17-19,21H,5-6,9-16H2,1-4H3
DMK6SMW CS CCOC1=C(C=C2C(=C1)C(=NC(=N2)N3CCOCC3)N4CCC(CC4)N5C(=O)C6=C(C=CC(=C6)C)N(C5=O)C)OCC
DMK6SMW IK MXOWYPVUVPQDNZ-UHFFFAOYSA-N
DMK6SMW IU 3-[1-(6,7-diethoxy-2-morpholin-4-ylquinazolin-4-yl)piperidin-4-yl]-1,6-dimethylquinazoline-2,4-dione
DMK6SMW DE Discovery agent
DMPBDW0 ID DMPBDW0
DMPBDW0 DN KF26777
DMPBDW0 HS Investigative
DMPBDW0 SN KF 26777
DMPBDW0 DT Small molecular drug
DMPBDW0 PC 154730657
DMPBDW0 DE Discovery agent
DMOUW0A ID DMOUW0A
DMOUW0A DN KF-66490
DMOUW0A HS Investigative
DMOUW0A SN K-34; PDE 4 inhibitors (dermatitis/rheumatoid arthritis); PDE 4 inhibitors (dermatitis/rheumatoid arthritis), Kyowa Hakko Kirin
DMOUW0A CP Kyowa Hakko Kirin Co Ltd
DMOUW0A DT Small molecular drug
DMOUW0A PC 281833
DMOUW0A MW 374.4
DMOUW0A FM C18H22N4O5
DMOUW0A IC InChI=1S/C18H22N4O5/c1-8-12(19)15(24)11-9(7-27-17(25)21-4-5-21)18(26-3)16-10(20(16)2)6-22(18)13(11)14(8)23/h9-10,16H,4-7,19H2,1-3H3
DMOUW0A CS CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N5CC5)OC)N4C)N
DMOUW0A IK FZLZUGFFXNJCRD-UHFFFAOYSA-N
DMOUW0A IU (11-amino-7-methoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl)methyl aziridine-1-carboxylate
DMOUW0A DE Atopic dermatitis
DMFBMYG ID DMFBMYG
DMFBMYG DN KF-A5
DMFBMYG HS Investigative
DMFBMYG SN KF-A5; CHEMBL491754; SCHEMBL10704523; BDBM50249782
DMFBMYG DT Small molecular drug
DMFBMYG PC 14014889
DMFBMYG MW 336.5
DMFBMYG FM C22H28N2O
DMFBMYG IC InChI=1S/C22H28N2O/c1-3-23(4-2)16-10-5-11-17-24-20-14-8-6-12-18(20)22(25)19-13-7-9-15-21(19)24/h6-9,12-15H,3-5,10-11,16-17H2,1-2H3
DMFBMYG CS CCN(CC)CCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31
DMFBMYG IK YCWGZWYJTIJTHX-UHFFFAOYSA-N
DMFBMYG IU 10-[5-(diethylamino)pentyl]acridin-9-one
DMFBMYG DE Discovery agent
DMQJ3T5 ID DMQJ3T5
DMQJ3T5 DN KF-A6
DMQJ3T5 HS Investigative
DMQJ3T5 SN KF-A6; CHEMBL491889; SCHEMBL13438391; BDBM50249783
DMQJ3T5 DT Small molecular drug
DMQJ3T5 PC 44566054
DMQJ3T5 MW 350.5
DMQJ3T5 FM C23H30N2O
DMQJ3T5 IC InChI=1S/C23H30N2O/c1-3-24(4-2)17-11-5-6-12-18-25-21-15-9-7-13-19(21)23(26)20-14-8-10-16-22(20)25/h7-10,13-16H,3-6,11-12,17-18H2,1-2H3
DMQJ3T5 CS CCN(CC)CCCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31
DMQJ3T5 IK YHXSELHUXJAOLR-UHFFFAOYSA-N
DMQJ3T5 IU 10-[6-(diethylamino)hexyl]acridin-9-one
DMQJ3T5 DE Discovery agent
DMCE8Q9 ID DMCE8Q9
DMCE8Q9 DN KH-164
DMCE8Q9 HS Investigative
DMCE8Q9 SN 115305-61-8; 141109-86-6; KH-161
DMCE8Q9 DT Small molecular drug
DMCE8Q9 PC 471377
DMCE8Q9 MW 1017.3
DMCE8Q9 FM C57H76N8O9
DMCE8Q9 IC InChI=1S/C57H76N8O9/c1-34(2)28-43(49(67)33-50(68)60-45(29-35(3)4)53(70)62-44(52(58)69)30-38-18-10-8-11-19-38)61-56(73)51(36(5)6)64-54(71)46(31-39-20-12-9-13-21-39)63-55(72)48-26-17-27-65(48)57(74)47(59-37(7)66)32-41-24-16-23-40-22-14-15-25-42(40)41/h8-16,18-25,34-36,43-49,51,67H,17,26-33H2,1-7H3,(H2,58,69)(H,59,66)(H,60,68)(H,61,73)(H,62,70)(H,63,72)(H,64,71)/t43-,44-,45-,46-,47-,48-,49-,51-/m0/s1
DMCE8Q9 CS CC(C)C[C@@H]([C@H](CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC5=CC=CC=C54)NC(=O)C
DMCE8Q9 IK WBMREBMOCPFYEP-FKUHLYKMSA-N
DMCE8Q9 IU (2S)-1-[(2S)-2-acetamido-3-naphthalen-1-ylpropanoyl]-N-[(2S)-1-[[(2S)-1-[[(3S,4S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DMCE8Q9 DE Discovery agent
DMSOB3U ID DMSOB3U
DMSOB3U DN KH-CB19
DMSOB3U HS Investigative
DMSOB3U SN KH CB19
DMSOB3U DT Small molecular drug
DMSOB3U PC 44237094
DMSOB3U MW 338.2
DMSOB3U FM C15H13Cl2N3O2
DMSOB3U IC InChI=1S/C15H13Cl2N3O2/c1-3-22-15(21)14-11(8(6-18)7-19)9-4-5-10(16)12(17)13(9)20(14)2/h4-6H,3,18H2,1-2H3/b8-6-
DMSOB3U CS CCOC(=O)C1=C(C2=C(N1C)C(=C(C=C2)Cl)Cl)/C(=C\\N)/C#N
DMSOB3U IK CXJCGSPAPOTTSF-VURMDHGXSA-N
DMSOB3U IU ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methylindole-2-carboxylate
DMSOB3U DE Discovery agent
DMLG2EA ID DMLG2EA
DMLG2EA DN Ki-11502
DMLG2EA HS Investigative
DMLG2EA SN Ki 11502; PDGF Receptor Tyrosine Kinase Inhibitor V
DMLG2EA DT Small molecular drug
DMLG2EA PC 11554659
DMLG2EA MW 473.5
DMLG2EA FM C26H23N3O4S
DMLG2EA IC InChI=1S/C26H23N3O4S/c1-16-6-4-5-7-19(16)25(30)29-26(34)28-17-8-10-18(11-9-17)33-22-12-13-27-21-15-24(32-3)23(31-2)14-20(21)22/h4-15H,1-3H3,(H2,28,29,30,34)
DMLG2EA CS CC1=CC=CC=C1C(=O)NC(=S)NC2=CC=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC
DMLG2EA IK ZXGIBSBJQLLUEE-UHFFFAOYSA-N
DMLG2EA IU N-[[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]carbamothioyl]-2-methylbenzamide
DMLG2EA CA CAS 347155-76-4
DMLG2EA CB CHEBI:133397
DMLG2EA DE Discovery agent
DMJTDK9 ID DMJTDK9
DMJTDK9 DN Ki16425
DMJTDK9 HS Investigative
DMJTDK9 SN SCHEMBL13385834
DMJTDK9 DT Small molecular drug
DMJTDK9 PC 10367662
DMJTDK9 MW 475
DMJTDK9 FM C23H23ClN2O5S
DMJTDK9 IC InChI=1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10,15H,11-13H2,1-2H3,(H,25,29)(H,27,28)
DMJTDK9 CS CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2Cl)C3=CC=C(C=C3)CSCCC(=O)O
DMJTDK9 IK LLIFMNUXGDHTRO-UHFFFAOYSA-N
DMJTDK9 IU 3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylsulfanyl]propanoic acid
DMJTDK9 CA CAS 355025-24-0
DMJTDK9 CB CHEBI:91194
DMJTDK9 DE Discovery agent
DM9M3VC ID DM9M3VC
DM9M3VC DN Ki-20227
DM9M3VC HS Investigative
DM9M3VC SN Ki 20227; Ki20227
DM9M3VC DT Small molecular drug
DM9M3VC PC 9869779
DM9M3VC MW 480.5
DM9M3VC FM C24H24N4O5S
DM9M3VC IC InChI=1S/C24H24N4O5S/c1-14(23-26-9-10-34-23)27-24(29)28-17-6-5-15(11-20(17)30-2)33-19-7-8-25-18-13-22(32-4)21(31-3)12-16(18)19/h5-14H,1-4H3,(H2,27,28,29)
DM9M3VC CS CC(C1=NC=CS1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)OC
DM9M3VC IK SHPFDGWALWEPGS-UHFFFAOYSA-N
DM9M3VC IU 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methoxyphenyl]-3-[1-(1,3-thiazol-2-yl)ethyl]urea
DM9M3VC CA CAS 623142-96-1
DM9M3VC DE Discovery agent
DMHEOBY ID DMHEOBY
DMHEOBY DN KIN-3031
DMHEOBY HS Investigative
DMHEOBY SN Mu opioid angonist (CNS formulation, pain), Kinentia
DMHEOBY CP Kinentia Biosciences LLC
DMHEOBY DE Pain
DMO8JQM ID DMO8JQM
DMO8JQM DN KIN-4044
DMO8JQM HS Investigative
DMO8JQM SN Mu opioid antagonist (NSCLC), Kinentia
DMO8JQM CP Kinentia Biosciences LLC
DMO8JQM DE Non-small-cell lung cancer
DMDL21W ID DMDL21W
DMDL21W DN kisspeptin-10
DMDL21W HS Investigative
DMDL21W SN RITKWYDZSSQNJI-INXYWQKQSA-N; Kisspeptin-10; KP-10; CHEMBL376756; 374675-21-5; Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2; KP10; KISS1; Kisspeptin 10 (human); GTPL1283; SCHEMBL15930211; BDBM26349; MolPort-023-276-491; Metastin (45-54) amide, human; BDBM50045513; AKOS024457174; Gene product (112-121) amide, human; Metastin (45-54) amide, human, > H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2
DMDL21W DT Small molecular drug
DMDL21W PC 25240297
DMDL21W MW 1302.4
DMDL21W FM C63H83N17O14
DMDL21W IC InChI=1S/C63H83N17O14/c1-34(2)24-45(58(90)74-43(18-11-23-70-63(68)69)57(89)75-44(54(67)86)26-35-12-5-3-6-13-35)73-53(85)32-72-56(88)46(27-36-14-7-4-8-15-36)77-62(94)50(33-81)80-61(93)49(30-52(66)84)79-59(91)47(28-38-31-71-42-17-10-9-16-40(38)42)78-60(92)48(29-51(65)83)76-55(87)41(64)25-37-19-21-39(82)22-20-37/h3-10,12-17,19-22,31,34,41,43-50,71,81-82H,11,18,23-30,32-33,64H2,1-2H3,(H2,65,83)(H2,66,84)(H2,67,86)(H,72,88)(H,73,85)(H,74,90)(H,75,89)(H,76,87)(H,77,94)(H,78,92)(H,79,91)(H,80,93)(H4,68,69,70)/t41-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1
DMDL21W CS CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)N
DMDL21W IK RITKWYDZSSQNJI-INXYWQKQSA-N
DMDL21W IU (2S)-N-[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]butanediamide
DMDL21W CA CAS 374675-21-5
DMDL21W DE Discovery agent
DMPJKBV ID DMPJKBV
DMPJKBV DN KJM429
DMPJKBV HS Investigative
DMPJKBV SN MK-056; CHEMBL228451; thiourea analogue, 1; SCHEMBL1268701; BDBM20315; N-(4-t-butylbenzyl)-N'-[4-(methyl-sulfonylamino)benzyl]thiourea
DMPJKBV DT Small molecular drug
DMPJKBV PC 10135969
DMPJKBV MW 405.6
DMPJKBV FM C20H27N3O2S2
DMPJKBV IC InChI=1S/C20H27N3O2S2/c1-20(2,3)17-9-5-15(6-10-17)13-21-19(26)22-14-16-7-11-18(12-8-16)23-27(4,24)25/h5-12,23H,13-14H2,1-4H3,(H2,21,22,26)
DMPJKBV CS CC(C)(C)C1=CC=C(C=C1)CNC(=S)NCC2=CC=C(C=C2)NS(=O)(=O)C
DMPJKBV IK LOMAEJPLJSUBML-UHFFFAOYSA-N
DMPJKBV IU 1-[(4-tert-butylphenyl)methyl]-3-[[4-(methanesulfonamido)phenyl]methyl]thiourea
DMAU1SZ ID DMAU1SZ
DMAU1SZ DN KKHT-10318
DMAU1SZ HS Investigative
DMAU1SZ SN KKHT-10318; CHEMBL388401; SCHEMBL8227931; BDBM50196478
DMAU1SZ DT Small molecular drug
DMAU1SZ PC 44422402
DMAU1SZ MW 426.9
DMAU1SZ FM C22H23ClN4O3
DMAU1SZ IC InChI=1S/C22H23ClN4O3/c23-17-6-3-15(4-7-17)14-27-21(29)18-8-5-16(13-19(18)25-22(27)30)20(28)24-9-12-26-10-1-2-11-26/h3-8,13H,1-2,9-12,14H2,(H,24,28)(H,25,30)
DMAU1SZ CS C1CCN(C1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMAU1SZ IK VJRGAGPCQUZOLU-UHFFFAOYSA-N
DMAU1SZ IU 3-[(4-chlorophenyl)methyl]-2,4-dioxo-N-(2-pyrrolidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMAU1SZ DE Discovery agent
DMYT381 ID DMYT381
DMYT381 DN KKHT-10608
DMYT381 HS Investigative
DMYT381 SN KKHT-10608; CHEMBL223331; SCHEMBL8222478; BDBM50196469
DMYT381 DT Small molecular drug
DMYT381 PC 25196629
DMYT381 MW 424.5
DMYT381 FM C23H25FN4O3
DMYT381 IC InChI=1S/C23H25FN4O3/c24-18-6-4-5-16(13-18)15-28-22(30)19-8-7-17(14-20(19)26-23(28)31)21(29)25-9-12-27-10-2-1-3-11-27/h4-8,13-14H,1-3,9-12,15H2,(H,25,29)(H,26,31)
DMYT381 CS C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC(=CC=C4)F
DMYT381 IK YKQRXGQZAGVEJY-UHFFFAOYSA-N
DMYT381 IU 3-[(3-fluorophenyl)methyl]-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMYT381 DE Discovery agent
DMMI1H0 ID DMMI1H0
DMMI1H0 DN KKHT-10609
DMMI1H0 HS Investigative
DMMI1H0 SN KKHT-10609; CHEMBL224778; SCHEMBL8230066; BDBM50196473
DMMI1H0 DT Small molecular drug
DMMI1H0 PC 25196630
DMMI1H0 MW 424.5
DMMI1H0 FM C23H25FN4O3
DMMI1H0 IC InChI=1S/C23H25FN4O3/c24-18-7-4-16(5-8-18)15-28-22(30)19-9-6-17(14-20(19)26-23(28)31)21(29)25-10-13-27-11-2-1-3-12-27/h4-9,14H,1-3,10-13,15H2,(H,25,29)(H,26,31)
DMMI1H0 CS C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)F
DMMI1H0 IK PYCLIFABZLPONX-UHFFFAOYSA-N
DMMI1H0 IU 3-[(4-fluorophenyl)methyl]-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMMI1H0 DE Discovery agent
DM1H5TO ID DM1H5TO
DM1H5TO DN KKHT-10613
DM1H5TO HS Investigative
DM1H5TO SN KKHT-10613; CHEMBL225543; SCHEMBL8230911; BDBM50295829
DM1H5TO DT Small molecular drug
DM1H5TO PC 25196633
DM1H5TO MW 398.5
DM1H5TO FM C22H30N4O3
DM1H5TO IC InChI=1S/C22H30N4O3/c27-20(23-11-14-25-12-5-2-6-13-25)16-9-10-18-19(15-16)24-22(29)26(21(18)28)17-7-3-1-4-8-17/h9-10,15,17H,1-8,11-14H2,(H,23,27)(H,24,29)
DM1H5TO CS C1CCC(CC1)N2C(=O)C3=C(C=C(C=C3)C(=O)NCCN4CCCCC4)NC2=O
DM1H5TO IK NNJAFUNKEIDAAF-UHFFFAOYSA-N
DM1H5TO IU 3-cyclohexyl-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DM1H5TO DE Discovery agent
DMW704S ID DMW704S
DMW704S DN KKHT-10618
DMW704S HS Investigative
DMW704S SN KKHT-10618; CHEMBL225601; SCHEMBL8230918; BKSKSEWIBBBRSQ-UHFFFAOYSA-N; BDBM50196465; 3-(4-chlorobenzyl)-2,4-dioxo-N-(2-(piperidin-1-yl)ethyl)-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid (2-piperidine-1-yl-ethyl)-amide
DMW704S DT Small molecular drug
DMW704S PC 25196743
DMW704S MW 440.9
DMW704S FM C23H25ClN4O3
DMW704S IC InChI=1S/C23H25ClN4O3/c24-18-7-4-16(5-8-18)15-28-22(30)19-9-6-17(14-20(19)26-23(28)31)21(29)25-10-13-27-11-2-1-3-12-27/h4-9,14H,1-3,10-13,15H2,(H,25,29)(H,26,31)
DMW704S CS C1CCN(CC1)CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMW704S IK BKSKSEWIBBBRSQ-UHFFFAOYSA-N
DMW704S IU 3-[(4-chlorophenyl)methyl]-2,4-dioxo-N-(2-piperidin-1-ylethyl)-1H-quinazoline-7-carboxamide
DMW704S DE Discovery agent
DM4F96I ID DM4F96I
DM4F96I DN KKHT-11018
DM4F96I HS Investigative
DM4F96I SN KKHT-11018; CHEMBL225485; BDBM50196480
DM4F96I DT Small molecular drug
DM4F96I PC 44422187
DM4F96I MW 469
DM4F96I FM C25H29ClN4O3
DM4F96I IC InChI=1S/C25H29ClN4O3/c1-2-20-5-3-4-13-29(20)14-12-27-23(31)18-8-11-21-22(15-18)28-25(33)30(24(21)32)16-17-6-9-19(26)10-7-17/h6-11,15,20H,2-5,12-14,16H2,1H3,(H,27,31)(H,28,33)
DM4F96I CS CCC1CCCCN1CCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DM4F96I IK FKCDNDBJVOQPJB-UHFFFAOYSA-N
DM4F96I IU 3-[(4-chlorophenyl)methyl]-N-[2-(2-ethylpiperidin-1-yl)ethyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
DM4F96I DE Discovery agent
DMLB4TU ID DMLB4TU
DMLB4TU DN KKHT-20718
DMLB4TU HS Investigative
DMLB4TU SN KKHT-20718; CHEMBL224227; YMGCQAHDDYCKLB-UHFFFAOYSA-N; BDBM50196472; 3-(4-chlorobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid [3-(2-methyl-piperidine-1-yl)-propyl]-amide
DMLB4TU DT Small molecular drug
DMLB4TU PC 25196850
DMLB4TU MW 469
DMLB4TU FM C25H29ClN4O3
DMLB4TU IC InChI=1S/C25H29ClN4O3/c1-17-5-2-3-13-29(17)14-4-12-27-23(31)19-8-11-21-22(15-19)28-25(33)30(24(21)32)16-18-6-9-20(26)10-7-18/h6-11,15,17H,2-5,12-14,16H2,1H3,(H,27,31)(H,28,33)
DMLB4TU CS CC1CCCCN1CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMLB4TU IK YMGCQAHDDYCKLB-UHFFFAOYSA-N
DMLB4TU IU 3-[(4-chlorophenyl)methyl]-N-[3-(2-methylpiperidin-1-yl)propyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
DMLB4TU DE Discovery agent
DMP1A3C ID DMP1A3C
DMP1A3C DN KKHT-20818
DMP1A3C HS Investigative
DMP1A3C SN KKHT-20818; CHEMBL376596; SCHEMBL8230083; PRICKWSOIKQPFF-UHFFFAOYSA-N; BDBM50196466; 3-(4-chlorobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-2,4-dioxoquinazoline-7-carboxamide; 3-(4-chlorobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid [3-(2-ethyl-piperidine-1-yl)-propyl]-amide
DMP1A3C DT Small molecular drug
DMP1A3C PC 16066792
DMP1A3C MW 483
DMP1A3C FM C26H31ClN4O3
DMP1A3C IC InChI=1S/C26H31ClN4O3/c1-2-21-6-3-4-14-30(21)15-5-13-28-24(32)19-9-12-22-23(16-19)29-26(34)31(25(22)33)17-18-7-10-20(27)11-8-18/h7-12,16,21H,2-6,13-15,17H2,1H3,(H,28,32)(H,29,34)
DMP1A3C CS CCC1CCCCN1CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMP1A3C IK PRICKWSOIKQPFF-UHFFFAOYSA-N
DMP1A3C IU 3-[(4-chlorophenyl)methyl]-N-[3-(2-ethylpiperidin-1-yl)propyl]-2,4-dioxo-1H-quinazoline-7-carboxamide
DMP1A3C DE Discovery agent
DMTW4Q1 ID DMTW4Q1
DMTW4Q1 DN KKHT-20918
DMTW4Q1 HS Investigative
DMTW4Q1 SN KKHT-20918; CHEMBL224246; SCHEMBL8227894; IWAHUQRZIUVMSG-UHFFFAOYSA-N; KUC112514N; BDBM50196475; KSC-323-47-1-1; 3-(4-chlorobenzyl)-2,4-dioxo-N-(3-(piperidin-1-yl)propyl)-1,2,3,4-tetrahydroquinazoline-7-carboxamide; 3-(4-Chloro-benzyl)-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-7-carboxylic acid (3-piperidine-1-yl-propyl)-amide
DMTW4Q1 DT Small molecular drug
DMTW4Q1 PC 25196851
DMTW4Q1 MW 454.9
DMTW4Q1 FM C24H27ClN4O3
DMTW4Q1 IC InChI=1S/C24H27ClN4O3/c25-19-8-5-17(6-9-19)16-29-23(31)20-10-7-18(15-21(20)27-24(29)32)22(30)26-11-4-14-28-12-2-1-3-13-28/h5-10,15H,1-4,11-14,16H2,(H,26,30)(H,27,32)
DMTW4Q1 CS C1CCN(CC1)CCCNC(=O)C2=CC3=C(C=C2)C(=O)N(C(=O)N3)CC4=CC=C(C=C4)Cl
DMTW4Q1 IK IWAHUQRZIUVMSG-UHFFFAOYSA-N
DMTW4Q1 IU 3-[(4-chlorophenyl)methyl]-2,4-dioxo-N-(3-piperidin-1-ylpropyl)-1H-quinazoline-7-carboxamide
DMTW4Q1 DE Discovery agent
DMG3FDE ID DMG3FDE
DMG3FDE DN KL044
DMG3FDE HS Investigative
DMG3FDE SN KL 044; KL-044
DMG3FDE DT Small molecular drug
DMG3FDE PC 91827381
DMG3FDE MW 359.8
DMG3FDE FM C21H14ClN3O
DMG3FDE IC InChI=1S/C21H14ClN3O/c22-17-9-5-6-14(12-23)21(17)24-20(26)13-25-18-10-3-1-7-15(18)16-8-2-4-11-19(16)25/h1-11H,13H2,(H,24,26)
DMG3FDE CS C1=CC=C2C(=C1)C3=CC=CC=C3N2CC(=O)NC4=C(C=CC=C4Cl)C#N
DMG3FDE IK ZDAKKNHUWVTCRS-UHFFFAOYSA-N
DMG3FDE IU 2-carbazol-9-yl-N-(2-chloro-6-cyanophenyl)acetamide
DMG3FDE DE Discovery agent
DMG594K ID DMG594K
DMG594K DN KM-01221
DMG594K HS Investigative
DMG594K SN Chymase inhibitors (cardiovascular disease); KM-06864; MWP-00965; TY-51076; Chymase inhibitors (cardiovascular disease), Toa Eiyo
DMG594K CP Toa Eiyo KK
DMG594K DT Small molecular drug
DMG594K PC 2819266
DMG594K MW 442.3
DMG594K FM C17H13Cl2N3O3S2
DMG594K IC InChI=1S/C17H13Cl2N3O3S2/c1-26-17-14(27(24,25)13-8-6-12(19)7-9-13)15(21-22-17)20-16(23)10-2-4-11(18)5-3-10/h2-9H,1H3,(H2,20,21,22,23)
DMG594K CS CSC1=NNC(=C1S(=O)(=O)C2=CC=C(C=C2)Cl)NC(=O)C3=CC=C(C=C3)Cl
DMG594K IK OOEJKNSQVFIOEF-UHFFFAOYSA-N
DMG594K IU 4-chloro-N-[4-(4-chlorophenyl)sulfonyl-3-methylsulfanyl-1H-pyrazol-5-yl]benzamide
DMG594K DE Cardiovascular disease
DMZSYKC ID DMZSYKC
DMZSYKC DN KM-233
DMZSYKC HS Investigative
DMZSYKC SN 628263-22-9; KM-233; DTXSID50745439
DMZSYKC DT Small molecular drug
DMZSYKC PC 10248110
DMZSYKC MW 362.5
DMZSYKC FM C25H30O2
DMZSYKC IC InChI=1S/C25H30O2/c1-16-11-12-20-19(13-16)23-21(26)14-18(15-22(23)27-25(20,4)5)24(2,3)17-9-7-6-8-10-17/h6-11,14-15,19-20,26H,12-13H2,1-5H3/t19-,20-/m1/s1
DMZSYKC CS CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)C(C)(C)C4=CC=CC=C4)O
DMZSYKC IK GZYXCXRHVALIJD-WOJBJXKFSA-N
DMZSYKC IU (6aR,10aR)-6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMZSYKC CA CAS 628263-22-9
DMZSYKC DE Discovery agent
DMK4IBO ID DMK4IBO
DMK4IBO DN KM-233-M
DMK4IBO HS Investigative
DMK4IBO SN KM-233-M; CHEMBL512531; BDBM50244322; 3-[1-(3-Fluoro-phenyl)-1-methyl-ethyl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol
DMK4IBO DT Small molecular drug
DMK4IBO PC 44593431
DMK4IBO MW 380.5
DMK4IBO FM C25H29FO2
DMK4IBO IC InChI=1S/C25H29FO2/c1-15-9-10-20-19(11-15)23-21(27)13-17(14-22(23)28-25(20,4)5)24(2,3)16-7-6-8-18(26)12-16/h6-9,12-14,19-20,27H,10-11H2,1-5H3/t19-,20-/m1/s1
DMK4IBO CS CC1=CC[C@@H]2[C@@H](C1)C3=C(C=C(C=C3OC2(C)C)C(C)(C)C4=CC(=CC=C4)F)O
DMK4IBO IK IKKCHJJZMJZQEO-WOJBJXKFSA-N
DMK4IBO IU (6aR,10aR)-3-[2-(3-fluorophenyl)propan-2-yl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
DMK4IBO DE Discovery agent
DMK17GN ID DMK17GN
DMK17GN DN KM-4056
DMK17GN HS Investigative
DMK17GN SN Anti-LGR5 monoclonal antibody (cancer), Kyowa Hakko Kirin
DMK17GN CP Kyowa Hakko Kirin Co Ltd
DMK17GN DT Antibody
DMK17GN DE Solid tumour/cancer
DMLRVEJ ID DMLRVEJ
DMLRVEJ DN KMI-172
DMLRVEJ HS Investigative
DMLRVEJ SN KMI-172; CHEMBL239383
DMLRVEJ PC 44431062
DMLRVEJ MW 1031.099
DMLRVEJ FM C47H66N8O16S
DMLRVEJ IC InChI=1S/C47H66N8O16S/c1-24(2)20-31(51-45(68)38(25(3)4)55-41(64)29(48)16-18-35(56)57)44(67)54-34(23-72-28-14-10-7-11-15-28)39(62)46(69)52-32(22-37(60)61)43(66)49-26(5)40(63)50-30(17-19-36(58)59)42(65)53-33(47(70)71)21-27-12-8-6-9-13-27/h6-15,24-26,29-34,38-39,62H,16-23,48H2,1-5H3,(H,49,66)(H,50,63)(H,51,68)(H,52,69)(H,53,65)(H,54,67)(H,55,64)(H,56,57)(H,58,59)(H,60,61)(H,70,71)/t26-,29-,30-,31-,32-,33-,34-,38-,39+/m0/s1
DMLRVEJ CS C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]([C@H](CSC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)N)O
DMLRVEJ IK FTFBGPHXUHIRHS-OGBCTUIFSA-N
DMLRVEJ IU (4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[(2R,3R)-4-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMLRVEJ DE Discovery agent
DMQ4WNB ID DMQ4WNB
DMQ4WNB DN KMI-494
DMQ4WNB HS Investigative
DMQ4WNB SN KMI-494
DMQ4WNB DT Small molecular drug
DMQ4WNB PC 44431065
DMQ4WNB MW 775.8
DMQ4WNB FM C39H49N7O10
DMQ4WNB IC InChI=1S/C39H49N7O10/c1-20(2)13-30(35(50)44-29(14-22-9-6-5-7-10-22)32(47)37(52)43-27-12-8-11-23(18-27)38(53)54)45-36(51)31(21(3)4)46-34(49)28(41)19-42-33(48)24-15-25(39(55)56)17-26(40)16-24/h5-12,15-18,20-21,28-32,47H,13-14,19,40-41H2,1-4H3,(H,42,48)(H,43,52)(H,44,50)(H,45,51)(H,46,49)(H,53,54)(H,55,56)/t28-,29-,30-,31-,32+/m0/s1
DMQ4WNB CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C(=O)NC2=CC=CC(=C2)C(=O)O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CNC(=O)C3=CC(=CC(=C3)N)C(=O)O)N
DMQ4WNB IK HJXHSIMUTPLJNT-QEUNAIBPSA-N
DMQ4WNB IU 3-amino-5-[[(2S)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2S,3R)-4-(3-carboxyanilino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropyl]carbamoyl]benzoic acid
DMQ4WNB DE Discovery agent
DMX9EA7 ID DMX9EA7
DMX9EA7 DN KMI-538
DMX9EA7 HS Investigative
DMX9EA7 SN KMI-538; CHEMBL395967
DMX9EA7 DT Small molecular drug
DMX9EA7 PC 16725937
DMX9EA7 MW 807.9
DMX9EA7 FM C39H49N7O10S
DMX9EA7 IC InChI=1S/C39H49N7O10S/c1-20(2)13-29(44-36(51)31(21(3)4)46-34(49)28(41)18-42-33(48)23-14-24(39(55)56)16-25(40)15-23)35(50)45-30(19-57-27-11-6-5-7-12-27)32(47)37(52)43-26-10-8-9-22(17-26)38(53)54/h5-12,14-17,20-21,28-32,47H,13,18-19,40-41H2,1-4H3,(H,42,48)(H,43,52)(H,44,51)(H,45,50)(H,46,49)(H,53,54)(H,55,56)/t28-,29-,30-,31-,32+/m0/s1
DMX9EA7 CS CC(C)C[C@@H](C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](C(=O)NC2=CC=CC(=C2)C(=O)O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CNC(=O)C3=CC(=CC(=C3)N)C(=O)O)N
DMX9EA7 IK DFWUMZBCWONAOR-QEUNAIBPSA-N
DMX9EA7 IU 3-amino-5-[[(2S)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2R,3R)-4-(3-carboxyanilino)-3-hydroxy-4-oxo-1-phenylsulfanylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropyl]carbamoyl]benzoic acid
DMX9EA7 DE Discovery agent
DMXUETW ID DMXUETW
DMXUETW DN KMI-596
DMXUETW HS Investigative
DMXUETW DT Small molecular drug
DMXUETW PC 136106170
DMXUETW MW 695.8
DMXUETW FM C34H45N7O9
DMXUETW IC InChI=1S/C34H45N7O9/c1-18(2)15-25(38-32(47)27(19(3)4)39-30(45)23(35)13-14-26(42)43)31(46)37-24(16-20-9-6-5-7-10-20)28(44)33(48)36-22-12-8-11-21(17-22)29-40-34(49)50-41-29/h5-12,17-19,23-25,27-28,44H,13-16,35H2,1-4H3,(H,36,48)(H,37,46)(H,38,47)(H,39,45)(H,42,43)(H,40,41,49)/t23-,24-,25-,27-,28+/m0/s1
DMXUETW CS CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](C(=O)NC2=CC=CC(=C2)C3=NOC(=O)N3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)N
DMXUETW IK WXPDDAQNFBWSRN-WZFFGLSISA-N
DMXUETW IU (4S)-4-amino-5-[[(2S)-1-[[(2S)-1-[[(2S,3R)-3-hydroxy-4-oxo-4-[3-(5-oxo-4H-1,2,4-oxadiazol-3-yl)anilino]-1-phenylbutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMXUETW DE Discovery agent
DMP1GQB ID DMP1GQB
DMP1GQB DN KMJ-372
DMP1GQB HS Investigative
DMP1GQB SN MK-271; TRPV1 antagonists (pain), Digital Biotech/Grunenthal; TRPV1 antagonists (pain), Medifron/Grunenthal; VR1 antagonists (pain), Digital Biotech/Grunenthal; Vanilloid antagonists (analgesic), Digital Biotech/Grunenthal; (S)-KMJ-372
DMP1GQB CP Digital Biotech Co Ltd
DMP1GQB DE Pain
DMFVS16 ID DMFVS16
DMFVS16 DN KML110
DMFVS16 HS Investigative
DMFVS16 SN KML110
DMFVS16 DT Small molecular drug
DMFVS16 PC 91827387
DMFVS16 MW 377.4
DMFVS16 FM C22H23N3O3
DMFVS16 IC InChI=1S/C22H23N3O3/c1-15-18-9-8-17(25(27)28)14-19(18)21(16-6-4-3-5-7-16)20(15)22(26)24-12-10-23(2)11-13-24/h3-9,14-15H,10-13H2,1-2H3
DMFVS16 CS CC1C2=C(C=C(C=C2)[N+](=O)[O-])C(=C1C(=O)N3CCN(CC3)C)C4=CC=CC=C4
DMFVS16 IK BBPOBHFPZPRPGB-UHFFFAOYSA-N
DMFVS16 IU (1-methyl-5-nitro-3-phenyl-1H-inden-2-yl)-(4-methylpiperazin-1-yl)methanone
DMFVS16 DE Discovery agent
DM2K81B ID DM2K81B
DM2K81B DN KMS-88009
DM2K81B HS Investigative
DM2K81B SN KMS-88016; KMSB-600; Aminostyrylbenzofuran derivative beta amyloid fibril formation inhibitors (Alzheimer's disease), Korea Institute of Science and Technology/Seoul National University/Hanmi Pharmaceutical
DM2K81B CP Korea Institute of Science and Technology
DM2K81B DE Alzheimer disease
DMLZ89P ID DMLZ89P
DMLZ89P DN KN-62
DMLZ89P HS Investigative
DMLZ89P SN KN-62 (non-isomeric); GTPL6001; HMS3229A04; CCG-206863
DMLZ89P DT Small molecular drug
DMLZ89P PC 5312126
DMLZ89P MW 721.8
DMLZ89P FM C38H35N5O6S2
DMLZ89P IC InChI=1S/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9-3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3/t35-/m0/s1
DMLZ89P CS CN([C@@H](CC1=CC=C(C=C1)OS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C(=O)N4CCN(CC4)C5=CC=CC=C5)S(=O)(=O)C6=CC=CC7=C6C=CN=C7
DMLZ89P IK RJVLFQBBRSMWHX-DHUJRADRSA-N
DMLZ89P IU [4-[(2S)-2-[isoquinolin-5-ylsulfonyl(methyl)amino]-3-oxo-3-(4-phenylpiperazin-1-yl)propyl]phenyl] isoquinoline-5-sulfonate
DMLZ89P CA CAS 127191-97-3
DMLZ89P CB CHEBI:131159
DMLZ89P DE Discovery agent
DMPTMKH ID DMPTMKH
DMPTMKH DN KN-93
DMPTMKH HS Investigative
DMPTMKH SN kn-93; 139298-40-1; KN 93; KN93; Methoxybenzene-sulfonamide; C26H29ClN2O4S; CHEMBL155333; (E)-N-(2-(((3-(4-Chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide; 2-(N-(2-Hydroxyethyl)-N-(4-methoxybenzenesulfonyl))amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; N-(2-(((3-(4-Chlorophenyl)-2-propenyl)methylamino)methyl)phenyl)-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide; Benzenesulfonamide, N-(2-(((3-(4-chlorophenyl)-2-propenyl)methylamino)methyl)ph
DMPTMKH DT Small molecular drug
DMPTMKH PC 5312122
DMPTMKH MW 501
DMPTMKH FM C26H29ClN2O4S
DMPTMKH IC InChI=1S/C26H29ClN2O4S/c1-28(17-5-6-21-9-11-23(27)12-10-21)20-22-7-3-4-8-26(22)29(18-19-30)34(31,32)25-15-13-24(33-2)14-16-25/h3-16,30H,17-20H2,1-2H3/b6-5+
DMPTMKH CS CN(C/C=C/C1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC
DMPTMKH IK LLLQTDSSHZREGW-AATRIKPKSA-N
DMPTMKH IU N-[2-[[[(E)-3-(4-chlorophenyl)prop-2-enyl]-methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide
DMPTMKH CA CAS 139298-40-1
DMPTMKH CB CHEBI:91460
DMPTMKH DE Discovery agent
DMMISH6 ID DMMISH6
DMMISH6 DN KNI-10006
DMMISH6 HS Investigative
DMMISH6 SN KNI-10006; CHEMBL231522; (4r)-3-[(2s,3s)-3-{[(2,6-Dimethylphenoxy)acetyl]amino}-2-Hydroxy-4-Phenylbutanoyl]-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 3kdb; 3fnu; 3qs1; SCHEMBL13788265; BDBM50209559; 461444-55-3
DMMISH6 DT Small molecular drug
DMMISH6 PC 9895503
DMMISH6 MW 631.8
DMMISH6 FM C35H41N3O6S
DMMISH6 IC InChI=1S/C35H41N3O6S/c1-21-11-10-12-22(2)31(21)44-19-28(40)36-26(17-23-13-6-5-7-14-23)30(41)34(43)38-20-45-35(3,4)32(38)33(42)37-29-25-16-9-8-15-24(25)18-27(29)39/h5-16,26-27,29-30,32,39,41H,17-20H2,1-4H3,(H,36,40)(H,37,42)/t26-,27+,29-,30-,32+/m0/s1
DMMISH6 CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMMISH6 IK KKTYZYHUPKXLPL-RIQJEONASA-N
DMMISH6 IU (4R)-3-[(2S,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMMISH6 DE Discovery agent
DMLOXMQ ID DMLOXMQ
DMLOXMQ DN KNI-10033
DMLOXMQ HS Investigative
DMLOXMQ SN KNI-10033; CHEMBL440965; (4r)-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-3-[(2s,3s)-2-Hydroxy-3-({n-[(Isoquinolin-5-Yloxy)acetyl]-S-Methyl-L-Cysteinyl}amino)-4-Phenylbutanoyl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 2pk6; BDBM50209552; O33
DMLOXMQ DT Small molecular drug
DMLOXMQ PC 16122614
DMLOXMQ MW 771.9
DMLOXMQ FM C40H45N5O7S2
DMLOXMQ IC InChI=1S/C40H45N5O7S2/c1-40(2)36(38(50)44-34-28-14-8-7-12-25(28)19-31(34)46)45(23-54-40)39(51)35(48)29(18-24-10-5-4-6-11-24)43-37(49)30(22-53-3)42-33(47)21-52-32-15-9-13-26-20-41-17-16-27(26)32/h4-17,20,29-31,34-36,46,48H,18-19,21-23H2,1-3H3,(H,42,47)(H,43,49)(H,44,50)/t29-,30-,31+,34-,35-,36+/m0/s1
DMLOXMQ CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O)C(=O)N[C@@H]5[C@@H](CC6=CC=CC=C56)O)C
DMLOXMQ IK NLPSIHQYIUXYOW-SHJYOGRKSA-N
DMLOXMQ IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMLOXMQ DE Discovery agent
DMMZ6AO ID DMMZ6AO
DMMZ6AO DN KNI-10061
DMMZ6AO HS Investigative
DMMZ6AO SN KNI-10061; CHEMBL266020; BDBM50209557
DMMZ6AO DT Small molecular drug
DMMZ6AO PC 44425655
DMMZ6AO MW 812
DMMZ6AO FM C43H49N5O7S2
DMMZ6AO IC InChI=1S/C43H49N5O7S2/c1-43(2)39(41(53)47-37-32-20-11-10-15-28(32)22-35(37)49)48(26-57-43)42(54)38(51)33(21-27-13-6-4-7-14-27)46-40(52)34(25-56-3)45-36(50)24-55-31-19-12-18-30(23-31)44-29-16-8-5-9-17-29/h4-20,23,33-35,37-39,44,49,51H,21-22,24-26H2,1-3H3,(H,45,50)(H,46,52)(H,47,53)/t33-,34-,35+,37-,38-,39+/m0/s1
DMMZ6AO CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC(=C3)NC4=CC=CC=C4)O)C(=O)N[C@@H]5[C@@H](CC6=CC=CC=C56)O)C
DMMZ6AO IK KAHOVIZPKWWDDX-GCELDIMASA-N
DMMZ6AO IU (4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(3-anilinophenoxy)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMMZ6AO DE Discovery agent
DMYSDN4 ID DMYSDN4
DMYSDN4 DN KNI-10062
DMYSDN4 HS Investigative
DMYSDN4 SN KNI-10062; CHEMBL411155; BDBM50209566
DMYSDN4 DT Small molecular drug
DMYSDN4 PC 44425657
DMYSDN4 MW 758.9
DMYSDN4 FM C39H42N4O8S2
DMYSDN4 IC InChI=1S/C39H42N4O8S2/c1-39(2)34(37(49)42-32-24-14-8-7-13-23(24)18-29(32)45)43(21-53-39)38(50)33(46)26(17-22-11-5-4-6-12-22)40-35(47)27(20-52-3)41-36(48)31-19-28(44)25-15-9-10-16-30(25)51-31/h4-16,19,26-27,29,32-34,45-46H,17-18,20-21H2,1-3H3,(H,40,47)(H,41,48)(H,42,49)/t26-,27-,29+,32-,33-,34+/m0/s1
DMYSDN4 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)C3=CC(=O)C4=CC=CC=C4O3)O)C(=O)N[C@@H]5[C@@H](CC6=CC=CC=C56)O)C
DMYSDN4 IK KMPZTBYBVXRNNV-CJFFKWHBSA-N
DMYSDN4 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-3-methylsulfanyl-2-[(4-oxochromene-2-carbonyl)amino]propanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMYSDN4 DE Discovery agent
DMM5SDT ID DMM5SDT
DMM5SDT DN KNI-10074
DMM5SDT HS Investigative
DMM5SDT SN KNI-10074; CHEMBL510300; (4r)-3-[(2s,3s)-3-{[(2,6-Dichlorophenoxy)acetyl]amino}-2-Hydroxy-4-Phenylbutanoyl]-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 3kdc; BDBM50273738; JZP
DMM5SDT DT Small molecular drug
DMM5SDT PC 44588310
DMM5SDT MW 672.6
DMM5SDT FM C33H35Cl2N3O6S
DMM5SDT IC InChI=1S/C33H35Cl2N3O6S/c1-33(2)30(31(42)37-27-21-12-7-6-11-20(21)16-25(27)39)38(18-45-33)32(43)28(41)24(15-19-9-4-3-5-10-19)36-26(40)17-44-29-22(34)13-8-14-23(29)35/h3-14,24-25,27-28,30,39,41H,15-18H2,1-2H3,(H,36,40)(H,37,42)/t24-,25+,27-,28-,30+/m0/s1
DMM5SDT CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C=CC=C3Cl)Cl)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMM5SDT IK XMAMZSZKRBFNLW-UPZHSWQNSA-N
DMM5SDT IU (4R)-3-[(2S,3S)-3-[[2-(2,6-dichlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMM5SDT DE Discovery agent
DMCZOX9 ID DMCZOX9
DMCZOX9 DN KNI-10079
DMCZOX9 HS Investigative
DMCZOX9 SN KNI-10079; CHEMBL509164; BDBM50273719
DMCZOX9 DT Small molecular drug
DMCZOX9 PC 44588291
DMCZOX9 MW 617.8
DMCZOX9 FM C34H39N3O6S
DMCZOX9 IC InChI=1S/C34H39N3O6S/c1-21-11-7-10-16-27(21)43-19-28(39)35-25(17-22-12-5-4-6-13-22)30(40)33(42)37-20-44-34(2,3)31(37)32(41)36-29-24-15-9-8-14-23(24)18-26(29)38/h4-16,25-26,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t25-,26+,29-,30-,31+/m0/s1
DMCZOX9 CS CC1=CC=CC=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMCZOX9 IK LXIUKNRDJTWBGH-XPLSERNMSA-N
DMCZOX9 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-methylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMCZOX9 DE Discovery agent
DMEN4DZ ID DMEN4DZ
DMEN4DZ DN KNI-10080
DMEN4DZ HS Investigative
DMEN4DZ SN KNI-10080; CHEMBL453415; BDBM50273720
DMEN4DZ DT Small molecular drug
DMEN4DZ PC 44588292
DMEN4DZ MW 617.8
DMEN4DZ FM C34H39N3O6S
DMEN4DZ IC InChI=1S/C34H39N3O6S/c1-21-10-9-14-24(16-21)43-19-28(39)35-26(17-22-11-5-4-6-12-22)30(40)33(42)37-20-44-34(2,3)31(37)32(41)36-29-25-15-8-7-13-23(25)18-27(29)38/h4-16,26-27,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DMEN4DZ CS CC1=CC(=CC=C1)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMEN4DZ IK LAVCSYCCYHZRBK-VFCPCCRCSA-N
DMEN4DZ IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-methylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMEN4DZ DE Discovery agent
DM1Z7QK ID DM1Z7QK
DM1Z7QK DN KNI-10081
DM1Z7QK HS Investigative
DM1Z7QK SN KNI-10081; CHEMBL508116; BDBM50273721
DM1Z7QK DT Small molecular drug
DM1Z7QK PC 44588293
DM1Z7QK MW 617.8
DM1Z7QK FM C34H39N3O6S
DM1Z7QK IC InChI=1S/C34H39N3O6S/c1-21-13-15-24(16-14-21)43-19-28(39)35-26(17-22-9-5-4-6-10-22)30(40)33(42)37-20-44-34(2,3)31(37)32(41)36-29-25-12-8-7-11-23(25)18-27(29)38/h4-16,26-27,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DM1Z7QK CS CC1=CC=C(C=C1)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DM1Z7QK IK CJVKWQTVDIZBSG-VFCPCCRCSA-N
DM1Z7QK IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-methylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM1Z7QK DE Discovery agent
DMYN2U4 ID DMYN2U4
DMYN2U4 DN KNI-10087
DMYN2U4 HS Investigative
DMYN2U4 SN KNI-10087; CHEMBL442632; BDBM50273732
DMYN2U4 DT Small molecular drug
DMYN2U4 PC 44588304
DMYN2U4 MW 618.7
DMYN2U4 FM C33H38N4O6S
DMYN2U4 IC InChI=1S/C33H38N4O6S/c1-33(2)30(31(41)36-28-24-14-7-6-11-21(24)16-26(28)38)37(19-44-33)32(42)29(40)25(15-20-9-4-3-5-10-20)35-27(39)18-43-23-13-8-12-22(34)17-23/h3-14,17,25-26,28-30,38,40H,15-16,18-19,34H2,1-2H3,(H,35,39)(H,36,41)/t25-,26+,28-,29-,30+/m0/s1
DMYN2U4 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMYN2U4 IK LQEMUNLLUUKMPD-DOWNBTJOSA-N
DMYN2U4 IU (4R)-3-[(2S,3S)-3-[[2-(3-aminophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMYN2U4 DE Discovery agent
DM4GASE ID DM4GASE
DM4GASE DN KNI-10088
DM4GASE HS Investigative
DM4GASE SN KNI-10088; CHEMBL499956; BDBM50273733
DM4GASE DT Small molecular drug
DM4GASE PC 44588305
DM4GASE MW 618.7
DM4GASE FM C33H38N4O6S
DM4GASE IC InChI=1S/C33H38N4O6S/c1-33(2)30(31(41)36-28-24-11-7-6-10-21(24)17-26(28)38)37(19-44-33)32(42)29(40)25(16-20-8-4-3-5-9-20)35-27(39)18-43-23-14-12-22(34)13-15-23/h3-15,25-26,28-30,38,40H,16-19,34H2,1-2H3,(H,35,39)(H,36,41)/t25-,26+,28-,29-,30+/m0/s1
DM4GASE CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM4GASE IK YGKGGCBHYIMPFH-DOWNBTJOSA-N
DM4GASE IU (4R)-3-[(2S,3S)-3-[[2-(4-aminophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM4GASE DE Discovery agent
DMV1KI2 ID DMV1KI2
DMV1KI2 DN KNI-10092
DMV1KI2 HS Investigative
DMV1KI2 SN KNI-10092; CHEMBL506575; BDBM50273722
DMV1KI2 DT Small molecular drug
DMV1KI2 PC 44588294
DMV1KI2 MW 633.8
DMV1KI2 FM C34H39N3O7S
DMV1KI2 IC InChI=1S/C34H39N3O7S/c1-34(2)31(32(41)36-29-23-14-8-7-13-22(23)18-25(29)38)37(20-45-34)33(42)30(40)24(17-21-11-5-4-6-12-21)35-28(39)19-44-27-16-10-9-15-26(27)43-3/h4-16,24-25,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t24-,25+,29-,30-,31+/m0/s1
DMV1KI2 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMV1KI2 IK JFCIKXOPSCFWBJ-ZNIFFWLPSA-N
DMV1KI2 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-methoxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMV1KI2 DE Discovery agent
DMGY5Z0 ID DMGY5Z0
DMGY5Z0 DN KNI-10093
DMGY5Z0 HS Investigative
DMGY5Z0 SN KNI-10093; CHEMBL452345; BDBM50273723
DMGY5Z0 DT Small molecular drug
DMGY5Z0 PC 44588295
DMGY5Z0 MW 633.8
DMGY5Z0 FM C34H39N3O7S
DMGY5Z0 IC InChI=1S/C34H39N3O7S/c1-34(2)31(32(41)36-29-25-15-8-7-12-22(25)17-27(29)38)37(20-45-34)33(42)30(40)26(16-21-10-5-4-6-11-21)35-28(39)19-44-24-14-9-13-23(18-24)43-3/h4-15,18,26-27,29-31,38,40H,16-17,19-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DMGY5Z0 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMGY5Z0 IK JUVIZUPSXSIJMO-VFCPCCRCSA-N
DMGY5Z0 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-methoxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMGY5Z0 DE Discovery agent
DMJIQG2 ID DMJIQG2
DMJIQG2 DN KNI-10094
DMJIQG2 HS Investigative
DMJIQG2 SN KNI-10094; CHEMBL453959; BDBM50273724
DMJIQG2 DT Small molecular drug
DMJIQG2 PC 44588296
DMJIQG2 MW 633.8
DMJIQG2 FM C34H39N3O7S
DMJIQG2 IC InChI=1S/C34H39N3O7S/c1-34(2)31(32(41)36-29-25-12-8-7-11-22(25)18-27(29)38)37(20-45-34)33(42)30(40)26(17-21-9-5-4-6-10-21)35-28(39)19-44-24-15-13-23(43-3)14-16-24/h4-16,26-27,29-31,38,40H,17-20H2,1-3H3,(H,35,39)(H,36,41)/t26-,27+,29-,30-,31+/m0/s1
DMJIQG2 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMJIQG2 IK QGAHVOMMQMAYSQ-VFCPCCRCSA-N
DMJIQG2 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-methoxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMJIQG2 CA CAS 820220-93-7
DMJIQG2 DE Discovery agent
DMEHPVF ID DMEHPVF
DMEHPVF DN KNI-10095
DMEHPVF HS Investigative
DMEHPVF SN KNI-10095; CHEMBL507473; BDBM50273734
DMEHPVF DT Small molecular drug
DMEHPVF PC 44588306
DMEHPVF MW 648.7
DMEHPVF FM C33H36N4O8S
DMEHPVF IC InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-22-13-7-6-12-21(22)17-25(28)38)36(19-46-33)32(42)29(40)23(16-20-10-4-3-5-11-20)34-27(39)18-45-26-15-9-8-14-24(26)37(43)44/h3-15,23,25,28-30,38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t23-,25+,28-,29-,30+/m0/s1
DMEHPVF CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3[N+](=O)[O-])O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMEHPVF IK NJMYSVGWPKMYBH-OIRZSGMBSA-N
DMEHPVF IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-nitrophenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMEHPVF DE Discovery agent
DMBTRHG ID DMBTRHG
DMBTRHG DN KNI-10106
DMBTRHG HS Investigative
DMBTRHG SN KNI-10106; CHEMBL448257; BDBM50273731
DMBTRHG DT Small molecular drug
DMBTRHG PC 44588303
DMBTRHG MW 618.7
DMBTRHG FM C33H38N4O6S
DMBTRHG IC InChI=1S/C33H38N4O6S/c1-33(2)30(31(41)36-28-22-13-7-6-12-21(22)17-25(28)38)37(19-44-33)32(42)29(40)24(16-20-10-4-3-5-11-20)35-27(39)18-43-26-15-9-8-14-23(26)34/h3-15,24-25,28-30,38,40H,16-19,34H2,1-2H3,(H,35,39)(H,36,41)/t24-,25+,28-,29-,30+/m0/s1
DMBTRHG CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMBTRHG IK CTMJCAZSOKTPFA-VOULMWPJSA-N
DMBTRHG IU (4R)-3-[(2S,3S)-3-[[2-(2-aminophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMBTRHG DE Discovery agent
DM78A6F ID DM78A6F
DM78A6F DN KNI-10113
DM78A6F HS Investigative
DM78A6F SN KNI-10113; CHEMBL506609; BDBM50273728
DM78A6F DT Small molecular drug
DM78A6F PC 44588300
DM78A6F MW 633.8
DM78A6F FM C34H39N3O7S
DM78A6F IC InChI=1S/C34H39N3O7S/c1-34(2)31(32(42)36-29-24-14-8-6-12-22(24)17-26(29)39)37(20-45-34)33(43)30(41)25(16-21-10-4-3-5-11-21)35-28(40)19-44-27-15-9-7-13-23(27)18-38/h3-15,25-26,29-31,38-39,41H,16-20H2,1-2H3,(H,35,40)(H,36,42)/t25-,26+,29-,30-,31+/m0/s1
DM78A6F CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3CO)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM78A6F IK XBWSFLDHKBAMBA-XPLSERNMSA-N
DM78A6F IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-[2-(hydroxymethyl)phenoxy]acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM78A6F DE Discovery agent
DMA9104 ID DMA9104
DMA9104 DN KNI-10124
DMA9104 HS Investigative
DMA9104 SN KNI-10124; CHEMBL448977; BDBM50273729
DMA9104 DT Small molecular drug
DMA9104 PC 44588301
DMA9104 MW 633.8
DMA9104 FM C34H39N3O7S
DMA9104 IC InChI=1S/C34H39N3O7S/c1-34(2)31(32(42)36-29-25-14-7-6-12-23(25)17-27(29)39)37(20-45-34)33(43)30(41)26(16-21-9-4-3-5-10-21)35-28(40)19-44-24-13-8-11-22(15-24)18-38/h3-15,26-27,29-31,38-39,41H,16-20H2,1-2H3,(H,35,40)(H,36,42)/t26-,27+,29-,30-,31+/m0/s1
DMA9104 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)CO)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMA9104 IK NRLFBLHYKZDHHW-VFCPCCRCSA-N
DMA9104 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-[3-(hydroxymethyl)phenoxy]acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMA9104 DE Discovery agent
DMDBERC ID DMDBERC
DMDBERC DN KNI-10125
DMDBERC HS Investigative
DMDBERC SN KNI-10125; CHEMBL448631; BDBM50273730
DMDBERC DT Small molecular drug
DMDBERC PC 44588302
DMDBERC MW 633.8
DMDBERC FM C34H39N3O7S
DMDBERC IC InChI=1S/C34H39N3O7S/c1-34(2)31(32(42)36-29-25-11-7-6-10-23(25)17-27(29)39)37(20-45-34)33(43)30(41)26(16-21-8-4-3-5-9-21)35-28(40)19-44-24-14-12-22(18-38)13-15-24/h3-15,26-27,29-31,38-39,41H,16-20H2,1-2H3,(H,35,40)(H,36,42)/t26-,27+,29-,30-,31+/m0/s1
DMDBERC CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)CO)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMDBERC IK RJJNWINGYKEUKL-VFCPCCRCSA-N
DMDBERC IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-[4-(hydroxymethyl)phenoxy]acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMDBERC DE Discovery agent
DMNBUS4 ID DMNBUS4
DMNBUS4 DN KNI-10152
DMNBUS4 HS Investigative
DMNBUS4 SN KNI-10152; CHEMBL509473; BDBM50273740
DMNBUS4 DT Small molecular drug
DMNBUS4 PC 44588312
DMNBUS4 MW 687.9
DMNBUS4 FM C39H49N3O6S
DMNBUS4 IC InChI=1S/C39H49N3O6S/c1-23(2)27-17-12-18-28(24(3)4)35(27)48-21-32(44)40-30(19-25-13-8-7-9-14-25)34(45)38(47)42-22-49-39(5,6)36(42)37(46)41-33-29-16-11-10-15-26(29)20-31(33)43/h7-18,23-24,30-31,33-34,36,43,45H,19-22H2,1-6H3,(H,40,44)(H,41,46)/t30-,31+,33-,34-,36+/m0/s1
DMNBUS4 CS CC(C)C1=C(C(=CC=C1)C(C)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMNBUS4 IK QPUVMQNOWWLTBU-SQKWSBCUSA-N
DMNBUS4 IU (4R)-3-[(2S,3S)-3-[[2-[2,6-di(propan-2-yl)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMNBUS4 DE Discovery agent
DM1PKWA ID DM1PKWA
DM1PKWA DN KNI-10155
DM1PKWA HS Investigative
DM1PKWA SN KNI-10155; CHEMBL503181; BDBM50273742
DM1PKWA DT Small molecular drug
DM1PKWA PC 44588314
DM1PKWA MW 647.8
DM1PKWA FM C35H41N3O7S
DM1PKWA IC InChI=1S/C35H41N3O7S/c1-20-14-24(39)15-21(2)31(20)45-18-28(41)36-26(16-22-10-6-5-7-11-22)30(42)34(44)38-19-46-35(3,4)32(38)33(43)37-29-25-13-9-8-12-23(25)17-27(29)40/h5-15,26-27,29-30,32,39-40,42H,16-19H2,1-4H3,(H,36,41)(H,37,43)/t26-,27+,29-,30-,32+/m0/s1
DM1PKWA CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)O
DM1PKWA IK RFANRLZGSPNNFF-RIQJEONASA-N
DM1PKWA IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-hydroxy-2,6-dimethylphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM1PKWA DE Discovery agent
DM64NBG ID DM64NBG
DM64NBG DN KNI-10216
DM64NBG HS Investigative
DM64NBG SN KNI-10216; CHEMBL509323; BDBM50273726
DM64NBG DT Small molecular drug
DM64NBG PC 44588298
DM64NBG MW 619.7
DM64NBG FM C33H37N3O7S
DM64NBG IC InChI=1S/C33H37N3O7S/c1-33(2)30(31(41)35-28-24-14-7-6-11-21(24)16-26(28)38)36(19-44-33)32(42)29(40)25(15-20-9-4-3-5-10-20)34-27(39)18-43-23-13-8-12-22(37)17-23/h3-14,17,25-26,28-30,37-38,40H,15-16,18-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DM64NBG CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM64NBG IK KSGNCVYBLWHGKD-DOWNBTJOSA-N
DM64NBG IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-hydroxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM64NBG DE Discovery agent
DMHLFAE ID DMHLFAE
DMHLFAE DN KNI-10217
DMHLFAE HS Investigative
DMHLFAE SN KNI-10217; CHEMBL448365; BDBM50273727
DMHLFAE DT Small molecular drug
DMHLFAE PC 44588299
DMHLFAE MW 619.7
DMHLFAE FM C33H37N3O7S
DMHLFAE IC InChI=1S/C33H37N3O7S/c1-33(2)30(31(41)35-28-24-11-7-6-10-21(24)17-26(28)38)36(19-44-33)32(42)29(40)25(16-20-8-4-3-5-9-20)34-27(39)18-43-23-14-12-22(37)13-15-23/h3-15,25-26,28-30,37-38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DMHLFAE CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMHLFAE IK QQMINRBEIWYLOV-DOWNBTJOSA-N
DMHLFAE IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-hydroxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMHLFAE DE Discovery agent
DMQY1ST ID DMQY1ST
DMQY1ST DN KNI-10232
DMQY1ST HS Investigative
DMQY1ST SN KNI-10232; CHEMBL411559; BDBM50209553
DMQY1ST DT Small molecular drug
DMQY1ST PC 44425659
DMQY1ST MW 718.9
DMQY1ST FM C38H46N4O6S2
DMQY1ST IC InChI=1S/C38H46N4O6S2/c1-23-12-8-9-15-25(23)20-31(44)39-29(21-49-4)35(46)40-28(18-24-13-6-5-7-14-24)33(45)37(48)42-22-50-38(2,3)34(42)36(47)41-32-27-17-11-10-16-26(27)19-30(32)43/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMQY1ST CS CC1=CC=CC=C1CC(=O)N[C@@H](CSC)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMQY1ST IK BUCXGTGXIGORNK-DYCNJNKSSA-N
DMQY1ST IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(2-methylphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMQY1ST DE Discovery agent
DMV3U9Z ID DMV3U9Z
DMV3U9Z DN KNI-10255
DMV3U9Z HS Investigative
DMV3U9Z SN KNI-10255; CHEMBL508023; BDBM50273735
DMV3U9Z DT Small molecular drug
DMV3U9Z PC 44588307
DMV3U9Z MW 648.7
DMV3U9Z FM C33H36N4O8S
DMV3U9Z IC InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-24-14-7-6-11-21(24)16-26(28)38)36(19-46-33)32(42)29(40)25(15-20-9-4-3-5-10-20)34-27(39)18-45-23-13-8-12-22(17-23)37(43)44/h3-14,17,25-26,28-30,38,40H,15-16,18-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DMV3U9Z CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC(=C3)[N+](=O)[O-])O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMV3U9Z IK RFMOODWRTXUAKX-DOWNBTJOSA-N
DMV3U9Z IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(3-nitrophenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMV3U9Z DE Discovery agent
DMZFVHT ID DMZFVHT
DMZFVHT DN KNI-10256
DMZFVHT HS Investigative
DMZFVHT SN KNI-10256; CHEMBL500010; BDBM50273736
DMZFVHT DT Small molecular drug
DMZFVHT PC 44588308
DMZFVHT MW 648.7
DMZFVHT FM C33H36N4O8S
DMZFVHT IC InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-24-11-7-6-10-21(24)17-26(28)38)36(19-46-33)32(42)29(40)25(16-20-8-4-3-5-9-20)34-27(39)18-45-23-14-12-22(13-15-23)37(43)44/h3-15,25-26,28-30,38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1
DMZFVHT CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=C(C=C3)[N+](=O)[O-])O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMZFVHT IK PABVKNPJQYYVNK-DOWNBTJOSA-N
DMZFVHT IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(4-nitrophenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZFVHT DE Discovery agent
DMZXI6U ID DMZXI6U
DMZXI6U DN KNI-10260
DMZXI6U HS Investigative
DMZXI6U SN KNI-10260; CHEMBL503590; BDBM50273739
DMZXI6U DT Small molecular drug
DMZXI6U PC 44588311
DMZXI6U MW 663.8
DMZXI6U FM C35H41N3O8S
DMZXI6U IC InChI=1S/C35H41N3O8S/c1-35(2)32(33(42)37-29-23-14-9-8-13-22(23)18-25(29)39)38(20-47-35)34(43)30(41)24(17-21-11-6-5-7-12-21)36-28(40)19-46-31-26(44-3)15-10-16-27(31)45-4/h5-16,24-25,29-30,32,39,41H,17-20H2,1-4H3,(H,36,40)(H,37,42)/t24-,25+,29-,30-,32+/m0/s1
DMZXI6U CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C=CC=C3OC)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMZXI6U IK UXPUZKDVSUQPJT-GBHWDNFXSA-N
DMZXI6U IU (4R)-3-[(2S,3S)-3-[[2-(2,6-dimethoxyphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZXI6U DE Discovery agent
DMQLB3T ID DMQLB3T
DMQLB3T DN KNI-10265
DMQLB3T HS Investigative
DMQLB3T SN KNI-10265; CHEMBL509191; (4r)-3-[(2s,3s)-3-{[(2,6-Difluorophenoxy)acetyl]amino}-2-Hydroxy-4-Phenylbutanoyl]-N-[(1s,2r)-2-Hydroxy-2,3-Dihydro-1h-Inden-1-Yl]-5,5-Dimethyl-1,3-Thiazolidine-4-Carboxamide; 3kdd; BDBM50273737; JZQ
DMQLB3T DT Small molecular drug
DMQLB3T PC 44588309
DMQLB3T MW 639.7
DMQLB3T FM C33H35F2N3O6S
DMQLB3T IC InChI=1S/C33H35F2N3O6S/c1-33(2)30(31(42)37-27-21-12-7-6-11-20(21)16-25(27)39)38(18-45-33)32(43)28(41)24(15-19-9-4-3-5-10-19)36-26(40)17-44-29-22(34)13-8-14-23(29)35/h3-14,24-25,27-28,30,39,41H,15-18H2,1-2H3,(H,36,40)(H,37,42)/t24-,25+,27-,28-,30+/m0/s1
DMQLB3T CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C=CC=C3F)F)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMQLB3T IK KCNWMHBIZSWXTB-UPZHSWQNSA-N
DMQLB3T IU (4R)-3-[(2S,3S)-3-[[2-(2,6-difluorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMQLB3T DE Discovery agent
DMP2E3I ID DMP2E3I
DMP2E3I DN KNI-10266
DMP2E3I HS Investigative
DMP2E3I SN KNI-10266; CHEMBL499762; BDBM50273741
DMP2E3I DT Small molecular drug
DMP2E3I PC 44588313
DMP2E3I MW 649.8
DMP2E3I FM C35H40FN3O6S
DMP2E3I IC InChI=1S/C35H40FN3O6S/c1-20-14-24(36)15-21(2)31(20)45-18-28(41)37-26(16-22-10-6-5-7-11-22)30(42)34(44)39-19-46-35(3,4)32(39)33(43)38-29-25-13-9-8-12-23(25)17-27(29)40/h5-15,26-27,29-30,32,40,42H,16-19H2,1-4H3,(H,37,41)(H,38,43)/t26-,27+,29-,30-,32+/m0/s1
DMP2E3I CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)F
DMP2E3I IK CCRMGTSJDCJISE-RIQJEONASA-N
DMP2E3I IU (4R)-3-[(2S,3S)-3-[[2-(4-fluoro-2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMP2E3I DE Discovery agent
DMAR35H ID DMAR35H
DMAR35H DN KNI-10282
DMAR35H HS Investigative
DMAR35H SN KNI-10282; CHEMBL504596; BDBM50273745
DMAR35H DT Small molecular drug
DMAR35H PC 25147780
DMAR35H MW 674.9
DMAR35H FM C37H46N4O6S
DMAR35H IC InChI=1S/C37H46N4O6S/c1-22-16-26(40(5)6)17-23(2)33(22)47-20-30(43)38-28(18-24-12-8-7-9-13-24)32(44)36(46)41-21-48-37(3,4)34(41)35(45)39-31-27-15-11-10-14-25(27)19-29(31)42/h7-17,28-29,31-32,34,42,44H,18-21H2,1-6H3,(H,38,43)(H,39,45)/t28-,29+,31-,32-,34+/m0/s1
DMAR35H CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)C
DMAR35H IK MHHYVTRSEKCASG-ZYOXRPPDSA-N
DMAR35H IU (4R)-3-[(2S,3S)-3-[[2-[4-(dimethylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMAR35H DE Discovery agent
DMGVBIT ID DMGVBIT
DMGVBIT DN KNI-10283
DMGVBIT HS Investigative
DMGVBIT DT Small molecular drug
DMGVBIT PC 44588316
DMGVBIT MW 660.8
DMGVBIT FM C36H44N4O6S
DMGVBIT IC InChI=1S/C36H44N4O6S/c1-21-15-25(37-5)16-22(2)32(21)46-19-29(42)38-27(17-23-11-7-6-8-12-23)31(43)35(45)40-20-47-36(3,4)33(40)34(44)39-30-26-14-10-9-13-24(26)18-28(30)41/h6-16,27-28,30-31,33,37,41,43H,17-20H2,1-5H3,(H,38,42)(H,39,44)/t27-,28+,30-,31-,33+/m0/s1
DMGVBIT CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NC
DMGVBIT IK MFQZSFZGLACSHP-LPOYSWGPSA-N
DMGVBIT IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(methylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMGVBIT DE Discovery agent
DMP7M8O ID DMP7M8O
DMP7M8O DN KNI-10313
DMP7M8O HS Investigative
DMP7M8O SN KNI-10313; CHEMBL394359; BDBM50209562
DMP7M8O DT Small molecular drug
DMP7M8O PC 44425663
DMP7M8O MW 718.9
DMP7M8O FM C38H46N4O6S2
DMP7M8O IC InChI=1S/C38H46N4O6S2/c1-23-14-16-25(17-15-23)19-31(44)39-29(21-49-4)35(46)40-28(18-24-10-6-5-7-11-24)33(45)37(48)42-22-50-38(2,3)34(42)36(47)41-32-27-13-9-8-12-26(27)20-30(32)43/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMP7M8O CS CC1=CC=C(C=C1)CC(=O)N[C@@H](CSC)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMP7M8O IK OMAVDDWHFQLABL-DYCNJNKSSA-N
DMP7M8O IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(4-methylphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMP7M8O DE Discovery agent
DMYGNZA ID DMYGNZA
DMYGNZA DN KNI-10314
DMYGNZA HS Investigative
DMYGNZA SN KNI-10314; CHEMBL266257; BDBM50209556
DMYGNZA DT Small molecular drug
DMYGNZA PC 44425676
DMYGNZA MW 734.9
DMYGNZA FM C38H46N4O7S2
DMYGNZA IC InChI=1S/C38H46N4O7S2/c1-38(2)34(36(47)41-32-26-16-10-8-14-24(26)19-29(32)43)42(22-51-38)37(48)33(45)27(18-23-12-6-5-7-13-23)40-35(46)28(21-50-4)39-31(44)20-25-15-9-11-17-30(25)49-3/h5-17,27-29,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t27-,28-,29+,32-,33-,34+/m0/s1
DMYGNZA CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=CC=C3OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMYGNZA IK IJOKPTZPLSVFMX-CPPBRJAYSA-N
DMYGNZA IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(2-methoxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMYGNZA DE Discovery agent
DM1OPYT ID DM1OPYT
DM1OPYT DN KNI-10315
DM1OPYT HS Investigative
DM1OPYT SN KNI-10315; CHEMBL389083; BDBM50209563
DM1OPYT DT Small molecular drug
DM1OPYT PC 44425680
DM1OPYT MW 734.9
DM1OPYT FM C38H46N4O7S2
DM1OPYT IC InChI=1S/C38H46N4O7S2/c1-38(2)34(36(47)41-32-27-13-9-8-12-25(27)20-30(32)43)42(22-51-38)37(48)33(45)28(18-23-10-6-5-7-11-23)40-35(46)29(21-50-4)39-31(44)19-24-14-16-26(49-3)17-15-24/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DM1OPYT CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=C(C=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM1OPYT IK GJESXLGDWNCUSK-DYCNJNKSSA-N
DM1OPYT IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(4-methoxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM1OPYT DE Discovery agent
DMMIDCG ID DMMIDCG
DMMIDCG DN KNI-10316
DMMIDCG HS Investigative
DMMIDCG SN KNI-10316; CHEMBL411609; BDBM50209558
DMMIDCG DT Small molecular drug
DMMIDCG PC 44425679
DMMIDCG MW 734.9
DMMIDCG FM C38H46N4O7S2
DMMIDCG IC InChI=1S/C38H46N4O7S2/c1-38(2)34(36(47)41-32-27-16-9-8-14-25(27)20-30(32)43)42(22-51-38)37(48)33(45)28(18-23-11-6-5-7-12-23)40-35(46)29(21-50-4)39-31(44)19-24-13-10-15-26(17-24)49-3/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMMIDCG CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC(=CC=C3)OC)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMMIDCG IK CLMDKZSFODILEW-DYCNJNKSSA-N
DMMIDCG IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(3-methoxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMMIDCG DE Discovery agent
DMKVPMS ID DMKVPMS
DMKVPMS DN KNI-10332
DMKVPMS HS Investigative
DMKVPMS SN KNI-10332; CHEMBL411605; BDBM50209564
DMKVPMS DT Small molecular drug
DMKVPMS PC 44425662
DMKVPMS MW 718.9
DMKVPMS FM C38H46N4O6S2
DMKVPMS IC InChI=1S/C38H46N4O6S2/c1-23-11-10-14-25(17-23)19-31(44)39-29(21-49-4)35(46)40-28(18-24-12-6-5-7-13-24)33(45)37(48)42-22-50-38(2,3)34(42)36(47)41-32-27-16-9-8-15-26(27)20-30(32)43/h5-17,28-30,32-34,43,45H,18-22H2,1-4H3,(H,39,44)(H,40,46)(H,41,47)/t28-,29-,30+,32-,33-,34+/m0/s1
DMKVPMS CS CC1=CC(=CC=C1)CC(=O)N[C@@H](CSC)C(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O
DMKVPMS IK RKUUAMZSZJEKQE-DYCNJNKSSA-N
DMKVPMS IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(3-methylphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMKVPMS DE Discovery agent
DMF9P25 ID DMF9P25
DMF9P25 DN KNI-10341
DMF9P25 HS Investigative
DMF9P25 SN KNI-10341; CHEMBL411607; BDBM50209561
DMF9P25 DT Small molecular drug
DMF9P25 PC 44425671
DMF9P25 MW 720.9
DMF9P25 FM C37H44N4O7S2
DMF9P25 IC InChI=1S/C37H44N4O7S2/c1-37(2)33(35(47)40-31-25-15-9-7-13-23(25)18-29(31)43)41(21-50-37)36(48)32(45)26(17-22-11-5-4-6-12-22)39-34(46)27(20-49-3)38-30(44)19-24-14-8-10-16-28(24)42/h4-16,26-27,29,31-33,42-43,45H,17-21H2,1-3H3,(H,38,44)(H,39,46)(H,40,47)/t26-,27-,29+,31-,32-,33+/m0/s1
DMF9P25 CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=CC=C3O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMF9P25 IK BJANBLOVCAEXPY-CFLSISTJSA-N
DMF9P25 IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(2-hydroxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMF9P25 DE Discovery agent
DMDM5BL ID DMDM5BL
DMDM5BL DN KNI-10342
DMDM5BL HS Investigative
DMDM5BL SN KNI-10342; CHEMBL230510; BDBM50209554
DMDM5BL DT Small molecular drug
DMDM5BL PC 44425672
DMDM5BL MW 720.9
DMDM5BL FM C37H44N4O7S2
DMDM5BL IC InChI=1S/C37H44N4O7S2/c1-37(2)33(35(47)40-31-26-15-8-7-13-24(26)19-29(31)43)41(21-50-37)36(48)32(45)27(17-22-10-5-4-6-11-22)39-34(46)28(20-49-3)38-30(44)18-23-12-9-14-25(42)16-23/h4-16,27-29,31-33,42-43,45H,17-21H2,1-3H3,(H,38,44)(H,39,46)(H,40,47)/t27-,28-,29+,31-,32-,33+/m0/s1
DMDM5BL CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC(=CC=C3)O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DMDM5BL IK RBPFZWDTXSAZMR-ACUZRORGSA-N
DMDM5BL IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[[2-(3-hydroxyphenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMDM5BL DE Discovery agent
DM8SIRL ID DM8SIRL
DM8SIRL DN KNI-10368
DM8SIRL HS Investigative
DM8SIRL SN KNI-10368; CHEMBL410591; BDBM50209560
DM8SIRL DT Small molecular drug
DM8SIRL PC 44425667
DM8SIRL MW 719.9
DM8SIRL FM C37H45N5O6S2
DM8SIRL IC InChI=1S/C37H45N5O6S2/c1-37(2)33(35(47)41-31-26-15-8-7-13-24(26)19-29(31)43)42(21-50-37)36(48)32(45)27(17-22-10-5-4-6-11-22)40-34(46)28(20-49-3)39-30(44)18-23-12-9-14-25(38)16-23/h4-16,27-29,31-33,43,45H,17-21,38H2,1-3H3,(H,39,44)(H,40,46)(H,41,47)/t27-,28-,29+,31-,32-,33+/m0/s1
DM8SIRL CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC(=CC=C3)N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM8SIRL IK OSOTUWUUAVSXOF-ACUZRORGSA-N
DM8SIRL IU (4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(3-aminophenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM8SIRL DE Discovery agent
DM97STY ID DM97STY
DM97STY DN KNI-10369
DM97STY HS Investigative
DM97STY SN KNI-10369; CHEMBL502985; BDBM50273725
DM97STY DT Small molecular drug
DM97STY PC 44588297
DM97STY MW 619.7
DM97STY FM C33H37N3O7S
DM97STY IC InChI=1S/C33H37N3O7S/c1-33(2)30(31(41)35-28-22-13-7-6-12-21(22)17-25(28)38)36(19-44-33)32(42)29(40)23(16-20-10-4-3-5-11-20)34-27(39)18-43-26-15-9-8-14-24(26)37/h3-15,23,25,28-30,37-38,40H,16-19H2,1-2H3,(H,34,39)(H,35,41)/t23-,25+,28-,29-,30+/m0/s1
DM97STY CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)COC3=CC=CC=C3O)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM97STY IK ZHDZQXHOQVYYCG-OIRZSGMBSA-N
DM97STY IU (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-[[2-(2-hydroxyphenoxy)acetyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM97STY DE Discovery agent
DM4AUCE ID DM4AUCE
DM4AUCE DN KNI-10372
DM4AUCE HS Investigative
DM4AUCE SN KNI-10372; CHEMBL266256; BDBM50209565
DM4AUCE DT Small molecular drug
DM4AUCE PC 44425666
DM4AUCE MW 719.9
DM4AUCE FM C37H45N5O6S2
DM4AUCE IC InChI=1S/C37H45N5O6S2/c1-37(2)33(35(47)41-31-25-15-9-7-13-23(25)18-29(31)43)42(21-50-37)36(48)32(45)27(17-22-11-5-4-6-12-22)40-34(46)28(20-49-3)39-30(44)19-24-14-8-10-16-26(24)38/h4-16,27-29,31-33,43,45H,17-21,38H2,1-3H3,(H,39,44)(H,40,46)(H,41,47)/t27-,28-,29+,31-,32-,33+/m0/s1
DM4AUCE CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)CC3=CC=CC=C3N)O)C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)C
DM4AUCE IK JXPOIFQLOPSPRM-ACUZRORGSA-N
DM4AUCE IU (4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(2-aminophenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM4AUCE DE Discovery agent
DMEN2L3 ID DMEN2L3
DMEN2L3 DN KNI-10526
DMEN2L3 HS Investigative
DMEN2L3 SN KNI-10526; CHEMBL444759; BDBM50273750
DMEN2L3 DT Small molecular drug
DMEN2L3 PC 44588320
DMEN2L3 MW 737.9
DMEN2L3 FM C41H47N5O6S
DMEN2L3 IC InChI=1S/C41H47N5O6S/c1-25-17-30(43-22-28-13-10-16-42-21-28)18-26(2)37(25)52-23-34(48)44-32(19-27-11-6-5-7-12-27)36(49)40(51)46-24-53-41(3,4)38(46)39(50)45-35-31-15-9-8-14-29(31)20-33(35)47/h5-18,21,32-33,35-36,38,43,47,49H,19-20,22-24H2,1-4H3,(H,44,48)(H,45,50)/t32-,33+,35-,36-,38+/m0/s1
DMEN2L3 CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCC6=CN=CC=C6
DMEN2L3 IK HBTCIJNHNMLBFP-CTRNRRKFSA-N
DMEN2L3 IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pyridin-3-ylmethylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMEN2L3 DE Discovery agent
DMU4K7O ID DMU4K7O
DMU4K7O DN KNI-10527
DMU4K7O HS Investigative
DMU4K7O SN KNI-10527; CHEMBL452725; BDBM50273751
DMU4K7O DT Small molecular drug
DMU4K7O PC 44588321
DMU4K7O MW 737.9
DMU4K7O FM C41H47N5O6S
DMU4K7O IC InChI=1S/C41H47N5O6S/c1-25-18-30(43-22-28-14-16-42-17-15-28)19-26(2)37(25)52-23-34(48)44-32(20-27-10-6-5-7-11-27)36(49)40(51)46-24-53-41(3,4)38(46)39(50)45-35-31-13-9-8-12-29(31)21-33(35)47/h5-19,32-33,35-36,38,43,47,49H,20-24H2,1-4H3,(H,44,48)(H,45,50)/t32-,33+,35-,36-,38+/m0/s1
DMU4K7O CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCC6=CC=NC=C6
DMU4K7O IK LZKUFQZJJUVPHA-CTRNRRKFSA-N
DMU4K7O IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pyridin-4-ylmethylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMU4K7O DE Discovery agent
DMDRWYG ID DMDRWYG
DMDRWYG DN KNI-10529
DMDRWYG HS Investigative
DMDRWYG SN KNI-10529; CHEMBL449918; BDBM50273746
DMDRWYG DT Small molecular drug
DMDRWYG PC 44588317
DMDRWYG MW 674.9
DMDRWYG FM C37H46N4O6S
DMDRWYG IC InChI=1S/C37H46N4O6S/c1-6-38-26-16-22(2)33(23(3)17-26)47-20-30(43)39-28(18-24-12-8-7-9-13-24)32(44)36(46)41-21-48-37(4,5)34(41)35(45)40-31-27-15-11-10-14-25(27)19-29(31)42/h7-17,28-29,31-32,34,38,42,44H,6,18-21H2,1-5H3,(H,39,43)(H,40,45)/t28-,29+,31-,32-,34+/m0/s1
DMDRWYG CS CCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMDRWYG IK MWCQAFKRDJYAQP-ZYOXRPPDSA-N
DMDRWYG IU (4R)-3-[(2S,3S)-3-[[2-[4-(ethylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMDRWYG DE Discovery agent
DM7XEIY ID DM7XEIY
DM7XEIY DN KNI-10538
DM7XEIY HS Investigative
DM7XEIY SN KNI-10538; CHEMBL508668; BDBM50273749; (R)-3-((2S,3S)-3-(2-(2,6-dimethyl-4-(pyridin-2-ylmethylamino)phenoxy)acetamido)-2-hydroxy-4-phenylbutanoyl)-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-5,5-dimethylthiazolidine-4-carboxamide
DM7XEIY DT Small molecular drug
DM7XEIY PC 25147781
DM7XEIY MW 737.9
DM7XEIY FM C41H47N5O6S
DM7XEIY IC InChI=1S/C41H47N5O6S/c1-25-18-30(43-22-29-15-10-11-17-42-29)19-26(2)37(25)52-23-34(48)44-32(20-27-12-6-5-7-13-27)36(49)40(51)46-24-53-41(3,4)38(46)39(50)45-35-31-16-9-8-14-28(31)21-33(35)47/h5-19,32-33,35-36,38,43,47,49H,20-24H2,1-4H3,(H,44,48)(H,45,50)/t32-,33+,35-,36-,38+/m0/s1
DM7XEIY CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCC6=CC=CC=N6
DM7XEIY IK IEOXTIHUYRYEJG-CTRNRRKFSA-N
DM7XEIY IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pyridin-2-ylmethylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM7XEIY DE Discovery agent
DMLWOFY ID DMLWOFY
DMLWOFY DN KNI-10539
DMLWOFY HS Investigative
DMLWOFY SN KNI-10539; CHEMBL502445; BDBM50273747
DMLWOFY DT Small molecular drug
DMLWOFY PC 44588318
DMLWOFY MW 702.9
DMLWOFY FM C39H50N4O6S
DMLWOFY IC InChI=1S/C39H50N4O6S/c1-6-7-17-40-28-18-24(2)35(25(3)19-28)49-22-32(45)41-30(20-26-13-9-8-10-14-26)34(46)38(48)43-23-50-39(4,5)36(43)37(47)42-33-29-16-12-11-15-27(29)21-31(33)44/h8-16,18-19,30-31,33-34,36,40,44,46H,6-7,17,20-23H2,1-5H3,(H,41,45)(H,42,47)/t30-,31+,33-,34-,36+/m0/s1
DMLWOFY CS CCCCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMLWOFY IK YFOGAJAJKAWILS-SQKWSBCUSA-N
DMLWOFY IU (4R)-3-[(2S,3S)-3-[[2-[4-(butylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMLWOFY DE Discovery agent
DMP87U4 ID DMP87U4
DMP87U4 DN KNI-10541
DMP87U4 HS Investigative
DMP87U4 SN KNI-10541; CHEMBL507484; BDBM50273748
DMP87U4 DT Small molecular drug
DMP87U4 PC 44588319
DMP87U4 MW 716.9
DMP87U4 FM C40H52N4O6S
DMP87U4 IC InChI=1S/C40H52N4O6S/c1-6-7-13-18-41-29-19-25(2)36(26(3)20-29)50-23-33(46)42-31(21-27-14-9-8-10-15-27)35(47)39(49)44-24-51-40(4,5)37(44)38(48)43-34-30-17-12-11-16-28(30)22-32(34)45/h8-12,14-17,19-20,31-32,34-35,37,41,45,47H,6-7,13,18,21-24H2,1-5H3,(H,42,46)(H,43,48)/t31-,32+,34-,35-,37+/m0/s1
DMP87U4 CS CCCCCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMP87U4 IK MLHPSGOBOHSFGF-IVJJLKHCSA-N
DMP87U4 IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-(pentylamino)phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMP87U4 DE Discovery agent
DMGUABP ID DMGUABP
DMGUABP DN KNI-10737
DMGUABP HS Investigative
DMGUABP SN KNI-10737; CHEMBL1209492; BDBM50323464
DMGUABP DT Small molecular drug
DMGUABP PC 49862498
DMGUABP MW 689.9
DMGUABP FM C37H47N5O6S
DMGUABP IC InChI=1S/C37H47N5O6S/c1-22-16-26(39-15-14-38)17-23(2)33(22)48-20-30(44)40-28(18-24-10-6-5-7-11-24)32(45)36(47)42-21-49-37(3,4)34(42)35(46)41-31-27-13-9-8-12-25(27)19-29(31)43/h5-13,16-17,28-29,31-32,34,39,43,45H,14-15,18-21,38H2,1-4H3,(H,40,44)(H,41,46)/t28-,29+,31-,32-,34+/m0/s1
DMGUABP CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCCN
DMGUABP IK KGNXIOMLRKTRJD-ZYOXRPPDSA-N
DMGUABP IU (4R)-3-[(2S,3S)-3-[[2-[4-(2-aminoethylamino)-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMGUABP DE Discovery agent
DMPWY6H ID DMPWY6H
DMPWY6H DN KNI-10740
DMPWY6H HS Investigative
DMPWY6H SN KNI-10740; CHEMBL1209496; BDBM50323468
DMPWY6H DT Small molecular drug
DMPWY6H PC 49862502
DMPWY6H MW 717.9
DMPWY6H FM C39H51N5O6S
DMPWY6H IC InChI=1S/C39H51N5O6S/c1-24-18-28(43(6)17-16-40-5)19-25(2)35(24)50-22-32(46)41-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(3,4)36(44)37(48)42-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,40,45,47H,16-17,20-23H2,1-6H3,(H,41,46)(H,42,48)/t30-,31+,33-,34-,36+/m0/s1
DMPWY6H CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)CCNC
DMPWY6H IK LDLOTPBPEFKMMQ-SQKWSBCUSA-N
DMPWY6H IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-[methyl-[2-(methylamino)ethyl]amino]phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMPWY6H DE Discovery agent
DM7TW4C ID DM7TW4C
DM7TW4C DN KNI-10741
DM7TW4C HS Investigative
DM7TW4C SN KNI-10741; CHEMBL1209497; BDBM50323470
DM7TW4C DT Small molecular drug
DM7TW4C PC 49862504
DM7TW4C MW 717.9
DM7TW4C FM C39H51N5O6S
DM7TW4C IC InChI=1S/C39H51N5O6S/c1-6-40-16-17-41-28-18-24(2)35(25(3)19-28)50-22-32(46)42-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(4,5)36(44)37(48)43-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,40-41,45,47H,6,16-17,20-23H2,1-5H3,(H,42,46)(H,43,48)/t30-,31+,33-,34-,36+/m0/s1
DM7TW4C CS CCNCCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DM7TW4C IK QWIMGFUQWCHOOH-SQKWSBCUSA-N
DM7TW4C IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-(ethylamino)ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM7TW4C DE Discovery agent
DM4D9T3 ID DM4D9T3
DM4D9T3 DN KNI-10742
DM4D9T3 HS Investigative
DM4D9T3 SN KNI-10742; CHEMBL1209499; (4R)-3-[(2S,3S)-3-[2-[4-[2-azanylethyl(ethyl)amino]-2,6-dimethyl-phenoxy]ethanoylamino]-2-oxidanyl-4-phenyl-butanoyl]-5,5-dimethyl-N-[(1S,2R)-2-oxidanyl-2,3-dihydro-1H-inden-1-yl]-1,3-thiazolidine-4-carboxamide; BDBM50323472; 8VF
DM4D9T3 DT Small molecular drug
DM4D9T3 PC 49862506
DM4D9T3 MW 717.9
DM4D9T3 FM C39H51N5O6S
DM4D9T3 IC InChI=1S/C39H51N5O6S/c1-6-43(17-16-40)28-18-24(2)35(25(3)19-28)50-22-32(46)41-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(4,5)36(44)37(48)42-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,45,47H,6,16-17,20-23,40H2,1-5H3,(H,41,46)(H,42,48)/t30-,31+,33-,34-,36+/m0/s1
DM4D9T3 CS CCN(CCN)C1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DM4D9T3 IK QVEVEYWLPLMZQY-SQKWSBCUSA-N
DM4D9T3 IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-aminoethyl(ethyl)amino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM4D9T3 DE Discovery agent
DM0VSPE ID DM0VSPE
DM0VSPE DN KNI-10743
DM0VSPE HS Investigative
DM0VSPE SN KNI-10743; CHEMBL1208799; (4R)-3-[(2S,3S)-3-[2-[4-[2-(dimethylamino)ethyl-methyl-amino]-2,6-dimethyl-phenoxy]ethanoylamino]-2-oxidanyl-4-phenyl-butanoyl]-5,5-dimethyl-N-[(1S,2R)-2-oxidanyl-2,3-dihydro-1H-inden-1-yl]-1,3-thiazolidine-4-carboxamide; BDBM50323469; (R)-3-((2S,3S)-3-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2,6-dimethylphenoxy)acetamido)-2-hydroxy-4-phenylbutanoyl)-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-5,5-dimethylthiazolidine-4-carboxamide
DM0VSPE DT Small molecular drug
DM0VSPE PC 49862503
DM0VSPE MW 731.9
DM0VSPE FM C40H53N5O6S
DM0VSPE IC InChI=1S/C40H53N5O6S/c1-25-19-29(44(7)18-17-43(5)6)20-26(2)36(25)51-23-33(47)41-31(21-27-13-9-8-10-14-27)35(48)39(50)45-24-52-40(3,4)37(45)38(49)42-34-30-16-12-11-15-28(30)22-32(34)46/h8-16,19-20,31-32,34-35,37,46,48H,17-18,21-24H2,1-7H3,(H,41,47)(H,42,49)/t31-,32+,34-,35-,37+/m0/s1
DM0VSPE CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)CCN(C)C
DM0VSPE IK IZETWNQXMIHLNU-IVJJLKHCSA-N
DM0VSPE IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-(dimethylamino)ethyl-methylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM0VSPE DE Discovery agent
DMM2A5Q ID DMM2A5Q
DMM2A5Q DN KNI-10758
DMM2A5Q HS Investigative
DMM2A5Q SN KNI-10758; CHEMBL1209500; BDBM50323473
DMM2A5Q DT Small molecular drug
DMM2A5Q PC 49862507
DMM2A5Q MW 746
DMM2A5Q FM C41H55N5O6S
DMM2A5Q IC InChI=1S/C41H55N5O6S/c1-7-42-18-19-45(8-2)30-20-26(3)37(27(4)21-30)52-24-34(48)43-32(22-28-14-10-9-11-15-28)36(49)40(51)46-25-53-41(5,6)38(46)39(50)44-35-31-17-13-12-16-29(31)23-33(35)47/h9-17,20-21,32-33,35-36,38,42,47,49H,7-8,18-19,22-25H2,1-6H3,(H,43,48)(H,44,50)/t32-,33+,35-,36-,38+/m0/s1
DMM2A5Q CS CCNCCN(CC)C1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMM2A5Q IK TYAUZZDMTCDBHN-CTRNRRKFSA-N
DMM2A5Q IU (4R)-3-[(2S,3S)-3-[[2-[4-[ethyl-[2-(ethylamino)ethyl]amino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMM2A5Q DE Discovery agent
DMAF1W3 ID DMAF1W3
DMAF1W3 DN KNI-10759
DMAF1W3 HS Investigative
DMAF1W3 SN KNI-10759; CHEMBL1209501; BDBM50323474
DMAF1W3 DT Small molecular drug
DMAF1W3 PC 49862508
DMAF1W3 MW 774
DMAF1W3 FM C43H59N5O6S
DMAF1W3 IC InChI=1S/C43H59N5O6S/c1-8-46(9-2)20-21-47(10-3)32-22-28(4)39(29(5)23-32)54-26-36(50)44-34(24-30-16-12-11-13-17-30)38(51)42(53)48-27-55-43(6,7)40(48)41(52)45-37-33-19-15-14-18-31(33)25-35(37)49/h11-19,22-23,34-35,37-38,40,49,51H,8-10,20-21,24-27H2,1-7H3,(H,44,50)(H,45,52)/t34-,35+,37-,38-,40+/m0/s1
DMAF1W3 CS CCN(CC)CCN(CC)C1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMAF1W3 IK FEJYRCRZYXAOJX-MQKWNYJDSA-N
DMAF1W3 IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-(diethylamino)ethyl-ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMAF1W3 DE Discovery agent
DMT5FIP ID DMT5FIP
DMT5FIP DN KNI-10760
DMT5FIP HS Investigative
DMT5FIP SN KNI-10760; CHEMBL1209498; BDBM50323471
DMT5FIP DT Small molecular drug
DMT5FIP PC 49862505
DMT5FIP MW 746
DMT5FIP FM C41H55N5O6S
DMT5FIP IC InChI=1S/C41H55N5O6S/c1-7-45(8-2)19-18-42-30-20-26(3)37(27(4)21-30)52-24-34(48)43-32(22-28-14-10-9-11-15-28)36(49)40(51)46-25-53-41(5,6)38(46)39(50)44-35-31-17-13-12-16-29(31)23-33(35)47/h9-17,20-21,32-33,35-36,38,42,47,49H,7-8,18-19,22-25H2,1-6H3,(H,43,48)(H,44,50)/t32-,33+,35-,36-,38+/m0/s1
DMT5FIP CS CCN(CC)CCNC1=CC(=C(C(=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C
DMT5FIP IK MOXFYRJTMGBJQV-CTRNRRKFSA-N
DMT5FIP IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-(diethylamino)ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMT5FIP DE Discovery agent
DMXUTWZ ID DMXUTWZ
DMXUTWZ DN KNI-10761
DMXUTWZ HS Investigative
DMXUTWZ SN KNI-10761; CHEMBL1209494; BDBM50323466
DMXUTWZ DT Small molecular drug
DMXUTWZ PC 49862500
DMXUTWZ MW 717.9
DMXUTWZ FM C39H51N5O6S
DMXUTWZ IC InChI=1S/C39H51N5O6S/c1-24-18-28(40-16-17-43(5)6)19-25(2)35(24)50-22-32(46)41-30(20-26-12-8-7-9-13-26)34(47)38(49)44-23-51-39(3,4)36(44)37(48)42-33-29-15-11-10-14-27(29)21-31(33)45/h7-15,18-19,30-31,33-34,36,40,45,47H,16-17,20-23H2,1-6H3,(H,41,46)(H,42,48)/t30-,31+,33-,34-,36+/m0/s1
DMXUTWZ CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCCN(C)C
DMXUTWZ IK MXFYEUZYULOCTL-SQKWSBCUSA-N
DMXUTWZ IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-(dimethylamino)ethylamino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMXUTWZ DE Discovery agent
DM73WB2 ID DM73WB2
DM73WB2 DN KNI-10762
DM73WB2 HS Investigative
DM73WB2 SN KNI-10762; CHEMBL1209495; BDBM50323467
DM73WB2 DT Small molecular drug
DM73WB2 PC 49862501
DM73WB2 MW 703.9
DM73WB2 FM C38H49N5O6S
DM73WB2 IC InChI=1S/C38H49N5O6S/c1-23-17-27(42(5)16-15-39)18-24(2)34(23)49-21-31(45)40-29(19-25-11-7-6-8-12-25)33(46)37(48)43-22-50-38(3,4)35(43)36(47)41-32-28-14-10-9-13-26(28)20-30(32)44/h6-14,17-18,29-30,32-33,35,44,46H,15-16,19-22,39H2,1-5H3,(H,40,45)(H,41,47)/t29-,30+,32-,33-,35+/m0/s1
DM73WB2 CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N(C)CCN
DM73WB2 IK DQMDEHSLPXZFSC-WLYLRDIASA-N
DM73WB2 IU (4R)-3-[(2S,3S)-3-[[2-[4-[2-aminoethyl(methyl)amino]-2,6-dimethylphenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM73WB2 DE Discovery agent
DMKAY5G ID DMKAY5G
DMKAY5G DN KNI-10763
DMKAY5G HS Investigative
DMKAY5G SN KNI-10763; CHEMBL1209493; BDBM50323465
DMKAY5G DT Small molecular drug
DMKAY5G PC 49862499
DMKAY5G MW 703.9
DMKAY5G FM C38H49N5O6S
DMKAY5G IC InChI=1S/C38H49N5O6S/c1-23-17-27(40-16-15-39-5)18-24(2)34(23)49-21-31(45)41-29(19-25-11-7-6-8-12-25)33(46)37(48)43-22-50-38(3,4)35(43)36(47)42-32-28-14-10-9-13-26(28)20-30(32)44/h6-14,17-18,29-30,32-33,35,39-40,44,46H,15-16,19-22H2,1-5H3,(H,41,45)(H,42,47)/t29-,30+,32-,33-,35+/m0/s1
DMKAY5G CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)NCCNC
DMKAY5G IK MGDBCLMLZKHXCE-WLYLRDIASA-N
DMKAY5G IU (4R)-3-[(2S,3S)-3-[[2-[2,6-dimethyl-4-[2-(methylamino)ethylamino]phenoxy]acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMKAY5G DE Discovery agent
DMZX430 ID DMZX430
DMZX430 DN KNI-1293
DMZX430 HS Investigative
DMZX430 SN KNI-1293; CHEMBL466535; (R)-N-[(1S,2R)-2-Hydroxyindan-1-yl]-3-[(2S,3S)-3-(4-amino-2,6-dimethyphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide; BDBM50273743; (R)-N-[(1S,2R)-2-Hydroxyindan-1-yl]-3-[(2S,3S)-3-(4-amino-2,6-dimethylphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZX430 DT Small molecular drug
DMZX430 PC 44588315
DMZX430 MW 646.8
DMZX430 FM C35H42N4O6S
DMZX430 IC InChI=1S/C35H42N4O6S/c1-20-14-24(36)15-21(2)31(20)45-18-28(41)37-26(16-22-10-6-5-7-11-22)30(42)34(44)39-19-46-35(3,4)32(39)33(43)38-29-25-13-9-8-12-23(25)17-27(29)40/h5-15,26-27,29-30,32,40,42H,16-19,36H2,1-4H3,(H,37,41)(H,38,43)/t26-,27+,29-,30-,32+/m0/s1
DMZX430 CS CC1=CC(=CC(=C1OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)N[C@@H]4[C@@H](CC5=CC=CC=C45)O)(C)C)O)C)N
DMZX430 IK ABHNHNZCHPWXFW-RIQJEONASA-N
DMZX430 IU (4R)-3-[(2S,3S)-3-[[2-(4-amino-2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMZX430 DE Discovery agent
DMS61DB ID DMS61DB
DMS61DB DN KNI-227
DMS61DB HS Investigative
DMS61DB SN Kynostatin 227; Kni-227; Kynostatin-227; 147384-69-8; CHEMBL231622; KYNOSTATIN; Qoa-Mta-Apns-Thz-NH-tBu; AC1L22EK; AC1Q5L2G; BDBM719; SCHEMBL2772022; DTXSID30163692; N-(1,1-Dimethylethyl)-3-[2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3-methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-5,5-dimethyl]-4-thiazolidinecarboxamide,[4R-[3[2S*,3S*(R*)],4R*]]; (4R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-[S-methyl-N-(5-isoquinolinyloxyacetyl)-L-cysteinylamino]-4-phenylbutyryl]-5,5-dimethylthiazolidine-4alpha-carboxamide
DMS61DB DT Small molecular drug
DMS61DB PC 65012
DMS61DB MW 695.9
DMS61DB FM C35H45N5O6S2
DMS61DB IC InChI=1S/C35H45N5O6S2/c1-34(2,3)39-32(44)30-35(4,5)48-21-40(30)33(45)29(42)25(17-22-11-8-7-9-12-22)38-31(43)26(20-47-6)37-28(41)19-46-27-14-10-13-23-18-36-16-15-24(23)27/h7-16,18,25-26,29-30,42H,17,19-21H2,1-6H3,(H,37,41)(H,38,43)(H,39,44)/t25-,26-,29-,30+/m0/s1
DMS61DB CS CC1([C@H](N(CS1)C(=O)[C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSC)NC(=O)COC3=CC=CC4=C3C=CN=C4)O)C(=O)NC(C)(C)C)C
DMS61DB IK AHWCYDXQIXZVRK-RPQLRNILSA-N
DMS61DB IU (4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[[(2R)-2-[(2-isoquinolin-5-yloxyacetyl)amino]-3-methylsulfanylpropanoyl]amino]-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DMS61DB CA CAS 147384-69-8
DMS61DB DE Discovery agent
DM105NU ID DM105NU
DM105NU DN KNI-727
DM105NU HS Investigative
DM105NU SN KNI-727; KNI 727; 189357-33-3; JE-1482; N-(3-((4R)-4-(N-(tert-Butyl)carbamoyl)-5,5-dimethyl(1,3-thiazolidin-3-yl))(1S,2S)-2-hydroxy-3-oxo-1-benzylpropyl)-2-(2,6-dimethylphenoxy)acetamide; Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[(2S,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-1-oxo-4-phenylbutyl]-5,5-dimethyl-, (4R)-; N-(3-{(4R)-4-[N-(tert-Butyl)carbamoyl]-5,5-dimethyl(1,3-thiazolidin-3-yl)}(1S,2S)-2-hydroxy-3-oxo-1-benzylpropyl)-2-(2,6-dimethylphenoxy)acetamide
DM105NU DT Small molecular drug
DM105NU PC 451416
DM105NU MW 555.7
DM105NU FM C30H41N3O5S
DM105NU IC InChI=1S/C30H41N3O5S/c1-19-12-11-13-20(2)25(19)38-17-23(34)31-22(16-21-14-9-8-10-15-21)24(35)28(37)33-18-39-30(6,7)26(33)27(36)32-29(3,4)5/h8-15,22,24,26,35H,16-18H2,1-7H3,(H,31,34)(H,32,36)/t22-,24-,26+/m0/s1
DM105NU CS CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@@H](C(=O)N3CSC([C@H]3C(=O)NC(C)(C)C)(C)C)O
DM105NU IK CSWRAOHDICNMPU-LLZJGCNPSA-N
DM105NU IU (4R)-N-tert-butyl-3-[(2S,3S)-3-[[2-(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
DM105NU CA CAS 189357-33-3
DM105NU DE Discovery agent
DMZF3E9 ID DMZF3E9
DMZF3E9 DN KNT-5
DMZF3E9 HS Investigative
DMZF3E9 SN KNT-5
DMZF3E9 DT Small molecular drug
DMZF3E9 PC 46232162
DMZF3E9 MW 391.9
DMZF3E9 FM C21H26ClNO4
DMZF3E9 IC InChI=1S/C21H25NO4.ClH/c1-22(11-12-2-3-12)16-10-13-4-5-14(23)18-17(13)20-8-9-25-21(16,20)7-6-15(24)19(20)26-18;/h4-5,12,16,19,23H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-;/m1./s1
DMZF3E9 CS CN(CC1CC1)[C@@H]2CC3=C4C(=C(C=C3)O)O[C@@H]5[C@@]46[C@]2(CCC5=O)OCC6.Cl
DMZF3E9 IK BJCCGWJRMXDEPD-OPHZJPRHSA-N
DMZF3E9 IU (1S,5R,13S,17R)-17-[cyclopropylmethyl(methyl)amino]-8-hydroxy-6,16-dioxapentacyclo[9.5.2.01,13.05,13.07,12]octadeca-7,9,11-trien-4-one;hydrochloride
DMZF3E9 DE Discovery agent
DM9M5HC ID DM9M5HC
DM9M5HC DN KNT-62
DM9M5HC HS Investigative
DM9M5HC SN CHEMBL594654
DM9M5HC DT Small molecular drug
DM9M5HC PC 46906981
DM9M5HC MW 474.5
DM9M5HC FM C28H30N2O5
DM9M5HC IC InChI=1S/C28H30N2O5/c31-19-9-8-17-14-20-28-11-10-27(33,23(35-28)24(32)29-18-4-2-1-3-5-18)25-26(28,21(17)22(19)34-25)12-13-30(20)15-16-6-7-16/h1-5,8-9,16,20,23,25,31,33H,6-7,10-15H2,(H,29,32)/t20-,23+,25-,26+,27+,28-/m1/s1
DM9M5HC CS C1CC1CN2CC[C@]34[C@@H]5[C@@]6(CC[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O[C@H]6C(=O)NC8=CC=CC=C8)O
DM9M5HC IK YYNRSCGPLWDLNI-VQBGKWCDSA-N
DM9M5HC IU (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-11,15-dihydroxy-N-phenyl-13,17-dioxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-triene-16-carboxamide
DM9M5HC DE Discovery agent
DM0U5N9 ID DM0U5N9
DM0U5N9 DN KNT-63
DM0U5N9 HS Investigative
DM0U5N9 SN CHEMBL593980
DM0U5N9 DT Small molecular drug
DM0U5N9 PC 46225291
DM0U5N9 MW 474.5
DM0U5N9 FM C28H30N2O5
DM0U5N9 IC InChI=1S/C28H30N2O5/c31-19-9-8-17-14-20-28-11-10-27(33,23(35-28)24(32)29-18-4-2-1-3-5-18)25-26(28,21(17)22(19)34-25)12-13-30(20)15-16-6-7-16/h1-5,8-9,16,20,23,25,31,33H,6-7,10-15H2,(H,29,32)/t20-,23+,25+,26-,27-,28+/m0/s1
DM0U5N9 CS C1CC1CN2CC[C@]34[C@@H]5[C@@]6(CC[C@]3([C@@H]2CC7=C4C(=C(C=C7)O)O5)O[C@@H]6C(=O)NC8=CC=CC=C8)O
DM0U5N9 IK YYNRSCGPLWDLNI-PEBCJGEWSA-N
DM0U5N9 IU (1S,2S,6S,14R,15R,16S)-5-(cyclopropylmethyl)-11,15-dihydroxy-N-phenyl-13,17-dioxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-triene-16-carboxamide
DM0U5N9 DE Discovery agent
DMNWXCA ID DMNWXCA
DMNWXCA DN KNX-Monoclonal204
DMNWXCA HS Investigative
DMNWXCA SN KNX-Monoclonal205; KNX-Monoclonal205); Passive immunotherapy (Alzheimers disease), Kinexis
DMNWXCA CP University of California Irvine
DMNWXCA DT Antibody
DMNWXCA DE Alzheimer disease
DMVGNZJ ID DMVGNZJ
DMVGNZJ DN KO-286011
DMVGNZJ HS Investigative
DMVGNZJ SN 132657-47-7
DMVGNZJ DT Small molecular drug
DMVGNZJ PC 131539
DMVGNZJ MW 600.8
DMVGNZJ FM C32H61N2O6P
DMVGNZJ IC InChI=1S/C32H61N2O6P/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-20-27-37-29-32(38-6-2)30-40-41(35,36)39-28-21-19-24-34-25-22-31(23-26-34)33(3)4/h22-23,25-26,32H,5-21,24,27-30H2,1-4H3
DMVGNZJ CS CCCCCCCCCCCCCCCCOCC(COP(=O)([O-])OCCCC[N+]1=CC=C(C=C1)N(C)C)OCC
DMVGNZJ IK ZVLFCHBGXDQHSD-UHFFFAOYSA-N
DMVGNZJ IU 4-[4-(dimethylamino)pyridin-1-ium-1-yl]butyl (2-ethoxy-3-hexadecoxypropyl) phosphate
DMVGNZJ CA CAS 132657-47-7
DMVGNZJ DE Discovery agent
DMAJKRX ID DMAJKRX
DMAJKRX DN Kodaistatin A
DMAJKRX HS Investigative
DMAJKRX SN Kodaistatin A
DMAJKRX DT Small molecular drug
DMAJKRX PC 54708847
DMAJKRX MW 630.6
DMAJKRX FM C35H34O11
DMAJKRX IC InChI=1S/C35H34O11/c1-5-17(2)12-18(3)6-9-22(38)14-25-30(35(45,19(4)36)33(43)31(25)41)24-16-27(40)26(39)15-23(24)29-32(42)28(46-34(29)44)13-20-7-10-21(37)11-8-20/h6-13,15-17,33,37,39-40,42-43,45H,5,14H2,1-4H3/b9-6+,18-12+,28-13-
DMAJKRX CS CCC(C)/C=C(\\C)/C=C/C(=O)CC1=C(C(C(C1=O)O)(C(=O)C)O)C2=CC(=C(C=C2C3=C(/C(=C/C4=CC=C(C=C4)O)/OC3=O)O)O)O
DMAJKRX IK YACYONYLJTYMLP-AIXQLNHRSA-N
DMAJKRX IU (5Z)-3-[2-[5-acetyl-2-[(3E,5E)-5,7-dimethyl-2-oxonona-3,5-dienyl]-4,5-dihydroxy-3-oxocyclopenten-1-yl]-4,5-dihydroxyphenyl]-4-hydroxy-5-[(4-hydroxyphenyl)methylidene]furan-2-one
DMAJKRX DE Discovery agent
DM72WQ3 ID DM72WQ3
DM72WQ3 DN Kodaistatin C
DM72WQ3 HS Investigative
DM72WQ3 PC 54721310
DM72WQ3 MW 646.6
DM72WQ3 FM C35H34O12
DM72WQ3 IC InChI=1S/C35H34O12/c1-5-16(2)10-17(3)6-8-20(37)13-23-30(35(46,18(4)36)33(44)31(23)42)22-15-27(41)26(40)14-21(22)29-32(43)28(47-34(29)45)12-19-7-9-24(38)25(39)11-19/h6-12,14-16,33,38-41,43-44,46H,5,13H2,1-4H3/b8-6+,17-10+,28-12-
DM72WQ3 CS CCC(C)/C=C(\\C)/C=C/C(=O)CC1=C(C(C(C1=O)O)(C(=O)C)O)C2=CC(=C(C=C2C3=C(/C(=C/C4=CC(=C(C=C4)O)O)/OC3=O)O)O)O
DM72WQ3 IK KFMTUTLQSGURRM-MARNYXESSA-N
DM72WQ3 IU (5Z)-3-[2-[5-acetyl-2-[(3E,5E)-5,7-dimethyl-2-oxonona-3,5-dienyl]-4,5-dihydroxy-3-oxocyclopenten-1-yl]-4,5-dihydroxyphenyl]-5-[(3,4-dihydroxyphenyl)methylidene]-4-hydroxyfuran-2-one
DM72WQ3 DE Discovery agent
DMP84CS ID DMP84CS
DMP84CS DN KOJIC ACID
DMP84CS HS Investigative
DMP84CS SN kojic acid; 501-30-4; 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 5-Hydroxy-2-(hydroxymethyl)-4-pyrone; 5-Hydroxy-2-hydroxymethyl-4-pyrone; 4H-PYRAN-4-ONE, 5-HYDROXY-2-(HYDROXYMETHYL)-; 5-hydroxy-2-(hydroxymethyl)pyran-4-one; acido kojico; 2-Hydroxymethyl-5-hydroxy-gamma-pyrone; 2-(Hydroxymethyl)-5-hydroxy-4H-pyran-4-one; UNII-6K23F1TT52; CCRIS 4131; 5-Hydroxy-2-hydroxymethyl-4H-4-pyranone; NSC 1942; EINECS 207-922-4; BRN 0120895; Pyran-4-one, 5-hydroxy-2-(hydroxymethyl); 5-Hydroxy-2-hydroxymethyl-4H-pyran-4-one; AI3-02549
DMP84CS DT Small molecular drug
DMP84CS PC 3840
DMP84CS MW 142.11
DMP84CS FM C6H6O4
DMP84CS IC InChI=1S/C6H6O4/c7-2-4-1-5(8)6(9)3-10-4/h1,3,7,9H,2H2
DMP84CS CS C1=C(OC=C(C1=O)O)CO
DMP84CS IK BEJNERDRQOWKJM-UHFFFAOYSA-N
DMP84CS IU 5-hydroxy-2-(hydroxymethyl)pyran-4-one
DMP84CS CA CAS 501-30-4
DMP84CS CB CHEBI:43572
DMP84CS DE Discovery agent
DMRB1AT ID DMRB1AT
DMRB1AT DN Kojic acid-phenylalanine amide
DMRB1AT HS Investigative
DMRB1AT SN Kojic acid-phenylalanine amide; CHEMBL573709
DMRB1AT DT Small molecular drug
DMRB1AT PC 45482673
DMRB1AT MW 332.31
DMRB1AT FM C16H16N2O6
DMRB1AT IC InChI=1S/C16H16N2O6/c17-15(21)12(6-10-4-2-1-3-5-10)18-16(22)24-8-11-7-13(19)14(20)9-23-11/h1-5,7,9,12,20H,6,8H2,(H2,17,21)(H,18,22)/t12-/m0/s1
DMRB1AT CS C1=CC=C(C=C1)C[C@@H](C(=O)N)NC(=O)OCC2=CC(=O)C(=CO2)O
DMRB1AT IK FIDUCYJXWXTROD-LBPRGKRZSA-N
DMRB1AT IU (5-hydroxy-4-oxopyran-2-yl)methyl N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]carbamate
DMRB1AT DE Discovery agent
DMYDGA7 ID DMYDGA7
DMYDGA7 DN KOS1326
DMYDGA7 HS Investigative
DMYDGA7 SN 4'' deoxy EM-A enolether
DMYDGA7 DT Small molecular drug
DMYDGA7 PC 10259168
DMYDGA7 MW 699.9
DMYDGA7 FM C37H65NO11
DMYDGA7 IC InChI=1S/C37H65NO11/c1-14-26-37(10,42)31(40)22(5)29-19(2)16-36(9,49-29)32(48-34-28(39)25(38(11)12)15-20(3)45-34)23(6)30(24(7)33(41)46-26)47-27-18-35(8,43-13)17-21(4)44-27/h20-28,30-32,34,39-40,42H,14-18H2,1-13H3/t20-,21+,22+,23+,24-,25+,26-,27+,28-,30+,31-,32-,34+,35+,36-,37-/m1/s1
DMYDGA7 CS CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@](C[C@@H](O3)C)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)(C)O
DMYDGA7 IK UJUXMUPAZCCNTJ-ANUGEFLXSA-N
DMYDGA7 IU (2R,3R,4S,5R,8R,9S,10S,11R,12R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3,4-dihydroxy-9-[(2S,4S,6S)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMYDGA7 DE Discovery agent
DM1SKNP ID DM1SKNP
DM1SKNP DN KOSN1559
DM1SKNP HS Investigative
DM1SKNP CP Kosan Bioscience
DM1SKNP TC Anticancer Agents
DM1SKNP DE Solid tumour/cancer
DMT1H9Z ID DMT1H9Z
DMT1H9Z DN KOTALANOL
DMT1H9Z HS Investigative
DMT1H9Z SN Kotalanol; 214491-07-3; CHEMBL1093264; (1S,2R,3R,4S)-1-{(1S)-2-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrothiophenium-1-yl]-1-hydroxyethyl}-2,3,4,5-tetrahydroxypentyl sulfate; CHEMBL1233894; DTXSID10655282; BDBM50316179; FT-0670687; 1,4-Dideoxy-1,4-[(S)-[7-deoxy-5-O-sulfo-D-glycero-D-galacto-heptitol-7-yl]episulfoniumylidene]-D-arabinitol Inner Salt; 1,4-Dideoxy-1,4-[[2S,3S,4R,5R,6S-2,4,5,6,7-pentahydroxy-3-(sulfooxy)heptyl]-(R-)epi-sulfoniumylidine]-D-arabinitol
DMT1H9Z DT Small molecular drug
DMT1H9Z PC 42632210
DMT1H9Z MW 424.4
DMT1H9Z FM C12H24O12S2
DMT1H9Z IC InChI=1S/C12H24O12S2/c13-1-5(15)10(19)11(20)12(24-26(21,22)23)7(17)4-25-3-6(16)9(18)8(25)2-14/h5-20H,1-4H2/t5-,6+,7+,8+,9-,10+,11+,12+,25?/m0/s1
DMT1H9Z CS C1[C@H]([C@@H]([C@H]([S+]1C[C@H]([C@H]([C@@H]([C@@H]([C@H](CO)O)O)O)OS(=O)(=O)[O-])O)CO)O)O
DMT1H9Z IK OMKXVFDVAGCPBS-GTEYUELZSA-N
DMT1H9Z IU [(2S,3S,4R,5R,6S)-1-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6,7-pentahydroxyheptan-3-yl] sulfate
DMT1H9Z CA CAS 214491-07-3
DMT1H9Z DE Discovery agent
DMUZSJ2 ID DMUZSJ2
DMUZSJ2 DN KP772
DMUZSJ2 HS Investigative
DMUZSJ2 DE Discovery agent
DMC4YGT ID DMC4YGT
DMC4YGT DN KR-33889
DMC4YGT HS Investigative
DMC4YGT SN KR-34285; PARP-1 inhibitors (myocardial infarction), KRICT
DMC4YGT CP Korea Research Institute of Chemical Technology
DMC4YGT DE Myocardial infarction
DMIEKJ4 ID DMIEKJ4
DMIEKJ4 DN KR61639
DMIEKJ4 HS Investigative
DMIEKJ4 DT Small molecular drug
DMIEKJ4 PC 56603772
DMIEKJ4 MW 495.6
DMIEKJ4 FM C31H29NO5
DMIEKJ4 IC InChI=1S/C31H29NO5/c1-31(2,3)37-27(33)18-36-20-14-12-19(13-15-20)16-24-28(25-17-32-26-11-7-6-8-21(25)26)22-9-4-5-10-23(22)29(34)30(24)35/h4-15,17,21,26,32H,16,18H2,1-3H3
DMIEKJ4 CS CC(C)(C)OC(=O)COC1=CC=C(C=C1)CC2=C(C3=CC=CC=C3C(=O)C2=O)C4=CNC5C4C=CC=C5
DMIEKJ4 IK FUPVNXIRQSPKMZ-UHFFFAOYSA-N
DMIEKJ4 IU tert-butyl 2-[4-[[1-(3a,7a-dihydro-1H-indol-3-yl)-3,4-dioxonaphthalen-2-yl]methyl]phenoxy]acetate
DMIEKJ4 DE Discovery agent
DM7G8KR ID DM7G8KR
DM7G8KR DN KR-62436
DM7G8KR HS Investigative
DM7G8KR SN KR-62436; CHEMBL184651; 761414-79-3; KR-60436 free base; SCHEMBL1083441; AOB5513; BDBM50150854; NCGC00165817-01; 6-{2-[2-(5-Cyano-4,5-dihydro-pyrazol-1-yl)-2-oxo-ethylamino]-ethylamino}-nicotinonitrile; 6-(2-(2-(5-cyano-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethylamino)ethylamino)nicotinonitrile; 3-Pyridinecarbonitrile, 6-((2-((2-(5-cyano-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl)amino)ethyl)amino)-; 1H-Pyrazole-5-carbonitrile, 1-(((2-((5-cyano-2-pyridinyl)amino)ethyl)amino)acetyl)-4,5-dihydro-
DM7G8KR DT Small molecular drug
DM7G8KR PC 11403745
DM7G8KR MW 297.32
DM7G8KR FM C14H15N7O
DM7G8KR IC InChI=1S/C14H15N7O/c15-7-11-1-2-13(19-9-11)18-6-5-17-10-14(22)21-12(8-16)3-4-20-21/h1-2,4,9,12,17H,3,5-6,10H2,(H,18,19)
DM7G8KR CS C1C=NN(C1C#N)C(=O)CNCCNC2=NC=C(C=C2)C#N
DM7G8KR IK XNYVGGJJENHRBZ-UHFFFAOYSA-N
DM7G8KR IU 6-[2-[[2-(3-cyano-3,4-dihydropyrazol-2-yl)-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile
DM7G8KR CA CAS 761414-79-3
DM7G8KR DE Non-insulin dependent diabetes
DMXFBER ID DMXFBER
DMXFBER DN KRH-102053
DMXFBER HS Investigative
DMXFBER SN PHD2 activators (hypoxic cancer), Chonbuk National University/SK Chemicals
DMXFBER CP Chonbuk National University
DMXFBER DE Solid tumour/cancer
DMLIK7X ID DMLIK7X
DMLIK7X DN KRP 203-phosphate
DMLIK7X HS Investigative
DMLIK7X SN GTPL2923; SCHEMBL20478074; [2-amino-2-(2-{2-chloro-4-[(3-phenoxyphenyl)sulfanyl]phenyl}ethyl)-3-hydroxypropoxy]phosphonic acid
DMLIK7X DT Small molecular drug
DMLIK7X PC 56947075
DMLIK7X MW 509.9
DMLIK7X FM C23H25ClNO6PS
DMLIK7X IC InChI=1S/C23H25ClNO6PS/c24-22-14-21(10-9-17(22)11-12-23(25,15-26)16-30-32(27,28)29)33-20-8-4-7-19(13-20)31-18-5-2-1-3-6-18/h1-10,13-14,26H,11-12,15-16,25H2,(H2,27,28,29)
DMLIK7X CS C1=CC=C(C=C1)OC2=CC(=CC=C2)SC3=CC(=C(C=C3)CCC(CO)(COP(=O)(O)O)N)Cl
DMLIK7X IK BZVUYJGCYLMFGX-UHFFFAOYSA-N
DMLIK7X IU [2-amino-4-[2-chloro-4-(3-phenoxyphenyl)sulfanylphenyl]-2-(hydroxymethyl)butyl] dihydrogen phosphate
DMLIK7X DE Discovery agent
DMJX9E1 ID DMJX9E1
DMJX9E1 DN KRP-100
DMJX9E1 HS Investigative
DMJX9E1 SN Mu opioid receptor antagonist, Kyorin
DMJX9E1 CP Kyorin Holdings Inc
DMJX9E1 DE Discovery agent
DM5KFBP ID DM5KFBP
DM5KFBP DN KRP-107
DM5KFBP HS Investigative
DM5KFBP CP Kyorin Pharmaceutical Co Ltd
DM5KFBP DE Autoimmune diabetes
DME9HZC ID DME9HZC
DME9HZC DN KRP-110
DME9HZC HS Investigative
DME9HZC SN IDDBCP262221
DME9HZC CP Kyorin Pharmaceutical Co Ltd
DME9HZC DE Constipation
DMC92ER ID DMC92ER
DMC92ER DN KSG-504
DMC92ER HS Investigative
DMC92ER SN 4(R)-[N-(3-Methoxypropyl)-N-pentylcarbamoyl]-5-(2-naphthylsulfonyl)pentanoic acid L-arginine salt monohydrate
DMC92ER DT Small molecular drug
DMC92ER PC 74030547
DMC92ER MW 669.8
DMC92ER FM C31H51N5O9S
DMC92ER IC InChI=1S/C25H35NO6S.C6H14N4O2.H2O/c1-3-4-7-15-26(16-8-17-32-2)25(29)22(12-14-24(27)28)19-33(30,31)23-13-11-20-9-5-6-10-21(20)18-23;7-4(5(11)12)2-1-3-10-6(8)9;/h5-6,9-11,13,18,22H,3-4,7-8,12,14-17,19H2,1-2H3,(H,27,28);4H,1-3,7H2,(H,11,12)(H4,8,9,10);1H2
DMC92ER CS CCCCCN(CCCOC)C(=O)C(CCC(=O)O)CS(=O)(=O)C1=CC2=CC=CC=C2C=C1.C(CC(C(=O)O)N)CN=C(N)N.O
DMC92ER IK XIGWXYNWZKIGCQ-UHFFFAOYSA-N
DMC92ER IU 2-amino-5-(diaminomethylideneamino)pentanoic acid;5-[3-methoxypropyl(pentyl)amino]-4-(naphthalen-2-ylsulfonylmethyl)-5-oxopentanoic acid;hydrate
DMC92ER DE Pancreatic malfunction
DM5DTMQ ID DM5DTMQ
DM5DTMQ DN KSG-LDTKNYKQTSV
DM5DTMQ HS Investigative
DM5DTMQ SN CHEMBL505051; KSG-LDTKNYKQTSV
DM5DTMQ PC 44568938
DM5DTMQ MW 1568.7
DM5DTMQ FM C67H113N19O24
DM5DTMQ IC InChI=1S/C67H113N19O24/c1-32(2)25-42(75-50(94)29-74-56(98)46(30-87)82-55(97)38(71)13-7-10-22-68)60(102)81-45(28-51(95)96)63(105)86-53(34(5)89)65(107)78-40(15-9-12-24-70)58(100)80-44(27-49(73)93)62(104)79-43(26-36-16-18-37(91)19-17-36)61(103)76-39(14-8-11-23-69)57(99)77-41(20-21-48(72)92)59(101)85-54(35(6)90)66(108)83-47(31-88)64(106)84-52(33(3)4)67(109)110/h16-19,32-35,38-47,52-54,87-91H,7-15,20-31,68-71H2,1-6H3,(H2,72,92)(H2,73,93)(H,74,98)(H,75,94)(H,76,103)(H,77,99)(H,78,107)(H,79,104)(H,80,100)(H,81,102)(H,82,97)(H,83,108)(H,84,106)(H,85,101)(H,86,105)(H,95,96)(H,109,110)/t34-,35-,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,52+,53+,54+/m1/s1
DM5DTMQ CS C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)O
DM5DTMQ IK LZIFLRQJFWVNPC-NBGMAUTBSA-N
DM5DTMQ IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylbutanoic acid
DM5DTMQ DE Discovery agent
DMPLFRC ID DMPLFRC
DMPLFRC DN KSG-YEKLSSIESDV
DMPLFRC HS Investigative
DMPLFRC SN CHEMBL445253; KSG-YEKLSSIESDV
DMPLFRC PC 44568937
DMPLFRC MW 1541.7
DMPLFRC FM C66H108N16O26
DMPLFRC IC InChI=1S/C66H108N16O26/c1-7-34(6)53(65(106)74-40(19-21-50(91)92)58(99)78-45(29-84)62(103)76-43(26-51(93)94)61(102)81-52(33(4)5)66(107)108)82-64(105)47(31-86)80-63(104)46(30-85)79-59(100)41(24-32(2)3)75-56(97)38(13-9-11-23-68)72-57(98)39(18-20-49(89)90)73-60(101)42(25-35-14-16-36(87)17-15-35)71-48(88)27-70-55(96)44(28-83)77-54(95)37(69)12-8-10-22-67/h14-17,32-34,37-47,52-53,83-87H,7-13,18-31,67-69H2,1-6H3,(H,70,96)(H,71,88)(H,72,98)(H,73,101)(H,74,106)(H,75,97)(H,76,103)(H,77,95)(H,78,99)(H,79,100)(H,80,104)(H,81,102)(H,82,105)(H,89,90)(H,91,92)(H,93,94)(H,107,108)/t34-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,52-,53-/m0/s1
DMPLFRC CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N
DMPLFRC IK OYOJPGJCPOXGEB-QBAAMSOUSA-N
DMPLFRC IU (4S)-5-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
DMPLFRC DE Discovery agent
DMXBITO ID DMXBITO
DMXBITO DN KSP-BCS-1-alpha-CHF2-1624F2-2
DMXBITO HS Investigative
DMXBITO SN CHEMBL220140; KSP-BCS-1-alpha-CHF2-1624F2-2
DMXBITO DT Small molecular drug
DMXBITO PC 16094778
DMXBITO MW 512.7
DMXBITO FM C30H44F4O2
DMXBITO IC InChI=1S/C30H44F4O2/c1-6-29(36,7-2)30(33,34)16-14-19(3)25-12-13-26-21(9-8-15-28(25,26)5)10-11-22-17-23(35)18-24(20(22)4)27(31)32/h10-12,19,23-24,26-27,35-36H,4,6-9,13-18H2,1-3,5H3/b21-10+,22-11-/t19-,23-,24+,26+,28-/m1/s1
DMXBITO CS CCC(CC)(C(CC[C@@H](C)C1=CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)C(F)F)O)C)(F)F)O
DMXBITO IK CUKDGTJRZFQGCK-HBXJJCJFSA-N
DMXBITO IU (1S,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(2R)-6-ethyl-5,5-difluoro-6-hydroxyoctan-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-5-(difluoromethyl)-4-methylidenecyclohexan-1-ol
DMXBITO DE Discovery agent
DMJV3R7 ID DMJV3R7
DMJV3R7 DN KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH
DMJV3R7 HS Investigative
DMJV3R7 SN CHEMBL376093; KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH
DMJV3R7 DT Small molecular drug
DMJV3R7 PC 16094779
DMJV3R7 MW 494.7
DMJV3R7 FM C30H48F2O3
DMJV3R7 IC InChI=1S/C30H48F2O3/c1-6-30(34,7-2)16-9-17-35-21(4)26-13-14-27-22(10-8-15-29(26,27)5)11-12-23-18-24(33)19-25(20(23)3)28(31)32/h11-12,21,24-28,33-34H,3,6-10,13-19H2,1-2,4-5H3/b22-11+,23-12-/t21-,24-,25+,26-,27+,29-/m1/s1
DMJV3R7 CS CCC(CC)(CCCO[C@H](C)[C@H]1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C/3\\C[C@H](C[C@@H](C3=C)C(F)F)O)C)O
DMJV3R7 IK JHEXIWJRXZGBMA-AFLZJIMUSA-N
DMJV3R7 IU (1S,3Z,5S)-3-[(2E)-2-[(1S,3aS,7aS)-1-[(1R)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-5-(difluoromethyl)-4-methylidenecyclohexan-1-ol
DMJV3R7 DE Discovery agent
DMT0CR5 ID DMT0CR5
DMT0CR5 DN KST-5468
DMT0CR5 HS Investigative
DMT0CR5 SN T-type calcium channel antagonist (pain); T-type calcium channel antagonist (pain), SNU/KIST
DMT0CR5 CP Seoul National University
DMT0CR5 DE Pain
DMOBYU3 ID DMOBYU3
DMOBYU3 DN KT 5823
DMOBYU3 HS Investigative
DMOBYU3 SN kt 5823; KT-5823; KT5823; UNII-WY40BAB02W; 126643-37-6; WY40BAB02W; 9-Methoxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epxoy-1H,8H,11H-2,7b-11a-triazadibenzo(a,g)cycloocta(cde)-trinden-1-one; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-, methyl ester, (9R-(9alpha,10beta,12alpha))-; C29H25N3O5; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10
DMOBYU3 DT Small molecular drug
DMOBYU3 PC 108152
DMOBYU3 MW 495.5
DMOBYU3 FM C29H25N3O5
DMOBYU3 IC InChI=1S/C29H25N3O5/c1-28-29(36-4,27(34)35-3)13-20(37-28)31-18-11-7-5-9-15(18)22-23-17(14-30(2)26(23)33)21-16-10-6-8-12-19(16)32(28)25(21)24(22)31/h5-12,20H,13-14H2,1-4H3/t20-,28+,29+/m1/s1
DMOBYU3 CS C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CN(C6=O)C)(C(=O)OC)OC
DMOBYU3 IK QTYMDECKVKSGSM-YMUMJAELSA-N
DMOBYU3 IU methyl (15S,16R,18R)-16-methoxy-4,15-dimethyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DMOBYU3 CA CAS 126643-37-6
DMOBYU3 CB CHEBI:85102
DMOBYU3 DE Discovery agent
DM9J50F ID DM9J50F
DM9J50F DN KT-5720
DM9J50F HS Investigative
DM9J50F SN KT 5720; KT5720; 108068-98-0; GTPL337; ZINC3873013; KT 5720, > hexyl (15R,16R,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaene-16-carboxylate; (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3 inverted exclamation marka,2 inverted exclamation marka,1 inverted exclamation marka-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-c
DM9J50F DT Small molecular drug
DM9J50F PC 454202
DM9J50F MW 537.6
DM9J50F FM C32H31N3O5
DM9J50F IC InChI=1S/C32H31N3O5/c1-3-4-5-10-15-39-30(37)32(38)16-23-34-21-13-8-6-11-18(21)25-26-20(17-33-29(26)36)24-19-12-7-9-14-22(19)35(28(24)27(25)34)31(32,2)40-23/h6-9,11-14,23,38H,3-5,10,15-17H2,1-2H3,(H,33,36)/t23-,31+,32+/m0/s1
DM9J50F CS CCCCCCOC(=O)[C@@]1(C[C@H]2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)[C@@]1(O2)C)CNC6=O)O
DM9J50F IK ZHEHVZXPFVXKEY-RUAOOFDTSA-N
DM9J50F IU hexyl (15R,16S,18S)-16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylate
DM9J50F CA CAS 108068-98-0
DM9J50F CB CHEBI:85085
DM9J50F DE Discovery agent
DMXIUO5 ID DMXIUO5
DMXIUO5 DN KT6006
DMXIUO5 HS Investigative
DMXIUO5 SN KT 6006; 118736-03-1; 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-5,10,16-trihydroxy-9-methyl-1-oxo-, methyl ester, (9S-(9alpha,10alpha,12alpha))-
DMXIUO5 DT Small molecular drug
DMXIUO5 PC 196744
DMXIUO5 MW 499.5
DMXIUO5 FM C27H21N3O7
DMXIUO5 IC InChI=1S/C27H21N3O7/c1-27-16(26(34)37-35-2)9-19(36-27)29-17-5-3-11(31)7-13(17)21-22-15(10-28-25(22)33)20-14-8-12(32)4-6-18(14)30(27)24(20)23(21)29/h3-8,16,19,31-32H,9-10H2,1-2H3,(H,28,33)/t16-,19-,27+/m1/s1
DMXIUO5 CS C[C@@]12[C@H](C[C@@H](O1)N3C4=C(C=C(C=C4)O)C5=C6C(=C7C8=C(N2C7=C53)C=CC(=C8)O)CNC6=O)C(=O)OOC
DMXIUO5 IK JKEBWJSRGQOXNU-TUZCJGOLSA-N
DMXIUO5 IU methyl (15S,16S,18R)-10,23-dihydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboperoxoate
DMXIUO5 CA CAS 118736-03-1
DMXIUO5 DE Discovery agent
DMRDZ7I ID DMRDZ7I
DMRDZ7I DN KT6528
DMRDZ7I HS Investigative
DMRDZ7I SN AC1L31GQ
DMRDZ7I DT Small molecular drug
DMRDZ7I PC 132714
DMRDZ7I MW 469.4
DMRDZ7I FM C26H19N3O6
DMRDZ7I IC InChI=1S/C26H19N3O6/c1-25-26(33,11-30)10-16(35-25)27-14-8-4-2-6-12(14)17-19-20(24(32)29(34)23(19)31)18-13-7-3-5-9-15(13)28(25)22(18)21(17)27/h2-9,16,30,33-34H,10-11H2,1H3/t16-,25-,26-/m0/s1
DMRDZ7I CS C[C@@]12[C@](C[C@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C(=O)N(C6=O)O)(CO)O
DMRDZ7I IK KNJUOEDHHOTPLA-LADPQGRPSA-N
DMRDZ7I IU (15S,16S,18S)-4,16-dihydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-3,5-dione
DMRDZ7I DE Discovery agent
DMQWS6U ID DMQWS6U
DMQWS6U DN KU-0060648
DMQWS6U HS Investigative
DMQWS6U SN KU 0060648
DMQWS6U DT Small molecular drug
DMQWS6U PC 11964036
DMQWS6U MW 582.7
DMQWS6U FM C33H34N4O4S
DMQWS6U IC InChI=1S/C33H34N4O4S/c1-2-35-12-14-36(15-13-35)21-29(39)34-26-11-10-23(33-31(26)25-6-3-4-9-28(25)42-33)22-7-5-8-24-27(38)20-30(41-32(22)24)37-16-18-40-19-17-37/h3-11,20H,2,12-19,21H2,1H3,(H,34,39)
DMQWS6U CS CCN1CCN(CC1)CC(=O)NC2=C3C4=CC=CC=C4SC3=C(C=C2)C5=CC=CC6=C5OC(=CC6=O)N7CCOCC7
DMQWS6U IK AATCBLYHOUOCTO-UHFFFAOYSA-N
DMQWS6U IU 2-(4-ethylpiperazin-1-yl)-N-[4-(2-morpholin-4-yl-4-oxochromen-8-yl)dibenzothiophen-1-yl]acetamide
DMQWS6U CB CHEBI:94302
DMQWS6U DE Discovery agent
DMDT42X ID DMDT42X
DMDT42X DN KU-55933
DMDT42X HS Investigative
DMDT42X SN KU-55933; 587871-26-9; ATM Kinase Inhibitor; KU55933; 2-Morpholino-6-(thianthren-1-yl)-4H-pyran-4-one; 2-Morpholin-4-yl-6-thianthren-1-ylpyran-4-one; KU 55933; 2-Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one; UNII-O549494L5D; CHEMBL222102; KU-55933 (ATM Kinase Inhibitor); O549494L5D; 2-morpholino-6-thianthren-1-yl-pyran-4-one; 2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one; 4H-Pyran-4-one, 2-(4-morpholinyl)-6-(1-thianthrenyl)-; AC1NQSSP; PubChem22474; cc-73; SCHEMBL1984941; GTPL5928
DMDT42X DT Small molecular drug
DMDT42X PC 5278396
DMDT42X MW 395.5
DMDT42X FM C21H17NO3S2
DMDT42X IC InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7,12-13H,8-11H2
DMDT42X CS C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4
DMDT42X IK XRKYMMUGXMWDAO-UHFFFAOYSA-N
DMDT42X IU 2-morpholin-4-yl-6-thianthren-1-ylpyran-4-one
DMDT42X CA CAS 587871-26-9
DMDT42X CB CHEBI:91372
DMDT42X DE Solid tumour/cancer
DMVGY6K ID DMVGY6K
DMVGY6K DN KU-58684
DMVGY6K HS Investigative
DMVGY6K SN SCHEMBL863338; 623578-11-0
DMVGY6K DT Small molecular drug
DMVGY6K PC 11725479
DMVGY6K MW 351.3
DMVGY6K FM C19H14FN3O3
DMVGY6K IC InChI=1S/C19H14FN3O3/c20-14-6-5-11(10-16(14)23-17(24)7-8-18(23)25)9-15-12-3-1-2-4-13(12)19(26)22-21-15/h1-6,10H,7-9H2,(H,22,26)
DMVGY6K CS C1CC(=O)N(C1=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F
DMVGY6K IK YQSZNYLPVBOGPO-UHFFFAOYSA-N
DMVGY6K IU 1-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]phenyl]pyrrolidine-2,5-dione
DMVGY6K DE Discovery agent
DMAVM94 ID DMAVM94
DMAVM94 DN Kuanoniamine D
DMAVM94 HS Investigative
DMAVM94 SN Kuanoniamine D; CHEMBL127872; BDBM50030271; N-[2-(8H-6-Thia-3,4,8-triaza-benzo[de]cyclopenta[b]anthracen-7-yl)-ethyl]-acetamide; Acetamide, N-(2-(8H-pyrido(4,3,2-mn)thiazolo(4,5-b)acridin-9-yl)ethyl)-
DMAVM94 DT Small molecular drug
DMAVM94 PC 10067080
DMAVM94 MW 360.4
DMAVM94 FM C20H16N4OS
DMAVM94 IC InChI=1S/C20H16N4OS/c1-11(25)21-8-7-14-17-16-13(12-4-2-3-5-15(12)24-17)6-9-22-18(16)19-20(14)26-10-23-19/h2-6,9-10,24H,7-8H2,1H3,(H,21,25)
DMAVM94 CS CC(=O)NCCC1=C2C3=C(C=CN=C3C4=C1SC=N4)C5=CC=CC=C5N2
DMAVM94 IK GUSIRVISUKPQFL-UHFFFAOYSA-N
DMAVM94 IU N-[2-(4-thia-6,9,19-triazapentacyclo[10.7.1.03,7.08,20.013,18]icosa-1,3(7),5,8,10,12(20),13,15,17-nonaen-2-yl)ethyl]acetamide
DMAVM94 CA CAS 133401-13-5
DMAVM94 DE Discovery agent
DMLDUJ1 ID DMLDUJ1
DMLDUJ1 DN Kuraidin
DMLDUJ1 HS Investigative
DMLDUJ1 SN KURAIDIN; kuraridin; CHEMBL243362; PIAPWPAWQGDOMN-SXAWMYDMSA-N; ZINC13817033
DMLDUJ1 DT Small molecular drug
DMLDUJ1 PC 44428631
DMLDUJ1 MW 438.5
DMLDUJ1 FM C26H30O6
DMLDUJ1 IC InChI=1S/C26H30O6/c1-15(2)6-7-18(16(3)4)12-20-23(30)14-24(32-5)25(26(20)31)21(28)11-9-17-8-10-19(27)13-22(17)29/h6,8-11,13-14,18,27,29-31H,3,7,12H2,1-2,4-5H3/b11-9+/t18-/m1/s1
DMLDUJ1 CS CC(=CC[C@H](CC1=C(C(=C(C=C1O)OC)C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)C(=C)C)C
DMLDUJ1 IK PIAPWPAWQGDOMN-SXAWMYDMSA-N
DMLDUJ1 IU (E)-1-[2,4-dihydroxy-6-methoxy-3-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]phenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMLDUJ1 CA CAS 34981-25-4
DMLDUJ1 DE Discovery agent
DMRV5YE ID DMRV5YE
DMRV5YE DN KURARINOL
DMRV5YE HS Investigative
DMRV5YE SN Kurarinol; CHEBI:81093; 855746-98-4; CHEMBL455667; MolPort-039-338-650; ZINC13817026; BDBM50366788; C17444
DMRV5YE DT Small molecular drug
DMRV5YE PC 44563198
DMRV5YE MW 456.5
DMRV5YE FM C26H32O7
DMRV5YE IC InChI=1S/C26H32O7/c1-14(2)15(8-9-26(3,4)31)10-18-20(29)12-23(32-5)24-21(30)13-22(33-25(18)24)17-7-6-16(27)11-19(17)28/h6-7,11-12,15,22,27-29,31H,1,8-10,13H2,2-5H3/t15-,22+/m1/s1
DMRV5YE CS CC(=C)[C@H](CCC(C)(C)O)CC1=C2C(=C(C=C1O)OC)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O
DMRV5YE IK XMUPAAIHKAIUSU-QRQCRPRQSA-N
DMRV5YE IU (2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-8-[(2R)-5-hydroxy-5-methyl-2-prop-1-en-2-ylhexyl]-5-methoxy-2,3-dihydrochromen-4-one
DMRV5YE CA CAS 855746-98-4
DMRV5YE CB CHEBI:81093
DMRV5YE DE Discovery agent
DMH0G8W ID DMH0G8W
DMH0G8W DN Kurarinone
DMH0G8W HS Investigative
DMH0G8W SN (-)-kurarinone; Kurarinone; CHEMBL243796; SCHEMBL10307523; BDBM50208612
DMH0G8W DT Small molecular drug
DMH0G8W PC 11982640
DMH0G8W MW 438.5
DMH0G8W FM C26H30O6
DMH0G8W IC InChI=1S/C26H30O6/c1-14(2)6-7-16(15(3)4)10-19-21(29)12-24(31-5)25-22(30)13-23(32-26(19)25)18-9-8-17(27)11-20(18)28/h6,8-9,11-12,16,23,27-29H,3,7,10,13H2,1-2,4-5H3/t16-,23+/m1/s1
DMH0G8W CS CC(=CC[C@H](CC1=C2C(=C(C=C1O)OC)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O)C(=C)C)C
DMH0G8W IK LTTQKYMNTNISSZ-MWTRTKDXSA-N
DMH0G8W IU (2S)-2-(2,4-dihydroxyphenyl)-7-hydroxy-5-methoxy-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMH0G8W CA CAS 34981-26-5
DMH0G8W CB CHEBI:66150
DMH0G8W DE Discovery agent
DMPKDJ4 ID DMPKDJ4
DMPKDJ4 DN KUR-CXCR4
DMPKDJ4 HS Investigative
DMPKDJ4 CP Tobira Therapeutics Inc
DMPKDJ4 DE Discovery agent
DMCFHPD ID DMCFHPD
DMCFHPD DN KUSHENOL A
DMCFHPD HS Investigative
DMCFHPD SN Kushenol A; 99217-63-7; CHEMBL455679; MolPort-039-337-120; BDBM50377945; ZINC33832185; AKOS032948966
DMCFHPD DT Small molecular drug
DMCFHPD PC 44563121
DMCFHPD MW 408.5
DMCFHPD FM C25H28O5
DMCFHPD IC InChI=1S/C25H28O5/c1-14(2)9-10-16(15(3)4)11-18-20(27)12-21(28)24-22(29)13-23(30-25(18)24)17-7-5-6-8-19(17)26/h5-9,12,16,23,26-28H,3,10-11,13H2,1-2,4H3/t16-,23+/m1/s1
DMCFHPD CS CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=CC=C3O)C(=C)C)C
DMCFHPD IK OGBMVWVBHWHRGD-MWTRTKDXSA-N
DMCFHPD IU (2S)-5,7-dihydroxy-2-(2-hydroxyphenyl)-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMCFHPD CA CAS 99217-63-7
DMCFHPD DE Discovery agent
DMY13UR ID DMY13UR
DMY13UR DN Kushenol N
DMY13UR HS Investigative
DMY13UR SN NSC668937; Kushenol N; 2-(2,4-Dihydroxyphenyl)-3,7-dihydroxy-8-(2-isopropenyl-5-methyl-4-hexenyl)-5-methoxy-2,3-dihydro-4H-chromen-4-one; 102490-65-3; 4H-1-Benzopyran-4-one,2-(2,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-5-methoxy-8-[(2R)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-,(2R,3S)-; ACMC-20bulp; AC1Q6KJK; AC1L8I5S; CTK4A1130; DTXSID50327597; NSC-668937; NCI60_024046; 2-(2,4-dihydroxyphenyl)-3,7-dihydroxy-8-(2-isopropenyl-5-methyl-hex-4-enyl)-5-methoxy-chroman-4-one
DMY13UR DT Small molecular drug
DMY13UR PC 381851
DMY13UR MW 454.5
DMY13UR FM C26H30O7
DMY13UR IC InChI=1S/C26H30O7/c1-13(2)6-7-15(14(3)4)10-18-20(29)12-21(32-5)22-23(30)24(31)26(33-25(18)22)17-9-8-16(27)11-19(17)28/h6,8-9,11-12,15,24,26-29,31H,3,7,10H2,1-2,4-5H3
DMY13UR CS CC(=CCC(CC1=C2C(=C(C=C1O)OC)C(=O)C(C(O2)C3=C(C=C(C=C3)O)O)O)C(=C)C)C
DMY13UR IK QKEDJCCCNZWOBS-UHFFFAOYSA-N
DMY13UR IU 2-(2,4-dihydroxyphenyl)-3,7-dihydroxy-5-methoxy-8-(5-methyl-2-prop-1-en-2-ylhex-4-enyl)-2,3-dihydrochromen-4-one
DMY13UR CA CAS 102490-65-3
DMY13UR DE Discovery agent
DMVQDNR ID DMVQDNR
DMVQDNR DN kuwanon H
DMVQDNR HS Investigative
DMVQDNR SN Kuwanon H; Kuwanone H; 76472-87-2; CHEBI:6147; kumanon H; AC1NQYUS; GTPL622; SCHEMBL150578; CHEMBL506234; ZINC8234329; 8-[(1S,5R,6S)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methyl-1-cyclohex-2-enyl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one; C10100
DMVQDNR DT Small molecular drug
DMVQDNR PC 5281668
DMVQDNR MW 760.8
DMVQDNR FM C45H44O11
DMVQDNR IC InChI=1S/C45H44O11/c1-21(2)6-10-27-33(48)15-14-29(41(27)53)42(54)38-31(26-12-8-24(46)18-34(26)49)16-23(5)17-32(38)39-36(51)20-37(52)40-43(55)30(11-7-22(3)4)44(56-45(39)40)28-13-9-25(47)19-35(28)50/h6-9,12-15,17-20,31-32,38,46-53H,10-11,16H2,1-5H3/t31-,32-,38-/m0/s1
DMVQDNR CS CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C(C=C(C5=C4OC(=C(C5=O)CC=C(C)C)C6=C(C=C(C=C6)O)O)O)O
DMVQDNR IK DKBPTKFKCCNXNH-QXGWMLRCSA-N
DMVQDNR IU 8-[(1S,5R,6S)-6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3-methylbut-2-enyl)chromen-4-one
DMVQDNR CA CAS 76472-87-2
DMVQDNR CB CHEBI:6147
DMVQDNR DE Discovery agent
DMFSUJB ID DMFSUJB
DMFSUJB DN Kuwanon J
DMFSUJB HS Investigative
DMFSUJB SN CHEMBL570475
DMFSUJB DT Small molecular drug
DMFSUJB PC 10394786
DMFSUJB MW 678.7
DMFSUJB FM C40H38O10
DMFSUJB IC InChI=1S/C40H38O10/c1-20(2)4-9-26-32(44)14-12-28(38(26)48)40(50)36-29(25-10-8-24(42)19-35(25)47)16-21(3)17-30(36)37-33(45)15-11-27(39(37)49)31(43)13-6-22-5-7-23(41)18-34(22)46/h4-8,10-15,17-19,29-30,36,41-42,44-49H,9,16H2,1-3H3/b13-6+
DMFSUJB CS CC1=CC(C(C(C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)C(=O)/C=C/C5=C(C=C(C=C5)O)O)O
DMFSUJB IK KBAPHKOHTBBCTO-AWNIVKPZSA-N
DMFSUJB IU (E)-1-[3-[6-[2,4-dihydroxy-3-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMFSUJB CA CAS 83709-26-6
DMFSUJB DE Discovery agent
DMX4D1Q ID DMX4D1Q
DMX4D1Q DN Kuwanon L
DMX4D1Q HS Investigative
DMX4D1Q SN Kuwanon L; CHEMBL377937; 88524-65-6; AC1L4FQH; CTK5G0055; 4H-1-Benzopyran-4-one,2-[3-[(1S,5R,6S)-6- (2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)- 3-methyl-2-cyclohexen-1-yl]-2,4- dihydroxyphenyl]-2,3-dihydro-5,7-dihydroxy-,(2S)-; BDBM50179009; AKOS030566805; 4H-1-Benzopyran-4-one, 2-(3-(6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methyl-2-cyclohexen-1-yl)-2,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (1S-(1alpha(R*),5alpha,6beta))-
DMX4D1Q DT Small molecular drug
DMX4D1Q PC 184877
DMX4D1Q MW 626.6
DMX4D1Q FM C35H30O11
DMX4D1Q IC InChI=1S/C35H30O11/c1-15-8-22(19-4-2-16(36)10-25(19)40)31(34(44)20-5-3-17(37)11-26(20)41)23(9-15)32-24(39)7-6-21(35(32)45)29-14-28(43)33-27(42)12-18(38)13-30(33)46-29/h2-7,9-13,22-23,29,31,36-42,45H,8,14H2,1H3/t22-,23-,29-,31-/m0/s1
DMX4D1Q CS CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C=CC(=C4O)[C@@H]5CC(=O)C6=C(C=C(C=C6O5)O)O)O
DMX4D1Q IK ZEZOBFSLMMTYFF-HQSFFLIMSA-N
DMX4D1Q IU (2S)-2-[3-[(1S,5R,6S)-6-(2,4-dihydroxybenzoyl)-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one
DMX4D1Q CA CAS 88524-65-6
DMX4D1Q DE Discovery agent
DMEZOT9 ID DMEZOT9
DMEZOT9 DN Kuwanon R
DMEZOT9 HS Investigative
DMEZOT9 SN CHEMBL570526
DMEZOT9 DT Small molecular drug
DMEZOT9 PC 45485202
DMEZOT9 MW 662.7
DMEZOT9 FM C40H38O9
DMEZOT9 IC InChI=1S/C40H38O9/c1-21(2)4-11-28-34(45)18-24(19-35(28)46)39(48)37-30(27-12-10-26(42)20-36(27)47)16-22(3)17-31(37)38-33(44)15-13-29(40(38)49)32(43)14-7-23-5-8-25(41)9-6-23/h4-10,12-15,17-20,30-31,37,41-42,44-47,49H,11,16H2,1-3H3/b14-7+/t30-,31+,37-/m1/s1
DMEZOT9 CS CC1=C[C@@H]([C@@H]([C@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=CC(=C(C(=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)C(=O)/C=C/C5=CC=C(C=C5)O)O
DMEZOT9 IK PXFKYAIDSYKIJA-DLBCFTNOSA-N
DMEZOT9 IU (E)-1-[3-[(1S,5S,6R)-6-[3,5-dihydroxy-4-(3-methylbut-2-enyl)benzoyl]-5-(2,4-dihydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
DMEZOT9 DE Discovery agent
DM84M20 ID DM84M20
DM84M20 DN Kuwanon V
DM84M20 HS Investigative
DM84M20 SN CHEMBL570609
DM84M20 DT Small molecular drug
DM84M20 PC 45485203
DM84M20 MW 646.7
DM84M20 FM C40H38O8
DM84M20 IC InChI=1S/C40H38O8/c1-22(2)4-14-29-35(45)20-26(21-36(29)46)39(47)37-31(25-8-12-28(42)13-9-25)18-23(3)19-32(37)38-34(44)17-15-30(40(38)48)33(43)16-7-24-5-10-27(41)11-6-24/h4-13,15-17,19-21,31-32,37,41-42,44-46,48H,14,18H2,1-3H3/b16-7+/t31-,32+,37-/m1/s1
DM84M20 CS CC1=C[C@@H]([C@@H]([C@H](C1)C2=CC=C(C=C2)O)C(=O)C3=CC(=C(C(=C3)O)CC=C(C)C)O)C4=C(C=CC(=C4O)C(=O)/C=C/C5=CC=C(C=C5)O)O
DM84M20 IK MYKDNKGHXHALEF-SJIVMEQQSA-N
DM84M20 IU (E)-1-[3-[(1S,5S,6R)-6-[3,5-dihydroxy-4-(3-methylbut-2-enyl)benzoyl]-5-(4-hydroxyphenyl)-3-methylcyclohex-2-en-1-yl]-2,4-dihydroxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
DM84M20 DE Discovery agent
DM7RFUC ID DM7RFUC
DM7RFUC DN KwFwLL-NH2
DM7RFUC HS Investigative
DM7RFUC SN CHEMBL506986; KwFwLL-NH2
DM7RFUC DT Small molecular drug
DM7RFUC PC 44576247
DM7RFUC MW 891.1
DM7RFUC FM C49H66N10O6
DM7RFUC IC InChI=1S/C49H66N10O6/c1-29(2)22-39(44(52)60)55-46(62)40(23-30(3)4)57-49(65)43(26-33-28-54-38-20-11-9-17-35(33)38)59-47(63)41(24-31-14-6-5-7-15-31)58-48(64)42(56-45(61)36(51)18-12-13-21-50)25-32-27-53-37-19-10-8-16-34(32)37/h5-11,14-17,19-20,27-30,36,39-43,53-54H,12-13,18,21-26,50-51H2,1-4H3,(H2,52,60)(H,55,62)(H,56,61)(H,57,65)(H,58,64)(H,59,63)/t36-,39-,40-,41-,42+,43+/m0/s1
DM7RFUC CS CC(C)C[C@@H](C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCCN)N
DM7RFUC IK ZGQSDHNDIKTEJD-XLAQBFAFSA-N
DM7RFUC IU (2S)-2,6-diamino-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]hexanamide
DM7RFUC DE Discovery agent
DMA9VBD ID DMA9VBD
DMA9VBD DN KY-382
DMA9VBD HS Investigative
DMA9VBD CP Kyoto Pharmaceutical Industries Ltd
DMA9VBD PC 10454368
DMA9VBD MW 412.5
DMA9VBD FM C19H32N4O4S
DMA9VBD IC InChI=1S/C19H32N4O4S/c1-7-27-11-10-23-9-8-14-12(2)15(22-28(20,25)26)13(3)16(17(14)23)21-18(24)19(4,5)6/h22H,7-11H2,1-6H3,(H,21,24)(H2,20,25,26)
DMA9VBD CS CCOCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)NS(=O)(=O)N)C
DMA9VBD IK PXCNVWWWTVXCME-UHFFFAOYSA-N
DMA9VBD IU N-[1-(2-ethoxyethyl)-4,6-dimethyl-5-(sulfamoylamino)-2,3-dihydroindol-7-yl]-2,2-dimethylpropanamide
DMA9VBD DE Arteriosclerosis
DM3MID9 ID DM3MID9
DM3MID9 DN KYS-05001
DM3MID9 HS Investigative
DM3MID9 SN KYS-05001; CHEMBL114695; SCHEMBL14417320; BDBM50148175; N-Benzyl-2-(3-phenyl-2-piperidin-1-yl-3,4-dihydro-quinazolin-4-yl)-acetamide
DM3MID9 DT Small molecular drug
DM3MID9 PC 9980573
DM3MID9 MW 438.6
DM3MID9 FM C28H30N4O
DM3MID9 IC InChI=1S/C28H30N4O/c33-27(29-21-22-12-4-1-5-13-22)20-26-24-16-8-9-17-25(24)30-28(31-18-10-3-11-19-31)32(26)23-14-6-2-7-15-23/h1-2,4-9,12-17,26H,3,10-11,18-21H2,(H,29,33)
DM3MID9 CS C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
DM3MID9 IK IROXHJVGJHVBSD-UHFFFAOYSA-N
DM3MID9 IU N-benzyl-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DM3MID9 DE Discovery agent
DM1JU8F ID DM1JU8F
DM1JU8F DN KYS-05040
DM1JU8F HS Investigative
DM1JU8F SN KYS-05040; CHEMBL115159; SCHEMBL14417350; BDBM50148177; N-(4-Amino-benzyl)-2-(3-phenyl-2-piperidin-1-yl-3,4-dihydro-quinazolin-4-yl)-acetamide
DM1JU8F DT Small molecular drug
DM1JU8F PC 44342044
DM1JU8F MW 453.6
DM1JU8F FM C28H31N5O
DM1JU8F IC InChI=1S/C28H31N5O/c29-22-15-13-21(14-16-22)20-30-27(34)19-26-24-11-5-6-12-25(24)31-28(32-17-7-2-8-18-32)33(26)23-9-3-1-4-10-23/h1,3-6,9-16,26H,2,7-8,17-20,29H2,(H,30,34)
DM1JU8F CS C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=C(C=C5)N
DM1JU8F IK NEMYASVJMUEWED-UHFFFAOYSA-N
DM1JU8F IU N-[(4-aminophenyl)methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DM1JU8F DE Discovery agent
DMVA6LH ID DMVA6LH
DMVA6LH DN KYS-05041
DMVA6LH HS Investigative
DMVA6LH PC 10031616
DMVA6LH MW 607.8
DMVA6LH FM C35H37N5O3S
DMVA6LH IC InChI=1S/C35H37N5O3S/c1-26-14-20-30(21-15-26)44(42,43)38-28-18-16-27(17-19-28)25-36-34(41)24-33-31-12-6-7-13-32(31)37-35(39-22-8-3-9-23-39)40(33)29-10-4-2-5-11-29/h2,4-7,10-21,33,38H,3,8-9,22-25H2,1H3,(H,36,41)
DMVA6LH CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CNC(=O)CC3C4=CC=CC=C4N=C(N3C5=CC=CC=C5)N6CCCCC6
DMVA6LH IK TWRWYNXGPAASHN-UHFFFAOYSA-N
DMVA6LH IU N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DMVA6LH DE Discovery agent
DMM6G4H ID DMM6G4H
DMM6G4H DN KYS-05042
DMM6G4H HS Investigative
DMM6G4H PC 10416322
DMM6G4H MW 611.7
DMM6G4H FM C34H34FN5O3S
DMM6G4H IC InChI=1S/C34H34FN5O3S/c35-26-15-19-29(20-16-26)44(42,43)38-27-17-13-25(14-18-27)24-36-33(41)23-32-30-11-5-6-12-31(30)37-34(39-21-7-2-8-22-39)40(32)28-9-3-1-4-10-28/h1,3-6,9-20,32,38H,2,7-8,21-24H2,(H,36,41)
DMM6G4H CS C1CCN(CC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=C(C=C5)NS(=O)(=O)C6=CC=C(C=C6)F
DMM6G4H IK RMQZAKOLGVUVAD-UHFFFAOYSA-N
DMM6G4H IU N-[[4-[(4-fluorophenyl)sulfonylamino]phenyl]methyl]-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DMM6G4H DE Discovery agent
DMXR3V4 ID DMXR3V4
DMXR3V4 DN KYS-05050
DMXR3V4 HS Investigative
DMXR3V4 DT Small molecular drug
DMXR3V4 PC 135401968
DMXR3V4 MW 531.7
DMXR3V4 FM C34H37N5O
DMXR3V4 IC InChI=1S/C34H37N5O/c35-22-10-3-11-23-36-34-38-31-17-9-8-16-30(31)32(24-33(40)37-25-26-12-4-1-5-13-26)39(34)29-20-18-28(19-21-29)27-14-6-2-7-15-27/h1-2,4-9,12-21,32H,3,10-11,22-25,35H2,(H,36,38)(H,37,40)
DMXR3V4 CS C1=CC=C(C=C1)CNC(=O)CC2C3=CC=CC=C3NC(=NCCCCCN)N2C4=CC=C(C=C4)C5=CC=CC=C5
DMXR3V4 IK PHOBNPDRNIKURV-UHFFFAOYSA-N
DMXR3V4 IU 2-[2-(5-aminopentylimino)-3-(4-phenylphenyl)-1,4-dihydroquinazolin-4-yl]-N-benzylacetamide
DMXR3V4 DE Solid tumour/cancer
DMRVOT7 ID DMRVOT7
DMRVOT7 DN KYS-05055
DMRVOT7 HS Investigative
DMRVOT7 SN KYS-05055; CHEMBL457084; SCHEMBL14417339; BDBM50251383; N-(4-nitrobenzyl)-2-(2-(dimethylamino)-3-phenyl-3,4-dihydroquinazolin-4-yl)acetamide
DMRVOT7 DT Small molecular drug
DMRVOT7 PC 44567629
DMRVOT7 MW 443.5
DMRVOT7 FM C25H25N5O3
DMRVOT7 IC InChI=1S/C25H25N5O3/c1-28(2)25-27-22-11-7-6-10-21(22)23(29(25)19-8-4-3-5-9-19)16-24(31)26-17-18-12-14-20(15-13-18)30(32)33/h3-15,23H,16-17H2,1-2H3,(H,26,31)
DMRVOT7 CS CN(C)C1=NC2=CC=CC=C2C(N1C3=CC=CC=C3)CC(=O)NCC4=CC=C(C=C4)[N+](=O)[O-]
DMRVOT7 IK HCOLRSVHDDZVKO-UHFFFAOYSA-N
DMRVOT7 IU 2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]-N-[(4-nitrophenyl)methyl]acetamide
DMRVOT7 DE Discovery agent
DMP6S0L ID DMP6S0L
DMP6S0L DN KYS-05056
DMP6S0L HS Investigative
DMP6S0L SN KYS-05056; CHEMBL459245; SCHEMBL14417338; BDBM50251382
DMP6S0L DT Small molecular drug
DMP6S0L PC 44567628
DMP6S0L MW 413.5
DMP6S0L FM C25H27N5O
DMP6S0L IC InChI=1S/C25H27N5O/c1-29(2)25-28-22-11-7-6-10-21(22)23(30(25)20-8-4-3-5-9-20)16-24(31)27-17-18-12-14-19(26)15-13-18/h3-15,23H,16-17,26H2,1-2H3,(H,27,31)
DMP6S0L CS CN(C)C1=NC2=CC=CC=C2C(N1C3=CC=CC=C3)CC(=O)NCC4=CC=C(C=C4)N
DMP6S0L IK ADQNFSXMHBVQJA-UHFFFAOYSA-N
DMP6S0L IU N-[(4-aminophenyl)methyl]-2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]acetamide
DMP6S0L DE Discovery agent
DM7BYG8 ID DM7BYG8
DM7BYG8 DN KYS-05057
DM7BYG8 HS Investigative
DM7BYG8 SN KYS-05057; CHEMBL460646; SCHEMBL14417341; BDBM50251823; N-(4-(4-methylphenylsulfonamido)benzyl)-2-(2-(dimethylamino)-3-phenyl-3,4-dihydroquinazolin-4-yl)acetamide
DM7BYG8 DT Small molecular drug
DM7BYG8 PC 44568141
DM7BYG8 MW 567.7
DM7BYG8 FM C32H33N5O3S
DM7BYG8 IC InChI=1S/C32H33N5O3S/c1-23-13-19-27(20-14-23)41(39,40)35-25-17-15-24(16-18-25)22-33-31(38)21-30-28-11-7-8-12-29(28)34-32(36(2)3)37(30)26-9-5-4-6-10-26/h4-20,30,35H,21-22H2,1-3H3,(H,33,38)
DM7BYG8 CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CNC(=O)CC3C4=CC=CC=C4N=C(N3C5=CC=CC=C5)N(C)C
DM7BYG8 IK BUARRUHMMCHOQJ-UHFFFAOYSA-N
DM7BYG8 IU 2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]-N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]acetamide
DM7BYG8 DE Discovery agent
DM61GPQ ID DM61GPQ
DM61GPQ DN KYS-05064
DM61GPQ HS Investigative
DM61GPQ SN KYS-05064; CHEMBL217660; SCHEMBL14417343; BDBM50192101; 2-(3-ethyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)-N-(4-(4-methylphenylsulfonamido)benzyl)acetamide
DM61GPQ DT Small molecular drug
DM61GPQ PC 11964508
DM61GPQ MW 559.7
DM61GPQ FM C31H37N5O3S
DM61GPQ IC InChI=1S/C31H37N5O3S/c1-3-36-29(27-9-5-6-10-28(27)33-31(36)35-19-7-4-8-20-35)21-30(37)32-22-24-13-15-25(16-14-24)34-40(38,39)26-17-11-23(2)12-18-26/h5-6,9-18,29,34H,3-4,7-8,19-22H2,1-2H3,(H,32,37)
DM61GPQ CS CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=C(C=C4)NS(=O)(=O)C5=CC=C(C=C5)C
DM61GPQ IK AAULUGZZFCAQJP-UHFFFAOYSA-N
DM61GPQ IU 2-(3-ethyl-2-piperidin-1-yl-4H-quinazolin-4-yl)-N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]acetamide
DM61GPQ DE Discovery agent
DMA8LFD ID DMA8LFD
DMA8LFD DN KYS-05065
DMA8LFD HS Investigative
DMA8LFD SN KYS-05065; CHEMBL480968; SCHEMBL14417346; BDBM50251822; N-(4-(4-fluorophenylsulfonamido)benzyl)-2-(3-ethyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)acetamide
DMA8LFD DT Small molecular drug
DMA8LFD PC 44568140
DMA8LFD MW 563.7
DMA8LFD FM C30H34FN5O3S
DMA8LFD IC InChI=1S/C30H34FN5O3S/c1-2-36-28(26-8-4-5-9-27(26)33-30(36)35-18-6-3-7-19-35)20-29(37)32-21-22-10-14-24(15-11-22)34-40(38,39)25-16-12-23(31)13-17-25/h4-5,8-17,28,34H,2-3,6-7,18-21H2,1H3,(H,32,37)
DMA8LFD CS CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=C(C=C4)NS(=O)(=O)C5=CC=C(C=C5)F
DMA8LFD IK PEIFDCMYVCGNKX-UHFFFAOYSA-N
DMA8LFD IU 2-(3-ethyl-2-piperidin-1-yl-4H-quinazolin-4-yl)-N-[[4-[(4-fluorophenyl)sulfonylamino]phenyl]methyl]acetamide
DMA8LFD DE Discovery agent
DMRJQY3 ID DMRJQY3
DMRJQY3 DN KYS-05070
DMRJQY3 HS Investigative
DMRJQY3 SN KYS-05070; CHEMBL214498; SCHEMBL14417348
DMRJQY3 DT Small molecular drug
DMRJQY3 PC 44416787
DMRJQY3 MW 519.7
DMRJQY3 FM C28H33N5O3S
DMRJQY3 IC InChI=1S/C28H33N5O3S/c1-5-33-26(24-8-6-7-9-25(24)30-28(33)32(3)4)18-27(34)29-19-21-12-14-22(15-13-21)31-37(35,36)23-16-10-20(2)11-17-23/h6-17,26,31H,5,18-19H2,1-4H3,(H,29,34)
DMRJQY3 CS CCN1C(C2=CC=CC=C2N=C1N(C)C)CC(=O)NCC3=CC=C(C=C3)NS(=O)(=O)C4=CC=C(C=C4)C
DMRJQY3 IK UBFZYFFOQNFRPD-UHFFFAOYSA-N
DMRJQY3 IU 2-[2-(dimethylamino)-3-ethyl-4H-quinazolin-4-yl]-N-[[4-[(4-methylphenyl)sulfonylamino]phenyl]methyl]acetamide
DMRJQY3 DE Discovery agent
DM7K5Z3 ID DM7K5Z3
DM7K5Z3 DN KYS-05071
DM7K5Z3 HS Investigative
DM7K5Z3 SN KYS-05071; CHEMBL214951
DM7K5Z3 DT Small molecular drug
DM7K5Z3 PC 44416758
DM7K5Z3 MW 523.6
DM7K5Z3 FM C27H30FN5O3S
DM7K5Z3 IC InChI=1S/C27H30FN5O3S/c1-4-33-25(23-7-5-6-8-24(23)30-27(33)32(2)3)17-26(34)29-18-19-9-13-21(14-10-19)31-37(35,36)22-15-11-20(28)12-16-22/h5-16,25,31H,4,17-18H2,1-3H3,(H,29,34)
DM7K5Z3 CS CCN1C(C2=CC=CC=C2N=C1N(C)C)CC(=O)NCC3=CC=C(C=C3)NS(=O)(=O)C4=CC=C(C=C4)F
DM7K5Z3 IK HWGHVXQPQONJBP-UHFFFAOYSA-N
DM7K5Z3 IU 2-[2-(dimethylamino)-3-ethyl-4H-quinazolin-4-yl]-N-[[4-[(4-fluorophenyl)sulfonylamino]phenyl]methyl]acetamide
DM7K5Z3 DE Discovery agent
DMYRWQ3 ID DMYRWQ3
DMYRWQ3 DN KYS-05074
DMYRWQ3 HS Investigative
DMYRWQ3 SN KYS-05074; CHEMBL384090
DMYRWQ3 DT Small molecular drug
DMYRWQ3 PC 44416844
DMYRWQ3 MW 390.5
DMYRWQ3 FM C24H30N4O
DMYRWQ3 IC InChI=1S/C24H30N4O/c1-2-28-22(17-23(29)25-18-19-11-5-3-6-12-19)20-13-7-8-14-21(20)26-24(28)27-15-9-4-10-16-27/h3,5-8,11-14,22H,2,4,9-10,15-18H2,1H3,(H,25,29)
DMYRWQ3 CS CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=CC=C4
DMYRWQ3 IK OTPISXIISBCQOC-UHFFFAOYSA-N
DMYRWQ3 IU N-benzyl-2-(3-ethyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
DMYRWQ3 DE Discovery agent
DMHW40F ID DMHW40F
DMHW40F DN KYS-05077
DMHW40F HS Investigative
DMHW40F SN KYS-05077; CHEMBL393304; BDBM50197241; BDBM50005356
DMHW40F DT Small molecular drug
DMHW40F PC 25112470
DMHW40F MW 523.7
DMHW40F FM C33H41N5O
DMHW40F IC InChI=1S/C33H41N5O/c1-36(21-11-4-12-22-37-23-13-14-24-37)33-35-30-20-10-9-19-29(30)31(38(33)28-17-7-3-8-18-28)25-32(39)34-26-27-15-5-2-6-16-27/h2-3,5-10,15-20,31H,4,11-14,21-26H2,1H3,(H,34,39)
DMHW40F CS CN(CCCCCN1CCCC1)C2=NC3=CC=CC=C3C(N2C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
DMHW40F IK DKHAGFIMNLTLHC-UHFFFAOYSA-N
DMHW40F IU N-benzyl-2-[2-[methyl(5-pyrrolidin-1-ylpentyl)amino]-3-phenyl-4H-quinazolin-4-yl]acetamide
DMHW40F DE Discovery agent
DM57BXZ ID DM57BXZ
DM57BXZ DN KYS-05080
DM57BXZ HS Investigative
DM57BXZ SN KYS-05080; CHEMBL248088; SCHEMBL10019252; BDBM50197240; N-benzyl-2-{3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetamide
DM57BXZ DT Small molecular drug
DM57BXZ PC 16048644
DM57BXZ MW 599.8
DM57BXZ FM C39H45N5O
DM57BXZ IC InChI=1S/C39H45N5O/c1-42(25-11-4-12-26-43-27-13-14-28-43)39-41-36-20-10-9-19-35(36)37(29-38(45)40-30-31-15-5-2-6-16-31)44(39)34-23-21-33(22-24-34)32-17-7-3-8-18-32/h2-3,5-10,15-24,37H,4,11-14,25-30H2,1H3,(H,40,45)
DM57BXZ CS CN(CCCCCN1CCCC1)C2=NC3=CC=CC=C3C(N2C4=CC=C(C=C4)C5=CC=CC=C5)CC(=O)NCC6=CC=CC=C6
DM57BXZ IK SXLKSZQOUGOJGV-UHFFFAOYSA-N
DM57BXZ IU N-benzyl-2-[2-[methyl(5-pyrrolidin-1-ylpentyl)amino]-3-(4-phenylphenyl)-4H-quinazolin-4-yl]acetamide
DM57BXZ DE Discovery agent
DM92RHP ID DM92RHP
DM92RHP DN KYS-05090
DM92RHP HS Investigative
DM92RHP SN KYS-05090; CHEMBL394956; CHEMBL1269457; SCHEMBL10019253; BDBM50222222; N-benzyl-2-(3-(biphenyl-4-yl)-2-((5-(dimethylamino)pentyl)(methyl)amino)-3,4-dihydroquinazolin-4-yl)acetamide; N-Benzyl-3-(4-biphenylyl)-2-[5-(dimethylamino)pentyl(methyl)amino]-3,4-dihydroquinazoline-4-acetamide
DM92RHP DT Small molecular drug
DM92RHP PC 23661603
DM92RHP MW 573.8
DM92RHP FM C37H43N5O
DM92RHP IC InChI=1S/C37H43N5O/c1-40(2)25-13-6-14-26-41(3)37-39-34-20-12-11-19-33(34)35(27-36(43)38-28-29-15-7-4-8-16-29)42(37)32-23-21-31(22-24-32)30-17-9-5-10-18-30/h4-5,7-12,15-24,35H,6,13-14,25-28H2,1-3H3,(H,38,43)
DM92RHP CS CN(C)CCCCCN(C)C1=NC2=CC=CC=C2C(N1C3=CC=C(C=C3)C4=CC=CC=C4)CC(=O)NCC5=CC=CC=C5
DM92RHP IK QVXCZTNUVKNCGU-UHFFFAOYSA-N
DM92RHP IU N-benzyl-2-[2-[5-(dimethylamino)pentyl-methylamino]-3-(4-phenylphenyl)-4H-quinazolin-4-yl]acetamide
DM92RHP DE Discovery agent
DMB73Y4 ID DMB73Y4
DMB73Y4 DN L 691121
DMB73Y4 HS Investigative
DMB73Y4 SN L 691121 001X
DMB73Y4 DT Small molecular drug
DMB73Y4 PC 164390
DMB73Y4 MW 493
DMB73Y4 FM C22H25ClN4O5S
DMB73Y4 IC InChI=1S/C22H24N4O5S.ClH/c1-32(28,29)25-16-3-5-21-17(13-16)20(27)14-22(30-21)7-10-26(11-8-22)9-6-15-2-4-18-19(12-15)24-31-23-18;/h2-5,12-13,25H,6-11,14H2,1H3;1H
DMB73Y4 CS CS(=O)(=O)NC1=CC2=C(C=C1)OC3(CCN(CC3)CCC4=CC5=NON=C5C=C4)CC2=O.Cl
DMB73Y4 IK NHRIUQWDVKKIAZ-UHFFFAOYSA-N
DMB73Y4 IU N-[1'-[2-(2,1,3-benzoxadiazol-5-yl)ethyl]-4-oxospiro[3H-chromene-2,4'-piperidine]-6-yl]methanesulfonamide;hydrochloride
DMB73Y4 CA CAS 136075-60-0
DMB73Y4 DE Discovery agent
DMK07MI ID DMK07MI
DMK07MI DN L-(cis)-diltiazem
DMK07MI HS Investigative
DMK07MI SN L-cis-diltiazem; CHEBI:82813; [(2R,3R)-5-(2-dimethylaminoethyl)-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate; L-(cis)-diltiazem; ent-diltiazem; cis-3-Acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one; (-)-cis-diltiazem; Lopac-D-2521; BSPBio_001357; SCHEMBL676914; GTPL2349; AC1L54N5; CHEMBL1397935; ZINC601259; HMS1791D19; HMS1989D19; NCGC00016818-04; NCGC00015332-01; NCGC00163133-03; NCGC00015332-02; NCGC00016818-01; CAS-33286-22-5; BRD-K81029756-001-02-8
DMK07MI DT Small molecular drug
DMK07MI PC 198107
DMK07MI MW 414.5
DMK07MI FM C22H26N2O4S
DMK07MI IC InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m0/s1
DMK07MI CS CC(=O)O[C@H]1[C@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
DMK07MI IK HSUGRBWQSSZJOP-LEWJYISDSA-N
DMK07MI IU [(2R,3R)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
DMK07MI CA CAS 56209-45-1
DMK07MI CB CHEBI:82813
DMK07MI DE Discovery agent
DMYWD6C ID DMYWD6C
DMYWD6C DN L000021649
DMYWD6C HS Investigative
DMYWD6C SN pyrazolo[1,5-a]pyrimidine 4e; AC1NS6UK; SCHEMBL7622425; L000021649; CHEMBL333021; BDBM5413; VOYMOBPSYVKQGF-UHFFFAOYSA-N; 3-(3-Thienyl)-6-[4-(2-piperidinoethoxy)phenyl]pyrazolo[1,5-a]pyrimidine; 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-thiophen-3-ylpyrazolo[1,5-a]pyrimidine; 1-(2-{4-[3-(thiophen-3-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenoxy}ethyl)piperidine
DMYWD6C DT Small molecular drug
DMYWD6C PC 5329450
DMYWD6C MW 404.5
DMYWD6C FM C23H24N4OS
DMYWD6C IC InChI=1S/C23H24N4OS/c1-2-9-26(10-3-1)11-12-28-21-6-4-18(5-7-21)20-14-24-23-22(15-25-27(23)16-20)19-8-13-29-17-19/h4-8,13-17H,1-3,9-12H2
DMYWD6C CS C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CSC=C5)N=C3
DMYWD6C IK VOYMOBPSYVKQGF-UHFFFAOYSA-N
DMYWD6C IU 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-thiophen-3-ylpyrazolo[1,5-a]pyrimidine
DMYWD6C DE Discovery agent
DM9KWUR ID DM9KWUR
DM9KWUR DN L023103
DM9KWUR HS Investigative
DM9KWUR SN L 023103; L-023103
DM9KWUR DT Small molecular drug
DM9KWUR PC 135413562
DM9KWUR MW 625.1
DM9KWUR FM C30H33ClN6O5S
DM9KWUR IC InChI=1S/C30H33ClN6O5S/c1-36(2)19-5-18-32-27(38)17-10-21-8-15-24(16-9-21)43(41,42)37(23-13-11-22(31)12-14-23)20-28(39)34-35-29-25-6-3-4-7-26(25)33-30(29)40/h3-4,6-9,11-16,33,40H,5,10,17-20H2,1-2H3,(H,32,38)
DM9KWUR CS CN(C)CCCNC(=O)CCC1=CC=C(C=C1)S(=O)(=O)N(CC(=O)N=NC2=C(NC3=CC=CC=C32)O)C4=CC=C(C=C4)Cl
DM9KWUR IK BOPHFCQTNVDEDL-UHFFFAOYSA-N
DM9KWUR IU 3-[4-[(4-chlorophenyl)-[2-[(2-hydroxy-1H-indol-3-yl)diazenyl]-2-oxoethyl]sulfamoyl]phenyl]-N-[3-(dimethylamino)propyl]propanamide
DM9KWUR DE Discovery agent
DMQR6ZX ID DMQR6ZX
DMQR6ZX DN L-054,522
DMQR6ZX HS Investigative
DMQR6ZX SN L054522; L 054522
DMQR6ZX DT Small molecular drug
DMQR6ZX PC 15965425
DMQR6ZX MW 645.8
DMQR6ZX FM C35H47N7O5
DMQR6ZX IC InChI=1S/C35H47N7O5/c1-22(25-21-37-26-12-6-5-11-24(25)26)30(31(43)38-28(14-9-10-18-36)32(44)47-35(2,3)4)40-33(45)41-19-16-23(17-20-41)42-29-15-8-7-13-27(29)39-34(42)46/h5-8,11-13,15,21-23,28,30,37H,9-10,14,16-20,36H2,1-4H3,(H,38,43)(H,39,46)(H,40,45)/t22-,28-,30+/m0/s1
DMQR6ZX CS C[C@@H](C1=CNC2=CC=CC=C21)[C@H](C(=O)N[C@@H](CCCCN)C(=O)OC(C)(C)C)NC(=O)N3CCC(CC3)N4C5=CC=CC=C5NC4=O
DMQR6ZX IK WFCIXKAZBUIFTR-PKIMSIDOSA-N
DMQR6ZX IU tert-butyl (2S)-6-amino-2-[[(2R,3S)-3-(1H-indol-3-yl)-2-[[4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carbonyl]amino]butanoyl]amino]hexanoate
DMQR6ZX DE Discovery agent
DMXB7G5 ID DMXB7G5
DMXB7G5 DN L-054852
DMXB7G5 HS Investigative
DMXB7G5 CP Merck
DMXB7G5 DT Small molecular drug
DMXB7G5 PC 56603773
DMXB7G5 MW 561.8
DMXB7G5 FM C32H43N5O2S
DMXB7G5 IC InChI=1S/C32H43N5O2S/c1-21(2)30(40-19-16-33)36-29(38)28(22(3)25-20-34-27-11-7-5-9-24(25)27)35-31(39)37-17-14-32(15-18-37)13-12-23-8-4-6-10-26(23)32/h4-11,20-22,28,30,34H,12-19,33H2,1-3H3,(H,35,39)(H,36,38)
DMXB7G5 CS CC(C)C(NC(=O)C(C(C)C1=CNC2=CC=CC=C21)NC(=O)N3CCC4(CCC5=CC=CC=C54)CC3)SCCN
DMXB7G5 IK UDRSIUYQZOTMRD-UHFFFAOYSA-N
DMXB7G5 IU N-[1-[[1-(2-aminoethylsulfanyl)-2-methylpropyl]amino]-3-(1H-indol-3-yl)-1-oxobutan-2-yl]spiro[1,2-dihydroindene-3,4'-piperidine]-1'-carboxamide
DMXB7G5 DE Acromegaly
DMWNJV0 ID DMWNJV0
DMWNJV0 DN L-136662
DMWNJV0 HS Investigative
DMWNJV0 SN CHEMBL1222280; L-136662; AC1M5I9D; BDBM50324737; AKOS008966462; 3-(2-aminoethyl)-5-(4-(dimethylamino)benzylidene)thiazolidine-2,4-dione
DMWNJV0 DT Small molecular drug
DMWNJV0 PC 2329349
DMWNJV0 MW 291.37
DMWNJV0 FM C14H17N3O2S
DMWNJV0 IC InChI=1S/C14H17N3O2S/c1-16(2)11-5-3-10(4-6-11)9-12-13(18)17(8-7-15)14(19)20-12/h3-6,9H,7-8,15H2,1-2H3/b12-9-
DMWNJV0 CS CN(C)C1=CC=C(C=C1)/C=C\\2/C(=O)N(C(=O)S2)CCN
DMWNJV0 IK BOQIVKJIDMTNLR-XFXZXTDPSA-N
DMWNJV0 IU (5Z)-3-(2-aminoethyl)-5-[[4-(dimethylamino)phenyl]methylidene]-1,3-thiazolidine-2,4-dione
DMWNJV0 DE Discovery agent
DMVGX7Z ID DMVGX7Z
DMVGX7Z DN L-152,804
DMVGX7Z HS Investigative
DMVGX7Z SN L-152804; L152804
DMVGX7Z DT Small molecular drug
DMVGX7Z PC 3765615
DMVGX7Z MW 366.4
DMVGX7Z FM C23H26O4
DMVGX7Z IC InChI=1S/C23H26O4/c1-22(2)9-14(24)20(15(25)10-22)19-13-7-5-6-8-17(13)27-18-12-23(3,4)11-16(26)21(18)19/h5-8,19-20H,9-12H2,1-4H3
DMVGX7Z CS CC1(CC(=O)C(C(=O)C1)C2C3=CC=CC=C3OC4=C2C(=O)CC(C4)(C)C)C
DMVGX7Z IK XQDXIHYKAGHZRX-UHFFFAOYSA-N
DMVGX7Z IU 2-(3,3-dimethyl-1-oxo-4,9-dihydro-2H-xanthen-9-yl)-5,5-dimethylcyclohexane-1,3-dione
DMVGX7Z CA CAS 6508-43-6
DMVGX7Z CB CHEBI:91696
DMVGX7Z DE Discovery agent
DMOX8JE ID DMOX8JE
DMOX8JE DN L-159093
DMOX8JE HS Investigative
DMOX8JE SN CHEMBL24322; L-159093; BDBM50041969; L006880; 3-{2-Butyl-4-oxo-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3,4-dihydro-quinazolin-6-yl}-1-isopropyl-1-methyl-urea
DMOX8JE DT Small molecular drug
DMOX8JE PC 9829012
DMOX8JE MW 550.7
DMOX8JE FM C31H34N8O2
DMOX8JE IC InChI=1S/C31H34N8O2/c1-5-6-11-28-33-27-17-16-23(32-31(41)38(4)20(2)3)18-26(27)30(40)39(28)19-21-12-14-22(15-13-21)24-9-7-8-10-25(24)29-34-36-37-35-29/h7-10,12-18,20H,5-6,11,19H2,1-4H3,(H,32,41)(H,34,35,36,37)
DMOX8JE CS CCCCC1=NC2=C(C=C(C=C2)NC(=O)N(C)C(C)C)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
DMOX8JE IK XUXPOYGCLABTCS-UHFFFAOYSA-N
DMOX8JE IU 3-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]-1-methyl-1-propan-2-ylurea
DMOX8JE DE Discovery agent
DMZOW96 ID DMZOW96
DMZOW96 DN L-162313
DMZOW96 HS Investigative
DMZOW96 SN L-162,313; 151488-11-8; L-162313; CHEMBL288174; butyl 3-(4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)-5-isobutylthiophen-2-ylsulfonylcarbamate; 5,7-Dimethyl-2-ethyl-3-[[4-[2-(n-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]imidazo-[4,5-b]-pyridine; 5,7-Dimethyl-2-ethyl-3-[[4-[2(N-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]Imidazo[4,5,6]pyridine; L 162313; Lopac-L-1415; AC1O7G4F; Lopac0_000697; MLS002153426; SCHEMBL9132197; GTPL3936; C30H38N4O4S2; HMS3262K15
DMZOW96 DT Small molecular drug
DMZOW96 PC 6603900
DMZOW96 MW 582.8
DMZOW96 FM C30H38N4O4S2
DMZOW96 IC InChI=1S/C30H38N4O4S2/c1-7-9-14-38-30(35)33-40(36,37)29-25(17-24(39-29)15-19(3)4)23-12-10-22(11-13-23)18-34-26(8-2)32-27-20(5)16-21(6)31-28(27)34/h10-13,16-17,19H,7-9,14-15,18H2,1-6H3,(H,33,35)
DMZOW96 CS CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C(=NC4=C3N=C(C=C4C)C)CC
DMZOW96 IK RINPELQWLUGERM-UHFFFAOYSA-N
DMZOW96 IU butyl N-[3-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate
DMZOW96 DE Discovery agent
DMWSP6H ID DMWSP6H
DMWSP6H DN L-162782
DMWSP6H HS Investigative
DMWSP6H SN L-162782; CHEMBL289614; SCHEMBL9133104; BDBM50141059; butyl (4'-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonylcarbamate; N-Butyloxycarbonyl-4''-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-5-isobutyl-biphenyl-2-sulfonic acid amide
DMWSP6H DT Small molecular drug
DMWSP6H PC 10031067
DMWSP6H MW 576.8
DMWSP6H FM C32H40N4O4S
DMWSP6H IC InChI=1S/C32H40N4O4S/c1-7-9-16-40-32(37)35-41(38,39)28-15-12-25(17-21(3)4)19-27(28)26-13-10-24(11-14-26)20-36-29(8-2)34-30-22(5)18-23(6)33-31(30)36/h10-15,18-19,21H,7-9,16-17,20H2,1-6H3,(H,35,37)
DMWSP6H CS CCCCOC(=O)NS(=O)(=O)C1=C(C=C(C=C1)CC(C)C)C2=CC=C(C=C2)CN3C(=NC4=C3N=C(C=C4C)C)CC
DMWSP6H IK GABMQILPAPONQS-UHFFFAOYSA-N
DMWSP6H IU butyl N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(2-methylpropyl)phenyl]sulfonylcarbamate
DMWSP6H DE Discovery agent
DMYC7AK ID DMYC7AK
DMYC7AK DN L-163,101
DMYC7AK HS Investigative
DMYC7AK SN L-163101
DMYC7AK DT Small molecular drug
DMYC7AK PC 73755245
DMYC7AK MW 580.7
DMYC7AK FM C34H36N4O3S
DMYC7AK IC InChI=1S/C34H36N4O3S/c1-6-31-36-32-23(4)19-24(5)35-33(32)38(31)21-25-12-15-27(16-13-25)29-20-26(18-22(2)3)14-17-30(29)42(40,41)37-34(39)28-10-8-7-9-11-28/h7-17,19-20,22H,6,18,21H2,1-5H3,(H,37,39)
DMYC7AK CS CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=C(C=CC(=C4)CC(C)C)S(=O)(=O)NC(=O)C5=CC=CC=C5)N=C(C=C2C)C
DMYC7AK IK BRUYKNQQCIYYNP-UHFFFAOYSA-N
DMYC7AK IU N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-4-(2-methylpropyl)phenyl]sulfonylbenzamide
DMYC7AK DE Discovery agent
DMZP7YM ID DMZP7YM
DMZP7YM DN L-165041
DMZP7YM HS Investigative
DMZP7YM SN L165041
DMZP7YM DT Small molecular drug
DMZP7YM PC 6603901
DMZP7YM MW 402.4
DMZP7YM FM C22H26O7
DMZP7YM IC InChI=1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
DMZP7YM CS CCCC1=C(C=CC(=C1O)C(=O)C)OCCCOC2=CC=C(C=C2)OCC(=O)O
DMZP7YM IK HBBVCKCCQCQCTJ-UHFFFAOYSA-N
DMZP7YM IU 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid
DMZP7YM CA CAS 79558-09-1
DMZP7YM CB CHEBI:94812
DMZP7YM DE Discovery agent
DMKBSGN ID DMKBSGN
DMKBSGN DN L-165461
DMKBSGN HS Investigative
DMKBSGN SN L-165461; CHEMBL279053; SCHEMBL6753428; GTPL2690; BDBM50126016; AKOS027321335; L165461; L 165461; 3-Chloro-4-[3-(3-ethyl-7-propyl-1,2-benzisoxazole-6-yloxy)propylthio]benzeneacetic acid; 2-(3-chloro-4-(3-(3-ethyl-7-propylbenzo[d]isoxazol-6-yloxy)propylthio)phenyl)acetic acid; {3-Chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMKBSGN DT Small molecular drug
DMKBSGN PC 9889841
DMKBSGN MW 448
DMKBSGN FM C23H26ClNO4S
DMKBSGN IC InChI=1S/C23H26ClNO4S/c1-3-6-17-20(9-8-16-19(4-2)25-29-23(16)17)28-11-5-12-30-21-10-7-15(13-18(21)24)14-22(26)27/h7-10,13H,3-6,11-12,14H2,1-2H3,(H,26,27)
DMKBSGN CS CCCC1=C(C=CC2=C1ON=C2CC)OCCCSC3=C(C=C(C=C3)CC(=O)O)Cl
DMKBSGN IK LBEYMGDIPDOUKK-UHFFFAOYSA-N
DMKBSGN IU 2-[3-chloro-4-[3-[(3-ethyl-7-propyl-1,2-benzoxazol-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMKBSGN DE Discovery agent
DM3UGMD ID DM3UGMD
DM3UGMD DN L-168049
DM3UGMD HS Investigative
DM3UGMD SN Glucagon antagonists (diabetes); SCH-900822; Glucagon antagonists (diabetes), Merck & Co
DM3UGMD CP Merck Research Laboratories
DM3UGMD DT Small molecular drug
DM3UGMD PC 5311276
DM3UGMD MW 467.8
DM3UGMD FM C24H20BrClN2O
DM3UGMD IC InChI=1S/C24H20BrClN2O/c1-2-13-29-23-8-5-18(25)14-20(23)21-15-22(16-3-6-19(26)7-4-16)28-24(21)17-9-11-27-12-10-17/h3-12,14-15,28H,2,13H2,1H3
DM3UGMD CS CCCOC1=C(C=C(C=C1)Br)C2=C(NC(=C2)C3=CC=C(C=C3)Cl)C4=CC=NC=C4
DM3UGMD IK HHBOWXZOLYQFNY-UHFFFAOYSA-N
DM3UGMD IU 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine
DM3UGMD CA CAS 191034-25-0
DM3UGMD CB CHEBI:92326
DM3UGMD DE Diabetic complication
DMZ4KO0 ID DMZ4KO0
DMZ4KO0 DN L17
DMZ4KO0 HS Investigative
DMZ4KO0 SN Hydroxybutorphanol tartrate; AC1MI7CW; Morphinan-3,14-diol, 17-((3-trans-hydroxycyclobutyl)methyl)-, tartrate (2:1), l-; l-17-((3-trans-Hydroxycyclobutyl)methyl)morphinan-3,14-diol tartrate (2:1); Morphinan-3,14-diol, 17-((3-hydroxycyclobutyl)methyl)-, (17(trans))-, (R-(R*,R*))-2,3-dihydroxybutanedioate (2:1) (salt)
DMZ4KO0 DT Small molecular drug
DMZ4KO0 PC 3064245
DMZ4KO0 MW 837
DMZ4KO0 FM C46H64N2O12
DMZ4KO0 IC InChI=1S/2C21H29NO3.C4H6O6/c2*23-16-4-3-15-11-19-21(25)6-2-1-5-20(21,18(15)12-16)7-8-22(19)13-14-9-17(24)10-14;5-1(3(7)8)2(6)4(9)10/h2*3-4,12,14,17,19,23-25H,1-2,5-11,13H2;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1
DMZ4KO0 CS C1CCC2(C3CC4=C(C2(C1)CCN3CC5CC(C5)O)C=C(C=C4)O)O.C1CCC2(C3CC4=C(C2(C1)CCN3CC5CC(C5)O)C=C(C=C4)O)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
DMZ4KO0 IK HIJHYZCQDMUGEP-CEAXSRTFSA-N
DMZ4KO0 IU (2R,3R)-2,3-dihydroxybutanedioic acid;17-[(3-hydroxycyclobutyl)methyl]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
DMZ4KO0 DE Discovery agent
DMEK65F ID DMEK65F
DMEK65F DN L-249313
DMEK65F HS Investigative
DMEK65F SN L-249313; CHEMBL52735; AC1N966E; SCHEMBL13932309; BDBM50059376; methyl 9-methyl-2-phenyl-5H-[1,2,4]triazolo[5,1-a][2,7]naphthyridine-6-carboxylate; 9-Methyl-2-phenyl-5,9-dihydro-[1,2,4]triazolo[5,1-a][2,7]naphthyridine-6-carboxylic acid methyl ester
DMEK65F DT Small molecular drug
DMEK65F PC 4355631
DMEK65F MW 320.3
DMEK65F FM C18H16N4O2
DMEK65F IC InChI=1S/C18H16N4O2/c1-21-9-8-13-14(10-21)17-19-16(12-6-4-3-5-7-12)20-22(17)11-15(13)18(23)24-2/h3-10H,11H2,1-2H3
DMEK65F CS CN1C=CC2=C(CN3C(=NC(=N3)C4=CC=CC=C4)C2=C1)C(=O)OC
DMEK65F IK DBROFPXBIMMIMF-UHFFFAOYSA-N
DMEK65F IU methyl 9-methyl-2-phenyl-5H-[1,2,4]triazolo[5,1-a][2,7]naphthyridine-6-carboxylate
DMEK65F DE Discovery agent
DMV6018 ID DMV6018
DMV6018 DN L-269,289
DMV6018 HS Investigative
DMV6018 SN L-269289; AC1O6807; AE-641/30108011; [2-(2-{2-Aza-2-[4-(8-chloro(10H,11H-dibenzo[b,f]thiepin-10-yl))piperazinyl]vinyl}phenoxy)ethyl]dimethylamine; 2-[2-[(Z)-[4-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]iminomethyl]phenoxy]-N,N-dimethyl-ethanamine; N-[4-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-1-piperazinyl]-N-{2-[2-(dimethylamino)ethoxy]benzylidene}amine
DMV6018 DT Small molecular drug
DMV6018 PC 6448387
DMV6018 MW 521.1
DMV6018 FM C29H33ClN4OS
DMV6018 IC InChI=1S/C29H33ClN4OS/c1-32(2)17-18-35-27-9-5-3-8-23(27)21-31-34-15-13-33(14-16-34)26-19-22-7-4-6-10-28(22)36-29-12-11-24(30)20-25(26)29/h3-12,20-21,26H,13-19H2,1-2H3/b31-21-
DMV6018 CS CN(C)CCOC1=CC=CC=C1/C=N\\N2CCN(CC2)C3CC4=CC=CC=C4SC5=C3C=C(C=C5)Cl
DMV6018 IK OKSZYIOFSXRHJB-YQYKVWLJSA-N
DMV6018 IU 2-[2-[(Z)-[4-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]iminomethyl]phenoxy]-N,N-dimethylethanamine
DMV6018 DE Discovery agent
DMWQCRD ID DMWQCRD
DMWQCRD DN L-2-Amino-4-(Guanidinooxy)Butyric Acid
DMWQCRD HS Investigative
DMWQCRD SN L-canavanine; canavanine; Canavanin; 543-38-4; 2-Amino-4-(guanidinooxy)butyric acid; L-2-AMINO-4-(GUANIDINOOXY)BUTYRIC ACID; UNII-3HZV514J4B; O-((Aminoiminomethyl)amino)-L-homoserine; O-carbamimidamido-L-homoserine; 3HZV514J4B; CHEMBL443732; CHEBI:609827; (L)-CANAVANINE; O-((Aminoiminomethyl)amino)homoserine; GGB; HSDB 3471; AI3-52153; L-Homoserine, O-((aminoiminomethyl)amino)-; Butyric acid, 2-amino-4-(guanidinooxy)-, L-; C5H12N4O3; L(+)-Canavanine; Tocris-0673; Spectrum_001137; Spectrum3_001206; Spectrum2_000800
DMWQCRD DT Small molecular drug
DMWQCRD PC 439202
DMWQCRD MW 176.17
DMWQCRD FM C5H12N4O3
DMWQCRD IC InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1
DMWQCRD CS C(CON=C(N)N)[C@@H](C(=O)O)N
DMWQCRD IK FSBIGDSBMBYOPN-VKHMYHEASA-N
DMWQCRD IU (2S)-2-amino-4-(diaminomethylideneamino)oxybutanoic acid
DMWQCRD CA CAS 543-38-4
DMWQCRD CB CHEBI:609827
DMWQCRD DE Discovery agent
DM1WMHO ID DM1WMHO
DM1WMHO DN L-365,209
DM1WMHO HS Investigative
DM1WMHO SN L-365209; L 365209
DM1WMHO DT Small molecular drug
DM1WMHO PC 9810632
DM1WMHO MW 738.9
DM1WMHO FM C40H50N8O6
DM1WMHO IC InChI=1S/C40H50N8O6/c1-4-26(2)34-40(54)48-32(19-12-22-42-48)39(53)47-31(18-11-21-41-47)37(51)45(3)33(25-28-16-9-6-10-17-28)38(52)46-23-13-20-30(46)36(50)43-29(35(49)44-34)24-27-14-7-5-8-15-27/h5-10,14-17,21-22,26,29-34H,4,11-13,18-20,23-25H2,1-3H3,(H,43,50)(H,44,49)/t26-,29+,30-,31-,32+,33+,34-/m0/s1
DM1WMHO CS CC[C@H](C)[C@H]1C(=O)N2[C@H](CCC=N2)C(=O)N3[C@@H](CCC=N3)C(=O)N([C@@H](C(=O)N4CCC[C@H]4C(=O)N[C@@H](C(=O)N1)CC5=CC=CC=C5)CC6=CC=CC=C6)C
DM1WMHO IK IFHSSGUGRIXWQU-NSTWBPGMSA-N
DM1WMHO IU (1R,8S,11R,17S,20R,23S)-11,20-dibenzyl-23-[(2S)-butan-2-yl]-10-methyl-3,4,10,13,19,22,25,26-octazatetracyclo[23.4.0.03,8.013,17]nonacosa-4,26-diene-2,9,12,18,21,24-hexone
DM1WMHO DE Discovery agent
DMGQE1B ID DMGQE1B
DMGQE1B DN L-366,509
DMGQE1B HS Investigative
DMGQE1B SN L-366509
DMGQE1B DT Small molecular drug
DMGQE1B PC 3083288
DMGQE1B MW 459.6
DMGQE1B FM C25H33NO5S
DMGQE1B IC InChI=1S/C25H33NO5S/c1-22(2)19-8-10-24(22,25(29,15-19)16-21(27)28)17-32(30,31)26-13-11-23(12-14-26)9-7-18-5-3-4-6-20(18)23/h3-7,9,19,29H,8,10-17H2,1-2H3,(H,27,28)
DMGQE1B CS CC1(C2CCC1(C(C2)(CC(=O)O)O)CS(=O)(=O)N3CCC4(CC3)C=CC5=CC=CC=C45)C
DMGQE1B IK XKVDTEPESVJNPJ-UHFFFAOYSA-N
DMGQE1B IU 2-[2-hydroxy-7,7-dimethyl-1-(spiro[indene-1,4'-piperidine]-1'-ylsulfonylmethyl)-2-bicyclo[2.2.1]heptanyl]acetic acid
DMGQE1B CA CAS 138382-23-7
DMGQE1B DE Discovery agent
DMAS5P8 ID DMAS5P8
DMAS5P8 DN L-366,682
DMAS5P8 HS Investigative
DMAS5P8 SN cyclo(Pro-Trp-Ile-Pip-Pip-His); L 366682
DMAS5P8 DT Small molecular drug
DMAS5P8 PC 196819
DMAS5P8 MW 755.9
DMAS5P8 FM C40H53N9O6
DMAS5P8 IC InChI=1S/C40H53N9O6/c1-3-26(2)34(38(54)49-19-10-7-15-40(49,24-50)39(55)47-16-8-4-9-17-47)46-35(51)32(20-27-22-43-31-13-6-5-12-29(27)31)45-36(52)33-14-11-18-48(33)37(53)30(41)21-28-23-42-25-44-28/h3,5-6,12-13,22-26,30,32-34,43H,1,4,7-11,14-21,41H2,2H3,(H,42,44)(H,45,52)(H,46,51)/t26-,30+,32+,33-,34-,40-/m0/s1
DMAS5P8 CS C[C@@H](C=C)[C@@H](C(=O)N1CCCC[C@]1(C=O)C(=O)N2CCCCC2)NC(=O)[C@@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CN=CN6)N
DMAS5P8 IK QHUGACUEEILSLD-NNWJBWDNSA-N
DMAS5P8 IU (2S)-1-[(2R)-2-amino-3-(1H-imidazol-5-yl)propanoyl]-N-[(2R)-1-[[(2S,3S)-1-[(2S)-2-formyl-2-(piperidine-1-carbonyl)piperidin-1-yl]-3-methyl-1-oxopent-4-en-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DMAS5P8 DE Discovery agent
DM31NXF ID DM31NXF
DM31NXF DN L-366,948
DM31NXF HS Investigative
DM31NXF SN L 366948; L-366948
DM31NXF DT Small molecular drug
DM31NXF PC 188397
DM31NXF MW 768.9
DM31NXF FM C42H56N8O6
DM31NXF IC InChI=1S/C42H56N8O6/c1-3-28(2)35(46-37(53)33(43)24-29-15-16-30-13-6-7-14-31(30)23-29)36(52)41(27-51)17-12-22-50(41)38(54)34(44)25-32-26-45-42(47-32,39(55)48-18-8-4-9-19-48)40(56)49-20-10-5-11-21-49/h6-7,13-16,23,26-28,33-35H,3-5,8-12,17-22,24-25,43-44H2,1-2H3,(H,46,53)/t28-,33-,34+,35-,41-/m0/s1
DM31NXF CS CC[C@H](C)[C@@H](C(=O)[C@]1(CCCN1C(=O)[C@@H](CC2=NC(N=C2)(C(=O)N3CCCCC3)C(=O)N4CCCCC4)N)C=O)NC(=O)[C@H](CC5=CC6=CC=CC=C6C=C5)N
DM31NXF IK OCVKQRQVXSMCCJ-HWFQYKCLSA-N
DM31NXF IU (2S)-2-amino-N-[(2S,3S)-1-[(2S)-1-[(2R)-2-amino-3-[2,2-bis(piperidine-1-carbonyl)imidazol-4-yl]propanoyl]-2-formylpyrrolidin-2-yl]-3-methyl-1-oxopentan-2-yl]-3-naphthalen-2-ylpropanamide
DM31NXF DE Discovery agent
DMQ369D ID DMQ369D
DMQ369D DN L-367,773
DMQ369D HS Investigative
DMQ369D SN L-367773; L 367773
DMQ369D DT Small molecular drug
DMQ369D PC 10413997
DMQ369D MW 510.7
DMQ369D FM C28H38N4O3S
DMQ369D IC InChI=1S/C28H38N4O3S/c1-26(2)21-8-10-28(26,24(15-21)31-25(33)16-22-17-29-19-30-22)18-36(34,35)32-13-11-27(12-14-32)9-7-20-5-3-4-6-23(20)27/h3-6,17,19,21,24H,7-16,18H2,1-2H3,(H,29,30)(H,31,33)/t21-,24+,28-/m1/s1
DMQ369D CS CC1([C@@H]2CC[C@]1([C@H](C2)NC(=O)CC3=CN=CN3)CS(=O)(=O)N4CCC5(CCC6=CC=CC=C65)CC4)C
DMQ369D IK VQAVBHLGXVZOKM-RASJMTDNSA-N
DMQ369D IU N-[(1S,2S,4R)-7,7-dimethyl-1-(spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylsulfonylmethyl)-2-bicyclo[2.2.1]heptanyl]-2-(1H-imidazol-5-yl)acetamide
DMQ369D DE Discovery agent
DMC1Z0L ID DMC1Z0L
DMC1Z0L DN L-370,518
DMC1Z0L HS Investigative
DMC1Z0L SN CHEMBL2062141; L-370518; CHEMBL442024; BDBM50454822; BDBM50056772; (S)-1-((R)-2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2-carboxylic acid [(S)-1-(4-amino-cyclohexyl)-2-methylcarbamoyl-2-oxo-ethyl]-amide
DMC1Z0L DT Small molecular drug
DMC1Z0L PC 10322542
DMC1Z0L MW 471.6
DMC1Z0L FM C25H37N5O4
DMC1Z0L IC InChI=1S/C25H37N5O4/c1-27-19(15-16-7-4-3-5-8-16)25(34)30-14-6-9-20(30)23(32)29-21(22(31)24(33)28-2)17-10-12-18(26)13-11-17/h3-5,7-8,17-21,27H,6,9-15,26H2,1-2H3,(H,28,33)(H,29,32)/t17?,18?,19-,20+,21+/m1/s1
DMC1Z0L CS CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C3CCC(CC3)N)C(=O)C(=O)NC
DMC1Z0L IK ISJCFAFNSYZJRO-KJFGXLEFSA-N
DMC1Z0L IU (2S)-N-[(1S)-1-(4-aminocyclohexyl)-3-(methylamino)-2,3-dioxopropyl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMC1Z0L DE Discovery agent
DMQV974 ID DMQV974
DMQV974 DN L-372662
DMQV974 HS Investigative
DMQV974 SN L-372662; CHEMBL306645; L372662; L012255; 1-[1-[2-methoxy-4-[1-[(2-methyl-1-oxidopyridin-1-ium-3-yl)methyl]piperidin-4-yl]oxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one; AC1NSK7B; GTPL2253; SCHEMBL17423352; BDBM50064711; 162045-26-3; 1-(1-{2-Methoxy-4-[1-(2-methyl-1-oxy-pyridin-3-ylmethyl)-piperidin-4-yloxy]-benzoyl}-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one
DMQV974 DT Small molecular drug
DMQV974 PC 5311202
DMQV974 MW 586.7
DMQV974 FM C33H38N4O6
DMQV974 IC InChI=1S/C33H38N4O6/c1-23-24(7-5-15-36(23)40)21-34-16-13-27(14-17-34)43-28-9-10-29(31(20-28)41-2)32(38)35-18-11-26(12-19-35)37-30-8-4-3-6-25(30)22-42-33(37)39/h3-10,15,20,26-27H,11-14,16-19,21-22H2,1-2H3
DMQV974 CS CC1=C(C=CC=[N+]1[O-])CN2CCC(CC2)OC3=CC(=C(C=C3)C(=O)N4CCC(CC4)N5C6=CC=CC=C6COC5=O)OC
DMQV974 IK SKWSXDUHUVMPBT-UHFFFAOYSA-N
DMQV974 IU 1-[1-[2-methoxy-4-[1-[(2-methyl-1-oxidopyridin-1-ium-3-yl)methyl]piperidin-4-yl]oxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one
DMQV974 DE Discovery agent
DMQWKPM ID DMQWKPM
DMQWKPM DN L-375378
DMQWKPM HS Investigative
DMQWKPM SN CHEMBL19080; L-37378; 199294-70-7; AC1L4BPU; L-375378; DTXSID80276443; ZINC1487441; BDBM50067797; N-[(6-amino-2-methyl-3-pyridinyl)methyl]-2-[6-methyl-2-oxo-3-(2-phenylethylamino)-1-pyrazinyl]acetamide; A814081; N-(6-Amino-2-methyl-pyridin-3-ylmethyl)-2-(6-methyl-2-oxo-3-phenethylamino-2H-pyrazin-1-yl)-acetamide; N-[(6-azanyl-2-methyl-pyridin-3-yl)methyl]-2-[6-methyl-2-oxidanylidene-3-(2-phenylethylamino)pyrazin-1-yl]ethanamide
DMQWKPM DT Small molecular drug
DMQWKPM PC 154118
DMQWKPM MW 406.5
DMQWKPM FM C22H26N6O2
DMQWKPM IC InChI=1S/C22H26N6O2/c1-15-12-26-21(24-11-10-17-6-4-3-5-7-17)22(30)28(15)14-20(29)25-13-18-8-9-19(23)27-16(18)2/h3-9,12H,10-11,13-14H2,1-2H3,(H2,23,27)(H,24,26)(H,25,29)
DMQWKPM CS CC1=CN=C(C(=O)N1CC(=O)NCC2=C(N=C(C=C2)N)C)NCCC3=CC=CC=C3
DMQWKPM IK PVDHYBJORRALSQ-UHFFFAOYSA-N
DMQWKPM IU N-[(6-amino-2-methylpyridin-3-yl)methyl]-2-[6-methyl-2-oxo-3-(2-phenylethylamino)pyrazin-1-yl]acetamide
DMQWKPM CA CAS 199294-70-7
DMQWKPM DE Discovery agent
DM0P4V6 ID DM0P4V6
DM0P4V6 DN L-454560
DM0P4V6 HS Investigative
DM0P4V6 SN MK-0359; UNII-G6GSO9SDNJ; L-454560; G6GSO9SDNJ; 346629-30-9; CHEMBL372575; Quinoline, 6-(1-methyl-1-(methylsulfonyl)ethyl)-8-(3-((1E)-2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)ethenyl)phenyl)-; SCHEMBL4027148; GTPL9852; MolPort-042-665-643; ZINC3964061; BDBM50174022; MK0359; KB-78879; L-454,560; 8-(3-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-2-(4-(methylsulfonyl)phenyl)vinyl)phenyl)-6-(2-(methylsulfonyl)propan-2-yl)quinoline
DM0P4V6 DT Small molecular drug
DM0P4V6 PC 9853498
DM0P4V6 MW 587.7
DM0P4V6 FM C31H29N3O5S2
DM0P4V6 IC InChI=1S/C31H29N3O5S2/c1-20-33-30(39-34-20)28(22-11-13-26(14-12-22)40(4,35)36)17-21-8-6-9-23(16-21)27-19-25(31(2,3)41(5,37)38)18-24-10-7-15-32-29(24)27/h6-19H,1-5H3/b28-17+
DM0P4V6 CS CC1=NOC(=N1)/C(=C/C2=CC(=CC=C2)C3=C4C(=CC(=C3)C(C)(C)S(=O)(=O)C)C=CC=N4)/C5=CC=C(C=C5)S(=O)(=O)C
DM0P4V6 IK YYGZHVJDHMMABU-OGLMXYFKSA-N
DM0P4V6 IU 3-methyl-5-[(E)-1-(4-methylsulfonylphenyl)-2-[3-[6-(2-methylsulfonylpropan-2-yl)quinolin-8-yl]phenyl]ethenyl]-1,2,4-oxadiazole
DM0P4V6 CA CAS 346629-30-9
DM0P4V6 DE Discovery agent
DMHL901 ID DMHL901
DMHL901 DN L-5-(bromovinyl)deoxyuridine
DMHL901 HS Investigative
DMHL901 SN CHEMBL261850; L-5-(bromovinyl)deoxyuridine; SCHEMBL4314668; BDBM50375781
DMHL901 DT Small molecular drug
DMHL901 PC 25323027
DMHL901 MW 333.13
DMHL901 FM C11H13BrN2O5
DMHL901 IC InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9-/m0/s1
DMHL901 CS C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O
DMHL901 IK ODZBBRURCPAEIQ-RNVICZODSA-N
DMHL901 IU 5-[(E)-2-bromoethenyl]-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
DMHL901 DE Discovery agent
DM3Q0JL ID DM3Q0JL
DM3Q0JL DN L-5-iodo-2'-deoxyuridine
DM3Q0JL HS Investigative
DM3Q0JL SN CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil
DM3Q0JL DT Small molecular drug
DM3Q0JL PC 512326
DM3Q0JL MW 354.1
DM3Q0JL FM C9H11IN2O5
DM3Q0JL IC InChI=1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7-/m0/s1
DM3Q0JL CS C1[C@@H]([C@H](O[C@@H]1N2C=C(C(=O)NC2=O)I)CO)O
DM3Q0JL IK XQFRJNBWHJMXHO-XVMARJQXSA-N
DM3Q0JL IU 1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
DM3Q0JL CA CAS 54-42-2
DM3Q0JL DE Discovery agent
DMENUOD ID DMENUOD
DMENUOD DN L-644,698
DMENUOD HS Investigative
DMENUOD SN L644698; L-644698
DMENUOD DT Small molecular drug
DMENUOD PC 9908595
DMENUOD MW 393.5
DMENUOD FM C21H31NO4S
DMENUOD IC InChI=1S/C21H31NO4S/c1-2-3-4-7-18(23)13-14-22-19(24)15-27-20(22)8-5-6-16-9-11-17(12-10-16)21(25)26/h9-12,18,20,23H,2-8,13-15H2,1H3,(H,25,26)
DMENUOD CS CCCCCC(CCN1C(SCC1=O)CCCC2=CC=C(C=C2)C(=O)O)O
DMENUOD IK NDAXAJCKSWCWQI-UHFFFAOYSA-N
DMENUOD IU 4-[3-[3-(3-hydroxyoctyl)-4-oxo-1,3-thiazolidin-2-yl]propyl]benzoic acid
DMENUOD DE Discovery agent
DMA23LP ID DMA23LP
DMA23LP DN L-652,343
DMA23LP HS Investigative
DMA23LP DT Small molecular drug
DMA23LP PC 3035865
DMA23LP MW 445.5
DMA23LP FM C22H14F3NO2S2
DMA23LP IC InChI=1S/C22H14F3NO2S2/c23-22(24,25)14-8-9-18-15(11-14)19(27)20(30-18)21(28)26-12-16(17-7-4-10-29-17)13-5-2-1-3-6-13/h1-12,27H,(H,26,28)/b16-12+
DMA23LP CS C1=CC=C(C=C1)/C(=C\\NC(=O)C2=C(C3=C(S2)C=CC(=C3)C(F)(F)F)O)/C4=CC=CS4
DMA23LP IK MWRHQMNEBAXDOF-FOWTUZBSSA-N
DMA23LP IU 3-hydroxy-N-[(E)-2-phenyl-2-thiophen-2-ylethenyl]-5-(trifluoromethyl)-1-benzothiophene-2-carboxamide
DMA23LP CA CAS 102565-09-3
DMA23LP DE Discovery agent
DM360VU ID DM360VU
DM360VU DN L-652731
DM360VU HS Investigative
DM360VU SN CHEMBL297624; L-652731; AC1OCET6; SCHEMBL7018011; BDBM50366241; U-80271; (2R,5R)-2,5-bis(3,4,5-trimethoxyphenyl)oxolane; ([trans-2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran])
DM360VU DT Small molecular drug
DM360VU PC 6917920
DM360VU MW 404.5
DM360VU FM C22H28O7
DM360VU IC InChI=1S/C22H28O7/c1-23-17-9-13(10-18(24-2)21(17)27-5)15-7-8-16(29-15)14-11-19(25-3)22(28-6)20(12-14)26-4/h9-12,15-16H,7-8H2,1-6H3/t15-,16-/m1/s1
DM360VU CS COC1=CC(=CC(=C1OC)OC)[C@H]2CC[C@@H](O2)C3=CC(=C(C(=C3)OC)OC)OC
DM360VU IK YCCPYTPBHUIHGW-HZPDHXFCSA-N
DM360VU IU (2R,5R)-2,5-bis(3,4,5-trimethoxyphenyl)oxolane
DM360VU DE Discovery agent
DM4CDIB ID DM4CDIB
DM4CDIB DN L-655708
DM4CDIB HS Investigative
DM4CDIB SN 130477-52-0; CHEMBL52030; NCGC00025115-02; Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate; Lopac0_000700; SCHEMBL5533646; YKYOQIXTECBVBB-AWEZNQCLSA-N; MolPort-003-983-605; HMS3262K21; ZINC2584032; Tox21_500700; MFCD02684528; BN0287; BDBM50067424; AKOS024456530; FG-8094; API0007742; LP00700; CCG-204785; CS-4943; NCGC00261385-01; NCGC00025115-04; NCGC00025115-03; HY-14426; KB-78047; EU-0100700; L-655,708, >
DM4CDIB DT Small molecular drug
DM4CDIB PC 5311203
DM4CDIB MW 341.4
DM4CDIB FM C18H19N3O4
DM4CDIB IC InChI=1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1
DM4CDIB CS CCOC(=O)C1=C2[C@@H]3CCCN3C(=O)C4=C(N2C=N1)C=CC(=C4)OC
DM4CDIB IK YKYOQIXTECBVBB-AWEZNQCLSA-N
DM4CDIB IU ethyl (7S)-15-methoxy-12-oxo-2,4,11-triazatetracyclo[11.4.0.02,6.07,11]heptadeca-1(17),3,5,13,15-pentaene-5-carboxylate
DM4CDIB DE Discovery agent
DMY0IQ6 ID DMY0IQ6
DMY0IQ6 DN L-658,758
DMY0IQ6 HS Investigative
DMY0IQ6 SN L-658758; L 658758; L-658,758; CHEMBL446371; L 658,758; (6R-cis)-1-((3-((Acetyloxy)methyl)-7-methoxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-yl)carbonyl)-L-proline S,S-dioxide; 3-Acetoxymethyl-7-methoxy-1-aza-5-thia-8-oxo-bicyclo(4.2.0)oct-2-ene-2-carboxypyrrolidine carboxamide; 116507-04-1; L-Proline, 1-((3-((acetyloxy)methyl)-7-methoxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-yl)carbonyl)-, S,S-dioxide, (6R-cis)-; AC1L3TQJ; SCHEMBL18498419; BDBM50368407; LS-186924; LS-187574; UNII-YMN4MD1ZGQ component SMZXYXKZTNLA
DMY0IQ6 DT Small molecular drug
DMY0IQ6 PC 121963
DMY0IQ6 MW 416.4
DMY0IQ6 FM C16H20N2O9S
DMY0IQ6 IC InChI=1S/C16H20N2O9S/c1-8(19)27-6-9-7-28(24,25)15-12(26-2)14(21)18(15)11(9)13(20)17-5-3-4-10(17)16(22)23/h10,12,15H,3-7H2,1-2H3,(H,22,23)/t10-,12-,15+/m0/s1
DMY0IQ6 CS CC(=O)OCC1=C(N2[C@@H]([C@H](C2=O)OC)S(=O)(=O)C1)C(=O)N3CCC[C@H]3C(=O)O
DMY0IQ6 IK SMZXYXKZTNLAKY-ITDIGPHOSA-N
DMY0IQ6 IU (2S)-1-[(6R,7S)-3-(acetyloxymethyl)-7-methoxy-5,5,8-trioxo-5lambda6-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carbonyl]pyrrolidine-2-carboxylic acid
DMY0IQ6 CA CAS 116507-04-1
DMY0IQ6 DE Discovery agent
DMDF0KZ ID DMDF0KZ
DMDF0KZ DN L-659,699
DMDF0KZ HS Investigative
DMDF0KZ SN L 659699; hymeglusin; antibiotic 1233A
DMDF0KZ DT Small molecular drug
DMDF0KZ PC 6440895
DMDF0KZ MW 324.4
DMDF0KZ FM C18H28O5
DMDF0KZ IC InChI=1S/C18H28O5/c1-12(8-13(2)9-14(3)10-17(20)21)6-4-5-7-16-15(11-19)18(22)23-16/h9-10,12,15-16,19H,4-8,11H2,1-3H3,(H,20,21)/b13-9+,14-10+/t12-,15-,16-/m1/s1
DMDF0KZ CS C[C@H](CCCC[C@@H]1[C@H](C(=O)O1)CO)C/C(=C/C(=C/C(=O)O)/C)/C
DMDF0KZ IK ODCZJZWSXPVLAW-KXCGKLMDSA-N
DMDF0KZ IU (2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoic acid
DMDF0KZ CA CAS 29066-42-0
DMDF0KZ DE Discovery agent
DMP4QCJ ID DMP4QCJ
DMP4QCJ DN L-671,480
DMP4QCJ HS Investigative
DMP4QCJ DE Discovery agent
DMJUQT1 ID DMJUQT1
DMJUQT1 DN L-685,818
DMJUQT1 HS Investigative
DMJUQT1 DT Small molecular drug
DMJUQT1 PC 445642
DMJUQT1 MW 808
DMJUQT1 FM C43H69NO13
DMJUQT1 IC InChI=1S/C43H69NO13/c1-10-29-18-23(2)37(48)24(3)19-35(54-8)39-36(55-9)20-26(5)43(52,57-39)40(49)41(50)44-16-12-11-13-30(44)42(51)56-38(27(6)32(46)22-33(29)47)25(4)17-28-14-15-31(45)34(21-28)53-7/h17-18,24,26-32,34-39,45-46,48,52H,10-16,19-22H2,1-9H3/b23-18+,25-17+/t24-,26-,27-,28+,29-,30+,31-,32+,34-,35+,36+,37-,38-,39-,43-/m1/s1
DMJUQT1 CS CC[C@@H]1/C=C(/[C@H]([C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC)C)O)\\C
DMJUQT1 IK NOQNPBXNHMZMTC-UGTSZWOVSA-N
DMJUQT1 IU (1R,9S,12S,13R,14S,17R,18E,20S,21R,23S,24R,25S,27R)-17-ethyl-1,14,20-trihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DMJUQT1 DE Discovery agent
DMCH3ZK ID DMCH3ZK
DMCH3ZK DN L-689,037
DMCH3ZK HS Investigative
DMCH3ZK SN L-689037; CHEMBL314337; 136668-50-3; 1-((4-Chlorophenyl)methyl)-3-(3,3-dimethyl-1-oxobutyl)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-1H-indole-2-propanoic acid; L 689037; L-689,037; ACMC-20mw95; L 689,037; SCHEMBL2108178; CTK0H7100; BDBM50229761; 1H-Indole-2-propanoic acid, 1-((4-chlorophenyl)methyl)-3-(3,3-dimethyl-1-oxobutyl)-alpha,alpha-dimethyl-5-(2-quinolinylmethoxy)-
DMCH3ZK DT Small molecular drug
DMCH3ZK PC 11758240
DMCH3ZK MW 597.1
DMCH3ZK FM C36H37ClN2O4
DMCH3ZK IC InChI=1S/C36H37ClN2O4/c1-35(2,3)20-32(40)33-28-18-27(43-22-26-15-12-24-8-6-7-9-29(24)38-26)16-17-30(28)39(21-23-10-13-25(37)14-11-23)31(33)19-36(4,5)34(41)42/h6-18H,19-22H2,1-5H3,(H,41,42)
DMCH3ZK CS CC(C)(C)CC(=O)C1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O
DMCH3ZK IK IUHIISLXVJPCRU-UHFFFAOYSA-N
DMCH3ZK IU 3-[1-[(4-chlorophenyl)methyl]-3-(3,3-dimethylbutanoyl)-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoic acid
DMCH3ZK CA CAS 136668-50-3
DMCH3ZK DE Discovery agent
DM42BGX ID DM42BGX
DM42BGX DN L-689065
DM42BGX HS Investigative
DM42BGX SN CHEMBL295761; L-689065; SCHEMBL9581325; BDBM50045667; 3-[1-(4-Chloro-benzyl)-4-methyl-6-(5-phenyl-pyridin-2-ylmethoxy)-4,5-dihydro-1H-thiopyrano[2,3,4-cd]indol-2-yl]-2,2-dimethyl-propionic acid; 3-[1-(4-Chloro-benzyl)-4-methyl-6-(5-phenyl-pyridin-2-ylmethoxy)-4,5-dihydro-1H-3-thia-1-aza-acenaphthylen-2-yl]-2,2-dimethyl-propionic acid
DM42BGX DT Small molecular drug
DM42BGX PC 9960281
DM42BGX MW 597.2
DM42BGX FM C35H33ClN2O3S
DM42BGX IC InChI=1S/C35H33ClN2O3S/c1-22-17-28-31(41-21-27-14-11-25(19-37-27)24-7-5-4-6-8-24)16-15-29-32(28)33(42-22)30(18-35(2,3)34(39)40)38(29)20-23-9-12-26(36)13-10-23/h4-16,19,22H,17-18,20-21H2,1-3H3,(H,39,40)
DM42BGX CS CC1CC2=C(C=CC3=C2C(=C(N3CC4=CC=C(C=C4)Cl)CC(C)(C)C(=O)O)S1)OCC5=NC=C(C=C5)C6=CC=CC=C6
DM42BGX IK UWFKZJIWHDTXTG-UHFFFAOYSA-N
DM42BGX IU 3-[2-[(4-chlorophenyl)methyl]-6-methyl-9-[(5-phenylpyridin-2-yl)methoxy]-5-thia-2-azatricyclo[6.3.1.04,12]dodeca-1(12),3,8,10-tetraen-3-yl]-2,2-dimethylpropanoic acid
DM42BGX DE Discovery agent
DMAB1RW ID DMAB1RW
DMAB1RW DN L-692289
DMAB1RW HS Investigative
DMAB1RW SN CHEMBL437438; L-692289; AC1MHQQ8; BDBM50285493; N-{(2R,6S,9S,11R,14aS,15S,20S,23S,25aS)-20-[(1R)-3-Amino-1-hydroxy-3-oxopropyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-23-[(1R)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
DMAB1RW PC 3009699
DMAB1RW MW 1033.2
DMAB1RW FM C50H80N8O15
DMAB1RW IC InChI=1S/C50H80N8O15/c1-5-27(2)20-28(3)12-10-8-6-7-9-11-13-40(67)53-34-22-32(61)25-52-48(71)44-36(63)18-19-57(44)50(73)43(38(65)24-39(51)66)56-47(70)42(37(64)21-30-14-16-31(60)17-15-30)55-46(69)35-23-33(62)26-58(35)49(72)41(29(4)59)54-45(34)68/h14-17,27-29,32-38,41-44,59-65H,5-13,18-26H2,1-4H3,(H2,51,66)(H,52,71)(H,53,67)(H,54,68)(H,55,69)(H,56,70)/t27?,28?,29-,32-,33-,34+,35+,36+,37-,38-,41+,42+,43+,44+/m1/s1
DMAB1RW CS CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H](CNC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H](CC4=CC=C(C=C4)O)O)[C@@H](CC(=O)N)O)O)O
DMAB1RW IK ZDGSWUBIMMFISL-IQTRWBIESA-N
DMAB1RW IU N-[(3S,6S,9S,11R,15S,18S,20R,24S,25S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-6-[(1R)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
DMAB1RW DE Discovery agent
DMMUYHX ID DMMUYHX
DMMUYHX DN L-693612
DMMUYHX HS Investigative
DMMUYHX SN (-)-(2S,4S)-6-(3-Methoxypropyl)-4-(propylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide; 138301-71-0
DMMUYHX DT Small molecular drug
DMMUYHX PC 67668482
DMMUYHX MW 396.6
DMMUYHX FM C14H24N2O5S3
DMMUYHX IC InChI=1S/C14H24N2O5S3/c1-3-6-16-12-8-10(5-4-7-21-2)23(17,18)14-11(12)9-13(22-14)24(15,19)20/h9-10,12,16H,3-8H2,1-2H3,(H2,15,19,20)/t10-,12-/m0/s1
DMMUYHX CS CCCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC
DMMUYHX IK JNPHBSXNRNBLCV-JQWIXIFHSA-N
DMMUYHX IU (4S,6S)-6-(3-methoxypropyl)-7,7-dioxo-4-(propylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
DMMUYHX CA CAS 138301-71-0
DMMUYHX DE Glaucoma/ocular hypertension
DM92X5T ID DM92X5T
DM92X5T DN L-702-539
DM92X5T HS Investigative
DM92X5T SN CHEMBL97380; SCHEMBL9300407; L-702-539
DM92X5T DT Small molecular drug
DM92X5T PC 44329500
DM92X5T MW 453.5
DM92X5T FM C28H23NO5
DM92X5T IC InChI=1S/C28H23NO5/c29-14-19-8-21-11-23(4-5-25(21)26(10-19)20-6-7-31-16-20)32-15-18-2-1-3-22(9-18)28(30)12-24-17-33-27(13-28)34-24/h1-11,16,24,27,30H,12-13,15,17H2
DM92X5T CS C1C2COC(O2)CC1(C3=CC=CC(=C3)COC4=CC5=C(C=C4)C(=CC(=C5)C#N)C6=COC=C6)O
DM92X5T IK CHLJRXIFRPILDX-UHFFFAOYSA-N
DM92X5T IU 4-(furan-3-yl)-7-[[3-(3-hydroxy-6,8-dioxabicyclo[3.2.1]octan-3-yl)phenyl]methoxy]naphthalene-2-carbonitrile
DM92X5T DE Discovery agent
DMUOPRT ID DMUOPRT
DMUOPRT DN L-703,606
DMUOPRT HS Investigative
DMUOPRT SN L-703606
DMUOPRT DT Small molecular drug
DMUOPRT PC 132629
DMUOPRT MW 508.4
DMUOPRT FM C27H29IN2
DMUOPRT IC InChI=1S/C27H29IN2/c28-24-14-8-7-13-23(24)19-29-26-22-15-17-30(18-16-22)27(26)25(20-9-3-1-4-10-20)21-11-5-2-6-12-21/h1-14,22,25-27,29H,15-19H2/t26-,27-/m1/s1
DMUOPRT CS C1CN2CCC1[C@H]([C@H]2C(C3=CC=CC=C3)C4=CC=CC=C4)NCC5=CC=CC=C5I
DMUOPRT IK WSLTYZVXORBNLB-KAYWLYCHSA-N
DMUOPRT IU (2R,3R)-2-benzhydryl-N-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
DMUOPRT CA CAS 144425-84-3
DMUOPRT DE Discovery agent
DMWYIJ3 ID DMWYIJ3
DMWYIJ3 DN L-708,906
DMWYIJ3 HS Investigative
DMWYIJ3 SN L-708906; CHEMBL19977; SCHEMBL4935528; L-708,906; AC1L9T47; CTK7I3759; BDBM107681; 4-(3,5-dibenzyloxyphenyl)-2,4-dioxo-butanoic acid; 4-[3,5-bis(benzyloxy)phenyl]-2,4-dioxobutanoic acid; 4-(3,5-Bis-benzyloxy-phenyl)-2,4-dioxo-butyric acid; 4-[3,5-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid; (2Z)-4-[3,5-bis(benzyloxy)phenyl]-2-hydroxy-4- oxobut-2-enoic acid (Compound 2)
DMWYIJ3 DT Small molecular drug
DMWYIJ3 PC 475514
DMWYIJ3 MW 404.4
DMWYIJ3 FM C24H20O6
DMWYIJ3 IC InChI=1S/C24H20O6/c25-22(14-23(26)24(27)28)19-11-20(29-15-17-7-3-1-4-8-17)13-21(12-19)30-16-18-9-5-2-6-10-18/h1-13H,14-16H2,(H,27,28)
DMWYIJ3 CS C1=CC=C(C=C1)COC2=CC(=CC(=C2)C(=O)CC(=O)C(=O)O)OCC3=CC=CC=C3
DMWYIJ3 IK SLRLQBRWUMWEOZ-UHFFFAOYSA-N
DMWYIJ3 IU 4-[3,5-bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid
DMWYIJ3 DE Discovery agent
DM3QUCS ID DM3QUCS
DM3QUCS DN L-708474
DM3QUCS HS Investigative
DM3QUCS SN CHEMBL58699; L-708474; SCHEMBL9301528; BDBM50040666
DM3QUCS DT Small molecular drug
DM3QUCS PC 9953071
DM3QUCS MW 404.5
DM3QUCS FM C24H28N4O2
DM3QUCS IC InChI=1S/C24H28N4O2/c1-16-9-8-12-18(15-16)25-24(30)27-22-23(29)28(2)20-14-7-6-13-19(20)21(26-22)17-10-4-3-5-11-17/h6-9,12-15,17,22H,3-5,10-11H2,1-2H3,(H2,25,27,30)/t22-/m0/s1
DM3QUCS CS CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)C4CCCCC4)C
DM3QUCS IK MYNLMIGJXBPKMR-QFIPXVFZSA-N
DM3QUCS IU 1-[(3R)-5-cyclohexyl-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DM3QUCS DE Discovery agent
DMLMV9P ID DMLMV9P
DMLMV9P DN L-708568
DMLMV9P HS Investigative
DMLMV9P SN L-708568; CHEMBL23129; 2-Acetylamino-3-(1H-indol-3-yl)-propionic acid 3,5-dimethyl-benzyl ester; BDBM50030133; (S)-2-Acetylamino-3-(1H-indol-3-yl)-propionic acid 3,5-dimethyl-benzyl ester
DMLMV9P DT Small molecular drug
DMLMV9P PC 10473960
DMLMV9P MW 364.4
DMLMV9P FM C22H24N2O3
DMLMV9P IC InChI=1S/C22H24N2O3/c1-14-8-15(2)10-17(9-14)13-27-22(26)21(24-16(3)25)11-18-12-23-20-7-5-4-6-19(18)20/h4-10,12,21,23H,11,13H2,1-3H3,(H,24,25)/t21-/m0/s1
DMLMV9P CS CC1=CC(=CC(=C1)COC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)C)C
DMLMV9P IK YIHWPQQGVKFHTC-NRFANRHFSA-N
DMLMV9P IU (3,5-dimethylphenyl)methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate
DMLMV9P DE Discovery agent
DM9KCYQ ID DM9KCYQ
DM9KCYQ DN L-709,587
DM9KCYQ HS Investigative
DM9KCYQ SN L-709,587; C32-O-(1-METHYL-INDOL-5-YL) 18-HYDROXY-ASCOMYCIN; 1qpl; DB03621
DM9KCYQ DT Small molecular drug
DM9KCYQ PC 5496872
DM9KCYQ MW 937.2
DM9KCYQ FM C52H76N2O13
DM9KCYQ IC InChI=1S/C52H76N2O13/c1-11-35-23-29(2)46(57)30(3)24-44(63-9)48-45(64-10)25-32(5)52(61,67-48)49(58)50(59)54-20-13-12-14-39(54)51(60)66-47(33(6)40(55)28-41(35)56)31(4)22-34-15-18-42(43(26-34)62-8)65-37-16-17-38-36(27-37)19-21-53(38)7/h16-17,19,21-23,27,30,32-35,39-40,42-48,55,57,61H,11-15,18,20,24-26,28H2,1-10H3/b29-23+,31-22+/t30-,32-,33-,34+,35-,39+,40+,42-,43-,44+,45+,46-,47-,48-,52-/m1/s1
DM9KCYQ CS CC[C@@H]1/C=C(/[C@H]([C@@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)OC5=CC6=C(C=C5)N(C=C6)C)/C)O)C)OC)OC)C)O)\\C
DM9KCYQ IK APSPCHLQXFEUHG-CPBVNLROSA-N
DM9KCYQ IU (1R,9S,12S,13R,14S,17R,18E,20S,21R,23S,24R,25S,27R)-17-ethyl-1,14,20-trihydroxy-23,25-dimethoxy-12-[(E)-1-[(1R,3R,4R)-3-methoxy-4-(1-methylindol-5-yl)oxycyclohexyl]prop-1-en-2-yl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
DM9KCYQ DE Discovery agent
DM7YVUT ID DM7YVUT
DM7YVUT DN L-731,988
DM7YVUT HS Investigative
DM7YVUT SN L-731988; CHEMBL50605; 251922-77-7; AC1Q5RH2; SCHEMBL4936294; AC1L9T44; CTK4F5172; BDBM23399; 4-[1-(4-fluorobenzyl)-1h-pyrrol-2-yl]-2,4-dioxobutanoic acid; 4-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxobutanoic acid; 4-(1-(4-Fluoro-benzyl)-1H-pyrrol-2-yl)-2,4-dioxo-butyric acid; 1H-Pyrrole-2-butanoicacid, 1-[(4-fluorophenyl)methyl]-a,g-dioxo-; 4-{1-[(4-fluorophenyl)methyl]-1H-pyrrol-2-yl}-2,4-dioxobutanoic acid; 1H-Pyrrole-2-butanoic acid, 1-((4-fluorophenyl)methyl)-alpha,gamma-dioxo-
DM7YVUT DT Small molecular drug
DM7YVUT PC 475513
DM7YVUT MW 289.26
DM7YVUT FM C15H12FNO4
DM7YVUT IC InChI=1S/C15H12FNO4/c16-11-5-3-10(4-6-11)9-17-7-1-2-12(17)13(18)8-14(19)15(20)21/h1-7H,8-9H2,(H,20,21)
DM7YVUT CS C1=CN(C(=C1)C(=O)CC(=O)C(=O)O)CC2=CC=C(C=C2)F
DM7YVUT IK PJIBKQJSMPMZCH-UHFFFAOYSA-N
DM7YVUT IU 4-[1-[(4-fluorophenyl)methyl]pyrrol-2-yl]-2,4-dioxobutanoic acid
DM7YVUT CA CAS 251922-77-7
DM7YVUT DE Discovery agent
DM8WCUY ID DM8WCUY
DM8WCUY DN L-731120
DM8WCUY HS Investigative
DM8WCUY SN L 731120
DM8WCUY DT Small molecular drug
DM8WCUY PC 9931928
DM8WCUY MW 420.5
DM8WCUY FM C23H32O7
DM8WCUY IC InChI=1S/C23H32O7/c1-16(13-17(2)14-18-10-6-4-7-11-18)9-5-3-8-12-19(21(26)27)23(30,22(28)29)15-20(24)25/h4,6-7,10-11,13,17,19,30H,3,5,8-9,12,14-15H2,1-2H3,(H,24,25)(H,26,27)(H,28,29)/b16-13+
DM8WCUY CS CC(CC1=CC=CC=C1)/C=C(\\C)/CCCCCC(C(=O)O)C(CC(=O)O)(C(=O)O)O
DM8WCUY IK NLNJIEVMUWDLAZ-DTQAZKPQSA-N
DM8WCUY IU (E)-2-hydroxy-9,11-dimethyl-12-phenyldodec-9-ene-1,2,3-tricarboxylic acid
DM8WCUY DE Discovery agent
DMTHLUN ID DMTHLUN
DMTHLUN DN L-731128
DMTHLUN HS Investigative
DMTHLUN SN L 731128
DMTHLUN DT Small molecular drug
DMTHLUN PC 9889873
DMTHLUN MW 448.5
DMTHLUN FM C25H36O7
DMTHLUN IC InChI=1S/C25H36O7/c1-18(16-19(2)11-9-14-20-12-6-4-7-13-20)10-5-3-8-15-21(23(28)29)25(32,24(30)31)17-22(26)27/h4,6-7,9,12-14,18-19,21,32H,3,5,8,10-11,15-17H2,1-2H3,(H,26,27)(H,28,29)(H,30,31)/b14-9+
DMTHLUN CS CC(CCCCCC(C(=O)O)C(CC(=O)O)(C(=O)O)O)CC(C)C/C=C/C1=CC=CC=C1
DMTHLUN IK DSEOFKAKDCUIFI-NTEUORMPSA-N
DMTHLUN IU (E)-2-hydroxy-9,11-dimethyl-14-phenyltetradec-13-ene-1,2,3-tricarboxylic acid
DMTHLUN DE Discovery agent
DMDNVTF ID DMDNVTF
DMDNVTF DN L-734115
DMDNVTF HS Investigative
DMDNVTF SN CHEMBL40502; L-734115; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)
DMDNVTF DT Small molecular drug
DMDNVTF PC 9913833
DMDNVTF MW 498.6
DMDNVTF FM C21H34N6O6S
DMDNVTF IC InChI=1S/C21H34N6O6S/c1-2-3-12-34(32,33)25-17(21(30)31)14-23-19(28)16-13-18-20(29)26(10-11-27(18)24-16)9-6-15-4-7-22-8-5-15/h13,15,17,22,25H,2-12,14H2,1H3,(H,23,28)(H,30,31)/t17-/m0/s1
DMDNVTF CS CCCCS(=O)(=O)N[C@@H](CNC(=O)C1=NN2CCN(C(=O)C2=C1)CCC3CCNCC3)C(=O)O
DMDNVTF IK FXBDPMBWPSLDQZ-KRWDZBQOSA-N
DMDNVTF IU (2S)-2-(butylsulfonylamino)-3-[[4-oxo-5-(2-piperidin-4-ylethyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-2-carbonyl]amino]propanoic acid
DMDNVTF DE Discovery agent
DMY60MG ID DMY60MG
DMY60MG DN L-735,821
DMY60MG HS Investigative
DMY60MG SN CHEMBL332826; AC1NQZS7; C13853; CHEBI:34807; L 735821; (E)-3-(2,4-dichlorophenyl)-N-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]prop-2-enamide; SureCN8611879; SCHEMBL8837547; SCHEMBL8611879; GTPL2592; CHEBI:303776; BDBM50061218; L735821; N-[[(3R)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin]-3-yl]-2,4-dichlorobenzeneacrylamide; 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-acrylamide
DMY60MG DT Small molecular drug
DMY60MG PC 5282279
DMY60MG MW 464.3
DMY60MG FM C25H19Cl2N3O2
DMY60MG IC InChI=1S/C25H19Cl2N3O2/c1-30-21-10-6-5-9-19(21)23(17-7-3-2-4-8-17)29-24(25(30)32)28-22(31)14-12-16-11-13-18(26)15-20(16)27/h2-15,24H,1H3,(H,28,31)/b14-12+/t24-/m1/s1
DMY60MG CS CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)/C=C/C3=C(C=C(C=C3)Cl)Cl)C4=CC=CC=C4
DMY60MG IK BYULDQRRUINTAA-SWDTZWKESA-N
DMY60MG IU (E)-3-(2,4-dichlorophenyl)-N-[(3R)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]prop-2-enamide
DMY60MG CB CHEBI:34807
DMY60MG DE Discovery agent
DM8BVJQ ID DM8BVJQ
DM8BVJQ DN L-735021
DM8BVJQ HS Investigative
DM8BVJQ SN L 735021
DM8BVJQ DT Small molecular drug
DM8BVJQ PC 9853075
DM8BVJQ MW 696.8
DM8BVJQ FM C38H48O12
DM8BVJQ IC InChI=1S/C38H48O12/c1-25(16-13-21-27-17-5-3-6-18-27)14-9-10-22-29(39)48-31-30(40)36(23-12-11-15-26(2)24-28-19-7-4-8-20-28)49-32(33(41)42)37(47,34(43)44)38(31,50-36)35(45)46/h3-9,14,17-20,25-26,30-32,40,47H,10-13,15-16,21-24H2,1-2H3,(H,41,42)(H,43,44)(H,45,46)/b14-9+/t25?,26?,30-,31-,32?,36?,37?,38?/m1/s1
DM8BVJQ CS CC(CCCCC12[C@@H]([C@H](C(O1)(C(C(O2)C(=O)O)(C(=O)O)O)C(=O)O)OC(=O)CC/C=C/C(C)CCCC3=CC=CC=C3)O)CC4=CC=CC=C4
DM8BVJQ IK ZOTNYZYRJOAANS-OIAIRNFISA-N
DM8BVJQ IU (6R,7R)-4,7-dihydroxy-1-(5-methyl-6-phenylhexyl)-6-[(E)-6-methyl-9-phenylnon-4-enoyl]oxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
DM8BVJQ DE Discovery agent
DMJNLSI ID DMJNLSI
DMJNLSI DN L-736281
DMJNLSI HS Investigative
DMJNLSI SN L-736281; CHEMBL27003; SCHEMBL19440986; BDBM50052283; 2-[3-(3,5-Bis-trifluoromethyl-benzyloxy)-2-phenyl-piperidin-1-yl]-acetamide
DMJNLSI DT Small molecular drug
DMJNLSI PC 9890435
DMJNLSI MW 460.4
DMJNLSI FM C22H22F6N2O2
DMJNLSI IC InChI=1S/C22H22F6N2O2/c23-21(24,25)16-9-14(10-17(11-16)22(26,27)28)13-32-18-7-4-8-30(12-19(29)31)20(18)15-5-2-1-3-6-15/h1-3,5-6,9-11,18,20H,4,7-8,12-13H2,(H2,29,31)/t18-,20-/m0/s1
DMJNLSI CS C1C[C@@H]([C@@H](N(C1)CC(=O)N)C2=CC=CC=C2)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
DMJNLSI IK SUZSWSSXVHSRLT-ICSRJNTNSA-N
DMJNLSI IU 2-[(2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidin-1-yl]acetamide
DMJNLSI DE Discovery agent
DMM5AYL ID DMM5AYL
DMM5AYL DN L-736380
DMM5AYL HS Investigative
DMM5AYL SN L 736380; L736380
DMM5AYL DT Small molecular drug
DMM5AYL PC 9935175
DMM5AYL MW 487.6
DMM5AYL FM C25H29N9O2
DMM5AYL IC InChI=1S/C25H29N9O2/c1-33(24-29-31-32-30-24)18-12-8-11-17(15-18)26-25(36)28-22-23(35)34(2)20-14-7-6-13-19(20)21(27-22)16-9-4-3-5-10-16/h6-8,11-16,22H,3-5,9-10H2,1-2H3,(H2,26,28,36)(H,29,30,31,32)/t22-/m0/s1
DMM5AYL CS CN1C2=CC=CC=C2C(=N[C@H](C1=O)NC(=O)NC3=CC(=CC=C3)N(C)C4=NNN=N4)C5CCCCC5
DMM5AYL IK MYPNMQPMQUAOTH-QFIPXVFZSA-N
DMM5AYL IU 1-[(3R)-5-cyclohexyl-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-[3-[methyl(2H-tetrazol-5-yl)amino]phenyl]urea
DMM5AYL DE Discovery agent
DMAHC9Z ID DMAHC9Z
DMAHC9Z DN L-739750
DMAHC9Z HS Investigative
DMAHC9Z SN L-739,750; 2(S)-{2(S)-[2(R)-AMINO-3-MERCAPTO]PROPYLAMINO-3(S)-METHYL}PENTYLOXY-3-PHENYLPROPIONYLMETHIONINE SULFONE; (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoic acid; AC1NR9VU; L 739750; GTPL8030; SCHEMBL2723214; (2S)-2-{[(2S)-2-{[(2S,3S)-2-{[(2R)-2-amino-3-sulfanylpropyl]amino}-3-methylpentyl]oxy}-3-phenylpropanoyl]amino}-4-(methylsulfonyl)butanoic acid
DMAHC9Z DT Small molecular drug
DMAHC9Z PC 5287548
DMAHC9Z MW 517.7
DMAHC9Z FM C23H39N3O6S2
DMAHC9Z IC InChI=1S/C23H39N3O6S2/c1-4-16(2)20(25-13-18(24)15-33)14-32-21(12-17-8-6-5-7-9-17)22(27)26-19(23(28)29)10-11-34(3,30)31/h5-9,16,18-21,25,33H,4,10-15,24H2,1-3H3,(H,26,27)(H,28,29)/t16-,18+,19-,20+,21-/m0/s1
DMAHC9Z CS CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)O)NC[C@H](CS)N
DMAHC9Z IK SIEXHGZWGJLLAC-OSTWSGHESA-N
DMAHC9Z IU (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoic acid
DMAHC9Z DE Discovery agent
DM5IAXN ID DM5IAXN
DM5IAXN DN L-739758
DM5IAXN HS Investigative
DM5IAXN SN CHEMBL78760; L-739758; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid
DM5IAXN DT Small molecular drug
DM5IAXN PC 9958398
DM5IAXN MW 522.7
DM5IAXN FM C22H26N4O5S3
DM5IAXN IC InChI=1S/C22H26N4O5S3/c27-20(25-13-18(21(28)29)26-34(30,31)17-2-1-7-24-12-17)19-11-15-10-16(32-22(15)33-19)4-3-14-5-8-23-9-6-14/h1-2,7,10-12,14,18,23,26H,3-6,8-9,13H2,(H,25,27)(H,28,29)/t18-/m0/s1
DM5IAXN CS C1CNCCC1CCC2=CC3=C(S2)SC(=C3)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C4=CN=CC=C4
DM5IAXN IK QDIFCBMBPLLNGR-SFHVURJKSA-N
DM5IAXN IU (2S)-3-[[2-(2-piperidin-4-ylethyl)thieno[2,3-b]thiophene-5-carbonyl]amino]-2-(pyridin-3-ylsulfonylamino)propanoic acid
DM5IAXN DE Discovery agent
DMVA2D0 ID DMVA2D0
DMVA2D0 DN L-740093
DMVA2D0 HS Investigative
DMVA2D0 SN L-740093; CHEMBL420783; L 740093; L-740,093; CHEMBL545122; 1-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea; PDSP1_000900; L740093; GTPL881; 154967-59-6; SCHEMBL7627122; L 740,093; AC1L31Y3; PDSP2_000886; BDBM50059319; BDBM50040667; N-(5-(3-Azabicyclo(3.2.2)nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea; L-741545
DMVA2D0 DT Small molecular drug
DMVA2D0 PC 132980
DMVA2D0 MW 445.6
DMVA2D0 FM C26H31N5O2
DMVA2D0 IC InChI=1S/C26H31N5O2/c1-17-6-5-7-20(14-17)27-26(33)29-23-25(32)30(2)22-9-4-3-8-21(22)24(28-23)31-15-18-10-11-19(16-31)13-12-18/h3-9,14,18-19,23H,10-13,15-16H2,1-2H3,(H2,27,29,33)/t18?,19?,23-/m0/s1
DMVA2D0 CS CC1=CC(=CC=C1)NC(=O)N[C@H]2C(=O)N(C3=CC=CC=C3C(=N2)N4CC5CCC(C4)CC5)C
DMVA2D0 IK QYERABWMFRRINX-XWEVFREBSA-N
DMVA2D0 IU 1-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
DMVA2D0 CA CAS 154967-59-6
DMVA2D0 DE Discovery agent
DMCYQJF ID DMCYQJF
DMCYQJF DN L-741626
DMCYQJF HS Investigative
DMCYQJF SN L-741,626; 81226-60-0; L-741626; 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole; L 741626; L 741,626; CHEMBL445102; 4-(4-Chlorophenyl)-1-(1H-indol-3-ylmethyl)-4-piperidinol; 4-(4-chlorophenyl)-1-(1h-indol-3-ylmethyl)piperidin-4-ol; C20H21ClN2O; 4-Piperidinol, 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)-; SR-01000075973; Tocris-1003; NCGC00015591-01; Lopac-L-135; Biomol-NT_000036; AC1Q3NO6; Lopac0_000742; GTPL177; MLS000860079; ZINC6788; BPBio1_001094; AC1L335F; SCHEMBL11253588; CHEBI:92090; CTK3I9542; DTXSID30230974
DMCYQJF DT Small molecular drug
DMCYQJF PC 133633
DMCYQJF MW 340.8
DMCYQJF FM C20H21ClN2O
DMCYQJF IC InChI=1S/C20H21ClN2O/c21-17-7-5-16(6-8-17)20(24)9-11-23(12-10-20)14-15-13-22-19-4-2-1-3-18(15)19/h1-8,13,22,24H,9-12,14H2
DMCYQJF CS C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CC3=CNC4=CC=CC=C43
DMCYQJF IK LLBLNMUONVVVPG-UHFFFAOYSA-N
DMCYQJF IU 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)piperidin-4-ol
DMCYQJF CA CAS 81226-60-0
DMCYQJF CB CHEBI:92090
DMCYQJF DE Discovery agent
DMP75YK ID DMP75YK
DMP75YK DN L-741742
DMP75YK HS Investigative
DMP75YK SN L-741742; UNII-C5B89UM05U; CHEMBL444309; C5B89UM05U; L 741742; L-741,742; L741742; Cmpepi-3; Tocris-1004; Biomol-NT_000048; GTPL3302; SCHEMBL1388774; BPBio1_001096; DTXSID0043894; CHEBI:92229; ZINC602172; AC1L3203; BDBM50050476; NCGC00024933-02; NCGC00024933-01; L016523; L 741,742; BRD-K13211965-001-02-2; BRD-K13211965-003-01-0; BRD-K13211965-001-01-4; 5-(4-chlorophenyl)-4-methyl-3-(1-phenethylpiperidin-4-yl)-1,2-oxazole; 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole
DMP75YK DT Small molecular drug
DMP75YK PC 133008
DMP75YK MW 380.9
DMP75YK FM C23H25ClN2O
DMP75YK IC InChI=1S/C23H25ClN2O/c1-17-22(25-27-23(17)20-7-9-21(24)10-8-20)19-12-15-26(16-13-19)14-11-18-5-3-2-4-6-18/h2-10,19H,11-16H2,1H3
DMP75YK CS CC1=C(ON=C1C2CCN(CC2)CCC3=CC=CC=C3)C4=CC=C(C=C4)Cl
DMP75YK IK QDMAKDIDFJTXEL-UHFFFAOYSA-N
DMP75YK IU 5-(4-chlorophenyl)-4-methyl-3-[1-(2-phenylethyl)piperidin-4-yl]-1,2-oxazole
DMP75YK CA CAS 156337-32-5
DMP75YK CB CHEBI:92229
DMP75YK DE Discovery agent
DMRC8MT ID DMRC8MT
DMRC8MT DN L-746233
DMRC8MT HS Investigative
DMRC8MT SN CHEMBL79294; L-746233; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid
DMRC8MT DT Small molecular drug
DMRC8MT PC 10324223
DMRC8MT MW 515.6
DMRC8MT FM C24H29N5O6S
DMRC8MT IC InChI=1S/C24H29N5O6S/c30-22(27-14-21(24(32)33)28-36(34,35)19-2-1-8-26-13-19)17-3-4-18-15-29(23(31)20(18)12-17)11-7-16-5-9-25-10-6-16/h1-4,8,12-13,16,21,25,28H,5-7,9-11,14-15H2,(H,27,30)(H,32,33)/t21-/m0/s1
DMRC8MT CS C1CNCCC1CCN2CC3=C(C2=O)C=C(C=C3)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C4=CN=CC=C4
DMRC8MT IK FVGFTYFYGPWTIR-NRFANRHFSA-N
DMRC8MT IU (2S)-3-[[3-oxo-2-(2-piperidin-4-ylethyl)-1H-isoindole-5-carbonyl]amino]-2-(pyridin-3-ylsulfonylamino)propanoic acid
DMRC8MT DE Discovery agent
DMUY8MP ID DMUY8MP
DMUY8MP DN L-746530
DMUY8MP HS Investigative
DMUY8MP SN L-746530; CHEMBL207057; BDBM50182300
DMUY8MP DT Small molecular drug
DMUY8MP PC 44410706
DMUY8MP MW 472.5
DMUY8MP FM C27H21FN2O5
DMUY8MP IC InChI=1S/C27H21FN2O5/c28-19-6-18(27(31)10-22-15-34-26(11-27)35-22)7-21(8-19)33-13-16-1-2-23-24(17-3-4-32-14-17)9-20(12-29)30-25(23)5-16/h1-9,14,22,26,31H,10-11,13,15H2/t22-,26+,27-/m0/s1
DMUY8MP CS C1[C@H]2CO[C@H](O2)C[C@@]1(C3=CC(=CC(=C3)F)OCC4=CC5=NC(=CC(=C5C=C4)C6=COC=C6)C#N)O
DMUY8MP IK GZOVJNIKHQXVIU-FDJWOJMMSA-N
DMUY8MP IU 7-[[3-fluoro-5-[(1S,3S,5R)-3-hydroxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]phenoxy]methyl]-4-(furan-3-yl)quinoline-2-carbonitrile
DMUY8MP DE Discovery agent
DMBPWSJ ID DMBPWSJ
DMBPWSJ DN L-747201
DMBPWSJ HS Investigative
DMBPWSJ SN CHEMBL116092; L-747201; SCHEMBL9075818; BDBM50060419; L010227; 3-(2-Pyrrolizinoethyl)-5-(4H-1,2,4-triazol-4-yl)-1H-indole
DMBPWSJ DT Small molecular drug
DMBPWSJ PC 10468938
DMBPWSJ MW 281.36
DMBPWSJ FM C16H19N5
DMBPWSJ IC InChI=1S/C16H19N5/c1-2-7-20(6-1)8-5-13-10-17-16-4-3-14(9-15(13)16)21-11-18-19-12-21/h3-4,9-12,17H,1-2,5-8H2
DMBPWSJ CS C1CCN(C1)CCC2=CNC3=C2C=C(C=C3)N4C=NN=C4
DMBPWSJ IK WYXPLVWYFDBFBS-UHFFFAOYSA-N
DMBPWSJ IU 3-(2-pyrrolidin-1-ylethyl)-5-(1,2,4-triazol-4-yl)-1H-indole
DMBPWSJ DE Discovery agent
DMEGU5J ID DMEGU5J
DMEGU5J DN L748328
DMEGU5J HS Investigative
DMEGU5J SN L-748328; L-748,328
DMEGU5J DT Small molecular drug
DMEGU5J PC 10323892
DMEGU5J MW 505.6
DMEGU5J FM C23H27N3O6S2
DMEGU5J IC InChI=1S/C23H27N3O6S2/c24-33(28,29)23-8-4-5-21(15-23)32-17-20(27)16-25-14-13-18-9-11-19(12-10-18)26-34(30,31)22-6-2-1-3-7-22/h1-12,15,20,25-27H,13-14,16-17H2,(H2,24,28,29)/t20-/m0/s1
DMEGU5J CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CCNC[C@@H](COC3=CC(=CC=C3)S(=O)(=O)N)O
DMEGU5J IK CVPJSQZQNBKALR-FQEVSTJZSA-N
DMEGU5J IU 3-[(2S)-3-[2-[4-(benzenesulfonamido)phenyl]ethylamino]-2-hydroxypropoxy]benzenesulfonamide
DMEGU5J DE Discovery agent
DM7CPBU ID DM7CPBU
DM7CPBU DN L-748337
DM7CPBU HS Investigative
DM7CPBU SN L-748,337; L 748337
DM7CPBU DT Small molecular drug
DM7CPBU PC 10028830
DM7CPBU MW 497.6
DM7CPBU FM C26H31N3O5S
DM7CPBU IC InChI=1S/C26H31N3O5S/c1-20(30)28-17-22-6-5-7-25(16-22)34-19-24(31)18-27-15-14-21-10-12-23(13-11-21)29-35(32,33)26-8-3-2-4-9-26/h2-13,16,24,27,29,31H,14-15,17-19H2,1H3,(H,28,30)/t24-/m0/s1
DM7CPBU CS CC(=O)NCC1=CC(=CC=C1)OC[C@H](CNCCC2=CC=C(C=C2)NS(=O)(=O)C3=CC=CC=C3)O
DM7CPBU IK AWIONHVPTYTSHZ-DEOSSOPVSA-N
DM7CPBU IU N-[[3-[(2S)-3-[2-[4-(benzenesulfonamido)phenyl]ethylamino]-2-hydroxypropoxy]phenyl]methyl]acetamide
DM7CPBU DE Discovery agent
DMJZXAF ID DMJZXAF
DMJZXAF DN L-748780
DMJZXAF HS Investigative
DMJZXAF SN L-748780; CHEMBL159315; 168086-64-4; L 748780; L 748,780; AC1L2SX2; SCHEMBL3240332; L-748,780; CTK0H7371; DTXSID40168476; WUJUBERMAKRECF-UHFFFAOYSA-N; BDBM50289085; 5-Methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-1H-indole-3-acetic acid; 1 -(2,4,6-Trichlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetic acid; 1H-Indole-3-aceticacid, 5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)-; 1-(2,4,6-Trichlorobenzoyl)-2-methyl-5-methoxy-1H-indole-3-acetic acid; 2-[5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)indol-3-yl]acetic acid
DMJZXAF DT Small molecular drug
DMJZXAF PC 127942
DMJZXAF MW 426.7
DMJZXAF FM C19H14Cl3NO4
DMJZXAF IC InChI=1S/C19H14Cl3NO4/c1-9-12(8-17(24)25)13-7-11(27-2)3-4-16(13)23(9)19(26)18-14(21)5-10(20)6-15(18)22/h3-7H,8H2,1-2H3,(H,24,25)
DMJZXAF CS CC1=C(C2=C(N1C(=O)C3=C(C=C(C=C3Cl)Cl)Cl)C=CC(=C2)OC)CC(=O)O
DMJZXAF IK WUJUBERMAKRECF-UHFFFAOYSA-N
DMJZXAF IU 2-[5-methoxy-2-methyl-1-(2,4,6-trichlorobenzoyl)indol-3-yl]acetic acid
DMJZXAF CA CAS 168086-64-4
DMJZXAF DE Discovery agent
DM2WUKF ID DM2WUKF
DM2WUKF DN L-750,667
DM2WUKF HS Investigative
DM2WUKF SN Lopac-L-133; L750667; L-750667
DM2WUKF DT Small molecular drug
DM2WUKF PC 6603897
DM2WUKF MW 418.3
DM2WUKF FM C18H19IN4
DM2WUKF IC InChI=1S/C18H19IN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)
DM2WUKF CS C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)I
DM2WUKF IK OOEUHRGMLFVKQO-UHFFFAOYSA-N
DM2WUKF IU 3-[[4-(4-iodophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine
DM2WUKF CA CAS 1021868-80-3
DM2WUKF CB CHEBI:92507
DM2WUKF DE Discovery agent
DM9QAP4 ID DM9QAP4
DM9QAP4 DN L-750034
DM9QAP4 HS Investigative
DM9QAP4 SN L-750034; CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid
DM9QAP4 DT Small molecular drug
DM9QAP4 PC 11743533
DM9QAP4 MW 432.5
DM9QAP4 FM C20H24N4O5S
DM9QAP4 IC InChI=1S/C20H24N4O5S/c25-19(15-6-8-16(9-7-15)24-12-10-21-11-13-24)22-14-18(20(26)27)23-30(28,29)17-4-2-1-3-5-17/h1-9,18,21,23H,10-14H2,(H,22,25)(H,26,27)/t18-/m0/s1
DM9QAP4 CS C1CN(CCN1)C2=CC=C(C=C2)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C3=CC=CC=C3
DM9QAP4 IK PXSDSRKJCWOYNE-SFHVURJKSA-N
DM9QAP4 IU (2S)-2-(benzenesulfonamido)-3-[(4-piperazin-1-ylbenzoyl)amino]propanoic acid
DM9QAP4 DE Discovery agent
DMEQWSB ID DMEQWSB
DMEQWSB DN L-756568
DMEQWSB HS Investigative
DMEQWSB SN CHEMBL96097; L-756568; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)
DMEQWSB DT Small molecular drug
DMEQWSB PC 9805998
DMEQWSB MW 500.6
DMEQWSB FM C24H28N4O6S
DMEQWSB IC InChI=1S/C24H28N4O6S/c29-23(26-14-22(24(30)31)28-35(32,33)19-4-2-1-3-5-19)21-13-17-12-18(6-7-20(17)27-21)34-15-16-8-10-25-11-9-16/h1-7,12-13,16,22,25,27-28H,8-11,14-15H2,(H,26,29)(H,30,31)/t22-/m0/s1
DMEQWSB CS C1CNCCC1COC2=CC3=C(C=C2)NC(=C3)C(=O)NC[C@@H](C(=O)O)NS(=O)(=O)C4=CC=CC=C4
DMEQWSB IK CFKZYRJYUHWTIW-QFIPXVFZSA-N
DMEQWSB IU (2S)-2-(benzenesulfonamido)-3-[[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]amino]propanoic acid
DMEQWSB DE Discovery agent
DMQJNDX ID DMQJNDX
DMQJNDX DN L-759,633
DMQJNDX HS Investigative
DMQJNDX SN L759633; L-759633
DMQJNDX DT Small molecular drug
DMQJNDX PC 5311215
DMQJNDX MW 384.6
DMQJNDX FM C26H40O2
DMQJNDX IC InChI=1S/C26H40O2/c1-8-9-10-11-14-25(3,4)19-16-22(27-7)24-20-15-18(2)12-13-21(20)26(5,6)28-23(24)17-19/h12,16-17,20-21H,8-11,13-15H2,1-7H3/t20-,21-/m1/s1
DMQJNDX CS CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=CC[C@H]3C(O2)(C)C)C)C(=C1)OC
DMQJNDX IK SUFMHSFGODDLKI-NHCUHLMSSA-N
DMQJNDX IU (6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene
DMQJNDX DE Discovery agent
DM5SOR4 ID DM5SOR4
DM5SOR4 DN L-759,656
DM5SOR4 HS Investigative
DM5SOR4 SN L759656; L-759656
DM5SOR4 DT Small molecular drug
DM5SOR4 PC 5311216
DM5SOR4 MW 384.6
DM5SOR4 FM C26H40O2
DM5SOR4 IC InChI=1S/C26H40O2/c1-8-9-10-11-14-25(3,4)19-16-22(27-7)24-20-15-18(2)12-13-21(20)26(5,6)28-23(24)17-19/h16-17,20-21H,2,8-15H2,1,3-7H3/t20-,21-/m1/s1
DM5SOR4 CS CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=C)CC[C@H]3C(O2)(C)C)C(=C1)OC
DM5SOR4 IK BJIIKHXAZBTGLF-NHCUHLMSSA-N
DM5SOR4 IU (6aR,10aR)-1-methoxy-6,6-dimethyl-9-methylidene-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6aH-benzo[c]chromene
DM5SOR4 DE Discovery agent
DMA9VDN ID DMA9VDN
DMA9VDN DN L-760790
DMA9VDN HS Investigative
DMA9VDN SN L-760790; CHEMBL420965; SCHEMBL4358113; JCFDYNJSFCXYRT-FQEVSTJZSA-N; BDBM50060425; Benzyl-{(S)-1-[2-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-ethyl]-pyrrolidin-3-ylmethyl}-amine
DMA9VDN DT Small molecular drug
DMA9VDN PC 10386282
DMA9VDN MW 400.5
DMA9VDN FM C24H28N6
DMA9VDN IC InChI=1S/C24H28N6/c1-2-4-19(5-3-1)13-25-14-20-8-10-29(16-20)11-9-21-15-26-24-7-6-22(12-23(21)24)30-17-27-28-18-30/h1-7,12,15,17-18,20,25-26H,8-11,13-14,16H2/t20-/m0/s1
DMA9VDN CS C1CN(C[C@@H]1CNCC2=CC=CC=C2)CCC3=CNC4=C3C=C(C=C4)N5C=NN=C5
DMA9VDN IK JCFDYNJSFCXYRT-FQEVSTJZSA-N
DMA9VDN IU N-benzyl-1-[(3S)-1-[2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethyl]pyrrolidin-3-yl]methanamine
DMA9VDN DE Discovery agent
DM0A2MG ID DM0A2MG
DM0A2MG DN L-761000
DM0A2MG HS Investigative
DM0A2MG SN CHEMBL352174; L-761000; SCHEMBL7070915; AXFSURYONUFFTK-UHFFFAOYSA-N; BDBM50289087; 4-(1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)-3-methylbutanoic acid; 4-[1-(4-Bromo-benzyl)-5-methoxy-2-methyl-1H-indol-3-yl]-3-methyl-butyric acid
DM0A2MG DT Small molecular drug
DM0A2MG PC 9867333
DM0A2MG MW 430.3
DM0A2MG FM C22H24BrNO3
DM0A2MG IC InChI=1S/C22H24BrNO3/c1-14(11-22(25)26)10-19-15(2)24(13-16-4-6-17(23)7-5-16)21-9-8-18(27-3)12-20(19)21/h4-9,12,14H,10-11,13H2,1-3H3,(H,25,26)
DM0A2MG CS CC1=C(C2=C(N1CC3=CC=C(C=C3)Br)C=CC(=C2)OC)CC(C)CC(=O)O
DM0A2MG IK AXFSURYONUFFTK-UHFFFAOYSA-N
DM0A2MG IU 4-[1-[(4-bromophenyl)methyl]-5-methoxy-2-methylindol-3-yl]-3-methylbutanoic acid
DM0A2MG CA CAS 176045-83-3
DM0A2MG DE Discovery agent
DMG5KVS ID DMG5KVS
DMG5KVS DN L-764406
DMG5KVS HS Investigative
DMG5KVS SN L 764406; L764406
DMG5KVS DT Small molecular drug
DMG5KVS PC 9818466
DMG5KVS MW 318.8
DMG5KVS FM C15H11ClN2O2S
DMG5KVS IC InChI=1S/C15H11ClN2O2S/c16-15-14(17-12-8-4-5-9-13(12)18-15)10-21(19,20)11-6-2-1-3-7-11/h1-9H,10H2
DMG5KVS CS C1=CC=C(C=C1)S(=O)(=O)CC2=NC3=CC=CC=C3N=C2Cl
DMG5KVS IK AMNQYONRCBZMGT-UHFFFAOYSA-N
DMG5KVS IU 2-(benzenesulfonylmethyl)-3-chloroquinoxaline
DMG5KVS DE Discovery agent
DMH0TUZ ID DMH0TUZ
DMH0TUZ DN L-765314
DMH0TUZ HS Investigative
DMH0TUZ SN L-765314; CHEMBL19476; CGWOIDCAGBKOQL-FQEVSTJZSA-N; NCGC00094440-01; 189349-50-6; NCGC00015604-01; Lopac-L-3040; AC1O7G4J; GTPL506; SCHEMBL7820114; ZINC84638100; BDBM50063907; AKOS032960320; NCGC00165822-01; HY-101385; CS-0021271; benzyl (S)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2-(tert-butylcarbamoyl)piperazine-1-carboxylate; 1-piperazinecarboxylic acid, 4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-2-[[(1,1-dimethylethyl)amino]carbonyl]-, phenylmethyl ester, (S)-
DMH0TUZ DT Small molecular drug
DMH0TUZ PC 6603904
DMH0TUZ MW 522.6
DMH0TUZ FM C27H34N6O5
DMH0TUZ IC InChI=1S/C27H34N6O5/c1-27(2,3)31-24(34)20-15-32(11-12-33(20)26(35)38-16-17-9-7-6-8-10-17)25-29-19-14-22(37-5)21(36-4)13-18(19)23(28)30-25/h6-10,13-14,20H,11-12,15-16H2,1-5H3,(H,31,34)(H2,28,29,30)/t20-/m0/s1
DMH0TUZ CS CC(C)(C)NC(=O)[C@@H]1CN(CCN1C(=O)OCC2=CC=CC=C2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC
DMH0TUZ IK CGWOIDCAGBKOQL-FQEVSTJZSA-N
DMH0TUZ IU benzyl (2S)-4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-2-(tert-butylcarbamoyl)piperazine-1-carboxylate
DMH0TUZ DE Discovery agent
DM96SPJ ID DM96SPJ
DM96SPJ DN L-767679
DM96SPJ HS Investigative
DM96SPJ SN L-767679; CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-
DM96SPJ DT Small molecular drug
DM96SPJ PC 177364
DM96SPJ MW 384.4
DM96SPJ FM C20H24N4O4
DM96SPJ IC InChI=1S/C20H24N4O4/c1-2-15(11-19(26)27)22-18(25)13-24-8-5-14-3-4-16(12-17(14)20(24)28)23-9-6-21-7-10-23/h1,3-4,12,15,21H,5-11,13H2,(H,22,25)(H,26,27)/t15-/m1/s1
DM96SPJ CS C#C[C@H](CC(=O)O)NC(=O)CN1CCC2=C(C1=O)C=C(C=C2)N3CCNCC3
DM96SPJ IK QTVKUFZTCJLGEJ-OAHLLOKOSA-N
DM96SPJ IU (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid
DM96SPJ CA CAS 182198-53-4
DM96SPJ DE Discovery agent
DM5O0CM ID DM5O0CM
DM5O0CM DN L-772,405
DM5O0CM HS Investigative
DM5O0CM SN L-772405; L 772405
DM5O0CM DT Small molecular drug
DM5O0CM PC 9847194
DM5O0CM MW 462.6
DM5O0CM FM C26H31FN6O
DM5O0CM IC InChI=1S/C26H31FN6O/c27-21-5-3-19(4-6-21)26(16-34)31-22-9-12-32(13-10-22)11-1-2-20-15-28-25-8-7-23(14-24(20)25)33-17-29-30-18-33/h3-8,14-15,17-18,22,26,28,31,34H,1-2,9-13,16H2/t26-/m0/s1
DM5O0CM CS C1CN(CCC1N[C@@H](CO)C2=CC=C(C=C2)F)CCCC3=CNC4=C3C=C(C=C4)N5C=NN=C5
DM5O0CM IK HNKDAQNYMJNLCC-SANMLTNESA-N
DM5O0CM IU (2R)-2-(4-fluorophenyl)-2-[[1-[3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]propyl]piperidin-4-yl]amino]ethanol
DM5O0CM DE Discovery agent
DMMUAW5 ID DMMUAW5
DMMUAW5 DN L-779,976
DMMUAW5 HS Investigative
DMMUAW5 SN L 779976; L-779976
DMMUAW5 DT Small molecular drug
DMMUAW5 PC 5311372
DMMUAW5 MW 585.7
DMMUAW5 FM C33H43N7O3
DMMUAW5 IC InChI=1S/C33H43N7O3/c1-21(26-20-35-27-10-3-2-9-25(26)27)30(31(41)36-19-23-8-6-7-22(17-23)18-34)38-32(42)39-15-13-24(14-16-39)40-29-12-5-4-11-28(29)37-33(40)43/h2-5,9-12,20-24,30,35H,6-8,13-19,34H2,1H3,(H,36,41)(H,37,43)(H,38,42)/t21-,22+,23+,30+/m0/s1
DMMUAW5 CS C[C@@H](C1=CNC2=CC=CC=C21)[C@H](C(=O)NC[C@@H]3CCC[C@H](C3)CN)NC(=O)N4CCC(CC4)N5C6=CC=CC=C6NC5=O
DMMUAW5 IK DDVPVAOEMZRZQU-JONNCTARSA-N
DMMUAW5 IU N-[(2R,3S)-1-[[(1R,3R)-3-(aminomethyl)cyclohexyl]methylamino]-3-(1H-indol-3-yl)-1-oxobutan-2-yl]-4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carboxamide
DMMUAW5 DE Discovery agent
DM51B74 ID DM51B74
DM51B74 DN L-779450
DM51B74 HS Investigative
DM51B74 SN 303727-31-3; L-779450; L-779,450; 2-chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl)phenol; L779450; CHEMBL373011; 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol; 2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole; 2-Chloro-5-[2-phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol; C20H14ClN3O; L 779450; 2-chloro-5-[2-phenyl-5-(pyridin-4-yl)-1H-imidazol-4-yl]phenol; 2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenol; 2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol
DM51B74 DT Small molecular drug
DM51B74 PC 9950176
DM51B74 MW 347.8
DM51B74 FM C20H14ClN3O
DM51B74 IC InChI=1S/C20H14ClN3O/c21-16-7-6-15(12-17(16)25)19-18(13-8-10-22-11-9-13)23-20(24-19)14-4-2-1-3-5-14/h1-12,25H,(H,23,24)
DM51B74 CS C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC(=C(C=C4)Cl)O
DM51B74 IK WXJLXRNWMLWVFB-UHFFFAOYSA-N
DM51B74 IU 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol
DM51B74 CA CAS 303727-31-3
DM51B74 CB CHEBI:93773
DM51B74 DE Discovery agent
DM6OTGE ID DM6OTGE
DM6OTGE DN L-783483
DM6OTGE HS Investigative
DM6OTGE SN F3MethylAA
DM6OTGE DT Small molecular drug
DM6OTGE PC 9935197
DM6OTGE MW 487.9
DM6OTGE FM C22H21ClF3NO4S
DM6OTGE IC InChI=1S/C22H21ClF3NO4S/c1-2-4-14-17(7-6-15-20(14)31-27-21(15)22(24,25)26)30-9-3-10-32-18-8-5-13(11-16(18)23)12-19(28)29/h5-8,11H,2-4,9-10,12H2,1H3,(H,28,29)
DM6OTGE CS CCCC1=C(C=CC2=C1ON=C2C(F)(F)F)OCCCSC3=C(C=C(C=C3)CC(=O)O)Cl
DM6OTGE IK TZBRFAASYWFUGK-UHFFFAOYSA-N
DM6OTGE IU 2-[3-chloro-4-[3-[[7-propyl-3-(trifluoromethyl)-1,2-benzoxazol-6-yl]oxy]propylsulfanyl]phenyl]acetic acid
DM6OTGE DE Discovery agent
DMJKAQR ID DMJKAQR
DMJKAQR DN L-790070
DMJKAQR HS Investigative
DMJKAQR SN L-790070; CHEMBL303144; 189442-43-1; MRK-48; SCHEMBL4025110; BDBM15459; CTK4E0131; DTXSID50430959; 4-[1-methyl-2-(piperidin-4-yl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine; 4-{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl}-N-[(1S)-1-phenylethyl]pyridin-2-amine; 2-PYRIDINAMINE, 4-[1-METHYL-2-(4-PIPERIDINYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOL-5-YL]-N-[(1S)-1-PHENYLETHYL]-
DMJKAQR DT Small molecular drug
DMJKAQR PC 9806182
DMJKAQR MW 505.6
DMJKAQR FM C29H30F3N5
DMJKAQR IC InChI=1S/C29H30F3N5/c1-19(20-7-4-3-5-8-20)35-25-18-23(13-16-34-25)27-26(22-9-6-10-24(17-22)29(30,31)32)36-28(37(27)2)21-11-14-33-15-12-21/h3-10,13,16-19,21,33H,11-12,14-15H2,1-2H3,(H,34,35)/t19-/m0/s1
DMJKAQR CS C[C@@H](C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(N=C(N3C)C4CCNCC4)C5=CC(=CC=C5)C(F)(F)F
DMJKAQR IK ZLQKJFNLHHGAQF-IBGZPJMESA-N
DMJKAQR IU 4-[3-methyl-2-piperidin-4-yl-5-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine
DMJKAQR CA CAS 189442-43-1
DMJKAQR DE Autoimmune diabetes
DM5D892 ID DM5D892
DM5D892 DN L-791943
DM5D892 HS Investigative
DM5D892 SN L-791943; CHEMBL286224; SCHEMBL12013401; BDBM50113425; 4-{2-(3,4-Bis-difluoromethoxy-phenyl)-2-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-ethyl}-pyridin-1-ol anion
DM5D892 DT Small molecular drug
DM5D892 PC 9808191
DM5D892 MW 573.4
DM5D892 FM C24H17F10NO4
DM5D892 IC InChI=1S/C24H17F10NO4/c25-20(26)38-18-6-3-15(12-19(18)39-21(27)28)17(11-13-7-9-35(37)10-8-13)14-1-4-16(5-2-14)22(36,23(29,30)31)24(32,33)34/h1-10,12,17,20-21,36H,11H2
DM5D892 CS C1=CC(=CC=C1C(CC2=CC=[N+](C=C2)[O-])C3=CC(=C(C=C3)OC(F)F)OC(F)F)C(C(F)(F)F)(C(F)(F)F)O
DM5D892 IK VIOWRSXFEPSZFI-UHFFFAOYSA-N
DM5D892 IU 2-[4-[1-[3,4-bis(difluoromethoxy)phenyl]-2-(1-oxidopyridin-1-ium-4-yl)ethyl]phenyl]-1,1,1,3,3,3-hexafluoropropan-2-ol
DM5D892 DE Discovery agent
DMINOFE ID DMINOFE
DMINOFE DN L-796,778
DMINOFE HS Investigative
DMINOFE SN L796778; L-796778
DMINOFE DT Small molecular drug
DMINOFE PC 5311373
DMINOFE MW 584.7
DMINOFE FM C29H40N6O7
DMINOFE IC InChI=1S/C29H40N6O7/c1-3-4-12-23(26(36)32-24(28(38)42-2)13-8-9-18-30)33-29(39)34-25(19-20-10-6-5-7-11-20)27(37)31-21-14-16-22(17-15-21)35(40)41/h5-7,10-11,14-17,23-25H,3-4,8-9,12-13,18-19,30H2,1-2H3,(H,31,37)(H,32,36)(H2,33,34,39)/t23-,24+,25+/m1/s1
DMINOFE CS CCCC[C@H](C(=O)N[C@@H](CCCCN)C(=O)OC)NC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)[N+](=O)[O-]
DMINOFE IK KEATTYUTWJKTRT-DSITVLBTSA-N
DMINOFE IU methyl (2S)-6-amino-2-[[(2R)-2-[[(2S)-1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoylamino]hexanoyl]amino]hexanoate
DMINOFE DE Discovery agent
DMWTGQM ID DMWTGQM
DMWTGQM DN L-796449
DMWTGQM HS Investigative
DMWTGQM SN L-796449; UNII-O937X0Z5EM; CHEMBL278994; O937X0Z5EM; 194608-80-5; KAPDPGZDHUCILF-UHFFFAOYSA-N; GTPL2689; SCHEMBL4296303; BDBM50085040; Benzeneacetic acid, 3-chloro-4-((3-((3-phenyl-7-propyl-6-benzofuranyl)oxy)propyl)thio)-; L796449; L 796449; L-796,449; 3-chloro-4-(3-(3-phenyl-7-propylbenzofuran-6-yloxy)propylthio)-phenylacetic acid; {3-Chloro-4-[3-(3-phenyl-7-propyl-benzofuran-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid; 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMWTGQM DT Small molecular drug
DMWTGQM PC 9891946
DMWTGQM MW 495
DMWTGQM FM C28H27ClO4S
DMWTGQM IC InChI=1S/C28H27ClO4S/c1-2-7-22-25(12-11-21-23(18-33-28(21)22)20-8-4-3-5-9-20)32-14-6-15-34-26-13-10-19(16-24(26)29)17-27(30)31/h3-5,8-13,16,18H,2,6-7,14-15,17H2,1H3,(H,30,31)
DMWTGQM CS CCCC1=C(C=CC2=C1OC=C2C3=CC=CC=C3)OCCCSC4=C(C=C(C=C4)CC(=O)O)Cl
DMWTGQM IK KAPDPGZDHUCILF-UHFFFAOYSA-N
DMWTGQM IU 2-[3-chloro-4-[3-[(3-phenyl-7-propyl-1-benzofuran-6-yl)oxy]propylsulfanyl]phenyl]acetic acid
DMWTGQM CA CAS 194608-80-5
DMWTGQM DE Discovery agent
DM96ASN ID DM96ASN
DM96ASN DN L-797,591
DM96ASN HS Investigative
DM96ASN SN L797591
DM96ASN DT Small molecular drug
DM96ASN PC 9938757
DM96ASN MW 607.8
DM96ASN FM C38H49N5O2
DM96ASN IC InChI=1S/C38H49N5O2/c1-29(19-22-39)27-38(2,3)28-41-36(44)35(26-32-16-11-15-31-14-7-8-18-34(31)32)42-37(45)43(24-20-30-12-5-4-6-13-30)25-21-33-17-9-10-23-40-33/h4-18,23,29,35H,19-22,24-28,39H2,1-3H3,(H,41,44)(H,42,45)/t29?,35-/m1/s1
DM96ASN CS CC(CCN)CC(C)(C)CNC(=O)[C@@H](CC1=CC=CC2=CC=CC=C21)NC(=O)N(CCC3=CC=CC=C3)CCC4=CC=CC=N4
DM96ASN IK MZKKCMXXGCRPGX-LMZJGDDPSA-N
DM96ASN IU (2R)-N-(6-amino-2,2,4-trimethylhexyl)-3-naphthalen-1-yl-2-[[2-phenylethyl(2-pyridin-2-ylethyl)carbamoyl]amino]propanamide
DM96ASN DE Discovery agent
DM4FMGJ ID DM4FMGJ
DM4FMGJ DN L-798,106
DM4FMGJ HS Investigative
DM4FMGJ SN L798106; L-798106
DM4FMGJ DT Small molecular drug
DM4FMGJ PC 15551229
DM4FMGJ MW 536.4
DM4FMGJ FM C27H22BrNO4S
DM4FMGJ IC InChI=1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+
DM4FMGJ CS COC1=C(C=C(C=C1)Br)S(=O)(=O)NC(=O)/C=C/C2=CC=CC=C2CC3=CC4=CC=CC=C4C=C3
DM4FMGJ IK ODTKFNUPVBULRJ-NTCAYCPXSA-N
DM4FMGJ IU (E)-N-(5-bromo-2-methoxyphenyl)sulfonyl-3-[2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide
DM4FMGJ CA CAS 244101-02-8
DM4FMGJ CB CHEBI:138743
DM4FMGJ DE Discovery agent
DMWBRDK ID DMWBRDK
DMWBRDK DN L-803,087
DMWBRDK HS Investigative
DMWBRDK SN L803087
DMWBRDK DT Small molecular drug
DMWBRDK PC 5311374
DMWBRDK MW 485.5
DMWBRDK FM C25H29F2N5O3
DMWBRDK IC InChI=1S/C25H29F2N5O3/c1-35-24(34)20(10-6-12-30-25(28)29)31-21(33)11-5-9-17-18-13-16(26)14-19(27)23(18)32-22(17)15-7-3-2-4-8-15/h2-4,7-8,13-14,20,32H,5-6,9-12H2,1H3,(H,31,33)(H4,28,29,30)/t20-/m0/s1
DMWBRDK CS COC(=O)[C@H](CCCN=C(N)N)NC(=O)CCCC1=C(NC2=C1C=C(C=C2F)F)C3=CC=CC=C3
DMWBRDK IK OPNMQSFIGUSHDH-FQEVSTJZSA-N
DMWBRDK IU methyl (2S)-5-(diaminomethylideneamino)-2-[4-(5,7-difluoro-2-phenyl-1H-indol-3-yl)butanoylamino]pentanoate
DMWBRDK DE Discovery agent
DM8YT7X ID DM8YT7X
DM8YT7X DN L-817,818
DM8YT7X HS Investigative
DM8YT7X SN L 817818; L817818; L-817818
DM8YT7X DT Small molecular drug
DM8YT7X PC 5311375
DM8YT7X MW 536.7
DM8YT7X FM C33H36N4O3
DM8YT7X IC InChI=1S/C33H36N4O3/c1-21(35)20-40-33(39)29(12-6-7-17-34)36-30(38)19-28-27-16-15-23-9-4-5-11-26(23)32(27)37-31(28)25-14-13-22-8-2-3-10-24(22)18-25/h2-5,8-11,13-16,18,21,29,37H,6-7,12,17,19-20,34-35H2,1H3,(H,36,38)/t21-,29-/m0/s1
DM8YT7X CS C[C@@H](COC(=O)[C@H](CCCCN)NC(=O)CC1=C(NC2=C1C=CC3=CC=CC=C32)C4=CC5=CC=CC=C5C=C4)N
DM8YT7X IK NFVRGDRCCNEGBS-LGGPFLRQSA-N
DM8YT7X IU [(2S)-2-aminopropyl] (2S)-6-amino-2-[[2-(2-naphthalen-2-yl-1H-benzo[g]indol-3-yl)acetyl]amino]hexanoate
DM8YT7X DE Discovery agent
DMYJ6QZ ID DMYJ6QZ
DMYJ6QZ DN L-826266
DMYJ6QZ HS Investigative
DMYJ6QZ SN MF266-3; LS-193774; compound 10b [PMID: 11504634]
DMYJ6QZ DT Small molecular drug
DMYJ6QZ PC 9808643
DMYJ6QZ MW 570.9
DMYJ6QZ FM C27H21BrClNO4S
DMYJ6QZ IC InChI=1S/C27H21BrClNO4S/c1-34-25-12-10-23(28)17-26(25)35(32,33)30-27(31)13-9-22-16-24(29)11-8-21(22)15-18-6-7-19-4-2-3-5-20(19)14-18/h2-14,16-17H,15H2,1H3,(H,30,31)/b13-9+
DMYJ6QZ CS COC1=C(C=C(C=C1)Br)S(=O)(=O)NC(=O)/C=C/C2=C(C=CC(=C2)Cl)CC3=CC4=CC=CC=C4C=C3
DMYJ6QZ IK DYXFUJYHEDGCLS-UKTHLTGXSA-N
DMYJ6QZ IU (E)-N-(5-bromo-2-methoxyphenyl)sulfonyl-3-[5-chloro-2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide
DMYJ6QZ DE Discovery agent
DMKEDU6 ID DMKEDU6
DMKEDU6 DN L-869298
DMKEDU6 HS Investigative
DMKEDU6 SN L-869298; UNII-2I921E370K; CHEMBL199015; 2I921E370K; MK-298; 362718-73-8; SCHEMBL3225083; (+)-L-869298; BDBM50174020; 2-Thiazolemethanol, 5-((1S)-1-(3-(cyclopropyloxy)-4-(difluoromethoxy)phenyl)-2-(1-oxido-3-pyridinyl)ethyl)-alpha,alpha-bis(trifluoromethyl)-; 3-[(S)-beta-[2-[1-Hydroxy-1-(trifluoromethyl)-2,2,2-trifluoroethyl]-5-thiazolyl]-3-(cyclopropyloxy)-4-(difluoromethoxy)phenethyl]pyridine 1-oxide
DMKEDU6 DT Small molecular drug
DMKEDU6 PC 11039077
DMKEDU6 MW 570.5
DMKEDU6 FM C23H18F8N2O4S
DMKEDU6 IC InChI=1S/C23H18F8N2O4S/c24-20(25)37-16-6-3-13(9-17(16)36-14-4-5-14)15(8-12-2-1-7-33(35)11-12)18-10-32-19(38-18)21(34,22(26,27)28)23(29,30)31/h1-3,6-7,9-11,14-15,20,34H,4-5,8H2/t15-/m0/s1
DMKEDU6 CS C1CC1OC2=C(C=CC(=C2)[C@H](CC3=C[N+](=CC=C3)[O-])C4=CN=C(S4)C(C(F)(F)F)(C(F)(F)F)O)OC(F)F
DMKEDU6 IK YDLQPURWTSDWCC-HNNXBMFYSA-N
DMKEDU6 IU 2-[5-[(1S)-1-[3-cyclopropyloxy-4-(difluoromethoxy)phenyl]-2-(1-oxidopyridin-1-ium-3-yl)ethyl]-1,3-thiazol-2-yl]-1,1,1,3,3,3-hexafluoropropan-2-ol
DMKEDU6 CA CAS 362718-73-8
DMKEDU6 DE Discovery agent
DMUP516 ID DMUP516
DMUP516 DN L-873724
DMUP516 HS Investigative
DMUP516 SN L-873724; UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth
DMUP516 DT Small molecular drug
DMUP516 PC 9913088
DMUP516 MW 481.5
DMUP516 FM C23H26F3N3O3S
DMUP516 IC InChI=1S/C23H26F3N3O3S/c1-15(2)14-20(22(30)28-13-12-27)29-21(23(24,25)26)18-6-4-16(5-7-18)17-8-10-19(11-9-17)33(3,31)32/h4-11,15,20-21,29H,13-14H2,1-3H3,(H,28,30)/t20-,21-/m0/s1
DMUP516 CS CC(C)C[C@@H](C(=O)NCC#N)N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C)C(F)(F)F
DMUP516 IK VYFDSJLOCIGIKP-SFTDATJTSA-N
DMUP516 IU (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide
DMUP516 CA CAS 603139-12-4
DMUP516 DE Asthma
DMMAIQ2 ID DMMAIQ2
DMMAIQ2 DN L-888,291
DMMAIQ2 HS Investigative
DMMAIQ2 SN L-883,595
DMMAIQ2 DT Small molecular drug
DMMAIQ2 PC 44450494
DMMAIQ2 MW 375.8
DMMAIQ2 FM C19H15ClFNO2S
DMMAIQ2 IC InChI=1S/C19H15ClFNO2S/c20-12-1-4-14(5-2-12)25-19-15-6-3-13(21)10-16(15)22-8-7-11(18(19)22)9-17(23)24/h1-6,10-11H,7-9H2,(H,23,24)
DMMAIQ2 CS C1CN2C3=C(C=CC(=C3)F)C(=C2C1CC(=O)O)SC4=CC=C(C=C4)Cl
DMMAIQ2 IK GSBAVONRPNJJOH-UHFFFAOYSA-N
DMMAIQ2 IU 2-[4-(4-chlorophenyl)sulfanyl-7-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-3-yl]acetic acid
DMMAIQ2 CA CAS 1030017-51-6
DMMAIQ2 DE Discovery agent
DMJCTWO ID DMJCTWO
DMJCTWO DN L-888607
DMJCTWO HS Investigative
DMJCTWO SN L-888607; UNII-LMX71OP17X; LMX71OP17X; CHEMBL370606; L 888607; 860033-06-3; GTPL1907; ZINC6745293; BDBM50174361; AJ-56816; 1H-Pyrrolo(1,2-a)indole-1-acetic acid, 9-((4-chlorophenyl)thio)-6-fluoro-2,3-dihydro-, (1S)-; HY-111271; CS-0034796; L-888,607; [(S)-9-(4-Chloro-phenylsulfanyl)-6-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl]-acetic acid; 2-[(1S)-9-[(4-chlorophenyl)sulfanyl]-6-fluoro-1H,2H,3H-benzo[b]pyrrolizin-1-yl]acetic acid
DMJCTWO DT Small molecular drug
DMJCTWO PC 44403763
DMJCTWO MW 375.8
DMJCTWO FM C19H15ClFNO2S
DMJCTWO IC InChI=1S/C19H15ClFNO2S/c20-12-1-4-14(5-2-12)25-19-15-6-3-13(21)10-16(15)22-8-7-11(18(19)22)9-17(23)24/h1-6,10-11H,7-9H2,(H,23,24)/t11-/m0/s1
DMJCTWO CS C1CN2C3=C(C=CC(=C3)F)C(=C2[C@@H]1CC(=O)O)SC4=CC=C(C=C4)Cl
DMJCTWO IK GSBAVONRPNJJOH-NSHDSACASA-N
DMJCTWO IU 2-[(3S)-4-(4-chlorophenyl)sulfanyl-7-fluoro-2,3-dihydro-1H-pyrrolo[1,2-a]indol-3-yl]acetic acid
DMJCTWO CA CAS 860033-06-3
DMJCTWO DE Discovery agent
DMIORW9 ID DMIORW9
DMIORW9 DN L902688
DMIORW9 HS Investigative
DMIORW9 SN 8-aza-1-decarboxy-11-deoxy-16,16-difluoro-16-phenyl-omega-tetranor-1-(5-tetrazolo) PGE1
DMIORW9 DT Small molecular drug
DMIORW9 PC 11316084
DMIORW9 MW 419.5
DMIORW9 FM C21H27F2N5O2
DMIORW9 IC InChI=1S/C21H27F2N5O2/c22-21(23,16-8-4-3-5-9-16)18(29)13-11-17-12-14-20(30)28(17)15-7-2-1-6-10-19-24-26-27-25-19/h3-5,8-9,11,13,17-18,29H,1-2,6-7,10,12,14-15H2,(H,24,25,26,27)/b13-11+/t17-,18+/m0/s1
DMIORW9 CS C1CC(=O)N([C@H]1/C=C/[C@H](C(C2=CC=CC=C2)(F)F)O)CCCCCCC3=NNN=N3
DMIORW9 IK WPTLQOYLIXWRNN-SLKVGHROSA-N
DMIORW9 IU (5R)-5-[(E,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-1-enyl]-1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one
DMIORW9 CA CAS 634193-54-7
DMIORW9 DE Discovery agent
DMYDR2N ID DMYDR2N
DMYDR2N DN L-97-1 intravenous
DMYDR2N HS Investigative
DMYDR2N SN L-97-1; L-97-1 (intravenous, sepsis/pneumonic plague), Endacea; L-97-1 (oral, asthma/pneumonic plague/renal failure),Endacea
DMYDR2N CP Endacea Inc
DMYDR2N DT Small molecular drug
DMYDR2N PC 11627742
DMYDR2N MW 518.6
DMYDR2N FM C29H38N6O3
DMYDR2N IC InChI=1S/C29H38N6O3/c1-3-15-35-28(37)26-27(34(29(35)38)16-14-22-10-12-24(30)13-11-22)31-25(21-23-8-6-5-7-9-23)33(26)18-17-32(4-2)19-20-36/h5-13,36H,3-4,14-21,30H2,1-2H3
DMYDR2N CS CCCN1C(=O)C2=C(N=C(N2CCN(CC)CCO)CC3=CC=CC=C3)N(C1=O)CCC4=CC=C(C=C4)N
DMYDR2N IK QVEHDKFBFDUCEZ-UHFFFAOYSA-N
DMYDR2N IU 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-[2-[ethyl(2-hydroxyethyl)amino]ethyl]-1-propylpurine-2,6-dione
DMYDR2N CA CAS 770703-20-3
DMYDR2N DE Sepsis
DMY6K2A ID DMY6K2A
DMY6K2A DN LA22-radioimmunoconjugates
DMY6K2A HS Investigative
DMY6K2A SN LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22
DMY6K2A CP Welson Pharmaceuticals Inc
DMY6K2A DE Solid tumour/cancer
DMP1V8Y ID DMP1V8Y
DMP1V8Y DN LA-480
DMP1V8Y HS Investigative
DMP1V8Y SN Bispecific c-Met monoclonal antibody (cancer), Lilly
DMP1V8Y CP Eli Lilly & Co
DMP1V8Y DT Antibody
DMP1V8Y DE Solid tumour/cancer
DMJIU3Y ID DMJIU3Y
DMJIU3Y DN Lactoferrin
DMJIU3Y HS Investigative
DMJIU3Y PC 126456119
DMJIU3Y MW 3125.8
DMJIU3Y FM C141H226N46O29S3
DMJIU3Y IC InChI=1S/C141H226N46O29S3/c1-11-77(6)111(133(212)186-112(80(9)189)134(213)183-106(74-218)130(209)184-110(76(4)5)132(211)176-97(49-32-61-161-141(155)156)120(199)170-93(45-28-57-157-137(147)148)116(195)166-78(7)113(192)180-103(136(215)216)66-82-36-16-13-17-37-82)185-128(207)104(72-188)181-131(210)107-50-33-62-187(107)135(214)79(8)165-109(191)71-164-115(194)100(64-75(2)3)177-121(200)92(44-24-27-56-144)168-117(196)91(43-23-26-55-143)169-125(204)99(53-63-219-10)175-119(198)94(46-29-58-158-138(149)150)172-126(205)101(67-83-69-162-88-40-20-18-38-85(83)88)179-124(203)98(51-52-108(146)190)174-127(206)102(68-84-70-163-89-41-21-19-39-86(84)89)178-122(201)96(48-31-60-160-140(153)154)171-118(197)95(47-30-59-159-139(151)152)173-129(208)105(73-217)182-123(202)90(42-22-25-54-142)167-114(193)87(145)65-81-34-14-12-15-35-81/h12-21,34-41,69-70,75-80,87,90-107,110-112,162-163,188-189,217-218H,11,22-33,42-68,71-74,142-145H2,1-10H3,(H2,146,190)(H,164,194)(H,165,191)(H,166,195)(H,167,193)(H,168,196)(H,169,204)(H,170,199)(H,171,197)(H,172,205)(H,173,208)(H,174,206)(H,175,198)(H,176,211)(H,177,200)(H,178,201)(H,179,203)(H,180,192)(H,181,210)(H,182,202)(H,183,213)(H,184,209)(H,185,207)(H,186,212)(H,215,216)(H4,147,148,157)(H4,149,150,158)(H4,151,152,159)(H4,153,154,160)(H4,155,156,161)/t77-,78-,79-,80+,87-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,110-,111-,112-/m0/s1
DMJIU3Y CS CC[C@H](C)[C@@H](C(=N[C@@H]([C@@H](C)O)C(=N[C@@H](CS)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](CCCNC(=N)N)C(=N[C@@H](C)C(=N[C@@H](CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C([C@H](CO)N=C([C@@H]2CCCN2C(=O)[C@H](C)N=C(CN=C([C@H](CC(C)C)N=C([C@H](CCCCN)N=C([C@H](CCCCN)N=C([C@H](CCSC)N=C([C@H](CCCNC(=N)N)N=C([C@H](CC3=CNC4=CC=CC=C43)N=C([C@H](CCC(=N)O)N=C([C@H](CC5=CNC6=CC=CC=C65)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCCNC(=N)N)N=C([C@H](CS)N=C([C@H](CCCCN)N=C([C@H](CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O
DMJIU3Y IK CSSYQJWUGATIHM-IKGCZBKSSA-N
DMJIU3Y IU (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxy-4-methylsulfanylbutylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxyhexylidene]amino]-1-hydroxy-4-methylpentylidene]amino]-1-hydroxyethylidene]amino]propanoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-methylpentylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-5-carbamimidamido-1-hydroxypentylidene]amino]-1-hydroxypropylidene]amino]-3-phenylpropanoic acid
DMJIU3Y CA 339615-76-8
DMJIU3Y DE Discovery agent
DMZ0O1X ID DMZ0O1X
DMZ0O1X DN Lactoquinomycin
DMZ0O1X HS Investigative
DMZ0O1X SN Lactoquinomycin; SCHEMBL12324296
DMZ0O1X TC Anticancer Agents
DMZ0O1X DT Small molecular drug
DMZ0O1X PC 12967404
DMZ0O1X MW 457.5
DMZ0O1X FM C24H27NO8
DMZ0O1X IC InChI=1S/C24H27NO8/c1-9-17-19(24-15(31-9)8-16(26)33-24)22(29)12-6-5-11(21(28)18(12)23(17)30)14-7-13(25(3)4)20(27)10(2)32-14/h5-6,9-10,13-15,20,24,27-28H,7-8H2,1-4H3/t9-,10-,13-,14-,15-,20-,24+/m1/s1
DMZ0O1X CS C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)[C@H](O[C@H]5[C@@H]4OC(=O)C5)C)O)N(C)C)O
DMZ0O1X IK NYJGMJFBEVSQNN-CNRHASOASA-N
DMZ0O1X IU (11R,15R,17R)-5-[(2R,4R,5S,6R)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-4-hydroxy-17-methyl-12,16-dioxatetracyclo[8.7.0.03,8.011,15]heptadeca-1(10),3(8),4,6-tetraene-2,9,13-trione
DMZ0O1X CA CAS 60227-09-0
DMZ0O1X CB CHEBI:31808
DMZ0O1X DE Haematological malignancy
DMM0Z6Y ID DMM0Z6Y
DMM0Z6Y DN Lactose
DMM0Z6Y HS Investigative
DMM0Z6Y SN D(+)Cellobiose; Glcbeta1,4Glc; Lactose, beta-; D-(+)-Cellobiose; D-Glucose, 4-O-beta-D-glucopyranosyl-; NSC2559; beta-D-Glucopyranose, 4-O-beta-D-galactopyranosyl-; 4-O-beta-D-Glucopyranosyl-D-glucose; 528-50-7; beta-Lactose; Cellobiose, beta-; Lactopress; 4-O-Hexopyranosylhexopyranose; ss-Lactose; Lactose NF; beta-Cellobiose; beta-D-Lactose; D-Glucose, 4-O-beta-D-galactopyranosyl-; beta-Maltose monohydrate; SCHEMBL684118; AC1Q28M2; AC1L18X1; SCHEMBL20276017
DMM0Z6Y DT Small molecular drug
DMM0Z6Y PC 6134
DMM0Z6Y MW 342.3
DMM0Z6Y FM C12H22O11
DMM0Z6Y IC InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
DMM0Z6Y CS C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
DMM0Z6Y IK GUBGYTABKSRVRQ-DCSYEGIMSA-N
DMM0Z6Y IU (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
DMM0Z6Y CA CAS 63-42-3
DMM0Z6Y CB CHEBI:36218
DMM0Z6Y DE Discovery agent
DMTZ17V ID DMTZ17V
DMTZ17V DN Laevulinic Acid
DMTZ17V HS Investigative
DMTZ17V SN Levulinic acid; LEVULINIC ACID; 4-Oxopentanoic acid; 123-76-2; Laevulinic acid; Pentanoic acid, 4-oxo-; 4-Oxovaleric acid; Levulic acid; 3-Acetylpropionic acid; 4-Ketovaleric acid; LEVA; gamma-Ketovaleric acid; Acetopropionic acid; Levulinsaeure; Laevulic acid; Valeric acid, 4-oxo-; beta-Acetylpropionic acid; USAF CZ-1; 4-oxo-pentanoic acid; Propionic acid, 3-acetyl-; 4-Oxopentansaeure; Acidum laevulinicum; 3-Acetylpropionsaeure; 3-Ketobutane-1-carboxylic acid; UNII-RYX5QG61EI; NSC 3716; Acetylpropionic acid; FEMA No 2627; Pentanoic acid, 4-oxo; Levulinic Acid
DMTZ17V DT Small molecular drug
DMTZ17V PC 11579
DMTZ17V MW 116.11
DMTZ17V FM C5H8O3
DMTZ17V IC InChI=1S/C5H8O3/c1-4(6)2-3-5(7)8/h2-3H2,1H3,(H,7,8)
DMTZ17V CS CC(=O)CCC(=O)O
DMTZ17V IK JOOXCMJARBKPKM-UHFFFAOYSA-N
DMTZ17V IU 4-oxopentanoic acid
DMTZ17V CA CAS 123-76-2
DMTZ17V CB CHEBI:45630
DMTZ17V DE Discovery agent
DMH6XTP ID DMH6XTP
DMH6XTP DN L-Ala-L-boroPro
DMH6XTP HS Investigative
DMH6XTP DT Small molecular drug
DMH6XTP PC 44422917
DMH6XTP MW 187.03
DMH6XTP FM C7H16BN2O3+
DMH6XTP IC InChI=1S/C7H15BN2O3/c1-5(9)7(11)10-4-2-3-6(10)8(12)13/h5-6,12-13H,2-4,9H2,1H3/p+1/t5-,6-/m0/s1
DMH6XTP CS B([C@@H]1CCCN1C(=O)[C@H](C)[NH3+])(O)O
DMH6XTP IK WDFZXMUIFGGBQF-WDSKDSINSA-O
DMH6XTP IU [(2S)-1-[(2R)-2-boronopyrrolidin-1-yl]-1-oxopropan-2-yl]azanium
DMH6XTP DE Discovery agent
DMLGK27 ID DMLGK27
DMLGK27 DN LA-N8
DMLGK27 HS Investigative
DMLGK27 SN GlycoPEG-FVIII; Long-acting recombinant FVIIII (N8), Novo Nordisk; Factor VIII (recombinant/GlycoPEGylated, hemophilia A), Novo Nordisk/Neose
DMLGK27 CP Neose Technologies Inc
DMLGK27 DE Factor VIII deficiency
DMHN74V ID DMHN74V
DMHN74V DN Lanosterol
DMHN74V HS Investigative
DMHN74V SN lanosterol; 79-63-0; Lanosterin; Lanster; Botalan base 138; Lanosta-8,24-dienol; Lanosta-8,24-dien-3beta-ol; (3beta)-lanosta-8,24-dien-3-ol; UNII-1J05Z83K3M; NSC60677; Botalan base; CHEBI:16521; Lanosta-8,24-dien-3.beta.-ol; CAHGCLMLTWQZNJ-BQNIITSRSA-N; 1J05Z83K3M; MFCD00021108; Lanostadien-3-beta-ol; NSC 60677; Lanosta-8,24-dien-3-ol, (3beta)-; Lanosta-8,24-dien-3-ol; Lanosta-8,24-dien-3-ol, (3.beta.)-; Lanosta-8,24-dien-3-beta-ol; 4,4',14alpha-Trimethyl-5alpha-cholesta-8,24-dien-3beta-ol; EINECS 201-214-9
DMHN74V DT Small molecular drug
DMHN74V PC 246983
DMHN74V MW 426.7
DMHN74V FM C30H50O
DMHN74V IC InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22-,25+,26+,28-,29-,30+/m1/s1
DMHN74V CS C[C@H](CCC=C(C)C)[C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
DMHN74V IK CAHGCLMLTWQZNJ-BQNIITSRSA-N
DMHN74V IU (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
DMHN74V CA CAS 79-63-0
DMHN74V CB CHEBI:16521
DMHN74V DE Discovery agent
DMPJFGI ID DMPJFGI
DMPJFGI DN L-AP4
DMPJFGI HS Investigative
DMPJFGI SN (2S)-2-Amino-4-phosphonobutanoic acid; 23052-81-5; (2S)-2-amino-4-phosphonobutanoic acid; L-(+)-2-Amino-4-phosphonobutyric acid; L-APB; (S)-2-amino-4-phosphonobutanoic acid; CHEMBL33567; L-AP-4; S-2-amino-4-phosphonobutyrate; [3H]AP4; L-2-amino-4-phosphonobutiric acid; L-1-amino-4-phosphonobutanoic acid; Tocris-0103; NCIStruc2_000128; NCIStruc1_000162; SCHEMBL1969235; GTPL1410; GTPL1412; AC1L456H; MolPort-002-514-399; NCI30079; ZINC2033983; BN0084; CCG-37553; NCGC00013365
DMPJFGI DT Small molecular drug
DMPJFGI PC 179394
DMPJFGI MW 183.1
DMPJFGI FM C4H10NO5P
DMPJFGI IC InChI=1S/C4H10NO5P/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H2,8,9,10)/t3-/m0/s1
DMPJFGI CS C(CP(=O)(O)O)[C@@H](C(=O)O)N
DMPJFGI IK DDOQBQRIEWHWBT-VKHMYHEASA-N
DMPJFGI IU (2S)-2-amino-4-phosphonobutanoic acid
DMPJFGI CA CAS 23052-81-5
DMPJFGI CB CHEBI:143992
DMPJFGI DE Discovery agent
DMSYLIJ ID DMSYLIJ
DMSYLIJ DN LARGAZOLE
DMSYLIJ HS Investigative
DMSYLIJ SN LARGAZOLE; CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395
DMSYLIJ DT Small molecular drug
DMSYLIJ PC 24757913
DMSYLIJ MW 622.9
DMSYLIJ FM C29H42N4O5S3
DMSYLIJ IC InChI=1S/C29H42N4O5S3/c1-5-6-7-8-9-13-24(35)39-14-11-10-12-20-15-22(34)30-16-23-31-21(17-40-23)26-33-29(4,18-41-26)28(37)32-25(19(2)3)27(36)38-20/h10,12,17,19-20,25H,5-9,11,13-16,18H2,1-4H3,(H,30,34)(H,32,37)/b12-10+/t20-,25+,29+/m1/s1
DMSYLIJ CS CCCCCCCC(=O)SCC/C=C/[C@@H]1CC(=O)NCC2=NC(=CS2)C3=N[C@@](CS3)(C(=O)N[C@H](C(=O)O1)C(C)C)C
DMSYLIJ IK AXESYCSCGBQJBL-SZPBEECKSA-N
DMSYLIJ IU S-[(E)-4-[(5R,8S,11S)-5-methyl-6,9,13-trioxo-8-propan-2-yl-10-oxa-3,17-dithia-7,14,19,20-tetrazatricyclo[14.2.1.12,5]icosa-1(18),2(20),16(19)-trien-11-yl]but-3-enyl] octanethioate
DMSYLIJ CA CAS 1009815-87-5
DMSYLIJ DE Discovery agent
DMWGPO6 ID DMWGPO6
DMWGPO6 DN L-aspartic acid
DMWGPO6 HS Investigative
DMWGPO6 SN L-Asp; L-aspartate; Aspatofort
DMWGPO6 DT Small molecular drug
DMWGPO6 PC 5960
DMWGPO6 MW 133.1
DMWGPO6 FM C4H7NO4
DMWGPO6 IC InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1
DMWGPO6 CS C([C@@H](C(=O)O)N)C(=O)O
DMWGPO6 IK CKLJMWTZIZZHCS-REOHCLBHSA-N
DMWGPO6 IU (2S)-2-aminobutanedioic acid
DMWGPO6 CA CAS 56-84-8
DMWGPO6 CB CHEBI:17053
DMYNL40 ID DMYNL40
DMYNL40 DN LASSBio-881
DMYNL40 HS Investigative
DMYNL40 CP Universidade Federal do Rio de Janeiro
DMYNL40 DT Small molecular drug
DMYNL40 PC 135779789
DMYNL40 MW 441.5
DMYNL40 FM C23H27N3O6
DMYNL40 IC InChI=1S/C23H27N3O6/c1-22(2,3)15-7-13(8-16(20(15)27)23(4,5)6)11-24-25-21(28)14-9-18-19(32-12-31-18)10-17(14)26(29)30/h7-11,27H,12H2,1-6H3,(H,25,28)/b24-11+
DMYNL40 CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=N/NC(=O)C2=CC3=C(C=C2[N+](=O)[O-])OCO3
DMYNL40 IK XEYZVZBNMMRXSN-BHGWPJFGSA-N
DMYNL40 IU N-[(E)-(3,5-ditert-butyl-4-hydroxyphenyl)methylideneamino]-6-nitro-1,3-benzodioxole-5-carboxamide
DMYNL40 DE Pain
DMMDZ4B ID DMMDZ4B
DMMDZ4B DN LAU-0901
DMMDZ4B HS Investigative
DMMDZ4B SN PAF receptor antagonist (brain ischemia/ corneal disease), Louisiana State University; Platelet-activating factor receptor antagonist (brain ischemia/ corneal disease), Louisiana State University
DMMDZ4B CP Louisiana State University
DMMDZ4B DE Brain ischaemia
DM9C8KQ ID DM9C8KQ
DM9C8KQ DN Lauric Acid
DM9C8KQ HS Investigative
DM9C8KQ SN lauric acid; DODECANOIC ACID; 143-07-7; n-Dodecanoic acid; Dodecylic acid; Vulvic acid; Laurostearic acid; Dodecoic acid; Duodecylic acid; 1-Undecanecarboxylic acid; Aliphat No. 4; Neo-fat 12; C12 fatty acid; Ninol AA62 Extra; Wecoline 1295; Neo-fat 12-43; Hydrofol acid 1295; Hydrofol acid 1255; Duodecyclic acid; Hystrene 9512; Dodecylcarboxylate; Lauric acid (natural); Univol U-314; Lauric acid, pure; Coconut oil fatty acids; ABL; Undecane-1-carboxylic acid; Laurinsaeure; NSC-5026; CCRIS 669; C-1297; UNII-1160N9NU9U; n-Dodecanoate
DM9C8KQ DT Small molecular drug
DM9C8KQ PC 3893
DM9C8KQ MW 200.32
DM9C8KQ FM C12H24O2
DM9C8KQ IC InChI=1S/C12H24O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H,13,14)
DM9C8KQ CS CCCCCCCCCCCC(=O)O
DM9C8KQ IK POULHZVOKOAJMA-UHFFFAOYSA-N
DM9C8KQ IU dodecanoic acid
DM9C8KQ CA CAS 143-07-7
DM9C8KQ CB CHEBI:30805
DM9C8KQ DE Discovery agent
DM3W2OE ID DM3W2OE
DM3W2OE DN Lauryl Dimethylamine-N-Oxide
DM3W2OE HS Investigative
DM3W2OE SN 1643-20-5; Lauramine oxide; Lauryldimethylamine oxide; Lauryldimethylamine N-oxide; Dodecyldimethylamine oxide; LDAO; Empigen OB; Ammonyx LO; Ammonyx AO; Aromox DMCD; Conco XAL; Dimethyldodecylamine oxide; Dimethylaurylamine oxide; 1-Dodecanamine, N,N-dimethyl-, N-oxide; DDNO; n-Dodecyldimethylamine oxide; Dodecyldimethylamine N-oxide; dodecyl(dimethyl)amine oxide; Dimethyldodecylamine N-oxide; N,N-dimethyldodecan-1-amine oxide; LAURYL DIMETHYLAMINE-N-OXIDE; Aromox dmmc-W; Dimethyllaurylamine oxide; Amonyx AO; Refan [Russian]
DM3W2OE DT Small molecular drug
DM3W2OE PC 15433
DM3W2OE MW 229.4
DM3W2OE FM C14H31NO
DM3W2OE IC InChI=1S/C14H31NO/c1-4-5-6-7-8-9-10-11-12-13-14-15(2,3)16/h4-14H2,1-3H3
DM3W2OE CS CCCCCCCCCCCC[N+](C)(C)[O-]
DM3W2OE IK SYELZBGXAIXKHU-UHFFFAOYSA-N
DM3W2OE IU N,N-dimethyldodecan-1-amine oxide
DM3W2OE CA CAS 1643-20-5
DM3W2OE CB CHEBI:131762
DM3W2OE DE Discovery agent
DMH3X06 ID DMH3X06
DMH3X06 DN LAVENDUSTIN A
DMH3X06 HS Investigative
DMH3X06 SN Lavendustin A; 125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid
DMH3X06 DT Small molecular drug
DMH3X06 PC 3894
DMH3X06 MW 381.4
DMH3X06 FM C21H19NO6
DMH3X06 IC InChI=1S/C21H19NO6/c23-16-6-8-19(25)14(9-16)12-22(11-13-3-1-2-4-18(13)24)15-5-7-20(26)17(10-15)21(27)28/h1-10,23-26H,11-12H2,(H,27,28)
DMH3X06 CS C1=CC=C(C(=C1)CN(CC2=C(C=CC(=C2)O)O)C3=CC(=C(C=C3)O)C(=O)O)O
DMH3X06 IK ULTTYPMRMMDONC-UHFFFAOYSA-N
DMH3X06 IU 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid
DMH3X06 CA CAS 125697-92-9
DMH3X06 CB CHEBI:92413
DMH3X06 DE Discovery agent
DMOK6IP ID DMOK6IP
DMOK6IP DN LAVYPWT
DMOK6IP HS Investigative
DMOK6IP SN CHEMBL395723; LAVYPWT
DMOK6IP DT Small molecular drug
DMOK6IP PC 25054651
DMOK6IP MW 849
DMOK6IP FM C43H60N8O10
DMOK6IP IC InChI=1S/C43H60N8O10/c1-22(2)18-30(44)38(55)46-24(5)37(54)49-35(23(3)4)41(58)48-33(19-26-13-15-28(53)16-14-26)42(59)51-17-9-12-34(51)40(57)47-32(39(56)50-36(25(6)52)43(60)61)20-27-21-45-31-11-8-7-10-29(27)31/h7-8,10-11,13-16,21-25,30,32-36,45,52-53H,9,12,17-20,44H2,1-6H3,(H,46,55)(H,47,57)(H,48,58)(H,49,54)(H,50,56)(H,60,61)/t24-,25+,30-,32-,33-,34-,35-,36-/m0/s1
DMOK6IP CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N)O
DMOK6IP IK HOZWDBPFSGBJBM-DTSDQQARSA-N
DMOK6IP IU (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DMOK6IP DE Discovery agent
DM5GNFO ID DM5GNFO
DM5GNFO DN LAWSARITOL
DM5GNFO HS Investigative
DM5GNFO SN lawsaritol; CHEMBL202496; stigmast-4-en-3beta-ol
DM5GNFO DT Small molecular drug
DM5GNFO PC 14890646
DM5GNFO MW 414.7
DM5GNFO FM C29H50O
DM5GNFO IC InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h18-21,23-27,30H,7-17H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1
DM5GNFO CS CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C[C@H](CC[C@]34C)O)C)C(C)C
DM5GNFO IK BBTIMXAYZRWPNG-VJSFXXLFSA-N
DM5GNFO IU (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
DM5GNFO DE Discovery agent
DM3H9ZY ID DM3H9ZY
DM3H9ZY DN LB30812
DM3H9ZY HS Investigative
DM3H9ZY DT Small molecular drug
DM3H9ZY PC 56603775
DM3H9ZY MW 662.7
DM3H9ZY FM C30H33F3N6O6S
DM3H9ZY IC InChI=1S/C28H32N6O4S.C2HF3O2/c29-26(30)22-13-11-19(12-14-22)17-32-27(35)23-15-16-34(18-23)28(36)25(33-39(31,37)38)24(20-7-3-1-4-8-20)21-9-5-2-6-10-21;3-2(4,5)1(6)7/h1-14,23-25,33H,15-18H2,(H3,29,30)(H,32,35)(H2,31,37,38);(H,6,7)/t23-,25-;/m1./s1
DM3H9ZY CS C1CN(C[C@@H]1C(=O)NCC2=CC=C(C=C2)C(=N)N)C(=O)[C@@H](C(C3=CC=CC=C3)C4=CC=CC=C4)NS(=O)(=O)N.C(=O)(C(F)(F)F)O
DM3H9ZY IK RNDLEWFHHMPODL-ZHEQYFEDSA-N
DM3H9ZY IU (3R)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-3,3-diphenyl-2-(sulfamoylamino)propanoyl]pyrrolidine-3-carboxamide;2,2,2-trifluoroacetic acid
DM3H9ZY DE Discovery agent
DM6RH19 ID DM6RH19
DM6RH19 DN LB42908
DM6RH19 HS Investigative
DM6RH19 SN LB 42908
DM6RH19 DT Small molecular drug
DM6RH19 PC 91623355
DM6RH19 MW 535.6
DM6RH19 FM C32H33N5O3
DM6RH19 IC InChI=1S/C32H33N5O3/c1-34-11-13-36(14-12-34)32(38)29-20-35(19-28(29)27-8-4-6-24-5-2-3-7-26(24)27)18-25-16-33-21-37(25)17-23-9-10-30-31(15-23)40-22-39-30/h2-10,15-16,19-21,30-31H,11-14,17-18,22H2,1H3
DM6RH19 CS CN1CCN(CC1)C(=O)C2=CN(C=C2C3=CC=CC4=CC=CC=C43)CC5=CN=CN5CC6=CC7C(C=C6)OCO7
DM6RH19 IK VZWZHIJGBPHRDI-UHFFFAOYSA-N
DM6RH19 IU [1-[[3-(3a,7a-dihydro-1,3-benzodioxol-5-ylmethyl)imidazol-4-yl]methyl]-4-naphthalen-1-ylpyrrol-3-yl]-(4-methylpiperazin-1-yl)methanone
DM6RH19 DE Discovery agent
DMENM1B ID DMENM1B
DMENM1B DN L-beta-BA
DMENM1B HS Investigative
DMENM1B SN L-beta-threo-benzyl-aspartate
DMENM1B DT Small molecular drug
DMENM1B PC 11622683
DMENM1B MW 223.22
DMENM1B FM C11H13NO4
DMENM1B IC InChI=1S/C11H13NO4/c12-9(11(15)16)8(10(13)14)6-7-4-2-1-3-5-7/h1-5,8-9H,6,12H2,(H,13,14)(H,15,16)/t8-,9-/m0/s1
DMENM1B CS C1=CC=C(C=C1)C[C@@H]([C@@H](C(=O)O)N)C(=O)O
DMENM1B IK KMVYGTIPJNGNRD-IUCAKERBSA-N
DMENM1B IU (2S,3S)-2-amino-3-benzylbutanedioic acid
DMENM1B DE Discovery agent
DMTNQCE ID DMTNQCE
DMTNQCE DN L-betagamma-meATP
DMTNQCE HS Investigative
DMTNQCE SN UFZTZBNSLXELAL-IOSLPCCCSA-N; AMP-PCP; beta,gamma-Methylene ATP; phosphomethylphosphonic acid adenylate ester; CHEMBL133463; CHEBI:40532; 5'-O-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)adenosine; ADENOSINE 5'-[BETA,GAMMA-METHYLENE]TRIPHOSPHATE; ADENOSINE-5'-[BETA, GAMMA-METHYLENE]TRIPHOSPHATE; 3469-78-1; adenosine 5'-beta,gamma-mu-methylenetriphosphate; ({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid; AMPPCP; betagamma-methylene-adenosine 5'-triphosphate; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
DMTNQCE DT Small molecular drug
DMTNQCE PC 91532
DMTNQCE MW 505.21
DMTNQCE FM C11H18N5O12P3
DMTNQCE IC InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-31(24,25)28-30(22,23)4-29(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H,24,25)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1
DMTNQCE CS C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(CP(=O)(O)O)O)O)O)N
DMTNQCE IK UFZTZBNSLXELAL-IOSLPCCCSA-N
DMTNQCE IU [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methylphosphonic acid
DMTNQCE CA CAS 3469-78-1
DMTNQCE CB CHEBI:40532
DMTNQCE DE Discovery agent
DMQ2DFN ID DMQ2DFN
DMQ2DFN DN LBQ657
DMQ2DFN HS Investigative
DMQ2DFN SN LBQ-657
DMQ2DFN DT Small molecular drug
DMQ2DFN PC 10430040
DMQ2DFN MW 383.4
DMQ2DFN FM C22H25NO5
DMQ2DFN IC InChI=1S/C22H25NO5/c1-15(22(27)28)13-19(23-20(24)11-12-21(25)26)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h2-10,15,19H,11-14H2,1H3,(H,23,24)(H,25,26)(H,27,28)/t15-,19+/m1/s1
DMQ2DFN CS C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O)C(=O)O
DMQ2DFN IK DOBNVUFHFMVMDB-BEFAXECRSA-N
DMQ2DFN IU (2R,4S)-4-(3-carboxypropanoylamino)-2-methyl-5-(4-phenylphenyl)pentanoic acid
DMQ2DFN CA CAS 149709-44-4
DMQ2DFN DE Discovery agent
DMGWSCI ID DMGWSCI
DMGWSCI DN LC34AD3
DMGWSCI HS Investigative
DMGWSCI SN GPR119 agonists (type 2 diabetes), LG Life Sciences; G-protein coupled receptor 119 agonist (type 2 diabetes), LG Life Sciences
DMGWSCI CP LG Life Sciences Ltd
DMGWSCI DE Non-insulin dependent diabetes
DMYONVF ID DMYONVF
DMYONVF DN LC-445
DMYONVF HS Investigative
DMYONVF CP Alkermes
DMYONVF TC Anticancer Agents
DMYONVF DT Small molecular drug
DMYONVF PC 35595
DMYONVF DE Solid tumour/cancer
DMPZ8XH ID DMPZ8XH
DMPZ8XH DN L-CCG-I
DMPZ8XH HS Investigative
DMPZ8XH SN 3,4-Cyclopropylglutamate; CCPG; L-2-(Carboxypropyl)glycine
DMPZ8XH DT Small molecular drug
DMPZ8XH PC 1271
DMPZ8XH MW 159.14
DMPZ8XH FM C6H9NO4
DMPZ8XH IC InChI=1S/C6H9NO4/c7-4(6(10)11)2-1-3(2)5(8)9/h2-4H,1,7H2,(H,8,9)(H,10,11)
DMPZ8XH CS C1C(C1C(=O)O)C(C(=O)O)N
DMPZ8XH IK GZOVEPYOCJWRFC-UHFFFAOYSA-N
DMPZ8XH IU 2-[amino(carboxy)methyl]cyclopropane-1-carboxylic acid
DMPZ8XH CA CAS 22255-17-0
DMPZ8XH DE Discovery agent
DME4TUQ ID DME4TUQ
DME4TUQ DN Lck inhibitor
DME4TUQ HS Investigative
DME4TUQ SN 213743-31-8; 7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine; CHEMBL47940; KIN001-051; RK-24466; 7-Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine; 4-Amino-5-(4-Phenoxyphenyl)-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl-Cyclopentane; 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 4-Amino-5-(4-phenoxyphenyl)-7H-pyrrolo[3,2-d]pyrimidin-7-yl-cyclopentane; 3vry; 3gen; B43; NCGC00015280-01; Lopac-C-8863; AC1O7G1S; Lopac0_000450; MLS002153184
DME4TUQ DT Small molecular drug
DME4TUQ PC 11785878
DME4TUQ MW 530.6
DME4TUQ FM C31H30N8O
DME4TUQ IC InChI=1S/C31H30N8O/c1-20-7-6-8-21(2)27(20)39-29(40)24-19-32-30(35-28(24)38-26-10-5-4-9-25(26)34-31(38)39)33-22-11-13-23(14-12-22)37-17-15-36(3)16-18-37/h4-14,19H,15-18H2,1-3H3,(H,32,33,35)
DME4TUQ CS CC1=C(C(=CC=C1)C)N2C(=O)C3=CN=C(N=C3N4C2=NC5=CC=CC=C54)NC6=CC=C(C=C6)N7CCN(CC7)C
DME4TUQ IK BHJJWVDKNXABFS-UHFFFAOYSA-N
DME4TUQ IU 9-(2,6-dimethylphenyl)-4-[4-(4-methylpiperazin-1-yl)anilino]-1,3,5,9,11-pentazatetracyclo[8.7.0.02,7.012,17]heptadeca-2,4,6,10,12,14,16-heptaen-8-one
DME4TUQ DE Discovery agent
DMD5GO0 ID DMD5GO0
DMD5GO0 DN LD-101
DMD5GO0 HS Investigative
DMD5GO0 SN AKT-SI-1
DMD5GO0 CP H Lee Moffitt Cancer Center and Research Institute
DMD5GO0 PC 24773090
DMD5GO0 MW 337.29
DMD5GO0 FM C13H15N5O6
DMD5GO0 IC InChI=1S/C13H15N5O6/c14-10-6-7(20)4(11(15)23)1-18(12(6)17-3-16-10)13-9(22)8(21)5(2-19)24-13/h1,3,5,8-9,13,19,21-22H,2H2,(H2,15,23)(H2,14,16,17)/t5-,8-,9-,13-/m1/s1
DMD5GO0 CS C1=C(C(=O)C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N
DMD5GO0 IK SPBWHPXCWJLQRU-FITJORAGSA-N
DMD5GO0 IU 4-amino-8-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-oxopyrido[2,3-d]pyrimidine-6-carboxamide
DMD5GO0 CA CAS 36707-00-3
DMD5GO0 DE Solid tumour/cancer
DMC5XQ6 ID DMC5XQ6
DMC5XQ6 DN LD201t1
DMC5XQ6 HS Investigative
DMC5XQ6 DT Aptamer
DMC5XQ6 DE Inflammation
DMH7R6L ID DMH7R6L
DMH7R6L DN LDC1267
DMH7R6L HS Investigative
DMH7R6L SN LDC1267; 1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
DMH7R6L DT Small molecular drug
DMH7R6L PC 56847486
DMH7R6L MW 560.5
DMH7R6L FM C30H26F2N4O5
DMH7R6L IC InChI=1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)
DMH7R6L CS CCOC1=CN(N=C1C(=O)NC2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)F)C5=C(C=C(C=C5)F)C
DMH7R6L IK ISPBCAXOSOLFME-UHFFFAOYSA-N
DMH7R6L IU N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-4-ethoxy-1-(4-fluoro-2-methylphenyl)pyrazole-3-carboxamide
DMH7R6L DE Discovery agent
DM57Z8J ID DM57Z8J
DM57Z8J DN LDN-214117
DM57Z8J HS Investigative
DM57Z8J SN compound 10 [PMID: 25101911]
DM57Z8J DT Small molecular drug
DM57Z8J PC 91754554
DM57Z8J MW 419.5
DM57Z8J FM C25H29N3O3
DM57Z8J IC InChI=1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3
DM57Z8J CS CC1=C(C=C(C=N1)C2=CC=C(C=C2)N3CCNCC3)C4=CC(=C(C(=C4)OC)OC)OC
DM57Z8J IK BHUXVRVMMYAXKN-UHFFFAOYSA-N
DM57Z8J IU 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine
DM57Z8J DE Discovery agent
DMTSLGF ID DMTSLGF
DMTSLGF DN LDN-91946
DMTSLGF HS Investigative
DMTSLGF SN compound 7
DMTSLGF DT Small molecular drug
DMTSLGF PC 950368
DMTSLGF MW 314.3
DMTSLGF FM C15H10N2O4S
DMTSLGF IC InChI=1S/C15H10N2O4S/c16-10-8-6-9(15(20)21)13(19)17-14(8)22-12(10)11(18)7-4-2-1-3-5-7/h1-6H,16H2,(H,17,19)(H,20,21)
DMTSLGF CS C1=CC=C(C=C1)C(=O)C2=C(C3=C(S2)NC(=O)C(=C3)C(=O)O)N
DMTSLGF IK OJHMDRZMENMQFP-UHFFFAOYSA-N
DMTSLGF IU 3-amino-2-benzoyl-6-oxo-7H-thieno[2,3-b]pyridine-5-carboxylic acid
DMTSLGF DE Discovery agent
DMZ21HU ID DMZ21HU
DMZ21HU DN LEACHIANONE A
DMZ21HU HS Investigative
DMZ21HU SN leachianone A; 97938-31-3; Isokurarinone; (S)-5,7-Dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-((R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl)chroman-4-one; CHEBI:66559; (2S)-5,7,4'-trihydroxy-8-lavandulyl-2'-methoxyflavanone; (2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-2,3-dihydro-4H-chromen-4-one; (2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-3,4-dihydro-2H-1-benzopyran-4-one; CHEMBL453642; MolPort-028-754-113
DMZ21HU DT Small molecular drug
DMZ21HU PC 44593449
DMZ21HU MW 438.5
DMZ21HU FM C26H30O6
DMZ21HU IC InChI=1S/C26H30O6/c1-14(2)6-7-16(15(3)4)10-19-20(28)12-21(29)25-22(30)13-24(32-26(19)25)18-9-8-17(27)11-23(18)31-5/h6,8-9,11-12,16,24,27-29H,3,7,10,13H2,1-2,4-5H3/t16-,24+/m1/s1
DMZ21HU CS CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C
DMZ21HU IK YLTPWCZXKJSORQ-GYCJOSAFSA-N
DMZ21HU IU (2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
DMZ21HU CA CAS 97938-31-3
DMZ21HU CB CHEBI:66559
DMZ21HU DE Discovery agent
DML0GZ2 ID DML0GZ2
DML0GZ2 DN Lead acetate
DML0GZ2 HS Investigative
DML0GZ2 SN LEAD ACETATE; Lead diacetate; Lead(II) acetate; Lead(2+) acetate; 301-04-2; Acetic acid, lead salt; Unichem PBA; Lead di(acetate); Normal lead acetate; Dibasic lead acetate; Lead dibasic acetate; Bleiacetat [German]; lead(2+) diacetate; Plumbous acetate; Salt of saturn; Sugar of lead; Caswell No. 523A; Lead acetate (anhydrous); RCRA waste number U144; Acetate de plomb [French]; Lead acetate (Pb(Ac)2); Acetic acid lead(2+) salt; CCRIS 356; Acetic acid, lead(2+) salt; Acetic acid, lead(2 +) salt; UNII-KL498O6790; Acetate de plomb
DML0GZ2 DT Small molecular drug
DML0GZ2 PC 9317
DML0GZ2 MW 325
DML0GZ2 FM C4H6O4Pb
DML0GZ2 IC InChI=1S/2C2H4O2.Pb/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
DML0GZ2 CS CC(=O)[O-].CC(=O)[O-].[Pb+2]
DML0GZ2 IK GUWSLQUAAYEZAF-UHFFFAOYSA-L
DML0GZ2 IU lead(2+);diacetate
DML0GZ2 CA CAS 301-04-2
DML0GZ2 DE Discovery agent
DMZ7OHP ID DMZ7OHP
DMZ7OHP DN Lecanindole D
DMZ7OHP HS Investigative
DMZ7OHP SN Lecanindole D; CHEMBL1076438
DMZ7OHP DT Small molecular drug
DMZ7OHP PC 44605900
DMZ7OHP MW 353.5
DMZ7OHP FM C23H31NO2
DMZ7OHP IC InChI=1S/C23H31NO2/c1-20(2)18(25)10-11-21(3)22(4)14(9-12-23(20,21)26)13-16-15-7-5-6-8-17(15)24-19(16)22/h5-8,14,18,24-26H,9-13H2,1-4H3/t14-,18+,21+,22+,23+/m0/s1
DMZ7OHP CS C[C@]12CC[C@H](C([C@@]1(CC[C@@H]3[C@@]2(C4=C(C3)C5=CC=CC=C5N4)C)O)(C)C)O
DMZ7OHP IK QJRNEHJGTLWRJJ-BVYMYZFFSA-N
DMZ7OHP IU (1S,12S,15S,17R,20R)-1,16,16,20-tetramethyl-3-azapentacyclo[10.8.0.02,10.04,9.015,20]icosa-2(10),4,6,8-tetraene-15,17-diol
DMZ7OHP DE Discovery agent
DM0CEY3 ID DM0CEY3
DM0CEY3 DN Lefaxin
DM0CEY3 HS Investigative
DM0CEY3 SN PYRIDOSTIGMINE BROMIDE; 101-26-8; Mestinon; Kalimin; Regonal; Kalymin; Mestinon bromide; 3-((Dimethylcarbamoyl)oxy)-1-methylpyridin-1-ium bromide; 3-(Dimethylcarbamoyloxy)-1-methylpyridinium Bromide; Pyridostigmine (bromide); UNII-KVI301NA53; Piridostigmina bromuro [DCIT]; CCRIS 6798; HSDB 3924; 3-[(dimethylcarbamoyl)oxy]-1-methylpyridin-1-ium bromide; Pyridostigmini bromidum [INN-Latin]; EINECS 202-929-9; Ro 1-5130; Bromure de pyridostigmine [INN-French]; Pyridostigmini bromidum; Bromuro de piridostigmina [INN-Spanish
DM0CEY3 DT Small molecular drug
DM0CEY3 PC 7550
DM0CEY3 MW 261.12
DM0CEY3 FM C9H13BrN2O2
DM0CEY3 IC InChI=1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1
DM0CEY3 CS C[N+]1=CC=CC(=C1)OC(=O)N(C)C.[Br-]
DM0CEY3 IK VNYBTNPBYXSMOO-UHFFFAOYSA-M
DM0CEY3 IU (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate;bromide
DM0CEY3 CA CAS 101-26-8
DM0CEY3 CB CHEBI:8666
DM0CEY3 DE Discovery agent
DM5LY1H ID DM5LY1H
DM5LY1H DN Leptin
DM5LY1H HS Investigative
DM5LY1H SN Leptin (Alzheimer's disease)
DM5LY1H CP Neurotez Inc
DM5LY1H DE Alzheimer disease
DME91CG ID DME91CG
DME91CG DN Lerdelimumab
DME91CG HS Investigative
DME91CG DT Antibody
DME91CG DE Discovery agent
DMDV67S ID DMDV67S
DMDV67S DN lergotrile
DMDV67S HS Investigative
DMDV67S SN LY 79907
DMDV67S DT Small molecular drug
DMDV67S PC 6918447
DMDV67S MW 299.8
DMDV67S FM C17H18ClN3
DMDV67S IC InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1
DMDV67S CS CN1C[C@@H](C[C@H]2[C@H]1CC3=C(NC4=CC=CC2=C34)Cl)CC#N
DMDV67S IK JKAHWGPTNVUTNB-IXPVHAAZSA-N
DMDV67S IU 2-[(6aR,9S,10aR)-5-chloro-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile
DMDV67S CA CAS 36945-03-6
DMDV67S DE Discovery agent
DMV4OKR ID DMV4OKR
DMV4OKR DN L-erythro-3-hydroxyaspartate
DMV4OKR HS Investigative
DMV4OKR SN (3R)-3-hydroxy-L-aspartate; erythro-3-Hydroxy-L-aspartate; L-erythro-3-hydroxyaspartate; L-erythro-beta-hydroxyaspartate; erythro-3-hydroxy-aspartic acid; CHEBI:58196; (3R)-3-hydroxy-L-aspartate anion; (3R)-3-hydroxy-L-aspartate(1-); ZB015320
DMV4OKR DT Small molecular drug
DMV4OKR PC 28125549
DMV4OKR MW 148.09
DMV4OKR FM C4H6NO5-
DMV4OKR IC InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)/p-1/t1-,2+/m0/s1
DMV4OKR CS [C@H]([C@H](C(=O)[O-])O)(C(=O)[O-])[NH3+]
DMV4OKR IK YYLQUHNPNCGKJQ-NHYDCYSISA-M
DMV4OKR IU (2S,3R)-2-azaniumyl-3-hydroxybutanedioate
DMV4OKR CB CHEBI:58196
DMV4OKR DE Neurodegenerative disorder
DMV40XH ID DMV40XH
DMV40XH DN leualacin
DMV40XH HS Investigative
DMV40XH SN 128140-12-5
DMV40XH DT Small molecular drug
DMV40XH PC 197283
DMV40XH MW 573.7
DMV40XH FM C31H47N3O7
DMV40XH IC InChI=1S/C31H47N3O7/c1-19(2)15-23(33)27(39)30(18-35,34(7)29(41)25(37)17-21(5)6)31(26(38)13-14-32,22-11-9-8-10-12-22)28(40)24(36)16-20(3)4/h8-12,18-20,23-25,36-37H,5,13-17,32-33H2,1-4,6-7H3/t23-,24?,25-,30-,31?/m0/s1
DMV40XH CS CC(C)C[C@@H](C(=O)[C@@](C=O)(C(C1=CC=CC=C1)(C(=O)CCN)C(=O)C(CC(C)C)O)N(C)C(=O)[C@H](CC(=C)C)O)N
DMV40XH IK ZPYMSTAWPQJBRU-DJQJIUKYSA-N
DMV40XH IU (2S)-N-[(4S,6S)-4-amino-7-(3-aminopropanoyl)-6-formyl-9-hydroxy-2,11-dimethyl-5,8-dioxo-7-phenyldodecan-6-yl]-2-hydroxy-N,4-dimethylpent-4-enamide
DMV40XH CA CAS 128140-12-5
DMV40XH DE Discovery agent
DM94JXH ID DM94JXH
DM94JXH DN Leucettamidine
DM94JXH HS Investigative
DM94JXH SN leucettamidine; CHEMBL485054
DM94JXH DT Small molecular drug
DM94JXH PC 20704716
DM94JXH MW 488.5
DM94JXH FM C25H24N6O5
DM94JXH IC InChI=1S/C25H24N6O5/c1-29-17(9-15-5-7-19-21(11-15)36-13-34-19)16(8-14-4-6-18-20(10-14)35-12-33-18)27-25(29)28-22-23(32)31(3)24(26)30(22)2/h4-7,10-11,26H,8-9,12-13H2,1-3H3/b26-24?,28-22+
DM94JXH CS CN1C(=C(N=C1/N=C/2\\C(=O)N(C(=N)N2C)C)CC3=CC4=C(C=C3)OCO4)CC5=CC6=C(C=C5)OCO6
DM94JXH IK RZKRATQHPLTYSI-GQZUJQTPSA-N
DM94JXH IU (5E)-5-[4,5-bis(1,3-benzodioxol-5-ylmethyl)-1-methylimidazol-2-yl]imino-2-imino-1,3-dimethylimidazolidin-4-one
DM94JXH DE Discovery agent
DMIZVA6 ID DMIZVA6
DMIZVA6 DN LEUCETTAMINE A
DMIZVA6 HS Investigative
DMIZVA6 SN Leucettamol A; Leucettamine A (lipid); 151124-32-2; AC1O5ZHI; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R*,3S*,5Z,8Z,11Z,14Z,20Z,28S*,29R*)-(+-)-; 334010-39-8; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R*,3S*,5Z,8Z,11Z,14Z,20Z,28S*,29R*)-; 5,8,11,14,17,20-Triacontahexaene-3,28-diol, 2,29-diamino-, (2R,3S,5Z,8Z,11Z,14Z,20Z,28S,29R)-rel-
DMIZVA6 DT Small molecular drug
DMIZVA6 PC 10021742
DMIZVA6 MW 365.4
DMIZVA6 FM C20H19N3O4
DMIZVA6 IC InChI=1S/C20H19N3O4/c1-23-15(7-13-3-5-17-19(9-13)27-11-25-17)14(22-20(23)21)6-12-2-4-16-18(8-12)26-10-24-16/h2-5,8-9H,6-7,10-11H2,1H3,(H2,21,22)
DMIZVA6 CS CN1C(=C(N=C1N)CC2=CC3=C(C=C2)OCO3)CC4=CC5=C(C=C4)OCO5
DMIZVA6 IK CHUHMZZQHYOKBF-UHFFFAOYSA-N
DMIZVA6 IU 4,5-bis(1,3-benzodioxol-5-ylmethyl)-1-methylimidazol-2-amine
DMIZVA6 DE Discovery agent
DMFQEWM ID DMFQEWM
DMFQEWM DN LEUCETTAMINE B
DMFQEWM HS Investigative
DMFQEWM SN leucettamine B; CHEMBL485053; SCHEMBL13219029
DMFQEWM DT Small molecular drug
DMFQEWM PC 10037501
DMFQEWM MW 245.23
DMFQEWM FM C12H11N3O3
DMFQEWM IC InChI=1S/C12H11N3O3/c1-15-11(16)8(14-12(15)13)4-7-2-3-9-10(5-7)18-6-17-9/h2-5H,6H2,1H3,(H2,13,14)/b8-4-
DMFQEWM CS CN1C(=O)/C(=C/C2=CC3=C(C=C2)OCO3)/N=C1N
DMFQEWM IK PKEDBIGNILOTHW-YWEYNIOJSA-N
DMFQEWM IU (5Z)-2-amino-5-(1,3-benzodioxol-5-ylmethylidene)-3-methylimidazol-4-one
DMFQEWM DE Discovery agent
DMBYND6 ID DMBYND6
DMBYND6 DN leucettine L41
DMBYND6 HS Investigative
DMBYND6 DT Small molecular drug
DMBYND6 PC 135398522
DMBYND6 MW 307.3
DMBYND6 FM C17H13N3O3
DMBYND6 IC InChI=1S/C17H13N3O3/c21-16-13(8-11-6-7-14-15(9-11)23-10-22-14)19-17(20-16)18-12-4-2-1-3-5-12/h1-9H,10H2,(H2,18,19,20,21)/b13-8-
DMBYND6 CS C1OC2=C(O1)C=C(C=C2)/C=C\\3/C(=O)NC(=N3)NC4=CC=CC=C4
DMBYND6 IK PGPHHJBZEGSUNE-JYRVWZFOSA-N
DMBYND6 IU (4Z)-2-anilino-4-(1,3-benzodioxol-5-ylmethylidene)-1H-imidazol-5-one
DMBYND6 DE Discovery agent
DMT2CZK ID DMT2CZK
DMT2CZK DN Leucine-enkephalin
DMT2CZK HS Investigative
DMT2CZK SN YGGFL; URLZCHNOLZSCCA-UHFFFAOYSA-N; 2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid; Spectrum_001429; AC1L1GYW; Spectrum5_000656; Spectrum4_001048; Spectrum2_001177; Spectrum3_001521; AC1Q1P3H; KBioSS_001909; KBioGR_001316; BSPBio_002902
DMT2CZK DT Small molecular drug
DMT2CZK PC 461776
DMT2CZK MW 555.6
DMT2CZK FM C28H37N5O7
DMT2CZK IC InChI=1S/C28H37N5O7/c1-17(2)12-23(28(39)40)33-27(38)22(14-18-6-4-3-5-7-18)32-25(36)16-30-24(35)15-31-26(37)21(29)13-19-8-10-20(34)11-9-19/h3-11,17,21-23,34H,12-16,29H2,1-2H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)(H,39,40)/t21-,22-,23-/m0/s1
DMT2CZK CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
DMT2CZK IK URLZCHNOLZSCCA-VABKMULXSA-N
DMT2CZK IU (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
DMT2CZK CA CAS 58822-25-6
DMT2CZK CB CHEBI:89656
DMT2CZK DE Discovery agent
DM6W27F ID DM6W27F
DM6W27F DN LEUCOSCEPTOSIDE A
DM6W27F HS Investigative
DM6W27F DT Small molecular drug
DM6W27F PC 10394343
DM6W27F MW 638.6
DM6W27F FM C30H38O15
DM6W27F IC InChI=1S/C30H38O15/c1-14-23(36)24(37)25(38)30(42-14)45-28-26(39)29(41-10-9-16-3-6-17(32)19(34)11-16)43-21(13-31)27(28)44-22(35)8-5-15-4-7-18(33)20(12-15)40-2/h3-8,11-12,14,21,23-34,36-39H,9-10,13H2,1-2H3/b8-5+/t14-,21+,23-,24+,25+,26+,27+,28+,29+,30-/m0/s1
DM6W27F CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)OC)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
DM6W27F IK ZMYQRHSOVRDQDL-CPPDSBOHSA-N
DM6W27F IU [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
DM6W27F DE Discovery agent
DMYX2NJ ID DMYX2NJ
DMYX2NJ DN Leukotoxin
DMYX2NJ HS Investigative
DMYX2NJ SN Leukothera; Leukotoxin (cancer treatment); Leukotoxin (cancer treatment), Actinobac Biomed
DMYX2NJ CP Actinobac Biomed Inc
DMYX2NJ DT Small molecular drug
DMYX2NJ PC 9966640
DMYX2NJ MW 314.5
DMYX2NJ FM C18H34O4
DMYX2NJ IC InChI=1S/C18H34O4/c1-2-3-4-5-7-10-13-16(19)17(20)14-11-8-6-9-12-15-18(21)22/h7,10,16-17,19-20H,2-6,8-9,11-15H2,1H3,(H,21,22)/b10-7-
DMYX2NJ CS CCCCC/C=C\\CC(C(CCCCCCCC(=O)O)O)O
DMYX2NJ IK XEBKSQSGNGRGDW-YFHOEESVSA-N
DMYX2NJ IU (Z)-9,10-dihydroxyoctadec-12-enoic acid
DMYX2NJ CA CAS 53734-70-6
DMYX2NJ CB CHEBI:72663
DMYX2NJ DE Autoimmune diabetes
DMU075F ID DMU075F
DMU075F DN Leupeptin
DMU075F HS Investigative
DMU075F SN 2-(2-Acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methylvaleramide; AC1L97IT; Valeramide, 2-(2-acetamido-4-methylvaleramido)-N-(1-formyl-4-guanidinobutyl)-4-methyl-; 24365-55-7; (2S)-2-acetamido-N-[1-[[5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide
DMU075F DT Small molecular drug
DMU075F PC 72429
DMU075F MW 426.6
DMU075F FM C20H38N6O4
DMU075F IC InChI=1S/C20H38N6O4/c1-12(2)9-16(24-14(5)28)19(30)26-17(10-13(3)4)18(29)25-15(11-27)7-6-8-23-20(21)22/h11-13,15-17H,6-10H2,1-5H3,(H,24,28)(H,25,29)(H,26,30)(H4,21,22,23)/t15-,16-,17-/m0/s1
DMU075F CS CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)C
DMU075F IK GDBQQVLCIARPGH-ULQDDVLXSA-N
DMU075F IU (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide
DMU075F CA CAS 55123-66-5
DMU075F CB CHEBI:6426
DMU075F DE Malaria
DMPYSIT ID DMPYSIT
DMPYSIT DN levetimide
DMPYSIT HS Investigative
DMPYSIT SN l-benzetimide
DMPYSIT DT Small molecular drug
DMPYSIT PC 30844
DMPYSIT MW 362.5
DMPYSIT FM C23H26N2O2
DMPYSIT IC InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m0/s1
DMPYSIT CS C1CN(CCC1[C@]2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4
DMPYSIT IK LQQIVYSCPWCSSD-QHCPKHFHSA-N
DMPYSIT IU (3R)-3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione
DMPYSIT CA CAS 21888-99-3
DMPYSIT DE Discovery agent
DMWDJ0H ID DMWDJ0H
DMWDJ0H DN LEVONORDEFRIN
DMWDJ0H HS Investigative
DMWDJ0H SN levonordefrin; Corbadrine; Neo-Cobefrin; Nordefrin; 829-74-3; Corbadrinum; Corbadrina; alpha-Methylnoradrenaline; Corbadrinum [INN-Latin]; Corbadrina [INN-Spanish]; L-alpha-Methylnoradrenaline; Levonordefrin [USP]; Nordefrin, (-)-; UNII-V008L6478D; CHEBI:10304; 4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol; Corbadrine (INN); Corbadrine [INN]; Levonordefrin (USP); V008L6478D; CAS-829-74-3; DSSTox_RID_81553; DSSTox_CID_26349
DMWDJ0H DT Small molecular drug
DMWDJ0H PC 164739
DMWDJ0H MW 183.2
DMWDJ0H FM C9H13NO3
DMWDJ0H IC InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1
DMWDJ0H CS C[C@@H]([C@@H](C1=CC(=C(C=C1)O)O)O)N
DMWDJ0H IK GEFQWZLICWMTKF-CDUCUWFYSA-N
DMWDJ0H IU 4-[(1R,2S)-2-amino-1-hydroxypropyl]benzene-1,2-diol
DMWDJ0H CA CAS 829-74-3
DMWDJ0H CB CHEBI:10304
DMWDJ0H DE Discovery agent
DMV3P89 ID DMV3P89
DMV3P89 DN Levoverbenone
DMV3P89 HS Investigative
DMV3P89 SN Levoverbenone; DCSCXTJOXBUFGB-JGVFFNPUSA-N; L(-)-Verbenone; Pin-2-en-4-one; VERBENONE; VERBENONE,(L); Verbenone, (L)-; l-Verbenone; l-verbenoe; (-)-2-Pinen-4-one; (-)-Verbenone; (-)-cis-verbenone; (1S)-(-)-Verbenone; (1S)-(-)-Verbenone, 94%; (1S,5S)-4,6,6-Trimethylbicyclo[3.1.1]hept-3-en-2-one; (S)-(-)-Verbenone; 1196-01-6; 2XP0J7754U; 80-57-9; AI3-23128; Bicyclo(3.1.1)hept-3-en-2-one, 4,6,6-trimethyl-, (1S,5S)-; Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl-, (1S,5S)-; CHEBI:78316; EINECS 214-807-2; NSC 6831; UNII-2XP0J7754U
DMV3P89 PC 92874
DMV3P89 MW 150.22
DMV3P89 FM C10H14O
DMV3P89 IC DCSCXTJOXBUFGB-JGVFFNPUSA-N
DMV3P89 CS CC1=CC(=O)C2CC1C2(C)C
DMV3P89 IK 1S/C10H14O/c1-6-4-9(11)8-5-7(6)10(8,2)3/h4,7-8H,5H2,1-3H3/t7-,8+/m0/s1
DMV3P89 IU (1S,5S)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one
DMV3P89 CA CAS 1196-01-6
DMV3P89 CB CHEBI:78316
DMV3P89 DE Pulmonary tuberculosis
DMOEQTN ID DMOEQTN
DMOEQTN DN LF-160335
DMOEQTN HS Investigative
DMOEQTN PC 9853328
DMOEQTN MW 723.7
DMOEQTN FM C35H36Cl2N6O5S
DMOEQTN IC InChI=1S/C35H36Cl2N6O5S/c1-21-19-22(2)40-32-25(21)5-3-7-29(32)48-20-26-27(36)12-13-30(31(26)37)49(46,47)43-14-4-6-28(43)35(45)42-17-15-41(16-18-42)34(44)24-10-8-23(9-11-24)33(38)39/h3,5,7-13,19,28H,4,6,14-18,20H2,1-2H3,(H3,38,39)/t28-/m0/s1
DMOEQTN CS CC1=CC(=NC2=C1C=CC=C2OCC3=C(C=CC(=C3Cl)S(=O)(=O)N4CCC[C@H]4C(=O)N5CCN(CC5)C(=O)C6=CC=C(C=C6)C(=N)N)Cl)C
DMOEQTN IK XJEBAAYNUNGRSF-NDEPHWFRSA-N
DMOEQTN IU 4-[4-[(2S)-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carbonyl]piperazine-1-carbonyl]benzenecarboximidamide
DMOEQTN DE Discovery agent
DM5G307 ID DM5G307
DM5G307 DN LFA703
DM5G307 HS Investigative
DM5G307 SN LFA703; 8-[2-((2S)-4-HYDROXY-1-{[5-(HYDROXYMETHYL)-6-METHOXY-2-NAPHTHYL]METHYL}-6-OXOPIPERIDIN-2-YL)ETHYL]-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2-METHYLBUTANOATE; AAY; 1xdd; AC1L9MT5; LFA-703; DB03932; (1S,3R,7S,8S,8aR)-8-{2-[(2S,4R)-4-hydroxy-1-{[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl}-6-oxopiperidin-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
DM5G307 DT Small molecular drug
DM5G307 PC 449169
DM5G307 MW 603.8
DM5G307 FM C37H49NO6
DM5G307 IC InChI=1S/C37H49NO6/c1-6-23(3)37(42)44-34-16-22(2)15-27-9-7-24(4)30(36(27)34)13-11-28-18-29(40)19-35(41)38(28)20-25-8-12-31-26(17-25)10-14-33(43-5)32(31)21-39/h7-10,12,14-15,17,22-24,28-30,34,36,39-40H,6,11,13,16,18-21H2,1-5H3/t22-,23-,24-,28-,29+,30-,34-,36-/m0/s1
DM5G307 CS CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H]3C[C@H](CC(=O)N3CC4=CC5=C(C=C4)C(=C(C=C5)OC)CO)O)C
DM5G307 IK WPVRNXUYVXQXPY-YFAYRSKXSA-N
DM5G307 IU [(1S,3R,7S,8S,8aR)-8-[2-[(2S,4R)-4-hydroxy-1-[[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl]-6-oxopiperidin-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
DM5G307 DE Discovery agent
DMTXWCZ ID DMTXWCZ
DMTXWCZ DN LFM-A13
DMTXWCZ HS Investigative
DMTXWCZ SN lfm-a13; 244240-24-2; (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide; SMR001230714; SR-01000075965; 62004-35-7; C11H8Br2N2O2; 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; BiomolKI_000050; LFMA13; BiomolKI2_000056; AC1L1H0E; AC1NS4I5; Lopac0_000650; SCHEMBL51142; BSPBio_001239; BMK1-F2; MLS006010694; MLS002153290; GTPL9262; CHEBI:95065; 2-cyano-N-(2,5-dibromophenyl); MolPort-003-958-579; HMS1362M21; HMS3403M21; HMS2235P16; HMS1990M21; HMS1792M21; BCP12817; 3781AH; s7734; BS0111; ZINC37868487; AKOS024456516; CS-3890
DMTXWCZ DT Small molecular drug
DMTXWCZ PC 54676905
DMTXWCZ MW 360
DMTXWCZ FM C11H8Br2N2O2
DMTXWCZ IC InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-
DMTXWCZ CS C/C(=C(\\C#N)/C(=O)NC1=C(C=CC(=C1)Br)Br)/O
DMTXWCZ IK UVSVTDVJQAJIFG-VURMDHGXSA-N
DMTXWCZ IU (Z)-2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
DMTXWCZ CB CHEBI:95065
DMTXWCZ DE Discovery agent
DMEK4FY ID DMEK4FY
DMEK4FY DN LG100754
DMEK4FY HS Investigative
DMEK4FY SN LG 100754; LG754
DMEK4FY DT Small molecular drug
DMEK4FY PC 6442223
DMEK4FY MW 396.6
DMEK4FY FM C26H36O3
DMEK4FY IC InChI=1S/C26H36O3/c1-8-14-29-23-17-22-21(25(4,5)12-13-26(22,6)7)16-20(23)19(3)11-9-10-18(2)15-24(27)28/h9-11,15-17H,8,12-14H2,1-7H3,(H,27,28)/b10-9+,18-15+,19-11-
DMEK4FY CS CCCOC1=CC2=C(C=C1/C(=C\\C=C\\C(=C\\C(=O)O)\\C)/C)C(CCC2(C)C)(C)C
DMEK4FY IK HNODNXQAYXJFMQ-LQUSFLDPSA-N
DMEK4FY IU (2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid
DMEK4FY CA CAS 180713-37-5
DMEK4FY DE Discovery agent
DMG1UOR ID DMG1UOR
DMG1UOR DN LG-120838
DMG1UOR HS Investigative
DMG1UOR SN LG-120838; CHEMBL302362; SCHEMBL4175160; SCHEMBL4175162; BDBM50067684; 5-(2-Methylbenzylidene)-2,2,4-trimethyl-1,2-dihydro-5H-1-aza-6-oxachrysene
DMG1UOR DT Small molecular drug
DMG1UOR PC 9951771
DMG1UOR MW 379.5
DMG1UOR FM C27H25NO
DMG1UOR IC InChI=1S/C27H25NO/c1-17-9-5-6-10-19(17)15-24-26-21(20-11-7-8-12-23(20)29-24)13-14-22-25(26)18(2)16-27(3,4)28-22/h5-16,28H,1-4H3/b24-15-
DMG1UOR CS CC1=CC=CC=C1/C=C\\2/C3=C(C=CC4=C3C(=CC(N4)(C)C)C)C5=CC=CC=C5O2
DMG1UOR IK YXKBVHXOKVRRKO-IWIPYMOSSA-N
DMG1UOR IU (5Z)-2,2,4-trimethyl-5-[(2-methylphenyl)methylidene]-1H-chromeno[3,4-f]quinoline
DMG1UOR DE Discovery agent
DMMHYQ4 ID DMMHYQ4
DMMHYQ4 DN LG-121071
DMMHYQ4 HS Investigative
DMMHYQ4 SN LGD-121071
DMMHYQ4 DT Small molecular drug
DMMHYQ4 PC 9839132
DMMHYQ4 MW 296.29
DMMHYQ4 FM C15H15F3N2O
DMMHYQ4 IC InChI=1S/C15H15F3N2O/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19H,2-4H2,1H3,(H,20,21)
DMMHYQ4 CS CCC1CCNC2=C1C=C3C(=CC(=O)NC3=C2)C(F)(F)F
DMMHYQ4 IK SZPPQFARTYXRKU-UHFFFAOYSA-N
DMMHYQ4 IU 6-ethyl-4-(trifluoromethyl)-6,7,8,9-tetrahydro-1H-pyrido[3,2-g]quinolin-2-one
DMMHYQ4 DE Discovery agent
DMO1FCU ID DMO1FCU
DMO1FCU DN LG190178
DMO1FCU HS Investigative
DMO1FCU SN LG-190178
DMO1FCU DT Small molecular drug
DMO1FCU PC 15521397
DMO1FCU MW 458.6
DMO1FCU FM C28H42O5
DMO1FCU IC InChI=1S/C28H42O5/c1-8-28(9-2,21-10-12-24(19(3)14-21)32-17-23(30)16-29)22-11-13-25(20(4)15-22)33-18-26(31)27(5,6)7/h10-15,23,26,29-31H,8-9,16-18H2,1-7H3
DMO1FCU CS CCC(CC)(C1=CC(=C(C=C1)OCC(CO)O)C)C2=CC(=C(C=C2)OCC(C(C)(C)C)O)C
DMO1FCU IK AIKLCYAFOOBGEV-UHFFFAOYSA-N
DMO1FCU IU 3-[4-[3-[4-(2-hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]pentan-3-yl]-2-methylphenoxy]propane-1,2-diol
DMO1FCU DE Discovery agent
DM1W8Y0 ID DM1W8Y0
DM1W8Y0 DN LG-888
DM1W8Y0 HS Investigative
DM1W8Y0 SN Coagulation stimulator (factor VIII deficiency, protein recombinant), Lentigen; Factor VIII agonist (factor VIII deficiency, protein chimeric), Lentigen
DM1W8Y0 CP Lentigen Corp
DM1W8Y0 DE Factor VIII deficiency
DMIHDEB ID DMIHDEB
DMIHDEB DN LG-889
DMIHDEB HS Investigative
DMIHDEB SN Adult multipotent stem cell (hemophilia A), Lentigen/Expression/Emory
DMIHDEB CP Lentigen Corp
DMIHDEB DE Factor VIII deficiency
DMKRSZY ID DMKRSZY
DMKRSZY DN LGD-2226
DMKRSZY HS Investigative
DMKRSZY SN LGD-2226; UNII-RI376RM5MT; LGD2226; RI376RM5MT; CHEMBL436784; 328947-93-9; 6-[bis(2,2,2-Trifluoroethyl)amino]-4-(Trifluoromethyl)quinolin-2(1h)-One; 2hvc; SCHEMBL1771552; BDBM18524; DTXSID10186546; ZINC14968232; 6-(Bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one; DB08089; 4-(Trifluoromethyl)-6-[bis(2,2,2-trifluoroethyl)amino]quinoline-2(1H)-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1H-quinolin-2-one; 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1,2-dihydroquinolin-2-one
DMKRSZY DT Small molecular drug
DMKRSZY PC 11560224
DMKRSZY MW 392.22
DMKRSZY FM C14H9F9N2O
DMKRSZY IC InChI=1S/C14H9F9N2O/c15-12(16,17)5-25(6-13(18,19)20)7-1-2-10-8(3-7)9(14(21,22)23)4-11(26)24-10/h1-4H,5-6H2,(H,24,26)
DMKRSZY CS C1=CC2=C(C=C1N(CC(F)(F)F)CC(F)(F)F)C(=CC(=O)N2)C(F)(F)F
DMKRSZY IK ULBPQWIGZUGPHU-UHFFFAOYSA-N
DMKRSZY IU 6-[bis(2,2,2-trifluoroethyl)amino]-4-(trifluoromethyl)-1H-quinolin-2-one
DMKRSZY CA CAS 328947-93-9
DMKRSZY DE Discovery agent
DM67KWM ID DM67KWM
DM67KWM DN LGD-5552
DM67KWM HS Investigative
DM67KWM SN LGD-5552; CHEMBL259820; SCHEMBL4166143
DM67KWM DT Small molecular drug
DM67KWM PC 24816375
DM67KWM MW 443.5
DM67KWM FM C28H26FNO3
DM67KWM IC InChI=1S/C28H26FNO3/c1-15-7-6-8-17(26(15)29)13-22-24-18(25-21(33-22)12-11-20(31)27(25)32-5)9-10-19-23(24)16(2)14-28(3,4)30-19/h6-14,30-31H,1-5H3/b22-13-
DM67KWM CS CC1=C(C(=CC=C1)/C=C\\2/C3=C(C=CC4=C3C(=CC(N4)(C)C)C)C5=C(O2)C=CC(=C5OC)O)F
DM67KWM IK ACYYHAZVNHMRMQ-XKZIYDEJSA-N
DM67KWM IU (5Z)-5-[(2-fluoro-3-methylphenyl)methylidene]-10-methoxy-2,2,4-trimethyl-1H-chromeno[3,4-f]quinolin-9-ol
DM67KWM DE Discovery agent
DMKI70D ID DMKI70D
DMKI70D DN LHD-4
DMKI70D HS Investigative
DMKI70D SN Conjugated low molecular weight heparin derivatives (cancer); Conjugated low molecular weight heparin derivatives (cancer), Seoul National University; LHD-1.5
DMKI70D CP Seoul National University
DMKI70D DE Solid tumour/cancer
DML83XP ID DML83XP
DML83XP DN L-homoarginine
DML83XP HS Investigative
DML83XP SN L-Homoarginine; homoarginine; 156-86-5; H-HoArg-OH; homo-l-arginine; L-N(sup 6)-Amidinolysine; n6-amidino-lysine; UNII-JF751CK38I; (S)-2-Amino-6-guanidinohexanoic acid; N6-amidino-L-Lysine; L-Lysine, N(sup 6)-(aminoiminomethyl)-; NSC 27429; LYSINE, N(sup 6)-AMIDINO-, L-; CHEMBL589752; JF751CK38I; N6-(Aminoiminomethyl)-L-lysine; CHEBI:27747; QUOGESRFPZDMMT-YFKPBYRVSA-N; AK-49431; L-Lysine, N6-(aminoiminomethyl)- (9CI); L-alpha-Amino-epsilon-guanidinohexanoic acid; Q-201303; h-Homoarginine; h-har-oh; L-N(6)-amidinolysine
DML83XP DT Small molecular drug
DML83XP PC 9085
DML83XP MW 188.23
DML83XP FM C7H16N4O2
DML83XP IC InChI=1S/C7H16N4O2/c8-5(6(12)13)3-1-2-4-11-7(9)10/h5H,1-4,8H2,(H,12,13)(H4,9,10,11)/t5-/m0/s1
DML83XP CS C(CCN=C(N)N)C[C@@H](C(=O)O)N
DML83XP IK QUOGESRFPZDMMT-YFKPBYRVSA-N
DML83XP IU (2S)-2-amino-6-(diaminomethylideneamino)hexanoic acid
DML83XP CA CAS 156-86-5
DML83XP CB CHEBI:27747
DML83XP DE Discovery agent
DMB4ACY ID DMB4ACY
DMB4ACY DN LHRH
DMB4ACY HS Investigative
DMB4ACY SN SCHEMBL7378993
DMB4ACY PC 36523
DMB4ACY MW 1182.3
DMB4ACY FM C55H75N17O13
DMB4ACY IC InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)
DMB4ACY CS CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6
DMB4ACY IK XLXSAKCOAKORKW-UHFFFAOYSA-N
DMB4ACY IU N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
DMB4ACY CA CAS 33515-09-2
DMB4ACY DE Endometriosis
DMWY0TN ID DMWY0TN
DMWY0TN DN LICOAGROCHACONE A
DMWY0TN HS Investigative
DMWY0TN SN licochalcone a; 58749-22-7; Licochalcone-A; UNII-JTV5467968; 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone; CHEMBL139702; C21H22O4; JTV5467968; (E)-3-[5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one; Licochalcone-A, Synthetic; Q-100677; (E)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-
DMWY0TN DT Small molecular drug
DMWY0TN PC 5318998
DMWY0TN MW 338.4
DMWY0TN FM C21H22O4
DMWY0TN IC InChI=1S/C21H22O4/c1-5-21(2,3)17-12-15(20(25-4)13-19(17)24)8-11-18(23)14-6-9-16(22)10-7-14/h5-13,22,24H,1H2,2-4H3/b11-8+
DMWY0TN CS CC(C)(C=C)C1=C(C=C(C(=C1)/C=C/C(=O)C2=CC=C(C=C2)O)OC)O
DMWY0TN IK KAZSKMJFUPEHHW-DHZHZOJOSA-N
DMWY0TN IU (E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
DMWY0TN CA CAS 58749-22-7
DMWY0TN CB CHEBI:125689
DMWY0TN DE Discovery agent
DMY65ZP ID DMY65ZP
DMY65ZP DN LICOAGROCHALCONE A
DMY65ZP HS Investigative
DMY65ZP SN licoagrochalcone A; 3-Prenyl-4,2',4'-trihydroxychalcone; CHEMBL229885; 2',4,4'-trihydroxy-3-prenylchalcone; 202815-28-9; SCHEMBL632907; LMPK12120068; BDBM50212400; ACM202815289; (E)-2',4,4'-Trihydroxy-3-prenylchalcone; 1-(2,4-Dihydroxyphenyl)-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-prop-2-en-1-one
DMY65ZP DT Small molecular drug
DMY65ZP PC 11099375
DMY65ZP MW 324.4
DMY65ZP FM C20H20O4
DMY65ZP IC InChI=1S/C20H20O4/c1-13(2)3-6-15-11-14(4-9-18(15)22)5-10-19(23)17-8-7-16(21)12-20(17)24/h3-5,7-12,21-22,24H,6H2,1-2H3/b10-5+
DMY65ZP CS CC(=CCC1=C(C=CC(=C1)/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)C
DMY65ZP IK TVUGLERLRIQATC-BJMVGYQFSA-N
DMY65ZP IU (E)-1-(2,4-dihydroxyphenyl)-3-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one
DMY65ZP CA CAS 202815-28-9
DMY65ZP DE Discovery agent
DM2UBQ8 ID DM2UBQ8
DM2UBQ8 DN LIM-5310
DM2UBQ8 HS Investigative
DM2UBQ8 SN LNS-5310; Efflux transport activator (neurotoxicity), Limerick
DM2UBQ8 CP Limerick BioPharma Inc
DM2UBQ8 DE Toxicity
DMGZQ5P ID DMGZQ5P
DMGZQ5P DN Linalool
DMGZQ5P HS Investigative
DMGZQ5P SN Linalool; 78-70-6; 3,7-Dimethylocta-1,6-dien-3-ol; Linalol; 3,7-Dimethyl-1,6-octadien-3-ol; beta-Linalool; allo-Ocimenol; LINALYL ALCOHOL; 1,6-Octadien-3-ol, 3,7-dimethyl-; p-Linalool; (+-)-Linalool; Linanool; 2,6-Dimethyl-2,7-octadien-6-ol; 2,6-Dimethylocta-2,7-dien-6-ol; .beta.-Linalool; Linalool (natural); 2,6-Dimethyl-2,7-octadiene-6-ol; Caswell No. 526A; Linolool; FEMA Number 2635; NSC 3789; FEMA No. 2635; CCRIS 3726; CCRIS 6557; HSDB 645; Linalool, 97%; EINECS 201-134-4; EINECS 245-083-6; 3,7-dimethyl-octa-1,6-dien-3-ol; EPA Pest
DMGZQ5P DT Small molecular drug
DMGZQ5P PC 6549
DMGZQ5P MW 154.25
DMGZQ5P FM C10H18O
DMGZQ5P IC InChI=1S/C10H18O/c1-5-10(4,11)8-6-7-9(2)3/h5,7,11H,1,6,8H2,2-4H3
DMGZQ5P CS CC(=CCCC(C)(C=C)O)C
DMGZQ5P IK CDOSHBSSFJOMGT-UHFFFAOYSA-N
DMGZQ5P IU 3,7-dimethylocta-1,6-dien-3-ol
DMGZQ5P CA CAS 78-70-6
DMGZQ5P CB CHEBI:17580
DMGZQ5P DE Discovery agent
DMD3AJH ID DMD3AJH
DMD3AJH DN Linear peptide of RES-701-1
DMD3AJH HS Investigative
DMD3AJH PC 77282233
DMD3AJH MW 2061.199
DMD3AJH FM C103H117N23O24
DMD3AJH IC InChI=1S/C103H117N23O24/c1-54(113-101(147)89(55(2)127)125-87(133)52-111-90(136)78(43-63-51-107-53-112-63)121-96(142)77(41-61-49-109-70-24-13-10-21-67(61)70)119-97(143)79(44-84(105)130)114-86(132)47-104)102(148)126-35-15-26-83(126)100(146)123-81(46-88(134)135)99(145)120-76(40-60-48-108-69-23-12-9-20-66(60)69)95(141)117-72(36-56-16-5-3-6-17-56)91(137)115-73(37-57-18-7-4-8-19-57)93(139)122-80(45-85(106)131)98(144)118-74(38-58-27-31-64(128)32-28-58)92(138)116-75(39-59-29-33-65(129)34-30-59)94(140)124-82(103(149)150)42-62-50-110-71-25-14-11-22-68(62)71/h3-14,16-25,27-34,48-51,53-55,72-83,89,108-110,127-129H,15,26,35-47,52,104H2,1-2H3,(H2,105,130)(H2,106,131)(H,107,112)(H,111,136)(H,113,147)(H,114,132)(H,115,137)(H,116,138)(H,117,141)(H,118,144)(H,119,143)(H,120,145)(H,121,142)(H,122,139)(H,123,146)(H,124,140)(H,125,133)(H,134,135)(H,149,150)/t54-,55+,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-/m0/s1
DMD3AJH CS C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)N[C@@H](CC8=CNC9=CC=CC=C98)C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)CN)O
DMD3AJH IK ZUENRBCVCNXGQC-RYIFUXPHSA-N
DMD3AJH IU (3S)-3-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[(2-aminoacetyl)amino]-4-oxobutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DMD3AJH DE Discovery agent
DMDGPY9 ID DMDGPY9
DMDGPY9 DN Linoleic acid
DMDGPY9 HS Investigative
DMDGPY9 SN linoleic acid; 60-33-3; Linolic acid; Telfairic acid; (9Z,12Z)-octadeca-9,12-dienoic acid; cis,cis-Linoleic acid; Grape seed oil; Linoleate; cis,cis-9,12-Octadecadienoic acid; Emersol 315; cis-9,cis-12-Octadecadienoic acid; 9,12-Linoleic acid; Unifac 6550; 9Z,12Z-Linoleic acid; Extra Linoleic 90; 9-cis,12-cis-Linoleic acid; Polylin 515; Emersol 310; Polylin No. 515; Oils, grape; 9Z,12Z-octadecadienoic acid; alpha-Linoleic acid; all-cis-9,12-Octadecadienoic acid; Linoleic; acide linoleique; (Z,Z)-9,12-Octadecadienoic acid; acido lino
DMDGPY9 DT Small molecular drug
DMDGPY9 PC 5280450
DMDGPY9 MW 280.4
DMDGPY9 FM C18H32O2
DMDGPY9 IC InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10H,2-5,8,11-17H2,1H3,(H,19,20)/b7-6-,10-9-
DMDGPY9 CS CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)O
DMDGPY9 IK OYHQOLUKZRVURQ-HZJYTTRNSA-N
DMDGPY9 IU (9Z,12Z)-octadeca-9,12-dienoic acid
DMDGPY9 CA CAS 60-33-3
DMDGPY9 CB CHEBI:17351
DMDGPY9 DE Discovery agent
DMW9Z7N ID DMW9Z7N
DMW9Z7N DN Lipid Fragment
DMW9Z7N HS Investigative
DMW9Z7N SN 2,10,23-TRIMETHYL-TETRACOSANE
DMW9Z7N DT Small molecular drug
DMW9Z7N PC 17754177
DMW9Z7N MW 380.7
DMW9Z7N FM C27H56
DMW9Z7N IC InChI=1S/C27H56/c1-25(2)21-17-13-10-8-6-7-9-11-15-19-23-27(5)24-20-16-12-14-18-22-26(3)4/h25-27H,6-24H2,1-5H3/t27-/m1/s1
DMW9Z7N CS C[C@H](CCCCCCCCCCCCC(C)C)CCCCCCCC(C)C
DMW9Z7N IK ZADHKSJXSZBQFB-HHHXNRCGSA-N
DMW9Z7N IU (10R)-2,10,23-trimethyltetracosane
DMW9Z7N DE Discovery agent
DMUIVCX ID DMUIVCX
DMUIVCX DN LIPOCRINE
DMUIVCX HS Investigative
DMUIVCX SN CHEMBL194823; LIPOCRINE; Rac-Lipocrine; tacrine-lipoic acid hybrid 7; SCHEMBL14341601; BDBM10512
DMUIVCX DT Small molecular drug
DMUIVCX PC 11375002
DMUIVCX MW 478.1
DMUIVCX FM C24H32ClN3OS2
DMUIVCX IC InChI=1S/C24H32ClN3OS2/c25-17-10-11-20-22(16-17)28-21-8-3-2-7-19(21)24(20)27-14-5-13-26-23(29)9-4-1-6-18-12-15-30-31-18/h10-11,16,18H,1-9,12-15H2,(H,26,29)(H,27,28)
DMUIVCX CS C1CCC2=NC3=C(C=CC(=C3)Cl)C(=C2C1)NCCCNC(=O)CCCCC4CCSS4
DMUIVCX IK QVGXTQPZHCDXRZ-UHFFFAOYSA-N
DMUIVCX IU N-[3-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]propyl]-5-(dithiolan-3-yl)pentanamide
DMUIVCX DE Discovery agent
DM6YSG3 ID DM6YSG3
DM6YSG3 DN LIQUIRTIGENIN
DM6YSG3 HS Investigative
DM6YSG3 SN 578-86-9; 4',7-Dihydroxyflavanone; (S)-7-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-liquiritigenin; 5-DEOXYFLAVANONE; UNII-T194LKP9W6; 7-hydroxy-2-(4-hydroxy-phenyl)-chroman-4-one; T194LKP9W6; CHEMBL252642; CHEBI:28777; AK121923; (2S)-7-Hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-2-(4-hydroxyphenyl)-7-oxidanyl-2,3-dihydrochromen-4-one
DM6YSG3 DT Small molecular drug
DM6YSG3 PC 114829
DM6YSG3 MW 256.25
DM6YSG3 FM C15H12O4
DM6YSG3 IC InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2/t14-/m0/s1
DM6YSG3 CS C1[C@H](OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)O
DM6YSG3 IK FURUXTVZLHCCNA-AWEZNQCLSA-N
DM6YSG3 IU (2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DM6YSG3 CA CAS 578-86-9
DM6YSG3 CB CHEBI:28777
DM6YSG3 DE Discovery agent
DM54D1G ID DM54D1G
DM54D1G DN Lisinopril
DM54D1G HS Investigative
DM54D1G SN Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
DM54D1G CP Merck & Co
DM54D1G TC Antiviral Agents
DM54D1G DT Small molecular drug
DM54D1G PC 5362119
DM54D1G MW 405.5
DM54D1G FM C21H31N3O5
DM54D1G IC InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
DM54D1G CS C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
DM54D1G IK RLAWWYSOJDYHDC-BZSNNMDCSA-N
DM54D1G IU (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
DM54D1G CA CAS 76547-98-3
DM54D1G CB CHEBI:43755
DM54D1G DE Hypertension; Coronavirus Disease 2019 (COVID-19)
DMQ42KU ID DMQ42KU
DMQ42KU DN lisinopril-tryptophan
DMQ42KU HS Investigative
DMQ42KU SN (S)-1-N2-(1-Carboxy-3-Phenylpropyl)-L-Lysyl-L-Tryptophan; Lisinopril-tryptophan; GTPL7893; N~2~-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-D-tryptophan; X95; (2S)-2-[[(2S)-6-amino-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-phenylbutanoic acid
DMQ42KU DT Small molecular drug
DMQ42KU PC 45480144
DMQ42KU MW 494.6
DMQ42KU FM C27H34N4O5
DMQ42KU IC InChI=1S/C27H34N4O5/c28-15-7-6-12-22(30-23(26(33)34)14-13-18-8-2-1-3-9-18)25(32)31-24(27(35)36)16-19-17-29-21-11-5-4-10-20(19)21/h1-5,8-11,17,22-24,29-30H,6-7,12-16,28H2,(H,31,32)(H,33,34)(H,35,36)/t22-,23-,24+/m0/s1
DMQ42KU CS C1=CC=C(C=C1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N[C@H](CC2=CNC3=CC=CC=C32)C(=O)O
DMQ42KU IK JXNGDSIPMBNTNL-KMDXXIMOSA-N
DMQ42KU IU (2S)-2-[[(2S)-6-amino-1-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-1-oxohexan-2-yl]amino]-4-phenylbutanoic acid
DMQ42KU DE Discovery agent
DM26AB4 ID DM26AB4
DM26AB4 DN L-Iso-Aspartate
DM26AB4 HS Investigative
DM26AB4 SN L-Iso-Aspartate
DM26AB4 DT Small molecular drug
DM26AB4 PC 12049686
DM26AB4 MW 132.09
DM26AB4 FM C4H6NO4-
DM26AB4 IC InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/p-1/t2-/m1/s1
DM26AB4 CS C([C@H](C(=O)[O-])N)C(=O)O
DM26AB4 IK CKLJMWTZIZZHCS-UWTATZPHSA-M
DM26AB4 IU (2R)-2-amino-4-hydroxy-4-oxobutanoate
DM26AB4 DE Discovery agent
DM6RKOC ID DM6RKOC
DM6RKOC DN L-Isofagomine
DM6RKOC HS Investigative
DM6RKOC SN L-Isofagomine; CHEMBL501385; ( )-Isofagomine; SCHEMBL2435882; BDBM50263043
DM6RKOC DT Small molecular drug
DM6RKOC PC 44578588
DM6RKOC MW 147.17
DM6RKOC FM C6H13NO3
DM6RKOC IC InChI=1S/C6H13NO3/c8-3-4-1-7-2-5(9)6(4)10/h4-10H,1-3H2/t4-,5-,6-/m0/s1
DM6RKOC CS C1[C@H]([C@@H]([C@H](CN1)O)O)CO
DM6RKOC IK QPYJXFZUIJOGNX-ZLUOBGJFSA-N
DM6RKOC IU (3S,4S,5S)-5-(hydroxymethyl)piperidine-3,4-diol
DM6RKOC DE Discovery agent
DM4B6H3 ID DM4B6H3
DM4B6H3 DN L-isoleucine
DM4B6H3 HS Investigative
DM4B6H3 SN l-isoleucine; Isoleucine; 73-32-5; (2S,3S)-2-Amino-3-methylpentanoic acid; H-Ile-OH; (S)-Isoleucine; 2S,3S-Isoleucine; (S,S)-Isoleucine; 2-Amino-3-methylvaleric acid; erythro-L-Isoleucine; L-(+)-Isoleucine; L-Ile; alpha-Amino-beta-methylvaleric acid; 443-79-8; Isoleucine (VAN); Isoleucinum [Latin]; Isoleucina [Spanish]; Valeric acid, 2-amino-3-methyl-; Norvaline, 3-methyl-; L-Norvaline, 3-methyl-, erythro-; ISOLEUCINE, L-; Acetic acid, amino-sec-butyl-; Pentanoic acid, 2-amino-3-methyl-; CCRIS 5229; iso-leucine
DM4B6H3 DT Small molecular drug
DM4B6H3 PC 6306
DM4B6H3 MW 131.17
DM4B6H3 FM C6H13NO2
DM4B6H3 IC InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1
DM4B6H3 CS CC[C@H](C)[C@@H](C(=O)O)N
DM4B6H3 IK AGPKZVBTJJNPAG-WHFBIAKZSA-N
DM4B6H3 IU (2S,3S)-2-amino-3-methylpentanoic acid
DM4B6H3 CA CAS 443-79-8
DM4B6H3 CB CHEBI:17191
DM4B6H3 DE Discovery agent
DMVSAUL ID DMVSAUL
DMVSAUL DN L-isoleucyl-L-prolinamide
DMVSAUL HS Investigative
DMVSAUL SN L-isoleucyl-L-prolinamide; CHEMBL224341
DMVSAUL DT Small molecular drug
DMVSAUL PC 11673051
DMVSAUL MW 227.3
DMVSAUL FM C11H21N3O2
DMVSAUL IC InChI=1S/C11H21N3O2/c1-3-7(2)9(12)11(16)14-6-4-5-8(14)10(13)15/h7-9H,3-6,12H2,1-2H3,(H2,13,15)/t7?,8-,9-/m0/s1
DMVSAUL CS CCC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMVSAUL IK HCKIVERTZIJTOT-NPPUSCPJSA-N
DMVSAUL IU (2S)-1-[(2S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carboxamide
DMVSAUL DE Discovery agent
DMHYLQ2 ID DMHYLQ2
DMHYLQ2 DN Lithium chloride
DMHYLQ2 HS Investigative
DMHYLQ2 SN LITHIUM CHLORIDE; 7447-41-8; Lithiumchloride; Lithium chloride (LiCl); LiCl; chlorure de lithium; Chlorku litu; chlorolithium; Lithiumchlorid; Chlorku litu [Polish]; Luthium chloride; Chlorure de lithium [French]; CCRIS 5924; UNII-G4962QA067; HSDB 4281; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; CHEMBL69710; CHEBI:48607; NSC327172; MFCD00011078; G4962QA067; Lithium chloride, 99%, extra pure; ClLi; Lithium chloride, 99+%, ACS reagent; Lithium chloride, 99%, for molecular biology; Lithium chloride, 99%, for analysis, anhyd
DMHYLQ2 DT Small molecular drug
DMHYLQ2 PC 433294
DMHYLQ2 MW 42.4
DMHYLQ2 FM ClLi
DMHYLQ2 IC InChI=1S/ClH.Li/h1H;/q;+1/p-1
DMHYLQ2 CS [Li+].[Cl-]
DMHYLQ2 IK KWGKDLIKAYFUFQ-UHFFFAOYSA-M
DMHYLQ2 IU lithium;chloride
DMHYLQ2 CA CAS 7447-41-8
DMHYLQ2 CB CHEBI:48607
DMHYLQ2 DE Discovery agent
DME76CQ ID DME76CQ
DME76CQ DN lithocholylcholine
DME76CQ HS Investigative
DME76CQ SN lithocholylcholine; GTPL326; BDBM86049
DME76CQ DT Small molecular drug
DME76CQ PC 22991950
DME76CQ MW 448.7
DME76CQ FM C29H54NO2+
DME76CQ IC InChI=1S/C29H54NO2/c1-20(8-7-9-23(32)19-30(4,5)6)25-12-13-26-24-11-10-21-18-22(31)14-16-28(21,2)27(24)15-17-29(25,26)3/h20-27,31-32H,7-19H2,1-6H3/q+1
DME76CQ CS CC(CCCC(C[N+](C)(C)C)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C
DME76CQ IK KWEWGNPMETZMTR-UHFFFAOYSA-N
DME76CQ IU [2-hydroxy-6-(3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptyl]-trimethylazanium
DME76CQ DE Discovery agent
DMPAKQV ID DMPAKQV
DMPAKQV DN Lithospermic acid
DMPAKQV HS Investigative
DMPAKQV SN Lithospermic acid; 28831-65-4; UNII-100IP83JAC; CHEMBL518243; 100IP83JAC; Lithospermic-acid; AC1O5VFB; 4-(3-(1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxo-1-propenyl)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-3-benzofurancarboxylic acid; SCHEMBL13284084; MolPort-020-005-934; ZINC4097774; BDBM50250808; AKOS026674259; 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid; 3-Benzofurancarboxylic acid, 4-(3-(1-carboxy-2-(3,4-dihydr
DMPAKQV DT Small molecular drug
DMPAKQV PC 6441498
DMPAKQV MW 538.5
DMPAKQV FM C27H22O12
DMPAKQV IC InChI=1S/C27H22O12/c28-15-5-1-12(9-18(15)31)10-20(26(34)35)38-21(33)8-4-13-2-7-17(30)25-22(13)23(27(36)37)24(39-25)14-3-6-16(29)19(32)11-14/h1-9,11,20,23-24,28-32H,10H2,(H,34,35)(H,36,37)/b8-4+/t20-,23+,24-/m1/s1
DMPAKQV CS C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@@H]([C@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O)O)O
DMPAKQV IK UJZQBMQZMKFSRV-RGKBJLTCSA-N
DMPAKQV IU (2S,3S)-4-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid
DMPAKQV CA CAS 28831-65-4
DMPAKQV DE Discovery agent
DM6J1BY ID DM6J1BY
DM6J1BY DN LIVIDOMYCIN A
DM6J1BY HS Investigative
DM6J1BY SN lividomycin A; Lividomycin; Quintomycin B; Mannosyldeoxyparomomycin; Antibiotic 503-2; Antibiotic SF 767 A; Lividomycinum; Lividomycine; 36441-41-5; Lividomicina; SF 767 A; Livodymycin; Lividomycin [INN:DCF]; Lividomycinum [INN-Latin]; Lividomycine [INN-French]; Lividomicina [INN-Spanish]; UNII-A606AJ494W; BRN 6763509; CHEBI:71961; Lividomycin A sulfate salt; A606AJ494W
DM6J1BY DT Small molecular drug
DM6J1BY PC 72394
DM6J1BY MW 761.8
DM6J1BY FM C29H55N5O18
DM6J1BY IC InChI=1S/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1
DM6J1BY CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N
DM6J1BY IK DBLVDAUGBTYDFR-SWMBIRFSSA-N
DM6J1BY IU (2R,3S,4S,5S,6R)-2-[(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-4-hydroxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DM6J1BY CA CAS 36441-41-5
DM6J1BY CB CHEBI:71961
DM6J1BY DE Discovery agent
DMJ108U ID DMJ108U
DMJ108U DN LJP-1207
DMJ108U HS Investigative
DMJ108U SN LJP-1200; LJP-1233; LJP-1586; SSAO inhibitors (inflammation); SSAO inhibitors, La Jolla; VAP-1 inhibitors, La Jolla; Vascular adhesion protein-1 inhibitors, La Jolla; Semi-carbazide-sensitive amine oxidase, La Jolla
DMJ108U CP La Jolla Pharmaceutical Co
DMJ108U PC 11615193
DMJ108U MW 148.2
DMJ108U FM C9H12N2
DMJ108U IC InChI=1S/C9H12N2/c1-8(7-11-10)9-5-3-2-4-6-9/h2-6,11H,1,7,10H2
DMJ108U CS C=C(CNN)C1=CC=CC=C1
DMJ108U IK IHEVYQFGSZLVRV-UHFFFAOYSA-N
DMJ108U IU 2-phenylprop-2-enylhydrazine
DMJ108U DE Cerebrovascular ischaemia
DMLVTXM ID DMLVTXM
DMLVTXM DN LK 204-545
DMLVTXM HS Investigative
DMLVTXM SN LK-204545
DMLVTXM DT Small molecular drug
DMLVTXM PC 5311116
DMLVTXM MW 484.5
DMLVTXM FM C25H32N4O6
DMLVTXM IC InChI=1S/C25H32N4O6/c26-14-19-13-23(34-12-11-33-16-18-1-2-18)7-8-24(19)35-17-22(31)15-27-9-10-28-25(32)29-20-3-5-21(30)6-4-20/h3-8,13,18,22,27,30-31H,1-2,9-12,15-17H2,(H2,28,29,32)
DMLVTXM CS C1CC1COCCOC2=CC(=C(C=C2)OCC(CNCCNC(=O)NC3=CC=C(C=C3)O)O)C#N
DMLVTXM IK VAWYRUMIUGPAEX-UHFFFAOYSA-N
DMLVTXM IU 1-[2-[[3-[2-cyano-4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-2-hydroxypropyl]amino]ethyl]-3-(4-hydroxyphenyl)urea
DMLVTXM DE Discovery agent
DM6RCES ID DM6RCES
DM6RCES DN LL-6531
DM6RCES HS Investigative
DM6RCES SN PPAR modulators (diabetes), Lupin
DM6RCES CP Lupin Ltd
DM6RCES DE Diabetic complication
DMO1Z5Q ID DMO1Z5Q
DMO1Z5Q DN L-lactic acid
DMO1Z5Q HS Investigative
DMO1Z5Q SN L-lactate; lactate; (S)-lactate; (S)-lactic acid
DMO1Z5Q DT Small molecular drug
DMO1Z5Q PC 107689
DMO1Z5Q MW 90.08
DMO1Z5Q FM C3H6O3
DMO1Z5Q IC InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1
DMO1Z5Q CS C[C@@H](C(=O)O)O
DMO1Z5Q IK JVTAAEKCZFNVCJ-REOHCLBHSA-N
DMO1Z5Q IU (2S)-2-hydroxypropanoic acid
DMO1Z5Q CA CAS 79-33-4
DMO1Z5Q CB CHEBI:422
DMO1Z5Q DE Discovery agent
DMQHN7I ID DMQHN7I
DMQHN7I DN L-leucine
DMQHN7I HS Investigative
DMQHN7I SN leucine; 61-90-5; (S)-2-Amino-4-methylpentanoic acid; H-Leu-OH; (S)-Leucine; (2S)-2-amino-4-methylpentanoic acid; (S)-(+)-Leucine; Leucin; L-Norvaline, 4-methyl-; (S)-2-Amino-4-methylvaleric acid; L-leucin; L-alpha-Aminoisocaproic acid; Leucin [German]; LEUCINE, L-; Leucine (VAN); leu; Leucinum; (2S)-alpha-leucine; L-(-)-2-Amino-4-methylpentanoic acid; 2-amino-4-methylvaleric acid; Leucinum [INN-Latin]; Leucine [USAN:INN]; L-Leuzin; Leucina [INN-Spanish]; Leucina [Latin,Spanish]; alpha-Aminoisocaproic acid
DMQHN7I DT Small molecular drug
DMQHN7I PC 6106
DMQHN7I MW 131.17
DMQHN7I FM C6H13NO2
DMQHN7I IC InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1
DMQHN7I CS CC(C)C[C@@H](C(=O)O)N
DMQHN7I IK ROHFNLRQFUQHCH-YFKPBYRVSA-N
DMQHN7I IU (2S)-2-amino-4-methylpentanoic acid
DMQHN7I CA CAS 61-90-5
DMQHN7I CB CHEBI:15603
DMQHN7I DE Discovery agent
DM41MS3 ID DM41MS3
DM41MS3 DN L-leucyl-L-prolinamide
DM41MS3 HS Investigative
DM41MS3 SN L-leucyl-L-prolinamide; CHEMBL224340; Leu-Pro-NH2; leucyl-l-proline amide; SCHEMBL4411036; DZWHFXYOHKJJJA-IUCAKERBSA-N
DM41MS3 DT Small molecular drug
DM41MS3 PC 11557656
DM41MS3 MW 227.3
DM41MS3 FM C11H21N3O2
DM41MS3 IC InChI=1S/C11H21N3O2/c1-7(2)6-8(12)11(16)14-5-3-4-9(14)10(13)15/h7-9H,3-6,12H2,1-2H3,(H2,13,15)/t8-,9-/m0/s1
DM41MS3 CS CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DM41MS3 IK DZWHFXYOHKJJJA-IUCAKERBSA-N
DM41MS3 IU (2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidine-2-carboxamide
DM41MS3 DE Discovery agent
DMOD5CK ID DMOD5CK
DMOD5CK DN L-lysine
DMOD5CK HS Investigative
DMOD5CK SN Enisyl
DMOD5CK DT Small molecular drug
DMOD5CK PC 5962
DMOD5CK MW 146.19
DMOD5CK FM C6H14N2O2
DMOD5CK IC InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1
DMOD5CK CS C(CCN)C[C@@H](C(=O)O)N
DMOD5CK IK KDXKERNSBIXSRK-YFKPBYRVSA-N
DMOD5CK IU (2S)-2,6-diaminohexanoic acid
DMOD5CK CA CAS 56-87-1
DMOD5CK CB CHEBI:18019
DMOD5CK DE Discovery agent
DMOGZLU ID DMOGZLU
DMOGZLU DN LLZ16406
DMOGZLU HS Investigative
DMOGZLU SN hydrogen chloride; Muriatic acid; 7647-01-0; Chlorohydric acid; Acide chlorhydrique; Chlorwasserstoff; Spirits of salt; Hydrogen chloride (HCl); chlorane; Chlorowodor; Chloorwaterstof; Anhydrous hydrochloric acid; Bowl Cleaner; Acido cloridrico; Aqueous hydrogen chloride; chlorure d'hydrogene; Hydrochloric acid gas; 4-D Bowl Sanitizer; Chlorowodor [Polish]; Emulsion Bowl Cleaner; Caswell No. 486; Chloorwaterstof [Dutch]; Marine acid; Hydrochloric acid [JAN]; Spirit of salt; Chlorwasserstoff [German]; UN 1789 (solut
DMOGZLU DT Small molecular drug
DMOGZLU DE Discovery agent
DM783BP ID DM783BP
DM783BP DN LLZ16407
DM783BP HS Investigative
DM783BP DE Discovery agent
DMWLMTD ID DMWLMTD
DMWLMTD DN LM-4108
DMWLMTD HS Investigative
DMWLMTD SN N-(2-Phenylethyl)indomethacin Amide; 261766-32-9; CHEMBL95311; N-(2-Phenylethyl)indomethacinamide; C27H25ClN2O3; 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethylacetamide; 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}-N-(2-phenylethyl)acetamide; LM-4108; 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-n-phenethylacetamide; LM 4108; AC1L1HU5; Indomethacin derivative, 19; SCHEMBL678111; BDBM22966; CTK8E8937; DTXSID80274424; MolPort-001-581-215; HMS3649K21; ZINC602343; STK226516
DMWLMTD DT Small molecular drug
DMWLMTD PC 4292
DMWLMTD MW 460.9
DMWLMTD FM C27H25ClN2O3
DMWLMTD IC InChI=1S/C27H25ClN2O3/c1-18-23(17-26(31)29-15-14-19-6-4-3-5-7-19)24-16-22(33-2)12-13-25(24)30(18)27(32)20-8-10-21(28)11-9-20/h3-13,16H,14-15,17H2,1-2H3,(H,29,31)
DMWLMTD CS CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)NCCC4=CC=CC=C4
DMWLMTD IK VYDBTNADENXYSN-UHFFFAOYSA-N
DMWLMTD IU 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(2-phenylethyl)acetamide
DMWLMTD CA CAS 261766-32-9
DMWLMTD DE Discovery agent
DMK12C0 ID DMK12C0
DMK12C0 DN L-mannitol derivative
DMK12C0 HS Investigative
DMK12C0 SN CHEMBL410049; L-mannitol derivative; BDBM50173733
DMK12C0 DT Small molecular drug
DMK12C0 PC 11578664
DMK12C0 MW 796.5
DMK12C0 FM C34H44Br2N4O8
DMK12C0 IC InChI=1S/C34H44Br2N4O8/c1-33(2,3)23-13-9-21(10-14-23)29(43)37-39-31(45)27(47-19-7-17-35)25(41)26(42)28(48-20-8-18-36)32(46)40-38-30(44)22-11-15-24(16-12-22)34(4,5)6/h7-18,25-28,41-42H,19-20H2,1-6H3,(H,37,43)(H,38,44)(H,39,45)(H,40,46)/b17-7+,18-8+/t25-,26-,27-,28-/m1/s1
DMK12C0 CS CC(C1=CC=C(C=C1)C(=O)NNC(=O)[C@H](OC/C=C/Br)[C@H](O)[C@@H](O)[C@@H](OC/C=C/Br)C(=O)NNC(=O)C2=CC=C(C=C2)C(C)(C)C)(C)C
DMK12C0 IK GBIFQWZWWHMHND-MNSGAQFXSA-N
DMK12C0 IU (2R,3R,4R,5R)-2,5-bis[(E)-3-bromoprop-2-enoxy]-1-N',6-N'-bis(4-tert-butylbenzoyl)-3,4-dihydroxyhexanedihydrazide
DMK12C0 DE Discovery agent
DME8G1U ID DME8G1U
DME8G1U DN L-methionine
DME8G1U HS Investigative
DME8G1U SN Acimethin; Cymethion
DME8G1U DT Small molecular drug
DME8G1U PC 6137
DME8G1U MW 149.21
DME8G1U FM C5H11NO2S
DME8G1U IC InChI=1S/C5H11NO2S/c1-9-3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1
DME8G1U CS CSCC[C@@H](C(=O)O)N
DME8G1U IK FFEARJCKVFRZRR-BYPYZUCNSA-N
DME8G1U IU (2S)-2-amino-4-methylsulfanylbutanoic acid
DME8G1U CA CAS 63-68-3
DME8G1U CB CHEBI:16643
DME8G1U DE Discovery agent
DM8LVQF ID DM8LVQF
DM8LVQF DN L-Myo-Inositol-1-Phosphate
DM8LVQF HS Investigative
DM8LVQF SN (1R,2S,3R,4R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl phosphate; AC1NRBXQ; CHEBI:58401; 1D-myo-inositol 3-phosphate(2-); DB03542; [(2S,3R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]
DM8LVQF DT Small molecular drug
DM8LVQF PC 5288700
DM8LVQF MW 258.12
DM8LVQF FM C6H11O9P-2
DM8LVQF IC InChI=1S/C6H13O9P/c7-1-2(8)4(10)6(5(11)3(1)9)15-16(12,13)14/h1-11H,(H2,12,13,14)/p-2/t1?,2-,3+,4-,5-,6?/m0/s1
DM8LVQF CS [C@H]1([C@@H](C([C@H]([C@@H](C1O)O)O)OP(=O)([O-])[O-])O)O
DM8LVQF IK INAPMGSXUVUWAF-LXOASSSBSA-L
DM8LVQF IU [(2S,3R,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl] phosphate
DM8LVQF CB CHEBI:58401
DM8LVQF DE Discovery agent
DME9FAV ID DME9FAV
DME9FAV DN L-NIO
DME9FAV HS Investigative
DME9FAV SN n5-Iminoethyl-l-ornithine; n5-iminoethyl-l-ornithine; N5-(1-Iminoethyl)-L-ornithine; N(G)-Iminoethylornithine; CHEMBL11471; 36889-13-1; L-Ornithine, N5-(1-iminoethyl)-; ILO; C7H15N3O2; (e)-n5-(1-aminoethylidene)-l-ornithine; Tocris-0546; AC1Q5QLF; Lopac-I-8768; Lopac0_000683; SCHEMBL1569333; AC1L333Z; l-n5-(1-iminoethyl)-ornithine; L-NIO, 12; MolPort-006-394-636; UYZFAUAYFLEHRC-LURJTMIESA-N; BDBM152697; ZINC1886324; BDBM50072297; HSCI1_000259; AKOS030623044; (S)-5-Acetimidoylamino-2-amino-pent; CCG-204768; DB03305; NCGC00024644-01; NCGC00015568-01; N5-Iminoethyl-L-Ornithine
DME9FAV DT Small molecular drug
DME9FAV PC 107984
DME9FAV MW 173.21
DME9FAV FM C7H15N3O2
DME9FAV IC InChI=1S/C7H15N3O2/c1-5(8)10-4-2-3-6(9)7(11)12/h6H,2-4,9H2,1H3,(H2,8,10)(H,11,12)/t6-/m0/s1
DME9FAV CS CC(=NCCC[C@@H](C(=O)O)N)N
DME9FAV IK UYZFAUAYFLEHRC-LURJTMIESA-N
DME9FAV IU (2S)-2-amino-5-(1-aminoethylideneamino)pentanoic acid
DME9FAV CA CAS 36889-13-1
DME9FAV DE Discovery agent
DM7V30L ID DM7V30L
DM7V30L DN L-norleucyl-L-prolinamide
DM7V30L HS Investigative
DM7V30L SN CHEMBL388843; L-norleucyl-L-prolinamide
DM7V30L DT Small molecular drug
DM7V30L PC 11615534
DM7V30L MW 227.3
DM7V30L FM C11H21N3O2
DM7V30L IC InChI=1S/C11H21N3O2/c1-2-3-5-8(12)11(16)14-7-4-6-9(14)10(13)15/h8-9H,2-7,12H2,1H3,(H2,13,15)/t8-,9-/m0/s1
DM7V30L CS CCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DM7V30L IK AXARLGGBMIBEIZ-IUCAKERBSA-N
DM7V30L IU (2S)-1-[(2S)-2-aminohexanoyl]pyrrolidine-2-carboxamide
DM7V30L DE Discovery agent
DMIXFGC ID DMIXFGC
DMIXFGC DN L-norvalyl-L-prolinamide
DMIXFGC HS Investigative
DMIXFGC SN L-norvalyl-L-prolinamide; CHEMBL224628; 127896-84-8; Nva-Pro-NH2; NOBVHVGPMMOHAE-YUMQZZPRSA-N
DMIXFGC DT Small molecular drug
DMIXFGC PC 11687141
DMIXFGC MW 213.28
DMIXFGC FM C10H19N3O2
DMIXFGC IC InChI=1S/C10H19N3O2/c1-2-4-7(11)10(15)13-6-3-5-8(13)9(12)14/h7-8H,2-6,11H2,1H3,(H2,12,14)/t7-,8-/m0/s1
DMIXFGC CS CCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMIXFGC IK NOBVHVGPMMOHAE-YUMQZZPRSA-N
DMIXFGC IU (2S)-1-[(2S)-2-aminopentanoyl]pyrrolidine-2-carboxamide
DMIXFGC DE Discovery agent
DM2GBEW ID DM2GBEW
DM2GBEW DN Lobatamide A
DM2GBEW HS Investigative
DM2GBEW SN SCHEMBL82913
DM2GBEW DT Small molecular drug
DM2GBEW PC 10505925
DM2GBEW MW 512.6
DM2GBEW FM C27H32N2O8
DM2GBEW IC InChI=1S/C27H32N2O8/c1-18-11-13-20-7-4-9-23(31)26(20)27(34)37-21(17-25(33)36-19(2)12-14-22(18)30)8-5-15-28-24(32)10-6-16-29-35-3/h4-7,9-12,14-16,19,21-22,30-31H,8,13,17H2,1-3H3,(H,28,32)/b10-6-,14-12+,15-5+,18-11-,29-16-
DM2GBEW CS CC1/C=C/C(/C(=C\\CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)O1)C/C=C/NC(=O)/C=C\\C=N/OC)/C)O
DM2GBEW IK JYHIHHYYXXKTTJ-JSFHDESQSA-N
DM2GBEW IU (Z,4Z)-N-[(E)-3-[(9E,12Z)-11,19-dihydroxy-8,12-dimethyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DM2GBEW DE Discovery agent
DMD91RI ID DMD91RI
DMD91RI DN Lobatamide B
DMD91RI HS Investigative
DMD91RI SN SCHEMBL81777
DMD91RI DT Small molecular drug
DMD91RI PC 5353727
DMD91RI MW 512.6
DMD91RI FM C27H32N2O8
DMD91RI IC InChI=1S/C27H32N2O8/c1-18-11-13-20-7-4-9-23(31)26(20)27(34)37-21(17-25(33)36-19(2)12-14-22(18)30)8-5-15-28-24(32)10-6-16-29-35-3/h4-7,9-12,14-16,19,21-22,30-31H,8,13,17H2,1-3H3,(H,28,32)/b10-6+,14-12-,15-5+,18-11-,29-16-
DMD91RI CS CC1/C=C\\C(/C(=C\\CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)O1)C/C=C/NC(=O)/C=C/C=N\\OC)/C)O
DMD91RI IK JYHIHHYYXXKTTJ-PZRNTLOJSA-N
DMD91RI IU (E,4Z)-N-[(E)-3-[(9Z,12Z)-11,19-dihydroxy-8,12-dimethyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DMD91RI DE Discovery agent
DMFIDJS ID DMFIDJS
DMFIDJS DN Lobatamide C
DMFIDJS HS Investigative
DMFIDJS DT Small molecular drug
DMFIDJS PC 6519828
DMFIDJS MW 512.6
DMFIDJS FM C27H32N2O8
DMFIDJS IC InChI=1S/C27H32N2O8/c1-18-11-13-20-7-4-9-23(31)26(20)27(34)37-21(17-25(33)36-19(2)12-14-22(18)30)8-5-15-28-24(32)10-6-16-29-35-3/h4-7,9-12,14-16,19,21-22,30-31H,8,13,17H2,1-3H3,(H,28,32)/b10-6+,14-12+,15-5+,18-11?,29-16-
DMFIDJS CS CC1/C=C/C(C(=CCC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)O1)C/C=C/NC(=O)/C=C/C=N\\OC)C)O
DMFIDJS IK JYHIHHYYXXKTTJ-HPPATNPVSA-N
DMFIDJS IU (E,4Z)-N-[(E)-3-[(9E)-11,19-dihydroxy-8,12-dimethyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DMFIDJS DE Discovery agent
DMG706J ID DMG706J
DMG706J DN Lobatamide D
DMG706J HS Investigative
DMG706J SN Lobatamide E
DMG706J DT Small molecular drug
DMG706J PC 10792270
DMG706J MW 528.5
DMG706J FM C27H32N2O9
DMG706J IC InChI=1S/C27H32N2O9/c1-18-10-11-19-6-3-8-23(32)26(19)27(35)38-20(7-4-14-28-24(33)9-5-15-29-36-2)16-25(34)37-21(17-30)12-13-22(18)31/h3-6,8-10,12-15,20-22,30-32H,7,11,16-17H2,1-2H3,(H,28,33)/b9-5-,13-12+,14-4+,18-10-,29-15-
DMG706J CS C/C/1=C/CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)OC(/C=C/C1O)CO)C/C=C/NC(=O)/C=C\\C=N/OC
DMG706J IK JIRIKJKTSMGHQG-ZBKQNIHQSA-N
DMG706J IU (Z,4Z)-N-[(E)-3-[(9E,12Z)-11,19-dihydroxy-8-(hydroxymethyl)-12-methyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DMG706J DE Discovery agent
DM6BWGQ ID DM6BWGQ
DM6BWGQ DN Lobatamide F
DM6BWGQ HS Investigative
DM6BWGQ SN Lobatamide F
DM6BWGQ DT Small molecular drug
DM6BWGQ PC 45027775
DM6BWGQ MW 528.5
DM6BWGQ FM C27H32N2O9
DM6BWGQ IC InChI=1S/C27H32N2O9/c1-18-10-11-19-6-3-8-23(32)26(19)27(35)38-20(7-4-14-28-24(33)9-5-15-29-36-2)16-25(34)37-21(17-30)12-13-22(18)31/h3-6,8-10,12-15,20-22,30-32H,7,11,16-17H2,1-2H3,(H,28,33)/b9-5+,13-12+,14-4+,18-10-,29-15-
DM6BWGQ CS C/C/1=C/CC2=C(C(=CC=C2)O)C(=O)OC(CC(=O)OC(/C=C/C1O)CO)C/C=C/NC(=O)/C=C/C=N\\OC
DM6BWGQ IK JIRIKJKTSMGHQG-CFMTYHAKSA-N
DM6BWGQ IU (E,4Z)-N-[(E)-3-[(9E,12Z)-11,19-dihydroxy-8-(hydroxymethyl)-12-methyl-2,6-dioxo-3,7-dioxabicyclo[13.4.0]nonadeca-1(15),9,12,16,18-pentaen-4-yl]prop-1-enyl]-4-methoxyiminobut-2-enamide
DM6BWGQ DE Discovery agent
DMR2WQE ID DMR2WQE
DMR2WQE DN LOFENTANIL
DMR2WQE HS Investigative
DMR2WQE SN Lofentanil oxalate; Lofentanil oxalate [USAN]; Lofentanil oxalate (USAN); 61380-41-4; Lofentaniloxalat; R 34995; EINECS 262-750-7; cis-(-)-4-(Methoxycarbonyl)-3-methyl-1-phenethyl-4-(N-phenylpropionylamino)piperidinium hydrogen oxalate; R 34,995; AC1L23D4; (-)-Methyl cis-3-methyl-1-phenethyl-4-(N-phenylpropionamido)isonipecotate oxalate (1:1); FT-0670830; D04764; UNII-6C1599T3OQ component CBKLICUQYUTWQL-XWGBWKJCSA-N; methyl (3S,4R)-3-methyl-1-phenethyl-4-(N-propanoylanilino)piperidine-4-carboxylate
DMR2WQE DT Small molecular drug
DMR2WQE PC 10070040
DMR2WQE MW 408.5
DMR2WQE FM C25H32N2O3
DMR2WQE IC InChI=1S/C25H32N2O3/c1-4-23(28)27(22-13-9-6-10-14-22)25(24(29)30-3)16-18-26(19-20(25)2)17-15-21-11-7-5-8-12-21/h5-14,20H,4,15-19H2,1-3H3/t20-,25+/m1/s1
DMR2WQE CS CCC(=O)N(C1=CC=CC=C1)[C@]2(CCN(C[C@H]2C)CCC3=CC=CC=C3)C(=O)OC
DMR2WQE IK IMYHGORQCPYVBZ-NLFFAJNJSA-N
DMR2WQE IU methyl (3R,4S)-3-methyl-1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
DMR2WQE CA CAS 61380-40-3
DMR2WQE DE Discovery agent
DMWFAPJ ID DMWFAPJ
DMWFAPJ DN LONCHOCARPUSONE
DMWFAPJ HS Investigative
DMWFAPJ SN Lonchocarpusone; CHEMBL455604; SCHEMBL14139263
DMWFAPJ DT Small molecular drug
DMWFAPJ PC 44559034
DMWFAPJ MW 396.4
DMWFAPJ FM C23H24O6
DMWFAPJ IC InChI=1S/C23H24O6/c1-23(2)9-8-13-17(29-23)7-6-14-21(24)16(12-28-22(13)14)15-10-19(26-4)20(27-5)11-18(15)25-3/h6-11,16H,12H2,1-5H3
DMWFAPJ CS CC1(C=CC2=C(O1)C=CC3=C2OCC(C3=O)C4=CC(=C(C=C4OC)OC)OC)C
DMWFAPJ IK FHQIUPHJETXRLG-UHFFFAOYSA-N
DMWFAPJ IU 8,8-dimethyl-3-(2,4,5-trimethoxyphenyl)-2,3-dihydropyrano[2,3-f]chromen-4-one
DMWFAPJ DE Discovery agent
DMAH0RZ ID DMAH0RZ
DMAH0RZ DN Long-acting Factor VII conjugate
DMAH0RZ HS Investigative
DMAH0RZ SN HM-12260B; LAPS-Factor VII; Long-acting Factor VII conjugate (LAPS, hemorrhage); Long-acting Factor VII conjugate (LAPS, hemorrhage), Hanmi
DMAH0RZ CP Hanmi Pharmaceutical Co Ltd
DMAH0RZ DE Bleeding disorder
DMZUSJD ID DMZUSJD
DMZUSJD DN Long-acting factor VIII
DMZUSJD HS Investigative
DMZUSJD SN PolyXen PSA-Factor VIII; Long-acting factor VIII (PolyXen, blood clotting disorder); Polysialic factor VIII (PolyXen, blood clotting disorder), Lipoxen/Baxter; Long-acting factor VIII (PolyXen, blood clotting disorder), Lipoxen/Baxter
DMZUSJD CP Baxter International Inc
DMZUSJD DE Coagulation defect
DMD32IN ID DMD32IN
DMD32IN DN Long-acting FSH conjugate
DMD32IN HS Investigative
DMD32IN SN HM-12160B; LAPS-FSH; Long-acting FSH conjugate (LAPS); Long-acting FSH conjugate (LAPS), Hanmi; Long-acting follicle-stimulating hormone conjugate (LAPS, female infertility), Hanmi
DMD32IN CP Hanmi Pharmaceutical Co Ltd
DMD32IN DE Female infertility
DMH106Y ID DMH106Y
DMH106Y DN LONGANINE
DMH106Y HS Investigative
DMH106Y SN longanine; CHEMBL1097805
DMH106Y DT Small molecular drug
DMH106Y PC 46888588
DMH106Y MW 363.4
DMH106Y FM C19H25NO6
DMH106Y IC InChI=1S/C19H25NO6/c1-20-7-6-17-8-11(21)16(25-3)19(23)18(17,20)9-13(26-19)10-4-5-12(24-2)15(22)14(10)17/h4-5,11,13,16,21-23H,6-9H2,1-3H3/t11-,13-,16-,17-,18-,19+/m0/s1
DMH106Y CS CN1CC[C@@]23[C@]14C[C@@H](C5=C2C(=C(C=C5)OC)O)O[C@@]4([C@H]([C@H](C3)O)OC)O
DMH106Y IK UHRGPVJRLXHZFG-OOXWPESWSA-N
DMH106Y IU (1S,8S,10S,11S,12S,13S)-4,12-dimethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.18,11.01,10.02,7]octadeca-2(7),3,5-triene-3,11,13-triol
DMH106Y DE Discovery agent
DM5OHVN ID DM5OHVN
DM5OHVN DN Lophocladine a
DM5OHVN HS Investigative
DM5OHVN SN Lophocladine A; 887705-27-3; Lophocladines A; 2,7-Naphthyridin-1(2H)-one,4-phenyl-; CHEMBL472895; CTK2I1445; DTXSID90470935; AKOS030621149; 4-phenyl[2,7]naphthyridin-1(2H)-one; 2,7-Naphthyridin-1(2H)-one, 4-phenyl-
DM5OHVN DT Small molecular drug
DM5OHVN PC 11708368
DM5OHVN MW 222.24
DM5OHVN FM C14H10N2O
DM5OHVN IC InChI=1S/C14H10N2O/c17-14-13-8-15-7-6-11(13)12(9-16-14)10-4-2-1-3-5-10/h1-9H,(H,16,17)
DM5OHVN CS C1=CC=C(C=C1)C2=CNC(=O)C3=C2C=CN=C3
DM5OHVN IK JIWHQPVTDQXELV-UHFFFAOYSA-N
DM5OHVN IU 4-phenyl-2H-2,7-naphthyridin-1-one
DM5OHVN CA CAS 887705-27-3
DM5OHVN DE Discovery agent
DMASPV9 ID DMASPV9
DMASPV9 DN Lopinavir + ritonavir + interferon beta
DMASPV9 HS Investigative
DMASPV9 SN Aluviran + norvir + interferon beta
DMASPV9 TC Antiviral Agents
DMASPV9 DT Combination drug
DMASPV9 DE Middle East Respiratory Syndrome (MERS)
DM71BIC ID DM71BIC
DM71BIC DN LOR-220
DM71BIC HS Investigative
DM71BIC SN ML-220; PI3K-targeting small molecules (cancer), Lorus; Phosphoinositide-3 kinase-targeting small molecules (cancer), Lorus
DM71BIC CP Lorus Therapeutics Inc
DM71BIC DT Small molecular drug
DM71BIC PC 11851317
DM71BIC MW 412.3
DM71BIC FM C23H14BrN3
DM71BIC IC InChI=1S/C23H14BrN3/c24-13-9-10-20-18(11-13)19(12-25-20)23-26-21-16-7-3-1-5-14(16)15-6-2-4-8-17(15)22(21)27-23/h1-12,25H,(H,26,27)
DM71BIC CS C1=CC=C2C(=C1)C3=CC=CC=C3C4=C2NC(=N4)C5=CNC6=C5C=C(C=C6)Br
DM71BIC IK XFVVNPCUAYGFFE-UHFFFAOYSA-N
DM71BIC IU 2-(5-bromo-1H-indol-3-yl)-1H-phenanthro[9,10-d]imidazole
DM71BIC DE Bacterial infection
DM0ECUK ID DM0ECUK
DM0ECUK DN LORNEIC ACID A
DM0ECUK HS Investigative
DM0ECUK SN Lorneic acid A; CHEMBL1079947
DM0ECUK DT Small molecular drug
DM0ECUK PC 44605341
DM0ECUK MW 258.35
DM0ECUK FM C17H22O2
DM0ECUK IC InChI=1S/C17H22O2/c1-3-4-5-6-8-16-13-14(2)11-12-15(16)9-7-10-17(18)19/h6-9,11-13H,3-5,10H2,1-2H3,(H,18,19)/b8-6+,9-7+
DM0ECUK CS CCCC/C=C/C1=C(C=CC(=C1)C)/C=C/CC(=O)O
DM0ECUK IK BPISPUIKHXBPSU-CDJQDVQCSA-N
DM0ECUK IU (E)-4-[2-[(E)-hex-1-enyl]-4-methylphenyl]but-3-enoic acid
DM0ECUK DE Discovery agent
DMHKGCM ID DMHKGCM
DMHKGCM DN L-Ornithine
DMHKGCM HS Investigative
DMHKGCM SN OKG
DMHKGCM DT Small molecular drug
DMHKGCM PC 6262
DMHKGCM MW 132.16
DMHKGCM FM C5H12N2O2
DMHKGCM IC InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1
DMHKGCM CS C(C[C@@H](C(=O)O)N)CN
DMHKGCM IK AHLPHDHHMVZTML-BYPYZUCNSA-N
DMHKGCM IU (2S)-2,5-diaminopentanoic acid
DMHKGCM CA CAS 70-26-8
DMHKGCM CB CHEBI:15729
DMHKGCM DE Discovery agent
DMK5J9M ID DMK5J9M
DMK5J9M DN Lorpiprazole
DMK5J9M HS Investigative
DMK5J9M SN Lorpiprazole; Lorpiprazole [INN]; (-)-cis-5,5a,6,7,8,8a-Hexahydro-3-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)cyclopenta(3,4)pyrrolo(2,1-c)-s-triazole; 108785-69-9; AC1MIILX; DTXSID30883181; UNII-0M14O7T47Q component BNRMWKUVWLKDQJ-CRAIPNDOSA-N
DMK5J9M PC 3045380
DMK5J9M MW 405.5
DMK5J9M FM C21H26F3N5
DMK5J9M IC BNRMWKUVWLKDQJ-CRAIPNDOSA-N
DMK5J9M CS C1CC2CN3C(=NN=C3C2C1)CCN4CCN(CC4)C5=CC=CC(=C5)C(F)(F)F
DMK5J9M IK 1S/C21H26F3N5/c22-21(23,24)16-4-2-5-17(13-16)28-11-9-27(10-12-28)8-7-19-25-26-20-18-6-1-3-15(18)14-29(19)20/h2,4-5,13,15,18H,1,3,6-12,14H2/t15-,18-/m1/s1
DMK5J9M IU (1R,8S)-5-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-3,4,6-triazatricyclo[6.3.0.02,6]undeca-2,4-diene
DMK5J9M CA CAS 108785-69-9
DMK5J9M DE Anxiety disorder
DMWTJ3E ID DMWTJ3E
DMWTJ3E DN LP-0067
DMWTJ3E HS Investigative
DMWTJ3E SN CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma
DMWTJ3E CP LEO Pharma A/S
DMWTJ3E DE Autoimmune diabetes
DM8ZR17 ID DM8ZR17
DM8ZR17 DN LP-12
DM8ZR17 HS Investigative
DM8ZR17 SN compound 21 [PMID 17649988]
DM8ZR17 DT Small molecular drug
DM8ZR17 PC 23643664
DM8ZR17 MW 481.7
DM8ZR17 FM C32H39N3O
DM8ZR17 IC InChI=1S/C32H39N3O/c36-32(33-30-18-11-15-26-14-6-7-16-28(26)30)20-5-2-10-21-34-22-24-35(25-23-34)31-19-9-8-17-29(31)27-12-3-1-4-13-27/h1,3-4,6-9,12-14,16-17,19,30H,2,5,10-11,15,18,20-25H2,(H,33,36)
DM8ZR17 CS C1CC(C2=CC=CC=C2C1)NC(=O)CCCCCN3CCN(CC3)C4=CC=CC=C4C5=CC=CC=C5
DM8ZR17 IK NMZIDFFHGCRAJV-UHFFFAOYSA-N
DM8ZR17 IU 6-[4-(2-phenylphenyl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
DM8ZR17 DE Discovery agent
DMKDGLA ID DMKDGLA
DMKDGLA DN LP-211
DMKDGLA HS Investigative
DMKDGLA SN compound 25 [PMID 18800769]
DMKDGLA DT Small molecular drug
DMKDGLA PC 25107716
DMKDGLA MW 466.6
DMKDGLA FM C30H34N4O
DMKDGLA IC InChI=1S/C30H34N4O/c31-23-25-14-16-26(17-15-25)24-32-30(35)13-5-2-8-18-33-19-21-34(22-20-33)29-12-7-6-11-28(29)27-9-3-1-4-10-27/h1,3-4,6-7,9-12,14-17H,2,5,8,13,18-22,24H2,(H,32,35)
DMKDGLA CS C1CN(CCN1CCCCCC(=O)NCC2=CC=C(C=C2)C#N)C3=CC=CC=C3C4=CC=CC=C4
DMKDGLA IK BQEDZLDNNBDKDS-UHFFFAOYSA-N
DMKDGLA IU N-[(4-cyanophenyl)methyl]-6-[4-(2-phenylphenyl)piperazin-1-yl]hexanamide
DMKDGLA CA CAS 1052147-86-0
DMKDGLA DE Discovery agent
DMIWMZY ID DMIWMZY
DMIWMZY DN LP-403812
DMIWMZY HS Investigative
DMIWMZY SN LP 403812; LP403812
DMIWMZY DT Small molecular drug
DMIWMZY PC 59001466
DMIWMZY MW 494.7
DMIWMZY FM C26H34N6O2S
DMIWMZY IC InChI=1S/C26H34N6O2S/c1-17-9-11-18(12-10-17)23(33)28-25-27-22-21(35-25)20(29-32(22)26(2,3)4)24(34)31-15-7-8-19(31)16-30-13-5-6-14-30/h9-12,19H,5-8,13-16H2,1-4H3,(H,27,28,33)/t19-/m0/s1
DMIWMZY CS CC1=CC=C(C=C1)C(=O)NC2=NC3=C(S2)C(=NN3C(C)(C)C)C(=O)N4CCC[C@H]4CN5CCCC5
DMIWMZY IK GJBQMIZKUFMWPV-IBGZPJMESA-N
DMIWMZY IU N-[1-tert-butyl-3-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]pyrazolo[3,4-d][1,3]thiazol-5-yl]-4-methylbenzamide
DMIWMZY CA CAS 1142050-84-7
DMIWMZY DE Discovery agent
DM0C3SF ID DM0C3SF
DM0C3SF DN LP-44
DM0C3SF HS Investigative
DM0C3SF SN compound 5 [PMID 17649988]
DM0C3SF DT Small molecular drug
DM0C3SF PC 11224758
DM0C3SF MW 451.7
DM0C3SF FM C27H37N3OS
DM0C3SF IC InChI=1S/C27H37N3OS/c1-32-26-15-7-6-14-25(26)30-20-18-29(19-21-30)17-8-2-3-16-27(31)28-24-13-9-11-22-10-4-5-12-23(22)24/h4-7,10,12,14-15,24H,2-3,8-9,11,13,16-21H2,1H3,(H,28,31)
DM0C3SF CS CSC1=CC=CC=C1N2CCN(CC2)CCCCCC(=O)NC3CCCC4=CC=CC=C34
DM0C3SF IK JNBBJUHCODFLEG-UHFFFAOYSA-N
DM0C3SF IU 6-[4-(2-methylsulfanylphenyl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
DM0C3SF DE Discovery agent
DMGMO3Q ID DMGMO3Q
DMGMO3Q DN LP-661438
DMGMO3Q HS Investigative
DMGMO3Q SN deoxycytidine kinase inhibitors (cancer), Lexicon
DMGMO3Q DE Discovery agent
DMTZYQ3 ID DMTZYQ3
DMTZYQ3 DN LP99
DMTZYQ3 HS Investigative
DMTZYQ3 SN compound 60 [PMID: 25864491]
DMTZYQ3 DT Small molecular drug
DMTZYQ3 PC 91827372
DMTZYQ3 MW 516.1
DMTZYQ3 FM C26H30ClN3O4S
DMTZYQ3 IC InChI=1S/C26H30ClN3O4S/c1-16(2)15-35(33,34)28-22-11-12-24(31)30(26(22)18-5-7-19(27)8-6-18)20-9-10-21-17(3)13-25(32)29(4)23(21)14-20/h5-10,13-14,16,22,26,28H,11-12,15H2,1-4H3/t22-,26+/m0/s1
DMTZYQ3 CS CC1=CC(=O)N(C2=C1C=CC(=C2)N3[C@@H]([C@H](CCC3=O)NS(=O)(=O)CC(C)C)C4=CC=C(C=C4)Cl)C
DMTZYQ3 IK LVDRREOUMKACNJ-BKMJKUGQSA-N
DMTZYQ3 IU N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide
DMTZYQ3 DE Discovery agent
DMI5XR1 ID DMI5XR1
DMI5XR1 DN LPA
DMI5XR1 HS Investigative
DMI5XR1 SN 2-Hydroxy-3-(phosphonooxy)propyl oleate; lysophosphatidic acid; 1-Oleoyl-lyso-phosphatidic acid; Monooleylphosphatidic acid; Oleoyl lysophosphatidic acid; 1-Oleyllysophosphatidic acid; 22002-87-5; (2-hydroxy-3-phosphonooxypropyl) (Z)-octadec-9-enoate; 1-oleoyl-LPA; monooleylphosphatidate; [3H]1-oleoyl-LPA; [3H]lysophosphatidic acid; [3H]LPA; 1-oleoyl-lysophosphatidic acid; [3H]-LPA; AC1NUZKL; Lysophosphophatidic acid; Oleoyl lysophosphatidate; 1-Oleyllysophosphatidate; 1-Oleoyl-lysophosphatidate; lysophosphatidic acid
DMI5XR1 DT Small molecular drug
DMI5XR1 PC 5497152
DMI5XR1 MW 436.5
DMI5XR1 FM C21H41O7P
DMI5XR1 IC InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)27-18-20(22)19-28-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-
DMI5XR1 CS CCCCCCCC/C=C\\CCCCCCCC(=O)OCC(COP(=O)(O)O)O
DMI5XR1 IK WRGQSWVCFNIUNZ-KTKRTIGZSA-N
DMI5XR1 IU (2-hydroxy-3-phosphonooxypropyl) (Z)-octadec-9-enoate
DMI5XR1 CA CAS 22002-87-5
DMI5XR1 DE Discovery agent
DM1JGDM ID DM1JGDM
DM1JGDM DN Lpc-Ether
DM1JGDM HS Investigative
DM1JGDM SN LPC-ETHER; 1-O-OCTADECYL-SN-GLYCERO-3-PHOSPHOCHOLINE; LPE; 1-Octadecyl-sn-glycero-3-phosphocholine; AC1L9K7A; CBiol_001783; SCHEMBL11889677; Bio1_000558; Bio1_000069; Bio1_001047; ZINC8860508; DB03633; O-(1-O-Octadecyl-L-glycero-3-phospho)choline; SR-01000946544; SR-01000946544-1; (4S,7R)-4,7-dihydroxy-N,N,N-trimethyl-3,5,9-trioxa-4-phosphaheptacosan-1-aminium 4-oxide
DM1JGDM DT Small molecular drug
DM1JGDM PC 446876
DM1JGDM MW 510.7
DM1JGDM FM C26H57NO6P+
DM1JGDM IC InChI=1S/C26H56NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-31-24-26(28)25-33-34(29,30)32-23-21-27(2,3)4/h26,28H,5-25H2,1-4H3/p+1/t26-/m1/s1
DM1JGDM CS CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N+](C)(C)C)O
DM1JGDM IK XKBJVQHMEXMFDZ-AREMUKBSSA-O
DM1JGDM IU 2-[hydroxy-[(2R)-2-hydroxy-3-octadecoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
DM1JGDM DE Discovery agent
DMY1807 ID DMY1807
DMY1807 DN LRHYLNLLTRQRY-NH2
DMY1807 HS Investigative
DMY1807 SN Ac(Leu-28,31)npy(24-36)amide; NCGC00167292-01; N-Acetyl(leu(28),leu(31))npy(24-36)-amide; Neuropeptide Y (24-36) amide, N-acetyl-(leu(28,31))-; L-Tyrosinamide, N-acetyl-L-leucyl-L-arginyl-L-histidyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-leucyl-L-leucyl-L-threonyl-L-arginyl-L-glutaminyl-L-arginyl-
DMY1807 PC 91971032
DMY1807 MW 1787.1
DMY1807 FM C81H131N27O19
DMY1807 IC InChI=1S/C81H131N27O19/c1-40(2)30-56(96-45(10)110)71(120)98-52(15-12-28-93-80(87)88)69(118)106-61(36-48-38-91-39-95-48)75(124)105-60(35-47-19-23-50(112)24-20-47)74(123)102-58(32-42(5)6)73(122)107-62(37-64(83)114)76(125)103-57(31-41(3)4)72(121)104-59(33-43(7)8)77(126)108-65(44(9)109)78(127)100-53(16-13-29-94-81(89)90)67(116)99-54(25-26-63(82)113)70(119)97-51(14-11-27-92-79(85)86)68(117)101-55(66(84)115)34-46-17-21-49(111)22-18-46/h17-24,38-44,51-62,65,109,111-112H,11-16,25-37H2,1-10H3,(H2,82,113)(H2,83,114)(H2,84,115)(H,91,95)(H,96,110)(H,97,119)(H,98,120)(H,99,116)(H,100,127)(H,101,117)(H,102,123)(H,103,125)(H,104,121)(H,105,124)(H,106,118)(H,107,122)(H,108,126)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t44-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,65+/m1/s1
DMY1807 CS C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)C)O
DMY1807 IK LZKBNKKHNKAGAE-ZQWBWPFKSA-N
DMY1807 IU (2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pentanediamide
DMY1807 DE Discovery agent
DMUBF53 ID DMUBF53
DMUBF53 DN LS-192629
DMUBF53 HS Investigative
DMUBF53 SN LS 192629; LS192629
DMUBF53 DT Small molecular drug
DMUBF53 PC 6918604
DMUBF53 MW 471.5
DMUBF53 FM C28H29N3O4
DMUBF53 IC InChI=1S/C28H29N3O4/c1-19-8-6-7-11-24(19)20-12-14-22(15-13-20)28(34)31-18-23(30-35-2)16-25(31)27(33)29-17-26(32)21-9-4-3-5-10-21/h3-15,25-26,32H,16-18H2,1-2H3,(H,29,33)/b30-23+/t25-,26+/m0/s1
DMUBF53 CS CC1=CC=CC=C1C2=CC=C(C=C2)C(=O)N3C/C(=N/OC)/C[C@H]3C(=O)NC[C@H](C4=CC=CC=C4)O
DMUBF53 IK IBXGJPAYWMFXSF-OLFRMSBUSA-N
DMUBF53 IU (2S,4E)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-methoxyimino-1-[4-(2-methylphenyl)benzoyl]pyrrolidine-2-carboxamide
DMUBF53 DE Discovery agent
DM6WPIS ID DM6WPIS
DM6WPIS DN L-Serine
DM6WPIS HS Investigative
DM6WPIS SN L-serine; serine; 56-45-1; (S)-2-Amino-3-hydroxypropanoic acid; H-Ser-OH; (S)-Serine; beta-Hydroxyalanine; L-ser; L-(-)-Serine; Polyserine; Serine, L-; (2S)-2-amino-3-hydroxypropanoic acid; L-3-Hydroxy-alanine; Poly-L-serine; 2-Amino-3-hydroxypropionic acid; beta-Hydroxy-L-alanine; Serinum [Latin]; Serina [Spanish]; L-2-Amino-3-hydroxypropionic acid; Serine (VAN); L-3-Hydroxy-2-aminopropionic acid; Serine [USAN:INN]; SER (IUPAC abbrev); 3-Hydroxyalanine; L-Serin; (S)-(-)-Serine; (-)-Serine; alpha-Amino-beta-hydroxypropionic acid
DM6WPIS DT Small molecular drug
DM6WPIS PC 5951
DM6WPIS MW 105.09
DM6WPIS FM C3H7NO3
DM6WPIS IC InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1
DM6WPIS CS C([C@@H](C(=O)O)N)O
DM6WPIS IK MTCFGRXMJLQNBG-REOHCLBHSA-N
DM6WPIS IU (2S)-2-amino-3-hydroxypropanoic acid
DM6WPIS CA CAS 56-45-1
DM6WPIS CB CHEBI:17115
DM6WPIS DE Discovery agent
DMTJ1NH ID DMTJ1NH
DMTJ1NH DN L-serine-O-phosphate
DMTJ1NH HS Investigative
DMTJ1NH SN Phosphoserine; O-phospho-L-serine; Dexfosfoserine; phosphoserine; 407-41-0; L-O-Phosphoserine; Fosforina; O-Phosphoserine; L-SOP; L-Phosphoserine; PHOSPHONOSERINE; 3-phosphoserine; L-Serine O-phosphate; Dexfosfoserine [INN]; Phosphatidalserine; 3-O-Phosphoserine; H-Ser(PO3H2)-OH; O-phosphono-L-serine; serine, O-phosphono-; (+)-L-Serine dihydrogen phosphate (ester); L-Seryl phosphate; UNII-VI4F0K069V; L-3-Phosphoserine; L-O-Serine phosphate; L-Serinephosphoric acid; H-Ser(PO)-OH; L-2-amino-3-hydroxypropanoic acid 3-phosphate; LSOP; Phosphonoserine
DMTJ1NH DT Small molecular drug
DMTJ1NH PC 68841
DMTJ1NH MW 185.07
DMTJ1NH FM C3H8NO6P
DMTJ1NH IC InChI=1S/C3H8NO6P/c4-2(3(5)6)1-10-11(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9)/t2-/m0/s1
DMTJ1NH CS C([C@@H](C(=O)O)N)OP(=O)(O)O
DMTJ1NH IK BZQFBWGGLXLEPQ-REOHCLBHSA-N
DMTJ1NH IU (2S)-2-amino-3-phosphonooxypropanoic acid
DMTJ1NH CA CAS 407-41-0
DMTJ1NH CB CHEBI:15811
DMTJ1NH DE Discovery agent
DMWVTS3 ID DMWVTS3
DMWVTS3 DN LSN2463359
DMWVTS3 HS Investigative
DMWVTS3 SN LSN 2463359
DMWVTS3 DT Small molecular drug
DMWVTS3 PC 72551298
DMWVTS3 MW 265.31
DMWVTS3 FM C16H15N3O
DMWVTS3 IC InChI=1S/C16H15N3O/c1-12(2)19-16(20)15-6-5-14(11-18-15)4-3-13-7-9-17-10-8-13/h5-12H,1-2H3,(H,19,20)
DMWVTS3 CS CC(C)NC(=O)C1=NC=C(C=C1)C#CC2=CC=NC=C2
DMWVTS3 IK STAFRSGTRKNXHF-UHFFFAOYSA-N
DMWVTS3 IU N-propan-2-yl-5-(2-pyridin-4-ylethynyl)pyridine-2-carboxamide
DMWVTS3 CA CAS 1401031-52-4
DMWVTS3 DE Discovery agent
DMV9NP6 ID DMV9NP6
DMV9NP6 DN LSN2814617
DMV9NP6 HS Investigative
DMV9NP6 SN CHEMBL2431211; LSN2814617; SCHEMBL2161736; GTPL6395; BDBM50441231; ZINC72315650; BCP9000877; 5-[(7S)-3-tert-butyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyridin-7-yl]-3-(4-fluorophenyl)-1,2,4-oxadiazole
DMV9NP6 DT Small molecular drug
DMV9NP6 PC 53252525
DMV9NP6 MW 341.4
DMV9NP6 FM C18H20FN5O
DMV9NP6 IC InChI=1S/C18H20FN5O/c1-18(2,3)17-22-21-14-10-12(8-9-24(14)17)16-20-15(23-25-16)11-4-6-13(19)7-5-11/h4-7,12H,8-10H2,1-3H3/t12-/m0/s1
DMV9NP6 CS CC(C)(C)C1=NN=C2N1CC[C@@H](C2)C3=NC(=NO3)C4=CC=C(C=C4)F
DMV9NP6 IK NPRJTKMKUYJGAL-LBPRGKRZSA-N
DMV9NP6 IU 5-[(7S)-3-tert-butyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl]-3-(4-fluorophenyl)-1,2,4-oxadiazole
DMV9NP6 DE Discovery agent
DM74J10 ID DM74J10
DM74J10 DN LSP1-2111
DM74J10 HS Investigative
DM74J10 SN LSP1-2111; SCHEMBL4091094; GTPL6739; SCHEMBL10000472; (2S)-2-amino-4-{hydroxy[hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl}butanoic acid; (2s)-2-amino-4-[hydroxy[hydroxy(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl] butanoic acid
DM74J10 DT Small molecular drug
DM74J10 PC 46898088
DM74J10 MW 364.24
DM74J10 FM C12H17N2O9P
DM74J10 IC InChI=1S/C12H17N2O9P/c1-23-9-5-6(4-8(10(9)15)14(19)20)12(18)24(21,22)3-2-7(13)11(16)17/h4-5,7,12,15,18H,2-3,13H2,1H3,(H,16,17)(H,21,22)/t7-,12?/m0/s1
DM74J10 CS COC1=CC(=CC(=C1O)[N+](=O)[O-])C(O)P(=O)(CC[C@@H](C(=O)O)N)O
DM74J10 IK PEXVMHLARUAHNC-KAJCPDDVSA-N
DM74J10 IU (2S)-2-amino-4-[hydroxy-[hydroxy-(4-hydroxy-3-methoxy-5-nitrophenyl)methyl]phosphoryl]butanoic acid
DM74J10 DE Discovery agent
DMBWHGP ID DMBWHGP
DMBWHGP DN LSP4-2022
DMBWHGP HS Investigative
DMBWHGP SN LSP4-2022; GTPL6706; CHEMBL3114673; US9212196, Derivative 2; SCHEMBL13975986; BDBM196906; (2s)-2-amino-4-({[4-(carboxymethoxy)phenyl] (hydroxy)methyl}-(hydroxy)phosphoryl)butanoic acid; (2S)-2-amino-4-({[4-(carboxymethoxy)phenyl](hydroxy)methyl}(hydroxy)phosphoryl)butanoic acid
DMBWHGP DT Small molecular drug
DMBWHGP PC 71041983
DMBWHGP MW 347.26
DMBWHGP FM C13H18NO8P
DMBWHGP IC InChI=1S/C13H18NO8P/c14-10(12(17)18)5-6-23(20,21)13(19)8-1-3-9(4-2-8)22-7-11(15)16/h1-4,10,13,19H,5-7,14H2,(H,15,16)(H,17,18)(H,20,21)/t10-,13?/m0/s1
DMBWHGP CS C1=CC(=CC=C1C(O)P(=O)(CC[C@@H](C(=O)O)N)O)OCC(=O)O
DMBWHGP IK BGOFVWMHMQISHB-NKUHCKNESA-N
DMBWHGP IU (2S)-2-amino-4-[[[4-(carboxymethoxy)phenyl]-hydroxymethyl]-hydroxyphosphoryl]butanoic acid
DMBWHGP DE Discovery agent
DM702WR ID DM702WR
DM702WR DN LTC4
DM702WR HS Investigative
DM702WR SN leukotriene C4
DM702WR DT Small molecular drug
DM702WR PC 5280493
DM702WR MW 625.8
DM702WR FM C30H47N3O9S
DM702WR IC InChI=1S/C30H47N3O9S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-25(24(34)15-14-17-27(36)37)43-21-23(29(40)32-20-28(38)39)33-26(35)19-18-22(31)30(41)42/h6-7,9-13,16,22-25,34H,2-5,8,14-15,17-21,31H2,1H3,(H,32,40)(H,33,35)(H,36,37)(H,38,39)(H,41,42)/b7-6-,10-9-,12-11+,16-13+/t22-,23-,24-,25+/m0/s1
DM702WR CS CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N
DM702WR IK GWNVDXQDILPJIG-NXOLIXFESA-N
DM702WR IU (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DM702WR CA CAS 72025-60-6
DM702WR CB CHEBI:16978
DM702WR DE Discovery agent
DMIUZX3 ID DMIUZX3
DMIUZX3 DN LTD4
DMIUZX3 HS Investigative
DMIUZX3 SN S-[(4S,5R,6E,8E,10Z,13Z)-1-Carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine; 5(S)-Hydroxy-6(R)-S-cysteinylglycinyl-7-trans-9-trans-11-cis-14-cis-eicosatetraenoic Acid; Leukotriene D(sub 4); (5S,6R,7E,9E,11Z,14Z)-6-({2-amino-2-[(carboxymethyl)carbamoyl]ethyl}sulfanyl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid; LTD (sub 4); [3H]LTD4; [3H]-LTD4; S-[(4S,5R,6E,8E,10Z,13Z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]cysteinylglycine; AC1O5JI4; SCHEMBL4295683; GTPL3412; BML1-E08; GTPL3353; CHEMBL1521056; DTXSID6040533; YEESKJGWJFYOOK-LDDGIIIKSA-N; 73836-78-9; LTD; leukotriene D4
DMIUZX3 DT Small molecular drug
DMIUZX3 PC 5280878
DMIUZX3 MW 496.7
DMIUZX3 FM C25H40N2O6S
DMIUZX3 IC InChI=1S/C25H40N2O6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(28)15-14-17-23(29)30)34-19-20(26)25(33)27-18-24(31)32/h6-7,9-13,16,20-22,28H,2-5,8,14-15,17-19,26H2,1H3,(H,27,33)(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t20-,21-,22+/m0/s1
DMIUZX3 CS CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)N
DMIUZX3 IK YEESKJGWJFYOOK-IJHYULJSSA-N
DMIUZX3 IU (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DMIUZX3 CA CAS 73836-78-9
DMIUZX3 CB CHEBI:28666
DMIUZX3 DE Discovery agent
DMCPB0Q ID DMCPB0Q
DMCPB0Q DN LTE4
DMCPB0Q HS Investigative
DMCPB0Q SN Leukotriene E4; leukotriene E4; Leukotriene E; UNII-8EYT8ATL7G; 75715-89-8; 8EYT8ATL7G; CHEMBL509456; CHEBI:15650; OTZRAYGBFWZKMX-FRFVZSDQSA-N; 5S-hydroxy,6R-(S-cysteinyl),7E,9E,11Z,14Z-eicosatetraenoic acid; C23H37NO5S; (5S-(5R*,6S*(S*),7E,9E,11Z,14Z))-6-((2-Amino-2-carboxyethyl)thio)-5-hydroxy-7,9,11,14-eicosatetraenoic acid; (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid; [3H]LTE4; AC1NQXPM; LEUKOTRIEN E4; BSPBio_001370; leukotriene E
DMCPB0Q DT Small molecular drug
DMCPB0Q PC 5280879
DMCPB0Q MW 439.6
DMCPB0Q FM C23H37NO5S
DMCPB0Q IC InChI=1S/C23H37NO5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-21(30-18-19(24)23(28)29)20(25)15-14-17-22(26)27/h6-7,9-13,16,19-21,25H,2-5,8,14-15,17-18,24H2,1H3,(H,26,27)(H,28,29)/b7-6-,10-9-,12-11+,16-13+/t19-,20-,21+/m0/s1
DMCPB0Q CS CCCCC/C=C\\C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)O)N
DMCPB0Q IK OTZRAYGBFWZKMX-FRFVZSDQSA-N
DMCPB0Q IU (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-2-carboxyethyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid
DMCPB0Q CA CAS 75715-89-8
DMCPB0Q CB CHEBI:15650
DMCPB0Q DE Discovery agent
DMDU6F4 ID DMDU6F4
DMDU6F4 DN LTERHKILHRLLQEGSPSD
DMDU6F4 HS Investigative
DMDU6F4 PC 91935928
DMDU6F4 MW 2229.5
DMDU6F4 FM C96H161N31O30
DMDU6F4 IC InChI=1S/C96H161N31O30/c1-12-50(10)75(125-83(145)55(18-13-14-28-97)113-87(149)64(36-52-39-104-44-109-52)120-80(142)56(19-15-29-106-95(100)101)112-82(144)60(24-27-73(135)136)117-92(154)76(51(11)130)126-77(139)54(98)32-46(2)3)91(153)122-63(35-49(8)9)86(148)121-65(37-53-40-105-45-110-53)88(150)114-57(20-16-30-107-96(102)103)79(141)118-62(34-48(6)7)85(147)119-61(33-47(4)5)84(146)116-59(22-25-70(99)131)81(143)115-58(23-26-72(133)134)78(140)108-41-71(132)111-68(43-129)93(155)127-31-17-21-69(127)90(152)124-67(42-128)89(151)123-66(94(156)157)38-74(137)138/h39-40,44-51,54-69,75-76,128-130H,12-38,41-43,97-98H2,1-11H3,(H2,99,131)(H,104,109)(H,105,110)(H,108,140)(H,111,132)(H,112,144)(H,113,149)(H,114,150)(H,115,143)(H,116,146)(H,117,154)(H,118,141)(H,119,147)(H,120,142)(H,121,148)(H,122,153)(H,123,151)(H,124,152)(H,125,145)(H,126,139)(H,133,134)(H,135,136)(H,137,138)(H,156,157)(H4,100,101,106)(H4,102,103,107)/t50-,51+,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69?,75-,76-/m0/s1
DMDU6F4 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N2CCCC2C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)N
DMDU6F4 IK QPHCCOQIWMPOQX-KTGODZLYSA-N
DMDU6F4 IU (2S)-2-[[(2S)-2-[[1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]butanedioic acid
DMDU6F4 DE Discovery agent
DMP8O6R ID DMP8O6R
DMP8O6R DN L-Thiocitrulline
DMP8O6R HS Investigative
DMP8O6R SN L-thiocitrulline; (S)-2-Amino-5-(thioureido)pentanoic acid; CHEMBL93247; SCI; (2S)-2-amino-5-[(aminothioxomethyl)amino]pentanoic acid; AC1MBZ2U; KBioGR_000498; BSPBio_001158; KBioSS_000498; SCHEMBL156220; KBio3_000915; KBio2_005634; KBio2_003066; KBio2_000498; KBio3_000916; Thio-L-citrulline, > BKGWACHYAMTLAF-BYPYZUCNSA-N; HMS3403J19; HMS1990J19; Bio1_000374; HMS1362J19; Bio2_000899; HMS1792J19; Bio2_000419; Bio1_001352; Bio1_000863
DMP8O6R DT Small molecular drug
DMP8O6R PC 2733514
DMP8O6R MW 191.25
DMP8O6R FM C6H13N3O2S
DMP8O6R IC InChI=1S/C6H13N3O2S/c7-4(5(10)11)2-1-3-9-6(8)12/h4H,1-3,7H2,(H,10,11)(H3,8,9,12)/t4-/m0/s1
DMP8O6R CS C(C[C@@H](C(=O)O)N)CNC(=S)N
DMP8O6R IK BKGWACHYAMTLAF-BYPYZUCNSA-N
DMP8O6R IU (2S)-2-amino-5-(carbamothioylamino)pentanoic acid
DMP8O6R CA CAS 156719-37-8
DMP8O6R DE Discovery agent
DMFHTBX ID DMFHTBX
DMFHTBX DN L-threonine
DMFHTBX HS Investigative
DMFHTBX SN L-threonine; threonine; 72-19-5; H-Thr-OH; Threonin; L-(-)-Threonine; (2S,3R)-2-amino-3-hydroxybutanoic acid; (S)-Threonine; 2-amino-3-hydroxybutyric acid; H-DL-Thr-OH; Threonine (VAN); Treonina [Spanish]; Threoninum [Latin]; Threonine [USAN:INN]; Threonine, L-; (2S,3R)-2-Amino-3-hydroxybutyric acid; thre; L-Threonin; L-thr; (2S)-threonine; L-alpha-Amino-beta-hydroxybutyric acid; (2S,3R)-(-)-Threonine; 2-Amino-3-hydroxybutanoic acid, (R-(R*,S*))-; UNII-2ZD004190S; Butanoic acid, 2-amino-3-hydroxy-, (R-(R*,S*))-
DMFHTBX DT Small molecular drug
DMFHTBX PC 6288
DMFHTBX MW 119.12
DMFHTBX FM C4H9NO3
DMFHTBX IC InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1
DMFHTBX CS C[C@H]([C@@H](C(=O)O)N)O
DMFHTBX IK AYFVYJQAPQTCCC-GBXIJSLDSA-N
DMFHTBX IU (2S,3R)-2-amino-3-hydroxybutanoic acid
DMFHTBX CA CAS 72-19-5
DMFHTBX CB CHEBI:16857
DMFHTBX DE Discovery agent
DM83HWL ID DM83HWL
DM83HWL DN L-thyroxine
DM83HWL HS Investigative
DM83HWL SN DL-Thyroxin; L-3,5,3',5'-Tetraiodothyronine; L-Thyroxin; L-thyroxine; Laevothyroxinum; Laevothyroxinum (acid); Levothyroxin; Levothyroxinum (acid); T4 (Hormone); Tetraiodothyronine; Tetramet; Thyratabs; Thyrax; Thyreoideum; Thyroxinal; Thyroxine (VAN); Thyroxine (l); Thyroxine I 125; Thyroxine iodine; levothyroxine; thyroxin; thyroxine; (-)-Thyroxine; 3,3',5,5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodo-L-thyronine; 3,5,3',5'-Tetraiodothyronine; 51-48-9; L-T4; t4
DM83HWL PC 5819
DM83HWL MW 776.87
DM83HWL FM C15H11I4NO4
DM83HWL IC XUIIKFGFIJCVMT-LBPRGKRZSA-N
DM83HWL CS C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N
DM83HWL IK 1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1
DM83HWL IU (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
DM83HWL CA CAS 51-48-9
DM83HWL CB CHEBI:18332
DM83HWL DE Hypogonadism
DMW09LB ID DMW09LB
DMW09LB DN LTK-14
DMW09LB HS Investigative
DMW09LB SN 14-methoxy IG (isogarcinol); LTK14
DMW09LB DT Small molecular drug
DMW09LB PC 25226432
DMW09LB MW 616.8
DMW09LB FM C39H52O6
DMW09LB IC InChI=1S/C39H52O6/c1-23(2)12-15-27-21-38-22-28(16-13-24(3)4)37(9,10)45-34(38)31(32(41)26-14-17-30(44-11)29(40)20-26)33(42)39(35(38)43,36(27,7)8)19-18-25(5)6/h12-14,17-18,20,27-28,40H,15-16,19,21-22H2,1-11H3/t27-,28+,38+,39+/m1/s1
DMW09LB CS CC(=CC[C@@H]1C[C@]23C[C@@H](C(OC2=C(C(=O)[C@@](C3=O)(C1(C)C)CC=C(C)C)C(=O)C4=CC(=C(C=C4)OC)O)(C)C)CC=C(C)C)C
DMW09LB IK GEMUMPJYCDKSDU-OAKZDBKWSA-N
DMW09LB IU (1S,3S,9R,11R)-7-(3-hydroxy-4-methoxybenzoyl)-4,4,10,10-tetramethyl-3,9,11-tris(3-methylbut-2-enyl)-5-oxatricyclo[7.3.1.01,6]tridec-6-ene-8,13-dione
DMW09LB DE Discovery agent
DMYLONS ID DMYLONS
DMYLONS DN L-Tryptophan-L-2-aminoadipic acid
DMYLONS HS Investigative
DMYLONS SN CHEMBL515773; L-Tryptophan-L-2-aminoadipic acid
DMYLONS DT Small molecular drug
DMYLONS PC 25185696
DMYLONS MW 347.4
DMYLONS FM C17H21N3O5
DMYLONS IC InChI=1S/C17H21N3O5/c18-12(8-10-9-19-13-5-2-1-4-11(10)13)16(23)20-14(17(24)25)6-3-7-15(21)22/h1-2,4-5,9,12,14,19H,3,6-8,18H2,(H,20,23)(H,21,22)(H,24,25)/t12-,14-/m0/s1
DMYLONS CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCC(=O)O)C(=O)O)N
DMYLONS IK LKKDYAZRMNSFJN-JSGCOSHPSA-N
DMYLONS IU (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]hexanedioic acid
DMYLONS DE Discovery agent
DMYU65F ID DMYU65F
DMYU65F DN L-Tryptophan-L-arginine
DMYU65F HS Investigative
DMYU65F SN CHEMBL477417; CHEBI:74866; 88831-09-8; Tryptophyl-Arginine; L-tryptophyl-L-arginine; L-Arginine, L-tryptophyl-; L-Tryptophan-L-arginine; tryptophanyl-arginine; L-Trp-L-Arg; SCHEMBL4947728; CTK3A5775; WR; ZINC2561117; BDBM50266680; AKOS030606594; H-Trp-Arg-OH inverted exclamation mark currency 2 HCl
DMYU65F DT Small molecular drug
DMYU65F PC 25186251
DMYU65F MW 360.4
DMYU65F FM C17H24N6O3
DMYU65F IC InChI=1S/C17H24N6O3/c18-12(8-10-9-22-13-5-2-1-4-11(10)13)15(24)23-14(16(25)26)6-3-7-21-17(19)20/h1-2,4-5,9,12,14,22H,3,6-8,18H2,(H,23,24)(H,25,26)(H4,19,20,21)/t12-,14-/m0/s1
DMYU65F CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N
DMYU65F IK LCPVBXOHXMBLFW-JSGCOSHPSA-N
DMYU65F IU (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMYU65F CB CHEBI:74866
DMYU65F DE Discovery agent
DMWZMCA ID DMWZMCA
DMWZMCA DN L-Tryptophan-L-asparagine
DMWZMCA HS Investigative
DMWZMCA SN CHEMBL513911; 175027-11-9; WN dipeptide; H-Trp-Asn-OH; W-N Dipeptide; L-Tryptophyl-L-Asparagine; Tryptophan Asparagine dipeptide; L-Tryptophan-L-asparagine; CHEBI:141447; WN; ZINC2561118; BDBM50266679; (2S)-4-amino-2-{[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino}-4-oxobutanoic acid
DMWZMCA DT Small molecular drug
DMWZMCA PC 7020170
DMWZMCA MW 318.33
DMWZMCA FM C15H18N4O4
DMWZMCA IC InChI=1S/C15H18N4O4/c16-10(14(21)19-12(15(22)23)6-13(17)20)5-8-7-18-11-4-2-1-3-9(8)11/h1-4,7,10,12,18H,5-6,16H2,(H2,17,20)(H,19,21)(H,22,23)/t10-,12-/m0/s1
DMWZMCA CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)N
DMWZMCA IK GRQCSEWEPIHLBI-JQWIXIFHSA-N
DMWZMCA IU (2S)-4-amino-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoic acid
DMWZMCA CB CHEBI:141447
DMWZMCA DE Discovery agent
DMVFAD5 ID DMVFAD5
DMVFAD5 DN L-Tryptophan-L-aspartic acid
DMVFAD5 HS Investigative
DMVFAD5 SN H-TRP-ASP-OH; 71835-78-4; CHEMBL476008; CHEBI:74868; L-TRYPTOPHYL-L-ASPARTIC ACID; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)Propanamido)succinic acid; Tryptophyl-Aspartate; tryptophylaspartic acid; L-Tryptophan-L-aspartic acid; L-Trp-L-Asp; SCHEMBL10434701; CTK7I5235; WD; ZINC2556664; BDBM50266632
DMVFAD5 DT Small molecular drug
DMVFAD5 PC 7019108
DMVFAD5 MW 319.31
DMVFAD5 FM C15H17N3O5
DMVFAD5 IC InChI=1S/C15H17N3O5/c16-10(14(21)18-12(15(22)23)6-13(19)20)5-8-7-17-11-4-2-1-3-9(8)11/h1-4,7,10,12,17H,5-6,16H2,(H,18,21)(H,19,20)(H,22,23)/t10-,12-/m0/s1
DMVFAD5 CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)N
DMVFAD5 IK PEEAINPHPNDNGE-JQWIXIFHSA-N
DMVFAD5 IU (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]butanedioic acid
DMVFAD5 CB CHEBI:74868
DMVFAD5 DE Discovery agent
DMNMRHX ID DMNMRHX
DMNMRHX DN L-Tryptophan-L-glutamine
DMNMRHX HS Investigative
DMNMRHX SN CHEMBL476173; L-Tryptophan-L-glutamine; SCHEMBL5970454
DMNMRHX DT Small molecular drug
DMNMRHX PC 25187914
DMNMRHX MW 332.35
DMNMRHX FM C16H20N4O4
DMNMRHX IC InChI=1S/C16H20N4O4/c17-11(7-9-8-19-12-4-2-1-3-10(9)12)15(22)20-13(16(23)24)5-6-14(18)21/h1-4,8,11,13,19H,5-7,17H2,(H2,18,21)(H,20,22)(H,23,24)/t11-,13-/m0/s1
DMNMRHX CS C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N
DMNMRHX IK NZCPCJCJZHKFGZ-AAEUAGOBSA-N
DMNMRHX IU (2S)-5-amino-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoic acid
DMNMRHX CB CHEBI:157897
DMNMRHX DE Discovery agent
DMPV5D0 ID DMPV5D0
DMPV5D0 DN L-Tryptophan-L-leucine
DMPV5D0 HS Investigative
DMPV5D0 SN H-Trp-Leu-OH; 13123-35-8; L-tryptophyl-L-leucine; CHEMBL477627; CHEBI:74871; Tryptophyl-Leucine; L-Tryptophan-L-leucine; L-Trp-L-Leu; L-Trp-L-Leu-OH; L-Leucine,L-tryptophyl-; AC1OE28P; SCHEMBL7622341; (S)-2-((S)-2-Amino-3-(1H-indol-3-yl)propanamido)-4-methylpentanoic acid; CTK4B7168; ZINC1865984; WL; BDBM50266681; AKOS022180848; AJ-32151; FT-0772989; C-48470; (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid
DMPV5D0 DT Small molecular drug
DMPV5D0 PC 6997510
DMPV5D0 MW 317.4
DMPV5D0 FM C17H23N3O3
DMPV5D0 IC InChI=1S/C17H23N3O3/c1-10(2)7-15(17(22)23)20-16(21)13(18)8-11-9-19-14-6-4-3-5-12(11)14/h3-6,9-10,13,15,19H,7-8,18H2,1-2H3,(H,20,21)(H,22,23)/t13-,15-/m0/s1
DMPV5D0 CS CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N
DMPV5D0 IK LYMVXFSTACVOLP-ZFWWWQNUSA-N
DMPV5D0 IU (2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoic acid
DMPV5D0 CB CHEBI:74871
DMPV5D0 DE Discovery agent
DMGVELK ID DMGVELK
DMGVELK DN L-Tyrosinamide
DMGVELK HS Investigative
DMGVELK SN ACMC-20muar; 131948-41-9; L-Tyrosinamide,(4R)-4-hydroxy-1-(1H-indol-3-ylcarbonyl)-L-prolyl-N-methyl-N-(phenylmethyl)-(9CI)
DMGVELK DT Small molecular drug
DMGVELK PC 151243
DMGVELK MW 180.2
DMGVELK FM C9H12N2O2
DMGVELK IC InChI=1S/C9H12N2O2/c10-8(9(11)13)5-6-1-3-7(12)4-2-6/h1-4,8,12H,5,10H2,(H2,11,13)/t8-/m0/s1
DMGVELK CS C1=CC(=CC=C1C[C@@H](C(=O)N)N)O
DMGVELK IK PQFMNVGMJJMLAE-QMMMGPOBSA-N
DMGVELK IU (2S)-2-amino-3-(4-hydroxyphenyl)propanamide
DMGVELK CA CAS 4985-46-0
DMGVELK CB CHEBI:21412
DMGVELK DE Discovery agent
DMH693E ID DMH693E
DMH693E DN Lu AF21934
DMH693E HS Investigative
DMH693E SN (1S,2R)-2-[(aminooxy)methyl]-N-(3,4-dichlorophenyl)cyclohexane-1-carboxamide
DMH693E DT Small molecular drug
DMH693E PC 66553157
DMH693E MW 315.2
DMH693E FM C14H16Cl2N2O2
DMH693E IC InChI=1S/C14H16Cl2N2O2/c15-11-6-5-8(7-12(11)16)18-14(20)10-4-2-1-3-9(10)13(17)19/h5-7,9-10H,1-4H2,(H2,17,19)(H,18,20)/t9-,10+/m1/s1
DMH693E CS C1CC[C@@H]([C@@H](C1)C(=O)N)C(=O)NC2=CC(=C(C=C2)Cl)Cl
DMH693E IK AVKZWCJNDWOBAM-ZJUUUORDSA-N
DMH693E IU (1R,2S)-2-N-(3,4-dichlorophenyl)cyclohexane-1,2-dicarboxamide
DMH693E DE Discovery agent
DM7F3SE ID DM7F3SE
DM7F3SE DN LU302872
DM7F3SE HS Investigative
DM7F3SE SN CHEMBL102405; AC1O5FKI; SCHEMBL3894792; lu224332; BDBM50079417; L017653; 3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3,3-diphenylpropanoic acid; 3-[2-(3,4-Dimethoxy-phenyl)-ethoxy]-2-(4,6-dimethyl-pyrimidin-2-yloxy)-3,3-diphenyl-propionic acid; 2-[(4,6-Dimethylpyrimidine-2-yl)oxy]-3-[2-(3,4-dimethoxyphenyl)ethoxy]-3,3-diphenylpropionic acid
DM7F3SE DT Small molecular drug
DM7F3SE PC 9893800
DM7F3SE MW 528.6
DM7F3SE FM C31H32N2O6
DM7F3SE IC InChI=1S/C31H32N2O6/c1-21-19-22(2)33-30(32-21)39-28(29(34)35)31(24-11-7-5-8-12-24,25-13-9-6-10-14-25)38-18-17-23-15-16-26(36-3)27(20-23)37-4/h5-16,19-20,28H,17-18H2,1-4H3,(H,34,35)/t28-/m1/s1
DM7F3SE CS CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OCCC4=CC(=C(C=C4)OC)OC)C
DM7F3SE IK CLSJNXXMIVKULC-MUUNZHRXSA-N
DM7F3SE IU (2S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yl)oxy-3,3-diphenylpropanoic acid
DM7F3SE CA CAS 204267-33-4
DM7F3SE DE Discovery agent
DM2YOVC ID DM2YOVC
DM2YOVC DN LU32-176B
DM2YOVC HS Investigative
DM2YOVC SN LU32-176B; GTPL4756; SCHEMBL5726290
DM2YOVC DT Small molecular drug
DM2YOVC PC 11749893
DM2YOVC MW 398.4
DM2YOVC FM C23H24F2N2O2
DM2YOVC IC InChI=1S/C23H24F2N2O2/c24-17-10-6-15(7-11-17)19(16-8-12-18(25)13-9-16)3-2-14-26-20-4-1-5-21-22(20)23(28)27-29-21/h6-13,19-20,26H,1-5,14H2,(H,27,28)
DM2YOVC CS C1CC(C2=C(C1)ONC2=O)NCCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
DM2YOVC IK QOSIKKDOOCQXMT-UHFFFAOYSA-N
DM2YOVC IU 4-[4,4-bis(4-fluorophenyl)butylamino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-one
DM2YOVC DE Discovery agent
DMGYBSC ID DMGYBSC
DMGYBSC DN LU-53439
DMGYBSC HS Investigative
DMGYBSC SN 153420-96-3
DMGYBSC DT Small molecular drug
DMGYBSC PC 179342
DMGYBSC MW 330.4
DMGYBSC FM C17H18N2O3S
DMGYBSC IC InChI=1S/C17H18N2O3S/c1-9(2)16-19-18-15(23-16)8-21-12-5-6-13-10(3)11(4)17(20)22-14(13)7-12/h5-7,9H,8H2,1-4H3
DMGYBSC CS CC1=C(C(=O)OC2=C1C=CC(=C2)OCC3=NN=C(S3)C(C)C)C
DMGYBSC IK HQTNJPCZUQAYAB-UHFFFAOYSA-N
DMGYBSC IU 3,4-dimethyl-7-[(5-propan-2-yl-1,3,4-thiadiazol-2-yl)methoxy]chromen-2-one
DMGYBSC CA CAS 153420-96-3
DMGYBSC DE Discovery agent
DM34AYV ID DM34AYV
DM34AYV DN LU-AA33810
DM34AYV HS Investigative
DM34AYV SN LU-AE00654; Neuropeptide Y receptor subtype Y5 antagonists (depression); NPY5 antagonists (depression), Lundbeck; Neuropeptide Y receptor subtype Y5 antagonists (depression), Lundbeck
DM34AYV CP H Lundbeck A/S
DM34AYV DE Major depressive disorder
DMI9VNO ID DMI9VNO
DMI9VNO DN LUDARTIN
DMI9VNO HS Investigative
DMI9VNO SN Ludartin; CHEMBL1097764; 36149-87-8; BDBM50318394; 6,8a-Dimethyl-3-methylene-3a,4,5,7,7a,8a,8b,8c-octahydro-3H-1,8-dioxa-cyclopenta[h]cyclopropa[a]azulen-2-one (Ludartin)
DMI9VNO DT Small molecular drug
DMI9VNO PC 14355826
DMI9VNO MW 246.3
DMI9VNO FM C15H18O3
DMI9VNO IC InChI=1S/C15H18O3/c1-7-4-5-9-8(2)14(16)17-13(9)12-10(7)6-11-15(12,3)18-11/h9,11-13H,2,4-6H2,1,3H3/t9-,11+,12-,13-,15+/m0/s1
DMI9VNO CS CC1=C2C[C@@H]3[C@]([C@@H]2[C@@H]4[C@@H](CC1)C(=C)C(=O)O4)(O3)C
DMI9VNO IK QXJYIGSXUBOSID-JZEMPJKHSA-N
DMI9VNO IU (1S,2S,6S,12R,14S)-9,14-dimethyl-5-methylidene-3,13-dioxatetracyclo[8.4.0.02,6.012,14]tetradec-9-en-4-one
DMI9VNO DE Discovery agent
DMUPQED ID DMUPQED
DMUPQED DN LUF-5417
DMUPQED HS Investigative
DMUPQED SN LUF-5417; 4-methoxy-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide; CHEMBL305322; 331472-31-2; AC1LDIQV; SCHEMBL6942413; ZINC26474; MolPort-000-646-916; STL203008; BDBM50097423; AKOS000813206; MCULE-5464374219; VU0618369-1; F3394-1093; Z275024144; 4-Methoxy-N-(3-phenyl-[1,2,4]thiadiazol-5-yl)-benzamide
DMUPQED DT Small molecular drug
DMUPQED PC 667741
DMUPQED MW 311.4
DMUPQED FM C16H13N3O2S
DMUPQED IC InChI=1S/C16H13N3O2S/c1-21-13-9-7-12(8-10-13)15(20)18-16-17-14(19-22-16)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18,19,20)
DMUPQED CS COC1=CC=C(C=C1)C(=O)NC2=NC(=NS2)C3=CC=CC=C3
DMUPQED IK RGVXOHBJCGPTQH-UHFFFAOYSA-N
DMUPQED IU 4-methoxy-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide
DMUPQED DE Discovery agent
DME4O5D ID DME4O5D
DME4O5D DN LUF-5433
DME4O5D HS Investigative
DME4O5D SN LUF-5433; CHEMBL60156; 15850-34-7; 4-methoxy-N-(4-phenyl-1,3-thiazol-2-yl)benzamide; (Z)-4-methoxy-N-(4-phenylthiazol-2(3H)-ylidene)benzamide; AC1LDKPI; N-(4-phenylthiazol-2-yl)-4-methoxybenzamide; Oprea1_747035; Oprea1_074264; Oprea1_345855; AC1Q49Y1; SCHEMBL2753298; MolPort-001-029-705; MolPort-003-712-982; ZINC1508173; STK401912; BDBM50097431; AKOS001303429; AKOS024573980; MCULE-3254711297; ST042073; 4-methoxy-N-(4-phenylthiazol-2-yl)benzamide; 4-Methoxy-N-(4-phenyl-thiazol-2-yl)-benzamide; SR-01000394983; SR-01000394983-1
DME4O5D DT Small molecular drug
DME4O5D PC 668712
DME4O5D MW 310.4
DME4O5D FM C17H14N2O2S
DME4O5D IC InChI=1S/C17H14N2O2S/c1-21-14-9-7-13(8-10-14)16(20)19-17-18-15(11-22-17)12-5-3-2-4-6-12/h2-11H,1H3,(H,18,19,20)
DME4O5D CS COC1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=C3
DME4O5D IK FVWGKRAXWKLEHX-UHFFFAOYSA-N
DME4O5D IU 4-methoxy-N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DME4O5D DE Discovery agent
DM0DRO8 ID DM0DRO8
DM0DRO8 DN LUF-5437
DM0DRO8 HS Investigative
DM0DRO8 SN LUF-5437; CHEMBL164745; SCHEMBL4243345; BDBM50097451
DM0DRO8 DT Small molecular drug
DM0DRO8 PC 9994776
DM0DRO8 MW 297.3
DM0DRO8 FM C15H11N3O2S
DM0DRO8 IC InChI=1S/C15H11N3O2S/c19-12-8-6-11(7-9-12)14(20)17-15-16-13(18-21-15)10-4-2-1-3-5-10/h1-9,19H,(H,16,17,18,20)
DM0DRO8 CS C1=CC=C(C=C1)C2=NSC(=N2)NC(=O)C3=CC=C(C=C3)O
DM0DRO8 IK MIJWZALSSVTKAQ-UHFFFAOYSA-N
DM0DRO8 IU 4-hydroxy-N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide
DM0DRO8 DE Discovery agent
DM89FBX ID DM89FBX
DM89FBX DN LUF-5735
DM89FBX HS Investigative
DM89FBX SN CHEMBL222719; LUF-5735; 820961-65-7; N-(4,6-diphenylpyrimidin-2-yl)butanamide; SCHEMBL6499771; CTK3E2643; DTXSID60464548; MolPort-007-705-553; ZINC6716086; BDBM50157673; AKOS001552900; MCULE-5627024228; N-(4,6-diphenylpyrimidin-2-yl)butyramide; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DM89FBX DT Small molecular drug
DM89FBX PC 11392960
DM89FBX MW 317.4
DM89FBX FM C20H19N3O
DM89FBX IC InChI=1S/C20H19N3O/c1-2-9-19(24)23-20-21-17(15-10-5-3-6-11-15)14-18(22-20)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,21,22,23,24)
DM89FBX CS CCCC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM89FBX IK IGXLAZUQYPCBKI-UHFFFAOYSA-N
DM89FBX IU N-(4,6-diphenylpyrimidin-2-yl)butanamide
DM89FBX CA CAS 820961-65-7
DM89FBX DE Discovery agent
DMXFD3S ID DMXFD3S
DMXFD3S DN LUF-5737
DMXFD3S HS Investigative
DMXFD3S SN CHEMBL376778; LUF-5737; 820961-68-0; SCHEMBL6502989; CTK3E2640; DTXSID50464193; BDBM50157654; N-(4,6-diphenylpyrimidin-2-yl)isobutyramide; L023249; Propanamide, N-(4,6-diphenyl-2-pyrimidinyl)-2-methyl-
DMXFD3S DT Small molecular drug
DMXFD3S PC 11381543
DMXFD3S MW 317.4
DMXFD3S FM C20H19N3O
DMXFD3S IC InChI=1S/C20H19N3O/c1-14(2)19(24)23-20-21-17(15-9-5-3-6-10-15)13-18(22-20)16-11-7-4-8-12-16/h3-14H,1-2H3,(H,21,22,23,24)
DMXFD3S CS CC(C)C(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMXFD3S IK AGCKGTMTDBKSHH-UHFFFAOYSA-N
DMXFD3S IU N-(4,6-diphenylpyrimidin-2-yl)-2-methylpropanamide
DMXFD3S CA CAS 820961-68-0
DMXFD3S DE Discovery agent
DMQ3VHR ID DMQ3VHR
DMQ3VHR DN LUF-5764
DMQ3VHR HS Investigative
DMQ3VHR SN CHEMBL222504; LUF-5764; 820961-49-7; SCHEMBL4822595; CTK3E2654; DTXSID00466708; BDBM50157682; AKOS030569391; L023251; N-(2,6-diphenylpyrimidin-4-yl)-3,3-dimethylbutyramide; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-3,3-dimethyl-
DMQ3VHR DT Small molecular drug
DMQ3VHR PC 11462102
DMQ3VHR MW 345.4
DMQ3VHR FM C22H23N3O
DMQ3VHR IC InChI=1S/C22H23N3O/c1-22(2,3)15-20(26)24-19-14-18(16-10-6-4-7-11-16)23-21(25-19)17-12-8-5-9-13-17/h4-14H,15H2,1-3H3,(H,23,24,25,26)
DMQ3VHR CS CC(C)(C)CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMQ3VHR IK HRLXAMBTUIRRBL-UHFFFAOYSA-N
DMQ3VHR IU N-(2,6-diphenylpyrimidin-4-yl)-3,3-dimethylbutanamide
DMQ3VHR CA CAS 820961-49-7
DMQ3VHR DE Discovery agent
DMP08QO ID DMP08QO
DMP08QO DN LUF-5767
DMP08QO HS Investigative
DMP08QO SN CHEMBL223977; LUF-5767; 820961-47-5; SCHEMBL4829114; CTK3E2656; DTXSID70465602; BDBM50157656; AKOS030569390; L023253; N-(2,6-diphenylpyrimidin-4-yl)-2-methylbutyramide; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-2-methyl-
DMP08QO DT Small molecular drug
DMP08QO PC 11427528
DMP08QO MW 331.4
DMP08QO FM C21H21N3O
DMP08QO IC InChI=1S/C21H21N3O/c1-3-15(2)21(25)24-19-14-18(16-10-6-4-7-11-16)22-20(23-19)17-12-8-5-9-13-17/h4-15H,3H2,1-2H3,(H,22,23,24,25)
DMP08QO CS CCC(C)C(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMP08QO IK OWPSSUJQRJLQHE-UHFFFAOYSA-N
DMP08QO IU N-(2,6-diphenylpyrimidin-4-yl)-2-methylbutanamide
DMP08QO CA CAS 820961-47-5
DMP08QO DE Discovery agent
DMQZDMH ID DMQZDMH
DMQZDMH DN LUF-5816
DMQZDMH HS Investigative
DMQZDMH SN LUF-5816; CHEMBL219625; BDBM50205286
DMQZDMH DT Small molecular drug
DMQZDMH PC 16109430
DMQZDMH MW 339.4
DMQZDMH FM C23H21N3
DMQZDMH IC InChI=1S/C23H21N3/c1-3-9-16(10-4-1)19-15-20(17-11-5-2-6-12-17)24-23-21(19)25-22(26-23)18-13-7-8-14-18/h1-6,9-12,15,18H,7-8,13-14H2,(H,24,25,26)
DMQZDMH CS C1CCC(C1)C2=NC3=C(N2)C(=CC(=N3)C4=CC=CC=C4)C5=CC=CC=C5
DMQZDMH IK LEUPSQCQJOFTFI-UHFFFAOYSA-N
DMQZDMH IU 2-cyclopentyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMQZDMH DE Discovery agent
DMYZGIK ID DMYZGIK
DMYZGIK DN LUF5831
DMYZGIK HS Investigative
DMYZGIK SN LUF 5831; LUF-5831
DMYZGIK DT Small molecular drug
DMYZGIK PC 135494270
DMYZGIK MW 312.3
DMYZGIK FM C15H12N4O2S
DMYZGIK IC InChI=1S/C15H12N4O2S/c16-7-11-13(9-1-3-10(21)4-2-9)12(8-17)15(19-14(11)18)22-6-5-20/h1-4,20-21H,5-6H2,(H2,18,19)
DMYZGIK CS C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCCO)N)C#N)O
DMYZGIK IK GYIHPWFWFRELQC-UHFFFAOYSA-N
DMYZGIK IU 2-amino-6-(2-hydroxyethylsulfanyl)-4-(4-hydroxyphenyl)pyridine-3,5-dicarbonitrile
DMYZGIK DE Discovery agent
DMDHUL8 ID DMDHUL8
DMDHUL8 DN LUF-5833
DMDHUL8 HS Investigative
DMDHUL8 SN A3 adenosine receptor allosteric enhancers (ischemia); LUF-6000; A3 adenosine receptor allosteric enhancers (ischemia), NIH/University of Leiden
DMDHUL8 CP Leiden; Amsterdam Center for Drug Research
DMDHUL8 DE Ischemia
DMZQU90 ID DMZQU90
DMZQU90 DN LUF-5853
DMZQU90 HS Investigative
DMZQU90 SN LUF-5853; CHEMBL176295; SCHEMBL6105939; KQKVGJJOJHCKQA-UHFFFAOYSA-N; BDBM50163463; 2-amino-4-(benzo[d][1,3]dioxol-5-yl)-6-(2-hydroxyethylthio)pyridine-3,5-dicarbonitrile; 2-Amino4-(1,3-benzodioxol-5-yl)-6-(2-hydroxyethyl)sulfanyl-3,5-pyridinedicarbonitrile; 2-Amino-4-benzo[1,3]dioxol-5-yl-6-(2-hydroxy-ethylsulfanyl)-pyridine-3,5-dicarbonitrile
DMZQU90 DT Small molecular drug
DMZQU90 PC 9884349
DMZQU90 MW 340.4
DMZQU90 FM C16H12N4O3S
DMZQU90 IC InChI=1S/C16H12N4O3S/c17-6-10-14(9-1-2-12-13(5-9)23-8-22-12)11(7-18)16(20-15(10)19)24-4-3-21/h1-2,5,21H,3-4,8H2,(H2,19,20)
DMZQU90 CS C1OC2=C(O1)C=C(C=C2)C3=C(C(=NC(=C3C#N)SCCO)N)C#N
DMZQU90 IK KQKVGJJOJHCKQA-UHFFFAOYSA-N
DMZQU90 IU 2-amino-4-(1,3-benzodioxol-5-yl)-6-(2-hydroxyethylsulfanyl)pyridine-3,5-dicarbonitrile
DMZQU90 DE Discovery agent
DMG4YWM ID DMG4YWM
DMG4YWM DN LUF-5956
DMG4YWM HS Investigative
DMG4YWM SN LUF-5956; CHEMBL204780; BDBM50186590
DMG4YWM DT Small molecular drug
DMG4YWM PC 11536936
DMG4YWM MW 314.4
DMG4YWM FM C20H18N4
DMG4YWM IC InChI=1S/C20H18N4/c1-13(2)18-22-17-16(14-9-5-3-6-10-14)21-19(24-20(17)23-18)15-11-7-4-8-12-15/h3-13H,1-2H3,(H,21,22,23,24)
DMG4YWM CS CC(C)C1=NC2=NC(=NC(=C2N1)C3=CC=CC=C3)C4=CC=CC=C4
DMG4YWM IK WOKKQPCDRVUEPM-UHFFFAOYSA-N
DMG4YWM IU 2,6-diphenyl-8-propan-2-yl-7H-purine
DMG4YWM DE Discovery agent
DMJFMH9 ID DMJFMH9
DMJFMH9 DN LUF-5957
DMJFMH9 HS Investigative
DMJFMH9 SN LUF-5957; CHEMBL207529; BDBM50186599
DMJFMH9 DT Small molecular drug
DMJFMH9 PC 11523232
DMJFMH9 MW 354.4
DMJFMH9 FM C23H22N4
DMJFMH9 IC InChI=1S/C23H22N4/c1-4-10-16(11-5-1)19-20-23(26-21(24-19)17-12-6-2-7-13-17)27-22(25-20)18-14-8-3-9-15-18/h1-2,4-7,10-13,18H,3,8-9,14-15H2,(H,24,25,26,27)
DMJFMH9 CS C1CCC(CC1)C2=NC3=NC(=NC(=C3N2)C4=CC=CC=C4)C5=CC=CC=C5
DMJFMH9 IK IGJKVZBNIOTBGI-UHFFFAOYSA-N
DMJFMH9 IU 8-cyclohexyl-2,6-diphenyl-7H-purine
DMJFMH9 DE Discovery agent
DMR6LIE ID DMR6LIE
DMR6LIE DN LUF-5962
DMR6LIE HS Investigative
DMR6LIE SN LUF-5962; CHEMBL207824; 8-cyclopentyl-2,6-diphenyl-7H-purine; GTPL9813; LUF5962; LUF 5962; BDBM50186588
DMR6LIE DT Small molecular drug
DMR6LIE PC 11617054
DMR6LIE MW 340.4
DMR6LIE FM C22H20N4
DMR6LIE IC InChI=1S/C22H20N4/c1-3-9-15(10-4-1)18-19-22(26-21(24-19)17-13-7-8-14-17)25-20(23-18)16-11-5-2-6-12-16/h1-6,9-12,17H,7-8,13-14H2,(H,23,24,25,26)
DMR6LIE CS C1CCC(C1)C2=NC3=NC(=NC(=C3N2)C4=CC=CC=C4)C5=CC=CC=C5
DMR6LIE IK NDJOQVVSPLVIDN-UHFFFAOYSA-N
DMR6LIE IU 8-cyclopentyl-2,6-diphenyl-7H-purine
DMR6LIE DE Discovery agent
DMCTM3L ID DMCTM3L
DMCTM3L DN LUF-5978
DMCTM3L HS Investigative
DMCTM3L SN LUF-5978; CHEMBL221486; BDBM50205280
DMCTM3L DT Small molecular drug
DMCTM3L PC 44418996
DMCTM3L MW 327.4
DMCTM3L FM C22H21N3
DMCTM3L IC InChI=1S/C22H21N3/c1-15(2)13-20-24-21-18(16-9-5-3-6-10-16)14-19(23-22(21)25-20)17-11-7-4-8-12-17/h3-12,14-15H,13H2,1-2H3,(H,23,24,25)
DMCTM3L CS CC(C)CC1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMCTM3L IK PPFWSQNEFCXMGP-UHFFFAOYSA-N
DMCTM3L IU 2-(2-methylpropyl)-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMCTM3L DE Discovery agent
DMGOIF5 ID DMGOIF5
DMGOIF5 DN LUF-5980
DMGOIF5 HS Investigative
DMGOIF5 SN LUF-5980; CHEMBL221343; BDBM50205281
DMGOIF5 DT Small molecular drug
DMGOIF5 PC 16109428
DMGOIF5 MW 313.4
DMGOIF5 FM C21H19N3
DMGOIF5 IC InChI=1S/C21H19N3/c1-14(2)20-23-19-17(15-9-5-3-6-10-15)13-18(22-21(19)24-20)16-11-7-4-8-12-16/h3-14H,1-2H3,(H,22,23,24)
DMGOIF5 CS CC(C)C1=NC2=C(N1)C(=CC(=N2)C3=CC=CC=C3)C4=CC=CC=C4
DMGOIF5 IK REXYMDQLBZWOMA-UHFFFAOYSA-N
DMGOIF5 IU 5,7-diphenyl-2-propan-2-yl-1H-imidazo[4,5-b]pyridine
DMGOIF5 DE Discovery agent
DMHO3XL ID DMHO3XL
DMHO3XL DN LUF-5981
DMHO3XL HS Investigative
DMHO3XL SN LUF-5981; CHEMBL219160; GTPL5607; LUF5981; LUF 5981; BDBM50205283; 2,6-diphenyl-8-cyclohexyl-1-deazapurine
DMHO3XL DT Small molecular drug
DMHO3XL PC 16109435
DMHO3XL MW 353.5
DMHO3XL FM C24H23N3
DMHO3XL IC InChI=1S/C24H23N3/c1-4-10-17(11-5-1)20-16-21(18-12-6-2-7-13-18)25-24-22(20)26-23(27-24)19-14-8-3-9-15-19/h1-2,4-7,10-13,16,19H,3,8-9,14-15H2,(H,25,26,27)
DMHO3XL CS C1CCC(CC1)C2=NC3=C(N2)C(=CC(=N3)C4=CC=CC=C4)C5=CC=CC=C5
DMHO3XL IK DXBBMCIVYYJMJC-UHFFFAOYSA-N
DMHO3XL IU 2-cyclohexyl-5,7-diphenyl-1H-imidazo[4,5-b]pyridine
DMHO3XL DE Discovery agent
DM0K75N ID DM0K75N
DM0K75N DN LUF-6258
DM0K75N HS Investigative
DM0K75N SN LUF-6258; CHEMBL1090687; BDBM50315855
DM0K75N DT Small molecular drug
DM0K75N PC 46203501
DM0K75N MW 810.8
DM0K75N FM C39H45Cl2N7O6S
DM0K75N IC InChI=1S/C39H45Cl2N7O6S/c40-27-13-8-23(18-28(27)41)33(50)31-26-14-16-47(19-30(26)55-36(31)42)15-6-4-2-1-3-5-7-17-53-25-11-9-24(10-12-25)46-37-32-38(44-21-43-37)48(22-45-32)39-35(52)34(51)29(20-49)54-39/h8-13,18,21-22,29,34-35,39,49,51-52H,1-7,14-17,19-20,42H2,(H,43,44,46)/t29-,34-,35-,39-/m1/s1
DM0K75N CS C1CN(CC2=C1C(=C(S2)N)C(=O)C3=CC(=C(C=C3)Cl)Cl)CCCCCCCCCOC4=CC=C(C=C4)NC5=C6C(=NC=N5)N(C=N6)[C@H]7[C@@H]([C@@H]([C@H](O7)CO)O)O
DM0K75N IK DERHYILBHUKLGL-VMPBLTEISA-N
DM0K75N IU [2-amino-6-[9-[4-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenoxy]nonyl]-5,7-dihydro-4H-thieno[2,3-c]pyridin-3-yl]-(3,4-dichlorophenyl)methanone
DM0K75N DE Discovery agent
DMYRCHV ID DMYRCHV
DMYRCHV DN LUFFARIELLOLIDE
DMYRCHV HS Investigative
DMYRCHV SN Luffariellolide; 111149-87-2; 3-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,7-dienyl]-2-hydroxy-2H-furan-5-one; AC1NTS09; CHEMBL451037; SCHEMBL10422020; MolPort-044-561-235; NSC622149; AKOS025294086; NSC-622149; SMP2_000178; RT-013604; C19901; J-002531; 4-((3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-enyl)deca-3,7-dienyl)-5-hydroxyfuran-2(5H)-one; 2(5H)-Furanone, 4-(4,8-dimethyl-10-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3,7-decadienyl)-5-hydroxy-, (E,E)-
DMYRCHV DT Small molecular drug
DMYRCHV PC 5387248
DMYRCHV MW 386.6
DMYRCHV FM C25H38O3
DMYRCHV IC InChI=1S/C25H38O3/c1-18(11-7-13-21-17-23(26)28-24(21)27)9-6-10-19(2)14-15-22-20(3)12-8-16-25(22,4)5/h10-11,17,24,27H,6-9,12-16H2,1-5H3/b18-11+,19-10+
DMYRCHV CS CC1=C(C(CCC1)(C)C)CC/C(=C/CC/C(=C/CCC2=CC(=O)OC2O)/C)/C
DMYRCHV IK JPWPYTMXSXYUPG-QZPYEDBESA-N
DMYRCHV IU 3-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,7-dienyl]-2-hydroxy-2H-furan-5-one
DMYRCHV CA CAS 111149-87-2
DMYRCHV DE Discovery agent
DM4ZLUH ID DM4ZLUH
DM4ZLUH DN LUPEOL
DM4ZLUH HS Investigative
DM4ZLUH SN Fagarsterol; Lupenol; EINECS 208-889-9; NSC 90487; (3-beta)-Lup-20(29)-en-3-ol; Lup-20(29)-en-3-ol, (3beta)-; (1R,3aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-1-isopropenyl-3a,5a,5b,8,8,11a-hexamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; Lup-20(29)-en-3-ol; Lup-20(29)-en-3-beta-ol; Lup-20(29)-en-3-ol, (3-beta)-; Lup-20(29)-en-3-ol, (3.beta.)-; AC1L2J5Q; SCHEMBL561024; Lup-20(29)-en-3beta-ol; LS-88199; AN-14996
DM4ZLUH DT Small molecular drug
DM4ZLUH PC 259846
DM4ZLUH MW 426.7
DM4ZLUH FM C30H50O
DM4ZLUH IC InChI=1S/C30H50O/c1-19(2)20-11-14-27(5)17-18-29(7)21(25(20)27)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21+,22-,23+,24-,25+,27+,28-,29+,30+/m0/s1
DM4ZLUH CS CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C
DM4ZLUH IK MQYXUWHLBZFQQO-QGTGJCAVSA-N
DM4ZLUH IU (1R,3aR,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol
DM4ZLUH CA CAS 545-47-1
DM4ZLUH CB CHEBI:6570
DM4ZLUH DE Discovery agent
DM68RPD ID DM68RPD
DM68RPD DN L-valine
DM68RPD HS Investigative
DM68RPD SN L-valine; valine; 72-18-4; (S)-Valine; H-Val-OH; (S)-2-Amino-3-methylbutanoic acid; 2-Amino-3-methylbutyric acid; (2S)-2-amino-3-methylbutanoic acid; (S)-2-Amino-3-methylbutyric acid; L-alpha-Amino-beta-methylbutyric acid; Valinum [Latin]; Valina [Spanish]; Valine (VAN); Valine [USAN:INN]; Butanoic acid, 2-amino-3-methyl-; VALINE, L-; L(+)-alpha-Aminoisovaleric acid; (S)-alpha-Amino-beta-methylbutyric acid; Butanoic acid, 2-amino-3-methyl-, (S)-; 2-Amino-3-methylbutyric acid, (S)-; 2-Amino-3-methylbutanoic acid, (S)-; L-valin
DM68RPD DT Small molecular drug
DM68RPD PC 6287
DM68RPD MW 117.15
DM68RPD FM C5H11NO2
DM68RPD IC InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1
DM68RPD CS CC(C)[C@@H](C(=O)O)N
DM68RPD IK KZSNJWFQEVHDMF-BYPYZUCNSA-N
DM68RPD IU (2S)-2-amino-3-methylbutanoic acid
DM68RPD CA CAS 72-18-4
DM68RPD CB CHEBI:16414
DM68RPD DE Discovery agent
DMPGT80 ID DMPGT80
DMPGT80 DN L-Val-L-boroPro
DMPGT80 HS Investigative
DMPGT80 DT Small molecular drug
DMPGT80 PC 44422920
DMPGT80 MW 215.08
DMPGT80 FM C9H20BN2O3+
DMPGT80 IC InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/p+1/t7-,8-/m0/s1
DMPGT80 CS B([C@@H]1CCCN1C(=O)[C@H](C(C)C)[NH3+])(O)O
DMPGT80 IK FKCMADOPPWWGNZ-YUMQZZPRSA-O
DMPGT80 IU [(2S)-1-[(2R)-2-boronopyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]azanium
DMPGT80 DE Discovery agent
DMH7TNA ID DMH7TNA
DMH7TNA DN L-valyl-L-prolinamide
DMH7TNA HS Investigative
DMH7TNA SN CHEMBL375933; 76362-52-2; L-valyl-L-prolinamide; L-Prolinamide, L-valyl-; CTK2G7856; DTXSID40469490
DMH7TNA DT Small molecular drug
DMH7TNA PC 11615440
DMH7TNA MW 213.28
DMH7TNA FM C10H19N3O2
DMH7TNA IC InChI=1S/C10H19N3O2/c1-6(2)8(11)10(15)13-5-3-4-7(13)9(12)14/h6-8H,3-5,11H2,1-2H3,(H2,12,14)/t7-,8-/m0/s1
DMH7TNA CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N)N
DMH7TNA IK AGVCUVJROUBIKP-YUMQZZPRSA-N
DMH7TNA IU (2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carboxamide
DMH7TNA CA CAS 76362-52-2
DMH7TNA DE Discovery agent
DMQZ13A ID DMQZ13A
DMQZ13A DN L-valyl-L-proline benzylamide
DMQZ13A HS Investigative
DMQZ13A SN CHEMBL376375; L-valyl-L-proline benzylamide
DMQZ13A DT Small molecular drug
DMQZ13A PC 11645153
DMQZ13A MW 303.4
DMQZ13A FM C17H25N3O2
DMQZ13A IC InChI=1S/C17H25N3O2/c1-12(2)15(18)17(22)20-10-6-9-14(20)16(21)19-11-13-7-4-3-5-8-13/h3-5,7-8,12,14-15H,6,9-11,18H2,1-2H3,(H,19,21)/t14-,15-/m0/s1
DMQZ13A CS CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NCC2=CC=CC=C2)N
DMQZ13A IK LCASDNOITBVYIV-GJZGRUSLSA-N
DMQZ13A IU (2S)-1-[(2S)-2-amino-3-methylbutanoyl]-N-benzylpyrrolidine-2-carboxamide
DMQZ13A DE Discovery agent
DMX4DRV ID DMX4DRV
DMX4DRV DN L-valyl-L-proline hexylamide
DMX4DRV HS Investigative
DMX4DRV SN CHEMBL375490; L-valyl-L-proline hexylamide; SCHEMBL6245007
DMX4DRV DT Small molecular drug
DMX4DRV PC 11623539
DMX4DRV MW 297.44
DMX4DRV FM C16H31N3O2
DMX4DRV IC InChI=1S/C16H31N3O2/c1-4-5-6-7-10-18-15(20)13-9-8-11-19(13)16(21)14(17)12(2)3/h12-14H,4-11,17H2,1-3H3,(H,18,20)/t13-,14-/m0/s1
DMX4DRV CS CCCCCCNC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N
DMX4DRV IK BWJSLNXXZBEGLH-KBPBESRZSA-N
DMX4DRV IU (2S)-1-[(2S)-2-amino-3-methylbutanoyl]-N-hexylpyrrolidine-2-carboxamide
DMX4DRV DE Discovery agent
DMIO405 ID DMIO405
DMIO405 DN LVAYPWT
DMIO405 HS Investigative
DMIO405 SN CHEMBL395724
DMIO405 DT Small molecular drug
DMIO405 PC 25054652
DMIO405 MW 849
DMIO405 FM C43H60N8O10
DMIO405 IC InChI=1S/C43H60N8O10/c1-22(2)18-30(44)38(55)49-35(23(3)4)41(58)46-24(5)37(54)48-33(19-26-13-15-28(53)16-14-26)42(59)51-17-9-12-34(51)40(57)47-32(39(56)50-36(25(6)52)43(60)61)20-27-21-45-31-11-8-7-10-29(27)31/h7-8,10-11,13-16,21-25,30,32-36,45,52-53H,9,12,17-20,44H2,1-6H3,(H,46,58)(H,47,57)(H,48,54)(H,49,55)(H,50,56)(H,60,61)/t24-,25+,30-,32-,33-,34-,35-,36-/m0/s1
DMIO405 CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O
DMIO405 IK KBSQBKDKTBPPIE-DTSDQQARSA-N
DMIO405 IU (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DMIO405 DE Discovery agent
DM78Z9D ID DM78Z9D
DM78Z9D DN LVVAPWT
DM78Z9D HS Investigative
DM78Z9D SN CHEMBL241983
DM78Z9D DT Small molecular drug
DM78Z9D PC 25054913
DM78Z9D MW 784.9
DM78Z9D FM C39H60N8O9
DM78Z9D IC InChI=1S/C39H60N8O9/c1-19(2)16-26(40)33(49)44-31(21(5)6)37(53)45-30(20(3)4)36(52)42-22(7)38(54)47-15-11-14-29(47)35(51)43-28(34(50)46-32(23(8)48)39(55)56)17-24-18-41-27-13-10-9-12-25(24)27/h9-10,12-13,18-23,26,28-32,41,48H,11,14-17,40H2,1-8H3,(H,42,52)(H,43,51)(H,44,49)(H,45,53)(H,46,50)(H,55,56)/t22-,23+,26-,28-,29-,30-,31-,32-/m0/s1
DM78Z9D CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O
DM78Z9D IK AHEGGNDTVLEUNO-YIHGEGNXSA-N
DM78Z9D IU (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DM78Z9D DE Discovery agent
DM1QPG7 ID DM1QPG7
DM1QPG7 DN LVVYPWT
DM1QPG7 HS Investigative
DM1QPG7 SN Spinorphin; 137201-62-8; LVVYPWT; Leu-val-val-tyr-pro-trp-thr; CHEMBL395493; L-Threonine, N-(N-(1-(N-(N-(N-L-leucyl-L-valyl)-L-valyl)-L-tyrosyl)-L-prolyl)-L-tryptophyl)-; (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid; LVV-hemorphin-4; AC1MIXNC; SPINORPHIN, BOVINE
DM1QPG7 DT Small molecular drug
DM1QPG7 PC 3081832
DM1QPG7 MW 877
DM1QPG7 FM C45H64N8O10
DM1QPG7 IC InChI=1S/C45H64N8O10/c1-23(2)19-31(46)39(56)50-37(25(5)6)43(60)51-36(24(3)4)42(59)49-34(20-27-14-16-29(55)17-15-27)44(61)53-18-10-13-35(53)41(58)48-33(40(57)52-38(26(7)54)45(62)63)21-28-22-47-32-12-9-8-11-30(28)32/h8-9,11-12,14-17,22-26,31,33-38,47,54-55H,10,13,18-21,46H2,1-7H3,(H,48,58)(H,49,59)(H,50,56)(H,51,60)(H,52,57)(H,62,63)/t26-,31+,33+,34+,35+,36+,37+,38+/m1/s1
DM1QPG7 CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N)O
DM1QPG7 IK BXIFNVGZIMFBQB-DYDSHOKNSA-N
DM1QPG7 IU (2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoic acid
DM1QPG7 CA CAS 137201-62-8
DM1QPG7 DE Discovery agent
DMGSVL0 ID DMGSVL0
DMGSVL0 DN LXA4
DMGSVL0 HS Investigative
DMGSVL0 SN Lipoxin A4; lipoxin A4; 5S,6R-LipoxinA4; 89663-86-5; 5S,6R,15S-trihydroxy-7E,9E,11Z,13E-Eicosatetraenoic acid; CHEBI:6498; (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid; (7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoic acid; (5S,6R,15S)-Trihydroxy-(7E,9E,11Z,13E)-Eicosatetraenoic acid; Lipoxin A; 5,6,15-trihydroxy-7,9,11,13-eicosatetraenoic acid; 5,6,15-triHETE; 5S,6S-Lipoxin A4; AC1NQXRP; BSPBio_001378; 6R-LXA4; Lipoxin A4, ethanol solution; GTPL1034; BML1-E11; CHEMBL392438; 5,6,15-triHETE ; [3H]LXA4
DMGSVL0 DT Small molecular drug
DMGSVL0 PC 5280914
DMGSVL0 MW 352.5
DMGSVL0 FM C20H32O5
DMGSVL0 IC InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
DMGSVL0 CS CCCCC[C@@H](/C=C/C=C\\C=C\\C=C\\[C@H]([C@H](CCCC(=O)O)O)O)O
DMGSVL0 IK IXAQOQZEOGMIQS-SSQFXEBMSA-N
DMGSVL0 IU (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
DMGSVL0 CA CAS 89663-86-5
DMGSVL0 CB CHEBI:6498
DMGSVL0 DE Discovery agent
DM0LKPE ID DM0LKPE
DM0LKPE DN LXT-101
DM0LKPE HS Investigative
DM0LKPE SN DepoLXT-101; GnRH antagonist (sustained release, prostate cancer), Beijing Institute of Pharmacology and Toxicology
DM0LKPE CP Beijing Institute of Pharmacology and Toxicology
DM0LKPE PC 46174261
DM0LKPE MW 1414.1
DM0LKPE FM C70H93ClN18O12
DM0LKPE IC InChI=1S/C70H93ClN18O12/c1-40(2)32-52(61(94)83-51(20-12-30-79-70(75)76)68(101)89-31-13-21-58(89)67(100)80-41(3)59(72)92)84-64(97)56(37-46-16-10-28-77-38-46)85-60(93)50(19-11-29-78-69(73)74)82-66(99)57(39-90)88-65(98)54(34-43-14-6-5-7-15-43)87-63(96)55(35-44-23-26-49(71)27-24-44)86-62(95)53(81-42(4)91)36-45-22-25-47-17-8-9-18-48(47)33-45/h5-10,14-18,22-28,33,38,40-41,50-58,90H,11-13,19-21,29-32,34-37,39H2,1-4H3,(H2,72,92)(H,80,100)(H,81,91)(H,82,99)(H,83,94)(H,84,97)(H,85,93)(H,86,95)(H,87,96)(H,88,98)(H4,73,74,78)(H4,75,76,79)/t41-,50+,51+,52+,53-,54-,55-,56-,57+,58+/m1/s1
DM0LKPE CS C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CC=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
DM0LKPE IK CRMRBNHNJMIODJ-OIIKBFRESA-N
DM0LKPE IU (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
DM0LKPE DE Prostate cancer
DM9IU21 ID DM9IU21
DM9IU21 DN LY 165,163
DM9IU21 HS Investigative
DM9IU21 SN PAPP; LY-165163
DM9IU21 DT Small molecular drug
DM9IU21 PC 121930
DM9IU21 MW 349.4
DM9IU21 FM C19H22F3N3
DM9IU21 IC InChI=1S/C19H22F3N3/c20-19(21,22)16-2-1-3-18(14-16)25-12-10-24(11-13-25)9-8-15-4-6-17(23)7-5-15/h1-7,14H,8-13,23H2
DM9IU21 CS C1CN(CCN1CCC2=CC=C(C=C2)N)C3=CC=CC(=C3)C(F)(F)F
DM9IU21 IK GAAKALASJNGQKD-UHFFFAOYSA-N
DM9IU21 IU 4-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]aniline
DM9IU21 CA CAS 1814-64-8
DM9IU21 CB CHEBI:92250
DM9IU21 DE Discovery agent
DMNB82L ID DMNB82L
DMNB82L DN LY063518
DMNB82L HS Investigative
DMNB82L SN LY 063518; LY-063518
DMNB82L DT Small molecular drug
DMNB82L PC 56947076
DMNB82L MW 278.76
DMNB82L FM C12H11ClN4S
DMNB82L IC InChI=1S/C12H11ClN4S/c13-10-7-6-9(18-10)11(16-17-12(14)15)8-4-2-1-3-5-8/h1-7H,(H4,14,15,17)/b16-11+
DMNB82L CS C1=CC=C(C=C1)/C(=N\\N=C(N)N)/C2=CC=C(S2)Cl
DMNB82L IK LXZSGGMOFNDLPW-LFIBNONCSA-N
DMNB82L IU 2-[(E)-[(5-chlorothiophen-2-yl)-phenylmethylidene]amino]guanidine
DMNB82L DE Discovery agent
DMYNCQR ID DMYNCQR
DMYNCQR DN LY108742
DMYNCQR HS Investigative
DMYNCQR SN LY-108742; LY 108742
DMYNCQR DT Small molecular drug
DMYNCQR PC 13878027
DMYNCQR MW 356.5
DMYNCQR FM C21H28N2O3
DMYNCQR IC InChI=1S/C21H28N2O3/c1-12(24)13(2)26-21(25)15-8-17-16-6-5-7-18-20(16)14(10-22(18)3)9-19(17)23(4)11-15/h5-7,10,12-13,15,17,19,24H,8-9,11H2,1-4H3
DMYNCQR CS CC(C(C)OC(=O)C1CC2C(CC3=CN(C4=CC=CC2=C34)C)N(C1)C)O
DMYNCQR IK YLCYDARNSJPGCV-UHFFFAOYSA-N
DMYNCQR IU 3-hydroxybutan-2-yl 4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate
DMYNCQR DE Discovery agent
DMT0JXC ID DMT0JXC
DMT0JXC DN LY134046
DMT0JXC HS Investigative
DMT0JXC SN LY 134046; LY-134046
DMT0JXC DT Small molecular drug
DMT0JXC PC 121938
DMT0JXC MW 216.1
DMT0JXC FM C10H11Cl2N
DMT0JXC IC InChI=1S/C10H11Cl2N/c11-9-4-3-7-2-1-5-13-6-8(7)10(9)12/h3-4,13H,1-2,5-6H2
DMT0JXC CS C1CC2=C(CNC1)C(=C(C=C2)Cl)Cl
DMT0JXC IK IADAQXMUWITWNG-UHFFFAOYSA-N
DMT0JXC IU 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine
DMT0JXC CA CAS 71274-97-0
DMT0JXC DE Discovery agent
DMI01YM ID DMI01YM
DMI01YM DN LY178002
DMI01YM HS Investigative
DMI01YM SN LY-178002; 107889-32-7; LY 178002; AC1O5R3B; SCHEMBL3263474; 5-(3,5-Bis(tert-butyl)-4-hydroxyphenyl)methylene-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-
DMI01YM DT Small molecular drug
DMI01YM PC 6439155
DMI01YM MW 319.5
DMI01YM FM C18H25NO2S
DMI01YM IC InChI=1S/C18H25NO2S/c1-17(2,3)12-7-11(9-14-16(21)19-10-22-14)8-13(15(12)20)18(4,5)6/h7-9,20H,10H2,1-6H3,(H,19,21)/b14-9-
DMI01YM CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)NCS2
DMI01YM IK BUDGLLLMROWLOB-ZROIWOOFSA-N
DMI01YM IU (5Z)-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-1,3-thiazolidin-4-one
DMI01YM CA CAS 107889-32-7
DMI01YM DE Discovery agent
DMVHQGF ID DMVHQGF
DMVHQGF DN LY2033298
DMVHQGF HS Investigative
DMVHQGF SN LY 2033298; LY-2033298
DMVHQGF DT Small molecular drug
DMVHQGF PC 11536903
DMVHQGF MW 311.79
DMVHQGF FM C13H14ClN3O2S
DMVHQGF IC InChI=1S/C13H14ClN3O2S/c1-5-7-9(15)10(11(18)16-6-3-4-6)20-13(7)17-12(19-2)8(5)14/h6H,3-4,15H2,1-2H3,(H,16,18)
DMVHQGF CS CC1=C2C(=C(SC2=NC(=C1Cl)OC)C(=O)NC3CC3)N
DMVHQGF IK CTEGQKDJTBWFHW-UHFFFAOYSA-N
DMVHQGF IU 3-amino-5-chloro-N-cyclopropyl-6-methoxy-4-methylthieno[2,3-b]pyridine-2-carboxamide
DMVHQGF CA CAS 886047-13-8
DMVHQGF DE Discovery agent
DMIS82X ID DMIS82X
DMIS82X DN LY2087101
DMIS82X HS Investigative
DMIS82X SN LY 2087101; LY-2087101
DMIS82X DT Small molecular drug
DMIS82X PC 11964458
DMIS82X MW 318.4
DMIS82X FM C15H11FN2OS2
DMIS82X IC InChI=1S/C15H11FN2OS2/c1-9-14(13(19)10-6-7-20-8-10)21-15(17-9)18-12-4-2-11(16)3-5-12/h2-8H,1H3,(H,17,18)
DMIS82X CS CC1=C(SC(=N1)NC2=CC=C(C=C2)F)C(=O)C3=CSC=C3
DMIS82X IK PEAMDZVDNYENPN-UHFFFAOYSA-N
DMIS82X IU [2-(4-fluoroanilino)-4-methyl-1,3-thiazol-5-yl]-thiophen-3-ylmethanone
DMIS82X CA CAS 913186-74-0
DMIS82X DE Discovery agent
DMAWTG3 ID DMAWTG3
DMAWTG3 DN LY2109761
DMAWTG3 HS Investigative
DMAWTG3 SN LY-2109761; LY 2109761
DMAWTG3 DT Small molecular drug
DMAWTG3 PC 11655119
DMAWTG3 MW 441.5
DMAWTG3 FM C26H27N5O2
DMAWTG3 IC InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2
DMAWTG3 CS C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6
DMAWTG3 IK IHLVSLOZUHKNMQ-UHFFFAOYSA-N
DMAWTG3 IU 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine
DMAWTG3 CA CAS 700874-71-1
DMAWTG3 DE Discovery agent
DM4IELQ ID DM4IELQ
DM4IELQ DN LY2119620
DM4IELQ HS Investigative
DM4IELQ SN LY 2119620; LY-2119620
DM4IELQ DT Small molecular drug
DM4IELQ PC 57664406
DM4IELQ MW 437.9
DM4IELQ FM C19H24ClN5O3S
DM4IELQ IC InChI=1S/C19H24ClN5O3S/c1-10-13-15(21)16(17(27)22-11-3-4-11)29-19(13)23-18(14(10)20)28-9-12(26)25-7-5-24(2)6-8-25/h11H,3-9,21H2,1-2H3,(H,22,27)
DM4IELQ CS CC1=C2C(=C(SC2=NC(=C1Cl)OCC(=O)N3CCN(CC3)C)C(=O)NC4CC4)N
DM4IELQ IK TYTGOXSAAQWLPJ-UHFFFAOYSA-N
DM4IELQ IU 3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]thieno[2,3-b]pyridine-2-carboxamide
DM4IELQ DE Discovery agent
DMKZJVA ID DMKZJVA
DMKZJVA DN LY214352
DMKZJVA HS Investigative
DMKZJVA SN 8-Chloro-4-(2-chloro-4-fluorophenoxy)quinoline; 124495-31-4; Quinoline,8-chloro-4-(2-chloro-4-fluorophenoxy)-; LY214352; AC1L2WYE; ACMC-1C12P; SCHEMBL7044612; CTK4B3930; DTXSID10154407; ZXLMSTBJMZJAAH-UHFFFAOYSA-N; LY-214352; 8-chloro-4-(2-chloro-4-fluorophenoxy) quinoline
DMKZJVA DT Small molecular drug
DMKZJVA PC 130197
DMKZJVA MW 308.1
DMKZJVA FM C15H8Cl2FNO
DMKZJVA IC InChI=1S/C15H8Cl2FNO/c16-11-3-1-2-10-13(6-7-19-15(10)11)20-14-5-4-9(18)8-12(14)17/h1-8H
DMKZJVA CS C1=CC2=C(C=CN=C2C(=C1)Cl)OC3=C(C=C(C=C3)F)Cl
DMKZJVA IK ZXLMSTBJMZJAAH-UHFFFAOYSA-N
DMKZJVA IU 8-chloro-4-(2-chloro-4-fluorophenoxy)quinoline
DMKZJVA CA CAS 124495-31-4
DMKZJVA DE Discovery agent
DM5RG7J ID DM5RG7J
DM5RG7J DN LY215840
DM5RG7J HS Investigative
DM5RG7J SN LY 215840; LY-215840; LY-215,840
DM5RG7J DT Small molecular drug
DM5RG7J PC 132049
DM5RG7J MW 395.5
DM5RG7J FM C24H33N3O2
DM5RG7J IC InChI=1S/C24H33N3O2/c1-14(2)27-13-15-11-21-18(17-6-4-8-20(27)23(15)17)10-16(12-26(21)3)24(29)25-19-7-5-9-22(19)28/h4,6,8,13-14,16,18-19,21-22,28H,5,7,9-12H2,1-3H3,(H,25,29)/t16-,18?,19+,21-,22-/m1/s1
DM5RG7J CS CC(C)N1C=C2C[C@@H]3C(C[C@H](CN3C)C(=O)N[C@H]4CCC[C@H]4O)C5=C2C1=CC=C5
DM5RG7J IK IMSDOBUYDTVEHN-LUKLFJNJSA-N
DM5RG7J IU (6aR,9R)-N-[(1S,2R)-2-hydroxycyclopentyl]-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
DM5RG7J CA CAS 137328-52-0
DM5RG7J DE Discovery agent
DM8SU6N ID DM8SU6N
DM8SU6N DN LY-2183240
DM8SU6N HS Investigative
DM8SU6N SN LY2183240; 874902-19-9; LY 2183240; UNII-2WBU91OKM7; 2WBU91OKM7; CHEMBL509860; LY-2183240; 5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide; LY2183240/LY-2183240; 1H-Tetrazole-1-carboxamide, 5-([1,1'-biphenyl]-4-ylmethyl)-N,N-dimethyl-; 1H-Tetrazole-1-carboxamide, 5-((1,1'-biphenyl)-4-ylmethyl)-N,N-dimethyl-; SCHEMBL2184828; CTK8E8366; CHEBI:92670; KS-00001CUG; BDBM26736; AOB2582; MolPort-023-219-146; HMS3269E15; BCP22610; ZINC13813297; MFCD08703123; 3796AH; AKOS024457108; CS-0913; BCP9000870; LP01268; NCGC00159571-01
DM8SU6N DT Small molecular drug
DM8SU6N PC 11507802
DM8SU6N MW 307.35
DM8SU6N FM C17H17N5O
DM8SU6N IC InChI=1S/C17H17N5O/c1-21(2)17(23)22-16(18-19-20-22)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
DM8SU6N CS CN(C)C(=O)N1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
DM8SU6N IK GZNIYOXWFCDBBJ-UHFFFAOYSA-N
DM8SU6N IU N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide
DM8SU6N CA CAS 874902-19-9
DM8SU6N CB CHEBI:92670
DM8SU6N DE Discovery agent
DM5VWCI ID DM5VWCI
DM5VWCI DN Ly231514 Tetra Glu
DM5VWCI HS Investigative
DM5VWCI DT Small molecular drug
DM5VWCI PC 135678105
DM5VWCI MW 814.8
DM5VWCI FM C35H42N8O15
DM5VWCI IC InChI=1S/C35H42N8O15/c36-35-42-28-27(30(50)43-35)18(15-37-28)6-3-16-1-4-17(5-2-16)29(49)41-22(34(57)58)9-13-25(46)39-20(32(53)54)7-11-23(44)38-19(31(51)52)8-12-24(45)40-21(33(55)56)10-14-26(47)48/h1-2,4-5,15,19-22H,3,6-14H2,(H,38,44)(H,39,46)(H,40,45)(H,41,49)(H,47,48)(H,51,52)(H,53,54)(H,55,56)(H,57,58)(H4,36,37,42,43,50)/t19-,20-,21?,22-/m0/s1
DM5VWCI CS C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O
DM5VWCI IK DICHBVJYDUDAIQ-QEGIFBSNSA-N
DM5VWCI IU 2-[[(4S)-4-[[(4S)-4-[[(4S)-4-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
DM5VWCI DE Discovery agent
DMPV6N9 ID DMPV6N9
DMPV6N9 DN LY-2318912
DMPV6N9 HS Investigative
DMPV6N9 SN CHEMBL486037; LY-2318912; BDBM50242639
DMPV6N9 DT Small molecular drug
DMPV6N9 PC 44560315
DMPV6N9 MW 441.19
DMPV6N9 FM C12H12IN9O2
DMPV6N9 IC InChI=1S/C12H12IN9O2/c1-21(2)12(24)22-10(17-19-20-22)6-15-11(23)7-3-4-9(16-18-14)8(13)5-7/h3-5H,6H2,1-2H3,(H,15,23)
DMPV6N9 CS CN(C)C(=O)N1C(=NN=N1)CNC(=O)C2=CC(=C(C=C2)N=[N+]=[N-])I
DMPV6N9 IK QJNXEOBTVAWQME-UHFFFAOYSA-N
DMPV6N9 IU 5-[[(4-azido-3-iodobenzoyl)amino]methyl]-N,N-dimethyltetrazole-1-carboxamide
DMPV6N9 DE Discovery agent
DMC82DA ID DMC82DA
DMC82DA DN LY233053
DMC82DA HS Investigative
DMC82DA SN LY-233053; LY 233053
DMC82DA DT Small molecular drug
DMC82DA PC 3035974
DMC82DA MW 211.22
DMC82DA FM C8H13N5O2
DMC82DA IC InChI=1S/C8H13N5O2/c14-8(15)6-3-5(1-2-9-6)4-7-10-12-13-11-7/h5-6,9H,1-4H2,(H,14,15)(H,10,11,12,13)/t5-,6+/m0/s1
DMC82DA CS C1CN[C@H](C[C@H]1CC2=NNN=N2)C(=O)O
DMC82DA IK FAAVTENFCLADRE-NTSWFWBYSA-N
DMC82DA IU (2R,4S)-4-(2H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid
DMC82DA CA CAS 125546-04-5
DMC82DA DE Discovery agent
DMBFLOJ ID DMBFLOJ
DMBFLOJ DN LY2365109
DMBFLOJ HS Investigative
DMBFLOJ SN LY-2365109; LY 2365109
DMBFLOJ DT Small molecular drug
DMBFLOJ PC 11552757
DMBFLOJ MW 385.5
DMBFLOJ FM C22H27NO5
DMBFLOJ IC InChI=1S/C22H27NO5/c1-22(2,3)17-11-15(16-6-8-19-20(12-16)28-14-27-19)5-7-18(17)26-10-9-23(4)13-21(24)25/h5-8,11-12H,9-10,13-14H2,1-4H3,(H,24,25)
DMBFLOJ CS CC(C)(C)C1=C(C=CC(=C1)C2=CC3=C(C=C2)OCO3)OCCN(C)CC(=O)O
DMBFLOJ IK FKPLJWGRBCQLTL-UHFFFAOYSA-N
DMBFLOJ IU 2-[2-[4-(1,3-benzodioxol-5-yl)-2-tert-butylphenoxy]ethyl-methylamino]acetic acid
DMBFLOJ DE Discovery agent
DM1KCHN ID DM1KCHN
DM1KCHN DN LY256548
DM1KCHN HS Investigative
DM1KCHN SN LY-256548; 107889-31-6; LY 25648; SCHEMBL8532777; AC1O5R38; AKOS030552230; 5-(3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene-N-methyl-4-thiazolidinone; 4-Thiazolidinone, 5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methylene)-3-methyl-
DM1KCHN DT Small molecular drug
DM1KCHN PC 6439154
DM1KCHN MW 333.5
DM1KCHN FM C19H27NO2S
DM1KCHN IC InChI=1S/C19H27NO2S/c1-18(2,3)13-8-12(9-14(16(13)21)19(4,5)6)10-15-17(22)20(7)11-23-15/h8-10,21H,11H2,1-7H3/b15-10-
DM1KCHN CS CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)/C=C\\2/C(=O)N(CS2)C
DM1KCHN IK IXCMEASJCGKKQS-GDNBJRDFSA-N
DM1KCHN IU (5Z)-5-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]-3-methyl-1,3-thiazolidin-4-one
DM1KCHN CA CAS 107889-31-6
DM1KCHN DE Discovery agent
DMX5H3T ID DMX5H3T
DMX5H3T DN LY-266111
DMX5H3T HS Investigative
DMX5H3T SN CHEMBL29166; LY-266111; SCHEMBL7796296; KTBSRSVHEOTHLD-UKRRQHHQSA-N; BDBM50044879; (4aR,10bR)-8-Chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydro-2H-benzo[f]quinolin-3-one; 8-Chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydro-2H-benzo[f]quinolin-3-one; (R)(+)-trans-4-methyl-8-chloro-10b-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one
DMX5H3T DT Small molecular drug
DMX5H3T PC 10106832
DMX5H3T MW 263.76
DMX5H3T FM C15H18ClNO
DMX5H3T IC InChI=1S/C15H18ClNO/c1-15-8-7-14(18)17(2)13(15)6-3-10-9-11(16)4-5-12(10)15/h4-5,9,13H,3,6-8H2,1-2H3/t13-,15-/m1/s1
DMX5H3T CS C[C@]12CCC(=O)N([C@@H]1CCC3=C2C=CC(=C3)Cl)C
DMX5H3T IK KTBSRSVHEOTHLD-UKRRQHHQSA-N
DMX5H3T IU (4aR,10bR)-8-chloro-4,10b-dimethyl-2,4a,5,6-tetrahydro-1H-benzo[f]quinolin-3-one
DMX5H3T DE Discovery agent
DMHC853 ID DMHC853
DMHC853 DN LY266500
DMHC853 HS Investigative
DMHC853 SN CHEMBL510900; AC1LDAWE; 2-(3-Chloro-4-fluorophenyl)-3(2H)-isothiazolone; SCHEMBL4700504; OOOJWRSQJXGEDS-UHFFFAOYSA-N; MolPort-002-906-771; ZINC12367067; BDBM50247868; AKOS022310026; MCULE-1464379671; 2-(3-chloro-4-fluorophenyl)-1,2-thiazol-3-one; 2-(3-Chloro-4-fluorophenyl)isothiazole-3(2H)-one
DMHC853 DT Small molecular drug
DMHC853 PC 615184
DMHC853 MW 229.66
DMHC853 FM C9H5ClFNOS
DMHC853 IC InChI=1S/C9H5ClFNOS/c10-7-5-6(1-2-8(7)11)12-9(13)3-4-14-12/h1-5H
DMHC853 CS C1=CC(=C(C=C1N2C(=O)C=CS2)Cl)F
DMHC853 IK OOOJWRSQJXGEDS-UHFFFAOYSA-N
DMHC853 IU 2-(3-chloro-4-fluorophenyl)-1,2-thiazol-3-one
DMHC853 DE Discovery agent
DMBSFDE ID DMBSFDE
DMBSFDE DN LY-282210
DMBSFDE HS Investigative
DMBSFDE SN CHEMBL88337; LY-282210; BDBM50029482; L009647; 6-[3-(4-Acetyl-2-ethyl-5-hydroxy-phenoxy)-propoxy]-5-(2-carboxy-ethyl)-9-oxo-9H-xanthene-2-carboxylic acid
DMBSFDE DT Small molecular drug
DMBSFDE PC 9893718
DMBSFDE MW 548.5
DMBSFDE FM C30H28O10
DMBSFDE IC InChI=1S/C30H28O10/c1-3-17-13-21(16(2)31)23(32)15-26(17)39-12-4-11-38-24-9-6-20-28(35)22-14-18(30(36)37)5-8-25(22)40-29(20)19(24)7-10-27(33)34/h5-6,8-9,13-15,32H,3-4,7,10-12H2,1-2H3,(H,33,34)(H,36,37)
DMBSFDE CS CCC1=CC(=C(C=C1OCCCOC2=C(C3=C(C=C2)C(=O)C4=C(O3)C=CC(=C4)C(=O)O)CCC(=O)O)O)C(=O)C
DMBSFDE IK HGMXXGVRUCAMMK-UHFFFAOYSA-N
DMBSFDE IU 6-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-5-(2-carboxyethyl)-9-oxoxanthene-2-carboxylic acid
DMBSFDE DE Discovery agent
DML36ZE ID DML36ZE
DML36ZE DN LY-292223
DML36ZE HS Investigative
DML36ZE SN 2-(4-Morpholinyl)-4H-1-benzopyran-4-one; 2-morpholinochromone; LY-292223; CHEMBL367315; 2-morpholino-4H-chromen-4-one; 130735-56-7; U67154; AC1L2YUR; U-67154; SCHEMBL3361567; 2-morpholin-4-ylchromen-4-one; DTXSID30156701; 2-Morpholin-4-yl-chromen-4-one; QNFWERYZJLBANZ-UHFFFAOYSA-N; BDBM50098118; 2-(4-Morpholinyl)-4H-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-
DML36ZE DT Small molecular drug
DML36ZE PC 131255
DML36ZE MW 231.25
DML36ZE FM C13H13NO3
DML36ZE IC InChI=1S/C13H13NO3/c15-11-9-13(14-5-7-16-8-6-14)17-12-4-2-1-3-10(11)12/h1-4,9H,5-8H2
DML36ZE CS C1COCCN1C2=CC(=O)C3=CC=CC=C3O2
DML36ZE IK QNFWERYZJLBANZ-UHFFFAOYSA-N
DML36ZE IU 2-morpholin-4-ylchromen-4-one
DML36ZE CA CAS 130735-56-7
DML36ZE DE Discovery agent
DM2HQ9O ID DM2HQ9O
DM2HQ9O DN LY301875
DM2HQ9O HS Investigative
DM2HQ9O SN LY-301875; LY 301875
DM2HQ9O DT Small molecular drug
DM2HQ9O PC 73755246
DM2HQ9O MW 642.7
DM2HQ9O FM C30H34N4O10S
DM2HQ9O IC InChI=1S/C30H34N4O10S/c1-2-3-4-5-9-23(33-17-26(31-18-33)32-27(35)22-8-6-7-10-25(22)45(41,42)43)28(36)34-16-21(15-24(34)30(39)40)44-20-13-11-19(12-14-20)29(37)38/h6-8,10-14,17-18,21,23-24H,2-5,9,15-16H2,1H3,(H,32,35)(H,37,38)(H,39,40)(H,41,42,43)/t21-,23-,24-/m0/s1
DM2HQ9O CS CCCCCC[C@@H](C(=O)N1C[C@H](C[C@H]1C(=O)O)OC2=CC=C(C=C2)C(=O)O)N3C=C(N=C3)NC(=O)C4=CC=CC=C4S(=O)(=O)O
DM2HQ9O IK HHFYOGBTLFTWQX-XWGVYQGASA-N
DM2HQ9O IU (2S,4S)-4-(4-carboxyphenoxy)-1-[(2S)-2-[4-[(2-sulfobenzoyl)amino]imidazol-1-yl]octanoyl]pyrrolidine-2-carboxylic acid
DM2HQ9O DE Discovery agent
DMY9WTE ID DMY9WTE
DMY9WTE DN LY303336
DMY9WTE HS Investigative
DMY9WTE SN LY 303336; LY-303336
DMY9WTE DT Small molecular drug
DMY9WTE PC 10416728
DMY9WTE MW 642.7
DMY9WTE FM C30H34N4O10S
DMY9WTE IC InChI=1S/C30H34N4O10S/c1-2-3-4-5-9-23(33-17-26(31-18-33)32-27(35)22-8-6-7-10-25(22)45(41,42)43)28(36)34-16-21(15-24(34)30(39)40)44-20-13-11-19(12-14-20)29(37)38/h6-8,10-14,17-18,21,23-24H,2-5,9,15-16H2,1H3,(H,32,35)(H,37,38)(H,39,40)(H,41,42,43)/t21-,23+,24-/m0/s1
DMY9WTE CS CCCCCC[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)O)OC2=CC=C(C=C2)C(=O)O)N3C=C(N=C3)NC(=O)C4=CC=CC=C4S(=O)(=O)O
DMY9WTE IK HHFYOGBTLFTWQX-QTJGBDASSA-N
DMY9WTE IU (2S,4S)-4-(4-carboxyphenoxy)-1-[(2R)-2-[4-[(2-sulfobenzoyl)amino]imidazol-1-yl]octanoyl]pyrrolidine-2-carboxylic acid
DMY9WTE DE Discovery agent
DMWAHYX ID DMWAHYX
DMWAHYX DN LY314228
DMWAHYX HS Investigative
DMWAHYX SN LY 314228; LY-314228
DMWAHYX DT Small molecular drug
DMWAHYX PC 56947077
DMWAHYX MW 368.4
DMWAHYX FM C20H24N4O3
DMWAHYX IC InChI=1S/C20H24N4O3/c1-3-4-18-15(7-10-17(13(2)25)19(18)26)12-27-16-8-5-14(6-9-16)11-23-24-20(21)22/h5-11,26H,3-4,12H2,1-2H3,(H4,21,22,24)/b23-11-
DMWAHYX CS CCCC1=C(C=CC(=C1O)C(=O)C)COC2=CC=C(C=C2)/C=N\\N=C(N)N
DMWAHYX IK TUXHQPAMNGTVLT-KSEXSDGBSA-N
DMWAHYX IU 2-[(Z)-[4-[(4-acetyl-3-hydroxy-2-propylphenyl)methoxy]phenyl]methylideneamino]guanidine
DMWAHYX DE Discovery agent
DMD2J97 ID DMD2J97
DMD2J97 DN LY-314657
DMD2J97 HS Investigative
DMD2J97 DE Discovery agent
DMK3Y5U ID DMK3Y5U
DMK3Y5U DN LY320135
DMK3Y5U HS Investigative
DMK3Y5U SN LY 320135; LY-320135
DMK3Y5U DT Small molecular drug
DMK3Y5U PC 5311257
DMK3Y5U MW 383.4
DMK3Y5U FM C24H17NO4
DMK3Y5U IC InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3
DMK3Y5U CS COC1=CC=C(C=C1)C2=C(C3=C(O2)C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)C#N
DMK3Y5U IK RYNSGDFWBJWWSZ-UHFFFAOYSA-N
DMK3Y5U IU 4-[6-methoxy-2-(4-methoxyphenyl)-1-benzofuran-3-carbonyl]benzonitrile
DMK3Y5U CA CAS 176977-56-3
DMK3Y5U CB CHEBI:93387
DMK3Y5U DE Discovery agent
DM3DOI7 ID DM3DOI7
DM3DOI7 DN LY320954
DM3DOI7 HS Investigative
DM3DOI7 SN PDSP2_001613; PDSP1_001629; LY-320954
DM3DOI7 DT Small molecular drug
DM3DOI7 PC 56947078
DM3DOI7 MW 382.5
DM3DOI7 FM C21H26N4O3
DM3DOI7 IC InChI=1S/C21H26N4O3/c1-3-5-17-15(8-11-18(20(17)27)19(26)4-2)13-28-16-9-6-14(7-10-16)12-24-25-21(22)23/h6-12,27H,3-5,13H2,1-2H3,(H4,22,23,25)/b24-12-
DM3DOI7 CS CCCC1=C(C=CC(=C1O)C(=O)CC)COC2=CC=C(C=C2)/C=N\\N=C(N)N
DM3DOI7 IK TUJFUBGJRSXFHG-MSXFZWOLSA-N
DM3DOI7 IU 2-[(Z)-[4-[(3-hydroxy-4-propanoyl-2-propylphenyl)methoxy]phenyl]methylideneamino]guanidine
DM3DOI7 DE Discovery agent
DMN53M4 ID DMN53M4
DMN53M4 DN LY-326449
DMN53M4 HS Investigative
DMN53M4 SN LY-326449; CHEMBL292495; BDBM50052039; 3,4-[[(S)-3-Oxa-4-(hydroxymethyl)hexane-1,6-diyl]bis(1H-indole-1,3-diyl)]-3-pyrroline-2,5-dione
DMN53M4 DT Small molecular drug
DMN53M4 PC 10455969
DMN53M4 MW 441.5
DMN53M4 FM C26H23N3O4
DMN53M4 IC InChI=1S/C26H23N3O4/c30-15-16-9-10-28-13-19(17-5-1-3-7-21(17)28)23-24(26(32)27-25(23)31)20-14-29(11-12-33-16)22-8-4-2-6-18(20)22/h1-8,13-14,16,30H,9-12,15H2,(H,27,31,32)/t16-/m0/s1
DMN53M4 CS C1CN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO[C@@H]1CO)C6=CC=CC=C65)C(=O)NC4=O
DMN53M4 IK BGVKOUSMQGMSDY-INIZCTEOSA-N
DMN53M4 IU (18S)-18-(hydroxymethyl)-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
DMN53M4 DE Discovery agent
DMFHT3U ID DMFHT3U
DMFHT3U DN LY334362
DMFHT3U HS Investigative
DMFHT3U SN LY-334362; LY 334362
DMFHT3U DT Small molecular drug
DMFHT3U PC 56947079
DMFHT3U MW 372.4
DMFHT3U FM C22H20N4O2
DMFHT3U IC InChI=1S/C22H20N4O2/c23-22(24)26-25-14-17-5-4-8-20(13-17)28-15-16-9-11-19(12-10-16)21(27)18-6-2-1-3-7-18/h1-14H,15H2,(H4,23,24,26)/b25-14-
DMFHT3U CS C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)COC3=CC=CC(=C3)/C=N\\N=C(N)N
DMFHT3U IK ROCDIHAUKUGXMY-QFEZKATASA-N
DMFHT3U IU 2-[(Z)-[3-[(4-benzoylphenyl)methoxy]phenyl]methylideneamino]guanidine
DMFHT3U DE Discovery agent
DMUXFZQ ID DMUXFZQ
DMUXFZQ DN LY-3390334
DMUXFZQ HS Investigative
DMUXFZQ SN 206444-72-6; LY-339840; LY-367366; LY-393053
DMUXFZQ DE Discovery agent
DM8S7AO ID DM8S7AO
DM8S7AO DN LY339434
DM8S7AO HS Investigative
DM8S7AO SN LY-339434; LY 339434
DM8S7AO DT Small molecular drug
DM8S7AO PC 69636646
DM8S7AO MW 313.3
DM8S7AO FM C18H19NO4
DM8S7AO IC InChI=1S/C18H19NO4/c19-16(18(22)23)11-15(17(20)21)7-3-4-12-8-9-13-5-1-2-6-14(13)10-12/h1-6,8-10,15-16H,7,11,19H2,(H,20,21)(H,22,23)/b4-3+
DM8S7AO CS C1=CC=C2C=C(C=CC2=C1)/C=C/CC(CC(C(=O)O)N)C(=O)O
DM8S7AO IK KNAYYBRIBNEIAL-ONEGZZNKSA-N
DM8S7AO IU 2-amino-4-[(E)-3-naphthalen-2-ylprop-2-enyl]pentanedioic acid
DM8S7AO DE Discovery agent
DMS7KW8 ID DMS7KW8
DMS7KW8 DN LY341770
DMS7KW8 HS Investigative
DMS7KW8 DT Small molecular drug
DMS7KW8 PC 135488887
DMS7KW8 MW 451.4
DMS7KW8 FM C20H21N9O4
DMS7KW8 IC InChI=1S/C20H21N9O4/c21-20-24-16-15(18(31)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(30)23-13(19(32)33)7-8-14-26-28-29-27-14/h1-2,4-5,9,13H,3,6-8H2,(H,23,30)(H,32,33)(H,26,27,28,29)(H4,21,22,24,25,31)/t13-/m0/s1
DMS7KW8 CS C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC4=NNN=N4)C(=O)O
DMS7KW8 IK MXAFDBCLWLMXSI-ZDUSSCGKSA-N
DMS7KW8 IU (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]-4-(2H-tetrazol-5-yl)butanoic acid
DMS7KW8 DE Discovery agent
DM8LSQP ID DM8LSQP
DM8LSQP DN LY344864
DM8LSQP HS Investigative
DM8LSQP SN LY 344864 racemate; LY344864; LY-344864; GTPL21; LY344864 racemate HCl; SCHEMBL7665368; CHEMBL3186179; BDBM85195; GKWHICIUSVVNGX-UHFFFAOYSA-N; BCP23551; PDSP2_001556; PDSP1_001572; HY-13788C; NSC_5311097; CAS_5311097; NCGC00167736-01; 186543-64-6; CS-0022633; L000365; N-(6-dimethylamino-6,7,8,9-tetrahydro-5H-carbazol-3-yl)-4-fluorobenzamide
DM8LSQP DT Small molecular drug
DM8LSQP PC 18971832
DM8LSQP MW 351.4
DM8LSQP FM C21H22FN3O
DM8LSQP IC InChI=1S/C21H22FN3O/c1-25(2)16-8-10-20-18(12-16)17-11-15(7-9-19(17)24-20)23-21(26)13-3-5-14(22)6-4-13/h3-7,9,11,16,24H,8,10,12H2,1-2H3,(H,23,26)
DM8LSQP CS CN(C)C1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F
DM8LSQP IK GKWHICIUSVVNGX-UHFFFAOYSA-N
DM8LSQP IU N-[6-(dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide
DM8LSQP DE Discovery agent
DMME40U ID DMME40U
DMME40U DN LY-379268
DMME40U HS Investigative
DMME40U SN LY 379268; LY-379268; CHEMBL275079; LY379268; 191471-52-0; SCHEMBL2454646; GTPL1394; (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid; CTK8F0567; DTXSID90436637; ZINC3952369; BDBM50074749; FCH888149; AKOS006306876; API0003234; NCGC00159572-01; LS-98795; RT-013615; LY-379,268; B7061; J-012378; 4-Amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid; (1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid; (1R,4R,5S,6R)-4-Amino-2-oxa-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMME40U DT Small molecular drug
DMME40U PC 10197984
DMME40U MW 187.15
DMME40U FM C7H9NO5
DMME40U IC InChI=1S/C7H9NO5/c8-7(6(11)12)1-13-4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
DMME40U CS C1[C@]([C@@H]2[C@H]([C@@H]2O1)C(=O)O)(C(=O)O)N
DMME40U IK YASVRZWVUGJELU-MDASVERJSA-N
DMME40U IU (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DMME40U CA CAS 191471-52-0
DMME40U DE Discovery agent
DMWKYFO ID DMWKYFO
DMWKYFO DN LY382884
DMWKYFO HS Investigative
DMWKYFO SN LY-382884; LY 382884
DMWKYFO DT Small molecular drug
DMWKYFO PC 656723
DMWKYFO MW 317.4
DMWKYFO FM C18H23NO4
DMWKYFO IC InChI=1S/C18H23NO4/c20-17(21)13-4-1-11(2-5-13)7-12-3-6-14-10-19-16(18(22)23)9-15(14)8-12/h1-2,4-5,12,14-16,19H,3,6-10H2,(H,20,21)(H,22,23)/t12-,14+,15-,16+/m1/s1
DMWKYFO CS C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CC3=CC=C(C=C3)C(=O)O)C(=O)O
DMWKYFO IK YVMADKYPKNLVGU-BVUBDWEXSA-N
DMWKYFO IU (3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DMWKYFO CA CAS 211566-75-5
DMWKYFO CB CHEBI:34808
DMWKYFO DE Discovery agent
DM6Y2XG ID DM6Y2XG
DM6Y2XG DN LY-389795
DM6Y2XG HS Investigative
DM6Y2XG SN CHEMBL88999; LY389795; LY-389795; GTPL3349; BDBM50089897; LY 389795; (4S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid; 4-Amino-2-thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid(LY389795)
DM6Y2XG DT Small molecular drug
DM6Y2XG PC 10058694
DM6Y2XG MW 203.22
DM6Y2XG FM C7H9NO4S
DM6Y2XG IC InChI=1S/C7H9NO4S/c8-7(6(11)12)1-13-4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3?,4?,7+/m1/s1
DM6Y2XG CS C1[C@](C2[C@H](C2S1)C(=O)O)(C(=O)O)N
DM6Y2XG IK QBHIOYZCUZBIEN-RSWQVWFLSA-N
DM6Y2XG IU (4S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
DM6Y2XG CA CAS 222529-89-7
DM6Y2XG DE Discovery agent
DM1KW0L ID DM1KW0L
DM1KW0L DN LY-392098
DM1KW0L HS Investigative
DM1KW0L SN AMPA modulators, Eli Lilly; LY-404187; LY-4516146; LY-451616; LY-451646; LY-503430; PF-4775874
DM1KW0L CP Eli Lilly & Co
DM1KW0L DT Small molecular drug
DM1KW0L PC 9873570
DM1KW0L MW 323.5
DM1KW0L FM C16H21NO2S2
DM1KW0L IC InChI=1S/C16H21NO2S2/c1-12(2)21(18,19)17-10-13(3)14-4-6-15(7-5-14)16-8-9-20-11-16/h4-9,11-13,17H,10H2,1-3H3
DM1KW0L CS CC(C)S(=O)(=O)NCC(C)C1=CC=C(C=C1)C2=CSC=C2
DM1KW0L IK QFAUPDBCVKBKSH-UHFFFAOYSA-N
DM1KW0L IU N-[2-(4-thiophen-3-ylphenyl)propyl]propane-2-sulfonamide
DM1KW0L CA CAS 211311-66-9
DM1KW0L DE Cognitive impairment
DMHQ0T2 ID DMHQ0T2
DMHQ0T2 DN LY433221
DMHQ0T2 HS Investigative
DMHQ0T2 CP Lilly
DMHQ0T2 TC Psychiatric
DMHQ0T2 DE Depression
DMP8OXG ID DMP8OXG
DMP8OXG DN LY433222
DMP8OXG HS Investigative
DMP8OXG CP Lilly
DMP8OXG TC Psychiatric
DMP8OXG DE Depression
DM86Y1V ID DM86Y1V
DM86Y1V DN LY456066
DM86Y1V HS Investigative
DM86Y1V SN LY-456066; LY 456066
DM86Y1V DT Small molecular drug
DM86Y1V PC 9840951
DM86Y1V MW 341.5
DM86Y1V FM C19H23N3OS
DM86Y1V IC InChI=1S/C19H23N3OS/c23-9-10-24-19-21-17-8-4-3-7-16(17)18(22-19)20-15-11-13-5-1-2-6-14(13)12-15/h1-2,5-6,15,23H,3-4,7-12H2,(H,20,21,22)
DM86Y1V CS C1CCC2=C(C1)C(=NC(=N2)SCCO)NC3CC4=CC=CC=C4C3
DM86Y1V IK VZJHTQZXSTXJNO-UHFFFAOYSA-N
DM86Y1V IU 2-[[4-(2,3-dihydro-1H-inden-2-ylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]sulfanyl]ethanol
DM86Y1V DE Discovery agent
DMROFX8 ID DMROFX8
DMROFX8 DN LY456236
DMROFX8 HS Investigative
DMROFX8 SN LY-456236; LY 456236
DMROFX8 DT Small molecular drug
DMROFX8 PC 9926999
DMROFX8 MW 281.31
DMROFX8 FM C16H15N3O2
DMROFX8 IC InChI=1S/C16H15N3O2/c1-20-12-5-3-11(4-6-12)19-16-14-9-13(21-2)7-8-15(14)17-10-18-16/h3-10H,1-2H3,(H,17,18,19)
DMROFX8 CS COC1=CC=C(C=C1)NC2=NC=NC3=C2C=C(C=C3)OC
DMROFX8 IK XPJOMFBGKIABQW-UHFFFAOYSA-N
DMROFX8 IU 6-methoxy-N-(4-methoxyphenyl)quinazolin-4-amine
DMROFX8 CB CHEBI:93528
DMROFX8 DE Discovery agent
DMK64AZ ID DMK64AZ
DMK64AZ DN LY-465608
DMK64AZ HS Investigative
DMK64AZ SN LY465608; LY 465608
DMK64AZ DT Small molecular drug
DMK64AZ PC 9890319
DMK64AZ MW 457.5
DMK64AZ FM C28H27NO5
DMK64AZ IC InChI=1S/C28H27NO5/c1-19-25(17-18-32-23-13-15-24(16-14-23)34-28(2,3)27(30)31)29-26(33-19)22-11-9-21(10-12-22)20-7-5-4-6-8-20/h4-16H,17-18H2,1-3H3,(H,30,31)
DMK64AZ CS CC1=C(N=C(O1)C2=CC=C(C=C2)C3=CC=CC=C3)CCOC4=CC=C(C=C4)OC(C)(C)C(=O)O
DMK64AZ IK JDJHTJNBMZSSLK-UHFFFAOYSA-N
DMK64AZ IU 2-methyl-2-[4-[2-[5-methyl-2-(4-phenylphenyl)-1,3-oxazol-4-yl]ethoxy]phenoxy]propanoic acid
DMK64AZ DE Discovery agent
DM97NBO ID DM97NBO
DM97NBO DN LY466195
DM97NBO HS Investigative
DM97NBO SN LY-466195; LY 466195
DM97NBO DT Small molecular drug
DM97NBO PC 9935648
DM97NBO MW 346.37
DM97NBO FM C16H24F2N2O4
DM97NBO IC InChI=1S/C16H24F2N2O4/c17-16(18)5-13(15(23)24)20(8-16)7-9-1-2-10-6-19-12(14(21)22)4-11(10)3-9/h9-13,19H,1-8H2,(H,21,22)(H,23,24)/t9-,10-,11+,12-,13-/m0/s1
DM97NBO CS C1C[C@H]2CN[C@@H](C[C@H]2C[C@H]1CN3CC(C[C@H]3C(=O)O)(F)F)C(=O)O
DM97NBO IK OXQXJYQSWZFDBB-WJTVCTBASA-N
DM97NBO IU (3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoropyrrolidin-1-yl]methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
DM97NBO CA CAS 317844-33-0
DM97NBO DE Discovery agent
DMQVF41 ID DMQVF41
DMQVF41 DN LY-593039
DMQVF41 HS Investigative
DMQVF41 DE Discovery agent
DMQE89J ID DMQE89J
DMQE89J DN LY593093
DMQE89J HS Investigative
DMQE89J SN LY-593093; LY 593093
DMQE89J DT Small molecular drug
DMQE89J PC 9893054
DMQE89J MW 507.6
DMQE89J FM C32H30FN3O2
DMQE89J IC InChI=1S/C32H30FN3O2/c1-21(36(2)20-22-8-15-27(33)16-9-22)34-28-17-14-26-18-30(37)31(29(26)19-28)35-32(38)25-12-10-24(11-13-25)23-6-4-3-5-7-23/h3-17,19,30-31,37H,18,20H2,1-2H3,(H,35,38)/t30-,31-/m1/s1
DMQE89J CS CC(=NC1=CC2=C(C[C@H]([C@@H]2NC(=O)C3=CC=C(C=C3)C4=CC=CC=C4)O)C=C1)N(C)CC5=CC=C(C=C5)F
DMQE89J IK KOQVBYSCBCRVQJ-FIRIVFDPSA-N
DMQE89J IU N-[(1R,2R)-6-[1-[(4-fluorophenyl)methyl-methylamino]ethylideneamino]-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-4-phenylbenzamide
DMQE89J CA CAS 1108748-12-4
DMQE89J DE Discovery agent
DM5TYMG ID DM5TYMG
DM5TYMG DN LY86057
DM5TYMG HS Investigative
DM5TYMG SN LY-86057; LY 86057
DM5TYMG DT Small molecular drug
DM5TYMG PC 13878025
DM5TYMG MW 342.4
DM5TYMG FM C20H26N2O3
DM5TYMG IC InChI=1S/C20H26N2O3/c1-11(23)12(2)25-20(24)14-7-16-15-5-4-6-17-19(15)13(9-21-17)8-18(16)22(3)10-14/h4-6,9,11-12,14,16,18,21,23H,7-8,10H2,1-3H3
DM5TYMG CS CC(C(C)OC(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)C)O
DM5TYMG IK GOHDSZGHAHFEHG-UHFFFAOYSA-N
DM5TYMG IU 3-hydroxybutan-2-yl 7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxylate
DM5TYMG DE Discovery agent
DMTNVP4 ID DMTNVP4
DMTNVP4 DN LY97241
DMTNVP4 HS Investigative
DMTNVP4 SN LY 97241; LY-97241
DMTNVP4 DT Small molecular drug
DMTNVP4 PC 175064
DMTNVP4 MW 320.5
DMTNVP4 FM C19H32N2O2
DMTNVP4 IC InChI=1S/C19H32N2O2/c1-3-5-6-7-9-16-20(4-2)17-10-8-11-18-12-14-19(15-13-18)21(22)23/h12-15H,3-11,16-17H2,1-2H3
DMTNVP4 CS CCCCCCCN(CC)CCCCC1=CC=C(C=C1)[N+](=O)[O-]
DMTNVP4 IK YTYATOMQOOFRNA-UHFFFAOYSA-N
DMTNVP4 IU N-ethyl-N-[4-(4-nitrophenyl)butyl]heptan-1-amine
DMTNVP4 CA CAS 72456-63-4
DMTNVP4 DE Discovery agent
DMVX19Q ID DMVX19Q
DMVX19Q DN LYCOGARUBIN B
DMVX19Q HS Investigative
DMVX19Q SN LYCOGARUBIN B; CHEMBL439675
DMVX19Q DT Small molecular drug
DMVX19Q PC 11441783
DMVX19Q MW 429.4
DMVX19Q FM C24H19N3O5
DMVX19Q IC InChI=1S/C24H19N3O5/c1-31-23(29)21-19(15-10-25-17-6-4-3-5-13(15)17)20(22(27-21)24(30)32-2)16-11-26-18-8-7-12(28)9-14(16)18/h3-11,25-28H,1-2H3
DMVX19Q CS COC(=O)C1=C(C(=C(N1)C(=O)OC)C2=CNC3=CC=CC=C32)C4=CNC5=C4C=C(C=C5)O
DMVX19Q IK SZBJDRXMLSSPCV-UHFFFAOYSA-N
DMVX19Q IU dimethyl 3-(5-hydroxy-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dicarboxylate
DMVX19Q DE Discovery agent
DMH0Q9V ID DMH0Q9V
DMH0Q9V DN Lys[Z(NO2)]-Lys[Z(NO2)]
DMH0Q9V HS Investigative
DMH0Q9V SN Lys[Z(NO2)]-Lys[Z(NO2)]; GTPL4499
DMH0Q9V DT Small molecular drug
DMH0Q9V PC 73755095
DMH0Q9V MW 618.6
DMH0Q9V FM C27H34N6O11
DMH0Q9V IC InChI=1S/C27H34N6O11/c28-22(5-1-3-16-30-27(38)44-21-13-11-20(12-14-21)33(41)42)24(34)31-23(25(35)36)6-2-4-15-29-26(37)43-17-18-7-9-19(10-8-18)32(39)40/h7-14,22-23H,1-6,15-17,28H2,(H,29,37)(H,30,38)(H,31,34)(H,35,36)
DMH0Q9V CS C1=CC(=CC=C1COC(=O)NCCCCC(C(=O)[O-])NC(=O)C(CCCCNC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])[NH3+])[N+](=O)[O-]
DMH0Q9V IK AJUWOKKXEQNXLT-UHFFFAOYSA-N
DMH0Q9V IU 2-[[2-azaniumyl-6-[(4-nitrophenoxy)carbonylamino]hexanoyl]amino]-6-[(4-nitrophenyl)methoxycarbonylamino]hexanoate
DMH0Q9V DE Discovery agent
DMJX4GA ID DMJX4GA
DMJX4GA DN Lys[Z(NO2)]-Pro
DMJX4GA HS Investigative
DMJX4GA SN Lys[Z(NO2)]-Pro; GTPL4498; (2S)-1-{2-amino-6-[(4-nitrophenoxycarbonyl)amino]hexanoyl}pyrrolidine-2-carboxylic acid
DMJX4GA DT Small molecular drug
DMJX4GA PC 73755094
DMJX4GA MW 408.4
DMJX4GA FM C18H24N4O7
DMJX4GA IC InChI=1S/C18H24N4O7/c19-14(16(23)21-11-3-5-15(21)17(24)25)4-1-2-10-20-18(26)29-13-8-6-12(7-9-13)22(27)28/h6-9,14-15H,1-5,10-11,19H2,(H,20,26)(H,24,25)/t14?,15-/m0/s1
DMJX4GA CS C1C[C@H](N(C1)C(=O)C(CCCCNC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])N)C(=O)O
DMJX4GA IK XECWFUGQRJPWRP-LOACHALJSA-N
DMJX4GA IU (2S)-1-[2-amino-6-[(4-nitrophenoxy)carbonylamino]hexanoyl]pyrrolidine-2-carboxylic acid
DMJX4GA DE Discovery agent
DM4MGAQ ID DM4MGAQ
DM4MGAQ DN lysergic acid
DM4MGAQ HS Investigative
DM4MGAQ SN D-lysergic acid; isolysergic acid; (+)-lysergic acid
DM4MGAQ DT Small molecular drug
DM4MGAQ PC 6717
DM4MGAQ MW 268.31
DM4MGAQ FM C16H16N2O2
DM4MGAQ IC InChI=1S/C16H16N2O2/c1-18-8-10(16(19)20)5-12-11-3-2-4-13-15(11)9(7-17-13)6-14(12)18/h2-5,7,10,14,17H,6,8H2,1H3,(H,19,20)/t10-,14-/m1/s1
DM4MGAQ CS CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)O
DM4MGAQ IK ZAGRKAFMISFKIO-QMTHXVAHSA-N
DM4MGAQ IU (6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxylic acid
DM4MGAQ CA CAS 82-58-6
DM4MGAQ CB CHEBI:6604
DM4MGAQ DE Discovery agent
DM1OHF8 ID DM1OHF8
DM1OHF8 DN lysergol
DM1OHF8 HS Investigative
DM1OHF8 SN lysergole
DM1OHF8 DT Small molecular drug
DM1OHF8 PC 14987
DM1OHF8 MW 254.33
DM1OHF8 FM C16H18N2O
DM1OHF8 IC InChI=1S/C16H18N2O/c1-18-8-10(9-19)5-13-12-3-2-4-14-16(12)11(7-17-14)6-15(13)18/h2-5,7,10,15,17,19H,6,8-9H2,1H3/t10-,15-/m1/s1
DM1OHF8 CS CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)CO
DM1OHF8 IK BIXJFIJYBLJTMK-MEBBXXQBSA-N
DM1OHF8 IU [(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]methanol
DM1OHF8 CA CAS 602-85-7
DM1OHF8 CB CHEBI:60528
DM1OHF8 DE Discovery agent
DMIZQW6 ID DMIZQW6
DMIZQW6 DN LYSICAMINE
DMIZQW6 HS Investigative
DMIZQW6 SN Lysicamine; Oxonuciferine; 15444-20-9; CCRIS 3813; NSC 628003; BRN 1486372; UNII-6L30DD6R7O; CHEMBL510090; 6L30DD6R7O; CHEBI:70650; 1,2-Dimethoxy-7H-dibenzo(de,g)quinolin-7-one; NSC628003; 7H-Dibenzo(de,g)quinolin-7-one, 1,2-dimethoxy-; Noraporphin-7-one, 4,5,6,6a-tetradehydro-1,2-dimethoxy-; 7H-Dibenzo[de,g]quinolin-7-one, 1,2-dimethoxy-; 5-21-13-00382 (Beilstein Handbook Reference); (+)-ushinsunine-beta-N-oxide; SCHEMBL2046474; AC1L3V30; DTXSID00165628; MolPort-044-754-181; DPBMWJXWUINLQT-UHFFFAOYSA-N; BDBM50292452
DMIZQW6 DT Small molecular drug
DMIZQW6 PC 122691
DMIZQW6 MW 291.3
DMIZQW6 FM C18H13NO3
DMIZQW6 IC InChI=1S/C18H13NO3/c1-21-13-9-10-7-8-19-16-14(10)15(18(13)22-2)11-5-3-4-6-12(11)17(16)20/h3-9H,1-2H3
DMIZQW6 CS COC1=C(C2=C3C(=C1)C=CN=C3C(=O)C4=CC=CC=C42)OC
DMIZQW6 IK DPBMWJXWUINLQT-UHFFFAOYSA-N
DMIZQW6 IU 15,16-dimethoxy-10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2,4,6,9,11,13,15-octaen-8-one
DMIZQW6 CA CAS 15444-20-9
DMIZQW6 CB CHEBI:70650
DMIZQW6 DE Discovery agent
DMW1YK3 ID DMW1YK3
DMW1YK3 DN Lysine Nz-Carboxylic Acid
DMW1YK3 HS Investigative
DMW1YK3 SN Lysine Nz-Carboxylic Acid; N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301
DMW1YK3 DT Small molecular drug
DMW1YK3 PC 17754054
DMW1YK3 MW 190.2
DMW1YK3 FM C7H14N2O4
DMW1YK3 IC InChI=1S/C7H14N2O4/c8-5(6(10)11)3-1-2-4-9-7(12)13/h5,9H,1-4,8H2,(H,10,11)(H,12,13)/t5-/m0/s1
DMW1YK3 CS C(CCNC(=O)O)C[C@@H](C(=O)O)N
DMW1YK3 IK PWIKLEYMFKCERQ-YFKPBYRVSA-N
DMW1YK3 IU (2S)-2-amino-6-(carboxyamino)hexanoic acid
DMW1YK3 CB CHEBI:43575
DMW1YK3 DE Discovery agent
DMOGFVH ID DMOGFVH
DMOGFVH DN Lysophosphatidylcholine
DMOGFVH HS Investigative
DMOGFVH SN Lysophosphatidylcholine; 1-acetyl-sn-glycero-3-phosphocholine; AC1NSKBT; GTPL2508; SCHEMBL19821626; CHEBI:138424; LMGP01050043; [(2R)-3-acetyloxy-2-hydroxypropyl] 2-trimethylazaniumylethyl phosphate; [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate; 3,5,9-Trioxa-4-phosphaundecan-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (R)-
DMOGFVH DT Small molecular drug
DMOGFVH PC 5311264
DMOGFVH MW 299.26
DMOGFVH FM C10H22NO7P
DMOGFVH IC InChI=1S/C10H22NO7P/c1-9(12)16-7-10(13)8-18-19(14,15)17-6-5-11(2,3)4/h10,13H,5-8H2,1-4H3/t10-/m1/s1
DMOGFVH CS CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
DMOGFVH IK RYCNUMLMNKHWPZ-SNVBAGLBSA-N
DMOGFVH IU [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
DMOGFVH CA CAS 9008-30-4
DMOGFVH CB CHEBI:138424
DMOGFVH DE Discovery agent
DMI4FKH ID DMI4FKH
DMI4FKH DN lysophosphatidylethanolamine
DMI4FKH HS Investigative
DMI4FKH SN monoacylglycerophosphoethanolamine
DMI4FKH DT Small molecular drug
DMI4FKH PC 73755142
DMI4FKH MW 256.17
DMI4FKH FM C7H15NO7P-
DMI4FKH IC InChI=1S/C7H16NO7P/c1-6(9)13-4-7(10)5-15-16(11,12)14-3-2-8/h7,10H,2-5,8H2,1H3,(H,11,12)/p-1/t7-/m1/s1
DMI4FKH CS CC(=O)OC[C@H](COP(=O)([O-])OCCN)O
DMI4FKH IK CWRILEGKIAOYKP-SSDOTTSWSA-M
DMI4FKH IU [(2R)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate
DMI4FKH DE Discovery agent
DMETM3R ID DMETM3R
DMETM3R DN lysophosphatidylinositol
DMETM3R HS Investigative
DMETM3R SN LPI; L-alpha-lysophosphatidylinositol
DMETM3R DT Small molecular drug
DMETM3R PC 73755067
DMETM3R MW 376.25
DMETM3R FM C11H21O12P
DMETM3R IC InChI=1S/C11H21O12P/c1-4(12)21-2-5(13)3-22-24(19,20)23-11-9(17)7(15)6(14)8(16)10(11)18/h5-11,13-18H,2-3H2,1H3,(H,19,20)/t5-,6?,7-,8+,9+,10+,11?/m0/s1
DMETM3R CS CC(=O)OC[C@@H](COP(=O)(O)OC1[C@@H]([C@H](C([C@H]([C@H]1O)O)O)O)O)O
DMETM3R IK FBDBXJJQMHPGMP-FNFFQOHASA-N
DMETM3R IU [(2S)-2-hydroxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] acetate
DMETM3R DE Discovery agent
DMKG7J2 ID DMKG7J2
DMKG7J2 DN lysophosphatidylserine
DMKG7J2 HS Investigative
DMKG7J2 SN lysoPS; lysophosphatidyl-L-serine
DMKG7J2 DT Small molecular drug
DMKG7J2 PC 42607474
DMKG7J2 MW 525.6
DMKG7J2 FM C24H48NO9P
DMKG7J2 IC InChI=1S/C24H48NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(27)32-18-21(26)19-33-35(30,31)34-20-22(25)24(28)29/h21-22,26H,2-20,25H2,1H3,(H,28,29)(H,30,31)/t21-,22+/m1/s1
DMKG7J2 CS CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)O
DMKG7J2 IK ZPDQFUYPBVXUKS-YADHBBJMSA-N
DMKG7J2 IU (2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-octadecanoyloxypropoxy]phosphoryl]oxypropanoic acid
DMKG7J2 CA CAS 119786-67-3
DMKG7J2 CB CHEBI:85403
DMKG7J2 DE Discovery agent
DMIG3FX ID DMIG3FX
DMIG3FX DN Lysophosphotidylserine
DMIG3FX HS Investigative
DMIG3FX SN LYSOPHOSPHOTIDYLSERINE; O-{HYDROXY[((2R)-2-HYDROXY-3-{[(1S)-1-HYDROXYPENTADECYL]OXY}PROPYL)OXY]PHOSPHORYL}-L-SERINE; AC1NRBY2; O-[(R)-hydroxy{[(2R)-2-hydroxy-3-{[(1R)-1-hydroxypentadecyl]oxy}propyl]oxy}phosphoryl]-L-serine; (2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-(1-hydroxypentadecoxy)propoxy]phosphoryl]oxypropanoic acid
DMIG3FX DT Small molecular drug
DMIG3FX PC 5288706
DMIG3FX MW 485.5
DMIG3FX FM C21H44NO9P
DMIG3FX IC InChI=1S/C21H44NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-20(24)29-15-18(23)16-30-32(27,28)31-17-19(22)21(25)26/h18-20,23-24H,2-17,22H2,1H3,(H,25,26)(H,27,28)/t18-,19+,20?/m1/s1
DMIG3FX CS CCCCCCCCCCCCCCC(O)OC[C@H](COP(=O)(O)OC[C@@H](C(=O)O)N)O
DMIG3FX IK RPZLJDFLPRHXGM-LFPSWIHMSA-N
DMIG3FX IU (2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-(1-hydroxypentadecoxy)propoxy]phosphoryl]oxypropanoic acid
DMIG3FX DE Discovery agent
DME15MN ID DME15MN
DME15MN DN Lys-thiol
DME15MN HS Investigative
DME15MN SN 6-Amino-2-mercapto-hexanoic acid; CHEMBL432852; Lys-thiol; GTPL8667; SCHEMBL11506085; 6-amino-2-sulfanylhexanoic acid; BDBM50036831
DME15MN DT Small molecular drug
DME15MN PC 20384324
DME15MN MW 163.24
DME15MN FM C6H13NO2S
DME15MN IC InChI=1S/C6H13NO2S/c7-4-2-1-3-5(10)6(8)9/h5,10H,1-4,7H2,(H,8,9)
DME15MN CS C(CCN)CC(C(=O)O)S
DME15MN IK JNQDJHCXDRGZJD-UHFFFAOYSA-N
DME15MN IU 6-amino-2-sulfanylhexanoic acid
DME15MN DE Discovery agent
DMJQG82 ID DMJQG82
DMJQG82 DN M&B 28767
DMJQG82 HS Investigative
DMJQG82 SN M&B-28767; Dpt-prostaglandin E1
DMJQG82 DT Small molecular drug
DMJQG82 PC 5311223
DMJQG82 MW 374.5
DMJQG82 FM C22H30O5
DMJQG82 IC InChI=1S/C22H30O5/c23-18(16-27-19-8-4-3-5-9-19)14-12-17-13-15-21(24)20(17)10-6-1-2-7-11-22(25)26/h3-5,8-9,12,14,17-18,20,23H,1-2,6-7,10-11,13,15-16H2,(H,25,26)/b14-12+/t17-,18+,20+/m0/s1
DMJQG82 CS C1CC(=O)[C@@H]([C@H]1/C=C/[C@H](COC2=CC=CC=C2)O)CCCCCCC(=O)O
DMJQG82 IK NZGFSDWJUZOAAX-KAVAACISSA-N
DMJQG82 IU 7-[(1R,2R)-2-[(E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]heptanoic acid
DMJQG82 CA CAS 80558-61-8
DMJQG82 DE Discovery agent
DMYU3Z7 ID DMYU3Z7
DMYU3Z7 DN M372049
DMYU3Z7 HS Investigative
DMYU3Z7 SN M 372049; M-372049
DMYU3Z7 DT Small molecular drug
DMYU3Z7 PC 59787819
DMYU3Z7 MW 887
DMYU3Z7 FM C43H58N12O9
DMYU3Z7 IC InChI=1S/C43H58N12O9/c1-5-23(3)35(37(44)59)54-38(60)29(12-9-18-47-43(45)46)52-39(61)31(21-34(57)58)53-41(63)36(24(4)6-2)55-19-17-30(42(55)64)51-33(56)20-25-13-15-26(16-14-25)49-40(62)32-22-48-27-10-7-8-11-28(27)50-32/h7-8,10-11,13-16,22-24,29-31,35-36H,5-6,9,12,17-21H2,1-4H3,(H2,44,59)(H,49,62)(H,51,56)(H,52,61)(H,53,63)(H,54,60)(H,57,58)(H4,45,46,47)/t23-,24-,29+,30+,31-,35-,36-/m0/s1
DMYU3Z7 CS CC[C@H](C)[C@@H](C(=O)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)N1CC[C@H](C1=O)NC(=O)CC2=CC=C(C=C2)NC(=O)C3=NC4=CC=CC=C4N=C3
DMYU3Z7 IK VINFYKMOVBYUSF-ZCWPROOASA-N
DMYU3Z7 IU (3S)-4-[[(2R)-1-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[(2S,3S)-3-methyl-2-[(3R)-2-oxo-3-[[2-[4-(quinoxaline-2-carbonylamino)phenyl]acetyl]amino]pyrrolidin-1-yl]pentanoyl]amino]-4-oxobutanoic acid
DMYU3Z7 DE Discovery agent
DMJK1RE ID DMJK1RE
DMJK1RE DN M3A6S
DMJK1RE HS Investigative
DMJK1RE SN CHEMBL214040; 3-Acetylmorphine 6-sulfate; 3-O-acetylmorphine-6-sulfate
DMJK1RE DT Small molecular drug
DMJK1RE PC 44414842
DMJK1RE MW 407.4
DMJK1RE FM C19H21NO7S
DMJK1RE IC InChI=1S/C19H21NO7S/c1-10(21)25-14-5-3-11-9-13-12-4-6-15(27-28(22,23)24)18-19(12,7-8-20(13)2)16(11)17(14)26-18/h3-6,12-13,15,18H,7-9H2,1-2H3,(H,22,23,24)/t12-,13+,15-,18-,19-/m0/s1
DMJK1RE CS CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMJK1RE IK AVTOGXGTGWUJBM-SSTWWWIQSA-N
DMJK1RE IU [(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMJK1RE DE Discovery agent
DMAHGBF ID DMAHGBF
DMAHGBF DN M3B6S
DMAHGBF HS Investigative
DMAHGBF SN CHEMBL209751
DMAHGBF DT Small molecular drug
DMAHGBF PC 44414877
DMAHGBF MW 469.5
DMAHGBF FM C24H23NO7S
DMAHGBF IC InChI=1S/C24H23NO7S/c1-25-12-11-24-16-8-10-19(32-33(27,28)29)22(24)31-21-18(9-7-15(20(21)24)13-17(16)25)30-23(26)14-5-3-2-4-6-14/h2-10,16-17,19,22H,11-13H2,1H3,(H,27,28,29)/t16-,17+,19-,22-,24-/m0/s1
DMAHGBF CS C[NH+]1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC(=O)C6=CC=CC=C6)O[C@H]3[C@H](C=C4)OS(=O)(=O)[O-]
DMAHGBF IK IQMPFHWIBSSPBS-MJFIPZRTSA-N
DMAHGBF IU [(4R,4aR,7S,7aR,12bS)-9-benzoyloxy-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMAHGBF DE Discovery agent
DM0UOF1 ID DM0UOF1
DM0UOF1 DN M3IBu6S
DM0UOF1 HS Investigative
DM0UOF1 SN CHEMBL211576
DM0UOF1 DT Small molecular drug
DM0UOF1 PC 44414863
DM0UOF1 MW 435.5
DM0UOF1 FM C21H25NO7S
DM0UOF1 IC InChI=1S/C21H25NO7S/c1-11(2)20(23)27-15-6-4-12-10-14-13-5-7-16(29-30(24,25)26)19-21(13,8-9-22(14)3)17(12)18(15)28-19/h4-7,11,13-14,16,19H,8-10H2,1-3H3,(H,24,25,26)/t13-,14+,16-,19-,21-/m0/s1
DM0UOF1 CS CC(C)C(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DM0UOF1 IK GABBKMMVICEZHE-AYHJQLAQSA-N
DM0UOF1 IU [(4R,4aR,7S,7aR,12bS)-3-methyl-9-(2-methylpropanoyloxy)-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DM0UOF1 DE Discovery agent
DMXT87E ID DMXT87E
DMXT87E DN M3P6S
DMXT87E HS Investigative
DMXT87E SN CHEMBL213228
DMXT87E DT Small molecular drug
DMXT87E PC 44414864
DMXT87E MW 449.5
DMXT87E FM C22H27NO7S
DMXT87E IC InChI=1S/C22H27NO7S/c1-21(2,3)20(24)28-15-7-5-12-11-14-13-6-8-16(30-31(25,26)27)19-22(13,9-10-23(14)4)17(12)18(15)29-19/h5-8,13-14,16,19H,9-11H2,1-4H3,(H,25,26,27)/t13-,14+,16-,19-,22-/m0/s1
DMXT87E CS CC(C)(C)C(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMXT87E IK NEUKRIIKAHFBFQ-JYSMHPMOSA-N
DMXT87E IU [(4R,4aR,7S,7aR,12bS)-9-(2,2-dimethylpropanoyloxy)-3-methyl-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMXT87E DE Discovery agent
DMMC8RN ID DMMC8RN
DMMC8RN DN M3Pr6S
DMMC8RN HS Investigative
DMMC8RN SN CHEMBL385048; 3-Propionylmorphine 6-sulfate
DMMC8RN DT Small molecular drug
DMMC8RN PC 44414843
DMMC8RN MW 421.5
DMMC8RN FM C20H23NO7S
DMMC8RN IC InChI=1S/C20H23NO7S/c1-3-16(22)26-14-6-4-11-10-13-12-5-7-15(28-29(23,24)25)19-20(12,8-9-21(13)2)17(11)18(14)27-19/h4-7,12-13,15,19H,3,8-10H2,1-2H3,(H,23,24,25)/t12-,13+,15-,19-,20-/m0/s1
DMMC8RN CS CCC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[NH+]4C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMMC8RN IK LWKYBVFQVUJKDT-ILIJTDRLSA-N
DMMC8RN IU [(4R,4aR,7S,7aR,12bS)-3-methyl-9-propanoyloxy-1,2,3,4,4a,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMMC8RN DE Discovery agent
DMWADOY ID DMWADOY
DMWADOY DN M3S
DMWADOY HS Investigative
DMWADOY DE Discovery agent
DM3IX2E ID DM3IX2E
DM3IX2E DN M5
DM3IX2E HS Investigative
DM3IX2E SN Fibrinolytic agent, Vascular Laboratory/Thrombolytic Sciences; M5, Vascular Laboratory/Thrombolytic Science
DM3IX2E CP Vascular Laboratory Inc
DM3IX2E DT Small molecular drug
DM3IX2E PC 15345559
DM3IX2E MW 411.4
DM3IX2E FM C17H12F3N3O2S2
DM3IX2E IC InChI=1S/C17H12F3N3O2S2/c18-17(19,20)16-13-9-26-14-4-2-1-3-12(14)15(13)23(22-16)10-5-7-11(8-6-10)27(21,24)25/h1-8H,9H2,(H2,21,24,25)
DM3IX2E CS C1C2=C(C3=CC=CC=C3S1)N(N=C2C(F)(F)F)C4=CC=C(C=C4)S(=O)(=O)N
DM3IX2E IK ACFQQDXFCVFBIX-UHFFFAOYSA-N
DM3IX2E IU 4-[3-(trifluoromethyl)-4H-thiochromeno[4,3-c]pyrazol-1-yl]benzenesulfonamide
DM3IX2E DE Cerebrovascular ischaemia
DMM5X8Z ID DMM5X8Z
DMM5X8Z DN M55113
DMM5X8Z HS Investigative
DMM5X8Z SN SCHEMBL8124161; 6-Chloro-2-naphthyl 4-[1-(4-pyridyl)-4-piperidinylmethyl]piperazino sulfone
DMM5X8Z DT Small molecular drug
DMM5X8Z PC 9826652
DMM5X8Z MW 485
DMM5X8Z FM C25H29ClN4O2S
DMM5X8Z IC InChI=1S/C25H29ClN4O2S/c26-23-3-1-22-18-25(4-2-21(22)17-23)33(31,32)30-15-13-28(14-16-30)19-20-7-11-29(12-8-20)24-5-9-27-10-6-24/h1-6,9-10,17-18,20H,7-8,11-16,19H2
DMM5X8Z CS C1CN(CCC1CN2CCN(CC2)S(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)Cl)C5=CC=NC=C5
DMM5X8Z IK BFNYDPSXRNYUIS-UHFFFAOYSA-N
DMM5X8Z IU 1-(6-chloronaphthalen-2-yl)sulfonyl-4-[(1-pyridin-4-ylpiperidin-4-yl)methyl]piperazine
DMM5X8Z DE Discovery agent
DMFS7QK ID DMFS7QK
DMFS7QK DN M-5MPEP
DMFS7QK HS Investigative
DMFS7QK SN M-5MPEP; 872428-47-2; 2-[2-(3-methoxyphenyl)ethynyl]-5-methylpyridine; GTPL6396; CHEMBL504706; SCHEMBL3955131; CCQPQKFLWKYOMJ-UHFFFAOYSA-N; ZINC34874630; ACN-053377; KB-274285
DMFS7QK DT Small molecular drug
DMFS7QK PC 16036762
DMFS7QK MW 223.27
DMFS7QK FM C15H13NO
DMFS7QK IC InChI=1S/C15H13NO/c1-12-6-8-14(16-11-12)9-7-13-4-3-5-15(10-13)17-2/h3-6,8,10-11H,1-2H3
DMFS7QK CS CC1=CN=C(C=C1)C#CC2=CC(=CC=C2)OC
DMFS7QK IK CCQPQKFLWKYOMJ-UHFFFAOYSA-N
DMFS7QK IU 2-[2-(3-methoxyphenyl)ethynyl]-5-methylpyridine
DMFS7QK DE Discovery agent
DMRB4YV ID DMRB4YV
DMRB4YV DN M6G thiosaccharide analogue
DMRB4YV HS Investigative
DMRB4YV DE Discovery agent
DMFCUN4 ID DMFCUN4
DMFCUN4 DN M6S
DMFCUN4 HS Investigative
DMFCUN4 DE Discovery agent
DM9NPE4 ID DM9NPE4
DM9NPE4 DN M826
DM9NPE4 HS Investigative
DM9NPE4 SN compound 4sx
DM9NPE4 DT Small molecular drug
DM9NPE4 PC 9851134
DM9NPE4 MW 575.7
DM9NPE4 FM C28H45N7O6
DM9NPE4 IC InChI=1S/C28H45N7O6/c1-8-10-11-12-13-34(7)16-22(36)19(14-24(37)38)30-26(39)21(9-2)35-17-23(28(4,5)6)31-25(27(35)40)29-15-20-18(3)32-41-33-20/h17,19,21H,8-16H2,1-7H3,(H,29,31)(H,30,39)(H,37,38)
DM9NPE4 CS CCCCCCN(C)CC(=O)C(CC(=O)O)NC(=O)C(CC)N1C=C(N=C(C1=O)NCC2=NON=C2C)C(C)(C)C
DM9NPE4 IK XIMITGPWYYFUQF-UHFFFAOYSA-N
DM9NPE4 IU 3-[2-[5-tert-butyl-3-[(4-methyl-1,2,5-oxadiazol-3-yl)methylamino]-2-oxopyrazin-1-yl]butanoylamino]-5-[hexyl(methyl)amino]-4-oxopentanoic acid
DM9NPE4 DE Discovery agent
DM8I0TY ID DM8I0TY
DM8I0TY DN M8-B
DM8I0TY HS Investigative
DM8I0TY SN GTPL6376; SCHEMBL14078338; CHEMBL2442052; ZINC38225225; NCGC00370691-03
DM8I0TY DT Small molecular drug
DM8I0TY PC 11675630
DM8I0TY MW 396.5
DM8I0TY FM C22H24N2O3S
DM8I0TY IC InChI=1S/C22H24N2O3S/c1-26-20-14-18(9-10-19(20)27-16-17-6-3-2-4-7-17)15-24(12-11-23)22(25)21-8-5-13-28-21/h2-10,13-14H,11-12,15-16,23H2,1H3
DM8I0TY CS COC1=C(C=CC(=C1)CN(CCN)C(=O)C2=CC=CS2)OCC3=CC=CC=C3
DM8I0TY IK UOGGWHBYFVBUIY-UHFFFAOYSA-N
DM8I0TY IU N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]thiophene-2-carboxamide
DM8I0TY DE Discovery agent
DMKWQ52 ID DMKWQ52
DMKWQ52 DN MA-2029
DMKWQ52 HS Investigative
DMKWQ52 SN MA2029
DMKWQ52 DT Small molecular drug
DMKWQ52 PC 73755070
DMKWQ52 MW 593.2
DMKWQ52 FM C31H46ClFN4O4
DMKWQ52 IC InChI=1S/C31H45FN4O4.ClH/c1-9-34-28(38)24(18-21-12-15-26(37)23(16-21)31(4,5)6)35-29(39)27(19(2)3)36(8)30(40)25(33-7)17-20-10-13-22(32)14-11-20;/h10-16,19,24-25,27,33,37H,9,17-18H2,1-8H3,(H,34,38)(H,35,39);1H/t24-,25-,27-;/m0./s1
DMKWQ52 CS CCNC(=O)[C@H](CC1=CC(=C(C=C1)O)C(C)(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC2=CC=C(C=C2)F)NC.Cl
DMKWQ52 IK AMSDRHOIAWZBTJ-PBQYMGKRSA-N
DMKWQ52 IU (2S)-N-[(2S)-3-(3-tert-butyl-4-hydroxyphenyl)-1-(ethylamino)-1-oxopropan-2-yl]-2-[[(2S)-3-(4-fluorophenyl)-2-(methylamino)propanoyl]-methylamino]-3-methylbutanamide;hydrochloride
DMKWQ52 DE Discovery agent
DMDHGM2 ID DMDHGM2
DMDHGM2 DN Maackiain
DMDHGM2 HS Investigative
DMDHGM2 SN Maackiain; (-)-Maackiain; Inermin; Inermine; 2035-15-6; L-Maackiain; CHEBI:99; UNII-TF360D25IJ; (6ar,12ar)-6a,12a-dihydro-6h-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol; TF360D25IJ; HUKSJTUUSUGIDC-ZBEGNZNMSA-N; 19908-48-6; 3-Hydroxy-8,9-methylenedioxypterocarpan; ST077155; (6aR,12aR)-3-hydroxy-8,9-methylenedioxypterocarpane; (6aR,12aR)-6a,12a-Dihydro-6H-[1,3]dioxolo[4',5':5,6]benzofuro[3,2-c]chromen-3-ol; Maackiaine; Trifolirhizin aglycone; (+/-)-Maackiain; AC1Q70VV; CHEMBL334918; AC1L3M84; (-)-(6aR,12aR)-maackiain
DMDHGM2 DT Small molecular drug
DMDHGM2 PC 91510
DMDHGM2 MW 284.26
DMDHGM2 FM C16H12O5
DMDHGM2 IC InChI=1S/C16H12O5/c17-8-1-2-9-12(3-8)18-6-11-10-4-14-15(20-7-19-14)5-13(10)21-16(9)11/h1-5,11,16-17H,6-7H2/t11-,16-/m0/s1
DMDHGM2 CS C1[C@@H]2[C@H](C3=C(O1)C=C(C=C3)O)OC4=CC5=C(C=C24)OCO5
DMDHGM2 IK HUKSJTUUSUGIDC-ZBEGNZNMSA-N
DMDHGM2 IU (1R,12R)-5,7,11,19-tetraoxapentacyclo[10.8.0.02,10.04,8.013,18]icosa-2,4(8),9,13(18),14,16-hexaen-16-ol
DMDHGM2 CA CAS 2035-15-6
DMDHGM2 CB CHEBI:99
DMDHGM2 DE Discovery agent
DM1ICOW ID DM1ICOW
DM1ICOW DN mab 224G11
DM1ICOW HS Investigative
DM1ICOW SN MAb 224G11; C-Met antagonist monoclonal antibody (cancer); C-Met antagonist monoclonal antibody (cancer), Pierre Fabre/Abbott
DM1ICOW CP Pierre Fabre SA
DM1ICOW DT Antibody
DM1ICOW DE Solid tumour/cancer
DMJX2CS ID DMJX2CS
DMJX2CS DN mabionHER2
DMJX2CS HS Investigative
DMJX2CS SN Humanized monoclonal antibody (breast cancer), Mabion
DMJX2CS CP Mabion Ltd
DMJX2CS DT Antibody
DMJX2CS DE Breast cancer
DMDLF0J ID DMDLF0J
DMDLF0J DN Macbecin
DMDLF0J HS Investigative
DMDLF0J TC Anticancer Agents
DMDLF0J DT Small molecular drug
DMDLF0J PC 433447
DMDLF0J MW 558.7
DMDLF0J FM C30H42N2O8
DMDLF0J IC InChI=1S/C30H42N2O8/c1-16-10-9-11-17(2)29(35)32-23-15-21(33)14-22(25(23)34)27(38-7)20(5)13-24(37-6)28(39-8)19(4)12-18(3)26(16)40-30(31)36/h9-12,14-16,19-20,24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)
DMDLF0J CS CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C=C(C1OC)C2=O)C)C)OC(=O)N)C)C)OC)OC
DMDLF0J IK PLTGBUPHJAKFMA-UHFFFAOYSA-N
DMDLF0J IU (13,14,17-trimethoxy-4,8,10,12,16-pentamethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl) carbamate
DMDLF0J DE Solid tumour/cancer
DMOMG7S ID DMOMG7S
DMOMG7S DN MACLURAXANTHONE
DMOMG7S HS Investigative
DMOMG7S SN Macluraxanthone; 5848-14-6; NSC107228; 3-Hydroxyblancoxanthone; Spectrum_000523; SpecPlus_000294; CHEBI:6623; 12-(1,1-dimethylallyl)-5,9,10-trihydroxy-2,2-dimethyl-pyrano[3,2-b]xanthen-6-one; MACLUROXANTHONE; NSC 107228; AC1NQYT1; Spectrum3_000165; Spectrum2_000431; Spectrum5_000191; Spectrum4_001486; C10076; KBioSS_001003; KBioGR_002091; BSPBio_001629; DivK1c_006390; SPBio_000442; SCHEMBL2546452; CHEMBL478960; KBio2_003571; KBio2_006139; KBio2_001003; KBio1_001334; KBio3_001129; DTXSID40207172; MolPort-001-736-557; ZINC5447704
DMOMG7S DT Small molecular drug
DMOMG7S PC 5281646
DMOMG7S MW 394.4
DMOMG7S FM C23H22O6
DMOMG7S IC InChI=1S/C23H22O6/c1-6-22(2,3)15-19-12(9-10-23(4,5)29-19)17(26)14-16(25)11-7-8-13(24)18(27)20(11)28-21(14)15/h6-10,24,26-27H,1H2,2-5H3
DMOMG7S CS CC1(C=CC2=C(C3=C(C(=C2O1)C(C)(C)C=C)OC4=C(C3=O)C=CC(=C4O)O)O)C
DMOMG7S IK XRVLGJCHUWXTDX-UHFFFAOYSA-N
DMOMG7S IU 5,9,10-trihydroxy-2,2-dimethyl-12-(2-methylbut-3-en-2-yl)pyrano[3,2-b]xanthen-6-one
DMOMG7S CA CAS 5848-14-6
DMOMG7S CB CHEBI:6623
DMOMG7S DE Discovery agent
DMFULZO ID DMFULZO
DMFULZO DN Macrocyclic tripeptide motif
DMFULZO HS Investigative
DMFULZO SN macrocyclic tripeptide motif; CHEMBL317974
DMFULZO DT Small molecular drug
DMFULZO PC 44331282
DMFULZO MW 731.8
DMFULZO FM C36H45N9O8
DMFULZO IC InChI=1S/C36H45N9O8/c37-36(38)39-16-4-8-26-31(49)34(52)44-27(19-22-6-2-1-3-7-22)32(50)42-24(18-23-10-13-25(47)14-11-23)12-15-30(48)40-20-28(41-21-46)35(53)45-17-5-9-29(45)33(51)43-26/h1-3,6-7,10-15,21,24,26-29,47H,4-5,8-9,16-20H2,(H,40,48)(H,41,46)(H,42,50)(H,43,51)(H,44,52)(H4,37,38,39)/b15-12-/t24-,26+,27-,28+,29+/m0/s1
DMFULZO CS C1C[C@@H]2C(=O)N[C@@H](C(=O)C(=O)N[C@H](C(=O)N[C@@H](/C=C\\C(=O)NC[C@H](C(=O)N2C1)NC=O)CC3=CC=C(C=C3)O)CC4=CC=CC=C4)CCCN=C(N)N
DMFULZO IK CDWXSPKJKIUEQF-SMUYMMTFSA-N
DMFULZO IU N-[(3R,7Z,9R,12S,16R,19R)-12-benzyl-16-[3-(diaminomethylideneamino)propyl]-9-[(4-hydroxyphenyl)methyl]-2,6,11,14,15,18-hexaoxo-1,5,10,13,17-pentazabicyclo[17.3.0]docos-7-en-3-yl]formamide
DMFULZO DE Discovery agent
DMSQL19 ID DMSQL19
DMSQL19 DN MAGGIEMYCIN
DMSQL19 HS Investigative
DMSQL19 SN Maggiemycin; 81341-47-1; methyl (1R,2R)-2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate; AC1Q6OOS; CTK3E8246; DTXSID70231061; AC1L3370; 1-naphthacenecarboxylic acid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester,(1r-trans)-; 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,12-tetrahydroxy-4,6,11-trioxo-, methyl ester, (1R-trans)-
DMSQL19 DT Small molecular drug
DMSQL19 PC 133657
DMSQL19 MW 426.4
DMSQL19 FM C22H18O9
DMSQL19 IC InChI=1S/C22H18O9/c1-3-22(30)7-10(24)12-13(16(22)21(29)31-2)20(28)14-15(19(12)27)18(26)11-8(17(14)25)5-4-6-9(11)23/h4-6,16,23,27-28,30H,3,7H2,1-2H3/t16-,22+/m0/s1
DMSQL19 CS CC[C@]1(CC(=O)C2=C([C@H]1C(=O)OC)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)O)O
DMSQL19 IK FCUPTGDGQULLKX-KSFYIVLOSA-N
DMSQL19 IU methyl (1R,2R)-2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate
DMSQL19 CA CAS 81341-47-1
DMSQL19 DE Discovery agent
DM5WNH8 ID DM5WNH8
DM5WNH8 DN Mahureone D
DM5WNH8 HS Investigative
DM5WNH8 SN Mahureone D
DM5WNH8 DT Small molecular drug
DM5WNH8 PC 54708912
DM5WNH8 MW 528.7
DM5WNH8 FM C32H48O6
DM5WNH8 IC InChI=1S/C32H48O6/c1-10-11-22(17-25(34)35)27-29-32(15-14-20(4)5,18-23(31(27,8)9)13-12-19(2)3)28(36)26(30(37)38-29)24(33)16-21(6)7/h12,14,21-23,36H,10-11,13,15-18H2,1-9H3,(H,34,35)
DM5WNH8 CS CCCC(CC(=O)O)C1=C2C(CC(C1(C)C)CC=C(C)C)(C(=C(C(=O)O2)C(=O)CC(C)C)O)CC=C(C)C
DM5WNH8 IK MEQHOADCAUKYIE-UHFFFAOYSA-N
DM5WNH8 IU 3-[4-hydroxy-7,7-dimethyl-3-(3-methylbutanoyl)-4a,6-bis(3-methylbut-2-enyl)-2-oxo-5,6-dihydrochromen-8-yl]hexanoic acid
DM5WNH8 DE Discovery agent
DMKE03Q ID DMKE03Q
DMKE03Q DN Makaluvamine N
DMKE03Q HS Investigative
DMKE03Q SN CHEMBL1162277
DMKE03Q DT Small molecular drug
DMKE03Q PC 135496970
DMKE03Q MW 266.09
DMKE03Q FM C10H8BrN3O
DMKE03Q IC InChI=1S/C10H8BrN3O/c11-6-7(12)10(15)9-5-4(3-14-9)1-2-13-8(5)6/h3,15H,1-2,12H2
DMKE03Q CS C1CN=C2C3=C1C=NC3=C(C(=C2Br)N)O
DMKE03Q IK UMVGTIHJQQYCQI-UHFFFAOYSA-N
DMKE03Q IU 10-amino-9-bromo-2,7-diazatricyclo[6.3.1.04,12]dodeca-1(11),2,4(12),7,9-pentaen-11-ol
DMKE03Q DE Discovery agent
DMMCJLH ID DMMCJLH
DMMCJLH DN Malate
DMMCJLH HS Investigative
DMMCJLH SN Apple acid; Butanedioic acid, hydroxy-, (2S)-; J3TZF807X5; L(-)-Malic acid; L-(-)-Malic acid; L-2-Hydroxybutanedioic acid; L-Apple acid; L-Hydroxybutanedioic acid; L-Hydroxysuccinic acid; L-Malic acid; L-malate; Malic acid, L-; S-(-)-Malic acid; S-2-Hydroxybutanedioic acid; (-)-(S)-Malic acid; (-)-Hydroxysuccinic acid; (-)-L-Malic acid; (-)-Malic acid; (2S)-2-Hydroxybutanedioic acid; (S)-(-)-Hydroxysuccinic acid; (S)-2-hydroxysuccinic acid; (S)-Malic acid; (S)-malate; 97-67-6; MFCD00064213; NSC9232; UNII-J3TZF807X5
DMMCJLH PC 222656
DMMCJLH MW 134.09
DMMCJLH FM C4H6O5
DMMCJLH IC BJEPYKJPYRNKOW-REOHCLBHSA-N
DMMCJLH CS C(C(C(=O)O)O)C(=O)O
DMMCJLH IK 1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)/t2-/m0/s1
DMMCJLH IU (2S)-2-hydroxybutanedioic acid
DMMCJLH CA CAS 636-61-3
DMMCJLH CB CHEBI:30797
DMMCJLH DE Discovery agent
DM4OQWZ ID DM4OQWZ
DM4OQWZ DN Malate Like Intermediate
DM4OQWZ HS Investigative
DM4OQWZ SN MALATE LIKE INTERMEDIATE; AC1NRDBV; DB03343; (Z,2R)-2,4-dihydroxy-4-oxidobut-3-enoate
DM4OQWZ DT Small molecular drug
DM4OQWZ PC 5289457
DM4OQWZ MW 132.07
DM4OQWZ FM C4H4O5-2
DM4OQWZ IC InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h1-2,5-7H,(H,8,9)/p-2/t2-/m1/s1
DM4OQWZ CS C(=C(\\O)/[O-])\\[C@H](C(=O)[O-])O
DM4OQWZ IK QFBHYOKSQPPXHZ-UWTATZPHSA-L
DM4OQWZ IU (Z,2R)-2,4-dihydroxy-4-oxidobut-3-enoate
DM4OQWZ DE Discovery agent
DM4L0R7 ID DM4L0R7
DM4L0R7 DN Maleic Acid
DM4L0R7 HS Investigative
DM4L0R7 SN 2-(2-ethoxyethyl)-3-ethylbut-2-enedioic acid; 6309-80-4; AC1L5ZJW; CTK6G3643; CTK5B7536; DTXSID10285386; Maleic acid,(2-ethoxyethyl)ethyl- (8CI)
DM4L0R7 DT Small molecular drug
DM4L0R7 PC 444266
DM4L0R7 MW 116.07
DM4L0R7 FM C4H4O4
DM4L0R7 IC InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1-
DM4L0R7 CS C(=C\\C(=O)O)\\C(=O)O
DM4L0R7 IK VZCYOOQTPOCHFL-UPHRSURJSA-N
DM4L0R7 IU (Z)-but-2-enedioic acid
DM4L0R7 CA CAS 110-16-7
DM4L0R7 CB CHEBI:18300
DM4L0R7 DE Discovery agent
DMU3O5H ID DMU3O5H
DMU3O5H DN malic acid
DMU3O5H HS Investigative
DMU3O5H SN malate
DMU3O5H DT Small molecular drug
DMU3O5H PC 525
DMU3O5H MW 134.09
DMU3O5H FM C4H6O5
DMU3O5H IC InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)
DMU3O5H CS C(C(C(=O)O)O)C(=O)O
DMU3O5H IK BJEPYKJPYRNKOW-UHFFFAOYSA-N
DMU3O5H IU 2-hydroxybutanedioic acid
DMU3O5H CA CAS 6915-15-7
DMU3O5H CB CHEBI:6650
DMU3O5H DE Discovery agent
DM9ECWN ID DM9ECWN
DM9ECWN DN Mallotinic acid
DM9ECWN HS Investigative
DM9ECWN SN Mallotinic acid; CHEMBL448796; CHEBI:81154; SCHEMBL5381585; BDBM50250994; C17521; Galloyl 3-O,6-O-[4-(2,3,4-trihydroxy-6-carboxyphenoxy)-4',5,5',6,6'-pentahydroxybiphenyl-2,2'-diylbis(carbonyl)]-beta-D-glucopyranoside
DM9ECWN DT Small molecular drug
DM9ECWN PC 10056140
DM9ECWN MW 802.6
DM9ECWN FM C34H26O23
DM9ECWN IC InChI=1S/C34H26O23/c35-11-1-7(2-12(36)19(11)39)31(50)57-34-27(47)29-23(43)16(55-34)6-53-32(51)8-3-13(37)20(40)24(44)17(8)18-9(33(52)56-29)5-15(22(42)25(18)45)54-28-10(30(48)49)4-14(38)21(41)26(28)46/h1-5,16,23,27,29,34-47H,6H2,(H,48,49)/t16-,23-,27-,29+,34+/m1/s1
DM9ECWN CS C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)OC6=C(C(=C(C=C6C(=O)O)O)O)O)O
DM9ECWN IK AJIFASHLGBHDDS-GEFDNOIESA-N
DM9ECWN IU 2-[[(1S,19R,21S,22R,23R)-7,8,11,12,13,22,23-heptahydroxy-3,16-dioxo-21-(3,4,5-trihydroxybenzoyl)oxy-2,17,20-trioxatetracyclo[17.3.1.04,9.010,15]tricosa-4,6,8,10,12,14-hexaen-6-yl]oxy]-3,4,5-trihydroxybenzoic acid
DM9ECWN CB CHEBI:81154
DM9ECWN DE Discovery agent
DMHX9P8 ID DMHX9P8
DMHX9P8 DN Mallotusinic acid
DMHX9P8 HS Investigative
DMHX9P8 SN Mallotusinic acid; C10235; 66421-47-4; beta-D-Glucopyranose, cyclic 3-2:6-2'-(4-(6-carboxy-2,3,4-trihydroxyphenoxy)-4',5,5',6,6'-pentahydroxy(1,1'-biphenyl)-2,2'-dicarboxylate) cyclic 2-7:4-5-(3,6-dihydro-2,9,10,11,11-pentahydroxy-3-oxo-2,6-methano-2H-1-benzoxocin-5,7-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), stereoisomer
DMHX9P8 DT Small molecular drug
DMHX9P8 PC 16131237
DMHX9P8 MW 1120.7
DMHX9P8 FM C48H32O32
DMHX9P8 IC InChI=1S/C48H32O32/c49-15-1-9(2-16(50)27(15)55)41(65)79-46-39-38-36(76-45(69)13-7-22(54)48(72)47(70,71)26(13)25-11(43(67)78-39)4-19(53)30(58)37(25)80-48)21(75-46)8-73-42(66)10-3-17(51)28(56)32(60)23(10)24-12(44(68)77-38)6-20(31(59)33(24)61)74-35-14(40(63)64)5-18(52)29(57)34(35)62/h1-7,21,26,36,38-39,46,49-53,55-62,70-72H,8H2,(H,63,64)
DMHX9P8 CS C1C2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C7C(=CC(=O)C(C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)OC1=C(C(=C(C=C1C(=O)O)O)O)O
DMHX9P8 IK MWPRJJBXNINUTQ-UHFFFAOYSA-N
DMHX9P8 IU 2-[[1,14,15,18,19,20,34,35,39,39-decahydroxy-2,5,10,23,31-pentaoxo-28-(3,4,5-trihydroxybenzoyl)oxy-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-13-yl]oxy]-3,4,5-trihydroxybenzoic acid
DMHX9P8 CA CAS 66421-47-4
DMHX9P8 DE Discovery agent
DMAJDU7 ID DMAJDU7
DMAJDU7 DN Malonate sodium
DMAJDU7 HS Investigative
DMAJDU7 DE Discovery agent
DMM5QXL ID DMM5QXL
DMM5QXL DN Malonic acid
DMM5QXL HS Investigative
DMM5QXL SN malonic acid; propanedioic acid; 141-82-2; Dicarboxymethane; Carboxyacetic acid; Methanedicarboxylic acid; Kyselina malonova; USAF EK-695; Dicarboxylate; Dicarboxylic acid; Kyselina malonova [Czech]; PROPANEDIOLIC ACID; UNII-9KX7ZMG0MK; NSC 8124; METAHNEDICARBOXYLIC ACID; Methanedicarbonic acid; Malonic acid, 99%; Thallium malonate; AI3-15375; 1,3-Propanedioic acid; EINECS 205-503-0; 9KX7ZMG0MK; BRN 1751370; DICARBOXYLIC ACID C3; alpha,omega-Dicarboxylic acid; CHEBI:30794; NSC8124; OFOBLEOULBTSOW-UHFFFAOYSA-N; MFCD00002707; malons
DMM5QXL DT Small molecular drug
DMM5QXL PC 867
DMM5QXL MW 104.06
DMM5QXL FM C3H4O4
DMM5QXL IC InChI=1S/C3H4O4/c4-2(5)1-3(6)7/h1H2,(H,4,5)(H,6,7)
DMM5QXL CS C(C(=O)O)C(=O)O
DMM5QXL IK OFOBLEOULBTSOW-UHFFFAOYSA-N
DMM5QXL IU propanedioic acid
DMM5QXL CA CAS 141-82-2
DMM5QXL CB CHEBI:30794
DMM5QXL DE Neurodegenerative disorder
DMMY542 ID DMMY542
DMMY542 DN Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam
DMMY542 HS Investigative
DMMY542 DT Small molecular drug
DMMY542 PC 46936258
DMMY542 MW 516.5
DMMY542 FM C18H32N2O15
DMMY542 IC InChI=1S/C18H32N2O15/c21-1-4-14(9(26)11(28)16(19-4)20-31)34-18-13(30)10(27)15(6(3-23)33-18)35-17-12(29)8(25)7(24)5(2-22)32-17/h4-15,17-18,21-31H,1-3H2,(H,19,20)/t4-,5+,6-,7+,8-,9-,10-,11+,12+,13-,14+,15-,17-,18+/m1/s1
DMMY542 CS C([C@@H]1[C@@H]([C@@H]([C@@H](C(=N1)NO)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)O)O)O)O
DMMY542 IK AHRWQUNEPBVNOT-JUQSOTOUSA-N
DMMY542 IU (2R,3S,4R,5R,6S)-2-[(2R,3S,4R,5R,6R)-6-[[(2R,3S,4R,5R)-4,5-dihydroxy-6-(hydroxyamino)-2-(hydroxymethyl)-2,3,4,5-tetrahydropyridin-3-yl]oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMMY542 DE Discovery agent
DM213MD ID DM213MD
DM213MD DN M-Aminophenylboronic Acid
DM213MD HS Investigative
DM213MD SN 3-Aminophenylboronic acid; 30418-59-8; 3-Aminobenzeneboronic acid; (3-aminophenyl)boronic acid; M-AMINOPHENYLBORONIC ACID; 3-aminophenyl boronic acid; m-aminophenyl boronic acid; 3-amino phenylboronic acid; CHEMBL20852; Boronic acid, (3-aminophenyl)-; MFCD00007755; 280563-63-5; (m-Aminophenyl)metaboric acid; 3-Boronoaniline; EINECS 250-189-0; zlchem 430; 3-Aminophenylboronicacid; ACMC-1CTTO; 3amino phenylboronic acid; 3aminophenyl boronic acid; AC1L3NRS; (3-aminophenyl)boranediol; 3-amino-phenylboronic acid; AC1Q51DZ
DM213MD DT Small molecular drug
DM213MD PC 92269
DM213MD MW 136.95
DM213MD FM C6H8BNO2
DM213MD IC InChI=1S/C6H8BNO2/c8-6-3-1-2-5(4-6)7(9)10/h1-4,9-10H,8H2
DM213MD CS B(C1=CC(=CC=C1)N)(O)O
DM213MD IK JMZFEHDNIAQMNB-UHFFFAOYSA-N
DM213MD IU (3-aminophenyl)boronic acid
DM213MD CA CAS 30418-59-8
DM213MD DE Discovery agent
DMNUA6S ID DMNUA6S
DMNUA6S DN Man-b-4MU
DMNUA6S HS Investigative
DMNUA6S SN VZ29453; Man-b-4MU; 4-methylumbelliferyl beta-d-mannopyranoside; SCHEMBL308899; ZINC13536768; ZX-AFC001336; 4-Methyl-7-(((2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2H-chromen-2-one; 4-Methylumbelliferyl beta-D-mannopyranoside; 4-Methylumbelliferyl mannoside; 4-Methylumbelliferyl-beta-D-mannopyranoside; 4MUBM; 67909-30-2; 7-((2S,3R,4S,5S)-tetrahydro-3,4,5-trihydroxy-6-(hydroxymethyl)-2H-pyran-2-yloxy)-4-methyl-2H-chromen-2-one; CHEMBL3797837; para-Methylumbelliferyl-beta-D-mannopyranoside
DMNUA6S PC 194267
DMNUA6S MW 338.31
DMNUA6S FM C16H18O8
DMNUA6S IC YUDPTGPSBJVHCN-NZBFACKJSA-N
DMNUA6S CS CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O
DMNUA6S IK 1S/C16H18O8/c1-7-4-12(18)23-10-5-8(2-3-9(7)10)22-16-15(21)14(20)13(19)11(6-17)24-16/h2-5,11,13-17,19-21H,6H2,1H3/t11-,13-,14+,15+,16-/m1/s1
DMNUA6S IU 4-methyl-7-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
DMNUA6S CA CAS 67909-30-2
DMNUA6S DE Discovery agent
DMKT129 ID DMKT129
DMKT129 DN Manganese
DMKT129 HS Investigative
DMKT129 SN Colloidal manganese; Cutaval; MANGANESE COMPOUNDS; Magnacat; Mangan; Mangan [Polish]; Mangan nitridovany; Mangan nitridovany [Czech]; Manganese; Manganese element; Manganese fume; Manganese ion(4 ); Manganese metal alloy; Manganese(1-); Manganese(4 ); Manganese(7+); Manganese, 99+%, powder, -40 mesh; Manganese, elemental; Manganese, ion (Mn1-); Manganese, ion (Mn4 ); Manganese-55; Teprosyn M; Tronamang; manganeso; manganide; manganum
DMKT129 DT Small molecular drug
DMKT129 PC 23930
DMKT129 MW 54.938
DMKT129 FM Mn
DMKT129 IC InChI=1S/Mn
DMKT129 CS [Mn]
DMKT129 IK PWHULOQIROXLJO-UHFFFAOYSA-N
DMKT129 IU manganese
DMKT129 CA CAS 7439-96-5
DMKT129 CB ChEBI:18291
DMWAF5Z ID DMWAF5Z
DMWAF5Z DN MANGIFERIN
DMWAF5Z HS Investigative
DMWAF5Z SN Mangiferin; 4773-96-0; Hedysarid; Chinomin; Alpizarin; Chinonin; Aphloiol; Alpizarine; UNII-1M84LD0UMD; 1M84LD0UMD; CHEBI:6682; 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one; (1S)-1,5-anhydro-1-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-D-glucitol; 1,3,6,7-Tetrahydroxyxanthone-C2-b-D-glucoside; Chinoinin; 9H-Xanthen-9-one, 2-.beta.-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; C19H18O11; NSC 248870; 9H-Xanthen-9-one, 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-; cid_5358385; Mangiferin;; Alpizarine;; Chinomin;
DMWAF5Z DT Small molecular drug
DMWAF5Z PC 5281647
DMWAF5Z MW 422.3
DMWAF5Z FM C19H18O11
DMWAF5Z IC InChI=1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1
DMWAF5Z CS C1=C2C(=CC(=C1O)O)OC3=C(C2=O)C(=C(C(=C3)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
DMWAF5Z IK AEDDIBAIWPIIBD-ZJKJAXBQSA-N
DMWAF5Z IU 1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one
DMWAF5Z CA CAS 4773-96-0
DMWAF5Z CB CHEBI:6682
DMWAF5Z DE Discovery agent
DMOWZUB ID DMOWZUB
DMOWZUB DN MANGOSTANIN
DMOWZUB HS Investigative
DMOWZUB SN 9-Hydroxycalabaxanthone; Mangostanin; 35349-68-9; CHEMBL561643; Q-100424; 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)pyrano[3,2-b]xanthen-6-one; AC1NUY37; SCHEMBL5617031; MolPort-029-887-080; ZINC13382495; BDBM50311741; AKOS032962410; W2653; 2H,6H-Pyrano[3,2-b]xanthen-6-one,5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methyl-2-butenyl)-; 1,6-dihydroxy-7-methoxy-8-(3-methylbut-2-enyl)-6'',6''-dimethylpyrano(2'',3'':3,2)xanthone
DMOWZUB DT Small molecular drug
DMOWZUB PC 5495929
DMOWZUB MW 408.4
DMOWZUB FM C24H24O6
DMOWZUB IC InChI=1S/C24H24O6/c1-12(2)6-7-14-19-17(10-15(25)23(14)28-5)29-18-11-16-13(8-9-24(3,4)30-16)21(26)20(18)22(19)27/h6,8-11,25-26H,7H2,1-5H3
DMOWZUB CS CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(C4=C(C=C3O2)OC(C=C4)(C)C)O)O)OC)C
DMOWZUB IK HQWHKELJHUFLGD-UHFFFAOYSA-N
DMOWZUB IU 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)pyrano[3,2-b]xanthen-6-one
DMOWZUB CA CAS 35349-68-9
DMOWZUB DE Discovery agent
DMG3DUE ID DMG3DUE
DMG3DUE DN MANGOSTANOL
DMG3DUE HS Investigative
DMG3DUE SN MANGOSTANOL; 184587-72-2; CHEMBL1224250; (+)-Mangostanol; MolPort-035-706-483; BDBM50325676; AKOS032961774; W2661; 2H,6H-Pyrano[3,2-b]xanthen-6-one,3,4-dihydro-3,5,9-trihydroxy-8-methoxy-2,2-dimethyl-7-(3-methyl-2-buten-1-yl)-,(+)-
DMG3DUE DT Small molecular drug
DMG3DUE PC 10048103
DMG3DUE MW 426.5
DMG3DUE FM C24H26O7
DMG3DUE IC InChI=1S/C24H26O7/c1-11(2)6-7-12-19-16(9-14(25)23(12)29-5)30-17-10-15-13(21(27)20(17)22(19)28)8-18(26)24(3,4)31-15/h6,9-10,18,25-27H,7-8H2,1-5H3
DMG3DUE CS CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(C4=C(C=C3O2)OC(C(C4)O)(C)C)O)O)OC)C
DMG3DUE IK KCMPFWGUVNEDHW-UHFFFAOYSA-N
DMG3DUE IU 3,5,9-trihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-enyl)-3,4-dihydropyrano[3,2-b]xanthen-6-one
DMG3DUE CA CAS 184587-72-2
DMG3DUE DE Discovery agent
DMNRZ3S ID DMNRZ3S
DMNRZ3S DN MANGOSTENONE F
DMNRZ3S HS Investigative
DMNRZ3S SN CHEMBL1224411; MANGOSTENONE F; BDBM50325677
DMNRZ3S DT Small molecular drug
DMNRZ3S PC 49866102
DMNRZ3S MW 408.4
DMNRZ3S FM C24H24O6
DMNRZ3S IC InChI=1S/C24H24O6/c1-11(2)6-7-13-20-18(9-15(25)24(13)28-5)30-19-10-17-14(8-16(29-17)12(3)4)22(26)21(19)23(20)27/h6,9-10,16,25-26H,3,7-8H2,1-2,4-5H3
DMNRZ3S CS CC(=CCC1=C(C(=CC2=C1C(=O)C3=C(C4=C(C=C3O2)OC(C4)C(=C)C)O)O)OC)C
DMNRZ3S IK AWFULCQUYOKYCM-UHFFFAOYSA-N
DMNRZ3S IU 4,8-dihydroxy-7-methoxy-6-(3-methylbut-2-enyl)-2-prop-1-en-2-yl-2,3-dihydrofuro[3,2-b]xanthen-5-one
DMNRZ3S DE Discovery agent
DM4I2NR ID DM4I2NR
DM4I2NR DN MANGOSTENONE G
DM4I2NR HS Investigative
DM4I2NR SN CHEMBL1224412; MANGOSTENONE G; BDBM50325678
DM4I2NR DT Small molecular drug
DM4I2NR PC 49866103
DM4I2NR MW 394.4
DM4I2NR FM C23H22O6
DM4I2NR IC InChI=1S/C23H22O6/c1-10(2)5-6-12-14(24)8-18-20(21(12)26)22(27)19-13-7-16(11(3)4)29-23(13)15(25)9-17(19)28-18/h5,8-9,16,24-26H,3,6-7H2,1-2,4H3
DM4I2NR CS CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C4=C(C(=C3)O)OC(C4)C(=C)C)O)C
DM4I2NR IK SEGCUVJLNASWOR-UHFFFAOYSA-N
DM4I2NR IU 4,8,10-trihydroxy-9-(3-methylbut-2-enyl)-2-prop-1-en-2-yl-1,2-dihydrofuro[3,2-a]xanthen-11-one
DM4I2NR DE Discovery agent
DMYQGDV ID DMYQGDV
DMYQGDV DN MANGOSTIN
DMYQGDV HS Investigative
DMYQGDV SN alpha-Mangostin; Mangostin; 6147/11/1; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; Mangostine; NSC30552; NSC27593; NSC-30552; UNII-U6RIV93RU1; U6RIV93RU1; CHEMBL323197; CHEBI:67547; GNRIZKKCNOBBMO-UHFFFAOYSA-N; 1,3,6-trihydroxy-7-methoxy-2,8-diprenylxanthone; TNP00140; NSC 27593; NSC 30552; NSC 139154; AK105375; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; Q-100010
DMYQGDV DT Small molecular drug
DMYQGDV PC 5281650
DMYQGDV MW 410.5
DMYQGDV FM C24H26O6
DMYQGDV IC InChI=1S/C24H26O6/c1-12(2)6-8-14-16(25)10-19-21(22(14)27)23(28)20-15(9-7-13(3)4)24(29-5)17(26)11-18(20)30-19/h6-7,10-11,25-27H,8-9H2,1-5H3
DMYQGDV CS CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CC=C(C)C)O)C
DMYQGDV IK GNRIZKKCNOBBMO-UHFFFAOYSA-N
DMYQGDV IU 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one
DMYQGDV CA CAS 6147-11-1
DMYQGDV CB CHEBI:67547
DMYQGDV DE Discovery agent
DMSO8EU ID DMSO8EU
DMSO8EU DN Mannotetraose
DMSO8EU HS Investigative
DMSO8EU SN Mannotetraose; Q27132313; 51327-76-5; CHEBI:62973; Mannose, O-beta-D-mannopyranosyl-(1-4)-O-beta-D-mannopyranosyl-(1-4)-O-beta-D-mannopyranosyl-(1-4)-, D-; O-MTE; beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp; beta-D-mannopyranosyl-(1->4)-beta-D-mannopyranosyl-(1->4)-beta-D-mannopyranosyl-(1->4)-D-mannopyranose
DMSO8EU PC 53477669
DMSO8EU MW 666.6
DMSO8EU FM C24H42O21
DMSO8EU IC LUEWUZLMQUOBSB-MHJOMNRISA-N
DMSO8EU CS C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)O)CO)CO)CO)O)O)O)O
DMSO8EU IK 1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16+,17+,18-,19-,20-,21?,22+,23+,24+/m1/s1
DMSO8EU IU (2S,3S,4S,5S,6R)-2-[(2R,3S,4R,5S,6S)-6-[(2R,3S,4R,5S,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
DMSO8EU CA CAS 51327-76-5
DMSO8EU CB CHEBI:62973
DMSO8EU DE Alzheimer disease
DMB3GNC ID DMB3GNC
DMB3GNC DN MANZAMINE A
DMB3GNC HS Investigative
DMB3GNC SN Manzamine A; 104196-68-1; CHEMBL611781; SCHEMBL11915472
DMB3GNC DT Small molecular drug
DMB3GNC PC 6509753
DMB3GNC MW 548.8
DMB3GNC FM C36H44N4O
DMB3GNC IC InChI=1S/C36H44N4O/c41-36-18-10-4-1-2-5-11-20-39-22-17-30(35(25-39)23-26-13-7-3-6-12-21-40(26)34(35)36)29(24-36)32-33-28(16-19-37-32)27-14-8-9-15-31(27)38-33/h1,4,7-9,13-16,19,24,26,30,34,38,41H,2-3,5-6,10-12,17-18,20-23,25H2/b4-1-,13-7-/t26-,30-,34+,35-,36-/m0/s1
DMB3GNC CS C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)O)C6=NC=CC7=C6NC8=CC=CC=C78
DMB3GNC IK FUCSLKWLLSEMDQ-MKYGIPPKSA-N
DMB3GNC IU (1R,2R,4R,5Z,12R,13S,16Z)-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DMB3GNC CA CAS 104196-68-1
DMB3GNC CB CHEBI:66667
DMB3GNC DE Discovery agent
DMOI9RT ID DMOI9RT
DMOI9RT DN Manzamine E
DMOI9RT HS Investigative
DMOI9RT SN Manzamine E
DMOI9RT DT Small molecular drug
DMOI9RT PC 6474830
DMOI9RT MW 564.8
DMOI9RT FM C36H44N4O2
DMOI9RT IC InChI=1S/C36H44N4O2/c41-26-10-9-20-40-25(13-14-26)22-35-24-39-19-8-4-2-1-3-7-17-36(42,34(35)40)23-29(30(35)16-21-39)32-33-28(15-18-37-32)27-11-5-6-12-31(27)38-33/h1,3,5-6,11-12,15,18,23,25,30,34,38,42H,2,4,7-10,13-14,16-17,19-22,24H2/b3-1-/t25?,30-,34?,35-,36-/m0/s1
DMOI9RT CS C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)(C4[C@]3(C2)CC5N4CCCC(=O)CC5)O)C6=NC=CC7=C6NC8=CC=CC=C78
DMOI9RT IK LTHULOBARTYAMF-JUOMLHCBSA-N
DMOI9RT IU (1R,2R,13S,16Z)-13-hydroxy-25-(9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-16,25-dien-7-one
DMOI9RT DE Discovery agent
DMC7ADZ ID DMC7ADZ
DMC7ADZ DN Manzamine Y
DMC7ADZ HS Investigative
DMC7ADZ SN manzamine Y; CHEBI:66668; (4aR,7S,7aR,13Z,14aR,15aR,18Z)-5-(6-hydroxy-9H-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3H-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1H,7aH)-ol
DMC7ADZ DT Small molecular drug
DMC7ADZ PC 10393120
DMC7ADZ MW 564.8
DMC7ADZ FM C36H44N4O2
DMC7ADZ IC InChI=1S/C36H44N4O2/c41-26-12-13-31-28(21-26)27-14-17-37-32(33(27)38-31)29-23-36(42)16-8-4-1-2-5-9-18-39-20-15-30(29)35(24-39)22-25-11-7-3-6-10-19-40(25)34(35)36/h1,4,7,11-14,17,21,23,25,30,34,38,41-42H,2-3,5-6,8-10,15-16,18-20,22,24H2/b4-1-,11-7-/t25-,30-,34+,35-,36-/m0/s1
DMC7ADZ CS C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@H]/5N4CCCC/C=C5)O)C6=NC=CC7=C6NC8=C7C=C(C=C8)O
DMC7ADZ IK CANRNZBVKKQKEQ-FFMUKQARSA-N
DMC7ADZ IU (1R,2R,4R,5Z,12R,13S,16Z)-25-(6-hydroxy-9H-pyrido[3,4-b]indol-1-yl)-11,22-diazapentacyclo[11.11.2.12,22.02,12.04,11]heptacosa-5,16,25-trien-13-ol
DMC7ADZ CB CHEBI:66668
DMUCE93 ID DMUCE93
DMUCE93 DN MAP4
DMUCE93 HS Investigative
DMUCE93 SN MAP4; (S)-2-Amino-2-methyl-4-phosphonobutanoic acid; 157381-42-5; (2S)-2-amino-2-methyl-4-phosphonobutanoic acid; Tocris-0711; AC1LX6MM; MAP-4; SCHEMBL179781; GTPL1414; CHEMBL1488784; MolPort-003-983-618; ZINC2139819; BN0320; AKOS006272533; NCGC00024744-02; NCGC00024744-01; B6414; SR-01000597625; 381A425; J-009412
DMUCE93 DT Small molecular drug
DMUCE93 PC 1795545
DMUCE93 MW 197.13
DMUCE93 FM C5H12NO5P
DMUCE93 IC InChI=1S/C5H12NO5P/c1-5(6,4(7)8)2-3-12(9,10)11/h2-3,6H2,1H3,(H,7,8)(H2,9,10,11)/t5-/m0/s1
DMUCE93 CS C[C@](CCP(=O)(O)O)(C(=O)O)N
DMUCE93 IK HONKEGXLWUDTCF-YFKPBYRVSA-N
DMUCE93 IU (2S)-2-amino-2-methyl-4-phosphonobutanoic acid
DMUCE93 DE Discovery agent
DMKT21X ID DMKT21X
DMKT21X DN MAR-531
DMKT21X HS Investigative
DMKT21X SN Glucagon analogs (injector pen, hypoglycemia); Glucagon analogs (injector pen, hypoglycemia), Marcadia/ Eli Lilly
DMKT21X CP Marcadia Biotech Inc
DMKT21X DE Hypoglycemia
DMGF7XC ID DMGF7XC
DMGF7XC DN MAR--99
DMGF7XC HS Investigative
DMGF7XC SN BRN 5609020
DMGF7XC CP Roussel Morishita Pharmaceutical Co Ltd
DMGF7XC DT Small molecular drug
DMGF7XC PC 127154
DMGF7XC MW 303.31
DMGF7XC FM C15H17N3O4
DMGF7XC IC InChI=1S/C15H17N3O4/c1-3-9(2)22-12-7-5-4-6-11(12)17-15-16-8-10(14(20)21)13(19)18-15/h4-9H,3H2,1-2H3,(H,20,21)(H2,16,17,18,19)
DMGF7XC CS CCC(C)OC1=CC=CC=C1NC2=NC=C(C(=O)N2)C(=O)O
DMGF7XC IK GPASXNHOXQCREW-UHFFFAOYSA-N
DMGF7XC IU 2-(2-butan-2-yloxyanilino)-6-oxo-1H-pyrimidine-5-carboxylic acid
DMGF7XC CA CAS 98772-05-5
DMGF7XC DE Asthma
DMN9UX3 ID DMN9UX3
DMN9UX3 DN MASLINIC ACID
DMN9UX3 HS Investigative
DMN9UX3 SN Maslinic acid; 4373-41-5; Crategolic acid; Masilinic acid; Crataegolic acid; UNII-E233J88OHQ; E233J88OHQ; CHEMBL201515; CHEBI:66682; Maslic acid; 2alpha,3beta-dihydroxyurs-12-en-29-oic acid; (4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; Maslinicacid
DMN9UX3 DT Small molecular drug
DMN9UX3 PC 73659
DMN9UX3 MW 472.7
DMN9UX3 FM C30H48O4
DMN9UX3 IC InChI=1S/C30H48O4/c1-25(2)12-14-30(24(33)34)15-13-28(6)18(19(30)16-25)8-9-22-27(5)17-20(31)23(32)26(3,4)21(27)10-11-29(22,28)7/h8,19-23,31-32H,9-17H2,1-7H3,(H,33,34)/t19-,20+,21-,22+,23-,27-,28+,29+,30-/m0/s1
DMN9UX3 CS C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)O)O)C
DMN9UX3 IK MDZKJHQSJHYOHJ-LLICELPBSA-N
DMN9UX3 IU (4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DMN9UX3 CA CAS 4373-41-5
DMN9UX3 CB CHEBI:66682
DMN9UX3 DE Discovery agent
DMDZIHT ID DMDZIHT
DMDZIHT DN mast cell degranulating peptide
DMDZIHT HS Investigative
DMDZIHT SN MCDP; MCD peptide; Peptide 401
DMDZIHT DT Small molecular drug
DMDZIHT PC 16132290
DMDZIHT MW 2587.2
DMDZIHT FM C110H192N40O24S4
DMDZIHT IC InChI=1S/C110H192N40O24S4/c1-11-58(7)83(118)103(169)136-66(30-17-22-38-113)94(160)142-77-53-176-175-51-75(89(155)128-50-82(153)131-64(28-15-20-36-111)90(156)138-71(88(119)154)46-80(116)151)144-106(172)85(59(8)12-2)147-95(161)67(31-18-23-39-114)132-92(158)68(33-25-41-126-109(120)121)135-100(166)78-54-178-177-52-76(143-96(162)74(47-81(117)152)140-101(77)167)99(165)134-65(29-16-21-37-112)91(157)133-69(34-26-42-127-110(122)123)93(159)139-72(44-62-48-124-55-129-62)97(163)146-84(57(5)6)104(170)149-87(61(10)14-4)105(171)137-70(32-19-24-40-115)108(174)150-43-27-35-79(150)102(168)141-73(45-63-49-125-56-130-63)98(164)148-86(60(9)13-3)107(173)145-78/h48-49,55-79,83-87H,11-47,50-54,111-115,118H2,1-10H3,(H2,116,151)(H2,117,152)(H2,119,154)(H,128,155)(H,131,153)(H,132,158)(H,133,157)(H,134,165)(H,135,166)(H,136,169)(H,137,171)(H,138,156)(H,139,159)(H,140,167)(H,141,168)(H,142,160)(H,143,162)(H,144,172)(H,145,173)(H,146,163)(H,147,161)(H,148,164)(H,149,170)(H4,120,121,126)(H4,122,123,127)
DMDZIHT CS CCC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CCCNC(=N)N)NC(=O)C(NC(=O)C(NC(=O)C3CCCN3C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCCCN)CCCNC(=N)N)CC4C=NC=N4)C(C)C)C(C)CC)CCCCN)CC5C=NC=N5)C(C)CC)CC(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)N)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)N
DMDZIHT IK QMBRLNFAEHGOLY-UHFFFAOYSA-N
DMDZIHT IU 2-[[6-amino-2-[[2-[[40-[[6-amino-2-[(2-amino-3-methylpentanoyl)amino]hexanoyl]amino]-16,31,51-tris(4-aminobutyl)-37-(2-amino-2-oxoethyl)-4,19,48-tri(butan-2-yl)-28,54-bis(3-carbamimidamidopropyl)-7,25-bis(4H-imidazol-4-ylmethyl)-3,6,9,15,18,21,24,27,30,33,36,39,47,50,53,56-hexadecaoxo-22-propan-2-yl-42,43,58,59-tetrathia-2,5,8,14,17,20,23,26,29,32,35,38,46,49,52,55-hexadecazatricyclo[32.22.4.010,14]hexacontane-45-carbonyl]amino]acetyl]amino]hexanoyl]amino]butanediamide
DMDZIHT CA CAS 32908-73-9
DMDZIHT DE Discovery agent
DM9KLQC ID DM9KLQC
DM9KLQC DN MB-03966
DM9KLQC HS Investigative
DM9KLQC SN AK inhibitors, Gensia; AK inhibitors, SICOR; Adenosine kinase inhibitors, Metabasis; Adenosine kinase inhibitors, SICOR; GP-3966; GP-4364; MB-03691; MB-4587; Tubercidin derivatives, Metabasis
DM9KLQC CP SICOR Inc
DM9KLQC DE Epileptic seizures
DMNRMKA ID DMNRMKA
DMNRMKA DN MB-3
DMNRMKA HS Investigative
DMNRMKA SN alpha-methylene-gamma-butyrolactone 3
DMNRMKA DT Small molecular drug
DMNRMKA PC 91827357
DMNRMKA MW 186.16
DMNRMKA FM C8H10O5
DMNRMKA IC InChI=1S/C8H10O5/c1-2-3-4-5(7(10)11)6(9)8(12)13-4/h4-5H,2-3H2,1H3,(H,10,11)/t4-,5-/m0/s1
DMNRMKA CS CCC[C@H]1[C@@H](C(=O)C(=O)O1)C(=O)O
DMNRMKA IK AKWJFOMNTDKSRR-WHFBIAKZSA-N
DMNRMKA IU (2S,3S)-4,5-dioxo-2-propyloxolane-3-carboxylic acid
DMNRMKA DE Discovery agent
DM89WA1 ID DM89WA1
DM89WA1 DN MBX-3254
DM89WA1 HS Investigative
DM89WA1 SN GPR119 follow-on compounds (diabetes); GPR119 follow-on compounds (diabetes), Metabolex; MBX-2982 follow-on compounds (diabetes), Metabolex
DM89WA1 CP Metabolex Inc
DM89WA1 DE Non-insulin dependent diabetes
DMPTNUQ ID DMPTNUQ
DMPTNUQ DN MC-113
DMPTNUQ HS Investigative
DMPTNUQ SN Sigma opoid receptor agonist (oral, CNS diseases), M's Science
DMPTNUQ CP M's Science Corp
DMPTNUQ DE Central nervous system disease
DMQC9UB ID DMQC9UB
DMQC9UB DN MC-116
DMQC9UB HS Investigative
DMQC9UB SN MC-116 series; Sigma opioid receptor-1 agonists (oral, CNS diseases), M's Science
DMQC9UB CP M's Science Corp
DMQC9UB DE Central nervous system disease
DM5RVO0 ID DM5RVO0
DM5RVO0 DN MC-1301
DM5RVO0 HS Investigative
DM5RVO0 SN 134523-85-6
DM5RVO0 DT Small molecular drug
DM5RVO0 PC 6439378
DM5RVO0 MW 458.7
DM5RVO0 FM C30H50O3
DM5RVO0 IC InChI=1S/C30H50O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h13-14,21,25-28,31-33H,4,6-12,15-20H2,1-3,5H3/b23-13+,24-14+/t21?,25-,26?,27+,28+,29-/m1/s1
DM5RVO0 CS CCC(CC)(CCCCC(C)C1CC[C@@H]\\2[C@@]1(CCC/C2=C\\C=C\\3/C[C@H](C[C@@H](C3=C)O)O)C)O
DM5RVO0 IK DFOWDEBIOXYKFC-WIAGJZICSA-N
DM5RVO0 IU (1R,3S,5E)-5-[(2E)-2-[(3aS,7aR)-1-(7-ethyl-7-hydroxynonan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
DM5RVO0 CA CAS 134523-85-6
DM5RVO0 DE Discovery agent
DM6J2UZ ID DM6J2UZ
DM6J2UZ DN MCC950
DM6J2UZ HS Investigative
DM6J2UZ SN MCC950; 210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea
DM6J2UZ DT Small molecular drug
DM6J2UZ PC 9910393
DM6J2UZ MW 404.5
DM6J2UZ FM C20H24N2O5S
DM6J2UZ IC InChI=1S/C20H24N2O5S/c1-20(2,24)14-10-17(27-11-14)28(25,26)22-19(23)21-18-15-7-3-5-12(15)9-13-6-4-8-16(13)18/h9-11,24H,3-8H2,1-2H3,(H2,21,22,23)
DM6J2UZ CS CC(C)(C1=COC(=C1)S(=O)(=O)NC(=O)NC2=C3CCCC3=CC4=C2CCC4)O
DM6J2UZ IK HUUSXLKCTQDPGL-UHFFFAOYSA-N
DM6J2UZ IU 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(2-hydroxypropan-2-yl)furan-2-yl]sulfonylurea
DM6J2UZ CA CAS 210826-40-7
DM6J2UZ DE Discovery agent
DMAHN4L ID DMAHN4L
DMAHN4L DN MC-CAM
DMAHN4L HS Investigative
DMAHN4L SN CHEMBL386272; MC-CAM; BDBM50195674; BDBM50091405; 14-[(4-Chlorocinnamoyl)amino]-4,5alpha-epoxy-17-(cyclopropylmethyl)-3-methoxymorphinan-6-one; 1N-[4-cyclopropylmethyl-10-methoxy-14-oxo-(17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-17-yl]-3-(4-chlorophenyl)-(E)-2-propenamide(Methyoclocinnamox (MC-CAM))
DMAHN4L DT Small molecular drug
DMAHN4L PC 44417373
DMAHN4L MW 519
DMAHN4L FM C30H31ClN2O4
DMAHN4L IC InChI=1S/C30H31ClN2O4/c1-36-23-10-7-20-16-24-30(32-25(35)11-6-18-4-8-21(31)9-5-18)13-12-22(34)28-29(30,26(20)27(23)37-28)14-15-33(24)17-19-2-3-19/h4-11,19,24,28H,2-3,12-17H2,1H3,(H,32,35)/b11-6+/t24-,28+,29+,30-/m1/s1
DMAHN4L CS COC1=C2C3=C(C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)NC(=O)/C=C/C7=CC=C(C=C7)Cl)C=C1
DMAHN4L IK LZSMGMMAKBCSRL-WDJVXPEUSA-N
DMAHN4L IU (E)-N-[(4R,4aS,7aR,12bR)-3-(cyclopropylmethyl)-9-methoxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-3-(4-chlorophenyl)prop-2-enamide
DMAHN4L DE Discovery agent
DMKTX1A ID DMKTX1A
DMKTX1A DN MCCG
DMKTX1A HS Investigative
DMKTX1A SN MCCG-I
DMKTX1A DT Small molecular drug
DMKTX1A PC 5311457
DMKTX1A MW 173.17
DMKTX1A FM C7H11NO4
DMKTX1A IC InChI=1S/C7H11NO4/c1-7(8,6(11)12)4-2-3(4)5(9)10/h3-4H,2,8H2,1H3,(H,9,10)(H,11,12)/t3-,4-,7-/m0/s1
DMKTX1A CS C[C@]([C@H]1C[C@@H]1C(=O)O)(C(=O)O)N
DMKTX1A IK KFACHLANPCGTFI-FVSJBQLASA-N
DMKTX1A IU (1S,2S)-2-[(1S)-1-amino-1-carboxyethyl]cyclopropane-1-carboxylic acid
DMKTX1A CB CHEBI:125551
DMKTX1A DE Discovery agent
DMM1J2D ID DMM1J2D
DMM1J2D DN m-chlorophenylpiperazine
DMM1J2D HS Investigative
DMM1J2D SN 1-(m-chlorophenyl)piperazine; meta chlorophenyl piperazine
DMM1J2D DT Small molecular drug
DMM1J2D PC 1355
DMM1J2D MW 196.67
DMM1J2D FM C10H13ClN2
DMM1J2D IC InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
DMM1J2D CS C1CN(CCN1)C2=CC(=CC=C2)Cl
DMM1J2D IK VHFVKMTVMIZMIK-UHFFFAOYSA-N
DMM1J2D IU 1-(3-chlorophenyl)piperazine
DMM1J2D CA CAS 6640-24-0
DMM1J2D CB CHEBI:10588
DMM1J2D DE Discovery agent
DMZ1YGI ID DMZ1YGI
DMZ1YGI DN MCI
DMZ1YGI HS Investigative
DMZ1YGI SN AC1L1B35; CTK8A8774; (2-mercaptomethyl-4-phenyl-butyrylimino)-(5-tetrazol-1-ylmethyl-thiophen-2-yl)-acetic acid; 2-[4-phenyl-2-(sulfanylmethyl)butanoyl]imino-2-[5-(tetrazol-1-ylmethyl)thiophen-2-yl]acetic acid
DMZ1YGI DT Small molecular drug
DMZ1YGI PC 1263
DMZ1YGI MW 429.5
DMZ1YGI FM C19H19N5O3S2
DMZ1YGI IC InChI=1S/C19H19N5O3S2/c25-18(14(11-28)7-6-13-4-2-1-3-5-13)21-17(19(26)27)16-9-8-15(29-16)10-24-12-20-22-23-24/h1-5,8-9,12,14,28H,6-7,10-11H2,(H,26,27)
DMZ1YGI CS C1=CC=C(C=C1)CCC(CS)C(=O)N=C(C2=CC=C(S2)CN3C=NN=N3)C(=O)O
DMZ1YGI IK DUKDFMPUZRDWLT-UHFFFAOYSA-N
DMZ1YGI IU 2-[4-phenyl-2-(sulfanylmethyl)butanoyl]imino-2-[5-(tetrazol-1-ylmethyl)thiophen-2-yl]acetic acid
DMZ1YGI DE Discovery agent
DMFTPMX ID DMFTPMX
DMFTPMX DN MCL0129
DMFTPMX HS Investigative
DMFTPMX SN MCL-0129; TCMDC-134847
DMFTPMX DT Small molecular drug
DMFTPMX PC 6918688
DMFTPMX MW 546.8
DMFTPMX FM C34H47FN4O
DMFTPMX IC InChI=1S/C34H47FN4O/c1-27(2)38-22-24-39(25-23-38)33(29-11-14-30(35)15-12-29)26-37-20-18-36(19-21-37)17-7-6-10-32-31-9-5-4-8-28(31)13-16-34(32)40-3/h4-5,8-9,11-16,27,33H,6-7,10,17-26H2,1-3H3/t33-/m1/s1
DMFTPMX CS CC(C)N1CCN(CC1)[C@H](CN2CCN(CC2)CCCCC3=C(C=CC4=CC=CC=C43)OC)C5=CC=C(C=C5)F
DMFTPMX IK SLGLZEJKMBCODK-MGBGTMOVSA-N
DMFTPMX IU 1-[(1S)-1-(4-fluorophenyl)-2-[4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazin-1-yl]ethyl]-4-propan-2-ylpiperazine
DMFTPMX DE Discovery agent
DMQIGZ7 ID DMQIGZ7
DMQIGZ7 DN MCL-117
DMQIGZ7 HS Investigative
DMQIGZ7 SN MCL-117; CHEMBL1790045; (-)3-hydroxy-N-propargylmorphinan; BDBM50366764
DMQIGZ7 DT Small molecular drug
DMQIGZ7 PC 6602241
DMQIGZ7 MW 281.4
DMQIGZ7 FM C19H23NO
DMQIGZ7 IC InChI=1S/C19H23NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h1,6-7,13,16,18,21H,3-5,8-12H2/t16-,18+,19+/m0/s1
DMQIGZ7 CS C#CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O
DMQIGZ7 IK OKICQDFBWUMTDE-QXAKKESOSA-N
DMQIGZ7 IU (1R,9R,10R)-17-prop-2-ynyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DMQIGZ7 DE Discovery agent
DMQZC0U ID DMQZC0U
DMQZC0U DN MCL-129
DMQZC0U HS Investigative
DMQZC0U SN MCL-129; CHEMBL362985; SCHEMBL5318500; SLGLZEJKMBCODK-UHFFFAOYSA-N; BDBM50166529; PDSP2_001273; PDSP1_001289; 1-(2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl)-4-(4-(2-methoxynaphthalen-1-yl)butyl)piperazine; 1-[2-(4-fluorophenyl)-2-(4-isopropylhexahydro-1-pyrazinyl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]hexahydropyrazine; (+/-)-1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]piperazine
DMQZC0U DT Small molecular drug
DMQZC0U PC 10098971
DMQZC0U MW 546.8
DMQZC0U FM C34H47FN4O
DMQZC0U IC InChI=1S/C34H47FN4O/c1-27(2)38-22-24-39(25-23-38)33(29-11-14-30(35)15-12-29)26-37-20-18-36(19-21-37)17-7-6-10-32-31-9-5-4-8-28(31)13-16-34(32)40-3/h4-5,8-9,11-16,27,33H,6-7,10,17-26H2,1-3H3
DMQZC0U CS CC(C)N1CCN(CC1)C(CN2CCN(CC2)CCCCC3=C(C=CC4=CC=CC=C43)OC)C5=CC=C(C=C5)F
DMQZC0U IK SLGLZEJKMBCODK-UHFFFAOYSA-N
DMQZC0U IU 1-[1-(4-fluorophenyl)-2-[4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazin-1-yl]ethyl]-4-propan-2-ylpiperazine
DMQZC0U DE Discovery agent
DMQ1BDZ ID DMQ1BDZ
DMQ1BDZ DN MCL-139
DMQ1BDZ HS Investigative
DMQ1BDZ SN MCL-139; CHEMBL203251
DMQ1BDZ DT Small molecular drug
DMQ1BDZ PC 44406697
DMQ1BDZ MW 705
DMQ1BDZ FM C46H60N2O4
DMQ1BDZ IC InChI=1S/C46H60N2O4/c49-43(51-35-15-13-33-25-41-37-11-1-3-19-45(37,39(33)27-35)21-23-47(41)29-31-7-5-8-31)17-18-44(50)52-36-16-14-34-26-42-38-12-2-4-20-46(38,40(34)28-36)22-24-48(42)30-32-9-6-10-32/h13-16,27-28,31-32,37-38,41-42H,1-12,17-26,29-30H2/t37?,38?,41-,42-,45-,46-/m1/s1
DMQ1BDZ CS C1CC[C@@]23CCN([C@@H](C2C1)CC4=C3C=C(C=C4)OC(=O)CCC(=O)OC5=CC6=C(C[C@@H]7C8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMQ1BDZ IK XZOSATCOBKLHCF-JNDXSTKLSA-N
DMQ1BDZ IU bis[(1R,9R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] butanedioate
DMQ1BDZ DE Discovery agent
DMW7ZF8 ID DMW7ZF8
DMW7ZF8 DN MCL-144
DMW7ZF8 HS Investigative
DMW7ZF8 SN MCL-144; CHEMBL147511; BDBM50135806; di[17-cyclobutylmethyl-(1R,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] sebacate
DMW7ZF8 DT Small molecular drug
DMW7ZF8 PC 9897164
DMW7ZF8 MW 789.1
DMW7ZF8 FM C52H72N2O4
DMW7ZF8 IC InChI=1S/C52H72N2O4/c55-49(57-41-23-21-39-31-47-43-17-7-9-25-51(43,45(39)33-41)27-29-53(47)35-37-13-11-14-37)19-5-3-1-2-4-6-20-50(56)58-42-24-22-40-32-48-44-18-8-10-26-52(44,46(40)34-42)28-30-54(48)36-38-15-12-16-38/h21-24,33-34,37-38,43-44,47-48H,1-20,25-32,35-36H2/t43-,44-,47+,48+,51+,52+/m0/s1
DMW7ZF8 CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OC(=O)CCCCCCCCC(=O)OC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMW7ZF8 IK LWMXWHIOMHIBJP-SPKNWQAQSA-N
DMW7ZF8 IU bis[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] decanedioate
DMW7ZF8 DE Discovery agent
DMJXU67 ID DMJXU67
DMJXU67 DN MCL-145
DMJXU67 HS Investigative
DMJXU67 DT Small molecular drug
DMJXU67 PC 10462426
DMJXU67 MW 703
DMJXU67 FM C46H58N2O4
DMJXU67 IC InChI=1S/C46H58N2O4/c49-43(51-35-15-13-33-25-41-37-11-1-3-19-45(37,39(33)27-35)21-23-47(41)29-31-7-5-8-31)17-18-44(50)52-36-16-14-34-26-42-38-12-2-4-20-46(38,40(34)28-36)22-24-48(42)30-32-9-6-10-32/h13-18,27-28,31-32,37-38,41-42H,1-12,19-26,29-30H2/b18-17+/t37-,38-,41+,42+,45+,46+/m0/s1
DMJXU67 CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OC(=O)/C=C/C(=O)OC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMJXU67 IK AJIAOWVCYKDFGH-KBJNHENKSA-N
DMJXU67 IU bis[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] (E)-but-2-enedioate
DMJXU67 DE Discovery agent
DMH5SMT ID DMH5SMT
DMH5SMT DN MCL-147
DMH5SMT HS Investigative
DMH5SMT SN MCL-147; CHEMBL242756; SCHEMBL14419222; Aminothiazolo-N-Cyclopropylmorphinan
DMH5SMT DT Small molecular drug
DMH5SMT PC 9798655
DMH5SMT MW 353.5
DMH5SMT FM C21H27N3S
DMH5SMT IC InChI=1S/C21H27N3S/c22-20-23-17-11-16-14(10-19(17)25-20)9-18-15-3-1-2-6-21(15,16)7-8-24(18)12-13-4-5-13/h10-11,13,15,18H,1-9,12H2,(H2,22,23)/t15-,18+,21+/m0/s1
DMH5SMT CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)N=C(S5)N)CC6CC6
DMH5SMT IK OQGLRMIBYLADSW-RRMPHLOHSA-N
DMH5SMT IU (1R,12R,13R)-20-(cyclopropylmethyl)-7-thia-5,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),5,9-tetraen-6-amine
DMH5SMT DE Discovery agent
DMTWY94 ID DMTWY94
DMTWY94 DN MCL-149
DMTWY94 HS Investigative
DMTWY94 SN MCL-149; CHEMBL299220; 3-aminocyclorphan; SCHEMBL13383188; 3-Amino-N-cyclopropylmethylmorphinan; ZINC13532322
DMTWY94 DT Small molecular drug
DMTWY94 PC 11392313
DMTWY94 MW 296.4
DMTWY94 FM C20H28N2
DMTWY94 IC InChI=1S/C20H28N2/c21-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-22(19)13-14-4-5-14/h6-7,12,14,17,19H,1-5,8-11,13,21H2/t17-,19+,20+/m0/s1
DMTWY94 CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)N)CC5CC5
DMTWY94 IK JUWFFFGTHLQORF-DFQSSKMNSA-N
DMTWY94 IU (1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DMTWY94 DE Discovery agent
DMCPW5F ID DMCPW5F
DMCPW5F DN MCL-153
DMCPW5F HS Investigative
DMCPW5F DT Small molecular drug
DMCPW5F PC 11411315
DMCPW5F MW 677
DMCPW5F FM C46H64N2O2
DMCPW5F IC InChI=1S/C46H64N2O2/c1-3-19-45-21-23-47(31-33-9-7-10-33)43(39(45)13-1)27-35-15-17-37(29-41(35)45)49-25-5-6-26-50-38-18-16-36-28-44-40-14-2-4-20-46(40,42(36)30-38)22-24-48(44)32-34-11-8-12-34/h15-18,29-30,33-34,39-40,43-44H,1-14,19-28,31-32H2/t39-,40-,43+,44+,45+,46+/m0/s1
DMCPW5F CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OCCCCOC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DMCPW5F IK FETCHTUKZYXAPU-DODYBPFYSA-N
DMCPW5F IU (1R,9R,10R)-17-(cyclobutylmethyl)-4-[4-[[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]oxy]butoxy]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DMCPW5F DE Discovery agent
DM3PIHV ID DM3PIHV
DM3PIHV DN MCL-154
DM3PIHV HS Investigative
DM3PIHV SN CHEMBL151872; BDBM50135811; (1R,9R,10R)-17-(cyclobutylmethyl)-4-[(10-{[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-yl]oxy}decyl)oxy]-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-triene
DM3PIHV DT Small molecular drug
DM3PIHV PC 44365804
DM3PIHV MW 761.2
DM3PIHV FM C52H76N2O2
DM3PIHV IC InChI=1S/C52H76N2O2/c1(3-5-11-31-55-43-23-21-41-33-49-45-19-7-9-25-51(45,47(41)35-43)27-29-53(49)37-39-15-13-16-39)2-4-6-12-32-56-44-24-22-42-34-50-46-20-8-10-26-52(46,48(42)36-44)28-30-54(50)38-40-17-14-18-40/h21-24,35-36,39-40,45-46,49-50H,1-20,25-34,37-38H2/t45-,46-,49+,50+,51+,52+/m0/s1
DM3PIHV CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)OCCCCCCCCCCOC5=CC6=C(C[C@@H]7[C@H]8[C@@]6(CCCC8)CCN7CC9CCC9)C=C5)CC1CCC1
DM3PIHV IK NDMWWBDABLNMKI-YMWIEQFASA-N
DM3PIHV IU (1R,9R,10R)-17-(cyclobutylmethyl)-4-[10-[[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]oxy]decoxy]-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
DM3PIHV DE Discovery agent
DM39YW1 ID DM39YW1
DM39YW1 DN MCL-182
DM39YW1 HS Investigative
DM39YW1 SN MCL-182; CHEMBL49143; 3-aminobutorphan; 3-Amino-N-cyclobutylmethylmorphinan
DM39YW1 DT Small molecular drug
DM39YW1 PC 11255361
DM39YW1 MW 310.5
DM39YW1 FM C21H30N2
DM39YW1 IC InChI=1S/C21H30N2/c22-17-8-7-16-12-20-18-6-1-2-9-21(18,19(16)13-17)10-11-23(20)14-15-4-3-5-15/h7-8,13,15,18,20H,1-6,9-12,14,22H2/t18-,20+,21+/m0/s1
DM39YW1 CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)N)CC5CCC5
DM39YW1 IK HXKMQQLYEGWJQB-CEWLAPEOSA-N
DM39YW1 IU (1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DM39YW1 DE Discovery agent
DMVR51Z ID DMVR51Z
DMVR51Z DN MCL-183
DMVR51Z HS Investigative
DMVR51Z SN MCL-183; CHEMBL390866; SCHEMBL14419223
DMVR51Z DT Small molecular drug
DMVR51Z PC 11303119
DMVR51Z MW 367.6
DMVR51Z FM C22H29N3S
DMVR51Z IC InChI=1S/C22H29N3S/c23-21-24-18-12-17-15(11-20(18)26-21)10-19-16-6-1-2-7-22(16,17)8-9-25(19)13-14-4-3-5-14/h11-12,14,16,19H,1-10,13H2,(H2,23,24)/t16-,19+,22+/m0/s1
DMVR51Z CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)N=C(S5)N)CC6CCC6
DMVR51Z IK HEIQNYAVPBPIJD-DKZVUGQWSA-N
DMVR51Z IU (1R,12R,13R)-20-(cyclobutylmethyl)-7-thia-5,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),5,9-tetraen-6-amine
DMVR51Z DE Discovery agent
DM78F6A ID DM78F6A
DM78F6A DN MCL-1-specific antisense oligonucleotide + midostaurin(PKC412)
DM78F6A HS Investigative
DM78F6A TC Antisense
DM78F6A DT Combination drug (Antisense drug)
DM78F6A DE Systemic mastocytosis
DM72GLY ID DM72GLY
DM72GLY DN MCL-1-specific antisense oligonucleotide + nilotinib (AMN107)
DM72GLY HS Investigative
DM72GLY SN 641571-10-0; UNII-F41401512X; Nilotinib (AMN-107); CHEMBL255863; CHEBI:52172; C28H22F3N7O; HHZIURLSWUIHRB-UHFFFAOYSA-N; NSC747599
DM72GLY TC Antisense
DM72GLY DT Combination drug (Antisense drug)
DM72GLY DE Systemic mastocytosis
DMXBHE4 ID DMXBHE4
DMXBHE4 DN MCL-428
DMXBHE4 HS Investigative
DMXBHE4 SN MCL-428; CHEMBL242048
DMXBHE4 DT Small molecular drug
DMXBHE4 PC 44427183
DMXBHE4 MW 430.6
DMXBHE4 FM C28H34N2O2
DMXBHE4 IC InChI=1S/C28H34N2O2/c31-27(29-22-9-2-1-3-10-22)32-23-13-12-21-17-26-24-11-4-5-14-28(24,25(21)18-23)15-16-30(26)19-20-7-6-8-20/h1-3,9-10,12-13,18,20,24,26H,4-8,11,14-17,19H2,(H,29,31)
DMXBHE4 CS C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NC5=CC=CC=C5)CC6CCC6
DMXBHE4 IK UDWPHJLFGHTIHV-UHFFFAOYSA-N
DMXBHE4 IU [17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-phenylcarbamate
DMXBHE4 DE Discovery agent
DM1XH04 ID DM1XH04
DM1XH04 DN MCL-429
DM1XH04 HS Investigative
DM1XH04 SN MCL-429; CHEMBL397035
DM1XH04 DT Small molecular drug
DM1XH04 PC 44427178
DM1XH04 MW 416.6
DM1XH04 FM C27H32N2O2
DM1XH04 IC InChI=1S/C27H32N2O2/c30-26(28-21-6-2-1-3-7-21)31-22-12-11-20-16-25-23-8-4-5-13-27(23,24(20)17-22)14-15-29(25)18-19-9-10-19/h1-3,6-7,11-12,17,19,23,25H,4-5,8-10,13-16,18H2,(H,28,30)
DM1XH04 CS C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NC5=CC=CC=C5)CC6CC6
DM1XH04 IK PNQVNINMHSUQSR-UHFFFAOYSA-N
DM1XH04 IU [17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-phenylcarbamate
DM1XH04 DE Discovery agent
DMISHCW ID DMISHCW
DMISHCW DN MCL-431
DMISHCW HS Investigative
DMISHCW SN MCL-431; CHEMBL241823
DMISHCW DT Small molecular drug
DMISHCW PC 44427175
DMISHCW MW 328.4
DMISHCW FM C20H28N2O2
DMISHCW IC InChI=1S/C20H28N2O2/c1-3-21-19(23)24-15-8-7-14-12-18-16-6-4-5-9-20(16,17(14)13-15)10-11-22(18)2/h7-8,13,16,18H,3-6,9-12H2,1-2H3,(H,21,23)
DMISHCW CS CCNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3C)C=C1
DMISHCW IK ZNJDUQHDGFWNKK-UHFFFAOYSA-N
DMISHCW IU (17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl) N-ethylcarbamate
DMISHCW DE Discovery agent
DMPOFAR ID DMPOFAR
DMPOFAR DN MCL-432
DMPOFAR HS Investigative
DMPOFAR SN MCL-432; CHEMBL242047
DMPOFAR DT Small molecular drug
DMPOFAR PC 44427182
DMPOFAR MW 382.5
DMPOFAR FM C24H34N2O2
DMPOFAR IC InChI=1S/C24H34N2O2/c1-2-25-23(27)28-19-10-9-18-14-22-20-8-3-4-11-24(20,21(18)15-19)12-13-26(22)16-17-6-5-7-17/h9-10,15,17,20,22H,2-8,11-14,16H2,1H3,(H,25,27)
DMPOFAR CS CCNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CCC5)C=C1
DMPOFAR IK CDJRHRPFKCSONV-UHFFFAOYSA-N
DMPOFAR IU [17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-ethylcarbamate
DMPOFAR DE Discovery agent
DMD3OAQ ID DMD3OAQ
DMD3OAQ DN MCL-433
DMD3OAQ HS Investigative
DMD3OAQ SN MCL-433; CHEMBL245049
DMD3OAQ DT Small molecular drug
DMD3OAQ PC 44427174
DMD3OAQ MW 314.4
DMD3OAQ FM C19H26N2O2
DMD3OAQ IC InChI=1S/C19H26N2O2/c1-20-18(22)23-14-7-6-13-11-17-15-5-3-4-8-19(15,16(13)12-14)9-10-21(17)2/h6-7,12,15,17H,3-5,8-11H2,1-2H3,(H,20,22)
DMD3OAQ CS CNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3C)C=C1
DMD3OAQ IK YJGQAUOQIDQXIT-UHFFFAOYSA-N
DMD3OAQ IU (17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl) N-methylcarbamate
DMD3OAQ DE Discovery agent
DMR31VO ID DMR31VO
DMR31VO DN MCL-434
DMR31VO HS Investigative
DMR31VO SN MCL-434; CHEMBL241824
DMR31VO DT Small molecular drug
DMR31VO PC 44427176
DMR31VO MW 354.5
DMR31VO FM C22H30N2O2
DMR31VO IC InChI=1S/C22H30N2O2/c1-23-21(25)26-17-8-7-16-12-20-18-4-2-3-9-22(18,19(16)13-17)10-11-24(20)14-15-5-6-15/h7-8,13,15,18,20H,2-6,9-12,14H2,1H3,(H,23,25)
DMR31VO CS CNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CC5)C=C1
DMR31VO IK SGHKXPYOPVKZJP-UHFFFAOYSA-N
DMR31VO IU [17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-methylcarbamate
DMR31VO DE Discovery agent
DMLSYD9 ID DMLSYD9
DMLSYD9 DN MCL-435
DMLSYD9 HS Investigative
DMLSYD9 SN MCL-435; CHEMBL242046
DMLSYD9 DT Small molecular drug
DMLSYD9 PC 44427180
DMLSYD9 MW 368.5
DMLSYD9 FM C23H32N2O2
DMLSYD9 IC InChI=1S/C23H32N2O2/c1-24-22(26)27-18-9-8-17-13-21-19-7-2-3-10-23(19,20(17)14-18)11-12-25(21)15-16-5-4-6-16/h8-9,14,16,19,21H,2-7,10-13,15H2,1H3,(H,24,26)
DMLSYD9 CS CNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CCC5)C=C1
DMLSYD9 IK NHTWPKUCTUYFEM-UHFFFAOYSA-N
DMLSYD9 IU [17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-methylcarbamate
DMLSYD9 DE Discovery agent
DM8LTQ4 ID DM8LTQ4
DM8LTQ4 DN MCL-443
DM8LTQ4 HS Investigative
DM8LTQ4 SN MCL-443; CHEMBL394624
DM8LTQ4 DT Small molecular drug
DM8LTQ4 PC 44427184
DM8LTQ4 MW 444.6
DM8LTQ4 FM C29H36N2O2
DM8LTQ4 IC InChI=1S/C29H36N2O2/c32-28(30-19-21-7-2-1-3-8-21)33-24-13-12-23-17-27-25-11-4-5-14-29(25,26(23)18-24)15-16-31(27)20-22-9-6-10-22/h1-3,7-8,12-13,18,22,25,27H,4-6,9-11,14-17,19-20H2,(H,30,32)
DM8LTQ4 CS C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NCC5=CC=CC=C5)CC6CCC6
DM8LTQ4 IK VTNMTWBEHGIRGV-UHFFFAOYSA-N
DM8LTQ4 IU [17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-benzylcarbamate
DM8LTQ4 DE Discovery agent
DM8HALS ID DM8HALS
DM8HALS DN MCL-444
DM8HALS HS Investigative
DM8HALS SN MCL-444; CHEMBL263096
DM8HALS DT Small molecular drug
DM8HALS PC 44427179
DM8HALS MW 430.6
DM8HALS FM C28H34N2O2
DM8HALS IC InChI=1S/C28H34N2O2/c31-27(29-18-20-6-2-1-3-7-20)32-23-12-11-22-16-26-24-8-4-5-13-28(24,25(22)17-23)14-15-30(26)19-21-9-10-21/h1-3,6-7,11-12,17,21,24,26H,4-5,8-10,13-16,18-19H2,(H,29,31)
DM8HALS CS C1CCC23CCN(C(C2C1)CC4=C3C=C(C=C4)OC(=O)NCC5=CC=CC=C5)CC6CC6
DM8HALS IK VSBFHNWLJXFFTK-UHFFFAOYSA-N
DM8HALS IU [17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-benzylcarbamate
DM8HALS DE Discovery agent
DMR2K4F ID DMR2K4F
DMR2K4F DN MCL-445
DMR2K4F HS Investigative
DMR2K4F SN MCL-445; CHEMBL243195; BDBM50210553
DMR2K4F DT Small molecular drug
DMR2K4F PC 44429065
DMR2K4F MW 367.5
DMR2K4F FM C23H33N3O
DMR2K4F IC InChI=1S/C23H33N3O/c1-24-22(27)25-18-9-8-17-13-21-19-7-2-3-10-23(19,20(17)14-18)11-12-26(21)15-16-5-4-6-16/h8-9,14,16,19,21H,2-7,10-13,15H2,1H3,(H2,24,25,27)/t19-,21+,23+/m0/s1
DMR2K4F CS CNC(=O)NC1=CC2=C(C[C@@H]3[C@H]4[C@@]2(CCCC4)CCN3CC5CCC5)C=C1
DMR2K4F IK URMRSPJBIISGIL-XKCSPQBFSA-N
DMR2K4F IU 1-[(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-3-methylurea
DMR2K4F DE Discovery agent
DMXF73G ID DMXF73G
DMXF73G DN MCL-446
DMXF73G HS Investigative
DMXF73G SN MCL-446; CHEMBL428038; BDBM50210549
DMXF73G DT Small molecular drug
DMXF73G PC 44429064
DMXF73G MW 353.5
DMXF73G FM C22H31N3O
DMXF73G IC InChI=1S/C22H31N3O/c1-23-21(26)24-17-8-7-16-12-20-18-4-2-3-9-22(18,19(16)13-17)10-11-25(20)14-15-5-6-15/h7-8,13,15,18,20H,2-6,9-12,14H2,1H3,(H2,23,24,26)/t18-,20+,22+/m0/s1
DMXF73G CS CNC(=O)NC1=CC2=C(C[C@@H]3[C@H]4[C@@]2(CCCC4)CCN3CC5CC5)C=C1
DMXF73G IK NXVBILHYMWWGLP-CZTZKLFOSA-N
DMXF73G IU 1-[(1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-3-methylurea
DMXF73G DE Discovery agent
DMSTGNH ID DMSTGNH
DMSTGNH DN MCL-447
DMSTGNH HS Investigative
DMSTGNH SN MCL-447; CHEMBL394573; BDBM50210555
DMSTGNH DT Small molecular drug
DMSTGNH PC 44429063
DMSTGNH MW 353.5
DMSTGNH FM C22H31N3O
DMSTGNH IC InChI=1S/C22H31N3O/c23-21(26)24-17-8-7-16-12-20-18-6-1-2-9-22(18,19(16)13-17)10-11-25(20)14-15-4-3-5-15/h7-8,13,15,18,20H,1-6,9-12,14H2,(H3,23,24,26)/t18-,20+,22+/m0/s1
DMSTGNH CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC(=O)N)CC5CCC5
DMSTGNH IK UYFRBZFZZCVVGT-CZTZKLFOSA-N
DMSTGNH IU [(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]urea
DMSTGNH DE Discovery agent
DMSJGA9 ID DMSJGA9
DMSJGA9 DN MCL-448
DMSJGA9 HS Investigative
DMSJGA9 SN MCL-448; CHEMBL242968; BDBM50210550
DMSJGA9 DT Small molecular drug
DMSJGA9 PC 44429062
DMSJGA9 MW 339.5
DMSJGA9 FM C21H29N3O
DMSJGA9 IC InChI=1S/C21H29N3O/c22-20(25)23-16-7-6-15-11-19-17-3-1-2-8-21(17,18(15)12-16)9-10-24(19)13-14-4-5-14/h6-7,12,14,17,19H,1-5,8-11,13H2,(H3,22,23,25)/t17-,19+,21+/m0/s1
DMSJGA9 CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NC(=O)N)CC5CC5
DMSJGA9 IK HEUGOTHWUMOSSR-FBBABVLZSA-N
DMSJGA9 IU [(1R,9R,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]urea
DMSJGA9 DE Discovery agent
DMQ890N ID DMQ890N
DMQ890N DN MCL-449
DMQ890N HS Investigative
DMQ890N SN MCL-449; CHEMBL427862
DMQ890N DT Small molecular drug
DMQ890N PC 44427177
DMQ890N MW 368.5
DMQ890N FM C23H32N2O2
DMQ890N IC InChI=1S/C23H32N2O2/c1-2-24-22(26)27-18-9-8-17-13-21-19-5-3-4-10-23(19,20(17)14-18)11-12-25(21)15-16-6-7-16/h8-9,14,16,19,21H,2-7,10-13,15H2,1H3,(H,24,26)
DMQ890N CS CCNC(=O)OC1=CC2=C(CC3C4C2(CCCC4)CCN3CC5CC5)C=C1
DMQ890N IK RVWFZRGYOXCUSN-UHFFFAOYSA-N
DMQ890N IU [17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] N-ethylcarbamate
DMQ890N DE Discovery agent
DM7I6U8 ID DM7I6U8
DM7I6U8 DN MCL-450
DM7I6U8 HS Investigative
DM7I6U8 SN CHEMBL373984; MCL-450; BDBM50194274
DM7I6U8 DT Small molecular drug
DM7I6U8 PC 16083055
DM7I6U8 MW 732.9
DM7I6U8 FM C45H56N4O5
DM7I6U8 IC InChI=1S/C45H56N4O5/c1-28-20-34(50)21-29(2)36(28)25-39(46)44(53)49-27-33-11-4-3-10-31(33)22-41(49)43(52)47-18-15-42(51)54-35-14-13-32-23-40-37-12-5-6-16-45(37,38(32)24-35)17-19-48(40)26-30-8-7-9-30/h3-4,10-11,13-14,20-21,24,30,37,39-41,50H,5-9,12,15-19,22-23,25-27,46H2,1-2H3,(H,47,52)/t37-,39-,40+,41-,45+/m0/s1
DM7I6U8 CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCCC(=O)OC4=CC5=C(C[C@@H]6[C@H]7[C@@]5(CCCC7)CCN6CC8CCC8)C=C4)N)C)O
DM7I6U8 IK FYEXOHKTNZXZQH-KKEISOQISA-N
DM7I6U8 IU [(1R,9R,10R)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl] 3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]propanoate
DM7I6U8 DE Discovery agent
DMP523A ID DMP523A
DMP523A DN MCL-451
DMP523A HS Investigative
DMP523A SN MCL-451; CHEMBL384915; H-Dmt-Tic-beta-Ala-OH
DMP523A DT Small molecular drug
DMP523A PC 16083058
DMP523A MW 439.5
DMP523A FM C24H29N3O5
DMP523A IC InChI=1S/C24H29N3O5/c1-14-9-18(28)10-15(2)19(14)12-20(25)24(32)27-13-17-6-4-3-5-16(17)11-21(27)23(31)26-8-7-22(29)30/h3-6,9-10,20-21,28H,7-8,11-13,25H2,1-2H3,(H,26,31)(H,29,30)/t20-,21-/m0/s1
DMP523A CS CC1=CC(=CC(=C1C[C@@H](C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)NCCC(=O)O)N)C)O
DMP523A IK FEJBKZCTAXWTTN-SFTDATJTSA-N
DMP523A IU 3-[[(3S)-2-[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]propanoic acid
DMP523A DE Discovery agent
DMORMGU ID DMORMGU
DMORMGU DN MCL-457
DMORMGU HS Investigative
DMORMGU SN MCL-457; CHEMBL242967; BDBM50210558
DMORMGU DT Small molecular drug
DMORMGU PC 44429060
DMORMGU MW 338.4
DMORMGU FM C21H26N2O2
DMORMGU IC InChI=1S/C21H26N2O2/c24-20-22-17-9-14-10-18-15-3-1-2-6-21(15,16(14)11-19(17)25-20)7-8-23(18)12-13-4-5-13/h9,11,13,15,18H,1-8,10,12H2,(H,22,24)/t15-,18+,21+/m0/s1
DMORMGU CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)OC(=O)N5)CC6CC6
DMORMGU IK QLWCMBZVQJGYTM-RRMPHLOHSA-N
DMORMGU IU (1R,12R,13R)-20-(cyclopropylmethyl)-5-oxa-7,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),9-trien-6-one
DMORMGU DE Discovery agent
DMZN93Y ID DMZN93Y
DMZN93Y DN MCL-458
DMZN93Y HS Investigative
DMZN93Y SN MCL-458; CHEMBL390912; BDBM50210556
DMZN93Y DT Small molecular drug
DMZN93Y PC 44429061
DMZN93Y MW 352.5
DMZN93Y FM C22H28N2O2
DMZN93Y IC InChI=1S/C22H28N2O2/c25-21-23-18-10-15-11-19-16-6-1-2-7-22(16,17(15)12-20(18)26-21)8-9-24(19)13-14-4-3-5-14/h10,12,14,16,19H,1-9,11,13H2,(H,23,25)/t16-,19+,22+/m0/s1
DMZN93Y CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=CC5=C(C=C34)OC(=O)N5)CC6CCC6
DMZN93Y IK PSLNEDDFOIXXGT-DKZVUGQWSA-N
DMZN93Y IU (1R,12R,13R)-20-(cyclobutylmethyl)-5-oxa-7,20-diazapentacyclo[10.5.3.01,13.02,10.04,8]icosa-2,4(8),9-trien-6-one
DMZN93Y DE Discovery agent
DMTB8D4 ID DMTB8D4
DMTB8D4 DN MCL-515
DMTB8D4 HS Investigative
DMTB8D4 SN MCL-515; CHEMBL513174; BDBM50254065
DMTB8D4 DT Small molecular drug
DMTB8D4 PC 25181482
DMTB8D4 MW 351.4
DMTB8D4 FM C22H25NO3
DMTB8D4 IC InChI=1S/C22H25NO3/c1-4-9-23-10-8-16-11-17(25-3)13-18-21(16)19(23)12-15-6-5-7-20(22(15)18)26-14(2)24/h5-7,11,13,19H,4,8-10,12H2,1-3H3/t19-/m1/s1
DMTB8D4 CS CCCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)OC)C(=CC=C4)OC(=O)C
DMTB8D4 IK ICIICPHBNXIOKJ-LJQANCHMSA-N
DMTB8D4 IU [(6aR)-2-methoxy-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] acetate
DMTB8D4 CA CAS 1100920-50-0
DMTB8D4 DE Discovery agent
DMQA7ZI ID DMQA7ZI
DMQA7ZI DN MCL-516
DMQA7ZI HS Investigative
DMQA7ZI SN MCL-516; CHEMBL482276; BDBM50252323; (R)-2-Methoxyaporphin-11-yl pentanoate
DMQA7ZI DT Small molecular drug
DMQA7ZI PC 44593524
DMQA7ZI MW 365.5
DMQA7ZI FM C23H27NO3
DMQA7ZI IC InChI=1S/C23H27NO3/c1-4-5-9-21(25)27-20-8-6-7-15-13-19-22-16(10-11-24(19)2)12-17(26-3)14-18(22)23(15)20/h6-8,12,14,19H,4-5,9-11,13H2,1-3H3/t19-/m1/s1
DMQA7ZI CS CCCCC(=O)OC1=CC=CC2=C1C3=CC(=CC4=C3[C@@H](C2)N(CC4)C)OC
DMQA7ZI IK NMUGDOOOAXACRK-LJQANCHMSA-N
DMQA7ZI IU [(6aR)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl] pentanoate
DMQA7ZI DE Discovery agent
DML3AZG ID DML3AZG
DML3AZG DN McN-A-343
DML3AZG HS Investigative
DML3AZG SN McN-A-343; 55-45-8; MCN A-343 chloride; McN-A 343; MCN A-343; UNII-CW55R761RE; (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride; CW55R761RE; A 343; 4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; 2-Butyn-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-N,N,N-trimethyl-, chloride; Carbanilic acid, m-chloro-, ester with (4-hydroxy-2-butynyl)trimethylammonium chloride; Butyl-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-N,N,N-trimethyl-, chloride
DML3AZG DT Small molecular drug
DML3AZG PC 5926
DML3AZG MW 317.2
DML3AZG FM C14H18Cl2N2O2
DML3AZG IC InChI=1S/C14H17ClN2O2.ClH/c1-17(2,3)9-4-5-10-19-14(18)16-13-8-6-7-12(15)11-13;/h6-8,11H,9-10H2,1-3H3;1H
DML3AZG CS C[N+](C)(C)CC#CCOC(=O)NC1=CC(=CC=C1)Cl.[Cl-]
DML3AZG IK CXFZFEJJLNLOTA-UHFFFAOYSA-N
DML3AZG IU 4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride
DML3AZG CA CAS 55-45-8
DML3AZG DE Discovery agent
DM0GLYB ID DM0GLYB
DM0GLYB DN MCP-203
DM0GLYB HS Investigative
DM0GLYB SN Delta opioid receptor agonist (depression/Parkinson's disease), Mt Cook Pharma
DM0GLYB CP Mt Cook Pharma
DM0GLYB DE Major depressive disorder
DM0RZDF ID DM0RZDF
DM0RZDF DN MCP-204
DM0RZDF HS Investigative
DM0RZDF SN Delta opioid receptor agonist (urology therapy/neuropathic pain), Mt Cook Pharma
DM0RZDF CP Mt Cook Pharma
DM0RZDF DE Bladder disease
DM3RYUZ ID DM3RYUZ
DM3RYUZ DN MCP-205
DM3RYUZ HS Investigative
DM3RYUZ SN Delta opioid receptor agonist (cardiac ischemia), Mt Cook Pharma
DM3RYUZ CP Mt Cook Pharma
DM3RYUZ DE Ischemic heart disease
DMEUWB8 ID DMEUWB8
DMEUWB8 DN MDA-19
DMEUWB8 HS Investigative
DMEUWB8 SN Cannabinoid CB2 agonist (neuropathic pain), MD Anderson Cancer Center
DMEUWB8 CP MD Anderson Cancer Center
DMEUWB8 DT Small molecular drug
DMEUWB8 PC 135743701
DMEUWB8 MW 349.4
DMEUWB8 FM C21H23N3O2
DMEUWB8 IC InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14,26H,2-4,10,15H2,1H3
DMEUWB8 CS CCCCCCN1C2=CC=CC=C2C(=C1O)N=NC(=O)C3=CC=CC=C3
DMEUWB8 IK ICNRTDOKKSWDRL-UHFFFAOYSA-N
DMEUWB8 IU N-(1-hexyl-2-hydroxyindol-3-yl)iminobenzamide
DMEUWB8 CA CAS 1048973-47-2
DMEUWB8 DE Neuropathic pain
DMZJPOB ID DMZJPOB
DMZJPOB DN MDDR 287569
DMZJPOB HS Investigative
DMZJPOB SN N-[1-[3-(4-Methylpiperazin-1-ylsulfonyl)propyl]piperidin-4-ylmethyl]-2,3-dihydro-1,4-benzodioxin-5-carboxamide
DMZJPOB DE Urinary incontinence
DMLI5VH ID DMLI5VH
DMLI5VH DN MDL 100,453
DMLI5VH HS Investigative
DMLI5VH SN D-Norvaline, 4-oxo-5-phosphono-; CHEMBL431029; MDL-100483; 129938-34-7; 4-Opnv; Mdl 100453; 4-Oxo-5-phosphononorvaline; AC1MHZND; SCHEMBL195547; (r)-4-oxo-5-phosphononorvaline; BDBM50010893; AKOS030593176; MDL-100453; 2-Amino-4-oxo-5-phosphono-pentanoic acid; (2R)-2-amino-4-oxo-5-phosphonopentanoic acid; (R)-2-Amino-4-oxo-5-phosphono-pentanoic acid
DMLI5VH DT Small molecular drug
DMLI5VH PC 3035602
DMLI5VH MW 211.11
DMLI5VH FM C5H10NO6P
DMLI5VH IC InChI=1S/C5H10NO6P/c6-4(5(8)9)1-3(7)2-13(10,11)12/h4H,1-2,6H2,(H,8,9)(H2,10,11,12)/t4-/m1/s1
DMLI5VH CS C([C@H](C(=O)O)N)C(=O)CP(=O)(O)O
DMLI5VH IK OLCWOBHEVRCMLO-SCSAIBSYSA-N
DMLI5VH IU (2R)-2-amino-4-oxo-5-phosphonopentanoic acid
DMLI5VH CA CAS 129938-34-7
DMLI5VH DE Discovery agent
DMTVOWC ID DMTVOWC
DMTVOWC DN MDL-18962
DMTVOWC HS Investigative
DMTVOWC SN Plomestane; UNII-FL3VS913TW; MDL-18962; 77016-85-4; FL3VS913TW; 10-(2-Propynyl)estr-4-ene-3,17-dione; Plomestane [USAN:INN]; MDL 18,962; 10-propargylestr-4-ene-3,17-dione; Estr-4-ene-3,17-dione, 10-(2-propynyl)-; Plomestane (USAN/INN); SCHEMBL3434; CHEMBL2105261; JKPDEYAOCSQBSZ-OEUJLIAZSA-N; ZINC4217337; BDBM50421840; 10beta-propargyl-estra-4-ene-3,17-dione; 10-(2-propynyl)-estr-4-ene-3,17-dione
DMTVOWC DT Small molecular drug
DMTVOWC PC 9904788
DMTVOWC MW 310.4
DMTVOWC FM C21H26O2
DMTVOWC IC InChI=1S/C21H26O2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18H,4-12H2,2H3/t16-,17-,18-,20-,21-/m0/s1
DMTVOWC CS C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=CC(=O)CC[C@]34CC#C
DMTVOWC IK JKPDEYAOCSQBSZ-OEUJLIAZSA-N
DMTVOWC IU (8R,9S,10S,13S,14S)-13-methyl-10-prop-2-ynyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
DMTVOWC CA CAS 77016-85-4
DMTVOWC DE Discovery agent
DMUHJ2C ID DMUHJ2C
DMUHJ2C DN MDL-28163
DMUHJ2C HS Investigative
DMUHJ2C SN MDL-28163; CHEMBL95051; SCHEMBL9196398; DIPBPGRFGZKMEF-UHFFFAOYSA-N; BDBM50175511; 1-(4-Fluorobenzyl)-2-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinylcarbonyl]-1H-benzimidazole; [1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl][1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methanone
DMUHJ2C DT Small molecular drug
DMUHJ2C PC 10917690
DMUHJ2C MW 471.6
DMUHJ2C FM C29H30FN3O2
DMUHJ2C IC InChI=1S/C29H30FN3O2/c1-35-25-12-8-21(9-13-25)14-17-32-18-15-23(16-19-32)28(34)29-31-26-4-2-3-5-27(26)33(29)20-22-6-10-24(30)11-7-22/h2-13,23H,14-20H2,1H3
DMUHJ2C CS COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
DMUHJ2C IK DIPBPGRFGZKMEF-UHFFFAOYSA-N
DMUHJ2C IU [1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]methanone
DMUHJ2C CA CAS 124461-07-0
DMUHJ2C DE Discovery agent
DMF76M8 ID DMF76M8
DMF76M8 DN MDL-28618
DMF76M8 HS Investigative
DMF76M8 SN MDL-28618; UNII-9O1J7OU9Q5; 9O1J7OU9Q5; CHEMBL497666; BDBM50272710; MDL-28618A, (+)-; 1H-Indene-2-methanamine, 2,3-dihydro-N-methyl-1-(4-(trifluoromethyl)phenoxy)-, (1R-cis)-; (1R,2S)-2,3-Dihydro-N-methyl-1-[4-(trifluoromethyl)phenoxy]-1H-indene-2-methanamine; N-methyl((1R,2S)-1-(4-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-2-yl)methanamine
DMF76M8 DT Small molecular drug
DMF76M8 PC 14595987
DMF76M8 MW 321.3
DMF76M8 FM C18H18F3NO
DMF76M8 IC InChI=1S/C18H18F3NO/c1-22-11-13-10-12-4-2-3-5-16(12)17(13)23-15-8-6-14(7-9-15)18(19,20)21/h2-9,13,17,22H,10-11H2,1H3/t13-,17+/m0/s1
DMF76M8 CS CNC[C@@H]1CC2=CC=CC=C2[C@@H]1OC3=CC=C(C=C3)C(F)(F)F
DMF76M8 IK BDCMARKCSKLIKU-SUMWQHHRSA-N
DMF76M8 IU N-methyl-1-[(1R,2S)-1-[4-(trifluoromethyl)phenoxy]-2,3-dihydro-1H-inden-2-yl]methanamine
DMF76M8 CA CAS 130182-74-0
DMF76M8 DE Discovery agent
DMF8VX3 ID DMF8VX3
DMF8VX3 DN MDL-74156
DMF8VX3 HS Investigative
DMF8VX3 SN Mdl 74156; Hydrodolasetron; Mdl-74156; 127951-99-9; 1H-Indole-3-carboxylicacid, octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; 1-H-Indole-3-carboxylic acid, trans-octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; ACMC-20msnw; AC1L4LYC; CHEMBL498572; SCHEMBL7281981; AC1Q60Y9; CTK4B5810; 1H-Indole-3-carboxylic acid, octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester; BDBM50412171; AKOS030254922; 10-hydroxy-8-azatricyclo[5.3.1.03,8]undec-5-yl 1h-indole-3-carboxylate; LS-172694; J-005559
DMF8VX3 DT Small molecular drug
DMF8VX3 PC 159502
DMF8VX3 MW 326.4
DMF8VX3 FM C19H22N2O3
DMF8VX3 IC InChI=1S/C19H22N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,18,20,22H,5-8,10H2
DMF8VX3 CS C1C2CC3CC(CC1N3CC2O)OC(=O)C4=CNC5=CC=CC=C54
DMF8VX3 IK MLWGAEVSWJXOQJ-UHFFFAOYSA-N
DMF8VX3 IU (10-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-5-yl) 1H-indole-3-carboxylate
DMF8VX3 CA CAS 127951-99-9
DMF8VX3 DE Discovery agent
DM8ZK12 ID DM8ZK12
DM8ZK12 DN MDP-01
DM8ZK12 HS Investigative
DM8ZK12 SN Peptabody-EGF (anticancer), Med Discovery
DM8ZK12 CP Med Discovery SA
DM8ZK12 DE Solid tumour/cancer
DMSF4UI ID DMSF4UI
DMSF4UI DN MDT-006
DMSF4UI HS Investigative
DMSF4UI SN EPX-16006; Chronic constipation, IBS-C therapy (PolyCap), MicroDose Therapeutx; P2Y2 agonist (oral, constipation/irritable bowel syndrome), EPIX; Purinoceptor P2Y2 agonist (oral, constipation/IBS), EPIX
DMSF4UI CP EPIX Pharmaceuticals Inc
DMSF4UI DE Constipation
DM9ZTX4 ID DM9ZTX4
DM9ZTX4 DN MDX-1147
DM9ZTX4 HS Investigative
DM9ZTX4 CP Medarex Inc
DM9ZTX4 DE Prostate cancer
DMMFYP9 ID DMMFYP9
DMMFYP9 DN ME bromodomain inhibitor
DMMFYP9 HS Investigative
DMMFYP9 SN CHEMBL3769729; Methyl (2r)-2-[(4s)-6-(4-Chlorophenyl)-8-Methoxy-1-Methyl-4h-[1,2,4]triazolo[4,3-A][1,4]benzodiazepin-4-Yl]propanoate; ME bromodomain inhibitor; GTPL7807; SCHEMBL16771925
DMMFYP9 DT Small molecular drug
DMMFYP9 PC 86277842
DMMFYP9 MW 424.9
DMMFYP9 FM C22H21ClN4O3
DMMFYP9 IC InChI=1S/C22H21ClN4O3/c1-12(22(28)30-4)19-21-26-25-13(2)27(21)18-10-9-16(29-3)11-17(18)20(24-19)14-5-7-15(23)8-6-14/h5-12,19H,1-4H3/t12-,19+/m1/s1
DMMFYP9 CS CC1=NN=C2N1C3=C(C=C(C=C3)OC)C(=N[C@H]2[C@@H](C)C(=O)OC)C4=CC=C(C=C4)Cl
DMMFYP9 IK FENXDXHDXYVGRJ-BLVKFPJESA-N
DMMFYP9 IU methyl (2R)-2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]propanoate
DMMFYP9 DE Discovery agent
DMCLT1V ID DMCLT1V
DMCLT1V DN ME0328
DMCLT1V HS Investigative
DMCLT1V SN ME-0328; compound 5b [PMID 24188023]
DMCLT1V DT Small molecular drug
DMCLT1V PC 135566764
DMCLT1V MW 321.4
DMCLT1V FM C19H19N3O2
DMCLT1V IC InChI=1S/C19H19N3O2/c1-13(14-7-3-2-4-8-14)20-18(23)12-11-17-21-16-10-6-5-9-15(16)19(24)22-17/h2-10,13H,11-12H2,1H3,(H,20,23)(H,21,22,24)/t13-/m0/s1
DMCLT1V CS C[C@@H](C1=CC=CC=C1)NC(=O)CCC2=NC3=CC=CC=C3C(=O)N2
DMCLT1V IK QIHBWVVVRYYYRO-ZDUSSCGKSA-N
DMCLT1V IU 3-(4-oxo-3H-quinazolin-2-yl)-N-[(1S)-1-phenylethyl]propanamide
DMCLT1V DE Discovery agent
DMOZAQ6 ID DMOZAQ6
DMOZAQ6 DN ME36
DMOZAQ6 HS Investigative
DMOZAQ6 SN N-ethyl,N-methyl EM-A
DMOZAQ6 DT Small molecular drug
DMOZAQ6 PC 14487390
DMOZAQ6 MW 748
DMOZAQ6 FM C38H69NO13
DMOZAQ6 IC InChI=1S/C38H69NO13/c1-14-26-38(11,46)31(42)21(5)28(40)19(3)17-36(9,45)33(52-35-29(41)25(39(12)15-2)16-20(4)48-35)22(6)30(23(7)34(44)50-26)51-27-18-37(10,47-13)32(43)24(8)49-27/h19-27,29-33,35,41-43,45-46H,14-18H2,1-13H3
DMOZAQ6 CS CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)CC)O)(C)O)C)C)O)(C)O
DMOZAQ6 IK DYYAPFZVDGCKCL-UHFFFAOYSA-N
DMOZAQ6 IU 14-ethyl-6-[4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
DMOZAQ6 DE Discovery agent
DMO5E2L ID DMO5E2L
DMO5E2L DN ME4
DMO5E2L HS Investigative
DMO5E2L SN EM-A enolether; erythromycin enol ether; ME-4
DMO5E2L DT Small molecular drug
DMO5E2L PC 83954
DMO5E2L MW 715.9
DMO5E2L FM C37H65NO12
DMO5E2L IC InChI=1S/C37H65NO12/c1-14-25-37(10,43)30(40)20(4)28-18(2)16-36(9,50-28)32(49-34-27(39)24(38(11)12)15-19(3)45-34)21(5)29(22(6)33(42)47-25)48-26-17-35(8,44-13)31(41)23(7)46-26/h19-27,29-32,34,39-41,43H,14-17H2,1-13H3/t19-,20+,21+,22-,23+,24+,25-,26+,27-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
DMO5E2L CS CC[C@@H]1[C@@]([C@@H]([C@H](C2=C(C[C@@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)(C)O
DMO5E2L IK JFVYXJKGJMUGRG-KJPZRSJGSA-N
DMO5E2L IU (2R,3R,4S,5R,8R,9S,10S,11R,12R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3,4-dihydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DMO5E2L CA CAS 33396-29-1
DMO5E2L DE Discovery agent
DM3C6X2 ID DM3C6X2
DM3C6X2 DN ME67
DM3C6X2 HS Investigative
DM3C6X2 SN EM-B enolether
DM3C6X2 DT Small molecular drug
DM3C6X2 PC 10032648
DM3C6X2 MW 699.9
DM3C6X2 FM C37H65NO11
DM3C6X2 IC InChI=1S/C37H65NO11/c1-14-26-20(4)28(39)21(5)30-18(2)16-37(10,49-30)33(48-35-29(40)25(38(11)12)15-19(3)44-35)22(6)31(23(7)34(42)46-26)47-27-17-36(9,43-13)32(41)24(8)45-27/h19-29,31-33,35,39-41H,14-17H2,1-13H3/t19-,20-,21-,22+,23-,24+,25+,26-,27+,28+,29-,31+,32+,33-,35+,36-,37+/m1/s1
DM3C6X2 CS CC[C@@H]1[C@H]([C@@H]([C@H](C2=C(C[C@](O2)([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)C)C)C)O)C
DM3C6X2 IK RVWZXQUMKFWVJM-GKMPZCCESA-N
DM3C6X2 IU (2R,3S,4S,5R,8R,9S,10S,11R,12S)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-ethyl-3-hydroxy-9-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one
DM3C6X2 DE Discovery agent
DM0P59E ID DM0P59E
DM0P59E DN MEBUDIPINE
DM0P59E HS Investigative
DM0P59E SN mebudipine; CHEMBL1095098; BAY-n-6391
DM0P59E DT Small molecular drug
DM0P59E PC 10407950
DM0P59E MW 388.4
DM0P59E FM C20H24N2O6
DM0P59E IC InChI=1S/C20H24N2O6/c1-11-15(18(23)27-6)17(13-8-7-9-14(10-13)22(25)26)16(12(2)21-11)19(24)28-20(3,4)5/h7-10,17,21H,1-6H3
DM0P59E CS CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC
DM0P59E IK YXPRKGBMFPQBDH-UHFFFAOYSA-N
DM0P59E IU 5-O-tert-butyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM0P59E DE Discovery agent
DMYQOKX ID DMYQOKX
DMYQOKX DN MeBut-RYYRIK-NH2
DMYQOKX HS Investigative
DMYQOKX SN CHEMBL270394
DMYQOKX DT Small molecular drug
DMYQOKX PC 44455999
DMYQOKX MW 965.2
DMYQOKX FM C47H76N14O8
DMYQOKX IC InChI=1S/C47H76N14O8/c1-5-28(3)38(45(69)56-33(39(49)63)16-10-11-23-48)61-42(66)35(18-13-25-55-47(52)53)58-43(67)37(27-31-19-21-32(62)22-20-31)60-44(68)36(26-30-14-8-7-9-15-30)59-41(65)34(17-12-24-54-46(50)51)57-40(64)29(4)6-2/h7-9,14-15,19-22,28-29,33-38,62H,5-6,10-13,16-18,23-27,48H2,1-4H3,(H2,49,63)(H,56,69)(H,57,64)(H,58,67)(H,59,65)(H,60,68)(H,61,66)(H4,50,51,54)(H4,52,53,55)/t28-,29?,33-,34-,35-,36-,37-,38-/m0/s1
DMYQOKX CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(C)CC
DMYQOKX IK XDTYNZLRQJEAAQ-QABIKYMTSA-N
DMYQOKX IU (2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-(2-methylbutanoylamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]hexanamide
DMYQOKX DE Discovery agent
DMNKSX3 ID DMNKSX3
DMNKSX3 DN Medazepam
DMNKSX3 HS Investigative
DMNKSX3 SN Aensius; Ansilan; Azepamide; Benaon; Enobrin; Lerisum; Medaurin; Medazepam [INN:BAN:JAN]; Medazepamum [INN-Latin]; Narsis; Navizil; Nivelton; Nobraksin; Nobral; Nobrium; Nobrium HCl; P0J3387W3S; RB 252; Resmit; Rudotel; Stratium; YLCXGBZIZBEVPZ-UHFFFAOYSA-N; medazepam; 1H-1,4-BENZODIAZEPINE, 7-CHLORO-2,3-DIHYDRO-1-METHYL-5-PHENYL-; 7-Chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine; BRN 0407983; CHEMBL28333; DEA No. 2836; EINECS 220-783-4; NCGC00164523-01; UNII-P0J3387W3S
DMNKSX3 PC 4041
DMNKSX3 MW 270.75
DMNKSX3 FM C16H15ClN2
DMNKSX3 IC YLCXGBZIZBEVPZ-UHFFFAOYSA-N
DMNKSX3 CS CN1CCN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
DMNKSX3 IK 1S/C16H15ClN2/c1-19-10-9-18-16(12-5-3-2-4-6-12)14-11-13(17)7-8-15(14)19/h2-8,11H,9-10H2,1H3
DMNKSX3 IU 7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
DMNKSX3 CA CAS 2898-12-6
DMNKSX3 CB CHEBI:31807
DMNKSX3 DE Discovery agent
DMQ5S9C ID DMQ5S9C
DMQ5S9C DN MEDI-552
DMQ5S9C HS Investigative
DMQ5S9C SN B-cell depleting anti-CD20 monoclonal antibody, Cellective; B-cell depleting anti-CD20 monoclonal antibody, MedImmune
DMQ5S9C DE Discovery agent
DM960DQ ID DM960DQ
DM960DQ DN MEDI-553
DM960DQ HS Investigative
DM960DQ SN B-cell depleting anti-CD22 monoclonal antibody, Cellective; B-cell depleting anti-CD22 monoclonal antibody, MedImmune
DM960DQ CP Cellective Therapeutics Inc
DM960DQ DT Antibody
DM960DQ DE Autoimmune diabetes
DML2GFB ID DML2GFB
DML2GFB DN medica 16
DML2GFB HS Investigative
DML2GFB SN medic-16
DML2GFB DT Small molecular drug
DML2GFB PC 121871
DML2GFB MW 342.5
DML2GFB FM C20H38O4
DML2GFB IC InChI=1S/C20H38O4/c1-19(2,15-17(21)22)13-11-9-7-5-6-8-10-12-14-20(3,4)16-18(23)24/h5-16H2,1-4H3,(H,21,22)(H,23,24)
DML2GFB CS CC(C)(CCCCCCCCCCC(C)(C)CC(=O)O)CC(=O)O
DML2GFB IK HYSMCRNFENOHJH-UHFFFAOYSA-N
DML2GFB IU 3,3,14,14-tetramethylhexadecanedioic acid
DML2GFB CA CAS 87272-20-6
DML2GFB CB CHEBI:149582
DML2GFB DE Discovery agent
DMDJ6RE ID DMDJ6RE
DMDJ6RE DN MEDIORESINOL
DMDJ6RE HS Investigative
DMDJ6RE SN MEDIORESINOL; CHEMBL513023; (-) Medioresinol; AC1L7B3T; BDBM50259877; NSC329245; NSC-329245
DMDJ6RE DT Small molecular drug
DMDJ6RE PC 181681
DMDJ6RE MW 388.4
DMDJ6RE FM C21H24O7
DMDJ6RE IC InChI=1S/C21H24O7/c1-24-16-6-11(4-5-15(16)22)20-13-9-28-21(14(13)10-27-20)12-7-17(25-2)19(23)18(8-12)26-3/h4-8,13-14,20-23H,9-10H2,1-3H3/t13-,14-,20+,21+/m0/s1
DMDJ6RE CS COC1=CC(=CC(=C1O)OC)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O)OC
DMDJ6RE IK VJOBNGRIBLNUKN-BMHXQBNDSA-N
DMDJ6RE IU 4-[(3S,3aR,6S,6aR)-3-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-2,6-dimethoxyphenol
DMDJ6RE CA CAS 40957-99-1
DMDJ6RE CB CHEBI:67644
DMDJ6RE DE Discovery agent
DMNEAJG ID DMNEAJG
DMNEAJG DN Medrogestone
DMNEAJG HS Investigative
DMNEAJG SN Colpro; Colprone; Etogyn; MEDROGESTONE; Medrogesterone; Medrogeston; Medrogestona; Medrogestona [INN-Spanish]; Medrogestone (USAN/INN); Medrogestone [USAN:INN:BAN]; Medrogestonum; Medrogestonum [INN-Latin]; Metrogestone; Prothil; R 13615; SCHEMBL140614; 077DN93G5B; 6,17-Dimethyl-6-dehydroprogesterone; 6,17-Dimethylpregna-4,6-diene-3,20-dione; 6-Methyl-6-dehydro-17-methylprogesterone; 977-79-7; AY 13615S; AY-62022; BRN 2302887; EINECS 213-555-0; NSC 123018; NSC-123018; Pregna-4,6-diene-3,20-dione, 6,17-dimethyl-; UNII-077DN93G5B
DMNEAJG PC 9949848
DMNEAJG MW 340.5
DMNEAJG FM C23H32O2
DMNEAJG IC HCFSGRMEEXUOSS-JXEXPEPMSA-N
DMNEAJG CS CC1=CC2C(CCC3(C2CCC3(C)C(=O)C)C)C4(C1=CC(=O)CC4)C
DMNEAJG IK 1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
DMNEAJG IU (8R,9S,10R,13S,14S,17S)-17-acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
DMNEAJG CA CAS 977-79-7
DMNEAJG CB CHEBI:135446
DMNEAJG DE Corpus luteum cyst
DMYJI90 ID DMYJI90
DMYJI90 DN MEK inhibitor I
DMYJI90 HS Investigative
DMYJI90 SN MEK Inhibitor I; SCHEMBL6749464; GTPL6006; HMS3229K14; CCG-206865; J-017629
DMYJI90 DT Small molecular drug
DMYJI90 PC 9951490
DMYJI90 MW 374.5
DMYJI90 FM C21H18N4OS
DMYJI90 IC InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+
DMYJI90 CS C1=CC=C(C(=C1)N)S/C(=C(\\C#N)/C2=CC=CC(=C2)C(C3=CC=NC=C3)O)/N
DMYJI90 IK NHBMKTBZZSJUGA-HEHNFIMWSA-N
DMYJI90 IU (Z)-3-amino-3-(2-aminophenyl)sulfanyl-2-[3-[hydroxy(pyridin-4-yl)methyl]phenyl]prop-2-enenitrile
DMYJI90 DE Discovery agent
DM08SVH ID DM08SVH
DM08SVH DN MEL57A
DM08SVH HS Investigative
DM08SVH SN CHEMBL1253475; MEL57A; GTPL6260; SCHEMBL16410080; BDBM50326990; 3-[(Z)-4-[[(Z)-4-(7, 8-dimethoxy-2-oxo-1H-3-benzazepin-3-yl)but-2-enyl]-[(2R)-2-(3, 4-dimethoxyphenyl)propyl]amino]but-2-enyl]-7, 8-dimethoxy-1H-3-benzazepin-2-one
DM08SVH DT Small molecular drug
DM08SVH PC 46937420
DM08SVH MW 737.9
DM08SVH FM C43H51N3O8
DM08SVH IC InChI=1S/C43H51N3O8/c1-30(31-12-13-36(49-2)37(22-31)50-3)29-44(16-8-10-18-45-20-14-32-23-38(51-4)40(53-6)25-34(32)27-42(45)47)17-9-11-19-46-21-15-33-24-39(52-5)41(54-7)26-35(33)28-43(46)48/h8-15,20-26,30H,16-19,27-29H2,1-7H3/b10-8-,11-9-/t30-/m0/s1
DM08SVH CS C[C@H](C1=CC(=C(C=C1)OC)OC)CN(C/C=C\\CN2C(=O)CC3=CC(=C(C=C3C=C2)OC)OC)C/C=C\\CN4C(=O)CC5=CC(=C(C=C5C=C4)OC)OC
DM08SVH IK WCJGGTAAPIAIJS-PSEQGZRXSA-N
DM08SVH IU 3-[(Z)-4-[[(Z)-4-(7,8-dimethoxy-2-oxo-1H-3-benzazepin-3-yl)but-2-enyl]-[(2R)-2-(3,4-dimethoxyphenyl)propyl]amino]but-2-enyl]-7,8-dimethoxy-1H-3-benzazepin-2-one
DM08SVH DE Discovery agent
DMY57L0 ID DMY57L0
DMY57L0 DN melanin-concentrating hormone
DMY57L0 HS Investigative
DMY57L0 SN Melanin-concentrating hormone; Melanin concentrating hormone; GTPL1298
DMY57L0 DT Small molecular drug
DMY57L0 PC 16167454
DMY57L0 MW 2099.5
DMY57L0 FM C89H139N27O24S4
DMY57L0 IC InChI=1S/C89H139N27O24S4/c1-43(2)67-82(135)101-40-64(119)102-53(18-12-30-97-87(91)92)74(127)113-68(44(3)4)83(136)109-59(36-47-22-24-49(118)25-23-47)77(130)107-58(20-14-32-99-89(95)96)85(138)116-33-15-21-63(116)81(134)111-62(80(133)108-60(37-48-39-100-52-17-11-10-16-50(48)52)78(131)104-55(26-27-65(120)121)75(128)114-69(45(5)6)86(139)140)42-144-143-41-61(79(132)105-57(29-35-142-9)76(129)112-67)110-72(125)54(19-13-31-98-88(93)94)103-73(126)56(28-34-141-8)106-84(137)70(46(7)117)115-71(124)51(90)38-66(122)123/h10-11,16-17,22-25,39,43-46,51,53-63,67-70,100,117-118H,12-15,18-21,26-38,40-42,90H2,1-9H3,(H,101,135)(H,102,119)(H,103,126)(H,104,131)(H,105,132)(H,106,137)(H,107,130)(H,108,133)(H,109,136)(H,110,125)(H,111,134)(H,112,129)(H,113,127)(H,114,128)(H,115,124)(H,120,121)(H,122,123)(H,139,140)(H4,91,92,97)(H4,93,94,98)(H4,95,96,99)
DMY57L0 CS CC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CCSC)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCSC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)O)CCCNC(=N)N)CC5=CC=C(C=C5)O)C(C)C)CCCNC(=N)N
DMY57L0 IK ORRDHOMWDPJSNL-UHFFFAOYSA-N
DMY57L0 IU 4-[[2-[[24-[[2-[[2-[[2-[(2-amino-3-carboxypropanoyl)amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3,12-bis(3-carbamimidamidopropyl)-6-[(4-hydroxyphenyl)methyl]-21-(2-methylsulfanylethyl)-2,5,8,11,14,17,20,23,31-nonaoxo-9,18-di(propan-2-yl)-26,27-dithia-1,4,7,10,13,16,19,22,30-nonazabicyclo[30.3.0]pentatriacontane-29-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-[(1-carboxy-2-methylpropyl)amino]-5-oxopentanoic acid
DMY57L0 DE Discovery agent
DM2ES7Z ID DM2ES7Z
DM2ES7Z DN Melanocortin-4 Receptor antagonist
DM2ES7Z HS Investigative
DM2ES7Z SN Methyl 16-hydroxyhexadecanoate; AOTMRIXFFOGWDT-UHFFFAOYSA-N; 36575-67-4; Methyl juniperate; MC4 Receptor antagonist; AC1MRQ5C; SCHEMBL1245383; Methyl 16-hydroxy-hexadecanoate; CTK1B6241; DTXSID80393043; Melanocortin 4 Receptor antagonist; HS028; AKOS005066798; 16-hydroxyhexadecanoic Acid Methyl Ester; Hexadecanoic acid, 16-hydroxy-, methyl ester
DM2ES7Z CP Santhera
DM2ES7Z DT Small molecular drug
DM2ES7Z PC 3496888
DM2ES7Z MW 286.4
DM2ES7Z FM C17H34O3
DM2ES7Z IC InChI=1S/C17H34O3/c1-20-17(19)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18/h18H,2-16H2,1H3
DM2ES7Z CS COC(=O)CCCCCCCCCCCCCCCO
DM2ES7Z IK AOTMRIXFFOGWDT-UHFFFAOYSA-N
DM2ES7Z IU methyl 16-hydroxyhexadecanoate
DM2ES7Z CA CAS 36575-67-4
DM2ES7Z DE Anorexia nervosa cachexia
DMTKLH8 ID DMTKLH8
DMTKLH8 DN Melibiose
DMTKLH8 HS Investigative
DMTKLH8 SN D-Gal-alpha(1->6)-D-glucose; D-Gal-alpha1->6D-Glucose; D-Melibiose; D-mellibiose; Gal-alpha(1,6)Glc; SCHEMBL2504901; alpha-D-Gal-(1->6)-D-Glc; melibiose; 585-99-9; 6-(alpha-D-galactosido)-D-glucose; 6-O-(alpha-D-Galactopyranosyl)-D-glucopyranose; 6-O-alpha-D-Galactopyranosyl-D-glucopyranose; CHEBI:28053; Epitope ID:140529; M0050; alpha-D-Galp-(1->6)-D-Glc; alpha-D-Galp-(1->6)-D-Glcp; alpha-D-galactopyranosyl-1-6-D-glucopyranose; alpha-D-galactosyl-(1->6)-D-glucose; bmse000233
DMTKLH8 PC 440658
DMTKLH8 MW 342.3
DMTKLH8 FM C12H22O11
DMTKLH8 IC DLRVVLDZNNYCBX-ABXHMFFYSA-N
DMTKLH8 CS C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)O)O)O)O)O)O
DMTKLH8 IK 1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8+,9-,10-,11?,12+/m1/s1
DMTKLH8 IU (3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
DMTKLH8 CA CAS 585-99-9
DMTKLH8 CB CHEBI:28053
DMTKLH8 DE Discovery agent
DME54M7 ID DME54M7
DME54M7 DN Melogatran
DME54M7 HS Investigative
DME54M7 DE Discovery agent
DM3492O ID DM3492O
DM3492O DN MELOSMINE
DM3492O HS Investigative
DM3492O DT Small molecular drug
DM3492O PC 72329
DM3492O MW 337.4
DM3492O FM C20H19NO4
DM3492O IC InChI=1S/C20H19NO4/c1-20(2)13-9-10(22)5-6-11(13)14-15-12(7-8-21-19(15)20)17(24-3)18(25-4)16(14)23/h5-9,22-23H,1-4H3
DM3492O CS CC1(C2=C(C=CC(=C2)O)C3=C(C(=C(C4=C3C1=NC=C4)OC)OC)O)C
DM3492O IK CUEIWVZJOPCMPT-UHFFFAOYSA-N
DM3492O IU 14,15-dimethoxy-8,8-dimethyl-10-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9,11,13(17),14-octaene-5,16-diol
DM3492O CA CAS 81525-68-0
DM3492O DE Discovery agent
DM9S30P ID DM9S30P
DM9S30P DN MEMOQUIN
DM9S30P HS Investigative
DM9S30P SN MEMOQUIN; 616885-87-1; SCHEMBL4365745; ZINC101086292
DM9S30P DT Small molecular drug
DM9S30P PC 9917279
DM9S30P MW 632.9
DM9S30P FM C38H56N4O4
DM9S30P IC InChI=1S/C38H56N4O4/c1-5-41(29-31-19-11-13-21-37(31)45-3)25-17-9-7-15-23-39-33-27-36(44)34(28-35(33)43)40-24-16-8-10-18-26-42(6-2)30-32-20-12-14-22-38(32)46-4/h11-14,19-22,27-28,39-40H,5-10,15-18,23-26,29-30H2,1-4H3
DM9S30P CS CCN(CCCCCCNC1=CC(=O)C(=CC1=O)NCCCCCCN(CC)CC2=CC=CC=C2OC)CC3=CC=CC=C3OC
DM9S30P IK VPXVPJQOPRBXPO-UHFFFAOYSA-N
DM9S30P IU 2,5-bis[6-[ethyl-[(2-methoxyphenyl)methyl]amino]hexylamino]cyclohexa-2,5-diene-1,4-dione
DM9S30P DE Discovery agent
DMEIRDX ID DMEIRDX
DMEIRDX DN MEN-14295
DMEIRDX HS Investigative
DMEIRDX SN MEN-14536; MEN-15658; Rebeccamycin analogs, Menarini; Topoisomerase inhibitors (cancer); Topoisomerase inhibitors (cancer), Menarini
DMEIRDX CP The Menarini Group
DMEIRDX DE Solid tumour/cancer
DMU8L7C ID DMU8L7C
DMU8L7C DN Mepacrine
DMU8L7C HS Investigative
DMU8L7C SN quinacrine; mepacrine; atabrine; Acrinamine; Acriquine; 83-89-6; Quinactine; Antimalarina; Haffkinine; Akrichin; Italchine; acrichine; Erion; Mepacrinum; Quinacrine hydrochloride; Mepacrine [INN:BAN]; St 439; Mepacrinum [INN-Latin]; Mepacrina [INN-Spanish]; atebrin; Malaricida; Methoquine; Palacrin; Italchin; Pentilen; Palusan; Atebrine; Metochin; Mecryl; Quinacrine, Mepacrine; 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine; 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine; HSDB 3253
DMU8L7C DT Small molecular drug
DMU8L7C PC 237
DMU8L7C MW 400
DMU8L7C FM C23H30ClN3O
DMU8L7C IC InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)
DMU8L7C CS CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC
DMU8L7C IK GPKJTRJOBQGKQK-UHFFFAOYSA-N
DMU8L7C IU 4-N-(6-chloro-2-methoxyacridin-9-yl)-1-N,1-N-diethylpentane-1,4-diamine
DMU8L7C CA CAS 83-89-6
DMU8L7C CB CHEBI:8711
DMU8L7C DE Discovery agent
DMZIA1R ID DMZIA1R
DMZIA1R DN mercaptoacrylate inhibitor of calpain 1
DMZIA1R HS Investigative
DMZIA1R SN mercaptoacrylate inhibitor of calpain 1; GTPL8570; CHEMBL3221938; (Z)-3-(5-bromo-1H-indol-3-yl)-2-sulfanylprop-2-enoic acid
DMZIA1R DT Small molecular drug
DMZIA1R PC 90668184
DMZIA1R MW 298.16
DMZIA1R FM C11H8BrNO2S
DMZIA1R IC InChI=1S/C11H8BrNO2S/c12-7-1-2-9-8(4-7)6(5-13-9)3-10(16)11(14)15/h1-5,13,16H,(H,14,15)/b10-3-
DMZIA1R CS C1=CC2=C(C=C1Br)C(=CN2)/C=C(/C(=O)O)\\S
DMZIA1R IK RLEKFRNXGFHPHZ-KMKOMSMNSA-N
DMZIA1R IU (Z)-3-(5-bromo-1H-indol-3-yl)-2-sulfanylprop-2-enoic acid
DMZIA1R DE Discovery agent
DM68FZK ID DM68FZK
DM68FZK DN Mercaptosuccinate
DM68FZK HS Investigative
DM68FZK SN Butanedioic acid, mercapto-; DL-Mercaptosuccinic acid; Malic acid, 2-thio-; Mercaptosuccinate; Mercaptosuccinic acid; Monomercaptosuccinic acid; NJRXVEJTAYWCQJ-UHFFFAOYSA-N; SUCCINIC ACID, MERCAPTO-; Thiomalate; Thiomalic acid; USAF EK-P-6297; USAF M-2; butanedioic acid, 2-mercapto-; (+/-)-Mercaptosuccinic acid; (1)-Mercaptosuccinic acid; .alpha.-Mercaptosuccinic acid; 2-Mercaptosuccinic acid; 2-Thiomalic acid; 2-sulfanylbutanedioic acid; 70-49-5; AI3-22956; BRN 1099858; C4H6O4S; EINECS 200-736-4; EINECS 211-423-7; NSC 7302
DM68FZK PC 6268
DM68FZK MW 150.16
DM68FZK FM C4H6O4S
DM68FZK IC NJRXVEJTAYWCQJ-UHFFFAOYSA-N
DM68FZK CS C(C(C(=O)O)S)C(=O)O
DM68FZK IK 1S/C4H6O4S/c5-3(6)1-2(9)4(7)8/h2,9H,1H2,(H,5,6)(H,7,8)
DM68FZK IU 2-sulfanylbutanedioic acid
DM68FZK CA CAS 70-49-5
DM68FZK CB CHEBI:38705
DM68FZK DE Discovery agent
DMD25I6 ID DMD25I6
DMD25I6 DN MERCK-544
DMD25I6 HS Investigative
DMD25I6 SN MERCK-544; 327093-42-5; CHEMBL256777; 3-ADAMANTAN-1-YL-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[4.3-A]AZEPINE; Compound 544; 3-(Adamantan-1-yl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; AC1MTUPG; Merck 544; Oprea1_175789; SCHEMBL5095978; DTXSID40394475; ZINC5494877; BDBM50239401; AKOS015969399; 3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine; MCULE-4943397141; SR-01000029295; SR-01000029295-1; Z55729757; 3-(adamantan-1-yl)-5H,6H,7H,8H,9H-[1,2,4]triazolo[4,3-a]azepine
DMD25I6 DT Small molecular drug
DMD25I6 PC 3630776
DMD25I6 MW 271.4
DMD25I6 FM C17H25N3
DMD25I6 IC InChI=1S/C17H25N3/c1-2-4-15-18-19-16(20(15)5-3-1)17-9-12-6-13(10-17)8-14(7-12)11-17/h12-14H,1-11H2
DMD25I6 CS C1CCC2=NN=C(N2CC1)C34CC5CC(C3)CC(C5)C4
DMD25I6 IK VFTQRHWULYJKCI-UHFFFAOYSA-N
DMD25I6 IU 3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
DMD25I6 CA CAS 327093-42-5
DMD25I6 DE Discovery agent
DMT56ER ID DMT56ER
DMT56ER DN Mercuribenzoic Acid
DMT56ER HS Investigative
DMT56ER SN Mercuribenzoic acid; MERCURIBENZOIC ACID; (4-carboxyphenyl)mercury; p-mercuribenzoic acid; (4-CARBOXYPHENYL)(CHLORO)MERCURY; BE7; MBO; HGB; 4-mercuribenzoic acid; AC1L1RM7; SCHEMBL677378; CTK7I7797; CHEBI:28886
DMT56ER DT Small molecular drug
DMT56ER PC 8747
DMT56ER MW 321.7
DMT56ER FM C7H5HgO2
DMT56ER IC InChI=1S/C7H5O2.Hg/c8-7(9)6-4-2-1-3-5-6;/h2-5H,(H,8,9);
DMT56ER CS C1=CC(=CC=C1C(=O)O)[Hg]
DMT56ER IK FVFZSVRSDNUCGG-UHFFFAOYSA-N
DMT56ER IU (4-carboxyphenyl)mercury
DMT56ER CB CHEBI:28886
DMT56ER DE Discovery agent
DMPZ0XJ ID DMPZ0XJ
DMPZ0XJ DN Merimepodib
DMPZ0XJ HS Investigative
DMPZ0XJ SN Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid
DMPZ0XJ CP GSK
DMPZ0XJ TC Antiviral Agents
DMPZ0XJ DT Small molecular drug
DMPZ0XJ PC 153241
DMPZ0XJ MW 452.5
DMPZ0XJ FM C23H24N4O6
DMPZ0XJ IC InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
DMPZ0XJ CS COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4
DMPZ0XJ IK JBPUGFODGPKTDW-SFHVURJKSA-N
DMPZ0XJ IU [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
DMPZ0XJ CA CAS 198821-22-6
DMPZ0XJ DE Gastric adenocarcinoma; Head and neck squamous cell carcinoma; Hepatitis C virus infection; Hepatitis virus infection; Refractory breast cancer; Coronavirus Disease 2019 (COVID-19)
DMJT93H ID DMJT93H
DMJT93H DN MERIOLIN 1
DMJT93H HS Investigative
DMJT93H SN MERIOLIN 1; 341998-55-8; 4-(1H-PYRROLO[2,3-B]PYRIDIN-3-YL)PYRIMIDIN-2-AMINE; 2-Pyrimidinamine, 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-; SCHEMBL2241315; CHEMBL405665; HQHSJJZIICGOIX-UHFFFAOYSA-; CTK1B7876; DTXSID60469811; BDBM50371404; ZINC29135178; AKOS027252841; 4-(7-aza-indol-3-yl)-2-amino pyrimidine; 3-(2-Amino-4-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine
DMJT93H DT Small molecular drug
DMJT93H PC 11637090
DMJT93H MW 211.22
DMJT93H FM C11H9N5
DMJT93H IC InChI=1S/C11H9N5/c12-11-14-5-3-9(16-11)8-6-15-10-7(8)2-1-4-13-10/h1-6H,(H,13,15)(H2,12,14,16)
DMJT93H CS C1=CC2=C(NC=C2C3=NC(=NC=C3)N)N=C1
DMJT93H IK HQHSJJZIICGOIX-UHFFFAOYSA-N
DMJT93H IU 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMJT93H CA CAS 341998-55-8
DMJT93H DE Discovery agent
DM413XJ ID DM413XJ
DM413XJ DN MERIOLIN 2
DM413XJ HS Investigative
DM413XJ SN MERIOLIN 2; SCHEMBL2999865; CHEMBL270897; 1H-Pyrrolo[2,3-b]pyridin-4-ol, 3-(2-amino-4-pyrimidinyl)-; BDBM50371403; 954143-47-6
DM413XJ DT Small molecular drug
DM413XJ PC 24801699
DM413XJ MW 227.22
DM413XJ FM C11H9N5O
DM413XJ IC InChI=1S/C11H9N5O/c12-11-14-3-1-7(16-11)6-5-15-10-9(6)8(17)2-4-13-10/h1-5H,(H2,12,14,16)(H2,13,15,17)
DM413XJ CS C1=CNC2=C(C1=O)C(=CN2)C3=NC(=NC=C3)N
DM413XJ IK JYGNOLIKBUTZNC-UHFFFAOYSA-N
DM413XJ IU 3-(2-aminopyrimidin-4-yl)-1,7-dihydropyrrolo[2,3-b]pyridin-4-one
DM413XJ DE Discovery agent
DMVE95S ID DMVE95S
DMVE95S DN MERIOLIN 3
DMVE95S HS Investigative
DMVE95S SN MERIOLIN 3; 954143-48-7; 4-(4-Methoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2996575; CHEMBL270686; BDBM50371402; ZINC16052675; DB08178; KB-274295
DMVE95S DT Small molecular drug
DMVE95S PC 23727981
DMVE95S MW 241.25
DMVE95S FM C12H11N5O
DMVE95S IC InChI=1S/C12H11N5O/c1-18-9-3-5-14-11-10(9)7(6-16-11)8-2-4-15-12(13)17-8/h2-6H,1H3,(H,14,16)(H2,13,15,17)
DMVE95S CS COC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMVE95S IK GGEWEQJWGGJUHO-UHFFFAOYSA-N
DMVE95S IU 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMVE95S DE Discovery agent
DMIJMZQ ID DMIJMZQ
DMIJMZQ DN MERIOLIN 4
DMIJMZQ HS Investigative
DMIJMZQ SN MERIOLIN 4; SCHEMBL3001373; CHEMBL406464
DMIJMZQ DT Small molecular drug
DMIJMZQ PC 24801697
DMIJMZQ MW 255.28
DMIJMZQ FM C13H13N5O
DMIJMZQ IC InChI=1S/C13H13N5O/c1-2-19-10-4-6-15-12-11(10)8(7-17-12)9-3-5-16-13(14)18-9/h3-7H,2H2,1H3,(H,15,17)(H2,14,16,18)
DMIJMZQ CS CCOC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMIJMZQ IK CJJMNECGBUPMAV-UHFFFAOYSA-N
DMIJMZQ IU 4-(4-ethoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMIJMZQ DE Discovery agent
DMGVLR0 ID DMGVLR0
DMGVLR0 DN MERIOLIN 5
DMGVLR0 HS Investigative
DMGVLR0 SN MERIOLIN 5; 1011711-76-4; 4-(4-Propoxy-1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-2-Amine; 4-{4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-amine; SCHEMBL2997013; CHEMBL270687; ZINC16052674; BDBM50371400; DB08182
DMGVLR0 DT Small molecular drug
DMGVLR0 PC 23727982
DMGVLR0 MW 269.3
DMGVLR0 FM C14H15N5O
DMGVLR0 IC InChI=1S/C14H15N5O/c1-2-7-20-11-4-6-16-13-12(11)9(8-18-13)10-3-5-17-14(15)19-10/h3-6,8H,2,7H2,1H3,(H,16,18)(H2,15,17,19)
DMGVLR0 CS CCCOC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMGVLR0 IK ZHMRPXZRUZLCNL-UHFFFAOYSA-N
DMGVLR0 IU 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMGVLR0 DE Discovery agent
DMW5AXC ID DMW5AXC
DMW5AXC DN MERIOLIN 6
DMW5AXC HS Investigative
DMW5AXC SN MERIOLIN 6; CHEMBL406463; SCHEMBL2999009
DMW5AXC DT Small molecular drug
DMW5AXC PC 24801185
DMW5AXC MW 269.3
DMW5AXC FM C14H15N5O
DMW5AXC IC InChI=1S/C14H15N5O/c1-8(2)20-11-4-6-16-13-12(11)9(7-18-13)10-3-5-17-14(15)19-10/h3-8H,1-2H3,(H,16,18)(H2,15,17,19)
DMW5AXC CS CC(C)OC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DMW5AXC IK YRURITXEWXPMAI-UHFFFAOYSA-N
DMW5AXC IU 4-(4-propan-2-yloxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
DMW5AXC DE Discovery agent
DM8D3NY ID DM8D3NY
DM8D3NY DN MERIOLIN 7
DM8D3NY HS Investigative
DM8D3NY SN MERIOLIN 7; SCHEMBL2239805; CHEMBL405074
DM8D3NY DT Small molecular drug
DM8D3NY PC 24801186
DM8D3NY MW 285.3
DM8D3NY FM C14H15N5O2
DM8D3NY IC InChI=1S/C14H15N5O2/c1-20-6-7-21-11-3-5-16-13-12(11)9(8-18-13)10-2-4-17-14(15)19-10/h2-5,8H,6-7H2,1H3,(H,16,18)(H2,15,17,19)
DM8D3NY CS COCCOC1=C2C(=CNC2=NC=C1)C3=NC(=NC=C3)N
DM8D3NY IK NFOHQNIARGGZFN-UHFFFAOYSA-N
DM8D3NY IU 4-[4-(2-methoxyethoxy)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-amine
DM8D3NY DE Discovery agent
DM0E95B ID DM0E95B
DM0E95B DN MERIOLIN 8
DM0E95B HS Investigative
DM0E95B SN MERIOLIN 8; SCHEMBL2991886; CHEMBL406102
DM0E95B DT Small molecular drug
DM0E95B PC 24801181
DM0E95B MW 241.25
DM0E95B FM C12H11N5O
DM0E95B IC InChI=1S/C12H11N5O/c1-17-6-7(8-2-4-15-12(13)16-8)10-9(18)3-5-14-11(10)17/h2-6H,1H3,(H,14,18)(H2,13,15,16)
DM0E95B CS CN1C=C(C2=C1NC=CC2=O)C3=NC(=NC=C3)N
DM0E95B IK PYDJIICXCHAWOI-UHFFFAOYSA-N
DM0E95B IU 3-(2-aminopyrimidin-4-yl)-1-methyl-7H-pyrrolo[2,3-b]pyridin-4-one
DM0E95B DE Discovery agent
DMYVUCE ID DMYVUCE
DMYVUCE DN MESCALINE
DMYVUCE HS Investigative
DMYVUCE SN mescaline; Mescalin; Tmpea; Mezcaline; 3,4,5-Trimethoxyphenethylamine; 54-04-6; 2-(3,4,5-Trimethoxyphenyl)ethanamine; 3,4,5-Trimethoxyphenylethylamine; Mezcalin; 3,4,5-Trimethoxybenzeneethanamine; mezcalina; mescalina; Meskalin; Benzeneethanamine, 3,4,5-trimethoxy-; Mescalin [German]; Mescline; Mezcline; Phenethylamine, 3,4,5-trimethoxy-; UNII-RHO99102VC; NSC 30419; Ethane, 1-amino-2-(3,4,5-trimethoxyphenyl)-; EINECS 200-190-7; BRN 1374088; 2-(3,4,5-trimethoxy-phenyl)-ethylamine; CHEMBL26687; RHO99102VC
DMYVUCE DT Small molecular drug
DMYVUCE PC 4076
DMYVUCE MW 211.26
DMYVUCE FM C11H17NO3
DMYVUCE IC InChI=1S/C11H17NO3/c1-13-9-6-8(4-5-12)7-10(14-2)11(9)15-3/h6-7H,4-5,12H2,1-3H3
DMYVUCE CS COC1=CC(=CC(=C1OC)OC)CCN
DMYVUCE IK RHCSKNNOAZULRK-UHFFFAOYSA-N
DMYVUCE IU 2-(3,4,5-trimethoxyphenyl)ethanamine
DMYVUCE CA CAS 54-04-6
DMYVUCE CB CHEBI:28346
DMYVUCE DE Discovery agent
DM86WRO ID DM86WRO
DM86WRO DN meso-DAP
DM86WRO HS Investigative
DM86WRO SN meso-diaminopimeilic acid
DM86WRO DT Small molecular drug
DM86WRO PC 99290
DM86WRO MW 190.2
DM86WRO FM C7H14N2O4
DM86WRO IC InChI=1S/C7H14N2O4/c8-4(6(10)11)2-1-3-5(9)7(12)13/h4-5H,1-3,8-9H2,(H,10,11)(H,12,13)/t4-,5+
DM86WRO CS C(C[C@H](C(=O)O)N)C[C@@H](C(=O)O)N
DM86WRO IK GMKMEZVLHJARHF-SYDPRGILSA-N
DM86WRO IU (2S,6R)-2,6-diaminoheptanedioic acid
DM86WRO CA CAS 922-54-3
DM86WRO CB CHEBI:16488
DM86WRO DE Discovery agent
DMZ12GE ID DMZ12GE
DMZ12GE DN MESUAGENIN A
DMZ12GE HS Investigative
DMZ12GE SN MESUAGENIN A; CHEMBL1277495
DMZ12GE DT Small molecular drug
DMZ12GE PC 49870983
DMZ12GE MW 472.6
DMZ12GE FM C30H32O5
DMZ12GE IC InChI=1S/C30H32O5/c1-18(2)10-9-14-30(5)15-13-21-27(33)26(23(31)16-19(3)4)29-25(28(21)35-30)22(17-24(32)34-29)20-11-7-6-8-12-20/h6-8,10-13,15,17,19,33H,9,14,16H2,1-5H3
DMZ12GE CS CC(C)CC(=O)C1=C2C(=C3C(=C1O)C=CC(O3)(C)CCC=C(C)C)C(=CC(=O)O2)C4=CC=CC=C4
DMZ12GE IK STYQYOHXCPHKKX-UHFFFAOYSA-N
DMZ12GE IU 5-hydroxy-2-methyl-6-(3-methylbutanoyl)-2-(4-methylpent-3-enyl)-10-phenylpyrano[2,3-f]chromen-8-one
DMZ12GE DE Discovery agent
DMKXG3V ID DMKXG3V
DMKXG3V DN MESUAGENIN B
DMKXG3V HS Investigative
DMKXG3V SN MESUAGENIN B; CHEMBL1277588
DMKXG3V DT Small molecular drug
DMKXG3V PC 13917758
DMKXG3V MW 472.6
DMKXG3V FM C30H32O5
DMKXG3V IC InChI=1S/C30H32O5/c1-6-19(4)26(32)25-27(33)21-14-16-30(5,15-10-11-18(2)3)35-28(21)24-22(17-23(31)34-29(24)25)20-12-8-7-9-13-20/h7-9,11-14,16-17,19,33H,6,10,15H2,1-5H3
DMKXG3V CS CCC(C)C(=O)C1=C2C(=C3C(=C1O)C=CC(O3)(C)CCC=C(C)C)C(=CC(=O)O2)C4=CC=CC=C4
DMKXG3V IK GEYVIFNRNUBPHZ-UHFFFAOYSA-N
DMKXG3V IU 5-hydroxy-2-methyl-6-(2-methylbutanoyl)-2-(4-methylpent-3-enyl)-10-phenylpyrano[2,3-f]chromen-8-one
DMKXG3V DE Discovery agent
DMLZGO7 ID DMLZGO7
DMLZGO7 DN Mesuagenin D
DMLZGO7 HS Investigative
DMLZGO7 SN Mesuagenin D; CHEMBL1277681
DMLZGO7 DT Small molecular drug
DMLZGO7 PC 52945557
DMLZGO7 MW 492.6
DMLZGO7 FM C30H36O6
DMLZGO7 IC InChI=1S/C30H36O6/c1-17(2)12-13-29(5,34)30(6)16-21-26(33)25(22(31)14-18(3)4)28-24(27(21)36-30)20(15-23(32)35-28)19-10-8-7-9-11-19/h7-11,15,17-18,33-34H,12-14,16H2,1-6H3
DMLZGO7 CS CC(C)CCC(C)(C1(CC2=C(C(=C3C(=C2O1)C(=CC(=O)O3)C4=CC=CC=C4)C(=O)CC(C)C)O)C)O
DMLZGO7 IK PABMLJMVAOFHKY-UHFFFAOYSA-N
DMLZGO7 IU 4-hydroxy-2-(2-hydroxy-5-methylhexan-2-yl)-2-methyl-5-(3-methylbutanoyl)-9-phenyl-3H-furo[2,3-f]chromen-7-one
DMLZGO7 DE Discovery agent
DMKGWAH ID DMKGWAH
DMKGWAH DN MESULERGINE
DMKGWAH HS Investigative
DMKGWAH SN Mesulergine; Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206
DMKGWAH DT Small molecular drug
DMKGWAH PC 68848
DMKGWAH MW 362.5
DMKGWAH FM C18H26N4O2S
DMKGWAH IC InChI=1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3/t13-,15+,17+/m0/s1
DMKGWAH CS CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C
DMKGWAH IK JLVHTNZNKOSCNB-YSVLISHTSA-N
DMKGWAH IU (6aR,9S,10aR)-9-(dimethylsulfamoylamino)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline
DMKGWAH CA CAS 64795-35-3
DMKGWAH CB CHEBI:73378
DMKGWAH DE Discovery agent
DMEA8GP ID DMEA8GP
DMEA8GP DN meta-chlorphenylbiguanide
DMEA8GP HS Investigative
DMEA8GP SN m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide; 1-(3-chlorophenyl)biguanide; m-chlorophenylbiguanide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide
DMEA8GP DT Small molecular drug
DMEA8GP PC 1354
DMEA8GP MW 211.65
DMEA8GP FM C8H10ClN5
DMEA8GP IC InChI=1S/C8H10ClN5/c9-5-2-1-3-6(4-5)13-8(12)14-7(10)11/h1-4H,(H6,10,11,12,13,14)
DMEA8GP CS C1=CC(=CC(=C1)Cl)N=C(N)N=C(N)N
DMEA8GP IK DIHXJZHAIHGSAW-UHFFFAOYSA-N
DMEA8GP IU 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine
DMEA8GP CA CAS 48144-44-1
DMEA8GP CB CHEBI:32347
DMEA8GP DE Discovery agent
DMTGMB1 ID DMTGMB1
DMTGMB1 DN Metanephrine
DMTGMB1 HS Investigative
DMTGMB1 SN Metanephrine; Metadrenaline; 5001-33-2; DL-Metanephrine; 3-Methoxyadrenaline; m-O-Methyladrenaline; (+/-)-Metanephrine; 4-[1-Hydroxy-2-(methylamino)ethyl]-2-methoxyphenol; CHEBI:89633; JWJCTZKFYGDABJ-UHFFFAOYSA-N; 3-methoxy-adrenaline; epinephrine metabolite; 3-O-Methylepinephrine; 3-O-methyl-Adrenaline; Adrenaline, 3-methoxy-; AC1L2HML; Prestwick2_000122; Prestwick0_000122; DL-3-O-Methyladrenaline; Prestwick3_000122; Prestwick1_000122; Adrenaline, 3-O-methyl-; DL-METANEPHRINE HCI; CHEMBL775; Vanillyl alcohol, .alpha.-[(methylamin
DMTGMB1 DT Small molecular drug
DMTGMB1 PC 21100
DMTGMB1 MW 197.23
DMTGMB1 FM C10H15NO3
DMTGMB1 IC InChI=1S/C10H15NO3/c1-11-6-9(13)7-3-4-8(12)10(5-7)14-2/h3-5,9,11-13H,6H2,1-2H3
DMTGMB1 CS CNCC(C1=CC(=C(C=C1)O)OC)O
DMTGMB1 IK JWJCTZKFYGDABJ-UHFFFAOYSA-N
DMTGMB1 IU 4-[1-hydroxy-2-(methylamino)ethyl]-2-methoxyphenol
DMTGMB1 CA CAS 5001-33-2
DMTGMB1 CB CHEBI:89633
DMTGMB1 DE Discovery agent
DMITMN9 ID DMITMN9
DMITMN9 DN Meta-Nitro-Tyrosine
DMITMN9 HS Investigative
DMITMN9 SN 3-Nitro-L-tyrosine; 621-44-3; 3-Nitrotyrosine; H-Tyr(3-NO2)-OH; L-3-Nitrotyrosine; Meta-Nitro-Tyrosine; Tyrosine, 3-nitro-; L-Tyrosine, 3-nitro-; H-3-Nitro-Tyr-OH; UNII-7COY1HA6HK; Tyrosine, 3-nitro-, L-; 3-Mononitrotyrosine; CCRIS 3566; (S)-2-Amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid; (2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid; EINECS 210-688-6; NSC 37413; 7COY1HA6HK; AI3-63160; H-4-Hydroxy-3-nitro-Phe-OH; CHEBI:44454; FBTSQILOGYXGMD-LURJTMIESA-N; MFCD00007123; 3-Nitro-L-tyrosine crystalline; m-Nitrotyrosine
DMITMN9 DT Small molecular drug
DMITMN9 PC 65124
DMITMN9 MW 226.19
DMITMN9 FM C9H10N2O5
DMITMN9 IC InChI=1S/C9H10N2O5/c10-6(9(13)14)3-5-1-2-8(12)7(4-5)11(15)16/h1-2,4,6,12H,3,10H2,(H,13,14)/t6-/m0/s1
DMITMN9 CS C1=CC(=C(C=C1C[C@@H](C(=O)O)N)[N+](=O)[O-])O
DMITMN9 IK FBTSQILOGYXGMD-LURJTMIESA-N
DMITMN9 IU (2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoic acid
DMITMN9 CA CAS 621-44-3
DMITMN9 CB CHEBI:44454
DMITMN9 DE Discovery agent
DMSK0QX ID DMSK0QX
DMSK0QX DN Meta-sirtinol
DMSK0QX HS Investigative
DMSK0QX DT Small molecular drug
DMSK0QX PC 135461039
DMSK0QX MW 394.5
DMSK0QX FM C26H22N2O2
DMSK0QX IC InChI=1S/C26H22N2O2/c1-18(19-8-3-2-4-9-19)28-26(30)21-11-7-12-22(16-21)27-17-24-23-13-6-5-10-20(23)14-15-25(24)29/h2-18,29H,1H3,(H,28,30)
DMSK0QX CS CC(C1=CC=CC=C1)NC(=O)C2=CC(=CC=C2)N=CC3=C(C=CC4=CC=CC=C43)O
DMSK0QX IK USDKSBHPFQRCGR-UHFFFAOYSA-N
DMSK0QX IU 3-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-(1-phenylethyl)benzamide
DMSK0QX DE Discovery agent
DM0748C ID DM0748C
DM0748C DN Meta-Tyrosine
DM0748C HS Investigative
DM0748C SN L-m-Tyrosine; 587-33-7; 3-HYDROXY-L-PHENYLALANINE; Meta-Tyrosine; (S)-2-amino-3-(3-hydroxyphenyl)propanoic acid; m-Tyrosine; 3-tyrosine; m-L-Tyrosine; 3-Hydroxyphenylalanine; UNII-D5YF57V4QW; 3-(m-Hydroxyphenyl)alanine; L-mTyr; (2S)-2-amino-3-(3-hydroxyphenyl)propanoic acid; L-M-TYR; D5YF57V4QW; L-Phenylalanine, 3-hydroxy-; MFCD00063059; AK-86473; L-META-TYROSINE; 3-(3-HYDROXYPHENYL)-L-ALANINE; D-3-hydroxyphenylalanine; L-PHE(3-OH)-OH; (2S)-2-azaniumyl-3-(3-hydroxyphenyl)propanoate; Tyrosine, meta-; MTY; m-Tyrosine, L-
DM0748C DT Small molecular drug
DM0748C PC 6950578
DM0748C MW 181.19
DM0748C FM C9H11NO3
DM0748C IC InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-2-1-3-7(11)4-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
DM0748C CS C1=CC(=CC(=C1)O)C[C@@H](C(=O)O)N
DM0748C IK JZKXXXDKRQWDET-QMMMGPOBSA-N
DM0748C IU (2S)-2-amino-3-(3-hydroxyphenyl)propanoic acid
DM0748C CA CAS 587-33-7
DM0748C CB CHEBI:44303
DM0748C DE Discovery agent
DMQBGH9 ID DMQBGH9
DMQBGH9 DN Metazamide
DMQBGH9 HS Investigative
DMQBGH9 SN METAZAMIDE; UNII-T3Y0F5VOB8; 14058-90-3; GPA-878; T3Y0F5VOB8; Metazamidum; 1-(4-methoxyphenyl)-5-methyl-2,3-dihydro-1H-imidazol-2-one; Metazamide [INN]; Metazamid; GPA 878; AC1L1B4L; 3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one; 1-(4-Methoxyphenyl)-5-methyl-4-imidazolin-2-on; ZINC472; SCHEMBL193544; CHEMBL2104723; DTXSID80161441; MolPort-027-352-367; AKOS017548002; 1-(p-Methoxyphenyl)-5-methyl-4-imidazolin-2-one; 4-Imidazolin-2-one, 1-(4-methoxyphenyl)-5-methyl-
DMQBGH9 DT Small molecular drug
DMQBGH9 PC 26433
DMQBGH9 MW 204.22
DMQBGH9 FM C11H12N2O2
DMQBGH9 IC InChI=1S/C11H12N2O2/c1-8-7-12-11(14)13(8)9-3-5-10(15-2)6-4-9/h3-7H,1-2H3,(H,12,14)
DMQBGH9 CS CC1=CNC(=O)N1C2=CC=C(C=C2)OC
DMQBGH9 IK NHUPEUMBGMETKD-UHFFFAOYSA-N
DMQBGH9 IU 3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one
DMQBGH9 CA CAS 14058-90-3
DMQBGH9 DE Discovery agent
DMB6T23 ID DMB6T23
DMB6T23 DN METAZOCINE
DMB6T23 HS Investigative
DMB6T23 SN Methobenzmorphan; METAZOCINE; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-; NSC611380; 3734-52-9; 2'-Hydroxy-2,5,9-trimethyl-6,7-benzomorphan; AC1Q7AHP; AC1L1XA2; SCHEMBL26347; CHEMBL33376; YGSVZRIZCHZUHB-UHFFFAOYSA-N; PDSP1_001246; PDSP2_001230; NSC-611380; LS-90663; LS-90665
DMB6T23 DT Small molecular drug
DMB6T23 PC 62518
DMB6T23 MW 231.33
DMB6T23 FM C15H21NO
DMB6T23 IC InChI=1S/C15H21NO/c1-10-14-8-11-4-5-12(17)9-13(11)15(10,2)6-7-16(14)3/h4-5,9-10,14,17H,6-8H2,1-3H3
DMB6T23 CS CC1C2CC3=C(C1(CCN2C)C)C=C(C=C3)O
DMB6T23 IK YGSVZRIZCHZUHB-UHFFFAOYSA-N
DMB6T23 IU 1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMB6T23 CA CAS 3734-52-9
DMB6T23 DE Discovery agent
DMDASC6 ID DMDASC6
DMDASC6 DN Metformin
DMDASC6 HS Investigative
DMDASC6 SN Fortamet
DMDASC6 TC Antiviral Agents
DMDASC6 DT Small molecular drug
DMDASC6 PC 4091
DMDASC6 MW 129.16
DMDASC6 FM C4H11N5
DMDASC6 IC InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
DMDASC6 CS CN(C)C(=N)N=C(N)N
DMDASC6 IK XZWYZXLIPXDOLR-UHFFFAOYSA-N
DMDASC6 IU 3-(diaminomethylidene)-1,1-dimethylguanidine
DMDASC6 CA CAS 657-24-9
DMDASC6 CB CHEBI:6801
DMDASC6 DE Coronavirus Disease 2019 (COVID-19)
DMZVF6M ID DMZVF6M
DMZVF6M DN Methanandamide
DMZVF6M HS Investigative
DMZVF6M SN methanandamide; (R)-methanandamide; R(+)-Methanandamide; AM-356; (R)-(+)-Methanandamide; CHEMBL120526; 157182-49-5; N-(1R-methyl-2-hydroxy-ethyl) arachidonoyl amine; N-(1R-methyl-2-hydroxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine; (5Z,8Z,11Z,14Z)-N-[(2R)-1-hydroxypropan-2-yl]icosa-5,8,11,14-tetraenamide; (R)-N-(2-Hydroxy-1-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide; R-1 Methanandamide; R-(+)-methanandamide; BSPBio_001285; SCHEMBL338871; AC1O424C; GTPL2506; BML2-C03; BCBcMAP01_000201; MolPort-003-958-659
DMZVF6M DT Small molecular drug
DMZVF6M PC 6321351
DMZVF6M MW 361.6
DMZVF6M FM C23H39NO2
DMZVF6M IC InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-23(26)24-22(2)21-25/h7-8,10-11,13-14,16-17,22,25H,3-6,9,12,15,18-21H2,1-2H3,(H,24,26)/b8-7-,11-10-,14-13-,17-16-/t22-/m1/s1
DMZVF6M CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N[C@H](C)CO
DMZVF6M IK SQKRUBZPTNJQEM-FQPARAGTSA-N
DMZVF6M IU (5Z,8Z,11Z,14Z)-N-[(2R)-1-hydroxypropan-2-yl]icosa-5,8,11,14-tetraenamide
DMZVF6M CA CAS 157182-49-5
DMZVF6M DE Discovery agent
DMVQSEH ID DMVQSEH
DMVQSEH DN Methimepip
DMVQSEH HS Investigative
DMVQSEH SN Methimepip; GTPL1254; CHEMBL175782; SCHEMBL8320104; BDBM22909; ZINC6716245; AKOS027324257; 4-(3H-imidazol-4-ylmethyl)-1-methylpiperidine; 4-(1H-imidazol-5-ylmethyl)-1-methylpiperidine; L009044
DMVQSEH DT Small molecular drug
DMVQSEH PC 11313837
DMVQSEH MW 179.26
DMVQSEH FM C10H17N3
DMVQSEH IC InChI=1S/C10H17N3/c1-13-4-2-9(3-5-13)6-10-7-11-8-12-10/h7-9H,2-6H2,1H3,(H,11,12)
DMVQSEH CS CN1CCC(CC1)CC2=CN=CN2
DMVQSEH IK KIAVPENCSGKVQP-UHFFFAOYSA-N
DMVQSEH IU 4-(1H-imidazol-5-ylmethyl)-1-methylpiperidine
DMVQSEH CA CAS 151070-80-3
DMVQSEH DE Discovery agent
DMEIP6H ID DMEIP6H
DMEIP6H DN methionine benzimidazole 6
DMEIP6H HS Investigative
DMEIP6H SN CHEMBL1770297; N-[1-(1H-benzimidazol-2-yl)-3-methylsulfanylpropyl]-5-ethoxy-3-methyl-1-benzofuran-2-carboxamide; methionine benzimidazole 6; AC1N7MKZ; GTPL5829
DMEIP6H DT Small molecular drug
DMEIP6H PC 4329947
DMEIP6H MW 423.5
DMEIP6H FM C23H25N3O3S
DMEIP6H IC InChI=1S/C23H25N3O3S/c1-4-28-15-9-10-20-16(13-15)14(2)21(29-20)23(27)26-19(11-12-30-3)22-24-17-7-5-6-8-18(17)25-22/h5-10,13,19H,4,11-12H2,1-3H3,(H,24,25)(H,26,27)
DMEIP6H CS CCOC1=CC2=C(C=C1)OC(=C2C)C(=O)NC(CCSC)C3=NC4=CC=CC=C4N3
DMEIP6H IK AIMYRLXVAOYQLA-UHFFFAOYSA-N
DMEIP6H IU N-[1-(1H-benzimidazol-2-yl)-3-methylsulfanylpropyl]-5-ethoxy-3-methyl-1-benzofuran-2-carboxamide
DMEIP6H DE Discovery agent
DMOUTNA ID DMOUTNA
DMOUTNA DN Methionine Phosphonate
DMOUTNA HS Investigative
DMOUTNA SN METHIONINE PHOSPHONATE; (1-AMINO-3-METHYLSULFANYL-PROPYL)-PHOSPHONIC ACID; 1pfu; AC1L9GS3; SCHEMBL4321583; DB02151; [(R)-1-Amino-3-(methylthio)propyl]phosphonic acid; [(1R)-1-amino-3-methylsulfanylpropyl]phosphonic acid; [(1R)-1-amino-3-(methylsulfanyl)propyl]phosphonic acid
DMOUTNA DT Small molecular drug
DMOUTNA PC 444719
DMOUTNA MW 185.18
DMOUTNA FM C4H12NO3PS
DMOUTNA IC InChI=1S/C4H12NO3PS/c1-10-3-2-4(5)9(6,7)8/h4H,2-3,5H2,1H3,(H2,6,7,8)/t4-/m1/s1
DMOUTNA CS CSCC[C@H](N)P(=O)(O)O
DMOUTNA IK XKCSXHUCPYVQIW-SCSAIBSYSA-N
DMOUTNA IU [(1R)-1-amino-3-methylsulfanylpropyl]phosphonic acid
DMOUTNA DE Discovery agent
DMKE18W ID DMKE18W
DMKE18W DN Methionine Sulfoxide
DMKE18W HS Investigative
DMKE18W SN Methionine sulfoxide; DL-Methionine sulfoxide; methionine sulfoxide; 62697-73-8; 454-41-1; dl-methioninesulfoxide; 2-Amino-4-(methylsulfinyl)butanoic acid; Uethionine, S-oxide; Methionine, S-oxide; Butanoic acid, 2-amino-4-(methylsulfinyl)-; 2-Amino-4-(methylsulfinyl)butyric acid; H-DL-Met(O)-OH; 2-amino-4-methanesulfinylbutanoic acid; BUTYRIC ACID, 2-AMINO-4-(METHYLSULFINYL)-; SQ 2292; 2-Amino-4-(methylsulphinyl)butyric acid; MFCD00002620; S-OXYMETHIONINE; (1)-2-Amino-4-(methylsulphinyl)butyric acid; 4241-59-2; methioninsulfoxid; S-Oxymethionine
DMKE18W DT Small molecular drug
DMKE18W PC 847
DMKE18W MW 165.21
DMKE18W FM C5H11NO3S
DMKE18W IC InChI=1S/C5H11NO3S/c1-10(9)3-2-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)
DMKE18W CS CS(=O)CCC(C(=O)O)N
DMKE18W IK QEFRNWWLZKMPFJ-UHFFFAOYSA-N
DMKE18W IU 2-amino-4-methylsulfinylbutanoic acid
DMKE18W CA CAS 62697-73-8
DMKE18W CB CHEBI:49033
DMKE18W DE Discovery agent
DMMC0I7 ID DMMC0I7
DMMC0I7 DN METHIOTHEPIN
DMMC0I7 HS Investigative
DMMC0I7 SN methiothepin; Metitepine; Methiothepine; Metitepinum; Metitepina; Metitepine [INN]; Metitepinum [INN-Latin]; Metitepina [INN-Spanish]; BRN 0626221; 20229-30-5; (+-)-10-(4-Methylpiperazinyl)-8-(methylthio)-10,11-dihydrodibenzo(b,f)thiepin; (+-)-8-Methylthio-10-(4-methylpiperazino)-10,11-dihydrodibenzo(b,f)thiepin; (+-)-1-(10,11-Dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-4-methylpiperazine; CHEBI:64203; 1-(10,11-Dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-4-methylpiperazine; NCGC00024665-03; DSSTox_CID_24000
DMMC0I7 DT Small molecular drug
DMMC0I7 PC 4106
DMMC0I7 MW 356.6
DMMC0I7 FM C20H24N2S2
DMMC0I7 IC InChI=1S/C20H24N2S2/c1-21-9-11-22(12-10-21)18-13-15-5-3-4-6-19(15)24-20-8-7-16(23-2)14-17(18)20/h3-8,14,18H,9-13H2,1-2H3
DMMC0I7 CS CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)SC
DMMC0I7 IK RLJFTICUTYVZDG-UHFFFAOYSA-N
DMMC0I7 IU 1-methyl-4-(3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazine
DMMC0I7 CA CAS 20229-30-5
DMMC0I7 CB CHEBI:64203
DMMC0I7 DE Discovery agent
DMH2CKX ID DMH2CKX
DMH2CKX DN METHOCTRAMINE
DMH2CKX HS Investigative
DMH2CKX SN Methoctramine; CHEBI:73339; UNII-NVJ76B897D; CHEMBL27673; NVJ76B897D; n,n'-bis{6-[(2-methoxybenzyl)amino]hexyl}octane-1,8-diamine; N1,N8-bis(6-(2-methoxybenzylamino)hexyl)octane-1,8-diamine; N,N'-bis[6-[(2-Methoxyphenyl)methylamino]hexyl]octane-1,8-diamine; N,N'-Bis(6-((2-methoxyphenyl)methylamino)hexyl)octane-1,8-diamine; N,N'-Bis[6-[[(2-methoxyphenyl)methyl]amino]hexyl]-1,8-octanediamine; N,N'-Bis(6-(((2-methoxyphenyl)methyl)amino)hexyl)-1,8-octanediamine; Methoctramine free base; NCGC00015626-01; Lopac-M-105
DMH2CKX DT Small molecular drug
DMH2CKX PC 107759
DMH2CKX MW 728.7
DMH2CKX FM C36H66Cl4N4O2
DMH2CKX IC InChI=1S/C36H62N4O2.4ClH/c1-41-35-23-13-11-21-33(35)31-39-29-19-9-7-17-27-37-25-15-5-3-4-6-16-26-38-28-18-8-10-20-30-40-32-34-22-12-14-24-36(34)42-2;;;;/h11-14,21-24,37-40H,3-10,15-20,25-32H2,1-2H3;4*1H
DMH2CKX CS COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC2=CC=CC=C2OC.Cl.Cl.Cl.Cl
DMH2CKX IK CDKGGOUDHGSFAF-UHFFFAOYSA-N
DMH2CKX IU N,N'-bis[6-[(2-methoxyphenyl)methylamino]hexyl]octane-1,8-diamine;tetrahydrochloride
DMH2CKX CA CAS 104807-46-7
DMH2CKX CB CHEBI:73452
DMH2CKX DE Discovery agent
DM58A0W ID DM58A0W
DM58A0W DN methoprene acid
DM58A0W HS Investigative
DM58A0W SN Methoprene acid; 53092-52-7; 11-Methoxy-3,7,11-trimethyl-2E,4E-dodecadienoic acid; (2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID; 2,4-Dodecadienoic acid, 11-methoxy-3,7,11-trimethyl-, (2E,4E)-; EINECS 258-355-4; ZR-725; AC1NS4JK; Spectrum5_001945; AC1Q5T6M; BSPBio_001416; SCHEMBL3052148; GTPL2812; CHEMBL289635; BML2-E11; SCHEMBL3052151; CHEBI:91685; HMS3402G18; HMS1989G18; HMS1791G18; HMS1361G18; Methoprene acid, >=98% (TLC); MFCD01317817; (+-)-(2E,4E)-11-Methoxy-3,7,11-trimethyl-2,4-dodecadienoic acid
DM58A0W DT Small molecular drug
DM58A0W PC 5353760
DM58A0W MW 268.39
DM58A0W FM C16H28O3
DM58A0W IC InChI=1S/C16H28O3/c1-13(10-7-11-16(3,4)19-5)8-6-9-14(2)12-15(17)18/h6,9,12-13H,7-8,10-11H2,1-5H3,(H,17,18)/b9-6+,14-12+
DM58A0W CS CC(CCCC(C)(C)OC)C/C=C/C(=C/C(=O)O)/C
DM58A0W IK MNYBEULOKRVZKY-TZOAMJEDSA-N
DM58A0W IU (2E,4E)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoic acid
DM58A0W CA CAS 53092-52-7
DM58A0W CB CHEBI:91685
DM58A0W DE Discovery agent
DM8P526 ID DM8P526
DM8P526 DN Methotrexate gamma-hydroxamic acid
DM8P526 HS Investigative
DM8P526 SN methotrexate gamma-hydroxamic acid; CHEMBL244883
DM8P526 DT Small molecular drug
DM8P526 PC 44428664
DM8P526 MW 469.5
DM8P526 FM C20H23N9O5
DM8P526 IC InChI=1S/C20H23N9O5/c1-29(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(30)28-34/h2-5,8,13,34H,6-7,9H2,1H3,(H,25,31)(H,28,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
DM8P526 CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)NO)C(=O)O
DM8P526 IK YUQBNZUBNMWBAQ-ZDUSSCGKSA-N
DM8P526 IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-(hydroxyamino)-5-oxopentanoic acid
DM8P526 DE Discovery agent
DMELK2A ID DMELK2A
DMELK2A DN Methotrexate gamma-L-phenylalaninehydroxamic acid
DMELK2A HS Investigative
DMELK2A SN CHEMBL396296; methotrexate gamma-L-phenylalaninehydroxamic acid
DMELK2A DT Small molecular drug
DMELK2A PC 16216218
DMELK2A MW 616.6
DMELK2A FM C29H32N10O6
DMELK2A IC InChI=1S/C29H32N10O6/c1-39(15-18-14-32-25-23(33-18)24(30)36-29(31)37-25)19-9-7-17(8-10-19)26(41)35-20(28(43)44)11-12-22(40)34-21(27(42)38-45)13-16-5-3-2-4-6-16/h2-10,14,20-21,45H,11-13,15H2,1H3,(H,34,40)(H,35,41)(H,38,42)(H,43,44)(H4,30,31,32,36,37)/t20-,21-/m0/s1
DMELK2A CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)N[C@@H](CC4=CC=CC=C4)C(=O)NO)C(=O)O
DMELK2A IK QHQOEZXEZMHMER-SFTDATJTSA-N
DMELK2A IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-[[(2S)-1-(hydroxyamino)-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid
DMELK2A DE Discovery agent
DMPYJLA ID DMPYJLA
DMPYJLA DN Methotrexate gamma-L-proline-hydroxamic acid
DMPYJLA HS Investigative
DMPYJLA SN CHEMBL388879; methotrexate gamma-L-proline-hydroxamic acid
DMPYJLA DT Small molecular drug
DMPYJLA PC 44428667
DMPYJLA MW 566.6
DMPYJLA FM C25H30N10O6
DMPYJLA IC InChI=1S/C25H30N10O6/c1-34(12-14-11-28-21-19(29-14)20(26)31-25(27)32-21)15-6-4-13(5-7-15)22(37)30-16(24(39)40)8-9-18(36)35-10-2-3-17(35)23(38)33-41/h4-7,11,16-17,41H,2-3,8-10,12H2,1H3,(H,30,37)(H,33,38)(H,39,40)(H4,26,27,28,31,32)/t16-,17-/m0/s1
DMPYJLA CS CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)N4CCC[C@H]4C(=O)NO)C(=O)O
DMPYJLA IK UYVVHTPVCDOQRA-IRXDYDNUSA-N
DMPYJLA IU (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-[(2S)-2-(hydroxycarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid
DMPYJLA DE Discovery agent
DMX8QK0 ID DMX8QK0
DMX8QK0 DN Methoxy arachidonyl fluorophosphonate
DMX8QK0 HS Investigative
DMX8QK0 SN MAFP; MAPF; AC1NS4JN; SCHEMBL8253710; 188404-10-6; AKOS015909076; RT-013646; I14-33366; Phosphonofluoridic acid, methyl-5Z,8Z,11Z,14Z-eicosatetraenyl ester
DMX8QK0 DT Small molecular drug
DMX8QK0 PC 10429254
DMX8QK0 MW 370.5
DMX8QK0 FM C21H36FO2P
DMX8QK0 IC InChI=1S/C21H36FO2P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(22,23)24-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-21H2,1-2H3/b8-7-,11-10-,14-13-,17-16-
DMX8QK0 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCP(=O)(OC)F
DMX8QK0 IK KWKZCGMJGHHOKJ-ZKWNWVNESA-N
DMX8QK0 IU (5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]icosa-5,8,11,14-tetraene
DMX8QK0 DE Discovery agent
DMN8HRU ID DMN8HRU
DMN8HRU DN Methoxyphenamine
DMN8HRU HS Investigative
DMN8HRU SN Euspirol; METHOXYPHENAMINE; Methamphetamine, 2-methoxy; Methoxifenaminio; Methoxiphenadrin; Methoxiphenadrinum; Methoxyphenadrine; Methoxyphenamin; Methoxyphenamine [INN:BAN]; Methoxyphenaminum; Methoxyphenaminum [INN-Latin]; Metossifenamina [DCIT]; Metoxifenaminio [INN-Spanish]; Orthoxine; Ortodrinex; Ortoxine; Oxalacetic acid orthoxine; Proasma; 2-Methoxy-N,alpha-dimethylphenethylamin; 2-Methoxy-N-methylamphetamine; 2-Methoxymethamphetamine; 93-30-1; Asmi; EINECS 202-237-7; o-Methoxy-N,alpha-dimethylphenethylamine
DMN8HRU PC 4117
DMN8HRU MW 179.26
DMN8HRU FM C11H17NO
DMN8HRU IC OEHAYUOVELTAPG-UHFFFAOYSA-N
DMN8HRU CS CC(CC1=CC=CC=C1OC)NC
DMN8HRU IK 1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3
DMN8HRU IU 1-(2-methoxyphenyl)-N-methylpropan-2-amine
DMN8HRU CA CAS 93-30-1
DMN8HRU CB CHEBI:134817
DMN8HRU DE Chronic obstructive pulmonary disease
DMY0O7X ID DMY0O7X
DMY0O7X DN METHOXYUNDECYLPHOSPHINIC ACID
DMY0O7X HS Investigative
DMY0O7X SN Methoxyundecylphosphinic Acid; MUP; AC1L9KBG; methoxy(undecyl)phosphinic acid; methoxy undecyl phosphinic acid; SCHEMBL9079355; SCHEMBL20553273; methyl hydrogen (S)-undecylphosphonate
DMY0O7X DT Small molecular drug
DMY0O7X PC 446977
DMY0O7X MW 250.31
DMY0O7X FM C12H27O3P
DMY0O7X IC InChI=1S/C12H27O3P/c1-3-4-5-6-7-8-9-10-11-12-16(13,14)15-2/h3-12H2,1-2H3,(H,13,14)
DMY0O7X CS CCCCCCCCCCCP(=O)(O)OC
DMY0O7X IK JBVUSHKPEBKWQP-UHFFFAOYSA-N
DMY0O7X IU methoxy(undecyl)phosphinic acid
DMY0O7X DE Discovery agent
DMGYZHU ID DMGYZHU
DMGYZHU DN Methyl 10H-phenothiazine-10-carboxylate
DMGYZHU HS Investigative
DMGYZHU SN methyl 10H-phenothiazine-10-carboxylate; CHEMBL480755; methyl phenothiazine-10-carboxylate; Phenothiazine-10-carboxylic acid methyl ester; AC1MJ71I; SCHEMBL8739119; MolPort-001-898-173; ZINC4007353; STK373134; BDBM50292600; AKOS005447210; MCULE-7901457115; BAS 00444618; 68825-31-0; ST50909034; 10H-Phenothiazine-10-carboxylic acid methyl ester; SR-01000320795; SR-01000320795-1; 10H-Phenothiazine-10-carboxylic acid, methyl ester
DMGYZHU DT Small molecular drug
DMGYZHU PC 3107576
DMGYZHU MW 257.31
DMGYZHU FM C14H11NO2S
DMGYZHU IC InChI=1S/C14H11NO2S/c1-17-14(16)15-10-6-2-4-8-12(10)18-13-9-5-3-7-11(13)15/h2-9H,1H3
DMGYZHU CS COC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DMGYZHU IK WWHYODNLUNCVDI-UHFFFAOYSA-N
DMGYZHU IU methyl phenothiazine-10-carboxylate
DMGYZHU DE Discovery agent
DMV1AL5 ID DMV1AL5
DMV1AL5 DN Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate
DMV1AL5 HS Investigative
DMV1AL5 SN CHEMBL555832; Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate
DMV1AL5 DT Small molecular drug
DMV1AL5 PC 45267095
DMV1AL5 MW 354.5
DMV1AL5 FM C20H38N2O3
DMV1AL5 IC InChI=1S/C20H38N2O3/c1-3-4-17-21-20(24)22-18-15-13-11-9-7-5-6-8-10-12-14-16-19(23)25-2/h5,7H,3-4,6,8-18H2,1-2H3,(H2,21,22,24)/b7-5-
DMV1AL5 CS CCCCNC(=O)NCCCCC/C=C\\CCCCCCC(=O)OC
DMV1AL5 IK CGNYGIBRDHWVDW-ALCCZGGFSA-N
DMV1AL5 IU methyl (Z)-14-(butylcarbamoylamino)tetradec-8-enoate
DMV1AL5 DE Discovery agent
DMBKU9M ID DMBKU9M
DMBKU9M DN Methyl 2-(2-oxo-8-phenyloctanamido)acetate
DMBKU9M HS Investigative
DMBKU9M SN CHEMBL488440
DMBKU9M DT Small molecular drug
DMBKU9M PC 44563076
DMBKU9M MW 305.4
DMBKU9M FM C17H23NO4
DMBKU9M IC InChI=1S/C17H23NO4/c1-22-16(20)13-18-17(21)15(19)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11H,2-3,5,8-9,12-13H2,1H3,(H,18,21)
DMBKU9M CS COC(=O)CNC(=O)C(=O)CCCCCCC1=CC=CC=C1
DMBKU9M IK MUJNYULVHMASQZ-UHFFFAOYSA-N
DMBKU9M IU methyl 2-[(2-oxo-8-phenyloctanoyl)amino]acetate
DMBKU9M DE Discovery agent
DMVYGBU ID DMVYGBU
DMVYGBU DN Methyl 2-(2-oxohexadecanamido)acetate
DMVYGBU HS Investigative
DMVYGBU SN Methyl 2-(2-oxohexadecanamido)acetate; SCHEMBL1873320
DMVYGBU DT Small molecular drug
DMVYGBU PC 25166397
DMVYGBU MW 341.5
DMVYGBU FM C19H35NO4
DMVYGBU IC InChI=1S/C19H35NO4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-17(21)19(23)20-16-18(22)24-2/h3-16H2,1-2H3,(H,20,23)
DMVYGBU CS CCCCCCCCCCCCCCC(=O)C(=O)NCC(=O)OC
DMVYGBU IK PZEVUHTWLYMLFR-UHFFFAOYSA-N
DMVYGBU IU methyl 2-(2-oxohexadecanoylamino)acetate
DMVYGBU DE Discovery agent
DMA82IQ ID DMA82IQ
DMA82IQ DN Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate
DMA82IQ HS Investigative
DMA82IQ SN CHEMBL247131; methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate; BDBM50213924
DMA82IQ DT Small molecular drug
DMA82IQ PC 43091550
DMA82IQ MW 282.76
DMA82IQ FM C15H19ClO3
DMA82IQ IC InChI=1S/C15H19ClO3/c1-18-15(17)10-19-14-8-7-12(16)9-13(14)11-5-3-2-4-6-11/h7-9,11H,2-6,10H2,1H3
DMA82IQ CS COC(=O)COC1=C(C=C(C=C1)Cl)C2CCCCC2
DMA82IQ IK AZDVRVGZFMVXTH-UHFFFAOYSA-N
DMA82IQ IU methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate
DMA82IQ DE Discovery agent
DMP06I3 ID DMP06I3
DMP06I3 DN Methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate
DMP06I3 HS Investigative
DMP06I3 SN CHEMBL461539; methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate; SCHEMBL2164164; CRHSFDPXTRFSMK-UHFFFAOYSA-N
DMP06I3 DT Small molecular drug
DMP06I3 PC 44554610
DMP06I3 MW 315.4
DMP06I3 FM C18H21NO4
DMP06I3 IC InChI=1S/C18H21NO4/c1-22-18(21)15-13-23-17(19-15)16(20)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DMP06I3 CS COC(=O)C1=COC(=N1)C(=O)CCCCCCC2=CC=CC=C2
DMP06I3 IK CRHSFDPXTRFSMK-UHFFFAOYSA-N
DMP06I3 IU methyl 2-(7-phenylheptanoyl)-1,3-oxazole-4-carboxylate
DMP06I3 DE Discovery agent
DM9FA26 ID DM9FA26
DM9FA26 DN Methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate
DM9FA26 HS Investigative
DM9FA26 SN CHEMBL220784; methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate; SCHEMBL3140826; Methyl 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylate; BIKPWTFTYRRSPI-UHFFFAOYSA-N
DM9FA26 DT Small molecular drug
DM9FA26 PC 11991809
DM9FA26 MW 315.4
DM9FA26 FM C18H21NO4
DM9FA26 IC InChI=1S/C18H21NO4/c1-22-18(21)16-13-19-17(23-16)15(20)12-8-3-2-5-9-14-10-6-4-7-11-14/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
DM9FA26 CS COC(=O)C1=CN=C(O1)C(=O)CCCCCCC2=CC=CC=C2
DM9FA26 IK BIKPWTFTYRRSPI-UHFFFAOYSA-N
DM9FA26 IU methyl 2-(7-phenylheptanoyl)-1,3-oxazole-5-carboxylate
DM9FA26 DE Discovery agent
DMB1PXR ID DMB1PXR
DMB1PXR DN Methyl 2-(Benzylamino)-1H-indole-3-carboxylate
DMB1PXR HS Investigative
DMB1PXR SN CHEMBL483067; BDBM31109; 2-substituted indole-3-carboxylate, 27f
DMB1PXR DT Small molecular drug
DMB1PXR PC 44158012
DMB1PXR MW 280.32
DMB1PXR FM C17H16N2O2
DMB1PXR IC InChI=1S/C17H16N2O2/c1-21-17(20)15-13-9-5-6-10-14(13)19-16(15)18-11-12-7-3-2-4-8-12/h2-10,18-19H,11H2,1H3
DMB1PXR CS COC(=O)C1=C(NC2=CC=CC=C21)NCC3=CC=CC=C3
DMB1PXR IK TWNCELFDSJZJAX-UHFFFAOYSA-N
DMB1PXR IU methyl 2-(benzylamino)-1H-indole-3-carboxylate
DMB1PXR DE Discovery agent
DMB74WP ID DMB74WP
DMB74WP DN Methyl 2-(Diallylamino)-1H-indole-3-carboxylate
DMB74WP HS Investigative
DMB74WP SN CHEMBL483269; BDBM31111; 2-substituted indole-3-carboxylate, 27h
DMB74WP DT Small molecular drug
DMB74WP PC 44158013
DMB74WP MW 270.33
DMB74WP FM C16H18N2O2
DMB74WP IC InChI=1S/C16H18N2O2/c1-4-10-18(11-5-2)15-14(16(19)20-3)12-8-6-7-9-13(12)17-15/h4-9,17H,1-2,10-11H2,3H3
DMB74WP CS COC(=O)C1=C(NC2=CC=CC=C21)N(CC=C)CC=C
DMB74WP IK VOAOXYYRHVDNNJ-UHFFFAOYSA-N
DMB74WP IU methyl 2-[bis(prop-2-enyl)amino]-1H-indole-3-carboxylate
DMB74WP DE Discovery agent
DMF6MRS ID DMF6MRS
DMF6MRS DN Methyl 2-(naphthalen-2-yl)benzoate
DMF6MRS HS Investigative
DMF6MRS SN CHEMBL103936; methyl 2-(naphthalen-2-yl)benzoate; SCHEMBL16683936; BDBM50090973; ZINC13809589; 2-(2-Naphthyl)benzoic acid methyl ester; 2-Naphthalen-2-yl-benzoic acid methyl ester
DMF6MRS DT Small molecular drug
DMF6MRS PC 44332186
DMF6MRS MW 262.3
DMF6MRS FM C18H14O2
DMF6MRS IC InChI=1S/C18H14O2/c1-20-18(19)17-9-5-4-8-16(17)15-11-10-13-6-2-3-7-14(13)12-15/h2-12H,1H3
DMF6MRS CS COC(=O)C1=CC=CC=C1C2=CC3=CC=CC=C3C=C2
DMF6MRS IK SKSUKRWKVAZHJI-UHFFFAOYSA-N
DMF6MRS IU methyl 2-naphthalen-2-ylbenzoate
DMF6MRS DE Discovery agent
DMWM814 ID DMWM814
DMWM814 DN Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate
DMWM814 HS Investigative
DMWM814 SN CHEMBL608140; Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate; SCHEMBL9642312; FEWHBUJYQHXFMV-UHFFFAOYSA-N; BDBM50307219; 1-benzyl-5-imidazole propionic acid methyl ester
DMWM814 DT Small molecular drug
DMWM814 PC 14535954
DMWM814 MW 244.29
DMWM814 FM C14H16N2O2
DMWM814 IC InChI=1S/C14H16N2O2/c1-18-14(17)8-7-13-9-15-11-16(13)10-12-5-3-2-4-6-12/h2-6,9,11H,7-8,10H2,1H3
DMWM814 CS COC(=O)CCC1=CN=CN1CC2=CC=CC=C2
DMWM814 IK FEWHBUJYQHXFMV-UHFFFAOYSA-N
DMWM814 IU methyl 3-(3-benzylimidazol-4-yl)propanoate
DMWM814 DE Discovery agent
DMWG9BE ID DMWG9BE
DMWG9BE DN Methyl 3beta-hydroxyolean-12-en-28-oate
DMWG9BE HS Investigative
DMWG9BE SN CHEMBL381707; methyl 3beta-hydroxyolean-12-en-28-oate
DMWG9BE DT Small molecular drug
DMWG9BE PC 44411771
DMWG9BE MW 456.7
DMWG9BE FM C30H48O3
DMWG9BE IC InChI=1S/C30H48O3/c1-26(2)16-17-30(25(32)33-7)15-10-20-19(21(30)18-26)8-9-23-28(20,5)13-11-22-27(3,4)24(31)12-14-29(22,23)6/h8,20-24,31H,9-18H2,1-7H3/t20?,21-,22?,23-,24-,28-,29-,30+/m0/s1
DMWG9BE CS C[C@@]12CCC3[C@@]([C@H]1CC=C4C2CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)(CC[C@@H](C3(C)C)O)C
DMWG9BE IK QQTTYKDXVIONSQ-HHKCSUCSSA-N
DMWG9BE IU methyl (4aR,6aS,6bR,10S,12aR,14bS)-10-hydroxy-2,2,6b,9,9,12a-hexamethyl-3,4,5,6,6a,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylate
DMWG9BE DE Discovery agent
DM9S210 ID DM9S210
DM9S210 DN Methyl 4-(3-cyclohexylureido)butanoate
DM9S210 HS Investigative
DM9S210 SN methyl 4-(3-cyclohexylureido)butanoate; CHEMBL220415; BDBM50192957
DM9S210 DT Small molecular drug
DM9S210 PC 11160856
DM9S210 MW 242.31
DM9S210 FM C12H22N2O3
DM9S210 IC InChI=1S/C12H22N2O3/c1-17-11(15)8-5-9-13-12(16)14-10-6-3-2-4-7-10/h10H,2-9H2,1H3,(H2,13,14,16)
DM9S210 CS COC(=O)CCCNC(=O)NC1CCCCC1
DM9S210 IK QDXXGVVKSQMYHV-UHFFFAOYSA-N
DM9S210 IU methyl 4-(cyclohexylcarbamoylamino)butanoate
DM9S210 DE Discovery agent
DMUROGX ID DMUROGX
DMUROGX DN Methyl 4-(4-hydroxybenzylideneamino)benzoate
DMUROGX HS Investigative
DMUROGX DT Small molecular drug
DMUROGX PC 969280
DMUROGX MW 255.27
DMUROGX FM C15H13NO3
DMUROGX IC InChI=1S/C15H13NO3/c1-19-15(18)12-4-6-13(7-5-12)16-10-11-2-8-14(17)9-3-11/h2-10,17H,1H3
DMUROGX CS COC(=O)C1=CC=C(C=C1)N=CC2=CC=C(C=C2)O
DMUROGX IK RMGZSIQUVXIPDP-UHFFFAOYSA-N
DMUROGX IU methyl 4-[(4-hydroxyphenyl)methylideneamino]benzoate
DMUROGX DE Discovery agent
DMSBCL6 ID DMSBCL6
DMSBCL6 DN Methyl 4-(4-tert-butylbenzylideneamino)benzoate
DMSBCL6 HS Investigative
DMSBCL6 SN CHEMBL572526; methyl 4-(4-tert-butylbenzylideneamino)benzoate
DMSBCL6 DT Small molecular drug
DMSBCL6 PC 45483180
DMSBCL6 MW 295.4
DMSBCL6 FM C19H21NO2
DMSBCL6 IC InChI=1S/C19H21NO2/c1-19(2,3)16-9-5-14(6-10-16)13-20-17-11-7-15(8-12-17)18(21)22-4/h5-13H,1-4H3
DMSBCL6 CS CC(C)(C)C1=CC=C(C=C1)C=NC2=CC=C(C=C2)C(=O)OC
DMSBCL6 IK SONMMTHLONHMSH-UHFFFAOYSA-N
DMSBCL6 IU methyl 4-[(4-tert-butylphenyl)methylideneamino]benzoate
DMSBCL6 DE Discovery agent
DM9BPQ1 ID DM9BPQ1
DM9BPQ1 DN Methyl 6-(3-cyclohexylureido)hexanoate
DM9BPQ1 HS Investigative
DM9BPQ1 SN methyl 6-(3-cyclohexylureido)hexanoate; CHEMBL219974; BDBM50192964
DM9BPQ1 DT Small molecular drug
DM9BPQ1 PC 43608139
DM9BPQ1 MW 270.37
DM9BPQ1 FM C14H26N2O3
DM9BPQ1 IC InChI=1S/C14H26N2O3/c1-19-13(17)10-6-3-7-11-15-14(18)16-12-8-4-2-5-9-12/h12H,2-11H2,1H3,(H2,15,16,18)
DM9BPQ1 CS COC(=O)CCCCCNC(=O)NC1CCCCC1
DM9BPQ1 IK WHXVJNIBTQCTJK-UHFFFAOYSA-N
DM9BPQ1 IU methyl 6-(cyclohexylcarbamoylamino)hexanoate
DM9BPQ1 DE Discovery agent
DMBLW1A ID DMBLW1A
DMBLW1A DN Methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate
DMBLW1A HS Investigative
DMBLW1A SN CHEMBL598251
DMBLW1A DT Small molecular drug
DMBLW1A PC 46216786
DMBLW1A MW 297.3
DMBLW1A FM C17H15NO4
DMBLW1A IC InChI=1S/C17H15NO4/c1-20-14-9-8-12(11-6-4-3-5-7-11)13-10-15(22-16(13)14)18-17(19)21-2/h3-10H,1-2H3,(H,18,19)
DMBLW1A CS COC1=C2C(=C(C=C1)C3=CC=CC=C3)C=C(O2)NC(=O)OC
DMBLW1A IK CJZGJASKUWFLQA-UHFFFAOYSA-N
DMBLW1A IU methyl N-(7-methoxy-4-phenyl-1-benzofuran-2-yl)carbamate
DMBLW1A DE Discovery agent
DM9HLXD ID DM9HLXD
DM9HLXD DN Methyl 7-tert-butyl-9H-carbazole-3-carboxylate
DM9HLXD HS Investigative
DM9HLXD SN CHEMBL1173167; methyl 7-tert-butyl-9H-carbazole-3-carboxylate; BDBM50322578; ZINC53299021; 7-tert-Butyl-9H-carbazole-3-carboxylic acid methyl ester
DM9HLXD DT Small molecular drug
DM9HLXD PC 46244082
DM9HLXD MW 281.3
DM9HLXD FM C18H19NO2
DM9HLXD IC InChI=1S/C18H19NO2/c1-18(2,3)12-6-7-13-14-9-11(17(20)21-4)5-8-15(14)19-16(13)10-12/h5-10,19H,1-4H3
DM9HLXD CS CC(C)(C)C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)C(=O)OC
DM9HLXD IK UIUMIPOASYICHI-UHFFFAOYSA-N
DM9HLXD IU methyl 7-tert-butyl-9H-carbazole-3-carboxylate
DM9HLXD DE Discovery agent
DM4DIS3 ID DM4DIS3
DM4DIS3 DN Methyl 9H-carbazole-2-carboxylate
DM4DIS3 HS Investigative
DM4DIS3 SN Methyl 9H-carbazole-2-carboxylate; 26000-33-9; CHEMBL1172394; C14H11NO2; 9H-CARBAZOLE-2-CARBOXYLIC ACID METHYL ESTER; SCHEMBL2483277; CTK4F6920; DTXSID40461636; WDNZNDZRMLZWNC-UHFFFAOYSA-N; MolPort-005-941-204; ZINC22003793; BDBM50322587; ANW-71443; AKOS015967094; ACM26000339; OR340090; AJ-80205; DS-17387; KB-257852; TC-160188; AX8111765; 9H-Carbazole-2-carboxylicacid, methyl ester; X5228; 9H-Carbazole-2-carboxylic acid, methyl ester
DM4DIS3 DT Small molecular drug
DM4DIS3 PC 11299083
DM4DIS3 MW 225.24
DM4DIS3 FM C14H11NO2
DM4DIS3 IC InChI=1S/C14H11NO2/c1-17-14(16)9-6-7-11-10-4-2-3-5-12(10)15-13(11)8-9/h2-8,15H,1H3
DM4DIS3 CS COC(=O)C1=CC2=C(C=C1)C3=CC=CC=C3N2
DM4DIS3 IK WDNZNDZRMLZWNC-UHFFFAOYSA-N
DM4DIS3 IU methyl 9H-carbazole-2-carboxylate
DM4DIS3 CA CAS 26000-33-9
DM4DIS3 DE Discovery agent
DMAXEH3 ID DMAXEH3
DMAXEH3 DN Methyl arachidonyl fluorophosphonate
DMAXEH3 HS Investigative
DMAXEH3 SN (5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenyl methyl phosphorofluoridate; SCHEMBL177496; GTPL5218; methylarachidonoylflurophosphonate; methyl arachidonyl fluorophosphate; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-yl methyl fluorophosphonate; Fluorophosphonic acid methyl(5Z,8Z,11Z,14Z)-5,8,11,14-icosatetrenyl ester
DMAXEH3 DT Small molecular drug
DMAXEH3 PC 25021170
DMAXEH3 MW 386.5
DMAXEH3 FM C21H36FO3P
DMAXEH3 IC InChI=1S/C21H36FO3P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-26(22,23)24-2/h7-8,10-11,13-14,16-17H,3-6,9,12,15,18-21H2,1-2H3/b8-7-,11-10-,14-13-,17-16-
DMAXEH3 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCOP(=O)(OC)F
DMAXEH3 IK HNVKMEOEBANRAT-ZKWNWVNESA-N
DMAXEH3 IU (5Z,8Z,11Z,14Z)-1-[fluoro(methoxy)phosphoryl]oxyicosa-5,8,11,14-tetraene
DMAXEH3 DE Discovery agent
DMG8XD1 ID DMG8XD1
DMG8XD1 DN Methyl estradiol-16-beta-carboxylate
DMG8XD1 HS Investigative
DMG8XD1 DT Small molecular drug
DMG8XD1 PC 44407416
DMG8XD1 MW 330.4
DMG8XD1 FM C20H26O4
DMG8XD1 IC InChI=1S/C20H26O4/c1-20-8-7-14-13-6-4-12(21)9-11(13)3-5-15(14)17(20)10-16(18(20)22)19(23)24-2/h4,6,9,14-18,21-22H,3,5,7-8,10H2,1-2H3/t14?,15?,16-,17?,18-,20-/m0/s1
DMG8XD1 CS C[C@]12CCC3C(C1C[C@@H]([C@@H]2O)C(=O)OC)CCC4=C3C=CC(=C4)O
DMG8XD1 IK ATXQVYDXJMHPHM-ASCAHHBESA-N
DMG8XD1 IU methyl (13S,16S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxylate
DMG8XD1 DE Discovery agent
DM9O5S6 ID DM9O5S6
DM9O5S6 DN Methyl icosylphosphonofluoridate
DM9O5S6 HS Investigative
DM9O5S6 SN methyl icosylphosphonofluoridate; CHEMBL462609; BDBM50247048; Fluoroicosylphosphinic acid methyl ester
DM9O5S6 DT Small molecular drug
DM9O5S6 PC 44563660
DM9O5S6 MW 378.5
DM9O5S6 FM C21H44FO2P
DM9O5S6 IC InChI=1S/C21H44FO2P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(22,23)24-2/h3-21H2,1-2H3
DM9O5S6 CS CCCCCCCCCCCCCCCCCCCCP(=O)(OC)F
DM9O5S6 IK IRQAGEYFWAZZPI-UHFFFAOYSA-N
DM9O5S6 IU 1-[fluoro(methoxy)phosphoryl]icosane
DM9O5S6 DE Discovery agent
DME4JGF ID DME4JGF
DME4JGF DN methyl isocyanate
DME4JGF HS Investigative
DME4JGF SN isocyanatomethane; methyl carbonimide; isocyanic acid
DME4JGF DT Small molecular drug
DME4JGF PC 12228
DME4JGF MW 57.05
DME4JGF FM C2H3NO
DME4JGF IC InChI=1S/C2H3NO/c1-3-2-4/h1H3
DME4JGF CS CN=C=O
DME4JGF IK HAMGRBXTJNITHG-UHFFFAOYSA-N
DME4JGF IU methylimino(oxo)methane
DME4JGF CA CAS 624-83-9
DME4JGF CB CHEBI:59059
DME4JGF DE Discovery agent
DMBHUKV ID DMBHUKV
DMBHUKV DN Methyl L-phenylalaninate
DMBHUKV HS Investigative
DMBHUKV SN Methyl 2-amino-3-phenylpropanoate; 15028-44-1; Methyl 3-phenyl-DL-alaninate; H-DL-Phe-OMe HCl; DL-phenylalanine methyl ester; VSDUZFOSJDMAFZ-UHFFFAOYSA-N; 2-Amino-3-phenyl-propionic acid methyl ester; phenylalanine, methyl ester; F2147-0643; l-phe methyl ester; EINECS 239-109-5; AC1L2PEY; Phenylalanine, methylester; AC1Q41SQ; AC1Q41SP; AC1Q41RL; SCHEMBL74887; D,L-phenylalanine methyl ester; DL-Phenylalanine, methyl ester; Methyl L-phenylalaninate (HCl); CTK4C6579; STK019373; MFCD00044582; NSC522409; BBL009783; AKOS016042462
DMBHUKV DT Small molecular drug
DMBHUKV PC 736234
DMBHUKV MW 179.22
DMBHUKV FM C10H13NO2
DMBHUKV IC InChI=1S/C10H13NO2/c1-13-10(12)9(11)7-8-5-3-2-4-6-8/h2-6,9H,7,11H2,1H3/t9-/m0/s1
DMBHUKV CS COC(=O)[C@H](CC1=CC=CC=C1)N
DMBHUKV IK VSDUZFOSJDMAFZ-VIFPVBQESA-N
DMBHUKV IU methyl (2S)-2-amino-3-phenylpropanoate
DMBHUKV CA CAS 2577-90-4
DMBHUKV CB CHEBI:49339
DMBHUKV DE Discovery agent
DM6YEW4 ID DM6YEW4
DM6YEW4 DN Methyl Mercury Ion
DM6YEW4 HS Investigative
DM6YEW4 SN Methylmercury(1+); Methylmercury II; Methyl Mercury Ion; Methylmercury ion; Methyl mercury; METHYLMERCURY(II) CATION; Monomethylmercury cation; Methylmercury ion(1+); CH3Hg+; Mercury(1+), methyl-; 22967-92-6; methylmercury(II); AC1L1NGS; Methyl mercury(II) cation; CH3Hg(+); [HgMe](+); Mercury(1+), methyl-, ion; DTXSID9024198; [HgCH3](+); CTK8D8906; HSDB 3930; CHEBI:49747; AKOS015903545; BRN 3902999; LS-89823; C18672; I14-18601; I14-114322
DM6YEW4 DT Small molecular drug
DM6YEW4 PC 6860
DM6YEW4 MW 215.63
DM6YEW4 FM CH3Hg+
DM6YEW4 IC InChI=1S/CH3.Hg/h1H3;/q;+1
DM6YEW4 CS C[Hg+]
DM6YEW4 IK DBUXSCUEGJMZAE-UHFFFAOYSA-N
DM6YEW4 IU methylmercury(1+)
DM6YEW4 CA CAS 22967-92-6
DM6YEW4 CB CHEBI:49747
DM6YEW4 DE Discovery agent
DMOCXLW ID DMOCXLW
DMOCXLW DN Methyl Methylsulfinylmethyl Sulfide
DMOCXLW HS Investigative
DMOCXLW SN 33577-16-1; methyl methylsulfinylmethyl sulfide; Methyl (methylsulfinyl)methyl sulfide; FAMSO; Methanesulfinyl-methylsulfanyl-methane; Methane, (methylsulfinyl)(methylthio)-; Formaldehyde dimethyl mercaptal S-oxide; Methyl (methylthio)methyl sulfoxide; (Methylsulfinyl)(methylthio)methane; Formaldehyde methyl mercaptal S-oxide; Sulfide, methyl (methylsulfinyl)methyl; Methyl methylthiomethyl sulfoxide; Methyl methylthiomethyl sulphoxide; NSC 181492; (Methylthio)dimethyl sulfoxide; OTKFCIVOVKCFHR-UHFFFAOYSA-N
DMOCXLW DT Small molecular drug
DMOCXLW PC 99129
DMOCXLW MW 124.23
DMOCXLW FM C3H8OS2
DMOCXLW IC InChI=1S/C3H8OS2/c1-5-3-6(2)4/h3H2,1-2H3
DMOCXLW CS CSCS(=O)C
DMOCXLW IK OTKFCIVOVKCFHR-UHFFFAOYSA-N
DMOCXLW IU methylsulfanyl(methylsulfinyl)methane
DMOCXLW CA CAS 33577-16-1
DMOCXLW CB CHEBI:167080
DMOCXLW DE Discovery agent
DM096SI ID DM096SI
DM096SI DN Methyl Phosphinic Acid
DM096SI HS Investigative
DM096SI SN METHYL PHOSPHINIC ACID; AC1MQ62K; AC1O4J1T; hydroxy-methyl-oxophosphanium; CTK4I5667; AKOS006290593; DB02845; Phosphinic acid,methyl- (7CI,8CI,9CI)
DM096SI DT Small molecular drug
DM096SI PC 6369390
DM096SI MW 79.015
DM096SI FM CH4O2P+
DM096SI IC InChI=1S/CH3O2P/c1-4(2)3/h1H3/p+1
DM096SI CS C[P+](=O)O
DM096SI IK OFSFQGSFEXXHNH-UHFFFAOYSA-O
DM096SI IU hydroxy-methyl-oxophosphanium
DM096SI CA CAS 4206-94-4
DM096SI DE Discovery agent
DMO58UW ID DMO58UW
DMO58UW DN methyl p-hydroxybenzoate
DMO58UW HS Investigative
DMO58UW SN methylparaben; nipagin
DMO58UW DT Small molecular drug
DMO58UW PC 7456
DMO58UW MW 152.15
DMO58UW FM C8H8O3
DMO58UW IC InChI=1S/C8H8O3/c1-11-8(10)6-2-4-7(9)5-3-6/h2-5,9H,1H3
DMO58UW CS COC(=O)C1=CC=C(C=C1)O
DMO58UW IK LXCFILQKKLGQFO-UHFFFAOYSA-N
DMO58UW IU methyl 4-hydroxybenzoate
DMO58UW CA CAS 99-76-3
DMO58UW CB CHEBI:31835
DMO58UW DE Discovery agent
DMW2R3M ID DMW2R3M
DMW2R3M DN Methyl piperate
DMW2R3M HS Investigative
DMW2R3M SN Methyl piperate; CHEMBL42965; (2E,4E)-methyl 5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienoate; Piperinic acid methyl ester; Piperinsaure-methylester; Piperic acid methyl ester; SCHEMBL3244271; VOZJBFJHMHRLDN-ZUVMSYQZSA-N; 2,4-Pentadienoic acid, 5-(1,3-benzodioxol-5-yl)-, methyl ester, (2E,4E)-; BDBM50305644; 2,4-Pentadienoic acid, 5-(1,3-benzodioxol-5-yl)-, methyl ester, (E,E)-; (2E,4E)-5-Benzo[1,3]dioxol-5-yl-penta-2,4-dienoic acid methyl ester
DMW2R3M DT Small molecular drug
DMW2R3M PC 9921021
DMW2R3M MW 232.23
DMW2R3M FM C13H12O4
DMW2R3M IC InChI=1S/C13H12O4/c1-15-13(14)5-3-2-4-10-6-7-11-12(8-10)17-9-16-11/h2-8H,9H2,1H3/b4-2+,5-3+
DMW2R3M CS COC(=O)/C=C/C=C/C1=CC2=C(C=C1)OCO2
DMW2R3M IK VOZJBFJHMHRLDN-ZUVMSYQZSA-N
DMW2R3M IU methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
DMW2R3M DE Discovery agent
DMKCG8H ID DMKCG8H
DMKCG8H DN methyl salicylate
DMKCG8H HS Investigative
DMKCG8H SN methyl salicylate; Methyl 2-hydroxybenzoate; 119-36-8; Wintergreen oil; Gaultheria oil; Betula oil; Teaberry oil; Sweet birch oil; OIL OF WINTERGREEN; Analgit; Spicewood Oil; Wintergruenoel; 2-Hydroxybenzoic acid methyl ester; Gaultheriaoel; Flucarmit; Exagien; Betula; Methyl o-hydroxybenzoate; 2-Carbomethoxyphenol; 2-(Methoxycarbonyl)phenol; Natural Wintergreen Oil; Betula Lenta; BIRCH-ME; Salicylic acid, methyl ester; Synthetic Wintergreen Oil; Benzoic acid, 2-hydroxy-, methyl ester; Gaultheria oil, artificial; Wintergreen Oil, syn
DMKCG8H DT Small molecular drug
DMKCG8H PC 4133
DMKCG8H MW 152.15
DMKCG8H FM C8H8O3
DMKCG8H IC InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3
DMKCG8H CS COC(=O)C1=CC=CC=C1O
DMKCG8H IK OSWPMRLSEDHDFF-UHFFFAOYSA-N
DMKCG8H IU methyl 2-hydroxybenzoate
DMKCG8H CA CAS 119-36-8
DMKCG8H CB CHEBI:31832
DMKCG8H DE Discovery agent
DM9Y4FL ID DM9Y4FL
DM9Y4FL DN Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine
DM9Y4FL HS Investigative
DM9Y4FL SN N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; 10409-15-1; N-methyl-N-1,2,3,4-tetrahydronaphthalen-1-ylamine; Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine; 64037-95-2; ACMC-20mk8d; AC1L2G4R; 1-Naphthalenamine,1,2,3,4-tetrahydro-N-methyl-, (1R)-; SCHEMBL61095; 1-Naphthalenamine, 1,2,3,4-tetrahydro-N-methyl-; AC1Q410F; AC1Q410E; CTK4A2694; DTXSID70275501; JQEUPNKUYMHYPW-UHFFFAOYSA-N; MolPort-001-794-098; HMS1783D04; AKOS017269129; AKOS000118469; ENAMINE-BB EN300-11723; MCULE-6929246555; MB03780; NCGC00338944-02
DM9Y4FL DT Small molecular drug
DM9Y4FL PC 46475
DM9Y4FL MW 161.24
DM9Y4FL FM C11H15N
DM9Y4FL IC InChI=1S/C11H15N/c1-12-11-8-4-6-9-5-2-3-7-10(9)11/h2-3,5,7,11-12H,4,6,8H2,1H3
DM9Y4FL CS CNC1CCCC2=CC=CC=C12
DM9Y4FL IK JQEUPNKUYMHYPW-UHFFFAOYSA-N
DM9Y4FL IU N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
DM9Y4FL CA CAS 10409-15-1
DM9Y4FL DE Discovery agent
DMQU9VD ID DMQU9VD
DMQU9VD DN Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
DMQU9VD HS Investigative
DMQU9VD SN CHEMBL179529; Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
DMQU9VD DT Small molecular drug
DMQU9VD PC 44388719
DMQU9VD MW 190.27
DMQU9VD FM C10H10N2S
DMQU9VD IC InChI=1S/C10H10N2S/c1-11-10-5-4-9(13-10)8-3-2-6-12-7-8/h2-7,11H,1H3
DMQU9VD CS CNC1=CC=C(S1)C2=CN=CC=C2
DMQU9VD IK OUEHWWLIEPNPDR-UHFFFAOYSA-N
DMQU9VD IU N-methyl-5-pyridin-3-ylthiophen-2-amine
DMQU9VD DE Discovery agent
DMZVBLT ID DMZVBLT
DMZVBLT DN Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine
DMZVBLT HS Investigative
DMZVBLT SN CHEMBL243640; SCHEMBL5428301; KPEUWXDPXPGBFC-UHFFFAOYSA-N; ZINC28711877; BDBM50220158; AKOS023382952; N-methyl-4'-(trifluoromethyl)-4-biphenylamine
DMZVBLT DT Small molecular drug
DMZVBLT PC 23625978
DMZVBLT MW 251.25
DMZVBLT FM C14H12F3N
DMZVBLT IC InChI=1S/C14H12F3N/c1-18-13-8-4-11(5-9-13)10-2-6-12(7-3-10)14(15,16)17/h2-9,18H,1H3
DMZVBLT CS CNC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F
DMZVBLT IK KPEUWXDPXPGBFC-UHFFFAOYSA-N
DMZVBLT IU N-methyl-4-[4-(trifluoromethyl)phenyl]aniline
DMZVBLT DE Discovery agent
DMOA54M ID DMOA54M
DMOA54M DN Methyl3beta-hydroxyolean-12-en-27-oate
DMOA54M HS Investigative
DMOA54M SN CHEMBL207494; methyl3beta-hydroxyolean-12-en-27-oate
DMOA54M DT Small molecular drug
DMOA54M PC 44411982
DMOA54M MW 470.7
DMOA54M FM C31H50O3
DMOA54M IC InChI=1S/C31H50O3/c1-26(2)15-16-28(5)17-18-31(25(33)34-8)20(21(28)19-26)9-10-23-29(6)13-12-24(32)27(3,4)22(29)11-14-30(23,31)7/h9,21-24,32H,10-19H2,1-8H3/t21-,22?,23+,24-,28+,29-,30+,31+/m0/s1
DMOA54M CS C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C(=O)OC
DMOA54M IK HEDYWHFMTAMIIX-IPZPPPCKSA-N
DMOA54M IU methyl (4aR,6aR,6aR,6bR,10S,12aR,14bR)-10-hydroxy-2,2,4a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-6a-carboxylate
DMOA54M DE Discovery agent
DMTPL4W ID DMTPL4W
DMTPL4W DN Methylamine
DMTPL4W HS Investigative
DMTPL4W SN Aminomethane; Anhydrous Methylamine; BAVYZALUXZFZLV-UHFFFAOYSA-N; Carbinamine; METHYLAMINE; Mercurialin; Methanamine; Methylamine aq; Methylamine solutions; Methylamine, anhydrous; Methylamine, in aqueous solution; Methylaminen; Methylaminen [Dutch]; Metilamine; Metilamine [Italian]; Metyloamina; Metyloamina [Polish]; Monomethylamine; N-Methylamine; UN1061; UN1235; methyl-amine; monomethyl amine; 74-89-5; AI3-15637-X; BSF23SJ79E; CCRIS 2508; CH3NH2; CHEBI:16830; EINECS 200-820-0; HSDB 810; MeNH2; UNII-BSF23SJ79E
DMTPL4W PC 6329
DMTPL4W MW 31.057
DMTPL4W FM CH5N
DMTPL4W IC BAVYZALUXZFZLV-UHFFFAOYSA-N
DMTPL4W CS CN
DMTPL4W IK 1S/CH5N/c1-2/h2H2,1H3
DMTPL4W IU methanamine
DMTPL4W CA CAS 74-89-5
DMTPL4W CB CHEBI:16830
DMTPL4W DE Discovery agent
DM9JECY ID DM9JECY
DM9JECY DN METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID
DM9JECY HS Investigative
DM9JECY SN METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID; CHEMBL11306; PLH; (n-(2-hydroxamatemethylene-4-methyl-pentoyl)phenylalanyl)methyl amine; 1mnc; 3-BMMHMH; AC1Q5QCC; AC1L4YVK; (2r)-n4-hydroxy-n1-[(2s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide; SCHEMBL5502507; PNU-99533; BDBM50031795; DB08403; 108383-58-0; (R)-N*4*-Hydroxy-2-isobutyl-N*1*-((S)-1-methylcarbamoyl-2-phenyl-ethyl)-succinamide; 3-((Benzyl)(methylaminocarbonyl)methylaminocarbonyl)N-hydroxy-5-methylhexanamide
DM9JECY DT Small molecular drug
DM9JECY PC 194777
DM9JECY MW 349.4
DM9JECY FM C18H27N3O4
DM9JECY IC InChI=1S/C18H27N3O4/c1-12(2)9-14(11-16(22)21-25)17(23)20-15(18(24)19-3)10-13-7-5-4-6-8-13/h4-8,12,14-15,25H,9-11H2,1-3H3,(H,19,24)(H,20,23)(H,21,22)/t14-,15+/m1/s1
DM9JECY CS CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NC
DM9JECY IK MOPRTFSMCQNUCT-CABCVRRESA-N
DM9JECY IU (2R)-N'-hydroxy-N-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)butanediamide
DM9JECY CA CAS 108383-58-0
DM9JECY DE Discovery agent
DMDP84X ID DMDP84X
DMDP84X DN Methylcarbamic Acid Biphenyl-3-yl Ester
DMDP84X HS Investigative
DMDP84X SN CHEMBL486290; Methylcarbamic Acid Biphenyl-3-yl Ester; SCHEMBL12133520; BDBM50270688
DMDP84X DT Small molecular drug
DMDP84X PC 44585603
DMDP84X MW 227.26
DMDP84X FM C14H13NO2
DMDP84X IC InChI=1S/C14H13NO2/c1-15-14(16)17-13-9-5-8-12(10-13)11-6-3-2-4-7-11/h2-10H,1H3,(H,15,16)
DMDP84X CS CNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMDP84X IK NYOGSYRWQAQOKA-UHFFFAOYSA-N
DMDP84X IU (3-phenylphenyl) N-methylcarbamate
DMDP84X DE Discovery agent
DMV865Q ID DMV865Q
DMV865Q DN methylcarbamyl PAF
DMV865Q HS Investigative
DMV865Q SN methyl-carbamyl platelet-activating factor; mc-PAF
DMV865Q DT Small molecular drug
DMV865Q PC 124663
DMV865Q MW 538.7
DMV865Q FM C26H55N2O7P
DMV865Q IC InChI=1S/C26H55N2O7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-32-23-25(35-26(29)27-2)24-34-36(30,31)33-22-20-28(3,4)5/h25H,6-24H2,1-5H3,(H-,27,29,30,31)/t25-/m1/s1
DMV865Q CS CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)NC
DMV865Q IK FNFHZBKBDFRYHS-RUZDIDTESA-N
DMV865Q IU [(2R)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
DMV865Q CA CAS 91575-58-5
DMV865Q DE Discovery agent
DMP204G ID DMP204G
DMP204G DN Methylenedioxyamphetamine
DMP204G HS Investigative
DMP204G SN Tenamfetamine; 3,4-methylenedioxyamphetamine; Methylenedioxyamphetamine; 4764-17-4; 3,4-Methylenedioxy-amphetamine; MDA (pharmaceutical); Tenamfetamine [INN]; Tenamfetaminum [Latin]; Tenamfetamina [Spanish]; 1-(1,3-benzodioxol-5-yl)propan-2-amine; BRN 0150196; DEA No. 7400; AI3-24882; alpha-Methyl-1,3-benzodioxole-5-ethanamine; 1,3-Benzodioxole-5-ethanamine, alpha-methyl-; CHEMBL6731; ALPHA-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE; NGBBVGZWCFBOGO-UHFFFAOYSA-N; 5-19-08-00417 (Beilstein Handbook Reference); Phenethylamine, alp
DMP204G DT Small molecular drug
DMP204G PC 1614
DMP204G MW 179.22
DMP204G FM C10H13NO2
DMP204G IC InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
DMP204G CS CC(CC1=CC2=C(C=C1)OCO2)N
DMP204G IK NGBBVGZWCFBOGO-UHFFFAOYSA-N
DMP204G IU 1-(1,3-benzodioxol-5-yl)propan-2-amine
DMP204G CA CAS 4764-17-4
DMP204G CB CHEBI:166520
DMP204G DE Discovery agent
DMYVU47 ID DMYVU47
DMYVU47 DN Methylenedioxymethamphetamine
DMYVU47 HS Investigative
DMYVU47 SN 3,4-Methylenedioxymethamphetamine; MDMA; 3,4-methylenedioxymethamphetamine; Ecstasy; Methylenedioxymethamphetamine; 42542-10-9; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; DL-(3,4-Methylenedioxy)methamphetamine; (RS)-3,4-(methylenedioxy)methamphetamine; Midomafetamine; MDMA (unspecified); N,alpha-Dimethyl-1,3-benzodioxole-5-ethanamine; HSDB 6929; 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine; CHEBI:1391; DEA No 7405; (+-)-(3,4-Methylenedioxy)methamphetamine; (+-)-N-Methyl-3,4-(methylenedioxy)amphetamine; 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-
DMYVU47 DT Small molecular drug
DMYVU47 PC 1615
DMYVU47 MW 193.24
DMYVU47 FM C11H15NO2
DMYVU47 IC InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3
DMYVU47 CS CC(CC1=CC2=C(C=C1)OCO2)NC
DMYVU47 IK SHXWCVYOXRDMCX-UHFFFAOYSA-N
DMYVU47 IU 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine
DMYVU47 CA CAS 42542-10-9
DMYVU47 CB CHEBI:1391
DMYVU47 DE Discovery agent
DMZ318I ID DMZ318I
DMZ318I DN methylfurmethide
DMZ318I HS Investigative
DMZ318I SN 5-methylfurmithide; 5 MFT
DMZ318I DT Small molecular drug
DMZ318I PC 4141
DMZ318I MW 154.23
DMZ318I FM C9H16NO+
DMZ318I IC InChI=1S/C9H16NO/c1-8-5-6-9(11-8)7-10(2,3)4/h5-6H,7H2,1-4H3/q+1
DMZ318I CS CC1=CC=C(O1)C[N+](C)(C)C
DMZ318I IK KOWVJDFMEZKDDT-UHFFFAOYSA-N
DMZ318I IU trimethyl-[(5-methylfuran-2-yl)methyl]azanium
DMZ318I CA CAS 14172-53-3
DMZ318I CB CHEBI:94038
DMZ318I DE Discovery agent
DMRC3OZ ID DMRC3OZ
DMRC3OZ DN methylglyoxal
DMRC3OZ HS Investigative
DMRC3OZ SN pyruvaldehyde; pyruvic aldehyde; 2-Oxopropanal; acetylformaldehyde; 78-98-8; Acetylformyl; Propanal, 2-oxo-; 2-Ketopropionaldehyde; Propanedione; Propanolone; Pyroracemic aldehyde; Glyoxal, methyl; 2-Oxopropionaldehyde; alpha-Ketopropionaldehyde; 1-Ketopropionaldehyde; Propionaldehyde, 2-keto; Propionaldehyde, 2-oxo-; 1,2-Propanedione; Acetalformaldehyde; alpha-Ketopropionic aldehyde; 2-oxo-Propionaldehyde; CH3COCHO; FEMA No 2969; CCRIS 1741; 2-oxo-propanal; NSC 79019; NSC 626580; Pyruvoyl Group
DMRC3OZ DT Small molecular drug
DMRC3OZ PC 880
DMRC3OZ MW 72.06
DMRC3OZ FM C3H4O2
DMRC3OZ IC InChI=1S/C3H4O2/c1-3(5)2-4/h2H,1H3
DMRC3OZ CS CC(=O)C=O
DMRC3OZ IK AIJULSRZWUXGPQ-UHFFFAOYSA-N
DMRC3OZ IU 2-oxopropanal
DMRC3OZ CA CAS 78-98-8
DMRC3OZ CB CHEBI:17158
DMRC3OZ DE Discovery agent
DMUBY4J ID DMUBY4J
DMUBY4J DN Methylglyoxal
DMUBY4J HS Investigative
DMUBY4J SN Acetylformyl; Glyoxal, methyl; METHYL GLYOXAL; Propanal, 2-oxo-; Propanedione; Propanolone; Propionaldehyde, 2-keto; Propionaldehyde, 2-oxo-; Pyroracemic aldehyde; acetylformaldehyde; alpha-Ketopropionaldehyde; alpha-Ketopropionic aldehyde; methyl-glyoxal; methylglyoxal; pyruvaldehyde; pyruvic aldehyde; 1,2-Propanedione; 1-Ketopropionaldehyde; 2-Ketopropionaldehyde; 2-Oxopropanal; 2-Oxopropionaldehyde; 2-oxo-Propionaldehyde; 2-oxo-propanal; 78-98-8; Acetalformaldehyde; CCRIS 1741; CH3COCHO; FEMA No. 2969; NSC 626580; NSC 79019
DMUBY4J PC 880
DMUBY4J MW 72.06
DMUBY4J FM C3H4O2
DMUBY4J IC AIJULSRZWUXGPQ-UHFFFAOYSA-N
DMUBY4J CS CC(=O)C=O
DMUBY4J IK 1S/C3H4O2/c1-3(5)2-4/h2H,1H3
DMUBY4J IU 2-oxopropanal
DMUBY4J CA CAS 78-98-8
DMUBY4J CB CHEBI:17158
DMUBY4J DE Alzheimer disease
DM7PRDY ID DM7PRDY
DM7PRDY DN methylhistaprodifen
DM7PRDY HS Investigative
DM7PRDY SN N-methylhistaprodifen
DM7PRDY DT Small molecular drug
DM7PRDY PC 10403687
DM7PRDY MW 319.4
DM7PRDY FM C21H25N3
DM7PRDY IC InChI=1S/C21H25N3/c1-22-15-14-19-16-23-21(24-19)13-12-20(17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,16,20,22H,12-15H2,1H3,(H,23,24)
DM7PRDY CS CNCCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3
DM7PRDY IK YMVWDVNGNLXSKR-UHFFFAOYSA-N
DM7PRDY IU 2-[2-(3,3-diphenylpropyl)-1H-imidazol-5-yl]-N-methylethanamine
DM7PRDY DE Discovery agent
DM9YE6K ID DM9YE6K
DM9YE6K DN METHYLHONOKIOL
DM9YE6K HS Investigative
DM9YE6K SN 4-O-Methylhonokiol; 68592-15-4; METHYLHONOKIOL; 4-O-Methyl honokiol; 4-methoxyhonokiol; HONOKIOL MONO-METHYL ETHER; CHEMBL89700; (1,1'-Biphenyl)-2-ol, 4'-methoxy-3',5-di-2-propenyl-; [1,1'-Biphenyl]-2-ol, 4'-methoxy-3',5-di-2-propenyl-; Magreth-14a; NSC293101; 4'-O-Methylhonokiol; AC1L4DQF; 4'-O-methylhonokiol, MH; SCHEMBL12391677; CTK5C8246; DTXSID50218693; ZINC1566147; HY-U00450; BDBM50295926; AKOS028111321; NSC-293101; CS-0035406; 5,3''-Diallyl-4''-methoxy-biphenyl-2-ol; 3,5'-diallyl-2'-hydroxy-4-methoxybiphenyl
DM9YE6K DT Small molecular drug
DM9YE6K PC 155160
DM9YE6K MW 280.4
DM9YE6K FM C19H20O2
DM9YE6K IC InChI=1S/C19H20O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h4-5,8-13,20H,1-2,6-7H2,3H3
DM9YE6K CS COC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)O)CC=C
DM9YE6K IK OQFHJKZVOALSPV-UHFFFAOYSA-N
DM9YE6K IU 2-(4-methoxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
DM9YE6K CA CAS 68592-15-4
DM9YE6K DE Discovery agent
DMOWMPL ID DMOWMPL
DMOWMPL DN METHYLNORADRENALINE
DMOWMPL HS Investigative
DMOWMPL SN Methylnoradrenaline; Isoadrenaline; Nordephrine; alpha-Methylnorepinephrine; Dioxynorepinephrine; Dihydroxyphenylpropanolamine; l-alpha-Methylnorepinephrine; 6539-57-7; 1,2-Benzenediol, 4-(2-amino-1-hydroxypropyl)-; 2-Amino-1-(3,4-dihydroxyphenyl)propan-1-ol; 4-(2-amino-1-hydroxypropyl)benzene-1,2-diol; 3,4-Dihydrophenyl-1-amino-2-propanol-1; 4-(2-Amino-1-hydroxypropyl)-1,2-benzenediol; EINECS 229-452-9; CHEMBL764; CHEBI:81386
DMOWMPL DT Small molecular drug
DMOWMPL PC 3917
DMOWMPL MW 183.2
DMOWMPL FM C9H13NO3
DMOWMPL IC InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3
DMOWMPL CS CC(C(C1=CC(=C(C=C1)O)O)O)N
DMOWMPL IK GEFQWZLICWMTKF-UHFFFAOYSA-N
DMOWMPL IU 4-(2-amino-1-hydroxypropyl)benzene-1,2-diol
DMOWMPL CA CAS 6539-57-7
DMOWMPL CB CHEBI:81386
DMOWMPL DE Discovery agent
DMQ7THK ID DMQ7THK
DMQ7THK DN Methyl-pentyl-prop-2-ynyl-amine oxalic acid
DMQ7THK HS Investigative
DMQ7THK DE Discovery agent
DMR7HV3 ID DMR7HV3
DMR7HV3 DN METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE
DMR7HV3 HS Investigative
DMR7HV3 SN METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE; CHEMBL125181; L-371912; MIN; (2S)-N-[(4-aminocyclohexyl)methyl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide; 1tom; AC1L9MBI; SCHEMBL7585036; BDBM50366827; BDBM50056771; DB08187; N-methyl-D-phenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide; (2S)-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]-N-{[(1s,4s)-4-aminocyclohexyl]methyl}pyrrolidine-2-carboxamide
DMR7HV3 DT Small molecular drug
DMR7HV3 PC 448763
DMR7HV3 MW 386.5
DMR7HV3 FM C22H34N4O2
DMR7HV3 IC InChI=1S/C22H34N4O2/c1-24-19(14-16-6-3-2-4-7-16)22(28)26-13-5-8-20(26)21(27)25-15-17-9-11-18(23)12-10-17/h2-4,6-7,17-20,24H,5,8-15,23H2,1H3,(H,25,27)/t17?,18?,19-,20+/m1/s1
DMR7HV3 CS CN[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)NCC3CCC(CC3)N
DMR7HV3 IK MDSVGJAUFNXYRR-TUNPWDSISA-N
DMR7HV3 IU (2S)-N-[(4-aminocyclohexyl)methyl]-1-[(2R)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide
DMR7HV3 DE Discovery agent
DMKTOPJ ID DMKTOPJ
DMKTOPJ DN methyl-piperidino-pyrazole
DMKTOPJ HS Investigative
DMKTOPJ DT Small molecular drug
DMKTOPJ PC 135484659
DMKTOPJ MW 469.6
DMKTOPJ FM C29H31N3O3
DMKTOPJ IC InChI=1S/C29H31N3O3/c1-21-28(22-5-11-25(33)12-6-22)30-32(24-9-13-26(34)14-10-24)29(21)23-7-15-27(16-8-23)35-20-19-31-17-3-2-4-18-31/h5-16,33-34H,2-4,17-20H2,1H3
DMKTOPJ CS CC1=C(N(N=C1C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)OCCN5CCCCC5
DMKTOPJ IK TXLGPGWHIIHRHH-UHFFFAOYSA-N
DMKTOPJ IU 4-[1-(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidin-1-ylethoxy)phenyl]pyrazol-3-yl]phenol
DMKTOPJ DE Discovery agent
DMU3JBL ID DMU3JBL
DMU3JBL DN Methylthioribose phosphate
DMU3JBL HS Investigative
DMU3JBL SN D-ribofuranoside; S5-methyl-5-thio-D-ribose-1-phosphate; 5-methylthio-5-deoxy-D-ribose-1-phosphate; 5-Methylthioribose 1-phosphate; 5-Methylthioribose 1-phosphate; 5-Methylthio-5-deoxy-D-ribose 1-phosphate
DMU3JBL PC 53477720
DMU3JBL MW 260.2
DMU3JBL FM C6H13O7PS
DMU3JBL IC JTFITTQBRJDSTL-WATOWXBHSA-N
DMU3JBL CS CSCC1C(C(C(O1)OP(=O)(O)O)O)O
DMU3JBL IK 1S/C6H13O7PS/c1-15-2-3-4(7)5(8)6(12-3)13-14(9,10)11/h3-8H,2H2,1H3,(H2,9,10,11)/t3?,4-,5-,6?/m1/s1
DMU3JBL IU [(3R,4S)-3,4-dihydroxy-5-(methylsulfanylmethyl)oxolan-2-yl] dihydrogen phosphate
DMU3JBL CA CAS 72843-83-5
DMU3JBL DE Discovery agent
DMAEQB6 ID DMAEQB6
DMAEQB6 DN Methylurea
DMAEQB6 HS Investigative
DMAEQB6 SN METHYLUREA; 1-Methylurea; N-Methylurea; 598-50-5; Monomethylurea; Urea, methyl-; Methyl urea; urea, N-methyl-; Methylmocovina; N-methyl urea; Methylmocovina [Czech]; Methylharnstoff [German]; CCRIS 9137; EINECS 209-935-0; 1-Methylurea;1-Methylurea; UNII-VZ89YBW3P8; VZ89YBW3P8; AI3-15088; XGEGHDBEHXKFPX-UHFFFAOYSA-N; Methylurea, 97%; Methylharnstoff; methylisourea; methyl-urea; 3-methyl-urea; N-Methylurea, 97%; CH3NHCONH2; ACMC-1AKB9; bmse000738; EC 209-935-0; AC1L1XZ6; KSC271C6B; GTPL4662; DTXSID5060510; CTK1H1160; CHEBI:44383
DMAEQB6 DT Small molecular drug
DMAEQB6 PC 11719
DMAEQB6 MW 74.08
DMAEQB6 FM C2H6N2O
DMAEQB6 IC InChI=1S/C2H6N2O/c1-4-2(3)5/h1H3,(H3,3,4,5)
DMAEQB6 CS CNC(=O)N
DMAEQB6 IK XGEGHDBEHXKFPX-UHFFFAOYSA-N
DMAEQB6 IU methylurea
DMAEQB6 CA CAS 598-50-5
DMAEQB6 CB CHEBI:44383
DMAEQB6 DE Discovery agent
DMO7JGS ID DMO7JGS
DMO7JGS DN Metiamide
DMO7JGS HS Investigative
DMO7JGS SN METIAMIDE; 34839-70-8; Methiamide; Metiamidum; Metiamida; F 92058; 1-Methyl-3-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)thiourea; Metiamidum [INN-Latin]; Metiamida [INN-Spanish]; SKF 92058; NSC 307755; F-92058; CHEBI:6896; C9H16N4S2; UNII-3K7670861M; FPBPLBWLMYGIQR-UHFFFAOYSA-N; 1-Methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)-2-thiourea; Thiourea, N-methyl-N'-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)-; 3-Methyl-1-(2-((5-methyl-4-imidazolyl)methylthio)ethyl)thiourea; 3K7670861M; Urea, 1-
DMO7JGS DT Small molecular drug
DMO7JGS PC 1548992
DMO7JGS MW 244.4
DMO7JGS FM C9H16N4S2
DMO7JGS IC InChI=1S/C9H16N4S2/c1-7-8(13-6-12-7)5-15-4-3-11-9(14)10-2/h6H,3-5H2,1-2H3,(H,12,13)(H2,10,11,14)
DMO7JGS CS CC1=C(N=CN1)CSCCNC(=S)NC
DMO7JGS IK FPBPLBWLMYGIQR-UHFFFAOYSA-N
DMO7JGS IU 1-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]thiourea
DMO7JGS CA CAS 34839-70-8
DMO7JGS CB CHEBI:6896
DMO7JGS DE Discovery agent
DMZBLQD ID DMZBLQD
DMZBLQD DN Met-Lys-bradykinin
DMZBLQD HS Investigative
DMZBLQD SN Met-kallidin
DMZBLQD DT Small molecular drug
DMZBLQD PC 3035449
DMZBLQD MW 1319.6
DMZBLQD FM C61H94N18O13S
DMZBLQD IC InChI=1S/C61H94N18O13S/c1-93-32-25-39(63)50(82)72-40(19-8-9-26-62)51(83)73-41(20-10-27-68-60(64)65)56(88)79-31-14-24-48(79)58(90)78-30-12-22-46(78)54(86)70-35-49(81)71-43(33-37-15-4-2-5-16-37)52(84)76-45(36-80)57(89)77-29-13-23-47(77)55(87)75-44(34-38-17-6-3-7-18-38)53(85)74-42(59(91)92)21-11-28-69-61(66)67/h2-7,15-18,39-48,80H,8-14,19-36,62-63H2,1H3,(H,70,86)(H,71,81)(H,72,82)(H,73,83)(H,74,85)(H,75,87)(H,76,84)(H,91,92)(H4,64,65,68)(H4,66,67,69)/t39-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m0/s1
DMZBLQD CS CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CO)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N
DMZBLQD IK SSXPFNXUSFJJEI-BHEJXMHWSA-N
DMZBLQD IU (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
DMZBLQD CA CAS 550-19-6
DMZBLQD DE Discovery agent
DM70RDZ ID DM70RDZ
DM70RDZ DN Metrenperone
DM70RDZ HS Investigative
DM70RDZ SN Metrenperone; 81043-56-3; UNII-W1O4FV809G; W1O4FV809G; R 50 970; Metrenperona; Metrenperonum; 3-[2-[4-(4-Fluorobenzoyl)-1-piperidyl]ethyl]-2,7-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; Metrenperonum [INN-Latin]; Metrenperona [INN-Spanish]; Sinomedol; Metrenperone [USAN:INN:BAN]; 3-(2-(4-(4-Fluorobenzoyl)-1-piperidyl)ethyl)-2,7-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; EINECS 279-678-7; Metrenperone (USAN/INN); AC1Q4NI9; AC1L2H8G; SCHEMBL2109868; CHEMBL2104852; BDBM82382; DTXSID20230867; ZINC537997; NSC_72005; CAS_72005
DM70RDZ DT Small molecular drug
DM70RDZ PC 72005
DM70RDZ MW 407.5
DM70RDZ FM C24H26FN3O2
DM70RDZ IC InChI=1S/C24H26FN3O2/c1-16-3-8-22-26-17(2)21(24(30)28(22)15-16)11-14-27-12-9-19(10-13-27)23(29)18-4-6-20(25)7-5-18/h3-8,15,19H,9-14H2,1-2H3
DM70RDZ CS CC1=CN2C(=NC(=C(C2=O)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F)C)C=C1
DM70RDZ IK AXQRPYKSPHUOGZ-UHFFFAOYSA-N
DM70RDZ IU 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2,7-dimethylpyrido[1,2-a]pyrimidin-4-one
DM70RDZ CA CAS 81043-56-3
DM70RDZ DE Discovery agent
DMGH8WV ID DMGH8WV
DMGH8WV DN MeTRH
DMGH8WV HS Investigative
DMGH8WV SN 38983-06-1; His(1-methyl)-TRH; [3H]MeTRH; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-1-methyl-5-oxopyrrolidine-2-carboxamide; [3H]Me-thyrotropin-releasing hormone; AC1NSKDH; His(1-methyl)-thyrotropin-releasing hormone; GTPL2141; GTPL2137; CTK1A8669; DTXSID50415524; pGlu-His(1(tau)-methyl)-ProNH2; [3H]pGlu-His(1(tau)-methyl)-ProNH2; L-Prolinamide, 1-methyl-5-oxo-L-prolyl-L-histidyl-; His(1-methyl)-TRH; pGlu-His(1(t)-methyl)-ProNH2
DMGH8WV DT Small molecular drug
DMGH8WV PC 5311291
DMGH8WV MW 376.4
DMGH8WV FM C17H24N6O4
DMGH8WV IC InChI=1S/C17H24N6O4/c1-22-13(4-5-14(22)24)16(26)21-11(7-10-8-19-9-20-10)17(27)23-6-2-3-12(23)15(18)25/h8-9,11-13H,2-7H2,1H3,(H2,18,25)(H,19,20)(H,21,26)/t11-,12-,13-/m0/s1
DMGH8WV CS CN1[C@@H](CCC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N
DMGH8WV IK DJLHRAHTTSWYAW-AVGNSLFASA-N
DMGH8WV IU (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-1-methyl-5-oxopyrrolidine-2-carboxamide
DMGH8WV CA CAS 38983-06-1
DMGH8WV DE Discovery agent
DMHTGCR ID DMHTGCR
DMHTGCR DN METYRAPOL
DMHTGCR HS Investigative
DMHTGCR SN Metyrapol; 17159-42-1; CHEMBL933; 2-Methyl-1,2-bis(3-pyridyl)-1-propanol; 3-Pyridineethanol, b,b-dimethyl-a-3-pyridinyl-; SU-5236; 2-methyl-1,2-dipyridin-3-ylpropan-1-ol; METYRAPOL (MPOL); AC1Q773J; AC1L4P01; CTK4D3983; BDBM50028160; AKOS030241945; 2-Methyl-1,2-di-pyridin-3-yl-propan-1-ol
DMHTGCR DT Small molecular drug
DMHTGCR PC 161210
DMHTGCR MW 228.29
DMHTGCR FM C14H16N2O
DMHTGCR IC InChI=1S/C14H16N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10,13,17H,1-2H3
DMHTGCR CS CC(C)(C1=CN=CC=C1)C(C2=CN=CC=C2)O
DMHTGCR IK DDFNHFXLQJLFSX-UHFFFAOYSA-N
DMHTGCR IU 2-methyl-1,2-dipyridin-3-ylpropan-1-ol
DMHTGCR CA CAS 17159-42-1
DMHTGCR DE Discovery agent
DMVYWJS ID DMVYWJS
DMVYWJS DN MEZILAMINE
DMVYWJS HS Investigative
DMVYWJS SN Mezilamine; Mezilamine [INN]; Mezilaminum [INN-Latin]; Mezilamina [INN-Spanish]; UNII-V243ORA40X; 50335-55-2; BRN 0666978; CHEMBL407641; V243ORA40X; 4-Chloro-2-methylamino-5-methylthio-6-(4-methyl-1-piperazinyl)pyrimidine; 4-Chloro-N-methyl-6-(4-methyl-1-piperazinyl)-5-(methylthio)-2-pyrimidinamine; Mezilaminum; Mezilamina; 4-Chloro-2-(methylamino)-6-(4-methyl-1-piperazinyl)-5-(methylthio)pyrimidine; Pyrimidine, 4-chloro-2-(methylamino)-5-(methylthio)-6-(4-methyl-1-piperazinyl)-; 2-Pyridinamine, 4-chloro-N-methyl-6-(4-met
DMVYWJS DT Small molecular drug
DMVYWJS PC 68678
DMVYWJS MW 287.81
DMVYWJS FM C11H18ClN5S
DMVYWJS IC InChI=1S/C11H18ClN5S/c1-13-11-14-9(12)8(18-3)10(15-11)17-6-4-16(2)5-7-17/h4-7H2,1-3H3,(H,13,14,15)
DMVYWJS CS CNC1=NC(=C(C(=N1)Cl)SC)N2CCN(CC2)C
DMVYWJS IK ITYXRJDDBZMFAY-UHFFFAOYSA-N
DMVYWJS IU 4-chloro-N-methyl-6-(4-methylpiperazin-1-yl)-5-methylsulfanylpyrimidin-2-amine
DMVYWJS CA CAS 50335-55-2
DMVYWJS DE Discovery agent
DMBLUSA ID DMBLUSA
DMBLUSA DN MF-152
DMBLUSA HS Investigative
DMBLUSA SN 916888-66-9; 2-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxamide; CHEMBL576820; MF-152; SCHEMBL3467167; KS-00000RND; DTXSID60474965; MolPort-035-675-701; ZINC45288748; BDBM50301057; AKOS022171752; 2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]-1,3-thiazole-5-carboxamide; DS-5323; ACN-025269; BC261397; AK136241; SC-94064; KB-222046; AJ-110396
DMBLUSA DT Small molecular drug
DMBLUSA PC 11973722
DMBLUSA MW 384.4
DMBLUSA FM C16H15F3N4O2S
DMBLUSA IC InChI=1S/C16H15F3N4O2S/c17-16(18,19)11-4-2-1-3-10(11)14(25)22-5-7-23(8-6-22)15-21-9-12(26-15)13(20)24/h1-4,9H,5-8H2,(H2,20,24)
DMBLUSA CS C1CN(CCN1C2=NC=C(S2)C(=O)N)C(=O)C3=CC=CC=C3C(F)(F)F
DMBLUSA IK XCYAUDKMHBMJSP-UHFFFAOYSA-N
DMBLUSA IU 2-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]-1,3-thiazole-5-carboxamide
DMBLUSA CA CAS 916888-66-9
DMBLUSA DE Discovery agent
DMSYQP9 ID DMSYQP9
DMSYQP9 DN MF266-1
DMSYQP9 HS Investigative
DMSYQP9 SN CHEMBL185346; MF266-1; GTPL6068; BDBM50160909; 1-[5-[3-[5-chloro-2-(phenylmethoxy)phenyl]thiophen-2-yl]pyridin-3-yl]-2,2,2-trifluoroethane-1,1-diol
DMSYQP9 DT Small molecular drug
DMSYQP9 PC 11306423
DMSYQP9 MW 491.9
DMSYQP9 FM C24H17ClF3NO3S
DMSYQP9 IC InChI=1S/C24H17ClF3NO3S/c25-18-6-7-21(32-14-15-4-2-1-3-5-15)20(11-18)19-8-9-33-22(19)16-10-17(13-29-12-16)23(30,31)24(26,27)28/h1-13,30-31H,14H2
DMSYQP9 CS C1=CC=C(C=C1)COC2=C(C=C(C=C2)Cl)C3=C(SC=C3)C4=CC(=CN=C4)C(C(F)(F)F)(O)O
DMSYQP9 IK JCCQFQOPADDTRS-UHFFFAOYSA-N
DMSYQP9 IU 1-[5-[3-(5-chloro-2-phenylmethoxyphenyl)thiophen-2-yl]pyridin-3-yl]-2,2,2-trifluoroethane-1,1-diol
DMSYQP9 DE Discovery agent
DM1FEVB ID DM1FEVB
DM1FEVB DN MF-8623
DM1FEVB HS Investigative
DM1FEVB DE Discovery agent
DM3RUT8 ID DM3RUT8
DM3RUT8 DN MG-101
DM3RUT8 HS Investigative
DM3RUT8 SN 110044-82-1
DM3RUT8 DT Small molecular drug
DM3RUT8 PC 443118
DM3RUT8 MW 383.5
DM3RUT8 FM C20H37N3O4
DM3RUT8 IC InChI=1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1
DM3RUT8 CS CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C
DM3RUT8 IK FMYKJLXRRQTBOR-BZSNNMDCSA-N
DM3RUT8 IU (2S)-2-acetamido-4-methyl-N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxohexan-2-yl]amino]pentan-2-yl]pentanamide
DM3RUT8 CA CAS 110044-82-1
DM3RUT8 CB CHEBI:2423
DM3RUT8 DE Discovery agent
DM710KZ ID DM710KZ
DM710KZ DN MG-1101
DM710KZ HS Investigative
DM710KZ SN MBR-193.02; MBRI-93.02; PTH (osteoporosis), Green Cross/BDD/CCDRD; parathyroid gland-secreted peptide (osteoporosis), Green Cross; parathyroid hormone, Green Cross/BDD/CCDRD
DM710KZ DE Discovery agent
DMHR1GX ID DMHR1GX
DMHR1GX DN MG-1104
DMHR1GX HS Investigative
DMHR1GX CP Green Cross Corp
DMHR1GX DE Factor IX deficiency
DMG56EU ID DMG56EU
DMG56EU DN MG-111
DMG56EU HS Investigative
DMG56EU SN 134865-04-6; EGF, Hitachi
DMG56EU PC 16143379
DMG56EU MW 6222
DMG56EU FM C270H401N73O83S7
DMG56EU IC InChI=1S/C270H401N73O83S7/c1-24-134(19)217(262(420)293-112-201(355)298-161(69-74-205(359)360)229(387)301-160(45-35-82-286-269(279)280)228(386)333-192(119-428)255(413)307-162(68-73-198(274)352)230(388)316-176(94-141-54-64-150(350)65-55-141)241(399)304-159(44-34-81-285-268(277)278)227(385)325-186(105-212(373)374)248(406)313-169(87-127(5)6)235(393)302-158(43-31-33-80-272)226(384)318-179(97-144-108-289-156-41-29-27-39-153(144)156)243(401)319-178(96-143-107-288-155-40-28-26-38-152(143)155)242(400)305-164(71-76-207(363)364)231(389)312-170(88-128(7)8)236(394)310-167(267(425)426)46-36-83-287-270(281)282)341-250(408)174(92-139-50-60-148(348)61-51-139)300-203(357)113-292-261(419)214(131(13)14)340-264(422)216(133(17)18)339-259(417)195(122-431)335-246(404)182(101-200(276)354)322-257(415)191(118-427)332-220(378)137(22)297-234(392)175(93-140-52-62-149(349)63-53-140)315-225(383)157(42-30-32-79-271)303-247(405)185(104-211(371)372)326-237(395)168(86-126(3)4)311-219(377)136(21)296-224(382)163(70-75-206(361)362)309-265(423)218(135(20)25-2)342-251(409)177(95-142-56-66-151(351)67-57-142)317-233(391)166(78-85-433-23)308-256(414)194(121-430)336-263(421)215(132(15)16)338-204(358)114-291-223(381)184(103-210(369)370)323-244(402)180(98-145-109-283-124-294-145)320-238(396)171(89-129(9)10)314-258(416)193(120-429)334-240(398)173(91-138-48-58-147(347)59-49-138)299-202(356)111-290-222(380)183(102-209(367)368)324-245(403)181(99-146-110-284-125-295-146)321-254(412)190(117-346)330-239(397)172(90-130(11)12)328-260(418)197-47-37-84-343(197)266(424)196(123-432)337-232(390)165(72-77-208(365)366)306-252(410)189(116-345)331-249(407)187(106-213(375)376)327-253(411)188(115-344)329-221(379)154(273)100-199(275)353/h26-29,38-41,48-67,107-110,124-137,154,157-197,214-218,288-289,344-351,427-432H,24-25,30-37,42-47,68-106,111-123,271-273H2,1-23H3,(H2,274,352)(H2,275,353)(H2,276,354)(H,283,294)(H,284,295)(H,290,380)(H,291,381)(H,292,419)(H,293,420)(H,296,382)(H,297,392)(H,298,355)(H,299,356)(H,300,357)(H,301,387)(H,302,393)(H,303,405)(H,304,399)(H,305,400)(H,306,410)(H,307,413)(H,308,414)(H,309,423)(H,310,394)(H,311,377)(H,312,389)(H,313,406)(H,314,416)(H,315,383)(H,316,388)(H,317,391)(H,318,384)(H,319,401)(H,320,396)(H,321,412)(H,322,415)(H,323,402)(H,324,403)(H,325,385)(H,326,395)(H,327,411)(H,328,418)(H,329,379)(H,330,397)(H,331,407)(H,332,378)(H,333,386)(H,334,398)(H,335,404)(H,336,421)(H,337,390)(H,338,358)(H,339,417)(H,340,422)(H,341,408)(H,342,409)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,371,372)(H,373,374)(H,375,376)(H,425,426)(H4,277,278,285)(H4,279,280,286)(H4,281,282,287)/t134-,135-,136-,137-,154-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,214-,215-,216-,217-,218-/m0/s1
DMG56EU CS CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC8=CC=C(C=C8)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC9=CN=CN9)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N
DMG56EU IK GVUGOAYIVIDWIO-UFWWTJHBSA-N
DMG56EU IU (4S)-5-[[(2S)-1-[[(2R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-[[2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-4-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-carboxy-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2S)-4-carboxy-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]butanoyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]butanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoic acid
DMG56EU CA CAS 62253-63-8
DMG56EU DE Discovery agent
DM7V58G ID DM7V58G
DM7V58G DN MG149
DM7V58G HS Investigative
DM7V58G SN MG-149; MG 149
DM7V58G DT Small molecular drug
DM7V58G PC 49864204
DM7V58G MW 340.5
DM7V58G FM C22H28O3
DM7V58G IC InChI=1S/C22H28O3/c1-2-3-4-5-6-8-17-11-13-18(14-12-17)15-16-19-9-7-10-20(23)21(19)22(24)25/h7,9-14,23H,2-6,8,15-16H2,1H3,(H,24,25)
DM7V58G CS CCCCCCCC1=CC=C(C=C1)CCC2=C(C(=CC=C2)O)C(=O)O
DM7V58G IK WBHQYBZRTAEHRR-UHFFFAOYSA-N
DM7V58G IU 2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acid
DM7V58G DE Discovery agent
DMN1F7Z ID DMN1F7Z
DMN1F7Z DN MG-28
DMN1F7Z HS Investigative
DMN1F7Z SN FAS inhibitor (cancer), Institut Catala d'Oncologia; Fatty acid synthase inhibitor (cancer), Institut Catala d'Oncologia
DMN1F7Z CP Institut Catala d'Oncologia
DMN1F7Z DE Solid tumour/cancer
DMIMKFZ ID DMIMKFZ
DMIMKFZ DN MGS0028
DMIMKFZ HS Investigative
DMIMKFZ SN MGS 0028; MGS-0028
DMIMKFZ DT Small molecular drug
DMIMKFZ PC 9837317
DMIMKFZ MW 217.15
DMIMKFZ FM C8H8FNO5
DMIMKFZ IC InChI=1S/C8H8FNO5/c9-8(6(14)15)3-2(11)1-7(10,4(3)8)5(12)13/h3-4H,1,10H2,(H,12,13)(H,14,15)/t3-,4-,7+,8-/m1/s1
DMIMKFZ CS C1C(=O)[C@@H]2[C@H]([C@@]1(C(=O)O)N)[C@]2(C(=O)O)F
DMIMKFZ IK KFAGJPNFERWZJA-JKBXLQNXSA-N
DMIMKFZ IU (1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
DMIMKFZ CA CAS 321963-33-1
DMIMKFZ DE Discovery agent
DMZ9MCR ID DMZ9MCR
DMZ9MCR DN MHL cyclohexylthiosemicarbazone
DMZ9MCR HS Investigative
DMZ9MCR DT Small molecular drug
DMZ9MCR PC 135529100
DMZ9MCR MW 645.7
DMZ9MCR FM C33H31N3O9S
DMZ9MCR IC InChI=1S/C33H31N3O9S/c1-13-19(37)11-18-23(26(13)38)30(42)25-24(27(18)39)29(41)22-17(31(25)45-2)9-8-14-10-15(21(32(43)44)28(40)20(14)22)12-34-36-33(46)35-16-6-4-3-5-7-16/h10-12,16,37-38,40-41H,3-9H2,1-2H3,(H,43,44)(H2,35,36,46)/b34-12+
DMZ9MCR CS CC1=C(C=C2C(=C1O)C(=O)C3=C(C4=C(C5=C(C(=C(C=C5CC4)/C=N/NC(=S)NC6CCCCC6)C(=O)O)O)C(=C3C2=O)O)OC)O
DMZ9MCR IK FVWBMJCLBWIYFZ-PONZDJLKSA-N
DMZ9MCR IU 3-[(E)-(cyclohexylcarbamothioylhydrazinylidene)methyl]-1,9,11,14-tetrahydroxy-7-methoxy-10-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid
DMZ9MCR DE Discovery agent
DMCN91V ID DMCN91V
DMCN91V DN MI-1148
DMCN91V HS Investigative
DMCN91V SN 4-guanidinomethyl-phenylacteyl-Arg-Tle-Arg-4-amidinobenzylamide; para-guanidinomethyl-Phac-R-Tle-R-Amba
DMCN91V DT Small molecular drug
DMCN91V PC 91758390
DMCN91V MW 763.9
DMCN91V FM C36H57N15O4
DMCN91V IC InChI=1S/C36H57N15O4/c1-36(2,3)28(32(55)50-25(6-4-16-45-33(39)40)30(53)47-19-23-12-14-24(15-13-23)29(37)38)51-31(54)26(7-5-17-46-34(41)42)49-27(52)18-21-8-10-22(11-9-21)20-48-35(43)44/h8-15,25-26,28H,4-7,16-20H2,1-3H3,(H3,37,38)(H,47,53)(H,49,52)(H,50,55)(H,51,54)(H4,39,40,45)(H4,41,42,46)(H4,43,44,48)/t25-,26-,28+/m0/s1
DMCN91V CS CC(C)(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC1=CC=C(C=C1)C(=N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CC2=CC=C(C=C2)CN=C(N)N
DMCN91V IK HXVPWVPTVOOCMV-UNCTUWKVSA-N
DMCN91V IU (2S)-N-[(2S)-1-[(4-carbamimidoylphenyl)methylamino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-[4-[(diaminomethylideneamino)methyl]phenyl]acetyl]amino]pentanoyl]amino]-3,3-dimethylbutanamide
DMCN91V DE Discovery agent
DM196LK ID DM196LK
DM196LK DN MI-219
DM196LK HS Investigative
DM196LK SN CHEMBL572933; (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; 908027-55-4; SCHEMBL2624351; BDBM50300121; US8680132, MI- 219; (2''R,3S,4''R,5''R)-6-chloro-4''-(3-chlorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2''-neopentyl-2-oxospiro[indoline-3,3''-pyrrolidine]-5''-carboxamide; (3S)-N-[(3S)-3,4-Dihydroxybutyl]-5-fluoro-6-chloro-2-oxo-2'alpha-(2,2-dimethylpropyl)-4'beta-(3-chlorophenyl)spiro[1H-indole-3(2H),3'-pyrrolidine]-5'alpha-carboxamide
DM196LK DT Small molecular drug
DM196LK PC 24877503
DM196LK MW 552.5
DM196LK FM C27H32Cl2FN3O4
DM196LK IC InChI=1S/C27H32Cl2FN3O4/c1-26(2,3)12-21-27(17-10-19(30)18(29)11-20(17)32-25(27)37)22(14-5-4-6-15(28)9-14)23(33-21)24(36)31-8-7-16(35)13-34/h4-6,9-11,16,21-23,33-35H,7-8,12-13H2,1-3H3,(H,31,36)(H,32,37)/t16-,21+,22-,23+,27-/m0/s1
DM196LK CS CC(C)(C)C[C@@H]1[C@]2([C@H]([C@@H](N1)C(=O)NCC[C@@H](CO)O)C3=CC(=CC=C3)Cl)C4=CC(=C(C=C4NC2=O)Cl)F
DM196LK IK UNXQGBMZYKHQCO-NVHWNKAKSA-N
DM196LK IU (2'R,3S,3'R,5'R)-6-chloro-3'-(3-chlorophenyl)-N-[(3S)-3,4-dihydroxybutyl]-5'-(2,2-dimethylpropyl)-5-fluoro-2-oxospiro[1H-indole-3,4'-pyrrolidine]-2'-carboxamide
DM196LK DE Triple negative breast cancer
DMJ4D1P ID DMJ4D1P
DMJ4D1P DN Micrococcin
DMJ4D1P HS Investigative
DMJ4D1P SN Micrococcin P1; BRN 1070340; Micrococcin P, 13',19'-didehydro-19'-deoxy-28,44-dihydro-44-hydroxy-; 67401-56-3
DMJ4D1P DT Small molecular drug
DMJ4D1P PC 5282052
DMJ4D1P MW 1144.4
DMJ4D1P FM C48H49N13O9S6
DMJ4D1P IC InChI=1S/C48H49N13O9S6/c1-8-24(37(65)49-12-20(5)62)51-38(66)28-15-73-46(56-28)32-18-74-45(58-32)26-11-10-23-36(50-26)27-13-75-48(53-27)35(22(7)64)61-41(69)31-17-76-47(57-31)33(19(3)4)59-39(67)30-16-72-44(55-30)25(9-2)52-42(70)34(21(6)63)60-40(68)29-14-71-43(23)54-29/h8-11,13-22,33-35,62-64H,12H2,1-7H3,(H,49,65)(H,51,66)(H,52,70)(H,59,67)(H,60,68)(H,61,69)/b24-8-,25-9-/t20-,21+,22+,33+,34-,35-/m0/s1
DMJ4D1P CS C/C=C\\1/C2=NC(=CS2)C(=O)N[C@@H](C3=NC(=CS3)C(=O)N[C@H](C4=NC(=CS4)C5=C(C=CC(=N5)C6=NC(=CS6)C7=NC(=CS7)C(=O)N/C(=C\\C)/C(=O)NC[C@H](C)O)C8=NC(=CS8)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)[C@@H](C)O)C(C)C
DMJ4D1P IK MQGFYNRGFWXAKA-GXSYYHJRSA-N
DMJ4D1P IU 2-[2-[(12S,19R,26Z,29S)-26-ethylidene-12,29-bis[(1R)-1-hydroxyethyl]-14,21,28,31-tetraoxo-19-propan-2-yl-10,17,24,34-tetrathia-6,13,20,27,30,35,36,37,38-nonazahexacyclo[30.2.1.18,11.115,18.122,25.02,7]octatriaconta-1(35),2(7),3,5,8,11(38),15,18(37),22,25(36),32-undecaen-5-yl]-1,3-thiazol-4-yl]-N-[(Z)-1-[[(2S)-2-hydroxypropyl]amino]-1-oxobut-2-en-2-yl]-1,3-thiazole-4-carboxamide
DMJ4D1P CB CHEBI:29631
DMJ4D1P DE Discovery agent
DMTMLRN ID DMTMLRN
DMTMLRN DN Microcystin-LR
DMTMLRN HS Investigative
DMTMLRN SN Akerstox; Microcystin-a; 5-L-Argininecyanoginosin LA; Toxin I (Microcystis aeruginosa); Cyanoginosin LA, 5-L-arginine-; Toxin T 17 (Microcystis aeruginosa); BRN 4779759; Toxin, blue green alga, Microcystis aeruginosa; AC1O5MXK; DTXSID00424146; 128657-50-1; LS-55782
DMTMLRN DT Small molecular drug
DMTMLRN PC 445434
DMTMLRN MW 995.2
DMTMLRN FM C49H74N10O12
DMTMLRN IC InChI=1S/C49H74N10O12/c1-26(2)23-37-46(66)58-40(48(69)70)30(6)42(62)55-35(17-14-22-52-49(50)51)45(65)54-34(19-18-27(3)24-28(4)38(71-10)25-33-15-12-11-13-16-33)29(5)41(61)56-36(47(67)68)20-21-39(60)59(9)32(8)44(64)53-31(7)43(63)57-37/h11-13,15-16,18-19,24,26,28-31,34-38,40H,8,14,17,20-23,25H2,1-7,9-10H3,(H,53,64)(H,54,65)(H,55,62)(H,56,61)(H,57,63)(H,58,66)(H,67,68)(H,69,70)(H4,50,51,52)/b19-18+,27-24+/t28-,29-,30-,31+,34-,35-,36+,37-,38-,40+/m0/s1
DMTMLRN CS C[C@H]1[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)C(=C)N(C(=O)CC[C@@H](NC1=O)C(=O)O)C)C)CC(C)C)C(=O)O)C)CCCN=C(N)N)/C=C/C(=C/[C@H](C)[C@H](CC2=CC=CC=C2)OC)/C
DMTMLRN IK ZYZCGGRZINLQBL-GWRQVWKTSA-N
DMTMLRN IU (5R,8S,11R,12S,15S,18S,19S,22R)-15-[3-(diaminomethylideneamino)propyl]-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylidene-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid
DMTMLRN CA CAS 101043-37-2
DMTMLRN CB CHEBI:6925
DMTMLRN DE Discovery agent
DM7Y9AD ID DM7Y9AD
DM7Y9AD DN Microxine
DM7Y9AD HS Investigative
DM7Y9AD SN microxine; CHEMBL478797; SCHEMBL18686351; BDBM50269842
DM7Y9AD TC Analgesics
DM7Y9AD DT Small molecular drug
DM7Y9AD PC 10061827
DM7Y9AD MW 273.27
DM7Y9AD FM C8H11N5O4S
DM7Y9AD IC InChI=1S/C8H11N5O4S/c1-13-5-6(9-2-3-18(15,16)17)10-4-11-7(5)12-8(13)14/h4H,2-3H2,1H3,(H,15,16,17)(H2,9,10,11,12,14)
DM7Y9AD CS CN1C2=C(NC1=O)N=CN=C2NCCS(=O)(=O)O
DM7Y9AD IK OTYWCUOKKIHICD-UHFFFAOYSA-N
DM7Y9AD IU 2-[(7-methyl-8-oxo-9H-purin-6-yl)amino]ethanesulfonic acid
DM7Y9AD DE Pain
DM462BT ID DM462BT
DM462BT DN Milchsaure
DM462BT HS Investigative
DM462BT SN (+/-)-Lactic acid; 1-Hydroxyethanecarboxylic acid; 2-hydroxypropanoic acid; 2-hydroxypropionic acid; 26100-51-6; Acidum lacticum; Aethylidenmilchsaeure; DL-Lactic acid; DL-Milchsaeure; Ethylidenelactic acid; Kyselina 2-hydroxypropanova; Kyselina mlecna; Lactic acid; Lactic acid (natural); Lactic acid USP; Lacticum acidum; Lactovagan; Milchsaeure; Milchsaure; Milchsaure [German]; Milk acid; Ordinary lactic acid; Polylactic acid; Propanoic acid, 2-hydroxy-; Racemic lactic acid; Tonsillosan; alpha-Hydroxypropionic acid; lactate; lactic acid
DM462BT DT Small molecular drug
DM462BT PC 612
DM462BT MW 90.078
DM462BT FM C3H6O3
DM462BT IC InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)
DM462BT CS CC(C(=O)O)O
DM462BT IK JVTAAEKCZFNVCJ-UHFFFAOYSA-N
DM462BT IU 2-hydroxypropanoic acid
DM462BT CA CAS 50-21-5
DM462BT CB CHEBI:78320
DM462BT DE Cardiotonic; Metabolic acidosis
DM6BANS ID DM6BANS
DM6BANS DN Miller-9E-enolide
DM6BANS HS Investigative
DM6BANS SN miller-9E-enolide; CHEMBL187789; (4R,5E,11S)-2,3,3abeta,4,7,8,9,10,11,11aalpha-Decahydro-2-oxo-3,10-bismethylene-11-hydroxy-4-(methacryloyloxy)cyclodeca[b]furan-6-carbaldehyde
DM6BANS DT Small molecular drug
DM6BANS PC 44398214
DM6BANS MW 346.4
DM6BANS FM C19H22O6
DM6BANS IC InChI=1S/C19H22O6/c1-10(2)18(22)24-14-8-13(9-20)7-5-6-11(3)16(21)17-15(14)12(4)19(23)25-17/h8-9,14-17,21H,1,3-7H2,2H3/b13-8+/t14-,15-,16+,17+/m1/s1
DM6BANS CS CC(=C)C(=O)O[C@@H]1/C=C(\\CCCC(=C)[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)/C=O
DM6BANS IK CCWGXWKAXMNGSZ-PBMXCAIQSA-N
DM6BANS IU [(3aR,4R,5E,11S,11aS)-6-formyl-11-hydroxy-3,10-dimethylidene-2-oxo-4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DM6BANS DE Discovery agent
DMFMOX5 ID DMFMOX5
DMFMOX5 DN Miller-9Z-enolide
DMFMOX5 HS Investigative
DMFMOX5 SN miller-9Z-enolide
DMFMOX5 DT Small molecular drug
DMFMOX5 PC 12015910
DMFMOX5 MW 346.4
DMFMOX5 FM C19H22O6
DMFMOX5 IC InChI=1S/C19H22O6/c1-10(2)18(22)24-14-8-13(9-20)7-5-6-11(3)16(21)17-15(14)12(4)19(23)25-17/h8-9,14-17,21H,1,3-7H2,2H3/b13-8-/t14-,15-,16+,17+/m1/s1
DMFMOX5 CS CC(=C)C(=O)O[C@@H]1/C=C(/CCCC(=C)[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)\\C=O
DMFMOX5 IK CCWGXWKAXMNGSZ-KSKPACDFSA-N
DMFMOX5 IU [(3aR,4R,5Z,11S,11aS)-6-formyl-11-hydroxy-3,10-dimethylidene-2-oxo-4,7,8,9,11,11a-hexahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DMFMOX5 DE Discovery agent
DM7DT20 ID DM7DT20
DM7DT20 DN Mimovax
DM7DT20 HS Investigative
DM7DT20 SN MV-01; AFFITOPE-based vaccine targeting truncated Abeta40/42 (Alzheimer's disease), AFFiRiS
DM7DT20 CP AFFiRiS AG
DM7DT20 DT Vaccine
DM7DT20 DE Alzheimer disease
DMDQK9G ID DMDQK9G
DMDQK9G DN Miocamycin
DMDQK9G HS Investigative
DMDQK9G SN Macroral; Midecamycin acetate (JP17); Midecamycin acetate [JAN]; Miocamen; Miocamycin; Miocamycin (TN); Miocamycine; Miokamycin; Myocamicin; Ponsinomycin; SCHEMBL139293; ZINC169677000; midecamycin acetate; 3'',9-Diacetylmydecamycin; 3T48CPS7U2; 55881-07-7; 9,3''-Di-O-Acetylmidecamycin; 9,3''-Diacetylmidecamycin; AC1NQZMS; Acecamycin; C45H71NO17; CHEMBL1091024; DTXSID60905087; EINECS 259-879-6; Leucomycin V, 3(sup B),9-diacetate 3,4(sup B)-dipropanoate; Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate; MOM; Mosil; UNII-3T48CPS7U2
DMDQK9G PC 5282188
DMDQK9G MW 898
DMDQK9G FM C45H71NO17
DMDQK9G IC GQNZGCARKRHPOH-RQIKCTSVSA-N
DMDQK9G CS CCC(=O)OC1CC(=O)OC(CC=CC=CC(C(CC(C(C1OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C
DMDQK9G IK 1S/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+/t25-,26-,27-,28+,31+,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1
DMDQK9G IU [(4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-acetyloxy-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4-acetyloxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate
DMDQK9G CA CAS 55881-07-7
DMDQK9G DE Pulmonary tuberculosis
DM2IGD1 ID DM2IGD1
DM2IGD1 DN MIP-1231
DM2IGD1 HS Investigative
DM2IGD1 SN MIP-1232; MIP-1233; MIP-1259; MIP-1260; MIP-1271; MIP-1272; Seprase inhibitors (cancer, imaging); Iodine-131-MIP-1232; Seprase inhibitors (cancer, imaging), Molecular Insight; FAP-alpha antagonists (cancer, imaging), Molecular Insight; Fibroblast-activating protein antagonists (cancer, imaging), Molecular Insight
DM2IGD1 CP Molecular Insight Pharmaceuticals Inc
DM2IGD1 DE Solid tumour/cancer
DM0J38I ID DM0J38I
DM0J38I DN MIP-1375
DM0J38I HS Investigative
DM0J38I SN PSMA inhibitor (prostate cancer), Molecular Insight; Prostate-specific membrane antigen inhibitor (prostate cancer), Molecular Insight
DM0J38I CP Molecular Insight Pharmaceuticals Inc
DM0J38I DE Prostate cancer
DM4P9LJ ID DM4P9LJ
DM4P9LJ DN MiR-375
DM4P9LJ HS Investigative
DM4P9LJ DE Discovery agent
DMYB0HK ID DMYB0HK
DMYB0HK DN Misonidazole
DMYB0HK HS Investigative
DMYB0HK SN Misonidazol [INN-Spanish]; Misonidazole; Misonidazolum [INN-Latin]; Ro 7-0582; SR 1354; SRI 1354; 1-(2'-hydroxy-3'-methoxypropyl)-2-nitroimidazole; 1-(2-Hydroxy-3-methoxypropyl)-2-nitroimidazole; 1-(2-NITRO-1-IMIDAZOLYL)-3-METHOXY-2-PROPANOL; 1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol; 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol; 13551-87-6; BRN 0613655; CCRIS 1160; EINECS 236-931-6; MLS003115361; NSC-261,037; NSC-261037; NSC261037; alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol
DMYB0HK PC 26105
DMYB0HK MW 201.18
DMYB0HK FM C7H11N3O4
DMYB0HK IC OBBCSXFCDPPXOL-UHFFFAOYSA-N
DMYB0HK CS COCC(CN1C=CN=C1[N+](=O)[O-])O
DMYB0HK IK 1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3
DMYB0HK IU 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
DMYB0HK CA CAS 13551-87-6
DMYB0HK DE Discovery agent
DM13TUY ID DM13TUY
DM13TUY DN MIV-710
DM13TUY HS Investigative
DM13TUY SN MIV-711; MIV-711); Cathepsin K inhibitor (oral, osteoporosis), Medivir
DM13TUY CP Medivir AB
DM13TUY DE Bone metastases
DMMP6YH ID DMMP6YH
DMMP6YH DN MJ-451
DMMP6YH HS Investigative
DMMP6YH SN 129655-17-0; potassium channel openers, National Taiwan University
DMMP6YH PC 9818365
DMMP6YH MW 316.35
DMMP6YH FM C17H20N2O4
DMMP6YH IC InChI=1S/C17H20N2O4/c1-17(2)16(22)15(19-11(9-20)4-6-14(19)21)12-7-10(8-18)3-5-13(12)23-17/h3,5,7,11,15-16,20,22H,4,6,9H2,1-2H3/t11-,15+,16-/m0/s1
DMMP6YH CS CC1([C@H]([C@@H](C2=C(O1)C=CC(=C2)C#N)N3[C@@H](CCC3=O)CO)O)C
DMMP6YH IK PBEGNZBJXJTFMB-XZJROXQQSA-N
DMMP6YH IU (3S,4R)-3-hydroxy-4-[(2S)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
DMMP6YH CA CAS 129655-17-0
DMMP6YH DE Discovery agent
DMRSBWT ID DMRSBWT
DMRSBWT DN MJN228
DMRSBWT HS Investigative
DMRSBWT SN MJN228; SCHEMBL602647; GTPL8515; MolPort-044-561-486; ZINC114193322
DMRSBWT DT Small molecular drug
DMRSBWT PC 22660592
DMRSBWT MW 364.4
DMRSBWT FM C20H20N4O3
DMRSBWT IC InChI=1S/C20H20N4O3/c1-22-9-11-23(12-10-22)20(25)19-18(14-5-3-2-4-6-14)16-13-15(24(26)27)7-8-17(16)21-19/h2-8,13,21H,9-12H2,1H3
DMRSBWT CS CN1CCN(CC1)C(=O)C2=C(C3=C(N2)C=CC(=C3)[N+](=O)[O-])C4=CC=CC=C4
DMRSBWT IK BLSWPPPBUQFKHH-UHFFFAOYSA-N
DMRSBWT IU (4-methylpiperazin-1-yl)-(5-nitro-3-phenyl-1H-indol-2-yl)methanone
DMRSBWT DE Discovery agent
DMTFRLO ID DMTFRLO
DMTFRLO DN MK-0343
DMTFRLO HS Investigative
DMTFRLO SN GABA-A alpha-2/alpha-3 agonists (anxiolytics), Merck & Co; IDDBCP174406; MRK-409; TPA-023B
DMTFRLO PC 22609888
DMTFRLO MW 397.4
DMTFRLO FM C19H17F2N7O
DMTFRLO IC InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3
DMTFRLO CS CN1C(=NC=N1)COC2=NN3C(=NN=C3C4=C(C=CC=C4F)F)C=C2C5CCC5
DMTFRLO IK GOIFCXRIFSYPFG-UHFFFAOYSA-N
DMTFRLO IU 7-cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
DMTFRLO CA CAS 233275-76-8
DMTFRLO DE Discovery agent
DMVBFJP ID DMVBFJP
DMVBFJP DN MK-0668
DMVBFJP HS Investigative
DMVBFJP SN MK-0668; UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-
DMVBFJP DT Small molecular drug
DMVBFJP PC 11433918
DMVBFJP MW 685.6
DMVBFJP FM C31H30Cl2N6O6S
DMVBFJP IC InChI=1S/C31H30Cl2N6O6S/c32-24-15-35-16-25(33)28(24)30(41)37-21-9-7-18(8-10-21)12-26(31(42)43)38-29(40)27-13-22(36-20-4-2-5-20)17-39(27)46(44,45)23-6-1-3-19(11-23)14-34/h1,3,6-11,15-16,20,22,26-27,36H,2,4-5,12-13,17H2,(H,37,41)(H,38,40)(H,42,43)/t22-,26+,27+/m1/s1
DMVBFJP CS C1CC(C1)N[C@@H]2C[C@H](N(C2)S(=O)(=O)C3=CC=CC(=C3)C#N)C(=O)N[C@@H](CC4=CC=C(C=C4)NC(=O)C5=C(C=NC=C5Cl)Cl)C(=O)O
DMVBFJP IK USYYNLPEWBGIMJ-ICTDUYRTSA-N
DMVBFJP IU (2S)-2-[[(2S,4R)-1-(3-cyanophenyl)sulfonyl-4-(cyclobutylamino)pyrrolidine-2-carbonyl]amino]-3-[4-[(3,5-dichloropyridine-4-carbonyl)amino]phenyl]propanoic acid
DMVBFJP CA CAS 865110-07-2
DMVBFJP DE Discovery agent
DMI7859 ID DMI7859
DMI7859 DN MK-10
DMI7859 HS Investigative
DMI7859 SN MK-10
DMI7859 DT Small molecular drug
DMI7859 PC 46877881
DMI7859 MW 813.9
DMI7859 FM C41H55N11O7
DMI7859 IC InChI=1S/C41H55N11O7/c42-36(55)29-14-6-7-19-45-34(53)17-18-35(54)52-21-9-16-33(52)40(59)51-31(22-25-10-2-1-3-11-25)38(57)49-30(15-8-20-46-41(43)44)37(56)50-32(39(58)48-29)23-26-24-47-28-13-5-4-12-27(26)28/h1-5,10-13,24,29-33,47H,6-9,14-23H2,(H2,42,55)(H,45,53)(H,48,58)(H,49,57)(H,50,56)(H,51,59)(H4,43,44,46)/t29-,30+,31-,32-,33+/m0/s1
DMI7859 CS C1CCNC(=O)CCC(=O)N2CCC[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC=CC=C5
DMI7859 IK RSZGGZUMSYSTES-HJCKZFGESA-N
DMI7859 IU (11S,14S,17R,20S,23R)-20-benzyl-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-2,5,13,16,19,22-hexaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carboxamide
DMI7859 DE Discovery agent
DM4FG32 ID DM4FG32
DM4FG32 DN MK-11
DM4FG32 HS Investigative
DM4FG32 SN Menaquinone 11; Vitamin MK 11; 19228-10-5; MK-11; menaquinone-11; 2-METHYL-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-UNDECAMETHYLTETRATETRACONTA-2,6,10,14,18,22,26,30,34,38,42-UNDECAEN-1-YL]NAPHTHALENE-1,4-DIONE; AC1O5WR2; MK11; SCHEMBL14164358; MK 11; ZINC150341901; 2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione
DM4FG32 DT Small molecular drug
DM4FG32 PC 6442190
DM4FG32 MW 921.5
DM4FG32 FM C66H96O2
DM4FG32 IC InChI=1S/C66H96O2/c1-50(2)26-16-27-51(3)28-17-29-52(4)30-18-31-53(5)32-19-33-54(6)34-20-35-55(7)36-21-37-56(8)38-22-39-57(9)40-23-41-58(10)42-24-43-59(11)44-25-45-60(12)48-49-62-61(13)65(67)63-46-14-15-47-64(63)66(62)68/h14-15,26,28,30,32,34,36,38,40,42,44,46-48H,16-25,27,29,31,33,35,37,39,41,43,45,49H2,1-13H3/b51-28+,52-30+,53-32+,54-34+,55-36+,56-38+,57-40+,58-42+,59-44+,60-48+
DM4FG32 CS CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DM4FG32 IK YYDMANIEKFAEJC-RYZSZPJESA-N
DM4FG32 IU 2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione
DM4FG32 CA CAS 19228-10-5
DM4FG32 DE Discovery agent
DM3NDWK ID DM3NDWK
DM3NDWK DN MK-1925
DM3NDWK HS Investigative
DM3NDWK SN CHEMBL560667; MK-1925; SCHEMBL3540877; BDBM50296579
DM3NDWK DT Small molecular drug
DM3NDWK PC 44178080
DM3NDWK MW 362.4
DM3NDWK FM C19H21F3N4
DM3NDWK IC InChI=1S/C19H21F3N4/c1-12-18(11-24-17-4-3-14(20)10-17)25-26(6-2-5-23)19(12)13-7-15(21)9-16(22)8-13/h7-9,14,17,24H,2-4,6,10-11H2,1H3/t14-,17+/m1/s1
DM3NDWK CS CC1=C(N(N=C1CN[C@H]2CC[C@H](C2)F)CCC#N)C3=CC(=CC(=C3)F)F
DM3NDWK IK LJTOZIFFXNLWEQ-PBHICJAKSA-N
DM3NDWK IU 3-[5-(3,5-difluorophenyl)-3-[[[(1S,3R)-3-fluorocyclopentyl]amino]methyl]-4-methylpyrazol-1-yl]propanenitrile
DM3NDWK DE Discovery agent
DMYO8T6 ID DMYO8T6
DMYO8T6 DN MK-212
DMYO8T6 HS Investigative
DMYO8T6 SN 64022-27-1
DMYO8T6 DT Small molecular drug
DMYO8T6 PC 107992
DMYO8T6 MW 198.65
DMYO8T6 FM C8H11ClN4
DMYO8T6 IC InChI=1S/C8H11ClN4/c9-7-5-11-6-8(12-7)13-3-1-10-2-4-13/h5-6,10H,1-4H2
DMYO8T6 CS C1CN(CCN1)C2=CN=CC(=N2)Cl
DMYO8T6 IK CJAWPFJGFFNXQI-UHFFFAOYSA-N
DMYO8T6 IU 2-chloro-6-piperazin-1-ylpyrazine
DMYO8T6 CA CAS 64022-27-1
DMYO8T6 CB CHEBI:92360
DMYO8T6 DE Discovery agent
DMP4Q0J ID DMP4Q0J
DMP4Q0J DN MK-2894
DMP4Q0J HS Investigative
DMP4Q0J SN EP4 antagonists (inflammatory pain); L-161982; MF-310; MF-498; MF-592; MF-766; EP4 antagonists (inflammatory pain), Merck Frosst Canada; Prostaglandin E2 subtype 4 receptor antagonists (pain/inflammation), Merck Frosst
DMP4Q0J CP Merck Frosst Canada & Co
DMP4Q0J DT Small molecular drug
DMP4Q0J PC 24952929
DMP4Q0J MW 473.5
DMP4Q0J FM C25H22F3NO3S
DMP4Q0J IC InChI=1S/C25H22F3NO3S/c1-14-20(13-16-3-7-19(8-4-16)25(26,27)28)21(15(2)33-14)22(30)29-24(11-12-24)18-9-5-17(6-10-18)23(31)32/h3-10H,11-13H2,1-2H3,(H,29,30)(H,31,32)
DMP4Q0J CS CC1=C(C(=C(S1)C)C(=O)NC2(CC2)C3=CC=C(C=C3)C(=O)O)CC4=CC=C(C=C4)C(F)(F)F
DMP4Q0J IK QJZQFVRFJCGDKF-UHFFFAOYSA-N
DMP4Q0J IU 4-[1-[[2,5-dimethyl-4-[[4-(trifluoromethyl)phenyl]methyl]thiophene-3-carbonyl]amino]cyclopropyl]benzoic acid
DMP4Q0J CA CAS 1006036-87-8
DMP4Q0J DE Inflammation
DM5EQ7F ID DM5EQ7F
DM5EQ7F DN MK-3901
DM5EQ7F HS Investigative
DM5EQ7F SN P2X3 receptor antagonists (pain); P2X3 receptor antagonists (pain), Merck
DM5EQ7F CP Merck & Co Inc
DM5EQ7F DE Pain
DMS7C6R ID DMS7C6R
DMS7C6R DN MK-5046
DMS7C6R HS Investigative
DMS7C6R SN MK 5046; MK5046
DMS7C6R DT Small molecular drug
DMS7C6R PC 49871766
DMS7C6R MW 444.4
DMS7C6R FM C20H18F6N4O
DMS7C6R IC InChI=1S/C20H18F6N4O/c21-19(22,23)17(6-7-17)10-14-12-27-16(29-14)11-18(31,20(24,25)26)13-2-4-15(5-3-13)30-9-1-8-28-30/h1-5,8-9,12,31H,6-7,10-11H2,(H,27,29)/t18-/m0/s1
DMS7C6R CS C1CC1(CC2=CN=C(N2)C[C@](C3=CC=C(C=C3)N4C=CC=N4)(C(F)(F)F)O)C(F)(F)F
DMS7C6R IK UJINBEQCDMOAHM-SFHVURJKSA-N
DMS7C6R IU (2S)-1,1,1-trifluoro-2-(4-pyrazol-1-ylphenyl)-3-[5-[[1-(trifluoromethyl)cyclopropyl]methyl]-1H-imidazol-2-yl]propan-2-ol
DMS7C6R DE Discovery agent
DMU8VRB ID DMU8VRB
DMU8VRB DN MK-5435
DMU8VRB HS Investigative
DMU8VRB SN DFMTI; CHEMBL579062; 864864-86-8; MK-5435; SCHEMBL1500017; GTPL6335; KKZVYGIANGOHBS-UHFFFAOYSA-N; MolPort-044-724-496; KS-00001CM3; BDBM50301804; ZINC13983201; AKOS032944969; CS-5849; HY-100404; M-265; L023906; 2-Isopropyl-5-[1-(2,4-difluorophenyl)-5-methyl-1H-1,2,3-triazole-4-yl]isoindoline-1-one; 5-[1-(2,4-difluorophenyl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one.; 5-[1-(2,4-difluorophenyl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one
DMU8VRB DT Small molecular drug
DMU8VRB PC 15985251
DMU8VRB MW 368.4
DMU8VRB FM C20H18F2N4O
DMU8VRB IC InChI=1S/C20H18F2N4O/c1-11(2)25-10-14-8-13(4-6-16(14)20(25)27)19-12(3)26(24-23-19)18-7-5-15(21)9-17(18)22/h4-9,11H,10H2,1-3H3
DMU8VRB CS CC1=C(N=NN1C2=C(C=C(C=C2)F)F)C3=CC4=C(C=C3)C(=O)N(C4)C(C)C
DMU8VRB IK KKZVYGIANGOHBS-UHFFFAOYSA-N
DMU8VRB IU 5-[1-(2,4-difluorophenyl)-5-methyltriazol-4-yl]-2-propan-2-yl-3H-isoindol-1-one
DMU8VRB DE Discovery agent
DMLWMZ4 ID DMLWMZ4
DMLWMZ4 DN MK-5596
DMLWMZ4 HS Investigative
DMLWMZ4 SN CB1 inverse agonists (obesity), Merck
DMLWMZ4 CP Merck Research Laboratories
DMLWMZ4 DT Small molecular drug
DMLWMZ4 PC 24871527
DMLWMZ4 MW 541.9
DMLWMZ4 FM C27H23Cl3N4O2
DMLWMZ4 IC InChI=1S/C27H23Cl3N4O2/c1-14-10-22(34-33-14)25(35)31-23-13-27(2,3)36-26-20(23)12-19(15-4-6-16(28)7-5-15)24(32-26)18-9-8-17(29)11-21(18)30/h4-12,23H,13H2,1-3H3,(H,31,35)(H,33,34)/t23-/m1/s1
DMLWMZ4 CS CC1=CC(=NN1)C(=O)N[C@@H]2CC(OC3=C2C=C(C(=N3)C4=C(C=C(C=C4)Cl)Cl)C5=CC=C(C=C5)Cl)(C)C
DMLWMZ4 IK IDUFEEHNNASCMH-HSZRJFAPSA-N
DMLWMZ4 IU N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide
DMLWMZ4 DE Obesity
DMR9C4Q ID DMR9C4Q
DMR9C4Q DN MK-6892
DMR9C4Q HS Investigative
DMR9C4Q SN Nicotinic acid 1 receptor (GPR109A) agonists, Merck
DMR9C4Q CP Merck Frosst Canada & Co
DMR9C4Q DT Small molecular drug
DMR9C4Q PC 135416394
DMR9C4Q MW 386.4
DMR9C4Q FM C19H22N4O5
DMR9C4Q IC InChI=1S/C19H22N4O5/c1-19(2,18(27)21-13-6-4-3-5-12(13)17(25)26)9-15-22-16(23-28-15)14-8-7-11(24)10-20-14/h7-8,10,24H,3-6,9H2,1-2H3,(H,21,27)(H,25,26)
DMR9C4Q CS CC(C)(CC1=NC(=NO1)C2=NC=C(C=C2)O)C(=O)NC3=C(CCCC3)C(=O)O
DMR9C4Q IK CJHXBFSJXDUJHP-UHFFFAOYSA-N
DMR9C4Q IU 2-[[3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]-2,2-dimethylpropanoyl]amino]cyclohexene-1-carboxylic acid
DMR9C4Q CA CAS 917910-45-3
DMR9C4Q DE Arteriosclerosis
DM4YQV0 ID DM4YQV0
DM4YQV0 DN MK-771
DM4YQV0 HS Investigative
DM4YQV0 SN 66537-55-1
DM4YQV0 DT Small molecular drug
DM4YQV0 PC 163122
DM4YQV0 MW 394.5
DM4YQV0 FM C16H22N6O4S
DM4YQV0 IC InChI=1S/C16H22N6O4S/c17-14(24)12-6-27-8-22(12)16(26)11(4-9-5-18-7-19-9)21-15(25)10-2-1-3-13(23)20-10/h5,7,10-12H,1-4,6,8H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12+/m0/s1
DM4YQV0 CS C1C[C@H](NC(=O)C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CSC[C@@H]3C(=O)N
DM4YQV0 IK OGUDACTYCTVDNZ-SDDRHHMPSA-N
DM4YQV0 IU (4S)-3-[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-6-oxopiperidine-2-carbonyl]amino]propanoyl]-1,3-thiazolidine-4-carboxamide
DM4YQV0 CA CAS 66537-55-1
DM4YQV0 DE Discovery agent
DM3EP59 ID DM3EP59
DM3EP59 DN MK-7725
DM3EP59 HS Investigative
DM3EP59 SN BRS-3 agonists (obesity); BRS-3 agonists (obesity), Merck; Bombesin receptor subtype-3 agonists (obesity), Merck
DM3EP59 CP Merck & Co Inc
DM3EP59 DT Small molecular drug
DM3EP59 PC 46200989
DM3EP59 MW 615.5
DM3EP59 FM C25H19F6N5O5S
DM3EP59 IC InChI=1S/C25H19F6N5O5S/c1-23(2,37)22-34-21(35-41-22)16-4-3-5-17-19(16)36(12-13-6-11-18(24(26,27)28)33-20(13)32-17)42(38,39)15-9-7-14(8-10-15)40-25(29,30)31/h3-11,37H,12H2,1-2H3,(H,32,33)
DM3EP59 CS CC(C)(C1=NC(=NO1)C2=C3C(=CC=C2)NC4=C(CN3S(=O)(=O)C5=CC=C(C=C5)OC(F)(F)F)C=CC(=N4)C(F)(F)F)O
DM3EP59 IK WQQNCCUPGPFWOI-UHFFFAOYSA-N
DM3EP59 IU 2-[3-[6-[4-(trifluoromethoxy)phenyl]sulfonyl-2-(trifluoromethyl)-5,11-dihydropyrido[3,2-c][1,5]benzodiazepin-7-yl]-1,2,4-oxadiazol-5-yl]propan-2-ol
DM3EP59 CA CAS 1034152-95-8
DM3EP59 DE Obesity
DMKEG2B ID DMKEG2B
DMKEG2B DN MK-9
DMKEG2B HS Investigative
DMKEG2B PC 6289935
DMKEG2B MW 785.2
DMKEG2B FM C56H80O2
DMKEG2B IC InChI=1S/C56H80O2/c1-42(2)22-14-23-43(3)24-15-25-44(4)26-16-27-45(5)28-17-29-46(6)30-18-31-47(7)32-19-33-48(8)34-20-35-49(9)36-21-37-50(10)40-41-52-51(11)55(57)53-38-12-13-39-54(53)56(52)58/h12-13,22,24,26,28,30,32,34,36,38-40H,14-21,23,25,27,29,31,33,35,37,41H2,1-11H3/b43-24+,44-26+,45-28+,46-30+,47-32+,48-34+,49-36+,50-40+
DMKEG2B CS CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CC/C=C(\\C)/CCC=C(C)C
DMKEG2B IK WCRXHNIUHQUASO-UVZVDVBNSA-N
DMKEG2B IU 2-methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]naphthalene-1,4-dione
DMKEG2B CA CAS 523-39-7
DMKEG2B CB CHEBI:44147
DMKEG2B DE Discovery agent
DM4ZNOU ID DM4ZNOU
DM4ZNOU DN ML 10375
DM4ZNOU HS Investigative
DM4ZNOU SN ML-10375; ML10375
DM4ZNOU DT Small molecular drug
DM4ZNOU PC 9905972
DM4ZNOU MW 340.8
DM4ZNOU FM C17H25ClN2O3
DM4ZNOU IC InChI=1S/C17H25ClN2O3/c1-11-6-12(2)10-20(9-11)4-5-23-17(21)13-7-14(18)15(19)8-16(13)22-3/h7-8,11-12H,4-6,9-10,19H2,1-3H3
DM4ZNOU CS CC1CC(CN(C1)CCOC(=O)C2=CC(=C(C=C2OC)N)Cl)C
DM4ZNOU IK BUEFUOFMOXJXAR-UHFFFAOYSA-N
DM4ZNOU IU 2-(3,5-dimethylpiperidin-1-yl)ethyl 4-amino-5-chloro-2-methoxybenzoate
DM4ZNOU DE Discovery agent
DMM5P8Q ID DMM5P8Q
DMM5P8Q DN ML-10302
DMM5P8Q HS Investigative
DMM5P8Q SN 148868-55-7
DMM5P8Q DT Small molecular drug
DMM5P8Q PC 5311299
DMM5P8Q MW 312.79
DMM5P8Q FM C15H21ClN2O3
DMM5P8Q IC InChI=1S/C15H21ClN2O3/c1-20-14-10-13(17)12(16)9-11(14)15(19)21-8-7-18-5-3-2-4-6-18/h9-10H,2-8,17H2,1H3
DMM5P8Q CS COC1=CC(=C(C=C1C(=O)OCCN2CCCCC2)Cl)N
DMM5P8Q IK RVFIAQAAZUEPPE-UHFFFAOYSA-N
DMM5P8Q IU 2-piperidin-1-ylethyl 4-amino-5-chloro-2-methoxybenzoate
DMM5P8Q CA CAS 148868-55-7
DMM5P8Q DE Discovery agent
DMPB7EL ID DMPB7EL
DMPB7EL DN ML169
DMPB7EL HS Investigative
DMPB7EL SN VU0405652; ML-169
DMPB7EL DT Small molecular drug
DMPB7EL PC 44475955
DMPB7EL MW 506.3
DMPB7EL FM C21H17BrFN3O4S
DMPB7EL IC InChI=1S/C21H17BrFN3O4S/c1-13-8-20(25-30-13)24-21(27)12-31(28,29)19-11-26(18-5-3-2-4-16(18)19)10-14-9-15(22)6-7-17(14)23/h2-9,11H,10,12H2,1H3,(H,24,25,27)
DMPB7EL CS CC1=CC(=NO1)NC(=O)CS(=O)(=O)C2=CN(C3=CC=CC=C32)CC4=C(C=CC(=C4)Br)F
DMPB7EL IK RUYRNYRGPSAXTK-UHFFFAOYSA-N
DMPB7EL IU 2-[1-[(5-bromo-2-fluorophenyl)methyl]indol-3-yl]sulfonyl-N-(5-methyl-1,2-oxazol-3-yl)acetamide
DMPB7EL DE Discovery agent
DMHJCN6 ID DMHJCN6
DMHJCN6 DN ML-18
DMHJCN6 HS Investigative
DMHJCN6 SN ML-18; ML 18; 1422269-30-4; GTPL8505; MolPort-039-338-066; ZINC263621864; AKOS027470221; CS-6869; HY-101844; ML-18,,ML18,ML-18,ML 18,BRS-3 antagonist,1422269-30-4; (2S)-3-(1H-indol-3-yl)-N-{[1-(4-methoxyphenyl)cyclohexyl]methyl}-2-{[(4-nitrophenyl)carbamoyl]amino}propanamide
DMHJCN6 DT Small molecular drug
DMHJCN6 PC 91827363
DMHJCN6 MW 569.6
DMHJCN6 FM C32H35N5O5
DMHJCN6 IC InChI=1S/C32H35N5O5/c1-42-26-15-9-23(10-16-26)32(17-5-2-6-18-32)21-34-30(38)29(19-22-20-33-28-8-4-3-7-27(22)28)36-31(39)35-24-11-13-25(14-12-24)37(40)41/h3-4,7-16,20,29,33H,2,5-6,17-19,21H2,1H3,(H,34,38)(H2,35,36,39)/t29-/m0/s1
DMHJCN6 CS COC1=CC=C(C=C1)C2(CCCCC2)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)NC5=CC=C(C=C5)[N+](=O)[O-]
DMHJCN6 IK JOKVJNCYOSFDGC-LJAQVGFWSA-N
DMHJCN6 IU (2S)-3-(1H-indol-3-yl)-N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]-2-[(4-nitrophenyl)carbamoylamino]propanamide
DMHJCN6 DE Discovery agent
DM15YL0 ID DM15YL0
DM15YL0 DN ML204
DM15YL0 HS Investigative
DM15YL0 SN 5465-86-1; ML204; ML 204; 4-methyl-2-(piperidin-1-yl)quinoline; 4-Methyl-2-(1-piperidinyl)-quinoline; 4-methyl-2-piperidin-1-ylquinoline; 4-Methyl-2-(1-piperidinyl)quinoline; VU0024172-3; NSC25850; AC1Q4W9R; Cambridge id 5563912; AC1L5K4A; MLS001007138; 4-methyl-2-piperidylquinoline; 4-methyl-2-piperidinoquinoline; 2-Piperidino-4-methylquinoline; GTPL4255; cid_230710; 4-methyl-2-piperidino-quinoline; SCHEMBL14975993; CHEMBL1459962; CTK5A2131; BDBM77617; DTXSID30282438; EX-A938; AOB1526; MolPort-000-220-757; HMS2704E20; BCP28617
DM15YL0 DT Small molecular drug
DM15YL0 PC 230710
DM15YL0 MW 226.32
DM15YL0 FM C15H18N2
DM15YL0 IC InChI=1S/C15H18N2/c1-12-11-15(17-9-5-2-6-10-17)16-14-8-4-3-7-13(12)14/h3-4,7-8,11H,2,5-6,9-10H2,1H3
DM15YL0 CS CC1=CC(=NC2=CC=CC=C12)N3CCCCC3
DM15YL0 IK USYRQXDHKXGTCK-UHFFFAOYSA-N
DM15YL0 IU 4-methyl-2-piperidin-1-ylquinoline
DM15YL0 CA CAS 5465-86-1
DM15YL0 DE Discovery agent
DMFAUGP ID DMFAUGP
DMFAUGP DN ML213
DMFAUGP HS Investigative
DMFAUGP SN ML 213; ML-213
DMFAUGP DT Small molecular drug
DMFAUGP PC 3111211
DMFAUGP MW 257.37
DMFAUGP FM C17H23NO
DMFAUGP IC InChI=1S/C17H23NO/c1-10-6-11(2)16(12(3)7-10)18-17(19)15-9-13-4-5-14(15)8-13/h6-7,13-15H,4-5,8-9H2,1-3H3,(H,18,19)
DMFAUGP CS CC1=CC(=C(C(=C1)C)NC(=O)C2CC3CCC2C3)C
DMFAUGP IK SIQGKPGBLYKQBB-UHFFFAOYSA-N
DMFAUGP IU N-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-2-carboxamide
DMFAUGP CA CAS 489402-47-3
DMFAUGP CB CHEBI:91537
DMFAUGP DE Discovery agent
DM3D21X ID DM3D21X
DM3D21X DN ML218
DM3D21X HS Investigative
DM3D21X SN ML-218; ML 218
DM3D21X DT Small molecular drug
DM3D21X PC 45115620
DM3D21X MW 369.3
DM3D21X FM C19H26Cl2N2O
DM3D21X IC InChI=1S/C19H26Cl2N2O/c1-19(2,3)4-5-23-10-16-15(17(16)11-23)9-22-18(24)12-6-13(20)8-14(21)7-12/h6-8,15-17H,4-5,9-11H2,1-3H3,(H,22,24)/t15?,16-,17+
DM3D21X CS CC(C)(C)CCN1C[C@@H]2[C@H](C1)C2CNC(=O)C3=CC(=CC(=C3)Cl)Cl
DM3D21X IK GSJIGYLGKSBYBC-ALOPSCKCSA-N
DM3D21X IU 3,5-dichloro-N-[[(1R,5S)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]benzamide
DM3D21X CB CHEBI:91745
DM3D21X DE Discovery agent
DM3OEP4 ID DM3OEP4
DM3OEP4 DN ML221
DM3OEP4 HS Investigative
DM3OEP4 SN ML221; 877636-42-5; ML 221; CHEMBL2158347; ML-221; 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate; [4-oxo-6-(pyrimidin-2-ylsulfanylmethyl)pyran-3-yl] 4-nitrobenzoate; AC1OHVTH; MLS003389520; GTPL6282; SCHEMBL17326564; CHEBI:92965; AOB1262; MolPort-003-127-646; ZINC4377282; BCP28945; BDBM50393964; AKOS016372065; MCULE-7007021256; SB19613; AS-16633; SMR002078184; HY-103254; CS-0026651; J3.654.307H; MLS-0437359.0002; MLS-0437359.0001; AB00687545-01; SR-01000020403; SR-01000020403-1; F2510-0124
DM3OEP4 DT Small molecular drug
DM3OEP4 PC 7217941
DM3OEP4 MW 385.4
DM3OEP4 FM C17H11N3O6S
DM3OEP4 IC InChI=1S/C17H11N3O6S/c21-14-8-13(10-27-17-18-6-1-7-19-17)25-9-15(14)26-16(22)11-2-4-12(5-3-11)20(23)24/h1-9H,10H2
DM3OEP4 CS C1=CN=C(N=C1)SCC2=CC(=O)C(=CO2)OC(=O)C3=CC=C(C=C3)[N+](=O)[O-]
DM3OEP4 IK UASIRTUMPRQVFY-UHFFFAOYSA-N
DM3OEP4 IU [4-oxo-6-(pyrimidin-2-ylsulfanylmethyl)pyran-3-yl] 4-nitrobenzoate
DM3OEP4 CB CHEBI:92965
DM3OEP4 DE Discovery agent
DM8CIE4 ID DM8CIE4
DM8CIE4 DN ML233
DM8CIE4 HS Investigative
DM8CIE4 SN ML233; CHEMBL3819625; GTPL6314; AOB1202; ZINC96024633; BDBM50183380; MLS-0437644.0001; [(1E)-5-cyclohexyl-2-methyl-4-oxocyclohexa-2,5-dien-1-ylidene]amino benzenesulfonate
DM8CIE4 DT Small molecular drug
DM8CIE4 PC 46905036
DM8CIE4 MW 359.4
DM8CIE4 FM C19H21NO4S
DM8CIE4 IC InChI=1S/C19H21NO4S/c1-14-12-19(21)17(15-8-4-2-5-9-15)13-18(14)20-24-25(22,23)16-10-6-3-7-11-16/h3,6-7,10-13,15H,2,4-5,8-9H2,1H3/b20-18-
DM8CIE4 CS CC\\1=CC(=O)C(=C/C1=N/OS(=O)(=O)C2=CC=CC=C2)C3CCCCC3
DM8CIE4 IK RSMZOLWJZGIWOV-ZZEZOPTASA-N
DM8CIE4 IU [(Z)-(5-cyclohexyl-2-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)amino] benzenesulfonate
DM8CIE4 DE Discovery agent
DMK6YC1 ID DMK6YC1
DMK6YC1 DN ML-253764
DMK6YC1 HS Investigative
DMK6YC1 SN CHEMBL40711; ML-253764; SCHEMBL3728758; ZINC3938671; BDBM50142895; 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1h-imidazole; 2-{2-[2-(5-Bromo-2-methoxy-phenyl)-ethyl]-3-fluoro-phenyl}-4,5-dihydro-1H-imidazole
DMK6YC1 DT Small molecular drug
DMK6YC1 PC 9842665
DMK6YC1 MW 377.2
DMK6YC1 FM C18H18BrFN2O
DMK6YC1 IC InChI=1S/C18H18BrFN2O/c1-23-17-8-6-13(19)11-12(17)5-7-14-15(3-2-4-16(14)20)18-21-9-10-22-18/h2-4,6,8,11H,5,7,9-10H2,1H3,(H,21,22)
DMK6YC1 CS COC1=C(C=C(C=C1)Br)CCC2=C(C=CC=C2F)C3=NCCN3
DMK6YC1 IK WCPPZGPJRHLSKP-UHFFFAOYSA-N
DMK6YC1 IU 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole
DMK6YC1 DE Discovery agent
DMQ98RS ID DMQ98RS
DMQ98RS DN ML277
DMQ98RS HS Investigative
DMQ98RS SN ML-277; ML 277
DMQ98RS DT Small molecular drug
DMQ98RS PC 53347902
DMQ98RS MW 471.6
DMQ98RS FM C23H25N3O4S2
DMQ98RS IC InChI=1S/C23H25N3O4S2/c1-16-6-12-19(13-7-16)32(28,29)26-14-4-3-5-21(26)22(27)25-23-24-20(15-31-23)17-8-10-18(30-2)11-9-17/h6-13,15,21H,3-5,14H2,1-2H3,(H,24,25,27)/t21-/m1/s1
DMQ98RS CS CC1=CC=C(C=C1)S(=O)(=O)N2CCCC[C@@H]2C(=O)NC3=NC(=CS3)C4=CC=C(C=C4)OC
DMQ98RS IK OXQNLLVUVDAEHC-OAQYLSRUSA-N
DMQ98RS IU (2R)-N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-1-(4-methylphenyl)sulfonylpiperidine-2-carboxamide
DMQ98RS DE Discovery agent
DMPOX4Q ID DMPOX4Q
DMPOX4Q DN ML290
DMPOX4Q HS Investigative
DMPOX4Q SN ML 290; compound 8 [PMID: 23764525]
DMPOX4Q DT Small molecular drug
DMPOX4Q PC 56593349
DMPOX4Q MW 506.5
DMPOX4Q FM C24H21F3N2O5S
DMPOX4Q IC InChI=1S/C24H21F3N2O5S/c1-15(2)34-21-13-6-4-11-19(21)23(31)29-20-12-5-3-10-18(20)22(30)28-16-8-7-9-17(14-16)35(32,33)24(25,26)27/h3-15H,1-2H3,(H,28,30)(H,29,31)
DMPOX4Q CS CC(C)OC1=CC=CC=C1C(=O)NC2=CC=CC=C2C(=O)NC3=CC(=CC=C3)S(=O)(=O)C(F)(F)F
DMPOX4Q IK RSYHJSDOGMSLDH-UHFFFAOYSA-N
DMPOX4Q IU 2-[(2-propan-2-yloxybenzoyl)amino]-N-[3-(trifluoromethylsulfonyl)phenyl]benzamide
DMPOX4Q DE Discovery agent
DMY40UG ID DMY40UG
DMY40UG DN ML297
DMY40UG HS Investigative
DMY40UG SN ML-297; ML 297
DMY40UG DT Small molecular drug
DMY40UG PC 56642816
DMY40UG MW 328.32
DMY40UG FM C17H14F2N4O
DMY40UG IC InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24)
DMY40UG CS CC1=NN(C(=C1)NC(=O)NC2=CC(=C(C=C2)F)F)C3=CC=CC=C3
DMY40UG IK IEKSMUSSYJUQMY-UHFFFAOYSA-N
DMY40UG IU 1-(3,4-difluorophenyl)-3-(5-methyl-2-phenylpyrazol-3-yl)urea
DMY40UG DE Discovery agent
DMNOREK ID DMNOREK
DMNOREK DN ML315
DMNOREK HS Investigative
DMNOREK SN ML315; CHEMBL1885748; 1440251-53-5; MLS004256649; GTPL8162; KUC107550N; BDBM50435474; ML 315; AKOS032952995; KSC-14-101; NCGC00241342-01; NCGC00241342-02; SMR003081704; BRD-K98168317-001-01-9; 5-(benzo[d][1,3]dioxol-5-yl)-N-(3,5-dichlorobenzyl)pyrimidin-4-amine
DMNOREK DT Small molecular drug
DMNOREK PC 46926514
DMNOREK MW 374.2
DMNOREK FM C18H13Cl2N3O2
DMNOREK IC InChI=1S/C18H13Cl2N3O2/c19-13-3-11(4-14(20)6-13)7-22-18-15(8-21-9-23-18)12-1-2-16-17(5-12)25-10-24-16/h1-6,8-9H,7,10H2,(H,21,22,23)
DMNOREK CS C1OC2=C(O1)C=C(C=C2)C3=CN=CN=C3NCC4=CC(=CC(=C4)Cl)Cl
DMNOREK IK JQSJAVBMIMDUFO-UHFFFAOYSA-N
DMNOREK IU 5-(1,3-benzodioxol-5-yl)-N-[(3,5-dichlorophenyl)methyl]pyrimidin-4-amine
DMNOREK DE Discovery agent
DM3S5UC ID DM3S5UC
DM3S5UC DN ML-3163
DM3S5UC HS Investigative
DM3S5UC SN ML 3163; CHEMBL111456; 4-[5-(4-Fluorophenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-3H-imidazol-4-yl]pyridine; SCHEMBL4106398; BDBM50114690; IN1229; 4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine; 4-(2-(4-(methylsulfinyl)benzylthio)-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine
DM3S5UC DT Small molecular drug
DM3S5UC PC 9845197
DM3S5UC MW 423.5
DM3S5UC FM C22H18FN3OS2
DM3S5UC IC InChI=1S/C22H18FN3OS2/c1-29(27)19-8-2-15(3-9-19)14-28-22-25-20(16-4-6-18(23)7-5-16)21(26-22)17-10-12-24-13-11-17/h2-13H,14H2,1H3,(H,25,26)
DM3S5UC CS CS(=O)C1=CC=C(C=C1)CSC2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
DM3S5UC IK PRYUWQSCZBKGMW-UHFFFAOYSA-N
DM3S5UC IU 4-[4-(4-fluorophenyl)-2-[(4-methylsulfinylphenyl)methylsulfanyl]-1H-imidazol-5-yl]pyridine
DM3S5UC DE Discovery agent
DMVELYW ID DMVELYW
DMVELYW DN ML321
DMVELYW HS Investigative
DMVELYW SN compound 65 [PMID 24666157]
DMVELYW DT Small molecular drug
DMVELYW PC 57377246
DMVELYW MW 410.5
DMVELYW FM C21H18N2O3S2
DMVELYW IC InChI=1S/C21H18N2O3S2/c1-23-17-13-14(20(24)22-11-10-15-5-4-12-27-15)8-9-19(17)28(26)18-7-3-2-6-16(18)21(23)25/h2-9,12-13H,10-11H2,1H3,(H,22,24)/t28-/m0/s1
DMVELYW CS CN1C2=C(C=CC(=C2)C(=O)NCCC3=CC=CS3)[S@@](=O)C4=CC=CC=C4C1=O
DMVELYW IK YXLLQNMKIDBOGH-NDEPHWFRSA-N
DMVELYW IU (11S)-5-methyl-6,11-dioxo-N-(2-thiophen-2-ylethyl)benzo[b][1,4]benzothiazepine-3-carboxamide
DMVELYW DE Discovery agent
DMXJY6W ID DMXJY6W
DMXJY6W DN ML-3375
DMXJY6W HS Investigative
DMXJY6W SN ML-3375; CHEMBL113419; SCHEMBL4460547; SCHEMBL13712659; ZINC13491685; BDBM50119524; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridine; 2-(Methylthio)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole
DMXJY6W DT Small molecular drug
DMXJY6W PC 9795838
DMXJY6W MW 285.3
DMXJY6W FM C15H12FN3S
DMXJY6W IC InChI=1S/C15H12FN3S/c1-20-15-18-13(10-2-4-12(16)5-3-10)14(19-15)11-6-8-17-9-7-11/h2-9H,1H3,(H,18,19)
DMXJY6W CS CSC1=NC(=C(N1)C2=CC=NC=C2)C3=CC=C(C=C3)F
DMXJY6W IK IKQIPPKRAFLUKQ-UHFFFAOYSA-N
DMXJY6W IU 4-[4-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl]pyridine
DMXJY6W DE Discovery agent
DMTQWI8 ID DMTQWI8
DMTQWI8 DN ML-3403
DMTQWI8 HS Investigative
DMTQWI8 SN p38 MAP Kinase Inhibitor III; ML3403; 549505-65-9; ML 3403; 4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)-N-(1-phenylethyl)pyridin-2-amine; CHEMBL111364; (RS)-{4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}-(1-phenylethyl)amine]; K00568a; AC1O4WCF; SCHEMBL2896072; GTPL6014; ml-3043; SCHEMBL15013352; MolPort-023-278-904; HMS3229M04; {4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine
DMTQWI8 DT Small molecular drug
DMTQWI8 PC 6419739
DMTQWI8 MW 404.5
DMTQWI8 FM C23H21FN4S
DMTQWI8 IC InChI=1S/C23H21FN4S/c1-15(16-6-4-3-5-7-16)26-20-14-18(12-13-25-20)22-21(27-23(28-22)29-2)17-8-10-19(24)11-9-17/h3-15H,1-2H3,(H,25,26)(H,27,28)
DMTQWI8 CS CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F
DMTQWI8 IK VXPWQNBKEIVYIS-UHFFFAOYSA-N
DMTQWI8 IU 4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-N-(1-phenylethyl)pyridin-2-amine
DMTQWI8 CA CAS 549505-65-9
DMTQWI8 DE Discovery agent
DMR8N36 ID DMR8N36
DMR8N36 DN ML347
DMR8N36 HS Investigative
DMR8N36 SN ML-347
DMR8N36 DT Small molecular drug
DMR8N36 PC 44577753
DMR8N36 MW 352.4
DMR8N36 FM C22H16N4O
DMR8N36 IC InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3
DMR8N36 CS COC1=CC=C(C=C1)C2=CN3C(=C(C=N3)C4=C5C=CC=NC5=CC=C4)N=C2
DMR8N36 IK FVRYPYDPKSZGNS-UHFFFAOYSA-N
DMR8N36 IU 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
DMR8N36 DE Discovery agent
DMXJASC ID DMXJASC
DMXJASC DN ML375
DMXJASC HS Investigative
DMXJASC SN VU0483253-3
DMXJASC DT Small molecular drug
DMXJASC PC 71598521
DMXJASC MW 424.8
DMXJASC FM C23H15ClF2N2O2
DMXJASC IC InChI=1S/C23H15ClF2N2O2/c24-16-8-6-15(7-9-16)23-18-4-2-1-3-17(18)22(30)28(23)12-11-27(23)21(29)14-5-10-19(25)20(26)13-14/h1-10,13H,11-12H2/t23-/m0/s1
DMXJASC CS C1CN([C@]2(N1C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)C5=CC(=C(C=C5)F)F
DMXJASC IK GXBAKXRLQAPKEE-QHCPKHFHSA-N
DMXJASC IU (9bS)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydroimidazo[2,1-a]isoindol-5-one
DMXJASC DE Discovery agent
DMQROC3 ID DMQROC3
DMQROC3 DN ML380
DMQROC3 HS Investigative
DMQROC3 SN VU0481443-3
DMQROC3 DT Small molecular drug
DMQROC3 PC 71737672
DMQROC3 MW 494.5
DMQROC3 FM C23H25F3N4O3S
DMQROC3 IC InChI=1S/C23H25F3N4O3S/c1-2-29(15-17-5-3-4-6-20(17)23(24,25)26)22(31)16-9-11-30(12-10-16)34(32,33)19-7-8-21-18(13-19)14-27-28-21/h3-8,13-14,16H,2,9-12,15H2,1H3,(H,27,28)
DMQROC3 CS CCN(CC1=CC=CC=C1C(F)(F)F)C(=O)C2CCN(CC2)S(=O)(=O)C3=CC4=C(C=C3)NN=C4
DMQROC3 IK FJPQEOQGIZSLES-UHFFFAOYSA-N
DMQROC3 IU N-ethyl-1-(1H-indazol-5-ylsulfonyl)-N-[[2-(trifluoromethyl)phenyl]methyl]piperidine-4-carboxamide
DMQROC3 DE Discovery agent
DMKCIP0 ID DMKCIP0
DMKCIP0 DN ML381
DMKCIP0 HS Investigative
DMKCIP0 SN VU0488130-1
DMKCIP0 DT Small molecular drug
DMKCIP0 PC 42519285
DMKCIP0 MW 379.4
DMKCIP0 FM C21H21N3O4
DMKCIP0 IC InChI=1S/C21H21N3O4/c1-14(19-9-4-5-10-22-19)24(3)21(26)20-12-18(28-23-20)13-27-17-8-6-7-16(11-17)15(2)25/h4-12,14H,13H2,1-3H3/t14-/m0/s1
DMKCIP0 CS C[C@@H](C1=CC=CC=N1)N(C)C(=O)C2=NOC(=C2)COC3=CC=CC(=C3)C(=O)C
DMKCIP0 IK JMYDHMCYZKRDPD-AWEZNQCLSA-N
DMKCIP0 IU 5-[(3-acetylphenoxy)methyl]-N-methyl-N-[(1S)-1-pyridin-2-ylethyl]-1,2-oxazole-3-carboxamide
DMKCIP0 DE Discovery agent
DMA0E2Q ID DMA0E2Q
DMA0E2Q DN ML398
DMA0E2Q HS Investigative
DMA0E2Q SN ML398; CHEMBL3335556; GTPL8440; BDBM50027083; VU0603865-1; VU0603865-2
DMA0E2Q DT Small molecular drug
DMA0E2Q PC 72737723
DMA0E2Q MW 315.8
DMA0E2Q FM C19H22ClNO
DMA0E2Q IC InChI=1S/C19H22ClNO/c20-18-9-6-17(7-10-18)14-21-12-13-22-19(15-21)11-8-16-4-2-1-3-5-16/h1-7,9-10,19H,8,11-15H2/t19-/m1/s1
DMA0E2Q CS C1CO[C@@H](CN1CC2=CC=C(C=C2)Cl)CCC3=CC=CC=C3
DMA0E2Q IK CVKXGRRJHJHUFY-LJQANCHMSA-N
DMA0E2Q IU (2R)-4-[(4-chlorophenyl)methyl]-2-(2-phenylethyl)morpholine
DMA0E2Q DE Discovery agent
DMP13VE ID DMP13VE
DMP13VE DN ML9
DMP13VE HS Investigative
DMP13VE SN ML-9 free base; UNII-LTJ3F5128V; 110448-31-2; LTJ3F5128V; CHEMBL429298; ML9; 1-[(5-chloro-1-naphthyl)sulfonyl]-1,4-diazepane; 1H-1,4-Diazepine, 1-[(5-chloro-1-naphthalenyl)sulfonyl]hexahydro-; Tocris-0431; ACMC-20mde5; BiomolKI_000043; AC1L1HOD; Lopac-C-1172; BiomolKI2_000008; Lopac0_000209; BSPBio_001271; GTPL4256; SCHEMBL2869228; CTK0D4761; CHEBI:93202; DTXSID00149246; ZINC402771; HMS1792O13; Bio1_000938; Bio1_001427; Bio1_000449; HMS3403O13; HMS1990O13; BDBM50216681; 1H-1,4-Diazepine, 1-((5-chloro-1-naphthalenyl)sulfonyl)hexahydro-)
DMP13VE DT Small molecular drug
DMP13VE PC 4217
DMP13VE MW 324.8
DMP13VE FM C15H17ClN2O2S
DMP13VE IC InChI=1S/C15H17ClN2O2S/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18/h1-2,4-7,17H,3,8-11H2
DMP13VE CS C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CC=C3Cl
DMP13VE IK OZSMSRIUUDGTEP-UHFFFAOYSA-N
DMP13VE IU 1-(5-chloronaphthalen-1-yl)sulfonyl-1,4-diazepane
DMP13VE CA CAS 110448-31-2
DMP13VE CB CHEBI:93202
DMP13VE DE Discovery agent
DMTU0IG ID DMTU0IG
DMTU0IG DN MLN-0905
DMTU0IG HS Investigative
DMTU0IG SN PLK-1 inhibitor (lymphoma), Millennium
DMTU0IG CP Millennium Pharmaceuticals Inc
DMTU0IG DT Small molecular drug
DMTU0IG PC 46235922
DMTU0IG MW 486.6
DMTU0IG FM C24H25F3N6S
DMTU0IG IC InChI=1S/C24H25F3N6S/c1-14-19(9-15(12-28-14)5-4-8-33(2)3)31-23-29-13-16-10-21(34)30-20-11-17(24(25,26)27)6-7-18(20)22(16)32-23/h6-7,9,11-13H,4-5,8,10H2,1-3H3,(H,30,34)(H,29,31,32)
DMTU0IG CS CC1=C(C=C(C=N1)CCCN(C)C)NC2=NC=C3CC(=S)NC4=C(C3=N2)C=CC(=C4)C(F)(F)F
DMTU0IG IK CODBZFJPKJDNDT-UHFFFAOYSA-N
DMTU0IG IU 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione
DMTU0IG CA CAS 1228960-69-7
DMTU0IG DE Lymphoma
DMYKNSP ID DMYKNSP
DMYKNSP DN MLN-120B
DMYKNSP HS Investigative
DMYKNSP SN MLN 120B; ML-120B; MLN120B; ML120B
DMYKNSP DT Small molecular drug
DMYKNSP PC 9929127
DMYKNSP MW 366.8
DMYKNSP FM C19H15ClN4O2
DMYKNSP IC InChI=1S/C19H15ClN4O2/c1-10-11(4-3-6-22-10)19(25)24-17-16-13(8-14(20)18(17)26-2)12-5-7-21-9-15(12)23-16/h3-9,23H,1-2H3,(H,24,25)
DMYKNSP CS CC1=C(C=CC=N1)C(=O)NC2=C3C(=CC(=C2OC)Cl)C4=C(N3)C=NC=C4
DMYKNSP IK ZNOLRTPMNMPLHY-UHFFFAOYSA-N
DMYKNSP IU N-(6-chloro-7-methoxy-9H-pyrido[3,4-b]indol-8-yl)-2-methylpyridine-3-carboxamide
DMYKNSP CA CAS 783348-36-7
DMYKNSP DE Discovery agent
DMPTBJZ ID DMPTBJZ
DMPTBJZ DN MLS1547
DMPTBJZ HS Investigative
DMPTBJZ SN MLS000051547
DMPTBJZ DT Small molecular drug
DMPTBJZ PC 1093278
DMPTBJZ MW 354.8
DMPTBJZ FM C19H19ClN4O
DMPTBJZ IC InChI=1S/C19H19ClN4O/c20-16-12-14(19(25)18-15(16)4-3-7-22-18)13-23-8-10-24(11-9-23)17-5-1-2-6-21-17/h1-7,12,25H,8-11,13H2
DMPTBJZ CS C1CN(CCN1CC2=CC(=C3C=CC=NC3=C2O)Cl)C4=CC=CC=N4
DMPTBJZ IK OPEJNANYABTIGC-UHFFFAOYSA-N
DMPTBJZ IU 5-chloro-7-[(4-pyridin-2-ylpiperazin-1-yl)methyl]quinolin-8-ol
DMPTBJZ DE Discovery agent
DMT1NP8 ID DMT1NP8
DMT1NP8 DN MM 11253
DMT1NP8 HS Investigative
DMT1NP8 SN MM-11253; MM11253
DMT1NP8 DT Small molecular drug
DMT1NP8 PC 10389639
DMT1NP8 MW 462.7
DMT1NP8 FM C28H30O2S2
DMT1NP8 IC InChI=1S/C28H30O2S2/c1-26(2)11-12-27(3,4)24-17-22(9-10-23(24)26)28(31-13-14-32-28)21-8-7-18-15-20(25(29)30)6-5-19(18)16-21/h5-10,15-17H,11-14H2,1-4H3,(H,29,30)
DMT1NP8 CS CC1(CCC(C2=C1C=CC(=C2)C3(SCCS3)C4=CC5=C(C=C4)C=C(C=C5)C(=O)O)(C)C)C
DMT1NP8 IK DPVGXUNWCVEIGT-UHFFFAOYSA-N
DMT1NP8 IU 6-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-dithiolan-2-yl]naphthalene-2-carboxylic acid
DMT1NP8 CA CAS 345952-44-5
DMT1NP8 DE Discovery agent
DMB74MS ID DMB74MS
DMB74MS DN MM3A6S
DMB74MS HS Investigative
DMB74MS SN CHEMBL379928; MM3A6S
DMB74MS DT Small molecular drug
DMB74MS PC 10454860
DMB74MS MW 421.5
DMB74MS FM C20H23NO7S
DMB74MS IC InChI=1S/C20H23NO7S/c1-11(22)26-15-6-4-12-10-14-13-5-7-16(28-29(23,24)25)19-20(13,8-9-21(14,2)3)17(12)18(15)27-19/h4-7,13-14,16,19H,8-10H2,1-3H3/t13-,14+,16-,19-,20-/m0/s1
DMB74MS CS CC(=O)OC1=C2C3=C(C[C@@H]4[C@H]5[C@]3(CC[N+]4(C)C)[C@@H](O2)[C@H](C=C5)OS(=O)(=O)[O-])C=C1
DMB74MS IK QNHZSCHPVZZALI-BKRJIHRRSA-N
DMB74MS IU [(4R,4aR,7S,7aR,12bS)-9-acetyloxy-3,3-dimethyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DMB74MS DE Discovery agent
DM9PGQI ID DM9PGQI
DM9PGQI DN MM3B6S
DM9PGQI HS Investigative
DM9PGQI SN CHEMBL211374; MM3B6S
DM9PGQI DT Small molecular drug
DM9PGQI PC 44414811
DM9PGQI MW 483.5
DM9PGQI FM C25H25NO7S
DM9PGQI IC InChI=1S/C25H25NO7S/c1-26(2)13-12-25-17-9-11-20(33-34(28,29)30)23(25)32-22-19(10-8-16(21(22)25)14-18(17)26)31-24(27)15-6-4-3-5-7-15/h3-11,17-18,20,23H,12-14H2,1-2H3/t17-,18+,20-,23-,25-/m0/s1
DM9PGQI CS C[N+]1(CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC(=O)C6=CC=CC=C6)O[C@H]3[C@H](C=C4)OS(=O)(=O)[O-])C
DM9PGQI IK RMPWVEGPFQZBPZ-SDSLYQAOSA-N
DM9PGQI IU [(4R,4aR,7S,7aR,12bS)-9-benzoyloxy-3,3-dimethyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-yl] sulfate
DM9PGQI DE Discovery agent
DMUL4PE ID DMUL4PE
DMUL4PE DN MMB-4
DMUL4PE HS Investigative
DMUL4PE SN Acetocholinesterase reactivator (poison intoxication), SwRI; Dimethanesulfonate (poison intoxication), SwRI
DMUL4PE CP Southwest Research Institute
DMUL4PE DT Small molecular drug
DMUL4PE PC 135545784
DMUL4PE MW 418.08
DMUL4PE FM C13H14Br2N4O2
DMUL4PE IC InChI=1S/C13H12N4O2.2BrH/c18-14-9-12-1-5-16(6-2-12)11-17-7-3-13(4-8-17)10-15-19;;/h1-10H,11H2;2*1H
DMUL4PE CS C1=C[N+](=CC=C1/C=N/O)C[N+]2=CC=C(C=C2)/C=N/O.[Br-].[Br-]
DMUL4PE IK ZKQNRRLCBJUEBC-UHFFFAOYSA-N
DMUL4PE IU (NE)-N-[[1-[[4-[(E)-hydroxyiminomethyl]pyridin-1-ium-1-yl]methyl]pyridin-1-ium-4-yl]methylidene]hydroxylamine;dibromide
DMUL4PE CA CAS 2058-89-1
DMUL4PE DE Poison intoxication
DMUWVGP ID DMUWVGP
DMUWVGP DN MMDA
DMUWVGP HS Investigative
DMUWVGP SN MMDA; 5-Methoxy-3,4-methylenedioxyamphetamine; (+-)-MMDA; DEA No. 7401; 13674-05-0; 3-Methoxy-4,5-methylenedioxyphenylisopropylamine; Amphetamine, 3,4-methylenedioxy-5-methoxy; 3-Methoxy-alpha-methyl-4,5-methylenedioxyphenethylamine; BRN 1246630; Phenethylamine, alpha-methyl-3-methoxy-4,5-(methylenedioxy)-; 1,3-benzodioxole-5-ethanamine, 7-methoxy-alpha-methyl-; 3-Methoxy-4,5-methylenedioxyamphetamine; beta-Methoxy-alpha-methyl-4,5-(methylenedioxy)phenethyl amine; Phenethylamine, 3-methoxy-alpha-methyl-4,5-(methylenedio
DMUWVGP DT Small molecular drug
DMUWVGP PC 26175
DMUWVGP MW 209.24
DMUWVGP FM C11H15NO3
DMUWVGP IC InChI=1S/C11H15NO3/c1-7(12)3-8-4-9(13-2)11-10(5-8)14-6-15-11/h4-5,7H,3,6,12H2,1-2H3
DMUWVGP CS CC(CC1=CC2=C(C(=C1)OC)OCO2)N
DMUWVGP IK YQYUWUKDEVZFDB-UHFFFAOYSA-N
DMUWVGP IU 1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine
DMUWVGP CA CAS 13674-05-0
DMUWVGP DE Discovery agent
DMH1YN6 ID DMH1YN6
DMH1YN6 DN MMI-175
DMH1YN6 HS Investigative
DMH1YN6 SN MMI-175; N-[(4S,5S,7R)-8-({(S)-1-[(BENZYLAMINO)OXOMETHYL]-2-METHYLPROPYL}AMINO)-5-HYDROXY-2,7-DIMETHYL-8-OXO-OCT-4-YL]-(4S,7S)-4-ISOPROPYL-2,5,9-TRIOXO-1-OXA-3,6,10-TRIAZACYCLOHEXADECANE-7-CARBOXAMIDE; 1xs7; AC1L9MVD; SCHEMBL8270563; CHEMBL362592; BDBM16271; amide-urethane derived inhibitor 2c; DB02378; (4S,7S)-N-[(1S,2S,4R)-5-{[(1S)-1-(benzylcarbamoyl)-2-methylpropyl]amino}-2-hydroxy-4-methyl-1-(2-methylpropyl)-5-oxopentyl]-4-(1-methylethyl)-2,5,9-trioxo-1-oxa-3,6,10-triazacyclohexadecane-7-carboxamide
DMH1YN6 DT Small molecular drug
DMH1YN6 PC 449218
DMH1YN6 MW 730.9
DMH1YN6 FM C38H62N6O8
DMH1YN6 IC InChI=1S/C38H62N6O8/c1-23(2)19-28(30(45)20-26(7)34(47)43-32(24(3)4)36(49)40-22-27-15-11-10-12-16-27)41-35(48)29-21-31(46)39-17-13-8-9-14-18-52-38(51)44-33(25(5)6)37(50)42-29/h10-12,15-16,23-26,28-30,32-33,45H,8-9,13-14,17-22H2,1-7H3,(H,39,46)(H,40,49)(H,41,48)(H,42,50)(H,43,47)(H,44,51)/t26-,28+,29+,30+,32+,33+/m1/s1
DMH1YN6 CS C[C@H](C[C@@H]([C@H](CC(C)C)NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@H](C(=O)N1)C(C)C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC2=CC=CC=C2
DMH1YN6 IK QJAPFAZHNSZLJE-CWURXVSKSA-N
DMH1YN6 IU (4S,7S)-N-[(4S,5S,7R)-8-[[(2S)-1-(benzylamino)-3-methyl-1-oxobutan-2-yl]amino]-5-hydroxy-2,7-dimethyl-8-oxooctan-4-yl]-2,5,9-trioxo-4-propan-2-yl-1-oxa-3,6,10-triazacyclohexadecane-7-carboxamide
DMH1YN6 DE Discovery agent
DM38N2K ID DM38N2K
DM38N2K DN MMI270
DM38N2K HS Investigative
DM38N2K SN CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; MMI270; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1
DM38N2K DT Small molecular drug
DM38N2K PC 446504
DM38N2K MW 393.5
DM38N2K FM C18H23N3O5S
DM38N2K IC InChI=1S/C18H23N3O5S/c1-13(2)17(18(22)20-23)21(12-14-5-4-10-19-11-14)27(24,25)16-8-6-15(26-3)7-9-16/h4-11,13,17,23H,12H2,1-3H3,(H,20,22)/t17-/m1/s1
DM38N2K CS CC(C)[C@H](C(=O)NO)N(CC1=CN=CC=C1)S(=O)(=O)C2=CC=C(C=C2)OC
DM38N2K IK BSIZUMJRKYHEBR-QGZVFWFLSA-N
DM38N2K IU (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide
DM38N2K CA CAS 161314-70-1
DM38N2K DE Discovery agent
DMVCNBH ID DMVCNBH
DMVCNBH DN MMP-408
DMVCNBH HS Investigative
DMVCNBH SN MMP-118; MMP-145; MMP-12 inhibitors (COPD); MMP-12 inhibitors (COPD), Pfizer; MMP-12 inhibitors (COPD), Wyeth
DMVCNBH CP Wyeth
DMVCNBH DE Chronic obstructive pulmonary disease
DMWMZL7 ID DMWMZL7
DMWMZL7 DN MMPIP
DMWMZL7 HS Investigative
DMWMZL7 SN mmpip hydrochloride; 479077-02-6; CHEMBL593489; 6-(4-methoxyphenyl)-5-methyl-3-(pyridin-4-yl)isoxazolo[4,5-c]pyridin-4(5H)-one; GTPL3341; SCHEMBL3014586; CTK8D4056; DTXSID90433202; MolPort-006-069-049; MMPIP, > BCP23933; BDBM50305877; ZINC34042470; BN0822; AKOS015851872; API0008470; NCGC00378759-01; QC-10186; KB-274653; S14-1930; 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridyl)isoxazolo[4,5-c]pyridine-4(5H)-one; 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[ 4,5-c]pyridin-4(5H)-one
DMWMZL7 DT Small molecular drug
DMWMZL7 PC 9945530
DMWMZL7 MW 333.3
DMWMZL7 FM C19H15N3O3
DMWMZL7 IC InChI=1S/C19H15N3O3/c1-22-15(12-3-5-14(24-2)6-4-12)11-16-17(19(22)23)18(21-25-16)13-7-9-20-10-8-13/h3-11H,1-2H3
DMWMZL7 CS CN1C(=CC2=C(C1=O)C(=NO2)C3=CC=NC=C3)C4=CC=C(C=C4)OC
DMWMZL7 IK PDWYBOZNEVALOV-UHFFFAOYSA-N
DMWMZL7 IU 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-yl-[1,2]oxazolo[4,5-c]pyridin-4-one
DMWMZL7 CA CAS 479077-02-6
DMWMZL7 DE Discovery agent
DM1XY5F ID DM1XY5F
DM1XY5F DN MN-462
DM1XY5F HS Investigative
DM1XY5F SN EF-6265; CPB/TAFIa inhibitor, MediciNova; CPB/TAFIa inhibitor, Meiji Seika Kaisha/MediciNova; Carboxypeptidase B/thrombin-activated fibrinolysis inhibitor, Meiji Seika Kaisha/MediciNova
DM1XY5F CP Meiji Seika Kaisha Ltd
DM1XY5F DE Thrombosis
DMBJFH9 ID DMBJFH9
DMBJFH9 DN MNI-135
DMBJFH9 HS Investigative
DMBJFH9 SN MNI 135
DMBJFH9 DT Small molecular drug
DMBJFH9 PC 73755191
DMBJFH9 MW 401.2
DMBJFH9 FM C17H12IN3O
DMBJFH9 IC InChI=1S/C17H12IN3O/c18-13-4-5-15-16(9-13)21-17(22)7-6-14(20-15)12-3-1-2-11(8-12)10-19/h1-5,8-9H,6-7H2,(H,21,22)
DMBJFH9 CS C1CC(=O)NC2=C(C=CC(=C2)I)N=C1C3=CC=CC(=C3)C#N
DMBJFH9 IK SJYIGECDHTXFFG-UHFFFAOYSA-N
DMBJFH9 IU 3-(9-iodo-2-oxo-3,4-dihydro-1H-1,6-benzodiazocin-5-yl)benzonitrile
DMBJFH9 DE Discovery agent
DM5C9VI ID DM5C9VI
DM5C9VI DN MNI-136
DM5C9VI HS Investigative
DM5C9VI SN MNI 136
DM5C9VI DT Small molecular drug
DM5C9VI PC 73755192
DM5C9VI MW 406.3
DM5C9VI FM C21H16BrN3O
DM5C9VI IC InChI=1S/C21H16BrN3O/c22-17-4-5-19-20(13-17)24-18(6-7-21(26)25-19)16-3-1-2-15(12-16)14-8-10-23-11-9-14/h1-5,8-13H,6-7H2,(H,25,26)
DM5C9VI CS C1CC(=O)NC2=C(C=C(C=C2)Br)N=C1C3=CC=CC(=C3)C4=CC=NC=C4
DM5C9VI IK BLAQAVITPVXJJS-UHFFFAOYSA-N
DM5C9VI IU 8-bromo-5-(3-pyridin-4-ylphenyl)-3,4-dihydro-1H-1,6-benzodiazocin-2-one
DM5C9VI DE Discovery agent
DMKRI1J ID DMKRI1J
DMKRI1J DN MNI-137
DMKRI1J HS Investigative
DMKRI1J SN MNI 137
DMKRI1J DT Small molecular drug
DMKRI1J PC 73755193
DMKRI1J MW 355.19
DMKRI1J FM C16H11BrN4O
DMKRI1J IC InChI=1S/C16H11BrN4O/c17-11-1-2-14-15(8-11)21-16(22)4-3-13(20-14)10-5-6-19-12(7-10)9-18/h1-2,5-8H,3-4H2,(H,21,22)
DMKRI1J CS C1CC(=O)NC2=C(C=CC(=C2)Br)N=C1C3=CC(=NC=C3)C#N
DMKRI1J IK JNLRDCDCGXPNKH-UHFFFAOYSA-N
DMKRI1J IU 4-(9-bromo-2-oxo-3,4-dihydro-1H-1,6-benzodiazocin-5-yl)pyridine-2-carbonitrile
DMKRI1J DE Discovery agent
DMLYVQB ID DMLYVQB
DMLYVQB DN MOD-3012
DMLYVQB HS Investigative
DMLYVQB SN Factor IX-CTP (sustained release/injectable/CTP, hemophilia), PROLOR; Long-acting Factor IX (sustained release/injectable/CTP, hemophilia), PROLOR
DMLYVQB CP PROLOR Biotech Inc
DMLYVQB DE Factor IX deficiency
DMKWBNA ID DMKWBNA
DMKWBNA DN MOD-5023
DMKWBNA HS Investigative
DMKWBNA SN Factor VII-CTP; FactroVIIa-CTP; Long-acting Factor VIIa (injectable/CTP, hemophilia), PROLOR; Long-acting Factor VIIa (peptide/injectable, hemophilia), PROLOR
DMKWBNA CP PROLOR Biotech Inc
DMKWBNA DE Hemophilia
DMB5OG8 ID DMB5OG8
DMB5OG8 DN modified HA14-1 compounds (cancer)
DMB5OG8 HS Investigative
DMB5OG8 SN Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals
DMB5OG8 DE Discovery agent
DMPYBHI ID DMPYBHI
DMPYBHI DN moexiprilat
DMPYBHI HS Investigative
DMPYBHI SN 103775-14-0
DMPYBHI DT Small molecular drug
DMPYBHI PC 55331
DMPYBHI MW 470.5
DMPYBHI FM C25H30N2O7
DMPYBHI IC InChI=1S/C25H30N2O7/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32)/t15-,19-,20-/m0/s1
DMPYBHI CS C[C@@H](C(=O)N1CC2=CC(=C(C=C2C[C@H]1C(=O)O)OC)OC)N[C@@H](CCC3=CC=CC=C3)C(=O)O
DMPYBHI IK CMPAGYDKASJORH-YSSFQJQWSA-N
DMPYBHI IU (3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
DMPYBHI CA CAS 103775-14-0
DMPYBHI DE Discovery agent
DMSF8UC ID DMSF8UC
DMSF8UC DN MOL 6131
DMSF8UC HS Investigative
DMSF8UC DT Small molecular drug
DMSF8UC PC 56603779
DMSF8UC MW 752.9
DMSF8UC FM C44H48N8O4
DMSF8UC IC InChI=1S/C44H48N8O4/c1-30-50(29-36-8-4-7-34-6-2-3-9-38(34)36)44(56)52-40(43(55)48-28-33-13-11-32(27-45)12-14-33)20-19-39(51(30)52)35-21-24-49(25-22-35)42(54)10-5-23-47-41(53)26-31-15-17-37(46)18-16-31/h2-4,6-9,11-20,35H,1,5,10,21-29,45-46H2,(H,47,53)(H,48,55)
DMSF8UC CS C=C1N(C(=O)N2N1C(=CC=C2C(=O)NCC3=CC=C(C=C3)CN)C4CCN(CC4)C(=O)CCCNC(=O)CC5=CC=C(C=C5)N)CC6=CC=CC7=CC=CC=C76
DMSF8UC IK VVCVJEWENXURHU-UHFFFAOYSA-N
DMSF8UC IU N-[[4-(aminomethyl)phenyl]methyl]-8-[1-[4-[[2-(4-aminophenyl)acetyl]amino]butanoyl]piperidin-4-yl]-1-methylidene-2-(naphthalen-1-ylmethyl)-3-oxo-[1,2,4]triazolo[1,2-a]pyridazine-5-carboxamide
DMSF8UC DE Discovery agent
DM0OWTS ID DM0OWTS
DM0OWTS DN MOLASSAMIDE
DM0OWTS HS Investigative
DM0OWTS SN molassamide; CHEMBL1077010
DM0OWTS DT Small molecular drug
DM0OWTS PC 45379965
DM0OWTS MW 963.1
DM0OWTS FM C48H66N8O13
DM0OWTS IC InChI=1S/C48H66N8O13/c1-9-14-36(59)49-26(5)41(61)53-39(27(6)57)44(64)54-40-28(7)69-48(68)38(25(3)4)52-43(63)34(23-30-17-19-31(58)20-18-30)55(8)47(67)35(24-29-15-12-11-13-16-29)56-37(60)22-21-33(46(56)66)51-42(62)32(10-2)50-45(40)65/h10-13,15-20,25-28,33-35,37-40,57-58,60H,9,14,21-24H2,1-8H3,(H,49,59)(H,50,65)(H,51,62)(H,52,63)(H,53,61)(H,54,64)/b32-10-/t26-,27+,28+,33-,34-,35-,37+,38-,39-,40-/m0/s1
DM0OWTS CS CCCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H]1[C@H](OC(=O)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](N2[C@@H](CC[C@@H](C2=O)NC(=O)/C(=C/C)/NC1=O)O)CC3=CC=CC=C3)C)CC4=CC=C(C=C4)O)C(C)C)C
DM0OWTS IK KXSGCAPYMUMVSH-VFYPFKDGSA-N
DM0OWTS IU (2S,3R)-N-[(2S,5S,8S,11R,12S,15Z,18S,21R)-2-benzyl-15-ethylidene-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]-2-[[(2S)-2-(butanoylamino)propanoyl]amino]-3-hydroxybutanamide
DM0OWTS DE Discovery agent
DMZ6H1X ID DMZ6H1X
DMZ6H1X DN Molecule 11
DMZ6H1X HS Investigative
DMZ6H1X SN 38293-71-9; AC1L1YVB; CTK4H9638; 2-CHLOROACETOPHENONE 2,4-DINITROPHENYLHYDRAZONE
DMZ6H1X DT Small molecular drug
DMZ6H1X PC 38003
DMZ6H1X MW 334.71
DMZ6H1X FM C14H11ClN4O4
DMZ6H1X IC InChI=1S/C14H11ClN4O4/c15-9-13(10-4-2-1-3-5-10)17-16-12-7-6-11(18(20)21)8-14(12)19(22)23/h1-8,16H,9H2
DMZ6H1X CS C1=CC=C(C=C1)C(=NNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])CCl
DMZ6H1X IK HNLCJXKVYWWDTN-UHFFFAOYSA-N
DMZ6H1X IU N-[(2-chloro-1-phenylethylidene)amino]-2,4-dinitroaniline
DMZ6H1X DE Discovery agent
DMA7T0N ID DMA7T0N
DMA7T0N DN Molecule 21
DMA7T0N HS Investigative
DMA7T0N SN EP3 antagonists (pain/ uterine disease), Ono Pharmaceutical; Prostaglandin-E receptor 3 antagonists (pain/ uterine disease); Prostaglandin-E receptor 3 antagonists (pain/ uterine disease), Ono Pharmaceutical
DMA7T0N CP Ono Pharmaceutical Co Ltd
DMA7T0N DE Pain
DM4OLAZ ID DM4OLAZ
DM4OLAZ DN MOLEPHANTIN
DM4OLAZ HS Investigative
DM4OLAZ SN Molephantin; BRN 1329450; 2-Propenoic acid, 2-methyl-, 2,3,3a,4,5,8,11,11a-octahydro-11-hydroxy-6,10-dimethyl-3-methylene-2,8-dioxocyclodeca(b)furan-4-yl ester, (3aR-(3aR*,4S*,6E,9Z,11S*,11aS*))-; AC1O5UKZ; LS-123706; 5-18-04-00355 (Beilstein Handbook Reference); [(3aR,4S,6Z,9Z,11S,11aS)-11-hydroxy-6,10-dimethyl-3-methylidene-2,8-dioxo-4,5,11,11a-tetrahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DM4OLAZ DT Small molecular drug
DM4OLAZ PC 5281484
DM4OLAZ MW 346.4
DM4OLAZ FM C19H22O6
DM4OLAZ IC InChI=1S/C19H22O6/c1-9(2)18(22)24-14-7-10(3)6-13(20)8-11(4)16(21)17-15(14)12(5)19(23)25-17/h6,8,14-17,21H,1,5,7H2,2-4H3/b10-6+,11-8-/t14-,15+,16-,17-/m0/s1
DM4OLAZ CS C/C/1=C\\C(=O)/C=C(\\[C@@H]([C@@H]2[C@@H]([C@H](C1)OC(=O)C(=C)C)C(=C)C(=O)O2)O)/C
DM4OLAZ IK LXINRHXYVUTAMQ-UKKSPWLWSA-N
DM4OLAZ IU [(3aR,4S,6E,9Z,11S,11aS)-11-hydroxy-6,10-dimethyl-3-methylidene-2,8-dioxo-4,5,11,11a-tetrahydro-3aH-cyclodeca[b]furan-4-yl] 2-methylprop-2-enoate
DM4OLAZ CB CHEBI:6962
DM4OLAZ DE Discovery agent
DMGNX6M ID DMGNX6M
DMGNX6M DN MOLEPHANTININ
DMGNX6M HS Investigative
DMGNX6M SN Molephantinin; MLS000728554; CHEMBL1992486
DMGNX6M DT Small molecular drug
DMGNX6M PC 5281485
DMGNX6M MW 360.4
DMGNX6M FM C20H24O6
DMGNX6M IC InChI=1S/C20H24O6/c1-6-11(3)19(23)25-15-8-10(2)7-14(21)9-12(4)17(22)18-16(15)13(5)20(24)26-18/h6-7,9,15-18,22H,5,8H2,1-4H3/b10-7+,11-6+,12-9-/t15-,16+,17-,18-/m0/s1
DMGNX6M CS C/C=C(\\C)/C(=O)O[C@H]1C/C(=C/C(=O)/C=C(\\[C@@H]([C@@H]2[C@@H]1C(=C)C(=O)O2)O)/C)/C
DMGNX6M IK VUURQISRHJCAJY-CXRMMEALSA-N
DMGNX6M IU [(3aR,4S,6E,9Z,11S,11aS)-11-hydroxy-6,10-dimethyl-3-methylidene-2,8-dioxo-4,5,11,11a-tetrahydro-3aH-cyclodeca[b]furan-4-yl] (E)-2-methylbut-2-enoate
DMGNX6M CB CHEBI:6963
DMGNX6M DE Discovery agent
DMLSEJN ID DMLSEJN
DMLSEJN DN Monastrol
DMLSEJN HS Investigative
DMLSEJN SN monastrol; 329689-23-8; 254753-54-3; ETHYL 4-(3-HYDROXYPHENYL)-6-METHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXYLATE; 4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester; CHEBI:75382; ( inverted exclamation markA)-Monastrol; SR-01000357662; AC1MGLGQ; Probes2_000257; Probes2_000376; Probes1_000312; Probes1_000042; Probes1_000001; Oprea1_487786; Lopac0_000821; KBioSS_000613; CBDivE_015834; KBioGR_000613; BSPBio_001273; MLS006011746; SCHEMBL3168349; KBio3_001085; KBio2_000613
DMLSEJN DT Small molecular drug
DMLSEJN PC 2987927
DMLSEJN MW 292.36
DMLSEJN FM C14H16N2O3S
DMLSEJN IC InChI=1S/C14H16N2O3S/c1-3-19-13(18)11-8(2)15-14(20)16-12(11)9-5-4-6-10(17)7-9/h4-7,12,17H,3H2,1-2H3,(H2,15,16,20)
DMLSEJN CS CCOC(=O)C1=C(NC(=S)NC1C2=CC(=CC=C2)O)C
DMLSEJN IK LOBCDGHHHHGHFA-UHFFFAOYSA-N
DMLSEJN IU ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxylate
DMLSEJN CA CAS 329689-23-8
DMLSEJN CB CHEBI:75382
DMLSEJN DE Discovery agent
DMNWCPB ID DMNWCPB
DMNWCPB DN Monocarboxylic acids
DMNWCPB HS Investigative
DM31YGM ID DM31YGM
DM31YGM DN Monoctanoin component C
DM31YGM HS Investigative
DM31YGM SN DICAPRYLIN; MONOCTANOIN COMPONENT C; 1069-87-0; 3-Hydroxypropane-1,2-diyl dioctanoate; 36354-80-0; diC8; Octanoic acid, 1-(hydroxymethyl)-1,2-ethanediyl ester; 1,2-Dicapryloylglycerol; 1,2-Dioctanoyl-rac-glycerol; 1,2-Dioctanoin; Octanoin, 1,2-di-; Glycerol 1,2-dicaprylate; AC1Q5YA4; SCHEMBL825310; CHEMBL24609; AC1L1B82; CTK4A4899; ZQBULZYTDGUSSK-UHFFFAOYSA-N; HSCI1_000084; IN1353; AKOS027383004; ACM36354800; (3-hydroxy-2-octanoyloxypropyl) octanoate; FT-0748382; 1-hydroxy-3-(octanoyloxy)propan-2-yl octa
DM31YGM DT Small molecular drug
DM31YGM PC 1323
DM31YGM MW 344.5
DM31YGM FM C19H36O5
DM31YGM IC InChI=1S/C19H36O5/c1-3-5-7-9-11-13-18(21)23-16-17(15-20)24-19(22)14-12-10-8-6-4-2/h17,20H,3-16H2,1-2H3
DM31YGM CS CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC
DM31YGM IK ZQBULZYTDGUSSK-UHFFFAOYSA-N
DM31YGM IU (3-hydroxy-2-octanoyloxypropyl) octanoate
DM31YGM CA CAS 1069-87-0
DM31YGM DE Discovery agent
DM59CR0 ID DM59CR0
DM59CR0 DN MONODICTYOCHROMONE B
DM59CR0 HS Investigative
DM59CR0 SN Monodictyochromone B; CHEMBL576579; CHEBI:66397; (2S,2'R)-5,5'-dihydroxy-2-[(2R,3R)-3-hydroxy-5-oxotetrahydrofuran-2-yl]-2,2',7-trimethyl-2'-[(2R,3S)-3-methyl-5-oxotetrahydrofuran-2-yl]-2,2',3,3'-tetrahydro-4H,4'H-6,6'-bichromene-4,4'-dione; Monodictyochromes B
DM59CR0 DT Small molecular drug
DM59CR0 PC 25256842
DM59CR0 MW 566.6
DM59CR0 FM C30H30O11
DM59CR0 IC InChI=1S/C30H30O11/c1-12-7-19-24(17(33)11-30(4,41-19)28-15(31)9-21(35)39-28)26(37)22(12)14-5-6-18-23(25(14)36)16(32)10-29(3,40-18)27-13(2)8-20(34)38-27/h5-7,13,15,27-28,31,36-37H,8-11H2,1-4H3/t13-,15+,27+,28+,29+,30-/m0/s1
DM59CR0 CS C[C@H]1CC(=O)O[C@H]1[C@]2(CC(=O)C3=C(O2)C=CC(=C3O)C4=C(C5=C(C=C4C)O[C@](CC5=O)(C)[C@H]6[C@@H](CC(=O)O6)O)O)C
DM59CR0 IK YSURVZRGQKOUAG-QXBVHLSASA-N
DM59CR0 IU (2S)-5-hydroxy-6-[(2R)-5-hydroxy-2-methyl-2-[(2R,3S)-3-methyl-5-oxooxolan-2-yl]-4-oxo-3H-chromen-6-yl]-2-[(2R,3R)-3-hydroxy-5-oxooxolan-2-yl]-2,7-dimethyl-3H-chromen-4-one
DM59CR0 CB CHEBI:66397
DM59CR0 DE Discovery agent
DMNJXHF ID DMNJXHF
DMNJXHF DN Monoisopropyl Ester Phosphonic Acid Group
DMNJXHF HS Investigative
DMNJXHF SN AC1NAQP0; MONOISOPROPYL ESTER PHOSPHONIC ACID GROUP; propan-2-yloxyphosphinic acid; SCHEMBL333601; Phosphonic acid isopropyl ester; AC1O4B47; ZINC5381386
DMNJXHF DT Small molecular drug
DMNJXHF PC 6383950
DMNJXHF MW 123.07
DMNJXHF FM C3H8O3P+
DMNJXHF IC InChI=1S/C3H7O3P/c1-3(2)6-7(4)5/h3H,1-2H3/p+1
DMNJXHF CS CC(C)O[P+](=O)O
DMNJXHF IK XZSFYYSNTQXWBM-UHFFFAOYSA-O
DMNJXHF IU hydroxy-oxo-propan-2-yloxyphosphanium
DMNJXHF DE Discovery agent
DM0OFT6 ID DM0OFT6
DM0OFT6 DN Monoisopropylphosphorylserine
DM0OFT6 HS Investigative
DM0OFT6 DT Small molecular drug
DM0OFT6 PC 46936220
DM0OFT6 MW 227.15
DM0OFT6 FM C6H14NO6P
DM0OFT6 IC InChI=1S/C6H14NO6P/c1-4(2)13-14(10,11)12-3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)(H,10,11)/t5-/m1/s1
DM0OFT6 CS CC(C)OP(=O)(O)OC[C@H](C(=O)O)N
DM0OFT6 IK DALHHSOTZKMXMV-RXMQYKEDSA-N
DM0OFT6 IU (2R)-2-amino-3-[hydroxy(propan-2-yloxy)phosphoryl]oxypropanoic acid
DM0OFT6 DE Discovery agent
DMU4JWM ID DMU4JWM
DMU4JWM DN monomethylfumarate
DMU4JWM HS Investigative
DMU4JWM SN Monomethyl fumarate; 2756-87-8; 4-methoxy-4-oxobut-2-enoic acid; Methyl hydrogen fumarate; mono-Methyl fumarate; (E)-4-methoxy-4-oxobut-2-enoic acid; Fumaric acid monomethyl ester; UNII-45IUB1PX8R; 45IUB1PX8R; CHEMBL589586; NKHAVTQWNUWKEO-NSCUHMNNSA-N; AK114632; (2E)-3-(methoxycarbonyl)prop-2-enoic acid; (E)-4-methoxy-4-oxobut-2-enoic acid(98%); 44836-34-2; EINECS 220-412-6; Fumaric acid 1-methyl; AC1NSSIL; Monomethyl fumarate [USAN]; mono-Methyl fumarate, 97%; SCHEMBL60132; SCHEMBL60133; GTPL5786; AC1Q5T88; MolPort-002-472-973
DMU4JWM DT Small molecular drug
DMU4JWM PC 21721168
DMU4JWM MW 129.09
DMU4JWM FM C5H5O4-
DMU4JWM IC InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/p-1/b3-2+
DMU4JWM CS COC(=O)/C=C/C(=O)[O-]
DMU4JWM IK NKHAVTQWNUWKEO-NSCUHMNNSA-M
DMU4JWM IU (E)-4-methoxy-4-oxobut-2-enoate
DMU4JWM DE Discovery agent
DM4QO9G ID DM4QO9G
DM4QO9G DN Mononitrophenol
DM4QO9G HS Investigative
DM4QO9G SN Paranitrofenol; Paranitrofenol [Dutch]; Paranitrofenolo; Paranitrofenolo [Italian]; Paranitrophenol; Paranitrophenol [French,German]; Phenol, 4-nitro-; 4-Nitrophenol; Niphen; Phenol, p-nitro-; RCRA waste no. U170; RCRA waste number U170; UN1663; p-Hydroxynitrobenzene; p-Nitrofenol; p-Nitrofenol [Czech]; p-nitrophenol; para-nitrophenol; 1-Hydroxy-4-nitrobenzene; 100-02-7; 4-Hydroxynitrobenzene; 4-Nitrofenol; 4-Nitrofenol [Dutch]; 4-nitro-phenol; Caswell No. 603; NCI-C55992; NSC 1317; PNP; UNII-Y92ZL45L4R
DM4QO9G PC 980
DM4QO9G MW 139.11
DM4QO9G FM C6H5NO3
DM4QO9G IC BTJIUGUIPKRLHP-UHFFFAOYSA-N
DM4QO9G CS C1=CC(=CC=C1[N+](=O)[O-])O
DM4QO9G IK 1S/C6H5NO3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8H
DM4QO9G IU 4-nitrophenol
DM4QO9G CA CAS 100-02-7
DM4QO9G CB CHEBI:16836
DM4QO9G DE Discovery agent
DMENSOZ ID DMENSOZ
DMENSOZ DN Monothioglycerol
DMENSOZ HS Investigative
DMENSOZ SN 3-Mercapto-1,2-propanediol; Monothioglycerol; 1-Thioglycerol; 96-27-5; THIOGLYCEROL; 3-Mercaptopropane-1,2-diol; Thioglycerine; Thioglycerin; Thiovanol; alpha-Thioglycerol; Glycerol-1-thiol; 1-Monothioglycerol; 1-Mercaptoglycerol; Monothioglycerin; 2,3-Dihydroxypropanethiol; alpha-Thiolglycerol; 3-Sulfanylpropane-1,2-diol; 1-Mercapto-2,3-propanediol; Glycerol, 1-thio-; alpha-Monothioglycerol; 1-Thio-2,3-propanediol; USAF CB-37; USAF B-40; 3-Mercapto-1,2-propanediole; 1,2-Propanediol, 3-mercapto-; NSC 5370; .alpha.-Thioglycerol
DMENSOZ DT Small molecular drug
DMENSOZ PC 7291
DMENSOZ MW 108.16
DMENSOZ FM C3H8O2S
DMENSOZ IC InChI=1S/C3H8O2S/c4-1-3(5)2-6/h3-6H,1-2H2
DMENSOZ CS C(C(CS)O)O
DMENSOZ IK PJUIMOJAAPLTRJ-UHFFFAOYSA-N
DMENSOZ IU 3-sulfanylpropane-1,2-diol
DMENSOZ CA CAS 96-27-5
DMENSOZ CB CHEBI:74537
DMENSOZ DE Discovery agent
DMWR0J1 ID DMWR0J1
DMWR0J1 DN MORACHALCONE A
DMWR0J1 HS Investigative
DMWR0J1 SN MORACHALCONE A; 76472-88-3; CHEMBL465880; SCHEMBL6818973; MolPort-035-705-759; BDBM50251013; LMPK12120119; ZINC14762498; W1241; 2,4,2'',4''-tetrahydroxy-3''-prenylchalcone; 2,2',4,4'-Tetrahydroxy-3'-(3-methyl-2-butenyl)chalcone
DMWR0J1 DT Small molecular drug
DMWR0J1 PC 9862769
DMWR0J1 MW 340.4
DMWR0J1 FM C20H20O5
DMWR0J1 IC InChI=1S/C20H20O5/c1-12(2)3-7-15-18(23)10-8-16(20(15)25)17(22)9-5-13-4-6-14(21)11-19(13)24/h3-6,8-11,21,23-25H,7H2,1-2H3/b9-5+
DMWR0J1 CS CC(=CCC1=C(C=CC(=C1O)C(=O)/C=C/C2=C(C=C(C=C2)O)O)O)C
DMWR0J1 IK NXBYIJSAISXPKJ-WEVVVXLNSA-N
DMWR0J1 IU (E)-1-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-3-(2,4-dihydroxyphenyl)prop-2-en-1-one
DMWR0J1 CA CAS 76472-88-3
DMWR0J1 DE Discovery agent
DM2OGZ5 ID DM2OGZ5
DM2OGZ5 DN Morin
DM2OGZ5 HS Investigative
DM2OGZ5 SN morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]
DM2OGZ5 DT Small molecular drug
DM2OGZ5 PC 5281670
DM2OGZ5 MW 302.23
DM2OGZ5 FM C15H10O7
DM2OGZ5 IC InChI=1S/C15H10O7/c16-6-1-2-8(9(18)3-6)15-14(21)13(20)12-10(19)4-7(17)5-11(12)22-15/h1-5,16-19,21H
DM2OGZ5 CS C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DM2OGZ5 IK YXOLAZRVSSWPPT-UHFFFAOYSA-N
DM2OGZ5 IU 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
DM2OGZ5 CA CAS 480-16-0
DM2OGZ5 CB CHEBI:75092
DM2OGZ5 DE Discovery agent
DMB91UL ID DMB91UL
DMB91UL DN morphanthridine
DMB91UL HS Investigative
DMB91UL SN MORPHANTHRIDINE; 11H-Dibenz[b,e]azepine; 11H-dibenzo[b,e]azepine; 256-86-0; CHEMBL1085101; Homoacridan; 11H-benzo[c][1]benzazepine; SCHEMBL1150250; GTPL6473; CTK1A3708; DTXSID00446803; IDWNSAXOQLJYOF-UHFFFAOYSA-N
DMB91UL DT Small molecular drug
DMB91UL PC 10878016
DMB91UL MW 193.24
DMB91UL FM C14H11N
DMB91UL IC InChI=1S/C14H11N/c1-2-7-13-10-15-14-8-4-3-6-12(14)9-11(13)5-1/h1-8,10H,9H2
DMB91UL CS C1C2=CC=CC=C2C=NC3=CC=CC=C31
DMB91UL IK IDWNSAXOQLJYOF-UHFFFAOYSA-N
DMB91UL IU 11H-benzo[c][1]benzazepine
DMB91UL CA CAS 256-86-0
DMB91UL DE Discovery agent
DM9A1RY ID DM9A1RY
DM9A1RY DN MORPHICEPTIN
DM9A1RY HS Investigative
DM9A1RY SN Morphiceptin; Deproceptin; Tyr-pro-phe-pro amide; Tyr-pro-phe-D-pro-NH2; beta-Casomorphine(1-4) amide; NH(4)-Tyr-pro-phe-pro-conh(2); Tyr-Pro-Phe-Pro-NH2; Tyrosyl-prolyl-phenylalanyl-D-prolinamide; UNII-97TZA8ANPC; H-Tyr-Pro-Phe-Pro-NH2; L-Tyrosyl-L-prolyl-L-phenylalanyl-L-prolinamide; 74135-04-9; b-Casomorphin-4-amide; 97TZA8ANPC; CHEMBL362991; L-Prolinamide, L-tyrosyl-L-prolyl-L-phenylalanyl-
DM9A1RY DT Small molecular drug
DM9A1RY PC 119303
DM9A1RY MW 521.6
DM9A1RY FM C28H35N5O5
DM9A1RY IC InChI=1S/C28H35N5O5/c29-21(16-19-10-12-20(34)13-11-19)27(37)33-15-5-9-24(33)26(36)31-22(17-18-6-2-1-3-7-18)28(38)32-14-4-8-23(32)25(30)35/h1-3,6-7,10-13,21-24,34H,4-5,8-9,14-17,29H2,(H2,30,35)(H,31,36)/t21-,22-,23-,24-/m0/s1
DM9A1RY CS C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N4CCC[C@H]4C(=O)N
DM9A1RY IK LSQXZIUREIDSHZ-ZJZGAYNASA-N
DM9A1RY IU (2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
DM9A1RY CA CAS 74135-04-9
DM9A1RY DE Discovery agent
DMTHFSE ID DMTHFSE
DMTHFSE DN Morphinan Cyclic Imine analogue
DMTHFSE HS Investigative
DMTHFSE DE Discovery agent
DM9LQIA ID DM9LQIA
DM9LQIA DN MORPHINONE
DM9LQIA HS Investigative
DM9LQIA SN Morphinone; 467-02-7; UNII-28MBK63MAW; EINECS 207-384-0; BRN 0042464; 28MBK63MAW; Didehydro-4,5-alpha-epoxy-3-hydroxy-17-methylmorphinan-6-one; CHEBI:16315; (5alpha)-7,8-Didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-one; Morphinan-6-one, 7,8-didehydro-4,5-epoxy-3-hydroxy-17-methyl-, (5-alpha)-; SCHEMBL427946; CHEMBL255467; CTK1D7902; DTXSID50196907; ZINC4095712; AKOS030240636; LS-92113; C01735; 3-hydroxy-17-methyl-7,8-didehydro-4,5-epoxy-5alpha-morphinan-6-one
DM9LQIA DT Small molecular drug
DM9LQIA PC 5459823
DM9LQIA MW 283.32
DM9LQIA FM C17H17NO3
DM9LQIA IC InChI=1S/C17H17NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,16,19H,6-8H2,1H3/t10-,11+,16-,17-/m0/s1
DM9LQIA CS CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)C=C4
DM9LQIA IK PFBSOANQDDTNGJ-YNHQPCIGSA-N
DM9LQIA IU (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DM9LQIA CA CAS 467-02-7
DM9LQIA CB CHEBI:16315
DM9LQIA DE Discovery agent
DM05L3S ID DM05L3S
DM05L3S DN Morpholino(1'H-phenothiazin-1'-yl)methanone
DM05L3S HS Investigative
DM05L3S SN CHEMBL590511; 10-(4-morpholinylcarbonyl)-10H-phenothiazine; Morpholin-4-yl-phenothiazin-10-yl-methanone; AC1LE3IO; morpholin-4-yl(phenothiazin-10-yl)methanone; Oprea1_836979; MLS000557099; ARONIS009572; ZINC91251; MolPort-019-748-219; MolPort-001-510-993; HMS2479C10; BDBM50308416; STK144997; AKOS000498790; MCULE-6825355538; KS-0000415F; BAS 04087810; SMR000178119; morpholin-4-yl phenothiazin-10-yl ketone; BB0286549; ST45046313; Morpholino(1''H-phenothiazin-1''-yl)methanone; AN-329/40200546
DM05L3S DT Small molecular drug
DM05L3S PC 705776
DM05L3S MW 312.4
DM05L3S FM C17H16N2O2S
DM05L3S IC InChI=1S/C17H16N2O2S/c20-17(18-9-11-21-12-10-18)19-13-5-1-3-7-15(13)22-16-8-4-2-6-14(16)19/h1-8H,9-12H2
DM05L3S CS C1COCCN1C(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM05L3S IK PWLGMYUBQYNSQV-UHFFFAOYSA-N
DM05L3S IU morpholin-4-yl(phenothiazin-10-yl)methanone
DM05L3S DE Discovery agent
DMV5T1I ID DMV5T1I
DMV5T1I DN MP-529
DMV5T1I HS Investigative
DMV5T1I SN SGI-1097; SGI-1215; SGI-498; SGI-503; Oral aurora kinase inhibitor (cancer), Montigen
DMV5T1I CP Montigen Pharmaceuticals Inc
DMV5T1I DE Solid tumour/cancer
DMONDP1 ID DMONDP1
DMONDP1 DN MPC-MECA
DMONDP1 HS Investigative
DMONDP1 SN CHEMBL2113610; GTPL460; BNXGNSTUSRFBCI-KSVNGYGVSA-N; BDBM50453540; Adenosine, N(6)-4-methoxybenzyl-4'-N-ethylcarbamoyl-4'-dehydroxymethyl-; 5'-Ethylamino-N-(4-methoxybenzyl)-5'-oxo-5'-deoxyadenosine
DMONDP1 DT Small molecular drug
DMONDP1 PC 10432715
DMONDP1 MW 428.4
DMONDP1 FM C20H24N6O5
DMONDP1 IC InChI=1S/C20H24N6O5/c1-3-21-19(29)16-14(27)15(28)20(31-16)26-10-25-13-17(23-9-24-18(13)26)22-8-11-4-6-12(30-2)7-5-11/h4-7,9-10,14-16,20,27-28H,3,8H2,1-2H3,(H,21,29)(H,22,23,24)/t14-,15+,16-,20+/m0/s1
DMONDP1 CS CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC=C(C=C4)OC)O)O
DMONDP1 IK BNXGNSTUSRFBCI-KSVNGYGVSA-N
DMONDP1 IU (2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-[6-[(4-methoxyphenyl)methylamino]purin-9-yl]oxolane-2-carboxamide
DMONDP1 DE Discovery agent
DMYX31S ID DMYX31S
DMYX31S DN MPDT
DMYX31S HS Investigative
DMYX31S SN BGC 20-761; 17375-63-2; UNII-6G5F6ESV5I; 6G5F6ESV5I; CHEMBL7318; BGC-20-761; 5-Methoxy-N,N-dimethyl-2-phenyl-1H-indole-3-ethanamine; 2-(5-methoxy-2-phenyl-1H-indol-3-yl)-N,N-dimethylethanamine; MPDT; AC1OCFJ3; GTPL71; SCHEMBL5763578; N,N-Dimethyl-2-(5-methoxy-2-phenylindol-3-yl)ethylamine; Indole, 3-(2-(dimethylamino)ethyl)-5-methoxy-2-phenyl-; 1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-2-phenyl-; MolPort-023-276-754; PDSP2_001402; BDBM50085970; PDSP1_001418; ZINC13805807; AKOS024457555; NCGC00370860-01
DMYX31S DT Small molecular drug
DMYX31S PC 6918515
DMYX31S MW 294.4
DMYX31S FM C19H22N2O
DMYX31S IC InChI=1S/C19H22N2O/c1-21(2)12-11-16-17-13-15(22-3)9-10-18(17)20-19(16)14-7-5-4-6-8-14/h4-10,13,20H,11-12H2,1-3H3
DMYX31S CS CN(C)CCC1=C(NC2=C1C=C(C=C2)OC)C3=CC=CC=C3
DMYX31S IK VSGPGYWZVPDDSK-UHFFFAOYSA-N
DMYX31S IU 2-(5-methoxy-2-phenyl-1H-indol-3-yl)-N,N-dimethylethanamine
DMYX31S CA CAS 17375-63-2
DMYX31S DE Discovery agent
DMJRK47 ID DMJRK47
DMJRK47 DN M-Phenoxybenzoic Acid For Cis-Isomer
DMJRK47 HS Investigative
DMJRK47 SN 3-Phenoxybenzoic acid; 3739-38-6; m-Phenoxybenzoic acid; Benzoic acid, 3-phenoxy-; 3-Carboxydiphenyl ether; UNII-69DC2655VH; BENZOIC ACID, m-PHENOXY-; 3-Phenoxy-benzoic acid; EINECS 223-121-2; CHEMBL663; BRN 2105574; M-PHENOXYBENZOIC ACID FOR CIS-ISOMER; CHEBI:72631; NXTDJHZGHOFSQG-UHFFFAOYSA-N; 69DC2655VH; VJJ; 3-Phenoxybenzoicacid; m-phenoxy benzoic acid; m-carboxydiphenyl ether; PubChem14424; 3-phenoxy benzoic acid; meta-phenoxybenzoic acid; ACMC-1CJQX; Enamine_000396; AC1L2EBV; Benzoic acid,3-phenoxy-; 3-PhOC6H4COOH
DMJRK47 DT Small molecular drug
DMJRK47 PC 19539
DMJRK47 MW 214.22
DMJRK47 FM C13H10O3
DMJRK47 IC InChI=1S/C13H10O3/c14-13(15)10-5-4-8-12(9-10)16-11-6-2-1-3-7-11/h1-9H,(H,14,15)
DMJRK47 CS C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)O
DMJRK47 IK NXTDJHZGHOFSQG-UHFFFAOYSA-N
DMJRK47 IU 3-phenoxybenzoic acid
DMJRK47 CA CAS 3739-38-6
DMJRK47 CB CHEBI:72631
DMJRK47 DE Discovery agent
DMJHQ9T ID DMJHQ9T
DMJHQ9T DN MPPG
DMJHQ9T HS Investigative
DMJHQ9T SN MPPG; 169209-65-8; 2-amino-2-(4-phosphonophenyl)propanoic acid; CHEMBL86508; AC1N11KO; GTPL1415; SCHEMBL12648709; CTK8F0596; DTXSID80398316; MolPort-003-983-629; MPPG, >=97% (NMR), solid; BDBM50089910; MFCD00672651; BN0344; AKOS024458668; API0007557; (RS)- -Methyl-4-phosphonophenylglycine; NCGC00024826-02; (RS)-; A-Methyl-4-phosphonophenylglycine; RT-013949; 2-Amino-2-(4-phosphono-phenyl)-propionic acid; L000410; SR-01000597457; J-010517; SR-01000597457-1; 2-Amino-2-(4-phosphono-phenyl)-propionic acid(RS-MPPG)
DMJHQ9T DT Small molecular drug
DMJHQ9T PC 3972752
DMJHQ9T MW 245.17
DMJHQ9T FM C9H12NO5P
DMJHQ9T IC InChI=1S/C9H12NO5P/c1-9(10,8(11)12)6-2-4-7(5-3-6)16(13,14)15/h2-5H,10H2,1H3,(H,11,12)(H2,13,14,15)
DMJHQ9T CS CC(C1=CC=C(C=C1)P(=O)(O)O)(C(=O)O)N
DMJHQ9T IK PAONCRJPUQXPRW-UHFFFAOYSA-N
DMJHQ9T IU 2-amino-2-(4-phosphonophenyl)propanoic acid
DMJHQ9T CA CAS 169209-65-8
DMJHQ9T DE Discovery agent
DMFKG7C ID DMFKG7C
DMFKG7C DN MP-RM-1
DMFKG7C HS Investigative
DMFKG7C SN Erbb-3 receptor-targeted mouse monoclonal antibody (cancer), Mediapharma
DMFKG7C CP MediaPharma Srl
DMFKG7C DT Antibody
DMFKG7C DE Solid tumour/cancer
DMWUK9G ID DMWUK9G
DMWUK9G DN MPrP
DMWUK9G HS Investigative
DMWUK9G DT Small molecular drug
DMWUK9G PC 135857091
DMWUK9G MW 467.6
DMWUK9G FM C30H33N3O2
DMWUK9G IC InChI=1S/C30H33N3O2/c1-22-29(24-11-15-27(34)16-12-24)31-33(26-13-17-28(35)18-14-26)30(22)25-9-7-23(8-10-25)6-5-21-32-19-3-2-4-20-32/h7-18,34-35H,2-6,19-21H2,1H3
DMWUK9G CS CC1=C(N(N=C1C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)CCCN5CCCCC5
DMWUK9G IK XXRGLZUCVWZDBP-UHFFFAOYSA-N
DMWUK9G IU 4-[1-(4-hydroxyphenyl)-4-methyl-5-[4-(3-piperidin-1-ylpropyl)phenyl]pyrazol-3-yl]phenol
DMWUK9G DE Discovery agent
DMQ357C ID DMQ357C
DMQ357C DN MQ1
DMQ357C HS Investigative
DMQ357C SN MQ-1; compound (R)-10a
DMQ357C DT Small molecular drug
DMQ357C PC 57521365
DMQ357C MW 429.6
DMQ357C FM C27H31N3O2
DMQ357C IC InChI=1S/C27H31N3O2/c1-18-25(29-27(31)21-7-10-24(11-8-21)32-17-20-5-6-20)12-9-22-15-23(16-28-26(18)22)19(2)30-13-3-4-14-30/h7-12,15-16,19-20H,3-6,13-14,17H2,1-2H3,(H,29,31)/t19-/m1/s1
DMQ357C CS CC1=C(C=CC2=CC(=CN=C12)[C@@H](C)N3CCCC3)NC(=O)C4=CC=C(C=C4)OCC5CC5
DMQ357C IK DFWKNBVJNXPUBW-LJQANCHMSA-N
DMQ357C IU 4-(cyclopropylmethoxy)-N-[8-methyl-3-[(1R)-1-pyrrolidin-1-ylethyl]quinolin-7-yl]benzamide
DMQ357C DE Discovery agent
DMS7FC6 ID DMS7FC6
DMS7FC6 DN MR-1029
DMS7FC6 HS Investigative
DMS7FC6 DT Small molecular drug
DMS7FC6 PC 71716573
DMS7FC6 MW 297.4
DMS7FC6 FM C19H23NO2
DMS7FC6 IC InChI=1S/C19H23NO2/c1-13-18-10-14-5-6-15(21)11-17(14)19(13,2)7-8-20(18)12-16-4-3-9-22-16/h3-6,9,11,13,18,21H,7-8,10,12H2,1-2H3/t13-,18+,19+/m0/s1
DMS7FC6 CS C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC4=CC=CO4)C)C=C(C=C3)O
DMS7FC6 IK ICHXZERPLTYYPM-MJXNMMHHSA-N
DMS7FC6 IU (1R,9R,13R)-10-(furan-2-ylmethyl)-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMS7FC6 DE Discovery agent
DM5WMXJ ID DM5WMXJ
DM5WMXJ DN MR-1526
DM5WMXJ HS Investigative
DM5WMXJ DT Small molecular drug
DM5WMXJ PC 73352838
DM5WMXJ MW 315.4
DM5WMXJ FM C19H25NO3
DM5WMXJ IC InChI=1S/C19H25NO3/c1-12-17-9-13-3-4-14(21)10-16(13)19(12,2)7-8-20(17)11-15-5-6-18(22)23-15/h3-4,10,12,15,17,21H,5-9,11H2,1-2H3/t12-,15+,17+,19-/m0/s1
DM5WMXJ CS C[C@H]1[C@H]2CC3=C([C@]1(CCN2C[C@H]4CCC(=O)O4)C)C=C(C=C3)O
DM5WMXJ IK HHASRPPPJAXSNL-IQRRUJBNSA-N
DM5WMXJ IU (5R)-5-[[(1S,9R,13R)-4-hydroxy-1,13-dimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-10-yl]methyl]oxolan-2-one
DM5WMXJ DE Discovery agent
DMM2WG7 ID DMM2WG7
DMM2WG7 DN MR-16089
DMM2WG7 HS Investigative
DMM2WG7 SN MR-16089; CHEMBL1095413; BDBM50318402
DMM2WG7 DT Small molecular drug
DMM2WG7 PC 46887422
DMM2WG7 MW 370.3
DMM2WG7 FM C20H13F3N2O2
DMM2WG7 IC InChI=1S/C20H13F3N2O2/c21-20(22,23)27-15-7-5-14(6-8-15)18-16(11-13-3-1-9-24-12-13)19(26)17-4-2-10-25(17)18/h1-12,18H/b16-11-
DMM2WG7 CS C1=CC(=CN=C1)/C=C\\2/C(N3C=CC=C3C2=O)C4=CC=C(C=C4)OC(F)(F)F
DMM2WG7 IK NUADOLYUKJMRKY-WJDWOHSUSA-N
DMM2WG7 IU (2Z)-2-(pyridin-3-ylmethylidene)-3-[4-(trifluoromethoxy)phenyl]-3H-pyrrolizin-1-one
DMM2WG7 DE Discovery agent
DMF04AG ID DMF04AG
DMF04AG DN MR-2034
DMF04AG HS Investigative
DMF04AG SN MR 2034; MR-2034; (-)-alpha-(1R,5R,9R)-5,9-Dimethyl-2-(L-tetrahydrofurfuryl)-2'-hydroxy-6,7-benzomorphan; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-((tetrahydro-2-furanyl)methyl)-, (2R-(2-alpha,3(R*),6-alpha,11R*))-; 57236-85-8; AC1Q7AHJ; (2r,6r)-6,11-dimethyl-3-[(2r)-tetrahydrofuran-2-ylmethyl]-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol; BDBM81932; MR2034; LS-90624; CAS_57236-85-8
DMF04AG DT Small molecular drug
DMF04AG PC 123980
DMF04AG MW 301.4
DMF04AG FM C19H27NO2
DMF04AG IC InChI=1S/C19H27NO2/c1-13-18-10-14-5-6-15(21)11-17(14)19(13,2)7-8-20(18)12-16-4-3-9-22-16/h5-6,11,13,16,18,21H,3-4,7-10,12H2,1-2H3/t13?,16-,18-,19-/m1/s1
DMF04AG CS CC1[C@H]2CC3=C([C@@]1(CCN2C[C@H]4CCCO4)C)C=C(C=C3)O
DMF04AG IK NLKLXMMOJZHSCB-SENCRUMESA-N
DMF04AG IU (1R,9R)-1,13-dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMF04AG CA CAS 57236-85-8
DMF04AG DE Discovery agent
DMEBQLK ID DMEBQLK
DMEBQLK DN MR-20492
DMEBQLK HS Investigative
DMEBQLK SN MR-20492; CHEMBL9165; SCHEMBL6064449; BDBM50070097; 6-(4-Chloro-phenyl)-7-[1-pyridin-4-yl-meth-(Z)-ylidene]-6,7-dihydro-5H-indolizin-8-one; 6-(4-Chlorophenyl)-7-(4-pyridylmethylene)-5,6-dihydroindolizine-8(7H)-one
DMEBQLK DT Small molecular drug
DMEBQLK PC 9819080
DMEBQLK MW 334.8
DMEBQLK FM C20H15ClN2O
DMEBQLK IC InChI=1S/C20H15ClN2O/c21-16-5-3-15(4-6-16)18-13-23-11-1-2-19(23)20(24)17(18)12-14-7-9-22-10-8-14/h1-12,18H,13H2/b17-12-
DMEBQLK CS C1C(/C(=C/C2=CC=NC=C2)/C(=O)C3=CC=CN31)C4=CC=C(C=C4)Cl
DMEBQLK IK OMGJLQMHGRFTAP-ATVHPVEESA-N
DMEBQLK IU (7Z)-6-(4-chlorophenyl)-7-(pyridin-4-ylmethylidene)-5,6-dihydroindolizin-8-one
DMEBQLK DE Discovery agent
DMC79YF ID DMC79YF
DMC79YF DN MR-20494
DMC79YF HS Investigative
DMC79YF SN MR-20494; CHEMBL1098737; BDBM50318405
DMC79YF DT Small molecular drug
DMC79YF PC 10019821
DMC79YF MW 334.8
DMC79YF FM C20H15ClN2O
DMC79YF IC InChI=1S/C20H15ClN2O/c21-16-7-5-15(6-8-16)18-13-23-10-2-4-19(23)20(24)17(18)11-14-3-1-9-22-12-14/h1-12,18H,13H2/b17-11-
DMC79YF CS C1C(/C(=C/C2=CN=CC=C2)/C(=O)C3=CC=CN31)C4=CC=C(C=C4)Cl
DMC79YF IK UQXVMFWGYFYXDC-BOPFTXTBSA-N
DMC79YF IU (7Z)-6-(4-chlorophenyl)-7-(pyridin-3-ylmethylidene)-5,6-dihydroindolizin-8-one
DMC79YF DE Discovery agent
DMTCG8M ID DMTCG8M
DMTCG8M DN MR-20496
DMTCG8M HS Investigative
DMTCG8M SN CHEMBL9179; MR-20496; BDBM50070095
DMTCG8M DT Small molecular drug
DMTCG8M PC 44265823
DMTCG8M MW 297.3
DMTCG8M FM C21H15NO
DMTCG8M IC InChI=1S/C21H15NO/c23-21-18-9-5-4-8-17(18)20(16-6-2-1-3-7-16)19(21)14-15-10-12-22-13-11-15/h1-14,20H/b19-14-
DMTCG8M CS C1=CC=C(C=C1)C\\2C3=CC=CC=C3C(=O)/C2=C\\C4=CC=NC=C4
DMTCG8M IK ALLOQIRZHVQYIA-RGEXLXHISA-N
DMTCG8M IU (2Z)-3-phenyl-2-(pyridin-4-ylmethylidene)-3H-inden-1-one
DMTCG8M DE Discovery agent
DMSR3OI ID DMSR3OI
DMSR3OI DN MR-20814
DMSR3OI HS Investigative
DMSR3OI DE Discovery agent
DMIQ8GL ID DMIQ8GL
DMIQ8GL DN MR-22388
DMIQ8GL HS Investigative
DMIQ8GL SN MR-22388; CHEMBL287508; 3-(3-hydroxy-4-methoxyphenyl)-8h-thieno[2,3-b]pyrrolizin-8-one; SCHEMBL7001747; Thienopyrrolizine derivative, 4g; IXGRUAKWRHZSAP-UHFFFAOYSA-N; BDBM50103203; 3-(3-Hydroxy-4-methoxy-phenyl)-thieno[2,3-b]pyrrolizin-8-one
DMIQ8GL DT Small molecular drug
DMIQ8GL PC 9904289
DMIQ8GL MW 297.3
DMIQ8GL FM C16H11NO3S
DMIQ8GL IC InChI=1S/C16H11NO3S/c1-20-13-5-4-9(7-12(13)18)10-8-21-16-14(10)17-6-2-3-11(17)15(16)19/h2-8,18H,1H3
DMIQ8GL CS COC1=C(C=C(C=C1)C2=CSC3=C2N4C=CC=C4C3=O)O
DMIQ8GL IK IXGRUAKWRHZSAP-UHFFFAOYSA-N
DMIQ8GL IU 3-(3-hydroxy-4-methoxyphenyl)thieno[2,3-b]pyrrolizin-8-one
DMIQ8GL DE Discovery agent
DMXWSIU ID DMXWSIU
DMXWSIU DN MR-2266
DMXWSIU HS Investigative
DMXWSIU SN Mrz 2266 BS; MR 2266; MR-2266; MR-2266-BS; (-)-Mr 2266; (-)-2-(3-Furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan; 56649-76-4; (+/-)-2-(3-Furylmethyl)-2'-hydroxy-5,9alpha-diethyl-6,7-benzomorphan hydrochloride; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,6R,11R)-; 2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R-(2alpha,6alpha,11R*))-; Mr1302 MS; Mr2267; Mr 2267; SCHEMBL4404993; BDBM82508; Mr2266; ZINC5492542; CAS_56649-76-4
DMXWSIU DT Small molecular drug
DMXWSIU PC 3034816
DMXWSIU MW 325.4
DMXWSIU FM C21H27NO2
DMXWSIU IC InChI=1S/C21H27NO2/c1-3-18-20-11-16-5-6-17(23)12-19(16)21(18,4-2)8-9-22(20)13-15-7-10-24-14-15/h5-7,10,12,14,18,20,23H,3-4,8-9,11,13H2,1-2H3/t18-,20+,21+/m0/s1
DMXWSIU CS CC[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC4=COC=C4)CC)C=C(C=C3)O
DMXWSIU IK HEYXXBUDMDVUNQ-CEWLAPEOSA-N
DMXWSIU IU (1R,9R,13R)-1,13-diethyl-10-(furan-3-ylmethyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
DMXWSIU CA CAS 56649-76-4
DMXWSIU DE Discovery agent
DMUK1PA ID DMUK1PA
DMUK1PA DN MRE 2029F20
DMUK1PA HS Investigative
DMUK1PA SN MRE-2029F20
DMUK1PA DT Small molecular drug
DMUK1PA PC 135484064
DMUK1PA MW 509.5
DMUK1PA FM C24H27N7O6
DMUK1PA IC InChI=1S/C24H27N7O6/c1-4-8-30-22-20(23(33)31(9-5-2)24(30)34)26-21(27-22)15-11-19(28-29(15)3)35-12-18(32)25-14-6-7-16-17(10-14)37-13-36-16/h6-7,10-11H,4-5,8-9,12-13H2,1-3H3,(H,25,32)(H,26,27)
DMUK1PA CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC(=NN3C)OCC(=O)NC4=CC5=C(C=C4)OCO5
DMUK1PA IK DBWQRFKXNBVPGA-UHFFFAOYSA-N
DMUK1PA IU N-(1,3-benzodioxol-5-yl)-2-[5-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-methylpyrazol-3-yl]oxyacetamide
DMUK1PA DE Discovery agent
DM72US0 ID DM72US0
DM72US0 DN MRE 3008F20
DM72US0 HS Investigative
DM72US0 SN CJRNHKSLHHWUAB-UHFFFAOYSA-N; MRE 3008-F20; 252979-43-4; CHEMBL302765; MCP-NECA; 3-[4-(furan-2-yl)-11-propyl-3,5,6,8,10,11-hexaazatricyclo[7300^{2,6}]dodeca-1(12),2,4,7,9-pentaen-7-yl]-1-(4-methoxyphenyl)urea; [3H]MRE 3008F20; GTPL477; GTPL459; SCHEMBL958405; BDBM85618; MolPort-023-277-046; ZINC602413; MRE-3008F-20; AKOS024457944; NCGC00378820-01; KB-274663; J1251181G; L000411; N-[2-(2-Furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-methoxyphenyl)urea; MRE 3008-F20
DM72US0 DT Small molecular drug
DM72US0 PC 5310960
DM72US0 MW 432.4
DM72US0 FM C21H20N8O3
DM72US0 IC InChI=1S/C21H20N8O3/c1-3-10-28-12-15-17(26-28)24-20(25-21(30)22-13-6-8-14(31-2)9-7-13)29-19(15)23-18(27-29)16-5-4-11-32-16/h4-9,11-12H,3,10H2,1-2H3,(H2,22,24,25,26,30)
DM72US0 CS CCCN1C=C2C(=N1)N=C(N3C2=NC(=N3)C4=CC=CO4)NC(=O)NC5=CC=C(C=C5)OC
DM72US0 IK CJRNHKSLHHWUAB-UHFFFAOYSA-N
DM72US0 IU 1-[4-(furan-2-yl)-11-propyl-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-yl]-3-(4-methoxyphenyl)urea
DM72US0 DE Discovery agent
DMMFJA8 ID DMMFJA8
DMMFJA8 DN MRE 3010F20
DMMFJA8 HS Investigative
DMMFJA8 SN MRE-3010F20
DMMFJA8 DT Small molecular drug
DMMFJA8 PC 73754994
DMMFJA8 MW 439.9
DMMFJA8 FM C21H22ClN7O2
DMMFJA8 IC InChI=1S/C21H22ClN7O2/c1-2-8-29-11-14-16-17(25-19(24-16)15-7-4-9-31-15)20(26-18(14)28-29)27-21(30)23-13-6-3-5-12(22)10-13/h3,5-6,10-11,15,17H,2,4,7-9H2,1H3,(H2,23,26,27,28,30)
DMMFJA8 CS CCCN1C=C2C3=NC(=NC3C(=NC2=N1)NC(=O)NC4=CC(=CC=C4)Cl)C5CCCO5
DMMFJA8 IK AQJYVSDITBKWSI-UHFFFAOYSA-N
DMMFJA8 IU 1-(3-chlorophenyl)-3-[4-(oxolan-2-yl)-11-propyl-3,5,8,10,11-pentazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-yl]urea
DMMFJA8 DE Discovery agent
DM7VQTO ID DM7VQTO
DM7VQTO DN MRK016
DM7VQTO HS Investigative
DM7VQTO SN MRK-016; MRK 016
DM7VQTO DT Small molecular drug
DM7VQTO PC 6918583
DM7VQTO MW 368.4
DM7VQTO FM C17H20N8O2
DM7VQTO IC InChI=1S/C17H20N8O2/c1-10-6-11(23-27-10)15-21-19-7-12-14(17(2,3)4)16(22-25(12)15)26-8-13-18-9-20-24(13)5/h6-7,9H,8H2,1-5H3
DM7VQTO CS CC1=CC(=NO1)C2=NN=CC3=C(C(=NN32)OCC4=NC=NN4C)C(C)(C)C
DM7VQTO IK QYSYOGCIDRANAR-UHFFFAOYSA-N
DM7VQTO IU 3-[3-tert-butyl-2-[(2-methyl-1,2,4-triazol-3-yl)methoxy]pyrazolo[1,5-d][1,2,4]triazin-7-yl]-5-methyl-1,2-oxazole
DM7VQTO CA CAS 342652-67-9
DM7VQTO DE Discovery agent
DM7IK68 ID DM7IK68
DM7IK68 DN MRS 2219
DM7IK68 HS Investigative
DM7IK68 SN MRS2219; MRS-2220
DM7IK68 DT Small molecular drug
DM7IK68 PC 3960826
DM7IK68 MW 231.14
DM7IK68 FM C8H10NO5P
DM7IK68 IC InChI=1S/C8H10NO5P/c1-5-8(10)7-4-14-15(11,12)13-3-6(7)2-9-5/h2,10H,3-4H2,1H3,(H,11,12)
DM7IK68 CS CC1=NC=C2COP(=O)(OCC2=C1O)O
DM7IK68 IK KCAJHODRYGNBSX-UHFFFAOYSA-N
DM7IK68 IU 3-hydroxy-8-methyl-3-oxo-1,5-dihydro-[1,3,2]dioxaphosphepino[5,6-c]pyridin-9-ol
DM7IK68 CA CAS 14141-47-0
DM7IK68 DE Discovery agent
DMBXKYR ID DMBXKYR
DMBXKYR DN MRS1041
DMBXKYR HS Investigative
DMBXKYR SN 3,5,7-Triethoxyflavone; MRS-1041; CHEMBL72862; 3,5,7-triethoxy-2-phenyl-chromen-4-one; GTPL392; SCHEMBL1663784; BDBM50051347; 3,5,7-triethoxyflavone; 3,5,7-Triethoxy-2-phenyl-chromen-4-one
DMBXKYR DT Small molecular drug
DMBXKYR PC 10247549
DMBXKYR MW 354.4
DMBXKYR FM C21H22O5
DMBXKYR IC InChI=1S/C21H22O5/c1-4-23-15-12-16(24-5-2)18-17(13-15)26-20(14-10-8-7-9-11-14)21(19(18)22)25-6-3/h7-13H,4-6H2,1-3H3
DMBXKYR CS CCOC1=CC2=C(C(=C1)OCC)C(=O)C(=C(O2)C3=CC=CC=C3)OCC
DMBXKYR IK YMQQPRDUZIXHBJ-UHFFFAOYSA-N
DMBXKYR IU 3,5,7-triethoxy-2-phenylchromen-4-one
DMBXKYR DE Discovery agent
DMVT865 ID DMVT865
DMVT865 DN MRS1042
DMVT865 HS Investigative
DMVT865 SN MRS-1042
DMVT865 DT Small molecular drug
DMVT865 PC 10500941
DMVT865 MW 396.5
DMVT865 FM C24H28O5
DMVT865 IC InChI=1S/C24H28O5/c1-4-12-26-18-15-19(27-13-5-2)21-20(16-18)29-23(17-10-8-7-9-11-17)24(22(21)25)28-14-6-3/h7-11,15-16H,4-6,12-14H2,1-3H3
DMVT865 CS CCCOC1=CC2=C(C(=C1)OCCC)C(=O)C(=C(O2)C3=CC=CC=C3)OCCC
DMVT865 IK ABZJCSJCNNCZRY-UHFFFAOYSA-N
DMVT865 IU 2-phenyl-3,5,7-tripropoxychromen-4-one
DMVT865 DE Discovery agent
DM50QBR ID DM50QBR
DM50QBR DN MRS1062
DM50QBR HS Investigative
DM50QBR SN MRS-1062
DM50QBR DT Small molecular drug
DM50QBR PC 18784677
DM50QBR MW 370.4
DM50QBR FM C24H18O4
DM50QBR IC InChI=1S/C24H18O4/c1-27-19-12-13-21-20(16-19)22(25)23(26)24(28-21,18-10-6-3-7-11-18)15-14-17-8-4-2-5-9-17/h2-13,16,23,26H,1H3
DM50QBR CS COC1=CC2=C(C=C1)OC(C(C2=O)O)(C#CC3=CC=CC=C3)C4=CC=CC=C4
DM50QBR IK ITOHYACNWAMSCT-UHFFFAOYSA-N
DM50QBR IU 3-hydroxy-6-methoxy-2-phenyl-2-(2-phenylethynyl)-3H-chromen-4-one
DM50QBR DE Discovery agent
DMYAHU3 ID DMYAHU3
DMYAHU3 DN MRS1065
DMYAHU3 HS Investigative
DMYAHU3 SN MRS 1065
DMYAHU3 DT Small molecular drug
DMYAHU3 PC 10710647
DMYAHU3 MW 318.3
DMYAHU3 FM C20H14O4
DMYAHU3 IC InChI=1S/C20H14O4/c1-22-20-15-9-10-23-17(15)12-18-19(20)16(21)11-14(24-18)8-7-13-5-3-2-4-6-13/h2-12H,1H3/b8-7+
DMYAHU3 CS COC1=C2C=COC2=CC3=C1C(=O)C=C(O3)/C=C/C4=CC=CC=C4
DMYAHU3 IK HTBFQFPYNPJVLO-BQYQJAHWSA-N
DMYAHU3 IU 4-methoxy-7-[(E)-2-phenylethenyl]furo[3,2-g]chromen-5-one
DMYAHU3 CA CAS 138565-05-6
DMYAHU3 DE Discovery agent
DMAEW9M ID DMAEW9M
DMAEW9M DN MRS1067
DMAEW9M HS Investigative
DMAEW9M SN MRS-1067
DMAEW9M DT Small molecular drug
DMAEW9M PC 252716
DMAEW9M MW 363.2
DMAEW9M FM C19H16Cl2O3
DMAEW9M IC InChI=1S/C19H16Cl2O3/c1-10(2)23-16-8-11(3)4-6-13(16)19-17(21)18(22)14-9-12(20)5-7-15(14)24-19/h4-10H,1-3H3
DMAEW9M CS CC1=CC(=C(C=C1)C2=C(C(=O)C3=C(O2)C=CC(=C3)Cl)Cl)OC(C)C
DMAEW9M IK PWGZOUCWGRTPSM-UHFFFAOYSA-N
DMAEW9M IU 3,6-dichloro-2-(4-methyl-2-propan-2-yloxyphenyl)chromen-4-one
DMAEW9M CA CAS 70460-45-6
DMAEW9M DE Discovery agent
DMKELWG ID DMKELWG
DMKELWG DN MRS1084
DMKELWG HS Investigative
DMKELWG SN 4-(propyloxy)-7-trans-styrylvisnagin
DMKELWG DT Small molecular drug
DMKELWG PC 10593671
DMKELWG MW 346.4
DMKELWG FM C22H18O4
DMKELWG IC InChI=1S/C22H18O4/c1-2-11-25-22-17-10-12-24-19(17)14-20-21(22)18(23)13-16(26-20)9-8-15-6-4-3-5-7-15/h3-10,12-14H,2,11H2,1H3/b9-8+
DMKELWG CS CCCOC1=C2C=COC2=CC3=C1C(=O)C=C(O3)/C=C/C4=CC=CC=C4
DMKELWG IK RCPBGBWHKGZPFO-CMDGGOBGSA-N
DMKELWG IU 7-[(E)-2-phenylethenyl]-4-propoxyfuro[3,2-g]chromen-5-one
DMKELWG DE Discovery agent
DM1K5E2 ID DM1K5E2
DM1K5E2 DN MRS1086
DM1K5E2 HS Investigative
DM1K5E2 SN MRS-1086
DM1K5E2 DT Small molecular drug
DM1K5E2 PC 10813088
DM1K5E2 MW 442.5
DM1K5E2 FM C25H30O7
DM1K5E2 IC InChI=1S/C25H30O7/c1-6-27-16-11-12-18(19(13-16)29-8-3)24-25(31-10-5)23(26)22-20(30-9-4)14-17(28-7-2)15-21(22)32-24/h11-15H,6-10H2,1-5H3
DM1K5E2 CS CCOC1=CC(=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3OCC)OCC)OCC)OCC
DM1K5E2 IK JVGSHXMDRPGOQM-UHFFFAOYSA-N
DM1K5E2 IU 2-(2,4-diethoxyphenyl)-3,5,7-triethoxychromen-4-one
DM1K5E2 DE Discovery agent
DMSKWL7 ID DMSKWL7
DMSKWL7 DN MRS1088
DMSKWL7 HS Investigative
DMSKWL7 SN 3,6-dichloroflavone; MRS-1088; NSC-74876
DMSKWL7 DT Small molecular drug
DMSKWL7 PC 252696
DMSKWL7 MW 291.1
DMSKWL7 FM C15H8Cl2O2
DMSKWL7 IC InChI=1S/C15H8Cl2O2/c16-10-6-7-12-11(8-10)14(18)13(17)15(19-12)9-4-2-1-3-5-9/h1-8H
DMSKWL7 CS C1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=CC(=C3)Cl)Cl
DMSKWL7 IK PTNKLWUWHUGKTA-UHFFFAOYSA-N
DMSKWL7 IU 3,6-dichloro-2-phenylchromen-4-one
DMSKWL7 CA CAS 13179-00-5
DMSKWL7 DE Discovery agent
DM801AO ID DM801AO
DM801AO DN MRS1093
DM801AO HS Investigative
DM801AO SN 3,7-Diethoxy-5-hydroxyflavone; MRS-1093
DM801AO DT Small molecular drug
DM801AO PC 10568125
DM801AO MW 326.3
DM801AO FM C19H18O5
DM801AO IC InChI=1S/C19H18O5/c1-3-22-13-10-14(20)16-15(11-13)24-18(12-8-6-5-7-9-12)19(17(16)21)23-4-2/h5-11,20H,3-4H2,1-2H3
DM801AO CS CCOC1=CC(=C2C(=C1)OC(=C(C2=O)OCC)C3=CC=CC=C3)O
DM801AO IK ZPEWNDIPSPULBP-UHFFFAOYSA-N
DM801AO IU 3,7-diethoxy-5-hydroxy-2-phenylchromen-4-one
DM801AO DE Discovery agent
DMLOHAZ ID DMLOHAZ
DMLOHAZ DN MRS1097
DMLOHAZ HS Investigative
DMLOHAZ SN MRS-1097
DMLOHAZ DT Small molecular drug
DMLOHAZ PC 9953766
DMLOHAZ MW 417.5
DMLOHAZ FM C26H27NO4
DMLOHAZ IC InChI=1S/C26H27NO4/c1-4-30-25(28)22-18(3)27-24(20-14-10-7-11-15-20)23(26(29)31-5-2)21(22)17-16-19-12-8-6-9-13-19/h6-17,21,27H,4-5H2,1-3H3/b17-16+
DMLOHAZ CS CCOC(=O)C1=C(NC(=C(C1/C=C/C2=CC=CC=C2)C(=O)OCC)C3=CC=CC=C3)C
DMLOHAZ IK XCXCNPNUEPMYRS-WUKNDPDISA-N
DMLOHAZ IU diethyl 2-methyl-6-phenyl-4-[(E)-2-phenylethenyl]-1,4-dihydropyridine-3,5-dicarboxylate
DMLOHAZ DE Discovery agent
DMY4C0G ID DMY4C0G
DMY4C0G DN MRS1132
DMY4C0G HS Investigative
DMY4C0G DT Small molecular drug
DMY4C0G PC 736736
DMY4C0G MW 256.68
DMY4C0G FM C15H9ClO2
DMY4C0G IC InChI=1S/C15H9ClO2/c16-13-14(17)11-8-4-5-9-12(11)18-15(13)10-6-2-1-3-7-10/h1-9H
DMY4C0G CS C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C3O2)Cl
DMY4C0G IK FHXDSQYFCFWKAW-UHFFFAOYSA-N
DMY4C0G IU 3-chloro-2-phenylchromen-4-one
DMY4C0G DE Discovery agent
DMBXTPU ID DMBXTPU
DMBXTPU DN MRS1177
DMBXTPU HS Investigative
DMBXTPU SN MRS1177; CHEMBL317382; GTPL468; SCHEMBL1663767; MRS-1177; BDBM50053925; HY-120090; CS-0069480; N-(9-chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)benzamide; N-(9-Chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-benzamide
DMBXTPU DT Small molecular drug
DMBXTPU PC 10045876
DMBXTPU MW 389.8
DMBXTPU FM C20H12ClN5O2
DMBXTPU IC InChI=1S/C20H12ClN5O2/c21-13-8-9-15-14(11-13)18-23-17(16-7-4-10-28-16)25-26(18)20(22-15)24-19(27)12-5-2-1-3-6-12/h1-11H,(H,22,24,27)
DMBXTPU CS C1=CC=C(C=C1)C(=O)NC2=NC3=C(C=C(C=C3)Cl)C4=NC(=NN42)C5=CC=CO5
DMBXTPU IK XIEBLXLGWFCYEP-UHFFFAOYSA-N
DMBXTPU IU N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]benzamide
DMBXTPU DE Discovery agent
DMGJ0IE ID DMGJ0IE
DMGJ0IE DN MRS1186
DMGJ0IE HS Investigative
DMGJ0IE SN MRS-1186
DMGJ0IE DT Small molecular drug
DMGJ0IE PC 10065929
DMGJ0IE MW 341.75
DMGJ0IE FM C16H12ClN5O2
DMGJ0IE IC InChI=1S/C16H12ClN5O2/c1-2-13(23)19-16-18-11-6-5-9(17)8-10(11)15-20-14(21-22(15)16)12-4-3-7-24-12/h3-8H,2H2,1H3,(H,18,19,23)
DMGJ0IE CS CCC(=O)NC1=NC2=C(C=C(C=C2)Cl)C3=NC(=NN31)C4=CC=CO4
DMGJ0IE IK SPZIDRYLSXDAEF-UHFFFAOYSA-N
DMGJ0IE IU N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]propanamide
DMGJ0IE DE Discovery agent
DM9WX3C ID DM9WX3C
DM9WX3C DN MRS1191
DM9WX3C HS Investigative
DM9WX3C SN MRS-1191
DM9WX3C DT Small molecular drug
DM9WX3C PC 393594
DM9WX3C MW 477.5
DM9WX3C FM C31H27NO4
DM9WX3C IC InChI=1S/C31H27NO4/c1-3-35-30(33)27-22(2)32-29(25-17-11-6-12-18-25)28(26(27)20-19-23-13-7-4-8-14-23)31(34)36-21-24-15-9-5-10-16-24/h4-18,26,32H,3,21H2,1-2H3
DM9WX3C CS CCOC(=O)C1=C(NC(=C(C1C#CC2=CC=CC=C2)C(=O)OCC3=CC=CC=C3)C4=CC=CC=C4)C
DM9WX3C IK SNVFDPHQAOXWJZ-UHFFFAOYSA-N
DM9WX3C IU 5-O-benzyl 3-O-ethyl 2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM9WX3C CA CAS 185222-90-6
DM9WX3C DE Discovery agent
DMT6JH9 ID DMT6JH9
DMT6JH9 DN MRS-1220
DMT6JH9 HS Investigative
DMT6JH9 SN MRS 1220; 183721-15-5; MRS-1220; CHEMBL88147; N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide; MRS1220; N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide; MRS 1200; NSC 695674; Tocris-1217; MRS 1220, solid; AC1Q3QZX; 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline; GTPL448; SCHEMBL927261; AC1L96H4; CTK8F0085; CHEBI:92667; MolPort-003-958-674; ZINC602092; HMS3267D09; NSC695674; BDBM50053929; AKOS024456471; NSC-695674
DMT6JH9 DT Small molecular drug
DMT6JH9 PC 393595
DMT6JH9 MW 403.8
DMT6JH9 FM C21H14ClN5O2
DMT6JH9 IC InChI=1S/C21H14ClN5O2/c22-14-8-9-16-15(12-14)20-25-19(17-7-4-10-29-17)26-27(20)21(23-16)24-18(28)11-13-5-2-1-3-6-13/h1-10,12H,11H2,(H,23,24,28)
DMT6JH9 CS C1=CC=C(C=C1)CC(=O)NC2=NC3=C(C=C(C=C3)Cl)C4=NC(=NN42)C5=CC=CO5
DMT6JH9 IK TWWFAXQOKNBUCR-UHFFFAOYSA-N
DMT6JH9 IU N-[9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]-2-phenylacetamide
DMT6JH9 CA CAS 183721-15-5
DMT6JH9 CB CHEBI:92667
DMT6JH9 DE Discovery agent
DMLQYN7 ID DMLQYN7
DMLQYN7 DN MRS1476
DMLQYN7 HS Investigative
DMLQYN7 SN MRS-1476
DMLQYN7 DT Small molecular drug
DMLQYN7 PC 9885773
DMLQYN7 MW 371.5
DMLQYN7 FM C21H25NO3S
DMLQYN7 IC InChI=1S/C21H25NO3S/c1-5-15-17(21(24)26-8-4)16(6-2)22-19(14-12-10-9-11-13-14)18(15)20(23)25-7-3/h9-13H,5-8H2,1-4H3
DMLQYN7 CS CCC1=C(C(=NC(=C1C(=O)OCC)C2=CC=CC=C2)CC)C(=O)SCC
DMLQYN7 IK WYZGZKCWULQWSH-UHFFFAOYSA-N
DMLQYN7 IU ethyl 4,6-diethyl-5-ethylsulfanylcarbonyl-2-phenylpyridine-3-carboxylate
DMLQYN7 DE Discovery agent
DMFJHMQ ID DMFJHMQ
DMFJHMQ DN MRS1486
DMFJHMQ HS Investigative
DMFJHMQ SN MRS-1486
DMFJHMQ DT Small molecular drug
DMFJHMQ PC 9843120
DMFJHMQ MW 385.5
DMFJHMQ FM C22H27NO3S
DMFJHMQ IC InChI=1S/C22H27NO3S/c1-5-12-17-18(22(25)27-8-4)16(6-2)19(21(24)26-7-3)20(23-17)15-13-10-9-11-14-15/h9-11,13-14H,5-8,12H2,1-4H3
DMFJHMQ CS CCCC1=NC(=C(C(=C1C(=O)SCC)CC)C(=O)OCC)C2=CC=CC=C2
DMFJHMQ IK GSMBGLUYORHXJR-UHFFFAOYSA-N
DMFJHMQ IU ethyl 4-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-6-propylpyridine-3-carboxylate
DMFJHMQ DE Discovery agent
DM3Q5NO ID DM3Q5NO
DM3Q5NO DN MRS1505
DM3Q5NO HS Investigative
DM3Q5NO SN MRS-1505
DM3Q5NO DT Small molecular drug
DM3Q5NO PC 9802941
DM3Q5NO MW 434
DM3Q5NO FM C23H28ClNO3S
DM3Q5NO IC InChI=1S/C23H28ClNO3S/c1-5-12-28-22(26)20-17(7-3)19(23(27)29-13-6-2)18(8-4)25-21(20)15-10-9-11-16(24)14-15/h9-11,14H,5-8,12-13H2,1-4H3
DM3Q5NO CS CCCOC(=O)C1=C(N=C(C(=C1CC)C(=O)SCCC)CC)C2=CC(=CC=C2)Cl
DM3Q5NO IK RPTCJTNYKDJGHU-UHFFFAOYSA-N
DM3Q5NO IU propyl 2-(3-chlorophenyl)-4,6-diethyl-5-propylsulfanylcarbonylpyridine-3-carboxylate
DM3Q5NO DE Discovery agent
DM4AONZ ID DM4AONZ
DM4AONZ DN MRS1523
DM4AONZ HS Investigative
DM4AONZ SN MRS 1523 ; MRS-1523
DM4AONZ DT Small molecular drug
DM4AONZ PC 3661570
DM4AONZ MW 399.5
DM4AONZ FM C23H29NO3S
DM4AONZ IC InChI=1S/C23H29NO3S/c1-5-12-17-19(23(26)28-8-4)18(7-3)24-21(16-13-10-9-11-14-16)20(17)22(25)27-15-6-2/h9-11,13-14H,5-8,12,15H2,1-4H3
DM4AONZ CS CCCC1=C(C(=NC(=C1C(=O)SCC)CC)C2=CC=CC=C2)C(=O)OCCC
DM4AONZ IK UUSHFEVEROROSP-UHFFFAOYSA-N
DM4AONZ IU propyl 6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-4-propylpyridine-3-carboxylate
DM4AONZ CA CAS 212329-37-8
DM4AONZ DE Discovery agent
DM5I7PL ID DM5I7PL
DM5I7PL DN MRS1706
DM5I7PL HS Investigative
DM5I7PL SN MRS-1706; MRS 1706
DM5I7PL DT Small molecular drug
DM5I7PL PC 5139184
DM5I7PL MW 503.5
DM5I7PL FM C27H29N5O5
DM5I7PL IC InChI=1S/C27H29N5O5/c1-4-14-31-25-23(26(35)32(15-5-2)27(31)36)29-24(30-25)19-8-12-21(13-9-19)37-16-22(34)28-20-10-6-18(7-11-20)17(3)33/h6-13H,4-5,14-16H2,1-3H3,(H,28,34)(H,29,30)
DM5I7PL CS CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NC4=CC=C(C=C4)C(=O)C
DM5I7PL IK ZKUCFFYOQOJLGT-UHFFFAOYSA-N
DM5I7PL IU N-(4-acetylphenyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
DM5I7PL CA CAS 264622-53-9
DM5I7PL DE Discovery agent
DMHJ47A ID DMHJ47A
DMHJ47A DN MRS-2160
DMHJ47A HS Investigative
DMHJ47A DT Small molecular drug
DMHJ47A PC 135539037
DMHJ47A MW 429.7
DMHJ47A FM C15H13ClN3O8P
DMHJ47A IC InChI=1S/C15H13ClN3O8P/c1-7-13(21)10(5-20)11(6-27-28(24,25)26)14(17-7)19-18-8-2-3-9(15(22)23)12(16)4-8/h2-5,21H,6H2,1H3,(H,22,23)(H2,24,25,26)
DMHJ47A CS CC1=C(C(=C(C(=N1)N=NC2=CC(=C(C=C2)C(=O)O)Cl)COP(=O)(O)O)C=O)O
DMHJ47A IK KMRWDYZPXRUNAQ-UHFFFAOYSA-N
DMHJ47A IU 2-chloro-4-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonooxymethyl)pyridin-2-yl]diazenyl]benzoic acid
DMHJ47A DE Discovery agent
DMIVGHB ID DMIVGHB
DMIVGHB DN MRS-2179
DMIVGHB HS Investigative
DMIVGHB SN MRS-2179; MRS2179; MRS 2179; GTPL1720; CCG-204841; NCGC00162239-02; NCGC00162239-01; [2-[(hydroxy-oxidophosphoryl)oxymethyl]-5-(6-methylaminopurin-9-yl)oxolan-3-yl] hydrogen phosphate
DMIVGHB DT Small molecular drug
DMIVGHB PC 24867852
DMIVGHB MW 423.21
DMIVGHB FM C11H15N5O9P2-2
DMIVGHB IC InChI=1S/C11H17N5O9P2/c1-12-10-9-11(14-4-13-10)16(5-15-9)8-2-6(25-27(20,21)22)7(24-8)3-23-26(17,18)19/h4-8H,2-3H2,1H3,(H,12,13,14)(H2,17,18,19)(H2,20,21,22)/p-2/t6-,7+,8+/m0/s1
DMIVGHB CS CNC1=C2C(=NC=N1)N(C=N2)[C@H]3C[C@@H]([C@H](O3)COP(=O)(O)[O-])OP(=O)(O)[O-]
DMIVGHB IK CCPLITQNIFLYQB-XLPZGREQSA-L
DMIVGHB IU [(2R,3S,5R)-3-[hydroxy(oxido)phosphoryl]oxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methyl hydrogen phosphate
DMIVGHB DE Discovery agent
DM2G5ZE ID DM2G5ZE
DM2G5ZE DN MRS2211
DM2G5ZE HS Investigative
DM2G5ZE SN MRS-2211
DM2G5ZE DT Small molecular drug
DM2G5ZE PC 136078744
DM2G5ZE MW 432.71
DM2G5ZE FM C14H14ClN4O8P
DM2G5ZE IC InChI=1S/C14H14ClN4O8P/c1-7-13(21)9(5-20)10(6-27-28(24,25)26)14(16-7)18-17-12-4-8(19(22)23)2-3-11(12)15/h2-4,20-21H,5-6H2,1H3,(H2,24,25,26)
DM2G5ZE CS CC1=C(C(=C(C(=N1)N=NC2=C(C=CC(=C2)[N+](=O)[O-])Cl)COP(=O)(O)O)CO)O
DM2G5ZE IK RYOZMXBRDOGYMB-UHFFFAOYSA-N
DM2G5ZE IU [2-[(2-chloro-5-nitrophenyl)diazenyl]-5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl dihydrogen phosphate
DM2G5ZE DE Discovery agent
DM0QGF3 ID DM0QGF3
DM0QGF3 DN MRS2279
DM0QGF3 HS Investigative
DM0QGF3 SN LPZJKPSGEADHTQ-HLTSFMKQSA-N; [(1S,2R,4R)-4-[(2-chloro-6-methylaminopurin-9-yl)methyl]-2-(phosphonooxymethyl)cyclopentyl] dihydrogen phosphate; [3H]MRS2279; [3H]-MRS2279; AC1NSKE5; GTPL1727; GTPL1721; [(1R,2S,4R)-4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-2-phosphonooxycyclopentyl]methyl dihydrogen; MRS-2279
DM0QGF3 DT Small molecular drug
DM0QGF3 PC 5311301
DM0QGF3 MW 471.73
DM0QGF3 FM C13H20ClN5O8P2
DM0QGF3 IC InChI=1S/C13H20ClN5O8P2/c1-15-11-10-12(18-13(14)17-11)19(6-16-10)4-7-2-8(5-26-28(20,21)22)9(3-7)27-29(23,24)25/h6-9H,2-5H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t7-,8-,9+/m1/s1
DM0QGF3 CS CNC1=C2C(=NC(=N1)Cl)N(C=N2)C[C@@H]3C[C@@H]([C@H](C3)OP(=O)(O)O)COP(=O)(O)O
DM0QGF3 IK LPZJKPSGEADHTQ-HLTSFMKQSA-N
DM0QGF3 IU [(1R,2S,4R)-4-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-2-phosphonooxycyclopentyl]methyl dihydrogen phosphate
DM0QGF3 DE Discovery agent
DMZ6EGA ID DMZ6EGA
DMZ6EGA DN MRS2298
DMZ6EGA HS Investigative
DMZ6EGA SN MRS-2298; MRS 2298
DMZ6EGA DT Small molecular drug
DMZ6EGA PC 10432920
DMZ6EGA MW 431.66
DMZ6EGA FM C10H16ClN5O8P2
DMZ6EGA IC InChI=1S/C10H16ClN5O8P2/c1-12-8-7-9(15-10(11)14-8)16(5-13-7)2-6(3-23-25(17,18)19)4-24-26(20,21)22/h5-6H,2-4H2,1H3,(H,12,14,15)(H2,17,18,19)(H2,20,21,22)
DMZ6EGA CS CNC1=C2C(=NC(=N1)Cl)N(C=N2)CC(COP(=O)(O)O)COP(=O)(O)O
DMZ6EGA IK GMCUIIHBWNOHIM-UHFFFAOYSA-N
DMZ6EGA IU [2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-3-phosphonooxypropyl] dihydrogen phosphate
DMZ6EGA DE Discovery agent
DM0CS3V ID DM0CS3V
DM0CS3V DN MRS2365
DM0CS3V HS Investigative
DM0CS3V SN (N)-methanocarba-2-MeSADP; MRS 2365
DM0CS3V DT Small molecular drug
DM0CS3V PC 73755043
DM0CS3V MW 549.28
DM0CS3V FM C13H16N5Na3O9P2S
DM0CS3V IC InChI=1S/C13H19N5O9P2S.3Na/c1-30-12-16-10(14)6-11(17-12)18(4-15-6)7-5-2-13(5,9(20)8(7)19)3-26-29(24,25)27-28(21,22)23;;;/h4-5,7-9,19-20H,2-3H2,1H3,(H,24,25)(H2,14,16,17)(H2,21,22,23);;;/q;3*+1/p-3/t5-,7?,8+,9+,13+;;;/m1.../s1
DM0CS3V CS CSC1=NC(=C2C(=N1)N(C=N2)C3[C@H]4C[C@]4([C@H]([C@H]3O)O)COP(=O)([O-])OP(=O)([O-])[O-])N.[Na+].[Na+].[Na+]
DM0CS3V IK ZYPJOXVKTCEBCA-PVMCGCOJSA-K
DM0CS3V IU trisodium;[[(1R,2R,3S,5S)-4-(6-amino-2-methylsulfanylpurin-9-yl)-2,3-dihydroxy-1-bicyclo[3.1.0]hexanyl]methoxy-oxidophosphoryl] phosphate
DM0CS3V DE Discovery agent
DM0CAKS ID DM0CAKS
DM0CAKS DN MRS2496
DM0CAKS HS Investigative
DM0CAKS SN MRS-2496
DM0CAKS DT Small molecular drug
DM0CAKS PC 10894633
DM0CAKS MW 399.66
DM0CAKS FM C10H16ClN5O6P2
DM0CAKS IC InChI=1S/C10H16ClN5O6P2/c1-12-8-7-9(15-10(11)14-8)16(5-13-7)2-6(3-23(17,18)19)4-24(20,21)22/h5-6H,2-4H2,1H3,(H,12,14,15)(H2,17,18,19)(H2,20,21,22)
DM0CAKS CS CNC1=C2C(=NC(=N1)Cl)N(C=N2)CC(CP(=O)(O)O)CP(=O)(O)O
DM0CAKS IK FFBIISIICFTESN-UHFFFAOYSA-N
DM0CAKS IU [2-[[2-chloro-6-(methylamino)purin-9-yl]methyl]-3-phosphonopropyl]phosphonic acid
DM0CAKS DE Discovery agent
DMNGTOY ID DMNGTOY
DMNGTOY DN MRS2500
DMNGTOY HS Investigative
DMNGTOY SN MRS-2500; MRS 2500
DMNGTOY DT Small molecular drug
DMNGTOY PC 44448831
DMNGTOY MW 561.16
DMNGTOY FM C13H18IN5O8P2
DMNGTOY IC InChI=1S/C13H18IN5O8P2/c1-15-10-9-11(18-12(14)17-10)19(5-16-9)7-2-8(27-29(23,24)25)13(3-6(7)13)4-26-28(20,21)22/h5-8H,2-4H2,1H3,(H,15,17,18)(H2,20,21,22)(H2,23,24,25)/t6-,7+,8+,13+/m1/s1
DMNGTOY CS CNC1=C2C(=NC(=N1)I)N(C=N2)[C@H]3C[C@@H]([C@]4([C@@H]3C4)COP(=O)(O)O)OP(=O)(O)O
DMNGTOY IK NMVWLEUONAKGCD-SMWKGLLFSA-N
DMNGTOY IU [(1R,2S,4S,5S)-4-[2-iodo-6-(methylamino)purin-9-yl]-2-phosphonooxy-1-bicyclo[3.1.0]hexanyl]methyl dihydrogen phosphate
DMNGTOY DE Discovery agent
DMUJEA9 ID DMUJEA9
DMUJEA9 DN MRS2567
DMUJEA9 HS Investigative
DMUJEA9 SN MRS2567; 4,4'-Diisothiocyanatobibenzyl; SCHEMBL1853024; GTPL1752; 1-isothiocyanato-4-[2-(4-isothiocyanatophenyl)ethyl]benzene
DMUJEA9 DT Small molecular drug
DMUJEA9 PC 11266452
DMUJEA9 MW 296.4
DMUJEA9 FM C16H12N2S2
DMUJEA9 IC InChI=1S/C16H12N2S2/c19-11-17-15-7-3-13(4-8-15)1-2-14-5-9-16(10-6-14)18-12-20/h3-10H,1-2H2
DMUJEA9 CS C1=CC(=CC=C1CCC2=CC=C(C=C2)N=C=S)N=C=S
DMUJEA9 IK KGPFLJVFCCOOEO-UHFFFAOYSA-N
DMUJEA9 IU 1-isothiocyanato-4-[2-(4-isothiocyanatophenyl)ethyl]benzene
DMUJEA9 DE Discovery agent
DMKMPS6 ID DMKMPS6
DMKMPS6 DN MRS2578
DMKMPS6 HS Investigative
DMKMPS6 SN MRS-2578; MRS 2578
DMKMPS6 DT Small molecular drug
DMKMPS6 PC 16078986
DMKMPS6 MW 472.7
DMKMPS6 FM C20H20N6S4
DMKMPS6 IC InChI=1S/C20H20N6S4/c27-13-23-15-5-3-7-17(11-15)25-19(29)21-9-1-2-10-22-20(30)26-18-8-4-6-16(12-18)24-14-28/h3-8,11-12H,1-2,9-10H2,(H2,21,25,29)(H2,22,26,30)
DMKMPS6 CS C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S
DMKMPS6 IK QOHNRGHTJPFMSL-UHFFFAOYSA-N
DMKMPS6 IU 1-(3-isothiocyanatophenyl)-3-[4-[(3-isothiocyanatophenyl)carbamothioylamino]butyl]thiourea
DMKMPS6 CA CAS 711019-86-2
DMKMPS6 DE Discovery agent
DMNGC79 ID DMNGC79
DMNGC79 DN MRS2603
DMNGC79 HS Investigative
DMNGC79 SN MRS 2603
DMNGC79 DT Small molecular drug
DMNGC79 PC 135545444
DMNGC79 MW 430.69
DMNGC79 FM C14H12ClN4O8P
DMNGC79 IC InChI=1S/C14H12ClN4O8P/c1-7-13(21)9(5-20)10(6-27-28(24,25)26)14(16-7)18-17-8-2-3-11(15)12(4-8)19(22)23/h2-5,21H,6H2,1H3,(H2,24,25,26)
DMNGC79 CS CC1=C(C(=C(C(=N1)N=NC2=CC(=C(C=C2)Cl)[N+](=O)[O-])COP(=O)(O)O)C=O)O
DMNGC79 IK AIYCSQYPGGJSRN-UHFFFAOYSA-N
DMNGC79 IU [2-[(4-chloro-3-nitrophenyl)diazenyl]-4-formyl-5-hydroxy-6-methylpyridin-3-yl]methyl dihydrogen phosphate
DMNGC79 DE Discovery agent
DMNS3RT ID DMNS3RT
DMNS3RT DN MRS2690
DMNS3RT HS Investigative
DMNS3RT SN MRS 2690; MRS-2690
DMNS3RT DT Small molecular drug
DMNS3RT PC 73755042
DMNS3RT MW 626.3
DMNS3RT FM C15H22N2Na2O16P2S
DMNS3RT IC InChI=1S/C15H24N2O16P2S.2Na/c18-3-5-8(20)10(22)12(24)14(31-5)32-35(27,28)33-34(25,26)29-4-6-9(21)11(23)13(30-6)17-2-1-7(19)16-15(17)36;;/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,25,26)(H,27,28)(H,16,19,36);;/q;2*+1/p-2/t5-,6-,8-,9-,10+,11-,12-,13-,14-;;/m1../s1
DMNS3RT CS C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O.[Na+].[Na+]
DMNS3RT IK TYVFMVSNSGMZPA-QBNUFUENSA-L
DMNS3RT IU disodium;[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate
DMNS3RT DE Discovery agent
DM2L3CJ ID DM2L3CJ
DM2L3CJ DN MRS2693
DM2L3CJ HS Investigative
DM2L3CJ SN MRS-2693; MRS 2693; 5-iodo-uridine-5'-diphosphate; 5-iodo-UDP
DM2L3CJ DT Small molecular drug
DM2L3CJ PC 44415771
DM2L3CJ MW 530.06
DM2L3CJ FM C9H13IN2O12P2
DM2L3CJ IC InChI=1S/C9H13IN2O12P2/c10-4-1-5(13)11-9(16)12(4)8-7(15)6(14)3(23-8)2-22-26(20,21)24-25(17,18)19/h1,3,6-8,14-15H,2H2,(H,20,21)(H,11,13,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1
DM2L3CJ CS C1=C(N(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)O)O)O)I
DM2L3CJ IK ZPKIYZBENSTKTC-YXZULKJRSA-N
DM2L3CJ IU [(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
DM2L3CJ DE Discovery agent
DM7EZBU ID DM7EZBU
DM7EZBU DN MRS2698
DM7EZBU HS Investigative
DM7EZBU SN MRS-2698; 2'-amino-2-thio-UTP
DM7EZBU DT Small molecular drug
DM7EZBU PC 16116566
DM7EZBU MW 499.22
DM7EZBU FM C9H16N3O13P3S
DM7EZBU IC InChI=1S/C9H16N3O13P3S/c10-6-7(14)4(23-8(6)12-2-1-5(13)11-9(12)29)3-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,4,6-8,14H,3,10H2,(H,18,19)(H,20,21)(H,11,13,29)(H2,15,16,17)/t4-,6-,7-,8-/m1/s1
DM7EZBU CS C1=CN(C(=S)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)N
DM7EZBU IK UWTUUIWWVPWHAA-XVFCMESISA-N
DM7EZBU IU [[(2R,3S,4R,5R)-4-amino-3-hydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM7EZBU DE Discovery agent
DMO5J39 ID DMO5J39
DMO5J39 DN MRS2768
DMO5J39 HS Investigative
DMO5J39 SN uridine-5'-tetraphosphate Delta-phenyl ester
DMO5J39 DT Small molecular drug
DMO5J39 PC 73755072
DMO5J39 MW 636.3
DMO5J39 FM C17H24N2O16P4
DMO5J39 IC InChI=1S/C17H24N2O16P4/c1-11-12(2)16(19-9-8-15(20)18-17(19)21)31-14(11)10-30-36(22,23)33-38(26,27)35-39(28,29)34-37(24,25)32-13-6-4-3-5-7-13/h3-9,11-12,14,16H,10H2,1-2H3,(H,22,23)(H,24,25)(H,26,27)(H,28,29)(H,18,20,21)/t11-,12+,14+,16+/m0/s1
DMO5J39 CS C[C@H]1[C@H]([C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC2=CC=CC=C2)N3C=CC(=O)NC3=O)C
DMO5J39 IK ACRDMMYBLHHSSD-KLZCAUPSSA-N
DMO5J39 IU [[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dimethyloxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy(phenoxy)phosphoryl]oxyphosphoryl] hydrogen phosphate
DMO5J39 DE Discovery agent
DMZSO4R ID DMZSO4R
DMZSO4R DN MRS2782
DMZSO4R HS Investigative
DMZSO4R SN Uridine-5'-alpha,beta-methylene-diphosphate triethylammonium salt
DMZSO4R DT Small molecular drug
DMZSO4R PC 44585949
DMZSO4R MW 402.19
DMZSO4R FM C10H16N2O11P2
DMZSO4R IC InChI=1S/C10H16N2O11P2/c13-6-1-2-12(10(16)11-6)9-8(15)7(14)5(23-9)3-22-25(20,21)4-24(17,18)19/h1-2,5,7-9,14-15H,3-4H2,(H,20,21)(H,11,13,16)(H2,17,18,19)/t5-,7-,8-,9-/m1/s1
DMZSO4R CS C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(CP(=O)(O)O)O)O)O
DMZSO4R IK PDEGDTTUBZXACY-ZOQUXTDFSA-N
DMZSO4R IU [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid
DMZSO4R DE Discovery agent
DMWKZCY ID DMWKZCY
DMWKZCY DN MRS2802
DMWKZCY HS Investigative
DMWKZCY SN MRS2802
DMWKZCY DT Small molecular drug
DMWKZCY PC 91827349
DMWKZCY MW 438.17
DMWKZCY FM C10H14F2N2O11P2
DMWKZCY IC InChI=1S/C10H14F2N2O11P2/c11-10(12,26(19,20)21)27(22,23)24-3-4-6(16)7(17)8(25-4)14-2-1-5(15)13-9(14)18/h1-2,4,6-8,16-17H,3H2,(H,22,23)(H,13,15,18)(H2,19,20,21)/t4-,6+,7+,8-/m1/s1
DMWKZCY CS C1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@H]([C@H](O2)COP(=O)(C(F)(F)P(=O)(O)O)O)O)O
DMWKZCY IK JKJYHYKRGKKASI-YDKYIBAVSA-N
DMWKZCY IU [[[(2R,3R,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]-difluoromethyl]phosphonic acid
DMWKZCY DE Discovery agent
DMGCPHO ID DMGCPHO
DMGCPHO DN MRS2905
DMGCPHO HS Investigative
DMGCPHO SN MRS2905
DMGCPHO DT Small molecular drug
DMGCPHO PC 91827348
DMGCPHO MW 432.28
DMGCPHO FM C11H18N2O10P2S
DMGCPHO IC InChI=1S/C11H18N2O10P2S/c14-7-1-2-13(11(26)12-7)10-9(16)8(15)6(23-10)5-22-25(20,21)4-3-24(17,18)19/h1-2,6,8-10,15-16H,3-5H2,(H,20,21)(H,12,14,26)(H2,17,18,19)/t6-,8+,9+,10-/m1/s1
DMGCPHO CS C1=CN(C(=S)NC1=O)[C@H]2[C@H]([C@H]([C@H](O2)COP(=O)(CCP(=O)(O)O)O)O)O
DMGCPHO IK RCFKBLDZKDFBNO-DOWZNPNQSA-N
DMGCPHO IU 2-[[(2R,3R,4S,5R)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]ethylphosphonic acid
DMGCPHO DE Discovery agent
DMB2A7Q ID DMB2A7Q
DMB2A7Q DN MRS2927
DMB2A7Q HS Investigative
DMB2A7Q SN Up4 -[1]3'-deoxy-3'-fluoroglucose; compound 34 [PMID:21528910]
DMB2A7Q DT Small molecular drug
DMB2A7Q PC 91827350
DMB2A7Q MW 727.3
DMB2A7Q FM C16H26FNO22P4
DMB2A7Q IC InChI=1S/C16H26FNO22P4/c17-9-10(21)6(3-19)36-16(12(9)23)37-42(28,29)39-44(32,33)40-43(30,31)38-41(26,27)34-4-7-11(22)13(24)14(35-7)5-1-2-8(20)18-15(5)25/h1-2,5-7,9-14,16,19,21-24H,3-4H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,18,20,25)/t5?,6-,7-,9+,10-,11-,12-,13-,14+,16-/m1/s1
DMB2A7Q CS C1=CC(=O)NC(=O)C1[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)F)O)O)O
DMB2A7Q IK SMNRFWMNPDABKZ-WVALLCKVSA-N
DMB2A7Q IU [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
DMB2A7Q DE Discovery agent
DMDSB1F ID DMDSB1F
DMDSB1F DN MRS2950
DMDSB1F HS Investigative
DMDSB1F SN MRS2950; GTPL5809
DMDSB1F DT Small molecular drug
DMDSB1F PC 73755158
DMDSB1F MW 451.4
DMDSB1F FM C20H20Cl2N4O2S
DMDSB1F IC InChI=1S/C20H20Cl2N4O2S/c1-12-13(2)25-28-19(12)26-29(3,4)16-8-5-14(6-9-16)23-20(27)24-15-7-10-17(21)18(22)11-15/h5-11,26H,3-4H2,1-2H3,(H2,23,24,27)
DMDSB1F CS CC1=C(ON=C1C)NS(=C)(=C)C2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)Cl
DMDSB1F IK ZRNSPTWPSVBOTC-UHFFFAOYSA-N
DMDSB1F IU 1-(3,4-dichlorophenyl)-3-[4-[[(3,4-dimethyl-1,2-oxazol-5-yl)amino]-dimethylidene-lambda6-sulfanyl]phenyl]urea
DMDSB1F DE Discovery agent
DMROQP6 ID DMROQP6
DMROQP6 DN MRS2957
DMROQP6 HS Investigative
DMROQP6 SN MRS 2957
DMROQP6 DT Small molecular drug
DMROQP6 PC 91827347
DMROQP6 MW 739.4
DMROQP6 FM C19H28N5O20P3
DMROQP6 IC InChI=1S/C19H28N5O20P3/c1-38-22-10-2-4-23(18(30)20-10)16-14(28)12(26)8(41-16)6-39-45(32,33)43-47(36,37)44-46(34,35)40-7-9-13(27)15(29)17(42-9)24-5-3-11(25)21-19(24)31/h2-5,8-9,12-17,26-29H,6-7H2,1H3,(H,32,33)(H,34,35)(H,36,37)(H,20,22,30)(H,21,25,31)/t8-,9-,12+,13+,14+,15+,16-,17-/m1/s1
DMROQP6 CS CONC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]3[C@@H]([C@@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O
DMROQP6 IK SIKKMGJHOOQSAP-AOUMTEFLSA-N
DMROQP6 IU [[(2R,3R,4S,5R)-3,4-dihydroxy-5-[4-(methoxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2R,3R,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate
DMROQP6 DE Discovery agent
DMWKXGP ID DMWKXGP
DMWKXGP DN MRS4062
DMWKXGP HS Investigative
DMWKXGP SN N4-phenylpropoxycytidine-5'-triphosphate; MRS-4062; MRS 4062
DMWKXGP DT Small molecular drug
DMWKXGP PC 53262902
DMWKXGP MW 617.3
DMWKXGP FM C18H26N3O15P3
DMWKXGP IC InChI=1S/C18H26N3O15P3/c22-15-13(11-33-38(28,29)36-39(30,31)35-37(25,26)27)34-17(16(15)23)21-9-8-14(19-18(21)24)20-32-10-4-7-12-5-2-1-3-6-12/h1-3,5-6,8-9,13,15-17,22-23H,4,7,10-11H2,(H,28,29)(H,30,31)(H,19,20,24)(H2,25,26,27)/t13-,15-,16-,17-/m1/s1
DMWKXGP CS C1=CC=C(C=C1)CCCONC2=NC(=O)N(C=C2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DMWKXGP IK FAYLMQPZASAIOS-MWQQHZPXSA-N
DMWKXGP IU [[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-oxo-4-(3-phenylpropoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DMWKXGP DE Discovery agent
DM1GUTC ID DM1GUTC
DM1GUTC DN MRS5151
DM1GUTC HS Investigative
DM1GUTC SN MRS5151
DM1GUTC DT Small molecular drug
DM1GUTC PC 91827346
DM1GUTC MW 539
DM1GUTC FM C26H27ClN6O5
DM1GUTC IC InChI=1S/C26H27ClN6O5/c1-28-25(38)26-10-16(26)20(21(36)22(26)37)33-13-32-19-23(30-12-31-24(19)33)29-11-14-6-5-8-17(27)15(14)7-3-2-4-9-18(34)35/h5-6,8,12-13,16,20-22,36-37H,2,4,9-11H2,1H3,(H,28,38)(H,34,35)(H,29,30,31)/t16-,20-,21+,22+,26+/m1/s1
DM1GUTC CS CNC(=O)[C@@]12C[C@@H]1[C@H]([C@@H]([C@@H]2O)O)N3C=NC4=C(N=CN=C43)NCC5=C(C(=CC=C5)Cl)C#CCCCC(=O)O
DM1GUTC IK CYQQUPOETXXUCK-CSTWGOEFSA-N
DM1GUTC IU 6-[2-chloro-6-[[[9-[(1S,2R,3S,4R,5S)-3,4-dihydroxy-5-(methylcarbamoyl)-2-bicyclo[3.1.0]hexanyl]purin-6-yl]amino]methyl]phenyl]hex-5-ynoic acid
DM1GUTC DE Discovery agent
DMDF6WG ID DMDF6WG
DMDF6WG DN MRS5698
DMDF6WG HS Investigative
DMDF6WG SN MRS-5698; MRS 5698
DMDF6WG DT Small molecular drug
DMDF6WG PC 57523213
DMDF6WG MW 565
DMDF6WG FM C28H23ClF2N6O3
DMDF6WG IC InChI=1S/C28H23ClF2N6O3/c1-32-27(40)28-11-17(28)22(23(38)24(28)39)37-13-34-21-25(33-12-15-3-2-4-16(29)9-15)35-20(36-26(21)37)8-6-14-5-7-18(30)19(31)10-14/h2-5,7,9-10,13,17,22-24,38-39H,11-12H2,1H3,(H,32,40)(H,33,35,36)/t17-,22-,23+,24+,28+/m1/s1
DMDF6WG CS CNC(=O)[C@@]12C[C@@H]1[C@H]([C@@H]([C@@H]2O)O)N3C=NC4=C(N=C(N=C43)C#CC5=CC(=C(C=C5)F)F)NCC6=CC(=CC=C6)Cl
DMDF6WG IK LYLLLJJYBWLGHW-CIZVZKTGSA-N
DMDF6WG IU (1S,2R,3S,4R,5S)-4-[6-[(3-chlorophenyl)methylamino]-2-[2-(3,4-difluorophenyl)ethynyl]purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide
DMDF6WG DE Discovery agent
DMMN42V ID DMMN42V
DMMN42V DN MRS923
DMMN42V HS Investigative
DMMN42V SN CHEMBL75169; 7555-80-8; 4H-1-Benzopyran-4-one, 2-(2,4-dimethoxyphenyl)-3,5,7-trimethoxy-; 2-(2,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one; Flavone, 2',3,4',5,7-pentamethoxy-; MRS923; Pentamethyl morin; AC1LCIM3; GTPL401; SCHEMBL1664225; CTK2G8883; MRS-923; DTXSID80348154; KPJGABLCRGWDRB-UHFFFAOYSA-N; 3,5,7,2',4'-pentamethoxyflavone; BDBM50049399; 2',3,4',5,7-Pentamethoxy flavone; AKOS030552861; 2-(2,4-Dimethoxy-phenyl)-3,5,7-trimethoxy-chromen-4-one; 2-(2,4-Dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one #
DMMN42V DT Small molecular drug
DMMN42V PC 631105
DMMN42V MW 372.4
DMMN42V FM C20H20O7
DMMN42V IC InChI=1S/C20H20O7/c1-22-11-6-7-13(14(8-11)24-3)19-20(26-5)18(21)17-15(25-4)9-12(23-2)10-16(17)27-19/h6-10H,1-5H3
DMMN42V CS COC1=CC(=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C=C3OC)OC)OC)OC
DMMN42V IK KPJGABLCRGWDRB-UHFFFAOYSA-N
DMMN42V IU 2-(2,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one
DMMN42V CA CAS 7555-80-8
DMMN42V DE Discovery agent
DMKJ9WM ID DMKJ9WM
DMKJ9WM DN MRS928
DMKJ9WM HS Investigative
DMKJ9WM SN 3,5,7-Trimethoxyflavone; 3,5,7-Trimethoxy-2-phenyl-4H-chromen-4-one; Galangin trimethyl ether; 26964-29-4; Galangin 3,5,7-trimethyl ether; 3,5,7-Trimethoxy-2-phenylchromen-4-one; Chromen-4-one, 3,5,7-trimethoxy-2-phenyl-; CHEMBL75772; CHEBI:5263; CBTHKWVPSIGKMI-UHFFFAOYSA-N; Flavone, 3,5,7-trimethoxy-; 3,5,7-Trimethoxy-2-phenyl-chromen-4-one; AC1L3LSQ; C10045; AC1Q6E1K; GTPL402; 3,5,7-Tri-O-methylgalangin; MEGxp0_001894; 4H-1-Benzopyran-4-one, 3,5,7-trimethoxy-2-phenyl-; SCHEMBL1664287; CTK8D5933; ACon1_000793; galangin trimethyl ether
DMKJ9WM DT Small molecular drug
DMKJ9WM PC 117900
DMKJ9WM MW 312.3
DMKJ9WM FM C18H16O5
DMKJ9WM IC InChI=1S/C18H16O5/c1-20-12-9-13(21-2)15-14(10-12)23-17(18(22-3)16(15)19)11-7-5-4-6-8-11/h4-10H,1-3H3
DMKJ9WM CS COC1=CC2=C(C(=C1)OC)C(=O)C(=C(O2)C3=CC=CC=C3)OC
DMKJ9WM IK CBTHKWVPSIGKMI-UHFFFAOYSA-N
DMKJ9WM IU 3,5,7-trimethoxy-2-phenylchromen-4-one
DMKJ9WM CA CAS 26964-29-4
DMKJ9WM CB CHEBI:5263
DMKJ9WM DE Discovery agent
DMYRCHG ID DMYRCHG
DMYRCHG DN MRT67307
DMYRCHG HS Investigative
DMYRCHG SN MRT-67307
DMYRCHG DT Small molecular drug
DMYRCHG PC 44464263
DMYRCHG MW 464.6
DMYRCHG FM C26H36N6O2
DMYRCHG IC InChI=1S/C26H36N6O2/c33-25(21-5-2-6-21)28-11-3-10-27-24-23(20-8-9-20)17-29-26(31-24)30-22-7-1-4-19(16-22)18-32-12-14-34-15-13-32/h1,4,7,16-17,20-21H,2-3,5-6,8-15,18H2,(H,28,33)(H2,27,29,30,31)
DMYRCHG CS C1CC(C1)C(=O)NCCCNC2=NC(=NC=C2C3CC3)NC4=CC=CC(=C4)CN5CCOCC5
DMYRCHG IK UKBGBACORPRCGG-UHFFFAOYSA-N
DMYRCHG IU N-[3-[[5-cyclopropyl-2-[3-(morpholin-4-ylmethyl)anilino]pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide
DMYRCHG CA CAS 1190378-57-4
DMYRCHG CB CHEBI:124930
DMYRCHG DE Discovery agent
DMTPGQ3 ID DMTPGQ3
DMTPGQ3 DN MS1943
DMTPGQ3 HS Investigative
DMTPGQ3 SN 2225938-17-8; SCHEMBL21271666; EX-A3962; s8918; HY-133129; CS-0112146; 6-(6-(4-(2-(2-((3r,5r,7r)-adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide; 6-(6-(4-(2-(2-(Adamantan-1-yl)acetamido)ethyl)piperazin-1-yl)pyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide
DMTPGQ3 DT Small molecular drug
DMTPGQ3 PC 139211327
DMTPGQ3 MW 718.9
DMTPGQ3 FM C42H54N8O3
DMTPGQ3 IC InChI=1S/C42H54N8O3/c1-26(2)50-37-18-33(17-34(36(37)25-46-50)40(52)45-24-35-27(3)13-28(4)47-41(35)53)32-5-6-38(44-23-32)49-11-9-48(10-12-49)8-7-43-39(51)22-42-19-29-14-30(20-42)16-31(15-29)21-42/h5-6,13,17-18,23,25-26,29-31H,7-12,14-16,19-22,24H2,1-4H3,(H,43,51)(H,45,52)(H,47,53)
DMTPGQ3 CS CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CN=C(C=C4)N5CCN(CC5)CCNC(=O)CC67CC8CC(C6)CC(C8)C7)C(C)C)C
DMTPGQ3 IK WQIQJFXBAJJKNT-UHFFFAOYSA-N
DMTPGQ3 IU 6-[6-[4-[2-[[2-(1-adamantyl)acetyl]amino]ethyl]piperazin-1-yl]pyridin-3-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylindazole-4-carboxamide
DMTPGQ3 DE Breast cancer
DMXC30P ID DMXC30P
DMXC30P DN MS417
DMXC30P HS Investigative
DMXC30P SN MS417; Methyl [(6s)-4-(4-Chlorophenyl)-2,3,9-Trimethyl-6h-Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepin-6-Yl]acetate; 916489-36-6; GGRCIHACOIMRKY-HNNXBMFYSA-N; 0S6; 4f3i; US9125915, compound 6; GTPL7512; CHEMBL3769755; SCHEMBL12228301; CHEBI:83406; BDBM179283; MS-417; ZINC95921068; HY-111139; CS-0034388; Methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; methyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6
DMXC30P DT Small molecular drug
DMXC30P PC 59190723
DMXC30P MW 414.9
DMXC30P FM C20H19ClN4O2S
DMXC30P IC InChI=1S/C20H19ClN4O2S/c1-10-11(2)28-20-17(10)18(13-5-7-14(21)8-6-13)22-15(9-16(26)27-4)19-24-23-12(3)25(19)20/h5-8,15H,9H2,1-4H3/t15-/m0/s1
DMXC30P CS CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC)C4=CC=C(C=C4)Cl)C
DMXC30P IK GGRCIHACOIMRKY-HNNXBMFYSA-N
DMXC30P IU methyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
DMXC30P CB CHEBI:83406
DMXC30P DE Discovery agent
DMNBFX0 ID DMNBFX0
DMNBFX0 DN MS436
DMNBFX0 HS Investigative
DMNBFX0 DT Small molecular drug
DMNBFX0 PC 135566899
DMNBFX0 MW 383.4
DMNBFX0 FM C18H17N5O3S
DMNBFX0 IC InChI=1S/C18H17N5O3S/c1-12-10-16(15(19)11-17(12)24)22-21-13-5-7-14(8-6-13)27(25,26)23-18-4-2-3-9-20-18/h2-11,24H,19H2,1H3,(H,20,23)
DMNBFX0 CS CC1=CC(=C(C=C1O)N)N=NC2=CC=C(C=C2)S(=O)(=O)NC3=CC=CC=N3
DMNBFX0 IK DZTGIRNXWSZBIM-UHFFFAOYSA-N
DMNBFX0 IU 4-[(2-amino-4-hydroxy-5-methylphenyl)diazenyl]-N-pyridin-2-ylbenzenesulfonamide
DMNBFX0 DE Discovery agent
DMBTPDL ID DMBTPDL
DMBTPDL DN MS453
DMBTPDL HS Investigative
DMBTPDL SN 2059892-29-2; N-(3-((6,7-dimethoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)amino)propyl)acrylamide; MS-453
DMBTPDL DT Small molecular drug
DMBTPDL PC 129896910
DMBTPDL MW 385.5
DMBTPDL FM C20H27N5O3
DMBTPDL IC InChI=1S/C20H27N5O3/c1-4-18(26)21-8-7-9-22-19-14-12-16(27-2)17(28-3)13-15(14)23-20(24-19)25-10-5-6-11-25/h4,12-13H,1,5-11H2,2-3H3,(H,21,26)(H,22,23,24)
DMBTPDL CS COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCCC3)NCCCNC(=O)C=C)OC
DMBTPDL IK QTHRXIUTSUVNPH-UHFFFAOYSA-N
DMBTPDL IU N-[3-[(6,7-dimethoxy-2-pyrrolidin-1-ylquinazolin-4-yl)amino]propyl]prop-2-enamide
DMBTPDL DE Discovery agent
DMS3O9H ID DMS3O9H
DMS3O9H DN MSC2032964A
DMS3O9H HS Investigative
DMS3O9H SN CHEMBL3330170; MSC 2032964A; 1124381-43-6; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]-3-pyridinecarboxamide; XUKGFHHTSUKORV-UHFFFAOYSA-N; MSC2032964A; SCHEMBL2788575; GTPL8076; MolPort-039-338-069; ZINC59102467; BDBM50023727; AKOS027470238; MRF-0000032; NCGC00479218-01; N-[5-(cyclopropylamino)-7-(trifluoromethyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide
DMS3O9H DT Small molecular drug
DMS3O9H PC 25214468
DMS3O9H MW 362.31
DMS3O9H FM C16H13F3N6O
DMS3O9H IC InChI=1S/C16H13F3N6O/c17-16(18,19)10-6-12(21-11-3-4-11)25-13(7-10)22-15(24-25)23-14(26)9-2-1-5-20-8-9/h1-2,5-8,11,21H,3-4H2,(H,23,24,26)
DMS3O9H CS C1CC1NC2=CC(=CC3=NC(=NN23)NC(=O)C4=CN=CC=C4)C(F)(F)F
DMS3O9H IK XUKGFHHTSUKORV-UHFFFAOYSA-N
DMS3O9H IU N-[5-(cyclopropylamino)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]pyridine-3-carboxamide
DMS3O9H DE Discovery agent
DMU67CE ID DMU67CE
DMU67CE DN MSOPPE
DMU67CE HS Investigative
DMU67CE SN alpha-methylserine-O-phosphate monophenyl ester
DMU67CE DT Small molecular drug
DMU67CE PC 5311463
DMU67CE MW 275.19
DMU67CE FM C10H14NO6P
DMU67CE IC InChI=1S/C10H14NO6P/c1-10(11,9(12)13)7-16-18(14,15)17-8-5-3-2-4-6-8/h2-6H,7,11H2,1H3,(H,12,13)(H,14,15)
DMU67CE CS CC(COP(=O)(O)OC1=CC=CC=C1)(C(=O)O)N
DMU67CE IK GBCGDIQJCHNFKA-UHFFFAOYSA-N
DMU67CE IU 2-amino-3-[hydroxy(phenoxy)phosphoryl]oxy-2-methylpropanoic acid
DMU67CE DE Discovery agent
DMUKWJ2 ID DMUKWJ2
DMUKWJ2 DN MST-400
DMUKWJ2 HS Investigative
DMUKWJ2 SN MST-400 series; MST-500 series; Integrin-linked kinase inhibitors (cancer); Integrin-linked kinase inhibitors (cancer), MetaSignal
DMUKWJ2 CP MetaSignal Therapeutics
DMUKWJ2 DE Solid tumour/cancer
DM4KM91 ID DM4KM91
DM4KM91 DN MSVIII-19
DM4KM91 HS Investigative
DM4KM91 SN 8,9-dideoxyneodysiherbaine
DM4KM91 DT Small molecular drug
DM4KM91 PC 72199906
DM4KM91 MW 258.25
DM4KM91 FM C11H16NO6-
DM4KM91 IC InChI=1S/C11H17NO6/c12-6(9(13)14)4-11(10(15)16)5-8-7(18-11)2-1-3-17-8/h6-8H,1-5,12H2,(H,13,14)(H,15,16)/p-1/t6-,7+,8+,11+/m0/s1
DM4KM91 CS C1C[C@@H]2[C@@H](C[C@](O2)(C[C@@H](C(=O)[O-])[NH3+])C(=O)[O-])OC1
DM4KM91 IK RZIYCCQNKHONBB-PRKAOEEVSA-M
DM4KM91 IU (2R,3aR,7aR)-2-[(2S)-2-azaniumyl-2-carboxylatoethyl]-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyran-2-carboxylate
DM4KM91 DE Discovery agent
DMF9HYI ID DMF9HYI
DMF9HYI DN MSX-3
DMF9HYI HS Investigative
DMF9HYI SN MSX-2
DMF9HYI CP Universitat Wurzburg
DMF9HYI DT Small molecular drug
DMF9HYI PC 10256041
DMF9HYI MW 518.4
DMF9HYI FM C21H21N4Na2O7P
DMF9HYI IC InChI=1S/C21H23N4O7P.2Na/c1-4-11-25-20(26)18-19(24(21(25)27)12-6-13-32-33(28,29)30)22-17(23(18)2)10-9-15-7-5-8-16(14-15)31-3;;/h1,5,7-10,14H,6,11-13H2,2-3H3,(H2,28,29,30);;/q;2*+1/p-2/b10-9+;;
DMF9HYI CS CN1C(=NC2=C1C(=O)N(C(=O)N2CCCOP(=O)([O-])[O-])CC#C)/C=C/C3=CC(=CC=C3)OC.[Na+].[Na+]
DMF9HYI IK ZYVZWCILYQDHNU-TTWKNDKESA-L
DMF9HYI IU disodium;3-[8-[(E)-2-(3-methoxyphenyl)ethenyl]-7-methyl-2,6-dioxo-1-prop-2-ynylpurin-3-yl]propyl phosphate
DMF9HYI DE Parkinson disease
DM7KIVX ID DM7KIVX
DM7KIVX DN MT-001
DM7KIVX HS Investigative
DM7KIVX SN Simvastatin (oral liquid formulation, pediatric hypercholesterolemia), Madeira Therapeutics
DM7KIVX CP Madeira Therapeutics LLC
DM7KIVX DE Hypercholesterolaemia
DMDK6BP ID DMDK6BP
DMDK6BP DN MT-061
DMDK6BP HS Investigative
DMDK6BP SN MT-061; Fatty acid biosynthesis inhibitor (Gram positive bacterial infection), MaxThera; MT-061 lead series, Biota; MT-061 lead series, MaxThera
DMDK6BP CP MaxThera Inc
DMDK6BP DE Gram-positive bacterial infection
DM5PD0G ID DM5PD0G
DM5PD0G DN MT-062
DM5PD0G HS Investigative
DM5PD0G SN EGFR inhibitor (melanoma), Medisyn Technologies
DM5PD0G CP Medisyn Technologies Inc
DM5PD0G DE Melanoma
DMKT1DA ID DMKT1DA
DMKT1DA DN MT-II
DMKT1DA HS Investigative
DMKT1DA SN Melanotan II; 121062-08-6; Melanotan-II; Melanotan (MT)-II; Melatonan; Melanotan II acetate salt; CHEMBL430239; L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide; (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide; Melanotan -Ii; C50H69N15O9; Asp5; Melanotan II acetate; D-Phe7; melanotan II; MTII; MTII Melanotan-II; Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2
DMKT1DA DT Small molecular drug
DMKT1DA PC 92432
DMKT1DA MW 1024.2
DMKT1DA FM C50H69N15O9
DMKT1DA IC InChI=1S/C50H69N15O9/c1-3-4-16-36(59-29(2)66)44(69)65-41-25-42(67)55-20-11-10-18-35(43(51)68)60-47(72)39(23-31-26-57-34-17-9-8-15-33(31)34)63-45(70)37(19-12-21-56-50(52)53)61-46(71)38(22-30-13-6-5-7-14-30)62-48(73)40(64-49(41)74)24-32-27-54-28-58-32/h5-9,13-15,17,26-28,35-41,57H,3-4,10-12,16,18-25H2,1-2H3,(H2,51,68)(H,54,58)(H,55,67)(H,59,66)(H,60,72)(H,61,71)(H,62,73)(H,63,70)(H,64,74)(H,65,69)(H4,52,53,56)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
DMKT1DA CS CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)N)NC(=O)C
DMKT1DA IK JDKLPDJLXHXHNV-MFVUMRCOSA-N
DMKT1DA IU (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide
DMKT1DA CA CAS 121062-08-6
DMKT1DA DE Female sexual arousal dysfunction
DMK2FOX ID DMK2FOX
DMK2FOX DN MT-Immucillin-H
DMK2FOX HS Investigative
DMK2FOX DT Small molecular drug
DMK2FOX PC 152743083
DMK2FOX MW 297.36
DMK2FOX FM C12H17N4O3S+
DMK2FOX IC InChI=1S/C12H16N4O3S/c1-20-3-6-10(17)11(18)8(16-6)5-2-13-9-7(5)14-4-15-12(9)19/h2,4,6-8,10-11,16-18H,3H2,1H3,(H,14,15,19)/p+1/t6-,7?,8-,10-,11-/m0/s1
DMK2FOX CS CSC[C@H]1[C@@H]([C@H]([C@@H]([NH2+]1)C2=CN=C3C2N=CNC3=O)O)O
DMK2FOX IK BRUVQLYKVACVPE-KTEKBNEVSA-O
DMK2FOX IU 7-[(2S,3S,4S,5R)-3,4-dihydroxy-5-(methylsulfanylmethyl)pyrrolidin-1-ium-2-yl]-3,7a-dihydropyrrolo[3,2-d]pyrimidin-4-one
DMK2FOX DE Discovery agent
DMXPIKT ID DMXPIKT
DMXPIKT DN M-tolyl 10H-phenothiazine-10-carboxylate
DMXPIKT HS Investigative
DMXPIKT SN CHEMBL481162; m-tolyl 10H-phenothiazine-10-carboxylate
DMXPIKT DT Small molecular drug
DMXPIKT PC 24905593
DMXPIKT MW 333.4
DMXPIKT FM C20H15NO2S
DMXPIKT IC InChI=1S/C20H15NO2S/c1-14-7-6-8-15(13-14)23-20(22)21-16-9-2-4-11-18(16)24-19-12-5-3-10-17(19)21/h2-13H,1H3
DMXPIKT CS CC1=CC(=CC=C1)OC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMXPIKT IK NSTBBOKFDNCGRF-UHFFFAOYSA-N
DMXPIKT IU (3-methylphenyl) phenothiazine-10-carboxylate
DMXPIKT DE Discovery agent
DM8KPWM ID DM8KPWM
DM8KPWM DN MTSEA
DM8KPWM HS Investigative
DM8KPWM SN methanethiosulfonate ethylammonium
DM8KPWM DT Small molecular drug
DM8KPWM PC 53443082
DM8KPWM MW 155.2
DM8KPWM FM C3H9NO2S2
DM8KPWM IC InChI=1S/C3H9NO2S2/c1-8(5,7)6-3-2-4/h2-4H2,1H3
DM8KPWM CS CS(=O)(=S)OCCN
DM8KPWM IK HKERMLQDWIEJQS-UHFFFAOYSA-N
DM8KPWM IU 2-methylsulfonothioyloxyethanamine
DM8KPWM DE Discovery agent
DM16F75 ID DM16F75
DM16F75 DN MUG trihydrate
DM16F75 HS Investigative
DM16F75 SN 4-methylumbelliferyl-beta-d-glucuronide; 4-Methylumbelliferone glucuronide; ARQXEQLMMNGFDU-JHZZJYKESA-N; MolMap_000057; ST044517; (2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid; 4-Methyl-2-oxo-2H-1-benzopyran-7-yl beta-D-glucopyranosiduronic acid; 4-Methylumbelliferyl beta-glucuronide; 4-Methylumbelliferyl glucuronide; 4-Methylumbelliferyl-beta-D-glucuronide; 4-methylumbelliferone beta-d-glucuronide; 6160-80-1; CHEBI:1904; MFCD00036772
DM16F75 PC 91553
DM16F75 MW 352.29
DM16F75 FM C16H16O9
DM16F75 IC ARQXEQLMMNGFDU-JHZZJYKESA-N
DM16F75 CS CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(C(O3)C(=O)O)O)O)O
DM16F75 IK 1S/C16H16O9/c1-6-4-10(17)24-9-5-7(2-3-8(6)9)23-16-13(20)11(18)12(19)14(25-16)15(21)22/h2-5,11-14,16,18-20H,1H3,(H,21,22)/t11-,12-,13+,14-,16+/m0/s1
DM16F75 IU (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(4-methyl-2-oxochromen-7-yl)oxyoxane-2-carboxylic acid
DM16F75 CA CAS 6160-80-1
DM16F75 CB CHEBI:1904
DM16F75 DE Discovery agent
DMYV49C ID DMYV49C
DMYV49C DN Mulberrofuran C
DMYV49C HS Investigative
DMYV49C SN Mulberrofuran C; 77996-04-4; CHEBI:7018; CHEMBL378806; AC1L4HGH; C08928; SCHEMBL2790659; MolPort-039-338-387; ZINC4097826; BDBM50179010; 4CN-0560; Methanone, ((1S,2R,6R)-2-(2,6-dihydroxy-4-(6-hydroxy-2-benzofuranyl)phenyl)-6-(2,4-dihydroxyphenyl)-4-methyl-3-cyclohexen-1-yl)(2,4-dihydroxyphenyl)-
DMYV49C DT Small molecular drug
DMYV49C PC 157143
DMYV49C MW 580.6
DMYV49C FM C34H28O9
DMYV49C IC InChI=1S/C34H28O9/c1-16-8-24(22-6-4-19(35)13-26(22)38)32(34(42)23-7-5-20(36)14-27(23)39)25(9-16)33-28(40)10-18(11-29(33)41)30-12-17-2-3-21(37)15-31(17)43-30/h2-7,9-15,24-25,32,35-41H,8H2,1H3/t24-,25+,32-/m0/s1
DMYV49C CS CC1=C[C@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C(C=C(C=C4O)C5=CC6=C(O5)C=C(C=C6)O)O
DMYV49C IK WTGKDESIYCVAOP-UNTHUGQZSA-N
DMYV49C IU [(1S,2R,6R)-2-[2,6-dihydroxy-4-(6-hydroxy-1-benzofuran-2-yl)phenyl]-6-(2,4-dihydroxyphenyl)-4-methylcyclohex-3-en-1-yl]-(2,4-dihydroxyphenyl)methanone
DMYV49C CA CAS 77996-04-4
DMYV49C CB CHEBI:7018
DMYV49C DE Discovery agent
DMMKH72 ID DMMKH72
DMMKH72 DN Mulberrofuran D
DMMKH72 HS Investigative
DMMKH72 SN Mulberrofuran D; NSC649227; CHEMBL517247; AC1Q7B8J; AC1NV3E8; SCHEMBL13233447; 5-[7-(3,7-dimethylocta-2,6-dien-1-yl)-6-hydroxy-1-benzofuran-2-yl]-4-(3-methylbut-2-en-1-yl)benzene-1,3-diol; BDBM50303006; NSC-649227; 5-[7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-hydroxy-benzofuran-2-yl]-4-(3-methylbut-2-enyl)benzene-1,3-diol; 5-[7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-hydroxy-1-benzofuran-2-yl]-4-(3-methylbut-2-enyl)benzene-1,3-diol
DMMKH72 DT Small molecular drug
DMMKH72 PC 5467256
DMMKH72 MW 446.6
DMMKH72 FM C29H34O4
DMMKH72 IC InChI=1S/C29H34O4/c1-18(2)7-6-8-20(5)10-13-24-26(31)14-11-21-15-28(33-29(21)24)25-16-22(30)17-27(32)23(25)12-9-19(3)4/h7,9-11,14-17,30-32H,6,8,12-13H2,1-5H3/b20-10+
DMMKH72 CS CC(=CCC/C(=C/CC1=C(C=CC2=C1OC(=C2)C3=C(C(=CC(=C3)O)O)CC=C(C)C)O)/C)C
DMMKH72 IK WCJPAQJEARHLGS-KEBDBYFISA-N
DMMKH72 IU 5-[7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6-hydroxy-1-benzofuran-2-yl]-4-(3-methylbut-2-enyl)benzene-1,3-diol
DMMKH72 DE Discovery agent
DMTV9P3 ID DMTV9P3
DMTV9P3 DN Mulberrofuran W
DMTV9P3 HS Investigative
DMTV9P3 SN mulberrofuran W; CHEMBL562810
DMTV9P3 DT Small molecular drug
DMTV9P3 PC 45273151
DMTV9P3 MW 446.6
DMTV9P3 FM C29H34O4
DMTV9P3 IC InChI=1S/C29H34O4/c1-19(2)7-5-8-20(3)9-6-10-21(4)11-14-25-26(16-24(31)17-27(25)32)29-15-22-12-13-23(30)18-28(22)33-29/h7,9,11-13,15-18,30-32H,5-6,8,10,14H2,1-4H3/b20-9-,21-11-
DMTV9P3 CS CC(=CCC/C(=C\\CC/C(=C\\CC1=C(C=C(C=C1O)O)C2=CC3=C(O2)C=C(C=C3)O)/C)/C)C
DMTV9P3 IK YUFBSQFJPYHMTK-QUYCRGELSA-N
DMTV9P3 IU 5-(6-hydroxy-1-benzofuran-2-yl)-4-[(2Z,6Z)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzene-1,3-diol
DMTV9P3 DE Discovery agent
DMW2Z4I ID DMW2Z4I
DMW2Z4I DN Multiform PI3K inhibitors
DMW2Z4I HS Investigative
DMW2Z4I SN Multiform PI3K inhibitors (inflammation); Multiform PI3K inhibitors (inflammation), UCB
DMW2Z4I CP UCB Celltech
DMW2Z4I DE Inflammation
DM6SYMH ID DM6SYMH
DM6SYMH DN Mumbaistatin
DM6SYMH HS Investigative
DM6SYMH SN MUMBAISTATIN; CHEMBL238371
DM6SYMH DT Small molecular drug
DM6SYMH PC 9850474
DM6SYMH MW 548.4
DM6SYMH FM C28H20O12
DM6SYMH IC InChI=1S/C28H20O12/c29-11(9-19(34)35)7-8-15(30)12-3-1-5-16(31)20(12)27(38)24-22-14(10-18(33)23(24)28(39)40)25(36)13-4-2-6-17(32)21(13)26(22)37/h1-6,10-11,29,31-33H,7-9H2,(H,34,35)(H,39,40)
DM6SYMH CS C1=CC2=C(C(=C1)O)C(=O)C3=C(C(=C(C=C3C2=O)O)C(=O)O)C(=O)C4=C(C=CC=C4O)C(=O)CCC(CC(=O)O)O
DM6SYMH IK XFESZXMDORIFAO-UHFFFAOYSA-N
DM6SYMH IU 1-[2-(5-carboxy-4-hydroxypentanoyl)-6-hydroxybenzoyl]-3,8-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid
DM6SYMH DE Discovery agent
DM4FR71 ID DM4FR71
DM4FR71 DN muramyl dipeptide
DM4FR71 HS Investigative
DM4FR71 SN Muramyl Dipeptide; N-Acetylmuramyl-L-alanyl-D-isoglutamine; muramyldipeptide; CHEBI:59414; MurNAc-L-Ala-gamma-D-Glu; Acetylmuramyl-L-alanyl-D-isoglutamine; Acetylmuramyl-alanyl-isoglutamine; 87420-48-2; 53678-77-6; (4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3s,4r,5r,6r)-5-Acetamido-2-(Hydroxymethyl)-3,6-Bis(Oxidanyl)oxan-4-Yl]oxypropanoyl]amino]propanoyl]amino]-5-Azanyl-5-Oxidanylidene-Pentanoic Acid
DM4FR71 DT Small molecular drug
DM4FR71 PC 451714
DM4FR71 MW 492.5
DM4FR71 FM C19H32N4O11
DM4FR71 IC InChI=1S/C19H32N4O11/c1-7(17(30)23-10(16(20)29)4-5-12(26)27)21-18(31)8(2)33-15-13(22-9(3)25)19(32)34-11(6-24)14(15)28/h7-8,10-11,13-15,19,24,28,32H,4-6H2,1-3H3,(H2,20,29)(H,21,31)(H,22,25)(H,23,30)(H,26,27)/t7-,8+,10+,11+,13+,14+,15+,19+/m0/s1
DM4FR71 CS C[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N)NC(=O)[C@@H](C)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@H]1O)CO)O)NC(=O)C
DM4FR71 IK BSOQXXWZTUDTEL-ZUYCGGNHSA-N
DM4FR71 IU (4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid
DM4FR71 CA CAS 87420-48-2
DM4FR71 CB CHEBI:59414
DM4FR71 DE Discovery agent
DMNDUJ5 ID DMNDUJ5
DMNDUJ5 DN Muscarine
DMNDUJ5 HS Investigative
DMNDUJ5 SN MUSCARINE; Muscarin; L-(+)-Muscarine; Muskarin; (+)-Muscarine; Muscarine (alkaloid); Muscarine (the alkaloid); UNII-7T101UWZ5W; (+)-(2S,4R,5S)-Muscarine; 300-54-9; EINECS 206-094-1; CHEMBL12587; CHEBI:7034; MUSCARINE CHLORIDE; 7T101UWZ5W; 2-Furanmethanaminium, tetrahydro-4-hydroxy-N,N,N,5-tetramethyl-, (2S-(2alpha,4beta,5alpha))-; Ammonium, trimethyl(tetrahydro-4-hydroxy-5-methylfurfuryl)-; D-ribo-Hexitol, 2,5-anhydro-1,4,6-trideoxy-6-(trimethyl)ammonio)-; CHEMBL292911; CHEMBL1255785
DMNDUJ5 DT Small molecular drug
DMNDUJ5 PC 9308
DMNDUJ5 MW 174.26
DMNDUJ5 FM C9H20NO2+
DMNDUJ5 IC InChI=1S/C9H20NO2/c1-7-9(11)5-8(12-7)6-10(2,3)4/h7-9,11H,5-6H2,1-4H3/q+1/t7-,8-,9+/m0/s1
DMNDUJ5 CS C[C@H]1[C@@H](C[C@H](O1)C[N+](C)(C)C)O
DMNDUJ5 IK UQOFGTXDASPNLL-XHNCKOQMSA-N
DMNDUJ5 IU [(2S,4R,5S)-4-hydroxy-5-methyloxolan-2-yl]methyl-trimethylazanium
DMNDUJ5 CA CAS 300-54-9
DMNDUJ5 CB CHEBI:7034
DMNDUJ5 DE Discovery agent
DMNTF2O ID DMNTF2O
DMNTF2O DN Muscimol
DMNTF2O HS Investigative
DMNTF2O SN muscimol; 2763-96-4; Pantherine; Agarin; Agarine; 3(2H)-Isoxazolone, 5-(aminomethyl)-; Pantherin; 5-Aminomethyl-3-isoxyzole; 3-Hydroxy-5-aminomethylisoxazole; 5-Aminomethyl-3-hydroxyisoxazole; 5-(Aminomethyl)-3-isoxazolol; 3-Isoxazolol, 5-(aminomethyl)-; 5-(Aminomethyl)-3(2H)-isoxazolone; RCRA waste number P007; NSC 333569; 3-Hydroxy-5-aminomethyl-isoxazole; UNII-D5M179TY2E; 3-Hydroxy-5-aminomethylisoxazole-agarin; CCRIS 3720; C4H6N2O2; CHEBI:7035; HSDB 6036; EINECS 220-430-4; RCRA waste no. P007; 5-(Aminomethyl)isoxazol-3-ol hydr
DMNTF2O DT Small molecular drug
DMNTF2O PC 4266
DMNTF2O MW 114.1
DMNTF2O FM C4H6N2O2
DMNTF2O IC InChI=1S/C4H6N2O2/c5-2-3-1-4(7)6-8-3/h1H,2,5H2,(H,6,7)
DMNTF2O CS C1=C(ONC1=O)CN
DMNTF2O IK ZJQHPWUVQPJPQT-UHFFFAOYSA-N
DMNTF2O IU 5-(aminomethyl)-1,2-oxazol-3-one
DMNTF2O CA CAS 2763-96-4
DMNTF2O CB CHEBI:7035
DMNTF2O DE Discovery agent
DMAY50R ID DMAY50R
DMAY50R DN Mutated growth hormone
DMAY50R HS Investigative
DMAY50R CP JCR Pharmaceuticals
DMAY50R DE Acromegaly
DMU65NK ID DMU65NK
DMU65NK DN Mycophenolic acid
DMU65NK HS Investigative
DMU65NK SN Acide mycophenolique; Acide mycophenolique [INN-French]; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycoph; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T
DMU65NK TC Antiviral Agents
DMU65NK DT Small molecular drug
DMU65NK PC 446541
DMU65NK MW 320.3
DMU65NK FM C17H20O6
DMU65NK IC InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
DMU65NK CS CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)O)O
DMU65NK IK HPNSFSBZBAHARI-RUDMXATFSA-N
DMU65NK IU (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
DMU65NK CA CAS 24280-93-1
DMU65NK CB CHEBI:168396
DMU65NK DE Middle East Respiratory Syndrome (MERS); Middle East Respiratory Syndrome (MERS)
DMUQP3J ID DMUQP3J
DMUQP3J DN Mycophenolic bis(sulfonamide)
DMUQP3J HS Investigative
DMUQP3J SN Mycophenolic bis(sulfonamide); CHEMBL476562
DMUQP3J DT Small molecular drug
DMUQP3J PC 44578788
DMUQP3J MW 394.4
DMUQP3J FM C13H18N2O8S2
DMUQP3J IC InChI=1S/C13H18N2O8S2/c1-7-9-5-23-13(17)10(9)11(16)8(12(7)22-2)3-4-15-25(20,21)6-24(14,18)19/h15-16H,3-6H2,1-2H3,(H2,14,18,19)
DMUQP3J CS CC1=C2COC(=O)C2=C(C(=C1OC)CCNS(=O)(=O)CS(=O)(=O)N)O
DMUQP3J IK IVAOVFUEHDFBPQ-UHFFFAOYSA-N
DMUQP3J IU N'-[2-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)ethyl]methanedisulfonamide
DMUQP3J DE Discovery agent
DM4YRAH ID DM4YRAH
DM4YRAH DN Mycophenolic hydroxamic acid
DM4YRAH HS Investigative
DM4YRAH SN CHEMBL238461; mycophenolic hydroxamic acid; BDBM50228085; N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enamide
DM4YRAH DT Small molecular drug
DM4YRAH PC 24749070
DM4YRAH MW 335.4
DM4YRAH FM C17H21NO6
DM4YRAH IC InChI=1S/C17H21NO6/c1-9(5-7-13(19)18-22)4-6-11-15(20)14-12(8-24-17(14)21)10(2)16(11)23-3/h4,20,22H,5-8H2,1-3H3,(H,18,19)/b9-4+
DM4YRAH CS CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)NO)O
DM4YRAH IK XUEGRBSFQYYISJ-RUDMXATFSA-N
DM4YRAH IU (E)-N-hydroxy-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enamide
DM4YRAH DE Discovery agent
DMX1POR ID DMX1POR
DMX1POR DN MYOSEVERIN
DMX1POR HS Investigative
DMX1POR SN myoseverin; 267402-71-1; 9-Isopropyl-N2,N6-bis-(4-methoxybenzyl)-9H-purine-2,6-diamine; 9-Isopropyl-N2,N6-bis(4-methoxybenzyl)-9H-purine-2,6-diamine; AC1L1HSM; AC1Q4VJQ; 9-Isopropyl-2,6-bis(4-methoxybenzylamino)purine; CHEMBL141689; SCHEMBL13325947; CTK8E8888; MolPort-003-958-703; HMS2043N15; KS-000012SJ; ZINC2583630; n,n'-bis(4-methoxybenzyl)-9-(propan-2-yl)-9h-purine-2,6-diamine; HSCI1_000041; IN1218; AKOS027326433; TRA0035814; SMP2_000092; NCGC00165829-01; ACM267402711; RT-013973; M2373; J-016534
DMX1POR DT Small molecular drug
DMX1POR PC 4273
DMX1POR MW 432.5
DMX1POR FM C24H28N6O2
DMX1POR IC InChI=1S/C24H28N6O2/c1-16(2)30-15-27-21-22(25-13-17-5-9-19(31-3)10-6-17)28-24(29-23(21)30)26-14-18-7-11-20(32-4)12-8-18/h5-12,15-16H,13-14H2,1-4H3,(H2,25,26,28,29)
DMX1POR CS CC(C)N1C=NC2=C(N=C(N=C21)NCC3=CC=C(C=C3)OC)NCC4=CC=C(C=C4)OC
DMX1POR IK IDCOTQWQVPRTNK-UHFFFAOYSA-N
DMX1POR IU 2-N,6-N-bis[(4-methoxyphenyl)methyl]-9-propan-2-ylpurine-2,6-diamine
DMX1POR DE Discovery agent
DMTV4L0 ID DMTV4L0
DMTV4L0 DN Myricetin
DMTV4L0 HS Investigative
DMTV4L0 SN myricetin; 529-44-2; Cannabiscetin; Myricetol; Myricitin; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; 3,3',4',5,5',7-Hexahydroxyflavone; 3,5,7,3',4',5'-Hexahydroxyflavone; UNII-76XC01FTOJ; NSC 407290; CCRIS 5838; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; EINECS 208-463-2; NSC407290; CHEMBL164; NSC-407290; BRN 0332331; 76XC01FTOJ
DMTV4L0 DT Small molecular drug
DMTV4L0 PC 5281672
DMTV4L0 MW 318.23
DMTV4L0 FM C15H10O8
DMTV4L0 IC InChI=1S/C15H10O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,16-20,22H
DMTV4L0 CS C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O
DMTV4L0 IK IKMDFBPHZNJCSN-UHFFFAOYSA-N
DMTV4L0 IU 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
DMTV4L0 CA CAS 529-44-2
DMTV4L0 CB CHEBI:18152
DMTV4L0 DE Discovery agent
DMVXW4L ID DMVXW4L
DMVXW4L DN MYRIOCIN
DMVXW4L HS Investigative
DMVXW4L SN Myriocin; thermozymocidin; 35891-70-4; ISP-I; ISP-1; UNII-YRM4E8R9ST; (2S,3R,4R,6E)-2-Amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxo-6-eicosenoic acid; YRM4E8R9ST; Myriocin, Mycelia sterilia; Myriocin from Mycelia sterilia; CHEBI:582124; NCGC00163597-02; NCGC00163597-03; DSSTox_CID_26360; DSSTox_RID_81561; (2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid; DSSTox_GSID_46360; [2S,3R,4R]-(E)-2-Amino-3,4-dihydroxy-2-[hydroxymethyl]-14-oxo-6-eicosenoic Acid
DMVXW4L DT Small molecular drug
DMVXW4L PC 6438394
DMVXW4L MW 401.5
DMVXW4L FM C21H39NO6
DMVXW4L IC InChI=1S/C21H39NO6/c1-2-3-4-10-13-17(24)14-11-8-6-5-7-9-12-15-18(25)19(26)21(22,16-23)20(27)28/h9,12,18-19,23,25-26H,2-8,10-11,13-16,22H2,1H3,(H,27,28)/b12-9+/t18-,19+,21+/m1/s1
DMVXW4L CS CCCCCCC(=O)CCCCCC/C=C/C[C@H]([C@@H]([C@@](CO)(C(=O)O)N)O)O
DMVXW4L IK ZZIKIHCNFWXKDY-GNTQXERDSA-N
DMVXW4L IU (E,2S,3R,4R)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoicos-6-enoic acid
DMVXW4L CA CAS 35891-70-4
DMVXW4L CB CHEBI:582124
DMVXW4L DE Discovery agent
DMVMHTC ID DMVMHTC
DMVMHTC DN Myrisglycerol-phosphate
DMVMHTC HS Investigative
DMVMHTC SN Myristoyl lysophosphatidic acid; PA(14:0/0:0); (2R)-2-hydroxy-3-(phosphonooxy)propyl myristate; 1-Myristoyl-sn-glycerol 3-phosphate; 1-O-myristoyl-sn-glycerol 3-phosphate; 1-O-tetradecanoyl-sn-glycerol 3-phosphate; 1-myristoyl LPA; 1-myristoyl lysophosphatidic acid; 1-myristoyl-2-lyso-sn-glycerol 3-phosphatidic acid; 1-myristoylglycerol 3-phosphate; 1-tetradecanoyl-sn-glycero-3-phosphate; 1-tetradecanoyl-sn-glycerol 3-phosphate; 1-tetradecanoylglycerol 3-phosphate; CHEBI:62833
DMVMHTC PC 9547180
DMVMHTC MW 382.4
DMVMHTC FM C17H35O7P
DMVMHTC IC FAZBDRGXCKPVJU-MRXNPFEDSA-N
DMVMHTC CS CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)O
DMVMHTC IK 1S/C17H35O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-17(19)23-14-16(18)15-24-25(20,21)22/h16,18H,2-15H2,1H3,(H2,20,21,22)/t16-/m1/s1
DMVMHTC IU [(2R)-2-hydroxy-3-phosphonooxypropyl] tetradecanoate
DMVMHTC CA CAS 65446-07-3
DMVMHTC CB CHEBI:62833
DMVMHTC DE Discovery agent
DMYX0BL ID DMYX0BL
DMYX0BL DN MYRISTIC ACID
DMYX0BL HS Investigative
DMYX0BL SN Tetradecanoic acid; MYRISTIC ACID; 544-63-8; n-Tetradecanoic acid; n-Tetradecoic acid; Crodacid; n-Tetradecan-1-oic acid; 1-Tridecanecarboxylic acid; Univol U 316S; Hydrofol acid 1495; Emery 655; Myristinsaeure; Myristate; tetradecoic acid; Hystrene 9014; Neo-fat 14; Myristic acid (natural); C14 fatty acid; Myristic acid, pure; n-Myristic acid; Tetradecanoate; acide tetradecanoique; NSC 5028; FEMA No. 2764; CCRIS 4724; CH3-[CH2]12-COOH; HSDB 5686; UNII-0I3V7S25AW; Philacid 1400; CHEBI:28875; AI3-15381; Prifac 2942; C14:0; EINECS 208-875-2
DMYX0BL DT Small molecular drug
DMYX0BL PC 11005
DMYX0BL MW 228.37
DMYX0BL FM C14H28O2
DMYX0BL IC InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)
DMYX0BL CS CCCCCCCCCCCCCC(=O)O
DMYX0BL IK TUNFSRHWOTWDNC-UHFFFAOYSA-N
DMYX0BL IU tetradecanoic acid
DMYX0BL CA CAS 544-63-8
DMYX0BL CB CHEBI:28875
DMYX0BL DE Discovery agent
DMV7NGS ID DMV7NGS
DMV7NGS DN Myristoyl-Coa
DMV7NGS HS Investigative
DMV7NGS SN MYA; AC1L9JG6; S-[2-[3-[[(2S)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] tetradecanethioate
DMV7NGS DT Small molecular drug
DMV7NGS PC 11966124
DMV7NGS MW 977.9
DMV7NGS FM C35H62N7O17P3S
DMV7NGS IC InChI=1S/C35H62N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h22-24,28-30,34,45-46H,4-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/t24-,28-,29-,30+,34-/m1/s1
DMV7NGS CS CCCCCCCCCCCCCC(=O)SCCNC(=O)CCNC(=O)[C@@H](C(C)(C)COP(=O)(O)OP(=O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)O
DMV7NGS IK DUAFKXOFBZQTQE-QSGBVPJFSA-N
DMV7NGS IU S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] tetradecanethioate
DMV7NGS CA CAS 3130-72-1
DMV7NGS CB CHEBI:15532
DMV7NGS DE Discovery agent
DMGJYIZ ID DMGJYIZ
DMGJYIZ DN MystiLol
DMGJYIZ HS Investigative
DMGJYIZ SN MystiLol (non-selective beta blocker, glaucoma), Mystic
DMGJYIZ CP Mystic Pharmaceuticals Inc
DMGJYIZ DE Glaucoma/ocular hypertension
DM16SVM ID DM16SVM
DM16SVM DN Myxopyronin B
DM16SVM HS Investigative
DM16SVM DT Small molecular drug
DM16SVM PC 135423114
DM16SVM MW 431.5
DM16SVM FM C24H33NO6
DM16SVM IC InChI=1S/C24H33NO6/c1-6-7-10-16(2)12-13-18(4)22(27)21-19(26)15-20(31-23(21)28)17(3)11-8-9-14-25-24(29)30-5/h9,12-15,17,26H,6-8,10-11H2,1-5H3,(H,25,29)/b14-9+,16-12+,18-13+/t17-/m1/s1
DM16SVM CS CCCC/C(=C/C=C(\\C)/C(=O)C1=C(C=C(OC1=O)[C@H](C)CC/C=C/NC(=O)OC)O)/C
DM16SVM IK SPQDIDVJAZFBRL-WXFBSNOUSA-N
DM16SVM IU methyl N-[(E,5R)-5-[5-[(2E,4E)-2,5-dimethylnona-2,4-dienoyl]-4-hydroxy-6-oxopyran-2-yl]hex-1-enyl]carbamate
DM16SVM CA CAS 88192-99-8
DM16SVM DE Discovery agent
DM093GO ID DM093GO
DM093GO DN N-((1H-indol-2-yl)methyl)(phenyl)methanamine
DM093GO HS Investigative
DM093GO SN CHEMBL45511; N-((1H-indol-2-yl)methyl)(phenyl)methanamine; Oprea1_729586; SCHEMBL4104078; MolPort-003-806-990; ZINC13807947; BDBM50087789; AKOS006041743; 2-[(phenylmethylamino)-methyl]-indole; Benzyl-(1H-indol-2-ylmethyl)-amine (FA4)
DM093GO DT Small molecular drug
DM093GO PC 13680885
DM093GO MW 236.31
DM093GO FM C16H16N2
DM093GO IC InChI=1S/C16H16N2/c1-2-6-13(7-3-1)11-17-12-15-10-14-8-4-5-9-16(14)18-15/h1-10,17-18H,11-12H2
DM093GO CS C1=CC=C(C=C1)CNCC2=CC3=CC=CC=C3N2
DM093GO IK CCDCVAKHGAIARI-UHFFFAOYSA-N
DM093GO IU N-(1H-indol-2-ylmethyl)-1-phenylmethanamine
DM093GO DE Discovery agent
DMYUAXR ID DMYUAXR
DMYUAXR DN N-((1H-indol-2-yl)methyl)-2-phenylethanamine
DMYUAXR HS Investigative
DMYUAXR SN CHEMBL446960; N-((1H-indol-2-yl)methyl)-2-phenylethanamine
DMYUAXR DT Small molecular drug
DMYUAXR PC 44588174
DMYUAXR MW 250.34
DMYUAXR FM C17H18N2
DMYUAXR IC InChI=1S/C17H18N2/c1-2-6-14(7-3-1)10-11-18-13-16-12-15-8-4-5-9-17(15)19-16/h1-9,12,18-19H,10-11,13H2
DMYUAXR CS C1=CC=C(C=C1)CCNCC2=CC3=CC=CC=C3N2
DMYUAXR IK LMNUEZRZRYCQSM-UHFFFAOYSA-N
DMYUAXR IU N-(1H-indol-2-ylmethyl)-2-phenylethanamine
DMYUAXR DE Discovery agent
DMBQ5NS ID DMBQ5NS
DMBQ5NS DN N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
DMBQ5NS HS Investigative
DMBQ5NS SN N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
DMBQ5NS DT Small molecular drug
DMBQ5NS PC 17945750
DMBQ5NS MW 285.34
DMBQ5NS FM C16H19N3O2
DMBQ5NS IC InChI=1S/C16H19N3O2/c17-11-12-18-15(21)16(9-5-2-6-10-16)19-14(20)13-7-3-1-4-8-13/h1,3-4,7-8H,2,5-6,9-10,12H2,(H,18,21)(H,19,20)
DMBQ5NS CS C1CCC(CC1)(C(=O)NCC#N)NC(=O)C2=CC=CC=C2
DMBQ5NS IK CSOZFSBRJJRGIA-UHFFFAOYSA-N
DMBQ5NS IU N-[1-(cyanomethylcarbamoyl)cyclohexyl]benzamide
DMBQ5NS DE Discovery agent
DMJWTH9 ID DMJWTH9
DMJWTH9 DN N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide
DMJWTH9 HS Investigative
DMJWTH9 SN CHEMBL228865; N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide
DMJWTH9 DT Small molecular drug
DMJWTH9 PC 44426498
DMJWTH9 MW 358.5
DMJWTH9 FM C24H26N2O
DMJWTH9 IC InChI=1S/C24H26N2O/c1-18(19-8-3-2-4-9-19)26-16-14-21(15-17-26)25-24(27)23-13-7-11-20-10-5-6-12-22(20)23/h2-13,18,21H,14-17H2,1H3,(H,25,27)
DMJWTH9 CS CC(C1=CC=CC=C1)N2CCC(CC2)NC(=O)C3=CC=CC4=CC=CC=C43
DMJWTH9 IK ZNKBVXRAPNKVHW-UHFFFAOYSA-N
DMJWTH9 IU N-[1-(1-phenylethyl)piperidin-4-yl]naphthalene-1-carboxamide
DMJWTH9 DE Discovery agent
DMMCGL3 ID DMMCGL3
DMMCGL3 DN N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide
DMMCGL3 HS Investigative
DMMCGL3 SN CHEMBL229023; N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide
DMMCGL3 DT Small molecular drug
DMMCGL3 PC 44426508
DMMCGL3 MW 358.5
DMMCGL3 FM C24H26N2O
DMMCGL3 IC InChI=1S/C24H26N2O/c1-18(19-7-3-2-4-8-19)26-15-13-23(14-16-26)25-24(27)22-12-11-20-9-5-6-10-21(20)17-22/h2-12,17-18,23H,13-16H2,1H3,(H,25,27)
DMMCGL3 CS CC(C1=CC=CC=C1)N2CCC(CC2)NC(=O)C3=CC4=CC=CC=C4C=C3
DMMCGL3 IK LVIBIBUWEMTPMC-UHFFFAOYSA-N
DMMCGL3 IU N-[1-(1-phenylethyl)piperidin-4-yl]naphthalene-2-carboxamide
DMMCGL3 DE Discovery agent
DMGYLC1 ID DMGYLC1
DMGYLC1 DN N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide
DMGYLC1 HS Investigative
DMGYLC1 SN CHEMBL395631; N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide
DMGYLC1 DT Small molecular drug
DMGYLC1 PC 44431465
DMGYLC1 MW 423.3
DMGYLC1 FM C23H23BrN2O
DMGYLC1 IC InChI=1S/C23H23BrN2O/c24-19-8-3-5-17(15-19)16-26-13-11-20(12-14-26)25-23(27)22-10-4-7-18-6-1-2-9-21(18)22/h1-10,15,20H,11-14,16H2,(H,25,27)
DMGYLC1 CS C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CC4=CC(=CC=C4)Br
DMGYLC1 IK USZMCEOIEOTIGM-UHFFFAOYSA-N
DMGYLC1 IU N-[1-[(3-bromophenyl)methyl]piperidin-4-yl]naphthalene-1-carboxamide
DMGYLC1 DE Discovery agent
DMRQKYC ID DMRQKYC
DMRQKYC DN N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMRQKYC HS Investigative
DMRQKYC SN CHEMBL395867; N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMRQKYC DT Small molecular drug
DMRQKYC PC 16725931
DMRQKYC MW 423.3
DMRQKYC FM C23H23BrN2O
DMRQKYC IC InChI=1S/C23H23BrN2O/c24-21-7-3-4-17(14-21)16-26-12-10-22(11-13-26)25-23(27)20-9-8-18-5-1-2-6-19(18)15-20/h1-9,14-15,22H,10-13,16H2,(H,25,27)
DMRQKYC CS C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC(=CC=C4)Br
DMRQKYC IK KMQWTBGTEFASGU-UHFFFAOYSA-N
DMRQKYC IU N-[1-[(3-bromophenyl)methyl]piperidin-4-yl]naphthalene-2-carboxamide
DMRQKYC DE Discovery agent
DMS9RDW ID DMS9RDW
DMS9RDW DN N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMS9RDW HS Investigative
DMS9RDW SN CHEMBL234472; N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide
DMS9RDW DT Small molecular drug
DMS9RDW PC 44431481
DMS9RDW MW 423.3
DMS9RDW FM C23H23BrN2O
DMS9RDW IC InChI=1S/C23H23BrN2O/c24-21-9-5-17(6-10-21)16-26-13-11-22(12-14-26)25-23(27)20-8-7-18-3-1-2-4-19(18)15-20/h1-10,15,22H,11-14,16H2,(H,25,27)
DMS9RDW CS C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)Br
DMS9RDW IK WZCSZVSNRKEGGN-UHFFFAOYSA-N
DMS9RDW IU N-[1-[(4-bromophenyl)methyl]piperidin-4-yl]naphthalene-2-carboxamide
DMS9RDW DE Discovery agent
DMAP4R8 ID DMAP4R8
DMAP4R8 DN N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide
DMAP4R8 HS Investigative
DMAP4R8 SN CHEMBL234644; N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide
DMAP4R8 DT Small molecular drug
DMAP4R8 PC 44431485
DMAP4R8 MW 389.4
DMAP4R8 FM C23H23N3O3
DMAP4R8 IC InChI=1S/C23H23N3O3/c27-23(20-8-7-18-3-1-2-4-19(18)15-20)24-21-11-13-25(14-12-21)16-17-5-9-22(10-6-17)26(28)29/h1-10,15,21H,11-14,16H2,(H,24,27)
DMAP4R8 CS C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC=C(C=C4)[N+](=O)[O-]
DMAP4R8 IK BAYSOSKDAJWQFJ-UHFFFAOYSA-N
DMAP4R8 IU N-[1-[(4-nitrophenyl)methyl]piperidin-4-yl]naphthalene-2-carboxamide
DMAP4R8 DE Discovery agent
DMQSLJI ID DMQSLJI
DMQSLJI DN N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide
DMQSLJI HS Investigative
DMQSLJI SN CHEMBL387952; N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide
DMQSLJI DT Small molecular drug
DMQSLJI PC 44426502
DMQSLJI MW 386.5
DMQSLJI FM C26H30N2O
DMQSLJI IC InChI=1S/C26H30N2O/c29-26(25-15-8-13-22-12-4-5-14-24(22)25)27-23-16-19-28(20-17-23)18-7-6-11-21-9-2-1-3-10-21/h1-5,8-10,12-15,23H,6-7,11,16-20H2,(H,27,29)
DMQSLJI CS C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CCCCC4=CC=CC=C4
DMQSLJI IK JATDEOORDLHCRO-UHFFFAOYSA-N
DMQSLJI IU N-[1-(4-phenylbutyl)piperidin-4-yl]naphthalene-1-carboxamide
DMQSLJI DE Discovery agent
DMZ84JH ID DMZ84JH
DMZ84JH DN N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide
DMZ84JH HS Investigative
DMZ84JH SN CHEMBL229025; N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide
DMZ84JH DT Small molecular drug
DMZ84JH PC 44426510
DMZ84JH MW 386.5
DMZ84JH FM C26H30N2O
DMZ84JH IC InChI=1S/C26H30N2O/c29-26(24-14-13-22-11-4-5-12-23(22)20-24)27-25-15-18-28(19-16-25)17-7-6-10-21-8-2-1-3-9-21/h1-5,8-9,11-14,20,25H,6-7,10,15-19H2,(H,27,29)
DMZ84JH CS C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CCCCC4=CC=CC=C4
DMZ84JH IK XYKZGGUQORZZTO-UHFFFAOYSA-N
DMZ84JH IU N-[1-(4-phenylbutyl)piperidin-4-yl]naphthalene-2-carboxamide
DMZ84JH DE Discovery agent
DMWP6OZ ID DMWP6OZ
DMWP6OZ DN N-(1,3,4-thiadiazol-2-yl)benzamide
DMWP6OZ HS Investigative
DMWP6OZ SN N-(1,3,4-Thiadiazol-2-yl)benzamide; RWOUBULBQYRRNL-UHFFFAOYSA-N; N-1,3,4-thiadiazol-2-yl-benzamide; 26861-95-0; BAS 03031913; AC1LC4SO; TimTec1_007967; CHEMBL390098; SCHEMBL3379803; CTK0I5904; DTXSID40341040; MolPort-001-017-069; HMS1556K03; ZINC892651; STK158583; AKOS000646792; MCULE-9389828263; N-[1,3,4]Thiadiazol-2-yl-benzamide; IDI1_033621; Benzamide, N-1,3,4-thiadiazol-2-yl-; N-([1,3,4]thiadiazol-2-yl)-benzamide; N~1~-(1,3,4-thiadiazol-2-yl)benzamide; ST50015221; phenyl-N-(1,3,4-thiadiazol-2-yl)carboxamide; SR-01000365353
DMWP6OZ DT Small molecular drug
DMWP6OZ PC 569548
DMWP6OZ MW 205.24
DMWP6OZ FM C9H7N3OS
DMWP6OZ IC InChI=1S/C9H7N3OS/c13-8(7-4-2-1-3-5-7)11-9-12-10-6-14-9/h1-6H,(H,11,12,13)
DMWP6OZ CS C1=CC=C(C=C1)C(=O)NC2=NN=CS2
DMWP6OZ IK RWOUBULBQYRRNL-UHFFFAOYSA-N
DMWP6OZ IU N-(1,3,4-thiadiazol-2-yl)benzamide
DMWP6OZ CA CAS 26861-95-0
DMWP6OZ DE Discovery agent
DMDW8VX ID DMDW8VX
DMDW8VX DN N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
DMDW8VX HS Investigative
DMDW8VX SN N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; CHEMBL191039; 77746-90-8; N-(2,5-diphenylpyrazol-3-yl)benzamide; AC1N4KII; Oprea1_790904; SCHEMBL2482825; CTK2G6100; DTXSID00400046; MolPort-003-805-392; HMS3519K01; ZINC3185886; BDBM50156065; AKOS005002190; MCULE-3316862201; DA-03411; FT-0732104; N-(1,3-Diphenyl-1H-pyrazole-5-yl)benzamide; N-(2,5-Diphenyl-2H-pyrazol-3-yl)-benzamide; Benzamide, N-(1,3-diphenyl-1H-pyrazol-5-yl)-
DMDW8VX DT Small molecular drug
DMDW8VX PC 4156919
DMDW8VX MW 339.4
DMDW8VX FM C22H17N3O
DMDW8VX IC InChI=1S/C22H17N3O/c26-22(18-12-6-2-7-13-18)23-21-16-20(17-10-4-1-5-11-17)24-25(21)19-14-8-3-9-15-19/h1-16H,(H,23,26)
DMDW8VX CS C1=CC=C(C=C1)C2=NN(C(=C2)NC(=O)C3=CC=CC=C3)C4=CC=CC=C4
DMDW8VX IK AYVLYDAJDALPHK-UHFFFAOYSA-N
DMDW8VX IU N-(2,5-diphenylpyrazol-3-yl)benzamide
DMDW8VX CA CAS 77746-90-8
DMDW8VX DE Discovery agent
DMEDJ7X ID DMEDJ7X
DMEDJ7X DN N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DMEDJ7X HS Investigative
DMEDJ7X SN CHEMBL206574; N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide
DMEDJ7X DT Small molecular drug
DMEDJ7X PC 11566992
DMEDJ7X MW 339.4
DMEDJ7X FM C22H17N3O
DMEDJ7X IC InChI=1S/C22H17N3O/c26-22(18-12-6-2-7-13-18)24-21-20(17-10-4-1-5-11-17)16-23-25(21)19-14-8-3-9-15-19/h1-16H,(H,24,26)
DMEDJ7X CS C1=CC=C(C=C1)C2=C(N(N=C2)C3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DMEDJ7X IK HIJQHIKXNPDXIT-UHFFFAOYSA-N
DMEDJ7X IU N-(2,4-diphenylpyrazol-3-yl)benzamide
DMEDJ7X DE Discovery agent
DMW460V ID DMW460V
DMW460V DN N-(14-methylallyl)norgalanthamine
DMW460V HS Investigative
DMW460V SN N-(14-methylallyl)norgalanthamine; CHEMBL442287
DMW460V DT Small molecular drug
DMW460V PC 24863955
DMW460V MW 327.4
DMW460V FM C20H25NO3
DMW460V IC InChI=1S/C20H25NO3/c1-13(2)11-21-9-8-20-7-6-15(22)10-17(20)24-19-16(23-3)5-4-14(12-21)18(19)20/h4-7,15,17,22H,1,8-12H2,2-3H3/t15-,17-,20-/m0/s1
DMW460V CS CC(=C)CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
DMW460V IK FEKQBPRIVQKBRM-KNBMTAEXSA-N
DMW460V IU (1S,12S,14R)-9-methoxy-4-(2-methylprop-2-enyl)-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMW460V DE Discovery agent
DMFRQ2U ID DMFRQ2U
DMFRQ2U DN N-(17-Methylmorphinan-3-yl)-N'-phenylurea
DMFRQ2U HS Investigative
DMFRQ2U SN CHEMBL568829; BDBM50303599
DMFRQ2U DT Small molecular drug
DMFRQ2U PC 44628003
DMFRQ2U MW 375.5
DMFRQ2U FM C24H29N3O
DMFRQ2U IC InChI=1S/C24H29N3O/c1-27-14-13-24-12-6-5-9-20(24)22(27)15-17-10-11-19(16-21(17)24)26-23(28)25-18-7-3-2-4-8-18/h2-4,7-8,10-11,16,20,22H,5-6,9,12-15H2,1H3,(H2,25,26,28)/t20-,22+,24+/m0/s1
DMFRQ2U CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)NC(=O)NC5=CC=CC=C5
DMFRQ2U IK CVZRQQXQPKBKNJ-BGWNEDDSSA-N
DMFRQ2U IU 1-[(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]-3-phenylurea
DMFRQ2U DE Discovery agent
DMD6N8V ID DMD6N8V
DMD6N8V DN N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea
DMD6N8V HS Investigative
DMD6N8V SN n-(1-adamantyl)-n'-(4-guanidinobenzyl)urea; AGB; 1ejn; AC1L1HTN; SCHEMBL4328331; WX293T; SCHEMBL14524522; CTK7G4253; BDBM16176; WX-293T; DB03782; 3-adamantan-1-yl-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(1-adamantyl)-1-[(4-carbamimidamidophenyl)methyl]urea; 3-(adamantan-1-yl)-1-[(4-carbamimidamidophenyl)methyl]urea; 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea; 1-{4-[(diaminomethylidene)amino]benzyl}-3-tricyclo[3.3.1.13,7]dec-1-ylurea
DMD6N8V DT Small molecular drug
DMD6N8V PC 4286
DMD6N8V MW 341.5
DMD6N8V FM C19H27N5O
DMD6N8V IC InChI=1S/C19H27N5O/c20-17(21)23-16-3-1-12(2-4-16)11-22-18(25)24-19-8-13-5-14(9-19)7-15(6-13)10-19/h1-4,13-15H,5-11H2,(H4,20,21,23)(H2,22,24,25)
DMD6N8V CS C1C2CC3CC1CC(C2)(C3)NC(=O)NCC4=CC=C(C=C4)N=C(N)N
DMD6N8V IK YQPLKJCBEOVDBS-UHFFFAOYSA-N
DMD6N8V IU 1-(1-adamantyl)-3-[[4-(diaminomethylideneamino)phenyl]methyl]urea
DMD6N8V DE Discovery agent
DM29QT4 ID DM29QT4
DM29QT4 DN N-(1-adamantyl)-N'-propylsulfamide
DM29QT4 HS Investigative
DM29QT4 SN CHEMBL374746; SCHEMBL3107083; ZINC35091097; BDBM50300769
DM29QT4 DT Small molecular drug
DM29QT4 PC 16103193
DM29QT4 MW 272.41
DM29QT4 FM C13H24N2O2S
DM29QT4 IC InChI=1S/C13H24N2O2S/c1-2-3-14-18(16,17)15-13-7-10-4-11(8-13)6-12(5-10)9-13/h10-12,14-15H,2-9H2,1H3
DM29QT4 CS CCCNS(=O)(=O)NC12CC3CC(C1)CC(C3)C2
DM29QT4 IK LLVZKPBHOPZCRW-UHFFFAOYSA-N
DM29QT4 IU N-(propylsulfamoyl)adamantan-1-amine
DM29QT4 DE Discovery agent
DM3WBZP ID DM3WBZP
DM3WBZP DN N-(1-benzofuran-3-ylmethyl)sulfamide
DM3WBZP HS Investigative
DM3WBZP SN CHEMBL1077117; N-(1-benzofuran-3-ylmethyl)sulfamide; Sulfamide, N-(3-benzofuranylmethyl)-; SCHEMBL4279478; XOBOZYKTCAJRGO-UHFFFAOYSA-N; N-(3-benzofuranylmethyl)-sulfamide; BDBM50310434
DM3WBZP DT Small molecular drug
DM3WBZP PC 11521450
DM3WBZP MW 226.25
DM3WBZP FM C9H10N2O3S
DM3WBZP IC InChI=1S/C9H10N2O3S/c10-15(12,13)11-5-7-6-14-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H2,10,12,13)
DM3WBZP CS C1=CC=C2C(=C1)C(=CO2)CNS(=O)(=O)N
DM3WBZP IK XOBOZYKTCAJRGO-UHFFFAOYSA-N
DM3WBZP IU 3-[(sulfamoylamino)methyl]-1-benzofuran
DM3WBZP DE Discovery agent
DMP9A7L ID DMP9A7L
DMP9A7L DN N-(1-Benzyl-2-oxo-ethyl)-benzamide
DMP9A7L HS Investigative
DMP9A7L SN CHEMBL287136; N-(1-Benzyl-2-oxo-ethyl)-benzamide; N-Benzoyl-L-phenylalaninal; benzamide, n-[(1s)-1-formyl-2-phenylethyl]-; AC1L4VU2; SCHEMBL40781; AC1Q6A59; ZINC3650451; BDBM50014566; N-[(2S)-1-oxo-3-phenylpropan-2-yl]benzamide; (2S)-2-(Benzoylamino)-3-phenylpropionaldehyde; Benzamide, N-(1-formyl-2-phenylethyl)-, (S)-
DMP9A7L DT Small molecular drug
DMP9A7L PC 193218
DMP9A7L MW 253.29
DMP9A7L FM C16H15NO2
DMP9A7L IC InChI=1S/C16H15NO2/c18-12-15(11-13-7-3-1-4-8-13)17-16(19)14-9-5-2-6-10-14/h1-10,12,15H,11H2,(H,17,19)/t15-/m0/s1
DMP9A7L CS C1=CC=C(C=C1)C[C@@H](C=O)NC(=O)C2=CC=CC=C2
DMP9A7L IK HIVDFHSZNYCJQH-HNNXBMFYSA-N
DMP9A7L IU N-[(2S)-1-oxo-3-phenylpropan-2-yl]benzamide
DMP9A7L CA CAS 35593-57-8
DMP9A7L DE Discovery agent
DM4HB7S ID DM4HB7S
DM4HB7S DN N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide
DM4HB7S HS Investigative
DM4HB7S SN CHEMBL214684; N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide; MolPort-008-305-779; STK491511; BDBM50192158; ZINC16603986; AKOS003382300; MCULE-7382461624; ST50942897
DM4HB7S DT Small molecular drug
DM4HB7S PC 14514271
DM4HB7S MW 354.4
DM4HB7S FM C21H26N2O3
DM4HB7S IC InChI=1S/C21H26N2O3/c1-25-19-12-17(13-20(14-19)26-2)21(24)22-18-8-10-23(11-9-18)15-16-6-4-3-5-7-16/h3-7,12-14,18H,8-11,15H2,1-2H3,(H,22,24)
DM4HB7S CS COC1=CC(=CC(=C1)C(=O)NC2CCN(CC2)CC3=CC=CC=C3)OC
DM4HB7S IK CBCISEXIJPDIBB-UHFFFAOYSA-N
DM4HB7S IU N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide
DM4HB7S DE Discovery agent
DMEKSHG ID DMEKSHG
DMEKSHG DN N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
DMEKSHG HS Investigative
DMEKSHG SN N-(1-Benzylpiperidin-4-Yl)-4-Sulfanylbutanamide; DB07734; N-(1-Benzylpiperidine-4-yl)-4-mercaptobutanamide; N-(1-benzyl-piperidin-4-yl)-4-mercapto-butyramide
DMEKSHG DT Small molecular drug
DMEKSHG PC 25134249
DMEKSHG MW 292.4
DMEKSHG FM C16H24N2OS
DMEKSHG IC InChI=1S/C16H24N2OS/c19-16(7-4-12-20)17-15-8-10-18(11-9-15)13-14-5-2-1-3-6-14/h1-3,5-6,15,20H,4,7-13H2,(H,17,19)
DMEKSHG CS C1CN(CCC1NC(=O)CCCS)CC2=CC=CC=C2
DMEKSHG IK XNIXPLIQGKQSIE-UHFFFAOYSA-N
DMEKSHG IU N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
DMEKSHG DE Discovery agent
DMUQ6P4 ID DMUQ6P4
DMUQ6P4 DN N-(1-benzylpiperidine-4-yl)-2-naphthamide
DMUQ6P4 HS Investigative
DMUQ6P4 SN CHEMBL228972; N-(1-benzylpiperidin-4-yl)naphthalene-2-carboxamide; N-(1-benzylpiperidine-4-yl)-2-naphthamide; MolPort-005-630-484; BDBM50203383; ZINC12985947; STK491618; AKOS003382305; MCULE-1935524858; N-(1-benzylpiperidin-4-yl)-2-naphthamide; ST50877721; 2-naphthyl-N-[1-benzyl(4-piperidyl)]carboxamide; Z32353863
DMUQ6P4 DT Small molecular drug
DMUQ6P4 PC 16725912
DMUQ6P4 MW 344.4
DMUQ6P4 FM C23H24N2O
DMUQ6P4 IC InChI=1S/C23H24N2O/c26-23(21-11-10-19-8-4-5-9-20(19)16-21)24-22-12-14-25(15-13-22)17-18-6-2-1-3-7-18/h1-11,16,22H,12-15,17H2,(H,24,26)
DMUQ6P4 CS C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CC4=CC=CC=C4
DMUQ6P4 IK RQEOFDOXFRRFQL-UHFFFAOYSA-N
DMUQ6P4 IU N-(1-benzylpiperidin-4-yl)naphthalene-2-carboxamide
DMUQ6P4 DE Discovery agent
DM054NF ID DM054NF
DM054NF DN N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide
DM054NF HS Investigative
DM054NF SN CHEMBL426133; AC1MAT99; N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide; MolPort-004-136-030; ZINC6082995; BDBM50184703; AKOS008916776; MCULE-9954960051; N-(1H-benzimidazol-2-yl)-3-cyanobenzamide; N-(1H-1,3-benzodiazol-2-yl)-3-cyanobenzamide; Z27664939
DM054NF DT Small molecular drug
DM054NF PC 2635761
DM054NF MW 262.27
DM054NF FM C15H10N4O
DM054NF IC InChI=1S/C15H10N4O/c16-9-10-4-3-5-11(8-10)14(20)19-15-17-12-6-1-2-7-13(12)18-15/h1-8H,(H2,17,18,19,20)
DM054NF CS C1=CC=C2C(=C1)NC(=N2)NC(=O)C3=CC=CC(=C3)C#N
DM054NF IK JSWLIGOCNPPDTR-UHFFFAOYSA-N
DM054NF IU N-(1H-benzimidazol-2-yl)-3-cyanobenzamide
DM054NF DE Discovery agent
DM0CWPX ID DM0CWPX
DM0CWPX DN N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide
DM0CWPX HS Investigative
DM0CWPX SN N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide; 301675-24-1; CHEMBL210658; N-(1H-benzimidazol-2-yl)-3-nitrobenzamide; AC1MTB3N; Cambridge id 7283005; Oprea1_384876; Oprea1_144350; MLS000418401; SCHEMBL3597174; MolPort-007-653-805; QPKROMNIEAEFQA-UHFFFAOYSA-N; MolPort-001-543-036; ZINC5033955; CS-M1436; STK433528; BDBM50184701; AKOS001825502; AKOS001141441; MCULE-1403873826; KB-78995; SMR000264931; CS-13909; ST50927847; N-benzimidazol-2-yl(3-nitrophenyl)carboxamide; 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide
DM0CWPX DT Small molecular drug
DM0CWPX PC 3572750
DM0CWPX MW 282.25
DM0CWPX FM C14H10N4O3
DM0CWPX IC InChI=1S/C14H10N4O3/c19-13(9-4-3-5-10(8-9)18(20)21)17-14-15-11-6-1-2-7-12(11)16-14/h1-8H,(H2,15,16,17,19)
DM0CWPX CS C1=CC=C2C(=C1)NC(=N2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
DM0CWPX IK QPKROMNIEAEFQA-UHFFFAOYSA-N
DM0CWPX IU N-(1H-benzimidazol-2-yl)-3-nitrobenzamide
DM0CWPX DE Discovery agent
DMIMJNU ID DMIMJNU
DMIMJNU DN N-(1H-indazol-5-yl)acetamide
DMIMJNU HS Investigative
DMIMJNU SN N-(1H-indazol-5-yl)acetamide; 95574-27-9; CHEMBL503641; Acetamide, N-1H-indazol-5-yl-; 5-acetylaminoindazole; SCHEMBL2565558; XGVHKKOLBJMLLQ-UHFFFAOYSA-N; MolPort-020-329-884; ZINC20495645; BDBM50246684; AKOS008998989
DMIMJNU DT Small molecular drug
DMIMJNU PC 17164245
DMIMJNU MW 175.19
DMIMJNU FM C9H9N3O
DMIMJNU IC InChI=1S/C9H9N3O/c1-6(13)11-8-2-3-9-7(4-8)5-10-12-9/h2-5H,1H3,(H,10,12)(H,11,13)
DMIMJNU CS CC(=O)NC1=CC2=C(C=C1)NN=C2
DMIMJNU IK XGVHKKOLBJMLLQ-UHFFFAOYSA-N
DMIMJNU IU N-(1H-indazol-5-yl)acetamide
DMIMJNU DE Discovery agent
DM63YJV ID DM63YJV
DM63YJV DN N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV HS Investigative
DM63YJV SN CHEMBL472897; N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV DT Small molecular drug
DM63YJV PC 25178128
DM63YJV MW 419.6
DM63YJV FM C27H37N3O
DM63YJV IC InChI=1S/C27H37N3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(31)29-25-20-21-26-24(22-25)23-28-30-26/h6-7,9-10,12-13,15-16,20-23H,2-5,8,11,14,17-19H2,1H3,(H,28,30)(H,29,31)/b7-6-,10-9-,13-12-,16-15-
DM63YJV CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NC1=CC2=C(C=C1)NN=C2
DM63YJV IK UYWJHPBUSXDXOJ-DOFZRALJSA-N
DM63YJV IU (5Z,8Z,11Z,14Z)-N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide
DM63YJV DE Discovery agent
DMHAGSW ID DMHAGSW
DMHAGSW DN N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine
DMHAGSW HS Investigative
DMHAGSW SN CHEMBL455981; N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine
DMHAGSW DT Small molecular drug
DMHAGSW PC 44588208
DMHAGSW MW 278.4
DMHAGSW FM C19H22N2
DMHAGSW IC InChI=1S/C19H22N2/c1-2-8-16(9-3-1)10-6-7-13-20-15-18-14-17-11-4-5-12-19(17)21-18/h1-5,8-9,11-12,14,20-21H,6-7,10,13,15H2
DMHAGSW CS C1=CC=C(C=C1)CCCCNCC2=CC3=CC=CC=C3N2
DMHAGSW IK OLWLANFDDNVPCZ-UHFFFAOYSA-N
DMHAGSW IU N-(1H-indol-2-ylmethyl)-4-phenylbutan-1-amine
DMHAGSW DE Discovery agent
DMCM51R ID DMCM51R
DMCM51R DN N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine
DMCM51R HS Investigative
DMCM51R SN CHEMBL461245; N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine
DMCM51R DT Small molecular drug
DMCM51R PC 44588139
DMCM51R MW 236.31
DMCM51R FM C16H16N2
DMCM51R IC InChI=1S/C16H16N2/c1-18(15-8-3-2-4-9-15)12-14-11-13-7-5-6-10-16(13)17-14/h2-11,17H,12H2,1H3
DMCM51R CS CN(CC1=CC2=CC=CC=C2N1)C3=CC=CC=C3
DMCM51R IK KHSLYBCUWUKVBX-UHFFFAOYSA-N
DMCM51R IU N-(1H-indol-2-ylmethyl)-N-methylaniline
DMCM51R DE Discovery agent
DMXD592 ID DMXD592
DMXD592 DN N-(1H-Indol-2-ylmethyl)-N-phenylamine
DMXD592 HS Investigative
DMXD592 SN CHEMBL447043; N-(1H-Indol-2-ylmethyl)-N-phenylamine; (phenylamino)methylindole; SCHEMBL10549005; MolPort-013-783-264; BDBM50273565; ZINC40829296
DMXD592 DT Small molecular drug
DMXD592 PC 20037787
DMXD592 MW 222.28
DMXD592 FM C15H14N2
DMXD592 IC InChI=1S/C15H14N2/c1-2-7-13(8-3-1)16-11-14-10-12-6-4-5-9-15(12)17-14/h1-10,16-17H,11H2
DMXD592 CS C1=CC=C(C=C1)NCC2=CC3=CC=CC=C3N2
DMXD592 IK SSQTZURIXXHEKY-UHFFFAOYSA-N
DMXD592 IU N-(1H-indol-2-ylmethyl)aniline
DMXD592 DE Discovery agent
DMY3UZH ID DMY3UZH
DMY3UZH DN N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine
DMY3UZH HS Investigative
DMY3UZH SN CHEMBL449889; N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine
DMY3UZH DT Small molecular drug
DMY3UZH PC 42776886
DMY3UZH MW 236.31
DMY3UZH FM C16H16N2
DMY3UZH IC InChI=1S/C16H16N2/c1-18-15(11-13-7-5-6-10-16(13)18)12-17-14-8-3-2-4-9-14/h2-11,17H,12H2,1H3
DMY3UZH CS CN1C2=CC=CC=C2C=C1CNC3=CC=CC=C3
DMY3UZH IK HTRZQOWAQJHGBR-UHFFFAOYSA-N
DMY3UZH IU N-[(1-methylindol-2-yl)methyl]aniline
DMY3UZH DE Discovery agent
DMI1HBR ID DMI1HBR
DMI1HBR DN N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR HS Investigative
DMI1HBR SN CHEMBL1288588; N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR DT Small molecular drug
DMI1HBR PC 52945617
DMI1HBR MW 259.22
DMI1HBR FM C12H12F3NO2
DMI1HBR IC InChI=1S/C12H12F3NO2/c1-2-10(7-17)16-11(18)8-4-3-5-9(6-8)12(13,14)15/h3-7,10H,2H2,1H3,(H,16,18)
DMI1HBR CS CCC(C=O)NC(=O)C1=CC(=CC=C1)C(F)(F)F
DMI1HBR IK BXZCQIXITWILKZ-UHFFFAOYSA-N
DMI1HBR IU N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide
DMI1HBR DE Discovery agent
DMU9YF6 ID DMU9YF6
DMU9YF6 DN N-(1-phenethylpiperidin-4-yl)-1-naphthamide
DMU9YF6 HS Investigative
DMU9YF6 SN CHEMBL229021; N-(1-phenethylpiperidin-4-yl)-1-naphthamide; MolPort-027-939-937; ZINC27938740; BDBM50203472; AKOS034266808; MCULE-9720193295; Z384293848; N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-1-carboxamide
DMU9YF6 DT Small molecular drug
DMU9YF6 PC 35295787
DMU9YF6 MW 358.5
DMU9YF6 FM C24H26N2O
DMU9YF6 IC InChI=1S/C24H26N2O/c27-24(23-12-6-10-20-9-4-5-11-22(20)23)25-21-14-17-26(18-15-21)16-13-19-7-2-1-3-8-19/h1-12,21H,13-18H2,(H,25,27)
DMU9YF6 CS C1CN(CCC1NC(=O)C2=CC=CC3=CC=CC=C32)CCC4=CC=CC=C4
DMU9YF6 IK BTQGBMYNQGZVOI-UHFFFAOYSA-N
DMU9YF6 IU N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-1-carboxamide
DMU9YF6 DE Discovery agent
DM9QA7Z ID DM9QA7Z
DM9QA7Z DN N-(1-phenethylpiperidin-4-yl)-2-naphthamide
DM9QA7Z HS Investigative
DM9QA7Z SN CHEMBL388620; N-(1-phenethylpiperidin-4-yl)-2-naphthamide; MolPort-027-676-242; ZINC27939121; BDBM50203471; AKOS034266810; MCULE-8266051883; Z384294180; N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-2-carboxamide
DM9QA7Z DT Small molecular drug
DM9QA7Z PC 35296170
DM9QA7Z MW 358.5
DM9QA7Z FM C24H26N2O
DM9QA7Z IC InChI=1S/C24H26N2O/c27-24(22-11-10-20-8-4-5-9-21(20)18-22)25-23-13-16-26(17-14-23)15-12-19-6-2-1-3-7-19/h1-11,18,23H,12-17H2,(H,25,27)
DM9QA7Z CS C1CN(CCC1NC(=O)C2=CC3=CC=CC=C3C=C2)CCC4=CC=CC=C4
DM9QA7Z IK JJJGQIPMMVJBLD-UHFFFAOYSA-N
DM9QA7Z IU N-[1-(2-phenylethyl)piperidin-4-yl]naphthalene-2-carboxamide
DM9QA7Z DE Discovery agent
DM6DEZ4 ID DM6DEZ4
DM6DEZ4 DN N-(1'-Phenyl-ethyl) estradiol-16-carboxamide
DM6DEZ4 HS Investigative
DM6DEZ4 SN SCHEMBL12379495
DM6DEZ4 DT Small molecular drug
DM6DEZ4 PC 44407376
DM6DEZ4 MW 419.6
DM6DEZ4 FM C27H33NO3
DM6DEZ4 IC InChI=1S/C27H33NO3/c1-16(17-6-4-3-5-7-17)28-26(31)23-15-24-22-10-8-18-14-19(29)9-11-20(18)21(22)12-13-27(24,2)25(23)30/h3-7,9,11,14,16,21-25,29-30H,8,10,12-13,15H2,1-2H3,(H,28,31)/t16?,21?,22?,23?,24?,25-,27-/m0/s1
DM6DEZ4 CS CC(C1=CC=CC=C1)NC(=O)C2CC3C4CCC5=C(C4CC[C@@]3([C@H]2O)C)C=CC(=C5)O
DM6DEZ4 IK NLFQZGZNWSXJNG-CDPVEVCASA-N
DM6DEZ4 IU (13S,17S)-3,17-dihydroxy-13-methyl-N-(1-phenylethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DM6DEZ4 DE Discovery agent
DMSHWYU ID DMSHWYU
DMSHWYU DN N-(1-PHENYL-PROPYL)-FORMAMIDE
DMSHWYU HS Investigative
DMSHWYU SN N-(1-PHENYL-PROPYL)-FORMAMIDE; AC1L9JS4; N-[(1R)-1-phenylpropyl]formamide; N-[(R)-alpha-Ethylbenzyl]formamide
DMSHWYU DT Small molecular drug
DMSHWYU PC 446532
DMSHWYU MW 163.22
DMSHWYU FM C10H13NO
DMSHWYU IC InChI=1S/C10H13NO/c1-2-10(11-8-12)9-6-4-3-5-7-9/h3-8,10H,2H2,1H3,(H,11,12)/t10-/m1/s1
DMSHWYU CS CC[C@H](C1=CC=CC=C1)NC=O
DMSHWYU IK UERJGKDKJBSKQN-SNVBAGLBSA-N
DMSHWYU IU N-[(1R)-1-phenylpropyl]formamide
DMSHWYU DE Discovery agent
DM6NC8G ID DM6NC8G
DM6NC8G DN N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide
DM6NC8G HS Investigative
DM6NC8G SN CHEMBL521733; N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide
DM6NC8G DT Small molecular drug
DM6NC8G PC 787236
DM6NC8G MW 340.4
DM6NC8G FM C23H20N2O
DM6NC8G IC InChI=1S/C23H20N2O/c26-23(19-12-10-18(11-13-19)17-6-2-1-3-7-17)24-15-14-20-16-25-22-9-5-4-8-21(20)22/h1-13,16,25H,14-15H2,(H,24,26)
DM6NC8G CS C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NCCC3=CNC4=CC=CC=C43
DM6NC8G IK GYEGDDXJVFNDOP-UHFFFAOYSA-N
DM6NC8G IU N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide
DM6NC8G DE Discovery agent
DM97Q6T ID DM97Q6T
DM97Q6T DN N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine
DM97Q6T HS Investigative
DM97Q6T SN CHEMBL233385; N-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]ethanamine; AC1NFZZ9; N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine; SCHEMBL5700011; ZINC8227211; BDBM50205773; AKOS002615028; MCULE-5007100183; Benzenemethanamine, 5-bromo-2-[(4-chlorophenyl)methoxy]-N-ethyl-
DM97Q6T DT Small molecular drug
DM97Q6T PC 4716524
DM97Q6T MW 354.7
DM97Q6T FM C16H17BrClNO
DM97Q6T IC InChI=1S/C16H17BrClNO/c1-2-19-10-13-9-14(17)5-8-16(13)20-11-12-3-6-15(18)7-4-12/h3-9,19H,2,10-11H2,1H3
DM97Q6T CS CCNCC1=C(C=CC(=C1)Br)OCC2=CC=C(C=C2)Cl
DM97Q6T IK ORVDFXFQIBURPI-UHFFFAOYSA-N
DM97Q6T IU N-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]ethanamine
DM97Q6T DE Discovery agent
DM57GQN ID DM57GQN
DM57GQN DN N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DM57GQN HS Investigative
DM57GQN SN CHEMBL264176
DM57GQN DT Small molecular drug
DM57GQN PC 44450092
DM57GQN MW 327.4
DM57GQN FM C20H25NO3
DM57GQN IC InChI=1S/C20H25NO3/c1-3-4-5-6-9-16-12-13-20(18(23)14-16)24-19-11-8-7-10-17(19)21-15(2)22/h7-8,10-14,23H,3-6,9H2,1-2H3,(H,21,22)
DM57GQN CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC=C2NC(=O)C)O
DM57GQN IK UNZWUCCAARAPNJ-UHFFFAOYSA-N
DM57GQN IU N-[2-(4-hexyl-2-hydroxyphenoxy)phenyl]acetamide
DM57GQN DE Discovery agent
DM4V7AS ID DM4V7AS
DM4V7AS DN N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide
DM4V7AS HS Investigative
DM4V7AS SN CHEMBL323332; N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide; SCHEMBL7018941; ACETAMIDE,N-[2-(5-METHOXY-3-BENZOFURANYL)- ETHYL]-; ZINC13474338; BDBM50037242; ACM27404359; 27404-35-9; 3-[2-(Acetylamino)ethyl]-5-methoxybenzofuran
DM4V7AS DT Small molecular drug
DM4V7AS PC 10059864
DM4V7AS MW 233.26
DM4V7AS FM C13H15NO3
DM4V7AS IC InChI=1S/C13H15NO3/c1-9(15)14-6-5-10-8-17-13-4-3-11(16-2)7-12(10)13/h3-4,7-8H,5-6H2,1-2H3,(H,14,15)
DM4V7AS CS CC(=O)NCCC1=COC2=C1C=C(C=C2)OC
DM4V7AS IK BTVRPXLAXZPZPV-UHFFFAOYSA-N
DM4V7AS IU N-[2-(5-methoxy-1-benzofuran-3-yl)ethyl]acetamide
DM4V7AS CA CAS 27404-35-9
DM4V7AS DE Discovery agent
DMLTROU ID DMLTROU
DMLTROU DN N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide
DMLTROU HS Investigative
DMLTROU SN CHEMBL1081811; BDBM50312964
DMLTROU DT Small molecular drug
DMLTROU PC 46880333
DMLTROU MW 279.29
DMLTROU FM C16H13N3O2
DMLTROU IC InChI=1S/C16H13N3O2/c1-11(20)18-15-5-4-13(12-6-8-17-9-7-12)16(19-15)14-3-2-10-21-14/h2-10H,1H3,(H,18,19,20)
DMLTROU CS CC(=O)NC1=NC(=C(C=C1)C2=CC=NC=C2)C3=CC=CO3
DMLTROU IK STFZQXRQDWXSGW-UHFFFAOYSA-N
DMLTROU IU N-[6-(furan-2-yl)-5-pyridin-4-ylpyridin-2-yl]acetamide
DMLTROU DE Discovery agent
DMWC70I ID DMWC70I
DMWC70I DN N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide
DMWC70I HS Investigative
DMWC70I SN 60480-69-5; N-(2,3,4,9-TETRAHYDRO-1H-CARBAZOL-3-YL)ACETAMIDE; CHEMBL41973; 3-Acetamido-1,2,3,4-tetrahydrocarbazole; N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide; SCHEMBL7406266; KS-00000TMN; CTK2F0321; DTXSID90494196; MolPort-042-663-532; DNJBLXBGYRYOBT-UHFFFAOYSA-N; BDBM50212923; AKOS027461084; 3-Acetamido-1,2,3,4-tetrahydrocarbazol; DS-19200; AK543106; Acetamide, N-(2,3,4,9-tetrahydro-1H-carbazol-3-yl)-
DMWC70I DT Small molecular drug
DMWC70I PC 12361788
DMWC70I MW 228.29
DMWC70I FM C14H16N2O
DMWC70I IC InChI=1S/C14H16N2O/c1-9(17)15-10-6-7-14-12(8-10)11-4-2-3-5-13(11)16-14/h2-5,10,16H,6-8H2,1H3,(H,15,17)
DMWC70I CS CC(=O)NC1CCC2=C(C1)C3=CC=CC=C3N2
DMWC70I IK DNJBLXBGYRYOBT-UHFFFAOYSA-N
DMWC70I IU N-(2,3,4,9-tetrahydro-1H-carbazol-3-yl)acetamide
DMWC70I CA CAS 60480-69-5
DMWC70I DE Discovery agent
DMUZL3J ID DMUZL3J
DMUZL3J DN N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE
DMUZL3J HS Investigative
DMUZL3J SN N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE; N-[(2,3-difluorophenyl)methyl]-4-sulfamoylbenzamide; F2B; N-(2,3-Difluorobenzyl)-4-sulfamoylbenzamide; 235088-49-0; 2,3-difluoro-SBB; AC1L1C1I; CTK0I7898; BDBM12016; DTXSID80274323; 1g52; 1g46; AKOS030577745; DB07742; Benzamide, 4-(aminosulfonyl)-N-[(2,3-difluorophenyl)methyl]-
DMUZL3J DT Small molecular drug
DMUZL3J PC 1700
DMUZL3J MW 326.32
DMUZL3J FM C14H12F2N2O3S
DMUZL3J IC InChI=1S/C14H12F2N2O3S/c15-12-3-1-2-10(13(12)16)8-18-14(19)9-4-6-11(7-5-9)22(17,20)21/h1-7H,8H2,(H,18,19)(H2,17,20,21)
DMUZL3J CS C1=CC(=C(C(=C1)F)F)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N
DMUZL3J IK QASSMVGOSBNFQY-UHFFFAOYSA-N
DMUZL3J IU N-[(2,3-difluorophenyl)methyl]-4-sulfamoylbenzamide
DMUZL3J CA CAS 235088-49-0
DMUZL3J DE Discovery agent
DMTLPDZ ID DMTLPDZ
DMTLPDZ DN N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ HS Investigative
DMTLPDZ SN CHEMBL470205; N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ DT Small molecular drug
DMTLPDZ PC 44591990
DMTLPDZ MW 260.3
DMTLPDZ FM C18H16N2
DMTLPDZ IC InChI=1S/C18H16N2/c1-2-7-15-12-16(11-14(15)6-1)20-18-17-8-4-3-5-13(17)9-10-19-18/h1-10,16H,11-12H2,(H,19,20)
DMTLPDZ CS C1C(CC2=CC=CC=C21)NC3=NC=CC4=CC=CC=C43
DMTLPDZ IK LJNDWVYBQFLXJV-UHFFFAOYSA-N
DMTLPDZ IU N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine
DMTLPDZ DE Discovery agent
DMJ6LI8 ID DMJ6LI8
DMJ6LI8 DN N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine
DMJ6LI8 HS Investigative
DMJ6LI8 SN CHEMBL471242; N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine; SCHEMBL9040263
DMJ6LI8 DT Small molecular drug
DMJ6LI8 PC 23186964
DMJ6LI8 MW 261.32
DMJ6LI8 FM C17H15N3
DMJ6LI8 IC InChI=1S/C17H15N3/c1-2-6-13-10-14(9-12(13)5-1)20-17-15-7-3-4-8-16(15)18-11-19-17/h1-8,11,14H,9-10H2,(H,18,19,20)
DMJ6LI8 CS C1C(CC2=CC=CC=C21)NC3=NC=NC4=CC=CC=C43
DMJ6LI8 IK CLVFUKGYGOFREN-UHFFFAOYSA-N
DMJ6LI8 IU N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine
DMJ6LI8 DE Discovery agent
DMPL26K ID DMPL26K
DMPL26K DN N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamide
DMPL26K HS Investigative
DMPL26K SN N-(2,3-dihydro-1H-phenalen-2-yl)acetamide; SCHEMBL8406961; CHEMBL320810; ZINC21623; NSODBKSYAOTJPJ-UHFFFAOYSA-N; N-[(2,3-Dihydro-1H-phenalen)-2-yl]acetamide
DMPL26K DT Small molecular drug
DMPL26K PC 9859366
DMPL26K MW 225.28
DMPL26K FM C15H15NO
DMPL26K IC InChI=1S/C15H15NO/c1-10(17)16-14-8-12-6-2-4-11-5-3-7-13(9-14)15(11)12/h2-7,14H,8-9H2,1H3,(H,16,17)
DMPL26K CS CC(=O)NC1CC2=CC=CC3=C2C(=CC=C3)C1
DMPL26K IK NSODBKSYAOTJPJ-UHFFFAOYSA-N
DMPL26K IU N-(2,3-dihydro-1H-phenalen-2-yl)acetamide
DMPL26K DE Discovery agent
DM5R3ZG ID DM5R3ZG
DM5R3ZG DN N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide
DM5R3ZG HS Investigative
DM5R3ZG SN CHEMBL1093043; BDBM50314143
DM5R3ZG DT Small molecular drug
DM5R3ZG PC 45141955
DM5R3ZG MW 292.37
DM5R3ZG FM C16H24N2O3
DM5R3ZG IC InChI=1S/C16H24N2O3/c1-12-8-7-9-14(13(12)2)17-15(19)10-5-3-4-6-11-16(20)18-21/h7-9,21H,3-6,10-11H2,1-2H3,(H,17,19)(H,18,20)
DM5R3ZG CS CC1=C(C(=CC=C1)NC(=O)CCCCCCC(=O)NO)C
DM5R3ZG IK HBVNZQXOOFVNBV-UHFFFAOYSA-N
DM5R3ZG IU N-(2,3-dimethylphenyl)-N'-hydroxyoctanediamide
DM5R3ZG DE Discovery agent
DMHI4Y6 ID DMHI4Y6
DMHI4Y6 DN N-(2,4-Dichloro-benzoyl)-benzenesulfonamide
DMHI4Y6 HS Investigative
DMHI4Y6 SN N-[2,4-dichlorobenzoyl]phenylsulfonamide; CHEMBL181855; SCHEMBL5491628; TXHQSKPOVJIXCS-UHFFFAOYSA-N; ZINC1492181; AKOS002221669
DMHI4Y6 DT Small molecular drug
DMHI4Y6 PC 9968373
DMHI4Y6 MW 330.2
DMHI4Y6 FM C13H9Cl2NO3S
DMHI4Y6 IC InChI=1S/C13H9Cl2NO3S/c14-9-6-7-11(12(15)8-9)13(17)16-20(18,19)10-4-2-1-3-5-10/h1-8H,(H,16,17)
DMHI4Y6 CS C1=CC=C(C=C1)S(=O)(=O)NC(=O)C2=C(C=C(C=C2)Cl)Cl
DMHI4Y6 IK TXHQSKPOVJIXCS-UHFFFAOYSA-N
DMHI4Y6 IU N-(benzenesulfonyl)-2,4-dichlorobenzamide
DMHI4Y6 DE Discovery agent
DM5COQ9 ID DM5COQ9
DM5COQ9 DN N-(2,4-dichlorophenyl)-2-nitrobenzamide
DM5COQ9 HS Investigative
DM5COQ9 SN N-(2,4-dichlorophenyl)-2-nitrobenzamide; CHEMBL558336; AC1LEZX8; Oprea1_748203; CBDivE_011688; ZINC69333; MolPort-001-485-938; STK416331; BDBM50297540; AKOS002953648; MCULE-3862746701; ST011164; AB00076626-01; AK-968/40072495
DM5COQ9 DT Small molecular drug
DM5COQ9 PC 695266
DM5COQ9 MW 311.12
DM5COQ9 FM C13H8Cl2N2O3
DM5COQ9 IC InChI=1S/C13H8Cl2N2O3/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17(19)20/h1-7H,(H,16,18)
DM5COQ9 CS C1=CC=C(C(=C1)C(=O)NC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-]
DM5COQ9 IK YDNSNBQUGLSJRG-UHFFFAOYSA-N
DM5COQ9 IU N-(2,4-dichlorophenyl)-2-nitrobenzamide
DM5COQ9 DE Discovery agent
DMHJOBQ ID DMHJOBQ
DMHJOBQ DN N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide
DMHJOBQ HS Investigative
DMHJOBQ SN N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide; CHEMBL551683; AC1Q2ECP; AC1LEFA7; Oprea1_406651; ZINC102894; BDBM50297547; AKOS002953737; MCULE-2443287207; ST011073
DMHJOBQ DT Small molecular drug
DMHJOBQ PC 711291
DMHJOBQ MW 325.1
DMHJOBQ FM C14H10Cl2N2O3
DMHJOBQ IC InChI=1S/C14H10Cl2N2O3/c1-8-2-3-9(6-13(8)18(20)21)14(19)17-12-5-4-10(15)7-11(12)16/h2-7H,1H3,(H,17,19)
DMHJOBQ CS CC1=C(C=C(C=C1)C(=O)NC2=C(C=C(C=C2)Cl)Cl)[N+](=O)[O-]
DMHJOBQ IK VNKILQNNNYOVJY-UHFFFAOYSA-N
DMHJOBQ IU N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide
DMHJOBQ DE Discovery agent
DMNT3JV ID DMNT3JV
DMNT3JV DN N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide
DMNT3JV HS Investigative
DMNT3JV SN CHEMBL207146; N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide
DMNT3JV DT Small molecular drug
DMNT3JV PC 44411127
DMNT3JV MW 291.26
DMNT3JV FM C14H13NO6
DMNT3JV IC InChI=1S/C14H13NO6/c16-9-2-1-7(10(17)5-9)6-15-14(21)8-3-11(18)13(20)12(19)4-8/h1-5,16-20H,6H2,(H,15,21)
DMNT3JV CS C1=CC(=C(C=C1O)O)CNC(=O)C2=CC(=C(C(=C2)O)O)O
DMNT3JV IK NWUBAFGVRZLIOR-UHFFFAOYSA-N
DMNT3JV IU N-[(2,4-dihydroxyphenyl)methyl]-3,4,5-trihydroxybenzamide
DMNT3JV DE Discovery agent
DM3IMXF ID DM3IMXF
DM3IMXF DN N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide
DM3IMXF HS Investigative
DM3IMXF SN CHEMBL206902; N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide
DM3IMXF DT Small molecular drug
DM3IMXF PC 44410889
DM3IMXF MW 275.26
DM3IMXF FM C14H13NO5
DM3IMXF IC InChI=1S/C14H13NO5/c16-10-3-1-9(12(18)6-10)7-15-14(20)8-2-4-11(17)13(19)5-8/h1-6,16-19H,7H2,(H,15,20)
DM3IMXF CS C1=CC(=C(C=C1C(=O)NCC2=C(C=C(C=C2)O)O)O)O
DM3IMXF IK QWXDIFRZEIADFB-UHFFFAOYSA-N
DM3IMXF IU N-[(2,4-dihydroxyphenyl)methyl]-3,4-dihydroxybenzamide
DM3IMXF DE Discovery agent
DM6U8SL ID DM6U8SL
DM6U8SL DN N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide
DM6U8SL HS Investigative
DM6U8SL SN CHEMBL437510; N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide
DM6U8SL DT Small molecular drug
DM6U8SL PC 11558153
DM6U8SL MW 275.26
DM6U8SL FM C14H13NO5
DM6U8SL IC InChI=1S/C14H13NO5/c16-10-2-1-8(13(19)6-10)7-15-14(20)9-3-11(17)5-12(18)4-9/h1-6,16-19H,7H2,(H,15,20)
DM6U8SL CS C1=CC(=C(C=C1O)O)CNC(=O)C2=CC(=CC(=C2)O)O
DM6U8SL IK OFDRVQUXDYIMFW-UHFFFAOYSA-N
DM6U8SL IU N-[(2,4-dihydroxyphenyl)methyl]-3,5-dihydroxybenzamide
DM6U8SL DE Discovery agent
DM3QWZU ID DM3QWZU
DM3QWZU DN N-(2,4-dimethoxyphenethyl)docos-13-enamide
DM3QWZU HS Investigative
DM3QWZU SN CHEMBL200121; N-(2,4-dimethoxyphenethyl)docos-13-enamide
DM3QWZU DT Small molecular drug
DM3QWZU PC 44406095
DM3QWZU MW 501.8
DM3QWZU FM C32H55NO3
DM3QWZU IC InChI=1S/C32H55NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-32(34)33-27-26-29-24-25-30(35-2)28-31(29)36-3/h11-12,24-25,28H,4-10,13-23,26-27H2,1-3H3,(H,33,34)/b12-11-
DM3QWZU CS CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)NCCC1=C(C=C(C=C1)OC)OC
DM3QWZU IK VUAYHPSOKPDUPI-QXMHVHEDSA-N
DM3QWZU IU (Z)-N-[2-(2,4-dimethoxyphenyl)ethyl]docos-13-enamide
DM3QWZU DE Discovery agent
DMRQSD2 ID DMRQSD2
DMRQSD2 DN N-(2,4-dimethoxyphenethyl)oleamide
DMRQSD2 HS Investigative
DMRQSD2 SN N-(2,4-dimethoxyphenethyl)oleamide; CHEMBL199649
DMRQSD2 DT Small molecular drug
DMRQSD2 PC 44406080
DMRQSD2 MW 445.7
DMRQSD2 FM C28H47NO3
DMRQSD2 IC InChI=1S/C28H47NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(30)29-23-22-25-20-21-26(31-2)24-27(25)32-3/h11-12,20-21,24H,4-10,13-19,22-23H2,1-3H3,(H,29,30)/b12-11-
DMRQSD2 CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=C(C=C(C=C1)OC)OC
DMRQSD2 IK YDMFQRINHJCRDN-QXMHVHEDSA-N
DMRQSD2 IU (Z)-N-[2-(2,4-dimethoxyphenyl)ethyl]octadec-9-enamide
DMRQSD2 DE Discovery agent
DME0YBF ID DME0YBF
DME0YBF DN N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide
DME0YBF HS Investigative
DME0YBF SN N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide; CHEMBL42427; Oprea1_091011; N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide; MolPort-002-962-230; ZINC3192499; AC1M5424; BDBM50108051; STK167661; AKOS001091335; MCULE-2861059800; ST50986910
DME0YBF DT Small molecular drug
DME0YBF PC 2321450
DME0YBF MW 317.34
DME0YBF FM C17H19NO5
DME0YBF IC InChI=1S/C17H19NO5/c1-20-12-5-6-15(16(10-12)23-4)18-17(19)11-7-13(21-2)9-14(8-11)22-3/h5-10H,1-4H3,(H,18,19)
DME0YBF CS COC1=CC(=C(C=C1)NC(=O)C2=CC(=CC(=C2)OC)OC)OC
DME0YBF IK MEYNLPQFSDKAAL-UHFFFAOYSA-N
DME0YBF IU N-(2,4-dimethoxyphenyl)-3,5-dimethoxybenzamide
DME0YBF DE Discovery agent
DMFZAS9 ID DMFZAS9
DMFZAS9 DN N-(2,4-dimethylphenyl)-2-nitrobenzamide
DMFZAS9 HS Investigative
DMFZAS9 SN N-(2,4-Dimethylphenyl)-2-nitrobenzamide; CHEMBL560086; AC1LB6XS; CBMicro_019379; Oprea1_664172; Oprea1_360147; WGMMCHJMOXWGPL-UHFFFAOYSA-N; MolPort-001-026-827; ZINC101882; CCG-7135; 2',4'-Dimethyl-2-nitrobenzanilide; BDBM50297545; STK017239; AKOS001297224; MCULE-5832294393; ST010752; BIM-0019204.P001; KB-100850; N-(2,4-Dimethylphenyl)-2-nitrobenzamide #; EU-0017382; N~1~-(2,4-dimethylphenyl)-2-nitrobenzamide; AB00082465-01; SR-01000509562; N-(2,4-dimethylphenyl)(2-nitrophenyl)carboxamide; AE-848/33212050; SR-01000509562-1
DMFZAS9 DT Small molecular drug
DMFZAS9 PC 577479
DMFZAS9 MW 270.28
DMFZAS9 FM C15H14N2O3
DMFZAS9 IC InChI=1S/C15H14N2O3/c1-10-7-8-13(11(2)9-10)16-15(18)12-5-3-4-6-14(12)17(19)20/h3-9H,1-2H3,(H,16,18)
DMFZAS9 CS CC1=CC(=C(C=C1)NC(=O)C2=CC=CC=C2[N+](=O)[O-])C
DMFZAS9 IK WGMMCHJMOXWGPL-UHFFFAOYSA-N
DMFZAS9 IU N-(2,4-dimethylphenyl)-2-nitrobenzamide
DMFZAS9 CA CAS 102630-95-5
DMFZAS9 DE Discovery agent
DMXA9MR ID DMXA9MR
DMXA9MR DN N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMXA9MR HS Investigative
DMXA9MR SN CHEMBL1092032; BDBM50314141
DMXA9MR DT Small molecular drug
DMXA9MR PC 45141956
DMXA9MR MW 292.37
DMXA9MR FM C16H24N2O3
DMXA9MR IC InChI=1S/C16H24N2O3/c1-12-9-10-14(13(2)11-12)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DMXA9MR CS CC1=CC(=C(C=C1)NC(=O)CCCCCCC(=O)NO)C
DMXA9MR IK MIPPPENLVLVVIQ-UHFFFAOYSA-N
DMXA9MR IU N-(2,4-dimethylphenyl)-N'-hydroxyoctanediamide
DMXA9MR DE Discovery agent
DMUVSM1 ID DMUVSM1
DMUVSM1 DN N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DMUVSM1 HS Investigative
DMUVSM1 SN N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide; CHEMBL558073; AC1LEFVJ; Cambridge id 5309469; Oprea1_724345; MolPort-002-143-797; ZINC103357; BDBM50297553; AKOS008477850; MCULE-4612892000; ST011243; AB00079960-01; AE-848/32724040; SR-01000203933; SR-01000203933-1; N-(2,5-dichlorophenyl)-3-nitro-4-methoxybenzamide
DMUVSM1 DT Small molecular drug
DMUVSM1 PC 711551
DMUVSM1 MW 341.1
DMUVSM1 FM C14H10Cl2N2O4
DMUVSM1 IC InChI=1S/C14H10Cl2N2O4/c1-22-13-5-2-8(6-12(13)18(20)21)14(19)17-11-7-9(15)3-4-10(11)16/h2-7H,1H3,(H,17,19)
DMUVSM1 CS COC1=C(C=C(C=C1)C(=O)NC2=C(C=CC(=C2)Cl)Cl)[N+](=O)[O-]
DMUVSM1 IK NGRNRPWPJLMWBI-UHFFFAOYSA-N
DMUVSM1 IU N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DMUVSM1 DE Discovery agent
DMOL79W ID DMOL79W
DMOL79W DN N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DMOL79W HS Investigative
DMOL79W SN CHEMBL1093357; BDBM50314144
DMOL79W DT Small molecular drug
DMOL79W PC 45141957
DMOL79W MW 292.37
DMOL79W FM C16H24N2O3
DMOL79W IC InChI=1S/C16H24N2O3/c1-12-9-10-13(2)14(11-12)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DMOL79W CS CC1=CC(=C(C=C1)C)NC(=O)CCCCCCC(=O)NO
DMOL79W IK QLSOBWNGPFAWKY-UHFFFAOYSA-N
DMOL79W IU N-(2,5-dimethylphenyl)-N'-hydroxyoctanediamide
DMOL79W DE Discovery agent
DM9ATQ6 ID DM9ATQ6
DM9ATQ6 DN N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide
DM9ATQ6 HS Investigative
DM9ATQ6 SN N-[(2,6-difluorophenyl)methyl]-4-sulfamoylbenzamide; n-(2,6-diflouro-benzyl)-4-sulfamoyl-benzamide; n-(2,6-difluoro-benzyl)-4-sulfamoyl-benzamide; F6B; 2,6-difluoro-SBB; AC1L1HTT; SCHEMBL678297; BDBM12019; 1g53; 1g48; DB03844; N-(2,6-Difluorobenzyl)-4-sulfamoylbenzamide
DM9ATQ6 DT Small molecular drug
DM9ATQ6 PC 4288
DM9ATQ6 MW 326.32
DM9ATQ6 FM C14H12F2N2O3S
DM9ATQ6 IC InChI=1S/C14H12F2N2O3S/c15-12-2-1-3-13(16)11(12)8-18-14(19)9-4-6-10(7-5-9)22(17,20)21/h1-7H,8H2,(H,18,19)(H2,17,20,21)
DM9ATQ6 CS C1=CC(=C(C(=C1)F)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)F
DM9ATQ6 IK ZFNCKGXGCCDDFN-UHFFFAOYSA-N
DM9ATQ6 IU N-[(2,6-difluorophenyl)methyl]-4-sulfamoylbenzamide
DM9ATQ6 DE Discovery agent
DMTBAPH ID DMTBAPH
DMTBAPH DN N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide
DMTBAPH HS Investigative
DMTBAPH SN CHEMBL1093358; BDBM50314145
DMTBAPH DT Small molecular drug
DMTBAPH PC 45141958
DMTBAPH MW 292.37
DMTBAPH FM C16H24N2O3
DMTBAPH IC InChI=1S/C16H24N2O3/c1-12-8-7-9-13(2)16(12)17-14(19)10-5-3-4-6-11-15(20)18-21/h7-9,21H,3-6,10-11H2,1-2H3,(H,17,19)(H,18,20)
DMTBAPH CS CC1=C(C(=CC=C1)C)NC(=O)CCCCCCC(=O)NO
DMTBAPH IK ZFUIPWQRONDTNH-UHFFFAOYSA-N
DMTBAPH IU N-(2,6-dimethylphenyl)-N'-hydroxyoctanediamide
DMTBAPH DE Discovery agent
DMK5AU4 ID DMK5AU4
DMK5AU4 DN N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide
DMK5AU4 HS Investigative
DMK5AU4 SN CHEMBL390535; 820961-46-4; N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide; SCHEMBL4827158; CTK3E2657; DTXSID00463914; BDBM50157671; AKOS030569389; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-2-ethyl-
DMK5AU4 DT Small molecular drug
DMK5AU4 PC 11371386
DMK5AU4 MW 345.4
DMK5AU4 FM C22H23N3O
DMK5AU4 IC InChI=1S/C22H23N3O/c1-3-16(4-2)22(26)25-20-15-19(17-11-7-5-8-12-17)23-21(24-20)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,23,24,25,26)
DMK5AU4 CS CCC(CC)C(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMK5AU4 IK ZMYSFVQFZFGCMP-UHFFFAOYSA-N
DMK5AU4 IU N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutanamide
DMK5AU4 CA CAS 820961-46-4
DMK5AU4 DE Discovery agent
DM6HGK4 ID DM6HGK4
DM6HGK4 DN N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide
DM6HGK4 HS Investigative
DM6HGK4 SN CHEMBL387322; 820961-45-3; N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide; SCHEMBL4829224; CTK3E2658; DTXSID90471528; BDBM50157665; AKOS030569392; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-3-methyl-
DM6HGK4 DT Small molecular drug
DM6HGK4 PC 11739042
DM6HGK4 MW 331.4
DM6HGK4 FM C21H21N3O
DM6HGK4 IC InChI=1S/C21H21N3O/c1-15(2)13-20(25)23-19-14-18(16-9-5-3-6-10-16)22-21(24-19)17-11-7-4-8-12-17/h3-12,14-15H,13H2,1-2H3,(H,22,23,24,25)
DM6HGK4 CS CC(C)CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DM6HGK4 IK LUPWFOJGRCESTC-UHFFFAOYSA-N
DM6HGK4 IU N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutanamide
DM6HGK4 CA CAS 820961-45-3
DM6HGK4 DE Discovery agent
DMQ0DMU ID DMQ0DMU
DMQ0DMU DN N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU HS Investigative
DMQ0DMU SN CHEMBL426565; 820961-40-8; N-(2,6-diphenylpyrimidin-4-yl)acetamide; SCHEMBL4823120; CTK3E2663; DTXSID10458098; ZINC13586450; BDBM50157676; AKOS030563968; Acetamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DMQ0DMU DT Small molecular drug
DMQ0DMU PC 11185362
DMQ0DMU MW 289.3
DMQ0DMU FM C18H15N3O
DMQ0DMU IC InChI=1S/C18H15N3O/c1-13(22)19-17-12-16(14-8-4-2-5-9-14)20-18(21-17)15-10-6-3-7-11-15/h2-12H,1H3,(H,19,20,21,22)
DMQ0DMU CS CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMQ0DMU IK ZFBASLSZDCISGS-UHFFFAOYSA-N
DMQ0DMU IU N-(2,6-diphenylpyrimidin-4-yl)acetamide
DMQ0DMU CA CAS 820961-40-8
DMQ0DMU DE Discovery agent
DMBW752 ID DMBW752
DMBW752 DN N-(2,6-diphenylpyrimidin-4-yl)benzamide
DMBW752 HS Investigative
DMBW752 SN CHEMBL441555; N-(2,6-diphenylpyrimidin-4-yl)benzamide; SCHEMBL4825271
DMBW752 DT Small molecular drug
DMBW752 PC 11245073
DMBW752 MW 351.4
DMBW752 FM C23H17N3O
DMBW752 IC InChI=1S/C23H17N3O/c27-23(19-14-8-3-9-15-19)26-21-16-20(17-10-4-1-5-11-17)24-22(25-21)18-12-6-2-7-13-18/h1-16H,(H,24,25,26,27)
DMBW752 CS C1=CC=C(C=C1)C2=CC(=NC(=N2)C3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DMBW752 IK GQFWFPVBIHHTGX-UHFFFAOYSA-N
DMBW752 IU N-(2,6-diphenylpyrimidin-4-yl)benzamide
DMBW752 DE Discovery agent
DM5EF71 ID DM5EF71
DM5EF71 DN N-(2,6-diphenylpyrimidin-4-yl)butyramide
DM5EF71 HS Investigative
DM5EF71 SN CHEMBL222384; 820961-42-0; N-(2,6-diphenylpyrimidin-4-yl)butyramide; SCHEMBL4827120; CTK3E2661; DTXSID60463536; BDBM50157659; AKOS030569388; Butanamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DM5EF71 DT Small molecular drug
DM5EF71 PC 11359018
DM5EF71 MW 317.4
DM5EF71 FM C20H19N3O
DM5EF71 IC InChI=1S/C20H19N3O/c1-2-9-19(24)22-18-14-17(15-10-5-3-6-11-15)21-20(23-18)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,21,22,23,24)
DM5EF71 CS CCCC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DM5EF71 IK UBJLQDSZSYHXLE-UHFFFAOYSA-N
DM5EF71 IU N-(2,6-diphenylpyrimidin-4-yl)butanamide
DM5EF71 CA CAS 820961-42-0
DM5EF71 DE Discovery agent
DMWPZCS ID DMWPZCS
DMWPZCS DN N-(2,6-diphenylpyrimidin-4-yl)isobutyramide
DMWPZCS HS Investigative
DMWPZCS SN CHEMBL222433; 820961-44-2; N-(2,6-diphenylpyrimidin-4-yl)isobutyramide; SCHEMBL4822464; CTK3E2659; DTXSID20462085; BDBM50157658; Propanamide, N-(2,6-diphenyl-4-pyrimidinyl)-2-methyl-
DMWPZCS DT Small molecular drug
DMWPZCS PC 11313151
DMWPZCS MW 317.4
DMWPZCS FM C20H19N3O
DMWPZCS IC InChI=1S/C20H19N3O/c1-14(2)20(24)23-18-13-17(15-9-5-3-6-10-15)21-19(22-18)16-11-7-4-8-12-16/h3-14H,1-2H3,(H,21,22,23,24)
DMWPZCS CS CC(C)C(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DMWPZCS IK ONJOWWUQGQUDTK-UHFFFAOYSA-N
DMWPZCS IU N-(2,6-diphenylpyrimidin-4-yl)-2-methylpropanamide
DMWPZCS CA CAS 820961-44-2
DMWPZCS DE Discovery agent
DM89NGE ID DM89NGE
DM89NGE DN N-(2,6-diphenylpyrimidin-4-yl)propionamide
DM89NGE HS Investigative
DM89NGE SN CHEMBL222474; 820961-41-9; N-(2,6-diphenylpyrimidin-4-yl)propionamide; SCHEMBL4825106; CTK3E2662; DTXSID00465933; BDBM50157672; Propanamide, N-(2,6-diphenyl-4-pyrimidinyl)-
DM89NGE DT Small molecular drug
DM89NGE PC 11438116
DM89NGE MW 303.4
DM89NGE FM C19H17N3O
DM89NGE IC InChI=1S/C19H17N3O/c1-2-18(23)21-17-13-16(14-9-5-3-6-10-14)20-19(22-17)15-11-7-4-8-12-15/h3-13H,2H2,1H3,(H,20,21,22,23)
DM89NGE CS CCC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
DM89NGE IK GFLZXPLJINFGKI-UHFFFAOYSA-N
DM89NGE IU N-(2,6-diphenylpyrimidin-4-yl)propanamide
DM89NGE CA CAS 820961-41-9
DM89NGE DE Discovery agent
DM7D3GL ID DM7D3GL
DM7D3GL DN N-(2-Acetamido)Iminodiacetic Acid
DM7D3GL HS Investigative
DM7D3GL SN 26239-55-4; N-(2-Acetamido)iminodiacetic acid; 2,2'-((2-Amino-2-oxoethyl)azanediyl)diacetic acid; Carbamoylmethylaminodiacetic acid; ADA; 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid; Glycine, N-(2-amino-2-oxoethyl)-N-(carboxymethyl)-; N-(Carbamoylmethyl)iminodiacetic acid; N-Carbamoylmethyliminodi(acetic acid); UNII-5C4R3O704E; (CARBAMOYLMETHYL-CARBOXYMETHYL-AMINO)-ACETIC ACID; 5C4R3O704E; N-[2-Acetamido]iminodiacetic acid; MFCD00008031; AK-41593; ADA, 99%, for biochemistry
DM7D3GL DT Small molecular drug
DM7D3GL PC 117765
DM7D3GL MW 190.15
DM7D3GL FM C6H10N2O5
DM7D3GL IC InChI=1S/C6H10N2O5/c7-4(9)1-8(2-5(10)11)3-6(12)13/h1-3H2,(H2,7,9)(H,10,11)(H,12,13)
DM7D3GL CS C(C(=O)N)N(CC(=O)O)CC(=O)O
DM7D3GL IK QZTKDVCDBIDYMD-UHFFFAOYSA-N
DM7D3GL IU 2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]acetic acid
DM7D3GL CA CAS 26239-55-4
DM7D3GL CB CHEBI:43960
DM7D3GL DE Discovery agent
DM6QZPH ID DM6QZPH
DM6QZPH DN N-(2-adamantyl)-N'-propylsulfamide
DM6QZPH HS Investigative
DM6QZPH SN CHEMBL218643; SCHEMBL3117688; BDBM50202584; ZINC35091103
DM6QZPH DT Small molecular drug
DM6QZPH PC 16103199
DM6QZPH MW 272.41
DM6QZPH FM C13H24N2O2S
DM6QZPH IC InChI=1S/C13H24N2O2S/c1-2-3-14-18(16,17)15-13-11-5-9-4-10(7-11)8-12(13)6-9/h9-15H,2-8H2,1H3
DM6QZPH CS CCCNS(=O)(=O)NC1C2CC3CC(C2)CC1C3
DM6QZPH IK HVLBCVJJDOICDV-UHFFFAOYSA-N
DM6QZPH IU N-(propylsulfamoyl)adamantan-2-amine
DM6QZPH DE Discovery agent
DM7VN9P ID DM7VN9P
DM7VN9P DN N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide
DM7VN9P HS Investigative
DM7VN9P SN CHEMBL1097063; N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide
DM7VN9P DT Small molecular drug
DM7VN9P PC 46887475
DM7VN9P MW 328.4
DM7VN9P FM C21H16N2O2
DM7VN9P IC InChI=1S/C21H16N2O2/c22-17-11-10-16(20-13-15-8-4-5-9-19(15)25-20)12-18(17)23-21(24)14-6-2-1-3-7-14/h1-13H,22H2,(H,23,24)
DM7VN9P CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC4=CC=CC=C4O3)N
DM7VN9P IK ABLQYLIPCDUOQX-UHFFFAOYSA-N
DM7VN9P IU N-[2-amino-5-(1-benzofuran-2-yl)phenyl]benzamide
DM7VN9P DE Discovery agent
DMY9HO8 ID DMY9HO8
DMY9HO8 DN N-(2-amino-5-(furan-2-yl)phenyl)benzamide
DMY9HO8 HS Investigative
DMY9HO8 SN CHEMBL1097651; N-(2-amino-5-(furan-2-yl)phenyl)benzamide
DMY9HO8 DT Small molecular drug
DMY9HO8 PC 46830328
DMY9HO8 MW 278.3
DMY9HO8 FM C17H14N2O2
DMY9HO8 IC InChI=1S/C17H14N2O2/c18-14-9-8-13(16-7-4-10-21-16)11-15(14)19-17(20)12-5-2-1-3-6-12/h1-11H,18H2,(H,19,20)
DMY9HO8 CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CO3)N
DMY9HO8 IK POPIQEQSLAJUGU-UHFFFAOYSA-N
DMY9HO8 IU N-[2-amino-5-(furan-2-yl)phenyl]benzamide
DMY9HO8 DE Discovery agent
DMI7W9N ID DMI7W9N
DMI7W9N DN N-(2-amino-5-(furan-3-yl)phenyl)benzamide
DMI7W9N HS Investigative
DMI7W9N SN CHEMBL1095095; N-(2-amino-5-(furan-3-yl)phenyl)benzamide; Benzamide, N-[2-amino-5-(3-furanyl)phenyl]-; BDBM50318000
DMI7W9N DT Small molecular drug
DMI7W9N PC 46830327
DMI7W9N MW 278.3
DMI7W9N FM C17H14N2O2
DMI7W9N IC InChI=1S/C17H14N2O2/c18-15-7-6-13(14-8-9-21-11-14)10-16(15)19-17(20)12-4-2-1-3-5-12/h1-11H,18H2,(H,19,20)
DMI7W9N CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=COC=C3)N
DMI7W9N IK MHJRDSWPLXKJLI-UHFFFAOYSA-N
DMI7W9N IU N-[2-amino-5-(furan-3-yl)phenyl]benzamide
DMI7W9N DE Discovery agent
DM1KVPG ID DM1KVPG
DM1KVPG DN N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide
DM1KVPG HS Investigative
DM1KVPG SN CHEMBL1095096; N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide
DM1KVPG DT Small molecular drug
DM1KVPG PC 46887378
DM1KVPG MW 289.3
DM1KVPG FM C18H15N3O
DM1KVPG IC InChI=1S/C18H15N3O/c19-16-7-6-15(13-8-10-20-11-9-13)12-17(16)21-18(22)14-4-2-1-3-5-14/h1-12H,19H2,(H,21,22)
DM1KVPG CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=NC=C3)N
DM1KVPG IK HVVKXFHTJQLADE-UHFFFAOYSA-N
DM1KVPG IU N-(2-amino-5-pyridin-4-ylphenyl)benzamide
DM1KVPG DE Discovery agent
DM2K0AJ ID DM2K0AJ
DM2K0AJ DN N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide
DM2K0AJ HS Investigative
DM2K0AJ SN CHEMBL1097278; N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide
DM2K0AJ DT Small molecular drug
DM2K0AJ PC 46887333
DM2K0AJ MW 295.4
DM2K0AJ FM C16H13N3OS
DM2K0AJ IC InChI=1S/C16H13N3OS/c17-13-7-6-12(16-18-8-9-21-16)10-14(13)19-15(20)11-4-2-1-3-5-11/h1-10H,17H2,(H,19,20)
DM2K0AJ CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=NC=CS3)N
DM2K0AJ IK FHTINQMYYLCTSM-UHFFFAOYSA-N
DM2K0AJ IU N-[2-amino-5-(1,3-thiazol-2-yl)phenyl]benzamide
DM2K0AJ DE Discovery agent
DMFYG79 ID DMFYG79
DMFYG79 DN N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide
DMFYG79 HS Investigative
DMFYG79 SN CHEMBL256440; N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide; SCHEMBL1066609
DMFYG79 DT Small molecular drug
DMFYG79 PC 44454416
DMFYG79 MW 295.4
DMFYG79 FM C16H13N3OS
DMFYG79 IC InChI=1S/C16H13N3OS/c17-13-6-5-11(15-4-2-8-21-15)9-14(13)19-16(20)12-3-1-7-18-10-12/h1-10H,17H2,(H,19,20)
DMFYG79 CS C1=CC(=CN=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
DMFYG79 IK VHWNADCYYRKHOX-UHFFFAOYSA-N
DMFYG79 IU N-(2-amino-5-thiophen-2-ylphenyl)pyridine-3-carboxamide
DMFYG79 DE Discovery agent
DMRK4FA ID DMRK4FA
DMRK4FA DN N-(2-aminoethyl)-1-aziridine-ethanamine
DMRK4FA HS Investigative
DMRK4FA SN NAAE; N-(2-aminoethyl)-1-aziridineethanamine
DMRK4FA TC Antiviral Agents
DMRK4FA DT Small molecular drug
DMRK4FA PC 98888
DMRK4FA MW 129.199
DMRK4FA FM C6H15N3
DMRK4FA IC InChI=1S/C6H15N3/c7-1-2-8-3-4-9-5-6-9/h8H,1-7H2
DMRK4FA CS C1CN1CCNCCN
DMRK4FA IK XJNAQZHMIAKQOK-UHFFFAOYSA-N
DMRK4FA IU N'-[2-(aziridin-1-yl)ethyl]ethane-1,2-diamine
DMRK4FA CA CAS 23435-23-6
DMRK4FA CB CHEBI:145998
DMRK4FA DE Severe acute respiratory syndrome (SARS)
DM7SUTQ ID DM7SUTQ
DM7SUTQ DN N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
DM7SUTQ HS Investigative
DM7SUTQ SN 3-carboxamido coumarin, 5; CHEMBL472638; SCHEMBL15892984; BDBM29156; AKOS005787848
DM7SUTQ DT Small molecular drug
DM7SUTQ PC 10657190
DM7SUTQ MW 232.23
DM7SUTQ FM C12H12N2O3
DM7SUTQ IC InChI=1S/C12H12N2O3/c13-5-6-14-11(15)9-7-8-3-1-2-4-10(8)17-12(9)16/h1-4,7H,5-6,13H2,(H,14,15)
DM7SUTQ CS C1=CC=C2C(=C1)C=C(C(=O)O2)C(=O)NCCN
DM7SUTQ IK ZZZHRZHNTZJEMF-UHFFFAOYSA-N
DM7SUTQ IU N-(2-aminoethyl)-2-oxochromene-3-carboxamide
DM7SUTQ DE Discovery agent
DMG2MSX ID DMG2MSX
DMG2MSX DN N-(2-aminoethyl)isoquinoline-5-sulfonamide
DMG2MSX HS Investigative
DMG2MSX SN N-(2-aminoethyl)isoquinoline-5-sulfonamide; AEIQS; 84468-17-7; N-(2-aminoethyl)-5-isoquinolinesulfonamide; Protein kinase C inhibitor H-9; H-9; (2-Aminoethyl)(5-isoquinolylsulfonyl)amine; 5-Isoquinolinesulfonamide, N-(2-aminoethyl)-; CHEMBL344314; DCVZSHVZGVWQKV-UHFFFAOYSA-N; H9; Isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; C11H13N3O2S; BRD7657; BRD-7657; N-(2-aminoethyl]-5-isoquinolinesulfonamide; IQU; N-(2-Aminoethyl)isoquinoline-5-sulfonamide hydrochloride (H9); Tocris-0396; Lopac-H-123; AC1Q6ULL; H-9, DiHCl; AC1L1G6B
DMG2MSX DT Small molecular drug
DMG2MSX PC 3544
DMG2MSX MW 251.31
DMG2MSX FM C11H13N3O2S
DMG2MSX IC InChI=1S/C11H13N3O2S/c12-5-7-14-17(15,16)11-3-1-2-9-8-13-6-4-10(9)11/h1-4,6,8,14H,5,7,12H2
DMG2MSX CS C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCN
DMG2MSX IK DCVZSHVZGVWQKV-UHFFFAOYSA-N
DMG2MSX IU N-(2-aminoethyl)isoquinoline-5-sulfonamide
DMG2MSX CA CAS 84468-17-7
DMG2MSX DE Discovery agent
DMLSFQI ID DMLSFQI
DMLSFQI DN N-(2-aminoethyl)-p-chlorobenzamide
DMLSFQI HS Investigative
DMLSFQI DE Discovery agent
DMT7JUC ID DMT7JUC
DMT7JUC DN N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide
DMT7JUC HS Investigative
DMT7JUC SN CHEMBL238569; N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide; SCHEMBL1064835
DMT7JUC DT Small molecular drug
DMT7JUC PC 9924962
DMT7JUC MW 358.4
DMT7JUC FM C23H22N2O2
DMT7JUC IC InChI=1S/C23H22N2O2/c24-20-6-2-3-7-21(20)25-23(26)18-11-9-16(10-12-18)13-17-14-19-5-1-4-8-22(19)27-15-17/h1-12,17H,13-15,24H2,(H,25,26)
DMT7JUC CS C1C(COC2=CC=CC=C21)CC3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N
DMT7JUC IK COJSUOYKFQWDMR-UHFFFAOYSA-N
DMT7JUC IU N-(2-aminophenyl)-4-(3,4-dihydro-2H-chromen-3-ylmethyl)benzamide
DMT7JUC DE Discovery agent
DMTKWUM ID DMTKWUM
DMTKWUM DN N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM HS Investigative
DMTKWUM SN N-(2-aminophenyl)-4-methoxybenzamide; AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394
DMTKWUM DT Small molecular drug
DMTKWUM PC 785232
DMTKWUM MW 242.27
DMTKWUM FM C14H14N2O2
DMTKWUM IC InChI=1S/C14H14N2O2/c1-18-11-8-6-10(7-9-11)14(17)16-13-5-3-2-4-12(13)15/h2-9H,15H2,1H3,(H,16,17)
DMTKWUM CS COC1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
DMTKWUM IK BDYVCYUXCNZYRW-UHFFFAOYSA-N
DMTKWUM IU N-(2-aminophenyl)-4-methoxybenzamide
DMTKWUM CA CAS 103517-57-3
DMTKWUM DE Discovery agent
DM8PB90 ID DM8PB90
DM8PB90 DN N-(2-aminophenyl)benzamide
DM8PB90 HS Investigative
DM8PB90 SN N-(2-aminophenyl)benzamide; 2'-AMINOBENZANILIDE; 721-47-1; CHEMBL405072; AC1LFSYX; AC1Q5NOK; ACMC-1AE0C; Oprea1_478192; MLS000084661; SCHEMBL407834; N-(2-amino-phenyl)-benzamide; AC1Q514U; Benzamide, N-(2-aminophenyl)-; CTK2H2825; DTXSID60353948; RFDVMOUXHKTCDO-UHFFFAOYSA-N; MolPort-001-783-352; ZINC225957; HMS2355D18; STL497474; BDBM50232046; AKOS000133162; MCULE-5545982713; NE17312; SMR000019009; TC-170926; KB-298435; ST51030142; EN300-31745; SR-01000389415; AE-641/00785046
DM8PB90 DT Small molecular drug
DM8PB90 PC 759408
DM8PB90 MW 212.25
DM8PB90 FM C13H12N2O
DM8PB90 IC InChI=1S/C13H12N2O/c14-11-8-4-5-9-12(11)15-13(16)10-6-2-1-3-7-10/h1-9H,14H2,(H,15,16)
DM8PB90 CS C1=CC=C(C=C1)C(=O)NC2=CC=CC=C2N
DM8PB90 IK RFDVMOUXHKTCDO-UHFFFAOYSA-N
DM8PB90 IU N-(2-aminophenyl)benzamide
DM8PB90 CA CAS 721-47-1
DM8PB90 DE Discovery agent
DMRDQ1B ID DMRDQ1B
DMRDQ1B DN N-(2-aminophenyl)nicotinamide
DMRDQ1B HS Investigative
DMRDQ1B SN N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)nicotinamide; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6
DMRDQ1B DT Small molecular drug
DMRDQ1B PC 1133083
DMRDQ1B MW 213.23
DMRDQ1B FM C12H11N3O
DMRDQ1B IC InChI=1S/C12H11N3O/c13-10-5-1-2-6-11(10)15-12(16)9-4-3-7-14-8-9/h1-8H,13H2,(H,15,16)
DMRDQ1B CS C1=CC=C(C(=C1)N)NC(=O)C2=CN=CC=C2
DMRDQ1B IK CEZRXCCXPZWXNX-UHFFFAOYSA-N
DMRDQ1B IU N-(2-aminophenyl)pyridine-3-carboxamide
DMRDQ1B CA CAS 436089-31-5
DMRDQ1B CB CHEBI:125506
DMRDQ1B DE Discovery agent
DMJXV7C ID DMJXV7C
DMJXV7C DN N-(2-aminophenyl)quinoxaline-6-carboxamide
DMJXV7C HS Investigative
DMJXV7C SN N-(2-aminophenyl)quinoxaline-6-carboxamide; benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424
DMJXV7C DT Small molecular drug
DMJXV7C PC 23648267
DMJXV7C MW 264.28
DMJXV7C FM C15H12N4O
DMJXV7C IC InChI=1S/C15H12N4O/c16-11-3-1-2-4-12(11)19-15(20)10-5-6-13-14(9-10)18-8-7-17-13/h1-9H,16H2,(H,19,20)
DMJXV7C CS C1=CC=C(C(=C1)N)NC(=O)C2=CC3=NC=CN=C3C=C2
DMJXV7C IK DINRLSVFUAZDMZ-UHFFFAOYSA-N
DMJXV7C IU N-(2-aminophenyl)quinoxaline-6-carboxamide
DMJXV7C DE Discovery agent
DM72BSO ID DM72BSO
DM72BSO DN N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine
DM72BSO HS Investigative
DM72BSO SN Benzyl-(1-methyl-1H-pyrrol-2-ylmethyl)-amine; 73325-58-3; CHEMBL223300; [(1-methylpyrrol-2-yl)methyl]benzylamine; N-benzyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine; pyrrole inhibitor 18; BAS 10796078; AC1M3ZOX; N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine; SCHEMBL11567290; CTK6I2711; BDBM15593; MolPort-000-863-754; ZINC2868930; SBB010992; STK511232; BBL030414; 8940AE; AKOS000285009; MCULE-8292930001; ST063683; benzyl[(1-methylpyrrol-2-yl)methyl]amine; TR-044376; KB-250848; benzyl (1-methyl-1h-pyrrol-2-ylmethyl)amine
DM72BSO DT Small molecular drug
DM72BSO PC 2222065
DM72BSO MW 200.28
DM72BSO FM C13H16N2
DM72BSO IC InChI=1S/C13H16N2/c1-15-9-5-8-13(15)11-14-10-12-6-3-2-4-7-12/h2-9,14H,10-11H2,1H3
DM72BSO CS CN1C=CC=C1CNCC2=CC=CC=C2
DM72BSO IK RFBDIJWXYJNKSB-UHFFFAOYSA-N
DM72BSO IU N-[(1-methylpyrrol-2-yl)methyl]-1-phenylmethanamine
DM72BSO DE Discovery agent
DMW5XLG ID DMW5XLG
DMW5XLG DN N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide
DMW5XLG HS Investigative
DMW5XLG SN CHEMBL223108; SCHEMBL3295792; MolPort-028-745-458; ZINC35324154
DMW5XLG DT Small molecular drug
DMW5XLG PC 16125122
DMW5XLG MW 322.34
DMW5XLG FM C14H14N2O5S
DMW5XLG IC InChI=1S/C14H14N2O5S/c1-22(19,20)15-13-8-7-12(16(17)18)9-14(13)21-10-11-5-3-2-4-6-11/h2-9,15H,10H2,1H3
DMW5XLG CS CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OCC2=CC=CC=C2
DMW5XLG IK XDQFGDRBMTXPFY-UHFFFAOYSA-N
DMW5XLG IU N-(4-nitro-2-phenylmethoxyphenyl)methanesulfonamide
DMW5XLG DE Discovery agent
DMFC564 ID DMFC564
DMFC564 DN N-(2-bromobenzoyloxy)-4-chlorobenzamide
DMFC564 HS Investigative
DMFC564 SN CHEMBL1253383; N-{[(2-bromophenyl)carbonyl]oxy}-4-chlorobenzamide; N-(2-bromobenzoyloxy)-4-chlorobenzamide; AC1LQE9K; CBMicro_012071; MolPort-002-189-016; ZINC1186119; SMSF0017521; STK185858; BDBM50326572; AKOS005412260; MCULE-4091237725; CB15272; [(4-chlorobenzoyl)amino] 2-bromobenzoate; BIM-0012056.P001; SR-01000230575
DMFC564 DT Small molecular drug
DMFC564 PC 1348789
DMFC564 MW 354.58
DMFC564 FM C14H9BrClNO3
DMFC564 IC InChI=1S/C14H9BrClNO3/c15-12-4-2-1-3-11(12)14(19)20-17-13(18)9-5-7-10(16)8-6-9/h1-8H,(H,17,18)
DMFC564 CS C1=CC=C(C(=C1)C(=O)ONC(=O)C2=CC=C(C=C2)Cl)Br
DMFC564 IK XBZVDYJKCJLDSB-UHFFFAOYSA-N
DMFC564 IU [(4-chlorobenzoyl)amino] 2-bromobenzoate
DMFC564 DE Discovery agent
DM4IEWG ID DM4IEWG
DM4IEWG DN N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide
DM4IEWG HS Investigative
DM4IEWG SN CHEMBL1269883; N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide
DM4IEWG DT Small molecular drug
DM4IEWG PC 52948346
DM4IEWG MW 357.2
DM4IEWG FM C19H14Cl2N2O
DM4IEWG IC InChI=1S/C19H14Cl2N2O/c20-17-7-5-13(6-8-17)15-9-16(11-22-10-15)19(24)23-12-14-3-1-2-4-18(14)21/h1-11H,12H2,(H,23,24)
DM4IEWG CS C1=CC=C(C(=C1)CNC(=O)C2=CN=CC(=C2)C3=CC=C(C=C3)Cl)Cl
DM4IEWG IK CKNIOMWTEPBNFF-UHFFFAOYSA-N
DM4IEWG IU 5-(4-chlorophenyl)-N-[(2-chlorophenyl)methyl]pyridine-3-carboxamide
DM4IEWG DE Discovery agent
DMU5R2O ID DMU5R2O
DMU5R2O DN N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMU5R2O HS Investigative
DMU5R2O SN AC1L1CNE; CTK8E7690; DTXSID60274346
DMU5R2O DT Small molecular drug
DMU5R2O PC 1977
DMU5R2O MW 366
DMU5R2O FM C22H36ClNO
DMU5R2O IC InChI=1S/C22H36ClNO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)24-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,24,25)
DMU5R2O CS CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCCl
DMU5R2O IK SCJNCDSAIRBRIA-UHFFFAOYSA-N
DMU5R2O IU N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide
DMU5R2O CA CAS 220556-69-4
DMU5R2O DE Discovery agent
DMZ4A2X ID DMZ4A2X
DMZ4A2X DN N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide
DMZ4A2X HS Investigative
DMZ4A2X SN CHEMBL122865; N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide; BDBM50106170; AKOS016689088
DMZ4A2X DT Small molecular drug
DMZ4A2X PC 11023656
DMZ4A2X MW 320.5
DMZ4A2X FM C19H32N2O2
DMZ4A2X IC InChI=1S/C19H32N2O2/c1-4-7-8-9-16-23-18-12-10-17(11-13-18)19(22)20-14-15-21(5-2)6-3/h10-13H,4-9,14-16H2,1-3H3,(H,20,22)
DMZ4A2X CS CCCCCCOC1=CC=C(C=C1)C(=O)NCCN(CC)CC
DMZ4A2X IK ZVGROIFLIDCWLT-UHFFFAOYSA-N
DMZ4A2X IU N-[2-(diethylamino)ethyl]-4-hexoxybenzamide
DMZ4A2X DE Discovery agent
DMMDXEO ID DMMDXEO
DMMDXEO DN N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMMDXEO HS Investigative
DMMDXEO SN CHEMBL1269649; N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMMDXEO DT Small molecular drug
DMMDXEO PC 52940635
DMMDXEO MW 252.31
DMMDXEO FM C16H16N2O
DMMDXEO IC InChI=1S/C16H16N2O/c1-3-12-6-4-5-7-13(12)17-16-18-14-10-11(2)8-9-15(14)19-16/h4-10H,3H2,1-2H3,(H,17,18)
DMMDXEO CS CCC1=CC=CC=C1NC2=NC3=C(O2)C=CC(=C3)C
DMMDXEO IK KQXHDGZITMHOPQ-UHFFFAOYSA-N
DMMDXEO IU N-(2-ethylphenyl)-5-methyl-1,3-benzoxazol-2-amine
DMMDXEO DE Discovery agent
DMDM50P ID DMDM50P
DMDM50P DN N-(2-Ethylphenyl)-N'-hydroxyoctanediamide
DMDM50P HS Investigative
DMDM50P SN CHEMBL1093040; BDBM50314142
DMDM50P DT Small molecular drug
DMDM50P PC 45141752
DMDM50P MW 292.37
DMDM50P FM C16H24N2O3
DMDM50P IC InChI=1S/C16H24N2O3/c1-2-13-9-7-8-10-14(13)17-15(19)11-5-3-4-6-12-16(20)18-21/h7-10,21H,2-6,11-12H2,1H3,(H,17,19)(H,18,20)
DMDM50P CS CCC1=CC=CC=C1NC(=O)CCCCCCC(=O)NO
DMDM50P IK COKQAZFZACGKGP-UHFFFAOYSA-N
DMDM50P IU N-(2-ethylphenyl)-N'-hydroxyoctanediamide
DMDM50P DE Discovery agent
DM3CZVW ID DM3CZVW
DM3CZVW DN N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide
DM3CZVW HS Investigative
DM3CZVW SN n-(2-flouro-benzyl)-4-sulfamoyl-benzamide; N-[(2-fluorophenyl)methyl]-4-sulfamoylbenzamide; n-(2-fluoro-benzyl)-4-sulfamoyl-benzamide; 2-fluoro-SBB; 1g1d; AC1L1HTZ; SCHEMBL678599; BDBM12014; 1g45; AKOS008607291; DB02069; n-(2-fluorobenzyl)-4-sulfamoylbenzamide
DM3CZVW DT Small molecular drug
DM3CZVW PC 4290
DM3CZVW MW 308.33
DM3CZVW FM C14H13FN2O3S
DM3CZVW IC InChI=1S/C14H13FN2O3S/c15-13-4-2-1-3-11(13)9-17-14(18)10-5-7-12(8-6-10)21(16,19)20/h1-8H,9H2,(H,17,18)(H2,16,19,20)
DM3CZVW CS C1=CC=C(C(=C1)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)F
DM3CZVW IK ULYMHSXFSKOHGH-UHFFFAOYSA-N
DM3CZVW IU N-[(2-fluorophenyl)methyl]-4-sulfamoylbenzamide
DM3CZVW DE Discovery agent
DM7BKUQ ID DM7BKUQ
DM7BKUQ DN N'-(2-fluorobenzoyl)-2-naphthohydrazide
DM7BKUQ HS Investigative
DM7BKUQ SN CHEMBL108888; N'-(2-fluorobenzoyl)naphthalene-2-carbohydrazide; NSC88634; AC1L60EG; ZINC1569432; BDBM50066318; NSC-88634; AKOS008432264; N''-(2-fluorobenzoyl)-2-naphthohydrazide; (2-Fluorophenyl)-N-(2-naphthylcarbonylamino)carboxamide; Naphthalene-2-carboxylic acid N''-(2-fluoro-benzoyl)-hydrazide
DM7BKUQ DT Small molecular drug
DM7BKUQ PC 259098
DM7BKUQ MW 308.3
DM7BKUQ FM C18H13FN2O2
DM7BKUQ IC InChI=1S/C18H13FN2O2/c19-16-8-4-3-7-15(16)18(23)21-20-17(22)14-10-9-12-5-1-2-6-13(12)11-14/h1-11H,(H,20,22)(H,21,23)
DM7BKUQ CS C1=CC=C2C=C(C=CC2=C1)C(=O)NNC(=O)C3=CC=CC=C3F
DM7BKUQ IK BHGKYYRQGUSTGE-UHFFFAOYSA-N
DM7BKUQ IU N'-(2-fluorobenzoyl)naphthalene-2-carbohydrazide
DM7BKUQ DE Discovery agent
DM27L53 ID DM27L53
DM27L53 DN N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide
DM27L53 HS Investigative
DM27L53 SN CHEMBL202471; N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3294121; BDBM50182531
DM27L53 DT Small molecular drug
DM27L53 PC 11493409
DM27L53 MW 316.38
DM27L53 FM C13H20N2O5S
DM27L53 IC InChI=1S/C13H20N2O5S/c1-3-4-5-6-9-20-13-10-11(15(16)17)7-8-12(13)14-21(2,18)19/h7-8,10,14H,3-6,9H2,1-2H3
DM27L53 CS CCCCCCOC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C
DM27L53 IK ZYLWBHCVEZSQJB-UHFFFAOYSA-N
DM27L53 IU N-(2-hexoxy-4-nitrophenyl)methanesulfonamide
DM27L53 DE Discovery agent
DM97MGE ID DM97MGE
DM97MGE DN N-(2-hydroxyethyl)linoleoylamide
DM97MGE HS Investigative
DM97MGE SN Linoleamide MEA; Linoleoyl ethanolamide; Linoleic ethanolamide; n-linoleoylethanolamine; N-(2-Hydroxyethyl)linoleamide; Anandamide (18:2, n-6); Linoleoyl monoethanolamide; UNII-889DYX0816; N-(2-hydroxyethyl)linoleoylamide; Linoleylethanolamide; 68171-52-8; Monoethanolamine linoleic acid amide; EINECS 269-029-6; N-(9Z,12Z-octadecadienoyl)-ethanolamine; CHEMBL149859; N-(2-Hydroxyethyl)-linoleamide; C20H37NO2; CHEBI:64032; 889DYX0816; (9Z,12Z)-N-(2-Hydroxyethyl)octadeca-9,12-dien-1-amide
DM97MGE DT Small molecular drug
DM97MGE PC 5283446
DM97MGE MW 323.5
DM97MGE FM C20H37NO2
DM97MGE IC InChI=1S/C20H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h6-7,9-10,22H,2-5,8,11-19H2,1H3,(H,21,23)/b7-6-,10-9-
DM97MGE CS CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NCCO
DM97MGE IK KQXDGUVSAAQARU-HZJYTTRNSA-N
DM97MGE IU (9Z,12Z)-N-(2-hydroxyethyl)octadeca-9,12-dienamide
DM97MGE CA CAS 68171-52-8
DM97MGE CB CHEBI:64032
DM97MGE DE Discovery agent
DM8ORQ4 ID DM8ORQ4
DM8ORQ4 DN N-(2-iodethyl)arachidonylamide
DM8ORQ4 HS Investigative
DM8ORQ4 SN N-(2-iodethyl)arachidonylamide; CHEMBL509376
DM8ORQ4 DT Small molecular drug
DM8ORQ4 PC 44569685
DM8ORQ4 MW 457.4
DM8ORQ4 FM C22H36INO
DM8ORQ4 IC InChI=1S/C22H36INO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)24-21-20-23/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,24,25)/b7-6-,10-9-,13-12-,16-15-
DM8ORQ4 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCI
DM8ORQ4 IK KOHVJRAXSGONGW-DOFZRALJSA-N
DM8ORQ4 IU (5Z,8Z,11Z,14Z)-N-(2-iodoethyl)icosa-5,8,11,14-tetraenamide
DM8ORQ4 DE Discovery agent
DMV84PQ ID DMV84PQ
DMV84PQ DN N-(2-iodoethyl)linoleoylamide
DMV84PQ HS Investigative
DMV84PQ SN N-(2-iodoethyl)linoleoylamide; CHEMBL448660
DMV84PQ DT Small molecular drug
DMV84PQ PC 44569684
DMV84PQ MW 433.4
DMV84PQ FM C20H36INO
DMV84PQ IC InChI=1S/C20H36INO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)22-19-18-21/h6-7,9-10H,2-5,8,11-19H2,1H3,(H,22,23)/b7-6-,10-9-
DMV84PQ CS CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NCCI
DMV84PQ IK WVKIJZMEKURTIW-HZJYTTRNSA-N
DMV84PQ IU (9Z,12Z)-N-(2-iodoethyl)octadeca-9,12-dienamide
DMV84PQ DE Discovery agent
DM0GOPV ID DM0GOPV
DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide
DM0GOPV HS Investigative
DM0GOPV SN CHEMBL193979
DM0GOPV DT Small molecular drug
DM0GOPV PC 44401305
DM0GOPV MW 224.28
DM0GOPV FM C10H12N2O2S
DM0GOPV IC InChI=1S/C10H12N2O2S/c13-9(11-6-7-15)10(14)12-8-4-2-1-3-5-8/h1-5,15H,6-7H2,(H,11,13)(H,12,14)
DM0GOPV CS C1=CC=C(C=C1)NC(=O)C(=O)NCCS
DM0GOPV IK NDECTIXXLKUOQM-UHFFFAOYSA-N
DM0GOPV IU N'-phenyl-N-(2-sulfanylethyl)oxamide
DM0GOPV DE Discovery agent
DMJLFOQ ID DMJLFOQ
DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide
DMJLFOQ HS Investigative
DMJLFOQ SN CHEMBL193959
DMJLFOQ DT Small molecular drug
DMJLFOQ PC 44401339
DMJLFOQ MW 252.33
DMJLFOQ FM C12H16N2O2S
DMJLFOQ IC InChI=1S/C12H16N2O2S/c15-11(13-8-9-17)6-7-12(16)14-10-4-2-1-3-5-10/h1-5,17H,6-9H2,(H,13,15)(H,14,16)
DMJLFOQ CS C1=CC=C(C=C1)NC(=O)CCC(=O)NCCS
DMJLFOQ IK DQJPTXLXOUGDMC-UHFFFAOYSA-N
DMJLFOQ IU N'-phenyl-N-(2-sulfanylethyl)butanediamide
DMJLFOQ DE Discovery agent
DM06S5Z ID DM06S5Z
DM06S5Z DN N-(2-methoxybenzyl)cinnamamidine
DM06S5Z HS Investigative
DM06S5Z SN N-(2-methoxybenzyl)cinnamamidine; CHEMBL158737; SCHEMBL4624632; BDBM50124885; N-(2-Methoxybenzyl)-trans-cinnamamidine; n-(2-methoxybenzyl)-3-phenylacrylamidine
DM06S5Z DT Small molecular drug
DM06S5Z PC 9900027
DM06S5Z MW 266.34
DM06S5Z FM C17H18N2O
DM06S5Z IC InChI=1S/C17H18N2O/c1-20-16-10-6-5-9-15(16)13-19-17(18)12-11-14-7-3-2-4-8-14/h2-12H,13H2,1H3,(H2,18,19)/b12-11+
DM06S5Z CS COC1=CC=CC=C1CN=C(/C=C/C2=CC=CC=C2)N
DM06S5Z IK YYJKWRHOJBQQMG-VAWYXSNFSA-N
DM06S5Z IU (E)-N'-[(2-methoxyphenyl)methyl]-3-phenylprop-2-enimidamide
DM06S5Z DE Discovery agent
DMH42YF ID DMH42YF
DMH42YF DN N-(2-Methyl-1H-indol-5-yl)benzamide
DMH42YF HS Investigative
DMH42YF SN CHEMBL1253578; N-(2-Methyl-1H-indol-5-yl)benzamide; BDBM50326842
DMH42YF DT Small molecular drug
DMH42YF PC 24219274
DMH42YF MW 250.29
DMH42YF FM C16H14N2O
DMH42YF IC InChI=1S/C16H14N2O/c1-11-9-13-10-14(7-8-15(13)17-11)18-16(19)12-5-3-2-4-6-12/h2-10,17H,1H3,(H,18,19)
DMH42YF CS CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3=CC=CC=C3
DMH42YF IK GXRAVFCYXQCDLO-UHFFFAOYSA-N
DMH42YF IU N-(2-methyl-1H-indol-5-yl)benzamide
DMH42YF DE Discovery agent
DM3SF5M ID DM3SF5M
DM3SF5M DN N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide
DM3SF5M HS Investigative
DM3SF5M SN CHEMBL1253605; N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide; MolPort-007-401-898; ZINC43771600; BDBM50326846
DM3SF5M DT Small molecular drug
DM3SF5M PC 46400456
DM3SF5M MW 256.339
DM3SF5M FM C16H20N2O
DM3SF5M IC InChI=1S/C16H20N2O/c1-11-9-13-10-14(7-8-15(13)17-11)18-16(19)12-5-3-2-4-6-12/h7-10,12,17H,2-6H2,1H3,(H,18,19)
DM3SF5M CS CC1=CC2=C(N1)C=CC(=C2)NC(=O)C3CCCCC3
DM3SF5M IK VFQGCSZINPSFBG-UHFFFAOYSA-N
DM3SF5M IU N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
DM3SF5M DE Discovery agent
DMXRSM1 ID DMXRSM1
DMXRSM1 DN N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide
DMXRSM1 HS Investigative
DMXRSM1 SN CHEMBL246026; N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide; 923600-01-5; CTK3F8796; DTXSID50653166; BDBM50197260; AKOS027754505; 2-Pyrazinecarboxamide, N-(2-methyl-2-phenylpropyl)-
DMXRSM1 DT Small molecular drug
DMXRSM1 PC 36039661
DMXRSM1 MW 255.31
DMXRSM1 FM C15H17N3O
DMXRSM1 IC InChI=1S/C15H17N3O/c1-15(2,12-6-4-3-5-7-12)11-18-14(19)13-10-16-8-9-17-13/h3-10H,11H2,1-2H3,(H,18,19)
DMXRSM1 CS CC(C)(CNC(=O)C1=NC=CN=C1)C2=CC=CC=C2
DMXRSM1 IK HMOMSNPWNJNCOE-UHFFFAOYSA-N
DMXRSM1 IU N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide
DMXRSM1 CA CAS 923600-01-5
DMXRSM1 DE Discovery agent
DMI4KNB ID DMI4KNB
DMI4KNB DN N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide
DMI4KNB HS Investigative
DMI4KNB SN CHEMBL251369; N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide; AC1MH48W; MLS001162447; SCHEMBL13148062; cid_2996093; N-[2-(morpholin-4-yl)phenyl]-5-nitrofuran-2-carboxamide; MolPort-002-305-194; HMS2967E08; ZINC4842600; STK355602; BDBM50223675; AKOS000458368; MCULE-3330873928; SMR000670465; VU0465060-1; N-(2-morpholin-4-ylphenyl)-5-nitro-2-furamide; AP-970/43481542; N-[2-(4-morpholinyl)phenyl]-5-nitro-2-furamide
DMI4KNB DT Small molecular drug
DMI4KNB PC 2996093
DMI4KNB MW 317.3
DMI4KNB FM C15H15N3O5
DMI4KNB IC InChI=1S/C15H15N3O5/c19-15(13-5-6-14(23-13)18(20)21)16-11-3-1-2-4-12(11)17-7-9-22-10-8-17/h1-6H,7-10H2,(H,16,19)
DMI4KNB CS C1COCCN1C2=CC=CC=C2NC(=O)C3=CC=C(O3)[N+](=O)[O-]
DMI4KNB IK BIQWNNXDPVEAPZ-UHFFFAOYSA-N
DMI4KNB IU N-(2-morpholin-4-ylphenyl)-5-nitrofuran-2-carboxamide
DMI4KNB DE Discovery agent
DMF5N4O ID DMF5N4O
DMF5N4O DN N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile
DMF5N4O HS Investigative
DMF5N4O SN dipeptide-derived nitrile, 38; CHEMBL200338; BDBM20117
DMF5N4O DT Small molecular drug
DMF5N4O PC 11652399
DMF5N4O MW 303.34
DMF5N4O FM C14H13N3O3S
DMF5N4O IC InChI=1S/C14H13N3O3S/c15-7-8-16-14(18)10-17-21(19,20)13-6-5-11-3-1-2-4-12(11)9-13/h1-6,9,17H,8,10H2,(H,16,18)
DMF5N4O CS C1=CC=C2C=C(C=CC2=C1)S(=O)(=O)NCC(=O)NCC#N
DMF5N4O IK LVYWXNHSBUSHNC-UHFFFAOYSA-N
DMF5N4O IU N-(cyanomethyl)-2-(naphthalen-2-ylsulfonylamino)acetamide
DMF5N4O DE Discovery agent
DMU6FPL ID DMU6FPL
DMU6FPL DN N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide
DMU6FPL HS Investigative
DMU6FPL SN CHEMBL202469; N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3295100; BDBM50182532
DMU6FPL DT Small molecular drug
DMU6FPL PC 11646165
DMU6FPL MW 358.5
DMU6FPL FM C16H26N2O5S
DMU6FPL IC InChI=1S/C16H26N2O5S/c1-3-4-5-6-7-8-9-12-23-16-13-14(18(19)20)10-11-15(16)17-24(2,21)22/h10-11,13,17H,3-9,12H2,1-2H3
DMU6FPL CS CCCCCCCCCOC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C
DMU6FPL IK QXUZIGSBVCSGCD-UHFFFAOYSA-N
DMU6FPL IU N-(4-nitro-2-nonoxyphenyl)methanesulfonamide
DMU6FPL DE Discovery agent
DMVGP02 ID DMVGP02
DMVGP02 DN N-(2-oxazolemethyl)milnacipran
DMVGP02 HS Investigative
DMVGP02 SN CHEMBL256408; N-(2-oxazolemethyl)milnacipran
DMVGP02 DT Small molecular drug
DMVGP02 PC 44454825
DMVGP02 MW 327.4
DMVGP02 FM C19H25N3O2
DMVGP02 IC InChI=1S/C19H25N3O2/c1-3-22(4-2)18(23)19(15-8-6-5-7-9-15)12-16(19)13-20-14-17-21-10-11-24-17/h5-11,16,20H,3-4,12-14H2,1-2H3
DMVGP02 CS CCN(CC)C(=O)C1(CC1CNCC2=NC=CO2)C3=CC=CC=C3
DMVGP02 IK NCRFMJNGTNNKEE-UHFFFAOYSA-N
DMVGP02 IU N,N-diethyl-2-[(1,3-oxazol-2-ylmethylamino)methyl]-1-phenylcyclopropane-1-carboxamide
DMVGP02 DE Discovery agent
DMBR1MX ID DMBR1MX
DMBR1MX DN N'-(2-phenylallyl)hydrazine hydrochloride
DMBR1MX HS Investigative
DMBR1MX SN CHEMBL536057; SCHEMBL18953115; N'-(2-Phenylallyl)Hydrazine HCl; LS-193138; N'-(2-phenyl-allyl)-hydrazine hydrochloride
DMBR1MX DT Small molecular drug
DMBR1MX PC 11679937
DMBR1MX MW 184.66
DMBR1MX FM C9H13ClN2
DMBR1MX IC InChI=1S/C9H12N2.ClH/c1-8(7-11-10)9-5-3-2-4-6-9;/h2-6,11H,1,7,10H2;1H
DMBR1MX CS C=C(CNN)C1=CC=CC=C1.Cl
DMBR1MX IK SSRWZZHWIPKMCQ-UHFFFAOYSA-N
DMBR1MX IU 2-phenylprop-2-enylhydrazine;hydrochloride
DMBR1MX DE Discovery agent
DM1ADE5 ID DM1ADE5
DM1ADE5 DN N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine
DM1ADE5 HS Investigative
DM1ADE5 SN pyrrole inhibitor 20; N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine; CHEMBL222368; BDBM15595; ZINC14959045; AKOS009004338
DM1ADE5 DT Small molecular drug
DM1ADE5 PC 16110292
DM1ADE5 MW 200.28
DM1ADE5 FM C13H16N2
DM1ADE5 IC InChI=1S/C13H16N2/c1-2-5-12(6-3-1)8-10-14-11-13-7-4-9-15-13/h1-7,9,14-15H,8,10-11H2
DM1ADE5 CS C1=CC=C(C=C1)CCNCC2=CC=CN2
DM1ADE5 IK HKFLTDDIRURSLM-UHFFFAOYSA-N
DM1ADE5 IU 2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
DM1ADE5 DE Discovery agent
DMJCO7F ID DMJCO7F
DMJCO7F DN N-(2-Phenylethyl)-1H-indole-2-carboxamide
DMJCO7F HS Investigative
DMJCO7F SN N-(2-phenylethyl)-1H-indole-2-carboxamide; CHEMBL460610; MolPort-003-002-251; ZINC12653902; STK321421; BDBM50273527; AKOS003377424; MCULE-6495379337; NCGC00317146-01; 57980-68-4; AB01204586-02
DMJCO7F DT Small molecular drug
DMJCO7F PC 12627221
DMJCO7F MW 264.32
DMJCO7F FM C17H16N2O
DMJCO7F IC InChI=1S/C17H16N2O/c20-17(18-11-10-13-6-2-1-3-7-13)16-12-14-8-4-5-9-15(14)19-16/h1-9,12,19H,10-11H2,(H,18,20)
DMJCO7F CS C1=CC=C(C=C1)CCNC(=O)C2=CC3=CC=CC=C3N2
DMJCO7F IK LANZFLJGXZCWQM-UHFFFAOYSA-N
DMJCO7F IU N-(2-phenylethyl)-1H-indole-2-carboxamide
DMJCO7F DE Discovery agent
DMUILX8 ID DMUILX8
DMUILX8 DN N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide
DMUILX8 HS Investigative
DMUILX8 SN N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide; CHEMBL379553; 171628-57-2; N-{2-phenylimidazo[1,2-a]pyridin-3-yl}benzamide; AC1LF77Z; Oprea1_830806; MLS001162915; CTK0E4651; DTXSID60353680; MolPort-002-132-975; HMS2842E11; ZINC193750; BDBM50187634; STK367224; AKOS001415177; MCULE-3771425109; SMR000495823; SR-01000196826; N-(2-Phenylimidazo[1,2-a]pyridine-3-yl)benzamide; SR-01000196826-1; Benzamide, N-(2-phenylimidazo[1,2-a]pyridin-3-yl)-
DMUILX8 DT Small molecular drug
DMUILX8 PC 748028
DMUILX8 MW 313.4
DMUILX8 FM C20H15N3O
DMUILX8 IC InChI=1S/C20H15N3O/c24-20(16-11-5-2-6-12-16)22-19-18(15-9-3-1-4-10-15)21-17-13-7-8-14-23(17)19/h1-14H,(H,22,24)
DMUILX8 CS C1=CC=C(C=C1)C2=C(N3C=CC=CC3=N2)NC(=O)C4=CC=CC=C4
DMUILX8 IK MFEAOWRPVOQOEV-UHFFFAOYSA-N
DMUILX8 IU N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide
DMUILX8 CA CAS 171628-57-2
DMUILX8 DE Discovery agent
DMA1LRF ID DMA1LRF
DMA1LRF DN N-(2-phenylpropyl)quinoxaline-2-carboxamide
DMA1LRF HS Investigative
DMA1LRF SN CHEMBL241699; N-(2-phenylpropyl)quinoxaline-2-carboxamide; SCHEMBL6083525; UWOAOBCILHACGX-UHFFFAOYSA-N; BDBM50197265
DMA1LRF DT Small molecular drug
DMA1LRF PC 22136331
DMA1LRF MW 291.3
DMA1LRF FM C18H17N3O
DMA1LRF IC InChI=1S/C18H17N3O/c1-13(14-7-3-2-4-8-14)11-20-18(22)17-12-19-15-9-5-6-10-16(15)21-17/h2-10,12-13H,11H2,1H3,(H,20,22)
DMA1LRF CS CC(CNC(=O)C1=NC2=CC=CC=C2N=C1)C3=CC=CC=C3
DMA1LRF IK UWOAOBCILHACGX-UHFFFAOYSA-N
DMA1LRF IU N-(2-phenylpropyl)quinoxaline-2-carboxamide
DMA1LRF DE Discovery agent
DMAQMXJ ID DMAQMXJ
DMAQMXJ DN N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide
DMAQMXJ HS Investigative
DMAQMXJ SN CHEMBL204184; N-(2-n-propyloxy-4-nitrophenyl)methanesulfonamide; 880145-98-2; N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide; SCHEMBL3301465; CTK6E5797; BDBM50182536; AKOS015965877; N-(4-nitro-2-propoxyphenyl)methanesulfonamide
DMAQMXJ DT Small molecular drug
DMAQMXJ PC 11680642
DMAQMXJ MW 274.3
DMAQMXJ FM C10H14N2O5S
DMAQMXJ IC InChI=1S/C10H14N2O5S/c1-3-6-17-10-7-8(12(13)14)4-5-9(10)11-18(2,15)16/h4-5,7,11H,3,6H2,1-2H3
DMAQMXJ CS CCCOC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C
DMAQMXJ IK GUPXOWXEFMIHHE-UHFFFAOYSA-N
DMAQMXJ IU N-(4-nitro-2-propoxyphenyl)methanesulfonamide
DMAQMXJ DE Discovery agent
DME9HNO ID DME9HNO
DME9HNO DN N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide
DME9HNO HS Investigative
DME9HNO SN n-(2-thienylmethyl)-2,5-thiophenedisulfonamide; 2-N-(thiophen-2-ylmethyl)thiophene-2,5-disulfonamide; 1bnw; AC1L1HU8; SCHEMBL677620; BDBM11931; STOTVDLYLKWVJB-UHFFFAOYSA-N; AL5415; DB02986; N-(2-Thienyl)methyl-2,5-thiophenedisulfonamide; N-(2-Thienylmethyl)thiophene-2,5-disulfonamide
DME9HNO DT Small molecular drug
DME9HNO PC 4293
DME9HNO MW 338.5
DME9HNO FM C9H10N2O4S4
DME9HNO IC InChI=1S/C9H10N2O4S4/c10-18(12,13)8-3-4-9(17-8)19(14,15)11-6-7-2-1-5-16-7/h1-5,11H,6H2,(H2,10,12,13)
DME9HNO CS C1=CSC(=C1)CNS(=O)(=O)C2=CC=C(S2)S(=O)(=O)N
DME9HNO IK STOTVDLYLKWVJB-UHFFFAOYSA-N
DME9HNO IU 2-N-(thiophen-2-ylmethyl)thiophene-2,5-disulfonamide
DME9HNO DE Discovery agent
DM0JE7H ID DM0JE7H
DM0JE7H DN N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine
DM0JE7H HS Investigative
DM0JE7H SN CHEMBL237790; N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine
DM0JE7H DT Small molecular drug
DM0JE7H PC 44433247
DM0JE7H MW 272.4
DM0JE7H FM C17H24N2O
DM0JE7H IC InChI=1S/C17H24N2O/c1-2-6-14(7-3-1)18-11-5-13-20-17-9-4-8-16-15(17)10-12-19-16/h4,8-10,12,14,18-19H,1-3,5-7,11,13H2
DM0JE7H CS C1CCC(CC1)NCCCOC2=CC=CC3=C2C=CN3
DM0JE7H IK QVATUGJQJMJAPA-UHFFFAOYSA-N
DM0JE7H IU N-[3-(1H-indol-4-yloxy)propyl]cyclohexanamine
DM0JE7H DE Discovery agent
DM2URTK ID DM2URTK
DM2URTK DN N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine
DM2URTK HS Investigative
DM2URTK SN CHEMBL392392; N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine
DM2URTK DT Small molecular drug
DM2URTK PC 44433248
DM2URTK MW 258.36
DM2URTK FM C16H22N2O
DM2URTK IC InChI=1S/C16H22N2O/c1-2-6-13(5-1)17-10-4-12-19-16-8-3-7-15-14(16)9-11-18-15/h3,7-9,11,13,17-18H,1-2,4-6,10,12H2
DM2URTK CS C1CCC(C1)NCCCOC2=CC=CC3=C2C=CN3
DM2URTK IK IYOLOIDWTZSJFT-UHFFFAOYSA-N
DM2URTK IU N-[3-(1H-indol-4-yloxy)propyl]cyclopentanamine
DM2URTK DE Discovery agent
DM4ZTF1 ID DM4ZTF1
DM4ZTF1 DN N-(3-(2,5-dimethoxyphenyl)propyl)acetamide
DM4ZTF1 HS Investigative
DM4ZTF1 SN CHEMBL1092400; N-(3-(2,5-dimethoxyphenyl)propyl)acetamide
DM4ZTF1 DT Small molecular drug
DM4ZTF1 PC 46885283
DM4ZTF1 MW 237.29
DM4ZTF1 FM C13H19NO3
DM4ZTF1 IC InChI=1S/C13H19NO3/c1-10(15)14-8-4-5-11-9-12(16-2)6-7-13(11)17-3/h6-7,9H,4-5,8H2,1-3H3,(H,14,15)
DM4ZTF1 CS CC(=O)NCCCC1=C(C=CC(=C1)OC)OC
DM4ZTF1 IK JFAQPXCGWLODGO-UHFFFAOYSA-N
DM4ZTF1 IU N-[3-(2,5-dimethoxyphenyl)propyl]acetamide
DM4ZTF1 DE Discovery agent
DMP8547 ID DMP8547
DMP8547 DN N-(3-(2-aminoethyl)phenyl)benzenesulfonamide
DMP8547 HS Investigative
DMP8547 SN CHEMBL212063; N-(3-(2-aminoethyl)phenyl)benzenesulfonamide; BDBM50193463
DMP8547 DT Small molecular drug
DMP8547 PC 11849194
DMP8547 MW 276.36
DMP8547 FM C14H16N2O2S
DMP8547 IC InChI=1S/C14H16N2O2S/c15-10-9-12-5-4-6-13(11-12)16-19(17,18)14-7-2-1-3-8-14/h1-8,11,16H,9-10,15H2
DMP8547 CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)CCN
DMP8547 IK SMDOJINITBXUQJ-UHFFFAOYSA-N
DMP8547 IU N-[3-(2-aminoethyl)phenyl]benzenesulfonamide
DMP8547 DE Discovery agent
DMLWGPC ID DMLWGPC
DMLWGPC DN N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide
DMLWGPC HS Investigative
DMLWGPC SN CHEMBL1091561; N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide
DMLWGPC DT Small molecular drug
DMLWGPC PC 46885284
DMLWGPC MW 251.32
DMLWGPC FM C14H21NO3
DMLWGPC IC InChI=1S/C14H21NO3/c1-4-18-14-8-7-13(17-3)10-12(14)6-5-9-15-11(2)16/h7-8,10H,4-6,9H2,1-3H3,(H,15,16)
DMLWGPC CS CCOC1=C(C=C(C=C1)OC)CCCNC(=O)C
DMLWGPC IK GTXCCVOUHCBPES-UHFFFAOYSA-N
DMLWGPC IU N-[3-(2-ethoxy-5-methoxyphenyl)propyl]acetamide
DMLWGPC DE Discovery agent
DMI452E ID DMI452E
DMI452E DN N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide
DMI452E HS Investigative
DMI452E SN CHEMBL1092062; N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide
DMI452E DT Small molecular drug
DMI452E PC 46885230
DMI452E MW 223.27
DMI452E FM C12H17NO3
DMI452E IC InChI=1S/C12H17NO3/c1-9(14)13-7-3-4-10-8-11(16-2)5-6-12(10)15/h5-6,8,15H,3-4,7H2,1-2H3,(H,13,14)
DMI452E CS CC(=O)NCCCC1=C(C=CC(=C1)OC)O
DMI452E IK OMOWUWLCRNGXCM-UHFFFAOYSA-N
DMI452E IU N-[3-(2-hydroxy-5-methoxyphenyl)propyl]acetamide
DMI452E DE Discovery agent
DMW59AY ID DMW59AY
DMW59AY DN N-(3-(3-aminopropyl)phenyl)benzenesulfonamide
DMW59AY HS Investigative
DMW59AY SN CHEMBL378179; N-(3-(3-aminopropyl)phenyl)benzenesulfonamide; SCHEMBL3125892; ZINC36093367
DMW59AY DT Small molecular drug
DMW59AY PC 11849197
DMW59AY MW 290.4
DMW59AY FM C15H18N2O2S
DMW59AY IC InChI=1S/C15H18N2O2S/c16-11-5-7-13-6-4-8-14(12-13)17-20(18,19)15-9-2-1-3-10-15/h1-4,6,8-10,12,17H,5,7,11,16H2
DMW59AY CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)CCCN
DMW59AY IK GTXNQXVWASTZFN-UHFFFAOYSA-N
DMW59AY IU N-[3-(3-aminopropyl)phenyl]benzenesulfonamide
DMW59AY DE Discovery agent
DMXL70A ID DMXL70A
DMXL70A DN N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide
DMXL70A HS Investigative
DMXL70A SN CHEMBL1081367; N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide
DMXL70A DT Small molecular drug
DMXL70A PC 46879969
DMXL70A MW 371.4
DMXL70A FM C22H17N3O3
DMXL70A IC InChI=1S/C22H17N3O3/c1-28-20-11-3-2-10-19(20)22(27)25-18-9-5-8-17(13-18)24-21(26)16-7-4-6-15(12-16)14-23/h2-13H,1H3,(H,24,26)(H,25,27)
DMXL70A CS COC1=CC=CC=C1C(=O)NC2=CC=CC(=C2)NC(=O)C3=CC=CC(=C3)C#N
DMXL70A IK YTAQUZZUBZVOFI-UHFFFAOYSA-N
DMXL70A IU N-[3-[(3-cyanobenzoyl)amino]phenyl]-2-methoxybenzamide
DMXL70A DE Discovery agent
DMH0LOT ID DMH0LOT
DMH0LOT DN N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide
DMH0LOT HS Investigative
DMH0LOT SN CHEMBL218708; N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide; BDBM50241105; AKOS030564511
DMH0LOT DT Small molecular drug
DMH0LOT PC 16094584
DMH0LOT MW 281.3
DMH0LOT FM C18H19NO2
DMH0LOT IC InChI=1S/C18H19NO2/c1-14(20)19-12-11-18(15-7-4-3-5-8-15)16-9-6-10-17(13-16)21-2/h3-11,13H,12H2,1-2H3,(H,19,20)/b18-11+
DMH0LOT CS CC(=O)NC/C=C(\\C1=CC=CC=C1)/C2=CC(=CC=C2)OC
DMH0LOT IK SJNURYXTMIYOKB-WOJGMQOQSA-N
DMH0LOT IU N-[(E)-3-(3-methoxyphenyl)-3-phenylprop-2-enyl]acetamide
DMH0LOT DE Discovery agent
DMSZ03N ID DMSZ03N
DMSZ03N DN N-(3-(3-methoxyphenyl)propyl)acetamide
DMSZ03N HS Investigative
DMSZ03N SN N-[3-(3-methoxyphenyl)propyl]acetamide; CHEMBL50398; N-(3-(3-methoxyphenyl)propyl)acetamide; Acetamide, N-[3-(3-methoxyphenyl)propyl]-; SCHEMBL8928104; BDBM50049516; 174688-91-6
DMSZ03N DT Small molecular drug
DMSZ03N PC 10750842
DMSZ03N MW 207.27
DMSZ03N FM C12H17NO2
DMSZ03N IC InChI=1S/C12H17NO2/c1-10(14)13-8-4-6-11-5-3-7-12(9-11)15-2/h3,5,7,9H,4,6,8H2,1-2H3,(H,13,14)
DMSZ03N CS CC(=O)NCCCC1=CC(=CC=C1)OC
DMSZ03N IK LOVJFNACINEBJW-UHFFFAOYSA-N
DMSZ03N IU N-[3-(3-methoxyphenyl)propyl]acetamide
DMSZ03N DE Discovery agent
DMKSM5A ID DMKSM5A
DMKSM5A DN N-(3-(3-methoxyphenyl)propyl)propionamide
DMKSM5A HS Investigative
DMKSM5A SN CHEMBL297947; N-(3-(3-methoxyphenyl)propyl)propionamide; N-[3-(3-Methoxyphenyl)propyl]propionamide; SCHEMBL8928118; BDBM50049554; ZINC13755749
DMKSM5A DT Small molecular drug
DMKSM5A PC 10104923
DMKSM5A MW 221.29
DMKSM5A FM C13H19NO2
DMKSM5A IC InChI=1S/C13H19NO2/c1-3-13(15)14-9-5-7-11-6-4-8-12(10-11)16-2/h4,6,8,10H,3,5,7,9H2,1-2H3,(H,14,15)
DMKSM5A CS CCC(=O)NCCCC1=CC(=CC=C1)OC
DMKSM5A IK VVTCACGOXCPEPB-UHFFFAOYSA-N
DMKSM5A IU N-[3-(3-methoxyphenyl)propyl]propanamide
DMKSM5A DE Discovery agent
DMOCZVB ID DMOCZVB
DMOCZVB DN N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DMOCZVB HS Investigative
DMOCZVB SN CHEMBL404983
DMOCZVB DT Small molecular drug
DMOCZVB PC 44450093
DMOCZVB MW 327.4
DMOCZVB FM C20H25NO3
DMOCZVB IC InChI=1S/C20H25NO3/c1-3-4-5-6-8-16-11-12-20(19(23)13-16)24-18-10-7-9-17(14-18)21-15(2)22/h7,9-14,23H,3-6,8H2,1-2H3,(H,21,22)
DMOCZVB CS CCCCCCC1=CC(=C(C=C1)OC2=CC=CC(=C2)NC(=O)C)O
DMOCZVB IK DCPQCSKZPKBKGX-UHFFFAOYSA-N
DMOCZVB IU N-[3-(4-hexyl-2-hydroxyphenoxy)phenyl]acetamide
DMOCZVB DE Discovery agent
DMILWPS ID DMILWPS
DMILWPS DN N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide
DMILWPS HS Investigative
DMILWPS SN CHEMBL1092047; N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide
DMILWPS DT Small molecular drug
DMILWPS PC 46884598
DMILWPS MW 223.27
DMILWPS FM C12H17NO3
DMILWPS IC InChI=1S/C12H17NO3/c1-9(14)13-7-3-4-10-5-6-11(15)12(8-10)16-2/h5-6,8,15H,3-4,7H2,1-2H3,(H,13,14)
DMILWPS CS CC(=O)NCCCC1=CC(=C(C=C1)O)OC
DMILWPS IK YOLSQHAXCLGSKL-UHFFFAOYSA-N
DMILWPS IU N-[3-(4-hydroxy-3-methoxyphenyl)propyl]acetamide
DMILWPS DE Discovery agent
DMHM0WI ID DMHM0WI
DMHM0WI DN N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide
DMHM0WI HS Investigative
DMHM0WI SN CHEMBL1091894; N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide
DMHM0WI DT Small molecular drug
DMHM0WI PC 46885285
DMHM0WI MW 265.35
DMHM0WI FM C15H23NO3
DMHM0WI IC InChI=1S/C15H23NO3/c1-4-10-19-15-8-7-14(18-3)11-13(15)6-5-9-16-12(2)17/h7-8,11H,4-6,9-10H2,1-3H3,(H,16,17)
DMHM0WI CS CCCOC1=C(C=C(C=C1)OC)CCCNC(=O)C
DMHM0WI IK WEZUVBIENKYWSC-UHFFFAOYSA-N
DMHM0WI IU N-[3-(5-methoxy-2-propoxyphenyl)propyl]acetamide
DMHM0WI DE Discovery agent
DMSC862 ID DMSC862
DMSC862 DN N-(3-(aminomethyl)phenyl)benzenesulfonamide
DMSC862 HS Investigative
DMSC862 SN CHEMBL209909; N-(3-(aminomethyl)phenyl)benzenesulfonamide; N-[3-(aminomethyl)phenyl]benzenesulfonamide; CTK7E5754; BDBM50193462; ZINC22142484
DMSC862 DT Small molecular drug
DMSC862 PC 11849791
DMSC862 MW 262.33
DMSC862 FM C13H14N2O2S
DMSC862 IC InChI=1S/C13H14N2O2S/c14-10-11-5-4-6-12(9-11)15-18(16,17)13-7-2-1-3-8-13/h1-9,15H,10,14H2
DMSC862 CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)CN
DMSC862 IK RMWBQRLIFOIUFM-UHFFFAOYSA-N
DMSC862 IU N-[3-(aminomethyl)phenyl]benzenesulfonamide
DMSC862 DE Discovery agent
DMSJX1H ID DMSJX1H
DMSJX1H DN N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide
DMSJX1H HS Investigative
DMSJX1H SN CHEMBL224122; N-(3-phenylsulfanyl-4-pyridinyl)methanesulfonamide; 833455-58-6; N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide; CTK3D2868; DTXSID10466638; BDBM50158452; Methanesulfonamide, N-[3-(phenylthio)-4-pyridinyl]-
DMSJX1H DT Small molecular drug
DMSJX1H PC 11460185
DMSJX1H MW 280.4
DMSJX1H FM C12H12N2O2S2
DMSJX1H IC InChI=1S/C12H12N2O2S2/c1-18(15,16)14-11-7-8-13-9-12(11)17-10-5-3-2-4-6-10/h2-9H,1H3,(H,13,14)
DMSJX1H CS CS(=O)(=O)NC1=C(C=NC=C1)SC2=CC=CC=C2
DMSJX1H IK SQQJATJQZCRBEZ-UHFFFAOYSA-N
DMSJX1H IU N-(3-phenylsulfanylpyridin-4-yl)methanesulfonamide
DMSJX1H CA CAS 833455-58-6
DMSJX1H DE Discovery agent
DM6UC8Y ID DM6UC8Y
DM6UC8Y DN N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide
DM6UC8Y HS Investigative
DM6UC8Y SN CHEMBL198832; N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide
DM6UC8Y DT Small molecular drug
DM6UC8Y PC 44405454
DM6UC8Y MW 387.4
DM6UC8Y FM C21H16F3NO3
DM6UC8Y IC InChI=1S/C21H16F3NO3/c22-21(23,24)28-19-8-4-5-15(13-19)14-25-20(26)16-9-11-18(12-10-16)27-17-6-2-1-3-7-17/h1-13H,14H2,(H,25,26)
DM6UC8Y CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC(=CC=C3)OC(F)(F)F
DM6UC8Y IK CPWFANWMCRGXMG-UHFFFAOYSA-N
DM6UC8Y IU 4-phenoxy-N-[[3-(trifluoromethoxy)phenyl]methyl]benzamide
DM6UC8Y DE Discovery agent
DMSMRF9 ID DMSMRF9
DMSMRF9 DN N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMSMRF9 HS Investigative
DMSMRF9 SN CHEMBL198563; N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMSMRF9 DT Small molecular drug
DMSMRF9 PC 11703439
DMSMRF9 MW 371.4
DMSMRF9 FM C21H16F3NO2
DMSMRF9 IC InChI=1S/C21H16F3NO2/c22-21(23,24)17-6-4-5-15(13-17)14-25-20(26)16-9-11-19(12-10-16)27-18-7-2-1-3-8-18/h1-13H,14H2,(H,25,26)
DMSMRF9 CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC(=CC=C3)C(F)(F)F
DMSMRF9 IK FWPNYHMMZRISQJ-UHFFFAOYSA-N
DMSMRF9 IU 4-phenoxy-N-[[3-(trifluoromethyl)phenyl]methyl]benzamide
DMSMRF9 DE Discovery agent
DM2Y5AP ID DM2Y5AP
DM2Y5AP DN N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide
DM2Y5AP HS Investigative
DM2Y5AP SN CHEMBL122341; N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide; ZINC13864671; BDBM50106166
DM2Y5AP DT Small molecular drug
DM2Y5AP PC 10979664
DM2Y5AP MW 305.5
DM2Y5AP FM C19H31NO2
DM2Y5AP IC InChI=1S/C19H31NO2/c1-5-6-7-8-15-22-17-11-9-16(10-12-17)18(21)20-14-13-19(2,3)4/h9-12H,5-8,13-15H2,1-4H3,(H,20,21)
DM2Y5AP CS CCCCCCOC1=CC=C(C=C1)C(=O)NCCC(C)(C)C
DM2Y5AP IK JPQPUSQXWSSOFH-UHFFFAOYSA-N
DM2Y5AP IU N-(3,3-dimethylbutyl)-4-hexoxybenzamide
DM2Y5AP DE Discovery agent
DMEUXOQ ID DMEUXOQ
DMEUXOQ DN N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide
DMEUXOQ HS Investigative
DMEUXOQ SN CHEMBL431682; N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide; SCHEMBL7214961; BDBM50106177
DMEUXOQ DT Small molecular drug
DMEUXOQ PC 11023651
DMEUXOQ MW 320.4
DMEUXOQ FM C21H24N2O
DMEUXOQ IC InChI=1S/C21H24N2O/c1-21(2,3)13-14-22-20(24)17-8-10-18(11-9-17)23-15-12-16-6-4-5-7-19(16)23/h4-12,15H,13-14H2,1-3H3,(H,22,24)
DMEUXOQ CS CC(C)(C)CCNC(=O)C1=CC=C(C=C1)N2C=CC3=CC=CC=C32
DMEUXOQ IK WFFDNQLEAMWQBV-UHFFFAOYSA-N
DMEUXOQ IU N-(3,3-dimethylbutyl)-4-indol-1-ylbenzamide
DMEUXOQ DE Discovery agent
DM6EJQ4 ID DM6EJQ4
DM6EJQ4 DN N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide
DM6EJQ4 HS Investigative
DM6EJQ4 SN CHEMBL121751; N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide; SCHEMBL7219320; BDBM50106184
DM6EJQ4 DT Small molecular drug
DM6EJQ4 PC 10870843
DM6EJQ4 MW 317.5
DM6EJQ4 FM C20H31NO2
DM6EJQ4 IC InChI=1S/C20H31NO2/c1-4-5-6-7-14-23-18-10-8-16(9-11-18)19(22)21-17-12-13-20(2,3)15-17/h8-11,17H,4-7,12-15H2,1-3H3,(H,21,22)
DM6EJQ4 CS CCCCCCOC1=CC=C(C=C1)C(=O)NC2CCC(C2)(C)C
DM6EJQ4 IK SPDGMSMRHOXECU-UHFFFAOYSA-N
DM6EJQ4 IU N-(3,3-dimethylcyclopentyl)-4-hexoxybenzamide
DM6EJQ4 DE Discovery agent
DMAXLVQ ID DMAXLVQ
DMAXLVQ DN N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide
DMAXLVQ HS Investigative
DMAXLVQ SN CHEMBL476529; N-(3,3-diphenylpropyl)-2,2-diphenylacetamide; N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide; AC1N5W5U; Oprea1_456266; ZINC3166084; BDBM50263033; AKOS003236993; MCULE-9181870252; ST45008037; SR-01000512723
DMAXLVQ DT Small molecular drug
DMAXLVQ PC 4225440
DMAXLVQ MW 405.5
DMAXLVQ FM C29H27NO
DMAXLVQ IC InChI=1S/C29H27NO/c31-29(28(25-17-9-3-10-18-25)26-19-11-4-12-20-26)30-22-21-27(23-13-5-1-6-14-23)24-15-7-2-8-16-24/h1-20,27-28H,21-22H2,(H,30,31)
DMAXLVQ CS C1=CC=C(C=C1)C(CCNC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4
DMAXLVQ IK LMRDWMVRJNJYIQ-UHFFFAOYSA-N
DMAXLVQ IU N-(3,3-diphenylpropyl)-2,2-diphenylacetamide
DMAXLVQ DE Discovery agent
DMBX0K1 ID DMBX0K1
DMBX0K1 DN N-(3,3-Diphenyl)propyl-2-phenylacetamide
DMBX0K1 HS Investigative
DMBX0K1 SN N-(3,3-diphenylpropyl)-2-phenylacetamide; CHEMBL502133; AC1LPTMM; N-(3,3-Diphenyl)propyl-2-phenylacetamide; MolPort-001-541-705; ZINC1115339; STK439151; BDBM50263154; AKOS003282986; MCULE-4189132608; ST50924105
DMBX0K1 DT Small molecular drug
DMBX0K1 PC 1293167
DMBX0K1 MW 329.4
DMBX0K1 FM C23H23NO
DMBX0K1 IC InChI=1S/C23H23NO/c25-23(18-19-10-4-1-5-11-19)24-17-16-22(20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-15,22H,16-18H2,(H,24,25)
DMBX0K1 CS C1=CC=C(C=C1)CC(=O)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
DMBX0K1 IK JFOKDVSVRVUJTI-UHFFFAOYSA-N
DMBX0K1 IU N-(3,3-diphenylpropyl)-2-phenylacetamide
DMBX0K1 DE Discovery agent
DM4PTR3 ID DM4PTR3
DM4PTR3 DN N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide
DM4PTR3 HS Investigative
DM4PTR3 SN CHEMBL563527; N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide; SCHEMBL4619635
DM4PTR3 DT Small molecular drug
DM4PTR3 PC 11976254
DM4PTR3 MW 330.4
DM4PTR3 FM C22H22N2O
DM4PTR3 IC InChI=1S/C22H22N2O/c25-22(16-18-8-7-14-23-17-18)24-15-13-21(19-9-3-1-4-10-19)20-11-5-2-6-12-20/h1-12,14,17,21H,13,15-16H2,(H,24,25)
DM4PTR3 CS C1=CC=C(C=C1)C(CCNC(=O)CC2=CN=CC=C2)C3=CC=CC=C3
DM4PTR3 IK FNEXDTNOFQXKRJ-UHFFFAOYSA-N
DM4PTR3 IU N-(3,3-diphenylpropyl)-2-pyridin-3-ylacetamide
DM4PTR3 DE Discovery agent
DMOXR4K ID DMOXR4K
DMOXR4K DN N-(3,3-Diphenyl-propyl)-isonicotinamide
DMOXR4K HS Investigative
DMOXR4K SN CHEMBL571898; N-(3,3-diphenylpropyl)pyridine-4-carboxamide; N-(3,3-Diphenyl-propyl)-isonicotinamide; AC1NQBE3; SCHEMBL5948064; MolPort-003-323-378; ZINC5509004; STK483446; BDBM50297397; AKOS001272797; MCULE-6529824249; ST50922884
DMOXR4K DT Small molecular drug
DMOXR4K PC 5193384
DMOXR4K MW 316.4
DMOXR4K FM C21H20N2O
DMOXR4K IC InChI=1S/C21H20N2O/c24-21(19-11-14-22-15-12-19)23-16-13-20(17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-12,14-15,20H,13,16H2,(H,23,24)
DMOXR4K CS C1=CC=C(C=C1)C(CCNC(=O)C2=CC=NC=C2)C3=CC=CC=C3
DMOXR4K IK FNZXNCPUNGHMCJ-UHFFFAOYSA-N
DMOXR4K IU N-(3,3-diphenylpropyl)pyridine-4-carboxamide
DMOXR4K DE Discovery agent
DMDYZ9K ID DMDYZ9K
DMDYZ9K DN N-(3,3-diphenyl-propyl)-nicotinamide
DMDYZ9K HS Investigative
DMDYZ9K SN N-(3,3-diphenyl-propyl)-nicotinamide; N-(3,3-diphenylpropyl)pyridine-3-carboxamide; CHEMBL560537; N-(3,3-Diphenylpropyl)Nicotinamide; 3i1y; AC1MS8VU; Oprea1_527290; Oprea1_467641; SCHEMBL5947875; AC1Q5P23; MolPort-001-843-393; ZINC4401896; STK414850; BDBM50297413; AKOS000975778; MCULE-6217519118; ST45002043; N-(3,3-diphenylpropyl)-3-pyridylcarboxamide; SR-01000509857; SR-01000509857-1
DMDYZ9K DT Small molecular drug
DMDYZ9K PC 3530525
DMDYZ9K MW 316.4
DMDYZ9K FM C21H20N2O
DMDYZ9K IC InChI=1S/C21H20N2O/c24-21(19-12-7-14-22-16-19)23-15-13-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18/h1-12,14,16,20H,13,15H2,(H,23,24)
DMDYZ9K CS C1=CC=C(C=C1)C(CCNC(=O)C2=CN=CC=C2)C3=CC=CC=C3
DMDYZ9K IK GDHXZIQAOUBZCC-UHFFFAOYSA-N
DMDYZ9K IU N-(3,3-diphenylpropyl)pyridine-3-carboxamide
DMDYZ9K CA CAS 303064-42-8
DMDYZ9K DE Discovery agent
DMQ5USA ID DMQ5USA
DMQ5USA DN N-(3,4,5-trihydroxyphenethyl)oleamide
DMQ5USA HS Investigative
DMQ5USA SN N-(3,4,5-trihydroxyphenethyl)oleamide; CHEMBL251733
DMQ5USA DT Small molecular drug
DMQ5USA PC 23661707
DMQ5USA MW 433.6
DMQ5USA FM C26H43NO4
DMQ5USA IC InChI=1S/C26H43NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-25(30)27-19-18-22-20-23(28)26(31)24(29)21-22/h9-10,20-21,28-29,31H,2-8,11-19H2,1H3,(H,27,30)/b10-9-
DMQ5USA CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC(=C(C(=C1)O)O)O
DMQ5USA IK MGJONYQVBJKXRL-KTKRTIGZSA-N
DMQ5USA IU (Z)-N-[2-(3,4,5-trihydroxyphenyl)ethyl]octadec-9-enamide
DMQ5USA DE Discovery agent
DMTERF6 ID DMTERF6
DMTERF6 DN N-(3,4-Dichlorophenyl)propyl-ETAV
DMTERF6 HS Investigative
DMTERF6 SN N-(3,4-Dichlorophenyl)propyl-ETAV; CHEMBL495100
DMTERF6 DT Small molecular drug
DMTERF6 PC 44568811
DMTERF6 MW 591.5
DMTERF6 FM C25H36Cl2N4O8
DMTERF6 IC InChI=1S/C25H36Cl2N4O8/c1-12(2)20(25(38)39)30-22(35)13(3)29-24(37)21(14(4)32)31-23(36)18(7-8-19(33)34)28-10-9-15-5-6-16(26)17(27)11-15/h5-6,11-14,18,20-21,28,32H,7-10H2,1-4H3,(H,29,37)(H,30,35)(H,31,36)(H,33,34)(H,38,39)/t13-,14?,18-,20-,21-/m0/s1
DMTERF6 CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC(=C(C=C1)Cl)Cl
DMTERF6 IK QVZKLLUMEYWUMT-WHJBMRRRSA-N
DMTERF6 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[2-(3,4-dichlorophenyl)ethylamino]-5-oxopentanoic acid
DMTERF6 DE Discovery agent
DMF2D4O ID DMF2D4O
DMF2D4O DN N-(3,4-Difluorophenyl)propyl-ETAV
DMF2D4O HS Investigative
DMF2D4O SN N-(3,4-Difluorophenyl)propyl-ETAV; CHEMBL538410
DMF2D4O DT Small molecular drug
DMF2D4O PC 44568812
DMF2D4O MW 558.6
DMF2D4O FM C25H36F2N4O8
DMF2D4O IC InChI=1S/C25H36F2N4O8/c1-12(2)20(25(38)39)30-22(35)13(3)29-24(37)21(14(4)32)31-23(36)18(7-8-19(33)34)28-10-9-15-5-6-16(26)17(27)11-15/h5-6,11-14,18,20-21,28,32H,7-10H2,1-4H3,(H,29,37)(H,30,35)(H,31,36)(H,33,34)(H,38,39)/t13-,14?,18-,20-,21-/m0/s1
DMF2D4O CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC(=C(C=C1)F)F
DMF2D4O IK VPSVLXPCERTAAH-WHJBMRRRSA-N
DMF2D4O IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-[2-(3,4-difluorophenyl)ethylamino]-5-oxopentanoic acid
DMF2D4O DE Discovery agent
DM67XSW ID DM67XSW
DM67XSW DN N-(3,4-dihydroxybenzyl)oleamide
DM67XSW HS Investigative
DM67XSW SN CHEMBL403034; N-(3,4-dihydroxybenzyl)oleamide; SCHEMBL10713028
DM67XSW DT Small molecular drug
DM67XSW PC 44454145
DM67XSW MW 403.6
DM67XSW FM C25H41NO3
DM67XSW IC InChI=1S/C25H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-25(29)26-21-22-18-19-23(27)24(28)20-22/h9-10,18-20,27-28H,2-8,11-17,21H2,1H3,(H,26,29)/b10-9-
DM67XSW CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCC1=CC(=C(C=C1)O)O
DM67XSW IK DMFNZWDAFAVBIA-KTKRTIGZSA-N
DM67XSW IU (Z)-N-[(3,4-dihydroxyphenyl)methyl]octadec-9-enamide
DM67XSW DE Discovery agent
DMEP2VM ID DMEP2VM
DMEP2VM DN N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide
DMEP2VM HS Investigative
DMEP2VM SN CHEMBL1093359; BDBM50314135
DMEP2VM DT Small molecular drug
DMEP2VM PC 45141959
DMEP2VM MW 292.37
DMEP2VM FM C16H24N2O3
DMEP2VM IC InChI=1S/C16H24N2O3/c1-12-9-10-14(11-13(12)2)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DMEP2VM CS CC1=C(C=C(C=C1)NC(=O)CCCCCCC(=O)NO)C
DMEP2VM IK NJRGPRXJOLGSNN-UHFFFAOYSA-N
DMEP2VM IU N-(3,4-dimethylphenyl)-N'-hydroxyoctanediamide
DMEP2VM DE Discovery agent
DM9B1ID ID DM9B1ID
DM9B1ID DN N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
DM9B1ID HS Investigative
DM9B1ID SN N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide; 331846-06-1; benzamide compound 3; AC1LGPDD; Asinex compound no. 6; Oprea1_295970; Oprea1_049304; CHEMBL217893; SCHEMBL18120561; CTK1B1898; BDBM14711; DTXSID50355395; MolPort-001-496-487; ZINC304714; STK020274; AKOS003270080; MCULE-1240652686; ST50693254; Benzamide, N-(3,5-dichlorophenyl)-2-methyl-3-nitro-; N-(3,5-dichlorophenyl)(2-methyl-3-nitrophenyl)carboxamide
DM9B1ID DT Small molecular drug
DM9B1ID PC 799096
DM9B1ID MW 325.1
DM9B1ID FM C14H10Cl2N2O3
DM9B1ID IC InChI=1S/C14H10Cl2N2O3/c1-8-12(3-2-4-13(8)18(20)21)14(19)17-11-6-9(15)5-10(16)7-11/h2-7H,1H3,(H,17,19)
DM9B1ID CS CC1=C(C=CC=C1[N+](=O)[O-])C(=O)NC2=CC(=CC(=C2)Cl)Cl
DM9B1ID IK NKIJNFMSYDSAJK-UHFFFAOYSA-N
DM9B1ID IU N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
DM9B1ID CA CAS 331846-06-1
DM9B1ID DE Discovery agent
DMDNUCL ID DMDNUCL
DMDNUCL DN N-(3,5-dichlorophenyl)-2-nitrobenzamide
DMDNUCL HS Investigative
DMDNUCL SN N-(3,5-dichlorophenyl)-2-nitrobenzamide; CHEMBL564612; AC1LEFLS; AC1Q1WV0; Oprea1_875451; Oprea1_856946; ZINC103151; BDBM50297529; AKOS002518902; MCULE-6306742768; ST011167; KB-101427
DMDNUCL DT Small molecular drug
DMDNUCL PC 711431
DMDNUCL MW 311.12
DMDNUCL FM C13H8Cl2N2O3
DMDNUCL IC InChI=1S/C13H8Cl2N2O3/c14-8-5-9(15)7-10(6-8)16-13(18)11-3-1-2-4-12(11)17(19)20/h1-7H,(H,16,18)
DMDNUCL CS C1=CC=C(C(=C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)[N+](=O)[O-]
DMDNUCL IK RHMRIXDZQJDDKE-UHFFFAOYSA-N
DMDNUCL IU N-(3,5-dichlorophenyl)-2-nitrobenzamide
DMDNUCL CA CAS 316142-28-6
DMDNUCL DE Discovery agent
DM8DAGL ID DM8DAGL
DM8DAGL DN N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DM8DAGL HS Investigative
DM8DAGL SN N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide; CHEMBL560684; AC1LEFV7; AC1Q44SN; MolPort-001-508-011; ZINC103353; STK082881; BDBM50297552; AKOS003266964; MCULE-2399924405; ST011242; AG-690/12072790; N-(3,5-dichlorophenyl)-3-nitro-4-(methyloxy)benzamide
DM8DAGL DT Small molecular drug
DM8DAGL PC 711547
DM8DAGL MW 341.1
DM8DAGL FM C14H10Cl2N2O4
DM8DAGL IC InChI=1S/C14H10Cl2N2O4/c1-22-13-3-2-8(4-12(13)18(20)21)14(19)17-11-6-9(15)5-10(16)7-11/h2-7H,1H3,(H,17,19)
DM8DAGL CS COC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)Cl)Cl)[N+](=O)[O-]
DM8DAGL IK BDZYJQMEFCDSIR-UHFFFAOYSA-N
DM8DAGL IU N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide
DM8DAGL DE Discovery agent
DMQ0LF2 ID DMQ0LF2
DMQ0LF2 DN N-(3,5-dichlorophenyl)imidodicarbonimidic diamide
DMQ0LF2 HS Investigative
DMQ0LF2 SN N-(3,5-dichlorophenyl)imidodicarbonimidic diamide; CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01
DMQ0LF2 DT Small molecular drug
DMQ0LF2 PC 558969
DMQ0LF2 MW 246.09
DMQ0LF2 FM C8H9Cl2N5
DMQ0LF2 IC InChI=1S/C8H9Cl2N5/c9-4-1-5(10)3-6(2-4)14-8(13)15-7(11)12/h1-3H,(H6,11,12,13,14,15)
DMQ0LF2 CS C1=C(C=C(C=C1Cl)Cl)N=C(N)N=C(N)N
DMQ0LF2 IK BUXACHZAYWAZJL-UHFFFAOYSA-N
DMQ0LF2 IU 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine
DMQ0LF2 CA CAS 1672-93-1
DMQ0LF2 DE Discovery agent
DM95SJU ID DM95SJU
DM95SJU DN N-(3,5-dimethoxyphenethyl)docos-13-enamide
DM95SJU HS Investigative
DM95SJU SN CHEMBL199870; N-(3,5-dimethoxyphenethyl)docos-13-enamide
DM95SJU DT Small molecular drug
DM95SJU PC 44406087
DM95SJU MW 501.8
DM95SJU FM C32H55NO3
DM95SJU IC InChI=1S/C32H55NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-32(34)33-25-24-29-26-30(35-2)28-31(27-29)36-3/h11-12,26-28H,4-10,13-25H2,1-3H3,(H,33,34)/b12-11-
DM95SJU CS CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)NCCC1=CC(=CC(=C1)OC)OC
DM95SJU IK WGUQNXILGCVNIV-QXMHVHEDSA-N
DM95SJU IU (Z)-N-[2-(3,5-dimethoxyphenyl)ethyl]docos-13-enamide
DM95SJU DE Discovery agent
DM1C40H ID DM1C40H
DM1C40H DN N-(3,5-dimethoxyphenethyl)oleamide
DM1C40H HS Investigative
DM1C40H SN N-(3,5-dimethoxyphenethyl)oleamide; CHEMBL199402
DM1C40H DT Small molecular drug
DM1C40H PC 44406076
DM1C40H MW 445.7
DM1C40H FM C28H47NO3
DM1C40H IC InChI=1S/C28H47NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(30)29-21-20-25-22-26(31-2)24-27(23-25)32-3/h11-12,22-24H,4-10,13-21H2,1-3H3,(H,29,30)/b12-11-
DM1C40H CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC(=CC(=C1)OC)OC
DM1C40H IK HOCMLWROGBYBPA-QXMHVHEDSA-N
DM1C40H IU (Z)-N-[2-(3,5-dimethoxyphenyl)ethyl]octadec-9-enamide
DM1C40H DE Discovery agent
DM43QHV ID DM43QHV
DM43QHV DN N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV HS Investigative
DM43QHV SN CHEMBL558660; N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV DT Small molecular drug
DM43QHV PC 45272830
DM43QHV MW 316.31
DM43QHV FM C16H16N2O5
DM43QHV IC InChI=1S/C16H16N2O5/c1-10-4-5-14(15(6-10)18(20)21)16(19)17-11-7-12(22-2)9-13(8-11)23-3/h4-9H,1-3H3,(H,17,19)
DM43QHV CS CC1=CC(=C(C=C1)C(=O)NC2=CC(=CC(=C2)OC)OC)[N+](=O)[O-]
DM43QHV IK GFSKVJZKSAGFJY-UHFFFAOYSA-N
DM43QHV IU N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide
DM43QHV DE Discovery agent
DM1L3FM ID DM1L3FM
DM1L3FM DN N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide
DM1L3FM HS Investigative
DM1L3FM SN CHEMBL1093713; BDBM50314133
DM1L3FM DT Small molecular drug
DM1L3FM PC 45141960
DM1L3FM MW 292.37
DM1L3FM FM C16H24N2O3
DM1L3FM IC InChI=1S/C16H24N2O3/c1-12-9-13(2)11-14(10-12)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-11,21H,3-8H2,1-2H3,(H,17,19)(H,18,20)
DM1L3FM CS CC1=CC(=CC(=C1)NC(=O)CCCCCCC(=O)NO)C
DM1L3FM IK PWVUDHKPAQOCJC-UHFFFAOYSA-N
DM1L3FM IU N-(3,5-dimethylphenyl)-N'-hydroxyoctanediamide
DM1L3FM DE Discovery agent
DMH3R21 ID DMH3R21
DMH3R21 DN N-(3-acetamidophenyl)-3-chlorobenzamide
DMH3R21 HS Investigative
DMH3R21 SN N-(3-acetamidophenyl)-3-chlorobenzamide; CHEMBL1080810; N-[3-(acetylamino)phenyl]-3-chlorobenzamide; 3-chloro-N-(3-acetamidophenyl)benzamide; AC1LDLQ1; AC1Q1KO6; Cambridge id 5554516; Oprea1_130541; Oprea1_356143; MLS002699912; CHEBI:93070; ZINC29723; MolPort-001-508-240; STK036460; BDBM50312136; AKOS001296542; MCULE-8869105852; 312632-92-1; ST042764; SMR001530668; EU-0002463; AB00088853-01; SR-01000407944; SR-01000407944-1; N-{3-[(3-chlorophenyl)carbonylamino]phenyl}acetamide; Z28281866
DMH3R21 DT Small molecular drug
DMH3R21 PC 669190
DMH3R21 MW 288.73
DMH3R21 FM C15H13ClN2O2
DMH3R21 IC InChI=1S/C15H13ClN2O2/c1-10(19)17-13-6-3-7-14(9-13)18-15(20)11-4-2-5-12(16)8-11/h2-9H,1H3,(H,17,19)(H,18,20)
DMH3R21 CS CC(=O)NC1=CC(=CC=C1)NC(=O)C2=CC(=CC=C2)Cl
DMH3R21 IK XZMOBKLRYXTSSS-UHFFFAOYSA-N
DMH3R21 IU N-(3-acetamidophenyl)-3-chlorobenzamide
DMH3R21 CB CHEBI:93070
DMH3R21 DE Discovery agent
DMYJB1A ID DMYJB1A
DMYJB1A DN N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide
DMYJB1A HS Investigative
DMYJB1A SN CHEMBL1097746; BDBM50317992
DMYJB1A DT Small molecular drug
DMYJB1A PC 46887437
DMYJB1A MW 330.4
DMYJB1A FM C21H18N2O2
DMYJB1A IC InChI=1S/C21H18N2O2/c1-14(24)16-8-5-9-17(12-16)18-10-11-19(22)20(13-18)23-21(25)15-6-3-2-4-7-15/h2-13H,22H2,1H3,(H,23,25)
DMYJB1A CS CC(=O)C1=CC=CC(=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMYJB1A IK CJDOOJYNFYUEAC-UHFFFAOYSA-N
DMYJB1A IU N-[5-(3-acetylphenyl)-2-aminophenyl]benzamide
DMYJB1A DE Discovery agent
DMJ6FP7 ID DMJ6FP7
DMJ6FP7 DN N-(3-aminophenyl)benzenesulfonamide
DMJ6FP7 HS Investigative
DMJ6FP7 SN N-(3-aminophenyl)benzenesulfonamide; 104997-09-3; Benzenesulfonamide, N-(3-aminophenyl)-; CHEMBL378618; ACMC-20f7rf; 3-phenylsulfonamidoaniline; AC1Q51QH; 3-benzenesulfonylaminoaniline; SCHEMBL2723618; CTK0G5849; DTXSID40474387; MolPort-004-296-827; RUYQFOIEMVGGQT-UHFFFAOYSA-N; ZINC22145186; BDBM50193461; AKOS000132984; NE22031; ACN-049935; MCULE-1854488236; EN300-40178; A839866
DMJ6FP7 DT Small molecular drug
DMJ6FP7 PC 11849198
DMJ6FP7 MW 248.3
DMJ6FP7 FM C12H12N2O2S
DMJ6FP7 IC InChI=1S/C12H12N2O2S/c13-10-5-4-6-11(9-10)14-17(15,16)12-7-2-1-3-8-12/h1-9,14H,13H2
DMJ6FP7 CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC(=C2)N
DMJ6FP7 IK RUYQFOIEMVGGQT-UHFFFAOYSA-N
DMJ6FP7 IU N-(3-aminophenyl)benzenesulfonamide
DMJ6FP7 CA CAS 104997-09-3
DMJ6FP7 DE Discovery agent
DMYSURL ID DMYSURL
DMYSURL DN N-(3-Benzooxazol-7-yl-propyl)-acetamide
DMYSURL HS Investigative
DMYSURL SN CHEMBL124488; N-(3-Benzooxazol-7-yl-propyl)-acetamide; SCHEMBL6787351
DMYSURL DT Small molecular drug
DMYSURL PC 22718532
DMYSURL MW 218.25
DMYSURL FM C12H14N2O2
DMYSURL IC InChI=1S/C12H14N2O2/c1-9(15)13-7-3-5-10-4-2-6-11-12(10)16-8-14-11/h2,4,6,8H,3,5,7H2,1H3,(H,13,15)
DMYSURL CS CC(=O)NCCCC1=C2C(=CC=C1)N=CO2
DMYSURL IK UVCQHPPYUDDOEQ-UHFFFAOYSA-N
DMYSURL IU N-[3-(1,3-benzoxazol-7-yl)propyl]acetamide
DMYSURL DE Discovery agent
DMKMESD ID DMKMESD
DMKMESD DN N-(3-Benzooxazol-7-yl-propyl)-butyramide
DMKMESD HS Investigative
DMKMESD SN CHEMBL124914; N-(3-Benzooxazol-7-yl-propyl)-butyramide
DMKMESD DT Small molecular drug
DMKMESD PC 44349108
DMKMESD MW 246.3
DMKMESD FM C14H18N2O2
DMKMESD IC InChI=1S/C14H18N2O2/c1-2-5-13(17)15-9-4-7-11-6-3-8-12-14(11)18-10-16-12/h3,6,8,10H,2,4-5,7,9H2,1H3,(H,15,17)
DMKMESD CS CCCC(=O)NCCCC1=C2C(=CC=C1)N=CO2
DMKMESD IK ADFZAUSXPZLXMN-UHFFFAOYSA-N
DMKMESD IU N-[3-(1,3-benzoxazol-7-yl)propyl]butanamide
DMKMESD DE Discovery agent
DMEMYS1 ID DMEMYS1
DMEMYS1 DN N-(3-Benzooxazol-7-yl-propyl)-propionamide
DMEMYS1 HS Investigative
DMEMYS1 SN CHEMBL124476; N-(3-Benzooxazol-7-yl-propyl)-propionamide; SCHEMBL6780633
DMEMYS1 DT Small molecular drug
DMEMYS1 PC 22718564
DMEMYS1 MW 232.28
DMEMYS1 FM C13H16N2O2
DMEMYS1 IC InChI=1S/C13H16N2O2/c1-2-12(16)14-8-4-6-10-5-3-7-11-13(10)17-9-15-11/h3,5,7,9H,2,4,6,8H2,1H3,(H,14,16)
DMEMYS1 CS CCC(=O)NCCCC1=C2C(=CC=C1)N=CO2
DMEMYS1 IK KCCKMLVZBSMOBW-UHFFFAOYSA-N
DMEMYS1 IU N-[3-(1,3-benzoxazol-7-yl)propyl]propanamide
DMEMYS1 DE Discovery agent
DMOQ08F ID DMOQ08F
DMOQ08F DN N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide
DMOQ08F HS Investigative
DMOQ08F SN CHEMBL186746; ZINC16740683
DMOQ08F DT Small molecular drug
DMOQ08F PC 11245786
DMOQ08F MW 374.64
DMOQ08F FM C13H9BrClNO3S
DMOQ08F IC InChI=1S/C13H9BrClNO3S/c14-10-3-1-2-9(8-10)13(17)16-20(18,19)12-6-4-11(15)5-7-12/h1-8H,(H,16,17)
DMOQ08F CS C1=CC(=CC(=C1)Br)C(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
DMOQ08F IK PCSRHSZMCDEYGU-UHFFFAOYSA-N
DMOQ08F IU 3-bromo-N-(4-chlorophenyl)sulfonylbenzamide
DMOQ08F DE Discovery agent
DM0Z1HJ ID DM0Z1HJ
DM0Z1HJ DN N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine
DM0Z1HJ HS Investigative
DM0Z1HJ SN CHEMBL1269727; N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine
DM0Z1HJ DT Small molecular drug
DM0Z1HJ PC 16117936
DM0Z1HJ MW 319.15
DM0Z1HJ FM C14H11BrN2O2
DM0Z1HJ IC InChI=1S/C14H11BrN2O2/c1-18-11-5-6-13-12(8-11)17-14(19-13)16-10-4-2-3-9(15)7-10/h2-8H,1H3,(H,16,17)
DM0Z1HJ CS COC1=CC2=C(C=C1)OC(=N2)NC3=CC(=CC=C3)Br
DM0Z1HJ IK ACSVVIUPZPFHSQ-UHFFFAOYSA-N
DM0Z1HJ IU N-(3-bromophenyl)-5-methoxy-1,3-benzoxazol-2-amine
DM0Z1HJ DE Discovery agent
DMEWQCN ID DMEWQCN
DMEWQCN DN N-(3-bromophenyl)-6-chloroquinazolin-4-amine
DMEWQCN HS Investigative
DMEWQCN SN CHEMBL1075626; N-(3-bromophenyl)-6-chloroquinazolin-4-amine; SCHEMBL4586988; BDBM50311876
DMEWQCN DT Small molecular drug
DMEWQCN PC 11056756
DMEWQCN MW 334.6
DMEWQCN FM C14H9BrClN3
DMEWQCN IC InChI=1S/C14H9BrClN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMEWQCN CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)Cl
DMEWQCN IK NBEFPXHBLZGXNK-UHFFFAOYSA-N
DMEWQCN IU N-(3-bromophenyl)-6-chloroquinazolin-4-amine
DMEWQCN DE Discovery agent
DMRIK7P ID DMRIK7P
DMRIK7P DN N-(3-bromophenyl)-6-fluoroquinazolin-4-amine
DMRIK7P HS Investigative
DMRIK7P SN CHEMBL1076333; N-(3-bromophenyl)-6-fluoroquinazolin-4-amine; BDBM50311858
DMRIK7P DT Small molecular drug
DMRIK7P PC 45375910
DMRIK7P MW 318.14
DMRIK7P FM C14H9BrFN3
DMRIK7P IC InChI=1S/C14H9BrFN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DMRIK7P CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)F
DMRIK7P IK FQRFQQLJZXACCG-UHFFFAOYSA-N
DMRIK7P IU N-(3-bromophenyl)-6-fluoroquinazolin-4-amine
DMRIK7P DE Discovery agent
DME6IKT ID DME6IKT
DME6IKT DN N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide
DME6IKT HS Investigative
DME6IKT SN CHEMBL192470; N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide; SCHEMBL12931994; ZINC13644475; BDBM50167059
DME6IKT DT Small molecular drug
DME6IKT PC 11379743
DME6IKT MW 251.75
DME6IKT FM C14H18ClNO
DME6IKT IC InChI=1S/C14H18ClNO/c15-12-7-4-8-13(10-12)16-14(17)9-11-5-2-1-3-6-11/h4,7-8,10-11H,1-3,5-6,9H2,(H,16,17)
DME6IKT CS C1CCC(CC1)CC(=O)NC2=CC(=CC=C2)Cl
DME6IKT IK POFHQQJQPBOESX-UHFFFAOYSA-N
DME6IKT IU N-(3-chlorophenyl)-2-cyclohexylacetamide
DME6IKT DE Discovery agent
DM3RQHG ID DM3RQHG
DM3RQHG DN N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide
DM3RQHG HS Investigative
DM3RQHG SN N-(3-Chlorophenyl)-3-cyano-5-fluorobenzamide; CHEMBL1209202; GTPL6437; BDBM50323289; compound 27 [PMID:; N-(3-Chlorophenyl)-3-cyano-5-fluorobenzamide; compound 27 [PMID: 20598884]; compound 27
DM3RQHG DT Small molecular drug
DM3RQHG PC 46911385
DM3RQHG MW 274.68
DM3RQHG FM C14H8ClFN2O
DM3RQHG IC InChI=1S/C14H8ClFN2O/c15-11-2-1-3-13(7-11)18-14(19)10-4-9(8-17)5-12(16)6-10/h1-7H,(H,18,19)
DM3RQHG CS C1=CC(=CC(=C1)Cl)NC(=O)C2=CC(=CC(=C2)C#N)F
DM3RQHG IK FNDUFJARTKDXEF-UHFFFAOYSA-N
DM3RQHG IU N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide
DM3RQHG DE Discovery agent
DM3AGJH ID DM3AGJH
DM3AGJH DN N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine
DM3AGJH HS Investigative
DM3AGJH SN CHEMBL1081540; N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine; SCHEMBL4738649; BDBM50311880
DM3AGJH DT Small molecular drug
DM3AGJH PC 24991329
DM3AGJH MW 273.69
DM3AGJH FM C14H9ClFN3
DM3AGJH IC InChI=1S/C14H9ClFN3/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,(H,17,18,19)
DM3AGJH CS C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)F
DM3AGJH IK FKNWIVATYZCUKH-UHFFFAOYSA-N
DM3AGJH IU N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine
DM3AGJH DE Discovery agent
DMQEPV0 ID DMQEPV0
DMQEPV0 DN N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine
DMQEPV0 HS Investigative
DMQEPV0 SN CHEMBL1080998; N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine; SCHEMBL2101452; BDBM50311878
DMQEPV0 DT Small molecular drug
DMQEPV0 PC 19595108
DMQEPV0 MW 285.73
DMQEPV0 FM C15H12ClN3O
DMQEPV0 IC InChI=1S/C15H12ClN3O/c1-20-12-5-6-14-13(8-12)15(18-9-17-14)19-11-4-2-3-10(16)7-11/h2-9H,1H3,(H,17,18,19)
DMQEPV0 CS COC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Cl
DMQEPV0 IK JDEKFVYZUIPHET-UHFFFAOYSA-N
DMQEPV0 IU N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine
DMQEPV0 CA CAS 153437-82-2
DMQEPV0 DE Discovery agent
DMIKP5Y ID DMIKP5Y
DMIKP5Y DN N-(3-chlorophenyl)-6-nitroquinazolin-4-amine
DMIKP5Y HS Investigative
DMIKP5Y SN N-(3-chlorophenyl)-6-nitroquinazolin-4-amine; 153436-72-7; CHEMBL1080816; SCHEMBL8871973; DTXSID00470764; BDBM50311879; ZINC38265601; AKOS027252204
DMIKP5Y DT Small molecular drug
DMIKP5Y PC 11695129
DMIKP5Y MW 300.7
DMIKP5Y FM C14H9ClN4O2
DMIKP5Y IC InChI=1S/C14H9ClN4O2/c15-9-2-1-3-10(6-9)18-14-12-7-11(19(20)21)4-5-13(12)16-8-17-14/h1-8H,(H,16,17,18)
DMIKP5Y CS C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)[N+](=O)[O-]
DMIKP5Y IK USAMIYATKINXLP-UHFFFAOYSA-N
DMIKP5Y IU N-(3-chlorophenyl)-6-nitroquinazolin-4-amine
DMIKP5Y CA CAS 153436-72-7
DMIKP5Y DE Discovery agent
DMC5G6Y ID DMC5G6Y
DMC5G6Y DN N-(3-Ethylphenyl)-N'-hydroxyoctanediamide
DMC5G6Y HS Investigative
DMC5G6Y SN CHEMBL1093041; BDBM50314134
DMC5G6Y DT Small molecular drug
DMC5G6Y PC 45141753
DMC5G6Y MW 292.37
DMC5G6Y FM C16H24N2O3
DMC5G6Y IC InChI=1S/C16H24N2O3/c1-2-13-8-7-9-14(12-13)17-15(19)10-5-3-4-6-11-16(20)18-21/h7-9,12,21H,2-6,10-11H2,1H3,(H,17,19)(H,18,20)
DMC5G6Y CS CCC1=CC(=CC=C1)NC(=O)CCCCCCC(=O)NO
DMC5G6Y IK HABCYDNCOYWETL-UHFFFAOYSA-N
DMC5G6Y IU N-(3-ethylphenyl)-N'-hydroxyoctanediamide
DMC5G6Y DE Discovery agent
DM0H8CK ID DM0H8CK
DM0H8CK DN N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine
DM0H8CK HS Investigative
DM0H8CK SN CHEMBL61273
DM0H8CK DT Small molecular drug
DM0H8CK PC 19096134
DM0H8CK MW 271.3
DM0H8CK FM C10H13N3O4S
DM0H8CK IC InChI=1S/C10H13N3O4S/c1-17-7-4-3-6(9(14)13-10(11)12)5-8(7)18(2,15)16/h3-5H,1-2H3,(H4,11,12,13,14)
DM0H8CK CS COC1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C
DM0H8CK IK JWTRVDCAXVYZOB-UHFFFAOYSA-N
DM0H8CK IU N-(diaminomethylidene)-4-methoxy-3-methylsulfonylbenzamide
DM0H8CK DE Discovery agent
DMSVQJP ID DMSVQJP
DMSVQJP DN N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine
DMSVQJP HS Investigative
DMSVQJP SN SCHEMBL9194592
DMSVQJP DT Small molecular drug
DMSVQJP PC 19096138
DMSVQJP MW 255.3
DMSVQJP FM C10H13N3O3S
DMSVQJP IC InChI=1S/C10H13N3O3S/c1-6-3-4-7(9(14)13-10(11)12)5-8(6)17(2,15)16/h3-5H,1-2H3,(H4,11,12,13,14)
DMSVQJP CS CC1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C
DMSVQJP IK LHXXNXYVTIIVIY-UHFFFAOYSA-N
DMSVQJP IU N-(diaminomethylidene)-4-methyl-3-methylsulfonylbenzamide
DMSVQJP DE Discovery agent
DM2D4KY ID DM2D4KY
DM2D4KY DN N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
DM2D4KY HS Investigative
DM2D4KY SN 2365-40-4; Isopentenyladenine; N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE; N6-Isopentenyladenine; N6-(2-Isopentenyl)adenine; Isopentenyl adenine; 6-(gamma,gamma-Dimethylallylamino)purine; IPADE; Dimethylallyladenine; N6-(2-Isopentenyl)-adenine; N6-Dimethylallyladenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta 2-Isopentenyl)-adenine; N(6)-(delta(2)-Isopentenyl)adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N-(3-methylbut-2-enyl)-7H-purin-6-amine; Adenine, N-
DM2D4KY DT Small molecular drug
DM2D4KY PC 92180
DM2D4KY MW 203.24
DM2D4KY FM C10H13N5
DM2D4KY IC InChI=1S/C10H13N5/c1-7(2)3-4-11-9-8-10(13-5-12-8)15-6-14-9/h3,5-6H,4H2,1-2H3,(H2,11,12,13,14,15)
DM2D4KY CS CC(=CCNC1=NC=NC2=C1NC=N2)C
DM2D4KY IK HYVABZIGRDEKCD-UHFFFAOYSA-N
DM2D4KY IU N-(3-methylbut-2-enyl)-7H-purin-6-amine
DM2D4KY CA CAS 2365-40-4
DM2D4KY CB CHEBI:17660
DM2D4KY DE Discovery agent
DMHZU8K ID DMHZU8K
DMHZU8K DN N-(3-phenethoxybenzyl)-4-hydroxybenzamide
DMHZU8K HS Investigative
DMHZU8K SN CHEMBL248875; N-(3-phenethoxybenzyl)-4-hydroxybenzamide; BDBM50220592; CJ 036878; Benzamide, 4-hydroxy-N-((3-(2-phenylethoxy)phenyl)methyl)-
DMHZU8K DT Small molecular drug
DMHZU8K PC 44442088
DMHZU8K MW 347.4
DMHZU8K FM C22H21NO3
DMHZU8K IC InChI=1S/C22H21NO3/c24-20-11-9-19(10-12-20)22(25)23-16-18-7-4-8-21(15-18)26-14-13-17-5-2-1-3-6-17/h1-12,15,24H,13-14,16H2,(H,23,25)
DMHZU8K CS C1=CC=C(C=C1)CCOC2=CC=CC(=C2)CNC(=O)C3=CC=C(C=C3)O
DMHZU8K IK VZKHCMVEWLIXIC-UHFFFAOYSA-N
DMHZU8K IU 4-hydroxy-N-[[3-(2-phenylethoxy)phenyl]methyl]benzamide
DMHZU8K CA CAS 951248-25-2
DMHZU8K DE Discovery agent
DMXF46V ID DMXF46V
DMXF46V DN N-(3-phenoxy-4-pyridinyl)ethanesulfonamide
DMXF46V HS Investigative
DMXF46V SN CHEMBL376143; 833455-54-2; N-(3-phenoxy-4-pyridinyl)ethanesulfonamide; CTK3D2870; DTXSID30457028; BDBM50158446; AKOS030595655; Ethanesulfonamide, N-(3-phenoxy-4-pyridinyl)-
DMXF46V DT Small molecular drug
DMXF46V PC 11150126
DMXF46V MW 278.33
DMXF46V FM C13H14N2O3S
DMXF46V IC InChI=1S/C13H14N2O3S/c1-2-19(16,17)15-12-8-9-14-10-13(12)18-11-6-4-3-5-7-11/h3-10H,2H2,1H3,(H,14,15)
DMXF46V CS CCS(=O)(=O)NC1=C(C=NC=C1)OC2=CC=CC=C2
DMXF46V IK FOUBNASCZPSQBW-UHFFFAOYSA-N
DMXF46V IU N-(3-phenoxypyridin-4-yl)ethanesulfonamide
DMXF46V CA CAS 833455-54-2
DMXF46V DE Discovery agent
DMN1DPJ ID DMN1DPJ
DMN1DPJ DN N-(3-phenoxy-4-pyridinyl)propanesulfonamide
DMN1DPJ HS Investigative
DMN1DPJ SN CHEMBL389485; N-(3-phenoxy-4-pyridinyl)propanesulfonamide
DMN1DPJ DT Small molecular drug
DMN1DPJ PC 11277773
DMN1DPJ MW 292.36
DMN1DPJ FM C14H16N2O3S
DMN1DPJ IC InChI=1S/C14H16N2O3S/c1-2-10-20(17,18)16-13-8-9-15-11-14(13)19-12-6-4-3-5-7-12/h3-9,11H,2,10H2,1H3,(H,15,16)
DMN1DPJ CS CCCS(=O)(=O)NC1=C(C=NC=C1)OC2=CC=CC=C2
DMN1DPJ IK LHXILNAQPGRTDA-UHFFFAOYSA-N
DMN1DPJ IU N-(3-phenoxypyridin-4-yl)propane-1-sulfonamide
DMN1DPJ DE Discovery agent
DM7CM3F ID DM7CM3F
DM7CM3F DN N-(3-phenoxypyridin-4-yl)methanesulfonamide
DM7CM3F HS Investigative
DM7CM3F SN CHEMBL148542; N-(3-phenoxy-4-pyridinyl)methanesulfonamide; 180194-78-9; N-(3-phenoxypyridin-4-yl)methanesulfonamide; CTK0E3181; DTXSID30437284; BDBM50120980; N-(3-Phenoxy-4-pyridyl)methanesulfonamide; N-(3-Phenoxy-pyridin-4-yl)-methanesulfonamide; Methanesulfonamide, N-(3-phenoxy-4-pyridinyl)-
DM7CM3F DT Small molecular drug
DM7CM3F PC 10244543
DM7CM3F MW 264.3
DM7CM3F FM C12H12N2O3S
DM7CM3F IC InChI=1S/C12H12N2O3S/c1-18(15,16)14-11-7-8-13-9-12(11)17-10-5-3-2-4-6-10/h2-9H,1H3,(H,13,14)
DM7CM3F CS CS(=O)(=O)NC1=C(C=NC=C1)OC2=CC=CC=C2
DM7CM3F IK CQEDUEBRINEBGP-UHFFFAOYSA-N
DM7CM3F IU N-(3-phenoxypyridin-4-yl)methanesulfonamide
DM7CM3F CA CAS 180194-78-9
DM7CM3F DE Discovery agent
DMSNF7W ID DMSNF7W
DMSNF7W DN N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)
DMSNF7W HS Investigative
DMSNF7W SN CHEMBL478643; N-(3-Phenyl)propyl-2-(4-bromophenylacetamide)
DMSNF7W DT Small molecular drug
DMSNF7W PC 44578696
DMSNF7W MW 408.3
DMSNF7W FM C23H22BrNO
DMSNF7W IC InChI=1S/C23H22BrNO/c24-21-15-13-20(14-16-21)22(19-11-5-2-6-12-19)23(26)25-17-7-10-18-8-3-1-4-9-18/h1-6,8-9,11-16,22H,7,10,17H2,(H,25,26)
DMSNF7W CS C1=CC=C(C=C1)CCCNC(=O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Br
DMSNF7W IK ACZAPKHQBWGJHX-UHFFFAOYSA-N
DMSNF7W IU 2-(4-bromophenyl)-2-phenyl-N-(3-phenylpropyl)acetamide
DMSNF7W DE Discovery agent
DM9XH18 ID DM9XH18
DM9XH18 DN N-(3-Phenyl)propyl-2,2-diphenylacetamide
DM9XH18 HS Investigative
DM9XH18 SN 2,2-diphenyl-N-(3-phenylpropyl)acetamide; CHEMBL476336; N-(3-Phenyl)propyl-2,2-diphenylacetamide; AC1M5U8J; MolPort-003-249-505; ZINC3269206; STK437441; BDBM50263151; AKOS001062446; MCULE-9627491940; N-(3-Phenylpropyl)-2,2-diphenylacetamide; ST50913753; Z26437312
DM9XH18 DT Small molecular drug
DM9XH18 PC 2385541
DM9XH18 MW 329.4
DM9XH18 FM C23H23NO
DM9XH18 IC InChI=1S/C23H23NO/c25-23(24-18-10-13-19-11-4-1-5-12-19)22(20-14-6-2-7-15-20)21-16-8-3-9-17-21/h1-9,11-12,14-17,22H,10,13,18H2,(H,24,25)
DM9XH18 CS C1=CC=C(C=C1)CCCNC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3
DM9XH18 IK GGASESVHBWYDKY-UHFFFAOYSA-N
DM9XH18 IU 2,2-diphenyl-N-(3-phenylpropyl)acetamide
DM9XH18 DE Discovery agent
DM4IA92 ID DM4IA92
DM4IA92 DN N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide
DM4IA92 HS Investigative
DM4IA92 SN N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide; CHEMBL165783; AC1M3OE0; N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide; MolPort-000-646-915; HMS3451M02; ZINC2889428; STL202734; BDBM50097440; AKOS000813205; MCULE-2440953367; UPCMLD0ENAT5889812:001; ST45223360; VU0618368-1; N-(3-Phenyl-1,2,4-thiadiazole-5-yl)benzamide; phenyl-N-(3-phenyl(1,2,4-thiadiazol-5-yl))carboxamide; F3394-1092
DM4IA92 DT Small molecular drug
DM4IA92 PC 2241548
DM4IA92 MW 281.3
DM4IA92 FM C15H11N3OS
DM4IA92 IC InChI=1S/C15H11N3OS/c19-14(12-9-5-2-6-10-12)17-15-16-13(18-20-15)11-7-3-1-4-8-11/h1-10H,(H,16,17,18,19)
DM4IA92 CS C1=CC=C(C=C1)C2=NSC(=N2)NC(=O)C3=CC=CC=C3
DM4IA92 IK AYSLYXJUYHXKHV-UHFFFAOYSA-N
DM4IA92 IU N-(3-phenyl-1,2,4-thiadiazol-5-yl)benzamide
DM4IA92 DE Discovery agent
DMJB7SE ID DMJB7SE
DMJB7SE DN N-(3-phenylamino-4-pyridinyl)methanesulfonamide
DMJB7SE HS Investigative
DMJB7SE SN N-(3-phenylamino-4-pyridinyl)methanesulfonamide; CHEMBL1079877; BDBM50311367
DMJB7SE DT Small molecular drug
DMJB7SE PC 44475843
DMJB7SE MW 263.32
DMJB7SE FM C12H13N3O2S
DMJB7SE IC InChI=1S/C12H13N3O2S/c1-18(16,17)15-11-7-8-13-9-12(11)14-10-5-3-2-4-6-10/h2-9,14H,1H3,(H,13,15)
DMJB7SE CS CS(=O)(=O)NC1=C(C=NC=C1)NC2=CC=CC=C2
DMJB7SE IK QOJPQADRTOBBQV-UHFFFAOYSA-N
DMJB7SE IU N-(3-anilinopyridin-4-yl)methanesulfonamide
DMJB7SE DE Discovery agent
DMKAX3Q ID DMKAX3Q
DMKAX3Q DN N-(3-Phenylpropyl)-1H-indole-2-carboxamide
DMKAX3Q HS Investigative
DMKAX3Q SN CHEMBL460609; N-(3-Phenylpropyl)-1H-indole-2-carboxamide; BDBM50273530; STL028133; AKOS005679593
DMKAX3Q DT Small molecular drug
DMKAX3Q PC 27647057
DMKAX3Q MW 278.3
DMKAX3Q FM C18H18N2O
DMKAX3Q IC InChI=1S/C18H18N2O/c21-18(17-13-15-10-4-5-11-16(15)20-17)19-12-6-9-14-7-2-1-3-8-14/h1-5,7-8,10-11,13,20H,6,9,12H2,(H,19,21)
DMKAX3Q CS C1=CC=C(C=C1)CCCNC(=O)C2=CC3=CC=CC=C3N2
DMKAX3Q IK RUVMVFFYHGKXTD-UHFFFAOYSA-N
DMKAX3Q IU N-(3-phenylpropyl)-1H-indole-2-carboxamide
DMKAX3Q DE Discovery agent
DMZ3I6U ID DMZ3I6U
DMZ3I6U DN N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
DMZ3I6U HS Investigative
DMZ3I6U SN pyrrole inhibitor 13; N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide; CHEMBL221171; BDBM15587
DMZ3I6U DT Small molecular drug
DMZ3I6U PC 16110288
DMZ3I6U MW 228.29
DMZ3I6U FM C14H16N2O
DMZ3I6U IC InChI=1S/C14H16N2O/c17-14(13-9-5-10-15-13)16-11-4-8-12-6-2-1-3-7-12/h1-3,5-7,9-10,15H,4,8,11H2,(H,16,17)
DMZ3I6U CS C1=CC=C(C=C1)CCCNC(=O)C2=CC=CN2
DMZ3I6U IK FQRIYWSUESDLNK-UHFFFAOYSA-N
DMZ3I6U IU N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
DMZ3I6U DE Discovery agent
DMA7X62 ID DMA7X62
DMA7X62 DN N-(3-Phenyl-propyl)-nicotinamide
DMA7X62 HS Investigative
DMA7X62 SN N-(3-phenylpropyl)pyridine-3-carboxamide; CHEMBL560538; N-(3-Phenyl-propyl)-nicotinamide; AC1NEVG1; SCHEMBL4182430; MolPort-001-620-971; ZINC2736778; BDBM50297409; STK440753; AKOS003254198; MCULE-2570363469; N-(3-phenylpropyl)-3-pyridylcarboxamide
DMA7X62 DT Small molecular drug
DMA7X62 PC 4648643
DMA7X62 MW 240.3
DMA7X62 FM C15H16N2O
DMA7X62 IC InChI=1S/C15H16N2O/c18-15(14-9-5-10-16-12-14)17-11-4-8-13-6-2-1-3-7-13/h1-3,5-7,9-10,12H,4,8,11H2,(H,17,18)
DMA7X62 CS C1=CC=C(C=C1)CCCNC(=O)C2=CN=CC=C2
DMA7X62 IK DGVNUZBITSWBPL-UHFFFAOYSA-N
DMA7X62 IU N-(3-phenylpropyl)pyridine-3-carboxamide
DMA7X62 DE Discovery agent
DM1V83P ID DM1V83P
DM1V83P DN N-(4-(2-aminoethyl)phenyl)benzenesulfonamide
DM1V83P HS Investigative
DM1V83P SN N-[4-(2-aminoethyl)phenyl]Benzenesulfonamide; CHEMBL434365; N-(4-(2-aminoethyl)phenyl)benzenesulfonamide; 159182-12-4; N-(4-[2-Aminoethyl]phenyl)Benzenesulfonamide; SCHEMBL5830405; PRODIAPRPOSQSM-UHFFFAOYSA-N; ZINC20224442; BDBM50193473; AKOS011587141; MCULE-5428014421; DA-09746; FT-0710145; N-(4-[2-aminoethyl]phenyl) benzenesulfonamide
DM1V83P DT Small molecular drug
DM1V83P PC 15281645
DM1V83P MW 276.36
DM1V83P FM C14H16N2O2S
DM1V83P IC InChI=1S/C14H16N2O2S/c15-11-10-12-6-8-13(9-7-12)16-19(17,18)14-4-2-1-3-5-14/h1-9,16H,10-11,15H2
DM1V83P CS C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)CCN
DM1V83P IK PRODIAPRPOSQSM-UHFFFAOYSA-N
DM1V83P IU N-[4-(2-aminoethyl)phenyl]benzenesulfonamide
DM1V83P DE Discovery agent
DMRH987 ID DMRH987
DMRH987 DN N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide
DMRH987 HS Investigative
DMRH987 SN AC1O17NE; CHEMBL425789
DMRH987 DT Small molecular drug
DMRH987 PC 6114166
DMRH987 MW 266.29
DMRH987 FM C16H14N2O2
DMRH987 IC InChI=1S/C16H14N2O2/c1-12(19)18-15-7-5-13(6-8-15)16(20)10-9-14-4-2-3-11-17-14/h2-11H,1H3,(H,18,19)/b10-9+
DMRH987 CS CC(=O)NC1=CC=C(C=C1)C(=O)/C=C/C2=CC=CC=N2
DMRH987 IK LAXKVXCZXLEVKG-MDZDMXLPSA-N
DMRH987 IU N-[4-[(E)-3-pyridin-2-ylprop-2-enoyl]phenyl]acetamide
DMRH987 DE Discovery agent
DMQDI5H ID DMQDI5H
DMQDI5H DN N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide
DMQDI5H HS Investigative
DMQDI5H SN CHEMBL262360
DMQDI5H DT Small molecular drug
DMQDI5H PC 44450061
DMQDI5H MW 327.4
DMQDI5H FM C20H25NO3
DMQDI5H IC InChI=1S/C20H25NO3/c1-3-4-5-6-7-16-8-13-20(19(23)14-16)24-18-11-9-17(10-12-18)21-15(2)22/h8-14,23H,3-7H2,1-2H3,(H,21,22)
DMQDI5H CS CCCCCCC1=CC(=C(C=C1)OC2=CC=C(C=C2)NC(=O)C)O
DMQDI5H IK MQSIKLFXBKTOER-UHFFFAOYSA-N
DMQDI5H IU N-[4-(4-hexyl-2-hydroxyphenoxy)phenyl]acetamide
DMQDI5H DE Discovery agent
DMIPKNQ ID DMIPKNQ
DMIPKNQ DN N-(4-(benzyloxy)phenethyl)pyridin-4-amine
DMIPKNQ HS Investigative
DMIPKNQ SN CHEMBL48029; N-(4-(benzyloxy)phenethyl)pyridin-4-amine; 212506-01-9; CTK0I9588; DTXSID00658166; ZINC29412450; BDBM50070788; AKOS030550684; N-{2-[4-(Benzyloxy)phenyl]ethyl}pyridin-4-amine; [2-(4-Benzyloxy-phenyl)-ethyl]-pyridin-4-yl-amine; 4-Pyridinamine, N-[2-[4-(phenylmethoxy)phenyl]ethyl]-
DMIPKNQ DT Small molecular drug
DMIPKNQ PC 44292136
DMIPKNQ MW 304.4
DMIPKNQ FM C20H20N2O
DMIPKNQ IC InChI=1S/C20H20N2O/c1-2-4-18(5-3-1)16-23-20-8-6-17(7-9-20)10-15-22-19-11-13-21-14-12-19/h1-9,11-14H,10,15-16H2,(H,21,22)
DMIPKNQ CS C1=CC=C(C=C1)COC2=CC=C(C=C2)CCNC3=CC=NC=C3
DMIPKNQ IK WPBRSJXCRWSAHJ-UHFFFAOYSA-N
DMIPKNQ IU N-[2-(4-phenylmethoxyphenyl)ethyl]pyridin-4-amine
DMIPKNQ CA CAS 212506-01-9
DMIPKNQ DE Discovery agent
DMZAOVG ID DMZAOVG
DMZAOVG DN N-(4-(diethylamino)phenyl)-2-nitrobenzamide
DMZAOVG HS Investigative
DMZAOVG SN N-[4-(diethylamino)phenyl]-2-nitrobenzamide; CHEMBL552222; N-(4-(diethylamino)phenyl)-2-nitrobenzamide; AC1LDVIK; CBMicro_033668; Oprea1_547325; Oprea1_003763; ARONIS021166; ZINC38831; KS-00004CPP; MolPort-001-026-902; BDBM50297531; STK073585; AKOS000487910; MCULE-3866338057; ST055105; BIM-0033840.P001; SR-01000220066; AN-329/12072549; SR-01000220066-1
DMZAOVG DT Small molecular drug
DMZAOVG PC 675939
DMZAOVG MW 313.35
DMZAOVG FM C17H19N3O3
DMZAOVG IC InChI=1S/C17H19N3O3/c1-3-19(4-2)14-11-9-13(10-12-14)18-17(21)15-7-5-6-8-16(15)20(22)23/h5-12H,3-4H2,1-2H3,(H,18,21)
DMZAOVG CS CCN(CC)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2[N+](=O)[O-]
DMZAOVG IK ILACFEJISPLWOY-UHFFFAOYSA-N
DMZAOVG IU N-[4-(diethylamino)phenyl]-2-nitrobenzamide
DMZAOVG DE Discovery agent
DMI74KM ID DMI74KM
DMI74KM DN N-(4-(phenylamino)quinazolin-6-yl)acrylamide
DMI74KM HS Investigative
DMI74KM SN CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide
DMI74KM DT Small molecular drug
DMI74KM PC 10401956
DMI74KM MW 290.32
DMI74KM FM C17H14N4O
DMI74KM IC InChI=1S/C17H14N4O/c1-2-16(22)20-13-8-9-15-14(10-13)17(19-11-18-15)21-12-6-4-3-5-7-12/h2-11H,1H2,(H,20,22)(H,18,19,21)
DMI74KM CS C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC=CC=C3
DMI74KM IK JGWHILNNHLDARR-UHFFFAOYSA-N
DMI74KM IU N-(4-anilinoquinazolin-6-yl)prop-2-enamide
DMZ0V8O ID DMZ0V8O
DMZ0V8O DN N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMZ0V8O HS Investigative
DMZ0V8O SN CHEMBL199074; N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide
DMZ0V8O DT Small molecular drug
DMZ0V8O PC 44405448
DMZ0V8O MW 371.4
DMZ0V8O FM C21H16F3NO2
DMZ0V8O IC InChI=1S/C21H16F3NO2/c22-21(23,24)17-10-6-15(7-11-17)14-25-20(26)16-8-12-19(13-9-16)27-18-4-2-1-3-5-18/h1-13H,14H2,(H,25,26)
DMZ0V8O CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC3=CC=C(C=C3)C(F)(F)F
DMZ0V8O IK JDGSUZBWUUXJCN-UHFFFAOYSA-N
DMZ0V8O IU 4-phenoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide
DMZ0V8O DE Discovery agent
DM086VJ ID DM086VJ
DM086VJ DN N-(4,4-Diphenyl-butyl)-nicotinamide
DM086VJ HS Investigative
DM086VJ SN CHEMBL561479; N-(4,4-Diphenyl-butyl)-nicotinamide
DM086VJ DT Small molecular drug
DM086VJ PC 44475209
DM086VJ MW 330.4
DM086VJ FM C22H22N2O
DM086VJ IC InChI=1S/C22H22N2O/c25-22(20-13-7-15-23-17-20)24-16-8-14-21(18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-7,9-13,15,17,21H,8,14,16H2,(H,24,25)
DM086VJ CS C1=CC=C(C=C1)C(CCCNC(=O)C2=CN=CC=C2)C3=CC=CC=C3
DM086VJ IK OIJGKBCGOHTERP-UHFFFAOYSA-N
DM086VJ IU N-(4,4-diphenylbutyl)pyridine-3-carboxamide
DM086VJ DE Discovery agent
DM34R10 ID DM34R10
DM34R10 DN N-(4,5-diphenylpyrimidin-2-yl)acetamide
DM34R10 HS Investigative
DM34R10 SN CHEMBL225244; 58413-41-5; N-(4,5-diphenylpyrimidin-2-yl)acetamide; CTK1E9829; DTXSID90482573; 2-acetamido-4,6-diphenylpyrimidine; ZINC13586468; BDBM50157675; AKOS030564193; Acetamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DM34R10 DT Small molecular drug
DM34R10 PC 12253310
DM34R10 MW 289.3
DM34R10 FM C18H15N3O
DM34R10 IC InChI=1S/C18H15N3O/c1-13(22)19-18-20-16(14-8-4-2-5-9-14)12-17(21-18)15-10-6-3-7-11-15/h2-12H,1H3,(H,19,20,21,22)
DM34R10 CS CC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DM34R10 IK ZDCIIHIXQUEUCV-UHFFFAOYSA-N
DM34R10 IU N-(4,6-diphenylpyrimidin-2-yl)acetamide
DM34R10 CA CAS 58413-41-5
DM34R10 DE Discovery agent
DMDP1QG ID DMDP1QG
DMDP1QG DN N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide
DMDP1QG HS Investigative
DMDP1QG SN CHEMBL374366; 820961-71-5; N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide; SCHEMBL6497567; CTK3E2637; DTXSID20461437; BDBM50157660; AKOS030569446; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-2-ethyl-
DMDP1QG DT Small molecular drug
DMDP1QG PC 11290921
DMDP1QG MW 345.4
DMDP1QG FM C22H23N3O
DMDP1QG IC InChI=1S/C22H23N3O/c1-3-16(4-2)21(26)25-22-23-19(17-11-7-5-8-12-17)15-20(24-22)18-13-9-6-10-14-18/h5-16H,3-4H2,1-2H3,(H,23,24,25,26)
DMDP1QG CS CCC(CC)C(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMDP1QG IK YOARGGKKYZIYSU-UHFFFAOYSA-N
DMDP1QG IU N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutanamide
DMDP1QG CA CAS 820961-71-5
DMDP1QG DE Discovery agent
DMQVPK9 ID DMQVPK9
DMQVPK9 DN N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide
DMQVPK9 HS Investigative
DMQVPK9 SN CHEMBL426390; 820961-63-5; 3-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide; N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide; CTK3E2645; DTXSID50459660; MolPort-007-705-564; BDBM50157667; ZINC13586467; AKOS001552650; MCULE-8841696019; Benzamide, 3-chloro-N-(4,6-diphenyl-2-pyrimidinyl)-
DMQVPK9 DT Small molecular drug
DMQVPK9 PC 11234532
DMQVPK9 MW 385.8
DMQVPK9 FM C23H16ClN3O
DMQVPK9 IC InChI=1S/C23H16ClN3O/c24-19-13-7-12-18(14-19)22(28)27-23-25-20(16-8-3-1-4-9-16)15-21(26-23)17-10-5-2-6-11-17/h1-15H,(H,25,26,27,28)
DMQVPK9 CS C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC(=CC=C3)Cl)C4=CC=CC=C4
DMQVPK9 IK BYALFPUQWRIWML-UHFFFAOYSA-N
DMQVPK9 IU 3-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMQVPK9 CA CAS 820961-63-5
DMQVPK9 DE Discovery agent
DMOAPJ1 ID DMOAPJ1
DMOAPJ1 DN N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide
DMOAPJ1 HS Investigative
DMOAPJ1 SN CHEMBL376672; 820961-70-4; N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide; SCHEMBL6501467; CTK3E2638; DTXSID50461763; MolPort-007-705-567; HMS3459C01; ZINC13586473; BDBM50157677; AKOS001873749; MCULE-2375799118; N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutanamide; Butanamide, N-(4,6-diphenyl-2-pyrimidinyl)-3-methyl-
DMOAPJ1 DT Small molecular drug
DMOAPJ1 PC 11301995
DMOAPJ1 MW 331.4
DMOAPJ1 FM C21H21N3O
DMOAPJ1 IC InChI=1S/C21H21N3O/c1-15(2)13-20(25)24-21-22-18(16-9-5-3-6-10-16)14-19(23-21)17-11-7-4-8-12-17/h3-12,14-15H,13H2,1-2H3,(H,22,23,24,25)
DMOAPJ1 CS CC(C)CC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMOAPJ1 IK RLCNDGHLHOXEDS-UHFFFAOYSA-N
DMOAPJ1 IU N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutanamide
DMOAPJ1 CA CAS 820961-70-4
DMOAPJ1 DE Discovery agent
DM1PSR7 ID DM1PSR7
DM1PSR7 DN N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide
DM1PSR7 HS Investigative
DM1PSR7 SN CHEMBL376034; 820961-59-9; N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide; CTK3E2649; DTXSID20458923; BDBM50157674; AKOS030577991; Benzamide, 4-chloro-N-(4,6-diphenyl-2-pyrimidinyl)-
DM1PSR7 DT Small molecular drug
DM1PSR7 PC 11211335
DM1PSR7 MW 385.8
DM1PSR7 FM C23H16ClN3O
DM1PSR7 IC InChI=1S/C23H16ClN3O/c24-19-13-11-18(12-14-19)22(28)27-23-25-20(16-7-3-1-4-8-16)15-21(26-23)17-9-5-2-6-10-17/h1-15H,(H,25,26,27,28)
DM1PSR7 CS C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4
DM1PSR7 IK GXFPQKORTZOVLZ-UHFFFAOYSA-N
DM1PSR7 IU 4-chloro-N-(4,6-diphenylpyrimidin-2-yl)benzamide
DM1PSR7 CA CAS 820961-59-9
DM1PSR7 DE Discovery agent
DMA214F ID DMA214F
DMA214F DN N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMA214F HS Investigative
DMA214F SN N-(4,6-diphenylpyrimidin-2-yl)benzamide; CHEMBL221455; SCHEMBL6498848; MolPort-007-705-557; HMS3458N22; ZINC13586462; BDBM50157680; AKOS001552924
DMA214F DT Small molecular drug
DMA214F PC 11314132
DMA214F MW 351.4
DMA214F FM C23H17N3O
DMA214F IC InChI=1S/C23H17N3O/c27-22(19-14-8-3-9-15-19)26-23-24-20(17-10-4-1-5-11-17)16-21(25-23)18-12-6-2-7-13-18/h1-16H,(H,24,25,26,27)
DMA214F CS C1=CC=C(C=C1)C2=CC(=NC(=N2)NC(=O)C3=CC=CC=C3)C4=CC=CC=C4
DMA214F IK YAAODHHMHPMCPL-UHFFFAOYSA-N
DMA214F IU N-(4,6-diphenylpyrimidin-2-yl)benzamide
DMA214F DE Discovery agent
DMJZ2IP ID DMJZ2IP
DMJZ2IP DN N-(4,6-diphenylpyrimidin-2-yl)propionamide
DMJZ2IP HS Investigative
DMJZ2IP SN CHEMBL222718; 820961-64-6; N-(4,6-diphenylpyrimidin-2-yl)propionamide; SCHEMBL6505603; CTK3E2644; DTXSID70461023; BDBM50157663; ZINC13586469; N-(4,6-Diphenylpyrimidine-2-yl)propanamide; Propanamide, N-(4,6-diphenyl-2-pyrimidinyl)-
DMJZ2IP DT Small molecular drug
DMJZ2IP PC 11278089
DMJZ2IP MW 303.4
DMJZ2IP FM C19H17N3O
DMJZ2IP IC InChI=1S/C19H17N3O/c1-2-18(23)22-19-20-16(14-9-5-3-6-10-14)13-17(21-19)15-11-7-4-8-12-15/h3-13H,2H2,1H3,(H,20,21,22,23)
DMJZ2IP CS CCC(=O)NC1=NC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3
DMJZ2IP IK AZXIPRTZIQWIHR-UHFFFAOYSA-N
DMJZ2IP IU N-(4,6-diphenylpyrimidin-2-yl)propanamide
DMJZ2IP CA CAS 820961-64-6
DMJZ2IP DE Discovery agent
DMIJLX6 ID DMIJLX6
DMIJLX6 DN N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide
DMIJLX6 HS Investigative
DMIJLX6 SN CHEMBL1099078; BDBM50317997
DMIJLX6 DT Small molecular drug
DMIJLX6 PC 46887380
DMIJLX6 MW 330.4
DMIJLX6 FM C21H18N2O2
DMIJLX6 IC InChI=1S/C21H18N2O2/c1-14(24)15-7-9-16(10-8-15)18-11-12-19(22)20(13-18)23-21(25)17-5-3-2-4-6-17/h2-13H,22H2,1H3,(H,23,25)
DMIJLX6 CS CC(=O)C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMIJLX6 IK NWHQDZJUELCUHQ-UHFFFAOYSA-N
DMIJLX6 IU N-[5-(4-acetylphenyl)-2-aminophenyl]benzamide
DMIJLX6 DE Discovery agent
DMCLRBK ID DMCLRBK
DMCLRBK DN N-(4-amino-2-propylquinolin-6-yl)cinnamamide
DMCLRBK HS Investigative
DMCLRBK SN CHEMBL385639; N-(4-amino-2-propylquinolin-6-yl)cinnamamide
DMCLRBK DT Small molecular drug
DMCLRBK PC 44418001
DMCLRBK MW 331.4
DMCLRBK FM C21H21N3O
DMCLRBK IC InChI=1S/C21H21N3O/c1-2-6-16-14-19(22)18-13-17(10-11-20(18)23-16)24-21(25)12-9-15-7-4-3-5-8-15/h3-5,7-14H,2,6H2,1H3,(H2,22,23)(H,24,25)/b12-9+
DMCLRBK CS CCCC1=CC(=C2C=C(C=CC2=N1)NC(=O)/C=C/C3=CC=CC=C3)N
DMCLRBK IK PWQSXBRFDPQGOC-FMIVXFBMSA-N
DMCLRBK IU (E)-N-(4-amino-2-propylquinolin-6-yl)-3-phenylprop-2-enamide
DMCLRBK DE Discovery agent
DMV6154 ID DMV6154
DMV6154 DN N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide
DMV6154 HS Investigative
DMV6154 SN CHEMBL1097747; BDBM50317991
DMV6154 DT Small molecular drug
DMV6154 PC 46887438
DMV6154 MW 318.4
DMV6154 FM C20H18N2O2
DMV6154 IC InChI=1S/C20H18N2O2/c1-24-17-9-5-8-15(12-17)16-10-11-18(21)19(13-16)22-20(23)14-6-3-2-4-7-14/h2-13H,21H2,1H3,(H,22,23)
DMV6154 CS COC1=CC=CC(=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMV6154 IK YILNPZMVPAGFAT-UHFFFAOYSA-N
DMV6154 IU N-[2-amino-5-(3-methoxyphenyl)phenyl]benzamide
DMV6154 DE Discovery agent
DM910BF ID DM910BF
DM910BF DN N-(4-amino-3'-methylbiphenyl-3-yl)benzamide
DM910BF HS Investigative
DM910BF SN CHEMBL1094108; BDBM50317995
DM910BF DT Small molecular drug
DM910BF PC 46887381
DM910BF MW 302.4
DM910BF FM C20H18N2O
DM910BF IC InChI=1S/C20H18N2O/c1-14-6-5-9-16(12-14)17-10-11-18(21)19(13-17)22-20(23)15-7-3-2-4-8-15/h2-13H,21H2,1H3,(H,22,23)
DM910BF CS CC1=CC(=CC=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DM910BF IK VPXVDXWJQKJAAI-UHFFFAOYSA-N
DM910BF IU N-[2-amino-5-(3-methylphenyl)phenyl]benzamide
DM910BF DE Discovery agent
DMIAGS8 ID DMIAGS8
DMIAGS8 DN N-(4-amino-4'-bromobiphenyl-3-yl)benzamide
DMIAGS8 HS Investigative
DMIAGS8 SN CHEMBL1097748; BDBM50317990
DMIAGS8 DT Small molecular drug
DMIAGS8 PC 46887439
DMIAGS8 MW 367.2
DMIAGS8 FM C19H15BrN2O
DMIAGS8 IC InChI=1S/C19H15BrN2O/c20-16-9-6-13(7-10-16)15-8-11-17(21)18(12-15)22-19(23)14-4-2-1-3-5-14/h1-12H,21H2,(H,22,23)
DMIAGS8 CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=C(C=C3)Br)N
DMIAGS8 IK MPUICDSEVNEGIC-UHFFFAOYSA-N
DMIAGS8 IU N-[2-amino-5-(4-bromophenyl)phenyl]benzamide
DMIAGS8 DE Discovery agent
DMR5D16 ID DMR5D16
DMR5D16 DN N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide
DMR5D16 HS Investigative
DMR5D16 SN CHEMBL1098337; SCHEMBL15398027; BDBM50317988
DMR5D16 DT Small molecular drug
DMR5D16 PC 46830345
DMR5D16 MW 306.3
DMR5D16 FM C19H15FN2O
DMR5D16 IC InChI=1S/C19H15FN2O/c20-16-9-6-13(7-10-16)15-8-11-17(21)18(12-15)22-19(23)14-4-2-1-3-5-14/h1-12H,21H2,(H,22,23)
DMR5D16 CS C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=C(C=C3)F)N
DMR5D16 IK LKRDHRWKHHRCOQ-UHFFFAOYSA-N
DMR5D16 IU N-[2-amino-5-(4-fluorophenyl)phenyl]benzamide
DMR5D16 DE Discovery agent
DM93PDA ID DM93PDA
DM93PDA DN N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide
DM93PDA HS Investigative
DM93PDA SN CHEMBL1095412; BDBM50317998
DM93PDA DT Small molecular drug
DM93PDA PC 46887379
DM93PDA MW 318.4
DM93PDA FM C20H18N2O2
DM93PDA IC InChI=1S/C20H18N2O2/c1-24-17-10-7-14(8-11-17)16-9-12-18(21)19(13-16)22-20(23)15-5-3-2-4-6-15/h2-13H,21H2,1H3,(H,22,23)
DM93PDA CS COC1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DM93PDA IK YOKIWEOZLFOUFK-UHFFFAOYSA-N
DM93PDA IU N-[2-amino-5-(4-methoxyphenyl)phenyl]benzamide
DM93PDA DE Discovery agent
DMSUJDH ID DMSUJDH
DMSUJDH DN N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide
DMSUJDH HS Investigative
DMSUJDH SN CHEMBL1096397; BDBM50318002
DMSUJDH DT Small molecular drug
DMSUJDH PC 46887334
DMSUJDH MW 314.4
DMSUJDH FM C21H18N2O
DMSUJDH IC InChI=1S/C21H18N2O/c1-2-15-8-10-16(11-9-15)18-12-13-19(22)20(14-18)23-21(24)17-6-4-3-5-7-17/h2-14H,1,22H2,(H,23,24)
DMSUJDH CS C=CC1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMSUJDH IK GUBGWFHGNFMNFP-UHFFFAOYSA-N
DMSUJDH IU N-[2-amino-5-(4-ethenylphenyl)phenyl]benzamide
DMSUJDH DE Discovery agent
DMY1FMG ID DMY1FMG
DMY1FMG DN N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG HS Investigative
DMY1FMG SN 894803-94-2; Acetamide,N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; Kinome_3025; aminopyridine deriv. 1; N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide; CHEMBL208637; SCHEMBL1145395; Acetamide, N-(4-amino-5-cyano-6-ethoxy-2-pyridinyl)-; BDBM15907; Aminopyridine-Based Inhibitor 6a; DXAJWOOLPAIVJG-UHFFFAOYSA-N; ZINC14959957; KB-74421
DMY1FMG DT Small molecular drug
DMY1FMG PC 11715520
DMY1FMG MW 220.23
DMY1FMG FM C10H12N4O2
DMY1FMG IC InChI=1S/C10H12N4O2/c1-3-16-10-7(5-11)8(12)4-9(14-10)13-6(2)15/h4H,3H2,1-2H3,(H3,12,13,14,15)
DMY1FMG CS CCOC1=C(C(=CC(=N1)NC(=O)C)N)C#N
DMY1FMG IK DXAJWOOLPAIVJG-UHFFFAOYSA-N
DMY1FMG IU N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide
DMY1FMG DE Discovery agent
DMUFVM6 ID DMUFVM6
DMUFVM6 DN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6 HS Investigative
DMUFVM6 SN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide; Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24
DMUFVM6 DT Small molecular drug
DMUFVM6 PC 11658882
DMUFVM6 MW 252.27
DMUFVM6 FM C14H12N4O
DMUFVM6 IC InChI=1S/C14H12N4O/c1-9(19)17-13-7-12(16)11(8-15)14(18-13)10-5-3-2-4-6-10/h2-7H,1H3,(H3,16,17,18,19)
DMUFVM6 CS CC(=O)NC1=NC(=C(C(=C1)N)C#N)C2=CC=CC=C2
DMUFVM6 IK GTMGQYXCPKUZAD-UHFFFAOYSA-N
DMUFVM6 IU N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
DMUFVM6 DE Discovery agent
DMSAD87 ID DMSAD87
DMSAD87 DN N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide
DMSAD87 HS Investigative
DMSAD87 SN N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide; CHEMBL378980; SCHEMBL1145050; BDBM15960; Aminopyridine-Based Inhibitor 19d
DMSAD87 DT Small molecular drug
DMSAD87 PC 11507052
DMSAD87 MW 248.28
DMSAD87 FM C12H16N4O2
DMSAD87 IC InChI=1S/C12H16N4O2/c1-3-4-5-18-12-9(7-13)10(14)6-11(16-12)15-8(2)17/h6H,3-5H2,1-2H3,(H3,14,15,16,17)
DMSAD87 CS CCCCOC1=C(C(=CC(=N1)NC(=O)C)N)C#N
DMSAD87 IK BOEQDOKWKLSDFP-UHFFFAOYSA-N
DMSAD87 IU N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide
DMSAD87 DE Discovery agent
DMLA92O ID DMLA92O
DMLA92O DN N-(4-aminobiphenyl-3-yl)benzamide
DMLA92O HS Investigative
DMLA92O SN N-(4-aminobiphenyl-3-yl)benzamide; CHEMBL271741; 3max; SCHEMBL16380794; BDBM50232053; N-(4-amino-biphenyl-3-yl)-benzamide
DMLA92O DT Small molecular drug
DMLA92O PC 44454143
DMLA92O MW 288.3
DMLA92O FM C19H16N2O
DMLA92O IC InChI=1S/C19H16N2O/c20-17-12-11-16(14-7-3-1-4-8-14)13-18(17)21-19(22)15-9-5-2-6-10-15/h1-13H,20H2,(H,21,22)
DMLA92O CS C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CC=CC=C3
DMLA92O IK ZWLFHHHQRUYIBT-UHFFFAOYSA-N
DMLA92O IU N-(2-amino-5-phenylphenyl)benzamide
DMLA92O DE Discovery agent
DMXVZIY ID DMXVZIY
DMXVZIY DN N-(4-aminobiphenyl-3-yl)nicotinamide
DMXVZIY HS Investigative
DMXVZIY SN CHEMBL255805; N-(4-aminobiphenyl-3-yl)nicotinamide; BDBM50232035
DMXVZIY DT Small molecular drug
DMXVZIY PC 44454415
DMXVZIY MW 289.3
DMXVZIY FM C18H15N3O
DMXVZIY IC InChI=1S/C18H15N3O/c19-16-9-8-14(13-5-2-1-3-6-13)11-17(16)21-18(22)15-7-4-10-20-12-15/h1-12H,19H2,(H,21,22)
DMXVZIY CS C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CN=CC=C3
DMXVZIY IK RAJXTGVDLBIWMD-UHFFFAOYSA-N
DMXVZIY IU N-(2-amino-5-phenylphenyl)pyridine-3-carboxamide
DMXVZIY DE Discovery agent
DMSNZV1 ID DMSNZV1
DMSNZV1 DN N-(4-bromo-2-methylphenyl)-2-naphthamide
DMSNZV1 HS Investigative
DMSNZV1 SN N-(4-bromo-2-methylphenyl)-2-naphthamide; N-(4-bromo-2-methylphenyl)naphthalene-2-carboxamide; 429627-41-8; naphthamide compound 2; AC1LGMF3; ChemBridge compound no. 2; CHEMBL217951; CTK1C8257; BDBM14710; DTXSID40356417; MolPort-002-208-677; ZINC342068; STK222653; AKOS000202277; MCULE-5174732523; AG-670/40742092; 2-Naphthalenecarboxamide, N-(4-bromo-2-methylphenyl)-
DMSNZV1 DT Small molecular drug
DMSNZV1 PC 823850
DMSNZV1 MW 340.2
DMSNZV1 FM C18H14BrNO
DMSNZV1 IC InChI=1S/C18H14BrNO/c1-12-10-16(19)8-9-17(12)20-18(21)15-7-6-13-4-2-3-5-14(13)11-15/h2-11H,1H3,(H,20,21)
DMSNZV1 CS CC1=C(C=CC(=C1)Br)NC(=O)C2=CC3=CC=CC=C3C=C2
DMSNZV1 IK QDOYRUBXBHREAH-UHFFFAOYSA-N
DMSNZV1 IU N-(4-bromo-2-methylphenyl)naphthalene-2-carboxamide
DMSNZV1 CA CAS 429627-41-8
DMSNZV1 DE Discovery agent
DMWHYOJ ID DMWHYOJ
DMWHYOJ DN N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea
DMWHYOJ HS Investigative
DMWHYOJ SN CHEMBL244510; SCHEMBL5436772; BDBM50220178
DMWHYOJ DT Small molecular drug
DMWHYOJ PC 11595053
DMWHYOJ MW 327.12
DMWHYOJ FM C13H9BrF2N2O
DMWHYOJ IC InChI=1S/C13H9BrF2N2O/c14-9-3-1-7(5-10(9)15)8-2-4-12(11(16)6-8)18-13(17)19/h1-6H,(H3,17,18,19)
DMWHYOJ CS C1=CC(=C(C=C1C2=CC(=C(C=C2)Br)F)F)NC(=O)N
DMWHYOJ IK SKBUTANQYXWCNX-UHFFFAOYSA-N
DMWHYOJ IU [4-(4-bromo-3-fluorophenyl)-2-fluorophenyl]urea
DMWHYOJ DE Discovery agent
DMC28SN ID DMC28SN
DMC28SN DN N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine
DMC28SN HS Investigative
DMC28SN SN CHEMBL62468
DMC28SN DT Small molecular drug
DMC28SN PC 23359276
DMC28SN MW 320.17
DMC28SN FM C9H10BrN3O3S
DMC28SN IC InChI=1S/C9H10BrN3O3S/c1-17(15,16)7-4-5(2-3-6(7)10)8(14)13-9(11)12/h2-4H,1H3,(H4,11,12,13,14)
DMC28SN CS CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)Br
DMC28SN IK PWHJRANRUUKGBX-UHFFFAOYSA-N
DMC28SN IU 4-bromo-N-(diaminomethylidene)-3-methylsulfonylbenzamide
DMC28SN DE Discovery agent
DMFG6MU ID DMFG6MU
DMFG6MU DN N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine
DMFG6MU HS Investigative
DMFG6MU SN CHEMBL62469
DMFG6MU DT Small molecular drug
DMFG6MU PC 19096151
DMFG6MU MW 275.71
DMFG6MU FM C9H10ClN3O3S
DMFG6MU IC InChI=1S/C9H10ClN3O3S/c1-17(15,16)7-4-5(2-3-6(7)10)8(14)13-9(11)12/h2-4H,1H3,(H4,11,12,13,14)
DMFG6MU CS CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)Cl
DMFG6MU IK AXVSLAVXNQSEKO-UHFFFAOYSA-N
DMFG6MU IU 4-chloro-N-(diaminomethylidene)-3-methylsulfonylbenzamide
DMFG6MU DE Discovery agent
DM0ARP8 ID DM0ARP8
DM0ARP8 DN N-(4'-chloro-4-biphenylyl)methanesulfonamide
DM0ARP8 HS Investigative
DM0ARP8 SN CHEMBL242150; SCHEMBL4661119; BDBM50220160; ZINC28711996
DM0ARP8 DT Small molecular drug
DM0ARP8 PC 11254540
DM0ARP8 MW 281.76
DM0ARP8 FM C13H12ClNO2S
DM0ARP8 IC InChI=1S/C13H12ClNO2S/c1-18(16,17)15-13-8-4-11(5-9-13)10-2-6-12(14)7-3-10/h2-9,15H,1H3
DM0ARP8 CS CS(=O)(=O)NC1=CC=C(C=C1)C2=CC=C(C=C2)Cl
DM0ARP8 IK XUCHFNFYOSJPDH-UHFFFAOYSA-N
DM0ARP8 IU N-[4-(4-chlorophenyl)phenyl]methanesulfonamide
DM0ARP8 DE Discovery agent
DMNO46U ID DMNO46U
DMNO46U DN N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine
DMNO46U HS Investigative
DMNO46U SN CHEMBL109274; N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine
DMNO46U DT Small molecular drug
DMNO46U PC 44339119
DMNO46U MW 310.8
DMNO46U FM C17H15ClN4
DMNO46U IC InChI=1S/C17H15ClN4/c1-10-2-4-11(5-3-10)12-6-7-13-14(8-12)16(22-17(19)20)21-9-15(13)18/h2-9H,1H3,(H4,19,20,21,22)
DMNO46U CS CC1=CC=C(C=C1)C2=CC3=C(C=C2)C(=CN=C3N=C(N)N)Cl
DMNO46U IK CHWRGRHMWONZIO-UHFFFAOYSA-N
DMNO46U IU 2-[4-chloro-7-(4-methylphenyl)isoquinolin-1-yl]guanidine
DMNO46U DE Discovery agent
DMGI9EA ID DMGI9EA
DMGI9EA DN N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine
DMGI9EA HS Investigative
DMGI9EA SN CHEMBL303297
DMGI9EA DT Small molecular drug
DMGI9EA PC 10849356
DMGI9EA MW 266.28
DMGI9EA FM C10H10N4O3S
DMGI9EA IC InChI=1S/C10H10N4O3S/c1-18(16,17)8-4-6(2-3-7(8)5-11)9(15)14-10(12)13/h2-4H,1H3,(H4,12,13,14,15)
DMGI9EA CS CS(=O)(=O)C1=C(C=CC(=C1)C(=O)N=C(N)N)C#N
DMGI9EA IK ASFBPCUWKPJTES-UHFFFAOYSA-N
DMGI9EA IU 4-cyano-N-(diaminomethylidene)-3-methylsulfonylbenzamide
DMGI9EA DE Discovery agent
DMW8S2D ID DMW8S2D
DMW8S2D DN N-(4-cyanophenyl)sulfamide
DMW8S2D HS Investigative
DMW8S2D SN N-(4-cyanophenyl)sulfamide; 164648-70-8; (4-cyanophenyl)sulfamide; CHEMBL166340; N-(4-cyanophenyl)aminosulfonamide; N-(4-cyanophenyl)sulfuric diamide; EN300-34005; AC1Q55HF; Sulfamide, (4-cyanophenyl)-; SCHEMBL1646278; Sulfamide, N-(4-cyanophenyl)-; CTK0E5869; DTXSID50597031; MolPort-004-336-840; 4-(Aminosulfonylamino)benzonitrile; ZINC13013704; BDBM50124179; AKOS000176530; FCH5272297; BBV-070788; NE46233; MCULE-1558116315; NCGC00338522-01; KB-299386; 79489-EP2305695A2; 79489-EP2305697A2; AB01330899-02; 79489-EP2305698A2
DMW8S2D DT Small molecular drug
DMW8S2D PC 18975977
DMW8S2D MW 197.22
DMW8S2D FM C7H7N3O2S
DMW8S2D IC InChI=1S/C7H7N3O2S/c8-5-6-1-3-7(4-2-6)10-13(9,11)12/h1-4,10H,(H2,9,11,12)
DMW8S2D CS C1=CC(=CC=C1C#N)NS(=O)(=O)N
DMW8S2D IK XFOYAXPHCAOZCA-UHFFFAOYSA-N
DMW8S2D IU 1-cyano-4-(sulfamoylamino)benzene
DMW8S2D CA CAS 164648-70-8
DMW8S2D DE Discovery agent
DMB3E7H ID DMB3E7H
DMB3E7H DN N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide
DMB3E7H HS Investigative
DMB3E7H SN CHEMBL75358; 18327-42-9; Acetamide, N-[4-(dimethylamino)-2-butyn-1-yl]-N-methyl-; AC1Q5IBV; AC1L2EPN; N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide; SCHEMBL11727547; CTK0A6148; DTXSID20274645; BDBM50009291; AKOS030565254; N-Methyl-N-[4-dimethylamino-2-butynyl]acetamide; N-[4-(dimethylamino)but-2-ynyl]-N-methylacetamide; n-[4-(dimethylamino)but-2-yn-1-yl]-n-methylacetamide; Acetamide, N-[4-(dimethylamino)-2-butynyl]-N-methyl-
DMB3E7H DT Small molecular drug
DMB3E7H PC 19718
DMB3E7H MW 168.24
DMB3E7H FM C9H16N2O
DMB3E7H IC InChI=1S/C9H16N2O/c1-9(12)11(4)8-6-5-7-10(2)3/h7-8H2,1-4H3
DMB3E7H CS CC(=O)N(C)CC#CCN(C)C
DMB3E7H IK FPUURHVXHFAVKC-UHFFFAOYSA-N
DMB3E7H IU N-[4-(dimethylamino)but-2-ynyl]-N-methylacetamide
DMB3E7H CA CAS 18327-42-9
DMB3E7H DE Discovery agent
DMU1ATH ID DMU1ATH
DMU1ATH DN N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH HS Investigative
DMU1ATH SN CHEMBL484204; N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide
DMU1ATH DT Small molecular drug
DMU1ATH PC 25139332
DMU1ATH MW 352.5
DMU1ATH FM C23H32N2O
DMU1ATH IC InChI=1S/C23H32N2O/c1-3-17-25(18-4-2)19-9-8-16-24-23(26)22-14-12-21(13-15-22)20-10-6-5-7-11-20/h5-7,10-15H,3-4,8-9,16-19H2,1-2H3,(H,24,26)
DMU1ATH CS CCCN(CCC)CCCCNC(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DMU1ATH IK HXCWGVSINJYYSW-UHFFFAOYSA-N
DMU1ATH IU N-[4-(dipropylamino)butyl]-4-phenylbenzamide
DMU1ATH DE Discovery agent
DM012TN ID DM012TN
DM012TN DN N-(4-Ethoxybutyl)-2-oxohexadecanamide
DM012TN HS Investigative
DM012TN SN CHEMBL461318
DM012TN DT Small molecular drug
DM012TN PC 16118461
DM012TN MW 369.6
DM012TN FM C22H43NO3
DM012TN IC InChI=1S/C22H43NO3/c1-3-5-6-7-8-9-10-11-12-13-14-15-18-21(24)22(25)23-19-16-17-20-26-4-2/h3-20H2,1-2H3,(H,23,25)
DM012TN CS CCCCCCCCCCCCCCC(=O)C(=O)NCCCCOCC
DM012TN IK ADDZROPIKDXVSC-UHFFFAOYSA-N
DM012TN IU N-(4-ethoxybutyl)-2-oxohexadecanamide
DM012TN DE Discovery agent
DMWTVJH ID DMWTVJH
DMWTVJH DN N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
DMWTVJH HS Investigative
DMWTVJH SN N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid (4-ethyl-phenyl)-amide; AC1LF7IS; ChemDiv3_001051; AC1Q2TK3; 3-carboxamido coumarin, 13; Oprea1_789803; Oprea1_049912; CHEMBL469583; BDBM29163; MolPort-000-375-251; HMS1475P17; ZINC130255; STK421228; AKOS000533669; MCULE-8672204127; IDI1_020017; BAS 00837926; ST45140661; EU-0002704; N-(4-ethylphenyl)-2-oxochromene-3-carboxamide; SR-01000410412; N-(4-ethylphenyl)(2-oxochromen-3-yl)carboxamide; SR-01000410412-1
DMWTVJH DT Small molecular drug
DMWTVJH PC 724200
DMWTVJH MW 293.3
DMWTVJH FM C18H15NO3
DMWTVJH IC InChI=1S/C18H15NO3/c1-2-12-7-9-14(10-8-12)19-17(20)15-11-13-5-3-4-6-16(13)22-18(15)21/h3-11H,2H2,1H3,(H,19,20)
DMWTVJH CS CCC1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMWTVJH IK CCRNXJJERVYHEO-UHFFFAOYSA-N
DMWTVJH IU N-(4-ethylphenyl)-2-oxochromene-3-carboxamide
DMWTVJH DE Discovery agent
DMIWNAY ID DMIWNAY
DMIWNAY DN N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMIWNAY HS Investigative
DMIWNAY SN CHEMBL1269648; N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine
DMIWNAY DT Small molecular drug
DMIWNAY PC 24759786
DMIWNAY MW 252.31
DMIWNAY FM C16H16N2O
DMIWNAY IC InChI=1S/C16H16N2O/c1-3-12-5-7-13(8-6-12)17-16-18-14-10-11(2)4-9-15(14)19-16/h4-10H,3H2,1-2H3,(H,17,18)
DMIWNAY CS CCC1=CC=C(C=C1)NC2=NC3=C(O2)C=CC(=C3)C
DMIWNAY IK NQAKLIGQCZLYKC-UHFFFAOYSA-N
DMIWNAY IU N-(4-ethylphenyl)-5-methyl-1,3-benzoxazol-2-amine
DMIWNAY DE Discovery agent
DMJ73T6 ID DMJ73T6
DMJ73T6 DN N-(4-Ethylphenyl)benzo[d]oxazol-2-amine
DMJ73T6 HS Investigative
DMJ73T6 SN CHEMBL1269619; N-(4-Ethylphenyl)benzo[d]oxazol-2-amine; SCHEMBL11966141; MolPort-009-215-967; BDBM50329392; ZINC32686273; N-(4-Ethylphenyl)benzoxazole-2-amine; AKOS034448323; MCULE-8409538696; SC-56930; N-(4-ethylphenyl)-1,3-benzoxazol-2-amine; BENZOOXAZOL-2-YL-(4-ETHYL-PHENYL)-AMINE; Z55890479
DMJ73T6 DT Small molecular drug
DMJ73T6 PC 39918957
DMJ73T6 MW 238.28
DMJ73T6 FM C15H14N2O
DMJ73T6 IC InChI=1S/C15H14N2O/c1-2-11-7-9-12(10-8-11)16-15-17-13-5-3-4-6-14(13)18-15/h3-10H,2H2,1H3,(H,16,17)
DMJ73T6 CS CCC1=CC=C(C=C1)NC2=NC3=CC=CC=C3O2
DMJ73T6 IK KKIDKWUGBUWNPR-UHFFFAOYSA-N
DMJ73T6 IU N-(4-ethylphenyl)-1,3-benzoxazol-2-amine
DMJ73T6 DE Discovery agent
DMKN8U6 ID DMKN8U6
DMKN8U6 DN N-(4-Ethylphenyl)-N'-hydroxyoctanediamide
DMKN8U6 HS Investigative
DMKN8U6 SN CHEMBL1093042; BDBM50314139
DMKN8U6 DT Small molecular drug
DMKN8U6 PC 45141954
DMKN8U6 MW 292.37
DMKN8U6 FM C16H24N2O3
DMKN8U6 IC InChI=1S/C16H24N2O3/c1-2-13-9-11-14(12-10-13)17-15(19)7-5-3-4-6-8-16(20)18-21/h9-12,21H,2-8H2,1H3,(H,17,19)(H,18,20)
DMKN8U6 CS CCC1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
DMKN8U6 IK OMRKYIIKVIYNKK-UHFFFAOYSA-N
DMKN8U6 IU N-(4-ethylphenyl)-N'-hydroxyoctanediamide
DMKN8U6 DE Discovery agent
DMP1ICB ID DMP1ICB
DMP1ICB DN N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide
DMP1ICB HS Investigative
DMP1ICB SN CHEMBL1091737; N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide
DMP1ICB DT Small molecular drug
DMP1ICB PC 46886448
DMP1ICB MW 356.4
DMP1ICB FM C23H17FN2O
DMP1ICB IC InChI=1S/C23H17FN2O/c24-21-9-5-17(6-10-21)16-26(22-11-13-25-14-12-22)23(27)20-8-7-18-3-1-2-4-19(18)15-20/h1-15H,16H2
DMP1ICB CS C1=CC=C2C=C(C=CC2=C1)C(=O)N(CC3=CC=C(C=C3)F)C4=CC=NC=C4
DMP1ICB IK MQJXOIDGELXEHE-UHFFFAOYSA-N
DMP1ICB IU N-[(4-fluorophenyl)methyl]-N-pyridin-4-ylnaphthalene-2-carboxamide
DMP1ICB DE Discovery agent
DM7O5WS ID DM7O5WS
DM7O5WS DN N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide
DM7O5WS HS Investigative
DM7O5WS SN CHEMBL434069; N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide; BDBM50054470; (5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoic acid 4-hydroxy-benzylamide
DM7O5WS DT Small molecular drug
DM7O5WS PC 10811495
DM7O5WS MW 409.6
DM7O5WS FM C27H39NO2
DM7O5WS IC InChI=1S/C27H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(30)28-24-25-20-22-26(29)23-21-25/h6-7,9-10,12-13,15-16,20-23,29H,2-5,8,11,14,17-19,24H2,1H3,(H,28,30)/b7-6-,10-9-,13-12-,16-15-
DM7O5WS CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCC1=CC=C(C=C1)O
DM7O5WS IK YSOGPKZWDUJRGP-DOFZRALJSA-N
DM7O5WS IU (5Z,8Z,11Z,14Z)-N-[(4-hydroxyphenyl)methyl]icosa-5,8,11,14-tetraenamide
DM7O5WS DE Discovery agent
DMC5H8G ID DMC5H8G
DMC5H8G DN N-(4-hydroxybiphenyl-3-yl)benzamide
DMC5H8G HS Investigative
DMC5H8G SN CHEMBL269935; N-(4-hydroxybiphenyl-3-yl)benzamide; SCHEMBL5724398; BDBM50232005
DMC5H8G DT Small molecular drug
DMC5H8G PC 44454650
DMC5H8G MW 289.3
DMC5H8G FM C19H15NO2
DMC5H8G IC InChI=1S/C19H15NO2/c21-18-12-11-16(14-7-3-1-4-8-14)13-17(18)20-19(22)15-9-5-2-6-10-15/h1-13,21H,(H,20,22)
DMC5H8G CS C1=CC=C(C=C1)C2=CC(=C(C=C2)O)NC(=O)C3=CC=CC=C3
DMC5H8G IK INXWGOLWSBWSOQ-UHFFFAOYSA-N
DMC5H8G IU N-(2-hydroxy-5-phenylphenyl)benzamide
DMC5H8G DE Discovery agent
DM4QR2C ID DM4QR2C
DM4QR2C DN N-(4-hydroxyphenylpropanyl)-spermine
DM4QR2C HS Investigative
DM4QR2C SN CHEMBL1096289; N-(4-hydroxyphenylpropanyl)-spermine
DM4QR2C DT Small molecular drug
DM4QR2C PC 46886661
DM4QR2C MW 334.5
DM4QR2C FM C19H34N4O
DM4QR2C IC InChI=1S/C19H34N4O/c20-12-6-15-21-13-4-5-14-22-16-7-17-23-19(24)11-10-18-8-2-1-3-9-18/h1-3,8-9,21-22H,4-7,10-17,20H2,(H,23,24)
DM4QR2C CS C1=CC=C(C=C1)CCC(=O)NCCCNCCCCNCCCN
DM4QR2C IK GLVZEIGFWZGDFV-UHFFFAOYSA-N
DM4QR2C IU N-[3-[4-(3-aminopropylamino)butylamino]propyl]-3-phenylpropanamide
DM4QR2C DE Discovery agent
DM6GFRP ID DM6GFRP
DM6GFRP DN N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide
DM6GFRP HS Investigative
DM6GFRP SN CHEMBL252013; N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide; AC1OW6PA
DM6GFRP DT Small molecular drug
DM6GFRP PC 7927254
DM6GFRP MW 407.13
DM6GFRP FM C14H9F3INO2
DM6GFRP IC InChI=1S/C14H9F3INO2/c15-14(16,17)21-12-7-1-9(2-8-12)13(20)19-11-5-3-10(18)4-6-11/h1-8H,(H,19,20)
DM6GFRP CS C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)I)OC(F)(F)F
DM6GFRP IK IUHUCVXLTXIWPU-UHFFFAOYSA-N
DM6GFRP IU N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide
DM6GFRP DE Discovery agent
DMK9FQG ID DMK9FQG
DMK9FQG DN N-(4-iodophenyl)-4-(trifluoromethyl)benzamide
DMK9FQG HS Investigative
DMK9FQG SN N-(4-iodophenyl)-4-(trifluoromethyl)benzamide; CHEMBL401308; AC1LKJKC; SCHEMBL7557294; MolPort-002-827-048; ZINC682493; BDBM50231097; AKOS008920216; MCULE-1341396811
DMK9FQG DT Small molecular drug
DMK9FQG PC 1019468
DMK9FQG MW 391.13
DMK9FQG FM C14H9F3INO
DMK9FQG IC InChI=1S/C14H9F3INO/c15-14(16,17)10-3-1-9(2-4-10)13(20)19-12-7-5-11(18)6-8-12/h1-8H,(H,19,20)
DMK9FQG CS C1=CC(=CC=C1C(=O)NC2=CC=C(C=C2)I)C(F)(F)F
DMK9FQG IK VTVLWVLMDYRPGZ-UHFFFAOYSA-N
DMK9FQG IU N-(4-iodophenyl)-4-(trifluoromethyl)benzamide
DMK9FQG DE Discovery agent
DMHANU5 ID DMHANU5
DMHANU5 DN N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea
DMHANU5 HS Investigative
DMHANU5 SN CHEMBL569724; BDBM50303601
DMHANU5 DT Small molecular drug
DMHANU5 PC 44626534
DMHANU5 MW 501.4
DMHANU5 FM C24H28IN3O
DMHANU5 IC InChI=1S/C24H28IN3O/c1-28-13-12-24-11-3-2-4-20(24)22(28)14-16-5-8-19(15-21(16)24)27-23(29)26-18-9-6-17(25)7-10-18/h5-10,15,20,22H,2-4,11-14H2,1H3,(H2,26,27,29)/t20-,22+,24+/m0/s1
DMHANU5 CS CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)NC(=O)NC5=CC=C(C=C5)I
DMHANU5 IK PNKGWKXKIPIROR-BGWNEDDSSA-N
DMHANU5 IU 1-(4-iodophenyl)-3-[(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-yl]urea
DMHANU5 DE Discovery agent
DM2N3TG ID DM2N3TG
DM2N3TG DN N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide
DM2N3TG HS Investigative
DM2N3TG SN CHEMBL1215730; BDBM50324614
DM2N3TG DT Small molecular drug
DM2N3TG PC 46901613
DM2N3TG MW 302.4
DM2N3TG FM C20H18N2O
DM2N3TG IC InChI=1S/C20H18N2O/c1-15(23)22-20-4-2-3-19(14-20)18-7-5-16(6-8-18)13-17-9-11-21-12-10-17/h2-12,14H,13H2,1H3,(H,22,23)
DM2N3TG CS CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)CC3=CC=NC=C3
DM2N3TG IK HURKLDLRCGKBKL-UHFFFAOYSA-N
DM2N3TG IU N-[3-[4-(pyridin-4-ylmethyl)phenyl]phenyl]acetamide
DM2N3TG DE Discovery agent
DM2MGSO ID DM2MGSO
DM2MGSO DN N-(4'-isopropyl-4-biphenylyl)urea
DM2MGSO HS Investigative
DM2MGSO SN CHEMBL397249; SCHEMBL5427819; BDBM50220192; ZINC28712010
DM2MGSO DT Small molecular drug
DM2MGSO PC 11630239
DM2MGSO MW 254.33
DM2MGSO FM C16H18N2O
DM2MGSO IC InChI=1S/C16H18N2O/c1-11(2)12-3-5-13(6-4-12)14-7-9-15(10-8-14)18-16(17)19/h3-11H,1-2H3,(H3,17,18,19)
DM2MGSO CS CC(C)C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)N
DM2MGSO IK COFIGWCWVNQCFO-UHFFFAOYSA-N
DM2MGSO IU [4-(4-propan-2-ylphenyl)phenyl]urea
DM2MGSO DE Discovery agent
DMHM3LC ID DMHM3LC
DMHM3LC DN N-(4-methoxybenzyl)oleamide
DMHM3LC HS Investigative
DMHM3LC SN N-(4-methoxybenzyl)oleamide; CHEMBL372530; SCHEMBL18255425
DMHM3LC DT Small molecular drug
DMHM3LC PC 11502240
DMHM3LC MW 401.6
DMHM3LC FM C26H43NO2
DMHM3LC IC InChI=1S/C26H43NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26(28)27-23-24-19-21-25(29-2)22-20-24/h10-11,19-22H,3-9,12-18,23H2,1-2H3,(H,27,28)/b11-10-
DMHM3LC CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCC1=CC=C(C=C1)OC
DMHM3LC IK AABDRJHZBVPFLI-KHPPLWFESA-N
DMHM3LC IU (Z)-N-[(4-methoxyphenyl)methyl]octadec-9-enamide
DMHM3LC DE Discovery agent
DM5NOSM ID DM5NOSM
DM5NOSM DN N-(4-methoxyphenethyl)oleamide
DM5NOSM HS Investigative
DM5NOSM SN N-(4-methoxyphenethyl)oleamide; CHEMBL199702; BDBM50175120; N-[2-(4-Methoxyphenyl)ethyl]oleic amide
DM5NOSM DT Small molecular drug
DM5NOSM PC 44406075
DM5NOSM MW 415.7
DM5NOSM FM C27H45NO2
DM5NOSM IC InChI=1S/C27H45NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27(29)28-24-23-25-19-21-26(30-2)22-20-25/h10-11,19-22H,3-9,12-18,23-24H2,1-2H3,(H,28,29)/b11-10-
DM5NOSM CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC=C(C=C1)OC
DM5NOSM IK LWJMRSYDIYWZOL-KHPPLWFESA-N
DM5NOSM IU (Z)-N-[2-(4-methoxyphenyl)ethyl]octadec-9-enamide
DM5NOSM DE Discovery agent
DMJVPK6 ID DMJVPK6
DMJVPK6 DN N-(4-methoxyphenyl)oleamide
DMJVPK6 HS Investigative
DMJVPK6 SN N-(4-methoxyphenyl)oleamide; CHEMBL199960; SCHEMBL20777965
DMJVPK6 DT Small molecular drug
DMJVPK6 PC 44406102
DMJVPK6 MW 387.6
DMJVPK6 FM C25H41NO2
DMJVPK6 IC InChI=1S/C25H41NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-25(27)26-23-19-21-24(28-2)22-20-23/h10-11,19-22H,3-9,12-18H2,1-2H3,(H,26,27)/b11-10-
DMJVPK6 CS CCCCCCCC/C=C\\CCCCCCCC(=O)NC1=CC=C(C=C1)OC
DMJVPK6 IK GVVBDSXGTXGHEV-KHPPLWFESA-N
DMJVPK6 IU (Z)-N-(4-methoxyphenyl)octadec-9-enamide
DMJVPK6 DE Discovery agent
DMO8L57 ID DMO8L57
DMO8L57 DN N-(4'-methyl-4-biphenylyl)urea
DMO8L57 HS Investigative
DMO8L57 SN CHEMBL244125; SCHEMBL5428805; N-(4''-methyl-4-biphenylyl)urea; ZINC28712009
DMO8L57 DT Small molecular drug
DMO8L57 PC 11593788
DMO8L57 MW 226.27
DMO8L57 FM C14H14N2O
DMO8L57 IC InChI=1S/C14H14N2O/c1-10-2-4-11(5-3-10)12-6-8-13(9-7-12)16-14(15)17/h2-9H,1H3,(H3,15,16,17)
DMO8L57 CS CC1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)N
DMO8L57 IK VXTBCYRTEKXSFH-UHFFFAOYSA-N
DMO8L57 IU [4-(4-methylphenyl)phenyl]urea
DMO8L57 DE Discovery agent
DMCZD37 ID DMCZD37
DMCZD37 DN N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine
DMCZD37 HS Investigative
DMCZD37 SN CHEMBL107354; SCHEMBL4629436; BDBM50107044
DMCZD37 DT Small molecular drug
DMCZD37 PC 22149251
DMCZD37 MW 281.35
DMCZD37 FM C17H19N3O
DMCZD37 IC InChI=1S/C17H19N3O/c1-13-7-9-15(10-8-13)16(21)20-17(18)19-12-11-14-5-3-2-4-6-14/h2-10H,11-12H2,1H3,(H3,18,19,20,21)
DMCZD37 CS CC1=CC=C(C=C1)C(=O)NC(=NCCC2=CC=CC=C2)N
DMCZD37 IK ZVURELUSYUBEQF-UHFFFAOYSA-N
DMCZD37 IU 4-methyl-N-[N'-(2-phenylethyl)carbamimidoyl]benzamide
DMCZD37 DE Discovery agent
DMZX2BH ID DMZX2BH
DMZX2BH DN N-(4-methyl-benzyl)-4-phenoxy-benzamide
DMZX2BH HS Investigative
DMZX2BH SN CHEMBL199174; N-(4-methyl-benzyl)-4-phenoxy-benzamide; AC1OVMY0; BDBM50174096
DMZX2BH DT Small molecular drug
DMZX2BH PC 7916852
DMZX2BH MW 317.4
DMZX2BH FM C21H19NO2
DMZX2BH IC InChI=1S/C21H19NO2/c1-16-7-9-17(10-8-16)15-22-21(23)18-11-13-20(14-12-18)24-19-5-3-2-4-6-19/h2-14H,15H2,1H3,(H,22,23)
DMZX2BH CS CC1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)OC3=CC=CC=C3
DMZX2BH IK ZMFAZMUZJXZNMY-UHFFFAOYSA-N
DMZX2BH IU N-[(4-methylphenyl)methyl]-4-phenoxybenzamide
DMZX2BH DE Discovery agent
DMXNMTD ID DMXNMTD
DMXNMTD DN N-(4'-methyl-piperazinyl) estradiol-16-carboxamide
DMXNMTD HS Investigative
DMXNMTD SN SCHEMBL12379484
DMXNMTD DT Small molecular drug
DMXNMTD PC 44407682
DMXNMTD MW 398.5
DMXNMTD FM C24H34N2O3
DMXNMTD IC InChI=1S/C24H34N2O3/c1-24-8-7-18-17-6-4-16(27)13-15(17)3-5-19(18)21(24)14-20(22(24)28)23(29)26-11-9-25(2)10-12-26/h4,6,13,18-22,27-28H,3,5,7-12,14H2,1-2H3/t18?,19?,20?,21?,22-,24-/m0/s1
DMXNMTD CS C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)N4CCN(CC4)C)CCC5=C3C=CC(=C5)O
DMXNMTD IK VNXBDWUNAYPTRF-OOBULCBASA-N
DMXNMTD IU [(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-(4-methylpiperazin-1-yl)methanone
DMXNMTD DE Discovery agent
DM03VXN ID DM03VXN
DM03VXN DN N-(4-methylthiazol-2-yl)-2-phenylacetamide
DM03VXN HS Investigative
DM03VXN SN N-(4-methylthiazol-2-yl)-2-phenylacetamide; 91392-19-7; N-(4-methyl-1,3-thiazol-2-yl)-2-phenylacetamide; AC1LIKML; CHEMBL388116; MolPort-000-563-422; ZINC563269; AKOS001315153; MCULE-5254964555; ST50771861; N-(4-methylthiazol-2-yl)-2-phenyl-acetamide; N-(4-methyl(1,3-thiazol-2-yl))-2-phenylacetamide
DM03VXN DT Small molecular drug
DM03VXN PC 956653
DM03VXN MW 232.3
DM03VXN FM C12H12N2OS
DM03VXN IC InChI=1S/C12H12N2OS/c1-9-8-16-12(13-9)14-11(15)7-10-5-3-2-4-6-10/h2-6,8H,7H2,1H3,(H,13,14,15)
DM03VXN CS CC1=CSC(=N1)NC(=O)CC2=CC=CC=C2
DM03VXN IK YUZOFWPNYHCMMW-UHFFFAOYSA-N
DM03VXN IU N-(4-methyl-1,3-thiazol-2-yl)-2-phenylacetamide
DM03VXN DE Discovery agent
DMTCA2Z ID DMTCA2Z
DMTCA2Z DN N-(4-methylthiazol-2-yl)benzamide
DMTCA2Z HS Investigative
DMTCA2Z SN N-(4-methylthiazol-2-yl)benzamide; N-(4-methyl-1,3-thiazol-2-yl)benzamide; 37529-67-2; N-(4-Methyl-thiazol-2-yl)-benzamide; CHEMBL209410; AC1LEZPY; BAS 00470405; Enamine_001521; TimTec1_007096; MLS001212480; SCHEMBL1270190; MolPort-000-432-004; HMS2828E18; HMS1554C12; HMS1398F03; ZINC5712475; BDBM50186335; AKOS000591433; AKOS002234121; MCULE-9983922498; DA-42608; SMR000514239; KB-109083; N-(4-Methylthiazol-2-yl)benzenecarboxamide; N-(4-methyl(1,3-thiazol-2-yl))benzamide; ST50002848; FT-0770347; EU-0040062; BB 0221669; SR-01000449566
DMTCA2Z DT Small molecular drug
DMTCA2Z PC 695178
DMTCA2Z MW 218.28
DMTCA2Z FM C11H10N2OS
DMTCA2Z IC InChI=1S/C11H10N2OS/c1-8-7-15-11(12-8)13-10(14)9-5-3-2-4-6-9/h2-7H,1H3,(H,12,13,14)
DMTCA2Z CS CC1=CSC(=N1)NC(=O)C2=CC=CC=C2
DMTCA2Z IK NEPIZAVYXKHUCD-UHFFFAOYSA-N
DMTCA2Z IU N-(4-methyl-1,3-thiazol-2-yl)benzamide
DMTCA2Z DE Discovery agent
DMGRFYV ID DMGRFYV
DMGRFYV DN N-(4-morpholinophenyl)docos-13-enamide
DMGRFYV HS Investigative
DMGRFYV SN CHEMBL199906; N-(4-morpholinophenyl)docos-13-enamide
DMGRFYV DT Small molecular drug
DMGRFYV PC 44406101
DMGRFYV MW 498.8
DMGRFYV FM C32H54N2O2
DMGRFYV IC InChI=1S/C32H54N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-32(35)33-30-22-24-31(25-23-30)34-26-28-36-29-27-34/h9-10,22-25H,2-8,11-21,26-29H2,1H3,(H,33,35)/b10-9-
DMGRFYV CS CCCCCCCC/C=C\\CCCCCCCCCCCC(=O)NC1=CC=C(C=C1)N2CCOCC2
DMGRFYV IK BNCLSGYMSOUADZ-KTKRTIGZSA-N
DMGRFYV IU (Z)-N-(4-morpholin-4-ylphenyl)docos-13-enamide
DMGRFYV DE Discovery agent
DMEBGF1 ID DMEBGF1
DMEBGF1 DN N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide
DMEBGF1 HS Investigative
DMEBGF1 SN CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244
DMEBGF1 DT Small molecular drug
DMEBGF1 PC 9995195
DMEBGF1 MW 304.3
DMEBGF1 FM C18H16N4O
DMEBGF1 IC InChI=1S/C18H16N4O/c1-3-17(23)21-14-7-8-16-15(10-14)18(20-11-19-16)22-13-6-4-5-12(2)9-13/h3-11H,1H2,2H3,(H,21,23)(H,19,20,22)
DMEBGF1 CS CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)NC(=O)C=C
DMEBGF1 IK AWQLTDUXGVCRBV-UHFFFAOYSA-N
DMEBGF1 IU N-[4-(3-methylanilino)quinazolin-6-yl]prop-2-enamide
DMEBGF1 DE Discovery agent
DMG6RTJ ID DMG6RTJ
DMG6RTJ DN N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide
DMG6RTJ HS Investigative
DMG6RTJ SN CHEMBL297968; N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide
DMG6RTJ DT Small molecular drug
DMG6RTJ PC 10494722
DMG6RTJ MW 304.3
DMG6RTJ FM C18H16N4O
DMG6RTJ IC InChI=1S/C18H16N4O/c1-3-17(23)21-14-7-8-15-16(10-14)19-11-20-18(15)22-13-6-4-5-12(2)9-13/h3-11H,1H2,2H3,(H,21,23)(H,19,20,22)
DMG6RTJ CS CC1=CC(=CC=C1)NC2=NC=NC3=C2C=CC(=C3)NC(=O)C=C
DMG6RTJ IK FAGJCAQBJKSOOS-UHFFFAOYSA-N
DMG6RTJ IU N-[4-(3-methylanilino)quinazolin-7-yl]prop-2-enamide
DMG6RTJ DE Discovery agent
DMUJS4Y ID DMUJS4Y
DMUJS4Y DN N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile
DMUJS4Y HS Investigative
DMUJS4Y SN phenylalanine derivative, 44; CHEMBL200235; BDBM20120
DMUJS4Y DT Small molecular drug
DMUJS4Y PC 11696652
DMUJS4Y MW 383.4
DMUJS4Y FM C24H21N3O2
DMUJS4Y IC InChI=1S/C24H21N3O2/c25-15-16-26-24(29)22(17-18-7-3-1-4-8-18)27-23(28)21-13-11-20(12-14-21)19-9-5-2-6-10-19/h1-14,22H,16-17H2,(H,26,29)(H,27,28)/t22-/m0/s1
DMUJS4Y CS C1=CC=C(C=C1)C[C@@H](C(=O)NCC#N)NC(=O)C2=CC=C(C=C2)C3=CC=CC=C3
DMUJS4Y IK DWFFMEGYLGKXHE-QFIPXVFZSA-N
DMUJS4Y IU N-[(2S)-1-(cyanomethylamino)-1-oxo-3-phenylpropan-2-yl]-4-phenylbenzamide
DMUJS4Y DE Discovery agent
DMTCMUG ID DMTCMUG
DMTCMUG DN N-(4-Phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG HS Investigative
DMTCMUG SN CHEMBL459543; N-(4-Phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG DT Small molecular drug
DMTCMUG PC 44588136
DMTCMUG MW 292.4
DMTCMUG FM C19H20N2O
DMTCMUG IC InChI=1S/C19H20N2O/c22-19(18-14-16-11-4-5-12-17(16)21-18)20-13-7-6-10-15-8-2-1-3-9-15/h1-5,8-9,11-12,14,21H,6-7,10,13H2,(H,20,22)
DMTCMUG CS C1=CC=C(C=C1)CCCCNC(=O)C2=CC3=CC=CC=C3N2
DMTCMUG IK LYMIBNDEHCKPTI-UHFFFAOYSA-N
DMTCMUG IU N-(4-phenylbutyl)-1H-indole-2-carboxamide
DMTCMUG CA CAS 1084920-00-2
DMTCMUG DE Discovery agent
DMSREW5 ID DMSREW5
DMSREW5 DN N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
DMSREW5 HS Investigative
DMSREW5 SN pyrrole inhibitor 15; N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide; CHEMBL220677
DMSREW5 DT Small molecular drug
DMSREW5 PC 16110290
DMSREW5 MW 242.32
DMSREW5 FM C15H18N2O
DMSREW5 IC InChI=1S/C15H18N2O/c18-15(14-10-6-12-16-14)17-11-5-4-9-13-7-2-1-3-8-13/h1-3,6-8,10,12,16H,4-5,9,11H2,(H,17,18)
DMSREW5 CS C1=CC=C(C=C1)CCCCNC(=O)C2=CC=CN2
DMSREW5 IK KBYBNLUYYDZWAT-UHFFFAOYSA-N
DMSREW5 IU N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
DMSREW5 DE Discovery agent
DMYD4PC ID DMYD4PC
DMYD4PC DN N-(4-Phenyl-pyridin-2-yl)-guanidine
DMYD4PC HS Investigative
DMYD4PC SN CHEMBL54467; N-(4-Phenyl-pyridin-2-yl)-guanidine; Guanidine, N-(4-phenyl-2-pyridinyl)-; 2-(4-Phenyl-2-pyridinyl)guanidine; BDBM50108355
DMYD4PC DT Small molecular drug
DMYD4PC PC 10219978
DMYD4PC MW 212.25
DMYD4PC FM C12H12N4
DMYD4PC IC InChI=1S/C12H12N4/c13-12(14)16-11-8-10(6-7-15-11)9-4-2-1-3-5-9/h1-8H,(H4,13,14,15,16)
DMYD4PC CS C1=CC=C(C=C1)C2=CC(=NC=C2)N=C(N)N
DMYD4PC IK LQYVUDQYWIIZAV-UHFFFAOYSA-N
DMYD4PC IU 2-(4-phenylpyridin-2-yl)guanidine
DMYD4PC DE Discovery agent
DMQS9OH ID DMQS9OH
DMQS9OH DN N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide
DMQS9OH HS Investigative
DMQS9OH SN CHEMBL222110; N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide; SCHEMBL1337989
DMQS9OH DT Small molecular drug
DMQS9OH PC 11774008
DMQS9OH MW 402.5
DMQS9OH FM C23H18N2O3S
DMQS9OH IC InChI=1S/C23H18N2O3S/c26-23(17-9-3-1-4-10-17)24-21-15-16-22(20-14-8-7-13-19(20)21)29(27,28)25-18-11-5-2-6-12-18/h1-16,25H,(H,24,26)
DMQS9OH CS C1=CC=C(C=C1)C(=O)NC2=CC=C(C3=CC=CC=C32)S(=O)(=O)NC4=CC=CC=C4
DMQS9OH IK WLKYPFNFQJMVGH-UHFFFAOYSA-N
DMQS9OH IU N-[4-(phenylsulfamoyl)naphthalen-1-yl]benzamide
DMQS9OH DE Discovery agent
DMPA91F ID DMPA91F
DMPA91F DN N-(4-Phenyl-thiazol-2-yl)-benzamide
DMPA91F HS Investigative
DMPA91F SN CHEMBL60334; N-(4-phenyl-1,3-thiazol-2-yl)benzamide; N-(4-Phenyl-thiazol-2-yl)-benzamide; 14269-45-5; N-(4-phenylthiazol-2-yl)benzamide; Enamine_004302; AC1LF3YD; AC1Q5LQ8; Cambridge id 5149845; Oprea1_016303; Oprea1_462006; Oprea1_007140; CBDivE_004384; SCHEMBL1270375; SCHEMBL18874193; CTK0F0159; DTXSID10353610; MolPort-000-432-183; HMS1406D12; 2-(Benzoylamino)-4-phenylthiazole; ZINC18022084; BDBM50101790; STK972349; STK337540; AKOS002233837; AKOS000478692; MCULE-8414212509; Benzamide, N-(4-phenyl-2-thiazolyl)-; NCGC00262409-01; BAS 0
DMPA91F DT Small molecular drug
DMPA91F PC 746475
DMPA91F MW 280.3
DMPA91F FM C16H12N2OS
DMPA91F IC InChI=1S/C16H12N2OS/c19-15(13-9-5-2-6-10-13)18-16-17-14(11-20-16)12-7-3-1-4-8-12/h1-11H,(H,17,18,19)
DMPA91F CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=CC=C3
DMPA91F IK NIRMZOKDACPPER-UHFFFAOYSA-N
DMPA91F IU N-(4-phenyl-1,3-thiazol-2-yl)benzamide
DMPA91F CA CAS 14269-45-5
DMPA91F DE Discovery agent
DM2OHVJ ID DM2OHVJ
DM2OHVJ DN N-(4-Phenylthiazol-2-yl)isonicotinamide
DM2OHVJ HS Investigative
DM2OHVJ SN N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide; CHEMBL482012; 5245-66-9; N-(4-Phenylthiazol-2-yl)isonicotinamide; BAS 03572091; AC1Q5OBS; AC1LG7OX; CBMicro_015073; n-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Cambridge id 5245669; Oprea1_303023; Oprea1_553111; SCHEMBL17107144; CTK4J5937; DTXSID30355050; MolPort-001-992-732; ZINC290573; STK483947; BDBM50255300; AKOS000569765; MCULE-9247268363; BIM-0015234.P001; N-(4-Phenyl-thiazol-2-yl)-isonicotinamide; ST50017829; N~4~-(4-phenyl-1,3-thiazol-2-yl)isonicotinamide; Z27772062
DM2OHVJ DT Small molecular drug
DM2OHVJ PC 790259
DM2OHVJ MW 281.3
DM2OHVJ FM C15H11N3OS
DM2OHVJ IC InChI=1S/C15H11N3OS/c19-14(12-6-8-16-9-7-12)18-15-17-13(10-20-15)11-4-2-1-3-5-11/h1-10H,(H,17,18,19)
DM2OHVJ CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)C3=CC=NC=C3
DM2OHVJ IK PUUUVNHZQJNJSV-UHFFFAOYSA-N
DM2OHVJ IU N-(4-phenyl-1,3-thiazol-2-yl)pyridine-4-carboxamide
DM2OHVJ CA CAS 5245-66-9
DM2OHVJ DE Discovery agent
DMG9D7A ID DMG9D7A
DMG9D7A DN N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A HS Investigative
DMG9D7A SN CHEMBL444128; N-(4-Propylaminobutyl)-4-biphenylcarboxamide
DMG9D7A DT Small molecular drug
DMG9D7A PC 25139331
DMG9D7A MW 310.4
DMG9D7A FM C20H26N2O
DMG9D7A IC InChI=1S/C20H26N2O/c1-2-14-21-15-6-7-16-22-20(23)19-12-10-18(11-13-19)17-8-4-3-5-9-17/h3-5,8-13,21H,2,6-7,14-16H2,1H3,(H,22,23)
DMG9D7A CS CCCNCCCCNC(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DMG9D7A IK QAAKBUYWNXINKR-UHFFFAOYSA-N
DMG9D7A IU 4-phenyl-N-[4-(propylamino)butyl]benzamide
DMG9D7A DE Discovery agent
DMHBWM9 ID DMHBWM9
DMHBWM9 DN N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide
DMHBWM9 HS Investigative
DMHBWM9 SN CHEMBL164087; N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide; AC1N3WC4; N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide; Oprea1_401409; MolPort-004-132-922; BDBM50097430; AKOS017070888; N-[4-(2-pyridyl)thiazol-2-yl]benzamide
DMHBWM9 DT Small molecular drug
DMHBWM9 PC 4119262
DMHBWM9 MW 281.3
DMHBWM9 FM C15H11N3OS
DMHBWM9 IC InChI=1S/C15H11N3OS/c19-14(11-6-2-1-3-7-11)18-15-17-13(10-20-15)12-8-4-5-9-16-12/h1-10H,(H,17,18,19)
DMHBWM9 CS C1=CC=C(C=C1)C(=O)NC2=NC(=CS2)C3=CC=CC=N3
DMHBWM9 IK NNBHDRDMPNNEKO-UHFFFAOYSA-N
DMHBWM9 IU N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide
DMHBWM9 DE Discovery agent
DMOMYDV ID DMOMYDV
DMOMYDV DN N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
DMOMYDV HS Investigative
DMOMYDV SN N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide; N-(4-Sulphamoylphenyl)-1H-indazole-3-carboxamide; 660822-60-6; 2vti; indazole amide, 14; CHEMBL455946; SCHEMBL4524087; BDBM24635; MNHPHKFLWAPNOV-UHFFFAOYSA-N; ZINC15270554; DB08133; DA-41761; FT-0707176; 1H-Indazole-3-carboxylic acid (4-sulphamoyl-phenyl)-amide
DMOMYDV DT Small molecular drug
DMOMYDV PC 9926933
DMOMYDV MW 316.34
DMOMYDV FM C14H12N4O3S
DMOMYDV IC InChI=1S/C14H12N4O3S/c15-22(20,21)10-7-5-9(6-8-10)16-14(19)13-11-3-1-2-4-12(11)17-18-13/h1-8H,(H,16,19)(H,17,18)(H2,15,20,21)
DMOMYDV CS C1=CC=C2C(=C1)C(=NN2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)N
DMOMYDV IK MNHPHKFLWAPNOV-UHFFFAOYSA-N
DMOMYDV IU N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
DMOMYDV DE Discovery agent
DMZDACT ID DMZDACT
DMZDACT DN N-(4-Sulfamoyl-phenyl)-benzamide
DMZDACT HS Investigative
DMZDACT SN N-(4-sulfamoylphenyl)benzamide; CHEMBL23559; 4389-07-5; N-(4-Sulfamoyl-phenyl)-benzamide; AC1LF2IT; Cambridge id 5227171; Oprea1_273437; CBDivE_015411; ARONIS016836; SCHEMBL8422583; aromatic sulfonamide compound 17; BDBM16652; 4-Benzoylamino-benzenesulfonamide; VGYAUYNBRQPION-UHFFFAOYSA-N; MolPort-000-656-907; ZINC125245; KS-000049EF; p-(N-benzoylamino)benzenesulfonamide; STK056377; N-[4-(aminosulfonyl)phenyl]benzamide; AKOS000484672; MCULE-6142099718; phenyl-N-(4-sulfamoylphenyl)carboxamide
DMZDACT DT Small molecular drug
DMZDACT PC 721954
DMZDACT MW 276.31
DMZDACT FM C13H12N2O3S
DMZDACT IC InChI=1S/C13H12N2O3S/c14-19(17,18)12-8-6-11(7-9-12)15-13(16)10-4-2-1-3-5-10/h1-9H,(H,15,16)(H2,14,17,18)
DMZDACT CS C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)N
DMZDACT IK VGYAUYNBRQPION-UHFFFAOYSA-N
DMZDACT IU N-(4-sulfamoylphenyl)benzamide
DMZDACT DE Discovery agent
DM3FW9Q ID DM3FW9Q
DM3FW9Q DN N-(4-Sulfamoyl-phenyl)-butyramide
DM3FW9Q HS Investigative
DM3FW9Q SN N-(4-sulfamoylphenyl)butanamide; CHEMBL23591; AC1MQZRR; Butanamide, N-[4-(aminosulfonyl)phenyl]-; SCHEMBL6254979; aromatic sulfonamide compound 11; BDBM16646; 4-n-Butanamido-benzenesulfonamide; ZINC6039278; AKOS003870402
DM3FW9Q DT Small molecular drug
DM3FW9Q PC 3510137
DM3FW9Q MW 242.3
DM3FW9Q FM C10H14N2O3S
DM3FW9Q IC InChI=1S/C10H14N2O3S/c1-2-3-10(13)12-8-4-6-9(7-5-8)16(11,14)15/h4-7H,2-3H2,1H3,(H,12,13)(H2,11,14,15)
DM3FW9Q CS CCCC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DM3FW9Q IK ZQNHPPBUHNMQIO-UHFFFAOYSA-N
DM3FW9Q IU N-(4-sulfamoylphenyl)butanamide
DM3FW9Q DE Discovery agent
DMJCXYQ ID DMJCXYQ
DMJCXYQ DN N-(4-Sulfamoyl-phenyl)-isobutyramide
DMJCXYQ HS Investigative
DMJCXYQ SN 2-methyl-N-(4-sulfamoylphenyl)propanamide; Propanamide, N-[4-(aminosulfonyl)phenyl]-2-methyl-; 114841-20-2; CHEMBL23417; ACMC-20mkv1; AC1MM1G7; SCHEMBL13391029; CTK0G0891; BDBM16647; aromatic sulfonamide compound 12; DTXSID70390682; 4-Isobutanamido-benzenesulfonamide; MolPort-006-401-341; ZINC5384022; AKOS003848097; MCULE-4244298519; N-[4-(Aminosulfonyl)phenyl]-2-methylpropanamide, AldrichCPR
DMJCXYQ DT Small molecular drug
DMJCXYQ PC 3253857
DMJCXYQ MW 242.3
DMJCXYQ FM C10H14N2O3S
DMJCXYQ IC InChI=1S/C10H14N2O3S/c1-7(2)10(13)12-8-3-5-9(6-4-8)16(11,14)15/h3-7H,1-2H3,(H,12,13)(H2,11,14,15)
DMJCXYQ CS CC(C)C(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DMJCXYQ IK VVHPZBGPXIXCQI-UHFFFAOYSA-N
DMJCXYQ IU 2-methyl-N-(4-sulfamoylphenyl)propanamide
DMJCXYQ CA CAS 114841-20-2
DMJCXYQ DE Discovery agent
DM7MHQD ID DM7MHQD
DM7MHQD DN N-(4-Sulfamoyl-phenyl)-propionamide
DM7MHQD HS Investigative
DM7MHQD SN N-(4-sulfamoylphenyl)propanamide; 4-propionamidobenzenesulfonamide; CHEMBL278395; 4708-37-6; AC1LI2CK; SCHEMBL13263684; aromatic sulfonamide compound 10; 4-Propionamido-benzenesulfonamide; BDBM16645; MolPort-001-490-167; ZINC381801; AKOS003252339; N-[4-(aminosulfonyl)phenyl]propanamide; MCULE-9928658311; ST45021659; AO-080/11989809
DM7MHQD DT Small molecular drug
DM7MHQD PC 847760
DM7MHQD MW 228.27
DM7MHQD FM C9H12N2O3S
DM7MHQD IC InChI=1S/C9H12N2O3S/c1-2-9(12)11-7-3-5-8(6-4-7)15(10,13)14/h3-6H,2H2,1H3,(H,11,12)(H2,10,13,14)
DM7MHQD CS CCC(=O)NC1=CC=C(C=C1)S(=O)(=O)N
DM7MHQD IK KEFCIQSZJXXOLO-UHFFFAOYSA-N
DM7MHQD IU N-(4-sulfamoylphenyl)propanamide
DM7MHQD DE Discovery agent
DM7QX03 ID DM7QX03
DM7QX03 DN N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide
DM7QX03 HS Investigative
DM7QX03 SN CHEMBL51668; Benzamide, 4-(aminosulfonyl)-N-[2-[4-(aminosulfonyl)phenyl]ethyl]-; 361438-75-7; 4-sulfamoyl-N-[2-(4-sulfamoylphenyl)ethyl]benzamide; CTK1B0192; BDBM11635; DTXSID30439107; AKOS001421782
DM7QX03 DT Small molecular drug
DM7QX03 PC 10385283
DM7QX03 MW 383.4
DM7QX03 FM C15H17N3O5S2
DM7QX03 IC InChI=1S/C15H17N3O5S2/c16-24(20,21)13-5-1-11(2-6-13)9-10-18-15(19)12-3-7-14(8-4-12)25(17,22)23/h1-8H,9-10H2,(H,18,19)(H2,16,20,21)(H2,17,22,23)
DM7QX03 CS C1=CC(=CC=C1CCNC(=O)C2=CC=C(C=C2)S(=O)(=O)N)S(=O)(=O)N
DM7QX03 IK DTWPVNTYGDBHCV-UHFFFAOYSA-N
DM7QX03 IU 4-sulfamoyl-N-[2-(4-sulfamoylphenyl)ethyl]benzamide
DM7QX03 CA CAS 361438-75-7
DM7QX03 DE Discovery agent
DMHX4F2 ID DMHX4F2
DMHX4F2 DN N-(4'-t-butyl-4-biphenylyl)urea
DMHX4F2 HS Investigative
DMHX4F2 SN CHEMBL244126; SCHEMBL5425660; N-(4''-t-butyl-4-biphenylyl)urea; BDBM50220188
DMHX4F2 DT Small molecular drug
DMHX4F2 PC 11659042
DMHX4F2 MW 268.35
DMHX4F2 FM C17H20N2O
DMHX4F2 IC InChI=1S/C17H20N2O/c1-17(2,3)14-8-4-12(5-9-14)13-6-10-15(11-7-13)19-16(18)20/h4-11H,1-3H3,(H3,18,19,20)
DMHX4F2 CS CC(C)(C)C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)N
DMHX4F2 IK CQQWFWURFCAFPP-UHFFFAOYSA-N
DMHX4F2 IU [4-(4-tert-butylphenyl)phenyl]urea
DMHX4F2 DE Discovery agent
DMN6DAZ ID DMN6DAZ
DMN6DAZ DN N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide
DMN6DAZ HS Investigative
DMN6DAZ SN CHEMBL183121; N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide; SCHEMBL3873012; JWPYMHAYISNKIC-UHFFFAOYSA-N; BDBM50160036; N-(4-tert-butylphenyl)-4-(2-pyridinyl)benzamide
DMN6DAZ DT Small molecular drug
DMN6DAZ PC 11472986
DMN6DAZ MW 330.4
DMN6DAZ FM C22H22N2O
DMN6DAZ IC InChI=1S/C22H22N2O/c1-22(2,3)18-11-13-19(14-12-18)24-21(25)17-9-7-16(8-10-17)20-6-4-5-15-23-20/h4-15H,1-3H3,(H,24,25)
DMN6DAZ CS CC(C)(C)C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)C3=CC=CC=N3
DMN6DAZ IK JWPYMHAYISNKIC-UHFFFAOYSA-N
DMN6DAZ IU N-(4-tert-butylphenyl)-4-pyridin-2-ylbenzamide
DMN6DAZ DE Discovery agent
DMFUBQ8 ID DMFUBQ8
DMFUBQ8 DN N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine
DMFUBQ8 HS Investigative
DMFUBQ8 SN CHEMBL207479; N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine; SCHEMBL5966378
DMFUBQ8 DT Small molecular drug
DMFUBQ8 PC 21866574
DMFUBQ8 MW 271.4
DMFUBQ8 FM C15H17N3S
DMFUBQ8 IC InChI=1S/C15H17N3S/c1-15(2,3)13-9-19-14(18-13)17-12-6-4-5-11-10(12)7-8-16-11/h4-9,16H,1-3H3,(H,17,18)
DMFUBQ8 CS CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=C2C=CN3
DMFUBQ8 IK ITGYBDHDFLFUCN-UHFFFAOYSA-N
DMFUBQ8 IU 4-tert-butyl-N-(1H-indol-4-yl)-1,3-thiazol-2-amine
DMFUBQ8 DE Discovery agent
DMMUX86 ID DMMUX86
DMMUX86 DN N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine
DMMUX86 HS Investigative
DMMUX86 SN CHEMBL378272; N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine
DMMUX86 DT Small molecular drug
DMMUX86 PC 44411492
DMMUX86 MW 283.4
DMMUX86 FM C16H17N3S
DMMUX86 IC InChI=1S/C16H17N3S/c1-16(2,3)14-10-20-15(19-14)18-13-6-4-5-11-9-17-8-7-12(11)13/h4-10H,1-3H3,(H,18,19)
DMMUX86 CS CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=C2C=CN=C3
DMMUX86 IK JVTUKUHMGYMFFT-UHFFFAOYSA-N
DMMUX86 IU 4-tert-butyl-N-isoquinolin-5-yl-1,3-thiazol-2-amine
DMMUX86 DE Discovery agent
DMBMAKG ID DMBMAKG
DMBMAKG DN N-(4-tert-butylthiazol-2-yl)quinolin-5-amine
DMBMAKG HS Investigative
DMBMAKG SN CHEMBL207857; N-(4-tert-butylthiazol-2-yl)quinolin-5-amine; SCHEMBL14433246
DMBMAKG DT Small molecular drug
DMBMAKG PC 9900444
DMBMAKG MW 283.4
DMBMAKG FM C16H17N3S
DMBMAKG IC InChI=1S/C16H17N3S/c1-16(2,3)14-10-20-15(19-14)18-13-8-4-7-12-11(13)6-5-9-17-12/h4-10H,1-3H3,(H,18,19)
DMBMAKG CS CC(C)(C)C1=CSC(=N1)NC2=CC=CC3=C2C=CC=N3
DMBMAKG IK RGBQNFYMCAUMHK-UHFFFAOYSA-N
DMBMAKG IU 4-tert-butyl-N-quinolin-5-yl-1,3-thiazol-2-amine
DMBMAKG DE Discovery agent
DMEW3L0 ID DMEW3L0
DMEW3L0 DN N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
DMEW3L0 HS Investigative
DMEW3L0 SN (5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid; N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE; 701223-63-4; DFW; 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]acetic acid; 2-({5,6-diphenylfuro[2,3-d]pyrimidin-4-yl}amino)acetic acid; 2brh; CBKinase1_018018; furanopyrimidine compound 4; CBKinase1_005618; AC1LI48C; SCHEMBL6748456; CHEMBL363302; BDBM14802; MolPort-002-125-656; ZINC383023; AKOS015957210; MCULE-9828982030; DB07653; L-3296; SR-01000273355; SR-01000273355-1; BRD-K42410867-001-01-6; F1684-0511
DMEW3L0 DT Small molecular drug
DMEW3L0 PC 848641
DMEW3L0 MW 345.4
DMEW3L0 FM C20H15N3O3
DMEW3L0 IC InChI=1S/C20H15N3O3/c24-15(25)11-21-19-17-16(13-7-3-1-4-8-13)18(14-9-5-2-6-10-14)26-20(17)23-12-22-19/h1-10,12H,11H2,(H,24,25)(H,21,22,23)
DMEW3L0 CS C1=CC=C(C=C1)C2=C(OC3=NC=NC(=C23)NCC(=O)O)C4=CC=CC=C4
DMEW3L0 IK VXTCEUDVOCLEJG-UHFFFAOYSA-N
DMEW3L0 IU 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]acetic acid
DMEW3L0 DE Discovery agent
DM47XR8 ID DM47XR8
DM47XR8 DN N-(5-Amino-6-oxo-heptyl)-acetamidine
DM47XR8 HS Investigative
DM47XR8 DT Small molecular drug
DM47XR8 PC 44393463
DM47XR8 MW 185.27
DM47XR8 FM C9H19N3O
DM47XR8 IC InChI=1S/C9H19N3O/c1-7(13)9(11)5-3-4-6-12-8(2)10/h9H,3-6,11H2,1-2H3,(H2,10,12)
DM47XR8 CS CC(=O)C(CCCCN=C(C)N)N
DM47XR8 IK ADHBRNMPDLVKQT-UHFFFAOYSA-N
DM47XR8 IU N'-(5-amino-6-oxoheptyl)ethanimidamide
DM47XR8 DE Discovery agent
DMTF8US ID DMTF8US
DMTF8US DN N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide
DMTF8US HS Investigative
DMTF8US SN N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)benzamide; CHEMBL600232; N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide; 305851-70-1; AC1LJXJU; Oprea1_574683; MolPort-000-184-059; ZINC626960; BDBM50308494; AKOS001011200; MCULE-6547152460; AB00666822-01; AQ-360/10877054
DMTF8US DT Small molecular drug
DMTF8US PC 981611
DMTF8US MW 384.5
DMTF8US FM C23H16N2O2S
DMTF8US IC InChI=1S/C23H16N2O2S/c26-20(17-12-6-2-7-13-17)21-19(16-10-4-1-5-11-16)24-23(28-21)25-22(27)18-14-8-3-9-15-18/h1-15H,(H,24,25,27)
DMTF8US CS C1=CC=C(C=C1)C2=C(SC(=N2)NC(=O)C3=CC=CC=C3)C(=O)C4=CC=CC=C4
DMTF8US IK PCQHQQZQXRSVDE-UHFFFAOYSA-N
DMTF8US IU N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)benzamide
DMTF8US DE Discovery agent
DMGAITY ID DMGAITY
DMGAITY DN N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine
DMGAITY HS Investigative
DMGAITY SN CHEMBL325094; N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine; SCHEMBL6998909; KMGPZVZUHUMNQX-UHFFFAOYSA-N; BDBM50147411
DMGAITY DT Small molecular drug
DMGAITY PC 21192457
DMGAITY MW 292.33
DMGAITY FM C17H16N4O
DMGAITY IC InChI=1S/C17H16N4O/c18-17(19)21-16-14-7-4-8-15(13(14)9-10-20-16)22-11-12-5-2-1-3-6-12/h1-10H,11H2,(H4,18,19,20,21)
DMGAITY CS C1=CC=C(C=C1)COC2=CC=CC3=C2C=CN=C3N=C(N)N
DMGAITY IK KMGPZVZUHUMNQX-UHFFFAOYSA-N
DMGAITY IU 2-(5-phenylmethoxyisoquinolin-1-yl)guanidine
DMGAITY DE Discovery agent
DMD5E8G ID DMD5E8G
DMD5E8G DN N-(5-Bromo-quinoxalin-6-yl)-guanidine
DMD5E8G HS Investigative
DMD5E8G SN CHEMBL883; 168329-48-4; BDBM50213216; AKOS027322398; Guanidine, N-(5-bromo-6-quinoxalinyl)-; (5-Bromo-6-quinoxalinyl)guanidine Hydrochloride
DMD5E8G DT Small molecular drug
DMD5E8G PC 14928441
DMD5E8G MW 266.1
DMD5E8G FM C9H8BrN5
DMD5E8G IC InChI=1S/C9H8BrN5/c10-7-5(15-9(11)12)1-2-6-8(7)14-4-3-13-6/h1-4H,(H4,11,12,15)
DMD5E8G CS C1=CC2=NC=CN=C2C(=C1N=C(N)N)Br
DMD5E8G IK WBGSURPVIDDDHF-UHFFFAOYSA-N
DMD5E8G IU 2-(5-bromoquinoxalin-6-yl)guanidine
DMD5E8G DE Discovery agent
DMHZ256 ID DMHZ256
DMHZ256 DN N-(5-chloro-2-(phenylthio)phenyl)butyramide
DMHZ256 HS Investigative
DMHZ256 SN CHEMBL371088; N-(5-chloro-2-(phenylthio)phenyl)butyramide
DMHZ256 DT Small molecular drug
DMHZ256 PC 11507784
DMHZ256 MW 305.8
DMHZ256 FM C16H16ClNOS
DMHZ256 IC InChI=1S/C16H16ClNOS/c1-2-6-16(19)18-14-11-12(17)9-10-15(14)20-13-7-4-3-5-8-13/h3-5,7-11H,2,6H2,1H3,(H,18,19)
DMHZ256 CS CCCC(=O)NC1=C(C=CC(=C1)Cl)SC2=CC=CC=C2
DMHZ256 IK XBVVQFDKYKYIDI-UHFFFAOYSA-N
DMHZ256 IU N-(5-chloro-2-phenylsulfanylphenyl)butanamide
DMHZ256 DE Discovery agent
DM2TFJE ID DM2TFJE
DM2TFJE DN N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide
DM2TFJE HS Investigative
DM2TFJE SN CHEMBL207096; N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide
DM2TFJE DT Small molecular drug
DM2TFJE PC 44410037
DM2TFJE MW 308.74
DM2TFJE FM C13H9ClN2O3S
DM2TFJE IC InChI=1S/C13H9ClN2O3S/c14-9-6-7-12-11(8-9)15-13(19-12)16-20(17,18)10-4-2-1-3-5-10/h1-8H,(H,15,16)
DM2TFJE CS C1=CC=C(C=C1)S(=O)(=O)NC2=NC3=C(O2)C=CC(=C3)Cl
DM2TFJE IK AGIHDQSDUKQVDK-UHFFFAOYSA-N
DM2TFJE IU N-(5-chloro-1,3-benzoxazol-2-yl)benzenesulfonamide
DM2TFJE DE Discovery agent
DM9JCD3 ID DM9JCD3
DM9JCD3 DN N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
DM9JCD3 HS Investigative
DM9JCD3 SN N-(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)BENZAMIDE; CHEMBL324942; N-(3-cyclopropyl-1H-pyrazol-5-yl)benzamide; N5B; 1vyz; AC1L9MPJ; SCHEMBL4314346; BDBM7127; LUCORKWTQSQFFU-UHFFFAOYSA-N; 3-Benzamidoaminopyrazole deriv. 4; DB02647
DM9JCD3 DT Small molecular drug
DM9JCD3 PC 449088
DM9JCD3 MW 227.26
DM9JCD3 FM C13H13N3O
DM9JCD3 IC InChI=1S/C13H13N3O/c17-13(10-4-2-1-3-5-10)14-12-8-11(15-16-12)9-6-7-9/h1-5,8-9H,6-7H2,(H2,14,15,16,17)
DM9JCD3 CS C1CC1C2=CC(=NN2)NC(=O)C3=CC=CC=C3
DM9JCD3 IK LUCORKWTQSQFFU-UHFFFAOYSA-N
DM9JCD3 IU N-(5-cyclopropyl-1H-pyrazol-3-yl)benzamide
DM9JCD3 DE Discovery agent
DMNQDLC ID DMNQDLC
DMNQDLC DN N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide
DMNQDLC HS Investigative
DMNQDLC SN CHEMBL500977; 30457-35-3; N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide; CTK8I1084; ZINC39121736; BDBM50256510; AKOS027393952; KB-299693; N-(5-ethyl-1,3,4-thiadiazol-2-yl)aminosulfonamide; N-(5-Ethyl-1,3,4-thiadiazol-2-yl)sulfuric diamide
DMNQDLC DT Small molecular drug
DMNQDLC PC 25154730
DMNQDLC MW 208.3
DMNQDLC FM C4H8N4O2S2
DMNQDLC IC InChI=1S/C4H8N4O2S2/c1-2-3-6-7-4(11-3)8-12(5,9)10/h2H2,1H3,(H,7,8)(H2,5,9,10)
DMNQDLC CS CCC1=NN=C(S1)NS(=O)(=O)N
DMNQDLC IK HVRGNGCSIVHKLU-UHFFFAOYSA-N
DMNQDLC IU 2-ethyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMNQDLC DE Discovery agent
DMUHKYW ID DMUHKYW
DMUHKYW DN N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide
DMUHKYW HS Investigative
DMUHKYW SN CHEMBL143802; N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide; SCHEMBL1233091; BDBM50082663; ZINC13801951; 6-[(4-Methoxybenzoyl)amino]hexanehydroxamic acid
DMUHKYW DT Small molecular drug
DMUHKYW PC 9835402
DMUHKYW MW 280.32
DMUHKYW FM C14H20N2O4
DMUHKYW IC InChI=1S/C14H20N2O4/c1-20-12-8-6-11(7-9-12)14(18)15-10-4-2-3-5-13(17)16-19/h6-9,19H,2-5,10H2,1H3,(H,15,18)(H,16,17)
DMUHKYW CS COC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NO
DMUHKYW IK ZSXRABTZDFXDGV-UHFFFAOYSA-N
DMUHKYW IU N-[6-(hydroxyamino)-6-oxohexyl]-4-methoxybenzamide
DMUHKYW DE Discovery agent
DMSUW7M ID DMSUW7M
DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide
DMSUW7M HS Investigative
DMSUW7M SN CHEMBL139999; N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide; SCHEMBL1232700; BDBM50082661; ZINC13472309
DMSUW7M DT Small molecular drug
DMSUW7M PC 9943996
DMSUW7M MW 295.29
DMSUW7M FM C13H17N3O5
DMSUW7M IC InChI=1S/C13H17N3O5/c17-12(15-19)4-2-1-3-9-14-13(18)10-5-7-11(8-6-10)16(20)21/h5-8,19H,1-4,9H2,(H,14,18)(H,15,17)
DMSUW7M CS C1=CC(=CC=C1C(=O)NCCCCCC(=O)NO)[N+](=O)[O-]
DMSUW7M IK GDAAHZPABCCCFD-UHFFFAOYSA-N
DMSUW7M IU N-[6-(hydroxyamino)-6-oxohexyl]-4-nitrobenzamide
DMSUW7M DE Discovery agent
DMZSGPB ID DMZSGPB
DMZSGPB DN N-(5-Hydroxycarbamoyl-pentyl)-benzamide
DMZSGPB HS Investigative
DMZSGPB SN CHEMBL143849; N-(5-Hydroxycarbamoyl-pentyl)-benzamide; SCHEMBL1232912; BDBM50082658; ZINC13801954; M-354
DMZSGPB DT Small molecular drug
DMZSGPB PC 9921260
DMZSGPB MW 250.29
DMZSGPB FM C13H18N2O3
DMZSGPB IC InChI=1S/C13H18N2O3/c16-12(15-18)9-5-2-6-10-14-13(17)11-7-3-1-4-8-11/h1,3-4,7-8,18H,2,5-6,9-10H2,(H,14,17)(H,15,16)
DMZSGPB CS C1=CC=C(C=C1)C(=O)NCCCCCC(=O)NO
DMZSGPB IK WOSZGUVOSPLDAN-UHFFFAOYSA-N
DMZSGPB IU N-[6-(hydroxyamino)-6-oxohexyl]benzamide
DMZSGPB DE Discovery agent
DMSQEXP ID DMSQEXP
DMSQEXP DN N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide
DMSQEXP HS Investigative
DMSQEXP SN 32873-56-6; 2-Acetylamino-5-mercapto-1,3,4-thiadiazole; N-(5-sulfanyl-1,3,4-thiadiazol-2-yl)acetamide; 2-Acetamido-5-mercapto-1,3,4-Thiadiazole; UNII-6B8475348K; MLS002703417; CHEMBL382111; DWSMAMSVZRCQMP-UHFFFAOYSA-N; N-(5-mercapto-1,3,4-thiadiazol-2-yl)acetamide; N-(5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)acetamide; 6B8475348K; {N}-(5-mercapto-1,3,4-thiadiazol-2-yl)acetamide; N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)acetamide; Acetamide,N-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-; C4H5N3OS2; NSC97893
DMSQEXP DT Small molecular drug
DMSQEXP PC 2723687
DMSQEXP MW 175.2
DMSQEXP FM C4H5N3OS2
DMSQEXP IC InChI=1S/C4H5N3OS2/c1-2(8)5-3-6-7-4(9)10-3/h1H3,(H,7,9)(H,5,6,8)
DMSQEXP CS CC(=O)NC1=NNC(=S)S1
DMSQEXP IK DWSMAMSVZRCQMP-UHFFFAOYSA-N
DMSQEXP IU N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)acetamide
DMSQEXP CA CAS 32873-56-6
DMSQEXP DE Discovery agent
DM91463 ID DM91463
DM91463 DN N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine
DM91463 HS Investigative
DM91463 SN CHEMBL539413; SCHEMBL7125185
DM91463 DT Small molecular drug
DM91463 PC 9992527
DM91463 MW 255.3
DM91463 FM C10H13N3O3S
DM91463 IC InChI=1S/C10H13N3O3S/c1-6-3-4-7(17(2,15)16)5-8(6)9(14)13-10(11)12/h3-5H,1-2H3,(H4,11,12,13,14)
DM91463 CS CC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N=C(N)N
DM91463 IK SSLQVRLYNHXNIS-UHFFFAOYSA-N
DM91463 IU N-(diaminomethylidene)-2-methyl-5-methylsulfonylbenzamide
DM91463 DE Discovery agent
DM8PNKC ID DM8PNKC
DM8PNKC DN N-(5-methylthiazol-2-yl)-2-phenylacetamide
DM8PNKC HS Investigative
DM8PNKC SN N-(5-methyl-1,3-thiazol-2-yl)-2-phenylacetamide; AC1NMTHK; CHEMBL425300; MolPort-006-386-848; ZINC3160947; STK408984; AKOS003243303; MCULE-9670423324; ST004442
DM8PNKC DT Small molecular drug
DM8PNKC PC 5015763
DM8PNKC MW 232.3
DM8PNKC FM C12H12N2OS
DM8PNKC IC InChI=1S/C12H12N2OS/c1-9-8-13-12(16-9)14-11(15)7-10-5-3-2-4-6-10/h2-6,8H,7H2,1H3,(H,13,14,15)
DM8PNKC CS CC1=CN=C(S1)NC(=O)CC2=CC=CC=C2
DM8PNKC IK BZGKXQSOFFPEDI-UHFFFAOYSA-N
DM8PNKC IU N-(5-methyl-1,3-thiazol-2-yl)-2-phenylacetamide
DM8PNKC DE Discovery agent
DMFI057 ID DMFI057
DMFI057 DN N-(5-methylthiazol-2-yl)benzamide
DMFI057 HS Investigative
DMFI057 SN N-(5-methyl-1,3-thiazol-2-yl)benzamide; AC1MBAM0; SCHEMBL1270133; CHEMBL390097; MolPort-006-054-218; ZINC3555837; STL456150; AKOS008918901; MCULE-4605210896; KB-102415; N-(5-Methylthiazol-2-yl)benzenecarboxamide; N~1~-(5-methyl-1,3-thiazol-2-yl)benzamide; Z29325335
DMFI057 DT Small molecular drug
DMFI057 PC 2673074
DMFI057 MW 218.28
DMFI057 FM C11H10N2OS
DMFI057 IC InChI=1S/C11H10N2OS/c1-8-7-12-11(15-8)13-10(14)9-5-3-2-4-6-9/h2-7H,1H3,(H,12,13,14)
DMFI057 CS CC1=CN=C(S1)NC(=O)C2=CC=CC=C2
DMFI057 IK HEGBNFORMCPFKO-UHFFFAOYSA-N
DMFI057 IU N-(5-methyl-1,3-thiazol-2-yl)benzamide
DMFI057 DE Discovery agent
DMS2X69 ID DMS2X69
DMS2X69 DN N-(5-m-Tolyl-furan-2-carbonyl)-guanidine
DMS2X69 HS Investigative
DMS2X69 SN CHEMBL364735; N-(5-m-Tolyl-furan-2-carbonyl)-guanidine; SCHEMBL4936806
DMS2X69 DT Small molecular drug
DMS2X69 PC 11390872
DMS2X69 MW 243.26
DMS2X69 FM C13H13N3O2
DMS2X69 IC InChI=1S/C13H13N3O2/c1-8-3-2-4-9(7-8)10-5-6-11(18-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)
DMS2X69 CS CC1=CC(=CC=C1)C2=CC=C(O2)C(=O)N=C(N)N
DMS2X69 IK BBOVVXJXVOJLSK-UHFFFAOYSA-N
DMS2X69 IU N-(diaminomethylidene)-5-(3-methylphenyl)furan-2-carboxamide
DMS2X69 DE Discovery agent
DMFNZSL ID DMFNZSL
DMFNZSL DN N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
DMFNZSL HS Investigative
DMFNZSL SN CHEMBL192634; N-(5-o-Tolyl-furan-2-carbonyl)-guanidine
DMFNZSL DT Small molecular drug
DMFNZSL PC 11218749
DMFNZSL MW 243.26
DMFNZSL FM C13H13N3O2
DMFNZSL IC InChI=1S/C13H13N3O2/c1-8-4-2-3-5-9(8)10-6-7-11(18-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)
DMFNZSL CS CC1=CC=CC=C1C2=CC=C(O2)C(=O)N=C(N)N
DMFNZSL IK ACPWXEWIQCMXFE-UHFFFAOYSA-N
DMFNZSL IU N-(diaminomethylidene)-5-(2-methylphenyl)furan-2-carboxamide
DMFNZSL DE Discovery agent
DMA21WB ID DMA21WB
DMA21WB DN N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB HS Investigative
DMA21WB SN CHEMBL475776; N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide
DMA21WB DT Small molecular drug
DMA21WB PC 44571849
DMA21WB MW 256.3
DMA21WB FM C8H8N4O2S2
DMA21WB IC InChI=1S/C8H8N4O2S2/c9-16(13,14)12-8-11-10-7(15-8)6-4-2-1-3-5-6/h1-5H,(H,11,12)(H2,9,13,14)
DMA21WB CS C1=CC=C(C=C1)C2=NN=C(S2)NS(=O)(=O)N
DMA21WB IK AYAZOMSTWAJWHN-UHFFFAOYSA-N
DMA21WB IU 2-phenyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMA21WB DE Discovery agent
DMNU68D ID DMNU68D
DMNU68D DN N-(5-Phenyl-furan-2-carbonyl)-guanidine
DMNU68D HS Investigative
DMNU68D SN CHEMBL192690; N-(5-Phenyl-furan-2-carbonyl)-guanidine; SCHEMBL4943707
DMNU68D DT Small molecular drug
DMNU68D PC 11470226
DMNU68D MW 229.23
DMNU68D FM C12H11N3O2
DMNU68D IC InChI=1S/C12H11N3O2/c13-12(14)15-11(16)10-7-6-9(17-10)8-4-2-1-3-5-8/h1-7H,(H4,13,14,15,16)
DMNU68D CS C1=CC=C(C=C1)C2=CC=C(O2)C(=O)N=C(N)N
DMNU68D IK SYROHGCLRGCTIR-UHFFFAOYSA-N
DMNU68D IU N-(diaminomethylidene)-5-phenylfuran-2-carboxamide
DMNU68D DE Discovery agent
DM3FCAI ID DM3FCAI
DM3FCAI DN N-(5'-Phosphopyridoxyl)-D-Alanine
DM3FCAI HS Investigative
DM3FCAI SN N-(5'-Phosphopyridoxyl)-D-alanine; N-(5'-PHOSPHOPYRIDOXYL)-D-ALANINE; N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-D-alanine; 2bmk; AC1L9K6I; SCHEMBL4997474; CHEBI:44743; DB01993; N-[2-Methyl-3-hydroxy-5-(phosphonooxymethyl)pyridine-4-ylmethyl]-D-alanine; (2R)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]propanoic
DM3FCAI DT Small molecular drug
DM3FCAI PC 446862
DM3FCAI MW 320.24
DM3FCAI FM C11H17N2O7P
DM3FCAI IC InChI=1S/C11H17N2O7P/c1-6-10(14)9(4-13-7(2)11(15)16)8(3-12-6)5-20-21(17,18)19/h3,7,13-14H,4-5H2,1-2H3,(H,15,16)(H2,17,18,19)/t7-/m1/s1
DM3FCAI CS CC1=NC=C(C(=C1O)CN[C@H](C)C(=O)O)COP(=O)(O)O
DM3FCAI IK WACJCHFWJNNBPR-SSDOTTSWSA-N
DM3FCAI IU (2R)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]propanoic acid
DM3FCAI CB CHEBI:44743
DM3FCAI DE Discovery agent
DMDZ9BY ID DMDZ9BY
DMDZ9BY DN N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide
DMDZ9BY HS Investigative
DMDZ9BY SN NSC698990; CHEMBL281376; N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)benzamide; 86029-44-9; N-(2-sulfamoyl-1,3,4-thiadiazol-5-yl)benzamide; Benzamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]-; SCHEMBL9795960; AC1L997Y; BDBM16669; CTK2I3789; DTXSID30327878; ZINC5925092; heterocyclic sulfonamide compound 34; AKOS030579978; NSC-698990; NCI60_035393; LS-25666; 2-benzoylamino-1,3,4-thiadiazole 5-sulfonamide
DMDZ9BY DT Small molecular drug
DMDZ9BY PC 394898
DMDZ9BY MW 284.3
DMDZ9BY FM C9H8N4O3S2
DMDZ9BY IC InChI=1S/C9H8N4O3S2/c10-18(15,16)9-13-12-8(17-9)11-7(14)6-4-2-1-3-5-6/h1-5H,(H2,10,15,16)(H,11,12,14)
DMDZ9BY CS C1=CC=C(C=C1)C(=O)NC2=NN=C(S2)S(=O)(=O)N
DMDZ9BY IK PMNNJWNEWDGYIV-UHFFFAOYSA-N
DMDZ9BY IU N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)benzamide
DMDZ9BY CA CAS 86029-44-9
DMDZ9BY DE Discovery agent
DM5E7OC ID DM5E7OC
DM5E7OC DN N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC HS Investigative
DM5E7OC SN CHEMBL475775; N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide
DM5E7OC DT Small molecular drug
DM5E7OC PC 44571846
DM5E7OC MW 236.3
DM5E7OC FM C6H12N4O2S2
DM5E7OC IC InChI=1S/C6H12N4O2S2/c1-6(2,3)4-8-9-5(13-4)10-14(7,11)12/h1-3H3,(H,9,10)(H2,7,11,12)
DM5E7OC CS CC(C)(C)C1=NN=C(S1)NS(=O)(=O)N
DM5E7OC IK JJBJNTIFYMQMKH-UHFFFAOYSA-N
DM5E7OC IU 2-tert-butyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DM5E7OC DE Discovery agent
DMDCX5O ID DMDCX5O
DMDCX5O DN N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide
DMDCX5O HS Investigative
DMDCX5O SN CHEMBL1086175; N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide; N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485112; WPJGFQOEGTUKTE-UHFFFAOYSA-N
DMDCX5O DT Small molecular drug
DMDCX5O PC 10380885
DMDCX5O MW 313.8
DMDCX5O FM C17H16ClN3O
DMDCX5O IC InChI=1S/C17H16ClN3O/c1-2-5-16(22)19-17-13-9-8-11(10-15(13)20-21-17)12-6-3-4-7-14(12)18/h3-4,6-10H,2,5H2,1H3,(H2,19,20,21,22)
DMDCX5O CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=CC=C3Cl
DMDCX5O IK WPJGFQOEGTUKTE-UHFFFAOYSA-N
DMDCX5O IU N-[6-(2-chlorophenyl)-1H-indazol-3-yl]butanamide
DMDCX5O DE Discovery agent
DMKGBZA ID DMKGBZA
DMKGBZA DN N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide
DMKGBZA HS Investigative
DMKGBZA SN CHEMBL1086639; N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6485118; UKQRPDHIQLHFNS-UHFFFAOYSA-N; BDBM50313706
DMKGBZA DT Small molecular drug
DMKGBZA PC 22319573
DMKGBZA MW 295.34
DMKGBZA FM C17H17N3O2
DMKGBZA IC InChI=1S/C17H17N3O2/c1-2-4-16(22)18-17-14-8-7-12(10-15(14)19-20-17)11-5-3-6-13(21)9-11/h3,5-10,21H,2,4H2,1H3,(H2,18,19,20,22)
DMKGBZA CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC(=CC=C3)O
DMKGBZA IK UKQRPDHIQLHFNS-UHFFFAOYSA-N
DMKGBZA IU N-[6-(3-hydroxyphenyl)-1H-indazol-3-yl]butanamide
DMKGBZA DE Discovery agent
DMDQEZG ID DMDQEZG
DMDQEZG DN N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide
DMDQEZG HS Investigative
DMDQEZG SN CHEMBL1086638; N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide; N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL6478145; DCCRABAZYMVLJU-UHFFFAOYSA-N
DMDQEZG DT Small molecular drug
DMDQEZG PC 10085818
DMDQEZG MW 294.35
DMDQEZG FM C17H18N4O
DMDQEZG IC InChI=1S/C17H18N4O/c1-2-3-16(22)19-17-14-9-6-12(10-15(14)20-21-17)11-4-7-13(18)8-5-11/h4-10H,2-3,18H2,1H3,(H2,19,20,21,22)
DMDQEZG CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=C(C=C3)N
DMDQEZG IK DCCRABAZYMVLJU-UHFFFAOYSA-N
DMDQEZG IU N-[6-(4-aminophenyl)-1H-indazol-3-yl]butanamide
DMDQEZG DE Discovery agent
DMP7UZB ID DMP7UZB
DMP7UZB DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMP7UZB HS Investigative
DMP7UZB SN CHEMBL1083014; N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX); SCHEMBL1404548; BDBM50320174
DMP7UZB DT Small molecular drug
DMP7UZB PC 24996885
DMP7UZB MW 491.8
DMP7UZB FM C24H21Cl3N2O3
DMP7UZB IC InChI=1S/C24H21Cl3N2O3/c1-24(2)11-20(28-21(31)12-30)18-10-17(13-3-5-14(25)6-4-13)22(29-23(18)32-24)16-8-7-15(26)9-19(16)27/h3-10,20,30H,11-12H2,1-2H3,(H,28,31)
DMP7UZB CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)CO)C
DMP7UZB IK LGJVWHPVWBOBEW-UHFFFAOYSA-N
DMP7UZB IU N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxyacetamide
DMP7UZB DE Discovery agent
DMDPXUA ID DMDPXUA
DMDPXUA DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX)
DMDPXUA HS Investigative
DMDPXUA SN CHEMBL1083016; N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX); SCHEMBL1404523; BDBM50320175
DMDPXUA DT Small molecular drug
DMDPXUA PC 24992105
DMDPXUA MW 533.9
DMDPXUA FM C27H27Cl3N2O3
DMDPXUA IC InChI=1S/C27H27Cl3N2O3/c1-26(2,14-33)25(34)31-22-13-27(3,4)35-24-20(22)12-19(15-5-7-16(28)8-6-15)23(32-24)18-10-9-17(29)11-21(18)30/h5-12,22,33H,13-14H2,1-4H3,(H,31,34)
DMDPXUA CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)C(C)(C)CO)C
DMDPXUA IK BRSUJFVKAISEFW-UHFFFAOYSA-N
DMDPXUA IU N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-3-hydroxy-2,2-dimethylpropanamide
DMDPXUA DE Discovery agent
DMSX5DI ID DMSX5DI
DMSX5DI DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX)
DMSX5DI HS Investigative
DMSX5DI SN CHEMBL1083025; N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX); BDBM50320176
DMSX5DI DT Small molecular drug
DMSX5DI PC 46891225
DMSX5DI MW 505.8
DMSX5DI FM C25H23Cl3N2O3
DMSX5DI IC InChI=1S/C25H23Cl3N2O3/c1-25(2)13-21(29-22(32)9-10-31)19-12-18(14-3-5-15(26)6-4-14)23(30-24(19)33-25)17-8-7-16(27)11-20(17)28/h3-8,11-12,21,31H,9-10,13H2,1-2H3,(H,29,32)
DMSX5DI CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)CCO)C
DMSX5DI IK CQVVMULTZQAZBA-UHFFFAOYSA-N
DMSX5DI IU N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-3-hydroxypropanamide
DMSX5DI DE Discovery agent
DM4M12J ID DM4M12J
DM4M12J DN N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide
DM4M12J HS Investigative
DM4M12J SN CHEMBL1084681; N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide; SCHEMBL4488738; ORRUGYIZWSJRJU-UHFFFAOYSA-N; BDBM50313680
DM4M12J DT Small molecular drug
DM4M12J PC 22319694
DM4M12J MW 297.33
DM4M12J FM C17H16FN3O
DM4M12J IC InChI=1S/C17H16FN3O/c1-2-3-16(22)19-17-14-9-6-12(10-15(14)20-21-17)11-4-7-13(18)8-5-11/h4-10H,2-3H2,1H3,(H2,19,20,21,22)
DM4M12J CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=C(C=C3)F
DM4M12J IK ORRUGYIZWSJRJU-UHFFFAOYSA-N
DM4M12J IU N-[6-(4-fluorophenyl)-1H-indazol-3-yl]butanamide
DM4M12J DE Discovery agent
DM8JLR4 ID DM8JLR4
DM8JLR4 DN N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide
DM8JLR4 HS Investigative
DM8JLR4 DT Small molecular drug
DM8JLR4 PC 135458003
DM8JLR4 MW 295.34
DM8JLR4 FM C17H17N3O2
DM8JLR4 IC InChI=1S/C17H17N3O2/c1-2-3-16(22)18-17-14-9-6-12(10-15(14)19-20-17)11-4-7-13(21)8-5-11/h4-10,21H,2-3H2,1H3,(H2,18,19,20,22)
DM8JLR4 CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=C(C=C3)O
DM8JLR4 IK VCIZMGNKKFEEHA-UHFFFAOYSA-N
DM8JLR4 IU N-[6-(4-hydroxyphenyl)-1H-indazol-3-yl]butanamide
DM8JLR4 DE Discovery agent
DMRGQTM ID DMRGQTM
DMRGQTM DN N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide
DMRGQTM HS Investigative
DMRGQTM SN CHEMBL1086781; N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1461525; ZGQZPFJWHPTRAH-UHFFFAOYSA-N; BDBM50313709
DMRGQTM DT Small molecular drug
DMRGQTM PC 9993220
DMRGQTM MW 269.3
DMRGQTM FM C15H15N3O2
DMRGQTM IC InChI=1S/C15H15N3O2/c1-2-3-14(19)16-15-12-5-4-10(8-13(12)17-18-15)11-6-7-20-9-11/h4-9H,2-3H2,1H3,(H2,16,17,18,19)
DMRGQTM CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=COC=C3
DMRGQTM IK ZGQZPFJWHPTRAH-UHFFFAOYSA-N
DMRGQTM IU N-[6-(furan-3-yl)-1H-indazol-3-yl]butanamide
DMRGQTM DE Discovery agent
DM3FOKL ID DM3FOKL
DM3FOKL DN N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide
DM3FOKL HS Investigative
DM3FOKL SN CHEMBL1085918; N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL6489919; CZTAWAQITKVBNQ-UHFFFAOYSA-N; BDBM50313686
DM3FOKL DT Small molecular drug
DM3FOKL PC 10016510
DM3FOKL MW 280.32
DM3FOKL FM C16H16N4O
DM3FOKL IC InChI=1S/C16H16N4O/c1-2-4-15(21)18-16-13-7-6-11(9-14(13)19-20-16)12-5-3-8-17-10-12/h3,5-10H,2,4H2,1H3,(H2,18,19,20,21)
DM3FOKL CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CN=CC=C3
DM3FOKL IK CZTAWAQITKVBNQ-UHFFFAOYSA-N
DM3FOKL IU N-(6-pyridin-3-yl-1H-indazol-3-yl)butanamide
DM3FOKL DE Discovery agent
DM4GRK8 ID DM4GRK8
DM4GRK8 DN N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide
DM4GRK8 HS Investigative
DM4GRK8 SN CHEMBL1086782; N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1460286; BBNQSWZLWJBJIN-UHFFFAOYSA-N; BDBM50313652
DM4GRK8 DT Small molecular drug
DM4GRK8 PC 10085059
DM4GRK8 MW 280.32
DM4GRK8 FM C16H16N4O
DM4GRK8 IC InChI=1S/C16H16N4O/c1-2-3-15(21)18-16-13-5-4-12(10-14(13)19-20-16)11-6-8-17-9-7-11/h4-10H,2-3H2,1H3,(H2,18,19,20,21)
DM4GRK8 CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=NC=C3
DM4GRK8 IK BBNQSWZLWJBJIN-UHFFFAOYSA-N
DM4GRK8 IU N-(6-pyridin-4-yl-1H-indazol-3-yl)butanamide
DM4GRK8 DE Discovery agent
DMNRSYP ID DMNRSYP
DMNRSYP DN N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide
DMNRSYP HS Investigative
DMNRSYP SN CHEMBL1083208; N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide; SCHEMBL1462380; KEXXQGBZRBKVRC-UHFFFAOYSA-N; BDBM50313653
DMNRSYP DT Small molecular drug
DMNRSYP PC 22319580
DMNRSYP MW 285.4
DMNRSYP FM C15H15N3OS
DMNRSYP IC InChI=1S/C15H15N3OS/c1-2-3-14(19)16-15-12-5-4-10(8-13(12)17-18-15)11-6-7-20-9-11/h4-9H,2-3H2,1H3,(H2,16,17,18,19)
DMNRSYP CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CSC=C3
DMNRSYP IK KEXXQGBZRBKVRC-UHFFFAOYSA-N
DMNRSYP IU N-(6-thiophen-3-yl-1H-indazol-3-yl)butanamide
DMNRSYP DE Discovery agent
DMMHD9Z ID DMMHD9Z
DMMHD9Z DN N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide
DMMHD9Z HS Investigative
DMMHD9Z SN N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide; CHEMBL1086640; 599191-49-8; N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide; SCHEMBL1462440; RVYSDAGRNRYYML-UHFFFAOYSA-N
DMMHD9Z DT Small molecular drug
DMMHD9Z PC 10265187
DMMHD9Z MW 271.24
DMMHD9Z FM C12H12F3N3O
DMMHD9Z IC InChI=1S/C12H12F3N3O/c1-2-3-10(19)16-11-8-5-4-7(12(13,14)15)6-9(8)17-18-11/h4-6H,2-3H2,1H3,(H2,16,17,18,19)
DMMHD9Z CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C(F)(F)F
DMMHD9Z IK RVYSDAGRNRYYML-UHFFFAOYSA-N
DMMHD9Z IU N-[6-(trifluoromethyl)-1H-indazol-3-yl]butanamide
DMMHD9Z DE Discovery agent
DMHINE0 ID DMHINE0
DMHINE0 DN N(6)-cyclohexyladenosine
DMHINE0 HS Investigative
DMHINE0 SN N6-Cyclohexyladenosine; 36396-99-3; (2R,3R,4S,5R)-2-(6-(Cyclohexylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; N(6)-Cyclohexyladenosine; C16H23N5O4; Adenosine, N-cyclohexyl-; CHEMBL45891; (2R,3R,4S,5R)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; n-cyclohexyladenosine; N6 -cyclohexyladenosine; N-6-cyclohexyladenosine; N6-Cyclohexylado (CHA); n6-cyclohexyl[3h]adenosine; Lopac0_000331; GTPL423; SCHEMBL145856; SZBULDQSDUXAPJ-XNIJJKJLSA-N; MolPort-027-835-536; HMS3261C03; ZINC4217017
DMHINE0 DT Small molecular drug
DMHINE0 PC 9841284
DMHINE0 MW 349.38
DMHINE0 FM C16H23N5O4
DMHINE0 IC InChI=1S/C16H23N5O4/c22-6-10-12(23)13(24)16(25-10)21-8-19-11-14(17-7-18-15(11)21)20-9-4-2-1-3-5-9/h7-10,12-13,16,22-24H,1-6H2,(H,17,18,20)/t10-,12-,13-,16-/m1/s1
DMHINE0 CS C1CCC(CC1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMHINE0 IK SZBULDQSDUXAPJ-XNIJJKJLSA-N
DMHINE0 IU (2R,3R,4S,5R)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMHINE0 DE Discovery agent
DMKWYMP ID DMKWYMP
DMKWYMP DN N-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate
DMKWYMP HS Investigative
DMKWYMP DE Discovery agent
DM0OCLU ID DM0OCLU
DM0OCLU DN N-(6-benzyl-1H-indazol-3-yl)butyramide
DM0OCLU HS Investigative
DM0OCLU SN CHEMBL1077260; N-(6-benzyl-1H-indazol-3-yl)butyramide; SCHEMBL6490520
DM0OCLU DT Small molecular drug
DM0OCLU PC 10266409
DM0OCLU MW 293.4
DM0OCLU FM C18H19N3O
DM0OCLU IC InChI=1S/C18H19N3O/c1-2-6-17(22)19-18-15-10-9-14(12-16(15)20-21-18)11-13-7-4-3-5-8-13/h3-5,7-10,12H,2,6,11H2,1H3,(H2,19,20,21,22)
DM0OCLU CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)CC3=CC=CC=C3
DM0OCLU IK UUOMNVRBMQQPLH-UHFFFAOYSA-N
DM0OCLU IU N-(6-benzyl-1H-indazol-3-yl)butanamide
DM0OCLU DE Discovery agent
DMJPL7E ID DMJPL7E
DMJPL7E DN N-(6-bromo-1H-indazol-3-yl)butyramide
DMJPL7E HS Investigative
DMJPL7E SN CHEMBL1086780; N-[6-bromo-1H-indazol-3-yl]butanamide; 599191-53-4; N-(6-bromo-1H-indazol-3-yl)butyramide; butanamide,n-(6-bromo-1h-indazol-3-yl)-; SCHEMBL6490286; QQVNXRROZHWJNS-UHFFFAOYSA-N; ZINC38816494; BDBM50313708
DMJPL7E DT Small molecular drug
DMJPL7E PC 10423871
DMJPL7E MW 282.14
DMJPL7E FM C11H12BrN3O
DMJPL7E IC InChI=1S/C11H12BrN3O/c1-2-3-10(16)13-11-8-5-4-7(12)6-9(8)14-15-11/h4-6H,2-3H2,1H3,(H2,13,14,15,16)
DMJPL7E CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)Br
DMJPL7E IK QQVNXRROZHWJNS-UHFFFAOYSA-N
DMJPL7E IU N-(6-bromo-1H-indazol-3-yl)butanamide
DMJPL7E DE Discovery agent
DMHGXPY ID DMHGXPY
DMHGXPY DN N-(6-chloro-1H-indazol-3-yl)butyramide
DMHGXPY HS Investigative
DMHGXPY SN CHEMBL1082235; N-(6-chloro-1H-indazol-3-yl)butanamide; N-(6-chloro-1H-indazol-3-yl)butyramide; SCHEMBL4497072; VHQZZDZWVQELLJ-UHFFFAOYSA-N
DMHGXPY DT Small molecular drug
DMHGXPY PC 10421683
DMHGXPY MW 237.68
DMHGXPY FM C11H12ClN3O
DMHGXPY IC InChI=1S/C11H12ClN3O/c1-2-3-10(16)13-11-8-5-4-7(12)6-9(8)14-15-11/h4-6H,2-3H2,1H3,(H2,13,14,15,16)
DMHGXPY CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)Cl
DMHGXPY IK VHQZZDZWVQELLJ-UHFFFAOYSA-N
DMHGXPY IU N-(6-chloro-1H-indazol-3-yl)butanamide
DMHGXPY DE Discovery agent
DMJV3UO ID DMJV3UO
DMJV3UO DN N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide
DMJV3UO HS Investigative
DMJV3UO SN CHEMBL1095040; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide; 3lfs; N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL1461347; WGVVIVGNBSSANI-UHFFFAOYSA-N; BDBM50313661; N-(5-phenyl-6-chloro-1H-indazol-3-yl)butanamide
DMJV3UO DT Small molecular drug
DMJV3UO PC 22319604
DMJV3UO MW 313.8
DMJV3UO FM C17H16ClN3O
DMJV3UO IC InChI=1S/C17H16ClN3O/c1-2-6-16(22)19-17-13-9-12(11-7-4-3-5-8-11)14(18)10-15(13)20-21-17/h3-5,7-10H,2,6H2,1H3,(H2,19,20,21,22)
DMJV3UO CS CCCC(=O)NC1=NNC2=CC(=C(C=C21)C3=CC=CC=C3)Cl
DMJV3UO IK WGVVIVGNBSSANI-UHFFFAOYSA-N
DMJV3UO IU N-(6-chloro-5-phenyl-1H-indazol-3-yl)butanamide
DMJV3UO DE Discovery agent
DMIN128 ID DMIN128
DMIN128 DN N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide
DMIN128 HS Investigative
DMIN128 SN CHEMBL1097694; N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide; SCHEMBL1461361; REESNWQQNIKZJK-UHFFFAOYSA-N; BDBM50313666
DMIN128 DT Small molecular drug
DMIN128 PC 22319511
DMIN128 MW 327.8
DMIN128 FM C18H18ClN3O
DMIN128 IC InChI=1S/C18H18ClN3O/c1-3-4-17(23)20-18-14-9-13(12-7-5-11(2)6-8-12)15(19)10-16(14)21-22-18/h5-10H,3-4H2,1-2H3,(H2,20,21,22,23)
DMIN128 CS CCCC(=O)NC1=NNC2=CC(=C(C=C21)C3=CC=C(C=C3)C)Cl
DMIN128 IK REESNWQQNIKZJK-UHFFFAOYSA-N
DMIN128 IU N-[6-chloro-5-(4-methylphenyl)-1H-indazol-3-yl]butanamide
DMIN128 DE Discovery agent
DM90KGB ID DM90KGB
DM90KGB DN N-(6-ethoxypyridin-2-yl)acetamide
DM90KGB HS Investigative
DM90KGB SN N-(6-ethoxypyridin-2-yl)acetamide; N-(6-ethoxy-pyridin-2-yl)-acetamide; 775-38-2; AC1LGO22; CHEMBL210256; BDBM15972; Aminopyridine-Based Inhibitor 46
DM90KGB DT Small molecular drug
DM90KGB PC 824661
DM90KGB MW 180.2
DM90KGB FM C9H12N2O2
DM90KGB IC InChI=1S/C9H12N2O2/c1-3-13-9-6-4-5-8(11-9)10-7(2)12/h4-6H,3H2,1-2H3,(H,10,11,12)
DM90KGB CS CCOC1=CC=CC(=N1)NC(=O)C
DM90KGB IK NSIROEGSOFOSDV-UHFFFAOYSA-N
DM90KGB IU N-(6-ethoxypyridin-2-yl)acetamide
DM90KGB DE Discovery agent
DMIZVMT ID DMIZVMT
DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide
DMIZVMT HS Investigative
DMIZVMT SN CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-
DMIZVMT DT Small molecular drug
DMIZVMT PC 9965141
DMIZVMT MW 264.32
DMIZVMT FM C14H20N2O3
DMIZVMT IC InChI=1S/C14H20N2O3/c17-13(16-19)10-6-1-2-7-11-15-14(18)12-8-4-3-5-9-12/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,18)(H,16,17)
DMIZVMT CS C1=CC=C(C=C1)C(=O)NCCCCCCC(=O)NO
DMIZVMT IK ATWJTSVDLBPZQP-UHFFFAOYSA-N
DMIZVMT IU N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
DMIZVMT CA CAS 174664-71-2
DMIZVMT DE Discovery agent
DM01Y37 ID DM01Y37
DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide
DM01Y37 HS Investigative
DM01Y37 SN CHEMBL112364; BDBM50223650
DM01Y37 DT Small molecular drug
DM01Y37 PC 11447748
DM01Y37 MW 237.36
DM01Y37 FM C13H19NOS
DM01Y37 IC InChI=1S/C13H19NOS/c15-13(12-8-4-3-5-9-12)14-10-6-1-2-7-11-16/h3-5,8-9,16H,1-2,6-7,10-11H2,(H,14,15)
DM01Y37 CS C1=CC=C(C=C1)C(=O)NCCCCCCS
DM01Y37 IK HCPPYAZFTICCOW-UHFFFAOYSA-N
DM01Y37 IU N-(6-sulfanylhexyl)benzamide
DM01Y37 DE Discovery agent
DMQRE5D ID DMQRE5D
DMQRE5D DN N-(6-methylpyridin-2-yl)-5-phenylpicolinamide
DMQRE5D HS Investigative
DMQRE5D SN CHEMBL396078; N-(6-methylpyridin-2-yl)-5-phenylpicolinamide
DMQRE5D DT Small molecular drug
DMQRE5D PC 44440732
DMQRE5D MW 289.3
DMQRE5D FM C18H15N3O
DMQRE5D IC InChI=1S/C18H15N3O/c1-13-6-5-9-17(20-13)21-18(22)16-11-10-15(12-19-16)14-7-3-2-4-8-14/h2-12H,1H3,(H,20,21,22)
DMQRE5D CS CC1=NC(=CC=C1)NC(=O)C2=NC=C(C=C2)C3=CC=CC=C3
DMQRE5D IK RDRCRZMPPOKVOV-UHFFFAOYSA-N
DMQRE5D IU N-(6-methylpyridin-2-yl)-5-phenylpyridine-2-carboxamide
DMQRE5D DE Discovery agent
DMQZMRG ID DMQZMRG
DMQZMRG DN N-(6-methylpyridin-2-yl)-6-phenylnicotinamide
DMQZMRG HS Investigative
DMQZMRG SN CHEMBL525384; N-(6-methylpyridin-2-yl)-6-phenylnicotinamide
DMQZMRG DT Small molecular drug
DMQZMRG PC 44157178
DMQZMRG MW 289.3
DMQZMRG FM C18H15N3O
DMQZMRG IC InChI=1S/C18H15N3O/c1-13-6-5-9-17(20-13)21-18(22)15-10-11-16(19-12-15)14-7-3-2-4-8-14/h2-12H,1H3,(H,20,21,22)
DMQZMRG CS CC1=NC(=CC=C1)NC(=O)C2=CN=C(C=C2)C3=CC=CC=C3
DMQZMRG IK SJCQCBNYZNABCO-UHFFFAOYSA-N
DMQZMRG IU N-(6-methylpyridin-2-yl)-6-phenylpyridine-3-carboxamide
DMQZMRG DE Discovery agent
DMBNJ2L ID DMBNJ2L
DMBNJ2L DN N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide
DMBNJ2L HS Investigative
DMBNJ2L SN CHEMBL377935; N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide; BDBM50186331; biphenyl-3-carboxylic acid (6-methyl-pyridin-2-yl)-amide
DMBNJ2L DT Small molecular drug
DMBNJ2L PC 44412879
DMBNJ2L MW 288.3
DMBNJ2L FM C19H16N2O
DMBNJ2L IC InChI=1S/C19H16N2O/c1-14-7-5-12-18(20-14)21-19(22)17-11-6-10-16(13-17)15-8-3-2-4-9-15/h2-13H,1H3,(H,20,21,22)
DMBNJ2L CS CC1=NC(=CC=C1)NC(=O)C2=CC=CC(=C2)C3=CC=CC=C3
DMBNJ2L IK WRRMPYACQDSPSL-UHFFFAOYSA-N
DMBNJ2L IU N-(6-methylpyridin-2-yl)-3-phenylbenzamide
DMBNJ2L DE Discovery agent
DM9K4WP ID DM9K4WP
DM9K4WP DN N-(6-phenethyl-1H-indazol-3-yl)butyramide
DM9K4WP HS Investigative
DM9K4WP SN CHEMBL1084684; N-(6-phenethyl-1H-indazol-3-yl)butyramide; SCHEMBL6489338
DM9K4WP DT Small molecular drug
DM9K4WP PC 22319484
DM9K4WP MW 307.4
DM9K4WP FM C19H21N3O
DM9K4WP IC InChI=1S/C19H21N3O/c1-2-6-18(23)20-19-16-12-11-15(13-17(16)21-22-19)10-9-14-7-4-3-5-8-14/h3-5,7-8,11-13H,2,6,9-10H2,1H3,(H2,20,21,22,23)
DM9K4WP CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)CCC3=CC=CC=C3
DM9K4WP IK FEGHHCWVRCSXNL-UHFFFAOYSA-N
DM9K4WP IU N-[6-(2-phenylethyl)-1H-indazol-3-yl]butanamide
DM9K4WP DE Discovery agent
DM2E5OX ID DM2E5OX
DM2E5OX DN N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide
DM2E5OX HS Investigative
DM2E5OX SN CHEMBL481289; N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide; SCHEMBL4239343; KBQZTNRCKHEJQM-UHFFFAOYSA-N; BDBM50251685; 1h-indole-3-carboxylic acid(6-phenoxy-pyridine-3-yl)-amide
DM2E5OX DT Small molecular drug
DM2E5OX PC 44250365
DM2E5OX MW 329.4
DM2E5OX FM C20H15N3O2
DM2E5OX IC InChI=1S/C20H15N3O2/c24-20(17-13-21-18-9-5-4-8-16(17)18)23-14-10-11-19(22-12-14)25-15-6-2-1-3-7-15/h1-13,21H,(H,23,24)
DM2E5OX CS C1=CC=C(C=C1)OC2=NC=C(C=C2)NC(=O)C3=CNC4=CC=CC=C43
DM2E5OX IK KBQZTNRCKHEJQM-UHFFFAOYSA-N
DM2E5OX IU N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide
DM2E5OX DE Discovery agent
DMVCPLU ID DMVCPLU
DMVCPLU DN N-(6-phenyl-1H-indazol-3-yl)butyramide
DMVCPLU HS Investigative
DMVCPLU SN CHEMBL1086174; N-(6-phenyl-1H-indazol-3-yl)butyramide; SCHEMBL4493121
DMVCPLU DT Small molecular drug
DMVCPLU PC 10085013
DMVCPLU MW 279.34
DMVCPLU FM C17H17N3O
DMVCPLU IC InChI=1S/C17H17N3O/c1-2-6-16(21)18-17-14-10-9-13(11-15(14)19-20-17)12-7-4-3-5-8-12/h3-5,7-11H,2,6H2,1H3,(H2,18,19,20,21)
DMVCPLU CS CCCC(=O)NC1=NNC2=C1C=CC(=C2)C3=CC=CC=C3
DMVCPLU IK BVIWKIBBSPTOPO-UHFFFAOYSA-N
DMVCPLU IU N-(6-phenyl-1H-indazol-3-yl)butanamide
DMVCPLU DE Discovery agent
DMO3Y0B ID DMO3Y0B
DMO3Y0B DN N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
DMO3Y0B HS Investigative
DMO3Y0B SN CHEMBL1085261; N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX); SCHEMBL1404507; BDBM50320173
DMO3Y0B DT Small molecular drug
DMO3Y0B PC 24996566
DMO3Y0B MW 457.3
DMO3Y0B FM C24H22Cl2N2O3
DMO3Y0B IC InChI=1S/C24H22Cl2N2O3/c1-24(2)12-20(27-21(30)13-29)18-11-17(14-7-9-15(25)10-8-14)22(28-23(18)31-24)16-5-3-4-6-19(16)26/h3-11,20,29H,12-13H2,1-2H3,(H,27,30)
DMO3Y0B CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl)NC(=O)CO)C
DMO3Y0B IK XFJREZUFRMFGKX-UHFFFAOYSA-N
DMO3Y0B IU N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-2-hydroxyacetamide
DMO3Y0B DE Discovery agent
DM5F27T ID DM5F27T
DM5F27T DN N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)
DM5F27T HS Investigative
DM5F27T SN CHEMBL1085566; SCHEMBL1404756; BDBM50320185; N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX); N-(7''-(2-CHLOROPHENYL)-6''-(4-CHLOROPHENYL)-3'',4''-DIHYDROSPIRO[CYCLOHEXANE-1,2''-PYRANO[2,3-B]PYRIDINE]-4''-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX)
DM5F27T DT Small molecular drug
DM5F27T PC 24995605
DM5F27T MW 525.5
DM5F27T FM C29H30Cl2N2O3
DM5F27T IC InChI=1S/C29H30Cl2N2O3/c1-28(2,35)27(34)32-24-17-29(14-6-3-7-15-29)36-26-22(24)16-21(18-10-12-19(30)13-11-18)25(33-26)20-8-4-5-9-23(20)31/h4-5,8-13,16,24,35H,3,6-7,14-15,17H2,1-2H3,(H,32,34)
DM5F27T CS CC(C)(C(=O)NC1CC2(CCCCC2)OC3=C1C=C(C(=N3)C4=CC=CC=C4Cl)C5=CC=C(C=C5)Cl)O
DM5F27T IK UTPSWDIIQDVVTK-UHFFFAOYSA-N
DM5F27T IU N-[7-(2-chlorophenyl)-6-(4-chlorophenyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclohexane]-4-yl]-2-hydroxy-2-methylpropanamide
DM5F27T DE Discovery agent
DMPMBC2 ID DMPMBC2
DMPMBC2 DN N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine
DMPMBC2 HS Investigative
DMPMBC2 SN CHEMBL107872; N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine
DMPMBC2 DT Small molecular drug
DMPMBC2 PC 44339283
DMPMBC2 MW 292.33
DMPMBC2 FM C17H16N4O
DMPMBC2 IC InChI=1S/C17H16N4O/c18-17(19)21-16-15-10-14(7-6-13(15)8-9-20-16)22-11-12-4-2-1-3-5-12/h1-10H,11H2,(H4,18,19,20,21)
DMPMBC2 CS C1=CC=C(C=C1)COC2=CC3=C(C=C2)C=CN=C3N=C(N)N
DMPMBC2 IK XOCIIIGBOXCOGZ-UHFFFAOYSA-N
DMPMBC2 IU 2-(7-phenylmethoxyisoquinolin-1-yl)guanidine
DMPMBC2 DE Discovery agent
DMH42L8 ID DMH42L8
DMH42L8 DN N-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide
DMH42L8 HS Investigative
DMH42L8 SN CHEMBL598250
DMH42L8 DT Small molecular drug
DMH42L8 PC 46230982
DMH42L8 MW 281.3
DMH42L8 FM C17H15NO3
DMH42L8 IC InChI=1S/C17H15NO3/c1-11(19)18-16-10-14-13(12-6-4-3-5-7-12)8-9-15(20-2)17(14)21-16/h3-10H,1-2H3,(H,18,19)
DMH42L8 CS CC(=O)NC1=CC2=C(C=CC(=C2O1)OC)C3=CC=CC=C3
DMH42L8 IK QFMYZXFFZWTGIP-UHFFFAOYSA-N
DMH42L8 IU N-(7-methoxy-4-phenyl-1-benzofuran-2-yl)acetamide
DMH42L8 DE Discovery agent
DMHFPE3 ID DMHFPE3
DMHFPE3 DN N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide
DMHFPE3 HS Investigative
DMHFPE3 SN CHEMBL1210476; N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide
DMHFPE3 DT Small molecular drug
DMHFPE3 PC 49863103
DMHFPE3 MW 320.3
DMHFPE3 FM C17H16N6O
DMHFPE3 IC InChI=1S/C17H16N6O/c1-2-3-7-13(24)21-16-14-17(20-10-19-16)23-15(22-14)12-6-4-5-11(8-12)9-18/h4-6,8,10H,2-3,7H2,1H3,(H2,19,20,21,22,23,24)
DMHFPE3 CS CCCCC(=O)NC1=NC=NC2=C1NC(=N2)C3=CC=CC(=C3)C#N
DMHFPE3 IK FKLAKSOWIZORFH-UHFFFAOYSA-N
DMHFPE3 IU N-[8-(3-cyanophenyl)-7H-purin-6-yl]pentanamide
DMHFPE3 DE Discovery agent
DMBD52I ID DMBD52I
DMBD52I DN N-(9H-beta-Carbolin-3-yl)-acetamide
DMBD52I HS Investigative
DMBD52I SN 91985-75-0; N-9h-pyrido[3,4-b]indol-3-yl-acetamide; 3-acetamino-beta-carboline; CHEMBL167732; SCHEMBL10645219; ZINC25307; JZIFOHJMLBAWQZ-UHFFFAOYSA-N; N-(beta-Carboline-3-yl)acetamide; N-(9H-pyrido[3,4-b]indol-3-yl)acetamide
DMBD52I DT Small molecular drug
DMBD52I PC 13315120
DMBD52I MW 225.25
DMBD52I FM C13H11N3O
DMBD52I IC InChI=1S/C13H11N3O/c1-8(17)15-13-6-10-9-4-2-3-5-11(9)16-12(10)7-14-13/h2-7,16H,1H3,(H,14,15,17)
DMBD52I CS CC(=O)NC1=NC=C2C(=C1)C3=CC=CC=C3N2
DMBD52I IK JZIFOHJMLBAWQZ-UHFFFAOYSA-N
DMBD52I IU N-(9H-pyrido[3,4-b]indol-3-yl)acetamide
DMBD52I DE Discovery agent
DM3KNSY ID DM3KNSY
DM3KNSY DN N-(9H-beta-Carbolin-3-yl)-formamide
DM3KNSY HS Investigative
DM3KNSY SN 95935-50-5; Formamide, N-9H-pyrido[3,4-b]indol-3-yl-; CHEMBL353110
DM3KNSY DT Small molecular drug
DM3KNSY PC 13450924
DM3KNSY MW 211.22
DM3KNSY FM C12H9N3O
DM3KNSY IC InChI=1S/C12H9N3O/c16-7-14-12-5-9-8-3-1-2-4-10(8)15-11(9)6-13-12/h1-7,15H,(H,13,14,16)
DM3KNSY CS C1=CC=C2C(=C1)C3=CC(=NC=C3N2)NC=O
DM3KNSY IK YLIKNFBWEFRNOD-UHFFFAOYSA-N
DM3KNSY IU N-(9H-pyrido[3,4-b]indol-3-yl)formamide
DM3KNSY DE Discovery agent
DMFONC1 ID DMFONC1
DMFONC1 DN N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide
DMFONC1 HS Investigative
DMFONC1 SN CHEMBL591468; AC1MLZYY; N-(1-adamantyl)phenothiazine-10-carboxamide; Oprea1_167795; ZINC6252722; BDBM50308401; AKOS004107814
DMFONC1 DT Small molecular drug
DMFONC1 PC 3253193
DMFONC1 MW 376.5
DMFONC1 FM C23H24N2OS
DMFONC1 IC InChI=1S/C23H24N2OS/c26-22(24-23-12-15-9-16(13-23)11-17(10-15)14-23)25-18-5-1-3-7-20(18)27-21-8-4-2-6-19(21)25/h1-8,15-17H,9-14H2,(H,24,26)
DMFONC1 CS C1C2CC3CC1CC(C2)(C3)NC(=O)N4C5=CC=CC=C5SC6=CC=CC=C64
DMFONC1 IK YTNHIPMOCAHDRX-UHFFFAOYSA-N
DMFONC1 IU N-(1-adamantyl)phenothiazine-10-carboxamide
DMFONC1 DE Discovery agent
DM87YJW ID DM87YJW
DM87YJW DN N-(benzyl),N-(pyrrol-2-ylmethyl)amine
DM87YJW HS Investigative
DM87YJW SN pyrrole inhibitor 17; N-(benzyl),N-(pyrrol-2-ylmethyl)amine; 1H-Pyrrole-2-methanamine, N-(phenylmethyl)-; CHEMBL223618; AC1L95K6; BDBM15591; benzyl(1H-pyrrol-2-ylmethyl)amine; ZINC1679613; AKOS009004155; 95116-31-7
DM87YJW DT Small molecular drug
DM87YJW PC 413448
DM87YJW MW 186.25
DM87YJW FM C12H14N2
DM87YJW IC InChI=1S/C12H14N2/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13-14H,9-10H2
DM87YJW CS C1=CC=C(C=C1)CNCC2=CC=CN2
DM87YJW IK YOGRUDYQEJQNLR-UHFFFAOYSA-N
DM87YJW IU 1-phenyl-N-(1H-pyrrol-2-ylmethyl)methanamine
DM87YJW DE Discovery agent
DMR18YI ID DMR18YI
DMR18YI DN N-(benzyloxycarbonyl)-leucyl-glycine-nitrile
DMR18YI HS Investigative
DMR18YI SN dipeptidyl nitrile, 1; Cbz-Leu-NH-CH2-CN; JMC487688 Compound 8; CHEMBL200161; SCHEMBL6183068; BDBM19768; UFXQLUZNMRVTPU-AWEZNQCLSA-N; 2-[(Z-L-Leu-)Amino]ethanenitrile; benzyl (S)-1-cyanomethylcarbamoyl-3-methylbutylcarbamate; benzyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate
DMR18YI DT Small molecular drug
DMR18YI PC 11702208
DMR18YI MW 303.36
DMR18YI FM C16H21N3O3
DMR18YI IC InChI=1S/C16H21N3O3/c1-12(2)10-14(15(20)18-9-8-17)19-16(21)22-11-13-6-4-3-5-7-13/h3-7,12,14H,9-11H2,1-2H3,(H,18,20)(H,19,21)/t14-/m0/s1
DMR18YI CS CC(C)C[C@@H](C(=O)NCC#N)NC(=O)OCC1=CC=CC=C1
DMR18YI IK UFXQLUZNMRVTPU-AWEZNQCLSA-N
DMR18YI IU benzyl N-[(2S)-1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]carbamate
DMR18YI DE Discovery agent
DMRCYB8 ID DMRCYB8
DMRCYB8 DN N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide
DMRCYB8 HS Investigative
DMRCYB8 SN CHEMBL475301; N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5327672
DMRCYB8 DT Small molecular drug
DMRCYB8 PC 23634372
DMRCYB8 MW 361.5
DMRCYB8 FM C18H23N3O3S
DMRCYB8 IC InChI=1S/C18H23N3O3S/c19-25(23,24)20-13-6-2-5-12-18(22)21-17-11-7-10-16(14-17)15-8-3-1-4-9-15/h1,3-4,7-11,14,20H,2,5-6,12-13H2,(H,21,22)(H2,19,23,24)
DMRCYB8 CS C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CCCCCNS(=O)(=O)N
DMRCYB8 IK XZBFBJMQHOJIMB-UHFFFAOYSA-N
DMRCYB8 IU N-(3-phenylphenyl)-6-(sulfamoylamino)hexanamide
DMRCYB8 DE Discovery agent
DM2ZQBS ID DM2ZQBS
DM2ZQBS DN N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine
DM2ZQBS HS Investigative
DM2ZQBS SN CHEMBL565950; N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine
DM2ZQBS DT Small molecular drug
DM2ZQBS PC 45484883
DM2ZQBS MW 286.3
DM2ZQBS FM C19H14N2O
DM2ZQBS IC InChI=1S/C19H14N2O/c1-2-7-14(8-3-1)15-9-6-10-16(13-15)20-19-17-11-4-5-12-18(17)22-21-19/h1-13H,(H,20,21)
DM2ZQBS CS C1=CC=C(C=C1)C2=CC(=CC=C2)NC3=NOC4=CC=CC=C43
DM2ZQBS IK RPYFHXRGVNEECB-UHFFFAOYSA-N
DM2ZQBS IU N-(3-phenylphenyl)-1,2-benzoxazol-3-amine
DM2ZQBS DE Discovery agent
DMSO7FW ID DMSO7FW
DMSO7FW DN N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide
DMSO7FW HS Investigative
DMSO7FW SN (2z)-N-Biphenyl-4-Yl-2-Cyano-3-Hydroxybut-2-Enamide; CHEMBL519160; DB07443; (2Z)-2-cyano-3-hydroxy-N-(4-phenylphenyl)but-2-enamide
DMSO7FW DT Small molecular drug
DMSO7FW PC 54727972
DMSO7FW MW 278.3
DMSO7FW FM C17H14N2O2
DMSO7FW IC InChI=1S/C17H14N2O2/c1-12(20)16(11-18)17(21)19-15-9-7-14(8-10-15)13-5-3-2-4-6-13/h2-10,20H,1H3,(H,19,21)/b16-12-
DMSO7FW CS C/C(=C(\\C#N)/C(=O)NC1=CC=C(C=C1)C2=CC=CC=C2)/O
DMSO7FW IK MUVPBAIVOHJDOC-VBKFSLOCSA-N
DMSO7FW IU (Z)-2-cyano-3-hydroxy-N-(4-phenylphenyl)but-2-enamide
DMSO7FW DE Discovery agent
DML10NT ID DML10NT
DML10NT DN N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine
DML10NT HS Investigative
DML10NT SN CHEMBL578782; N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine
DML10NT DT Small molecular drug
DML10NT PC 45484855
DML10NT MW 286.3
DML10NT FM C19H14N2O
DML10NT IC InChI=1S/C19H14N2O/c1-2-6-14(7-3-1)15-10-12-16(13-11-15)20-19-17-8-4-5-9-18(17)22-21-19/h1-13H,(H,20,21)
DML10NT CS C1=CC=C(C=C1)C2=CC=C(C=C2)NC3=NOC4=CC=CC=C43
DML10NT IK BKHHQJRHPIBTJZ-UHFFFAOYSA-N
DML10NT IU N-(4-phenylphenyl)-1,2-benzoxazol-3-amine
DML10NT DE Discovery agent
DMHPITZ ID DMHPITZ
DMHPITZ DN N-(biphenyl-4-ylsulfonyl)-D-leucine
DMHPITZ HS Investigative
DMHPITZ SN N-(biphenyl-4-ylsulfonyl)-D-leucine; DB07446; (R)-2-(biphenyl-4-ylsulfonamido)-4-methylpentanoic acid; (2R)-4-methyl-2-(4-phenylbenzenesulfonamido)pentanoic acid
DMHPITZ DT Small molecular drug
DMHPITZ PC 25271580
DMHPITZ MW 347.4
DMHPITZ FM C18H21NO4S
DMHPITZ IC InChI=1S/C18H21NO4S/c1-13(2)12-17(18(20)21)19-24(22,23)16-10-8-15(9-11-16)14-6-4-3-5-7-14/h3-11,13,17,19H,12H2,1-2H3,(H,20,21)/t17-/m1/s1
DMHPITZ CS CC(C)C[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C2=CC=CC=C2
DMHPITZ IK FBSVJQQVDISETN-QGZVFWFLSA-N
DMHPITZ IU (2R)-4-methyl-2-[(4-phenylphenyl)sulfonylamino]pentanoic acid
DMHPITZ DE Discovery agent
DMFGSLO ID DMFGSLO
DMFGSLO DN N-(Chlorophenyl)-N'-Hydroxyguanidine
DMFGSLO HS Investigative
DMFGSLO SN 130974-86-6; N-(CHLOROPHENYL)-N'-HYDROXYGUANIDINE; Guanidine, N-(4-chlorophenyl)-N'-hydroxy-; N-(4-chloro)phenyl-N'-hydroxyguanidine; Guanidine,N-(4-chlorophenyl)-N'-hydroxy-; C7H8ClN3O; ACMC-1CA1V; SCHEMBL2213727; CHEMBL323202; AC1L490B; CTK4B7016; DTXSID90156823; AKOS017474904; AKOS011771250; AKOS030602610; 1-(4-Chlorophenyl)-3-hydroxyguanidine; DB04559; 2-(4-chlorophenyl)-1-hydroxyguanidine
DMFGSLO DT Small molecular drug
DMFGSLO PC 181426
DMFGSLO MW 185.61
DMFGSLO FM C7H8ClN3O
DMFGSLO IC InChI=1S/C7H8ClN3O/c8-5-1-3-6(4-2-5)10-7(9)11-12/h1-4,12H,(H3,9,10,11)
DMFGSLO CS C1=CC(=CC=C1N=C(N)NO)Cl
DMFGSLO IK JYBXKTLYOMPMQY-UHFFFAOYSA-N
DMFGSLO IU 2-(4-chlorophenyl)-1-hydroxyguanidine
DMFGSLO CA CAS 130974-86-6
DMFGSLO DE Discovery agent
DM1TA5R ID DM1TA5R
DM1TA5R DN N-(cis-9-cis-12-octadecadienyl)sulfamide
DM1TA5R HS Investigative
DM1TA5R SN CHEMBL570988; N-(cis-9-cis-12-octadecadienyl)sulfamide; SCHEMBL3107035
DM1TA5R DT Small molecular drug
DM1TA5R PC 44614165
DM1TA5R MW 344.6
DM1TA5R FM C18H36N2O2S
DM1TA5R IC InChI=1S/C18H36N2O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-23(19,21)22/h6-7,9-10,20H,2-5,8,11-18H2,1H3,(H2,19,21,22)/b7-6-,10-9-
DM1TA5R CS CCCCC/C=C\\C/C=C\\CCCCCCCCNS(=O)(=O)N
DM1TA5R IK DGNCNCVVPPGGNM-HZJYTTRNSA-N
DM1TA5R IU (6Z,9Z)-18-(sulfamoylamino)octadeca-6,9-diene
DM1TA5R DE Discovery agent
DMTKREZ ID DMTKREZ
DMTKREZ DN N-(cyanomethyl)cyclohex-1-ene-1-carboxamide
DMTKREZ HS Investigative
DMTKREZ SN 1-Cyclohexene-1-carboxamide, N-(cyanomethyl)-; 875142-19-1
DMTKREZ DT Small molecular drug
DMTKREZ PC 11550059
DMTKREZ MW 164.2
DMTKREZ FM C9H12N2O
DMTKREZ IC InChI=1S/C9H12N2O/c10-6-7-11-9(12)8-4-2-1-3-5-8/h4H,1-3,5,7H2,(H,11,12)
DMTKREZ CS C1CCC(=CC1)C(=O)NCC#N
DMTKREZ IK ZVHMBSSCZBPAIY-UHFFFAOYSA-N
DMTKREZ IU N-(cyanomethyl)cyclohexene-1-carboxamide
DMTKREZ DE Discovery agent
DMI245K ID DMI245K
DMI245K DN N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
DMI245K HS Investigative
DMI245K SN N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine; DB07683; N-(dibenzo[b,d]thiophene-3-sulfonyl) valine; (2S)-3-methyl-2-{8-thiatricyclo[7.4.0.0^{2,7}]trideca-1(13),2,4,6,9,11-hexaene-5-sulfonamido}butanoic acid
DMI245K DT Small molecular drug
DMI245K PC 24794392
DMI245K MW 363.5
DMI245K FM C17H17NO4S2
DMI245K IC InChI=1S/C17H17NO4S2/c1-10(2)16(17(19)20)18-24(21,22)11-7-8-13-12-5-3-4-6-14(12)23-15(13)9-11/h3-10,16,18H,1-2H3,(H,19,20)/t16-/m0/s1
DMI245K CS CC(C)[C@@H](C(=O)O)NS(=O)(=O)C1=CC2=C(C=C1)C3=CC=CC=C3S2
DMI245K IK RZWYSEXQXOXWKA-INIZCTEOSA-N
DMI245K IU (2S)-2-(dibenzothiophen-3-ylsulfonylamino)-3-methylbutanoic acid
DMI245K DE Discovery agent
DMJ6U4H ID DMJ6U4H
DMJ6U4H DN N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3
DMJ6U4H HS Investigative
DMJ6U4H SN CHEMBL1160624
DMJ6U4H DT Small molecular drug
DMJ6U4H PC 44324667
DMJ6U4H MW 437.4
DMJ6U4H FM C20H30N4O5P-
DMJ6U4H IC InChI=1S/C20H31N4O5P/c1-5-13(3)18(24-30(27,28)29-6-2)20(26)23-17(19(25)21-4)11-14-12-22-16-10-8-7-9-15(14)16/h7-10,12-13,17-18,22H,5-6,11H2,1-4H3,(H,21,25)(H,23,26)(H2,24,27,28)/p-1/t13-,17?,18-/m0/s1
DMJ6U4H CS CC[C@H](C)[C@@H](C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC)NP(=O)([O-])OCC
DMJ6U4H IK IHAZHCJWGLQJQS-VCMPKCBFSA-M
DMJ6U4H IU ethoxy-[[(2S,3S)-1-[[3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]phosphinate
DMJ6U4H DE Discovery agent
DMLJZGD ID DMLJZGD
DMLJZGD DN N-(furan-2-ylmethyl)estradiol-16-carboxamide
DMLJZGD HS Investigative
DMLJZGD SN SCHEMBL12379478
DMLJZGD DT Small molecular drug
DMLJZGD PC 44407336
DMLJZGD MW 395.5
DMLJZGD FM C24H29NO4
DMLJZGD IC InChI=1S/C24H29NO4/c1-24-9-8-18-17-7-5-15(26)11-14(17)4-6-19(18)21(24)12-20(22(24)27)23(28)25-13-16-3-2-10-29-16/h2-3,5,7,10-11,18-22,26-27H,4,6,8-9,12-13H2,1H3,(H,25,28)/t18?,19?,20?,21?,22-,24-/m0/s1
DMLJZGD CS C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)NCC4=CC=CO4)CCC5=C3C=CC(=C5)O
DMLJZGD IK JKEJHEHCKBFOBU-OOBULCBASA-N
DMLJZGD IU (13S,17S)-N-(furan-2-ylmethyl)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMLJZGD DE Discovery agent
DM0DZ9J ID DM0DZ9J
DM0DZ9J DN N-(furan-2-ylmethyl)-estrone-16-methyl carboxamide
DM0DZ9J HS Investigative
DM0DZ9J SN SCHEMBL12379521
DM0DZ9J DT Small molecular drug
DM0DZ9J PC 44407578
DM0DZ9J MW 407.5
DM0DZ9J FM C25H29NO4
DM0DZ9J IC InChI=1S/C25H29NO4/c1-25-9-8-20-19-7-5-17(27)11-15(19)4-6-21(20)22(25)12-16(24(25)29)13-23(28)26-14-18-3-2-10-30-18/h2-3,5,7,10-11,16,20-22,27H,4,6,8-9,12-14H2,1H3,(H,26,28)/t16?,20?,21?,22?,25-/m0/s1
DM0DZ9J CS C[C@]12CCC3C(C1CC(C2=O)CC(=O)NCC4=CC=CO4)CCC5=C3C=CC(=C5)O
DM0DZ9J IK NSHKXWHQUTUXRS-HIUOCNRYSA-N
DM0DZ9J IU N-(furan-2-ylmethyl)-2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetamide
DM0DZ9J DE Discovery agent
DMW378C ID DMW378C
DMW378C DN N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine
DMW378C HS Investigative
DMW378C SN CHEMBL424689; N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine; SCHEMBL14433281
DMW378C DT Small molecular drug
DMW378C PC 9922232
DMW378C MW 296.4
DMW378C FM C18H20N2S
DMW378C IC InChI=1S/C18H20N2S/c1-18(2,3)11-14-12-21-17(19-14)20-16-10-6-8-13-7-4-5-9-15(13)16/h4-10,12H,11H2,1-3H3,(H,19,20)
DMW378C CS CC(C)(C)CC1=CSC(=N1)NC2=CC=CC3=CC=CC=C32
DMW378C IK RIPVNQXJGQJLHV-UHFFFAOYSA-N
DMW378C IU 4-(2,2-dimethylpropyl)-N-naphthalen-1-yl-1,3-thiazol-2-amine
DMW378C DE Discovery agent
DMFZPCD ID DMFZPCD
DMFZPCD DN N-(naphthalen-1-yl)-4-phenylthiazol-2-amine
DMFZPCD HS Investigative
DMFZPCD SN CHEMBL208452; N-(naphthalen-1-yl)-4-phenylthiazol-2-amine; AC1N24LJ; BDBM50183105; AKOS001583269; EU-0001073; N-naphthalen-1-yl-4-phenyl-1,3-thiazol-2-amine; SR-01000396392
DMFZPCD DT Small molecular drug
DMFZPCD PC 4015979
DMFZPCD MW 302.4
DMFZPCD FM C19H14N2S
DMFZPCD IC InChI=1S/C19H14N2S/c1-2-8-15(9-3-1)18-13-22-19(21-18)20-17-12-6-10-14-7-4-5-11-16(14)17/h1-13H,(H,20,21)
DMFZPCD CS C1=CC=C(C=C1)C2=CSC(=N2)NC3=CC=CC4=CC=CC=C43
DMFZPCD IK JWZVJRBKXQFLBH-UHFFFAOYSA-N
DMFZPCD IU N-naphthalen-1-yl-4-phenyl-1,3-thiazol-2-amine
DMFZPCD DE Discovery agent
DM2CBNG ID DM2CBNG
DM2CBNG DN N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine
DM2CBNG HS Investigative
DM2CBNG SN CHEMBL565960; N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine
DM2CBNG DT Small molecular drug
DM2CBNG PC 45484885
DM2CBNG MW 260.29
DM2CBNG FM C17H12N2O
DM2CBNG IC InChI=1S/C17H12N2O/c1-2-8-13-12(6-1)7-5-10-15(13)18-17-14-9-3-4-11-16(14)20-19-17/h1-11H,(H,18,19)
DM2CBNG CS C1=CC=C2C(=C1)C=CC=C2NC3=NOC4=CC=CC=C43
DM2CBNG IK SOIDHQDYGYBXPJ-UHFFFAOYSA-N
DM2CBNG IU N-naphthalen-1-yl-1,2-benzoxazol-3-amine
DM2CBNG DE Discovery agent
DM2NHVX ID DM2NHVX
DM2NHVX DN N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine
DM2NHVX HS Investigative
DM2NHVX SN CHEMBL577471; N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine
DM2NHVX DT Small molecular drug
DM2NHVX PC 45484884
DM2NHVX MW 260.29
DM2NHVX FM C17H12N2O
DM2NHVX IC InChI=1S/C17H12N2O/c1-2-6-13-11-14(10-9-12(13)5-1)18-17-15-7-3-4-8-16(15)20-19-17/h1-11H,(H,18,19)
DM2NHVX CS C1=CC=C2C=C(C=CC2=C1)NC3=NOC4=CC=CC=C43
DM2NHVX IK KQZPQVBDFIHPIN-UHFFFAOYSA-N
DM2NHVX IU N-naphthalen-2-yl-1,2-benzoxazol-3-amine
DM2NHVX DE Discovery agent
DMG8KXR ID DMG8KXR
DMG8KXR DN N-(Naphthalene-2-yl)ethyl-ETAV
DMG8KXR HS Investigative
DMG8KXR SN N-(Naphthalene-2-yl)ethyl-ETAV; CHEMBL493689
DMG8KXR DT Small molecular drug
DMG8KXR PC 44568837
DMG8KXR MW 572.6
DMG8KXR FM C29H40N4O8
DMG8KXR IC InChI=1S/C29H40N4O8/c1-16(2)24(29(40)41)32-26(37)17(3)31-28(39)25(18(4)34)33-27(38)22(11-12-23(35)36)30-14-13-19-9-10-20-7-5-6-8-21(20)15-19/h5-10,15-18,22,24-25,30,34H,11-14H2,1-4H3,(H,31,39)(H,32,37)(H,33,38)(H,35,36)(H,40,41)/t17-,18?,22-,24-,25-/m0/s1
DMG8KXR CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1=CC2=CC=CC=C2C=C1
DMG8KXR IK BVNXVJDQOOZPCM-FZDDQCGTSA-N
DMG8KXR IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(2-naphthalen-2-ylethylamino)-5-oxopentanoic acid
DMG8KXR DE Discovery agent
DME45J8 ID DME45J8
DME45J8 DN N-(pentafluorophenyl)sulfamide
DME45J8 HS Investigative
DME45J8 SN N-(pentafluorophenyl)sulfamide; CHEMBL169486
DME45J8 DT Small molecular drug
DME45J8 PC 44380941
DME45J8 MW 262.16
DME45J8 FM C6H3F5N2O2S
DME45J8 IC InChI=1S/C6H3F5N2O2S/c7-1-2(8)4(10)6(5(11)3(1)9)13-16(12,14)15/h13H,(H2,12,14,15)
DME45J8 CS C1(=C(C(=C(C(=C1F)F)F)F)F)NS(=O)(=O)N
DME45J8 IK UPYNRFQXRYOBBD-UHFFFAOYSA-N
DME45J8 IU 1,2,3,4,5-pentafluoro-6-(sulfamoylamino)benzene
DME45J8 DE Discovery agent
DMJO3B1 ID DMJO3B1
DMJO3B1 DN N'-(phenylsulfonyl)benzofuran-2-carbohydrazide
DMJO3B1 HS Investigative
DMJO3B1 SN CHEMBL205220; SCHEMBL6240233; AMGAILKMHSFVNJ-UHFFFAOYSA-N; BDBM50172929; N''-(phenylsulfonyl)benzofuran-2-carbohydrazide; Benzofuran-2-carboxylic acid 2-(phenylsulfonyl)hydrazide
DMJO3B1 DT Small molecular drug
DMJO3B1 PC 9879950
DMJO3B1 MW 316.3
DMJO3B1 FM C15H12N2O4S
DMJO3B1 IC InChI=1S/C15H12N2O4S/c18-15(14-10-11-6-4-5-9-13(11)21-14)16-17-22(19,20)12-7-2-1-3-8-12/h1-10,17H,(H,16,18)
DMJO3B1 CS C1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CC3=CC=CC=C3O2
DMJO3B1 IK AMGAILKMHSFVNJ-UHFFFAOYSA-N
DMJO3B1 IU N'-(benzenesulfonyl)-1-benzofuran-2-carbohydrazide
DMJO3B1 DE Discovery agent
DMQETUY ID DMQETUY
DMQETUY DN N'-(phenylsulfonyl)quinoline-6-carbohydrazide
DMQETUY HS Investigative
DMQETUY SN CHEMBL437697; SCHEMBL6235703; YPRPLJAGGWUKMX-UHFFFAOYSA-N; BDBM50172936; N''-(phenylsulfonyl)quinoline-6-carbohydrazide; Quinoline-6-carboxylic acid 2-(phenylsulfonyl)hydrazide
DMQETUY DT Small molecular drug
DMQETUY PC 9967156
DMQETUY MW 327.4
DMQETUY FM C16H13N3O3S
DMQETUY IC InChI=1S/C16H13N3O3S/c20-16(13-8-9-15-12(11-13)5-4-10-17-15)18-19-23(21,22)14-6-2-1-3-7-14/h1-11,19H,(H,18,20)
DMQETUY CS C1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CC3=C(C=C2)N=CC=C3
DMQETUY IK YPRPLJAGGWUKMX-UHFFFAOYSA-N
DMQETUY IU N'-(benzenesulfonyl)quinoline-6-carbohydrazide
DMQETUY DE Discovery agent
DMGHQJ8 ID DMGHQJ8
DMGHQJ8 DN N-(phosphonacetyl)-L-aspartate
DMGHQJ8 HS Investigative
DMGHQJ8 SN Sparfosic acid; PALA; n-(phosphonacetyl)-l-aspartic acid; N-(Phosphonoacetyl)-L-aspartic acid; Sparfosic Acid [INN]; NSC-224131; UNII-78QVZ7RG8L; 51321-79-0; L-ASPARTIC ACID, N-(PHOSPHONOACETYL)-; N-Phosphonacetyl-L-aspartate; Phosphonacetyl-L-aspartic acid; Acidum sparfosicum [INN-Latin]; Acido sparfosico [INN-Spanish]; Acide sparfosique [INN-French]; N-(Phosphonoacetyl)-asparaginsaeure; N-(Phosphonacetyl)-L-Aspartate; 78QVZ7RG8L; (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid; Acido sparfosico; Acide sparfosique; Acidum; SPARFOSIC ACID
DMGHQJ8 DT Small molecular drug
DMGHQJ8 PC 46926274
DMGHQJ8 MW 252.1
DMGHQJ8 FM C6H7NO8P-3
DMGHQJ8 IC InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/p-3/t3-/m0/s1
DMGHQJ8 CS C([C@@H](C(=O)[O-])NC(=O)CP(=O)(O)[O-])C(=O)[O-]
DMGHQJ8 IK ZZKNRXZVGOYGJT-VKHMYHEASA-K
DMGHQJ8 IU (2S)-2-[[2-[hydroxy(oxido)phosphoryl]acetyl]amino]butanedioate
DMGHQJ8 DE Discovery agent
DM9QIH4 ID DM9QIH4
DM9QIH4 DN N-(piperidin-4-yl)-N-propyl-2-naphthamide
DM9QIH4 HS Investigative
DM9QIH4 SN CHEMBL565638; N-(piperidin-4-yl)-N-propyl-2-naphthamide
DM9QIH4 DT Small molecular drug
DM9QIH4 PC 45487772
DM9QIH4 MW 296.4
DM9QIH4 FM C19H24N2O
DM9QIH4 IC InChI=1S/C19H24N2O/c1-2-13-21(18-9-11-20-12-10-18)19(22)17-8-7-15-5-3-4-6-16(15)14-17/h3-8,14,18,20H,2,9-13H2,1H3
DM9QIH4 CS CCCN(C1CCNCC1)C(=O)C2=CC3=CC=CC=C3C=C2
DM9QIH4 IK KPOGSLKDEJXGPM-UHFFFAOYSA-N
DM9QIH4 IU N-piperidin-4-yl-N-propylnaphthalene-2-carboxamide
DM9QIH4 DE Discovery agent
DMULBO9 ID DMULBO9
DMULBO9 DN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9 HS Investigative
DMULBO9 SN CHEMBL223707; N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide
DMULBO9 DT Small molecular drug
DMULBO9 PC 16124785
DMULBO9 MW 337.3
DMULBO9 FM C18H15N3O4
DMULBO9 IC InChI=1S/C18H15N3O4/c1-11-2-4-12(5-3-11)9-20-18(23)17(22)15-10-19-16-7-6-13(21(24)25)8-14(15)16/h2-8,10,19H,9H2,1H3,(H,20,23)
DMULBO9 CS CC1=CC=C(C=C1)CNC(=O)C(=O)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-]
DMULBO9 IK CXKKDMBQHWZSKG-UHFFFAOYSA-N
DMULBO9 IU N-[(4-methylphenyl)methyl]-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMULBO9 DE Discovery agent
DMTJ5WL ID DMTJ5WL
DMTJ5WL DN N-(propargyl),N-(pyrrol-2-ylmethyl)amine
DMTJ5WL HS Investigative
DMTJ5WL SN pyrrole inhibitor 35; N-(propargyl),N-(pyrrol-2-ylmethyl)amine; CHEMBL220832; BDBM15610; AKOS009008559
DMTJ5WL DT Small molecular drug
DMTJ5WL PC 16110306
DMTJ5WL MW 134.18
DMTJ5WL FM C8H10N2
DMTJ5WL IC InChI=1S/C8H10N2/c1-2-5-9-7-8-4-3-6-10-8/h1,3-4,6,9-10H,5,7H2
DMTJ5WL CS C#CCNCC1=CC=CN1
DMTJ5WL IK KRAVBWUZLLIIPH-UHFFFAOYSA-N
DMTJ5WL IU N-(1H-pyrrol-2-ylmethyl)prop-2-yn-1-amine
DMTJ5WL DE Discovery agent
DMXI4V8 ID DMXI4V8
DMXI4V8 DN N-(Propylamide-acetophenone)-1-deoxynojirimycin
DMXI4V8 HS Investigative
DMXI4V8 SN CHEMBL589341; N-(Propylamide-acetophenone)-1-deoxynojirimycin
DMXI4V8 DT Small molecular drug
DMXI4V8 PC 46229705
DMXI4V8 MW 434.5
DMXI4V8 FM C22H30N2O7
DMXI4V8 IC InChI=1S/C22H30N2O7/c1-2-12-31-16-6-4-15(5-7-16)18(26)8-9-20(28)23-10-3-11-24-13-19(27)22(30)21(29)17(24)14-25/h1,4-7,17,19,21-22,25,27,29-30H,3,8-14H2,(H,23,28)/t17-,19+,21-,22-/m1/s1
DMXI4V8 CS C#CCOC1=CC=C(C=C1)C(=O)CCC(=O)NCCCN2C[C@@H]([C@H]([C@@H]([C@H]2CO)O)O)O
DMXI4V8 IK AAWCULUAQOJFJX-HGIWEUDGSA-N
DMXI4V8 IU 4-oxo-4-(4-prop-2-ynoxyphenyl)-N-[3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl]butanamide
DMXI4V8 DE Discovery agent
DMCZHBI ID DMCZHBI
DMCZHBI DN N-(Propylamide-benzophenone)-1-deoxynojirimycin
DMCZHBI HS Investigative
DMCZHBI SN CHEMBL590070; N-(Propylamide-benzophenone)-1-deoxynojirimycin; BDBM50308672
DMCZHBI DT Small molecular drug
DMCZHBI PC 46229704
DMCZHBI MW 482.5
DMCZHBI FM C26H30N2O7
DMCZHBI IC InChI=1S/C26H30N2O7/c1-2-14-35-20-10-8-18(9-11-20)23(31)17-4-6-19(7-5-17)26(34)27-12-3-13-28-15-22(30)25(33)24(32)21(28)16-29/h1,4-11,21-22,24-25,29-30,32-33H,3,12-16H2,(H,27,34)/t21-,22+,24-,25-/m1/s1
DMCZHBI CS C#CCOC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C(=O)NCCCN3C[C@@H]([C@H]([C@@H]([C@H]3CO)O)O)O
DMCZHBI IK ISWDTKRAKJESLP-PEISPCAHSA-N
DMCZHBI IU 4-(4-prop-2-ynoxybenzoyl)-N-[3-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]propyl]benzamide
DMCZHBI DE Discovery agent
DMTHJL4 ID DMTHJL4
DMTHJL4 DN N-(pyridin-3-yl)indoline-1-carboxamide
DMTHJL4 HS Investigative
DMTHJL4 SN CHEMBL42327; N-(pyridin-3-yl)indoline-1-carboxamide; SCHEMBL9035888; 1-(3-pyridylcarbamoyl) indoline; MolPort-003-287-500; BDBM50321878; AKOS001223824; N-(3-Pyridinyl)-2,3-dihydro-1H-indole-1-carboxamide; 2,3-Dihydro-indole-1-carboxylic acid pyridin-3-ylamide
DMTHJL4 DT Small molecular drug
DMTHJL4 PC 10823903
DMTHJL4 MW 239.27
DMTHJL4 FM C14H13N3O
DMTHJL4 IC InChI=1S/C14H13N3O/c18-14(16-12-5-3-8-15-10-12)17-9-7-11-4-1-2-6-13(11)17/h1-6,8,10H,7,9H2,(H,16,18)
DMTHJL4 CS C1CN(C2=CC=CC=C21)C(=O)NC3=CN=CC=C3
DMTHJL4 IK ODXHNGJYIWHPAG-UHFFFAOYSA-N
DMTHJL4 IU N-pyridin-3-yl-2,3-dihydroindole-1-carboxamide
DMTHJL4 DE Discovery agent
DMBJKH1 ID DMBJKH1
DMBJKH1 DN N-(pyridin-3-ylmethyl) estradiol-16-carboxamide
DMBJKH1 HS Investigative
DMBJKH1 SN SCHEMBL12379481
DMBJKH1 DT Small molecular drug
DMBJKH1 PC 44407373
DMBJKH1 MW 406.5
DMBJKH1 FM C25H30N2O3
DMBJKH1 IC InChI=1S/C25H30N2O3/c1-25-9-8-19-18-7-5-17(28)11-16(18)4-6-20(19)22(25)12-21(23(25)29)24(30)27-14-15-3-2-10-26-13-15/h2-3,5,7,10-11,13,19-23,28-29H,4,6,8-9,12,14H2,1H3,(H,27,30)/t19?,20?,21?,22?,23-,25-/m0/s1
DMBJKH1 CS C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)NCC4=CN=CC=C4)CCC5=C3C=CC(=C5)O
DMBJKH1 IK JLDAJRITWUSQME-GYDLEPMTSA-N
DMBJKH1 IU (13S,17S)-3,17-dihydroxy-13-methyl-N-(pyridin-3-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMBJKH1 DE Discovery agent
DMIN60B ID DMIN60B
DMIN60B DN N-(pyridin-3-ylmethyl)aniline
DMIN60B HS Investigative
DMIN60B SN N-(pyridin-3-ylmethyl)aniline; Phenyl-pyridin-3-ylmethyl-amine; 73570-11-3; phenylpyridin-3-ylmethylamine; CHEMBL264669; N-((pyridine-3-yl)methyl)benzeneamine; BAS 06103406; 3ftv; 3ftw; 11X; 3-anilinomethylpyridine; AC1LLDK0; n-(3-pyridylmethyl)aniline; phenyl(3-pyridylmethyl)amine; 3-(phenylaminomethyl)pyridine; MLS000527027; SCHEMBL523753; BJXLHKJBRORJJJ-UHFFFAOYSA-N; N-[(pyridin-3-yl)methyl]aniline; MolPort-002-003-387; ZINC798246; HMS3604C11; HMS2177I23; N-(pyridin-3-ylmethyl)benzenamine; HMS1684G18
DMIN60B DT Small molecular drug
DMIN60B PC 1082702
DMIN60B MW 184.24
DMIN60B FM C12H12N2
DMIN60B IC InChI=1S/C12H12N2/c1-2-6-12(7-3-1)14-10-11-5-4-8-13-9-11/h1-9,14H,10H2
DMIN60B CS C1=CC=C(C=C1)NCC2=CN=CC=C2
DMIN60B IK BJXLHKJBRORJJJ-UHFFFAOYSA-N
DMIN60B IU N-(pyridin-3-ylmethyl)aniline
DMIN60B DE Discovery agent
DMYFAQV ID DMYFAQV
DMYFAQV DN N-(pyridin-4-ylmethyl) estradiol-16-carboxamide
DMYFAQV HS Investigative
DMYFAQV SN SCHEMBL12379498
DMYFAQV DT Small molecular drug
DMYFAQV PC 44407377
DMYFAQV MW 406.5
DMYFAQV FM C25H30N2O3
DMYFAQV IC InChI=1S/C25H30N2O3/c1-25-9-6-19-18-5-3-17(28)12-16(18)2-4-20(19)22(25)13-21(23(25)29)24(30)27-14-15-7-10-26-11-8-15/h3,5,7-8,10-12,19-23,28-29H,2,4,6,9,13-14H2,1H3,(H,27,30)/t19?,20?,21?,22?,23-,25-/m0/s1
DMYFAQV CS C[C@]12CCC3C(C1CC([C@@H]2O)C(=O)NCC4=CC=NC=C4)CCC5=C3C=CC(=C5)O
DMYFAQV IK PHCMYYPTUPNLMJ-GYDLEPMTSA-N
DMYFAQV IU (13S,17S)-3,17-dihydroxy-13-methyl-N-(pyridin-4-ylmethyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMYFAQV DE Discovery agent
DMYEQXH ID DMYEQXH
DMYEQXH DN N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide
DMYEQXH HS Investigative
DMYEQXH SN CHEMBL475714; N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5458681
DMYEQXH DT Small molecular drug
DMYEQXH PC 44591342
DMYEQXH MW 336.4
DMYEQXH FM C15H20N4O3S
DMYEQXH IC InChI=1S/C15H20N4O3S/c16-23(21,22)18-9-5-1-2-8-15(20)19-13-10-12-6-3-4-7-14(12)17-11-13/h3-4,6-7,10-11,18H,1-2,5,8-9H2,(H,19,20)(H2,16,21,22)
DMYEQXH CS C1=CC=C2C(=C1)C=C(C=N2)NC(=O)CCCCCNS(=O)(=O)N
DMYEQXH IK HIRQWWZRMZTUFZ-UHFFFAOYSA-N
DMYEQXH IU N-quinolin-3-yl-6-(sulfamoylamino)hexanamide
DMYEQXH DE Discovery agent
DMFC3XI ID DMFC3XI
DMFC3XI DN N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide
DMFC3XI HS Investigative
DMFC3XI SN CHEMBL454438; N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5359458; CGIYOYXFUHZSMD-UHFFFAOYSA-N
DMFC3XI DT Small molecular drug
DMFC3XI PC 25216938
DMFC3XI MW 336.4
DMFC3XI FM C15H20N4O3S
DMFC3XI IC InChI=1S/C15H20N4O3S/c16-23(21,22)18-10-3-1-2-6-15(20)19-13-7-8-14-12(11-13)5-4-9-17-14/h4-5,7-9,11,18H,1-3,6,10H2,(H,19,20)(H2,16,21,22)
DMFC3XI CS C1=CC2=C(C=CC(=C2)NC(=O)CCCCCNS(=O)(=O)N)N=C1
DMFC3XI IK CGIYOYXFUHZSMD-UHFFFAOYSA-N
DMFC3XI IU N-quinolin-6-yl-6-(sulfamoylamino)hexanamide
DMFC3XI DE Discovery agent
DML8EVA ID DML8EVA
DML8EVA DN N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide
DML8EVA HS Investigative
DML8EVA SN CHEMBL507114; N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide; SCHEMBL5330834
DML8EVA DT Small molecular drug
DML8EVA PC 25216936
DML8EVA MW 336.4
DML8EVA FM C15H20N4O3S
DML8EVA IC InChI=1S/C15H20N4O3S/c16-23(21,22)18-11-3-1-2-9-14(20)19-13-8-4-6-12-7-5-10-17-15(12)13/h4-8,10,18H,1-3,9,11H2,(H,19,20)(H2,16,21,22)
DML8EVA CS C1=CC2=C(C(=C1)NC(=O)CCCCCNS(=O)(=O)N)N=CC=C2
DML8EVA IK IQEBALPYRTUOEG-UHFFFAOYSA-N
DML8EVA IU N-quinolin-8-yl-6-(sulfamoylamino)hexanamide
DML8EVA DE Discovery agent
DM7O1F3 ID DM7O1F3
DM7O1F3 DN N-(quinolin-8-yl)thiophene-2-sulfonamide
DM7O1F3 HS Investigative
DM7O1F3 SN CHEMBL257234; N-(quinolin-8-yl)thiophene-2-sulfonamide; AC1LH19W; Oprea1_700618; SCHEMBL7190921; MolPort-003-066-216; ZINC353084; BDBM50372518; AKOS001422726; N-quinolin-8-ylthiophene-2-sulfonamide; MCULE-3746564892; N-(8-Quinolyl)-2-thiophenesulfonamide; NCGC00161717-01; SR-01000012975; CU-00000000139-1; SR-01000012975-1; Z115639124
DM7O1F3 DT Small molecular drug
DM7O1F3 PC 830459
DM7O1F3 MW 290.4
DM7O1F3 FM C13H10N2O2S2
DM7O1F3 IC InChI=1S/C13H10N2O2S2/c16-19(17,12-7-3-9-18-12)15-11-6-1-4-10-5-2-8-14-13(10)11/h1-9,15H
DM7O1F3 CS C1=CC2=C(C(=C1)NS(=O)(=O)C3=CC=CS3)N=CC=C2
DM7O1F3 IK CPSRVVXBTZFZPM-UHFFFAOYSA-N
DM7O1F3 IU N-quinolin-8-ylthiophene-2-sulfonamide
DM7O1F3 DE Discovery agent
DM2SNXB ID DM2SNXB
DM2SNXB DN N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)
DM2SNXB HS Investigative
DM2SNXB SN N-(R-CARBOXY-ETHYL)-ALPHA-(S)-(2-PHENYLETHYL); Inhibitor 1; IH4; AC1LCW3V; DB02505; methyl 2-[4-[4-[[[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl]-(4-pentylbenzoyl)amino]methyl]phenyl]phenyl]acetate; methyl 2-{4-[4-({N-[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl]-1-(4-pentylphenyl)formamido}methyl)phenyl]phenyl}acetate; methyl [4'-({[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino}methyl)biphenyl-4-yl]acetate
DM2SNXB DT Small molecular drug
DM2SNXB PC 657149
DM2SNXB MW 592.8
DM2SNXB FM C37H44N4O3
DM2SNXB IC InChI=1S/C37H44N4O3/c1-3-4-5-6-28-7-17-33(18-8-28)37(43)41(34-19-23-40(24-20-34)27-35-38-21-22-39-35)26-30-11-15-32(16-12-30)31-13-9-29(10-14-31)25-36(42)44-2/h7-18,21-22,34H,3-6,19-20,23-27H2,1-2H3,(H,38,39)
DM2SNXB CS CCCCCC1=CC=C(C=C1)C(=O)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)CC(=O)OC)C4CCN(CC4)CC5=NC=CN5
DM2SNXB IK JJVQUUYZGJWBPW-UHFFFAOYSA-N
DM2SNXB IU methyl 2-[4-[4-[[[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl]-(4-pentylbenzoyl)amino]methyl]phenyl]phenyl]acetate
DM2SNXB DE Discovery agent
DMWJDYZ ID DMWJDYZ
DMWJDYZ DN N-(Sulfanylacetyl)Tyrosylprolylmethioninamide
DMWJDYZ HS Investigative
DMWJDYZ SN N-(SULFANYLACETYL)TYROSYLPROLYLMETHIONINAMIDE; SD2; 1pwq; AC1NRD4A; SCHEMBL4315756; DB01883; N-(sulfanylacetyl)-L-tyrosyl-L-prolyl-L-methioninamide; (2S)-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-1-[(2S)-3-(4-hydroxyphenyl)-2-[(2-sulfanylacetyl)amino]propanoyl]pyrrolidine-2-carboxamide
DMWJDYZ DT Small molecular drug
DMWJDYZ PC 5289343
DMWJDYZ MW 482.6
DMWJDYZ FM C21H30N4O5S2
DMWJDYZ IC InChI=1S/C21H30N4O5S2/c1-32-10-8-15(19(22)28)24-20(29)17-3-2-9-25(17)21(30)16(23-18(27)12-31)11-13-4-6-14(26)7-5-13/h4-7,15-17,26,31H,2-3,8-12H2,1H3,(H2,22,28)(H,23,27)(H,24,29)/t15-,16-,17-/m0/s1
DMWJDYZ CS CSCC[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)CS
DMWJDYZ IK LNLWXWOYQHAKTD-ULQDDVLXSA-N
DMWJDYZ IU (2S)-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-1-[(2S)-3-(4-hydroxyphenyl)-2-[(2-sulfanylacetyl)amino]propanoyl]pyrrolidine-2-carboxamide
DMWJDYZ DE Discovery agent
DMJ0S5C ID DMJ0S5C
DMJ0S5C DN N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile
DMJ0S5C HS Investigative
DMJ0S5C SN dipeptide-derived nitrile, 9; CHEMBL197113; BDBM20088; tert-butyl N-[(1S,2R)-1-[(cyanomethyl)carbamoyl]-2-methylbutyl]carbamate
DMJ0S5C DT Small molecular drug
DMJ0S5C PC 23648531
DMJ0S5C MW 269.34
DMJ0S5C FM C13H23N3O3
DMJ0S5C IC InChI=1S/C13H23N3O3/c1-6-9(2)10(11(17)15-8-7-14)16-12(18)19-13(3,4)5/h9-10H,6,8H2,1-5H3,(H,15,17)(H,16,18)/t9-,10+/m1/s1
DMJ0S5C CS CC[C@@H](C)[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMJ0S5C IK HNTBSHVGXMFKKB-ZJUUUORDSA-N
DMJ0S5C IU tert-butyl N-[(2S,3R)-1-(cyanomethylamino)-3-methyl-1-oxopentan-2-yl]carbamate
DMJ0S5C DE Discovery agent
DMXYQWG ID DMXYQWG
DMXYQWG DN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile
DMXYQWG HS Investigative
DMXYQWG SN dipeptide-derived nitrile, 7; CHEMBL200160; SCHEMBL6257676; BDBM20087; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-methylbutyl]carbamate
DMXYQWG DT Small molecular drug
DMXYQWG PC 11492732
DMXYQWG MW 269.34
DMXYQWG FM C13H23N3O3
DMXYQWG IC InChI=1S/C13H23N3O3/c1-9(2)8-10(11(17)15-7-6-14)16-12(18)19-13(3,4)5/h9-10H,7-8H2,1-5H3,(H,15,17)(H,16,18)/t10-/m0/s1
DMXYQWG CS CC(C)C[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMXYQWG IK OMQSGXGRANQGLE-JTQLQIEISA-N
DMXYQWG IU tert-butyl N-[(2S)-1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]carbamate
DMXYQWG DE Discovery agent
DM3I0WZ ID DM3I0WZ
DM3I0WZ DN N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile
DM3I0WZ HS Investigative
DM3I0WZ SN dipeptide-derived nitrile, 12; CHEMBL381847; BDBM20091; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-3-(methylsulfanyl)propyl]carbamate
DM3I0WZ DT Small molecular drug
DM3I0WZ PC 11709032
DM3I0WZ MW 287.38
DM3I0WZ FM C12H21N3O3S
DM3I0WZ IC InChI=1S/C12H21N3O3S/c1-12(2,3)18-11(17)15-9(5-8-19-4)10(16)14-7-6-13/h9H,5,7-8H2,1-4H3,(H,14,16)(H,15,17)/t9-/m0/s1
DM3I0WZ CS CC(C)(C)OC(=O)N[C@@H](CCSC)C(=O)NCC#N
DM3I0WZ IK PDUKBZKBRGAZFC-VIFPVBQESA-N
DM3I0WZ IU tert-butyl N-[(2S)-1-(cyanomethylamino)-4-methylsulfanyl-1-oxobutan-2-yl]carbamate
DM3I0WZ DE Discovery agent
DMGF4XC ID DMGF4XC
DMGF4XC DN N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile
DMGF4XC HS Investigative
DMGF4XC SN dipeptide-derived nitrile, 13; CHEMBL383584; BDBM20092; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]pentyl]carbamate
DMGF4XC DT Small molecular drug
DMGF4XC PC 11637576
DMGF4XC MW 269.34
DMGF4XC FM C13H23N3O3
DMGF4XC IC InChI=1S/C13H23N3O3/c1-5-6-7-10(11(17)15-9-8-14)16-12(18)19-13(2,3)4/h10H,5-7,9H2,1-4H3,(H,15,17)(H,16,18)/t10-/m0/s1
DMGF4XC CS CCCC[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMGF4XC IK KXUSXCUMFSXFIW-JTQLQIEISA-N
DMGF4XC IU tert-butyl N-[(2S)-1-(cyanomethylamino)-1-oxohexan-2-yl]carbamate
DMGF4XC DE Discovery agent
DMOP5N7 ID DMOP5N7
DMOP5N7 DN N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile
DMOP5N7 HS Investigative
DMOP5N7 SN dipeptide-derived nitrile, 6; CHEMBL383816; BDBM20086; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]butyl]carbamate
DMOP5N7 DT Small molecular drug
DMOP5N7 PC 11514386
DMOP5N7 MW 255.31
DMOP5N7 FM C12H21N3O3
DMOP5N7 IC InChI=1S/C12H21N3O3/c1-5-6-9(10(16)14-8-7-13)15-11(17)18-12(2,3)4/h9H,5-6,8H2,1-4H3,(H,14,16)(H,15,17)/t9-/m0/s1
DMOP5N7 CS CCC[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMOP5N7 IK PBHMIOPVNIIFHR-VIFPVBQESA-N
DMOP5N7 IU tert-butyl N-[(2S)-1-(cyanomethylamino)-1-oxopentan-2-yl]carbamate
DMOP5N7 DE Discovery agent
DMP9JVT ID DMP9JVT
DMP9JVT DN N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile
DMP9JVT HS Investigative
DMP9JVT SN dipeptide-derived nitrile, 23; CHEMBL371893; BDBM20102; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamate
DMP9JVT DT Small molecular drug
DMP9JVT PC 11551481
DMP9JVT MW 319.36
DMP9JVT FM C16H21N3O4
DMP9JVT IC InChI=1S/C16H21N3O4/c1-16(2,3)23-15(22)19-13(14(21)18-9-8-17)10-11-4-6-12(20)7-5-11/h4-7,13,20H,9-10H2,1-3H3,(H,18,21)(H,19,22)/t13-/m0/s1
DMP9JVT CS CC(C)(C)OC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC#N
DMP9JVT IK ZMDCVKGQECBOGN-ZDUSSCGKSA-N
DMP9JVT IU tert-butyl N-[(2S)-1-(cyanomethylamino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate
DMP9JVT DE Discovery agent
DMUQBOP ID DMUQBOP
DMUQBOP DN N-(tert-butoxycarbonyl)-valyl-glycine-nitrile
DMUQBOP HS Investigative
DMUQBOP SN N-(tert-butoxycarbonyl)-L-valyl-glycine-nitrile; 191033-03-1; dipeptide-derived nitrile, 5; CHEMBL200004; BDBM20085; tert-butyl N-[(1S)-1-[(cyanomethyl)carbamoyl]-2-methylpropyl]carbamate
DMUQBOP DT Small molecular drug
DMUQBOP PC 14774521
DMUQBOP MW 255.31
DMUQBOP FM C12H21N3O3
DMUQBOP IC InChI=1S/C12H21N3O3/c1-8(2)9(10(16)14-7-6-13)15-11(17)18-12(3,4)5/h8-9H,7H2,1-5H3,(H,14,16)(H,15,17)/t9-/m0/s1
DMUQBOP CS CC(C)[C@@H](C(=O)NCC#N)NC(=O)OC(C)(C)C
DMUQBOP IK OHPJKVGJQUYVFQ-VIFPVBQESA-N
DMUQBOP IU tert-butyl N-[(2S)-1-(cyanomethylamino)-3-methyl-1-oxobutan-2-yl]carbamate
DMUQBOP DE Discovery agent
DM1N7AG ID DM1N7AG
DM1N7AG DN N-(thiazol-2-yl)benzamide
DM1N7AG HS Investigative
DM1N7AG SN N-(1,3-Thiazol-2-yl)benzamide; N-Thiazol-2-yl-benzamide; SCQBDADQAVXTMZ-UHFFFAOYSA-N; 13053-82-2; N-(thiazol-2-yl)benzamide; Benzamide, N-2-thiazolyl-; AC1LC4SL; AC1Q5LQU; n-thiazol-2-yl benzamide; N-(2-Thiazolyl)benzamide; MLS000711892; SCHEMBL995829; CHEMBL90846; Benzamide, N-(2-thiazolyl)-; IFLab1_003538; ZINC39994; MolPort-000-557-753; HMS1422A18; HMS2643F11; N-(1,3-Thiazol-2-yl)benzamide #; STK018313; AKOS005145274; AKOS000638160; MCULE-9395155160; IDI1_009645; SMR000281659; phenyl-N-(1,3-thiazol-2-yl)carboxamide; BAS 00332640
DM1N7AG DT Small molecular drug
DM1N7AG PC 569547
DM1N7AG MW 204.25
DM1N7AG FM C10H8N2OS
DM1N7AG IC InChI=1S/C10H8N2OS/c13-9(8-4-2-1-3-5-8)12-10-11-6-7-14-10/h1-7H,(H,11,12,13)
DM1N7AG CS C1=CC=C(C=C1)C(=O)NC2=NC=CS2
DM1N7AG IK SCQBDADQAVXTMZ-UHFFFAOYSA-N
DM1N7AG IU N-(1,3-thiazol-2-yl)benzamide
DM1N7AG CA CAS 13053-82-2
DM1N7AG DE Discovery agent
DM8JQEO ID DM8JQEO
DM8JQEO DN N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine
DM8JQEO HS Investigative
DM8JQEO SN CHEMBL89454; 1,4-Butanediamine, N1-(5-methyl-2-nitrophenyl)-; N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine; BDBM50065369; AKOS018628293
DM8JQEO DT Small molecular drug
DM8JQEO PC 10489277
DM8JQEO MW 223.27
DM8JQEO FM C11H17N3O2
DM8JQEO IC InChI=1S/C11H17N3O2/c1-9-4-5-11(14(15)16)10(8-9)13-7-3-2-6-12/h4-5,8,13H,2-3,6-7,12H2,1H3
DM8JQEO CS CC1=CC(=C(C=C1)[N+](=O)[O-])NCCCCN
DM8JQEO IK ANIBJVLRYPKMKX-UHFFFAOYSA-N
DM8JQEO IU N'-(5-methyl-2-nitrophenyl)butane-1,4-diamine
DM8JQEO DE Discovery agent
DME8KXT ID DME8KXT
DME8KXT DN N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine
DME8KXT HS Investigative
DME8KXT SN CHEMBL38754; N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine; BDBM50090212; AKOS009510501
DME8KXT DT Small molecular drug
DME8KXT PC 43450811
DME8KXT MW 232.24
DME8KXT FM C11H12N4O2
DME8KXT IC InChI=1S/C11H12N4O2/c12-5-6-13-11-4-1-8-7-9(15(16)17)2-3-10(8)14-11/h1-4,7H,5-6,12H2,(H,13,14)
DME8KXT CS C1=CC2=C(C=CC(=N2)NCCN)C=C1[N+](=O)[O-]
DME8KXT IK ULJORSRDDXAXJZ-UHFFFAOYSA-N
DME8KXT IU N'-(6-nitroquinolin-2-yl)ethane-1,2-diamine
DME8KXT DE Discovery agent
DM41TQB ID DM41TQB
DM41TQB DN N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine
DM41TQB HS Investigative
DM41TQB SN CHEMBL190147; N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine; BDBM50170836
DM41TQB DT Small molecular drug
DM41TQB PC 15366659
DM41TQB MW 322.4
DM41TQB FM C18H22N6
DM41TQB IC InChI=1S/C18H22N6/c1-3-7-13(8-4-1)11-19-18-23-16-15(20-12-21-16)17(24-18)22-14-9-5-2-6-10-14/h1,3-4,7-8,12,14H,2,5-6,9-11H2,(H3,19,20,21,22,23,24)
DM41TQB CS C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NCC4=CC=CC=C4
DM41TQB IK NPPHTZNKBUCRPG-UHFFFAOYSA-N
DM41TQB IU 2-N-benzyl-6-N-cyclohexyl-7H-purine-2,6-diamine
DM41TQB DE Discovery agent
DMFWN5U ID DMFWN5U
DMFWN5U DN N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine
DMFWN5U HS Investigative
DMFWN5U SN bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514
DMFWN5U DT Small molecular drug
DMFWN5U PC 2426
DMFWN5U MW 330.18
DMFWN5U FM C14H12BrN5
DMFWN5U IC InChI=1S/C14H12BrN5/c15-8-2-1-3-9(4-8)20-14-10-5-11(16)12(17)6-13(10)18-7-19-14/h1-7H,16-17H2,(H,18,19,20)
DMFWN5U CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=CC(=C(C=C32)N)N
DMFWN5U IK ADXSZLCTQCWMTE-UHFFFAOYSA-N
DMFWN5U IU 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine
DMFWN5U CA CAS 169205-87-2
DMFWN5U DE Discovery agent
DMUI8RC ID DMUI8RC
DMUI8RC DN N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine
DMUI8RC HS Investigative
DMUI8RC SN N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221
DMUI8RC DT Small molecular drug
DMUI8RC PC 5328042
DMUI8RC MW 315.17
DMUI8RC FM C14H11BrN4
DMUI8RC IC InChI=1S/C14H11BrN4/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
DMUI8RC CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=C(C=C3)N
DMUI8RC IK IZQHULBHKPGOAP-UHFFFAOYSA-N
DMUI8RC IU 4-N-(3-bromophenyl)quinazoline-4,6-diamine
DMUI8RC CA CAS 169205-78-1
DMUI8RC DE Discovery agent
DMO56XY ID DMO56XY
DMO56XY DN N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine
DMO56XY HS Investigative
DMO56XY SN CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline
DMO56XY DT Small molecular drug
DMO56XY PC 5328045
DMO56XY MW 315.17
DMO56XY FM C14H11BrN4
DMO56XY IC InChI=1S/C14H11BrN4/c15-9-2-1-3-11(6-9)19-14-12-5-4-10(16)7-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
DMO56XY CS C1=CC(=CC(=C1)Br)NC2=NC=NC3=C2C=CC(=C3)N
DMO56XY IK GHVBIROTJQDRQB-UHFFFAOYSA-N
DMO56XY IU 4-N-(3-bromophenyl)quinazoline-4,7-diamine
DMO56XY DE Discovery agent
DMNGSQK ID DMNGSQK
DMNGSQK DN N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine
DMNGSQK HS Investigative
DMNGSQK SN 91066-67-0; CHEMBL158113; N4-Benzyl-6-chloropyrimidine-2,4-diamine; N~4~-benzyl-6-chloropyrimidine-2,4-diamine; 4-N-benzyl-6-chloropyrimidine-2,4-diamine; N~4~-benzyl-6-chloro-2,4-pyrimidinediamine; 2,4-Pyrimidinediamine, 6-chloro-N4-(phenylmethyl)-; N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine; Oprea1_700029; AC1Q52S4; AC1LS938; SCHEMBL1319082; CTK6G7145; DTXSID50363293; GXNJAZPAQIPYMJ-UHFFFAOYSA-N; MolPort-001-843-083; KS-00003D1N; ALBB-022867; ZINC1398022; SBB098322; BDBM50022150; AKOS015993366
DMNGSQK DT Small molecular drug
DMNGSQK PC 1484270
DMNGSQK MW 234.68
DMNGSQK FM C11H11ClN4
DMNGSQK IC InChI=1S/C11H11ClN4/c12-9-6-10(16-11(13)15-9)14-7-8-4-2-1-3-5-8/h1-6H,7H2,(H3,13,14,15,16)
DMNGSQK CS C1=CC=C(C=C1)CNC2=CC(=NC(=N2)N)Cl
DMNGSQK IK GXNJAZPAQIPYMJ-UHFFFAOYSA-N
DMNGSQK IU 4-N-benzyl-6-chloropyrimidine-2,4-diamine
DMNGSQK CA CAS 91066-67-0
DMNGSQK DE Discovery agent
DMK674I ID DMK674I
DMK674I DN N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine
DMK674I HS Investigative
DMK674I SN CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882
DMK674I DT Small molecular drug
DMK674I PC 5328077
DMK674I MW 251.29
DMK674I FM C14H13N5
DMK674I IC InChI=1S/C14H13N5/c15-13-6-12-11(8-16-13)14(19-9-18-12)17-7-10-4-2-1-3-5-10/h1-6,8-9H,7H2,(H2,15,16)(H,17,18,19)
DMK674I CS C1=CC=C(C=C1)CNC2=NC=NC3=CC(=NC=C32)N
DMK674I IK JBRBEQRTMVYDCU-UHFFFAOYSA-N
DMK674I IU 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine
DMK674I DE Discovery agent
DMRNGV0 ID DMRNGV0
DMRNGV0 DN N*6*-Benzyl-quinazoline-2,4,6-triamine
DMRNGV0 HS Investigative
DMRNGV0 SN CHEMBL115474; N*6*-Benzyl-quinazoline-2,4,6-triamine; AC1LA5GO; ZINC5974540; BDBM50066486; N6-benzylquinazoline-2,4,6-triamine; 6-N-benzylquinazoline-2,4,6-triamine; 2,4-diamino-6-(benzylamino)quinazoline; 6-(Benzylamino)-2,4-quinazolinediamine
DMRNGV0 DT Small molecular drug
DMRNGV0 PC 462120
DMRNGV0 MW 265.31
DMRNGV0 FM C15H15N5
DMRNGV0 IC InChI=1S/C15H15N5/c16-14-12-8-11(6-7-13(12)19-15(17)20-14)18-9-10-4-2-1-3-5-10/h1-8,18H,9H2,(H4,16,17,19,20)
DMRNGV0 CS C1=CC=C(C=C1)CNC2=CC3=C(C=C2)N=C(N=C3N)N
DMRNGV0 IK PTWJNRZKGULCMJ-UHFFFAOYSA-N
DMRNGV0 IU 6-N-benzylquinazoline-2,4,6-triamine
DMRNGV0 DE Discovery agent
DM1K2A4 ID DM1K2A4
DM1K2A4 DN N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine
DM1K2A4 HS Investigative
DM1K2A4 SN CHEMBL191551; N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine
DM1K2A4 DT Small molecular drug
DM1K2A4 PC 11334464
DM1K2A4 MW 260.339
DM1K2A4 FM C13H20N6
DM1K2A4 IC InChI=1S/C13H20N6/c1-2-14-13-18-11-10(15-8-16-11)12(19-13)17-9-6-4-3-5-7-9/h8-9H,2-7H2,1H3,(H3,14,15,16,17,18,19)
DM1K2A4 CS CCNC1=NC2=C(C(=N1)NC3CCCCC3)NC=N2
DM1K2A4 IK XHOVJLBZYXEITR-UHFFFAOYSA-N
DM1K2A4 IU 6-N-cyclohexyl-2-N-ethyl-7H-purine-2,6-diamine
DM1K2A4 DE Discovery agent
DM3C8PJ ID DM3C8PJ
DM3C8PJ DN N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ HS Investigative
DM3C8PJ SN CHEMBL188592; N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine
DM3C8PJ DT Small molecular drug
DM3C8PJ PC 11243768
DM3C8PJ MW 308.4
DM3C8PJ FM C17H20N6
DM3C8PJ IC InChI=1S/C17H20N6/c1-3-7-12(8-4-1)20-16-14-15(19-11-18-14)22-17(23-16)21-13-9-5-2-6-10-13/h2,5-6,9-12H,1,3-4,7-8H2,(H3,18,19,20,21,22,23)
DM3C8PJ CS C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=CC=C4
DM3C8PJ IK FDFMDLSSHFEJOS-UHFFFAOYSA-N
DM3C8PJ IU 6-N-cyclohexyl-2-N-phenyl-7H-purine-2,6-diamine
DM3C8PJ DE Discovery agent
DMCOPR3 ID DMCOPR3
DMCOPR3 DN N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine
DMCOPR3 HS Investigative
DMCOPR3 SN CHEMBL365026; N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine
DMCOPR3 DT Small molecular drug
DMCOPR3 PC 11484484
DMCOPR3 MW 336.4
DMCOPR3 FM C19H24N6
DMCOPR3 IC InChI=1S/C19H24N6/c1-2-5-9-14(10-6-3-1)22-18-16-17(21-13-20-16)24-19(25-18)23-15-11-7-4-8-12-15/h4,7-8,11-14H,1-3,5-6,9-10H2,(H3,20,21,22,23,24,25)
DMCOPR3 CS C1CCCC(CCC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=CC=C4
DMCOPR3 IK MSEVQUIRSAPIPS-UHFFFAOYSA-N
DMCOPR3 IU 6-N-cyclooctyl-2-N-phenyl-7H-purine-2,6-diamine
DMCOPR3 DE Discovery agent
DMWKRJX ID DMWKRJX
DMWKRJX DN N',2-diphenylquinoline-4-carbohydrazide
DMWKRJX HS Investigative
DMWKRJX SN compound 2g [PMID: 16950620]
DMWKRJX DT Small molecular drug
DMWKRJX PC 16049828
DMWKRJX MW 427.5
DMWKRJX FM C25H21N3O4
DMWKRJX IC InChI=1S/C25H21N3O4/c1-31-23-21(24(29)27-28(25(30)32-2)18-13-7-4-8-14-18)19-15-9-10-16-20(19)26-22(23)17-11-5-3-6-12-17/h3-16H,1-2H3,(H,27,29)
DMWKRJX CS COC1=C(C2=CC=CC=C2N=C1C3=CC=CC=C3)C(=O)NN(C4=CC=CC=C4)C(=O)OC
DMWKRJX IK JLSTVOPSMZBZSR-UHFFFAOYSA-N
DMWKRJX IU methyl N-[(3-methoxy-2-phenylquinoline-4-carbonyl)amino]-N-phenylcarbamate
DMWKRJX DE Discovery agent
DMNJA3C ID DMNJA3C
DMNJA3C DN N',2-diphenylquinoline-4-carbohydrazide 8m
DMNJA3C HS Investigative
DMNJA3C SN compound 8m [PMID:16950617]
DMNJA3C DT Small molecular drug
DMNJA3C PC 11989776
DMNJA3C MW 569.7
DMNJA3C FM C33H36FN5O3
DMNJA3C IC InChI=1S/C33H36FN5O3/c1-33(2,3)38-20-18-37(19-21-38)22-26-28(31(40)36-39(32(41)42-4)24-14-9-6-10-15-24)25-16-11-17-27(34)30(25)35-29(26)23-12-7-5-8-13-23/h5-17H,18-22H2,1-4H3,(H,36,40)
DMNJA3C CS CC(C)(C)N1CCN(CC1)CC2=C(N=C3C(=C2C(=O)NN(C4=CC=CC=C4)C(=O)OC)C=CC=C3F)C5=CC=CC=C5
DMNJA3C IK KQNYTTDHCMFOME-UHFFFAOYSA-N
DMNJA3C IU methyl N-[[3-[(4-tert-butylpiperazin-1-yl)methyl]-8-fluoro-2-phenylquinoline-4-carbonyl]amino]-N-phenylcarbamate
DMNJA3C DE Discovery agent
DMOG37L ID DMOG37L
DMOG37L DN N,4-dibenzhydrylpiperazine-1-carboxamide
DMOG37L HS Investigative
DMOG37L SN CHEMBL599217; 381248-72-2; SCHEMBL3396540; CTK1A9093; DTXSID50435823; PPVBMJIAJXVQFX-UHFFFAOYSA-N; AKOS029837741; 1-Piperazinecarboxamide, N,4-bis(diphenylmethyl)-; 4-Benzhydryl-piperazine-1-carboxylic acid benzhydryl amide; 1-[(diphenylmethyl)aminocarbonyl]-4-(diphenylmethyl) piperazine
DMOG37L DT Small molecular drug
DMOG37L PC 10115592
DMOG37L MW 461.6
DMOG37L FM C31H31N3O
DMOG37L IC InChI=1S/C31H31N3O/c35-31(32-29(25-13-5-1-6-14-25)26-15-7-2-8-16-26)34-23-21-33(22-24-34)30(27-17-9-3-10-18-27)28-19-11-4-12-20-28/h1-20,29-30H,21-24H2,(H,32,35)
DMOG37L CS C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NC(C4=CC=CC=C4)C5=CC=CC=C5
DMOG37L IK PPVBMJIAJXVQFX-UHFFFAOYSA-N
DMOG37L IU N,4-dibenzhydrylpiperazine-1-carboxamide
DMOG37L CA CAS 381248-72-2
DMOG37L DE Discovery agent
DMMTQ3N ID DMMTQ3N
DMMTQ3N DN N,4-dimethyl-3,4-dihydroquinazolin-2-amine
DMMTQ3N HS Investigative
DMMTQ3N DT Small molecular drug
DMMTQ3N PC 44455897
DMMTQ3N DE Discovery agent
DM8G0WX ID DM8G0WX
DM8G0WX DN N,8-dihydroxy-8-(naphthalen-2-yl)octanamide
DM8G0WX HS Investigative
DM8G0WX SN CHEMBL319738; N,8-dihydroxy-8-(naphthalen-2-yl)octanamide; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide
DM8G0WX DT Small molecular drug
DM8G0WX PC 11044829
DM8G0WX MW 301.4
DM8G0WX FM C18H23NO3
DM8G0WX IC InChI=1S/C18H23NO3/c20-17(9-3-1-2-4-10-18(21)19-22)16-12-11-14-7-5-6-8-15(14)13-16/h5-8,11-13,17,20,22H,1-4,9-10H2,(H,19,21)
DM8G0WX CS C1=CC=C2C=C(C=CC2=C1)C(CCCCCCC(=O)NO)O
DM8G0WX IK JWCSCYWHCCHTEF-UHFFFAOYSA-N
DM8G0WX IU N,8-dihydroxy-8-naphthalen-2-yloctanamide
DM8G0WX DE Discovery agent
DMZXF36 ID DMZXF36
DMZXF36 DN N,8-diphenyl-9H-purin-6-amine
DMZXF36 HS Investigative
DMZXF36 SN CHEMBL1210175; N,8-diphenyl-9H-purin-6-amine; N,8-Diphenyl-9H-purine-6-amine; BDBM50322830; SR-01000661492
DMZXF36 DT Small molecular drug
DMZXF36 PC 46894037
DMZXF36 MW 287.32
DMZXF36 FM C17H13N5
DMZXF36 IC InChI=1S/C17H13N5/c1-3-7-12(8-4-1)15-21-14-16(18-11-19-17(14)22-15)20-13-9-5-2-6-10-13/h1-11H,(H2,18,19,20,21,22)
DMZXF36 CS C1=CC=C(C=C1)C2=NC3=C(N2)C(=NC=N3)NC4=CC=CC=C4
DMZXF36 IK OKZNIBWRMMFNQY-UHFFFAOYSA-N
DMZXF36 IU N,8-diphenyl-7H-purin-6-amine
DMZXF36 DE Discovery agent
DMIX0CT ID DMIX0CT
DMIX0CT DN N,N'-(1',10'-decylene)-bis-(-)-nor-MEP
DMIX0CT HS Investigative
DMIX0CT SN CHEMBL259523
DMIX0CT DT Small molecular drug
DMIX0CT PC 24827759
DMIX0CT MW 576.9
DMIX0CT FM C38H60N2O2
DMIX0CT IC InChI=1S/C38H60N2O2/c1-3-37(33-19-17-21-35(41)29-33)23-11-15-27-39(31-37)25-13-9-7-5-6-8-10-14-26-40-28-16-12-24-38(4-2,32-40)34-20-18-22-36(42)30-34/h17-22,29-30,41-42H,3-16,23-28,31-32H2,1-2H3/t37-,38-/m1/s1
DMIX0CT CS CC[C@]1(CCCCN(C1)CCCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMIX0CT IK PCOSLLZEMYSIRZ-XPSQVAKYSA-N
DMIX0CT IU 3-[(3S)-3-ethyl-1-[10-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]decyl]azepan-3-yl]phenol
DMIX0CT DE Discovery agent
DM5NVIO ID DM5NVIO
DM5NVIO DN N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP
DM5NVIO HS Investigative
DM5NVIO SN CHEMBL406885
DM5NVIO DT Small molecular drug
DM5NVIO PC 24827761
DM5NVIO MW 590.9
DM5NVIO FM C39H62N2O2
DM5NVIO IC InChI=1S/C39H62N2O2/c1-3-38(34-20-18-22-36(42)30-34)24-12-16-28-40(32-38)26-14-10-8-6-5-7-9-11-15-27-41-29-17-13-25-39(4-2,33-41)35-21-19-23-37(43)31-35/h18-23,30-31,42-43H,3-17,24-29,32-33H2,1-2H3/t38-,39-/m1/s1
DM5NVIO CS CC[C@]1(CCCCN(C1)CCCCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DM5NVIO IK IMWJSGSESWBQFI-LJEWAXOPSA-N
DM5NVIO IU 3-[(3S)-3-ethyl-1-[11-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]undecyl]azepan-3-yl]phenol
DM5NVIO DE Discovery agent
DMWI06H ID DMWI06H
DMWI06H DN N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP
DMWI06H HS Investigative
DMWI06H SN CHEMBL265214
DMWI06H DT Small molecular drug
DMWI06H PC 24827896
DMWI06H MW 604.9
DMWI06H FM C40H64N2O2
DMWI06H IC InChI=1S/C40H64N2O2/c1-3-39(35-21-19-23-37(43)31-35)25-13-17-29-41(33-39)27-15-11-9-7-5-6-8-10-12-16-28-42-30-18-14-26-40(4-2,34-42)36-22-20-24-38(44)32-36/h19-24,31-32,43-44H,3-18,25-30,33-34H2,1-2H3/t39-,40-/m1/s1
DMWI06H CS CC[C@]1(CCCCN(C1)CCCCCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMWI06H IK ZWQWXPDQHDYQPH-XRSDMRJBSA-N
DMWI06H IU 3-[(3S)-3-ethyl-1-[12-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]dodecyl]azepan-3-yl]phenol
DMWI06H DE Discovery agent
DM1LKEP ID DM1LKEP
DM1LKEP DN N,N'-(1',2'-ethylene)-bis-(-)-nor-MEP
DM1LKEP HS Investigative
DM1LKEP SN CHEMBL411226
DM1LKEP DT Small molecular drug
DM1LKEP PC 24827287
DM1LKEP MW 464.7
DM1LKEP FM C30H44N2O2
DM1LKEP IC InChI=1S/C30H44N2O2/c1-3-29(25-11-9-13-27(33)21-25)15-5-7-17-31(23-29)19-20-32-18-8-6-16-30(4-2,24-32)26-12-10-14-28(34)22-26/h9-14,21-22,33-34H,3-8,15-20,23-24H2,1-2H3/t29-,30-/m1/s1
DM1LKEP CS CC[C@]1(CCCCN(C1)CCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DM1LKEP IK RMHAJXOOJPBLSR-LOYHVIPDSA-N
DM1LKEP IU 3-[(3S)-3-ethyl-1-[2-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]ethyl]azepan-3-yl]phenol
DM1LKEP DE Discovery agent
DM4G6BT ID DM4G6BT
DM4G6BT DN N,N'-(1',3'-propylene)-bis-(-)-nor-MEP
DM4G6BT HS Investigative
DM4G6BT SN CHEMBL258468
DM4G6BT DT Small molecular drug
DM4G6BT PC 24827411
DM4G6BT MW 478.7
DM4G6BT FM C31H46N2O2
DM4G6BT IC InChI=1S/C31H46N2O2/c1-3-30(26-12-9-14-28(34)22-26)16-5-7-18-32(24-30)20-11-21-33-19-8-6-17-31(4-2,25-33)27-13-10-15-29(35)23-27/h9-10,12-15,22-23,34-35H,3-8,11,16-21,24-25H2,1-2H3/t30-,31-/m1/s1
DM4G6BT CS CC[C@]1(CCCCN(C1)CCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DM4G6BT IK SKYWWOFBHWQWFU-FIRIVFDPSA-N
DM4G6BT IU 3-[(3S)-3-ethyl-1-[3-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]propyl]azepan-3-yl]phenol
DM4G6BT DE Discovery agent
DMZHBTA ID DMZHBTA
DMZHBTA DN N,N'-(1',4'-butylene)-bis-(-)-nor-MEP
DMZHBTA HS Investigative
DMZHBTA SN CHEMBL409858
DMZHBTA DT Small molecular drug
DMZHBTA PC 24827413
DMZHBTA MW 492.7
DMZHBTA FM C32H48N2O2
DMZHBTA IC InChI=1S/C32H48N2O2/c1-3-31(27-13-11-15-29(35)23-27)17-5-7-19-33(25-31)21-9-10-22-34-20-8-6-18-32(4-2,26-34)28-14-12-16-30(36)24-28/h11-16,23-24,35-36H,3-10,17-22,25-26H2,1-2H3/t31-,32-/m1/s1
DMZHBTA CS CC[C@]1(CCCCN(C1)CCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMZHBTA IK QRRZAKFYWBRJNH-ROJLCIKYSA-N
DMZHBTA IU 3-[(3S)-3-ethyl-1-[4-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]butyl]azepan-3-yl]phenol
DMZHBTA DE Discovery agent
DMBPC0K ID DMBPC0K
DMBPC0K DN N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP
DMBPC0K HS Investigative
DMBPC0K SN CHEMBL408463
DMBPC0K DT Small molecular drug
DMBPC0K PC 44450568
DMBPC0K MW 506.8
DMBPC0K FM C33H50N2O2
DMBPC0K IC InChI=1S/C33H50N2O2/c1-3-32(28-14-12-16-30(36)24-28)18-6-10-22-34(26-32)20-8-5-9-21-35-23-11-7-19-33(4-2,27-35)29-15-13-17-31(37)25-29/h12-17,24-25,36-37H,3-11,18-23,26-27H2,1-2H3/t32-,33?/m1/s1
DMBPC0K CS CC[C@]1(CCCCN(C1)CCCCCN2CCCCC(C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMBPC0K IK XNVOHDDYQCZZQX-KWRHIPAJSA-N
DMBPC0K IU 3-[3-ethyl-1-[5-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]pentyl]azepan-3-yl]phenol
DMBPC0K DE Discovery agent
DMU4BIW ID DMU4BIW
DMU4BIW DN N,N'-(1',6-hexylene)-bis-(-)-nor-MEP
DMU4BIW HS Investigative
DMU4BIW SN CHEMBL258505
DMU4BIW DT Small molecular drug
DMU4BIW PC 24827524
DMU4BIW MW 520.799
DMU4BIW FM C34H52N2O2
DMU4BIW IC InChI=1S/C34H52N2O2/c1-3-33(29-15-13-17-31(37)25-29)19-7-11-23-35(27-33)21-9-5-6-10-22-36-24-12-8-20-34(4-2,28-36)30-16-14-18-32(38)26-30/h13-18,25-26,37-38H,3-12,19-24,27-28H2,1-2H3/t33-,34-/m1/s1
DMU4BIW CS CC[C@]1(CCCCN(C1)CCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMU4BIW IK YBOHCXLIWATJCJ-KKLWWLSJSA-N
DMU4BIW IU 3-[(3S)-3-ethyl-1-[6-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]hexyl]azepan-3-yl]phenol
DMU4BIW DE Discovery agent
DMSORHA ID DMSORHA
DMSORHA DN N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP
DMSORHA HS Investigative
DMSORHA SN CHEMBL258935
DMSORHA DT Small molecular drug
DMSORHA PC 24827526
DMSORHA MW 534.8
DMSORHA FM C35H54N2O2
DMSORHA IC InChI=1S/C35H54N2O2/c1-3-34(30-16-14-18-32(38)26-30)20-8-12-24-36(28-34)22-10-6-5-7-11-23-37-25-13-9-21-35(4-2,29-37)31-17-15-19-33(39)27-31/h14-19,26-27,38-39H,3-13,20-25,28-29H2,1-2H3/t34-,35-/m1/s1
DMSORHA CS CC[C@]1(CCCCN(C1)CCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMSORHA IK VZGOFBLWSLPNDR-VSJLXWSYSA-N
DMSORHA IU 3-[(3S)-3-ethyl-1-[7-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]heptyl]azepan-3-yl]phenol
DMSORHA DE Discovery agent
DMHFYK2 ID DMHFYK2
DMHFYK2 DN N,N'-(1',8'-octylene)-bis-(-)-nor-MEP
DMHFYK2 HS Investigative
DMHFYK2 SN CHEMBL410915
DMHFYK2 DT Small molecular drug
DMHFYK2 PC 24827639
DMHFYK2 MW 548.8
DMHFYK2 FM C36H56N2O2
DMHFYK2 IC InChI=1S/C36H56N2O2/c1-3-35(31-17-15-19-33(39)27-31)21-9-13-25-37(29-35)23-11-7-5-6-8-12-24-38-26-14-10-22-36(4-2,30-38)32-18-16-20-34(40)28-32/h15-20,27-28,39-40H,3-14,21-26,29-30H2,1-2H3/t35-,36-/m1/s1
DMHFYK2 CS CC[C@]1(CCCCN(C1)CCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMHFYK2 IK XFXBGPOUAKCCMC-LQFQNGICSA-N
DMHFYK2 IU 3-[(3S)-3-ethyl-1-[8-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]octyl]azepan-3-yl]phenol
DMHFYK2 DE Discovery agent
DMIWF7U ID DMIWF7U
DMIWF7U DN N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP
DMIWF7U HS Investigative
DMIWF7U SN CHEMBL406645; Bis(9)-( )-meptazinol
DMIWF7U DT Small molecular drug
DMIWF7U PC 24827641
DMIWF7U MW 562.9
DMIWF7U FM C37H58N2O2
DMIWF7U IC InChI=1S/C37H58N2O2/c1-3-36(32-18-16-20-34(40)28-32)22-10-14-26-38(30-36)24-12-8-6-5-7-9-13-25-39-27-15-11-23-37(4-2,31-39)33-19-17-21-35(41)29-33/h16-21,28-29,40-41H,3-15,22-27,30-31H2,1-2H3/t36-,37-/m1/s1
DMIWF7U CS CC[C@]1(CCCCN(C1)CCCCCCCCCN2CCCC[C@@](C2)(CC)C3=CC(=CC=C3)O)C4=CC(=CC=C4)O
DMIWF7U IK ZZKZUUMHRSWLQQ-FZNHDDJXSA-N
DMIWF7U IU 3-[(3S)-3-ethyl-1-[9-[(3S)-3-ethyl-3-(3-hydroxyphenyl)azepan-1-yl]nonyl]azepan-3-yl]phenol
DMIWF7U DE Discovery agent
DMLU27Y ID DMLU27Y
DMLU27Y DN N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine
DMLU27Y HS Investigative
DMLU27Y SN CHEMBL494706; N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine; BDBM50253380
DMLU27Y DT Small molecular drug
DMLU27Y PC 25128814
DMLU27Y MW 293.45
DMLU27Y FM C16H31N5
DMLU27Y IC InChI=1S/C16H31N5/c1-11(2)8-17-14-7-15(18-9-12(3)4)21-16(20-14)19-10-13(5)6/h7,11-13H,8-10H2,1-6H3,(H3,17,18,19,20,21)
DMLU27Y CS CC(C)CNC1=CC(=NC(=N1)NCC(C)C)NCC(C)C
DMLU27Y IK HVZSNANIMUMCPH-UHFFFAOYSA-N
DMLU27Y IU 2-N,4-N,6-N-tris(2-methylpropyl)pyrimidine-2,4,6-triamine
DMLU27Y DE Discovery agent
DMNZKCL ID DMNZKCL
DMNZKCL DN N,N`-bis-alkyl butylimmidazole 12b
DMNZKCL HS Investigative
DMNZKCL SN compound 12b [PMID: 23376252]
DMNZKCL DT Small molecular drug
DMNZKCL PC 73755247
DMNZKCL MW 717.6
DMNZKCL FM C35H31BrN10Na2
DMNZKCL IC InChI=1S/C35H30N10.BrH.2Na/c1-2-3-12-33-32(21-24-13-17-26(18-14-24)28-8-4-6-10-30(28)34-37-41-42-38-34)36-23-45(33)22-25-15-19-27(20-16-25)29-9-5-7-11-31(29)35-39-43-44-40-35;;;/h4-11,13-20,23H,2-3,12,21-22H2,1H3;1H;;/q-2;;2*+1
DMNZKCL CS CCCCC1=C(NC=[N+]1CC2=CC=C(C=C2)C3=CC=CC=C3C4=N[N-]N=N4)CC5=CC=C(C=C5)C6=CC=CC=C6C7=N[N-]N=N7.[Na+].[Na+].[Br-]
DMNZKCL IK JJOQDSLKSULNDS-UHFFFAOYSA-N
DMNZKCL IU disodium;5-[2-[4-[[4-butyl-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]-1H-imidazol-3-ium-5-yl]methyl]phenyl]phenyl]-1,2,4-triaza-3-azanidacyclopenta-1,4-diene;bromide
DMNZKCL DE Discovery agent
DMT4USP ID DMT4USP
DMT4USP DN N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea
DMT4USP HS Investigative
DMT4USP SN Aminoquinuride; Surfen; aminokinuride; UNII-08T7936572; 3811-56-1; N,N'-BIS(4-AMINO-2-METHYLQUINOLIN-6-YL)UREA; 1,3-bis(4-amino-2-methylquinolin-6-yl)urea; N,N'-Bis(4-amino-2-methyl-6-quinolinyl)urea; Aminochinurid; 08T7936572; Aminochinuridum; Aminoquinuridum; Aminoquinurida; Aminokinuridum; Aminochincarbamidum; Aminoquin carbamide; NSC12155; Aminoquinuride [INN]; NCGC00013130-04; NCGC00013130-03; 5424-37-3; Aminoquinuridum [INN-Latin]; Aminoquinurida [INN-Spanish]; 1pwp; N,N-Bis(4-aminochinaldyl-6)harnstoff
DMT4USP DT Small molecular drug
DMT4USP PC 71166
DMT4USP MW 372.4
DMT4USP FM C21H20N6O
DMT4USP IC InChI=1S/C21H20N6O/c1-11-7-17(22)15-9-13(3-5-19(15)24-11)26-21(28)27-14-4-6-20-16(10-14)18(23)8-12(2)25-20/h3-10H,1-2H3,(H2,22,24)(H2,23,25)(H2,26,27,28)
DMT4USP CS CC1=CC(=C2C=C(C=CC2=N1)NC(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N)N
DMT4USP IK HOUSDILKOJMENG-UHFFFAOYSA-N
DMT4USP IU 1,3-bis(4-amino-2-methylquinolin-6-yl)urea
DMT4USP CA CAS 3811-56-1
DMT4USP DE Discovery agent
DMLOP2B ID DMLOP2B
DMLOP2B DN N,N'-Bis-(4-butoxy-phenyl)-guanidine
DMLOP2B HS Investigative
DMLOP2B SN CHEMBL326502; SCHEMBL4983215; n,n'-bis(4-butoxyphenyl)guanidine; BDBM50066423
DMLOP2B DT Small molecular drug
DMLOP2B PC 10594376
DMLOP2B MW 355.5
DMLOP2B FM C21H29N3O2
DMLOP2B IC InChI=1S/C21H29N3O2/c1-3-5-15-25-19-11-7-17(8-12-19)23-21(22)24-18-9-13-20(14-10-18)26-16-6-4-2/h7-14H,3-6,15-16H2,1-2H3,(H3,22,23,24)
DMLOP2B CS CCCCOC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OCCCC)N
DMLOP2B IK UEKORNPZBHKKRD-UHFFFAOYSA-N
DMLOP2B IU 1,2-bis(4-butoxyphenyl)guanidine
DMLOP2B DE Discovery agent
DMOS2GH ID DMOS2GH
DMOS2GH DN N,N'-Bis-(4-butyl-phenyl)-guanidine
DMOS2GH HS Investigative
DMOS2GH SN CHEMBL109210; SCHEMBL4980235; N,N'-Bis(4-butylphenyl)guanidine; BDBM50066427
DMOS2GH DT Small molecular drug
DMOS2GH PC 10496171
DMOS2GH MW 323.5
DMOS2GH FM C21H29N3
DMOS2GH IC InChI=1S/C21H29N3/c1-3-5-7-17-9-13-19(14-10-17)23-21(22)24-20-15-11-18(12-16-20)8-6-4-2/h9-16H,3-8H2,1-2H3,(H3,22,23,24)
DMOS2GH CS CCCCC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)CCCC)N
DMOS2GH IK XDEXLYGQRYSUON-UHFFFAOYSA-N
DMOS2GH IU 1,2-bis(4-butylphenyl)guanidine
DMOS2GH DE Discovery agent
DM0CTG7 ID DM0CTG7
DM0CTG7 DN N,N'-Bis-(4-ethyl-phenyl)-guanidine
DM0CTG7 HS Investigative
DM0CTG7 SN CHEMBL78083; Guanidine, N,N'-bis(4-ethylphenyl)-; 128413-47-8; ACMC-20msu7; SCHEMBL6155127; SCHEMBL10825147; CTK0C1708; DTXSID70563854; 1,3-Bis(4-ethylphenyl)guanidine; N,N''-Bis(4-ethylphenyl)guanidine; BDBM50010736; ZINC13733770; AKOS030602502
DM0CTG7 DT Small molecular drug
DM0CTG7 PC 14771671
DM0CTG7 MW 267.37
DM0CTG7 FM C17H21N3
DM0CTG7 IC InChI=1S/C17H21N3/c1-3-13-5-9-15(10-6-13)19-17(18)20-16-11-7-14(4-2)8-12-16/h5-12H,3-4H2,1-2H3,(H3,18,19,20)
DM0CTG7 CS CCC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)CC)N
DM0CTG7 IK DXGARAMIKHFTJV-UHFFFAOYSA-N
DM0CTG7 IU 1,2-bis(4-ethylphenyl)guanidine
DM0CTG7 CA CAS 128413-47-8
DM0CTG7 DE Discovery agent
DM0RQGU ID DM0RQGU
DM0RQGU DN N,N'-Bis-(4-hexyl-phenyl)-guanidine
DM0RQGU HS Investigative
DM0RQGU SN CHEMBL326741; SCHEMBL4985473; N,N'-Bis(4-hexylphenyl)guanidine; BDBM50066419
DM0RQGU DT Small molecular drug
DM0RQGU PC 9821194
DM0RQGU MW 379.6
DM0RQGU FM C25H37N3
DM0RQGU IC InChI=1S/C25H37N3/c1-3-5-7-9-11-21-13-17-23(18-14-21)27-25(26)28-24-19-15-22(16-20-24)12-10-8-6-4-2/h13-20H,3-12H2,1-2H3,(H3,26,27,28)
DM0RQGU CS CCCCCCC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)CCCCCC)N
DM0RQGU IK UVGVWBZLIZBOEY-UHFFFAOYSA-N
DM0RQGU IU 1,2-bis(4-hexylphenyl)guanidine
DM0RQGU DE Discovery agent
DMM38BC ID DMM38BC
DMM38BC DN N,N'-Bis-(4-isopropyl-phenyl)-guanidine
DMM38BC HS Investigative
DMM38BC SN CHEMBL81626; SCHEMBL6154563; BDBM50010754; ZINC13733773; 1,3-Bis(4-isopropylphenyl)guanidine
DMM38BC DT Small molecular drug
DMM38BC PC 13781937
DMM38BC MW 295.4
DMM38BC FM C19H25N3
DMM38BC IC InChI=1S/C19H25N3/c1-13(2)15-5-9-17(10-6-15)21-19(20)22-18-11-7-16(8-12-18)14(3)4/h5-14H,1-4H3,(H3,20,21,22)
DMM38BC CS CC(C)C1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C(C)C)N
DMM38BC IK WIULPOAMZNPPJM-UHFFFAOYSA-N
DMM38BC IU 1,2-bis(4-propan-2-ylphenyl)guanidine
DMM38BC DE Discovery agent
DMFDXLB ID DMFDXLB
DMFDXLB DN N,N'-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB HS Investigative
DMFDXLB SN CHEMBL110909; CHEMBL320199; SCHEMBL4979578; BDBM50066057; 1,3-Bis(4-sec-butylphenyl)guanidine; AKOS030602595; N,N''-Bis-(4-sec-butyl-phenyl)-guanidine
DMFDXLB DT Small molecular drug
DMFDXLB PC 10526122
DMFDXLB MW 323.5
DMFDXLB FM C21H29N3
DMFDXLB IC InChI=1S/C21H29N3/c1-5-15(3)17-7-11-19(12-8-17)23-21(22)24-20-13-9-18(10-14-20)16(4)6-2/h7-16H,5-6H2,1-4H3,(H3,22,23,24)
DMFDXLB CS CCC(C)C1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C(C)CC)N
DMFDXLB IK CSOJBDHYOONOPF-UHFFFAOYSA-N
DMFDXLB IU 1,2-bis(4-butan-2-ylphenyl)guanidine
DMFDXLB DE Discovery agent
DMBQ0TY ID DMBQ0TY
DMBQ0TY DN N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide
DMBQ0TY HS Investigative
DMBQ0TY SN N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide; AC1LDLXQ; Cambridge id 5654537; Oprea1_349431; CHEMBL244919; ZINC29912; BDBM23727; MolPort-001-507-799; HMS1584M04; STK002684; AKOS003266947; MCULE-7184403963; ST042963; N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide, 11; SR-01000215998; N~1~,N~1~-bis(cyanomethyl)-3,4-dimethoxybenzamide; SR-01000215998-1
DMBQ0TY DT Small molecular drug
DMBQ0TY PC 669334
DMBQ0TY MW 259.26
DMBQ0TY FM C13H13N3O3
DMBQ0TY IC InChI=1S/C13H13N3O3/c1-18-11-4-3-10(9-12(11)19-2)13(17)16(7-5-14)8-6-15/h3-4,9H,7-8H2,1-2H3
DMBQ0TY CS COC1=C(C=C(C=C1)C(=O)N(CC#N)CC#N)OC
DMBQ0TY IK GZUJYYKDHAQDKU-UHFFFAOYSA-N
DMBQ0TY IU N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide
DMBQ0TY DE Discovery agent
DMM678B ID DMM678B
DMM678B DN N,N-bis(tosylmethyl)hexan-1-amine
DMM678B HS Investigative
DMM678B SN CHEMBL252145; N,N-bis(tosylmethyl)hexan-1-amine; AC1MWCYZ; N,N-bis[(4-methylphenyl)sulfonylmethyl]hexan-1-amine; N,N-Bis(tosylmethyl)hexane-1-amine
DMM678B DT Small molecular drug
DMM678B PC 3747253
DMM678B MW 437.6
DMM678B FM C22H31NO4S2
DMM678B IC InChI=1S/C22H31NO4S2/c1-4-5-6-7-16-23(17-28(24,25)21-12-8-19(2)9-13-21)18-29(26,27)22-14-10-20(3)11-15-22/h8-15H,4-7,16-18H2,1-3H3
DMM678B CS CCCCCCN(CS(=O)(=O)C1=CC=C(C=C1)C)CS(=O)(=O)C2=CC=C(C=C2)C
DMM678B IK JNUXLFWPSMEIDT-UHFFFAOYSA-N
DMM678B IU N,N-bis[(4-methylphenyl)sulfonylmethyl]hexan-1-amine
DMM678B DE Discovery agent
DM8TA0M ID DM8TA0M
DM8TA0M DN N,N'-Di-acenaphthen-5-yl-guanidine
DM8TA0M HS Investigative
DM8TA0M SN CHEMBL307395; 157970-69-9; Cns 1145; 1,3-di(1,2-dihydroacenaphthylen-5-yl)guanidine; AC1L4RHN; AC1Q4SU4; Cns-1145; SCHEMBL6155294; CTK4C9538; N,N'-Bis(5-acenaphthyl)guanidine; BDBM50285278; N,N''-Di-acenaphthen-5-yl-guanidine; AKOS030602590; 1,2-bis(1,2-dihydroacenaphthylen-5-yl)guanidine
DM8TA0M DT Small molecular drug
DM8TA0M PC 190902
DM8TA0M MW 363.5
DM8TA0M FM C25H21N3
DM8TA0M IC InChI=1S/C25H21N3/c26-25(27-21-13-11-17-9-7-15-3-1-5-19(21)23(15)17)28-22-14-12-18-10-8-16-4-2-6-20(22)24(16)18/h1-6,11-14H,7-10H2,(H3,26,27,28)
DM8TA0M CS C1CC2=CC=C(C3=CC=CC1=C23)NC(=NC4=CC=C5CCC6=C5C4=CC=C6)N
DM8TA0M IK DPWVUEQXMOBVOQ-UHFFFAOYSA-N
DM8TA0M IU 1,2-bis(1,2-dihydroacenaphthylen-5-yl)guanidine
DM8TA0M CA CAS 157970-69-9
DM8TA0M DE Discovery agent
DMSY571 ID DMSY571
DMSY571 DN N,N-diallyl[D-Pro-10]Dyn A-(1-11)
DMSY571 HS Investigative
DMSY571 SN CHEMBL266782; N,N-diallyl[D-Pro-10]Dyn A-(1-11)
DMSY571 PC 44325420
DMSY571 MW 1442.8
DMSY571 FM C69H111N21O13
DMSY571 IC InChI=1S/C69H111N21O13/c1-7-34-89(35-8-2)54(39-45-26-28-46(91)29-27-45)62(98)81-40-55(92)80-41-56(93)82-52(38-44-19-11-10-12-20-44)61(97)87-51(37-42(4)5)60(96)84-47(22-15-31-77-67(71)72)58(94)83-48(23-16-32-78-68(73)74)59(95)88-57(43(6)9-3)64(100)85-49(24-17-33-79-69(75)76)65(101)90-36-18-25-53(90)63(99)86-50(66(102)103)21-13-14-30-70/h7-8,10-12,19-20,26-29,42-43,47-54,57,91H,1-2,9,13-18,21-25,30-41,70H2,3-6H3,(H,80,92)(H,81,98)(H,82,93)(H,83,94)(H,84,96)(H,85,100)(H,86,99)(H,87,97)(H,88,95)(H,102,103)(H4,71,72,77)(H4,73,74,78)(H4,75,76,79)/t43-,47-,48-,49-,50-,51-,52-,53-,54-,57-/m0/s1
DMSY571 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N(CC=C)CC=C
DMSY571 IK PUPCCTCXOWBBTI-JHLTVMAUSA-N
DMSY571 IU (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DMSY571 DE Discovery agent
DMILJUE ID DMILJUE
DMILJUE DN N,N-dibenzyl[D-Pro-10]Dyn A-(1-11)
DMILJUE HS Investigative
DMILJUE SN CHEMBL267215; N,N-dibenzyl[D-Pro-10]Dyn A-(1-11)
DMILJUE PC 44325184
DMILJUE MW 1542.9
DMILJUE FM C77H115N21O13
DMILJUE IC InChI=1S/C77H115N21O13/c1-5-49(4)65(72(108)93-57(30-19-39-87-77(83)84)73(109)98-40-20-31-61(98)71(107)94-58(74(110)111)27-15-16-36-78)96-67(103)56(29-18-38-86-76(81)82)91-66(102)55(28-17-37-85-75(79)80)92-68(104)59(41-48(2)3)95-69(105)60(42-50-21-9-6-10-22-50)90-64(101)45-88-63(100)44-89-70(106)62(43-51-32-34-54(99)35-33-51)97(46-52-23-11-7-12-24-52)47-53-25-13-8-14-26-53/h6-14,21-26,32-35,48-49,55-62,65,99H,5,15-20,27-31,36-47,78H2,1-4H3,(H,88,100)(H,89,106)(H,90,101)(H,91,102)(H,92,104)(H,93,108)(H,94,107)(H,95,105)(H,96,103)(H,110,111)(H4,79,80,85)(H4,81,82,86)(H4,83,84,87)/t49-,55-,56-,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMILJUE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N(CC4=CC=CC=C4)CC5=CC=CC=C5
DMILJUE IK OHPCANLMUJRLSF-GOWLZWIFSA-N
DMILJUE IU (2S)-6-amino-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-(dibenzylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DMILJUE DE Discovery agent
DM1UCZ9 ID DM1UCZ9
DM1UCZ9 DN N,N-diCPM[D-Pro-10]Dyn A-(1-11)
DM1UCZ9 HS Investigative
DM1UCZ9 SN CHEMBL406893; N,N-diCPM[D-Pro-10]Dyn A-(1-11)
DM1UCZ9 PC 44325183
DM1UCZ9 MW 1470.8
DM1UCZ9 FM C71H115N21O13
DM1UCZ9 IC InChI=1S/C71H115N21O13/c1-5-43(4)59(66(102)87-51(20-13-33-81-71(77)78)67(103)92-34-14-21-55(92)65(101)88-52(68(104)105)17-9-10-30-72)90-61(97)50(19-12-32-80-70(75)76)85-60(96)49(18-11-31-79-69(73)74)86-62(98)53(35-42(2)3)89-63(99)54(36-44-15-7-6-8-16-44)84-58(95)39-82-57(94)38-83-64(100)56(37-45-26-28-48(93)29-27-45)91(40-46-22-23-46)41-47-24-25-47/h6-8,15-16,26-29,42-43,46-47,49-56,59,93H,5,9-14,17-25,30-41,72H2,1-4H3,(H,82,94)(H,83,100)(H,84,95)(H,85,96)(H,86,98)(H,87,102)(H,88,101)(H,89,99)(H,90,97)(H,104,105)(H4,73,74,79)(H4,75,76,80)(H4,77,78,81)/t43-,49-,50-,51-,52-,53-,54-,55-,56-,59-/m0/s1
DM1UCZ9 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)N(CC4CC4)CC5CC5
DM1UCZ9 IK XMFJUPAXGQSFIW-FOMVZIENSA-N
DM1UCZ9 IU (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[bis(cyclopropylmethyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM1UCZ9 DE Discovery agent
DMLVMJH ID DMLVMJH
DMLVMJH DN N,N'-dicyclohexyl-urea
DMLVMJH HS Investigative
DMLVMJH SN 1,3-Dicyclohexylurea; n,n'-dicyclohexylurea; 2387-23-7; Dicyclohexylurea; Urea, N,N'-dicyclohexyl-; UNII-ZV7823VVIM; ZV7823VVIM; CHEMBL1458; N,N'-Dicyclohexylurea, 98%; ADFXKUOMJKEIND-UHFFFAOYSA-N; MFCD00003829; Urea,3-dicyclohexyl-; Urea,N'-dicyclohexyl-; N,N inverted exclamation marka-Dicyclohexylurea; Urea, 1,3-dicyclohexyl-; dicylohexylurea; dicylcohexylurea; dicylohexyl urea; dicyclohexyl-urea; dicyclohexyl urea; DCW; EINECS 219-213-7; NSC 30023; NSC 17013; n.n'-dicyclohexylurea; Rupatadine Impurity 1; 1,3-dicyclohexyl-urea
DMLVMJH DT Small molecular drug
DMLVMJH PC 4277
DMLVMJH MW 224.34
DMLVMJH FM C13H24N2O
DMLVMJH IC InChI=1S/C13H24N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h11-12H,1-10H2,(H2,14,15,16)
DMLVMJH CS C1CCC(CC1)NC(=O)NC2CCCCC2
DMLVMJH IK ADFXKUOMJKEIND-UHFFFAOYSA-N
DMLVMJH IU 1,3-dicyclohexylurea
DMLVMJH CA CAS 2387-23-7
DMLVMJH CB CHEBI:93429
DMLVMJH DE Discovery agent
DMZ3EA1 ID DMZ3EA1
DMZ3EA1 DN N,N-diethyl estrone-16-methyl carboxamide
DMZ3EA1 HS Investigative
DMZ3EA1 SN SCHEMBL12379552
DMZ3EA1 DT Small molecular drug
DMZ3EA1 PC 44407575
DMZ3EA1 MW 383.5
DMZ3EA1 FM C24H33NO3
DMZ3EA1 IC InChI=1S/C24H33NO3/c1-4-25(5-2)22(27)14-16-13-21-20-8-6-15-12-17(26)7-9-18(15)19(20)10-11-24(21,3)23(16)28/h7,9,12,16,19-21,26H,4-6,8,10-11,13-14H2,1-3H3/t16?,19?,20?,21?,24-/m0/s1
DMZ3EA1 CS CCN(CC)C(=O)CC1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMZ3EA1 IK NUYXZZNRVPOMFS-HEYBVSAXSA-N
DMZ3EA1 IU N,N-diethyl-2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetamide
DMZ3EA1 DE Discovery agent
DM5K3D2 ID DM5K3D2
DM5K3D2 DN N,N-Diethyl-1'H-phenothiazine-1'-carboxamide
DM5K3D2 HS Investigative
DM5K3D2 SN CHEMBL589062; Phenothiazine-10-carboxylic acid diethylamide; N,N-diethyl-10H-phenothiazine-10-carboxamide; N,N-diethylphenothiazine-10-carboxamide; BAS 04087804; AC1LE3I9; MLS001212486; ARONIS009570; SCHEMBL7343904; ZINC91243; MolPort-001-593-657; MolPort-019-785-999; HMS1680D13; HMS2821P21; STK017216; CCG-22244; BDBM50308411; AKOS000498788; MCULE-7627155893; KS-0000415D; N,N-diethylphenothiazin-10-ylcarboxamide; SMR000518964; BB0286547; ST45046311; N,N-Diethyl-1''H-phenothiazine-1''-carboxamide; SR-01000506178; AN-329/41195338
DM5K3D2 DT Small molecular drug
DM5K3D2 PC 705771
DM5K3D2 MW 298.4
DM5K3D2 FM C17H18N2OS
DM5K3D2 IC InChI=1S/C17H18N2OS/c1-3-18(4-2)17(20)19-13-9-5-7-11-15(13)21-16-12-8-6-10-14(16)19/h5-12H,3-4H2,1-2H3
DM5K3D2 CS CCN(CC)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM5K3D2 IK VZWXJPGNJLOWRM-UHFFFAOYSA-N
DM5K3D2 IU N,N-diethylphenothiazine-10-carboxamide
DM5K3D2 DE Discovery agent
DM0UBI9 ID DM0UBI9
DM0UBI9 DN N,N-diethyl-2-(1H-indol-3-yl)ethanamine
DM0UBI9 HS Investigative
DM0UBI9 SN Diethyltryptamine; N,N-Diethyltryptamine; 61-51-8; N,N-Diethyl-2-(1H-indol-3-yl)ethanamine; 3-(2-Diethylaminoethyl)indole; UNII-916E8V4S2V; INDOLE, 3-(2-(DIETHYLAMINO)ETHYL)-; BRN 0153320; D.E.T.; CHEMBL142936; DEA No. 7434; 916E8V4S2V; 1H-Indole-3-ethanamine, N,N-diethyl-; AC1L1LS6; Oprea1_105894; 5-22-10-00050 (Beilstein Handbook Reference); SCHEMBL517713; DTXSID9052763; CTK5B3364; LSSUMOWDTKZHHT-UHFFFAOYSA-N; ZINC1999162; BDBM50094676; STK368075; AKOS005444987; 1H-Indole-3-ethanamine,N,N-diethyl-; 63938-63-6 (mono-hydrochloride)
DM0UBI9 DT Small molecular drug
DM0UBI9 PC 6090
DM0UBI9 MW 216.32
DM0UBI9 FM C14H20N2
DM0UBI9 IC InChI=1S/C14H20N2/c1-3-16(4-2)10-9-12-11-15-14-8-6-5-7-13(12)14/h5-8,11,15H,3-4,9-10H2,1-2H3
DM0UBI9 CS CCN(CC)CCC1=CNC2=CC=CC=C21
DM0UBI9 IK LSSUMOWDTKZHHT-UHFFFAOYSA-N
DM0UBI9 IU N,N-diethyl-2-(1H-indol-3-yl)ethanamine
DM0UBI9 CA CAS 61-51-8
DM0UBI9 DE Discovery agent
DMBFASY ID DMBFASY
DMBFASY DN N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMBFASY HS Investigative
DMBFASY SN CHEMBL99509; N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; BDBM50045858
DMBFASY DT Small molecular drug
DMBFASY PC 9995335
DMBFASY MW 306.4
DMBFASY FM C20H22N2O
DMBFASY IC InChI=1S/C20H22N2O/c1-3-22(4-2)19(23)14-17-16-12-8-9-13-18(16)21-20(17)15-10-6-5-7-11-15/h5-13,21H,3-4,14H2,1-2H3
DMBFASY CS CCN(CC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DMBFASY IK JAQRBHPLECRUHQ-UHFFFAOYSA-N
DMBFASY IU N,N-diethyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DMBFASY DE Discovery agent
DMV8QTR ID DMV8QTR
DMV8QTR DN N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMV8QTR HS Investigative
DMV8QTR SN CHEMBL98081; 142720-26-1; 1H-Indole-3-acetamide,N,N-dihexyl-2-phenyl-; ACMC-20n1pu; N,N-DIHEXYL-2-PHENYLINDOLE-3-ACETAMIDE; N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; CTK4C3254; DTXSID30440213; ZINC13833112; BDBM50045894; AKOS015965050
DMV8QTR DT Small molecular drug
DMV8QTR PC 10454732
DMV8QTR MW 418.6
DMV8QTR FM C28H38N2O
DMV8QTR IC InChI=1S/C28H38N2O/c1-3-5-7-14-20-30(21-15-8-6-4-2)27(31)22-25-24-18-12-13-19-26(24)29-28(25)23-16-10-9-11-17-23/h9-13,16-19,29H,3-8,14-15,20-22H2,1-2H3
DMV8QTR CS CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DMV8QTR IK GGNLGBYSSQXGBN-UHFFFAOYSA-N
DMV8QTR IU N,N-dihexyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DMV8QTR CA CAS 142720-26-1
DMV8QTR DE Discovery agent
DM4E8C9 ID DM4E8C9
DM4E8C9 DN N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide
DM4E8C9 HS Investigative
DM4E8C9 SN CHEMBL588172; Oprea1_258691; BDBM50308413
DM4E8C9 DT Small molecular drug
DM4E8C9 PC 12851057
DM4E8C9 MW 326.5
DM4E8C9 FM C19H22N2OS
DM4E8C9 IC InChI=1S/C19H22N2OS/c1-13(2)20(14(3)4)19(22)21-15-9-5-7-11-17(15)23-18-12-8-6-10-16(18)21/h5-14H,1-4H3
DM4E8C9 CS CC(C)N(C(C)C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM4E8C9 IK RSDPPDLPSMZJPP-UHFFFAOYSA-N
DM4E8C9 IU N,N-di(propan-2-yl)phenothiazine-10-carboxamide
DM4E8C9 DE Discovery agent
DMTWK7L ID DMTWK7L
DMTWK7L DN N,Ndimethyl milnacipran
DMTWK7L HS Investigative
DMTWK7L SN N,Ndimethyl milnacipran
DMTWK7L DT Small molecular drug
DMTWK7L PC 44454695
DMTWK7L MW 274.4
DMTWK7L FM C17H26N2O
DMTWK7L IC InChI=1S/C17H26N2O/c1-5-19(6-2)16(20)17(12-15(17)13-18(3)4)14-10-8-7-9-11-14/h7-11,15H,5-6,12-13H2,1-4H3
DMTWK7L CS CCN(CC)C(=O)C1(CC1CN(C)C)C2=CC=CC=C2
DMTWK7L IK NMRSWXVEITZBIQ-UHFFFAOYSA-N
DMTWK7L IU 2-[(dimethylamino)methyl]-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
DMTWK7L DE Discovery agent
DMWK91T ID DMWK91T
DMWK91T DN N,N-dimethyl(2-phenoxyphenyl)methanamine
DMWK91T HS Investigative
DMWK91T SN CHEMBL256058; AC1LGTAP; MolPort-002-800-902; ZINC346601; N,N-Dimethyl-2-phenoxybenzylamine; BDBM50371640; AKOS005066321; N,N-dimethyl-1-(2-phenoxyphenyl)methanamine
DMWK91T DT Small molecular drug
DMWK91T PC 826600
DMWK91T MW 227.3
DMWK91T FM C15H17NO
DMWK91T IC InChI=1S/C15H17NO/c1-16(2)12-13-8-6-7-11-15(13)17-14-9-4-3-5-10-14/h3-11H,12H2,1-2H3
DMWK91T CS CN(C)CC1=CC=CC=C1OC2=CC=CC=C2
DMWK91T IK BBLALPDUHCRAKZ-UHFFFAOYSA-N
DMWK91T IU N,N-dimethyl-1-(2-phenoxyphenyl)methanamine
DMWK91T DE Discovery agent
DM41C8E ID DM41C8E
DM41C8E DN N,N-dimethyl(pyridin-3-yl)methanamine
DM41C8E HS Investigative
DM41C8E SN Dimethyl-pyridin-3-ylmethyl-amine; 2055-21-2; N,N-Dimethyl-1-(pyridin-3-yl)methanamine; CHEMBL331904; N,N-dimethyl-3-Pyridinemethanamine; 3-Pyridinemethanamine, N,N-dimethyl-; N,N-dimethyl(pyridin-3-yl)methanamine; AC1OK4VN; 3-pyridylmethyl dimethylamine; 3-Pyridinylmethyldimethylamine; SCHEMBL3460939; dimethyl(pyridin-3-ylmethyl)amine; MolPort-000-165-254; ZINC4716433; BDBM50119559; AKOS009071365; N,N-dimethyl-1-pyridin-3-ylmethanamine; DB-066238
DM41C8E DT Small molecular drug
DM41C8E PC 7330459
DM41C8E MW 136.19
DM41C8E FM C8H12N2
DM41C8E IC InChI=1S/C8H12N2/c1-10(2)7-8-4-3-5-9-6-8/h3-6H,7H2,1-2H3
DM41C8E CS CN(C)CC1=CN=CC=C1
DM41C8E IK SLZCOYDOFRTTHF-UHFFFAOYSA-N
DM41C8E IU N,N-dimethyl-1-pyridin-3-ylmethanamine
DM41C8E DE Discovery agent
DM4CDYG ID DM4CDYG
DM4CDYG DN N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide
DM4CDYG HS Investigative
DM4CDYG SN N,N-dimethyl-10H-phenothiazine-10-carboxamide; CHEMBL592674; ARONIS26337; AC1M461Y; MolPort-003-255-540; HMS1760L14; ZINC3014186; KS-000047ZJ; STL261388; BDBM50308410; AKOS001144998; MCULE-9126277852; N,N-dimethylphenothiazine-10-carboxamide; 51858-81-2; BB0294327; SR-01000030731; N,N-Dimethyl-1''H-phenothiazine-1''-carboxamide; SR-01000030731-1
DM4CDYG DT Small molecular drug
DM4CDYG PC 2301676
DM4CDYG MW 270.4
DM4CDYG FM C15H14N2OS
DM4CDYG IC InChI=1S/C15H14N2OS/c1-16(2)15(18)17-11-7-3-5-9-13(11)19-14-10-6-4-8-12(14)17/h3-10H,1-2H3
DM4CDYG CS CN(C)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM4CDYG IK JVEMOBBCUXTLCS-UHFFFAOYSA-N
DM4CDYG IU N,N-dimethylphenothiazine-10-carboxamide
DM4CDYG DE Discovery agent
DMYUQDK ID DMYUQDK
DMYUQDK DN N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine
DMYUQDK HS Investigative
DMYUQDK SN CHEMBL248071; N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine
DMYUQDK DT Small molecular drug
DMYUQDK PC 44438719
DMYUQDK MW 342.5
DMYUQDK FM C19H22N2O2S
DMYUQDK IC InChI=1S/C19H22N2O2S/c1-15-8-10-17(11-9-15)24(22,23)21-14-16(12-13-20(2)3)18-6-4-5-7-19(18)21/h4-11,14H,12-13H2,1-3H3
DMYUQDK CS CC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=CC=CC=C32)CCN(C)C
DMYUQDK IK RJGTUGOGNODPPC-UHFFFAOYSA-N
DMYUQDK IU N,N-dimethyl-2-[1-(4-methylphenyl)sulfonylindol-3-yl]ethanamine
DMYUQDK DE Discovery agent
DM1DZEL ID DM1DZEL
DM1DZEL DN N,N-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine
DM1DZEL HS Investigative
DM1DZEL SN CHEMBL395870; BDBM50210123; N,N-dimethyl-2-(2''-methylbiphenyl-3-yl)ethanamine
DM1DZEL DT Small molecular drug
DM1DZEL PC 16747715
DM1DZEL MW 239.35
DM1DZEL FM C17H21N
DM1DZEL IC InChI=1S/C17H21N/c1-14-7-4-5-10-17(14)16-9-6-8-15(13-16)11-12-18(2)3/h4-10,13H,11-12H2,1-3H3
DM1DZEL CS CC1=CC=CC=C1C2=CC=CC(=C2)CCN(C)C
DM1DZEL IK HOMNPSYKSQTOHK-UHFFFAOYSA-N
DM1DZEL IU N,N-dimethyl-2-[3-(2-methylphenyl)phenyl]ethanamine
DM1DZEL DE Discovery agent
DM73PXI ID DM73PXI
DM73PXI DN N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DM73PXI HS Investigative
DM73PXI SN CHEMBL320626; N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; BDBM50045869
DM73PXI DT Small molecular drug
DM73PXI PC 10446279
DM73PXI MW 278.3
DM73PXI FM C18H18N2O
DM73PXI IC InChI=1S/C18H18N2O/c1-20(2)17(21)12-15-14-10-6-7-11-16(14)19-18(15)13-8-4-3-5-9-13/h3-11,19H,12H2,1-2H3
DM73PXI CS CN(C)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DM73PXI IK RVPIQASKQHYEBT-UHFFFAOYSA-N
DM73PXI IU N,N-dimethyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DM73PXI DE Discovery agent
DMMD9A0 ID DMMD9A0
DMMD9A0 DN N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine
DMMD9A0 HS Investigative
DMMD9A0 SN CHEMBL61616; 228272-02-4; N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine; SCHEMBL12827198; CTK0J6066; DTXSID40436622; BDBM50115808; AKOS030595283; Dimethyl 2-(3-pyridinyloxy)ethylamine; Dimethyl-[2-(pyridin-3-yloxy)-ethyl]-amine; N,N-dimethyl-2-(pyridin-3-yloxy)ethanaminium; Ethanamine, N,N-dimethyl-2-(3-pyridinyloxy)-
DMMD9A0 DT Small molecular drug
DMMD9A0 PC 10197862
DMMD9A0 MW 166.22
DMMD9A0 FM C9H14N2O
DMMD9A0 IC InChI=1S/C9H14N2O/c1-11(2)6-7-12-9-4-3-5-10-8-9/h3-5,8H,6-7H2,1-2H3
DMMD9A0 CS CN(C)CCOC1=CN=CC=C1
DMMD9A0 IK NNKLMOMWOOXRDH-UHFFFAOYSA-N
DMMD9A0 IU N,N-dimethyl-2-pyridin-3-yloxyethanamine
DMMD9A0 CA CAS 228272-02-4
DMMD9A0 DE Discovery agent
DM9XZJN ID DM9XZJN
DM9XZJN DN N,N-dimethyl-2,2,2-triphenylacetamide
DM9XZJN HS Investigative
DM9XZJN SN N,N-Dimethyl-2,2,2-triphenylacetamide; AC1LDGNY; N,N-Dimethyl-triphenylacetamide; JGBIXOAQARJTNI-UHFFFAOYSA-N; N,N-Dimethyl-2,2,2-triphenylacetamide #; Acetamide, N,N-dimethyl-2,2,2-triphenyl-
DM9XZJN DT Small molecular drug
DM9XZJN PC 618190
DM9XZJN MW 315.4
DM9XZJN FM C22H21NO
DM9XZJN IC InChI=1S/C22H21NO/c1-23(2)21(24)22(18-12-6-3-7-13-18,19-14-8-4-9-15-19)20-16-10-5-11-17-20/h3-17H,1-2H3
DM9XZJN CS CN(C)C(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3
DM9XZJN IK JGBIXOAQARJTNI-UHFFFAOYSA-N
DM9XZJN IU N,N-dimethyl-2,2,2-triphenylacetamide
DM9XZJN DE Discovery agent
DMJDQGR ID DMJDQGR
DMJDQGR DN N,N-dimethyl-2,2-diphenylethanamine
DMJDQGR HS Investigative
DMJDQGR SN UNII-MXF0417QII; MXF0417QII; AC1L35TO; CHEMBL10602; diphenylalkylamine (DPA), 4c; BDBM35931; ZINC1249433; 2-Dimethylamino-1,1-diphenylethane; 2-Dimethylamino-1,1-diphenyl-aethan; N,N-Dimethyl-2,2-diphenylethylamine; STL298137; AKOS022110055; MCULE-9768764141; NCGC00246407-01; Ethylamine, N,N-dimethyl-2,2-diphenyl-; Benzeneethanamine, N,N-dimethyl-beta-phenyl-; 2,2-diphenylethyl(dimethyl)amine; 2-Dimethylamino-1,1-diphenyl-aethan [WHO-DD]
DMJDQGR DT Small molecular drug
DMJDQGR PC 83632
DMJDQGR MW 225.33
DMJDQGR FM C16H19N
DMJDQGR IC InChI=1S/C16H19N/c1-17(2)13-16(14-9-5-3-6-10-14)15-11-7-4-8-12-15/h3-12,16H,13H2,1-2H3
DMJDQGR CS CN(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
DMJDQGR IK UAUJDKBNVRSJBD-UHFFFAOYSA-N
DMJDQGR IU N,N-dimethyl-2,2-diphenylethanamine
DMJDQGR CA CAS 7647-54-3
DMJDQGR DE Discovery agent
DMIP5K7 ID DMIP5K7
DMIP5K7 DN N,N-Dimethyl-3,3-diphenylpropan-1-amine
DMIP5K7 HS Investigative
DMIP5K7 SN 3,3-Diphenyl-N-dimethylpropylamine; 4646-55-3; Oprea1_032403; N,N-Dimethyl-3,3-diphenylpropan-1-amine; AC1Q3WP9; AC1L45WF; diphenylalkylamine (DPA), 5c; SCHEMBL1802493; 3,3-Diphenylpropyldimethylamine; CHEMBL610739; CTK1C5217; BDBM35934; DTXSID90196845; (3,3-diphenylpropyl)dimethylamine; ZINC1679452; 3,3-diphenyl-N,N-dimethylpropylamine; AKOS016035475; Benzenepropanamine, N,N-dimethyl-gamma-phenyl-
DMIP5K7 DT Small molecular drug
DMIP5K7 PC 151221
DMIP5K7 MW 239.35
DMIP5K7 FM C17H21N
DMIP5K7 IC InChI=1S/C17H21N/c1-18(2)14-13-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
DMIP5K7 CS CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=C2
DMIP5K7 IK YHDCGYWZEFIUHE-UHFFFAOYSA-N
DMIP5K7 IU N,N-dimethyl-3,3-diphenylpropan-1-amine
DMIP5K7 CA CAS 4646-55-3
DMIP5K7 DE Discovery agent
DMI3CUZ ID DMI3CUZ
DMI3CUZ DN N,N-dimethyl-3,4-dihydroquinazolin-2-amine
DMI3CUZ HS Investigative
DMI3CUZ SN CHEMBL270409; N,N-dimethyl-3,4-dihydroquinazolin-2-amine
DMI3CUZ DT Small molecular drug
DMI3CUZ PC 12683497
DMI3CUZ MW 175.23
DMI3CUZ FM C10H13N3
DMI3CUZ IC InChI=1S/C10H13N3/c1-13(2)10-11-7-8-5-3-4-6-9(8)12-10/h3-6H,7H2,1-2H3,(H,11,12)
DMI3CUZ CS CN(C)C1=NCC2=CC=CC=C2N1
DMI3CUZ IK MNTBAXGKERZVOZ-UHFFFAOYSA-N
DMI3CUZ IU N,N-dimethyl-1,4-dihydroquinazolin-2-amine
DMI3CUZ DE Discovery agent
DMLX0PI ID DMLX0PI
DMLX0PI DN N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMLX0PI HS Investigative
DMLX0PI SN CHEMBL150893; N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine; BDBM50138494; Dimethyl-(4-pyridin-3-yl-but-3-ynyl)-amine
DMLX0PI DT Small molecular drug
DMLX0PI PC 44366245
DMLX0PI MW 174.24
DMLX0PI FM C11H14N2
DMLX0PI IC InChI=1S/C11H14N2/c1-13(2)9-4-3-6-11-7-5-8-12-10-11/h5,7-8,10H,4,9H2,1-2H3
DMLX0PI CS CN(C)CCC#CC1=CN=CC=C1
DMLX0PI IK SGURIVLPISZAAK-UHFFFAOYSA-N
DMLX0PI IU N,N-dimethyl-4-pyridin-3-ylbut-3-yn-1-amine
DMLX0PI DE Discovery agent
DMX9U7S ID DMX9U7S
DMX9U7S DN N,N-dimethyl-4,4-diphenylbutan-1-amine
DMX9U7S HS Investigative
DMX9U7S SN N,N-dimethyl-4,4-diphenylbutan-1-amine; AC1L3QT1; diphenylalkylamine (DPA), 6c; CHEMBL608689; BDBM35937; ZINC5957503; AKOS016035539
DMX9U7S DT Small molecular drug
DMX9U7S PC 120445
DMX9U7S MW 253.4
DMX9U7S FM C18H23N
DMX9U7S IC InChI=1S/C18H23N/c1-19(2)15-9-14-18(16-10-5-3-6-11-16)17-12-7-4-8-13-17/h3-8,10-13,18H,9,14-15H2,1-2H3
DMX9U7S CS CN(C)CCCC(C1=CC=CC=C1)C2=CC=CC=C2
DMX9U7S IK BDSUMBDGCUOHGR-UHFFFAOYSA-N
DMX9U7S IU N,N-dimethyl-4,4-diphenylbutan-1-amine
DMX9U7S DE Discovery agent
DMWJ2PM ID DMWJ2PM
DMWJ2PM DN N,N-Dimethylaminoethyl 18-methoxycoronaridinate
DMWJ2PM HS Investigative
DMWJ2PM SN CHEMBL607047
DMWJ2PM DT Small molecular drug
DMWJ2PM PC 44324799
DMWJ2PM MW 425.6
DMWJ2PM FM C25H35N3O3
DMWJ2PM IC InChI=1S/C25H35N3O3/c1-27(2)11-13-31-24(29)25-15-17-14-18(9-12-30-3)23(25)28(16-17)10-8-20-19-6-4-5-7-21(19)26-22(20)25/h4-7,17-18,23,26H,8-16H2,1-3H3/t17?,18-,23?,25+/m0/s1
DMWJ2PM CS CN(C)CCOC(=O)[C@@]12CC3C[C@@H](C1N(C3)CCC4=C2NC5=CC=CC=C45)CCOC
DMWJ2PM IK NLVQALDWFSJMGA-WXPGHXCBSA-N
DMWJ2PM IU 2-(dimethylamino)ethyl (1S,17R)-17-(2-methoxyethyl)-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
DMWJ2PM DE Discovery agent
DM0Y8OW ID DM0Y8OW
DM0Y8OW DN N,N-dimethylarginine
DM0Y8OW HS Investigative
DM0Y8OW SN N,N-dimethylarginine; ADMA; Asymmetric dimethylarginine; 30315-93-6; Dimethyl-L-arginine; NG,NG-dimethyl-L-arginine; N(G)-Dimethylarginine; Guanidino-N,N-dimethylarginine; N(G),N(G)-Dimethylarginine; (S)-2-Amino-5-(3,3-dimethylguanidino)pentanoic acid; N(G1),N(G1)-Dimethylarginine; Lopac-D-4268; N(5)-((Dimethylamino)iminomethyl)-L-ornithine; N(omega),N(omega)-dimethyl-L-arginine; NG,NG-DIMETHYLARGININE HYDROCHLORIDE; CHEBI:17929; YDGMGEXADBMOMJ-LURJTMIESA-N; N5-[(Dimethylamino)iminomethyl]-L-ornithine
DM0Y8OW DT Small molecular drug
DM0Y8OW PC 123831
DM0Y8OW MW 202.25
DM0Y8OW FM C8H18N4O2
DM0Y8OW IC InChI=1S/C8H18N4O2/c1-12(2)8(10)11-5-3-4-6(9)7(13)14/h6H,3-5,9H2,1-2H3,(H2,10,11)(H,13,14)/t6-/m0/s1
DM0Y8OW CS CN(C)C(=NCCC[C@@H](C(=O)O)N)N
DM0Y8OW IK YDGMGEXADBMOMJ-LURJTMIESA-N
DM0Y8OW IU (2S)-2-amino-5-[[amino(dimethylamino)methylidene]amino]pentanoic acid
DM0Y8OW CA CAS 30315-93-6
DM0Y8OW CB CHEBI:17929
DM0Y8OW DE Discovery agent
DM8WPD2 ID DM8WPD2
DM8WPD2 DN N,N-dimethylhistamine
DM8WPD2 HS Investigative
DM8WPD2 SN N,N-Dimethylhistamine; 4-(2-Dimethylaminoethyl)imidazole; SU-416; Na,Na-Dimethylhistamine; 673-46-1; N(sup alpha),N(sup alpha)-Dimethylhistamine; N',N'-Dimethylhistamine; [2-(1H-imidazol-4-yl)ethyl]dimethylamine; 1H-Imidazole-4-ethanamine, N,N-dimethyl-; Imidazole, 4-[2-(dimethylamino)ethyl]-; IMIDAZOLE, 4-(2-(DIMETHYLAMINO)ETHYL)-; 4-[2-(Dimethylamino)ethyl]-Imidazole; 4-(2-(Dimethylamino)ethyl)-Imidazole; Hippospongine ; N-dimethylhistamine; CHEMBL12704; Nalpha,Nalpha-Dimethylhistamine; SCHEMBL1239352; AC1L202F; GTPL1270
DM8WPD2 DT Small molecular drug
DM8WPD2 PC 12656
DM8WPD2 MW 139.2
DM8WPD2 FM C7H13N3
DM8WPD2 IC InChI=1S/C7H13N3/c1-10(2)4-3-7-5-8-6-9-7/h5-6H,3-4H2,1-2H3,(H,8,9)
DM8WPD2 CS CN(C)CCC1=CN=CN1
DM8WPD2 IK ZJDIMSMQXMWMCF-UHFFFAOYSA-N
DM8WPD2 IU 2-(1H-imidazol-5-yl)-N,N-dimethylethanamine
DM8WPD2 CA CAS 673-46-1
DM8WPD2 DE Discovery agent
DM8769D ID DM8769D
DM8769D DN N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide
DM8769D HS Investigative
DM8769D SN CHEMBL589063; N,N-dipropyl-10H-phenothiazine-10-carboxamide; 81225-62-9; N,N-dipropylphenothiazine-10-carboxamide; AC1M3CI8; SCHEMBL8428712; ARONIS009768; MolPort-001-593-661; ZINC2883002; KS-000041AV; BDBM50308412; STL064303; AKOS000499526; MCULE-9250306994; phenothiazin-10-yl-N,N-dipropylcarboxamide; BB0286744; ST45046508; N,N-Dipropyl-1''H-phenothiazine-1''-carboxamide
DM8769D DT Small molecular drug
DM8769D PC 2235291
DM8769D MW 326.5
DM8769D FM C19H22N2OS
DM8769D IC InChI=1S/C19H22N2OS/c1-3-13-20(14-4-2)19(22)21-15-9-5-7-11-17(15)23-18-12-8-6-10-16(18)21/h5-12H,3-4,13-14H2,1-2H3
DM8769D CS CCCN(CCC)C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM8769D IK VELWLEWVSKZOLN-UHFFFAOYSA-N
DM8769D IU N,N-dipropylphenothiazine-10-carboxamide
DM8769D DE Discovery agent
DMYCV7U ID DMYCV7U
DMYCV7U DN N,O6-Disulfo-Glucosamine
DMYCV7U HS Investigative
DMYCV7U SN N,O6-Disulfo-Glucosamine; 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose; SGN; AC1L9G8A; SCHEMBL1009127; DB03959; 6-O-sulfo-N-sulfo-alpha-d-glucosamine; J3.578.180C; 6-O-Sulfo-2-(sulfoamino)-2-deoxy-alpha-D-glucopyranose; [(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid; WURCS=2.0/1,1,0/[a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O]/1/
DMYCV7U DT Small molecular drug
DMYCV7U PC 444389
DMYCV7U MW 339.3
DMYCV7U FM C6H13NO11S2
DMYCV7U IC InChI=1S/C6H13NO11S2/c8-4-2(1-17-20(14,15)16)18-6(10)3(5(4)9)7-19(11,12)13/h2-10H,1H2,(H,11,12,13)(H,14,15,16)/t2-,3-,4-,5-,6+/m1/s1
DMYCV7U CS C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O
DMYCV7U IK DQTRACMFIGDHSN-UKFBFLRUSA-N
DMYCV7U IU [(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(sulfooxymethyl)oxan-3-yl]sulfamic acid
DMYCV7U DE Discovery agent
DM7FT8D ID DM7FT8D
DM7FT8D DN N,O-Didansyl-L-Tyrosine
DM7FT8D HS Investigative
DM7FT8D SN N,O-DIDANSYL-L-TYROSINE; CHEMBL176072; 1jg0; N,O-diansyl-L-tyrosine; AC1L9JPF; Dansyl derivative, DDT, 1L; Dansyltyrosine deriviative 21B; SCHEMBL4325460; ZINC24640039; BDBM50161779; Dansyl derivatives 18A, (R) isomer; DB03157; N,O-bis{[5-(dimethylamino)naphthalen-1-yl]sulfonyl}-L-tyrosine; (S)-2-(5-Dimethylamino-naphthalene-1-sulfonylamino)-3-[4-(5-dimethylamino-naphthalene-1-sulfonyloxy)-phenyl]-propionic acid
DM7FT8D DT Small molecular drug
DM7FT8D PC 446468
DM7FT8D MW 647.8
DM7FT8D FM C33H33N3O7S2
DM7FT8D IC InChI=1S/C33H33N3O7S2/c1-35(2)29-13-5-11-26-24(29)9-7-15-31(26)44(39,40)34-28(33(37)38)21-22-17-19-23(20-18-22)43-45(41,42)32-16-8-10-25-27(32)12-6-14-30(25)36(3)4/h5-20,28,34H,21H2,1-4H3,(H,37,38)/t28-/m0/s1
DM7FT8D CS CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)N[C@@H](CC3=CC=C(C=C3)OS(=O)(=O)C4=CC=CC5=C4C=CC=C5N(C)C)C(=O)O
DM7FT8D IK LUBOPDUYHWABFG-NDEPHWFRSA-N
DM7FT8D IU (2S)-2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-3-[4-[5-(dimethylamino)naphthalen-1-yl]sulfonyloxyphenyl]propanoic acid
DM7FT8D DE Discovery agent
DMCGVAB ID DMCGVAB
DMCGVAB DN N/OFQ-(1-13)-NH2
DMCGVAB HS Investigative
DMCGVAB SN RHMALYOXPBRJBG-CGUXNFSNSA-N; nociceptin(1-13)NH2; CHEMBL384755; 178064-02-3; OFQ/N; FGGFTGARKSARK; nociceptin(1-13)-NH2; Nociceptin (1-13)NH2; orphanin FQ(1-13)NH2; Demethyl-AMPA; nociceptin/orphanin FQ(1-13)NH2; Nociceptin Orphanin FQ1-13-NH2; H-FGGFTGARKSARK-NH2; AC1O44IO; GTPL1682; BDBM85822; N/OFQ(1-13)NH2; NC(1-13)NH2; Nociceptin analogueNC(1-13)-NH2; BDBM50106479; OFQ/N (1-11); AKOS024456547; NCGC00167157-01; nociceptin(1-13)NH2
DMCGVAB DT Small molecular drug
DMCGVAB PC 6324645
DMCGVAB MW 1381.6
DMCGVAB FM C61H100N22O15
DMCGVAB IC InChI=1S/C61H100N22O15/c1-34(75-47(87)32-74-59(98)49(36(3)85)83-57(96)44(29-38-18-8-5-9-19-38)77-48(88)31-72-46(86)30-73-53(92)39(64)28-37-16-6-4-7-17-37)51(90)79-43(23-15-27-71-61(68)69)55(94)81-41(21-11-13-25-63)56(95)82-45(33-84)58(97)76-35(2)52(91)80-42(22-14-26-70-60(66)67)54(93)78-40(50(65)89)20-10-12-24-62/h4-9,16-19,34-36,39-45,49,84-85H,10-15,20-33,62-64H2,1-3H3,(H2,65,89)(H,72,86)(H,73,92)(H,74,98)(H,75,87)(H,76,97)(H,77,88)(H,78,93)(H,79,90)(H,80,91)(H,81,94)(H,82,95)(H,83,96)(H4,66,67,70)(H4,68,69,71)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,45-,49-/m0/s1
DMCGVAB CS C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O
DMCGVAB IK RHMALYOXPBRJBG-CGUXNFSNSA-N
DMCGVAB IU (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide
DMCGVAB DE Discovery agent
DMLTYPS ID DMLTYPS
DMLTYPS DN N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide
DMLTYPS HS Investigative
DMLTYPS SN CHEMBL1084919; N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide; SCHEMBL4276579; FBZAPOBZDNKPQH-UHFFFAOYSA-N; BDBM50310430
DMLTYPS DT Small molecular drug
DMLTYPS PC 11623927
DMLTYPS MW 321.2
DMLTYPS FM C9H9BrN2O2S2
DMLTYPS IC InChI=1S/C9H9BrN2O2S2/c10-7-2-1-3-8-9(7)6(5-15-8)4-12-16(11,13)14/h1-3,5,12H,4H2,(H2,11,13,14)
DMLTYPS CS C1=CC2=C(C(=C1)Br)C(=CS2)CNS(=O)(=O)N
DMLTYPS IK FBZAPOBZDNKPQH-UHFFFAOYSA-N
DMLTYPS IU 4-bromo-3-[(sulfamoylamino)methyl]-1-benzothiophene
DMLTYPS DE Discovery agent
DMVOJFW ID DMVOJFW
DMVOJFW DN N-[(4-methoxyphenyl)sulfonyl]-D-alanine
DMVOJFW HS Investigative
DMVOJFW SN n-4'-methoxybenzenesulfonyl-d-alanine; N-[(4-methoxyphenyl)sulfonyl]-D-alanine; 918330-60-6; AC1LE3DF; SCHEMBL4618694; CTK3H8025; ZINC91137; DTXSID60351641; MolPort-013-146-011; AKOS017427177; DB08599; D-Alanine, N-[(4-methoxyphenyl)sulfonyl]-; (R)-2-(4-Methoxyphenylsulfonamido)propanoic acid; (2R)-2-(4-methoxybenzenesulfonamido)propanoic acid; (2R)-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid
DMVOJFW DT Small molecular drug
DMVOJFW PC 705712
DMVOJFW MW 259.279
DMVOJFW FM C10H13NO5S
DMVOJFW IC InChI=1S/C10H13NO5S/c1-7(10(12)13)11-17(14,15)9-5-3-8(16-2)4-6-9/h3-7,11H,1-2H3,(H,12,13)/t7-/m1/s1
DMVOJFW CS C[C@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)OC
DMVOJFW IK XTCIPBHRVYICGT-SSDOTTSWSA-N
DMVOJFW IU (2R)-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid
DMVOJFW CA CAS 918330-60-6
DMVOJFW DE Discovery agent
DMYJHRV ID DMYJHRV
DMYJHRV DN N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide
DMYJHRV HS Investigative
DMYJHRV SN CHEMBL1084675; N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide; SCHEMBL4274889; PURBZUVIUSNPGZ-UHFFFAOYSA-N; BDBM50310436
DMYJHRV DT Small molecular drug
DMYJHRV PC 11572651
DMYJHRV MW 276.8
DMYJHRV FM C9H9ClN2O2S2
DMYJHRV IC InChI=1S/C9H9ClN2O2S2/c10-7-1-2-9-8(3-7)6(5-15-9)4-12-16(11,13)14/h1-3,5,12H,4H2,(H2,11,13,14)
DMYJHRV CS C1=CC2=C(C=C1Cl)C(=CS2)CNS(=O)(=O)N
DMYJHRV IK PURBZUVIUSNPGZ-UHFFFAOYSA-N
DMYJHRV IU 5-chloro-3-[(sulfamoylamino)methyl]-1-benzothiophene
DMYJHRV DE Discovery agent
DMHNR36 ID DMHNR36
DMHNR36 DN N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE
DMHNR36 HS Investigative
DMHNR36 SN N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE; 2-[(cyclohexylcarbamoyl)amino]acetic acid; CHEMBL66380; 33557-91-4; 2-(3-cyclohexylureido)acetic acid; Glycine, N-[(cyclohexylamino)carbonyl]-; 4-(3-CYCLOHEXYLURIEDO)-ETHANOIC ACID; NC3; 2-(cyclohexylcarbamoylamino)acetic acid; 1zd2; N-(cyclohexylcarbamoyl)glycine; AC1Q760W; AC1N5Q71; CTK1B1676; DTXSID90399930; MolPort-002-472-569; HMS3604L13; (3-Cyclohexyl-ureido)-acetic acid; ZINC6691828; BDBM50143914; AKOS000132958; NE25644; MCULE-8014113453; DB08256; [(cyclohexylcarbamoyl)amino]acetic acid
DMHNR36 DT Small molecular drug
DMHNR36 PC 4149241
DMHNR36 MW 200.23
DMHNR36 FM C9H16N2O3
DMHNR36 IC InChI=1S/C9H16N2O3/c12-8(13)6-10-9(14)11-7-4-2-1-3-5-7/h7H,1-6H2,(H,12,13)(H2,10,11,14)
DMHNR36 CS C1CCC(CC1)NC(=O)NCC(=O)O
DMHNR36 IK NVORCMBCUHQRDL-UHFFFAOYSA-N
DMHNR36 IU 2-(cyclohexylcarbamoylamino)acetic acid
DMHNR36 CA CAS 33557-91-4
DMHNR36 DE Discovery agent
DMI9GQV ID DMI9GQV
DMI9GQV DN N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMI9GQV HS Investigative
DMI9GQV SN CHEMBL233863; N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMI9GQV DT Small molecular drug
DMI9GQV PC 44430730
DMI9GQV MW 279.3
DMI9GQV FM C15H13N5O
DMI9GQV IC InChI=1S/C15H13N5O/c16-15(17)20-14(21)10-6-2-1-5-9(10)13-18-11-7-3-4-8-12(11)19-13/h1-8H,(H,18,19)(H4,16,17,20,21)
DMI9GQV CS C1=CC=C(C(=C1)C2=NC3=CC=CC=C3N2)C(=O)N=C(N)N
DMI9GQV IK FJRZRURKRDCIKZ-UHFFFAOYSA-N
DMI9GQV IU 2-(1H-benzimidazol-2-yl)-N-(diaminomethylidene)benzamide
DMI9GQV DE Discovery agent
DMM7T13 ID DMM7T13
DMM7T13 DN N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide
DMM7T13 HS Investigative
DMM7T13 SN N-[2-(1H-INDOL-5-YL)-BUTYL]-4-SULFAMOYL-BENZAMIDE; N-[(2S)-2-(1H-indol-5-yl)butyl]-4-sulfamoylbenzamide; SBB; AC1NUYV7
DMM7T13 DT Small molecular drug
DMM7T13 PC 5496599
DMM7T13 MW 371.5
DMM7T13 FM C19H21N3O3S
DMM7T13 IC InChI=1S/C19H21N3O3S/c1-2-13(15-5-8-18-16(11-15)9-10-21-18)12-22-19(23)14-3-6-17(7-4-14)26(20,24)25/h3-11,13,21H,2,12H2,1H3,(H,22,23)(H2,20,24,25)/t13-/m1/s1
DMM7T13 CS CC[C@H](CNC(=O)C1=CC=C(C=C1)S(=O)(=O)N)C2=CC3=C(C=C2)NC=C3
DMM7T13 IK FSRPBGBMEKDSIJ-CYBMUJFWSA-N
DMM7T13 IU N-[(2S)-2-(1H-indol-5-yl)butyl]-4-sulfamoylbenzamide
DMM7T13 DE Discovery agent
DMPKBT1 ID DMPKBT1
DMPKBT1 DN N-[2-(4'-Nitrophenyl)ethyl]-imidazole
DMPKBT1 HS Investigative
DMPKBT1 SN 1-(4-nitrophenethyl)-1H-imidazole; 56643-91-5; 1-[2-(4-nitrophenyl)ethyl]-1H-imidazole; CHEMBL1098425; 1H-Imidazole, 1-[2-(4-nitrophenyl)ethyl]-; 1-[2-(4-nitrophenyl)ethyl]imidazole; AC1MOACC; MLS001195428; SCHEMBL9663626; CTK1F4146; DTXSID30391397; MolPort-002-886-896; HCPMKJOVCNZGSD-UHFFFAOYSA-N; HMS2885O15; ZINC4025449; BDBM50318407; AKOS010189447; MCULE-3977633271; MS-1973; KS-0000281S; SMR000550723; N-[2-(4''-Nitrophenyl)ethyl]-imidazole; SR-01000308458
DMPKBT1 DT Small molecular drug
DMPKBT1 PC 3317166
DMPKBT1 MW 217.22
DMPKBT1 FM C11H11N3O2
DMPKBT1 IC InChI=1S/C11H11N3O2/c15-14(16)11-3-1-10(2-4-11)5-7-13-8-6-12-9-13/h1-4,6,8-9H,5,7H2
DMPKBT1 CS C1=CC(=CC=C1CCN2C=CN=C2)[N+](=O)[O-]
DMPKBT1 IK HCPMKJOVCNZGSD-UHFFFAOYSA-N
DMPKBT1 IU 1-[2-(4-nitrophenyl)ethyl]imidazole
DMPKBT1 CA CAS 56643-91-5
DMPKBT1 DE Discovery agent
DM5FQH8 ID DM5FQH8
DM5FQH8 DN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide
DM5FQH8 HS Investigative
DM5FQH8 SN CHEMBL394636; BDBM22995; N-arachidonoylserotonin analogue, 1h
DM5FQH8 DT Small molecular drug
DM5FQH8 PC 24749271
DM5FQH8 MW 358.5
DM5FQH8 FM C22H34N2O2
DM5FQH8 IC InChI=1S/C22H34N2O2/c1-2-3-4-5-6-7-8-9-10-11-22(26)23-15-14-18-17-24-21-13-12-19(25)16-20(18)21/h12-13,16-17,24-25H,2-11,14-15H2,1H3,(H,23,26)
DM5FQH8 CS CCCCCCCCCCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DM5FQH8 IK MOQBGJJXYJJJFQ-UHFFFAOYSA-N
DM5FQH8 IU N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]dodecanamide
DM5FQH8 DE Discovery agent
DMG5PL7 ID DMG5PL7
DMG5PL7 DN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide
DMG5PL7 HS Investigative
DMG5PL7 SN CHEMBL236385; BDBM22991; N-arachidonoylserotonin analogue, 1d
DMG5PL7 DT Small molecular drug
DMG5PL7 PC 24749267
DMG5PL7 MW 438.6
DMG5PL7 FM C28H42N2O2
DMG5PL7 IC InChI=1S/C28H42N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(32)29-21-20-24-23-30-27-19-18-25(31)22-26(24)27/h6-7,9-10,18-19,22-23,30-31H,2-5,8,11-17,20-21H2,1H3,(H,29,32)/b7-6-,10-9-
DMG5PL7 CS CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DMG5PL7 IK YJVMJUDLMFBYFZ-HZJYTTRNSA-N
DMG5PL7 IU (9Z,12Z)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]octadeca-9,12-dienamide
DMG5PL7 DE Discovery agent
DMC1GYH ID DMC1GYH
DMC1GYH DN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide
DMC1GYH HS Investigative
DMC1GYH SN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide; CHEMBL394635; BDBM22994; N-arachidonoylserotonin analogue, 1g
DMC1GYH DT Small molecular drug
DMC1GYH PC 24749270
DMC1GYH MW 344.5
DMC1GYH FM C21H32N2O2
DMC1GYH IC InChI=1S/C21H32N2O2/c1-2-3-4-5-6-7-8-9-10-21(25)22-14-13-17-16-23-20-12-11-18(24)15-19(17)20/h11-12,15-16,23-24H,2-10,13-14H2,1H3,(H,22,25)
DMC1GYH CS CCCCCCCCCCC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DMC1GYH IK RNYSECALLZNZML-UHFFFAOYSA-N
DMC1GYH IU N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide
DMC1GYH DE Discovery agent
DMJ8W6F ID DMJ8W6F
DMJ8W6F DN N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate
DMJ8W6F HS Investigative
DMJ8W6F SN CHEMBL202881
DMJ8W6F DT Small molecular drug
DMJ8W6F PC 44406804
DMJ8W6F MW 326.5
DMJ8W6F FM C18H18N2S2
DMJ8W6F IC InChI=1S/C18H18N2S2/c21-18(22-13-14-6-2-1-3-7-14)19-11-10-16-12-15-8-4-5-9-17(15)20-16/h1-9,12,20H,10-11,13H2,(H,19,21)
DMJ8W6F CS C1=CC=C(C=C1)CSC(=S)NCCC2=CC3=CC=CC=C3N2
DMJ8W6F IK UDMBZULQHCKYPT-UHFFFAOYSA-N
DMJ8W6F IU benzyl N-[2-(1H-indol-2-yl)ethyl]carbamodithioate
DMJ8W6F DE Discovery agent
DMU89FH ID DMU89FH
DMU89FH DN N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide
DMU89FH HS Investigative
DMU89FH SN CHEMBL125665; N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide; SCHEMBL6789609
DMU89FH DT Small molecular drug
DMU89FH PC 22718561
DMU89FH MW 246.3
DMU89FH FM C14H18N2O2
DMU89FH IC InChI=1S/C14H18N2O2/c1-3-13-16-12-8-4-6-11(14(12)18-13)7-5-9-15-10(2)17/h4,6,8H,3,5,7,9H2,1-2H3,(H,15,17)
DMU89FH CS CCC1=NC2=CC=CC(=C2O1)CCCNC(=O)C
DMU89FH IK UGHYQTDENFVMRW-UHFFFAOYSA-N
DMU89FH IU N-[3-(2-ethyl-1,3-benzoxazol-7-yl)propyl]acetamide
DMU89FH DE Discovery agent
DM7OA4R ID DM7OA4R
DM7OA4R DN N-[3'-(trifluoromethyl)-4-biphenylyl]urea
DM7OA4R HS Investigative
DM7OA4R SN CHEMBL244690; BDBM50220199
DM7OA4R DT Small molecular drug
DM7OA4R PC 23626453
DM7OA4R MW 280.24
DM7OA4R FM C14H11F3N2O
DM7OA4R IC InChI=1S/C14H11F3N2O/c15-14(16,17)11-3-1-2-10(8-11)9-4-6-12(7-5-9)19-13(18)20/h1-8H,(H3,18,19,20)
DM7OA4R CS C1=CC(=CC(=C1)C(F)(F)F)C2=CC=C(C=C2)NC(=O)N
DM7OA4R IK MHFIGSQWRVHNRG-UHFFFAOYSA-N
DM7OA4R IU [4-[3-(trifluoromethyl)phenyl]phenyl]urea
DM7OA4R DE Discovery agent
DMKPYEU ID DMKPYEU
DMKPYEU DN N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide
DMKPYEU HS Investigative
DMKPYEU SN N-(3,3-diphenylpropyl)benzamide; CHEMBL556303; AC1LOGD3; Oprea1_468003; N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide; SCHEMBL5948102; MolPort-001-492-275; ZINC995229; STK448927; BDBM50297396; AKOS003256160; MCULE-7987321913; ST50916006
DMKPYEU DT Small molecular drug
DMKPYEU PC 1220236
DMKPYEU MW 315.4
DMKPYEU FM C22H21NO
DMKPYEU IC InChI=1S/C22H21NO/c24-22(20-14-8-3-9-15-20)23-17-16-21(18-10-4-1-5-11-18)19-12-6-2-7-13-19/h1-15,21H,16-17H2,(H,23,24)
DMKPYEU CS C1=CC=C(C=C1)C(CCNC(=O)C2=CC=CC=C2)C3=CC=CC=C3
DMKPYEU IK NSSSSHDNQFPODZ-UHFFFAOYSA-N
DMKPYEU IU N-(3,3-diphenylpropyl)benzamide
DMKPYEU DE Discovery agent
DMIP8AK ID DMIP8AK
DMIP8AK DN N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide
DMIP8AK HS Investigative
DMIP8AK SN CHEMBL563216; N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide; SCHEMBL5947860; PGLSPMQRWMIFOQ-UHFFFAOYSA-N; BDBM50297398
DMIP8AK DT Small molecular drug
DMIP8AK PC 11976535
DMIP8AK MW 352.4
DMIP8AK FM C21H18F2N2O
DMIP8AK IC InChI=1S/C21H18F2N2O/c22-18-7-3-15(4-8-18)20(16-5-9-19(23)10-6-16)11-13-25-21(26)17-2-1-12-24-14-17/h1-10,12,14,20H,11,13H2,(H,25,26)
DMIP8AK CS C1=CC(=CN=C1)C(=O)NCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F
DMIP8AK IK PGLSPMQRWMIFOQ-UHFFFAOYSA-N
DMIP8AK IU N-[3,3-bis(4-fluorophenyl)propyl]pyridine-3-carboxamide
DMIP8AK DE Discovery agent
DMWDCV1 ID DMWDCV1
DMWDCV1 DN N-[3H]alpha-methylhistamine
DMWDCV1 HS Investigative
DMWDCV1 SN N-alpha-methylhistamine; 1H-Imidazole-4-ethanamine, N-methyl-; 4-(2-Methylaminoethyl)imidazole; N(sup alpha)-Methylhistamine; NAMH; Nalpha-Methylhistamine; UNII-Y7QR253130; N(alpha)-methylhistamine; Y7QR253130; Imidazole, 4-[2-(methylamino)ethyl]-; Imidazole, 4-(2-(methylamino)ethyl)-; [2-(1H-imidazol-5-yl)ethyl](methyl)amine; 2-(3H-imidazol-4-yl)-N-methylethanamine; [3H]-Na-methylhistamine; [3H]NAMH; N-alpha-methyl histamine
DMWDCV1 DT Small molecular drug
DMWDCV1 PC 912
DMWDCV1 MW 125.17
DMWDCV1 FM C6H11N3
DMWDCV1 IC InChI=1S/C6H11N3/c1-7-3-2-6-4-8-5-9-6/h4-5,7H,2-3H2,1H3,(H,8,9)
DMWDCV1 CS CNCCC1=CN=CN1
DMWDCV1 IK PHSPJQZRQAJPPF-UHFFFAOYSA-N
DMWDCV1 IU 2-(1H-imidazol-5-yl)-N-methylethanamine
DMWDCV1 CA CAS 673-50-7
DMWDCV1 DE Discovery agent
DM0CI4L ID DM0CI4L
DM0CI4L DN N-[3H]methylhistamine
DM0CI4L HS Investigative
DM0CI4L SN 1-Methylhistamine; Tele-methylhistamine; 501-75-7; N1-Methylhistamine; N-Telle-methylhistamine; 2-(1-methyl-1H-imidazol-4-yl)ethanamine; 2-(1-methyl-1H-imidazol-4-yl)ethan-1-amine; 1-Methyl-1H-imidazole-4-ethanamine; 1H-Imidazole-4-ethanamine, 1-methyl-; 1-Methyl-4-histamine; UNII-KCB81T4EOF; N(sup 1)-Methylhistamine; NSC 66736; N-tele-Methylhistamine; CHEBI:29009; 1-methyl-4-(b-aminoethyl)imidazole; 1-Methyl-4-(2-aminoethyl)imidazole; KCB81T4EOF; 1-Methyl-4-(beta-aminoethyl)imidazole; BRN 0110757
DM0CI4L DT Small molecular drug
DM0CI4L PC 3614
DM0CI4L MW 125.17
DM0CI4L FM C6H11N3
DM0CI4L IC InChI=1S/C6H11N3/c1-9-4-6(2-3-7)8-5-9/h4-5H,2-3,7H2,1H3
DM0CI4L CS CN1C=C(N=C1)CCN
DM0CI4L IK FHQDWPCFSJMNCT-UHFFFAOYSA-N
DM0CI4L IU 2-(1-methylimidazol-4-yl)ethanamine
DM0CI4L CA CAS 501-75-7
DM0CI4L CB CHEBI:29009
DM0CI4L DE Discovery agent
DMITN82 ID DMITN82
DMITN82 DN N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide
DMITN82 HS Investigative
DMITN82 SN CHEMBL242180; N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide; SCHEMBL5535049
DMITN82 DT Small molecular drug
DMITN82 PC 11737887
DMITN82 MW 292.31
DMITN82 FM C13H12N2O4S
DMITN82 IC InChI=1S/C13H12N2O4S/c14-20(16,17)15-11-4-1-9(2-5-11)10-3-6-12-13(7-10)19-8-18-12/h1-7,15H,8H2,(H2,14,16,17)
DMITN82 CS C1OC2=C(O1)C=C(C=C2)C3=CC=C(C=C3)NS(=O)(=O)N
DMITN82 IK ZFMUZDFMEJBCPQ-UHFFFAOYSA-N
DMITN82 IU 5-[4-(sulfamoylamino)phenyl]-1,3-benzodioxole
DMITN82 DE Discovery agent
DMT6LX9 ID DMT6LX9
DMT6LX9 DN N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMT6LX9 HS Investigative
DMT6LX9 SN CHEMBL233862; N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine
DMT6LX9 DT Small molecular drug
DMT6LX9 PC 44430728
DMT6LX9 MW 279.3
DMT6LX9 FM C15H13N5O
DMT6LX9 IC InChI=1S/C15H13N5O/c16-15(17)20-14(21)10-7-5-9(6-8-10)13-18-11-3-1-2-4-12(11)19-13/h1-8H,(H,18,19)(H4,16,17,20,21)
DMT6LX9 CS C1=CC=C2C(=C1)NC(=N2)C3=CC=C(C=C3)C(=O)N=C(N)N
DMT6LX9 IK RAYGWMJYTDFZDD-UHFFFAOYSA-N
DMT6LX9 IU 4-(1H-benzimidazol-2-yl)-N-(diaminomethylidene)benzamide
DMT6LX9 DE Discovery agent
DMLV18K ID DMLV18K
DMLV18K DN N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide
DMLV18K HS Investigative
DMLV18K SN CHEMBL223185; N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide; N-(4-(3-amino-1H-indazol-4-yl)phenyl)benzamide; benzamide,n-[4-(3-amino-1h-indazol-4-yl)phenyl]-; BDBM50207504; ZINC35324132; 935660-76-7
DMLV18K DT Small molecular drug
DMLV18K PC 16125109
DMLV18K MW 328.4
DMLV18K FM C20H16N4O
DMLV18K IC InChI=1S/C20H16N4O/c21-19-18-16(7-4-8-17(18)23-24-19)13-9-11-15(12-10-13)22-20(25)14-5-2-1-3-6-14/h1-12H,(H,22,25)(H3,21,23,24)
DMLV18K CS C1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N
DMLV18K IK ZBWAOEUPXWDTQS-UHFFFAOYSA-N
DMLV18K IU N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide
DMLV18K DE Discovery agent
DMC62K1 ID DMC62K1
DMC62K1 DN N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide
DMC62K1 HS Investigative
DMC62K1 SN CHEMBL381482; N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide; SCHEMBL4153643
DMC62K1 DT Small molecular drug
DMC62K1 PC 11615675
DMC62K1 MW 243.29
DMC62K1 FM C12H9N3OS
DMC62K1 IC InChI=1S/C12H9N3OS/c1-9(16)14-12-15-11(8-17-12)5-4-10-3-2-6-13-7-10/h2-3,6-8H,1H3,(H,14,15,16)
DMC62K1 CS CC(=O)NC1=NC(=CS1)C#CC2=CN=CC=C2
DMC62K1 IK LNYMBABMFUHLAP-UHFFFAOYSA-N
DMC62K1 IU N-[4-(2-pyridin-3-ylethynyl)-1,3-thiazol-2-yl]acetamide
DMC62K1 DE Discovery agent
DMA4L5P ID DMA4L5P
DMA4L5P DN N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide
DMA4L5P HS Investigative
DMA4L5P SN CHEMBL27393; N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide; BDBM50022717
DMA4L5P DT Small molecular drug
DMA4L5P PC 14162480
DMA4L5P MW 337.5
DMA4L5P FM C21H27N3O
DMA4L5P IC InChI=1S/C21H27N3O/c25-21(19-9-3-1-4-10-19)22-13-7-8-14-23-15-17-24(18-16-23)20-11-5-2-6-12-20/h1-6,9-12H,7-8,13-18H2,(H,22,25)
DMA4L5P CS C1CN(CCN1CCCCNC(=O)C2=CC=CC=C2)C3=CC=CC=C3
DMA4L5P IK SPKHLKULRLEZKZ-UHFFFAOYSA-N
DMA4L5P IU N-[4-(4-phenylpiperazin-1-yl)butyl]benzamide
DMA4L5P DE Discovery agent
DMD5F6Z ID DMD5F6Z
DMD5F6Z DN N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea
DMD5F6Z HS Investigative
DMD5F6Z SN CHEMBL244512; BDBM50220161
DMD5F6Z DT Small molecular drug
DMD5F6Z PC 23626454
DMD5F6Z MW 322.4
DMD5F6Z FM C15H15FN2O3S
DMD5F6Z IC InChI=1S/C15H15FN2O3S/c1-2-22(20,21)12-6-3-10(4-7-12)11-5-8-14(13(16)9-11)18-15(17)19/h3-9H,2H2,1H3,(H3,17,18,19)
DMD5F6Z CS CCS(=O)(=O)C1=CC=C(C=C1)C2=CC(=C(C=C2)NC(=O)N)F
DMD5F6Z IK FGSMXSWRTDKBBK-UHFFFAOYSA-N
DMD5F6Z IU [4-(4-ethylsulfonylphenyl)-2-fluorophenyl]urea
DMD5F6Z DE Discovery agent
DMCTZFP ID DMCTZFP
DMCTZFP DN N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide
DMCTZFP HS Investigative
DMCTZFP SN CHEMBL390629; N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide; SCHEMBL5531754; WELQTBDQZUFHMC-UHFFFAOYSA-N; ZINC28711911; BDBM50220182
DMCTZFP DT Small molecular drug
DMCTZFP PC 11232325
DMCTZFP MW 316.3
DMCTZFP FM C13H11F3N2O2S
DMCTZFP IC InChI=1S/C13H11F3N2O2S/c14-13(15,16)11-5-1-9(2-6-11)10-3-7-12(8-4-10)18-21(17,19)20/h1-8,18H,(H2,17,19,20)
DMCTZFP CS C1=CC(=CC=C1C2=CC=C(C=C2)NS(=O)(=O)N)C(F)(F)F
DMCTZFP IK WELQTBDQZUFHMC-UHFFFAOYSA-N
DMCTZFP IU 1-[4-(sulfamoylamino)phenyl]-4-(trifluoromethyl)benzene
DMCTZFP DE Discovery agent
DMPVKWG ID DMPVKWG
DMPVKWG DN N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea
DMPVKWG HS Investigative
DMPVKWG SN CHEMBL243885; N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea; SCHEMBL5427766; VTGXCQVBAHHGLK-UHFFFAOYSA-N; BDBM50220195
DMPVKWG DT Small molecular drug
DMPVKWG PC 11652296
DMPVKWG MW 296.31
DMPVKWG FM C14H11F3N2S
DMPVKWG IC InChI=1S/C14H11F3N2S/c15-14(16,17)11-5-1-9(2-6-11)10-3-7-12(8-4-10)19-13(18)20/h1-8H,(H3,18,19,20)
DMPVKWG CS C1=CC(=CC=C1C2=CC=C(C=C2)NC(=S)N)C(F)(F)F
DMPVKWG IK VTGXCQVBAHHGLK-UHFFFAOYSA-N
DMPVKWG IU [4-[4-(trifluoromethyl)phenyl]phenyl]thiourea
DMPVKWG DE Discovery agent
DMMHQRT ID DMMHQRT
DMMHQRT DN N-[4'-(trifluoromethyl)-4-biphenylyl]urea
DMMHQRT HS Investigative
DMMHQRT SN CHEMBL243883; SCHEMBL5427711; ZINC28711905; BDBM50220162
DMMHQRT DT Small molecular drug
DMMHQRT PC 11623295
DMMHQRT MW 280.24
DMMHQRT FM C14H11F3N2O
DMMHQRT IC InChI=1S/C14H11F3N2O/c15-14(16,17)11-5-1-9(2-6-11)10-3-7-12(8-4-10)19-13(18)20/h1-8H,(H3,18,19,20)
DMMHQRT CS C1=CC(=CC=C1C2=CC=C(C=C2)NC(=O)N)C(F)(F)F
DMMHQRT IK SUCPPONDZMGXRQ-UHFFFAOYSA-N
DMMHQRT IU [4-[4-(trifluoromethyl)phenyl]phenyl]urea
DMMHQRT DE Discovery agent
DMMX65T ID DMMX65T
DMMX65T DN N-[4-(trifluoromethyl)phenyl]sulfamide
DMMX65T HS Investigative
DMMX65T SN N-[4-(trifluoromethyl)phenyl]sulfamide; CHEMBL167179; N-[4-(trifluoromethyl)phenyl]sulfuric diamide; 556068-13-4; (4-trifluoromethylphenyl)sulfamide; SCHEMBL1645153; ZINC13488092; BDBM50124177; AKOS027393975; KB-300897; 79478-EP2305698A2; 79478-EP2305696A2; 79478-EP2305697A2
DMMX65T DT Small molecular drug
DMMX65T PC 10421755
DMMX65T MW 240.21
DMMX65T FM C7H7F3N2O2S
DMMX65T IC InChI=1S/C7H7F3N2O2S/c8-7(9,10)5-1-3-6(4-2-5)12-15(11,13)14/h1-4,12H,(H2,11,13,14)
DMMX65T CS C1=CC(=CC=C1C(F)(F)F)NS(=O)(=O)N
DMMX65T IK LTJDGKNETMQCBO-UHFFFAOYSA-N
DMMX65T IU 1-(sulfamoylamino)-4-(trifluoromethyl)benzene
DMMX65T DE Discovery agent
DMP5A8K ID DMP5A8K
DMP5A8K DN N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine
DMP5A8K HS Investigative
DMP5A8K SN CHEMBL372051; N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine; SCHEMBL4939618
DMP5A8K DT Small molecular drug
DMP5A8K PC 11172909
DMP5A8K MW 257.29
DMP5A8K FM C14H15N3O2
DMP5A8K IC InChI=1S/C14H15N3O2/c1-2-9-5-3-4-6-10(9)11-7-8-12(19-11)13(18)17-14(15)16/h3-8H,2H2,1H3,(H4,15,16,17,18)
DMP5A8K CS CCC1=CC=CC=C1C2=CC=C(O2)C(=O)N=C(N)N
DMP5A8K IK CCKFOHBQWASBLB-UHFFFAOYSA-N
DMP5A8K IU N-(diaminomethylidene)-5-(2-ethylphenyl)furan-2-carboxamide
DMP5A8K DE Discovery agent
DMZ9V18 ID DMZ9V18
DMZ9V18 DN N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
DMZ9V18 HS Investigative
DMZ9V18 SN CHEMBL425186; N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine
DMZ9V18 DT Small molecular drug
DMZ9V18 PC 11349219
DMZ9V18 MW 274.23
DMZ9V18 FM C12H10N4O4
DMZ9V18 IC InChI=1S/C12H10N4O4/c13-12(14)15-11(17)10-6-5-9(20-10)7-3-1-2-4-8(7)16(18)19/h1-6H,(H4,13,14,15,17)
DMZ9V18 CS C1=CC=C(C(=C1)C2=CC=C(O2)C(=O)N=C(N)N)[N+](=O)[O-]
DMZ9V18 IK KLPHIGVDYLBNDU-UHFFFAOYSA-N
DMZ9V18 IU N-(diaminomethylidene)-5-(2-nitrophenyl)furan-2-carboxamide
DMZ9V18 DE Discovery agent
DMSI4PE ID DMSI4PE
DMSI4PE DN N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE HS Investigative
DMSI4PE SN CHEMBL451538; N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMSI4PE DT Small molecular drug
DMSI4PE PC 25154731
DMSI4PE MW 240.3
DMSI4PE FM C4H8N4O2S3
DMSI4PE IC InChI=1S/C4H8N4O2S3/c1-2-11-4-7-6-3(12-4)8-13(5,9)10/h2H2,1H3,(H,6,8)(H2,5,9,10)
DMSI4PE CS CCSC1=NN=C(S1)NS(=O)(=O)N
DMSI4PE IK CHUOTDNKSODBJL-UHFFFAOYSA-N
DMSI4PE IU 2-ethylsulfanyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMSI4PE DE Discovery agent
DMH7QOF ID DMH7QOF
DMH7QOF DN N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide
DMH7QOF HS Investigative
DMH7QOF SN CHEMBL337584; N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide; TWZ-109
DMH7QOF DT Small molecular drug
DMH7QOF PC 44359538
DMH7QOF MW 250.29
DMH7QOF FM C13H18N2O3
DMH7QOF IC InChI=1S/C13H18N2O3/c16-11-15(18)10-6-2-5-9-14-13(17)12-7-3-1-4-8-12/h1,3-4,7-8,11,18H,2,5-6,9-10H2,(H,14,17)
DMH7QOF CS C1=CC=C(C=C1)C(=O)NCCCCCN(C=O)O
DMH7QOF IK XZVIJIAWKVHBTR-UHFFFAOYSA-N
DMH7QOF IU N-[5-[formyl(hydroxy)amino]pentyl]benzamide
DMH7QOF DE Discovery agent
DMXLJGR ID DMXLJGR
DMXLJGR DN N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR HS Investigative
DMXLJGR SN CHEMBL459356; N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide
DMXLJGR DT Small molecular drug
DMXLJGR PC 44571848
DMXLJGR MW 226.3
DMXLJGR FM C3H6N4O2S3
DMXLJGR IC InChI=1S/C3H6N4O2S3/c1-10-3-6-5-2(11-3)7-12(4,8)9/h1H3,(H,5,7)(H2,4,8,9)
DMXLJGR CS CSC1=NN=C(S1)NS(=O)(=O)N
DMXLJGR IK AJEMPSSJQSOJKR-UHFFFAOYSA-N
DMXLJGR IU 2-methylsulfanyl-5-(sulfamoylamino)-1,3,4-thiadiazole
DMXLJGR DE Discovery agent
DMVY7RX ID DMVY7RX
DMVY7RX DN N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX)
DMVY7RX HS Investigative
DMVY7RX SN CHEMBL1097456; N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX); SCHEMBL1404641; BDBM50316519
DMVY7RX DT Small molecular drug
DMVY7RX PC 24996886
DMVY7RX MW 573.8
DMVY7RX FM C26H22Cl3F3N2O3
DMVY7RX IC InChI=1S/C26H22Cl3F3N2O3/c1-25(2)12-20(33-22(36)11-21(35)26(30,31)32)18-10-17(13-3-5-14(27)6-4-13)23(34-24(18)37-25)16-8-7-15(28)9-19(16)29/h3-10,20-21,35H,11-12H2,1-2H3,(H,33,36)
DMVY7RX CS CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=C(C=C(C=C4)Cl)Cl)NC(=O)CC(C(F)(F)F)O)C
DMVY7RX IK ONIULYGRFWGEHO-UHFFFAOYSA-N
DMVY7RX IU N-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydropyrano[2,3-b]pyridin-4-yl]-4,4,4-trifluoro-3-hydroxybutanamide
DMVY7RX DE Discovery agent
DM6EICU ID DM6EICU
DM6EICU DN N-[O-Phosphono-Pyridoxyl]-Isoleucine
DM6EICU HS Investigative
DM6EICU SN ILP; AC1L9K3U; (3S)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]-3-methylpentanoic acid
DM6EICU DT Small molecular drug
DM6EICU PC 46936443
DM6EICU MW 362.32
DM6EICU FM C14H23N2O7P
DM6EICU IC InChI=1S/C14H23N2O7P/c1-4-8(2)12(14(18)19)16-6-11-10(7-23-24(20,21)22)5-15-9(3)13(11)17/h5,8,12,16-17H,4,6-7H2,1-3H3,(H,18,19)(H2,20,21,22)/t8-,12+/m1/s1
DM6EICU CS CC[C@@H](C)[C@@H](C(=O)O)NCC1=C(C(=NC=C1COP(=O)(O)O)C)O
DM6EICU IK GZZDWFDWHXPWJK-PELKAZGASA-N
DM6EICU IU (2S,3R)-2-[[3-hydroxy-2-methyl-5-(phosphonooxymethyl)pyridin-4-yl]methylamino]-3-methylpentanoic acid
DM6EICU DE Discovery agent
DMN493F ID DMN493F
DMN493F DN N-[Tosyl-D-Prolinyl]Amino-Ethanethiol
DMN493F HS Investigative
DMN493F SN N-[TOSYL-D-PROLINYL]AMINO-ETHANETHIOL; TP2; AC1L9I3U; SCHEMBL4308892; DB03818; 1-[(4-methylphenyl)sulfonyl]-N-(2-sulfanylethyl)-D-prolinamide
DMN493F DT Small molecular drug
DMN493F PC 445503
DMN493F MW 328.5
DMN493F FM C14H20N2O3S2
DMN493F IC InChI=1S/C14H20N2O3S2/c1-11-4-6-12(7-5-11)21(18,19)16-9-2-3-13(16)14(17)15-8-10-20/h4-7,13,20H,2-3,8-10H2,1H3,(H,15,17)/t13-/m1/s1
DMN493F CS CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@@H]2C(=O)NCCS
DMN493F IK NWUYDTGYTUQMDG-CYBMUJFWSA-N
DMN493F IU (2R)-1-(4-methylphenyl)sulfonyl-N-(2-sulfanylethyl)pyrrolidine-2-carboxamide
DMN493F DE Discovery agent
DMX4QKU ID DMX4QKU
DMX4QKU DN N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE
DMX4QKU HS Investigative
DMX4QKU SN 41472-49-5; N-(4-Sulfamoylphenethyl)acetamide; N-[2-(4-sulfamoylphenyl)ethyl]acetamide; N-{2-[4-(Aminosulfonyl)phenyl]ethyl}acetamide; N-(2-(4-(Aminosulphonyl)phenyl)ethyl)acetamide; N-Acetyl-4-(2-aminoethyl)benzenesulfonamide; 2nns; 2nmx; EINECS 255-386-5; 4-(2-Acetylaminoethyl)benzenesulfonamide; AC1LF2Y7; Oprea1_087799; CBDivE_010614; SCHEMBL9016571; DTXSID10194368; MolPort-000-563-758; IIMGUEXQORZTID-UHFFFAOYSA-N; ZINC188952; HMS3604G22; HMS1786I07; DK-42; p-(2-acetamidoethyl)benzenesulfonamide; AKOS000987732
DMX4QKU DT Small molecular drug
DMX4QKU PC 745994
DMX4QKU MW 242.3
DMX4QKU FM C10H14N2O3S
DMX4QKU IC InChI=1S/C10H14N2O3S/c1-8(13)12-7-6-9-2-4-10(5-3-9)16(11,14)15/h2-5H,6-7H2,1H3,(H,12,13)(H2,11,14,15)
DMX4QKU CS CC(=O)NCCC1=CC=C(C=C1)S(=O)(=O)N
DMX4QKU IK IIMGUEXQORZTID-UHFFFAOYSA-N
DMX4QKU IU N-[2-(4-sulfamoylphenyl)ethyl]acetamide
DMX4QKU CA CAS 41472-49-5
DMX4QKU DE Discovery agent
DM74KHG ID DM74KHG
DM74KHG DN N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide
DM74KHG HS Investigative
DM74KHG SN CHEMBL222111; N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide; SCHEMBL1339724
DM74KHG DT Small molecular drug
DM74KHG PC 11270007
DM74KHG MW 416.5
DM74KHG FM C24H20N2O3S
DM74KHG IC InChI=1S/C24H20N2O3S/c27-24(19-11-5-2-6-12-19)26-22-15-16-23(21-14-8-7-13-20(21)22)30(28,29)25-17-18-9-3-1-4-10-18/h1-16,25H,17H2,(H,26,27)
DM74KHG CS C1=CC=C(C=C1)CNS(=O)(=O)C2=CC=C(C3=CC=CC=C32)NC(=O)C4=CC=CC=C4
DM74KHG IK QPJKMKVTEJYYGG-UHFFFAOYSA-N
DM74KHG IU N-[4-(benzylsulfamoyl)naphthalen-1-yl]benzamide
DM74KHG DE Discovery agent
DM90U5P ID DM90U5P
DM90U5P DN N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea
DM90U5P HS Investigative
DM90U5P SN CHEMBL389588; SCHEMBL5434550; BDBM50220177
DM90U5P DT Small molecular drug
DM90U5P PC 11695867
DM90U5P MW 344.31
DM90U5P FM C14H11F3N2O3S
DM90U5P IC InChI=1S/C14H11F3N2O3S/c15-14(16,17)23(21,22)12-7-3-10(4-8-12)9-1-5-11(6-2-9)19-13(18)20/h1-8H,(H3,18,19,20)
DM90U5P CS C1=CC(=CC=C1C2=CC=C(C=C2)S(=O)(=O)C(F)(F)F)NC(=O)N
DM90U5P IK ISQOEHFLTNIEGX-UHFFFAOYSA-N
DM90U5P IU [4-[4-(trifluoromethylsulfonyl)phenyl]phenyl]urea
DM90U5P DE Discovery agent
DMEIB69 ID DMEIB69
DMEIB69 DN N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea
DMEIB69 HS Investigative
DMEIB69 SN CHEMBL244511; SCHEMBL5434921; BDBM50220203
DMEIB69 DT Small molecular drug
DMEIB69 PC 11695302
DMEIB69 MW 312.31
DMEIB69 FM C14H11F3N2OS
DMEIB69 IC InChI=1S/C14H11F3N2OS/c15-14(16,17)21-12-7-3-10(4-8-12)9-1-5-11(6-2-9)19-13(18)20/h1-8H,(H3,18,19,20)
DMEIB69 CS C1=CC(=CC=C1C2=CC=C(C=C2)SC(F)(F)F)NC(=O)N
DMEIB69 IK FHOBREWUJUOKGZ-UHFFFAOYSA-N
DMEIB69 IU [4-[4-(trifluoromethylsulfanyl)phenyl]phenyl]urea
DMEIB69 DE Discovery agent
DMO3VLJ ID DMO3VLJ
DMO3VLJ DN N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMO3VLJ HS Investigative
DMO3VLJ SN CHEMBL574107; N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMO3VLJ DT Small molecular drug
DMO3VLJ PC 45481863
DMO3VLJ MW 343.4
DMO3VLJ FM C22H17NO3
DMO3VLJ IC InChI=1S/C22H17NO3/c24-18-5-3-4-16(14-18)9-8-15-10-12-17(13-11-15)23-21(25)19-6-1-2-7-20(19)22(23)26/h1-7,10-14,24H,8-9H2
DMO3VLJ CS C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC=C(C=C3)CCC4=CC(=CC=C4)O
DMO3VLJ IK TUMZBTITCWKZAT-UHFFFAOYSA-N
DMO3VLJ IU 2-[4-[2-(3-hydroxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DMO3VLJ DE Discovery agent
DMZ4N7Q ID DMZ4N7Q
DMZ4N7Q DN N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
DMZ4N7Q HS Investigative
DMZ4N7Q SN CHEMBL572484; N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide
DMZ4N7Q DT Small molecular drug
DMZ4N7Q PC 45481844
DMZ4N7Q MW 357.4
DMZ4N7Q FM C23H19NO3
DMZ4N7Q IC InChI=1S/C23H19NO3/c1-27-19-6-4-5-17(15-19)10-9-16-11-13-18(14-12-16)24-22(25)20-7-2-3-8-21(20)23(24)26/h2-8,11-15H,9-10H2,1H3
DMZ4N7Q CS COC1=CC=CC(=C1)CCC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O
DMZ4N7Q IK CNZNMDJWLSHLJZ-UHFFFAOYSA-N
DMZ4N7Q IU 2-[4-[2-(3-methoxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DMZ4N7Q DE Discovery agent
DMXU5IS ID DMXU5IS
DMXU5IS DN N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMXU5IS HS Investigative
DMXU5IS SN CHEMBL575857; N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide
DMXU5IS DT Small molecular drug
DMXU5IS PC 45481821
DMXU5IS MW 343.4
DMXU5IS FM C22H17NO3
DMXU5IS IC InChI=1S/C22H17NO3/c24-18-13-9-16(10-14-18)6-5-15-7-11-17(12-8-15)23-21(25)19-3-1-2-4-20(19)22(23)26/h1-4,7-14,24H,5-6H2
DMXU5IS CS C1=CC=C2C(=C1)C(=O)N(C2=O)C3=CC=C(C=C3)CCC4=CC=C(C=C4)O
DMXU5IS IK OFQPQJJVXCUPFR-UHFFFAOYSA-N
DMXU5IS IU 2-[4-[2-(4-hydroxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DMXU5IS DE Discovery agent
DM0S71O ID DM0S71O
DM0S71O DN N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide
DM0S71O HS Investigative
DM0S71O SN CHEMBL575856; N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide; BDBM50298668
DM0S71O DT Small molecular drug
DM0S71O PC 44537911
DM0S71O MW 357.4
DM0S71O FM C23H19NO3
DM0S71O IC InChI=1S/C23H19NO3/c1-27-19-14-10-17(11-15-19)7-6-16-8-12-18(13-9-16)24-22(25)20-4-2-3-5-21(20)23(24)26/h2-5,8-15H,6-7H2,1H3
DM0S71O CS COC1=CC=C(C=C1)CCC2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C3=O
DM0S71O IK CRWGIKAUSJNKIC-UHFFFAOYSA-N
DM0S71O IU 2-[4-[2-(4-methoxyphenyl)ethyl]phenyl]isoindole-1,3-dione
DM0S71O DE Discovery agent
DML35GB ID DML35GB
DML35GB DN N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
DML35GB HS Investigative
DML35GB SN N~3~-(3-Pyridin-3-Ylbenzyl)pyridine-2,3-Diamine; 2ohr; SCHEMBL8264924; CHEMBL220346; BDBM15782; 3-Substituted 2-Aminopyridine 6a; ZINC10339547; DB07284; 3-N-{[3-(pyridin-3-yl)phenyl]methyl}pyridine-2,3-diamine
DML35GB DT Small molecular drug
DML35GB PC 11701820
DML35GB MW 276.34
DML35GB FM C17H16N4
DML35GB IC InChI=1S/C17H16N4/c18-17-16(7-3-9-20-17)21-11-13-4-1-5-14(10-13)15-6-2-8-19-12-15/h1-10,12,21H,11H2,(H2,18,20)
DML35GB CS C1=CC(=CC(=C1)C2=CN=CC=C2)CNC3=C(N=CC=C3)N
DML35GB IK NQSBHBFOOVYRNM-UHFFFAOYSA-N
DML35GB IU 3-N-[(3-pyridin-3-ylphenyl)methyl]pyridine-2,3-diamine
DML35GB DE Discovery agent
DMOCQ9I ID DMOCQ9I
DMOCQ9I DN N~3~-BENZYLPYRIDINE-2,3-DIAMINE
DMOCQ9I HS Investigative
DMOCQ9I SN N3-benzylpyridine-2,3-diamine; 79707-12-3; N~3~-Benzylpyridine-2,3-Diamine; N3-BENZYL-PYRIDINE-2,3-DIAMINE; 2-amino-3-benzylaminopyridine; 3-N-benzylpyridine-2,3-diamine; N~3~-Benzyl-2,3-pyridinediamine; aminopyridine 3; N'-benzylpyridine-2,3-diamine; 2ohm; 2,3-Pyridinediamine, N3-(phenylmethyl)-; CHEMBL435747; SCHEMBL11069733; CTK5E7044; BDBM15781; DTXSID40439234; 3-Substituted 2-Aminopyridine 5; MUKAGFLFIMVSQN-UHFFFAOYSA-N; MolPort-008-154-365; ALBB-013372; ZINC10339550; 9869AE; AKOS005174206; MCULE-5416742943; DB07281
DMOCQ9I DT Small molecular drug
DMOCQ9I PC 10397869
DMOCQ9I MW 199.25
DMOCQ9I FM C12H13N3
DMOCQ9I IC InChI=1S/C12H13N3/c13-12-11(7-4-8-14-12)15-9-10-5-2-1-3-6-10/h1-8,15H,9H2,(H2,13,14)
DMOCQ9I CS C1=CC=C(C=C1)CNC2=C(N=CC=C2)N
DMOCQ9I IK MUKAGFLFIMVSQN-UHFFFAOYSA-N
DMOCQ9I IU 3-N-benzylpyridine-2,3-diamine
DMOCQ9I CA CAS 79707-12-3
DMOCQ9I DE Discovery agent
DM6HM5S ID DM6HM5S
DM6HM5S DN N1-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S HS Investigative
DM6HM5S SN DIETHYLENETRIAMINE; 111-40-0; Bis(2-aminoethyl)amine; 2,2'-Diaminodiethylamine; Diethylene triamine; Barsamide 115; Epicure T; Ancamine DETA; 1,4,7-Triazaheptane; 2,2'-Iminodiethylamine; N,N-Bis(2-aminoethyl)amine; Aminoethylethandiamine; 3-Azapentane-1,5-diamine; 1,2-Ethanediamine, N-(2-aminoethyl)-; Imino-bis-ethylamine; ChS-P 1; N-(2-Aminoethyl)-1,2-ethanediamine; N-(2-aminoethyl)ethane-1,2-diamine; 1,5-Diamino-3-azapentane; 2,2'-Iminobis(ethanamine); Bis(beta-aminoethyl)amine; 2-(2-Aminoethylamino)ethylamine; Epon 3223
DM6HM5S DT Small molecular drug
DM6HM5S PC 8111
DM6HM5S MW 103.17
DM6HM5S FM C4H13N3
DM6HM5S IC InChI=1S/C4H13N3/c5-1-3-7-4-2-6/h7H,1-6H2
DM6HM5S CS C(CNCCN)N
DM6HM5S IK RPNUMPOLZDHAAY-UHFFFAOYSA-N
DM6HM5S IU N'-(2-aminoethyl)ethane-1,2-diamine
DM6HM5S CA CAS 111-40-0
DM6HM5S CB CHEBI:30629
DM6HM5S DE Discovery agent
DM5F04D ID DM5F04D
DM5F04D DN N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide
DM5F04D HS Investigative
DM5F04D SN CHEMBL219785
DM5F04D DT Small molecular drug
DM5F04D PC 44420656
DM5F04D MW 312.4
DM5F04D FM C18H20N2O3
DM5F04D IC InChI=1S/C18H20N2O3/c21-17(13-18(22)20-23)19-12-11-16(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-10,16,23H,11-13H2,(H,19,21)(H,20,22)
DM5F04D CS C1=CC=C(C=C1)C(CCNC(=O)CC(=O)NO)C2=CC=CC=C2
DM5F04D IK UYRUQIFSLBHLGY-UHFFFAOYSA-N
DM5F04D IU N-(3,3-diphenylpropyl)-N'-hydroxypropanediamide
DM5F04D DE Discovery agent
DMSRHJA ID DMSRHJA
DMSRHJA DN N1-(3-phenoxybenzyl)-N3-hydroxymalonamide
DMSRHJA HS Investigative
DMSRHJA SN CHEMBL220392
DMSRHJA DT Small molecular drug
DMSRHJA PC 16116575
DMSRHJA MW 300.31
DMSRHJA FM C16H16N2O4
DMSRHJA IC InChI=1S/C16H16N2O4/c19-15(10-16(20)18-21)17-11-12-5-4-8-14(9-12)22-13-6-2-1-3-7-13/h1-9,21H,10-11H2,(H,17,19)(H,18,20)
DMSRHJA CS C1=CC=C(C=C1)OC2=CC=CC(=C2)CNC(=O)CC(=O)NO
DMSRHJA IK AKGLDBDNAJLOMB-UHFFFAOYSA-N
DMSRHJA IU N'-hydroxy-N-[(3-phenoxyphenyl)methyl]propanediamide
DMSRHJA DE Discovery agent
DMCH7GO ID DMCH7GO
DMCH7GO DN N1-(4-bromophenyl)-N2,N2-dipentylphthalamide
DMCH7GO HS Investigative
DMCH7GO SN CHEMBL523749; N'-(4-bromophenyl)-N,N-dipentylbenzene-1,2-dicarboxamide; AC1MDHAQ; N1-(4-bromophenyl)-N2,N2-dipentylphthalamide; MolPort-002-139-379; ZINC9510931; BDBM50265685; STK055903; AKOS005386817; MCULE-4023922974
DMCH7GO DT Small molecular drug
DMCH7GO PC 2836828
DMCH7GO MW 459.4
DMCH7GO FM C24H31BrN2O2
DMCH7GO IC InChI=1S/C24H31BrN2O2/c1-3-5-9-17-27(18-10-6-4-2)24(29)22-12-8-7-11-21(22)23(28)26-20-15-13-19(25)14-16-20/h7-8,11-16H,3-6,9-10,17-18H2,1-2H3,(H,26,28)
DMCH7GO CS CCCCCN(CCCCC)C(=O)C1=CC=CC=C1C(=O)NC2=CC=C(C=C2)Br
DMCH7GO IK OITHNNNIGWHOAY-UHFFFAOYSA-N
DMCH7GO IU 1-N-(4-bromophenyl)-2-N,2-N-dipentylbenzene-1,2-dicarboxamide
DMCH7GO DE Discovery agent
DMJ025O ID DMJ025O
DMJ025O DN N1-(4-chlorobenzyl)-2-amino-N3-hydroxymalonamide
DMJ025O HS Investigative
DMJ025O SN CHEMBL385996
DMJ025O DT Small molecular drug
DMJ025O PC 16115629
DMJ025O MW 257.67
DMJ025O FM C10H12ClN3O3
DMJ025O IC InChI=1S/C10H12ClN3O3/c11-7-3-1-6(2-4-7)5-13-9(15)8(12)10(16)14-17/h1-4,8,17H,5,12H2,(H,13,15)(H,14,16)
DMJ025O CS C1=CC(=CC=C1CNC(=O)C(C(=O)NO)N)Cl
DMJ025O IK OGTJYIPAKYEFNR-UHFFFAOYSA-N
DMJ025O IU 2-amino-N-[(4-chlorophenyl)methyl]-N'-hydroxypropanediamide
DMJ025O DE Discovery agent
DMTMDZ4 ID DMTMDZ4
DMTMDZ4 DN N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide
DMTMDZ4 HS Investigative
DMTMDZ4 SN CHEMBL374577; N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide; BDBM50206546
DMTMDZ4 DT Small molecular drug
DMTMDZ4 PC 16114883
DMTMDZ4 MW 332.8
DMTMDZ4 FM C17H17ClN2O3
DMTMDZ4 IC InChI=1S/C17H17ClN2O3/c18-14-8-6-13(7-9-14)11-19-16(21)15(17(22)20-23)10-12-4-2-1-3-5-12/h1-9,15,23H,10-11H2,(H,19,21)(H,20,22)
DMTMDZ4 CS C1=CC=C(C=C1)CC(C(=O)NCC2=CC=C(C=C2)Cl)C(=O)NO
DMTMDZ4 IK MDFALTKCDXYVEX-UHFFFAOYSA-N
DMTMDZ4 IU 2-benzyl-N-[(4-chlorophenyl)methyl]-N'-hydroxypropanediamide
DMTMDZ4 DE Discovery agent
DMS1P85 ID DMS1P85
DMS1P85 DN N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide
DMS1P85 HS Investigative
DMS1P85 SN CHEMBL219618; N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide; BDBM50206556
DMS1P85 DT Small molecular drug
DMS1P85 PC 16114884
DMS1P85 MW 316.33
DMS1P85 FM C17H17FN2O3
DMS1P85 IC InChI=1S/C17H17FN2O3/c18-14-8-6-13(7-9-14)11-19-16(21)15(17(22)20-23)10-12-4-2-1-3-5-12/h1-9,15,23H,10-11H2,(H,19,21)(H,20,22)
DMS1P85 CS C1=CC=C(C=C1)CC(C(=O)NCC2=CC=C(C=C2)F)C(=O)NO
DMS1P85 IK HPODXRZHNDBMJC-UHFFFAOYSA-N
DMS1P85 IU 2-benzyl-N-[(4-fluorophenyl)methyl]-N'-hydroxypropanediamide
DMS1P85 DE Discovery agent
DMMQXON ID DMMQXON
DMMQXON DN N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide
DMMQXON HS Investigative
DMMQXON SN CHEMBL473270; N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide
DMMQXON DT Small molecular drug
DMMQXON PC 44591267
DMMQXON MW 340.4
DMMQXON FM C20H24N2O3
DMMQXON IC InChI=1S/C20H24N2O3/c23-19(13-6-1-2-7-14-20(24)22-25)21-18-12-8-11-17(15-18)16-9-4-3-5-10-16/h3-5,8-12,15,25H,1-2,6-7,13-14H2,(H,21,23)(H,22,24)
DMMQXON CS C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)CCCCCCC(=O)NO
DMMQXON IK RDYLEVRHTUDZCQ-UHFFFAOYSA-N
DMMQXON IU N'-hydroxy-N-(3-phenylphenyl)octanediamide
DMMQXON DE Discovery agent
DMZA8NC ID DMZA8NC
DMZA8NC DN N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide
DMZA8NC HS Investigative
DMZA8NC SN CHEMBL512644; N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide; SCHEMBL8226957
DMZA8NC DT Small molecular drug
DMZA8NC PC 25032059
DMZA8NC MW 340.4
DMZA8NC FM C20H24N2O3
DMZA8NC IC InChI=1S/C20H24N2O3/c23-19(10-6-1-2-7-11-20(24)22-25)21-18-14-12-17(13-15-18)16-8-4-3-5-9-16/h3-5,8-9,12-15,25H,1-2,6-7,10-11H2,(H,21,23)(H,22,24)
DMZA8NC CS C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)CCCCCCC(=O)NO
DMZA8NC IK MIYLHRAVWYBTPV-UHFFFAOYSA-N
DMZA8NC IU N'-hydroxy-N-(4-phenylphenyl)octanediamide
DMZA8NC DE Discovery agent
DMYGCSV ID DMYGCSV
DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine
DMYGCSV HS Investigative
DMYGCSV SN N-(1-Naphthyl)ethylenediamine; 551-09-7; N1-(naphthalen-1-yl)ethane-1,2-diamine; N-(1-naphthyl)ethane-1,2-diamine; 1,2-Ethanediamine, N-1-naphthalenyl-; UNII-02X37521XE; CHEMBL1214195; CHEBI:53510; NULAJYZBOLVQPQ-UHFFFAOYSA-N; N-naphthalen-1-ylethane-1,2-diamine; 02X37521XE; 1,2-Ethanediamine, N1-1-naphthalenyl-; N-(naphthalen-1-yl)ethane-1,2-diamine; NCGC00163705-03; N-1-naphthylethylenediamine; Oprea1_329986; EINECS 208-992-9; (2-aminoethyl)naphthylamine; N-1-naphthylethylene diamine; SCHEMBL233681
DMYGCSV DT Small molecular drug
DMYGCSV PC 15107
DMYGCSV MW 186.25
DMYGCSV FM C12H14N2
DMYGCSV IC InChI=1S/C12H14N2/c13-8-9-14-12-7-3-5-10-4-1-2-6-11(10)12/h1-7,14H,8-9,13H2
DMYGCSV CS C1=CC=C2C(=C1)C=CC=C2NCCN
DMYGCSV IK NULAJYZBOLVQPQ-UHFFFAOYSA-N
DMYGCSV IU N'-naphthalen-1-ylethane-1,2-diamine
DMYGCSV CA CAS 551-09-7
DMYGCSV CB CHEBI:53510
DMYGCSV DE Discovery agent
DMM59IS ID DMM59IS
DMM59IS DN N1,2-dibenzyl-N3-hydroxymalonamide
DMM59IS HS Investigative
DMM59IS SN CHEMBL113827; N1,2-dibenzyl-N3-hydroxymalonamide; 2N-dibenzyl-N''-hydroxy-malonamide; BDBM50062474
DMM59IS DT Small molecular drug
DMM59IS PC 10709191
DMM59IS MW 298.34
DMM59IS FM C17H18N2O3
DMM59IS IC InChI=1S/C17H18N2O3/c20-16(18-12-14-9-5-2-6-10-14)15(17(21)19-22)11-13-7-3-1-4-8-13/h1-10,15,22H,11-12H2,(H,18,20)(H,19,21)
DMM59IS CS C1=CC=C(C=C1)CC(C(=O)NCC2=CC=CC=C2)C(=O)NO
DMM59IS IK WKIMWNKNDQXNCK-UHFFFAOYSA-N
DMM59IS IU N,2-dibenzyl-N'-hydroxypropanediamide
DMM59IS DE Discovery agent
DM1L89K ID DM1L89K
DM1L89K DN N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide
DM1L89K HS Investigative
DM1L89K SN CHEMBL426572
DM1L89K DT Small molecular drug
DM1L89K PC 16114768
DM1L89K MW 402.5
DM1L89K FM C25H26N2O3
DM1L89K IC InChI=1S/C25H26N2O3/c28-24(26-30)23(18-21-12-6-2-7-13-21)25(29)27(19-22-14-8-3-9-15-22)17-16-20-10-4-1-5-11-20/h1-15,23,30H,16-19H2,(H,26,28)
DM1L89K CS C1=CC=C(C=C1)CCN(CC2=CC=CC=C2)C(=O)C(CC3=CC=CC=C3)C(=O)NO
DM1L89K IK PQZSZTWFWIQBGX-UHFFFAOYSA-N
DM1L89K IU N,2-dibenzyl-N'-hydroxy-N-(2-phenylethyl)propanediamide
DM1L89K DE Discovery agent
DMJ10WH ID DMJ10WH
DMJ10WH DN N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH HS Investigative
DMJ10WH SN CHEMBL449527; N-1,3,4-thiadiazol-2-ylsulfamide
DMJ10WH DT Small molecular drug
DMJ10WH PC 25154729
DMJ10WH MW 180.21
DMJ10WH FM C2H4N4O2S2
DMJ10WH IC InChI=1S/C2H4N4O2S2/c3-10(7,8)6-2-5-4-1-9-2/h1H,(H,5,6)(H2,3,7,8)
DMJ10WH CS C1=NN=C(S1)NS(=O)(=O)N
DMJ10WH IK TXIIDPYBTNXTDC-UHFFFAOYSA-N
DMJ10WH IU 2-(sulfamoylamino)-1,3,4-thiadiazole
DMJ10WH DE Discovery agent
DMVIGCJ ID DMVIGCJ
DMVIGCJ DN N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
DMVIGCJ HS Investigative
DMVIGCJ SN N-butyl-S-methyl-isothiourea; NTU; 100319-25-3; AC1L9JBU; SCHEMBL11844558; methyl N'-butylcarbamimidothioate
DMVIGCJ DT Small molecular drug
DMVIGCJ PC 11740154
DMVIGCJ MW 374.7
DMVIGCJ FM C18H38N4S2
DMVIGCJ IC InChI=1S/C18H38N4S2/c1-23-17(19)21-15-13-11-9-7-5-3-4-6-8-10-12-14-16-22-18(20)24-2/h3-16H2,1-2H3,(H2,19,21)(H2,20,22)
DMVIGCJ CS CSC(=NCCCCCCCCCCCCCCN=C(N)SC)N
DMVIGCJ IK IOKDMHHZKWLWKO-UHFFFAOYSA-N
DMVIGCJ IU methyl N'-[14-[[amino(methylsulfanyl)methylidene]amino]tetradecyl]carbamimidothioate
DMVIGCJ DE Discovery agent
DMSDVGQ ID DMSDVGQ
DMSDVGQ DN N1,N2-bis(dihydrocaffeoyl)spermine
DMSDVGQ HS Investigative
DMSDVGQ SN Kukoamine A; 75288-96-9; CHEMBL79129; CHEBI:81220; N1,N2-bis(dihydrocaffeoyl)spermine; AC1NSXD9; SCHEMBL16547596; 1,14-Bis(dihydrocaffeoyl)spermine; BDBM50240622; ZINC13513540; AKOS032945995; FT-0686649; C17615; 3-(3,4-dihydroxyphenyl)-N-[3-[4-[3-[3-(3,4-dihydroxyphenyl)propanoylamino]propylamino]butylamino]propyl]propanamide; 3-(3,4-Dihydroxy-phenyl)-N-[3-(4-{3-[3-(3,4-dihydroxy-phenyl)-propionylamino]-propylamino}-butylamino)-propyl]-propionamide
DMSDVGQ DT Small molecular drug
DMSDVGQ PC 5318865
DMSDVGQ MW 530.7
DMSDVGQ FM C28H42N4O6
DMSDVGQ IC InChI=1S/C28H42N4O6/c33-23-9-5-21(19-25(23)35)7-11-27(37)31-17-3-15-29-13-1-2-14-30-16-4-18-32-28(38)12-8-22-6-10-24(34)26(36)20-22/h5-6,9-10,19-20,29-30,33-36H,1-4,7-8,11-18H2,(H,31,37)(H,32,38)
DMSDVGQ CS C1=CC(=C(C=C1CCC(=O)NCCCNCCCCNCCCNC(=O)CCC2=CC(=C(C=C2)O)O)O)O
DMSDVGQ IK IOLDDENZPBFBHV-UHFFFAOYSA-N
DMSDVGQ IU 3-(3,4-dihydroxyphenyl)-N-[3-[4-[3-[3-(3,4-dihydroxyphenyl)propanoylamino]propylamino]butylamino]propyl]propanamide
DMSDVGQ CA CAS 75288-96-9
DMSDVGQ CB CHEBI:81220
DMSDVGQ DE Discovery agent
DMA5Z7P ID DMA5Z7P
DMA5Z7P DN N1,N3-bis(3-methoxybenzyl)isophthalamide
DMA5Z7P HS Investigative
DMA5Z7P SN CHEMBL605201; N1,N3-bis(3-methoxybenzyl)isophthalamide; SCHEMBL5332068
DMA5Z7P DT Small molecular drug
DMA5Z7P PC 10111838
DMA5Z7P MW 404.5
DMA5Z7P FM C24H24N2O4
DMA5Z7P IC InChI=1S/C24H24N2O4/c1-29-21-10-3-6-17(12-21)15-25-23(27)19-8-5-9-20(14-19)24(28)26-16-18-7-4-11-22(13-18)30-2/h3-14H,15-16H2,1-2H3,(H,25,27)(H,26,28)
DMA5Z7P CS COC1=CC=CC(=C1)CNC(=O)C2=CC(=CC=C2)C(=O)NCC3=CC(=CC=C3)OC
DMA5Z7P IK XDBOLPFDJWTESQ-UHFFFAOYSA-N
DMA5Z7P IU 1-N,3-N-bis[(3-methoxyphenyl)methyl]benzene-1,3-dicarboxamide
DMA5Z7P DE Discovery agent
DMRO7JX ID DMRO7JX
DMRO7JX DN N1,N4-bis(5-chloro-2-methylphenyl)succinamide
DMRO7JX HS Investigative
DMRO7JX SN CHEMBL566931; N,N'-bis(5-chloro-2-methylphenyl)butanediamide; N1,N4-bis(5-chloro-2-methylphenyl)succinamide; AC1LK29V; Cambridge id 7313591; Oprea1_225764; MLS000535625; cid_1010578; MolPort-001-547-717; ZINC670958; HMS2360E14; STK435362; BDBM50303376; AKOS003303190; MCULE-2700246651; SMR000143061; ST50923735; N,N'-bis(5-chloro-2-methylphenyl)succinamide
DMRO7JX DT Small molecular drug
DMRO7JX PC 1010578
DMRO7JX MW 365.2
DMRO7JX FM C18H18Cl2N2O2
DMRO7JX IC InChI=1S/C18H18Cl2N2O2/c1-11-3-5-13(19)9-15(11)21-17(23)7-8-18(24)22-16-10-14(20)6-4-12(16)2/h3-6,9-10H,7-8H2,1-2H3,(H,21,23)(H,22,24)
DMRO7JX CS CC1=C(C=C(C=C1)Cl)NC(=O)CCC(=O)NC2=C(C=CC(=C2)Cl)C
DMRO7JX IK GNEGOXDKOUMPJX-UHFFFAOYSA-N
DMRO7JX IU N,N'-bis(5-chloro-2-methylphenyl)butanediamide
DMRO7JX DE Discovery agent
DM4Q86B ID DM4Q86B
DM4Q86B DN N1-[4-(Phenylmethoxy)phenyl]-D-aspartamine
DM4Q86B HS Investigative
DM4Q86B SN Amino acid analog, 4d; CHEMBL478360; BDBM24254; (3R)-3-amino-3-{[4-(benzyloxy)phenyl]carbamoyl}propanoic acid
DM4Q86B DT Small molecular drug
DM4Q86B PC 24901602
DM4Q86B MW 314.34
DM4Q86B FM C17H18N2O4
DM4Q86B IC InChI=1S/C17H18N2O4/c18-15(10-16(20)21)17(22)19-13-6-8-14(9-7-13)23-11-12-4-2-1-3-5-12/h1-9,15H,10-11,18H2,(H,19,22)(H,20,21)/t15-/m1/s1
DM4Q86B CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@@H](CC(=O)O)N
DM4Q86B IK VTMSXGVEMJOFRJ-OAHLLOKOSA-N
DM4Q86B IU (3R)-3-amino-4-oxo-4-(4-phenylmethoxyanilino)butanoic acid
DM4Q86B DE Discovery agent
DMK10WX ID DMK10WX
DMK10WX DN N1-[4-(Phenylmethoxy)phenyl]-D-glutamine
DMK10WX HS Investigative
DMK10WX SN Amino acid analog, 4c; CHEMBL477478; BDBM24253; (4R)-4-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid
DMK10WX DT Small molecular drug
DMK10WX PC 24901601
DMK10WX MW 328.4
DMK10WX FM C18H20N2O4
DMK10WX IC InChI=1S/C18H20N2O4/c19-16(10-11-17(21)22)18(23)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,23)(H,21,22)/t16-/m1/s1
DMK10WX CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@@H](CCC(=O)O)N
DMK10WX IK IYYBWKOXCQKLHX-MRXNPFEDSA-N
DMK10WX IU (4R)-4-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DMK10WX DE Discovery agent
DMLEMUX ID DMLEMUX
DMLEMUX DN N1-[4-(Phenylmethoxy)phenyl]-L-aspartamine
DMLEMUX HS Investigative
DMLEMUX SN (3S)-3-amino-4-oxo-4-[(4-phenylmethoxyphenyl)amino]butanoic acid; Amino acid analog, 4b; CHEMBL477307; BDBM24252; N-[4-(benzyloxy)phenyl]-L-alpha-asparagine; (3S)-3-amino-3-{[4-(benzyloxy)phenyl]carbamoyl}propanoic acid
DMLEMUX DT Small molecular drug
DMLEMUX PC 24768559
DMLEMUX MW 314.34
DMLEMUX FM C17H18N2O4
DMLEMUX IC InChI=1S/C17H18N2O4/c18-15(10-16(20)21)17(22)19-13-6-8-14(9-7-13)23-11-12-4-2-1-3-5-12/h1-9,15H,10-11,18H2,(H,19,22)(H,20,21)/t15-/m0/s1
DMLEMUX CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@H](CC(=O)O)N
DMLEMUX IK VTMSXGVEMJOFRJ-HNNXBMFYSA-N
DMLEMUX IU (3S)-3-amino-4-oxo-4-(4-phenylmethoxyanilino)butanoic acid
DMLEMUX DE Discovery agent
DM9XCZS ID DM9XCZS
DM9XCZS DN N1-[4-(Phenylmethoxy)phenyl]-L-glutamine
DM9XCZS HS Investigative
DM9XCZS SN Amino acid analog, 4a; CHEMBL478550; BDBM24251; (4S)-4-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid
DM9XCZS DT Small molecular drug
DM9XCZS PC 24901600
DM9XCZS MW 328.4
DM9XCZS FM C18H20N2O4
DM9XCZS IC InChI=1S/C18H20N2O4/c19-16(10-11-17(21)22)18(23)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,23)(H,21,22)/t16-/m0/s1
DM9XCZS CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)[C@H](CCC(=O)O)N
DM9XCZS IK IYYBWKOXCQKLHX-INIZCTEOSA-N
DM9XCZS IU (4S)-4-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DM9XCZS DE Discovery agent
DMXSFWK ID DMXSFWK
DMXSFWK DN N1-benzyl-N3-hydroxy-2-isobutylmalonamide
DMXSFWK HS Investigative
DMXSFWK SN CHEMBL220253; N1-benzyl-N3-hydroxy-2-isobutylmalonamide; BDBM50197494
DMXSFWK DT Small molecular drug
DMXSFWK PC 16116576
DMXSFWK MW 264.32
DMXSFWK FM C14H20N2O3
DMXSFWK IC InChI=1S/C14H20N2O3/c1-10(2)8-12(14(18)16-19)13(17)15-9-11-6-4-3-5-7-11/h3-7,10,12,19H,8-9H2,1-2H3,(H,15,17)(H,16,18)
DMXSFWK CS CC(C)CC(C(=O)NCC1=CC=CC=C1)C(=O)NO
DMXSFWK IK BOQZRPQZGWWCDJ-UHFFFAOYSA-N
DMXSFWK IU N-benzyl-N'-hydroxy-2-(2-methylpropyl)propanediamide
DMXSFWK DE Discovery agent
DM76CLF ID DM76CLF
DM76CLF DN N1-dansyl-spermine
DM76CLF HS Investigative
DM76CLF SN N1-DnsSpm; N1-dansyl-spermine; dansyl spermine; N1-dansyl-spermidine; GTPL4260; SCHEMBL5361425; CHEMBL1184349; BDBM86164; DNS-343; 191410-24-9
DM76CLF DT Small molecular drug
DM76CLF PC 9889212
DM76CLF MW 435.6
DM76CLF FM C22H37N5O2S
DM76CLF IC InChI=1S/C22H37N5O2S/c1-27(2)21-11-5-10-20-19(21)9-6-12-22(20)30(28,29)26-18-8-17-25-15-4-3-14-24-16-7-13-23/h5-6,9-12,24-26H,3-4,7-8,13-18,23H2,1-2H3
DM76CLF CS CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCCCNCCCCNCCCN
DM76CLF IK NSUSGNAFCIMCDH-UHFFFAOYSA-N
DM76CLF IU N-[3-[4-(3-aminopropylamino)butylamino]propyl]-5-(dimethylamino)naphthalene-1-sulfonamide
DM76CLF DE Discovery agent
DMXE8CB ID DMXE8CB
DMXE8CB DN N1-guanyl-1,7-diaminoheptane
DMXE8CB HS Investigative
DMXE8CB PC 90657844
DMXE8CB MW 174.29
DMXE8CB FM C8H22N4+2
DMXE8CB IC InChI=1S/C8H20N4/c9-6-4-2-1-3-5-7-12-8(10)11/h1-7,9H2,(H4,10,11,12)/p+2
DMXE8CB CS C(CCC[NH3+])CCC[NH+]=C(N)N
DMXE8CB IK YAOAMZOGXBMLFQ-UHFFFAOYSA-P
DMXE8CB IU 7-azaniumylheptyl(diaminomethylidene)azanium
DMXE8CB DE Discovery agent
DMF6RVS ID DMF6RVS
DMF6RVS DN N1-hydroxy-2-isobutyl-N3-phenethylmalonamide
DMF6RVS HS Investigative
DMF6RVS SN CHEMBL220010; N1-hydroxy-2-isobutyl-N3-phenethylmalonamide; BDBM50197502
DMF6RVS DT Small molecular drug
DMF6RVS PC 16114635
DMF6RVS MW 278.35
DMF6RVS FM C15H22N2O3
DMF6RVS IC InChI=1S/C15H22N2O3/c1-11(2)10-13(15(19)17-20)14(18)16-9-8-12-6-4-3-5-7-12/h3-7,11,13,20H,8-10H2,1-2H3,(H,16,18)(H,17,19)
DMF6RVS CS CC(C)CC(C(=O)NCCC1=CC=CC=C1)C(=O)NO
DMF6RVS IK WODYKKMWHBZSIB-UHFFFAOYSA-N
DMF6RVS IU N-hydroxy-2-(2-methylpropyl)-N'-(2-phenylethyl)propanediamide
DMF6RVS DE Discovery agent
DMOZARM ID DMOZARM
DMOZARM DN N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide
DMOZARM HS Investigative
DMOZARM SN CHEMBL511212; N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide; BDBM50258645
DMOZARM DT Small molecular drug
DMOZARM PC 10383069
DMOZARM MW 347.4
DMOZARM FM C17H21N3O3S
DMOZARM IC InChI=1S/C17H21N3O3S/c21-15(10-6-1-2-7-11-16(22)20-23)19-17-18-14(12-24-17)13-8-4-3-5-9-13/h3-5,8-9,12,23H,1-2,6-7,10-11H2,(H,20,22)(H,18,19,21)
DMOZARM CS C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)CCCCCCC(=O)NO
DMOZARM IK BDTAPZUZFJRPNM-UHFFFAOYSA-N
DMOZARM IU N'-hydroxy-N-(4-phenyl-1,3-thiazol-2-yl)octanediamide
DMOZARM DE Discovery agent
DM5LC3D ID DM5LC3D
DM5LC3D DN N-1-isopropyl-5-MeOT
DM5LC3D HS Investigative
DM5LC3D SN N-1-isopropyl-5-methoxytryptamine
DM5LC3D DT Small molecular drug
DM5LC3D PC 24820144
DM5LC3D MW 232.32
DM5LC3D FM C14H20N2O
DM5LC3D IC InChI=1S/C14H20N2O/c1-10(2)16-9-11(6-7-15)13-8-12(17-3)4-5-14(13)16/h4-5,8-10H,6-7,15H2,1-3H3
DM5LC3D CS CC(C)N1C=C(C2=C1C=CC(=C2)OC)CCN
DM5LC3D IK WFNIDMQOBQYSBC-UHFFFAOYSA-N
DM5LC3D IU 2-(5-methoxy-1-propan-2-ylindol-3-yl)ethanamine
DM5LC3D DE Discovery agent
DM25NLH ID DM25NLH
DM25NLH DN N-1-isopropyltryptamine
DM25NLH HS Investigative
DM25NLH SN 1-Isopropyltryptamine; 2-(1-propan-2-ylindol-3-yl)ethanamine; N-1-isopropyltryptamine; AC1NOM56; GTPL159; SCHEMBL7749047; BDBM84943; MolPort-001-788-641; ZINC4600317; SBB081239; STK075425; AKOS000276209; MCULE-5027387412; 40619-60-1; 2-[1-(methylethyl)indol-3-yl]ethylamine
DM25NLH DT Small molecular drug
DM25NLH PC 5115445
DM25NLH MW 202.3
DM25NLH FM C13H18N2
DM25NLH IC InChI=1S/C13H18N2/c1-10(2)15-9-11(7-8-14)12-5-3-4-6-13(12)15/h3-6,9-10H,7-8,14H2,1-2H3
DM25NLH CS CC(C)N1C=C(C2=CC=CC=C21)CCN
DM25NLH IK ARHHZLRATAUACE-UHFFFAOYSA-N
DM25NLH IU 2-(1-propan-2-ylindol-3-yl)ethanamine
DM25NLH DE Discovery agent
DMGJEH9 ID DMGJEH9
DMGJEH9 DN N2-(3-trifluoromethylphenyl)guanine
DMGJEH9 HS Investigative
DMGJEH9 DT Small molecular drug
DMGJEH9 PC 135435057
DMGJEH9 MW 295.22
DMGJEH9 FM C12H8F3N5O
DMGJEH9 IC InChI=1S/C12H8F3N5O/c13-12(14,15)6-2-1-3-7(4-6)18-11-19-9-8(10(21)20-11)16-5-17-9/h1-5H,(H3,16,17,18,19,20,21)
DMGJEH9 CS C1=CC(=CC(=C1)NC2=NC3=C(C(=O)N2)NC=N3)C(F)(F)F
DMGJEH9 IK IOWPKEYIXBBDOQ-UHFFFAOYSA-N
DMGJEH9 IU 2-[3-(trifluoromethyl)anilino]-1,7-dihydropurin-6-one
DMGJEH9 CA CAS 123994-68-3
DMGJEH9 DE Discovery agent
DMOZ1IY ID DMOZ1IY
DMOZ1IY DN N2-[4-(benzyloxy)benzyl]glycinamide
DMOZ1IY HS Investigative
DMOZ1IY SN 2-({[4-(benzyloxy)phenyl]methyl}amino)acetamide; CHEMBL348597; EN300-53966; 774506-05-7; N2-[4-(benzyloxy)benzyl]glycinamide; AC1Q4ZPD; SCHEMBL7391510; CTK7D3324; MolPort-004-292-381; ZINC21956233; BDBM50221278; AKOS000127788; MCULE-6620856689; NE46952; BBV-007676; 2-(4-Benzyloxy-benzylamino)-acetamide; 2-[[4-(Benzyloxy)benzyl]amino]acetamide
DMOZ1IY DT Small molecular drug
DMOZ1IY PC 10588118
DMOZ1IY MW 270.33
DMOZ1IY FM C16H18N2O2
DMOZ1IY IC InChI=1S/C16H18N2O2/c17-16(19)11-18-10-13-6-8-15(9-7-13)20-12-14-4-2-1-3-5-14/h1-9,18H,10-12H2,(H2,17,19)
DMOZ1IY CS C1=CC=C(C=C1)COC2=CC=C(C=C2)CNCC(=O)N
DMOZ1IY IK QPCKNQVICWJWJF-UHFFFAOYSA-N
DMOZ1IY IU 2-[(4-phenylmethoxyphenyl)methylamino]acetamide
DMOZ1IY DE Discovery agent
DMHJ2IP ID DMHJ2IP
DMHJ2IP DN N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide
DMHJ2IP HS Investigative
DMHJ2IP SN CHEMBL156994; N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide; SCHEMBL962597; ZBEJIFHLSRYHPP-UHFFFAOYSA-N; BDBM50221276; ZINC53246395; 2-[4-(3-chlorobenzyloxy)benzyl]aminoacetamide; 2-[4-(3-chlorobenzyl)oxybenzyl] aminoacetamide; 2-[4-(3-Chloro-benzyloxy)-benzylamino]-acetamide
DMHJ2IP DT Small molecular drug
DMHJ2IP PC 11324179
DMHJ2IP MW 304.77
DMHJ2IP FM C16H17ClN2O2
DMHJ2IP IC InChI=1S/C16H17ClN2O2/c17-14-3-1-2-13(8-14)11-21-15-6-4-12(5-7-15)9-19-10-16(18)20/h1-8,19H,9-11H2,(H2,18,20)
DMHJ2IP CS C1=CC(=CC(=C1)Cl)COC2=CC=C(C=C2)CNCC(=O)N
DMHJ2IP IK ZBEJIFHLSRYHPP-UHFFFAOYSA-N
DMHJ2IP IU 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]acetamide
DMHJ2IP DE Discovery agent
DMEWP9L ID DMEWP9L
DMEWP9L DN N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide
DMEWP9L HS Investigative
DMEWP9L SN CHEMBL231583; N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide; SCHEMBL963386
DMEWP9L DT Small molecular drug
DMEWP9L PC 23625203
DMEWP9L MW 288.32
DMEWP9L FM C16H17FN2O2
DMEWP9L IC InChI=1S/C16H17FN2O2/c17-14-3-1-2-13(8-14)11-21-15-6-4-12(5-7-15)9-19-10-16(18)20/h1-8,19H,9-11H2,(H2,18,20)
DMEWP9L CS C1=CC(=CC(=C1)F)COC2=CC=C(C=C2)CNCC(=O)N
DMEWP9L IK UZDHMFDYNZICFG-UHFFFAOYSA-N
DMEWP9L IU 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide
DMEWP9L DE Discovery agent
DMLPJGX ID DMLPJGX
DMLPJGX DN N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide
DMLPJGX HS Investigative
DMLPJGX SN CHEMBL396267; N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide
DMLPJGX DT Small molecular drug
DMLPJGX PC 23625353
DMLPJGX MW 304.77
DMLPJGX FM C16H17ClN2O2
DMLPJGX IC InChI=1S/C16H17ClN2O2/c17-14-5-1-13(2-6-14)11-21-15-7-3-12(4-8-15)9-19-10-16(18)20/h1-8,19H,9-11H2,(H2,18,20)
DMLPJGX CS C1=CC(=CC=C1CNCC(=O)N)OCC2=CC=C(C=C2)Cl
DMLPJGX IK OIWXOGDFIRHEKD-UHFFFAOYSA-N
DMLPJGX IU 2-[[4-[(4-chlorophenyl)methoxy]phenyl]methylamino]acetamide
DMLPJGX DE Discovery agent
DMAVB0G ID DMAVB0G
DMAVB0G DN N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide
DMAVB0G HS Investigative
DMAVB0G SN CHEMBL242409; N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide
DMAVB0G DT Small molecular drug
DMAVB0G PC 23625204
DMAVB0G MW 315.32
DMAVB0G FM C16H17N3O4
DMAVB0G IC InChI=1S/C16H17N3O4/c17-16(20)10-18-9-12-3-7-15(8-4-12)23-11-13-1-5-14(6-2-13)19(21)22/h1-8,18H,9-11H2,(H2,17,20)
DMAVB0G CS C1=CC(=CC=C1CNCC(=O)N)OCC2=CC=C(C=C2)[N+](=O)[O-]
DMAVB0G IK RHNXUKDDIOAEGX-UHFFFAOYSA-N
DMAVB0G IU 2-[[4-[(4-nitrophenyl)methoxy]phenyl]methylamino]acetamide
DMAVB0G DE Discovery agent
DM3WTDL ID DM3WTDL
DM3WTDL DN N-2-phenylethyl-1H-pyrrole-2-carboxamide
DM3WTDL HS Investigative
DM3WTDL SN N-(2-phenylethyl)-1H-pyrrole-2-carboxamide; pyrrole inhibitor 11; N-2-phenylethyl-1H-pyrrole-2-carboxamide; CHEMBL426546; BDBM15585; ZINC14959022
DM3WTDL DT Small molecular drug
DM3WTDL PC 16110286
DM3WTDL MW 214.26
DM3WTDL FM C13H14N2O
DM3WTDL IC InChI=1S/C13H14N2O/c16-13(12-7-4-9-14-12)15-10-8-11-5-2-1-3-6-11/h1-7,9,14H,8,10H2,(H,15,16)
DM3WTDL CS C1=CC=C(C=C1)CCNC(=O)C2=CC=CN2
DM3WTDL IK JSHPCVXIXZUURL-UHFFFAOYSA-N
DM3WTDL IU N-(2-phenylethyl)-1H-pyrrole-2-carboxamide
DM3WTDL DE Discovery agent
DMLK0J8 ID DMLK0J8
DMLK0J8 DN N-2-Thiophen-2-Yl-Acetamide Boronic Acid
DMLK0J8 HS Investigative
DMLK0J8 SN AC1L9IFX
DMLK0J8 DT Small molecular drug
DMLK0J8 PC 2671
DMLK0J8 MW 199.04
DMLK0J8 FM C7H10BNO3S
DMLK0J8 IC InChI=1S/C7H10BNO3S/c10-7(9-5-8(11)12)4-6-2-1-3-13-6/h1-3,11-12H,4-5H2,(H,9,10)
DMLK0J8 CS B(CNC(=O)CC1=CC=CS1)(O)O
DMLK0J8 IK VXAPSUDMBNWYNC-UHFFFAOYSA-N
DMLK0J8 IU [(2-thiophen-2-ylacetyl)amino]methylboronic acid
DMLK0J8 CA CAS 448211-54-9
DMLK0J8 DE Discovery agent
DMFRD09 ID DMFRD09
DMFRD09 DN N-3-(4-bromophenyl)propyl imidazole
DMFRD09 HS Investigative
DMFRD09 SN CHEMBL386256; N-3-(4-bromophenyl)propyl imidazole; 1H-Imidazole, 1-[3-(4-bromophenyl)propyl]-; SCHEMBL11404089; BDBM50191795
DMFRD09 DT Small molecular drug
DMFRD09 PC 12870397
DMFRD09 MW 265.15
DMFRD09 FM C12H13BrN2
DMFRD09 IC InChI=1S/C12H13BrN2/c13-12-5-3-11(4-6-12)2-1-8-15-9-7-14-10-15/h3-7,9-10H,1-2,8H2
DMFRD09 CS C1=CC(=CC=C1CCCN2C=CN=C2)Br
DMFRD09 IK QCQTVUDLIJGAGO-UHFFFAOYSA-N
DMFRD09 IU 1-[3-(4-bromophenyl)propyl]imidazole
DMFRD09 DE Discovery agent
DMWZTKD ID DMWZTKD
DMWZTKD DN N-3'-ethylaplysinopsin
DMWZTKD HS Investigative
DMWZTKD DT Small molecular drug
DMWZTKD PC 135412764
DMWZTKD MW 282.34
DMWZTKD FM C16H18N4O
DMWZTKD IC InChI=1S/C16H18N4O/c1-4-17-16-19(2)14(15(21)20(16)3)9-11-10-18-13-8-6-5-7-12(11)13/h5-10,21H,4H2,1-3H3/b11-9+,17-16?
DMWZTKD CS CCN=C1N(C(=C(N1C)O)/C=C/2\\C=NC3=CC=CC=C32)C
DMWZTKD IK UIFLDXAMSCVLFF-BKFIXLGBSA-N
DMWZTKD IU 2-ethylimino-5-[(Z)-indol-3-ylidenemethyl]-1,3-dimethylimidazol-4-ol
DMWZTKD DE Discovery agent
DMQEGJU ID DMQEGJU
DMQEGJU DN N3-GHQMFYYPra-NH2
DMQEGJU HS Investigative
DMQEGJU SN N3-GHQMFYYPra-NH2; CHEMBL251540
DMQEGJU PC 44444785
DMQEGJU MW 1080.2
DMQEGJU FM C50H61N15O11S
DMQEGJU IC InChI=1S/C50H61N15O11S/c1-3-7-34(43(53)69)57-46(72)38(23-29-10-14-32(66)15-11-29)61-48(74)39(24-30-12-16-33(67)17-13-30)62-47(73)37(22-28-8-5-4-6-9-28)60-45(71)36(20-21-77-2)59-44(70)35(18-19-41(51)68)58-49(75)40(25-31-26-55-27-56-31)63-50(76)42(52)64-65-54/h1,4-6,8-17,26-27,34-40,42,66-67H,7,18-25,52H2,2H3,(H2,51,68)(H2,53,69)(H,55,56)(H,57,72)(H,58,75)(H,59,70)(H,60,71)(H,61,74)(H,62,73)(H,63,76)/t34?,35-,36-,37-,38-,39-,40-,42?/m0/s1
DMQEGJU CS CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NC(CC#C)C(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC4=CN=CN4)NC(=O)C(N)N=[N+]=[N-]
DMQEGJU IK WFAPVEQHLBEDFX-OPPKEQMHSA-N
DMQEGJU IU (2S)-2-[[(2S)-2-[(2-amino-2-azidoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(1-amino-1-oxopent-4-yn-2-yl)amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]pentanediamide
DMQEGJU DE Discovery agent
DM561Z7 ID DM561Z7
DM561Z7 DN N4-(3-chlorophenyl)quinazoline-4,6-diamine
DM561Z7 HS Investigative
DM561Z7 SN CHEMBL343352; Anilinoquinazoline, 4c; N4-(3-chlorophenyl)quinazoline-4,6-diamine; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline
DM561Z7 DT Small molecular drug
DM561Z7 PC 11807783
DM561Z7 MW 270.72
DM561Z7 FM C14H11ClN4
DM561Z7 IC InChI=1S/C14H11ClN4/c15-9-2-1-3-11(6-9)19-14-12-7-10(16)4-5-13(12)17-8-18-14/h1-8H,16H2,(H,17,18,19)
DM561Z7 CS C1=CC(=CC(=C1)Cl)NC2=NC=NC3=C2C=C(C=C3)N
DM561Z7 IK AWAYNEMCHILZCF-UHFFFAOYSA-N
DM561Z7 IU 4-N-(3-chlorophenyl)quinazoline-4,6-diamine
DM561Z7 DE Discovery agent
DMDRYJ7 ID DMDRYJ7
DMDRYJ7 DN N4-(3-methylphenyl)-4,6-quinazolinediamine
DMDRYJ7 HS Investigative
DMDRYJ7 SN CHEMBL336113; Anilinoquinazoline, 4a; N4-(3-methylphenyl)-4,6-quinazolinediamine; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N*4*-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline
DMDRYJ7 DT Small molecular drug
DMDRYJ7 PC 10220590
DMDRYJ7 MW 250.3
DMDRYJ7 FM C15H14N4
DMDRYJ7 IC InChI=1S/C15H14N4/c1-10-3-2-4-12(7-10)19-15-13-8-11(16)5-6-14(13)17-9-18-15/h2-9H,16H2,1H3,(H,17,18,19)
DMDRYJ7 CS CC1=CC(=CC=C1)NC2=NC=NC3=C2C=C(C=C3)N
DMDRYJ7 IK NFBCSWGEYDCCDW-UHFFFAOYSA-N
DMDRYJ7 IU 4-N-(3-methylphenyl)quinazoline-4,6-diamine
DMDRYJ7 DE Discovery agent
DMARZHU ID DMARZHU
DMARZHU DN N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine
DMARZHU HS Investigative
DMARZHU SN DNVZYSMOLXCOLY-HNNXBMFYSA-N; UAMC00039; CHEMBL98869; SCHEMBL6824340; GTPL6538; ZINC13561228; BDBM50146972; NCGC00379239-01; 1-[(S)-2-Amino-4-[(4-chlorobenzyl)amino]butyryl]piperidine; (S)-4-(4-chlorobenzylamino)-2-amino-1-(piperidin-1-yl)butan-1-one; (2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one; 2-(S)-Amino-4-(4-chloro-benzylamino)-1-piperidin-1-yl-butan-1-one
DMARZHU DT Small molecular drug
DMARZHU PC 11232124
DMARZHU MW 309.83
DMARZHU FM C16H24ClN3O
DMARZHU IC InChI=1S/C16H24ClN3O/c17-14-6-4-13(5-7-14)12-19-9-8-15(18)16(21)20-10-2-1-3-11-20/h4-7,15,19H,1-3,8-12,18H2/t15-/m0/s1
DMARZHU CS C1CCN(CC1)C(=O)[C@H](CCNCC2=CC=C(C=C2)Cl)N
DMARZHU IK DNVZYSMOLXCOLY-HNNXBMFYSA-N
DMARZHU IU (2S)-2-amino-4-[(4-chlorophenyl)methylamino]-1-piperidin-1-ylbutan-1-one
DMARZHU DE Discovery agent
DMYPZMO ID DMYPZMO
DMYPZMO DN N4-(N,N-diphenylcarbamoyl)-aminoguanidine
DMYPZMO HS Investigative
DMYPZMO DE Discovery agent
DMCR13E ID DMCR13E
DMCR13E DN N4,N6-dibenzylpyrimidine-4,6-dicarboxamide
DMCR13E HS Investigative
DMCR13E SN N4,N6-dibenzylpyrimidine-4,6-dicarboxamide; CHEMBL468901; 135002-40-3; ZINC14574; BDBM16594; Pyrimidine Dicarboxamide Inhibitor, 2; N,N -dibenzylpyrimidine-4,6-dicarboxamide; AX8335280
DMCR13E DT Small molecular drug
DMCR13E PC 15052873
DMCR13E MW 346.4
DMCR13E FM C20H18N4O2
DMCR13E IC InChI=1S/C20H18N4O2/c25-19(21-12-15-7-3-1-4-8-15)17-11-18(24-14-23-17)20(26)22-13-16-9-5-2-6-10-16/h1-11,14H,12-13H2,(H,21,25)(H,22,26)
DMCR13E CS C1=CC=C(C=C1)CNC(=O)C2=CC(=NC=N2)C(=O)NCC3=CC=CC=C3
DMCR13E IK WIUCYEOLRGUYEH-UHFFFAOYSA-N
DMCR13E IU 4-N,6-N-dibenzylpyrimidine-4,6-dicarboxamide
DMCR13E DE Discovery agent
DMV7ORJ ID DMV7ORJ
DMV7ORJ DN N4-[4-(Phenylmethoxy)phenyl]-L-aspartamine
DMV7ORJ HS Investigative
DMV7ORJ SN Amino acid analog, 4e; CHEMBL517209; BDBM24255; (2S)-2-amino-3-{[4-(benzyloxy)phenyl]carbamoyl}propanoic acid
DMV7ORJ DT Small molecular drug
DMV7ORJ PC 24901603
DMV7ORJ MW 314.34
DMV7ORJ FM C17H18N2O4
DMV7ORJ IC InChI=1S/C17H18N2O4/c18-15(17(21)22)10-16(20)19-13-6-8-14(9-7-13)23-11-12-4-2-1-3-5-12/h1-9,15H,10-11,18H2,(H,19,20)(H,21,22)/t15-/m0/s1
DMV7ORJ CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)C[C@@H](C(=O)O)N
DMV7ORJ IK MKNOYEISPOGYTN-HNNXBMFYSA-N
DMV7ORJ IU (2S)-2-amino-4-oxo-4-(4-phenylmethoxyanilino)butanoic acid
DMV7ORJ DE Discovery agent
DM1N73J ID DM1N73J
DM1N73J DN N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide
DM1N73J HS Investigative
DM1N73J SN CHEMBL596553; N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide
DM1N73J DT Small molecular drug
DM1N73J PC 45257110
DM1N73J MW 333.4
DM1N73J FM C17H23N3O4
DM1N73J IC InChI=1S/C17H23N3O4/c1-2-3-11-18-16(22)12-14(17(23)20-24)19-15(21)10-9-13-7-5-4-6-8-13/h4-10,14,24H,2-3,11-12H2,1H3,(H,18,22)(H,19,21)(H,20,23)/b10-9+/t14-/m1/s1
DM1N73J CS CCCCNC(=O)C[C@H](C(=O)NO)NC(=O)/C=C/C1=CC=CC=C1
DM1N73J IK INBRHSSIAXLSEI-ATWMFIQVSA-N
DM1N73J IU (2R)-N'-butyl-N-hydroxy-2-[[(E)-3-phenylprop-2-enoyl]amino]butanediamide
DM1N73J DE Discovery agent
DM7KX2V ID DM7KX2V
DM7KX2V DN N4-phenylethoxycytidine-5'-triphosphate
DM7KX2V HS Investigative
DM7KX2V SN N4-(phenylethoxy)-CTP; compound 15 [PMID:21528910]
DM7KX2V DT Small molecular drug
DM7KX2V PC 53262890
DM7KX2V MW 603.3
DM7KX2V FM C17H24N3O15P3
DM7KX2V IC InChI=1S/C17H24N3O15P3/c21-14-12(10-32-37(27,28)35-38(29,30)34-36(24,25)26)33-16(15(14)22)20-8-6-13(18-17(20)23)19-31-9-7-11-4-2-1-3-5-11/h1-6,8,12,14-16,21-22H,7,9-10H2,(H,27,28)(H,29,30)(H,18,19,23)(H2,24,25,26)/t12-,14-,15-,16-/m1/s1
DM7KX2V CS C1=CC=C(C=C1)CCONC2=NC(=O)N(C=C2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O
DM7KX2V IK WREOTYWODABZMH-DTZQCDIJSA-N
DM7KX2V IU [[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
DM7KX2V DE Discovery agent
DMY3O6N ID DMY3O6N
DMY3O6N DN N5-(1-Imino-3-Butenyl)-L-Ornithine
DMY3O6N HS Investigative
DMY3O6N SN 1-{[(4S)-4-amino-4-carboxybutyl]amino}butan-1-iminium
DMY3O6N DT Small molecular drug
DMY3O6N PC 5289554
DMY3O6N MW 202.27
DMY3O6N FM C9H20N3O2+
DMY3O6N IC InChI=1S/C9H19N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h7H,2-6,10H2,1H3,(H2,11,12)(H,13,14)/p+1/t7-/m0/s1
DMY3O6N CS CCCC(=[NH+]CCC[C@@H](C(=O)O)N)N
DMY3O6N IK KRILJVOCVSUPMA-ZETCQYMHSA-O
DMY3O6N IU 1-aminobutylidene-[(4S)-4-amino-4-carboxybutyl]azanium
DMY3O6N DE Discovery agent
DMB62OI ID DMB62OI
DMB62OI DN N5-(1-iminobut-3-enyl)-L-ornithine
DMB62OI HS Investigative
DMB62OI SN Vinyl-L-NIO; LMDRHVQXMBGSGU-ZETCQYMHSA-N; (2S)-2-amino-5-(1-aminobut-3-enylideneamino)pentanoic Acid; v-NIO; hDDAH inhibitor, 1a; L-VNIO; AC1L9KK2; SCHEMBL2184864; GTPL8830; CTK7D1091; BDBM235685; ZINC2047715; AKOS006278503; compound 2e [PMID: 19013076]; (2S)-2-amino-5-[(Z)-(1-aminobut-3-en-1-ylidene)amino]pentanoic acid
DMB62OI DT Small molecular drug
DMB62OI PC 91935539
DMB62OI MW 199.25
DMB62OI FM C9H17N3O2
DMB62OI IC InChI=1S/C9H17N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h2,4,7H,3,5-6,10H2,1H3,(H2,11,12)(H,13,14)/b4-2+/t7-/m0/s1
DMB62OI CS C/C=C/C(=NCCC[C@@H](C(=O)O)N)N
DMB62OI IK RIIDRLUFTKIGSQ-XBBYQOBLSA-N
DMB62OI IU (2S)-2-amino-5-[[(E)-1-aminobut-2-enylidene]amino]pentanoic acid
DMB62OI DE Discovery agent
DMT893N ID DMT893N
DMT893N DN N5-(1-iminobutyl)-L-ornithine
DMT893N HS Investigative
DMT893N SN CHEMBL442896; N5-(1-iminobutyl)-L-ornithine; Ethyl-L-NIO; AC1NRDHJ; (2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid; BDBM152700; BDBM50255074; ZINC12503853; (S)-2-Amino-5-butyrimidoylamino-pentanoic acid; (S)-2-Amino-5-butyrimidamidopentanoic acid (9)
DMT893N DT Small molecular drug
DMT893N PC 5289555
DMT893N MW 201.27
DMT893N FM C9H19N3O2
DMT893N IC InChI=1S/C9H19N3O2/c1-2-4-8(11)12-6-3-5-7(10)9(13)14/h7H,2-6,10H2,1H3,(H2,11,12)(H,13,14)/t7-/m0/s1
DMT893N CS CCCC(=NCCC[C@@H](C(=O)O)N)N
DMT893N IK KRILJVOCVSUPMA-ZETCQYMHSA-N
DMT893N IU (2S)-2-amino-5-(1-aminobutylideneamino)pentanoic acid
DMT893N DE Discovery agent
DM0TS21 ID DM0TS21
DM0TS21 DN N5-(1-iminopent-3-enyl)-L-ornithine
DM0TS21 HS Investigative
DM0TS21 SN Propenyl-L-NIO; hDDAH inhibitor, 1c; L-ENIPO; MolPort-009-019-384; JUSNBVJTFYDFKR-SGJFDWMWSA-N; BDBM235686; ZINC100017163; L-N5-(1-Imino-3-pentenyl) ornithine
DM0TS21 DT Small molecular drug
DM0TS21 PC 91935312
DM0TS21 MW 213.28
DM0TS21 FM C10H19N3O2
DM0TS21 IC InChI=1S/C10H19N3O2/c1-2-3-6-9(12)13-7-4-5-8(11)10(14)15/h3,6,8H,2,4-5,7,11H2,1H3,(H2,12,13)(H,14,15)/b6-3+/t8-/m0/s1
DM0TS21 CS CC/C=C/C(=NCCC[C@@H](C(=O)O)N)N
DM0TS21 IK CIYWWIHMEYBDFA-HFSLJOEWSA-N
DM0TS21 IU (2S)-2-amino-5-[[(E)-1-aminopent-2-enylidene]amino]pentanoic acid
DM0TS21 DE Discovery agent
DM05O7J ID DM05O7J
DM05O7J DN N5-(1-iminopropyl)-L-ornithine
DM05O7J HS Investigative
DM05O7J SN N5-(1-iminopropyl)-L-ornithine; CHEMBL507472; L-IPO, 13; BDBM152699; ZINC40380536; BDBM50254450; N~5~-[(1Z)-propanimidoyl]-L-ornithine; (S)-2-Amino-5-propionimidoylamino-pentanoic acid; (S)-2-Amino-5-propionimidamidopentanoic acid (8); (2S)-2-azanyl-5-(propanimidoylamino)pentanoic acid
DM05O7J DT Small molecular drug
DM05O7J PC 44593548
DM05O7J MW 187.24
DM05O7J FM C8H17N3O2
DM05O7J IC InChI=1S/C8H17N3O2/c1-2-7(10)11-5-3-4-6(9)8(12)13/h6H,2-5,9H2,1H3,(H2,10,11)(H,12,13)/t6-/m0/s1
DM05O7J CS CCC(=NCCC[C@@H](C(=O)O)N)N
DM05O7J IK ZYIBCZWVLDODOL-LURJTMIESA-N
DM05O7J IU (2S)-2-amino-5-(1-aminopropylideneamino)pentanoic acid
DM05O7J DE Discovery agent
DMNVK6T ID DMNVK6T
DMNVK6T DN N5-(4-Phenoxyphenyl)-L-glutamine
DMNVK6T HS Investigative
DMNVK6T SN CHEMBL442816; Modified amino acid analog, 8e; BDBM24270; (2S)-2-amino-4-[(4-phenoxyphenyl)carbamoyl]butanoic acid
DMNVK6T DT Small molecular drug
DMNVK6T PC 24901615
DMNVK6T MW 314.34
DMNVK6T FM C17H18N2O4
DMNVK6T IC InChI=1S/C17H18N2O4/c18-15(17(21)22)10-11-16(20)19-12-6-8-14(9-7-12)23-13-4-2-1-3-5-13/h1-9,15H,10-11,18H2,(H,19,20)(H,21,22)/t15-/m0/s1
DMNVK6T CS C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMNVK6T IK YWTHXARKKQRUCI-HNNXBMFYSA-N
DMNVK6T IU (2S)-2-amino-5-oxo-5-(4-phenoxyanilino)pentanoic acid
DMNVK6T DE Discovery agent
DMXUODT ID DMXUODT
DMXUODT DN N5-[(4-Phenoxy)-3-pyridyl]-L-glutamamide
DMXUODT HS Investigative
DMXUODT SN CHEMBL478551; Modified amino acid analog, 8d; BDBM24269
DMXUODT DT Small molecular drug
DMXUODT PC 24901614
DMXUODT MW 314.34
DMXUODT FM C16H18N4O3
DMXUODT IC InChI=1S/C16H18N4O3/c17-13(16(18)22)7-8-14(21)20-11-6-9-15(19-10-11)23-12-4-2-1-3-5-12/h1-6,9-10,13H,7-8,17H2,(H2,18,22)(H,20,21)/t13-/m0/s1
DMXUODT CS C1=CC=C(C=C1)OC2=NC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMXUODT IK LJOISTVTSQVPGY-ZDUSSCGKSA-N
DMXUODT IU (2S)-2-amino-N'-(6-phenoxypyridin-3-yl)pentanediamide
DMXUODT DE Discovery agent
DMJT4UR ID DMJT4UR
DMJT4UR DN N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide
DMJT4UR HS Investigative
DMJT4UR SN CHEMBL478549; Modified amino acid analog, 8b; BDBM24267
DMJT4UR DT Small molecular drug
DMJT4UR PC 24901612
DMJT4UR MW 286.33
DMJT4UR FM C15H18N4O2
DMJT4UR IC InChI=1S/C15H18N4O2/c16-13(15(17)21)7-8-14(20)18-11-3-5-12(6-4-11)19-9-1-2-10-19/h1-6,9-10,13H,7-8,16H2,(H2,17,21)(H,18,20)/t13-/m0/s1
DMJT4UR CS C1=CN(C=C1)C2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMJT4UR IK XUUJHPOHRREVET-ZDUSSCGKSA-N
DMJT4UR IU (2S)-2-amino-N'-(4-pyrrol-1-ylphenyl)pentanediamide
DMJT4UR DE Discovery agent
DMR2C94 ID DMR2C94
DMR2C94 DN N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide
DMR2C94 HS Investigative
DMR2C94 SN CHEMBL478983; Modified amino acid analog, 9c; BDBM24280
DMR2C94 DT Small molecular drug
DMR2C94 PC 24901625
DMR2C94 MW 327.4
DMR2C94 FM C18H21N3O3
DMR2C94 IC InChI=1S/C18H21N3O3/c1-12-4-2-3-5-16(12)24-14-8-6-13(7-9-14)21-17(22)11-10-15(19)18(20)23/h2-9,15H,10-11,19H2,1H3,(H2,20,23)(H,21,22)/t15-/m0/s1
DMR2C94 CS CC1=CC=CC=C1OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMR2C94 IK UHWCMHMPSGPFGU-HNNXBMFYSA-N
DMR2C94 IU (2S)-2-amino-N'-[4-(2-methylphenoxy)phenyl]pentanediamide
DMR2C94 DE Discovery agent
DM97H52 ID DM97H52
DM97H52 DN N5-[4-(2-Oxo-3-phenylpropoxy)phenyl]-L-glutamine
DM97H52 HS Investigative
DM97H52 SN CHEMBL518118; Modified amino acid analog, 8k; BDBM24276; (2S)-2-amino-4-{[4-(2-oxo-2-phenylethoxy)phenyl]carbamoyl}butanoic acid
DM97H52 DT Small molecular drug
DM97H52 PC 24901621
DM97H52 MW 356.4
DM97H52 FM C19H20N2O5
DM97H52 IC InChI=1S/C19H20N2O5/c20-16(19(24)25)10-11-18(23)21-14-6-8-15(9-7-14)26-12-17(22)13-4-2-1-3-5-13/h1-9,16H,10-12,20H2,(H,21,23)(H,24,25)/t16-/m0/s1
DM97H52 CS C1=CC=C(C=C1)C(=O)COC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DM97H52 IK JXSYVANIFASLIX-INIZCTEOSA-N
DM97H52 IU (2S)-2-amino-5-oxo-5-(4-phenacyloxyanilino)pentanoic acid
DM97H52 DE Discovery agent
DMR1XJN ID DMR1XJN
DMR1XJN DN N5-[4-(2-phenylethoxy)phenyl]-L-glutamine
DMR1XJN HS Investigative
DMR1XJN SN CHEMBL478993; Modified amino acid analog, 8i; BDBM24274; (2S)-2-amino-4-{[4-(2-phenylethoxy)phenyl]carbamoyl}butanoic acid
DMR1XJN DT Small molecular drug
DMR1XJN PC 24901619
DMR1XJN MW 342.4
DMR1XJN FM C19H22N2O4
DMR1XJN IC InChI=1S/C19H22N2O4/c20-17(19(23)24)10-11-18(22)21-15-6-8-16(9-7-15)25-13-12-14-4-2-1-3-5-14/h1-9,17H,10-13,20H2,(H,21,22)(H,23,24)/t17-/m0/s1
DMR1XJN CS C1=CC=C(C=C1)CCOC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMR1XJN IK LXNLZSBSUTWVJA-KRWDZBQOSA-N
DMR1XJN IU (2S)-2-amino-5-oxo-5-[4-(2-phenylethoxy)anilino]pentanoic acid
DMR1XJN DE Discovery agent
DMTO8KS ID DMTO8KS
DMTO8KS DN N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide
DMTO8KS HS Investigative
DMTO8KS SN CHEMBL446500; Modified amino acid analog, 9d; BDBM24281
DMTO8KS DT Small molecular drug
DMTO8KS PC 24901626
DMTO8KS MW 327.4
DMTO8KS FM C18H21N3O3
DMTO8KS IC InChI=1S/C18H21N3O3/c1-12-3-2-4-15(11-12)24-14-7-5-13(6-8-14)21-17(22)10-9-16(19)18(20)23/h2-8,11,16H,9-10,19H2,1H3,(H2,20,23)(H,21,22)/t16-/m0/s1
DMTO8KS CS CC1=CC(=CC=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMTO8KS IK JZBKUKPJKVOVGL-INIZCTEOSA-N
DMTO8KS IU (2S)-2-amino-N'-[4-(3-methylphenoxy)phenyl]pentanediamide
DMTO8KS DE Discovery agent
DMINK9Q ID DMINK9Q
DMINK9Q DN N5-[4-(3-Phenylpropoxy)phenyl]-L-glutamine
DMINK9Q HS Investigative
DMINK9Q SN CHEMBL477513; Modified amino acid analog, 8j; BDBM24275; (2S)-2-amino-4-{[4-(3-phenylpropoxy)phenyl]carbamoyl}butanoic acid
DMINK9Q DT Small molecular drug
DMINK9Q PC 24901620
DMINK9Q MW 356.4
DMINK9Q FM C20H24N2O4
DMINK9Q IC InChI=1S/C20H24N2O4/c21-18(20(24)25)12-13-19(23)22-16-8-10-17(11-9-16)26-14-4-7-15-5-2-1-3-6-15/h1-3,5-6,8-11,18H,4,7,12-14,21H2,(H,22,23)(H,24,25)/t18-/m0/s1
DMINK9Q CS C1=CC=C(C=C1)CCCOC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMINK9Q IK NFTAKLODMXBWJT-SFHVURJKSA-N
DMINK9Q IU (2S)-2-amino-5-oxo-5-[4-(3-phenylpropoxy)anilino]pentanoic acid
DMINK9Q DE Discovery agent
DM6PXMJ ID DM6PXMJ
DM6PXMJ DN N5-[4-(4-(3-Furyl)phenoxy)phenyl]-L-glutamamide
DM6PXMJ HS Investigative
DM6PXMJ SN CHEMBL515470; Modified amino acid analog, 9g; BDBM24284
DM6PXMJ DT Small molecular drug
DM6PXMJ PC 24901629
DM6PXMJ MW 379.4
DM6PXMJ FM C21H21N3O4
DM6PXMJ IC InChI=1S/C21H21N3O4/c22-19(21(23)26)9-10-20(25)24-16-3-7-18(8-4-16)28-17-5-1-14(2-6-17)15-11-12-27-13-15/h1-8,11-13,19H,9-10,22H2,(H2,23,26)(H,24,25)/t19-/m0/s1
DM6PXMJ CS C1=CC(=CC=C1C2=COC=C2)OC3=CC=C(C=C3)NC(=O)CC[C@@H](C(=O)N)N
DM6PXMJ IK LYOSKDSEWRJQAH-IBGZPJMESA-N
DM6PXMJ IU (2S)-2-amino-N'-[4-[4-(furan-3-yl)phenoxy]phenyl]pentanediamide
DM6PXMJ DE Discovery agent
DMMV1CB ID DMMV1CB
DMMV1CB DN N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide
DMMV1CB HS Investigative
DMMV1CB SN CHEMBL479157; Modified amino acid analog, 9e; BDBM24282
DMMV1CB DT Small molecular drug
DMMV1CB PC 24901627
DMMV1CB MW 327.4
DMMV1CB FM C18H21N3O3
DMMV1CB IC InChI=1S/C18H21N3O3/c1-12-2-6-14(7-3-12)24-15-8-4-13(5-9-15)21-17(22)11-10-16(19)18(20)23/h2-9,16H,10-11,19H2,1H3,(H2,20,23)(H,21,22)/t16-/m0/s1
DMMV1CB CS CC1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMMV1CB IK SNPCQHHCCJNFNQ-INIZCTEOSA-N
DMMV1CB IU (2S)-2-amino-N'-[4-(4-methylphenoxy)phenyl]pentanediamide
DMMV1CB DE Discovery agent
DMH8VYM ID DMH8VYM
DMH8VYM DN N5-[4-(N-Phenylamino)phenyl]-L-glutamine
DMH8VYM HS Investigative
DMH8VYM SN CHEMBL517211; Modified amino acid analog, 8g; SCHEMBL20238887; BDBM24272; (2S)-2-amino-4-{[4-(phenylamino)phenyl]carbamoyl}butanoic acid
DMH8VYM DT Small molecular drug
DMH8VYM PC 24901617
DMH8VYM MW 313.35
DMH8VYM FM C17H19N3O3
DMH8VYM IC InChI=1S/C17H19N3O3/c18-15(17(22)23)10-11-16(21)20-14-8-6-13(7-9-14)19-12-4-2-1-3-5-12/h1-9,15,19H,10-11,18H2,(H,20,21)(H,22,23)/t15-/m0/s1
DMH8VYM CS C1=CC=C(C=C1)NC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMH8VYM IK CKEDBZVOBFKCJM-HNNXBMFYSA-N
DMH8VYM IU (2S)-2-amino-5-(4-anilinoanilino)-5-oxopentanoic acid
DMH8VYM DE Discovery agent
DMUVP5L ID DMUVP5L
DMUVP5L DN N5-[4-(Phenylmethoxy)phenyl]-D-glutamine
DMUVP5L HS Investigative
DMUVP5L SN Amino acid analog, 4g; CHEMBL478534; BDBM24257; (2R)-2-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid
DMUVP5L DT Small molecular drug
DMUVP5L PC 24901604
DMUVP5L MW 328.4
DMUVP5L FM C18H20N2O4
DMUVP5L IC InChI=1S/C18H20N2O4/c19-16(18(22)23)10-11-17(21)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,21)(H,22,23)/t16-/m1/s1
DMUVP5L CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CC[C@H](C(=O)O)N
DMUVP5L IK BYSBXIPCDJNEBG-MRXNPFEDSA-N
DMUVP5L IU (2R)-2-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DMUVP5L DE Discovery agent
DMMYIJ0 ID DMMYIJ0
DMMYIJ0 DN N5-[4-(Phenylmethoxy)phenyl]-L-glutamamide
DMMYIJ0 HS Investigative
DMMYIJ0 SN CHEMBL478717; Modified amino acid analog, 6c
DMMYIJ0 DT Small molecular drug
DMMYIJ0 PC 24901607
DMMYIJ0 MW 327.4
DMMYIJ0 FM C18H21N3O3
DMMYIJ0 IC InChI=1S/C18H21N3O3/c19-16(18(20)23)10-11-17(22)21-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H2,20,23)(H,21,22)/t16-/m0/s1
DMMYIJ0 CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMMYIJ0 IK PKTMQSKBGCPRGD-INIZCTEOSA-N
DMMYIJ0 IU (2S)-2-amino-N'-(4-phenylmethoxyphenyl)pentanediamide
DMMYIJ0 DE Discovery agent
DMCG26A ID DMCG26A
DMCG26A DN N5-[4-(Phenylmethoxy)phenyl]-L-glutamine
DMCG26A HS Investigative
DMCG26A SN (2S)-2-amino-4-{[4-(benzyloxy)phenyl]carbamoyl}butanoic acid; (2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acid; Amino acid analog, 4f; CHEMBL478381; BDBM24256; N-[4-(benzyloxy)phenyl]-L-glutamine; DB07102; N-[4-(phenylmethoxy)phenyl]-L-glutamine
DMCG26A DT Small molecular drug
DMCG26A PC 24768560
DMCG26A MW 328.4
DMCG26A FM C18H20N2O4
DMCG26A IC InChI=1S/C18H20N2O4/c19-16(18(22)23)10-11-17(21)20-14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H,20,21)(H,22,23)/t16-/m0/s1
DMCG26A CS C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)O)N
DMCG26A IK BYSBXIPCDJNEBG-INIZCTEOSA-N
DMCG26A IU (2S)-2-amino-5-oxo-5-(4-phenylmethoxyanilino)pentanoic acid
DMCG26A DE Discovery agent
DMH6O4G ID DMH6O4G
DMH6O4G DN N5-[4-Benzylphenyl]-L-glutamamide
DMH6O4G HS Investigative
DMH6O4G SN CHEMBL478379; Modified amino acid analog, 8f; BDBM24271
DMH6O4G DT Small molecular drug
DMH6O4G PC 24901616
DMH6O4G MW 311.4
DMH6O4G FM C18H21N3O2
DMH6O4G IC InChI=1S/C18H21N3O2/c19-16(18(20)23)10-11-17(22)21-15-8-6-14(7-9-15)12-13-4-2-1-3-5-13/h1-9,16H,10-12,19H2,(H2,20,23)(H,21,22)/t16-/m0/s1
DMH6O4G CS C1=CC=C(C=C1)CC2=CC=C(C=C2)NC(=O)CC[C@@H](C(=O)N)N
DMH6O4G IK RYHUMGNBCPJDFD-INIZCTEOSA-N
DMH6O4G IU (2S)-2-amino-N'-(4-benzylphenyl)pentanediamide
DMH6O4G DE Discovery agent
DML0R9M ID DML0R9M
DML0R9M DN N5-methylfolate
DML0R9M HS Investigative
DML0R9M SN 5-methyl-THF; 5-methyl-tetrahydrofolate; 5-methyltetrahydrofolate
DML0R9M DT Small molecular drug
DML0R9M PC 135483998
DML0R9M MW 459.5
DML0R9M FM C20H25N7O6
DML0R9M IC InChI=1S/C20H25N7O6/c1-27-12(9-23-16-15(27)18(31)26-20(21)25-16)8-22-11-4-2-10(3-5-11)17(30)24-13(19(32)33)6-7-14(28)29/h2-5,12-13,22H,6-9H2,1H3,(H,24,30)(H,28,29)(H,32,33)(H4,21,23,25,26,31)/t12?,13-/m1/s1
DML0R9M CS CN1C(CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)N[C@H](CCC(=O)O)C(=O)O
DML0R9M IK ZNOVTXRBGFNYRX-ZGTCLIOFSA-N
DML0R9M IU (2R)-2-[[4-[(2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
DML0R9M CA CAS 134-35-0
DML0R9M DE Discovery agent
DMXSZ1A ID DMXSZ1A
DMXSZ1A DN N6 benzyl-cAMP
DMXSZ1A HS Investigative
DMXSZ1A SN N6-benzyl cyclic AMP
DMXSZ1A DT Small molecular drug
DMXSZ1A PC 161733
DMXSZ1A MW 419.3
DMXSZ1A FM C17H18N5O6P
DMXSZ1A IC InChI=1S/C17H18N5O6P/c23-13-14-11(7-26-29(24,25)28-14)27-17(13)22-9-21-12-15(19-8-20-16(12)22)18-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,23H,6-7H2,(H,24,25)(H,18,19,20)/t11-,13-,14-,17-/m1/s1
DMXSZ1A CS C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C(N=CN=C43)NCC5=CC=CC=C5)O)OP(=O)(O1)O
DMXSZ1A IK GDDBIAMRTVTOBL-LSCFUAHRSA-N
DMXSZ1A IU (4aR,6R,7R,7aS)-6-[6-(benzylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
DMXSZ1A CA CAS 32115-08-5
DMXSZ1A DE Discovery agent
DM30KXV ID DM30KXV
DM30KXV DN N6-((+/-)-endo-norborn-2-yl)adenosine
DM30KXV HS Investigative
DM30KXV SN CHEMBL489640; N6-((+/-)-endo-norborn-2-yl)adenosine; N-(2-Norbornyl)adenosine; SCHEMBL10608249
DM30KXV DT Small molecular drug
DM30KXV PC 10021483
DM30KXV MW 361.4
DM30KXV FM C17H23N5O4
DM30KXV IC InChI=1S/C17H23N5O4/c23-5-11-13(24)14(25)17(26-11)22-7-20-12-15(18-6-19-16(12)22)21-10-4-8-1-2-9(10)3-8/h6-11,13-14,17,23-25H,1-5H2,(H,18,19,21)/t8?,9?,10?,11-,13-,14-,17-/m1/s1
DM30KXV CS C1CC2CC1CC2NC3=C4C(=NC=N3)N(C=N4)[C@H]5[C@@H]([C@@H]([C@H](O5)CO)O)O
DM30KXV IK YKPCEENRZZBDMC-STHLEMNDSA-N
DM30KXV IU (2R,3R,4S,5R)-2-[6-(2-bicyclo[2.2.1]heptanylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DM30KXV DE Discovery agent
DM2W9NO ID DM2W9NO
DM2W9NO DN N6-(3-Iodobenzyl)-2'-O-methyladenosine
DM2W9NO HS Investigative
DM2W9NO SN CHEMBL428377; BDBM50215115
DM2W9NO DT Small molecular drug
DM2W9NO PC 44436081
DM2W9NO MW 497.3
DM2W9NO FM C18H20IN5O4
DM2W9NO IC InChI=1S/C18H20IN5O4/c1-27-15-14(26)12(7-25)28-18(15)24-9-23-13-16(21-8-22-17(13)24)20-6-10-3-2-4-11(19)5-10/h2-5,8-9,12,14-15,18,25-26H,6-7H2,1H3,(H,20,21,22)/t12-,14-,15-,18-/m1/s1
DM2W9NO CS CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)CO)O
DM2W9NO IK OATZXEKAXIIRDK-SCFUHWHPSA-N
DM2W9NO IU (2R,3R,4R,5R)-2-(hydroxymethyl)-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-4-methoxyoxolan-3-ol
DM2W9NO DE Discovery agent
DM5Q71U ID DM5Q71U
DM5Q71U DN N6-(4-hydroxybenzyl)adenine riboside
DM5Q71U HS Investigative
DM5Q71U SN N6-(4-Hydroxybenzyl)-adenosine; 110505-75-4; n6-(4-hydroxybenzyl)adenosine; N6-(4-hydroxybenzyl)adenine riboside; CHEMBL224024; C17H19N5O5; p-Topolin riboside; Adenosine, N-[(4-hydroxyphenyl)methyl]-; SCHEMBL639446; N6-(p-hydroxybenzyl)-adenosine; KS-00001DDJ; CTK0D4708; DTXSID00440568; UGVIXKXYLBAZND-LSCFUAHRSA-N; MolPort-023-332-931; ZINC28638129; BDBM50208945; 1962AA; ANW-64712; AKOS016007097; CS-5067; NCGC00484059-01; HY-18775; AJ-83558; TC-153457; KB-258567; AB3000026; AX8235067
DM5Q71U DT Small molecular drug
DM5Q71U PC 10474479
DM5Q71U MW 373.4
DM5Q71U FM C17H19N5O5
DM5Q71U IC InChI=1S/C17H19N5O5/c23-6-11-13(25)14(26)17(27-11)22-8-21-12-15(19-7-20-16(12)22)18-5-9-1-3-10(24)4-2-9/h1-4,7-8,11,13-14,17,23-26H,5-6H2,(H,18,19,20)/t11-,13-,14-,17-/m1/s1
DM5Q71U CS C1=CC(=CC=C1CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)O
DM5Q71U IK UGVIXKXYLBAZND-LSCFUAHRSA-N
DM5Q71U IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(4-hydroxyphenyl)methylamino]purin-9-yl]oxolane-3,4-diol
DM5Q71U CA CAS 110505-75-4
DM5Q71U DE Discovery agent
DM0WMKJ ID DM0WMKJ
DM0WMKJ DN N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine
DM0WMKJ HS Investigative
DM0WMKJ SN CHEMBL496985; N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine
DM0WMKJ DT Small molecular drug
DM0WMKJ PC 25104892
DM0WMKJ MW 392.5
DM0WMKJ FM C24H20N6
DM0WMKJ IC InChI=1S/C24H20N6/c25-19-11-13-20(14-12-19)27-23-21-24(29-22(28-23)18-9-5-2-6-10-18)30(16-26-21)15-17-7-3-1-4-8-17/h1-14,16H,15,25H2,(H,27,28,29)
DM0WMKJ CS C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)C4=CC=CC=C4)NC5=CC=C(C=C5)N
DM0WMKJ IK RVUVWWRSIWGIQQ-UHFFFAOYSA-N
DM0WMKJ IU 4-N-(9-benzyl-2-phenylpurin-6-yl)benzene-1,4-diamine
DM0WMKJ DE Discovery agent
DMVNLPF ID DMVNLPF
DMVNLPF DN N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine
DMVNLPF HS Investigative
DMVNLPF SN CHEMBL496984; N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine
DMVNLPF DT Small molecular drug
DMVNLPF PC 25104891
DMVNLPF MW 422.4
DMVNLPF FM C24H18N6O2
DMVNLPF IC InChI=1S/C24H18N6O2/c31-30(32)20-13-11-19(12-14-20)26-23-21-24(28-22(27-23)18-9-5-2-6-10-18)29(16-25-21)15-17-7-3-1-4-8-17/h1-14,16H,15H2,(H,26,27,28)
DMVNLPF CS C1=CC=C(C=C1)CN2C=NC3=C(N=C(N=C32)C4=CC=CC=C4)NC5=CC=C(C=C5)[N+](=O)[O-]
DMVNLPF IK AQQCBPZYBVKEFU-UHFFFAOYSA-N
DMVNLPF IU 9-benzyl-N-(4-nitrophenyl)-2-phenylpurin-6-amine
DMVNLPF DE Discovery agent
DMBT2HW ID DMBT2HW
DMBT2HW DN N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine
DMBT2HW HS Investigative
DMBT2HW SN CHEMBL478298; Modified amino acid analog, 10; BDBM24285; (3S)-3-amino-5-[(4-phenoxyphenyl)carbamoyl]pentanoic acid
DMBT2HW DT Small molecular drug
DMBT2HW PC 24901630
DMBT2HW MW 328.4
DMBT2HW FM C18H20N2O4
DMBT2HW IC InChI=1S/C18H20N2O4/c19-13(12-18(22)23)6-11-17(21)20-14-7-9-16(10-8-14)24-15-4-2-1-3-5-15/h1-5,7-10,13H,6,11-12,19H2,(H,20,21)(H,22,23)/t13-/m0/s1
DMBT2HW CS C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)CC[C@@H](CC(=O)O)N
DMBT2HW IK YAELJSOADOXCDL-ZDUSSCGKSA-N
DMBT2HW IU (3S)-3-amino-6-oxo-6-(4-phenoxyanilino)hexanoic acid
DMBT2HW DE Discovery agent
DMDMI7P ID DMDMI7P
DMDMI7P DN N-6060
DMDMI7P HS Investigative
DMDMI7P SN N-6338; N-6371; N-6446; N-6463; N-6501; N-6537; N-6603; S-nitrosoglutathione reductase inhibitors, N30
DMDMI7P CP N30 Pharmaceuticals LLC
DMDMI7P DE Asthma
DM814EQ ID DM814EQ
DM814EQ DN N-6547
DM814EQ HS Investigative
DM814EQ CP N30 Pharmaceuticals LLC
DM814EQ DE Inflammatory bowel disease
DM71MO2 ID DM71MO2
DM71MO2 DN N6-Benzyl Adenosine-5'-Diphosphate
DM71MO2 HS Investigative
DM71MO2 SN N6-BENZYL ADENOSINE-5'-DIPHOSPHATE; AC1L9K3K; SCHEMBL4319955; DB01893; N-benzyladenosine 5'-(trihydrogen diphosphate); [(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM71MO2 DT Small molecular drug
DM71MO2 PC 446795
DM71MO2 MW 517.299
DM71MO2 FM C17H21N5O10P2
DM71MO2 IC InChI=1S/C17H21N5O10P2/c23-13-11(7-30-34(28,29)32-33(25,26)27)31-17(14(13)24)22-9-21-12-15(19-8-20-16(12)22)18-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,23-24H,6-7H2,(H,28,29)(H,18,19,20)(H2,25,26,27)/t11-,13-,14-,17-/m1/s1
DM71MO2 CS C1=CC=C(C=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)OP(=O)(O)O)O)O
DM71MO2 IK MRHGMAGSDAQUFH-LSCFUAHRSA-N
DM71MO2 IU [(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
DM71MO2 DE Discovery agent
DMD6AJO ID DMD6AJO
DMD6AJO DN N6-cyclopentyladenosine
DMD6AJO HS Investigative
DMD6AJO SN N6-Cyclopentyladenosine; 41552-82-3; n-cyclopentyladenosine; (2R,3R,4S,5R)-2-(6-(Cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Cyclopentyladenosine; CHEMBL68738; MLS000028368; N(6)-Cyclopentyladenosine; SMR000058639; (2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol; Adenosine, N-cyclopentyl-; UNII-7LG47VG1ID; 7LG47VG1ID; N6-CyclopentylAdo; n-cyclopentyl-adenosine; n6-cyclopentyl-adenosine; AC1LCWG1; Opera_ID_1056; GTPL380; MLS002153196; MLS001077332; SCHEMBL120481
DMD6AJO DT Small molecular drug
DMD6AJO PC 657378
DMD6AJO MW 335.36
DMD6AJO FM C15H21N5O4
DMD6AJO IC InChI=1S/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
DMD6AJO CS C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMD6AJO IK SQMWSBKSHWARHU-SDBHATRESA-N
DMD6AJO IU (2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMD6AJO CA CAS 41552-82-3
DMD6AJO DE Discovery agent
DMSEL5W ID DMSEL5W
DMSEL5W DN N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine
DMSEL5W HS Investigative
DMSEL5W SN CHEMBL223327; N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine; SCHEMBL4380052; BDBM50205697
DMSEL5W DT Small molecular drug
DMSEL5W PC 10318664
DMSEL5W MW 398.4
DMSEL5W FM C18H18N6O5
DMSEL5W IC InChI=1S/C18H18N6O5/c1-28-23-16-13-17(22-12(21-16)6-5-10-4-2-3-7-19-10)24(9-20-13)18-15(27)14(26)11(8-25)29-18/h2-4,7,9,11,14-15,18,25-27H,8H2,1H3,(H,21,22,23)/t11-,14-,15-,18-/m1/s1
DMSEL5W CS CONC1=C2C(=NC(=N1)C#CC3=CC=CC=N3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMSEL5W IK CMMXTSNUEHRJEY-XKLVTHTNSA-N
DMSEL5W IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-pyridin-2-ylethynyl)purin-9-yl]oxolane-3,4-diol
DMSEL5W DE Discovery agent
DMP7246 ID DMP7246
DMP7246 DN N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine
DMP7246 HS Investigative
DMP7246 SN CHEMBL223328; N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine; SCHEMBL4384438
DMP7246 DT Small molecular drug
DMP7246 PC 16115478
DMP7246 MW 398.4
DMP7246 FM C18H18N6O5
DMP7246 IC InChI=1S/C18H18N6O5/c1-28-23-16-13-17(22-12(21-16)5-4-10-3-2-6-19-7-10)24(9-20-13)18-15(27)14(26)11(8-25)29-18/h2-3,6-7,9,11,14-15,18,25-27H,8H2,1H3,(H,21,22,23)/t11-,14-,15-,18-/m1/s1
DMP7246 CS CONC1=C2C(=NC(=N1)C#CC3=CN=CC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DMP7246 IK XQAKVNKMDSEKNH-XKLVTHTNSA-N
DMP7246 IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-pyridin-3-ylethynyl)purin-9-yl]oxolane-3,4-diol
DMP7246 DE Discovery agent
DM8LR62 ID DM8LR62
DM8LR62 DN N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine
DM8LR62 HS Investigative
DM8LR62 SN CHEMBL220158; N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine; SCHEMBL4381643
DM8LR62 DT Small molecular drug
DM8LR62 PC 10320311
DM8LR62 MW 427.4
DM8LR62 FM C20H21N5O6
DM8LR62 IC InChI=1S/C20H21N5O6/c1-29-12-6-3-11(4-7-12)5-8-14-22-18(24-30-2)15-19(23-14)25(10-21-15)20-17(28)16(27)13(9-26)31-20/h3-4,6-7,10,13,16-17,20,26-28H,9H2,1-2H3,(H,22,23,24)/t13-,16-,17-,20-/m1/s1
DM8LR62 CS COC1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DM8LR62 IK MZYNTNQYNANXII-AEVYOOLXSA-N
DM8LR62 IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-[2-(4-methoxyphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol
DM8LR62 DE Discovery agent
DM1KA9R ID DM1KA9R
DM1KA9R DN N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine
DM1KA9R HS Investigative
DM1KA9R SN CHEMBL426537; N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine; SCHEMBL4386994
DM1KA9R DT Small molecular drug
DM1KA9R PC 9801709
DM1KA9R MW 411.4
DM1KA9R FM C20H21N5O5
DM1KA9R IC InChI=1S/C20H21N5O5/c1-11-3-5-12(6-4-11)7-8-14-22-18(24-29-2)15-19(23-14)25(10-21-15)20-17(28)16(27)13(9-26)30-20/h3-6,10,13,16-17,20,26-28H,9H2,1-2H3,(H,22,23,24)/t13-,16-,17-,20-/m1/s1
DM1KA9R CS CC1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DM1KA9R IK QEUCNKIJAMGFSL-AEVYOOLXSA-N
DM1KA9R IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-[2-(4-methylphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol
DM1KA9R DE Discovery agent
DMQ5K8R ID DMQ5K8R
DMQ5K8R DN N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine
DMQ5K8R HS Investigative
DMQ5K8R SN CHEMBL374320; N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine; SCHEMBL4381145
DMQ5K8R DT Small molecular drug
DMQ5K8R PC 10389852
DMQ5K8R MW 467.5
DMQ5K8R FM C24H29N5O5
DMQ5K8R IC InChI=1S/C24H29N5O5/c1-3-4-5-6-15-7-9-16(10-8-15)11-12-18-26-22(28-33-2)19-23(27-18)29(14-25-19)24-21(32)20(31)17(13-30)34-24/h7-10,14,17,20-21,24,30-32H,3-6,13H2,1-2H3,(H,26,27,28)/t17-,20-,21-,24-/m1/s1
DMQ5K8R CS CCCCCC1=CC=C(C=C1)C#CC2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)NOC
DMQ5K8R IK SQMZMNPGRAKQJD-FGSUIDRYSA-N
DMQ5K8R IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-[2-(4-pentylphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol
DMQ5K8R DE Discovery agent
DM9H3W8 ID DM9H3W8
DM9H3W8 DN N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine
DM9H3W8 HS Investigative
DM9H3W8 SN CHEMBL220899; N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine; SCHEMBL4384730
DM9H3W8 DT Small molecular drug
DM9H3W8 PC 16115753
DM9H3W8 MW 398.4
DM9H3W8 FM C18H18N6O5
DM9H3W8 IC InChI=1S/C18H18N6O5/c1-28-23-16-13-17(22-12(21-16)3-2-10-4-6-19-7-5-10)24(9-20-13)18-15(27)14(26)11(8-25)29-18/h4-7,9,11,14-15,18,25-27H,8H2,1H3,(H,21,22,23)/t11-,14-,15-,18-/m1/s1
DM9H3W8 CS CONC1=C2C(=NC(=N1)C#CC3=CC=NC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
DM9H3W8 IK NZIZYIGAKAUPPW-XKLVTHTNSA-N
DM9H3W8 IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-pyridin-4-ylethynyl)purin-9-yl]oxolane-3,4-diol
DM9H3W8 DE Discovery agent
DMRBS50 ID DMRBS50
DMRBS50 DN N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine
DMRBS50 HS Investigative
DMRBS50 SN CHEMBL267421; N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine; SCHEMBL4378430
DMRBS50 DT Small molecular drug
DMRBS50 PC 16115477
DMRBS50 MW 393.47
DMRBS50 FM C16H23N5O5Si
DMRBS50 IC InChI=1S/C16H23N5O5Si/c1-25-20-14-11-15(19-10(18-14)5-6-27(2,3)4)21(8-17-11)16-13(24)12(23)9(7-22)26-16/h8-9,12-13,16,22-24H,7H2,1-4H3,(H,18,19,20)/t9-,12-,13-,16-/m1/s1
DMRBS50 CS CONC1=C2C(=NC(=N1)C#C[Si](C)(C)C)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
DMRBS50 IK UOJJCTHGWLSJEL-RVXWVPLUSA-N
DMRBS50 IU (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-trimethylsilylethynyl)purin-9-yl]oxolane-3,4-diol
DMRBS50 DE Discovery agent
DMDG59X ID DMDG59X
DMDG59X DN N6-methoxy-2-phenylethynyladenosine
DMDG59X HS Investigative
DMDG59X SN CHEMBL441707; N6-methoxy-2-phenylethynyladenosine
DMDG59X DT Small molecular drug
DMDG59X PC 44420681
DMDG59X MW 397.4
DMDG59X FM C19H19N5O5
DMDG59X IC InChI=1S/C19H19N5O5/c1-28-23-17-14-18(22-13(21-17)8-7-11-5-3-2-4-6-11)24(10-20-14)19-16(27)15(26)12(9-25)29-19/h2-6,10,12,15-16,19,25-27H,9H2,1H3,(H,21,22,23)/t12-,15+,16+,19+/m0/s1
DMDG59X CS CONC1=C2C(=NC(=N1)C#CC3=CC=CC=C3)N(C=N2)[C@H]4[C@@H]([C@@H]([C@@H](O4)CO)O)O
DMDG59X IK GWYJBOYUQUUQGN-GCUGWZBJSA-N
DMDG59X IU (2S,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methoxyamino)-2-(2-phenylethynyl)purin-9-yl]oxolane-3,4-diol
DMDG59X DE Discovery agent
DM6XDZA ID DM6XDZA
DM6XDZA DN N7-hydroxy-2-methoxy-N1-phenylheptanediamide
DM6XDZA HS Investigative
DM6XDZA SN CHEMBL251206; N7-hydroxy-2-methoxy-N1-phenylheptanediamide; SCHEMBL8143763
DM6XDZA DT Small molecular drug
DM6XDZA PC 25065710
DM6XDZA MW 280.32
DM6XDZA FM C14H20N2O4
DM6XDZA IC InChI=1S/C14H20N2O4/c1-20-12(9-5-6-10-13(17)16-19)14(18)15-11-7-3-2-4-8-11/h2-4,7-8,12,19H,5-6,9-10H2,1H3,(H,15,18)(H,16,17)
DM6XDZA CS COC(CCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DM6XDZA IK GTYJNCDOILRMGX-UHFFFAOYSA-N
DM6XDZA IU N'-hydroxy-2-methoxy-N-phenylheptanediamide
DM6XDZA DE Discovery agent
DMDJUZX ID DMDJUZX
DMDJUZX DN N7-hydroxy-N1-phenyl-2-propoxyheptanediamide
DMDJUZX HS Investigative
DMDJUZX SN CHEMBL251406; N7-hydroxy-N1-phenyl-2-propoxyheptanediamide; SCHEMBL8144856
DMDJUZX DT Small molecular drug
DMDJUZX PC 25065713
DMDJUZX MW 308.37
DMDJUZX FM C16H24N2O4
DMDJUZX IC InChI=1S/C16H24N2O4/c1-2-12-22-14(10-6-7-11-15(19)18-21)16(20)17-13-8-4-3-5-9-13/h3-5,8-9,14,21H,2,6-7,10-12H2,1H3,(H,17,20)(H,18,19)
DMDJUZX CS CCCOC(CCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DMDJUZX IK HYIYBZGKHUILKH-UHFFFAOYSA-N
DMDJUZX IU N'-hydroxy-N-phenyl-2-propoxyheptanediamide
DMDJUZX DE Discovery agent
DMHC32M ID DMHC32M
DMHC32M DN N8,2-dihydroxy-N1-phenyloctanediamide
DMHC32M HS Investigative
DMHC32M SN CHEMBL251009; N8,2-dihydroxy-N1-phenyloctanediamide; SCHEMBL8144564
DMHC32M DT Small molecular drug
DMHC32M PC 25065929
DMHC32M MW 280.32
DMHC32M FM C14H20N2O4
DMHC32M IC InChI=1S/C14H20N2O4/c17-12(9-5-2-6-10-13(18)16-20)14(19)15-11-7-3-1-4-8-11/h1,3-4,7-8,12,17,20H,2,5-6,9-10H2,(H,15,19)(H,16,18)
DMHC32M CS C1=CC=C(C=C1)NC(=O)C(CCCCCC(=O)NO)O
DMHC32M IK ZJKUBOBFXFZYHR-UHFFFAOYSA-N
DMHC32M IU N',2-dihydroxy-N-phenyloctanediamide
DMHC32M DE Discovery agent
DM7OZ2T ID DM7OZ2T
DM7OZ2T DN N8-hydroxy-2-methoxy-N1-phenyloctanediamide
DM7OZ2T HS Investigative
DM7OZ2T SN CHEMBL251010; N8-hydroxy-2-methoxy-N1-phenyloctanediamide; SCHEMBL8158442
DM7OZ2T DT Small molecular drug
DM7OZ2T PC 25065930
DM7OZ2T MW 294.35
DM7OZ2T FM C15H22N2O4
DM7OZ2T IC InChI=1S/C15H22N2O4/c1-21-13(10-6-3-7-11-14(18)17-20)15(19)16-12-8-4-2-5-9-12/h2,4-5,8-9,13,20H,3,6-7,10-11H2,1H3,(H,16,19)(H,17,18)
DM7OZ2T CS COC(CCCCCC(=O)NO)C(=O)NC1=CC=CC=C1
DM7OZ2T IK JHNWNLJPMOWGAH-UHFFFAOYSA-N
DM7OZ2T IU N'-hydroxy-2-methoxy-N-phenyloctanediamide
DM7OZ2T DE Discovery agent
DMML1J4 ID DMML1J4
DMML1J4 DN N-9xxx
DMML1J4 HS Investigative
DMML1J4 SN N-9xxx (oral, COPD)
DMML1J4 CP N30 Pharmaceuticals LLC
DMML1J4 DE Vascular disease
DM51DW6 ID DM51DW6
DM51DW6 DN NAADP
DM51DW6 HS Investigative
DM51DW6 SN nicotinic acid adenine dinucleotide phosphate; NAADP+
DM51DW6 DT Small molecular drug
DM51DW6 PC 123953
DM51DW6 MW 745.4
DM51DW6 FM C21H28N6O18P3+
DM51DW6 IC InChI=1S/C21H27N6O18P3/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(44-46(33,34)35)14(29)11(43-20)6-41-48(38,39)45-47(36,37)40-5-10-13(28)15(30)19(42-10)26-3-1-2-9(4-26)21(31)32/h1-4,7-8,10-11,13-16,19-20,28-30H,5-6H2,(H6-,22,23,24,31,32,33,34,35,36,37,38,39)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1
DM51DW6 CS C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O)C(=O)O
DM51DW6 IK QOTXBMGJKFVZRD-HISDBWNOSA-O
DM51DW6 IU 1-[(2R,3R,4S,5R)-5-[[[[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]pyridin-1-ium-3-carboxylic acid
DM51DW6 CB CHEBI:76072
DM51DW6 DE Discovery agent
DMFGOW0 ID DMFGOW0
DMFGOW0 DN NAAG
DMFGOW0 HS Investigative
DMFGOW0 SN N-acetylaspartylglutamate; spaglumic acid; isospaglumic acid
DMFGOW0 DT Small molecular drug
DMFGOW0 PC 188803
DMFGOW0 MW 304.25
DMFGOW0 FM C11H16N2O8
DMFGOW0 IC InChI=1S/C11H16N2O8/c1-5(14)12-7(4-9(17)18)10(19)13-6(11(20)21)2-3-8(15)16/h6-7H,2-4H2,1H3,(H,12,14)(H,13,19)(H,15,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1
DMFGOW0 CS CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O
DMFGOW0 IK OPVPGKGADVGKTG-BQBZGAKWSA-N
DMFGOW0 IU (2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]pentanedioic acid
DMFGOW0 CA CAS 3106-85-2
DMFGOW0 CB CHEBI:73688
DMFGOW0 DE Discovery agent
DMRKIYB ID DMRKIYB
DMRKIYB DN NA-alpha-D-glucosamine
DMRKIYB HS Investigative
DMRKIYB SN N-Acetyl-alpha-D-glucosamine; N-acetyl-alpha-D-glucosamine; T13TI5GH3D; alpha-GlcNAc; 10036-64-3; 1rdn; 2-(ACETYLAMINO)-2-DEOXY-A-D-GLUCOPYRANOSE; 2-(acetylamino)-2-deoxy-D-glucose; 2-(acetylamino)-2-deoxy-alpha-D-glucopyranose; 2-Acetamido-2-deoxy-alpha-D-glucopyranose; AC1L335S; AC1Q5JMQ; CHEBI:44278; CHEMBL1234669; EINECS 233-115-1; N-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide; N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; SCHEMBL19899; UNII-T13TI5GH3D; alpha-D-GlcNAc
DMRKIYB PC 82313
DMRKIYB MW 221.21
DMRKIYB FM C8H15NO6
DMRKIYB IC OVRNDRQMDRJTHS-PVFLNQBWSA-N
DMRKIYB CS CC(=O)NC1C(C(C(OC1O)CO)O)O
DMRKIYB IK 1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6-,7-,8+/m1/s1
DMRKIYB IU N-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
DMRKIYB CA CAS 10036-64-3
DMRKIYB CB CHEBI:44278
DMRKIYB DE Discovery agent
DMZW9AC ID DMZW9AC
DMZW9AC DN N-Acetylalanine
DMZW9AC HS Investigative
DMZW9AC SN N-Acetyl-DL-alanine; 1115-69-1; 2-acetamidopropanoic acid; Ac-DL-Ala-OH; 2-Acetylaminopropionic acid; N-ACETYLALANINE; Acetyl-DL-Alanine; DL-Alanine, N-acetyl-; N-alpha-Acetyl-DL-alanine; 2-Acetylamino-propionic acid; N-Acetyl-S-alanine; L-Alanine, N-acetyl-; KTHDTJVBEPMMGL-UHFFFAOYSA-N; N-Acetyl-DL-2-aminopropionic Acid; 2-(acetylamino)propanoic acid; n-acetylalanin; Alanine, N-acetyl-; Alanine, N-acetyl-, L-; L-Alanine, N-acetyl- (9CI); Alanine, N-acetyl-, L- (8CI); ac-dl-alanine; n-acetyl-dl-ala; N-Acetylalanine #; EINECS 214-
DMZW9AC DT Small molecular drug
DMZW9AC PC 88064
DMZW9AC MW 131.13
DMZW9AC FM C5H9NO3
DMZW9AC IC InChI=1S/C5H9NO3/c1-3(5(8)9)6-4(2)7/h3H,1-2H3,(H,6,7)(H,8,9)/t3-/m0/s1
DMZW9AC CS C[C@@H](C(=O)O)NC(=O)C
DMZW9AC IK KTHDTJVBEPMMGL-VKHMYHEASA-N
DMZW9AC IU (2S)-2-acetamidopropanoic acid
DMZW9AC CA CAS 97-69-8
DMZW9AC CB CHEBI:40992
DMZW9AC DE Discovery agent
DM9WQ6V ID DM9WQ6V
DM9WQ6V DN N-Acetylmethionine
DM9WQ6V HS Investigative
DM9WQ6V SN N-Acetyl-DL-methionine; 1115-47-5; Ac-DL-Met-OH; Acetyl-DL-methionine; DL-N-Acetylmethionine; Methionamine; METHIONINE, N-ACETYL-; DL-Methionine, N-acetyl-; Ac-Met-OH; Methionine, N-acetyl-, DL-; 2-Acetamido-4-(methylthio)butanoic acid; dl-Acetylmethionine; Thiomedon; L-Methionine, N-acetyl-; NSC 7633; EINECS 214-224-3; N-ACETYL-METHIONINE; N-Acetyl(methyl)homocysteine; BRN 1725554; Acetylmethionin; Methionin; C7H13NO3S; XUYPXLNMDZIRQH-UHFFFAOYSA-N; MFCD00008681; 2-acetamido-4-methylsulfanylbutanoic acid
DM9WQ6V DT Small molecular drug
DM9WQ6V PC 448580
DM9WQ6V MW 191.25
DM9WQ6V FM C7H13NO3S
DM9WQ6V IC InChI=1S/C7H13NO3S/c1-5(9)8-6(7(10)11)3-4-12-2/h6H,3-4H2,1-2H3,(H,8,9)(H,10,11)/t6-/m0/s1
DM9WQ6V CS CC(=O)N[C@@H](CCSC)C(=O)O
DM9WQ6V IK XUYPXLNMDZIRQH-LURJTMIESA-N
DM9WQ6V IU (2S)-2-acetamido-4-methylsulfanylbutanoic acid
DM9WQ6V CA CAS 65-82-7
DM9WQ6V CB CHEBI:21557
DM9WQ6V DE Discovery agent
DMUNCFQ ID DMUNCFQ
DMUNCFQ DN N-Acetyl-N'-Beta-D-Glucopyranosyl Urea
DMUNCFQ HS Investigative
DMUNCFQ SN N-ACETYL-N'-BETA-D-GLUCOPYRANOSYL UREA; CHEMBL443455; 1kti; DB03218; AC1L9K3W; SCHEMBL4307948; BDBM50263770; N-Acetyl-N'-(beta-D-glucopyranosyl)urea; N-(acetylcarbamoyl)-beta-D-glucopyranosylamine; N-ACETYL-N''-BETA-D-GLUCOPYRANOSYL UREA; N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]acetamide; N-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-ylcarbamoyl)acetamide
DMUNCFQ DT Small molecular drug
DMUNCFQ PC 446801
DMUNCFQ MW 264.23
DMUNCFQ FM C9H16N2O7
DMUNCFQ IC InChI=1S/C9H16N2O7/c1-3(13)10-9(17)11-8-7(16)6(15)5(14)4(2-12)18-8/h4-8,12,14-16H,2H2,1H3,(H2,10,11,13,17)/t4-,5-,6+,7-,8-/m1/s1
DMUNCFQ CS CC(=O)NC(=O)N[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O
DMUNCFQ IK UQKBNLXZEGBQAF-JAJWTYFOSA-N
DMUNCFQ IU N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]acetamide
DMUNCFQ DE Discovery agent
DME8O69 ID DME8O69
DME8O69 DN N-acetyl-phenylalanyl-glycine-nitrile
DME8O69 HS Investigative
DME8O69 SN phenylalanine derivative, 42; CHEMBL197181; SCHEMBL15634553; BDBM20118; ITHLBMBCVIAAIX-LBPRGKRZSA-N; ZINC13676602; (N-acetyl-l-phenylalanyl)aminoacetonitrile; SR-03000002938; SR-03000002938-1; (S)-2-Acetamido-N-(cyanomethyl)-3-phenylpropanamide
DME8O69 DT Small molecular drug
DME8O69 PC 11086036
DME8O69 MW 245.28
DME8O69 FM C13H15N3O2
DME8O69 IC InChI=1S/C13H15N3O2/c1-10(17)16-12(13(18)15-8-7-14)9-11-5-3-2-4-6-11/h2-6,12H,8-9H2,1H3,(H,15,18)(H,16,17)/t12-/m0/s1
DME8O69 CS CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC#N
DME8O69 IK ITHLBMBCVIAAIX-LBPRGKRZSA-N
DME8O69 IU (2S)-2-acetamido-N-(cyanomethyl)-3-phenylpropanamide
DME8O69 DE Discovery agent
DMJ4SBM ID DMJ4SBM
DMJ4SBM DN N-acetylserotonin
DMJ4SBM HS Investigative
DMJ4SBM SN N-Acetyl-5-hydroxytryptamine; 1210-83-9; N-ACETYL SEROTONIN; N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]acetamide; acetylserotonin; Normelatonin; O-Demethylmelatonin; 5-Hydroxy-N-acetyltryptamine; UNII-P4TO3C82WV; Acetyl-5-hydroxy-tryptamine; 5-Hydroxymelatonin; N-(2-(5-Hydroxy-1H-indol-3-yl)ethyl)acetamide; 3-(2-Acetamidoethyl)-5-hydroxyindole; P4TO3C82WV; CHEMBL33103; CHEBI:17697; MVAWJSIDNICKHF-UHFFFAOYSA-N; Acetamide, N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-; A-1300; Desmethylmelatonin; N-acetyl-serotonin; O-demethylmelatonin; N-acetyl-5-hydroxytryptamine; N-[2-(5-Hydroxy-1H-indol-3-yl)-ethyl]-acetamide
DMJ4SBM DT Small molecular drug
DMJ4SBM PC 903
DMJ4SBM MW 218.25
DMJ4SBM FM C12H14N2O2
DMJ4SBM IC InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15)
DMJ4SBM CS CC(=O)NCCC1=CNC2=C1C=C(C=C2)O
DMJ4SBM IK MVAWJSIDNICKHF-UHFFFAOYSA-N
DMJ4SBM IU N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide
DMJ4SBM CA CAS 1210-83-9
DMJ4SBM CB CHEBI:17697
DMJ4SBM DE Discovery agent
DM1XH8D ID DM1XH8D
DM1XH8D DN N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
DM1XH8D HS Investigative
DM1XH8D SN CHEMBL61092; 1046-70-4; SCHEMBL8288058; CTK0D7916; DTXSID50658232; BDBM50143356; 1,4-Butanediamine, N'-9-acridinyl-N,N-diethyl-; N''-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine
DM1XH8D DT Small molecular drug
DM1XH8D PC 44300061
DM1XH8D MW 321.5
DM1XH8D FM C21H27N3
DM1XH8D IC InChI=1S/C21H27N3/c1-3-24(4-2)16-10-9-15-22-21-17-11-5-7-13-19(17)23-20-14-8-6-12-18(20)21/h5-8,11-14H,3-4,9-10,15-16H2,1-2H3,(H,22,23)
DM1XH8D CS CCN(CC)CCCCNC1=C2C=CC=CC2=NC3=CC=CC=C31
DM1XH8D IK OALXTIRPFIITPC-UHFFFAOYSA-N
DM1XH8D IU N-acridin-9-yl-N',N'-diethylbutane-1,4-diamine
DM1XH8D CA CAS 1046-70-4
DM1XH8D DE Discovery agent
DM3ORGM ID DM3ORGM
DM3ORGM DN NADA
DM3ORGM HS Investigative
DM3ORGM SN N-arachidonyl dopamine
DM3ORGM DT Small molecular drug
DM3ORGM PC 5282105
DM3ORGM MW 439.6
DM3ORGM FM C28H41NO3
DM3ORGM IC InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15-
DM3ORGM CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCC1=CC(=C(C=C1)O)O
DM3ORGM IK MVVPIAAVGAWJNQ-DOFZRALJSA-N
DM3ORGM IU (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide
DM3ORGM CA CAS 199875-69-9
DM3ORGM CB CHEBI:31231
DM3ORGM DE Discovery agent
DMSR4A6 ID DMSR4A6
DMSR4A6 DN N-adamantanemethyloxypentyl-1-deoxynojirimycin
DMSR4A6 HS Investigative
DMSR4A6 SN AMP-Deoxynojirimycin; AMP-DNM; 216758-20-2; CHEMBL574645; N-adamantanemethyloxypentyl-1-deoxynojirimycin; SCHEMBL17132950; SCHEMBL13777990; CTK4E7471; MolPort-044-562-021; ZINC33989734; BDBM50299749; 1613AH; AKOS030538164; RT-011277; N-(Adamantanemethyloxypentyl)-Deoxynojirimycin; J-014228; (2R,3R,4R,5S)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol; 3,4,5-PIPERIDINETRIOL, 2-(HYDROXYMETHYL)-1-[5-(TRICYCLO[3.3.1.13,7]DEC-1-YLMETHOXY)PENTYL]-, (2R,3R,4R,5S)-
DMSR4A6 DT Small molecular drug
DMSR4A6 PC 9822159
DMSR4A6 MW 397.5
DMSR4A6 FM C22H39NO5
DMSR4A6 IC InChI=1S/C22H39NO5/c24-13-18-20(26)21(27)19(25)12-23(18)4-2-1-3-5-28-14-22-9-15-6-16(10-22)8-17(7-15)11-22/h15-21,24-27H,1-14H2/t15?,16?,17?,18-,19+,20-,21-,22?/m1/s1
DMSR4A6 CS C1[C@@H]([C@H]([C@@H]([C@H](N1CCCCCOCC23CC4CC(C2)CC(C4)C3)CO)O)O)O
DMSR4A6 IK XVYLNHVEAOOEGI-FAIWKWDXSA-N
DMSR4A6 IU (2R,3R,4R,5S)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
DMSR4A6 DE Discovery agent
DMZ43N1 ID DMZ43N1
DMZ43N1 DN N-adamantyl-N'-cyclohexylurea
DMZ43N1 HS Investigative
DMZ43N1 SN CHEMBL242255; N-1-adamantyl-N'-cyclohexylurea; AC1NMPQQ; Urea-based compound, 13; ChemDiv3_000178; Oprea1_419513; 1-adamantyl-3-cyclohexylurea; MLS000719875; SCHEMBL653168; BDBM25732; MolPort-003-713-177; HMS2616F12; HMS1473I02; 3-adamantan-1-yl-1-cyclohexylurea; 1-(1-adamantyl)-3-cyclohexylurea; ZINC3895072; AKOS001483388; MCULE-6291906995; 1-(Adamantane-1-yl)-3-cyclohexylurea; IDI1_019496; N-adamantanyl(cyclohexylamino)carboxamide; NCGC00177652-01; SMR000304404; EU-0000129; ST51030996; US8815951, 192; SR-01000389488
DMZ43N1 DT Small molecular drug
DMZ43N1 PC 5029871
DMZ43N1 MW 276.4
DMZ43N1 FM C17H28N2O
DMZ43N1 IC InChI=1S/C17H28N2O/c20-16(18-15-4-2-1-3-5-15)19-17-9-12-6-13(10-17)8-14(7-12)11-17/h12-15H,1-11H2,(H2,18,19,20)
DMZ43N1 CS C1CCC(CC1)NC(=O)NC23CC4CC(C2)CC(C4)C3
DMZ43N1 IK VESXWSWSGQONHC-UHFFFAOYSA-N
DMZ43N1 IU 1-(1-adamantyl)-3-cyclohexylurea
DMZ43N1 DE Discovery agent
DM75Q34 ID DM75Q34
DM75Q34 DN NADPH
DM75Q34 HS Investigative
DM75Q34 SN NADP-reduced; reduced Cozymase II; reduced Coenzyme II; b-NADPH; reduced Codehydrase II; Dihydrocodehydrogenase II; dihydronicotinamide adenine dinucleotide-P; GTPL3041; Triphosphopyridine nucleotide reduced; Reduced triphosphopyridine nucleotide; dihydrotriphosphopyridine nucleotide reduced; Nicotinamide-adenine-dinucleotide-phosphorate; b-Nicotinamide-adenine-dinucleotide-phosphorate; Nicotinamide-adenine-dinucleotide-phosphoric acid; beta-Nicotinamide-adenine-dinucleotide-phosphorate
DM75Q34 DT Small molecular drug
DM75Q34 PC 5884
DM75Q34 MW 745.4
DM75Q34 FM C21H30N7O17P3
DM75Q34 IC InChI=1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM75Q34 CS C1C=CN(C=C1C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)OP(=O)(O)O)O)O)O
DM75Q34 IK ACFIXJIJDZMPPO-NNYOXOHSSA-N
DM75Q34 IU [[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM75Q34 CA CAS 53-57-6
DM75Q34 CB CHEBI:16474
DM75Q34 DE Discovery agent
DM38XWZ ID DM38XWZ
DM38XWZ DN NAEPA
DM38XWZ HS Investigative
DM38XWZ SN N-acyl ethanolamide phosphate
DM38XWZ DT Small molecular drug
DM38XWZ PC 44343825
DM38XWZ MW 405.5
DM38XWZ FM C20H40NO5P
DM38XWZ IC InChI=1S/C20H40NO5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(22)21-18-19-26-27(23,24)25/h9-10H,2-8,11-19H2,1H3,(H,21,22)(H2,23,24,25)/b10-9-
DM38XWZ CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCCOP(=O)(O)O
DM38XWZ IK BCSUWOZFWWBYSX-KTKRTIGZSA-N
DM38XWZ IU 2-[[(Z)-octadec-9-enoyl]amino]ethyl dihydrogen phosphate
DM38XWZ CA CAS 24435-25-4
DM38XWZ CB CHEBI:145794
DM38XWZ DE Discovery agent
DM79KLR ID DM79KLR
DM79KLR DN nafadotride
DM79KLR HS Investigative
DM79KLR SN Nafadotride; 149649-22-9; (+-)-nafadotride; N-[(1-BUTYL-2-PYRROLIDINYL)METHYL]-4-CYANO-1-METHOXY-2-NAPHTHALENECARBOXAMIDE; N-[(1-butylpyrrolidin-2-yl)methyl]-4-cyano-1-methoxynaphthalene-2-carboxamide; CHEMBL286252; CHEBI:64191; A1-01951; SMR000466292; AC1MPBUT; GTPL44; MLS000758952; MLS001424218; SCHEMBL635866; DTXSID1042603; CTK8H0240; MolPort-023-276-076; HMS3394A15; HMS3267P15; HMS2232B11; HMS2052A15; HMS3370D02; BCP27779; BDBM50133923; AKOS024257976; TRA0072321; CCG-101119; NC00369; SAM001247092; CPD000466292; LS-186981; LS-187623
DM79KLR DT Small molecular drug
DM79KLR PC 3408722
DM79KLR MW 365.5
DM79KLR FM C22H27N3O2
DM79KLR IC InChI=1S/C22H27N3O2/c1-3-4-11-25-12-7-8-17(25)15-24-22(26)20-13-16(14-23)18-9-5-6-10-19(18)21(20)27-2/h5-6,9-10,13,17H,3-4,7-8,11-12,15H2,1-2H3,(H,24,26)
DM79KLR CS CCCCN1CCCC1CNC(=O)C2=C(C3=CC=CC=C3C(=C2)C#N)OC
DM79KLR IK IDZASIQMRGPBCQ-UHFFFAOYSA-N
DM79KLR IU N-[(1-butylpyrrolidin-2-yl)methyl]-4-cyano-1-methoxynaphthalene-2-carboxamide
DM79KLR CA CAS 149649-22-9
DM79KLR CB CHEBI:64191
DM79KLR DE Discovery agent
DM0FROP ID DM0FROP
DM0FROP DN Nafoxidine
DM0FROP HS Investigative
DM0FROP SN Nafoxidine; 1845-11-0; Nafoxidine [INN]; Nafoxidinum [INN-Latin]; Nafoxidina [INN-Spanish]; UNII-4RIY10WM82; U-11000A; BRN 1440873; CHEMBL28211; 4RIY10WM82; CHEBI:34881; NSC 70735; C29H31NO2; JEYWNNAZDLFBFF-UHFFFAOYSA-N; 1-(2-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine; Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-; 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine; Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl
DM0FROP DT Small molecular drug
DM0FROP PC 4416
DM0FROP MW 425.6
DM0FROP FM C29H31NO2
DM0FROP IC InChI=1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3
DM0FROP CS COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5
DM0FROP IK JEYWNNAZDLFBFF-UHFFFAOYSA-N
DM0FROP IU 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
DM0FROP CA CAS 1845-11-0
DM0FROP CB CHEBI:34881
DM0FROP DE Discovery agent
DML7UVA ID DML7UVA
DML7UVA DN NAG 1-phosphate
DML7UVA HS Investigative
DML7UVA SN N-Acetyl-glucosamine 1-phosphate; N-Acetylglucosamine 1-phosphate; N-Acetylglucosamine-1-phosphate; SCHEMBL5679031; delta-glucosamine 1-phosphate; 2-acetamido-2-deoxy-1-O-phosphono-D-glucopyranose; 2-acetamido-2-deoxy-D-glucopyranose 1-phosphate; 6866-69-9; AC1L990N; C04256; CHEBI:7125; CTK2F5371; DTXSID90988348; N-Acetyl-D-glucosamine 1-phosphate; N-acetyl-alpha-delta-glucosamine 1-phosphate; N-acetyl-delta-glucosamine 1-phosphate; N-ACETYL-D-GLUCOSAMINE-1-P; bmse000163
DML7UVA PC 440272
DML7UVA MW 301.19
DML7UVA FM C8H16NO9P
DML7UVA IC FZLJPEPAYPUMMR-RTRLPJTCSA-N
DML7UVA CS CC(=O)NC1C(C(C(OC1OP(=O)(O)O)CO)O)O
DML7UVA IK 1S/C8H16NO9P/c1-3(11)9-5-7(13)6(12)4(2-10)17-8(5)18-19(14,15)16/h4-8,10,12-13H,2H2,1H3,(H,9,11)(H2,14,15,16)/t4-,5-,6-,7-,8?/m1/s1
DML7UVA IU [(3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate
DML7UVA CA CAS 6866-69-9
DML7UVA CB CHEBI:7125
DML7UVA DE Discovery agent
DM1LWMU ID DM1LWMU
DM1LWMU DN nahuoic acid A
DM1LWMU HS Investigative
DM1LWMU SN nahuoic acid A; GTPL7022; (2E)-3-[(1R,2R,4aR,5R,7R,8R,8aS)-5,7-dihydroxy-3,4a,8-trimethyl-2-[(2E,5S,7R,8S,9S)-5,7,9-trihydroxy-8,10-dimethylundec-2-en-2-yl]-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-2-methylprop-2-enoic acid
DM1LWMU DT Small molecular drug
DM1LWMU PC 71521340
DM1LWMU MW 522.7
DM1LWMU FM C30H50O7
DM1LWMU IC InChI=1S/C30H50O7/c1-15(2)28(35)20(7)23(32)12-21(31)10-9-16(3)26-18(5)14-30(8)25(34)13-24(33)19(6)27(30)22(26)11-17(4)29(36)37/h9,11,14-15,19-28,31-35H,10,12-13H2,1-8H3,(H,36,37)/b16-9+,17-11+/t19-,20-,21-,22-,23+,24+,25+,26+,27+,28-,30+/m0/s1
DM1LWMU CS C[C@H]1[C@@H](C[C@H]([C@@]2([C@H]1[C@H]([C@@H](C(=C2)C)/C(=C/C[C@@H](C[C@H]([C@H](C)[C@H](C(C)C)O)O)O)/C)/C=C(\\C)/C(=O)O)C)O)O
DM1LWMU IK ZNAYXHSDZPSFLO-UWXUHECCSA-N
DM1LWMU IU (E)-3-[(1R,2R,4aR,5R,7R,8R,8aS)-5,7-dihydroxy-3,4a,8-trimethyl-2-[(E,5S,7R,8S,9S)-5,7,9-trihydroxy-8,10-dimethylundec-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1H-naphthalen-1-yl]-2-methylprop-2-enoic acid
DM1LWMU DE Discovery agent
DM0CP36 ID DM0CP36
DM0CP36 DN NalBzOH
DM0CP36 HS Investigative
DM0CP36 SN Naloxone benzoylhydrazone; Nalbzoh; 119630-94-3; 6-Desoxy-6-benzoylhydrazido-N-allyl-14-hydroxydihydronormorphinone; Benzoic acid, ((5alpha)-4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-ylidene)hydrazide; Lopac0_000882; [(5alpha)-4,5-Epoxy-; MLS000860072; Naloxone benzoylhydrazone, solid; SCHEMBL15423902; CHEMBL1256836; MolPort-003-958-927; MFCD05662358; AKOS024456586; CCG-204964; NCGC00092281-03; NCGC00092281-02; NCGC00092281-04; NCGC00092281-01; SMR000326930; N-165; EU-0100882; SR-01000075513; SR-01000075513-1
DM0CP36 DT Small molecular drug
DM0CP36 PC 9601084
DM0CP36 MW 445.5
DM0CP36 FM C26H27N3O4
DM0CP36 IC InChI=1S/C26H27N3O4/c1-2-13-29-14-12-25-21-17-8-9-19(30)22(21)33-23(25)18(10-11-26(25,32)20(29)15-17)27-28-24(31)16-6-4-3-5-7-16/h2-9,20,23,30,32H,1,10-15H2,(H,28,31)/b27-18+/t20-,23+,25+,26-/m1/s1
DM0CP36 CS C=CCN1CC[C@]23[C@@H]4/C(=N/NC(=O)C5=CC=CC=C5)/CC[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)O
DM0CP36 IK AKXCFAYOTIEFOH-XTNAHFASSA-N
DM0CP36 IU N-[(E)-[(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]amino]benzamide
DM0CP36 CA CAS 119630-94-3
DM0CP36 DE Discovery agent
DM9T0OK ID DM9T0OK
DM9T0OK DN N-alkyl urea hydroxamic acids
DM9T0OK HS Investigative
DM9T0OK DT Small molecular drug
DM9T0OK PC 56603781
DM9T0OK MW 416.5
DM9T0OK FM C21H32N6O3
DM9T0OK IC InChI=1S/C21H32N6O3/c1-16(25-30)15-26(13-4-9-17-7-2-3-8-17)21(29)27-14-5-10-18(27)19(28)24-20-22-11-6-12-23-20/h6,11-12,17-18,25,30H,1-5,7-10,13-15H2,(H,22,23,24,28)/t18-/m0/s1
DM9T0OK CS C=C(CN(CCCC1CCCC1)C(=O)N2CCC[C@H]2C(=O)NC3=NC=CC=N3)NO
DM9T0OK IK RQNVLLHARFXNPH-SFHVURJKSA-N
DM9T0OK IU (2S)-1-N-(3-cyclopentylpropyl)-1-N-[2-(hydroxyamino)prop-2-enyl]-2-N-pyrimidin-2-ylpyrrolidine-1,2-dicarboxamide
DM9T0OK DE Discovery agent
DM30LI6 ID DM30LI6
DM30LI6 DN N-allyl[D-Pro-10]Dyn A-(1-11)
DM30LI6 HS Investigative
DM30LI6 SN CHEMBL406338; N-allyl[D-Pro-10]Dyn A-(1-11)
DM30LI6 PC 44325372
DM30LI6 MW 1402.7
DM30LI6 FM C66H107N21O13
DM30LI6 IC InChI=1S/C66H107N21O13/c1-6-29-74-48(35-42-24-26-43(88)27-25-42)55(91)79-37-52(89)78-38-53(90)80-50(36-41-17-9-8-10-18-41)59(95)85-49(34-39(3)4)58(94)82-44(20-13-30-75-64(68)69)56(92)81-45(21-14-31-76-65(70)71)57(93)86-54(40(5)7-2)61(97)83-46(22-15-32-77-66(72)73)62(98)87-33-16-23-51(87)60(96)84-47(63(99)100)19-11-12-28-67/h6,8-10,17-18,24-27,39-40,44-51,54,74,88H,1,7,11-16,19-23,28-38,67H2,2-5H3,(H,78,89)(H,79,91)(H,80,90)(H,81,92)(H,82,94)(H,83,97)(H,84,96)(H,85,95)(H,86,93)(H,99,100)(H4,68,69,75)(H4,70,71,76)(H4,72,73,77)/t40-,44-,45-,46-,47-,48-,49-,50-,51-,54-/m0/s1
DM30LI6 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC=C
DM30LI6 IK MKKPRLAUMQVIGT-QNKLTTAESA-N
DM30LI6 IU (2S)-6-amino-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S,3S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-3-(4-hydroxyphenyl)-2-(prop-2-enylamino)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM30LI6 DE Discovery agent
DMZQUMB ID DMZQUMB
DMZQUMB DN N-allyl-4-hydroxy-N-phenylbenzenesulfonamide
DMZQUMB HS Investigative
DMZQUMB SN CHEMBL426849; N-allyl-4-hydroxy-N-phenylbenzenesulfonamide
DMZQUMB DT Small molecular drug
DMZQUMB PC 44407887
DMZQUMB MW 289.4
DMZQUMB FM C15H15NO3S
DMZQUMB IC InChI=1S/C15H15NO3S/c1-2-12-16(13-6-4-3-5-7-13)20(18,19)15-10-8-14(17)9-11-15/h2-11,17H,1,12H2
DMZQUMB CS C=CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMZQUMB IK CZEIYINPLQLEHQ-UHFFFAOYSA-N
DMZQUMB IU 4-hydroxy-N-phenyl-N-prop-2-enylbenzenesulfonamide
DMZQUMB DE Discovery agent
DMRXA8N ID DMRXA8N
DMRXA8N DN N-ALLYLNORGALANTHAMINE
DMRXA8N HS Investigative
DMRXA8N SN N-allylnorgalanthamine; CHEMBL399515; SCHEMBL13043536
DMRXA8N DT Small molecular drug
DMRXA8N PC 44447598
DMRXA8N MW 313.4
DMRXA8N FM C19H23NO3
DMRXA8N IC InChI=1S/C19H23NO3/c1-3-9-20-10-8-19-7-6-14(21)11-16(19)23-18-15(22-2)5-4-13(12-20)17(18)19/h3-7,14,16,21H,1,8-12H2,2H3/t14-,16-,19-/m0/s1
DMRXA8N CS COC1=C2C3=C(CN(CC[C@]34C=C[C@@H](C[C@@H]4O2)O)CC=C)C=C1
DMRXA8N IK BQESVZIPHFRYNG-QOKNQOGYSA-N
DMRXA8N IU (1S,12S,14R)-9-methoxy-4-prop-2-enyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DMRXA8N DE Discovery agent
DM5W2VK ID DM5W2VK
DM5W2VK DN N-allylnorlitebamine
DM5W2VK HS Investigative
DM5W2VK SN N-allylnorlitebamine; CHEMBL465347; BDBM50250444
DM5W2VK DT Small molecular drug
DM5W2VK PC 10546795
DM5W2VK MW 365.4
DM5W2VK FM C22H23NO4
DM5W2VK IC InChI=1S/C22H23NO4/c1-4-8-23-9-7-14-15-6-5-13-10-18(24)19(26-2)11-16(13)20(15)22(27-3)21(25)17(14)12-23/h4-6,10-11,24-25H,1,7-9,12H2,2-3H3
DM5W2VK CS COC1=C(C=C2C=CC3=C4CCN(CC4=C(C(=C3C2=C1)OC)O)CC=C)O
DM5W2VK IK GFTFQCRSRIGURP-UHFFFAOYSA-N
DM5W2VK IU 9,11-dimethoxy-2-prop-2-enyl-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DM5W2VK DE Discovery agent
DM1SCU5 ID DM1SCU5
DM1SCU5 DN Nalorphine
DM1SCU5 HS Investigative
DM1SCU5 SN Nalorphine; Allorphine; Nalorphinium; Antorphin; Antorfin; Anthorphine; Nalorphin; Antorphine; N-Allylnormorphine; Anarcon; Nalorfina; Norfin; Nallin; 62-67-9; Acetorfin [Czech]; Nalorfina [DCIT]; NANM; Normorphine, N-allyl-; Nalorphine [INN:BAN]; Nalorphinum [INN-Latin]; UNII-U59WB2WRY2; N-Allyl-N-desmethylmorphine; HSDB 3278; EINECS 200-546-1; U59WB2WRY2; Acetorfin; CHEBI:7458; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-(2-propenyl)-, (5alpha,6alpha)-; N-Allyl-7,8-dehydro-4,5-epoxy-3,6-dihydroxymorphinan; DEA No. 9400
DM1SCU5 DT Small molecular drug
DM1SCU5 PC 5284595
DM1SCU5 MW 311.4
DM1SCU5 FM C19H21NO3
DM1SCU5 IC InChI=1S/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1
DM1SCU5 CS C=CCN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
DM1SCU5 IK UIQMVEYFGZJHCZ-SSTWWWIQSA-N
DM1SCU5 IU (4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
DM1SCU5 CA CAS 62-67-9
DM1SCU5 CB CHEBI:7458
DM1SCU5 DE Discovery agent
DM8ZMNH ID DM8ZMNH
DM8ZMNH DN naloxonazine
DM8ZMNH HS Investigative
DM8ZMNH SN NSC 612113
DM8ZMNH DT Small molecular drug
DM8ZMNH PC 9576413
DM8ZMNH MW 650.8
DM8ZMNH FM C38H42N4O6
DM8ZMNH IC InChI=1S/C38H42N4O6/c1-3-15-41-17-13-35-29-21-5-7-25(43)31(29)47-33(35)23(9-11-37(35,45)27(41)19-21)39-40-24-10-12-38(46)28-20-22-6-8-26(44)32-30(22)36(38,34(24)48-32)14-18-42(28)16-4-2/h3-8,27-28,33-34,43-46H,1-2,9-20H2/b39-23+,40-24+/t27-,28-,33+,34+,35+,36+,37-,38-/m1/s1
DM8ZMNH CS C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O
DM8ZMNH IK AJPSBXJNFJCCBI-YOHUGVJRSA-N
DM8ZMNH IU (4R,4aS,7E,7aR,12bS)-7-[(E)-[(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ylidene]hydrazinylidene]-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol
DM8ZMNH CA CAS 82824-01-9
DM8ZMNH DE Discovery agent
DMFNCQ1 ID DMFNCQ1
DMFNCQ1 DN N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2
DMFNCQ1 HS Investigative
DMFNCQ1 SN CHEMBL243724; BDBM50201411; N alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2
DMFNCQ1 DT Small molecular drug
DMFNCQ1 PC 44428306
DMFNCQ1 MW 723.8
DMFNCQ1 FM C38H45N9O6
DMFNCQ1 IC InChI=1S/C38H45N9O6/c1-53-26-15-13-24(14-16-26)19-31(46-38(40)41)37(52)47-17-7-12-32(47)36(51)43-22-33(48)44-30(20-25-21-42-28-11-6-5-10-27(25)28)35(50)45-29(34(39)49)18-23-8-3-2-4-9-23/h2-6,8-11,13-16,21,29-32,42H,7,12,17-20,22H2,1H3,(H2,39,49)(H,43,51)(H,44,48)(H,45,50)(H4,40,41,46)/t29-,30-,31-,32+/m0/s1
DMFNCQ1 CS COC1=CC=C(C=C1)C[C@@H](C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N=C(N)N
DMFNCQ1 IK OEGSFHSEWVWDGF-RTNMLALUSA-N
DMFNCQ1 IU (2R)-N-[2-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-1-[(2S)-2-(diaminomethylideneamino)-3-(4-methoxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMFNCQ1 DE Discovery agent
DM8QTSU ID DM8QTSU
DM8QTSU DN N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2
DM8QTSU HS Investigative
DM8QTSU SN CHEMBL243189; BDBM50201412; N alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2
DM8QTSU DT Small molecular drug
DM8QTSU PC 44428304
DM8QTSU MW 701.2
DM8QTSU FM C36H41ClN8O5
DM8QTSU IC InChI=1S/C36H41ClN8O5/c1-50-25-14-10-22(11-15-25)18-30(44-36(39)40)35(49)45-16-4-7-31(45)34(48)43-29(19-23-20-41-27-6-3-2-5-26(23)27)33(47)42-28(32(38)46)17-21-8-12-24(37)13-9-21/h2-3,5-6,8-15,20,28-31,41H,4,7,16-19H2,1H3,(H2,38,46)(H,42,47)(H,43,48)(H4,39,40,44)/t28-,29-,30-,31-/m0/s1
DM8QTSU CS COC1=CC=C(C=C1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=C(C=C5)Cl)C(=O)N)N=C(N)N
DM8QTSU IK IEBSBPORJZXBGY-ORYMTKCHSA-N
DM8QTSU IU (2S)-N-[(2S)-1-[[(2S)-1-amino-3-(4-chlorophenyl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-1-[(2S)-2-(diaminomethylideneamino)-3-(4-methoxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DM8QTSU DE Discovery agent
DMSC9FV ID DMSC9FV
DMSC9FV DN N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2
DMSC9FV HS Investigative
DMSC9FV SN CHEMBL390271; BDBM50201414; N alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2
DMSC9FV DT Small molecular drug
DMSC9FV PC 44428305
DMSC9FV MW 666.8
DMSC9FV FM C36H42N8O5
DMSC9FV IC InChI=1S/C36H42N8O5/c1-49-25-15-13-23(14-16-25)19-30(43-36(38)39)35(48)44-17-7-12-31(44)34(47)42-29(20-24-21-40-27-11-6-5-10-26(24)27)33(46)41-28(32(37)45)18-22-8-3-2-4-9-22/h2-6,8-11,13-16,21,28-31,40H,7,12,17-20H2,1H3,(H2,37,45)(H,41,46)(H,42,47)(H4,38,39,43)/t28-,29-,30-,31-/m0/s1
DMSC9FV CS COC1=CC=C(C=C1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC5=CC=CC=C5)C(=O)N)N=C(N)N
DMSC9FV IK QKBVJESURFKHSK-ORYMTKCHSA-N
DMSC9FV IU (2S)-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-1-[(2S)-2-(diaminomethylideneamino)-3-(4-methoxyphenyl)propanoyl]pyrrolidine-2-carboxamide
DMSC9FV DE Discovery agent
DMRAN5O ID DMRAN5O
DMRAN5O DN Naltrexone-6-alpha-ol
DMRAN5O HS Investigative
DMRAN5O SN CHEMBL468469; 20410-98-4; SCHEMBL679581; ZINC1656961; BDBM50254511; FT-0672601; 17-(Cyclopropylmethyl)-4,5; A-epoxy-morphinan-3,6; A,14-triol; A)-17-(Cyclopropylmethyl)-4,5-epoxy-morphinan-3,6,14-triol; 6alpha-Naltrexol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
DMRAN5O DT Small molecular drug
DMRAN5O PC 16099582
DMRAN5O MW 343.4
DMRAN5O FM C20H25NO4
DMRAN5O IC InChI=1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15+,18-,19-,20+/m0/s1
DMRAN5O CS C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@H]1O)OC5=C(C=C4)O)O
DMRAN5O IK JLVNEHKORQFVQJ-SBCNTATESA-N
DMRAN5O IU (4R,4aS,7S,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
DMRAN5O DE Discovery agent
DMNDOLZ ID DMNDOLZ
DMNDOLZ DN naltriben
DMNDOLZ HS Investigative
DMNDOLZ SN Naltrindole benzofuran; Naltriben; naltrindole benzofuran; 4,8-Methano-5H-bisbenzofuro(3,2-e:2',3'-g)isoquinoline-1,8a(9H)-diol, 7-(cyclopropylmethyl)-6,7,8,14b-tetrahydro-, (8R-(4bS*,8alpha,8beta,14bbeta))-; 111555-58-9; C26H25NO4; [3H]naltriben; [3H]-naltriben; NTB; naltrindolebenzofuran; GTPL1640; SCHEMBL1240717; CHEMBL100940; GTPL3828; BDBM82552; HMS2089G18; ZINC3874478; PDSP2_001551; LS-172157; CAS_111555-58-9; C20166; AB00691672-07; naltrindole benzofuran
DMNDOLZ DT Small molecular drug
DMNDOLZ PC 5486827
DMNDOLZ MW 415.5
DMNDOLZ FM C26H25NO4
DMNDOLZ IC InChI=1S/C26H25NO4/c28-18-8-7-15-11-20-26(29)12-17-16-3-1-2-4-19(16)30-22(17)24-25(26,21(15)23(18)31-24)9-10-27(20)13-14-5-6-14/h1-4,7-8,14,20,24,28-29H,5-6,9-13H2/t20-,24+,25+,26-/m1/s1
DMNDOLZ CS C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8O6
DMNDOLZ IK ZHVWWEYETMPAMX-IFKAHUTRSA-N
DMNDOLZ IU (1S,2S,13R,21R)-22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
DMNDOLZ CA CAS 111555-58-9
DMNDOLZ DE Discovery agent
DMWXBYC ID DMWXBYC
DMWXBYC DN N-Aminoethylmorpholine
DMWXBYC HS Investigative
DMWXBYC SN 4-(2-Aminoethyl)morpholine; 2038-03-1; 2-morpholinoethanamine; 4-Morpholineethanamine; 2-Morpholinoethylamine; N-Aminoethylmorpholine; 2-(Morpholin-4-Yl)Ethan-1-Amine; N-(2-Aminoethyl)morpholine; Morpholine, 4-(2-aminoethyl)-; N-2-Aminoethylmorpholine; 2-morpholin-4-ylethanamine; 2-morpholin-4-ylethylamine; 2-Morpholin-4-yl-ethylamine; N-2-Aminoethylmorfolin [Czech]; n-aminoethyl morpholine; N-2-Aminoethylmorfolin; N-(Aminoethyl)morpholine; beta-Aminoaethyl-morpholin [German]; 2-morpholino-1-ethanamine
DMWXBYC DT Small molecular drug
DMWXBYC PC 408285
DMWXBYC MW 130.19
DMWXBYC FM C6H14N2O
DMWXBYC IC InChI=1S/C6H14N2O/c7-1-2-8-3-5-9-6-4-8/h1-7H2
DMWXBYC CS C1COCCN1CCN
DMWXBYC IK RWIVICVCHVMHMU-UHFFFAOYSA-N
DMWXBYC IU 2-morpholin-4-ylethanamine
DMWXBYC CA CAS 2038-03-1
DMWXBYC DE Discovery agent
DM1EZ3N ID DM1EZ3N
DM1EZ3N DN Namn
DM1EZ3N HS Investigative
DM1EZ3N SN NaMN; nicotinate mononucleotide; 321-02-8; nicotinic acid mononucleotide; Nicotinic acid mono nucleotide; AC1NRCHP; NCN; DB02382; 3-carboxy-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridinium; [(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; [(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate; ((2R,3S,4R,5R)-5-(3-carboxypyridinium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate
DM1EZ3N DT Small molecular drug
DM1EZ3N PC 5288991
DM1EZ3N MW 335.2
DM1EZ3N FM C11H14NO9P
DM1EZ3N IC InChI=1S/C11H14NO9P/c13-8-7(5-20-22(17,18)19)21-10(9(8)14)12-3-1-2-6(4-12)11(15)16/h1-4,7-10,13-14H,5H2,(H2-,15,16,17,18,19)/t7-,8-,9-,10-/m1/s1
DM1EZ3N CS C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)O
DM1EZ3N IK JOUIQRNQJGXQDC-ZYUZMQFOSA-N
DM1EZ3N IU [(2R,3S,4R,5R)-5-(3-carboxypyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
DM1EZ3N CA CAS 321-02-8
DM1EZ3N DE Discovery agent
DMYDRB7 ID DMYDRB7
DMYDRB7 DN Naphthalen-1-yl 10H-phenothiazine-10-carboxylate
DMYDRB7 HS Investigative
DMYDRB7 SN CHEMBL451838; naphthalen-1-yl 10H-phenothiazine-10-carboxylate; naphthyl phenothiazine-10-carboxylate; BDBM50292622; ZINC27529770; AKOS002279100
DMYDRB7 DT Small molecular drug
DMYDRB7 PC 16645664
DMYDRB7 MW 369.4
DMYDRB7 FM C23H15NO2S
DMYDRB7 IC InChI=1S/C23H15NO2S/c25-23(26-20-13-7-9-16-8-1-2-10-17(16)20)24-18-11-3-5-14-21(18)27-22-15-6-4-12-19(22)24/h1-15H
DMYDRB7 CS C1=CC=C2C(=C1)C=CC=C2OC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DMYDRB7 IK BJICBLMMTYZFKB-UHFFFAOYSA-N
DMYDRB7 IU naphthalen-1-yl phenothiazine-10-carboxylate
DMYDRB7 DE Discovery agent
DM93CZW ID DM93CZW
DM93CZW DN Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone
DM93CZW HS Investigative
DM93CZW SN CHEMBL240899; naphthalen-1-yl(10H-phenothiazin-10-yl)methanone
DM93CZW DT Small molecular drug
DM93CZW PC 44435217
DM93CZW MW 353.4
DM93CZW FM C23H15NOS
DM93CZW IC InChI=1S/C23H15NOS/c25-23(18-11-7-9-16-8-1-2-10-17(16)18)24-19-12-3-5-14-21(19)26-22-15-6-4-13-20(22)24/h1-15H
DM93CZW CS C1=CC=C2C(=C1)C=CC=C2C(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DM93CZW IK JJKRMXKTTVOCBF-UHFFFAOYSA-N
DM93CZW IU naphthalen-1-yl(phenothiazin-10-yl)methanone
DM93CZW DE Discovery agent
DM08W6U ID DM08W6U
DM08W6U DN Naphthalen-2-yl 10H-phenothiazine-10-carboxylate
DM08W6U HS Investigative
DM08W6U SN CHEMBL518302; naphthalen-2-yl 10H-phenothiazine-10-carboxylate
DM08W6U DT Small molecular drug
DM08W6U PC 24905710
DM08W6U MW 369.4
DM08W6U FM C23H15NO2S
DM08W6U IC InChI=1S/C23H15NO2S/c25-23(26-18-14-13-16-7-1-2-8-17(16)15-18)24-19-9-3-5-11-21(19)27-22-12-6-4-10-20(22)24/h1-15H
DM08W6U CS C1=CC=C2C=C(C=CC2=C1)OC(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DM08W6U IK DFCQYZLDLAWXGY-UHFFFAOYSA-N
DM08W6U IU naphthalen-2-yl phenothiazine-10-carboxylate
DM08W6U DE Discovery agent
DMDXM2A ID DMDXM2A
DMDXM2A DN Naphthalen-2-yl cyclohexylcarbamate
DMDXM2A HS Investigative
DMDXM2A SN naphthalen-2-yl cyclohexylcarbamate; CHEMBL77250; NSC204269; AC1L796V; SCHEMBL1690685; ZINC1738803; BDBM50128573; naphthalen-2-yl N-cyclohexylcarbamate; NSC-204269; Cyclohexyl-carbamic acid naphthalen-2-yl ester; US8815951, 110
DMDXM2A DT Small molecular drug
DMDXM2A PC 306585
DMDXM2A MW 269.34
DMDXM2A FM C17H19NO2
DMDXM2A IC InChI=1S/C17H19NO2/c19-17(18-15-8-2-1-3-9-15)20-16-11-10-13-6-4-5-7-14(13)12-16/h4-7,10-12,15H,1-3,8-9H2,(H,18,19)
DMDXM2A CS C1CCC(CC1)NC(=O)OC2=CC3=CC=CC=C3C=C2
DMDXM2A IK ZYHUWMGJJOBBCF-UHFFFAOYSA-N
DMDXM2A IU naphthalen-2-yl N-cyclohexylcarbamate
DMDXM2A DE Discovery agent
DMW8BXG ID DMW8BXG
DMW8BXG DN Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone
DMW8BXG HS Investigative
DMW8BXG SN CHEMBL240900; naphthalen-2-yl(10H-phenothiazin-10-yl)methanone
DMW8BXG DT Small molecular drug
DMW8BXG PC 44435218
DMW8BXG MW 353.4
DMW8BXG FM C23H15NOS
DMW8BXG IC InChI=1S/C23H15NOS/c25-23(18-14-13-16-7-1-2-8-17(16)15-18)24-19-9-3-5-11-21(19)26-22-12-6-4-10-20(22)24/h1-15H
DMW8BXG CS C1=CC=C2C=C(C=CC2=C1)C(=O)N3C4=CC=CC=C4SC5=CC=CC=C53
DMW8BXG IK VEKGHAIWOIIXFF-UHFFFAOYSA-N
DMW8BXG IU naphthalen-2-yl(phenothiazin-10-yl)methanone
DMW8BXG DE Discovery agent
DML6FI3 ID DML6FI3
DML6FI3 DN Naphthalene Trisulfonate
DML6FI3 HS Investigative
DML6FI3 SN naphthalene-1,3,6-trisulfonic acid; 86-66-8; 1,3,6-Naphthalenetrisulfonic acid; Naphthalene-1,3,6-trisulphonic acid; CHEBI:32916; 123409-01-8; EINECS 201-690-8; AC1Q6WKO; 6321-17-1; 19437-42-4; SCHEMBL305166; AC1L1I64; CHEMBL1160117; DTXSID9058945; CTK2F6984; ZPBSAMLXSQCSOX-UHFFFAOYSA-N; ZINC1664865; Naphtalene-1,3,6-trisulfonic acid; 3611AC; AKOS015964183; OR51840; AJ-28977; AX8143250; KB-258586; ST50826289; 1,3, -Naphthalenetrisulfonicacid, trisodium salt, hydrate (9CI)
DML6FI3 DT Small molecular drug
DML6FI3 PC 4437
DML6FI3 MW 365.3
DML6FI3 FM C10H5O9S3-3
DML6FI3 IC InChI=1S/C10H8O9S3/c11-20(12,13)7-1-2-9-6(3-7)4-8(21(14,15)16)5-10(9)22(17,18)19/h1-5H,(H,11,12,13)(H,14,15,16)(H,17,18,19)/p-3
DML6FI3 CS C1=CC2=C(C=C(C=C2C=C1S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-]
DML6FI3 IK ZPBSAMLXSQCSOX-UHFFFAOYSA-K
DML6FI3 IU naphthalene-1,3,6-trisulfonate
DML6FI3 CA CAS 19437-42-4
DML6FI3 CB CHEBI:44434
DML6FI3 DE Discovery agent
DMOQ43W ID DMOQ43W
DMOQ43W DN Naphthalene-1,4-diol
DMOQ43W HS Investigative
DMOQ43W SN Naphthalene-1,4-diol; 1,4-Dihydroxynaphthalene; 571-60-8; 1,4-NAPHTHALENEDIOL; 1,4-Naphthohydroquinone; Hydronaphthoquinone; Naphthohydroquinone; 1,4-Naphthoquinol; alpha-Naphthoquinhydrone; UNII-AML1P6T42C; CCRIS 7897; Naphthalene-1,4-dio; alpha-Naphthohydroquinone; EINECS 209-336-4; BRN 1307689; AML1P6T42C; CHEMBL206816; CHEBI:34063; PCILLCXFKWDRMK-UHFFFAOYSA-N; 1,4-Naphththalenediol; 1-Hydroxy-4-naphthol; 1,4-Naphthalene diol; napthalene- 1,4-diol; ACMC-1AXHC; Naphthalenediol-(1,4); 1,4-Dihydroxy-naphthalene; AC1L1X2M
DMOQ43W DT Small molecular drug
DMOQ43W PC 11305
DMOQ43W MW 160.17
DMOQ43W FM C10H8O2
DMOQ43W IC InChI=1S/C10H8O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6,11-12H
DMOQ43W CS C1=CC=C2C(=C1)C(=CC=C2O)O
DMOQ43W IK PCILLCXFKWDRMK-UHFFFAOYSA-N
DMOQ43W IU naphthalene-1,4-diol
DMOQ43W CA CAS 571-60-8
DMOQ43W CB CHEBI:34063
DMOQ43W DE Discovery agent
DMLHWNG ID DMLHWNG
DMLHWNG DN Naphthalene-2,6-disulfonic acid
DMLHWNG HS Investigative
DMLHWNG SN Naphthalene-2,6-disulfonic acid; 581-75-9; 2,6-NAPHTHALENEDISULFONIC ACID; 2,6-Naphthalene disulfonic acid; Ebert-Merz beta-acid; Naphthalene-2,6-disulphonic acid; UNII-BOR133U3TN; Ebert-Merz .beta.-acid; BOR133U3TN; CHEBI:41070; NSC37041; BIH; EINECS 209-471-9; NSC 37041; AC1L1X9A; 2,6-Naphthalenedisulfonicacid; SCHEMBL300937; CHEMBL1206869; DTXSID2060385; CTK1H0701; 2, 6-Naphthalenedisulfonic acid; FITZJYAVATZPMJ-UHFFFAOYSA-N; ZINC1669723; NSC-37041; AKOS015897573; OR51838; 2,6-NAPHTHALENEDISULPHONIC ACID; VZ33464; 1655-45-4 (di-hyd
DMLHWNG DT Small molecular drug
DMLHWNG PC 11390
DMLHWNG MW 288.3
DMLHWNG FM C10H8O6S2
DMLHWNG IC InChI=1S/C10H8O6S2/c11-17(12,13)9-3-1-7-5-10(18(14,15)16)4-2-8(7)6-9/h1-6H,(H,11,12,13)(H,14,15,16)
DMLHWNG CS C1=CC2=C(C=CC(=C2)S(=O)(=O)O)C=C1S(=O)(=O)O
DMLHWNG IK FITZJYAVATZPMJ-UHFFFAOYSA-N
DMLHWNG IU naphthalene-2,6-disulfonic acid
DMLHWNG CA CAS 581-75-9
DMLHWNG CB CHEBI:41070
DMLHWNG DE Discovery agent
DMG8A74 ID DMG8A74
DMG8A74 DN Naphthalene-2-carboxylic acid hydroxyamide
DMG8A74 HS Investigative
DMG8A74 SN 2-Naphthohydroximic acid; 2-Naphthylhydroxamic acid; N,N-Naphthaloylhydroxylamine; 2-NAPHTHOHYDROXAMIC ACID; 10335-79-2; 2-Naphthoylhydroxamic acid; 2-Naphthalenecarboxamide, N-hydroxy-; N-Hydroxy-2-naphthalenecarboxamide; Naphthalene-2-carboxylic acid hydroxyamide; CHEMBL156672; N-hydroxynaphthalene-2-carboxamide; SCHEMBL6010034; AC1L18K7; DTXSID70145795; KUC110312N; BDBM50015160; AKOS000178377; KSC-264-28-1; LS-95339; 2-Naphthalenecarboxamide, N-hydroxy- (9CI)
DMG8A74 DT Small molecular drug
DMG8A74 PC 25164
DMG8A74 MW 187.19
DMG8A74 FM C11H9NO2
DMG8A74 IC InChI=1S/C11H9NO2/c13-11(12-14)10-6-5-8-3-1-2-4-9(8)7-10/h1-7,14H,(H,12,13)
DMG8A74 CS C1=CC=C2C=C(C=CC2=C1)C(=O)NO
DMG8A74 IK PCJLUGWQCHMMAG-UHFFFAOYSA-N
DMG8A74 IU N-hydroxynaphthalene-2-carboxamide
DMG8A74 CA CAS 10335-79-2
DMG8A74 DE Discovery agent
DMTWEQP ID DMTWEQP
DMTWEQP DN Naphthyridinomycin
DMTWEQP HS Investigative
DMTWEQP SN AC1MJ44U; 62046-87-1; DADMe-ImmH
DMTWEQP PC 102148112
DMTWEQP MW 417.5
DMTWEQP FM C21H27N3O6
DMTWEQP IC InChI=1S/C21H27N3O6/c1-8-17(26)13-12(18(27)19(8)29-3)11(7-25)24-16-14-9(6-10(20(24)28)22(14)2)21-23(15(13)16)4-5-30-21/h9-11,14-16,20-21,25,28H,4-7H2,1-3H3/t9?,10?,11-,14?,15+,16+,20-,21+/m0/s1
DMTWEQP CS CC1=C(C(=O)C2=C(C1=O)[C@@H]3[C@H]4C5C(CC(N5C)[C@@H](N4[C@H]2CO)O)[C@@H]6N3CCO6)OC
DMTWEQP IK SXDWNOFDSOXRRM-KZXGJYSISA-N
DMTWEQP IU (4R,9R,16R,18R,21S)-21-hydroxy-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-5-oxa-8,17,20-triazahexacyclo[15.3.1.03,19.04,8.09,18.010,15]henicosa-10(15),12-diene-11,14-dione
DMTWEQP DE Discovery agent
DM0OEGV ID DM0OEGV
DM0OEGV DN NAPHTHYRIDINONE
DM0OEGV HS Investigative
DM0OEGV SN NAPHTHYRIDINONE; CHEMBL204232; N-[3-Acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl]acetamide; N-(3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)acetamide; SCHEMBL762298; VHSIAYLBCLUAFT-UHFFFAOYSA-N
DM0OEGV DT Small molecular drug
DM0OEGV PC 11386747
DM0OEGV MW 514.799
DM0OEGV FM C25H18Cl3N3O3
DM0OEGV IC InChI=1S/C25H18Cl3N3O3/c1-12(32)21-23(29-13(2)33)19-11-18(14-4-6-15(26)7-5-14)22(30-24(19)31(3)25(21)34)17-9-8-16(27)10-20(17)28/h4-11H,1-3H3,(H,29,33)
DM0OEGV CS CC(=O)C1=C(C2=CC(=C(N=C2N(C1=O)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)NC(=O)C
DM0OEGV IK VHSIAYLBCLUAFT-UHFFFAOYSA-N
DM0OEGV IU N-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide
DM0OEGV DE Discovery agent
DM8F5LR ID DM8F5LR
DM8F5LR DN NAPQI
DM8F5LR HS Investigative
DM8F5LR SN Napqi; Acetimidoquinone; 50700-49-7; N-acetyl-4-benzoquinone imine; N-Acetyl-4-benzoquinoneimine; N-Acetyl-p-benzoquinone imine; N-Acetylbenzoquinoneimine; N-Acetyl-P-benzoquinoneimine; N-Acetyl-p-quinonimine; N-Acetyl-p-benzoquinone; N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide; UNII-G6S9BN13TI; CCRIS 5789; N-acetyl-1,4-benzoquinone imine; BRN 2435621; G6S9BN13TI; 2,5-Cyclohexadien-1-one, 4-acetylimino-; N-(4-Oxo-2,5-cyclohexadienylidene)acetamide; CHEBI:29132; N-(4-Oxo-2,5-cyclohexadien-1-ylidene)acetamide; Acetamide, N-(4
DM8F5LR DT Small molecular drug
DM8F5LR PC 39763
DM8F5LR MW 149.15
DM8F5LR FM C8H7NO2
DM8F5LR IC InChI=1S/C8H7NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5H,1H3
DM8F5LR CS CC(=O)N=C1C=CC(=O)C=C1
DM8F5LR IK URNSECGXFRDEDC-UHFFFAOYSA-N
DM8F5LR IU N-(4-oxocyclohexa-2,5-dien-1-ylidene)acetamide
DM8F5LR CA CAS 50700-49-7
DM8F5LR CB CHEBI:29132
DM8F5LR DE Autoimmune disease
DM85RJ1 ID DM85RJ1
DM85RJ1 DN N-arachidonoylglycine
DM85RJ1 HS Investigative
DM85RJ1 SN NAGly
DM85RJ1 DT Small molecular drug
DM85RJ1 PC 5283389
DM85RJ1 MW 361.5
DM85RJ1 FM C22H35NO3
DM85RJ1 IC InChI=1S/C22H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21(24)23-20-22(25)26/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-20H2,1H3,(H,23,24)(H,25,26)/b7-6-,10-9-,13-12-,16-15-
DM85RJ1 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCC(=O)O
DM85RJ1 IK YLEARPUNMCCKMP-DOFZRALJSA-N
DM85RJ1 IU 2-[[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]amino]acetic acid
DM85RJ1 CA CAS 179113-91-8
DM85RJ1 CB CHEBI:58961
DM85RJ1 DE Discovery agent
DMF9U2O ID DMF9U2O
DMF9U2O DN N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMF9U2O HS Investigative
DMF9U2O SN CHEMBL204403; N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine
DMF9U2O DT Small molecular drug
DMF9U2O PC 11559610
DMF9U2O MW 363.5
DMF9U2O FM C22H37NO3
DMF9U2O IC InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23(26)20-21-24/h6-7,9-10,12-13,15-16,24,26H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMF9U2O CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)N(CCO)O
DMF9U2O IK GSKSTUBDYCGHNA-DOFZRALJSA-N
DMF9U2O IU (5Z,8Z,11Z,14Z)-N-hydroxy-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide
DMF9U2O DE Discovery agent
DM49HIO ID DM49HIO
DM49HIO DN N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine
DM49HIO HS Investigative
DM49HIO SN CHEMBL382444; N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine; 883296-70-6; MolPort-009-019-187; HMS3650G10; BDBM50185034; ZINC13685181; 1875AH; SR-01000946282; SR-01000946282-1
DM49HIO DT Small molecular drug
DM49HIO PC 11710300
DM49HIO MW 363.5
DM49HIO FM C22H37NO3
DM49HIO IC InChI=1S/C22H37NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-26-21-20-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-
DM49HIO CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NOCCO
DM49HIO IK ANMKTCMIIFBOGG-DOFZRALJSA-N
DM49HIO IU (5Z,8Z,11Z,14Z)-N-(2-hydroxyethoxy)icosa-5,8,11,14-tetraenamide
DM49HIO DE Discovery agent
DMLVGT8 ID DMLVGT8
DMLVGT8 DN N-arachidonylmaleimide
DMLVGT8 HS Investigative
DMLVGT8 SN N-Arachidonylmaleimide; N-Arachidonyl Maleimide; CHEMBL561924; BDBM50295658; 876305-42-9; SCHEMBL5086361; BDBM60419; GZNZRHSGGQUYAP-DOFZRALJSA-N; MolPort-019-939-191; HMS3650G15; ZINC27645447; 1913AH; N-Arachidonylmaleimide, > SR-01000946786; SR-01000946786-1; Eicosa-5Z,8Z,11Z,14Z-tetraenyl-1-pyrrole-2,5-dione
DMLVGT8 DT Small molecular drug
DMLVGT8 PC 25021164
DMLVGT8 MW 369.5
DMLVGT8 FM C24H35NO2
DMLVGT8 IC InChI=1S/C24H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-25-23(26)20-21-24(25)27/h6-7,9-10,12-13,15-16,20-21H,2-5,8,11,14,17-19,22H2,1H3/b7-6-,10-9-,13-12-,16-15-
DMLVGT8 CS CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCN1C(=O)C=CC1=O
DMLVGT8 IK GZNZRHSGGQUYAP-DOFZRALJSA-N
DMLVGT8 IU 1-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl]pyrrole-2,5-dione
DMLVGT8 DE Discovery agent
DMI7A6R ID DMI7A6R
DMI7A6R DN Narciclasine
DMI7A6R HS Investigative
DMI7A6R SN Narciclasine; Lycoricidinol; 29477-83-6; Lycoricidin-A; Narciclasina; NSC 266535; BRN 1087400; NSC266535; Lycorcidinol; Nacriclasine; C14H13NO7; CHEMBL98745; 3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one; CHEBI:70169; (2s,3r,4s,4ar)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2h)-one; (2S,3R,4S,4aR)-2,3,4,7-Tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
DMI7A6R DT Small molecular drug
DMI7A6R PC 72376
DMI7A6R MW 307.25
DMI7A6R FM C14H13NO7
DMI7A6R IC InChI=1S/C14H13NO7/c16-6-1-5-4-2-7-13(22-3-21-7)11(18)8(4)14(20)15-9(5)12(19)10(6)17/h1-2,6,9-10,12,16-19H,3H2,(H,15,20)/t6-,9+,10+,12-/m0/s1
DMI7A6R CS C1OC2=C(O1)C(=C3C(=C2)C4=C[C@@H]([C@H]([C@H]([C@@H]4NC3=O)O)O)O)O
DMI7A6R IK LZAZURSABQIKGB-AEKGRLRDSA-N
DMI7A6R IU (2S,3R,4S,4aR)-2,3,4,7-tetrahydroxy-3,4,4a,5-tetrahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one
DMI7A6R CA CAS 29477-83-6
DMI7A6R CB CHEBI:70169
DMI7A6R DE Melanoma
DM4DG1Y ID DM4DG1Y
DM4DG1Y DN Naringin
DM4DG1Y HS Investigative
DM4DG1Y SN Naringoside; AC1NR4U8; 4',5,7-Trihydroxyflavanone-7-rutinoside; 4',5,7-Trihydroxyflavanone-7-rhamnoglucoside
DM4DG1Y DT Small molecular drug
DM4DG1Y PC 442428
DM4DG1Y MW 580.5
DM4DG1Y FM C27H32O14
DM4DG1Y IC InChI=1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
DM4DG1Y CS C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O
DM4DG1Y IK DFPMSGMNTNDNHN-ZPHOTFPESA-N
DM4DG1Y IU (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DM4DG1Y CA CAS 10236-47-2
DM4DG1Y CB CHEBI:28819
DM4DG1Y DE Discovery agent
DMMUABE ID DMMUABE
DMMUABE DN Naringin
DMMUABE HS Investigative
DMMUABE SN Naringenin 7-O-neohesperidoside; Naringenin 7-Rhamnoglucoside; Naringenin,(S); Naringenine-7-rhamnosidoglucoside; Naringin hydrate; Naringoside; SR-01000736681; aurantiin; naringin; (2S)-Naringin; 10236-47-2; 4',5,7-trihydroxyflavanone 7-rhamnoglucoside; 4'5-diOH-Flavone-7-rhgluc; AI3-19008; C27H32O14; CHEBI:28819; CHEMBL451532; EINECS 233-566-4; MFCD00148888; N7TD9J649B; Naringenin 7-O-[alpha-L-rhamnosyl-(1->2)-beta-D-glucoside]; Naringenin-7-beta-neohesperidoside; UNII-N7TD9J649B
DMMUABE PC 442428
DMMUABE MW 580.5
DMMUABE FM C27H32O14
DMMUABE IC DFPMSGMNTNDNHN-ZPHOTFPESA-N
DMMUABE CS CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O
DMMUABE IK 1S/C27H32O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-7,10,16,18,20-30,32-36H,8-9H2,1H3/t10-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
DMMUABE IU (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
DMMUABE CA CAS 10236-47-2
DMMUABE CB CHEBI:28819
DMMUABE DE Ovarian cancer
DM3RP25 ID DM3RP25
DM3RP25 DN NAVPNLRGDLQVLAQKVART
DM3RP25 HS Investigative
DM3RP25 PC 91935374
DM3RP25 MW 2163.5
DM3RP25 FM C93H163N31O28
DM3RP25 IC InChI=1S/C93H163N31O28/c1-41(2)34-57(82(142)108-47(13)73(133)112-55(26-28-63(96)126)78(138)114-53(22-17-18-30-94)79(139)120-69(44(7)8)88(148)109-48(14)74(134)111-54(24-20-32-105-93(102)103)80(140)123-72(50(16)125)91(151)152)119-89(149)70(45(9)10)121-81(141)56(27-29-64(97)127)115-84(144)59(36-43(5)6)117-86(146)61(39-68(131)132)110-67(130)40-106-77(137)52(23-19-31-104-92(100)101)113-83(143)58(35-42(3)4)116-85(145)60(38-66(99)129)118-87(147)62-25-21-33-124(62)90(150)71(46(11)12)122-75(135)49(15)107-76(136)51(95)37-65(98)128/h41-62,69-72,125H,17-40,94-95H2,1-16H3,(H2,96,126)(H2,97,127)(H2,98,128)(H2,99,129)(H,106,137)(H,107,136)(H,108,142)(H,109,148)(H,110,130)(H,111,134)(H,112,133)(H,113,143)(H,114,138)(H,115,144)(H,116,145)(H,117,146)(H,118,147)(H,119,149)(H,120,139)(H,121,141)(H,122,135)(H,123,140)(H,131,132)(H,151,152)(H4,100,101,104)(H4,102,103,105)/t47-,48-,49-,50+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,69-,70-,71-,72-/m0/s1
DM3RP25 CS C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)N)O
DM3RP25 IK BIPRZBFRCFOBDQ-KAGUSELOSA-N
DM3RP25 IU (3S)-4-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid
DM3RP25 DE Discovery agent
DMO6T9C ID DMO6T9C
DMO6T9C DN NAX-5055
DMO6T9C HS Investigative
DMO6T9C DE Epileptic seizures
DMNM6GQ ID DMNM6GQ
DMNM6GQ DN NB3178
DMNM6GQ HS Investigative
DMNM6GQ CP New biotics
DMNM6GQ DE Gram-positive bacterial infection
DM7K36E ID DM7K36E
DM7K36E DN NB-325
DM7K36E HS Investigative
DM7K36E SN PEHMB; Polyethylene hexamethylene biguanide
DM7K36E CP Novaflux Biosciences Inc
DM7K36E DT Small molecular drug
DM7K36E PC 15954275
DM7K36E MW 495.5
DM7K36E FM C16H36Cl2N14
DM7K36E IC InChI=1S/C16H34N14.2ClH/c17-5-8-27-15(22)29-13(20)25-6-3-1-2-4-7-26-14(21)30-16(23)28-10-9-24-12(19)11-18;;/h1-10,17H2,(H2,19,24)(H5,20,22,25,27,29)(H5,21,23,26,28,30);2*1H
DM7K36E CS C(CCC[NH+]=C(N)NC(=NCCN=C(C#N)N)N)CC[NH+]=C(N)NC(=NCCN)N.[Cl-].[Cl-]
DM7K36E IK CNGBVJCBMLEXDO-UHFFFAOYSA-N
DM7K36E IU [amino-[[N'-[2-[[amino(cyano)methylidene]amino]ethyl]carbamimidoyl]amino]methylidene]-[6-[amino-[[N'-(2-aminoethyl)carbamimidoyl]amino]methylidene]azaniumylhexyl]azanium;dichloride
DM7K36E DE Human immunodeficiency virus infection
DMJHWGS ID DMJHWGS
DMJHWGS DN NB3322
DMJHWGS HS Investigative
DMJHWGS CP New biotics
DMJHWGS DE Gram-positive bacterial infection
DMTZ1XV ID DMTZ1XV
DMTZ1XV DN NBBCC
DMTZ1XV HS Investigative
DMTZ1XV SN N-Butyl-beta-carboline-3-carboxylate; beta-Ccb; 84454-35-3; N-Butyl beta-carboline-3-carboxylate; butyl; butyl 9H-pyrido[3,4-b]indole-3-carboxylate; beta-CARBOLINE-3-CARBOXYLIC ACID BUTYL ESTER; WGNGIELOOKACSB-UHFFFAOYSA-N; Tocris-0405; Biomol-NT_000274; AC1Q66WT; I(2)-CCB; GTPL2374; SCHEMBL2214572; CHEMBL148296; BPBio1_001057; AC1L2U46; CHEBI:34867; Butyl -carboline-3-carboxylate; DTXSID90233426; MolPort-023-275-884; HMS3266M05; Butyl beta-carboline-3-carboxylate; ZINC2555360; Butyl; n-butyl-beta-carboline-3-carboxylate
DMTZ1XV DT Small molecular drug
DMTZ1XV PC 128618
DMTZ1XV MW 268.31
DMTZ1XV FM C16H16N2O2
DMTZ1XV IC InChI=1S/C16H16N2O2/c1-2-3-8-20-16(19)14-9-12-11-6-4-5-7-13(11)18-15(12)10-17-14/h4-7,9-10,18H,2-3,8H2,1H3
DMTZ1XV CS CCCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2
DMTZ1XV IK WGNGIELOOKACSB-UHFFFAOYSA-N
DMTZ1XV IU butyl 9H-pyrido[3,4-b]indole-3-carboxylate
DMTZ1XV CA CAS 84454-35-3
DMTZ1XV CB CHEBI:34867
DMTZ1XV DE Discovery agent
DMX0Y79 ID DMX0Y79
DMX0Y79 DN N-BENZOYL-D-ALANINE
DMX0Y79 HS Investigative
DMX0Y79 SN n-benzoyl-d-alanine; Bz-D-Ala-Oh; 17966-60-8; D-Alanine, N-benzoyl-; BZO-D-ALA-OH; 2-Benzoylamino-propionic acid; Benzoyl-D-Alanine; N-Benzoyl-D-Ala-OH; AC1Q5JMF; AC1Q29AE; AC1L3M8G; CHEMBL55771; (R)-2-benzamidopropanoic acid; SCHEMBL2796740; (2R)-2-benzamidopropanoic acid; CTK0H2174; ANW-60729; ZINC82068115; 9422AA; AKOS000352443; DB08508; AB02521; (2R)-2-(phenylformamido)propanoic acid; KB-48541; AS-48959; AJ-11083; TC-149474; FT-0695165
DMX0Y79 DT Small molecular drug
DMX0Y79 PC 91514
DMX0Y79 MW 193.2
DMX0Y79 FM C10H11NO3
DMX0Y79 IC InChI=1S/C10H11NO3/c1-7(10(13)14)11-9(12)8-5-3-2-4-6-8/h2-7H,1H3,(H,11,12)(H,13,14)/t7-/m1/s1
DMX0Y79 CS C[C@H](C(=O)O)NC(=O)C1=CC=CC=C1
DMX0Y79 IK UAQVHNZEONHPQG-SSDOTTSWSA-N
DMX0Y79 IU (2R)-2-benzamidopropanoic acid
DMX0Y79 DE Discovery agent
DM7U81L ID DM7U81L
DM7U81L DN N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea
DM7U81L HS Investigative
DM7U81L SN N-BENZOYL-N'-BETA-D-GLUCOPYRANOSYL UREA; CHEMBL489799; BZD; 2qnb; DB04295; AC1L9JVC; SCHEMBL4311564; 1k08; 1k06; BDBM50263771; 1-(beta-D-Glucopyranosyl)-3-benzoylurea; N-BENZOYL-N''-BETA-D-GLUCOPYRANOSYL UREA; N-[(phenylcarbonyl)carbamoyl]-beta-D-glucopyranosylamine; N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide; N-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-ylcarbamoyl)benzamide
DM7U81L DT Small molecular drug
DM7U81L PC 446600
DM7U81L MW 326.3
DM7U81L FM C14H18N2O7
DM7U81L IC InChI=1S/C14H18N2O7/c17-6-8-9(18)10(19)11(20)13(23-8)16-14(22)15-12(21)7-4-2-1-3-5-7/h1-5,8-11,13,17-20H,6H2,(H2,15,16,21,22)/t8-,9-,10+,11-,13-/m1/s1
DM7U81L CS C1=CC=C(C=C1)C(=O)NC(=O)N[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
DM7U81L IK JSBCZGSPFATCOV-BZNQNGANSA-N
DM7U81L IU N-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide
DM7U81L DE Discovery agent
DMRJ4B1 ID DMRJ4B1
DMRJ4B1 DN N-benzoyl-phenylalanyl-glycine-nitrile
DMRJ4B1 HS Investigative
DMRJ4B1 SN phenylalanine derivative, 43; SCHEMBL5517755; CHEMBL371466; BDBM20119
DMRJ4B1 DT Small molecular drug
DMRJ4B1 PC 11702265
DMRJ4B1 MW 307.3
DMRJ4B1 FM C18H17N3O2
DMRJ4B1 IC InChI=1S/C18H17N3O2/c19-11-12-20-18(23)16(13-14-7-3-1-4-8-14)21-17(22)15-9-5-2-6-10-15/h1-10,16H,12-13H2,(H,20,23)(H,21,22)/t16-/m0/s1
DMRJ4B1 CS C1=CC=C(C=C1)C[C@@H](C(=O)NCC#N)NC(=O)C2=CC=CC=C2
DMRJ4B1 IK WEIUVZVWLANUJJ-INIZCTEOSA-N
DMRJ4B1 IU N-[(2S)-1-(cyanomethylamino)-1-oxo-3-phenylpropan-2-yl]benzamide
DMRJ4B1 DE Discovery agent
DMOQMEU ID DMOQMEU
DMOQMEU DN N-benzyl brucine
DMOQMEU HS Investigative
DMOQMEU SN BNO
DMOQMEU DT Small molecular drug
DMOQMEU PC 44358893
DMOQMEU MW 485.6
DMOQMEU FM C30H33N2O4+
DMOQMEU IC InChI=1S/C30H33N2O4/c1-34-23-13-21-22(14-24(23)35-2)31-27(33)15-25-28-20-12-26-30(21,29(28)31)9-10-32(26,17-19(20)8-11-36-25)16-18-6-4-3-5-7-18/h3-8,13-14,20,25-26,28-29H,9-12,15-17H2,1-2H3/q+1/t20-,25-,26-,28-,29-,30+,32?/m0/s1
DMOQMEU CS COC1=C(C=C2C(=C1)[C@]34CC[N+]5([C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)CC8=CC=CC=C8)OC
DMOQMEU IK XFMQETLKDRNYRE-QIBSSCBHSA-N
DMOQMEU IU (4aR,5aS,8aS,13aS,15aS,15bR)-6-benzyl-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-6-ium-14-one
DMOQMEU DE Discovery agent
DMN9WZ3 ID DMN9WZ3
DMN9WZ3 DN N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
DMN9WZ3 HS Investigative
DMN9WZ3 SN CHEMBL456005; N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
DMN9WZ3 DT Small molecular drug
DMN9WZ3 PC 44590783
DMN9WZ3 MW 347.5
DMN9WZ3 FM C24H29NO
DMN9WZ3 IC InChI=1S/C24H29NO/c1-3-4-14-26-24-13-12-22-16-21(10-11-23(22)17-24)15-19(2)25-18-20-8-6-5-7-9-20/h5-13,16-17,19,25H,3-4,14-15,18H2,1-2H3
DMN9WZ3 CS CCCCOC1=CC2=C(C=C1)C=C(C=C2)CC(C)NCC3=CC=CC=C3
DMN9WZ3 IK YIPJGAAYIMEAQI-UHFFFAOYSA-N
DMN9WZ3 IU N-benzyl-1-(6-butoxynaphthalen-2-yl)propan-2-amine
DMN9WZ3 DE Discovery agent
DMKJ6F8 ID DMKJ6F8
DMKJ6F8 DN N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
DMKJ6F8 HS Investigative
DMKJ6F8 SN CHEMBL510214; N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
DMKJ6F8 DT Small molecular drug
DMKJ6F8 PC 44590782
DMKJ6F8 MW 305.4
DMKJ6F8 FM C21H23NO
DMKJ6F8 IC InChI=1S/C21H23NO/c1-16(22-15-17-6-4-3-5-7-17)12-18-8-9-20-14-21(23-2)11-10-19(20)13-18/h3-11,13-14,16,22H,12,15H2,1-2H3
DMKJ6F8 CS CC(CC1=CC2=C(C=C1)C=C(C=C2)OC)NCC3=CC=CC=C3
DMKJ6F8 IK KYXRSMFSOLANEF-UHFFFAOYSA-N
DMKJ6F8 IU N-benzyl-1-(6-methoxynaphthalen-2-yl)propan-2-amine
DMKJ6F8 DE Discovery agent
DMHVRFM ID DMHVRFM
DMHVRFM DN N-Benzyl,N-methyl-1H-indole-2-carboxamide
DMHVRFM HS Investigative
DMHVRFM SN CHEMBL456107; N-Benzyl,N-methyl-1H-indole-2-carboxamide; BDBM50273490; AKOS008916266
DMHVRFM DT Small molecular drug
DMHVRFM PC 23020609
DMHVRFM MW 264.32
DMHVRFM FM C17H16N2O
DMHVRFM IC InChI=1S/C17H16N2O/c1-19(12-13-7-3-2-4-8-13)17(20)16-11-14-9-5-6-10-15(14)18-16/h2-11,18H,12H2,1H3
DMHVRFM CS CN(CC1=CC=CC=C1)C(=O)C2=CC3=CC=CC=C3N2
DMHVRFM IK DIVKZMHOMDSMBZ-UHFFFAOYSA-N
DMHVRFM IU N-benzyl-N-methyl-1H-indole-2-carboxamide
DMHVRFM DE Discovery agent
DM8I7N2 ID DM8I7N2
DM8I7N2 DN N-benzyl,N-methyl-1H-pyrrole-2-carboxamide
DM8I7N2 HS Investigative
DM8I7N2 SN CHEMBL352538; N-benzyl-N-methyl-1H-pyrrole-2-carboxamide; pyrrole inhibitor 10; N-benzyl,N-methyl-1H-pyrrole-2-carboxamide; BDBM15584; ZINC13493570
DM8I7N2 DT Small molecular drug
DM8I7N2 PC 11085165
DM8I7N2 MW 214.26
DM8I7N2 FM C13H14N2O
DM8I7N2 IC InChI=1S/C13H14N2O/c1-15(10-11-6-3-2-4-7-11)13(16)12-8-5-9-14-12/h2-9,14H,10H2,1H3
DM8I7N2 CS CN(CC1=CC=CC=C1)C(=O)C2=CC=CN2
DM8I7N2 IK HDVIQRKATXBZHO-UHFFFAOYSA-N
DM8I7N2 IU N-benzyl-N-methyl-1H-pyrrole-2-carboxamide
DM8I7N2 DE Discovery agent
DM2YZC5 ID DM2YZC5
DM2YZC5 DN N-benzyl[D-Pro-10]Dyn A-(1-11)
DM2YZC5 HS Investigative
DM2YZC5 SN CHEMBL268818; N-benzyl[D-Pro-10]Dyn A-(1-11); BDBM50059583
DM2YZC5 PC 44325182
DM2YZC5 MW 1452.7
DM2YZC5 FM C70H109N21O13
DM2YZC5 IC InChI=1S/C70H109N21O13/c1-5-43(4)58(65(101)87-50(25-16-34-80-70(76)77)66(102)91-35-17-26-55(91)64(100)88-51(67(103)104)22-12-13-31-71)90-61(97)49(24-15-33-79-69(74)75)85-60(96)48(23-14-32-78-68(72)73)86-62(98)53(36-42(2)3)89-63(99)54(38-44-18-8-6-9-19-44)84-57(94)41-82-56(93)40-83-59(95)52(37-45-27-29-47(92)30-28-45)81-39-46-20-10-7-11-21-46/h6-11,18-21,27-30,42-43,48-55,58,81,92H,5,12-17,22-26,31-41,71H2,1-4H3,(H,82,93)(H,83,95)(H,84,94)(H,85,96)(H,86,98)(H,87,101)(H,88,100)(H,89,99)(H,90,97)(H,103,104)(H4,72,73,78)(H4,74,75,79)(H4,76,77,80)/t43-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1
DM2YZC5 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC4=CC=CC=C4
DM2YZC5 IK SCUDNMPTYPZVCN-RSZDUZASSA-N
DM2YZC5 IU (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-(benzylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM2YZC5 DE Discovery agent
DM7SEM1 ID DM7SEM1
DM7SEM1 DN N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine
DM7SEM1 HS Investigative
DM7SEM1 SN CHEMBL571560; N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine; MCL-630
DM7SEM1 DT Small molecular drug
DM7SEM1 PC 44627901
DM7SEM1 MW 400.6
DM7SEM1 FM C28H36N2
DM7SEM1 IC InChI=1S/C28H36N2/c1-2-7-21(8-3-1)19-29-24-13-12-23-17-27-25-11-4-5-14-28(25,26(23)18-24)15-16-30(27)20-22-9-6-10-22/h1-3,7-8,12-13,18,22,25,27,29H,4-6,9-11,14-17,19-20H2/t25-,27+,28+/m0/s1
DM7SEM1 CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NCC5=CC=CC=C5)CC6CCC6
DM7SEM1 IK WFGYABIAABXTFI-KJYTXNCISA-N
DM7SEM1 IU (1R,9R,10R)-N-benzyl-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DM7SEM1 DE Discovery agent
DMLP9VM ID DMLP9VM
DMLP9VM DN N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine
DMLP9VM HS Investigative
DMLP9VM SN CHEMBL571998; N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine; MCL-610
DMLP9VM DT Small molecular drug
DMLP9VM PC 44627790
DMLP9VM MW 386.6
DMLP9VM FM C27H34N2
DMLP9VM IC InChI=1S/C27H34N2/c1-2-6-20(7-3-1)18-28-23-12-11-22-16-26-24-8-4-5-13-27(24,25(22)17-23)14-15-29(26)19-21-9-10-21/h1-3,6-7,11-12,17,21,24,26,28H,4-5,8-10,13-16,18-19H2/t24-,26+,27+/m0/s1
DMLP9VM CS C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)NCC5=CC=CC=C5)CC6CC6
DMLP9VM IK CDLAPAAACNSKLQ-WYMJOSIYSA-N
DMLP9VM IU (1R,9R,10R)-N-benzyl-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-amine
DMLP9VM DE Discovery agent
DMA3YWU ID DMA3YWU
DMA3YWU DN N-Benzyl-1H-indole-2-carboxamide
DMA3YWU HS Investigative
DMA3YWU SN N-Benzyl-1H-indole-2-carboxamide; CHEMBL464799; AC1OYZAF; SCHEMBL2735969; MolPort-002-497-469; HMS1751G10; ZINC6649233; STL100558; BDBM50273489; AKOS005715761; MCULE-5762597832; NCGC00300187-01; AB01108905-02; Z27748935
DMA3YWU DT Small molecular drug
DMA3YWU PC 8023988
DMA3YWU MW 250.29
DMA3YWU FM C16H14N2O
DMA3YWU IC InChI=1S/C16H14N2O/c19-16(17-11-12-6-2-1-3-7-12)15-10-13-8-4-5-9-14(13)18-15/h1-10,18H,11H2,(H,17,19)
DMA3YWU CS C1=CC=C(C=C1)CNC(=O)C2=CC3=CC=CC=C3N2
DMA3YWU IK AYMFXIQFBKQBGU-UHFFFAOYSA-N
DMA3YWU IU N-benzyl-1H-indole-2-carboxamide
DMA3YWU DE Discovery agent
DMC7XST ID DMC7XST
DMC7XST DN N-Benzyl-1'H-phenothiazine-1'-carboxamide
DMC7XST HS Investigative
DMC7XST SN CHEMBL589078; N-benzyl-10H-phenothiazine-10-carboxamide; ChemDiv3_004499; AC1LE3H3; Oprea1_734190; ZINC91218; MolPort-000-807-945; HMS1485M11; N-benzylphenothiazine-10-carboxamide; STK825822; BDBM50308407; N-benzylphenothiazin-10-ylcarboxamide; AKOS001676383; MCULE-7023337069; CCG-113838; IDI1_022409; ST51040739; N-Benzyl-1''H-phenothiazine-1''-carboxamide; AB00121381-01; SR-01000506160; SR-01000506160-1; BRD-K82322069-001-01-0
DMC7XST DT Small molecular drug
DMC7XST PC 705757
DMC7XST MW 332.4
DMC7XST FM C20H16N2OS
DMC7XST IC InChI=1S/C20H16N2OS/c23-20(21-14-15-8-2-1-3-9-15)22-16-10-4-6-12-18(16)24-19-13-7-5-11-17(19)22/h1-13H,14H2,(H,21,23)
DMC7XST CS C1=CC=C(C=C1)CNC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMC7XST IK ZGPOCYPNYDVRTG-UHFFFAOYSA-N
DMC7XST IU N-benzylphenothiazine-10-carboxamide
DMC7XST DE Discovery agent
DM73ZHV ID DM73ZHV
DM73ZHV DN N-benzyl-1H-pyrrole-2-carboxamide
DM73ZHV HS Investigative
DM73ZHV SN N-benzyl-1H-pyrrole-2-carboxamide; CHEMBL174040; pyrrole inhibitor 9; 1H-Pyrrole-2-carboxamide, N-(phenylmethyl)-; SCHEMBL2576103; BDBM15583; AKOS027595596
DM73ZHV DT Small molecular drug
DM73ZHV PC 11019886
DM73ZHV MW 200.24
DM73ZHV FM C12H12N2O
DM73ZHV IC InChI=1S/C12H12N2O/c15-12(11-7-4-8-13-11)14-9-10-5-2-1-3-6-10/h1-8,13H,9H2,(H,14,15)
DM73ZHV CS C1=CC=C(C=C1)CNC(=O)C2=CC=CN2
DM73ZHV IK PSYQATYJXPGBDC-UHFFFAOYSA-N
DM73ZHV IU N-benzyl-1H-pyrrole-2-carboxamide
DM73ZHV DE Discovery agent
DM8A23B ID DM8A23B
DM8A23B DN N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8A23B HS Investigative
DM8A23B SN N-benzyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM8A23B DT Small molecular drug
DM8A23B PC 3149447
DM8A23B MW 278.3
DM8A23B FM C17H14N2O2
DM8A23B IC InChI=1S/C17H14N2O2/c20-16(14-11-18-15-9-5-4-8-13(14)15)17(21)19-10-12-6-2-1-3-7-12/h1-9,11,18H,10H2,(H,19,21)
DM8A23B CS C1=CC=C(C=C1)CNC(=O)C(=O)C2=CNC3=CC=CC=C32
DM8A23B IK HWOWPGLTTSFLOQ-UHFFFAOYSA-N
DM8A23B IU N-benzyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM8A23B CA CAS 55654-71-2
DM8A23B DE Discovery agent
DMMT65J ID DMMT65J
DMMT65J DN N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J HS Investigative
DMMT65J SN CHEMBL75307; N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide; N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxo-acetamide
DMMT65J DT Small molecular drug
DMMT65J PC 10426330
DMMT65J MW 323.3
DMMT65J FM C17H13N3O4
DMMT65J IC InChI=1S/C17H13N3O4/c21-16(17(22)19-9-11-4-2-1-3-5-11)14-10-18-15-7-6-12(20(23)24)8-13(14)15/h1-8,10,18H,9H2,(H,19,22)
DMMT65J CS C1=CC=C(C=C1)CNC(=O)C(=O)C2=CNC3=C2C=C(C=C3)[N+](=O)[O-]
DMMT65J IK JYXHNHBKWZQGLB-UHFFFAOYSA-N
DMMT65J IU N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMMT65J DE Discovery agent
DM0ZXBQ ID DM0ZXBQ
DM0ZXBQ DN N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
DM0ZXBQ HS Investigative
DM0ZXBQ SN CHEMBL1085780; N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine; BDBM50319968
DM0ZXBQ DT Small molecular drug
DM0ZXBQ PC 46891014
DM0ZXBQ MW 254.33
DM0ZXBQ FM C15H18N4
DM0ZXBQ IC InChI=1S/C15H18N4/c1-2-6-13(7-3-1)12-17-14-8-9-16-15(18-14)19-10-4-5-11-19/h1-3,6-9H,4-5,10-12H2,(H,16,17,18)
DM0ZXBQ CS C1CCN(C1)C2=NC=CC(=N2)NCC3=CC=CC=C3
DM0ZXBQ IK PGBNXXDXGXQQRQ-UHFFFAOYSA-N
DM0ZXBQ IU N-benzyl-2-pyrrolidin-1-ylpyrimidin-4-amine
DM0ZXBQ DE Discovery agent
DM3C0P2 ID DM3C0P2
DM3C0P2 DN N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide
DM3C0P2 HS Investigative
DM3C0P2 SN CHEMBL94764; AC1Q2LMI; N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide; AC1MT671; ZINC5121035; BDBM50146383; AKOS003681368; MCULE-1042732308; N-benzyl-2-[(4-methylphenyl)sulfonylamino]benzamide
DM3C0P2 DT Small molecular drug
DM3C0P2 PC 3545567
DM3C0P2 MW 380.5
DM3C0P2 FM C21H20N2O3S
DM3C0P2 IC InChI=1S/C21H20N2O3S/c1-16-11-13-18(14-12-16)27(25,26)23-20-10-6-5-9-19(20)21(24)22-15-17-7-3-2-4-8-17/h2-14,23H,15H2,1H3,(H,22,24)
DM3C0P2 CS CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC3=CC=CC=C3
DM3C0P2 IK ASKBFNKCMLTGPX-UHFFFAOYSA-N
DM3C0P2 IU N-benzyl-2-[(4-methylphenyl)sulfonylamino]benzamide
DM3C0P2 DE Discovery agent
DMQCGFL ID DMQCGFL
DMQCGFL DN N-benzyl-2-morpholinopyrimidin-4-amine
DMQCGFL HS Investigative
DMQCGFL SN CHEMBL1085781; N-benzyl-2-morpholinopyrimidin-4-amine; BDBM50319969; AKOS028689215; SR-01000647481
DMQCGFL DT Small molecular drug
DMQCGFL PC 46891015
DMQCGFL MW 270.33
DMQCGFL FM C15H18N4O
DMQCGFL IC InChI=1S/C15H18N4O/c1-2-4-13(5-3-1)12-17-14-6-7-16-15(18-14)19-8-10-20-11-9-19/h1-7H,8-12H2,(H,16,17,18)
DMQCGFL CS C1COCCN1C2=NC=CC(=N2)NCC3=CC=CC=C3
DMQCGFL IK PKTXFNWLILBNOJ-UHFFFAOYSA-N
DMQCGFL IU N-benzyl-2-morpholin-4-ylpyrimidin-4-amine
DMQCGFL DE Discovery agent
DMJ29MN ID DMJ29MN
DMJ29MN DN N-benzyl-2-oxo-2H-chromene-3-carboxamide
DMJ29MN HS Investigative
DMJ29MN SN 3-(Benzylcarbamoyl)coumarin; BRN 0257384; Coumarin, 3-(benzylcarbamoyl)-; 2H-1-Benzopyran-3-carboxamide, 2-oxo-N-(phenylmethyl)-; 1846-90-8; 2-Oxo-2H-chromene-3-carboxylic acid benzylamide; 2-Oxo-N-(phenylmethyl)-2H-1-benzopyran-3-carboxamide; N-benzyl-2-oxo-2H-chromene-3-carboxamide; AC1L3R3J; Oprea1_583472; Oprea1_560940; 3-carboxamido coumarin, 36; MLS001210650; CHEMBL469976; CTK0H5459; BDBM29186; DTXSID90171596; MolPort-000-375-285; ZINC130283; HMS2837I12; STK078064; N-benzyl-2-oxochromene-3-carboxamide; AKOS002234224
DMJ29MN DT Small molecular drug
DMJ29MN PC 120587
DMJ29MN MW 279.29
DMJ29MN FM C17H13NO3
DMJ29MN IC InChI=1S/C17H13NO3/c19-16(18-11-12-6-2-1-3-7-12)14-10-13-8-4-5-9-15(13)21-17(14)20/h1-10H,11H2,(H,18,19)
DMJ29MN CS C1=CC=C(C=C1)CNC(=O)C2=CC3=CC=CC=C3OC2=O
DMJ29MN IK BEUWFLKNYNXOJA-UHFFFAOYSA-N
DMJ29MN IU N-benzyl-2-oxochromene-3-carboxamide
DMJ29MN CA CAS 1846-90-8
DMJ29MN DE Discovery agent
DMRJMGK ID DMRJMGK
DMRJMGK DN N-benzyl-2-thiomorpholinopyrimidin-4-amine
DMRJMGK HS Investigative
DMRJMGK SN CHEMBL1086014; N-benzyl-2-thiomorpholinopyrimidin-4-amine
DMRJMGK DT Small molecular drug
DMRJMGK PC 46871648
DMRJMGK MW 286.4
DMRJMGK FM C15H18N4S
DMRJMGK IC InChI=1S/C15H18N4S/c1-2-4-13(5-3-1)12-17-14-6-7-16-15(18-14)19-8-10-20-11-9-19/h1-7H,8-12H2,(H,16,17,18)
DMRJMGK CS C1CSCCN1C2=NC=CC(=N2)NCC3=CC=CC=C3
DMRJMGK IK SPJWTUJGKPIRMF-UHFFFAOYSA-N
DMRJMGK IU N-benzyl-2-thiomorpholin-4-ylpyrimidin-4-amine
DMRJMGK DE Discovery agent
DMUD85N ID DMUD85N
DMUD85N DN N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide
DMUD85N HS Investigative
DMUD85N SN CHEMBL343071; N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide; BDBM50102429
DMUD85N DT Small molecular drug
DMUD85N PC 10593843
DMUD85N MW 348.4
DMUD85N FM C21H20N2O3
DMUD85N IC InChI=1S/C21H20N2O3/c24-19-10-11-20(25)17(12-19)14-22-18-8-6-16(7-9-18)21(26)23-13-15-4-2-1-3-5-15/h1-12,22,24-25H,13-14H2,(H,23,26)
DMUD85N CS C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)NCC3=C(C=CC(=C3)O)O
DMUD85N IK QQMFNDVDKBSOEC-UHFFFAOYSA-N
DMUD85N IU N-benzyl-4-[(2,5-dihydroxyphenyl)methylamino]benzamide
DMUD85N DE Discovery agent
DMCJWQT ID DMCJWQT
DMCJWQT DN N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
DMCJWQT HS Investigative
DMCJWQT SN CHEMBL492871; N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide
DMCJWQT DT Small molecular drug
DMCJWQT PC 25107518
DMCJWQT MW 441.6
DMCJWQT FM C29H35N3O
DMCJWQT IC InChI=1S/C29H35N3O/c33-29(30-24-25-12-4-1-5-13-25)18-8-3-11-19-31-20-22-32(23-21-31)28-17-10-9-16-27(28)26-14-6-2-7-15-26/h1-2,4-7,9-10,12-17H,3,8,11,18-24H2,(H,30,33)
DMCJWQT CS C1CN(CCN1CCCCCC(=O)NCC2=CC=CC=C2)C3=CC=CC=C3C4=CC=CC=C4
DMCJWQT IK LQFAQQWXFSOOQJ-UHFFFAOYSA-N
DMCJWQT IU N-benzyl-6-[4-(2-phenylphenyl)piperazin-1-yl]hexanamide
DMCJWQT DE Discovery agent
DMUNL5Q ID DMUNL5Q
DMUNL5Q DN N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide
DMUNL5Q HS Investigative
DMUNL5Q SN CHEMBL475493; Cambridge id 5211146; AC1LL0O9; Oprea1_380259; N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide; CBDivE_007294; SCHEMBL5623492; MolPort-002-316-866; BDBM50277135; AKOS008461950; MCULE-3410949273; AB00075261-01; SR-01000198591; SR-01000198591-1
DMUNL5Q DT Small molecular drug
DMUNL5Q PC 1076739
DMUNL5Q MW 439.3
DMUNL5Q FM C18H19BrN2O4S
DMUNL5Q IC InChI=1S/C18H19BrN2O4S/c19-16-7-6-15(18(22)20-13-14-4-2-1-3-5-14)12-17(16)26(23,24)21-8-10-25-11-9-21/h1-7,12H,8-11,13H2,(H,20,22)
DMUNL5Q CS C1COCCN1S(=O)(=O)C2=C(C=CC(=C2)C(=O)NCC3=CC=CC=C3)Br
DMUNL5Q IK DEVYAXBKQQLYGQ-UHFFFAOYSA-N
DMUNL5Q IU N-benzyl-4-bromo-3-morpholin-4-ylsulfonylbenzamide
DMUNL5Q DE Discovery agent
DMUFR62 ID DMUFR62
DMUFR62 DN N-benzyl-4-cyclopentylpiperazine-1-carboxamide
DMUFR62 HS Investigative
DMUFR62 SN CHEMBL219757; N-benzyl-4-cyclopentylpiperazine-1-carboxamide; MolPort-009-268-235; ZINC32779618; BDBM50193214; AKOS027663191; MCULE-5408375837; Z332433676
DMUFR62 DT Small molecular drug
DMUFR62 PC 40012125
DMUFR62 MW 287.4
DMUFR62 FM C17H25N3O
DMUFR62 IC InChI=1S/C17H25N3O/c21-17(18-14-15-6-2-1-3-7-15)20-12-10-19(11-13-20)16-8-4-5-9-16/h1-3,6-7,16H,4-5,8-14H2,(H,18,21)
DMUFR62 CS C1CCC(C1)N2CCN(CC2)C(=O)NCC3=CC=CC=C3
DMUFR62 IK HVJJGTXESXSGPU-UHFFFAOYSA-N
DMUFR62 IU N-benzyl-4-cyclopentylpiperazine-1-carboxamide
DMUFR62 DE Discovery agent
DM5TPEJ ID DM5TPEJ
DM5TPEJ DN N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ HS Investigative
DM5TPEJ SN CHEMBL203860; N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ DT Small molecular drug
DM5TPEJ PC 44407802
DM5TPEJ MW 339.4
DM5TPEJ FM C19H17NO3S
DM5TPEJ IC InChI=1S/C19H17NO3S/c21-18-11-13-19(14-12-18)24(22,23)20(17-9-5-2-6-10-17)15-16-7-3-1-4-8-16/h1-14,21H,15H2
DM5TPEJ CS C1=CC=C(C=C1)CN(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)O
DM5TPEJ IK IXILNJSCQSTWEB-UHFFFAOYSA-N
DM5TPEJ IU N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide
DM5TPEJ DE Discovery agent
DMCIJU0 ID DMCIJU0
DMCIJU0 DN N-Benzyl-4-Sulfamoyl-Benzamide
DMCIJU0 HS Investigative
DMCIJU0 SN n-benzyl-4-sulfamoyl-benzamide; N-benzyl-4-sulfamoylbenzamide; CHEMBL302715; 107619-27-2; Benzamide, 4-(aminosulfonyl)-N-(phenylmethyl)-; 1g4o; ACMC-20mb2s; AC1L1HYJ; SCHEMBL678390; 4-Sulfamoyl-N-benzylbenzamide; CTK0D6518; BDBM12013; DTXSID80274429; MolPort-004-614-705; ZINC403946; HMS3604F04; AKOS001408419; MCULE-1382374853; DB01748; 4-(AMINOSULFONYL)-N-PHENYLMETHYLBENZAMIDE
DMCIJU0 DT Small molecular drug
DMCIJU0 PC 4347
DMCIJU0 MW 290.34
DMCIJU0 FM C14H14N2O3S
DMCIJU0 IC InChI=1S/C14H14N2O3S/c15-20(18,19)13-8-6-12(7-9-13)14(17)16-10-11-4-2-1-3-5-11/h1-9H,10H2,(H,16,17)(H2,15,18,19)
DMCIJU0 CS C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)S(=O)(=O)N
DMCIJU0 IK CZKNSZUJCJHTTM-UHFFFAOYSA-N
DMCIJU0 IU N-benzyl-4-sulfamoylbenzamide
DMCIJU0 CA CAS 107619-27-2
DMCIJU0 DE Discovery agent
DM2XLHY ID DM2XLHY
DM2XLHY DN N-benzyl-5-(4-chlorophenyl)nicotinamide
DM2XLHY HS Investigative
DM2XLHY SN CHEMBL1271417; N-benzyl-5-(4-chlorophenyl)nicotinamide
DM2XLHY DT Small molecular drug
DM2XLHY PC 46032908
DM2XLHY MW 322.8
DM2XLHY FM C19H15ClN2O
DM2XLHY IC InChI=1S/C19H15ClN2O/c20-18-8-6-15(7-9-18)16-10-17(13-21-12-16)19(23)22-11-14-4-2-1-3-5-14/h1-10,12-13H,11H2,(H,22,23)
DM2XLHY CS C1=CC=C(C=C1)CNC(=O)C2=CN=CC(=C2)C3=CC=C(C=C3)Cl
DM2XLHY IK FWHXSLFSGPLDBM-UHFFFAOYSA-N
DM2XLHY IU N-benzyl-5-(4-chlorophenyl)pyridine-3-carboxamide
DM2XLHY DE Discovery agent
DM7NHRV ID DM7NHRV
DM7NHRV DN N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide
DM7NHRV HS Investigative
DM7NHRV SN CHEMBL576449; N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide
DM7NHRV DT Small molecular drug
DM7NHRV PC 45487805
DM7NHRV MW 324.3
DM7NHRV FM C16H15F3N2O2
DM7NHRV IC InChI=1S/C16H15F3N2O2/c17-16(18,19)8-9-23-14-7-6-13(11-20-14)15(22)21-10-12-4-2-1-3-5-12/h1-7,11H,8-10H2,(H,21,22)
DM7NHRV CS C1=CC=C(C=C1)CNC(=O)C2=CN=C(C=C2)OCCC(F)(F)F
DM7NHRV IK KOPBISOWPWQPSS-UHFFFAOYSA-N
DM7NHRV IU N-benzyl-6-(3,3,3-trifluoropropoxy)pyridine-3-carboxamide
DM7NHRV DE Discovery agent
DMDRE64 ID DMDRE64
DMDRE64 DN N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide
DMDRE64 HS Investigative
DMDRE64 SN Acridone-Based Inhibitor, 8c; N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide; CHEMBL230199
DMDRE64 DT Small molecular drug
DMDRE64 PC 16748635
DMDRE64 MW 328.4
DMDRE64 FM C21H16N2O2
DMDRE64 IC InChI=1S/C21H16N2O2/c24-20-16-8-4-5-9-18(16)23-19-12-15(10-11-17(19)20)21(25)22-13-14-6-2-1-3-7-14/h1-12H,13H2,(H,22,25)(H,23,24)
DMDRE64 CS C1=CC=C(C=C1)CNC(=O)C2=CC3=C(C=C2)C(=O)C4=CC=CC=C4N3
DMDRE64 IK YUICSGTVFUPFFC-UHFFFAOYSA-N
DMDRE64 IU N-benzyl-9-oxo-10H-acridine-3-carboxamide
DMDRE64 DE Discovery agent
DM26R4P ID DM26R4P
DM26R4P DN N-benzylacetimidamide hydrobromide
DM26R4P HS Investigative
DM26R4P SN N-Benzylacetamidine Hydrobromide; 186545-76-6; CHEMBL462334; 1-(Benzylamino)ethaniminium bromide; N-benzylacetimidamide hydrobromide; C9H12N2.HBr; CTK8E6104; DTXSID10649404; MolPort-009-019-600; 1916AH; AKOS025294782; RT-023317; J-011977; (1E)-N'-Benzylethanimidamide--hydrogen bromide (1/1)
DM26R4P DT Small molecular drug
DM26R4P PC 25231659
DM26R4P MW 229.12
DM26R4P FM C9H13BrN2
DM26R4P IC InChI=1S/C9H12N2.BrH/c1-8(10)11-7-9-5-3-2-4-6-9;/h2-6H,7H2,1H3,(H2,10,11);1H
DM26R4P CS CC(=NCC1=CC=CC=C1)N.Br
DM26R4P IK RUQJDXJQOUUQHG-UHFFFAOYSA-N
DM26R4P IU N'-benzylethanimidamide;hydrobromide
DM26R4P CA CAS 186545-76-6
DM26R4P DE Discovery agent
DMNPS4R ID DMNPS4R
DMNPS4R DN N-Benzyl-ETAV
DMNPS4R HS Investigative
DMNPS4R SN N-Benzyl-ETAV; CHEMBL492643
DMNPS4R DT Small molecular drug
DMNPS4R PC 44568794
DMNPS4R MW 508.6
DMNPS4R FM C24H36N4O8
DMNPS4R IC InChI=1S/C24H36N4O8/c1-13(2)19(24(35)36)27-21(32)14(3)26-23(34)20(15(4)29)28-22(33)17(10-11-18(30)31)25-12-16-8-6-5-7-9-16/h5-9,13-15,17,19-20,25,29H,10-12H2,1-4H3,(H,26,34)(H,27,32)(H,28,33)(H,30,31)(H,35,36)/t14-,15?,17-,19-,20-/m0/s1
DMNPS4R CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCC1=CC=CC=C1
DMNPS4R IK DETDSGXQMKQDNJ-VFWSWVEUSA-N
DMNPS4R IU (4S)-4-(benzylamino)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMNPS4R DE Discovery agent
DMDZ5XI ID DMDZ5XI
DMDZ5XI DN N-Benzylmethylphenidate
DMDZ5XI HS Investigative
DMDZ5XI SN N-Benzylmethylphenidate; CHEMBL1254757; BDBM50327137; (alphaR,2R)-alpha-Phenyl-1-benzylpiperidine-2beta-acetic acid methyl ester
DMDZ5XI DT Small molecular drug
DMDZ5XI PC 52948224
DMDZ5XI MW 323.4
DMDZ5XI FM C21H25NO2
DMDZ5XI IC InChI=1S/C21H25NO2/c1-24-21(23)20(18-12-6-3-7-13-18)19-14-8-9-15-22(19)16-17-10-4-2-5-11-17/h2-7,10-13,19-20H,8-9,14-16H2,1H3/t19-,20-/m1/s1
DMDZ5XI CS COC(=O)[C@@H]([C@H]1CCCCN1CC2=CC=CC=C2)C3=CC=CC=C3
DMDZ5XI IK BUSOTANDABQRSW-WOJBJXKFSA-N
DMDZ5XI IU methyl (2R)-2-[(2R)-1-benzylpiperidin-2-yl]-2-phenylacetate
DMDZ5XI DE Discovery agent
DM0NJAL ID DM0NJAL
DM0NJAL DN N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine
DM0NJAL HS Investigative
DM0NJAL SN CHEMBL462054; N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine
DM0NJAL DT Small molecular drug
DM0NJAL PC 44588172
DM0NJAL MW 250.34
DM0NJAL FM C17H18N2
DM0NJAL IC InChI=1S/C17H18N2/c1-19(12-14-7-3-2-4-8-14)13-16-11-15-9-5-6-10-17(15)18-16/h2-11,18H,12-13H2,1H3
DM0NJAL CS CN(CC1=CC=CC=C1)CC2=CC3=CC=CC=C3N2
DM0NJAL IK YJDMPOSBUYNPGY-UHFFFAOYSA-N
DM0NJAL IU N-(1H-indol-2-ylmethyl)-N-methyl-1-phenylmethanamine
DM0NJAL DE Discovery agent
DMT2GSI ID DMT2GSI
DMT2GSI DN N-benzyl-N-(phenylsulfonyl)benzamide
DMT2GSI HS Investigative
DMT2GSI SN N-benzyl-N-(phenylsulfonyl)benzamide; CHEMBL241160
DMT2GSI DT Small molecular drug
DMT2GSI PC 10893520
DMT2GSI MW 351.4
DMT2GSI FM C20H17NO3S
DMT2GSI IC InChI=1S/C20H17NO3S/c22-20(18-12-6-2-7-13-18)21(16-17-10-4-1-5-11-17)25(23,24)19-14-8-3-9-15-19/h1-15H,16H2
DMT2GSI CS C1=CC=C(C=C1)CN(C(=O)C2=CC=CC=C2)S(=O)(=O)C3=CC=CC=C3
DMT2GSI IK FRBJVLSQTZFTED-UHFFFAOYSA-N
DMT2GSI IU N-(benzenesulfonyl)-N-benzylbenzamide
DMT2GSI DE Discovery agent
DM6QK7E ID DM6QK7E
DM6QK7E DN N-benzyl-N-isobutylpiperidin-4-amine
DM6QK7E HS Investigative
DM6QK7E SN CHEMBL207837; N-benzyl-N-isobutylpiperidin-4-amine; SCHEMBL5994946; ZINC36093165
DM6QK7E DT Small molecular drug
DM6QK7E PC 44411431
DM6QK7E MW 246.39
DM6QK7E FM C16H26N2
DM6QK7E IC InChI=1S/C16H26N2/c1-14(2)12-18(16-8-10-17-11-9-16)13-15-6-4-3-5-7-15/h3-7,14,16-17H,8-13H2,1-2H3
DM6QK7E CS CC(C)CN(CC1=CC=CC=C1)C2CCNCC2
DM6QK7E IK LDELVNUHOAVIQP-UHFFFAOYSA-N
DM6QK7E IU N-benzyl-N-(2-methylpropyl)piperidin-4-amine
DM6QK7E DE Discovery agent
DMVEZH1 ID DMVEZH1
DMVEZH1 DN N-benzylnorlitebamine
DMVEZH1 HS Investigative
DMVEZH1 SN N-benzylnorlitebamine; CHEMBL464944; BDBM50250453
DMVEZH1 DT Small molecular drug
DMVEZH1 PC 10597941
DMVEZH1 MW 415.5
DMVEZH1 FM C26H25NO4
DMVEZH1 IC InChI=1S/C26H25NO4/c1-30-23-13-20-17(12-22(23)28)8-9-19-18-10-11-27(14-16-6-4-3-5-7-16)15-21(18)25(29)26(31-2)24(19)20/h3-9,12-13,28-29H,10-11,14-15H2,1-2H3
DMVEZH1 CS COC1=C(C=C2C=CC3=C4CCN(CC4=C(C(=C3C2=C1)OC)O)CC5=CC=CC=C5)O
DMVEZH1 IK ITXWZNATGXDCEV-UHFFFAOYSA-N
DMVEZH1 IU 2-benzyl-9,11-dimethoxy-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DMVEZH1 DE Discovery agent
DM7S5Y4 ID DM7S5Y4
DM7S5Y4 DN NBI-59159
DM7S5Y4 HS Investigative
DM7S5Y4 SN CHEMBL1628570; NBI-59159; GTPL4626; BDBM50410451; (2S)-2-amino-3-[(9H-fluoren-2-yl)carbamoyl]propanoic acid
DM7S5Y4 DT Small molecular drug
DM7S5Y4 PC 11369932
DM7S5Y4 MW 296.32
DM7S5Y4 FM C17H16N2O3
DM7S5Y4 IC InChI=1S/C17H16N2O3/c18-15(17(21)22)9-16(20)19-12-5-6-14-11(8-12)7-10-3-1-2-4-13(10)14/h1-6,8,15H,7,9,18H2,(H,19,20)(H,21,22)/t15-/m0/s1
DM7S5Y4 CS C1C2=CC=CC=C2C3=C1C=C(C=C3)NC(=O)C[C@@H](C(=O)O)N
DM7S5Y4 IK QDIIRLCSVINDSC-HNNXBMFYSA-N
DM7S5Y4 IU (2S)-2-amino-4-(9H-fluoren-2-ylamino)-4-oxobutanoic acid
DM7S5Y4 DE Discovery agent
DMURC6X ID DMURC6X
DMURC6X DN NBI-74330
DMURC6X HS Investigative
DMURC6X SN 473722-68-8; 855527-92-3; (plusmn)-NBI 74330; GTPL839; SCHEMBL15064525; MolPort-035-765-750; NBI74330; AKOS024458204; NCGC00379149-01; KB-79291; ( inverted exclamation markA)-NBI 74330; (+/-)-NBI 74330; N-1-[(3-4(-Ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(3-pyridinylmethyl)-3-(trifluoromethyl)benzeneacetamide
DMURC6X DT Small molecular drug
DMURC6X PC 45784923
DMURC6X MW 605.6
DMURC6X FM C32H27F4N5O3
DMURC6X IC InChI=1S/C32H27F4N5O3/c1-3-44-24-11-9-23(10-12-24)41-30(39-29-25(31(41)43)7-5-15-38-29)20(2)40(19-22-6-4-14-37-18-22)28(42)17-21-8-13-27(33)26(16-21)32(34,35)36/h4-16,18,20H,3,17,19H2,1-2H3/t20-/m1/s1
DMURC6X CS CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2[C@@H](C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F
DMURC6X IK XMRGQUDUVGRCBS-HXUWFJFHSA-N
DMURC6X IU N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(pyridin-3-ylmethyl)acetamide
DMURC6X DE Discovery agent
DMJF9VA ID DMJF9VA
DMJF9VA DN N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide
DMJF9VA HS Investigative
DMJF9VA SN CHEMBL376650
DMJF9VA DT Small molecular drug
DMJF9VA PC 16116574
DMJF9VA MW 284.31
DMJF9VA FM C16H16N2O3
DMJF9VA IC InChI=1S/C16H16N2O3/c19-15(10-16(20)18-21)17-11-12-5-4-8-14(9-12)13-6-2-1-3-7-13/h1-9,21H,10-11H2,(H,17,19)(H,18,20)
DMJF9VA CS C1=CC=C(C=C1)C2=CC=CC(=C2)CNC(=O)CC(=O)NO
DMJF9VA IK FKVBZDLUQPPZNE-UHFFFAOYSA-N
DMJF9VA IU N'-hydroxy-N-[(3-phenylphenyl)methyl]propanediamide
DMJF9VA DE Discovery agent
DMWSDZ9 ID DMWSDZ9
DMWSDZ9 DN N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide
DMWSDZ9 HS Investigative
DMWSDZ9 SN 9H-Fluorene-2,7-dicarboxamide, 9-oxo-N,N'-bis(3-phenylpropyl)-; 443794-40-9; SCHEMBL4158879; CTK1C7933
DMWSDZ9 DT Small molecular drug
DMWSDZ9 PC 10117946
DMWSDZ9 MW 502.6
DMWSDZ9 FM C33H30N2O3
DMWSDZ9 IC InChI=1S/C33H30N2O3/c36-31-29-21-25(32(37)34-19-7-13-23-9-3-1-4-10-23)15-17-27(29)28-18-16-26(22-30(28)31)33(38)35-20-8-14-24-11-5-2-6-12-24/h1-6,9-12,15-18,21-22H,7-8,13-14,19-20H2,(H,34,37)(H,35,38)
DMWSDZ9 CS C1=CC=C(C=C1)CCCNC(=O)C2=CC3=C(C=C2)C4=C(C3=O)C=C(C=C4)C(=O)NCCCC5=CC=CC=C5
DMWSDZ9 IK OKGPGSVMCACUID-UHFFFAOYSA-N
DMWSDZ9 IU 9-oxo-2-N,7-N-bis(3-phenylpropyl)fluorene-2,7-dicarboxamide
DMWSDZ9 CA CAS 443794-40-9
DMWSDZ9 DE Discovery agent
DMVF420 ID DMVF420
DMVF420 DN NBTGR
DMVF420 HS Investigative
DMVF420 SN nitrobenzylthioguanosine
DMVF420 DT Small molecular drug
DMVF420 PC 96048
DMVF420 MW 434.4
DMVF420 FM C17H18N6O6S
DMVF420 IC InChI=1S/C17H18N6O6S/c18-17-20-14-11(19-7-22(14)16-13(26)12(25)10(5-24)29-16)15(21-17)30-6-8-1-3-9(4-2-8)23(27)28/h1-4,7,10,12-13,16,24-26H,5-6H2,(H2,18,20,21)/t10-,12-,13-,16-/m1/s1
DMVF420 CS C1=CC(=CC=C1CSC2=NC(=NC3=C2N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N)[N+](=O)[O-]
DMVF420 IK BRSNNJIJEZWSBU-XNIJJKJLSA-N
DMVF420 IU (2R,3R,4S,5R)-2-[2-amino-6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
DMVF420 CA CAS 13153-27-0
DMVF420 DE Discovery agent
DMAQT6S ID DMAQT6S
DMAQT6S DN N-Butyl 2beta-hydroxyolean-12-en-28-oate
DMAQT6S HS Investigative
DMAQT6S SN CHEMBL1077758; n-Butyl 2beta-hydroxyolean-12-en-28-oate
DMAQT6S DT Small molecular drug
DMAQT6S PC 44254244
DMAQT6S MW 512.799
DMAQT6S FM C34H56O3
DMAQT6S IC InChI=1S/C34H56O3/c1-9-10-19-37-28(36)34-17-15-29(2,3)22-25(34)24-11-12-27-31(6)21-23(35)20-30(4,5)26(31)13-14-33(27,8)32(24,7)16-18-34/h11,23,25-27,35H,9-10,12-22H2,1-8H3/t23-,25+,26+,27-,31+,32-,33-,34+/m1/s1
DMAQT6S CS CCCCOC(=O)[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H](CC5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C
DMAQT6S IK UZTYAEIRVQJQQC-XXJJMGNBSA-N
DMAQT6S IU butyl (4aS,6aR,6aS,6bR,8aS,11R,12aS,14bS)-11-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
DMAQT6S DE Discovery agent
DM157LQ ID DM157LQ
DM157LQ DN N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ HS Investigative
DM157LQ SN CHEMBL223476; N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide; N-Butyl-2-(1H-indol-3-yl)-2-oxo-acetamide; BAS 04280181; AC1MK4QP; MolPort-000-249-106; ZINC3635496; BDBM50206948; N-butyl-2-indol-3-yl-2-oxoacetamide; AKOS000530602; MCULE-8866008030; ST50101897
DM157LQ DT Small molecular drug
DM157LQ PC 3149449
DM157LQ MW 244.29
DM157LQ FM C14H16N2O2
DM157LQ IC InChI=1S/C14H16N2O2/c1-2-3-8-15-14(18)13(17)11-9-16-12-7-5-4-6-10(11)12/h4-7,9,16H,2-3,8H2,1H3,(H,15,18)
DM157LQ CS CCCCNC(=O)C(=O)C1=CNC2=CC=CC=C21
DM157LQ IK XTLXOIBNXHXNBR-UHFFFAOYSA-N
DM157LQ IU N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide
DM157LQ DE Discovery agent
DMH7Z4L ID DMH7Z4L
DMH7Z4L DN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L HS Investigative
DMH7Z4L SN CHEMBL222316; N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L DT Small molecular drug
DMH7Z4L PC 16124919
DMH7Z4L MW 289.29
DMH7Z4L FM C14H15N3O4
DMH7Z4L IC InChI=1S/C14H15N3O4/c1-2-3-6-15-14(19)13(18)11-8-16-12-5-4-9(17(20)21)7-10(11)12/h4-5,7-8,16H,2-3,6H2,1H3,(H,15,19)
DMH7Z4L CS CCCCNC(=O)C(=O)C1=CNC2=C1C=C(C=C2)[N+](=O)[O-]
DMH7Z4L IK FFNPFJOEAUFBBY-UHFFFAOYSA-N
DMH7Z4L IU N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide
DMH7Z4L DE Discovery agent
DMH5GW6 ID DMH5GW6
DMH5GW6 DN N-butyl-4-hydroxy-N-phenylbenzenesulfonamide
DMH5GW6 HS Investigative
DMH5GW6 SN CHEMBL203810; N-butyl-4-hydroxy-N-phenylbenzenesulfonamide; BDBM50177754
DMH5GW6 DT Small molecular drug
DMH5GW6 PC 44407804
DMH5GW6 MW 305.4
DMH5GW6 FM C16H19NO3S
DMH5GW6 IC InChI=1S/C16H19NO3S/c1-2-3-13-17(14-7-5-4-6-8-14)21(19,20)16-11-9-15(18)10-12-16/h4-12,18H,2-3,13H2,1H3
DMH5GW6 CS CCCCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMH5GW6 IK PPNFXEDTKPJHLX-UHFFFAOYSA-N
DMH5GW6 IU N-butyl-4-hydroxy-N-phenylbenzenesulfonamide
DMH5GW6 DE Discovery agent
DMMI8X4 ID DMMI8X4
DMMI8X4 DN N-butyl-4-methyl-3,4-dihydroquinazolin-2-amine
DMMI8X4 HS Investigative
DMMI8X4 DT Small molecular drug
DMMI8X4 PC 44456426
DMMI8X4 DE Discovery agent
DMW7BZT ID DMW7BZT
DMW7BZT DN N-Butylcarbamic Acid Biphenyl-3-yl Ester
DMW7BZT HS Investigative
DMW7BZT SN CHEMBL446837; n-Butylcarbamic Acid Biphenyl-3-yl Ester
DMW7BZT DT Small molecular drug
DMW7BZT PC 24881670
DMW7BZT MW 269.34
DMW7BZT FM C17H19NO2
DMW7BZT IC InChI=1S/C17H19NO2/c1-2-3-12-18-17(19)20-16-11-7-10-15(13-16)14-8-5-4-6-9-14/h4-11,13H,2-3,12H2,1H3,(H,18,19)
DMW7BZT CS CCCCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DMW7BZT IK KILLQYKNNVPEJL-UHFFFAOYSA-N
DMW7BZT IU (3-phenylphenyl) N-butylcarbamate
DMW7BZT DE Discovery agent
DMY3HEF ID DMY3HEF
DMY3HEF DN N-Butyl-ETAV
DMY3HEF HS Investigative
DMY3HEF SN N-Butyl-ETAV; CHEMBL494485
DMY3HEF DT Small molecular drug
DMY3HEF PC 44568834
DMY3HEF MW 474.5
DMY3HEF FM C21H38N4O8
DMY3HEF IC InChI=1S/C21H38N4O8/c1-6-7-10-22-14(8-9-15(27)28)19(30)25-17(13(5)26)20(31)23-12(4)18(29)24-16(11(2)3)21(32)33/h11-14,16-17,22,26H,6-10H2,1-5H3,(H,23,31)(H,24,29)(H,25,30)(H,27,28)(H,32,33)/t12-,13?,14-,16-,17-/m0/s1
DMY3HEF CS CCCCN[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O
DMY3HEF IK DGLIBFYKWHJASP-UPKCPHKASA-N
DMY3HEF IU (4S)-4-(butylamino)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
DMY3HEF DE Discovery agent
DMB06TA ID DMB06TA
DMB06TA DN N-butylgalactonojirimycin
DMB06TA HS Investigative
DMB06TA SN N-butylgalactonojirimycin; CHEMBL485842
DMB06TA DT Small molecular drug
DMB06TA PC 44560309
DMB06TA MW 235.28
DMB06TA FM C10H21NO5
DMB06TA IC InChI=1S/C10H21NO5/c1-2-3-4-11-6(5-12)7(13)8(14)9(15)10(11)16/h6-10,12-16H,2-5H2,1H3/t6-,7+,8+,9-,10+/m1/s1
DMB06TA CS CCCCN1[C@@H]([C@@H]([C@@H]([C@H]([C@@H]1O)O)O)O)CO
DMB06TA IK JNYIOZRCMYRRED-KBDSZGMXSA-N
DMB06TA IU (2S,3R,4S,5S,6R)-1-butyl-6-(hydroxymethyl)piperidine-2,3,4,5-tetrol
DMB06TA DE Discovery agent
DM8U70E ID DM8U70E
DM8U70E DN N-Butyl-N'-(4-methyl-benzoyl)-guanidine
DM8U70E HS Investigative
DM8U70E SN CHEMBL432963; SCHEMBL4629393; BDBM50107019; 1-Butyl-2-(4-methylbenzoyl)guanidine
DM8U70E DT Small molecular drug
DM8U70E PC 10955473
DM8U70E MW 233.31
DM8U70E FM C13H19N3O
DM8U70E IC InChI=1S/C13H19N3O/c1-3-4-9-15-13(14)16-12(17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H3,14,15,16,17)
DM8U70E CS CCCCN=C(N)NC(=O)C1=CC=C(C=C1)C
DM8U70E IK ALSYKIYWLYFZIK-UHFFFAOYSA-N
DM8U70E IU N-(N'-butylcarbamimidoyl)-4-methylbenzamide
DM8U70E DE Discovery agent
DMKCX5N ID DMKCX5N
DMKCX5N DN N-Butyl-N'-Hydroxyguanidine
DMKCX5N HS Investigative
DMKCX5N SN N-BUTYL-N'-HYDROXYGUANIDINE; N-BUTYL-N'-HYDROXY-GUANIDINE; 140215-98-1; 1-Butyl-2-hydroxyguanidine; BHH; 2-butyl-1-hydroxyguanidine; 1-butyl-3-hydroxyguanidine; AC1L9KE0; SCHEMBL611006; CHEMBL308745; SCHEMBL10339979; HMS3649P20; 1917AH; ZINC13536006; AKOS017474991; AKOS011771255; DB02727; SR-01000946753
DMKCX5N DT Small molecular drug
DMKCX5N PC 447030
DMKCX5N MW 131.18
DMKCX5N FM C5H13N3O
DMKCX5N IC InChI=1S/C5H13N3O/c1-2-3-4-7-5(6)8-9/h9H,2-4H2,1H3,(H3,6,7,8)
DMKCX5N CS CCCCN=C(N)NO
DMKCX5N IK ULDDTFAPYWLDGF-UHFFFAOYSA-N
DMKCX5N IU 2-butyl-1-hydroxyguanidine
DMKCX5N CA CAS 140215-98-1
DMKCX5N DE Discovery agent
DMNFTO6 ID DMNFTO6
DMNFTO6 DN N-butylnorlitebamine
DMNFTO6 HS Investigative
DMNFTO6 SN N-butylnorlitebamine; CHEMBL465346; BDBM50250442
DMNFTO6 DT Small molecular drug
DMNFTO6 PC 10619839
DMNFTO6 MW 381.5
DMNFTO6 FM C23H27NO4
DMNFTO6 IC InChI=1S/C23H27NO4/c1-4-5-9-24-10-8-15-16-7-6-14-11-19(25)20(27-2)12-17(14)21(16)23(28-3)22(26)18(15)13-24/h6-7,11-12,25-26H,4-5,8-10,13H2,1-3H3
DMNFTO6 CS CCCCN1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DMNFTO6 IK XLVUNDMFFLQJMP-UHFFFAOYSA-N
DMNFTO6 IU 2-butyl-9,11-dimethoxy-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DMNFTO6 DE Discovery agent
DM8STQA ID DM8STQA
DM8STQA DN N-butylresorcinol
DM8STQA HS Investigative
DM8STQA SN 4-Butylresorcinol; 4-butylbenzene-1,3-diol; 18979-61-8; 4-n-Butylresorcinol; Butylresorcinol; 4-Butylresorcin; N-butylresorcinol; Resorcinol, 4-butyl-; Rucinol; UNII-2IK4UQ3ZGA; 2,4-Dihydroxy-n-butyl benzen; BRN 1942645; 2IK4UQ3ZGA; CHEMBL450195; 2,4-Dihydroxy-N-butyl benzene; CHEBI:81689; AK-81459; Q-200189; Kopcinol; 4-(2,4-dihydroxyphenyl)butane; n-butyl resorcinol; Rucinol (TN); EC 606-191-2; AC1L4FN4; ACMC-1CA91; 1,3-Benzenediol,4-butyl-; SCHEMBL68792; 4-06-00-06003 (Beilstein Handbook Reference); 1,3-Benzenediol, 4-butyl-
DM8STQA DT Small molecular drug
DM8STQA PC 205912
DM8STQA MW 166.22
DM8STQA FM C10H14O2
DM8STQA IC InChI=1S/C10H14O2/c1-2-3-4-8-5-6-9(11)7-10(8)12/h5-7,11-12H,2-4H2,1H3
DM8STQA CS CCCCC1=C(C=C(C=C1)O)O
DM8STQA IK CSHZYWUPJWVTMQ-UHFFFAOYSA-N
DM8STQA IU 4-butylbenzene-1,3-diol
DM8STQA CA CAS 18979-61-8
DM8STQA CB CHEBI:81689
DM8STQA DE Discovery agent
DMJCYMW ID DMJCYMW
DMJCYMW DN NC00075159
DMJCYMW HS Investigative
DMJCYMW SN 2-{(5Z)-5-[4-(dimethylamino)benzylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}propanoic acid; AC1NSO7A; NC00075159; GTPL7664; MolPort-000-500-763; SMSF0008623; 2-[5-[(4-dimethylaminophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid; AKOS001607119; AKOS016042842; CB00089; ST50147973; AB00099445-01; 2-{5-[4-(dimethylamino)benzylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}propanoic acid; 2-[(5Z)-5-[(4-dimethylaminophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
DMJCYMW DT Small molecular drug
DMJCYMW PC 5337173
DMJCYMW MW 336.4
DMJCYMW FM C15H16N2O3S2
DMJCYMW IC InChI=1S/C15H16N2O3S2/c1-9(14(19)20)17-13(18)12(22-15(17)21)8-10-4-6-11(7-5-10)16(2)3/h4-9H,1-3H3,(H,19,20)/b12-8-
DMJCYMW CS CC(C(=O)O)N1C(=O)/C(=C/C2=CC=C(C=C2)N(C)C)/SC1=S
DMJCYMW IK XGTGMKYGVNHPTC-WQLSENKSSA-N
DMJCYMW IU 2-[(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
DMJCYMW DE Discovery agent
DM6XGFE ID DM6XGFE
DM6XGFE DN NC1153
DM6XGFE HS Investigative
DM6XGFE DT Small molecular drug
DM6XGFE PC 373395
DM6XGFE MW 296.5
DM6XGFE FM C18H36N2O
DM6XGFE IC InChI=1S/C18H36N2O/c1-19(2)14-16-12-10-8-6-5-7-9-11-13-17(18(16)21)15-20(3)4/h16-17H,5-15H2,1-4H3
DM6XGFE CS CN(C)CC1CCCCCCCCCC(C1=O)CN(C)C
DM6XGFE IK HRQRILLGGNNYSD-UHFFFAOYSA-N
DM6XGFE IU 2,12-bis[(dimethylamino)methyl]cyclododecan-1-one
DM6XGFE DE Renal transplantation
DMJKZUC ID DMJKZUC
DMJKZUC DN NC-2100
DMJKZUC HS Investigative
DMJKZUC SN NC-2100; nc2100; SCHEMBL377641; NC 2100; 179068-64-5; 2,4-Thiazolidinedione, 5-((7-(phenylmethoxy)-3-quinolinyl)methyl)-
DMJKZUC DT Small molecular drug
DMJKZUC PC 9907086
DMJKZUC MW 364.4
DMJKZUC FM C20H16N2O3S
DMJKZUC IC InChI=1S/C20H16N2O3S/c23-19-18(26-20(24)22-19)9-14-8-15-6-7-16(10-17(15)21-11-14)25-12-13-4-2-1-3-5-13/h1-8,10-11,18H,9,12H2,(H,22,23,24)
DMJKZUC CS C1=CC=C(C=C1)COC2=CC3=NC=C(C=C3C=C2)CC4C(=O)NC(=O)S4
DMJKZUC IK AZKFGOQRYCSQPK-UHFFFAOYSA-N
DMJKZUC IU 5-[(7-phenylmethoxyquinolin-3-yl)methyl]-1,3-thiazolidine-2,4-dione
DMJKZUC CA CAS 179068-64-5
DMJKZUC DE Discovery agent
DM45MGZ ID DM45MGZ
DM45MGZ DN NC-2500
DM45MGZ HS Investigative
DM45MGZ SN Xanthine oxidoreductase inhibitor (hyperuricemia), Nippon Chemiphar
DM45MGZ CP Nippon Chemiphar Co Ltd
DM45MGZ DE Hyperuricaemia
DMJ13TR ID DMJ13TR
DMJ13TR DN N-Carbamoyl-L-Aspartate
DMJ13TR HS Investigative
DMJ13TR SN N-carbamoyl-L-aspartate; N-Carbamoyl-L-aspartic acid; Ureidosuccinate; L-Ureidosuccinic acid; L-Ureidosuccinate; Carbamyl-L-aspartic acid; Carbamoylaspartic acid; N-Carbamoyl-S-aspartic acid; L-N-Carbamoylaspartic acid; Succinic acid, ureido-; Carbamylaspartic acid; Aspartic acid, N-carbamoyl-; UNII-R2521024DK; N-Carbamoylaspartic acid; 2-Ureidobutanedioic acid; 13184-27-5; EINECS 236-134-3; NSC 14983; L-Aspartic acid, N-(aminocarbonyl)-; N-(aminocarbonyl)-L-aspartic acid; R2521024DK; carbamyl-aspartate
DMJ13TR DT Small molecular drug
DMJ13TR PC 93072
DMJ13TR MW 176.13
DMJ13TR FM C5H8N2O5
DMJ13TR IC InChI=1S/C5H8N2O5/c6-5(12)7-2(4(10)11)1-3(8)9/h2H,1H2,(H,8,9)(H,10,11)(H3,6,7,12)/t2-/m0/s1
DMJ13TR CS C([C@@H](C(=O)O)NC(=O)N)C(=O)O
DMJ13TR IK HLKXYZVTANABHZ-REOHCLBHSA-N
DMJ13TR IU (2S)-2-(carbamoylamino)butanedioic acid
DMJ13TR CA CAS 13184-27-5
DMJ13TR CB CHEBI:15859
DMJ13TR DE Discovery agent
DMX80JF ID DMX80JF
DMX80JF DN N-Carboxymethionine
DMX80JF HS Investigative
DMX80JF SN N-Carboxymethionine; N-carboxy-L-methionine; carboxyl-methionine; SCHEMBL1298472; CHEBI:41696
DMX80JF DT Small molecular drug
DMX80JF PC 17753927
DMX80JF MW 193.22
DMX80JF FM C6H11NO4S
DMX80JF IC InChI=1S/C6H11NO4S/c1-12-3-2-4(5(8)9)7-6(10)11/h4,7H,2-3H2,1H3,(H,8,9)(H,10,11)/t4-/m0/s1
DMX80JF CS CSCC[C@@H](C(=O)O)NC(=O)O
DMX80JF IK LWQBAQJPCYBWJQ-BYPYZUCNSA-N
DMX80JF IU (2S)-2-(carboxyamino)-4-methylsulfanylbutanoic acid
DMX80JF CB CHEBI:41696
DMX80JF DE Discovery agent
DME9U7Y ID DME9U7Y
DME9U7Y DN N-Carboxymethyl-N-cyclopentyl-phthalamic acid
DME9U7Y HS Investigative
DME9U7Y SN CHEMBL115153; N-Carboxymethyl-N-cyclopentyl-phthalamic acid
DME9U7Y DT Small molecular drug
DME9U7Y PC 44340905
DME9U7Y MW 291.3
DME9U7Y FM C15H17NO5
DME9U7Y IC InChI=1S/C15H17NO5/c17-13(18)9-16(10-5-1-2-6-10)14(19)11-7-3-4-8-12(11)15(20)21/h3-4,7-8,10H,1-2,5-6,9H2,(H,17,18)(H,20,21)
DME9U7Y CS C1CCC(C1)N(CC(=O)O)C(=O)C2=CC=CC=C2C(=O)O
DME9U7Y IK KOAQPWKIMYZORZ-UHFFFAOYSA-N
DME9U7Y IU 2-[carboxymethyl(cyclopentyl)carbamoyl]benzoic acid
DME9U7Y DE Discovery agent
DM5KNCX ID DM5KNCX
DM5KNCX DN N-cetylgallate
DM5KNCX HS Investigative
DM5KNCX SN Cetyl gallate; 5026-65-3; Hexadecyl Gallate; Hexadecyl 3,4,5-trihydroxybenzoate; Gallic Acid Cetyl Ester; n-cetylgallate; n-Hexadecyl-gallate; UNII-X1J85N35ZO; CHEMBL464675; X1J85N35ZO; 3,4,5-Trihydroxybenzoic acid hexadecyl ester; Cetylgallat; HexadecylGallate; EINECS 225-715-7; ACMC-209kkz; AC1L2VUG; AC1Q67EH; Gallic Acid Hexadecyl Ester; SCHEMBL36506; Benzoic acid, 3,4,5-trihydroxy-, hexadecyl ester; CTK8B1762; DTXSID00198254; MolPort-006-116-598; TYCUSKFOGZNIBO-UHFFFAOYSA-N; KS-000013SR; BDBM50250973; ANW-30945; ZINC33861467
DM5KNCX DT Small molecular drug
DM5KNCX PC 78729
DM5KNCX MW 394.5
DM5KNCX FM C23H38O5
DM5KNCX IC InChI=1S/C23H38O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-28-23(27)19-17-20(24)22(26)21(25)18-19/h17-18,24-26H,2-16H2,1H3
DM5KNCX CS CCCCCCCCCCCCCCCCOC(=O)C1=CC(=C(C(=C1)O)O)O
DM5KNCX IK TYCUSKFOGZNIBO-UHFFFAOYSA-N
DM5KNCX IU hexadecyl 3,4,5-trihydroxybenzoate
DM5KNCX CA CAS 5026-65-3
DM5KNCX DE Discovery agent
DM0JCN2 ID DM0JCN2
DM0JCN2 DN NCFP
DM0JCN2 HS Investigative
DM0JCN2 SN NCFP; 774548-65-1; GTPL6471; SCHEMBL4069818; ZINC34517852; KB-274800
DM0JCN2 DT Small molecular drug
DM0JCN2 PC 11373218
DM0JCN2 MW 409.8
DM0JCN2 FM C21H13ClFN3O3
DM0JCN2 IC InChI=1S/C21H13ClFN3O3/c22-13-7-8-16(25-19(27)17-6-1-2-9-24-17)12(10-13)11-26-20(28)14-4-3-5-15(23)18(14)21(26)29/h1-10H,11H2,(H,25,27)
DM0JCN2 CS C1=CC=NC(=C1)C(=O)NC2=C(C=C(C=C2)Cl)CN3C(=O)C4=C(C3=O)C(=CC=C4)F
DM0JCN2 IK WBXKMHFMMCOTOK-UHFFFAOYSA-N
DM0JCN2 IU N-[4-chloro-2-[(4-fluoro-1,3-dioxoisoindol-2-yl)methyl]phenyl]pyridine-2-carboxamide
DM0JCN2 DE Discovery agent
DMMRWJG ID DMMRWJG
DMMRWJG DN NCG21
DMMRWJG HS Investigative
DMMRWJG SN compound 12 [PMID: 19007110]; NGC21
DMMRWJG DT Small molecular drug
DMMRWJG PC 25098573
DMMRWJG MW 376.4
DMMRWJG FM C23H24N2O3
DMMRWJG IC InChI=1S/C23H24N2O3/c26-23(27)11-6-7-19-12-14-21(15-13-19)28-18-17-25(20-8-2-1-3-9-20)22-10-4-5-16-24-22/h1-5,8-10,12-16H,6-7,11,17-18H2,(H,26,27)
DMMRWJG CS C1=CC=C(C=C1)N(CCOC2=CC=C(C=C2)CCCC(=O)O)C3=CC=CC=N3
DMMRWJG IK WQXHZCYCKCQFQP-UHFFFAOYSA-N
DMMRWJG IU 4-[4-[2-(N-pyridin-2-ylanilino)ethoxy]phenyl]butanoic acid
DMMRWJG DE Discovery agent
DMY8RT9 ID DMY8RT9
DMY8RT9 DN NCGC00167772-01
DMY8RT9 HS Investigative
DMY8RT9 SN 10-DEBC
DMY8RT9 DT Small molecular drug
DMY8RT9 PC 10521421
DMY8RT9 MW 344.9
DMY8RT9 FM C20H25ClN2O
DMY8RT9 IC InChI=1S/C20H25ClN2O/c1-3-22(4-2)13-7-8-14-23-17-9-5-6-10-19(17)24-20-12-11-16(21)15-18(20)23/h5-6,9-12,15H,3-4,7-8,13-14H2,1-2H3
DMY8RT9 CS CCN(CC)CCCCN1C2=CC=CC=C2OC3=C1C=C(C=C3)Cl
DMY8RT9 IK GYBXAGDWMCJZJK-UHFFFAOYSA-N
DMY8RT9 IU 4-(2-chlorophenoxazin-10-yl)-N,N-diethylbutan-1-amine
DMY8RT9 CB CHEBI:94104
DMY8RT9 DE Discovery agent
DM6VEON ID DM6VEON
DM6VEON DN N-chloromethyl-brucine
DM6VEON HS Investigative
DM6VEON SN N-chloromethylbrucine
DM6VEON DT Small molecular drug
DM6VEON PC 44358908
DM6VEON MW 443.9
DM6VEON FM C24H28ClN2O4+
DM6VEON IC InChI=1S/C24H28ClN2O4/c1-29-17-8-15-16(9-18(17)30-2)26-21(28)10-19-22-14-7-20-24(15,23(22)26)4-5-27(20,12-25)11-13(14)3-6-31-19/h3,8-9,14,19-20,22-23H,4-7,10-12H2,1-2H3/q+1/t14-,19-,20-,22-,23-,24+,27?/m0/s1
DM6VEON CS COC1=C(C=C2C(=C1)[C@]34CC[N+]5([C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)CCl)OC
DM6VEON IK GCEPQLWZBVGLQN-CQIPDZJVSA-N
DM6VEON IU (4aR,5aS,8aS,13aS,15aS,15bR)-6-(chloromethyl)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-6-ium-14-one
DM6VEON DE Discovery agent
DMTCBLS ID DMTCBLS
DMTCBLS DN NCI-159878
DMTCBLS HS Investigative
DMTCBLS DT Small molecular drug
DMTCBLS PC 135444922
DMTCBLS MW 352.5
DMTCBLS FM C20H20N2O2S
DMTCBLS IC InChI=1S/C20H20N2O2S/c1-14-7-9-16(10-8-14)18-17(11-12-23)19(24)22-20(21-18)25-13-15-5-3-2-4-6-15/h2-10,23H,11-13H2,1H3,(H,21,22,24)
DMTCBLS CS CC1=CC=C(C=C1)C2=C(C(=O)NC(=N2)SCC3=CC=CC=C3)CCO
DMTCBLS IK MMKBRXXCKNYUMD-UHFFFAOYSA-N
DMTCBLS IU 2-benzylsulfanyl-5-(2-hydroxyethyl)-4-(4-methylphenyl)-1H-pyrimidin-6-one
DMTCBLS DE Discovery agent
DM9C7GP ID DM9C7GP
DM9C7GP DN NCI-58425
DM9C7GP HS Investigative
DM9C7GP SN NCI-58425; CHEMBL493092; 1-(4-butoxyphenoxy)-2-nitro-4-(trifluoromethyl)benzene; NSC58425; AC1L6H0N; NCIOpen2_007805; CTK6E3412; ZINC1689072; NSC-58425; BDBM50253286; 1-(4 butoxyphenoxy)-2-nitro-4-(trifluoromethyl)-benzene
DM9C7GP DT Small molecular drug
DM9C7GP PC 245951
DM9C7GP MW 355.31
DM9C7GP FM C17H16F3NO4
DM9C7GP IC InChI=1S/C17H16F3NO4/c1-2-3-10-24-13-5-7-14(8-6-13)25-16-9-4-12(17(18,19)20)11-15(16)21(22)23/h4-9,11H,2-3,10H2,1H3
DM9C7GP CS CCCCOC1=CC=C(C=C1)OC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
DM9C7GP IK AOQOXPPRTCVMPF-UHFFFAOYSA-N
DM9C7GP IU 1-(4-butoxyphenoxy)-2-nitro-4-(trifluoromethyl)benzene
DM9C7GP DE Discovery agent
DMH1BVG ID DMH1BVG
DMH1BVG DN NCL-1
DMH1BVG HS Investigative
DMH1BVG SN NCL-1; GTPL7024; ZINC94568752
DMH1BVG DT Small molecular drug
DMH1BVG PC 73755256
DMH1BVG MW 443.5
DMH1BVG FM C27H29N3O3
DMH1BVG IC InChI=1S/C27H29N3O3/c28-24-17-23(24)21-12-7-13-22(16-21)33-15-14-25(30-26(31)20-10-5-2-6-11-20)27(32)29-18-19-8-3-1-4-9-19/h1-13,16,23-25H,14-15,17-18,28H2,(H,29,32)(H,30,31)/t23-,24+,25+/m0/s1
DMH1BVG CS C1[C@H]([C@@H]1N)C2=CC(=CC=C2)OCC[C@H](C(=O)NCC3=CC=CC=C3)NC(=O)C4=CC=CC=C4
DMH1BVG IK DTPSXFMGMQOVTG-ISJGIBHGSA-N
DMH1BVG IU N-[(2R)-4-[3-[(1S,2R)-2-aminocyclopropyl]phenoxy]-1-(benzylamino)-1-oxobutan-2-yl]benzamide
DMH1BVG DE Discovery agent
DM1K64F ID DM1K64F
DM1K64F DN N-CPM[D-Pro-10]Dyn A-(1-11)
DM1K64F HS Investigative
DM1K64F SN CHEMBL442323; N-CPM[D-Pro-10]Dyn A-(1-11)
DM1K64F PC 44325419
DM1K64F MW 1416.7
DM1K64F FM C67H109N21O13
DM1K64F IC InChI=1S/C67H109N21O13/c1-5-40(4)55(62(98)84-47(20-13-31-77-67(73)74)63(99)88-32-14-21-52(88)61(97)85-48(64(100)101)17-9-10-28-68)87-58(94)46(19-12-30-76-66(71)72)82-57(93)45(18-11-29-75-65(69)70)83-59(95)50(33-39(2)3)86-60(96)51(35-41-15-7-6-8-16-41)81-54(91)38-79-53(90)37-80-56(92)49(78-36-43-22-23-43)34-42-24-26-44(89)27-25-42/h6-8,15-16,24-27,39-40,43,45-52,55,78,89H,5,9-14,17-23,28-38,68H2,1-4H3,(H,79,90)(H,80,92)(H,81,91)(H,82,93)(H,83,95)(H,84,98)(H,85,97)(H,86,96)(H,87,94)(H,100,101)(H4,69,70,75)(H4,71,72,76)(H4,73,74,77)/t40-,45-,46-,47-,48-,49-,50-,51-,52-,55-/m0/s1
DM1K64F CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)CNC(=O)[C@H](CC3=CC=C(C=C3)O)NCC4CC4
DM1K64F IK CFPWTFGNSPUUJD-RWKXLGHPSA-N
DM1K64F IU (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-(cyclopropylmethylamino)-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
DM1K64F DE Discovery agent
DM09UFT ID DM09UFT
DM09UFT DN NCT-400
DM09UFT HS Investigative
DM09UFT CP Nectid Inc
DM09UFT DE Major depressive disorder
DM1FOSP ID DM1FOSP
DM1FOSP DN NCX-1047
DM1FOSP HS Investigative
DM1FOSP SN GF-015647; GF-015646-00; NO-donating corticosteroids (skin inflammation), NicOx/Grupo Ferrer International
DM1FOSP CP NicOx SA
DM1FOSP DE Dermatitis
DMUHXRA ID DMUHXRA
DMUHXRA DN NCX-1067
DMUHXRA HS Investigative
DMUHXRA CP NicOx SA
DMUHXRA DE Discovery agent
DMYBWXR ID DMYBWXR
DMYBWXR DN NCX-125
DMYBWXR HS Investigative
DMYBWXR SN NO-donating latanoprost analog (glaucoma), NicOx
DMYBWXR CP NicOx SA
DMYBWXR DE Glaucoma/ocular hypertension
DM5T23S ID DM5T23S
DM5T23S DN N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide
DM5T23S HS Investigative
DM5T23S SN CHEMBL591233; BDBM50308398
DM5T23S DT Small molecular drug
DM5T23S PC 46229054
DM5T23S MW 296.4
DM5T23S FM C17H16N2OS
DM5T23S IC InChI=1S/C17H16N2OS/c20-17(18-12-6-5-7-12)19-13-8-1-3-10-15(13)21-16-11-4-2-9-14(16)19/h1-4,8-12H,5-7H2,(H,18,20)
DM5T23S CS C1CC(C1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM5T23S IK KNYQZMOQFRAHIS-UHFFFAOYSA-N
DM5T23S IU N-cyclobutylphenothiazine-10-carboxamide
DM5T23S DE Discovery agent
DM1GTVW ID DM1GTVW
DM1GTVW DN N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide
DM1GTVW HS Investigative
DM1GTVW SN CHEMBL578346; N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide
DM1GTVW DT Small molecular drug
DM1GTVW PC 45487773
DM1GTVW MW 308.4
DM1GTVW FM C20H24N2O
DM1GTVW IC InChI=1S/C20H24N2O/c23-20(17-9-8-15-4-1-2-5-16(15)14-17)22(18-6-3-7-18)19-10-12-21-13-11-19/h1-2,4-5,8-9,14,18-19,21H,3,6-7,10-13H2
DM1GTVW CS C1CC(C1)N(C2CCNCC2)C(=O)C3=CC4=CC=CC=C4C=C3
DM1GTVW IK AZTPZTRJVCAAMX-UHFFFAOYSA-N
DM1GTVW IU N-cyclobutyl-N-piperidin-4-ylnaphthalene-2-carboxamide
DM1GTVW DE Discovery agent
DMMW8J1 ID DMMW8J1
DMMW8J1 DN N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide
DMMW8J1 HS Investigative
DMMW8J1 SN CHEMBL591234; N-cyclohexyl-10H-phenothiazine-10-carboxamide; N-cyclohexylphenothiazine-10-carboxamide; AC1LE3I3; Oprea1_381015; ZINC91236; MolPort-002-173-208; BDBM50308400; STK225048; AKOS001676630; MCULE-5781141750; CCG-113839; N-cyclohexylphenothiazin-10-ylcarboxamide; 371937-04-1; ST51023365; AB00099848-01; N-Cyclohexyl-1''H-phenothiazine-1''-carboxamide; SR-01000506168
DMMW8J1 DT Small molecular drug
DMMW8J1 PC 705769
DMMW8J1 MW 324.4
DMMW8J1 FM C19H20N2OS
DMMW8J1 IC InChI=1S/C19H20N2OS/c22-19(20-14-8-2-1-3-9-14)21-15-10-4-6-12-17(15)23-18-13-7-5-11-16(18)21/h4-7,10-14H,1-3,8-9H2,(H,20,22)
DMMW8J1 CS C1CCC(CC1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DMMW8J1 IK OKOVWMHSIFSGRG-UHFFFAOYSA-N
DMMW8J1 IU N-cyclohexylphenothiazine-10-carboxamide
DMMW8J1 DE Discovery agent
DM8HS0B ID DM8HS0B
DM8HS0B DN N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide
DM8HS0B HS Investigative
DM8HS0B SN N-cyclohexyl-2-(4-methoxyphenyl)acetamide; CHEMBL192461; N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide; AC1LE46L; Oprea1_816678; Oprea1_273819; SCHEMBL5049577; ARONIS000952; MolPort-001-621-938; ZINC142289; KS-00003UJ3; BDBM50167045; STK011304; AKOS000490473; MCULE-1564646854; ST039784; KB-104378; EU-0043158; J3.583.162B; N-cyclohexyl-2-[4-(methyloxy)phenyl]acetamide; SR-01000082042; AG-690/11634830
DM8HS0B DT Small molecular drug
DM8HS0B PC 729989
DM8HS0B MW 247.33
DM8HS0B FM C15H21NO2
DM8HS0B IC InChI=1S/C15H21NO2/c1-18-14-9-7-12(8-10-14)11-15(17)16-13-5-3-2-4-6-13/h7-10,13H,2-6,11H2,1H3,(H,16,17)
DM8HS0B CS COC1=CC=C(C=C1)CC(=O)NC2CCCCC2
DM8HS0B IK OUQSDJMKYLLVED-UHFFFAOYSA-N
DM8HS0B IU N-cyclohexyl-2-(4-methoxyphenyl)acetamide
DM8HS0B CA CAS 330467-51-1
DM8HS0B DE Discovery agent
DMRA548 ID DMRA548
DMRA548 DN N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
DMRA548 HS Investigative
DMRA548 SN N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide; N-cyclohexyl-2-oxochromene-3-carboxamide; 2-Oxo-2H-chromene-3-carboxylic acid cyclohexylamide; 4021-23-2; BAS 00837943; ChemDiv2_003298; 3-carboxamido coumarin, 1; AC1Q5N8P; AC1LF7K7; Oprea1_254332; Oprea1_273725; CHEMBL472080; BDBM29152; CTK1C9968; DTXSID70352366; MolPort-001-028-458; ZINC130287; HMS1378F20; CCG-15837; STK408165; AKOS000533315; MCULE-8945496486; N-cyclohexyl(2-oxochromen-3-yl)carboxamide; EU-0035943; ST50185340; SR-01000410421; SR-01000410421-1
DMRA548 DT Small molecular drug
DMRA548 PC 724217
DMRA548 MW 271.31
DMRA548 FM C16H17NO3
DMRA548 IC InChI=1S/C16H17NO3/c18-15(17-12-7-2-1-3-8-12)13-10-11-6-4-5-9-14(11)20-16(13)19/h4-6,9-10,12H,1-3,7-8H2,(H,17,18)
DMRA548 CS C1CCC(CC1)NC(=O)C2=CC3=CC=CC=C3OC2=O
DMRA548 IK KUWSPPXPGQEHSQ-UHFFFAOYSA-N
DMRA548 IU N-cyclohexyl-2-oxochromene-3-carboxamide
DMRA548 CA CAS 4021-23-2
DMRA548 DE Discovery agent
DM15MQT ID DM15MQT
DM15MQT DN N-Cyclohexyl-2-phenyl-acetamide
DM15MQT HS Investigative
DM15MQT SN N-Cyclohexyl-2-phenylacetamide; N-Cyclohexylphenylacetamide; Acetamide, N-cyclohexyl-2-phenyl-; 10264-08-1; EINECS 233-602-9; N-Cyclohexylamide of phenylacetic acid; UNII-VY9DC35P8W; NSC 126805; BRN 2102004; VY9DC35P8W; MLS002919901; CHEMBL191355; SMR001797500; N-Cyclohexyl-2-phenyl-acetamide; NSC126805; N-Cyclohexylbenzeneacetamide; AC1L33JD; MLS006026924; 4-12-00-00045 (Beilstein Handbook Reference); Benzeneacetamide,N-cyclohexyl-; SCHEMBL3397254; CTK4A1359; DTXSID20145427; MolPort-002-799-328; ZINC339690; STK031107; BDBM50167047
DM15MQT DT Small molecular drug
DM15MQT PC 82500
DM15MQT MW 217.31
DM15MQT FM C14H19NO
DM15MQT IC InChI=1S/C14H19NO/c16-14(11-12-7-3-1-4-8-12)15-13-9-5-2-6-10-13/h1,3-4,7-8,13H,2,5-6,9-11H2,(H,15,16)
DM15MQT CS C1CCC(CC1)NC(=O)CC2=CC=CC=C2
DM15MQT IK ZFEBPJQSSNUJGT-UHFFFAOYSA-N
DM15MQT IU N-cyclohexyl-2-phenylacetamide
DM15MQT CA CAS 10264-08-1
DM15MQT DE Discovery agent
DMCDBM5 ID DMCDBM5
DMCDBM5 DN N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5 HS Investigative
DMCDBM5 SN CHEMBL382873; N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5 DT Small molecular drug
DMCDBM5 PC 44407801
DMCDBM5 MW 331.4
DMCDBM5 FM C18H21NO3S
DMCDBM5 IC InChI=1S/C18H21NO3S/c20-17-11-13-18(14-12-17)23(21,22)19(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1,3-4,7-8,11-14,16,20H,2,5-6,9-10H2
DMCDBM5 CS C1CCC(CC1)N(C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)O
DMCDBM5 IK INJVHCJLNBTEGC-UHFFFAOYSA-N
DMCDBM5 IU N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide
DMCDBM5 DE Discovery agent
DM2COR5 ID DM2COR5
DM2COR5 DN N-Cyclohexyl-4-phenyl-butyramide
DM2COR5 HS Investigative
DM2COR5 SN N-cyclohexyl-4-phenylbutanamide; CHEMBL192843; benzenebutanamide, n-cyclohexyl-; N-Cyclohexyl-4-phenyl-butyramide; NSC150176; AC1Q5NBS; Cambridge id 5104259; AC1L6AF5; Oprea1_396588; CBDivE_014082; 64353-78-2; SCHEMBL12932000; MolPort-002-130-322; ZINC365623; STL389940; BDBM50167062; AKOS008967884; NSC-150176; MCULE-1526608627
DM2COR5 DT Small molecular drug
DM2COR5 PC 288831
DM2COR5 MW 245.36
DM2COR5 FM C16H23NO
DM2COR5 IC InChI=1S/C16H23NO/c18-16(17-15-11-5-2-6-12-15)13-7-10-14-8-3-1-4-9-14/h1,3-4,8-9,15H,2,5-7,10-13H2,(H,17,18)
DM2COR5 CS C1CCC(CC1)NC(=O)CCCC2=CC=CC=C2
DM2COR5 IK NWKPABISVRIQLP-UHFFFAOYSA-N
DM2COR5 IU N-cyclohexyl-4-phenylbutanamide
DM2COR5 CA CAS 64353-78-2
DM2COR5 DE Discovery agent
DMCH5M1 ID DMCH5M1
DMCH5M1 DN N-Cyclohexylethyl-ETAV
DMCH5M1 HS Investigative
DMCH5M1 SN N-Cyclohexylethyl-ETAV; CHEMBL493688; SCHEMBL17856941
DMCH5M1 DT Small molecular drug
DMCH5M1 PC 44568836
DMCH5M1 MW 528.6
DMCH5M1 FM C25H44N4O8
DMCH5M1 IC InChI=1S/C25H44N4O8/c1-14(2)20(25(36)37)28-22(33)15(3)27-24(35)21(16(4)30)29-23(34)18(10-11-19(31)32)26-13-12-17-8-6-5-7-9-17/h14-18,20-21,26,30H,5-13H2,1-4H3,(H,27,35)(H,28,33)(H,29,34)(H,31,32)(H,36,37)/t15-,16?,18-,20-,21-/m0/s1
DMCH5M1 CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCCC1CCCCC1
DMCH5M1 IK APPLGLBBZPGQBX-GDEPEFMTSA-N
DMCH5M1 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(2-cyclohexylethylamino)-5-oxopentanoic acid
DMCH5M1 DE Discovery agent
DMIC8Z6 ID DMIC8Z6
DMIC8Z6 DN N-Cyclohexylmethyl-ETAV
DMIC8Z6 HS Investigative
DMIC8Z6 SN N-Cyclohexylmethyl-ETAV; CHEMBL494486
DMIC8Z6 DT Small molecular drug
DMIC8Z6 PC 44568835
DMIC8Z6 MW 514.6
DMIC8Z6 FM C24H42N4O8
DMIC8Z6 IC InChI=1S/C24H42N4O8/c1-13(2)19(24(35)36)27-21(32)14(3)26-23(34)20(15(4)29)28-22(33)17(10-11-18(30)31)25-12-16-8-6-5-7-9-16/h13-17,19-20,25,29H,5-12H2,1-4H3,(H,26,34)(H,27,32)(H,28,33)(H,30,31)(H,35,36)/t14-,15?,17-,19-,20-/m0/s1
DMIC8Z6 CS C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCC(=O)O)NCC1CCCCC1
DMIC8Z6 IK NRBYXUOJAWZKTA-VFWSWVEUSA-N
DMIC8Z6 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(cyclohexylmethylamino)-5-oxopentanoic acid
DMIC8Z6 DE Discovery agent
DMPSYRW ID DMPSYRW
DMPSYRW DN N-Cyclohexyl-N'-(4-Iodophenyl)Urea
DMPSYRW HS Investigative
DMPSYRW SN n-cyclohexyl-n'-(4-iodophenyl)urea; 1-cyclohexyl-3-(4-iodophenyl)urea; CIU; CHEBI:41480; 1-cyclohexyl-3-(p-iodophenyl)urea; N-cyclohexyl-N'-(p-iodophenyl)urea; 1ek1; 1vj5; AC1L1HZD; ARONIS008643; SCHEMBL4319424; CHEMBL1231797; CTK7G5624; MolPort-001-492-073; BDBM129304; HMS3604N07; KS-000040FO; ZINC1003537; STL069107; AKOS000497853; MCULE-2142424658; DB02029; KB-104481; ST45045386; (cyclohexylamino)-N-(4-iodophenyl)carboxamide; US8815951, 53
DMPSYRW DT Small molecular drug
DMPSYRW PC 4357
DMPSYRW MW 344.19
DMPSYRW FM C13H17IN2O
DMPSYRW IC InChI=1S/C13H17IN2O/c14-10-6-8-12(9-7-10)16-13(17)15-11-4-2-1-3-5-11/h6-9,11H,1-5H2,(H2,15,16,17)
DMPSYRW CS C1CCC(CC1)NC(=O)NC2=CC=C(C=C2)I
DMPSYRW IK AQTBUVAFYDVTFD-UHFFFAOYSA-N
DMPSYRW IU 1-cyclohexyl-3-(4-iodophenyl)urea
DMPSYRW CB CHEBI:41480
DMPSYRW DE Discovery agent
DMYF243 ID DMYF243
DMYF243 DN N-Cyclohexyl-N'-(Propyl)Phenyl Urea
DMYF243 HS Investigative
DMYF243 SN 1-cyclohexyl-3-(3-phenylpropyl)urea; n-cyclohexyl-n'-(propyl)phenyl urea; 1cr6; AC1L1HZG; Cambridge id 7261612; SCHEMBL4955112; CHEMBL1231909; MolPort-001-541-502; HMS3604O05; BDBM129287; ZINC2047156; STK432683; AKOS003282138; DB04213; MCULE-7021945009; ST50924514; (cyclohexylamino)-N-(3-phenylpropyl)carboxamide; US8815951, 104; SR-01000883953
DMYF243 DT Small molecular drug
DMYF243 PC 4358
DMYF243 MW 260.37
DMYF243 FM C16H24N2O
DMYF243 IC InChI=1S/C16H24N2O/c19-16(18-15-11-5-2-6-12-15)17-13-7-10-14-8-3-1-4-9-14/h1,3-4,8-9,15H,2,5-7,10-13H2,(H2,17,18,19)
DMYF243 CS C1CCC(CC1)NC(=O)NCCCC2=CC=CC=C2
DMYF243 IK HBTZVNKXMFGOOJ-UHFFFAOYSA-N
DMYF243 IU 1-cyclohexyl-3-(3-phenylpropyl)urea
DMYF243 DE Discovery agent
DM17G82 ID DM17G82
DM17G82 DN N-Cyclohexyl-N'-Decylurea
DM17G82 HS Investigative
DM17G82 SN n-cyclohexyl-n'-decylurea; 1-cyclohexyl-3-decylurea; CHEMBL67158; 287185-28-8; 1ek2; AC1L1HZJ; 1-Cyclohexyl-3-decyl-urea; Urea, N-cyclohexyl-N'-decyl-; SCHEMBL4997375; CTK0J1876; DTXSID50274431; N-CYCLOHEXYL-N''-DECYLUREA; ZINC14880861; BDBM50143925; AKOS003880320; MCULE-7968258309; DB03677; US8815951, 153
DM17G82 DT Small molecular drug
DM17G82 PC 4359
DM17G82 MW 282.5
DM17G82 FM C17H34N2O
DM17G82 IC InChI=1S/C17H34N2O/c1-2-3-4-5-6-7-8-12-15-18-17(20)19-16-13-10-9-11-14-16/h16H,2-15H2,1H3,(H2,18,19,20)
DM17G82 CS CCCCCCCCCCNC(=O)NC1CCCCC1
DM17G82 IK LPXYBLIRYGCMPQ-UHFFFAOYSA-N
DM17G82 IU 1-cyclohexyl-3-decylurea
DM17G82 CA CAS 287185-28-8
DM17G82 DE Discovery agent
DMJ0T3W ID DMJ0T3W
DMJ0T3W DN N-cyclohexylquinazolin-4-amine
DMJ0T3W HS Investigative
DMJ0T3W SN N-cyclohexylquinazolin-4-amine; CHEMBL513012; 81080-06-0; Oprea1_305199; CTK2I7170; DTXSID10530489; 4-Quinazolinamine, N-cyclohexyl-; MolPort-008-958-618; ZINC27534370; BDBM50278114; AKOS008969009; MCULE-5342672910; SR-01000467804; SR-01000467804-1
DMJ0T3W DT Small molecular drug
DMJ0T3W PC 13231190
DMJ0T3W MW 227.3
DMJ0T3W FM C14H17N3
DMJ0T3W IC InChI=1S/C14H17N3/c1-2-6-11(7-3-1)17-14-12-8-4-5-9-13(12)15-10-16-14/h4-5,8-11H,1-3,6-7H2,(H,15,16,17)
DMJ0T3W CS C1CCC(CC1)NC2=NC=NC3=CC=CC=C32
DMJ0T3W IK CIFOBGKTSPXVQX-UHFFFAOYSA-N
DMJ0T3W IU N-cyclohexylquinazolin-4-amine
DMJ0T3W CA CAS 81080-06-0
DMJ0T3W DE Discovery agent
DMJY2PA ID DMJY2PA
DMJY2PA DN N-cyclohexylquinolin-4-amine
DMJY2PA HS Investigative
DMJY2PA SN CHEMBL449616; N-cyclohexylquinolin-4-amine; BDBM50278115
DMJY2PA DT Small molecular drug
DMJY2PA PC 44591867
DMJY2PA MW 226.32
DMJY2PA FM C15H18N2
DMJY2PA IC InChI=1S/C15H18N2/c1-2-6-12(7-3-1)17-15-10-11-16-14-9-5-4-8-13(14)15/h4-5,8-12H,1-3,6-7H2,(H,16,17)
DMJY2PA CS C1CCC(CC1)NC2=CC=NC3=CC=CC=C32
DMJY2PA IK XRSBCRPPSASDNY-UHFFFAOYSA-N
DMJY2PA IU N-cyclohexylquinolin-4-amine
DMJY2PA DE Discovery agent
DM0KDSA ID DM0KDSA
DM0KDSA DN N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide
DM0KDSA HS Investigative
DM0KDSA SN CHEMBL601297; AC1LE08W; Cambridge id 6793618; Oprea1_215546; ZINC88021; MolPort-002-222-847; BDBM50308399; AKOS001667643; MCULE-5831533144; N-cyclopentylphenothiazine-10-carboxamide; EU-0013438; AB00119419-01
DM0KDSA DT Small molecular drug
DM0KDSA PC 704267
DM0KDSA MW 310.4
DM0KDSA FM C18H18N2OS
DM0KDSA IC InChI=1S/C18H18N2OS/c21-18(19-13-7-1-2-8-13)20-14-9-3-5-11-16(14)22-17-12-6-4-10-15(17)20/h3-6,9-13H,1-2,7-8H2,(H,19,21)
DM0KDSA CS C1CCC(C1)NC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
DM0KDSA IK WVGVWICAQSPEPE-UHFFFAOYSA-N
DM0KDSA IU N-cyclopentylphenothiazine-10-carboxamide
DM0KDSA DE Discovery agent
DMDPKCM ID DMDPKCM
DMDPKCM DN N-cyclopentyl-6-(2-phenylethynyl)nicotinamide
DMDPKCM HS Investigative
DMDPKCM SN CHEMBL551958; N-cyclopentyl-6-(2-phenylethynyl)nicotinamide
DMDPKCM DT Small molecular drug
DMDPKCM PC 44224196
DMDPKCM MW 290.4
DMDPKCM FM C19H18N2O
DMDPKCM IC InChI=1S/C19H18N2O/c22-19(21-18-8-4-5-9-18)16-11-13-17(20-14-16)12-10-15-6-2-1-3-7-15/h1-3,6-7,11,13-14,18H,4-5,8-9H2,(H,21,22)
DMDPKCM CS C1CCC(C1)NC(=O)C2=CN=C(C=C2)C#CC3=CC=CC=C3
DMDPKCM IK GKYRUZWYDPUSOV-UHFFFAOYSA-N
DMDPKCM IU N-cyclopentyl-6-(2-phenylethynyl)pyridine-3-carboxamide
DMDPKCM DE Discovery agent
DMMODRE ID DMMODRE
DMMODRE DN ND-2110
DMMODRE HS Investigative
DMMODRE SN CHEMBL3361254; 2-[(3~{R})-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.0^{2,6}]dodeca-1(8),2(6),9,11-tetraen-3-yl]ethanamide; ND-2110; GTPL8082; SCHEMBL15228032; SCHEMBL10344171; BDBM50040806; ZINC299825077; 2-[(3R)-12-{[(1r,4r)-4-(morpholin-4-yl)cyclohexyl]oxy}-7-thia-9,11-diazatricyclo[6.4.0.0(2),]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
DMMODRE DT Small molecular drug
DMMODRE PC 68115559
DMMODRE MW 416.5
DMMODRE FM C21H28N4O3S
DMMODRE IC InChI=1S/C21H28N4O3S/c22-17(26)11-13-1-6-16-18(13)19-20(23-12-24-21(19)29-16)28-15-4-2-14(3-5-15)25-7-9-27-10-8-25/h12-15H,1-11H2,(H2,22,26)/t13-,14?,15?/m1/s1
DMMODRE CS C1CC2=C([C@H]1CC(=O)N)C3=C(N=CN=C3S2)OC4CCC(CC4)N5CCOCC5
DMMODRE IK VZOLINZYKOLXAC-WLYUNCDWSA-N
DMMODRE IU 2-[(3R)-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraen-3-yl]acetamide
DMMODRE DE Discovery agent
DMH7GLE ID DMH7GLE
DMH7GLE DN ND-2158
DMH7GLE HS Investigative
DMH7GLE SN CHEMBL3361255; ND-2158; GTPL8083; SCHEMBL15227691; SCHEMBL15115519; BDBM50040805
DMH7GLE DT Small molecular drug
DMH7GLE PC 86343751
DMH7GLE MW 446.6
DMH7GLE FM C22H30N4O4S
DMH7GLE IC InChI=1S/C22H30N4O4S/c23-20(28)16(27)11-13-1-6-17-18(13)19-21(24-12-25-22(19)31-17)30-15-4-2-14(3-5-15)26-7-9-29-10-8-26/h12-16,27H,1-11H2,(H2,23,28)/t13-,14?,15?,16+/m1/s1
DMH7GLE CS C1CC2=C([C@H]1C[C@@H](C(=O)N)O)C3=C(N=CN=C3S2)OC4CCC(CC4)N5CCOCC5
DMH7GLE IK ZSMULWAVKYFPSS-LMPOIIKSSA-N
DMH7GLE IU (2S)-2-hydroxy-3-[(3R)-12-(4-morpholin-4-ylcyclohexyl)oxy-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(12),2(6),8,10-tetraen-3-yl]propanamide
DMH7GLE DE Discovery agent
DMT0NQS ID DMT0NQS
DMT0NQS DN ND-401
DMT0NQS HS Investigative
DMT0NQS SN ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals
DMT0NQS CP NeED Pharmaceuticals Srl
DMT0NQS DE Human immunodeficiency virus infection
DM7NJI2 ID DM7NJI2
DM7NJI2 DN NDC-1022
DM7NJI2 HS Investigative
DM7NJI2 SN Estrogen receptor beta agonists (cancer); NDC-1308; Estrogen receptor beta agonists (cancer), Endece
DM7NJI2 CP Endece LLC
DM7NJI2 DE Solid tumour/cancer
DMBFC1U ID DMBFC1U
DMBFC1U DN N-desalkylquetiapine
DMBFC1U HS Investigative
DMBFC1U SN norquetiapine
DMBFC1U DT Small molecular drug
DMBFC1U PC 11369918
DMBFC1U MW 295.4
DMBFC1U FM C17H17N3S
DMBFC1U IC InChI=1S/C17H17N3S/c1-3-7-15-13(5-1)17(20-11-9-18-10-12-20)19-14-6-2-4-8-16(14)21-15/h1-8,18H,9-12H2
DMBFC1U CS C1CN(CCN1)C2=NC3=CC=CC=C3SC4=CC=CC=C42
DMBFC1U IK JLOAJISUHPIQOX-UHFFFAOYSA-N
DMBFC1U IU 6-piperazin-1-ylbenzo[b][1,4]benzothiazepine
DMBFC1U CA CAS 5747-48-8
DMBFC1U DE Discovery agent
DMV5RZM ID DMV5RZM
DMV5RZM DN N-dodecylgallate
DMV5RZM HS Investigative
DMV5RZM SN Dodecyl gallate; Lauryl gallate; 1166-52-5; Dodecyl 3,4,5-trihydroxybenzoate; Nipagallin LA; Progallin LA; Gallic acid, dodecyl ester; Gallic acid, lauryl ester; n-Dodecyl gallate; n-dodecylgallate; BENZOIC ACID, 3,4,5-TRIHYDROXY-, DODECYL ESTER; Gallic Acid Dodecyl Ester; Lauryl 3,4,5-trihydroxybenzoate; antioxidant E 312; E-312 antioxidant; E 312 antioxidant; Dodecylester kyseliny gallove; antioxidant E-312; NSC 133463; CCRIS 5568; GALLIC ACID LAURYL ESTER; UNII-45612DY463; EINECS 214-620-6; Dodecylester kyseliny gallove [Czech
DMV5RZM DT Small molecular drug
DMV5RZM PC 14425
DMV5RZM MW 338.4
DMV5RZM FM C19H30O5
DMV5RZM IC InChI=1S/C19H30O5/c1-2-3-4-5-6-7-8-9-10-11-12-24-19(23)15-13-16(20)18(22)17(21)14-15/h13-14,20-22H,2-12H2,1H3
DMV5RZM CS CCCCCCCCCCCCOC(=O)C1=CC(=C(C(=C1)O)O)O
DMV5RZM IK RPWFJAMTCNSJKK-UHFFFAOYSA-N
DMV5RZM IU dodecyl 3,4,5-trihydroxybenzoate
DMV5RZM CA CAS 1166-52-5
DMV5RZM DE Discovery agent
DMTMHW2 ID DMTMHW2
DMTMHW2 DN NDP-alpha-MSH
DMTMHW2 HS Investigative
DMTMHW2 PC 16154396
DMTMHW2 MW 1646.8
DMTMHW2 FM C78H111N21O19
DMTMHW2 IC InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
DMTMHW2 CS CCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N5CCC[C@H]5C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)C
DMTMHW2 IK UAHFGYDRQSXQEB-LEBBXHLNSA-N
DMTMHW2 IU (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
DMTMHW2 CA CAS 75921-69-6
DMTMHW2 CB CHEBI:136034
DMTMHW2 DE Discovery agent
DMRV16G ID DMRV16G
DMRV16G DN NDP-SYSMEHFRWGKPVG
DMRV16G HS Investigative
DMRV16G PC 91936745
DMRV16G MW 2007.2
DMRV16G FM C90H127N25O26S
DMRV16G IC InChI=1S/C90H127N25O26S/c1-47(2)74(87(139)100-43-73(125)126)113-86(138)68-21-13-31-114(68)88(140)59(18-9-10-29-91)102-70(120)42-99-76(128)62(36-50-40-98-55-17-8-7-16-53(50)55)108-77(129)56(19-11-30-97-90(94)95)103-80(132)60(34-48-14-5-4-6-15-48)106-82(134)63(37-51-41-96-46-101-51)109-78(130)57(26-27-71(121)122)104-79(131)58(28-33-142-3)105-83(135)65(44-116)111-81(133)61(35-49-22-24-52(118)25-23-49)107-84(136)66(45-117)112-85(137)67-20-12-32-115(67)89(141)64(39-72(123)124)110-75(127)54(92)38-69(93)119/h4-8,14-17,22-25,40-41,46-47,54,56-68,74,98,116-118H,9-13,18-21,26-39,42-45,91-92H2,1-3H3,(H2,93,119)(H,96,101)(H,99,128)(H,100,139)(H,102,120)(H,103,132)(H,104,131)(H,105,135)(H,106,134)(H,107,136)(H,108,129)(H,109,130)(H,110,127)(H,111,133)(H,112,137)(H,113,138)(H,121,122)(H,123,124)(H,125,126)(H4,94,95,97)/t54-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,74-/m0/s1
DMRV16G CS CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CO)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N
DMRV16G IK BUVGQEXSQXRZQG-LBQSHGEUSA-N
DMRV16G IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-(carboxymethylamino)-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-3-carboxy-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-oxopentanoic acid
DMRV16G DE Discovery agent
DMFKX7Z ID DMFKX7Z
DMFKX7Z DN NDT9520492
DMFKX7Z HS Investigative
DMFKX7Z SN NDT9520492; GTPL578; SCHEMBL5136510; NDT-9520492; 610297-00-2
DMFKX7Z DT Small molecular drug
DMFKX7Z PC 10218379
DMFKX7Z MW 554.7
DMFKX7Z FM C38H35FN2O
DMFKX7Z IC InChI=1S/C38H35FN2O/c1-26(38(42)41(25-31-15-6-9-20-36(31)39)32-23-29-13-2-3-14-30(29)24-32)40-22-21-28-12-5-8-18-34(28)37(40)35-19-10-16-27-11-4-7-17-33(27)35/h2-20,26,32,37H,21-25H2,1H3/t26-,37+/m0/s1
DMFKX7Z CS C[C@@H](C(=O)N(CC1=CC=CC=C1F)C2CC3=CC=CC=C3C2)N4CCC5=CC=CC=C5[C@@H]4C6=CC=CC7=CC=CC=C76
DMFKX7Z IK OEINKGYXWSIVKM-KJICVINHSA-N
DMFKX7Z IU (2S)-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluorophenyl)methyl]-2-[(1R)-1-naphthalen-1-yl-3,4-dihydro-1H-isoquinolin-2-yl]propanamide
DMFKX7Z DE Discovery agent
DMGSNU4 ID DMGSNU4
DMGSNU4 DN NE-10575
DMGSNU4 HS Investigative
DMGSNU4 SN NE-10575; CHEMBL99553; 3-(2-Hydroxy-2,2-Diphosphonoethyl)-1-Methylpyridinium; GTPL3184; SCHEMBL8384475; BDBM50373099; NE 10575; 3-(2-hydroxy-2,2-diphosphonoethyl)-1-methylpyridin-1-ium; [1-Hydroxy-2-(1-methylpyridinium-3-yl)ethylidene]bisphosphonic acid
DMGSNU4 DT Small molecular drug
DMGSNU4 PC 9847474
DMGSNU4 MW 298.15
DMGSNU4 FM C8H14NO7P2+
DMGSNU4 IC InChI=1S/C8H13NO7P2/c1-9-4-2-3-7(6-9)5-8(10,17(11,12)13)18(14,15)16/h2-4,6,10H,5H2,1H3,(H3-,11,12,13,14,15,16)/p+1
DMGSNU4 CS C[N+]1=CC=CC(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMGSNU4 IK BBNRLGQPSIXFHZ-UHFFFAOYSA-O
DMGSNU4 IU [1-hydroxy-2-(1-methylpyridin-1-ium-3-yl)-1-phosphonoethyl]phosphonic acid
DMGSNU4 DE Discovery agent
DMVESO2 ID DMVESO2
DMVESO2 DN NE10790
DMVESO2 HS Investigative
DMVESO2 SN NE 10790
DMVESO2 DT Small molecular drug
DMVESO2 PC 10014835
DMVESO2 MW 247.14
DMVESO2 FM C8H10NO6P
DMVESO2 IC InChI=1S/C8H10NO6P/c10-7(11)8(12,16(13,14)15)4-6-2-1-3-9-5-6/h1-3,5,12H,4H2,(H,10,11)(H2,13,14,15)
DMVESO2 CS C1=CC(=CN=C1)CC(C(=O)O)(O)P(=O)(O)O
DMVESO2 IK FJVYPXVLXQXDHM-UHFFFAOYSA-N
DMVESO2 IU 2-hydroxy-2-phosphono-3-pyridin-3-ylpropanoic acid
DMVESO2 CA CAS 152831-36-2
DMVESO2 DE Discovery agent
DMR92HV ID DMR92HV
DMR92HV DN NE11808
DMR92HV HS Investigative
DMR92HV SN NE 11808
DMR92HV DT Small molecular drug
DMR92HV PC 406401
DMR92HV MW 282.13
DMR92HV FM C7H12N2O6P2
DMR92HV IC InChI=1S/C7H12N2O6P2/c10-16(11,12)7(17(13,14)15)5-9-6-3-1-2-4-8-6/h1-4,7H,5H2,(H,8,9)(H2,10,11,12)(H2,13,14,15)
DMR92HV CS C1=CC=NC(=C1)NCC(P(=O)(O)O)P(=O)(O)O
DMR92HV IK BHVCADPDEFLLGM-UHFFFAOYSA-N
DMR92HV IU [1-phosphono-2-(pyridin-2-ylamino)ethyl]phosphonic acid
DMR92HV CA CAS 105462-22-4
DMR92HV DE Discovery agent
DMILP0F ID DMILP0F
DMILP0F DN NE-2
DMILP0F HS Investigative
DMILP0F CP Diamyd Medical AB
DMILP0F DE Pain
DM58O3I ID DM58O3I
DM58O3I DN NE21650
DM58O3I HS Investigative
DM58O3I SN CHEMBL414849; NE-21650; Ne 21650; GTPL3167; BDBM50173792; 2-(2-aminophenyl)-1-hydroxyethane-1,1-diyldiphosphonic acid; [2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid; [2-(2-Amino-phenyl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid; hydrogen [2-(2-azaniumylphenyl)-1-hydroxy-1-phosphonatoethyl]phosphonate
DM58O3I DT Small molecular drug
DM58O3I PC 9994754
DM58O3I MW 297.14
DM58O3I FM C8H13NO7P2
DM58O3I IC InChI=1S/C8H13NO7P2/c9-7-4-2-1-3-6(7)5-8(10,17(11,12)13)18(14,15)16/h1-4,10H,5,9H2,(H2,11,12,13)(H2,14,15,16)
DM58O3I CS C1=CC=C(C(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O)N
DM58O3I IK VJXYJONFUZXZJZ-UHFFFAOYSA-N
DM58O3I IU [2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
DM58O3I DE Discovery agent
DMVSRYH ID DMVSRYH
DMVSRYH DN NE-28345
DMVSRYH HS Investigative
DMVSRYH SN Oleylhomovanillamide; NE 28345; N-oleylhomovanillamide; 4-Hydroxy-3-methoxy-N-9-octadecenylbenzeneacetamide (Z)-; Benzeneacetamide, 4-hydroxy-3-methoxy-N-9-octadecenyl-, (Z)-; NE-28345; N-oleyl-homovanillamide; AC1O5R2B; SCHEMBL504255; CHEMBL327447; AKOS030583210; LS-28555
DMVSRYH DT Small molecular drug
DMVSRYH PC 6439143
DMVSRYH MW 431.7
DMVSRYH FM C27H45NO3
DMVSRYH IC InChI=1S/C27H45NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21-28-27(30)23-24-19-20-25(29)26(22-24)31-2/h10-11,19-20,22,29H,3-9,12-18,21,23H2,1-2H3,(H,28,30)/b11-10-
DMVSRYH CS CCCCCCCC/C=C\\CCCCCCCCNC(=O)CC1=CC(=C(C=C1)O)OC
DMVSRYH IK PCZMUTQYZKAXBW-KHPPLWFESA-N
DMVSRYH IU 2-(4-hydroxy-3-methoxyphenyl)-N-[(Z)-octadec-9-enyl]acetamide
DMVSRYH CA CAS 107512-56-1
DMVSRYH DE Discovery agent
DM28ZPT ID DM28ZPT
DM28ZPT DN NE58018
DM28ZPT HS Investigative
DM28ZPT SN NE 58018; NE-58018
DM28ZPT DT Small molecular drug
DM28ZPT PC 405372
DM28ZPT MW 283.11
DM28ZPT FM C7H11NO7P2
DM28ZPT IC InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)5-6-3-1-2-4-8-6/h1-4,9H,5H2,(H2,10,11,12)(H2,13,14,15)
DM28ZPT CS C1=CC=NC(=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DM28ZPT IK XXNASZAYANFLID-UHFFFAOYSA-N
DM28ZPT IU (1-hydroxy-1-phosphono-2-pyridin-2-ylethyl)phosphonic acid
DM28ZPT CA CAS 105462-23-5
DM28ZPT DE Discovery agent
DMU4I8R ID DMU4I8R
DMU4I8R DN NE58027
DMU4I8R HS Investigative
DMU4I8R SN NE 58027
DMU4I8R DT Small molecular drug
DMU4I8R PC 14231197
DMU4I8R MW 289.16
DMU4I8R FM C7H17NO7P2
DMU4I8R IC InChI=1S/C7H17NO7P2/c9-7(16(10,11)12,17(13,14)15)5-6-3-1-2-4-8-6/h6,8-9H,1-5H2,(H2,10,11,12)(H2,13,14,15)
DMU4I8R CS C1CCNC(C1)CC(O)(P(=O)(O)O)P(=O)(O)O
DMU4I8R IK GKUBJNUBGKBXKR-UHFFFAOYSA-N
DMU4I8R IU (1-hydroxy-1-phosphono-2-piperidin-2-ylethyl)phosphonic acid
DMU4I8R DE Discovery agent
DMS7UNR ID DMS7UNR
DMS7UNR DN NE58043
DMS7UNR HS Investigative
DMS7UNR SN NE 58043
DMS7UNR DT Small molecular drug
DMS7UNR PC 10468166
DMS7UNR MW 267.11
DMS7UNR FM C7H11NO6P2
DMS7UNR IC InChI=1S/C7H11NO6P2/c9-15(10,11)7(16(12,13)14)4-6-2-1-3-8-5-6/h1-3,5,7H,4H2,(H2,9,10,11)(H2,12,13,14)
DMS7UNR CS C1=CC(=CN=C1)CC(P(=O)(O)O)P(=O)(O)O
DMS7UNR IK KZMOFWIRXNQJET-UHFFFAOYSA-N
DMS7UNR IU (1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
DMS7UNR CA CAS 75755-10-1
DMS7UNR DE Discovery agent
DMHIM6N ID DMHIM6N
DMHIM6N DN NE58062
DMHIM6N HS Investigative
DMHIM6N SN NE 58062
DMHIM6N DT Small molecular drug
DMHIM6N PC 15230201
DMHIM6N MW 286.16
DMHIM6N FM C7H16N2O6P2
DMHIM6N IC InChI=1S/C7H16N2O6P2/c1-5-3-2-4-8-6(5)9-7(16(10,11)12)17(13,14)15/h5,7H,2-4H2,1H3,(H,8,9)(H2,10,11,12)(H2,13,14,15)
DMHIM6N CS CC1CCCN=C1NC(P(=O)(O)O)P(=O)(O)O
DMHIM6N IK XUCBNFJYKWKAMN-UHFFFAOYSA-N
DMHIM6N IU [[(5-methyl-2,3,4,5-tetrahydropyridin-6-yl)amino]-phosphonomethyl]phosphonic acid
DMHIM6N DE Discovery agent
DMDWESP ID DMDWESP
DMDWESP DN NE97220
DMDWESP HS Investigative
DMDWESP SN NE 97220; CGA 103586; Q 332
DMDWESP DT Small molecular drug
DMDWESP PC 5276531
DMDWESP MW 282.13
DMDWESP FM C7H12N2O6P2
DMDWESP IC InChI=1S/C7H12N2O6P2/c1-5-3-2-4-8-6(5)9-7(16(10,11)12)17(13,14)15/h2-4,7H,1H3,(H,8,9)(H2,10,11,12)(H2,13,14,15)
DMDWESP CS CC1=C(N=CC=C1)NC(P(=O)(O)O)P(=O)(O)O
DMDWESP IK NAIJOBGUXRHQJW-UHFFFAOYSA-N
DMDWESP IU [[(3-methylpyridin-2-yl)amino]-phosphonomethyl]phosphonic acid
DMDWESP DE Discovery agent
DMNCU6H ID DMNCU6H
DMNCU6H DN Neamine
DMNCU6H HS Investigative
DMNCU6H SN Neamine; Neomycin A; Negamicin; Nebramycin X; Dekamycin V; 3947-65-7; Neamin; UNII-5981U00LY0; C12H26N4O6; BRN 0026714; 4-O-(2,6-Diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-2-deoxy-D-streptamine; 2-Desoxy-4-O-(2,6-diamino-2,6-didesoxy-alpha-D-glucopyranosyl)-D-streptamin; CHEBI:7489; 5981U00LY0; (1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; D-Streptamine, 2-deoxy-4-O-(2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl)-
DMNCU6H DT Small molecular drug
DMNCU6H PC 72392
DMNCU6H MW 322.36
DMNCU6H FM C12H26N4O6
DMNCU6H IC InChI=1S/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1
DMNCU6H CS C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O)O)N
DMNCU6H IK SYJXFKPQNSDJLI-HKEUSBCWSA-N
DMNCU6H IU (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxyoxane-3,4-diol
DMNCU6H CA CAS 3947-65-7
DMNCU6H CB CHEBI:7489
DMNCU6H DE Discovery agent
DMO0Q1F ID DMO0Q1F
DMO0Q1F DN Nectamazin C
DMO0Q1F HS Investigative
DMO0Q1F SN Nectamazin C; CHEMBL570290
DMO0Q1F DT Small molecular drug
DMO0Q1F PC 45487137
DMO0Q1F MW 420.5
DMO0Q1F FM C23H32O7
DMO0Q1F IC InChI=1S/C23H32O7/c1-8-9-14-12-22(29-6)13(2)18(23(30-7,20(14)24)21(22)25)15-10-16(26-3)19(28-5)17(11-15)27-4/h8,10-13,18,20-21,24-25H,1,9H2,2-7H3/t13-,18+,20-,21-,22+,23-/m0/s1
DMO0Q1F CS C[C@H]1[C@@H]([C@@]2([C@H](C(=C[C@@]1([C@@H]2O)OC)CC=C)O)OC)C3=CC(=C(C(=C3)OC)OC)OC
DMO0Q1F IK OHVTXDBRSOSKKO-BHIPVSGSSA-N
DMO0Q1F IU (1S,2S,5S,6S,7R,8S)-1,5-dimethoxy-6-methyl-3-prop-2-enyl-7-(3,4,5-trimethoxyphenyl)bicyclo[3.2.1]oct-3-ene-2,8-diol
DMO0Q1F DE Discovery agent
DM5EWIK ID DM5EWIK
DM5EWIK DN NEODYSIDENIN
DM5EWIK HS Investigative
DM5EWIK SN neodysidenin; CHEMBL392270
DM5EWIK DT Small molecular drug
DM5EWIK PC 15482063
DM5EWIK MW 546.2
DM5EWIK FM C17H23Cl6N3O2S
DM5EWIK IC InChI=1S/C17H23Cl6N3O2S/c1-9(16(18,19)20)7-12(25-13(27)8-10(2)17(21,22)23)15(28)26(4)11(3)14-24-5-6-29-14/h5-6,9-12H,7-8H2,1-4H3,(H,25,27)/t9-,10-,11+,12-/m0/s1
DM5EWIK CS C[C@@H](C[C@@H](C(=O)N(C)[C@H](C)C1=NC=CS1)NC(=O)C[C@H](C)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl
DM5EWIK IK MBVQTLXBQHZLRO-YFKTTZPYSA-N
DM5EWIK IU (2S,4S)-5,5,5-trichloro-N,4-dimethyl-N-[(1R)-1-(1,3-thiazol-2-yl)ethyl]-2-[[(3S)-4,4,4-trichloro-3-methylbutanoyl]amino]pentanamide
DM5EWIK DE Discovery agent
DM6D0JC ID DM6D0JC
DM6D0JC DN Neo-kauluamine
DM6D0JC HS Investigative
DM6D0JC SN neo-Kauluamine
DM6D0JC DT Small molecular drug
DM6D0JC PC 44448144
DM6D0JC MW 1163.5
DM6D0JC FM C72H90N8O6
DM6D0JC IC InChI=1S/C72H90N8O6/c81-58-22-17-37-79-40-29-61(58)86-72-32-23-60(85-47-69-46-78-36-16-8-3-1-5-13-30-70(83,66(69)79)42-53(55(69)27-39-78)63-65-51(25-34-74-63)49-19-10-12-21-57(49)76-65)59(82)28-41-80(72)67-68(44-72)45-77-35-15-7-4-2-6-14-31-71(67,84)43-52(54(68)26-38-77)62-64-50(24-33-73-62)48-18-9-11-20-56(48)75-64/h1-2,5-6,9-12,18-21,24-25,33-34,42-43,54-55,58-61,66-67,75-76,81-84H,3-4,7-8,13-17,22-23,26-32,35-41,44-47H2/b5-1-,6-2-/t54-,55-,58+,59-,60+,61-,66+,67+,68-,69+,70-,71-,72+/m0/s1
DM6D0JC CS C1CCN2CC[C@H]3C(=C[C@@](CC/C=C\\C1)([C@H]4[C@]3(C2)C[C@@]56N4CC[C@@H]([C@@H](CC5)OC[C@@]78CN9CCCC/C=C\\CC[C@@]([C@@H]7N1CCC[C@H]([C@@H](O6)CC1)O)(C=C([C@@H]8CC9)C1=NC=CC2=C1NC1=CC=CC=C21)O)O)O)C1=NC=CC2=C1NC1=CC=CC=C21
DM6D0JC IK QBYWKABDYAEEIS-VZMZVYMRSA-N
DM6D0JC IU (1R,3S,4R,9R,10S,13Z,22S,23S,26R,27S,31R,32S,35Z,44R,45R)-50,53-bis(9H-pyrido[3,4-b]indol-1-yl)-2,25-dioxa-8,19,30,41-tetrazadecacyclo[24.20.2.23,8.210,22.232,44.119,23.141,45.01,30.09,23.031,45]hexapentaconta-13,35,50,53-tetraene-4,10,27,32-tetrol
DM6D0JC DE Discovery agent
DMKFPA9 ID DMKFPA9
DMKFPA9 DN NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B
DMKFPA9 HS Investigative
DMKFPA9 SN Neolignan 9-nor-7,8-dehydro-isolicarin B; CHEMBL571199; BDBM50303146
DMKFPA9 DT Small molecular drug
DMKFPA9 PC 11243755
DMKFPA9 MW 308.3
DMKFPA9 FM C19H16O4
DMKFPA9 IC InChI=1S/C19H16O4/c1-3-4-12-7-14-10-16(23-19(14)18(8-12)20-2)13-5-6-15-17(9-13)22-11-21-15/h3,5-10H,1,4,11H2,2H3
DMKFPA9 CS COC1=CC(=CC2=C1OC(=C2)C3=CC4=C(C=C3)OCO4)CC=C
DMKFPA9 IK QHQQIGTXXBIMFB-UHFFFAOYSA-N
DMKFPA9 IU 5-(7-methoxy-5-prop-2-enyl-1-benzofuran-2-yl)-1,3-benzodioxole
DMKFPA9 DE Discovery agent
DM5GMOJ ID DM5GMOJ
DM5GMOJ DN NEORAUTENOL
DM5GMOJ HS Investigative
DM5GMOJ SN Neorautenol; CHEMBL1098728; BDBM50317432
DM5GMOJ DT Small molecular drug
DM5GMOJ PC 11500744
DM5GMOJ MW 322.4
DM5GMOJ FM C20H18O4
DM5GMOJ IC InChI=1S/C20H18O4/c1-20(2)6-5-11-7-14-17(9-16(11)24-20)22-10-15-13-4-3-12(21)8-18(13)23-19(14)15/h3-9,15,19,21H,10H2,1-2H3/t15-,19-/m0/s1
DM5GMOJ CS CC1(C=CC2=CC3=C(C=C2O1)OC[C@@H]4[C@H]3OC5=C4C=CC(=C5)O)C
DM5GMOJ IK OGFFMQWYZCTXCM-KXBFYZLASA-N
DM5GMOJ IU (2R,10R)-17,17-dimethyl-3,12,16-trioxapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(13),4(9),5,7,14,18,20-heptaen-6-ol
DM5GMOJ DE Discovery agent
DMXULGK ID DMXULGK
DMXULGK DN Neplanocin A
DMXULGK HS Investigative
DMXULGK SN 72877-50-0; NPC-A; A-11079-B1B; NEOPLANOCIN A; (1s,2r,5r)-5-(6-amino-9h-purin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; NSC 316458; CHEMBL8771; (-)-9-(trans-2,trans-3-Dihydroxy-4-(hydroxymethyl)-cyclopent-4-enyl)-adenine; 4-Cyclopentene-1,2-diol, 3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-, (1S,2R,3R)-; (1S,2R,5R)-5-(6-aminopurin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol; Nephanocin A; AC1Q4VG9; AC1L2J1E; SCHEMBL10469277; CTK5D6979; MolPort-044-561-069; ZINC3832328; BDBM50006222; CCG-208688; DIBRT
DMXULGK DT Small molecular drug
DMXULGK PC 72968
DMXULGK MW 263.25
DMXULGK FM C11H13N5O3
DMXULGK IC InChI=1S/C11H13N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h1,3-4,6,8-9,17-19H,2H2,(H2,12,13,14)/t6-,8-,9+/m1/s1
DMXULGK CS C1=C([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO
DMXULGK IK XUGWUUDOWNZAGW-VDAHYXPESA-N
DMXULGK IU (1S,2R,5R)-5-(6-aminopurin-9-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol
DMXULGK CA CAS 72877-50-0
DMXULGK DE Discovery agent
DM3AW8X ID DM3AW8X
DM3AW8X DN Nerve growth factor conjugated RAP peptide
DM3AW8X HS Investigative
DM3AW8X SN NGF-RAP; Nerve growth factor conjugated RAP peptide (NeuroTrans, neurodegenrative disease); Nerve growth factor conjugated RAP peptide (NeuroTrans, neurodegenrative disease), Raptor
DM3AW8X CP Raptor Pharmaceuticals Corp
DM3AW8X DE Neurodegenerative disorder
DM1W2GZ ID DM1W2GZ
DM1W2GZ DN N-ethyl estradiol-16-methyl carboxamide
DM1W2GZ HS Investigative
DM1W2GZ SN SCHEMBL12379571
DM1W2GZ DT Small molecular drug
DM1W2GZ PC 44407526
DM1W2GZ MW 357.5
DM1W2GZ FM C22H31NO3
DM1W2GZ IC InChI=1S/C22H31NO3/c1-3-23-20(25)12-14-11-19-18-6-4-13-10-15(24)5-7-16(13)17(18)8-9-22(19,2)21(14)26/h5,7,10,14,17-19,21,24,26H,3-4,6,8-9,11-12H2,1-2H3,(H,23,25)/t14?,17?,18?,19?,21-,22-/m0/s1
DM1W2GZ CS CCNC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DM1W2GZ IK ZQUXDOJBDFPTDM-LAULZOBPSA-N
DM1W2GZ IU 2-[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-N-ethylacetamide
DM1W2GZ DE Discovery agent
DMM9526 ID DMM9526
DMM9526 DN N-ethyl estrone-16-methyl carboxamide
DMM9526 HS Investigative
DMM9526 SN SCHEMBL12379557
DMM9526 DT Small molecular drug
DMM9526 PC 44407576
DMM9526 MW 355.5
DMM9526 FM C22H29NO3
DMM9526 IC InChI=1S/C22H29NO3/c1-3-23-20(25)12-14-11-19-18-6-4-13-10-15(24)5-7-16(13)17(18)8-9-22(19,2)21(14)26/h5,7,10,14,17-19,24H,3-4,6,8-9,11-12H2,1-2H3,(H,23,25)/t14?,17?,18?,19?,22-/m0/s1
DMM9526 CS CCNC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMM9526 IK DGCNLEJTGGXFLE-SSBKPBJFSA-N
DMM9526 IU N-ethyl-2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]acetamide
DMM9526 DE Discovery agent
DMQ3184 ID DMQ3184
DMQ3184 DN N-ethyl-2,2,2-triphenylacetamide
DMQ3184 HS Investigative
DMQ3184 DE Discovery agent
DMWLI4U ID DMWLI4U
DMWLI4U DN N-Ethyl-2-methylnorapomorphine hydrochloride
DMWLI4U HS Investigative
DMWLI4U SN CHEMBL562460
DMWLI4U DT Small molecular drug
DMWLI4U PC 45267373
DMWLI4U MW 295.4
DMWLI4U FM C19H21NO2
DMWLI4U IC InChI=1S/C19H21NO2/c1-3-20-7-6-13-8-11(2)9-14-17(13)15(20)10-12-4-5-16(21)19(22)18(12)14/h4-5,8-9,15,21-22H,3,6-7,10H2,1-2H3/t15-/m1/s1
DMWLI4U CS CCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C)C(=C(C=C4)O)O
DMWLI4U IK VNGYREUWVHTKAV-OAHLLOKOSA-N
DMWLI4U IU (6aR)-6-ethyl-2-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DMWLI4U DE Discovery agent
DM6HMBW ID DM6HMBW
DM6HMBW DN N-Ethyl-2-phenylnorapomorphine hydrochloride
DM6HMBW HS Investigative
DM6HMBW SN CHEMBL564909
DM6HMBW DT Small molecular drug
DM6HMBW PC 45271622
DM6HMBW MW 357.4
DM6HMBW FM C24H23NO2
DM6HMBW IC InChI=1S/C24H23NO2/c1-2-25-11-10-17-12-18(15-6-4-3-5-7-15)13-19-22(17)20(25)14-16-8-9-21(26)24(27)23(16)19/h3-9,12-13,20,26-27H,2,10-11,14H2,1H3/t20-/m1/s1
DM6HMBW CS CCN1CCC2=C3[C@H]1CC4=C(C3=CC(=C2)C5=CC=CC=C5)C(=C(C=C4)O)O
DM6HMBW IK RJCYHSVPFFEYKA-HXUWFJFHSA-N
DM6HMBW IU (6aR)-6-ethyl-2-phenyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
DM6HMBW DE Discovery agent
DMHY35A ID DMHY35A
DMHY35A DN N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide
DMHY35A HS Investigative
DMHY35A SN CHEMBL379234; N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide; Enamine_001944; Oprea1_552384; AC1M697W; SCHEMBL10904389; MolPort-004-000-970; HMS1399I08; ZINC3251814; BDBM50177761; AKOS008967166; MCULE-9434872926; N-ethyl-4-hydroxy-N-phenylbenzene-1-sulfonamide; Z56821525
DMHY35A DT Small molecular drug
DMHY35A PC 2368773
DMHY35A MW 277.34
DMHY35A FM C14H15NO3S
DMHY35A IC InChI=1S/C14H15NO3S/c1-2-15(12-6-4-3-5-7-12)19(17,18)14-10-8-13(16)9-11-14/h3-11,16H,2H2,1H3
DMHY35A CS CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)O
DMHY35A IK VGVYBVTUILCGFQ-UHFFFAOYSA-N
DMHY35A IU N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide
DMHY35A DE Discovery agent
DM873WR ID DM873WR
DM873WR DN N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide
DM873WR HS Investigative
DM873WR SN CHEMBL246476; N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide
DM873WR DT Small molecular drug
DM873WR PC 44440707
DM873WR MW 331.4
DM873WR FM C21H21N3O
DM873WR IC InChI=1S/C21H21N3O/c1-4-22-21(25)18-13-23-19(16-9-5-14(2)6-10-16)20(24-18)17-11-7-15(3)8-12-17/h5-13H,4H2,1-3H3,(H,22,25)
DM873WR CS CCNC(=O)C1=CN=C(C(=N1)C2=CC=C(C=C2)C)C3=CC=C(C=C3)C
DM873WR IK BAXIFQMQEGUGGQ-UHFFFAOYSA-N
DM873WR IU N-ethyl-5,6-bis(4-methylphenyl)pyrazine-2-carboxamide
DM873WR DE Discovery agent
DMPTNI8 ID DMPTNI8
DMPTNI8 DN N-Ethyl-ETAV
DMPTNI8 HS Investigative
DMPTNI8 SN N-Ethyl-ETAV; CHEMBL492431
DMPTNI8 DT Small molecular drug
DMPTNI8 PC 44568808
DMPTNI8 MW 446.5
DMPTNI8 FM C19H34N4O8
DMPTNI8 IC InChI=1S/C19H34N4O8/c1-6-20-12(7-8-13(25)26)17(28)23-15(11(5)24)18(29)21-10(4)16(27)22-14(9(2)3)19(30)31/h9-12,14-15,20,24H,6-8H2,1-5H3,(H,21,29)(H,22,27)(H,23,28)(H,25,26)(H,30,31)/t10-,11?,12-,14-,15-/m0/s1
DMPTNI8 CS CCN[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O
DMPTNI8 IK MEXXBWHVPQDHNP-FYOXFVTASA-N
DMPTNI8 IU (4S)-5-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-(ethylamino)-5-oxopentanoic acid
DMPTNI8 DE Discovery agent
DMYI87T ID DMYI87T
DMYI87T DN N-ethylhistamine
DMYI87T HS Investigative
DMYI87T SN 479408-49-6; 2-(1-ethyl-1h-imidazol-4-yl)ethanamine; 1-ETHYL-1H-IMIDAZOLE-4-ETHANAMINE; 2-(1-Ethyl-1H-imidazol-4-yl)ethan-1-amine; N-ethylhistamine; 2-(1-Ethyl-1H-imidazol-4-yl)ethylamine; CHEMBL46296; SCHEMBL589342; GTPL1271; CTK4J0489; DTXSID90658170; LIXGKSRWGHVUHT-UHFFFAOYSA-N; ZINC29412524; 2-(1-ethylimidazol-4-yl)ethanamine; AKOS006337816
DMYI87T DT Small molecular drug
DMYI87T PC 44292270
DMYI87T MW 139.2
DMYI87T FM C7H13N3
DMYI87T IC InChI=1S/C7H13N3/c1-2-10-5-7(3-4-8)9-6-10/h5-6H,2-4,8H2,1H3
DMYI87T CS CCN1C=C(N=C1)CCN
DMYI87T IK LIXGKSRWGHVUHT-UHFFFAOYSA-N
DMYI87T IU 2-(1-ethylimidazol-4-yl)ethanamine
DMYI87T CA CAS 479408-49-6
DMYI87T DE Discovery agent
DMMKSGL ID DMMKSGL
DMMKSGL DN N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine
DMMKSGL HS Investigative
DMMKSGL SN CHEMBL150948; N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine; BDBM50138487; 1-(3-Pyridinyl)-4-(methylethylamino)-1-butyne
DMMKSGL DT Small molecular drug
DMMKSGL PC 44366246
DMMKSGL MW 188.27
DMMKSGL FM C12H16N2
DMMKSGL IC InChI=1S/C12H16N2/c1-3-14(2)10-5-4-7-12-8-6-9-13-11-12/h6,8-9,11H,3,5,10H2,1-2H3
DMMKSGL CS CCN(C)CCC#CC1=CN=CC=C1
DMMKSGL IK DGPGTYZUJIIMAU-UHFFFAOYSA-N
DMMKSGL IU N-ethyl-N-methyl-4-pyridin-3-ylbut-3-yn-1-amine
DMMKSGL DE Discovery agent
DMOW2QS ID DMOW2QS
DMOW2QS DN Netropsin
DMOW2QS HS Investigative
DMOW2QS SN Netropsin; Antibiotic 1142; Congocidine; Antibiotic T-1384; UNII-64B3O0RD7N; CHEMBL307767; 64B3O0RD7N; NSC 3067; CH-777-A; IA 887; BRN 0376913; K-117; 2814-A; T 1384; N,4'-Bi(pyrrole-2-carboxamide), N'-(2-carbamoylethyl)-4-((2-guanidinoacetimidoyl)amino)-1,1'-dimethyl-; F 6; 1H-Pyrrole-2-carboxamide, 4-((((aminoiminomethyl)amino)acetyl)amino)-N-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1H-pyrrol-3-yl)-1-methyl-; BDBM17; AC1L1I7V; AC1Q5M1N; SCHEMBL197747; CTK8G1803; IDBIFFKSXLYUOT-UHFFFAOYSA-N; 63770-20-7 (hydrochloride
DMOW2QS DT Small molecular drug
DMOW2QS PC 4461
DMOW2QS MW 430.5
DMOW2QS FM C18H26N10O3
DMOW2QS IC InChI=1S/C18H26N10O3/c1-27-9-11(6-12(27)16(30)23-4-3-14(19)20)26-17(31)13-5-10(8-28(13)2)25-15(29)7-24-18(21)22/h5-6,8-9H,3-4,7H2,1-2H3,(H3,19,20)(H,23,30)(H,25,29)(H,26,31)(H4,21,22,24)
DMOW2QS CS CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NCCC(=N)N)C)NC(=O)CN=C(N)N
DMOW2QS IK IDBIFFKSXLYUOT-UHFFFAOYSA-N
DMOW2QS IU N-[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]-4-[[2-(diaminomethylideneamino)acetyl]amino]-1-methylpyrrole-2-carboxamide
DMOW2QS CA CAS 1438-30-8
DMOW2QS DE Discovery agent
DM9UXRP ID DM9UXRP
DM9UXRP DN neurokinin A
DM9UXRP HS Investigative
DM9UXRP SN substance K
DM9UXRP DT Small molecular drug
DM9UXRP PC 5311311
DM9UXRP MW 1133.3
DM9UXRP FM C50H80N14O14S
DM9UXRP IC InChI=1S/C50H80N14O14S/c1-26(2)18-34(45(73)58-32(42(53)70)15-17-79-6)57-38(67)23-55-49(77)40(27(3)4)63-47(75)35(19-29-12-8-7-9-13-29)60-48(76)37(24-65)62-46(74)36(21-39(68)69)61-50(78)41(28(5)66)64-44(72)33(14-10-11-16-51)59-43(71)31(52)20-30-22-54-25-56-30/h7-9,12-13,22,25-28,31-37,40-41,65-66H,10-11,14-21,23-24,51-52H2,1-6H3,(H2,53,70)(H,54,56)(H,55,77)(H,57,67)(H,58,73)(H,59,71)(H,60,76)(H,61,78)(H,62,74)(H,63,75)(H,64,72)(H,68,69)/t28-,31+,32+,33+,34+,35+,36+,37+,40+,41+/m1/s1
DM9UXRP CS C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)O
DM9UXRP IK HEAUFJZALFKPBA-JPQUDPSNSA-N
DM9UXRP IU (3S)-3-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
DM9UXRP CA CAS 86933-74-6
DM9UXRP DE Discovery agent
DM5O2MJ ID DM5O2MJ
DM5O2MJ DN NEUROKININ B
DM5O2MJ HS Investigative
DM5O2MJ SN Neurokinin B; CHEMBL437797; CHEBI:80312; 86933-75-7; NKB; Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2; Neurokinin B (human, porcine); Tachykinin-3; AC1NSKET; GTPL2090; BDBM50079412; AKOS024456682; C16098; SR-05000014260; SR-05000014260-1; (NKB)Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2; Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2(Neurokinin B)
DM5O2MJ DT Small molecular drug
DM5O2MJ PC 5311312
DM5O2MJ MW 1210.4
DM5O2MJ FM C55H79N13O14S2
DM5O2MJ IC InChI=1S/C55H79N13O14S2/c1-30(2)21-38(50(77)62-36(47(57)74)17-19-83-5)61-43(69)28-59-55(82)46(31(3)4)68-54(81)40(23-33-15-11-8-12-16-33)65-51(78)39(22-32-13-9-7-10-14-32)64-53(80)42(26-45(72)73)67-52(79)41(24-34-27-58-29-60-34)66-49(76)37(18-20-84-6)63-48(75)35(56)25-44(70)71/h7-16,27,29-31,35-42,46H,17-26,28,56H2,1-6H3,(H2,57,74)(H,58,60)(H,59,82)(H,61,69)(H,62,77)(H,63,75)(H,64,80)(H,65,78)(H,66,76)(H,67,79)(H,68,81)(H,70,71)(H,72,73)/t35-,36-,37-,38-,39-,40-,41-,42-,46-/m0/s1
DM5O2MJ CS CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)N
DM5O2MJ IK NHXYSAFTNPANFK-HDMCBQFHSA-N
DM5O2MJ IU (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
DM5O2MJ CB CHEBI:80312
DM5O2MJ DE Discovery agent
DMSJ6T1 ID DMSJ6T1
DMSJ6T1 DN Neuromed 2
DMSJ6T1 HS Investigative
DMSJ6T1 TC Analgesics
DMSJ6T1 DE Pain
DMXKT45 ID DMXKT45
DMXKT45 DN Neuromed 5
DMXKT45 HS Investigative
DMXKT45 TC Analgesics
DMXKT45 DE Pain
DMCXJLH ID DMCXJLH
DMCXJLH DN neuromedin B
DMCXJLH HS Investigative
DMCXJLH SN Neuromedin B; 87096-84-2; Gly-asn-leu-trp-ala-thr-gly-his-phe-met-NH2; NEUROMEDINB; Neuromedin B, porcine; GTPL613; AC1N8M58; Neuromedin B, > 2-[(2-aminoacetyl)amino]-N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DMCXJLH DT Small molecular drug
DMCXJLH PC 4345957
DMCXJLH MW 1132.3
DMCXJLH FM C52H73N15O12S
DMCXJLH IC InChI=1S/C52H73N15O12S/c1-27(2)17-36(64-51(78)40(21-41(54)69)61-42(70)22-53)48(75)66-38(19-31-23-57-34-14-10-9-13-33(31)34)47(74)60-28(3)46(73)67-44(29(4)68)52(79)58-25-43(71)62-39(20-32-24-56-26-59-32)50(77)65-37(18-30-11-7-6-8-12-30)49(76)63-35(45(55)72)15-16-80-5/h6-14,23-24,26-29,35-40,44,57,68H,15-22,25,53H2,1-5H3,(H2,54,69)(H2,55,72)(H,56,59)(H,58,79)(H,60,74)(H,61,70)(H,62,71)(H,63,76)(H,64,78)(H,65,77)(H,66,75)(H,67,73)
DMCXJLH CS CC(C)CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC3=CN=CN3)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CCSC)C(=O)N)NC(=O)C(CC(=O)N)NC(=O)CN
DMCXJLH IK YPFNACALNKVZNK-UHFFFAOYSA-N
DMCXJLH IU 2-[(2-aminoacetyl)amino]-N-[1-[[1-[[1-[[1-[[2-[[1-[[1-[(1-amino-4-methylsulfanyl-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]butanediamide
DMCXJLH DE Discovery agent
DM27WCE ID DM27WCE
DM27WCE DN NEUROTENSIN
DM27WCE HS Investigative
DM27WCE SN CHEMBL407196; 55508-42-4; 58889-67-1; Neurotensin (ox); (D-Tyr11)neurotensin; Neurotensin 1-13; 11-Tyr-neurotensin; Neurotensin, tyr(11)-; Neurotensin, tyrosine(11)-; GTPL1579; Neurotensin, > MolPort-016-581-032; Neurotensin (ox), 11-D-tyrosine-; MFCD00076678; BDBM50130880; NCGC00167274-01; NT(1-13); 889N671; pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu; pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH
DM27WCE DT Small molecular drug
DM27WCE PC 25077406
DM27WCE MW 1672.9
DM27WCE FM C78H121N21O20
DM27WCE IC InChI=1S/C78H121N21O20/c1-7-43(6)63(73(115)96-57(76(118)119)37-42(4)5)97-70(112)55(39-45-21-25-47(101)26-22-45)95-72(114)59-18-13-35-99(59)75(117)52(16-11-33-86-78(83)84)90-64(106)48(15-10-32-85-77(81)82)89-71(113)58-17-12-34-98(58)74(116)51(14-8-9-31-79)91-69(111)56(40-60(80)102)94-66(108)50(28-30-62(104)105)88-68(110)54(38-44-19-23-46(100)24-20-44)93-67(109)53(36-41(2)3)92-65(107)49-27-29-61(103)87-49/h19-26,41-43,48-59,63,100-101H,7-18,27-40,79H2,1-6H3,(H2,80,102)(H,87,103)(H,88,110)(H,89,113)(H,90,106)(H,91,111)(H,92,107)(H,93,109)(H,94,108)(H,95,114)(H,96,115)(H,97,112)(H,104,105)(H,118,119)(H4,81,82,85)(H4,83,84,86)/t43-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,63-/m0/s1
DM27WCE CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]5CCC(=O)N5
DM27WCE IK PCJGZPGTCUMMOT-ISULXFBGSA-N
DM27WCE IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-4-carboxy-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-4-methyl-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]butanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DM27WCE CA CAS 39379-15-2
DM27WCE CB CHEBI:7542
DM27WCE DE Discovery agent
DMOBU62 ID DMOBU62
DMOBU62 DN Neurotensin(8-13)
DMOBU62 HS Investigative
DMOBU62 SN CHEMBL342252; BDBM50240845; (S)-2-{(2S,3R)-2-[(S)-2-({(S)-1-[(S)-2-((S)-2-Amino-5-guanidino-pentanoylamino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-3-(4-hydroxy-phenyl)-propionylamino]-3-methyl-pentanoylamino}-4-methyl-pentanoic acid; 2-{(S)-2-[2-({(S)-1-[(S)-2-((S)-2-Amino-5-guanidino-pentanoylamino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-3-(4-hydroxy-phenyl)-propionylamino]-3-methyl-pentanoylamino}-4-(S)-methyl-pentanoic acid
DMOBU62 DT Small molecular drug
DMOBU62 PC 5311318
DMOBU62 MW 817
DMOBU62 FM C38H64N12O8
DMOBU62 IC InChI=1S/C38H64N12O8/c1-5-22(4)30(34(55)48-28(36(57)58)19-21(2)3)49-32(53)27(20-23-12-14-24(51)15-13-23)47-33(54)29-11-8-18-50(29)35(56)26(10-7-17-45-38(42)43)46-31(52)25(39)9-6-16-44-37(40)41/h12-15,21-22,25-30,51H,5-11,16-20,39H2,1-4H3,(H,46,52)(H,47,54)(H,48,55)(H,49,53)(H,57,58)(H4,40,41,44)(H4,42,43,45)/t22-,25-,26-,27-,28-,29-,30-/m0/s1
DMOBU62 CS CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N
DMOBU62 IK DQDBCHHEIKQPJD-ODKJCKIQSA-N
DMOBU62 IU (2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
DM6NS7H ID DM6NS7H
DM6NS7H DN nexturastat A
DM6NS7H HS Investigative
DM6NS7H SN S7473
DM6NS7H DT Small molecular drug
DM6NS7H PC 71462653
DM6NS7H MW 341.4
DM6NS7H FM C19H23N3O3
DM6NS7H IC InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)
DM6NS7H CS CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2
DM6NS7H IK JZWXMCPARMXZQV-UHFFFAOYSA-N
DM6NS7H IU 4-[[butyl(phenylcarbamoyl)amino]methyl]-N-hydroxybenzamide
DM6NS7H DE Discovery agent
DMJ4GO9 ID DMJ4GO9
DMJ4GO9 DN NF023
DMJ4GO9 HS Investigative
DMJ4GO9 SN NF-023
DMJ4GO9 DT Small molecular drug
DMJ4GO9 PC 4465
DMJ4GO9 MW 1162.9
DMJ4GO9 FM C35H20N4Na6O21S6
DMJ4GO9 IC InChI=1S/C35H26N4O21S6.6Na/c40-33(38-25-7-9-27(63(49,50)51)23-13-21(61(43,44)45)15-29(31(23)25)65(55,56)57)17-3-1-5-19(11-17)36-35(42)37-20-6-2-4-18(12-20)34(41)39-26-8-10-28(64(52,53)54)24-14-22(62(46,47)48)16-30(32(24)26)66(58,59)60;;;;;;/h1-16H,(H,38,40)(H,39,41)(H2,36,37,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60);;;;;;/q;6*+1/p-6
DMJ4GO9 CS C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=O)NC3=C4C(=CC(=CC4=C(C=C3)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC5=C6C(=CC(=CC6=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DMJ4GO9 IK FMQURVHYTBGYSQ-UHFFFAOYSA-H
DMJ4GO9 IU hexasodium;8-[[3-[[3-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoylamino]benzoyl]amino]naphthalene-1,3,5-trisulfonate
DMJ4GO9 CA CAS 104869-31-0
DMJ4GO9 DE Discovery agent
DMGMH8T ID DMGMH8T
DMGMH8T DN NF157
DMGMH8T HS Investigative
DMGMH8T SN NF-157
DMGMH8T DT Small molecular drug
DMGMH8T PC 11636757
DMGMH8T MW 1305.2
DMGMH8T FM C49H34F2N6O23S6
DMGMH8T IC InChI=1S/C49H34F2N6O23S6/c50-33-9-7-25(47(60)54-35-11-13-39(83(69,70)71)31-19-29(81(63,64)65)21-41(43(31)35)85(75,76)77)17-37(33)56-45(58)23-3-1-5-27(15-23)52-49(62)53-28-6-2-4-24(16-28)46(59)57-38-18-26(8-10-34(38)51)48(61)55-36-12-14-40(84(72,73)74)32-20-30(82(66,67)68)22-42(44(32)36)86(78,79)80/h1-22H,(H,54,60)(H,55,61)(H,56,58)(H,57,59)(H2,52,53,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)(H,78,79,80)
DMGMH8T CS C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=O)NC3=C(C=CC(=C3)C(=O)NC4=C5C(=CC(=CC5=C(C=C4)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)F)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)F
DMGMH8T IK UDVIAMRWOLIUAE-UHFFFAOYSA-N
DMGMH8T IU 8-[[4-fluoro-3-[[3-[[3-[[2-fluoro-5-[(4,6,8-trisulfonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonic acid
DMGMH8T DE Discovery agent
DMPSXR8 ID DMPSXR8
DMPSXR8 DN NF340
DMPSXR8 HS Investigative
DMPSXR8 SN NF-340; NF 340
DMPSXR8 DT Small molecular drug
DMPSXR8 PC 73755007
DMPSXR8 MW 986.8
DMPSXR8 FM C37H26N4Na4O15S4
DMPSXR8 IC InChI=1S/C37H30N4O15S4.4Na/c1-19-3-5-23(35(42)38-33-17-27(59(51,52)53)11-21-7-9-25(15-29(21)33)57(45,46)47)13-31(19)40-37(44)41-32-14-24(6-4-20(32)2)36(43)39-34-18-28(60(54,55)56)12-22-8-10-26(16-30(22)34)58(48,49)50;;;;/h3-18H,1-2H3,(H,38,42)(H,39,43)(H2,40,41,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56);;;;/q;4*+1/p-4
DMPSXR8 CS CC1=C(C=C(C=C1)C(=O)NC2=C3C=C(C=CC3=CC(=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)NC4=C(C=CC(=C4)C(=O)NC5=C6C=C(C=CC6=CC(=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+]
DMPSXR8 IK SJMHXBFWMZYDBY-UHFFFAOYSA-J
DMPSXR8 IU tetrasodium;4-[[3-[[5-[(3,7-disulfonatonaphthalen-1-yl)carbamoyl]-2-methylphenyl]carbamoylamino]-4-methylbenzoyl]amino]naphthalene-2,6-disulfonate
DMPSXR8 DE Discovery agent
DM816Z2 ID DM816Z2
DM816Z2 DN NF449
DM816Z2 HS Investigative
DM816Z2 SN Tocris-1391; NCGC00025139-01; GTPL4267; MolPort-003-983-648; HMS3267D22; 1,3-disodium 4-{[3-({[3,5-bis({2,4-bis[(sodiooxy)sulfonyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)-5-({2,4-bis[(sodiooxy)sulfonyl]phenyl}carbamoyl)benzene]amido}benzene-1,3-disulfonate
DM816Z2 DT Small molecular drug
DM816Z2 PC 6093161
DM816Z2 MW 1505.1
DM816Z2 FM C41H24N6Na8O29S8
DM816Z2 IC InChI=1S/C41H32N6O29S8.8Na/c48-37(44-29-5-1-25(77(53,54)55)15-33(29)81(65,66)67)19-9-20(38(49)45-30-6-2-26(78(56,57)58)16-34(30)82(68,69)70)12-23(11-19)42-41(52)43-24-13-21(39(50)46-31-7-3-27(79(59,60)61)17-35(31)83(71,72)73)10-22(14-24)40(51)47-32-8-4-28(80(62,63)64)18-36(32)84(74,75)76;;;;;;;;/h1-18H,(H,44,48)(H,45,49)(H,46,50)(H,47,51)(H2,42,43,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76);;;;;;;;/q;8*+1/p-8
DM816Z2 CS C1=CC(=C(C=C1S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)C2=CC(=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C(=O)NC4=C(C=C(C=C4)S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC5=C(C=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC6=C(C=C(C=C6)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
DM816Z2 IK KCBZSNWCUJBMHF-UHFFFAOYSA-F
DM816Z2 IU octasodium;4-[[3-[[3,5-bis[(2,4-disulfonatophenyl)carbamoyl]phenyl]carbamoylamino]-5-[(2,4-disulfonatophenyl)carbamoyl]benzoyl]amino]benzene-1,3-disulfonate
DM816Z2 DE Discovery agent
DMPZB31 ID DMPZB31
DMPZB31 DN NF546
DMPZB31 HS Investigative
DMPZB31 SN NF-546
DMPZB31 DT Small molecular drug
DMPZB31 PC 73755075
DMPZB31 MW 1180.7
DMPZB31 FM C47H44N6Na4O17P4
DMPZB31 IC InChI=1S/C47H48N6O17P4.4Na/c1-27-9-13-33(45(56)50-39-15-11-29(23-71(59,60)61)17-35(39)25-73(65,66)67)21-41(27)52-43(54)31-5-3-7-37(19-31)48-47(58)49-38-8-4-6-32(20-38)44(55)53-42-22-34(14-10-28(42)2)46(57)51-40-16-12-30(24-72(62,63)64)18-36(40)26-74(68,69)70;;;;/h3-22H,23-26H2,1-2H3,(H,50,56)(H,51,57)(H,52,54)(H,53,55)(H2,48,49,58)(H2,59,60,61)(H2,62,63,64)(H2,65,66,67)(H2,68,69,70);;;;/q;4*+1/p-4
DMPZB31 CS CC1=C(C=C(C=C1)C(=O)NC2=C(C=C(C=C2)CP(=O)(O)[O-])CP(=O)(O)[O-])NC(=O)C3=CC(=CC=C3)NC(=O)NC4=CC=CC(=C4)C(=O)NC5=C(C=CC(=C5)C(=O)NC6=C(C=C(C=C6)CP(=O)(O)[O-])CP(=O)(O)[O-])C.[Na+].[Na+].[Na+].[Na+]
DMPZB31 IK GSMUPMANKNAMAS-UHFFFAOYSA-J
DMPZB31 IU tetrasodium;[2-[[3-[[3-[[3-[[5-[[2,4-bis[[hydroxy(oxido)phosphoryl]methyl]phenyl]carbamoyl]-2-methylphenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]-4-methylbenzoyl]amino]-5-[[hydroxy(oxido)phosphoryl]methyl]phenyl]methyl-hydroxyphosphinate
DMPZB31 DE Discovery agent
DM7GBDX ID DM7GBDX
DM7GBDX DN N-Formylmethionine
DM7GBDX HS Investigative
DM7GBDX SN N-formyl-L-methionine; 4289-98-9; for-met-oh; N-FORMYLMETHIONINE; (S)-2-Formamido-4-(methylthio)butanoic acid; Formyl-L-methionine; formylmethionine; L-Methionine, N-formyl-; UNII-PS9357B4XH; N-Formyl-L -Methionine; PS9357B4XH; PYUSHNKNPOHWEZ-YFKPBYRVSA-N; N-Formyl methionine; L-Formylmethionine; L-N-Formylmethionine; N-Formyl(methyl)homocysteine #; Formyl-methionine; N-formyl-l-met; 2-formamido-4-methylsulfanylbutanoic acid; NSC 334322; Methionine, N-formyl-; AC1L97YW; SCHEMBL38595; CHEBI:16552; CTK1D5830; MolPort-006-116-105
DM7GBDX DT Small molecular drug
DM7GBDX PC 439750
DM7GBDX MW 177.22
DM7GBDX FM C6H11NO3S
DM7GBDX IC InChI=1S/C6H11NO3S/c1-11-3-2-5(6(9)10)7-4-8/h4-5H,2-3H2,1H3,(H,7,8)(H,9,10)/t5-/m0/s1
DM7GBDX CS CSCC[C@@H](C(=O)O)NC=O
DM7GBDX IK PYUSHNKNPOHWEZ-YFKPBYRVSA-N
DM7GBDX IU (2S)-2-formamido-4-methylsulfanylbutanoic acid
DM7GBDX CA CAS 4289-98-9
DM7GBDX CB CHEBI:16552
DM7GBDX DE Discovery agent
DMC48D9 ID DMC48D9
DMC48D9 DN NG-25
DMC48D9 HS Investigative
DMC48D9 SN NG25
DMC48D9 DT Small molecular drug
DMC48D9 PC 53340664
DMC48D9 MW 537.6
DMC48D9 FM C29H30F3N5O2
DMC48D9 IC InChI=1S/C29H30F3N5O2/c1-3-36-12-14-37(15-13-36)18-21-6-7-22(17-24(21)29(30,31)32)35-28(38)20-5-4-19(2)26(16-20)39-25-9-11-34-27-23(25)8-10-33-27/h4-11,16-17H,3,12-15,18H2,1-2H3,(H,33,34)(H,35,38)
DMC48D9 CS CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F
DMC48D9 IK SMPGEBOIKULBCT-UHFFFAOYSA-N
DMC48D9 IU N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide
DMC48D9 CA CAS 1315355-93-1
DMC48D9 DE Discovery agent
DMMC42Z ID DMMC42Z
DMMC42Z DN NGB 2904
DMMC42Z HS Investigative
DMMC42Z SN NGB-2904
DMMC42Z DT Small molecular drug
DMMC42Z PC 19366304
DMMC42Z MW 530.9
DMMC42Z FM C28H30Cl3N3O
DMMC42Z IC InChI=1S/C28H29Cl2N3O.ClH/c29-25-8-5-9-26(27(25)30)33-16-14-32(15-17-33)13-4-3-12-31-28(34)21-10-11-24-22(19-21)18-20-6-1-2-7-23(20)24;/h1-2,5-11,19H,3-4,12-18H2,(H,31,34);1H
DMMC42Z CS C1CN(CCN1CCCCNC(=O)C2=CC3=C(C=C2)C4=CC=CC=C4C3)C5=C(C(=CC=C5)Cl)Cl.Cl
DMMC42Z IK PFIWYJNBKGCVFM-UHFFFAOYSA-N
DMMC42Z IU N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]-9H-fluorene-2-carboxamide;hydrochloride
DMMC42Z DE Discovery agent
DMWD7I3 ID DMWD7I3
DMWD7I3 DN NGD 96-3
DMWD7I3 HS Investigative
DMWD7I3 CP Neurogen Corporation
DMWD7I3 DE Insomnia
DMPEZHC ID DMPEZHC
DMPEZHC DN N-glycylglycinehydroxamic acid
DMPEZHC HS Investigative
DMPEZHC SN N-glycylglycinehydroxamic acid; CHEMBL462481; AKOS013308170
DMPEZHC DT Small molecular drug
DMPEZHC PC 10057636
DMPEZHC MW 147.13
DMPEZHC FM C4H9N3O3
DMPEZHC IC InChI=1S/C4H9N3O3/c5-1-3(8)6-2-4(9)7-10/h10H,1-2,5H2,(H,6,8)(H,7,9)
DMPEZHC CS C(C(=O)NCC(=O)NO)N
DMPEZHC IK NXTDAODSZSXXAY-UHFFFAOYSA-N
DMPEZHC IU 2-amino-N-[2-(hydroxyamino)-2-oxoethyl]acetamide
DMPEZHC DE Discovery agent
DMBG3ZF ID DMBG3ZF
DMBG3ZF DN N-guanyl-1,7-diaminoheptane
DMBG3ZF HS Investigative
DMBG3ZF SN 2-(7-aminoheptyl)guanidine; 150333-69-0; CHEMBL229457; Guanidine, N-(7-aminoheptyl)-; 1-(7-aminoheptyl)guanidine; N1-Guanyl-1,7-diaminoheptane (GC7); AC1L9LWV; N-(7-Aminoheptyl)guanidine; N-Guanyl-1,7-heptanediamine; SCHEMBL433609; N-(7-Amino-heptyl)-guanidine; CTK8H0316; CHEBI:133366
DMBG3ZF DT Small molecular drug
DMBG3ZF PC 448393
DMBG3ZF MW 172.27
DMBG3ZF FM C8H20N4
DMBG3ZF IC InChI=1S/C8H20N4/c9-6-4-2-1-3-5-7-12-8(10)11/h1-7,9H2,(H4,10,11,12)
DMBG3ZF CS C(CCCN)CCCN=C(N)N
DMBG3ZF IK YAOAMZOGXBMLFQ-UHFFFAOYSA-N
DMBG3ZF IU 2-(7-aminoheptyl)guanidine
DMBG3ZF CB CHEBI:133366
DMBG3ZF DE Discovery agent
DMYAB79 ID DMYAB79
DMYAB79 DN NH-3
DMYAB79 HS Investigative
DMYAB79 SN thyromimetic, 5b; NH-3; CHEMBL109279; JMC496635 Compound 5; GTPL2633; SCHEMBL16993604; BDBM18885; 2-[4-({4-hydroxy-3-[2-(4-nitrophenyl)ethynyl]-5-(propan-2-yl)phenyl}methyl)-3,5-dimethylphenoxy]acetic acid; 2-[4-[[4-hydroxy-3-[2-(4-nitrophenyl)ethynyl]-5-propan-2-ylphenyl]methyl]-3,5-dimethylphenoxy]acetic acid
DMYAB79 DT Small molecular drug
DMYAB79 PC 10027822
DMYAB79 MW 473.5
DMYAB79 FM C28H27NO6
DMYAB79 IC InChI=1S/C28H27NO6/c1-17(2)25-14-21(15-26-18(3)11-24(12-19(26)4)35-16-27(30)31)13-22(28(25)32)8-5-20-6-9-23(10-7-20)29(33)34/h6-7,9-14,17,32H,15-16H2,1-4H3,(H,30,31)
DMYAB79 CS CC1=CC(=CC(=C1CC2=CC(=C(C(=C2)C(C)C)O)C#CC3=CC=C(C=C3)[N+](=O)[O-])C)OCC(=O)O
DMYAB79 IK IXMROOKFPWGDGF-UHFFFAOYSA-N
DMYAB79 IU 2-[4-[[4-hydroxy-3-[2-(4-nitrophenyl)ethynyl]-5-propan-2-ylphenyl]methyl]-3,5-dimethylphenoxy]acetic acid
DMYAB79 DE Discovery agent
DMSUZFO ID DMSUZFO
DMSUZFO DN NH-4
DMSUZFO HS Investigative
DMSUZFO SN ammonium; Ammonium ion; Ammonium(1+); azanium; NH4+; Ammonium cation; 14798-03-9; Ammonia ion; Ammonium ion(+); AMMONIUM CATION WITH D; UNII-54S68520I4; NH4(+); 54S68520I4; Ammonium Compounds; ND4; Quaternary ammonium compounds; Nitrogen cation; Ammonium(+); nitrogen(1+); Nitrogen tetrahydride; Ammonium ion(1+); Ammonium (NH4+); AC1NUTFY; AC1NUTFO; Ammonia ion (NH4+); Ammonium ion (NH4+); nitrogen(1+) trihydride; Ammonium (8CI,9CI); Ammonia, ion (NH41+); AC1Q1W88; AC1L18R7; DTXSID5043974; CHEBI:29352; CHEBI:28938; CTK0H5427
DMSUZFO DT Small molecular drug
DMSUZFO PC 223
DMSUZFO MW 18.039
DMSUZFO FM H4N+
DMSUZFO IC InChI=1S/H3N/h1H3/p+1
DMSUZFO CS [NH4+]
DMSUZFO IK QGZKDVFQNNGYKY-UHFFFAOYSA-O
DMSUZFO IU azanium
DMSUZFO CA CAS 14798-03-9
DMSUZFO CB CHEBI:28938
DMSUZFO DE Discovery agent
DMM0F2G ID DMM0F2G
DMM0F2G DN N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide
DMM0F2G HS Investigative
DMM0F2G SN CHEMBL329499; N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide; BDBM50045876
DMM0F2G DT Small molecular drug
DMM0F2G PC 10065495
DMM0F2G MW 334.5
DMM0F2G FM C22H26N2O
DMM0F2G IC InChI=1S/C22H26N2O/c1-2-3-4-10-15-23-21(25)16-19-18-13-8-9-14-20(18)24-22(19)17-11-6-5-7-12-17/h5-9,11-14,24H,2-4,10,15-16H2,1H3,(H,23,25)
DMM0F2G CS CCCCCCNC(=O)CC1=C(NC2=CC=CC=C21)C3=CC=CC=C3
DMM0F2G IK SVHWOYODYBUWLL-UHFFFAOYSA-N
DMM0F2G IU N-hexyl-2-(2-phenyl-1H-indol-3-yl)acetamide
DMM0F2G CA CAS 145040-30-8
DMM0F2G DE Discovery agent
DML27CG ID DML27CG
DML27CG DN N-Hexylcarbamic Acid Biphenyl-3-yl Ester
DML27CG HS Investigative
DML27CG SN CHEMBL488348; n-Hexylcarbamic Acid Biphenyl-3-yl Ester
DML27CG DT Small molecular drug
DML27CG PC 24881671
DML27CG MW 297.4
DML27CG FM C19H23NO2
DML27CG IC InChI=1S/C19H23NO2/c1-2-3-4-8-14-20-19(21)22-18-13-9-12-17(15-18)16-10-6-5-7-11-16/h5-7,9-13,15H,2-4,8,14H2,1H3,(H,20,21)
DML27CG CS CCCCCCNC(=O)OC1=CC=CC(=C1)C2=CC=CC=C2
DML27CG IK QPTMPZNXKZNQMF-UHFFFAOYSA-N
DML27CG IU (3-phenylphenyl) N-hexylcarbamate
DML27CG DE Discovery agent
DMZ2T59 ID DMZ2T59
DMZ2T59 DN N-hydroxy-1-naphthamide
DMZ2T59 HS Investigative
DMZ2T59 SN 1-Naphthohydroxamic acid; 6953-61-3; N-Hydroxy-1-naphthamide; 1-NAPHTHALENECARBOXAMIDE, N-HYDROXY-; NSC 57457; N-Hydroxynaphthalene-1-carboxamide; alpha-Naphthohydroxamic acid; a-Naphthohydroxamic acid; BRN 2094470; CHEMBL115468; Naphthalene-1-carboxylic acid hydroxyamide; 8GK; naphthylhydroxamic acid; AC1L2M8D; N-Hydroxy-1-naphthamide #; 4-09-00-02407 (Beilstein Handbook Reference); .alpha.-Naphthohydroxamic acid; ACMC-209o98; SCHEMBL2230679; CTK5D0341; DTXSID30219789; JRZGPWOEHDOVMC-UHFFFAOYSA-N
DMZ2T59 DT Small molecular drug
DMZ2T59 PC 23382
DMZ2T59 MW 187.19
DMZ2T59 FM C11H9NO2
DMZ2T59 IC InChI=1S/C11H9NO2/c13-11(12-14)10-7-3-5-8-4-1-2-6-9(8)10/h1-7,14H,(H,12,13)
DMZ2T59 CS C1=CC=C2C(=C1)C=CC=C2C(=O)NO
DMZ2T59 IK JRZGPWOEHDOVMC-UHFFFAOYSA-N
DMZ2T59 IU N-hydroxynaphthalene-1-carboxamide
DMZ2T59 CA CAS 6953-61-3
DMZ2T59 DE Discovery agent
DM56P1I ID DM56P1I
DM56P1I DN N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide
DM56P1I HS Investigative
DM56P1I SN CHEMBL575895; N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide
DM56P1I DT Small molecular drug
DM56P1I PC 44479457
DM56P1I MW 307.32
DM56P1I FM C14H13NO5S
DM56P1I IC InChI=1S/C14H13NO5S/c1-20-10-6-8-11(9-7-10)21(18,19)13-5-3-2-4-12(13)14(16)15-17/h2-9,17H,1H3,(H,15,16)
DM56P1I CS COC1=CC=C(C=C1)S(=O)(=O)C2=CC=CC=C2C(=O)NO
DM56P1I IK QPFIKHZWPMXTRS-UHFFFAOYSA-N
DM56P1I IU N-hydroxy-2-(4-methoxyphenyl)sulfonylbenzamide
DM56P1I DE Discovery agent
DM50NKS ID DM50NKS
DM50NKS DN N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide
DM50NKS HS Investigative
DM50NKS SN CHEMBL83508; N-Hydroxy-N~2~-[(4-Methoxyphenyl)sulfonyl]glycinamide; Hydroxamate 9; Z79; 3lk8; SCHEMBL7410575; BDBM11328; (4-Methoxyphenylsulfonylamino)acetohydroximic acid
DM50NKS DT Small molecular drug
DM50NKS PC 10445302
DM50NKS MW 260.269
DM50NKS FM C9H12N2O5S
DM50NKS IC InChI=1S/C9H12N2O5S/c1-16-7-2-4-8(5-3-7)17(14,15)10-6-9(12)11-13/h2-5,10,13H,6H2,1H3,(H,11,12)
DM50NKS CS COC1=CC=C(C=C1)S(=O)(=O)NCC(=O)NO
DM50NKS IK WLZISXXOYYGJNT-UHFFFAOYSA-N
DM50NKS IU N-hydroxy-2-[(4-methoxyphenyl)sulfonylamino]acetamide
DM50NKS DE Discovery agent
DM4VADN ID DM4VADN
DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN HS Investigative
DM4VADN SN CHEMBL575896; N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide
DM4VADN DT Small molecular drug
DM4VADN PC 10155934
DM4VADN MW 369.4
DM4VADN FM C19H15NO5S
DM4VADN IC InChI=1S/C19H15NO5S/c21-19(20-22)17-8-4-5-9-18(17)26(23,24)16-12-10-15(11-13-16)25-14-6-2-1-3-7-14/h1-13,22H,(H,20,21)
DM4VADN CS C1=CC=C(C=C1)OC2=CC=C(C=C2)S(=O)(=O)C3=CC=CC=C3C(=O)NO
DM4VADN IK MYZHQACPXTZCJY-UHFFFAOYSA-N
DM4VADN IU N-hydroxy-2-(4-phenoxyphenyl)sulfonylbenzamide
DM4VADN DE Discovery agent
DMISXUM ID DMISXUM
DMISXUM DN N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide
DMISXUM HS Investigative
DMISXUM SN CHEMBL182879; 834918-57-9; N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide; CTK3D2016; DTXSID40465831; BDBM50157325; AKOS030565680; Acetamide, N-hydroxy-2-(2-naphthalenylthio)-
DMISXUM DT Small molecular drug
DMISXUM PC 11436221
DMISXUM MW 233.29
DMISXUM FM C12H11NO2S
DMISXUM IC InChI=1S/C12H11NO2S/c14-12(13-15)8-16-11-6-5-9-3-1-2-4-10(9)7-11/h1-7,15H,8H2,(H,13,14)
DMISXUM CS C1=CC=C2C=C(C=CC2=C1)SCC(=O)NO
DMISXUM IK GNDJOJQVOFQQBM-UHFFFAOYSA-N
DMISXUM IU N-hydroxy-2-naphthalen-2-ylsulfanylacetamide
DMISXUM CA CAS 834918-57-9
DMISXUM DE Discovery agent
DMWIMR4 ID DMWIMR4
DMWIMR4 DN N-hydroxy-2,2'-bithiophene-5-carboxamide
DMWIMR4 HS Investigative
DMWIMR4 SN CHEMBL217750; SCHEMBL5903723; BDBM50198479
DMWIMR4 DT Small molecular drug
DMWIMR4 PC 44418185
DMWIMR4 MW 225.3
DMWIMR4 FM C9H7NO2S2
DMWIMR4 IC InChI=1S/C9H7NO2S2/c11-9(10-12)8-4-3-7(14-8)6-2-1-5-13-6/h1-5,12H,(H,10,11)
DMWIMR4 CS C1=CSC(=C1)C2=CC=C(S2)C(=O)NO
DMWIMR4 IK PSYPMKKEKUDELT-UHFFFAOYSA-N
DMWIMR4 IU N-hydroxy-5-thiophen-2-ylthiophene-2-carboxamide
DMWIMR4 DE Discovery agent
DMX3KRQ ID DMX3KRQ
DMX3KRQ DN N-hydroxy-2,2-diphenylacetamide
DMX3KRQ HS Investigative
DMX3KRQ SN Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, >
DMX3KRQ DT Small molecular drug
DMX3KRQ PC 239512
DMX3KRQ MW 227.26
DMX3KRQ FM C14H13NO2
DMX3KRQ IC InChI=1S/C14H13NO2/c16-14(15-17)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13,17H,(H,15,16)
DMX3KRQ CS C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NO
DMX3KRQ IK OFSBBVCLWMCGNY-UHFFFAOYSA-N
DMX3KRQ IU N-hydroxy-2,2-diphenylacetamide
DMX3KRQ CA CAS 4099-51-8
DMX3KRQ DE Discovery agent
DM7I2TD ID DM7I2TD
DM7I2TD DN N-hydroxy-2,2-diphenylpropanamide
DM7I2TD HS Investigative
DM7I2TD SN CHEMBL585365; N-hydroxy-2,2-diphenylpropanamide; SCHEMBL2844474
DM7I2TD DT Small molecular drug
DM7I2TD PC 45482660
DM7I2TD MW 241.28
DM7I2TD FM C15H15NO2
DM7I2TD IC InChI=1S/C15H15NO2/c1-15(14(17)16-18,12-8-4-2-5-9-12)13-10-6-3-7-11-13/h2-11,18H,1H3,(H,16,17)
DM7I2TD CS CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)NO
DM7I2TD IK LDAQHFMKFUATRE-UHFFFAOYSA-N
DM7I2TD IU N-hydroxy-2,2-diphenylpropanamide
DM7I2TD DE Discovery agent
DMZWIVJ ID DMZWIVJ
DMZWIVJ DN N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ HS Investigative
DMZWIVJ SN CHEMBL496717; N-hydroxy-2,3-bis(phenylsulfonamido)propanamide
DMZWIVJ DT Small molecular drug
DMZWIVJ PC 24857837
DMZWIVJ MW 399.4
DMZWIVJ FM C15H17N3O6S2
DMZWIVJ IC InChI=1S/C15H17N3O6S2/c19-15(17-20)14(18-26(23,24)13-9-5-2-6-10-13)11-16-25(21,22)12-7-3-1-4-8-12/h1-10,14,16,18,20H,11H2,(H,17,19)
DMZWIVJ CS C1=CC=C(C=C1)S(=O)(=O)NCC(C(=O)NO)NS(=O)(=O)C2=CC=CC=C2
DMZWIVJ IK WBWFDDZAXKMHEG-UHFFFAOYSA-N
DMZWIVJ IU 2,3-bis(benzenesulfonamido)-N-hydroxypropanamide
DMZWIVJ DE Discovery agent
DME96RF ID DME96RF
DME96RF DN N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide
DME96RF HS Investigative
DME96RF SN CHEMBL367336; N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide; ZINC28109710; BDBM50015187; (E)-2-Methyl-3-(2-naphthalenyl)-2-propenehydroximic acid
DME96RF DT Small molecular drug
DME96RF PC 20238032
DME96RF MW 227.26
DME96RF FM C14H13NO2
DME96RF IC InChI=1S/C14H13NO2/c1-10(14(16)15-17)8-11-6-7-12-4-2-3-5-13(12)9-11/h2-9,17H,1H3,(H,15,16)/b10-8+
DME96RF CS C/C(=C\\C1=CC2=CC=CC=C2C=C1)/C(=O)NO
DME96RF IK NPYWWIHEHONKOF-CSKARUKUSA-N
DME96RF IU (E)-N-hydroxy-2-methyl-3-naphthalen-2-ylprop-2-enamide
DME96RF DE Discovery agent
DMYDX34 ID DMYDX34
DMYDX34 DN N-Hydroxy-2-naphthalen-2-yl-acetamide
DMYDX34 HS Investigative
DMYDX34 SN N-hydroxy-2-(naphthalen-2-yl)acetamide; CHEMBL346935; 106359-52-8; 2-Naphthaleneacetamide, N-hydroxy-; N-Hydroxy-2-naphthalen-2-yl-acetamide; AC1Q7DIT; SCHEMBL1520280; CTK8A6801; MolPort-004-327-963; KUC108662N; ZINC19423737; BDBM50015114; AKOS000168393; NE14616; MCULE-5699071643; NCGC00186600-01; NCGC00186600-02; KSC-11-264-7
DMYDX34 DT Small molecular drug
DMYDX34 PC 24689999
DMYDX34 MW 201.22
DMYDX34 FM C12H11NO2
DMYDX34 IC InChI=1S/C12H11NO2/c14-12(13-15)8-9-5-6-10-3-1-2-4-11(10)7-9/h1-7,15H,8H2,(H,13,14)
DMYDX34 CS C1=CC=C2C=C(C=CC2=C1)CC(=O)NO
DMYDX34 IK IYXUERDUKOVYLR-UHFFFAOYSA-N
DMYDX34 IU N-hydroxy-2-naphthalen-2-ylacetamide
DMYDX34 DE Discovery agent
DMWXUCT ID DMWXUCT
DMWXUCT DN N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide
DMWXUCT HS Investigative
DMWXUCT SN CHEMBL252674; N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963
DMWXUCT DT Small molecular drug
DMWXUCT PC 44446270
DMWXUCT MW 233.22
DMWXUCT FM C12H11NO4
DMWXUCT IC InChI=1S/C12H11NO4/c14-11(13-16)6-5-9-7-8-3-1-2-4-10(8)17-12(9)15/h1-4,7,16H,5-6H2,(H,13,14)
DMWXUCT CS C1=CC=C2C(=C1)C=C(C(=O)O2)CCC(=O)NO
DMWXUCT IK HJRCGMHZQDXQAO-UHFFFAOYSA-N
DMWXUCT IU N-hydroxy-3-(2-oxochromen-3-yl)propanamide
DMWXUCT DE Discovery agent
DMA6EPH ID DMA6EPH
DMA6EPH DN N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH HS Investigative
DMA6EPH SN CHEMBL402990; N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
DMA6EPH DT Small molecular drug
DMA6EPH PC 44446277
DMA6EPH MW 263.25
DMA6EPH FM C13H13NO5
DMA6EPH IC InChI=1S/C13H13NO5/c1-18-10-3-4-11-9(7-10)6-8(13(16)19-11)2-5-12(15)14-17/h3-4,6-7,17H,2,5H2,1H3,(H,14,15)
DMA6EPH CS COC1=CC2=C(C=C1)OC(=O)C(=C2)CCC(=O)NO
DMA6EPH IK JUDXBTMVZVWJNP-UHFFFAOYSA-N
DMA6EPH IU N-hydroxy-3-(6-methoxy-2-oxochromen-3-yl)propanamide
DMA6EPH DE Discovery agent
DMY6Z0U ID DMY6Z0U
DMY6Z0U DN N-hydroxy-3-(naphthalen-1-yl)acrylamide
DMY6Z0U HS Investigative
DMY6Z0U SN CHEMBL245548; N-hydroxy-3-(naphthalen-1-yl)acrylamide; SCHEMBL14106948; BDBM50207560; (E)-3-(1-Naphthalenyl)-2-propenehydroximic acid
DMY6Z0U DT Small molecular drug
DMY6Z0U PC 24880249
DMY6Z0U MW 213.23
DMY6Z0U FM C13H11NO2
DMY6Z0U IC InChI=1S/C13H11NO2/c15-13(14-16)9-8-11-6-3-5-10-4-1-2-7-12(10)11/h1-9,16H,(H,14,15)/b9-8+
DMY6Z0U CS C1=CC=C2C(=C1)C=CC=C2/C=C/C(=O)NO
DMY6Z0U IK AOXOYUCWJCCUDO-CMDGGOBGSA-N
DMY6Z0U IU (E)-N-hydroxy-3-naphthalen-1-ylprop-2-enamide
DMY6Z0U DE Discovery agent
DMZ3INJ ID DMZ3INJ
DMZ3INJ DN N-Hydroxy-3-naphthalen-2-yl-acrylamide
DMZ3INJ HS Investigative
DMZ3INJ SN CHEMBL155443; N-Hydroxy-3-naphthalen-2-yl-acrylamide; N-Hydroxy-2-naphthaleneacrylamide; BDBM50015170; ZINC27654302; (E)-3-(2-Naphthalenyl)-2-propenehydroximic acid
DMZ3INJ DT Small molecular drug
DMZ3INJ PC 13687209
DMZ3INJ MW 213.23
DMZ3INJ FM C13H11NO2
DMZ3INJ IC InChI=1S/C13H11NO2/c15-13(14-16)8-6-10-5-7-11-3-1-2-4-12(11)9-10/h1-9,16H,(H,14,15)/b8-6+
DMZ3INJ CS C1=CC=C2C=C(C=CC2=C1)/C=C/C(=O)NO
DMZ3INJ IK NJQJPKBDKOPBGI-SOFGYWHQSA-N
DMZ3INJ IU (E)-N-hydroxy-3-naphthalen-2-ylprop-2-enamide
DMZ3INJ DE Discovery agent
DMVOPXE ID DMVOPXE
DMVOPXE DN N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide
DMVOPXE HS Investigative
DMVOPXE SN CHEMBL154575; N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide; BDBM50015102; (E)-3-(2-Naphthalenyl)-N-phenyl-2-propenehydroxamic acid
DMVOPXE DT Small molecular drug
DMVOPXE PC 13687213
DMVOPXE MW 289.3
DMVOPXE FM C19H15NO2
DMVOPXE IC InChI=1S/C19H15NO2/c21-19(20(22)18-8-2-1-3-9-18)13-11-15-10-12-16-6-4-5-7-17(16)14-15/h1-14,22H/b13-11+
DMVOPXE CS C1=CC=C(C=C1)N(C(=O)/C=C/C2=CC3=CC=CC=C3C=C2)O
DMVOPXE IK OSTLUPOHWIAJIK-ACCUITESSA-N
DMVOPXE IU (E)-N-hydroxy-3-naphthalen-2-yl-N-phenylprop-2-enamide
DMVOPXE DE Discovery agent
DMKBACJ ID DMKBACJ
DMKBACJ DN N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide
DMKBACJ HS Investigative
DMKBACJ SN CHEMBL366714; N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide; BDBM50015103; (E)-3-(2-Naphthalenyl)-N-(4-methylphenyl)-2-propenehydroxamic acid
DMKBACJ DT Small molecular drug
DMKBACJ PC 44386467
DMKBACJ MW 303.4
DMKBACJ FM C20H17NO2
DMKBACJ IC InChI=1S/C20H17NO2/c1-15-6-11-19(12-7-15)21(23)20(22)13-9-16-8-10-17-4-2-3-5-18(17)14-16/h2-14,23H,1H3/b13-9+
DMKBACJ CS CC1=CC=C(C=C1)N(C(=O)/C=C/C2=CC3=CC=CC=C3C=C2)O
DMKBACJ IK MXCQZPFMNOZXSH-UKTHLTGXSA-N
DMKBACJ IU (E)-N-hydroxy-N-(4-methylphenyl)-3-naphthalen-2-ylprop-2-enamide
DMKBACJ DE Discovery agent
DMPIMRC ID DMPIMRC
DMPIMRC DN N-Hydroxy-3-naphthalen-2-yl-propionamide
DMPIMRC HS Investigative
DMPIMRC SN CHEMBL154998; N-Hydroxy-3-naphthalen-2-yl-propionamide; SCHEMBL10362477; BDBM50015120
DMPIMRC DT Small molecular drug
DMPIMRC PC 13687220
DMPIMRC MW 215.25
DMPIMRC FM C13H13NO2
DMPIMRC IC InChI=1S/C13H13NO2/c15-13(14-16)8-6-10-5-7-11-3-1-2-4-12(11)9-10/h1-5,7,9,16H,6,8H2,(H,14,15)
DMPIMRC CS C1=CC=C2C=C(C=CC2=C1)CCC(=O)NO
DMPIMRC IK FUEAAJNBAJRTSE-UHFFFAOYSA-N
DMPIMRC IU N-hydroxy-3-naphthalen-2-ylpropanamide
DMPIMRC DE Discovery agent
DMTZ8RQ ID DMTZ8RQ
DMTZ8RQ DN N-hydroxy-3-phenoxybenzamide
DMTZ8RQ HS Investigative
DMTZ8RQ SN CHEMBL245741; N-hydroxy-3-phenoxybenzamide; SCHEMBL6671653
DMTZ8RQ DT Small molecular drug
DMTZ8RQ PC 10192705
DMTZ8RQ MW 229.23
DMTZ8RQ FM C13H11NO3
DMTZ8RQ IC InChI=1S/C13H11NO3/c15-13(14-16)10-5-4-8-12(9-10)17-11-6-2-1-3-7-11/h1-9,16H,(H,14,15)
DMTZ8RQ CS C1=CC=C(C=C1)OC2=CC=CC(=C2)C(=O)NO
DMTZ8RQ IK WFZFBIHVPMBSOS-UHFFFAOYSA-N
DMTZ8RQ IU N-hydroxy-3-phenoxybenzamide
DMTZ8RQ DE Discovery agent
DM9IPTV ID DM9IPTV
DM9IPTV DN N-Hydroxy-3-phenyl-acrylamide
DM9IPTV HS Investigative
DM9IPTV SN Cinnamoylhydroxamic acid; CINNAMOHYDROXAMIC ACID; Hydroxylamine, N-cinnamoyl-; 2-Propenamide, N-hydroxy-3-phenyl-; N-Hydroxycinnamamide; UNII-434STJ4H11; N-Hydroxy-3-phenyl-2-propenamide; NSC 42128; NSC-42128; NSC-44617; NSC 44617; CHEMBL154574; 3669-32-7; 434STJ4H11; WLN: QMV1U1R; N-Hydroxy-3-phenyl-acrylamide; Cinnamohydroxamic acid, (E)-; Cinnamoylhydroxamic acid [INCI]; MAZ 1704; MAZ-1704; 2-Propenamide, N-hydroxy-3-phenyl-, (E)-; 2-Propenamide, N-hydroxy-3-phenyl-, (2E)-; AC1Q5CS7; AC1NS7U4; SCHEMBL559917
DM9IPTV DT Small molecular drug
DM9IPTV PC 5355635
DM9IPTV MW 163.17
DM9IPTV FM C9H9NO2
DM9IPTV IC InChI=1S/C9H9NO2/c11-9(10-12)7-6-8-4-2-1-3-5-8/h1-7,12H,(H,10,11)/b7-6+
DM9IPTV CS C1=CC=C(C=C1)/C=C/C(=O)NO
DM9IPTV IK UVDDFTZLVFIQFL-VOTSOKGWSA-N
DM9IPTV IU (E)-N-hydroxy-3-phenylprop-2-enamide
DM9IPTV CA CAS 3669-32-7
DM9IPTV DE Discovery agent
DMCN91A ID DMCN91A
DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide
DMCN91A HS Investigative
DMCN91A SN SCHEMBL675474
DMCN91A DT Small molecular drug
DMCN91A PC 11231829
DMCN91A MW 298.34
DMCN91A FM C17H18N2O3
DMCN91A IC InChI=1S/C17H18N2O3/c1-2-15(12-6-4-3-5-7-12)17(21)18-14-10-8-13(9-11-14)16(20)19-22/h3-11,15,22H,2H2,1H3,(H,18,21)(H,19,20)/t15-/m1/s1
DMCN91A CS CC[C@H](C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMCN91A IK SPLALNOEMVSHPJ-OAHLLOKOSA-N
DMCN91A IU N-hydroxy-4-[[(2R)-2-phenylbutanoyl]amino]benzamide
DMCN91A DE Discovery agent
DMVK2Y3 ID DMVK2Y3
DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide
DMVK2Y3 HS Investigative
DMVK2Y3 SN SCHEMBL676080
DMVK2Y3 DT Small molecular drug
DMVK2Y3 PC 11312563
DMVK2Y3 MW 298.34
DMVK2Y3 FM C17H18N2O3
DMVK2Y3 IC InChI=1S/C17H18N2O3/c1-2-15(12-6-4-3-5-7-12)17(21)18-14-10-8-13(9-11-14)16(20)19-22/h3-11,15,22H,2H2,1H3,(H,18,21)(H,19,20)/t15-/m0/s1
DMVK2Y3 CS CC[C@@H](C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMVK2Y3 IK SPLALNOEMVSHPJ-HNNXBMFYSA-N
DMVK2Y3 IU N-hydroxy-4-[[(2S)-2-phenylbutanoyl]amino]benzamide
DMVK2Y3 DE Discovery agent
DMKELRB ID DMKELRB
DMKELRB DN N-hydroxy-4-(2-oleamidoethyl)benzamide
DMKELRB HS Investigative
DMKELRB SN CHEMBL251734; N-hydroxy-4-(2-oleamidoethyl)benzamide
DMKELRB DT Small molecular drug
DMKELRB PC 44441632
DMKELRB MW 444.6
DMKELRB FM C27H44N2O3
DMKELRB IC InChI=1S/C27H44N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(30)28-23-22-24-18-20-25(21-19-24)27(31)29-32/h9-10,18-21,32H,2-8,11-17,22-23H2,1H3,(H,28,30)(H,29,31)/b10-9-
DMKELRB CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCCC1=CC=C(C=C1)C(=O)NO
DMKELRB IK NGQCNQPGVUJPCK-KTKRTIGZSA-N
DMKELRB IU N-hydroxy-4-[2-[[(Z)-octadec-9-enoyl]amino]ethyl]benzamide
DMKELRB DE Discovery agent
DMHEQ41 ID DMHEQ41
DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide
DMHEQ41 HS Investigative
DMHEQ41 SN SCHEMBL676079
DMHEQ41 DT Small molecular drug
DMHEQ41 PC 11347053
DMHEQ41 MW 298.34
DMHEQ41 FM C17H18N2O3
DMHEQ41 IC InChI=1S/C17H18N2O3/c1-2-15(12-6-4-3-5-7-12)17(21)18-14-10-8-13(9-11-14)16(20)19-22/h3-11,15,22H,2H2,1H3,(H,18,21)(H,19,20)
DMHEQ41 CS CCC(C1=CC=CC=C1)C(=O)NC2=CC=C(C=C2)C(=O)NO
DMHEQ41 IK SPLALNOEMVSHPJ-UHFFFAOYSA-N
DMHEQ41 IU N-hydroxy-4-(2-phenylbutanoylamino)benzamide
DMHEQ41 DE Discovery agent
DMUOCQB ID DMUOCQB
DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide
DMUOCQB HS Investigative
DMUOCQB SN N-hydroxy-4-(3-phenylpropanamido)benzamide
DMUOCQB DE Discovery agent
DMQN6CL ID DMQN6CL
DMQN6CL DN N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
DMQN6CL HS Investigative
DMQN6CL SN CHEMBL366010; N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
DMQN6CL DT Small molecular drug
DMQN6CL PC 44404461
DMQN6CL MW 223.22
DMQN6CL FM C11H13NO4
DMQN6CL IC InChI=1S/C11H13NO4/c1-16-9-4-2-8(3-5-9)10(13)6-7-11(14)12-15/h2-5,15H,6-7H2,1H3,(H,12,14)
DMQN6CL CS COC1=CC=C(C=C1)C(=O)CCC(=O)NO
DMQN6CL IK YUAIIHPYXRCTLQ-UHFFFAOYSA-N
DMQN6CL IU N-hydroxy-4-(4-methoxyphenyl)-4-oxobutanamide
DMQN6CL DE Discovery agent
DMVEOBY ID DMVEOBY
DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide
DMVEOBY HS Investigative
DMVEOBY SN CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
DMVEOBY DT Small molecular drug
DMVEOBY PC 9994848
DMVEOBY MW 298.34
DMVEOBY FM C17H18N2O3
DMVEOBY IC InChI=1S/C17H18N2O3/c20-16(8-4-7-13-5-2-1-3-6-13)18-15-11-9-14(10-12-15)17(21)19-22/h1-3,5-6,9-12,22H,4,7-8H2,(H,18,20)(H,19,21)
DMVEOBY CS C1=CC=C(C=C1)CCCC(=O)NC2=CC=C(C=C2)C(=O)NO
DMVEOBY IK VZROKPBSFBHVTL-UHFFFAOYSA-N
DMVEOBY IU N-hydroxy-4-(4-phenylbutanoylamino)benzamide
DMVEOBY CA CAS 656261-24-4
DMVEOBY DE Discovery agent
DMISRMT ID DMISRMT
DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide
DMISRMT HS Investigative
DMISRMT SN SCHEMBL7311087
DMISRMT DT Small molecular drug
DMISRMT PC 11472431
DMISRMT MW 312.4
DMISRMT FM C18H20N2O3
DMISRMT IC InChI=1S/C18H20N2O3/c21-17(9-5-4-8-14-6-2-1-3-7-14)19-16-12-10-15(11-13-16)18(22)20-23/h1-3,6-7,10-13,23H,4-5,8-9H2,(H,19,21)(H,20,22)
DMISRMT CS C1=CC=C(C=C1)CCCCC(=O)NC2=CC=C(C=C2)C(=O)NO
DMISRMT IK ZCTKPFZOLLIQQR-UHFFFAOYSA-N
DMISRMT IU N-hydroxy-4-(5-phenylpentanoylamino)benzamide
DMISRMT DE Discovery agent
DMSHQE3 ID DMSHQE3
DMSHQE3 DN N-hydroxy-4-(naphthalen-1-yl)benzamide
DMSHQE3 HS Investigative
DMSHQE3 SN N-Hydroxy-4-naphthalen-1-yl-benzamide
DMSHQE3 DT Small molecular drug
DMSHQE3 PC 17748273
DMSHQE3 MW 263.29
DMSHQE3 FM C17H13NO2
DMSHQE3 IC InChI=1S/C17H13NO2/c19-17(18-20)14-10-8-13(9-11-14)16-7-3-5-12-4-1-2-6-15(12)16/h1-11,20H,(H,18,19)
DMSHQE3 CS C1=CC=C2C(=C1)C=CC=C2C3=CC=C(C=C3)C(=O)NO
DMSHQE3 IK PKQVYJOPUCLLCD-UHFFFAOYSA-N
DMSHQE3 IU N-hydroxy-4-naphthalen-1-ylbenzamide
DMSHQE3 DE Discovery agent
DMUSHZK ID DMUSHZK
DMUSHZK DN N-hydroxy-4-(oleamidomethyl)benzamide
DMUSHZK HS Investigative
DMUSHZK SN CHEMBL271701
DMUSHZK DT Small molecular drug
DMUSHZK PC 44454442
DMUSHZK MW 430.6
DMUSHZK FM C26H42N2O3
DMUSHZK IC InChI=1S/C26H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-25(29)27-22-23-18-20-24(21-19-23)26(30)28-31/h9-10,18-21,31H,2-8,11-17,22H2,1H3,(H,27,29)(H,28,30)/b10-9-
DMUSHZK CS CCCCCCCC/C=C\\CCCCCCCC(=O)NCC1=CC=C(C=C1)C(=O)NO
DMUSHZK IK SINCREJZYIHLQD-KTKRTIGZSA-N
DMUSHZK IU N-hydroxy-4-[[[(Z)-octadec-9-enoyl]amino]methyl]benzamide
DMUSHZK DE Discovery agent
DMGTNQY ID DMGTNQY
DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide
DMGTNQY HS Investigative
DMGTNQY SN CHEMBL143102
DMGTNQY DT Small molecular drug
DMGTNQY PC 44361923
DMGTNQY MW 250.29
DMGTNQY FM C13H18N2O3
DMGTNQY IC InChI=1S/C13H18N2O3/c1-2-3-4-12(16)14-9-10-5-7-11(8-6-10)13(17)15-18/h5-8,18H,2-4,9H2,1H3,(H,14,16)(H,15,17)
DMGTNQY CS CCCCC(=O)NCC1=CC=C(C=C1)C(=O)NO
DMGTNQY IK ZOLDKKORXZQAQV-UHFFFAOYSA-N
DMGTNQY IU N-hydroxy-4-[(pentanoylamino)methyl]benzamide
DMGTNQY DE Discovery agent
DMDUOH4 ID DMDUOH4
DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide
DMDUOH4 HS Investigative
DMDUOH4 SN CHEMBL143674; SCHEMBL673760
DMDUOH4 DT Small molecular drug
DMDUOH4 PC 11323577
DMDUOH4 MW 284.31
DMDUOH4 FM C16H16N2O3
DMDUOH4 IC InChI=1S/C16H16N2O3/c19-15(10-12-4-2-1-3-5-12)17-11-13-6-8-14(9-7-13)16(20)18-21/h1-9,21H,10-11H2,(H,17,19)(H,18,20)
DMDUOH4 CS C1=CC=C(C=C1)CC(=O)NCC2=CC=C(C=C2)C(=O)NO
DMDUOH4 IK YHZMFLZXDBVBJK-UHFFFAOYSA-N
DMDUOH4 IU N-hydroxy-4-[[(2-phenylacetyl)amino]methyl]benzamide
DMDUOH4 DE Discovery agent
DMEO7L5 ID DMEO7L5
DMEO7L5 DN N-Hydroxy-4-iodo-benzamide
DMEO7L5 HS Investigative
DMEO7L5 SN N-Hydroxy-4-iodobenzamide; CHEMBL155287; 2593-31-9; p-Iodobenzohydroxamic acid; N-Hydroxy-4-iodo-benzamide; AC1LDBQC; AC1Q7DII; 4-Iodobenzohydroximic acid; N-Hydroxy-4-iodobenzamide #; CTK8A6787; MolPort-005-220-499; HXIKIQLHKIBCOH-UHFFFAOYSA-N; BDBM50015131; ZINC20303936; AKOS008969031; NE46453; MCULE-3184298763; EN300-53710
DMEO7L5 DT Small molecular drug
DMEO7L5 PC 615643
DMEO7L5 MW 263.03
DMEO7L5 FM C7H6INO2
DMEO7L5 IC InChI=1S/C7H6INO2/c8-6-3-1-5(2-4-6)7(10)9-11/h1-4,11H,(H,9,10)
DMEO7L5 CS C1=CC(=CC=C1C(=O)NO)I
DMEO7L5 IK HXIKIQLHKIBCOH-UHFFFAOYSA-N
DMEO7L5 IU N-hydroxy-4-iodobenzamide
DMEO7L5 DE Discovery agent
DM16G80 ID DM16G80
DM16G80 DN N-Hydroxy-4-isobutyl-benzamide
DM16G80 HS Investigative
DM16G80 SN CHEMBL439659; N-Hydroxy-4-isobutyl-benzamide; SCHEMBL6919015; BDBM50015175; 4-(2-Methylpropyl)benzohydroximic acid
DM16G80 DT Small molecular drug
DM16G80 PC 20771934
DM16G80 MW 193.24
DM16G80 FM C11H15NO2
DM16G80 IC InChI=1S/C11H15NO2/c1-8(2)7-9-3-5-10(6-4-9)11(13)12-14/h3-6,8,14H,7H2,1-2H3,(H,12,13)
DM16G80 CS CC(C)CC1=CC=C(C=C1)C(=O)NO
DM16G80 IK ACMIPAPWWYGZNO-UHFFFAOYSA-N
DM16G80 IU N-hydroxy-4-(2-methylpropyl)benzamide
DM16G80 DE Discovery agent
DMMHQE8 ID DMMHQE8
DMMHQE8 DN N-Hydroxy-4-naphthalen-2-yl-benzamide
DMMHQE8 HS Investigative
DMMHQE8 SN CHEMBL154008; N-Hydroxy-4-naphthalen-2-yl-benzamide; SCHEMBL10361606; ZINC27653366; BDBM50015182; 4-(2-Naphthalenyl)benzohydroximic acid
DMMHQE8 DT Small molecular drug
DMMHQE8 PC 44369651
DMMHQE8 MW 263.29
DMMHQE8 FM C17H13NO2
DMMHQE8 IC InChI=1S/C17H13NO2/c19-17(18-20)14-8-5-13(6-9-14)16-10-7-12-3-1-2-4-15(12)11-16/h1-11,20H,(H,18,19)
DMMHQE8 CS C1=CC=C2C=C(C=CC2=C1)C3=CC=C(C=C3)C(=O)NO
DMMHQE8 IK CYVBBSVZKCLSIR-UHFFFAOYSA-N
DMMHQE8 IU N-hydroxy-4-naphthalen-2-ylbenzamide
DMMHQE8 DE Discovery agent
DMQSWO8 ID DMQSWO8
DMQSWO8 DN N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
DMQSWO8 HS Investigative
DMQSWO8 SN CHEMBL198055; N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide
DMQSWO8 DT Small molecular drug
DMQSWO8 PC 44404478
DMQSWO8 MW 285.29
DMQSWO8 FM C16H15NO4
DMQSWO8 IC InChI=1S/C16H15NO4/c18-15(10-11-16(19)17-20)12-6-8-14(9-7-12)21-13-4-2-1-3-5-13/h1-9,20H,10-11H2,(H,17,19)
DMQSWO8 CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)CCC(=O)NO
DMQSWO8 IK NOELKUBXWDTLKR-UHFFFAOYSA-N
DMQSWO8 IU N-hydroxy-4-oxo-4-(4-phenoxyphenyl)butanamide
DMQSWO8 DE Discovery agent
DMCRU17 ID DMCRU17
DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide
DMCRU17 HS Investigative
DMCRU17 SN CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
DMCRU17 DT Small molecular drug
DMCRU17 PC 11196500
DMCRU17 MW 270.28
DMCRU17 FM C15H14N2O3
DMCRU17 IC InChI=1S/C15H14N2O3/c18-14(10-11-4-2-1-3-5-11)16-13-8-6-12(7-9-13)15(19)17-20/h1-9,20H,10H2,(H,16,18)(H,17,19)
DMCRU17 CS C1=CC=C(C=C1)CC(=O)NC2=CC=C(C=C2)C(=O)NO
DMCRU17 IK VQGKLYBEQDAOSV-UHFFFAOYSA-N
DMCRU17 IU N-hydroxy-4-[(2-phenylacetyl)amino]benzamide
DMCRU17 CA CAS 656261-23-3
DMCRU17 DE Discovery agent
DMYKJZ2 ID DMYKJZ2
DMYKJZ2 DN N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide
DMYKJZ2 HS Investigative
DMYKJZ2 SN CHEMBL216509; N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide; SCHEMBL5903774; BDBM50198477
DMYKJZ2 DT Small molecular drug
DMYKJZ2 PC 10242569
DMYKJZ2 MW 220.25
DMYKJZ2 FM C10H8N2O2S
DMYKJZ2 IC InChI=1S/C10H8N2O2S/c13-10(12-14)9-5-4-8(15-9)7-3-1-2-6-11-7/h1-6,14H,(H,12,13)
DMYKJZ2 CS C1=CC=NC(=C1)C2=CC=C(S2)C(=O)NO
DMYKJZ2 IK ASGPYAWVOHEENA-UHFFFAOYSA-N
DMYKJZ2 IU N-hydroxy-5-pyridin-2-ylthiophene-2-carboxamide
DMYKJZ2 DE Discovery agent
DMK98LE ID DMK98LE
DMK98LE DN N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide
DMK98LE HS Investigative
DMK98LE SN CHEMBL216292; N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide; SCHEMBL5903988
DMK98LE DT Small molecular drug
DMK98LE PC 44418106
DMK98LE MW 220.25
DMK98LE FM C10H8N2O2S
DMK98LE IC InChI=1S/C10H8N2O2S/c13-10(12-14)9-4-3-8(15-9)7-2-1-5-11-6-7/h1-6,14H,(H,12,13)
DMK98LE CS C1=CC(=CN=C1)C2=CC=C(S2)C(=O)NO
DMK98LE IK VJJJKVTXSSPWSW-UHFFFAOYSA-N
DMK98LE IU N-hydroxy-5-pyridin-3-ylthiophene-2-carboxamide
DMK98LE DE Discovery agent
DM653RM ID DM653RM
DM653RM DN N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide
DM653RM HS Investigative
DM653RM SN CHEMBL217816; N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide; SCHEMBL5903934
DM653RM DT Small molecular drug
DM653RM PC 44418125
DM653RM MW 220.25
DM653RM FM C10H8N2O2S
DM653RM IC InChI=1S/C10H8N2O2S/c13-10(12-14)9-2-1-8(15-9)7-3-5-11-6-4-7/h1-6,14H,(H,12,13)
DM653RM CS C1=CN=CC=C1C2=CC=C(S2)C(=O)NO
DM653RM IK MDIKAACRDOZAQR-UHFFFAOYSA-N
DM653RM IU N-hydroxy-5-pyridin-4-ylthiophene-2-carboxamide
DM653RM DE Discovery agent
DMA2WUQ ID DMA2WUQ
DMA2WUQ DN N-hydroxy-5-phenylthiophene-2-carboxamide
DMA2WUQ HS Investigative
DMA2WUQ SN CHEMBL217573; N-hydroxy-5-phenylthiophene-2-carboxamide; SCHEMBL5903684
DMA2WUQ DT Small molecular drug
DMA2WUQ PC 25002768
DMA2WUQ MW 219.26
DMA2WUQ FM C11H9NO2S
DMA2WUQ IC InChI=1S/C11H9NO2S/c13-11(12-14)10-7-6-9(15-10)8-4-2-1-3-5-8/h1-7,14H,(H,12,13)
DMA2WUQ CS C1=CC=C(C=C1)C2=CC=C(S2)C(=O)NO
DMA2WUQ IK XIQUFDAAPVAKOR-UHFFFAOYSA-N
DMA2WUQ IU N-hydroxy-5-phenylthiophene-2-carboxamide
DMA2WUQ DE Discovery agent
DM0JNO2 ID DM0JNO2
DM0JNO2 DN N-hydroxy-6-oxo-6-phenylhexanamide
DM0JNO2 HS Investigative
DM0JNO2 SN CHEMBL95152; N-hydroxy-6-oxo-6-phenylhexanamide; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide
DM0JNO2 DT Small molecular drug
DM0JNO2 PC 11031415
DM0JNO2 MW 221.25
DM0JNO2 FM C12H15NO3
DM0JNO2 IC InChI=1S/C12H15NO3/c14-11(10-6-2-1-3-7-10)8-4-5-9-12(15)13-16/h1-3,6-7,16H,4-5,8-9H2,(H,13,15)
DM0JNO2 CS C1=CC=C(C=C1)C(=O)CCCCC(=O)NO
DM0JNO2 IK XCXZDISEAMNYJL-UHFFFAOYSA-N
DM0JNO2 IU N-hydroxy-6-oxo-6-phenylhexanamide
DM0JNO2 DE Discovery agent
DMUXZL1 ID DMUXZL1
DMUXZL1 DN N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide
DMUXZL1 HS Investigative
DMUXZL1 SN CHEMBL95990; N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide
DMUXZL1 DT Small molecular drug
DMUXZL1 PC 10858374
DMUXZL1 MW 265.3
DMUXZL1 FM C14H19NO4
DMUXZL1 IC InChI=1S/C14H19NO4/c1-19-12-9-7-11(8-10-12)13(16)5-3-2-4-6-14(17)15-18/h7-10,18H,2-6H2,1H3,(H,15,17)
DMUXZL1 CS COC1=CC=C(C=C1)C(=O)CCCCCC(=O)NO
DMUXZL1 IK NIGGAQZXTHMKPL-UHFFFAOYSA-N
DMUXZL1 IU N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide
DMUXZL1 DE Discovery agent
DM8Z4L0 ID DM8Z4L0
DM8Z4L0 DN N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide
DM8Z4L0 HS Investigative
DM8Z4L0 SN CHEMBL320909; N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide
DM8Z4L0 DT Small molecular drug
DM8Z4L0 PC 11129854
DM8Z4L0 MW 285.34
DM8Z4L0 FM C17H19NO3
DM8Z4L0 IC InChI=1S/C17H19NO3/c19-16(8-2-1-3-9-17(20)18-21)15-11-10-13-6-4-5-7-14(13)12-15/h4-7,10-12,21H,1-3,8-9H2,(H,18,20)
DM8Z4L0 CS C1=CC=C2C=C(C=CC2=C1)C(=O)CCCCCC(=O)NO
DM8Z4L0 IK AQLMJRZLPWGPGD-UHFFFAOYSA-N
DM8Z4L0 IU N-hydroxy-7-naphthalen-2-yl-7-oxoheptanamide
DM8Z4L0 DE Discovery agent
DMBUNAP ID DMBUNAP
DMBUNAP DN N-hydroxy-7-(naphthalen-2-yloxy)heptanamide
DMBUNAP HS Investigative
DMBUNAP SN CHEMBL217083; N-hydroxy-7-(naphthalen-2-yloxy)heptanamide
DMBUNAP DT Small molecular drug
DMBUNAP PC 16655084
DMBUNAP MW 287.35
DMBUNAP FM C17H21NO3
DMBUNAP IC InChI=1S/C17H21NO3/c19-17(18-20)9-3-1-2-6-12-21-16-11-10-14-7-4-5-8-15(14)13-16/h4-5,7-8,10-11,13,20H,1-3,6,9,12H2,(H,18,19)
DMBUNAP CS C1=CC=C2C=C(C=CC2=C1)OCCCCCCC(=O)NO
DMBUNAP IK KSNWLAUWIDTBGS-UHFFFAOYSA-N
DMBUNAP IU N-hydroxy-7-naphthalen-2-yloxyheptanamide
DMBUNAP DE Discovery agent
DMQW7JZ ID DMQW7JZ
DMQW7JZ DN N-hydroxy-7-oxo-7-phenylheptanamide
DMQW7JZ HS Investigative
DMQW7JZ SN CHEMBL95916; N-hydroxy-7-oxo-7-phenylheptanamide; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide
DMQW7JZ DT Small molecular drug
DMQW7JZ PC 10998964
DMQW7JZ MW 235.28
DMQW7JZ FM C13H17NO3
DMQW7JZ IC InChI=1S/C13H17NO3/c15-12(11-7-3-1-4-8-11)9-5-2-6-10-13(16)14-17/h1,3-4,7-8,17H,2,5-6,9-10H2,(H,14,16)
DMQW7JZ CS C1=CC=C(C=C1)C(=O)CCCCCC(=O)NO
DMQW7JZ IK IHUNPXAEVKBAPH-UHFFFAOYSA-N
DMQW7JZ IU N-hydroxy-7-oxo-7-phenylheptanamide
DMQW7JZ DE Discovery agent
DMSIMNR ID DMSIMNR
DMSIMNR DN N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide
DMSIMNR HS Investigative
DMSIMNR SN CHEMBL95885; N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
DMSIMNR DT Small molecular drug
DMSIMNR PC 11821974
DMSIMNR MW 279.33
DMSIMNR FM C15H21NO4
DMSIMNR IC InChI=1S/C15H21NO4/c1-20-14-10-7-6-8-12(14)13(17)9-4-2-3-5-11-15(18)16-19/h6-8,10,19H,2-5,9,11H2,1H3,(H,16,18)
DMSIMNR CS COC1=CC=CC=C1C(=O)CCCCCCC(=O)NO
DMSIMNR IK MFYBAPSRZVMJKO-UHFFFAOYSA-N
DMSIMNR IU N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide
DMSIMNR DE Discovery agent
DMD2K4T ID DMD2K4T
DMD2K4T DN N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide
DMD2K4T HS Investigative
DMD2K4T SN CHEMBL95835; N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
DMD2K4T DT Small molecular drug
DMD2K4T PC 10923922
DMD2K4T MW 279.33
DMD2K4T FM C15H21NO4
DMD2K4T IC InChI=1S/C15H21NO4/c1-20-13-10-8-12(9-11-13)14(17)6-4-2-3-5-7-15(18)16-19/h8-11,19H,2-7H2,1H3,(H,16,18)
DMD2K4T CS COC1=CC=C(C=C1)C(=O)CCCCCCC(=O)NO
DMD2K4T IK LIOTZVIDBXLBAC-UHFFFAOYSA-N
DMD2K4T IU N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide
DMD2K4T DE Discovery agent
DMRN1C6 ID DMRN1C6
DMRN1C6 DN N-hydroxy-8-(naphthalen-2-yl)non-8-enamide
DMRN1C6 HS Investigative
DMRN1C6 SN CHEMBL95535; N-hydroxy-8-(naphthalen-2-yl)non-8-enamide; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide
DMRN1C6 DT Small molecular drug
DMRN1C6 PC 11822609
DMRN1C6 MW 297.4
DMRN1C6 FM C19H23NO2
DMRN1C6 IC InChI=1S/C19H23NO2/c1-15(8-4-2-3-5-11-19(21)20-22)17-13-12-16-9-6-7-10-18(16)14-17/h6-7,9-10,12-14,22H,1-5,8,11H2,(H,20,21)
DMRN1C6 CS C=C(CCCCCCC(=O)NO)C1=CC2=CC=CC=C2C=C1
DMRN1C6 IK FMDUQUPDPRRDDD-UHFFFAOYSA-N
DMRN1C6 IU N-hydroxy-8-naphthalen-2-ylnon-8-enamide
DMRN1C6 DE Discovery agent
DMGZY1Q ID DMGZY1Q
DMGZY1Q DN N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide
DMGZY1Q HS Investigative
DMGZY1Q SN CHEMBL451182; N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide
DMGZY1Q DT Small molecular drug
DMGZY1Q PC 10891349
DMGZY1Q MW 283.4
DMGZY1Q FM C18H21NO2
DMGZY1Q IC InChI=1S/C18H21NO2/c20-18(19-21)11-5-3-1-2-4-8-15-12-13-16-9-6-7-10-17(16)14-15/h4,6-10,12-14,21H,1-3,5,11H2,(H,19,20)/b8-4+
DMGZY1Q CS C1=CC=C2C=C(C=CC2=C1)/C=C/CCCCCC(=O)NO
DMGZY1Q IK PGGPUSMJSOKMEA-XBXARRHUSA-N
DMGZY1Q IU (E)-N-hydroxy-8-naphthalen-2-yloct-7-enamide
DMGZY1Q DE Discovery agent
DMXQICK ID DMXQICK
DMXQICK DN N-hydroxy-8-(naphthalen-2-yl)octanamide
DMXQICK HS Investigative
DMXQICK SN CHEMBL95747; N-hydroxy-8-(naphthalen-2-yl)octanamide; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide
DMXQICK DT Small molecular drug
DMXQICK PC 11833001
DMXQICK MW 285.4
DMXQICK FM C18H23NO2
DMXQICK IC InChI=1S/C18H23NO2/c20-18(19-21)11-5-3-1-2-4-8-15-12-13-16-9-6-7-10-17(16)14-15/h6-7,9-10,12-14,21H,1-5,8,11H2,(H,19,20)
DMXQICK CS C1=CC=C2C=C(C=CC2=C1)CCCCCCCC(=O)NO
DMXQICK IK KWFDCRKEDDNSLQ-UHFFFAOYSA-N
DMXQICK IU N-hydroxy-8-naphthalen-2-yloctanamide
DMXQICK DE Discovery agent
DMO4CR7 ID DMO4CR7
DMO4CR7 DN N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide
DMO4CR7 HS Investigative
DMO4CR7 SN CHEMBL98911; N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide
DMO4CR7 DT Small molecular drug
DMO4CR7 PC 11128726
DMO4CR7 MW 250.29
DMO4CR7 FM C13H18N2O3
DMO4CR7 IC InChI=1S/C13H18N2O3/c16-12(11-6-5-9-14-10-11)7-3-1-2-4-8-13(17)15-18/h5-6,9-10,18H,1-4,7-8H2,(H,15,17)
DMO4CR7 CS C1=CC(=CN=C1)C(=O)CCCCCCC(=O)NO
DMO4CR7 IK AAHQDWBMLVLXAC-UHFFFAOYSA-N
DMO4CR7 IU N-hydroxy-8-oxo-8-pyridin-3-yloctanamide
DMO4CR7 DE Discovery agent
DMID3BF ID DMID3BF
DMID3BF DN N-hydroxy-9,10-dihydroanthracene-9-carboxamide
DMID3BF HS Investigative
DMID3BF SN CHEMBL575482; N-hydroxy-9,10-dihydroanthracene-9-carboxamide; SCHEMBL4541357
DMID3BF DT Small molecular drug
DMID3BF PC 45482666
DMID3BF MW 239.27
DMID3BF FM C15H13NO2
DMID3BF IC InChI=1S/C15H13NO2/c17-15(16-18)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-8,14,18H,9H2,(H,16,17)
DMID3BF CS C1C2=CC=CC=C2C(C3=CC=CC=C31)C(=O)NO
DMID3BF IK SIYRPEHGIQLXJG-UHFFFAOYSA-N
DMID3BF IU N-hydroxy-9,10-dihydroanthracene-9-carboxamide
DMID3BF DE Discovery agent
DM0DRHP ID DM0DRHP
DM0DRHP DN N-hydroxy-9H-xanthene-9-carboxamide
DM0DRHP HS Investigative
DM0DRHP SN N-hydroxy-9H-xanthene-9-carboxamide; CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446
DM0DRHP DT Small molecular drug
DM0DRHP PC 44626296
DM0DRHP MW 241.24
DM0DRHP FM C14H11NO3
DM0DRHP IC InChI=1S/C14H11NO3/c16-14(15-17)13-9-5-1-3-7-11(9)18-12-8-4-2-6-10(12)13/h1-8,13,17H,(H,15,16)
DM0DRHP CS C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)C(=O)NO
DM0DRHP IK ULUVQBMMAOHWSH-UHFFFAOYSA-N
DM0DRHP IU N-hydroxy-9H-xanthene-9-carboxamide
DM0DRHP DE Discovery agent
DMIC2A8 ID DMIC2A8
DMIC2A8 DN N-hydroxy-9-oxo-9-phenylnonanamide
DMIC2A8 HS Investigative
DMIC2A8 SN CHEMBL99810; N-hydroxy-9-oxo-9-phenylnonanamide; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide
DMIC2A8 DT Small molecular drug
DMIC2A8 PC 11139963
DMIC2A8 MW 263.33
DMIC2A8 FM C15H21NO3
DMIC2A8 IC InChI=1S/C15H21NO3/c17-14(13-9-5-4-6-10-13)11-7-2-1-3-8-12-15(18)16-19/h4-6,9-10,19H,1-3,7-8,11-12H2,(H,16,18)
DMIC2A8 CS C1=CC=C(C=C1)C(=O)CCCCCCCC(=O)NO
DMIC2A8 IK ZCJNQRRQDXSGEO-UHFFFAOYSA-N
DMIC2A8 IU N-hydroxy-9-oxo-9-phenylnonanamide
DMIC2A8 DE Discovery agent
DMR4J8G ID DMR4J8G
DMR4J8G DN N-hydroxybenzo[b]thiophene-2-carboxamide
DMR4J8G HS Investigative
DMR4J8G SN CHEMBL245946; N-hydroxybenzo[b]thiophene-2-carboxamide; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid
DMR4J8G DT Small molecular drug
DMR4J8G PC 11708207
DMR4J8G MW 193.22
DMR4J8G FM C9H7NO2S
DMR4J8G IC InChI=1S/C9H7NO2S/c11-9(10-12)8-5-6-3-1-2-4-7(6)13-8/h1-5,12H,(H,10,11)
DMR4J8G CS C1=CC=C2C(=C1)C=C(S2)C(=O)NO
DMR4J8G IK UGJNLGFANIDLSB-UHFFFAOYSA-N
DMR4J8G IU N-hydroxy-1-benzothiophene-2-carboxamide
DMR4J8G CA CAS 211172-97-3
DMR4J8G DE Discovery agent
DM41JIB ID DM41JIB
DM41JIB DN N-Hydroxycarbamoylmethyl-4-methoxy-benzamide
DM41JIB HS Investigative
DM41JIB SN BRN 2736542; 2-(p-Methoxybenzamido)acetohydroxamic acid; ACETOHYDROXAMIC ACID, 2-(p-METHOXYBENZAMIDO)-; CHEMBL198048; 65654-08-2; N-Hydroxycarbamoylmethyl-4-methoxy-benzamide; AC1L2IK9; SCHEMBL11668774; CTK5C2963; DTXSID60215890; BDBM50175547; LS-13134; N-[2-(hydroxyamino)-2-oxoethyl]-4-methoxybenzamide; N-(HYDROXYCARBAMOYLMETHYL)-4-METHOXY-BENZAMIDE
DM41JIB DT Small molecular drug
DM41JIB PC 47697
DM41JIB MW 224.21
DM41JIB FM C10H12N2O4
DM41JIB IC InChI=1S/C10H12N2O4/c1-16-8-4-2-7(3-5-8)10(14)11-6-9(13)12-15/h2-5,15H,6H2,1H3,(H,11,14)(H,12,13)
DM41JIB CS COC1=CC=C(C=C1)C(=O)NCC(=O)NO
DM41JIB IK ZJTICILORBZVBV-UHFFFAOYSA-N
DM41JIB IU N-[2-(hydroxyamino)-2-oxoethyl]-4-methoxybenzamide
DM41JIB CA CAS 65654-08-2
DM41JIB DE Discovery agent
DMDTX4L ID DMDTX4L
DMDTX4L DN N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
DMDTX4L HS Investigative
DMDTX4L SN CHEMBL198543; N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
DMDTX4L DT Small molecular drug
DMDTX4L PC 44404537
DMDTX4L MW 286.28
DMDTX4L FM C15H14N2O4
DMDTX4L IC InChI=1S/C15H14N2O4/c18-14(17-20)10-16-15(19)11-6-8-13(9-7-11)21-12-4-2-1-3-5-12/h1-9,20H,10H2,(H,16,19)(H,17,18)
DMDTX4L CS C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)NCC(=O)NO
DMDTX4L IK NBSITGWGPCATOG-UHFFFAOYSA-N
DMDTX4L IU N-[2-(hydroxyamino)-2-oxoethyl]-4-phenoxybenzamide
DMDTX4L DE Discovery agent
DM3J5MR ID DM3J5MR
DM3J5MR DN N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide
DM3J5MR HS Investigative
DM3J5MR SN CHEMBL557066; SCHEMBL3292989; SCHEMBL3292983; BDBM50293365
DM3J5MR DT Small molecular drug
DM3J5MR PC 15986508
DM3J5MR MW 273.71
DM3J5MR FM C15H12ClNO2
DM3J5MR IC InChI=1S/C15H12ClNO2/c16-14-8-6-13(7-9-14)12-4-1-11(2-5-12)3-10-15(18)17-19/h1-10,19H,(H,17,18)/b10-3+
DM3J5MR CS C1=CC(=CC=C1/C=C/C(=O)NO)C2=CC=C(C=C2)Cl
DM3J5MR IK GBZPSEMNRBQROD-XCVCLJGOSA-N
DM3J5MR IU (E)-3-[4-(4-chlorophenyl)phenyl]-N-hydroxyprop-2-enamide
DM3J5MR DE Discovery agent
DMVFKO4 ID DMVFKO4
DMVFKO4 DN N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide
DMVFKO4 HS Investigative
DMVFKO4 SN CHEMBL538710; SCHEMBL3292721; SCHEMBL3292715; BDBM50293355
DMVFKO4 DT Small molecular drug
DMVFKO4 PC 15986510
DMVFKO4 MW 264.28
DMVFKO4 FM C16H12N2O2
DMVFKO4 IC InChI=1S/C16H12N2O2/c17-11-13-3-8-15(9-4-13)14-6-1-12(2-7-14)5-10-16(19)18-20/h1-10,20H,(H,18,19)/b10-5+
DMVFKO4 CS C1=CC(=CC=C1/C=C/C(=O)NO)C2=CC=C(C=C2)C#N
DMVFKO4 IK NJUOLWKIAIFTKT-BJMVGYQFSA-N
DMVFKO4 IU (E)-3-[4-(4-cyanophenyl)phenyl]-N-hydroxyprop-2-enamide
DMVFKO4 DE Discovery agent
DMQCK5G ID DMQCK5G
DMQCK5G DN N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide
DMQCK5G HS Investigative
DMQCK5G SN CHEMBL556532; N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide; SCHEMBL3292226; SCHEMBL3290139
DMQCK5G DT Small molecular drug
DMQCK5G PC 42632368
DMQCK5G MW 239.27
DMQCK5G FM C15H13NO2
DMQCK5G IC InChI=1S/C15H13NO2/c17-15(16-18)11-8-12-6-9-14(10-7-12)13-4-2-1-3-5-13/h1-11,18H,(H,16,17)/b11-8+
DMQCK5G CS C1=CC=C(C=C1)C2=CC=C(C=C2)/C=C/C(=O)NO
DMQCK5G IK YMXJQEHWXZULBO-DHZHZOJOSA-N
DMQCK5G IU (E)-N-hydroxy-3-(4-phenylphenyl)prop-2-enamide
DMQCK5G DE Discovery agent
DM865Y2 ID DM865Y2
DM865Y2 DN N-Hydroxy-N'-(2-methylphenyl)octanediamide
DM865Y2 HS Investigative
DM865Y2 SN CHEMBL1076794; BDBM50314140
DM865Y2 DT Small molecular drug
DM865Y2 PC 46884055
DM865Y2 MW 250.29
DM865Y2 FM C13H18N2O3
DM865Y2 IC InChI=1S/C13H18N2O3/c1-10-6-2-3-7-11(10)14-12(16)8-4-5-9-13(17)15-18/h2-3,6-7,18H,4-5,8-9H2,1H3,(H,14,16)(H,15,17)
DM865Y2 CS CC1=CC=CC=C1NC(=O)CCCCC(=O)NO
DM865Y2 IK BUBGRWCYPBJWRL-UHFFFAOYSA-N
DM865Y2 IU N'-hydroxy-N-(2-methylphenyl)hexanediamide
DM865Y2 DE Discovery agent
DMYRC2M ID DMYRC2M
DMYRC2M DN N-Hydroxy-N'-(3-methylphenyl)octanediamide
DMYRC2M HS Investigative
DMYRC2M SN CHEMBL1089339; BDBM50314136
DMYRC2M DT Small molecular drug
DMYRC2M PC 46884056
DMYRC2M MW 250.29
DMYRC2M FM C13H18N2O3
DMYRC2M IC InChI=1S/C13H18N2O3/c1-10-5-4-6-11(9-10)14-12(16)7-2-3-8-13(17)15-18/h4-6,9,18H,2-3,7-8H2,1H3,(H,14,16)(H,15,17)
DMYRC2M CS CC1=CC(=CC=C1)NC(=O)CCCCC(=O)NO
DMYRC2M IK QJSROQKJUVLPRM-UHFFFAOYSA-N
DMYRC2M IU N'-hydroxy-N-(3-methylphenyl)hexanediamide
DMYRC2M DE Discovery agent
DMELB07 ID DMELB07
DMELB07 DN N-Hydroxy-N'-(4-methoxyphenyl)octanediamide
DMELB07 HS Investigative
DMELB07 SN CHEMBL1091487; BDBM50314137
DMELB07 DT Small molecular drug
DMELB07 PC 46884016
DMELB07 MW 266.29
DMELB07 FM C13H18N2O4
DMELB07 IC InChI=1S/C13H18N2O4/c1-19-11-8-6-10(7-9-11)14-12(16)4-2-3-5-13(17)15-18/h6-9,18H,2-5H2,1H3,(H,14,16)(H,15,17)
DMELB07 CS COC1=CC=C(C=C1)NC(=O)CCCCC(=O)NO
DMELB07 IK QYJANBGLOGFJLV-UHFFFAOYSA-N
DMELB07 IU N'-hydroxy-N-(4-methoxyphenyl)hexanediamide
DMELB07 DE Discovery agent
DM3DPZ8 ID DM3DPZ8
DM3DPZ8 DN N-Hydroxy-N'-(4-methylphenyl)octanediamide
DM3DPZ8 HS Investigative
DM3DPZ8 SN CHEMBL1092762; BDBM50314138
DM3DPZ8 DT Small molecular drug
DM3DPZ8 PC 46884057
DM3DPZ8 MW 250.29
DM3DPZ8 FM C13H18N2O3
DM3DPZ8 IC InChI=1S/C13H18N2O3/c1-10-6-8-11(9-7-10)14-12(16)4-2-3-5-13(17)15-18/h6-9,18H,2-5H2,1H3,(H,14,16)(H,15,17)
DM3DPZ8 CS CC1=CC=C(C=C1)NC(=O)CCCCC(=O)NO
DM3DPZ8 IK VUUHXDZTBBCMIT-UHFFFAOYSA-N
DM3DPZ8 IU N'-hydroxy-N-(4-methylphenyl)hexanediamide
DM3DPZ8 DE Discovery agent
DM4E8NJ ID DM4E8NJ
DM4E8NJ DN N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea
DM4E8NJ HS Investigative
DM4E8NJ SN CHEMBL167577; N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea; SCHEMBL9443901
DM4E8NJ DT Small molecular drug
DM4E8NJ PC 10561814
DM4E8NJ MW 236.31
DM4E8NJ FM C13H20N2O2
DM4E8NJ IC InChI=1S/C13H20N2O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)15(17)13(14)16/h4-7,9-10,17H,8H2,1-3H3,(H2,14,16)
DM4E8NJ CS CC(C)CC1=CC=C(C=C1)C(C)N(C(=O)N)O
DM4E8NJ IK FBLDKAJQWYMCKR-UHFFFAOYSA-N
DM4E8NJ IU 1-hydroxy-1-[1-[4-(2-methylpropyl)phenyl]ethyl]urea
DM4E8NJ DE Discovery agent
DMQ4ST2 ID DMQ4ST2
DMQ4ST2 DN N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide
DMQ4ST2 HS Investigative
DMQ4ST2 SN CHEMBL174161; N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide; BDBM50015154; 2,3,3-Triphenyl-N-methyl-2-propenehydroxamic acid
DMQ4ST2 DT Small molecular drug
DMQ4ST2 PC 44386837
DMQ4ST2 MW 329.4
DMQ4ST2 FM C22H19NO2
DMQ4ST2 IC InChI=1S/C22H19NO2/c1-23(25)22(24)21(19-15-9-4-10-16-19)20(17-11-5-2-6-12-17)18-13-7-3-8-14-18/h2-16,25H,1H3
DMQ4ST2 CS CN(C(=O)C(=C(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3)O
DMQ4ST2 IK ORTZIDPYVDIVSI-UHFFFAOYSA-N
DMQ4ST2 IU N-hydroxy-N-methyl-2,3,3-triphenylprop-2-enamide
DMQ4ST2 DE Discovery agent
DMNVD8I ID DMNVD8I
DMNVD8I DN N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide
DMNVD8I HS Investigative
DMNVD8I SN CHEMBL146477; N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide
DMNVD8I DT Small molecular drug
DMNVD8I PC 44364373
DMNVD8I MW 229.27
DMNVD8I FM C14H15NO2
DMNVD8I IC InChI=1S/C14H15NO2/c1-10(14(16)15(2)17)12-8-7-11-5-3-4-6-13(11)9-12/h3-10,17H,1-2H3
DMNVD8I CS CC(C1=CC2=CC=CC=C2C=C1)C(=O)N(C)O
DMNVD8I IK HMSPAZCQILPMIK-UHFFFAOYSA-N
DMNVD8I IU N-hydroxy-N-methyl-2-naphthalen-2-ylpropanamide
DMNVD8I DE Discovery agent
DMSRPI8 ID DMSRPI8
DMSRPI8 DN N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide
DMSRPI8 HS Investigative
DMSRPI8 SN CHEMBL175134; N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide; BDBM50015100
DMSRPI8 DT Small molecular drug
DMSRPI8 PC 15670548
DMSRPI8 MW 227.26
DMSRPI8 FM C14H13NO2
DMSRPI8 IC InChI=1S/C14H13NO2/c1-15(17)14(16)10-9-12-7-4-6-11-5-2-3-8-13(11)12/h2-10,17H,1H3/b10-9+
DMSRPI8 CS CN(C(=O)/C=C/C1=CC=CC2=CC=CC=C21)O
DMSRPI8 IK AQTNKWXWVAWKHS-MDZDMXLPSA-N
DMSRPI8 IU (E)-N-hydroxy-N-methyl-3-naphthalen-1-ylprop-2-enamide
DMSRPI8 DE Discovery agent
DMANTW0 ID DMANTW0
DMANTW0 DN N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide
DMANTW0 HS Investigative
DMANTW0 SN CHEMBL63882; N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide; BDBM50015178; ZINC26247459; N-Methyl-N-hydroxy-2-naphthaleneacrylamide; (E)-N-hydroxy-N-methyl-3-(naphthalen-2-yl)acrylamide; (E)-3-(2-Naphthalenyl)-N-methyl-2-propenehydroxamic acid
DMANTW0 DT Small molecular drug
DMANTW0 PC 13687210
DMANTW0 MW 227.26
DMANTW0 FM C14H13NO2
DMANTW0 IC InChI=1S/C14H13NO2/c1-15(17)14(16)9-7-11-6-8-12-4-2-3-5-13(12)10-11/h2-10,17H,1H3/b9-7+
DMANTW0 CS CN(C(=O)/C=C/C1=CC2=CC=CC=C2C=C1)O
DMANTW0 IK CORKVTFWNIPMDF-VQHVLOKHSA-N
DMANTW0 IU (E)-N-hydroxy-N-methyl-3-naphthalen-2-ylprop-2-enamide
DMANTW0 DE Discovery agent
DMMYV34 ID DMMYV34
DMMYV34 DN N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide
DMMYV34 HS Investigative
DMMYV34 SN CHEMBL367401; N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide; ZINC28086558
DMMYV34 DT Small molecular drug
DMMYV34 PC 44386825
DMMYV34 MW 229.27
DMMYV34 FM C14H15NO2
DMMYV34 IC InChI=1S/C14H15NO2/c1-15(17)14(16)9-7-11-6-8-12-4-2-3-5-13(12)10-11/h2-6,8,10,17H,7,9H2,1H3
DMMYV34 CS CN(C(=O)CCC1=CC2=CC=CC=C2C=C1)O
DMMYV34 IK BLIBCDZMLZUBQT-UHFFFAOYSA-N
DMMYV34 IU N-hydroxy-N-methyl-3-naphthalen-2-ylpropanamide
DMMYV34 DE Discovery agent
DMAN57F ID DMAN57F
DMAN57F DN N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide
DMAN57F HS Investigative
DMAN57F SN CHEMBL174557; N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide; ZINC28089401
DMAN57F DT Small molecular drug
DMAN57F PC 13746842
DMAN57F MW 277.3
DMAN57F FM C18H15NO2
DMAN57F IC InChI=1S/C18H15NO2/c1-19(21)18(20)11-7-13-6-10-17-15(12-13)9-8-14-4-2-3-5-16(14)17/h2-12,21H,1H3/b11-7+
DMAN57F CS CN(C(=O)/C=C/C1=CC2=C(C=C1)C3=CC=CC=C3C=C2)O
DMAN57F IK YYXIRZNCGWVYCR-YRNVUSSQSA-N
DMAN57F IU (E)-N-hydroxy-N-methyl-3-phenanthren-2-ylprop-2-enamide
DMAN57F DE Discovery agent
DMV8UCK ID DMV8UCK
DMV8UCK DN N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide
DMV8UCK HS Investigative
DMV8UCK SN CHEMBL174898; N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide; BDBM50015157
DMV8UCK DT Small molecular drug
DMV8UCK PC 13746843
DMV8UCK MW 277.3
DMV8UCK FM C18H15NO2
DMV8UCK IC InChI=1S/C18H15NO2/c1-19(21)18(20)11-7-13-6-8-15-10-9-14-4-2-3-5-16(14)17(15)12-13/h2-12,21H,1H3/b11-7+
DMV8UCK CS CN(C(=O)/C=C/C1=CC2=C(C=CC3=CC=CC=C32)C=C1)O
DMV8UCK IK IPSMBZZRHPTXDJ-YRNVUSSQSA-N
DMV8UCK IU (E)-N-hydroxy-N-methyl-3-phenanthren-3-ylprop-2-enamide
DMV8UCK DE Discovery agent
DMQBD27 ID DMQBD27
DMQBD27 DN N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide
DMQBD27 HS Investigative
DMQBD27 SN CHEMBL367247; N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide; ZINC28023141; BDBM50015150; (E)-3-(Phenanthren-9-yl)-N-methyl-2-propenehydroxamic acid
DMQBD27 DT Small molecular drug
DMQBD27 PC 13746844
DMQBD27 MW 277.3
DMQBD27 FM C18H15NO2
DMQBD27 IC InChI=1S/C18H15NO2/c1-19(21)18(20)11-10-14-12-13-6-2-3-7-15(13)17-9-5-4-8-16(14)17/h2-12,21H,1H3/b11-10+
DMQBD27 CS CN(C(=O)/C=C/C1=CC2=CC=CC=C2C3=CC=CC=C31)O
DMQBD27 IK NKRFCIWHWNMHCB-ZHACJKMWSA-N
DMQBD27 IU (E)-N-hydroxy-N-methyl-3-phenanthren-9-ylprop-2-enamide
DMQBD27 DE Discovery agent
DMDQWOB ID DMDQWOB
DMDQWOB DN N-Hydroxy-N-methyl-benzamide
DMDQWOB HS Investigative
DMDQWOB SN N-Hydroxy-N-methylbenzamide; N-Hydroxy-N-methyl-benzamide; benzamide, N-hydroxy-N-methyl-; NSC646164; CHEMBL101043; 2446-50-6; AC1Q5INQ; n-methylbenzohydroxamic acid; AC1L83FX; N-Methyl-N-hydroxybenzamide; SCHEMBL125680; N-benzoyl-N-methylhydroxylamine; CTK0J4869; DTXSID20327327; DDSSLJHUWRMSSP-UHFFFAOYSA-N; ZINC5497333; BDBM50015122; AKOS028111405; NSC-646164
DMDQWOB DT Small molecular drug
DMDQWOB PC 371715
DMDQWOB MW 151.16
DMDQWOB FM C8H9NO2
DMDQWOB IC InChI=1S/C8H9NO2/c1-9(11)8(10)7-5-3-2-4-6-7/h2-6,11H,1H3
DMDQWOB CS CN(C(=O)C1=CC=CC=C1)O
DMDQWOB IK DDSSLJHUWRMSSP-UHFFFAOYSA-N
DMDQWOB IU N-hydroxy-N-methylbenzamide
DMDQWOB CA CAS 2446-50-6
DMDQWOB DE Discovery agent
DMCIAJL ID DMCIAJL
DMCIAJL DN N-hydroxy-nor-L-arginine
DMCIAJL HS Investigative
DMCIAJL PC 446124
DMCIAJL MW 176.17
DMCIAJL FM C5H12N4O3
DMCIAJL IC InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-8-5(7)9-12/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9)/t3-/m0/s1
DMCIAJL CS C(CN=C(N)NO)[C@@H](C(=O)O)N
DMCIAJL IK KOBHCUDVWOTEKO-VKHMYHEASA-N
DMCIAJL IU (2S)-2-amino-4-[[amino-(hydroxyamino)methylidene]amino]butanoic acid
DMCIAJL CA CAS 189302-40-7
DMTDBMU ID DMTDBMU
DMTDBMU DN N-hydroxysulfamide
DMTDBMU HS Investigative
DMTDBMU SN N-hydroxysulfamide; CHEMBL195540; 2o4z; BDBM50165753
DMTDBMU DT Small molecular drug
DMTDBMU PC 16122590
DMTDBMU MW 112.11
DMTDBMU FM H4N2O3S
DMTDBMU IC InChI=1S/H4N2O3S/c1-6(4,5)2-3/h2-3H,(H2,1,4,5)
DMTDBMU CS NS(=O)(=O)NO
DMTDBMU IK FZTCJYJKHSXPEX-UHFFFAOYSA-N
DMTDBMU DE Discovery agent
DMJBC03 ID DMJBC03
DMJBC03 DN N-hydroxysulfonamides
DMJBC03 HS Investigative
DMJBC03 DE Discovery agent
DMPK2JO ID DMPK2JO
DMPK2JO DN NI-105
DMPK2JO HS Investigative
DMPK2JO SN Tau protein modulator (neurodegenerative disease); Tau protein modulator (neurodegenerative disease), Biogen Idec; Tau protein modulator (neurodegenerative disease), Neurimmune Therapeutics
DMPK2JO CP Neurimmune Therapeutics AG
DMPK2JO PC 10065825
DMPK2JO MW 340.3
DMPK2JO FM C16H15F3N2O3
DMPK2JO IC InChI=1S/C16H15F3N2O3/c1-8-13(10(3)22)14(15(21(23)24)9(2)20-8)11-6-4-5-7-12(11)16(17,18)19/h4-7,14,20H,1-3H3
DMPK2JO CS CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)C
DMPK2JO IK YYIGWZQIEFYARO-UHFFFAOYSA-N
DMPK2JO IU 1-[2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridin-3-yl]ethanone
DMPK2JO DE Neurodegenerative disorder
DM680XO ID DM680XO
DM680XO DN NI-1201
DM680XO HS Investigative
DM680XO SN Anti-interleukin-6 receptor mAb, NovImmune
DM680XO CP NovImmune SA
DM680XO DT Antibody
DM680XO DE Autoimmune diabetes
DMG9OBA ID DMG9OBA
DMG9OBA DN NI-1401
DMG9OBA HS Investigative
DMG9OBA SN Anti-interleukin-17 MAb, NovImmune
DMG9OBA CP NovImmune SA
DMG9OBA DT Antibody
DMG9OBA DE Autoimmune diabetes
DM52ITO ID DM52ITO
DM52ITO DN NI-57
DM52ITO HS Investigative
DM52ITO SN CHEMBL3752151; 1883548-89-7; 4-Cyano-~{n}-(1,3-Dimethyl-2-Oxidanylidene-Quinolin-6-Yl)-2-Methoxy-Benzenesulfonamide; GTPL8573; SCHEMBL17560720; MolPort-039-101-322; NI 57; EX-A1876; BDBM50157570; ZINC254286814; AKOS027470204; NCGC00483115-01; NI-57, > HY-19537; CS-0015636; 4-cyano-N-(1,3-dimethyl-2-oxoquinolin-6-yl)-2-methoxybenzenesulfonamide; 4-cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide
DM52ITO DT Small molecular drug
DM52ITO PC 91827373
DM52ITO MW 383.4
DM52ITO FM C19H17N3O4S
DM52ITO IC InChI=1S/C19H17N3O4S/c1-12-8-14-10-15(5-6-16(14)22(2)19(12)23)21-27(24,25)18-7-4-13(11-20)9-17(18)26-3/h4-10,21H,1-3H3
DM52ITO CS CC1=CC2=C(C=CC(=C2)NS(=O)(=O)C3=C(C=C(C=C3)C#N)OC)N(C1=O)C
DM52ITO IK UEMQPCYDWCSVCU-UHFFFAOYSA-N
DM52ITO IU 4-cyano-N-(1,3-dimethyl-2-oxoquinolin-6-yl)-2-methoxybenzenesulfonamide
DM52ITO DE Discovery agent
DMH6MVJ ID DMH6MVJ
DMH6MVJ DN NIBR-0213
DMH6MVJ HS Investigative
DMH6MVJ SN GTPL6997; SCHEMBL2796717; CHEMBL3086703; ZINC103273369; NIBR-0213, > (2S)-2-[[4-[3-[[(1R)-1-(4-chloro-3-methylphenyl)ethyl]amino]phenyl]-2,6-dimethylbenzoyl]amino]propanoic acid
DMH6MVJ DT Small molecular drug
DMH6MVJ PC 59393720
DMH6MVJ MW 465
DMH6MVJ FM C27H29ClN2O3
DMH6MVJ IC InChI=1S/C27H29ClN2O3/c1-15-11-20(9-10-24(15)28)18(4)29-23-8-6-7-21(14-23)22-12-16(2)25(17(3)13-22)26(31)30-19(5)27(32)33/h6-14,18-19,29H,1-5H3,(H,30,31)(H,32,33)/t18-,19+/m1/s1
DMH6MVJ CS CC1=CC(=CC(=C1C(=O)N[C@@H](C)C(=O)O)C)C2=CC(=CC=C2)N[C@H](C)C3=CC(=C(C=C3)Cl)C
DMH6MVJ IK KYHUARFFBDLROH-MOPGFXCFSA-N
DMH6MVJ IU (2S)-2-[[4-[3-[[(1R)-1-(4-chloro-3-methylphenyl)ethyl]amino]phenyl]-2,6-dimethylbenzoyl]amino]propanoic acid
DMH6MVJ DE Discovery agent
DMU0BMQ ID DMU0BMQ
DMU0BMQ DN NIBR-785
DMU0BMQ HS Investigative
DMU0BMQ SN NIBR-785
DMU0BMQ CP Novartis Institutes for BioMedical Research Inc
DMU0BMQ DT Small molecular drug
DMU0BMQ PC 46184240
DMU0BMQ MW 396.4
DMU0BMQ FM C22H24N2O5
DMU0BMQ IC InChI=1S/C22H24N2O5/c1-5-28-19-17(27-4)11-6-13-12-16(21(26)29-18(13)19)20(25)24-15-9-7-14(8-10-15)22(2,3)23/h6-12H,5,23H2,1-4H3,(H,24,25)
DMU0BMQ CS CCOC1=C(C=CC2=C1OC(=O)C(=C2)C(=O)NC3=CC=C(C=C3)C(C)(C)N)OC
DMU0BMQ IK NFOLAKWLEGGBTA-UHFFFAOYSA-N
DMU0BMQ IU N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide
DMU0BMQ DE Multiple sclerosis
DM4I6MD ID DM4I6MD
DM4I6MD DN NICARBAZIN
DM4I6MD HS Investigative
DM4I6MD SN Nicarbazin; 330-95-0; Nicarbazine; Nicrazine; Nicrazin; Nicoxin; Nirazin; Nicarb; Nicarbasin; Nicarbazin [BAN]; MK 75; UNII-11P9NUA12U; MK 75 (VAN); HSDB 7466; NSC 7171; EINECS 206-359-1; AI3-60130; 11P9NUA12U; CHEBI:81725; Urea, N,N'-bis(4-nitrophenyl)-, compd. with 4,6-dimethyl-2(1H)-pyrimidinone (1:1); 4,4'-Dinitrocarbanilide, 4,6-dimethyl-2-pyrimidinol; 1,3-bis(4-nitrophenyl)urea; 4,6-dimethyl-1H-pyrimidin-2-one; N,N'-Bis(4-nitrophenyl)urea compd. with 4,6-dimethyl-2-pyrimidinol (1:1); W-106788
DM4I6MD DT Small molecular drug
DM4I6MD PC 9507
DM4I6MD MW 426.4
DM4I6MD FM C19H18N6O6
DM4I6MD IC InChI=1S/C13H10N4O5.C6H8N2O/c18-13(14-9-1-5-11(6-2-9)16(19)20)15-10-3-7-12(8-4-10)17(21)22;1-4-3-5(2)8-6(9)7-4/h1-8H,(H2,14,15,18);3H,1-2H3,(H,7,8,9)
DM4I6MD CS CC1=CC(=NC(=O)N1)C.C1=CC(=CC=C1NC(=O)NC2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]
DM4I6MD IK UKHWDRMMMYWSFL-UHFFFAOYSA-N
DM4I6MD IU 1,3-bis(4-nitrophenyl)urea;4,6-dimethyl-1H-pyrimidin-2-one
DM4I6MD CA CAS 330-95-0
DM4I6MD CB CHEBI:81725
DM4I6MD DE Discovery agent
DMI12Y8 ID DMI12Y8
DMI12Y8 DN Nickel chloride
DMI12Y8 HS Investigative
DMI12Y8 SN NICKEL CHLORIDE; Nickel(II) chloride; 7718-54-9; Nickel dichloride; Nickelous chloride; NiCl2; Nickel(2+) chloride; Nickel chloride (NiCl2); dichloronickel; Nickelchloride; Nickel dichloride (nicl2); Nickel(II) chloride (1:2); Nichel(II) chloride; Nickel (II) chloride; Nickel(II) chloride, 98%; Nickel(II) chloride anhydrous; CCRIS 1788; HSDB 860; EINECS 231-743-0; EINECS 253-399-0; NSC 254532; Nickel chloride [Nickel and nickel compounds]; 37211-05-5; dichloro nickel; Nickel(II) chloride, 99.99%, (trace metal basis), anhydrous, po
DMI12Y8 DT Small molecular drug
DMI12Y8 PC 24385
DMI12Y8 MW 129.6
DMI12Y8 FM Cl2Ni
DMI12Y8 IC InChI=1S/2ClH.Ni/h2*1H;/q;;+2/p-2
DMI12Y8 CS Cl[Ni]Cl
DMI12Y8 IK QMMRZOWCJAIUJA-UHFFFAOYSA-L
DMI12Y8 IU dichloronickel
DMI12Y8 CA CAS 37211-0
DMI12Y8 CB CHEBI:34887
DMI12Y8 DE Discovery agent
DM0DFNJ ID DM0DFNJ
DM0DFNJ DN Nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime
DM0DFNJ HS Investigative
DM0DFNJ SN CHEMBL597445; nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime
DM0DFNJ DT Small molecular drug
DM0DFNJ PC 20872718
DM0DFNJ MW 313.35
DM0DFNJ FM C17H19N3O3
DM0DFNJ IC InChI=1S/C17H19N3O3/c1-2-3-11-22-16-8-6-15(7-9-16)20-17(21)23-19-13-14-5-4-10-18-12-14/h4-10,12-13H,2-3,11H2,1H3,(H,20,21)/b19-13+
DM0DFNJ CS CCCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CN=CC=C2
DM0DFNJ IK GPBQAYXYNOXDEZ-CPNJWEJPSA-N
DM0DFNJ IU [(E)-pyridin-3-ylmethylideneamino] N-(4-butoxyphenyl)carbamate
DM0DFNJ DE Discovery agent
DM957CK ID DM957CK
DM957CK DN Nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime
DM957CK HS Investigative
DM957CK SN CHEMBL598343; nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime
DM957CK DT Small molecular drug
DM957CK PC 20872722
DM957CK MW 285.3
DM957CK FM C15H15N3O3
DM957CK IC InChI=1S/C15H15N3O3/c1-2-20-14-7-5-13(6-8-14)18-15(19)21-17-11-12-4-3-9-16-10-12/h3-11H,2H2,1H3,(H,18,19)/b17-11+
DM957CK CS CCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CN=CC=C2
DM957CK IK LKOKEOYUZBYMCC-GZTJUZNOSA-N
DM957CK IU [(E)-pyridin-3-ylmethylideneamino] N-(4-ethoxyphenyl)carbamate
DM957CK DE Discovery agent
DMC9WAL ID DMC9WAL
DMC9WAL DN Nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime
DMC9WAL HS Investigative
DMC9WAL SN CHEMBL598545; nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime
DMC9WAL DT Small molecular drug
DMC9WAL PC 20872731
DMC9WAL MW 299.32
DMC9WAL FM C16H17N3O3
DMC9WAL IC InChI=1S/C16H17N3O3/c1-2-10-21-15-7-5-14(6-8-15)19-16(20)22-18-12-13-4-3-9-17-11-13/h3-9,11-12H,2,10H2,1H3,(H,19,20)/b18-12+
DMC9WAL CS CCCOC1=CC=C(C=C1)NC(=O)O/N=C/C2=CN=CC=C2
DMC9WAL IK RKEOSRSRXNLQCF-LDADJPATSA-N
DMC9WAL IU [(E)-pyridin-3-ylmethylideneamino] N-(4-propoxyphenyl)carbamate
DMC9WAL DE Discovery agent
DM9LRKB ID DM9LRKB
DM9LRKB DN Nicotinamide-Adenine-Dinucleotide
DM9LRKB HS Investigative
DM9LRKB SN NICOTINAMIDE-ADENINE-DINUCLEOTIDE (ACIDIC FORM); AC1NRCGS; [[(2R,3S,4R,5R)-5-(6-amino-7H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
DM9LRKB DT Small molecular drug
DM9LRKB PC 5892
DM9LRKB MW 663.4
DM9LRKB FM C21H27N7O14P2
DM9LRKB IC InChI=1S/C21H27N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-4,7-8,10-11,13-16,20-21,29-32H,5-6H2,(H5-,22,23,24,25,33,34,35,36,37)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1
DM9LRKB CS C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N
DM9LRKB IK BAWFJGJZGIEFAR-NNYOXOHSSA-N
DM9LRKB IU [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
DM9LRKB CA CAS 53-84-9
DM9LRKB CB CHEBI:44215
DMO7M2N ID DMO7M2N
DMO7M2N DN Nicotinyl alcohol
DMO7M2N HS Investigative
DMO7M2N SN Nicotinic alcohol; Nicotinyl alcohol; NU-2121; Niltuvin (free base); Pyridine-3-carbinol; Pyridine-3-methanol; Pyridyl-3-carbinol; Pyridyl-3-methanol; Pyridylcarbinol; Pyridylmethanol; Ro-1-5155; Roniacol; beta-Picolyl alcohol; beta-Pyridinecarbinol; beta-Pyridylcarbinol; pyridin-3-ylmethanol; (Pyridin-3-yl)methanol; .beta.-Pyridylcarbinol; 100-55-0; 3-(Hydroxymethyl)pyridine; 3-Hydroxymethylpyridine; 3-PYRIDINEMETHANOL; 3-PYRIDINYLCARBINOL; 3-Picolyl alcohol; 3-Pyridinylmethanol; 3-Pyridylcarbinol; 3-Pyridylmethanol
DMO7M2N PC 7510
DMO7M2N MW 109.13
DMO7M2N FM C6H7NO
DMO7M2N IC MVQVNTPHUGQQHK-UHFFFAOYSA-N
DMO7M2N CS C1=CC(=CN=C1)CO
DMO7M2N IK 1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2
DMO7M2N IU pyridin-3-ylmethanol
DMO7M2N CA CAS 100-55-0
DMO7M2N CB CHEBI:45213
DMO7M2N DE Hypertriglyceridaemia
DMIK40C ID DMIK40C
DMIK40C DN Nifeviroc
DMIK40C HS Investigative
DMIK40C SN NIFEVIROC; CHEMBL1172035; SCHEMBL14895241; BDBM50321682; AKOS027337129; SB16981; 4-Nitrobenzyl allyl(1-(((3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl)methyl)piperidin-4-yl)carbamate; (4-nitrophenyl)methyl N-allyl-N-[1-[[(3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenyl-pyrrolidin-3-yl]methyl]-4-piperidyl]carbamate; Carbamic acid, [1-[[(3S,4R)-1-(cyclopentylcarbonyl)-4-hydroxy-4-phenyl-3-pyrrolidinyl]methyl]-4-piperidinyl]2-propenyl-, (4-nitrophenyl)methyl ester; 934740-25-7
DMIK40C DT Small molecular drug
DMIK40C PC 16663418
DMIK40C MW 590.7
DMIK40C FM C33H42N4O6
DMIK40C IC InChI=1S/C33H42N4O6/c1-2-18-36(32(39)43-23-25-12-14-30(15-13-25)37(41)42)29-16-19-34(20-17-29)21-28-22-35(31(38)26-8-6-7-9-26)24-33(28,40)27-10-4-3-5-11-27/h2-5,10-15,26,28-29,40H,1,6-9,16-24H2/t28-,33-/m0/s1
DMIK40C CS C=CCN(C1CCN(CC1)C[C@H]2CN(C[C@@]2(C3=CC=CC=C3)O)C(=O)C4CCCC4)C(=O)OCC5=CC=C(C=C5)[N+](=O)[O-]
DMIK40C IK JNSKQYZFEVKYDB-UVMMSNCQSA-N
DMIK40C IU (4-nitrophenyl)methyl N-[1-[[(3S,4R)-1-(cyclopentanecarbonyl)-4-hydroxy-4-phenylpyrrolidin-3-yl]methyl]piperidin-4-yl]-N-prop-2-enylcarbamate
DMIK40C DE Discovery agent
DMDMG1O ID DMDMG1O
DMDMG1O DN NIHP
DMDMG1O HS Investigative
DMDMG1O SN NIHP; GTPL545; SCHEMBL15159029; 1-[4-(3-hydroxypropyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMDMG1O DT Small molecular drug
DMDMG1O PC 10587912
DMDMG1O MW 267.36
DMDMG1O FM C15H25NO3
DMDMG1O IC InChI=1S/C15H25NO3/c1-12(2)16-10-14(18)11-19-15-7-5-13(6-8-15)4-3-9-17/h5-8,12,14,16-18H,3-4,9-11H2,1-2H3
DMDMG1O CS CC(C)NCC(COC1=CC=C(C=C1)CCCO)O
DMDMG1O IK RUZBBQNQBDCLPE-UHFFFAOYSA-N
DMDMG1O IU 1-[4-(3-hydroxypropyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
DMDMG1O DE Discovery agent
DM0QJSO ID DM0QJSO
DM0QJSO DN NILTUBACIN
DM0QJSO HS Investigative
DM0QJSO SN NILTUBACIN; Probes1_000174; Probes2_000141; AC1O7Y2N; CHEMBL1213539; SCHEMBL14476139; DIOX-H_003550; 8-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]anilino]-8-oxooctanoic acid
DM0QJSO DT Small molecular drug
DM0QJSO PC 6675803
DM0QJSO MW 706.8
DM0QJSO FM C41H42N2O7S
DM0QJSO IC InChI=1S/C41H42N2O7S/c44-26-28-17-19-29(20-18-28)35-25-34(27-51-41-43-38(30-11-5-3-6-12-30)39(50-41)31-13-7-4-8-14-31)48-40(49-35)32-21-23-33(24-22-32)42-36(45)15-9-1-2-10-16-37(46)47/h3-8,11-14,17-24,34-35,40,44H,1-2,9-10,15-16,25-27H2,(H,42,45)(H,46,47)/t34-,35+,40+/m1/s1
DM0QJSO CS C1[C@@H](O[C@@H](O[C@@H]1C2=CC=C(C=C2)CO)C3=CC=C(C=C3)NC(=O)CCCCCCC(=O)O)CSC4=NC(=C(O4)C5=CC=CC=C5)C6=CC=CC=C6
DM0QJSO IK WLLKRNCIQXOQHG-YXQOSMAKSA-N
DM0QJSO IU 8-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]anilino]-8-oxooctanoic acid
DM0QJSO DE Discovery agent
DM8OGMA ID DM8OGMA
DM8OGMA DN Niludipine
DM8OGMA HS Investigative
DM8OGMA SN Niludipin; Niludipina; Niludipina [INN-Spanish]; Niludipine; Niludipine [INN:BAN]; Niludipinum; Niludipinum [INN-Latin]; Nilupidine; 22609-73-0; 9844OS3B0J; BAY-a 7168; BRN 0504197; Bay a 7168; Bis(2-propoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; Bis(2-propoxyethyl) 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; C25H34N2O8; EINECS 245-120-6; UNII-9844OS3B0J; bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM8OGMA PC 89767
DM8OGMA MW 490.5
DM8OGMA FM C25H34N2O8
DM8OGMA IC VZWXXKDFACOXNT-UHFFFAOYSA-N
DM8OGMA CS CCCOCCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOCCC)C)C
DM8OGMA IK 1S/C25H34N2O8/c1-5-10-32-12-14-34-24(28)21-17(3)26-18(4)22(25(29)35-15-13-33-11-6-2)23(21)19-8-7-9-20(16-19)27(30)31/h7-9,16,23,26H,5-6,10-15H2,1-4H3
DM8OGMA IU bis(2-propoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
DM8OGMA CA CAS 22609-73-0
DM8OGMA DE Cerebral vasospasm
DM8ZMB5 ID DM8ZMB5
DM8ZMB5 DN N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide
DM8ZMB5 HS Investigative
DM8ZMB5 DT Small molecular drug
DM8ZMB5 PC 44313346
DM8ZMB5 MW 304.3
DM8ZMB5 FM C19H16N2O2
DM8ZMB5 IC InChI=1S/C19H16N2O2/c22-18(15-11-20-16-8-4-3-7-14(15)16)19(23)21-17-10-9-12-5-1-2-6-13(12)17/h1-8,11,17,20H,9-10H2,(H,21,23)
DM8ZMB5 CS C1CC2=CC=CC=C2C1NC(=O)C(=O)C3=CNC4=CC=CC=C43
DM8ZMB5 IK HPOOEGNMALNZJV-UHFFFAOYSA-N
DM8ZMB5 IU N-(2,3-dihydro-1H-inden-1-yl)-2-(1H-indol-3-yl)-2-oxoacetamide
DM8ZMB5 DE Discovery agent
DMV53PH ID DMV53PH
DMV53PH DN NIP-142
DMV53PH HS Investigative
DMV53PH SN NIP-142; CHEMBL1671910; NIP 142; GTPL2408; BDBM50417965; N-[(3R,4S)-4-(cyclopropylamino)-3-hydroxy-2,2-dimethyl-7-nitrochroman-6-yl]-2-(4-methoxyphenyl)acetamide
DMV53PH CP Aventis
DMV53PH DT Small molecular drug
DMV53PH PC 9980734
DMV53PH MW 441.5
DMV53PH FM C23H27N3O6
DMV53PH IC InChI=1S/C23H27N3O6/c1-23(2)22(28)21(24-14-6-7-14)16-11-17(18(26(29)30)12-19(16)32-23)25-20(27)10-13-4-8-15(31-3)9-5-13/h4-5,8-9,11-12,14,21-22,24,28H,6-7,10H2,1-3H3,(H,25,27)/t21-,22+/m0/s1
DMV53PH CS CC1([C@@H]([C@H](C2=CC(=C(C=C2O1)[N+](=O)[O-])NC(=O)CC3=CC=C(C=C3)OC)NC4CC4)O)C
DMV53PH IK HWADWMAQVCHLHJ-FCHUYYIVSA-N
DMV53PH IU N-[(3R,4S)-4-(cyclopropylamino)-3-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydrochromen-6-yl]-2-(4-methoxyphenyl)acetamide
DMV53PH DE Atrial fibrillation
DMPV450 ID DMPV450
DMPV450 DN NIPECOTIC ACID
DMPV450 HS Investigative
DMPV450 SN Piperidine-3-carboxylic acid; 498-95-3; h-dl-nip-oh; EINECS 207-873-9; CHEMBL277498; dl-piperidine-3-carboxylic acid; 60252-41-7; CHEBI:116931; XJLSEXAGTJCILF-UHFFFAOYSA-N; MFCD00005992; SR-01000075612; Nipecotic; h-nip-oh; 3-carboxypiperidine; (y)-Nipecotic acid; ( inverted exclamation markA)-Nipecotic acid; PubChem6793; D-nipecotic acid-HCl; h-dl-pic(3)-oh; (RS)-nipecotic acid
DMPV450 DT Small molecular drug
DMPV450 PC 4498
DMPV450 MW 129.16
DMPV450 FM C6H11NO2
DMPV450 IC InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)
DMPV450 CS C1CC(CNC1)C(=O)O
DMPV450 IK XJLSEXAGTJCILF-UHFFFAOYSA-N
DMPV450 IU piperidine-3-carboxylic acid
DMPV450 CA CAS 498-95-3
DMPV450 CB CHEBI:116931
DMPV450 DE Discovery agent
DM1R0WC ID DM1R0WC
DM1R0WC DN NIS-62949
DM1R0WC HS Investigative
DM1R0WC DE Discovery agent
DMO4E9U ID DMO4E9U
DMO4E9U DN N-isobutyl-2-oxo-2H-chromene-3-carboxamide
DMO4E9U HS Investigative
DMO4E9U SN N-isobutyl-2-oxo-2H-chromene-3-carboxamide; AC1LGLK5; 3-carboxamido coumarin, 3; Oprea1_019533; CHEMBL512883; BDBM29154; MolPort-002-807-315; HMS1722A09; ZINC341401; AKOS001056674; MCULE-2251500223; 1846-84-0; ST50811140; N-(2-methylpropyl)-2-oxochromene-3-carboxamide; SR-01000051779; AG-670/14532137; N-(2-methylpropyl)(2-oxochromen-3-yl)carboxamide; SR-01000051779-1; N-(2-methylpropyl)-2-oxo-2H-chromene-3-carboxamide
DMO4E9U DT Small molecular drug
DMO4E9U PC 823440
DMO4E9U MW 245.27
DMO4E9U FM C14H15NO3
DMO4E9U IC InChI=1S/C14H15NO3/c1-9(2)8-15-13(16)11-7-10-5-3-4-6-12(10)18-14(11)17/h3-7,9H,8H2,1-2H3,(H,15,16)
DMO4E9U CS CC(C)CNC(=O)C1=CC2=CC=CC=C2OC1=O
DMO4E9U IK BKVFDOZWDVAMFZ-UHFFFAOYSA-N
DMO4E9U IU N-(2-methylpropyl)-2-oxochromene-3-carboxamide
DMO4E9U DE Discovery agent
DM9Z6VP ID DM9Z6VP
DM9Z6VP DN N-isobutylnorlitebamine
DM9Z6VP HS Investigative
DM9Z6VP SN N-isobutylnorlitebamine; CHEMBL517486; BDBM50250443
DM9Z6VP DT Small molecular drug
DM9Z6VP PC 10643561
DM9Z6VP MW 381.5
DM9Z6VP FM C23H27NO4
DM9Z6VP IC InChI=1S/C23H27NO4/c1-13(2)11-24-8-7-15-16-6-5-14-9-19(25)20(27-3)10-17(14)21(16)23(28-4)22(26)18(15)12-24/h5-6,9-10,13,25-26H,7-8,11-12H2,1-4H3
DM9Z6VP CS CC(C)CN1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DM9Z6VP IK WKTMDLQZTZEUIG-UHFFFAOYSA-N
DM9Z6VP IU 9,11-dimethoxy-2-(2-methylpropyl)-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DM9Z6VP DE Discovery agent
DMN1FIU ID DMN1FIU
DMN1FIU DN N-isobutylnoroxymorphone
DMN1FIU HS Investigative
DMN1FIU SN N-isobutylnoroxymorphone; CHEMBL490418; 17-Isobutyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one; SCHEMBL3835355; OEQLILQNMUXCHV-XFWGSAIBSA-N
DMN1FIU DT Small molecular drug
DMN1FIU PC 25178033
DMN1FIU MW 343.4
DMN1FIU FM C20H25NO4
DMN1FIU IC InChI=1S/C20H25NO4/c1-11(2)10-21-8-7-19-16-12-3-4-13(22)17(16)25-18(19)14(23)5-6-20(19,24)15(21)9-12/h3-4,11,15,18,22,24H,5-10H2,1-2H3/t15-,18+,19+,20-/m1/s1
DMN1FIU CS CC(C)CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
DMN1FIU IK OEQLILQNMUXCHV-XFWGSAIBSA-N
DMN1FIU IU (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-(2-methylpropyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
DMN1FIU DE Discovery agent
DM53AS0 ID DM53AS0
DM53AS0 DN N-isoleucylthiazolidine
DM53AS0 HS Investigative
DM53AS0 SN UNII-SDH8E9EM4L; SDH8E9EM4L; CHEMBL98408; 1-Pentanone, 2-amino-3-methyl-1-(3-thiazolidinyl)-, (2S,3S)-; thiazolidide 2; AC1OCFGU; 3-(L-Ile-)Thiazolidine; BMCL15687 Compound 4; (S)-Isoleucine Thiazolidide; SCHEMBL353709; BDBM11464; ZINC3931585
DM53AS0 DT Small molecular drug
DM53AS0 PC 6918465
DM53AS0 MW 202.32
DM53AS0 FM C9H18N2OS
DM53AS0 IC InChI=1S/C9H18N2OS/c1-3-7(2)8(10)9(12)11-4-5-13-6-11/h7-8H,3-6,10H2,1-2H3/t7-,8-/m0/s1
DM53AS0 CS CC[C@H](C)[C@@H](C(=O)N1CCSC1)N
DM53AS0 IK WCRLBFHWFPELKW-YUMQZZPRSA-N
DM53AS0 IU (2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one
DM53AS0 CA CAS 136259-20-6
DM53AS0 DE Discovery agent
DMC8L4J ID DMC8L4J
DMC8L4J DN N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide
DMC8L4J HS Investigative
DMC8L4J SN CHEMBL246478; N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide
DMC8L4J DT Small molecular drug
DMC8L4J PC 44440709
DMC8L4J MW 373.5
DMC8L4J FM C24H27N3O
DMC8L4J IC InChI=1S/C24H27N3O/c1-16(2)13-14-25-24(28)21-15-26-22(19-9-5-17(3)6-10-19)23(27-21)20-11-7-18(4)8-12-20/h5-12,15-16H,13-14H2,1-4H3,(H,25,28)
DMC8L4J CS CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NCCC(C)C
DMC8L4J IK DGPFCWKIBMZBAP-UHFFFAOYSA-N
DMC8L4J IU N-(3-methylbutyl)-5,6-bis(4-methylphenyl)pyrazine-2-carboxamide
DMC8L4J DE Discovery agent
DMFSW5M ID DMFSW5M
DMFSW5M DN N-isopropyl estradiol-16-carboxamide
DMFSW5M HS Investigative
DMFSW5M SN SCHEMBL12379487
DMFSW5M DT Small molecular drug
DMFSW5M PC 44407333
DMFSW5M MW 357.5
DMFSW5M FM C22H31NO3
DMFSW5M IC InChI=1S/C22H31NO3/c1-12(2)23-21(26)18-11-19-17-6-4-13-10-14(24)5-7-15(13)16(17)8-9-22(19,3)20(18)25/h5,7,10,12,16-20,24-25H,4,6,8-9,11H2,1-3H3,(H,23,26)/t16?,17?,18?,19?,20-,22-/m0/s1
DMFSW5M CS CC(C)NC(=O)C1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMFSW5M IK MIXZPWBCEXVAQM-GFEBWMDQSA-N
DMFSW5M IU (13S,17S)-3,17-dihydroxy-13-methyl-N-propan-2-yl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16-carboxamide
DMFSW5M DE Discovery agent
DMHJMTI ID DMHJMTI
DMHJMTI DN N-isopropyl estradiol-16-methyl carboxamide
DMHJMTI HS Investigative
DMHJMTI SN SCHEMBL12379570
DMHJMTI DT Small molecular drug
DMHJMTI PC 44407579
DMHJMTI MW 371.5
DMHJMTI FM C23H33NO3
DMHJMTI IC InChI=1S/C23H33NO3/c1-13(2)24-21(26)12-15-11-20-19-6-4-14-10-16(25)5-7-17(14)18(19)8-9-23(20,3)22(15)27/h5,7,10,13,15,18-20,22,25,27H,4,6,8-9,11-12H2,1-3H3,(H,24,26)/t15?,18?,19?,20?,22-,23-/m0/s1
DMHJMTI CS CC(C)NC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2([C@H]1O)C)C=CC(=C4)O
DMHJMTI IK FKSICUOFJYPFSV-XWFZVRCUSA-N
DMHJMTI IU 2-[(13S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]-N-propan-2-ylacetamide
DMHJMTI DE Discovery agent
DMZGMQJ ID DMZGMQJ
DMZGMQJ DN N-isopropyl estrone-16-methyl carboxamide
DMZGMQJ HS Investigative
DMZGMQJ SN SCHEMBL12379559
DMZGMQJ DT Small molecular drug
DMZGMQJ PC 44407487
DMZGMQJ MW 369.5
DMZGMQJ FM C23H31NO3
DMZGMQJ IC InChI=1S/C23H31NO3/c1-13(2)24-21(26)12-15-11-20-19-6-4-14-10-16(25)5-7-17(14)18(19)8-9-23(20,3)22(15)27/h5,7,10,13,15,18-20,25H,4,6,8-9,11-12H2,1-3H3,(H,24,26)/t15?,18?,19?,20?,23-/m0/s1
DMZGMQJ CS CC(C)NC(=O)CC1CC2C3CCC4=C(C3CC[C@@]2(C1=O)C)C=CC(=C4)O
DMZGMQJ IK OHQDRZHZEKGJSZ-OOGUNDJRSA-N
DMZGMQJ IU 2-[(13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]-N-propan-2-ylacetamide
DMZGMQJ DE Discovery agent
DM14L7O ID DM14L7O
DM14L7O DN N-Isopropyl-1'H-phenothiazine-1'-carboxamide
DM14L7O HS Investigative
DM14L7O SN CHEMBL592185; N-isopropyl-10H-phenothiazine-10-carboxamide; N-propan-2-ylphenothiazine-10-carboxamide; Oprea1_607910; MLS001196405; ARONIS009672; AC1LE088; SCHEMBL11315494; ZINC88005; MolPort-000-803-539; MolPort-019-786-000; HMS1587K22; HMS2859K14; STK126366; BDBM50308429; AKOS000498951; MCULE-3571561994; CCG-113325; SMR000556300; 81225-58-3; BB0286649; N-(methylethyl)phenothiazin-10-ylcarboxamide; EU-0046799; ST45046412; KS-00004187; N-Isopropyl-1''H-phenothiazine-1''-carboxamide; AN-329/41195442
DM14L7O DT Small molecular drug
DM14L7O PC 704259
DM14L7O MW 284.4
DM14L7O FM C16H16N2OS
DM14L7O IC InChI=1S/C16H16N2OS/c1-11(2)17-16(19)18-12-7-3-5-9-14(12)20-15-10-6-4-8-13(15)18/h3-11H,1-2H3,(H,17,19)
DM14L7O CS CC(C)NC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
DM14L7O IK DIHZRSIYRBANNR-UHFFFAOYSA-N
DM14L7O IU N-propan-2-ylphenothiazine-10-carboxamide
DM14L7O DE Discovery agent
DMRPUCA ID DMRPUCA
DMRPUCA DN N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide
DMRPUCA HS Investigative
DMRPUCA SN CHEMBL246477; N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide
DMRPUCA DT Small molecular drug
DMRPUCA PC 44440708
DMRPUCA MW 345.4
DMRPUCA FM C22H23N3O
DMRPUCA IC InChI=1S/C22H23N3O/c1-14(2)24-22(26)19-13-23-20(17-9-5-15(3)6-10-17)21(25-19)18-11-7-16(4)8-12-18/h5-14H,1-4H3,(H,24,26)
DMRPUCA CS CC1=CC=C(C=C1)C2=NC=C(N=C2C3=CC=C(C=C3)C)C(=O)NC(C)C
DMRPUCA IK IZKDGGVGSMLFPW-UHFFFAOYSA-N
DMRPUCA IU 5,6-bis(4-methylphenyl)-N-propan-2-ylpyrazine-2-carboxamide
DMRPUCA DE Discovery agent
DMIVO8P ID DMIVO8P
DMIVO8P DN N-Isopropyl-N'-Hydroxyguanidine
DMIVO8P HS Investigative
DMIVO8P SN N-ISOPROPYL-N'-HYDROXYGUANIDINE; N-HYDROXY-N'-ISOPROPYLGUANIDIE; 478806-77-8; IHG; AC1L9KDY; SCHEMBL564061; CHEMBL72434; 1-hydroxy-3-isopropylguanidine; SCHEMBL15424726; 1-hydroxy-2-propan-2-ylguanidine; (E)-2-hydroxy-1-isopropylguanidine; ZINC13535998; 2-hydroxy-1-(propan-2-yl)guanidine; AKOS017475215; AKOS011771464; 1-hydroxy-3-(1-methylethyl)guanidine; DB02143; ACM478806778
DMIVO8P DT Small molecular drug
DMIVO8P PC 447029
DMIVO8P MW 117.15
DMIVO8P FM C4H11N3O
DMIVO8P IC InChI=1S/C4H11N3O/c1-3(2)6-4(5)7-8/h3,8H,1-2H3,(H3,5,6,7)
DMIVO8P CS CC(C)N=C(N)NO
DMIVO8P IK OITVEDMMUMUWTL-UHFFFAOYSA-N
DMIVO8P IU 1-hydroxy-2-propan-2-ylguanidine
DMIVO8P CA CAS 478806-77-8
DMIVO8P DE Discovery agent
DMG8NB0 ID DMG8NB0
DMG8NB0 DN N-isopropylnorlitebamine
DMG8NB0 HS Investigative
DMG8NB0 SN N-isopropylnorlitebamine; CHEMBL516841; BDBM50250454
DMG8NB0 DT Small molecular drug
DMG8NB0 PC 10666657
DMG8NB0 MW 367.4
DMG8NB0 FM C22H25NO4
DMG8NB0 IC InChI=1S/C22H25NO4/c1-12(2)23-8-7-14-15-6-5-13-9-18(24)19(26-3)10-16(13)20(15)22(27-4)21(25)17(14)11-23/h5-6,9-10,12,24-25H,7-8,11H2,1-4H3
DMG8NB0 CS CC(C)N1CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O
DMG8NB0 IK AWJWBWOWUNPLTO-UHFFFAOYSA-N
DMG8NB0 IU 9,11-dimethoxy-2-propan-2-yl-3,4-dihydro-1H-naphtho[2,1-f]isoquinoline-8,12-diol
DMG8NB0 DE Discovery agent
DMDVO9T ID DMDVO9T
DMDVO9T DN N-isopropylnorlitebamineN-methoiodide
DMDVO9T HS Investigative
DMDVO9T SN N-isopropylnorlitebamineN-methoiodide
DMDVO9T DT Small molecular drug
DMDVO9T PC 10815529
DMDVO9T MW 509.4
DMDVO9T FM C23H28INO4
DMDVO9T IC InChI=1S/C23H27NO4.HI/c1-5-9-24(2)10-8-15-16-7-6-14-11-19(25)20(27-3)12-17(14)21(16)23(28-4)22(26)18(15)13-24;/h6-7,11-12H,5,8-10,13H2,1-4H3,(H-,25,26);1H
DMDVO9T CS CCC[N+]1(CCC2=C3C=CC4=CC(=C(C=C4C3=C(C(=C2C1)O)OC)OC)O)C.[I-]
DMDVO9T IK ATOFDXKLKQOFOQ-UHFFFAOYSA-N
DMDVO9T IU 9,11-dimethoxy-2-methyl-2-propyl-3,4-dihydro-1H-naphtho[2,1-f]isoquinolin-2-ium-8,12-diol;iodide
DMDVO9T DE Discovery agent
DMZBNH0 ID DMZBNH0
DMZBNH0 DN Nisoxetine
DMZBNH0 HS Investigative
DMZBNH0 SN Nisoxetine; 3-(2-Methoxyphenoxy)-N-methyl-3-phenylpropylamine; Compound 89218; 3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine; Nisoxetine [USAN:INN]; 3-(o-Methoxyphenoxy)-N-methyl-3-phenylpropylamine; N-Methyl-gamma-(2-methylphenoxy)phenylpropanolamine; Lilly 94939; 57226-61-6; DL-N-Methyl-3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine; CHEMBL295467; 53179-07-0; CHEBI:73410; ITJNARMNRKSWTA-UHFFFAOYSA-N; 57754-86-6; NCGC00015715-04; Nisoxetine Inhibitor; DSSTox_RID_80724; DSSTox_CID_25175; DSSTox_GSID_45175
DMZBNH0 DT Small molecular drug
DMZBNH0 PC 4500
DMZBNH0 MW 271.35
DMZBNH0 FM C17H21NO2
DMZBNH0 IC InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3
DMZBNH0 CS CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC
DMZBNH0 IK ITJNARMNRKSWTA-UHFFFAOYSA-N
DMZBNH0 IU 3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine
DMZBNH0 CA CAS 53179-07-0
DM